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Word of Welcome
On behalf of the EHA Board and the Scientific Program Committee of the 21st Congress of EHA we are
pleased to introduce this year’s Abstract Program.
The Scientific Program Committee has compiled an exciting up-to-date program of Simultaneous Oral
and Poster Sessions from over 2400 abstracts submitted. Selected posters will be presented during the
traditional Poster Walks allowing more time for discussion of results and conclusions. To better pro-
mote basic research in hematology, we introduced a new special presentation type: the poster pitch!
During selected oral sessions, 5-8 presenters will have the opportunity to pitch their abstract/poster to
the attendees of the session.
There are also E-posters available on the E-poster screens, for which a specific time is allocated dur-
ing the Poster Browsing Time at the end of each Walk. All presented posters and E-posters can be
viewed on the E-poster screens from Friday morning to Saturday evening. Posters will also be available
on the EHA Learning Center, for which you have complimentary access after the congress: learningcen-
ter.ehaweb.org.
The six Best Abstracts will be presented during the Presidential Symposium on Friday afternoon. One
of them has been selected from the record number of “late breaking abstracts” with “hot” data. Only the
most exciting results have been selected and will be presented in the Late Breaking Oral Session on
Sunday morning. There are also late breaking posters that are included in a poster walk of the relevant
topic. 
On behalf of the EHA Board, the committees and all the people involved in this years’ EHA congress,
we thank you for coming to Copenhagen and wish you an exciting meeting.
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SIMULTANEOUS SESSIONS I
New agents for myeloma treatment
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CARFILZOMIB WEEKLY PLUS MELPHALAN AND PREDNISONE IN NEWLY
DIAGNOSED ELDERLY MULTIPLE MYELOMA (IFM 2012-03)
X Leleu1,*, G Fouquet2, L Karlin3, B Kolb4, M Tiab5, C Araujo6, N Meuleman7,
T de Revel8, P Bourquard9, P Lenain10, M Roussel11, A Jaccard12, MO Petillon2,
K Belhadj-Merzoug13, G Lepeu14, ML Chretien15, J Fontan16, P Rodon17,
A Schmitt18, F Offner19, L Voillat20, S Cerejat21, F Kuhnowsko22,
S Rigaudeau23, O Decaux24, C Humbrecht-Kraut25, J Frayfer26, O Fitoussi27,
D Roos Weil28, JC Eisenmann29, V Dorvaux30, EG Voog31, C Hulin32, M Attal33,
P Moreau34, T Facon2
1Oncologie Hématologique Et Thérapie Cellulaire, Chu Poitiers, Poitiers, 2Chu
Lille, Lille, 3Chu Lyon Sud, Lyon, 4Chu Reims, Reims, 5Ch La Roche Sur Yon,
La Roche Sur Yon, 6Ch Bayonne, Bayonne, 7institut Bordet, Bruxelles, 8Ch
Clamart, Clamart, 9Chu Nimes, Nimes, 10Centre Henri Becquerel, Rouen,
11Cancer Research Center, Toulouse, 12Chu Limoges, Limoges, 13Chu Henri
Mondor, Creteil, 14Ch Avignon, Avignon, 15Chu Dijon, Dijon, 16Chu Besançon,
Besancon, 17Ch Périgueux, Perigueux, 18Institut Bergonié, Bordeaux, France,
19Universitair Ziekenhuis Gent, Gent, Belgium, 20Ch Chalon Sur Saone, Chalon
Sur Saone, 21Ch Corbeil Essonnes, Corbeil Essonnes, 22Institut Curie, Paris,
23Chu Versailles, Versailles, 24Chu De Rennes, Rennes, 25Ch Colmar, Colmar,
26Ch Meaux, Meaux, 27Polyclinique Bordeaux Nord, Bordeaux, 28Groupe Hos-
pitalier Pitié Salpétrière, Paris, 29Ch Mulhouse, Mulhouse, 30Ch Metz-Thionville,
Metz-Thionville, 31Centre Jean Bernard, Le Mans, 32Chru Nancy, Nancy, 33chu
Toulouse, Toulouse, 34Chu Nantes, Nantes, France
Background: Melphalan plus prednisone and bortezomib combination is the
most frequent standard of care used upfront for newly diagnosed elderly myelo-
ma (eNDMM). Despite significant improvements with bortezomib, such as sub-
cutaneous administration and weekly schedule, safety profile issues remain with
MPV, that only can be resolved with lowering the doses, albeit of the potential
loss of efficacy. Carfilzomib, a novel generation proteasome inhibitor, has differ-
ent safety profile with absence of neuropathy. Carmysap, a phase I/II trial of
twice weekly Carfilzomib plus MP in eNDMM, demonstrated carfilzomib MTD at
36mg/m2. The safety profile appeared otherwise good for this frail population.
Aims: We hypothesized that Carfilzomib can be used on a weekly schedule
allowing to increase the dose of Carfilzomib given its positive safety profile.
Methods: IFM2012-03 (carmysap weekly) is a phase 1/2 multicenter open
label single arm study to determine MTD during the phase 1 part and VGPR+CR
rate (IMWG criteria) during the phase 2 part of KMP (Carfilzomib Weekly Plus
Melphalan and Prednisone) regimen. The inclusion/exclusion criteria of interest
were eNDMM (65 and older), with CRAB and measurable disease, with
absolute neutrophils ≥1G/L, untransfused platelet count ≥75G/L, hemoglobine
≥8.5g/dL and clairance creatinine ≥30ml/min.
Induction comprised nine 5 weeks cycles. Carfilzomib is given 36, 45, 56 and
70 mg/m2 on days 1, 8, 15, 22 IV route in combination to oral Melphalan
0.25mg/kg/j and oral prednisone 60mg/m2, both on days 1 to 4.
Maintenance: Carfilzomib. 36 mg/m2 weekly, every two weeks IV route for 1
year. Melphalan and Prednisone is not pursued at maintenance. Analysis is
done on an Intent to Treat. Recruitment was 6 patients per cohort, 3 DLTs
meant MTD at the lower N-1 dose. The following are defined as DLTs: Any
hematologic toxicity of grade 4 intensity or preventing administration of 2 or
more of the 4 carfilzomib doses of the first treatment cycle; Grade ≥3 febrile
neutropenia; Grade ≥3 gastrointestinal toxicities; Any other grade ≥3 nonhema-
tologic toxicity considered related to CMP by the principal investigator; Grade
≥3 peripheral neuropathy persisting for more than 3 weeks after discontinuation
of study drugs. We report herein the phase 1 part of the study with the 2 cohorts
at 70mg/m2.
Results: 32 NDMM recruited, 30 treated in the study, 6 per cohort at 36 mg/m²
carfilzomib +MP, then 45, 56, and finally at 70mg/m². At the end of the first 70
cohort, the DSMB decided to add a second 70 cohort. The median age was 76
with 15 patients older than 75, sex ratio M/F 1.2, R-ISS 2 and 3 in 80%. There
was one DLT at 36 mg/m² carfilzomib (grade 4 lymphopenia), one at 45 (lysis
syndrome complicated with grade 4 renal insufficiency, two at 56 (cardiac insuf-
ficiency grade 3 and febrile neutropenia grade 3) and 2 at 70 (vomiting grade
3 and liver cholestase enzyme grade 3). As a whole for the study, the ORR is
87.5%, with 33% at least in CR. At data cut-off, with a median follow-up at 12
months, one patient had progressed and one patients had died of cardiac dys-
function considered related to Carfilzomib at the dose of 56mg/m2. Along with
the previous 2 patients, 2 other patients have stopped treatment for lysis syn-
drome (at 45) and pulmonary hypertension later in the disease course on cycle
5 at 56. Overall, there are 22 SAE reported for a total of greater than 200 cycles
administered of KMP. An extra 3 patients have had Carfilzomib dose reduction,
2 patients at 36 from 45 and one at 45 from 56, for neutropenia grade 4, throm-
bocytopenia grade 4, and dyspnea grade 3, respectively.
Summary/Conclusions: IFM2012-03, the study of KMP, Carfilzomib (Kyprolis)
plus Melphalan and Prednisone in elderly NDMM has not reached MTD up to
70mg/m2 of carfilzomib. The RP2D could then be at 70 for carfilzomib. KMP
appears feasible and manageable, the primary cause of AEs coming from dose
adaptation of Melphalan in very elderly NDMM. Updated data will be presented
at ASCO.
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IMPROVED EFFICACY AFTER INCORPORATING AUTOLOGOUS STEM
CELL TRANSPLANT (ASCT) INTO KRD TREATMENT WITH CARFILZOMIB
(CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE (DEX) IN NEWLY
DIAGNOSED MULTIPLE MYELOMA
A Jakubowiak1,*, N Raje2, R Vij3, D Reece4, J Berdeja5, D Vesole6, S Jagannath7,
C Cole8, M Faham9, J Nam1, L Stephens1, E Severson1, A Revethis1, B Wolfe1,
S Rosebeck1, S Gurbuxani1, C Rosenbaum1, J Jasielec10, D Dytfeld11,
K Griffith8, T Zimmerman1
1University of Chicago, Chicago, IL, 2Massachussetts General Hospital, Boston,
MA, 3Washington University, Saint Louis, MO, United States, 4Princess Mar-
garet Cancer Centre, Toronto, Canada, 5Sarah Cannon Research Institute,
Nashville, TN, 6John Theurer Cancer Center, Hackensack, NJ, 7Mount Sinai
Medical Center, New York, NY, 8University of Michigan, Ann Arbor, MI, 9Adaptive
Biotechnologies, Seattle, WA, 10Northshore University Health System,
Evanston, IL, United States, 11NJ University of Medical Sciences, Poznan,
Poland
Background: In a phase 1/2 trial (N=53), extended treatment with KRd without
(w/o) ASCT was highly active in newly diagnosed myeloma (NDMM) with stringent
complete response (sCR) 55% and 3-year progression-free survival (PFS) 79%.
Aims: In a subsequent phase 2 trial, we are evaluating whether extended KRd
can be further improved by incorporating ASCT (KRd+ASCT). We report results
from both trials after completion of enrollment into KRd+ASCT and after com-
pletion of KRd w/o ASCT (median follow-up [f/u] 4 years) as a historical control.
Methods: Both studies enrolled patients (pts) with NDMM based on similar eli-
gibility criteria except KRd+ASCT excluded transplant ineligible pts. The treat-
ment schemas were generally similar between studies. In KRd+ASCT, pts
received: four 28-day cycles of induction with CFZ IV 36 mg/m2 on Days (D) 1-
2, 8-9, 15-16 (CFZ 20 mg/m2 for D1-2, C1 only), LEN PO D1 21 at 25 mg, DEX
PO 40 mg/wk; followed by stem cell collection (SCC), melphalan 200 mg/m2
and ASCT; then KRd consolidation (C5-8) using the same doses and schedule
except LEN 15 mg in C5 with the option to escalate to prior dose, and DEX
reduced to 20 mg/wk; then KRd maintenance (C9-18) using the same doses
as in C8 except CFZ on Days 1-2, 15-16 only. In KRd w/o ASCT, transplant-eli-
gible pts underwent SCC after C4 then resumed KRd, and KRd maintenance
was longer (C9-24). Both studies recommended single-agent LEN off study.
The primary endpoint in KRd+ASCT is sCR at the end of C8. We hypothesized
that an improvement of sCR from 30% at the end of C8 (historical KRd w/o
ASCT) to >50% (KRd+ASCT) represents added benefit of ASCT with 5% type
I error (2 sided) and supports further evaluation. Minimal residual disease
(MRD) is evaluated by 10-color multiparameter flow cytometry (MFC, threshold
10-4-10-5) and by next-generation sequencing (NGS, LymphoSIGHTTM, thresh-
old at 10-6 for MRD negativity).
Results: The current KRd+ASCT study enrolled 76 pts with 72 evaluable. Base-
line characteristics were comparable between the KRd+ASCT and KRd w/o
ASCT study populations, including median age (59 and 59y) and high-risk
IMWG cytogenetics (36% and 33%). In the ongoing KRd+ASCT, 69 pts pro-
ceeded to ASCT at data cut-off (Jan 1, 2016), 50 completed KRd consolidation,
and 26 KRd maintenance, with remaining pts on treatment, except 1 patient
who progressed prior to transplant. At the end of C8, sCR was 72% for
KRd+ASCT (n=50) vs 30% for KRd w/o ASCT (n=44) and 88% (n=26) vs 51%
(n=41) at the end of C18. At median f/u of 17.8 months, 2-year PFS was 99%
for KRd+ASCT vs 92% for KRd w/o ASCT at median f/u of 47.5 months. In
KRd+ASCT, MRD by MFC was negative in 94% of pts tested (n=31) at the end
of C8 and 95% of pts tested (n=19) at the end of C18. In KRd w/o ASCT, 4-year
PFS was 69% overall, 78% in MRD-negative pts vs 60% in positive/unknown
pts by MFC, and 100% in pts with MRD negative status by NGS. Updated MRD
analyses and outcomes based on MRD status by both MFC and NGS will be
presented at the meeting. The types and rates of adverse events (AEs) pre-
and post-ASCT were comparable to AEs in KRd w/o ASCT.
Summary/Conclusions: Recognizing limitations of cross-study comparisons,
KRd+ASCT shows superior outcomes vs historical KRd w/o ASCT, supporting
further evaluation in the randomized setting. Both KRd studies compare favor-
ably to other NDMM studies.
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WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE
(WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB
(WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE
MYELOMA (NDMM)
S Bringhen1,*, L De Paoli2, A Larocca1, S Ballanti2, F Gentilini2, AM Liberati2,
R Passera3, A Bernardini1, F Esma1, P Galieni2, M Offidani2, P Corradini2,
G Gaidano2, M Boccadoro1, P Sonneveld4, A Palumbo1
1Myeloma Unit, Division of Hematology, University of Torino, Torino, 2Italian
Multiple Myeloma Network, GIMEMA, 3Divison of Nuclear Medicine 2, Azienda
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Background: Carfilzomib is a novel second-generation proteasome inhibitor
approved as a single agent and in combination with lenalidomide and dexam-
ethasone for the treatment of relapsed MM. The approved schedule of carfil-
zomib is twice-weekly, on days 1, 2, 8, 9, 15, and 16 of 28-day cycles. In a
recent phase I/II study in relapsed/refractory patients (pts) a more convenient
schedule of weekly Carfilzomib in combination with dexamethasone showed
to be effective (77% overall response rate; ORR) and safe (ASH 2015). The
ongoing phase III ARROW study compares weekly vs twice weekly Carfilzomib.
In the newly diagnosed setting, no data about weekly Carfilzomib are available.
We designed a phase 1/2 study of wKCyd for NDMM pts.
Aims: The primary objective was to determine the maximum tolerated dose
(MTD) of weekly Carfilzomib. The secondary objectives were to determine the
safety and the efficacy of wKCyd as induction and of wK as maintenance,
including response rate, progression-free survival and overall survival.
Methods: NDMM pts not eligible for autologous stem cell transplantation due to
age or co-morbidities were enrolled. Carfilzomib was administered intravenously
on days 1,8,15; cyclophosphamide orally on days 1, 8, 15 and dexamethasone
orally once weekly. Dose escalation used a standard 3+3 schema with dose-lim-
iting toxicities (DLTs) assessed during cycle 1. Three dose levels were studied
with Carfilzomib escalated from 45 to 70 mg/m2 with the standard doses of
cyclophosphamide 300 mg/m2 and dexamethasone 40 mg. After completion of
9 28-day cycles, patients receive 28-day maintenance cycles with Carfilzomib
(days 1, 8, 15) at the MTD defined by the phase I study until disease progression
or intolerance. Adverse events were graded by NCI-CTCAE v4. Response was
assessed according to the modified International Uniform Response Criteria.
Table 1. Adverse events of any grade and grade ≥3 occurring in ≥5% of
patients during induction and maintenance.
Results: Results of dose escalation phase 1 study have been previously report-
ed (Palumbo A et al, Blood 2014), the MTD of weekly Carfilzomib was estab-
lished as 70 mg/m2. Results are presented for all patients treated with KCyd
at the Carfilzomib MTD in both the phase 1 (n=3) and phase 2 (n=51) portions
of the study. Among these 54 pts, median age was 72 years (range 60-85),
33% had ISS stage III, 49% had unfavorable FISH profile [t(4;14) or t (14;16)
or del17p, del1 or amp1]. Median Carfilzomib treatment duration was 9.1
months (range 0.13-25.4). During induction, the ORR was 88%, the very good
partial response (VGPR) rate was 71%, the complete response (CR) rate was
12%. Twenty-nine pts could be evaluated for maintenance. After a median
duration of maintenance of 14.5 months, 7 pts (35%) improved response. Dur-
ing maintenance, the ORR was 95%, the VGPR rate was 80%, the CR rate
was 40%, including a stringent CR rate of 20%. The 1-year progression-free
survival was 79.4%. Ten pts (18%) discontinued treatment due to an adverse
event. The most common adverse events of any grade and of grade ≥3 during
induction and during maintenance are shown in the Table. Six pts died on study,
cause of death included disease progression, pulmonary edema, pulmonary
embolism, second primary malignancy, sudden death and pneumonia (1 each).
Summary/Conclusions: This is the first prospective study evaluating once
weekly Carfilzomib in NDMM. wKCyd as induction and wK as maintenance
appeared to be safe and effective. Responses became deeper with subsequent
cycles and improved during maintenance. The response rate observed with
weekly Carfilzomib compares favorably with similar studies with standard twice
weekly Carfilzomib infusion.
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A META-ANALYSIS OF OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE
MYELOMA TREATED WITH LENALIDOMIDE MAINTENANCE AFTER
HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANT
PL McCarthy1,*, A Palumbo2, SA Holstein3, V Lauwers-Cances4, MT Petrucci5,
PG Richardson6, C Hulin7, P Tosi8, KC Anderson6, D Caillot9, V Magarotto2,
P Moreau10, G Marit11, Z Yu12, M Attal4
1Blood and Marrow Transplant Program and Medicine Department, Roswell
Park Cancer Institute, Buffalo, NY, United States, 2University of Torino, Torino,
Italy, 3Roswell Park Cancer Institute, Buffalo, NY, United States, 4Departments
of Hematology and Biostatistics, Hôpital Purpan, Toulouse, France, 5University
La Sapienza, Rome, Italy, 6Jerome Lipper Multiple Myeloma Center, Depart-
ment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA, United States, 7Bordeaux Hospital University Center
(CHU), Bordeaux, France, 8Seràgnoli Institute of Hematology and Medical
Oncology, Bologna University, Bologna, Italy, 9Dijon University Hospital Center,
Dijon, 10University Hospital Hôtel-Dieu, Nantes, 11Centre Hospitalier Universi-
taire, Bordeaux, France, 12Celgene Corporation, Summit, NJ, United States
Background: Several studies demonstrate that lenalidomide (LEN) mainte-
nance post autologous stem cell transplant (ASCT) reduces the risk of disease
progression or death in patients with multiple myeloma (MM) by approximately
50% (Attal, NEJM, 2012; McCarthy, NEJM, 2012; Palumbo, NEJM, 2014).
However, these studies were not powered for overall survival (OS).
Aims: To conduct a meta-analysis assessing the effect of LEN maintenance
post ASCT on OS.
Methods: A prospectively planned meta-analysis assessed OS with LEN vs
placebo/no maintenance (control) after ASCT. A search identified 17 random-
ized controlled trials (RCTs) using LEN post ASCT. Three RCTs (IFM 2005-02,
CALGB 100104 [Alliance], GIMEMA RV-209) met prespecified inclusion criteria
(had patient-level data, had a control arm, and achieved database lock for pri-
mary efficacy analysis of patients with newly diagnosed MM receiving LEN
post ASCT). A March 2015 cutoff of the 3 RCTs enabled sufficient OS events
to test treatment effect (hazard ratio [HR]=0.78).
Figure A and Figure B.
Results: From 2005 to 2009, 1209 patients were randomized in the 3 RCTs to
receive LEN (n=605) 10 mg/day on days 1-21 (GIMEMA) or 1-28 (IFM and
CALGB) of 28-day cycles or control (n=604). With a median follow-up of 6.6
2 | haematologica | 2016; 101(s1)
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years, 491 patients (41%) had died. Baseline characteristics were generally
balanced in the pooled data. After induction and single (82%) or tandem (18%)
ASCT, 55% of patients achieved a complete response (CR) or very good partial
response (VGPR). Median OS for the LEN maintenance group was not reached
compared with 86 months for the control group (HR=0.74; 95% CI, 0.62-0.89;
log-rank P=.001; Figure A), and 5-, 6-, and 7-year OS were longer in the LEN
maintenance vs the control group (71% vs 66%, 65% vs 58%, and 62% vs
50%, respectively). Fisher’s combination test confirmed the significant OS ben-
efit in the meta-analysis (P=.001). Patients who achieved ≤PR post ASCT ben-
efited from LEN maintenance (HR=0.86; 95% CI, 0.65-1.15) as did patients
with CR/VGPR (HR=0.70; 95% CI, 0.54-0.90). OS benefit was generally con-
sistent across subgroups. Based on a heterogeneity test (Pignon, Lancet Oncol,
2001), the OS study results from the efficacy meta-analysis were considered
significantly heterogeneous (P=.047; Figure B) across studies for both the
intention-to-treat post-ASCT population and for all patients randomized. Poten-
tial factors contributing to the heterogeneity between the clinical trials were
explored and identified, including baseline/disease characteristics (such as
International Staging System stage, cytogenetics), study conduct, and second-
line therapy. Second primary malignancy data will be presented.
Summary/Conclusions: This large meta-analysis demonstrates that LEN
maintenance significantly prolonged OS vs control (placebo/no maintenance)
post ASCT, including in patients who achieved CR, demonstrating benefit in
patients in all response categories.
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UPFRONT OR RESCUE TRANSPLANT IN YOUNG PATIENTS WITH NEWLY
DIAGNOSED MULTIPLE MYELOMA: A POOLED ANALYSIS OF 529
PATIENTS
F Gay1,*, V Magarotto1, A Spencer2, F Di Raimondo3, L Pour4, V Scudla5,
M Genuardi1, AM Carella3, AM Liberati3, S Spada1, A Evangelista6, P Omedè1,
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D Ben Yehuda8, F Patriarca3, M Salvini1, P Corradini3, R Foà3, N Cascavilla3,
S Pulini3, MT Petrucci3, R Hajek9, M Boccadoro1, A Palumbo1
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Health-Monash University, Melbourne, Australia, 3Italian Multiple Myeloma Net-
work, GIMEMA, Italy, 4University Hospital Brno and Faculty of Medicine MU,
Brno, 5Department of Hemato-oncology, Faculty of Medicine and Dentistry,
Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech
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Background: In patients with newly diagnosed myeloma, upfront Melphalan
200 mg/m2 followed by ASCT (MEL200-ASCT) prolongs progression-free sur-
vival-1 (PFS1) in comparison with chemotherapy plus lenalidomide (CC+R) but
ASCT as salvage therapy at first relapse may still effectively rescue patients
who did not receive upfront ASCT.
Aims: The primary aim was to evaluate the long-term benefit of upfront ASCT
vs CC+R, including the impact of MEL200-ASCT vs CC+R in specific subgroups
of patients with different prognostic features. The secondary aim was to eval-
uate the efficacy of salvage ASCT in patients receiving upfront CC+R.
Methods: We performed an individual patient data meta-analysis of patients
enrolled in 2 phase III trials (RV-MM-209 and EMN-441) that randomized
patients to MEL200-ASCT vs CC+R. Primary endpoints were PFS1, PFS2,
overall survival (OS). Subgroup analyses according to baseline features, pro-
tocol and post MEL200-ASCT/CC+R maintenance were performed. We calcu-
lated the odds ratio (ORs) with 95% confidence intervals (CIs), as measure of
association between the upfront and rescue therapy (MEL200-ASCT vs CC+R
followed by rescue ASCT) with the 4-year risk of second progression/death
(PFS2) and death (OS).
Results: In the pooled analysis, 268 patients were randomized to MEL200-
ASCT and 261 to CC+R. Median follow-up was 46 months. MEL200-ASCT
significantly improved PFS1 in comparison with CC+R (median 42 vs 24
months, HR 0.53; P<0.001), with a significant advantage in all the subgroups
analyzed. In patients with R-ISS Stage I the 4-year PFS1 was 53% with
MEL200-ASCT vs 36% with CC+R; in patients with R-ISS Stage II/III the 4-
year PFS1 was 41% with MEL200-ASCT vs 23% with CC+R. 134 MEL200-
ASCT patients and 176 CC+R patients experienced first progression. 125
patients in the MEL200-ASCT group and 174 in the CC+R group received sec-
ond-line therapy. MEL200-ASCT significantly prolonged PFS2 in comparison
with CC+R (4-year PFS2: 71% vs 54%, HR 0.53, p<0.001). The long-term
advantage of MEL200-ASCT was evident in good and bad prognosis patients:
in patients with R-ISS Stage I, the 4-year PFS2 was 83% with MEL200-ASCT
vs 71% with CC+R; in patients with R-ISS Stage II/III the 4-year PFS2 was
67% with MEL200-ASCT and 48% with CC+R. The PFS1 and PFS2 advantage
translated into a significant OS benefit for patients randomized to MEL200-
ASCT in comparison with CC+R (4-year OS: 84% vs 70%, HR 0.51, P<0.001).
Subgroup analyses of OS were limited by a lower number of events but the
advantage with MEL200-ASCT was still evident in most of the subgroups ana-
lyzed. At data cut off, in the MEL200-ASCT group, 9% of patients received
again ASCT, 68% bortezomib, 16% immunomodulatory agents (IMIDs), 7%
other therapies. In the CC+R group, ASCT was recommended but not manda-
tory at relapse, and the choice of therapy was based on patient’s will and physi-
cian discretion according to patient eligibility to ASCT: 53% of patients received
ASCT, 38% bortezomib regimens, 6% IMIDs, and 3% other therapies. Upfront
ASCT regardless of salvage therapy significantly reduced the risk of second
progression/death (OR 0.31; P<0.001) and death (OR 0.41; P=0.003) at 4 years
in comparison with CC+R followed by salvage ASCT.
Summary/Conclusions: MEL200-ASCT significantly improved PFS1, PFS2
and OS in comparison with CC+R in good and bad prognosis patients. Upfront
ASCT significantly reduced the risk of death in comparison with CC+R and sal-
vage ASCT. These data confirm the role of upfront ASCT as the standard
approach for all young myeloma patients.
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BASELINE TOTAL METABOLIC VOLUME (TMTV) PREDICTS THE OUTCOME
OF PATIENTS WITH ADVANCED HODGKIN LYMPHOMA (HL) ENROLLED
IN THE AHL2011 LYSA TRIAL
O Casasnovas1,*, S Kanoun2, I Tal3, AS Cottereau4, V Edeline5, P Brice6,
R Bouabdallah7, G Salles8, A Stamatoullas9, J Dupuis10, O Reman11,
T Gastinne12, B Joly13, K Bouabdallah14, E Nicolas-Virelizier15, M Andre16,
N Mounier17, C Ferme18, M Meignan4, A Berriolo-Riedinger2
1Hematology, Hopital Le Bocage-CHU Dijon, 2Nuclear Medicine, Centre GF
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Lyon, France, 16Hematology, CHU Dinant Godinne, Yvoir, Belgium, 17Hema-
tology, CHU Nice, Nice, 18Hematology, Institut Gustave Roussy, Villejuif, France
Background: The TMTV assessed on the baseline FDG-PET is a novel
approach of tumor burden measurement quantifying the most active part of
the tumor. It has been reported to influence HL outcome in a retrospective
series (Kanoun et al, EJNM 2014; 41: 1735).
Aims: We designed a study evaluating the TMTV prognosis value in patients
(pts) prospectively enrolled in a phase III randomized trial testing a treatment
strategy driven by PET, compared to a standard treatment not monitored by PET.
Methods: Eligible pts for the present study had to be enrolled in the AHL2011
trial (NCT01358747) and to have a baseline PET (PET0) available for central
review and TMTV calculation. Pts were 16-60 y, with a previously untreated
advanced HL (Ann Arbor stage III, IV or high risk IIB) and were randomly
assigned to a treatment strategy driven by PET after 2 escalated BEACOPP
(BEA) cycles (PET2), delivering 4 cycles of ABVD for PET2 negative (PET2-)
pts and 4 cycles of BEA for PET2 positive (PET2+) pts or a standard treatment
not monitored by PET and delivering 6 cycles of BEA. PET2 were centrally
reviewed and interpreted according to Deauville criteria. TMTV was computed
on PET0 by summing the metabolic volumes of the individual lesions using
the 41% SUVmax thresholding method already described in lymphoma
(Meignan et al, EJNM 2014; 41: 113).
Results: 392 pts with a median age of 30 years were included: 64% were
male, 89% had stage III/IV, and 59% an IPS≥3. Median TMTV was 200 ml (23-
2149). Using a X-tile method a 350ml cut off value was firstly identified in a
training set of patients (n=262; 67%) randomly obtained from the whole popu-
lation, and found to predict PFS in both the training and validation sets of pts
(n=130; 33%). With a median follow up of 16 months, 2y-PFS was 81% vs
93% in pts with high and low TMTV respectively in the whole population
(p=0.0015; HR=3). PET2 positivity was also related to a lower 2y-PFS com-
pared to PET2- pts (76% vs 92%; p<0.0001). Then 3 groups could be identified:
pts with either [high TMTV and PET2+ (n=23; 6%)], or [high TMTV and PET2-
, or low TMTV and PET2+ (n=103; 27%)], or [low TMTV and PET2- (n=261;
67%)] had a 61%, 88%, 94% 2y-PFS respectively (p<0.0001).
Summary/Conclusions: The TMTV predicts the outcome of young advanced
HL pts independently of the early metabolic response to treatment. The com-
bination of TMTV and PET2 allows identifying 3 subsets of HL pts with signif-
icantly different outcome that may help clinician to better tailor therapy.
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LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE
HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN
HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS
PJ Bröckelmann*, H Görgen, A Plütschow, S Kreissl, C Bürkle, S Borchmann,
M Fuchs, P Borchmann, A Engert
Department I of Internal Medicine and German Hodgkin Study Group (GHSG),
University Hospital of Cologne, Cologne, Germany
Background: Combined modality treatment (CMT) is currently considered as
standard of care in patients with early-stage HL. During the years, a gradual
toxicity reduction through balancing extent and intensity of radiotherapy (RT)
and chemotherapy was achieved.
Aims: We evaluated long-term follow-up (FU) of pivotal trials, to ensure the
applied therapies are safe and beneficial for our patients.
Methods: We analyzed updated FU data of 4299 patients who were treated
for primary early-stage HL in previously published GHSG trials between 1993
and 2003. Patients with favorable disease were randomized in HD 7 to either
CMT with 2xABVD or to 40Gy extended-field (EF)-RT only, and in HD10 to
either 4x or 2xABVD and 20 or 30Gy involved-field (IF)-RT, respectively.
Patients with unfavorable HL in HD8 had received either 30Gy IF- or extend-
ed-field (EF)-RT after 2xCOPP/ABVD and in HD11 either 20 or 30Gy IF-RT
after 4xABVD or 4xBEACOPPbas. Progression-free (PFS) and overall survival
(OS) were analyzed according to the Kaplan-Meier method. Cumulative inci-
dences of secondary neoplasias (SN) were calculated and compared between
groups using Pepe&Mori’s test. Type of SN, salvage therapies and causes of
death were analyzed descriptively.
Results: The median FU was 120 and 98 months for patients in HD7 (n=627)
and HD10 (n=1190) and 153 and 106 months for patients in HD8 (n=1064)
and HD11 (n=1395), respectively. New FU data beyond the last evaluation
was available for only <50% of patients and last information was obtained
from population registries in 18-30%. In HD7, CMT was superior to EF-RT
with 15-year PFS estimates of 72.8% vs 52.2% and a hazard ratio (HR) of
0.45 (0.33-0.61). No significant differences were observed regarding OS (HR:
0.81 (0.56-1.18)) or the cumulative incidence of SN. In HD10, non-inferiority
of 2xABVD+20Gy IF-RT to more intensive treatment was confirmed with HRs
of 1.0 (0.6-1.5) and 0.9 (0.5-1.6) and 10-year estimates of 87.2% and 94.1%
for PFS and OS, respectively. No significant differences in SN were observed.
In HD8, non-inferiority of IF- compared to EF-RT was confirmed with HRs of
0.98 (0.76-1.25) and 0.88 (0.66-1.16) for PFS and OS, respectively. We
observed a non-significant trend towards more SN (15-year cumulative inci-
dence 17.1% and 14.2%, respectively, p=0.3) and deaths from SN after EF-
RT. In HD11, no difference in PFS was found with intensified chemotherapy
compared to standard ABVD with either 30Gy IF-RT (HR: 1.1 (0.7-1.5)) or
20Gy IF-RT (HR: 0.8 (0.6-1.1). In contrast, there was a significant difference
in 10-year PFS rates estimated at 77.6% versus 83.3% to the detriment of
ABVD-treated patients who had received 20Gy instead of 30Gy IF-RT with a
HR of 1.5 (1.0-2.1). After BEACOPPbas, 20Gy IF-RT was non-inferior to 30Gy
IF-RT with a HR of 1.0 (0.7-1.5) for PFS. No differences in terms of OS or
SN could be observed.
Summary/Conclusions: Long-term FU data of four large randomized GHSG
phase III trials confirm the current risk-adapted therapeutic strategies in early-
stage HL. Outcome in patients with early-stage favorable HL is optimal with
CMT consisting of 2xABVD+20Gy IF-RT with 10-year PFS and OS estimates
of 87.2% and 94.1%, respectively. 10-year PFS and OS estimates in early-
stage unfavorable HL treated with 4xABVD+30Gy IF-RT leave room for
improvement with 83.3% and 90.0%, respectively. Moderate intensification of
chemotherapy does not improve efficacy outcome but might facilitate the reduc-
tion of IF-RT-dose. Continued FU is necessary to assess long-term effects of
currently applied risk-adapted therapies.
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ADJUSTMENT OF THERAPY FOR HODGKIN LYMPHOMA BASED ON
INTERIM PET IS BENEFICIAL AND RADIOTHERAPY MAY BE SUBSTITUTED
WITH CHEMOTHERAPY IN PATIENTS WITH NEGATIVE INTERIM STUDY:
FINAL RESULTS OF H2 TRIAL
EJ Dann1,*, O Bairey2, R Bar-Shalom3, T Mashiach4, E Barzilai4, A Korenberg5,
L Akria6, T Tadmor7, K Filanovsky8, U Abadi9, O Kagna4, R Ruchlemer3,
R Abdah-Bortnyak4, N Goldschmidt10, R Epelbaum4, NA Horowitz4, D Lavie10,
D Ben-Yehuda10, O Shpilberg11, O Paltiel10
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ical Center, Zerifin, 6Galil Medical Center, Nahariya, 7Bnai Zion Medical Center,
Haifa, 8Kaplan Medical Center, Rehovot, 9Meir Medical Center, Kfar Saba,
10Hadassah Medical Center, Jerusalem, 11Assuta Medical Center, Tel-Aviv,
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Background: The main goal of therapy for Hodgkin lymphoma (HL) is to max-
imize response while minimizing long-term treatment-related toxicity.
Aims: The study aimed to explore the effect of therapy adjustment based on
early interim PET/CT (PET-2) on the HL patient outcome.
Methods: This prospective multicenter study recruited patients (pts) between
9/2006-8/2013. Pts with classic HL aged 18-60 years, stages I-IV were eligible.
Early HL (ED) was categorized into favorable (EF) and unfavorable (EU) dis-
ease. After 2 ABVD cycles, pts with EF and negative PET-2 underwent involved
site radiation therapy (ISRT) and EU pts received 2 more ABVD cycles (total
4) followed by ISRT In pts with negative PET-2, ISRT could be substituted by
two further ABVD courses. Pts with positive PET-2 received a total 4 or 6 ABVD
courses for EF and EU, respectively, followed by obligatory ISRT. Pts with
advanced HL (AD) (B symptoms or stages III/IV) were assigned to therapy
based on IPS: those with IPS 0-2 initially received ABVDx2 while pts with IPS
≥3 received escalated BEACOPP (EB) x2. If PET-2 was negative, therapy was
completed using ABVDx4. If PET-2 was positive, therapy was escalated to EB
with ISRT given to bulky mediastinal masses. A dynamic visual score (DS)
comparing PET-2 to baseline PET was used for decision-making regarding
therapeutic changes (Dann et al, Haematologica, 2010).Briefly, for pts with an
initial single site of uptake, PET-2 was considered positive if the intensity of
residual uptake was ≥normal mediastinal or liver blood pool (the hottest of the
two). For pts with multiple initial sites of HL, disappearance of uptake in all
sites or a residual single site uptake with markedly lower intensity on PET-2
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was considered a negative result. The Deauville score (performed post-hoc)
less or equal to 3 was defined as negative.
Results: HL progression was documented in 50 out of 355 pts, of whom 42
relapsed and 8 had primary progressive disease. PET-2 was negative in 86%
and positive in 7% of pts, according to both DS and Deauville score (93% con-
cordance by both systems; kappa 0.627). At a median follow-up of 47 months
(4-114), among 170 ED pts a highly significant difference in the 5-year pro-
gression-free survival (PFS) was demonstrated between those with negative
and positive PET-2 [0.91 and 0.68, respectively; hazard ratio (HR) 3.66; 95%
CI 1.4-9.7; p=0.009] by DS. The differences were even more marked after re-
assessment using the Deauville criteria (0.91 compared to 0.47,HR 7.6; 95%
CI 2.7-21.4 P<0.001). The 5-year PFS for pts with a negative PET-2 who did
not receive ISRT was 0.94 compared to 0.89 for the group receiving ISRT. In
the AD group (n=185), 18% (n=33) of pts progressed and 15% (n=27) had a
positive PET-2. The 5-year PFS for the whole group, PET-2 negative and pos-
itive subgroups was 0.80, 0.82 and 0.68, respectively (p=0.07). The 5-year OS
for ED and AD groups was 0.99 and 0.97, respectively.
Summary/Conclusions: Seventy six percent of relapses still occur in pts with
a negative PET-2. A positive PET-2 portends an adverse prognosis at all stages
of HL. ED pts with positive PET-2 have a poor prognosis if their therapy is con-
tinued with ABVD followed by ISRT. ISRT does not appear to improve the out-
come for ED pts with negative PET-2. The prognosis of AD patients with positive
PET-2 could be improved with administration of 4 additional EB cycles. If PET-
2 is negative, EB can be safely changed to ABVD in AD pts.
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PET-CT ADAPTED THERAPY AFTER 3 CYCLES OF ABVD TO ALL STAGES
OF HODGKIN LYMPHOMA. GATLA TRIAL HL-05
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Background: Positron emission tomography using fluoro-2-deoxy-d-glucose
(PET-CT) is an important tool for treatment response assessment in Hodgkin
Lymphoma (HL) treated with ABVD. 
Aims: Adapt therapy to all stage of Hodgkin Lymphoma to the result of PET-
CT after 3 ABVD (PET-CT+3). Reduce therapy in pts. who achieve early CR
with negative PET-CT. Intensify treatment, in pts. with positive PET-CT after 3
ABVD. Achieve CR, event free survival (EFS) and overall survival (OS), as
good as in our historical control (LH -96), when we used 3-6 ABVD adapted to
stage plus involved field radio therapy (IFRT) in all pts
Methods: Four hundred and one newly diagnosed pts. with HL Stages I-IV
have been included (LH-05). All pts. received 3 ABVD and were evaluated with
a PET-CT (PET-CT +3). Pts. with a negative PET-CT+3 were considered in CR
and received no further therapy. Pts in partial response (PR) completed 6 ABVD
and IFRT on PET-CT positive areas. Pts with less than PR received salvaje
chemotherapy. Three hundred and seventy seven pts have been evaluated.
With a median age of 35 yrs.and 38% age older than 59 years. Two hundred
and twenty eight 860%9 presented with localized stage (I-IIA) and 144 (40%)
presented with advanced stage (IIB-III-IV).
Figure 1.
Results: Of all pts. 260 (69%) achieved CR with negative PET-CT+3, 117
(31%) were PET-CT+3 positive, 101 pts. were in PR with chemo-sensitive dis-
ease and completed a total of 6 ABVD+IFRT in PET-CT positive areas. Eighty-
two (81%) achieved CR. With a median follow up of 68 months the EFS and
OS at 3 years is 80% and 96% respectively. Pts with negative PET-CT +3 had
an EFS of 90% both for localized and advances stage, compared to 58% for
pts. with positive PET-CT+3 and loc. stage and 5%for with a positive PET-
TC+3 and adv. stage. We perform a multivariate analysis for EFS which includ-
ed age, stage, IPS, bulky disease, extranodal areas and the result of the PET+3.
This last parameter together with age were the only ones with statistical signif-
icance (p=0.001 and 0.046 respectively), finding stage at diagnosis not signif-
icant. When comparing the results LH-05 with our previous clinical trial (LH-96)
there is no difference in EFS and OS at 36 months (83% vs 85% and 97 vs
96%) but in LH-05 only 30% received more than 3 cycles of ABVD and IFRT
compared to 61% and 100% in LH-96. This reduces the exposure to chemo
and radiotherapy.
Summary/Conclusions: With PET-CT adapted therapy for all stages of HL
after 3 ABVD, 260 pts. received only 3 cycles of ABVD as initial therapy with
an EFS and OS of 91% and 98% at 36 months. In the Cox regression model,
PET-CT at completion of treatment was the most significant factor associated
to EFS. Treatment with 3 cycles of ABVD can be adequate for pts. with negative
PET-CT+3 regardless their stage at diagnosis
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OSTEONECROSIS AS A TREATMENT COMPLICATION IN HODGKIN LYMPHOMA
PATIENTS: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP
(GHSG)
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Background: Hodgkin Lymphoma (HL) is one of the best curable hematological
malignancies. Therefore, a major focus for future improvements in the treatment
of this disease will be a reduction of short- and long-term side effects.
Osteonecrosis (ON) has been reported as an infrequent but sometimes debil-
itating late effect of HL therapy in a few case report series.
Aims: The aim of the present study is to provide a detailed analysis of ON as
a late effect after multimodality treatment for HL.
Methods: A total of 12,083 patients treated within the GHSG trials HD10-15
and HD18 between 05/98 and 07/14 were evaluated. During the trial duration
and prolonged follow-up, complications and late effects of trial participants are
registered. Using a trial-database-aided search for ON and related symptoms
as well as manual chart review, 66 incident cases of osteonecrosis were iden-
tified. Detailed information on patient characteristics, localizations, interventions
and outcomes were collected. Risk factors for ON after HL therapy were ana-
lyzed by multivariate logistic regression.
Results: The cumulative incidence of ON was 0.16% [CI: 0.08-0.30] in early
(favorable or unfavorable) stage HL (n=10) and 0.93% [CI: 0.71-1.21] in
advanced stage HL (n=54). The majority of ON cases were male (75%). A total
of 66 patients had a total of 140 ON. Most patients had more than one area
affected (71%) and the most commonly affected location was the femoral head
(73%). Most patients with available information needed surgical intervention
(54%) and had continuing symptoms despite treatment (66%), including inability
to walk and severe pain. Joint-saving interventions were attempted and suc-
cessful in 6 of 8 patients. The first ON event occurred within the first 3 years
after HL diagnosis in 83% of cases. Peak incidence was observed in the second
year after diagnosis with 41% of cases occurring between 12 and 24 months
after therapy. In a multivariate logistic regression including all patients, male
gender (OR 2.1; CI: 1.2-3.7) and advanced stage (OR 3.9; CI: 2.3-6.9) were
identified as risk factors for ON. Because ON was a very rare complication in
early stage HL, the following results focused on survivors of advanced stage
HL. The median cumulative prednisone dose in ON cases after advanced stage
HL was 8,400mg (range: 3,920-10,800) versus 7,350mg (range: 0-16,800) in
not affected patients. In a multivariate logistic regression model including only
patients with advanced stage HL, young age (OR 0.7 for each additional 10
years of age; CI: 0.5-0.9) and a higher cumulative dose of prednisone during
therapy (OR 1.3 for each additional 1gr; CI: 1.1-1.5) were identified as additional
risk factors. Nodal pain after alcohol ingestion (p=0.78), radiotherapy (p=0.29),
a large mediastinal tumor (p=0.13), international prognostic score (IPS) (p=0.09)
and body-mass-index (BMI) (p=0.99) were evaluated as potential risk factors
but did not significantly influence the risk for ON.
Summary/Conclusions: We provide the largest and most comprehensive
analysis of ON after HL therapy performed so far. ON after HL therapy, despite
being an infrequent event, often leads to significant disease burden in affected
patients and sometimes has dramatic effects on mobility and quality of life. The
described risk factors and peak incidence timeframe could be helpful in order
to identify patients at high risk for ON. Early evaluation of these often young
patients is recommended in case of symptoms suggestive of ON. This might
help to identify affected patients early and attempt bone and joint saving inter-
ventions whenever possible. High prednisone doses were identified as a risk
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factor for ON and future modifications of HL therapy leading to a decrease in
the cumulative corticosteroid dose might be able to decrease the incidence of
ON after HL therapy in the future.
Myeloproliferative neoplasms - Clinical 1
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OUTCOMES OF 121 PREGNANCIES IN PATIENTS WITH POLYCYTHEMIA
VERA (PV)
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Background: Very limited data are available regarding pregnancy (preg) out-
comes in patients with PV, less than 40 pregs being reported in the literature.
Within the European LeukemiaNet we collected 121 pregs in 48 PV patients
from 7 centers in France, Italy, Serbia, Romania, Switzerland and Germany.
Aims: Outcomes of pregancies in patients with polycythemia vera (PV).
Methods: Pregs were categorized in two groups. Group 1 consisted of pregs
before the diagnosis of PV (n=39). Group 2 (n=82) included all pregs after the
diagnosis of PV. Most patients in group 2 received low dose aspirin during preg
and low molecular weight heparin after delivery until the 6th week postpartum.
The target hematocrit during preg was 40% and therapeutic phlebotomy was
performed, if needed. Iron supplementation was not advised during preg.
Results: Median age at diagnosis of PV was 29 yrs (range 18-40), median
age at delivery 32 yrs (21-43). 13 out of 48 patients (27%) had high-risk PV
due to severe thromboembolic complications either at the time of diagnosis
or during follow up. These included 5 Budd Chiari syndromes, 4 portal vein
thromboses, 2 superior sagittal sinus thromboses, 3 deep vein thromboses,
and one pulmonary embolism. In group 2, a planned medical interruption
was performed in 6/82 pregs due to patients´ choice. The outcome of another
6 pregs cannot be reported yet (still ongoing in 3 and missing in another 3).
Thus, a total of 70 pregs are evaluable at time of abstract submission in
group 2. In group 1 live birth was recorded in 19/39 pregs (49%), while 20
pregs were unsuccessful due to spontaneous abortion (n=9; 23%), stillbirth
(n=8; 21%) or late fetal loss (n=3; 8%). In contrast, outcome was significantly
better in group 2 with 54 live births out of 70 pregs (77%) [chi square,
p=0,002]. In group 2 we observed 12 (17%) spontaneous abortions, one
ectopic preg (1%) and 3 (4%) stillbirths. Interferon alpha was used in 12 high
risk cases with 10 live births (83%) and 2 spontaneous abortions. Concerning
maternal complications, the rate of severe thromboembolic events was similar
between the two groups (group 1: one pulmonary embolism with cardiogenic
shock (2,6%), group 2: two Budd Chiari syndromes in 3rd trimester (2,8%).
There were no deaths. Of note, the bleeding rate was significantly higher in
group 2 (8 minor and 3 major bleedings) which was probably due to the treat-
ment with aspirin and low molecular weight heparin in this group while only
one minor bleeding was observed in group 1 [chi square, p=0,036]. Most PV
patients’ hematocrit values spontaneously decreased during preg, thus phle-
botomies were mainly performed during the first trimester. 6 twin pregs were
managed in group 2, five of them resulted in live births, and one patient had
a spontaneous abortion in the 22th week.
Summary/Conclusions: This is the largest series of PV pregs reported to
date collected across the European LeukemiaNet network. The success rate
of pregs was significantly better (49% versus 77%, respectively) for patients in
whom the diagnosis of PV was known and appropriate management performed
according to current guidelines. This high success rate of almost 80% is encour-
aging in this higher risk PV population. However, despite the use of aspirin
and molecular weight heparin major thrombotic events still occur and an
increased bleeding rate is observed.
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INCREASED RISK OF SECOND MALIGNANCIES IN PATIENTS WITH
MYELOPROLIFERATIVE NEOPLASMS DIAGNOSED IN SWEDEN 1973-
2009. A POPULATION-BASED COHORT STUDY OF 9,379 PATIENTS
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Background: The risk of developing acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS) in patients with myeloproliferative neo-
plasms (MPNs) is well established. Less is known, however, about the risk of
non-hematologic malignancies in patients with MPNs.
6 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Aims: To assess the risk of developing a wide range of second malignancies in
a large population-based study of MPN patients compared to matched controls.
Methods: All patients diagnosed with MPNs and reported to the Swedish
Cancer Registry or the Inpatient Registry between 1973 and 2009 were
included. Four controls matched by age, sex, and region of residence were
randomly selected from the Register of Total Population. End of follow-up
was December 31st 2010. Patients and controls were excluded if they had
any malignancy prior to the MPN diagnosis or corresponding time for controls.
We identified incident cases of cancer during follow-up by cross-linking to
the Swedish Cancer Registry. Hazard ratios (HRs) with 95% confidence inter-
vals (CIs) were calculated using a Cox regression model. A landmark analysis
was performed in order to reduce detection bias, where all patients with a
new malignant diagnosis within one and two years respectively from the MPN
diagnosis were excluded.
Results: In total, 9,379 MPN patients and 35,682 controls were identified. The
MPN cohort included 4,502 males (48%) and 4,877 females (52%), and the
median age at MPN diagnosis was 67.5 years. We found an overall significantly
increased risk of non-hematologic cancer with an HR of 1.60 (95% CI 1.50-
1.71). The relative risk of developing a second malignancy was similar across
all MPN subtypes, men and women, and calendar periods of MPN diagnosis.
The non-hematologic malignancies with the greatest observed risk increase
included non-melanoma skin cancer (HR 2.92, 2.51-3.39), malignant melanoma
(HR 1.85, 1.36-2.53), kidney cancer (HR 2.85, 2.01-4.03), brain cancer (HR
2.60, 1.76-3.86), and endocrine cancers including thyroid cancer HR 2.41, 1.59-
3.64) (Table). MPN patients were also at a significantly increased risk of devel-
oping second malignancies of the lung, head and neck, pancreas, esophagus,
and stomach compared to matched controls. The risk of developing a non-
hematologic malignancy tended to increase with follow-up time after MPN diag-
nosis. The risk of developing a second hematologic malignancy was significantly
increased, the HRs for lymphoproliferative malignancies (including acute lym-
phoblastic leukemia) were 2.62 (2.06-3.34) and for AML 47.04 (33.17-66.69).
The relative risk of a second non-hematological and hematological malignan-
cies in MPN patients remained similarly significantly elevated in the landmark
analysis starting one and two years after the MPN diagnosis.
Table 1. Risk of different types of malignancies in patients with myelo-
proliferative neoplasms compared to matched controls. HR=hazard ratio,
CI=confidence interval, ALL=acute lymphoblastic leukemia.
Summary/Conclusions: This population-based study is, to our knowledge,
the largest to date to support an increased risk of non-hematologic and hema-
tologic malignancies in MPN patients. The reason behind the increased risk
are not fully understood, but several possible factors exist; a genetic propensity
to develop malignancies, acquired somatic mutations, an altered immune func-
tion and mutagenic cytoreductive treatments. Clinicians should be aware of the
increased cancer risk and direct adequate attention to new symptoms in MPN
patients.
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RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN
PATIENTS WITH POLYCYTHEMIA VERA (PV) AND A NONPALPABLE
SPLEEN: RESULTS FROM THE PHASE IIIB RESPONSE-2 STUDY
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Background: PV is a myeloproliferative neoplasm characterized by erythro-
cytosis, burdensome symptoms, and increased risk of thrombosis. A key treat-
ment goal is to maintain hematocrit (HCT) control. In the phase 3 RESPONSE
study, the JAK1/JAK2 inhibitor ruxolitinib was superior to best available therapy
(BAT) in maintaining HCT control without phlebotomy (PBT), normalizing blood
cell count, reducing spleen volume, and improving symptoms in HU-
resistant/intolerant PV patients (pts) with splenomegaly.
Aims: RESPONSE-2 is an open-label phase 3b study comparing RUX with
BAT in HU-resistant/intolerant PV pts without palpable splenomegaly.
Methods: HU-resistant/intolerant pts without palpable splenomegaly who
required PBT for HCT control were randomized 1:1 to RUX 10 mg bid or BAT.
The primary endpoint was the proportion of pts who achieved HCT control at
wk 28 (defined as the absence of PBT eligibility [HCT >45% and ≥3 percentage
points from baseline, or HCT >48%] from wk 8 to 28, with ≤1 PBT eligibility
from wk 0 to 8). The key secondary endpoint was the proportion of pts who
achieved complete hematologic remission (CHR) at wk 28. Other endpoints
included patient-reported outcomes and safety. The MPN-SAF TSS was used
to assess 10 PV-related symptoms, each on a scale of 0 (absent) to 10 (worst
imaginable). BAT pts could cross over to RUX from wk 28. Primary analysis
occurred when all pts reached wk 28 or discontinued.
Figure. Percentage of Patients Achieving (A) the Primary and Key Sec-
ondary Endpoints and (B) Improvement in MPN-SAF TSS.
Results: 74 and 75 pts were randomized to RUX and BAT, respectively. The
median time since PV diagnosis was 6.5 and 6.7 y; 28% and 24% of pts had a
history of thromboembolic events; and 78% and 76% had ≥2 PBTs within 24
wk of screening, respectively. Overall, 29.5% of pts received >1 prior line of
PV-directed therapy. By the cutoff date (29 Sep 2015), 2 (3%) RUX and 56
(75%) BAT pts had discontinued randomized treatment, of which 1.4% and
8.0% were due to adverse events (AEs), respectively; 51 (68%) pts crossed
over to RUX. The median duration of exposure to RUX and BAT was 42 and
28 wk, respectively; median dose intensity for RUX was 20 mg/day. HCT control
(primary endpoint) was achieved in 62% of RUX vs 19% of BAT pts (P<.0001);
CHR (key secondary endpoint) was achieved in 23% and 5% of RUX and BAT
pts, respectively (P=.0019; Fig A). At wk 28, 45% of RUX pts, vs 23% of BAT
pts, had ≥50% improvement in MPN-SAF TSS; 50% vs 7.7% achieved com-
plete symptom resolution (Fig B). RUX pts had improvements in individual
symptoms; most symptoms worsened with BAT. Pruritus improved in RUX pts,
but did not change in most BAT pts; 60% of RUX vs 5.3% of BAT pts had a
much or very much improved condition in PGIC. Anemia or thrombocytopenia
occurred in 16.2% and 2.7% of pts in the RUX arm vs 2.7% and 8.0% in the
BAT arm. Corresponding grade 3/4 events were reported in 0% of RUX pts vs
1.3% and 4.0% of BAT pts, respectively. The most common nonhematologic
AEs (>10% of pts) in either the RUX or BAT arm were headache (12.2%;
10.7%), constipation (10.8%; 5.3%), hypertension (10.8%; 4.0%), pruritus
(10.8%; 20.0%), and weight increase (10.8%; 1.3%). All were grade 1/2, except
hypertension (6.8%; 4.0%) and pruritus (0%; 2.7%). No deaths were reported
in the RUX arm; 2 (2.7%) occurred in the BAT arm.
Summary/Conclusions: In this study, RUX was well tolerated and superior to
BAT in controlling HCT without PBT, normalizing blood counts, and improving
PV-related symptoms in pts with PV resistant to or intolerant of HU, thus extend-
ing the results from RESPONSE to pts without palpable splenomegaly.
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PHENOTYPIC DIFFERENCES AND TREATMENT RESPONSES IN MOLECULAR
SUBGROUPS OF ESSENTIAL THROMBOCYTHEMIA FROM ANALYSIS OF
THE PT1 COHORT
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Background: Somatically acquired mutations in JAK2, MPL or CALR are found
in 85% of patients with essential thrombocythemia (ET) and 15% of patients are
‘triple-negative’ (TN). However, no prospective data exist on the disease charac-
teristics or response to treatment of the different molecular subgroups of ET.
Aims: We aimed to characterise, in the prospective setting, whether baseline
clinical characteristics, bone marrow histology, adverse outcomes, and
response to treatment are influenced by mutation status in ET.
Methods: Patients aged 18 years or older with newly diagnosed or previously
diagnosed ET were enrolled into low, intermediate or high-risk PT-1 studies
depending on their risk of vascular complications. Median prospective follow-
up duration was 36 months (range, 2-87 months). JAK2, MPL and CALR
screening utilised PCR based methods. Clinical and laboratory features were
compared between the four molecular subgroups. Time-to-event data was ana-
lyzed using Kaplan-Meier curves, log-rank analyses and Cox proportional haz-
ards models. Response to treatment and drug dosage were analyzed using
non-parametric regression and linear mixed effects modeling respectively.
Results: JAK2, MPL and CALR mutated ET represented 53%, 4% and 26%
of patients and were mutually exclusive in most cases. 1% of patients harbored
>1 mutation in these genes and analysis of such patients using individual
hematopoietic colonies showed that JAK2, MPL or CALR mutations can be
successively acquired within the same tumour subclone. Within the PT-1 cohort,
CALR- and MPL-mutated subgroups affected males and females equally, in
contrast to the female predominance observed in JAK2-mutated and TN sub-
groups wherein only 37% and 31% of patients respectively were male
(p=0.0008, Chi-squared test). TN patients were significantly younger than any
of the other molecular subgroups with a median age of 44 years (p<0.0001 for
all comparisons, ANOVA). CALR-mutated patients were also significantly
younger than JAK2- (p=0.003, ANOVA) and MPL-mutated (p=0.005, ANOVA)
patients, with a median age of 54 years. CALR-mutated trephines had more
prominent megakaryocyte atypia (increased cluster frequency, cluster size,
tight clusters, paratrabecular megakaryocytes and fibrosis), and TN trephines
had relatively milder megakaryocyte abnormalities. CALR-mutated ET patients
presented with lower hemoglobin levels and total white cell counts, and higher
platelet counts. Whilst the majority of venous thrombotic events occurred in
the JAK2-mutated subgroup (21 of 27 events), CALR-mutated ET patients suf-
fered increased rates of myelofibrotic transformation (hazard ratio 3.15 com-
pared to the JAK2-mutated subgroup, p=0.03, Cox proportional hazards model
correcting for age, gender and treatment received). No interaction was noted
between treatment with either hydroxyurea or anagrelide and the incidence of
these adverse outcomes. Patients with CALRins5 mutations presented with
higher platelet counts than patients with CALRdel52 mutations but no other
differences in disease features or outcome. Platelet control was equivalent
between all molecular subgroups following treatment with either hydroxyurea
plus aspirin or anagrelide plus aspirin in high-risk patients. However, CALR-
mutated and MPL-mutated patients developed lower hemoglobin levels during
anagrelide therapy. This observation was not due to differences in anagrelide
dosage between molecular subgroups.
Summary/Conclusions: These results demonstrate that molecular testing
identifies distinct biological subgroups in ET with different clinical outcomes
and treatment responses.
S114
A GREATER UNDERLYING MUTATIONAL COMPLEXITY MAY CONTRIBUTE
TO THE DIFFERENTIAL PROGNOSTIC IMPACT OF PHENOTYPIC-DRIVER
MUTATION IN PRIMARY MYELOFIBROSIS
P Guglielmelli1,*, G Rotunno1, T Fanelli1,2, A Pacilli1, G Corbizi-Fattori1,2,
L Calabresi1, A Pancrazzi1, AM Vannucchi1
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Background: In primary myelofibrosis (PMF), JAK2/CALR/MPL mutational
status is prognostically informative, with “triple-negative” (TN) patients (pts)
displaying the worst survival (Rumi E, Blood 2014). Also, survival was signifi-
cantly shorter in CALR type 2/like (Ty2) vs type 1/like (Ty1) mutated pts (Tefferi
A, Blood 2014; Guglielmelli P, BCJ. 2015). A high-molecular risk category
(HMR) identifies pts with reduced survival if harboring any one of ASXL1, EZH2,
IDH1/2 and SRSF2 mutated genes (Vannucchi A, Leukemia 2013; Guglielmelli
P, Leukemia 2014).
Aims: To analyze the molecular landscape of PMF pts categorized according
to their driver mutation status and correlate with clinical endpoints and outcome.
Methods: All PMF pts (WHO-2008) provided informed consent. Established
methods were used for JAK2, MPL and CALR mutations. NGS analysis with
Ion Torrent platform was used to genotype 18 genes (referred as subclonal,
SC): all coding sequence of c-KIT, TET2, RUNX1, NRAS, KRAS, DNAMT3A,
IKZF1, EZH2, TP53; hot spot of IDH1/2 and SRSF2 and selected exons of
CBL, IDH2, ASXL1, SF3B1, NFE2, SH2B3, U2AF1. The nonparametric Wilcox-
on rank-sum test, Kaplan-Meier estimate of survival and log-rank test were
used as appropriate.
Results: We analyzed 126 pts: 43 were JAK2+ (34.1%), 42 TN ( 33.3%) and
41 CALR mut (32.6%; 26 (63.4%) Ty1 and 15 (36.6%) Ty2. Overall, 17 pts
(13.5%) progressed to AML. Death occurred in 69 pts (43.4%) after a median
follow up of 3.8y. There was no difference between Ty1 and Ty2 for common
hematologic and clinical variables; conversely, both Ty1 and Ty2 differed from
JAK2+ counterpart for younger age, lower leukocyte and higher platelet counts;
males were more represented among Ty1 pts that other genotypes. More
deaths occurred among Ty2 (45.8%), JAK2+ (37.0%) and TN (72.7%) pts com-
pared to Ty1 (20.0%) (P<.0001). Median survival of CALR Ty1 was 26.4y vs
8.59y for CALR Ty2, 10.3y for JAK2+ and 2.1 for TN (P<.0001). The corre-
sponding hazard ratio, taking CALR Ty1 pts as reference, was 3.0 (95%CI,
1.2-7.6), 2.4 (95%CI, 1.0-5.7) and 11.1 (95%CI, 5.0-25.01) for CALR Ty2,
JAK2+ and TN pts, respectively. HMR status was associated with shortened
survival ((HR 3.3, 95%CI 1.9-5.8; P<.001) as it was the number of HMR muta-
tions (HR 5.4, 95%CI 2.8-10.6; P<.001). Considering the individual mutations,
only EZH2, ASXL1 and SRSF2 predicted for shorter survival (2.7y, 1.93y and
1.03y respectively; P=.001; P=.01 and P<.0001). Pts harboring any one of SC
mutations were similarly distributed among groups: Ty1 61%, Ty2 67%, JAK2+
77%, TN 74%; exceptions were SRSF2 mutations (n=26) that were 0% Ty1,
6.7% Ty2, 14% JAK2+, 45% TN (P<.0001), and SF3B1 that was mutated in 3
Ty2 (20%) vs 1 pts in both Ty1 (4%) and JAK2+ (2%) and no TN pt (P=.009).
Conversely, the proportion of pts with ≥2 SC mutations was significantly higher
in TN (52%) vs the others (Ty1 15%, Ty2 20%, JAK2+ 42%)(P=.02). The pro-
portion of HMR was significantly higher in TN (67%) and JAK2+ (54%) pts
compared with CALR subtypes (35% in Ty1, 27% in Ty2) (P=.01), as it was the
percentage of pts having ≥2 HMR mutations (P=.006).
Summary/Conclusions: Overall, our findings support previous reports that
the prognostic advantage of CALR mutation in PMF regards only Ty1 mutation;
however, we did not find evidence that such difference might be ascribed to a
greater molecular complexity of Ty2. Conversely, the dismal outcome of TN
pts might be explained, at least in part, by occurrence of greater number of
prognostically negative HMR mutations, particularly of SRSF2 mutations.
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INTEGRATIVE ANALYSIS OF GENE MUTATIONS AND CHROMOSOMAL
ABNORMALITIES BY NEXT-GENERATION SEQUENCING AND FISH IN
HEMATOPOIETIC PROGENITORS OF PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
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Background: Chronic lymphocytic leukemia (CLL) is a highly genetically het-
erogeneous disease. Although CLL has been traditionally considered as a
mature B cell leukemia, few independent FISH and Next-Generation Sequenc-
ing (NGS) studies have shown that the genetic alterations may appear in CD34+
early hematopoietic progenitors. However, the presence of both chromosomal
aberrations and gene mutations in CD34+ cells from the same patients has not
been explored.
Aims: To analyze both chromosomal abnormalities and gene mutations in
CD34+ hematopoietic progenitors from CLL patients to elucidate whether these
genetic events appear previously during the B-cell differentiation process.
Methods: NGS and FISH studies were carried out in isolated CD19+ mature
B cells from 57 CLL bone marrow samples to assess the presence of gene
mutations and/or cytogenetic aberrations, respectively. Amplicon-based deep
NGS (454 Life Sciences, Roche) was performed to study the mutational status
of TP53, NOTCH1, SF3B1, FBXW7, MYD88 and XPO1. The presence of genet-
ic lesions on 11q, 12, 13q, 14q and 17p was studied by FISH. All cases with
any mutations in CD19+ cells were also sequenced in their corresponding
CD34+ early progenitors (coverage=1159X). Moreover, FISH was also per-
formed in the CD34+ fraction of a subset of CLL patients with cytogenetic
changes (n=9).
Results: NGS studies revealed a total of 28 mutations in 24 CLL patients
(24/57, 42.1%). NOTCH1 was the most frequently mutated gene (22.8%), fol-
lowed by XPO1 (8.8%), SF3B1 (7%), FBXW7 (5.3%), TP53 (3.5%) and MYD88
(1.8%). CLLs with mutations in any of these genes, except to MYD88, were
associated with an unmutated IGHV status (P=0.001). Most of the patients
showed the same mutations in their corresponding CD34+ cells (21/24, 87.5%).
Comparing the mutations in both cell populations, two different patterns could
be identified. In one group, the mutational burden remained similar between
both cell fractions. Mutations in NOTCH1 (11/13) and XPO1 (5/5) were pre-
dominant in this group. By contrast, the other group showed a high decrease
or even absence of these mutations in the CD34+ cells than the corresponding
B lymphocytes being mutations in TP53 (2/2), FBXW7 (2/3) and SF3B1 (3/4)
the most recurrent in this group. FISH analysis revealed that 5 out of 9 CLL
cases with cytogenetic alterations in B mature lymphocytes presented also the
same aberrations on the CD34+ cells. Of note, IGH alterations did not appear
in any of the CD34+ cases (0/2), whereas 11q- (2/2) and 13q- (3/5) were present
in the CD34+ early progenitors. Gathering both techniques, 2 out of 9 CLLs
had both chromosomal aberrations and mutations in their mature lymphocytes.
Noteworthy, one of these cases showed an IGH alteration and NOTCH1 muta-
tion (altered cells=80% and 51%, respectively) on the CD19+ population. How-
ever, only NOTCH1 mutation (31%) was found on the CD34+ cells. The other
patient presented 13q- (93%), 11q- (64%) and XPO1 mutation (39%) on the
CD19+ B cells. The same alterations were also present in hematopoietic pro-
genitors (72%, 49% and 31%, respectively).
Summary/Conclusions: Our data confirmed that chromosomal abnormalities
and gene mutations are present not only in mature B lymphocytes, but also in
the CD34+ early progenitors of CLL patients. Moreover, our findings shed light
about the hierarchy existing in the appearance of these events: 11q-, 13q-,
NOTCH1 and XPO1 mutations could be early hits on CLL pathogenesis, where-
as IGH alterations, TP53, SF3B1 and FBXW7 mutations seemed to show in a
later maturational level. Funding: PI15/01471; Junta de Castilla y León (MHS)
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OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: Signaling initiated by antigen binding to the B-cell receptor
immunoglobulin (BcR IG) is paramount for CLL development and evolution. Indeed,
BcR signaling pathways are constitutively active in all CLL cases and recently, a
cell-autonomous model of CLL cell activation has been proposed, whereby all CLL-
derived BcR IGs could promote Ca2+ influx and NF-κB target gene transcription
through the binding of a common internal epitope on the BcR IG.
Aims: We investigated the relevant molecular interactions underlying cell-
autonomous signaling in CLL cases with distinct and opposite clinical outcome
in order to understand the molecular basis of the clinical disease heterogeneity.
We focused on CLL stereotyped subset #4 (IGHV4-34/IGKV2-30), a particularly
indolent clinical subgroup with a characteristic anergic functional phenotype of
the malignant cells, and stereotyped subset #2 (IGHV3-21/IGLV3-21), noted
for a dismal prognosis, largely independent of p53 dysfunction.
Methods: We produced recombinant IG molecules from CLL leukemic cells.
The BcR IGs were analyzed for self-association using analytical ultracentrifu-
gation, and their structure was determined by x-ray crystallography. Recombi-
nant BcRs were transfected in the RAG2/λ5/SLP65 triple knockout murine pre
B-cell line (TKO cells) engineered to include a tamoxifen-inducible ERT2-SLP65
fusion protein. Addition of 4-hydroxy tamoxifen in the absence of exogenous
antigen induces an increase in Ca2+ influx in case of autonomous signaling of
the tested BcR.
Results: The BcR IGs of both subsets interact in the crystals in a geometry
highly indicative of specific homotypic recognition, albeit with distinct features.
In subset #4, the VH CDR3 binds to a conformational epitope spanning the
Heavy chain (VH and CH1 domains), while in subset #2 the VL CDR1 and
CDR2 loops contact a surface composed of residues from the Light chain (VL
FR1 and the linker between the VL and CL domains). Using analytical ultra-
centrifugation, we confirmed that the contacts observed in the experimental
crystal structures for both subsets were also occurring in solution. Interestingly,
the association in solution of the receptors was markedly different for the two
subsets with persistent binding in subset #4 cases with indolent disease, versus
weaker interactions in subset #2 aggressive cases. For both subsets, using
the TKO tamoxifen-inducible system and Ca2+ influx as a readout, we found
that the observed interactions activate cell-autonomous intracellular signaling
in the absence of exogenous antigen. Conversely, cells expressing epitope or
paratope mutants of either receptor did not demonstrate significant variations
in Ca2+ influx, confirming the relevance of the homotypic interactions revealed
by the crystal structures.
Summary/Conclusions: We provide the first description to high resolution of
a homotypic association process in BcRs that resembles antibody-antigen
recognition and leads to intracellular signaling in CLL cells. BcR IGs from CLL
cases with different prognosis bind homotypically via their combining sites to
specific, diverse epitopes to initiate intracellular signalling. Our results suggest
that the avidity of BcR self-recognition may directly underlie the clinical course
of CLL, since tight, persistent binding was noted in cases with indolent disease
whereas weaker interactions characterized the aggressive progressive cases.
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Background: CLL is the most common leukemia in the Western world. During
CLL development, incipient CLL cells undergo a multistep mutational process,
during which they acquire a set of genetic and/or epigenetic lesions, which ulti-
mately result in the leukemic state. CLL-associated mutations can be classified
into so-called driver mutations, which are essential for malignant growth and
passenger mutations, which are functionally less significant. Recent work has
revealed the identity of early, so-called trunk lesions and later-occurring sub-
clonal mutations that are associated with disease progression and (chemo-
)therapy resistance. Prominent examples for subclonal additional genetic events
are ATM and TP53 mutations, which are both associated with resistance against
genotoxic therapies.
Aims: We aimed at overcoming one of the biggest hurdles in preclinical CLL
research-the lack of mouse models that faithfully mimic the genetic events lead-
ing to CLL development.
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Methods: We combined the well established Eµ-TCL1 CLL mouse model with
a floxed Tp53- or Atm-allele. We made use of the Cd19-Cre mouse to specifically
delete Tp53 or Atm in the B cell compartment. The resulting Eµ-TCL1;Cd19Cre/wt;
Tp53fl/fl (TCP) and Eµ-TCL1;Cd19Cre/wt;Atmfl/fl (TCA) mice were carefully char-
acterized and subsequently used for treatment strategy testing.
Results: The increase of leukemic burden in the blood was significantly faster
in TCP and TCA mice, when compared to the Eµ-TCL1;Cd19Cre/wt (TC) control.
Thrombocytopenia and splenomegaly developed faster in the Atm- and Tp53-
deficient models. In agreement with this faster disease progression, TCP and
TCA mice succumbed faster to the disease than TC control animals (31.4
weeks, 36.9 weeks and 49.9 weeks, respectively). Despite faster diesase pro-
gression in TCP and TCA mice, splenomegaly at time of death was comparable
in all three cohorts. Histologically, the three lines were indistinguishable.
Richter’s transformation, as defined by loss of Cd5 expression, a strong
increase in cell size and a high proliferative index, was occassionally observed
in TCP and TC mice, but not in the TCA cohort. Interestingly, TCA mice showed
a significantly better response to cyclophosphamide when compared to TCP
animals, but TC mice did not. Looking more closely at disease kinetics, we
observed a significant increase in disease aggressiveness in the TC group up
to the level of TCP mice, suggesting the selection of an aggressive clone under
insufficient therapy. Lastly, we used the TCA model to investigate whether phar-
macological inhibition of PARP, a treatment strategy proven to be effective in
homologous recombination-deficient tumors of other entities, might be benefi-
cial in ATM-deficient CLL as well. Indeed, we could show a strong and signifi-
cant survival benefit by daily application of Parp inhibitor in our mice, an effect
not observed in the Atm-proficient controls.
Summary/Conclusions: We have, based on the Eµ-TCL1 allele, generated
mouse models mimicking the genetic alterations found in high-risk CLL patients,
namely the loss of TP53 and ATM. These novel mouse models might be used
as valuable tools for the development of new treatment strategies for these
high risk groups. We have done so by assessing the effectiveness of Parp inhi-
bition specifically in the Atm-deficient setting in this mouse model of CLL.
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AKT ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS PROMOTES
TRANSFORMATION TOWARDS AGGRESSIVE RICHTER’S SYNDROME
LYMPHOMA
M Al-Maarri1, N Nickel2, A Roth2, N Hövelmeyer3, M Hallek2, FT Wunderlich4,
C Pallasch2,*
1Max Planck Institute for Metabolism Research Cologne; Institute for Genetics,
University of Cologne; Cologne Excellence Cluster on Cellular Stress Respons-
es in Aging-associated Diseases (CECAD), University of Cologne, 2Department
I for Internal Medicine, Centre for Integrative Oncology CIO, University Hospital
of Cologne, Cologne, 3Institute for Molecular Medicine Mainz, University Hos-
pital of Mainz, Mainz, 4Max Planck Institute for Metabolism Research Cologne;
Institute for Genetics, University of Cologne; Cologne Excellence Cluster on
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of Cologne, Cologne, Germany
Background: Richter’s syndrome (RS) is an aggressive transformation of
Chronic Lymphocytic Leukemia (CLL) refractory to current therapies with dismal
prognosis. RS arises from CLL cells independent of common DLBCL-muta-
tions. Frequently mutations in p53, CDKN2 or cMyc genes are involved, but a
significant proportion displays no specifically acquired driver mutation.
Aims: Here we aim to elucidate the role of AKT in transformation towards
Richter´s syndrome in human patients and functionally address constitutively
AKT-activation in vivo. Ultimately, we aim to develop mouse models that can
be used to develop novel treatment options towards Richter’s syndrome.
Methods: FFPE sections of Richter syndrome patients were used for pAKT
staining. We have developed a mouse model allowing for Cre-activatable
expression of a myristoylated AKT constitutive active allele from the Rosa26
locus (AKT-C). We crossed that mice with Cd19Cre- and Cg1Cre-mediated B
cell-specific AKT-C expression in the Eµ:Tcl1 CLL mouse model.
Results: In biopsies revealed from patients with RS one third of cases
showed enhanced AKT activation. Strikingly, Richter’s transformation was
recapitulated when AKT was genetically over-activated in Eµ-Tcl-1 mice,
where AKT-C expressing cells developed a high-grade lymphoma phenotype
leading to significantly decreased survival. AKT-C expression in TCL1 mouse
model CLL cells furthermore induced morphology changes displaying fea-
tures of aggressive lymphoma such as large transformed B-cell phenotype
and frequent mitotic figures, enhanced proliferation indicated by KI67. The
phenotype of transformed aggressive lymphoma could be revealed inde-
pendently in both Cd19Cre- and Cg1Cre-mediated activation of AKT. Thus,
Eµ:Tcl1 transformed CLL cells act in concert with constitutively active AKT to
develop RS. Noteworthy, Cd19Cre;AKT-C double transgenic mice fail to devel-
op leukemia and lymphoma, indicating that CLL development in Eµ:Tcl1 mice
is a precondition to transformation. As for the downstream mechanisms of
AKT-mediated transformation we identified GSK-3b inhibition and subsequent
cMyc and Mcl-1 stabilization. This might confer contribute to resistance of
RS cells against DNA-damaging and PI3K-inhibiting compounds in this novel
model of Richter´s syndrome.
Summary/Conclusions: Collectively, we have generated the first murine
Richter’s Syndrome model providing novel mechanistic insights into the molec-
ular understanding of Richter’s transformation as an AKT-driven disease. The
new model is amenable to model therapeutic strategies and to address the
efficacy of synergistic treatment combinations in transformed lymphoma.
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FREQUENT RECURRING MUTATIONS DISRUPT THE ANTI-PROLIFERATIVE
FUNCTION OF ZBTB7A IN ACUTE MYELOID LEUKEMIA WITH T(8;21)
TRANSLOCATION
L Hartmann1,2,*, S Dutta1,2, S Opatz1,2, S Vosberg1,2, K Reiter1,2, G Leubolt1,2,
KH Metzeler1,2, T Herold1,2, SA Bamopoulos1, K Bräundl1,2, E Zellmeier1,
B Ksienzyk1, NP Konstandin1, S Schneider1, KP Hopfner3, A Graf4, S Krebs4,
H Blum4, JM Middeke2,5, F Stölzel2,5, C Thiede2,5, S Wolf6, SK Bohlander7,
C Preiss8, L Chen-Wichmann8, C Wichmann8, MC Sauerland9, T Büchner10,
WE Berdel10, BJ Wörmann11, J Braess12, W Hiddemann1,2, K Spiekermann1,2,
PA Greif1,2
1Internal Medicine 3, University Hospital, Ludwig-Maximilians-Universität (LMU)
München, Munich, 2German Cancer Consortium (DKTK), German Cancer
Research Center (DKFZ), Heidelberg, 3Department of Biochemistry, Gene Cen-
ter, 4Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, Lud-
wig-Maximilians-Universität (LMU) München, Munich, 5Medizinische Klinik und
Poliklinik I, Universitätsklinikum Dresden, Dresden, 6Genomics and Proteomics
Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany,
7Department of Molecular Medicine and Pathology, The University of Auckland,
Auckland, New Zealand, 8Department of Transfusion Medicine, Cell Therapeu-
tics and Hemostasis, University Hospital, Ludwig-Maximilians-Universität (LMU)
München, Munich, 9Institute of Biostatistics and Clinical Research, 10Depart-
ment of Medicine A- Hematology, Oncology and Pneumology, University of
Münster, Münster, 11Department of Hematology, Oncology and Tumor Immunol-
ogy, Charité University Medicine, Campus Virchow, Berlin, 12Oncology and
Hematology, St. John-of-God Hospital, Regensburg, Germany
Background: The t(8;21)(q22;q22) translocation results in the RUNX1/
RUNX1T1 rearrangement and is one of the most frequent chromosomal aber-
rations in AML. However, in vivo models indicate the requirement of additional
lesions, such as of KIT or FLT3 mutations, for leukemogenesis as the
RUNX1/RUNX1T1 fusion gene alone is not sufficient to induce leukemia.
Aims: We set out to identify cooperating mutations in AML patients with t(8;21)
translocation.
Methods: Exome and targeted sequencing, DNA pull-down, transcription
assay, immunofluorescence, retroviral transduction, gene expression profiling.
Figure A and Figure B.
Results: To identify additional cooperating mutations, we performed exome
sequencing of matched diagnostic and remission samples from two AML patients
with t(8;21) translocation. ZBTB7A was the only mutated gene identified in both
patients. ZBTB7A is a member of the POZ/BTB and Krüppel (POK) transcription
factor family. Previous studies suggested that ZBTB7A may act both as proto-
oncogene and as tumor suppressor. Using targeted amplicon sequencing of
ZBTB7A and 45 leukemia relevant genes, we screened 56 diagnostic AML
t(8;21) samples. ZBTB7A mutations were identified in 13 of 56 patients (23%).
Two recurring mutational hotspots (R402 and A175fs) in exon 2 were identified
(Figure A). Variant allele frequency (VAF) ranged from 5.4-76.2% and 4 of 13
patients (31%) harbored two mutations of ZBTB7A. On the protein level, we
confirmed the expression of a truncated ZBTB7A mutant (R377X) by Western
blot for one patient with available material. In our cohort, ZBTB7A and ASXL2
mutations occurred at similar frequencies and 5 of 13 patients carried mutations
in both genes, however, there was no significant association of mutated ZBTB7A
and mutations in ASXL2 (Fisher’s exact test, p=0.12) or any other recurrently
mutated gene. On a functional level, the ZBTB7A mutants R402H, R402C,
A175fs or R377X failed to repress a luciferase reporter containing ZBTB7A-
binding elements derived from the ARF-promoter. Structural modeling revealed
that Arginine 402 binds into the major groove of the DNA double helix and likely
contributes to the affinity or sequence specificity of the DNA interaction of the
zinc finger domain of ZBTB7A. Through DNA pull-down assays we confirmed
impaired DNA binding of A175fs and R402H. The truncating ZBTB7A mutants
A175fs and R377X showed altered cytoplasmic protein localization. In the t(8;21)
translocation positive AML cell line Kasumi-1 retroviral expression of wild-type
ZBTB7A inhibited cell growth, whereas this anti-proliferative effect was not
observed upon expression of the A175fs ZBTB7A mutant. The R402C mutant
expressing Kasumi1-cells showed a trend towards reduced cell growth, sug-
gesting residual activity (Figure B). Based on this observation, we expressed
ZBTB7A wild-type or its mutants together with the RUNX1/RUNX1T1 fusion in
lineage negative murine bone marrow cells and performed colony forming cell
(CFC) assays. ZBTB7A expression led to a significant decrease in the number
of colonies in primary CFC (87±12.6 versus 45±5.8, p<0.0001), while this effect
was lost for both mutants A175fs and R402C. These findings support an onco-
genic synergism between RUNX1/RUNX1T1 and ZBTB7A mutations. We cor-
related ZBTB7A expression with clinical outcome in a large cohort of AML
patients (GSE37642). Remarkably, in over 200 cytogenetically normal AML
patients treated on clinical trial (NCT00266136), high expression of ZBTB7A
was associated with a favorable outcome (p=0.0004), suggesting a relevance
in AML beyond the t(8;21) subgroup.
Summary/Conclusions: In summary, we have identified ZBTB7A as one of
the most frequently mutated genes in t(8;21) positive AML. Considering that
ZBTB7A mutations result in loss of function, we suggest that ZBTB7A acts as
a tumor suppressor in t(8;21) positive AML.
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HNRNP K: AN ONCOGENE AND TUMOR SUPPRESSOR, TWO DISCRETE
PATHS TO AML THROUGH ON GENE
M Gallardo1,*, MJ Hornbaker1, HJ Lee2, X Zhang1, C Bueso-Ramos3,
LR Pageon4, M McArthur4, A Multani5, T Manshouri1, J Parker-Thornburg5,
P Hu3, I Rapado6, A Quintas-Cardama1, SM Kornblau1, J Martinez-Lopez6,
SM Post1
1Leukemia, 2Lymphoma and Myeloma, 3Histopathology, 4Veterinary Medicine
& Surgery, 5Genetics, MD Anderson Cancer Center, Houston, United States,
6Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
Background: We have recently demonstrated that HNRNPK is a critical hap-
loinsufficient tumor suppressor residing at the 9q21.32 locus that is deleted in
a subset of patients with AML (Gallardo et al, Cancer Cell, 2016). In this study,
we generated a haploinsufficient Hnrnpk (Hnrnpk+/-) mouse model that exhib-
ited reduced survival and developed significant hematologic and myeloid malig-
nancies. However, in addition to HNRNPK haploinsufficiency, we found that a
large subset of AML patients without a 9q21.32 deletion, actually overexpress
HNRNP K, resulting in poor prognoses. These data suggest that hnRNP K may
have both tumor suppressive or oncogenic functions, depending on its expres-
sion levels.
Aims: This work will investigate the role of hnRNP K in AML, and to understand
how HNRNP K behaves as an oncogene or as a tumor suppressor.
Methods: We analyzed copy number variations and aberrant expression of
HNRNPK by FISH, qRT-PCR, and RPPA analyses in AML patients with and
without 9q21.32 deletions. To directly examine the contribution of aberrant
hnRNP K expression to malignant phenotypes, we generated two distinct
cohorts of genetically engineered mice. One cohort was haploinsufficient for
Hnrnpk, while the other specifically overexpressed hnRNP K in hematopoietic
progenitors (HnrnpkTg). Differences in survival, genomic stability, proliferation
and differentiation potential, tumor formation, and molecular analyses were
performed on hematological tissues using qRT-PCR, immunohistochemistry,
colony formation assays, western blot analyses, and transplantation assays.
Molecules of interest were further analyzed for interaction with hnRNP K via
ChIP and RIP assays.
Results: Initial evaluation of HNRNPK expression levels in AML patients
revealed that patients with the 9q21.32 deletion exhibited reduced hnRNP K
levels, while many patients without this deletion had significant HNRNPK over-
expression (Fig. 1A). This result was echoed in FISH analyses, as patients with
the 9q21.32 deletion showed HNRNPK loss, while nearly 37% of AML (n=43)
patients without the 9q deletion showed gene amplifications. In order to inves-
tigate the role of HNRNP K in AML, we generated both hnRNP K+/- and hnRNP
Ktg mice. While these two mouse models have significant differences in hnRNP
K expression compared to wild type (reduced versus overexpression), they
surprisingly, had extremely similar phenotypes (Fig. 1B). Mice from each cohort
suffered reduced survival, development of myeloid malignancies with high pen-
etrance, genomic instability, enhancement in proliferation and differentiation
potential in HSPCs, and the ability to generate myeloid hyperplasias following
transplantation (Fig. 1C). Even though these opposite hnRNP K expression
patterns result in extremely similar phenotypes, the molecular consequence of
aberrant hnRNP K expression is facilitated through discrete molecular mecha-
nisms. While hnRNP K haploinsufficiency directly decreased expression of anti-
proliferation and differentiation genes likes p21, C/EBPa, and C/EBPβ, its over-
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expression resulted in the direct activation of pro-growth genes like c-Myc. Giv-
en that hnRNP K expression is known to be tightly in all eukarotyic organisms,
these data suggest that any alteration in hnRNP K expression may result in
drastic cellular consequences.
Figures.
Summary/Conclusions: These data provide evidence that hnRNP K has the
unique capacity to behave as an oncogene when overexpressed, or as a tumor
suppressor when is its expression is reduced. In either case, these imbalances
in hnRNP K expression are capable of directly contributing to the pathogenesis
of AML.
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INTEGRATED ANALYSIS OF THE HUMAN HEMATOPOIETIC NON-CODING
RNA LANDSCAPE REVEALS LNC-RNA STEM CELL SIGNATURE IN AML
S Emmrich1, A Schwarzer2, F Schmidt1, M Ng1, D Witte1, FF Adams2,
C Reimer1, A Maroz1, D Reinhardt3, JH Klusmann1,*
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Background: Long non-coding RNAs (lncRNAs) and miRNAs have emerged
as crucial regulators of gene expression, epigenetics and cell fate decisions.
Aims: We sought to establish a comprehensive resource for the exploration of
non-coding RNAs across the human hematopoietic hierarchy, to understand
their role in the pathogenesis of acute myeloid leukemia (AML).
Methods: Here we present an integrated quantitative and functional analysis
of the miRNA-, lncRNA- and mRNA-transcriptome of purified human
hematopoietic stem cells (HSCs) and their differentiated progenies, including
granulocytes, monocytes, T-cells, NK-cells, B-cells, megakaryocytes and ery-
throid precursors, which we correlated with the ncRNA expression profile of 46
pediatric AML samples to establish a core lncRNA stem cell signature in AML.
Results: For each blood cell population, RNA from 5 healthy donors was
hybridized onto three microarray platforms (Arraystar lncRNA V2.0, NCode™-
miRNA/-ncRNA), yielding a coverage of more than 40,000 lncRNAs, 25,000
mRNAs and 900 miRNAs on 146 arrays. Compared to mRNAs, the mean
expression level of lncRNAs was nearly 2-fold lower (p<2.2x10-16), highlighting
the challenge for RNA-Seq to provide adequate coverage of these rare tran-
scripts. T-distributed stochastic neighbor embedding (t-SNE) on lncRNA and
miRNA genes robustly structured the dataset into groups of samples that
matched the input populations, demonstrating their unique ncRNA expression
profiles. Self-organizing maps revealed clusters of lncRNAs and mRNAs that
were coordinately expressed in HSCs and during lineage commitment. To
demonstrate their functionality, we knocked down LINC00173 from the granu-
locytic core signature using two independent shRNA constructs, which resulted
in diminished granulocytic in vitro differentiation (2-fold reduction in percentage
of CD66b+/CD13+ granulocytes, p≤0.05), myeloid colony-formation (1.5-2-fold,
p≤0.05) and nuclear lobulation (MGG-staining). Accordingly, CRISPR-mediated
transcriptional repression of nuclear localized LINC00173 (RNA-FISH validated
by qRT-RNA of fractionated RNA) using dCas9-KRAB and three sgRNAs per
locus reduced proliferation of myeloid NB4 cells (2-3-fold, p≤0.01). Having estab-
lished a global human hematopoietic lncRNA expression resource, we extended
our findings to malignant hematopoiesis. Linear (PCA) and nonlinear (t-SNE)
dimensionality reduction of 46 pediatric AML samples including Down syndrome
AMKL, core-binding factor AMLs (inv[16] or t[8;21]) and MLL-rearranged
leukemias mapped most samples to a space between HSCs and differentiated
cells together with the myeloid progenitors. A subset of AML-samples mapped
closely to healthy HSCs, including most of the DS-AMKLs and MLL-AMLs. We
identified a stem-cell associated lncRNA signature that was absent in healthy
differentiated progenies, but upregulated in AML samples. A mesoscale CRISPRi
screening in AML cell lines suggested the importance of the lncRNA stem cell
core signature for the maintenance of leukemic growth.
Summary/Conclusions: The definition of a core lncRNA stem cell signature
in normal HSCs and AML blasts will guide our way towards an improved under-
standing of self-renewal and the underlying transcriptional program, which is
hijacked during malignant transformation.
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THE IMPACT OF CELLULAR AGE ON LEUKEMIC TRANSFORMATION
S Chaudhury1,*, B Gibson2, K Keeshan1
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Background: Treatment of pediatric acute myeloid leukemia (AML) is largely
extrapolated from adult trials despite age related disease heterogeneity. Indeed,
during healthy ageing there are age related hemopoietic stem and progenitor
(HSPC) cell proliferative and differentiative differences. We hypothesise that
cellular age influences leukemic transformation, having implications for disease
phenotype and response to therapy.
Aims: To determine if HSPC age affects oncogene-mediated leukemic trans-
formation.
Methods: Murine HSPCs including lin-sca1+cKit+ (LSK), common myeloid pro-
genitor (CMP) and granulocyte-macrophage progenitor (GMP) cells from fetal
liver (FL), 3 week(w), 10w and >60w adult bone marrow were isolated and
transduced with the fusion oncogenes Nup98HoxA9 (NH9), AML1ETO (AE)
and the mutant FLT3-ITD. Leukemic transformation was assessed in vitro by
serial colony forming cell (CFC) assays, by growth in liquid culture and in stro-
mal OP9 co-culture. In vivo leukemogenesis was assessed by transplantation
of pre-leukemic LSKs transduced with NH9 after 2 rounds of colony formation
(CFC2), into sublethally irradiated C57BL/6 mice. Gene expression was
assessed by QPCR using fluidigm technology.
Results: NH9 transformed LSKs from all 4 ages in vitro. NH9 did not result in
FL CMP and GMP transformation, while post-fetal (3w, 10w and >60w) CMPs
and GMPs all transformed. Consistent with this, AE and FLT3-ITD transformed
FL LSKs but not FL GMPs in vitro. This suggests that fetal transformation relies
on specific features of the LSK that are absent from committed myeloid pro-
genitors, independent from the oncogenic insult. To further assess age related
transformation differences, NH9 transformed FL, 3w, 10w and >60w LSKs were
assessed for AML in vivo. Older (10 and >60w) transformed cells led to a
shorter latency with more penetrance than young (FL and 3w) transformed
LSKs. Further, acute lymphoblastic leukemia (ALL) was observed in animals
transplanted with FL and 3w transformed LSKs, but not 10w or >60w LSKs,
suggesting young LSKs retain a lymphoid bias. As all NH9 transformed LSKs
in vitro acquired self-renewal properties, the transformation differences
observed in vivo may be cell autonomous or non-cell autonomous via the bone
marrow microenvironment. Gene expression analysis of microenvironmental
receptors and targets show the BMP pathway is upregulated in 10w and >60w
LSK transformed cells suggesting the BMP pathway may have a role in age
related transformation potential.
Summary/Conclusions: While LSKs from all 4 ages acquire self-renewal in
vitro, progression to leukemia in vivo is slower and less penetrant in young
compared to older transformed cells. This is in accordance with the lower inci-
dence of AML in childhood compared to older adults. Activation of the BMP
pathway has previously been associated with AML transformation, and our
data suggest that the BMP pathway may play a role in the progression to AML
specifically in older cells. The observation of ALL specifically in younger trans-
formed LSKs suggests that young HSPCs retain lymphoid programs after
myeloid oncogene expression, consistent with the higher incidence of ALL in
childhood. Our findings support that age defined therapies are appropriate as
HSPC age related biological differences are retained in leukemia and may
impact not only disease phenotype but response to therapy.
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NBEA: A NOVEL REGULATOR OF HEMATOPOIETIC STEM CELL IN VIVO
REPOPULATION
M Ganuza*, T Hall, S McKinney-Freeman
Hematology, St. Jude Children’s Research Hospital, Memphis, United States
Background: Hematopoietic Stem Cells (HSCs) differentiate to generate all
blood cells in a hierarchical manner. This has been exploited in HSC trans-
plantation (HSCT) to treat hematologic diseases. Better understanding the
molecular mechanisms implicated in HSCT should improve current transplant
protocols. In our recently published work (Holmfeldt et al. J.Exp.Med. 2016),
we have identified 17 new regulators of HSCT. Neurobeachin (Nbea) scored
as a positive regulator of HSCT. NBEA protein is localized near the Golgi appa-
ratus and regulates vesicular and protein trafficking. Patients with a disrupted
NBEA allele present platelets with an abnormal morphology.
Aims: To understand the role of Nbea in HSCT and normal hematopoiesis.
Methods: Nbea-/- mice. Bone marrow (BM) transplant: Competitive congenic
transplant into lethally irradiated recipients: Test cells (CD45.2+), competitor
cells (CD45.1+), recipient mice (CD45.1+/CD45.2+). Flow Cytometry Analysis
of Peripheral Blood (PB) and BM. RNA-microarray.
Results: Both adult BM Lineage-Sca-1+c-Kit+ (LSK) and E14.5 Fetal Liver
(FL) LSK cells lentivirally transduced with shRNAs targeting Nbea (>70% tran-
script knockdown), and competitively transplanted within 40 hours post-infection
into lethally irradiated recipient mice, suffer from a strong defect in short- and
long-term repopulating activity, as measured by PB chimerism of recipient mice
(>80% reduced). Thus, Nbea is required in LSK cells at different developmental
stages for efficient HSCT. As transplanted Nbea-deficient cells are detected in
the BM of recipients at 12 days post-transplantation, thus, a defect in homing
or in LSK cell BM retention in recipients can be excluded. 4 months post-trans-
plant, analysis of the major BM hematopoietic progenitor compartments (HPCs)
of recipients showed a 50% decreased in the chimerism of Nbea-deficient cells
in the HSC compartment. In contrast, Nbea-deficient cells were nearly absent
from downstream progenitor compartments, suggesting a differentiation block.
Nbea-/- mice die perinatally due to lack of synaptic transmissions There was
no difference in the frequency of HPCs in the E14.5 FL of Nbea-/- and Nbea+/+
littermates. Nbea-/- E14.5 FL-LSK cells showed no defect in engraftment ability
compared to Nbea+/+ controls, suggesting that embryonic plasticity has allowed
for compensation. When CD45.2+ LSK cells derived from primary recipients of
Nbea-/-E14.5 FL-LSK (CD45.2+) cells were isolated and transplanted into sec-
ondary recipients, a 25% reduction in repopulating activity was observed, sup-
porting a role for Nbea in HSCT and HSC self-renewal. To understand how
Nbea regulates HSC biology, we looked for differentially expressed genes using
arrays on total RNA isolated from E14.5 FL-CD150+CD48- LSK cells sorted
from both Nbea+/+ and Nbea-/- embryos. Gene sets implicated in Snare inter-
actions, vesicular transport, and Adherens junctions interactions were upregu-
lated in Nbea-/- cells, supporting a role for Nbea in these processes.
Summary/Conclusions: Nbea is a bona fide regulator of HSC in vivo repop-
ulation. Although Nbea is dispensable for native hematopoiesis, differences
present in genes with a role in both vesicular trafficking and Adherens Junctions
Interactions highlight the role of Nbea in these processes and how important
they are for proper HSC interactions with the BM niche during HSCT.
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ACUTE MYELOID LEUKEMIA (AML) PATIENTS CURED AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION GENERATE
TUMOR-SPECIFIC CYTOTOXIC ANTIBODIES THAT KILL AML BLASTS
M Hazenberg1,*, M Gillissen2, M Kedde3, G de Jong2, E Yasuda3, S Levie3,
A Bakker3, Y Claassen3, K Wagner3, M Bohne3, D Speijer4, P Hensbergen5,
P van Helden3, T Beaumont3, H Spits3
1Hematology, AMC, 2Hematology, Academic Medical Center, 3AIMM Thera-
peutics, 4Medical Biochemistry, Academic Medical Center, Amsterdam, 5 Center
for Proteomics and Metabolomics, Leiden University Medical Center, Leiden,
Netherlands
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) can
cure acute myeloid leukemia (AML) when the donor immune system generates
a potent graft versus leukemia (GvL) response. While the role of T cells and NK
cells in GvL immune responses has been established, the contribution of B cells
to GvL responses is less clear. Using SEREX and other techniques, the presence
of antibodies directed against established tumor antigens following allogeneic
HSCT has been demonstrated, but because these antibodies were not obtained
in monoclonal format, the function of these antibodies could not be analyzed.
Aims: To investigate the role of antibodies produced by donor-derived B cells
in GvL responses.
Methods: We selected five patients with high-risk AML who remained disease-
free for more than 5 years after allogeneic HSCT and thus have mounted a
potent GvL response. From the peripheral blood of these patients we isolated
memory B cells that we transduced with Bcl-6 and Bcl-xL, to establish anti-
body-producing clonal B cell lines. Blood was obtained 2 years after allogeneic
HSCT. B cell lines were screened for the production of antibodies that specifi-
cally bound to surface antigens on AML cell lines and AML blasts isolated from
patients in our clinic. Target identification was performed by immunoprecipitation
and mass-spectometry.
Results: We identified patient derived clonal B cell lines producing antibodies
that recognized antigens expressed on the cell surface of AML cells, but not on
normal hematopoietic and non-hematopoietic cells. Antibodies were donor-
derived, and a number of these antibodies recognized the U5 snRNP200 com-
plex. The U5 snRNP200 complex is a component of the spliceosome that in
normal cells is located in the nucleus but that is exposed on the cell membrane
of AML cells. U5 snRNP200 complex-specific antibodies were specific for allo-
geneic HSCT recipients with AML, as they were found in in 4 out of 5 AML
patients screened, but were not found in multiple myeloma patients who
received an allogeneic HSCT or in healthy individuals. Strikingly, U5 snRNP200
complex-specific antibodies induced death of AML cells in vitro, and, in a human
AML mouse model, in vivo. Cell death was induced in the absence of cytotoxic
leukocytes or of complement, through a non-apoptotic process that depended
on destabilization of the cytoskeleton as cell death could be blocked by incu-
bation of the target cells with cytochalasin D, an actin polymerization inhibitor.
Cytotoxicity of the U5 snRNP200 antibodies was present at 4°C and 37°C,
suggesting that cell death was induced by a passive process. Indeed, interac-
tion of the antibodies with their target cells did not induce a calcium flux. Cyto-
toxicity of the antibodies depended on the Fc region of the antibody, since
recombinant U5 snRNP200 complex-specific antibodies with a defective Fc
region were not cytotoxic. 
Summary/Conclusions: Allogeneic HSCT recipients with robust donor anti-
AML immunity generate antibodies against a component of the spliceosome,
the U5 snRNP200 complex, that is expressed on the membrane of AML blasts.
U5 snRNP200 antibodies are cytotoxic in vivo and in vitro, demonstrating the
potency of the humoral immune system in tumor immunology.
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INCREASED REACTIVE OXYGEN SPECIES AND EXHAUSTION OF QUIESCENT
CD34-POSITIVE BONE MARROW CELLS MAY CONTRIBUTE TO POOR
GRAFT FUNCTION AFTER ALLOTRANSPLANT
Y Kong1,2,*, Y Song2,3, Y Hu2,3, MM Shi2,3, XJ Huang2,3
1Collaborative Innovation Center of Hematology, Peking University, 2Peking
University Institute of Hematology, Peking University People’s Hospital, 3Acad-
emy for Advanced Interdisciplinary Studies, Peking-Tsinghua Center for Life
Sciences, Beijing, China
Background: Poor graft function is an important, often fatal complication fol-
lowing allogeneic hematopoietic stem cell transplantation. However, the under-
lying mechanism is unclear. In murine study, effective cross-talk between
hematopoietic stem cells (HSCs) and the bone marrow microenvironment is
important for normal hematopoiesis. Normal HSCs reside in a hypoxic bone
marrow microenvironment protecting them from oxidative stress which would
otherwise inhibit self-renewal resulting in bone marrow failure. We recently
reported an impaired bone marrow endosteal and vascular microenvironment
in subjects with poor graft function posttransplant. However, whether an
increased level of reactive oxygen species (ROS) causes poor graft function
following allotransplant remains to be elucidated. 
Aims: The aim of our study is to determine whether quantitative and/or func-
tional abnormalities of donor CD34+ bone marrow cells result in poor graft func-
tion post-allotransplant.
Methods: In the current prospective case-pair study,apoptosis, cell-cycle state
and colony forming capacity of CD34+ bone marrow cells were quantified in
subjects with poor or good graft function post-allotransplant. Moreover, expres-
sion of intracellular proteins including ROS, γ-H2AX, p53, phospho-p53, p21,
phospho-p38, caspase-3 and caspase-9 were analyzed by flow cytometry. To
study the effect of oxidative stress on post-allotransplant hematopoiesis, CD34+
cells from subjects with good graft function were treated of H2O2 with and with-
out N-acetyl-L-cysteine. Subsequently, the hematopoietic reconstituting activity
of the donor CD34+ bone marrow was evaluated using a NOD-PrkdcscidIL2rgnull
xenograft assay by intra-bone marrow injection.
Results: Increased levels of ROS were identified in CD34+ bone marrow cells
in transplant recipients with poor graft function. This increase in ROS levels
was associated with an elevated frequency of DNA double-strand breaks, apop-
tosis, exhaustion of quiescent CD34+ cells and defective colony-forming unit
plating efficiency, particularly in the CD34+CD38- fraction. Up-regulated intra-
cellular p53, phospho-p53, p21, caspase-3 and caspase-9 levels (but not phos-
pho-p38) were detected in CD34+ cells, particularly in the CD34+CD38- fraction.
To further study the potential role of ROS levels in post-transplant
hematopoiesis, CD34+ bone marrow cells from subjects with good graft function
and normals were treated with H2O2. Treatment with H2O2 increased ROS lev-
els, resulting in defective CD34+ cells, an effect partially reversed by N-acetyl-
L-cysteine. Moreover, CD34+ bone marrow cells from the donors to subjects
with poor or good graft function exhibited comparable hematopoietic reconsti-
tution capacities in the xeno-transplanted NOD-PrkdcscidIL2rgnull mice.
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Summary/Conclusions: Even if the transplanted donor’s bone marrow CD34+
cells are functionally normal pre-transplant, ROS-induced apoptosis may con-
tribute to the exhaustion of CD34+ bone marrow cells in subjects with poor
graft function following allotransplant. This effect could be partially reversed by
N-acetyl-L-cystine. Thus, our data suggest a potential approach for treating
poor graft function post-allotransplant.
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MDSC (MYELOID-DERIVED SUPPRESSOR CELLS) DIFFERENTIATE
UNDER GVHD (GRAFT-VERSUS-HOST DISEASE) CONDITIONS AND PREVENT
GVHD BY INDUCING TYPE 2 T CELL RESPONSES
J Messmann1, J Scheurer1, F Leithäuser2, KM Debatin1, G Strauss1,*
1Department of Pediatrics and Adolescent Medicine, University Medical Center
Ulm, 2Institute of Pathology, University of Ulm, Ulm, Germany
Background: Graft-versus-host disease (GVHD) still represents the major
complication after allogeneic bone marrow transplantation (BMT) since allo-
geneic transplant-derived T cells attack and destroy recipient tissues. There-
fore, a prerequisite for GVHD prevention is the interference with T cell activa-
tion, proliferation and functions. Myeloid-derived suppressor cells (MDSCs)
are a population of immature myeloid cells, which inhibit T cell functions by
versatile mechanisms.
Aims: Therefore, we tested whether co-transplantation of in vitro-generated
MDSCs prevents GVHD and elucidated the influence of GVHD conditions on
the differentiation of MDSCs.
Methods: MDSCs were generated in vitro by culturing BM cells in the presence
of GM-CSF and G-CSF. After 4 days more than 90% exhibited a Gr-1+CD11b+
MDSC phenotype. To test whether and how MDSCs prevent allogeneic T cell
functions, we co-transplanted MDSCs into lethally irradiated recipient mice
together with allogeneic BM and spleen cells or we cultivated MDSCs in medi-
um containing serum derived from GVHD developing mice.
Results: In vitro-generated MDSCs efficiently prevented T cell proliferation in
vitro. If co-transplanted with allogeneic BM and spleen cells, MDSCs inhibited
clinical GVHD and GVHD-associated death and attenuated histological GVHD.
Interestingly, MDSCs did not predominantly reduce the numbers of allogeneic
T cells but induced type 2 allogeneic T cells characterized by the expression
of Th2 specific cytokines and transcription factors. In vitro-generated MDSCs
represent a mixed population of CD11b+CD11c- and CD11b+CD11c+ cells. To
further investigate the Th2-inducing capacity of MDSCs, we cultured MDSCs
in medium supplemented with GVHD serum, which induced an expansion of
CD11b+CD11c+ cells. CD11b+CD11c+ cells expressed MHC class IIhigh, Gr-
1med, CD301bpos while CD11b+CD11c- cells were MHC class IIlow, Gr-1high
and CD301bneg. CD301 expression is associated with a Th2 inducing pheno-
type in dendritic cells just as the presence of transcription factors IRF4 and
Klf4, whose expression was also higher in CD11b+CD11c+ cells. Similarly,
MDSCs co-injected with the allogeneic transplant exhibited an expansion of
CD11b+CD11c+ cells in spleen and GVHD target organs preferentially in mice
developing GVHD. Comparable to the in vitro conditions, these CD11b+CD11c+
cells acquired a phenotype similar to antigen-presenting cells characterized
by CD80, CD86, CD40, and MHC class II expression. Isolation of the different
MDSC subpopulations in vitro and subsequent incubation with allogeneic
spleen cells showed that CD11b+CD1c+ MDSCs induce the secretion of Th2
cytokine IL-5, while CD11b+CD11c- cells provoked only a weak Th2 response.
Summary/Conclusions: In summary, we could show that transplantation of
MDSCs prevents GVHD after allogeneic BMT by inducing type 2 T cells. Th2
inducing capacity, however, was preferentially mediated by a subpopulation of
MDSCs. Further studies will elucidate the molecular mechanisms of Th2 induc-
tion and will clarify whether MDSC differentiation and functions are dependent
on the type of inflammatory environment.
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INDUCTION OF NAÏVE T CELLS TRANSITION INTO AN EFFECTIVE
CD4+CD25+FOXP3+CD127- REGULATORY T CELLS, IN VITRO, AS A
POTENTIAL ORDNANCE IN THE PREVENTION OF GRAFT-VERSUS-HOST
DISEASE
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Background: Allogeneic haematopoietic stem cell transplantation (HSCT) has
been used to treat some of haematological malignancies and inherited or
acquired non-malignant diseases. Unfortunately, graft-versus-host disease
(GVDH) occurred approximately 15% in transplant recipients and decreases
the success of allogeneic HSCT. At present, no effective treatment can com-
pletely prevent the GVHD from allogeneic HSCT patients. CD4+CD25+FoxP3+
regulatory T cells (Tregs) have been shown to be important in maintaining
immune homeostasis and preventing autoimmunity. However, 5% to 10% Tregs
could be measured in human CD4+ T cells and few Tregs would convert to
conventional activated T cells because of losing FoxP3 expression. It had been
reported to correlate with the occurrence and severity of GVHD in some study. 
Aims: In order to study the potential use of Treg cells for GVHD prevention,
we attempt to evaluate the better method to increase the number of induced
Treg cells (iTregs) in donor’s PB and stabilize the FoxP3 in iTreg cells. To
isolate the effective CD4+CD25+Foxp3+CD127-iTreg cells for clinical applica-
tion and to establish a quick method to identify the functional iTreg cells is the
study goal. Therefore, naïve T cells isolation for regulatory T cell induction is
an important issue.
Methods: Mouse splenocytes were prepared from mouse spleen. Human
PBSC were prepared from peripheral blood (PB) of healthy donors by Ficoll-
Hypaque density gradient centrifugation. All T cells were isolated by negative
selection; then CD4+naïve T cells were harvested. After that, the CD4+naïve
T cells were activated by anti-CD3/CD28 beads in the presence of IL-2, TGF-
β and retinoic acid (RA) containing RPMI1640 medium. The cells cultured with
3-day-nutrient-deprived medium (only 5% FBS), then refreshed the cells into
the full nutrient supplement (10% FBS) for another 5 days. The harvested cells
were analyzed by flow cytometry method with fluorescence-conjugated CD-
antibodies, including CD4, CD25, CD127 and FoxP3. After trypanblue staining,
the number of iTreg cell was counted by hemacytometer. The iTreg cells also
harvested and the expression of functional marker genes in iTreg cells were
analyzed via qPCR.
Results: In nutrient-deprived (5% FBS for 3 days in advance) culture system,
we found the TGF-β triggered the mouse iTreg cells formation in a dose-depen-
dent manner and increased iTreg cells formation efficiency under retinoic acid
condition. Our data showed that we could induce the CD4+CD25+
Foxp3+CD127-iTreg cells more than 90%. The supplement of retinoic acid (0.1
and 0.5 nM) stabilized the FoxP3+ gene expression in iTregs during this incu-
bation period; and the stability of FoxP3 expression and iTreg cell number
could be maintained at least 12 days in vitro. The stability of iTreg cells is an
important criterion for clinical use. Furthermore, we have analyzed the FoxP3
gene and the bio-functional marker genes expression in iTreg cells to confirm
the functional cells (Fig.1A). Based on these results, we consider the human
T cells should be used. Therefore, we have investigated the human regulatory
T cell induction. Human CD4+ naïve T cells were isolated from PB and activated
via antibodies. The CD4+CD25+Foxp3+CD127-iTreg cells were induced to
around 60~80% under IL-2 and TGF-β1 containing media, even without retinoic
acid supplement (Fig.1B). It indicated we could harvest more iTreg cells under
such condition. As we know, nTreg could suppress the induction of iTreg in
vivo; further, we should remove the nTreg for improving the iTreg formation
under cytokines supplement condition.
Figure 1. Functional iTreg cells induction. (A) The relative changes of
gene expression in functional i Treg cells. (B) The human CD4+naïve T
cells were isolated from human peripheral blood, and then activated with
anti-CD3/CD28 antibodies. After TGF-β1 induction, the number of
CD4+CD25+FoxP3+CD127- iTreg cells increased significantly in dose-
dependent manner, even without retinoic acid supplement.
Summary/Conclusions: Our study showed that the combination of IL-2, TGF-
β1 and RA in 3-day-nutrient-deprived medium could convert CD4+naïve T cells
to CD4+CD25+FoxP3+CD127- iTreg cells and stabilize FoxP3 expression in
the iTreg cells markedly. Further, we use the marker genes to clarify the bio-
logical function of iTregs in vitro. It may be to identify the functional iTreg cells
quickly, after iTreg cells induction. Based on this method, we could harvest
more and effective iTreg cells ready for use. It should be helpful for clinical
application. GVHD mouse model will be established by using allogeneic HSCT
to verify iTreg’s function in vivo.
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ARCADE (20090160): A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED
DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN THE TREATMENT OF ANEMIA
IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC
SYNDROMES (MDS)
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S Badre7, E Gasal7, B Mehta7, J Franklin7
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Background: Although erythropoiesis-stimulating agents (ESAs) are recom-
mended in clinical guidelines to treat anemia in patients with lower-risk MDS,
ESAs are not widely approved for this indication.
Aims: To evaluate the efficacy and safety of darbepoetin alfa (DAR) in IPSS
low / intermediate-1 (int-1) risk MDS patients with anemia, in a phase 3, ran-
domized, placebo(PBO)-controlled trial (EudraCT#2009-016522-14, NCT#
01362140).
Methods: Patients were enrolled from Dec 21, 2011 to Aug 27, 2014 in 9 Euro-
pean countries. Eligible patients had low/int-1 MDS, anemia [hemoglobin (Hgb)
≤10 g/dL], low transfusion burden (<4 transfusion units in each of 2 consecutive
8-week periods prior to randomization), no previous treatment with ESAs or
biologic response modifiers, and endogenous erythropoietin (EPO) levels ≤500
mU/mL. Patients were randomized 2:1 to receive 24 weeks of subcutaneous
DAR 500 µg or PBO every 3 weeks (Q3W), stratified by IPSS status (low or int-
1). The dose was reduced if Hgb was >12.0 g/dL or if Hgb increased by >1.5
g/dL in 3 weeks without transfusion. Investigational product (IP) was discontin-
ued and the patient entered follow-up if >3 dose reductions were needed. Key
efficacy endpoints included (1) transfusion incidence from weeks 5-24 and (2)
erythroid response (HI E) per IWG 2006 criteria, ie, ≥1.5 g/dL increase from
baseline in Hgb with a mean rise of ≥1.5 g/dL for 8 weeks without transfusions.
Results from the 24-week double-blind period are reported here; patients could
then receive open-label DAR 500 µg Q3W for 48 weeks and were followed up
for survival and progression to AML status for up to 3 years (ongoing).
Results: A total of 147 patients were randomized; 50.7% of patients were IPSS
low risk and 49.3% were int 1 risk, median Hgb levels were 9.3 (Q1:8.8, Q3:9.7)
g/dL, median EPO levels were 69 (Q1:36, Q3:158) mU/mL, rates of good /
intermediate / poor IPSS karyotype were 91% / 9% / 0%, respectively, and%
WHO classifications were RA:15%, RARS:14%, RCMD:44%, del5q:9%, RAEB-
1:16%, and MDS U/unknown:2%. There were 146 (97 DAR, 49 PBO) patients
in the primary analysis set. Baseline demographic and disease characteristics
were generally similar between the two arms. Transfusion incidence from weeks
5-24 was significantly reduced with DAR vs PBO (DAR:36.1% vs PBO:59.2%,
p=0.008). The proportion achieving HI-E was significantly increased with DAR
vs PBO; DAR:14.7% (11 of 75 evaluable) vs PBO:0% (0 of 35 evaluable),
p=0.016. All patients with HI-E (n=11) had a baseline serum EPO level <100
mU/mL. Adverse events (AEs) occurring ≥5% more frequently in the DAR arm
than the PBO arm were fatigue, pyrexia, headache, and myalgia. Safety results
from this trial were consistent with the previous DAR phase 2 MDS trial
(Gabrilove BJH 2008, 142:379-393).
Table 1.
Summary/Conclusions: In this phase 3, randomized, double-blind, PBO-con-
trolled trial in low/int-1 MDS patients with anemia, 24 weeks of DAR Q3W sig-
nificantly reduced transfusions and increased rates of erythroid response with
no new safety signals.
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CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES (MDS) WITH OR WITHOUT PRETREATMENT THROMBOCYTOPENIA
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Background: The estimated prevalence of thrombocytopenia in MDS is 40-
65% (Kantarjian, Cancer, 2007). Severe thrombocytopenia (platelet count
<30x109/L) is one of the worst prognostic factors for patients (pts) with MDS
(Garcia-Manero, Am J Hematol, 2015). It has been suggested that pts with
IPSS Low or Intermediate (Int)-1 risk MDS with severe thrombocytopenia should
be considered higher-risk and receive disease-modifying therapy (DMT) at
diagnosis (Gonzalez-Porras, Cancer, 2011). Like other DMTs, azacitidine (AZA)
is associated with transient exacerbation of cytopenias during early treatment
(Tx), which improve as Tx continues (Santini, Eur J Haematol, 2010). CC-486,
the oral formulation of AZA, is in clinical development for Tx of hematologic
malignancies, including MDS.
Aims: Evaluate the safety and efficacy of CC-486 monotherapy in pts with
MDS with or without pretreatment thrombocytopenia.
Methods: Pts with MDS from three phase 1/2 CC-486 studies, two of which
included dose-finding periods, were included in these analyses. CC-486 dosing
regimens were: 120-600mg x7 days (d) (following a single SC AZA 75mg/m2
x7d/28d cycle), or (with no initial SC AZA cycle) 300mg QD or 200mg BID x14d
or 21d. All dosing regimens were administered in repeated 28d cycles. Throm-
bocytopenia was defined as platelet count ≤75x109/L. Overall Response includ-
ed complete remission (CR), partial remission (PR), hematologic improvement
(HI), and transfusion independence (TI) (Cheson, Blood, 2006).
Results: In all, 137 MDS pts participated in the three studies, including 72 pts
with platelet counts ≤75x109/L (LowPlt group). Median age of all pts was 72
years (range 31-91). Median platelet count at baseline in the LowPlt group was
32.5x109/L (range 2-75) and in pts with platelet counts >75x109/L (HiPlt group)
was 162x109/L (78-593). At entry, pts in the LowPlt cohort were less likely to
have WHO-defined refractory anemia (15% vs 42% of pts in the HiPlt group)
and more likely to have higher-risk (IPSS Int-2 or high) MDS (31% vs 12%,
respectively). Rate of CR+PR was 22% in the LowPlt cohort and 7% in the
HiPlt cohort, and Overall Response was the same in both groups (42%, Table).
In the LowPlt group, 2 pts (14%) attained platelet TI and 17 pts (24%) attained
HI-P. The most frequent Grade 3-4 treatment-emergent adverse events were
hematological; anemia, neutropenia, febrile neutropenia, and thrombocytopenia
occurred in 17%, 13%, 18%, and 21%, respectively, of pts in the LowPlt group,
and in 26%, 26%, 14%, and 14% of pts in the HiPlt group. Grade 3-4 bleeding
events were infrequent (n=9, 6.6%) and did not occur more often in the LowPlt
group (GI [n=2], vaginal or cerebral hemorrhage [n=1 each]) than in the HiPlt
group (GI [n=4] or ear hemorrhage [n=1]). Six deaths occurred during CC-486
treatment, 4 in the LowPlt group and 2 in the HiPlt group, including a 93-yr-old
HiPlt pt who died of GI hemorrhage related to a duodenal ulcer.
Table 1.
Summary/Conclusions: CC-486 was generally well tolerated in these MDS
pts, even in the LowPlt group with median pretreatment platelet counts border-
ing on severe thrombocytopenia. Grade 3-4 bleeding events were uncommon
overall and occurred less frequently in the LowPlt group. Death was more fre-
quent in the LowPlt cohort, consistent with the poor prognosis associated with
marked thrombocytopenia. However, more than 20% of pts in the LowPlt group
attained CR during CC-486 therapy and pts were equally likely to attain HI
whether in the LowPlt or HiPlt group.
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Background: Thrombocytopenia is a serious life-threatening complication in
patients with advanced myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML). Eltrombopag (EPAG), an oral thrombopoietin receptor agonist,
is approved for treatment of chronic immune thrombocytopenia, hepatitis C virus-
related thrombocytopenia, and severe aplastic anemia. Preclinical studies showed
that EPAG has potential antileukemic effects (Roth M et al. Blood. 2012;120:386–
94). A randomized, placebo-controlled, Phase 1/2 study in advanced MDS/AML
demonstrated an acceptable safety profile at EPAG doses up to 300 mg daily,
with no disease progression, and a trend toward improved platelet pharmacody-
namics (Platzbecker U et al. Lancet Haematol. 2015;2: e417–26).
Aims: To determine the effect of EPAG on reducing the number of clinically
relevant thrombocytopenic events (CRTE) in patients with MDS or AML who
have Grade 4 thrombocytopenia (platelets <25 Gi/L).
Methods: After 8 weeks of open-label, dose-defining EPAG treatment (Part 1
[Mittelman M et al. Blood. 2012;120(21): Abs 3822]), adult patients with
advanced MDS or AML were randomized 2:1 in a double-blind fashion (Part 2)
to 12 weeks of supportive care plus once daily EPAG (dose range 50–300 mg
over the course of treatment) or placebo. Patients were stratified by baseline
platelet count (<10 Gi/L vs ≥10 Gi/L) and disease severity (International Prog-
nostic Scoring System intermediate-2/high-risk MDS versus AML). Eligibility
included 10–50% baseline bone marrow blasts and a baseline platelet count
of <25 Gi/L. The primary endpoint was reduction in CRTEs (a composite of
platelet counts <10 Gi/L, platelet transfusions, and Grade ≥3 World Health
Organization [WHO] bleeding scale events) during Weeks 5–12. Secondary
endpoints included safety, platelet transfusion independence, maximum WHO
bleeding, hematologic improvement, and MDS progression (increased blast
percentage or leukemic transformation).
Results: At baseline, age ranged from 29–85 years (mean 72.3; n=98) in the
EPAG group vs 44–87 (mean 70.6; n=47) in the placebo group. More patients
had abnormal (53% vs 34%) or poor (34% vs 17%) karyotypes in the EPAG
group. Fewer EPAG patients had baseline platelets <10 Gi/L (34% vs 45%)
than placebo patients. Other baseline characteristics were similar. Efficacy
results are described in the Table. EPAG-treated patients showed significantly
lower CRTE than placebo (54% vs 69%; odds ratio=0.202, P=0.03). Propor-
tionately fewer patients on EPAG than placebo experienced independent
reviewer-assessed disease progression (42% vs 60%). The most frequent
adverse events in this study were petechiae (42% vs 23%), epistaxis (28% vs
23%), pyrexia (24% vs 28%), diarrhea (21% vs 17%), and fatigue (25% vs 9%)
on EPAG versus placebo, respectively. More EPAG (31.6%) than placebo
(14.9%) patients discontinued due to AEs. During Part 2, 35% of EPAG and
28% of placebo patients died (P=0.287). The primary cause of death for both
groups was the disease under study (EPAG 27%; placebo 23%).
Table 1. Efficacy results of 12-week, randomized, double-blind treatment
in the ASPIRE study.
Summary/Conclusions: Treatment of patients with advanced MDS or AML
with the thrombopoietin receptor agonist EPAG versus placebo for 12 weeks
resulted in fewer CRTEs and did not result in an increase of disease progres-
sion. Rates of WHO Grade 3/4 bleeding were lower with EPAG. EPAG did not
demonstrate overall hematologic improvement in this study. This study
(NCT01440374) was sponsored by GlaxoSmithKline; however, as of March 2,
2015, eltrombopag became an asset of Novartis AG.
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Background: Splicing factor mutations in MDS patients (pts), notably SF3B1,
correlate with bone marrow ring sideroblasts (RS) and ineffective erythropoiesis
(IE). Luspatercept (ACE-536), a fusion protein containing modified activin
receptor type IIB, is being developed for treatment of anemia due to IE in MDS.
Luspatercept binds GDF11 and other TGF-β superfamily ligands to promote
late-stage erythroid differentiation and increase hemoglobin (Hgb) levels (Sura-
gani R, Nat Med and Attie K, Am J Hematol, 2014).
Aims: This is an ongoing, phase 2, multicenter, open-label, dose-finding study
followed by a long-term extension study to evaluate the effects of luspatercept in
pts with low-intermediate risk MDS. Endpoints included erythroid response (IWG
HI-E), RBC transfusion independence (RBC-TI, ≥8 weeks), duration of HI-E,
pharmacodynamic and iron metabolism biomarkers, safety, and pt-reported QOL.
Methods: Inclusion criteria included age ≥18 yr, Hgb <10 g/dL (if <4U RBC/8
weeks), ESA refractory or EPO >500 U/L, no prior HMA, and no current
lenalidomide or ESA. Luspatercept was administered SC every 3 wks for up to
5 doses in the base study, including 7 dose escalation cohorts (n=27 total,
0.125 to 1.75 mg/kg) and an expansion cohort (n=31, starting dose 1.0 mg/kg,
max. 1.75 mg/kg). An amendment to the base study allows for additional pt
subgroups (n=~50). A 2-year extension study (n=32 to date) is ongoing.
Results: Data (as of 31 Aug 2015) were available for 58 pts. Of these, 39 pts
received ≥4U RBC/8 weeks (high transfusion burden, HTB) and 19 pts <4U
RBC/8 weeks (low transfusion burden, LTB). Median age was 72 yr (range 27-
90 yr) and 66% had prior ESA. Median RBC transfusion burden was 6U/8
weeks (range 4-18 units, HTB pts) and median Hgb was 8.7 g/dL (range 6.4-
10.1 g/dL, LTB pts). 82% pts were RS+ (≥15% RS in bone marrow), including
19% RARS and 50% RCMD-RS.
LTB: IWG HI-E was achieved in 8/17 (47%) pts in the higher dose groups,
compared with 0/2 in the lower dose groups in the base study. In the extension
study, 9/13 (69%) pts achieved HI-E. Mean Hgb increase at Week 12 was 2.9
g/dL in HI-E responders and 1.3 g/dL in HI-E non-responders. 3/3 LTB pts who
had 2U RBC/8 weeks at baseline became RBC-TI.
HTB: IWG HI-E was achieved in 16/32 (50%) in the higher dose groups
(≥0.75mg/kg), compared with 2/7 (29%) in the lower dose groups, and 8/32
(25%) became RBC-TI in the base study. In the extension study, 13/19 (68%)
achieved HI-E and 8/19 (42%) became RBC-TI (duration up to 50+ wks). IWG
HI-E was achieved in 22/40 (55%) RS+ pts and 2/7 (29%) RS- pts. Response
rates were 64% for EPO <200 U/L, 36% for EPO 200-500 U/L, 57% for ESA-
naïve, and 46% for those refractory to prior ESA treatment. 18/30 (60%) pts
with SF3B1 mutation responded; other potential predictors of response are
being explored. Luspatercept was well tolerated, with 3 possibly related grade
3 adverse events of myalgia, worsening of general condition, and blast cell
count increase. The most common possibly related AEs in the base study were
diarrhea, fatigue (3 pts each), injection site erythema, bone pain, myalgia, and
hypertension (2 pts each).
Summary/Conclusions: Luspatercept treatment was well tolerated and led
to erythroid response in ~50% of low-intermediate risk MDS pts. Higher
response rates were observed in RS+ and SF3B1mut pts, and responders
included pts who were both ESA naïve and ESA-refractory, or with EPO up to
500 U/L. A Phase 3 study of luspatercept in regularly-transfused RS+ patients
with lower-risk MDS according to IPSS-R is ongoing (MEDALIST study; clini-
caltrials.gov NCT02631070).
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COMPARISON OF 1690 MDS PATIENTS FROM THE EUROPEAN
LEUKEMIANET REGISTRY AND REFERENCE POPULATIONS – EVIDENCE
FOR A SIGNIFICANT IMPAIRMENT IN QOL IN MDS AND DEFINITION OF
PREDICTORS OF DIMINISHED QOL
R Stauder1,*, G Yu2, T Bagguley2, P Fenaux3, A Symeonidis4, G Sanz5,
J Cermak6, M Mittelman7, E Hellström-Lindberg8, S Langemeijer9, MS Holm10,
K Mądry11, L Malcovati12, A Tatic13, U Germing14, A Savic15, C van Marrewijk9,
A Guerci-Bresler16, E Luño17, J Droste9, K Koinig18, A Smith2, D Bowen19,
T de Witte20
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5Dep. of Haematology, Hospital Universitario y Politécnico La Fe, Valencia,
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Praha, Czech Republic, 7Dep. of Medicine A, Tel Aviv Sourasky (Ichilov) Medical
Center, Tel Aviv, Israel, 8Dep. of Medicine, Div. Hematology, Karolinska Insti-
tutet, Stockholm, Sweden, 9Dep. of Hematology, Radboud University Medical
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Warszawa Medical University, Warszawa, Poland, 12Dep. of Hematology Oncol-
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ical Institute, Bucharest, Romania, 14Dep. of Hematology, Oncology and Clinical
Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany, 15Clinic of
Hematology-Clinical Center of Vojvodina, University of Novi Sad, Novi Sad,
Serbia, 16Service d’Hématologie, Centre Hospitalier Universitaire Brabois Van-
doeuvre, Nancy, Nancy, France, 17Servicio d’Hematología, Servicio de Salud
del Principado de Asturias Oviedo, Oviedo, Spain, 18Dep. of Internal Medicine
V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Aus-
tria, 19St. James’s Institute of Oncology, Leeds Teaching Hospitals, Leeds, Unit-
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Background: Health-related quality of life (HRQoL) has been introduced by
authorities, stakeholders and clinicians as a relevant patient reported outcome.
Description of HRQoL-profile in MDS-patients is essential for individualized
treatment algorithms.
Aims: To analyze the impact of MDS on HRQoL at initial diagnosis as compared
to sex- and age-matched reference populations and to define predictors of
impaired HRQoL.
Methods: A prospective European Registry (EUMDS) for newly diagnosed
IPSS low-/int-1 MDS was initiated by the European Leukemianet. The EQ-5D
descriptive system was introduced in EUMDS at initial diagnosis. EQ-5D data
from MDS-patients were compared with sex- and age-matched reference pop-
ulations published by the Euroquol Group.
Results: 1985 EUMDS patients from 140 hematology centers in 15 European
countries diagnosed between December 2007 to February 2016 were included.
1690 (85.1%) patients (median age 74; range 18 – 95 yrs) and 61.5% male,
completed both EQ-5D descriptive system and EQ VAS at the time of inclusion.
Demographic characteristics of patients who completed EQ-5D questionnaire
did not differ substantially from the whole cohort. Overall, the HRQoL-data in
the sample analyzed were likely missing at random. A significant proportion of
MDS-patients were characterized by moderate/severe restrictions in the dimen-
sions mobility in 41%, self-care 13.3%, usual activities 36.1%, pain/discomfort
49.5%, and anxiety/depression 37.9%, respectively. Overall, Wilcoxon signed
ranks tests showed that in MDS a significantly higher proportion of patients
reported problems in mobility (41.0 vs 33.5%), usual activities (36.1 vs 26.0%)
and anxiety/depression (37.9 vs 14.9%) than in European norms (p<0.001).
Similarly, both EQ-5D index and VAS were more unfavorable in MDS as com-
pared to references (0.74 vs 0.76; p<0.05) (69.6 vs 71.8; p<0.05) (paired t-
tests). Most impairments in HRQoL were significantly correlated with advanced
age, female sex, a higher comorbidity burden (defined by HCT-CI or MDS-CI),
low Hb-level (<10 vs ≥10 g/dl) and red blood cell transfusion need (0 vs
≥1))(p<0.001). In contrast the impact of WHO-diagnosis and IPSS-R on HRQoL
was only marginal. Comparisons with European reference norms revealed pro-
nounced impairments in MDS-patients in usual activities and anxiety/depression
in all age groups (<60 vs 60-75 vs 75+ yrs) (p<0.001 for each subgroup) and in
both sexes (p<0.001). The impact of MDS on mobility was most prominent in
male (p<0.001) and elderly persons (60-75 (p<0.01) vs 75+ yrs (p<0.001)). VAS
was more often diminished in women (p<0.05) and at advanced age (75+ yrs
(p<0.001)), as compared to reference cohorts. A hierarchical multilevel analysis
was preformed to assess whether there was a significant difference in HRQoL
between groups with different demographic and clinical parameters. Based on
univariate analyses advanced age, female gender, pronounced comorbidities,
low Hb and transfusion need were major determinants, both of EQ-5D index
and VAS (p<.001). In multivariate modeling there was a significant loss in HRQoL
for elderly (-0.082 for EQ-5D index and -7.33 for VAS for those 75+ yrs), for
advanced comorbidities (-0.059; -6.21 for MDS-CI int/high), low Hb-levels (-
0.053; -5.56), transfusion need (-0.045; -4.02) and female sex (-0.077; -3.64).
Summary/Conclusions: This study demonstrates profound restrictions in dis-
tinct dimensions of the EQ-5D in MDS-patients at diagnosis as compared with
age- and sex-matched reference populations and defines major predictors of
HRQoL. This analysis forms the basis to address specific needs of MDS-
patients and provides data for benchmark analyses.
Red blood cells and iron
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GENETIC LOSS OF ERYTHROID TFR2 STRONGLY AFFECTS THE
THALASSEMIC PHENOTYPE IN MICE
A Nai1,2,*, MR Lidonnici2,3, I Artuso1,2, G Mandelli3, L Silvestri1,2, G Ferrari2,3,
C Camaschella1,2
1Division of Genetics and Cell Biology, San Raffaele Scientific Institute, 2Vita-
Salute San Raffaele University, 3SR-TIGET – San Raffaele Telethon Institute
for Gene Therapy, Division of Regenerative Medicine, Gene Therapy and Stem
Cells, San Raffaele Scientific Institute, Milan, Italy
Background: Transferrin receptor 2 (TFR2) is a multifaceted protein that in
the liver activates hepcidin, the master regulator of iron homeostasis, while in
erythroid cells is a component of the erythropoietin (EPO) receptor complex.
We have shown that the lack of Tfr2 in the bone marrow (BM) increases the
EPO sensitivity of erythroid cells and mimics iron-deficiency (Nai et al., Blood
2015). β-thalassemias are recessive severe disorders of beta-globin gene,
characterized by microcytic anemia, ineffective erythropoiesis, splenomegaly
and secondary iron overload. Several studies demonstrated that iron restriction
partially corrects the β-thalassemia phenotype in the Hbbth3/+ model of tha-
lassemia intermedia.
Aims: In order to verify if the absence of Tfr2, mimicking iron-deficiency, could
ameliorate the thalassemic phenotype we generated thalassemic animals with
BM selective Tfr2 inactivation.
Methods: We generated thalassemic mice with (Hbbth3/+) or without BM Tfr2
(Tfr2BMKO/Hbbth3/+) by transplanting BM cells from Hbbth3/+ or Tfr2-/-/Hbbth3/+
mutants into lethally irradiated wild-type mice. Chimerism and hematological
parameters were evaluated at 2 months. Mice were sacrificed 4 months after
BM transplantation (BMT). At sacrifice blood was collected for hematological
analysis, transferrin saturation (TS) and Epo levels; liver, spleen and BM cells
were used for gene expression, tissue iron quantification, histology and flow
cytometry analysis.
Results: Two months after BMT the engraftment of donor cells was 98-99%.
Tfr2BMKO/Hbbth3/+ and Hbbth3/+ animals appear viable and indistinguishable
from one another. Tfr2BMKO/Hbbth3/+ mice have greater red cells count and Hb
levels as compared to Hbbth3/+ animals. On the contrary, 4 months after BMT
Tfr2BMKO/Hbbth3/+ mice are smaller and more anemic than Hbbth3/+controls,
have increased spleen size, TS and hepatic iron, but reduced spleen iron con-
tent. The alteration of body iron homeostasis is likely due to their lower hepcidin
levels as compared with Hbbth3/+mice. The ineffective erythropoiesis is exac-
erbated in the absence of Tfr2 and results in extramedullary spleen and liver
erythropoiesis. Anemia is accompanied by increased Epo gene trascription in
the kidney and by increased expression of Epo target genes, such as Epor,
Bcl-xL and erythroferrone (Erfe) in BM. 
Summary/Conclusions: Deleting erythroid Tfr2 in Hbbth3/+ animals has a tran-
sient beneficial effect, but is detrimental in long-term. Reasonably the loss of
Tfr2 increases the sensitivity of thalassemic erythroid cells to Epo stimulation
(as we demonstrated for normal cells), favouring erythroid reconstitution after
BMT. However, when erythropoiesis reaches a steady state, increased stimu-
lation becomes deleterious. We propose that this occurs through high and per-
sistent production of erythroferrone, the soluble factor released by the erythrob-
lasts in order to inhibit the hepcidin expression. This would increase iron absorp-
tion and release, causing iron overload, further impairing the thalassemic ery-
thropoiesis and generating a “thalassemia major-like phenotype” in Tfr2BMKO
Hbbth3/+ mice. Further studies will better elucidate the mechanism of the
observed biphasic effect on the phenotype and whether a time-controlled mod-
ulation of Tfr2 might improve β-thalassemia.
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HIGH SYSTEMIC IRON LEVEL IS A RISK FACTOR FOR CARDIOVASCULAR
DISEASE
F Vinchi1,*, A Simmelbauer1, S Altamura1, B Galy2, MW Hentze3,
MU Muckenthaler1
1Molecular Medicine Partnership Unit (MMPU), University of Heidelberg &
EMBL, 2Infection, inflammation and cancer, German Cancer Research Center
(DKFZ), 3Molecular Medicine Partnership Unit (MMPU), European Molecular
Biology Laboratory (EMBL), Heidelberg, Germany
Background: Iron accumulates in atherosclerotic lesions but its role in athero-
genesis is still debated. In the “iron hypothesis” (1981), Sullivan proposed that
iron is detrimental for the cardiovascular system, promoting atherosclerosis
progression. So far, epidemiological data and studies in animal models have
provided conflicting evidence regarding a role of excess iron in atherogenesis
and cardiovascular disease.
Aims: In this study we aimed to investigate the role of iron overload in the
development of atherosclerosis.
Methods: To this purpose, a mouse model of type IV Hereditary Hemochro-
matosis, in which the hepcidin/ferroportin regulatory circuitry is disrupted due
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to a point mutation in the iron exporter ferroportin (FPNC326S; Altamura et al.,
Cell Metabolism 2014), was interbred with ApoE-null mice(ApoE-/-), that show
increased susceptibility to atherosclerosis. Plaque formation was analyzed in
ApoE-/-FPNwt/C326S mice at 6 and 12 months of age.
Figure 1.
Results: ApoE-/-FPNwt/C326S mice show high serum iron and cholesterol lev-
els, as expected. Importantly, these mice show strongly increased lesion size
and number at both 6 and 12 months of age compared to age-matched Apo-/-
mice (6 months: 1.44±0.23 vs 5±0.53% aortic lesion area, P=0.0001; 12
months: 10.24±1.21 vs 20.44±2.69% aortic lesion area, P=0.0065). The ath-
erosclerotic phenotype positively correlates with higher levels of circulating
iron (12 months: 122.2±6.57 vs 337±19.22 mg iron/dl serum, P<0.0001) and
oxidized LDLs (12 months: 2151±136.8 vs 3243±193.9 nmol oxLDL/ml serum,
P=0.0002). Iron is deposited in the artery media layer, which correlates with
vascular smooth muscle cell senescence, calcifications, vascular oxidative
stress (12 months: 2.45±0.2 vs 4.33±0.32 nmol MDA/mg aorta protein,
P=0.047) and DNA damage. We observe increased vascular permeability (6
months: 0.95±0.2 vs 3.11±0.51 mg aorta Evans Blue, P=0.0022), reduced nitric
oxide availability and sustained activation and inflammation of the vascular
endothelium (P<0.05). Within the atherosclerotic plaques, collagen deposition
is reduced (P=0.0023) and lipid content is increased (P=0.0495), indicating
enhanced plaque instability and faster disease progression. Plaque
macrophages are significantly elevated and correlate with increased iron-
induced CCL2 levels (12 months: 155.5±23.27 vs 305±38.39 pmol CCL2/ml
serum, P=0.01), potentially contributing to increased lesion vulnerability (12
months: plaque vulnerability index P=0.0276). Ecocardiography in ApoE-/-
FPNwt/C326S mice reveals an increased left ventricle mass and increased left
ventricle area and volume in dyastole, plausibly as an attempt to compensate
for increased arterial stiffness. Our mouse model further shows increased fib-
rinogen and pro-thrombin levels (P<0.05), suggesting a pro-thrombotic role for
high systemic iron levels. Prolonged administration of a low-iron diet rescues
the severe atherosclerotic phenotype, proving that iron is detrimental for this
disease. Experiments are ongoing to test the effect of iron chelation therapy.
Summary/Conclusions: Our data suggest that high circulating iron levels
strongly enhance the severity and promote the progression of atherosclerosis,
indicating that systemic iron overload is a risk factor for atherosclerosis and
predisposes to cardiovascular disease. Our findings have potential implications
for those pathological conditions with elevated systemic iron levels, ranging
from patients with hemochromatosis to anemic patients dependent on chronic
blood transfusions, as well as for individuals subjected to intravenous iron
administration (e.g. patients undergoing hemodialysis).
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THE PYRUVATE KINASE ACTIVATOR AG-348 IMPROVES MURINE
Β-THALASSEMIC ANEMIA AND CORRECTS INEFFECTIVE ERYTHROPOIESIS
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A iolascon4, L de falco4, L dang2, C kung2, L De Franceschi1,*
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Background: β-thalassemias (β-thal) are worldwide distributed red cell disor-
ders, characterized by ineffective erythropoiesis and reduced red blood cell
(RBC) lifespan. Increased levels of reactive oxygen species (ROS) have been
reported to play a key role in anemia of β thal, targeting both erythropoiesis
and circulating RBCs. Pyruvate kinase (PK) is an important enzyme in the gly-
colytic pathway, responsible for conversion of phosphoenolpyruvate to pyru-
vate, with concomitant formation of the energy carrier adenosine triphosphate
(ATP). As mature erythrocytes lack mitochondria, they rely almost exclusively
on glycolysis to generate ATP, as well as the interlinked pentose phosphate
pathway shunt to generate the reducing agent NADPH. The possible impact
of PK activity on erythropoiesis is supported by evidence of ineffective erythro-
poiesis in human subjects with PK deficiency as well as mouse models of PK
deficiency. The PK activator AG-348 has been evaluated in Phase I trials in
healthy human subjects (NCT02149966) and is currently in Phase II studies in
PK deficiency patients (NCT02476916). In the Phase I studies, AG-348 was
shown to decrease levels of an upstream metabolite 2,3-diphosphoglycerate
(2,3-DPG) and increased levels of ATP in whole blood, consistent with in vivo
activation of PK.
Aims: To evaluate the impact of AG-348 on anemia and ineffective erythro-
poiesis in a mouse model of β thal intermedia.
Methods: Mouse strains C57B6/2J, as wildtype (WT) controls, and Hbbth3/+,
as a mouse model of β-thal intermedia, were used. Female mice aged between
2-3 months were treated with either vehicle or AG-348 at 50 mg/kg bid by oral
gavage. Hematologic parameters, RBC indices, morphology, and reticulocyte
count were evaluated at baseline, 7, 14, 21 days of treatment. Mouse erythro-
poiesis was studied using the CD44/TER119 gating strategy by FACS. ROS
levels and the amount of Annexin-V+ cells were evaluated in erythroblast pop-
ulations. Liver iron accumulation was evaluated by Pearl’s staining and expres-
sion of liver hepcidin was measured by RT-PCR.
Results: In Hbb3th/+ mice, 21 days of AG-348 treatment was associated with
(i) a marked amelioration of anisopoykylocytosis; (ii) significantly increased Hb
levels, MCV and MCH; (iii) a significant reduction in circulating erythroblasts
(Es) and reticulocyte count; and (iv) reduction of ROS levels in circulating
RBCs. In addition, AG-348 significantly decreased the amount of membrane
precipitated α-globin chains and increased the amount of soluble Hb compared
to the vehicle treated Hbb3th/+ group. Consistent with these findings, we
observed (i) a reduction of extramedullar erythropoiesis as indicated by both a
decrease in spleen weight/mouse weight ratio and total Es (CD44TER119 Fsc
high cells); (ii) a significant increase in pro-Es and basophilic Es, associated
with reduction in orthochromatic Es; (iii) a reduction in ROS levels of Hbb3th/+
Es and the amount of apoptotic orthochromatic Es compared to vehicle treated
Hbb3th/+ mice, suggesting an amelioration of β thal ineffective erythropoiesis.
The amelioration of ineffective erythropoiesis was paralleled by a reduction in
liver iron overload and up-regulation of hepcidin mRNA in liver from AG-348
treated Hbb3th/+ mice.
Summary/Conclusions: Our data show that the PK activator AG-348 benefi-
cially affects ineffective erythropoiesis in a mouse model of β thal and might
represent a novel therapeutic tool in clinical management of anemia in β tha-
lassemic syndromes.
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RAP-536 (MURINE ANALOG OF ACE-536/LUSPATERCEPT) INHIBITS
SMAD2/3 SIGNALING AND PROMOTES ERYTHROID DIFFERENTIATION
BY RESTORING GATA-1 FUNCTION IN A MURINE MODEL OF
Β-THALASSEMIA
P Martinez1,*, M Bhasin2, R Li1, S Pearsall1, R Kumar1, R Suragani1
1Preclinical, Acceleron Pharma, Cambridge, 2Genomics and Proteomics Cen-
ter, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
United States
Background: Previously, we reported elevated Smad2/3 signaling in diseases
characterized by ineffective erythropoiesis such as myelodysplastic syndromes
(MDS) and β-thalassemia (Suragani et al. 2014). Luspatercept (modified ActRI-
IB receptor-Fc fusion protein), a Smad 2/3 ligand trap, has demonstrated effi-
cacy in correcting ineffective erythropoiesis and the resulting anemia in murine
models of MDS and β-thalassemia. RAP-536 (murine version of ACE-536/lus-
patercept) treatment also alleviated disease pathology in β-thalassemic mice.
Aims: In this study, we investigated the molecular mechanism of action of
RAP-536 in a murine model of β-thalassemia.
Methods: Wildtype and β-thalassemic mice were used in this study. β-tha-
lassemic mice (Hbbth3/+) were administered a single bolus of vehicle (VEH) or
RAP-536 (30 mg/kg, i.p) (N=2/group). At 16 hours, splenic basophilic erythrob-
lasts (CD71+Ter119+FSChigh) were sorted by flow cytometry. RNA was isolated
and subjected to genome wide transcriptome profiling using RNA sequencing
analysis. Mouse erythroid leukemic (MEL) cells, primary fetal liver erythroid
and β-thalassemic erythroid precursors were treated with GDF11 in the pres-
ence or absence of ACE-536 as described below. 
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Results: Transcriptome analysis of β-thalassemic erythroblasts identified 74
genes that were differentially expressed (absolute fold change >1.5, false dis-
covery rate adjusted P value <0.05) in RAP-536 treated samples vs VEH treat-
ment. To identify molecular mechanisms, we performed gene set enrichment
analysis (GSEA) (Subramanian et al., 2005) on these samples. The analysis
depicted significant upregulation of target genes of multiple transcriptional reg-
ulators including GATA-1. Previously, multiple studies have established GATA-
1 as a master transcriptional regulator of terminal erythroid differentiation. Fur-
ther GSEA of GATA-1 activator signatures against RAP-536 treatment data
revealed a significant up-regulation of 158 activated genes (Normalized Enrich-
ment Score=2.7, P=0) involved in heme biosynthesis (such as Ppox, Fech, and
Abcb10) and terminal erythroid differentiation (such as Fog1, Klf1 and Bcl-xl).
ACE-536 is known to bind and inhibit Smad2/3 ligands such as GDF8, GDF11
and activin B but not activin A (Suragani et al 2014). Consistent with this data,
treatment of MEL and fetal liver erythroid cells with GDF11 (50ng/mL) induced
Smad2/3 phosphorylation and ACE-536 co-treatment inhibited the increase in
pSmad2/3. In differentiating erythroid cells, GDF11 treatment displayed reduced
nuclear GATA-1 protein levels by both western blotting and immunofluores-
cence studies. Additionally, reactive oxygen species (ROS) levels indicative of
oxidative stress were elevated in MEL and primary fetal liver cells following
GDF11 treatment. Consistent with the increase in ROS, we found decreased
mitochondrial transmembrane potential (Δψm) indicative of unhealthy cells and
increased caspase 3/7 activity in erythroid cells treated with GDF11. Importantly,
treatment of erythroid cells with ACE-536 and GDF11 decreased ROS, restored
Δψm and GATA-1 levels to control levels. Immunofluorescence studies demon-
strated decreased GATA-1 levels in the nucleus of erythroid precursors from b-
thalassemic cells compared to wild type mice. Treatment of these b-thalassemic
erythroid precursors with ACE-536 prevented the decrease in GATA-1 levels.
Summary/Conclusions: Together, these data done with RAP-536 provide a
potential mechanistic role for luspatercept as a novel treatment of β-tha-
lassemia. By inhibiting pSmad2/3 signaling, RAP-536 treatment decreases
ROS, prevents caspase 3/7 activation and GATA-1 cleavage. Thus by restoring
GATA-1 availability and functional activity, RAP-536 treatment causes upregu-
lation of genes involved in promoting terminal erythroid maturation, and con-
sequently corrects anemia in b-thalassemia. Luspatercept currently completed




ETHNICITY AND THE EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM:
A POPULATION-BASED STUDY
A Lazo-Langner1,*, K Liu2, S Shariff2, A Garg1, J Ray3
1Western University, 2Institute for Clinical Evaluative Sciences, London, 3Uni-
versity of Toronto, Toronto, Canada
Background: The epidemiology of Venous thromboembolism (VTE) has been
largely studied in White populations, with much less known among non-Caucasians.
Differences may exist in the biological predisposition to VTE but little is known
about the epidemiology of VTE among immigrants or in relation to ethnicity.
Aims: To generate estimates of the incidence of VTE in immigrants to Ontario,
Canada, grouped by their geographical region of origin as a proxy for ethnicity,
and estimate risk ratios (RR) for different ethnic groups compared to Whites.
Methods: We conducted a population-based retrospective matched cohort
study using linked health care and administrative databases in Ontario, Cana-
da. These datasets were linked using unique, encoded identifiers and ana-
lyzed at the Institute for Clinical Evaluative Sciences (ICES) according to a
pre-specified protocol that was approved by the research ethics board at
Sunnybrook Health Sciences Centre (Toronto, Canada). We identified patients
who immigrated to Ontario between Jan. 1, 2000 and Dec. 31, 2010. A non-
immigrant comparison cohort was matched based on age, sex and place of
residence. The main study exposure was an individual’s ethnicity based on
world geographical region of origin using a previously validated algorithm.
Patients were divided in the following ethnic groups: 1) White, 2) Black, 3)
Latin American, 4) Arab, 5) East Asian (including Chinese, Japanese, Korean,
Filipino and other South East Asian), 6) South Asian, and 7) West Asian. Main
study outcome was the occurrence of a first VTE. Secondary outcomes includ-
ed deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients were
followed until the occurrence of an outcome, death, emigration from the
province or end of follow up period (Dec. 31st, 2014). We calculated age-and
sex specific incidence rates (IR) per 1000 person-years (PY). RR were cal-
culated using Poisson regression models.
Results: We included 1,195,791 people in the immigrant and non-immigrant
cohorts respectively, with a total period of observation >17,000,000 PY. Overall,
the incidence rate for any VTE was 1.25 per 1000 PY (95% CI 1.23 to 1.27).
For DVT the IR was 0.97 per 1000 PY (95% CI 0.96 to 0.99) and for PE it was
0.36 per 1000 PY (95% CI 0.35 to 0.37). The IR for VTE was lower among
immigrants (0.87 per 1000 PY; 95% CI 0.85 to 0.89) than non-immigrants (1.59
per 1000 PY; 95% CI 1.56 to 1.61). Compared to white immigrants, the age-
specific RR were consistently lower for both men and women of East Asian
(RR 0.19-0.33) and South Asian (RR 0.29-0.65) ethnicity across all age groups.
For patients of West Asian and Arab ethnicity the age-specific RR were also
generally lower except for patients <30 or >80 years old. IR for immigrants of
Black and Latin American ethnicity were no different across most age groups.
RR for Black women less than 40 years old were higher compared to White
immigrants. Among immigrants of Black, Arab and South Asian ethnicity who
developed a VTE there was a higher prevalence of a previous delivery or C-
section compared to White immigrants.
Summary/Conclusions: Incidence of VTE is lower among immigrants com-
pared to non-immigrants in Ontario. Among immigrants, those of East and
South Asian ethnicity have a lower risk of VTE compared to whites. This study
was supported by the Institute for Clinical Evaluative Sciences (ICES), which
is funded by an annual grant from the Ontario Ministry of Health and Long-
Term Care (MOHLTC). The opinions, results and conclusions reported in this
paper are those of the authors and are independent from the funding sources.
No endorsement by ICES or the Ontario MOHLTC is intended or should be
inferred. AL-L was supported for this study by a grant from the Academic Med-
ical Organization of South Western Ontario Opportunities fund and by the ICES
Western Faculty Scholars program.
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DECODING THE RISK OF THROMBOEMBOLIC EVENTS IN LYMPHOMA
PATIENTS
D Antic1,*, N Milic2, S Nikolovski1, M Todorovic1, J Bila1, P Djurdjevic3,
B Andjelic1, V Djurasinovic1, A Sretetnovic1, V Vukovic1, J Jelicic1,
B Mihaljevic1
1Clinic For Hematology, Clinical Center Serbia, 2Institute for Medical Statistics
and Informatics, Belgrade, 3Clinic For Hematology, Clinical Centre Kragujevac,
Kragujevac, Serbia
Background: Considering data about increased incidence of thrombosis in lym-
phoma patients and the impact of thrombosis on the survival of lymphoma
patients, the main question was “Which lymphoma patients are candidates for
thromboprophylaxis after establishing the diagnosis of lymphoma and during
chemotherapy?” Owing to risk of thrombocytopenia due to disease or chemother-
apy, patients with hematologic malignancies are often excluded from thrombo-
prophylaxis and those with nonhematologic malignancies are preferred.
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Aims: The aim of this study was to develop the prognostic risk score based on
individual clinical and laboratory parameters that would allow physicians to
designate patients at risk for thromboembolic event.
Methods: We developed prognostic Thrombosis Lymphoma – ThroLy score
based on the study population including 1820 lymphoma patients, who received
at least one cycle of chemotherapy. The study population was divided based
on a split-sample random method into the model developing and validation
cohorts. The model was developed using data from a derivation, and further
assessed in the validation cohort.
Results: 99 patients (5.4%) developed thromboembolic events. The variables
independently associated with risk of thromboembolism were: previous venous
and/or arterial events, mediastinum involvement, BMI>30 kg/m2, reduced mobil-
ity, extranodal localization, development of neutropenia and hemoglobin level
<100g/L. Based on the risk model score the population was divided into the fol-
lowing risk categories: low (score 0-1), intermediate (score 2-3), and high (score
>3). For patients in the derivation cohort classified as at risk for TE (score >1),
the model produced a negative predictive value (probability of not experiencing
TE in patients designated low risk) of 98.5%, and the positive predictive value
(probability of TE occurring in patient designated at risk) of 25.1%. The sensitivity
(probability of being classified as at risk in patients experiencing TE) was 75.4%,
and the specificity (probability of being classified as low risk in patients not expe-
riencing TE) was 87.5%. Interestingly, a high-risk score ≥4 had a positive pre-
dictive value (probability of TE occurring in patient designated at high risk) of
65.2%. The risk model was then applied to the validation cohort (n=584) in
which 34 patients (5.8%) developed TE. Similarly, in the validation cohort, the
negative predictive value was 97.6%; the positive predictive value was 28.9%;
the sensitivity was 64.7%; and the specificity was 90.2%.
Summary/Conclusions: ThroLy score is more specific for lymphoma patients
than any other available score targeting cancer patients. Moreover, it is dynamic,
can be changed during the different phases of therapy, does not require non-rou-
tine laboratory analysis and is not limited to hospitalized or outpatient settings.
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MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH NOAC OR VKA
IN REAL-LIFE: CLINICAL PRESENTATION, MANAGEMENT AND OUTCOME
L Franco1,*, C Becattini1, J Beyer-Westendorf2, L Masotti3, C Nitti4, S Vanni5,
G Manina6, S Cattinelli7, R Cappelli8, R Sbrojavacca9, F Pomero10, S Marten2,
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4Emergency Medicine, Ospedali Riuniti Umberto I-Lancisi- Salesi, Ancona,
5Emergency Medicine, Careggi University Hospital, Firenze, 6Emergency Med-
icine, Policlinico Maggiore, Milano, 7Emergency Medicine, Ospedale Cattinara,
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Santa Maria della Misericordia Hospital, Udine, 10Internal Medicine, Santa
Croce Hospita, Cuneo, Italy
Background: Limited data are available on major bleeding (MB) occurring
during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anti-
coagulants (NOACs) outside clinical trials.
Aims: The aim of this study was to compare clinical presentation, management
and outcome of MB in patients on treatment with VKA or NOAC in real-life.
Methods: Patients hospitalized for MB while on treatment with VKAs or NOACs
were included in a multicenter study to compare clinical presentation, man-
agement and outcome of bleeding. The primary study outcome was in-hospital
death.
Results: As for September 2015, 806 patients with MB were included in the
study, 76% on VKAs and 24% on NOACs. MB was an intracranial hemorrhage
in 51% and 21% patients on VKAs or NOACs, respectively (Odds Ratio [OR]
3.79; 95% confidence interval [CI] 2.59-5.54) a gastrointestinal bleeding in 46%
and 25% patients on NOACs and VKAs, respectively (OR 2.62; 95% CI 1.87-
3.68). In-hospital death occurred in 134 patients (17%), 19% of VKA and 10%
of NOAC patients (OR 2.08; 95% CI 1.24-3.49, p=0.005). The rate of in-hospital
death was similar in NOAC and VKA patients with intracranial hemorrhage
(27% and 26% respectively; OR 1.02, 95% CI 0.49-2.12) and gastrointestinal
bleeding (7% and 11%; OR 0.62, 95% CI 0.23-1.64) and lower in NOAC than
VKA patients with other MBs (3% and 11%; OR 0.39, 95% CI 0.11-0.39).
Summary/Conclusions: Among patients hospitalized for MB while on treat-
ment with anticoagulants, patients on NOACs are less frequently admitted for
intracranial hemorrhage and more frequently for gastrointestinal bleeding as
compared with patients treated with VKA. Mortality is lower in patients with
MBs on NOACs than VKAs although this finding varies across the different
types of MBs. 
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PODOPLANIN EXPRESSION AND INTRAVASCULAR PLATELET AGGREGATES:
THE MISSING LINK BETWEEN CANCER AND THROMBOSIS IN PRIMARY
MALIGNANT BRAIN TUMORS
J Riedl1,*, M Preusser2, F Posch1, PMS Nazari1, S Panzer3, C Marosi2,
P Birner4, J Thaler1, C Brostjan5, D Lötsch6, W Berger6, J Hainfellner7,
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Background: Venous thromboembolism (VTE) is a common clinical problem
in patients with primary malignant brain tumors, and underlying mechanisms
are unclear.
Aims: In a prospective observational study, we explored the association of
podoplanin, a sialomucin-like glycoprotein that has the ability to induce blood
platelet activation and aggregation, with VTE in primary malignant brain tumors.
Furthermore, we investigated the ability of primary human glioblastoma cells,
isolated from a patient with glioblastoma and thrombotic complications, to acti-
vate human platelets in-vitro.
Methods: Immunohistochemical (IHC) staining against podoplanin and platelet
surface protein CD61 was performed in brain tumor specimens of 213 adult
patients (mostly high-grade gliomas [89%]) included in the Vienna Cancer and
Thrombosis Study (CATS), a prospective observational cohort study of patients
with newly diagnosed cancer or progressive disease. Primary endpoint was
symptomatic VTE. In-vitro, co-incubation experiments were performed using
primary glioblastoma cells isolated from a patient included in CATS who had
developed pulmonary embolism (PE) during follow up and whose tumor stained
positive for podoplanin in IHC. Activation and aggregation of human platelets
upon co-incubation with different concentrations of cancer cells was investi-
gated by light transmission aggregometry and macro- and microscopical visu-
alization.
Results: During 2-year-follow-up, 29 (13.6%) patients developed VTE. In
total, 151 (70.9%) tumor specimens stained positive for podoplanin (33 high
expression, 47 medium expression, 71 low expression). Patients with
podoplanin positive tumors had a lower blood platelet count (Median [25th-
75th percentile], G/l: 227 [186-285] vs 286 [241-355]; p<0.001) and higher D-
dimer levels (mg/ml: 0.85 [0.46-1.92] vs 0.42 [0.23-0.79]; p<0.001). Increas-
ing podoplanin-staining intensity was associated with increasing levels of
CD61-positive intravascular platelet aggregates in tumor specimens
(p<0.001). In Cox regression analysis, high podoplanin expression was asso-
ciated with increased risk of VTE (hazard ratio [HR] for high vs no podoplanin
expression: 5.75, 95% confidence interval [CI]: 1.71-19.27; p=0.005). This
association was independent of age, sex and tumor grade (HR 5.71, 95%CI:
1.52-21.26; p=0.010). Figure 1 shows cumulative incidence curves of VTE
according to podoplanin expression levels. Podoplanin-positive glioblastoma
cells induced platelet aggregation, measured by light transmission aggre-
gometry, in a dose-dependent manner, which was not observed in a
podoplanin-negative control glioblastoma cell line. Podoplanin-positive
glioblastoma cells also induced marked macro- and microscopically visible
blood coagulation upon co-incubation with whole blood from a healthy donor,
while this was not observed for podoplanin-negative control cells.
Figure 1. Cumulative incidence of venous thromboembolism (VTE)
accounting for competing risk (death of any cause other than fatal VTE)
according to expression levels of podoplanin. The probability of VTE sig-
nificantly increased with increasing levels of podoplanin staining inten-
sity (log-rank p=0.019).
Summary/Conclusions: High podoplanin expression in primary malignant
brain tumors, which correlated with intravascular platelet aggregates, lower
blood platelet counts and higher D-dimer levels, was associated with increased
risk of VTE. In-vitro, podoplanin-positive cancer cells isolated from a glioblas-
toma patient who developed PE induced marked platelet activation and aggre-
gation. Our study might provide a novel mechanistic insight into the pathogen-
esis of VTE in patients with primary malignant brain tumors.
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HUMAN HEMATOPOIETIC STEM CELL DIFFERENTIATION FOLLOWS A
CONTINUOUS WADDINGTON-LIKE LANDSCAPE
L Velten1, S Haas2, S Raffel2, S Blaszkiewicz2, C Lutz3, E Buss3, D Nowak4,
T Boch4, WK Hofmann4, A Ho3, W Huber1, A Trumpp2, M Essers2,*,
L Steinmetz1
1EMBL, 2HI-STEM gGmbH /DKFZ, 3Department of Internal Medicine V, Uni-
versity of Heidelberg, Heidelberg, 4Department of Hematology and Oncology,
Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Background: Blood formation is believed to occur via the step-wise progression
of haematopoietic stem cells (HSCs) through a tree-like hierarchy of discrete
progenitor cell types. Although several recent studies have challenged different
aspects of this dogma, a comprehensive model of haematopoiesis and entry of
HSCs into lineage commitment is currently lacking. Here, we mapped human
bone marrow haematopoiesis by quantitatively integrating flow cytometric, tran-
scriptomic and functional lineage fate data at the single-cell level.
Aims: Reconstruction of how individual HSCs enter lineage commitment by
quantitatively integrating transcriptomic and functional single cell data that per-
mits the reconstruction of developmental trajectories during HSC differentiation. 
Methods: Healthy human BM HSPCs (Lin-CD34+) were individually sorted and
surface marker fluorescence intensities of a panel of FACS surface markers com-
monly used to characterize these HSPCs were recorded to retrospectively recon-
struct immunophenotypes. Index-sorted HSPCs were subjected to RNAseq
(“index-omics”, 379 cells) to determine their transcriptomes or individually cultured
ex vivo (“index-culture”, 1021 cells) to quantify lineage potential. Subsequently,
the functional and transcriptomic data sets were integrated using commonly
indexed surface marker expression to identify molecular and cellular events asso-
ciated with the differentiation of human HSCs at the single cell level.
Results: We found that individual HSCs neither enter lineage commitment at
binary branching points nor pass through discrete intermediate progenitor cell
stages. In contrast, HSC lineage commitment occurs in a gradual manner best
described by a continuous Waddington landscape with initially flat but progres-
sively deepening valleys. Our data determine a detailed model of developmental
trajectories within this landscape, as well as their underlying gene expression
modules and biological processes.
Summary/Conclusions: Integration of transcriptomic and functional cell fate
data at the single-cell level reveals that human hematopoiesis is not organized
in a hierarchical “tree” of cell types, but follows a continuous differentiation flow
within a Waddington-like landscape with initially flat and gradually deepening
valleys.
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SINGLE-CELL PROFILING OF HUMAN MEGAKARYOCYTE-ERYTHROID
PROGENITORS IDENTIFIES DISTINCT MEGAKARYOCYTE AND ERYTHROID
DIFFERENTIATION PATHWAYS
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Background: The conventional haematopoietic hierarchy proposes that
megakaryocytes (MK) and erythroid cells (E) derive from a shared progenitor,
the MEP. However, the MEP was defined using “bulk” assays and recent studies
have suggested that MEP and other myeloid progenitor populations may be het-
erogeneous. Advances in single-cell techniques now provide the opportunity to
dissect cellular heterogeneity within populations and to uncover rare cell types.
Aims: To integrate multiple different single-cell molecular and cell biology
approaches to uncover heterogeneity in human MEP and to establish a new
FACS strategy to prospectively purify and functionally validate the novel sub-
populations.
Methods: Surface immunophenotype (10 markers) and gene expression pro-
files (GEP) of individual human MEP were correlated using index-FACS and
parallel, targeted multiplex PCR using a specifically designed panel of 87 genes.
Differentiation potential was tested in novel single-cell differentiation assays
(Figure 1).
Results: A total of 681 single Lin-CD34+CD38+CD123-CD45RA-MEPs were
analysed by index sorting and GEP. Principal component analysis of GEP data
identified three distinct MEP subpopulations. Correlation with cell surface
immunophenotype revealed how these novel populations could be prospec-
tively purified using the additional cell surface markers CD44, CD71 and CD41.
MEP Population 1 (CD44hi71-41-; ~43.6% of MEP) showed increased expres-
sion of CD34, CSF3R and FLT3 and lower expression of GATA1 in single-cell
and population-based analyses. Population 2 (CD44mod CD71+CD41-; 37.4%)
showed increased E-associated gene expression (e.g. KLF1, TMOD1, TAL1,
LEF1). Population 3 (CD44mod CD71+CD41+; 5.1%) showed distinct expres-
sion of MK-associated genes (e.g. FLI1, VWF, NH1B, MPL). Single-cell in vitro
differential assays demonstrated that the transcriptional profiles corresponded
to functional differences in lineage potential: Population 1 (designated Pre-
MEPs) contained almost all of the residual myeloid potential within the MEP
compartment and showed frequent MK-E bipotent cells. In contrast, populations
2 (E-MEP) and 3 (MK-MEP) showed a marked lineage bias toward E and MK
lineage commitment respectively. Pseudo-temporal ordering of the cells along
their differentiation trajectory (Monocle analysis) was also compatible with a
more primitive phenotype for Pre-MEP, and suggested that CD42 expression
correlated with loss of E-associated gene expression, a finding confirmed in
functional assays with high MK but absence of E potential in
CD71+CD41+CD42+ MEPs, while CD71+41+42- MK-MEP retained residual
low level capacity to generate E progeny.
Figure 1.
Summary/Conclusions: This report illustrates the power of combining three
single-cell techniques to interrogate cellular heterogeneity within populations,
an approach that is applicable to many other systems. We show that classically
defined MEP in fact contain three distinct subpopulations: (1)“Pre-MEP”,
enriched for E/MK progenitors but with residual myeloid differentiation capacity,
(2)“E-MEP”, strongly biased towards E differentiation, and (3)“MK-MEP”, a rare
population of bipotent cells that primarily generate MK progeny. Importantly,
only a minority of classically defined MEP give rise to mixed E/MK colonies;
the majority of the cells are transcriptionally-primed to generate cells of a single
lineage. We believe that prospective identification of specific intermediate pro-
genitor populations will allow for in-depth study of disorders of erythro-
megakaryopoiesis, including myeloproliferative neoplasms and ery-
thromegakaryocytic leukemias.
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INTERFERON ALPHA MEDIATED REMODELING OF THE BONE MARROW
STEM CELL VASCULAR NICHE
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M Essers1,2
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Background: Bone marrow endothelial cells (ECs) are a major part of the
bone marrow (BM) vascular niche, regulating hematopoietic stem cell (HSC)
function and fate. Furthermore, ECs significantly influence the response of an
organism to infection, the primary response to which involves synthesis of
immune-modulatory cytokines, such as interferon alpha (IFNα). In contrast to
the anti-proliferative effect of IFNα on HSCs in vitro, we, and others, have
shown that IFNα induces cell cycle entry of HSCs in vivo. Here we have inves-
tigated the result of acute IFNα treatment on the BM vascular niche in vivo.
Aims: To investigate the stimulatory effects of acute IFNα treatment on the BM
stem cell vascular niche and its role in the chemotherapeutic response.
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Methods: To characterize the response of the BM vascular niche to IFNα, wild-
type mice were treated with recombinant IFNα or pI:C and were sacrificed 4h
or 24h later. BM ECs were subsequently assessed for key inflammatory and
EC-stimulatory markers by FACS. IFNα-mediated increased BM vascularity
was quantified by in vivo labelling using Alexa 633. BM vessel integrity was
assessed using the Evans blue assay. VEGF signalling was antagonized using
the Anti-VEGF treatment, Avastin. Mice were co-treated with 5-FU and pI:C to
evaluate the effect of IFNα-signalling of chemotherapeutic treatment.
Results: IFNα treatment induced a rapid stimulation of BM ECs in vivo, result-
ing in increased bone marrow (BM) vascularity and vascular leakage. IFNα-
mediated activation of ECs involved the expression of key inflammatory and
EC-stimulatory markers. Abrogation of BM EC activation in vivo, using the Anti-
VEGF treatment, Avastin, linked VEGF signalling, mediated by BM cell types
including HSCs, to IFNα-mediated activation of ECs. Finally, following a period
of recovery, IFNα-signalling led to a rapid recovery of 5-FU-mediated cell acti-
vation and BM homeostasis. 
Summary/Conclusions: Our data shows that IFNα stimulation in vivo leads
to remodelling of the BM stem cell vascular niche, mediated by VEGF. These
data increase our current understanding of the effect of IFNα and anti-VEGF
treatment on HSCs and the stem cell niche in vivo. IFNα-mediated recovery
from 5-FU treatment has obvious implications for therapy, and thus this effect
may influence the clinical application of IFNα.
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CELL-EXTRINSIC HAEMATOPOIETIC IMPACT OF EZH2 INACTIVATION IN
FOETAL LIVER ENDOTHELIAL CELLS
WH Neo1,2,*, C Booth1,2, E Azzoni2, M de Bruijn2, SE Jacobsen1,2, A Mead1,2
1Haemopoietic Stem Cell Laboratory, Weatherall Institute for Molecular Medi-
cine, 2MRC Molecular Haematology Unit, University of Oxford, Oxford, United
Kingdom
Background: The cell-intrinsic role of many different epigenetic factors in the
regulation of normal haematopoiesis and development of blood cancers is well
established. However, the possible role and function of epigenetic regulators
in components of the haematopoietic niche remains largely unexplored. Ezh2,
is a histone methyltransferase and key component of the polycomb repressive
complex 2 (PRC2). Loss of function of PRC2 causes a cell-intrinsic defect in
adult haematopoietic stem cells (HSCs) and block in T- and B-lymphopoiesis.
Further, both increased and reduced PRC2 activity has been implicated in a
range of blood cancers. However, the haematopoietic impact of Ezh2 inactiva-
tion in components of the niche has not been explored.
Aims: Recent evidence supports that vascular endothelial cells (VECs) are
key components of the haematopoietic niche during foetal development and
we therefore aimed to study the haematopoietic impact of Ezh2 depletion in
foetal liver (FL) VECs.
Methods: Ezh2 was depleted in haematopoietic cells with or without deletion
in VECs using Tie2-Cre (Tie2-KO) or Vav-iCre (Vav-KO) respectively, and the
impact on foetal haematopoiesis was explored through phenotypic and func-
tional assays.
Results: At E12.5, both Vav-KO and Tie2-KO embryos showed close to 100%
recombination efficiency in haematopoietic cells, whereas only Tie2-KO showed
high levels of recombination in VECs (CD45-Ter119-CD31+). There was a strik-
ing difference in survival, with embryonic lethality at E13.5 in Tie2-KO embryos
in contrast to Vav-KO which survived beyond E18.5. Numbers of phenotypic
HSCs (LSKCD48-CD150+) were normal in Tie2-KO at E12.5 and expanded
through to E18.5 in Vav-KO embryos, confirmed in functional (in vivo reconsti-
tution) assays, excluding an impact of Ezh2 loss on FL HSCs. In contrast, there
was a Tie2-KO specific loss of E12.5 FL cellularity (fc=0.44; p=0.0006) and
reduction in progenitor cells (LSKCD48+CD150-; fc=0.33; p<0.0001) that was
not present in Vav-KO embryos. Furthermore, Tie2-KO but not Vav-KO E12.5
FLs were severely anaemic, with a marked loss of CD71+Ter119+ erythroid pre-
cursors (fc=0.07; p=0.0010). We reasoned that depletion of Ezh2 in VECs was
causing a cell-extrinsic suppression of FL progenitors, particularly those of ery-
thropoietic lineage. This Tie2-KO phenotype was highly reminiscent of that seen
in Steel mice, and although KitL mRNA expression was increased (fc=3.62;
p=0.0291), immunofluorescence staining demonstrated an almost complete
loss of the membrane bound form of KitL (mKL) in Tie2-KO FL. The loss of mKL
was not VEC-specific, but also affected Tie2-KO hepatoblasts (CD45-Ter119-
CD31-Alb+), which express KitL but are not targeted by Tie2-Cre. As mKL is a
known target of Mmp9, and Mmp9 is a known target of Ezh2, we next examined
Mmp9 mRNA expression and showed this was upregulated in Tie2-KO FLs
(fc=12.41; p=0.0236). In order to confirm the mechanistic role of Mmp9, we
demonstrated that Ezh2-depleted VECs from Tie2-KO FL had reduced capability
to support erythropoietic colony formation in vitro in co-culture assays (fc=0.22;
p=0.0036), which could be fully rescued with Mmp9 inhibitor treatment.
Summary/Conclusions: These data demonstrate a marked cell-extrinsic
haematopoietic impact of PRC2 inactivation in VECs through loss of mKL
expression caused by a marked upregulation of Mmp9 expression. This pro-
vides evidence that modulation of epigenetic regulators can have a major cell-
extrinsic impact on haematopoiesis, of relevance for the development of epi-




STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT
OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF
THE EURO-SKI TRIAL
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Background: The advent of tyrosine kinase inhibitors (TKI) has dramatically
improved survival in chronic myeloid leukemia (CML) with a high percentage
of patients reaching deep molecular responses (MR; Hehlmann 2014). In sev-
eral studies, it could be shown that in a substantial part of patients with deep
MR, TKI treatment can be safely and successfully stopped (Mahon 2010, Ross
2013). However, exact preconditions for stopping treatment in CML have not
yet been defined.
Aims: The EURO-SKI study (European stop TKI study) was set up to define
prognostic markers to increase the rate of patients in durable deep MR after
stopping TKI. Already in an interim analysis the null hypothesis (relapse-free
survival ≤40% at 6 months (m) could be discarded (Mahon ASH 2014, Saussele
EHA2014).
Methods: Adult CML patients in chronic phase (CP) on TKI treatment for at
least 3 years and in MR4 for at least one year, confirmed by 3 consecutive PCR
results during the last 12 m prior to inclusion were eligible. Final MR4 confirma-
tion was performed in a EUTOS standardized laboratory. Patients with a prior
TKI failure were excluded. Primary endpoint is the assessment of molecular
relapse-free survival after stopping TKI defined as survival without loss of major
molecular remission (MMR) at one time point. We here, per protocol, report the
results of all patients, with a minimum follow-up of 6 m. A further follow-up after
3 years is planned. Analyses were done on an intention-to-treat basis.
Results: From June 2012 to December 2014, 868 patients in CP CML from 11
countries were included. 96 were excluded (withdrawal of consent n=1, inclu-
sion criteria violation n=23, atypical or unknown transcript n=8, pending cases
n=64). Of the eligible 772 patients, 46.6% were female. Median age at diagno-
sis was 51.9 years (range 11.2 to 85.5); median age at stop was 60.3 years
(range 19.5 to 89.9). 10% and 18% were high-risk according to EUTOS and
Sokal Score, respectively. One patient decided not to stop therapy after inclu-
sion. 390 patients were mostly pretreated with hydroxyurea prior to TKI therapy,
and 87 patients received interferon before TKI. First-line TKI was imatinib in
94%, dasatinib in 2% and nilotinib in 4%. 115 patients switched to second-line
TKI due to intolerance, 58 to dasatinib, 7 to imatinib, and 49 to nilotinib (one
missing information). Time from diagnosis of CML to first day of stopping TKI
varied from 36.7m to 270.7m, median time was 92.7m. Median duration of TKI
treatment was 91m (range 36.3 to 170.3) and median duration of MR4 prior to
TKI stop was 56.3m (range 12.6. to 159.8). MR4 was reached after a median
time of 21.0m (only first-line patients, range 3.0 to 140.0). 717 patients had
assessable molecular data for the estimation of molecular relapse-free survival.
The median molecular follow-up is 10m. Of these patients, 331 lost MMR, 4
died in remission and 381 are still in MMR at last follow-up (range 1-36 months).
This resulted in a molecular relapse-free survival of 62% (95% confidence
interval (CI): 58%-65%) at 6m, 56% (CI: 52%-59%) at 12m and 51% (CI: 47%-
55%) at 24m (see Fig.1). First univariate analyses in 401 patients with complete
records on all prognostic variables confirmed statistically significant influence
of duration of TKI treatment and of duration of MR4 on molecular relapse-free
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survival up to 6m. Neither sex nor any of the variables part of any of the 2
scores (Sokal, EUTOS) showed a significant association with MMR status at
6m. Data will be completed and multivariate modelling will be presented at the
meeting.
Figure 1.
Summary/Conclusions: In the setting of the EURO-SKI study, high molecular
relapse-free remission rates are achievable. First univariate analysis demon-
strated the importance of the duration of TKI treatment as well as of MR4 prior
to stop. The EURO-SKI trial will further elucidate prognostic factors that improve
the rate of patients in durable MMR after withdrawal of TKI.
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ASSOCIATES WITH SHORTER SURVIVAL AND CONTRIBUTES TO THE
INFERIOR OUTCOMES OF ELDERLY PATIENTS WITH ACUTE MYELOID
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Background: High-throughput sequencing techniques have shown that AML
patients (pts) in complete morphological remission may harbor persistent
preleukemic clones, which might be a source of leukemic relapse. Somatic
mutations in epigenetic modifiers including DNMT3A, TET2 and ASXL1 occur
in ageing-associated clonal hematopoiesis, and mutations in these genes are
frequently present in preleukemic clones of AML pts. Previous studies demon-
strated adverse outcomes of pts with persistent leukemia-associated mutations
in remission (Klco et al., JAMA 2015; PMID: 26305651).
Aims: We studied persistence of driver mutations in remission and clinical out-
comes in a cohort of uniformly treated AML patients.
Methods: We studied 107 adult AML pts (median age, 53 years [y]; range 20-
80y) who received intensive induction chemotherapy within the German multi-
center AMLCG-2008 trial, and reached either complete remission (CR) (80/107,
75%) or CR with incomplete blood count recovery (CRi) (27/107, 25%). Most
patients (90%) had de novo AML, 5% had secondary AML and 5% had thera-
py-related AML. We analyzed bone marrow (BM) or peripheral blood (pB) spec-
imens obtained at diagnosis (BM, n=96; pB, n=11) and during first remission
(BM, n=101; pB, n=6). Ninety-two percent of remission samples were collected
within 180 days after the start of induction therapy. We studied 68 genes recur-
rently mutated in myeloid neoplasms by multiplexed amplicon sequencing (Agi-
lent Technologies), with a mean target coverage of 540x. Sequence alterations
with a variant allele frequency (VAF) of ≥2% were classified as known/putative
driver mutations, variants of unknown significance, or known germline poly-
morphisms based on published data including dbSNP, the Catalogue Of Somat-
ic Mutations In Cancer (COSMIC) and The Cancer Genome Atlas (TCGA).
Results: At diagnosis, 426 driver mutations were detected in 42 genes (median,
4 mutations per patient; range, 0-10). In the paired remission samples, 66 muta-
tions in 15 genes were still present (VAF, ≥2%) in 40/107 pts (37%), while 67
pts (63%) had no persistent mutation. Persistence of mutations during mor-
phological remission was most commonly observed for DNMT3A (23/37 pts
with mutations at diagnosis; 62%), TET2 (9/13; 69%), SRSF2 (5/8; 63%) and
ASXL1 (5/12; 42%). Mutations in other genes including NPM1, FLT3, WT1,
and NRAS were no longer found in the remission samples. Sixty-nine percent
of mutations detected in remission had VAFs >10%. Analyses of minimal resid-
ual disease (MRD) by flow cytometry or quantitative PCR for NPM1 mutations
or MLL-PTD showed similar MRD levels in remission specimens with and with-
out persisting mutations. These findings suggest that mutations detected during
remission are present in a pre-leukemic clone rather than in residual leukemic
cells. Pts with ≥1 persisting mutation in remission were older (median, 63 years
[y]) than pts without any persisting mutation (median, 48y; p<.001). Patients
with non-DNMT3A persisting mutations tended to be older than those with per-
sisting DNMT3A mutations (median, 66.5y vs 60y). Persistence of at ≥1 driver
mutation in remission, in contrast to complete mutation clearance, associated
with shorter relapse-free survival (RFS; median, 14.3 vs 58.0 months; p=.009)
and shorter overall survival (OS; median, 39.6 vs >72 months; p=.005) (Figure
A). Similar outcomes were observed for pts with persisting DNMT3A mutations
and those with other persisting mutations (Figure B). In multivariate analyses
adjusting for age, ELN genetic risk groups, and remission status (CR vs CRi),
detection of any persisting mutation remained associated with inferior RFS
(hazard ratio, 2.2; p=.02) and OS (hazard ratio, 3.0; p=.008).
Figure 1.
Summary/Conclusions: Detection of persisting leukemia-associated driver
mutations during first CR or CRi is common in older AML pts and likely indicates
persistence of a preleukemic clone. Mutation persistence associates with shorter
RFS and OS and might contribute to the inferior outcomes of elderly AML pts.
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DISSECTING THE CONTRIBUTION OF UNREGULATED MACROPHAGE
IRON RECYCLING AND DIETARY IRON UPTAKE IN GENERATING SYSTEMIC
IRON OVERLOAD IN HEMOCHROMATOSIS
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Background: Systemic iron levels are balanced by the hepatic iron hormone
hepcidin and its “receptor” ferroportin (Fpn) to prevent the pathological conse-
quences of iron overload or iron deficiency. Hepcidin binding to the iron exporter
FPN reduces dietary iron export from duodenal enterocytes and iron recycling
from aging erythrocytes in reticuloendothelial macrophages. Mutations as the
Fpn(C326S), that disrupt the hepcidin/FPN regulatory loop, cause an uncon-
trolled iron export from spleen and duodenum resulting in systemic iron overload
(Altamura et al, Cell Met. 2014).
Aims: The aim of this study is to quantify the individual contributions of
macrophage iron recycling and dietary iron uptake to systemic iron levels. This
knowledge is an important prerequisite to develop specific pharmacological
strategies to limit iron export in iron-related disorders.
Methods: By applying cre/lox technology, we generated mouse lines express-
ing the Fpn(C326S) mutation only in duodenal enterocytes (Villin−Cre/
FpnC326S) or in macrophages (Lyz−Cre/FpnC326S) to dissect the single con-
tribution of these two iron exporting cell types in generating iron overload.
10−week old C57BL6/J congenic male mice have been analyzed in this study.
Results: Mice carrying the Fpn(C326S) mutation exclusively in the duodenum
show identical hematological alterations as found both in hemochromatotic
patients and in constitutive Fpn(C326S) mice: increased hemoglobin (Hb),
hematocrit (HCT) and mean corpuscular volume (MCV). Serum iron content
and transferrin saturation are strongly increased further consistent with the
hemochromatotic phenotype. Hepatic iron measurement revealed severe iron
deposition that correlates with increased hepcidin expression. Elevated hepcidin
levels cause iron retention in reticuloendothelial macrophages of the spleen
generating splenic iron overload. Interestingly, Lyz−Cre/FpnC326S mice that
show hepcidin independent macrophage iron export failed to show alterations
in hematological parameters and serum iron levels. However the spleen is iron
depleted, in line with a constitutively expressed iron exporter. By contrast hepat-
ic iron content and hepcidin expression are similar compared to control mice. 
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Summary/Conclusions: Our results show for the first time that increased duo-
denal iron export is the major if not the only contributor in the generation of
systemic iron overload in hemochromatosis. This finding opens new insights
in developing pharmacological strategies aimed to specifically limit dietary iron
import for the treatment of primary and secondary iron overload diseases.
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ETV6-RELATED THROMBOCYTOPENIA (ETV6-RT): CLINICAL AND
PATHOGENETIC CHARACTERIZATION OF AN INHERITED THROMBOCYTOPENIA
(IT) PREDISPOSING TO CHILDHOOD ACUTE LYMPHOBLASTIC
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Background: ETV6-RT is an autosomal dominant IT recently identified in a
few families and suspected to predispose to hematological malignancies.
Aims: To gain information on the clinical and laboratory picture of this new IT,
in particular on predisposition to hematological malignancies.
Methods: 130 unrelated and consecutive patients with ITs were enrolled to
the study: all of them had no definite diagnosis because they did not fit the cri-
teria for any known IT. ETV6 mutations were investigated by whole exome
sequencing (84 probands) or Sanger sequencing (46 probands): whenever
ETV6 mutations were identified, all available relatives of probands were also
investigated. 5 patients from 2 known ETV6-RT families already partially
described (Noetzli L et al, Nat Genet 2015, 47:535) were also included. Each
patient underwent to phenotypic characterization through the following inves-
tigations: complete blood count and platelet sizing, flow cytometry of platelet
membrane glycoproteins, “in vitro” platelet aggregation, platelet activation,
platelet adhesion and spreading, differentiation of human megakaryocytes
(Mks) and morphological analysis, Mk flow cytometry, evaluation of proplatelet
formation by in vitro differentiated Mks.
Results: Overall, 20 subjects from 7 families bearing 5 different ETV6 muta-
tions were identified. The bleeding tendency and the degree of thrombocy-
topenia were mild, but we found that 4 of 20 patients (20%) had childhood ALL,
thus confirming that early leukemic transformation is a major risk of this IT.
Moreover, one patient developed JAK2+ polycythemia vera at age 37, sug-
gesting that this disease should be added to the list of malignancies to which
the ETV6-RT predisposes. Clinical and laboratory findings (platelet aggrega-
tion, surface glycoproteins, activation and adhesion) did not identify any peculiar
defect that can be used to suspect this disorder. In vitro studies revealed that
patient Mks have defective maturation and proplatelet formation, while platelets
have reduced ability to spread on fibrinogen. At variance with most ITs, platelet
size was not enlarged: this finding is shared with ITs due to monoallelic muta-
tions in RUNX1 and ANKRD26, which also have normal platelet size and pre-
dispose to leukemia (the familial platelet disorder with predisposition to acute
myeloid leukemia, and the ANKRD26-RT, respectively). Considering the pos-
sibility that patients with ITs have ETV6-RT is important both for the risk to
develop hematological malignancies, and because this disorder is relatively
frequent: in our series of 274 consecutive propositi, ETV6-RT was identified in
8 families and had, therefore, a relative prevalence of 2.9% in the whole case
series, and of 6.1% in the series of patients with known ITs. In our experience,
the frequency of ETV6-RT was lower only to that of monoallelic Bernard-Soulier
syndrome (BSS, 12.2% in the whole series), MYH9-related disease (11.4%),
ANKRD26-RT (9.4%), and biallelic BSS (5.7%).
Summary/Conclusions: Our study showed that monoallelic ETV6 mutations
cause one of the most frequent forms of ITs and confirmed that affected sub-
jects have little bleeding tendency but high propensity to hematological malig-
nancies, in particular childhood ALL. Since ETV6-RT is one of the few autoso-
mal dominant forms of IT without platelet macrocytosis, the screening for ETV6
mutations is recommended in all patients with these characteristics, along with
the screening for RUNX1 and ANKRD26 mutations.
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BLINATUMOMAB IMPROVED OVERALL SURVIVAL IN PATIENTS WITH
RELAPSED OR REFRACTORY PHILADELPHIA NEGATIVE B-CELL
PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN A RANDOMIZED,
OPEN-LABEL PHASE 3 STUDY (TOWER)
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Background: Blinatumomab, a bispecific T-cell engager antibody construct,
binds specifically to CD19 (B cells) and CD3 (T cells) to facilitate lysis of CD19-
positive target B-lineage cells. Based on a single-arm phase 2 study, blinatu-
momab received approvals in the US (accelerated) and EU (conditional) for
the treatment of Philadelphia chromosome-negative (Ph–) relapsed/refractory
(r/r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Aims: This phase 3, randomized, open-label study investigated the effect of
blinatumomab on overall survival (OS) compared with standard of care (SOC)
chemotherapy in adult patients with Ph– r/r BCP-ALL.
Methods: Patients with r/r BCP-ALL (if first relapse, within 1 y) were random-
ized 2:1 to receive either blinatumomab or SOC chemotherapy (investigator’s
choice of 1 of 4 defined regimens). Randomization was stratified by age, prior
salvage therapy, and prior allogeneic stem cell transplant (alloSCT). Blinatu-
momab was given in 6-week cycles of 4 weeks on (continuous infusion of 9
µg/d in week 1 of cycle 1, then 28 µg/d) and 2 weeks off; dexamethasone was
given pre-dose to prevent cytokine release syndrome. Patients in remission
after 2 induction cycles were eligible to continue therapy until relapse. OS was
the primary efficacy endpoint. Complete remission (CR) and combined CR or
CR with partial or incomplete hematologic recovery (CR/CRh/CRi) were sec-
ondary efficacy endpoints. The primary analysis was scheduled to occur after
330 deaths had accrued. This prespecified interim analysis for an independent
data monitoring committee (DMC) occurred after 248 deaths (75%).
Results: A total of 405 patients were randomized to blinatumomab (n=271) or
SOC (n=134) and analyzed for efficacy; 2% and 19%, respectively, elected to
receive no study treatment. Baseline characteristics were balanced between
treatment groups (blinatumomab, SOC): median age (37y, 37y); median bone
marrow blasts (80%, 79%); prior salvage therapy (56%, 52%); and prior
alloSCT (35%, 34%). Using results from the DMC analysis, median OS was
7.8 months (95%CI: 5.7, 10.0) for blinatumomab and 4.0 months (95%CI: 2.9,
5.4) for SOC (stratified log-rank test p=.011; hazard ratio=0.71), surpassing
the prespecified O’Brien-Fleming boundary p value of 0.0183. Improvement in
OS was consistent between subgroups based on age, prior salvage therapy,
or prior alloSCT. Response rates were higher for blinatumomab vs SOC, includ-
ing CR (39% vs 19%; p<.001) and CR/CRh/CRi (46% vs 28%, p=.001). A total
of 373 patients received ≥1 dose of blinatumomab (N=266) or SOC (N=107;
47 FLAG±anthracycline; 19 HiDAC-based; 22 high-dose methotrexate-based;
and 19 clofarabine-based) and were analyzed for safety; 57% and 25%, respec-
tively, started at least 2 cycles. Safety outcomes were similar between blinatu-
momab and SOC (table 1).
Table 1. Incidence Rates of Adverse Events (AE), Regardless of Causality.
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Summary/Conclusions: This prespecified interim analysis showed that blina-
tumomab, as compared with SOC chemotherapy, improved the primary end-
point of OS in the phase 3 TOWER study of adults with Ph– r/r BCP-ALL.
Remission rates also were higher in the blinatumomab group. AEs in the blina-
tumomab group were consistent with previous studies. Based on these findings,
the DMC recommended stopping the TOWER study for efficacy before the
planned final analysis.
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COMPARATIVE ANALYSIS OF GENE REGULATORY NETWORKS IN LYMPHOID
LEUKEMIAS USING THE INTERACTIVE HEMAP RESOURCE
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Background: Acute lymphoblastic leukemia (ALL) is a paradigmatic example
of a disease that can develop at an early age as a result of genetic lesions that
impede lineage commitment. In normal development, cells commit to their lin-
eage and differentiated phenotype state by the activation of transcription factors
(TFs), or TF modules, in a series of decision points at which a choice is made
between alternative lineage fates. In parallel, epigenetic regulation has emerged
as an important mechanism that can corrupt the gene regulatory network.
Aims: We set out to examine whether patient expression profiles could be
used to quantitatively detect the blocks to differentiation and to reveal aberrantly
active TF loci. We further evaluated how amenable lymphoblastic leukemia
cases may be to treatment with drugs acting on epigenetic modifiers.
Methods: We analyzed 1,304 pre-B-ALL, 385 T-ALL and 801 B-CLL transcrip-
tomes as part of a curated set of 9,544 transcriptomes collected across 36
hematological malignancies to facilitate the characterization of mechanisms
that can corrupt the regulatory network in lymphoblastic leukemias. Sample
similarity was assessed using t-Distributed Stochastic Neighbor Embedding (t-
SNE) maps that permitted detecting changes in gene expression at subtype
resolution and association with specific TF translocations, epigenetic changes
and aberrant enhancers. The expression of genes that encode epigenetic mod-
ifiers with existing small molecule drugs (list from ChEMBL) was compared
between ALL and chronic lymphoblastic leukemia (CLL) and other hematolog-
ical malignancies.
Results: We scored gene sets of blood cell type lineage-determining TFs
across the transcriptome dataset and found that cancer samples lack the char-
acteristic mutually exclusive lineage-restricted pattern of these TF sets. Analysis
of stem cell similarity revealed predominant expression of a subset of
hematopoietic stem cell TFs across all acute leukemias. Of these, ERG expres-
sion was highest in pre-B-ALL and correlated with high activity of a super-
enhancer based on DNAse hypersensitivity and enhancer RNA expression. In
addition, we found disease cluster-specific activation of transcription-regulating
gene loci with low or undetectable expression in normal blood cell types. In the
cluster of the common pre-B-ALL subtype carrying the t12;21 translocation
(ETV6-RUNX1 fusion), four TFs (IRX1, MYOCD, NR3C2 and SOX11) had a
subtype-specific elevated expression level. We validated with overexpression
and silencing of ETV6-RUNX1 that the observed upregulation of IRX1 occurs
downstream of the fusion TF. Furthermore, high expression of epigenetic mod-
ifiers with existing small molecule drugs (available from ChEMBL) was signifi-
cantly enriched in CLL, T-ALL, one pre-B-ALL and one AML cluster among the
9,544 hematological samples.
Summary/Conclusions: We demonstrate that there are recurrent patterns of
aberrant TF expression in leukemia disease clusters. Misregulated expression
of ERG in pre-B-ALL appears to be mediated by a stem cell super-enhancer
based on the deep sequencing results presented. Moreover, elevated expres-
sion of drug targets that function as epigenetic modifiers was enriched in specific
leukemia clusters. Their inhibition potentially restores expression of a larger
repertoire of misregulated genes. Particularly in CLL, these genes represent
promising treatment targets for the reconditioning of blast cells.
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MEF2C DYSREGULATION IS ASSOCIATED WITH CDKN1B DELETIONS
AND PREDICTS POOR GLUCOCORTICOID RESPONSE IN PEDIATRIC
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
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A Attarbaschi3, S Strehl1
1CCRI, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung
e.V., Vienna, Austria, 2MPIMG, Max Planck Institute for Molecular Genetics,
Berlin, Germany, 3Department of Pediatric Hematology and Oncology, St. Anna
Children’s Hospital, Medical University of Vienna, Vienna, Austria
Background: T-cell acute lymphoblastic leukemias (T-ALLs) are aggressive
hematologic tumors resulting from the malignant transformation of T-cell pro-
genitors and account for 10 15% of pediatric ALL cases. T-ALL is a heteroge-
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neous disease characterized by a number of specific genetic alterations, which
define molecular subgroups associated with distinct gene expression signa-
tures, including the TAL/LMO, TLX1, TLX3, HOXA clusters as well as the
recently identified proliferative and immature subtypes, typically overexpressing
NKX2 1 or NKX2 2 and MEF2C, respectively. The latter, at least in part, over-
laps with early T-cell phenotype- (ETP-) like ALL. However, a number of recur-
rent abnormalities such as CDKN1B deletions occurring in about 12% of T-
ALL have not as yet been assigned to any specific disease entity.
Aims: In this study we sought to characterize pediatric T-ALL patients with
CDKN1B deletions, which represent one of the most frequent copy number
alterations, in more detail.
Methods: Array comparative genomic hybridization (aCGH) of 102 pediatric
T-ALL patients enrolled in the Austrian ALL-BFM 90, 95 or 2000 clinical trials
was performed. Cytogenetic analysis and immunophenotyping were done as
part of the routine diagnostic work-up. The presence of specific chromosomal
abnormalities was furthermore determined by fluorescence in situ hybridization
(FISH) and/or RT-PCR. Moreover, the samples were subjected to RT-qPCR
for MEF2C expression.
Results: By aCGH analysis and quantitative genomic PCR we detected the
presence of CDKN1B deletions in 14 cases. Further genetic characterization
of these cases led to their classification into the major T-ALL subtypes:
TAL/LMO (n=1), TLX1 (n=1),TLX3 (n=1), or HOXA (n=3). Since many of the
cases did not fall into any of these groups, we determined whether they
belonged to the immature cluster characterized by MEF2C expression and
compared them to CDKN1B wild-type cases. Remarkably, while only 14%
(4/28) of CDKN1B wild-type samples showed MEF2C dysregulation, this was
observed in 54% (6/11) of the CDKN1B-deleted cases for which appropriate
material for RT-qPCR was available (p=0.017), suggesting an association
between loss of CDKN1B and MEF2C expression. Since MEF2C is considered
as one of the driving oncogenes of immature/ETP-like ALL, we next evaluated
whether the MEF2C-dysregulated cases displayed the immunophenotypic
characteristics of ETP-ALL: CD1a/CD4/CD8 negative; absent or weak CD5,
and expression of one or more myeloid and/or stem cell antigens. Notably,
while all cases immunophenotypically defined as ETP-like cases showed
upregulation of MEF2C expression, only 30% (3/10) of MEF2C-dysregulated
cases showed an ETP-like phenotype. However, virtually all of them expressed
myeloid or B-lineage-specific markers, suggesting a certain lineage plasticity.
Furthermore, high MEF2C expression levels in primary leukemia samples were
associated with a significantly higher proportion of the patients being resistant
to glucocorticoid therapy (p=0.0033).
Summary/Conclusions: In summary, our data provide evidence that CDKN1B
deletions are associated with immature/MEF2C-dysregulated T-ALL and that
MEF2C overexpression, though associated with, is not exclusively found in ETP-
like ALL. Furthermore, our results indicate that MEF2C expression is associated
with or may even be predictive of the response to glucocorticoid treatment.
P152
HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC
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Background: The hedgehog signaling pathway contributes to embryonic pat-
tern formation and adult tissue homeostasis as it is important to regulate cell
proliferation, survival and differentiation. Aberrant activation of the hedgehog
pathway through overexpression of the ligands (SHH, IHH) or mutations in sig-
naling components (PTCH1, SMO, SUFU, GLI1) has been described in various
solid tumors. The Hedgehog pathway is important for normal T-cell develop-
ment, but its potential role in the development of T-cell acute lymphoblastic
leukemia (T-ALL) is poorly characterized.
Aims: Our aim was to investigate the role of the hedgehog pathway as an
oncogenic factor and a potential target for therapy in T-ALL. 
Methods: We analyzed gene expression profiles of human T-ALL samples
from two independent cohorts. We determined the effects of hedgehog ligand
stimulation, downregulation of critical signaling components or pharmacological
inhibition of the pathway in T-ALL cell lines, a mouse T-ALL model and in patient
derived xenografts.
Results: Gene expression data analysis of primary T-ALL samples revealed
that about 25% of T-ALL cases show ectopic expression of the ligands of the
hedgehog pathway. A strong correlation between the ligands SHH and IHH
with the main transcriptional factors GLI1 and GLI2 and known GLI target genes
was observed, indicative of hedgehog pathway activation through an autocrine
loop. Pharmacological inhibition of the hedgehog pathway, or siRNA mediated
knock-down of key signaling components caused a decrease of proliferation
of a subset of T-ALL cell lines, and sensitized the T-ALL cell lines to chemother-
apy. In our JAK3-dependent T-ALL mouse model expression of Shh or Ihh pro-
vided a growth advantage to the JAK3(M511I) leukemia cells. Finally, we tested
if hedgehog pathway inhibition could inhibit the growth of primary T-ALL cells.
For this reason patient derived T-ALL xenograft samples were treated with two
hedgehog inhibitors ex vivo and in vivo. T-ALL samples with high GLI1 expres-
sion were sensitive in both ex vivo and in vivo experimental set up, while T-
ALL samples with low or no GLI1 expression were insensitive.
Summary/Conclusions: We demonstrate that the hedgehog pathway is acti-
vated in a subset of T-ALL patients and that hedgehog pathway activation
affects T-ALL cell proliferation and provides partial protection against
chemotherapy. Data from patient derived xenograft T-ALL samples confirms
that high GLI1 expression predicts sensitivity of T-ALL samples to hedgehog
pathway inhibitors.
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Background: T-cell acute lymphoblastic leukemia (T-ALL) is characterized by
clonal and mutual exclusive chromosomal rearrangements that recurrently acti-
vate TAL1, LMO2, TLX1, NKX2-1, TLX3, HOXA or MEF2C oncogenes. Most
of these translocations or chromosomal rearrangements occur as erroneous
D-J or V-DJ rearrangement attempts of T-cell receptor beta (TCRB) or TCR
alpha/delta (TCRAD) genes, positioning oncogenes under the transcriptional
control of TCR enhancer elements. Alternatively, oncogenes can also be acti-
vated as consequence of BCL11B chromosomal rearrangements. Although
many oncogenes are known in T-ALL, the driving oncogenic lesion in particular
T-ALL cases remains unknown.
Aims: In this study, we aimed to clone reciprocal breakpoint sequences by Targeted
Locus Amplification (TLA) to elucidate cellular mechanisms that lead to recurrent
BCL11B-TLX3 chromosomal translocations. Moreover, we want to identify onco-
gene candidates in various T-ALL patients with BCL11B-, TCRB- or TCRAD-translo-
cations for which the candidate oncogenes have not been identified.
Methods: We used the TLA procedure, a recently developed method that relies
on the crosslinking of DNA in live cells, DNA digestion and re-ligation to allow
formation of circular DNA ligation fragment. Inverted polymerase chain reaction
amplification from specific view-point loci that closely flank chromosomal
rearrangement breakpoint followed by next generation sequencing allows for
the identification of a 100kb genomic region.
Results: We resolved the nucleotide sequence of chromosomal breakpoints
in 30 T-ALL patient samples that were previously characterized by FISH and/or
QRT-PCR. For some cases, we confirmed classical chromosomal transloca-
tions or rearrangements for TAL1, LMO2, TLX1, TLX3 or NKX2-1 oncogenes
to TCRAD, TCRB or BCL11B loci. We identified unusual translocations in 8
cases, including SPI1-BCL11B t(11;14)(p13;q32), LMO2-BCL11B t(11;14)
(p13;q32), TCL1-TCRAD t(14)(q11;q32), NKX2.5-BCL11B t(5;14)(q35;q32),
TLX1-RPP30 t(10)(q32;q24), TLX3-TCRB t(5;7)(q35;q34) and CENPP-TCRAD
t(9;14)(q22;q11). For TLX3-BCL11B translocations, most breakpoints were
found in the close vicinity of the TLX3 oncogene and the BCL11B enhancer
region (major peak) and DNase hypersensitivity sites. However, one TLX3-
BCL11B sample was not translocated to the major peak, pointing to other
enhancer regions that may drive TLX3 expression.
Summary/Conclusions: Identification of chromosomal rearrangements by
Targeted Locus Amplification reveals classic chromosomal rearrangements as
previously detected by FISH or QRT-PCR in 30 selected patients. By TLA,
breakpoint junctions were resolved in 22 patients. In addition, in 8 selected
cases from which we were unable to identify a fusion partner by FISH, TLA led
to the identification of genomic breakpoints for uncommon translocations. TLA
therefore proved a useful tool to identify novel translocation partners from var-
ious loci such as the TCR or BCL11B genes that are recurrently involved in
these chromosomal rearrangements in T-ALL. Cloning of molecular transloca-
tion breakpoints of diagnostic T-ALL patient samples may further provide excel-
lent minimal residual disease markers for disease monitoring during the course
of treatment.
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Background: Acute Lymphoblastic Leukemia (ALL), the most common
leukemia in childhood, is characterized by genomic alterations, such as chro-
mosomal translocations typically affecting a limited number of recurrent genes
(targets) with several variable partner genes (partners). Fusion genes can be
targeted by chemotherapy and/or new drugs, therefore genomic profiling of
ALL has the potential to identify important new prognostic markers and poten-
tially druggable targets.
Aims: Herein, we researched and developed a bioinformatic solution, ‘Break-
ingPoint’, for the robust detection of fusion genes. This was implemented in
the context of an expert evaluation of Target Capture Next-Generation Sequenc-
ing (NGS-TC) protocols both at the DNA and RNA level on ALL samples. The
platform will eventually be evaluated for routine clinical diagnosis.
Methods: ‘BreakingPoint’ has been developed to detect fusion genes from
NGS-TC datasets from any sequencing technology and any biological material.
Its distinctive feature is that it initially identifies all aligned reads indicating hypo-
thetical breakpoints on the ‘targets’, then clusters these into longer (thus more
informative) consensus sequences, which are then studied across the genome
to identify the unknown ‘partners’. We tested ‘BreakingPoint’ on NGS-TC
datasets of: (i) DNA material from 10 patients with 7 known gene fusions (Illu-
mina Nextera DNA capture); (ii) RNA material of 6 patients with 8 known gene
fusions (NuGen Ovation RNA Fusion Panel); all on Illumina’s MiSeq platform.
We additionally compared our method to the popular ‘Delly’ tool (DNA) and the
‘TopHat Alignment App’ on the ‘Illumina BaseSpace Cloud’ (RNA).
Results: On the DNA dataset, ‘BreakingPoint’ identified 6/7 known fusion genes
(e.g. BCR/ABL1, PAX5/AUTS2) plus one not previously known. The missing
P2RY8/CRLF2 gene fusion was most probably due to the low complexity of
chromosome X affecting the in vitro capture and in silico alignment steps. Our
method also detected deletions affecting the IKZF1 ‘target’, a gene prone to
mutation in ALL patients. ‘Delly’ identified 5/7 known gene fusions, missing
PAX5/AUTS2 and P2RY8/CRLF2. On the RNA dataset, ‘BreakingPoint’ identi-
fied all 8 known fusion genes, including P2RY8/CRLF2, plus a novel gene
fusion (PAX5/ZCCHC7). Illumina’s ‘TopHat Alignment App’ detected 5/8 known
gene fusions and the novel PAX5/ZCCHC7 rearrangement; false negatives
(BCR/ABL1; MLL/AF4;P2RY8/CRLF2) were most likely caused by low read
numbers affecting ‘targets’ coverage. ‘BreakingPoint’ false positives showed a
common pattern of low sequence complexity and few representative reads
(less than 2), and in many cases breakpoints fell in long intron non-coding
regions (LINC), making them easily recognizable when compared to true pos-
itives. Finally, we have implemented a graphical user interface to run ‘Break-
ingPoint’ (and other plug-in methods, including ‘Delly’, if the user so wishes)
and browse the results.
Summary/Conclusions: These results indicate that our approach sensitively
and reliably detects fusion genes, irrespective of biological material or protocol,
even in cases of low reads coverage. This already provides the potential to
identify novel and conventional targetable fusion genes. Eventually, after further
validation and evaluation, and coupled with the user-friendly interface, we
believe that the ‘BreakingPoint’ platform can be introduced in routine clinical
diagnosis.
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THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT
OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
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Background: The episomal NUP214-ABL1 fusion is observed in 6% of T-ALL
patients. The resulting NUP214-ABL1 fusion protein is a constitutively activated
tyrosine kinase, which activates STAT5 and ERK signalling, thereby stimulating
proliferation and survival. Significantly, almost all T-ALL cases with the NUP214-
ABL1 fusion also harbour chromosomal translocations resulting in the overex-
pression of the homeobox transcription factors TLX1 or TLX3.
Aims: To determine whether (i) co-expression of NUP214-ABL1 fusion and
TLX1 cooperate together in leukemia development; and (ii) to understand the
molecular mechanisms underlying any cooperation at the transcriptional level. 
Methods: We have generated a conditional loxP-STOP-loxP NUP214-ABL1
knock-in mouse model, in which NUP214-ABL1 expression can be activated
by Cre. We crossed these mice with Tg(CD4-Cre) mice, in which Cre is
expressed in developing T-cells, and then subsequently with Tg(Lck-TLX1)
mice, expressing TLX1 under control of the T-cell specific Lck promoter. These
crossings resulted in a Tg(CD4-Cre, NUP214-ABL1, Lck-TLX1) mouse model.
Using RNA-sequencing and ChIP-sequencing, we determined gene expression
profiles and binding patterns of STAT5 and TLX1.
Results: The Tg(CD4-Cre, NUP214-ABL1, Lck-TLX1) mouse model developed
a transplantable CD4+/CD8+ T-ALL with a significantly shorter latency (median
survival of 193 days) compared to the Tg(Lck-TLX1) mouse model (median
survival 385 days) or the Tg(CD4-Cre, NUP214-ABL1) mouse model (no dis-
ease), indicating true cooperation between NUP214-ABL1 and TLX1 during T-
ALL development. Gene expression profiling revealed that there is significant
upregulation of the JAK-STAT pathway, the mTOR signalling pathway and the
Notch1 signaling pathway in the Tg(CD4-Cre, NUP214-ABL1, Lck-TLX1)
mouse model, compared to the Tg(Lck-TLX1) mouse model. The cooperation
between NUP214-ABL1 and TLX1 was also investigated in a human context
using the T-ALL cell line ALL-SIL, which carries these two oncogenic alterations.
ChIP sequencing results showed that STAT5 and TLX1 have overlapping bind-
ing patterns on genes that have been identified as STAT5 target genes. We
are currently validating these results in our transgenic mouse model. 
Summary/Conclusions: The NUP214-ABL1 fusion and TLX1 overexpression
cooperate to drive T-ALL development.
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Background: B-progenitor acute lymphoblastic leukemia (B-ALLs) accounts
for 85% of pediatric ALL and currently categorized into molecular subgroups
according to their ploidy and recurrent translocations, such as ETV6 -RUNX1
(TEL-AML1), TCF3-PBX1 (E2A-PBX1), BCR-ABL1 or MLL-rearrangements.
In addition, recent genetic studies using high-throughput sequencing have dis-
closed a number of novel gene mutations in each subgroup. However, the land-
scape of driver mutations and their relevance to clinical outcome have not been
fully investigated in a large cohort of B-ALL patients. 
Aims: The purpose of this study is to characterize the distribution of genetic
alterations and their clinical relevance in pediatric B-ALLs using high-throughput
sequencing in a large cohort of B-ALL patients.
Methods: A total of 524 pediatric B-ALL patients were enrolled in this study,
who were uniformly treated according to the Japan Association of Childhood
Leukemia Study (JACLS) ALL-02 protocol between 2002 and 2008. These
patients were categorized into three risk groups, including standard risk, high
risk, and extremely high risk. Infantile, BCR-ABL1–positive and Down syn-
drome–associated ALLs were not enrolled in this cohort. A total of 158 known
or putative driver genes in pediatric ALL were analyzed for somatic mutations
by targeted-capture deep sequencing using SureSelect (Agilent). Single
nucleotide polymorphism-baits were also included, which were designed to
allow for genome-wide copy number detection based on deep sequencing.
Results: The median age at diagnosis and observation period were 5.2 years
(1-18.5) and 4.2 years (1.8-9), respectively. Sixty-six of the 524 patients (13%)
had relapsed diseases and 47 patients (9%) were dead. Real-time RT-PCR
and conventional cytogenetic analyses revealed ETV6-RUNX1, TCF3-PBX1,
MLL rearrangements, hyperdiploidy (>50 chromosomes) and hypodiploidy (<44
chromosomes) in 113 (22%), 42 (8%), 10 (2%), 95 (18%), and 2 (0.4%) patients,
respectively, and the remaining 262 patients (50%) had none of these abnor-
malities. The mean depth of the targeted sequencing was 569× across the
entire cohort. In total, 74% of the patients harbored at least one mutation (medi-
an, 2 per patient; range, 0-9), and the mean number of mutations in ETV6-
RUNX1, TCF3-PBX1, MLL-rearranged, hyperdiploid, hypodiploid ALLs were
0.63, 1.19, 1, 3.05 and 4, respectively. CDKN2A, KRAS, NRAS, PAX5, and
ETV6 were among the most frequently affected genes, which were mutated or
deleted in 24%, 21%, 18%, 18%, and 15% of the cases, respectively. In terms
of functional pathways, RAS pathway was most frequently affected and altered
as many as 50% of the patients, followed by the pathways involved in epigenetic
regulation, cell cycle, and B-cell development. Frequency of mutations showed
a significant variation among B-ALL subtypes. For instance, RAS pathway
mutations were detected in as many as 87% of hyperdiploid ALLs, compared
to 3% of TCF3-PBX1 ALLs. On the other hand, IKZF1 mutations/deletions were
only indentified in those without recurrent translocations, hyperdiploidy and
hypodiploidy.
Summary/Conclusions: We revealed the landscape of driver mutations and
copy number alterations in pediatric B-ALL and their diversity in B-ALL subtypes.
Further analyses are underway to better clarify the prognostic significance of
driver gene mutations.
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CHARACTERIZATION OF AN EX VIVO T-CELL CULTURE MODEL FOR
THE STUDY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
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Background: T-cell acute lymphoblastic leukemia is caused by the combined
deregulation of various cellular functions, including NOTCH1 signaling, kinase
signaling, and transcriptional regulation. Deregulated kinase signaling is often
studied in the Ba/F3 pro-B cell line, but an easy T-cell system is lacking. 
Early T cell progenitor cells undergo extensive expansion at the double negative
two (DN2) stage in vivo, which allows for their expansion and culture ex vivo.
Importantly, these cells maintain their potential to differentiate into mature T
cells in vivo. This makes this culture method a suitable model to study T cell
development and transformation events in pre-leukemic cells. 
Aims: This study aimed to develop and characterize a T-cell model to dissect
molecular mechanisms of T cell development and signalling pathways that are
implicated in the development of T-ALL. We aimed to identify key transcriptional
pathways and regulators during T cell differentiation and to study the effect of
oncogenic mutations on these pathways.
Methods: Hematopoietic stem cells were cultured in the presence of SCF and
IL7 on delta like ligand 4 (DLL4) coated plates, to induce differentiation into
early T cell progenitors. Transcriptional profiling using RNA-sequencing of these
pro-T cells was used to identify the key transcriptional pathways and genes
induced by IL7, SCF or Notch signalling. Next, dominant oncogenic mutants of
AKT, JAK3, NOTCH1 or KRAS were introduced with retroviral vectors, and
Pten gene was inactivated using Crispr/Cas genome editing. These cells were
analyzed for their possibility to grow in the absence of SCF, IL7 and/or DLL4.
Results: We identified transcriptional signatures, which were specific to IL7,
SCF and DLL4 stimulation or induced in a synergistic manner. For example
IL7, SCF and DLL4 by themselves were able to induce the expression of the
transcription factor Myc. However, only Notch-signalling induced expression
of Hey1, Dtx1, Hes1 or CCR7. Using computational tools, we identified tran-
scription factors that mediated expression of these genes, specific to SCF and
IL7 stimulation. Furthermore, SCF activated mainly the PI3K-Akt pathway and
was unable to induce Stat5a/b phosphorylation. IL7 stimulation, on the other
hand, resulted in activation of the Jak-Stat pathway, but provided less activation
of Akt. In line with these observations, overexpression of the AKT(E17K) mutant
or Crispr/Cas9 mediated Pten deletion resulted in SCF independent growth,
whereas cells remained IL7 and DLL4 dependent. Furthermore, some, but not
all, JAK3 mutants were able to transform cells to grow in the absence of IL7
and induced Stat5 phosphorylation. KRAS(G12D) mutants allowed the cells to
grow in the absence of SCF and IL7. Upon transduction with ligand independent
Notch1 mutants, cells became independent of DLL4 stimulation.
Summary/Conclusions: This model system for the SCF/IL7/DLL4 dependent
ex vivo culturing of primary mouse T-cells enables the study of T-ALL oncogenic
events in a T cell context.
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SENSITIZATION IN ACUTE LYMPHOBLASTIC LEUKEMIA
S Demir1,*, G Selivanova2, E Tausch3, L Wiesmüller4, S Stilgenbauer3,
G te Kronnie5, KM Debatin1, LH Meyer1
1Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm,
Germany, 2Department of Microbiology, Tumor and Cell Biology, Karolinska
Institute, Stockholm, Sweden, 3Department of Internal Medicine III, 4Depart-
ment of Obstetrics and Gynaecology, Ulm University Medical Center, Ulm, Ger-
many, 5Department of Women`s and Children`s Health, University of Padova,
Padova, Italy
Background: In acute lymphoblastic leukemia (ALL), TP53 alterations are
rarely found at diagnosis but in about 12% of patients at relapse. TP53 muta-
tions (TP53mut) have been described to be associated with poor response to
therapy and inferior outcome in ALL. Compounds targeting mutated p53 such
as APR-246 demonstrated activity in different types of TP53mut malignancies.
In ALL however, targeting mutant TP53 has so far not been addressed.
Aims: To evaluate mutant TP53 as target for directed anti-leukemia therapy in ALL.
Methods: Patient-derived primograft samples established in our NOD/
SCID/huALL mouse model were analyzed for TP53mut by denaturating high-
performance liquid chromatography and validated by Sanger sequencing. Sen-
sitivities of ALL cells in response to different drugs and combinations were
assessed analyzing half maximal inhibitory concentrations (IC50) and combi-
nation indices (CI). Apoptosis was detected by caspase-3 activation and Annex-
in-V/propidium iodide positivity. Activation of p53 was analyzed by phosphory-
lation of p53 (p53pSer15, flowcytometry), expression of p53 downstream mol-
ecules and confirmation of phosphorylation was carried out by western blot
analysis. p53 deficient cell lines were generated by lentiviral shRNA mediated
knock-down.
Results: Of 62 primograft samples, 4 cases with TP53mut (6.5%) were iden-
tified, corresponding to reported numbers in clinical studies. In parallel, we
analyzed 6 BCP-ALL cell lines and identified 2 TP53mut and 4 wild type
(TP53wt) lines. We analyzed the effects of the DNA damaging agent doxoru-
bicin and the p53 targeting small molecule APR-246 (kindly provided by Aprea,
Stockholm, Sweden) and observed an insensitivity to doxorubicin in TP53mut
cell lines and primografts (mean IC50: 100 nM and >65 nM) compared to sen-
sitive TP53wt cell lines and primografts (mean IC50: 9 nM and 7.4 nM). In con-
trast, TP53mut ALL cells were highly sensitive to APR-246 (mean IC50: 4.5
μM and 4.4 μM), compared to insensitivity of TP53wt cell lines and primografts
(mean IC50: 58.3 μM and >90 μM). Increased Annexin-V/PI positivity and cas-
pase-3 activity upon APR-246 exposure indicated apoptosis as mechanism of
APR-246 mediated cell death. In order to investigate the specificity of APR-
246 for p53, we investigated APR-246 mediated cell death induction in 2 genet-
ically modified, p53 deficient ALL cell lines. No cell death induction could be
detected upon p53 absence in contrast to high APR-246 sensitivity in the control
transduced cell lines, clearly indicating dependency of APR-246 on the pres-
ence of mutant p53. Most importantly, a clear activation of p53 was identified
upon APR-246 exposure in TP53mut but not TP53wt leukemias indicated by
increased p53 phosphorylation and increased expression of the p53 target
molecules NOXA and PUMA, pointing to restoration of p53 function and induc-
tion of downstream signaling in TP53mut ALL by APR-246. Moreover, we inves-
tigated the ability of APR-246 to re-sensitize TP53mut, DNA damage resistant
ALL. Upon exposure of TP53mut ALL cell lines and primografts to combinations
of APR-246 and doxorubicin, a strong synergism and re-sensitization to DNA-
damage induced cell death was observed.
Summary/Conclusions: We provide evidence that APR-246 specifically tar-
gets TP53mut BCP-ALL leading to re-activation of p53, apoptosis induction,
and re-sensitization of DNA-damage resistant TP53mut ALL cells. Thus, tar-
geting mutated p53 provides a promising novel strategy for therapeutic inter-
vention in this high-risk subtype of BCP-ALL.
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ACTIVATING MUTATIONS IN IL7R SIGNALING AS CAUSE OF STEROID
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Background: Response to therapy in children with acute lymphoblastic
leukemia (ALL) including in vitro or in vivo steroid response is a strong predictor
for survival and cure. T-ALL patients in particular have a high risk to relapse
and are refractory to further treatment due to acquired therapy resistance. The
mechanisms that underlie steroid resistance are poorly understood.
Aims: This study aimed to investigate the mutational landscape of pediatric T-ALL
patients to identify molecular disease mechanisms underlying steroid resistance.
Methods: Whole-genome sequencing (WGS) of 13 T-ALL diagnostic tumor-
remission pairs in the pilot group was performed by Complete Genomics to
detect chromosomal rearrangements and somatic nucleotide variations. Tar-
geted exome resequencing of 251 genes was performed in a validation cohort
of 82 pediatric T-ALL samples, and mutation data was integrated with loss-of-
heterozygosity data as obtained by array-comparative genomic hybridization
for 53 T-ALL cases. Integrated data was related to clinical outcome and in vitro
drug responses.
Results: WGS revealed intra-chromosomal (range of 5-25 per patient) and
inter-chromosomal (range of 2-11) breakpoint junctions as consequence of
deletions, duplications, inversions, translocations or complex rearrangements.
Integrated mutation and copy-number data revealed 151 mutated genes (range
of 0-51). Deletions in NR3C1—which are common in 5q chromosomal deletions
in patients with the ALL subtype ETP-ALL (early thymus progenitor ALL)—are
associated with steroid resistance. Moreover, we found that mutations in inter-
leukin-7 receptor (IL7R) signaling molecules associated with steroid resistance
while leaving cellular sensitivity levels to other chemotherapeutics unchanged.
IL7R signaling mutations do not impair NR3C1 function, but activate MEK-ERK
and PI3K-AKT pathways and downstream anti-apoptotic proteins BCL-XL and
MCL1 while inhibiting GSK3B, a key regulator of steroid-induced pro-apoptotic
BIM. Importantly, inhibitors of IL7R signaling reversed steroid resistance in T-
ALL cells in vitro, whereas a GSK3B inhibitor conferred steroid resistance.
Summary/Conclusions: We revealed the mutational landscape of pediatric
T-ALL patients. NR3C1 deletions and IL7R signaling mutations were identified
as cause for steroid resistance. This study supports the recommendation for
the clinical application of IL7R signaling inhibitors to restore—or improve—
steroid sensitivity of T-ALL cells.
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NOTCH PATHWAY
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Background: NOTCH signaling is a developmental pathway known to play
critical roles during embryonic development as well as for the regulation of self-
renewing tissues. Aberrant activation of NOTCH signaling leads to deregulation
of the self-renewal process resulting in sustained proliferation, evasion of cell
death, loss of differentiation capacity, invasion and metastasis, all of which are
hallmarks of cancer. Over activation of NOTCH in human cancers can be a
consequence of over expression of NOTCH ligands/receptors, GOF mutations
in NOTCH receptors as well as chromosomal translocations leading to consti-
tutive activation of the pathway.
Aims: Given the importance of Notch signaling in human cancers, several ther-
apeutic approaches have been utilized to block NOTCH signaling. Two of these
strategies are; a) the use of monoclonal blocking antibodies (Mabs) against
NOTCH ligands and receptors and b) the use of small molecule -secretase
inhibitors (GSIs). However, these approaches can only be effective if tumor
cells express full-length ligand or receptor molecules. On the contrary, in human
cancers harbouring NOTCH gene fusion due to chromosomal translocations,
the use of Mabs and GSIs will have very limited clinical benefits. A third, yet not
fully explored approach could be the blockage of NOTCH signalling by targeting
the most downstream event in the NOTCH cascade i,e NOTCH transcriptional
activation complex using small molecule inhibitors.
Methods: Here we report discovery and identification of a novel, orally-active
small molecule inhibitor, named CB-103, of the NOTCH pathway that blocks
NOTCH signaling by targeting the NOTCH transcriptional activation complex
in the nucleus.
Results: CB-103 has shown the ability to block NOTCH signalling in human T
cell acute lymphoblastic leukemia cancer cell lines, induce neurogenic pheno-
type in drosophila, induce muscle cell differentiation and inhibit NOTCH depend-
ent cellular processes in mice. Furthermore, CB-103 has shown a remarkable
activity in exvivo and invivo patient derived models of human T-ALL harbouring
activation of the NOTCH pathway. In addition, CB-103 exhibit anti-tumor efficacy
in a xenograft model of human triple negative breast cancer resistant to GSIs
and Mabs against NOTCH ligands/receptors.
Summary/Conclusions: Based on in vivo pharmacokinetic/ADME studies,
CB-103 has been nominated as development candidate for further preclinical
and clinical development.
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Background: Therapy resistance and treatment failure in B-cell precursor
acute lymphoblastic leukemia (BCP-ALL) are closely associated with deficient
cell death pathways. Anti-apoptotic Bcl-2 family proteins are central apoptosis
regulators, thereby serving as promising targets for novel, directed therapies.
ABT-199 binds selectively to Bcl-2, inhibits its anti-apoptotic function and releas-
es pro-death Bcl-2 family molecules leading to apoptosis induction. ABT-199
demonstrated activity in different hematological malignancies, pre-clinically and
in early clinical trials. However, resistance for ABT-199 highlights the need for
predictive markers and effective combination treatment strategies.
Aims: We addressed the effectivity of ABT-199 on BCP-ALL including pre-clin-
ical in vivo evaluation and addressed resistance mechanisms and strategies to
overcome ABT-199 insensitivity. 
Methods: The effects of different drugs or combinations on BCP-ALL cell lines
(n=6) and patient-derived BCP-ALL primografts (n=16) established by trans-
plantation of primary patient ALL cells onto NOD/SCID mice were investigated
analyzing half maximal inhibitory concentrations (IC50) and combination indices
(CI). Anti-leukemic activity of ABT-199 was evaluated pre-clinically in vivo.
Expression of apoptosis regulators was detected by western blot analysis. Mcl-
1 deficient cell lines were generated by CRISPR/Cas gene engineering.
Results: A high sensitivity for ABT-199 was identified in 4 of 6 BCP-ALL cell
lines with nanomolar IC50 values (mean 212 nM) in contrast to ABT-199 insen-
sitivity in two other lines (IC50 >1µM). Similarly, a high sensitivity for ABT-199
was identified in the majority of ALL primografts (14 of 16, IC50 2 to 156 nM)
with two insensitive cases (IC50 >1 µM). Of note, PBMCs from healthy donors
also showed ABT-199 insensitivity. We assessed the expression of the apop-
tosis regulating molecules Bcl-2 and Mcl-1 and found high Bcl-2 levels in ABT-
199 sensitive compared to low Bcl-2 levels in resistant ALL. In contrast, ABT-
199 resistant leukemias showed high Mcl-1 expression and low levels were
found in ABT-199 sensitive cases. Interestingly, CRISPR/Cas9-mediated knock-
out of Mcl-1 clearly sensitized ABT-199 insensitive cell lines for ABT-199 medi-
ated cell death, indicating the role of Mcl-1 as mediator but also marker for
ABT-199 resistance. Most interestingly, the CDK inhibitor dinaciclib induced
rapid down-regulation of Mcl-1 at low nanomolar concentrations leading to sen-
sitization for ABT-199 in resistant cell lines and primograft ALL. We also com-
bined ABT-199 with chemotherapeutic agents used for remission induction in
current therapy regimens. Co-exposure of ALL cells to vincristine, dexametha-
sone and asparaginase combined with ABT-199 showed a clear synergistic
effect, both in cell lines and primograft ALL. Moreover, in a preclinical setting,
recipient animals bearing a high-risk, t(11;19) leukemia were treated with ABT-
199 or solvent. Importantly, a clear reduction of leukemia load was observed
upon ABT-199 in vivo therapy compared to vehicle treated recipients (p<0.01).
Summary/Conclusions: Taken together, our data show apoptosis induction
and high efficacy of ABT-199 as single compound, both ex vivo and pre-clinically
in vivo, and synergy upon combination with conventional induction chemother-
apy. Importantly, Mcl-1 was identified as mediator and indicator for ABT-199
resistance. Most importantly, the CDK-inhibitor dinaciclib was found to down-
regulate Mcl-1 leading to sensitization for ABT-199 in previously resistant, Mcl-
1 high expressing leukemia cells.
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LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE
SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING
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Background: To improve treatment outcome of patients with B-cell acute lym-
phoblastic leukemia (B-ALL), several immunotherapeutic approaches have
been developed in recent years. E.g., direct targeting of CD19 or CD20 by (bis-
pecific) antibodies or chimeric antigen receptors result in effective control of
the disease. In contrast, introduction of alemtuzumab which targets the gly-
cophosphatidylinositol (GPI)-anchored CD52 protein resulted in unsatisfactory
clinical efficacy, potentially due to development of escape variants. Indeed, in
previous studies (Nijmeijer et al, 2010) we have found outgrowth of CD52-neg-
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ative escape variants following alemtuzumab treatment in a mouse model
engrafted with human B-ALL. Further analysis showed that these variants
expressed normal CD52 mRNA levels, but lacked CD52 membrane expression
due to loss of GPI-anchor expression.
Aims: To unravel the mechanism underlying the loss of CD52/GPI expression
in B-ALL
Methods: The presence and frequency of CD52/GPI-negative cells was ana-
lyzed by flowcytometry in peripheral blood (PB; n=10) and bone marrow (BM;
n=8) samples taken with informed consent from B-ALL patients at diagnosis.
Diagnosis samples of patients with chronic lymphocytic leukemia (CLL, n= 5),
mantle cell leukemia (MCL, n=5) and hairy cell leukemia (HCL, n=6), and PB
samples from 5 healthy donors were similarly analyzed in parallel. To investigate
the mechanism of GPI loss, gene expression analysis was performed for the 26
genes that comprise the GPI anchor biosynthesis pathway in GPI positive and
GPI negative B-ALL populations purified by flowcytometric cell sorting.
Results: To study the presence and frequency of CD52/GPI-negative cells at
diagnosis, we analyzed PB and BM samples from B-ALL patients at diagnosis
by flowcytometry. GPI-negative cells were present in 6/10 PB and 5/8 BM sam-
ples and comprised between 0.01% and 4.98% of the B-cell population. These
obvious GPI-negative B-cell populations were not found in CLL (n=5), MCL
(n=5), and HCL (n=6) diagnosis samples, or in healthy donors (n=5). To inves-
tigate the mechanism of GPI-anchor loss, gene expression analysis was per-
formed for the 26 GPI biosynthesis pathway genes. In contrast to purified GPI-
positive B-ALL populations, loss of PIGH mRNA expression, but not of any of
the other genes, was found in all GPI-negative populations (n=9). To validate
the relevance of this finding, GPI-negative and GPI-positive B-ALL cell cultures
were generated from diagnosis material (n=2) and transduced with a retroviral
construct encoding PIGH. Restored GPI-anchor expression and coinciding
CD52 membrane expression was observed in the GPI-negative B-ALL cultures
upon transduction with PIGH, but not empty vector. To explore the mechanism
underlying the loss of PIGH mRNA expression in CD52/GPI-negative B-ALL
cells, we performed DNA screening and assessed promoter CpG methylation,
comparing GPI-negative with GPI-positive B-ALL cultures from the same indi-
vidual (n=2). These analyses revealed that in GPI-negative cultures both alleles
of the PIGH gene were present, unmutated and intact, but with a heavier methy-
lated promoter region compared to the GPI-positive counterparts. Additionally,
a 14 day treatment of GPI-negative B-ALL cultures with the demethylating
agent 5-Azacitidine resulted in re-expression of the GPI-anchor
Summary/Conclusions: In conclusion, the majority of B-ALL patients pre-
sented a CD52/GPI-negative, alemtuzumab resistant, B-ALL population already
at diagnosis. These cells lost PIGH expression, a key component in GPI-anchor
synthesis. This is not due to genomic instability, but to epigenetic downregula-
tion. Combining epigenetic modulatory drugs with alemtuzumab might be a
promising therapeutic strategy to prevent outgrowth of CD52/GPI-negative
escape variants in B-ALL.
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Background: The activating mutations in RAS signaling pathway including
NRAS, KRAS and PTPN11 genes have been described in B-precursor acute
lymphoblastic leukemia (ALL). However, the correlation of RAS pathway gene
mutations with recurrent genetic abnormalities was not addressed.
Aims: We aimed to investigate the frequencies, and the association with genet-
ic/cytogenetic abnormalities as well as prognostic relevance of RAS pathway
mutations in Taiwanese children with B-precursor ALL, the largest cohort in
Asians.
Methods: Between 1995 and 2012, bone marrow samples at diagnosis from
538 children were studied. Mutations at codons 12, 13, and 61 in exons 1 and
2 of NRAS and KRAS genes, as well as the entire coding region of PTPN11
were analyzed using PCR-based assay followed by direct sequencing. The
mutational status of each gene was correlated with the clinico-hematological
features, recurrent genetic abnormalities, and outcomes for those treated with
TPOG-ALL-2002 protocol (n=348).
Results: The frequencies of NRAS, KRAS, and PTPN11 mutations were 10.5%
(56/533), 10.1% (54/533), and 3.4% (18/529), respectively. Mutations of NRAS,
KRAS, and PTPN11 were mutually exclusive with rare exception, including 4
co-occurrence of NRAS and KRAS mutations, and 2 co-existence of KRAS
and PTPN11 mutations. Together, 23.0% of B-precursor ALL patients had gene
mutations involving RAS signaling pathway. No differences in age, Hb level,
WBC or platelet counts were observed in patients with or without NRAS and
PTPN11 mutations. The frequency of PTPN11 mutations was significantly high-
er in girls than in boys (1.4% vs 6.0%, P=0.006). Patients with KRAS mutations
presented with significantly younger age (P=0.004) and lower platelet counts
(P=0.007). Only one out of 21BCR-ABL1 ALL had a mutation (NRAS) in RAS
pathway. ETV6/RUNX1 was associated with a lower frequency of NRAS muta-
tions (2.2% vs 12.3%, P=0.002) and a trend of less PTPN11 mutations (0% vs
4.1%, P=0.053); none of patients with TCF3/PBX1 had KRAS mutation
(P=0.024) whereas 2 of the 3 hypodiploid ALL had KRAS mutations (P=0.028);
KRAS mutations occurred more frequently in patients with MLL rearranged
(23.5% vs 9.2%, P=0.014, but the difference was not significant if we excluded
infant ALL (n=30) (20% vs 8.7%, P=0.223). NRAS mutations were more com-
monly detected in hyperdiploid ALL (18.0% vs 9.5%, P=0.069). Patients without
specific genetic/cytogenetic subtypes had a significantly lower frequency of
NRAS mutations as compared to those without any of these recurrent genetic
abnormalities (7.5% vs 13.2%, P=0.048) and a higher rate of PTPN11 muta-
tions (5.0% vs 1.6%, P=0.051). There were no differences in 5-year EFS and
OS with regard to mutational status of NRAS (70.7% vs 79.0%, P=0.575; 89.6%
vs 82.3%, P=0.863, respectively) and of PTPN11 (80.8% vs 77.7%, P=0.490;
90.0% vs 82.2%, P=0.317, respectively). KRAS mutations were associated
with inferior outcomes (66.0% vs 79.7%, P=0.039 for EFS and 74.8% vs 84.0%,
P=0.058 for OS) but there was no difference in non-infant ALL (P=0.381 for
EFS and P=0.635 for OS).
Summary/Conclusions: Patients with recurrent genetic abnormalities had
rare occurrence of RAS pathway mutations in non-infant pediatric B-precursor
ALL. NRAS mutations were more frequently detected in patients with hyper-
diploidy, whereas KRAS mutations were highly associated with infant ALL with
MLL rearranged. (Grants support: MMH-E-99009, MOST103-2314-B-195-008-
MY3, MOST104-2314-B-182-032-MY3, OMRPG3C0021 and grant from Terry
Fox Foundation).
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Background: T-Acute Lymphoblastic Leukaemia (T-ALL) is a heterogeneous
and aggressive hematologic cancer arising from the malignant proliferation of
T-cell progenitor cells, arrested at different stages of development. Although
recently developed multi-agent chemotherapy protocols significantly improved
the clinical outcome of this disease, the prognosis of patients undergoing
relapse or therapy resistance remains poor. Since T-ALL chemo-resistance is
linked to the activation of pathways that promote and sustain the self-renewal
of leukemic initiating cells (LICs), it becomes imperative to develop novel ther-
apies to eradicate these cells. To accomplish this objective it is necessary to
perform pre-clinical, functional studies with primary T-ALL patient samples, a
challenging task given that tools enabling an efficient genetic manipulation of
primary T-ALL cells are still lacking.
Aims: To develop novel strategies to genetically manipulate T-ALL leukaemia
initiating cells.
Methods: Fresh or thawed primary T-ALL samples were transduced with lentivi-
ral vectors pseudotyped with a baboon envelop chmeric glycoprotein (BaEV).
Two days post-transduction, 500.000-700.000 transduced cells were injected
into cohorts of primary NSG(NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ) mice to
verify stable gene expression and T-ALL development from the transduced
clones. The leukemic engraftment of the transduced cells was than evaluated
by FACS analysis, based on GFP, CD45 and CD7 expression in the bone mar-
row, spleen and peripheral blood. To further assess the leukemic initiating ability
of the transduced cells, 500.000-700.000 bone marrow cells issued from pri-
mary animals were injected into serial cohorts of NSG mice.
Results: Our work revealed that lentiviral vectors pseudotyped with a Baboon
retroviral envelope glycoprotein (BaEV-LVs) are excellent tools to genetically
modify T-ALL leukaemia initiating cells. These lentiviral vectors enabled high-
level transduction rates (40-80%) at low multiplicity of infection (MOI=10) as
they entered primary T-ALL blasts using ASCT1 and ASCT2, two aminoacid
transporters that were highly expressed on all T-ALL subtypes. The transduced
blasts engrafted cohorts of primary, secondary and tertiary mice, where they
infiltrated bone marrow, spleen and peripheral blood, thus demonstrating that
BaEV-LVs target leukemic-initiating cells. Importantly, this high performance
was not linked to particular oncogenic features of the primary blasts not to a
specific stage of maturation arrest. Competitive xenograft experiments, more-
over, demonstrated the transduced clones did not acquire a selective growth
advantage nor were outcompeted by the not-transduced clones, as evidenced
by the relative ratio between GFP positive and GFP negative cells, which
remained stable in all the mice serially transplanted. Hence, BaEV-LV mediated
transduction does not alter LICs self-renewing pathways. This feature is an
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essential pre-requisite to functionally investigate the signalling cascades
involved in T-ALL initiation and development.
Summary/Conclusions: BaEV-LV vectors are essential and highly efficient
tools to manipulate leukemic-initiating cells and to functionally investigate the
molecular pathways involved in T-ALL development and clonal evolution.
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Background: Tyrosine kinase inhibitor (TKI) treatment of patients with Philadel-
phia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL)
improves response and survival in younger adults and has allowed de-escala-
tion of conventional chemotherapy, particularly in older patients. Similar thera-
peutic approaches may also benefit patients with the Philadelphia chromo-
some-like (Ph-like) B-ALL subtype recently described in children and adoles-
cents/young adults (AYA), as these leukemias are driven by activating mutations
in kinase-associated signaling pathways. The frequency of adult Ph-like B-ALL
is largely unknown, however. 
Aims: We analyzed diagnostic B-ALL specimens from adult patients (range
18-88 years) by a validated, highly sensitive 15-gene low-density gene expres-
sion array (LDA) to determine the frequency of Ph-like ALL. 
Methods: We analyzed 90 cryopreserved B-ALL samples from the institutional
tissue banks at the University of Pennsylvania and University of Michigan by
LDA to identify specimens with a kinase-active gene expression profile, as pre-
viously reported (Harvey, et al. Blood 2013, 123(21):826a). All samples were
tested by reverse transcriptase-polymerase chain reaction (RT-PCR) for BCR-
ABL1 fusion. LDA signature-positive specimens without detected BCR-ABL1
transcript (Ph-like ALL) were categorized as CRLF2 (cytokine receptor-like fac-
tor 2)-overexpressing or non-overexpressing using LDA quantification of expres-
sion levels. CRLF2-overexpressing specimens were subsequently assessed
for IGH-CRLF2 and P2RY8-CRLF2 rearrangements and JAK1 and JAK2 muta-
tions via FISH, PCR, or RT-PCR with Sanger sequencing. 
Results: By RT-PCR, 37.8% (34/90) of ALL specimens were BCR-ABL1+.
Additionally, we identified a 20.0% (18/90) incidence of Ph-like ALL with a medi-
an age at diagnosis of 43 years (range 19-64). 77.8% (14/18) of the Ph-like
ALL specimens harbored CRLF2 rearrangements, including 7 patients with
concomitant JAK2 mutations. Using multiplexed RT-PCR, the 4 non-CRLF2-
overexpressing Ph-like specimens were then evaluated for 39 published Ph-
like kinase fusions; no recurrent gene fusions were identified. Correlative biol-
ogy studies confirmed activation of JAK/STAT and/or ABL pathway signaling in
primary Ph-like ALL specimens, as well as therapeutic efficacy of JAK or ABL
kinase inhibition in adult Ph-like ALL patient-derived xenograft models. 
Figure 1.
Summary/Conclusions: We identified a Ph-like gene expression signature in
20% of adults with B-ALL. Importantly, we also demonstrate for the first time
that the majority of adult B-ALL is associated with activated kinase signaling.
Unlike pediatric/AYA Ph-like ALL, in which kinase fusions occur frequently,
CRLF2 rearrangement is the predominant genetic lesion in adult Ph-like ALL.
We propose that adult ALL diagnostic testing algorithms include flow cytometric
assessment of surface CRLF2 (thymic stromal lymphopoietin receptor) expres-
sion, a surrogate marker for CRLF2 rearrangement, with subsequent genetic
confirmation. Finally, we demonstrate a substantial population of patients ≥40
years of age with non-Ph+ B-ALL who may also benefit from TKI therapies.
The efficacy of such treatments should be evaluated via appropriate clinical tri-
als, as clinical translation of our findings will potentially transform therapeutic
approaches for adults with Ph-like ALL.
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Background: In adults aged 18-60 years, many acute lymphoblastic leukemia
(ALL) protocols have now incorporated L-asparaginase (ASPA) as part of induc-
tion regimen. As in children, adult patients are thus often exposed to pancre-
atitis, thrombosis, liver injury and allergic reactions. Thus some investigators
do not use ASPA at all, like in the Hyper-CVAD regimen. In the GRAALL net-
work, most of the centers started to use ASPA during induction when the pedi-
atric-inspired GRAALL protocol was introduced in 2003.
Aims: The aim of this study was to report the real-life experience of the use of
ASPA in the GRAALL-2005 trial and to identify factors associated with 1) main
ASPA-related Adverse Events (AEs) and 2) the frequency and the impact of
suboptimal ASPA dose administration.
Methods: Between 2006 and 2014, 787 adult patients with newly diagnosed
Ph1-negative ALL were included in the multicenter French-Belgian-Swiss
GRAALL-2005 trial. After a 7-day steroid prophase, patients received a 5-drug
sequential induction including prednisone (PDN), vincristine (VCR), daunoru-
bicine (DNR), cyclophosphamide (CPM) and ASPA (6000 IU/sqm/day for 8
days). Patients with induction failure received a high-dose cytarabine-based
salvage course. AEs were assessed according to WHO classification. Four
patients were excluded due to the lack of data.
Results: The median age of this cohort of 783 patients (505 BCP- and 278 T-
ALL) was 36.1 years (range: 18.1-60.0). Median body mass index (BMI) was
23.6 kg/sqm (range: 15.7-46.3). Initial median WBC was 11.8 G/L (range: 0.4-
645) and 55 patients had CNS involvement (7.0%). A complete remission (CR)
was achieved in 720/783 (92.0%). A resistance to first induction phase was
observed in 36/738 (4.9%) patients evaluable for CR. A grade 3-4 liver toxicity
was observed in 272 patients (34.6%), a grade 3-4 pancreatitis in 43 patients
(5.5%), and a cerebral venous thrombosis (CVT) in 25 patients (3.3%). An
older age was significantly associated with an increased incidence of liver tox-
icity but a lower incidence of CVT. Pancreatitis was not associated with age. A
high BMI was associated with liver toxicity and pancreatitis. In multivariate
analysis, age, BMI, CNS involvement, and BCP-phenotype were associated
with liver toxicity; BMI and female gender were associated with pancreatitis.
During induction phase, patients received 97.8% of ASPA scheduled dose,
99.0% if younger than 45 years old but only 84.8% if older (p<.0001). In com-
parison, no difference in the administration of myelosuppressive drugs (DNR,
CPM) was observed. In multivariate analysis, patient-related variables associ-
ated with less than 90% of scheduled ASPA administration (41% of patients)
were older age, high BMI, and high ECOG score. In this model, center enroll-
ment volume but also inclusion time period were statistically associated with a
higher rate of ASPA administration, suggesting a learning effect. Finally, covari-
ates independently associated with induction failure were higher WBC (OR
1.04 [95%CI, 1.01-1.07]), slower bone marrow clearance at D8 (OR 0.07
[95%CI, 0.02-0.20]), lower ASPA injection number (OR 0.72 [95%CI, 0.60-
0.85]), and lower VCR injection number (OR 0.69 [95%CI, 0.55-0.88]), exclud-
ing all other induction drug dose variation.
Summary/Conclusions: During ALL induction, most ASPA-related toxicities
seen in adult patients are correlated to age and BMI. Experience in the man-
agement of ASPA administration may enhance protocol compliance and thus
contribute to reduce induction failure risk.
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Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-calicheam-
icin conjugate, has demonstrated superior response vs standard care for
relapsed/refractory acute lymphoblastic leukemia (ALL) in the ongoing phase 3
INO-VATE trial (complete remission [CR]/CR with incomplete hematologic recov-
ery [CRi], 81% [95% CI; 72–88]; minimal residual disease [MRD] negativity in
responders, 78% [68–87]; median remission duration [DoR], 4.6 [3.9–5.4] months).
Aims: To assess the efficacy and safety of InO in patients with relapsed/refrac-
tory ALL aged ≥55 vs <55 years
Methods: Per protocol, the intent-to-treat analyses of CR/CRi included the first
218 of 326 patients randomized (ITT218). The safety population included 139
patients who received ≥1 InO dose (max 1.8 mg/m2/cycle [0.8 mg/m2 on day 1;
0.5 mg/m2 on days 8 and 15 of a 21–28 day cycle for ≤6 cycles]). MRD negativity
was assessed by central flow cytometry (<0.01%). Data as of October 2, 2014
are presented (trial ongoing). Informed consent was obtained from all patients.
Results: 109 patients in the ITT218 received InO (median age, 47 [range, 18–
78] years; patients ≥55 years, 43 [39%]). Remission rates and DoR were similar
whereas MRD-negativity rates in responders were numerically higher in older
patients (Table). In the safety population, grade ≥3 adverse events (AEs) were
most frequently cytopenias (neutropenia, 46%; thrombocytopenia, 37%; febrile
neutropenia, 24%); these grade ≥3 AEs were more common in patients ≥55
(n=53) vs <55 years (n=86): thrombocytopenia (49% vs 29%), neutropenia (53%
vs 42%), febrile neutropenia (28% vs 21%). Patients ≥55 vs <55 years had sim-
ilar discontinuation rates due to AEs (both 17%). For patients ≥55 vs <55 years,
any grade hepatobiliary AE rates were similar (both 26%) and included, hyper-
bilirubinemia (both 15%), and veno-occlusive liver disease (VOD) including post-
SCT VOD (both 11%; 2 fatal in patients <55 years [1 after second SCT]).
Table 1.
Summary/Conclusions: InO was highly effective in older patients with
relapsed/refractory ALL for whom treatment options are currently limited;
responses and safety profiles were generally similar to younger patients and
the overall study population.
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THE COMBINATION OF BORTEZOMIB AND CHEMOTHERAPY IS AN
EFFECTIVE TREATMENT TO RE-INDUCE REMISSION IN RELAPSED/
REFRACTORY B-CELL PRECURSOR OR T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA
A Bertaina1,*, S Gaspari1, P Merli1, V Ferruzzi1, L Strocchio1, F Del Bufalo1,
V Bertaina1, R Caruso1, B Lucarelli1, L Vinti1, F Locatelli1,2
1Hematology-Oncology, Ospedale Bambino Gesù, Roma, 2Pediatrics, Uni-
veristy of Pavia, Pavia, Italy
Background: Achievement of a new complete remission (CR) in relapsed/
refractory pediatric acute lymphoblastic leukemia (ALL) is hampered by a low
response rate and high toxicity, especially after second or subsequent relapses.
Bortezomib, the first proteasome inhibitor approved by Food and Drug Admin-
istration for multiple myeloma and relapsed non-Hodgkin lymphoma, showed
preclinical activity against ALL blasts. Moreover, a phase II study reported by
the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study
group demonstrated that the combination of bortezomib with vincristine, dex-
amethasone, pegylated asparaginase and doxorubicin carried acceptable tox-
icity and good efficacy in patients with relapsed B-cell precursor ALL who failed
2-3 previous regimens (Messinger, Blood 2012).
Aims: In order to improve the CR rate of children with relapsed/refractory ALL,
we evaluated the use of bortezomib in combination with vincristine, dexam-
ethasone, pegylated asparaginase and doxorubicin, as a salvage/re-induction
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treatment in 24 and 7 children with B-cell precursor and T-cell ALL (2 ETP),
respectively. Patient characteristics are reported in Table I.
Methods: Bortezomib (1.3 mg/m2/dose) was administered intravenously on
day 1, 4, 8, and 11. Dexamethasone 10 mg/m2/day was given orally for 14 con-
secutive days. Doxorubicin 60 mg/m2 was given intravenously on day 1. Vin-
cristine 1.5 mg/m2/dose (2 mg maximum dose) was administered intravenously
on day 1, 8, 15, and 22. Pegylated asparaginase 2500 units/m2/dose was given
intravenously weekly for 4 doses. All patients received intrathecal (IT) cytarabine
on day 1. Patients without CNS involvement were given IT methotrexate on
day 15. Patients with CNS involvement at time of treatment were given IT
methotrexate, methylprednisolone, and cytarabine on day 8, 15, and 22.
Results: Between February 2012 and July 2015, 24 pediatric patients with
relapsed B-cell precursor and 7 with T-cell ALL were given the treatment
detailed above at the Hematology/Oncology Department of the IRCCS Bambino
Gesù Children’s Hospital, Rome, Italy. Seventeen patients were males and 14
females, median age at diagnosis and at time of last leukemia relapse being
6.7 years (range 1-20.9) and 9.9 years (2.6-24.1), respectively. Four patients
were CNS-positive at diagnosis, while 4/31 experienced a combined bone mar-
row (BM) and extramedullary relapse (2 CNS, 1 kidney and 1 gut, respectively).
Fourteen children had previously received allogeneic hematopoietic stem cell
transplantation (HSCT, see table 1 for details on the donor). Grade 3 (CTCAE
v4.03) peripheral motor and sensory neuropathy developed in 5 (16%) patients.
Six out of the 31 patients (19.5%) experienced severe infections (2 sepsis due
to Geotrycum, 3 to Candida and 1 to multidrug resistant Klebsiella Pneumoni-
ae). Despite the introduction of broad-spectrum antibacterial and antifungal
therapy, 4 of them (13%) died (2 each with Geotrycum and Candida infection)
without recovering neutrophils. Twenty patients achieved CR (10 with a
MRD<0.1%), this leading to a 64.5% overall response rate. Interestingly, in our
cohort, not only B-cell precursor patients had a good outcome (15/24, 62.5%
CR rate), but also T-cell ALL responded well to this combination of drugs (5/7,
71.4% CR rate). Fifteen of these patients had a long-lasting CR allowing them
to receive HSCT resulting in a 2-year Overall Survival (OS) of 37.1% (SE 13.2).
Table 1.
Summary/Conclusions: In conclusion, the regimen of bortezomib combined
with a 4-drug (vincristine dexamethasone, pegylated asparaginase and dox-
orubicin) re-induction therapy is effective for children with relapsed/refractory
B-cell precursor or T-cell ALL. Considering the risk of life-threatening/fatal infec-
tions in a such vulnerable population, an intensive antibacterial and antifungal
prophylaxis is strongly recommended.
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EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB
VERSUS 1ST- AND 2ND-GENERATION TYROSINE KINASE INHIBITORS
FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND
META-REGRESSION
E Jabbour1,*, M DerSarkissian2, N McCormick2, WY Cheng2, LJ McGarry3,
A Souroutzidis2, H Huang3, MS Duh2
1University of Texas MD Anderson Cancer Center, Houston, 2Analysis Group,
Inc., Boston, 3ARIAD Pharmaceuticals, Inc., Cambridge, United States
Background: The combination of a tyrosine kinase inhibitor (TKI) and either
chemotherapy or corticosteroids is effective induction therapy in de novo
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Ponatinib is a multi-targeted TKI that is a more potent BCR-ABL1 inhibitor than
previous generations of TKIs and selectively suppresses T315I resistance.
However, evidence on the comparative effectiveness of ponatinib relative to
other TKIs in de novo Ph+ ALL has not been well-established.
Aims: This study aims to evaluate the effectiveness, as measured by complete
molecular response (CMR) and 2-year overall survival (OS), of front-line treat-
ment combinations with ponatinib versus first- and second-generation TKIs
(i.e., imatinib, dasatinib, and nilotinib) in Ph+ ALL. 
Methods: Nineteen Phase 2 through 4 trials and one retrospective analysis of
front-line Ph+ ALL treatments were identified from a 2015 targeted literature
review published by the American Society of Hematology. One study used
ponatinib with chemotherapy and nineteen studies used a combination of first-
or second-generation TKIs with either chemotherapy or corticosteroids. The
proportions of patients achieving CMR and 2-year OS were extracted from all
study arms and summarized by TKI group (ponatinib vs all other TKIs) using
pooled estimates with 95% confidence intervals (CIs) from a random-effects
meta-analysis. A binomial distribution was assumed to calculate the 95% CIs
for the ponatinib trial. Multivariate logistic meta-regressions were conducted to
examine the association between TKI groups and CMR rates as well as
between TKI groups and 2-year OS, adjusting for age, gender, and in the OS
model only, the proportion of patients receiving subsequent hematopoietic stem
cell transplantation (SCT). P-values were calculated using non-parametric boot-
strapping with 20,000 permutations.
Results: Across the 30 TKI-treatment arms from the 20 included studies, the
median (range) age was 46 years (38-69 years), percent of male patients was
53% (40-67%), and percent of patients receiving subsequent SCT was 63% (0-
100%). The pooled proportion of patients achieving CMR with ponatinib was 78%
(95% CI: 62-90%) vs 30% (95% CI: 22-38%) with other TKIs. The pooled 2-year
OS with ponatinib was 80% (95% CI: 65-92%) compared to 58% (95% CI: 53-
63%) with other TKIs. The odds ratio (OR) for ponatinib vs other TKIs from the
adjusted meta-regression for CMR (N=18) was 9.12 (95% CI: 1.59-52.21,
p=0.025), and was 3.00 (95% CI: 0.63-14.43, p=0.136) for 2-year OS (N=19).
Summary/Conclusions: Our results support the hypothesis that ponatinib in
combination with chemotherapy is associated with better clinical efficacy in
newly diagnosed Ph+ ALL than combination therapy with older TKIs. In partic-
ular, compared to first- and second-generation TKIs, ponatinib was associated
with a statistically significant 9-fold increase in the odds of CMR and a higher,
though non-statistically significant, odds of 2-year OS. A limitation of our analy-
sis is its reliance on study-level data from a small number of studies with het-
erogeneous therapy combinations; adjustment for heterogeneity across studies
was limited to available covariates only. Nevertheless, our results suggest that
ponatinib in combination with chemotherapy may represent a highly effective
front-line treatment option for patients newly diagnosed with Ph+ ALL. Further
prospective head-to-head clinical trials to confirm these results are warranted.
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RISK OF CEREBRAL VEIN THROMBOSIS (CVT) IN ADULT ALL PATIENTS
IN FINLAND 1999-2012: SUGGESTION FOR A LEUKEMIA-RELATED
PREDICTIVE SCORING MODEL
S Roininen1,*, O Laine2, M Kauppila2, M Vesanen3, M Sinisalo2, E Jantunen4,
P Koistinen5, M Säily5, R Räty1, E Elonen1, U Wartiovaara-Kautto1
1Comprehensive Cancer Center, Department of Hematology, Helsinki University
Hospital, Helsinki, 2Dept. of Internal Medicine, Tampere University Hospital,
Tampere, 3Dept. of Internal Medicine, Turku University Hospital, Turku, 4Dept.
of Internal Medicine, Kuopio University Hospital, Kuopio, 5Dept. of Internal Med-
icine, Oulu University Hospital, Oulu, Finland
Background: Thrombosis causes remarkable morbidity among patients with
cancer and is the second leading cause of death after malignancy itself in this
patient group. Khorana score estimates the risk of deep venous thrombosis
(DVT) in solid tumor neoplasms, and may help physicians to prevent thrombotic
complications. However, Khorana score is not applicable in acute leukemias
and specific leukemia-related thrombosis risk score is still called for. Previous
analyses focusing on thrombosis in ALL patients have mainly been conducted
on pediatric study groups. Thrombotic risk profile in adult patients could, how-
ever, differ from children and these studies may not be converted straight-for-
ward to adult setting.
Aims: To identify patient characteristics detectable at ALL diagnosis and pos-
sibly predisposing to CVT, which often represents with the most drastic conse-
quences in patient’s life.
Methods: We performed a population-based retrospective registry analysis on
186 adult-ALL patients treated with a national study protocol ALL2000 between
years 1999-2012 in Finland.
Results: Of patients, 118 patients had pre-B ALL, 37 Philadelphia chromosome
positive ALL and 31 T-ALL. Thirty-one patients (19%) suffered from a venous
thrombosis (VT), whereof 9 (27%) from a CVT. Patients with CVT were thinner
(p=0.018 and p=0.010) and had more T-ALL (Pearson Chi-Square values:
10.61, p=0.005 and 9.93, p=0.007), extramedullary leukemia (Pearson Chi-
Square values: 5.167, p=0.023 and 5.412, p=0.046), and a higher pre-
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chemotherapy CRP (p=0.033 and p=0.123) compared with both patients with-
out VT and with other VTs, respectively (Table 1). A trend for younger age,
higher pre-chemotherapy D-dimer, leukocyte and blood blast counts, and a
lower platelet count was also detected in patients with CVT in this setting. CVT
patients also presented with a higher pre-chemotherapy hemoglobin compared
with patients without VT but this distinction did not reach statistical significance.
Notably, most CVTs (n=5/9) occurred prior to the introduction of asparaginase,
which is known to be the major factor predisposing ALL patients to thrombotic
complications. None of the CVT patients had received intrathecal cytostatic
treatment during the previous week before the thrombosis was diagnosed.
Based on these results we constructed a risk model for CVT, which takes into
account seven basic features detectable in patients at ALL diagnosis (Table
1). Patients scoring ≥5 points represented with a 20-fold risk for CVT compared
with the low-risk (<5 points) patients (HR=20.841, p<0.0001, CI: 5.208-83.401)
in our study group. The scoring model showed a very good specificity and sat-
isfying sensitivity (NPV: 0.982, PPV: 0.375) in this study and is currently under
validation in another patient cohort.
Table 1. Clinical and laboratory characteristics recorded at ALL diagnosis
in patients obtaining CVT during the first three months of chemotherapy
compared with other patient groups.
Summary/Conclusions: Thrombotic events and especially CVTs often have
a major impact on patients with ALL during their course of leukemia treatment
and after. Here, we present a set of laboratory and clinical characteristics iden-
tifiable at ALL diagnosis and associating with a very high risk of CVT during
the first months of ALL treatment. These high-risk characteristics (e.g. low BMI
and young age) are partly in contradiction to the acknowledged features pre-
disposing patients to other forms of VT. This phenomenon hints for a distinctive
mechanism of CVT in ALL patients possibly in linkage with ALL biology.
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INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE
PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC
LEUKAEMIA
N Morley1,*, A Kirkwood2, A Moorman3, P Smith2, C Rowntree4, B Wrench5,
E Marwood2, P Patrick2, J Snowden1, A Rijneveld6, D Marks7, A Fielding8
1Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,
2CR UK and UCL Cancer Trials Centre, UCL, London, 3Leukaemia Research
Cytogenetics Group, Newcastle University, Newcastle, 4University Hospital
Wales, Cardiff, 5Barts Health NHS Trust, London, United Kingdom, 6Erasmus
MC, Rotterdam, Netherlands, 7University Hospitals Bristol NHS Trust, Bristol,
8UCL Cancer Institute, UCL, London, United Kingdom
Background: The outcome for older adults with acute lymphoblastic leukaemia
(ALL) is generally poor. The UKALL12/ECOG2993 study reported a greater
incidence of high risk cytogenetic abnormalities, increased toxicity (e.g. 18%
Induction death rate) and poorer outcomes (CR rate 73% and 5 year overall
survival 21%) in those 55- 65 years of age. There is a dearth of studies which
focus on patients at the very oldest end of the age spectrum despite an increas-
ing incidence with age. 
Aims: We aimed to conduct a pragmatic study intended to establish baseline
chemotherapy from which to design widely-applicable studies of novel agents
in older people.
Methods: We established UKALL60+ as a collaboration between the UK
National Cancer Research Institute Adult ALL Group and HOVON to study
treatment choice and outcomes in patients aged 60 years and over (or 55 years
and over with co-morbidities) with ALL. The study offers five ‘arms’ to be decid-
ed by investigator and patient choice; Non-intensive (designed to be delivered
primarily out of hospital), Intensive, Intensive+, Philadelphia positive (Ph+) and
Registration only (in which treatment is at investigators discretion, including
no active therapy). Any elderly patient with newly diagnosed ALL is eligible.
There are no exclusions for co-morbidities, including prior malignancies. Base-
line characteristics of each group including Charlson index, ECOG, Karnofsky
and CRASH scores are being collected with the aim of determining why each
regimen was allocated. The primary endpoint is the rate of complete remission
(CR) after 2 phases of induction. Secondary objectives include determination
of MRD status at 3 time points, EFS and OS at 1 year, treatment related mor-
tality and quality of life assessments.
Results: Since activation in December 2012 81 patients (84% of those
screened) with a median age of 67 years (Range 55-83) have been enrolled.
Median follow up is 9.4 months (Range 1 day to 29.8 months). ECOG perform-
ance status was 1 in 33 (40%), 2 in 37 (45%) and ≥3 in 13 (15%). Treatment
allocation has been non-Intensive n=11, Intensive n=34, Intensive+ n=7, Ph+
n=18 and Registration only n=11 patients. It is too early to perform a full analysis
of the reasons given for choosing each regimen but age appears to be a major
factor for Ph-ve patients, with the average age 74 years (Range 64-82) in the
non-Intensive arm compared with 66 years (Range 56-76) in the Intensive and
Intensive+ arms. A total of 32/80 patients (40%) had high risk cytogenetics
including BCR-ABL1 (n=18), low hypodiploidy (n=10), complex karyotype (n=2)
and KMT2A-AFF1 (aka MLL-AF4) (n=1). So far forty-eight patients have com-
pleted 2 phases of induction chemotherapy with 37 of these attaining CR (77%).
Failure to complete this was very common (n=17); reasons include inadequate
response/relapse=8, death=5, clinician or patient decision=4. Baseline MRD
samples were received for 62 patients, 43 of which have been evaluated to
date by immunoglobulin heavy chain/T cell receptor re-arrangement quantifi-
cation or BCR-ABL quantification. Only 3 of these patients were MRD negative
following the first cycle of induction chemotherapy. Grade 3/4 AEs were seen
in 54/58 assessable patients. The most common toxicities were haematological
(71%) and infections (38%). To date 28 deaths have been reported; 18 patients
died of ALL, 5 infection, 1 cardiac, 1 multi-organ failure and 3 data outstanding.
Quality of life data has been collected and the results are anticipated.
Summary/Conclusions: ALL in older patients is difficult to treat with a delicate
balance between efficacy and toxicity. Treatment choices currently vary widely.
The goal of our trial is to provide a representative view of elderly ALL treatment,
to identify a group where the current therapeutic approaches need improvement
and to pave the way for older individuals to be at the forefront of development
of novel approaches in de novo ALL.
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RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN OLDER/ELDERLY
PATIENTS - A SWEDISH POPULATION-BASED STUDY
E Bergfelt1,*, P Kozlowski2, L Ahlberg3, P Bernell4, E Hulegårdh5, H Karbach6,
K Karlsson7, B Tomaszewska-Toporska7, M Åström2, H Hallböök1
1Haematology, Dept of Medical Sciences, Uppsala University, Uppsala,
2Haematology, Dept of Medical Sciences, Faculty of Medicine and Health, Öre-
bro University, Örebro, 3Dept of Haematology, University Hospital of Linköping,
Linköping, 4Div of Haematology, Dept of Medicine, Karolinska Institutet, Karolin-
ska University, Stockholm, 5Dept of Haematology and Coagulation, Sahlgren-
ska University Hospital, Göteborg, 6Dept of Haematology, Cancer Centre, Uni-
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pital, Lund, Sweden
Background: Knowledge about relapsed acute lymphoblastic leukaemia (ALL)
in older/elderly patients is scarce.
Aims: To study the outcome of ALL relapse treatment in a population-based
cohort of older/elderly patients.
Methods: Out of the Swedish ALL-registry and cause of death-registry patients
55-85 years (y) old diagnosed with B- and T-ALL from 2005 to 2012 were iden-
tified. Clinical, laboratory and treatment data were validated and supplemented
from medical records. Informed consent was obtained and the study approved
by the local ethical committee in accordance with the declaration of Helsinki.
Proportions were compared with chi-square test. Overall survival (OS) was
estimated by the Kaplan Meier method and distribution compared with log-
rank test using IBM SPSS package (v 23). Confidence intervals (CI) of 95%
were obtained.
Results: Of 103 patients with B- and T-ALL receiving intensive treatment with
achieved first complete remission (CR1), 63 (61%) relapsed (28 males and 35
females). Median age at relapse was 67y (57-83). B-ALL was present in 57/63,
T-ALL in 6/63, and Philadelphia-positive (Ph+) disease in 19 of 61 patients
(31%) (two with unknown Ph-status). Bone marrow was the sole relapse local
in 57 (91%) patients. Median time from CR1 to relapse (TTR) was 9 moths
(range: 1-93) and seven relapsed after allogeneic hematopoietic stem cell
transplantation (hSCT). Treatment with the goal of a second complete remission
(CR2) was applied in 33 patients and the first course consisted of the Swedish
protocol ABCDV (n=8), FLAG-Asp (n=6), FLAG-Ida (n=3), MEA (n=4), FLAG
(n=1), Hyper-CVAD (n=3), NOPHO adult protocol (n=1), nelarabine (n=1) or
other combinations (n=6). Regimens were supplemented with tyrosine kinase
inhibitor (TKI) in six patients, DLI in one and CAR-T in one patient. hSCT in
CR2 was performed in three patients (of 10 considered for the procedure). Two
of them died of relapse and transplant related mortality respectively and one
is still alive after seven years. Palliation was given to the 30 remaining patients
with CHOP/COP (n=5, with rituximab added in 2), other intravenous chemother-
apy combinations (n=5), TKI [alone (n=5), with chemotherapy/cortisone (n=3),
radiotherapy (n=1) and DLI (n=1)], cortisone and/or oral chemotherapy com-
binations (n=7), no treatment (n=1) and unknown (n=2). Remission induction
was given predominantly in late (>1y) relapse [18/27 (67%) vs 15/36 (42%);
P=0.049]. In total, CR2 was achieved in 18 patients (29%) - 14/33 (42%) after
remission induction and 4/30 (13%) after palliative treatment. Higher proportion
of patients attained CR2 in late as compared with early relapse [13/27 (48%)
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vs 5/36 (14%); P=0.003]. Median survival after relapse was 4 months (range:
0-95). The estimated 1 and 3y OS after relapse was 17 (CI: 7, 27)% and 7 (CI:
0, 14)%. There was no significant difference in OS between patients receiving
remission induction and palliation. Age at relapse did not influence OS. Patients
with late relapse had improved survival (P=0.001). CR2 achievement (as com-
pared with treatment failure) enhanced survival in late [3y OS, CI: 34 (5, 64)%
vs 7 (0, 21)%; P=0.001] but not early relapse (no survivors at 3y; P=0.22).
Summary/Conclusions: Intensive treatment can be considered in older ALL
patients in case of late relapse. However, for the majority of the patients, the
prognosis was poor, which supports alternative approaches such as
immunotherapy or novel drugs.
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ADULTS AND CHILDREN (1-45 YEARS) WITH PH-NEGATIVE ALL HAVE
ALMOST IDENTICAL OUTCOME IN RISK-STRATIFIED ANALYSIS OF
NOPHO ALL2008
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Background: Compared with children, adults with acute lymphoblastic leukemia
(ALL) have had inferior survival, when treated with traditional adult ALL regi-
mens.
Aims: The aim of this study was to examine the event free survival (EFS) of
children and adults with ALL (1-45 years) diagnosed, risk stratified, and treated
uniformly according to the NOPHO ALL2008 protocol.
Methods: We collected information on 1509 patients from Sweden, Norway,
Iceland (children only), Finland (children only), Denmark, Lithuania, and Estonia
diagnosed 7/2008-12/2014 with Ph-negative ALL and treated according to the
NOPHO ALL2008 protocol. Patients were registered in the NOPHO ALL2008
database upon diagnosis and subsequently followed systematically at three
months intervals.
Results: Of 1509 patients, 1022 were children 1-9 years (484 female), 266
were 10-17 years (106 female) and 221 were adults 18-45 years (85 females).
Adult patients more often had T-ALL (9% (1-9 years), 25% (10-17 years) and
32% (18-45 years), p<0.001), and KMT2A (a.k.a MLL) rearrangements
(KMT2A-r, 3% (1-9 years), 5% (10-17 years) and 6% (18-45 years) , p<0.001),
but lower median WBC when stratified by lineage (B-lineage 9.9 (1-9 years),
8.1 (10-17 years) and 6.8 (18-45 years) x109/L, p=0.01; T-lineage 134 (1- 9
years), 71.7 (10-17 years) and 38.8 (18-45 years) x109/L, p<0.001). Day 29
MRD was significantly higher for adults (p<0.001). Based on immunophenotype,
WBC at diagnosis, MRD (discriminator 0.1%, FCM for BCP and PCR for T) at
day 29 and 79, and presence of intermediate (dic(9:20) or iAMP21[RUNX1] or
t(1;19)) or high risk cytogenetics (KMT2A-r or hypodiploidy (modal number
<45)), patients were stratified into 4 risk groups (SR, IR, HR, and HR+hSCT,
Table 1). Only MRD d29 ≥5% or d79>0.1% stratified to hSCT in 1st complete
remission (CR1). Older patients were skewed towards higher risk group (Toft,
Eur J Haematol 2013), but for each treatment arm severe toxicities (except for
thrombosis and osteonecrosis) and intervals between treatment phases were
almost identical for children and adults (Toft, Eur J Haematol 2015). After a
median follow up for patients in CR1 of 4.0 years (75% range: 2.4-5.9 years),
16 patients (3 patients 18-45 years) had died during induction (induction failure),
and 50 patients (12 patients 18-45 years) had died in first remission. A total of
123 patients relapsed (36 patients 18-45 years), and 12 children and 1 adult
developed a second malignancy. The overall 5y-EFS for patients 1-9, 10-17
and 18-45 years was 88% (95%CI: 86; 90), 79% (95%CI: 73; 85) and 73%
(95%CI: 67; 79), respectively, p <0.001. However, when stratified by risk group,
the poorer EFS for adults was significant only for patients with intermediate
risk ALL (Table 1).
Table 1.
Summary/Conclusions: The EFS for adult ALL patients has improved marked-
ly with NOPHO ALL2008 treatment compared with historical data. Although
adult patients more often have higher risk ALL, their overall cure rates are close
to those of children when stratified by risk group.
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MICRORNA-155 AND MICRORNA-708 ARE OPPOSING MODULATORS OF
HOXA9 ACTIVITY IN ACUTE MYELOID LEUKEMIA
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C Buske1, H Döhner5, L Bullinger5, M Heuser6, K Döhner5, RK Humphries3,
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Background: In order to identify microRNAs (miRNA) relevant in acute myeloid
leukemia (AML), we profiled global miRNA expression in a murine AML pro-
gression model based on Hoxa9 and Meis1 overexpression. 
Aims: We found miR-155 and miR-708 as the most significantly upregulated
miRNAs in leukemic Hoxa9/Meis1 cells compared to the preleukemic Hoxa9/ctrl
cells (both p<0.01). Subsequent analysis of primary AML cases (n=38) com-
prising various AML subtypes showed significantly elevated levels of miR-155
and miR-708 in all samples compared to total bone marrow from healthy donors,
indicating potential oncogenic roles for these miRNAs. We further investigated,
in vivo, the role of miR-155 in AML by retroviral overexpression with Hoxa9 in
murine bone marrow (mbm) cells followed by syngeneic transplantation. Over-
expression of miR-155 in conjunction with Hoxa9 (Hoxa9/miR-155) caused a
significantly accelerated onset of a myelomonocytic leukemia (p<0.001), but
still a less aggressive course of disease compared to mice transplanted with
Hoxa9/Meis1 (p<0.001). In order to assess if miR-155 is dispensable for the
onset of AML, we transformed miR-155-/- and miR-155+/+ mbm with
Hoxa9/Meis1 followed by syngeneic transplantation. No difference in onset of
AML was observed. Further analysis revealed that absence of miR-155 impaired
homing of Hoxa9/Meis1 cells but did not impact their proliferation rate, which
eventually compensated for impaired engraftment in this AML model.
Methods: We then hypothesized that the combination of miR-155 and miR-
708 could further replace the oncogenic potential of Meis1. Therefore, mbm
cells were retrovirally transduced with Hoxa9, miR-155 and miR-708
(Hoxa9/miR-155/miR-708) or Hoxa9 and miR-708 (Hoxa9/miR-708) and func-
tionally analyzed in vitro and in vivo. To our surprise, miR-708 abrogated the
leukemogenic effect of Hoxa9, alone or in combination with Hoxa9/miR-155 in
vivo (p=0.0117, p<0.0001), with little or no engraftment. Transcriptome analysis
revealed that miR-155 and miR-708 have opposite effects on Hoxa9-induced
transcription.
Results: To further understand why miR-708, a potent tumor suppressor miR-
NA, is upregulated in the highly aggressive Hoxa9/Meis1 AML cells, we
explored the role of miR-708 in leukemia initiating cells (LIC). Hoxa9/Meis1
cell subpopulations enriched for LIC based on c-kit, Mac-1 and Gr-1 expression
were FACS-sorted and transplanted into syngeneic mice. The c-kit+Gr-1-Mac-
1- cells caused a significantly shorter survival of transplanted mice compared
to the other sorted subpopulations (p=0.0072 and p=0.0021, respectively), with
the c-kit-Gr-1+Mac-1+ subpopulation resulting in the longest survival. This was
mirrored by lower expression of miR-708 in the LIC-enriched c-kit+Gr-1-Mac-
1- subpopulation compared to bulk (p=0.032), whereas there was no difference
in miR-155 expression. Similar findings were made in human AML samples
(n=7) sorted into LIC-enriched subpopulations using CD117, CD34 and CD38.
Together, these results highlight the role of miR-708 as an orchestrator of the
leukemic hierarchy through its tumor suppressor activity. 
Summary/Conclusions: In conclusion, we demonstrate for the first time a
functional role for miR-155 in homing of AML cells. In addition, we propose as
a novel concept where miR-708, a tumor suppressor miRNA, stratifies the
leukemic hierarchy.
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VENTX INDUCES EXPANSION OF PRIMITIVE ERYTHROID CELLS AND
CONTRIBUTES TO THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA
IN MICE
E Gentner1,*, NM Vegi1, MA Mulaw1, T Mandal1, A Tasdogan2, L Quintanilla-Martinez3,
K Döhner4, H Döhner4, L Bullinger4, T Haferlach5, C Buske1, VP Rawat1,
M Feuring-Buske4
1Institute of Experimental Cancer Research, CCC and University Hospital of
Ulm, 2Institute of Immunology, Ulm University, Ulm, 3Institute of Pathology, Uni-
versity of Tübingen, Tübingen, 4Department of Internal Medicine III, University
Hospital of Ulm, Ulm, 5MLL Munich Leukemia Laboratory, Munich, Germany
Background: Homeobox genes are key factors in the development of acute
leukemias. So far, little is known about the role of non-clustered homeobox
genes such as VENTX. The Vent-like homeobox gene VENTX is a member of
the Vent gene family in mammals and is the mammalian homolog of the Xeno-
pus xvent gene. Our group has previously shown that the homeobox gene
VENTX shows high and aberrant expression in human acute myeloid leukemia
(AML) characterized by the AML1-ETO (AE) fusion (Rawat et al., PNAS 2010).
Aims: With this study, we wanted to test the functional relevance of VENTX in
the development of AE positive AML in mice.
Methods: To address this, mice were transplanted with bone marrow progenitor
cells retrovirally engineered to express VENTX or AML1-ETO alone or in com-
bination.
Results: Whereas none of the AML1-ETO mice developed any disease, all
the recipients of AML1-ETO/VENTX double transduced cells succumbed to
AML after a median latency of 334 days (range 19-403 days) post transplan-
tation. Of note, induced AML cases were positive for erythroid markers such
as CD71 and Ter119. Strikingly, VENTX alone induced a massive expansion
of the primitive erythroid compartment in all transplanted mice. Furthermore,
this massive perturbation in differentiation converted into an acute ery-
throleukemia in a fraction of mice. All leukemias in the AE/VENTX and the
VENTX experimental arms were rapidly transplantable with a median latency
of 40 days until leukemia induced death, characterized by high blast counts in
the bone marrow (83%, range 55% - 92%). Ex vivo, leukemic cells grew per-
manently generating AE/VENTX positive cell lines. RNA-Seq analyses from
CD34+ cord blood transduced with VENTX documented 279 differentially
expressed genes compared to the empty vector control, comprising pathways
belonging to the categories “viral carcinogenesis”, “cytokine-cytokine receptor
interaction”, “JAK-STAT signaling”, “cancer”, “signaling pathways in cancer”,
“transcriptional misregulation in cancer” and “Huntington’s disease” in the
KEGG analysis. Genes necessary for terminal erythroid differentiation such as
the EPO-receptor and GATA1 were downregulated by constitutive VENTX
expression. In line with the observation of VENTX induced primitive erythroid
expansion in mice, VENTX was highly expressed in patients with primary
human erythroleukemias and polycythemia vera. Knockdown of VENTX in the
erythroleukemic HEL cell line significantly blocked growth in vitro and engraft-
ment in NSG mice. Overexpression of VENTX impaired expression of genes
linked to erythroid differentiation in human stem and progenitor cells.
Summary/Conclusions: In summary, these data indicate that aberrant expres-
sion of VENTX induces expansion of primitive erythroid cells and collaborates
with AML1-ETO in inducing AML in mice.
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ABNORMAL INTRAGENIC TRANSCRIPTIONAL ACTIVATION IN MLL-AF9
AND KAT6A-CREBBP ACUTE MYELOID LEUKEMIA (AML)
AE Marneth1,*, K Prange2, SM Bergevoet1, A Obulkasim3, CM Zwaan3,
MM Van Den Heuvel-Eibrink3, T Haferlach4, M Fornerod3, JH Jansen1,
J Martens2, BA Van Der Reijden1
1Laboratory Medicine, Laboratory of Hematology, Radboudumc, 2Department
of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life
Sciences, Radboud University, Nijmegen, 3Pediatric Oncology/Hematology,
Erasmus MC-Sophia Children’s Hospital, Rotterdam, Netherlands, 4MLL
Munich Leukemia Laboratory, Munich, Germany
Background: The mutated transcription factors AML1-ETO, CBFB-MYH11
and CEBPA cause unique pathogenic gene expression profiles (GEPs) in AML.
Previously, we identified an AML subgroup with a unique GEP characterized
by outlier high expression of the BRE gene. Most cases with this unique GEP
harbor the oncogenic transcriptional regulator MLL-AF9. However, since ~50%
of adult MLL-AF9+ AML cases does not exhibit this unique GEP nor outlier
high BRE expression, we postulated that another pathogenic mechanism
besides the MLL-AF9 translocation causes this unique GEP.
Aims: We aimed at characterizing outlier high BRE expression and the asso-
ciated unique GEP in MLL-AF9+ AML, whether these phenomena were exclu-
sive to MLL-AF9+ AML and whether they associated with known oncogenic
pathways.
Methods: AML samples were subjected to RNA-sequencing (n=4), H3K4me3
(n=7) and/or H3K27ac (n=3) ChIP-sequencing. Informed consent was obtained
from all subjects prior to this study. 5’ Rapid Amplification of cDNA Ends (RACE)
was performed to characterize the 5’ end of BRE transcripts. BRE gene expres-
sion was measured by qRT-PCR. Expression of an alternate BRE transcript
was normalized to PBGD expression and a control sample without outlier high
BRE expression. A normalized value >500 was considered high. Ingenuity
pathway analyses were performed on the top 200 genes positively associated
with BRE expression in MLL-AF9+ AML.
Results: RNA-seq and qRT-PCR of MLL-AF9+ patient samples showed a
marked increase in BRE expression starting from exon 5, exclusively in sam-
ples with outlier high BRE expression. H3K4me3 and H3K27ac ChIP-sequenc-
ing revealed clear marks in BRE intron 4, 3 kb upstream of BRE exon 5, only
in AML cases with outlier high BRE expression. To demonstrate that this region
relates to active transcription, we performed 5’ RACE. A new transcript starting
in BRE intron 4 near the H3K4me3/H3K27ac marks was identified, with
sequences spliced to BRE exon 5. A qRT-PCR specific for the alternate BRE
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transcript showed that it was frequently expressed in adult MLL-AF9 samples
and in samples with the KAT6A-CREBBP fusion gene (18/35, median expres-
sion high 8580, low 0.6). This is in line with published data showing that part of
MLL-AF9+ and KAT6A-CREBBP+ samples share a common GEP. Also child-
hood MLL-rearranged and KAT6A-CREBBP+ AML samples frequently
expressed the alternate BRE transcript (31/43, median expression high 8172,
low 26.9). Alternate BRE expression was generally low in patients with other
types of AML (n=42, 1.4) and non-AML hematological malignancies (n=10, 0.4)
or normal CD34+ and bone marrow cells (n=14, 0.3). A polymorphism in BRE
intron 5 revealed that alternate BRE transcription initiation is bi-allelic. Impor-
tantly, analysis of genome-wide H3K4me3 marks and RNA-seq data uncovered
98 potential intragenic transcriptional activation sites, several of which are in
genes correlating with high BRE expression. Ingenuity pathway analyses using
the top 200 genes positively associated with BRE expression, identified poten-
tial pathogenic pathways including p53 and protein kinase A signaling (p<0.03).
Summary/Conclusions: Alternate transcription initiation in the ALK gene was
recently identified as oncogenic mechanism causing melanoma (Wiesner et
al., Nature, 2015). Our data show genome-wide alternate transcription initiation
as new phenomenon in MLL-AF9+ and KAT6A-CREBBP+ AML cases that
exhibit a unique GEP. Potential oncogenic pathways were identified in these
AML subgroups. Further studies investigating the molecular mechanisms con-
tributing to alternate transcription initiation in AML are warranted.
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HHEX TRANSFORMS PROMYELOCYTES AND COOPERATES WITH FACTOR
INDEPENDENCE TO CAUSE PROMYELOCYTIC LEUKEMIA IN MICE
JT Jackson1,*, A Ng1, WS Alexander1, S Haupt2, Y Haupt2, MP McCormack1
1Cancer & Haematology Division, The Walter & Eliza Hall Institute of Medical
Research, Parkville, 2Tumour Suppression Laboratory, The Peter MacCallum
Cancer Centre, East Melbourne, Australia
Background: The transcription factor Hhex (Hematopoietically-expressed
homeobox gene) is important for lymphoid commitment and causes T-cell
leukemia when overexpressed. We have recently found that Hhex is overex-
pressed in human myeloid leukemias and maintains leukemia stem cell self-
renewal in mouse models of AML via repression of Cdkn2a. However, whether
Hhex overexpression also affects hematopoietic differentiation is not known.
Aims: The aims of this study are to investigate the effects of high levels of
Hhex expression in growth factor independent hematopoietic progenitor cells
and the roles of the functional domains of Hhex.
Methods: To study the effects of Hhex on haematopoietic progenitor differen-
tiation, we immature Lin-Sca+Kit+ (LSK) hematopoietic progenitors were trans-
duced with retroviruses expressing wild-type and mutant forms of Hhex.
Results: Hhex overexpression in LSK cells caused serial replating of myeloid
progenitors and to the rapid establishment of IL-3-dependent promyelocytic cell-
lines. Structure function analysis demonstrated a requirement of the DNA binding
domain and the N-terminal repressive domains of Hhex in promyelocytic trans-
formation. This included a PML protein interaction domain, although loss of PML
failed to prevent Hhex-induced promyelocyte transformation in vitro. RNA-Seq
analysis showed that Hhex overexpression leads to repression of myeloid devel-
opmental genes including MPO. To test the leukemic potential of Hhex, Hhex-
transformed promyelocyte lines were rendered growth factor-independent using
a constitutively active IL-3 receptor common β subunit (βcV449E). The resultant
cell-lines caused rapid promyelocytic leukemia in mice.
Summary/Conclusions: In addition to its role in repressing tumor suppressor
pathways in myeloid leukemias, overexpression of Hhex causes a differentiation
blockade and contributes to promyelocytic leukemia in vivo. As such, Hhex over-
expression may contribute to human myeloid leukemias via multiple pathways.
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A SOMATIC MUTATION OF GFI1B IDENTIFIED IN LEUKEMIA ALTERS
CELL FATE VIA A SPI1 (PU.1) CENTERED GENETIC REGULATORY
NETWORK
E Anguita1,*, R Gupta2, V Olariu3, PJ Valk4, C Peterson3, R Delwel4,
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versity Medical Center, Rotterdam, Netherlands
Background: Establishing a link between leukemia mutations and the malig-
nant process requires functional assessment of their biological impact in the
context of appropriate normal and malignant primary cells. Against this back-
drop, we have identified a mutation (D262N) in the erythroid/megakaryocytic
affliated transcriptional repressor GFI1B in acute myeloid leukemia (AML) and
explored its biological properties.
Aims: Establishing a link between a GFI1B mutation and leukemia in the con-
text of normal and malignant primary cells.
Methods: Human material and clinical information was obtained with informed
consent and approval of institutional ethics committee from 69 patients with AML.
Point mutation analysis: GFI1B coding regions were analyzed by DHPLC. Next
generation sequencing performed with Hiseq2000 (Illumina) allowed the iden-
tification of a novel mutation. Cloning: GFI1B cDNA was amplified, cloned in
pGEM-T easy vector and sequenced. Point mutation was introduced by PCR.
Wild-type or mutated coding cDNA was cloned into pHRSINCSGW lentivirus
vector, expressing green fluorescent protein (GFP). The SPI1 hairpin was
cloned into the SLX vector, with or without wild-type or mutant GFI1B. Enrich-
ment of hematopoietic stem and progenitors: Enrichment of human CD34+
cells from mobilized peripheral blood was by magnetic selection (Miltenyi
Biotec). Transduced GFP/CD34 positive cells were sorted. Methylcellulose
Colony-Forming Cell (CFC) assays: CFC assays were performed with
MethoCult H4436 (StemCell Technologies), 15 days. Liquid differentiation
assays: CD34+ cells expressing mutant or wild type GFI1B were maintained
under liquid culture conditions that support multi-lineage differentiation: Mye-
locult® H5100 with human cytokines, SCF, FLT3L (50 ng/ml); IL-3, GM-CSF,
M-CSF (10 ng/ml); G-CSF (0.1 MUI); EPO (100 ng/ml) for 5-6 days. MDS cell
culture: CD34+ cells were cultured in MyeloCult® H5100 with 10% (v/v) HS-5
conditioned medium, human SCF and IL-3 (both 50 ng/ml). AML patients gene
expression profiling and data analysis: This has been published
(www.ncbi.nlm.nih.gov/geo, GSE1159).
Results: We identified a GFI1B new mutation (D262N) in an AML patient with
antecedent myelodysplastic syndrome (MDS). The GFI1B-D262N mutant func-
tionally antagonizes the transcriptional activity of wild-type GFI1B. GFI1B-
D262N promoted myelomonocytic versus erythroid output from primary human
hematopoietic precursors and enhanced cell survival of both normal and MDS
derived human precursors. Re-analysis of 285 AMLs transcriptome data
revealed a significant subset of patients in which expression of wild-type GFI1B
was inversely correlated with that of SPI1 (PU.1). In delineating this GFI1B-
SPI1 relationship we show (I) SPI1 is a direct target of GFI1B, (II) expression
of GFI1B-D262N produces elevated expression of SPI1, (III) SPI1-knockdown
restores balanced lineage output from GFI1B-D262N-expressing precursors,
(IV) we also observed that GFI1B produced an increase in MLLT3, while expres-
sion of mutant GFI1B reduced MLLT3 expression.
Summary/Conclusions: In conclusion, our data links GFI1B to both the
myeloid and erythroid transcriptional networks by repressing SPI1 and increas-
ing MLLT3 expression, helping to understand its role in lineage specification
and its potential in promoting blood malignancy. In fact, our clinical findings
and experimental data show that the GFI1B D262N mutant plays a role in AML
in humans and does so primarily through the agency of master transcriptional
regulator SPI1, reflecting GFI1B physiological function in SPI1 regulation.
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COMPARATIVE FUNCTIONAL ANALYSIS OF THE COMMON INTERACTORS
OF 7 MLL FUSION PROTEINS
A Skucha1,*, A César Razquin1, A Stukalov1, M Muhar2, J Colinge1, K Bennett1,
J Zuber2, G Superti-Furga1, F Grebien3
1CeMM Research Center for Molecular Medicine of the Austrian Academy of
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Background: The Mixed Lineage Leukemia gene (MLL) is a frequent target of
chromosomal rearrangements in human malignancies. Balanced translocations
result in the fusion of the MLL gene to over 65 different fusion partner genes,
leading to the production of novel chimeric proteins. Critical effectors of distinct
MLL fusion proteins have previously been identified, and some of them were
shown to hold great potential for targeted therapies. However, it is not clear if
these effectors are conserved among all MLL fusion proteins or if different
molecular mechanisms of transformation exist for distinct MLL fusion proteins.
Aims: We aimed to identify common critical effectors of 7 selected MLL fusion
proteins (MLL-AF1p, MLL-AF4, MLL-AF9, MLL-CBP, MLL-EEN, MLL-ENL,
MLL-GAS7), which have been presumed to employ different molecular mech-
anisms of oncogenic transformation. 
Methods: Stable cell lines allowing for inducible expression of 7 different affin-
ity-tagged MLL fusion proteins were prepared and transgene expression was
verified by qRT-PCR and Western Blotting. Affinity purification coupled to mass
spectrometry (AP-MS) identified novel interactors of the 7 MLL fusions. Func-
tional annotation of the resulting interactome revealed significant enrichment
of a large number of protein complexes. To assign functional information to a
subset of 128 interactors, which were found to bind to ≥5 MLL fusions, we
employed a RNAi screening approach. The MLL-AF9-positive MOLM-13 cell
line was transduced with pools of viral vectors allowing for the expression of 6
shRNAs targeting the same candidate gene. We established a screening
methodology that is suitable for positive and negative selection readouts. To
confirm and further validate selected high-confidence candidates we performed
additional RNAi screens in other MLL-rearranged- and MLL-wild-type leukemia
cell lines and characterized RNAi-knock down efficiencies in various human
and murine cell systems.
Results: Advanced statistical filtering using a novel, improved algorithm devel-
oped by us yielded a densely connected protein-protein interaction network of
>950 proteins around 7 MLL fusions. Many protein complexes previously shown
to be associated with MLL were significantly enriched, such as PAF-, SWI/SNF-
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and the RNA Pol II containing coactivator complexes. 128 proteins were found
to interact with ≥5 of the 7 MLL-fusions. This list of conserved MLL-interactors
is highly enriched for proteins with known functions in chromatin metabolism
and transcriptional control. Several RNAi screens in different human leukemia
cell lines were used to functionally dissect the conserved MLL-fusion interac-
tome. Our screening methodology identified known MLL interacting proteins
such as Menin, DPY30 and HCFC1 as critical effectors of MLL fusion proteins,
validating the approach. In addition, we selected a small set of novel interactors
of MLL fusion proteins for further validation experiments, including a protein
involved in cytoskeletal organization.
Summary/Conclusions: In conclusion, we developed a robust experimental
pipeline allowing for the functional characterization of cellular effects of MLL
fusion proteins in a comprehensive and comparative manner, which will con-
tribute to further clarify the molecular mechanisms of MLL-fusion dependent
leukemogenesis.
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TRANSFORMING ACTIVITY OF THE NUP98-MLL FUSION IN A CONDITIONAL
TRANSGENIC MOUSE MODEL
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Background: Genes encoding for mixed-lineage leukaemia (MLL) and nucleo-
porin 98 (NUP98) are both involved in multiple recurrent chromosomal rearrange-
ments associated with haematological malignancies. Inv(11)(p15q23), present
as a sole cytogenetic abnormality in patients with myelodysplastic syndromes
(MDS) or acute myeloid leukaemia (AML), was reported to lead to the expression
of a fusion containing the FG-repeats of NUP98 and almost the entire open read-
ing frame of MLL but lacking the N-terminal menin/LEDGF interaction domain,
known to be critical for transformation of all currently known MLL fusions through
expression of critical downstream targets like the HOXA gene cluster.
Aims: To address the transforming potential of the NUP98-MLL fusion we
established conditional transgenic mice.
Methods: The human NUP98-MLL fusion ORF of 13kb was integrated into
the Hprt gene locus under the control of a tetracycline (Tet) responsive element
in mouse ES cells harbouring a reverse Tet transactivator (rtTA) in the Rosa26
locus and allowing conditional expression of the transgene by doxycycline
(DOX) administration. The effects of conditional NUP98-MLL expression on
the haematopoietic system were analysed.
Results: Ex vivo expression of NUP98-MLL in lineage-marker depleted bone
marrow (BM) cells increased colony formation and replating in methylcellulose.
In liquid cultures, NUP98-MLL increased proliferation and impaired differenti-
ation of the cells shown by cell morphology and flow cytometric analysis for
Gr-1, Mac-1, CD34 and c-Kit expression. In vivo induction of NUP98-MLL led
to an MDS-like disease with progression to an AML phenotype after a median
latency of 78 weeks. The pre-leukemic phenotype was characterized by the
presence of dysplastic myeloid cells in the periphery, decreased Mac-1/Gr-1
expression in the BM, and extensive extramedullary haematopoiesis, especially
erythropoiesis in the spleen. These mice also exhibited an increased number
of haematopoietic stem and progenitor cells (HSPCs) that provided a significant
competitive repopulation advantage when transplanted into irradiated syngene-
ic recipients. So far, 4 mice have progressed to AML characterized by increased
white blood counts, presence of blasts in the periphery with infiltration of the
BM, spleen, and other organs. The disease was transplantable into irradiated
recipients and depended on NUP98-MLL expression since propagation of the
disease was significantly impaired in the absence of DOX. As the fusion lacks
the menin/LEDGF interaction domain we addressed the sensitivity to small
molecules targeting this interface and expression of the HOX gene cluster.
Interestingly, in contrast to cells immortalized by the MLL-AF9 or MLL-ENL
fusions, NUP98-MLL expressing cells were resistant to the small molecule Mi2-
2 menin inhibitor and did not express high levels of the HOX-A-B-C genes. In
addition, treatment with the bromodomain inhibitor JQ-1 did not induce cell
cycle arrest or significant cytotoxicity but increased the fraction of cells in >G2
phase suggesting alternative transforming mechanisms of NUP98-MLL impli-
cating the cell cycle checkpoint control.
Summary/Conclusions: We show that transgenic NUP98-MLL expression in
mice resulted in an “MDS-like” pre-leukemic state progressing to AML after a
long latency. The transforming mechanisms of NUP98-MLL fusion differed from
other MLL-fusions resulting in relative resistance to small molecules that are
currently being explored for targeted AML therapy.
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CONDITIONAL DELETION OF THE HOXA CLUSTER IN MLL-AF9 IS
INCOMPATIBLE WITH LEUKEMIA MAINTENANCE
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Background: Hox gene expression is high in hematopoietic stem/progenitor
cells (HSPCs), decreases during normal differentiation but remains elevated
in leukemia subtypes. Polycomb repressor complexes and histone modifiers,
e.g. Mixed Lineage Leukemia (MLL), are key regulators of Hox expression.
MLL rearrangements, frequent in acute leukemia, are associated high HOXA
expression. However, necessity for the HoxA cluster in MLL-leukemia mainte-
nance is not fully elucidated.
Aims: Determine the criticality of the HoxA cluster in MLL-AF9 leukemia main-
tenance.
Methods: Ectopic overexpression of MLL-AF9 (MA9) in HSPCs in conditional
compound transgenic mouse backgrounds MxCre+/HoxAflox/flox (MAFF) or Hox-
Aflox/flox (AFlox) models resulted in increased colony formation and growth in liq-
uid culture. Transformed colonies, serially re-plated (n=5) in methylcellulose and
transplanted into sub-lethally irradiated recipient mice, resulted in primary
leukemia. Initially, MAFF-MA9 leukemias were used to examine in vivo deletion
of the HoxA cluster using intraperitoneal injections of Poly(I:C) to initiate an inter-
feron response. To further examine the necessity for the HoxA cluster in disease
maintenance, AFlox-MA9 leukemias were treated ex vivo with Cre-recombinase
(MSCV-Cre-GFP) or vector control (MSCV-GFP), sorted based on GFP expres-
sion and used for gDNA-PCR, gene expression (Illumina NextSeq) and trans-
plantation into sub-lethally irradiated recipient mice (500 cGy).
Results: Generation of MLL-AF9 leukemias in the MAFF background (MAFF-
MA9) resulted in deletion of one HoxA cluster allele (HoxA+/-), validated by
genomic PCR and gDNA sequencing from expanded single colonies, presum-
ably due to viral-induced activation of the Mx1 promoter. Poly(I:C) treatment of
these mice resulted in a modest extension in survival (1-2 days) compared to
controls. Direct treatment of MAFF-MA9 cells with interferon-α (in vitro) resulted
in further deletion of the HoxA cluster (HoxA-/hypo) and significant reduction in
colony formation compared to controls. Although non-leukemic MAFF HSPCs
retained colony forming ability after complete HoxA cluster deletion (HoxA-/-)
no HoxA-/- colonies were recovered from the interferon-α treated MAFF-MA9
cultures. Cre-recombinase-induced deletion of the HoxA cluster from AFlox-
MA9 leukemia cells was confirmed by gDNA-PCR and sequencing. Transplan-
tation of Cre-treated AFlox-MA9 cells resulted in significant increased survival
(P<0.002) by up to 74 days in recipient mice, compared to controls. Further
examination of the leukemias that developed from these Cre-treated AFlox-
MA9 cells demonstrated retention of one allele of the HoxA cluster, as a result
of escapees. To gain insight into the molecular mechanisms underlying the
HoxA requirement for MLL-AF9 maintenance, matched Cre- or control treated
AFlox-MA9 samples used for the transplantation were further examined for dif-
ferential gene expression by Illumina NextSeq analysis. Gene expression sig-
natures obtained from this analysis were submitted to the LINCS database to
identify candidate small molecules that can mimic the HoxA deletion in MLL-
AF9 leukemia.
Summary/Conclusions: Together these data support a fundamental role for
the HoxA cluster in MLL-AF9 maintenance indicating dependency for this
leukemia subtype which may be exploited for therapeutic benefit. 
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TRIB2 TRANSFORMED GMP AS THE MYELOID LEUKEMIA INITIATING
CELL
K Yalla*, C O’Connor, J Campos, K Keeshan
Paul O’Gorman Leukemia Research Centre; Institute of Cancer Sciences, Uni-
versity of Glasgow, Glasgow, United Kingdom
Background: TRIB2 is a member of the mammalian Tribbles family of
serine/threonine pseudokinases. When ectopically expressed in hematopoietic
stem and progenitor cell (HSPC) enriched bone marrow cells, TRIB2 was
shown to induce acute myeloid leukemia (AML) in a murine transplant model
dependent on C/EBPα degradation, showing it to be a potent myeloid onco-
gene. The cell of origin or leukemia initiating cell (LIC) refers to the cell from
which a specific leukemia normally arises, and it is hypothesised that the LIC
may influence the progression, disease phenotype and response to therapy. It
remains unclear whether the LIC is a HSC or a more committed progenitor cell
in TRIB2-driven AML. 
Aims: Our current study focuses on identifying the LIC in TRIB2-driven AML
and characterizing its role in disease potency and maintenance. 
Methods: FACS sorted CD45.2+ stem and progenitor cell populations (HSC,
MPP, CMP, GMP and MEP) transduced with a lentiviral vector encoding TRIB2
were cultured in methocult supplemented with cytokines that support myeloid
cell growth and differentiation. Following the first plating (P1), GFP+ cells were
sorted and serially replated. Cells which still formed colonies by the third
replating (P3) implied acquisition of self-renewal ability and increased prolif-
eration characteristic of myeloid transformation. These CD45.2+ cells from P3
were transplanted into sublethally irradiated CD45.1+ C57BL/6 recipient mice
and chimeric animals were monitored for 1 year. Chemoresistance experi-
ments were performed on the bulk bone marrow population (CD45.2+ cells
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>95%) from the TRIB2 AML mice. Cells were treated with a range of concen-
trations of daunorubicin (DNR), followed by trypan blue cell counts to assess
viability.
Results: Our study identified that while lentivirally transduced TRIB2 can trans-
form all stem and progenitor cell populations of the hematopoietic system with
variable efficiencies in vitro, the GMP subpopulation was identified as the LIC
of TRIB2-driven AML. TRIB2 transformed GMP cells generated a more potent
AML with complete penetrance and shortened latency compared to all other
HSPC populations analysed. Indeed, phenotypically different diseases were
propagated from TRIB2 expression in the HSC and GMP, with the former having
a weakly penetrant, longer latency AML with a mixed lineage phenotype, where-
as the later was a dominantly myeloid disease phenotype with a short latency.
We next addressed the chemotherapeutic response of TRIB2 positive AML
cells. We show that GMP-TRIB2 AML and bulk TRIB2 AML cells are chemore-
sistant. TRIB2 overexpression decreases DNR induced apoptosis, and knock-
down of TRIB2 expression in AML cells leads to an increase in apoptotic gene
expression. Our studies illustrate that TRIB2 expression is key in mediating
the anti-apoptotic signals following DNR treatment.
Summary/Conclusions: We identify the GMP as the LIC in TRIB2 driven AML.
Our findings are further supported by our previous work showing that degrada-
tion of C/EBPa is required for TRIB2-driven AML and the GMP population
expresses the highest level of C/EBPa in hematopoiesis. We provide evidence
for TRIB2 role in chemoresistance, and that the TRIB2 LIC is a highly chemore-
sistant cell. Our findings provide insight into the molecular events contributing
to AML, and provide potential for novel avenues for therapeutic targeting.
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TRIB2 REGULATES THE CELL CYCLE UNDER STRESS CONDITIONS IN
A MURINE CELL MODEL OF LEUKEMIA
M Salomè*, K Keeshan
Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences,
MVLS, University of Glasgow, Glasgow, United Kingdom
Background: TRIB2 is a known oncogene in different leukemias (AML, T-ALL)
and can interact with different signalling pathways promoting the modulation of
transcription factor and kinase proteins activation and expression in cancer.
The expression level of TRIB2 is low in the myeloid lineage, but can be aber-
rantly increased in AML and other cancer types by different transcription factors
(e.g. NOTCH1, MEIS1, E2F1, C/EBPα p30, PITX1 and TAL1). The tumorigenic
mechanism of deregulated TRIB2 in myeloid cells has been elucidated, and
involves degradation of the tumor suppressor C/EBPα p42. Far less is known
about TRIB2 role in other AML oncogenic pathways. A link between TRIB2 and
other key AML oncogenes has been documented, where TRIB2 is one of the
targets of Meis1 in NUP98/HOXD13/MEIS1-AML cells and HOXA9 has been
shown to cooperate with TRIB2 to accelerate Trib2 driven AML. The mechanism
of TRIB2 oncogenic cooperativity in AML is currently not known. 
Aims: To assess the role of TRIB2 in the AML oncogenic pathways. In particular,
we aimed to unravel the link between Trib2 and cell cycle progression after
genotoxic stress. 
Methods: To study the function of TRIB2, we utilised hematopoietic stem and
progenitor cells (HSPCs) from WT and Trib2-/- mice. We generated an in vitro
model of transformed leukemic cells by retrovirally expressing the fusion gene
NUP98/HOXA9 (NH9) in murine HSPC and expanding them continuously in
presence of IL3. Immortalized WT and Trib2-/- NH9 cell lines were challenged
with the chemotherapeutic drug Daunorubicin (DNR) and apoptosis, cell cycle
progression and DNA damage signalling pathways were analysed and com-
pared between WT and Trib2-/- transformed cells using standard FACS, WB
and qPCR techniques.
Results: Sensitivity to DNR is comparable between WT and Trib2-/- NH9 cells,
as shown by AnnexinV-DNA double staining. Despite this, analysis of cell dis-
tribution within the cell cycle phases (GO, G1, S-G2-M) in the presence of DNR
showed that Trib2-/- NH9 cells do not arrest in GO in response to the treatment
as WT NH9 cells do, but rather continue to progress through to G2/M cell cycle
phases. Moreover Trib2-/- NH9 cells exhibit higher expression of the mitotic
marker Phospho-Histone H3 after the DNR treatment. Gene expression analy-
sis revealed that Trib2-/- NH9 cells treated with DNR show evidence of DNA
damage signalling pathways activation (with upregulation of p21, p16 and
GADD45a). This response was higher than in the WT counterpart, suggesting
a stronger or unresolved damage signalling in the Trib2-/- NH9 cells. MAPK p38
has a role in the activation of cell cycle check points after DNA damage, and is
involved in cell cycle arrest to allow cells to repair the DNA before re-entering
the cell cycle. WB analysis suggests that Trib2-/- NH9 cells have impaired phos-
phorylation of p38 in response to DNA insult consistent with the absence of a
cell cycle arrest. Consistent with the absence of cell cycle checkpoint, p21 pro-
tein levels are also reduced in Trib2-/- NH9 cells compared to the WT cells after
DNR treatment. Evidence for γH2Ax modification in Trib2-/- NH9 cells confirms
that the damage was present and accumulated unresolved. 
Summary/Conclusions: Our results show that Trib2 plays a role in the cell
cycle checkpoint in transformed cells following DNA damage. The absence of
Trib2 results in the loss of checkpoint controls including p38 MAPK and p21
activation and downstream activation of protective cell cycle mechanisms.
These data suggest that the expression of Trib2 in AML may protect cells from
genotoxic stress by preventing the accumulation of DNA damaged cells.
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CHROMOTHRIPSIS: A NEW MECHANISM OF CANCER INITIATION AND
PROGRESSION IN ADULT ACUTE MYELOID LEUKEMIA
MC Fontana1,*, G Marconi1, JD Milosevic Feenstra2, L Semerad3,
V Guadagnuolo1, C Papayannidis1, G Simonetti1, A Padella1, A Ferrari1,
E Franchini1, S Soverini1, S Paolini1, S Parisi1, MC Abbenante1, C Sartor1,
M Manfrini1, F Volpato1, M Doubek3, M Steurer4, Z Racil3, R Kralovics2,
G Martinelli1
1DIMES, Institute of Hematology, University of Bologna, Bologna, Italy, 2CeMM
Research Center for Molecular Medicine of the Austrian Academy of Sciences,
Vienna, Austria, 3Department of Internal Medicine - Hematology and Oncology,
Masaryk University and University Hospital Brno, Brno, Czech Republic, 4Divi-
sion of Hematology and Oncology, Medical University of Innsbruck, Innsbruck,
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Background: Chromosomal abnormalities are predictive of response in Acute
Myeloid Leukemia (AML) and guide therapeutic strategies. Chromothripsis, a
one-step catastrophic mechanism of genomic instability, could represent a driv-
ing force in the development and progression of hematological diseases.
Aims: To discover the mechanisms underlying the pathogenesis, chromosomal
instability and heterogeneity of AML, we used single-nucleotide polymorphism
(SNP) microarrays to study chromothripsis in our cohort of patients (pts).
Methods: We performed classical cytogenetic karyotyping and microarray analy-
sis using Genome-Wide Human SNP Arrays 6.0 or Cytoscan HD Arrays
(Affymetrix) in 303 AML pts at diagnosis (both de novo and secondary). SNP Array
data were analyzed by Nexus Copy Number™ v7.5 (BioDiscovery, v.7.5). The
survival analysis was performed with Kaplan-Meier method using Mantel-Cox test.
Figure 1.
Results: Twenty-three out of 303 pts (7.6%) showed chromothripsis events
involving different chromosomes (2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 15, 16, 17
and 20), reflecting the random distribution of the one-step catastrophic event.
By Nexus Copy Number we defined chromothripsis as a 2-3 variation of copy
number (CN) state with at least 5 subsequent rearrangements, including CN
gain and loss, interspersed with regions of diploid state and variable number of
breakpoints. The pts affected by chromotripsis had a median age of 67.5 years,
complex karyotype and high risk (HR) disease according to ELN definition. This
group was screened for FLT3, NPM1, IDH1, IDH2 and TP53 mutational status.
TP53 was evaluated in 21/23 pts, displaying that the majority (17/21) of the pts
with chromothripsis harbored a TP53 mutation, while 4/21 pts were wild type for
TP53 but 2 of those had a single-copy loss of the gene. TP53 mutation has a
significantly higher incidence in chromothripsis pts than in others without chro-
mothripsis (p<0.001). Chromothripsis defines a group of pts with poor prognosis
compared with other in the cohort (p<0.001), with a median survival of 2.9
months and 19.1 months respectively. Remarkably, chromothripsis defines the
group with the worst prognosis even if compared with pts harboring HR[JM1]
karyotype features without chromothripsis (p<0.001) (Fig.1). Median survival
was 2.9 months in pts with chromothripsis, 17.3 months in HR pts without chro-
mothripsis, and 26.0 months for pts with standard risk features. Moreover, by
comparing pts with (23/303) and without (280/303) chromothripsis, we identified
several genes differentially altered between the 2 groups (p<0.001). The statis-
tically most common deleted genes in chromothripsis are RAD50, MARCH3,
PRDM6, SSBP2, CDC23, HDAC3, CHD1, TBCA, LMNB1, JMY, with 5q being
the main altered chromosomic region. While the significant amplifications includ-
ed ZDPM2, RUNX2, RUNX1T1, FLT3, ERG, TTC3 and GPC6. The most signif-
icantly affected pathways in the chromothripsis group of pts are: regulation and
extension of axon, canonical Wnt signaling pathway involved in regulation of
cell proliferation, positive regulation of mitotic cell cycle, chromatin organization,
telomere formation and maintenance (p<0.001).
Summary/Conclusions: Chromothripsis is a recurrent event in adult AML and
independently defines a group of pts with poor prognosis. It is strongly associ-
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ated with TP53 mutations and losses, highlighting the importance of TP53 for
maintaining genomic stability in adult AML.
Acknowledgements: ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-
12 (L. Bolondi), FP7 NGS-PTL project.
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AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN
PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKAEMIA
(THE UK NCRI AML17 STUDY)
S Knapper1,*, A Grech1, P Cahalin2, H Kaur3, P Mehta4, D Richardson5,
D Taussig6, R Hills1, A Burnett7, N Russell8
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Background: Pacritinib (formerly SB1518) is a third generation tyrosine kinase
inhibitor with activity against a number of targets of relevance to acute myeloid
leukaemia (AML). Kinases with IC50 <50nM to pacritinib include JAK2 (6nM),
JAK2V617F (9nM), FLT3 (15nM), interleukin-1 receptor-associated kinase (IRAK1)
(14nM) and c-FMS / colony-stimulating factor-1 (CSF1R) (40nM). FLT3 remains of
intense interest as a therapeutic target in AML; activating mutations of FLT3 are
associated with early relapse after chemotherapy and poor survival. Efficacy against
JAK2 has motivated study of pacritinib in myelofibrosis. Although JAK2 mutations
are rare in AML, the JAK-STAT pathway is frequently activated and may represent
a mechanism of resistance to FLT3 inhibitors. There is also pre-clinical evidence
that activity against IRAK1 and CSF1R may overcome microenvironmental resist-
ance mechanisms. For these reasons we undertook a preliminary assessment of
pacritinib as part of the UK NCRI AML17 Trial (ISRCTN55675535).
Aims: To assess the safety and efficacy of pacritinib monotherapy in FLT3-
mutated AML patients who had relapsed following chemotherapy.
Methods: Patients commenced pacritinib at an oral dose of 200mg bid with
the option, if well-tolerated, of increasing to 300mg bid after 14 days of treat-
ment. Clinical assessments included optional bone marrow at day 14 and for-
mal response assessment including blood and bone marrow examination at
day 28. Toxicity was assessed using NCI-CTC Version 3.0. Treatment beyond
day 28 was at the investigator’s discretion. Patients were permitted to continue
on pacritinib for up to 12 months and/or proceed to salvage chemotherapy with
or without allogeneic SCT.
Results: A total of 30 patients received pacritinib therapy. Median age was 54
years (16-68), median presenting WBC was 35.6x109/l (1.2-182) and all had cyto-
genetically intermediate risk disease. 26 patients (87%) had FLT3-ITD mutations
(median FLT3-ITD allelic burden 30% [7-94]) and 4(13%) had FLT3-TKD point
mutations; 16 patients (53%) had concomitant mutated NPM1. Four patients had
received previous TKI therapy, all with lestaurtinib (CEP701) alongside first-line
chemotherapy. Eight patients had received prior allogeneic SCT. 28 of the patients
had relapsed disease; median duration of first CR was 6.5 months (1-65). 23
patients were in first relapse (including 1 molecular relapse) and 5 in second
relapse. Two patients had primary refractory disease. Patients received a median
of 64 days pacritinib (3-200); all were dosed at 200mg bid with 1 patient escalating
to 300mg bid. Most toxicities were minor (grade1/2). The most common toxicities
were nausea/vomiting (53%), diarrhoea (33%) and raised ALT (30%). One patient
stopped pacritinib after 3 days due to nausea (grade 2). 6 further patients were
considered non-evaluable either due to early death (2 patients; infections), inad-
equate response evaluation sampling (2 patients) or the addition of salvage
chemotherapy within the 28-day evaluation period (2 patients). In evaluable
patients, the overall rate of response to pacritinib monotherapy at the day 28
assessment was 17% (4/23) including 3 CRi (2 CRp) and 1 PR; 3 of these patients
were successfully bridged to allogeneic SCT with the fourth patient relapsing at
day 60. 3 additional patients (13%) achieved >50% reduction in bone marrow
blasts without evidence of peripheral count recovery, 2 going on to receive salvage
chemotherapy with FLAG-Ida. 16 patients (70%) were considered non-respon-
ders. The 7 clinical responders included 6 patients treated in first relapse and 1
with primary refractory disease; all had FLT3-ITD mutations.
Summary/Conclusions: This is the first clinical experience of pacritinib in
AML. Tolerability was encouraging and, in the challenging setting of relapsed/
primary refractory FLT3-mutated AML where FLT3-directed monotherapy has
seldom achieved complete remission, clinical responses were seen in one-
third of evaluable patients. Importantly, several patients were successfully
bridged to potentially-curative allogeneic SCT. Further clinical evaluation of
pacritinib in this setting is warranted.
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ORAL THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG TREATMENT
DURING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOGENOUS
LEUKEMIA (AML): RESULTS OF A RANDOMIZED, DOUBLE-BLIND,
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Background: Thrombocytopenia is a significant problem for patients with AML
due to the disease process and the side effects of its treatment. Eltrombopag
is an orally bioavailable, small molecule, thrombopoietin receptor agonist that
stimulates platelet production by a mechanism similar but not identical to
endogenous thrombopoietin. A randomized, placebo-controlled, Phase 1 study
suggested a benefit of eltrombopag treatment of up to 300 mg daily in patients
with advanced myelodysplastic syndromes or AML (Platzbecker U, et al. Lancet
Haematol. 2015;2:e417-26).
Aims: To assess the safety and tolerability of daily treatment with eltrombopag
versus placebo in patients with AML receiving anthracycline-based induction
treatment; these included rates of adverse events (AEs), changes in left ven-
tricular ejection fraction (LVEF), and clinical laboratory parameters including
effects on cytopenias.
Methods: In this randomized, double-blind, Phase 2 study, adult patients with
AML of any subtype (except M3 and M7) (n=148), and who had not received
previous treatment for AML, received standard induction chemotherapy with
daunorubicin on Days 1-3 and cytarabine on Days 1-7 (Table 1), and eltrom-
bopag 200mg (100mg for East Asians) or placebo daily, starting on Day 4.
Study drug could be titrated to 100-300mg based on platelet counts. Random-
ization was stratified by antecedent malignant hematologic disorder (yes/no)
and age (18-60 vs >60 years). Safety was the primary endpoint. The trial began
in September 2013, enrollment is completed, and all patients completed induc-
tion/reinduction. Follow up for survival continues. This primary analysis repre-
sents results through June 2015.
Table 1. Primary safety and efficacy results of a randomized, placebo-
controlled, Phase 2 study of the thrombopoietin receptor agonist eltrom-
bopag in patients with AML receiving anthracyclines-based induction
chemotherapy.
Results: The eltrombopag versus placebo groups, respectively, were well
matched at baseline: overall median (range) age 58.5 (23-77) versus 59.5
(21-75); median (range) platelet counts 51.5 (5-241) Gi/L versus 50.0 (9-232)
Gi/L; 51% versus 42% females; and 22% poor karyotype in both groups. The
frequency of AEs did not differ between treatment groups, but frequencies of
serious AEs and deaths were greater in the eltrombopag group (with more
deaths due to hemorrhage and cancer, which included disease under study
and other malignancies) (Table 1). Deaths due to hemorrhage included pul-
monary and intracranial/cerebral/brain hemorrhages, and occured during peri-
ods of thrombocytopenia. Thromboembolic events were similar between
groups (7% vs 6% for eltrombopag vs placebo). Reductions in LVEF (a poten-
tial effect of drug-drug interaction between eltrombopag and daunorubicin) did
not differ between groups (Table 1). Increases from baseline in Grade 3/4 lab-
oratory AEs for thrombocytopenia, neutropenia, or anemia did not differ sig-
nificantly between treatment groups. Time to platelet recovery, time to platelets
>100 Gi/L, overall disease response, and survival also did not differ signifi-
cantly between groups (Table 1).
Summary/Conclusions: The thrombopoietin receptor agonist eltrombopag
did not significantly affect rates of thrombocytopenia during induction therapy
with daunorubicin and cytarabine or disease response in adults with AML com-
pared with placebo in this primary analysis. No statistically significant difference
in LVEF events between eltrombopag and placebo was observed. Funding:
This study (NCT01890746) was sponsored by GlaxoSmithKline; however, as
of March 2, 2015, eltrombopag became an asset of Novartis AG.
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SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH
CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION
AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED
FLT3+ AML
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Background: Combining tyrosine kinase inhibitors (TKIs) of FLT3, such as
midostaurin, with chemotherapy in FLT3+ mutant AML has improved CR rates
(59% vs 53%) as well as overall survival (OS). Crenolanib is a novel, type I,
oral pan-FLT3 TKI demonstrating encouraging single-agent activity against
multiply relapsed FLT3-ITD and tyrosine kinase domain (TKD) mutant AML.
We here report interim data from a Phase II trial to evaluate the safety and effi-
cacy of crenolanib in combination with upfront chemotherapy (cytarabine plus
idarubicin or daunorubicin) in patients (pts) with newly diagnosed FLT3+ AML.
Aims: To assess the safety and tolerability of crenolanib (100 mg TID) with
induction and consolidation chemotherapy in newly diagnosed FLT3+ AML.
Secondary objectives are to assess CR rate and relapse-free survival following
crenolanib and chemotherapy. 
Methods: Patients >18 years (y), with newly diagnosed FLT3+ AML (ITD and/or
TKD mutants including secondary AML) are eligible. Crenolanib, 100 mg TID, is
given daily from day (d) 9 following 7+3 induction (cytarabine 100 mg/m2/d and
either daunorubicin d1-3 (<60y: 90 mg/m2; ≥60y: 60 mg/m2) or idarubicin 12
mg/m2 d1-3). Re-induction is permitted for inadequate leukemia cytoreduction
on days 15-28. Consolidation with 6 doses of high dose cytarabine (HiDAC)
(<60y: 3 g/m2; ≥60y: 1g/m2) is given with daily crenolanib (100 mg TID) starting
d7. Eligible pts can proceed to allogeneic SCT. Crenolanib maintenance can be
given for 1y post HiDAC or SCT. Crenolanib is held if total bilirubin is abnormal.
Results: 19 pts with newly diagnosed FLT3+ AML have so far been enrolled
(11 females, 8 males) with a median age of 55y (range 23-74y). Median base-
line WBC was 27,740/μL (range 1,760-248,800; 4 pts had WBC >100,000/μL).
13/17 (76%) of pts had normal karyotype, 2 pts had trisomy 8, 1 pt was pseu-
dodiploid and 1 pt had complex karyotype. Majority of pts, 79% (15/19), were
FLT3-ITD+ve with 10/15 also carrying NPM1 mutation. 4/19 (28%) pts were
FLT3-D835+ve with 1 pt also carrying NPM1 mutation and 1 pt carrying
D835Y and N841T mutations. 11/19 pts were tested for other mutations pres-
ent at baseline: DNMT3A in 6/11 pts (55%), SF3B1, IDH1, TET2 and RUNX1
each in 2/11 pts (18%), and IDH2, MLL, SRSF2 and WT1 each in 1/11 pts
(9%). All 19 pts have received induction chemotherapy: 13 received daunoru-
bicin (8 pts at 90 mg/m2, 5 pts at 60 mg/m2) and 6 received idarubicin (12
mg/m2) No pt has required a second induction. 2 pts died prior to starting
crenolanib during induction 1 (due to sepsis and respiratory failure) and are
not evaluable. Crenolanib 100 mg TID has been well-tolerated in combination
with cytarabine/anthracycline induction with only 2 pts requiring dose reduc-
tions (due to rash and periorbital edema, respectively). Common AEs are
consistent with what is seen with crenolanib monotherapy, including grade 1
or 2 nausea, vomiting, diarrhea and rash. Crenolanib did not appear to delay
count recovery; median count recovery for WBC was 28d (range 16-43d) and
platelet was 27d (22-46d). A high CR rate was seen in the 14 pts who are
currently evaluable: 13/14 pts (93%) achieved CR with full count recovery,
and all pts became FLT3-ve. Only 1 pt was refractory after first cycle of induc-
tion therapy and was taken off study. To date, 9 pts have received a total of
13 cycles of consolidation with HiDAC and crenolanib. 2 pts have undergone
allogeneic SCT.
Summary/Conclusions: Crenolanib can be safely administered at full doses
with cytarabine/anthracycline induction chemotherapy and HiDAC consolida-
tion. Initial CR rates after just one cycle of induction with 7+3 and crenolanib
are high. To date, no patients have relapsed. Accrual to this trial continues.
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PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING
WITH DECITABINE IN OLDER PATIENTS WITH AML
T Kadia*, J Cortes, G Borthakur, E Jabbour, N Daver, N Pemmaraju, S Verstovsek,
J Burger, A Ferrajoli, W Wierda, M Konopleva, C DiNardo, N Jain, M Brandt,
C Tuttle, X Wang, F Ravandi, G Garcia-Manero, H Kantarjian
Leukemia, MD Anderson Cancer Center, Houston, United States
Background: Treatment of AML in older and unfit patients (pts) with intensive
chemotherapy is complicated by increased toxicity and high early mortality.
Additionally, many of these pts are not ideal candidates for stem cell transplant
(SCT). Lower intensity approaches using hypomethylating agents (HMAs) are
currently used for these pts, but more effective therapies are needed. Cladrib-
ine, which itself has hypomethylating properties, has been shown to improve
survival in AML in combination with standard-dose araC (Holowiecki JCO
2012).
Aims: We developed a low-intensity, prolonged-maintenance treatment proto-
col studying the combination of cladribine and low-dose araC (LDAC) alternat-
ing with decitabine (DAC) in patients aged ≥60. 
Methods: Pts with adequate organ function and newly diagnosed AML (exclud-
ing APL), including secondary- (s-AML) and therapy-related AML (t-AML), and
high risk MDS were eligible. Induction was cladribine 5 mg/m2 IV over 30 min-
utes on days 1-5 followed by araC 20mg SQ BID on days 1-10. Consolidation/
maintenance consisted of 2 cycles of cladribine 5 mg/m2 IV over 30 minutes
on days 1-3 + araC 20 mg SQ BID on days 1-10 alternating with 2 cycles of
DAC 20 mg/m2 on days 1-5, for a maximum of 18 cycles. One cycle was 4
weeks and up to 2 cycles of induction were allowed.
Results: A total of 86 pts have been enrolled with a median age of 69 years
(range, 49-85), including 37 pts (43%) ≥age 70. 49 pts (57%) had s-AML or t-
AML and 16 pts (19%) had therapy for an antecedent hematologic disorder. Pt
characteristics are listed in Table 1. Of the 86 pts evaluable for response, there
were 52 CR (60%), 5 CRp (6%), 2 CRi (2%) and 1 PR (1%) for an overall
response rate (CR/CRp/CRi) of 69% (59/86). Of the 49 pts who achieved a
CR/CRp and had minimal residual disease (MRD) testing by flow cytometry at
day 29, 24 pts (49%), achieved MRD negativity. However, MRD negativity at
day 29 did not correlate with improved OS. 13 of the 57 pts (23%) who achieved
a CR/CRp went on to SCT. With a median follow-up of 24+ months (m), the
median OS is 13.8 m (16.5m in responders) and the median CR duration is
21.1m. (Figure 1a) The 1-year OS estimate is 57%. All pts had cytogenetic
and molecular characterization of their AML prior to treatment, allowing corre-
lation with outcomes (Figure 1b). Responses and median OS among different
subgroups are shown in Table 1. The 4-week mortality was 1%. Grade ≥3 infec-
tions occurred in 16% of pts. There were no treatment-related grade 3/4 non-
heme adverse events (AEs). Most common non-hematologic AEs were ele-
vated bilirubin, nausea/vomiting, rash/itching, diarrhea and mucositis.
Table 1. Patient Characteristics (N=74).
Figure 1.
Summary/Conclusions: The low intensity program of cladribine + LDAC alter-
nating with DAC produces durable responses and is a well-tolerated ambulatory
regimen for older patients, including those with unfavorable-risk features.
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Background: FLT3 inhibitors show substantial clinical activity in
relapsed/refractory FLT3-ITD mutated acute myeloid leukemia (AML). A subset
of patients show a clinical response manifest by terminal differentiation of bone
marrow blasts into granulocytes that contain FLT3-ITD. From clinical trials of
the FLT3 inhibitor quizartinib (AC220), we observed this differentiation response
predominantly among patients with a normal karyotype and mutated NPM1
and/or DNMT3A (Nybakken, et al. Leukemia 2015).
Aims: To confirm whether observations from quizartinib trials reflect a common
response pattern to FLT3 inhibitor treatment.
Methods: We performed analysis of the local institutional cohort of patients
enrolled on a phase 1/2 study of gilteritinib (ASP2215) for relapsed/refractory
AML (NCT02014558). All subjects were screened for 33 AML-associated muta-
tions at study entry by next generation sequencing and all available histomor-
phologic, and cytogenetic material underwent an independent pathologist’s
blinded review.
Results: We restricted our analysis to the 25 FLT3-mutated subjects who
received single-agent gilteritinib at ≥80 mg/day, as correlative pharmacody-
namic data showed that this dose consistently generated continuous, potent
FLT3 target inhibition (Levis MJ, et al. ASCO abstracts 2015). 2 subjects were
withdrawn prior to the first treatment response assessment (refractory leukemia
and lethal infection); 2 subjects had technically insufficient marrows. The
remaining 21 subjects were evaluable for marrow response. Subjects had a
median age of 61 years (range 22-86 years) and were relapsed or refractory
after a median of 2 prior lines of chemotherapy (range 1-7). Subjects received
gilteritinib at a median dose of 200 mg (range 80-300) for a median of 154
days (range 38-642). Baseline karyotype was normal in 9/20 (45%). 19/21
patients had FLT3-ITD mutation (3 had both FLT3-ITD and FLT3-TKD), and 2
had FLT3-TKD only. Gene mutations seen in >10% of subjects included NPM1
(13, 62%), DNMT3A (11, 52%), WT1 (8, 38%), TET2 (7, 33%), and IDH1/2 (4,
19%). All subjects treated for >28 days showed complete or near-total eradi-
cation of peripheral blood blasts. Thirteen subjects (62%) experienced a differ-
entiation response defined by markedly left-shifted clonal granulocytic hyper-
plasia with persistent FLT3-ITD:WT allelic ratio, ≥50% reduction in overall blast
percentage from baseline, and peripheral blood neutrophil recovery. 11/13
(85%) subjects with differentiation response had mutated NPM1, but only 6/12
(50%) had a normal karyotype. While 2/3 NPM1 mutated subjects with WT
DNMT3A did experience differentiation response, 10/11 subjects with DNMT3A
mutation also had NPM1 mutations, confounding our ability to associate differ-
entiation response and DNMT3A mutation status alone. 3/21 subjects demon-
strated both undetectable leukemic blasts from the marrow along with marked
allelic ratio reduction or elimination of detectable FLT3-ITD, suggesting alter-
nate mechanisms of treatment response (e.g. cytotoxicity or clonal selection
without differentiation). Additionally, 5/21 evaluable subjects showed minimal
to no reduction in marrow blasts. Considering the 8 non-differentiation respons-
es plus the sole patient with growing AML prior to day 28, only 2/9 (22%) had
an NPM1 mutation, and 5/8 had abnormal karyotype.
Summary/Conclusions: Differentiation response to gilteritinib is strongly
enriched among relapsed/refractory FLT3-mutated patients with NPM1 and
DNMT3A mutations. Our data inform response interpretation and may promote
future trial enrichment strategies.
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PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH 5-AZACYTIDINE
(AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
N Daver1,*, J Cortes1, F Ravandi1, S Basu2, G Garcia-Manero1, E Jabbour1,
N Pemmaraju1, S Hendrickson1, S Pierce1, J Ning3, G Gonzales3, M Konopleva1,
M Andreeff1, G Borthakur1, C Bueso-Ramos4, J Blando2, J Allison2,
H Kantarjian1, P Sharma2
1Department of Leukemia, 2Immunotherapy Platform, 3Department of Biosta-
tistics, 4Department of Hematopathology, University of Texas MD Anderson
Cancer Center, Houston, United States
Background: PD1+ T-cells are significantly increased in the bone marrow
(BM) of pts with relapsed AML as compared to healthy adult donor BM (Daver
et al., AACR 2016). Epigenetic therapy upregulates PD1 and PD-L1 in
MDS/AML and upregulation of these genes may be associated with the emer-
gence of resistance and inferior survival (Yang et al., Leukemia 2013).
Aims: This single-center phase Ib/II study was conducted to determine the
recommended phase 2 dose (RP2D), efficacy and safety of nivolumab in com-
bination with AZA in pts with relapsed AML.
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Methods: Pts are eligible if they have AML and failed prior therapy, have ade-
quate performance status (ECOG ≤2), and organ function. The first six pts
received AZA 75mg/m2 days 1-7 with nivolumab 3mg/kg on Day 1 and 14.
Courses were repeated approximately every 4-5 weeks. One of six pts had a
dose limiting toxicity (grade 3 pneumonitis) and this dose was established as
the RP2D. 24 additional pts have been treated at the RP2D.
Results: To date, 30 pts (15 de novo, 15 secondary AML) with a median age
of 72 years (range, 45-76) have been enrolled. They included 9 (30%) pts with
diploid, 14 (47%) with adverse, and 7 (23%) with miscellaneous cytogenetics.
Median number of prior therapies was 2 (range, 1-4), including hypomethylating
agent-based (n=17), high dose cytarabine-based (n=15), intermediate dose
cytarabine-based (n=7), and targeted therapies (n=5). Median bone marrow
blast%, WBC, hemoglobin, and platelet counts were 43% (13-90), 2.3x109/L
(0.5-81), 9.3g/dL (7.4-12.7), and 28x109/L (8-145), respectively. Baseline bone
marrow samples from all pts were analyzed for common myeloid mutations by
next generation sequencing. The most frequently detected mutations were
DNMT3A (n=9), ASXL1 (n=6), CEBPA (n=4), RAS (n=4), TP53 (n=3), and TET2
(n=4). 22 pts are evaluable for response (Fig 1): 4 (18%) achieved complete
remission (CR)/ complete remission with insufficient count recovery (CRi), 2
(9%) had hematologic improvement (HI) with blast reduction, 5 (23%) had HI
only, and 5 (23%) had ≥50% BM blast reduction only. 6 pts had stable disease
(n=2) or progression (n=4). 8 pts are too early for response assessment at this
time. Median number of cycles to any response was 2 (1-4). The median fol-
low-up is 3.6 months (1.5-8.7). Grade 3/4 and Grade 2 immune toxicities were
observed in 6 (20%) and 5 (17%) pts, respectively. These included 6 pneu-
monitis, 2 nephritis, 1 skin rash, and 2 transaminitis. Time to onset of toxicities
ranged from 4 days to 3.5 months. All toxicities responded rapidly to steroids
and all pts were successfully rechallenged with nivolumab. No pts came off
study due to immune toxicities. No association between toxicities and response
was identifiable. The median progression free and overall survival for 22 evalu-
able pts was 3.5 and 5.9 months, respectively. These results compare favorably
to a historical cohort of 99 relapsed AML pts treated on other hypomethylating
agent combination protocols at our institution between 2005-2015 (Table 1).
Identification of baseline and dynamic biomarkers of response and survival by
sequential immunohistochemistry, flow-cytometry, and RNA-sequencing is cur-
rently ongoing.
Table 1. AZA+nivolumab versus historical HMA-combinations at MDACC
Figure 1. Response in 22 evaluable patients.
Summary/Conclusions: Combination of AZA and nivolumab is effective in pts
with relapsed AML. Immune mediated toxicities occur and may be adequately
managed with early recognition and systemic steroids.
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CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS
CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION
INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A
PHASE IIA STUDY
G Borthakur1,*, MS Tallman2, Y Ofran3, J Foran4, GL Uy5, JF DiPersio5,
A Nagler6, JM Rowe7, MM Showel8, JK Altman9, A Peled10, M Abraham10,
Y Pereg11, A Vainstein11, G Oberkovitz11, A Aharon11, C Bueso-Ramos1,
JE Cortes1, M Andreeff1
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Sloan Kettering Cancer Center, New York, United States, 3Rambam Health
Care Campus, Haifa, Israel, 4Mayo Clinic, Jacksonville, 5Washington University
Medical School, St. Louis, United States, 6Chaim Sheba Medical Center, Tel
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Sidney Kimmel Comprehensive Cancer Center, Baltimore, 9Robert H Lurie
Medical Research Center, Chicago, United States, 10Biokine Therapeutics,
Rehovot, 11BioLineRx Ltd., Modi’in, Israel
Background: The bone marrow (BM) niche protects acute myeloid leukemia
(AML) cells from chemotherapy. BM retention of AML cells is dependent on
CXCR4 and its ligand CXCL12 (SDF-1); high CXCR4 expression correlates
with poor survival in AML patients. Blocking CXCR4 disrupts the interaction of
AML blasts with the BM and augments the anti-leukemic effect of chemotherapy.
BL-8040 (BKT140) is a high affinity CXCR4 inhibitor with long receptor occu-
pancy. Recent clinical trials have demonstrated BL-8040’s robust hematopoietic
cell mobilization from the BM. BL-8040’s anti leukemic effect is mediated
through robust leukemic blast mobilization, induction of leukemia cell differen-
tiation and apoptosis. Here we report results of a phase 2a study evaluating
BL-8040 in combination with cytarabine (Ara-C) for the treatment of
relapsed/refractory AML patients (NCT01838395). 
Aims: To assess the safety, efficacy and PK/PD parameters of BL-8040 in
combination with Ara-C in relapsed/refractory AML patients.
Methods: The study included a dose escalation phase (3+3 design) followed
by an expansion phase. Each patient received a once daily SC dose of BL-
8040 as monotherapy on days 1-2 followed by the same dose of BL-8040 plus
Ara-C (1.5g/m2 for patients ≥60; 3g/m2 for patients <60) on days 3-7. Six BL-
8040 doses (0.5-2.0mg/kg) were tested in the escalation phase with 1.5 mg/kg
selected for the expansion phase. PD parameters such as extent of mobiliza-
tion, induction of differentiation and apoptosis, CXCR4 expression and receptor
occupancy were assessed by BM biopsy on day 3 and throughout the study.
Remission was determined by BM biopsy on day 30.
Results: Forty five patients (median age, 61y; range, 23-75y) were treated
with BL-8040 (including 3 patients treated on compassionate use basis). BL-
8040 was escalated up to 2.0 mg/kg without reaching the MTD. Combination
with Ara-C was safe and well tolerated at all doses. Three SAE’s (Sweet’s Syn-
drome, PCP pneumonia and allergic type reaction) were reported by the inves-
tigators as possibly related to BL-8040. Primary BL-8040 related AEs were
transient, mild to severe injection site and systemic reactions, none of which
were considered as DLT. The available composite complete remission
(CR+CRi) rate is 38% in patients receiving BL-8040 doses of 1 mg/kg and high-
er (n=39). While baseline BM disease burden was comparable between respon-
ders (R) and non-responders (NR) (38% vs 40% BM blasts, respectively),
responders demonstrated significantly lower levels of circulating blasts at base-
line compared to non-responders (2.9% vs 19.3%, respectively). Furthermore,
response to treatment was associated with higher mobilization of AML blasts
following 2 days of BL-8040 monotherapy (CR=7.0, CRi=4.2, PD=1.1, SD=0.4,
fold change) and with induction of granulocytic differentiation in the BM (R=3.2
vs NR=1.4, fold change). PD analysis further confirmed BL-8040’s long receptor
occupancy and its ability to induce apoptosis.
Summary/Conclusions: The results demonstrate that, in difficult to treat AML
patients, sustained blockade of CXCR4 with BL-8040 combined with Ara-C may
improve the clinical response rates achieved historically with Ara-C. In addition
the data, for the first time, may suggest that better clinical responses are seen
in patients with more efficient CXCR4 inhibition (reflected by higher mobilization
and induction of granulocytic differentiation) and lower peripheral circulating
blasts (despite comparable marrow blasts) at baseline. This finding may serve
as a biomarker for patient selection in future BL-8040 studies in AML.
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RESULTS OF A PHASE I STUDY OF GMI-1271, A NOVEL E-SELECTIN
ANTAGONIST IN COMBINATION WITH INDUCTION CHEMOTHERAPY IN
RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN
WITH A HIGH REMISSION RATE
DJ DeAngelo1,*, ME O’Dwyer2, PS Becker3, JL Liesveld4, DL Bixby5,
JL Magnani6, HM Thackray6, BA Jonas7
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Unit-
ed States, 2Department of Haematology, National University of Ireland, Galway,
Ireland, 3Department of Medicine, Division of Hematology, University of Wash-
ington, Seattle, 4Department of Medicine, Hematology/Oncology, University of
Rochester Medical Center, Rochester, 5Department of Internal Medicine, Divi-
sion of Hematology and Oncology, University of Michigan, Ann Arbor, 6Gly-
coMimetics, Rockville, 7Department of Medicine, Division of Hematology and
Oncology, UC Davis Comprehensive Cancer Center, Sacramento, United
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Background: The treatment of patients with relapsed and refractory acute
myeloid leukemia (AML) remains a significant challenge with poor outcomes
primarily due to low remission rates as well as short remission duration.
Although cytotoxic chemotherapy remains the standard approach for the treat-
ment of patients with relapsed or refractory (R/R) AML, novel agents are urgent-
ly needed to improve clinical outcomes. The regimen consisting of mitoxantrone,
etoposide, and cytarabine (MEC) is commonly used for patients with R/R AML,
with remission rates of 25-30%. Binding of leukemic blasts to E-selectin, an
adhesion molecule expressed constitutively in the bone marrow endothelium,
activates leukemic cell survival pathways, thereby contributing to chemotherapy
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resistance. GMI-1271 is a novel antagonist of E-selectin. Here we report initial
results from a phase 1/2 trial of GMI-1271 with MEC for the treatment of patients
with R/R AML.
Aims: To evaluate the safety, tolerability, pharmacokinetics (PK), and
antileukemic activity of the combination of GMI-1271 plus MEC.
Methods: An open-label phase 1/2 trial enrolled patients with R/R AML receiv-
ing MEC induction chemotherapy. Eligible patients (ECOG 0–2) must have
received ≤2 prior induction regimens, have no active CNS disease and ade-
quate renal and hepatic function. Adjunctive treatment with GMI-1271 at
increasing doses was administered concurrent with chemotherapy (24 hours
prior, throughout, and 48 hours post MEC); MEC consisted of mitoxantrone 10
mg/m2/d, etoposide 100 mg/m2/d, and cytarabine 1000 mg/m2/d IV for 5 days
and supportive care given as per institutional guidelines. Dose limiting toxicity
(DLT) was defined as either persistent neutropenia and/or thrombocytopenia
beyond day 42 in the absence of disease or any grade 3 non-hematologic tox-
icity that did not resolve to Grade 2 by day 42.
Results: Two dose level cohorts have been completed, with 13 subjects treated
(GMI-1271 at 5 mg/kg (N=6) and10 mg/kg (N=7)). The median age was 51
(range 26 –74) and 9 were male (69%). Seven patients (54%) had adverse
cytogenetic risk (SWOG) and 6 patients (46%) had intermediate cytogenetic
risk; none were favorable. Eight patients (62%) had relapsed disease and 5
(38%) were refractory to primary therapy. Two patients had relapsed within a
year of hematopoietic cell transplant (HCT), 2/13 were FLT3-ITD mutated, 1
patient had extramedullary disease (EMD). All subjects tolerated GMI-
1271+MEC well and completed study treatment without dose reduction or inter-
ruption; 30 day mortality was 0%. Mucositis developed in 5 subjects (4 at 5
mg/kg), of whom 2 required IV nutrition (both at 5 mg/kg). No DLTs were
observed. Initial population PK analysis showed 28% lower clearance than
healthy adults and overall similarity in PK profile. Seven of 13 subjects achieved
CR (54%); one achieved CRi (transplanted before CR documented); one
achieved morphologic leukemia-free state (inadequate count recovery); and
four had persistent disease. CR/CRi rate was 8/13 subjects (62%). Of 5 with
data post CR/CRi, 1 proceeded to HCT, one relapsed at 90 days, 3 remain in
CR (4, 4, and 2 months duration). Responders include refractory AML (3),
relapsed FLT3-ITD mutated (1) and EMD (1).
Summary/Conclusions: In early clinical assessment of the novel E-selectin
antagonist GMI-1271, we report in a group of R/R AML patients a CR/CRi rate
of 62%, higher than expected given the high risk cytogenetic features in this
group. No DLTs have been observed. Enrollment in a third cohort is ongoing
and will be reported. A Phase 2 expansion cohort is planned in both R/R AML
as well as elderly de novo AML.
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RESULTS OF A PHASE 1B STUDY OF VENETOCLAX PLUS DECITABINE
OR AZACITIDINE IN UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS
≥65 YEARS INELIGIBLE FOR STANDARD INDUCTION THERAPY
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Background: Venetoclax (VEN) is a potent, orally bioavailable BCL-2 inhibitor
with single-agent activity in relapsed/refractory acute myeloid leukemia (AML)
patients (pts), displaying synergistic activity with hypomethylating agents in
preclinical studies. This trial evaluates VEN plus decitabine (DEC) or azacitidine
(AZA) in treatment (Tx)-naive AML pts ≥65 y (NCT02203773).
Aims: The objectives of the study include safety, preliminary efficacy, and bio-
marker evaluations.
Methods: Tx-naive pts (ECOG PS ≤2, ≥65 y, intermediate- or poor-risk kary-
otype) not eligible for standard induction therapy received DEC (Arm A: 20 mg/m2
iv) daily on days (D) 1-5 or AZA (Arm B: 75mg/m2; subcutaneous or iv) daily on
D 1-7 of each 28-D cycle in combination with once-daily continuous oral VEN.
VEN dose escalation follows a 3+3 design; 1200 mg is the final dose level.
Results: As of 11/28/15, 39 pts (49% male; median age 74 y [65-85 y]) have
been enrolled in Arm A (n=20) and Arm B (n=19). Median time on study is 111
D (6-375 D); 16 pts (41%) remain on therapy. Biomarker analysis and response
evaluations have been completed in 34 pts with 400-mg and 800-mg VEN dos-
es. As of 9/19/15, overall response rate (ORR; complete response [CR]/CR
with incomplete marrow recovery [CRi]/partial remission [PR]) within this pop-
ulation was 76% (CR: 13/CRi: 11/PR: 2; 26/34 pts). Poor-risk cytogenetics and
IDH1/2 mutations were reported in 24% (8/34) and 32% (11/34) of pts; ORR
was 88% (7/8) and 82% (9/11), respectively. Median time to CR/CRi was 29.5
D (24-112 D). Most common treatment emergent adverse events (TEAEs) were
nausea (54%), febrile neutropenia (41%), diarrhea (44%), decreased appetite
(33%), and peripheral edema (31%). No dose-limiting toxicity was reported.
Febrile neutropenia (41%) and neutropenia (33%) were the most common
Grade 3/4 TEAEs. Most frequent serious AE was febrile neutropenia (28%).
Four relapses occurred, all on Arm A. Six deaths occurred (3 disease progres-
sion, 1 sepsis, 1 respiratory failure, 1 bacteremia). MTD has not been reached. 
Summary/Conclusions: Tx with VEN plus DEC or AZA shows a tolerable
safety profile, with high response rates observed in Tx-naive AML pts ≥65 y,
including those with adverse biologic disease features.
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A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/
THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID
MALIGNANCIES
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J Scandura3, A Letai4, M Frattini1,*
1Columbia University Medical Center, New York, United States, 2Institut Pasteur
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Background: Using a chemosensitivity screening assay, we previously demon-
strated that decitabine and thioguanine combinations can rescue therapeutic
efficacy in primary leukemia cells isolated from patients with relapsed and
refractory acute myeloid leukemia (AML). Although decitabine and thioguanine
have single-agent anti-leukemic activity, they have not previously been used
concurrently.
Aims: To test the safety and preliminarily assess additive/synergistic activity
of this combination, we performed a Phase I dose escalation trial of thioguanine
given with standard dose decitabine.
Methods: Patients with AML >60 yrs not candidates for standard induction,
relapsed/refractory AML, advanced MDS, and CMML were eligible. Two
thioguanine dose levels were evaluated: 80 and 120 mg/m2/day, given on Days
1-12 of induction and Days 1-7 of maintenance. Decitabine at 20mg/m2 was
administered on Days 3-12 during induction and on Days 3-7 during mainte-
nance. Standard safety measures, clinical outcomes, and activity of decitabine
and thioguanine was assessed by patient-specific pharmacodynamics including
an in vitro chemosensitivity assay, genome-wide analysis of DNA methylation
changes, and BH3 profiling in order to measure the degree to which samples
were primed to undergo apoptotic cell death.
Results: Twelve patients (median age, 67) with denovo AML (1), transformed
AML (6), relapsed/refractory AML (4), and CMML (1) were treated. DLT’s were
seen in two patients. One developed acute renal failure requiring hemodialysis
(80mg/m2) and another persistent grade 4 leukopenia/thrombocytopenia
(120mg/m2). Grade 3 infectious complications were common: neutropenic coli-
tis, bacteremias, and pneumonias. 10 of 12 patients completed therapy with 4
undergoing Allogeneic-BMT (3 AML, 1 CMML), 4 removed for disease pro-
gression, and 2 for DLT. One patient relocated after induction, and another
declined therapy after induction. Median cycles given was 3. Bone marrow
blast reductions to <5% were seen in 6 of 7 evaluable patients with AML (1 CR
and 3 CRi). The overall response rate in this high-risk patient population was
67%. The patient who achieved a CR (relapsed AML) received 4 previous
cycles of single-agent decitabine, demonstrating that the decitabine and
thioguanine combination regimen can rescue previous hypomethylating agent
failure. The chemosensitivity assay results for thioguanine on pretreatment
mononuclear cells directly correlated with clinical outcome in both response to
therapy and clinical resistance. BH3 profiling was also performed on pre-treat-
ment myeloblasts. Significant apoptotic priming corresponded to good initial
clinical response. In addition, in the single patient who responded and subse-
quently relapsed, decreased apoptotic priming was observed in the relapsed
sample, suggesting that the thioguanine/decitabine regimen applies selective
pressure for reduction in apoptotic priming.
Summary/Conclusions: The decitabine and thioguanine combination was
well-tolerated and showed surprising anti-leukemic activity. Importantly,
chemosensitivity and BH3 profiling accurately predicted responses and con-
firmed the etiology of the loss of therapeutic response. A muti-center Phase II
clinical trial is being planned.
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Microenvironment and signaling in CLL
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GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS
INDICATES THAT EARLY DETECTION OF DRIVER MUTATIONS AND
SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSE CLINICAL
OUTCOME
S Barrio1,*, TD Shanafelt2, J Ojha1, KG Chaffee3, C Secreto2, MK Kortüm1,
SL Slager3, R Fonseca1, NE Kay2, E Braggio1
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Background: High-count monoclonal B-cell lymphocytosis (MBL) is an asymp-
tomatic expansion of clonal B-cells with less than 5x109/L B-cells in the periph-
eral blood and without other manifestations of chronic lymphocytic leukemia
(CLL). Yearly, 1% of individuals with MBL evolve to CLL requiring therapy; thus
it is critical to develop a better understanding of the biologic events that deter-
mine which MBLs progress to intermediate/advanced CLL stages. High-count
monoclonal B-cell lymphocytosis (MBL) is an asymptomatic expansion of clonal
B-cells with less than 5x109/L B-cells in the peripheral blood and without other
manifestations of chronic lymphocytic leukemia (CLL). Yearly, 1% of individuals
with MBL evolve to CLL requiring therapy; thus it is critical to develop a better
understanding of the biologic events that determine which MBLs progress to
intermediate/advanced CLL stages.
Aims: We performed a longitudinal sequencing analysis on a cohort of high-
count MBL, assessing the mutation profile, clonal heterogeneity and clonal
dynamics over time and their impact on disease progression. 
Methods: We performed targeted deep sequencing (TDS) on 48 high-count
MBL individuals and explored the mutation status of 21 driver genes recurrently
mutated in CLL. We analyzed the clonal evolution in 45 of these 48 MBLs by
screening 2-4 sequential samples (average time between samples 56 months,
range 10-119 months). At the last follow-up, 19 cases (39%) had progressed
to Rai>0, and 10 cases (20%) required treatment. We analyzed 152 DNA sam-
ples from 48 cases (104 tumor CD5+/CD19+ samples and the 48 germ line
CD5-/CD19- controls) using semiconductor-sequencing technology (IonTorrent
PGM). Genetic information was integrated with relevant clinical and biological
parameters. Subsequently, we evaluated the role of mutations and clonal evo-
lution with progression to intermediate/advanced stage CLL (Rai stages I-IV)
and time to treatment (TTT).
Results: We found somatic non-synonymous mutations in 25 MBLs (52%) at
the initial time-point analyzed, including 13 (27%) with >1 mutated gene. Recur-
rent mutations were found in SF3B1 (10% of cases), BIRC3, DDX3X, CHD2
(8% each), NOTCH1 (6%), and ATM, BRAF, EGR2, FBXW7, KRAS, MED12,
MYD88, and ZMYM3 (4% each). Furthermore, BCOR, ITPKB, POT1, RIPK1
and SAMHD1 were each mutated in one case. No mutations were found in
HIST1H1E, TP53 and XPO1. In cases that subsequently progressed to inter-
mediate/advanced stage CLL, mutations were detected 41 months (median
time) prior to progression. Except for NOTCH1, TP53 and XPO1, which have
shown a lower incidence in MBL, driver genes were mutated with a similar
prevalence to CLL, indicating the early origin of most driver mutations in the
MBL/CLL continuum. Subclonal expansion of mutated drivers was found in 6
out of 10 (60%) cases who progressed to require treatment, compared with
only 5 of 35 (14%) non-treated cases. Individuals with clonal expansion had
both significantly shorter PFS (HR: 5.3 95% CI: 1.3-20.9; p=0.02), as well as
significantly shorter TTT (HR: 6.4 95% CI: 1.8-23.2; p=0.005).
Summary/Conclusions: The findings of this study suggest that mutations in
driver genes are an early event in the MBL-CLL continuum and predict progression
to clinically significant CLL. Clonal heterogeneity and subclonal expansion is
already found in individuals with high count MBL and its presence predicts an ear-
lier development of CLL. Sequential genetic evaluation of individuals with MBL
provides insights that add to our understanding of the events that contribute to
progression from MBL to CLL and have potentially profound clinical implications.
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Background: B cell receptor (BCR) signaling is one of the main pathways acti-
vated in the Chronic Lymphocytic Leukemia (CLL) microenvironment. Nurselike
cells (NLC), an important monocytic component of this microenvironment, spon-
taneously outgrow in vitro from high density CLL-PBMC cultures, and can expose
proteins on their surface, which can be recognized by the CLL-BCRs and activate
BCR signaling. CLL cases whose cells carry unmutated immunogloblulin heavy
variable (IGHV) genes (U-CLL) generally experience an aggressive disease
course, and U-CLL BCRs are highly polyreactive towards a variety of self-anti-
gens, most of them still incompletely characterized.
Aims: The aim of this study was to characterize BCR signaling in the CLL-NLC
co-culture system and to identify novel CLL-BCR antigens expressed by NLC.
Methods: CLL-PBMCs were cultured in vitro for 14 days until outgrowth of
NLC, which was confirmed by phase contrast microscopy. CLL cells were then
removed from the NLC co-culture and tested for BCR expression by flow cytom-
etry and activation of BCR signaling by Western Blot. Chemokine secretion
was tested in co-culture supernatants by ELISA. Concomitantly, NLC were har-
vested and lysed, followed by immunoprecipitation of protein lysates with
recombinant monoclonal antibodies obtained by cloning of 4 U-CLL BCR
sequences, all of them carrying 100% identity with the germline IGHV
sequence. Protein lysates from the human mesenchymal stromal cell line
hTERT were also tested, as control. Immunoprecipitated proteins were ana-
lyzed by label-free mass spectrometry followed by bioinformatic data analysis
with the softwares Max Quant and Perseus. 
Results: Down-modulation of IgM-BCR surface levels was observed after 14
days of co-culture of 10 CLL cases onto NLC. IgM levels recovered after 48
hours following in vitro culture in the absence of NLC, reaching pre-exposure
levels after 72 hours. Activation of AKT and ERK kinases and induction of MYC
protein were observed in 10 CLL cases after 14 days of CLL-NLC co-culture,
and phosphorylation/expression levels of these proteins were reduced when
CLL cells were removed from the NLC support. We also detected high levels of
the BCR-related chemokines CCL3 and CCL4 in 18 CLL-NLC supernatants, in
particular in the ones derived from U-CLL cases. Immunoprecipitation of 3 NLC
lysates and the hTERT control with 4 recombinant U-CLL BCRs, followed by
label-free mass spectrometry and bioinformatic data analysis, allowed the iden-
tification of 6 clusters of commonly recognized proteins (Figure 1). One cluster
(Cluster 5) included 11 putative CLL-BCR antigens that were expressed by all
3 NLC samples, but not by hTERT, and included cytoskeletal proteins and mem-
brane-associated proteins, some of them known autoantigens in other diseases.
Figure 1.
Summary/Conclusions: The BCR signaling pathway is activated following co-
culture of CLL cells with NLC, which can expose CLL-BCR ligands on their sur-
face. By applying a novel mass-spectrometry based approach, we identified a
number of putative CLL-BCR antigens expressed by NLC, which will be further
validated for BCR binding and signaling activation properties, as well as for
expression and localization in CLL-NLC co-cultures and lymph node sections
from CLL patients. Overall, these results will allow a better characterization of
the molecular mechanisms regulating BCR signaling in the CLL microenviron-
ment and the identification of novel therapeutic targets for CLL therapy.
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CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS
EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE
CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
E Hinterseer1, E Hutterer1, PW Krenn1, P Reinthaler1, J Höpner1, M Hopfinger1,
D Eulberg2, C Maasch2, A Kruschinski2, A Vater2, A Egle1, R Greil1, TN Hartmann1,*
1Laboratory for Immunological and Molecular Cancer Research, Third Medical
Department, Paracelsus Medical University, Salzburg, Austria, 2NOXXON Phar-
ma AG, Berlin, Germany
Background: The pathophysiology of chronic lymphocytic leukemia (CLL)
depends on the interactions of the malignant B cells with the lymphoid tumor
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microenvironment. The chemokine stromal cell-derived factor 1 (SDF-1, CXCL12)
is constitutively secreted and presented by stroma under normal as well as malig-
nant conditions. In CLL, binding of CXCL12 to its over-expressed classical recep-
tor CXCR4 regulates cell migration and increases cell survival and cell adhe-
sion-mediated therapy resistance, making this signaling axis a therapeutic target.
Olaptesed pegol (NOX-A12), a PEGylated L-stereoisomer RNA aptamer, is a
novel high-affinity CXCL12 antagonist. Using short term adoptive transfers of
human leukemia cells into immune deficient mice, we recently demonstrated that
olaptesed pegol antagonizes CLL cell homing to bone marrow.
Aims: Here, we aimed to determine the potential of olaptesed pegol to mobilize
CLL cells from lymphoid organs and to antagonize disease progression in vivo
using the murine Tcl transgenic (tg) CLL transplantation model.
Methods: Splenocytes from Tcl1 tg mice with overt leukemia were transplanted
into the peritoneal cavity of C57BL/6J wildtype mice. Engrafted recipients with
active leukemia (defined by a peripheral blood CD5+/CD19+ tumor cell con-
centration ≥10%) were randomized to treatment with olaptesed pegol or the
CXCR4 antagonist AMD3100. CLL cell mobilization into peripheral blood was
analyzed via flow cytometric detection of CD5+/CD19+ cells before substance
application, and 1 h, 3 h, 6 h, and 24 h post application. Treatment studies of
engrafted animals were performed using either olaptesed pegol or fludarabine,
or ibrutinib followed by olaptesed pegol compared to ibrutinib alone. Readout
parameters were tumor cell concentration and overall survival of mice.
Results: Olaptesed pegol induced a substantial mobilization of CLL cells into
peripheral blood with an approx. 2-fold increased leukemic cell count compared
to pre-application levels. Raised CLL cell counts in blood were observed within
1 hour, reached a peak upon 6 hours and were still visible at 24 hours post
treatment while AMD3100 treatment did not result in consistent CLL cell mobi-
lization. In long-term treatment experiments, olaptesed pegol prolonged overall
survival of mice as efficient as fludarabine. Whereas ibrutinib followed by
olaptesed pegol reduced blood tumor burden to a comparable extent as ibru-
tinib monotherapy, the combination had a stronger effect on median survival
which was prolonged by 36% vs vehicle control and 18% vs ibrutinib alone. 
Summary/Conclusions: Our data demonstrate the potential of olaptesed pegol
as a CLL cell mobilizing and therapeutic agent. Further studies corroborating its
efficiency as a single treatment using primary Tcl transgenic animals are ongoing.
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THE PAN-PIM KINASE INHIBITOR LGB321 TARGETS APOPTOTIC
PATHWAYS AND MICROENVIRONMENTAL INTERACTIONS IN CLL
S Decker1,*, S Kissel1, K Aumann2, K Zirlik1, C Dierks1
1Internal Medicine I, 2Pathology, University Hospital Freiburg, Freiburg, Ger-
many
Background: In recent years, the emergance of kinase inhibitors like Ibrutinib
has drastically altered treatment strategies and improved outcomes in CLL
patients, but lack of cure and resistance to therapy still remain serious prob-
lems. PIM kinases are involved in various important disease mechanisms in
CLL, with PIM1 regulating CXCR4 surface expression impacting its interaction
with the microenvironment, and PIM2/3 affecting the apoptotic machinery by
regulating BAD. The Pan-PIM kinase inhibitor LGB321 (Novartis) targets all 3
PIM kinases and therefore affects both, CLL apoposis and its interaction with
the microenvironment.
Aims: In the study presented here, we aimed to investigate the effect of the
Pan-PIM inhibitor LGB321 on CLL in vitro and in vivo.
Methods: CLL patient samples: Peripheral blood samples were obtained with
informed consent in accordance with the declaration of Helsinki from B-CLL
patients who were either untreated or off therapy for at least 6 months.
Immunoblotting: Protein expression of PIM1, PIM2, PIM3, CXCR4, pCXCR4,
pBAD, BAD and beta-Actin was determined after Pan-PIM inhibitor treatment
and was analyzed using the ImageJ software. Apoptosis Assay: PBMCs were
plated with or without support of the murine stromal cell line M2-10B4 and
treated with LGB321. After 24 and 48 h of incubation, cells were stained with
a CD5-V450 and a CD19-APC antibody, followed by AnnexinV/7-AAD staining
(BD) according to the manufacturer´s instructions. CLL cell homing into NOG
mice: NOG mice were transplanted at 8 weeks of age. Primary human CLL
cells were treated with LGB321 for 12 hours. CLL cells were resuspended in
HBSS and mice received transplants via teil vein injection. Mice were analyzed
4 hours after transplantation. LGB treatment of CLL-Xenograft mice: PBMCs
were transplanted using both retro-orbital and intraperitoneal application. Treat-
ment started one week after transplantation and LGB321 was applied using
oral gavage. After 2 weeks of treatment, mice were sacrificed, and spleen and
bone marrow cells were harvested and stained for human CD5, CD19 and
CD45 (BD).
Results: LGB321 was highly effective in inducing apoptosis in primary CLL
cells, independent of risk factors like 17p deletions or the mutation status.
Apoptosis induction correlated with reduced pBAD and BAD levels. Further-
more, LGB321 was also effective in the presence of protective stromal cells
and could completely overcome the stroma protective effects. Mechanistically,
we found that LGB321 treatment blocked the CXCR4/CXCL12 axis by dephos-
phorylating the CXCR4 receptor on Ser339, by reducing total CXCR4 protein
levels and by blocking the externalization of the CXCR4 receptor. Concordantly,
PIM inhibition blocked CXCR4 functions like migration towards a CXCL12 gra-
dient (P<.0001), and reduced homing of LGB321-pretreated primary CLL cells
towards the bone marrow (P=.0001) of NOG mice in vivo. In vivo experiments
comfirmed the efficacy of LGB321 in 4 different CLL xenograft studies. Trans-
plantation of primary human CLL cells into NOG mice and treatment with
LGB321 for 2 weeks strongly reduced WBC counts, spleen size and spleen
infiltration with human CLL cells (P=.0295) in all four CLL cases, and blocked
BAD as well as CXCR4 phosphorylation also in vivo.
Summary/Conclusions: Our results demonstrate, that the Pan-PIM kinase
inhibitor LGB321 might be an effective treatment option for CLL patients by impair-
ing PIM2/3 mediated CLL-cell survival, and by blocking the PIM1/CXCR4-mediated
interaction of CLL cells with their protective microenvironment in vitro and in vivo.
Future clinical trials should be performed to validate its efficacy in human CLL.
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IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS
OF CHRONIC LYMPHOCYTIC LEUKEMIA
PH Nguyen*, N Reinart, G Krause, M Hallek
Department I of Internal Medicine, University Hospital of Cologne, Cologne,
Germany
Background: The introduction of therapeutics targeting B cell receptor (BCR)
signaling such as the inhibitors of BTK and PI3K-δ has been changing the field
of CLL therapy formidably. Inhibition of LYN, a central molecule of the BCR sig-
naling, efficiently induced apoptosis in vitro but its effectiveness in vivo is still
unclear. In CLL cells, LYN is found to be aberrantly expressed and highly acti-
vated. Not only the classical BCR molecules downstream of LYN such as SYK
or PI3K, but also several other substrates such as HS1, procaspase-8, cortactin
or PP2A have been indicated to be deregulated in CLL. These downstream mol-
ecules could support the aggressiveness and apoptosis resistance of the malig-
nant cells. Besides, the expression levels of LYN mRNA was associated with
treatment-free survival of CLL patients, providing further perspectives for LYN as
a valuable therapy target. However, studies about the role of LYN in CLL have
only been conducted from isolated cells in vitro, and modulations of Lyn activity
in CLL were only performed using inhibitors with insufficient specificity. Thus, the
contribution of LYN in CLL pathogenesis is far from being fully understood. We
have demonstrated that Lyn kinase is essential for the development of CLL in
vivo (Nguyen et al., in revision). Interestingly, loss of Lyn in leukemic B cells
results in higher proliferation rate, early malignant transformation and apoptosis
resistance, and can potently induce CLL in immune competent syngeneic recip-
ients. In stark contrast, our results suggest a striking role of Lyn for the formation
of a tumor microenvironment that supports CLL expansion.
Aims: So far studies about the role of LYN in CLL have only been conducted
from isolated cells in vitro, and modulations of Lyn activity in CLL were only per-
formed using inhibitors with insufficient specificity. Thus, the contribution of LYN
in CLL pathogenesis is far from being fully understood. Using the well-established
mouse model for CLL, the Eμ-TCL1 mouse model, we investigated the functional
contribution of LYN in the pathogenesis of CLL in on the in vivo level.
Methods: To better understand the physiological consequences of overex-
pressing LYN observed in human CLL cells, we generated a novel mouse mod-
el with constitutively active LYN mutation. The conditional knockin mice have
a point mutation at the inhibitory phosphorylation tyrosine of the Lyn gene
(Y508F), resulting in its constitutively active conformation that expresses specif-
ically in B cells due to Cre-induced recombination under the CD19 promoter
(LYNup-B). This novel mouse model was intercrossed with the Eµ-TCL1 model
(TCL1+LYNup-B) and monitored for CLL development.
Results: B cells isolated from TCL1+LYNup-B mice exhibited remarkably
enhanced activation of BCR-associated kinases such as SRC family kinases,
SYK, AKT and ERK1/2 compared to control TCL1+LYNwt B cells, particularly
upon IgM stimulation. Our analysis also revealed a higher malignant transfor-
mation rate of TCL1+LYNup-B B cells starting at six months of age, and a more
progressive CLL burden in the peripheral blood of TCL1+LYNup-B mice, partic-
ularly when the CLL clones had been well established at eight months of age.
However, moribund mice from both cohorts showed similar infiltration of CLL
cells in the lymphoid organs, and the slight increased CLL burden in peripheral
blood did not affect overall survival of TCL1+LYNup-B mice compared to
TCL1+LYNwt counterparts.
Summary/Conclusions: Our results suggest that constitutively active LYN
and the hyperactive BCR signaling in leukemic cells contribute moderately to
the progression of CLL in the Eμ-TCL1 mouse model.
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MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIASIGNALLING
IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM
APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY
D Mertens1,2,*, I Idler2, D Yosifov1, M Reichenzeller2, V Meyer-Pannwitt1,
A Scheffold1, H Doehner1, S Stilgenbauer1
1Internal Medicine III, University Ulm, Ulm, 2Mechanisms of Leukemogenesis,
DKFZ, Heidelberg, Germany
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Background: Microenvironmental support protects malignant cells from apop-
tosis and cancer therapy, in part by induction of hypoxia-regulated pathways.
Hypoxia-regulated pathways are conceivable as therapeutic targets in solid
cancers, but not so much in leukemias.
Aims: Here we show that in chronic lymphocytic leukemia (CLL) cells hypox-
ia-regulated pathways are the most important mediators of support by bone
marrow derived stromal cells (BMSC). These pathways can be targeted ther-
apeutically.
Methods: We compared the transcriptomes of primary CLL cells protected by
coculture with BMSCs to the transcriptomes of non-protected CLL cells that
undergo apoptosis. To identify compounds that are active against the microen-
vironmental support, we determined the differential transcriptomic signature of
CLL cells between in vitro co-culture and unsupported culture and compared it
to a database of transcriptomes induced by bioactive compounds in cell lines
(“connectivity map”). We tested emetine for efficacy in a syngeneic transplan-
tation model of murine CLL, using three different treatment schedules - a short
high dose intensity and two continuous lower dose intensity scheme.
Figure 1.
Results: The cellular pathways most differentially regulated in primary CLL cells
protected by coculture compared to unprotected CLL cells were involved in
oxidative phosphorylation and mitochondrial function. Transcriptional differences
were already evident at 6-8 h, directly before induction of apoptosis in unpro-
tected cells. In line with this finding, the support of primary CLL cells by the
BMSCs could be mimicked in vitro by hypoxia. By the comparison of the dys-
regulated CLL transcriptomic signature to the connectivity map database, we
identified the cardiac glycoside ouabain and the ipecac alkaloid emetine as
inducing the most correlated transcriptomic signatures. In vitro, these substances
were highly active on primary CLL cells protected by coculture (IC50s 287 nM,
190 nM and 35 nM, respectively; the IC50 of fludarabine was 5 µM). In vitro
characterization of the substances revealed suppression of HIF-1 alpha activity.
This suppression coincided with a stronger oxidation of the mitochondrial and
cytoplasmic redox homeostatic system compared to 20 redox-active compounds.
We tested the efficacy of emetine in vivo using three different treatment sched-
ules - a short one of high dose intensity (24 mg/kg every 4th day for 3 applica-
tions) and two continuous ones of lower dose intensity (3 or 8 mg/kg every 4th
day). We transplanted murine CLL tumors induced by Eµ-driven overexpression
of TCL1A into microenvironmentally intact wildtype syngeneic mice. Continuous
low dose treatment did not lead to weight reduction in mice, whereas treatment
with three high doses of emetine resulted in a significant loss of weight. However,
while continuously administered low doses of emetine were not beneficial for
survival of transplanted mice (Figure 1a), three high doses of emetine doubled
median survival of diseased mice (31.5 days vs 15 days, p=0.0002, Figure 1b).
This enhanced survival coincided with decreased numbers of CLL cells in periph-
eral blood, spleen and most pronounced in bone marrow (BM), which led to
recovery of hematological parameters.
Summary/Conclusions: CLL cells are supported by bone-marrow derived
stromal cells first of all through modulation of hypoxia-regulated pathways. This
microenvironmental support can be therapeutically targeted by cardiac glyco-
sides and ipecac alkaloids, both of which increase the intracellular oxidation of
CLL cells even when they are protected by coculture. In a mouse model of
CLL, this is reflected by doubled median survival of mice treated with emetine.
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IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED
BY THE CXCR4/SDF-1 AXIS
G Pavlasova1,2,*, M Borsky2, V Seda1,2, K Cerna1,2, J Osickova1,2, M Doubek2,
J Mayer2, R Calogero3, S Pospisilova1,2, M Davids4, J Brown4, M Mraz1,2
1Molecular Medicine, CEITEC MU, 2Dept. of Internal Medicine - Hematology
and Oncology, University Hospital Brno and Faculty of Medicine MU, Brno,
Czech Republic, 3Dept. of Biotechnology and Health Sciences, University of
Torino, Torino, Italy, 4Dept. of Medical Oncology, Dana-Farber Cancer Institute,
Boston, United States
Background: It was shown that BCR inhibitors such as ibrutinib interrupt
microenvironmental interactions and mobilize CLL cells from lymph node nich-
es and bone marrow into the blood stream. Therefore, it has been suggested
that a combinatorial therapy of BCR-inhibitors with anti-CD20 or other anti-
bodies might be an effective therapeutic combination.
Aims: The aim of this study was to test for the ibrutinib effect on the expression
of selected CLL cell-surface molecules that could be potentially targeted by
available monoclonal antibodies.
Methods: Peripheral blood samples were obtained from untreated CLL
patients or patients treated with ibrutinib as a single agent (420 mg once daily).
The study was approved by the institutional review board and samples were
obtained with written informed consent.
Results: We performed gene expression profiling in samples obtained from CLL
patients treated with ibrutinib as a single agent (pre-ibrutinib vs day 15 and/or
week 5/12) and analyzed changes in >20 cell-surface molecules that could be
potentially targeted by different available therapeutic antibodies. Surprisingly, we
observed that CD20 mRNA had the most significantly changed expression (down-
modulation of 3.4-fold; P<0.0001). This suggested that CD20 expression might
be regulated by a yet unknown mechanism in the context of microenvironmental
interactions impaired by ibrutinib. The co-culture of primary CLL cells with stromal
cell line HS-5 induced higher CD20 surface levels on CLL cells, and ibrutinib inhib-
ited this CD20 up-regulation. Then we assessed the CD20 expression on CLL cell
populations defined according to CXCR4 and CD5 levels. CLL cells that have
recently exited the lymph node microenvironment to the peripheral blood express
lower levels of chemokine receptor CXCR4 and higher levels of activation marker
CD5 (CXCR4dimCD5bright cells) than those cells circulating in the blood stream for
a long time (CXCR4brightCD5dim cells). The CXCR4dimCD5bright cells had 2-times
higher CD20 surface as well as mRNA expression (P<0.01) suggesting that
changes of CD20 levels within immune niches reflect the changes in its transcrip-
tion. Moreover, CD20 expression gradually decreased with CLL cells’ transition
from CXCR4dimCD5bright to CXCR4brightCD5dim (P<0.01). This led us to hypothe-
size that CXCR4/SDF-1 is directly implicated in CD20 regulation. Indeed, in vitro
treatment of CLL cells with SDF-1α (ligand for CXCR4 produced by stromal cells)
up-regulated CD20 expression (P<0.01). The application of plerixafor (CXCR4
inhibitor) or ibrutinib abolished the SDF-1 mediated CD20 up-regulation (P<0.01).
Altogether, this represents the first known mechanism of CD20 regulation in CLL
cells. Notably, it has been shown that addition of rituximab to ibrutinib in vivo is
able to eliminate CLL cells despite lower levels of CD20 suggesting that there
must be other mechanism of ibrutinib action that allows for the effect of rituximab.
The screening of anti-apoptotic molecules revealed that Mcl1 levels were signifi-
cantly down-modulated after ibrutinib treatment in vivo (P=0.002), and ibrutinib
also inhibited Mcl1 induction in CLL cells co-cultured with HS-5. As Mcl1 was
described to directly protect CLL cells from rituximab-induced apoptosis and CDC,
we suggest that ibrutinib-mediated Mcl1 reduction is a mechanism that facilitates
rituximab efficacy.
Summary/Conclusions: We have described the first known mechanism of
CD20 regulation in CLL cells. The CXCR4/SDF-1 axis up-regulates CD20
expression in CLL B cells, this is inhibited by ibrutinib. Supported by the Min-
istry of Education, Youth and Sports of the Czech Rep, project CEITEC 2020
(LQ1601); Ministry of Health of the Czech Rep, grant nr. 16-29622A; GACR
(GA16-13334Y); TACR (TEO2000058/2014-2019); MUNI/A/1028/2015; MSMT
COST CZ (LD15144); Horizon 2020 (No. 692298); and G.P. is a city of Ostrava
scholarship holder.
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FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL
CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC
LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND
GENE EXPRESSION MODIFICATION
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Background: Chronic Lymphocytic Leukemia (CLL) is the most common
leukemia in Western countries and is characterized by the accumulation of
CD5/CD19+ monoclonal B-cells in peripheral blood and secondary lymphoid
tissues. The interactions between CLL cells and the bone marrow (BM)
microenvironment (notably composed by mesenchymal stromal cells - MSC)
play an important role in promoting the increased survival of leukemic B-cells.
Extracellular vesicles (EVs) produced by leukemic cells and the microenviron-
ment may be implicated in this cross-talk. EVs, including microparticles and
exosomes, are small plasma membrane fragments with sizes ranging from
0.01 to 1µm, and contain products specific to the original cell, such as microR-
NA, mRNA and proteins.
Aims: Our objective is to assess the role of EVs in the cross-talk between
malignant cells and their microenvironment by functional studies and microarray
analyzes.
Methods: Ultracentrifugation (150000g) was applied to isolate EVs from super-
natant of BM-MSC. Different concentrations of EVs were added to CLL B-cells to
evaluate their impact on cell survival, migration and chemoresistance. The gene
expression change induced by EVs in CLL cells was also defined by microarray
analysis (Affymetrix) after their incubation (24h) with BM-MSC-EVs. Some genes
identified as differentially expressed were validated by real-time PCR.
Results: We demonstrated that BM-MSC EVs are able to enter in CLL-B-cells
(PKH67 labeling): after 24h, >95% of CLL cells had integrated EVs. Apoptosis
was assessed by flow cytometry: addition of increasing concentrations of EVs
showed a protective effect on CLL-B-cells from spontaneous cell death (n=21/p-
value<0.0001). CLL-B-cells pre-incubated with EVs (4h) displayed an increased
spontaneous migration index and also in response to SDF1α (n=10/p-
value=0.002). We also observed that EVs rescue CLL-B-cells from drug
induced apoptosis. Microarray analysis reveals a significant effect on the
expression of 987 genes after the integration of EVs in CLL-B-cells, notably
implicated in apoptosis, epigenetic, adhesion, migration, cell activation, actin
cytoskeleton regulation and immune pathways.
Summary/Conclusions: Here we show for the first time that BM-MSC-EVs
protect CLL cells from spontaneous apoptosis and influence their migration
and chemoresistance capacities. The implication of EVs in several cell functions
was observed by microarray analyzes. This study demonstrates the existence
of a powerful cross talk between BM-MSC and CLL-B-cells mediated by EVs.
It provides new insight in the biology of CLL.
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THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR
MICROENVIRONMENT IN CLL
M Van Attekum1,*, S Endstra1, E Reinen1, M Von Lindern2, E Slinger1, E Elder-
ing1, A Kater3
1Experimental Immunology, Academic Medical Center, 2Hematopoiesis, San-
quin, 3Hematology, Academic Medical Center, Amsterdam, Netherlands
Background: Survival of chronic lymphocytic leukemia (CLL) cells critically
depends on signals from bystanders cells, such as T-cells and macrophages,
within micro-environmental niches such as lymph nodes. The mechanisms of
this intricate interplay are however unknown. Moreover, whether CLL cells
actively participate in shaping their pro-survival niche is poorly understood.
Aims: 1) whether T-cell stimulation initiates active recruitment of monocytes
by CLL cells, 2) whether CLL cells are able to differentiate these monocytes
towards a supporting phenotype and 3) by which mechanism macrophages
induce CLL survival.
Methods: migration assays with inhibitors, microarray, Luminex, flow cytometry,
western blot, immunohistochemistry, survival assays, RNAi, polysome gradient
fractionation 
Results: 1) In in vitro migration assays we found that CLL cells can actively
recruit monocytes after T-cell or CD40L stimulation. T-cell stimulation of CLL
cells resulted in secretion of several chemokines, of which CCL2 was respon-
sible for the enhanced monocyte migration. 2) We next examined and com-
pared polarization patterns of monocytes after differentiation with serum derived
from CLL patients (N=25) or pooled healthy donor serum and found that CLL
serum was able to differentiate macrophages towards a tumor supporting M2
phenotype. This finding was confirmed ex vivo by IHC, as M2 marker CD206
co-localizes with CD68 cells in CLL LNs, while the majority of macrophages in
non-CLL derived LNs are CD80+ (M1 type). 3) Lastly, we found that
macrophages induce CLL cell survival and that this survival resulted from an
AKT-dependent upregulation of pro-survival protein MCL-1, which was trans-
lationally stabilized. Interestingly, the mechanism of MCL-1 stabilization was
independent of NF-κB signaling.
Summary/Conclusions: These studies shed light on reciprocal cellular inter-
actions in the CLL LN that shape pro-tumor differentiation of supporting cells,
that in turn cause survival by changing the apoptotic balance. These interac-
tions can be targeted at different levels, creating new treatment venues for this
still incurable disease.
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METABOLIC ALTERATIONS INDUCED BY IBRUTINIB IN CLL CELLS AS A
BIOCHEMICAL BASIS FOR MECHANISM-BASED DRUG COMBINATION
TO ENHANCE THERAPEUTIC ACTIVITY
H Pelicano1,*, A Huang1, F Li1, J Liu1, J Huang1, WG Wierda2, MJ Keating2,
P Huang1
1Translational Molecular Pathology, 2Leukemia, UT MD Anderson Cancer Cen-
ter, houston, United States
Background: Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia in the Western countries and is currently still incurable. Ibrutinib, a
small molecule compound designed to target Bruton’s tyrosine kinase (BTK)
essential for CLL cell survival, exhibits impressive therapeutic activity in CLL,
and significantly improves the clinical outcome of CLL patients. However, drug
resistance and disease relapse may occur in a small percent of patients.
Aims: The main objectives of this study were to investigate the potential effect
of Ibrutinib on CLL metabolism, and to develop novel strategies to enhance
the therapeutic activity of Ibrutinib and reduce drug resistance.
Methods: Primary CLL cells were isolated from the peripheral blood samples
of CLL patients for in vitro study. Metabolic alterations including changes in
oxygen consummption (OCR) as an indicator of mitochondrial respiration and
extracellular acidification rate (ECAR) as an indication of lactate production
from glycolysis were measured by a Seahorse metabolic analyzer XFe24. Cel-
lular reactive oxygen species (ROS) were detected using a redoxsensitive flu-
orescence probe DCFH-DA. 
Results: Since active generation of reactive oxygen species (ROS) is a meta-
bolic feature of CLL cells, we first used DCFH-DA to test the potential effect of
Ibrutinib on ROS production in primary CLL cells isolated from patients. We
found that Ibrutinib induced a substantial increase of ROS as early as 90 min
and lasted for up to 24 h. Mechanistic study suggests that the mitochondrial
respiratory chain might be the major source of this abnormal ROS generation,
since inhibition of the mitochondrial respiratory complex I by rotenone or sup-
pression of flavoproteins (components of mitochondrial respiratory chain or
NAD(P)H oxidase) by diphenyleneiodonium largely abrogated Ibrutinib-induced
ROS generation. To further investigate the potential effect of Ibrutinib on mito-
chondria, we used the extracellular flux analyzer (XFe24). In a CLL cells-stromal
cells co-culture system (to maintain long-term viability of CLL cells), Ibrutinib
induced little changes in OCR and ECAR during the first 48-72 h. However,
prolonged drug exposure (up to 7 days) caused a consistent and significant
decrease in OCR compared to the untreated CLL cells co-cultured with stromal
cells for the same period. Importantly, CLL cells isolated from patients under
Ibrutinib treatment for 7 days also exhibited a significant decrease in OCR
compared to the pre-treatment samples from the same patients, suggesting
that the impact of Ibrutinib on mitochondria occurred in vivo. Western blot analy-
sis revealed that Ibrutinib induced a decreased expression of certain respiratory
chain components. Functional analysis showed that Ibrutinib caused CLL cells
to take up less glutamine but did not affect glucose uptake, suggesting that
Ibrutinib might preferentially impact glutamine metabolism. Based on these
new findings, we further tested the possibility that the metabolic alterations
and mitochondrial dysfunction induced by Ibrutinib might render CLL cells vul-
nerable to compounds that impact mitochondria or inhibit glutamine metabo-
lism. Indeed, our further study showed that combination of Ibrutinib with met-
formin (a drug that inhibits mitochondrial OXPHOS) or with C968 (a glutaminase
inhibitor) had synergistic activity against CLL cells and induced massive
leukemia cell death.
Summary/Conclusions: Overall, our study suggests that ibrutinib could induce
metabolic alterations characterized by decreased mitochondrial respiration and
attenuated glutamine metabolism. Such metabolic alterations provide a bio-
chemical basis for mechanism-based drug combination to enhance the thera-
peutic activity of Ibrutinib. Since metformin is a diabetes drug with low toxicity,
it is feasible to test its combination with Ibrutinib for treatment of CLL to poten-
tially enhance therapeutic activity.
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BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL
HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC
LEUKEMIA
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Background: Endothelin 1 (ET-1) is a 21-aa peptide that mediates its action
by activating two G-protein-coupled receptor (GPCR) subtypes, ETA and ETB
receptors. CLL cells secrete ET-1 and express ETA and ETB receptors on the
cellular surface. ET-1 signaling improves CLL survival and proliferation and
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reduces CLL sensitivity to phosphoinositide-3-kinase δ inhibitor idelalisib and
fludarabine.
Aims: We asked whether ET-1 pathway may be involved in CLL homing and
B-cell receptor (BCR) signaling pathway. Macitentan, a novel double inhibitor
of ETA and ETB receptors, was tested in CLL in combination with the Btk
inhibitor ibrutinib.
Methods: CD19+ CLL cells isolated from patients were treated in vitro with
100nM ET-1 with or without the addition of BQ-123, specific ETAR inhibitor,
BQ-788, specific ETBR inhibitor or macitentan, a double ETAR/ETBR inhibitor.
In some instances, CLL cells were pre-incubated with ibrutinib 0.5µM. We eval-
uated CLL migration, adhesion to stromal cells, calcium efflux and BCR signal-
ing pathway. Moreover, the expression of ET-1, ETAR and ETBR in CD49d+
CLL vs CD49d- CLL as well as in CXCR4high CLL vs CXCR4low CLL was meas-
ured in peripheral blood of CLL patients by flow cytometry. We also evaluated
big ET-1 level by ELISA in plasma samples from MBL, CLL patients at diagnosis
and at first progression, in fludarabine resistant CLL and in CLL after ibrutinib
treatment.
Results: First, we found that circulating CXCR4high CLL cells express higher
levels of ET-1 and ET1 receptors than CXCR4low fraction (p<0.05). In vitro,
ET-1 acts as a chemotactic factor for CLL cells. The blockage of ET receptors
impairs CLL migration to ET-1 and also to other stimuli as CXCL12. In addition,
ET-1 signaling is involved in CLL adhesion, as inferred on the basis of the fol-
lowing observations: (i) the blockage of ET receptors leads to CLL detachment
from stromal cell supports; (ii) ET-1 stimulation promotes the phosphorylation
of FAK, GSK3β, AKT and increases ILK expression in CLL cells and (iii) higher
levels of ET-1 and ET receptors characterize CD49d+ CLL subset. Furthermore,
we found that ET receptor triggering promotes calcium release in CLL. Blockage
of both ET receptors by macitentan disrupts BCR signaling pathway and BCR-
mediated calcium release in CLL cells in combination with ibrutinib. In plasma
samples, big ET-1, the precursor of ET-1, was detectable in variable levels
ranging from 0.6 to 67 pg/mL. Mean big ET-1 levels were equal to 2 pg/mL in
MBL patients, 3.5 pg/mL in CLL at diagnosis, 7.9 pg/mL at first progression, 8.2
pg/mL at relapse, and 28.8 pg/ml in fludarabine-resistant CLL patients. In 4
CLL cases with plasma samples available before and after ibrutinib treatment,
we found a significant decrease of big ET-1 in plasma from 10.8 to 3.9 pg/mL
(p<0.05).
Summary/Conclusions: Collectively, our data describe for the first time an
involvement of ET-1 signaling in CLL homing and BCR pathway. Moreover, ET-
1 seems to accumulate in CLL patients with worse clinical features. Our results
also envision the possibility to interfere with ET receptors activity using maci-
tentan as a possible novel therapeutic strategy for CLL patients.
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Background: Immune evasion is important for the expansion of the tumoral
clone in chronic lymphocytic leukemia (CLL). Impaired NK-cell activity and dys-
functional CD4+ and CD8+ T-cells with abnormal cytoskeletal dynamics and
immune synapses have been reported in CLL. T and NK-cell dysregulation
may be relevant in CLL-like monoclonal B-cell lymphocytosis (MBL) and initial
stages of CLL, although it has not been studied in depth.
Aims: To compare the gene expression patterns of CD4+ and CD8+ T-cells
and NK-cells from the peripheral blood of healthy controls, MBL subjects and
CLL-A(0) patients. To assess the T and NK-cell dysfunction in these entities.
Methods: Samples from thirty-eight individuals (17M/21F, median age=72yrs)
were collected: 9 healthy controls, 15 MBLs and 14 CLL-A(0) with an absolute
lymphocyte count <12x109/L. T-cells (CD4+ or CD8+) and NK-cells (CD56+
CD3-) from all subjects were isolated by immunomagnetic methods (Miltenyi
Biotec). Good quality extracted RNA (RIN>7) was hybridized to 113 Human
Gene 2.0 ST arrays (Affymetrix). Differential gene expression between groups
was evaluated employing linear models for microarrays in R. Genes with a P-
value<0.05 and |logFC|>0.58 were considered as potentially relevant. Func-
tional analysis was performed using Ingenuity Pathway Analysis (IPA). For the
CD4+ T-cell fraction, expression results were validated by qPCR in the same
and in an independent cohort composed by 10 MBL and 5 CLL-A(0) individuals. 
Results: Unsupervised hierarchical clustering analysis clearly discriminated
healthy controls from both MBL and CLL for CD4+ and NK-cells, where the
major differences in the gene expression were found. Regarding CD4+, gene
upregulation was notably predominant in MBL and CLL-A(0), mainly in terms
of cytotoxicity (GZMB, PRF1, GNLY, SERPING1, CLU, NKG7 and FCRL6) and
signaling, cytoskeleton and membrane dynamics leading to an increased
inflammatory response (RAB31, VNN1, TNFSF4, ITGAM, TLR2). Strikingly,
MBL showed more upregulated networks and expressed genes with higher
|logFC| values than CLL-A(0). Furthermore, some of the activated genes (CCL5,
MAP3K8, IL18RAP, NKG7, GZMH and PRF1) have been previously described
in Th1-cells, which points to a bias towards this T-cell subset in the Th1-Th2
axis. Additional qPCR analysis validated the expression results in this cell frac-
tion. In contrast to previously described dysfunction of CD8+ T-cells in CLL,
functional analysis did not reveal differences involving cellular migration, adhe-
sion or cytotoxicity neither in MBL nor CLL-A(0). Regarding NK-cells, functional
analyses showed a decrease of the NK function in both MBL and CLL-A(0),
the latter showing higher number of differentially expressed genes and |logFC|
values. The most relevant downregulated pathways were related to chemotaxis,
adhesion and cell-to-cell binding (downregulation of AMICA1, CCR4, CD4,
FPR2, FPR3, KIT and XCL1), as well as activation, cytotoxicity and cytoskeleton
organization (down-regulation of CD28, CD86, FCAR, FPR2, FPR3, ICOS and
up-regulation of FCGR2B).
Summary/Conclusions: 1. CD4+ T-cells show an unusual activation of cyto-
toxicity and inflammation that are higher in MBL than in CLL-A(0) patients. A
Th1 expression pattern is also observed in these entities. 2. CD8+ T-cells dys-
function do not occur in our cohort of MBL and initial CLL. 3. NK-cell dysregu-
lation in cytotoxicity and migration is already detectable in MBL, and increases
progressively with the evolution of the disease. 4. These are preliminary results,
validation and functional studies are ongoing.
Acknowledgements: PI11/1621, 14SGR585, Fundació LaCaixa.
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Background: Treatment with the B-cell receptor (BCR) signaling inhibitor ibru-
tinib (IB) has demonstrated high response rates and improved survival in chron-
ic lymphocytic leukemia (CLL). IB treatment is associated with a highly variable
degree of transient lymphocytosis, due to a reduction of CLL cell adhesion and
efflux of CLL cells from tissue sites. CD49d, a strong negative prognosticator
in CLL, is the alpha-chain of the integrin heterodimer CD49d/CD29 (VLA-4), a
key molecule in CLL microenvironmental interactions. Inside-out activation of
VLA-4 by BCR signals increases its adhesive properties, although the role of
the BCR as a VLA-4 activator in CLL is unknown.
Aims: To correlate the kinetics of transient lymphocytosis with the expression
and levels of activation of VLA-4.
Methods: Two cohorts of IB treated patients (IB-CLL) with data of absolute
lymphocyte count (ALC) at pre-treatment and at different time points of IB treat-
ment were available: 1) 28 refractory/relapsed CLL patients (15 CD49d+) treat-
ed with IB on a compassionate basis (IT cohort); 2) 26 CLL patients (14
CD49d+) enrolled in the investigator-initiated phase II study of ibrutinib
NCT01500733 (US cohort).VLA-4 activation was assessed by flow cytometry
using conformation sensitive anti-CD29 mAb HUTS-21 in conjunction with LDV-
containing VLA-4 specific ligand. The levels of activated VLA-4 was measured
as VLA-4 receptor occupancy (RO) in values ranging from 0.0 (no RO) to 1.0
(100% RO) as in Chigaev et al. (J Biol Chem, 2009): higher RO indicates a
larger fraction of activated (i.e. with a higher affinity) VLA-4. BCR engagement
was performed using goat F(ab’)2 anti–human IgM. CD49d, CD29, IgM expres-
sion, and Ca++ release were cytometrically analysed. Adhesion assays were
performed on VCAM-1-coated slides.
Results: Correlation between CD49d expression and IB-induced lymphocytosis
was performed in both cohorts. Median ALC at baseline were 23x106/mL and
29x106/mL (IT cohort) and 67x106/mL and 95x106/mL (US cohort) for CD49d-
and CD49d+ CLL, respectively. Despite these different baseline ALC, and
although ALC data were available at slightly different timepoints, CD49d- CLL
showed a more pronounced increase in ALC than CD49d+ cases in both
cohorts (Figure 1). To explain the observed differences in ALC kinetics in
CD49d+ and CD49d- CLL, VLA-4 inside-out activation upon BCR stimulation
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was evaluated in CD49d+ CLL cells that were exposed in-vivo to IB. Cells col-
lected from IB-CLL on t30 (n=7), showed slightly decreased (79-86%) CD49d,
CD29, and IgM MFI levels compared to pre-treatment cells. Despite an overall
impairment of BCR-dependent Ca++ signaling (mean Ca++ release: 12.4% at
pre-treatment, 3.6% at t30), IgM stimulation increased both VLA-4 RO (mean
0.53-range 0.40-0.73-, compared to 0.36-range 0.22-0.52-, at pre-treatment,
p=0.004; 0.53-range 0.41-0.84-, compared to 0.27-range 0.01-0.45-, at t30,
p=0.010) and CLL cell adhesion (mean values of adherent cells/control= 4.6
vs 3.7 at pre-treatment and 4.5 vs 1.6 at day 30). Similarly, cells from IB-CLL
on day 60-90 of treatment (n=3) kept showing an increased VLA-4 RO upon
IgM stimulation (from 0.14, range 0.10-0.17 to 0.34, range 0.20-0.56), although
Ca++ release was relevantly decreased.
Figure 1.
Summary/Conclusions: BCR triggering in CLL cells activates VLA-4 via an
inside-out pathway at least in part independent from IB binding to BTK. CD49d+
cells retain VLA-4 activation after IB treatment, with implications for CLL cell
adhesion, and treatment-induced lymphocytosis. These observations should
be considered in the design of IB therapies.
CLL - Efficacy and safety of new treatments 1
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Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differen-
tiated safety profile from other PI3Kδ inhibitors, and proven activity in patients
(pts) with advanced hematologic malignancies. TGR-1202 is in clinical devel-
opment as monotherapy and in combination with the glycoengineered CD20
mAb, ublituximab (UTX).
Aims: An integrated-analysis was conducted of pts dosed with TGR-1202
monotherapy or combined with ublituximab with a focus on outcomes in
patients with CLL/SLL.
Methods: In both studies, there were no limits on prior therapies (Tx) and
TGR-1202 was administered once-daily and escalated in 3 + 3 design with
expansion cohorts explored. In the combo study, UTX was administered at a
fixed dose of 900 mg per infusion. The primary endpoint was safety and efficacy
was a secondary endpoint.
Results: Across both studies, a total of 152 pts (81 monotherapy/71 combined
with UTX), including 40 CLL/SLL and 112 NHL patients were exposed to at least
one dose of TGR-1202. Median age 65 yrs (22-86); 100 M/52 F; median # prior
Tx=3 (1-14); 53% refractory to immediate prior Tx. Most frequent reported AE’s
(all grades; Gr 3/4): nausea (44%; 1%), diarrhea (42%; 2%), fatigue (36%; 3%),
vomiting (23%; 0%) and neutropenia (19%; 16%). AST/ALT increase was 6%
(3% Gr 3/4), pneumonia 6% (5% Gr 3/4) and pneumonitis 1% (<1% Gr 3/4). 64
pts received TGR-1202 for ≥6 mos, 33 for ≥1 year, with longest on >30 mos.
Discontinuations due to AE’s occurred in 8% of pts. Across both studies, 27
CLL/SLL pts received the therapeutic targeted dose of ≥800 mg (17 single agent,
10 combo with UTX) and were evaluable for efficacy. 48% of CLL patients exhib-
ited high-risk cytogenetics (17p and/or 11q del). The combined ORR was 89%
(4% CR) of which 22% had persistent lymphocytosis (all PR-L pts were on
monotherapy). The median PFS in CLL was 24 mo (95% CI: 7.4, NR) as a
single agent, and has not been reached for the TGR+UTX combo.
Figure 1.
Summary/Conclusions: TGR-1202 has exhibited a markedly differentiated
safety profile from other PI3Kδ inhibitors to date with few discontinuations due
to AE’s and limited G 3/4 events. In particular we highlight the minimal rates of
transaminitis / pneumonitis / colitis events across a large CLL/NHL population.
Robust activity was observed in CLL, leading to a global Phase 3 trial evaluating
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TGR-1202 in combination with UTX in treatment naïve and relapsed CLL.
Based on the safety profile observed to date, combination Phase 1 & 2 trials
exploring TGR-1202+ibrutinib, and the triple combinations of TGR-1202+
UTX+ibrutinib, and TGR-1202+UTX+pembrolizumab are ongoing. TGR-1202
is also being evaluated in a Phase 2 study in CLL patients intolerant to a BTK
or PI3K delta inhibitor.
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Background: A global named patient program (NPP) was opened in numerous
countries worldwide in order to allow access to ibrutinib for eligible patients
with relapsed/refractory chronic lymphocytic leukemia (CLL) prior to approval
in those countries. This program provides real-world data on estimated out-
comes with ibrutinib across a large, global CLL population.
Aims: To use real-world data from the ibrutinib CLL NPP to investigate whether
treatment benefits reported in randomized clinical trials are reflected in out-
comes observed in clinical practice.
Methods: In an analysis of ibrutinib ordering/reordering, we estimated patient
time on treatment in order to provide a conservative approximation of progres-
sion-free survival (PFS) using Kaplan-Meier analysis and Cox proportional haz-
ards regression. Reordering data were censored at the date of last ibrutinib
supply or resupply (ibrutinib was resupplied every 1-3 months depending on
stage of the NPP). Patients transferring to commercial ibrutinib after approval
were censored at the time of NPP closure in their country.
Figures.
Results: Overall, 2908 patients with CLL from 30 countries participating in the
global NPP were included in this analysis; median age was 69 years, and 66.3%
were male. After 12 months, 77.3% (95% CI, 74.7-79.6%) of the global popu-
lation remained on treatment. This estimate is similar to the 12-month time on
treatment (81.5% [95% CI, 75.3-86.3%]) and PFS (83.8% [95% CI, 77.8-
88.3%]) rates observed in the phase 3 RESONATETM study of ibrutinib for
relapsed/refractory CLL (inclusion criteria were similar for the CLL NPP and
the RESONATETM trial). Moreover, Kaplan-Meier curves for time on treatment
for the global CLL NPP population and the RESONATETM study were not sta-
tistically different (Figure 1A; CLL NPP versus RESONATETM: HR, 1.20 [95%
CI, 0.86-1.67]). Limited baseline demographic information collected at NPP
enrollment allowed an exploration of time on treatment via multivariate analysis
(Figure 1B). Younger patients or those achieving complete/partial response to
prior therapy had significantly longer time on treatment. Strong trends indicating
longer time on treatment were observed for patients who had received fewer
prior lines of therapy, as well as for male patients, those who were diagnosed
with CLL within the last 5 years, and those with a progression-free interval of
≥3 months prior to ibrutinib treatment. Neither refractory disease (defined as
no response to prior therapy [ie, stable disease or progression]) nor duration
of response to prior therapy additionally impacted time on treatment. In total,
332 patients (11.4%) discontinued treatment during the observation period, the
most common reasons being death (4.2%), disease progression (1.9%), and
adverse events (1.7%).
Summary/Conclusions: Although NPP data are based on physician declara-
tions and are unmonitored, this analysis provides a real-world estimate of time
on treatment, which can be considered a conservative proxy for PFS. The esti-
mates, determined from a large, global CLL population, were similar to those
reported for RESONATETM, suggesting that results observed in ibrutinib clinical
trials are reproducible in clinical practice.
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Background: Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-
2 inhibitor. High overall response rates (ORR, 79%) and complete response
rates (CR, 20%) were attained in a first-in-human dose-escalation study (M12-
175) of VEN monotherapy in patients (pts) with relapsed/refractory (R/R) chronic
lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The addi-
tion of monthly rituximab (R; months 1-6) in combination with VEN is being
evaluated in an ongoing phase 1b dose-escalation study (M13-365) and as of
28Oct2015, the observed ORR is 86% and the CR rate is 47%. Entry criteria
for the two studies were similar, but distribution of pt demographic and disease
characteristics differed.
Aims: To assess the effect of adding R to VEN on response rate as well as on
the quality and duration of the response, relative to VEN monotherapy using
post hoc exploratory multivariable analyses.
Methods: Analyses used a cutoff of 25 Aug 2015 for M12-175 and 28 Oct 2015
for M13-365. The median follow-up was 17 and 21 months for M12-175 and
M13-365, respectively. Demographic and disease characteristics were analyzed
if their distribution differed between the studies and/or they had been identified
as VEN response-modifiers in prior exploratory analyses (Roberts et al, NEJM
2016). Included variables were: age, number of prior therapies received (<3 vs
≥3), maximum lymph node diameter (≤5 vs >5cm), 17p status by FISH (not
deleted vs deleted), and VEN dose (evaluated using assigned dose cohort in
each study: 400 vs <400mg [150, 200, 300mg] or >400 mg [500, 600, 800mg]).
Pt inclusion required available data for all variables analyzed. Forward stepwise
selection was applied for the model, starting with therapy (VEN plus R vs VEN
monotherapy); a significance threshold of p<0.2 was used to add or remove
variables to/from the model. Logistic regression analyses were performed for
ORR (responder vs non-responder) and CR (CR/CRi vs all other pts). A Cox
proportional hazards model was applied to evaluate differences in duration of
response (DoR).
Table 1.
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Results: Final models from stepwise regression analyses are summarized in
the table. Following selection of the final model, 157 pts were evaluated for
ORR (84, M12-175; 45, M13-365), 156 for CR (83, M12-175; 45, M13-365),
and 105 for DoR (66, M12-175; 39, M13-365). Combination therapy did not
influence ORR relative to VEN monotherapy (odds ratio: 1.142 [95% CI: 0.433-
3.015]; p=0.79). Responses of CR/CRi were more likely with combination ther-
apy (odds ratio: 3.292 [95% CI: 1.527-7.097]; p=0.002) and they were more
durable, with longer DoR with combination versus VEN monotherapy (hazard
ratio for progression: 0.235 [95% CI: 0.078-0.703]; p=0.01). When analyzed
across both studies, pts who received <3 prior therapies were more likely to
achieve a response. Confirming prior exploratory analyses, pts with maximum
nodal diameter ≤5 cm were more likely to achieve CR. Pts receiving <400 mg
VEN (400 mg is the phase 2 dose of VEN combined with R or monotherapy)
had shorter DoR. The effects of other variables were not significant.
Summary/Conclusions: Results of these exploratory, cross-study, post hoc
analyses support the choice of 400 mg VEN dosing and indicate higher CR
rates and longer DoR with the combination of VEN plus R after adjusting for pt
demographics and disease characteristics. VEN combined with R is currently
being evaluated in the ongoing, phase 3 MURANO study randomized against
bendamustine with R.
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Background: FCR is a standard initial therapy for younger patients (pts) with
CLL; however, only about 20% of pts will achieve complete response (CR) with
bone marrow minimal residual disease negativity (BM MRD-neg) (Boettcher et
al., 2012), which is likely a prerequisite for cure. Ibrutinib is an oral BTK inhibitor
with an excellent efficacy and safety profile in CLL. We report on the preliminary
results of an investigator-initiated, phase II study of ibrutinib plus FCR (iFCR)
as upfront treatment for young, fit CLL pts (NCT02251548).
Aims: The primary aim of this open-label, single arm, multicenter phase II
study is to determine the rate of CR with BM MRD-neg in younger CLL pts
treated upfront with iFCR. Secondary aims are to assess response rates and
safety/tolerability.
Methods: Ibrutinib 420 mg daily monotherapy is given for 7 days, and FCR
per standard dosing is added on day 8. Up to 6 cycles of FCR are given con-
currently with daily ibrutinib; growth factor support and antimicrobial prophylaxis
are mandatory. Responders continue on ibrutinib maintenance until time of
progression or unacceptable toxicity. Eligibility criteria include: age ≤65, requir-
ing initial treatment by IW-CLL criteria, ECOG PS ≤1, and adequate organ func-
tion. CTCAE v4 and IW-CLL criteria are used to evaluate toxicity and efficacy,
with response evaluations after 3 cycles, 2 mos. after final FCR, and q6 mos.
thereafter. MRD is assessed by 4-color flow cytometry (10-4 sensitivity).
Results: As of 22 February 2016, 27 pts were enrolled. The median age at
enrollment was 55 yrs (range 43-65). 7/25 (28%) had del (11q) and 1/25 (4%)
had del (17p) with TP53 mutation. Unmutated IGHV was present in 11/17
(65%), ZAP-70 was positive in 17/23 (74%), and 1/16 (6%) patient had
NOTCH1 mutation. In a 10 patient safety lead-in, there was no unexpected
toxicity. Of the 27 total pts, hematologic toxicity includes neutropenia (26%;
15% gr 3-4), thrombocytopenia (56%; 19% gr 3-4), and anemia (19%, 4% gr
3-4). All grade non-hematologic toxicities occurring in ≥15% of pts include gr
1/2 nausea (63%), fatigue (33%), bruising (33%), rash (19%), and gr 1 diar-
rhea (15%). The only bleeding event was gr 1 epistaxis in 1 pt. SAEs include
gr 4 febrile neutropenia, gr 3 atrial fibrillation, and gr 3 transaminitis in 1
patient each. In the 17 pts who have undergone re-staging after completing
the iFCR combination, the ORR is 100%, including 8/17 (47%) with CR or
CRi, all of whom are BM MRD-neg, and 9/17 (53%) with PR. The rate of
MRD-neg in the BM is 13/17 (76%), including 5 patients in PR. 8/9 pts with
PR have residual lymph nodes <2.5 cm in long axis by CT imaging. The medi-
an duration of therapy is 7.7 months (range 0.5-16.2), and 25 of the 27 pts
remain on treatment. A pt who completed 6 cycles of iFCR and achieved CR
with BM MRD-neg declined ibrutinib maintenance and remains in CR on
observation, and the pt with del(17p) achieved PR and elected to pursue allo-
geneic stem cell transplant.
Summary/Conclusions: iFCR is a highly active combination for young, fit
pts with CLL, with toxicities similar to FCR and ibrutinib given as individual
therapies. Although the ORR and CR rates are similar to FCR historical con-
trols, the 47% rate of CR with BM MRD-neg compares favorably to the 20%
rate observed on the FCR arm of the CLL8 study. Additionally, several pts
who achieved PR are BM MRD-neg, have small residual lymph nodes, and
will be monitored for conversion to CR while on ibrutinib maintenance in this
ongoing trial.
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PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN
CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT-FREE
SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS
B Stamatopoulos*, D Bruce, A Timbs, H Dreau, A Schuh
Molecular Diagnostic Center, University of Oxford, Oxford, United Kingdom
Background: The immunoglobulin heavy-chain gene (IgHV) mutational status
is considered the gold standard of prognostication in CLL and is currently deter-
mined by Sanger Sequencing (SSeq) that only allows for analysis of the major
clone. Next-generation sequencing (NGS), in the other hand, is able to highlight
multiple rearrangements within a patient. However, the prognostic significance
of multiple subclones in CLL is still unknown.
Aims: The aim of the present work was to investigate the prognostic impact of
multiple IgHV rearrangements on treatment-free (TFS) and/or overall (OS survival).
Methods: Using NGS, we sequenced the IgHV gene from 2 independent
cohorts: (I) 270 unselected CLL patient samples obtained at diagnosis with a
median follow-up of 83 months (range, 1-397) and (II) 227 patients from the
UK Arctic-Admire FCR-based clinical trial with a median follow-up of 24 months
(range, 0.1-215). The data were after correlated with TFS and/or OS.
Results: The presence of multiple rearrangements was confirmed by fluores-
cence electrophoresis of DNA fragments. We also showed that some IgHV
biclonal patients had multiple clones by flow cytometry using a CD5/CD19/Kap-
pa/Lambda staining. Accuracy of sequences obtained by NGS was validated
by SSeq. In order to control for potential PCR/sequencing errors, only the most
abundant sequences with a median depth of 32631 reads (range, 639-354763)
were used to calculate the IgHV mutational status allowing a perfect concor-
dance between SSeq and NGS. Reproducibility of results was confirmed by
independent duplicate experiments. Based on IgHV-NGS subclonal profiles,
we were able to define 5 different categories: patients with (a) multiple M clones,
(b) 1M clone, (c) a mix of M-UM clones, (d) 1UM clone, (e) multiple UM clones.
In the population obtained at diagnosis (composed of treated and untreated
patients), IgHV-NGS classification stratified patients into 5 different subgroups
with median TFS of >280 (a), 131 (b), 61 (c), 29 (d), 18 (e) months (P<0.0001)
and a median OS of >397 (a), 292 (b), 196 (c), 137 (d), 106 (e) months
(P<0.0001). The subgroups were associated with well-known prognostic factors
such as ZAP70, CD38, LPL, lymphocyte doubling time or cytogenetic abnor-
malities. In the clinical trial population (composed only of treated patients),
IgHV-NGS classification stratified patients into 5 different subgroups with medi-
an TFS of >38 (a), 37 (b), 17 (c), 19 (d) and 4 (e) months (P=0.0017). The very
favorable prognosis of patients with multiple mutated rearrangements was not
confirmed in the clinical trial population: indeed, this subgroup is composed of
85% of untreated patients in population (I) who were excluded in trial population
(II) which by definition only contains treated patients. On the contrary, the very
short median TFS of patient with multiple unmutated rearrangements was con-
firmed in both populations: patients with multiple unmutated IgHV have a sig-
nificantly shorter TFS than patients with only one unmutated rearrangement (I.
P=0.0190 and II. P=0.0359). In addition, their chance of requiring a treatment
within the 4 first years after diagnosis is associated with a positive predictive
value of 94% (I) and 90% (II).
Figure 1.
Summary/Conclusions: Here, we showed for the first time that patients with
multiple unmutated IgHV rearrangements determined by deep NGS have very
aggressive disease with a very short TFS compared to patient with only one
unmutated rearrangement. These finding will help identify patients at diagnosis
who will require early treatment and consequently closer follow-up.
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NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC
LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL
M Larrayoz1, MJ Rose-Zerilli1, H Parker1, SJ Blakemore1, J Forster1, Z Davis2,
AJ Steele1, M Else3, D Catovsky3, DG Oscier2, JC Strefford4,*
1Cancer Sciences Unit, Faculty of Medicine, University of Southampton,
Southampton, 2Department of Molecular Pathology, Royal Bournemouth Hos-
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Background: NOTCH1 is recurrently mutated in approximately 10% of patients
with Chronic Lymphocytic Leukaemia (CLL) and associates with reduced sur-
vival and Richters transformation. Whilst mutations were initially localized to
exon 34 (termed ‘coding’), recent whole genome sequencing analysis (Nature
2015, 526:519) showed additional mutations in the 3’ UTR of NOTCH1 (termed
‘non-coding’) resulting in in the same constitutive activation of Notch1. However,
the clinical impact of these mutations on patients requiring therapy, enrolled
into a clinical trial has not been ascertained.
Aims: To assess the incidence of NOTCH1 non-coding mutations in the UK
CLL4 trial and identify any associations with clinico-biological characteristics,
progression free- (PFS) and overall survival (OS).
Methods: 489 CLL patients with available material were included in this study.
High-resolution melt analysis, Sanger and high-throughput sequencing were
employed to identify NOTCH1 mutations. 
Results: We identified 47/489 (9.6%) and 11/489 (2.2%) coding and non-coding
mutations, respectively, with the latter being the those previously reported
[139390152 A>G (n=7) and 139390145 A>G (n=4), Nature 2015, 526:519] (Fig-
ure 1A). The non-coding variants constituted 19% of the total NOTCH1 muta-
tions, with 11.8% of CLL4 patients carrying either NOTCH1 mutation. NOTCH1
non-coding mutations were mutually exclusive of TP53, MYD88, RPS15 and
NFKBIE mutations (Figure 1B). When considering all 58 mutations together,
mutant NOTCH1 was associated with unmutated IGHV genes (OR:2.93,
95%CI:1.38-6.23, P=0.005), CD38 (OR:4.48, 95%CI:2.30-8.72, P<0.001) and
ZAP70 positive expression (OR:3.11, 95%CI:1.52-6.37, P=0.002) and the pres-
ence of trisomy 12 (OR:4.00, 95%CI:2.16-7.38, P<0.001). For non-coding muta-
tions in isolation, only the association with trisomy 12 remained significant
(OR:5.55, 95%CI:1.64-18.83, P=0.006). We analysed the impact of the two
types of NOTCH1 mutations on survival. Considered together, coding and non-
coding mutations were associated with a significant reduction in OS and PFS
with medians of 53.4 months versus 74.7 months (HR:1.63, 95%CI:1.22-2.17,
P=0.001) and 19.3 versus 27.7 (HR:1.59, 95%CI:1.20-2.11, P=0.001), respec-
tively, compared to wild-type patients. Considered separately, NOTCH1 non-
coding and coding mutations presented a significantly shorter OS than wild-
type patients (median 43.2, 54.8 and 74.6 months to death, respectively,
P=0.012 and P=0.013, respectively) (Figure 1C). Only coding NOTCH1 muta-
tions were significantly associated with reduced PFS compare to wild-type
(median 22.0 versus 27.7 months, respectively, P=0.005) (Figure 1D). How-
ever, whilst not statistically significant, UTR mutations did exhibit reduced PFS
(median 12.72, P=0.055) compared to wild-type patients. Cases with non-cod-
ing NOTCH1 mutations were 80% (HR: 1.80, 95%CI: 0.99-3.28, P=0.055) more
likely to progress and two-fold more likely to die (HR: 2.14, 95%CI: 1.17-3.92,
P=0.013) than wild-type patients at last follow-up. When non-coding and coding
mutations were combined, two additional features were noted: 1) combined
NOTCH1 status captured 11 more of both PFS and OS events compared to
coding mutations alone, and 2) a trend was observed between the presence of
NOTCH1 mutations and death from Richters transformation (P=0.062).
Figure 1.
Summary/Conclusions: NOTCH1 non-coding mutations constitute 19% of the
total NOTCH1 truncating mutational burden in patients requiring treatment in
the UK CLL4 trial. Importantly, these non-coding mutations have a comparable
impact on OS after first-line treatment with chemotherapy. This work supports
the detection of non-coding NOTCH1 mutations in patients requiring therapy.
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Background: Idelalisib (IDELA) is an oral PI3Kδ inhibitor approved within the
EU for use with rituximab in pts with relapsed CLL and as first-line treatment of
CLL with either del(17p) or TP53 mutation in patients unsuitable for chemo-
immunotherapy. This open-label study (NCT01659021) compared IDELA + ofa-
tumumab (OFA) vs OFA in pts with relapsed CLL. Results of the primary end-
point analysis were previously reported (Robak et al, EHA 2015) and are updat-
ed here with an additional 8.5 mos of follow-up. In the primary analysis, the
combination yielded superior PFS and the KM estimated median OS was 20.9
and 19.4 mos in the IDELA + OFA and OFA arms, respectively.
Aims: To evaluate the safety and efficacy of IDELA + OFA vs OFA alone in
patients with relapsed CLL.
Methods: Pts with CLL progressing ≤24 mo from last therapy, who had received
≥2 cycles of a purine analogue or bendamustine, were randomized 2:1 to either
Arm A (IDELA 150 mg BID continuously plus OFA, 300 mg IV wk 1, then 1 g IV q
wk x 7 and q 4 wk x 4) or Arm B (OFA, same as Arm A except 2 g was substituted
for 1 g dosing) with stratification factors relapsed vs refractory, del(17p) and/or
TP53 mutation, and IGHV mutation. The primary endpoint was PFS as determined
by an Independent Review Committee using modified IWCLL 2008 criteria.
Results: Pt characteristics were balanced in the 2 arms: med age 67; Rai
II/III/IV 18/13/51%, med no. prior regimens 3, refractory 49%, del(17)p/TP53mut
40%, IGHV unmut 78%. Exposure, disposition, and efficacy are shown in the
table. Results were consistent across risk groups. Gr ≥3 AEs in Arm A included
diarrhea/colitis (23.1%), pneumonia (19.7%), and pneumonitis (4.6%).
Table 1.
Summary/Conclusions: With >8 mos longer follow-up, IDELA + OFA vs OFA
continues to show superior PFS and ORR, and now demonstrates superior OS in
pts with del(17p)/TP53mut and a trend of improvement of OS in the ITT population.
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AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC
FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3
RANDOMIZED STUDIES
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Background: The International Prognostic Index for patients (pts) with chronic
lymphocytic leukemia (CLL-IPI) is a scoring system with prognostic value for
overall survival (OS) in untreated CLL (Bahlo J et al. Haematologica 2015; 100:
313), but has not been studied in relapsed/refractory (R/R) CLL or in the context
of novel agents. The CLL-IPI is a risk-weighted model consisting of 5 risk factors:
age (relative weight, 1), stage (1), β2-microglobulin (2), IGHV mutation status
(2), and del(17p)/TP53 mutation (17p-/TP53M) (4). Since IDELA is active in CLL
with 17p-/TP53M, which is a major contributor to the CLL-IPI, we hypothesized
that IDELA would overcome the negative impact of a high CLL-IPI.
Aims: 1) To assess the prognostic utility of CLL-IPI in R/R CLL in IDELA phase
3 randomized trials; 2) To determine if IDELA overcomes the negative impact
of a high CLL-IPI; 3) To identify independent risk factors for OS in pts with R/R
CLL and in pts treated with IDELA
Methods: The CLL-IPI was analyzed among 460 pts with R/R CLL requiring
treatment who received IDELA+rituximab (R) vs placebo+R (NCT01539512),
or IDELA+ofatumumab (O) vs O (NCT01659021). Subgroup analyses were
conducted in 274 pts treated with IDELA+R or IDELA+O (IDELA cohort) and
186 pts treated with R or O (Control). Median OS was estimated using the
Kaplan-Meier method for the 4 CLL-IPI risk groups: low (score 0-1), interme-
diate (2-3), high (4-6), and very high (7-10). The log-rank test was used to
compare survival distributions across CLL-IPI risk groups. Multivariate analyses
of prognostic factors for OS were performed. Factors with a p-value of <0.1 in
the univariate analysis (log-rank test) were included in the multivariate analyses
(Cox proportion hazards model).
Results: Most pts with R/R CLL have very high (40.9%) and high risk CLL-IPI
(49.6%), and intermediate (8.3%) and low risk CLL-IPI (1.3%) are rare. Notably,
only 0.6% pts with R/R CLL were Rai 0/Binet A. At a median follow-up of 14.7
months, the CLL-IPI score was validated in pts with R/R CLL with significant
differences in OS across CLL-IPI risk groups (p=0.0001). In subgroup analyses,
the CLL-IPI was prognostic for OS in the Control (p=0.0007) but not in the
IDELA cohort (p=0.086). In the multivariate analyses: 17p-/TP53M, B2M, LDH
and Karnofsky performance status (KPS) were independently prognostic for
OS in pts with R/R CLL. While B2M, KPS and 17p-/TP53M were independently
prognostic for OS in the Control cohort, only LDH and age were independently
prognostic for OS in the IDELA cohort.
Table 1.
Figure 1.
Summary/Conclusions: Although low/intermediate-risk CLL-IPI is uncommon
in R/R CLL, the CLL-IPI may be prognostic for OS in this population. These
data suggest that IDELA overcomes the negative impact of high-risk CLL-IPI.
While 17p-/TP53M, B2M, LDH and KPS were prognostic for OS in pts with
R/R CLL, the current analysis indicates that only age and LDH may be prog-
nostic for OS in pts treated with IDELA in combination with an anti-CD20 mon-
oclonal antibody. Additional work is needed to develop adjusted risk models
for pts with R/R CLL and for pts treated with targeted agents.
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AN EVALUATION OF OUTCOMES
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Background: There have been reports of rapid decline leading to death in
patients with CLL following discontinuation of B-cell receptor pathway-targeted
therapy (Jain, et al. Blood. 2015;125(13):2062-7). Idelalisib (IDELA) is a first
in class PI3Kδ inhibitor which inhibits multiple signaling pathways, including
those downstream of the B-cell receptor, CXCR4, and CXCR5. It is adminis-
tered orally until disease progression or intolerance. Outcomes of patients with
CLL who discontinued IDELA treatment either due to progressive disease (PD)
or adverse events (AEs) have not been described comprehensively.
Aims: The objective of this post hoc analysis was to examine the outcomes of
patients with R/R CLL who discontinued IDELA.
Methods: Data were pooled for patients with R/R CLL who were randomized
to treatment with either IDELA+ofatumumab (n=173) in Study 119 or IDELA+rit-
uximab (n=110) in Study 116 (including long-term follow up in extension Study
117). Time-dependent endpoints were calculated from the dates of IDELA dis-
continuation, including: time to next therapy (TTNT), and time to death (TTD).
Kaplan-Meier analysis was used to estimate overall survival (OS) from the date
of randomization. Subgroup OS analyses were performed using the integrated
safety data set.
Results: Of 283 patients in the safety population, 124 (44%) remained on
IDELA, 28 (10%) discontinued due to PD (22 CLL progressions and 6 Richter’s
transformations (RT), and 131 (46%) discontinued for reasons other than PD.
Presence of -17p/TP53 mutation at baseline was reported for 54% of patients
who discontinued due to PD, 41% of patients who discontinued due to AEs,
and 37% of patients who remained on IDELA treatment. The clinical outcomes
for those patients who discontinued IDELA treatment due to PD are tabulated.
Table 1.
Summary/Conclusions: In contrast to reports for other B-cell receptor path-
way inhibitors, discontinuation of IDELA due to progression of CLL does not
appear to be associated with shortened survival.
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ASSOCIATION BETWEEN KIR/HLA GENOTYPE AND OUTCOME IN THE
CLL11 STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
RECEIVING CHLORAMBUCIL ALONE OR IN COMBINATION WITH
OBINUTUZUMAB OR RITUXIMAB
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Background: Interaction between killer cell immunoglobulin-like receptors
(KIRs) and HLA class I molecules results in negative regulation of natural killer
(NK) cells. Depending on an individual’s KIR/HLA genotype, the number of
possible inhibitory KIR/HLA interactions can range from 1-3. Previous analyses
suggest a negative correlation between response to monoclonal antibody ther-
apy and number of KIR/HLA interactions, with a lower number resulting in
increased NK cell activation and a stronger response to treatment. Findings
from in-vitro studies suggest that inhibitory signaling through KIRs observed
with the conventional anti-CD20 antibody rituximab (R) may be overridden by
the enhanced NK-cell activation associated with the glycoengineered anti-
CD20 antibody obinutuzumab (GA101; GAZYVA/GAZYVARO; G).
Aims: To analyze the association between KIR/HLA genotype and treatment
outcome using data from the CLL11 study (NCT01010061) comparing chlo-
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rambucil (Clb), R plus Clb (R-Clb), and G plus Clb (G-Clb) as first-line treatment
in patients (pts) with CLL.
Methods: Pts with available DNA who provided informed consent for genomic
analysis were included. Genotyping was performed for the inhibitory KIR genes
2DL1, 2DL2/3 and 3DL1 and their respective HLA ligands HLA-C2, HLA-C1
and HLA-Bw4. Multivariate Cox regression analysis was performed to deter-
mine the association between number of KIR/HLA interactions (based on the
presence of a receptor-ligand pair) and progression-free survival (PFS). Overall
response rate (ORR) and minimal residual disease (MRD) negativity at end of
treatment by number of KIR/HLA interactions was also evaluated. In the main
analysis, pts carrying genes for 1 or 2 interactions (1-2i) were compared with
pts carrying genes for all 3 interactions (3i). As this was an exploratory analysis,
p-values were not adjusted for multiple testing.
Results: In total, 489 pts were included in the analysis (Clb, n=74; R-Clb,
n=203; G-Clb, n=212). The number of KIR/HLA interactions was: 1 in 104 pts
(21%); 2 in 221 pts (45%); and 3 in 164 pts (34%). In the Clb arm, KIR/HLA
genotype did not significantly influence PFS (median PFS: 1-2i, 11.1 months
[mo]; 3i, 10.6 mo; adjusted HR 0.75, 95% CI 0.42-1.34, p=0.33). The impact of
KIR/HLA genotype on PFS tended to be stronger in pts treated with R-Clb
(median PFS: 1-2i, 18.0 mo; 3i, 14.7 mo; HR 0.79; 95% CI 0.56-1.10; p=0.16)
or G-Clb (median PFS: 1-2i, 29.6 mo; 3i, 22.9 mo; HR 0.69, 95% CI 0.47-1.00,
p=0.05). A similar effect was seen for ORR, although differences were not sta-
tistically significant (Clb: 1-2i, 31% vs 3i, 39%; R-Clb: 1-2i, 70% vs 3i, 59%; G-
Clb: 1-2i, 79% vs 3i, 71%). MRD negativity appeared higher for 1-2i pts in the
G-Clb arm (39% vs 3i, 26%), but not in the R-Clb arm (3% vs 3i, 2%); p>0.05
for both arms. No pt achieved MRD negativity in the Clb arm. Analysis of pts
with 1i vs 2i vs 3i suggested a trend of association between the KIR/HLA inter-
action number and PFS in G-Clb pts (median PFS: 33.5 mo vs 29.1 mo vs 22.9
mo, respectively; HR 1i vs 3i 0.60, 95% CI 0.36-1.00, p=0.05; HR 2i vs 3i 0.73,
95% CI 0.49-1.10, p=0.13).
Summary/Conclusions: Pts with a lower number of KIR/HLA interactions
appeared to have a consistently better outcome across a number of efficacy
parameters when treated with anti-CD20 antibodies; the strongest effect was
observed in the G-Clb arm. These findings warrant investigation of combined
KIR-blockade with anti-CD20 antibody treatment in pts with CLL to decrease
the impact of these inhibitory interactions on antibody-dependent cell-mediated
cytotoxicity.
CLL - Efficacy and safety of new treatments 2
P217
IMPROVEMENT IN QUALITY OF LIFE AND WELL-BEING IN OLDER
PATIENTS WITH TREATMENT-NAÏVE (TN) CLL: RESULTS FROM THE
RANDOMIZED PHASE 3 STUDY OF IBRUTINIB (IBR) VERSUS CHLORAMBUCIL
(CLB) (RESONATE-2(TM))
P Ghia1,*, A Tedeschi2, PM Barr3, T Robak4, C Owen5, O Bairey6, P Hillmen7,
NL Bartlett8, J Li9, D Simpson10, S Grosicki11, S Devereux12, H McCarthy13,
S Coutre14, F Offner15, C Moreno16, C Zhou17, L Styles17, DF James17,
TJ Kipps18, JA Burger19
1Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raf-
faele, 2Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy, 3Wilmot Cancer
Institute, University of Rochester, Rochester, United States, 4Medical University
of Lodz and Copernicus Memorial Hospital, Lodz, Poland, 5Tom Baker Cancer
Centre, Calgary, Canada, 6Rabin Medical Center, Beilinson Hospital and Sack-
ler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 7The Leeds Teaching
Hospitals, St. James Institute of Oncology, Leeds, United Kingdom, 8Washing-
ton University School of Medicine, Saint Louis, United States, 9Jiangsu Province
Hospital, Nanjing, China, 10North Shore Hospital, Auckland, New Zealand,
11Department of Cancer Prevention, School of Public Health, Medical University
of Silesia, Katowice, Poland, 12Kings College Hospital, London, 13Royal
Bournemouth Hospital, Bournemouth, United Kingdom, 14Stanford University
School of Medicine, Stanford, United States, 15University Hospital Gent, Gent,
Belgium, 16Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 17Pharma-
cyclics LLC, an AbbVie Company, Sunnyvale, 18University of California San
Diego, Moores Cancer Center, San Diego, 19The University of Texas MD Ander-
son Cancer Center, Houston, United States
Background: CLL primarily affects older pts who often have comorbidities and
disease-related immunosuppression. Improvement of health-related quality of
life (QOL) is an important therapy endpoint. In pts with CLL, QOL per EORTC
QLQ-C30 is significantly compromised (Holtzer-Goor Qual Life Res 2015). Ibr
is the first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase approved
for CLL pts with ≥1 prior therapy. Ibr was associated with improvement in QOL
in R/R CLL pts on RESONATE study (Barrientos ASH 2014). The recent phase
3 PCYC-1115 trial (RESONATE-2) showed superior PFS, OS, response, and
hematologic improvement with ibr vs clb in older TN pts with CLL, with a favor-
able safety profile (Burger NEJM 2015).
Aims: To evaluate outcomes associated with pt well-being from RESONATE-
2 in 1st-line CLL.
Methods: After informed consent, TN pts ≥65 years (yrs) received 420 mg ibr
once daily until progression or clb for up to 12 cycles. Patient-reported QOL
was measured by change from baseline to each assessment time for FACIT-
Fatigue (F) and QLQ-C30 in the ITT population.
Figure 1.
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Results: In 269 randomized pts, median age was 73 yrs (≥70 yrs in 70%) and
69% had comorbidities (CIRS score >6, reduced creatinine clearance, or ECOG
status 2). Median follow-up was 18.4 mo. Ibr resulted in greater improvements
over time compared to clb in FACIT-F (P=0.0004) and QLQ-C30 global health
(P=0.0002) by repeated measures (Figure 1). Baseline hemoglobin (Hb) cor-
related with FACIT-F; Hb improvement was associated with meaningful
improvement in fatigue. Sustained improvement in hematologic function
occurred in 84% of ibr pts with baseline anemia and 77% with baseline throm-
bocytopenia (vs 45% and 43% for clb), both occurring earlier with ibr; median
time to first sustained improvement in Hb was 4 mo (vs 12 mo with clb;
P=0.0003) and in platelets was 3 mo with ibr (vs 11 mo with clb; P=0.0269).
Lymph node (LN) and spleen reductions ≥50% occurred in 95% and 95% of
ibr pts vs 40% and 52% with clb, with complete resolution in lymphadenopathy
and splenomegaly in 42% and 56% vs 7% and 22%, respectively. At first
assessment (4 mo), median reductions of 73% in LN and 72% in spleen
occurred with ibr vs 17% and 17% with clb. Disease symptoms including
fatigue, night sweats, and weight loss improved more frequently with ibr vs clb.
No decrement in median IgG or IgM levels was observed for ibr, with relative
increase in IgA. Median exposure for ibr was 17.4 mo vs 7.1 mo for clb. Most
frequent ibr adverse events (AEs) were largely mild (grade 1) including diar-
rhea, fatigue, cough and nausea. Atrial fibrillation occurred in 8 pts on ibr (6
within the first 6 mo), which was largely grade 1-2 with 2 grade 3 events. Anti-
coagulants and antiplatelet agents were frequently used (53% of pts), most
commonly aspirin. Major hemorrhage was observed in 6 ibr pts including 2
within first 6 mo, 3 during mo 6-12, and 1 during mo 12-18. Clb arm had 2
major hemorrhages, 1 each in first 6 mo and 6-12 mo. The exposure-adjusted
infection rate for pts treated with ibr vs clb was 7.5 versus 10.1 per 100 patient-
mo. Grade ≥3 infections decreased with time for ibr. AEs leading to ibr discon-
tinuation were infrequent with most occurring during first 6 mo. 87% of pts con-
tinued ibr.
Summary/Conclusions: In TN CLL pts, ibr compared with clb was associated
with greater improvements in QOL and hematologic function, as well as reduc-
tion in disease burden. The safety profile was favorable allowing for 87% of
this elderly population with frequent comorbidity to continue therapy after medi-
an 1.5 yrs of follow-up.
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Background: TP53 aberrations (del(17p) and/or TP53 mutations) are well-
characterized as a prognostic marker in chronic lymphocytic leukemia (CLL).
However, subclonal TP53 aberrations as low as 0.3% allelic burden has been
demonstrated to result in as poor survival as for patients (pts) with clonal TP53
aberrations (Rossi et al. Blood. 2014, Nadeau et al. Blood. 2016). As low allelic
burden TP53 mutations are expected to influence choice of treatment for pts
with CLL, it is of the outmost importance to develop a robust, reproducible,
and sensitive assay. We here describe the development of an assay refining
the detection of subclonal levels of TP53 as low as 0.1% based on algorithms
combined with a dilution step.
Aims: To establish a clinical tool to evaluate very small subclonal TP53 aberrations.
Methods: Purified DNA from four CLL pts with known clonal levels of TP53
mutations (detected by Sanger) were diluted with wild type (wt)-TP53 DNA to
10%, 1%, and 0.1%. wt-TP53 DNA was used as reference. Twenty-one ampli-
cons of approximately 180 base pairs (bp) lengths covering TP53 exons 2-10
were generated and in order to minimize the error rate of nucleotide incorpora-
tion a proofreading DNA polymerase was used. Amplicons were purified, adaptor
ligated, and sequenced using targeted next generation sequencing (tNGS). All
sequences were trimmed 5’ and 3’ to remove primer DNA in silico. To diminish
background noise, variants were only called if a minimum of 10 reads of the
aberration were detected, and only if variants were also present in a dilution at
the expected frequency. The same method was applied with four breast cancer
pts with known clonal levels of TP53 insertions or deletions (INDELS), to test
performance of our algorithm with INDELS. These samples were first diluted
with wt-TP53 DNA into subclonal levels (5% patient DNA) and then further dilut-
ed in a 1:3 and 1:10 ratio. We further optimized our test by reducing the number
of 180-220 bp amplicons needed to cover TP53 exons 2-10.
Results: With a median coverage of 30,587x (range: 0-94,696x, with 85%
>13,331x) and 41,465x (range: 134-113,468x, with 85% >14,116x) for the pts
with CLL and breast cancer respectively, we were able to detect the known
mutations in all eight samples (3 substitutions, 3 deletions, and 2 insertions).
One CLL sample also contained a previously unknown subclonal substitution.
All background noise could be clearly eliminated in silico with the inclusion of
the dilution step. Including a 1:3 or a 1:10 dilution step showed same results.
The current detection level for the assay is approximately 0.1% allelic burden
(Figure 1). However, mutations were still detectable as low as 0.02% allelic
burden. One single variant call within the tested eight samples was above 0.3%
allelic burden but discarded as background noise (163 reads at 51,000x) based
on our novel dilution algorithm. This false positive aberration would have been
called as a true mutation with the cut-off based on statistical algorithms used
by other groups in previous publications.
Figure 1.
Summary/Conclusions: We here describe for the first time the development
of a more robust tNGS assay enabling the detection of very low allelic burden
TP53 mutations. At the same time, false positive variant calls can be discarded
based on the inclusion of a dilution step, while the sensitivity for both substitu-
tions and INDELS is as low as 0.1%. The assay is undergoing further validation
in a retrospective cohort of pts with CLL. The assay will subsequently be imple-
mented as part of the diagnostic tools available at Copenhagen University Hos-
pital, Rigshospitalet.
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PATIENTS TREATED WITH REDUCED DOSE IBRUTINIB: RESULTS FROM
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Background: Ibrutinib (Ibr) is a first-in-class oral covalent inhibitor of Bruton’s
tyrosine kinase (BTK). Ibr is dosed according to guidelines for chronic lympho-
cytic leukemia (CLL) patients at 420mg daily to achieve >90% BTK occupancy
(≥2.5mg/kg/day). Although fewer patients achieve >90% occupancy at <420mg
daily, it is unknown whether lower Ibr doses translate into inferior outcomes.
To address this question, we conducted a multi-center study to capture expe-
riences of CLL patients treated with Ibr below suggested starting doses.
Aims: This study evaluated survival outcomes for CLL patients treated with
Ibr at reduced doses.
Methods: We conducted a multi-center, IRB approved, retrospective study of
all Ibr-treated CLL patients between 1/2010 and 10/2015. Demographics, Ibr
dose, clinical responses, and outcomes were recorded. Reduced Ibr dose was
defined as sustained (≥2 months) dosing at <420mg/day, either at treatment
initiation or within 3 months of initiation. The primary study endpoints were pro-
gression-free survival (PFS) and overall survival (OS), estimated by the Kaplan
Meier method and stratified by Ibr dose (standard dose versus reduced dose).
For comparison, log rank tests and Cox regressions were performed.
Results: 197 Ibr-treated CLL patients were identified (83% with relapsed or
refractory disease). 37 patients (19%) received reduced dose Ibr. Median fol-
low-up time was 13.5 months. For reduced dose patients, median dose was
4.3mg/kg/day (4% <2.5mg/kg/day). The most common reasons for reducing
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Ibr dose were GI toxicity, bleeding, rash, cardiotoxicity, and pre-existing renal
insufficiency. 5% of patients in the reduced dose group were taking a mild-
moderate CYP3A4 inhibitor. The best overall response rate (CR+PR+PR-L)
for the entire cohort was 85%, versus 84% in the reduced dose group. Median
PFS for standard dose and reduced dose cohorts were 37.4 months and not
reached, respectively (p=0.6, LR test). Median OS for standard dose and
reduced dose cohorts were both not reached (p=0.5, LR test). Ibr dose did not
impact PFS (1.2, 95% CI 0.5-2.6) or OS (0.6, 95% CI 0.14-2.7).
Figure 1.
Summary/Conclusions: We describe the largest real-world experience of
reduced dose Ibr in CLL patients. Reduced Ibr doses do not appear to affect
clinical outcomes. Most patients treated with doses <420mg/day achieve a dose
of >2.5mg/kg/day, and therefore adequate BTK occupancy. Weight-based dosing
should be considered in future studies and pharmacoeconomic analyses. Com-




PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS
SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH
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Background: Cytogenetic abnormalities detected by FISH define prognostic
groups in chronic lymphocytic leukemia (CLL). Complex karyotypes (CK) confer
poor prognosis in patients treated with chemoimmunotherapy and novel agents.
However, only 28-50% of patients with CK carry TP53 deletions [delTP53]. The
relationship between delTP53 and CK, and its clinical impact, remain to be elu-
cidated.
Aims: 1. To describe the clinico-biological profile of CLL and monoclonal B-cell
lymphocytosis (MBL) patients regarding the karyotype complexity by chromo-
some banding analysis (CBA) 2. To compare the clinical outcome of patients
with CK lacking high-risk FISH deletions (HR-FISH), TP53 and/or ATM, and
those with HR-FISH and non-CK.
Methods: Our database comprising 2756 MBL and CLL patients from Grupo
Cooperativo Español de Citogenética Hematológica and Grupo Español de
Leucemia Linfática Crónica was screened for patients with CBA results available
at diagnosis or prior to treatment. The clinico-biological data and outcome of
patients with CK (≥3 abnormalities) were compared with those with normal or <3
abnormalities [non-CK]. Time to first treatment (TFT) and overall survival (OS)
were assessed according to both karyotype complexity and HR-FISH deletions.
Results: CBA results were available for 1149 patients (703M/446F, median age
67), 199 MBL and 1050 CLL. Most karyotypes (75%) were assessed on peripheral
blood TPA-based cultures. 438/1149 (38.1%) patients displayed abnormal kary-
otypes, 82 showing a CK. CK cases showed features of more advanced and
aggressive disease than non-CK: more Binet B/C stages (23 vs 12%; P=0.008),
higher LDH (379 vs 304 IU/L; P<0.001) and β2-microglobulin (2.8 vs 2 mg/L;
P<0.001), higher positivity rates for CD38 (38% vs 21%; P<0.001) and ZAP70
(50% vs 33%; P<0.001) and increased +12 (32% vs 18%; P<0.001), delATM
(19% vs 7%; P=0.001) and delTP53 (42% vs 6%; P<0.001) by FISH. Indeed,
patients with CK showed a shorter median TFT (119m vs 43m, P<0.001) and OS
(163m vs 93m; P<0.001). Although the CK group was significantly enriched in
delTP53, only 29/78 (37.2%) patients with delTP53 showed CK. Of note, CK
negatively impacted on OS even among patients with delTP53 (132m vs 38m;
P<0.001). Categorization of patients regarding HR-FISH and CK allowed strati-
fication in terms of TFT (Figure). Nonetheless, while patients with both HR-FISH
and CK showed the worst OS (39m) being clearly distinct from those non-CK
and non-HR-FISH (not reached), survival analysis did not show significant differ-
ences between patients with only one high-risk cytogenetic marker (CK or HR-
FISH) (Figure). Similarly, no differences in OS for CK patients lacking delTP53
and those with delTP53 and non-CK were observed (209m vs 133m; P=0.795).
In the multivariate analysis for TFT and OS, both CK and delATM or delTP53
remained statistically significant (OS HR: 2.6, 2.1 and 2, respectively; P<0.001).
Table 1.
Figure 1.
Summary/Conclusions: 1. CK is associated to advanced disease and poor
prognostic markers; however, only 42% of them carry delTP53. 2. Patients with
CK lacking delTP53 show an equivalent impaired clinical evolution as those with
delTP53 and non-CK. 3. Other mechanisms than TP53/ATM dysfunction could
be responsible for the outcome of CK. A better characterization of CK patients is




LARGE SCALE, REAL-WORLD RESULTS ON IBRUTINIB FOR 428
FRENCH PATIENTS WITH 17P DELETION OR RELAPSED/REFRACTORY
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AUTHORIZATION FOR USE (ATU) PROGRAM
L Ysebaert1,*, T Aurran-Schleinitz2, C Dartigeas3, MS Dilhuydy4, P Feugier5,
AS Michallet6, O Tournilhac7, J Dupuis8, P Sinet9, C Albrecht9, F Cymbalista10
1Sce Hematologie, IUC Toulouse Oncopole, Toulouse, 2Sce Hematologie, Insti-
tut Paoli Calmettes, Marseille, 3Sce Hematologie, CHU Bretonneau, Tours,
4Sce Hematologie, CHU Bordeaux, Bordeaux, 5Sce Hematologie, CHU Nancy,
Nancy, 6Sce Hematologie, Centre Leon Berard, Lyon, 7Sce Hematologie, CHU
Clermont-Ferrand, Clermont-Ferrand, 8Sce Hematologie, CHU Henri Mondor,
haematologica | 2016; 101(s1) | 57
Copenhagen, Denmark, June 9 – 12, 2016
Creteil, 9Janssen-Cilag, Issy-les-Moulineaux, 10Sce Hematologie, Hopital Avi-
cenne, Bobigny, France
Background: Ibrutinib is an oral once-daily first-in-class covalent Bruton’s tyro-
sine kinase inhibitor approved in Europe for adult patients with CLL who have
received at least one prior therapy, or in first line in the presence of 17p deletion
or TP53 mutation in patients unsuitable for chemo-immunotherapy. We report
here the largest series of real-world results in 428 patients receiving ibrutinib
through a temporary authorization for use (ATU) granted by the French National
Agency for Medicines and Health Product Safety (ANSM).
Aims: Herein we describe key baseline characteristics and initial outcomes
for all patients with CLL/SLL submitting an access-to-ibrutinib form throughout
the period of the ATU (December 2013-November 2014).
Methods: Data reported herein represent the final report. As a real-world analy-
sis, all data are declarative in nature (by physicians in charge of the patients),
and medical files were not monitored.
Results: Among 428 CLL/SLL patients, most were male (67.1%) with a median
age of 70 years (range 33-93, 35%>75y). Median time from diagnosis was 8.1
years. 50.4% of patients had lymph nodes ≥5 cm. Binet stage was A for 7,1%,
B for 36.2% and C for 56.7%. Cytogenetic data were reported for 381 patients,
among which 45.1% had del17p and/or TP53 mutation, and 24.6% had del11q.
A median of 3 prior therapies was reported (range 0-10), including fludarabine-
cyclophosphamide-rituximab (63.6%), bendamustine-rituximab (59.8%), and
alemtuzumab (27%). Thirty seven patients had undergone prior stem cell trans-
plantation (22 allo, 15 autoSCT). At least one concomitant disease was reported
for 232 patients (54.2%), including 24.5% with vascular disorder, 16.6% with
metabolism/nutrition disorder, and 11.2% with cardiac disorder. At least one
other co-medication was reported in 66.1% of cases (including antithrombotic
agents (14%)). The risk of grade 3-4 haemorrhages were 1.6% vs 2.6%,
respectively for taking these drugs. (no or yes). After a median follow-up of 3
months (range 1-279 days), investigator-assessed ORR was 88.5% including
44.1% PR with lymphocytosis and 1.5% had progressive disease (out of 340
patients with assessable disease). The median PFS, OS and DOR have not
been reached. Definitive discontinuation of ibrutinib was reported in 14.5% of
372 evaluable patients, with main reasons including adverse drug reaction
(n=20), death (n=19), disease progression (n=8), contra-indication to pursuit
of ibrutinib (n=3), and allogeneic transplantation (n=4). In the analysis for safety,
73.4% had at least one AE, 33.2% at least one SAE (among 150 patients above
75y: 34%). Of note, frequency of SAE either in total (34% vs 33.2%) or of spe-
cial interest, infections (11.2% vs 10.7%), gastrointestinal disorders including
diarrhoea (1.9% vs 2%), and cardiac disorders including atrial fibrillation (6.3%
vs 9.3%), were not statistically increased in elderly patients.
Summary/Conclusions: This is the largest real-world analysis on ibrutinib
given for 17p deletion or relapsed/refractory CLL, covering a vast territory
(France), both in public/private practice. Efficacy and adverse events profiles
were similar to those reported from published clinical trials, especially the RES-
ONATE trial (with the acknowledged limitations inherent to such programs,
declarative nature of the data and lack of patient monitoring).
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DURABLE TREATMENT-FREE REMISSION AND EFFECTIVE RETREATMENT
IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC
LEUKEMIA WHO ACHIEVED A DEEP RESPONSE WITH VENETOCLAX
COMBINED WITH RITUXIMAB
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Background: Venetoclax (VEN) is a selective, potent, orally bioavailable BCL-
2 inhibitor. VEN monotherapy induces rapid, deep, and durable responses,
with a 79% ORR (20% CR) for patients (pts) with relapsed/refractory (R/R)
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Based on preclinical evidence of synergy, combination therapy of VEN plus rit-
uximab (R) is being assessed in an ongoing Phase 1b study. In this study, pts
with CR/CRi or MRD-negative (neg) PR may stop VEN, remain on study, and
be retreated upon disease progression by iwCLL criteria.
Aims: To assess outcomes in pts with R/R CLL who had CR/CRi or MRD-neg
PR and stopped therapy per study protocol.
Methods: Pts who achieved CR/CRi or MRD-neg PR could stop therapy and
remain on study with clinical monitoring and peripheral blood (PB) counts every
3 months. Pts who then progressed could re-initiate VEN once daily with weekly
ramp-up at 20, 50, 100, 200 to 400 mg. R could be added at month 4 or earlier
per investigator’s discretion. Responses and progression were assessed by
iwCLL criteria with CT scan and bone marrow (BM) biopsy. MRD was assessed
in blood and BM aspirates using ≥4 color flow cytometry (min sensitivity: 0.01%).
Results: 49 pts (48 CLL/1 SLL) were enrolled. Median number of prior regi-
mens was 2 (range: 1-5); 45 (90%) received prior R (14 [29%] R-refractory)
and 28 (57%) received fludarabine (9 [18%] fludarabine-refractory). 15/45
(33%) pts had del(17p) and/or TP53 mutation. Common adverse events (AEs)
were mild diarrhea, neutropenia, upper respiratory tract infection, and nausea.
As of 28Oct2015, ORR was 86% (47% CR/CRi), with 55% MRD-neg (17
CR/CRi; 10 PR). While on therapy, disease progression was observed in 7 pts,
with 4 occurring after PR, 1 after SD, and 2 had primary PD. 11 pts elected to
stop therapy after achieving MRD-neg CR/CRi (8), MRD-pos CR/CRi (2), or
MRD-neg PR (1); 9 remain in active follow-up and 2 discontinued from the
study with no evidence of progression. Demographics and disease character-
istics of these 11 pts were similar to the total study population and median time
on VEN was 9 (range: 5–36) months. As of 28Oct2015, 7/9 pts have not pro-
gressed (all MRD-neg) and remain in follow-up for a median of 8 (range: 2-25)
months off VEN. 2 pts with MRD-pos CR/CRi as best response had subsequent
asymptomatic progression off VEN. The first pt stopped VEN plus R at month
7 and had asymptomatic progression (lymphocytosis, BM infiltrate, and
splenomegaly) 24 months later. This pt was retreated with VEN monotherapy,
achieved PR after 4 months of VEN, and remains in response with ongoing
treatment. AEs reported during retreatment were all Grade 1/2 and similar to
those seen during first treatment. The second pt stopped VEN at 9 months
and had asymptomatic progression (lymphocytosis) 24 months later (PB MRD
levels increased after 14 months off VEN). This pt recently reinitiated VEN
monotherapy and has not yet had disease reassessment.
Figure 1.
Summary/Conclusions: The combination of VEN plus R induced deep
responses, with 47% pts achieving CR/CRi and 55% reaching MRD negativity
in BM. The rate of disease progression was low for pts continuing VEN with
current follow-up. Pts achieving deep responses who stop VEN per study pro-
tocol do not relapse rapidly, and treatment-free remissions can be durable, as
7 MRD-neg pts still off VEN maintain remission to date. Progression has been
observed after 24 months off VEN in two pts whose best response was MRD-
pos; preliminary data suggest that ongoing retreatment is well tolerated and
effective.
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Background: Supraventricular tachyarrhythmias, particularly atrial fibrillation
(AF), are an adverse effect of ibrutinib. In 3 phase 3 CLL studies, AF incidence
was 5-7.7%, significantly higher than seen in control arms (0.5-2.4%). AF is
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associated with deleterious effects on cardiac function and with risk of arterial
thromboembolism, particularly stroke; patients receive prophylactic anti-platelet
or anticoagulant medication according to individual thromboembolic risk (eg.
CHADS2-VASC score). The clinical consequences of tachyarrhythmias and
their optimal management in CLL patients treated with ibrutinib are unclear; in
particular, the anti-platelet effect of ibrutinib may increase bleeding risk from
thromboembolism prophylaxis.
Aims: We characterized clinical course and management of 59 CLL patients who
received ibrutinib and developed supraventricular arrhythmia (AF/flutter 56, SVT 3).
Methods: We retrospectively reviewed data from 59 patients treated from 2010-
2015 with ibrutinib 420mg/d (n=53) or ibrutinib plus rituximab (n=6): 31 patients
were treated at FILO centers (France/Belgium), 22 at MD Anderson Cancer
Center and 6 at Peter MacCallum Cancer Centre, Australia. 
Results: Median age was 70. Median time to onset was 3.8 months. Baseline
risk for AF was not increased: mean HATCH score (a risk index for AF) was
1.39, similar to an age-matched population. Hypertension requiring treatment
was present in 63% cases, similar to an age-matched population; mild-moderate
mitral regurgitation or aortic stenosis was present in 9/36 (25%) of cases with
available echocardiogram results; LVEF was <50% in 10/36 (28%) and <35%
in 5/36 (14%), with clinical congestive heart failure in 7/59 of all patients (12%)
and angina in 7 cases (12%). Recent infection (<1 month) was present 10 cases
(17%). Fifteen of 56 (27%) patients with AF/flutter had a previous history of
AF/flutter; all were in sinus rhythm when ibrutinib treatment was started. 90% of
the patients received an antiarrhythmic medication and/or procedure. Pharma-
cological antiarrhythmic therapy was: amiodarone in 19 cases (32%), flecainide
in 5 (8%), beta-blockers in 40 (68%) and calcium channel blockers in 4 cases
(6%). Seven patients underwent cardioversion; sustained conversion to sinus
rhythm was achieved in 2/7. Tachyarrhythmias were persistent in 35/59 (59%)
cases despite treatment, whether Ibrutinib was discontinued or not. 71% of
patients with atrial fibrillation/flutter had a CHADS2-VASC score ≥2, considered
an indication for anticoagulation: 48% of patients with AF/flutter received anti-
coagulation, 34% received anti-platelet therapy and 27% received neither ther-
apy. Median CHADS2/VASC score was 2 in patients who received or did not
receive thromboembolism prophylaxis. Clinical consequences of tachyarrhyth-
mias were: 3 episodes of severe cardiac failure (one fatal); 1 stroke; 8 non-
thrombocytopenic patients (13.5%) experienced grade 3-4 bleeding, including
2 subdural hemorrhages and 2 cases of hemorrhagic cardiac tamponade. Figure
1 outlines the management of ibrutinib dosing in patients with tachyarrhythmias.
Altogether, Ibrutinib was permanently discontinued due to arrhythmia in 23/59
cases (39%), limiting effective antineoplastic therapy.
Figure 1.
Summary/Conclusions: AF in ibrutinib-treated patients with CLL is frequent
and associated with significant consequences. Management, even in academic
centers, was variable. Guidelines for prevention and management of AF in
patients receiving ibrutinib are urgently required, particularly as ibrutinib use
increases in community practice.
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INTEGRATED SAFETY ANALYSIS OF VENETOCLAX MONOTHERAPY IN
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
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Background: Venetoclax is a potent, selective, oral BCL-2 inhibitor that has
activity in patients (pts) with relapsed/refractory (R/R) CLL, with an objective
response rate of >70%.
Aims: Here we report the aggregated venetoclax monotherapy safety analysis
from 3 pooled trials in R/R CLL.
Methods: An integrated safety analysis was conducted for pts with R/R CLL
who received venetoclax monotherapy in a phase 1 dose escalation and two
phase 2 trials (N=328). Pts who received the recommended phase 2 dose of
400mg once daily (QD) were analyzed for incidence and timing of adverse
events (AEs) and are reported here.
Results: Pts receiving 400 mg QD (n=279) included 181 pts with del 17p and
75 pts with previous B cell receptor inhibitor failure. As of Aug 25, 2015, the
median duration on treatment was 10.3 months and 65.6% of pts were still on
study. Discontinuation occurred in 96 pts, with 24 pts discontinuing due to
adverse events (AEs). The most common (>20% pts) AEs of any grade (Gr)
were neutropenia (38%), diarrhea (38%), nausea (36%), anemia (26%), fatigue
(24%), and upper respiratory tract infection (21%). The most common (>10%
pts) Gr 3/4 AEs were neutropenia (36%), anemia (15%), and thrombocytopenia
(13%). Cytopenias occurred early and rates decreased over time. Serious AEs
(>2% pts) were pneumonia (5%), febrile neutropenia (5%), pyrexia (3%), and
autoimmune hemolytic anemia (3%). There were 41 deaths, 11 due to AEs not
associated with disease progression. Under the most recent tumor lysis syn-
drome (TLS) mitigation guidelines, which align prophylactic measures with the
pt’s relative risk, 4/105 pts (4%) experienced laboratory TLS, all Gr 3. All TLS
events were observed within the initial 5-wk dose ramp-up and were managed
with hydration, electrolyte correction, and dose interruption. All pts were able
to resume dosing without clinical sequelae.
Summary/Conclusions: Venetoclax 400mg QD has an established and man-
ageable safety profile for the treatment of R/R CLL pts, including those who
may not be appropriate candidates for other approved treatments.
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MANAGEMENT OF TRANSAMINASE ELEVATIONS ASSOCIATED WITH
IDELALISIB
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Background: Idelalisib (IDELA), a first-in-class, selective oral PI3Kδ inhibitor,
has been associated with increased alanine transaminase (ALT) and aspartate
transaminase (AST) elevations in clinical trials. These transaminase elevations
typically occur early during treatment (median onset of 8 weeks) and are gen-
erally asymptomatic. Currently recommended management of grade ≥3 (>5-
20X ULN AST/ALT) elevation involves dose interruption with re-initiation of ther-
apy possible following resolution to grade ≤1.
Aims: This post hoc analysis evaluated outcomes following treatment-emergent
grade ≥3 ALT/AST in IDELA clinical trials.
Table 1.
Methods: An integrated analysis of safety was conducted for 1073 patients
across 9 studies: 538 with previously treated chronic lymphocytic leukemia
(CLL), 105 with untreated CLL or small lymphocytic lymphoma (SLL), and 430
with other relapsed/refractory B-cell malignancies (indolent non-Hodgkin lym-
phomas, mantle cell lymphoma, diffuse large B-cell lymphoma, Hodgkin lym-
phoma, acute myeloid leukemia, and multiple myeloma) who received IDELA
alone (doses=50 mg BID to 350 mg BID) or as part of a combination regimen
(IDELA doses=100 or 150 mg BID). Clinical laboratory findings were evaluated
for highest grade of ALT/AST elevation and summarized according to MedDRA
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and Common Terminology Criteria for Adverse Events (CTCAE) liver-related
laboratory tests and categories. Those with grade ≥3 ALT/AST elevation were
evaluated for rate of resolution to grade ≤1 ALT/AST, and recurrence of the
event at any time on study. Patients were grouped by use of IDELA alone or
as part of a combination regimen.
Results: Among patients with any disease type or regimen (N=1073), the inci-
dence of any grade ALT/AST elevation was 51%, and the incidence of grade
≥3 ALT/AST elevation was 14% (Table). Of patients with transaminase eleva-
tion, 73% (398/543) experienced grade 1 or grade 2 events. The incidences of
grade ≥3 ALT/AST elevations, and outcomes for patients with grade ≥3
ALT/AST elevation (Table) were comparable whether IDELA was used alone
or in combination. 92% of patients with grade ≥3 ALT/AST elevation were man-
aged with dose interruption and achieved resolution to grade ≤1. The majority
(69%) of patients with subsequent IDELA rechallenge experienced no recur-
rence of the event; of events that did recur, the vast majority (94%) resolved in
the analysis time period.
Summary/Conclusions: These data support the management of ALT/AST
elevation with IDELA using dose interruption at grade 3 with reintroduction
after resolution at the discretion of the treating physician. Studies Included in
this Analysis: 101-02: NCT00710528; 101-07: NCT01088048; 101-08:
NCT01203930; 101-09: NCT01282424; 101-10: NCT01306643; 101-11:
NCT01393106; 101-99 (extension): NCT01090414; GS-US-312-0116:
NCT01539512; GS-US-312-0117 (extension): NCT01539291; GS-US-312-
0119: NCT01659021
Chronic myeloid leukemia - Clinical 1
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DE-ESCALATION OF TYROSINE KINASE INHIBITOR THERAPY IS SAFE
IN CHRONIC MYELOID LEUKAEMIA IN DURABLE MOLECULAR
RESPONSE (≥ MR3 FOR ≥12 MONTHS): INITIAL RESULTS IN THE BRITISH
DESTINY STUDY
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Background: Some chronic myeloid leukaemia (CML) patients with prolonged
and deep molecular remissions on tyrosine kinase inhibitor (TKI) therapy can
discontinue treatment. However, study of this has been restricted to patients
in stable MR4 (BCR-ABL1<0.01%), and it is not known whether some patients
in stable major molecular response (MR3; BCR-ABL<0.1%) but not MR4 can
discontinue treatment. In addition, it is plausible that while some patients might
not be able to completely discontinue TKI therapy, they may be able to maintain
good molecular remissions on TKI doses that are less than standard, with con-
current improvement in any TKI-related adverse events; this has not been pre-
viously investigated.
Aims: The British DESTINY study is examining the safety and efficacy of ini-
tially de-escalating therapy to half the standard TKI dose (i.e. imatinib 200mg
daily, nilotinib 200mg twice daily, or dasatinib 50mg daily) for 12 months, then
stopping altogether.
Methods: Entrants must be in stable MR3 or better, on all PCR results (mini-
mum of 3) in the preceding 12 months, and must have received TKI for at least
3 years, and not switched TKI (except that a single switch was permitted if
solely due to intolerance). The primary endpoint is loss of MR3; monthly molec-
ular monitoring is carried out centrally.
Results: During 16 months recruitment to April 2015, 174 patients (male 98;
female 76) were recruited after giving informed consent by 20 sites. At entry,
125 (72%) were in MR4 and 49 (28%) in MR3 but not MR4; 148 were receiving
imatinib, 16 on nilotinib and 10 on dasatinib. During 12 months of de-escalation
in the first 100 patients, no deaths, disease progressions or losses of cytoge-
netic response have been seen, though 7 serious adverse events have
occurred (6 Grade 3+), all unrelated to TKI. Thirteen patients reported 14 new
events of musculoskeletal disorders since decreasing TKI therapy (all Grade
1), comprising pain, stiffness or cramps in the joints, legs, chest, neck and/or
back (13) with one additional event of arthritis. Individual side effects (lethargy,
diarrhoea, rash, nausea, periorbital oedema, hair thinning) all improve in the
first 1-2 months of de-escalation but not significantly thereafter, though the
FACT-BRM or EQ-5D Quality of Life data are already optimal at trial entry, sug-
gesting that TKI side effects in entrants do not impact Quality of Life. During
the de-escalation phase in the first 100 patients there have been 7 molecular
relapses (defined as loss of MR3 on 2 consecutive samples), occurring during
the second (1 case), third (2), seventh (1) and eighth (3) month of de-escalation.
Four of these were in the 31 patients in MR3 but not MR4 at trial entry, giving
a relapse rate of 12.9%; similarly 3 of 69 patients (4.3%) relapsed in the ‘MR4
at entry’ group. No relapses have occurred in the quartile with the shortest
duration of prior TKI treatment (less than 4.8 years), while 3 of the 7 relapses
have occurred in the quartile with the longest pre-entry TKI treatment (>10.2
years). All 7 patients have regained at least MR3 within 4 months of resumption
of standard dose TKI. Overall, 26 (84%) ‘MR3 but not MR4’ and 64 (93%) ‘MR4
at entry’ patients have proceeded to the stopping phase.
Summary/Conclusions: In this first DESTINY trial report focussed on de-
escalation, halving the standard TKI dose for 12 months in CML patients in at
least MR3 appears safe, does not compromise disease control, and is associ-
ated with a rapid improvement in side effects. Mild musculoskeletal symptoms
may occur in about 13% of patients.
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PRETREATED LEUKEMIA PATIENTS: 4-YEAR RESULTS FROM THE
PIVOTAL PHASE 2 PACE TRIAL 
JE Cortes1,*, J Pinilla-Ibarz2, PD le Coutre3, R Paquette4, C Chuah5, FE Nicolini6,
JF Apperley7, HJ Khoury8, M Talpaz9, M Baccarani10, S Lustgarten11,
FG Haluska11, F Guilhot12, MW Deininger13, A Hochhaus14, TP Hughes15,
NP Shah16, HM Kantarjian1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2H. Lee
Moffitt Cancer Center & Research Institute, Tampa, FL, United States, 3Charité
Universitätsmedizin Berlin, Berlin, Germany, 4Ronald Reagan UCLA Medical
60 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Center, University of California, Los Angeles, CA, United States, 5Singapore
General Hospital and Duke-National University of Singapore Graduate Medical
School, Singapore, Singapore, 6Centre Hospitalier Lyon Sud, Pierre Bénite,
Lyon, France, 7Centre for Haematology, Imperial College, London, United King-
dom, 8Winship Cancer Institute of Emory University, Atlanta, GA, 9Comprehen-
sive Cancer Center, University of Michigan, Ann Arbor, MI, United States, 10S.
Orsola-Malpighi University Hospital, Bologna, Italy, 11ARIAD Pharmaceuticals,
Inc., Cambridge, MA, United States, 12Inserm CIC 1402, CHU de Poitiers,
Poitiers, France, 13Huntsman Cancer Institute, University of Utah, Salt Lake
City, UT, United States, 14Jena University Hospital, Jena, Germany, 15Institute
of Medicine and Veterinary Science, Adelaide, Australia, 16University of Cali-
fornia San Francisco, San Francisco, CA, United States
Background: The approved tyrosine kinase inhibitor (TKI) ponatinib is potently
active against native and resistant BCR-ABL, including T315I. 
Aims: The pivotal phase 2 PACE trial (NCT01207440) evaluated the efficacy
and safety of ponatinib.
Methods: Patients with chronic myeloid leukemia (CML) or Philadelphia-pos-
itive acute lymphoblastic leukemia (Ph+ALL) refractory to dasatinib or nilotinib,
or with T315I, were enrolled in PACE (starting dose 45 mg once daily). All
patients gave informed consent. Dose reductions were recommended in Octo-
ber 2013 due to observed arterial occlusive events (AOEs). Efficacy and safety
at 4 years, as well as by year for chronic phase (CP) CML patients are reported
(data as of 3 August, 2015). Exposure-adjusted incidence rates of new AOEs
are reported as the number of events/100 patient-years.
Results: Of 449 patients, 59% received ≥3 prior TKIs. At analysis, 30%
(133/449) of patients (median follow-up 37.3, range 0.1–58.5 months) and 41%
(110/270) of CP-CML pts (48.2, 0.1–58.5 months) remained on study. Primary
reasons for discontinuation were disease progression (22.5% overall, 10.4%
CP-CML) and adverse events (AEs) (16.0% overall, 18.5% CP-CML). Respons-
es continued to deepen over time (Table 1, CP-CML patients) despite dose
reductions. Among CP-CML patients, estimated 4-year rates for PFS, OS, and
maintenance of major cytogenetic response (MCyR) and major molecular
response (MMR) were 56%, 77%, 82% and 61%, respectively. For accelerated
phase patients, the estimated 4-year OS was 51%; median OS for blast
phase/Ph+ALL patients was 6.9 months (95% CI, 5.0-9.2). Common (in ≥30%
of patients) treatment-emergent AEs were thrombocytopenia 44%, abdominal
pain 43%, rash 42%, constipation 37%, headache 37%, dry skin 36%, fatigue
and hypertension 30%. AOE rate/serious AOE rate was 23%/19%, including
cardio- 13%/9%, cerebro- 9%/7%, and peripheral-vascular 9%/7%. Of patients
with AOEs (n=104), 38% remained on study. Exposure-adjusted incidence rates
of new AOEs fell after the first 2 years: 15.5 Year 1, 15.7 Year 2, 10.4 Year 3,
and 9.6 Year 4. Nearly 2 years after recommended dose reductions, 87%
(114/131) and 74% (70/95) of CP-CML pts were estimated to maintain MCyR
and MMR, respectively, and 8% (6/75) of all dose-reduced pts without a prior
AOE on trial had an AOE. 
Table 1.
Summary/Conclusions: After 4 years, heavily pretreated patients continue to
show deep and lasting responses on ponatinib, and approximately 2 years post
recommended dose reductions, maintenance of response is high, and the inci-
dence of newly occurring AOEs has decreased. 
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Background: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI)
that exhibits significant efficacy as first- or second-line treatment in patients
with chronic myeloid leukemia (CML). Superior rates of deeper molecular
responses (DMR) were achieved with nilotinib vs imatinib in patients newly
diagnosed with CML in chronic phase (CML-CP) in the ENESTnd trial. Recently,
treatment free remission (TFR) is one of the goals in CML treatment. Indeed,
prospective trials suggest that imatinib therapy may be safely and successfully
discontinued in 40% of CML patients with DMR (Mahon et al, Lancet Oncol
2010, Ross et al, Blood 2013). 
Aims: The purpose of this study is to evaluate the efficacy of two-year consol-
idation by nilotinib for successful TFR in patients with CML-CP who had
achieved MR4.5 with imatinib.
Methods: Patients with CML-CP who had achieved MR4.5 (BCR-ABL1
≤0.0032% on the International Scale [IS]) by real- time quantitative poly-
merase chain reaction (RQ-PCR) on imatinib were eligible. At study entry,
patients treatment was switched from imatinib to nilotinib and nilotinib was
taken twice daily (600mg/day) for 2 years as a consolidation phase. Patients
who had sustained MR4.5 for 2 years after initiation of the study were able to
stop nilotinib in TFR phase. Thirty-three institutions in STAT study group par-
ticipated. The study was conducted in accordance with the principles of the
Declaration of Helsinki. Informed consent was written by all patients according
to institutional guidelines. The study was approved by all institutional review
boards and registered with ClinicalTrials.gov (number UMIN000005904). The
primary objective of this multicenter phase II, single-treatment arm, open-
label clinical study was to identify the MR4.5 rate at 12 months after discon-
tinuation of nilotinib treatment in patients who have sustained MR4.5 for 2
years after initiation of the study. The molecular response was evaluated
using IS-PCR (Molecular MD One-Step qRT-PCR BCR-ABL kit) at a central
laboratory (BML, Inc., Kawagoe, Japan) upon study entry, every 3 months
during the consolidation phase, every month the first year in TFR phase,
every 2 months the second year in TFR phase, and every 3 months the third
year in TFR phase thereafter. Molecular recurrence of CML was defined as
confirmed loss of MR4.5 (2 consecutive BCR-ABL1 IS >0.0032%) according
to STIM criteria (Mahon Lancet Oncol 2010).
Results: Between July, 2011 and December, 2012, 96 Japanese patients were
enrolled, and 75 patients who had sustained MR4.5 during the consolidation
phase were eligible to discontinue nilotinib. The median age was 56 years. The
ratio of men to women was 60:36 and the risk groups according to Sokal Score
were low: 56, intermediate: 20, high: 18, respectively. Sixteen patients were
treated with interferon prior to imatinib therapy. All patients showed MR4.5 at
the time of entry into the study and the median time to DMR on imatinib therapy
was 50.8 months. Median follow up duration in TFR phase of STAT2 trial was
16 month (range: 3 - 30 months). Among the 75 patients who entered the TFR
phase, 52 patients (69.4%, 95%CI: [58.9% to 79.8%]) remained without molec-
ular recurrence the first 12 months (Figure 1). TFR rate at 12M was 69.4%,
which was superior to the previous reports, although we have to carefully val-
idate that the population baseline characteristics are similar to those from other
trials. Furthermore, the 23 patients with molecular recurrence who were treated
with nilotinib again achieved MR4.5 within 6 months.
Figure 1.
Summary/Conclusions: 2-year consolidation by nilotinib is associated with
successful TFR in CML patients with MR4.5 on imatinib.
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IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT
BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE
CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB:
PRACTICAL ASPECT FOR THE TRUE LIFE
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Background: Early molecular response (BCR-ABL1 level at 3 months) has
been associated with clinical outcome in chronic phase chronic myeloid
leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI). However,
a single measurement of BCR-ABL1 transcript levels does not seem enough
to define failure and the European Leukemia Net (ELN) recommendations
define first line-failure only at 6 months if BCR-ABL1 transcript level is above
10%. The transcript rate decline from baseline has been demonstrated to be
more predictive than a single BCR-ABL1 level at 3 months however it cannot
be used routinely because ABL1, as an internal gene control reliable for BCR-
ABL1 quantification is above 10%.
Aims: This study aimed to compare clinical outcome and molecular response
of CML patients, depending on the percentage of decrease of BCR-ABL1 tran-
script from M3 to M6 using ABL1 as an internal control gene, used by most
laboratories that provide results on the International Scale.
Methods: The first CML patient cohort (University Hospitals of Bordeaux n=116)
was used to develop the model and the second one (University Hospitals of
Lyon n=107) was taken to confirm and validate the predictive model. All patients
were in chronic phase from September 2000 to October 2014, treated by front-
line imatinib 400 mg, and for whom M3 and M6 molecular data were available.
Event-free (EFS), failure-free (FFS), progression-free (PFS) and overall survivals
(OS) defined according to ELN, were measured from M6 to the date of event or
death. Survival differences estimated by Kaplan-Meier analysis were assessed
using a log-rank test. The analysis of the area under the time-dependent ROC
curve (AUC) using the inverse probability of censoring weighting (IPCW)
approach was used to define the best cut-off for the percentage of decline. The
cut-off was obtained by the closest “top left” method. Associations with MR4 or
MR4.5 and multivariate analysis including Sokal, age and BCR-ABL1 level ≤ or
>10% at 3 months were assessed by Cox regression. Significant results
obtained in the first cohort were validated in the second cohort.
Results: The percentage of BCR-ABL1 decline from M3 to M6 was significantly
linked to the EFS and the PFS (p=0.002). A common cut-off of 72% of decline
at 24, 36 and 60 months after M6, predicted the better risk of having an event
with respectively a sensibility of 0.69, 0.72, 0.56 and a specificity of 0.74, 0.80,
0.82 for each time point. Patients with a percentage of decrease below 72%
have worse EFS as compared to those having a higher decrease (p<0.001
cohort 1; p=0.028 cohort 2; figure1). The estimated 5-years EFS are 60.75%
and 51.76% for patients with less than 72% of decline vs 84.78% and 71.63%
for patients with a higher decline, for cohort 1 and 2 respectively. The impact
was maintained in the first cohort if we remove from all events treatment ces-
sation for toxicity (p=0.017). However, only a trend is observed in the second
cohort (p=0.073). The impact is independent of the Sokal score, age and BCR-
ABL1 level ≤ or >10% at 3 months.
Figure 1.
Summary/Conclusions: Since the slope between diagnosis and 3 months
cannot be reliable using ABL1 as an internal gene control, the second decline
rate of BCR-ABL1 transcript between M3 and M6 could efficiently identify
patients at higher risk of presenting an event and could help physicians to man-
age CML patients treated with imatinib or generic imatinib and to decide to
switch to another TKI in the true life.
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Background: In chronic phase (CP) chronic myeloid leukemia (CML) nilotinib
has shown better efficacy compared to imatinib, but it has been associated to
a higher incidence of arterial thrombotic events (ATEs). Considering that aging
is linked to a higher cardiovascular risk, elderly patients treated with nilotinib
may experience more ATEs, which ultimately may impact on their outcome.
Aims: To investigate the efficacy and safety, particularly the cardiovascular
safety, of nilotinib in elderly chronic phase chronic myeloid leukemia patients.
Methods: We analyzed 345 patients with CP CML enrolled in clinical trials of
the GIMEMA CML WP investigating nilotinib as first-line treatment. Patients
were treated with: nilotinib 400 mg BID (n=73); rotation of nilotinib 400 mg BID
/ imatinib 400 mg OD (3-month periods for each drug)(n=123); nilotinib 300
mg BID (n=149). The median follow-up was 58 months. The median age was
53 years. We analyzed in detail the response rates, events and outcome of 89
patients ≥65 years of age; these patients were also compared to the 245
patients <65 years. Definitions: Major molecular response (MMR): BCR-
ABL≤0.1% (IS), with >10.000 ABL copies; MR4: BCR-ABL≤0.01% (IS), with
>10.000 ABL copies. Events: permanent discontinuation of nilotinib for adverse
events, progression to accelerated/blast phase (AP/BP), or death for any rea-
son. ATEs: peripheral arterial obstructive disease (PAOD), acute coronary syn-
drome, chronic ischemic heart disease, significant carotid stenosis and
ischemic stroke.
Results: In elderly patients, the Sokal risk distribution was: low, 9%; interme-
diate, 69%; high, 22%. The median age was 71 years. Males were 49%. Molec-
ular response rates were as follows: BCR-ABL/ABL <10% at 3 months, 89%;
MMR at 12 months, 54%; MR4 at 12 months, 25%; cumulative incidence of
MMR by 5 years, 93%; cumulative incidence of MR4 by 5 years, 75%. These
response rates were similar to those observed in patients <65 years (all p
>0.05). Overall, events leading to permanent discontinuation of nilotinib were
observed in 38% of elderly patients, a proportion significantly higher than that
of patients <65 years (23%; p=0.005). ATEs occurred in 15 (16.9%) elderly
patients, and were the reason of permanent nilotinib discontinuation in 12
(13.4%) of them. As expected, the rate of ATEs in younger patients was signif-
icantly lower (5.8%; p=0.0035). Nine (10%) elderly patients died during the fol-
low-up: a patient after progression to AP/BP (the only progression observed in
patients ≥65 years), while the others died in CP for concomitant diseases /
age-related conditions (2 patients had a previous ATE). The 6-year progres-
sion-free survival and overall survival in elderly patients were 85%.
Summary/Conclusions: Nilotinib as first-line treatment of newly diagnosed
CP CML patients showed high efficacy in patients ≥65 years, with molecular
response rates comparable to those observed in younger patients. However,
a significantly higher proportion of elderly patients discontinued nilotinib, par-
tially because of the occurrence of ATEs. Even though a relevant morbidity
was associated to some ATEs, they did not significantly impacted on the long-
term outcome of elderly patients.
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Background: As already demonstrated in different trials, it is possible to safely
discontinue imatinib treatment in patients (pts) affected by Chronic Myeloid
Leukemia (CML) who achieve a durable complete negativity by Q-RT-PCR.
However a variable fraction of them become PCR positive but never loose
Major Molecular Response (MMR). Here we report an update of the Imatinib
Suspension And Validation (ISAV) study at 52 months (mts) of follow-up (FUP).
Aims: The ISAV study is aimed at validating the capability of digital PCR (dPCR)
to predict relapses after imatinib discontinuation in CML pts with negative Q-
RT-PCR results and to evaluate relapse rate, time of recurrence, survival and
the impact of imatinib treatment on Quality of Life (QoL).
Methods: This study involves 15 sites worldwide. CML pts (Chronic or Accel-
erated Phase) under imatinib therapy since more than 2 years and in complete
molecular remission (CMR) were eligible. Patients had to be in CMR for at least
18 mts, with a minimum of 3 Q-RT-PCR performed at their own sites. After dis-
continuation of imatinib therapy, Q-RT-PCR was performed monthly (mts 1-6),
bimonthly for 36 mts and then every 6 months for additional 2 years, to assess
the maintenance of the molecular remission. The loss of molecular remission
was defined as two consecutive positive Q-RT-PCR tests with at least one
BCR-ABL/ABL value above 0.1%. Patients losing molecular remission resumed
imatinib treatment at the same dosage used before interruption. Patients’ QoL
during imatinib discontinuation/resumption was evaluated through the EORTC
QLQ–C30 questionnaire.
Results: The ISAV study enrolled 112 pts with a median FUP time of 35.5 mts
[95% CI: 33.5-36.0]. The cumulative probability of survival at 3 years is 94.7%
[95% CI: 81.4-98.6]. dPCR results showed that 23.1% of pts were positive and
75.9% negative at the time of discontinuation, with a Negative Predictive Value
ratio (dPCR/Q-RT-PCR) of 1.01 [95% CI: 1.22-0.99]. At 52 mts from imatinib
discontinuation, 55 pts (50.9%, 95% CI: 41.1-60.7) of the 108 eligible ones
relapsed and resumed imatinib; 70.9% of them relapsed in the first 9 mts. Of
the 53 not-relapsed pts, 39 (36.1% of the total) regained Q-RT-PCR positivity
without losing MMR. The median time to Q-RT-PCR positivity was 3.0 mts [95%
CI: 2.1-3.1] in the relapsed pts and 4.8 mts [95% CI: 2.9-7.8] in pts who devel-
oped only PCR positivity. In this latter group 2 pts experienced late relapses,
at 30.5 and 45.5 mts respectively (Fig. 1). No case of CML progression or
resistance to imatinib was observed. No significant correlation between relapse
and previous duration of imatinib treatment, use of interferon, time to CCyR,
Sokal score or duration of CMR was identified, while an inverse relationship
between pts age and risk of relapse was evident. The analysis of QoL evidenced
a statistically significant improvement in the general well-being and symptoms
scales at 1 month after imatinib discontinuation and in particular nausea, diar-
rhea and fatigue (p<0.01). An inverse and transient trend toward increased
pain emerged at mts 1 and 3.
Figure 1. Time to Relapse (months) Kaplan-Meier curve evaluable patients
Summary/Conclusions: At 52 mts from the beginning of the study, with a
median FUP of 35.5 mts, 50.9% of pts relapsed; the majority of relapses devel-
oped in the first 9 mts after imatinib discontinuation but late relapses also
occurred, up to the 4th year. Therefore pts who discontinue imatinib should be
monitored for a long period of time, especially if they showed positive PCR val-
ues after imatinib discontinuation.
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Background: The majority of chronic myeloid leukemia (CML) patients achieve
excellent therapy responses to tyrosine kinase inhibitors (TKIs). However, a
proportion of patients still fail to respond to the assigned first-line TKI. Currently,
treatment responses are usually assessed first time at the 3 months time-point.
As the treatment responses to TKIs are in general very fast, we hypothesized
that the prediction of overall treatment response could be done at an earlier
time-point than 3 months especially with emerging of newer TKIs.
Aims: To evaluate the feasibility of using the reduction of BCR-ABL1 levels
after one month of TKI treatment to predict therapy response.
Methods: 52 first-line TKI treated chronic phase CML patients were included
(imatinib n=26, dasatinib n=21, nilotinib n=5). BCR-ABL1 transcript levels were
measured at diagnosis, 1, 3, 6, 12, 18, 24, and 36 months in EUTOS standard-
ized laboratories. The patients were divided into groups based on the decline
of BCR-ABL1 at 1 month compared to the diagnostic values. The patients with
a fold change (FC) higher than 1 (i.e. no decrease in BCR-ABL1 values during
the first month [FC>1]) were named non-responders, while those lower than 1
(FC<1) were responders. The median FC for the responders was 0.31, and
this group of patients was further divided into intermediate responders (FC
0.31-1) and good responders (FC<0.31)
Results: One fifth (n=11, 21% of total) of patients had no decrease in BCR-
ABL1 after 1 month and were identified as non-responders. All non-responders
had used full doses of their assigned TKIs according to their drug accountability
logs in the clinical trial records and therefore the lack of response was not due
to non-compliance. Surprisingly, at the diagnosis, the non-responders had lower
BCR-ABL1 compared to the responders (31% vs 48%, p=0.0083). Further, the
non-responders had significantly more often enlarged spleen (55% vs 15%;
p<0.01), lower hemoglobin levels (median 105g/L, range 88-122g/L vs 128g/L,
range 82-154g/L; p<0.001), and higher percentage of Ph+ CD34+CD38- cells
in the bone marrow (91% vs 75%, p<0.05). These three factors might be a
better reflection of the total tumor load in the body than the initial level of BCR-
ABL1, and therefore explain the slower response to therapy. In addition, the
eradication of leukemic stem cells was slower in the non-responders in com-
parison to the responders. The non-responders had a modest decrease in
Ph+CD34+CD38- after 1 month (medians at dg 91.3% vs 56.2% at 1m; p<0.05),
while the decrease was quite dramatic in responders (at dg 75.3% vs 11.1% at
1m; p<0.0001). Similarly for Ph+CD34+CD38+ progenitor cells, the non-respon-
ders still had high percentages at 1 month (median at dg 99% and at 1m 86.5%;
p<0.05,) while they were rapidly decreased in the responders (at dg 94.7% and
at 1m 32.0%, p<0.0001). Long-term follow-up of molecular responses showed
that the major molecular response (MMR) rates were inferior in the non-respon-
ders when compared to the responders (at 12m 18% vs 64%, p<0.01; 18m
27% vs 75%, p<0.01, 24m 55% vs 87%, p<0.01). In the latest ELN recommen-
dations the 3 month BCR-ABL<10% is a marker for good response. In our
patients, we observed that BCR-ABL1 was <10% at 3 months in all good
responder cases (n=17), while 24% (5/21 cases) of the intermediate group and
36% (4/11 cases) of the non-responder group had BCR-ABL1 >10% at 3
months (p<0.01).
Summary/Conclusions: The early 1 month treatment response analysis
defines a biologically distinct patient subgroup with less satisfactory long-term
response.
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Background: Frequent molecular monitoring of chronic myeloid leukemia
patients using high quality BCR-ABL1 tests standardized to the International
Scale (IS) is recommended for proper disease management, especially when
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treatment cessation is considered. Currently, many laboratories standardize to
the IS by exchanging patient samples with reference laboratories, an expensive
and time-consuming process. A BCR-ABL1 reference panel accredited by the
World Health Organization (WHO) has been developed as a primary standard
for IS calibration (MR1-MR4), but access to the material is restricted.
Aims: (1) To develop a secondary reference panel that is traceable to and
faithfully replicates the WHO panel in manufacturing materials and methods,
with an additional MR4.5 level. (2) To assess the secondary panel in an inter-
national multi-center study.
Methods: As with the WHO panel, the secondary panel was manufactured by
lyophilizing K-562 and HL-60 cell mixtures. Reverse-transcription droplet digital
polymerase chain reaction (RT-ddPCR) was used to quality assess and cali-
brate the secondary panel to the WHO panel. The secondary panel was sub-
sequently evaluated by 44 laboratories to determine the optimal sample input
for each assay, and to assess assay performance including PCR efficiency, IS
accuracy, sensitivity, linearity and precision.
Results: A secondary panel with BCR-ABL1 levels of MR1, MR2, MR3, MR4
and MR4.5 was successfully developed and IS calibrated to the WHO panel
using RT-ddPCR against ABL1, BCR and GUSB. Quality control assessments
indicated that the secondary panel had minimal residual moisture, excellent
vial-to-vial homogeneity and >2.5 years real-time stability. The multi-center
evaluation of the panel demonstrated compatibility with >44 BCR-ABL1 assays
of different configurations. Interestingly, in a standard curve experiment, we
found that >40% of BCR-ABL1 assays showed signs of inadequate optimization
such as poor linearity and suboptimal PCR efficiency. When optimized sample
inputs were used, 60% of tests achieved mean%BCR-ABL1 values within 2-
fold of the panel’s assigned values. Furthermore, 84% achieved good precision
(≤0.25 log standard deviation) from MR1 to MR4, and 76% achieved a 100%
detection rate at MR4.5. Finally, 58% obtained IS conversion factors from the
secondary panel equivalent to their current ones, most of which were obtained
via sample exchange. Correlation analysis indicated that better PCR optimiza-
tion was associated with better assay performance, and increased sample
input improved detection rate and precision at MR4.5. Different assay configu-
rations were not found to be correlated with alterations in%BCR-ABL1 results.
Summary/Conclusions: We successfully developed the first secondary panel
that is traceable to and fully replicates the WHO primary standards, with an
additional MR4.5 level. The panel was shown to be compatible with BCR-ABL1
assays of different configurations in an international multi-center study. Impor-
tantly, once assay conditions were optimized, a high degree of precision and
MR4.5 sensitivity were achievable, yet IS accuracy was demonstrated in only
60% of cases. These findings indicate that there remains an unmet need for a
simple and broadly available calibration mechanism, such as this secondary
panel, to ensure IS accuracy is maintained in laboratories over time. The sec-
ondary panel and its derivatives can also be used as reference samples for
assay analytical validation, optimization and quality assessment.
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Background: In the last 10 years different studies analyzed the outcome of
patients (pts) with sustained complete molecular remission (CMR) who dis-
continued imatinib, reporting rates of treatment-free remission (TFR) ranging
from 33 to 66% depending on the definition of molecular relapse. On these
bases it is judged safe to discontinue treatment with tyrosine-kinase inhibitors
(TKIs) in experimental contexts.
Aims: To evaluate TFR in the setting of clinical practice according to the Italian
experience where most of the pts who discontinued TKIs were not included in
prospective protocols. 
Methods: We retrospectively analyzed the outcome of pts treated in 23 Divi-
sions of Hematology in Italy, who discontinued TKIs in deep molecular response
(MR). General and clinical information such as TKI at discontinuation, line of
treatment, type of MR at discontinuation, reasons for discontinuation were col-
lected. We estimated TFR with the Kaplan-Meier method. Prognostic factors
for TFR were assessed by univariate Cox regression model analysis.
Results: We analyzed a total of 208 pts who discontinued TKIs from June 2003
to October 2015. Median age was 59 years (Interquartile Range, IQR, 46-72).
102 were male, 106 female; 52%, 35% and 13% were low, intermediate and
high Sokal score respectively. 168 pts (81%) discontinued in first line; 38 pts in
second line (63% for intolerance to prior TKIs) and 2 pts in third line. 153 pts
(74%) were on treatment with imatinib (all frontline), 26% with either nilotinib or
dasatinib. Median duration of treatment with the last TKI was 75.2 mos (IQR
50-114); median time to CMR (undetectable transcript or MR4/MR4.5/MR5) with
the last TKI was 23.3 mos (IQR 11.1-45.2). Median duration of CMR was 23
mos (IQR 11-45) before stop. At 3 mos of last TKI 28% of pts were in MR3, 26%
were in PCyR and/or had a transcript <10%, 45% were in CCyR and/or had a
transcript <1%, and 1% had no response. 184 pts had a response defined
according to molecular standardization: 8% were MR3, 30% were MR4, 36%
were MR4.5, 26% were MR5. Reasons for discontinuation were: toxicity for
28% of pts, pregnancy for 10%, pt request for 56%, enrollment in ISAV protocol
for 10 pts. After a median follow-up of 11 mos (IQR 1-149), estimated TFR was
71% (95%CI 64.6%>78.1%) (figure 1). 69 pts restarted treatment. Reasons for
restarting were: loss of MR4 for 20% of pts, loss of MR3 for 55%, loss of CCyR
for 12%, other reasons for 13%. Median time to restart treatment was 6 mos
(IQR 4-11). We assessed age, sex, Sokal score, type of transcript, previous IFN
therapy, duration of TKI therapy, response at 3 mos, time to CMR, CMR duration,
line of therapy at stop, depth of MR, reasons for stop as potential prognostic
factors for TFR, but no statistically significant association were found, with the
exception of response MR5 at stop (MR5 vs MR4, HR: 0.43, 95%CI 0.21-0.87,
p=0.02) and age [HR 0.62 (95%CI 0.42-0.93, p=0.02), i.e. a decreased risk in
older vs younger pts (difference of age=26 years)]. Pts who had to restart therapy
were treated with imatinib (57), nilotinib (10), dasatinib (2). All of them regained
at least MR3. No pts progressed. All pts were alive at the last follow up with the
exception of 7 who died for reasons unrelated to CML.
Figure 1. TFR of patients who discontinued TKIs in Italy.
Summary/Conclusions: Although our population is heterogeneous and worthy
of specific sub-analysis, our experience confirms that discontinuation of ima-
tinib, nilotinib and dasatinib is feasible and safe in the clinical practice. No pro-
gressions occurred, considering that 1/4 of our population had a follow-up
longer than 12 years.
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Background: Background The European LeukemiaNet (ELN) has produced
recommendations for monitoring and assessing the response to tyrosine kinase
inhibitors (TKI) at particular time points. Response criteria hve been developed
and revised by ELN over the years and have been validated in adults with
chronic myeloid leukemia (CML). In 2014, de La Fuente et al (BJH,2014) pro-
posed the modified ELN guidelines for the management of children and young
adults with CML treated with imatinib (IM). To date, both the 2013 ELN guideline
and the modified ELN recommendations have not been yet validated in children
with CML.
Aims: The aims of this study were: a) to analyze treatment results in patients
less than 18 years of age at initial diagnosis of chronic phase CP-CML, treated
and monitored according to local guidelines designed to standardize disease
management in pediatric patients; b) to evaluate the 2013 ELN recommenda-
tions and the modified ELN guidelines in this pediatric population.
Methods: CML patients in CP, diagnosed between March 2001 and March
2014 and followed for at least 18 months were included in this analysis. The
local guidelines provided cytogenetics on bone marrow (BM) cells before and
every 3 months during IM therapy as well as molecular analysis on peripheral
blood (PB) monthly and on BM every 3 months. Allogeneic stem cell transplan-
tation (SCT) was considered for children who failed IM. Quantitative RT-PCR
(qPCR) was assessed according to the ELN recommendations. BCR-ABL1
kinase domain mutation analysis was planned in patients with IM failure. Cyto-
genetic and molecular monitoring at planned time points, as well as treatment
response according to the 2013 ELN recommendations and modified ELN
guidelines were evaluated in this cohort of patients managed according to the
local guidelines.
Results: Fifty-one CP-CML patients, 19 females and 32 males, median age at
diagnosis: 11.2 years (range: 3.1-17,9), were managed at 11 Italian pediatric
centers according to the local guidelines. Assessments of response at 3, 6, 12
and 18 months were carried out in 92%, 91%, 91%, 95% and 92% of patients,
respectively. Figure 1 shows the response rates according to the 2013 ELN
and modified ELN guidelines (B). The response rates at 3, 6, and 12 months
were higher according to the modified ELN guidelines compared to the 2013
ELN criteria, owing to the high number of not evaluable (NE) patients using the
modified ELN guideline. IM was discontinued in 29.5% of patients, due to tox-
icity (8%) or failure (21.5%), that occurred after a median of 24 months. Patients
who failed IM had an optimal (82%) or a suboptimal response (18%) at 3
months. BCR-ABL35INS and no mutations were found in 45.5% and 54.5% of
patients who failed IM, respectively. Fifteen% of patients with optimal response
at 3 months underwent a SCT, all before 2009. IM was successfully discontin-
ued in 8% of patients showing a durable deep molecular response. All patients
are alive at a median follow-up of 75 months (range: 21-151.3).
Figure 1.
Summary/Conclusions: Our experience confirms that collaborative studies
have been useful to better manage children and adolescents with CML. Taking
into account the rarity of the condition and the differences in the biology, clinical
presentation, progression and response to treatment in adults compared tochil-
dren, international collaborative studies and a shared clinical database for pedi-
atric CML will be useful to address unanswered questions and issues.
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RESULTS FROM ENESTOP: TREATMENT-FREE REMISSION (TFR)
FOLLOWING SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH
CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
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Background: Prior clinical studies of imatinib (IM) have demonstrated proof of
concept for TFR; in the STIM trial, TFR (no loss of deep molecular response
[MR]) was maintained 1 y after treatment discontinuation by ≈40% of pts with
sustained deep MR on long-term frontline IM. In ENESTcmr, pts who did not
achieve deep MR (MR4.5; BCR-ABL1 ≤0.0032% on the International Scale [IS])
with IM were more likely to achieve this response with a switch to NIL.
Aims: To present results from the single-arm phase 2 ENESTop study
(NCT01698905) evaluating the ability to maintain TFR in pts who achieve and
sustain MR4.5 on NIL following a switch from IM to NIL treatment.
Methods: Eligible pts had CML-CP, received prior tyrosine kinase inhibitor
(TKI) treatment for ≥3 y (including IM for >4 wk followed by NIL for ≥2 y), and
achieved MR4.5 with NIL. All pts provided informed consent. Upon enrollment,
pts continued NIL for 1 y (consolidation phase; RQ-PCR assessments every
12 wk). Pts without confirmed loss of MR4.5 (consecutive BCR-ABL1IS
>0.0032%) during the consolidation phase were eligible to stop NIL (TFR phase;
RQ-PCR assessments every 4 wk for the first 48 wk). NIL was reinitiated (ReRx
phase) upon confirmed loss of MR4 (consecutive BCR-ABL1IS >0.01%) or loss
of MMR (BCR-ABL1IS >0.1%). The primary endpoint was the proportion of pts
with ongoing TFR 48 wk after stopping NIL. This analysis was conducted when
all pts who entered the TFR phase had completed 48 wk of TFR, entered the
ReRx phase, or discontinued from the study (data cutoff, 26 Nov 2015).
Results: A total of 163 pts were enrolled and entered the consolidation phase;
126 entered the TFR phase. Median age at baseline was 56 y; prior to entering
the TFR phase, median durations of TKI and NIL treatments were 88 (range,
49-171) and 53 (range, 37-109) mo, respectively. Of 126 pts, 57.9% (95% CI,
48.8-66.7%) remained in TFR at wk 48 (primary endpoint); 53.2% (95% CI,
44.1-62.1%) of pts had MR4.5 at wk 48. Of 53 pts who discontinued from the
TFR phase, 51 entered the ReRx phase (loss of MMR, n=34; confirmed loss
of MR4, n=17), and 2 permanently discontinued from the study (1 with confirmed
MR4 loss did not enter ReRx phase due to investigator decision; 1 was found
to have atypical transcripts). In the ReRx phase, 50 pts (98.0%) regained MMR
or better by the data cutoff, and 48 (94.1%) and 47 (92.2%) regained MR4 and
MR4.5, respectively; median times to regain MR4 and MR4.5 were 12.0 and
13.1 wk, respectively. No new safety signals were observed with NIL. Adverse
event rates were 77.0% vs 73.8% in the consolidation vs the TFR phase (full
analysis set). Events in the musculoskeletal pain grouping (defined as muscu-
loskeletal pain, myalgia, pain in extremity, arthralgia, bone pain, and/or spinal
pain) were reported in 42.1% (n=53) of pts (grade 3/4, 1.6%) in the first 48 wk
of the TFR phase; most of these pts (37 of 53; 69.8%) had no history of mus-
culoskeletal pain. In the TFR phase, the majority of events (46 of 54) in this
grouping occurred during the first 24 wk; most events were still ongoing.
Summary/Conclusion: ENESTop provides the largest set of prospective TFR
data to date in pts with CML-CP who achieved sustained deep MR after switching
from IM to NIL. After stopping NIL, 58% of pts remained in TFR at 48 wk. The
results of ENESTop, together with those from ENESTcmr showing that a higher
proportion of pts switching to NIL reach deep MR, suggest that a higher proportion
of pts switching to NIL will achieve TFR compared with pts continuing on IM.
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Background: Mutation-derived neoepitopes have been suggested as a major
component for immune recognition of solid tumors with a high mutational load,
e.g. Melanoma and Non-Small-Cell Lung Cancer (NSCLC). Myelodysplastic
syndromes (MDS) are a heterogeneous group of myeloid neoplasms charac-
terized by increasing bone marrow failure due to clonal expansion of immature
dysplastic cells in the bone marrow. Compared to Melanoma and NSCLC,
these dysplastic cells carry low numbers of point mutations, but high levels of
frameshifts, indels, splice variations or epigenetic changes. All of which may
contribute to the generation of tumor-specific neoepitopes. 
Aims: Assess if immune recognition of tumor specific neoepitopes is evident
in MDS. Such neoepitopes may serve a potential important novel targets for
immune therapy in hematological malignancies. 
Methods: We identified personalized tumor specific mutations based on whole
exome sequencing of MDS blasts and corresponding germline DNA. HLA bind-
ing regions covering these mutation sites were characterized by prediction of
peptide-HLA binding using a specially designed program (MuPeXI, the Mutant
Peptide Extractor and Informer), including state-of-the-art prediction tools based
on netMHC. 
Results: We identified 60-250 peptides per patients, for 6 MDS patient. These
neoepitopes covered point mutations (70%) and indels/frameshifts (30%). Pep-
tide-MHC multimer reagents where generated for each of these peptides,
matching the HLA expression of the patient. We screened bone-barrow-derived
T cells for recognition of these large pMHC libraries using a novel multiplex
technology based on DNA barcode labeled MHC multimers. This technique
allows screening for T cell recognition of >1000 different pMHC complexes in
a single sample. 
Summary/Conclusions: Potential neoepitopes where identified from all 6
MDS patients included. Bone marrow-derived T cells where successfully ana-
lyzed both directly ex-vivo and following in-vitro expansion. Data analyses are
currently ongoing. This study proves the feasibility for identification of neoepi-
topes in MDS and confirms the barcode-labeled MHC multimer complexes as
a strong tool to discover the T cell recognition of mutation derived neoepitopes.
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VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2’-
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Background: Cancer patients are often deficient in vitamin C, which is an
essential cofactor for the ten-eleven translocation (TET) enzymes. Since TET
enzymes initiate DNA demethylation by oxidation of 5-methylcytosine (5mC)
to 5-hydroxymethylcytosine (5hmC), restoring vitamin C to physiological levels
might raise the levels of 5hmC in cancer cells. DNA methyltransferase inhibitors
(DNMTi’s), 5-aza-2’-deoxycytidine (5-aza-CdR) and 5-azacytidine (5-aza-CR),
are drugs of choice in higher risk myelodysplastic syndromes (MDS) and have
shown efficiency in the treatment of acute myeloid leukemia (AML). Our group
recently showed that low dose DNMTi causes upregulation of endogenous
retroviruses (ERVs) that induce the viral defense pathway to elicit an interferon
response, which may play an important role in the efficiency of DNMTi’s.
Aims: The aim of this study was to explore if vitamin C would enhance growth
inhibition and apoptosis induced by DNMTi via; 1) improved activation of TET
enzymes and the formation of 5hmC and 2) enhanced induction of ERVs and
activation of the viral defense pathway.
Methods: We measured the blood levels of vitamin C in 24 patients with hema-
tological malignancies using high performance liquid chromatography (HPLC).
Next, we explored the synergy between physiological doses of vitamin C and
low doses of 5-aza-CdR in five cell lines measuring growth inhibition by
CellTiter-Glo luminescent cell viability assay and apoptosis by annexin V affinity
assay using flow cytometry. Upregulation of ERVs and viral defense genes
were determined by RT-qPCR, gene expression microarrays and RNA
sequencing. Finally, to detect global 5hmC changes we performed dot blot
analysis using a specific antibody against 5hmC as well as Illumina Infinium
HM450 DNA methylation assay to detect global 5mC changes. Bisulfite
sequencing and a Hydroxymethyl Collector kit were used for detection of 5mC
and 5hmC at the long terminal repeat (LTR) regions of the ERVs.
Results: We first document that hematological cancer patients are indeed vita-
min C deficient. By adding vitamin C at physiological concentrations to low
doses of 5-aza-CdR in vitro, we showed a synergistic inhibition of cancer cell
proliferation and enhanced apoptosis. These effects are associated with
enhanced immune signals including increased expression of bi-directionally
transcribed ERV transcripts, increased presence of cytosolic double stranded
RNAs (dsRNA), and activation of an interferon induced cellular response to
these transcripts. In addition, we show that the TET product, 5hmC, is enriched
both globally and locally at the LTR regions, which initiates transcription of
ERVs.
Summary/Conclusions: Our work shows a remarkable synergy between
physiological doses of vitamin C and 5-Aza-CdR, and the combination
enhances a “viral mimicry” response by upregulation of ERVs, including dsRNA
production and induction of an innate immune response. This may be essential
for the responses of patients to this class of drugs. Since patients with hema-
tological cancers are markedly vitamin C deficient, the addition of vitamin C to
treatment protocols may therefore be a straightforward way to increase the
clinical efficacies of these drugs in MDS/AML patients. A.D.Ø., M.L., W.Z. and
H.O. contributed equally to this work.
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GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS
CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN
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Background: Studies on germline mutations responsible for cancer predispo-
sition provide an important clue to the pathobiology and potentially the man-
agement of relevant cancers. Within acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS), only a handful of genes, including RUNX1,
CEBPA, GATA2, ETV6, and ANKRD26, have been implicated in early onset
familial cases, with germline mutations rarely seen in sporadic cases. Recently,
we have identified novel germline variants of the DDX41 gene that predispose
to AML/MDS, using whole exome sequencing (WES) of familial cases with
MDS/AML. In contrast to the variants of other MDS/AML-predisposing genes,
germline DDX41 variants are associated with a late onset disease typically
diagnosed at the age of over 60, which could obscure their genetic predispo-
sition, raising a possibility that germline DDX41 variants might be found in
apparently sporadic cases with MDS/AML.
Aims: This study was designed to assess the impact of germline DDX41 muta-
tions on the AML/MDS development in Asian and Caucasian cohorts of spo-
radic AML/MDS.
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Methods: We performed WES (N=55) or targeted-capture sequencing (N=1,035)
in patients from the Asian cohort of sporadic AML/MDS (N=1,090), where the
germline or somatic origin of the detected mutations was determined by using
paired tumor and matched germline DNA if available. These results were com-
pared to those from the Caucasian cohort of AML/MDS (N=1,034). The effect
size of each variant for AML/MDS development was estimated by using the data
from healthy populations in Asian countries (N=6,434) (BioBank Japan, Tohoku
Medical Megabank Organization, and Exome Aggregation Consortium (ExAC)
database) and in Caucasian countries (N=33,364)(ExAC database).
Results: In the Asian cohort of AML/MDS, germline DDX41 variants were found
in 42 patients (3.9%), of whom 15 (1.4%) also harbored a somatic DDX41
mutation. In Caucasians, 8 patients (0.8%) had germline variants, and 2 (0.19%)
for simultaneous germline and somatic mutations. Asian patients with germline
variants had a median age of 56.6 (21-89), which was almost similar with that
of the whole Asian cohort of AML/MDS {55 (6-93)}. In total, 8 and 1 recurrent
germline variant alleles were observed in the Asian and Caucasian cohorts,
respectively. Among them, the most predominant variants were p.A500fs (n=23;
55%) and p.Y259C (n=6; 14%) in the Asian cohort and p.D140fs (n=6; 75%) in
Caucasians. Notably, no variants were shared by both populations, except for
p.E256K, which are thought to be derived from a common ancestor. In contrast,
a prominent hotspot mutation involving a highly conserved amino-acid within
the helicase domain (p.R525H) was observed in both cohorts, accounting for
67% of second-hit DDX41 somatic mutations. As a whole, these germline vari-
ants showed significant enrichment in AML/MDS cases compared to the respec-
tive control populations: odds ratio (OR)=18, {95% confidence interval (CI): 10-
33} for Asian variants, and OR=10.8 (4.9-24) for Caucasian variants. As for
individual variants, the enrichment in AML/MDS also showed various effect
sizes: OR=19 (8.5-46) for p.A500fs, 8.9 (2.5-32) for p.Y259C in Asians, and
19.5 (7.1-54) for p.D140fs in Caucasians.
Summary/Conclusions: Germline DDX41 variants are found in 0.8% to 3.9%
in sporadic cases with MDS/AML depending of different ethnic populations.
These germline DDX41 alleles are present in the general population at low fre-
quencies but account for the largest genetic predisposition to MDS/AML with
high absolute risks. Second-hit mutations are common and show a prominent
hotspot within the catalytic domain (p.R525). Given the high prevalence of
DDX41 germline variants and the late onset of associated MDS/AML, their
detection may help clinicians to better manage patients with AML/MDS and to
find other family members at risk, even when no family history is known.
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SF3B1-K700E MUTATION
F Liberante*, K Lappin, K Savage, K Mills
CCRCB, Queen’s University Belfast, Belfast, United Kingdom
Background: In recent years, mutations in the SF3B1 gene have been dis-
covered in a variety of cancers, especially myelodysplastic syndromes (MDS),
acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The
majority are a single A>G transition resulting in a K700E codon change within
the HEAT repeats. Very recent data have demonstrated that this mutation dras-
tically alters the branch point preference of the SF3B1 protein. The high preva-
lence of mutations in SF3B1 in MDS alludes to an important role in the disease.
In terms of clinical utility, identifying therapies which target cells harbouring
mutant SF3B1 would be of great benefit, as there is pressing need to improve
available therapies for MDS, a disease of the elderly.
Aims: To identify the downstream effects of mutant SF3B1 in primary MDS and
assess the sensitivity of SF3B1 mutant cells to standard and advanced molecular
therapies; using isogenic pre-clinical models of SF3B1 mutant MDS and AML.
Methods: An RNA-Seq data set from CD34+ cells from a panel of SF3B1 wild-
type and mutant MDS together with normal donors was analysed. More specif-
ically, the dSpliceType tool was used to identify differential and cryptic-splicing
between both SF3B1 mutant and wildtype MDS samples or SF3B1 mutant
MDS and normal donors. In addition to analysis of primary material, we used
genome-editing via CRISPR/Cas9 nucleases to create isogenic models for in
vitro comparisons. The generated SF3B1 mutant cell lines have been validated
by mass spectrometry and profiled by numerous assays. In order to ascertain
the effects of SF3B1 mutation on both splicing and the wider transcriptome, we
are currently validating RNA-Seq from these isogenic clones.
Results: The analysis of primary MDS RNA-Seq characterised nearly 3,000
differentially-spliced transcripts. Perhaps unsurprisingly, there was an enrich-
ment of genes with roles in RNA processing, suggesting a possible feedback
or compensatory mechanism in SF3B1 mutant cells. Of the altered transcripts,
only around 150 were related to alternative 3’ splice site recognition, which is
likely to be directly attributable to SF3B1K700E. Interestingly, this set of genes
was enriched for phosphoproteins, which may suggest an impact of
SF3B1K700E on kinase cascades within the cell. The isogenic models were
successfully created by introducing the A>G transition at the K700 codon in
one allele of the endogenous SF3B1 gene. The expression of the mutant was
confirmed both by sequencing and mass spectrometry. The mutant cells do
show a slightly slower growth rate, but are generally similar to wildtype cells.
Altered splicing in these clones was validated using qPCR, which targeted tran-
scripts identified in the primary samples. Further studies comparing differenti-
ation and clonogenic potential, together with response to a wide range of ther-
apeutics, are starting to yield interesting differences.
Summary/Conclusions: This study has shown that SF3B1 mutation leads to
an altered transcriptome in primary MDS samples and many atypical transcripts.
Furthermore, it has identified a potential role for SF3B1 in modulating the splicing
of phosphoproteins representing a potential source of clinical targets that could
be employed in the clinic. In addition, the successful creation of an isogenic
model that recapitulates the altered splicing seen in the primary disease provides
an opportunity for the screening of therapeutics for MDS or secondary AML.
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Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is the only curative therapy for patients with myelodysplastic syndromes (MDS),
but its benefit is often offset by high mortality and morbidity accompanied. Dur-
ing the past decade, substantial advances have been made in our understand-
ing of the genetic basis of myelodysplastic syndromes (MDS), through which a
full spectrum of major mutational targets was delineated and their impacts on
disease phenotypes and clinical outcome have been intensively studied. How-
ever, few studies addressed the effects of these mutations and other genetic
alterations in the setting of allo-HSCT in a large series.
Aims: We aimed to elucidate the effect of genetic alterations on the clinical
outcome of allo-HSCT for MDS based on a large scale-genotyping.
We aimed to elucidate the effect of genetic alterations on the clinical outcome
of allo-HSCT for MDS based on a large scale-genotyping.
Methods: We performed targeted deep sequencing of genomic DNA from 865
MDS patients who received unrelated bone marrow transplantation via Japan
Marrow Donor Program between 1998 and 2013, through which somatic muta-
tions in the major drivers in MDS (68 genes) and other copy number abnormal-
ities(CNAs) and their association to clinical outcomes were interrogated. 
Results: The median age at HSCT and observation period were 52 years (1-
66) and 1121 days (48-5,747), respectively. At the diagnosis, 5%, 26%, 20%,
and 8% of the patients were classified into low, intermediate-1, intermediate-2,
and high risk categories based on the International Prognostic Scoring System,
respectively (42% were not informative). At HSCT, 28%, 35%, 19%, 4%, and
15% were diagnosed with low-risk MDS, refractory anemia with excess blasts
(RAEB), secondary acute myeloid leukemia (sAML), myelodysplastic/ myelo-
proliferative neoplasms (MDS/MPN), and MDS not specified, respectively. In
total, 79% of the patients had either somatic mutations (75%) or CNAs (45%).
RUNX1, U2AF1, ASXL1, and TP53 were among the most frequently mutated
genes and mutated in >10% of the cases. Complex karyotype, -7/del(7q),
del(5q), and trisomy 8 were identified in 17.4, 16.3, 9.6, and 6.7%, respectively.
In univariate analysis, mutations in TP53 (hazard ratio (HR):2.76), CBL (2.15),
PHF6 (2.06), NRAS (1.85), PTPN11 (1.83), EZH2 (1.65), FLT3 (1.63), and
RUNX1 (1.39) showed negative effect on overall survival. In multivariate analy-
sis combining these mutations, CNAs and clinical parameters, mutations in
CBL (HR:2.72), KRAS (2.60), EZH2 (2.37), PHF6 (2.29), and TP53 (1.95) were
independently associated with significantly poor survival, together with red
blood cell transfusions before HSCT (2.99), multiple HSCTs (1.91), 3≥points of
Hematopoietic Cell Transplantation-Comorbidity Index (1.72), male recipients
(1.62), serological HLA mismatch (1.59), grade II-IV of acute graft versus host
disease (GVHD) (1.50), and diagnosis of RAEB, sAML and MDS/MPN
(HR:1.66, 1.76, and 2.08, respectively). We also analyzed the impact of muta-
tions on relapse in cases who achieved complete response (CR) after HSCT
(n=765; 88.4%). Multivariate analysis revealed mutations in TP53 (HR:9.66),
ATRX (7.12), CUX1 (5.60), ETV6 (5.15), RUNX1 (2.71), del(11q) (11.7), loss
of heterozygosity of 6p (5.03), disease status of relapse (7.89), refractory dis-
ease (2.69), CR (2.98), and partial response (2.69) at HSCT (compared to
treatment naive cases), and diagnosis of sAML (2.85) significantly correlated
with unfavorable outcomes, whereas PTPN11 (0.04) mutations predicted a
favorable prognosis.
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Summary/Conclusions: This large study of MDS cases treated by unrelated
HSCT demonstrated that somatic mutations of specific driver genes could
predict clinical outcomes of MDS patients treated by HSCT and better guide
therapy.
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17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML
AND COMPLEX ABERRANT KARYOTYPE
R Schaab1,*, C Ganster1, S Dierks1, M Tallo Parra1, R Martin1, U Germing2,
U Platzbecker3, K Shirneshan1, F Lange4, N Kröger5, K Döhner6, B Glaß7,
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and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Ger-
many
Background: Alterations of the TP53 gene, either by molecular mutations or
by cytogenetic deletions of the 17p13 region (where TP53 is localized), are
frequent in patients (pts.) with myelodysplastic syndromes (MDS) with complex
aberrant karyotypes (≥3 clonal cytogenetic aberrations (CA)). Both, molecular
as well as cytogenetic alterations of TP53 were shown to be prognostically
adverse in pts. with MDS.
Aims: This study investigates the interrelations between mutational status (het-
ero- vs homozygous, cytogenetic deletion vs molecular mutation) of TP53 with
the extent of (cyto)genetic instability and with prognosis of MDS/AML pts. with
complex aberrant karyotypes.
Methods: We included 123 pts. with MDS (N=91), sAML after MDS (N=15)
and de novo AML (N=17) all with complex aberrant karyotypes (≥3 clonal cyto-
genetic aberrations). Pts. were comprehensively characterized by chromoso-
mal banding analysis (CBA), interphase fluorescence in situ hybridization
(FISH) including 17p13/TP53, multicolor FISH (mFISH), sequencing of TP53
and molecular karyotyping (MK, SNP-array analysis). The extent of genetic
imbalances was quantified by the number of CA, the number of fusions as
shown by mFISH and the size of total genomic aberrations (TGA) measured
by MK.
Results: We identified molecular TP53 mutations in 62/123 (50.4%) pts. from
our study cohort (all with complex aberrant karyotypes). FISH/CBA revealed
deletions of TP53 on 17p in 31/89 (34.8%) pts. Combining the different aber-
ration types a total of 50/89 pts. (56.2%) showed molecular and/or cytogenetic
changes of TP53. In detail, a total of 28/89 pts. (31.5%) showed any alteration
(chromosomal or molecular) of one allele (corresponding to a heterozygous
status of TP53), two TP53 aberrations (corresponding to a homozygous state)
were found in 22/89 pts. (24.7%). In 39/89 (43.8%) pts. we could not identify
any TP53 mutation. Pts. with a molecular TP53 mutation showed a higher num-
ber of CA (median 7; range 1-41; vs 4; 3-23; p=0.014), a tendency for larger
TGA size (median 362 Mb; range; 97-981; vs 163 Mb; 64-600 Mb; p=0.135)
and for a higher number of fusions (median 2; range, 0-17; vs 3.5; 0-13;
p=0.093) as compared to pts. without a molecular TP53 mutation. Likewise
the number of CA and fusions was significantly higher in pts. with a homozy-
gous mutational status of TP53 (CA: median 8; range 3-41; fusions: 5; 0-13)
and those with a heterozygous TP53 mutational status (CA: 8; 1-25; fusions:
3; 0-10) in comparison to pts. with no aberration of TP53 (CA: 4; 3-23; p=0.001;
fusions: 2; 0-17; p=0.012). Preliminary follow-up analysis suggests an additional
impact of the number of CA on survival outcomes of complex aberrant pts.
with molecular TP53 mutations. Currently, we are collecting further survival
data for additional validation of this observation.
Summary/Conclusions: We were able to confirm a high proportion of molec-
ular and/or cytogenetic aberrations of TP53 in 56.2% of pts. with cytogenetically
complex aberrant MDS/AML. Complex aberrant pts. with evidence of molecular
and/or cytogenetic TP53 aberrations showed higher levels of genetic instability
as measured by the number of CA, genetic fusions and TGA size as compared
to those without any TP53 aberration. The extent of cytogenetic complexity
may be prognostically relevant for complex aberrant MDS/AML pts. with molec-
ular TP53 mutations. We aim to collect further data to prove this observation.
Those 43.8% of MDS pts. with a complex aberrant karyotype but without any
TP53 aberration raise the question whether other genes of the TP53 pathway
might be involved causing a “TP53-like” phenotype.
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TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS
TREATED WITH HYPOMETHYLATING AGENTS IN MDS
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Background: Azacitidine (AZA) is a hypomethylating drug, which obtains a 40
to 50% of overall responses in MDS. Blast<15%, normal karyotype and no
previous treatment seem to be independent factors for better response. How-
ever, the potential value of the gene mutations has not been extensively
explored.
Aims: To evaluate the impact of gene mutations detected by next generation
sequencing (NGS) on treatment response to hypomethylating agents in MDS
patients; and to define predictive factors of survival.
Methods: Eighty-four MDS patients were included. According to WHO classi-
fication the diagnosis was: RA (1%), RCMD (22%), RAEB1 (25%), RAEB2
(23%), MDS isolated del5q (2%), CMML (8%), MDS/AML 20-30% blasts (13%)
and unclassified MDS (6%). Very low, low, intermediate, high and very high-
risk categories according to IPSS-R were found in 2%, 18%, 24%, 27%, and
25% of patients, respectively. For NGS, Ion Torrent Proton (Life Technologies,
Palo Alto, CA) system was used. We selected a panel of 34 genes related to
myeloid pathologies. An optimal depth of coverage, median about 2000, was
reached, contributing to a high sensitivity. Additionally, clinical characteristics
were considered: sex, age, WHO classification, cytogenetic risk, IPSS-R,
response to AZA (IWG response criteria) and outcome.
Results: The median age was 69 years (range: 49-99). The median follow-up
time was 17 months (range: 1-93). Mean numbers of cycles received per patient
were 9 (range 1-55). Overall response to AZA was 42%, included complete
remission 17%, partial remission 5% and hematologic improvement 20%. A
total of 181 somatic mutations were found in 78 out of 84 patients (93%). The
more frequent mutations involved TET2 (25%), TP53 (20%), RUNX1 (18%),
DNMT3A (18%), EZH2 (14%), ASXL1 (13%), U2AF1 (12%), SF3B1 (11%),
ZRSR2 (10%), and the remainder had frequencies of <10%. Considering clin-
ical characteristics and mutational status in the univariate analysis of the impact
on response, the number of AZA cycles (p=0.003), and the number of mutations
per patient (p=0.032) were associated with overall response. Taking into
account genes related to DNA methylation pathway (TET2, DNMT3A, IDH1
and IDH2), the presence of at least 1 mutation in any of these genes was asso-
ciated with complete remission (p=0.031). In the multivariate analysis, these
parameters remained significant for overall response after adjusting by IPSS-
R and age: number of AZA cycles (p=0.006; OR=1.2; 95%CI 1.1-1.4), number
of mutations per patient (p=0.042; OR= 0.6; 95%CI 0.3-0.9), and mutations in
methylation pathway genes (p=0.024; OR=4.4; 95%CI 1.2-15.7). In univariate
analysis of survival, platelet counts, cytogenetic risk, IPSS-R, WHO classifica-
tion, response to AZA and TP53, RUNX1, and EZH2 mutational status were
associated with overall survival. By contrast, in multivariate analysis, consid-
ering these clinical and molecular variables significant, only TP53 and EZH2
mutations remained as independent adverse prognostic factors for overall sur-
vival (HR=3.9; 95% CI: 1.9-7.8; p<0.001 for TP53, and HR=2.5; 95% CI: 1.2-
5.1; p=0.012 for EZH2), regardless of the response to AZA (figure 1).
Figure 1.
Summary/Conclusions: In our series of patients treated with AZA, we found
than more number of AZA cycles, less number of mutations per patient and
the presence of at least 1 mutation in genes related to DNA methylation (TET2,
DNMT3A, IDH1, and IDH2) were predictive factors for AZA response. However,
a lower overall survival was associated with TP53 and EZH2 mutations regard-
less of this response.
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AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE
OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS
PATIENTS
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Background: Tregs are expanded in late-stage MDS and may compromise
tumor immunity. Signal transducer and activator of transcription (STAT) proteins
regulate Treg differentiation, while aberrant immune signaling via STATs drives
disease pathobiology in various malignancies. We have previously shown that,
compared to RAEB-2 and AML/MDS patients, the CMML-2 ones display a dis-
tinct STAT signaling profile in Tregs which is also differentially modulated by
azacytidine (AZA).
Aims: We have now updated our work by including more patients and normal
donors and an extended panel of signaling nodes.
Methods: Peripheral blood mononuclear cells of 41 patients were obtained
before, 15 days after AZA initiation and after the 6th cycle. According to WHO,
20 (48,7%) patients had RAEB-2, 12 (29,2%), 12 (29,2%) CMML-2, 7 (17%)
AML/MDS and 2 (4,8%) RCMD. Based on the IWG criteria patients were divided
into responders (CR and hematologic improvement, n=17) and non-responders
(stable disease and failure, n=24). We applied phospho-specific flow cytometry
to measure either basal or potentiated phospho-STAT1, STAT3 and STAT5 lev-
els with simultaneous staining for FOXP3. The following potentiated, i.e.
target/stimuli, signaling nodes (SN) were studied: IFNα/pSTAT1, IFNα/pSTAT5,
IL-6/pSTAT1, IL-6/pSTAT3 and IL-2/pSTAT5. Clustering of SNs was performed
with hierarchical cluster analysis and was correlated with response, disease
subtype, transfusion burden, IPSS-R and cytogenetics by using χ2 or Fisher
Exact tests. 
Results: Treg levels decreased in responders after cycle 6 (p=0.04), whereas
non-responders showed a nonsignificant increase (p=0.17). Also, non-respon-
ders upregulated significantly the transcription factor Helios at 6 months
(p=0.02), whereas responders retained stable levels. Unsupervised clustering
of pretreatment SNs demonstrated that patients bear a different Treg STAT
biosignature from age-matched normal donors (p=0.003), characterized by
blunted response in cytokine stimulation and higher basal levels of STAT3. Nor-
mal donors still formed a separate cluster on day 15 (p=0.03), but clustering
after cycle 6 separated two main clusters (figure 1). Cluster 1 encompassed all
normal donors and was enriched in responders (p=0.04), whereas non-respon-
ders segregated in cluster 2 which was characterized by weak potentiated
responses. Clustering of the fold-change of SNs in Tregs after the 6th cycle
(MFI cycle 6 – MFI pretreatment/MFI pretreatment) discriminated responders
from non-responders in 2 clusters (p=0.03). The first group upregulated both
basal and potentiated nodes, while the second downregulated most SNs and
upregulated pSTAT1 responses in IL-6 and IFNα.
Figure 1.
Summary/Conclusions: Collectively, we demonstrate for the first time that
the STAT signaling biosignature of Tregs in late-stage MDS patients is patho-
logical, characterized by blunted response to cytokines. AZA induced a dis-
parate effect in Tregs which was linked with clinical response; Responders
decreased Treg numbers and normalized their STAT biosignature by restoring
Treg responsiveness to cytokines, while non-responders tend to increase Tregs,
displayed a marked increase in Helios expression and retained the abnormal
STAT biosignature as they upregulated only pSTAT1 responses. Our results
are suggestive of a clinically relevant immunomodulatory effect of AZA by mod-
ifying the cytokine/STAT signaling axis in Tregs. Further elucidation of the patho-
biological significance of alterations in individual nodes will provide novel
insights in the mechanisms of action and resistance to AZA.
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Background: The bone marrow (BM) constitutes a complex microenvironment
that maintains and regulates hematopoiesis, and promotes differentiation. Little
is known about the microenvironment of myelodysplastic syndrome with ringed
sideroblasts (MDS-RS), of which >80% of patients harbor splice factor SF3B1
mutations. We recently showed that MDS-RS erythropoiesis fails in particular
during its terminal phase, a process that normally requires the formation of ery-
throid islands (Conte et al, BrJH 2015). Currently available culture models
remain inefficacious to simultaneously support the formation of erythroid islands,
enucleation of erythroblasts, and ring sideroblast development in MDS-RS,
hence we lack adequate systems to model and target terminal erythropoiesis
in MDS.
Aims: Our aim was to develop an in vitro culture model to study normal and
MDS-RS hematopoiesis under conditions simulating the human in vivo BM
microenvironment, and for the first time to be able to generate an MDS-RS
phenotype in vitro.
Methods: Mononuclear cells including autologous stromal cells (MNC+) and
CD34+ cells were isolated from 8 MDS-RS patients and 9 healthy individuals,
and seeded into scaffolds made out of collagen-coated polyurethane (3D cul-
ture), or into previously established suspension cultures. The in vitro conditions
were optimized for erythropoiesis by testing different cytokines and media. Cells
were extracted weekly to evaluate proliferation, cellular composition and enu-
cleation by flow cytometry, and ringed sideroblast quantification using morpho-
logical assessments by Perl´s Prussian blue staining. Self-renewal potential of
cultured cells was assessed by long-term culture initiating cell assays (LTC-
ICs) and allelic burden of SF3B1 mutations with pyrosequencing. Scaffolds
were sectioned for morphological assessment.
Results: The optimal medium composition included an initial phase aiming
for erythroid progenitor enrichment followed by a high concentration of iron
loaded human transferrin and EPO to induce erythroid maturation. Both MNC+
cultures and CD34+ 3D cultures maintained proliferation for up to 4 weeks.
Interestingly, self-renewal potential, as assessed by LTC-ICs, was also main-
tained following this culture period. By contrast, conventional CD34+ cultures
lost proliferative capacity after 2 weeks and did not give rise to LTC-ICs. The
allelic burden of SF3B1 was maintained in the 3D cultures (with MNC+ and
CD34+ cells), but decreased within 4 weeks in suspension cultures. The MNC+
cultures were able to retain different lineages of hematopoiesis (including
myeloid, lymphoid and erythroid) although primarily facilitating erythroid cells,
while the CD34+ cultures (3D and suspension) only generated cells of the ery-
throid lineage. We identified enucleated erythroid cells from all cultures except
for CD34+ suspension cultures. Importantly, erythroid islands carrying central
macrophages were formed during week 3 and 4 in the MNC+ 3D culture. Mor-
phologic quantification confirmed that 9-50% of the erythroblasts extracted at
the end of the MNC+ cultures (3D and suspension) and CD34+ in 3D cultures
were ringed sideroblasts.
Summary/Conclusions: We report for the first time that a 3D culture model
seeded with BM MNC including autologous stromal cells is able to mimic
hematopoiesis of healthy and MDS-RS BM in vitro, and provide support for for-
mation of terminal erythropoiesis both from normal and SF3B1 mutated bone
marrow cells. This novel in vitro system should enable studies of MDS associ-
ated erythroid maturation defects in vitro.
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IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC
SYNDROMES (MDS)
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Background: The increasing resolution of modern molecular genetics tech-
nologies has recently enabled the discovery of a novel phenomenon of genome
instability that plays a role in cancer genesis and its progression. This phenom-
enon, termed chromothripsis, affects single chromosomes and/or chromosome
regions that are shattered into many small pieces in a single catastrophic event.
Chromothripsis was first described in 2011 by Stephens and colleagues. Since
then, the occurrence of chromothripsis was detected in a wide range of tumor
entities including hematologic malignancies. According to the published data it
can be seen in approximately 2%–3% of all human cancers and is strongly
associated with complex karyotypes. However, the real frequency of chromoth-
ripsis is likely to be much higher than was originally suspected.
Aims: The aim of the study was to assess the incidence and clinical significance
of chromothripsis in bone marrow cells of the previously untreated patients with
myelodysplastic syndromes (MDS) and complex chromosomal aberrations (CCAs).
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Methods: A detailed retrospective genome-wide analysis of fixed bone-marrow
cells from adults with CCAs (³3 aberrations) identified with conventional G-
banding at the diagnosis of MDS was performed. The CCAs were studied
through FISH with Vysis DNA probes (Abbott, Des Plaines, IL) and
mFISH/mBAND methods using the 24XCyte and the XCyte color kits (Meta-
Systems, Altlussheim, Germany). Genomic imbalances were identified with
CytoChip Cancer SNP 180K (BlueGnome, Cambridge, UK) or with Illumina
Human CytoSNP-12 arrays (Illumina, San Diego, CA).
Results: We examined a large group of 222 patients with MDS and CCAs
(104 females, 118 males; median age 68 years). The chromothripsis signature
was revealed in 66.7% cases, both in the main clones as well as in one or
more subclones. On the cytogenetic level, chromothripsis was manifested by
multiple deletions, insertions, ring chromosomes, amplification of individual
genes or chromosomal regions, and/or by the formation of chaotically reassem-
bled marker chromosomes. The fragmentation or shattering of chromosomes
into many pieces was observed as well. The most frequently shattered were
chromosomes 5, 7, 17, and 12. In cases with signs of chromothripsis a higher
frequency of the loss of heterozygosity (LOH) of 17p and/or the copy number
neutral LOH (cnLOH) of 17p was observed (p=0.05). It is usually associated
with homozygous mutations of TP53 gene. Patients with chromothripsis had
significantly worse overall survival (median OS, 3 months). 
Summary/Conclusions: The results of this study confirmed chromothripsis
as a frequent finding in patients with MDS and CCAs. This phenomenon was
associated with a higher frequency of LOH/cnLOH 17p, very poor prognosis
and rapid disease progression. The poor outcome could be explained by the
fact that the function of many important genes becomes affected. The early
identification of chromothripsis in patients with MDS can help with prognosti-
cation. Moreover, a better understanding of the mechanistic basis of chromoth-
ripsis could lead to the development of new treatment strategies based on
drugs targeting genes present in amplified or deleted regions, and/or the DNA
damage response pathways.
This study was supported by research projects RVO-VFN64165, GACR
P302/12/G157, PRVOUK-P27/LF1/1, and MHCR 00023736.
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Background: Azacitidine (Aza) is first-line treatment for patients with higher
risk MDS. Since Aza is an inhibitor of DNMT1, demethylation of tumor sup-
pressor genes has been proposed as the principal mechanism of action.
Demethylation of specific genes has however been difficult to link to increased
gene expression and a more comprehensive mapping of epigenetic and tran-
scriptional effects of Aza on stem / early progenitor cells is warranted.
Aims: To comprehensively map epigenetic and transcriptional effects of Aza
in primary MDS progenitors.
Methods: We selected 11 consecutive patients with higher-risk MDS (n=6),
AML with 21-29% marrow blasts and multilinear dysplasia (n=4) and CMML
type II (n=1). The patients were well characterized with regard to clinical data
and mutations in recurrently mutated genes. CD34+ cells from these patients
were cultured with or without Aza(1µM). Cells were harvested after 24h and
48h; treated and untreated cells were compared with regards to genome-wide
DNA methylation using the Illumina 450k array (n=9), transcription levels using
RNA sequencing (n=4), enrichment of the repressive chromatin mark H3K9me3
(n=6) and the activating mark H3K18ac (n=2) by ChIP seq.
Results: Cell growth and viability over 48 h showed little variation between
untreated and treated cells. Gene expression increased over time in the control
culture, while methylation changes patterns remained unchanged over time.
We observed a strong correlation between gene expression, DNA promotor
methylation (p=1.57e−22 ) and promotor H3K18ac (p=2.72e−61) in the untreat-
ed samples. Exposure to Aza for 24 h resulted in global DNA demethylation,
with 18 657 and 908 promotors being demethylated and hypermethylated,
respectively. The absolute change in methylation was however very modest
with a median reduction in beta-value of 0.015 per gene. Similarly, the effects
of Aza on the histone modifications H3K9me3 and H3K18ac were modest with
12 718 and 13 091 differentially enriched genes, respectively, whereof 52%
and 44% being positively enriched in the Aza samples,; median fold change
were 1.03 and 0.94, respectively. By contrast, the effect of Aza on gene expres-
sion was substantial with 8596 up- and 1804 downregulated; median fold
change per gene was 1.61. Figure 1 illustrates global effects on gene expres-
sion and epigenetic changes with all genes plotted as bars on the X-axis sorted
from most decrease to most increase. The relatively large changes observed
in gene expression could not be explained by corresponding changes in pro-
motor DNA methylation (p=1.88e−01), H3K9me3 (p=6.09e−01) or promotor
H3K18ac (p=5.02e−01). GO analysis of the upregulated genes display enrich-
ment in pathways involved in gene expression, protein synthesis and protein
localization. Principal component analyses of epigenetic data displayed clus-
tering based on patient identity while Aza-treatment had minor impact on clus-
tering pattern.
Figure 1.
Summary/Conclusions: in vitro Aza-treatment induces modest epigenetic
changes in primary MDS progenitors. There are more pronounced effects on
gene expression but since there is no correlation with changes in DNA methy-
lation, H3K9me3 or H3K18ac, these effects must be a result of other mecha-
nisms such as modulation of transcription factors. The limited epigenetic effect
observed in the progenitor cells might be an explanation why Aza fails to
achieve long-term remissions and the short-term remissions may be due to
epigenetic effects on more differentiated cells.
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Background: Erythropoiesis stimulating agents (ESA) are first choice for treat-
ing anemia in lower-risk MDS patients (pts), but no ESA is approved for this
indication. This international, Phase 3, randomized, double-blind, placebo
(PBO)-controlled, multicenter study assessed the efficacy and safety of epoet-
in-alfa (epoetin-a; Eprex®) in pts with IPSS Low- or Int-1 risk MDS suffering
from anemia. 
Aims: To evaluate whether epoetin-a improves anemia (by erythroid response
[ER]; IWG 2006) vs PBO over 24 weeks (w) of treatment. Duration of ER,% of
pts maintaining ER up to w48, time to 1st RBC transfusion, transfusion-free
interval, # of RBC transfusions, changes in PROs/ QoL and safety were also
assessed.
Methods: Pts with de novo IPSS Low or Int-1 MDS with Hb ≤10.0 g/dl, trans-
fusions ≤4 RBC units within 8-w before randomization, baseline serum EPO
level <500 mU/mL, adequate iron and vitamin stores were eligible. The study
included 3 phases: 3-w screening, 24-w double-blind treatment, and 24-w dou-
ble-blind treatment extension in responders. Pts were randomized 2:1 to receive
either epoetin-a 450 IU/kg (max tot. starting dose 40k IU) or matching PBO,
once weekly sc, stratified according to transfusion need (yes/no) & serum EPO
level (<200 mU/mL vs ≥200 mU/mL). Dose adjustments driven by ER and
weekly Hb levels, included increase up to 1050 IU/kg (max tot. dose 80k IU)
and dose reduction/withhold according to weekly Hb regardless of ER status.
Primary endpoint was ER during first 24-w based on IWG 2006 criteria by inves-
tigators and an independent Response Review Committee (RRC). An ad hoc
analysis was conducted in subjects who responded at any time of the study,
regardless the IWG 2006 criteria, to allow assessment following dose adjust-
ments and a longer period of observation.
Results: 130 pts were randomized, 85 to epoetin-a group; 54.6% were male;
median age was 75 years. Baseline characteristics were comparable between
groups. 70 (82.4%) epoetin-a pts completed the 24-w treatment; 39 (45.9%)
epoetin-a pts entered the extension phase vs 1 (2.2%) PBO pt. 31.8% of epo-
etin-a pts achieved primary endpoint vs 4.4% of PBO pts, p<0.001. In the ad
hoc analysis, 45.9% of epoetin-a pts vs 4.4% of PBO pts achieved ER, p<0.001.
Median ER duration for epoetin-a pts was 197 days. Within 8-w prior to baseline,
51.8% of epoetin-a pts needed transfusions; this decreased to 24.7% by w-24.
Transfusion need remained unchanged in the PBO pts (48.9% - 54.1%). Time
to 1st transfusion was longer in the epoetin-a group (p=0.046). In a post-hoc
analysis improvement in QoL scores was observed at w-24 in the epoetin-a
arm in responders vs non responders (FACT-An p=0.025, EQ-5D p=0.007, EQ
VAS p=0.037). Safety data were comparable up to w24; 77.6% of pts on epo-
etin-a reported ≥1 treatment-emergent adverse event (TEAE) vs 88.9% with
PBO. Drug discontinuation due to AE was 10.6% in epoetin-a vs 13.3% in PBO.
4 pts in the epoetin-a arm (4.7%) and none in PBO reported ≥1 TVE. There
were 4 TEAEs with fatal outcome in the epoetin-a arm vs 1 in PBO arm; none
was reported to be related to the study drug. During the study progression to
AML was similar between groups (3.5% in epoetin-a; 4.4% in PBO).
Summary/Conclusions: Epoetin-a significantly improved anemia by increas-
ing Hb and reducing transfusion requirement in patients with Low or Int-1 MDS.
Improved QoL was observed in responders. No new safety signals were detect-
ed in this study. These results confirm experience from clinical practice. 
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OVERALL SURVIVAL (OS) AND SUBGROUP RESULTS FROM A RANDOMIZED
PHASE 2 STUDY OF SGI-110 (GUADECITABINE) IN PREVIOUSLY TREATED
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Background: Guadecitabine (formerly SGI-110) is a next generation small vol-
ume subcutaneous (SC) hypomethylating agent (HMA) with a differentiated PK
profile and clinical activity reported in previously treated MDS and AML patients
(pts) in Phase 1 (Issa et al, Lancet Oncology 2015). Responses were also seen
in a Phase 2 study in both newly diagnosed and previously treated MDS and
chronic myelomonocytic leukemia (CMML) pts randomized to guadecitabine
SC 60 mg or 90 mg/m2 QDx5 with no significant differences between the 2
dose groups (Garcia-Manero et al, ASH 2014).
Aims: To report the clinical activity, safety, long term OS, and subgroup analy-
ses results for guadecitabine in previously treated MDS and CMML pts.
Methods: Intermediate (Int), or High Risk (HR) MDS by IPSS score, and CMML
pts who were previously treated with azacitidine (AZA) and/or decitabine (DAC)
were randomized to either 60 mg/m2 or 90 mg/m2 QDx5 every 28 days in this
Phase 2 study. Clinical responses were assessed using the IWG 2006 criteria.
Safety was assessed using CTCAE grades.
Results: 53 relapsed/refractory (r/r) MDS or CMML pts were randomized to
either guadecitabine 60 mg/m2 (26 pts) or 90 mg/m2 (27 pts). There were no
major differences between the 2 dose groups so data from both groups were
combined for this report. Median age was 72 y (range 52-88y); ECOG PS was
0/1/2 in 21, 58, and 21% of patients. Patients were previously treated with AZA
(77%) and/or DAC (32%) with 75% of patients receiving at least 6 months of
prior treatment; 19% of patients had CMML, 47% had HR MDS; and 66% were
transfusion-dependent. The median baseline bone marrow (BM) blasts were
8% (range 0-19%), baseline median Hb was 9.3 g/dL (range 7.1-13.5), median
neutrophils were 0.81 x109/L (range 0.1-15.6), and median platelets count was
37 x109/L (range 7-328). Patients received a median number of 5 cycles of
guadecitabine (range 1-29). Complete Response (CR) was achieved in 2 pts
(4%), marrow CR in 15 pts (28%), and Hematological Improvement (HI) in 11
pts (21%). Median OS was 11.7 months (m). Patients who achieved a clinical
response (CR, mCR, or HI) had longer OS than those with no response
(p=.006). Median OS was 19.8 m for CMML; 12.3 m for Int MDS; and 10.1 m
for HR MDS. Baseline BM blasts >5% and transfusion dependence predicted
poor OS (p=0.07 and 0.06 respectively), with the worst OS in pts with both BM
blasts >5% and transfusion dependence (p=0.007). Treatment was reasonably
well tolerated. The most common Grade ≥3 AEs regardless of relationship to
treatment were thrombocytopenia (55% of patients), anemia (51%), neutropenia
(45%), febrile neutropenia (38%) and pneumonia (32%). All-cause 60-day mor-
tality was reported in only 1 patient (1.9%).
Summary/Conclusions: SC guadecitabine (SGI-110) is a well-tolerated novel
HMA with clinical activity and OS of almost 12 months in heavily HMA treated
r/r Int and HR MDS and CMML pts that warrants further development. Clinical
responses were associated with improved OS, and pts with both baseline BM
blasts >5% and transfusion-dependence had the worst OS.
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MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC
SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC
RELEVANCE
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Background: Cohesin, a multimeric protein complex, is essential for chromo-
somal stability and transcriptional regulation. Perturbation of cohesin complex
genes may contribute to malignant transformation and clonal evolution of
hematopoietic cells. Recently, mutations within the cohesin complex were found
in patients with myeloid neoplasms, but the reports concerning their clinical
implications in myelodysplastic syndrome (MDS) are limited.
Aims: We aimed to elucidate the clinic–biological features and prognostic rel-
evance of cohesin mutations in a large cohort of de novo MDS patients.
Methods: The mutational status for cohesin complex genes, including RAD21,
STAG1, STAG2, SMC1A and SMC3, and 18 other molecular genetic alterations
were analyzed in 420 patients with de novo MDS based on the FAB classifica-
tion. Among them, the disease of 324 patients fulfilled the criteria of MDS
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according to the 2008 WHO classification. The clinical features, cytogenetics,
molecular alterations, and treatment outcomes were compared between
patients with and without cohesin mutations.
Results: Cohesin mutations were identified in 31 (7.4%) of 420 patients, includ-
ing two (0.5%) with STAG1 mutations, 27 (6.4%) with STAG2 mutations, and
2 (0.5%) with SMC1A mutations, respectively. The patients with cohesin muta-
tions were older (P=0.0368), and had lower absolute neutrophil counts
(P=0.0361) at diagnosis. Cohesin mutations occurred frequently in patients
with refractory anemia with excess blasts (RAEB1/RAEB2), those with higher-
risk International Prognostic Scoring System (IPSS) and revised IPSS
(P=0.0107, P=0.0207 and P=0.0011, respectively). Clonal chromosomal abnor-
malities were detected in 168 (42.5%) of 395 patients who had chromosomal
data. There was no difference in the distribution of karyotypes between patients
with cohesin mutations and those without. Twenty-seven (87.1%) of the
cohesin-mutated patients had concurrently other gene mutations. The patients
with cohesin mutations had significantly higher incidences of concurrent
RUNX1 (25.8% vs 11.3%, P=0.0403), IDH1 (12.9% vs 0%, P<0.001), ASXL1
(61.3% vs 19.5%, P<0.001), and SRSF2 mutations (45.2% vs 11.1%, P<0.001),
but a trend of lower incidence of TP53 mutation (0% vs 10.5%, P=0.0587) than
those with wild type cohesin. With a median follow up duration of 42.9 months,
there was a close correlation between cohesin mutations and acute leukemia
transformation (3-year leukemia transformation rate, 78.5% vs 25.1%, for
patients with and without cohesin mutations; P<0.001). MDS patients, based
either by the FAB or 2008 WHO classification, had a significantly shorter overall
survival if they harbored cohesin mutations than those who did not (median,
22.5 months vs 34 months, P=0.004 and 28.3 months vs 48.1 months, P=0.003,
respectively). The difference remained significant when the analysis was per-
formed in the subgroup of patients with lower risk MDS defined by the FAB
classification (including RA and RARS), the WHO classification (other than
RAEB, subtypes with blasts <5%), IPSS (including low- and intermediate 1-
risk groups) or IPSS-R (including very low-, low- and intermediate–risk groups).
However, there was no prognostic impact of cohesin mutations in the patients
with higher risk MDS.
Summary/Conclusions: Cohesin mutations can be detected in a portion of
MDS patients and are closely associated with mutations of RUNX1, IDH1,
ASXL1 and SRSF2. The presence of cohesin mutations predicts shorter sur-
vival, especially in the patients with lower risk MDS.
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Background: High through-put sequencing studies have revealed a large num-
ber of mutated genes in patients with myelodysplastic syndromes (MDS), of
which RNA splicing factors and epigenetic factors constitute the two most fre-
quent groups. Several studies have suggested that mutational screening may
be beneficial to predict prognosis and clinical outcome of MDS patients.
Aims: In the present study we investigated molecular profiles in Nordic MDS
patients, asking the question whether these population-based cohorts differ
from that of previously published patient materials.
Methods: A total of 495 consecutive samples from Sweden, Denmark, and
Norway were included in this study, encompassing all MDS subgroups, CMML,
mixed MDS-MPN and RARS-T. The respective regional ethical committees
approved the study, and all patients provided informed consent. Clinical data
was collected based on national health registry systems.
Fresh bone marrow MNCs were isolated using gradient centrifugation and
genomic DNA was extracted using column based DNA purification kits. Target-
ed enrichment of protein coding genomic regions of 42-75 frequently mutated
genes were carried out and analyzed by next generation sequencing.
Results: Samples were successfully sequenced with an average coverage over
500 reads, allowing us to set the mutation detection to an allelic burden of ≥3%.
In addition, we set the detection limit to 1% for TP53, considering the putative
prognostic role of mutations in this gene. In our cohort, only 28 patients (6%)
showed no mutations. We found that eleven genes; TET2, SF3B1, ASXL1,
SRSF2, DNMT3A, TP53, RUNX1, U2AF1, EZH2, IDH2 and ZRSR2 were mutat-
ed in more than 5% of the patients (Fig.1), as compared to 7 genes, in the study
by Papaemmanuil, et al, (Blood, 2013, 122(22): 3616-3627). Correspondingly,
7 genes showed a mutation rate >10%, compared to 4 in that study. Although
our top gene list was similar to those reported in previous large studies we noted
some interesting differences. Mutations in AXSL1 (15%), RUNX1 (10%), and
TP53 (10.7%) were more frequent than in the study reported by Papaemmanuil
(12%, 6% and 5%, respectively). The higher TP53 mutation rate can to some
extent be attributed to the higher sensitivity, since 7 mutations had an allelic
burden between 1% and 5%. Moreover, 34% (174 Patients) of our cohort had
≥3-mutated genes, compared to 20% in the Papaemmanuil paper.
Figure 1.
Summary/Conclusions: The representativeness of reported studies based
on selected patient cohorts constitutes a concern. Here, we show evidence
that the mutational spectrum of a consecutive population-based Nordic cohort
has an overall higher risk profile than previously published patient materials.
This is valuable information, as mutation profiling will be soon part of standard
clinical practice. In addition we believe that screening for TP53 mutations in
MDS patients should be performed with sensitive methods, allowing for detec-
tion also of small subclones.
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CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS
(PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK
MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q)
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Background: In the phase 3 MDS-005 study of LEN in RBC-TD lower-risk
(LR) non-del(5q) MDS pts ineligible for/refractory to erythropoiesis-stimulating
agents (ESAs), a statistically significant and clinically relevant higher proportion
of LEN-treated pts achieved RBC transfusion independence (RBC-TI) ≥8 wks
vs placebo (PBO) (P <0.001); other measures of efficacy collected included
erythroid improvement and cytogenetic response (CyR).
Aims: To evaluate the relationship between LEN and clinically meaningful
measures of response in pts from MDS-005.
Table 1.
Methods: Pts were randomized 2:1 to LEN 10 mg/day (n=160) or PBO (n=79)
once daily. Clinical benefit ≥8 wks was defined as the composite endpoint of
RBC-TI ≥8 wks, or transfusion reduction of ≥4 units packed RBCs (pRBCs) ≥8
wks, or hemoglobin (Hb) increase ≥1.5 g/dL at 8 wks (IWG 2006), or CyR. The
rate of transfusion reduction was calculated using data collected during a 112-
day assessment period to account for on-study differences in transfusion bur-
den. CyR was also evaluated separately.
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Results: Clinical benefit was higher in pts treated with LEN vs PBO (Table 1).
In evaluable pts with ≥1 follow-up assessment (n=43), CyR with LEN was report-
ed in 9 (33.3%) pts (major: n=5; minor: n=4). No CyR occurred in the PBO
group. Among pts with CyR, 5 (55.6%) also achieved RBC-TI ≥8 wks.
Summary/Conclusions: In RBC-TD pts with LR non-del(5q) MDS ineligible
for or refractory to ESAs, LEN was associated with significantly greater clinical
benefit, as measured by this newly defined composite endpoint, vs PBO. This
analysis provides evidence that other measures of response in addition to RBC-
TI may be valuable in the management of LR non-del(5q) MDS. Clinically mean-
ingful responses to LEN in non-del(5q) pts include CyR, decrease in transfu-
sions, and increased Hb, in addition to RBC-TI.
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Background: Hypomethylating agents (HMA) are typically administered par-
enterally and adjusted to body surface area (BSA) in order to achieve target
pharmacokinetic (PK) parameters associated with response. Much of the vari-
ation associated with administration of HMAs is related to the intrinsic variability
of the activity of cytidine deaminase (CDA) an enzyme with highest levels in
the gut and liver which rapidly metabolizes HMAs.
Aims: To assess PK comparability with the aim of matching PK parameters of
BSA adjusted dosing with IV decitabine (DAC) with a novel fixed-dose oral
combination (ASTX727), of DAC and E7727, a CDA inhibitor. Preliminary safety
and clinical activity were previously reported (Savona M, Blood:126(23);
1683,2015).
Methods: Adult patients with Int-1/Int-2 or HR MDS or Chronic Myelomonocytic
Leukemia (CMML) were enrolled in a Phase I, dose-escalation trial, aiming to
achieve a mean AUC of DAC following oral ASTX727 comparable to IV DAC
at the approved dose of 20mg/m2. In the first cycle, each patient received an
IV DAC dose of 20mg/m2 on Day 1 as an internal comparator followed by oral
ASTX727 on Days 2-5 escalated by cohort. Only one component at a time
was escalated in each cohort and oral doses were not adjusted for weight or
body surface area. Full PK assessments were performed on Days 1, 2 and 5.
Results: 43 patients were treated in 5 cohorts of 6 patients each plus a dose
confirmation cohort of 13 patients. In cohorts 1-3 ASTX727 was given as a
fixed oral DAC dose of 20mg with escalating doses of oral E7727 at 40, 60,
and 100mg, respectively. In cohort 4, the oral DAC dose was escalated to 40mg
while E7727 was kept at 100mg and Cohort 5 evaluated 30 mg DAC and 100mg
E7727. DAC AUC increased with increasing doses of E7727. The AUC on Day
5 of dosing was higher than that on Day 2 of dosing due to residual levels of
inhibitor E7727 present systemically 24 hours post dosing. Thirty patients were
male, 13 female, their median weight was 87.8kg (range=51.1-204.1) and medi-
an BSA was 2.0m2 (range 1.28-2.67). The Day 1 AUC for IV DAC 20mg/m2
over all 5 cohorts was 188(+/-76) ng*hr/mL, CV= 41%. The Day 5 mean DAC
AUC for ASTX727 increased with dose escalation from 31 to 148% of the Day
1 IV DAC AUC. (Table 1) Cohort 5 achieved ~90% oral DAC AUC exposures
to IV with the acceptable variability of CV=50%. Linear regression between
weight and DAC AUC for cohort 5 showed no correlation (p=0.7887).
Table 1. Mean Plasma DAC AUC and SD by Cohort for the Study
afterASTX727 and IV DAC.
Summary/Conclusions: Despite wide ranges in weight and BSA, oral
ASTX727 administered in a fixed low dose of decitabine and E7727 delivers
an AUC comparable to BSA adjusted IV decitabine in both exposure and vari-
ation. The low PK variability is attributed to the elimination of variations due to
CDA activity through CDA inhibition by E7727 which appears to compensate
for body mass disparities. An ongoing randomized cross-over Phase 2 trial is
currently studying the PK and pharmacodynamic effects of full 5-day cycles of
IV DAC and ASTX727.
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THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS
THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT
DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY
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Background: Myelodysplastic syndrome (MDS) prognosis, risk stratification
and management is currently dictated by the IPSS-R with metaphase chromo-
some analysis being the only current contributing genetic factor. The UK NHS
genetic service offers metaphase cytogenetics (MC) as the only routine test,
which is not only time consuming but ultimately only detects an abnormal kary-
otype in approximately 45% samples. Although there is no single technology
that can identify the various genomic and genetic aberrations observed in MDS
in a single test, the cytogenetic aberrations seen in MDS are mostly copy num-
ber changes (with the exception of 3q26 MECOM gene rearrangements) and
therefore microarray analysis offers an alternative approach to MC. High density
single nucleotide polymorphism microarrays (SNP-A) offer genome wide copy
number analysis at a resolution beyond that of MC analysis, and often down to
the single gene, and even exon, and can identify regions of copy number neutral
loss of heterozygosity (CN-LOH) that may harbour biallelic gene mutations.
Consequently microarray analysis has the potential to increase genetic abnor-
mality detection rates thereby improving diagnosis.
Aims: The West Midlands Regional Genetic Laboratory has undertaken a two
year study to use SNP-A analysis as a complementary tool to MC in patients
with confirmed or highly suspected MDS both at presentation and during the
disease course. The aim of the first arm of the study is to determine the utility
of high density SNP-A as the primary test for MDS patients to replace MC
analysis at diagnosis. This includes comparison of abnormal karyotype detec-
tion rate and aberrational yield.
Methods: SNP-A analysis was performed on DNA extracted from marrow sam-
ples of 102 MDS patients. All 102 patients’ samples were, in parallel, subjected
by MC analysis. DNA was interrogated using Affymetrix CytoScan HD SNP
arrays which contain 2.6 million markers including approximately 750,000 SNPs.
Data was analysed using Affymetrix Chromosome Analysis Suite (ChAS).
Results: Forty four cases (43%) were found to have no reportable abnormalities
by both MC and SNP-A analysis, and 40 cases (39%) were found to be abnor-
mal by both techniques. The remaining 18 cases (15%) were discrepant: 15
cases were found to be abnormal by SNP-A but normal by MC analysis, where-
as 3 cases were found to be abnormal by MC analysis but normal by SNP-A
analysis. The karyotype of 33 cases were discrepant between MC and SNP-A.
A total of 39 additional abnormalities in 30 cases were detected by SNP-A that
were not seen or identified by MC analysis, including: 18 regions of CN-LOH;
gain of chromosome 4; loss of chromosome 7; loss of 7q; two TET2 deletions,
two CUX1 deletions; a partial deletion of RUNX1; and a partial tandem dupli-
cation of KMT2A. Regions of CN-LOH (>10 Mb, extending to the telomere)
were found in 17 patients (18%), with 7q being the region most affected (5
patients). Three aberrations were identified by MC that were not detected by
SNP-A: a low level trisomy 8 clone (~1% clone); an insertion resulting in a
RUNX1 rearrangement as the sole abnormality; and a 3q translocation resulting
in a MECOM rearrangement as part of a complex karyotype.
Summary/Conclusions: SNP array analysis increased the number of cases
identified as genetically abnormal from 43% to 54% and identified an additional
39 aberrations compared to MC analysis. Additional aberrations detected by
SNP array, including gene deletions and CN-LOH, have the potential to refine
risk stratification and prognosis in MDS. The detection of cytogenetically cryptic
and potentially prognostically significant abnormalities in these MDS patients
highlights the need for higher resolution genomic detection methods in the diag-
nosis of this disease.
Acknowledgements: This work was funded by Affymetrix.
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PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH
AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC
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Background: The Hedgehog signaling pathway (HhP) is known to be aber-
rantly activated in leukemias and myelodysplastic syndrome (MDS), promoting
cancer stem cell maintenance. Glasdegib is a potent, selective, oral HhP
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inhibitor which acts by inhibition of Smoothened (SMO), with activity in pre-
clinical models and antitumor efficacy in vivo. A Ph.1 study of glasdegib
monotherapy in patients (pts) with hematologic malignancies suggested the
drug is well tolerated and active. When glasdegib was combined with low-dose
cytarabine, decitabine or standard induction chemotherapy in 7 previously
untreated high-risk MDS pts, 2 achieved complete responses (CR) and 3 had
marrow (m)CRs. Further, blocking the HhP with SMO inhibitors in combination
with azacitidine (aza) demonstrated synergy in vitro and inhibited primary malig-
nant myeloid cells ex vivo.
Aims: Primary objective of the open-label Ph.1b part of this study
(NCT02367456) was to assess the safety of combining glasdegib with aza in
pts with previously untreated higher risk MDS (IPSS score risk: high or Int-2),
oligoblastic acute myeloid leukemia (oAML) with 20-30% blasts and multi lin-
eage dysplasia (WHO 2008 criteria), or non-proliferative chronic myelomono-
cytic leukemia (NP-CMML) with white blood cells <13x109/L.
Methods: Adult pts gave informed consent and received glasdegib 100mg
once daily in combination with standard aza 75mg/m2 days 1-7 every 28 days
for as long as pts received clinical benefit. Patients were assessed for safety,
tolerability and efficacy. 
Results: As of Dec 30, 2015, 12 pts (7 males) with a mean age of 72 years
(range 59-89) were enrolled. Primary baseline diagnosis was MDS: 7 (IPSS-
risk Int-2: 5, high risk: 2), oAML: 3, NP-CMML: 1, other (erythroleukemia): 1.
Across all cycles the median dose intensity was 80% for glasdegib and 97%
for aza. At data cutoff, 8 pts (67%) discontinued treatment due to an adverse
event (AE) (n=5), physician decision (n=2) or patient decision (n=1). Plasma
exposure of both agents was unchanged when coadministered. The most com-
mon, all-cause AEs included anemia and constipation (75% each), nausea
(67%), fatigue (58%), dysgeusia and neutropenia (50% each). Non-hematologic
grade (G)3-4 AEs of sepsis occurred in 2 pts (17%); additional G3-4 AEs occur-
ring in 1 pt (8%) are listed in the Table 1. Eight pts (67%) experienced serious
AEs (SAEs); SAEs occurring in 2 pts (17%): cellulitis, febrile neutropenia, and
pyrexia. Four of the 12 pts had an investigator-assessed response by IWG cri-
teria: 3 CR and 1 mCR; 4 pts had stable disease. Three pts died from disease
progression, sepsis with multi-organ failure, and myocardial infarction due to
underlying CAD. Six-month survival was 67%.
Table 1. Non-hematologic G3-4 AEs (n=1).
G3: Fatigue, prolonged QT, muscle spasms, hyponatremia, urinary tract infection, hematoma,
hypophosphatemia, hypoxia, bacteremia, diverticulitis, hemarthrosis, hypokalemia, lung malig-
nancy, mental status changes, musculoskeletal chest pain, neutropenic sepsis, osteomyelitis,
procedural hypotension, respiratory tract infection, and tachycardia
G4: Dyspnea, cellulitis, hypotension, pneumonia, acute kidney injury, acute respiratory distress
syndrome, ischemic hepatitis, respiratory distress, and septic shock
Summary/Conclusions: The addition of glasdegib to standard-of-care aza in
the treatment of pts with MDS, CMML or oAML appears to have an acceptable
safety profile. The number of CRs observed so far appears favorable in the
context of the 15-17% CR rate seen with aza alone. A randomized trial of glas-
degib in combination with aza is planned in MDS.
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RESULTS FROM PHASE I/II STUDY OF THE COMBINATION OF ORAL
RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES (MDS)
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Background: Rigosertib is a Ras-mimetic (Athuluri-Divakar, Cell 2016, in
press) that inhibits the PI3K and PLK cellular signaling pathways by binding
directly to the Ras-binding domain found in Ras effector proteins. In vitro, the
combination of rigosertib with azacitidine synergistically inhibits growth and
induces apoptosis of leukemic cells in a sequence-dependent fashion (rigosert-
ib administered prior to azacitidine) (Skidan, AACR 2006). Phase I results of
this study in pts with MDS or AML showed the combination of oral rigosertib
and standard-dose azacitidine to be well-tolerated with evidence of efficacy
(Navada, Blood 2014).
Aims: Phase II was initiated to further study the combination in pts with MDS.
Methods: Oral rigosertib was administered twice daily on Day 1-21 of a 28-
day cycle at the recommended Phase II dose (560 mg qAM and 280 mg qPM).
Azacitidine 75 mg/m2/d was administered SC or IV for 7 days starting on Day
8. A complete blood count was performed weekly and a bone marrow aspirate
and/or biopsy at baseline, Day 29, and every 8 weeks thereafter.
Results: Pts with MDS previously untreated with an HMA or progressing/failing
to respond to a prior HMA are presented. Oral rigosertib/azacitidine was admin-
istered to 40 pts with MDS. Demographic data are available on 37 pts, among
whom 73% were male; median age was 64 years (range: 25-85); ECOG per-
formance status was 0, 1, and 2 in 24%, 73%, and 3%, respectively. Fourteen
pts (38%) had received prior HMA therapy: 10 (27%) azacitidine, 3 (8%)
decitabine, and 1 (3%) both. Patients received 1-27+ months of treatment with
the doublet, with a median duration of 4 months. Seven pts have been treated
>1 year and 1 for >2 years. Thirty pts were evaluable for response: Phase I
(N=8) or Phase II (N=22). Among these 30 pts, hematologic response per the
International Working Group (IWG: Cheson, Blood 2006) criteria was seen in
23 (77%) of pts in Phase I/II: 6 (20%) with complete remission (CR), 16 (53%)
marrow CR (mCR), and 1 (3%) hematologic improvement (HI). Six (20%) pts
had stable disease (SD) and 1 (3%) had progressive disease (PD). Among the
27 of 30 pts with sufficient follow-up for a peripheral blood lineage response
evaluation (3 were too early to evaluate), 13 (48%) had an HI: 11 erythroid, 12
platelet, 7 neutrophil. The table shows response by International Prognosis
Scoring System (IPSS-R; Greenberg, Blood 2012) risk categories for the 30
evaluable MDS pts. Among the 11 evaluable pts with MDS who had failed to
respond/progressed/relapsed on prior treatment with an HMA, 7 (64%) had a
response after rigosertib was added: CR (1), mCR (4), mCR plus HI (2). For
HMA-naïve patients (N=19); 16 (84%) responded per IWG. The most frequent
adverse events (AEs) in Cycle 1 were nausea and fatigue (27% each) and
pyrexia and thrombocytopenia (24% each). The most frequent AEs for ≥Cycle
2 were constipation and neutropenia (22% each). Three deaths due to adverse
events have been reported.
Table 1.
Summary/Conclusions: The combination of oral rigosertib and standard-dose
azacitidine was well tolerated in repetitive cycles in pts with MDS. Among the
30 evaluable MDS pts in Phase I/II, hematologic response was seen in 23
(77%), with responses seen in 64% of patients who failed HMA therapy. These
results suggest potential synergistic interaction of the combination and the
capability to reverse clinical HMA resistance, and supports continued study of
this unique combination in pts with MDS.
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FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA
OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF
PROGRESSION TO MYELODYSPLASTIC SYNDROME
JW Hansen1,*, MK Westman2, LD Sjö3, L Saft4, LS Kristensen1, AD Ørskov1,
M Treppendahl5, MK Andersen2, K Grønbæk2
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mark, 4Department of Pathology, Karolinska University Hospital, Solna, Stock-
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Background: Peripheral blood cytopenia is a common finding in the elderly
population, and an extensive diagnostic work up is often done trying to unravel
its causality. Next generation sequencing may be a valuable new diagnostic
tool in these patients, and clonal cytopenia of undetermined significance (CCUS)
has recently been introduced to describe patients with cytopenia of unknown
significance who carry a mutation characteristic of myeloid malignancies.
Aims: The purpose of the present study was to investigate the frequency of
mutations in patients with persistent cytopenia and an undetermined diagnosis
after routine workup.
Methods: We included 60 patients between 2008-2015, who all had persistent
cytopenia for more than six months, and an undetermined diagnosis after routine
workup. Median (range) age was 70 years (25-89) (Table). Diagnosis according
to bone marrow morphology was reviewed in a blinded fashion by two
hematopathologists. Patients with aberrant cytogenetics, except deletion of the
Y-chromosome, were excluded. DNA from peripheral neutrophils or from
mononuclear cells from the bone marrow were sequenced with a targeted 20
gene panel, including genes frequently mutated in myelodysplastic syndrome
(MDS).
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Results: Twenty-one (35%) patients had only one cytopenia, 30 (50%) had
two cytopenias and nine(15%) had pancytopenia. Patients with a mutation had
a lower level of neutrophils compared to non-clonal patients, otherwise the
characteristics were very similar between the two groups (Table). At time of
inclusion mutations in 15 of the 20 genes included in the sequencing panel
was identified. Thirty-seven (62%) patients carried at least one mutation. TET2
was the most frequently mutated gene, found in 26 (43%) patients. There was
no association with the number of cytopenias and the risk of having a mutation
detected at time of inclusion. Follow-up was 1-8 years and during this period
six patients (10%) progressed to MDS or chronic myelomonocytic leukemia
(CMML). Among these patients, five had mutations at the time of inclusion. At
time of progression to MDS or CMML four had a new co-occurring mutation in
NRAS, TP53, GATA2 or ASXL1.
Table 1.
Summary/Conclusions: Patients with persistent cytopenia and an undeter-
mined diagnosis often carry mutations in genes associated with myeloid malig-
nancies. Next generation sequencing is a promising supplement in the diag-
nostic workup as it may identify patients with increased risk of disease pro-
gression.
Molecular characterization of MM
P258
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Background: Multiple myeloma (MM) is a malignant proliferation of antibody-
secreting bone marrow plasma cells (PCs) characterized by a wide clinical
spectrum ranging from the presumed pre-malignant condition called monoclonal
gammopathy of undetermined significance (MGUS), to smoldering MM (SMM),
truly overt and symptomatic MM, and extra-medullary myeloma/plasma cell
leukemia (PCL). Although many efforts have recently contributed to improve
our knowledge of molecular pathogenesis of MM, the role and significance of
long non-coding RNAs (lncRNAs) in PC malignancies remains virtually absent.
Aims: We investigated the lncRNA expression profiles in a large and repre-
sentative cohort of PC dyscrasia, with the aim of identifying deregulated lncR-
NAs putatively associated with MM pathogenesis and possibly linked to the
multi-step process underlining the different stages of the disease.
Methods: We developed a custom annotation pipeline on Gene 1.0 ST microar-
ray data, to investigate lncRNA expression in highly purified bone marrow PCs
from 20 MGUS, 33 SMM, 170 MM, 36 PCL and 9 healthy donors, collected
from proprietary and publicly available datasets.
Results: Our study identified 31 lncRNAs deregulated in pathological samples
compared to the healthy condition. In particular, the upregulation of MALAT1 in
symptomatic patients was associated with molecular pathways involving cell cycle
regulation, p53-mediated DNA damage response, and mRNA maturation
processes. Furthermore, we found 21 lncRNAs whose expression was progres-
sively deregulated trough the more aggressive stages of PC dyscrasia, suggest-
ing a possible role in the progression of the disease. In the context of molecular
heterogeneity of MM, we identified a transcriptional fingerprint in hyperdiploid
(HD) patients, characterized by the upregulation of lncRNAs/pseudogenes related
to ribosomal protein genes. These findings are in line with the global up-regulation
of the translational machinery, including genes involved in protein biosynthesis,
characterizing HD group. To gain evidences of lncRNAs that may potentially act
on gene expression, we evaluated the correlation of each of the differentially
expressed lncRNAs with all the transcripts unambiguously detectable by the
arrays. By focusing on high correlation coefficient, we identified five lncRNAs
suggestive of an in cis rather than an in trans interaction. Finally, based on several
evidences that have suggested the interplay of the various non-coding species,
we investigated the liaison between lncRNAs and miRNAs in 125 samples out of
our series for which miRNA expression profiling was available. We identified 290
lncRNA-miRNA couples significantly anti-correlated in our database. Hence, to
add confidence to the anti-correlation connection, we inspected which of the 290
lncRNAs anti-correlated to miRNAs could also be miRNAs targets. Based on
RNA22 prediction algorithm, we identified nine lncRNA-miRNA couples with tran-
scripts resulting anti-correlated and for which lncRNA is a predicted miRNA target.
Particularly interesting is lnc-MAP1LC3B2-2, found upregulated in MM with MAF
translocation and anti-correlated with miR-222 and miR-221.
Summary/Conclusions: Our study reported many lncRNAs deregulated in
different forms of PC dyscrasia, providing an important source for future func-
tional studies on lncRNAs in MM disease.
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RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND
ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE
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Background: Deletions of chromosomal region 1p22 are found in ~20% of
multiple myeloma patients and have been identified as a negative prognostic
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factor for progression-free survival (PFS) and overall survival (OS) in newly
diagnosed patients (Hebraud et al., Leukemia, 2013). These findings suggest
the presence of an unidentified tumor suppressor gene on 1p22.
Aims: We aimed to delineate a minimal deleted region (MDR) on 1p22 to identify
potential tumor suppressor genes in this region. Additionally, we were interested
in the clinical relevance of lowered expression of genes in the MDR on 1p22.
Methods: We investigated 1p22 deletions using high resolution copy number
arrays in a cohort of 35 multiple myeloma patients. The expression of the genes
in the MDR and their correlation with clinical outcome was further investigated
in data of the MMRC, the phase III HOVON-65/ GMMG-HD4 trial and the APEX
trial. In vitro experiments in mouse B-cells were done to investigate the corre-
lation between expression levels of one of the genes (RPL5) in the MDR with
sensitivity to proteasome inhibitors.
Results: Using high resolution genomic profiling, we delimit a 58 kb minimal
deleted region on 1p22.1 encompassing two genes: ectopic viral integration
site 5 (EVI5) and ribosomal protein L5 (RPL5). Although mutations in 1p22
genes are rare in multiple myeloma, a tumor suppressor role for EVI5 and RPL5
may also be supported by the fact that these genes show the highest frequency
of mutations predicted to impair protein function on 1p22. Interestingly, inacti-
vation of RPL5 was also recently described in T-cell acute lymphoblastic
leukemia (T-ALL) and glioblastoma. We also found that 1p22 deleted patients
have significantly lower levels of EVI5 and RPL5 mRNA expression. Whereas
1p22 deletion status correlates well with EVI5 expression in all patients, it is a
bad predictor of RPL5 expression level in some, suggesting that other mecha-
nisms besides 1p22 deletion can downregulate RPL5 expression in multiple
myeloma. In agreement with what is known for deletion of 1p22, we saw that
low mRNA expression of EVI5 and RPL5 is associated with worse PFS and OS
in diagnostic patients. Interestingly, reduction of RPL5 expression in B-cells
caused 2-fold sensitization to the proteasome inhibitors bortezomib and carfil-
zomib. In addition, RPL5 but not EVI5 mRNA expression levels were significantly
lower in multiple myeloma patients showing clinical response to bortezomib
compared to patients that are not responding. Furthermore, PFS of newly diag-
nosed patients with low RPL5 expression was significantly longer when they
were treated on a bortezomib containing protocol (median PFS bortezomib pro-
tocol 29.8 months versus 18.7 months for non-bortezomib, p=0.03, data phase
III HOVON-65/ GMMG-HD4 trial). In contrast, PFS of RPL5 high patients was
not influenced by bortezomib. These associations between RPL5 expression
level and bortezomib response were confirmed when performing the same
analyses on the PFS data from relapse patients in the APEX trial. For low EVI5
expressing patients, there was a non-significant trend towards benefit from
bortezomib which was not present in the EVI5 high cases.
Summary/Conclusions: We provide genetic data that point towards a tumor
suppressor role for EVI5 and RPL5 on 1p22. Although the exact role of these
genes in promoting MM progression remains to be determined, we identify
RPL5 mRNA expression as a relevant biomarker for initial response to borte-
zomib and subsequent survival benefit after long-term treatment.
P260
COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE
OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P
REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH
CORRELATE WITH A POOR PROGNOSIS
D Hofste op Bruinink1,*, R Hoogenboezem1, M Sanders1, E Bindels1,
C Erpelinck-Verschueren1, P van Strien1, J Koenders1, F Kavelaars1, K Misund2,
B Beverloo3, B van der Holt4, I Touw1, A Waage2, H Avet-Loiseau5, P Sonneveld1
1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Nether-
lands, 2Department of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology, Trondheim, Norway, 3Department of
Clinical Genetics, Erasmus MC, 4HOVON Data Center, Department of Hema-
tology, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, Nether-
lands, 5Department of Hematology, University Cancer Center of Toulouse,
Toulouse, France
Background: A deletion of chromosome 17p (del17p) is detected in 10% of
multiple myeloma (MM) patients at diagnosis and is associated with a dismal
prognosis, classifying it as high-risk disease. Moreover, its prevalence is known
to increase during disease progression. Even though this suggests that it may
be a driver of disease, little is known about the genetic defects that are involved
in its pathology. Del17p in MM usually involves a hemizygous loss of a com-
monly deleted region (CDR) on 17p13.1, in which several potential tumor sup-
pressor genes reside that could be bi-allelically inactivated by the deletion itself
and a concomitant mutation. Of these, TP53 is the most studied gene in del17p
MM, but previous targeted sequencing efforts failed to identify a high prevalence
of mutations herein. We therefore hypothesized that relevant genetic lesions
might have been missed in either TP53 itself, in other genes in the CDR on
chromosome 17p (Chr17p), or in disease-relevant pathways, that could explain
the aggressive clinical behavior of this type of MM.
Aims: With this study, we sought to systematically analyze the genomes of
del17p MM tumors, in order to identify recurrent genetic aberrations and to
assess their prognostic significance within this disease subgroup.
Methods: DNA was isolated from peripheral blood and CD138+ enriched bone
marrow mononuclear cells from chemotherapy-naive MM patients with a del17p
in ≥50% of plasma cells, as detected with fluorescent in situ hybridization
(FISH). Libraries were generated using a custom capture (SeqCap EZ Exome
Plus, Nimblegen) of 111 Mb, comprising the whole exome, Chr17p and the
IgH, Igk, IgL and MYC regions. Paired-end sequencing was performed on a
HiSeq2500 platform, followed by data analysis using an in-house bioinformatics
pipeline at Erasmus MC, including SNPExpress, MutSigCV and GISTIC2. Sin-
gle nucleotide variants in TP53, FAM46C, KRAS, NRAS, DIS3 and BRAF were
validated using a custom amplicon panel (TruSeq Custom Amplicon Assay
v1.5, Illumina), followed by deep sequencing on a MiSeq System.
Results: We captured and sequenced tumor and germline DNA from 44
patients, which resulted in an average coverage of 90x and overall coverage
of 94%. Clinical data were available from 40/44 patients, with a median follow-
up time of 18 months. We identified a CDR on Chr17p of 235 kb, in which one
or more somatic, nonsynonymous aberrations in TP53 were detected in 25/44
(57%) patients (adj. p<1x10-10; n=17 missense, n=9 nonsense, n=2 splicing).
All other genes in the CDR on Chr17p lacked any nonsynonymous mutations.
Besides TP53, we found FAM46C and KRAS to be significantly mutated. RB1,
TRAF3 and FAM46C were significantly deleted in our patient cohort. TP53
mutated patients had a worse overall survival (OS) than TP53 wildtype patients
(p=0.008). Patients with TP53 missense mutations showed the worst OS
(p<1x10-3), as well as progression-free survival (PFS) (p=0.015).
Summary/Conclusions: (1) TP53 is somatically mutated in the majority of
del17p MM patients; others lack any nonsynonymous somatic event in the
CDR on Chr17p. (2) Particularly TP53 missense mutations have a significantly
negative impact on both OS and PFS in del17p MM patients. (3) The rest of
the genomic landscape of del17p MM is characterized by significant mutations
in FAM46C and KRAS, as well as deletions of RB1, TRAF3 and FAM46C.
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Background: The importance of glutamine (Gln) metabolism in multiple myelo-
ma (MM) cells and its potential role as a therapeutic target are still under inves-
tigation, although it has been reported several years ago that human myeloma
cell lines (HMCL)s are highly sensitive to Gln depletion. Moreover, MM cells pro-
duce an excess of ammonium (NH4+) in the presence of Gln and hyperammone-
mia is a possible rare clinical manifestation in relapsed/refractory MM patients.
Aims: The aim of this study was to investigate the relationship between NH4+
production and Gln-dependence in MM cells, as well as the mechanisms involved
therein, actually unknown, in order to identify a new potential target in MM patients.
Methods: A total cohort of 64 patients with Plasma cell (PC) disorders were
included in the study: 6 patients with monoclonal gammopathy of undetermined
significance (MGUS), 12 with smoldering myeloma (SMM), and 46 with active
MM including 28 newly diagnosed MM (ND-MM) and 18 relapsed MM (R-MM).
NH4+ levels in bone marrow (BM) plasma and produced by HMCLs (JJN3,
OPM2, RPMI 8226, XG1, KMS-12-BM) and primary CD138+ cells purified from
BM aspirates in the presence or in the absence of Gln were assessed by the
Roche Cobas NH3 Ammonia assay. BM plasma content of amino acids was
determined by HPLC. The expression of the main enzymes involved in Gln
metabolism (Glutaminase (GLS); Glutamine Synthetase (GS) and Asparagi-
nase) and Gln transporters were evaluated. The effect on MM cell viability of
E. chrysanthemi L-Asparaginase (ASNase), with glutaminolytic activity, was
tested alone or in combination with Bortezomib (0-10 nM). The intracellular
levels of Gln, Glutamate (Glu), and 2-oxoglutarate (2-OG) were measured with
mass spectrometry. Furthermore, gene expression profiles of glutamine trans-
porters were evaluated in two PC dyscrasia datasets, generated using 3 pro-
prietary (GSE13591, GSE6205 and GSE66293) and 3 publicly available
(GSE6477, GSE6691 and GSE47552) datasets. Anti-SLC1A5 shRNA lentiviral
vector was used for ASCT2 stable knockdown in HMCLs, whereas the scramble
lentiviral vector was used as control. For the in vivo experiment 8 SCID-NOD
mice for group were injected subcutaneously with JJN3 stably transfected with
anti-SLC1A5 containing plasmid vectors or with JJN3 stably transfected with
the empty vector and then tumor growth was monitored.
Results: We found that both HMCLs and primary BM CD138+ cells produced
large amounts of NH4+ in the presence of Gln. Active MM patients have higher
BM plasma NH4+ and Glu and lower Gln levels in comparison with patients with
indolent monoclonal gammopathies. Interestingly, HMCLs expressed GLS and
were sensitive to its inhibition with BPTES and CB-839, while exhibited negligible
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expression of GS. High GLS and low GS expression were also observed in pri-
mary CD138+ cells. Gln-free incubation or treatment with the glutaminolytic
enzyme ASNase depleted the cell contents of Gln, Glu and the anaplerotic sub-
strate 2-OG, inhibiting MM cell growth. Moreover, ASNase effect on HMCL via-
bility was potentiated in the presence of Bortezomib. In line with the dependence
of MM cells on extracellular Gln, the gene expression profile analysis showed an
increased expression of the Gln transporters SNAT1, ASCT2, and LAT1 by
CD138+ cells across the progression of monoclonal gammopathies. Interestingly,
among these transporters, only ASCT2 inhibition in HMCLs caused a marked
decrease in Gln uptake. Consistently, ASCT2 stable down-regulation inhibited
HMCL growth both in vitro. Finally, in the in vivo mouse model we found that
mice inoculated with the ASCT2-silenced cells developed significantly smaller
plasmacytomas than animals injected with the scramble-transfected cells.
Summary/Conclusions: In conclusion, MM cells strictly depend upon extra-
cellular Gln and show features of Gln-addiction. Therefore, the inhibition of Gln
uptake is a new attractive therapeutic strategy for MM.
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Background: Venetoclax/ABT-199 is the first in class Bcl-2 specific BH3 mimetic
and among the most promising targeted therapy in oncology. Venetoclax has
already demonstrated its efficacy in chronic lymphoid leukemia and is currently
under investigation in multiple myeloma. Multiple myeloma is heterogeneous
and includes patients with translocation of the IgH locus on chromosome 14
with different chromosomes (4, 6, 11 or 16) and patients with a hyperdiploidy
involving odd chromosomes. Venetoclax induces apoptotic cell death in a sub-
group of myeloma patients that carried the t(11;14) translocation and expressed
a high Bcl-2/Mcl-1 gene expression ratio. In contrast, resistance to venetoclax
is mediated by a high Mcl-1 expression in other myeloma subgroups.
Aims: The expected use of venetoclax alone or in combination with other
agents in the treatment of myeloma leads us to explore the mechanisms of
acquired venetoclax resistance. We investigated whether the acquired resist-
ance to venetoclax might be different from the intrinsic resistance.
Methods: We derived resistant sublines from initially KMS12-PE and XG5 t(11;14)
myeloma venetoclax highly sensitive cell lines (LD50 15 and 5nM respectively).
Cell lines were cultured during several months with increasing venetoclax con-
centrations until cells were able to maintain viability with 2mM venetoclax. Patterns
of Bcl-2 family gene and protein expression were compared between parental and
resistant sublines by quantitative PCR and western blotting analysis. BH3 profiling
approach by flow cytometry was used to analyze the mitochondrial priming of
parental and subline.and their dependence on individual anti-apoptotic family mem-
ber. Bax exon sequencing was performed to analyze potential mutations.
Results: We first provided evidence that venetoclax resistant sublines (XG5-
199R and KMS12PE-199R) displayed cross-resistance to bortezomib. We then
demonstrated that both resistant sublines exhibited a strong increase in both
Mcl-1 mRNA and protein levels. Beside Mcl-1, the other Bcl-2 anti-apoptotic
proteins were not significantly modified. Strikingly, a total lack of both Bax and
Bak effector proteins characterized the XG5-199R subline. According to its strong
sensitivity to venetoclax, XG5 cells exhibited a primed Bcl-2 profile. In contrast,
we found that XG5-199R cells were unprimed. The XG5-199R unprimed status
could be explained by the absence of Bax and Bak effector proteins. Finally, by
sequencing BAX gene, we identified a mutation at position Q52 leading to a
stop codon, which resulted in a very short Bax truncated protein missing all the
BH domains. KMS12PE-199R was characterized by a decline in several pro-
apoptotic proteins (i.e., Bak, Bim, Bik and Puma). Like XG5, KMS12-PE had a
primed Bcl-2 profile. Of interest, a switch in the dependence on Bcl-2 in
KMS12PE cells towards Mcl-1 was demonstrated in KMS12PE-199R cells.
Finally, we found that KMS12PE-199 acquired resistance could be overcome
by A1210477, a recently discovered potent Mcl-1 inhibitor.
Summary/Conclusions: The XG5199R and KMS12PE199R acquired models
of venetoclax resistance in myeloma reflect two main ways to escape to apop-
tosis, either by a reduction of BH3 only proteins or by a loss of effector multido-
main proteins both being accompanied by an increase of Mcl-1 level of expres-
sion. Both models of acquired resistance affect the mitochondrial priming and/or
the dependency on individual anti-apoptotic protein of the cells.
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LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT
PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA
E Lozano1,*, T Diaz1, MP Mena1, X Calvo1, M Calderon1, B Martin-Antonio1,2,
MT Cibeira1, L Rosinol1, J Bladé1,2, C Fernandez de Larrea1,2
1Hematology Department, Hospital Clínic-IDIBAPS, 2Josep Carreras
Leukaemia Research Institute, University of Barcelona, Barcelona, Spain
Background: Immune regulation may control proliferation of aberrant plasma
cells (PCs) in the asymptomatic monoclonal gammopathy of undetermined sig-
nificance (MGUS). Loss of inhibitory pathways could lead to progression from
MGUS to active multiple myeloma (MM). CD85j (LILRB1) molecule is an
inhibitory immunoreceptor containing four immunoreceptor tyrosine-based
inhibitor motifs (ITIM). Binding of HLA-G to CD85j suppresses B cell responses.
The role of CD85j in MM pathogenesis remains to be elucidated.
Aims: The aim of this study was to investigate CD85j contribution to immune
regulation in monoclonal gammopathies and its role in progression from MGUS
to MM.
Methods: CD138+ PCs from bone marrow (BM) aspirates from individuals with
MGUS (n=20) and patients with active MM (n=20) were isolated with immuno-
magnetic beads. Both fractions CD138+ and CD138neg were analyzed by real-
time PCR. CD85j expression and cell proliferation assays were assessed by
multi-parameter 8-color flow cytometry. Effects of ligation of CD85j with specific
anti-CD85j monoclonal antibodies were analyzed on myeloma cell lines and
ex vivo BM functional assays.
Results: Gene expression of CD85j (lilrb1) and its ligand S100A9 was signifi-
cantly downregulated in BMPCs from patients with MM compared to PCs from
individuals with MGUS. Consistently, flow analysis showed that the inhibitory
molecule CD85j was mainly expressed on the BMPCs and B cells in MGUS.
In contrast, patients with MM showed significantly lower levels of CD85j com-
pared to those with MGUS. On the other hand, the expression of this inhibitory
checkpoint was recovered in patients in complete remission but not in progres-
sion (Fig.1). In asymptomatic MGUS, flow cytometry analysis identified PCs at
distinct stages of the malignant transformation: (i) normal PCs were CD85jhigh,
(ii) PCs positive for CD85j and with abnormal expression of CD56 or CD117
and, finally, (iii) PCs expressing CD56 or CD117 that lost CD85j expression
like malignant PCs observed in MM. In MGUS, CD85j expression was signifi-
cantly decreased when the proportion of aberrant PC was higher than 40%,
suggesting that loss of CD85j may be an early event promoting tumor immune
escape. Furthermore, our functional assays showed that ligation with anti-CD85j
antibody decreased the number of normal ex vivo BMPCs from patients with
MGUS. In contrast, malignant PCs from patients with MM and MM cell lines
were resistant to treatment with anti-CD85j. Finally, we wanted to investigate
whether other inhibitory members of the LILRB family were also downregulated
in MM. Consistent with our results on CD85j expression, lilrb2 (CD85d) and
lilrb3 (CD85a) were significantly decreased in PCs from patients with MM com-
pared to PCs from individuals with MGUS.
Figure 1. Flow cytometry analysis of bone marrow samples. Frequency
of plasma cells and CD85j MFI are shown.
Summary/Conclusions: Similar to loss of tumor suppressor function, loss of
inhibitory immune checkpoints such as CD85j may provide a selective advan-
tage for malignant cell clones promoting immune escape and tumor survival.
In this emerging era of cancer immunotherapies, it is crucial to better understand
relevant immune checkpoint signaling playing a role in tumor progression. Fur-
ther investigation is needed to discover whether downregulation of inhibitory
receptors on malignant PC may provide a novel mechanism of immune escape
associated with myeloma progression.
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PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOW-
ERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE
ARREST
S Manni1,2,*, M Carrino1,2, S Canovas Nunes1,2, K Gianesin1,2,
P Macaccaro1,2, L Quotti Tubi1,2, A Cabrelle2, G Semenzato1,2, F Piazza1,2
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Background: Multiple myeloma (MM) is a malignant plasma cell neoplasm,
accounting for about 10% of all blood tumors. Despite the introduction of pro-
teasome inhibitors and immunomodulatory drugs (such as lenalidomide) in the
therapy of MM, it remains still incurable. Recently, it was shown in myelodys-
plastic syndromes that lenalidomide determines the degradation of Protein
Kinase CK1α. CK1α is a serine/threonine kinase essential for the function of
signaling pathways that could be involved in MM pathobiology: the canonical
Wnt/β-catenin cascade, the Hedgehog and the NF-κB pathways and the p53-
driven response (here by stimulating the binding to Mdm2 and p53 inhibition).
Recent evidence indicates that protein kinase CK1α may play a key role in
myeloma cell growth and its inactivation determines MM cell death.
Aims: In this study we have investigated CK1α expression, cellular localization
and its contribution to MM survival. We investigated the therapeutic potential
of the combination of lenalidomide and CK1α inactivation analyzing whether
lenalidomide could cause CK1α degradation and whether CK1α could take
part in lenalidomide-induced MM cell apoptosis and cell cycle arrest. We next
studied whether blocking CK1α αcould influence pro-survival signalling path-
ways, accounting for resistance to lenalidomide.
Methods: CK1α expression and activity were evaluated in MM cells and con-
trols; the consequences of CK1α inhibition, with a small ATP-competitive com-
pound (D4476) or by RNA interference in association with lenalidomide, on
MM cell survival and proliferation were investigated with Annexin V/PI and Ki-
67/PI staining and FACS analysis or PARP and caspase cleavage, p21 and
Mdm2 protein expression level detection. CK1a-dependent signalling events
were analyzed by WB.
Results: We found that CK1α is overexpressed in a fraction of MM patient
and cell lines. CK1α inactivation caused MM apoptosis and cell cycle arrest.
Treatment of cells with lenalidomide not only caused MM death and cell cycle
impairment, but strikingly determined a time-and dose-dependent reduction of
CK1α expression and activation (monitored with a reduction of its target Ser
45 β-catenin). A therapeutic potential of the combination of lenalidomide and
CK1α inactivation was established. Remarkably, the association of lenalidomide
and D4476 increased MM cell apoptosis and reduced the S-G2/M and G1
phases of the cell cycle, suggesting a cooperative effect of the two compounds.
Ki-67 staining showed a clear reduction of active proliferating cells in the com-
bination therapy. Activation of apoptosis and derangement of the cell cycle
were also confirmed by the raise of p21 with concomitant decline of Mdm2
protein levels (indicating an activation of p53 axis) in the combination treatment
compared to the single treatments. Most importantly these results were con-
firmed by RNA interference using siRNAs targeting the α isoform of CK1.
Summary/Conclusions: Our findings suggest that the combination of lenalido-
mide and CK1α inactivation could be a promising therapeutic approach for MM
therapy. The identification of the exact mechanism of action and of the path-
ways targeted by CK1α/lenalidomide in MM plasma cells is the subject of future
research.
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QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND
CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH
NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR
IMPACT ON PATIENT SURVIVAL
I Misiewicz-Krzeminska1,2,*, E Rojas1,2, L Corchete1,2, V Gutierrez3, T Prieto3,
I Isidro3, J Martinez-Lopez4, R Garcia-Sanz2,3, A Oriol5, J Bladé6, JJ Lahuerta4,
J San Miguel7, MV Mateos2,3, NC Gutierrez2,3
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Background: Multiple myeloma has been comprehensively analyzed using
high-throughput genomic technologies. Although a large number of biomarkers
have been described, most of them were not subsequently validated at the pro-
tein level. In fact, the unresolved difficulties in studying the proteome have made
the quantification of messenger RNA (mRNA) an indirect measure of protein
expression. However, many studies have shown that levels of mRNA cannot
be used as surrogates for protein levels. The amount of myeloma cells obtained
after purification of patient samples is usually very limited, which precludes the
posibility of quantify protein levels using standard Western Blot analysis.
Aims: To quantify the steady state levels of cyclin D1, cyclin D2, ikaros, aiolos
and cereblon proteins, and correlate them with the corresponding gene expres-
sion (mRNA). To analyze the impact of the protein expression compared to
gene expression on MM prognosis.
Methods: Bone marrow aspirates from 64 newly diagnosed MM patients treat-
ed with lenalidomide- and bortezomib-containing regimens were included in
the study. Myeloma cells were purified by anti-CD138 magnetic microbeads
using the AutoMACs separation system (purity was above 90%) and next, were
stored in RLT+ buffer at -800C. We developed and optimized a protocol for
extraction of DNA, RNA and proteins from the same single sample. Total protein
quantification and particular proteins expression analysis were performed using
the capillary electrophoresis with immunoassay methodology (patented by the
ProteinSimple company as WES system). mRNA expression was quantified
using Taqman assays by q-RT-PCR.
Results: After the analysis of total protein content, 61 MM samples fulfilled the
quantity and quality requirements. Cyclin D1 protein levels were strongly cor-
related with mRNA levels (R2 0.804, p<0.01). The highest cyclin D1 protein
expression was found in MM samples with t(11;14), whereas intermediate cyclin
D1 levels were observed in those patients with polysomy 11. Lower correlations
between protein and mRNA levels were observed for cyclin D2/CCND2 (R2
0.409, p<0.01), aiolos/IKZF3 (R20.383, p<0.01) and ikaros/IKZF1 (R2 0.337,
p<0.01). On the contrary, no significant correlation was seen for cereblon pro-
tein levels and the corresponding CRBN expression. Higher protein levels of
cereblon and ikaros were significantly associated with longer progression free
survival (PFS) and overall survival (OS). Interestingly, no impact on prognosis
was observed when survival analysis was carried out using the mRNA levels
of CRBN, IKZF1 and IKZF3.
Figure 1.
Summary/Conclusions: The capillary electrophoresis with immunoassay
methodology allowed us to analyze the steady state expression of mRNA and
protein obtained from the same one MM sample. The preliminary results
showed that protein measurement of cereblon and ikaros discriminate prog-
nosis of patients with MM better than mRNA levels. The Capilary Immunoassay
offers the novel opportunity to automatically analyze, for the first time, the
expression of proteins encoded by key genes in the development of MM, with
high levels of sensitivity and reproducibly.
Acknowledgement: This work is funded by a grant from the International Myelo-
ma Foundation’s Black Swan Research Initiative®. WES platform was acquired
thanks to INNOCAMPUS Program (CEI10-1-0010).
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DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC
PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS
K Takada*, Y Kamihara, T Sato, Y Kawano, K Murase, Y Arihara, S Kikuchi,
N Hayasaka, M Usami, S Iyama, K Miyanishi, M Kobune, J Kato
Medical Oncology and Hematology, Sapporo Medical University School of Med-
icine, Sapporo, Japan
Background: Iron is an element essential for many indispensable cellular func-
tions, including proliferation and DNA synthesis. Accumulating evidence sug-
gests that abnormal iron metabolism plays an important role in carcinogenesis
and in the progression of many cancers. In cancer cells, the demand for iron
increases in response to sustained, accelerated cell proliferation and DNA syn-
thesis. Multiple myeloma (MM) is characterized by clonal proliferation of long-
lived plasma cells within the bone marrow. Despite recent advances in its treat-
ment, MM remains an incurable disease, underlining the need to continue
exploring its molecular characteristics. Recently, two independent groups
reported that serum ferritin, which is used as a marker for iron overload, can
be a negative prognostic indicator in MM. However, the underlying mechanisms
of this effect have not been clarified, and the significance of iron metabolism in
MM cells remains unclear.
Aims: Our study was aimed to investigate iron metabolisms and iron chelation
therapy with deferasirox (DFX) in MM cells.
Methods: We analyzed the prognostic relevance of iron metabolism-related
genes by integrating a data set in the public domain (MAQC-II Project MM data
set). We also evaluated mRNA expression of iron metabolism-related genes in
MM cell lines and primary cells. Intracellular iron concentrations were measured
with fluorescent probes FeRhoNox-1. The effect of DFX, an orally active, long-
acting iron chelator approved for iron overload, on MM cell lines was examined
using a WST-1 cell proliferation assay. To elucidate the cytotoxic mechanism
of DFX, immunoblotting and flow cytometry analysis were performed. To clarify
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the mechanisms of DFX-induced apoptosis in MM, we analyzed the phospho-
inositide 3-kinase (PI3K)/Akt signaling pathway using PCR arrays. Subsequent-
ly, Pyk2 downstream target molecules were analyzed with immunoblotting and
qPCR. To test the therapeutic potential of DFX, we evaluated its ability to sup-
press tumor growth in vivo using the subcutaneous RPMI8226 murine xenograft
model of human MM.
Results: Overall survival was significantly longer MM patients with high ferro-
portin levels, a cellular iron exporter. qRT-PCR studies showed lower ferroprtin
expression in both cell lines and primary cells compared to control cells.
Increased intracellular iron concentrations were noted in MM cells. DFX induced
apoptosis in MM cells and overcame the survival advantage conferred by the
bone marrow microenvironment. The FAK transcript was substantially sup-
pressed following DFX treatment in PCR array. However, no expression of FAK
protein in three of four MM cell lines was observed. Next, we investigated Pyk2,
which is a member of the FAK family and has a 48% amino acid sequence
identify with FAK. We assessed Pyk2 activation after treatment with DFX. DFX
significantly reduced phosphorylation of Pyk2(Tyr402), resulting in inactivation
of Pyk2 activity. beta-catenin protein levels were decreased by DFX treatment,
accompanied by decreased levels of phosphorylated-GSK-3beta (inactive
form). Treatment with DFX reduced the mRNA levels of Axin2 and c-Myc, which
are Wnt target genes; in particular, Axin2 is a robust and specific Wnt target
gene. We detected an increase in apoptotic tumor cells in animals treated with
DFX compared to vehicle-treated mice, as evaluated by Cleaved PARP staining
and immunoblotting.
Summary/Conclusions: This study has demonstrated that low expression of
ferroportin is associated with a poor prognosis in MM, and had been revealed
that increased intracellular iron contributes to MM pathogenesis. Our results
suggest the potential clinical application of DFX for iron overloaded and/or
Pyk2/beta-catenin driven MM treatment.
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DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT
SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE
GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR
DIAGNOSTIC SERVICE
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A Papenfuss1,2, D Westerman1,3, M Prince1,3, M Dickinson1,3
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Background: In the genomic context, treatment decisions in patients with
myeloma are currently influenced by (i) the presence of copy number changes
(e.g. TP53) and balanced chromosomal translocations (e.g. t(4;14)) (ii) response
to therapy as assessed by minimal residual disease (MRD) testing (e.g. with
IGVH MRD) and (iii) the presence of potentially targetable mutations (e.g. BRAF
V600E). In addition, there are numerous novel genomic factors that may influ-
ence treatment including gene expression based prognostic scores, gene
expression signatures indicating sensitivity to novel therapeutics and response
to therapy as measured by circulating tumour DNA (ctDNA) monitoring.
Aims: We aimed to develop, validate and implement a suite of molecular tools
and workflow in a molecular diagnostic laboratory setting to enable compre-
hensive molecular characterisation of multiple myeloma biosamples, prioritising
genetic lesions that now or may in the future influence patient management.
Moreover, we aimed to utilise this molecular workflow to establish a local com-
pendium of genomic data on cases of myeloma.
Methods: DNA and RNA is extracted from CD138+ MACS selected plasma
cells from patients undergoing bone marrow biopsies for either newly diagnosed
or relapsed myeloma at Peter MacCallum Cancer Centre (Melbourne, Aus-
tralia). Amplicon library preparation is performed using a Fluidigm Access Array
IFC. Whole transcriptome RNA-seq RNA libraries are prepared using Illumina
TruSeq RNA. Low-coverage Whole Genome Sequencing (LC-WGS) is per-
formed using DNA libraries prepared by Kapa Hyper Library Prep (Kapa Biosys-
tems). Sequencing is performed on an Illumina NextSeq (RNA-seq and LC-
WGS) and an Illumina MiSeq (amplicon panel).
Results: Targeted amplicon sequencing is performed using an in-house
designed panel which includes the most frequently mutated genes in myeloma
(BRAF, NRAS, KRAS and TP53). This provides relatively rapid feedback to
clinical teams on the presence of genetic lesions which may direct manage-
ment. Assessment of myeloma samples is aligned with other next-generation
sequencing amplicon assays within the laboratory in order to minimise turn-
around times and achieve efficiencies in laboratory workflow. Whole transcrip-
tome RNA-seq is performed and used for (i) variant calling to correlate with the
mutations identified from the targeted-amplicon panel and also as a discovery
platform for novel mutations (ii) assessment against established gene expres-
sion profile classifiers for cytogenetic lesions and prognosis (e.g. GEP70) and
(iii) assessment of expression of therapeutic targets (e.g. CD38, SLAMF7,
CRBN). LC-WGS is then used to detect copy number changes. During the val-
idation phase, findings from RNA-seq and LC-WGS were validated using
orthogonal methods including conventional metaphase cytogenetics and FISH.
Novel bioinformatics and clinical informatics tools including a copy number call-
ing pipeline, RNA-seq variant calling and differential expression pipeline, copy
number browser and an IGVH analysis interface have been developed to
analyse and report samples. Approximately 50 samples have been processed
with this workflow to date with the results used to inform patient management.
Summary/Conclusions: We have successfully developed and implemented
a suite of molecular testing for multiple myeloma within a molecular diagnostic
laboratory to detect key genomic lesions which affect patient management as
well as establishing a local discovery-level data set to answer future research
questions.
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DYNAMIC EVOLUTION OF COPY NUMBER ABERRATIONS ACCOMPANIES
DISEASE RELAPSE IN MULTIPLE MYELOMA
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Background: Despite novel and effective therapies, the clinical course of mul-
tiple myeloma is that of a relapsing-remitting disease. In general, remission
times shorten with each subsequent therapy, finally resulting in refractory dis-
ease. Changes in the predominance of molecular subclones have been impli-
cated in disease relapse.
Aims: To identify the longitudinal changes in predominant copy number aber-
rations in myeloma patients from new diagnosis to first relapse.
Methods: Matched presentation and relapse CD138 immunomagnetically
selected bone marrow tumour material from 69 patients treated in the NCRI
Myeloma XI trial were analysed. Median time between samples was 19 months
(range 2 – 39 months). Cases were molecularly profiled using a combination
of MLPA and qRT-PCR (Boyle EM, et al. Gen Chrom Canc 2015; Kaiser MF, et
al. Leukemia 2014). Copy number by MLPA is inferred by comparison of target
regions against control regions. 
Results: Three regions showed frequent changes in copy number from diag-
nosis to relapse: TP53 at 17p, CKS1B at 1q, and MYC at 8q. In 20% of cases,
copy number of at least one of the regions changed between the timepoints.
The frequency of predominant clones with TP53 deletion increased from 10.1%
at presentation to 15.9% at relapse with five patients showing a novel TP53
deletion at first relapse. Copy number of CKS1B changed in 16% of cases
between presentation and relapse: eight cases demonstrated novel gain or
amplification of CKS1B, whereas in three cases copy number gain of CKS1B
reverted to normal at relapse. The frequency of gain(1q) was 34.7% at presen-
tation and 42.0% at relapse. A novel, predominant clone with gain of MYC was
detected in four cases at relapse. Gain of MYC reverted to normal in three
cases from presentation to first relapse. 
Summary/Conclusions: We found dynamic changes in predominant clones
between presentation and first relapse. Deletion of TP53/del(17p) and gain(1q)
were more frequent at relapse than at presentation, indicative of clonal advan-
tage under therapeutic selective pressure early in the disease course. Although
novel gains of 8q suggest a clonal advantage for MYC, this appears to be con-
text-dependent and further longitudinal studies are required to assess its impact
over time.
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IMPACT OF CYTOGENETIC RISK STATUS ON EFFICACY AND SAFETY
OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD
IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE
GLOBAL TOURMALINE-MM1 STUDY
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Background: The phase 3 TOURMALINE-MM1 study (NCT01564537) showed
a significant 35% improvement in progression-free survival (PFS) with IRd vs place-
bo-Rd (hazard ratio [HR] 0.742, p=0.012) in 722 patients (pts) with relapsed/refrac-
tory multiple myeloma (RRMM) (Moreau et al, ASH 2015). Data from this study led
to the approval by the US FDA of ixazomib, in combination with Rd, for the treatment
of pts with MM who have received at least one prior therapy.
Aims: A key secondary endpoint was overall survival (OS) in patients with
del(17p), and another secondary endpoint was outcome in patients with high-
risk cytogenetic abnormalities. Here, we analyze the efficacy and safety of IRd
vs placebo-Rd by cytogenetic risk status.
Methods: Pts with RRMM were randomized 1:1 to receive IRd or placebo-Rd
(ixazomib 4 mg or matching placebo on days 1, 8, and 15, plus lenalidomide
25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in
28-day cycles) until disease progression or unacceptable toxicity. Stratification
factors were number of prior therapies (1 vs 2 or 3), proteasome inhibitor-
exposed vs -naïve status, and ISS stage I or II vs III. Cytogenetic risk status
was assessed using FISH at a CLIA-certified central laboratory. High-risk abnor-
malities were defined as del(17p), t(4;14) or t(14;16); cut-off values for these
abnormalities were, per protocol, based on the false-positive rates (technical
cut-offs) of the Kreatech FISH probes used, which were 5%, 3%, and 3% pos-
itive cells, respectively. The standard-risk group consisted of all other patients
with known baseline cytogenetics. Post-hoc analyses were performed using
different cut-off values for del(17p) and t(4;14).
Table 1.
Results: A total of 552 patients (76% of the 722 pts enrolled) had cytogenetic
results (97% central laboratory-confirmed), of whom 137 had high-risk abnor-
malities, 75 in the IRd arm and 62 in the placebo-Rd arm. After a median fol-
low-up of ~15 mos, PFS was improved with IRd vs placebo-Rd in both pts with
high-risk and pts with standard-risk cytogenetics (Table); in high-risk pts, the
median PFS with IRd was similar to that in all pts and in standard-risk pts. The
PFS benefit with IRd vs placebo-Rd was consistent using different cut-off values
for defining del(17p) and t(4;14) positivity. For del(17p), median PFS with IRd
vs placebo-Rd was 21.4 vs 6.7 mos (HR 0.611) with a 20% cut-off (n=59), and
15.7 vs 5.1 mos (HR 0.49) with a 60% cut-off (n=33). For t(4;14) alone using a
cut-off of 10% (n=59), median PFS was 18.5 vs 12.0 mos (HR 0.444) with IRd
vs placebo-Rd. Median time to progression with IRd vs placebo-Rd was 21.4
vs 12.0 mos and 20.6 vs 15.9 mos in high-risk and standard-risk pts. Overall
response rate with IRd vs placebo-Rd was 79% vs 60% in high-risk pts and
80% vs 73% in standard-risk pts, including CR+VGPR rates of 45% vs 21%
and 51% vs 44%, respectively. At data cut-off, OS data were not mature, with
8 (11%) deaths in the IRd arm vs 13 (21%) in the Rd arm for high-risk pts, and
21 (11%) deaths in the IRd arm vs 32 (15%) in the Rd arm for standard-risk pts.
At a 23-month analysis, rates of grade ≥3 adverse events (AEs) with IRd vs
placebo-Rd were 66% vs 73% in high-risk pts and 75% vs 65% in standard-risk
pts; rates of serious AEs were 42% vs 52% and 45% vs 47%, respectively.
Summary/Conclusions: IRd showed substantial benefit vs placebo-Rd in
RRMM pts with high-risk cytogenetic abnormalities, irrespective of the cut-offs
used, with limited additional toxicity. Molecular studies, including analyses of
the impact of p53 mutation on outcomes, will also be presented.
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HIGH CUT-OFF HAEMODIALYSIS (HCO-HD) DOES NOT IMPROVE
OUTCOMES IN MYELOMA CAST NEPHROPATHY: RESULTS OF EUROPEAN
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Background: Severe acute kidney injury (AKI) secondary to myeloma cast
nephropathy (MCN) and requiring acute dialysis is associated with poor patient
survival. MCN is caused by the pathogenic (involved) immunoglobulin serum
free light chain (sFLC). High cut-off haemodialysis (HCO-HD) can remove large
quantities of sFLC and retrospective uncontrolled clinical trials using HCO-HD
have reported renal function recovery (from dialysis) in over 60% of patients.
This is compared to historic reports of 20% renal recovery. Recovery of renal
function is associated with improved survival. However, it is not known if these
better outcomes were associated with HCO-HD or novel chemotherapy regi-
mens. There have been no RCTs of the efficacy of HCO-HD or the efficacy of
bortezomib based chemotherapy in patients with MCN and severe AKI requiring
dialysis treatment.
Aims: To carry out a prospective multi-centre RCT in patients with newly diag-
nosed MM and associated MCN who required acute dialysis treatment, com-
paring HCO-HD to standard high flux (HF)-HD, and using bortezomib based
chemotherapy as the standard of care.
Methods: Ninety patients with a first diagnosis of MM & MCN confirmed by
kidney biopsy, sFLC levels of the involved LC >500 mg/l (Freelite™), and a
requirement for acute dialysis, were randomised to receive HCO-HD or stan-
dard HF-HD. HCO-HD was carried out with two 1.1 m2 Baxter-Gambro HCO
1100 dialyser in series. The dialysis regimen was based on studies that iden-
tified an optimal protocol for FLC removal. All patients received bortezomib,
doxorubicin, and dexamethasone chemotherapy to a maximum of 8 cycles.
Primary outcome was independence of dialysis at 3-months. Patients were fol-
lowed for 2-years. Other pre-defined outcomes included; 3-week sFLC levels,
overall renal recovery, stem-cell transplantation, 2-year OS. All results are
reported as intention to treat (ITT). Where statistical tests are not stated the
chi-squared test is reported.
Figure 1.
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Results: There was no difference between groups for sFLC levels (mg/L, medi-
an, range (Mann-Whitney test)) by isotype at randomisation. These were: kappa
LC; HCO- HD 12000 (1839-61900), HF-HD 11800 (1200-76322), lambda LC;
HCO-HD 6031 (1950-33196), HF-HD 8400 (574-38400). There was no differ-
ence at randomisation between HCO-HD and HF-HD for age, ethnicity, gender,
myeloma type (light chain only vs intact Ig). Serum FLC levels levels on the
first full protocol dialysis decreased for kappa LC and lambda LC by 75.6%
and 71.2% for HCO-HD, and 20.2% and 9.1% for HF-HD, respectively
(P<0.001). However, there was no difference in the percentage reduction of
sFLC level from baseline at 3 weeks between HCO-HD and HF-HD. 24/43
patients (55.8%) in the HCO-HD group and 24/47 patients (51.6%) in the HF-
HD group recovered renal function by 3 months (not significant, NS). Kaplan–
Meier analysis is shown in the figure. Overall recovery of renal function was
62%; 58.1% in the HCO-HD group, 66% in the HF-HD group (NS). 35% in the
HCO-HD group and 32.2% in the HF-HD received a stem-cell transplant (NS).
OS at 2-years was 24 (55.8%) in the HCO-HD group and 36 (76.6%) in the HF-
HD group (P=0.037; odds ratio (95% confidence interval), 1.583 (1.048-2.392)).
There were more lung infections in the first 3-months in the HCO-HD group (12
vs 3, P=0.014).
Summary/Conclusions: In this RCT, where all patients received bortezomib
based chemotherapy, 62.2% of patients recovered renal function and overall
survival at 2-years was 66.7%. HCO-HD, compared to HF-HD, did not improve
renal recovery rates in patients with severe AKI secondary to MCN. There was
worse overall survival in the HCO-HD group.
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OPROZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (OPOMD) IN
PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE
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Background: Oprozomib (OPZ), an irreversible proteasome inhibitor has
demonstrated activity in pts with RRMM (Vij, Haematologica 2015;100[suppl
1]:abst P646; Hari, Haematologica 2015;100[suppl 1]:abst P653). 
Aims: The primary objective of the phase 1b portion of this study was to deter-
mine the maximum tolerated dose (MTD) and recommended phase 3 dose
(RP3D) of OPZ in the OPomd regimen and to evaluate safety and tolerability.
Secondary objectives included estimating overall response rate (≥partial
response) and clinical benefit rate (≥minimal response), and evaluating OPZ
pharmacokinetics (PK).
Methods: Pts with RRMM (≥2 prior regimens) were eligible; pts must have
received ≥2 consecutive cycles of both bortezomib and either lenalidomide or
thalidomide. Prior carfilzomib (CFZ) was allowed if CFZ was not discontinued
due to an adverse event (AE). Pts received OPZ orally once-daily on days (D)
1-5 and 15-19 (i.e., 5/14 schedule) or on D1, 2, 8, 9, 15, 16, 22, 23 (i.e., 2/7
schedule) of 28-day cycles. Pts received pomalidomide (POM) orally on D1–
21 and dexamethasone (DEX) 20 mg orally on D1, 2, 8, 9, 15, 16, 22, 23. The
starting OPZ dose in the 5/14 schedule was 150mg/day and in the 2/7 schedule
was 210mg/day; subsequent escalation was in a standard 3+3 dose-escalation
schema. The starting POM dose for both schedules was 4mg.
Results: Thirty-one pts were enrolled (5/14 schedule, n=4; 2/7 schedule, n=17
and n=10 for the expansion arm). In the 5/14 schedule, pts received OPZ 150
mg/day + POM 4 mg/day (n=3); or OPZ 150 mg/day + POM 2 mg/day (n=1).
In the 2/7 schedule, pts received OPZ 210 mg/day + POM 4 mg/day (n=17
including expansion arm patients); or OPZ 240 mg/day + POM 4 mg/day (n=10).
Median age was 57 yr (5/14 schedule), 61 yr (2/7 schedule OPZ 210 mg/d)
and 71 yr (2/7 schedule OPZ 240 mg/d). Pts received a median (range) of 7 (3-
22) prior regimens in the 5/14 schedule, 3 (2-8) in the 2/7 schedule OPZ 210
mg/d and 3.5 (1-11) in the 2/7 schedule OPZ 240 mg/d. At data cutoff (10/26/15),
pts in the 5/14 and 2/7 schedules had been on treatment for a median duration
of 17.8 wk (range, 3.3-38.6) and 19.3 wk (range, 3.3-50.9) for all study drugs,
respectively. Three dose-limiting toxicities (DLTs) were reported in 2 pts in the
5/14 schedule: 1 pt grade (Gr) 3 mucositis and rash; 1 pt Gr 3 abdominal dis-
tention and impaired cognitive function. One DLT occurred in the 2/7 schedule
(OPZ 210 mg/d): Gr 3 gastric hemorrhage with severe erosive gastritis identified
in endoscopy. One pt in the 5/14 schedule (25%) and 1 pt (5.9%) in the 2/7
schedule OPZ 210 mg/d discontinued treatment due to an AE. No pts died on
study. The most common hematologic and of clinical interest AEs (any Gr and
Gr ≥3) are shown in the table. In the 2/7 schedule, a partial response or better
was reported in 71% of the OPZ 210 mg/d patients (and in 4 of 5 CFZ-refractory
patients) and 50% of the OPZ 240 mg/day patients; 50% of patients in the 5/14
schedule also achieved partial response or better. Considering current meas-
ures of variability and sample size, the PK of OPZ, when given in combination
with POM and DEX, were generally consistent with previous OPZ studies.
Table 1. Adverse events of any grade occurring in >25% and grade ≥3
adverse events occurring in ≥10% of patients.
Summary/Conclusions: Initial results from this ongoing phase 1b study sug-
gest that the combination of OPomd has significant anti-myeloma activity, is
active in a highly refractory patient population, and is generally well tolerated.
The most common grade ≥3 AEs observed were anemia (47%) and diarrhea
(11%) with 210 mg OPZ in the 2/7 schedule. The MTD of OPZ in combination
with POM/DEX was not reached on either schedule.
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Background: BCL-2 and MCL-1 promote multiple myeloma (MM) cell survival.
Bortezomib (BTZ) inhibits MCL-1 activity, and venetoclax (VEN), an oral, selec-
tive BCL-2 inhibitor, enhances its efficacy in MM xenograft models.
Aims: The objectives of the study are to evaluate safety and preliminary efficacy
of VEN with BTZ and dexamethasone (Dex) in relapsed/refractory (RR).
Methods: Patients received daily VEN, per assigned dose escalation cohorts
(50-1200mg), combined with BTZ (1.3mg/m2 SC) and Dex (20mg PO) for 11
cycles, and then VEN alone thereafter.
Table 1.
Results: 45 patients were enrolled as of 9/17/15. Median age was 65, with 29
males and 16 females; 24 patients had ISS stage II/III. The median (range)
number of prior lines of therapy was 4 (1-13). 38 patients received prior BTZ
(19 refractory), 36 had lenalidomide (26 refractory), and 32 had prior SCT.
Adverse events occurring in ≥30% of patients were constipation (40%), diarrhea
(38%), thrombocytopenia (33%), and insomnia (29%). Grade 3/4 adverse
events in ≥10% were thrombocytopenia (22%), and anemia (16%). Serious
adverse events in ≥2 patients were pneumonia (n=3), cardiac failure, embolism,
pyrexia, respiratory failure, sepsis, and thrombocytopenia (n=2 each). One
dose limiting toxicity was observed, and maximum tolerated dose was not
reached. 30 patients discontinued (DC): 24 related to disease progression (3
died), 2 due to adverse events, and 4 withdrew consent. Dose-normalized PK
for VEN with BTZ+Dex was similar to VEN monotherapy. 41 out of45 patients
were evaluable for efficacy (Table 1). Preliminary results also indicate that
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patients who had received 1-3 prior lines of therapy (N=18) had higher ORR
(83.3%) as compared to patients who had received 4-6 (N=13, 38.5% ORR)
or ≥7 prior lines of therapy (N=10, 10% ORR).
Summary/Conclusions: Venetoclax with bortezomib and dexamethasone has
an acceptable safety profile and evidence of anti-tumor activity in RR MM;
response rates were highest in patients who were naïve or sensitive to prior
bortezomib, or had received 1–3 prior therapies. Currently, dose escalation is
complete and safety expansion is ongoing at 800 mg.
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Background: The PI3K/AKT pathway is constitutively active in multiple myelo-
ma (MM), providing proliferative and anti-apoptotic signals, and contributing to
drug resistance in preclinical models. Afuresertib is an orally bioavailable, ATP-
competitive, reversible inhibitor of all 3 AKT kinases. Single-agent activity has
been seen in patients (pts) with heavily pretreated MM. Preclinical studies have
shown that combining afuresertib with bortezomib results in downstream target
inhibition and synergistic cell death in myeloma cell lines.
Aims: The aims of the current study were to determine the safety, tolerability,
and MTD of afuresertib when dosed in combination with bortezomib and dex-
amethasone for pts with relapsed/refractory (R/R) MM. Secondary endpoints
included pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity. 
Methods: In this Phase Ib open-label study, pts (aged ≥18 years, ECOG PS ≤2)
with MM who had failed ≥1 line of systemic therapy were enrolled into the dose
escalation part of the study (part 1). The initial dose of afuresertib (75 mg QD)
was increased in 25 mg increments until the MTD was reached. Bortezomib was
dosed at 1.0 mg/m2 IV in the first cohort and 1.3 mg/m2 IV for all other cohorts.
Dexamethasone was administered at 20 mg (40 mg for the MTD cohort) on the
same days as bortezomib. Pts received induction with afuresertib, bortezomib,
and dexamethasone for eight 21-day cycles, and then continued single-agent
afuresertib until treatment discontinuation criteria were met. Pts were enrolled
into the dose expansion part of the study (part 2) at the MTD. Two cohorts were
explored in part 2: a PK/PD and a safety/efficacy cohort. Pts with bortezomib-
refractory disease were eligible for part 1, but were excluded in part 2.
Table 1. Clinical activity of afuresertib in combination with bortezomib
category.
Results: 90 pts were enrolled (34 in part 1, 10 in the PK/PD cohort, and 46 in
the safety/efficacy cohort). Pts had a median age of 64 years and had received
a median of 3 prior lines of treatment (range: 1-10). Pts received a median of
105 days (range: 5-1050) of afuresertib treatment and a median of 5 cycles
(range: 0-8) of bortezomib plus dexamethasone. In the safety/efficacy cohort,
median time on study was 119 days (range: 5-757). DLTs were reported in the
100 mg cohort (Grade [G] 2 ALT elevation, n=1), the 125 mg cohort (G3 ery-
thema multiforme, n=1), and the 175 mg cohort (G3 rash, n=1; G3 rash/G3
diarrhea/G3 thrombocytopenia, n=1). The MTD and recommended dose for
Phase 2 was established as 150 mg QD afuresertib plus 1.3 mg/m2 bortezomib
and 40 mg dexamethasone on Days 1, 4, 8, and 11. In the part 2 safety/efficacy
cohort, the most common AEs were diarrhea (65%), fatigue (59%), nausea
(52%), thrombocytopenia (37%), constipation (35%), hyperglycemia (35%),
and anaemia (35%). G3/4 AEs occurring in >10% of pts were thrombocytopenia
(26%), diarrhea (22%), hyperglycemia (15%), and orthostatic hypotension
(13%). The overall response rate across all cohorts was 53% (95% CI:
42.5%,63.9%) and 65% (95% CI: 49.8%,78.6%) in the safety/efficacy cohort.
Responses were observed in 8/24 pts who were refractory to prior bortezomib
(Table 1). Afuresertib PK profiles were generally dose proportional and mean
afuresertib exposure was similar alone or in combination with bortezomib and
dexamethasone. Survival data will be presented at the meeting.
Summary/Conclusions: Treatment of R/R MM with afuresertib plus borte-
zomib and dexamethasone demonstrated a manageable safety profile and
showed promising clinical activity. The PK profile of afuresertib was not affected
by bortezomib or dexamethasone.
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Background: Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody
with multiple modes of action for killing tumor cells through direct tumor target-
ing and immune cell engagement. We report updated data from an ongoing
Phase II dose finding study of ISA monotherapy in patients with RRMM
(NCT01084252).
Aims: Primary objective: evaluation of ISA activity (overall response rate [ORR;
IMWG]).
Methods: Patients with RRMM (≥3 lines of anti-MM therapy or refractory to
immunomodulatory drugs [IMiDs] and proteasome inhibitors [PIs]) were ran-
domized to ISA 3 mg/kg Q2W, 10 mg/kg Q2W x 2 cycles then Q4W, or 10
mg/kg Q2W. Randomization stratified by prior pomalidomide and/or carfilzomib
therapy. Emerging PK data prompted enrollment of a 4th treatment arm at 20
mg/kg QW x 4 doses then Q2W. 1 cycle=28 days. All patients signed an IRB
approved informed consent.
Results: 97 patients treated: median age, 62.5 (38-85) y; median time from
diagnosis, 5.9 (1.2-24.1) y; ISS stage 3, 37%; median prior lines of therapy, 5 (2-
14); 86%, 61%, 80%, 57%, 88% refractory to lenalidomide, pomalidomide, borte-
zomib, carfilzomib, or IMiD+PI, respectively. 24/56 cytogenetics-evaluable
patients (43%) had t(4;14) and/or del(17p). Median treatment duration, 13.1 wks;
22 patients remain on treatment (cut-off Nov 2015). ORR: 9% (2/23), 20% (5/25),
29% (7/24) & 24% (6/25) at ISA 3 Q2W, 10 Q2W/Q4W, 10 Q2W, & 20 mg/kg
QW/Q2W, respectively; 14/20 responders continue without progression. At ≥10
mg/kg: ORR was 24% (18/74), similar in subgroups (age, CrCl, prior lines of
therapy), and 44% (8/18) in patients with abnormal cytogenetics. Median time to
1st response, 1.35 mo; median duration of response at data cut-off, 6.6 mo.
Most common adverse events (AEs) were nausea (33%), fatigue (30%), dyspnea
(26%), and cough (24%), which were typically grade ≤2. Infusion-associated
reactions (IARs) occurred in 49% of patients, mostly grade ≤2, 94% during the
1st infusion. 6 patients discontinued therapy due to AEs, 2 due to IARs.
Summary/Conclusions: ISA monotherapy is active and generally well toler-
ated in heavily pretreated RRMM, with efficacy greatest at ≥10 mg/kg (ORR
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24%). ORR was similar in subgroups, including high-risk cytogenetics. Pro-
gression-free survival and overall survival data will be presented.
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Background: As previously reported, treatment with carfilzomib, lenalidomide,
and dexamethasone (KRd) significantly improved progression-free survival
(PFS) and treatment responses versus lenalidomide and dexamethasone (Rd)
in patients (Pts) with relapsed multiple myeloma (ASPIRE; NCT01080391). Per
trial protocol, carfilzomib (CFZ) was discontinued after 18 cycles (28 days/cycle)
so optimal duration of KRd treatment was not determined; all Pts continued to
receive Rd treatment until disease progression.
Aims: To evaluate post hoc the time to cumulative complete response or better
(≥CR) and PFS hazard ratio (HR) at 18 months from randomization for KRd vs
Rd treatment.
Methods: Cumulative rates of ≥CR overtime were evaluated from start of treat-
ment for KRd (CFZ starting dose 20 mg/m2 and target dose 27 mg/m2, lenalido-
mide 25 mg, and dexamethasone 40 mg) vs Rd (same doses lenalidomide and
dexamethasone) arms This analysis was done on treated patients. PFS HR at
18 months for the intent-to-treat population was evaluated using piecewise Cox
regression analyses based on the method of Collett (2003).
Results: KRd (n=396) and Rd (n=396) Pts were followed for a median of 31
and 30 months for PFS, respectively. A total of 126 and 37 Pts in the KRd and
Rd groups achieved ≥CR with sample median time from treatment start to ≥CR
of 6.7 and 8.3 months, respectively. The increase in rate of ≥CR Pts over time
was greater in the KRd group than the Rd group, most notably in the first 15
months; cumulative ≥CR rates increased steadily thereafter (Table). The overall
PFS HR in ASPIRE for KRd vs Rd was 0.69 (95% CI, 0.57 to 0.83). For the first
18 months, the PFS HR was 0.58 (95% CI, 0.46 to 0.72).
Table 1.
Summary/Conclusions: CFZ combined with Rd provides greater response
and improvements/benefits in PFS compared with Rd alone. Cumulative ≥CR
rates increased over time in the KRd arm with rates rising rapidly in the first 15
months. The 18 month PFS HR was lower than the overall study PFS HR, pos-
sibly related to KRd Pts receiving CFZ for a maximum of 18 months.
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Background: Prognostic markers for Multiple Myeloma (MM) are recommend-
ed in most guidelines and consensus papers for clinical use and for risk stratified
trials. A prognostic marker is considered suitable for clinical use when it identifies
a reasonable fraction of all patients with sufficiently differential outcome (hazard
ratio), and is reproducible in multiple independent clinical studies. SKY92 risk
stratification was performed in eight independent clinical datasets for which
gene expression profiling was available along with overall survival (OS). Three
datasets also had progression free survival (PFS), which is an important meas-
ure to identify the patient’s response to therapy and which is often a relatively
early indication of the severity of the disease. Patients with a shorter PFS
require care at a higher frequency, possibly a different treatment strategy and
likely need higher intensity treatment than patients with longer progression free
survival. It would therefore be useful to reliably identify patients that are expect-
ed to have a shorter OS and PFS in an early stage. The SKY92 signature has
been reported to be a robust predictor for OS as well as PFS (Kuiper et al.
2012, Kuiper et al. 2015). 
Aims: To validate the prognostic value for PFS and OS of the SKY92 high risk
marker in newly diagnosed and relapsed refractory Multiple Myeloma across a
wide variety of clinical trial datasets.
Methods: OS data and gene expression profiling (GEP) data, either publicly avail-
able or obtained by analysis of the CE IVD MMprofiler assay (that includes the
SKY92 signature), of eight clinical datasets (Figure 1) were used to evaluate the
proportion of cases, hazard ratios and p-values associated with the SKY92 risk
marker. The datasets included both newly diagnosed MM (TT2, TT3, MRC-IX,
MMGI, HOVON87) and relapsed refractory MM (APEX and TT6) and also elderly
(>65 yrs) MM (HOVON87 and about half of MRC-IX). The Cox proportional hazards
model was used to calculate Hazard Ratios (HR), and associated p-values.
Results: Figure 1 shows Kaplan Meier curves for eight datasets comparing
cases that are high risk for SKY92 versus those that are standard risk for
SKY92. The proportion of high risk cases was very similar in all cohorts (range
15.4% - 20.7%). For OS the (high risk) / (standard risk) hazard ratios range
from HR=2.2 (MRC-IX) to HR=10.3 (TT6) and are all significant, see Figure
1A, including the relapsed stage cohorts TT6 and APEX. For PFS, the hazard
ratios range from HR=1.7 (APEX) to HR=2.2 (HOVON87) and are all significant,
see Figure 1B. The hazard ratios for OS (Figure 1A) are larger than for PFS
(Figure 1B), which seems to suggest that the SKY92 signature is prognostic
beyond the first line of treatment.
Figure 1. A) Prognostic value for OS of SKY92 in eight clinical datasets
including NDMM and RRMM; B) for PFS (bottom) in three clinical datasets
including NDMM and RRMM. TT2 |n=351|, TT3 |n=139|, MRC-IX |n=246|,
APEX |n=264|, MMGI |n=91|, HOVON-87/ NMSG-18 |n=143|, Czech E-MTAB-
1038 |n=66|, TT6 |n=55|. Note that follow up time (x-axis) differs between
studies.
Summary/Conclusions: SKY92 is a powerful and robust prognostic marker,
not only for OS but also for PFS in younger, elderly, newly diagnosed, relapsed
(refractory) MM patients across various treatments including transplant, thalido-
mide, lenalidomide and bortezomib. It can therefore be used reliably as a pre-
dictor for survival to optimize follow-up and treatment strategies in an early stage.
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A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH
BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY
MULTIPLE MYELOMA
N Bahlis1,*, C Chen2, M Sebag3, C Venner4, T Kouroukis5, H Sutherland6,
R LeBlanc7, D Bergstrom8, A McCurdy9, M Lalancette10, C Choe-Juliak11,
C Picklesimer11, JR Saint-Martin11, J Jeha11, M Kauffman11, S Shacham11,
R Kotb12
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Background: The nuclear export protein exportin 1, (XPO1) is overexpressed
in a wide variety of cancers including multiple myeloma (MM). Selinexor is an
oral Selective Inhibitor of Nuclear Export (SINE), specifically a XPO1 antago-
nist. Selinexor forces nuclear retention and reactivation of tumor suppressor
proteins (TSPs; NF-κB, p53 and FOXO) and reduction of many proto-onco-
genes, including MDM2, MYC and Cyclin D. Preclinical activity for selinexor
has been demonstrated in combination with pomalidomide (pom), bortezomib
(bort) or lenalidomide (len). There is in vitro and in vivo evidence of selinexor
synergy with bort (e.g. proteasome inhibitors) through repression of NF-κB
pathway and induction of autophagy in MM. In MM xenografts model, selinexor
in combination with IMiDs have shown synergy in tumor growth inhibition and
increased overall survival when compared to single agents alone. In addition,
phase 1 and 2 clinical studies demonstrated selinexor single agent anti-myelo-
ma efficacy.
Aims: To independently assess the efficacy and safety of three combination
therapies for the treatment of patients (pts) with relapsed/refractory MM. The
combinations are selinexor + dexamethasone (dex) + either Pom (SdP), Bort
(SdB), or Len (SdL).
Methods: The dose escalation phase, conducted via the standard 3+3 design,
consists of 3 treatment arms (SdP, SdB, and SdL), each arm including two treat-
ment cohorts (once-weekly (80 mg, 100 mg) vs twice-weekly (60 mg, 80 mg)
selinexor dosing). These 3 treatment arms are evaluated in parallel. Pom (4 mg),
len (25mg) and dex (20mg with each selinexor dose) will not be dose escalated.
For the SdB arm, bort (1.3mg/m2 given SC) will be dose escalated from once-
weekly to twice-weekly dosing (consistent with its approved, labeled dose).
Results: As of 10-Feb-2016, 4 pts (2M/2F, median of 8 prior regimens, median
age 61 yrs) have been enrolled in the SdP arm. Ten pts (5M/5F, median of 8
prior regimens, median age 65 yrs) have been enrolled in the SdB arm. Com-
mon grade 1/2 adverse events (AEs) in the SdP arm are nausea (2 pts, 50%)
and dysgeusia (2 pts, 50%). One grade 4 AE, neutropenia, was reported in the
SdP arm. The most common related grade 1/2 AEs in the SdB are fatigue (2
pts, 20%), nausea (1 pt, 10%), and diarrhea (1 pt, 10%). Thrombocytopenia (5
pts, 50%) is the only Grade 3 AE reported in the SdB arm. Two pts were evalu-
able for response in SdP arm and achieved a very good partial response
(VGPR, n=1) and a minor response (MR, n=1). Seven pts were evaluable for
responses in the SdB arm including 3 partial responses (PR, 2 pts were bort
refractory and 2 with del17p in >60%), 2 MR, 1 stable disease and 1 progressive
disease.
Summary/Conclusions: Significant responses are observed in both treatment
combinations of selinexor + dex + pom and selinexor + dex + bort, even in
heavily pretreated patients with del17p and/or prior refractoriness to borte-
zomib. In patients with relapsed/refractory MM whose disease has progressed
after PI and/or IMIDs based regimen, the addition of selinexor to bortezomib
or pomalidomide is well tolerated. The early response rate observed is prom-
ising given the history of extensive pretreatment in this patient group. Updated
results from this ongoing phase I/II trial will be presented at the meeting. (clin-
icalTrials.gov #NCT02343042)
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A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984,
ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM
RESULTS FROM 2 NEW DOSE COHORTS
N Lendvai1,*, R Vij2, TG Martin3, R Baz4, F Campana5, F Mazuir6, E Charpen-
tier5, DM Benson7
1Memorial Sloan Kettering Cancer Center, New York, NY, 2Washington Uni-
versity, St. Louis, MO, 3University of California, San Francisco, CA, 4Moffitt
Cancer Center, Tampa, FL, 5Sanofi Oncology, Cambridge, MA, United States,
6Sanofi Research & Development, Alfortville, France, 7Ohio State University,
Columbus, OH, United States
Background: Isatuximab (ISA), a humanized anti-CD38 monoclonal antibody,
has demonstrated activity in patients with RRMM in combination with lenalido-
mide and dexamethasone (Len/Dex) in an ongoing Phase 1b study
(NCT01749969). Overall response rate (ORR) was 63% at ISA 10 mg/kg Q2W
(n=24). Here, we report data from 2 new cohorts evaluating a higher ISA dose
and a different administration schedule.
Aims: Primary objective: to determine the maximum tolerated dose (MTD).
Methods: Patients with RRMM (≥2 prior MM therapies) were sequentially
enrolled to ISA 10 or 20 mg/kg (weekly × 4 doses, then every 2 wks; initial infu-
sion rate 175 and 250 mg/h at 10 and 20 mg/kg, respectively) plus Len 25 mg
(days [D]1-21) and Dex 40 mg (D1, 8, 15, and 22), in 28-day cycles. All patients
signed an IRB approved informed consent.
Results: An additional 26 patients were treated in the 2 cohorts: median age 65
(42-76) yrs; median yrs from diagnosis 4.5 (1.8-16.6). Median 4.5 (1-8) & 6 (3-
10) prior lines of therapy at 10 & 20 mg/kg, respectively; Len-refractory (67% &
86%), pomalidomide+carfilzomib-refractory (25% & 64%), immunomodulatory
drug+proteasome inhibitor-refractory (50% & 86%). At data cut-off (Dec 2015),
median duration of dosing was 21.5 wks (10 mg/kg) and 9.9 wks (20 mg/kg); 13
patients remain on treatment. 4 patients discontinued therapy due to adverse
events (AEs) (grade [Gr] 3 infusion-associated reactions [IARs] [n=3], dose-lim-
iting toxicity of Gr 3 pneumonia [n=1]), all at 20 mg/kg in Cycle 1; these patients
were excluded from the efficacy analysis. Most frequent AEs were fatigue (46%),
pyrexia (35%) and diarrhea (31%). IARs occurred in 65% of patients, mostly Gr
≤2, and >90% during 1st infusion. MTD has not been reached. In evaluable
patients, ORR (IMWG criteria; confirmed responses) was 50% in both cohorts
(10 mg/kg [n=12]: VGPR 25%; PR 25%. 20 mg/kg [n=10]: VGPR 20%; PR 30%).
Clinical benefit rate (≥MR) was 83% and 50% in the 10 and 20 mg/kg cohorts,
respectively. Median time to 1st response was 4 (4-16) wks.
Summary/Conclusions: The combination of ISA ≥10 mg/kg and Len/Dex was
generally tolerated and clinically active in heavily pretreated RRMM. Responses
were observed after approximately 4 wks. PK, biomarker, and longer term fol-
low-up data will be presented.
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MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR
LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA:
DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA
STUDY
M Raab1,*, M Chatterjee2, H Goldschmidt1, H Agis3, I Blau4, H Einsele2,
M Engelhardt5, B Ferstl6, M Gramatzki7, C Röllig8, K Weisel9, P Klöpfer10,
D Weinelt10, J Endell10, R Boxhammer10, C Peschel11
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AKH Wien, Vienna, Austria, 4Department of Internal Medicine III, Charité Cam-
pus Benjamin Franklin, Berlin, 5Hematology & Oncology Department, Medical
University Hospital, Freiburg, 6Department of Internal Medicine 5 - Hematology
and Oncology, Friedrich-Alexander-University Erlangen-Nuernberg, Erlangen,
7Department of Medicine, University Hospital Schleswig-Holstein Division of
Stem Cell Transplantation and Immunotherapy, Kiel, 8Department of Medicine
I, University Hospital Carl Gustav Carus, Dresden, 9Department of Hematology,
Oncology, Immunology, Rheumatology and Pulmonology, University Hospital
of Tuebingen, Tuebingen, 10MorphoSys AG, Martinsried, 11Department of Inter-
nal Medicine III, Technical University of Munich, Munich, Germany
Background: MOR202, a HuCAL-derived, human IgG1 CD38 monoclonal
antibody induces potent ADCC and ADCP; preclinical models show high activity
of single-agent MOR202 and synergy in combination with immunomodulatory
drugs (IMiDs), lenalidomide (LEN) or pomalidomide (POM). Unlike other CD38
antibodies, MOR202 does not induce complement-dependent cytotoxicity
thought to be a major contributor to infusion-related reactions (IRRs).
Aims: The primary objectives of the study were to evaluate the safety, maxi-
mum tolerated dose (MTD)/recommended phase II dose of MOR202 in patients
with relapsed or refractory multiple myeloma.
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Methods: This is an interim analysis of a multicenter, dose-escalation phase
I/IIa study of MOR202. Preliminary safety and efficacy data from 3 cohorts of
patients treated with MOR202 alone or with an IMiD are presented: MOR202 4,
8 and 16 mg/kg weekly; MOR202 8 or 16 mg/kg weekly with either LEN or POM.
Results: As of January 29, 20 patients were treated: 11 patients with MOR202
alone, 5 patients with MOR202+LEN and 4 patients with MOR202+POM.
Patients receiving MOR202 alone or with POM were relapsed or refractory to
prior bortezomib and LEN with a median of 4 prior regimens. Patients given
MOR202 with LEN had a median of 2 prior regimens, mainly bortezomib,
cyclophosphamide and autologous stem cell transplant. The MTD has not been
reached. MOR202 alone or with an IMiD was well tolerated with mainly hema-
tological toxicity. No MOR202-related study discontinuations or deaths were
recorded. A 2-hour MOR202 infusion was feasible in all patients. IRRs (grade
1) were seen in only 1/20 patients. Responses were reported in 8/18 evaluable
patients: 3/10 responses (1 very good partial response [VGPR] and 2 partial
responses [PR]) in the MOR202 alone, 3/4 responses (all PR) in the
MOR202+LEN and 2/4 responses (1 complete response and 1 VGPR) in the
MOR202+POM cohorts. In total, 7/8 responses were still ongoing, the longest
duration of response was >10 months in a patient given MOR202 alone. Preser-
vation of high CD38 levels on MM cells under MOR202 therapy was shown.
Summary/Conclusions: In this analysis, MOR202 given as a 2-hour infusion
showed excellent infusion tolerability and overall safety profile. Promising pre-
liminary efficacy and long-lasting tumor control was seen for MOR202 +/- IMiDs.
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ELOTUZUMAB + LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2
POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM
DIAGNOSIS AND PRIOR LINES OF THERAPY
MA Dimopoulos1,*, A Palumbo2, K Weisel3, P Richardson4, MV Mateos5,
P Moreau6, M Gupta7, J Sheng7, C Passey7, O Sy7, J Katz7, S Lonial8
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Background: Elotuzumab, an immunostimulatory monoclonal antibody target-
ing SLAMF7, kills myeloma cells by both directly activating natural killer cells
and mediating antibody-dependent cell-mediated cytotoxicity. ELOQUENT-2
(NCT01239797) is a Phase 3 study comparing elotuzumab plus lenalidomide
and dexamethasone (ELd) with lenalidomide and dexamethasone (Ld) in
patients (pts) with relapsed/refractory multiple myeloma (RRMM). Pts had a
median time from diagnosis of 3.5 yrs. In a 3-yr follow-up, ELd showed a 27%
reduction in the risk of disease progression/death (hazard ratio [HR] 0.73; 95%
CI 0.60–0.89; p=0.0014), with durable efficacy across key subgroups.1 Pts in
the ELd group also demonstrated a delay of 1 yr in time to next treatment
(TTNT) vs the Ld group, with a median (95% CI) TTNT of 33 (26.2–40.2) months
in the ELd group vs 21 (18.1–23.2) months in the Ld group (HR 0.62; 95% CI
0.50–0.77).1 Interim overall survival (OS) analysis indicated a strong trend in
favor of long-term benefit of ELd vs Ld.1
Aims: To examine the effect of time from diagnosis and number of prior lines
of therapy on progression-free survival (PFS), and to assess tumor
shrinkage/regrowth, indicated by serum M protein, via dynamic modeling.
Methods: RRMM pts with 1–3 prior therapies were randomized to ELd or Ld
in 28-day cycles until disease progression/unacceptable toxicity. PFS was a
co-primary endpoint. An exploratory, post-hoc Kaplan-Meier analysis evaluated
the impact of time from diagnosis and prior lines of therapy on PFS. Serum M
protein dynamic, non-linear, mixed-effect modeling assessed the rate of serum
M protein suppression as well as tumor regrowth, based on longitudinal serum
M protein data from baseline. 
Results: 646 RRMM pts were randomized (ELd n=321; Ld n=325). Baseline
demographics: median age 66 yrs; 32% of pts had del(17p), 9% had t(4;14);
35% of pts were refractory to their last therapy. In pts with ≥median time from
diagnosis, median PFS in the ELd group was 26.0 months vs 17.3 months in
the Ld group (HR 0.60; p=0.0004). In the ELd group, pts with ≥median time
from diagnosis and 1 prior line of therapy (n=48) had a 53% reduction in the
risk of progression/death (HR 0.47; p=0.013) vs the Ld group (n=61). PFS HR
in pts with ≥median time from diagnosis and >1 prior line of therapy was 0.59
(p=0.004; ELd n=111; Ld n=96). Serum M protein dynamic modeling showed
the pattern of tumor regrowth; specifically, regrowth rate was slower for pts in
the ELd vs the Ld group regardless of whether pts had ≥or <median time since
diagnosis. The slowest rate of tumor regrowth (0.00145 g/dL.Day-1) was in pts
in the ELd group with ≥median time from diagnosis (vs 0.00234 g/dL.Day-1 in
Ld group; <median time from diagnosis: ELd, 0.00279 g/dL.Day-1; Ld, 0.00389
g/dL.Day-1).
Summary/Conclusions: ELOQUENT-2 data show a PFS benefit with elo-
tuzumab plus Ld vs Ld across key subgroups. Data from the current analyses
indicate that PFS is favorable for ELd vs Ld across pt subgroups according to
time from diagnosis, including in pts with a longer time from diagnosis and with
either 1 or >1 prior therapy. This finding is further supported by serum M protein
dynamic modeling, which suggests that elotuzumab may differentially slow the
rate of tumor regrowth, thus providing sustainable and long-term survival ben-
efits for pts, as an immuno-oncology agent. Further investigations to identify pt
subgroups with increased PFS and OS benefit from elotuzumab are ongoing.
Funding: BMS and AbbVie Biotherapeutics. Writing assistance: A Bexfield,
Caudex, funded by BMS.
Reference
1. Dimopoulos M et al. ASH Annual Meeting, 2015; Oral 28.
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(RRMM)
A Palumbo1,*, V Magarotto1, P Sonneveld2, T Plesner3, C Paba-Prada4,
P Voorhees5, UH Mellqvist6, C Byrne7, J Harmenberg8, E Nordström9,
H Zubair8, PG Richardson4
1University of Torino Oncology Department, Myeloma Unit Division of Hema-
tology, Torino, Italy, 2Erasmus MC, Rotterdam, Netherlands, 3Hematology, Vejle
Hospital, Vejle, Denmark, 4Dana Farber Cancer Institute, Boston MA, 5Univer-
sity of North Carolina, Chapel Hill, NC, United States, 6Södra Älvsborgs
Sjukhus, Borås, Sweden, 7Oncopeptides AB, Miami FL, United States,
8Oncopeptides AB, 9Oncopeptides AB, Clinical, Stockholm, Sweden
Background: Melflufen is a peptidase potentiated therapy with an alkylating
payload, designed for efficient targeting of tumor cells with a unique mechanism
of action. As a highly potent anti-angiogenic compound, melflufen triggers rapid,
robust and irreversible DNA damage and exerts its cytotoxicity through alkyla-
tion of DNA. The lipophilicity of melflufen leads to rapid and extensive distribu-
tion into cells where it is readily metabolized by intracellular peptidases (often
over-expressed in malignant cells) into hydrophilic alkylating metabolites lead-
ing to 50-fold enrichment in MM cells of these metabolites.
Aims: To study the efficacy and safety of melflufen in combination with dexam-
ethasone (dex) in patients (pts) with RRMM.
Methods: 40 mg melflufen was given in 28-day cycles in combination with 40
mg weekly dex in RRMM pts with ≥2 prior lines of therapy, including lenalidomide
and bortezomib, and who progressed on or within 60 days of last therapy.
Results: As of 11 Feb 2016, recruitment was complete (N=40). Median time
from initial diagnosis to first dose of melflufen was 5.0 years (range 1-20) and
the median number of prior therapies was 4 (range 2-9). 12 patients had ISS
stage I, 16 stage II, 10 stage III and 2 unknown. 12 pts (30%) had high cytoge-
netic risk (del17p, t(4;14) or t(14;16)). 62% were double-refractory and 56%
alkylator-refractory. Median duration of treatment was 4.0 months (m), (range
0.7-15) with 4 pts still ongoing. The best response achieved in the 30 efficacy
evaluable pts (defined as received ≥2 cycles with appropriate assessments)
was VGPR in 3 and PR in 9 for an overall response rate (ORR, ≥PR) of 40%.
An additional 7 pts achieved MR for a clinical benefit rate (≥MR) of 63%. 10 pts
achieved SD and 1 PD. Similar results were seen regardless of refractory status
with an ORR of 35% in double-refractory pts and 53% in alkylator-refractory
pts. The ORR was 33% in pts with high-risk cytogenetics. Time to first response
(≥MR) was rapid with a median of 1.0 m (range 0.6-5.5). ORR in all 40 treated
pts was 30%. The median Progression-Free Survival (PFS) was 8.0 m (95%
conf. int. [CI] 4.1-13.6) based on 21 events in 30 pts in the efficacy evaluable
population. Median PFS was 4.5 m (95% CI 3.7-11.0) based on 30 events in
all 40 treated pts. Median duration of response was 8.8 m and overall survival
was not yet measurable. Hematologic toxicity was common but manageable
with cycle prolongations, dose modifications and supportive therapy. Melflufen
treatment-related Grade 3/4 adverse events (AE) were reported in 85% of
patients; thrombocytopenia 63%, neutropenia 58%, anemia 43% and neutrophil
count decreased 10% followed by febrile neutropenia, asthenia, pyrexia, fatigue
and pneumonia that each occurred in 5% of patients. 16 patients (40%) expe-
rienced serious AEs and 12 patients (30%) had melflufen treatment-related
serious AEs. 58% of the pts required RBC transfusions, 43% platelet transfu-
sions and 53% G-CSF.
Summary/Conclusions: Melflufen produces rapid and durable responses in
MM pts refractory to the major classes of therapy and with high-risk cytogenet-
ics. Clinical benefit (≥MR) was achieved among 63% of these advanced and
heavily pretreated pts. Median PFS was 8.0 m in efficacy evaluable pts. Hema-
tological AEs were common but manageable and non-hematological AEs were
infrequent. Results support continued development of melflufen with its unique
mechanism of action. Recruitment continues to a cohort of single-agent
melflufen. Updated information will be presented at the time of the conference.
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Background: The SKY92 signature is a tool to identify high risk Multiple Myelo-
ma (MM) patients. This signature has been clinically validated on eight inde-
pendent cohorts, spanning patients from newly diagnosed to the relapsed/refrac-
tory setting. For clinical application and patient management, analytical valida-
tion is required on top of the clinical validation. That is, the precision should be
such that given the technical variability of the assay its prognostic value can be
guaranteed. Here the results of the MMprofiler precision studies, Repeatability,
Intermediate Precision, and Reproducibility are reported.
Aims: To demonstrate the precision as part of the analytical validation of the
SKY92 high risk signature and the MMprofiler assay.
Methods: The CE-IVD MMprofiler assay employs an Affymetrix Gene Expres-
sion Profiling (GEP) microarray, and standardized reagents and lab procedures.
The assay reports the qualitative SKY92 result, i.e. an MM patient can either be
standard risk or high risk. This result depends on an underlying quantitative
SKY92 score and cut point, which was therefore used to assess the precision.
Seven standard QC samples were created using representative samples cover-
ing the entire detection range of the SKY92 score. The repeatability (successive
measurements of the same sample under the same conditions, also known as
within run precision) and intermediate precision were assessed at the site in The
Netherlands, by performing 18 runs of the seven samples in duplicate, while
alternating three microarray lots, three reagent lots, three technicians, and two
Affymetrix DX2 machines, providing a total of 252 MMprofiler analyses. For the
reproducibility study, two external sites (UK, and USA) performed five runs of
the same seven samples in duplicate (70 MMprofilers per site). In accordance
with CLSI standard EP5-A2, the precision close to the cut point was estimated
as the 95% confidence interval upper limit of the standard deviation (SD). Prior
to the execution of the precision studies, the maximal tolerable SD at which the
SKY92 signature would remain prognostic was established to be 0.80.
Results: A total of 392 MMprofiler assays were performed at three different sites
(UK, USA, NL), for which the SKY92 scores were plotted, see Figure 1. The
variation due to Repeatability was found to be SD=0.22, and the other sources
of variation amount to SD=0.19. Combined, the Intermediate Precision, was
found to be SD=0.28, which is only 4.4% of the range of SKY92 scores seen in
a reference cohort of samples. Next, the Reproducibility was assessed across
the three participating sites (SD=0.34), which corresponds to 5.4% of the refer-
ence range. All SD estimates were well below the acceptance criterion of 0.80,
and thus the prognostic value of the SKY92 signature can be guaranteed.
Figure 1. Scatterplot showing the SKY92 scores from seven QC samples
performed on 18 days using alternating reagent lots/machines/techni-
cians at the NL site. An additional five runs have been performed at two
external sites in the UK and USA. The Tables below shows the SDs, also
expressed relative to the range of SKY92 scores observed in a clinical
reference cohort.
Summary/Conclusions: The precision estimates of the SKY92 signature and
MMprofiler were found to be small, at most 5.4% of the range of SKY92 scores
seen in a clinical reference cohort. This shows that the MMprofiler SKY92 mark-
er provides reliable results for determination of prognosis across different sites.
This allows worldwide comparison of the MMprofiler results for clinical
(research) purposes.
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Background: Multiple Myeloma (MM) is a disease with a heterogeneous genetic
makeup across patients, and differing survival. Various prognostic markers have
been identified, which may be employed in risk stratified treatment paradigms.
A large comparison has unveiled that the combination of SKY92 + ISS is the
best prognostic marker for identifying high risk and low risk patients. However, a
recurring question is how this marker model relates to the currently established
iFISH abnormalities such as t(4;14), and del(17), which have earlier been asso-
ciated with poor overall survival (OS). Here, we demonstrate that iFISH is out-
performed by the SKY92 + ISS marker combination for risk stratification.
Aims: To show the prognostic relevance of iFISH markers in perspective of
the SKY92 + ISS risk stratification model for prognosis of MM patients.
Methods: Four datasets were gathered, HOVON-65/GMMG-HD4 (n=329),
HOVON-87/NMSG-18 (n=143), MRC-IX (n=246), and a Czech cohort (E-
MTAB-1038, n=66). Pooled, this provided n=559 MM patients for which GEP
data, iFISH annotation, Overall Survival (OS), and ISS were available. The
pooled dataset was split into three risk strata as previously proposed (Kuiper
et al., 2015): SKY92 standard risk (SR) and ISS1 (low risk), SKY92 Standard
Risk and ISS2/3 (intermediate risk), SKY92 high risk (HR). Subsequently, each
of these three risk strata were further refined into two groups: those that had
either iFISH t(4;14) and/or del(17p) characteristics and those without. The Cox
proportional Hazards model was applied to those two groups in each of the
three strata separately, to calculate hazard ratios and associated p-values.
Since groups would become too small, splitting the groups into all possible
FISH subgroups was not performed, i.e. positive for both t(4;14) and del(17p),
and those positive for one and negative for the other.
Results: The four datasets were pooled and then split into three risk strata,
providing n=140 low risk (25.0%, SKY92 SR and ISS1), n=289 intermediate
risk (51.7%, SKY92 SR and ISS2/3), and n=130 high risk (23.3%, SKY92 HR)
MM patients, see Figure 1A. Out of the 140 low risk patients 28 (20%) had a
t(4;14) and/or del17, whose survival was equivalent to those without iFISH
aberrations (HR=2.4, p=0.054, see Figure 1B). Moreover, their survival was
much longer than those in the SKY92 HR group, signifying that they would be
at risk for overtreatment when iFISH would be used for risk stratification. Sim-
ilarly, 55 (19%) out of 289 intermediate risk patients were found to harbor either
iFISH t(4;14) or del(17p), but with no impact on their survival (hazard ratio=1.3,
p=0.17, see Figure 1C). Finally, the group of SKY92 high risk patients were
clearly overrepresented for t(4;14) and del(17p), with 65 out of 130 cases
(50%). However, those 50% of patients that did not bear a t(4;14) and/or
del(17p) aberration (i.e. non high risk by iFISH) had the same poor OS as
those with them (hazard ratio=1.0, p=0.82, see Figure 1D). As a consequence,
applying the current prognostic models using iFISH, those 50% HR patients
not detected by iFISH would be at risk of undertreatment.
Figure 1. Kaplan Meier plots for the SKY92 + ISS risk stratification scheme
on the four pooled datasets (top left). Each of the three strata were sub-
sequently split based on the presence of at least one of the iFISH markers
t(4;14) or del(17p) or absence thereof.
Summary/Conclusions: Risk stratification based on SKY92 and ISS is a pow-
erful tool to identify both high risk MM patients and low risk MM patients.
Patients identified to be iFISH t(4;14) and/or del(17p) are only high risk when
they co-occur with SKY92 HR. Moreover, when they are SKY92 SR, their prog-
nosis is better defined by their ISS stage.
P284
CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT
WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS
OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS
E Terpos*, E Kastritis, D Christoulas, E Eleutherakis-Papaiakovou,
86 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
M Gavriatopoulou, D Fotiou, I Panagiotidis, D Ziogas, E Kafantari, M Migkou,
M Roussou, MA Dimopoulos
Department of Clinical Therapeutics, National and Kapodistrian University of
Athens, School of Medicine, Athens, Greece
Background: Consolidation therapy with the combination of bortezomib,
lenalidomide and dexamethasone (VRD) is an effective therapy in patients with
multiple myeloma (MM) post autologous stem cell transplantation (ASCT). Bis-
phosphonates (BPs) are given for at least for 12 months after diagnosis in
these patients.
Aims: The primary endpoint of the study was to explore the efficacy of VR con-
solidation, without dexamethasone, in newly-diagnosed MM patients who
received bortezomib-based induction treatment and then underwent ASCT.
Secondary endpoints included: safety, time to progression (TTP), time to next
treatment (TtNT), overall survival and effects of VR on bone metabolism, in the
absence of BPs.
Methods: Patients who achieved at least stable disease post-ASCT were eli-
gible for participation in the study. Consolidation consisted of 4 cycles of VR,
which started on day 100 post-ASCT. Bortezomib was given at a dose of 1.3
mg/m2, on days 1, 4, 8 and 11 of a 21-day cycle, while lenalidomide was given
at a dose of 25 mg, on days 1-14. Patients did not receive any BP during or
post-ASCT and during VR consolidation. The following bone remodeling mark-
ers were measured on the day of SC collection, before and after VR consoli-
dation: i) osteoclast regulators RANKL and OPG, ii) osteoblast inhibitors Dkk-
1 and sclerostin, iii) bone resorption markers CTX and TRACP-5b and iv) bone
formation markers bALP and osteocalcin (OC).
Results: Fifty-nine patients (30M/29F, median age 54 year, range 37-68 years)
participated in the study. After induction, one (1.7%) patient achieved sCR, one
(1.7%) CR, 30 (50.8%) vgPR, 22 (37.3%) PR, while 5 (8.5%) patients had stable
disease. After ASCT, 34 (57.6%) patients improved their status of response; in
total, 14 (23.7%) achieved sCR, one (1.7%) CR, 35 (59.3%) vgPR and 9 (15.3%)
PR. After VR consolidation, 23/59 (39%) patients further improved their
response; overall, 30 (50.8%) patients achieved sCR, one (1.7%) CR, 26
(44.1%) vgPR and two (3.4%) PR. The most common adverse events included
neutropenia (68%, grade 3/4 23%), thrombocytopenia (59%, grade 3/4 7%),
peripheral neuropathy (56%, grade 3/4 2%), anemia (50%, grade 3/4 4.5%) and
skin rash (34%, grade 3/4 9%). Fifteen patients (34.1%) experienced at least
one infectious episode (grade 1 and 2). Post-VR consolidation there was a
reduction of sRANKL/OPG ratio and sclerostin (p<0.001) in all patients. Patients
who achieved at least vgPR showed higher reductions of sRANKL/OPG and
sclerostin compared to all others (p<0.01). There was no reduction of bone
resorption markers throughout the study period, possibly due to the dramatic
reduction of these markers during induction therapy, when zoledronic acid was
given. Furthermore, there were no alterations in Dkk-1, bALP and OC, despite
the use of bortezomib which has bone anabolic effects. This may be due to the
enhanced expression of Dkk-1 caused by lenalidomide and the short period of
observation. No skeletal-related events (SREs) were observed during the study
period. The median follow-up after ASCT was 35 months and 54% of patients
have progressed. The median TTP after ASCT was 42 months (95% CI 29-54
months). There was a trend for longer TTP in patients achieving sCR (48 vs 35
months, p=0.145). The median TtNT has not been reached.
Summary/Conclusions: Four cycles of VR consolidation without dexametha-
sone improves the quality of response in approximately 40% of patients and
produces long TTP. In the absence of bisphosphonates, VR consolidation has
beneficial effects on bone metabolism and is related with no SREs.
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LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF
FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO
RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT
E Terpos1,*, N Kanellias1, LA Moulopoulos2, D Christoulas1, M Gavriatopoulou1,
M Migkou1, A Koureas2, T Bagratuni1, V Koutoulidis2, E Kastritis1,
MA Dimopoulos1
1Department of Clinical Therapeutics, 2Department of Radiology, National and
Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background: Skeletal-related events (SREs) which include pathological frac-
tures, spinal cord compression (SCC) and need for radiotherapy or surgery to
bone are frequent complications of multiple myeloma (MM)
Aims: The aim of the study was to evaluate SRE rate in MM patients who
received frontline therapy with bortezomib or IMiD-based therapies and explore
possible correlations with disease or genetic features
Methods: We studied MM patients who received frontline therapy with novel
agents in a single center, since 2007. All patients had a whole body skeletal
survey using conventional radiography (WBXR) at diagnosis and then at the
time of relapse or whenever clinically indicated; MRI of the spine and pelvis at
diagnosis was recorded if available. SNPs in genes that are involved in bone
destruction were also evaluated: LRP5 (rs4988321), GC vitamin D (rs4588),
TNFRSF11A (rs3018362), DKK1 (rs1569198), RANKL (rs9594759), OPG
(rs6469804) and ERS1 (rs1038304).
Results: Since 2007, 463 consecutive patients with symptomatic MM
(237M/226F, median age: 68 years) were studied. At diagnosis, the skeletal
survey detected osteolytic disease in 328 (71%) patients. MRI was available
in 243 patients: 36% of patients had focal, 40% diffuse, 20% normal, and 4%
variegated pattern of marrow involvement. SREs were observed in 194 (42%)
patients at diagnosis: 120 (26%) patients presented with pathological fractures
(89 with vertebral fractures, 21 with rib fractures and 17 with fractures of the
long bones; 28 patients had both vertebral and long bone or rib fractures),
while 22 (4.7%) patients needed surgery to bone, 21 (4.5%) radiotherapy and
20 (4.3%) patients presented with SCC. The incidence of SREs was higher in
patients with osteolytic lesions (52% vs 19%, p<0.001) or abnormal MRI pat-
tern (51% vs 22%, p=0.001). However, we noted that approximately 1/4
patients without lytic lesions in WBXR or with normal MRI pattern presented
with a SRE at diagnosis. No correlation was found between the presence of
SREs and a specific polymorphism of those studied. Frontline therapy with
IMiD-based regimens was given in 38% of patients; 36% patients received
bortezomib-based regimens and 26% both IMiD and bortezomib (VTD or
VRD). BPs were given in all but 86 patients (18.5%) at diagnosis, mainly due
to renal insufficiency; however, almost 60% of them (n=51) received BPs later
in the course of their therapy. The vast majority (91%) of patients received
zoledronic acid. During first line treatment, 8 (1.7%) patients developed a SRE:
2 on bortezomib- and 6 on IMiD-based regimens. The rate of SREs was higher
in patients who did not receive upfront BPs (5% vs 1%; p=0.021). The median
follow-up was 63 months. At the time of first relapse (data available for 218
patients), 12 patients presented with fractures and 35 patients required local
radiotherapy to bone (SRE rate: 21.5%). Patients who had received only borte-
zomib-based regimens had lower SRE rate (8% vs 24%, p=0.06). In total, dur-
ing the course of their disease, 52.8% of the patients presented with at least
one SRE. Presentation with SREs at diagnosis did not predispose for SREs
during the disease course.
Summary/Conclusions: Our data, from the first systematic report on the inci-
dence and characteristics of SREs in the era of novel agents, indicate that
SREs remain a significant complication in MM at diagnosis. Importantly, despite
high response rates after first line therapy more than 20% of patients develop
an SRE, which was lower in patients who received first line therapy with borte-
zomib-based regimens
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PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER
CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY
MULTIPLE MYELOMA
T Casneuf1,*, XS Xu2, H Adams III3, A Axel3, B Verbist1, K Liu3, I Khan2,
T Ahmadi3, X Yan2, S Lonial4, T Plesner5, H Lokhorst6, NW van de Donk6,
PL Clemens3, AK Sasser3
1Janssen Research & Development, Beerse, Belgium, 2Janssen Research &
Development, LLC, Raritan, NJ, 3Janssen Research & Development, LLC,
Spring House, PA, 4Department of Hematology and Medical Oncology, Winship
Cancer Institute, Emory University, Atlanta, GA, United States, 5Vejle Hospital,
Vejle, Denmark, 6Department of Hematology, VU University Medical Center,
Amsterdam, Netherlands
Background: Daratumumab (DARA), a human IgG1 monoclonal antibody that
targets CD38, was recently approved in the United States for patients with
relapsed/refractory multiple myeloma (RR MM) who have received ≥3 lines of
prior therapy, including a proteasome inhibitor (PI) and immunomodulatory drug
(IMiD), or who are double refractory to PI/IMiD. High levels of CD38 are expressed
on MM cells, and to a lesser extent on immune cells, including natural killer (NK)
cells. We assessed the exposure-response relationship of DARA and NK cells,
and the impact on clinical outcomes of RR MM patients treated with DARA.
Aims: To characterize the relationship between DARA exposure, NK cell kinet-
ics, and patient clinical outcomes.
Methods: ADCC and CDC assays were performed following DARA treatment
of NK cells isolated from peripheral blood mononuclear cells of normal, healthy
donors. Samples were pooled from 2 DARA monotherapy studies in patients
with RR MM (GEN501, N=104; SIRIUS, N=124). We explored the kinetics of
total NK cells (CD16+CD56+) and activated NK cells (CD16+CD56dim) after
DARA infusion. Associations between changes in NK cells post-treatment and
DARA exposure, safety, and efficacy were evaluated.
Results: High levels of CD38 were expressed on the surface of NK cells, making
these cells sensitive to DARA-mediated ADCC and CDC in vitro. After infusion
of DARA in patients, the numbers of total and activated NK cells were rapidly
and significantly reduced in a dose-dependent manner in whole blood and bone
marrow, but recovered post-treatment (Figure 1). A hyperbolic maximum effect
(Emax) dose- or concentration-response relationship was observed for the max-
imum reduction in NK cells in the peripheral blood. While baseline levels of NK
cells (total or activated) between responders and nonresponders were similar,
a trend towards higher overall response rate was associated with greater reduc-
tion in NK cells following DARA treatment, suggesting that depletion of NK cells
did not interfere with the clinical activity of DARA. No correlations were observed
between reductions in the number of NK cells and onset of grade ≥3 adverse
events (AEs), infections of any grade, grade ≥3 infections, or herpes zoste.
haematologica | 2016; 101(s1) | 87
Copenhagen, Denmark, June 9 – 12, 2016
Figure 1. Rapid reduction of total NK cell counts and recovery after DARA
treatment.
Summary/Conclusions: CD38 is expressed on NK cells, which are sensitive
to DARA treatment. The peripheral NK cells decreased with increasing DARA
exposure, exhibiting an Emax-type exposure-response relationship. This finding
suggests that NK cells can be used as a pharmacodynamic marker for DARA.
However, no apparent relationship was observed between NK cell reduction
during treatment and incidence of grade ≥3 AEs or infections of any grade.
Myeloproliferative neoplasms - Biology 
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CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS
PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING
SYNERGISTIC ACTIVITY IN MPN MODELS
M Balliu1,*, N Bartalucci1, L Calabresi1, S Martinelli1, C Bogani1, JL Villeval2,
F Annunziato1, P Guglielmelli1, AM Vannucchi1
1Department of Experimental and Clinical Medicine, University of Florence,
Florence, Italy, 2INSERM, Gustave Roussy, Villejuif, France
Background: The constitutive activation of the JAK/STAT pathway by
JAK2V617F (VF) and other driver mutations in myeloproliferative neoplasms
(MPN) on turn promotes deregulation of other intracellular signaling pathways
including the PI3K/mTOR. We previously reported that drugs targeting the PI3K
pathway induce cell cycle arrest and attenuate dissemination of JAK2VF cells
infused in immunodeficient mice (JCellMolMed 2013;17:1385). Also, the mTOR
inhibitor RAD001 demonstrated clinical efficacy in a phase I/II trial in MPN
patients (Blood 2011;118:2069).
Aims: Herein we have addressed the molecular mechanisms of the efficacy
of PI3K inhibitors, using as relevant drugs the pan-PI3K inhibitor BKM120 and
the mTORC1 complex inhibitor RAD001, that were employed as single agents
or combined with the JAK1/JAK2 inhibitor Ruxolitinib (Ruxo).
Methods: As MPN models, we used in vitro, JAK2VF-mutated SET2 and HEL
cell lines, ex vivo, the primary CD34+cells from MPN patients and in vivo,
JAK2V617F knock-in (KI) mice (Blood 2013;122:1464).
Results: Treatment of JAK2VF SET2 and HEL cell lines and JAK2V617F KI
mice with BKM120 caused a marked decrease of p-mTOR and its target p-
4EBP1, that were accompanied by reduction of p-STAT5 levels. We found that
cells treated with BKM120 showed marked dephosphorylation of serines (Ser)
residues of STAT5, specifically Ser193/Ser731, while p-tyrosine (Tyr) residues,
particularly p-Tyr694, were unaffected. Conversely, Ruxo caused reduction of
p-Tyr694 with irrelevant effects on Ser residues. To understand the mechanisms
of BKM120-induced Ser dephosphorylation, we sought to identify involved pro-
tein phosphatases. We found that only the downregulation of serine/threonine
protein phosphatase 2A (PP2A) effectively abrogated drug-induced dephos-
phorylation of Ser residues. In addition, the mRNA and protein levels of the
cancerous inhibitor of protein phosphatase 2A (CIP2A) were strongly reduced
by PI3K-inhibitors both in cell lines and primary samples from patients who
showed responsiveness to RAD001 treatment. Also, downregulation of the
PI3K downstream effector SNAI1 induced by BKM120 treatment leads to
upregulation of miR-375, which is involved in the stability of CIP2A mRNA (Mol-
BiolCell 2013;24:1638-48). Therefore, inhibition of p-STAT5 by PI3K inhibitors
in MPN cells results from a microcircuit involving miR-375, CIP2A and PP2A
overall controlling phospho status of STAT5 Ser residues. Owing that
PI3K/mTOR and JAK2 inhibitors induced dephosphorylation at different STAT5
residues, we evaluated the combination of BKM120, RAD001 and Ruxo to
induces complete STAT5 inactivation, both in vitro and in vivo models. In vitro,
triple drug combination showed the highest synergic activity (CI<0.25; Chou
and Talalay combination index) in reducing proliferation of JAK2VF cell lines
and colonies formation from patients’ cells, as compared to double combina-
tions (BKM120+Ruxo CI<0.65; RAD001+Ruxo CI<0.3). Immunoblots of cells
treated with triple-combo showed a concomitant dephosphorylation of both
Tyr694 and Ser193/Ser731 reflecting stronger STAT5 inhibition. In vivo,
JAK2V617F KI mice treated with triple-combo showed dramatic reduction of
splenomegaly and control of blood cell counts much more effectively than sin-
gle-drug treated (p<0.5) and control (p<0.1) animals.
Summary/Conclusions: Overall, these data reinforce the functional cross-
talk between the JAK/STAT and PI3K/mTOR pathways in MPN cells and, by
providing evidence of drug synergism mediated by differential targeting of
STAT5 phosphoresidues, supporting the combined use of JAK1/2 and
PI3K/mTOR inhibitors for the treatment of MPN.
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ACE-1332 (TGFB LIGAND TRAP) INHIBITS ELEVATED TGFΒ1 SIGNALING
AND REDUCES FIBROSIS IN A MURINE MODEL OF MYELOFIBROSIS
NVSR Suragani1,*, P Martinez1, R Li1, SR Pearsall1, R Kumar2
1Pre Clinical Pharmacology, 2Biology, Acceleron Pharma, Cambridge, United
States
Background: Myeloproliferative neoplasms (MPN) are group of clonal stem
cell disorders that originate from acquired mutations in the hematopoietic lin-
eage cell leading to abnormal kinase signaling, cell proliferation, cytokine
expression, splenomegaly and bone marrow (BM) fibrosis. Primary myelofi-
brosis (PMF), post-polycythemia vera (PV) MF and post-essential thrombo-
cythemia MF are categorized under myelofibrosis (MF) with overlapping dis-
ease phenotypes including progression to BM fibrosis. Mutations in JAK2 have
been highly correlated with MF and currently, JAK2 kinase inhibitor therapy is
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the only available treatment that offers symptomatic benefit, but does not alter
the natural history of the disease or improve BM fibrosis. It is known that TGFβ1
is a critical regulator of fibrosis in many disease states and may be an important
therapeutic target for improving bone marrow fibrosis in MPN.
Aims: Elevated TGFβ1 levels were reported to be important for fibrosis in
patients with MF. We hypothesize that inhibition of TGFβ1 signaling may prevent
fibrosis and help reduce secondary morbidities associated with disease in MF
patients. Therefore, we evaluated this hypothesis using ACE-1332 in a murine
model of MF.
Methods: Transgenic JAK2 (V617F) mutant mice (MF model) and age matched
wild-type controls were used in the studies. Mice were dosed with RAP-1332
(murine ortholog of ACE-1332) twice weekly (10 mg/kg) by subcutaneous injec-
tion. Expression of TGFβ and inflammatory cytokines at different ages (2-12
months) during disease progression was determined by serum ELISA and qRT-
PCR. Bone marrow and spleen cells were analyzed for different cell lineages
by flow cytometry. BM sections were stained with H&E and reticulin to determine
cellularity or degree of fibrosis respectively.
Results: To understand the onset and progression of MF disease in JAK2
(V617F) mice, we initially analyzed the complete blood counts and degree of
fibrosis at various ages (2, 3, 4, 5, 8, 10 and 12 months) compared to wild-type
mice. These data were then correlated with the expression of TGFβ and inflam-
matory cytokines. As expected, red blood cells (RBC) and platelets were ele-
vated in JAK2 mutant mice at all ages compared to wild-type mice, although a
trend towards a progressive increase was observed between 2 to 5 months
followed by a decrease from 8 to 14 months. BM fibrosis was detected starting
at 5 months and worsened with age. JAK2 mutant mice also displayed
splenomegaly that increased as the disease progressed. Interestingly, serum
levels of TGFβ1 and TGFβ3 increased at earlier ages (2-5 months) compared
to the latter ages, a trend similar to RBC levels. These levels peaked during
the initiation of fibrosis at 5 months. In contrast, inflammatory cytokines (such
as IL6, IL-1β, and TNFα) were elevated at later ages consistent with disease
progression. We initiated treatment with RAP-1332 in JAK2 (V617F) mice (N=8/
treatment group) at 4 months of age, the age corresponding to elevated serum
TGFβ1 levels and prior to the onset of fibrosis (at 5 months of age). Following
6 months of treatment, vehicle (VEH) treated JAK2 mutant mice displayed ele-
vated RBC (+37.1%, P<0.001), platelets (+74.5%, P<0.001) and spleen weights
(+9.5 fold, P<0.001) compared to wild-type mice. BM and spleen sections from
VEH treated JAK2 mutant mice revealed severe fibrosis. TGFβ1 antagonism
by RAP-1332 treatment of JAK2 mice displayed moderate effect on RBC (-
8.4%, N.S) without any effect on platelet counts compared to VEH treatment.
Flow-cytometry identified a reduced proportion of Ter119+ erythroid precursors
in BM and spleen (-15%, P<0.05) and no change in CD41+ megakaryocytes.
RAP-1332 treated mice displayed reduced spleen weights (-29%, P<0.01), and
marked reduction in bone marrow (Figure) and spleen fibrosis compared to
VEH. Consistent with the reduction in fibrosis, RAP-1332 treated JAK2 mice
displayed reduced IL-6 levels (-48.9%, P<0.05) compared to VEH treatment.
Figure 1.
Summary/Conclusions: These data demonstrate that TGFβ1 levels were cor-
related with bone marrow fibrosis in a murine model of MF disease. Inhibition
of TGFβ1 using RAP-1332 reduces fibrosis, splenomegaly and inflammation
in this the JAK2 V617Fmurine model of myelofibrosis.
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TARGETING OF BRD4 AS A NOVEL THERAPEUTIC CONCEPT IN JAK2
V617F+ MPN 
A Keller1,2,*, B Peter1,2, J Zuber3, D Berger2, PB Staber2, P Bettelheim4,
P Valent1,2, E Hadzijusufovic1,2,5
1Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, 2Medical
University of Vienna, 3Research Institute of Molecular Pathology, Vienna, 4Elis-
abethinen Hospital Linz, Linz, 5University of Veterinary Medicine Vienna, Vien-
na, Austria
Background: Myeloproliferative neoplasms (MPN) are characterized by clonal
expansion and accumulation of myeloid cells, erythrocytes, and/or platelets in
the bone marrow (BM) and peripheral blood. Classical MPN are polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
In patients with MPN, the JAK2 V617F mutation is frequently detected. Although
MPN are chronic and indolent diseases in most patients, fatal progression may
occur. So far, the only curative approach for these patients is hematopoietic
stem cell transplantation. Therefore, current research is evaluating new thera-
peutic targets. The epigenetic reader bromodomain-containing protein 4 (BRD4)
has recently been identified as a promising target in acute myeloid leukemia.
Aims: The aim of the present study was to investigate the potential value of
BRD4 as a molecular target in MPN.
Methods: We employed two JAK2 V617F+ cell lines, SET-2 and HEL, as well
as BM samples obtained from 19 patients with JAK2 V617F+ MPN (ET: n=6;
PV: n=7; PMF: n=6). Three BRD4 inhibitors were applied: JQ1, BI2536, and
BI6727.
Results: As assessed by qPCR, SET-2, HEL, and primary MPN cells were
found to express BRD4 mRNA and mRNA of the BRD4-downstream target
MYC. In 3H-thymidine uptake experiments, all three BRD4 blockers were found
to suppress the proliferation of both cell lines and all tested MPN patient sam-
ples (7/7). The effects of these drugs were dose-dependent with reasonable
IC50 values (Table 1). In addition, we analyzed the effects of the BRD4 inhibitors
on the putative (neoplastic) stem cells (CD34+/CD38-). In one PMF and one
PV patient, exposure to JQ1 was followed by a decrease in the percentage of
CD34+/CD38- cells (PMF: control: 0.16% vs JQ1: 0.045%; PV: control: 0.078%
vs JQ1: 0.056%). In the PV patient, the effects of BI2536 and BI6727 were
also tested and found to be comparable to JQ1. To confirm the role of BRD4
as a potential target in MPN cells, we performed target-knockdown experiments
in SET-2 and HEL cells using two different BRD4 shRNAs. Knockdown of BRD4
was found to block proliferation in transfected cells when compared to untrans-
fected or random shRNA-transfected cells. In a next step, we examined the
effects of the BRD4 inhibitors on cell cycle progression. BI2536 and BI6727
were found to induce a G2/M phase arrest in both cell lines. In contrast, JQ1
induced a G1-arrest in HEL cells, but did not show a significant effect in SET-
2 cells. In addition, we found that all three BRD4 blockers induced apoptosis in
SET-2 and HEL cells in a dose-dependent manner (ED50 values: Table 1).
Finally, we examined whether exposure to BRD4 inhibitors is associated with
modulation of MYC mRNA expression. JQ1, BI2536, and BI6727 were found
to downregulate MYC mRNA levels in SET-2 and HEL cells after 2 hours. As
assessed by Western blotting, protein levels of MYC were found to be reduced
in the MPN cell lines after 24 hours of treatment with BRD4-targeting drugs.
Table 1.
Summary/Conclusions: In conclusion, our data show that BRD4 is expressed
in JAK2 V617F+ MPN cells and that BRD4 inhibition is associated with
decreased proliferation and survival of neoplastic cells. The clinical value of
BRD4 as a therapeutic target in JAK2-mutated MPN remains to be determined
in clinical trials.
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LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS
E Rumi1,2,*, A Harutyunyan3, D Pietra1, C Cavalloni2, E Roncoroni1, I Casetti2,
M Bellini2, C Milanesi1, C Astori1, R Kralovics3,4, M Cazzola1,2
1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Mat-
teo, 2Department of Molecular Medicine, University o Pavia, Pavia, Italy, 3CeMM
Research Center for Molecular Medicine of the Austrian Academy of Sciences,
4Department of Internal Medicine I, Division of Hematology and Blood Coagu-
lation, Medical University of Vienna, Vienna, Austria
Background: Myeloproliferative neoplasms (MPN), including polycythemia
vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF)
have in most instances a sporadic occurrence. However, familial clustering of
MPN has been reported. Common mutations involved in the pathogenesis of
MPN such as JAK2 V617F, CALR, and MPL mutations are not inherited, but
somatically acquired also in familial cases. The SH2B adaptor protein 3
(SH2B3) gene, also known as LNK gene, encodes a negative regulator of
cytokine signaling: Lnk negatively regulates erythropoietin receptor signaling
and thrombopoietin receptor signaling, by attenuating Jak2 activation and thus
reducing erythropoiesis and megakaryopoiesis, respectively. LNK mutations
have been described in some patients with sporadic MPN and in a small number
of cases with idiopathic erythrocytosis and subnormal Epo levels. The majority
of mutations occur in exon 2 and is acquired although rare cases of germline
LNK mutations have been reported. To date, there are no data regarding the
occurrence of LNK mutations in familial myeloproliferative neoplasms.
Aims: In an attempt to identify the germline genetic factors that underlie familial
clustering of MPN we applied next generation sequencing to our MPN families.
Methods: Our cohort of 94 MPN families was analyzed with two strategies. First
we applied whole exome sequencing (Illumina instrument) in a subgroup of 16
families with MPN. As this approach resulted in the identification of a exon 2 LNK
mutation in one family, next we screened for exon 2 LNK mutations by Sanger
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sequencing the remaining 93 families. Variants were validated by Sanger sequenc-
ing. All samples were collected after subjects gave their written informed consent.
Results: Exome sequencing resulted in the identification of an E208Q LNK
mutation in a patient with familial PV belonging to family 36. Then we screened
for exon 2 LNK mutations the remaining 93 families. Of 149 patients affected
with familial MPN, two patients (1.4%) showed E208Q LNK mutation (including
the initial case, identified through exome sequencing). The pedigrees and the
LNK sequences of the two mutated cases (MeF and MPC12_294, belonging
to family 36 and family 38 respectively) are reported in Figure 1. Both patients
were affected with JAK2 V617F mutated polycythemia vera. Unfortunately DNA
from healthy relatives of family 36 and 38 was not available. The two patients
carried the mutation both in granulocyte and T lymphocyte DNA, thus suggest-
ing a germline mutation. In both families the other family member affected with
MPN (MeR and MPC07_24) did not carry any mutation of the LNK gene, thus
excluding segregation of the E208Q mutation with the disease phenotype. This
raised the suspicious that the mutation might be an early mutation occurred in
the hematopoietic system instead of a real germline mutation. To test this
hypothesis we recalled patient MeF to collect DNA from his hair. E208Q muta-
tion was found also in DNA from hair roots, thus confirming that the E208Q
mutation was a real germline mutation.
Figure 1.
Summary/Conclusions: LNK germline mutations may rarely occur in familial
MPN, also in the presence of JAK2 V617F mutation, but do not segregate with
the disease phenotype.
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HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH
MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY
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Background: The pathogenesis of acquired myeloperoxidase (MPO) deficien-
cy, a rare phenomenon observed in patients with Philadelphia chromosome-
negative myeloproliferative neoplasms (MPN), is unknown. MPO is a glyco-
protein chaperoned by Calreticulin (CALR) in the endoplasmic reticulum. Muta-
tions in CALR are frequently found in patients with myelofibrosis (MF) and
essential thrombocythemia (ET) with nonmutated Januskinase 2 (JAK2). 
Aims: We aimed to determine whether acquired MPO deficiency in MPN is
associated with the presence of CALR mutations. 
Methods: A cohort of 317 MPN patients (142 polycythemia vera (PV), 94 ET
and 81 MF) was screened for MPO deficiency using an ADVIA hematology
analyzer. Molecular and cell biological analyses were performed in order to
determine the underlying mechanism implicated in cases with MPO deficiency. 
Results: MPO deficiency was observed in 6/81 MF patients (7.4%), but not in
PV or ET patients. Susceptibility to infections had been documented in 2/6
(33%) MPO deficient patients. Five out of six patients with MPO deficiency
carried a homozygous CALR mutation and were also deficient in eosinophilic
peroxidase (EPX). In contrast, one MF patient with a JAK2-V617F mutation
and MPO deficiency carried two previously reported MPO mutations and
showed normal EPX activity. Importantly, we did not find patients with homozy-
gous CALR mutations and normal MPO activity or patients with heterozygous
CALR mutations and MPO deficiency in our cohort. Although additional MPN-
associated mutations were detected in patients with homozygous CALR muta-
tions, none of them was recurrent within these patients. Patients with homozy-
gous CALR mutations had reduced MPO protein, but normal MPO mRNA levels
supporting a post-transcriptional defect in MPO production. Finally, we demon-
strate in vitro that in the absence of CALR immature MPO protein precursors
are degraded in the proteasome.
Summary/Conclusions: Four decades after the first description of acquired
MPO deficiency in MPN we provide the molecular correlate associated with
this phenomenon and evidence that CALR mutations can affect the biosynthe-
sis of glycoproteins.
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CHARACTERISATION OF THE INFLAMMATORY MICROENVIRONMENT
IN MYELOPROLIFERATIVE NEOPLASMS AND ITS FUNCTIONAL IMPACT
ON STEM AND PROGENITOR CELLS
NF Øbro1,*, J Grinfeld1,2, MS Shepherd1, OB Harris1, JC Prick1, AL Miller1,
EJ Baxter2, AR Green1,2, DG Kent1
1Department of Haematology, University of Cambridge, 2Department of
Haematology, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background: The immune microenvironment in the bone marrow can have
tumor-promoting activity in leukaemia. However, the role of the microenviron-
ment in the initiation and evolution of early myeloid malignancies in not well
understood. 
Aims: The aim of this study is to characterise the inflammatory microenviron-
ment in chronic myeloproliferative neoplasms (MPNs), including essential
thrombocythaemia (ET), polycythaemia vera (PV), and myelofibrosis (MF). We
undertook a cell surface marker screen and secreted molecule screen in an
effort to identify disease biomarkers and to functionally characterise their impact
on pre-malignant stem and progenitor cells. 
Methods: We performed a screen of cell surface markers (n=244 markers in
7 patients, followed by 7 candidate markers in 18 patients) and cytokine levels
(n=38 cytokines, 193 patients) in MPN patient mononuclear cells and peripheral
blood serum (and in 12 normal controls). Statistical analyses to identify candi-
dates for disease subtype and/or progression was undertaken. Colony assays
were performed in patient samples with and without candidate cytokines.
Results: A cell surface marker screen of 244 antigens identified an increase
in the frequency of markers associated with activated T- and NK-cells in myelofi-
brosis patients. We therefore undertook a screen of inflammatory cytokines in
the serum of 193 patients to determine if specific cytokines were driving disease
progression. Using multi-plexed cytokine bead arrays (Millipore) with 38 ana-
lytes, we identified a range of serum cytokines that displayed differential serum
concentration across the MPN subtypes. Higher levels of IL-8, IP-10, IFN-gam-
ma and TNF-alpha all associated with myelofibrosis. Distinct cytokine profiles
were also seen for PV and ET, incl. increased EGF in ET and increased TGF-
alpha in PV patients. In colony assays, a direct effect on the growth of stem
and progenitor cells was observed with IFN-gamma treatment. Single HSCs
from ET, PV and MF patients were treated with IFN-gamma, and progenitor
expansion was decreased in ET, unaffected in PV and increased in MF. Further
analyses are now underway to determine the longitudinal changes in serum
cytokines over the course of disease and transformation as well as additional
functional data in single stem and progenitor cell assays. 
Summary/Conclusions: Together these data implicate the immune microen-
vironment as a major player in MPN biology with several cytokines showing
differential levels across subtypes of MPN.
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MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE
MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND
PROLIFERATION CAPACITY
B Rambaldi1,2,*, A Pievani2, E Diral2,3, IM Michelozzi2, L Antolini4, P Pioltelli3,
A Biondi5, EM Elli3, M Serafini2
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of Pediatrics, Dulbecco Telethon Institute at Centro Ricerca Tettamanti, Uni-
versity of Milano- Bicocca, 3Hematology Division, San Gerardo Hospital, Uni-
versity of Milano-Bicocca, 4Centro di Biostatistica per l’Epidemiologia Clinica,
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Pediatric Hematology-Oncology Department and “Tettamanti” Research Cen-
tre, Milano-Bicocca University, “Fondazione MBBM,” San Gerardo Hospital,
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Background: MSC play an important role in the structure of the bone marrow
(BM) niche and regulation of stem cells homeostasis. In Ph-neg MPN, including
Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Myelofibrosis
(MF), there is a substantial alteration of the BM niche, characterized by massive
deposition of fibrous tissue, neoangiogenesis and osteosclerosis, with con-
comitant loss of the hematopoietic tissue.
Aims: The aim of this work is to study possible alterations in the mesenchymal
compartment in Ph-neg MPN in relationship to the BM fibrosis grade.
Methods: MSC were characterized after isolation from BM biopsies of 23
patients with Ph-neg MPN and BM harvests of 6 healthy donors (HD), from
washouts of transplant bags, as previously described (Pievani A. et al. Cytother-
apy. 2014 Jul;16(7):893-905). BM fragments were digested using collagenase
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soltion and repeatedly washed with a syringe with 25-Gauge needle using fresh
PBS, in order to collect mononuclear cells (MNC). Patients were classified in 3
groups according to diagnosis of Ph-neg MPN and grade of BM fibrosis (WHO
criteria): low fibrosis (0-1) no MF (LF-NOMF), low fibrosis MF (LF-MF) and high
fibrosis (2-3) MF (HF-MF), respectively formed by 11, 4, and 8 patients. Muta-
tions of JAK2, CALR and MPL genes were present respectively in 65%, 22%
and 9% of cases. A triple negativity was documented only in one case (4%).
Results: The median age at the time of cell collection was 54 years (range:
38-77) for the patients and 50.5 years (44-58) for the HD group. A remarkably
different number of MNC was harvested from biopsies digestion in different
patients groups with a median value of 0.70x106cells/mm (0.23-2.88) for HF-
MF and 2.27x106cells/mm (1.75-3.18) for LF-MF (p 0.028). LF-NOMF cellularity
was 1.44x106cells/mm (0.40-2.78). No difference was noted between the two
group with LF (p 0.131) (Fig.1A). Median value of CFU per 102 plated cells
was 10.70 (0-14.50) for HF-MF, significantly reduced compared to the other
groups: LF-MF 31.50 (11.70-36.30; p 0.042), LF-NOMF 36.70 (9.30-59.70; p
0.0049) and HD 32.50 (25.30-38.00; p 0,0012) (Fig.1B). The proliferation capac-
ity was investigated by the population doubling (PD) assay. The median cumu-
lative PD value at passage 5 for HF-MF was 5.78 (0.43-8.14), significantly
reduced compared to other groups: LF-MF 8.31 (5.66-8.42; p 0.05), LF-NOMF
7.83 (5.68-10.26; p 0.0097) and HD 8.71 (6.90-9.46; p 0.014) (Fig.1C). All
patient’s MSC lines express the typical markers of mesenchymal cells (CD90,
CD105, CD73, CD146), similarly to HD. Regarding trilineage differentiation
potential, Ph-neg MPN-MSC showed a normal differentiation capacity into adi-
pogenic tissue and the up-regulation of key adipogenic differentiation genes
(FABP4, LPL, PPARG), with a similar trend compared to HD. In the same
patients, MSC were efficiently differentiated into osteogenic lineage with a com-
parable up-regulation of key osteogenic differentiation genes (RUNX2, ALPL,
COL1A2, SPP1, SPARC, BGLAP) with respect to the HD group. Ph-neg MPN-
MSC were also able to differentiate into cartilagineous pellets, showing an up-
regulation of key differentiation genes (COL2A1, COL10A1, SOX9, ACAN) sim-
ilar to HD. No evident differences were observed between the 3 groups of
patients. Finally, MSCs were tested for the presence of the respective HSC
mutations (JAK2, MPL, CALR) and no one harbored them.
Figure 1.
Summary/Conclusions: Ph-neg MPN-MSC with HF showed a reduced clono-
genicity and proliferation capacity compared to the LF groups, independently
from the type of disease. These data suggest an alteration of MSC of Ph-neg
MPN restricted to the MSC derived from patients who already have a HF in
the BM.
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NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED
CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE
MYELOFIBROSIS
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Background: Phenotype driver mutations (mut.) in JAK2, CALR, and MPL
are present in ~90% of patients (pts) with myelofibrosis (MF). As these mut.
are considered mutually exclusive, the diagnostic workup via PCR or melting
analysis is limited to analyzing exon 14 of JAK2, exon 10 of MPL, and exon
9 of CALR.
Aims: Next-generation sequencing (NGS) is likely to enter clinical practice in
near future. We compared an NGS-based approach to standard PCR tech-
niques in detecting driver mut. in MF.
Methods: Genomic DNA was isolated according to standard procedures from
whole-blood samples of 129 pts with MF (68 males; median age 60 y). JAK2,
MPL, and CALR mut. analysis via PCR were performed as published. Next,
NGS was performed: Coding regions and adjacent intronic sequences of 23
selected genes were amplified by multiplex PCR with a primer panel (692 primer
pairs). PCR products were purified and ligated to adapters specific for NGS
using the Ion AmpliSeq workflow (Thermo Fisher Scientific). DNA libraries were
used for templating the sequencing particles. For sequencing, the semiconduc-
tor-sequencing technology of the Ion Torrent PGM sequencing platform (Thermo
Fisher Scientific) was used. Sequencing reads were aligned to the human
genome (hg19) with the Torrent Suite Software, variants were called using the
Torrent Variant Caller, and variant annotation was done with the Ion Reporter
Software (Thermo Fisher Scientific) according to the HGVS nomenclature.
Results: Standard PCR detected JAK2V617F, MPLW515L, and mutated CALR
in 81 (63%), 1 (0.8%), and 25 (19.4%) pts respectively. One patient (0.8%) har-
boured both mutated JAK2 and CALR. NGS identified JAK2 mut. at positions
R1063H [exon 24; (n=6)] and R893T [exon 20; (n=1)] in JAK2V617F+ pts and
in MPL at positions W515L + E335K, E259K, Y591D (n=3), and Y591D (n=2).
TET2 and ASXL1 mut. were found in 27 (21%) and 25 (19%) pts respectively.
None of the pts with JAK2R1063H or JAK2R893T mut. carried a TET2 or
ASXL1 mut. JAK2–TET2 double-mutant cells were present in 16 (12%) pts.
Interestingly, 4 of 5 MPL mut. were found in the JAK2–TET2 mutated group
and non in the CALR mutated or triple negative cohorts. Patients with the JAK2–
MPL-TET2 mut. were older, had a higher JAK2V617F allele burden, larger
spleens, and a more proliferative disease in terms of WBC and peripheral blasts
compared to the JAK2V617F+ “only” cohort. Except for age and peripheral
blasts, the clinical phenotype of JAK2–MPL-TET2 and JAK2–TET2 mutated
pts was similar (table).
Table 1. Patients characteristics (n=129).
Summary/Conclusions: With NGS, additional activating mut. such as
MPLY591D (a gain of function mut. in exon 12 of MPL) could be detected
through the inclusion of all coding exons of JAK2 and MPL. Our data provide
evidence that driver mutations are not always mutually exclusive as was the
case in 4% of pts and imply that combination of mut. could have a specific
effect on clinical phenotype. Analysis of larger cohorts will provide accurate
estimates of the frequency of concomitant JAK2 and MPL mut. Serial NGS
permits the study of the chronology of mut. which might influence the biology
of the disease and/or response to therapy.
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THE INNATE AND ADAPTIVE IMMUNE SYSTEM IS SIGNIFICANTLY
DYSREGULATED IN MYELOFIBROSIS: EVIDENCE OF A CENTRAL ROLE
OF MUTATIONAL STATUS
M Romano1,2, D Sollazzo2, S Trabanelli3, N Polverelli2, M Perricone2, D Forte2,
F Lapi2, S Fatica2, S Luatti2, M Cavo2, N Vianelli2, C Jandus3, F Palandri2,
L Catani2,*
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don, United Kingdom, 2Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna, Institute of Hematology “L. e A. Seragnoli”,
Bologna, Italy, 3Ludwig Center for Cancer Research, Lausanne, Switzerland
Background: Myelofibrosis (MF) is a clonal neoplasia associated with myelo-
proliferation, extramedullary haematopoiesis and bone marrow fibrosis. MF
patients have severely reduced life expectancy, with infectious complications
constituting more than 10% of all causes of death. Besides molecular abnor-
malities (Janus Kinase 2 (JAK2), Calreticulin (CALR) and myeloproliferative
leukemia protein (MPL) genes mutations), chronic inflammation has emerged
as a key-player in MF pathogenesis and progression. However, thus far, few
and incomplete studies focused on the contribution of the innate and adaptive
immunity to MF pathogenesis. 
Aims: To better understand MF pathogenesis and the mechanisms involved in
infectious events, we studied key immune-cells and plasma cytokine levels in
MF patients according to their mutational status. We evaluated circulating den-
dritic cells (DCs) and monocytes, focusing on their DCs differentiation capacity.
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DCs promote T cell polarization into different subsets of T-helper cells (Th)
responsible for the clearance of intra and extracellular pathogens. For these
reasons, we analysed the percentages of Th1, Th2 and Th17 cells; in addition,
the role of natural regulatory T cells (Tregs) was investigated. Due to the aber-
rant cytokine compartment in MF, we also evaluated Innate Lymphoid Cells
(ILCs), a novel family of immune effector cells with a critical role in inflammation
and immunosurveillance.
Methods: Mutations were monitored using RT-PCR (JAK2 and MPL genes) and
exon 9 Next Generation Sequencing approach (CALR gene). Circulating Th1,
Th2 and Th17 cells (identified as CD3+CD4+CD45RO+CXCR3+CRTH2-CCR6-,
CD3+CD4+CD45RO+CXCR3-CRTH2+ and CD3+CD4+CD161+CCR6+ cells,
respectively), myeloid and plasmacytoid DCs (identified as Lin−HLA-DR+/CD11c+
or CD123+ cells, respectively) from 36 untreated patients and 10 healthy subjects
were evaluated by flow cytometry. Percentages and function of total Tregs and
ILCs (identified as CD3+CD4+CD25highCD127neg and Lin−CD127+) plus their
cognate subpopulations were analysed as well. After immunomagnetic isolation,
we tested phenotype of circulating monocytes and their capacity to differentiate
into DCs. Cytokines plasma levels were measured by ELISA.
Results: We demonstrated that in MF specific crucial subsets of the immune
system show quantitative and/or qualitative abnormalities identifying a muta-
tion-driven immunological signature. Th17, mDCs and Tregs Population II
reduction, associated with an increase in ILC1 is specific of JAK2 mutated
patients. Alternatively, CALR mutated patients are characterised by increased
ILC3 population, diminished Th1 compartment together with reduced monocyte
capacity to mature in vitro into DCs. Of note, Tregs from CALR mutated patients
were less suppressive than the normal counterpart. This may be due to the
increased in vitro proliferative capacity of responder T cells carrying CALR
mutation. Nevertheless, irrespective of mutation status, ILC1 and 2 were hypo-
functional. Finally, patients showed a reduced plasma levels of interleukin (IL)
-4, -5 and Interferon-γ with concomitant increased levels of IL-1β, -6, -12, -13,
-17, and Tumor Necrosis Factor-α.
Summary/Conclusions: This study shows that MF patients are characterized
by a mutation-driven state of immunosuppression, with key cellular components
of the immune system showing defective number/function. This state of immune
deficiency may play a role in disease pathogenesis and explain, in part, the
susceptibility of MF patients to infectious complications.
M.R., D.S. and S.T. equally contributed; F.P. and L.C. equally contributed. This
research was supported by BolognAIL
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THE H3K4 METHYLTRANSFERASE SETD1B IS ESSENTIAL FOR
HAEMATOPOIETIC STEM CELL HOMEOSTASIS IN MICE
K Schmidt1,*, A Kranz1, A Tasdogan2, HJ Fehling2, F Stewart1, K Anastassiadis1
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Background: Lineage- and cell-specific transcription programs are established
and maintained by a complex network of epigenetic modifications. Pertubations
of epigenetic regulation are associated with many human diseases such as
cancer. All expressed genes are trimethylated at histone 3 lysine 4 (H3K4me3)
on promoter nucleosomes. The responsible enzymatic machinery belongs to
the trithorax group of proteins and comprises six different enzymes: MLL1,
MLL2, MLL3, MLL4, SETD1A and SETD1B. The founding member MLL1 has
been identified due to frequent involvement in chromosomal translocations that
are commonly found in human ‘mixed-lineage leukaemias’. On the other hand,
hardly anything is known about the specific roles of the other H3K4 methyl-
transferases in haematopoiesis.
Aims: The present study specifically addresses the function of Setd1b in the
haematopoietic system of the adult mouse. Since the constitutive deletion of
Setd1b turned out to be embryonic lethal before E11.5, we generated a condi-
tional knockout mouse strain that relies on the tamoxifen-inducible Rosa26-
CreER(T2) technology.
Results: Upon deletion of Setd1b mice progressively weaken, develop
splenomegaly and do not survive beyond 30 weeks after tamoxifen treatment.
Blood count analysis reveals general cytopenias in knockout mice, however
both neutrophil granulocytes and monocytes are significantly increased in
peripheral blood. Cytospin preparations and histological stainings further con-
firm an increased abundance of more immature myeloid cells that infiltrate both
bone marrow and splenic tissue. Subsequent flow cytometric analysis of
haematopoietic stem and progenitor cells (HSPCs) reveals an increased LSK
fraction (Lin- Sca-1+ c-Kit+) and an abnormal ratio among individual stem cell
types. One very prominent observation relates to an accumulation of short-
term HSCs (CD34+ Flt3-) that are more myeloid-biased based on higher expres-
sion of key myeloid transcription factors such as Pu-1. Both in vivo - by BrdU
incorporation - and in vitro - by methylcellulose replating assays - we were
able to demonstrate an enhanced self-renewal capacity in Setd1b-deficient
HSPCs. Finally, to rule out any putative effects derived from the stem cell niche,
we performed bone marrow transplantations and additionally bred our mice to
the haematopoietic-specific Vav-Cre deleter. In either case a comparable neo-
plastic phenotype was generated highlighting the intrinsic requirement of
Setd1b in the haematopoietic compartment.
Summary/Conclusions: In conclusion, these findings strongly support an
essential function of Setd1b to maintain haematopoietic homeostasis and pro-
vide a new model to study epigenetic changes that accompany myeloid malig-
nancies. Given the known role of Mll1 in haematopoiesis, this study further
highlights the importance of epigenetic regulation in both steady-state and
malignant haematopoiesis. Future investigations will focus on the specific
molecular pathways that depend on Setd1b function. In this respect, expression
profiling data was recently generated and will be of great use.
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STAT2 DEFICIENCY ENHANCES THE JAK2 V617F-INDUCED MPN
THROMBOCYTOSIS PHENOTYPE: A NEW STAT PLAYER IN MYELOPRO
LIFERATIVE NEOPLASMS AND RELEVANCE TO INTERFERON TREAT-
MENT
C Pecquet1, JP Defour2, A Hashim3, G Vertenoeil2,4, S Caglayan3, Y Ould-
Amer2,4, C Lambert5, L Knoops5, JL Villeval6,7,8, X Cahu2,4, I Jonson9, I
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of Oslo, Oslo, Norway, 4SIGN Pole, de Duve Institute, Université catholique de
Louvain, 5Cliniques universitaires St Luc, Université catholique de Louvain,
Brussels, Belgium, 6Inserm UMR1170, 7Paris-Saclay, UMR 1170, 8Gustave
Roussy, UMR 1170, Villejuif, France, 93Centre for Molecular Medicine Norway
(NCMM), Nordic EMBL Partnership, University of Oslo, 10Department of Hema-
tology, Oslo University Hospital Rikshospitalet, 11Norwegian Stem Cell Center,
University of Oslo, Oslo, Norway
Background: STAT5 is a recognized driver of myeloproliferative neoplasms
(MPNs), STAT1 is promoting megakaryopoiesis and STAT3 plays dual roles,
reducing megakaryopoiesis, but promoting inflammation. No information exists
for STAT2 role in MPN.
Aims: To determine the role of STAT2 in MPNs knowing that STAT2 is key for
interferon action and is activated also by Tpo.
Methods: We used a combination of in vivo models and biochemical studies
to determine what is the impact of STAT2 on MPN phenotype induced by
JAK2V617F, and on gene expression induced via TpoR.
Results: Here we show that ablation of STAT2 enhances the thrombocytosis
phenotype in a knock-in model of JAK2 V617F MPN. Furthermore, we show that
STAT2 exerts a negative effects on thrombopoiesis. In addition to STAT5/1/3,
Tpo can activate in also STAT2, resulting both STAT1/STAT2/IRF9 complexes,
which are hallmarks of type I interferon signaling for anti-proliferative and anti-
viral activities and other STAT2-containing complexes. We show that STAT2 acti-
vation by Tpo is globally defective in MPN patient platelets. Tpo activated STAT2
induces both common genes with type I interferon via STAT1/STAT2/IRF9, as
well as distinct genes that are regulated by STAT2. The gene expression
response varies with the amount of expressed JAK2 and STAT2.
Summary/Conclusions: Our results identify a novel regulator of the MPN
phenotype and indicate that the cross-talk between Tpo and interferon path-
ways might be essential for the MPN phenotype. Given than type I interferon
is effective in MPNs, we suggest that basal TpoR-mediated induction of STAT2
activity primes stem and progenitor cells for type I interferon action.
92 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Myeloproliferative neoplasms - Clinical 1
P296
SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS
INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM JUMP: AN OPEN
LABEL, MULTICENTER, SINGLE-ARM, EXPANDED-ACCESS STUDY
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Background: Ruxolitinib (RUX) is a potent JAK1/JAK2 inhibitor that has shown
improvements in splenomegaly and symptoms and prolonged overall survival
(OS) in patients (pts) with intermediate (Int)-2– and high-risk MF by the Interna-
tional Prognostic Scoring System (IPSS) in the phase 3 COMFORT studies.
JUMP is a phase 3b, expanded-access trial in countries with no access to RUX
outside a clinical trial and includes pts with IPSS Int-1 MF. Unlike the IPSS, which
is used at diagnosis, the Dynamic IPSS (DIPSS) has been validated for use over
the disease course and allows for comparisons with other MF populations.
Aims: To assess the safety and efficacy of RUX in pts with DIPSS Int-1 MF (N=700).
Methods: Pts with IPSS high- or Int-2–risk MF, or Int-1 MF and a palpable
spleen (≥5 cm) were eligible for JUMP. Starting dose was based on baseline
platelet (PLT) count (5 mg bid [≥50 to <100×109/L], 15 mg bid [100-200×109/L],
or 20 mg bid [>200×109/L]) and was titrated during treatment. The primary end-
point was safety. OS data were investigated along with Int-1 pts in the DIPSS
database who received standard therapy (N=74; Passamonti Blood 2010).
Figure 1. Best percent change from baseline in palpable spleen length at
any time by week 72.
Results: JUMP includes 700 Int-1 pts (primary MF, 57%) who started treatment
≥1 y before data cutoff (01 Jan 2015). At baseline, median age was 64 y (range,
18-88); mean spleen length, 13 cm (SD, 6.6); time since diagnosis, 50 mo (SD,
61.4). DIPSS parameters (% of pts): >65 y, 43%; Hb <10 g/dL, 3%; ≥1% periph-
eral blasts, 19%; constitutional symptoms, 82%; WBC >25×109/L, 8%. The
majority of pts started at 20 mg bid (n=468) or 15 mg bid (n=190); median expo-
sure, 15.4 mo (range, 0.2-37.5). At time of data cutoff, most pts either remained
on treatment (46%) or completed per protocol (27%). Main reasons for treatment
discontinuation included adverse events (AEs; 14%) and disease progression
(6%). The most common hematologic grade 3/4 AEs were anemia (22%) and
thrombocytopenia (10%), which led to discontinuation of treatment in 1% and
2% of pts. Rates of nonhematologic grade 3/4 AEs were low (<2%). Infections
(≥5%) included urinary tract infection (all grade, 6% [grade 3/4, 0.7%]), herpes
zoster (6% [0.4%]), and nasopharyngitis (5% [0%]). At wk 24, 62% (339/547) of
pts had a ≥50% reduction from baseline in spleen length, and 21% (117/547)
had 25-50% reductions; rates were similar at wk 48 (68% [276/407] and 19%
[78/407]), respectively. Best response in spleen length by wk 72 is shown in the
Figure 1; 78.5% of pts achieved ≥50% reductions, including 192 (29%) with
complete resolution of splenomegaly. Median time to response was 4.7 wk (0.1-
75.0), and the estimated probability of maintaining a response was 0.92 (95%
CI, 0.89-0.94) at 48 wk. From wk 4 to 48, 40-50% of pts achieved a clinically
meaningful response on the FACT-Lym TS (wk 4, 46% [295/641]; wk 48, 44%
[171/388]) and FACIT-Fatigue (wk 4, 51% [327/644]; wk 48, 43% [164/382]).
The Kaplan-Meier estimated OS probabilities at wk 48 were similar between
JUMP (median follow-up, 65 wk) and the DIPSS database (0.98 [95% CI, 0.97-
0.99] vs 0.987 [0.96-1.00]), as expected in Int-1 pts given the short time period.
Summary/Conclusions: JUMP is the largest study of pts with MF treated with
RUX and includes the largest cohort of DIPSS Int-1–risk pts, a risk group not
included in the COMFORT studies. Pts with DIPSS Int-1–risk MF achieved spleen
size reduction and symptom improvement similar to those seen in pts with Int-1
MF by IPSS and the overall JUMP population. The safety and efficacy of RUX in
Int-1 pts in JUMP are consistent with that in the phase 3 COMFORT studies.
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PHASE 3 TRIAL TEAM-ET IN 106 HIGH-RISK ESSENTIAL THROMBOCYTHEMIA
PATIENTS, DEMONSTRATING NON-INFERIORITY OF ANATHROMB, A NOVEL,
EXTENDED-RELEASE ANAGRELIDE FORMULATION, TO THE LICENSED
COMPARATOR
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N Tzvetkov12, M Całbecka13, T Shneyder14, K Warzocha15, M Jurgutis16,
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Background: Anathromb (AR) is a novel, extended-release formulation of ana-
grelide hydrochloride (ana), a well-known compound used to selectively nor-
malize platelet counts (plc) by inhibiting megakaryocyte development and mat-
uration in high-risk patients suffering from the myeloproliferative neoplasm
Essential Thrombocythemia (ET). Common side-effects of licensed formulations
may be largely due to ana and its 3OH-metabolite peak plasma concentrations,
whereas efficacy is proportional to AUC. Moreover, licensed formulations need
to be dosed twice daily.
Aims: The aim of this study was to demonstrate the non-inferiority of Anathromb
in comparison to the licensed comparator in a phase 3, randomized, active-con-
trol, double-blind, parallel group non-inferiority setting.
Methods: AR was compared to a commercially available ana formulation,
Thromboreductin (TR) in a phase 3, randomized, active-control, double-blind,
parallel group non-inferiority trial in high-risk ET patients, either ana-naïve or
ana-experienced. After a 6 to 12 weeks titration period, the primary endpoint
was the mean plc in the maintenance phase (3 consecutive measurements,
centrally assessed, each 2 weeks apart).
Results: 106 patients (91 ana-naïve) were randomized and treated. All patients
fulfilled the WHO 2008 diagnostic criteria, the median age was 61, roughly two-
thirds were female, and both treatment arms were well balanced. The mean
plc at screening was 821 for AR and 797 for TR groups, during the maintenance
phase mean plc was 283 for AR and 316 for TR. Thus, both treatments were
highly effective in normalizing plc, and the primary endpoint was met formally
demonstrating non-inferiority of AR to the licensed TR (p<0,0001). Time from
randomization to maintenance phase and number of responders were similar
in both treatment arms. Results were consistent between ana-naïve and –expe-
rienced patients. Importantly, plc normalization was achieved in three-quarters
of patients with a dosing corresponding to 1-2 tablets AR once daily, whereas
>90% of the patients required 3 or more capsules TR per day divided in two
doses morning and evening. Treatment was well-tolerated, in line with the
known side effect profile of ana, the most frequent adverse events were cardiac,
CNS and GI disorders. There was no statistically significant difference between
the two treatment arms, numerically cardiac disorders occurred less frequently
in the AR arm, whereas the opposite trend was observed for CNS and GI. Eval-
uation of potential differences between AR and TR regarding tolerability requires
additional studies with more patients and longer exposure.
Summary/Conclusions: In summary, the novel extended-release formulation
AR was well tolerated and equally effective as the licensed comparator TR in
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normalizing plc. AR provides a more convenient once-daily dosing schedule
and may offer an alternative to licensed immediate-release ana formulations
in particular for patients not well tolerating ana side effects.
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CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC
MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST
CELL DISEASE
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Background: In a substantial fraction of systemic mastocytosis (SM) patients,
SM coexists with an associated clonal hematological non-mast cell (MC) line-
age disease (AHNMD). Most SM-AHNMD patients carry KIT mutations and
AHNMD-associated genetic alterations; however, there is limited information
about the frequency and clinical impact of the coexistence of both types of
genetic/molecular alterations in distinct bone marrow (BM) cell compartments.
Aims: we report on the clinic-biological, immunophenotypic, genetic and prog-
nostic features of 65 SM-AHNMD patients classified into three different onto-
genetic groups based on the pattern of involvement of BM MC, AHNMD tumor
cells and other residual BM cells, by both the KIT mutation and AHNMD-asso-
ciated cytogenetic/molecular alterations
Methods: Here we studied 65 SM-AHNMD patients grouped into SM-AHNMD
cases with: i) unrelated genetic alterations; ii) shared KIT mutation in BM MC
and AHNMD tumor cells, in the absence of AHNMD-associated genetic alter-
ations in BM MC, and; iii) shared AHNMD-associated genetic alterations. Cell
Purification. Purification of specific BM cell populations was performed using a
FACSAria flow cytometer (BD). Interphase fluorescence in situ hybridization
(iFISH) and human androgen receptor assay (HUMARA) studies. iFISH studies
aimed at detection of t(9;22), t(8;21), inv(16), 11q abnormalities, -5/del(5q), -
7/del(7q), del(20q), trisomy 8, nulisomy Y, trisomy 12, del(17p13.1), del(13q14),
t(14q32), t(18q21), t(11;14), t(3q27) and del(6q21) were performed on interphase
nuclei from different FACS-purified and methanol/acetic fixed 3/1 (v/v) cell pop-
ulations. KIT mutational analysis. The KIT D816V mutation was assessed in
genomic DNA from FACS-purified cell populations, using a previously described
polymerase chain reaction and peptide nucleic acid-clamping technique.
Figure 1.
Results: Overall, patients with shared AHNMD-associated genetic alterations
showed a significantly poorer progression-free survival (PFS) and overall sur-
vival (OS) vs the other two groups (p<0.01). In addition, the pattern of involve-
ment of BM cell compartments other than MC by the KIT mutation and the sub-
types of SM and AHNMD, were also relevant prognostic factors in the univariate
analysis (p<0.01). Multivariate analysis confirmed that the best combination of
independent prognostic factors for OS and PFS were the pattern of involvement
of BM cells by the KIT mutation (p<0.001 and p<0.01, respectively) and the
oncogenetic subgroup of AHNMD (p=0.02 and p<0.01, respectively) together
or not with the type of AHNMD (HR, 27.9; p<0.001), respectively.
Summary/Conclusions: Overall, patients with shared AHNMD-associated
genetic alterations showed a significantly poorer progression-free survival
(PFS) and overall survival (OS) vs the other two groups (p<0.01). In addition,
the pattern of involvement of BM cell compartments other than MC by the KIT
mutation and the subtypes of SM and AHNMD, were also relevant prognostic
factors in the univariate analysis (p<0.01). Multivariate analysis confirmed that
the best combination of independent prognostic factors for OS and PFS were
the pattern of involvement of BM cells by the KIT mutation (p<0.001 and p<0.01,
respectively) and the oncogenetic subgroup of AHNMD (p=0.02 and p<0.01,
respectively) together or not with the type of AHNMD (HR, 27.9; p<0.001),
respectively. SM-AHNMD patients show different oncogenetic profiles with an
impact on disease outcome. Coexistence of the KIT mutation and AHNMD-
associated genetic markers in BM MC andAHNMD cells is an adverse prog-
nostic factor in SM-ANMD.
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MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY
MASSIVE SEQUENCING
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Background: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm char-
acterized by the presence of JAK2 V617F and MPL mutation in 65% and 10%
of cases, respectively. CALR mutations have been described recently in most
cases of JAK-/MPL- myelofibrosis. In the last years other gene mutations have
been identified, some of them with a probably prognostic value.
Aims: Investigate the frequency and clinical significance of mutations deter-
mined by massive sequencing (NGS) in patients with MF.
Methods: We retrospectively studied 155 patients diagnosed with primary MF
(PMF) (n=98, 63%) or secundary MF: post-ET MF (n=29, 19%) or post-PV MF
(n=28, 18%), according to the WHO 2008 (see table “clinical characteristics”).
Sequencing was performed on a MiSeq NGS (Illumina) system using a panel
of 99 genes previously related to myeloid malignancies. Sequencing results
were analyzed by using the VariantStudio software package (Illumina), the
threshold for mutation calling was set to 5%.
Table 1.
Results: We found mutations in 153 patients (98.7%). A total of 465 gene vari-
ations were detected in 64 different genes. The median number of mutated
genes by case was 3 (1-10). JAK2 V617F mutation was present in 98 patients
(63.2%), CALR in 25 (16.1%) and MPL in 13 (8.4%), with 19 triple negative
cases (12.3%). The most prevalent mutated genes were: JAK2, ASXL1 (n=38,
24.5%), TET2 (n=35, 22.6%), CALR, SRSF2 (n=20, 12.9%), RUNX1 and
U2AF1 (n=15, 9.7%), MPL, DNMT3A (n=11, 7.1%), TP53 (n=10, 6.5%),
KMT2D, PTPN11 and EZH2 (n=9, 5.8%), and SETBP1 (n=8, 5.2%). Only 5
cases (3.2%) showed IDH1 mutations while IDH2 was mutated in 3 patients
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(1.9%). The mutation profile was similar in PMF and post-ET/PV MF. We
observed relationship between LMA transformation and mutation in EZH2
(p=0.007), IDH1 (p=0.003), SF3B1 (p=0.026), TET2 (p=0.026) and CDH13
(p=0.010). In the multivariate analysis, only EZH2 (p=0.008 [1.72-37.44]) and
IDH1 mutations (p=0.008 [2.01-114.93]) remained statistically significant. The
3-years overall survival (OS) was 68.5% with a median follow-up of 37 months
(1.6-219.4). The presence of int-2/high risk IPPS was associated with a shorter
OS (p=0.000). Moreover, ≥4 mutated genes by case was also related to a worse
outcome (median OS: 39 vs 83 months) (p=0.005). Mutations associated to a
bad prognosis such as ASXL1, SRSF2, EZH2, IDH1 and IDH2 (n=58, 37.4%)
showed a shorter OS (p=0.000). In contrast, CALR mutated cases had a better
outcome (median OS: 147 vs 52 months) (p=0.001). In addition, a shorter OS
was observed in patients showing mutations in U2AF1 (p=0.004), TP53
(p=0.029), SETBP1 (p=0.000), PHF6 (p=0.015) and ETV6 (p=0.000). However,
the presence of DNMT3A mutations showed a trend of a long OS (p=0.049).
In the multivariate analysis, the variables showing a worse prognosis in terms
of OS were: int-2/high risk IPSS (p=0.000, HR 3.53 [2.02-6.16]), mutations in
ASXL1, SRSF2, EZH2, IDH1 and IDH2 (p=0.003, HR 2.12 [1.28-3.49]), TP53
mutation (p=0.022, HR 3.1 [1.18-8.19]), and SETBP1 mutation (p=0.014, HR
3.34 [1.27-8.72]); while the presence of CALR (p=0.015, HR 0.33 [0.13-0.81])
or DNMT3A mutations (p=0.019, HR 0.22 [0.06-0.77]) were associated to a
better outcome.
Summary/Conclusions: The presence of mutations in ASXL1, SRSF2, EZH2,
IDH1, IDH2, TP53 and SETBP1 is associated to a bad prognosis in MF. By con-
trast, CALR and DNMT3A mutated cases have a better outcome. There is a
relationship between LMA transformation and mutation in EZH2 and IDH1. The
use of NGS should be explored in addition to characterization of MF prognosis.
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PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH
PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA
MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS
MYELOFIBROSIS (POST-ET MF
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Background: There is no standard therapy for patients (pts) with intermediate
(int)-2 or high risk myelofibrosis (MF) who have failed or are intolerant to Janus
kinase (JAK) inhibitors such as ruxolitinib. Second mitochondria-derived acti-
vator of caspases (Smac) mimetics, also known as, inhibitors of apoptosis (IAP)
antagonists, lead to increased apoptotic cancer cell death, especially in high
TNFα-expressing tumor models.
Aims: Primary objective: to determine efficacy (IWG-MRT, 2013) of LCL161
as monotherapy for pts with MF. Secondary objectives: to determine safety,
durability of response, and change in symptom burden [Myeloproliferative Neo-
plasm (MPN)-Total Symptom Score (TSS)]. Exploratory objectives: to assess
JAK2V617F and CALR allele burden; 28-gene panel for molecular mutations
via next-generation sequencing; and LCL161 target inhibition.
Methods: We conducted an investigator-initiated, single-center, phase II study
of LCL161 for pts with MF in a Simon’s Optimal two-stage design. Pts age ≥18,
PS=0-2, int-2 to high risk MF, who were intolerant to, ineligible for, or
relapsed/refractory to JAK inhibitors were eligible. There was no threshold
requirement for spleen size or platelet (plt) count, and pts with prior allogeneic
stem cell transplant (SCT) were eligible. LCL161, an oral (po) drug, was given
at starting dose 1500mg po once weekly. Each cycle=28 days. After 3 cycles,
bone marrow exam and objective response assessments were performed.
Figure 1.
Results: From January 2015 to January 2016, 13 pts have been enrolled. Base-
line pt characteristics are listed in Table 1. JAK2V617F mutations were present
in 7(54%), CALR mutations in 3(23%), and MPLW515L mutation in 1(8%) pt.
Additionally, the most common other molecular mutations were: DNMT3A(n=2);
TET2(n=2); RAS(n=2); EZH2(n=1). 10(77%) had ≥2 prior therapies. 2 pts had
prior SCT. By IPSS, 11(85%) were high risk MF; 2(15%) were int-2. Median
number of cycles received=5[1-13], median treatment duration=4.4 months
(mos)[1-11.8]. All 13 pts are alive, with median follow-up of 4.7 mos[1-11.8]. 4
pts had 5 objective responses (1 pt: 2 separate IWG-MRT responses, Figure
1): Clinical improvement (CI) (anemia) in 2 pts; CI (Symptom) in 2 pts; CI
(Spleen) in 1 pt. Grade 3/4 non-hematologic adverse events: syncope, n=2. No
pts had cytokine release syndrome. Most common grade 1/2 non-hematologic
toxicities: fatigue (n=7), nausea (n=6), dizziness/vertigo (n=3). Dose reductions:
6 pts, all to dose -1 level (1200 mg po once weekly); most common reason:
grade 2 fatigue (n=5). 7 pts are now off study [n=3 pt request; n=2 progression
of MF; n=1 progression to extramedullary AML (74 year old pt with high risk MF,
4 prior therapies, and prior SCT); n=1 proceeded to SCT]. Preliminary, ongoing
correlative studies demonstrate significant on-target inhibition (by Western blot)
of CIAP1 in 3/3 responding pts with available samples.
Table 1.
Summary/Conclusions: In this study, in an older group of pts with MF, 85%
IPSS high risk, with median plt count of 36 at study entry, in whom 77% had
received ≥2 prior therapies, we observed 5 objective responses in 4 pts among
the first 13 pts enrolled. LCL161 has a convenient (po, weekly) dosing schedule,
represents a novel target for pts with MPNs, and is able to be administered to
pts who have failed or intolerant/ineligible for JAK inhibitor therapy. This study
has met criteria for the pre-planned analysis for efficacy (Simon Stage 1) and
therefore is able to proceed to Simon Stage 2. This clinical trial is registered at
www.clinicaltrials.gov/ct2/show/NCT02098161.
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PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA
VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR
HYDROXYUREA ALONE
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Background: Hematocrit control below 45% is associated with a lower rate of
thrombosis in polycythemia vera (PV).
Aims: To assess if patients treated with hydroxyurea plus phlebotomies have
the same risk of thrombosis than those controlled with hydroxyurea alone.
Methods: The Spanish Registry of Polycythemia Vera is a live ambispective
study including, by February 2016, 1353 patients in which baseline character-
istics, therapies and complications during follow-up are periodically updated.
From this cohort, a total of 533 patients treated with hydroxyurea were selected
for the present study. Data from the first 60 months of therapy with hydroxyurea
were retrospectively recovered including Hematocrit, WBC, platelet count and
number of phlebotomies. Hematocrit response was defined as a hematocrit
<45% (with or without phlebotomy requirement) and complete hematological
response (CHR) as the presence of hematocrit <45%, WBC <10x109/L and
platelet count <400x109/L. Hematocrit response and CHR were assessed at
months 6, 12, 18, 24, 36, 48 and 60. Sustained response was defined as a
response lasting more than 50% of follow-up. Intermittent response was defined
as a response lasting less than 50% of follow-up. Phlebotomy requirement dur-
ing the time of study was recorded. Patients requiring ≥4 phlebotomies per year
while they received therapy with Hu were categorized as phlebotomy dependent. 
Results: Median follow-up was 36 months (range: 6-60). One or more phle-
botomies were performed in 304 (57%) patients, 24% of patients were phle-
botomy dependent. Hematocrit response and CHR was more frequently
achieved in patients without phlebotomy dependency. Hydroxyurea dose was
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similar among both groups of patients. A total of 36 thrombotic events (22 arte-
rial, 14 venous) were recorded resulting in a 3 and 5-year probability of throm-
bosis of 6.9% and 11%, respectively. Phlebotomy dependent patients showed
a higher rate of thrombosis than the reminder (19.3% versus 4.4% at 3 years,
p<0.0001). Adjusting phlebotomy requirement by response in the hematocrit
showed a higher risk of thrombosis for phlebotomy dependent patients (HR:
3.9, 95%CI: 1.9-8.1, p<0.0001) whereas sustained hematocrit response did not
(HR: 0.98, 95%CI: 0.5-1.98, p=0.9). Multivariate analysis including sex, cardio-
vascular risk factors, thrombosis at PV diagnosis and need for phlebotomies
showed a higher risk of thrombosis in phlebotomy dependent patients (HR: 3.5,
95%CI: 1.7-6.9, p<0.0001) whereas time in hematocrit response or in CHR
were not associated with a lower risk of thrombosis. Twenty five bleeding events
(6 major, 19 minor) were registered resulting in a 3- and 5-year probability of
4.4% and 7.2%, respectively. The 3-year probability of bleeding was higher in
phlebotomy dependent patients than in the remainder (10% versus 3.2%,
respectively, p=0.01). In multivariate analysis, dependency for phlebotomies
showed a higher risk of bleeding (HR: 2.6 95%CI: 1.1-5.9, p=0.028) after adjust-
ing for age and treatment with antiplatelet agents and oral anticoagulants.
Figure 1.
Summary/Conclusions: Patients treated with Hu who remain dependent on
phlebotomies have a higher risk of thrombosis and bleeding than those con-
trolled with Hu alone.
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Background: First line therapy for essential thrombocythemia (ET), hydroxycar-
bamide (HC), has mutagenic properties and there is a concern for possible leuke-
mogenicity. The issue has not been conclusively settled in previous studies.
Aims: To assess risk of acute leukemia and non-hematological malignancies
in patients treated with HC or anagrelide (ANA) in the EXELS study.
Methods: EXELS, a prospective 5-year study, recruited 3649 high risk ET
patients, on or needing cytoreductive therapy, given at the discretion of the
treating physician. Previous exposure to ANA and HC was based on patient
history. All subjects were followed until death or end of study. Risk of acute
leukemia (AL) after study enrolment was estimated by the cumulative incidence.
Disease progression may be confounding, influencing therapy choice, so a
minimum exposure time of 6 months was used to account for this. The relative
risk of AL transformation and non-hematologic malignancies was estimated as
age-, gender- and country- standardized incidence ratios (SIRs) with 95% con-
fidence intervals based on background cancer incidence in enrolling European
countries. The relative risk ratio of AL for HC vs ANA was assessed using the
ratio of SIRs. To estimate a 95% confidence interval around this, non-parametric
bootstrapping with 10,000 samples was used.
Results: At registration, 481 patients had ANA treatment, 2305 had HC and
656 had been exposed to a combination of the two. Together these treatments
included 94% of the patients. The median age in patients on ANA was 51 years,
in the HC group 71 years. The SIR for all malignancies was close to 1 for all
groups (table 1), indicating no increased risk for ET patients. In skin cancer,
the SIR for patients on HC was higher than expected (1.14) and higher than
for patients on ANA and patients with neither(1.15 vs 0.41 and 0.50). Due to
the low number of events, the CIs were wide, and no statistically significant dif-
ferences could be shown (table 1). A total of 67 cases of AL and 19 cases of
myelodysplastic syndrome (MDS) were observed. With a minimum exposure
time of 6 months, 62 cases of AL indicated a markedly increased risk for ET
patients compared with a normal population, with high SIRs for all groups (table
1). Due to the low number of cases in the ANA group the CIs were wide and
no statistically significant difference could be seen for HC vs ANA (table 1).
Assessing the ratio of SIRs for HU and ANA did not reveal any significant dif-
ferences; RR 0.91, 95% CI 0.52-3.27.
Table 1. Relative risks in each treatment category, as standardized inci-
dence ratios (SIR) with 95% confidence intervals (CI), using a lag time of
180 days for exposure.
Summary/Conclusions: EXELS data enables a comparison of malignant
transformation with treatments for ET. We previously showed that the AL event
rate per 100 years of exposure for ANA was 0.07 compared with 0.28 for other
cytoreductive treatment, and transformation to MDS only occurred in the HC
group (event rate 0.12) Higher event rates for other malignancies were also
shown (Birgegård et al). However, the age difference between treatment groups
was large. This difference was accounted for in this study by estimating SIRs
using country-specific cancer registry data. For non-hematologic malignancies
the SIRs were close to 1, indicating no increased risk for any group. An
increased risk of AL was seen for all patients. Most AL occurred in patients on
HC, but likely due to a low event number there was no statistically significant
difference between HC and ANA. The concern over risk of leukemia and skin
cancer due to HC remains but could not be substantiated, probably due to the
low number of events within the time frame of the study. There was no
increased risk of other malignancies.
Reference
1. Birgegård G et al. Haematologica 2015;100:160-1.
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MIDOSTAURIN (PKC412) IN INDOLENT SYSTEMIC MASTOCYTOSIS: A
PHASE 2 TRIAL
B Van Anrooij1,*, J Oude Elberink1, L Span2, J de Monchy1, S Rosati3,
A Mulder4, J Kluin-Nelemans2
1Allergology, 2Hematology, 3Pathology, 4Laboratory Medicine, University Med-
ical Centre Groningen, Groningen, Netherlands
Background: Indolent systemic mastocytosis (ISM) is characterized by mast
cell infiltration of several organs, notably the skin and bone marrow, without
evidence of organ dysfunction. Although ISM patients have a near normal life
expectancy, in some the disease is associated with severe mediator-related
symptoms such as anaphylaxis, fatigue, flushing, pruritus, osteoporosis and
depression. The activating mutations (typically KITD816V) in the cKIT receptor
of mast cells hinder inhibition by most tyrosine kinase inhibitors. Midostaurin,
a multiproteinase inhibitor that inhibits the tyrosine kinase activity of KITD816V,
showed in a large phase II trial impressive activity in patients with aggressive
mastocytosis (Blood 2014;124, abstract 636). The drug appeared safe and
showed rapid symptom reduction. 
Aims: Because of this, we felt justified to investigate the potential therapeutic
effect of Midostaurin on symptom severity, quality of life and mast cell burden
in ISM patients.
Methods: In this investigator-initiated single center phase II study 20 patients
with KITD816V+ ISM, elevated tryptase levels, and severe refractory symptoms
were enrolled after written informed consent. They received oral Midostaurin
100 mg twice daily for 24 weeks with the option for continuation after a 2 month
wash-out period. Midostaurin was supplied by Novartis Pharmaceutical Cor-
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poration, which offered additional financial support. The primary endpoint was
symptom response, defined as a reduction in the Mastocytosis Symptom
Assessment Form (MSAF) sumscore at week 12. Secondary endpoints were
improvements at week 12 and 24 of skin and bone marrow mast cell infiltration,
serum tryptase levels, and disease-related quality of life. Study recruitment is
closed; patient treatment and follow-up are ongoing. The study is registered
with Clinical Trials.gov, NCT01920204.
Results: Three patients dropped out due to adverse events (all nausea) before
week 12. Analysis is based on intention-to-treat. At week twelve 16 (80%)
patients had significant median 35% (p=0.002; IQR: 16% - 56%%) reduction in
symptom severity that further improved to an average 38% reduction at week
24 and was accompanied by a significant median 25% (p=0.001, IQR 12% -
47%) improvement of disease related quality of life. After 4 weeks all patients
showed a statistically significant (P<0.000) reduction in tryptase levels (from
36.0 to 15.5 ug/l, P<0.001) that remained stably reduced for all but 1 patient
throughout the study. At 24 weeks, 8 out of 16 histologically assessable bone
marrow biopsies showed a reduction in mast cell infiltration, 2 an increase and
6 no change. Urticaria pigmentosa improved in 12 (80%) of the 15 patients
with skin symptoms with the strongest reduction seen in the intensity of lesions.
Grade 1-2 adverse events were reported by all patients; the most common
being nausea (n=14), diarrhea (n=11) and headache (n=9). There was one
SAE deemed to be probably not treatment related and 3 grade 3-4 adverse
events (anaphylaxis, syncope and elevated AST). Notably, there were no hema-
tological adverse events. After stopping of the drug at week 24 according to
protocol, 16 patients showed a rapid relapse of symptoms objectified by an
increase in tryptase levels. From them, 10 patients strongly favored restarting
of Midostaurin.
Figure 1.
Summary/Conclusions: In conclusion, Midostaurin is effective in symptom-
reduction and even mast cell infiltration in patients with indolent mastocytosis.
Despite side effects, most patients favor continuation of the drug.
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RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR
ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT
TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD
RANDOMIZED TRIAL
C Harrison1,*, A Mead2, A Panchal3, S Fox3, C Yap3, A Houlton4, S Aliman1,
M Wood5, F Chen6, J Coppell7, N Panoskaltsis8, R Scherber9, H Geyer10,
A Dueck11, R Mesa12, MF McMullin13
1Guy’s and St Thomas’ NHS Foundation Trust, London, 2Weatherall Institute
of Molecular Medicine, University of Oxford, Oxford, 3Cancer Research UK
Clinical Trials Unit, 4Cancer Research UK Clincal Trials Unit, University of Birm-
ingham, Birmingham, 5Colchester Hospital University NHS Foundation Trust,
Colchester, 6Centre for Clinical Haematology, University Hospitals Birmingham
NHS Foundation Trust, Birmingham, 7Royal Devon and Exeter NHS Foundation
Trust, Exeter, 8Department of Haematology, London North West Healthcare
NHS Trust, London, United Kingdom, 9Department of Hematology and Oncol-
ogy, Oregon Health and Sciences University, Portland, 10Division of Hospital
Medicine, 11Section of Biostatistics, 12Division of Hematology and Medical
Oncology, Mayo Clinic, Scottsdale, United States, 13Centre for Cancer
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Background: Ruxolitinib (RUX), a Janus kinase (JAK) 1 & 2 inhibitor has sig-
nificant clinical benefits in myelofibrosis (MF) & those patients with poly-
cythaemia vera whom are resistant or intolerant to Hydroxycarbamide (HC).
We conducted a randomized, phase II, trial of RUX vs Best Available Therapy
(BAT) in patients with essential thrombocythemia (ET) who were resistant or
intolerant to HC.
Aims: To evaluate the activity & safety of RUX treatment of patients with ET
who met modified European LeukaemiaNet (ELN) criteria for resistance or intol-
erance to HC. The primary end-point was rate of achievement of complete
hematological response within 1 year (according to ELN guidelines); secondary
endpoints included partial hematological response, safety, thrombosis, hemor-
rhage, transformation (adjudicated by central review), as well as symptom &
quality of life assessment.
Methods: Patients with ET were recruited over 30 months (2012-2015), strat-
ified by JAK2V617F status & randomized to receive 25mg bd of RUX or BAT.
Post-ET MF was excluded at trial entry. Patients eligible for the modified inten-
tion to treat (mITT) analysis were those who commenced study treatment &
received at least one response assessment. Patient reported outcome & quality
of life were assessed using EQ5D, MDASI & MPN Symptom Assessment Form
(MPN10). Symptom response was defined as ≥ 50% reduction in MPN10 total
symptom score (TSS) & compared between arms using a linear mixed model
of post-baseline scores through month 12 adjusting for baseline.
Results: Overall 116 patients were recruited, 110 were eligible for mITT analy-
sis, 58 (52%) & 52 (48%) in RUX & BAT arms respectively, comprising 44
males, 66 females, mean age 64.2ys, who were resistant (24.5%), intolerant
(51.8%) or both (22.7%) to HC. Baseline characteristics at randomization were
balanced, (Table 1). The primary end point was achieved in 27 (46.6%) of the
patients in the RUX arm vs 23 (44.2%) in the BAT arm (p= 0.81). Partial
response occurred in 26 (44.8%) & 27 (51.9%) of those treated with RUX &
BAT respectively. The median dose of RUX received was 15mg bd, & median
follow-up at this analysis was 1.8 years. No new pattern of safety events for
RUX was noted: grade 3 or 4 anemia occurred in 19% and 0% of RUX patients
vs 0% in the BAT arm, grade 3 or 4 thrombocytopenia in 5.2% & 1.7% of RUX
vs 0% of BAT patients respectively, & grade 3 and 4 infections occurred in
10.3% of patients in the RUX arm compared to 3.6% in the BAT arm. Overall
2 patients discontinued for anemia & none discontinued for thrombocytopenia.
In RUX treated patients, thrombotic or hemorrhagic events were experienced
by 9 patients (10 events) & 1 patient respectively vs 5 thrombotic and 5 hem-
orrhagic events in BAT patients (adjusted following central review). Transfor-
mations to post-ET MF occurred in 8 RUX vs 3 BAT treated patients, 1 RUX
patient developed acute myeloid leukemia. There were 2 patient deaths in each
arm, due to 1 each of multiple organ failure, cerebral hemorrhage in the BAT
arm, bowel infarction due to adhesions, & ischemic cardiomyopathy in the RUX
arm. Mean MPN-10 TSS for early satiety, itching, & weight loss during the first
12 months were all significantly lower for RUX vs BAT (all p<0.05).
Table 1. Baseline characteristics for ET patients.
Summary/Conclusion: We report primary results from the ET arm of the
MAJIC study, the first randomized study of RUX in ET, 110 patients were eligible
for the mITT analysis. The results suggest that there is no significant difference
in complete hematological response rates between RUX & BAT therapy. Partial
hematological responses, transformation, thrombosis & hemorrhage rates
appear similar. However symptom scores for early satiety, itching & weight loss
were significantly improved by RUX. The side effect profile of RUX was as pre-
viously reported.
haematologica | 2016; 101(s1) | 97
Copenhagen, Denmark, June 9 – 12, 2016
Hodgkin lymphoma - Clinical
P304
RISK FACTORS (RF) FOR RELAPSE IN PATIENTS WITH RELAPSED OR
REFRACTORY HODGKIN LYMPHOMA (RRHL) AFTER AUTOLOGOUS
STEM CELL TRANSPLANT (ASCT): A REAL-WORLD ANALYSIS IN
GERMANY AND THE UNITED KINGDOM (UK)
EA Zagadailov1,*, S Corman2, M Hagan3, V Chirikov2, C Johnson2,
C Macahilig3, MR Dalal1, PJ Bröckelmann4
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
maceutical Company Limited, Cambridge, MA, 2Pharmerit International,
Bethesda, MD, 3Medical Data Analytics, Parsippany, NJ, United States,
4Department I of Internal Medicine and German Hodgkin Study Group, Uni-
versity Hospital of Cologne, Cologne, Germany
Background: With the advance of novel therapeutic options, RFs for post-
ASCT outcomes in patients with RRHL are of immediate interest. Several risk
factors for relapse have been previously documented; however, there are lim-
ited data with respect to the prevalence and distribution of RFs in post-ASCT
RRHL patients who have and have not had a subsequent relapse. 
Aims: We aimed to describe the prevalence and distribution of RFs after ASCT
in patients with RRHL in a sample of real-world patients in Germany and the UK.
Methods: We included patients who were ≥18 years old at the time of HL diag-
nosis, received ASCT between 1 January 2008 and 30 June 2014, were not
enrolled in an HL-related clinical trial and treated under real-world setting at 45
clinical sites in Germany and the UK. This analysis included randomly selected
post-ASCT patients, and was augmented by patients who relapsed post-ASCT.
Patient characteristics including RFs for relapse were analyzed descriptively.
RFs of interest included patient age; sex; B symptoms, extranodal disease,
bulkiness, clinical stage, and/or ECOG performance status at the time of ASCT;
number of salvage regimens prior to ASCT; response to salvage treatment;
and time to relapse.
Results: A total of 350, predominantly male patients, with a median follow-up
of 2.2 years post-ASCT were included (196 in Germany, 154 in the UK). The
mean age at diagnosis was 42 years. In total, 267 (76%) had a relapse during
the follow-up period. A similar proportion of patients who did and did not relapse
had B symptoms at the time of ASCT, extranodal disease at the time of ASCT,
and less than a partial response to salvage chemotherapy (Table). A greater
proportion of patients who relapsed were male and ≥45 years old. Among the
patients who relapsed, 83% had ECOG ≥1 at the time of first relapse relapse,
31% had stage IV disease, and 16% had bulky disease. The median number
(range) of RFs present was 2 (0-7) in patients who relapsed and 0 (0-1) in
patients who did not relapse.
Table 1. Prevalence of risk factors in patients who did and did not relapse
after ASCT.
Summary/Conclusions: This real-world study demonstrates the prevalence
and distribution of a myriad of RFs in patients post-ASCT RRHL. RF profiles
are different in patients who did and did not have a subsequent relapse, and,
as such, clinical evaluation of RFs is critical to identify patients at increased
risk of subsequent relapse.
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BRENTUXIMAB VEDOTIN (BV) IN PATIENTS WHO ARE INELIGIBLE FOR
AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) WITH RELAPSED OR
REFRACTORY HODGKIN LYMPHOMA (RRHL): A UK AND GERMANY
RETROSPECTIVE STUDY
PJ Bröckelmann1,*, EA Zagadailov2, S Corman3, M Hagan4, V Chirikov3,
C Johnson3, C Macahilig4, MR Dalal2
1Department I of Internal Medicine and German Hodgkin Study Group, Uni-
versity Hospital of Cologne, Cologne, Germany, 2Millennium Pharmaceuticals,
Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,
Cambridge, MA, 3Pharmerit International, Bethesda, MD, 4Medical Data Ana-
lytics, Parsippany, NJ, United States
Background: BV is an anti-CD30 antibody-drug conjugate indicated for the
treatment of CD30+ RRHL following ASCT or following at least two prior ther-
apies in patients who are ASCT-ineligible. Clinical outcomes in the ASCT-inel-
igible population have not yet been evaluated in a real-world study.
Aims: We aimed to describe outcomes in real-world ASCT-ineligible patients
with RRHL in two countries known to have different practice patterns in RRHL.
Methods: This was a retrospective medical chart review study that enrolled
patients at 45 clinical sites representative of routine clinical practice in Germany
and the UK. The study included patients ≥18 years old at the time of HL diag-
nosis, who progressed after ≥2 multi-drug chemotherapy regimens between 1
January 2008 and 30 June 2014 and were not ASCT candidates as identified
by their clinicians, were subsequently treated with BV, and were not enrolled
in an HL-related clinical trial. Patient demographics (eg, age, gender), clinical
characteristics (disease stage, type, ECOG status, reason for ASCT ineligibil-
ity), and treatment characteristics (dose and duration of treatment) were
described. Clinical outcomes included best response to treatment, progres-
sion-free survival (PFS), and overall survival (OS). All outcomes were descrip-
tive, and reported in the full study population and by country.
Results: A total of 125 patients were included in this analysis (69 in Germany
and 56 in the UK). The median age of study patients at HL diagnosis was 70
years, and 60% were male. Nearly all patients had had classical HL (96%),
and over half had non-bulky (<5 cm) disease (55%). The most common reasons
for ASCT ineligibility were comorbidities (74%), age (57%), and disease pro-
gression (11%). Coronary artery disease (41%), diabetes (25%), and chronic
pulmonary disease (14%) were the most common comorbidities among study
patients. Eighty-six percent of patients received at least 2 lines of treatment
prior to initiating BV. At the time of BV initiation, 24% of patients had stage IV
disease and 22% had extranodal involvement. The median duration of follow-
up was 3.1 years from the time of HL diagnosis. Nearly three fourths of patients
had a partial or complete response (Table). Other outcomes of interest included
leukopenia (12%; of which 47% were serious), neuropathy (10%; all serious),
and anemia (8%; 40% serious).
Table 1. Treatment, Response, and Survival in ASCT-Ineligible Patients
Receiving Brentuximab Vedotin.
Summary/Conclusions: Progression-free and overall survival in ASCT-ineli-
gible patients receiving brentuximab vedotin were 12.3 and 15.6 months,
respectively, after initiation of treatment.
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REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS
OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY
HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL
TRANSPLANTATION (ASCT)
EA Zagadailov1,*, S Corman2, M Hagan3, V Chirikov2, C Johnson2,
C Macahilig3, MR Dalal1, PJ Bröckelmann4
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Phar-
maceutical Company Limited, Cambridge, MA, 2Pharmerit International,
Bethesda, MD, 3Medical Data Analytics, Parsippany, NJ, United States,
4Department I of Internal Medicine and German Hodgkin Study Group, Uni-
versity Hospital of Cologne, Cologne, Germany
Background: BV is an anti-CD30 antibody-drug conjugate indicated for the
treatment of CD30+ RRHL following ASCT or following at least two prior ther-
apies in patients who are ASCT-ineligible. While no randomized trials have
been conducted in the post-ASCT RRHL setting, patients receiving BV have
been shown to have higher complete response rates and longer overall survival
(OS) compared to historical control groups.
Aims: We aimed to compare effectiveness in post-ASCT patients with RRHL
receiving BV to those receiving other treatments or no treatment in clinical set-
tings in Germany and the UK.
Methods: A retrospective medical chart review study was conducted that
enrolled patients at 45 clinical sites in Germany and the UK. The study included
patients ≥18 years old at the time of HL diagnosis, who received ASCT between
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1 January 2008 and 30 June 2014, had at least 12 months of available clinical
data from the initiation of post-ASCT treatment, and were not enrolled in an HL-
related clinical trial. This analysis included randomly selected post-ASCT
patients who subsequently relapsed, and an augmented sample of patients who
relapsed post-ASCT and were treated with BV or another treatment regimen
after relapse. Patients were grouped according to the first line of therapy
received after post-ASCT relapse (BV, salvage chemotherapy, or no treatment).
Patient demographics (eg, age, gender), clinical characteristics (disease stage,
type, ECOG status), and treatment characteristics (dose and duration of treat-
ment) were described for BV and non-BV patients. Clinical outcomes included
progression-free survival (PFS), OS, and best response. Median PFS and OS
were calculated using Kaplan-Meier methods; all other outcomes were summa-
rized using descriptive statistics, by treatment (BV and non-BV) and country.
Results: A total of 267 patients were included in the study (131 Germany, 136
UK). Of these, 163 received BV (88 Germany, 75 UK), 87 received other treat-
ments, (39 Germany, 48 UK), and 17 received no treatment for post-ASCT RRHL
(4 Germany, 13 UK). The groups were similar in median age at diagnosis (42,
46, and 50 years, respectively), gender (56%, 59%, and 65% male), and type of
HL (>96% classical HL in all groups). The most common salvage chemotherapy
regimens in the non-BV group were gemcitabine-based regimens (41% and 42%
in Germany and UK) and CHOP (13% in both countries). Patients in the BV
group received a median of 7 of the potential 16 cycles of treatment (Table). The
median duration of follow-up was approximately 2 years in all groups. Median
PFS was 8.6 months longer in patients receiving BV compared to those receiving
salvage chemotherapy. Median OS could not be estimated because <50% of
patients died during the follow-up period. Other events of interest included anemia
(12%) and leukopenia (12%) in the BV group and leukopenia (12%) and throm-
bocytopenia (6%) in the salvage chemotherapy group.
Table 1. Treatment and Survival Outcomes in Patients with RRHL after
ASCT relapse.
NE, not estimable
Summary/Conclusions: In this observational, real-world study, patients receiving
BV as the first post-relapse line of therapy after RRHL had longer PFS than patients
receiving salvage chemotherapy; however, confidence intervals were wide.
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ABDOMEN/PELVIS COMPUTED TOMOGRAPHY IN STAGING OF PEDIATRIC
HODGKIN LYMPHOMA: IS IT ALWAYS NECESSARY?
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Background: Cancer incidence and use of computed tomography (CT) and
positron emission tomography (PET) in childhood have been increasing over
time and in some studies an association between pediatric CT and cancer risk
was found. The risk linked to overuse of diagnostic radiation has recently
inspired 2 different international campaigns, “Image Gently” and “Eurosafe,”
both aimed at understanding what are the most careful practices and in 2013
the American Society of Hematology, included “surveillance CT scans in asymp-
tomatic patients after curative-intent treatment for aggressive lymphoma”
among tests not well supported by evidence.
Aims: Based on the evidence that the majority of HL presentation is in the
mediastinum and/or in a superficial lymphadenopathy (abdomen/pelvis disease
is present in 39.0% in the present series) we decided to determine if
abdomen/pelvis CT can be safety omitted in the staging of a subgroup of chil-
dren with Hodgkin Lymphoma (HL). Since it is well known that the measure-
ment accuracy of US is inferior to CT, a randomized trial would be addressed
as not ethical, and so we organized a complex study with a centralized revision
of CT images.
Methods: Every participating center sent local staging reports of PET and
abdominal ultrasound (US) along with digital images of staging CT to the inves-
tigation center where the CT scans were evaluated by an experienced pediatric
radiologist. The local radiologist who performed the US was unaware of local
CT and PET reports (both carried out after US), and the reviewer radiologist
examining the CT images was unaware of local US, PET and CT reports. A
Final Staging (FS) of 123 patients performed on the basis of local US and PET
reports and centralized CT report was compared to a Test Staging (TS) based
on local US and PET. US/PET evaluation of lymphonodes (LNs), spleen and
liver (no other site was affected) was based on criteria adopted in the Euronet-
PHL-C1 trial and could be positive (involved), negative (not involved) or doubtful
(table 1 and 2). Also the TS (table 3) could result positive, negative or doubtful
(cases where CT was mandatory to assess the involvement).
Results: There were 71/123 patients with a negative TS: no new lesion was
diagnosed by CT. In 27/123 patients the TS was positive: no site was added or
withdrawn by CT, and specifically in the group of isolated US positivity (or con-
cordant US/PET positivity ) in spleen + concordant US/PET negativity in LNs
no additional information was provided by CT. In 25/123 patients the TS was
doubtful: in 21 (84%) the FS was positive, and in 4 (16%) negative. According
to the study methods, in doubtful TS cases at least one technique (US and/or
PET) was doubtful or positive: if we consider these cases positive, the analysis
in terms of sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) shows these results: 1)Sensitivity: 1.00 (CI: 0.89-1.00);
2)Specificity: 0.95 (CI: 0.87-0.99); 3)PPV: 0.92 (CI: 0.81-0.98); 3)NPV: 1.00
(CI: 0.93-1.00).
Table.
Summary/Conclusions: We think CT remains useful in whatever type of LN
positivity in PET and/or US since CT can better assist the choice as to radio-
therapy planning. At the same time, we think that, with the strictest approach,
it is possible to omit CT at least in PET/US negative patients (57.7%) even
though it seems that CT could be safely omitted also in cases of isolated US
positivity (or concordant US/PET positivity ) in spleen + concordant US/PET
negativity in LNs (9.7%). Avoiding abdomen/pelvis CT would have some positive
effects in patients in whom it is deemed possible: 1)Reducing radiation expo-
sure. 2)Cutting possible side effects and adverse/allergic reactions of contrast
materials and of general anesthesia (in the minority of patients needing it).3)Cut-
ting the costs. All these advantages would be present even compared to an ini-
tial staging performed through combined PET/CT (where usually a CT scan
with iodine contrast media is performed after PET) or, apart from the radiation
risk, through chest CT and abdomen/pelvis MRI, which is a much more com-
plicated approach.
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INCREASED CORONARY ARTERY CALCIUM SCORE AFTER RADIOTHERAPY
IN HODGKIN LYMPHOMA SURVIVORS
E Van Leeuwen-Segarceanu1,*, J Bijl2, J van der Heyden2, B Rensing2,
WJ Bos1, D Biesma1
1Internal Medicine, 2Cardiology, St. Antonius Hospital, Nieuwegein, Nether-
lands
Background: Coronary artery disease (CAD) is a well know complication of
mediastinal radiotherapy (MRT). Long term survivors of Hodgkin Lymphoma
have an increased risk of myocardial infarction compared to the general pop-
ulation. Pre-clinical CAD, detected using modern imaging techniques, has been
rarely described in these patients.
Aims: The aim of this study is to compare computer tomography (CT) detected
CAC-scores in HLS treated with and without MRT. Furthermore we tried to iden-
tify risk factors (RFs) predisposing HLS to develop coronary artery calcifications.
Methods: In this cross-sectional study we describe 82 Hodgkin Lymphoma
survivors (HLS) with a mean current age of 47.8 years and mean follow-up
time from diagnosis of 13.4 years. Fifty patients were treated with MRT with or
without chemotherapy. Seventy-five patients underwent coronary artery calcium
(CAC) score measurements.
Results: Significantly increased CAC-scores (i.e. CAC-score >75th percentile
for age and gender) were more frequently observed in HLS treated with MRT
41.3%, than in HLS treated without MRT 10.3% (p=.004). In multivariable analy-
sis, HLS treated with MRT ≥10 years ago had an odds ratio of 12.1 of having
a CAC-score >75th percentile compared to HLS treated without MRT. HLS
irradiated <10 years ago had a similar incidence of significantly increased CAC-
scores compared to the no-MRT group. HLS treated with MRT and CAC-score
>75th percentile had more traditional cardiovascular risk factors (median 3)
than HLS treated with MRT with a CAC-score <75th percentile (median 2),
p=.036. Five HLS treated with MRT and one treated without MRT had already
developed symptomatic CAD before screening. During four years follow-up
after screening, two more patients developed CAD for which revascularisation
therapy was needed.
Figure 1.
Summary/Conclusions: We therefore recommend that screening HLS by
CAC-score measurements should begin 10 years after MRT and that traditional
cardiovascular risk factors should be addressed in this high risk population.
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CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN
LYMPHOMA PATIENTS
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Background: Classical Hodgkin lymphoma (cHL) is the most common lym-
phoid malignancy under the age of 30. Despite the relatively high curability,
about 20-30% of patients relapse after front-line therapy. Recent years have
brought novel information about close Hodgkin/Reed-Sternberg (HRS): lym-
phoma associated macrophages (LAM) cross-talk promoting tumor growth and
resistance to therapy.
Aims: To assess the prognostic role of LAM to HRS ratio in lymph node biop-
sies using a novel automated system for scanning large tumor sample areas
in cHL patients.
Methods: High-quality tissue samples obtained from 38 patients at time of
diagnosis were analyzed. The median age at diagnosis was 35 (17.5-93) years;
the male-to-female ratio was 0.66:1. The lymphoma subtypes were nodular
sclerosis (NS) in 25 (66%) and mixed cellularity (MC) in 13 (34%) patients.
German Hodgkin Study Group stages were: limited in 4 (12%), intermediate in
8 (23%) and advanced in 23 (66%) patients. Chemotherapy was given to 35
patients (92%): BEACOPP in 20 (57.1%), ABVD in 6 (17.1%), Stanford V in 4
(11.4%) and other (COPP, COPP/ABV) in 5 (14.3%) cases. Involved-field radio-
therapy was applied in 11 (29%) cases. Tissue array analyses were performed
using the TissueFAXS (TissueGnostics, Austria). Data were analyzed with Tis-
sueQuest software. Paraffin-embedded biopsies were prepared from diagnostic
samples stained with anti-CD30 and anti-CD68. Analyzed areas were reviewed
by pathologist and fibrotic (≥10%), necrotic or residual lymphatic structures
were excluded.
Results: After treatment, 31 (82%) patients achieved complete remission, three
partial remission, one stable disease and three patients progressed. After a
median follow-up of 64.3 months, 9 (24%) patients relapsed or progressed and
7 (18%) died. Five-year overall survival (5-y OS) reached 81.0%; 5-year pro-
gression survival (PFS) was 68.3%. The mean sample scanned area covered
27.2±13.5 mm2 with the mean total number of cells 461,504±286,491. The
means (medians) of HRS and LAM densities were 279±232 (181) and
1724±1115 (1317) cells per mm2, respectively. Mean and median number LAM
per HRS cell (LAM to HRS ratio, LHR) achieved 13.1 and 7.48, respectively.
LHR did not correlate with sex (p=0.44), age (p=0.19), systemic symptoms
(p=0.68), tumor bulk (p=0.35) or Ann Arbor stage (p=0.59). High LHR (>7.48)
correlates with lower probability of CR achievement (63% vs 95%, p=0.02).
High LHR was associated with inferior 5-y PFS (41.1% vs 94.7%, p<0.001)
and OS (62.2% vs 100%, p=0.004). Multivariate Cox regression identified high
LHR as an unfavorable prognostic factor for PFS (p=0.01, HR=13.3) independ-
ent of age, sex, disease stage and lymphoma subtype.
Figure 1.
Summary/Conclusions: This is the first evidence about the possible predictive
role of LAM to HRS ratio in cHL patients. High LHR at diagnosis is associated
lower probability of CR and higher risk of lymphoma progression or death.
Automated image analysis is a new tool overcoming technical limitations
caused by small (microarray) samples in lymphomas with high intra-tumor het-
erogeneity. Further analyses will define the role of HRS and LAM density analy-
sis in cHL in the context of risk-adapted and CD30-targeted therapies.
Acknowledgement: Supported by grants from: Palacky University (IGA_LF_
2016_001) and Takeda Pharmaceuticals International AG (IISR-2015-101289).
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THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH
CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT
A Cuccaro1,*, M Martini2, S Annunziata3, E Cupelli1, T Cenci2, E Galli1,
ML Calcagni3, V Rufini3, F D’Alò1, A Giordano3, LM Larocca2, S Hohaus1
1Institute of Hematology, 2Institute of Pathology, 3Institute of Nuclear Medicine,
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Background: Risk stratification in classical Hodgkin Lymphoma (cHL) is largely
based on clinical, radiological and laboratory findings. In the last years, interim
PET-CT has added important prognostic information for therapy stratification.
Among risk factors that reflect tumor biology, Bcl2 expression in Hodgkin/Reed-
Sternberg cells (HRS) has been reported to be an adverse prognostic factor in
HL. More recently, studies using genome-wide expression data have identified
the number of tumor-infiltrating macrophages (TAMs) as an important tissue bio-
marker. Several studies have shown that patients with TAMs over 5% identified
by immunohistochemical staining for the CD68 antigen had an inferior outcome.
Aims: The aim of this study was to evaluate Bcl-2 expression in HRS cells,
analyze for associations of Bcl-2 expression with clinical characteristics, interim
PET-CT and in particular, the CD68+ cell count and clinical outcome.
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Methods: We studied 122 patients with cHL (58 females, 64 males, median
age 38 years), diagnosed at our Institution between 2004 and 2016, and treated
with ABVD (95 patients), BEACOPP (21 patients) or COPP (6 patients). Tissue
sections of patients were stained for Bcl-2, and cases were considered positive
if any HRS cell expressed Bcl-2 (Rassidakis, Blood 2002; 100;3935). CD68+
cells were assessed by staining with the PGM-1 antibody. PET was performed
after 2 cycles of chemotherapy in 95 patients and evaluated according to the
5-point Deauville scale (5p-DS). Primary endpoint was event-free survival
(EFS), defined as time from date of diagnosis to date of first relapse, disease
progression, or death from any cause.
Results: Bcl-2 was expressed in HRS cells of 60/122 (49%) cases. CD68 count
was >5% in 66/122 (54%) cases. We found a significant association between
Bcl-2 expression and the CD68+ count >5% (p=0.04). Both Bcl-2-positivity and
CD68+ cell count >5% were associated to elevated levels of LDH (p=0.006;
p=0.02 respectively) and the nodular sclerosis type 2 according to BNLI criteria
(p=0.002; p=0.005 respectively). Using a score of >3 as cut to define a positive
interim PET-CT, 83 patients had a negative interim PET, 12 patients were PET-
positive. No association was found between Bcl-2-positivity and the PET result;
instead we observed a direct correlation between CD68+ count and 5p-DS
(p<0.002). Bcl-2 expression was associated only with a trend for poor EFS
(p=0.07), while the CD68+ count >5% was a strong predictor for reduced EFS
(p<0.001). In a multivariate analysis adjusted for the type of chemotherapy,
CD68+ count and interim PET retained their independent prognostic signifi-
cance (p<0.001, and p<0.001, respectively).
Summary/Conclusions: Our study suggests that BCL-2 expression in HRS cells
does not provide prognostic information in addition to the CD68+ cell count and
interim PET-CT that remain strong and independent outcome predictors in cHL.
P311
AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) IS HIGHLY
EFFECTIVE IN RELAPSED NODULAR LYMPHOCYTE-PREDOMINANT
HODGKIN LYMPHOMA (NLPHL): A RETROSPECTIVE STUDY BY THE
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Background: NLPHL is a rare CD20-positive subtype of Hodgkin lymphoma
(HL). Although long term survival is better than in classical HL, frequent relapses
are common and progression / transformation to aggressive non-Hodgkin lym-
phoma (NHL) may happen. Whilst high-dose therapy (HDT) with auto-SCT is
considered as standard treatment for relapsed / refractory classical HL, infor-
mation on auto-SCT in relapsed / refractory NLPHL is sparse. 
Aims: We report a registry study of auto-SCT for NLPHL using the EBMT data-
base, representing the largest sample analyzed to date.
Methods: Eligible for this study were patients 18 years or above with NLPHL
who underwent auto-SCT between 2003 to 2013 and were reported to the
EBMT. Baseline patient, disease, and transplant data were collected from EBMT
MED-A standard forms. Centers with potentially eligible patients were contacted
to provide additional treatment and follow-up information including a written
histopathology report for central review. Statistical analysis was descriptive and
employed log rank comparisons for univariate assessment of the impact of
baseline characteristics on survival endpoints.
Results: Altogether, 92 patients met the inclusion criteria and had a full data
set including written diagnostic report available. Of these, 36 patients had to
be excluded after histopathology report review (17 classical HL, 2 NHL, 17 no
sufficient information), leaving 56 patients in the final study sample. There was
a predominance of male patients (88%), and the median age was 36 (interquar-
tile range (IQR) 29-50) years. Prior to auto-SCT, 71% had 2, 20% had 3, and
the remainder more than 3 lines of treatment (median 2 lines), containing rit-
uximab in 62% of the patients. Median time from diagnosis to auto-SCT was
21 (IQR 14-51) months. At auto-SCT, 54% of the patients were in complete
remission (CR), and 43% in partial remission (PR). BEAM was used as HDT in
the vast majority of patients (84%), with additional rituximab in 13%. With a
median follow-up of survivors of 5.0 (IQR 3.6-6.6) years, the 5-year progres-
sion-free and overall survival were 67% (95%CI 55-82), and 86% (95%CI
77%>96%). 5-year incidence of relapse was 32% (95%CI 20-46). There were
no transplant-related deaths. Univariate comparisons considering age, time
from diagnosis to transplant, number of pretreatment lines, disease status at
auto-SCT and rituximab use during induction, salvage and/or HDT failed to
identify significant predictors of any survival endpoint.
Summary/Conclusions: Patients with relapsed NLPHL undergoing auto-SCT
have an excellent outcome, even after failing many lines, comparing favorably
with historical data on auto-SCT for relapsed classical HL. In this retrospective
analysis, a significant effect of rituximab treatment prior to and/or during HDT
did not emerge.
Non-Hodgkin & Hodgkin lymphoma - Novel agents
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BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND
CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN
WALDENSTROM’S MACROGLOBULINEMIA
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Background: Waldenström’s macroglobulinemia (WM) is characterized by
bone marrow (BM) infiltration of lymphoplasmacytic lymphoma along with a
serum IgM monoclonal protein. Recently, MYD88 and CXCR4 activating somat-
ic mutations were identified in approximately 90% and 35% of WM patients,
respectively. CXCR4 mutations occur almost exclusively in MYD88 mutated
patients. Ibrutinib is an oral BTK inhibitor and the only drug specifically approved
for WM by the European Medical Association. Ibrutinib is highly active in pre-
viously treated WM patients with the best responses in MYD88 mutated CXCR4
wild-type (WT) patients. The serum cytokine profile for WM based on MYD88
and CXCR4 genotype has yet to be defined and the serum cytokine response
to ibrutinib based therapy has not been previously studied in WM.
Aims: The aim of this study is to define cytokines that correlate with WM clinical
characteristics, MYD88 and CXCR4 mutation status, and response to ibrutinib
therapy.
Methods: A total of 137 peripheral blood derived plasma samples were tested,
obtained from 52 previously untreated WM patients and 34 previously treated
and symptomatic WM patients who received ibrutinib therapy as part of a
prospective clinical trial (Treon et al, NEJM 2015). The untreated group included
23 patients that were MYD88 mutated and CXCR4 wild type, 20 patients that
were both MYD88 and CXCR4 mutated, and 9 patients that were MYD88 and
CXCR4 wild type. The patients participating in the ibrutinib trial were tested just
before and one year after initiation of ibrutinib therapy. Twenty age and gender
matched healthy controls were included for comparison. Cytokines were tested
using magnetic multiplex enzyme- linked immunosorbent assays (R&D Systems
Inc., Minneapolis, MN). The following 27 cytokines were tested: TNF, IL6, IFNG,
CXCL10, IL10, CCL2, IL8, IL1b, IL7, IL1RA, CCL3, CCL4, CCL5, IL17A, IL4,
IL5, IL2, GMCSF, IL2RA, CXCL9, IL12, IL15, IL13, CCL11, CXCL12, CXCL13
and CD27. Statistical analysis was performed with R statistical computing soft-
ware. Clinical parameters and cytokine levels were analyzed following log trans-
formation. Correlation between variables was tested using Spearman’s rho and
when appropriate Holm-Bonferroni multiple hypothesis correction was applied.
Adjusted p-values <0.05 were deemed significant for this analysis.
Figure 1.
Results: CXL10, IL10, IL2RA, CXCL13 and CD27 were significantly higher
between WM patients versus controls. At baseline CXCL13, IL2RA and CD27
strongly correlated with HGB levels (p<0.001 for all) with correlation coefficients
of -0.55, -0.55, and -0.47, respectively. CXCL13 (rho=0.56; p<0.001) and CD27
(rho=0.46; p<0.001) correlated with BM infiltration. None of the cytokines
showed significant correlated with IgM levels. Based on CXCR4 mutation status
within MYD88 mutated patients, IL2RA (p=0.025), IL1RA (p=0.003), CXCL10
(p=0.026) and CD27 (p=0.016) were higher in CXCR4 WT patients. No signif-
icant difference in cytokine levels based on MYD88 mutation status was noted
though this was due to MYD88 WT cytokine levels being similar to those found
in CXCR4 mutated patients. Twelve cytokines were significantly changed after
1 year on ibrutinib (Figure 1). Only the change in CXCL13 was significantly
correlated to achieving at least at least a partial response (PR; >50% decrease
in serum IgM; p=0.019). Baseline CXCL13 levels were significantly higher in
patients that subsequently reached at least a partial response (PR; >50%
decrease in serum IgM) after 1 year (p=0.048). This was also true using logistic
regression to account for age, gender, MYD88/CXCR4 mutation status, and
baseline BM involvement (p=0.035).
Summary/Conclusions: CXCL13 is a strong biomarker of BM tumor involve-
ment in WM and baseline levels are predictive of achieving a major response
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to ibrutinib. These data suggest a role of CXCL13 in WM tumor biology and
warrants further study.
P313
A PHASE III STUDY OF OFATUMUMAB VS RITUXIMAB IN INDOLENT
B-CELL NON-HODGKIN LYMPHOMA RELAPSED AFTER RITUXIMAB
CONTAINING THERAPY (HOMER): RESULTS OF THE INTERIM ANALYSIS
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Background: Rituximab, (R) as a single agent or in combination, is standard
therapy for untreated or relapsed indolent B-cell non-Hodgkin lymphoma (iNHL).
Due to the ubiquitous use of R in the treatment of iNHL and the invariable
relapse of patients with iNHL, there remains an unmet need for novel therapies
in relapsed iNHL. Ofatumumab (OFA) is an anti-CD20 human monoclonal anti-
body (mAb) that binds to a membrane-proximal epitope of the CD20 molecule.
Aims: The study aimed to evaluate the efficacy and safety of treatment with
OFA compared with R in iNHL patients who had relapsed following R-containing
treatment. Here we report the results of the interim futility analysis.
Methods: In this Phase III, multicentre, open-label study, patients (aged ≥18
years) who had relapsed following R-based therapy were randomized to receive
either 1000 mg OFA or 375 mg/m2 R every week for 4 weeks, followed by every
2 months for four additional doses. All patients provided informed consent and
were R-sensitive: a complete or partial response to their last prior R-containing
therapy lasting at least 6 months beyond the end of R treatment was required.
Randomization was stratified by FLIPI score (0–2 vs 3–5), disease type (FL vs
non-FL), and prior R (monotherapy vs combination). The primary endpoint was
progression-free survival (PFS), as assessed by an independent radiology
reviewer (IRR). An interim futility analysis was reviewed by an independent data
monitoring committee (IDMC) when 50% of the 373 planned events for the pri-
mary endpoint analysis had been reported. A recommendation to stop the study
would occur if the IRR-assessed PFS had a conditional power ≤30%.
Results: A total of 409 patients (205 in the OFA arm and 204 in the R arm)
were enrolled and evaluated in the interim analysis. The majority of patients
(98%) had follicular lymphoma. Patient and disease characteristics were similar
between the treatment arms. Just under a third of patients (31% OFA, 27% R)
discontinued from study treatment, with the most common reason being dis-
ease progression (21%). The IRR-assessed median PFS was 16.2 months in
the OFA arm and 21.2 months in the R arm (Table 1). IRR-assessed response
rates were 50% and 63% in the OFA and R arms, respectively. Investigator
(INV)-assessed median PFS was 16.1 months and 17.9 months in the OFA
and R arms, respectively. INV-assessed response rates were 47% for OFA
and 58% for R. Median overall survival and median time to next therapy
appeared to be similar between arms. Infusion-related adverse events
appeared higher in the OFA arm vs R arm (any grade: 87% vs 58%; grade 3/4:
22% vs 5%), and mostly affected the first infusion administered. Incidences of
gastrointestinal disorders appeared higher in the OFA arm vs R arm (38% vs
27%), whereas neutropenia (OFA: 3% vs R: 7%) and pyrexia (OFA: 4% vs R:
10%) appeared to be more frequent in the R arm.
Table 1. Efficacy endpoints of the HOMER study.
Summary/Conclusions: Based on the reported observations of efficacy, the
IDMC recommended stopping the study for futility, as there was little likelihood
of OFA demonstrating superiority over R, and accrual was terminated.
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A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY
OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS
WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA
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Background: Even with modern chemo-immunotherapy regimens, outcomes
for patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (DLB-
CL) or follicular lymphoma (FL) remain poor. Atezolizumab (atezo), a human-
ized engineered IgG1 monoclonal antibody (mAb) against programmed death-
ligand 1 (PD-L1), blocks the interaction between PD-L1 and its receptors PD-
1 and B7.1, thereby preventing inhibition of T-cell activity. Atezo monotherapy
has demonstrated clinical activity in multiple types of cancers, including non-
Hodgkin lymphoma (NHL). Increased PD-L1/PD-1 expression has been report-
ed in DLBCL and FL on cancer cells, stromal cells and tumor-infiltrating immune
cells and may represent escape from immune surveillance. Obinutuzumab
(obi) is a next-generation anti-CD20 mAb with enhanced ADCC.
Aims: To determine whether the combination of atezo and obi can activate both
innate and adaptive immunity to enhance anti-tumor responses in lymphoma.
Methods: This multicenter, open-label Phase Ib study (NCT02220842) is
assessing atezo combined with obi in pts with relapsed or refractory DLBCL or
FL. Primary endpoints are safety and tolerability; secondary endpoints are
pharmacokinetics and clinical activity. Key eligibility criteria were measurable
disease and treatment with ≥1 prior chemo-immunotherapy regimen. Prior
autologous stem cell transplant was allowed but not allogeneic stem cell trans-
plant. In cycle 1, pts received obi intravenously (IV) alone on days 1 (100 mg),
2 (900 mg), 8 and 15 (1000 mg). From cycles 2–8, atezo (1200 mg) and obi
(1000 mg) were administered IV on day 1 q3w. Atezo consolidation followed
(1200 mg q3w) for an additional 6 mo. Objective response rate (ORR) was
assessed by IWG NHL criteria. Pretreatment biopsies and on-treatment sam-
ples were collected to determine PD-L1 expression levels and examine other
biomarkers of response and resistance.
Results: As of Feb 5, 2016, 31 pts (17 DLBCL; 14 FL) were evaluable for
safety. Median age was 60 yrs (range 26–90) and 58% of pts were male.
Median disease burden at baseline was 3027.9 mm2 (range 598.0–31400.0).
Median duration of therapy was 43 days (range 2–387) for DLBCL and 117
days (range 2–211) for FL. 1 potentially atezo-related adverse event (AE)
(Grade 2 myalgia) led to treatment discontinuation. AEs led to study drug inter-
ruptions in 7 pts. 26 pts experienced ≥1 treatment emergent (TE) AE (Gr 1–
4). The most common Gr 3–4 TEAEs were neutropenia (12.9%) and abdom-
inal pain (6.5%). 4 deaths (3 due to disease progression; 1 unknown cause)
were reported. 20 pts with ≥1 imaging assessment were evaluable for efficacy
and had a median of 3 prior therapies (range, 2–7). At the first response
assessment (after cycle 4), the ORR was 15%; 2 FL pts achieved a complete
response, and 1 FL pt had a partial response. 6 pts had stable disease (1 with
DLBCL; 5 with FL). PD-L1 expression was detected in DLBCL and FL; corre-
sponding measurements of biomarkers associated with immune activity includ-
ing infiltration by CD8+ T cells were seen. Updated safety, efficacy and bio-
marker data will be presented.
Summary/Conclusions: Preliminary results indicate that atezo combined with
obi is well tolerated with evidence of clinical activity in pts with heavily pretreated
relapsed or refractory DLBCL and FL.
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LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA
INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE
RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY
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Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differen-
tiated safety profile from other PI3Kδ inhibitors, and proven activity in patients
(pts) with advanced hematologic malignancies. TGR-1202 is in clinical devel-
opment as monotherapy and in combination with the glycoengineered CD20
mAb, ublituximab (UTX).
Aims: An integrated-analysis was conducted of pts dosed with TGR-1202
monotherapy or combined with ublituximab with a focus on patients with indo-
lent and aggressive NHL.
Methods: In both studies, there were no limits on prior therapies (Tx) and TGR-
1202 was administered once-daily and escalated in 3 + 3 design with expansion
cohorts explored. In the combo study, UTX was administered at a fixed dose
of 900 mg per infusion. The primary endpoint was safety and efficacy was a
secondary endpoint.
Results: Across both studies, a total of 152 pts (81 monotherapy/71 combined
with UTX) were exposed to at least one dose of TGR-1202, including 40
CLL/SLL and 112 lymphoma patients. Among patients with lymphoma, histolo-
gies included 41 Follicular (FL), 38 DLBCL, 11 Marginal Zone (MZL), 9 Hodgkins
(HL), 8 Mantle Cell (MCL) and 5 other. Median age 65 yrs (22-86); 100 M/52
F; median # prior Tx=3 (1-14); 53% refractory to immediate prior Tx. Most fre-
quent reported AE’s (all grades; Gr 3/4): nausea (44%; 1%), diarrhea (42%;
2%), fatigue (36%; 3%), vomiting (23%; 0%) and neutropenia (19%; 16%).
AST/ALT increase was 6% (3% Gr 3/4), pneumonia 6% (5% Gr 3/4) and pneu-
monitis 1% (<1% Gr 3/4). 64 pts received TGR-1202 for ≥6 mos, 33 for ≥1 year,
with longest on >30 mos. Discontinuations due to AE’s occurred in 8% of pts.
Across both studies, 74 NHL pts received the therapeutic targeted dose and
were evaluable for efficacy. Amongst 37 patients with indolent NHL (FL and
MZL), the ORR was 49% (11% CR), and amongst 37 patients with aggressive
NHL (DLBCL, MCL, and Richter’s), the ORR was 24% (8% CR). Notably,
greater activity was observed in patients treated with the combination of TGR-
1202 + UTX, with an ORR of 71% (24% CR) in indolent NHL and an ORR of
32% (16% CR) in aggressive NHL patients treated with the combination. The
majority of DLBCL responses were observed with the combination of TGR-
1202 + UTX, including 3 CR’s and were mostly of GCB subtype. The median
PFS for TGR-1202 monotherapy in indolent NHL was 27 mo, and has not been
reached for patients treated with the TGR+UTX combo.
Summary/Conclusions: TGR-1202 has exhibited a markedly differentiated
safety profile from other PI3Kδ inhibitors to date with few discontinuations due
to AE’s and limited G 3/4 events. In particular we highlight the minimal rates of
transaminitis / pneumonitis / colitis events across a large CLL/NHL population.
A global Phase 3 trial evaluating TGR-1202 in combination with UTX is ongoing
in patients with treatment naïve and relapsed CLL. Registration directed Phase
2 and Phase 3 studies in patients with DLBCL and indolent NHL are planned.
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THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY
ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/
REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF
THE PHASE II AIM STUDY
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Background: The targeted agents ibrutinib & venetoclax (ABT-199) individually
achieve response rates of 68-75% in patients (pts) with relapsed/refractory
(R/R) mantle cell lymphoma (MCL). However, individually both drugs are asso-
ciated with complete remissions (CR) in <25%, and median remissions <18
months. Multiple preclinical models showed synergy between ibrutinib and
venetoclax.
Aims: We report the first-in-human experience with the combination of ibrutinib
and venetoclax in the ongoing phase II, investigator-initiated AIM study.
Methods: Pts gave written consent, have R/R MCL, ECOG ≤2, and adequate
marrow and organ function. The treatment plan comprises of 4 weeks ibrutinib
induction at 560mg daily, followed by a 4 week ramp-up of venetoclax (to a tar-
get dose 400mg daily) with tumour lysis syndrome (TLS) monitoring, and con-
tinuation of both drugs thereafter. At full recruitment (n=24), the AIM study is
powered to show improvement in CR rate after 4 months (primary endpoint)
from a historic 9% for ibrutinib alone, to ≥30%. Pts are restaged using FDG
PET/CT scans & minimal residual disease (MRD) by flow cytometry, ASO-PCR
and circulating tumor DNA.
Results: As of 29-Jan-2016, 8 pts were enrolled: median follow-up was 38
days (range, 1-188), median age was 72 years (53–77), median prior therapies
was 2 (1–7); 63% of pts had high MIPI scores. The most common adverse
events (AE, all grade 1-2) were nausea (n=4), diarrhea (n=2) and oral candidi-
asis (n=2). Six serious AE have occurred: none were related to study drugs.
Response to 4 weeks of ibrutinib induction were 2 partial responses (PR), 2
stable disease and 1 progressive disease; 3 pts were still receiving induction.
The full dose of 400mg was reached in all 4 pts entering venetoclax ramp-up,
without occurrence of laboratory or clinical TLS. Three pts have completed pri-
mary staging at 4 months (1 month of ibrutinib and 3 months of ibrutinib & vene-
toclax): 2 subjects were in CR with normalization of PET±endoscopy, and com-
plete clearance of previous marrow involvement, including flow cytometry at
>10-4 sensitivity (Figure). The remaining pt had uninvolved marrow and non-
FDG avid, small volume disease following ibrutinib induction that was inade-
quately visualized on the 4-month PET/CT scan, and was thus classified as
PR. Updated safety, efficacy & MRD data (available in at least 8 pts) will be
presented at the meeting.
Figure 1.
Summary/Conclusions: The early experience with ibrutinib and venetoclax
in combination shows no unexpected safety signals, and indicates promising
efficacy.
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IDELALISIB MONOTHERAPY IN RELAPSED/REFRACTORY FOLLICULAR
LYMPHOMA (FL): EXPERIENCE THROUGH AN EARLY ACCESS
PROGRAM IN EUROPE AND AUSTRALIA
JJ Li1, M Breuleux1, C Smith1, A Davies2,*
1Gilead Sciences, Inc., Foster City, CA, United States, 2Cancer Sciences Unit,
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, United
Kingdom
Background: Idelalisib (IDELA) is an oral first-in-class selective PI3Kδ inhibitor
approved in EU for use as a monotherapy in patients (pts) with FL who are
refractory to two prior lines of treatment. Pts with FL of any grade (grade 1, 2,
or 3a) who were refractory to two prior lines of treatment were eligible for this
post-authorization, pre-national reimbursement early access program (EAP).
Refractoriness required 2 out of the following criteria to be confirmed: (i) refrac-
tory to rituximab with chemotherapy; (ii) refractory to alkylating agent (adminis-
tered with or without rituximab) or (iii) refractory to rituximab without chemother-
apy. IDELA data outside clinical trials and in the real-world is limited.
Aims: The objective of this analysis was to characterize the baseline charac-
teristics of refractory FL pts treated with IDELA monotherapy, in a real-world
setting. The serious adverse events (SAE) reported are also presented.
Table 1.
*Indicates mandatory information collected upon enrolment
Methods: This analysis only included pts with refractory FL treated with IDELA
monotherapy within the EAP, in Australia, Belgium, Greece and Spain. This
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program began enrollment from March 2015 and the data cut off was January
15, 2016. Available data were collected from de-identified pt registration data,
follow-up resupply data and SAEs reports. This analysis summarizes the base-
line pt characteristics reported which were either mandatory or optional on the
pt enrolment form. SAEs were reported whilst the pts were on treatment. The
proportion of missing data where information was unreported or unrecoverable
is also shown in the table. Of 66 pts with refractory FL who had documented
prior treatment regimens (60 pts with specific treatment documented and 6
with number of prior regimens only), the most common prior agents included
rituximab (98.4%), cyclophosphamide (96.7%), prednisolone (95%), vincristine
(95%), doxorubicin (76.7%) and etoposide (46.7%). A total of 12 pts (20%) had
received a prior autologous stem cell transplant. With a median follow up of
109 days (range: 3-309), IDELA monotherapy was well-tolerated with 6/66 pts
(9.1%) reporting an SAE. Reported SAEs, regardless of causality, include 1
(1.5%) each of febrile neutropenia, neutropenia, diarrhea, gastrointestinal
inflammatory disorder, pancytopenia, progressive disease, liver enzyme ele-
vation, hypotension and colon adenocarcinoma.
Results: Of 66 pts with refractory FL who had documented prior treatment
regimens (60 pts with specific treatment documented and 6 with number of
prior regimens only), the most common prior agents included rituximab (98.4%),
cyclophosphamide (96.7%), prednisolone (95%), vincristine (95%), doxorubicin
(76.7%) and etoposide (46.7%). A total of 12 pts (20%) had received a prior
autologous stem cell transplant. With a median follow up of 109 days (range:
3-309), IDELA monotherapy was well-tolerated with 6/66 pts (9.1%) reporting
an SAE. Reported SAEs, regardless of causality, include 1 (1.5%) each of
febrile neutropenia, neutropenia, diarrhea, gastrointestinal inflammatory dis-
order, pancytopenia, progressive disease, liver enzyme elevation, hypotension
and colon adenocarcinoma.
Summary/Conclusions: The results of this large real-world cohort of pts with
FL who are refractory to 2 prior lines of therapy treated by IDELA monotherapy
outside of the clinical trial setting confirm the acceptable tolerability profile of
IDELA.
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PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K)
INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY,
INDOLENT OR AGGRESSIVE LYMPHOMA
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Background: Copanlisib (BAY 80-6946) is a potent and selective pan-class I
PI3K inhibitor with preferential activity against the δ- and α-isoforms. In an
expansion cohort of a phase I study, promising activity was seen in patients
with non-Hodgkin lymphoma (NHL), with 6 of 6 responses in follicular lym-
phoma (FL) patients [2 of which were durable (>3 years) complete responses
per post-hoc radiologic review (Patnaik et al, submitted)] and 1 of 3 diffuse
large B-cell lymphoma (DLBCL) patients achieving a partial response (PR).
Aims: We therefore investigated the efficacy and safety of copanlisib in sub-
jects with relapsed/refractory indolent or aggressive NHL or chronic lymphocytic
leukemia (CLL). (NCT01660451)
Methods: Patients with histologically confirmed indolent or aggressive lym-
phoma or CLL, relapsed or refractory to ≥2 prior lines of treatment were
enrolled. Copanlisib (0.8 mg/kg) was administered intravenously on days 1, 8
and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
The primary endpoint was objective response rate (ORR) as assessed by inde-
pendent radiology review according to the response criteria for lymphoma (Che-
son et al, JCO 1999) or the guidelines for diagnosis and treatment of CLL
(Hallek et al, Blood 2008). Secondary endpoints included progression-free sur-
vival (PFS) and duration of response (DOR), safety and tolerability.
Results: A total of 20 patients with indolent NHL (iNHL; 16 FL, 3 marginal zone
lymphoma, 1 small lymphocytic lymphoma), 13 CLL and 48 with aggressive
NHL [15 DLBCL, 14 peripheral T-cell lymphoma, 11 mantle cell lymphoma
(MCL), 6 transformed, 1 mediastinal, and 1 Grade 3b FL] were treated; median
age 67 years; 53% male; median 3 (range 1-10) number of previous lines of
treatment and prior rituximab in 80% of patients. At the time of analysis, the
ORR was 47% (90% CI 27-68) and stable disease (SD) was 47% (CI 27-68)
in patients with iNHL, 38% (CI 17-65) and 46% (CI 22-71) in CLL, and 26% (CI
16-39) and 17% (CI 9-29) in aggressive NHL, respectively. For patients with
FL, the ORR was 40% (CI 19-64), with 1 CR, 2 uCRs, and 3 PRs; SD in 53%
(CI 30-76). The ORR in the MCL patients was 64% (CI 35-86; 2 uCR and 5
PRs). The median DOR was 390 days in the indolent group and 166 days in
the aggressive group. The most common treatment-related adverse events
(AEs) of all grades (G) were hyperglycemia (59%), hypertension (54%), diar-
rhea (33%), and fatigue (28%). G3-4 treatment-related AEs occurring in >10%
of patients included hypertension (39%) and hyperglycemia (25%). Treatment-
related AEs leading to dose reduction were observed in 4%, interruption in
36%, interruption and reduction in 7%, or permanent discontinuation in 17% of
patients, respectively. There were 4 treatment-related grade 5 events: menin-
gitis, respiratory failure and 2 lung infections.
Summary/Conclusions: Copanlisib is active as a single agent in heavily pre-
treated patients with a variety of relapsed/refractory indolent or aggressive lym-
phoma subtypes, with promising CR activity in FL and MCL. Copanlisib exhib-
ited a manageable toxicity profile. Final results of survival rates will be pre-
sented. Based on these encouraging results, phase II studies in patients with
FL, MCL, and DLBCL are ongoing.
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PRELIMINARY SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS
OF DUVELISIB PLUS RITUXIMAB OR OBINUTUZUMAB IN PATIENTS WITH
PREVIOUSLY UNTREATED CD20+ FOLLICULAR LYMPHOMA
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Background: Duvelisib (IPI-145), a dual PI3K-δ,γ inhibitor, is being evaluated
as an oral therapeutic for hematologic malignancies as a monotherapy or in
combination with anti-CD20 antibodies.
Aims: We report herein results for the CONTEMPO (NCT02391545) study, an
ongoing 2-part, 2-arm, Phase 1b/2 study that evaluates the safety, pharmaco-
kinetics, pharmacodynamics and efficacy of duvelisib combined with the anti-
CD20 antibodies rituximab (DR) or obinutuzumab (DO) in patients with previ-
ously untreated CD20+ follicular lymphoma. 
Methods: Duvelisib is administered at 25 mg BID continuously in 28-day treat-
ment cycles combined either with rituximab (375 mg/m2 for 4 weekly doses,
then 1 dose every 2 cycles) or obinutuzumab (1000 mg for 4 weekly doses,
then 1 dose every 2 cycles). We report results from Part 1 which evaluated the
safety of the combinations by monitoring adverse events (AEs) and dose lim-
iting toxicities (DLTs). 
Results: Twelve patients were treated in Part 1 of the study (6 DR and 6 DO).
At the time of data cut-off, patients had received duvelisib for a median of 2.5
(DR) and 1.9 (DO) months. No DLT occurred with DR. One DLT of treatment-
related Grade 3 elevated lipase occurred with DO (Cycle 1). No serious AEs
occurred on either arm, and no patient discontinued treatment. Four patients
(1 DR; 3 DO) had ≥Grade 3 AEs (DR: amylase increased, lipase increased;
DO: neutropenia, ALT increased, lipase increased). Duvelisib was rapidly
absorbed (tmax~1 hour; Cmax~910 ng/mL; single dose); after multiple doses,
plasma steady state levels were ~500-540 ng/mL and approximately half of
the duvelisib was transformed into its metabolite IPI-656. Postdose serum
cytokine levels were decreased by Cycle 1 Day 8 compared to baseline. Pre-
liminary activity will be reported at the time of the meeting. 
Summary/Conclusions: Combination of duvelisib 25 mg BID with rituximab
or obinutuzumab was well tolerated in these patients, with one DLT observed.
Both DR and DO arms were continued to Part 2 of the study, which is ongoing. 
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SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY
IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA
(EMZL)
AJ Ferreri1,*, C Cecchetti1, B Kiesewetter2, M Sassone1, T Calimeri1, L Scarfò1,
M Raderer2
1Department of OncoHematology, San Raffaele Scientific Institute, Milano,
Italy, 2Dept. of Internal Medicine I, Medical University of Vienna, Wien, Austria
Background: Macrolides have been proposed as new anticancer agents. In
particular, clarithromycin displays different immunomodulatory effects on sev-
eral pathways, and is active in different tumor models. Two phase II trials have
demonstrated that clarithromycin monotherapy is safe and active in patients
(pts) with relapsed/refractory EMZL (Govi et al. BJH 2010; Ferreri et al. Ann
Oncol 2015), but the best administration schedule of this antibiotic as antineo-
plastic agent remains to be defined.
Aims: To address tolerability, activity and efficacy of clarithromycin monother-
apy in a large retrospective series of pts with EMZL. Results with three different
administration schedules were analyzed. 
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Methods: 55 pts with EMZL and at least one measurable/parametrable lesion
treated with single-agent clarithromycin between 2003 and 2015 were analyzed.
Clarithromycin was used with three different schedules: a 6-month regimen at
500 mg twice a day, every day (n=13); three courses of 500 mg twice a day,
days 1-21, every 35 days (n=19); or four courses of 2.000 mg/d, days 1-14,
every 21 days (n=23).
Results: Median age of analyzed pts was 65 years (range 30-88), with a M:F
ratio of 0.57. EMZL affected a single organ in 40 pts, and was multifocal in 15:
the most commonly involved organs were ocular adnexae (n=30), stomach
(n=9) and lung (n=7). International Prognostic Index (IPI) score was 0-1 in 40
pts and 2-4 in 15; the IELSG risk score (age, LDH and stage) was 0 in 25 pts,
1 in 23 and >1 in 7. A prior history of chronic infection was recorded in 20 pts:
HBV/HCV, H. pylori and C. psittaci in 5 pts each, with multiple combinations of
these micro-organisms in 5. Clarithromycin was the first treatment line in 8 pts,
the second in 24, the third in 15, and the 4th-6th in 8. Tolerability was excellent:
only 2 pts had grade-3 toxicity (nausea); the main side effects were grade 1-2
nausea (17 pts), dysgeusia (7), dizziness (4), headache (3), arthralgia (2), and
rash (2). Five pts interrupted treatment due to nausea (3), rash or dysgeusia.
There were no differences in feasibility and tolerability among different treatment
schedules, but nausea was significantly more common when a daily dose of
2.000 mg was used (52% vs 25%; Fisher exact, p=0.03). Objective response
after clarithromycin treatment was complete in 13 (24%) pts and partial in 13,
with an overall response rate (ORR) of 47% (95% CI= 34-60). Responses were
more common among pts with gastric MALT lymphoma (7/9 vs 19/46; p=0.04).
ORR was not associated with prior treatment, IPI, IELSG score, and clar-
ithromycin dose. At a median follow-up of 33 months (range 7-137), 29 pts
remain progression-free, with a 3-year PFS of 52±7%. Pts with lymphoma
refractory to prior treatment and pts with IPI score ≥2 had a significantly and
independently poorer PFS. Conversely, clarithromycin dose was not associated
with outcome, with a 3-year PFS of 60±9% and 42±10% (log-rank test; p=0.47)
for pts treated with a daily dose of 1 g and 2 g, respectively. Fifty-two pts are
alive, with a 3-year OS of 96±3%; causes of death were liver failure, stroke and
lung cancer.
Summary/Conclusions: Clarithromycin monotherapy is active in pts with
EMZL, and exhibits an excellent safety profile when used at a dose of up to 2
g/d for 4-6 months. The recommended daily dose of clarithromycin in pts with
EMZL is 1 g as it is associated with a lower incidence of nausea and similar
efficacy than 2 g. Further investigation of clarithromycin, alone or associated
with immunomodulators, in lymphoma pts is warranted.
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A PHASE I STUDY IN T CELL LYMPHOMA PATIENTS TREATED WITH
ANTI-CD70 SIMPLE ANTIBODY™ ARGX-110
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Background: CD70 is a cell surface marker transiently expressed on activated
B, T and dendritic cells. The interaction via its receptor CD27 results in survival,
proliferation and lymphocyte differentiation. In a large number of solid tumours
types CD70 is overexpressed, but without receptor co-expression. The
CD70/CD27 axis appears critical for proliferation and survival of malignant cells
in T-cell lymphoma. Indeed, overexpression of CD70 is paralleled by high
expression of its receptor CD27 in TCL.
Aims: ARGX-110 is a novel glycoengineered monoclonal antibody targeting
CD70 and blocking CD27 signaling, leading to a direct mode of action lysing
CD70+ tumor cells (via CDC, ADCP and enhanced ADCC) and indirect anti-
tumor restoring immune surveillance. (NCT01813539) A phase I trial was initi-
ated with ARGX-110, dose escalated to investigate safety, clinical pharmacology
and determine the RP2D, in refractory or relapsed solid tumors and hemato-
logical malignancies.
Methods: Patients with >10% CD70+ expression on the tumor in immunohis-
tochemistry were included in the study. ARGX-110 was given to 65 patients at
doses from 0.1 to 10 mg/kg intravenously every 3W. In TCL patient’s biomarkers
were measured during the course of treatment.
Results: Immunohistochemistry on TCL patient samples confirmed overex-
pression of CD70 (>10% CD70+ tumor cells) in 40/73 PTCL (55%) and 15/21
CTCL (71%) samples. In 68% of these samples CD70 and CD27 were simul-
taneously expressed. Serum soluble CD27 levels were elevated in TCL patients
compared to healthy subjects (670±1096 vs 192±44 IU/ml, respectively,
p=0.0062). Nine patients TCL patients were included in the study (3 Cutaneous
TCL (CTCL) and 6 Peripheral TCL (PTCL)). ARGX-110 was well tolerated with
no grade >3 adverse events related to the study drug. A clinical and/or biological
response was observed in 4/9 of T-cell Lymphoma cohort patients; CTCL (n=3)
and PTCL-AITL (n=1) patients. The activity in 2 patients with Sezary syndrome
(treated at 0.1 and 10 mg/kg, respectively) resulted in a >90% reduction in the
circulating malignant clone and a clinical partial response in the skin in one
patient. The patient with CTCL TFH lymphoma (TFHL; 5 mg/kg) achieved a PR.
One patient with AITL reached a PR (5 mg/kg dose) and had a resolution of
lymphoma associated auto-immune hemolytic anemia.
Summary/Conclusions: In the TCL patients treated with ARGX-110, we
observed a clinical and/or biological response in 4/9 patients. These preliminary
results support further investigation of ARGX-110 in TCL.
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TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL
IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS
L Liu*, X Li, Q Qu, Y Yao, M Zhu, L Dai, W Shen, Y Xu, X Wu, G Chen, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is a widely used therapy for a lot of malignant and nonmalignant hematologic
diseases. Graft-versus-host disease (GVHD) remains one of the major barriers
to a more widespread and successful application of allo-HSCT. Despite
immune-suppressive prophylaxis, most survivors develop chronic GVHD
(cGVHD). Identification of biologic markers of the syndrome could facilitate
significant advances in understanding to help guide prevention and treatment
approaches. Data in humans support a role of both T- and B-cells in a highly
complex network leading to cGVHD. However, there was no report about bio-
logical marker gene associated with B cell in cGVHD patients. 
Aims: So we screened biological marker gene associated with B cell in cGVHD
patients. Microarrays were used to detect expressed gene profiles of peripheral
blood mononuclear cells total RNA from subjects in the mild-moderate cGVHD,
severe cGVHD, non-cGVHD, immune tolerance and healthy donors groups.
Methods: Microarrays were used to detect expressed gene profiles of periph-
eral blood mononuclear cells total RNA from subjects in the mild-moderate
cGVHD, severe cGVHD, non-cGVHD, immune tolerance and healthy donors
groups. Found out the genes associated with B cell in cGVHD patients reached
statistical significance after a false discovery rate (FDR) correction was applied
to the data. Real-time quantitative RT-PCR was used to confirm the B cell genes.
Results: Found out the genes associated with B cell in cGVHD patients
reached statistical significance after a false discovery rate (FDR) correction
was applied to the data. Real-time quantitative RT-PCR was used to confirm
the B cell genes. 284 genes were found by microarrays between cGVHD
patients and patients without cGVHD, 5 genes (CDKN2A, SOX4, ZBTB32,
CD70, IL21R) associated with B cell. 800 genes were found by microarrays
between immune tolerance patients and patients without cGVHD, 3 genes
(NFAM1, CD27, BST1) associated with B cell. Real-time quantitative RT-PCR
confirmed significantly lower expression of CDKN2A in cGVHD relative to with-
out cGVHD patients (P=0.001). Significantly higher expression of CD27 and
lower expression of BST1 in immune tolerance relative to without cGVHD
patients (P=0.038, P=0.022).
Summary/Conclusions: The preliminary results indicated that CDKN2A gene
had significantly lower expression in cGVHD relative to without cGVHD
patients, CD27 gene had significantly higher expression and BST1 gene had
significantly lower expression lower expression in immune tolerance patients
relative to without cGVHD patients. The changes of these genes may be poten-
tial biomarkers for cGVHD and immune tolerance.
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MITOCHONDRIAL INHIBITION BY NICOTINAMIDE RIBOSIDE POTENTLY
STIMULATES HEMATOPOIESIS AFTER TRANSPLANTATION VIA THE
MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE
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L Tauzin3, E Pirinen1, D Vanhecke2, G Coukos1, J Auwerx1, M Lutolf1,
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1Institute of Bioengineering, Ecole Polytechnique Federale de Lausanne, 2Lud-
wig Center for Cancer Research, UNIL, 3Flow Cytometry Core Facility, Ecole
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Background: The slow nature of blood regeneration from hematopoietic stem
cells (HSCs) severely compromises the survival of patients upon primary bone
marrow failure, intensive ablative chemotherapy or HSC transplantation. Cur-
rent strategies to accelerate HSC regeneration and shorten the time of bone
marrow aplasia, including treatment with granulocyte colony stimulating factor
(G-CSF), are insufficient to avoid severe and often lethal infections during the
time of aplasia. Indeed, HSCs are predominantly quiescent during homeostasis.
The proliferative stress imposed on HSCs to reconstitute the full hematopoietic
system in the 4-6 weeks following HSC transplantation entails activation of
oxidative phosphorylation within mitochondria, interfering with pyruvate dehy-
drogenase kinase (PDK) and hypoxia-inducible factor (HIFa)-driven metabolic
checkpoints of HSC self-renewal and thus induces premature HSC aging. In
turn, activation of the mitochondrial unfolded protein response (UPRmt)
enhances mitochondrial health and prolongs lifespan from C. elegans to mice,
mostly due to the activation of the Sirtuins and their convergence into DAF-
16/FOXO3 signaling, also shown to regulate HSCs maintenance.
Aims: We set to test whether mitochondrial inhibition and/or activation of
UPRmt in HSCs would lead to accelerated recovery from aplasia after bone
marrow transplantation in mice.
Methods: Wildtype C57BL/6 mice or NOD-SCID mice reconstituted with
human CD34+ cells were treated with Nicotinamide Riboside for 7 days during
homeostasis, and from day -7 to 35 in the context of HSC transplantation.
Results: Here we show that distinct hematopoietic progenitor compartments
show specific increases in mitochondrial activity during commitment, and that
mitochondrial activity is a functional predictor of HSC engraftment both in vivo
and in vitro. We have shown that modulating mitochondrial potential through
the use of uncouplers can displace the long-term (LT)/short-term (ST) -HSC
equilibrium in vivo by maintaining LT-HSCs while increasing the ST-HSC pool.
Dietary supplementation in NAD+-boosting agent Nicotinamide Riboside (NR)
inhibits mitochondrial activity via UPRmt and activation of autophagy within
long-term HSCs, resulting in the expansion of functional short-term HSCs with-
out HSC exhaustion in mice. Indeed, NR treatment dramatically improves sur-
vival and accelerates blood recovery after murine HSC transplantation, also
increasing the production of human blood cells in humanized mice.
Summary/Conclusions: Our work establishes a novel link between UPRmt
and autophagy in self-renewing HSCs, demonstrates for the first time an effect
of NAD+ boosting strategies at the level of the most primitive blood stem cells,
and unveils the potential of NR to improve the outcome of patients suffering
from bone marrow insufficiency.
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MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION
AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS
M Hazenberg1,*, V van Hoeven1, M Munneke1, A Cornelissen2, S Omar1,
M Spruit1, J Bernink3, H Spits3, C Voermans2
1Hematology, Academic Medical Center, 2Sanquin, 3Academic Medical Center,
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Background: Graft-versus-host disease (GvHD) remains a challenging com-
plication after allogeneic hematopoietic stem cell transplantation (HSCT). Mes-
enchymal stromal cells (MSCs) are increasingly applied to treat steroid-refrac-
tory GvHD. The therapeutic effect of MSCs is mainly ascribed to their ability to
suppress the proliferation of (alloreactive) lymphocytes and to enhance the tis-
sue repair activity of endothelial cells, fibroblasts, and epithelial cells. However,
only about half of the GvHD patients actually respond to MSC therapy, and
which determinants are related to MSC responsiveness remains to be eluci-
dated. We recently found an inverse association between the proportion of cir-
culating, activated type 3 innate lymphoid cells (ILC3s) before allogeneic HSCT
and susceptibility to GvHD development, which may be related to the ability of
ILC3s to produce tissue-protective interleukin 22 (IL-22).
Aims: To investigate the potential interaction between MSCs and ILC3s in
vitro. In particular we aimed to test whether MSCs can induce ILC3s to produce
the tissue protective cytokine IL-22.
Methods: ILC3s isolated from human tonsils were CellTrace-labeled and co-
cultured with bone-marrow derived MSCs for 5 days in the presence of IL-2.
Following co-culture, we determined ILC3 proliferation and cytokine production,
and analyzed surface-marker expression on MSCs by flow cytometry.
Results: Co-culture with MSCs significantly enhanced the proliferation of ILC3s
and resulted in an increased production of IL-22. ILC3s proliferated slightly
better in the presence of MSC culture supernatant compared to IL-2 only, and
addition of IL-7 blocking antibodies to MSC-ILC3 co-cultures had an inhibitory
effect on ILC3 proliferation in MSC-ILC3 co-cultures. These findings suggest
that the MSC-driven stimulation was at least partly mediated via IL-7. In tran-
swell experiments, however, proliferation of ILC3s was significantly reduced
when ILC3s and MSCs were cultured in separate compartments, showing that
cell-cell proximity or cell-cell contact is important for the stimulation of ILC3s
by MSCs. Reciprocally, ILC3s also influenced the MSCs, as ICAM1 and
VCAM1 expression was upregulated in co-cultures. Addition of blocking anti-
bodies against ICAM1, VCAM1, or the integrin subunits these adhesion mole-
cules bind to, did not affect the proliferation of ILC3s. 
Summary/Conclusions: We here show that MSCs can interact with ILC3s in
vitro, resulting in enhanced proliferation and cytokine production of ILC3s.
These results suggest that MSCs may have a dual mechanism by which they
contribute to the control of GvHD: (1) by inhibiting the proliferation of (allore-
active) T lymphocytes and NK cells, and (2) by promoting expansion and IL-
22 production of tissue-protective ILC3s.
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GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION
INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS
L Xuan1,*, X Wu2, L Gao1, Z Fan1, Z Jin2, X Wang2, Y Li2, Q Liu1
1Department of Hematology, Nanfang Hospital, Southern Medical University,
2Institute of Hematology, Medical College, Jinan University, Guangzhou, China
Background: The immune modulatory effect of granulocyte colony-stimulating
factor (G-CSF) on T cells resulted in an unexpected low incidence of graft-ver-
sus-host disease (GVHD) in allogeneic peripheral blood stem cell transplanta-
tion. Our previous studies demonstrated that G-CSF mobilization influenced
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the distribution and clonality of TRGV and TRDV repertoire (T cell receptors of
γδ T cells). Regulatory γδ T cells (γδ Tregs), which express Foxp3 and primarily
belong to CD27+CD25high phenotype, are a novel subset of cells with immuno-
suppressive function. However, whether G-CSF mobilization could influence
the expression and immunosuppressive function of γδ Tregs remains unknown.
Aims: To explore the effect of G-CSF mobilization on γδ Tregs, the expression
and immunosuppressive function of γδ Tregs before and after G-CSF mobi-
lization were compared.
Methods: Peripheral blood γδ+ T cells were sorted by magnetic activated cell-
sorting (MACS) from 10 donors before and after G-CSF mobilization, respec-
tively. MACS-sorted γδ T cells were used as effector cells in the carboxylﬂuores-
cein diacetate succinimidyl ester (CFSE) assays and cell immunophenotyping
was analyzed by flow cytometry. Autologous CD4+ T cells were puriﬁed by
MACS, labeled with CFSE, used as responder cells, and finally co-cultured
with effector cells. After 5 d incubation, cells were harvested and analyzed for
ﬂow cytometry by gating on the CFSE-labeled cells. The percentages of divided
responder T cells before and after G-CSF mobilization were compared.
Results: Compared with that before mobilization, the proportions of Foxp3+γδ
T, Foxp3+ Vδ1 T and Foxp3+ Vδ2 T cells were significantly increased in sorted
γδ T cells after G-CSF mobilization (P=0.035, P=0.017 and P=0.004). The pro-
portions of CD27+γδ T, CD27+Vδ1 T and CD27+Vδ2 T cells were also signifi-
cantly increased in sorted γδ T cells after G-CSF mobilization (P=0.035,
P=0.026, P=0.037). The proportions of CD25+γδ T, CD25+ Vδ1 T and CD25+Vδ2
T cells were similar in sorted γδ T cells before and after mobilization (P=0.252,
P=0.126, P=0.237). We then compared the inhibitory effect of sorted γδ T cells
before and after G-CSF mobilization on the proliferation of autologous CD4+ T
cells. We found that MACS-sorted γδ T cells before and after G-CSF mobilization
both exerted certain suppression on proliferation, whereas γδ T cells after G-
CSF mobilization had a more significant suppressive effect on CD4+ T cells than
γδ T cells before mobilization (P=0.002).
Summary/Conclusions: G-CSF mobilization could increase the proportions
of regulatory T cells in sorted γδ T cells, thus having a higher suppressive effect
on CD4+ T cells.
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PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL
REGENERATION AFTER THEIR COTRANSPLANTATION WITH
HEMATOPOIETIC STEM CELLS
S Kuci*, Z Kuci, B Eising, K Michel, H Kreyenberg, T Klingebiel, P Bader
University Hospital Frankfurt Department for Children and Adolescents, Frank-
furt am Main, Germany
Background: Mesenchymal stromal cells (MSCs) are known to support
hematopoiesis both in vitro and in vivo. However, there is scant evidence on
the effect of preactivated MSCs with inflammatory cytokines on the engraftment
of hematopoietic stem/progenitor cells. 
Aims: The aim of this study was therefore to investigate whether preactivation
(“licensing”) of subsets of MSCs with inflammatory cytokines (IFN-gamma, TNF-
alpha) may affect regeneration of T-cells after hematopoietic cell transplantation.
Methods: MSCs were generated from positively selected CD271+ bone marrow
mononuclear cells (CD271-MSCs) by using the MSC Research Tool Box–
CD271 (LNGFR)-APC (Miltenyi Biotec GmbH), according to manufacturer’s
instructions. CD34+ hematopoietic stem/progenitor cells (HSCs) were cotrans-
planted with either resting or preactivated (“licensed”) CD271-MSCs with IFN-
γ or TNF-α in immunodeficient NSG-mice.
Results: Flow cytometric analysis of peripheral blood (PB) of NSG-mice 4
weeks after cotransplantation of CD34+ cells with CD271-MSCs demonstrated
that CD34+ HSCs differentiated in B and NK-cells, but not in T-cells. However,
FACS analysis of PB at week 14, showed a 6.6-fold increase of T-cells in the
cotransplanted group versus the group transplanted with CD34+ HSCs only
(control group). Moreover, cotransplanted mice with “licensed” CD271-MSCs
with TNF-α or IFN-γ showed a significantly increased number of T-cells (23- or
30-fold, respectively) compared to control group. All regenerated T-cells (helper
and cytotoxic) had a naïve (CD3+CD4+CD45RA+CCR7+ or CD3+CD8+
CD45RA+CCR7+) but not an effector phenotype. Both, resting and preactivated
CD271-MSCs normalized the CD4/CD8 ratio from 0.8 (control group) to 1.3.
TREC-analysis of the thymus cells revealed no difference between cotrans-
planted groups and control. However, Vβ spectratyping (23 Vβ-subgroups) of
spleen cells showed an increased T cell repertoire complexity (Vß2, Vß3, Vß4,
Vß9, Vß17 und Vß21) in the group cotransplanted with IFN-γ preactivated
CD271-MSCs and CD34+HSCs. T-cell regeneration was also confirmed by
immunohistochemistry of the spleen.
Summary/Conclusions: Cotransplantation of preactivated CD271-MSCs with
IFN-γ appears to be a novel strategy to improve T-cell regeneration and devel-
opment of T-cell receptor repertoire after hematopoietic transplantation.
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EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT 
ASSOCIATED THROMBOTIC MICROANGIOPATHY
E Gavriilaki1,2,*, P Imus3, X Yuan2, A Baines2, R Jones3, R Brodsky2
1Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece, 2Division of Hematology, Department of Medicine, 3Department of
Oncology, Johns Hopkins University School of Medicine, Baltimore, United States
Background: Transplant-associated thrombotic microangiopathy (taTMA) is a
devastating complication occurring in 10-39% of patients undergoing
hematopoietic cell transplantation (HCT) with a high mortality rate. However,
our understanding of the pathophysiology which is strongly related to diagnosis
and treatment options is limited. Recent evidence has linked taTMA with atypical
hemolytic uremic syndrome (aHUS), a disease of excessive activation of the
alternative pathway of complement (APC) that is successfully treated by termi-
nal complement inhibition with eculizumab. We have recently developed the
modified Ham test as a functional assay that can reliably distinguish APC acti-
vation observed in aHUS from other TMAs.
Aims: We aimed firstly to detect evidence of increased APC activation by the
modified Ham test in taTMA and secondly to test the in vitro ability of eculizumab
to inhibit APC activation in taTMA.
Methods: Patients were enrolled in a prospective fashion from December 2014
to April 2015 as all patients admitted to our service with taTMA according to
clinical judgement, in keeping with the current diagnostic criteria (BMT-CTN or
IWG). Patients with graft-versus-host-disease / GVHD and transplanted patients
with neither complication / controls were enrolled during the same timeframe.
APC activation was detected in the modified Ham test, a cell proliferation assay
that measures complement-mediated cell killing caused by patient serum, and
was compared to a previously described marker of complement activation,
serum C5b-9 levels. Eculizumab containing serum (ECU) was collected from
a patient with paroxysmal nocturnal hemoglobinuria (PNH) within 60 minutes
after the infusion and used to test complement blockade by eculizumab in the
modified Ham test.
Results: We studied 5 patients with taTMA, 4 patients with GVHD and 6 trans-
planted patients with neither complication. We first measured C5b-9 levels as
a biomarker of terminal complement activation. There was no difference in
serum C5b-9 levels among patients with taTMA, patients with GVHD and con-
trols (57.8±28.1, 49.2±25.5 and 53.4±31.9 ng/ml respectively, p=0.913). We
next utilized the modified Ham test, which detected increased APC activation
in taTMA. Serum from patients with taTMA caused significantly increased com-
plement-mediated killing compared to patients with GVHD and controls (Figure
1). As previously described, increased complement activation was also found
in taTMA patients while on eculizumab (grey symbols in Figure 1). In the ROC
curve analysis, a cutoff of 23.5% identified taTMA with 100% sensitivity and
specificity in this small cohort. Then, we evaluated the efficacy of complement
inhibition by eculizumab in the modified Ham test. Mixing eculizumab serum
(ECU) with taTMA sera demonstrated a dose-killing relationship that was con-
sistent across the three patients.
Summary/Conclusions: Our results confirm recent suggestions that comple-
ment dysregulation is involved in the pathophysiology of taTMA. If confirmed
in larger series, the modified Ham test may also form the basis for therapeutic
trials based upon complement inhibition.
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FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL
DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD
AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY
H Rafii1,2,*, F Bernaudin3, M Cavazzana4, V Vanneaux5, A Cras5, V Gauthereau6,
A Stanislas4, H Rouard7, C Ferry8, C Kenzey1,2, B Cappelli2, A Ruggeri1,2,
M De Montalembert9, C Rieux10, M Kuentz11, R Girot12, J Larghero5,
E Gluckman1,2
1Eurocord - Monacord, Hôpital Saint-Louis, AP-HP, Paris, France, 2Eurocord -
Monacord, Centre Scientifique de Monaco, Monaco, Monaco, 3Centre de
référence de la Drépanocytose, Hôpital Intercommunal de Créteil, AP-HP,
Creteil, 4Département de Biothérapie, Hôpital Necker, AP-HP, 5Unité de
Thérapie Cellulaire, Centre d’Investigation Clinique en Biothérapies, Hôpital
Saint-Louis, AP-HP, 6Fédération Parisienne Pour le Dépistage et la Prévention
des Handicaps de l’Enfant (FPDPHE), Hôpital Necker, AP-HP, Paris, 7Unité́
d’Ingénierie et de Thérapie Cellulaire, EFS Ile de France, Créteil, 8Service de
Greffe de Moelle, Hôpital Saint-Louis, AP-HP, 9Service de Pédiatrie, Hôpital
Necker, AP-HP, Paris, 10Unité d’Hémovigilance, site Henri-Mondor, EFS Ile de
France, 11Service d’Hématologie, Hôpital Henri-Mondor, AP-HP, Créteil, 12Ser-
vice d’hématologie biologique, Hôpital Tenon, AP-HP, Paris, France
Background: Cord blood transplantation (CBT) from a related family member
is an effective therapy for patients with Sickle Cell Disease (SCD) resulting in
encouraging outcomes with similar or superior survival to adult donor transplant.
Efforts to implement family-directed umbilical cord blood (UCB) banking have
been developed in the past two decades for siblings requiring stem cell trans-
plantation (SCT).
Aims: Public umbilical cord blood banks are faced with the challenge regarding
the units to be stored or to be discarded or used for other endeavors such as
research. To this end, we report our 20-year experience of family-directed UCB
banking for SCD and review the characteristics of the UCB units collected
between 1995 and 2014.
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Methods: Families were eligible if they had a child with SCD, and expecting the
birth of a sibling. Participation was voluntary and free of charge. All mothers
underwent a panel of serologic blood donor screening assays. UCB units were
collected in remote sites, cryopreserved and stored in a single bank. UCB testing
included viral serology, bacterial cultures and cell counts. HLA typing on the UCB
were not routinely performed unless requested by the transplant physician.
Results: 189 families from 27 different centers were enrolled. 17 (10%) families
had >1 UCB unit stored, due to multiple pregnancies. Potential recipients had
a median age of 6 years (range 11 months - 12 years) at time of UCB harvest.
14 families had >1 affected child. A total of 210 UCB units were collected from
189 mothers. All UCBs were negative for HIV and 64 UCBs (30%) had positive
anti-HBs and/or anti-HBc with negative HBsAg. Median UCB volume at cryop-
reservation was 92.5 mL (range 33-194).Median total nucleated cell (TNC)
count at cryopreservation was 9.2 x108 (range 1-75.3). The median collected
CD34+ and CFU-GM cell counts were 4.5 x106 (range 0.18-61) and 4.5 x105
(range 0.14-67) respectively. The hemoglobin status of the UCB units was
assessed through the neonatal screening. Data were available for 179 UCBs
(85%) including 64 (30%) hemoglobin AA, 85 (40%) hemoglobin AS, 25 (14%)
hemoglobin SS, 3 (<1%) hemoglobin AC, 1 S-beta+-thal and 1 beta-thal. Eight
(4%) out of the 210 banked UCB units were released for CBT with a median
TNC count of 7.0x108 (3.0x108 - 21.8x108). Five patients were transplanted
using a single UCB and 3 patients with the sibling’s bone marrow and UCB.
Post-transplant data were available for 6 patients: all of them had stable engraft-
ment of donor cells and are alive, free of SCD.
Summary/Conclusions: Our data showed that family-directed UCB banking is
feasible and yields good quality cord blood units for sibling transplantation. How-
ever, the number of CBT performed is disappointing despite the good results of
sibling transplantation in SCD. Therefore, we must think about the cost-effec-
tiveness of this approach when HLA identical sibling donor is available.
Stem cell transplantation - Clinical 1
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CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1
AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND
REDUCED INTENSITY CONDITIONING
A Szabo1,*, A Dinmohamed1,2,3, B van der Holt4, J Versluis1, M de Groot5,
S Zeerleder6, H Schouten7, M Schaap8, E Meijer9, E Petersen10,
F Falkenburg11, A Rijneveld1, J Cornelissen1
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tute, Rotterdam, 5Hematology, University Medical Center Groningen, Gronin-
gen, 6Hematology, Academic Medical Center, Amsterdam, 7Hematology, Uni-
versity Hospital Maastricht, Maastricht, 8Radboudumc, Nijmegen, 9Hematology,
VU University Medical Center, Amsterdam, 10Hematology, University Medical
Center, Utrecht, 11Hematology, Leiden University Medical Center, Leiden,
Netherlands
Background: While survival in ALL patients<40 years has improved with the
introduction of pediatric regimens, outcome in patients ≥40 years is still disap-
pointing. Complete remission (CR1) rates upon induction therapy estimate 70-
80%, but inferior survival is caused by both enhanced relapse and a higher
incidence of treatment-related mortality (TRM). Reduced intensity conditioning
(RIC) allogeneic stem cell transplantation (alloSCT) was developed as a less
toxic but effective type of consolidation therapy and applied as from 2000 in
several centers in the Netherlands, while some centers continued to apply
myeloablative (MAB) alloSCT.
Aims: We set out to retrospectively compare RIC alloSCT and MAB alloSCT
as consolidation therapies in patients with ALL aged 40-69 years in CR1.
Methods: 151 patients (age: 40-67 years) with ALL in CR1 receiving consoli-
dation by alloSCT between 2001 and 2013 were included. Data were provided
by the Dutch Stem Cell Transplantation Working Group of HOVON. The median
follow up was 68 months for MAB alloSCT (n=62) and 56 months for RIC
alloSCT recipients (n=89). MAB was predominantly applied by the combination
of total body irradiation (TBI) and cyclophosphamide, while RIC by the Seattle
regimen (fludarabin and 2 Gy TBI). Univariable and multivariable Cox-regres-
sion analysis were performed with endpoints overall survival (OS), relapse free
survival (RFS), TRM and relapse. Cox-regression was adjusted for age, white
blood cell count at diagnosis, cytogenetic risk, interval from diagnosis to
alloSCT, year of treatment, donor type.
Results: Statistically significant differences between RIC and MAB recipients
were found with respect to age (median 55 vs 47 years, p<0.001) and year
of transplantation (median 2009 vs 2006, p=0.001). Although not statistically
significant, RIC alloSCT patients had higher EBMT scores (score 3-4: 62%
vs 45%, p=0.105) and more alternative donors were used in RIC alloSCT
patients (48% vs 35%, p=0.071). Underlying ALL risk parameters did not
differ between either type of alloSCT. The relapse rate at 5 years was signif-
icantly higher after RIC alloSCT as compared to MAB alloSCT (47% vs 20%,
p=0.001, Figure). TRM was predominantly affected by age and interval from
diagnosis to transplantation. By univariate analysis, improved OS was found
in recipients of MAB alloSCT as compared to RIC alloSCT, which appeared
significantly affected by age and type of conditioning. Multivariable analysis
showed again that RIC alloSCT was associated with a significantly higher
relapse rate (HR: 3.47 [95% CI: 1.70-7.11] p=0.001) and significant reduction
of TRM (HR: 0.42 [95% CI: 0.18-0.97] p=0.043). These opposing effects,
however, resulted in a non-significant difference between RIC and MAB as
regards RFS (HR: 1.47 [95% CI: 0.88-2.47] p=0.144) and OS (HR: 1.27 [95%
CI: 0.74-2.19] p=0.392).
Figure 1.
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Summary/Conclusions: Recipients of RIC and MAB conditioning appeared
to differ for a number of variables, which hampered an unbiased comparison.
Nevertheless, RIC alloSCT was associated with a significantly higher relapse
rate, while these patients did not exhibit more high-risk ALL features. Due to
less TRM, that difference did not translate into a significant difference in RFS
and OS. Collectively, these results suggest that MAB alloSCT may provide a
more effective type of consolidation therapy for reduction of relapse and that
RIC alloSCT may especially be applied in patients at higher risk for TRM
because of age, EBMT score and/or comorbidities.
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RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN
LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE
AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT
RESPONSE TO SALVAGE CHEMOTHERAPY?
N Elmusharaf1,*, MH Iqbal1, V Trainer2, AJ Mahdi1, D Davies1, P Fielding2,
S Al-Ismail3, W Ingram1, K Wilson1
1Haematology, 2Radiology, University Hospital of Wales, Cardiff, 3Haematology,
Singleton Hospital, Swansea, United Kingdom
Background: High dose chemotherapy and autologous stem cell transplanta-
tion (ASCT) have been shown to increase overall (OS) and event-free survival
(EFS) in patients with chemo-sensitive relapsed or refractory high grade B cell
Non-Hodgkin lymphoma (NHL) as assessed by computerized tomography (CT).
Positron Emission Tomography (PET) scanning, when compared to CT, has
been shown to upstage disease both at diagnosis and assessment of treatment
response and can help to predict outcome. However, the positive predictive
value for end of treatment PET scans varies widely, especially for patients treat-
ed with rituximab. It is therefore unclear whether CT responders who have
residual PET positive lesions will benefit from ASCT since this has not been
evaluated in a randomized controlled trial. This question is important since his-
torically (prior to PET) these patients will do poorly when treated with conven-
tional dose chemotherapy alone. We therefore assessed whether ongoing PET
positivity adversely affected outcome in chemo-sensitive patients with high
grade B cell NHL who received ASCT by the South Wales Blood and Marrow
Transplant (SWBMT) Programme. 
Aims: To compare outcome in patients who had ASCT for chemo-sensitive
relapsed/refractory high grade B cell NHL (as defined by CT) according to the
presence or absence of residual PET positive lesions.
Methods: The prospectively maintained database of the SWBMT programme
which serves 77% of the Welsh population (mid-2014 census estimate) was
interrogated to identify patients with high grade B cell NHL who received ASCT
between January 1999 and December 2014 to allow a minimum of 12 months
follow up. All patients with a pre-ASCT PET were assessed by the Deauville
criteria to define their response with patients being considered to have achieved
a complete metabolic response (CMR) if lesions demonstrated uptake of grade
3 or less. The data was analyzed according to patients achieving CMR, less
than CMR or no prior PET.
Table 1.
Results: A total of 101 patients received ASCT for chemo-sensitive refractory
or relapsed high grade B cell NHL between 1999 and 2014. Patient character-
istics are summarised in the Table. The median age was 54 (range 17-69) years
and there was an overall male predominance (62%). The most common sub-
type was DLBCL (76%) and the majority had stage IV disease. Two-thirds of
patients had primary refractory disease and a median of 3 (range 1-7) lines of
therapy were administered prior to ASCT. Forty-two of 61 (69%) patients with
no PET received rituximab compared with 37/40 (93%) of the PET group. Of
the 40 patients with a pre-ASCT PET, 22 had achieved a CMR (PET NEG) and
18 had residual lesions (PET POS). Relapse occurred in 28% of the No PET
and PET POS groups compared to 23% in the PET NEG group. With a median
follow-up of 5.0 (1.5-15.2) years 62 (61%) of patients are alive: No PET 52% v
PET NEG 73% v PET POS 78%. 
Summary/Conclusions: This study with relatively long follow-up beyond the
typical relapse interval of 2 years, shows that residual PET positivity did not
adversely affect outcome in chemo-sensitive relapsed/refractory patients under-
going ASCT for high grade B cell NHL. This may be explained by the fact that
the majority of the PET group (93%) received rituximab, a known association
with false PET positivity. In addition, patients with residual PET lesions did not
routinely undergo biopsy to evaluate the significance of the lesions. The older
No PET group which used CT to assess response, experienced survival similar
to the pivotal Parma Trial (Philips et al, NEJM 1995) with 52% being alive at
7.8 years compared to 53% 5 year survival. In the more recently treated PET
POS group, which is the current equivalent of the No PET group, survival had
improved to 78% at 3.8 years follow-up. Given the similarity in relapse rate,
this probably reflects improved supportive care. However, given that survival
was not inferior to the contemporaneous PET NEG group it is probably prema-
ture to exclude these patients from ASCT solely on the basis of residual PET
lesions. We suggest that patients with chemo-sensitive relapsed/refractory high
grade NHL should not be denied ASCT on the basis of residual PET lesions
and that randomized trials are needed to further address this question.
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MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE
GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
A Ganetsky1,*, LM Crisalli1, AP Huffman2, EP Acosta3, JK Mangan1, SM Luger1,
AW Loren1, EO Hexner1, NV Frey1, EA Stadtmauer1, JA Hoxie1,
RH Vonderheide1, DL Porter1, R Reshef2
1University of Pennsylvania, Philadelphia, 2Columbia University, New York,
3University of Alabama at Birmingham, Birmingham, United States
Background: We previously published favorable results with the use of mar-
aviroc (MVC), a CCR5 antagonist, as a prevention strategy against acute graft-
versus-host disease (GVHD) (Reshef et al. NEJM 2012). Various genetic and
physiologic factors affect the pharmacokinetic (PK) profile of MVC, which leads
to significant interpatient variability in MVC exposure. Whether variability in
MVC PK affects the protective activity of MVC against GVHD is unknown.
Aims: We sought to identify whether a relationship exists between MVC trough
concentrations and clinical outcomes in hematopoietic stem cell transplantation
(HCT) recipients.
Methods: We evaluated the associations between MVC trough concentrations
and clinical outcomes in a post hoc analysis combining data from two prospec-
tive clinical trials that tested the addition of MVC to tacrolimus/methotrexate in
67 patients (pts) undergoing their first allogeneic HCT at the University of Penn-
sylvania between 2009 and 2015. All pts received a uniform reduced-intensity
conditioning (RIC) regimen consisting of fludarabine (120mg/m2) and busulfan
(6.4mg/kg), followed by infusion of peripheral-blood stem cells. Most pts were
at high-risk for HCT-related complications given their age (median 62, range
21-74 years), donor source (matched unrelated 72%; single-antigen mismatch
unrelated 16%; matched related 12%), and HCT-comorbidity index (low 30%,
intermediate 34%, high 36%). The most common underlying diseases were
acute myeloid leukemia (55%) and myelodysplastic syndromes (18%). All pts
included in this PK analysis received MVC 300mg twice daily (BID) except for
4 pts in the first trial that received MVC 150mg BID as part of a dose-finding
phase. The primary endpoint was cumulative incidence (CI) of acute grade 2-
4 GVHD by day 180. Univariate analyses were performed using cumulative
incidence and Cox regression models. Multivariate models were constructed
using the backward elimination method.
Results: The median MVC trough concentrations (range) at days 0, 7, and 14
were 64.9 (11.7-315.7), 72.7 (7.9-555.0), and 142.0 (10.9-1064.0) ng/mL,
respectively. The day-180 CI (±SE) of acute grade 2-4 GVHD and acute grade
3-4 GVHD were 24.7±5.1% and 11.3±3.8%, respectively. Pts with a day 0 MVC
trough concentration ≤ median had a higher incidence of acute grade 2-4 GVHD
compared with pts > median (38.7±8.6% vs 6.1±4.2%; P=.001). In multivariate
analysis, day 0 MVC concentration remained an independent predictor of acute
grade 2-4 GVHD (HR 0.35; 0.13-0.95; P=.039), as shown in Figure 1. We also
observed a nonsignificant trend towards a higher incidence of acute grade 3-4
GVHD in pts with day 0 MVC trough concentrations ≤ median (12.2±5.9% vs
3±3%; P=.20). In addition, no pt (n=20) with day 0 MVC trough concentration
>100ng/mL developed GVHD by day 180. The CI of relapse at 1 year was
42.5±5.9%. Interestingly, pts with a day 0 MVC trough concentration ≤ median
had a higher relapse incidence (62.4±8.7% vs 21.7±7.4%; P=.001). Day 0 MVC
concentrations were not significant predictors of chronic GVHD or survival. No
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associations between clinical outcomes and MVC concentrations on day 7 or
14 were noted. We repeated the same analysis including only pts who received
MVC 300mg BID and observed similar results.
Figure 1.
Summary/Conclusions: Higher MVC concentrations on day 0 of RIC HCT
were associated with significantly reduced risk of both acute grade 2-4 GVHD
and relapse. These data highlight the importance of optimizing initial dosing of
MVC in RIC HCT recipients.
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HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS,
OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS
O Lopez Godino1,*, E Pérez López1, L López Corral1, R Pérez López2, S Alonso1,
M Cabrero1, J Labrador1, L Vázquez1, D Caballero1
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Background: Hyperacute graft versus host disease (haGVHD) is associated
with poor prognosis in the context of acute GVHD due to its severity and to its
worse response to steroids. Most reports include majority patients receiving
calcineurin inhibitors/MTX prophylaxis.
Aims: Analysis of patients with haGVHD vs patients who developed other
acute GVHD comparing clinical characteristics, outcomes, response to treat-
ment and risk factors in both groups, specially in those with tacrolimus/sirolimus
prophylaxis in our Unit.
Methods: We prospectively analysed 627 patients consecutively transplanted
in our Unit between 1995-2014 excluding paediatrics and 2ndallo-HSCT.
HaGVDH was defined as that occurring within 14 days after HSCT.
Table 1.
Results: 70 patients (11%) developed II-IV haGVHD, 264 (42%) other acute
II-IV GVHD (oaGVHD). Median of days to haGVHD and oaGVHD were +10
(4-14) and +35 (12-362) respectively. Patient’s characteristics are shown in
table 1. Differences between haGVHD and oaGVHD include a higher skin
involvement and a higher proportion skin III-IV grades in haGVHD: 75 vs 45%,
p=0,00 and 44% vs 18%, p=0,03 respectively. In multivariate analysis, risk fac-
tors associated with haGVHD include sex mismatch (p=0,004; OR 2,1; IC95%
1,02-4,4), conditioning regimen other than Fludarabina-Busulfan (p=0,00),
Tacrolimus-Sirolimus prophylaxis (p=0,001; OR 2,1; IC95% 1,4-3,4) and unre-
lated donor +/- mismatch (p=0,004, OR 3,2, IC95% 1,4-7,1), whereas only mis-
match unrelated donor was associated with a higher risk of oaGVHD (p=0,003,
OR 3,2, IC95% 1,4-7,1). Steroids resistance was similar in both groups
(haGVHD 23% vs 17% in oaGVHD). Factors influencing higher risk of steroid
resistance in the multivariate analysis were HLA mismatch (p=0,04; OR 5,9;
IC95% 1,05-33,7) and grade III-IV (p=0,004, OR 11,7, IC95% 2,2-62) in
haGVHD and grades III-IV (p=0,00, OR 21, IC95% 9,2-48) in the group of
oaGVHD. With a median follow-up of 38 months, OS and TRM for the whole
series is 57% and 19%. Comparing haGVHD vs oaGVHD, haGVHD hadn’t
impact neither in OS (56% vs 51%; p=0,5) and TRM (33% vs 25%; p=0,17).
While Tacrolimus/sirolimus prophylaxis was associated with a higher risk of
haGVHD, this scheme was also associated with a better OS in the global series
(p=0,002, HR 0,38, IC95% 0,2-0,7). Although we investigated the role of serum
immunosuppressive levels in this group, we failed to demonstrate that infrather-
apeutic levels had a role in the haGVHD development.
Summary/Conclusions: According to our centre experience, haGVHD is char-
acterized for a higher skin preference; it was not associated with a poorer out-
come neither with a higher steroid resistance as compared with oaGVHD;
althought tacrolimus/sirolimus is one of the risk factors to develop haGVHD,
this regimen is also associated with a better OS.
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REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS
PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA:
RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080)
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Background: For young patients with MCL, standard therapy comprises high
dose cytarabine based chemotherapy which is usually consolidated by autol-
ogous stem-cell transplantation (ASCT). Although the median overall survival
with this approach is impressive (>10 years in some series) no plateau is
observed, whereas at relapse, allogeneic transplantation can lead to long term
disease-free survival in some individuals. Up front allogeneic stem cell trans-
plantation is rarely used in this condition due to concerns over the associated
mortality and morbidity, however it is the treatment of choice following relapse.
Aims: This was a prospective study evaluating reduced induced conditioning
allogeneic transplantation (RIC allo) as part of first consolidation for patients
responding following front line chemotherapy. The primary endpoint was a pro-
gression free survival (PFS) improvement from 45% to 70%, (15/25 patients)
after 2 years. 
Methods: This study evaluated the role of RIC-Allo in first remission for MCL.
The induction chemotherapy adopted was at the physicians discretion but
patients required at least a partial response to be able to receive the transplant.
Eligible patients received a BEAM-C (BCNU, etoposide, Ara-C, melphalan and
alemtuzumab) conditioned sibling or unrelated donor allograft in first remission.
Donor lymphocyte infusions (DLI) were administered for persistent, mixed
chimerism or at relapse. 
Results: Twenty-five patients were recruited from 8 centres (January 2010 -
September 2013). The median age was 54 (34-70) and 22 (88%) were male.
Eleven (44%) were in CR and 14 (56%) PR at registration. Eleven (44%) donors
were siblings and 15 (56%) were unrelated. All 25 patients engrafted by day
100. Toxicity was as expected: grade 3-4 adverse events in 96%; the treatment
related mortality (TRM) rate was 8% (2/25). GvHD incidence was low, in keeping
with T cell depletion: acute GvHD (12%); chronic GVHD (24%). Fifteen patients
were alive and progression free at 2 years (with 2 more yet to reach this point).
The 2 year PFS estimate was 68% (95% CI: 46.1 - 82.5%). Of those alive and
in remission, 14/16 (88%) have reached full donor T-cell chimerism, 5 after DLI.
Summary/Conclusions: RIC-Allo is a feasible option for consolidation of first
remission in MCL. In this study, the target endpoint for PFS was achieved and
further exploration of RIC-Allo in patients identified to be at high risk of disease
progression with ASCT is warranted.
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F López Cadenas1,*, M Cabrero Calvo2, AA Martin López2, O López Godino2,
E Pérez López2, O Ferré Bermejo2, L García Martín2, J Labrador Gómez3,
110 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
F Ramos4, L Vázquez López1, L López corral1, M Díez-Campelo1,
MC Del Cañizo1, MD Caballero Barrigón1
1Department of Hematology, 2Department of Hematology, Hospital Clínico Uni-
versitario de Salamanca, Hospital Clínico Universitario De Salamanca (Sanidad
Castilla y León), Salamanca, 3Department of Hematology, Hospital Universitario
de Burgos, Burgos, 4Department of Hematology, Complejo Asistencial Univer-
sitario de León, León, Spain
Background: Allogenic hematopoietic stem cell transplant (HSCT) remains
the only curative treatment for high-risk hematological malignancies and post-
HSCT relapses confer a particularly bad prognosis. Optimal therapy in this sit-
uation keeps unclear; hypomethylating agents (HMA) such as 5-azacitidine
(5Aza) or decitabine (Dec) can be feasible therapy in this set of patients.
Aims: Analyze the outcome of patients receiving HMA for acute myeloid
leukemia (AML) or myelodysplastic syndromes (MDS) relapsing after HSCT.
Methods: From 355 AML/MDS patients who underwent HSCT in our institution
from November 1995 to December 2015, relapse occurred in 112 (32%), and
45 of them (40%) were treated with HMA. From the total of these patients, we
selected 40 patients with a follow-up period longer than 30 days and we ana-
lyzed them in terms of response rate (RR) and overall survival (OS).
Results: Median age was 54 years (25-71) and 19 (47%) were male. Diag-
noses were AML in 30 (75%) and MDS in 10 (25%), with high risk cytogenetic
in 43%. Peripheral blood was the stem cell source in 36 patients (90%) and
donor was related in 70%. Reduced-intensity conditioning was used in 75%.
Mean number of previous therapies was 2 (1-5); 5-azacitidine had been used
before HSCT in 15 (37%), with 87% of patients responding. Patients relapsed
after a median of 98 days (20-524), 56% with <10% blast, 22% with 10-20%
blast and 22% with >20% blast. 5Aza was the HMA used in 39 patients (97%)
and Dec in 1. Median number of HMA courses was 3 (1-19). Together with this
strategy, the immune effect was enhanced in 38 patients (95%), tapering
immunosuppressive treatment in 30 (75%) and with donor lymphocyte infusion
(DLI) in 8 (21%). Chronic or acute graft versus host disease (GVHD) occurred
in 21 patients (52%). Overall response rate (ORR) was 60% (n=24), including
19 CR (47%) (17 of them with negative minimal residual disease (MRD) by
flow cytometry). Median time to best response was 91 days (21-209) and it
was reached after a median of 2 cycles (1-8). Thirteen out of 24 responding
patients (54%) progressed or relapsed after a median of 214 days (84-729).
With a median follow up of 174 days (34-1779) from time of relapse, estimated
OS was 55% at 6 months and 37% at 1 year post-relapse. Variables with sig-
nificant influence on OS in univariate Kaplan-Meier analysis were: response to
HMA [6 months OS: 82.5% for those responding vs 14% for non-responders;
p=0.000], blast percentage at time of relapse considering >10% [6m OS: 48%
vs 64%; p=0.05] and >20% blast [29% vs 65%; p=0.0014], developing GVHD
after relapse [6m OS: 71% vs 36%; p=0.015]. Early relapses considered as
<120 days after HCST was also associated with a better OS [6m OS: 62% vs
52%; p=0.078] although did not achieved statistical significance in univariate
analysis. In a Cox multivariate regression model, all these variables (response
to HMA, tumor burden at relapse, development of GVHD and early vs late
relapse) showed to be independent factors with influence in OS.
Summary/Conclusions: 5-Azacitidine is an effective treatment for AML/MDS
patients who relapse after HCST, especially for those with lower tumor burden
and late relapses. In addiction enhancement of graft versus tumor effect togeth-
er with HMA is a capital strategy to achieve longer OS.
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IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL
TRANSPLANTATION WHEN COMPARED TO A PROPENSITY
SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A
MULTICENTER STUDY
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Background: The effects of haploidentical(H) rhG-CSF-mobilized blood(B)
and marrow(M) transplantation (HBMT) on hematological malignances are well
established. Previous prospective single-center studies have demonstrated
better survival after HBMT vs haploidentical rhG-CSF-mobilized peripheral
blood stem cells transplantation (HPBSCT) for acute leukemia (AL) not in remis-
sion (NR) or in more than second complete remission (>CR2).
Aims: The aim of this study was to test the hypothesis that HBMT would still
be a superior method for patients with AL, multiple myeloma (MM), and Non-
Hodgkin lymphomas(NHL) in CR1/CR2 and patients with chronic myeloid
leukaemia in first and second chronic phase lacking a matched donor as com-
pared to HPBSCT.
Methods: We designed a propensity score method based multicenter study.
Results: Hematopoietic recovery, acute graft-versus-host disease (aGVHD),
chronic GVHD was comparable between HBMT group(n=168) and HPBSCT
group (n=42). No significant differences were found in the non-relapse mortality
(20.17%±3.58% and 27.24%±7.16%, P=0.18) rates and relapse rates
(19.96%±3.72% and 28.49%±8.25%, P=0.32) between HBMT group and HPB-
SCT group. HBMT recipients had better overall survival (65.0%±4.2% and
54.2%±8.3%, P=0.037) and disease free survival (59.9%±4.6% and
44.3%±8.7%, P=0.051). Multivariate analysis showed that HPBSCT was asso-
ciated with poorer DFS (HR(95%CI), 1.639(0.995-2.699), P=0.052).
Summary/Conclusions: Our comparisons showed that HBMT was superior
compared to HPBSCT as postremission treatment for patients lacking an iden-
tical donor.
P336
TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A
COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION
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Background: Chronic Graft Versus Host Disease (cGVHD) still has a large
impact on morbidity and mortality after allogeneic hematopoietic stem cell trans-
plantation (HSCT). Affected patients require long term use of immunosuppres-
sive drugs, mainly corticosteroids, which lead to development of severe side
effects. Therapeutic approaches for cGVHD are limited. Generally recommend-
ed first line therapy consists of glucocorticoid therapy combined with a cal-
cineurin inhibitor. Options for second line therapy are numerous but no con-
sensus on the most favourable choice of agents has been reached.
Aims: Both monotherapy with rituximab and monotherapy with tyrosine kinase
inhibitors have shown to be effective in reducing cGVHD symptoms. We aimed to
test whether the sequential therapy of the anti CD20 antibody rituximab followed by
a 6 month treatment period with the tyrosine kinase inhibitor nilotinib is a good treat-
ment strategy for patients with sclerotic cGVHD (EudraCT nr 2008-004125-42).
Methods: We treated patients with sclerotic cGVHD with 4 infusions of ritux-
imab (375mg/m2 i.v. once weekly) followed by six months of nilotinib (start
dose 300mg b.i.d.). Patients were followed up monthly for 13 months.
Results: We included 29 patients, 4 patients went offstudy, 13 patients have
currently completed the follow up. Of these 13 patients, 1 patient reached a
complete response, 8 patients showed a partial response and 4 patients
remained in stable disease. Moreover, 2 out of 5 patients who suffered from
severe ulcerations at the start of the study had a complete resolution of ulcers
at the end of the treatment period. There is a significant decrease in cGVHD
affected body surface area (Figure 1). Patients with a (partial) response also
show a decrease in self attributed severity of cGVHD and their immunosup-
pressive drugs could be tapered. Sixty percent of responding patients could
taper >50% of prednisolone dose.
Figure 1.
Summary/Conclusions: The sequential therapy of B-cell depletion and tyro-
sine kinase inhibition provides a new and interesting alternative treatment option
for this difficult and heavily pretreated patient category. Approximately 70% of
patients achieve a (partial) response that results in a significant reduction in
use of corticosteroids.
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Background: Acute graft-versus-host disease (aGVHD) is a major complica-
tion of allogeneic hematopoietic cell transplantation (HCT), and glucocorticoids
are typically used as first-line treatment.
Aims: The aim of our study was to evaluate the effect of ECP +/- steroid therapy
in order to reduce the incidence of infections and toxicity.
Methods: From December 2010 to November 2015, 47 of 179 pts (26%), were
diagnosed with aGVHD grade ≥2 following alloSCT and 33 (70%) pts were
treated with ECP +/- steroid as first-line therapy. 8 (25%) pts were treated with
ECP only, 24 (75%) pts with ECP + steroid 1 or 2 mg/kg/day, with a total of 32
pts evaluated for aGVHD response. Conditioning regimen was myeloablative
(MAC) n=7, nonmyeloblative (NMA) n=14 or reduced-intensity (RIC) n=11.
Acute GVHD diagnosis was performed using Keystone criteria and scored by
Seattle and IBMTR criteria. ECP was performed using the offline technique.
ECP was started as soon as possible with a treatment schedule consisted of
4 rounds of two procedures per week, 3 rounds of two procedures every other
week and finally two procedures every month until clinical improvement and/or
immunosuppressive therapy (IST) tapering.
Results: The median follow-up time was 20 (range: 5-60) months. The median
age was 51 (20-71). 17 pts were affected by lymphoma, 8 by AML, 3 by MM, 2
by ALL, 1 by CLL and 1 by MDS. Donors were: haploidentical (n=21), HLA-
identical (n=5), matched unrelated (n=5) and cord blood (n=1). Stem cell source
was: peripheral blood (PBSC, n=17) and bone marrow (BM, n=14). aGVHD
was diagnosed after a median time of 39 days (13-150) from alloSCT. aGVHD
grade was 2 in 28 (88%), 3 in 2 (6%) and 4 in 2 (6%) pts. Visceral involvement
was reported in 5 (15%) pts: gut (n=4) and liver (n=1). ECP was started after a
median of 4 (0-30) days from aGVHD diagnosis. The median duration of steroid
therapy was 29 days (3-104) and every patient underwent a median of 19 (2-
83) ECP procedures, during a median time of 6 months. At 30 days from GVHD
diagnosis, 21 (66%) pts achieved complete remission and 6 (19%) pts partial
remission, with an overall response rate of 85%. At univariate analysis, we found
a trend towards higher risk of GVHD progression for pts receiving PBSC and
with visceral involvement (Table 1). Among responders, 6 (22%) pts had aGVHD
relapse during steroid tapering or discontinuation. Overall, not responders
patients were 11 (34%), and 10 pts received second-line therapy (1 pt not includ-
ed for early death). From GVDH diagnosis, 17 (53%) had cytomegalovirus reac-
tivation, 12 (38%) had a bacterial infection and 3 (9%) fungal pneumonias were
reported. The cumulative incidence of chronic GVHD was 26.5% (95% CI: 12.2-
43.3), the 1-yr cumulative incidence of relapse and non-relapse mortality were
16.4% (95% CI: 5.8-31.8) and 22.7% (95% CI: 9.8-38.9), respectively. The 1-yr
overall survival and GVHD-free/relapse-free survival were 70.0% (95% CI: 53.5-
86.5) and 34.7% (95% CI: 17.6-51.8), respectively.
Table 1. Univariate analysis of variables predicting lack of response to
first-line therapy.
Summary/Conclusions: This observational study suggests that ECP +/-
steroids is safe and effective first-line treatment for aGVHD after alloSCT. The
response rate is high with a low cumulative dose of steroids. However, the
duration and speed of steroid tapering needs to be further assessed, in order
to maintain a sustained response, when patients received PBSC and had vis-
ceral GVHD involvement.
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Background: Donor lymphocyte infusions (DLI) can induce durable remissions
in multiple myeloma (MM) patients, but this occurs only in a fraction of the
patients. The T cell-mediated graft-versus-tumor (GvT) effect of DLI depends
on the presence of host dendritic cells (DC), but these are rapidly replaced by
donor DC after allogeneic stem cell transplantation (alloSCT).
Aims: We tested in a prospective phase I/II trial whether the efficacy of DLI in
MM patients could be improved by simultaneous vaccination with ex vivo gen-
erated host DCs. As the donor T cells involved in GVT are mainly directed at
mismatched minor histocompatibility antigens (mHags), we also analyzed the
possibility to further improve the GvT effect by loading the host-DCs with pep-
tides of mismatched hematopoietic cell-specific mHags.
Methods: Eleven MM patients, not responding to a first DLI, were treated with
a second equivalent dose DLI combined with DC vaccinations, generated from
host-monocytes (moDC). In four of these patients the DCs were loaded with
mHag peptides. 
Results: Toxicity was limited and no acute graft-versus-host disease (GvHD)
occurred. Most patients developed objective but temporary anti-host T cell
responses however, with only modest clinical effects. In a patient vaccinated
with mHag ACC-1 peptide-loaded DCs, a distinct ACC-1 specific T cell
response accompanied a temporary clinical response. 
Summary/Conclusions: These findings confirm that DLI combined with host-
DC vaccination, either unloaded or loaded with mHag peptides, is feasible,
safe and capable of inducing host-specific T-cell responses. The limited clinical
effects observed in some patients may be improved by developing more
immunogenic DC products or by combining this therapy with immune potenti-
ating modalities like immune checkpoint inhibitors.
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TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE
PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF
HEMORRHAGIC CYSTITIS (HC)
J Zanabili Al-Sibai, MDP Palomo Moraleda, AP González Rodríguez*,
T Arias Fernández, LF Ávila Idrovo, L Morais Bras, S Melón, AJ González Huerta,
S González Muñiz
Hematology, HUCA, Oviedo, Spain
Background: BK virus (BKV) and JC virus (JCV) are frequently identified in
the urine of HSCT pts with hemorrhagic cystitis (HC). However, viruria is com-
mon even in asymptomatic pts, making difficult to establish a direct causative
role of these viruses.
Aims: Many studies have identified an association between polyomaviruses
and late HC and the studies have noted that viruria preceded or coincided with
the onset of disease. Some of these studies indicate that some factors, such
as conditioning regimen intensity, unrelated donor, etc contribute to the devel-
opment of HC and others, like receiving prophylaxis with quinolones could pro-
tect for this disease.
Methods: We conducted a prospective monitorization of urinary BK and JC
shedding by qPCR in 968 urine samples from 128 pts who underwent 135 allo-
HSCT between January 2010 and December 2014. BKV and JCV quantitative
polymerase chain reaction (qPCR) were performed in urine samples collected
at admission for transplant and weekly until discharge. Seventy-seven were
male (57%). Median age was 49 years old (range: 1-68). Most frecuent baseline
disease was acute leukemia (n=53). Seventy-two (53.3%) received cells from
unrelated donor, 58 (43%) from matched siblings and the remainder haploiden-
tical-HSCT. Stem cell source were bone marrow (n=59), peripheral blood (n=27)
and umbilical cord (n=9).
Table 1.
Results: BK viruria was demonstrated in 85 pts (63%), JCV in 56 patients (41.5%)
and both viruses in 36 pts (19.2%). BKV was excreted at day +5.5 as a median
(range: -12 to +167) during 20 days (range: 1-554). There was a significant corre-
lation between the first and maximum BKV load and intensity of hematuria (R=.242;
p=.026 and R=0.408; p<.001). Also, we observed a direct correlation between the
maximum BKV load and the number of lymphocytes (R=0.248; p=.022) and an
inverse with the quantity of immunoglobulins (R=-0.28; p=.01). JCV was excreted
in 56 pts (41.5%) at day -6 (range: -12 to +347) for 27.5 days (range: 1-535). At
maximum viral load of JCV, there was an inverse correlation with the immunoglob-
ulins and platelets (R=-0.378; p=.005 and R=-0.289; p=.033) and a direct correlation
with the intensity of hematuria (R=.387; p=.004). Only one patient receiving stem
cell source from umbilical cord blood had urinary JCV excretion. Eighty-four percent
of pts who excreted JCV had received a fludarabine-based conditioning regimen
(p=.046). Fifteen patients (11.1%) developed HC, 13 out of 15 excreted BKV
(86.7%), 8 JCV (53.3%) and 6 (40%) both. Patients who excreted BKV had more
risk to developed HC (p=.044). The development of HC was correlated to excretion
of at least one polyomavirus in all cases (p=.018). Patients who had clinical HC
showed higher BK viral load at maximum detection (log10 8.3 vs 5.13copies/mL;
p=.004), more log copies/mL increase (1.96 vs 0.62, p=.012) and virus shedding
for a longer time (77 vs 16.5 days; p=.001). JCV maximum load detection and
days of excretion were higher in pts who develop HC but it is not significant. Eighty-
seven pts (64.4%) received prophylaxis with quinolones and 10.3% of them devel-
oped HC. Further, 60.9% and 73.25% of them excreted BKV and JCV respectively,
without differences with patients who did not get prophylaxis.
Summary/Conclusions: BK and JC excretion were frequent in our series of
allo-HSCT recipients. High viral load is correlated with more hematuria. Higher
increase in log BKV urine qPCR copies/mL, higher BKV load and longer shed-
ding were associated with risk of HC. We could not demonstrate that prophy-
laxis with quinolones impact on duration of excretion, amount of polyomavirus
shedding or protection of development of HC.
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Background: Double-hit lymphomas (DHL) - DLBCL with rearrangements of
MYC and BCL2 and/or BCL6 - and double expressing lymphomas (DEL) - DLB-
CL with co-expression of MYC and BCL2 by immunohistochemistry (IHC) - are
associated with poor outcomes after upfront therapy. Data are limited regarding
outcomes of patients with rel/ref DHL who undergo SCT, and no study to date
has examined SCT outcomes in patients with DEL.
Aims: Evaluate the prognostic impact of DHL and DEL status on SCT outcomes
in patients with rel/ref DLBCL.
Methods: We studied patients with rel/ref DLBCL or transformed indolent lym-
phoma (TIL) who underwent autologous SCT (autoSCT) at Dana-Farber Cancer
Institute (DFCI) or City of Hope between 1/2000 and 7/2013. We also studied
patients with rel/ref DLBCL or TIL who underwent allogeneic SCT (alloSCT) at
DFCI or Massachusetts General Hospital during the same period. In the
autoSCT cohort, IHC for MYC, BCL2, and BCL6 were performed and cutoffs
of ≥40% MYC-positive and ≥50% BCL2-positive cells were used to define DEL.
Cell-of-origin (COO) classification was determined by Hans criteria. In both
cohorts, FISH for MYC was performed using dual-color break-apart probes;
cases with MYC-rearrangement or copy gain (CG) also had BCL2 and BCL6
FISH performed. Rearrangement was defined as ≥10% nuclei with break-apart
signals, and CG was defined as ≥30% nuclei with extra signals. DHL had
rearrangement of MYC and BCL-2 and/or BCL-6, and “atypical DHL” had at
least 3+ MYC CG and BCL2 and/or BCL6 CG or rearrangement.
Figure 1.
Results: Cohort Characteristics AutoSCT cohort: 201 patients; median age
60y (range 30-77); 26% TIL; median 2 prior therapies; 99% prior rituximab;
53% primary refractory disease/relapse <6 mo; 59% CR at ASCT; median fol-
low-up 53 months. AlloSCT cohort: 61 patients; median age 55y (range 28-
69); 33% TIL; median 4 prior therapies; 64% prior autoSCT; 72% chemosensi-
tive; 80% reduced intensity conditioning; 30% matched related, 54% matched
unrelated, 6% mismatched unrelated, 5% haploidentical, 5% cord; median fol-
low-up 41 months. Overall, 4y progression-free survival (PFS)/overall survival
(OS) in the autoSCT were 44%/61%, and 3y PFS/OS in the alloSCT cohort
were 42%/47%, respectively. Outcomes AutoSCT: Of 184 autoSCT patients
with IHC data, 40% were DEL. 4y PFS in DEL v non-DEL patients was 37% v
52% (p=0.001), 4y OS was 52% v 69% (p=0.007). Of 167 autoSCT patients
with FISH and IHC data, 13% were DHL, 38% had atypical DHL with 3+ MYC
CG, and 8% had atypical DHL with 4+ MYC CG. 4y PFS in DHL v non-DHL
patients was 24% v 48% (p=0.005), 4y OS was 31% v 62% (p=0.002) [Figure].
In a multivariable model, only DEL (PFS HR 2.1, p=0.0005; OS HR 1.8,
p=0.022), DHL (HR 1.9, p=0.039; HR 2.4, p=0.012), and SD/PD at autoSCT
(HR 3.1, p=0.02; HR 3.4, p=0.014) were associated with inferior PFS and OS.
Neither PR vs CR status at autoSCT, isolated MYC, BCL2, or BCL6 expression,
atypical DHL with 3+ or 4+ MYC CG, nor COO were associated with outcome
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when DHL/DEL status was taken into account. AlloSCT: 51 alloSCT patients
had complete FISH data – 10% had DHL, 29% had atypical DHL with 3+ MYC
CG, and 10% had atypical DHL with 4+ MYC CG. 3y PFS/OS in DHL v non-
DHL patients were 20% v 47% (p=0.4) and 20% and 53% (p=0.24) [Figure].
Atypical DHL was not associated with outcome.
Summary/Conclusions: Rel/ref DEL and DHL are associated with inferior
PFS and OS after autoSCT, independent of other prognostic factors. Rel/ref
DHL appears to also have a worse outcome after alloSCT, but the sample size
is not large enough to draw definitive conclusions.
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BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL
SIBLING STEM CELL TRANSPLANTATION
N Santos1,*, R Rodríguez-Romanos2, S Brunet3, R de la Camara4, JB Nieto5,
JB Nieto6, C Martínez7, I Buño8, C Vallejo9, A Jiménez-Velasco10,
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Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA)
is thought to negatively regulate the proliferation and differentiation of T-cells
modifying immune response. The BTLA genotype has been associated with
the development of some autoimmune diseases. However, various in vivo mod-
els have showed that BTLA could have dissimilar roles in controlling immune
responses depending on the tissue examined. The BTLA gene is located on
chromosome 3 in q13.2 and consists of five exons
Aims: Here, we focus on the relevance of the rs9288953 BTLA C>T polymor-
phism on the clinical outcome after allogeneic stem cell transplant (allo-HSCT).
Methods: We carried out a retrospective analysis of 1060 allo-HSCTs from HLA-
identical sibling donors performed between 1991 and 2013. Patients who
received a T-depleted graft HSCT were not included. BTLA genotyping was
made by allelic discrimination assays and detection system Life Technologies
on DNA samples obtained from peripheral blood of the donors. Written informed
consent was obtained from patients and donors. Statistical cumulative incidence
was estimated for aGVHD, relapse and transplant related mortality (TRM)
according to BTLA donor’s genotype. TRM was defined as death due other caus-
es but relapse. The Kaplan Meier method was applied to analyze overall survival
(OS) and relapse-free survival (RFS), comparing curves by the log-rank test.
Multivariate analysis was performed using the Cox regression model.
Results: BTLA allele and genotype frequencies were similar to the previously
described in Caucasian populations. The homozygous BTLA CC genotype was
the predominant in 44.3% of cases. Homogeneity in clinical variables between
genotype groups was confirmed. There were not statistical differences in cumu-
lative incidence of aGVHD grades II-IV (p: 0.367) and the secondary clinical
endpoints OS (p: 0.500), TRM (p: 0.597) or RFS (p: 0.143), but we detected
higher cumulative incidence of relapse between BTLA CC versus TT/CT geno-
types (p: 0.015). Multivariate analysis identified BTLA genotype, stage of the
disease, and acute leukemia diagnosis as independent risk factors for relapse
(p: 0.038; HR1.3; 95%CI: 1 to 1.7; p<0.001; HR2.5; 95%CI: 1,9 to 3.2 and p:
0.03; HR1.6; 95%CI: 1.2 to 2.3 respectively).
Summary/Conclusions: The BTLA genotype of the donor seems to be inde-
pendent risk factor for relapse. There were no statistically differences in other
clinical endpoints, suggesting that BTLA should be relevant in the prevention
of relapses, but not in the initial process of allorecognition. These preliminary
results should be confirmed by other studies. This work has been financed by
grants PI11/01690 and PI14/01646 from the Instituto de Salud Carlos III, co-
financed by FEDER (Fondo Europeo de desarrollo regional) and by grant MTV3
Fundació Marató TV3.
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HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN
AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED
AGGRESSIVE B-CELL NON-HODGKIN’S LYMPHOMAS (NHL)
SA Srour*, S Lozano, Y Nieto, AM Alousi, UR Popat, MH Quazilbash, P Anderlini,
P Kebriaei, E Shpall, RE Champlin, C Hosing
Stem Cell Transplant and Cellular Therapy, The University of Texas MD Ander-
son Cancer Center, Houston, Texas, United States
Background: High-dose rituximab (HD-R) combined with carmustine, cytara-
bine, etoposide, and melphalan (BEAM) and SCT was effective and tolerable
in a single-arm study for relapsed/refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) and other aggressive B-cell NHLs. This prospective randomized
phase 2 study compared the efficacy and safety of HD-R vs standard-dose rit-
uximab (SD-R) combined with BEAM in R/R-NHL.
Aims: 1. To determine the disease-free survival (DFS) for patients with R/R
aggressive B-cell lymphomas in the two study arms: HD-R vs SD-R plus BEAM.
2. To compare the safety of the two treatment arms.
Methods: Patients with R/R-NHL (44 DLBCL, 49 other aggressive B-cell lym-
phomas) were randomized to HD-R or SD-R using Bayesian adaptive algo-
rithm. HD-R (1,000 mg/m2) or SD-R (375 m2) were administered on days +1
and +8 after stem cell infusion. Primary endpoint: DFS, defined as time from
SCT to disease progression or death. Overall survival (OS) and safety analysis
were secondary endpoints. Planned sample size was 100 patients; however,
the trial was closed to new patient entry by the Data and Safety Monitoring
Board after 93 patients were enrolled because it was considered extremely
unlikely that either treatment arm would be found significantly superior. Inten-
tion-to-treat Kaplan-Meier estimator (DFS & OS) and Cox proportional hazards
regression were used. An informed consent was granted from patients before
study enrollment.
Results: 93 patients (29% females) with a median age of 63 years (6-75) were
randomized to HD-R (n=42) or SD-R (n=51). No significant differences in
patient demographic and clinical characteristics. With a median follow-up of
7.92 years, the 5-year DFS and OS were 42% and 48% for the whole study
population, respectively. We found no statistically significant differences
between the HD-R and SD-R arms in 5-year DFS (37% vs 47%; p=0.2) and
OS (42% vs 52%; P=0.4) (Figure 1). In multivariate analyses, only disease
status at the time of SCT [complete remission (CR) vs no CR] (HR 0.57, 95%
CI: 0.35-0.95) and number of prior treatment lines (a line of treatment is defined
as any active treatment before BEAM and transplant, using chemotherapy
and/or chemoimmunotherapy as single agent or in combination), (≤2 vs >2)
(HR 0.53, 95% CI: 0.32-0.89) were associated with worse DFS. Similarly, these
were found to be significant poor prognostic factors for OS: HR 0.56 (95% CI
0.33-0.95, p=0.03) for CR at time of SCT, and HR 0.53 (95% CI 0.24-0.74,
p=0.002) for ≤2 lines of treatment. Patients transplanted in CR had better 5-
year DFS (50% vs 30%, P=0.026) and OS (57% vs 35%; P=0.02). Similarly,
those with ≤2 prior lines of treatment had significantly better 5-year DFS (45%
vs 30%, P=0.006) and OS (54% vs 30%, P=0.001). No differences in Grade 3-
4 toxicities, infection rates or engraftment were seen between both arms.
Figure 1.
Summary/Conclusions: SD-R is not significantly different from HD-R when
combined with BEAM in B-cell aggressive R/R-NHL in terms of DFS and OS.
Pre-transplant disease status (CR vs no CR) and numbers of treatments prior
to transplant (≤2 vs >2) were the only significant predictors for prognosis.
Patients with CR and those with ≤2 prior lines at time of SCT have the best
outcomes.
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INTERFERON GAMMA (IFN-GAMMA) NEUTRALIZATION AS A VALUABLE
THERAPEUTIC TARGET IN PRIMARY HLH
F Locatelli1,*, M Jordan2, C Allen3, S Cesaro4, F Fagioli5, M Henry6, MC Putti7,
C Rizzari8, C Rossig9, J Sevilla10, M Ballabio11, W Ferlin11, C De Min11
1Pediatric Hematology and Oncology, Ospedale Pediatrico Bambino Gesu’,
Roma, Italy, 2Cincinnati Children’s Hospital, Cincinnati, 3Texas Children’s Hos-
pital, Houston, United States, 4Policlinico GB Rossi, Verona, 5A.O. Regina
Margherita, Torino, Italy, 6Phoenix Children Hospital, Phoenix, United States,
7University Hospital, Padova, 8Ospedale S. Gerardo, Monza, Italy, 9University
Children’s Hospital, Muenster, Germany, 10Hospital Universitario Nino Jesus,
Madrid, Spain, 11Novimmune sa, Plan-Les-Ouates, Switzerland
Background: Primary HLH (pHLH) is a rare immune regulatory disorder which
is lethal if untreated. High production of IFNγ has been shown to play a critical
role in the pathophysiology of the disease. Immune-chemotherapy, primarily
etoposide-based regimens, is currently used to control HLH and bring patients
to allogeneic hematopoietic stem cell transplant (HSCT). In spite of recent
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attempts to further intensify treatment regimens, mortality and morbidity remain
high, also due to drug-related toxicities. NI-0501 is a fully human, high affinity,
anti-IFNγ monoclonal antibody that binds to and neutralizes human IFNγ, offer-
ing a novel and targeted therapeutic approach for HLH.
Aims: To evaluate the safety and efficacy of NI-0501 in children with pHLH.
Methods: We have evaluated patients enrolled in the Phase 2 international
study or who, although fulfilling the study criteria, were treated in Compassion-
ate Use since not transferrable to study sites. NI-0501 was administered at an
initial dose of 1 mg/kg every 3 days, possibly adjusted during treatment, along
with dexamethasone dosed between 5-10 mg/m2/day that could be tapered
depending on clinical evolution. HLH response to treatment, NI-0501 safety
profile and survival were assessed.
Results: A total of 20 patients (18 in the study, 2 in CU) have been evaluated
so far: 10F/10M, median age 1.0 yr (range 2.5 mo-13 yr), mostly at the severe
end of the HLH spectrum, and carrying significant toxicities from previous HLH
treatments. Eighteen patients received NI-0501 as second line treatment and
2 as first line. In 18 patients a known HLH genetic defect was documented (6
FHL2, 4 FHL3, 1 FHL4, 1 FHL5, 3 GS-2, 1 XLP1, 2 XLP2). Eight patients
started NI-0501 treatment in the presence of an active infection (mostly EBV
and CMV), likely to be the disease trigger. Five patients had CNS signs and
symptoms prior to NI-0501 administration requiring intrathecal therapy. To date,
11 patients received HSCT (2 also with additional HLH therapies), 4 achieved
HLH control and are awaiting for HSCT, and 3 are at week 2 of treatment. Two
patients died of HLH/MOF prior to HSCT. HLH parameters were positively
impacted by NI-0501 treatment, in particular platelet and neutrophil counts,
abnormal at baseline in 13 and 11 patients, normalized in 8 and 9, respectively,
at end of treatment (EoT, Fig.1). CNS signs and symptoms resolved in the 4
evaluable patients. Dexamethasone dose could be at least halved in 60% of
patients during the first 4 weeks of treatment. After transplantation, 9/11 patients
(82%) are alive with a median follow-up of 4 mo (1 wk-2.5 yrs) Two patients
died from HSCT complications (GvHD and graft rejection). IFNγ neutralization
was demonstrated by a sharp decrease in CXCL9, an IFNγ-induced chemokine.
NI-0501 was well tolerated and no safety concerns were identified. All infections
present at start of treatment resolved upon appropriate treatment. Infections
occurred during NI-0501 treatment only in patients who previously received
chemotherapy. None of the infections were caused by pathogens known to be
favored by IFNγ neutralization.
Figure 1. Response to NI-0501 treatment.
Summary/Conclusions: NI-0501 has shown to be safe and effective in
patients with pHLH both in second and in first line. Efficacy of NI-0501 seems
to be independent of the presence and type of causative mutations, as well as
the presence and type of an infectious trigger. None of the typical etoposide-
based regimen toxicities were observed, while a significant positive impact on
cytopenia was noted. Based on the data available to date, IFNγ neutralization
is proposed as a valuable pHLH therapy, and may be considered as first-line
approach for HLH.
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BIDIRECTIONAL RELATIONSHIP BETWEEN CMV-R AND AGVHD: CMV-R
HAS A BETTER OVERALL SURVIVAL AND T CELL RECONSTITUTION
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Background: Cytomegalovirus reactivation (CMV-R) and acute graft versus-
host disease (aGvHD) are early complications after hematopoietic stem cell
transplantation (HSCT). Multiple (m)CMV-Rs lead to an increased risk for devel-
opment of aGvHD and vice-versa. Nevertheless, the interaction between
aGvHD, CMV-R and their respective outcomes post HSCT is not well under-
stood.
Aims: In a bidirectional approach we investigated the interaction of CMV-R
and aGvHD on overall survival and T cell reconstituion
Methods: CMV-seropositive (R+) patients transplanted with hematopoietic
stem cells derived from CMV-seropositive donors (D+) between 2006 and 2013
at Medical School Hannover were included in this analysis (n=145). All patients
were monitored regularly for the development of T cells (CD8+, CD4+ T cells
and CMV-CTLs) from day +25 to 1 year post-HSCT. In this study, T cell analysis
was performed on day +50 and overall survival (OS) was evaluated at 2 years
after HSCT.
Results: Based on the sequence of single or (m)CMV-R and aGvHD we
analysed the influence of both CMV-R and aGvHD on OS. We observed that
patients with aGvHD grade II-IV prior to CMV-R had a ten-fold increased risk
to die (RR: 10.21, p=0.007), which was about the same as patients with aGvHD
grade II-IV only (RR: 9.30, p=0.026) when compared to patients without either
of these complications or to patients with CMV-R alone. Interestingly, patients
with CMV-R prior to aGvHD grade II-IV (RR: 4.18, p=0.04) had only a four-
fold risk to die, when compared to the patients without these complications.
Patients with CMV-R alone had no increased mortality when compared to
those without complications. We observed a rapid engraftment of CD8+ T cells
and increased inflammatory cytokine secretion (e.g. IL1Ra, IL18, Hu TRAIL,
MIP-1b and TNF-a) in the plasma of patient’s post-CMV-R which led to the
progression of aGvHD.
Summary/Conclusions: Our data suggest that the rapid reconstitution of
CD8+ T cells in concert with the secretion of inflammatory cytokines post-CMV-
R leads to the progression/development of aGvHD grade II or more. We could
also show that CMV-R itself is not a risk factor worse OS in the R+/D+ patient
group. However, as expected, aGvHD grade II-IV and CMV-R post-aGvHD
grade II-IV are associated with a higher risk to die after HSCT.
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HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE
POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA
PATIENTS WITH MYC/BCL2 CO-EXPRESSION
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Background: The concurrent immmunohistochemical (IHC) expression of MYC
and BCL2 has recently emerged as one of the strongest and most unfavorable
prognostic factor among naïve DLBCL patients after R-CHOP therapy, with a
3-year event free survival (EFS) and overall survival (OS) of 27-39% and 30-
43% respectively. Nevertheless, Horn et al (Leukemia 2015) have recently sug-
gested that the MYC/BCL2 co-expression is not strongly associated with inferior
survival among young DLBCL patients treated with more intense chemotherapy
regimens. This discordant result may be explained either by the lower prog-
nostic relevance of MYC/BCL2 among young DLBCL patients, but also by the
ability of more intense chemotherapy regimens to overcome the negative prog-
nostic features of MYC/BCL2 co-expression.
Aims: We investigated the clinical impact of MYC/BCL2 co-expression among
naive DLBCL patients treated with high dose chemotherapy followed by autol-
ogous stem cell transplantation in first line.
Methods: We analyzed a consecutive series of 71 naïve DLBCL patients treat-
ed with high-dose sequential chemotherapy integrated with monoclonal anti-
body Rituximab (R-HDS) between 2000 and 2015 at the Istituto Nazionale dei
Tumori Milano. R-HDS schedule is a typical ASCT-based program, including
the delivery of high-dose drugs from the start of treatment, the collection of
PBSC and a final autograft. Tumor samples from all enrolled patients were
analyzed for MYC and BCL2 expression by ICH with a 40% and 70% threshold,
respectively.
Results: All patients had an IPI score ≥1 and 65/71 (91%) had an Ann Arbor
stage ≥3. Among patients younger than 60 years, 30/47 (63%) were character-
ized by an age adjusted IPI≥2. No differences for IPI, ECOG score ≥2, Ann
Arbor stage >2, age, extranodal sites ≥2 and LDH levels were observed
between double expressor and non double expressor patients. The treatment
schedule was interrupted, and the transplant was not performed, in 16 (22.5%)
patients due to refractory and/or progressive disease (n=12) and adverse
events (n=4), including 2 patients who died of infection during treatment. After
a median follow up of 92 months (range 4-200), the overall 5-year EFS and OS
were 65.2% (95% CI, 59.4-71%) and 83.5% (95% CI, 78.7-88.3%) respectively.
MYC and BCL2 expression on IHC was observed in 31 (44%) and 37 (52%)
patients respectively. Among them, 20 (28%) were classified as MYC/BCL2
double expressors. The Ki-67 expression, MYC or BCL2 expression alone were
not associated with inferior outcome. Conversely the co-expression of
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MYC/BCL2 was associated with a trend of worse outcome: 5-year EFS 49.4%
(95% CI, 37.7-61.5%) vs 71.5% (95% CI, 65-78%); p=0.06 (Figure1a). How-
ever, this higher relapse risk did not affect final 5-year OS [76.7 (95% CI, 66.4-
87) vs 83.4 (78-88.8)] (Figure 1b). When only the 55 transplanted patients
where considered, MYC/BCL2 co-expression was not associated with any sig-
nificant difference in term of EFS and OS (Figure 1c-d). By multivariate analysis
(including age, bulky disease, ECOG≥2, Extra nodal sites≥2, IPI score≥2)
MYC/BCL2 co-expression retained its independent prognostic value for EFS
without affecting the final OS.
Figure 1.
Summary/Conclusions: In our R-HDS cohort the 5-year EFS and OS of dou-
ble expressor patients compared better with previous reports of different DLBCL
series treated with R-CHOP. This improvement was especially evident in trans-
planted patients, where R-HDS seems to be able to overcome the poor clinical
outcome associated with MYC/BCL2 co-expression. Finally, the double expres-
sor higher relapse risk did not affect the final whole series survival, suggesting
that a significant fraction of relapsed/refractory young patients may be rescued
with other intensive salvage therapies.
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ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS:
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Background: Allogeneic haematopoietic stem cell transplantation (allo-HSCT)
is the only curative treatment for many haematological diseases. Despite
advances in supportive therapies, acute Graft-versus-Host Disease (aGvHD)
remains the leading cause of morbidity and mortality. There are shortcomings
in the prediction of aGVHD, indicating the urgent need for non-invasive and
reliable laboratory tests to allow a precision-medicine tailored prophylactic
approach.
Aims: We conducted a prospective observational study to ascertain the poten-
tial usefulness of the levels of ten biomarkers, measured pre-transplant and at
+7 days post-transplant, in predicting the development and severity of aGvHD
in allo-HSCT patients. These time-points were chosen as early risk stratification
may provide a window for additional prophylactic measures.
Methods: We collected data from 120 consecutive patients (41 female and 79
male; median age 52, range 19-77 years) who underwent allo-HSCT at our
institute between 2014 and 2015. Most patients were affected by acute myeloid
leukaemia (n=62; 52%). Disease status at HSCT was “active disease” in 58%
of patients (n=70). Stem cell donors were unrelated (n=39, HLA matching 9/10
in 14 and 10/10 in 25), family haploidentical (n=56), HLA-identical sibling
(n=22), or cord blood (n=3). Post-transplant GvHD prophylaxis was with PT-
Cy in 65 patients, ATG in 28 patients, both agents in 18 cases whilst 9 patients
received neither. Additionally, sirolimus-based GvHD prophylaxis was used in
95 patients, while a CSA-based prophylaxis in 25 cases according to institu-
tional guidelines. The following biomarkers were measured 7 days pre- and
post-transplant: interleukin-6 (IL6), Ceruloplasmin (CER), Cholinesterase
(CHE), Albumin, Immunoglobulin A, Gammaglutyl-transferase (GGT), White
Blood Cells, Neutrophils, Haemoglobin and Platelets.
Results: In this cohort of 120 patients, 77 developed GvHD, of which 69 were
aGvHD. Of the aGvHD cases, 49 had skin, 12 had liver and 19 had gut involve-
ment. 39 of 120 patients died: 3/39 deaths were attributable to aGvHD. We
looked for associations between in-range and out-of-range levels of our ten
biomarkers with presence of aGvHD. At baseline, lower CHE concentrations
were significantly related to the risk of developing aGvHD and to some of its
main characteristics, such as severity (p=0.009), grade II-IV liver involvement
(p=0.016), and gut involvement (p=0.036). At 7 days after HSCT, concentrations
of IL6 were increased in patients who later developed grade II-IV gut GvHD
(p=0.03). We found that baseline albumin concentrations were reduced in
patients with subsequent liver aGvHD (p=0.027). Similarly, raised baseline
GGT values were correlated with liver involvement (p=0.05). Moreover, we
assessed the correlation of laboratory tests with non-relapse mortality (NRM:
death from any non-relapse complication) disease relapse and overall survival
(OS) at 100 days. Baseline albumin and CHE concentrations, together with
post-transplant IL6 levels, were correlated to OS and TRM. Disease relapse
was associated with baseline levels of albumin and IL6.
Summary/Conclusions: Pre-transplant CHE and GGT levels are predictors
of aGvHD, especially with regards to grade III-IV aGvHD and liver involvement.
Lower albumin levels were associated with liver aGvHD development, while
raised IL6 concentration 7 days after HSCT represented a risk factor for gut
aGvHD. These biomarkers will be incorporated in a treatment algorithm to
increase primary GvHD prophylaxis in patients at risk of severe aGVHD after
allo-HSCT.
P347
BONE MARROW WT1 LEVELS IN ALLOGENEIC HEMATOPOIETIC CELL
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Background: WT1 mRNA is overexpressed in most myeloid malignancies.
Standardized methods of quantitation have been developed and succesfully
used in minimal residual disease (MRD) assessment. The uncertaintity about
the levels with prognostic and/or therapeutic impact has precluded a more
widespread use of WT1 monitoring in HCT patients.
Aims: To investigate the WT1 levels and time points with clinical relevance in
patiens with myeloid malignancies who received a HCT.
Methods: Prospective collection of samples from consecutive patients with
acute myeloid leukemia (AML) and myelodysplasia (MDS) recipients of an allo-
geneic HCT in a University hospital. Normalized WT1 levels were obtained
using the ELN protocol and the Ipsogen© plasmid. Statistical correlations with
survival, relapse and other clinical variables were established.
Results: One hundred and ninety three consecutive allogeneic HCT recipients
with myeloid malignancies (148 AML, 45 MDS) treated from 2003 to 2014 were
included in the study. The analysis of pretransplant samples (n=177) showed
that with WT1 levels below 100 copies had better post-transplant outcome in
terms of overall survival at 5 years (OS:40±1 vs 29±6, p:0.004), disease-free
survival (DFS:35±9 vs 26±6, p:0.002) and cumulative incidence of relapse
(CIR:29±7 vs 37±6 p:0.051) than those patients with WT1>100 copies. When
we analyzed the marrow samples obtained just after the neutrophil recovery
(n=182), and using again the 100 copies threshold we also identified differences
in OS (40±7 vs 31±9 p:0.025), DFS (36±7 vs 30±8, p:0.004) and CIR (29±6 vs
54±9, p<0.001). In 104 cases four consecutive follow-up samples were avail-
able. Those patients with sustained WT1 levels below 100 copies had a signif-
icantly better outcome than those with one or more determination higher than
100 copies (OS: 68±11 vs 26±7, p<0.001; DFS: 63±11 vs 20±8, p<0.001;
CIR:20±8 vs 71±8, p<0.001).
Summary/Conclusions: Normalized bone marrow mRNA levels of WT1 pro-
vided useful information in patients with AML and MDS treated with HCT. In
patients with more than 100 copies pre and/or postransplant further therapeutic
interventions after the procedure are needed to avoid disease recurrence.
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TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL
DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH
TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING
METHOD
D Shasheleva1, L Shelikhova1, M Ilushina1, Z Shekhovtsova1, D Balashov1,
E Boyakova2, Y Skvortsova1, E Kurnikova3, P Trakhtman3, E Gutovskaya1,
Y Muzalevsky3, A Kazachenok3, A Abrosimov1, A Livshits1, S Blagov1,
G Novichkova4, A Maschan4, M Maschan4,*
1HSCT, 2Laboratory of biology of HSCT, 3Laboratory of Transplant Processing
and Cell Preparations, 4Dmitry Rogachev Federal Research Centre of Pediatric
Hematology, Oncology and Immunology, Moscow, Russian Federation
Background: Hematopoietic stem cell transplantation from non-sibling donors
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remains the only curative option for severe aplastic anemia patients refractory
to ATG/CsA immunosuppression. 
Aims: Although the results of MUD and haploidentical transplantation in SAA
have improved significantly, graft-versus host disease (GVHD) remains a seri-
ous problem, associated with significant morbidity and mortality. We investi-
gated the role of new method of graft processing - TCR alpha/beta depletion
as a way to improve the results of MUD and haploidentical transplants in SAA.
Methods: Thirty seven patients with SAA were treated since November 2012 till
November 2015. Median age at HSCT was 11(3-22) years, 22 male/15 female.
All pts were refractory/relapsed after at least two courses of ATG/CsA, 2 pts had
concurrent severe hemolytic PNH. Time from diagnosis to transplant was 4,3(1-
10) years. Donors were unrelated volunteers in 29 cases, haploidentical parent
in 8 cases. Preparative regimen included cyclophosphamide 100-150 mg/kg, flu-
darabine 150mg/kg, ATG and 2-6Gy thoraco-abdominal irradiation, in haplo trans-
plants patients additionaly recieved thiophosphamide at 10mg/kg. Two patients
recieved alemtuzumab instead of ATG because of anaphylaxis. Post-transplant
GVHD prophylaxis included Tacro and Mtx on days +1,+3,+6. PBSC grafts were
depleted of TCRalpha/beta cells and CD19 cells with CliniMACS device as rec-
ommended by the manufacturer. Patients recieved a median of 8,6(6,8-13,5)x106
CD34 per kg, 3(1-30) x104 TCRalpha/beta per kg.
Results: All patients engrafted with a median of 14 days for WBC and 13 days
for platelets. In 4 patients after MUD transplantation secondary graft failure
(rejection) developed, two of them were successfully retransplanted. Cumulative
incidence of aGVHD 2-4 was 3% (95% CI: 1-17%) and 50%(95% CI: 28-89%)
in MUD and haplo respectively. Cumulative incidence of aGVHD 3 was 0% and
12%(95% CI: 3-58%) in MUD and haplo respectively. Cumulative incidence of
cGVHD was 3%(95% CI: 0-25%) and 37%(95% CI: 15-92%) in MUD and haplo
respectively. A median follow up was 18 months. Six patients died. The reasons
of death were: viral infection (3 pts), viral infection plus GVHD (one pt), and 2
pts died after second transplantation (1 – toxoplasmosis, 1 – viral infection plus
GVHD). Overall survival was 81%(95% CI: 65-96%) and 87%(95% CI: 65-
100%) respectively. Prolonged mixed chimerism in T-cells was detected in
recipients of MUD grafts in contrast to haploidentical grafts.
Summary/Conclusions: TCR alpha/beta depletion is a robust platform for
allogeneic transplantation from MUD and haploidentical donors in severe aplas-
tic anemia. Results can be further improved by additional measures to control
viral infections and prevent rejection in MUD transplants.
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THE PRC2 COMPONENT JARID2 IS DISPENSABLE FOR HEMATOPOIETIC
STEM CELLS BUT CRITICAL FOR THE MAINTENANCE OF LEUKEMIC
STEM CELLS
AK Frank1,2,3,*, A Willer2,3,4, TL Jensen1,2,3, N Rapin1,2,3, FKB Lauridsen1,2,3,
T D’Altri1,2,3, A Wilhelmson1,2,3, Y Ge1,2,3, S Pundir1,2,3, M Hasemann1,2,3,
K Helin2,3,5, B Porse1,2,3
1The Finsen Laboratory, Rigshospitalet, Faculty of Health Sciences, University
of Copenhagen, 2Biotech Research and Innovation Centre (BRIC), 3Danish
Stem Cell Centre (DanStem), Faculty of Health Sciences, University of Copen-
hagen, 4Finsen Laboratoriet, Rigshospitalet, 5Centre for Epigenetics, University
of Copenhagen, Copenhagen, Denmark
Background: Hematopoietic stem cells (HSCs) are under tight transcriptional
regulation and erroneous regulation can confer unwanted properties to the cells
and ultimately lead to malignant transformation. Several studies have implicated
the epigenetic modulator Polycomb Repressive complex 2 (PRC2), which is
responsible for the deposition of the H3K27me3 mark associated with tran-
scriptional repression, in preserving correct HSC maintenance.
Aberrant function of PRC2 is shown to influence malignant transformation and
propagation of disease. A number of PRC2 auxiliary factors has been identified,
one being JARID2, which is involved in modulating the activity of the complex
by regulating binding to target genes.The role of JARID2 in the hematopoietic
system is essentially unknown.
Aims: To characterize the functional consequences of Jarid2 deletion in both
normal and malignant hematopoiesis.
Methods: Using a conditional knock out (KO) mouse model we have investi-
gated the loss of Jarid2 in the normal hematopoietic system. We also assayed
leukemic development and maintenance in our KO model using a Notch1
induced T cell acute lymphoblastic leukemia (T-ALL) model. Both settings were
studied by immunophenotypic analyses by FACS, RNAseq and micro array
based gene expression profiling, and ChIPseq analyses of histone marks. Mul-
ti-lineage reconstitution and self renewal capacity of the hematopoietic stem
cells were assayed by competitive and serial transplantations. Leukemic devel-
opment, maintenance, and frequency of leukemic stem cells (LSC) were
assessed by serial transplantation and limiting dilution transplants. Serially
transplanted T-ALL was further analysed by exome sequencing to identify muta-
tions altering LSC frequency.
Results: We found that JARID2 is dispensable for the numbers and function
of adult hematopoietic stem cells and observed only mild changes for the down
stream progenitor cells. These findings were further supported by a lack of
changes in gene expression and H3K27me3 levels in these cells. Through
transplantation assays, we found that the self-renewal capacity of normal HSCs
also remained intact after loss of JARID2.  These findings are in stark contrast
to the requirement for JARID2 in the leukemic setting. In a model of T-ALL we
observed an initial acceleration of leukemic onset, possibly explained by
improved homing abilities of the Jarid2 KO cells. However, KO T- ALL showed
a marked decrease in the ability to propagate leukemia in secondary recipients,
and the increased latency was reflected in a dramatic reduction in leukemic
stem cells (LSC) frequency. Furthermore, gene expression profiles for these
cells were inversely correlated with relapse signatures for childhood T-ALL.
Surprisingly, the latencies were reverted upon re-transplantation into tertiary
recipients, and this corresponded to a rise in LSC numbers. To study this further
we performed exome sequencing of serially transplanted T-ALL and identified
mutations in Pten and Ikzf1. These are likely candidates responsible for rescu-
ing the LSC deficiency observed for JARID2 depleted T-ALL.
Summary/Conclusions: JARID2 is, contrary to other PRC2 components, dis-
pensable for normal HSC function, but plays a key role in LSC maintenance in
NOTCH1 induced T-ALL. Loss of Jarid2 leads to a marked loss of LSCs but
their numbers can recover as a consequence of secondary mutations.
Thus, this study provides new insights into the function of PRC2 in normal and
malignant hematopoiesis as well as into mechanisms governing the behavior
of LSCs in T-ALL.
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HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS
VIA REPRESSION OF CDKN2A
JT Jackson1,*, BJ Shields1, W Shi2, L Di Rago1, D Metcalf1, N Nicola1,
MP McCormack1
1Cancer & Haematology Division, 2Bioinformatics Division, The Walter & Eliza
Hall Institute of Medical Research, Parkville, Australia
Background: The Hematopoietically-expressed homeobox transcription factor
(Hhex) is important for the maturation of definitive hematopoietic progenitors
and B-cells during development. We have recently shown that in adult
hematopoiesis Hhex is dispensable for maintenance of hematopoietic stem
cells (HSCs) and myeloid lineages but essential commitment of common lym-
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phoid progenitors to diverse lymphoid lineages. However, whether Hhex plays
a role in HSC self-renewal and myeloid expansion during hematopoietic stress
is unknown.
Aims: The aim of this is to determine the roles of Hhex in HSC self-renewal
and emergency hematopoiesis.
Methods: We employed inducible knock out mice for Hhex to assess the
requirement of this transcription factor in adult haematopoiesis. Serial bone
marrow transplantation was used to test the effect of Hhex deletion on HSC
self-renewal. In addition, the bone marrow response to myeloablation was test-
ed using 5- fluorouracil (5-FU) treatment, and the proliferation of immature
blast colony-forming units was tested in vitro using soft agar cultures.
Results: Here we show that Hhex-deleted HSCs are progressively lost during
serial bone marrow transplantation, revealing an intrinsic defect in HSC self-
renewal. Moreover, Hhex-deleted mice show markedly impaired hematopoietic
recovery after myeloablation using 5-FU. In vitro cultures demonstrated that
although Hhex-null donor bone marrow contained elevated numbers of
hematopoietic progenitors, immature blast colonies were specifically incapable
of replating. Thus, Hhex is essential for HSC self-renewal and immature
myeloid progenitor expansion in vitro and in vivo. RNAseq analysis of Hhex-
null LSK cells showed Hhex deletion led to the dysregulation of cell cycle reg-
ulators, including an upregulation of Cdkn2a-encoded p16Ink4a and p19Arf.
Consequently we crossed Hhex inducible knock-out mice with those lacking
Cdkn2a. Loss of Cdkn2a completely restored the expansion of Hhex-null pro-
genitors and blast colony replating in vitro, as well as hematopoietic reconsti-
tution following myeloablation in vivo.
Summary/Conclusions: These finding show that Hhex is a key transcriptional
mediator of HSC self-renewal and stress hematopoiesis, mediating these
effects by regulation of cell cycling via repression of Cdkn2a.
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WNT5A FROM THE NICHE REGULATES THE ACTIN REGULATORY
PATHWAY IN HEMATOPOIETIC STEM CELLS
C Schreck1, R Istvanffy1, C Ziegenhain2, T Sippenauer1, Á Prendergast3,
N Mende4, F Gärtner5, S Massberg5, M Essers3, C Waskow6, C Peschel1,
W Enard2, R Oostendorp1,*
1III. Medizinische Klinik, Klinikum rechts der Isar der TU München, 2Anthropol-
ogy and Human Genetics, Ludwig-Maximilians University, München, 3Hi-STEM,
Heidelberg, 4Institure of Immunology, TU Dresden, Dresden, 5Medizinische
Klinik und Poliklinik I, Ludwig-Maximilians University, München, 6Institute of
Immunology, TU Dresden, Dresden, Germany
Background: The niche regulates the quality of hematopoietic stem cells
(HSCs) that are regenerated under conditions of stress, such as transplanta-
tion. We found earlier, that WNT5A is overexpressed in stromal cells capable
of maintaining HSC activity in an in vitro model of culture stress.
Aims: We here wished to delineate the role of stromal WNT5A in hematopoietic
processes in vivo.
Methods: For this purpose, we performed transplantation experiments in which
wild-type (WT) HSCs were transplanted into a WNT5A haploinsufficient envi-
ronment. After trasnplantation the regenerated HSCs were subjected to rigor-
ous molecular and cellular asessment, as well as transplanted into secondary
WT recipients.
Results: We find that although HSCs efficiently find and lodge in the Wnt5a-
deficient niche, the reduced level of WNT5A in the niche regenerates HSCs,
which do not successfully engraft secondary recipients. In particular, RNA
sequencing shows a dysregulated Zeb1- and Nfatc-associated gene expres-
sion of multiple genes involved in the small GTPase- dependent actin poly-
merization pathway. Misexpression of these genes results in reduced ability to
direct polarized F-actin localization, leading to defects in adhesion, migratory
behavior and homing to the bone marrow of secondary recipients. Our study
also shows that the Wnt5a-deficient environment similarly affects p185-BCR-
ABL cells, which, in 42% of the studied recipients, fail to generate leukemia
and, in the remaining cases, fail to transfer leukemia to secondary hosts.
Summary/Conclusions: Thus, we show that Wnt5a in the niche is required
to regenerate HSCs and leukemic cells with functional ability to rearrange the
actin cytoskeleton which is required for successful engraftment.
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NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS
CH Ang1,2,*, Z Xu2, W Alexander1,2, S Glaser1,2
1Department of Medical Biology, Univerisity of Melbourne, 2Cancer and Haema-
tology, Walter and Eliza Hall Institute for Medical Research, Parkville, Australia
Background: The NPM1 gene encodes a multifunctional protein that shuttles
between nucleus and cytoplasm and is frequently mutated in hematological
malignancies. Recurrent mutations of NPM1 occur in 30% of acute myeloid
leukemia (AML) patients, causing a frame-shift in exon 12 that results in aber-
rant localization of the mutated protein, designated NPMc+, to the cytoplasm.
Although NPM1 is the most frequently mutated gene in AML, its role in leuke-
mogenesis is poorly understood, given its multiple cellular functions and attri-
bution as a proto-oncogene and a tumour suppressor. Previous studies showed
that constitutive homozygous deletion of NPM1 in mice is embryonic lethal due
to aberrant organogenesis and defects in primitive hematopoiesis, whilst het-
erozygous loss of a single NPM1 allele causes a hematological condition
resembling human myelodysplastic syndrome (MDS), a preleukemic condition
often progressing towards AML.
Aims: We aim to study the role of NPM1 in adult hematopoiesis.
Methods: We describe a conditional mouse model using Tamoxifen-inducible
Cre recombinase to delete NPM1 in adult hematopoiesis.
Results: We found that deletion of the NPM1 gene in adult mice resulted in
multiple hematopoietic abnormalities. Loss of NPM1 compromised hematopoi-
etic stem and progenitor cell (HSPCs) function, causing depletion of progenitors
and mature lineages, particularly the erythroid lineage. NPM1-null HSPCs
exhibited aberrant cell cycle status with increased number of cells in the syn-
thesis phase. Competitive transplantation and in vitro differentiation assays
revealed that NPM1-null HSPCs had reduced capacity to engraft and produce
mature hematopoietic lineages, including B-cells, T-cells, and myeloid cells
compared to wild-type controls, indicating impaired self-renewal and differen-
tiation of the stem cells. Phenotypically, NPM1-null mice were anemic and
leukopenic with splenomegaly, symptoms that resemble human MDS. 
Summary/Conclusions: In summary, this mouse model highlights the impor-
tant role of NPM1 in adult hematopoiesis. Knowledge of the role of NPM1 in
normal hematopoiesis is likely to improve our understanding of AML patho-
genesis associated with mutations in NPM1.
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PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION
AND CELL CYCLE PROGRESSION
C Vincent-Fabert1,*, N Platet1, A Vandevelde1, M Poplineau1, M Koubi1,
P Finetti2, Am Imbert3, F Bertucci2, E Duprez1
1CRCM Inserm U1068 CNRS 7258, Institut Paoli-Calmettes, 2CRCM Inserm
U1068 CNRS 7258, Department of Medical Oncolgy, Institut Paoli-Calmettes,
3CRCM Inserm U1068, Inserm CBT-1409 CIC Biothérapies, Institut Paoli-Cal-
mettes, Marseille, France
Background: Hematopoietic stem cells (HSCs) give rise to all blood popula-
tions due to their long-term self-renewal and multipotent differentiation capac-
ities. Because they have to persist throughout an organism’s life span, HSCs
tightly regulate the balance between proliferation and quiescence. As with most
tissues that have a high cellular turnover, hematopoietic tissue is sensitive to
aging, which results in multiple functional defects that accumulate in HSCs
from older individuals. Aging HSCs have a reduction in their regenerative
capacity and support decreased lymphoid lineage output together with
increased myeloid output. Surprisingly, the number of phenotypically-defined
HSCs increases with age; while it has long been known that aging has a major
impact on the frequency and cell-cycle kinetics of hematopoietic cell compart-
ments, mechanisms underlying this phenomenon remain poorly understood.
Aims: Here we investigated the role of the transcription factor, plzf in HSC fate
using the Zbtb16lu/lu mouse model, harboring a natural spontaneous mutation
that inactivates plzf.
Methods: We used the Zbtb16lu/lu mouse model in order to study the role of
plzf in HSCs. We performed serial and competitive transplantation assays to
evaluate Zbtb16lu/lu HSC function. Effect of Zbtb16lu/lu mutation at the
genomic level was addressed by transcriptomic analyses and plzf role on cell
cycle regulation was studied through a combination of flow cytometry and
BrdU injection.
Results: Regenerative stress revealed that Zbtb16lu/lu HSCs had a lineage
skewing potential from lymphopoiesis towards myelopoiesis, an increase in
the long-term-HSC pool and a decreased repopulation potential. Comparison
of young Zbtb16lu/lu HSCs with one-year-old HSCs for their competitive repop-
ulation ability showed that the Zbtb16lu/lu HSCs have a myeloid competitive
advantage and contribute more to the LT-HSC compartment relatively to ST-
HSC and MPP1 fractions. Furthermore, old plzf-mutant HSCs present an ampli-
fied aging phenotype. Comparative microarray-based gene expression data
from Zbtb16lu/lu and control HSCs revealed that Zbtb16lu/lu HSCs harbor a
transcriptional signature associated with a loss of stemness and cell-cycle
deregulation suggesting changes in HSC cell cycles induced by plzf mutation.
Indeed, cell-cycle analyses revealed an important role for plzf in the regulation
of the G1-S transition of HSCs. We also demonstrated a significant increase
in apoptosis in Zbtb16lu/lu HSC in comparison to WT cells that could account
for the limited accumulation of Zbtb16lu/lu HSCs in young PLZF-mutant. Inter-
estingly, apoptosis was not as increased in transplanted Zbtb16lu/lu HSCs.
Summary/Conclusions: These results suggest that Zbtb16lu/lu promotes pre-
mature-aging-like syndrome in mice after regenerative stress and imply a role
for plzf in the control of age-related mechanisms in HSC. Our study reveals a
new role for plzf in regulating HSC function that is linked to cell-cycle regulation
and positions plzf as a key player in controlling HSC homeostasis.
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IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM
CELLS IN VIVO
U Demel1,2,*, S Sujer1,2, S Blaszkiewicz1,2, A Kuck1,2, M Essers1,2
1Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-
STEM gGmbH), 2Hematopoietic Stem Cells and Stress Group, Division of Stem
Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg,
Germany
Background: The pro-inflammatory cytokines IL-1α and IL-1β play important
roles in the acute inflammatory response to infection and injury. Intracellular
IL-1α protein is highly expressed in endothelial cells and platelets, suggesting
that its release may function as a danger signal. In contrast, IL-1β is highly
secreted by monocytes and macrophages upon infection to initiate a systemic
pro-inflammatory response. In addition, IL-1 is involved in a variety of autoin-
flammatory diseases, which are often associated with hematopoietic dysfunc-
tions. However, thus far the effect of IL-1α and IL-1β on hematopoietic stem
cells (HSCs) remains unclear.
Aims: To investigate the effect of the pro-inflammatory cytokines IL-1α and IL-
1β on quiescent HSCs in vivo. 
Methods: To analyze the effect of IL-1α or IL-1β on quiescent HSCs, wild-type
(wt) or IL-1R-/- (IL-1 receptor knock-out) mice were injected with IL-1α or IL-1β.
HSC number, proliferation and cell cycle status were analyzed by FACS 18
hours following treatment. HSCs from treated mice were also isolated and
transplanted into lethally irradiated recipients to analyze the function of these
HSCs.
Results: Here, we could show that IL-1α and IL-1β efficiently induced the acti-
vation of quiescent HSCs in vivo. Within 18 hours after treatment of mice, HSCs
exited G0 phase and entered an active cell cycle. This effect was abrogated in
mice lacking the IL-1 receptor (IL-1R-/-), demonstrating the requirement of the
IL-1 receptor. Competitive bone marrow (BM) transplantations and serial trans-
plantation assays showed no functional impairment or reduced self-renewal
potential of HSCs upon short-term IL-1 treatment. Moreover, forward and
reverse BM chimeras showed that IL-1 signaling via the IL-1R in cells of the
BM niche is dispensable for the IL-1 effect on HSCs. Interestingly, mixed BM
chimeras with wt and IL-1R-/- HSCs indicated a direct effect of IL-1α on HSCs,
whereas the effect of IL-1β on HSCs was both direct and indirect via other cells
of the hematopoietic system. Furthermore, we could link the effect of IL-1 on
HSCs in vivo to NFkB signaling.
Summary/Conclusions: Our data show a strong effect of IL-1α and IL-1β on
quiescent HSCs in vivo. In addition to previous studies on other pro-inflamma-
tory cytokines, our data indicate that in vivo activation of HSCs by pro-inflam-
matory cytokines is a more general phenomenon, strongly linking the host
response to systemic inflammation to activation of quiescent HSCs. 
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SFRP2 FROM THE NICHE IS REQUIRED TO MAINTAIN THE REGENERATION
OF THE HEMATOPOIETIC STEM CELL POOL
F Ruf, C Schreck, S Grziwok, T Sippenauer, C pagel, A Wagner, K Götze,
C Peschel, R Istvanffy, R Oostendorp*
III. Medizinische Klinik, Klinikum rechts der Isar der TU München, München,
Germany
Background: We previously found that Sfrp2 was overexpressed in stromal
cells, which maintain hematopoietic stem cells (HSCs) in in vitro culture. 
Aims: Here, we determined the relevance of Sfrp2 expression by niche cells
for the maintenance of hematopoiesis under stress conditions in vivo.
Methods: To determine the role of Sfrp2 in HSC responses under stress con-
ditions, we studied in vitro cultures, 5-FU treatment in vivo, and HSC engraft-
ment in transplantation experiments.
Results: In in-vitro co-cultures with shSfrp2 stromal cells, the number line-
age-negative Kit+ Sca-1+ (LSK) and progenitors increased. The LSK cells
showed higher levels of Ki-67 expression, BrdU incorporation, and catenin-
dependent Wnt signaling. Yet, total repopulating activity of these cultures was
diminished, suggesting exhaustion of HSCs. These in vitro results were mir-
rored in in vivo models of stress, such as aging, 5-FU treatment and hematopoi-
etic regeneration in Sfrp2-/- recipients. In all three in vivo situations of stress,
we noted an increase of LSK cells, which in accompanied by increased levels
of ®- catenin and cyclin D1. In the transplantation experiments, the increase
in LSK cells was accociated with a progressive loss of HSCs in serial trans-
plantation recipients. Similarly, genotoxic stress in 5-FU-treated Sfrp2-/- mice
showed LSK cells with a higher cycling activity than wild-type (WT) littermates,
as shown by higher levels BrdU incorporation, and a higher expression of Ki-
67 and canonical Wnt signaling mediators. Importantly, increased cycling of
LSKs was accompanied with stress-induced senescence-associated DNA
damage response as indicated by ©H2A.X staining and depolarized localiza-
tion of acetylated H4K16.
Summary/Conclusions: Our experiments are consistent with the view that
Sfrp2 expression in the niche is required to limit stress-induced DNA damage
and canonical Wnt-mediated HSC activation, thus preventing HSC exhaustion.
P356
CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF
HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO
INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS
T Kumode*, H Tanaka, S Rai, Y Taniguchi, I Matsumura
Hematology and Rheumatology, Kinki University Faculty of Medicine, Osaka,
Japan
Background: Recent studies have suggested that megakaryocytes can be
generated from multiple pathways, through some processes bypassing multi-
potent common myeloid progenitor (CMP) and/or bipotent megakaryocyte/ery-
throcyte progenitor (MEP) stages. Furthermore, a recent research demonstrat-
ed the presence of a subset of megakaryocyte-committed cells within
hematopoietic stem cell (HSC) compartment that are activated by inflammatory
stress. However, the immunophenotype of these megakaryocyte-biased HSCs
remains poorly understood. Here, we show that the authentically identified HSC
population includes a functionally distinct subset expressing the C-type lectin-
like receptor 2, CLEC-2, which contributes to inflammation-induced emergent
megakaryopoiesis.
Aims: The present experiments were designed to characterize biological sig-
nificance of CLEC-2+ cells within the immunophenotypically defined HSC com-
partment.
Methods: Bone marrow (BM) cells were obtained from femurs and tibias of 6-
8 weeks old C57BL/6J mice. To induce inflammation, we injected a single dose
of 5 mg/kg pI:C into mice intraperitoneally. HSCs and stem/progenitor cells
were isolated by staining unfractionated BM cells. In this experiment, we defined
Lin-Sca1+c-Kithigh (LSK) CD150+CD34- cells as HSCs, Lin-Sca1-c-Kit+IL-7Rα-
FcRII/IIIlowCD34+ cells as CMP, and Lin-Sca1-c-Kit+IL-7Rα-FcRII/III-CD34- cells
as MEP, respectively.
Results: We first evaluated the expression of CLEC-2 on unfractionated BM
cells. CLEC-2 expression was significantly high on CD41(Itga2b)+ megakary-
ocytes and endothelial cells, but very low on multi- and bipotent committed pre-
cursors, such as CMPs and MEPs, that were sequentially placed downstream
of HSCs. On the other hand, we found that LSK CD150+CD34- HSCs fraction
contained a substantial number of CLEC-2+ cells. Interestingly, the treatment
with pI:C significantly augmented CLEC-2+ fraction from 0.6% to 4.9% in the
HSCs compartment, while it reduced CLEC-2- population. Cell cycle analysis
revealed that most CLEC-2+ HSCs are in G0/G1 and only a small population
are in S/G2/M phase of the cell cycle before stimulation with pI:C, indicating
that this population is also in a quiescent state as well as CLEC-2- HSCs without
stimulation. Although CLEC-2+ HSCs didn’t express CD41 protein, an early
marker of megakaryocytic maturation, before stimulation with pI:C, its expres-
sion was induced by pI:C treatment drastically on CLEC-2+ HSCs, suggesting
that inflammatory signals efficiently activated quiescent CLEC-2+ HSCs and
imposed commitment to the megakaryocyte lineage on these cells. To assess
whether CLEC-2 distinguished functionally different subpopulations of HSCs,
we evaluated colony types yielded from CLEC-2+ and CLEC-2- HSCs after 14-
day in vitro semiliquid cultures. While CLEC-2- HSCs produced numerous CFU-
Mix, CFU-GM/G/M, BFU-E colonies, CLEC-2+ HSCs were less potent to pro-
duce these colonies. On the other hand, CLEC-2+ HSCs had great potential to
produce CFU-Meg. Furthermore, qRT-PCR analysis revealed that CLEC-2+
HSCs exhibited a differential lineage profile from CLEC-2- HSCs, with
increased expression of megakaryocyte/platelet genes such as CD41, pf4, and
vwf, as well as transcription factors gata1, Fog-1, and klf1.
Summary/Conclusions: We identified viable megakaryocytes-biased HSCs
in the most primitive hematopoietic cell fraction of adult BM with a new marker
CLEC-2, which contributes to emergent megakaryopoiesis upon inflammatory
stimulation. Our findings provide a new insight into the hematopoietic hierarchy.
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IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED
HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS
R Ghazanfari1,*, H Li1, D Zacharaki1, HC Lim1, S Scheding1,2
1Stem Cell Center, University of Lund, 2Hematology Department, University
Hospital Lund, Lund, Sweden
Background: Human bone marrow contains a rare population of non-
hematopoietic stem/progenitor cells, the so-called mesenchymal stromal cells
(BM-MSCs). BM-MSCs are essential constituents of the hematopoietic niche
and give rise to skeletal tissues and the hematopoietic stroma. Although BM-
MSCs have been suggested to be stem cells, it has thus far not been thoroughly
investigated, whether or not BM-MSCs fulfill stringent cell properties, i.e. self-
renewal and differentiation in vitro and, importantly, in vivo.
Aims: Based on our recent finding that BM-MSCs were highly enriched in lin-
/CD45-/CD271+/CD140a- BM cells (Li et al, Stem Cell Reports 2014), the cur-
rent study aimed to study the stem cell properties of this putative stem cell pop-
ulation.
Methods: BM aspirates were obtained from healthy donors. Following lineage
depletion, mononuclear cells were antibody-labeled, FACS sorted (single-cell
and bulk), analyzed for single cell gene expression (Fluidigm), differentiation
potential, and propagated as either CFU-F in standard adherent MSC cultures
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or as non-adherent mesenspheres, the latter of which has been reported to
better conserve immature MSC features. Adherently-cultured and sphere-derived
cells were then compared side-by-side for their self-renewal and differentiation
potential in vitro and in vivo by serial xenotransplantation into NSG mice.
Results: Single cell Fluidigm analysis of lin-/CD45-/CD271+/CD140a- BM-
MSCs showed homogeneous mRNA expression levels of MSC associated
genes, such as VCAM1, BMP5, CXCL12, LEPR, and others. Furthermore,
similar progenitor cell frequencies and in vitro self-renewal capacities were
observed under CFU-F and mesensphere assays conditions. CFU-Fs and
mesenspheres displayed similar surface marker profiles and comparable in
vitro tri-lineage differentiation potential towards osteogenesis, adipogenesis
and chondrogenesis. In vivo self-renewal and differentiation potential of primary
BM-MSC were assessed by s.c. transplantation of lin-/CD45-/CD271+/CD140a-
-derived CFU-Fs and spheres into NSG mice. Whereas CFU-F numbers
decreased after transplantation, mesensphere in vivo self-renewal was docu-
mented by increasing numbers of spheres recovered after primary and sec-
ondary transplantation. Additionally, lin-/CD45-/CD271+/CD140a- -derived
spheres displayed full in vivo differentiation capacity in primary and secondary
transplantations.
Summary/Conclusions: Our data provide definite evidence that primary
human lin-/CD45-/CD271+/CD140a- cells fulfill stringent stem cell criteria, i.e.
in vitro and in vivo self-renewal and differentiation. However, BM-MSCs stem
cell properties were preserved only when cells were propagated as non-adher-
ent cells, but not under standard adherent culture conditions.
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GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY
21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS
A Roy1,*, B Liu1, K Goudevenou2, G Bohn2, S Filippi3, N Elliott1, G Cowan2,
D O’Connor2, N Bhatnagar2, S Chou4, M Weiss5, P Vyas6, A Karadimitris2,
I Roberts1,6
1Department of Paediatrics, University of Oxford, Oxford, 2Centre for Haema-
tology, Imperial College London, London, 3Department of Statistics, University
of Oxford, Oxford, United Kingdom, 4Division of Hematology, The Children’s
Hospital of Philadelphia, Philadelphia, 5Hematology, St. Jude Children’s
Research Hospital, Memphis, United States, 6MHU, Weatherall Institute of
Molecular Medicine, University of Oxford, Oxford, United Kingdom
Background: Trisomy 21 (T21) causes multilineage perturbation of fetal and
neonatal haematopoiesis. We have previously demonstrated that 2nd trimester
Down Syndrome (DS) fetal liver (FL) samples have increased numbers of
immunophenotypic haematopoietic stem cells (HSC) and megakaryocyte ery-
throid progenitors (MEP) together with a severe reduction in committed B pro-
genitors (CBP). Functional studies and Fluidigm gene expression assays sup-
port lineage bias favouring megakaryocyte-erythroid over B lymphoid differen-
tiation and proliferation but did not identify causative genes on chromosome
21 (Hsa21) reflecting the limited number of Hsa21 genes which can be included
on the panel1. Determining the mechanisms underlying these defects is likely
to be important for understanding why young children with DS are more prone
to myeloid and lymphoid leukaemias. 
Aims: To investigate the impact of the additional copy of chromosome 21
(Hsa21) on the transcriptome of primary FL HSC and progenitor cells (HSPC).
Specifically, to determine (a) whether there is a T21 ‘gene expression signature’
and whether this is consistent across all HSPC types and samples and (b)
whether T21 causes consistent patterns of genome-wide dysregulation of gene
expression in HSPC. 
Methods: Genome-wide transcriptome profiling was performed by RNA
sequencing of 8 flow-sorted FL HSPC populations (immunophenotypic HSC,
MPP, LMPP, CMP, MEP, GMP, ELP and CBP as previously described1) from 7
gestation-matched 2nd trimester FL samples: DS (n=4) and normal (n=3).
Indexed cDNA libraries were multiplexed and sequenced using Illumina
HiSeq2500. Raw reads generated were subjected to an in house RNASeq
analysis pipeline including adaptor trimming, QA, filtering and alignment of
genome and transcriptome using TopHat2. Read-count based expression
analysis was performed using DESeq2, and HTSeq-count; and differential
expression compared in each HSPC population between the DS and normal
FL samples. LOESS (Local polynomial regression fitting) was used for up/down
regulated chromosomal domains. Data analysis and visualisation was per-
formed with R.
Results: Using ANOVA, ~2700 genes were differentially expressed (DE)
between HSPC populations from all 7 samples (FDR<0.001). Principal Com-
ponent Analysis (PCA) showed good spatial segregation of HSPC into distinct
lineage-specific populations in both normal and DS FL. The best spatial segre-
gation was found using the top 300 DE genes which also showed that while
PC1 separated normal and T21 HSPC equally, PC2 accounted for a greater
segregation of T21 than normal FL HSPC. Although lineage-specific gene
expression patterns were largely maintained in DS HSPC, there were differ-
ences in levels of gene expression between DS and normal HSPC with the
number of significantly (FDR<0.05) DE genes ranging from 10 in CMP to 1225
in CBP. Perturbation of lineage-associated gene expression was particularly
prominent in CBP, HSC, MPP and MEP. More than half of all protein coding
Hsa21 genes (154/243) were expressed in both DS and normal FL HSPC. With-
in each HSPC population, a consistent Hsa21 gene expression profile was seen
in all 7 samples and most of the differences in Hsa21 gene expression between
DS and normal HSPC were an exaggeration of the ‘normal’ HSPC profile rather
than an aberrant expression of a different set of Hsa21 genes or a single Hsa21
gene. Using Loess smoothing, Hsa21 gene expression was consistently higher
in DS HSPC compared to normal HSPC along the entire length of Hsa21 rather
than in clearly defined domains. Finally, the majority of DE genes in all HSPC
populations were located on chromosomes other than Hsa21.
Summary/Conclusions: These data show that global perturbation of fetal
haematopoiesis by T21 is matched by genome-wide dysregulation of gene
expression affecting most chromosomes in all HSPC, particularly lymphoid
progenitors. Although DS FL HSPC populations all showed a ‘T21 gene expres-
sion signature’, this reflected more pronounced expression of the same Hsa21
genes as in normal HSPC rather than being driven by aberrant expression of
a small subset, or single, Hsa21 gene(s).
Reference
1. Roy A et al., PNAS 2012 Oct 23; 109(43):17579-84.
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GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM
CELL GENERATION
E De Pater1,*, P Solaimani Kartalaei2, C Vink2, R van der Linden2, E Dzierzak3
1Hematology, 2Cellbiology, Erasmus MC, Rotterdam, Netherlands, 3The
Queen’s Medical Research Institute College of Medicine and Veterinary Med-
icine, Edinburgh, United Kingdom
Background: Knowledge of the key factors that drive hematopoietic stem cell
(HSC) generation is of particular importance for current hematopoietic regen-
erative approaches and reprogramming strategies. At mouse embryonic day
(E)10.5, the permanent adult hematopoietic system initiates with the formation
of HSCs in clusters lining the major embryonic vasculature (aorta, vitelline and
umbilical arteries) in a process called endothelial-to-hematopoietic transition
(EHT). From all hemogenic endothelial cells (HECs) only few generate an HSC. 
Aims: We aime to find novel regulators of EHT and possibly a new and more
faithful HSC marker.
Methods: By CRISPR Cas9 genome editing we have generated a Gpr56
knockout zebrafish model to study its function during embryonic development
Results: A comparative RNA sequencing analysis of HEC versus HSCs from
mouse tissue by our lab has resulted in the identification of several candidate
regulatory genes of EHT. The top candidate, gpr56, showed a 4.88 log fold
(30x) increase during endothelial to HSC transition and was recently implicated
in HSC function in the adult mouse. Upon gpr56 knockdown, zebrafish embryos
showed severe reduction of cmyb expressing cells (HSC marker, a reduction
in CD41 expressing cells (expressed in HSCs and progenitors) and a reduction
in EHT events, showing a requirement for Gpr56 in HSC generation. Rescue
with both gpr56 zebrafish and mouse RNA resulted not only in the restoration
of cmyb expressing cells, but in an expansion and ectopic expression of cmyb
expressing cells to the axial vein. This shows that Gpr56 is sufficient for HSC
generation and suggests that the function of Gpr56 is conserved between
mouse and zebrafish.
Summary/Conclusions: Since Gpr56 is required for HSC generation and
functions at the membrane, it is a perfect target for manipulation by bioactive
compounds. Therefore, we want to identify the direct binding partners of Gpr56
(both its ligand and downstream signaling partners) and identify bioactive com-
pounds which regulate Gpr56 function and thus manipulate HSC generation
for possible therapeutic regenerative purposes.
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DENDRITIC CELL THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA
(MPM): FINAL RESULTS OF A PHASE I/II CLINICAL TRIAL
K Saevels1,*, S Anguille1, A Van de Velde1, A Snoeckx2, J Van Meerbeeck3,
T Van den Wijngaert4, E Lion5, B Stein5, G Nijs5, M Huizing6, V Van Tendeloo5,
P Germonpré3, E Smits5, Z Berneman1
1Haematology, 2Radiology, 3Thorax Oncology, 4Nuclear Medicine, 5Center for
Cell therapy and Regenerative Medicine, 6Oncology, University Hospital
Antwerp, Edegem, Belgium
Background: Cellular therapies, including the use of dendritic cells, are gaining
momentum as a therapeutic option in cancer patients, especially in light of
recent data showing that such therapies have the potential to improve survival
often without causing significant toxicity. Except for a small group of long-term
survivors (i.e. survival beyond 36m), patients with Malignant Pleural Mesothe-
lioma (MPM) face little prospect of survival by any of the mainstream treatments. 
Aims: The aim of this study was to establish the potential utility of dendritic cell
therapy for immune modulation in MPM patients.
Methods: Ten MPM patients with non-resectable disease (median age 62
years, stage 1-2, PS 0-1) were included in this open-label phase I/II clinical
trial (NCT01291420) after completion of frontline platinum/pemetrexed-based
chemotherapy. Autologous DCs were propagated in vitro from fresh peripheral
blood monocytes obtained by leukapheresis, according to our previously pub-
lished protocol (Van Tendeloo et al. PNAS 2010). Antigen loading of the DCs
was performed by electroporation of mRNA encoding the mesothelioma-asso-
ciated tumor antigen Wilms’ tumor-1 (WT1). DCs (10x106 cells per injection)
were administered 4 times on a biweekly basis, after which response evaluation
was performed by various immunological assays and imaging studies. 
Results: All patients completed the intended treatment schedule of 4 biweekly
DC vaccinations; most patients continued to receive DC vaccinations with a
mean number 18 vaccines administered per patient (range 5-44). The vacci-
nations were well tolerated; none of the patients showed overt signs of systemic
toxicity. All patients except one demonstrated a significant delayed-type hyper-
sensitivity skin reaction, providing evidence of vaccine-elicited immunity in vivo.
Progression-free survival, determined by repeated imaging studies, was 5
months. Median overall survival calculated from start of chemotherapy was 36
months. After exclusion of 4 long-term survivors, median overall survival was
corrected to 32 months. 
Summary/Conclusions: DC therapy in chemotherapy-treated MPM patients
is feasible, safe and immunogenic. Overall survival data of this study compare
favorably to the 22-month overall survival reported for a similar cohort of patients
(Hillerdal et al. J Thorac Oncol 2008). This is in line with other recent studies
showing that DC therapy can confer overall survival benefit to cancer patients.
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EXPLORING CHIMERIC NATURAL KILLER RECEPTOR NKP30 EXPRESSING
HUMAN T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY TO ACUTE
LEUKEMIA
P Ploch, S Khan, A Bhatti, L Krebs, M Theobald, UF Hartwig*
III. Dept. of Medicine - Hematology, Internal Oncology & Pneumology, University
Medical Center Mainz, Mainz, Germany
Background: Adoptive cellular therapy (ACT) of chimeric antigen receptor
(CAR)-reprogrammed T cells has advanced as a valuable personalized and
effective immunotherapy for leukemia and solid tumors. In particular, clinical
trials on CD19+ lymphomas using CD19 CAR expressing T lymphocytes have
revealed highly promising results. However, suitable antigens for an effective
and specific CAR-mediated therapy to acute myeloid leukemia (AML) are still
warranted as e.g. CD33 and CD123 CAR expressing T cells induce potent
immune responses not only to AML blasts but also recognize normal hematopoi-
etic stem cells (HSC). In contrast, B7H6, a member of the B7 family, is frequently
expressed on various tumor cells including AML blasts but not constitutively
expressed on normal tissues and recognized by the natural killer (NK) cell acti-
vating receptor NKp30. Moreover, NKp30 recognizes human leukocyte antigens
(HLA)-B-associated transcript 3, a nuclear factor that is secreted and translo-
cated to the cell surface in stressed and transformed cells.
Aims: In the current study, we therefore explored human T cells redirected by
retroviral transduction of a NKp30-based CAR for effective antileukemic immu-
nity in vitro and adoptive immunotherapy to AML in vivo using humanized mice. 
Methods: Peripheral blood mononuclear cells (PBMC) or immunomagnetically
purified human T cells were polyclonally stimulated and reprogrammed with a
CAR based on the external region of the NKp30 receptor fused to the CD3ζ
chain signaling domain (kindly provided by Dr. S. Klobuch, Dept. of Internal
Medicine 3, Medical University Regensburg, Germany) by retroviral gene trans-
fer. Transduced cells were further selectively expanded utilizing puromycin resist-
ance. NKp30 expression was determined by flow cytometry. IFN-γ ELISPOT
analyses and cytotoxicity assays were performed to assess antileukemic
responses to acute leukemia lines and primary AML blasts in vitro and in vivo
by adoptive transfer of redirected T cells into leukemia engrafted NSG mice.
Expression of B7H6 in target cells was examined by RNA-based RT PCR.
Results: Following transduction and puromycin selection ≥90% of CD3+ T cells
expressed the NKp30 CAR. Upon coculture with B7H6 expressing targets such
as K562 and HL-60 (myelogenous leukemia cell lines), NALM 16 (pre-B-ALL)
and AML MZ987 NKp30-redirected T cells elicited potent IFN –γ release and
exhibited cytolytic activity to both leukemia lines and primary AML blasts. These
responses were specific as no reactivity to the B7H6 negative myeloma line
U266 was observed. Furthermore, Mock transduced T cells used as controls
did not reveal significant alloreactive responses. To test for antitumor immunity
in vivo, we first examined reactivity of NKp30-redirected T cells to K562 cells
engrafted into NSG mice and observed clear reduction of tumor burden. More-
over, first studies revealed, that adoptive transfer of 1 - 5x106 HLA-matched,
NKp30-redirected CD3+ T cells into NSG mice engrafted with patient derived
AML blasts for up to 5% thus resembling minimal residual disease at time of
transfer resulted in significant leukemia regression. Further experiments to
elaborate the therapeutic efficacy and what extent CD4+ and CD8 T cells con-
tribute to this antileukemic immunity are in progress.
Summary/Conclusions: These studies demonstrate that human T lympho-
cytes can be successfully redirected to acute leukemia by NK cell activating
receptor based CARs such as the NKp30-CAR. As its ligand B7H6 has not
been reported to be expressed on CD34+ HSC, this antigen might be an inter-
esting target for adoptive immunotherapy to AML.
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TARGETING CD123+ ACUTE MYELOID LEUKEMIA CELLS WITH
REDIRECTED NATURAL KILLER CELLS
M Morgan1,*, J Dahlke1, O Oberschmidt2, S Kloess2, K Vu1, J Wenzl1,
C Neudoerfl3, A Kloos4, M Heuser4, U Koehl2, C Falk3, A Schambach1
1Institute of Experimental Hematology, 2Institute of Cellular Therapeutics, IFB-
Tx, 3Institute of Transplant Immunology, IFB-Tx, 4Hematology, Hemostasis,
Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover,
Germany
Background: The utility of immune cell modification via chimeric antigen recep-
tors (CARs) has been demonstrated clinically for T cells (e.g. versus CD19+
lymphatic leukemia) and is also currently investigated for natural killer (NK)
cells. The observation that CD123 is highly expressed on the surface of many
primary human acute myeloid leukemia (AML) cells makes CD123 a clinically
interesting target. 
Aims: The aim of this work was to engineer NK92 cells to express a CAR that
detects and eradicates CD123+ AML cells.
Methods: NK92 cells, an NK cell line, were transduced with state-of-the-art
alpharetroviral self-inactivating (SIN) vectors encoding EGFP alone as control
or a third generation CAR engineered with an anti- CD123 single chain variable
fragment (scFv) (with or without an HA-tag) and containing the CD28 trans-
membrane domain, the 4-1BB costimulatory domain, the CD3ζ signaling domain
and an internal ribosomal entry site (IRES) element for EGFP expression. EGFP,
CD123-CAR and HA-CD123-CAR protein expression were quantified by flow
cytometry and verified by immunoblotting after separation by SDS-PAGE. The
kinetics of cytotoxicity elicited by modified NK92 cells was monitored over 48
hours at effector:target ratios of 5:1 and 10:1 and quantified by flow cytometry.
Results: Transduction efficiencies were 76% for the EGFP control vector at
multiplicity of infection (MOI) of 0.3, 25% for the CD123-CAR vector at MOI of
0.3 and 30% for the HA-CD123-CAR vector at MOI of 1. Transduced NK92
cells were enriched to >95% purity by flow cytometric sorting based on EGFP
expression and sorted NK92 cell populations were used for the following exper-
iments. Using an anti-HA antibody, the HA-CD123-CAR was detected in >85%
of sorted NK92 cells modified with the HA-CD123-CAR but not in the EGFP
controls or in cells modified with the CD123-CAR lacking the HA-tag. The
CD123-CAR was detected with a goat-anti-human IgG antibody (approximately
60% of sorted cells), but the HA-CD123-CAR was less efficiently recognized
with this antibody (approximately 30% of sorted cells). Untransduced NK92
and EGFP-transduced NK92 cells served as negative controls for antibody
detection. Flow sight analysis provided evidence that the HA-CD123-CAR was
expressed on the surface of NK92 cells. SDS-PAGE and immunoblotting exper-
iments further demonstrated HA-CD123-CAR and EGFP transgene expression
in the respective samples. Transduced populations were stably cultivated and
expanded for several months. Compared with the EGFP-modified NK92 cells
used as a control, CD123-CAR- and HA-CD123-CAR-modified NK92 cells
exhibited greatly enhanced cytotoxicity against the CD123+ AML target cell line
KG1a upon coincubation at effector:target ratios of 5:1 and 10:1. The AML-
specific cytotoxicity of NK92-CD123-CAR cells is currently being confirmed
with primary AML cells.
Summary/Conclusions: We demonstrate efficient modification of NK92 cells
with a clinically relevant CAR designed to target CD123-expressing cells. Impor-
tantly, CD123-CAR modified NK92 cells exhibited greatly improved ability to
eliminate CD123+ AML cells. Thus, our results support the continued investi-
gation of NK cell redirection with molecules designed to target AML-specific
antigens.
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PRECLINICAL EVALUATION OF CHIMERIC ANTIGEN RECEPTOR
LYMPHOCYTES MODIFIED BY SLEEPING BEAUTY TRANSPOSON FOR
THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
CF F Magnani1,*, C Cappuzzello1, C Mezzanotte1, F Benedicenti2, A Calabria2,
E Tenderini2, S Tettamanti1, LJ Cooper3, A Aiuti2, E Montini2, A Biondi1, E Biagi1
1Department of Pediatrics, University of Milano-Bicocca, San Gerardo Hospi-
tal/Fondazione MBBM, Tettamanti Research Center, Monza, 2San Raffaele
Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy, 3The University
of Texas MD Anderson Cancer Center, Houston, United States
Background: Chimeric antigen receptor (CAR)-modified T-cell adoptive
immunotherapy is an emerging therapeutic option proven effective in the treat-
ment of hematological malignancies. However, the success of CAR-engineered
T cells strictly depends on the optimization of several critical parameters related
to cell manufacturing and gene therapy. 
Aims: We sought to develop a novel gene-modification protocol to engineer
cytokine-induced killer cells (CIKs) with CD19 CAR using the Sleeping Beauty
(SB) transposon system. 
Methods: With an improved SB transposon platform, we genetically modified
CIK cells to express the CAR specific for acute lymphoblastic leukemia (ALL)
CD19+ blasts and evaluated their preclinical efficacy and safety.
Results: The non-viral transduction protocol combined to the large scale pro-
duction process minimally affected the phenotype of the CD19 CAR CIK-cell
final product. Stable expression of CD19 CAR (average 60%) was achieved
together with an efficient T cell expansion suitable for clinical application. Fur-
thermore, modified cells displayed persistence of cell subsets with memory
phenotype, specific and effective anti-tumor activity. Upon comparison with
conventional T-SB platforms, our method achieved superior results in terms of
expansion, CAR expression and functionality. Adoptive transfer of CD19.CAR
lymphocytes led to a significant antitumor response in vivo. CD19.CAR CIK
cells also controlled leukemia in xenograft models of human ALL, bearing the
high-risk features of MLL–ENL and Ph-like (PAX5/AUTS2) gene rearrange-
ments. Frozen/thawed CD19.CAR CIK cells remained active in vitro and in
vivo with efficacy comparable with that of fresh CIK cells. Furthermore, NOD-
SCID-γchain-/- (NSG) mice were treated with CD19.CAR CIK cells to evaluate
general toxicity, tissue damage, and biodistribution. Notably, we found no evi-
dence of integration enrichment near cancer-related genes and transposase
expression in the final cell product. 
Summary/Conclusions: Taken all together, our findings describe a novel
donor-derived non-viral CAR approach characterized by efficient cell transfec-
tion and expansion that may widen the range of applications of T cell-based
immunotherapy. We are currently designing a phase I/II study for relapsing
and remitting ALL after Hematopoietic Stem Cell Transplantation (HSCT).
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CORD BLOOD DERIVED NK CELLS TRANSFER HISTONE H2AZ TO
MULTIPLE MYELOMA CELLS CAUSING DIRECT AND INDIRECT
CYTOTOXICITY
B Martín-Antonio1,*, G Suñe1, A Najjar2, L Perez1, E Lozano3, C Bueno4,
J Estanyol5, A Urbano-Ispizua1
1Hematology, Hospital Clinic/IDIBAPS/Josep Carreras Leukemia Research
Institute, Barcelona, Spain, 2Cancer Systems Imaging, MD Anderson Cancer
Center, Houston, United States, 3Hematology, Hospital Clinic/IDIBAPS, 4Hema-
tology, Josep Carreras Leukemia Research Institute, 5Proteomics, University
of Barcelona, Barcelona, Spain
Background: Cord blood derived natural killer cells (CB-NK) are a feasible
source of NK cells to use in immune cell therapy for hematological malignan-
cies. We previously showed that CB-NK exert a transmissible cytotoxicity
towards multiple myeloma (MM) cells, which involves lipid-protein vesicle trans-
fer between initial MM cells exposed to CB-NK (primary MM cells) and the
recipient MM cells exposed to primary MM cells (secondary MM cells).
Aims: We aimed to determine which proteins with cytotoxic activity were trans-
ferred from CB-NK to primary MM cells, and from primary to secondary MM cells.
Methods: CB-NK and MM cells (ARP1) were labeled with heavy aminoacids
(hAA) in independent experiments, then they were co-cultured and FACS sort-
ed before we performed TRANS-SILAC proteomics to identify proteins trans-
ferred from CB-NK to MM cells and from MM to CB-NK. Transfer of these pro-
teins was validated by confocal fluorescence microscopy. Functional assays
by lentiviral overexpression of these proteins were performed to evaluate cyto-
toxic effects in CB-NK and MM cells.
Results: We demonstrated CB-NK protein transfer between primary and sec-
ondary MM cells, which represents a dilution of the cytotoxic CB-NK material
from primary to secondary MM cells (Figure 1A). Interestingly, under the pres-
ence of CB-NK, primary MM cells transfer a high amount of their own proteome
to CB-NK and to secondary MM cells. A high number of Histone proteins were
on the list of transferred proteins. We focused on the functional role of Histone
H2AZ variant 1 which was transferred from CB-NK to primary and then to sec-
ondary MM cells. Time lapse in vivo confocal microscopy showed the direct
and secondary transfer of H2AZ between MM cells associated to cell death.
This transmission occurred either through vesicles or large intercellular struc-
tures (Figure 1B). H2AZ overexpression in CB-NK increased CB-NK cytotoxicity
against MM cells. Consistently, H2AZ induced overexpression was lethal not
only in MM cells but also in Burkitt Lymphoma (Ramos) and acute promyelocytic
leukemia (HL60) cell lines. This cell death was caspase independent (Figure
1C-D). H2AZ-mediated cytotoxicity was also transmissible from H2AZ-overex-
pressing MM cells to neighboring MM cells causing cell death in this secondary
MM population.
Figure 1.
Summary/Conclusions: Our findings reveal a novel mechanism of malignant
cell cytotoxicity performed by NK cells which is caspase independent and medi-
ated by histones. We demonstrate the relevance of cell-cell communication
mediated by intercellular structures as a mechanism leading to MM cell death.
Molecules transferred from CB-NK to MM cells can lead to the discovery of
novel therapeutic targets such as H2AZ in hematological malignancies.
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ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN
ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED
IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA
M Dusseaux*, D Le Clerre, A Gouble, J Smith
Cellectis, Paris, France
Background: Adoptive immunotherapy with autologous T-cells expressing
chimeric antigen receptors (CARs) targeting CD19 has achieved long-term
remissions in patients with B-cell leukemia, pointing out that CAR technology
may become a game changer in cancer treatment.
Aims: In the present study we have assessed the feasibility of CAR-mediated
targeting of the CD38 antigen, which is highly expressed on tumors cells from
most patients with acute lymphoblastic leukemia (T-ALL) and multiple myeloma
(MM). However, expression of CD38 on normal activated T-cells is a significant
hurdle for the development of CAR T-cells against this protein, since antigen-
expressing T-cells will be targeted, potentially preventing the efficient production
of anti-CD38 CAR T-cells.
Methods: To circumvent this issue we have used Transcription Activator-Like
Effector Nuclease (TALEN®) gene editing technology to inactivate the CD38
gene (CD38 KO) in T-cells, prior to transduction with a lentiviral vector encoding
an anti-CD38 CAR. To validate this approach, we have examined the capacity
of CD38 KO cells expressing an anti-CD19 CAR to eliminate CD19+ cells in
order to determine if the absence of CD38 has an impact on T-cell activity.
Experiments in an orthotopic Burkitt’s lymphoma mouse model showed that
CD38 disrupted T-cells expressing anti-CD19 CAR were able to mediate an in
vivo anti-tumor activity similar to unmodified T-cells expressing an anti-CD19
CAR. These results demonstrate that T-cells lacking CD38 are capable of medi-
ating efficient in vivo anti-tumor activity.
Results: Gene editing technology can also be used to manufacture T-cells
from healthy donors to generate allogeneic “off-the-shelf” engineered CAR+ T-
cell-based frozen products. We have previously demonstrated that TALEN®
mediated inactivation of the TCRa constant (TRAC) gene can be achieved at
high frequencies and eliminates the potential for edited T-cells to mediate Graft
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versus Host Disease (GvHD). Furthermore, multiplex genome editing can lead
to the production of double KO (TRAC and CD38) T-cells, allowing large scale
manufacturing non allo-reactive CD38 specific T-cells. We will present data
demonstrating that such gene-edited anti-CD38 CAR T-cells can be efficiently
produced and display high cytotoxic activity.
Summary/Conclusions: Thus, large-scale manufacturing of allogeneic, non-
alloreactive CD38 specific T-cells from a single healthy donor could offer the
possibility of an off-the-shelf treatment that would be immediately available for
administration to a large number of T-ALL and MM patients.
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OPTIMIZED AAV-MEDIATED HUMAN FACTOR VIII GENE THERAPY IN
HEMOPHILIA A MICE AND CYNOMOLGUS MACAQUES
JA Greig1,*, Q Wang1, AL Reicherter1, E Bote1, D McMenamin1, C Draper1,
SJ Chen1, AL Hanlon2, T Goode1, KR Clark3, S Wadsworth3, L Wang1,
JM Wilson1
1Gene Therapy Program, Department of Medicine, 2School of Nursing, Uni-
versity of Pennsylvania, Philadelphia, 3Dimension Therapeutics, Cambridge,
United States
Background: Hemophilia A is an X-linked bleeding disorder driven by a defi-
ciency in human coagulation factor VIII (hFVIII), which occurs at a frequency of
1 in 5,000 live male births. The bleeding manifestations of hemophilia, which
directly correlate with circulating FVIII activity, can result in significant disability
or even death. Protein replacement therapy is effective in maintaining a mild or
moderate phenotype. However, infusion frequency remains burdensome to
patients. AAV-based gene therapy has the potential to provide long-term improve-
ment of the disease phenotype following a single administration of vector.
Aims: In an effort to optimize expression of hFVIII for the treatment of hemophilia
A, an extensive study was performed combining liver-specific promoter and enhancer
elements with a codon-optimized human B-domain-deleted hFVIII transgene.
Methods: Due to the large size of the FVIII coding sequence, it is critical for
gene expression control elements to be as short as possible while retaining
hepatocyte-restricted transcription. Therefore, several strong liver-specific pro-
moters were shortened and combined, with combinations consisting of up to
three liver-specific enhancer sequences, to generate 42 enhancer/promoter
combinations. These 42 liver regulatory gene cassettes were then packaged
into the AAVrh10 capsid and tested in FVIII KO mice. Following intravenous
(IV) administration of 1010 genome copies (GC), mice were bled every 2 weeks
to follow hFVIII activity and antibody generation to the transgene.
Results: At week 2 post-injection, mice showed a range in hFVIII activity from
0.12-2.12 IU/ml. FVIII KO mice developed antibodies to hFVIII at week 4, and
by week 8, mice in most of the 42 vector groups had detectable anti-hFVIII IgG
levels. Based on the FVIII KO mouse studies and a small pilot rhesus macaque
study, 2 of the original 42 enhancer/promoter combinations were selected for
further evaluation in cynomolgus macaques, using 2 different Clade E capsids
for expression. Each of the 4 vector combinations were administered IV at a
dose of 1.2x1013 GC/kg into 5 macaques per group. With one capsid plus
enhancer/promoter combination, peak expression of 37% of normal FVIII levels
was seen at week 2 post-vector administration, which then plateaued at 20%
of normal. While antibodies to the hFVIII were detected in the majority of
macaques by week 8, antibodies remained undetectable in 2 animals at week
30 post-vector administration.
Summary/Conclusions: The use of an AAVrh10 vector to deliver a codon-
optimized, B-domain-deleted hFVIII transgene results in a substantial increase
in FVIII expression in both FVIII KO mice and cynomolgus macaques. The
majority of animals generated an anti-FVIII antibody response by week 8 post
vector delivery. However, 2 of the macaques dosed were free of a detectable
antibody response through week 30. Overall, our study supports the continued
development of AAV-based gene therapeutics for hemophilia A.
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A DOSE-ESCALATING PRECLINICAL STUDY TO DETERMINE THE SAFETY,
EFFICACY, AND MINIMUM EFFECTIVE DOSE OF A CLINICAL CANDIDATE
VECTOR IN A MOUSE MODEL OF HEMOPHILIA B
L Wang1,*, J White1, Z He1, T Goode1, D McMenamin1, C Draper1, C Brown1,
L Kattenhorn2, G Wilmes2, R Clark2, S Wadsworth2, JM Wilson1
1Gene Therapy Program, Department of Medicine, University of Pennsylvania,
Philadelphia, 2Dimension Therapeutics, Cambridge, United States
Background: While safe and effective recombinant FIX therapeutics are cur-
rently available, patients with Hemophilia B may gain additional clinical benefit
from longer-acting therapeutic options. The use of rAAV-based gene therapy
to obtain long-term expression of a human FIX (hFIX) transgene may be ideal
in this setting. In recent years, academic institutions have begun to generate
promising clinical data in this area. However, there is an ongoing need to repli-
cate and extend these results in a commercial setting in order to allow such
new therapies to become broadly available to patients.
Aims: Dose-dependent inflammatory responses that impact transgene expres-
sion have been reported in clinical trials with rAAV FIX vectors. This highlights
the need for clinical rAAV vectors to have the highest possible potency, allowing
the overall vector dose to be reduced. The goal of this study is to investigate
the potential of a clinical candidate AAV vector to achieve potent, safe, and
effective levels of hFIX expression in a mouse model of Hemophilia B, while
also mapping the vector’s minimum effective dose (MED).
Methods: We have developed a potent AAV serotype rh10 vector containing
codon-optimized human FIX (hFIXco) cDNA under the control of a highly active
liver-specific promoter with the goal of achieving approximately 10% of normal
FIX levels in patients. In preparation for a clinical trial, we tested this
AAVrh10.hFIXco vector for aspects of efficacy and safety in the factor IX knock-
out (FIX-KO) mouse model of Hemophilia B.
Results: A dose-dependent increase in FIX protein expression and activity was
observed following intravenous administration at vector doses between
1.6x1010 and 5.0x1013 GC/kg. FIX-KO mice that received AAVrh10.hFIXco at
1.6x1010 GC/kg achieved between 5% and 8% of normal hFIX expression by
2 weeks after dosing and maintained this level for the 90-day study period. In
comparison, with a dose of 5.0x1010 GC/kg, FIX-KO mice achieved between
30% and 42% of normal hFIX expression by day 14, which was also maintained
for the 90-day study period. From these results, we can estimate that the vector
dose required to achieve the stated goal of 10% of normal FIX expression
levels would be between 1.6x1010 GC/kg and 5.0x1010 GC/kg. Levels of hFIX
antigen expression correlated well with measured hFIX activity levels, where
doses between 1.6x1010 GC/kg and 5.0x1010 GC/kg corresponded with 8% to
35% of normal hFIX activity. FIX-KO mice also provide an excellent model to
examine the effects of AAVrh10.hFIXco on hemophilia B-related complications,
where mice are prone to spontaneous bleeds and often suffer from fatal hem-
orrhages after handling or trauma. In this study, 4 out of 7 animals in the Day
90 control group succumbed to hemophilia-related complications. In contrast,
FIX-KO mice receiving a single dose intravenous administration of
AAVrh10.hFIXco at doses of 1.6x1010, 5.0x1010, 1.6x1011, 5.0x1011, 5.0x1012,
and 5.0x1013 GC/kg showed no test article-related mortality, clinical pathology,
gross pathology, or histopathologic findings.
Summary/Conclusions: Overall, our study demonstrates the safety, efficacy,
and MED for a clinical candidate AAVrh10.hFIXco vector in FIX-KO mice. These
findings support the progress of a gene therapy based treatment for Hemophilia
B in its transition to clinical use.
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THE LCR-FREE GAMMA-GLOBIN LENTIVIRAL VECTOR COMBINING TWO
HPFH ACTIVATING ELEMENTS CORRECTS MURINE THALASSEMIC
PHENOTYPE IN VIVO
P Antoniou*, E Papanikolaou, M Georgomanoli, E Drakopoulou, N Anagnou
Cell and Gene Therapy, U. Athens and Biomedical Research Foundation of
the Academy of Athens, Athens, Greece
Background: The β-thalassemias result from reduced or absent expression
of the β-chain of adult hemoglobin (HbA;α2β2) causing precipitation of excess
α-chains and eventually apoptosis. Thus, factors that reduce the degree of
chain imbalance such as an innate ability to increase fetal hemoglobin
(HbF;α2γ2), as in the HPFH phenotype, have an ameliorating effect on the dis-
ease. Hence, gene therapy of β-thalassemia based on γ-globin addition via
viral vectors, displays a considerable advantage. 
Aims: In this study, we assessed the efficiency of our previously generated
LCR-free γ-globin self-inactivating vector GGHI (Papanikolaou et al. Hum Gene
Ther 23:15-31, 2012) to correct the thalassemic phenotype in vivo in the Hbth3/+
C57BL/6J mouse model (thal3 model). 
Methods: Recipient mice aged about 12 weeks, were treated with the myelo-
suppresant factor busulfan, while donor mice, of the same age and of the oppo-
site gender, were treated with 5-fluorouracil, prior to transplantation. Total bone
marrow was isolated from 5-fluorouracil–treated donors and was transduced
with GGHI in X-VIVO™ medium containing cytokines (mIL-1a, mIL-3, mIL-6
and mSCF) at an MOI=30, employing the spinoculation method. The trans-
duced cells were then transplanted via tail vein intravenous injection to the
recipients. To evaluate the therapeutic effect of GGHI, blood was collected from
recipient mice prior and post transplantation for 4 months, hemoglobin levels
(g/dl), hematocrit and total red blood cell count were assessed by a hemato-
logical analyzer. The expression of human γ-globin in peripheral blood was
assessed by flow cytometry using an anti-HbF monoclonal antibody. 
Results: Our results documented that transplanted thalassemic mice (n=4)
with GGHI-corrected hemopoietic stem cells, exhibited an increase in hemat-
ocrit values by 22.3% (ranging from 24.5% to 35.7%, p=0.02) with a concomi-
tant increase in hemoglobin levels, reaching an average of 11.1 g/dl in trans-
planted mice vs 8.8 g/dl to those prior to transplantation, which corresponds to
a 25.5% increase (p=0.008). Human γ-globin was detected in the peripheral
blood of all transplanted animals by flow cytometry and ranged from 20 to 45%.
Transduction efficiency in these experiments was estimated to be 35-50% as
assessed in vitro in CFUs by PCR for vector-specific sequences. 
Summary/Conclusions: In summary, these results demonstrate for the first
time that viral-mediated globin gene transfer via an LCR-free γ-globin lentiviral
vector in hemopoietic stem cells effectively corrects a severe hemoglobin dis-
order.
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BALANCE OF ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR)
BINDING AFFINITY AND DENSITY IN AN IN VITRO MODEL OF ACUTE
MYELOID LEUKEMIA
S Arcangeli1,*, M Bardelli2,3, MC Rotiroti1, L Simonelli2,3, CF Magnani1, A Biondi1,
E Biagi1, S Tettamanti1,2, L Varani3
1Pediatrics Department, M. Tettamanti Research Center, University of Milano
Bicocca, Monza, Italy, 2USI Università della Svizzera italiana, Lugano, 3Institute
for Research in Biomedicine, Bellinzona, Switzerland
Background: Chimeric Antigen Receptors (CARs)-redirected T lymphocytes
are a promising novel immunotherapeutic approach, nowadays object of accu-
rate preclinical evaluation also for the targeting of Acute Myeloid Leukemia
(AML). In this context, we recently developed a CAR against the CD123, over-
expressed on AML blasts and leukemic stem cells (LSCs). However, the poten-
tial recognition of low CD123-positive healthy tissues, through the so called
“on-target-off-organ” effect, limits the safe clinical employment of CAR-redi-
rected T cells. In order to address this issue, among the CAR design variables
under investigation, it has been found that CAR-T cell functional profiles can
be modulated by tuning the binding affinity to the target antigen, in an extremely
context-dependent manner.
Aims: We aimed therefore to unravel how the interplay existing between CAR
affinity, antigen density and CAR expression could impact on anti-CD123 CAR-
redirected effector cells efficacy against leukemic cells and safety towards
healthy cells.
Methods: We developed a novel integrated model for the functional screening
of in silico-selected CAR mutants, starting from predicted antibody binding
properties, that are then in vitro validated based on CAR-redirected T cell relat-
ed biological requirements. We therefore generated and tested anti-CD123
lower CAR affinity mutants by single residues substitution on the wt CAR. In
this way, the affinity mutants produced should provide the same binding site
as the original molecule, representing the binding properties variation the only
variable in the system.
Results: In particular, exploiting a panel of anti-CD123 CAR affinity mutants,
we defined both “lytic” and “activation” antigen thresholds showing that, while
the early cytotoxic activity is not affected neither by CAR expression nor by
CAR affinity tuning, the CAR expression represents the main variable impairing
later effector functions. In view of a future clinical translation of this approach,
the lowest affinity mutant suggested a potential threshold of affinity below which,
even if the safety profile is preserved, the antileukemic efficacy could be
impaired.
Summary/Conclusions: Overall, the full dissection of all these variables offers
additional knowledge for the proper design of suitable anti-CD123 CAR-based
approaches for the treatment of AML.
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PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF
GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR
FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY
VOLUNTEERS AND SCD PATIENTS
M Patel1,*, A Hutchaleelaha1, V Siu1, A Silva-Garcia1, D Oksenberg1,
J Lehrer-Graiwer2, T Mant3, E Ramos2
1Biology, 2Clinical, Global Blood Therapeutics, South San Francisco, United
States, 3Quintiles Drug Research Unit at Guy’s Hospital, London, United Kingdom
Background: SCD is caused by a point mutation in the β-globin gene produc-
ing hemoglobin S (HbS) that polymerizes upon deoxygenation with subsequent
formation of sickled red blood cells (RBCs). GBT440 is a novel, orally bioavail-
able small molecule that inhibits HbS polymerization by increasing the affinity
of O2 to hemoglobin (Hb). Based on this mechanism, a left-shift of the oxygen
equilibrium curve (OEC) at p20 or p50 (partial pressure of oxygen that results
in 20% or 50% saturation of Hb with oxygen, respectively) can potentially be
used as a PD marker of GBT440.
Aims: To determine PK of GBT440 in healthy volunteers (HV) and SCD
patients and correlate the GBT440 concentrations in RBCs to p20 and p50
values in these two populations.
Methods: A Phase 1/2, randomized, placebo-controlled, double-blind, single
and multiple ascending dose study of the tolerability and PK of GBT440 was
conducted in HV and SCD patients (6 treated and 2 placebo subjects in each
cohort). Part A of the study consisted of a single ascending dose evaluation in
healthy subjects (100 to 2800 mg) and SCD patients (1000 mg). Part B con-
sisted of a multiple ascending dose evaluation for up to 15 days in HV (300 to
900 mg QD) and up to 28 days in SCD patients (700 mg QD). Whole blood
and plasma concentrations of GBT440 were analyzed by LCMS. Samples were
obtained pre-dose and at various time points post-dose. OECs were measured
by a TCS Hemox analyzer and p20 and p50 values were determined.
Results: Both the maximum concentration (Cmax) and the area under the curve
(AUC) increased dose proportionally following single and multiple doses. When
a single dose of 1000 mg GBT440 was administered to HV and SCD patients,
GBT440 exposure was lower and the half-life (T1/2) was significantly shorter in
SCD patients relative to HV (Table 1). RBC/plasma ratio were 95:1 and 75:1
for HV and SCD subjects, respectively. The difference in PK is likely due to a
lower total Hb in SCD patients to which GBT440 binds, and possibly the more
rapid turnover of RBCs. Inter-subject variability at steady state was low in the
intended dose range (%CV <15%). A linear relationship between concentrations
of GBT440 in RBC ([GBT440]RBC) and p20 and p50 for both HV and SCD
patients was observed. Due to the biphasic nature of GBT440’s OECs, p20
appears to be a more sensitive parameter and has better correlation than p50
within the expected target therapeutic range (<40% Hb modification). p20 cor-
related well with [GBT440]RBC at ≥0.25 mM (~5% Hb modification; r2=0.83 and
0.55 for HV and SCD, respectively) and p50 at ≥0.5 mM (~10% Hb modification;
r2=0.48 and 0.40 for HV and SCD, respectively) (Image/Pictures).
Table 1
PK Parameters HV SCD
Cmax (µg/mL) 58.2 36.0
AUC0-∞ (µghr/mL) 6730 2480
T1/2 (hr) 69.1 38.8
Figure 1.
Summary/Conclusions: GBT440 is an orally bioavailable compound that has
potential to be used to treat SCD by once daily administration. The exposure
of GBT440 increased proportionally with dose. There was a linear relationship
between [GBT440]RBC and the degree of left-shifting of the OEC curve which
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demonstrates that GBT440 enhances O2 affinity of Hb. The high correlation
between [GBT440]RBC and the p20 indicates that the change in Hb-O2 affinity
can be used as a PD marker for GBT440.
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GBT440, A NOVEL HBS POLYMERIZATION INHIBITOR, INCREASES HB
OXYGEN AFFINITY AND RESULTS IN A RAPID IMPROVEMENT IN
HEMOLYSIS AND ANEMIA
J Lehrer-Graiwer1, C Hemmaway2, J Howard3, P Telfer4,*, M Layton5,
M Awogbade6, J Porter7, M Roberts-Harewood8, T Mant9, K Dufu1,
A Hutchaleelaha1, D Oksenberg1, M Patel1, M Tonda1, E Ramos1
1Global Blood Therapeutics, South San Francisco, United States, 2Haematology,
Queens Hospital, Romford, 3Haematology, Guy’s and St. Thomas NHS Trust,
4Haematology, The Royal London Hospital, 5Haematology, Imperial College
Healthcare NHS Trust, 6Haematology, King’s College Hospital, 7Haematology, Uni-
versity College London Hospital, 8Haematology, North Middlesex University Hos-
pital, 9Quintiles Drug Research Unit at Guy’s Hospital, London, United Kingdom
Background: Sickle cell disease (SCD) is caused by polymerization of Hemo-
globin S (HbS), resulting in hemolysis and vaso-occlusion. No therapy achieving
pancellular, direct inhibition of HbS polymerization is available. GBT440 is a
novel small molecule which increases hemoglobin oxygen affinity and inhibits
HbS polymerization and prevents sickling in vitro.
Aims: This study explored safety, pharmacokinetics (PK) and pharmacody-
namics (PD) of GBT440 in healthy volunteers (HV) and subjects with SCD and
anti-hemolytic and anti-sickling effects in SCD subjects.
Methods: This randomized, placebo-controlled, double-blind, phase I/II study
enrolled HV and HbSS and HbSB0 SCD subjects. GBT440 was dose orally.
The study was conducted in three parts: Part A, single ascending doses, Part
B multiple ascending doses for 28 days and Part C 90-day dosing (ongoing).
The primary endpoint was safety. Secondary endpoints included PK, PD and
hematologic response.
Table 1. Biomarker Results
ND=Not yet done, data still to be analyzed, NA=not applicable, LDH=lactate dehydrogenase
Figure 1. Relative chenge in unconjugated bilirubin from baseline (Median
and 25th and 75th percentile).
Results: As of 22 February 2016, 30 SCD subjects had completed Part B (10
at 500 mg; 12 at 700 mg; 8 received placebo [pbo]). The 1000 mg (28 days)
and 700 mg (90 days) cohorts in Parts B and C, respectively, were still under
evaluation; 60% were male, 40% were female; 20% were on hydroxyurea (HU);
80% had 0-1 painful crisis in the prior year (range 0-7); median age was 32 yrs.
GBT440 was well tolerated; there were no drug-related severe or serious
adverse events and the most common AEs were headache and pain. PK expo-
sures increased dose-proportionally; mean GBT440 blood half-life after a single
dose was 1.6 days in SCD subjects and RBC:Plasma ratio was 75:1. GBT440-
treated subjects demonstrated increased hemoglobin oxygen affinity (p50
moved towards the normal range) and a sustained decrease in unconjugated
bilirubin, a marker of hemolysis, during the treatment period, with return to
baseline by day 43 (Table 1, Figure 1). Other markers of hemolysis, hemoglobin
level, sickle cell counts, and erythropoietin levels improved concordantly, as
did the inflammatory marker P-Selectin (Table 1, change to day 28). At the EHA
conference, additional results, including hemolysis markers and exploratory
markers of RBC function, will be presented from Part B 1000 mg and Part C
700 mg cohorts.
Summary/Conclusions: GBT440 was well tolerated with dose-proportional
PK and increases in hemoglobin oxygen affinity. GBT440 resulted in a marked
and sustained reduction in clinical markers of hemolysis, an increase in hemo-
globin, and decreases in erythropoietin, circulating sickle cells, and the inflam-
matory marker P-Selectin. These results are consistent with inhibition of HbS
polymerization leading to decreased RBC damage, improved RBC lifespan,
improvement in inflammation and tissue oxygen delivery, and support further
investigation of GBT440 as a potential disease-modifying therapy for SCD.
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CEREBROVASCULAR RESERVE IN SICKLE CELL DISEASE ASSESSED
WITH PERFUSION MAGNETIC RESONANCE IMAGING
L Vaclavu1,*, HJ Mutsaerts1, CB Majoie1, ET van Bavel2, AJ Nederveen1,
BJ Biemond3
1Radiology, 2Biomedical Engineering & Physics, 3Internal Medicine, Haema-
tology, Academic Medical Center, Amsterdam, Netherlands
Background: Arterial Spin Labelling (ASL) MRI is a non-invasive perfusion
MRI technique that circumvents the need for PET-or-SPECT evaluations of
cerebral tissue viability, and allows us to assess haemodynamics in relation to
stroke risk in Sickle Cell Disease (SCD). SCD is a hereditary form of anaemia
leading to red blood cell damage, hampered oxygen transport and neurovas-
cular tissue damage. Local deficits in perfusion lead to silent ischaemic infarcts
as a result of impaired cerebrovascular reserve (CVR). 
Aims: Our aim was to gain understanding of cerebral haemodynamics in SCD
by utilising ASL MRI. We investigated the acute cerebral blood flow (CBF)
response to an administration of acetazolamide (ACZ)-a potent vasodilator-in
order to probe CVR in patients with SCD who were in a steady-disease state.
We hypothesised that patients would have impaired CVR due to pre-existing
increased vasodilation and elevated resting CBF1.
Methods: 23 SCD patients (aged 33±13y) with HbSS/HbSß0-thalassaemia,
and 6 age- and ethnicity-matched healthy controls (aged 30±14y; Wilcoxon
rank sum, p=0.38) were recruited from an outpatient clinic and invited to under-
go MRI. Blood samples were drawn from an antecubital vein prior to MRI. ASL-
MRI was performed prior to and 10 minutes after ACZ on a 3.0Tesla Philips
Ingenia system (Philips Healthcare, Best, the Netherlands). To avoid overesti-
mation of CBF, T1 of blood – a parameter used in the quantification of CBF
from ASL, and which is influenced by blood haematocrit(Hct) - was measured
in the sagittal sinus with a separate MRI sequence. ASL data were processed
with in-house developed software and CBF was quantified using a single-com-
partment flow model2. Wilcoxon rank-sum tests were performed to compare
groups on CBF at baseline, and CVR. CVR was calculated as (CBFACZ–
CBFB)/CBFB*100%, where CBFB is baseline and CBFACZ is post-ACZ CBF.
Pearson’s correlation was performed between baseline CBF, and Hct and CVR.
P<0.05 was considered statistically significant.
Results: Whole brain CBF was significantly higher in patients (mean 55±12
mL/100g/min) compared to controls (mean 31±3 mL/100g/min) at baseline
(p<0.001) and was significantly correlated with Hct in all subjects (R=-0.83,
p<0.001) and patients alone (r=-0.63, p=0.002). Mean CVR in patients
(24±13%) was significantly lower than in controls (69±11%; p<0.001). Figure 1
shows the inverse relationship between CBF and CVR.
Figure 1.
Summary/Conclusions: The finding that patients had higher CBF at baseline
compared to controls complements previous studies in which CBF increases
are associated with anaemia in SCD3. The finding that Hct was inversely cor-
related with CBF confirms previous findings in which perfusion increases com-
pensate for anaemia to cater for adequate oxygen delivery. The relatively low
CVR in SCD patients is in line with literature suggesting that maximum vasodi-
lation has been reached in SCD. Since this was observed in SCD patients in a
steady-state disease course, it is very imaginable that the CVR will become
exhausted during times of increased metabolic demand. The results show that
CVR could potentially be a cerebrovascular biomarker in SCD for treatment
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stratification in the future. In conclusion, ASL-based CBF measurements with
ACZ show robust CVR results and indicate that cerebral haemodynamics may
be impaired in SCD.
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RESTING STATE FUNCTIONAL MRI SHOWS HOW COGNITIVE PERFORMANCES
COULD BE PRESERVED IN CHILDREN WITH SICKLE CELL DISEASE
R Colombatti1,*, M Lucchetta2, M Montanaro1, P Rampazzo2, M Ermani2,
G Talenti2, A Favaro2, C Baracchini2, G Basso1, R Manara3, L Sainati1
1Clinic of Pediatric Hematology Oncology, Department of Child and Maternal
Health, 2Department of Neurosciences, Azienda Ospedaliera-Università di
Padova, Padova, Italy, Padova, 3Deparment of Neuroradiology, University of
Salerno, Salerno, Italy
Background: Sickle cell disease (SCD) is the most common genetic disorder
worldwide. Cerebrovascular complications are frequent events in children with
SCD. Overt ischemic stroke occurs in 11% of untreated children and cerebral
silent infarcts (CSI) affect 40% of children by the age of 14. In the past years
improvements have been made in the management of stroke and CSI and
algorithms for screening, prevention and management based on Transcranial
Doppler (TCD) and Magnetic Resonance Imaging/Angiography (MRI/MRA)
are routinely used. Less progress has been made in the management of cog-
nitive dysfunction, a major morbidity among children with SCD. Impairment of
cognitive function is reasonable in children who experienced an overt stroke
or present CSIs, due to the anatomical damage of the brain. But the patho-
physiology of cognitive impairment in children with normal neuroimaging is less
clear. Functional MRI allows the evaluation of resting state brain networks. The
Default Mode Network (DMN) is a brain network involving the precuneus and
posterior cingulate, the bilateral inferior–lateral–parietal and ventromedial
frontal cortex and is invoolved in the cognitive impairment of various diseases
Aims: We aimed at evaluating DMN connectivity by means of resting state
functional MRI hypothesizing that neurocognitive scores and parameters linked
to cognition in SCD, such as mean steady state hemoglobin and Oxygen sat-
uration (SatO2), could be related to brain connectivity in the DMN.
Table 1
             N° of Patients
Phenotype
       SS  39
       Sβ° 1
Gender
       M   21
       F     19
Age (years) 8,08 (4,6-15,0)
Transcranial Doppler
       Normal 40
       Conditional/Abnormal 0
       History of Condition/Abnormal 7
MRI
       Normal 20
       Silent Infarcts 20
MRA
       Normal 12
       Stenosis 28
Neurocognitive evaluation
       Full scale IQ
             Normal 33
             Low 7
       Verbal IQ
             Normal 29
             Low 11
       Performance IQ
             Normal 35
             Low 5
Hemoglobin (g/dL)
       ≥8  30
       <8  10
O2 pulse oxymetry
       ≥97% 31
       <97% 9
Methods: In this cross-sectional study 40 children with SS-Sβ° (mean age 8
years) underwent neurocognitive evaluation and comprehensive brain imaging
assessment with TCD, MRI, MRA, Resting State (RS) Functional MRI with
evaluation of the DMN. Sixteen healthy age-matched controls underwent MRI,
MRA and RS functional MRI. Brain connectivity was compared between
patients and controls and analyzed in patients according to TCD, MRI/MRA
results, haemoglobin and SatO2 values
Results: Patients characteristics are displayed in Table 1. Children with SCD
displayed increased brain connectivity in the DMN compared to controls, even
in the absence of alterations in standard imaging techniques. Patients with low
neurocognitive scores presented higher brain connectivity compared to children
without cognitive impairment or controls, suggesting an initial compensatory
mechanism to maintain performances. In our cohort steady state haemoglobin
level was not related to increased brain connectivity, but SatO2<97% was (Fig.
1 Functional MRI group analysis. (A) Increased connectivity in the DMN, in the
posterior precuneus, in patients versus controls; (B) Increased connectivity in
the DMN, in the medial prefrontal regions, in patients with normal Verbal IQ
compared to controls; (C) Increased connectivity in the DMN, in the right pre-
frontal region, in patients with normal MRI compared to controls; (D) Increased
connectivity in the posterior calcarine region in patients with SatO2≤97% com-
pared to patients with higher SatO2).
Figure 1.
Summary/Conclusions: Our findings provide novel evidence that SCD is
characterized by functional abnormalities in brain connectivity that are inde-
pendent from the known mechanisms of cerebral vasculopathy and are thus
not revealed by routinely used imaging techniques. fMRI might represent a
useful complimentary analysis for investigating the disease natural course in
studies linking physiopathology, anatomical and functional changes.
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INFLUENCE OF UNDERWEIGHT STATUS ON THE CLINICAL PHENOTYPE
OF AN INTERNATIONAL COHORT OF SICKLE CELL DISEASE PATIENTS:
THE CASIRE GROUP ANALYSIS
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C Antwi-Boasiako5, A Campbell15
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Medical School, Accra, Ghana, 6Pediatrics, University of Michigan, Ann Arbor,
Ann Arbor, 7Hematology/Oncology, Vanderbilt University School of Medicine,
Nashville, United States, 8Child Health, University of Ghana Medical School,
Accra, Ghana, 9Pediatrics, Case Western Reserve University, Cleveland,
10Pediatrics, University of Illinois at Chicago, Chicago, 11Pediatrics, Albert Ein-
stein College of Medicine, Bronx, United States, 126I° Policlinico II°Università
di Napoli, Naples, 13Pediatric Hematology Oncology, Azienda Ospedaliera-
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Background: The Consortium for the Advancement of Sickle Cell Research is
an international, multi-institutional group evaluating clinical severity of adults
and children with SCD through a validated questionnaire and medical chart
review. Sites include academic centers in Italy, U.S., and Ghana. Chawla et al
published on the clinical phenotype of underweight pediatric SCD patients in a
U.S. cohort and revealed male gender, older age, lower hemoglobin and SS
phenotype were statistically associated with being underweight. Although mal-
nutrition and SCD are both relatively common in parts of Ghana, the impact of
comorbid malnutrition on the SCD phenotype has not been published in an
international cohort.
Aims: The aim of this study was to determine the relationship between under-
weight status (<5th percentile body mass index (BMI)) and clinical markers of
SCD severity in the CASIRE cohort.
Methods: Subjects were enrolled following informed consent/assent. Cate-
gories for underweight, normal, overweight and obese were calculated using
the formula: weight (kg)/[height (m)]2. BMI alone was used to classify adults
into weight categories. For children, weight categories were determined using
gender- and age-associated BMI percentile charts. Demographic data included
age, gender, and country of residence. Clinical data included room air oxygen
saturation, hemoglobin phenotype (SS, Sβ0, Sβ+, SC), hemoglobin level, leuko-
cyte count, urine microalbumin, pain crisis frequency, emergency department
(ED) utilization frequency, as well as history of leg ulcers, acute chest syndrome
(ACS), priapism, stroke, and avascular necrosis (AVN). The relationship
between BMI and both demographic and clinical data was analyzed using SPSS
statistical software.
Results: There were 676 patients in the study and 56% were under age 18.
Patients were equally distributed between developed and developing countries
(48% U.S./Italy vs 52% Ghana). 16% of the patients were underweight (n=109).
Compared to normal, overweight and obese patients, underweight SCD patients
were more likely to be male (79% vs 52%, p<0.001), Ghanaian (83% vs 47%,
p<0.001), report less frequent pain crises/ year (<3/year 82.2% vs 64.6%,
p<0.001), have higher ED utilization for pain (>3/year 34.8% vs 21.6%, p=0.01),
have no prior history of acute chest syndrome (35.5% vs 18.7%, p=0.001),
have a history of leg ulcers (11% vs 4.4%, p=0.005), higher leukocyte count
(12.2 vs 10.5 x1000/ul, p=0.007), and lower hemoglobin (8.1 vs 9.2 g/dL,
p<0.001). In the U.S./Italy cohort only, underweight BMI was associated with
greater microalbuminuria (60.8 vs 25.2 mg/gm, p=0.04). In the SS and Sβ0
thalassemia group only, underweight patients were more likely to have AVN of
hips (25% vs 13%, p=0.02) or humeral head (13.8% vs 4.3% p=0.03) compared
to non-underweight patients. There was no significant relationship between
underweight BMI and age, hemoglobin phenotype, stroke, priapism, or room
air oxygen saturation.
Summary/Conclusions: We are the first to describe the clinical severity mark-
ers of an underweight SCD patient cohort that includes adults as well as indi-
viduals from both developed and developing nations. We have identified that
underweight SCD patients demonstrate a distinct clinical phenotype. Although
less likely to experience pain crises and develop ACS, they are more likely to
have far less clinically apparent complications such as AVN and early signs of
kidney damage. The strikingly high prevalence of underweight BMI in the Ghana-
ian cohort is particularly noteworthy and also warrants further investigation.
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IMPROVEMENT IN CARE QUALITY FOLLOWING DEVELOPMENT OF A
NEW ADULT SICKLE CELL DISEASE CENTER WITHIN AN ACADEMIC
CANCER CENTER
B Andemariam*, S Jones
Hematology/Oncology, University of Connecticut, Farmington, United States
Background: In the United States, a national shortage of specialized centers
with expertise in the management of adults with sickle cell disease (SCD)
remains a concerning public health disparity. As a result, poor quality of care is
delivered to this vulnerable population as the emergency department emerges
as the primary mode of care delivery with little emphasis on chronic disease
management. Yet, across the country there is an abundance of cancer centers
whose operational infrastructure is not only well-suited to the treatment of the
cancer patient, but also can provide medical and procedural care essential to
the management of SCD. In light of this, a new adult SCD center was formally
established within our academic hospital-based cancer center in 2009. 
Aims: To describe the development of the new center and measure its impact
on patient volume, acute care utilization patterns, and quality of care delivered. 
Methods: A single-institution retrospective chart review was conducted of all
SCD patient encounters occurring five years pre- and six years post-SCD center
establishment (2004-2015). Programmatic, demographic, clinical as well as
hospital utilization and care quality data were compared.
Results: Following establishment of the SCD center, the adult SCD population
grew from 22 to 193 patients over six years. Total visits increased from 153 to
>2500 per annum. The center was staffed by one primary academic hematol-
ogist, shared cancer center nursing staff, and a full-time dedicated social worker.
Patients received both preventative visits for chronic disease management
including hydroxyurea, scheduled blood transfusions where appropriate, as
well as treatment for acute painful episodes with intravenous opioids. Addition-
ally, four programs were developed to enhance care: a formal transition program
with the affiliated children’s hospital, a specialized red blood cell apheresis pro-
gram, a fast-track emergency department pain management protocol, and a
day hospital for individualized management of acute painful episodes. Post-
SCD center establishment, patients experienced increased average annual
outpatient preventative visits for chronic disease management (1 vs 5) and
fewer average hospitalizations yearly (2.4 vs 0.8). There was a decrease in
hospitalization rates for management of acute pain (50% vs 15%), average
hospitalization length of stay (12 vs 4.95 days), and the proportion of hospital
discharges resulting in readmission within thirty days (60% vs 26.5%). Ninety
percent of children were successfully transitioned to adult care. Hydroxyurea
use among eligible patients increased from 30% to 90%.
Summary/Conclusions: We conclude that embedding adult SCD centers with-
in existing cancer center infrastructures can improve patterns of health care
utilization and positively impact the delivery of quality care.
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KLOTHO GENE POLYMORPHISMS AND THEIR ASSOCIATION WITH
CLINICAL MANIFESTATIONS IN PATIENTS WITH SICKLE CELL ANEMIA
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B Hatzlhofer1, M Souza1, A Cunha2,*, F Ferreira Costa3, A Araujo4,
AR Lucena-Araujo1, MA Bezerra1
1Universidade Federal de Pernambuco, Recife, 2Universidade Federal de São
Carlos, São Carlos, 3Universidade Estadual de Campinas, Campinas, 4Hema-
tology and Hemotherapy Foundation of Pernambuco, Recife, Brazil
Background: Sickle cell anemia (SCA) is the most common genetic disease
worldwide. Although patients with SCA present the same genotype, the clinical
course may significantly vary among patients. Several evidence suggest that
such heterogeneity occurs due to environmental, social, and genetic factors.
Therefore, several studies aim to identify molecular markers that might explain
the different clinical courses of patients with SCA. An important gene to be
evaluated in these patients is KLOTHO. This gene encodes for a transmem-
brane and secreted proteins involved in many important processes in vascular
homeostasis, such as suppression of expression of adhesion molecules, nitric
oxide production and suppression of oxidative stress. These points are impor-
tant in the pathophysiology of SCA, justifying the importance of studying
KLOTHO on these patients.
Aims: The aim of this study was to investigate the clinical impact of two tag
single nucleotide polymorphisms (rs211239, G>A and rs685417, G>A) in
KLOTHO gene of the 703 patients with SCA followed in a single reference cen-
ter in northeast Brazil.
Methods: Patients with SCA were divided into two groups: cases (incidence of
osteonecrosis, priapism, leg ulcers, stroke, heart disease and/or acute chest
syndrome) and controls (patients without occurrence of such events). The entire
cohort were genotyped by PCR-RFLP.
Results: The recessive genotype (AA) of polymorphism rs211239 was asso-
ciated with the number of clinical complications of patients: only 2% of patients
with wild type genotype (GG) or heterozygous (GA) had three or more com-
plications and 5% with genotype AA showed this phenotype (P=0.036). For
the other variables, no association was found. In contrast, for the polymor-
phism rs685417, the wild genotype (GG) was significantly associated with
higher frequency of vaso-oclusion crises (P=0.009) and heart disease
(P=0.033). In addition, heterozygous genotype (GA) was significantly associ-
ated with the occurrence of leg ulcers (P=0.006), osteonecrosis (P=0.038)
and priapism (P=0.02).
Summary/Conclusions: Our results showed that the over dominant model
(GA genotype) of rs685417 is associated with priapism, leg ulcers and
osteonecrosis, while the dominant model (GG genotype) is associated with
heart disease and higher frequency of vaso-oclusion. Futhermore the recessive
model (AA genotype) of rs211239 is associated with the number of complica-
tions in SCA patients.
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ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND HOSPITAL
ADMISSIONS FOR SICKLE CELL DISEASE: A RETROSPECTIVE TIME
SERIES ANALYSIS
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Background: The clinical severity of sickle-cell disease (SCD) is extremely
variable. Genetic and genome wide association studies does not entirely
account for phenotypic variability. Investigations of the impact of environmental
factors, including climate and air quality, on the severity of the disease con-
ducted across a range of countries have provided inconsistent results. Accurate
identification of environmental factors triggering clinical complications in urban
settings could lead to better prevention measures, which could result in
improved quality of life for patients with SCD and their relatives as well as in
reductions in hospital admissions and health care costs.
Aims: To investigate the impact of climate change and air quality on the rate
of hospital admissions in urban European cities.
Methods: We extracted anonymised daily hospital admission records over 5
years (2008-2012) for patients with (SCD) less than 18 years living within a
radius of ten kilometres from each of the following hospitals: Kings College
Hospital (Camberwell), Evelina London Children’s Hospital (Lambeth) and Roy-
al London Hospital (Whitechapel) in London, and the Necker Hospital for Sick
Children in Paris. Recorded reasons for hospital admissions were pain, fever,
acute chest syndrome and other. Information on the genotype of patients, either
HbSS or HbSC, was available for the three London hospitals, but not in Paris.
Official meteorological data of daily rainfall (mm); air temperature (°C), relative
humidity (%), wind speed (knots) and pressure (hPa) were extracted from the
British Atmospheric Data Centre for several monitoring stations, including
Heathrow– the reference station in London - and St James Park– the nearest
station to the three hospitals. Data were purchased from Météo France only
for one meteorological station, Paris Montsouris (48°49’18”N, 2°20’12”E).
Official daily air quality data on carbon monoxide (CO, mg/m3), nitrogen dioxide
(NO2, µg/m3), sulphur dioxide (SO2, µg/m3), ozone (O3, µg/m3), particulate
matter ≤10 μm in diameter (PM10, µg/m3) and particulate matter ≤2.5 μm in
diameter (PM2.5, µg/m3), black carbon (µg/m3) and particle number (µg/m3)
were extracted from the London Air Data and AirParif websites. Missing data
were an issue: we kept only data from the most complete monitoring stations
(records available for ≥80% of days) and filled the gaps using an expectation–
maximization imputation algorithm for multivariate normal time series imple-
mented in the mnimput function of the mtsdi R package. Pollutant’s measure-
ment data were normalised using a log transformation. Cross-validation based
on a left-out sample of 100 daily records were conducted and the root mean
squared error (RMSE) and normalised root mean square error (NRMSE) were
calculated. All meteorological and air quality data were normalised for the analy-
ses. Statistical differences between admission rates per year, season, month
and day of the week were identified by ANOVAs with Tukey’s significant differ-
ence (HSD) test.
Results: Over the five-year study period, 1,887 and 346 hospital admissions
for SCD were recorded in London and Paris, respectively. In London, increased
admissions for acute pain in children with SCA was associated with increased
rainfall and wind speed, although no such pattern was seen in Paris, where
temperature had a significant effect. No air quality effects were seen in either
city, and there were no clear environmental effects on admissions for ACS or
in children with HbSC disease.
Table 1.
Summary/Conclusions: Using high-quality data from London and Paris, com-
bined with rigorous time-series analysis methods, our results do not support
associations between hospital admissions for SCD and temperature. Environ-
mental factors, which consistently appeared significant throughout our analy-
ses, were rainfall, wind speed and pressure. A better understanding of the envi-
ronmental factors triggering clinical complications in patients with SCD could
provide insight into prevention of acute events in SCD.
Infectious diseases, supportive care
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ITRACONAZOLE VS LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL
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Background: Febrile neutropenia, one of the most serious complications that
can occur during the treatment of hematological malignancies, is sometimes
caused by fungal pathogens. Prospective, randomized studies indicated the
utility of liposomal amphotericin B or caspofungin as empirical antifungal ther-
apy. Itraconazole is a broad spectrum triazole antifungal agent, effective against
Candida, Aspergillus, Trichosporon and Mucorales; however, its oral capsules
are poorly absorbed in the intestines, which makes it difficult to achieve a stable
serum drug concentration. An intravenous formulation of itraconazole has been
developed to allow a sufficient serum concentration to be achieved, which may,
therefore, offer a potentially safer and effective alternative.
Aims: The aim of this multicenter, open-label, randomized, non-inferiority trial
was to confirm the safety and efficacy of intravenous itraconazole versus lipo-
somal amphotericin B as empirical antifungal therapy in patients with hemato-
logical malignancies aged 20-79 years, who developed fever refractory to
broad-spectrum antimicrobial agents during neutropenia.
Methods: Patients were recruited from 19 institutes in Japan and randomly
assigned to either liposomal amphotericin B 3.0 mg/kg once daily group or
intravenous itraconazole 200 mg per dose group with five stratification factors
(risk, previous antifungal prophylaxis, age, sex and institute). The primary end-
point was defined as success of all components of a five-part composite sec-
ondary endpoint (overall favorable response), consisting of successful treat-
ment of baseline infection by the end of treatment, absence of breakthrough
infection, no discontinuation of the antifungal treatment due to drug-related
toxicity, resolution of fever during neutropenia (axillary temperature <37.5 °C
for at least 48 hours), and survival 7 days after termination of the antifungal
treatment. The non-inferiority margin for the difference between the experi-
mental and control arms for an overall favorable response was -10%, implying
that intravenous itraconazole is non-inferior if the lower limit of the 90% confi-
dence interval of the difference is larger than -10%.
Results: Between April 2011 and February 2015, 103 patients were registered.
The study was terminated early due to low patient recruitment. There were no
baseline fungal infections in both groups. The mean duration of antifungal ther-
apy was 14.4 days for liposomal amphotericin B (52 patients) and 14.0 days
for intravenous itraconazole (50 patients). Overall favorable response rates
were 32.7% for liposomal amphotericin B and 36.0% for intravenous itracona-
zole, with a difference of 4 percent (90% confidence interval, -12% to 20%),
which doesn’t fulfill the statistical criterion for non-inferiority of intravenous itra-
conazole. These rates were independent of the antifungal prophylaxis or risk.
All patients survived until 7 days after termination of the antifungal treatment.
The outcomes were similar between liposomal amphotericin B and intravenous
itraconazole with respect to documented breakthrough fungal infections (3.8%
vs 0.0%, P=0.50), discontinuation of treatment due to drug-related toxicity
(19.2% vs 10.0%, P=0.26), and resolution of fever during neutropenia (38.5%
vs 42.0%, P=0.84). Five patients who received liposomal amphotericin B were
later diagnosed with probable invasive fungal disease, while none of the
patients who received intravenous itraconazole developed fungal infections
(P=0.06). Significantly fewer patients in the intravenous itraconazole (14
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patients) than the liposomal amphotericin B (29 patients) group had events
associated with grade 3-4 hypokalemia (P<0.01). The incidence rates of other
adverse events were similar.
Summary/Conclusions: Intravenous itraconazole showed similar efficacy and
better safety outcomes compared to liposomal amphotericin B as empirical
antifungal therapy in hematological malignancy patients with persistent fever
and neutropenia, although its non-inferiority could not be demonstrated due to
the small sample size.
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PREVALENCE, STRUCTURE, AND PUTATIVE MECHANISM FOR TEMPLATED
INSERTIONS IN VDJ RECOMBINATION
MT Koning1, CA van Bergen1, IJ Trollmann1, U Scherer2, M Griffioen1,
R Toes2, H Veelken1,*
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Background: Functional immunoglobulin heavy chain genes are assembled
in pre-B cells by genetic VDJ recombination. Random N nucleotides are insert-
ed at the junctions of the participating gene segments by terminal desoxynu-
cleotidyl transferase. Together, combinatorial and junctional diversity create an
extremely diverse B-cell repertoire. Recently, insertion of long sequences of a
LAIR1 exon template at the V-D junction was described as a novel mechanism
to generate broadly neutralizing antibodies to parasital RIFIN antigens on P.
falciparum-infected erythrocytes (Tan et al., Nature 2016). In these antibodies,
the binding specificity of the LAIR1 element was shifted from its natural ligand
collagen to RIFINs by extensive somatic hypermutation, indicating passage
through a germinal center reaction and antigenic selection.
Aims: To investigate whether templated insertions (TI) occur in healthy donor
B-cell repertoires and to elucidate the mechanism behind these insertions.
Methods: We searched for TI in BCR repertoires from 6 healthy donors com-
prising >32,000 unique VDJ sequences. These repertoires were generated by
ARTISAN PCR, an anchored RT-PCR primed on constant immunoglobulin
regions and employing a template-switching reverse transcriptase. ARTISAN
amplicons were barcoded and analysed as full-length single molecules by
PacBio massive parallel sequencing. With its unbiased amplification and an
error rate of 0.126x10-3, ARTISAN PCR in combination with PacBio sequencing
accurately displays the entire repertoire of VDJ sequences in complex biological
samples (Koning et al., EHA 2015). VDJ sequences (n=719) belonging to the
highest percentile with respect to total length, length of the CDR3 region, or
combined length of N1 and N2 regions as identified by IMGT V-QUEST were
selected. Predicted N regions were submitted to BLAST search with an E cut-
off value of 0.00139 to correct for multiple testing.
Results: We searched for TI in BCR repertoires from 6 healthy donors com-
prising >32,000 unique VDJ sequences. These repertoires were generated by
ARTISAN PCR, an anchored RT-PCR primed on constant immunoglobulin
regions and employing a template-switching reverse transcriptase. ARTISAN
amplicons were barcoded and analysed as full-length single molecules by
PacBio massive parallel sequencing. With its unbiased amplification and an
error rate of 0.126x10-3, ARTISAN PCR in combination with PacBio sequencing
accurately displays the entire repertoire of VDJ sequences in complex biological
samples (Koning et al., EHA 2015). VDJ sequences (n=719) belonging to the
highest percentile with respect to total length, length of the CDR3 region, or
combined length of N1 and N2 regions as identified by IMGT V-QUEST were
selected. Predicted N regions were submitted to BLAST search with an E cut-
off value of 0.00139 to correct for multiple testing.
Summary/Conclusions: TI is a novel mechanism of antibody diversification
for which we propose the term “T region”. Unlike suggested by Tan et al., T
regions appear not to originate through repair of double-stranded DNA breaks
introduced by activation-induced deaminase in germinal center reactions. Their
presence in unmutated VDJ sequences that are presumably derived from naïve
B-cells, their exclusive positioning in V-D, D-J, or V-J junctions, and the universal
presence of cryptic RSS sites rather point to primary VDJ recombination as the
generating event. The combined evidence also suggests that certain loci (e.g.
the LAIR1 exon) and certain individuals are more prone to generate antibody
T regions. We speculate that juxtaposition of IGHV and T region templates is
mediated by RAG1/RAG2 via RSS binding during VDJ recombination, followed
by introduction of a double-strand break on the IGHV allele only and aberrant
repair by using the template in trans. As shown by Tan et al., VTDJ sequences
may be selected by antigenic stimulation if undergoing somatic hypermutation,
and may participate in protective immune responses.
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FLUOROQUINOLONE PROPHYLAXIS SIGNIFICANTLY AFFECTS BACTERIAL
EPIDEMIOLOLOGY AND ANTIBIOTIC RESISTANCE BUT DOES NOT
IMPACT ON INCIDENCE AND MORTALITY OF BLOODSTREAM
INFECTIONS IN ACUTE LEUKAEMIA
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Background: The efficacy of fluoroquinolones (FQ) prophylaxis in neutropenic
patients, including those with acute leukaemia (AL), has been demonstrated
more than ten years ago (Bucaneve 2005). With the recent emergence of mul-
tiresistant Gram-negative (G-neg) bacteria its usefulness has been challenged.
Indeed, FQ have been associated to an increased incidence of Extended Spec-
trum Beta-lactamases producing (ESBL+) enterobacteria and carbapenem-
resistant (CR) G-neg.
Aims: In order to better understand the impact of FQ prophylaxis on recent
bacterial epidemiology, we analyzed all BSI occurring during chemotherapy-
induced neutropenia in AL patients treated in 7 centres participating to the
regional network Rete Ematologica Lombarda (REL). 
Methods: From Dec-12 to Dec-14, all febrile/infectious episodes were prospec-
tively recorded. Data concerning incidence, bacterial epidemiology and resist-
ance, and outcome of BSI occurring during neutropenic phases of chemother-
apy cycles were analysed according to the administration or not of FQ prophy-
laxis (FQ cycles and nFQ cycles, respectively). The number of treatment cycles
delivered to AL patients during the period of observation was also requested to
each participating centre. 
Results: During the period of observation, 472 AL (376 myeloid and 96 lym-
phoblastic) patients underwent 1356 chemotherapy cycles. FQ prophylaxis was
administered in 946 (69.8%) of all cycles. Overall incidence of BSI did not differ
with or without FQ prophylaxis, as BSI occurred in 258/946 (27.3%) and in
121/410 (29.5%), respectively (p=0.43). Gram-positive (G-pos) BSI were sig-
nificantly more frequent with prophylaxis (FQ: 53.1% vs nFQ: 38.3%, p=0.0075),
whereas G-neg BSI were less frequent, although not significantly (FQ: 37.2%
vs nFQ: 44.6%, p=0.169), as well as polymicrobic (PMB) BSI (FQ: 9.3% vs
nFQ: 15%, p=0.1). Fungaemia was rare in both groups (FQ: 1/258, 0.4%; nFQ:
3/121, 2.5%, p=0.06). Among G-pos strains, coagulase-negative staphylococci
(CoNS) showed a trend to a higher frequency with FQ (FQ:33.7% vs
nFQ:24.8%, p=0.07). Considering G-neg, FQ significantly reduced the frequen-
cy of Enterobacteria other than E. coli (Enterob n/coli) BSI (FQ:5% vs
nFQ:16.5%; p=0.0002), as well as of P. aeruginosa (FQ: 5% vs nFQ: 15.7%;
p=0.0005). Considering resistant strains among G-neg, FQ significantly
increased the proportion of ESBL+ Enterobacteria (FQ: 29.2% vs nFQ: 14,8%;
p=0.048) whereas the frequency of CR G-neg BSI remained similar in the two
groups (FQ:8.3% vs nFQ:11.1%; p=0.57). Overall 30-day mortality was 23/379
(5.8%); it was 13/258 (5%) in FQ BSI and 10/121 (8.3%) in nFQ (p=0.22). How-
ever, Enterob n/coli and/or P. aeruginosa BSI were fatal in 5/10 cases in nFQ
group (50%) (15,4%) as compared to 2/13 in the FQ (p=0.07). The 30-day fatal-
ity rate of ESBL+/CR G-neg BSI were similar in the two groups (FQ 5/13, 38.5%
vs nFQ 4/10, 40%).
Summary/Conclusions: Our study shows that FQ prophylaxis did not influence
the overall incidence of BSI but it markedly affected bacterial epidemiology. G-
pos BSI, particularly CoNS, were significantly increased whereas G-neg BSI
by Enterob n/coli and P. aeruginosa were significantly decreased, although
ESBL+ strains became relatively more common. Overall 30-day mortality was
similar in both groups. However, a worrisome 50% mortality due to Enterob
n/coli and/or P. aeruginosa BSI among nFQ patients suggests extreme caution
and the need for close epidemiologic surveillance and controlled studies when
considering FQ prophylaxis discontinuation.
P381
VIRAL ENCEPHALITIS AFTER HAPLO-IDENTICAL HEMATOPOIETIC
STEM CELL TRANSPLANTATION: CAUSATIVE VIRAL SPECTRUM,
CHARACTERISTICS AND RISK FACTORS
XH Zhang*, JM Zhang, H Chen, YH Chen, W Han, FR Wang, JZ Wang,
YY Zhang, XD Mo, Y Chen, Y Wang, YJ Chang, LP Xu, KY Liu, XJ Huang
Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Hematopoietic stem cell transplantation (HSCT) is increasingly
used to treat hematologic, oncologic, autoimmune, immunodeficiency, and
genetic diseases. Up to 70% of patients develop neurological complications
after an allogeneic HSCT, of which approximately 25% of patients suffer from
more severe neurological complications involving the central nervous system
(CNS) and frequent infections, which are associated with high morbidity and
mortality. With an allo-HSCT, a recipient’s immunocompromised state and the
potential for donor-transmitted infections can result in a unique epidemiology
of encephalitis, including infection by certain uncommon causative viruses,
whichfeatures an increased risk of high morbidity and mortality due to encephali-
tis regardless of the specific cause compared with immunocompetent individ-
uals. Currently, most reports focus on HHV-6 and limited data are available on
the characteristics and independent risk factorsfor viral encephalitis (VE) in
patients after a haplo-identical HSCT. 
Aims: To retrospectively identify characteristics and risk factors of VE in patients
who underwent a haplo-identical HSCT.
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Methods: A nested case-control study was designed. Cases with VE and con-
trols matched for years of HSCT and length of follow-up were identified from a
cohort composed of 1274 patients who underwent a haplo-identical HSCT from
2012 to 2015.
Results: VE was identified in 30 patients (2.4%, 95% confidence interval
1.6%>3.2%).The median time from HSCT to diagnosis was 144.5 days (range
24–1077 days), but the onset times were lowest in patients with human her-
pesvirus-6 encephalitis and greatest in patients in which more than one virus
was detected.The viruses detected included RSV-B (43.3%), BKV (23.3%),
more than one virus (10%), CMV (6.7%), RSV-A (6.7%), HSV (3.3%), HHV-6
(3.3%) and CVB3 (3.3%). Seizures and alterations of consciousness were the
most frequently presented symptoms, followed by symptoms, including fever
(13 patients, 43.3%), tremor (8 patients, 26.7%), delirium (5 patients, 16.7%),
dysesthesia (4 patients, 13.3%), headache (4 patients, 13.3%), paralysis (4
patients, 13.3%), vomiting (2 patients, 6.7%), apathy (1 patient, 3.3%), and
irritability (1 patient, 3.3%).Neuroimaging detected abnormalities in 19 (76%)
patients,9 of whom showed focal white matter hyperintensity in T2-weighted
images and FLAIR, which is consistent with CNS demyelinating diseases.
These demyelination abnormalities were detected in encephalitis caused by
RSV-B or BKV, with especially high incidence in RSV-B encephalitis (63.6%).
The CSF cell count, protein and glucose concentration were elevated in 8
(26.7%), 18(60%), and 9 (30%) patients, respectively. Multivariate analyses
revealed that acute GVHD (grad III-IV), CMV viremia and engraftment syn-
drome were significantly and independently associated with VE. The probability
of a sustained response to treatment was 76.7%, but the treatment efficacy
and prognoses varied considerably based on the different causative viruses.
The cumulative mortality for patients suffering with viral encephalitis was sig-
nificantly higher than in the controls (p=0.003). Of the 22 patients who survived,
3 (14.3%) continued to exhibit prosopoplegia, spastic paralysis and anterograde
amnesia at the last follow-up.
Summary/Conclusions: Acute GVHD (grad III-IV), CMV viremia and engraft-
ment syndrome were associated with an increased risk of viral encephalitis
after a haplo-identical HSCT. Characteristics, such as onset time, response to
treatment and outcome, varied based onthe different causative viruses.
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COMPREHENSIVE MONITORING OF GUT MICROBIOTA DURING THERAPY
FOR ACUTE LEUKEMIA
M Aichholzer*, M Rau, H Einsele, A Geier, L Rasche
Department of Internal Medicine II, University Hospital Würzburg, Würzburg,
Germany
Background: Colonization and infection by multi-resistant bacteria increasingly
challenges the treatment of critical ill patients as well as the infrastructure of
care giving facilities. Especially patients with leukemia, where intensive antibi-
otic therapy is necessary to manage infectious complications during disease
and treatment associated cytopenias, are at high risk for acquiring resistant
pathogens.
Aims: In this study we longitudinal analyzed stool microbiota of patients with
acute leukemia beginning from admission to hospital to obtain insights in the
development of dysbiosis and correlated findings with clinical parameters.
Methods: We used a comprehensive strategy including 16s sequencing, quan-
titative (q) PCR, and cultivation techniques. A total number of 108 stool samples
were collected from 3 cohorts: (1) patients undergoing treatment for acute
leukemia (n=56), (2) outclinic patients with known multi-resistant bacteria col-
onization in anal swab (n=26) and (3) healthy controls (HC) (n=26).
Results: All leukemia patients experienced infectious complications requiring
antibiotic treatment with at least three different antibiotic regimens. Four out of
14 patients established multiresistent gram-negative bacteria (MRGN) and/or
vancomycin-resistent enterococcacae (VRE) in cultures from anal swab during
their course of disease. Considering quantitative assessment leukemia patients
displayed a significant decreased bacterial load when compared to HC or out-
clinic patients (5 vs 75 vs 43ng bacterial DNA /mg stool; p<.001) indicating a
decreased colonization resistance as risk factor of acquiring multi-resistant
bacteria. Dysbiosis in acute leukemia was characterized by a shift towards
enterococcacae including cases with >90% colonization. In contrast outclinic
patients and HC showed no relevant enteroccocacae fraction. Furthermore,
gram-negative bacteria increased during treatment of leukemia as it was also
observed in outclinic patients. Both, enterococcacae and gram-negative
pathogens were responsible for infectious complications with proof of the
respective bacteria in primary sterile liquids such as blood cultures. In 6/10
positive blood cultures the causative organism was found in gut microbiota
before. Interestingly, morbidity of enteroccocacae was only seen in patients
with >50% intestinal colonization whereas gram-negative infections also
occurred in patients with significant reduced proportion thereof. In some sam-
ples collected late during leukemia treatment staphylococcus aureus as well
as other staphylococcacae were found. On the other hand protective bacteria
such as blautia or prevotella disappeared. In general, a dramatic loss of diver-
sity could be observed. Outclinic patients with known multi-resistant bacteria
particularly showed a gram-negative fraction of intestinal bacteria as expression
of a sustained dysbiosis.
Summary/Conclusions: During treatment of leukemia a clinically relevant
dysbiosis was observed responsible for infectious complications.
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INVASIVE FUNGAL INFECTIONS IN LYMPHOPROLIFERATIVE DISORDERS:
REVISION OF INCIDENCE IN THE “MODERN TREATMENT” ERA
MC Tisi1,*, S Hohaus1, A Cuccaro1, I Innocenti1, E De Carolis2, T Za1,
G Dragonetti1, L Laurenti1, L Fianchi1, S Sica1, M Sanguinetti2, V De Stefano1,
L Pagano1
1Institute of Hematology, 2Institute of Microbiology, Catholic University Rome,
Rome, Italy
Background: Invasive fungal infections (IFIs) are serious, life-threatening com-
plications of hematological malignancies. While epidemiological data on
patients (pts) with acute myeloid leukemia have been updated during the past
few years, little information is available on IFIs in lymphoproliferative malig-
nancies.
Aims: Aim of the study was to identify the incidence and variety of IFIs, risk
factors, prognosis and outcome of IFIs in lymphoproliferative disorders.
Methods: We performed a monocentric retrospective analysis on 1191 adult
pts affected by lymphoproliferative disorders [Chronic lymphocytic leukemia
(CLL), n=305; Hodgkin lymphoma (HL), n=188; diffuse large B cell lymphoma
(DLBCL), n=350; follicular non Hodgkin lymphoma (FL), n=100; and multiple
myeloma (MM), n=248] diagnosed and treated in our hospital from 2006 to
2014. We included only probable or proven IFI (De Pauw, CID 2008). Data
were collected from routine clinical practice in order to provide information
regarding fungal infections and in particular epidemiology, diagnosis, treatment
and outcome. Clinical data were matched with microbiological (fungal culture
or serology) and radiological data. 
Results: Thirty-eight patients (3.2%) developed a proven/probable IFI. Invasive
Aspergillosis (IA) was the most frequent fungal infection (31 cases, 2.6%),
while the other 7 infections were caused by yeasts (0.6%) (Table 1). Fever
was present in 84% of patients with IFI and upper respiratory tract symptoms
in 47% of patients. Lung was the most frequent organ involved (76%). We
recorded five proven infections affecting the gastrointestinal system, blood and
urinary tract. IFI was the cause of death in only one patient (2.6%), while 7
patients died from the hematological disease with a concomitant IFI. The preva-
lence of IFI was highest in pts with MM (5.6%), followed by HL (3.7%) and
DLBCL (3.1%). Patients with FL and CLL patients were at lower risk for IFI (2%
and 1.3%, respectively) (Table 1) The majority of IFI (25/38, 66%) occurred
during first-line treatment, while 13 (34%) IFI occurred in patients treated with
salvage regimens for progressive or relapsed disease. Treatment-related fac-
tors that were frequently present in patients with IFI were: HSCT within 100
days (47% of pts), corticosteroid treatment (50% of pts) and neutropenia (47%
of pts). Restricting the analysis to patients with DLBCL, we observed that the
majority of patients (7/11) who developed IFI had a high-risk international prog-
nostic index (IPI) and developed IFI during consolidation phase including HSCT
that was our standard approach in these years for patients with young patients
with high-risk DLBCL. In a logistic regression analysis, this group of patients
had a 6.1-fold risk (OR; 95% CI 1.2-30, p=0.02) for IFI with respect to young
standard risk DLBCL (<65 years, treated with R-CHOP). In the same line, the
group of younger MM pts (<65 years) undergoing HSCT as part of their first-
line treatment were at higher risk for IFI than older patients (>65 years) treated
without HSCT (OR 15.4; 95% CI 1.9-127.4, p<0.01). In contrast, IFI were rare
during first-line treatment in patients with FL and CLL who developed IFI more
often during salvage treatment for relapsed/progressive disease.
Table 1. Incidence of fungal infections in lymphoproliferative disorders.
Summary/Conclusions: Treatment strategies in lymphoproliferative disorders
that include HSCT in addition to combined treatments of cytotoxic and immuno-
modulating and immunosuppressive agents can increase the risk of mycoses
and require continuous monitoring and revision of the specific risk factors for
fungal infections. 
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INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY
INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS
CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE
EMATOLOGICA LOMBARDA) STUDY
NS Fracchiolla1,*, E Todisco2, A Bilancia2, S Gandolfi2, V Mancini3, L Marbello3,
M Bernardi4, A Assanelli5, N Orofino1, F Guidotti1, R Cairoli6, F Ciceri4,
A Santoro2, G Rossi7, A Cortelezzi8
1Oncohematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, 2Hematology Unit, Humanitas Cancer Center, Rozzano,
3Hematology and Oncology, A.O. Ospedale Niguarda Cà Granda, 4Hematology
and Bone Marrow Transplantation Unit, San Raffaele Hospital Scientific Insti-
tute, 5Hematology and Bone Marrow Transplantation Unit, San Raffaele Hos-
pital Scientific Institute, 6Department of Hematology and Oncology, A.O.
Ospedale Niguarda Cà Granda, Milan, 7Department of Hematology, Spedali
Civili, Brescia, 8Oncohematology Unit, Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
Background: PICCs are vascular devices inserted in a peripheral vein provid-
ing a central venous access with an intermediate duration between jugular or
subclavian short term central venous catheters (STCVCs), and long term ones
(port-a-caths). Few clinical data from large oncohematologic patients (pts)
series are available on infectious and thrombotic complications occurring in
PICCs versus STCVCs.
Aims: To analyze the results of a large multicenter, retrospective study of the
REL group (Rete Ematologica Lombarda-Lombardy Hematologic Network, Italy)
aimed at comparing infectious and thrombotic complications in PICCs vs
STCVCs in oncohematologic pts management.
Methods: Four REL Hematology Centres participated to the study. The clinical
data of implanted PICCs and STCVCs from January 2010 to June 2015, were
retrospectively collected.
Results: 464 PICCs and 441 STCVCs were compared. Total in situ days were
48293 for PICCs and 9471 for STCVCs. Median age PICC vs STCVCs: 61
(range 10-88) vs 53 years (range 18-99). Underlying diseases in PICCs vs
CVCs: 199/133 non-Hodgkin’s lymphoma, 10 chronic lymphocytic leukemia
(PICCs), 110/203 acute myeloid leukemia, 46/54 acute lymphoblastic leukemia,
36/5 Hodgkin’s lymphoma, 40/22 multiple myeloma, 11/10 myelodysplastic/
myeloproliferative syndrome, 10 miscellaneous/14 severe aplastic anemias.
The median PICC vs STCVC life-span was 76/19 days (range 1-800; 1-78;
p<.0001). Complications (PICC vs STCVC) occurred in 185 vs 316 cases (40%,
3.8/1000 cath days vs 71.6%, 33.3/1000 cath days); in detail: 97 vs 284 infec-
tious (21%, 2/1000 cath days; 64.4%, 30/1000 cath days), 38 vs 6 thrombotic
(8%, 0.8/1000 cath days; 1.36%, 0.63/1000 cath days), 44 vs 24 mechanical
(9.5%, 1/1000 cath days; 5.4%, 2.5/1000 cath days) and 6 vs 2 miscellaneous
(1.2%, 0.1/1000 cath days; 0.5%, 0.2/1000 cath days). Among infectious com-
plications in PICC vs STCVC, we reported 18 vs 122 cases (3.8%, 0.37/1000
cath days vs 27.6%, 13/1000 cath days) of fever of unknown origin (FUO) and
79 vs 125 cases (17%, 1.6/1000 cath days vs 28%, 13.2/1000 cath days) of
BSI. Globally 400/463 (86%) PICCs were removed. Catheter related complica-
tions was the cause of PICC removal in 132/464 (28.4%) vs 154/441 (35%)
STCVC cases. In 55/97 (56.7%) PICCs and in 124/284 (50%) STCVCs (86
infectious and 38 local inflammation), the infectious episode led to catheter
removal. Thromboses caused removal in 28/38 (73%) PICCs and 6/6 (100%)
STCVCs. Comparing PICCs and STCVCs outcomes, PICCs presented a longer
duration (p<.0001), lower total complications rate (p<.0001), lower removal rate
for complication (p=.0363), fewer infectious complications (p<.0001), more
thromboses (p<.0001).
Summary/Conclusions: Our data suggest that PICCs, as an alternative to
STCVCs, are safe and effective in patients at high risk of hemorrhagic and
infective complications. In particular PICCs, compared to STCVCs, presented
a lower rate of infections (21%, 2/1000 cath days vs 64.4%, 30/1000 cath days),
and a higher rate of thrombotic complications (8%, 0.8/1000 catheter days vs
1.36%, 0.63/1000 catheter days). In particular, in terms of cath days, STCVCs
increase in infection complications largely overcome PICCs increase in throm-
bosis (30 vs 2/1000 cath days for infections compared to 0.63 vs 0.8/1000 cath
days for thrombosis). Therefore we conclude that PICCs compare favorably
with STCVCs in terms of complications (in particular infections), and facilitate
the proper management of complex and prolonged therapeutic programs in
oncohematologic patients.
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USEFULNESS OF SERUM 1,3-B-D-GLUCAN FOR DIAGNOSIS OF INVASIVE
FUNGAL DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES:
A RETROSPECTIVE ANALYSIS
B Weinbergerova1, I Kocmanova2, M Rolencova1, J Mayer1, Z Racil1,*
1Dept. of Internal Medicine - Hematology and Oncology, 2Dept. of Clinical Micro-
biology, Masaryk University and University Hospital Brno, Brno, Czech Republic
Background: Serologic detection of circulating 1,3-b-D-glucan (BG) fungal
biomarker shows promise for improving the diagnosis of invasive fungal dis-
eases (IFDs). Numerous studies have evaluated the diagnostic performance
of BG and proved its suboptimal sensitivity when used alone for early diagnosis
of IFDs. Moreover, the major limitation of this test mainly in hematological
patients (pts.) is the high frequency of false positive results.
Aims: We have evaluated the usefulness of the serum BG assay in real practice
for the diagnosis of IFDs in pts. with hematological malignancies.
Methods: We retrospectively analyzed serum BG samples collected from
patients with hematological malignancies in high risk of IFDs treated at our
department between 2010 and 2014. The Fungitell assay was used for detec-
tion of BG. We performed retrospective cross check of probable and proven
IFDs recorded in the Fungal INfection Database - FIND. BG results were not
used for the diagnosis of IFDs.
Results: Fungitell assay was performed on 1912 serum samples from 630
patients with hematological malignancy (3.0 samples/pt.). Depending on the
cut-off used (≥60; ≥80; ≥100; ≥150pg/ml) there were 231 positive BG samples
in 78 pts.; 185 samples in 64 pts.; 155 samples in 52 pts. and 108 samples in
33 pts, respectively. Proven and probable cases of IFD occurred only in 49
(21.2%) out of 231 positive samples (in 19 out of 78 patients) with BG ≥60
pg/ml - 11 probable invasive aspergillosis (IA), 4 proven IA, 3 invasive candidi-
asis and 1 invasive fusariosis. Eight pts. (1.5%) from the group with negative
BG samples (<60pg/ml) developed any IFD (6 probable IA, 1 proven IA and 1
invasive trichosporonosis). Depending on the criterion of positivity of BG used
(≥60/ ≥80/ ≥100/ ≥150pg/ml) sensitivity was 67.1/63.6/63.1/53.9%, specificity
was 90.1/92.9/93.6/95.4%, negative predictive value (NPV) was 98.6/98.6/
98.6/98.6% and positive predictive value (PPV) was 21.2/21.3/26.5/25.9%,
respectively.
Summary/Conclusions: Our study proved high specificity and NPV of serum
BG allowing to exclude patients with IFD. On the other hand we confirmed lim-
ited sensitivity and mainly very low PPV of the test as its major limitations. We
didn’t observe any significant differences in sensitivity and PPV between groups
with different cut-offs. Thus positive BG assay results in high risk hematological
patients should be carefully evaluated together with other clinical and microbi-
ological findings. This work was supported by grant MUNI/A/1028/2015.
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DIFFERENT ISOFORM LOCALIZATION GOVERNS SIGNALING QUALITY
OF DECTIN-1 IN THE REGULATION OF ANTI-FUNGAL IMMUNITY
M Fischer1, J Müller2, B Spies-Weisshart1, C Gräfe1, A Hochhaus1, S Scholl1,
U Schnetzke1,*
1Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkolo-
gie, 2Institut für Molekulare Zellbiologie, CMB, Universitätsklinikum Jena, Jena,
Germany
Background: Dectin-1, a C-type-lectin-like receptor, is recognized as a major
receptor for fungal ß-glucans and contributes to anti-fungal immunity. Two major
human isoforms (isoform A and B) are expressed in human monocyte popula-
tions by alternative splicing. They differ by the presence of a stalk region and
its N-linked glycosylation site.
Aims: The incidence of invasive fungal infections (IFI) in hematological patients
has substantially increased during the last decades. Thus, there is a need for
a better understanding of antifungal immunity. Here, we focus on dissecting
the specific characteristics of Dectin-1 isoform A and B concerning subcellular
localization, ligand binding capacity and protein signaling.
Methods: Expression of Dectin-1 isoform A and B was analyzed in monocyte-
derived cells. Cell lines stably expressing Dectin-1 isoform A or B were created
and characterized concering localization using flow cytometry and confocal
laser scanning microscopy and signaling quality using immune blotting.
Results: While glycosylated isoform A of Dectin-1, was found to be predomi-
nantly localized at the cell surface, Dectin-1 isoform B missing a N-glycosylation
site was retained intracellularly and remained unglycosylated. Inhibition of using
Tunicamycin resulted in efficient abrogation of surface expression of Dectin-1
isoform A. Binding of Zymosan and Syk- and p38- dependent signaling quality
of Zymosan stimulated cells expressing Dectin-1 isoform B was drastically
reduced compared to cells expressing Dectin-1 isoform A.
Summary/Conclusions: Glycosylation of Dectin-1 plays an important role for
surface expression and consequently Zymosan mediated signal transduction.
Different expression profiles of human Dectin-1 isoforms on monocyte-derived
cells may indicate distinct isoform usage as a cell-type specific mechanism of
regulating anti-fungal immunity.
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PRELIMINARY REPORT OF FUNGEMIA IN HEMATOLOGICAL MALIGNANCIES
FROM SEIFEM-2015 SURVEY
M Criscuolo1,*, G Dragonetti1, L Fianchi1, L Verga1, MI Del Principe2, M Picardi3,
B Veggia4, S Ballanti5, F Marchesi6, M Delia7, A Candoni8, G Nadali9,
C Castagnola10, N Decembrino11, V Mancini12, A Ferrari13, A Busca14,
S Vallero15, C Cattaneo1, A Giordano1, B Martino16, A Vacca17, L Iovino18,
E Calore19, R Fanci20, F Lessi21, D Zama22, S Cesaro23, F Aversa24, L Pagano1
1Hematology, Catholic University of Sacred Heart, 2Hematology, Tor Vergata
University, Rome, 3Clinical medicine and surgery, University of Napoli, Napoli,
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Bologna, 23Pediatric, University of Verona, Verona, 24Hematology, Azienda
Ospedaliero Universitaria di Parma, Parma, Italy
Background: In the era of mold active azoles prophylaxis, the incidence of
invasive fungal infections has varied.
Aims: We evaluated characteristics and outcome of patients (pts) with fungal
bloodstream infections (FBSI) during treatment of hematological malignancies
(HMs) on a retrospective/prospective study.
Methods: We gathered all consecutive documented FBSI diagnosed between
January 2011 and December 2015 in 29 Italian Hematology Departments (both
adults and pediatrics), referring to SEIFEM (Sorveglianza Epidemiologica
Infezioni Fungine Emopatie Maligne). 
Results: We collected 198 cases: M/F 116/82, median age 55 y.o. (range 3-
88). FBSI were detected in 82 AML pts (41.4%), 53 (26.8%) NHL, 24 (12.1%)
ALL, 14 (7.1%) MM, 13 (6.5%) MDS, 4 (2.1%) MPN, 5 (2.5%) CLL and 3 (1.5%)
HL. Regarding the underlying malignancies’ treatment at FBSI onset, 64 pts
(35.3%) experienced the first cycle of chemotherapy, 55 pts (43.9%) salvage
treatment for refractory/relapsed HMs, 21 pts (20.7%) subsequent treatment
after complete or partial remission; 58 pts (29.3%) underwent HSCT (16 autol-
ogous and 42 allogeneic). Central venous catheter had been placed in 182 pts
(92%), urinary catheter in 75 pts (37.8%) and nasogastric tube in 8 pts (4%);
76 pts (38.3%) were supported with parenteral nutrition. Among 114 (57.6%)
neutropenic pts at FBSI diagnosis (neutrophils count <500/mmc), 45 (39.5%)
recovered at the end of observation period, (median duration of neutropenia
13 days, range 1-100). Use of steroids was reported in 105 pts (53%), with a
median duration of 12 days (range 3-106). In 43 pts (21.7%) a skin, oral and/or
rectal fungal colonization was detected. FBSI was most frequently caused by
yeasts: 158 (79.8%) Candida spp. (49 albicans and 109 non albicans), 10
(5.1%) Geotrichum, 5 (2.5%) Trichosporon, 6 (3%) Rhodotorula, 4 (2%)
Saprochaeta and 1 (0.5%) Blastoschizomyces. Molds have been detected
rarely: 12 (6%) Fusarium, 1 each (0.5%) Scedosporium and Mucor. Antifungal
prophylaxis was administered in 121 pts: 11 received only topic antifungals. In
101 pts systemic antifungals were administered as follow: 38 (37.6%)
posaconazole, 38 (37.6%) fluconazole, 8 (7.9%) itraconazole, 6 (5.9%) liposo-
mal amphotericin B (L-AmB), 8 (7.9%) echinocandins (6 caspofungin and 2
micafungin), 3 (3%) voriconazole. The median duration of prophylaxis was 15
days (range 4-120). The residual 86 pts (43.5%) did not received any antifun-
gals. In 20 pts (10%) no systemic antifungal therapy was administered: 14 of
them experienced early mortality. The residual 178 pts were treated as follow:
89 (44.9%) echinocandins (77 caspofungin, 6 anidulafungin, 6 micafungin), 50
(25.2%) L-AmB, 31 (15.5%) azoles (20 fluconazole, 1 posaconazole, 7
voriconazole, 3 itraconazole) and 9 (4.4%) combo therapy (4 posa+L-AmB, 4
caspo+L-AmB, 1 vori+caspo). The median duration on treatment was 12 days
(range 2-180). At 30 days from FBSI diagnosis 81 pts (40.9%) were dead: 37
(18.6%) from fungal infection, 19 (9.6%) from HMs, 11 (5.5%) from other caus-
es; in 14 pts (7.1%) we cannot discriminate the cause of death (FBSI vs HMs).
Of note, 33 dead pts (16.6%) received no antifungal prophylaxis and 6 (3%)
received neither prophylaxis or therapy.
Summary/Conclusions: Our study confirms the rarity of FBSI in hematological
pts. The most frequently identified strains are Candida spp, especially non albi-
cans, yet molds are identified not so rarely, i.e. Fusarium spp. Although the
wider use of broad spectrum azoles prophylaxis and the early institution of
antifungal therapy, overall mortality in this setting is still high. 
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PROGNOSTIC FACTORS IN PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT: EXPERIENCE
WITH 335 PATIENTS FROM A SINGLE CENTER
A Rivas-Delgado1,*, C Fernandez de Larrea1, M Rinuaudo2, P Castro2,
M Suárez-Lledo1, S Fernández2, MT Cibeira1, JM Pericas2, D Monzon2,
M Rovira1, JM Nicolás2, J Esteve1
1Hematology, 2Medical Intensive Care Unit, Hospital Clinic, Barcelona, Spain
Background: In the last years, the prognosis of patients with hematological
malignancies has improved substantially due to the availability of more effective
treatments and better management of complications associated with the dis-
ease and treatments, including stem cell transplantation (SCT). Despite this
progress, patients with hematologic malignancies still have serious complica-
tions that requires admission to the intensive care unit (ICU). 
Aims: The aim of this study is to analyze the survival outcomes and identify the
prognostic value of different variables of patients with haematological malignancies
requiring admission to the ICU at our institution during the past fourteen years.
Methods: Three hundred thirty-five patients (140 F/195 M) with a diagnosis of
hematologic malignancy that required admission to the ICU from January 2000
to September 2013 were included. Thirthy-nine percent of patients had under-
gone SCT, mostly allogenic (73%), and approximately one half of the patients
were receiving front-line treatment. The main causes of admission were septic
shock (45.7%) and acute respiratory failure (37.6%). The most common hema-
tologic malignancy was acute myeloid leukemia (29.3%).
Results: Overall ICU and hospital mortality were 37.6% and 54.6%, respec-
tively, and a decrease in ICU mortality beyond 2005 (52% 2000-2004, 31%
2005-2008 and 32% 2009-2013, p <0.001) was observed (Figure 1). The vari-
ables associated with a worse overall survival in the ICU were being admitted
to ICU from the hematological unit, relapsing disease, severe thrombocytope-
nia, allogeneic SCT, high APACHE II (>19 points) and SOFA (>8 points) score,
previous use of antibiotics, use of vasopressors, non-invasive and invasive
mechanical ventilation (IMV) and renal replacement therapy. By contrast, the
potential myelotoxicity of previous chemotherapy as well as neutropenia had
no significant impact. In the multivariate analysis the need of IMV (HR 16.3; p
<0.001), renal replacement therapy (HR 3.28; p=0.003), previous use of antibi-
otics (HR 2.08; p=0.022) and APACHE II score greater than 19 points (HR
1.99, p=0.024) retained their independent prognostic value. Allogeneic SCT
was also associated with a shorter overall survival compared to other thera-
peutic modalities (p<0.001); however the characteristics associated with the
transplant (donor type, source of stem cells, conditioning regimen intensity or
the development of graft-versus host disease) had no effect on survival. The
prognosis of patients undergoing acute leukemia induction was similar to those
treated with autologous SCT.
Figure 1. Overall survival of patients admitted to ICU according to the
period.
Summary/Conclusions: The survival of patients with hematological malig-
nancies admitted to the ICU has improved in the last years. A previous allo-
geneic SCT transplantation, the need for mechanical ventilation and renal
replacement therapy, prior use of antibiotics and high APACHE II score are
factors associated with a worse prognosis in this group of patients.
132 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Transfusion Medicine
P389
SAFETY AND EFFICACY OF HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1)
HYPERIMMUNE GLOBULIN AGAINST HTLV-1 INFECTION IN A HUMANIZED
MOUSE MODEL
T Mizukami1,*, K Nojima1, W Kuribayashi1, E Sasaki1, M Kuramitsu1, K Ohkuma1,
S Matsuoka1, K Furuhata1, R Sobata2, C Matsumoto2, M Satake2, K Tadokoro2,
K Yamaguchi1, I Hamaguchi1
1Department of Safety Research on Blood and Biologicals, National Institute
of Infectious Diseases, 2Central Blood Institute, Japanese Red Cross, Tokyo,
Japan
Background: Adult T-cell leukemia (ATL) is a malignant disease caused by
infection with human T-lymphotropic virus 1 (HTLV-1). Prevention of HTLV-1
infection is the most effective strategy for eradicating ATL. However, there is
currently no effective vaccine or anti-viral agent for HTLV-1.
Aims: In this study, we aimed to develop a safe and effective HTLV-1 hyper-
immune globulin (HIG) by using donations from HTLV-1-positive carriers that
were screened at the Japanese Red Cross. Additionally, we assessed the viral
safety of HIG during the manufacturing process by spiking the samples with
HTLV-1.
Methods: First, we developed two in vitro screening methods to evaluate and
characterize the anti-viral effect of HTLV-1-positive plasma. We modeled HTLV-
1 infection by using an HTLV-1-infected cell line, MT-2, along with Jurkat or
SLB-1 cells. We then purified HIG from 30 typical HTLV-1-positive serum sam-
ples from the excluded blood donations to the Japan Red Cross, and we eval-
uated its effect in a humanized mouse (Hu-PBL NOG) model to assess its
ability to prevent HTLV-1 infection in vitro. Hu-PBL NOG (NOD.Cg-Prkdcscid
Il2rgtm1Sug/Jic) mice were treated with HIG for 5 days before HTLV-1 infection
by injection with mytomicine C-treated MT-2 cells (1x105) 3 days after the mice
received human peripheral blood mononuclear cells (1x107). To observe the
viral clearance ability throughout the HIG manufacturing process, we performed
a viral clearance study in which we purified HIG from HTLV-1-negative or -pos-
itive plasma that had been spiked with 1x105 MT-2 cells.
Results: We found that HTLV-1-positive plasma, defined as plasma isolated
from an HTLV-1 carrier with a proviral load above four, can effectively block
both HTLV-1 infection and syncytia formation in vitro. In in vivo experiments,
HTLV-1 was detected in the untreated HTLV-1-infected mice, but not in the
HIG-treated HTLV-1-infected mice on days 11 and 38 post-infection. HTLV-1-
infected cells (CD3+/CD4+/CCR4+/CD25+/CD30+) could be seen in the spleen,
liver, and lungs of the untreated HTLV-1-1infected mice, but no HTLV-1-infected
cells were observed in these tissues in the HIG-treated mice, even though their
normal T cells (CD3+/CD4+ and CD8+) were observed. We were still able to
detect the inhibitory effect of HIG treatment on HTLV-1 infection when we treat-
ed mice with HIG 20 days after the HTLV-1 infection. The results of a viral clear-
ance study show that high log reduction values were obtained during the HIG
manufacturing process. We were unable to detect any HTLV-1 genomes in the
purified HIG, and there was no HTLV-1 infectivity in the HIG purified from source
plasma spiked with 1x105 MT-2 cells.
Summary/Conclusions: We found that HTLV-1 HIG may be an effective and
safe therapy for the prevention of HTLV-1 infection.
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STABLE AND FULL PRODUCTION OF FETAL HAEMOGLOBIN AFTER
BONE MARROW TRANSPLANT FAILURE IN PATIENTS WITH THALASSAEMIA
MAJOR AND CLINICAL REMISSION: THE GENETIC BACKGROUND
K Paciaroni1,*, N Bianchi2, G De Angelis3, C Gallucci3, C Alfieri3, M Ribersani3,
P Sodani3, J Gaziev3, A Isgrò3, M Marziali3, F Agostini4, G Lucarelli3, R Gambari2
1Policlinic of “Tor Vergata” University, Rome, Italy, International Centre for Trans-
plantatin in Thalassemia and Sickle Cell Anaemia, Mediterranean Institute of
Haematology, Rome, 2Department of Life Sciences and Biotechnology, Ferrara,
3International Centre for Transplantatin in Thalassemia and Sickle Cell
Anaemia, Mediterranean Institute of Haematology, 4Department of Biomedicine
and Prevention, Policlinic of “Tor Vergata” University, Rome, Italy
Background: High fetal haemoglobin (HbF) levels ameliorate morbidity and
mortality in Sickle Cell Anaemia (SCA) and β-thalassaemia. The variability of
HbF levels is genetically controlled by multiple genes and recent studies provide
new insight into the molecular mechanisms in order to induce the HbF produc-
tion in adult haemopoietic cells as a promising therapeutic approach to ame-
liorate the severity high levels of HbF ameliorate the severity of the β -disorders.
A strong support to such novel approaches comes from recent clinical obser-
vations carried out by our group
Aims: To study the fetal haemoglobin levels and genetic background of three
thalassemic patients who underwent bone marrow transplant ( BMT) and exhib-
ited high HbF level after BMT failure and autologous reconstitution.
Methods: Out of 292 consecutive patients with β-haemoglobin disorders under-
going allogeneic Bone Marrow Transplant at our institution, we observed 3 BMT
recipients who developed the reactivation of HbF synthesis after BMT failure.
We analyzed the blood samples of three patients for the genetic polymorphisms
associated to increased level of HbF, genomic DNA sequencing, western blot-
ting, electrophoretic mobility shift assays, surface plasmon resonance (SPR)
biospecific interaction analysis, bioinformatics analyses based on docking
experiment.
Results: Three patients with β°-thalassaemia major underwent BMT and reject-
ed at +40, +90 and +18 days after transplant respectively. The autologous
recovery was documented (0% residual donor cells) in all cases. Transfusion
therapy was required to support anaemia until +118, +162 and +178 days after
transplant respectively. Afterwards the Hb levels were steadily over 10.2 g/dl
(range 10.2-11.8 gr/dL) without the use of transfusion support and the Hb elec-
trophoresis revealed HbF 99.8% in all 3 cases. At +93, +82 and +17 months
respectively of ongoing follow-up after graft failure, all 3 patients maintain the
sustained and full (99.8%) production of HbF and are transfusion-free. (See
the table).The genetic analysis documented that all patients were carrier of the
non-deletion form of hereditary persistence of HbF. The 3 thalassaemic patients
exhibit the homozygosity for the –158 (C->T) point mutation in the G γ promoter
sequence and we found in all three a novel polymorphism of the Aγ-globin gene
at position +25(G→A). This region belongs to a sequence recognized by DNA-
binding protein complexes, including LYAR (Ly-1 antibody reactive clone), a
zinc-finger transcription factor previously proposed to be involved in down-reg-
ulation of the expression of γ-globin genes in erythroid cells decreasing the
efficiency of the interaction between this sequence and specific DNA binding
protein complexes.
Summary/Conclusions: Our study showed that the reactivation of HbF syn-
thesis can occur in the adult age and the high levels of HbF provide a thera-
peutic benefit to the β-disorders. We found a novel polymorphism of the Aγ-
globin gene in all three thalassemic patients who failed BMT and developed
high levels of HbF. It is likely that the favorable genetic background in these
patients concurred the full HbF production.
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AUDIT OF TRANSFUSION PRACTICES IN PATIENTS RECEIVING
AUTOLOGOUS STEM CELL TRANSPLANTATION AT UNIVERSITY
HOSPITALS BIRMINGHAM
A Burke1,*, K Fordwor1, M Cook1, S Morton2
1Department of Clinical Haematology, University Hospitals Birmingham, 2NHS
Blood and Transplant, Birmingham, United Kingdom
Background: Autologous stem cell transplantation (autoSCT) is an effective
consolidation therapy, improving outcomes in a number of haematological con-
ditions. Blood product support is often required to treat anaemia and reduce
risk of haemorrhage. However many patients undergoing autoSCT have pre-
viously been treated with chemotherapy regimens that do not routinely require
support with blood products.
Aims: We examined transfusion practice at our transplant centre to investigate
whether patients undergoing autoSCT were receiving potentially avoidable
transfusions.
Methods: 121 consecutive patients who underwent autoSCT at University Hos-
pitals Birmingham between 01/09/14 and 31/10/15 were identified using the
Bone Marrow and Stem Cell Transplant registry.
Of the 26 patients receiving their pre transplant treatment in our centre, 16
(58%) received their first transfusion during the transplant period. Clinical and
laboratory data was collected from these patients from the electronic patient
record, and paper records when necessary.
Results: 69% were male, median age 60 years (range 31 to 68 years). Myelo-
ma was the most frequent indication for transplant (81%). There were 40 platelet
transfusions delivered to 16 patients, median 3 per patient (range 1-6). Of
these, 29 were apheresis and 11 were pooled doses. All were single unit trans-
fusions. There were 13 units of red cells transfused in 6 episodes to 5 patients,
median 2 per patient, with one single unit transfusion. Transfusions were deliv-
ered a median of 3 days before engraftment (range day -12 to day +53), with
15%, 45% and 75% being delivered within 1, 3 and 5 days of engraftment
respectively and a median of 4 days before discharge (range day -9 to day
+56), with 15%, 37% and 59% occurring within 1, 3 and 5 days respectively.
23 (57.5%) doses of platelets were assessed to be clinically justified based on
the available information. Of these, 11 were for platelet count less than or equal
to 10x109/L, 3 were for minor bleeding and the remaining 9 were for prophylaxis
during a septic episode to maintain platelet count greater than 20x109/L. The
16 platelet transfusions where no clinical justification was evident amounted to
28 potentially unnecessary donor exposures in 12 patients. 3 of the 6 red cell
episodes were justified by haemoglobin less than 80g/L. Two episodes were
not assessable due to lack of clinical noting. There were 3 patients who only
had a single platelet transfusion, involving 6 donors, and there was no apparent
clinical justification in any of these.
Summary/Conclusions: In conclusion we found transfusion practice during
autoSCT to be liberal, resulting in high donor exposures, of which at least 39%
were potentially avoidable. 12 (75%) patients (who were previously transfusion
naïve) were exposed to at least one transfusion which we believe was not clin-
ically justified. The median potentially avoidable donor exposures in these
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patients was 1.5 (range 1-6). Strict adherence to recent NICE guidelines and
local policy is expected to improve the donor exposure rate in autoSCT, par-
ticularly in those not previously transfused.
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COAGULATION PROFILE AND OUTCOME OF BLOOD COMPONENT
THERAPY IN SNAKE BITE VICTIMS
AM Rafi*, S Innah
Transfusion Medicine & Immunohematology, Jubilee Mission Medical College
& Research Institute, Thrissur, India
Background: Bites from poisonous snakes cause substantial human morbidity
and mortality in tropical and subtropical countries. Hemotoxic envenoming is
quite common in many parts of India, but only limited data exist on its accurate
incidence in the country, and clinical effects. Herein we present findings from
an observational study on coagulation profile and outcomes of blood compo-
nent therapy in patients with hemotoxic snake bites
Aims: To assess the coagulation profile and outcome of blood component ther-
apy in snake bite victims 
Methods: We undertook an observational study between January 2013 and
June 2014, on patients admitted to the medical ICU of our tertiary hospital,
with a history of snake bite and satisfying the inclusion criteria. The patients
underwent detailed evaluation of envenoming by clinical and laboratory inves-
tigations. The patients were screened by a standard, 20-minute Whole Blood
Clotting Time (WBCT) test (repeated four times at 30 min. intervals) and pro-
longation of at least one test result indicated hemotoxic envenoming. Routine
blood counts, Bleeding Time (BT), Prothrombin Time (PT), International Nor-
malized Ratio (INR), activated Partial Thromboplastin Time (aPTT), fibrinogen
and D-dimer levels were also monitored. Samples of plasma separated from
a citrated blood sample collected at the occurrence of deranged WBCT were
flash frozen and assayed for coagulation factors. Blood component therapy
and its outcomes were also monitored in the patients.
Results: Among 595 patients reporting with snake bites, 445 were adults.
Absence of signs of envenoming suggested non-venomous bites 282 patients.
One hundred and sixty three patients manifested features of envenoming, and
received Anti-Snake Venom (ASV). Species identification of the biting snake
was not possible in 50% of cases. Among the rest, Russel’s viper and Pit viper
accounted for 66 and 9 cases, respectively. Only the cases where the biting
species could be identified were studied further. Delayed treatment resulted in
severe local and systemic manifestations in patients. Hematological manifesta-
tions developed following bites from Russel’s viper, pit viper and unidentified
species as well. Acute Renal Failure (ARF) due to Disseminated Intravascular
Coagulation (DIC) and capillary leak syndrome developed only in patients with
bites from Russels viper, and necessitated hemodialysis. Coagulopathies
occurred in most patients with bites from Russel’s viper and pit viper. Patients
bitten by Russel’s viper manifested severe deficiency of Factor V and Factor X,
while it did not occur in pit viper bites. Qualitative testing for Factor XIII revealed
its deficiency specifically in cases of Russel’s viper bite. Most patients with
hemotoxic envenomation received transfusion of fresh frozen plasma (FFP),
24 hours after administration of ASV. Severe thrombocytopenia necessitated
the administration of platelet concentrate in seven patients. Packed Red Blood
Cells (PRBC) was administered in 4 patients with anemia. Blood component
therapy significantly increased hospital stay of the patients. No statistically sig-
nificant complications or mortality occurred after transfusion therapy.
Summary/Conclusions: Rural areas had higher incidence of snake bites.
Though BT and CT were sufficient to identify hemotoxicity, costlier and time-
consuming assessment of PT, aPTT, serum fibrinogen and D-dimers had more
sensitivity. Hematological manifestations occurred following bites from Russel’s
viper and pit viper, while the former produced major bleeding diatheses and a
higher incidence of DIC and ARF. The public need to be made aware of the
need for early identification and appropriate treatment of snake bites
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IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) USE ON
TRANSFUSION REQUIREMENTS AND BLOOD LOSS IN CARDIAC SURGERY
A Mo1,*, G Matalanis2, F Hong3, C Smith3
1Haematology, Monash Hospital, Clayton, 2Cardiothoracic surgery, 3Laboratory
Haematology, Austin Health, Heidelberg, Australia
Background: Cardiac surgery is associated with significant coagulopathy and
bleeding. This has led to off-label Prothrombin Complex Conccentrate (PCC)
use, despite minimal data regarding its efficacy in this setting. There have been
retrospective studies investigating use of four-factor PCCs in Europe showing
variable efficacy, however the only PCC available in Australia is Prothrom-
binex-VF, a three-factor PCC containing factors II, IX and X.
Aims: We aimed to retrospectively review the perioperative off-label use of
PCCs during cardiac surgery in our institution, to evaluate if PCC use reduced
postoperative bleeding or transfusion requirements, and its effect on other clin-
ical and laboratory parameters compared to patients who did not receive PCC.
Methods: A retrospective audit was performed, with the approval of the hospital
Research Ethics Committee, of all patients undergoing cardiac surgery from
1st June 2012 to 31st December 2012. Data was collected via the hospital’s
cardiac surgery database and medical records.
Results: 193 patients underwent cardiac surgery during the study period. 66
(34%) received PCC at a median dose of 22 IU/kg. There was a significant
reduction in the INR (medain INR reduced from 1.5 pre-PCC to 1.3 post-PCC),
with the change in INR greatest for patients with the highest pre-PCC INRs),
but no change to APTT following PCC use. Post-operative blood loss, as meas-
ured by the 4-hour chest drain output, was comparable to international studies
and did not decrease significantly with PCC (290mL versus 270mL, p=0.29).
The PCC group also had higher transfusion requirements, including more red
blood cells (median 4 units versus 0 units), more platelet transfusions (median
2 bags versus 0), more Fresh Frozen Plasma (both receiving a median of no
units however the PCC group had a greater IQR of 0-2 units), and more cryo-
precipitate transfusions (median 3.5 units versus 0) (p <0.0001). These results
were, however, potentially confounded by longer median cardiopulmonary
bypass time and a greater proportion of aortic surgeries in the PCC group.
Summary/Conclusions: A substantial proportion of patients undergoing car-
diac surgery are treated off-label with PCCs. This is associated with a reduction
in the INR, but no significant difference in the post-operative blood loss or blood
product transfusion rate.
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COMBINED PLASMA EXCHANGE AND ERYTHROCYTAPHERESIS FOR
TREATMENT OF MULTIORGAN FAILURE DUE TO SUSPECTED FAT
EMBOLISM SYNDROME IN SICKLE CELL DISEASE
D Avenoso*, S Deplano, B Sevillano, A Luqmani, N Cooper, L Eccersley,
S Thomas, R Haynes, L Alexander, M Layton
Haematology, Hammersmith Hospital - Imperial College NHS Trust, London,
United Kingdom
Background: Fat embolism syndrome (FES) as a consequence of bone mar-
row necrosis during a vaso-occlusive crisis is a devastating complication of
sickle cell disease (SCD) that affects all age groups and phenotypes with a
high mortality. Clinically FES is characterised by acute respiratory failure, neu-
rological impairment, cutaneous/mucosal petechiae, acute kidney injury, and
hepatic dysfunction. Additional markers that aid diagnosis include hypona-
traemia, thrombocytopenia and coagulopathy. Retrospective case reviews of
FES in SCD have highlighted the role of red cell exchange transfusion in
improving clinical outcome though mortality remains ~30%. These have not
differentiated between manual and automated red cell exchange. Previous
studies have shown reduction in inflammatory mediators after manual
exchange transfusion. Such an effect would not be expected from selective
removal of red cells during automated erythrocytapheresis (aRCE) increasingly
the modality of choice in specialist haemoglobinopathy centres. Since inflam-
matory mediators are likely to play a role in its pathogenesis we reasoned that
combined plasma exchange (PEX) and erythrocytapheresis could improve the
outcome of FES in SCD.
Aims: To report the outcome in adult SCD patients who developed multiorgan
failure and met diagnostic criteria for FES treated with combined aRCE and PEX.
Table 1. Clinical details at the onset of MOFS.
Methods: A retrospective analysis of 3 SCD patients aged 33-67 years with
suspected FES treated at Hammersmith Hospital. Clinical details of the patients
are summarized in table 1. Apheresis was performed using the Spectra Optia
Apheresis System according to our standard operating procedure with a target
HbS of <30% and plasma volume exchanged of 3L. Consecutive aRCE and
PEX were performed initially and a decision to repeat PEX subsequently based
on clinical response (median number PEX 2;range 1-3). Time to recovery was
defined by reversal of neurological and respiratory impairment and normalisa-
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tion of platelet count, liver and renal function and coagulation parameters. Over-
all survival (OS) was assessed 2 months post-treatment with a median follow
up of 16 months (range 2-21).
Results: All patients exhibited features of multiorgan failure compatible with the
diagnosis of FES. OS was 100% at 2 months. Rapid improvement in neurological
status was seen with normalisation of Glasgow Coma Scale within 24 hours of
completing PEX. No long-term neurological sequelae were observed. Median
time to recovery as defined above was 16 days (range 9-18).
Summary/Conclusions: Based on these favourable preliminary results in SCD
patients with multiorgan failure due to suspected FES it is recommended com-
bined aRCE/PEX is evaluated in a larger cohort of patients to determine its
efficacy in treatment of this life-threatening complication.
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REDUCTION OF ABO GLYCOSYLTRANSFERASE CAUSED BY SYNONYMOUS
VARIATION IN B309 ALLELE
JG Shin1, SH Oh1,*, HS Kim2, S Lee2, TS Park3, JY Lee1, HR Kim1, JN Lee1
1Laboratory Medicine, Inje University College of Medicine, BUSAN, 2School of
Life Science and Biotechnology, Kyungpook National University, Daegu, 3Lab-
oratory Medicine, School of Medicine, Kyung Hee University, Seoul, Korea,
Republic Of
Background: Non-synonymous single-nucleotide polymorphism in the ABO
gene can affect the enzyme characteristics and protein quantity producing many
kinds of ABO blood type subgroups. B3 phenotype including 11 variant alleles
reveals characteristic mixed field agglutination. Synonymous variations, for-
merly called ‘silent’ mutation, can result in aberrant protein expression and pro-
tein folding. Interestingly, B309 variant (255C>T on exon 6 in the background
of B101) was recently reported to have synonymous SNP (sSNP). We found
B309 alleles recurrently in Korean B3 phenotype individuals.
Aims: B309 allele’s effect on B antigenic expression was investigated in
patients and confirmed by the experimental model.
Methods: Individuals with mixed field agglutination with anti-B were tested by
direct sequencing. B309 allele were isolated and confirmed by TA cloning.
cDNAs from exon 5 to exon 7 were amplified and sequenced in B309 individuals
to exclude out the possibility of splice variant. B101 and B309 coding sequence
with 255C>T were cloned, inserted to the vectors with fluorescent tags and
transduced into the HeLa cells that have O/O genotype. The protein expression
and antigenic changes by sSNP were evaluated with fluorescent protein expres-
sion and flowcytometric analysis. 
Results: We found two unrelated Korean individuals and three family members
in one pedigree who have B309 alleles and all of them revealed B3 phenotypes.
Exon 6 of ABO transferese gene was not spliced out in their cDNAs. Protein
expression and antigenic expression were reduced in B309 variant (the median
MFI: 36.85) compared to B101 (MFI: 50.03).
Figure 1.
Summary/Conclusions: Individuals with B309 allele revealed B3 phenotypes
and their 255C>T synonymous polymorphism didn’t contribute to the alternative
splicing. 255C>T polymorphism was experimentally proven to cause the
reduced expression of ABO transferase and the subsequent weakening of B
antigens. This phenomenon implies that sSNP could also affect the expression
and function of the protein, and finally alter the immunohematologic reactions.
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EFFECTS OF IMPLEMENTATION OF A MASSIVE TRANSFUSION PROTOCOL
IN A TERTIARY REFERRAL HOSPITAL
I Giannoutsos1,*, E Tegg2, H Keenan3, JA Greaves3
1Haematology, Nepean Hospital, Kingswood, 2Haematology, 3Transfusion,
ICPMR, Westmead Hospital, Westmead, Australia
Background: Following the study in 2007 of Borgman et al regarding early plas-
ma product support in trauma patients receiving massive transfusion, the imple-
mentation of massive transfusion protocols (MTPs) has become the norm.Aims
of utilising a MTP include pre-emptive transfusion with plasma products platelets
in an effort to be proactive and overcome the effects of transfusing mostly large
amounts of packed red cells on coagulation, in patients with critical bleeding.
Aims: The effect of implementing a MTP in a tertiary referral hospital, for both
trauma and non-trauma–related critical bleeding was examined. Parameters
include the number of MTP ‘episodes’ or ‘activations’, the proportion of ‘true’ critical
bleeding episodes, the ratio of blood products transfused (Red Blood Cells:Fresh
Frozen Plasma:Cryoprecipitate:Platelets) and blood product wastage.The appro-
priateness of platelet transfusion and 28-day mortality were of interest.
Methods: Data regarding the issuing of blood products which was collected by
Blood Bank staff at the time of the MTP, as well as computer records regarding
laboratory parameters and blood product use was assessed retrospectively.The
first dataset period, denoted Period 1(P1), was prior to the implementation of
the MTP and the second period (P2) post-implementation.
Results: During P1 (16.5 months), the total number of massive transfusion
‘episodes’ was 53 and during P2 (7.5 months) there were 59 MTP
‘activations’.During P1 the average number of Red cells (RBC), Fresh Frozen
Plasma (FFP), Cryoprecipitate(Cryo) and Platelets (Plt) transfused per patient
were:15.1, 13.3, 13.6 and 1.5 respectively.4 RBCs or less were transfused in
only 3 episodes during P1.During P2 (7.5 months), the total number of activa-
tions included 57, and the corresponding average numbers of RBC, FFP, Cryo
and Plt per patient were 7.9, 6.9, 7.4 and 0.5.4 RBCs or less were transfused
in 27 episodes during P2.The proportion of deaths for the 53 patients during
P1 was 28% and during P2 the proportion of deaths was 31.6%.The RBC:FFP
ratio in P1 was 1.13:1 and in P2 it was 1.18:1. RBC:Cryo ratio was 1.11:1 for
P1 and 1.09:1 for P2. RBC:Plt ratios for P1 and P2 were 10.06:1 and 16.2:1.
Summary/Conclusions: The 2 periods contain similar numbers of patients,
however the time periods during which the ‘critical bleeding’ episodes were
recorded differ markedly (16.5/12pre vs 7.5/12post).This is mainly due to a large
number of MTP activations in which 4 or less RBC units were transfused in the
post-implementation period.The high proportion of patients who did not have
truly ‘massive bleeding’ but for whom the MTP was activated (47%), is similar
to that previously reported.Correspondingly, the number of blood products trans-
fused per patient was much higher in the pre-MTP protocol period. A cardinal
reason for the wastage of blood products is that in patients who are severely
injured, the MTP is activated after they have undergone an initial assessment
and plasma products are thawed, however they succumb to their injuries before
receiving these.Patient mortality did not differ in the periods before and after
the MTP implementation (28.3% v 31.6%).The ratio of RBC to plasma products
is similar in the pre- and post-MTP implementation periods.Fewer platelets were
transfused per patient in the post-MTP period than pre-implementation (0.5 v
1.5);this is most likely because the 1st MTP ‘shipment’ of blood products con-
taining 4 RBCs, 4 FFPs and 4 Cryo, would not normally include platelets.In
summary, implementation of a formal MTP protocol has resulted in more ‘acti-
vations’ than had been the case before, an increased number of ‘false’ activa-
tions, increased wastage of blood product, no significant changes in mortality
or ratio of plasma product to RBCs transfused.Possible ways to mitigate plasma
product wastage could include alteration of MTP activation criteria, extending
the lifespan of thawed products and the use of lyophilised fibrinogen.
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LOW PREVALENCE OF ALLOIMMUNIZATION AFTER RED BLOOD CELL
TRANSFUSION IN 182 CHILDREN WITH SICKLE CELL DISEASE
S Allali1,*, T Peyrard2, D Amiranoff3, M Chalumeau1, V Brousse1, M de Montalembert1
1Department of Pediatrics, Necker Hospital for Sick Children, 2Centre National
de Référence pour les Groupes Sanguins, Institut National de la Transfusion
Sanguine, 3Etablissement Français du Sang, Necker Hospital for Sick Children,
Paris, France
Background: A high prevalence (around 30%) of red blood cell alloimmuniza-
tion has been reported in patients with sickle cell disease (SCD), but few studies
have focused on children.
Aims: Our objectives were to study prevalence and risk factors of red blood
cell alloimmunization in a population of children affected with SCD.
Methods: We analyzed the medical and transfusion files of 245 children with
SCD, hospitalized in our center in 2014, and identified 182 patients aged 1 to
18 years who received at least one red cell concentrate in their lifetime. The
main clinical and immuno-haematological characteristics of alloimmunized and
non-alloimmunized patients were compared.
Results: The 182 patients received 1 to 339 red blood cell units with a median
of 10 (IQR: 4-46.7) units per patient. Six patients out of the 33 in whom a red
cell genotyping was performed (18.2%) had a partial antigen in the Rh blood
group system. Five patients (2.7%) had a S-s- rare blood type (either U+var or
U-). Excluding autoantibodies and the naturally-occurring antibodies identified
before any transfusion, the prevalence of alloimmunization was 13.7% (95%
CI [8.6-18.6]). After excluding the probable irregular natural antibodies (anti-M,
anti-Lea, anti-Leb), the prevalence dropped to 7.4% (95% CI [3.5-11.3]) and
the alloimmunization rate was 0.17/100 units received. These antibodies were
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directed against antigens of Rh (D, C, Ce and Cw), Kell (Kpa), Duffy (Fya, Fy3),
MNS (S, U) and Colton (Cob) blood group systems. Two anti-D alloimmuniza-
tions involving partial antigens could have been prevented by systematic RHD
genotyping. Main risk factors for alloimmunization were a higher number of
red blood cell units (median of 65 vs 10 units per patient; p=0.01) and the pres-
ence of one or more red cell autoantibodies (46.2 vs 4.7%; p<0.0001).
Summary/Conclusions: The relatively low frequency of alloimmunization in
our study is probably due to the fact that it is a pediatric population exclusively
transfused with blood systematically matched for C, c, E, e and K antigens,
and probably also for other blood group antigens as the number of donors of
African-Caribbean origin is high in the Paris region. The prevalence of red
blood cell alloimmunization is relatively low among SCD patients followed in
our pediatric center but it could still very likely be lowered by the implementation
of a systematic genotyping for the major blood group systems. The presence
of red cell autoantibodies appears to be a major risk factor for alloimmunization
and could justify specific transfusion guidelines.
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INTRAUTERINE BLOOD TRANSFUSIONS IN FETAL ANEMIA CAUSED BY
PARVOVIRUS B19 INFECTION
K Cadren1,*, M Falcón Rodriguez1, M Negrín López1, R García Delgado2,
R García Rodriguez2, M Medina Castellano2
1Hematology, 2Obstetrics and Gynecology, Hospital Insular de Gran Canaria,
Las Palmas de Gran Canaria, Spain
Background: Parvovirus B19 has an affinity for hematopoietic system cells,
including erythroid progenitor cell. The virus attacks cells of the red blood cell
lines in the bone marrow, causing hemolysis and red blood cell aplasia. Fetal
anemia is a serious complication in pregnancy associated with perinatal mor-
tality and morbidity. The immaturity of the fetal immune system asociated to its
inability of overproducing red blood cells leads to a physiological immunodefi-
ciency that can be life threathening producing serial fetus conditions such as
non inmune hydrops fetalis and spontaneous abortions. We present 8 cases
of fetal anemia induced by Parvovirus B 19 (PV19) infection diagnosed during
routine prenatal ultrasounds examination using the measurement of the middle
cerebral artery peak systolic velocity (MCA-PSV) and their subsequent treat-
ment by intrauterine blood transfusions (IBT).
Aims: To determine the impact of intrauterine blood transfusions on the cor-
rection of fetal anemia in fetal PV19.
Methods: A retrospective descriptive study was performed of all intrauterine
blood transfusions for PV19 between January 2014 and December 2014. The
study was carried out in the Complejo Hospitalario Materno- infantil de Las
Palmas de Gran Canaria. The patient’s clinical, laboratory and transfusion data
were obtained from hospital records. Incidental findings at routine second
trimester ultrasounds concerning an increase of the MCA- PSV>1.5 MoM cor-
related with fetal anemia. MCA-PSV is a sensitive, noninvasive means to deter-
mine the degree of fetal anemia that can be used accurately to time the first
and subsequent intrauterine transfusions. Pregnant women at risk were
assessed for the presence of PV19 infection by determining their IgM anti Par-
vovirus status and PCR. The primary management tool was cordocentesis to
assess fetal hemoglobin and performing IBT. Serial hematocrit determinations
were taken and IBT where performed until the resolution of anemia.
Results: In 2014, an outbreak of parvovirus B19 infection occurred. Eight asymp-
tomatic pregnant women were diagnosed. Their median gestational age at diag-
nosis was 20.5 weeks. Five of eight pregnant women were transfused. Out of the
five transfused fetus, three survived. The overall survival rate was 60% (Table 1).
Table 1.
* IUGR: Intrauterine growth restriction.
Summary/Conclusions: The development of an acute PV19 infection during
pregnancy can cause prenatal complications ranging from early pregnancy
loss to nonimmune hydrops and intrauterine death. Measurements of MCA-
PSV represent a non invasive procedure to diagnose fetal anemia, thus leading
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Background: Sickle cell anaemia (SCA) is an inherited red cell disorder char-
acterised by haemolytic anaemia, recurrent painful vaso-occlusive crises and
end organ damage. There are few treatment options. Platelets, activated by
ADP released through haemolysis, contribute to vaso-occlusion by forming
multi-cellular aggregates and promoting inflammation. Prasugrel is an oral,
third-generation thienopyridine inhibitor of ADP-mediated platelet activation
and aggregation. Prior studies showing a reduction in markers of platelet acti-
vation, as well as the rate and intensity of pain suggested a potential therapeutic
benefit of prasugrel in SCA.
Aims: To assess the efficacy of prasugrel in children with SCA, as measured
by reduction in the rate of vaso-occlusive crisis (VOC).
Methods: The DOVE trial was a phase 3 double-blind, placebo-controlled,
parallel-group, multinational trial of children with SCA, ages 2 to <18 years,
who were randomly assigned to receive oral prasugrel or placebo, dose titrated
to achieve a pre-specified reduction of platelet reactivity, for 9 to 24 months.
The primary endpoint was the rate of VOC, a composite of painful crisis or
acute chest syndrome (ACS). Secondary endpoints included electronic diary-
documented rate and intensity of sickle cell related pain, analgesic use and
school attendance; rates of sickle cell related RBC transfusion; and rates of
hospitalisation for VOC, painful crisis and ACS.
Figure 1.
Results: A total of 341 patients with SCA were randomized at 51 sites in 13
countries across the Americas, Europe, Asia, and Africa. Of these, 308 (90.3%)
had HbSS and 153 (45%) were receiving stable dose hydroxyurea (HU); 275
patients completed the 9 month visit, of which 266 continued beyond 9 months
and 9 discontinued prior to locking the database. A total of 736 VOC events
occurred in the study: 328 among 115 (67.3%) patients in the prasugrel group
and 408 among 123 (72.4%) patients in the placebo group. The rate of VOC
trended lower in the prasugrel compared to the placebo groups but did not reach
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significance: 2.30 per person-year and 2.77 per person-year, respectively (rate
ratio, 0.83; 95% CI, 0.66-1.05; P=0.12) (Figure). There were no significant differ-
ences between groups in the secondary diary-reported outcomes. Pre-specified
subgroup analyses identified a modest treatment effect in two subgroups; the
oldest age (≥12 to <18 years) group (0.72; 95% CI, 0.51-1.02; P=0.06) and
patients not on concomitant HU (0.74; 95%CI 0.54-1.01; P=0.06). Safety end-
points, including frequency of bleeding events requiring medical intervention,
treatment emergent adverse events, both haemorrhagic and non-haemorrhagic,
and discontinuations due to study drug did not significantly differ between groups.
Summary/Conclusions: In children with SCA, prasugrel did not significantly
reduce the rate of the primary composite endpoint of VOC at the levels of
platelet inhibition attained in this study. Prasugrel treatment had no impact on
secondary outcomes. The overall adverse event rate, including haemorrhagic
and non-haemorrhagic events, did not differ between the treatment groups. A
trend towards an effect of prasugrel on VOC in the ≥12 to <18 year age group
and in patients who were not receiving HU suggest that anti-platelet agents
may have a therapeutic role as part of a multi-drug approach toward the com-
plex pathophysiology of SCA. The DOVE study is the first multinational inter-
ventional trial in children with SCA and provides valuable guidance for future
multi-continental SCA clinical trials. (Funded by Daiichi Sankyo, Ltd and Eli
Lilly and Company; DOVE ClinicalTrials.gov number, NCT01794000).
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Background: Romiplostim could be a treatment option for symptomatic chil-
dren with ITP.
Aims: This was a phase 3, double-blind study designed to evaluate weekly
romiplostim or placebo (randomized 2:1) given for 24 weeks to children with
ITP for ≥6 months.
Methods: Dose was adjusted weekly from 1-10 μg/kg to target platelet counts
of 50-200×109/L. Platelet response was defined as platelet counts ≥50×109/L
any week of weeks 2-25 (excluding 4 weeks after rescue medication). The pri-
mary endpoint, durable platelet response, was defined as ≥6 weekly responses
during the final 8 weeks, weeks 18-25. Overall platelet response was defined
as ≥4 weekly responses weeks 2-25.
Table 1.
Results: Patients (n=62) had median (min-max) age 9.5 (3-17) years, ITP dura-
tion 2.1(0.5-10.7) years, and baseline platelet counts 18 (1-94)×109/L and 44%
were male; 66% were Caucasian, 13% African American, and 8% Asian. For
the primary endpoint, measured in the final 8 weeks after 16 weeks of dose
titration, the proportions of patients with a durable platelet response were romi-
plostim: 52% and placebo: 10% (p<0.002). The proportions of patients with over-
all platelet response were romiplostim: 71% and placebo: 20% (p=0.0002), and
with any platelet response were romiplostim: 81% and placebo: 55% (p=0.03).
For romiplostim, the median (min-max) time to first platelet response was 4.5
(1-20) weeks and the median average weekly dose was 3.9 (0.9-8.1) μg/kg.
Median platelet counts with romiplostim were ≥50×109/L from week 8 on. When
the number of bleeding events was divided by exposure time, duration-adjusted
rates per 100 patient-weeks of any bleeding (30.9 vs 47.3, p<0.0001), CTCAE
grade ≥2 bleeding (5.9 vs 17.9, p=0.0006), and composite bleeding episodes,
ie CTCAE grade ≥2 bleeding and/or rescue medication use (8.1 vs 18.4, p
<0.0001), were all significantly lower with romiplostim than placebo. No patients
withdrew due to adverse events (AE). Incidence rates of serious AEs (SAEs)
were romiplostim: 23.8% (10 patients) and placebo: 5.3% (1 patient). SAEs with
romiplostim consisted of 2 cases each of contusion, epistaxis, and headache,
and 1 case each of petechiae, thrombocytosis, nephrotic syndrome, nausea,
vomiting, bronchiolitis, fever, urinary tract infection, and seizure. Only one
headache SAE and the thrombocytosis SAE (same patient) were considered
treatment-related by the investigator. There were no thrombotic events, no malig-
nancies observed, and no findings indicating bone marrow dysplasia or fibrosis
in the only bone marrow biopsy performed (in a placebo-treated patient).
Figure 1.
Summary/Conclusions: In children with symptomatic ITP of ≥6 months dura-
tion, romiplostim was effective in inducing durable and overall platelet respons-
es and reducing bleeding. There were no new safety signals. Romiplostim may
be a treatment option for children with symptomatic chronic ITP.
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Background: The identification of ANKRD26 as the gene responsible for a
mild form of inherited thrombocytopenia stimulated revealed that this disorder
exposes subjects to the risk of haematological neoplasm. A similar pattern is
present in subject with platelet disorder due to mutations in RUNX1 and ETV6
related familial thrombocytopenia. A recent study about paediatric inherited
thrombocytopenia show a presence in the 5’ UTR of ANKRD26 gene of a new
mutation c.-140C>G, not previously described in the Italian population
Aims: Screening of 5’UTR of ANKRD26 gene in patients with mild form of
inherited thrombocytopenia
Methods: We studied 50 patients with mild form of inherited thrombocytopenia
lacking a definite genetic characterization followed at the 1st Clinical Medicine
of the University City Padua Hospital. Molecular analysis in the 5’-UTR of the
ANKRD26 was carried out to investigate the presence of the gene mutations.
Results: We identified 6 patients belonging three family trees and three spo-
radic cases with single nucleotide substitutions in the 5’-UTR region of the
ANKRD26 gene: one family presented with c. -128C>G mutation, one family
presented with c. -140C>G mutation, one family presented with c. -140C>G
and c. -134G>A mutations, three sporadic patients presented with c. -140C>G
mutation. The clinical features of the patients are mild thrombocytopenia
(>90×109/l), normal mean platelet volume (MPV), autosomal dominant trans-
mission and absence of haemorrhagic symptoms. One patient was first diag-
nosed as immune thrombocytopenia. Cases of malignancies registered in the
subjects with mutations are breast cancer, prostate cancer, kidney cancer and
acute myeloid leukaemia.
Summary/Conclusions: Thrombocytopenia with 5’UTR ANKRD26 gene muta-
tion must be considered in case of a mild thrombocytopenia with a low bleeding
tendency, associated with autosomal dominant transmission, normal platelet
size and history of malignancies. This newly described pathology is very prob-
ably under diagnosed. The new mutation c. -140C>G in the 5’-UTR region of
the ANKRD26 gene, recently described by Boutroux et al. in 2015, must be
investigated in patients with these clinical features.
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Background: The treatment of chronic/relapsing immune thrombocytopenia
purpura (ITP) is not well established due to the lack of evidence-based data,
and is particularly challenging in children who are more at risk of severe side-
effects secondary to prolonged steroid therapies. Mychofenolatemofetile (MMF)
is an immunosuppressor which reduces T and B-cells proliferation by inhibiting
the inosine monophosphate dehydrogenase. It has been shown to be safe and
effective in some series of patients with ITP, and in few cases of Evans Syndrome
secondary to ALPS. In the largest reported cohort of 46 adults with ITP, 52%
achieved a response, which was complete in 33%. However, data from larger
group of children and details on timing of response still have to be investigated.
Aims: The aim of this study is to evaluate the outcome, timing of response
and toxicity of children treated with MMF for ITP. 
Methods: We collected data of children undergoing MMF treatment for ITP,
with or without involvement of other cell lineages, in 8 Italian Centers. Patients
showing other signs of autoimmunity or with ITP secondary to an ALPS-related
disorder, defined as the presence of at least one absolute or primary additional
criterion for ALPS, were included in the study. Patients with ALPS were exclud-
ed. Complete response (CR) and partial response (PR) were defined as a
platelet count >/= 100x109/Land >30x109/L and at least 2 fold increase of the
baseline count, respectively. 
Results: 56 children with primary ITP (37, 66%) or secondary to an ALPS-like
disorder (19, 34%), were treated with MMF. 16/56 (28%) patients had also an
Evans syndrome (ES) due to the association of leukopenia (6), autoimmune
haemolytic anemia (5) or both (5). All patients but 2 who were treated as first
line therapy, received MMF as second (35), third (15) or fourth (2) line treatment.
35/54 (65%) evaluable patients responded to the treatment and achieved a
CR and PR in 25 (46%) and 10 (18%) cases, respectively. PR and CR were
obtained after 20 (range 7-137) and 37 (range 7-192) days of treatment, respec-
tively. 14/19 (73%), and 21/35 (60%) evaluable children with signs of autoim-
munity/ALPS-like syndromeand primitive disease achieved a response, respec-
tively. Patients with ES and with monolinear thrombocytopenia responded
in13/16 (81%) and in 22/38 (58%) cases, respectively. Six out of 37 (16%)
responding children relapsed at median of 283 days (range 189-1036) from
the response. Four patients (7%) reported mild toxicity consisting of
nausea/vomit (2), asthenia (1), skin hyperpigmentation (1) that didn’t require
the interruption of the treatment. Median duration of treatment and follow-up
were 7 months (range 1-42,8) and 12.7 months (range 1-92), respectively.
Summary/Conclusions: To the best of our knowledge this is the largest cohort
of patients treated with MMF for ITP or Evans Syndrome confirming its safe
profile and showing that children seem to have a better overall response com-
pared to what has been reported in adults, in particular a higher rate of CR. It
also shows, for the first time, that MMF represents a valid option also for chil-
dren with ES other than ALPS, who showed a better, although not statistically
significant, response compared to the ones with monolinear thrombocytopenia.
Thanks to the relatively short time of response, MMF can be considered as
second-line option before the use of more aggressive and expensive treatments
as Rituximab or splenectomy. Clinical trials are needed to confirm these results.
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Background: Although splenectomy remains an appropriate treatment for ITP,
it is associated with adverse events (AEs). The most recent guidelines for ITP
indicate that splenectomy should be designated a second-line treatment and
delayed for 6-12 months. Eltrombopag is an oral thrombopoietin receptor ago-
nist (TPO-RA) approved in Europe for treatment of splenectomized adult chron-
ic ITP patients who are refractory to other treatments, and as a second-line
treatment for adult nonsplenectomized patients in whom surgery is contraindi-
cated. The EXTEND study assessed long-term safety and efficacy of eltrom-
bopag in ITP patients previously enrolled in 6-week or 6-month placebo-con-
trolled trials.
Aims: To compare the safety and efficacy of long-term eltrombopag treatment
in patients with or without splenectomy in the EXTEND trial.
Methods: Eltrombopag was started at 50 mg weekly and titrated to maintain
platelet counts 50–200 Gi/L.
Results: Among patients enrolled in EXTEND (N=302), 115 splenectomized
(38%) and 187 nonsplenectomized (62%) patients had similar characteristics
at baseline, except that more splenectomized patients were receiving ITP med-
ications at baseline (47% vs 25%) and more had a history of bleeding (23% vs
13%). Greater than half of both groups received eltrombopag for ≥24 months.
After eltrombopag treatment, a greater proportion of nonsplenectomized
patients achieved platelets ≥50 Gi/L than splenectomized ones, and was con-
sistent by age group (Table). Nonsplenectomized patients experienced pro-
portionately fewer serious bleeding AEs (Table). Rates of any bleeding AE were
experienced by 49 (26%) and 35 (30%) nonsplenectomized and splenec-
tomized groups, respectively. Events occurring in ≥4% of patients in the
splenectomized and nonsplenectomized groups, respectively, included mouth
hemorrhage (4% and 1%), epistaxis (14% and 6%), petechiae (8% and 2%),
ecchymosis (2% and 4%), contusion (3% and 4%), and hematuria (2% and
4%). In each group, 13% had a sustained reduction or permanently stopped at
least one concomitant ITP medication without having received any on-treatment
rescue medication. Splenectomized patients had higher rates of Grade 1-4
World Health Organization bleeding at baseline (64% vs 52%), but rates
declined in both groups over time.
Table 1. Results of the EXTEND eltrombopag study by baseline splenec-
tomy status.
Summary/Conclusions: Long-term treatment with eltrombopag increased
platelets in both nonsplenectomized and splenectomized patients, with numer-
ically higher response rates in the former. Rates of AEs were similar to those
in patients with splenectomy.
Funding: This study (NCT00351468) is/remains sponsored by GlaxoSmithK-
line; however, as of March 2, 2015, eltrombopag is an asset of Novartis AG.
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Background: The thrombopoietin receptor agonist romiplostim is approved
for use in adults with chronic ITP. In this study, patients with ITP (N=169) had
bone marrow biopsies performed at baseline and after 1, 2, or 3 years of romi-
plostim; 24 patients discontinued romiplostim and entered remission.
Aims: To examine remission in patients with ITP receiving romiplostim in a
bone marrow study.
Methods:Patients with ITP entering the bone marrow study had a platelet
count <50x109/L and ≥1 prior ITP therapy. Romiplostim, received weekly for
up to 3 years, was adjusted from 1 10 μg/kg to target platelet counts of 50-
200x109/L; doses were reduced for platelet counts >200x109/L for 2 consec-
utive weeks and no romiplostim was given for platelet counts >400x109/L. A
post hoc analysis was conducted of those who entered remission, ie platelet
counts ≥50×109/L for ≥6 months with no ITP therapy, including romiplostim.
Results: The median years since ITP diagnosis for those who did (N=24) and
did not (N=145) enter remission (1.66 years vs 5.16 years) had overlapping
ranges [not significant (NS)], as did the median average weekly dose (1.1μg/kg
vs 3.5μg/kg, NS, included zero doses prior to last non-zero dose) (Table 1).
Adverse events (AEs) occurred at similar rates. A post hoc analysis examining
the association between remission and baseline factors including age, gender,
platelet count, prior splenectomy, ITP duration, and number of prior treatments
indicated that ITP duration ≤1 year could be a potential predictor for remission
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(hazard ratio 2.46, 95% CI: 1.04, 5.79, p=0.04); however, this association could
be due to multiple comparisons (ie, type I error). Median time of onset for remis-
sion was 52 weeks (range, 6-124 weeks) and median duration of remission
during the study was 88 weeks (range, 29-154 weeks); 21 of the 24 patients
were still in remission at the last observation on study.
Table 1.
Summary/Conclusions: In this post hoc analysis, 14% (24/169) of patients in
a romiplostim ITP bone marrow study were able to enter remission following
standard dosing rules; more studies are needed to confirm whether shorter ITP
duration is a predictor of remission.
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Background: Immune thrombocytopenia (ITP) is an autoimmune disorder in
which platelets are destroyed by macrophages. Macrophages can polarize into
pro-inflammatory M1 or anti-inflammatory M2 phenotypes in response to dif-
ferent environmental stimulation. Previous study showed that all-trans retinic
acid (ATRA) combined with IL-4 induced M2 differentiation in mice. However,
the effect of ATRA on macrophage polarization in ITP patients has not yet been
reported.
Aims: To investigate the immunomodulatory effects of retinic acid in adult ITP
patients.
Methods: Human spleens were obtained from 5 ITP patients and 5 patients
with traumatic spleen rupture. The M1/M2 ratio of splenocytes was evaluated
by immunofluorescence. Peripheral blood mononuclear cells (PBMCs) were
isolated from 18 untreated ITP patients and 12 steroid-resistant ITP patients
who were responsive to the ATRA therapy (10mg once, 3 times per day; median
time to response, 63 days). Human monocyte-derived macrophages were
induced and polarized into M1 or M2 by LPS plus IFN-γ or IL-4 respectively, in
the presence or absence of ATRA. The phenotypes of M1 or M2 were analyzed
by flow cytometry. The concentration of IL-10 and IL-12 in the culture super-
natant was assayed by ELISA. CFSE-labeled CD4+ or CD8+ T cells were co-
cultured with allogeneic M1, M2, ATRA-M1 or ATRA-M2. The proliferation of T
cells and the proportion of CD4+CD49b+LAG3+ regulatory T (Tr1) cells were
analyzed by flow cytometry. The secretion of IL-12, IL-10, IL-1β, IFN-γ, IL-2,
IL-4, IL-5, IL-6, TNF- a, GM-CSF and IL-18 in the co-culture supernatants were
detected with ProcartaPlex assays. The expression of transcription factor cAMP
response element-binding protein 1 (CREB1) was measured by RT-PCR. 
Results: Our data demonstrated that there was a preferred polarization of
macrophages towards M1 in the spleens of ITP patients compared with controls.
In monocyte-derived macrophages induced from the 18 untreated ITP patients,
the expression of M1 markers (CD80, CD86, TNF-α and IL-12) was dramatically
increased and the expression of M2 markers (IL-10 and CD209) decreased
compared to those from healthy controls. Macrophages induced from ITP
patients displayed a higher ability to promote both CD4+ T cell and CD8+ T cell
proliferation and a lower ability to induce Tr1 cells than those from controls. In
both M1 and M2 macrophages, ATRA effectively down-regulated the expression
of CD80, CCR7 and IL-12 while increased the expression of CD209 and IL-10.
ATRA also inhibited the expression of CD86 and HLA-DR in M2 macrophages.
ATRA-modulated macrophages (both M1 and M2) showed suppressive function
on T cell proliferation compared with the untreated macrophages. Moreover,
ATRA-modulated M2 macrophages expanded Tr1 cells but no effect was
observed on M1. The concentration of IL-12, IL-2, TNF-α, IFN-γ and IL-1β was
decreased while IL-4 and IL-10 increased in the co-culture supernatants with
ATRA-modulated macrophages and T cells compared with unmodulated sys-
tems, indicating that ATRA-modulated macrophages could affect Th1/Th2 polar-
ization by promoting Th2 responses. ATRA modulation was associated with
the elevated expression of CREB1 in macrophages. In vivo ATRA therapy could
correct the M1 deviation of macrophages and induce a M2 phenotype in the 12
steroid-resistant ITP patients.
Summary/Conclusions: Our findings demonstrate that an aberrant macrophage
polarization is involved in the pathogenesis of ITP, while ATRA could correct this
imbalance, thus being able to be used as a potential therapy for ITP.
P407
STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL AND MCL
PATIENTS TREATED WITH IBRUTINIB - PRELIMINARY RESULTS
B Sokolowska*, D Jawniak, A Nowaczynska, A Szymczyk, E Wasik-Szczepanek,
E Drab-Urbanek, W Tomczak, J Kozinska, M Hus
Department of Hematooncology, Medical University, Lublin, Poland
Background: Ibrutinib, an inhibitor of Bruton’s tyrosine kinase (BTK) has a sig-
nificant activity in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
(MCL). Although the treatment is well tolerated, some clinical studies reported
mucocutaneous bleeding complications. Such complications may be caused
by platelet or vessel abnormalities.
Aims: The aim of the study was to evaluate platelet function before and during
the ibrutinib therapy.
Methods: We examined 24 patients: 21 with CLL and three with MCL (11
females and 13 males, median age 68 (48-83).The majority of patients received
420 mg Ibrutinib. Two patients received the dose of 140 mg because of atrial
fibrillation. We performed platelet aggregation studies in whole blood samples
using Multiplate technology, in which platelets were activated by: adenosine
diphosphate (ADPtest), arachidonic acid (ASPItest), collagen (COLtest), TRAP-
6 (TRAPtest). Platelet function was evaluated three times: before Ibrutinib treat-
ment, after 1 or 2-4 months. The control group (CG) consisted of 20 healthy
persons: 6 males and 14 females, median age 44(26-59).
Results: We detected statistically significant impaired platelet function
[p<0.0001] in all the patients in COLtest in all points compared to the control
group [CCL patients COLtest 1 Median (M) 35.41,6-75; COLtest2 M18.89, 4-
35; COLtest 3 M:19.73,7-37; CG M 70.5, 49-107]. What is more, we observed
exacerbation of this platelet defects during the treatment. COLtest after 2-4
months was statistically significantly diminished compared to the value before
the treatment [COLtest 1: M: 35.41,6-75; COLtest 3 M: 19.73, 7-37, p=0,016].
We also detected statistically significant [p<0.0001] impaired platelet function
in ADP test in all points compared to the control group (CLL patients: ADP
1median(M) 30.45; 0-74; ADP2 M: 35.11; 1-80; ADP3 M: 38.91; 6-87, CG:M:
84.5; 54-102]. In other two tests: ASPItest and TRAPtest, platelet function was
statistically significantly impaired compared to the CG in all three points but a
very interesting tendency appeared. The value of the third point was raised
indicating some improvement in arachidonic acid and TRAP induced platelet
aggregation. This tendency was the most pronounced in ASPItest but not sta-
tistically significant. We observed bleeding complications in five patients: in two
patients there occurred nose bleeding, in three patients skin petechiae was
reported. Platelet function in these patients was impaired, all test values were
lower than in the patients without bleeding complication. However, this tendency
did not achieve statistical significance. In three out of five patients lower platelet
count (75-85G/l) was detected just before Ibrutinib therapy. In one patient
because of atrial fibrillation a new oral anticoagulant-pradaxa was introduced
causing aggravation of the skin petechiae. After diminishing the dose of pradaxa
the skin changes disappeared.
Summary/Conclusions: We detected impaired platelet aggregation measured
by Multiplate technology in all the patients. The impairment of collagen induced
platelet aggregation was exacerbated during ibrutinib treatment. On the other
hand, arachidonic acid and TRAP induced platelet aggregation tended to
improve during the treatment. Only 21% of ibrutinib patients presented some
mild bleeding complications.
P408
CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY
DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE
UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY
IU Doobaree*, K Conway, R Nandigam, A Newland, D Provan
Haematology, Barts and the London School of Medicine and Dentistry, London,
United Kingdom
Background: Primary immune thrombocytopenia purpura (ITP) is a rare
autoimmune bleeding disorder. In a platelet depleted state, ITP patients present
with bleeds or are at risk to bleeding. Treatment decisions may vary according
to the clinical profile at presentation and patients’ choice. This study sought to
understand how newly diagnosed ITP patients are treated with newer treatment
options becoming available.
Aims: To describe the demographic and clinical characteristics of newly diag-
nosed ITP patients and how these influence treatment choice.
Methods: The UK ITP Registry is a collaborative effort of 70 centres throughout
the UK, coordinated at the Royal London Hospital (RLH), to permit adequate
data collection on a rare disease. In this study, data collected on adults (≥18
years) up to July 2015 were analysed using various statistical techniques.
Results: A cohort of 1618 ITP patients [median age at diagnosis 49.3 (IQR
31.1, 64.2) years; 58.2% female; 76.2% European) contributed data for this
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study. Age distribution at diagnosis resembled an ‘M-shaped’ pattern with peaks
at 18 to 30 years (18%) and 50 to 70 years (17%) of age. The RLH (12.2%)
and Castle Hill Hospital (6.2%) had highest recruitment. The most prevalent
history of comorbidities before ITP were hypertension (16.7%), depression/anx-
iety (5.0%), diabetes (4.4%) osteoarthritis (4.1%) and arterial thromboembolism
(4.0%). The cohort’s median platelet count around diagnosis was 23.0 x109/L
([IQR 7-61 years]; 56.1% had platelet count <30 x109/L). Of those who received
treatment within 3 months of ITP diagnosis, 96.9% had 1st line treatment
[including prednisolone (86.1%) IVIg (34.3%), Anti-D (2.5%)], 19.8% had 2nd
line treatment [including rituximab (6.3%); splenectomy (1.8%) and others (<1%
to 4%)], and 11.9% had blood product transfusion [(platelet (8.8%), red blood
cells (4.7%)]. Throughout the entire cohort history, common treatments were
prednisolone (70.3%), IVIg (39.2%), splenectomy (12.8%), romiplostim
(9.24%), Anti-D (6.5%) and eltrombopag (6.1%), whereas 19.5% had no treat-
ment. For those with platelet counts <50 x109/L and bleed within 3 months of
diagnosis, there was a significant association with use of both 1st and 2nd line
treatment. A similar pattern of treatment was found for platelet counts ≥50
x109/L but to a lesser extent. Bleed from the respiratory system (e.g. haemop-
tysis), gastrointestinal system (exc. oral) and obstetric/gynaecological-related
ones were associated with receiving transfusion (including platelet). The medi-
an time from ITP diagnosis to having a splenectomy was 1.4 (IQR 0.5-3.9)
years; 77.1% were diagnosed below the age of 50. Fifteen individuals had this
procedure within 3 months of diagnosis, of which 60% were before 2010. Over
the last 2 decades there has been a decrease in the overall number of splenec-
tomies carried out [and in relation to the year that the splenectomised patients
were diagnosed (1990-99: 30.1%; 2000-09: 12.7%)], and for those diagnosed
within the last five years, 4.4% had this procedure. The same time periods saw
increased use of newer therapeutic agents (figure).
Figure 1.
Summary/Conclusions: Patients with low platelet and bleeding within the 1st
three months of ITP diagnosis were likely to receive both 1st and 2nd line treat-
ment options. Notable, is the decline of splenectomy as 2nd line treatment,
while there are different drug options available. It would be important to increase
the cohort size, including expanding internationally, to obtain more treatment
data on higher number of patients who received 2nd line treatment options and
long-term follow up data.
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EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL
FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT
S Ali*, LA Wakefield, K Saja
National Health Service, London, United Kingdom
Background: Patients with atrial fibrillation and severe renal impairment (CrCL
<30ml/min) were excluded from the ROCKET-AF study and, indeed, most of
the seminal phase 3 DOAC studies in atrial fibrillation. However, the summary
of product characteristics states that rivaroxaban may be used at a reduced
dose of 15mg OD for anti-coagulation management of atrial fibrillation in
patients with severe renal impairment (CrCl 15-29 ml/min). This recommenda-
tion was solely based on pharmacokinetic analyses and has not been validated
in a clinical study.
Aims: Assess safety and efficacy of rivaroxaban (15mg OD) in patients with
atrial fibrillation and severe renal impairment (CrCl 15 – 29 ml/min). The primary
safety point is occurrence of bleeding complications.
Methods: Retrospective cohort analysis of 30 patients with non-valvular atrial
fibrillation and severe renal impairment who were commenced on rivaroxaban
(15mg OD) in our anti-coagulation clinic between October 2012 and March
2015. Medical notes were reviewed and general practitioners were contacted
by telephone or fax. Information collected included age, weight, CHA2DS2-
Vasc and HAS-BLED scores, baseline blood investigations (CrCl, FBC, LFT
and clotting screen) and where available blood investigations at the time of the
bleeding event. 
Results: A total of 30 patients were retrospectively followed up for a minimum
of 10 months. The majority of patients were female (83.3%) with a median age
and weight of 89.5 years and 54 kilograms respectively. Median CHA2DS2-Vasc
score was 5, giving an estimated annual stroke risk of 6.7%, and approximately
76% of patients had a HAS-BLED score ≤2. Creatinine clearance was calculated
using the Cockcroft-Gault formula, and the median CrCl was 26.39 ml/min. During
the follow up period, 11 patients died (37%), one of whom died of massive gas-
trointestinal bleeding after being switched from rivaroxaban to warfarin due to
worsening renal function. The cause of death for one patient could not be
obtained, however there were no documented deaths due to rivaroxaban as a
primary or contributing cause. A total of 6 rivaroxaban related bleeding events
were identified with two events occurring in one patient. Bleeding sites included
nasal (epistaxis), gastro-intestinal and genitourinary tracts but there were no inci-
dents of intracranial haemorrhage or major bleeding as defined by the Interna-
tional Society on Thrombosis and Haemostasis. A patient who discontinued
rivaroxaban due to haematuria later developed acute limb ischemia requiring
embolectomy. Although compliance to treatment could not be assessed, a further
patient developed an ischemic stroke whilst on rivaroxaban.
Summary/Conclusions: Clinically relevant bleeding events occurred in
approximately 17% of our small cohort of very elderly patients with severe
renal impairment receiving rivaroxaban (15mg) as anti-coagulant therapy for
non-valvular atrial fibrillation. The event rate is almost identical to that in the
Rocket-AF study (16.7%) and there were no major bleeding events. Our find-
ings indicate that the use of rivaroxaban in this group of patients is feasible
and relatively safe.
P410
ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR
ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE
B Perez Villardon1,*, AM Garcia Bellon2, C Jimenez Rubio1, A Rubio Alcaide1,
L Perez Benito1, MA Ramirez Marrero2, M De Mora Martin2, E De Teresa Galvan3
1Cardiology, Hospital Comarcal Axarquia, Velez-Malaga, 2Cardiology, Hospital
Regional Carlos Haya, 3Cardiology, Hospital Clinico Universitario Virgen de la
Victoria, Malaga, Spain
Background: Atrial fibrillation (AF) is the most common arrhythmia. It leads to
significant morbidity and mortality. The new oral anticoagulants (NOAC) rep-
resent an improvement compared with standard treatment (vitamin K antago-
nists (AVK)) in the prevention of thromboembolic complications in patients with
non-valvular AF. 
Aims: The aim of this study is to analyse the clinical characteristics of the
patients (p) anticoagulated with NOAC and compared these with those taking
AVK, as well as to assess their effectiveness and safety. The primary study
outcome was the composite of stroke, systemic embolism, pulmonary
embolism, myocardial infarction or death (MACE). The primary safety outcome
was major haemorrhage.
Methods: We studied 688 p with a diagnosis of NVAF between November-
2011 and November-2014. We made a prospective analysis, with a median
follow-up of 14 months.
Results: A total of 688 p were included with a mean age of 73.4±7.9 in the
AVK group vs 73.9±8.3 in the NOAC group (p=0.432). In the NOAC group,
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hypertension was significantly more common (82.3% vs 92.2%, p<0.001), with
more frequent history of heart failure (15.3% vs 30.4%, p<0.001), and more
history of stroke or transient ischemic attack (10% vs 15.9%, p=0.022). Mean
scores for thromboembolic and bleeding risk indices are shown in Table 1.
Table 1.
SCORE ACENOCOUMAROL NOAC p
CHADS2 1.9±1.0 2.3±1.1 P<0.001
CHA2DS2VASc 3.5±1.3 3.9±1.5 P<0.001
HASBLED 1.3±0.7 1.4±0.7 P=0.086
The primary outcome occurred in 12 p receiving AVK (2.9%) and 11 p receiving
NOAC (4.1%) (p=0.413) (HR acenocoumarol vs NOAC 1.737; IC 95%: 0.760-
3.969, p=0.190). MACE were more common in patients with poor INR control
(58.3% vs 41.8%, p=0.037). In the univariate analysis, the factor associated
with MACE in the AVK group was the poor INR control (4.009 (1.266-12.696),
p=0.018), showing the sex female category a strong trend to be a protective
factor (0.228 (0.050-1.043), p=0.057). In the NOAC group, valvulopathy ≥mod-
erate (3.840 (1.166-12.652), p=0.027) and renal insufficiency (7.197 (1.743-
29-772), p=0.006) were significantly associated with MACE. The rate of major
bleeding was 3.51% with AVK, as compared with 0.6% per year in the group
that received NOAC (17 events -4.1% >vs. 2 events, 0.7%, p=0.009) (figure 1;
HR acenocoumarol vs NOAC 0.252; IC 95%: 0.058-1.101, p=0.067). In the
univariate analysis, the factors associated with bleeding in the AVK group were
age ≥75 years (3.187 (1.028-9.882), p=0.045) and HASBLED score (2.106
(1.072-4.136), p=0.031). The rate of intracranial bleeding was 1.02% with AVK
compared with 0.34% per year in NOAC group (5 events – 1.2% vs 1 event –
0.4%, p=0.248). There were no significantly differences in the rates of gastroin-
testinal bleeding (1.02% with AVK vs 0.94% per year, p=0.902) neither minor
bleeding (4.88% with AVK vs 3.51% per year, p=0.309). There was a signifi-
cantly higher rate of discontinuation with AVK (17.14% vs 6.68% per year,
p<0.001).
Figure 1.
Summary/Conclusions: Patients with NVAF anticoagulated with NOAC have
higher embolic risk than those that receive acenocoumarol. No differences
were found in efficiency. Patients anticoagulated with NOAC show a trend to
lower bleeding risk. In the multivariate analysis, the predictors of events in the
acenocoumarol group were the male category, poor INR control, ≥75 years,
anemia and HASBLED score. The predictors of events in the NOAC group
were valvulopathy≥moderate, renal insufficiency and anaemia.
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SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE
CLINICAL PRACTICE
F Cortiula*, U Venturelli, A Bertone, G Barillari
University Hospital of Udine, Center for Hemorrhagic and Thrombotic Diseases,
Udine, Italy, Udine, Italy
Background: New oral anti-coagulant drugs (NOACs) are largely used both in
AF (Atrial Fibrillation) and in VTE (Venous Thromboembolism) and, due to their
important advantages over older drugs, many patients have been switched
from VKA (Vitamin K antagonists), LMWH (Low Molecular Weight Heparin) or
Fondaparinux to NOACs. Current recommendations by scientific society sug-
gest switching from VKAs to NOACs according to the INR test result. Regarding
how to switch from Fondaparinux or LMWH to NOACs the suggested wash out
period is 24 hours.
Aims: Evaluate safety and efficacy of switching anticoagulant therapy from old
to new anticoagulant drugs without monitoring the INR. Safety outcomes were
major and minor bleeding rate. Effectiveness outcomes were VTE events. We
also evaluate the tolerability of the new treatment.
Methods: We switched patients, affected by AF or DVT, from VKAs or LMWH
or Fondaparinux to NOACs regardless from the INR. We follow current recom-
mendations for switching from LMWH and Fondaparinux; we applied to the
VKAs-DOACs switch the same schedule prescribed by current guidelines for
bridging therapy from VKAs to LMWH. Therefore, we began the NOACs treat-
ment after 24 hours since the last previous anticoagulant intake, if the patient
has been switched from LMWH, Fondaparinux or Acenocumarol. We began
the NOACs treatment after 48 hours if Warfarin was the patient’s therapy. We
checked the platelet count and the Creatinine Clearance collecting these lab-
oratory measurements within 30 days before the end of VKA treatment. We
collected outcomes measures until 30 days from the switch. Data are presented
as mean±standard deviation (SD). 
Results: We enrolled in the present study 603 patients: 458 have been
switched to NOACs from VKAs, 101 from LMWH and 44 patients from Fonda-
parinux. 179 patients were affected by AF and 424 by VTE. Thirty days after
the switching 99% of the patients were still on NOACs. Three patients com-
plained about nausea, dyspepsia and abdominal pain. Two of them came back
to VKAs and one patient change Rivaroxaban with Apixaban, without further
side effects. Two patients reported minor bleedings: gingival hemorrhage and
hematuria. One of them remained on NOACs treatment and another switch to
acetylsalicylic acid. There were no VTE recurrence and no bleedings in the
whole cohort.
Table 1.
Summary/Conclusions: Safety and efficacy of switching anticoagulant therapy
in our center are really satisfying compared to the studies that closely monitored
INR to adjust anticoagulant therapy switching, suggesting that monitoring INR
may not be routinely needed for the switch. Further studies are needed to con-
firm these findings.
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HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS:
CAUSALITY OR CONFOUNDING?
S Rögnvaldsson1,*, SH Lund1, M Hultcrantz2,3, G Eiríksdóttir4, TB Harris5,
V Guðnason4, SY Kristinsson1,2,6
1Faculty of Medicine, University of Iceland, Reykjavík, Iceland, 2Dept. of Hema-
tology, Karolinska Institutet, Uppsala, Sweden, 3Myeloma Service, Dept. of Med-
icine, Memorial Sloan Kettering Cancer Center, New York, United States, 4The
Icelandic Heart Association, Kópavogur, Iceland, 5Laboratory of Epidemiology
and Population Science, National Institute on Aging, Bethesda, United States,
6Dept. of Hematology, Landspítali University Hospital, Reykjavík, Iceland
Background: Patients with polycythemia vera are known to have an increased
risk for thrombotic events. This effect has also been observed among those
with high as well as low concentrations of hemoglobin (Hgb) in the general
population. However many of the earlier studies lack sufficient clinical data to
account for underlying disease or causes of high Hgb.
Aims: To assess whether high concentrations of Hgb is an independent risk
factor for thrombotic events.
Methods: Hgb measurements and baseline characteristics were obtained from
participants in the Reykjavik-AGES study at enrollment in 2002. The Reykjavik-
AGES study, a nationwide screening study of 5755 elderly individuals, includes
thorough medical history, physical examination, and blood measurements. Life-
time incidents of thrombotic events were recorded up to 2015 in the Icelandic
National Health Service and linked to the participants of the study through the
National Registry. Primary outcomes of arterial and venous thrombosis were
considered separately 10 years before and after enrollment. Hgb measure-
ments at enrollment were used to determine exposure, both as a continuous
variable in steps of 10g/L and stratified into five strata (<130, 130-144,145-
159,160-175 and >175g/L for men and <120, 120-134,135-149,150-159,
>160g/L for women). Men with Hgb concentrations of 120-144g/L and women
with Hgb concentration of 120-134g/L were used as reference. Cox proportional
hazard regression was used for the statistical analyses and adjusted for con-
founders (gender, age, body mass index (BMI), diabetes mellitus, smoking,
hypertension, and statin use) in three different models.
Results: Analysis of Hgb concentration as a continuous variable in steps of 10
g/L revealed increased risk of arterial and venous thrombosis with increasing Hgb
concentration (hazard ratio (HR) 1.06 95% confidence interval (CI) [1.04-1.09]
p<0.001 and HR 1.08 95% CI [1.05-1.106] p<0.001). Adjustment for confounders
revealed a reverse effect (HR 0.92 95% CI [0.89-0.94] p<0.001 and HR 0.89 95%
CI [0.87-0.92] p<0.001). After excluding anemic patients (Hgb <130g/L for men
and <120g/L for women) there was however, no association (Table 1). Crude
analysis, using stratified Hgb levels, revealed increased risk of arterial and venous
thrombosis associated with high Hgb (Hgb: 160-175g/L for men and 150-159g/L
for women. HR 1.10 95% CI [1.02-1.20] p=0.02 and HR 1.17 95% CI [1.07-1.29]
p<0.001). After adjusting for gender, age, and BMI, this association was no longer
evident. There was however marginally increased risk of venous thrombosis in
those with slightly higher Hgb concentrations than the reference group (Hgb: 145-
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159 g/L for men and 135-149 g/L for women. HR 0.91 CI [0.85-0.98] p=0.01).
Anemic participants had a decreased risk of both arterial and venous thrombosis
(HR 0.76 CI [0.70-0.83] p<0.001 and HR 0.74 CI [0.68-0.81] p<0.001) (Table).
Table 1.
Summary/Conclusions: In this large population based cross sectional cohort
study, including detailed clinical information on elderly individuals, we observed
that high concentrations of Hgb were not associated with risk of thrombosis
after adjusting for confounding factors. Furthermore, we found that low con-
centration of Hgb was associated with a lowered risk of thrombosis. This is
contradictory to many of the previous studies done with less extensive clinical
data and suggests that previous studies expressed association by confounding
rather than causality.
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HEMOSTATIC BIOMARKERS BASED PREDICTIVE MODEL FOR METASTATIC
DISEASE, PROGRESSION AND MORTALITY IN CANCER PATIENTS
E A Beleva1,*, T Deneva2, S Stoencheva2, V Popov1, Z Grudeva-Popova1
1Division of Medical Oncology, Department of Clinical Oncology, Medical Fac-
ulty, 2Department of Clinical Laboratory, Faculty of Pharmacy, Medical Univer-
sity - Plovdiv, Plovdiv, Bulgaria
Background: Hemostatic factors have been implicated as effectors in key
processes of tumor biology. Exploratory clinical studies of plasma hemostatic
components as potential tumor biomarkers with putative predictive and prog-
nostic potential could provide useful information for monitoring of cancer
patients and justifying novel anti-tumor strategies. 
Aims: To determine the predictive utility of TF-dependent microparticle activity
(MPTF), tissue factor antigen (TFAg), angiopoietin-2 (ANG-2) and soluble uroki-
nase activator receptor (suPAR) for metastatic disease at onset, disease pro-
gression and death in cancer patients undergoing chemotherapy.
Methods: MPTF, TFAg, ANG-2 and suPAR were measured in 128 patients
with various cancer types and in 82 healthy controls. MPTF was determined
with the Zymuphen MPTF kit; TFAg, ANG-2 and suPAR were measured by
ELISA. Conventional coagulation parameters: thrombin time, prothrombin time,
fibrinogen and mean platelet volume were determined and VTE score calcu-
lated for all patients as well. Patients were followed up prospectively for two
years (2013-2015) from chemotherapy initiation until metastatic progression
and/or death. Predictive value of the tested variables, including age and sex,
was analyzed by retrograde logistic regression. The study has been IRB
approved and written informed consent was obtained from all participants.
Results: MPTF activity was significantly decreased in cancer patients com-
pared to controls, while TFAg levels, ANG-2 and suPAR were significantly ele-
vated, p<0.0001. There was no significant association of MPTF, TFAg, ANG-2
with any of the VTE risk groups, however suPAR levels correlated significantly
with VTE score (ρ=0.235, p<0.05). Significant predictor variables were deter-
mined by logistic regression and the final model included VTE score, MPTF,
TFAg, ANG-2 and suPAR. The model tested significant regarding its ability to
determine presence of metastatic disease at onset (χ=16.779, p=0.01), disease
progression (χ=14.347, p=0.026) and death (χ=17.282, p=0.008). Elevated
levels of ANG-2 are associated with increased probability of metastatic disease
(ORANG-2=15.795, p=0.041), TFAg levels are associated with higher probability
of disease progression (ORTFAg=1.224, p=0.03), VTE score is associated with
mortality (OR=13.488, p=0.041).
Summary/Conclusions: The probability of primary metastatic disease, pro-
gression of disese and death in cancer patients increases with higher VTE
score, elevated levels of TFAg, ANG-2, suPAR and decreased MPTF proco-
agulant activity.
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ANNEXIN A5 M2 HAPLOTYPE: TO BE OR NOT TO BE, THAT’S THE QUESTION!
R Tenreiro1,*, AL Pinto1, Â Rodrigues2, P Martinho1, T Fidalgo1, C Godinho2,
C Barata2, R Salvado1, L Ribeiro1
1Hematology Department, Cento Hospitalar e Universitario de Coimbra,
2Obstetrics Department, Maternidade Bissaya Barreto - Centro Hospitalar e
Universitário de Coimbra, Coimbra, Portugal
Background: Hereditary thrombophilias are known to impair placental function
and cause adverse pregnancy outcomes (APO) such as recurrent pregnancy
loss, pre-term labour, intrauterine growth restriction or small for gestacional
age newborns. Mutations in blood coagulation factors II and V, alterations in
protein C and its co-factor protein S are commonly accepted as hereditary
thrombophilias. Furthermore alterations resulting in reduced fibrinolysis have
also been associated with APOs. More recently conflicting data on the possible
involvement of M2 Annexin A5 (ANXA5) haplotype have been published, with
evidence that supports its involvement in embryonic-induced anticoagulation.
So far consensus on its role in APO has not been achieved.
Aims: Assess the presence of M2 ANXA5 haplotype in a population of women
with a previous history of APO.
Methods: Retrospective case-control study including women referred to the
Pregnancy and Thrombophilia Consultation in our Center, between January
2012 and May 2015, with a previous history of APO including recurrent mis-
carriages (early and late), fetal death, pre-eclampsia and HELLP syndrome.
Detailed previous medical history was reviewed. Patients with hereditary throm-
bophilias, antiphospholipid syndrome or autoimmune diseases were excluded.
The genotyping for the presence or absence of carriage of the M2 ANXA5 pro-
moter haplotype was assessed. The possible relationship between M2 and
APO was evaluated by comparing our case-group with two independent control
groups. Odds ratio (OR) with 95% confidence intervals (CI) and chi-squared
tests were calculated. Statistical significance was defined as p<0.05.
Results: The case group included 110 women with a previous history of unex-
plained APO. They had a mean (range) age of 33.2 years (17-41), median gra-
vidity of 2 (0-7) and median parity of 1 (0-2). Forty-nine women had experienced
a total of 108 pregnancy losses (median 2, range 1-5), 91% in the first trimester.
Cardiovascular (CV) risk factors were distributed as follows: smoking habit
12.7% (n=14), dyslipidemia 10.9% (n=12), hypertension 2.7% (n=3), only 1
had previous history of diabetes. Mean body mass index (BMI) was 24.62±3.98
kg/m2. All but one were Caucasians. Eight patients had prior history of throm-
botic events (75% venous events). Presence of M2 ANXA5 promoter haplotype
was observed in 30% (n=33) of our case group individuals. When comparing
our case group with a general control population we found statistically signifi-
cant association between the presence of M2 haplotype and the presence of
unexplained APO (OR 2.35, 95% CI 1.47-3.77; p<0.001). When comparing
with a group of fertile female controls we also found a significant association
(OR 4.80, 95% CI 2.86-8.05; p<0.0001). No other differences in age, BMI, CV
risk factors were identified when comparing carriers of M2 versus non-carriers.
No association between carriage status for M2 haplotype and subtype of APO
was identified.
Summary/Conclusions: A higher frequency of the M2 ANXA5 haplotype was
found in our case group when compared with two independent control popu-
lations, suggesting a possible relationship between this specific genotype and
unexplained APO. Genotyping ANXA5 M2 status seems to be a well oriented
approach in the diagnostic of a subset of women with unexplained APO.
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IRON METABOLISM IN PATIENTS WITH PORTAL THROMBOSES
E Lukina*, A Dezhenkova, E Sysoeva, K Lukina
Department of Orphan Diseases, National Research Center for Hematology,
Moscow, Russian Federation
Background: Portal thrombosis (of portal, splenic or superior mesenteric vein)
is the most common cause of prehepatiс portal hypertension. Bleedings from
esophageal and/or gastric varices are the frequent complication of prehepatiс
portal hypertension. Posthemorrhagic anemia is diagnosed in 58% of patients
with prehepatiс portal hypertension and is usually considered to be an indication
for iron therapy.
Aims: To study iron metabolism in patients with prehepatiс portal hypertension
due to portal thrombosis and recurrent bleedings from esophageal and/or gas-
tric varices.
Methods: The study group included 70 patients (31 males and 39 females
aged from 22 to 73 years, median age 45 years) with prehepatiс portal hyper-
tension and portal thromboses diagnosed by abdominal Doppler ultrasonog-
raphy or computed tomography. Thirty seven patients (53%) of the study group
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had recurrent bleedings from esophageal and/or gastric varices. Patients were
divided into 2 groups based on the results of hematological examination (blood
count and bone marrow morphology): 43 patients with chronic myeloprolifera-
tive disorders and 27 patients with cytopenias associated with other disorders
(antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, inherited
thrombophilia). The following parameters were studied to characterize iron
metabolism: ferritin, transferrin, iron concentration and total iron binding capac-
ity. In patients previously treated with iron parameters of iron metabolism were
investigated not less than 2 weeks after termination of iron therapy.
Results: Anemia was revealed in 34 (48%) patients of the study group. Only 4
(12%) patients with anemia had laboratory signs of iron deficiency. Other 30
(88%) patients with anemia had laboratory signs of functional iron deficiency,
which is a key feature of anemia of chronic disease. All patients of the study
group were divided in 2 groups: 1) patients who received iron therapy in the
past (34 patients) 2) patients who never received iron treatment (36 patients).
Frequency of new thrombotic events (i.e., pulmonary embolism, mesenteric
thromboses, arterial thromboses, thromboses of jugular vein, myocardial infarc-
tion, transient ischemic attack) or portal rethromboses was 35% in the first
group of patients and 6% - in the second group. Frequency of recurrent bleed-
ings from esophageal and/or gastric varices was 79% in the first group of
patients and 28% - in the second group.
Summary/Conclusions: 88% of pts with prehepatiс portal hypertension due
to portal thrombosis had anemia of chronic disease. Iron therapy in such
patients was associated with higher incidence of new thrombotic events or por-
tal rethromboses and recurrent bleedings.
P416
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER-RELATED
VENOUS THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL DISEASES
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Background: The use of peripherally inserted central venous catheters (PICCs)
has been markedly increased during the last decade due to their advantages
over conventional central venous catheters, such as a reduced risk of compli-
cations during insertion and durable venous access. These characteristics
make PICC suitable for use in patients with hematological malignancies.
Catheter-related deep venous thrombosis (DVT) has been described as the
late complication of PICC. The incidence of PICC-related DVT in patients with
hematological disorders is however unknown.
Aims: The aim of this study was to establish the risk factors and evaluate the
incidence of the PICC-related DVT in patients with hematological disorders.
Methods: We performed a retrospective cohort study evaluating the thrombotic
complication of PICCs placed in a single center between 2011 and 2015 to the
patients with hematological malignancies or aplastic anemia with the need of
the prolonged venous access. Symptomatic catheter-related DVT was deter-
mined by Doppler ultrasound. The following information was retrieved for each
patient: type of disease, therapy applied through PICC, serum creatinine level,
hemoglobin (Hb) level, white blood counts (WBC) and platelet (Plt) number at
the time of PICC placement, and position of the tip of the catheter determined
by the chest x-ray. All data were retrieved from the medical records.
Results: A total of 182 patients (104 men/78 women, median age of 50,2 years
(range 17-82)) with hematological disorders were included, with 201 catheters
and total of 27056 catheter-days. 163 patients had one, and 19 patients had
two catheters inserted. Hematological disorders included 53 acute myeloid
leukemias, 35 acute lymphoblastic leukemias, 63 malignant lymphomas, 9 mul-
tiple myelomas, 9 aplastic anemias and 13 patients in the miscellaneous group
consisting of chronic myeloid leukemia, chronic lymphoid leukemia, chronic
myelomomocyctic leukemia and osteomyelofibrosis. Indication for the PICC
placement included necessity for venous access due to the need for a long-
term chemotherapy (129 catheters) and supportive treatment in case of difficult
venous access (72 catheters). The incidence of PICC-related venous throm-
bosis was 11,9% (0,88/1000 PICC days). The median duration form insertion
to diagnosis of catheter-related thrombosis was 17 days (range 1-241), with
45% of the events described within the first 7 days from the PICC insertion.
WBC count and catheter malposition were found as significant risk factors for
PICC-related DVT (p=0,007 and 0,008, respectively) in univariate analysis and
only catheter malposition in multivariant analysis (p=0,002, OR 4,37, CI 95%
1,69-11,33).
Summary/Conclusions: The study found catheter-related DVT as important
complication of PICC in patients with hematological malignances. Also, catheter
malpositioning was identified as s significant risk factor for developing throm-
bosis. Moreover, our study speaks in favor of the hypothesis suggesting that
thrombogenicity of PICC could be related to endothelial injury and phlebitis fol-
lowing the insertion of the catheter, since almost 50% of thrombosis happened
within the first seven days from the catheter placement. This study highlights
the need of vigilant evaluation of thrombosis risk previous to PICC insertion in
patients with malignant hematological diseases and careful monitoring of the
patient during the first week of the catheter dwelling. Also, better clinical out-
comes could be achieved by recognition of the catheter malposition, and the
correction of its position.
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EQUATIONS FOR ESTIMATING GFR: COMPARING RENAL FUNCTION
CATEGORISATION IN THE CATCH STUDY
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Background: The CATCH study was a randomized, multicenter study
(NCT01130025) of 900 patients comparing tinzaparin 175 IU/kg once daily with
dose-adjusted warfarin for 6 months in patients with active cancer and acute,
symptomatic venous thromboembolism. Only patients with very severe renal
impairment at baseline (estimated glomerular filtration rate [eGFR] below 20
mL/min) were excluded from the study. Over time, the recommendations for
estimating renal function have changed, reflecting that improved tools for
screening for renal impairment have been developed and validated in broader
patient populations. These tools have further standardized the estimation of
renal function, as they are based on results from isotope dilution mass spec-
trometry (IDMS) standardized assaying of serum creatinine.
Aims: To compare three different validated equations for estimating renal func-
tion in a population of patients with cancer-associated thrombosis, older age
and multiple ethnicities.
Methods: eGFR was evaluated in a patient population with cancer-associated
thrombosis. Creatinine was determined at baseline, and monthly during the 6-
month study. All samples were analyzed centrally using a validated (IDMS)
assay. Renal function was estimated using three different equations: the Mod-
ification of Diet in Renal Disease (MDRD) study equation, the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation and the Cockcroft-
Gault (CG) equation, using SI units only.
Results: During the CATCH study, 5238 samples were taken from which eGFR
could be calculated in 896 patients. Mean age was 59 years; 40% were male;
55% had metastatic cancer at baseline; 53% received anticancer treatment at
any time during the study. The racial distribution was: 50% White, 34% Asian,
2% Black, 14% Multiple or Other. The equations provided largely consistent
findings when eGFR estimations were below 60mL/min, with an overall agree-
ment between MDRD and CKD-EPI of 97%, between MDRD and CG: 88%,
and between CKD-EPI and CG: 89%. The CKD-EPI and MDRD equations had
similar results in eGFR range 60-90 mL/min, but whereas MDRD had eGFR
estimations ranging up to 350 mL/min, CKD-EPI yielded no eGFR estimations
beyond 200mL/min. When MDRD and CKD-EPI were compared with CG, the
eGFR above 60 mL/min varied to a much higher degree (Fig. 1). The MDRD/CG
comparison covered ranges up to 350–400 mL/min, whereas the CKD-EPI/CG
comparison tapered off, limited by CKD-EPI not yielding any values above
200mL/min. Categorisation of severe renal impairment (eGFR below 30
mL/min) differed in only four samples (0.1%) when comparing MDRD and CKD-
EPI, whereas when these were compared with CG, 63 and 64 samples (1.2%),
respectively, were discrepant.
Figure 1. Scatter plots to show the comparsion of equations for estimating
renal function, including x=y reference line.
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Summary/Conclusions: Overall, there was a strong agreement between
MDRD and CKD-EPI for estimating renal function when eGFR estimations
were below 60 mL/min. Estimating the eGFR using CG yielded results that
diverged to a greater degree from both MDRD and CKD-EPI. CKD-EPI had an
added limitation of yielding no eGFR estimations above 200mL/min.
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IMPACT OF CAPLACIZUMAB TREATMENT ON MORTALITY AND MAJOR
THROMBOEMBOLIC EVENTS IN ACQUIRED TTP: PHASE II TITAN STUDY
RESULTS
F Peyvandi1, M Scully2, JA Kremer Hovinga3, P Knöbl4, S Cataland5, K De Beuf6,
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Background: Acquired thrombotic thrombocytopenic purpura (TTP) is a poten-
tially life-threatening thrombotic microangiopathy in which aggregation of
platelets to von Willebrand Factor (vWF) leads to profound thrombocytopenia,
hemolytic anemia, and systemic microvascular thrombosis. In spite of treatment
with plasma exchange and immunosuppression, the current standard of care,
mortality from an episode of acquired TTP is approximately 20% and patients
remain at risk for thrombotic complications until remission is achieved[1]. Capla-
cizumab is an anti-vWF Nanobody® in development for the treatment of
acquired TTP. The efficacy of caplacizumab in conjunction with standard of
care in reducing the time to confirmed platelet count normalization was demon-
strated in the Phase II TITAN study of patients with acquired TTP[2].
Aims: To report the results of a post-hoc analysis which assessed the impact
of treatment with caplacizumab on the incidence of major thromboembolic
events during the study drug treatment period and the incidence of TTP-related
mortality during this Phase II study.
Methods: The occurrence of treatment-emergent major thromboembolic
adverse events was investigated in the Phase II clinical study database, using
the Standardized MedDRA Query (SMQ) for ‘embolic and thrombotic events’.
The proportion of subjects with at least one of these events together with the
total number of events were summarized and reported per treatment group.
Transient episodes were not considered major thromboembolic events and
were, therefore, not included in this analysis. TTP-related mortality during the
study was evaluated based on adverse events reporting, with relatedness to
TTP as judged by the Investigator.
Results: The safety population consisted of 35 caplacizumab-treated and 37 place-
bo-treated subjects. Four major thromboembolic events were reported in 4 subjects
in the caplacizumab group (1 pulmonary embolism and 3 TTP exacerbations). In
the placebo group, 20 major thromboembolic events were reported in 14 subjects
(2 acute myocardial infarctions, 1 ischemic and 1 hemorrhagic stroke, 1 pulmonary
embolism, 1 deep vein thrombosis, 1 venous thrombosis and 13 TTP exacerba-
tions). Two TTP-related deaths occurred during the study, both in the placebo treat-
ment group (causes of death: refractory TTP and cerebral hemorrhage). In total,
11.4% of caplacizumab-treated subjects versus 43.2% of placebo-treated subjects
experienced one or more thromboembolic events or died (Table 1).
Table 1. Treatment-emergent major thromboembolic events during the
treatment period and overall TTP-related mortality in the Safety Popula-
tion of the Phase II TITAN study.
Summary/Conclusions: Compared to subjects who received placebo and stan-
dard of care treatment, a lower proportion of those treated with caplacizumab
and standard of care had one or more major thromboembolic adverse events or
died. The results of this post-hoc analysis suggest that treatment with capla-
cizumab has the potential to reduce the significant morbidity and mortality asso-
ciated with acquired TTP. A phase III confirmatory study is ongoing and will include
a prospectively defined assessment of this clinically meaningful endpoint.
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Background: Red blood cell (RBC) transfusion support is standard of care in
the majority of patients with myelodysplastic syndromes (MDS). Despite that,
there is a dearth of information regarding its impact on patient quality of life
(QoL).
Aims: The main objective of this study was to investigate the burden of trans-
fusion dependency, by comparing patterns of QoL over time between transfu-
sion dependent (TD) versus transfusion independent (TI) patients.
Methods: Analysis is based on 280 newly diagnosed IPSS intermediate-2 or
high risk (i.e., higher risk) MDS patients who were consecutively enrolled in
an international prospective cohort observational study. Quality of life was
assessed at baseline (i.e., before treatment) with the well validated EORTC
QLQ-C30 questionnaire and thereafter at week 4 and week 8 after the first
treatment start. Transfusion dependency at baseline was defined as having
received at least one red blood cell transfusion every 8 weeks over a period
of 4 months (Malcovati L, et al, J Clin Oncol. 2007; 25: 3503-10). Differences
were assessed at baseline between TD and TI by Fisher exact and Wilcox-
on-Mann-Whitney tests as appropriate. Trajectories over time of QoL out-
comes were estimated for TD and TI patients by a linear mixed model with an
unstructured covariance structure which accounted for treatment received
(hypomethylating agents and intensive chemotherapy vs lower intensity ther-
apies). An overall F test was used to test the significance of possible differ-
ences of estimated QoL patterns over time between TD and TI groups. No
adjustment was performed for multiple testing thus statistical significance was
set as α=0.05.
Results: Median age was of 71 years and there were 176 men (63%) and 104
(37%) women. Mean Hb level for the overall population was 9.3 g/dl (range
4.1-15.8). There were 224 patients (68%) considered as TI and 56 (32%) con-
sidered as TD. At baseline, there were no statistically significant differences
between TD and TI patients with regard to age, gender, IPSS risk score (int.-2
vs high risk) and comorbidity. With regard to functional limitations at baseline,
worse statistically significant differences for TD patients were found for physical
functioning (P=0.003), role functioning (P=0.013), social functioning (P=0.039)
as well as for global QoL (P=0.012). Greater symptom severity for TD patients
were found for fatigue (P=0.020), pain (P=0.034) and dyspnea (P=0.008). After
baseline assessment, treatment with hypomethylating agents was the most
common one being received by 165 patients (59%). Investigation of QoL tra-
jectories over time between groups, since treatment start, revealed that patterns
of QoL changes was different between groups regardless of type of therapy.
QoL of the overall population generally deteriorated during the first two months
of therapy. However, the magnitude of this change was worse in TD patients.
This latter group, compared to TI patients, deteriorated to a greater extent with
regard to physical functioning (P=0.019) and role functioning (P=0.009). The
same pattern was observed for fatigue (P=0.019) and pain (P=0.014).
Summary/Conclusions: This study indicates that transfusion dependency not
only impairs QoL of MDS patients at baseline, but also limits recover over time
compared to patients who are not transfusion dependent at the start of therapy.
Future longer follow-up studies are needed.
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Background: The FIRST trial established a progression-free survival and over-
all survival benefit for transplant-ineligible patients with newly diagnosed mul-
tiple myeloma (NDMM) treated with lenalidomide plus low-dose dexamethasone
(Rd) until disease progression (Rd continuous) vs melphalan, prednisone, and
thalidomide (Benboubker et al, NEJM, 2014). Furthermore, treatment with Rd
improved health-related quality of life (HRQoL) over the first 18 months of treat-
ment (Delforge et al, Haematologica, 2015). HRQoL data were not collected
past 18 months.
Aims: The aim of this analysis was to examine the effect of Rd continuous on
HRQoL beyond 18 months by identifying predictors of change in HRQoL scores
using data from the FIRST trial.
Methods: Univariate linear mixed-effects regression analyses (n=535) identified
variables collected until progression as predictors of 7 preselected HRQoL
domains of interest: global QoL, physical functioning, fatigue, and pain (EORTC
QLQ-C30), disease symptoms and side effects of treatment (EORTC QLQ-
MY20), and health utility (EQ-5D). Variables with univariate P<.1 were combined
into multivariate models for each HRQoL domain; variables with P<.1 were
retained for final models. Modeled HRQoL domain score changes were validated
against observed score changes prior to 18 months and extended to extrapolate
HRQoL changes from baseline based on observed predictor values beyond 18
months for patients still receiving Rd at 24, 30, 36, 42, and 48 months.
Results: Key time-varying determinants of final mixed models of HRQoL
domains included: eastern Cooperative Oncology Group performance status:
all domains; ongoing hospitalization: global QoL, fatigue, side effects of treat-
ment, health utility; serum albumin: global QoL, physical functioning, fatigue,
pain, side effects of treatment, health utility; red blood cell transfusion within 30
days: fatigue, pain, disease symptoms; ongoing adverse events: global QoL;
ongoing grade ≥3 pain: physical functioning, fatigue, pain, disease symptoms,
side effects of treatment, health utility; ongoing grade ≥2 fatigue: fatigue; ongo-
ing grade 3/4 anemia: physical functioning, side effects of treatment. Nearly all
observed changes in HRQoL scores from baseline fell within the 95% confi-
dence interval of the final predictive models, including the final EQ-5D health
utility model (Figure 1). Exceptions were month 1 of the global QoL and fatigue
models and month 3 of the disease symptoms model.
Figure 1.
Summary/Conclusions: Our results suggest that the gains in HRQoL over the
first 18 months in Rd-treated patients with NDMM are maintained for patients
on treatment up to 48 months. The analysis is exploratory in nature; further
research is needed to better define the impact of continuous therapy on HRQoL
compared to a fixed duration of therapy followed by a period of observation.
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Background: The use of stem cell transplantation (SCT) in the U.S. in patients
(pts) with MM has increased from 5.1% to 25.1% between 1994 and 2005
(McCarthy 2013), with inpatient (inpt) costs increasing from $684 million in
2004 to $1.3 billion in 2007 for SCT procedures overall (Strangers 2009). How-
ever, improved supportive care has enabled a shift of SCT to the outpatient
(outpt) setting. Prior research in small cohorts suggests that this shift may pro-
duce substantial cost savings (Rizzo 1999; Frey 2002) but these studies were
based on single-institutional experiences and focused on short-term costs only.
Aims: The goal of this study was to compare short- and long-term costs of
outpt- vs inpt-based SCT among MM pts in a large, national, U.S. healthcare
claims database receiving SCT within 300 days post-initiation of initial MM-
directed therapy (frontline SCT).
Methods: Adult pts with newly diagnosed MM were identified between 1/2008
and 3/2015 from among commercially insured and Medicare Advantage ben-
eficiaries. Pts with continuous enrollment (CE) from 12 months (mos) prior to
the first observed claim for MM were included. Pts with frontline SCT were
identified and stratified according to SCT setting (inpt vs outpt). Short- and
long-term costs were estimated from 14 days prior to SCT through 100 days
and 12 mos after SCT, respectively, among pts with CE (including pts who
died). Total healthcare costs (payer + patient paid) during each time period
were calculated. Baseline characteristics and costs were compared using uni-
variate analysis (chi-square test for categorical and t-test for continuous vari-
ables). Generalized linear models compared 100-day and 12-mos costs for
the outpt vs inpt groups.
Results: Of 607 MM pts with frontline SCT, 97% received autologous SCT;
67% (n=407) underwent SCT during an inpt stay. Compared to pts receiving
outpt SCT, the inpt SCT group was older (median age: 58 vs 60 years old,
P=.02), but baseline Charlson Comorbidity index score and gender distributions
were similar across cohorts. In the inpt SCT group, initial hospitalization length
of stay was 17 days (IQR: 3). Post-SCT hospitalizations in the outpt SCT cohort
were more common than either rehospitalizations within 100 days (50% vs 20%,
p<0.001, n=536) or within 12 months (58% vs 40%, p<0.001, n=390) in the inpt
SCT cohort. Overall, the mean 100-day and 12-mos costs were $133,215 and
$228,497, respectively. Total mean 100-day costs were higher among the inpt
vs outpt SCT group (adjusted: $139,269 vs $121,313, p=0.004). Mean difference
in 12-mos costs remained higher among inpt vs outpt SCT (adjusted: $238,184
vs $211,734, p=0.059) but did not reach statistical significance (Table 1).
Table 1. Costs associated with frontline SCT among MM patients.
Summary/Conclusions: Total short-term costs were lower in pts undergoing
outpt SCT compared with the inpt SCT group. A trend towards lower long-term
total costs was noted in the outpt vs inpt SCT groups at 12 months. However,
in both time frames, the initial cost savings associated with outpt SCT were
partially offset by higher hospitalization rates both in the first 100 days and the
first 12 months after transplant. Future work will examine cost drivers, including
post-transplant complications.
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Background: Chronic lymphocytic leukemia (CLL) is incurable disease and
patients eventually relapse after lines of therapies. Ofatumumab (OFA) is the
first therapy approved by the Food Drug Agency as extended treatment in
relapsed CLL. PROLONG was phase III trial where 474 subjects in remission
after second- or third-line therapy for CLL were randomized 1:1 to OFA or
observation (OBS). OFA showed lengthened progression free survival (PFS)
by 14.2 months (median 29.4 vs 15.2; hazard ratio [HR] 0.49, p<0.0001) and
longer time to next treatment (median 38.0 vs 31.1 months; HR 0.623,
p=0.005). The estimated median overall survival (OS) was not reached in either
arm (HR 0.85; p=0.517). In addition to clinical efficacy, economic evaluation of
novel health care technologies is important for decision making in both Europe
and North America.
Aims: To evaluate the cost-effectiveness of OFA compared to OBS as main-
tenance treatment in patients with relapsed CLL who are in remission after
induction therapy.
Methods: A partitioned survival model, commonly adopted in economic evalu-
ations based on randomized clinical trials in oncology, was developed with three
health states: progression free, post-progression, and death. Parametric survival
functions for PFS, OS, and time to treatment discontinuation were developed
based on the PROLONG individual patient data. Model fit was assessed by
Akaike Information Criteria and Cox-Snell residual plots. Resource use was mod-
elled adopting a Canadian public health care system perspective. Costs (2015
CAD) included drug acquisition and administration, medical care for adverse
events, and pre- and post-progression routine care including follow up therapies
(a variety of mono and combo therapies) based on the PROLONG data. Utilities
were sourced from the literature, and used to calculate quality-adjusted life years
(QALYs) based on modeled PFS, OS, and adverse events (grade 3 or 4 events
occurring in at least 2% of the PROLONG patients). Cost-effectiveness was eval-
uated as the incremental cost per QALY gained, and uncertainty was explored
through deterministic and probabilistic sensitivity analyses.
Results: Lognormal functions were selected to model PFS and OS. The former
included a treatment effect (acceleration factor) that was applied for two years
(whilst patients remained progression free and on-therapy), consistent with the
trial; due to the immaturity of the OS data and the availability of effective salvage
treatments following relapse, no impact of OFA on OS was assumed. Over
patients’ modelled lifetime, OFA provided an additional 1.26 progression free
life years. After applying utilities and discounting (at 5% per annum), this trans-
lated into 0.44 QALYs gained. OFA was associated with approximately an addi-
tional cost of CAD $30,000 over patients’ lifetime. Incremental cost/QALY was
CAD $68,600 (95% confidence interval 49,900-107,600), with a 96% probability
of being cost-effective at a threshold of 100,000 CAD/QALY. Deterministic sen-
sitivity analyses suggested OFA’s cost-effectiveness was most sensitive to
shorter time horizons and quality of life weights for post-progression, but was
largely insensitive to alternative scenarios regarding PFS and OS functions,
including direct use of Kaplan-Meier survival estimates.
Summary/Conclusions: In the PROLONG trial OFA demonstrated substantial
gains in terms of PFS and time to next therapy. OFA may represent a cost-
effective addition to the management of relapsed CLL patients who have
responded to induction therapy.
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PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS
ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS
C Buerkle*, H Goergen, H Müller, P Bröckelmann, S Kreissl, M Fuchs, A Engert,
P Borchmann, K Behringer
German Hodgkin Study Group, University hospital of Cologne, Cologne, Ger-
many
Background: Hodgkin lymphoma (HL) survivors often report impaired quality
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of life due to side effects such as organ failure, fatigue or second malignancies.
Patient’s experiences, needs and worries related to therapy-associated and
social burden are mostly unclear.
Aims: To evaluate the relevance of efficacy outcomes and side effects from
the patient’s point of view, we created a questionnaire for long-term HL sur-
vivors. In addition, the impact of treatment efficacy was put into perspective
with long-term side effects of treatment.
Methods: The questionnaire was developed by an interdisciplinary team of
physicians, psychologists and statisticians. It consists of six blocks of questions,
each containing multiple aspects to be rated on four-point Likert scales. We
sent the questionnaire to randomly selected 150 male and 150 female patients
of each of our 5th generation trials (HD13, HD14, HD15) with no documented
refractory disease or relapse (rrHL) (N=900) and to all candidates with docu-
mented rrHL (N=249).
Results: 52% of eligible patients returned the questionnaire (N=484 without
rrHL, N=97 with rrHL) with a median follow up from study entry of 107 months.
Chemotherapy was a substantial burden for 76% of the participants, independ-
ent of stage, treatment and study. Patients in early favorable (HD13) and unfa-
vorable (HD14) stages, received standard radiotherapy (RT) with 30 Gy and
for 64% of them, this was a great or very great burden. In advanced stages
(HD15), RT was only performed in patients with PET-positive residual tissue
after chemotherapy. 26% of them rated RT as great or very great burden.
Fatigue was the most frequent side effect, reported by 87% during and 41%
after treatment, and considered as a great or very great burden by 75% of the
affected patients. Other acute side effects frequently considered as a burden
were related to social aspects such as strain for the family and loss in produc-
tivity. Most long-term side effects were significantly more frequent in patients
with rrHL. Socioeconomics aspects such as financial problems are considered
a very great burden. At the time of first diagnosis, >50% of participants had
concerns about acute and long-term side effects, relapse and death due to HL.
However, concern about relapse was mentioned most frequently. At the time of
survey, 25% of patients without rrHL still worried much or very much about side
effects of therapy and death from HL and 40% worried much or very much
about long-term effects and relapse. In participants with rrHL, concern of side
effects or death from HL was still present in 35%, whereas the percentage of
patients worrying about long-term effects or another relapse increased to about
60%. Cure of HL was rated as the most important treatment goal by 72% of
patients. Retrospectively, only 9 participants (2%) would have chosen a slightly
less effective therapy to avoid side effects. Overall, >80% of patients felt well
informed about their disease and therapy but 35% felt uninformed regarding
potential late effects.
Summary/Conclusions: HL patients frequently consider chemotherapy as a
great burden independent of duration and intensity of the administered regimen.
HL survivors are more concerned about relapsing than dying from HL, which
could be interpreted as fear of another treatment. The results suggest that
avoidance of relapse should be the primary therapy goal, and cure is more rel-
evant than possible side effects. Our results imply that progression-free survival
is a very important patient-relevant outcome in clinical studies in HL.
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UNDERESTIMATED IMPACT OF MILD COGNITIVE IMPAIRMENT IN
“CLINICALLY FIT” OLDER PATIENTS WITH MALIGNANT HEMOPATHIES
ADMITTED TO RECEIVE CHEMOTHERAPY
S Dubruille1, Y Libert2, A Ruiz3, M Roos4, A Collard4, N Meuleman3,
M Maerevoet3, D Razavi2, D Bron3,*
1Dpt of Hematology - Clinic of Psycho-Oncology, 2Clinic of Psycho-Oncology,
3Dpt of Hematology, 4Onco-geriatry Unit, Institut Jules Bordet (ULB), Brussels,
Belgium
Background: We reported recently that neither the G8 screening tool nor the
CGA total score (≥2 impairments) seem to predict chemotherapy completion
and overall survival (OS) among clinically fit older patients with malignant
hemopathies (1). Regarding survival, we found in a multivariate analysis that
only mild cognitive impairment (MCI) (MMSE<27 and/or MoCA<26) in the CGA
had a predictive value for one-year OS (1). However, this study did not inves-
tigate the relationship between MCI and other specific, clinical and biological
parameters of the CGA.
Aims: 1) To determine the predictive value of MCI, clinical and biological param-
eters in terms of chemotherapy completion and two-year OS. 2) To further
investigate whether MCI is correlated with specific clinical and biological param-
eters and two-year OS.
Methods: CGA were proposed to 117 consecutive patients (65-89yrs) with
malignant hemopathies assessed by their physicians as clinically fit to receive
chemotherapy, meaning no geriatric syndromes and/or irreversible comorbidities
significantly impairing their daily function. Biological parameters, chemotherapy
completion and causes of deaths were extracted from medical records.
Results: One hundred and two patients were evaluable. Eighty-six percent
had a favorable prognosis (CLL, Lymphoma or Multiple Myeloma) and 69%
received a full dose of chemotherapy at the time of treatment initiation. Non-
completion of chemotherapy (38%; n=39) was predicted only by polypharmacy
(drugs ≥5) at the time of treatment initiation (OR=2.83, 95%CI: 1.16-6.91;
p=0.023). After adjusting for established prognostic factors, two-year OS (54%,
n=52) was predicted by disease recurrence (HR=4.28, 95%CI: 1.42-12.88;
p=0.010); MCI (MoCA <26) (HR=4.83, 95%CI: 1.34-17.41; p=0.016), low albu-
min (HR=1.11, 95%CI: 1.01-1.22; p=0.040) and elevated potassium level
(HR=0.32, 95%CI: 0.11-0.89; p=0.030). MCI was associated with a reduced-
dose of chemotherapy at the time of treatment initiation (p=0.007), higher age
(p=0.025), loss of functional autonomy (p=0.002), a higher number of comor-
bidities (p=0.036).
Summary/Conclusions: In our selected population of clinically fit patient with
malignant hemopathies 1) polypharmacy predicted the non-completion of
chemotherapy 2) in addition to classical prognostic factor (advanced disease),
MCI, poor nutritional status and severe ionic impairment appear to be powerful
prognostic factors. The presence of MCI in clinically fit older patients with malig-
nant hemopathies may be a marker of an unsuspected vulnerability. Moreover,
MCI seems to be a risk factor for under-treatment of clinically fit older patients
with malignant hemopathies. Prospective trials are required to further determine
whether better identification and management of MCI in clinically fit older
patients with malignant hemopathies could improve survival.
Reference
1. Dubruille S et al. Identification of clinical parameters predictive of one-year 
    survival using two geriatric tools in clinically fit older patients with haemato-
    logical malignancies: major impact of cognition. J Geriatr Oncol, 2015, 6,
    362-369.
P424
WHAT DO PATIENT EXPERIENCE DATA REVEAL ABOUT THE DIAGNOSTIC
JOURNEY FOR MYELOMA PATIENTS? FINDINGS FROM SECONDARY
ANALYSIS OF NATIONAL CANCER PATIENT SURVEY DATA
S Richard*, E Low, C Shaw
Myeloma UK, Edinburgh, United Kingdom
Background: Despite improvements in long-term survival myeloma remains
one of the most difficult cancers to diagnose. In 2010 34% of myeloma (MM)
patients in England were diagnosed through an emergency route, one of the
highest rates of all cancers. While 78% of MM patients are now surviving >1
year after diagnosis this drops to 51% for patients diagnosed as an emergency.
Dealing with a diagnosis of a rare and complex cancer can be a major challenge
for patients. It is critical that MM patients receive clear and accurate information
during testing and subsequent diagnosis. To date there is little evidence derived
directly from MM patients to assess the current state of the myeloma diagnostic
journey. Such evidence is crucial for developing strategies for policy makers,
professionals and patient groups to improve patient experiences and outcomes.
Aims: The study aimed to explore patient experiences of the myeloma diag-
nostic journey from symptom presentation to receiving a diagnosis and compare
MM patient experiences during diagnosis with the all cancer (AC) average.
Methods: Myeloma UK obtained data from the National Cancer Patient Expe-
rience Survey (NCPES) 2014 to conduct secondary analysis of MM patients’
reported experiences of diagnosis. The NCPES is the largest NHS patient expe-
rience survey of its kind, covering a comprehensive journey through care. In
2014, 70,141 cancer patients responded across England, a response rate of
64%, including 4,023 MM patients. The large sample size provides a reliable
basis from which to draw conclusions about MM patients’ experiences of diag-
nosis. We compared MM patient responses to questions covering diagnosis
with those for AC patients using +/-5% to indicate practical significance.
Results: Our comparative analysis with the cancer average found MM patients
reported significantly worse diagnosis-related experiences than AC patients,
from length of time in primary care before referral to receiving information about
their tests and diagnosis. The data showed MM patients made significantly
more visits to their GP with symptoms than the AC average. Of those MM
patients who visited their GP with symptoms before their diagnosis 20% made
≥5 visits before being referred to hospital compared to just 9% of AC patients.
Only 31% of MM patients were referred after just one visit compared to 54% of
AC patients. There were also significant differences in how long it took patients
to see a hospital doctor after first suspecting something might be wrong, with
28% of MM patients reporting a wait of ≥3 months before seeing a hospital
doctor compared to 19% of AC patients. More MM patients (37%) said that
their health got worse during this time than AC patients (20%). In relation to
information provision, MM patients scored significantly worse than the AC aver-
age on receiving easy-to-understand written information before their diagnostic
test(s) (MM 80%, AC 87%) and their test results being explained in a way they
completely understood (MM 72%, AC 78%). Only 52% of MM patients said
they understood the explanation of their subsequent diagnosis compared to
73% of AC patients.
Summary/Conclusions: The analysis confirms that diagnosis is a particular
challenge in myeloma, right through from initial symptom presentation, testing
and receiving information following diagnosis. These data emphasise a critical
need to increase understanding of the barriers to early diagnosis in myeloma
and identify ways to tackle them. Follow-up qualitative research with patients
would be useful to explore their experiences of symptom presentation in primary
care in more depth. Myeloma UK will raise awareness of these findings and
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use them to further develop our Myeloma Diagnosis Pathway and other edu-
cational resources for general practitioners. Through targeted information pro-
vision and initiatives such as our Clinical Service Excellence Programme we
will continue to work with primary and secondary care professionals to ensure
every myeloma patient is given quality information at critical time-points through
their diagnosis journey.
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STREAMLINING OF THE CHEMOTHERAPY SERVICE WITH FOCUS ON
DRUG SUPPLY AND PATIENT SAFETY
H Reinhardt1,*, R Trittler2, S Wöhrl2, T Epting3, S Kaiser1,4, P Otte1,4,
M Szymaniak-Vits1,4, M Buck5, K Opeker1, B Lieberwirth6, S Kaiser5, M Ruch6,
D Jonas5, J Duyster1,4, M Jung7, MJ Hug2, M Engelhardt1
1Department of Hematology and Oncology, 2Pharmacy, 3Department of Clinical
Chemistry, 4Comprehensive Cancer Center Freiburg, 5Environmental Health
Sciences and Hospital Infection Control, University Medical Center Freiburg,
6MPS GmbH, 7Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität
Freiburg, Freiburg, Germany
Background: In times of increasingly complex requirements for preeminent
patient (pt) care accompanied by high pt turnover, organisational, safety, quality
and financial aspects play a pivotal role. In an interdepartmental, cross func-
tional cooperation, we are investigating the feasibility and benefits of imple-
menting dose-banding in chemotherapy (CTx) at our university center. The
dose-banding concept very elegantly and efficiently allows the preproduction
of frequently used doses for CTx substances with adequate stability data, offer-
ing potential to substantially improve the process of drug supply for pts. 
As part of the CTx service at Freiburg university medical center, CTx prescrip-
tions are generated via an e-database (Chemo-AS) by the physicians and clin-
ically checked by a surveillance team: the Clinical Cancer Research Group
(CCRG) in close cooperation with pharmacy. Any detected error is instantly
reported, corrected and recorded electronically. This system has now been
established for over 10 years resulting in an interception of 99.9% of the CTx
related errors (Lohfert award 2015).
Aims: a) Identify CTx substances suitable for dose banding from a practical
and stability point of view and to implement dose banding into clinical practice.
b) Gain insight into causes and potential consequences of CTx prescribing
errors. c) Design a next generation software with improved safety features.
Methods: Analysis of local prescribing practice via the pharmacy database
(Zenzy) applying the banding model described by Zavery et al (Clin Pharm
2011; 3:116-18). In order to simulate the worst case, microbiological stability
tests were performed using liquid media instead of CTx: samples were stored
for 3 months and incubated at different time points. In an additional container
integrity test, the stored infusion bags and syringes were inserted into a highly
contaminated broth for 1 hour, incubated and analysed for sterility. Physical
and chemical stability tests (colour, particles, pH-changes) for a maximum stor-
age period of 3 months of the respective CTx preparations at relevant concen-
trations were performed. A quantitative assay was conducted by HPLC analysis.
We also performed a detailed analysis of 406 CTx prescribing errors prevented
by CCRG initiative using SPSS. The data had been collected prospectively
over 2 years (2013/2014) via Chemo-AS by the CCRG. In an interdisciplinary
approach, in cooperation with IT specialists, the causes of the errors were
analysed for effective future preventability.
Figure 1. Analysis of CTx error preventability software engineering.
Results: Gemcitabine, 5-FU bolus and carboplatin were identified as most
suitable CTx preparations for dose banding by statistical analysis. Microbio-
logical stability could be demonstrated over the complete storage period and
all preparations passed the container integrity test. For the selected substances
physical and chemical stability over 3 months was shown. In line with interna-
tional guidelines, we determined a gemcitabine content of ≥95% at 12 weeks
storage. The 406 prescribing errors of 18.823 CTx orders were affecting 375
(2%) orders, 303 (12,4%) tumor pts and 508 (1,3%) CTxs. Errors were divided
into categories of potential consequences: overdose 203 (51%), underdose
59 (15%), incorrect length of cycle/CTx timing 56 (14%), wrong CTx 40 (11%),
CTx not ordered 38 (10%) (with 10 errors additive in consequence). 256 CTxs
were affected by the 203 overdosed CTx orders: 110 (43%) were overdosed
≤25%, 66 (26%) with 26-50%, 63 (25%) with 51-100% and 17 (7%) >100%. Of
all errors analysed, 61% were identified as avoidable by specific software
improvements. Results of the assessment of error preventability by program
engineering are shown in Figure 1.
Summary/Conclusions: This analysis shows that dose banding is feasible
for gemcitabine and possibly other CTx preparations taking into account sta-
tistical and stability aspects. Our “error analysis” was very useful for pinpointing
areas, where CTx error reduction by software engineering is possible. However
as, according to our analysis, 30-40% of errors are not electronically avoidable,
the CCRG, ward pharmacists or other surveillance teams remain indispensable. 
Dose banding, together with an upgraded CTx prescribing software tool, bear
high potential for moving towards standardisation and considerable improve-
ment of the CTx service at Freiburg university hospital. This contributes to a
very safe therapy and reduces waiting time for pts as well as ensuring support
for doctors and pharmacy staff. Moreover, our new CTx software will be avail-
able to other external hospitals, resulting in shared benefit for a large number
of pts and healthcare staff.
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INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/
GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY
DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA
W Wierda1, M Cifaldi2, LI Hsu2,*, E Cerri2, ME Verdugo2
1The University of Texas MD Anderson Cancer Center, Houston, 2AbbVie,
North Chicago, United States
Background: Chronic lymphocytic leukemia (CLL) is associated with reduced
health-related quality of life (HRQoL) with progressive severe fatigue being a
particularly relevant burden. Additionally, treatment can further reduce HRQoL,
based on a recent study from Netherlands (Holtzer-Goor KM et al. QLR 2015).
Recently, deep and durable responses to the oral BCL-2 inhibitor venetoclax
(VEN) were achieved in patients with relapsed/refractory (R/R) CLL with dele-
tion of chromosome 17p [del(17p)] in a phase 2 study (NCT01889186, Stil-
genbauer S et al. ASH 2015). 
Aims: To evaluate changes in HRQoL in patients with VEN monotherapy treat-
ment based on interim results from this study.
Methods: In this single-arm trial, patients ≥18 years of age with R/R del(17p)
CLL received VEN monotherapy. Patient-reported HRQoL measures were an
exploratory endpoint for this study and included the EORTC-QLQ-C30 and
EORTC-QLQ-CLL16. The mean changes from Baseline (BL) to visit Weeks 4,
12, 24, 36, and 48 were reported. Clinical relevance was based on minimum
important difference (MID) of values from BL at different assessment points.
The lower bound of 5–10 point changes, previously considered a “little” change
for EORTC-QLQ-C30 (Osoba D et al. JCO 1998 and Osoba D et al. QLR 1994)
was used for MID acceptance for this and EORTC-QLQ-CLL16.
Table 1.
Results: Clinically relevant gains in global health status and role, social, and
emotional functioning of the EORTC-QLQ-C30 occurred from Week 4 to Week
24 (Table 1). Furthermore, early and sustained improvements in fatigue were
shown in both EORTC-QLQ-C30 and EORTC-QLQ-CLL16 (Table 1). Associ-
ated with these positive HRQoL results was considered as a large effect (>20
points) in patient EORTC-QLQ-CLL16 future health views at Week 24 (Table
1) (Osoba D et al. JCO 1998 and Osoba D et al. QLR 1994). These clinically
relevant improvements were seen in patients having generally lower BL HRQoL
than patients in a recent Netherlands study using similar measures.
Summary/Conclusions: Understanding the effect of therapy on HRQoL and
patient well-being is an important factor when making treatment choices. These
interim results showed that in this very symptomatic and difficult to treat patient
population, VEN improved HRQoL and patients’ view of their future health.
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PRELIMINARY SAFETY DATA FROM THE PHASE 3B GREEN STUDY OF
OBINUTUZUMAB (G) ALONE OR COMBINED WITH CHEMOTHERAPY FOR
PREVIOUSLY UNTREATED OR RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL)
V Leblond1,*, MS Dilhuydy2, R Foà3, W Knauf4, M Montillo5, S Robinson6,
S Stilgenbauer7, E Gresko8, S Lasserre8, F Bosch9
1AP-HP Hôpital Pitié-Salpêtrière, UPMC, Paris, France, 2Hôpital du Haut-
Lévèque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France,
3‘Sapienza’ University, Rome, Italy, 4Onkologische Gemeinshaftspraxis, Frank-
furt, Germany, 5Niguarda Ca’ Granda Hospital, Niguarda Cancer Center, Milan,
Italy, 6QEII Health Sciences Centre, Halifax, Canada, 7University of Ulm, Ulm,
Germany, 8F. Hoffmann-La Roche Ltd, Basel, Switzerland, 9University Hospital
Vall d’Hebron, Barcelona, Spain
Background: GREEN (NCT01905943) is an ongoing phase 3b, open-label
trial of G alone or with chemotherapy in pts with previously untreated (1L) or
relapsed/refractory (R/R) CLL; the primary outcome is safety.
Aims: To assess the frequency, type and severity of AEs in all pts in GREEN,
based on a 6-month safety review (data cut-off for analysis, 26 August 2015).
Methods: Enrolled pts are aged ≥18 yrs with documented CLL, ECOG PS 0-
2 and adequate hematologic function. Pts receive G 1000mg IV, alone or with
chemotherapy (at investigator’s discretion), on days 1 (dose split over 2 days
[25+975mg or 100+900mg]), 8 and 15 of cycle (C)1, and day 1 of C2-6 (six 28-
day cycles). Chemotherapy options were: fludarabine and cyclophosphamide
(FC) for fit pts only (CIRS ≤6 and CrCl ≥70mL/min); chlorambucil (Clb) for unfit
pts only (CIRS >6 and/or CrCl <70mL/min), or bendamustine (B) for any pt. Pts
refractory to previous G monotherapy had to receive G with chemotherapy. All
pts gave informed consent.
Results: In 825 pts analyzed (1L, 485; R/R, 340), median age was 66.0 (33-
90) yrs, 63.4% were male, 434 (52.6%) were at risk of tumor lysis syndrome
(TLS; tumor burden ≥10cm or ≥5cm but <10cm with lymphocytes ≥25x109/L)
and 41.1%/33.5% were Binet stage B/C. Median observation time was 12.7
(0.1-22.1) months and median exposure time was 20.3 (0.1-33.1) weeks. AEs,
grade ≥3 AEs and SAEs occurred in 96.1%, 72.0% and 43.1% of 1L pts, and
96.5%, 73.8% and 46.5% of R/R pts, respectively (results by treatment group
in Table 1).
Table 1.
N (%)                                  Total          G alone           G-FC           G-Clb            G-B
                                       (n=825)       (n=106)        (n=159)       (n=97)        (n=463)
Any AE                            794 (96.2)     98 (92.5)     157 (98.7)    97 (100)     442 (95.5)
TLS                                   51 (6.2)         6 (5.7)          7 (4.4)        3 (3.1)        35 (7.6)
Grade ≥3 AEs                  600 (72.7)     66 (62.3)     133 (83.6)   63 (64.9)    338 (73.0)
Neutropenia                   369 (44.7)     26 (24.5)      93 (58.5)    41 (42.3)    209 (45.1)
TCP                                131 (15.9)     11 (10.4)      34 (21.4)    19 (19.6)     67 (14.5)
Grade ≥3 infections         123 (14.9)     17 (16.0)      17 (10.7)    16 (16.5)     73 (15.8)
Grade ≥3 IRRs                 152 (18.4)     25 (23.6)      33 (20.8)    19 (19.6)     75 (16.2)
Any SAE                          367 (44.5)     44 (41.5)      61 (38.4)    39 (40.2)    223 (48.2)
Any fatal AE                      32 (3.9%)      4 (3.8%)       4 (2.5%)      3 (3.1%)     21 (4.5%)
The most common grade ≥3 AEs were neutropenia (44.7%), thrombocytope-
nia (TCP; 15.9%), anemia (9.0%), febrile neutropenia (6.9%), and leukopenia
(6.2%). AEs were considered related to G treatment in 83.0% pts, most com-
monly neutropenia (36.0%), TCP (23.0%), pyrexia (21.7%), nausea (17.5%),
chills (15.3%) and anemia (10.4%). AEs of particular interest (any grade)
were: cardiac events, 8.7%; hemorrhagic events, 6.2%; TCP, 32.4%; and
secondary malignancies, 4.1%. Other AEs of interest (any grade) were: infu-
sion-related reactions (IRRs, i.e. events occurring during or within 24h of G
infusion and treatment-related), 63.3% (most common: pyrexia, 17.7%; chills,
14.8%; nausea, 12.5%; causing G discontinuation, 2.8%); infections, 45.2%
(most common: pneumonia, 7.0%; bronchitis, 5.0%; URTI, 5.0%); neutrope-
nia, 58.4% and TLS, 6.2%. In the G-B arm, TLS was more common in unfit
pts (23; 10.0%) than fit pts (12; 5.2%). AEs caused G discontinuation in 111
(13.5%) pts. In 43 pts who died (1L fit, 9 [3.4%]; 1L unfit, 10 [4.5%]; R/R, 24
[7.1%]), primary causes were AEs (n=32) and disease progression (n=11);
15 were related to underlying cancer. One pt in the G-B arm (1L unfit) died of
TLS before data cut-off.
Summary/Conclusions: Preliminary safety data from GREEN are in line with
the known safety profile of G in similar populations.
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QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE &
OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL
ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS
OF THE GCLLSG CLL11 STUDY
M Ritgen1,*, A Langerak2, V Goede3, J Bahlo3, S Kluth3, K Fischer3, M Steurer4,
M Trněný5, S Mulligan6, U Mey7, K Trunzer8, K Humphrey9, G Fingerle-Rowson8,
S Stilgenbauer10, S Böttcher1, M Bruggemann1, M Hallek3,11, M Kneba1,
J van Dongen2
1University of Schleswig-Holstein, Kiel, Germany, 2Erasmus University Medical
Center, Rotterdam, Netherlands, 3German CLL Study Group (GCLLSG),
Department I of Internal Medicine and Center of Integrated Oncology (CIO),
Cologne, Germany, 4Medical University of Innsbruck, Innsbruck, Austria,
5Charles University Hospital, Prague, Czech Republic, 6Royal North Shore
Hospital, University of Sydney, Sydney, Australia, 7Kantonsspital Graubünden,
Chur, Switzerland, 8F. Hoffmann-La Roche Ltd, Basel, Switzerland, 9Roche
Products Ltd, Welwyn, United Kingdom, 10University of Ulm, Ulm, Germany,
11Cologne Center of Excellence for Cellular Stress Response and Aging Relat-
ed Diseases (CECAD), University of Cologne, Cologne, Germany
Background: The CLL11 study (NCT01010061) is an ongoing open-label, ran-
domized, three-arm study in patients (pts) with previously untreated chronic
lymphocytic leukemia (CLL), comparing the efficacy and safety of obinutuzumab
(GA101; GAZYVA/GAZYVARO; G) plus chlorambucil (Clb; G-Clb) with ritux-
imab (R) plus Clb (R-Clb) or Clb alone.
Aims: To determine the prognostic value of minimal residual disease (MRD)
quantification with respect to clinical risk factors, treatment regimen, and MRD-
source tissue in an advanced-age CLL population.
Methods: In total, 781 patients with treatment-naïve CLL, a median age of 73
years and a Cumulative Illness Rating Scale total score of >6 were included
and randomized to receive Clb, G-Clb or R-Clb. Peripheral blood (PB) samples
were taken at repeated timepoints during and up to 12 months (mo) after treat-
ment. Bone marrow (BM) aspirate was taken 3 mo after end of treatment (EOT)
to confirm complete response (CR). MRD was analyzed by quantitative
immunoglobulin allele-specific real-time PCR. MRD results at EOT (PB or BM)
were available in 73% of pts. Outcome was analyzed according to known MRD
risk groups, i.e. MRD-positive (+ve; ≥1%), MRD intermediate (int; <1% and
≥0.01%) and MRD-negative (-ve; <0.01%), and other known risk factors.
Results: At EOT, combination treatment with either G-Clb or R-Clb achieved
higher MRD negativity rates in PB and BM compared with Clb alone (PB: G-Clb
35.8% vs R-Clb 3.3% vs Clb 0%; BM: G-Clb 18.2% vs R-Clb 2.6% vs Clb 0%).
Due to the absence of MRD negativity in the Clb arm, all further MRD analyses
were restricted to the comparison of G-Clb vs R-Clb. When measured in PB,
MRD risk groups significantly correlated with progression-free survival (PFS;
median PFS: MRD-ve 49.3 mo; MRDint 23.9 mo; MRD+ve 13.9 mo; p<0.001)
and overall survival (OS; median OS not reached in any group; p<0.001; see
Figure 1 for KM curves). When MRD was measured in PB, three-year OS rates
were: MRD-ve 94.3%; MRDint 87.3%; and MRD+ve 69.5%. When comparing
G-Clb with R-Clb, median PFS in the MRD-ve group was not significantly differ-
ent (p=0.15). Results were similar for MRD measured in PB after 3 cycles of
treatment (interim staging [IST]; median PFS: MRD-ve not reached; MRDint
27.3 mo; MRD+ve 15.2 mo; p<0.001). A total of 53/417 (12.7%) pts converted
from PB MRD+ve or MRDint at IST to MRD-ve at EOT across the G-Clb/R-Clb
arms. In multivariate analysis (including various baseline markers), MRD in PB
at EOT was an independent prognostic factor for PFS (HR 5.29, 95% CI 3.48-
8.04, p<0.001) and OS (HR 3.04, 95% CI 1.53-6.03, p=0.002), with the highest
weight in the model. When analyzing MRD in PB at EOT in conjunction with
clinical remission status, MRD-ve/CR and MRD-ve/PR pts had similar PFS
(median PFS 49.3 mo vs 56.4 mo, HR 1.74, 95% CI 0.79-3.86, p=0.17), whereas
MRD+ve/CR pts had a worse outcome than MRD-ve/CR pts (median PFS 32.7
mo vs 49.3 mo, HR 3.6, 95% CI 1.64-7.99, p=0.001).
Figure 1. Kaplan Meier curves for PFS (A) and OS (B) according to MRD
risk groups in PB at EOT.
Summary/Conclusions: Data presented are consistent with the CLL8 study
and confirm that, when measured in PB or BM, MRD is prognostic in elderly
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pts with comorbidities, with G-Clb achieving a much higher rate of MRD neg-
ativity than R-Clb and Clb alone. In this cohort, pts achieving MRD-ve status
at IST had a similar outcome to pts with later conversion (at EOT). Although
MRD measurement in BM seems to be more sensitive, MRD measurement in
PB, at least in this trial, is sufficient to identify MRD based risk groups.
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Background: Patients (pts) with deletion 17p (del17p) chronic lymphocytic
leukemia (CLL) have aggressive disease and poor outcomes with chemoim-
munotherapy. Ibrutinib (ibr), a once-daily oral inhibitor of Bruton’s tyrosine
kinase, is approved for pts with CLL after ≥1 prior therapy and for pts with
del17p CLL in the US (including first-line) and first-line with del17p or TP53
mutation unsuitable for chemoimmunotherapy in the EU. Ibr trials that enrolled
pts with del17p CLL include a phase 2 study in treatment-naïve (TN) or
relapsed/refractory (R/R) CLL (PCYC-1102) with extension (PCYC-1103),
phase 3 RESONATE study of pts with R/R CLL (PCYC-1112), and phase 2
RESONATE-17 study in pts with R/R CLL (PCYC-1117).
Aims: This study evaluated efficacy and safety outcomes in an integrated
analysis of pts with del17p CLL/SLL across 3 ibr clinical trials, including out-
comes with complex karyotype (CK) in 1 longstanding extension trial.
Methods: All pts gave informed consent. Del17p was determined by FISH in
a central laboratory (PCYC-1102/1117) or by local laboratory (PCYC-1112).
Pts received once-daily oral ibr 420 (n=232) or 840 mg (n=11) until progressive
disease (PD) or unacceptable toxicity. Sustained hematologic improvement
over baseline was defined as ≥56 days without transfusion support and included
platelet (PLT) or absolute neutrophil count (ANC) increase ≥50% and/or hemo-
globin (Hgb) increase ≥2 g/dL. In PCYC-1102, CK was defined as ≥3 unrelated
chromosomal abnormalities by stimulated cytogenetics as assessed by a ref-
erence laboratory.
Results: 243 CLL pts with del17p (241 R/R and 2 TN) were evaluated, with
median age 65 y (37% ≥70 y). At baseline, 63% had Rai stage III-IV disease,
and 53% had bulky disease ≥5 cm; cytopenias were observed in 68%. With
median 2 prior therapies (range, 0-12), del11q was observed in 18% of 239 pts
and unmutated IGHV in 80% of 201 pts. The median time on study was 28
mos; 66% received ibr for >2 y. ORR (including PR-L) was 84%; estimated
median PFS was 32 mo (95% CI: 28, 40), and estimated 30-mo landmark OS
was 67% (95% CI: 59, 74) (Figure 1).
Figure 1. PFS (A) and OS (B) in ibrutinib-treated Del17p Patients.
Sustained hematological improvement in Hgb, PLT, and ANC occurred in 61%,
68%, and 68% of pts with baseline cytopenias, respectively. For pts with PD,
Richter transformation tended to occur earlier at a median of 253 d (range, 31-
786) vs CLL progression at median 594 d (range, 26-1572). Of 36 pts with
del17p on PCYC-1102/1103, median time on study was 42 mo; baseline CK
was observed in 22 pts. Median number of prior therapies was 2.5 vs 4 in pts
without vs with CK, respectively. ORR was 80% in del17p pts without CK and
82% with CK. Estimated median PFS was 52 mo for pts without CK and 25 mo
in those with CK. Estimated median OS was not reached for pts without CK
and 32 mo with CK. Across all 243 pts with del17p, grade (Gr) ≥3 adverse
events occurring in ≥5% of pts over the >2 y median treatment period were
neutropenia (Gr 3/4, 5/14%), pneumonia (Gr 3/4/5, 9/1/2%), hypertension (Gr
3/4, 11/0%), thrombocytopenia (Gr 3/4, 5/5%), and anemia (Gr 3/4, 7/1%). Gr
3/4 atrial fibrillation occurred in 2/1% of pts. Gr ≥3 hemorrhage occurred in
6/1% (Gr 3/4). 110 pts (45%) remain on study treatment.
Summary/Conclusions: In this analysis of 243 pts, the estimated median
PFS and 30-mo OS for ibr surpass those of other therapies for del17p CLL.
Results from pts with central karyotype information suggest those without CK
experience more favorable PFS/OS outcomes. These results provide further
evidence of ibr’s robust clinical activity and survival outcomes in difficult-to-
treat CLL populations.
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Background: The international, double-blind, placebo-controlled, phase 3
HELIOS study evaluated ibrutinib (ibr)+bendamustine and rituximab (BR) vs
placebo (plb)+BR in patients with previously treated CLL/SLL. At 1st analysis
(median follow-up, 17.0 months), progression-free survival (PFS) was signifi-
cantly improved for ibr+BR vs plb+BR (HR [95% CI], 0.203 [0.15-0.28];
p<0.0001). Prior studies have shown deepening responses with continued once-
daily ibr treatment; thus, long-term follow-up assessing durability and depth of
response is important, as is evaluating safety and tolerability over time.
Aims: The 1st HELIOS study results were reported with a median follow-up of
17 months. 2-year data are now available with additional safety follow-up.
Because minimal residual disease negativity (MRD-ve) represents a lower dis-
ease burden and an endpoint that can potentially affect patient outcomes, we
focus on these data to better understand the benefit of ibr over time in previ-
ously treated CLL patients. 
Methods: 578 patients received BR (≤6 cycles) and were randomized 1:1 to
ibr (420 mg/d) or plb (N=289 per arm). Patients with del17p (≥20% of cells)
were excluded. The primary endpoint was independent review committee
(IRC)-assessed PFS. Key secondary endpoints were investigator (INV)-
assessed PFS, overall survival (OS), overall response rate (ORR; IRC and
INV), and rate of MRD-ve response. With continued follow-up, we report INV-
assessed clinical endpoints. At 1st analysis, overall concordance between IRC
and INV assessments for progressive disease (PD) was 90% in the ibr group
and 85% in the plb group.
Results: Median follow-up is now 25.4 months. Ibr+BR continues to show
improvement in PFS vs plb+BR (INV-assessed median, not reached vs 14.2
months; HR [95% CI], 0.199 [0.15-0.26]; p<0.0001; 2-yr rate, 74.8 vs 20.9%).
Median PFS2 (randomization to PD corresponding to the next line of treatment,
or death) is unreached in both arms but PFS2 was significantly longer for
patients assigned to ibr+BR vs plb+BR, despite crossover (HR [95% CI], 0.62
[0.42-0.92]; p=0.016). Median OS is still unreached in either arm (HR [95%
CI], 0.67 [0.44-1.02]; p=0.058; 2-yr rate, 86.2 vs 81.5%); 142 patients (49.1%)
in the plb+BR arm with confirmed PD have crossed over to receive ibr. The
updated INV-assessed best ORR (at any time point) is 87.2% for ibr+BR vs
66.1% for plb+BR (p<0.0001); updated rates of complete response (CR)/ CR
with incomplete bone marrow recovery (CR/CRi) are 33.9 vs 7.2% (rates at 1st
analysis, 21.4 vs 5.9%). Rates of MRD-ve response for the intent-to-treat pop-
ulation are 18.0% (52/289) for ibr+BR vs 4.8% (14/289) for plb+BR (p<0.0001)
(rates at 1st analysis, 12.8 vs 4.8%). Among patients who were evaluated for
MRD status post-BR, ibr showed a more sustained PFS over plb whether or
not MRD-ve response was achieved, though patients in the ibr arm who
achieved MRD negativity had a longer PFS than those who did not (Figure 1).
There were no new or unexpected safety signals reported in this update.
Summary/Conclusions: Ibr+BR continues to demonstrate superiority vs
plb+BR, with significantly longer PFS and higher ORR. Moreover, responses
continue to deepen with continuous ibr therapy, with rates of CR/CRi and MRD-
ve response increasing over time. Patients on the ibr arm demonstrate a more
sustained PFS at each MRD level (<0.01% and ≥10%) than those on the plb
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arm. Ibr maintains the same degree of safety as previously observed in CLL
patients. These 2-year follow-up data further confirm the important role of ibr
in patients with previously treated CLL.
Figure 1. PFS by MRD level for (A) ibr+BR and (B) plb+BR.
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Background: Btk is a kinase involved in B-cell receptor signaling and a critical
therapeutic target in CLL. Acalabrutinib—an irreversible, selective Btk inhibitor
has demonstrated clinical efficacy in relapsed CLL (Byrd NEJM 2015).
Aims: Here, we present preliminary results from an ongoing Phase 1-2 study
of acalabrutinib monotherapy in patients (pts) with previously untreated CLL.
Methods: Pts with previously untreated CLL who met IWCLL 2008 criteria for
treatment were eligible, irrespective of any cytopenias. Pts received oral acal-
abrutinib at 100 mg BID (n=37) or 200 mg QD (n=37). Pts had a median age of
64 (48-85) years, bulky lymph nodes ≥5 cm (47%) and unmutated IGHV gene
(57%, 38/67). CLL responses were assessed per modified IWCLL criteria.
Results: Results are presented through 07Dec2015 for the first 74 treated pts,
including 72 evaluable for response. Median time on study (N=74) was 11 (1-15)
months. Acalabrutinib was well tolerated with 97% (72/74) of pts continuing on
study drug. Most AEs were Grade (Gr) ≤2. The most common Gr 1-2 AEs (≥15%
pts) were headache (42%), diarrhea (35%), arthralgia (22%), contusion (18%),
nausea (18%) and increased weight (18%). Gr 3-4 AEs that occurred in ≥2 pts
were syncope (n=2, both Gr 3) and hypertension (n=2, both Gr 3). One Gr 5
event (pneumonia) has occurred. One Gr 3 upper GI bleed due to a gastric ulcer
and aspirin use has occurred. No atrial fibrillation was reported. Clinical activity
was observed with both dose schedules; Btk occupancy was highest with BID
dosing (98% vs 93% predose at Day 28). All pts had a rapid reduction in lym-
phadenopathy. Treatment-related lymphocytosis occurred in 53% (39/74) of pts
and resolved in 97% (38/39) of these pts. In general, lymphocytosis peaked at a
median of 1 week and resolved by a median of 7 (3-15) weeks. Best ORR was
96% (PR=86%, PR+L=10%, SD=4%, PD=0%). Median time to response was 2
(2-8) months. No CLL progression or Richter’s transformation have occurred.
Summary/Conclusions: In pts with previously untreated CLL, a favorable
safety profile and high response rates that appear durable were observed with
acalabrutinib therapy. Based on these results, a Phase 3 trial has commenced
(NCT02475681).
Chronic myeloid leukemia - Clinical
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Background: Imatinib generics could substantially decrease costs of CML
therapy, however there is a lack of data regarding the efficacy and safety of its
use in larger populations of CML patients.
Aims: The aim of the study was to evaluate the efficacy and safety of imatinib
generics in patients suffering from chronic phase CML treated de novo with
generics (…de novo” patients), and in the group of patients switched from glivec
to imatinib generics (…switched” patients) during a one-year therapy period. 
Methods: In …de novo” group the rate of BCR/ABL1 reduction to <10% at 3
months and to <1% at 6 months of therapy, the rate of optimal response, and
failure according to current ELN guidelines, the rate of CCyR,MMR,MR4, and
MR4,5 achieved at 12 months of therapy, and the rate of patients switched to
second generation TKI have been assessed. In the …switched” group the rate
of sustained, improved and worsened molecular response, the rate of CCyR,
MMR, MR4, and MR4,5 loss have been estimated. To assess the safety of ima-
tinib generics in both groups the rate of hematologic (3rd or 4th grade), and of
non-hematologic adverse events (all grades according to CTCAE criteria) have
been evaluated. In current report the results of one-year, “real-life” observation
started on 03.APR.2014 in 501 patients treated in 12 Polish Hematology Centers
are presented. Polish Adult Leukemia Group imatinib generics registry records
approximately 900 patients, in the current report only patients who completed
12-month observation (all patients with available RQ-PCR result at 12 month),
with MMR achieved before start of therapy with generics, and treated for more
than 12 months with generics (…switched” patients) have been analyzed.
Results: Forty patients started de novo treatment with generics (24 Nibix, 16
Meaxin), and 461 patients were switched from Glivec to imatinib generics (343
to Nibix, 118 to Meaxin). Early molecular response (BCR/ABL1 <10% at 3 months)
was achieved in 75%, and the reduction of BCR/ABL1 to <1% at 6 months in
68% of …de novo” patients. Optimal response (MMR at 12 months) was achieved
in 75% of …de novo” patients. Two patient from this group were switched to
2GTKI due to simultaneously occurred resistance and non-hematological toxicity.
Hematologic toxicity (grade 3 or 4) was observed in 2 patients (therapy was not
changed), non-hematologic toxicity occurred in 17 patients (2 patients were
switched to 2GTKI). In the …switched” group the molecular response under ther-
apy with generics was sustained, improved and worsened in 47.0%, 27.3%, and
25.5% of patients respectively. MMR was lost in 2.4%, CCyR in 0.4% and MR4.5
in 4.5% of patients switched to imatinib generics. During a one-year observation
4.5% of patients were switched to 2GTKI; 3,8% for intolerance (non-haematologic
toxicity only), 0.8% for resistance, and 0.6% for intolerance+resistance. 
Summary/Conclusions: This is the first report on “real life” imatinib generics
effectiveness and safety in a big cohort of CML patients. Two tested generics
of imatinib (Meaxin and Nibix) seem to be not less effective as Glivec in therapy
of patients with CML CP, safety profile of both generics is acceptable – no
increased switching rate between 1st and 2GTKI was noted.
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Background: Our pilot study on 10 CML patients demonstrated fast develop-
ment of hyperinsulinaemia, peripheral insulin resistance, hypoadiponectinaemia
and hypercholesterolemia during nilotinib (NILO) therapy.
Aims: The aim of this multicenter ENIGMA 2 study was to confirm these results
and to compare data obtained during NILO therapy with control groups of
patients treated with imatinib (IMA) and dasatinib (DASA).
Methods: Patients received intensive laboratory workup before the start of tyrosine
kinase inhibitor (TKI), after 3 and 12 months of therapy. This included oral glucose
tolerance test, fasting insulin, glucose, adiponectin and serum lipid concentration.
Patients with diabetes mellitus, TKI treatment interruption for >2 weeks (start-month
3) or >4 weeks (month 4-12) or TKI dose reduction for >25% were excluded.
Results: Between 2/2011-11/2015 87 CML patients in 6 centers initiated TKI
therapy – 48 NILO (1st line - 25; 2nd line - 23), 24 with IMA (all 1st line) and
15 with DASA (1st line - 5; 2nd line - 10). After 3 months of NILO treatment
patients evolved significant hyperinsulinaemia and hyperglycaemia (presented
in 75% of patients) as result of fast development of peripheral insulin resistance.
This was proved by significant increase in HOMA-2 index during this period
(appeared in 73% of patients). Moreover, total and LDL cholesterol concentra-
tion significantly increased already after this short NILO treatment (developed
in 92% and 87% of patients, respectively). All these abnormalities were signif-
icant also after 12 months of therapy (Table 1). A separate analysis of patients
treated with NILO either 1st or 2nd line confirmed these metabolic changes
after 3 months of treatment. On the contrary – none of these abnormalities
were detected in the control group of patients treated with IMA and DASA,
including any change in insulin resistance measured by HOMA-2 index.
Interestingly, previously described decrease in adiponectin (major insulin sen-
sitizer) concentration during NILO administration was confirmed subsequently
when all NILO treated patients were analyzed together. However, in separate
analysis decrease in adiponectin was proved only in patients with the 2nd line
NILO therapy (median concentration at baseline vs month 3 – 14.3 vs 7.1 mg/l,
p<0.001; at baseline vs month 12 – 14.3 vs 10.5 mg/l, p<0.001), but not in the
1st line NILO patients (median concentration at baseline vs month 3 – 7.3 vs
7.3 mg/l, p=0.875; at baseline vs month 12 – 7.3 vs 7.8 mg/l, p=0.917). While
in the control IMA group (but not DASA) adiponectin concentration was signif-
icantly and persistently increased. Thus hypoadiponectineamia observed in
the whole NILO group was caused by spontaneous decrease in adiponectin
after the stop of IMA in the subgroup of the 2nd line NILO-treated patients.
Table 1.
Summary/Conclusions: We proved fast and persisting development of periph-
eral insulin resistance during NILO therapy as underlying cause of glucose and
lipid metabolism impairment during NILO treatment. This was not proved for
patients treated with IMA and DASA. IMA administration significantly increases
serum adiponectin (major insulin sensitizer) concentration, which spontaneously
declines after discontinuation of IMA and start of 2nd line NILO therapy.
Supported by the CELL – the Czech Leukemia Study Group – for life.
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Background: The outcome of BCR-ABL+ chronic myeloid leukemia (CML)
has been significantly improved by the introduction of tyrosine kinase inhibitors
(TKIs) and, actually, many patients die of reasons unrelated to CML. A new
scoring system, the EUTOS long-term survival (ELTS) score, based on the
analysis of a large cohort of CML patients treated frontline with IM and aimed
to discriminate the probability of dying of CML, has been recently published
by the European LeukemiaNet (ELN). The relevant variables included were:
age, peripheral blasts, spleen size and platelet count (Pfirrmann et al.
Leukemia 16). Nilotinib (NIL) is a 2nd generation TKI approved as frontline
therapy of CML in many countries.
Aims: To investigate the prognostic value of the ELTS score in a cohort of
CML patients in early chronic phase treated with NIL-based regimens as first-
line therapy.
Methods: Three hundred and forty-five adult patients were included. The
patients were enrolled in three multicenter studies (ClinicalTrials.gov
NCT00481052, NCT00769327 and NCT01535391) conducted by the
GIMEMA CML WP, or treated at the University Hospital of Bologna, Italy.
The initial treatment was NIL 300 mg BID or NIL 400 mg BID. The intention-
to-treat population of each study was analyzed. Definitions: risk scores were
defined according to Sokal, EUTOS and ELTs formulations; major molecular
response (MMR): BCR-ABL1IS ratio <0.1%; MR4.0: BCR-ABL1IS ratio
<0.01% with >10,000 ABL1 copies; progression: transformation to advanced
phases according to ELN criteria; leukemia-related death (LRD): death after
progression. 
Results: The median age was 53 years (range 18-86). The patient distribution
according the different scoring systems was as follows: 41% low, 40% inter-
mediate and 19% high Sokal score, 94% low and 6% high EUTOS score,
59% low, 30% intermediate and 10% high ELTS score, respectively. The medi-
an follow-up was 59 months (range: 24-82 months). The cumulative incidence
of MMR and MR4.0 was 83% and 69%, respectively; the 6-year progression-
free survival (PFS), overall survival (OS) and cumulative incidence of LRD
were 91%, 92% and 4%, respectively. All the 3 scores were associated with
significantly different probabilities of MMR (cumulative incidence of MMR
according to ELTS score: 90%, 77% and 61% in low, intermediate and high
risk patients, respectively; p<0.001), but only the ELTS score was able to pre-
dict the achievement of MR4.0 (cumulative incidence of MR4.0: 75%, 63% and
53% in low, intermediate and high ELTS score patients, respectively; p=0.013).
Interestingly, both the Sokal score and the ELTS score, but not the EUTOS
score, predicted the OS (p=0.021 and p=0.037, respectively), while only the
ELTS score predicted a significantly different PFS (p=0.038); the 6-year cumu-
lative incidence of progression was 2%, 7% and 6% in patients with low, inter-
mediate and high ELTS score, respectively. Probably due to the low number
of deaths related to CML, all the 3 scores failed to predict LRD, but comparing
patients with low ELTS score versus patients with intermediate and high ELTS
risk the difference became significant.
Summary/Conclusions: In a cohort of CML patients treated with NIL-based
regimens as frontline therapy, the prognostic predictive ability of ELTS score
resulted superior to Sokal and EUTOS score.
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HIGH GENE EXPRESSION OF HIST1H2AG AND HIST1H4A REDUCES
IMATINIB UPTAKE INTO CML CELLS AND PREDICTS POOR RESPONSE
TO FRONTLINE IMATINIB THERAPY
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Background: Imatinib (IM), the first generation tyrosine kinase inhibitor (TKI),
remains standard frontline treatment for newly diagnosed patients with chron-
ic-phase chronic myeloid leukaemia (CP-CML). None of the second generation
TKIs have shown an overall survival advantage over IM. We have previously
demonstrated that the OCT-1 activity (OA) assay, (which measures the cellular
uptake of IM at diagnosis), is highly predictive of subsequent treatment out-
comes. To derive an assay more readily adaptable for other labs, and to under-
stand the biological basis of this functional assay we performed gene-expres-
sion profiling (GEP) of low and high OA patients.
Aims: To identify a set of genes measured at diagnosis that predicts patients
who have high IM uptake (high OA) and favourable clinical outcome.
Methods: RNA was isolated from total white cells collected from patients on
TOPS, TIDEL-I and TIDEL-II trials. The OA associated genes were identified
based on a pilot microarray study (n=14). Subsequently the identified genes
were validated by qRT-PCR in 110 diagnostic CP-CML samples also obtained
from these trials. Patients were divided into low and high gene expression
groups using the recursive partitioning and regression trees (rpart) with 10-
fold cross validation in the training cohort (n=55), and validation in an inde-
pendent cohort (n=55).
Results: Previous studies have associated low expression of histone genes
with higher rates of complete cytogenetic response (CCyR) by 12 months in
IM treated patients. We have measured the expression levels by qRT-PCR of
7 histone genes that demonstrated significant association with OA based on
our GEP. Importantly, we identified that low expression of 2 histone genes
(HIST1H2AG and HIST1H4A based on ΔCt 11.7 and 13.0 cutoff respectively)
was significantly associated with high OA in the training cohort, and this was
also validated in the independent patient test cohort by both Student’s t-test
and rpart statistical methods (Figure 1A). Significantly, in the validation cohort,
patients with low expression of these 2 histone genes (histonelow) demon-
strated superior rates of major molecular response (MMR: 79% vs 43%,
p=0.007) by 12 months, and superior rates of MR4.5 (52% vs 18%, p=0.005)
by 24 months compared to patients with high expression of these genes (his-
tonehigh; Figure 1B-C). There were 26 patients in the validation cohort with
histonelow based on the cut-offs above, and of these 18 were high OA patients
and 8 low OA patients. Although 8/26 (31%) patients were low OA, 7 of these
8 patients achieved MMR by 12 months. There were 6 patients with blast crisis
(BC) progression and/or mutations that classified as low OA, and all 6 were in
the histonehigh group. The histonehigh group is significantly associated with
high blast counts in our study compared to histonelow group (p=0.01), consis-
tent with a previous study that demonstrated BC patients have higher histone
GEP compared to CP patients. Furthermore, overexpression of HIST1H2AG
using lentiviral transduction significantly reduced the IM cellular uptake in K562
cells compared to empty vector control (p=0.001, Figure 1D), supporting our
clinical data observation.
Summary/Conclusions: Histone gene expression likely plays a role in regu-
lating the uptake of imatinib, and possibly BC progression. Patients with low
expression of HIST1H2AG and HIST1H4A are highly likely to achieve good
molecular responses and excellent clinical outcomes on imatinib.
Figure 1. Low HIST1H2AG and HIST1H4A gene expression predicts high
OCT-1 activity (OA) and favorable clinical outcomes.
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ALLELES OF SNPS IN REGULATORY REGIONS OF SLC22A4 AND
SLC22A5 GENES ARE SIGNIFICANTLY ASSOCIATED WITH STABLE
MAJOR MOLECULAR RESPONSE TO IMATINIB FIRST LINE IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA 
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Background: The bioavailability of imatinib (IM) in leukemic cells at a curative
concentration is an important pharmacokinetic factor influencing the response
to the treatment of chronic myeloid leukemia (CML) with IM. Pharmacoge-
netics represents a potential source of molecular markers as patients with
inherited haplotype associated with the key genes encoding drug transporters,
have genetic predisposition to respond optimally or non-optimally. IM transport
was confirmed for transporters encoded by some genes from SLC and ABC
families.
Aims: The aim of this study was to screen polymorphisms in the promoter
regions of selected SLC and ABC genes and to identify SNPs associated with
the response to the first line IM therapy of CML patients.
Methods: Using NGS we screened promoters of 15 SLC and 4 ABC genes on
testing cohort of 83 CML patients with optimal (n=42) and non-optimal (n=41)
response to IM. Patients were treated with 400mg/day of IM during the minimal
follow-up of 24 months. SNPs confirmation in SLC22A4 and SLC22A5 promot-
ers were performed by Sanger Sequencing in the validation cohort of 42
patients. Linkage disequilibrium analysis of genotyped SNPs on European pop-
ulation and proxy identification with the regulatory function in SLC22A4 and
SLC22A5 non-coding regions were performed using LDlink1.1. The Fisher´s
exact probability test and Chi-square test were used for allele frequency analy-
sis. Cumulative achievement of stable major molecular response (MMR) was
calculated using XLSTAT. Kaplan-Meier method was applied for event free sur-
vival calculation. Events were defined as loss of MMR, loss of cytogenetic
response, TKI switch, BCR-ABL1 mutations, death, hematological relapse and
progression.
Results: Among 1486 NGS evaluated sequences we identified 95 SNPs. In
the merged cohort of patients from testing and validation cohorts (n=125) we
revealed significant differences in the frequencies of rs460089-GC and
rs460089-GG (SLC22A4) genotypes among rs2631365-TC (SLC22A5) geno-
type carriers associated with optimal and non-optimal response, respectively.
We found that loci rs460089 and rs2631365 are in highly significant linkage
disequilibrium with another 12 regulatory loci (R2=0.98-1.0; P=0.0) located in
introns of SLC22A4 and SLC22A5 encoding OCTN1 and OCTN2 IM trans-
porters, respectively. Based on the genotypes association analysis with the
response to IM we revealed that rs460089-GC genotype carriers had signifi-
cantly higher probability to achieve stable MMR (P =0.001) and this was
enhanced in rs460089-GC_rs2631365-TC genotypes carriers (Figure 1;
P=0.000). Consequently, patients with rs460089-GC genotypes have higher
probability to survive without event in contrast to patients with rs460089-GG
(P=0.003), when the contrast was higher in patients with rs460089-
GC_rs2631365-TC genotypes in comparison to rs460089-GG_rs2631365-TC
(P<0.0001). 
Figure 1.
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Summary/Conclusions: We found that SNPs rs460089 and rs2631365 may
represent important genetic markers for European population of CML patients
by predicting response to the IM therapy at the time of diagnosis. Patients with
rs460089-GC_rs2631365-TC genotype would likely respond optimally, in con-
trast, rs460089-GG_rs2631365-TC genotype represents a risk factor for IM
failure and disease progression. This risk factor maybe associated with sub-
lethal concentration of IM, which may lead to resistant clone development and
disease progression. Patients with high-risk genotype rs460089-
GG_rs2631365-TC may profit from therapy with tyrosine kinase inhibitors that
are independent on OCTN1 and OCTN2 carriers.
Supported by the Ministry of Health of Czech Republic, grant IGA MZCR
NT/13899 and Charles University Prague, project GAUK/177815.
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15-YEAR FOLLOW-UP OF THE NORDIC MCL2-TRIAL: DESPITE
LONG-TERM RESPONSES LATE RELAPSES STILL OCCUR
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Background: Until recently, Mantle Cell Lymphoma (MCL) was associated
with an exceedingly poor prognosis with a median overall survival (OS) of 3-5
years (Herrmann, JCO, 2008). However, during the last 15 years the outcome
has improved substantially by an intensified Ara-C-containing induction regi-
men, addition of rituximab and consolidation with high-dose therapy and autol-
ogous stem cell transplantation (ASCT). One such regimen was introduced by
the MCL2 trial, conducted by the Nordic Lymphoma Group (NLG), and showed
a projected 10-year OS and PFS of 58% and 43%, respectively, after a median
follow-up time of 6.5 years (Geisler, BJH, 2012). 
Aims: The MCL2 regimen is still the 1-st-line regimen of choice for younger
patients in many centers worldwide. Here we present the updated results after
a median follow-up of 11.4 years of the MCL2 trial.
Methods and Patients: Between 2000 and 2006, 160 untreated stage II-IV MCL
patients younger than 66 years were enrolled in Denmark, Norway, Sweden and
Finland. Patient characteristics have previously been described elsewhere
(Geisler, Blood, 2008). Histological diagnoses were confirmed by a central pathol-
ogy review board. An informed consent was obtained from all patients.
Treatment: Six alternating cycles of maxi-CHOP and high-dose Ara-C, with
rituximab after cycle 3, followed by BEAM/BEAC and ASCT in responders
(n=145). Patients who subsequently developed solely molecular relapse detect-
ed by clonal IGHV or t(11;14) PCR received 4 weekly cycles of rituximab
(Andersen, JCO, 2009).
Results: With a median follow-up of 11.4 years, the median OS and PFS were
12.7 and 8.5 years, respectively (Figure 1A,B). The median response duration
(RD) of the 145 patients who underwent ASCT was 12.4 years (Figure 1C).
The MCL international prognostic index (MIPI) and the biological index (MIPI-
B) significantly divided patients into three risk groups according to OS, PFS
and RD (Figure 1D,E, data only shown for PFS). The median OS and PFS
were 4.0 and 2.5 years in the MIPI high-risk group, 11.0 and 8.0 years in the
intermediate risk group, and not reached and 12.8 years in low risk group, (Fig-
ure 1D). Interestingly, 17 patients relapsed after 5 years or more in CR, and 6
patients beyond 10 years, primarily from the intermediate and low risk groups.
Meanwhile, the MIPI high risk group reached a plateau at 24% (n=9) after 7
years. We recently proposed an improved prognosticator including expression
of micro-RNA-18b (MIPI-B-miR) based on the same patient cohort (Husby,
Blood, 2016). In the present update, it remains highly significant and identifies
a high-risk group of an exceedingly poor prognosis with OS and PFS of only
1.6 and 1.0 years, respectively (n=10) (Figure 1F), while still separating the
low- and intermediate risk groups.
Figure 1.
Summary/Conclusions: After an extended median follow-up of 11.4 years, the
outcome of the Nordic MCL2 trial is still good. However, a pattern of continuing
relapse is observed, seemingly precluding cure. MIPI, MIPI-B and, in particular,
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MIPI-B-miR remain valid prognosticators that clearly separate patients into risk
groups with different outcomes. All risk groups might benefit from addition of
novel agents, and such approaches are underway in large randomized trials.
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Background: MCL is a rare, aggressive B-cell lymphoma with a poor progno-
sis. For patients who fail initial therapy, conventional chemotherapy achieves
only short-term remissions. Ibrutinib is a first-in-class, once-daily, oral, covalent
inhibitor of Bruton’s tyrosine kinase shown to be highly active for patients with
MCL. The current pooled analysis from 3 ibrutinib studies (PCYC-1104,
MCL2001 [SPARK] and MCL3001 [RAY]) assessed the impact of baseline fac-
tors on overall survival (OS) in patients with relapsed/refractory (R/R) MCL.
Aims: To explore baseline factors impacting OS in patients with MCL receiving
ibrutinib.
Methods: Patients with R/R MCL were enrolled across 3 studies to receive
ibrutinib 560 mg orally once daily until progressive disease or unacceptable
toxicity. Inclusion and exclusion criteria were similar in all 3 studies; however,
patients in SPARK were required to have received both rituximab and borte-
zomib. Patient-level data from all 3 studies were combined into one database.
Simple descriptive statistics were used, and exploratory analyses were con-
ducted using Kaplan-Meier estimates for progression-free survival (PFS) and
OS. Univariate and multivariate analyses were also conducted with hazard
ratios to allow for comparisons of variables. All patients provided written
informed consent.
Results: Overall, 370 patients were included in this analysis (PCYC-1104,
n=111; SPARK, n=120; RAY, n=139); median age was 67.5 years, 94% had
ECOG 0-1, 45% and 32% had intermediate and high-risk sMIPI, most patients
had 1-3 prior lines of therapy (27%, 29%, 22% had 1, 2, 3 prior lines of therapy,
respectively), 49% had bulky disease (>5 cm) and 88% had non-blastoid histol-
ogy. Overall response rate (ORR) was 66% (20% CR; 46% PR), with a median
DOR, PFS and OS of 18.6, 12.8 and 25.0 months, respectively. ORR (CR) for
patients with 1, 2 and ≥3 prior lines of therapy was 77.8% (34%), 71% (24%)
and 64% (16%). Of patients who achieved a CR, 70% were progression-free
and 90% were alive at 2 years. Univariate analyses showed that patients with 1
vs >1 prior line of therapy had significantly longer OS, with longer OS also
observed in those who were younger and had non-blastoid histology (Figure 1),
non-bulky disease or better sMIPI score. Patients with blastoid and non-blastoid
histology had similar ORR (55 vs 72%) and time to best response (2.2 vs 2.1
months); however, DOR (8.6 vs 18.8 months), PFS (5.1 vs 14.6 months) and
OS (12.8 vs not reached) were significantly shorter in patients with blastoid his-
tology. Multivariate analyses identified ECOG, sMIPI, bulky disease and blastoid
histology as impacting OS, and sMIPI, bulky disease, blastoid histology and 1
prior line of therapy as impacting PFS.
Figure 1. Kaplan-Meier Curves of OS and PFS by Baseline Factors: 1 vs
>1 Prior Line of Therapy and Blastoid Histology.
Summary/Conclusions: Here we show that OS is significantly longer in ibruti-
nib-treated patients who are younger and who have fewer prior lines of therapy,
better sMIPI scores, non-bulky disease and non-blastoid histology. While PFS
and OS in patients with blastoid vs non-blastoid histology are shorter, these
rates are higher than seen with other agents, indicating that ibrutinib is an effec-
tive agent to achieve a response and potentially provide a bridge to transplant.
Multivariate analyses indicate that traditional poor prognostic factors adversely
impact OS, suggesting that worsening OS in later lines of therapy is associated
with disease characteristics rather than an impact of ibrutinib on postprogression
survival. Data support the preferential use of ibrutinib after initial vs later relapse,
as PFS and OS are longer in patients receiving 1 vs >1 prior line of therapy.
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Background: The phase 3 MCL3001 (RAY) study compared the efficacy and
safety of ibrutinib with that of temsirolimus in patients with relapsed or refractory
mantle-cell lymphoma (MCL). Ibrutinib significantly prolonged progression-free
survival (PFS) versus temsirolimus (14.6 vs 6.2 months; p <0.0001) and
increased overall response rate (ORR) (72 vs 40%; p <0.0001). The current
study explores underlying molecular mechanisms of resistance to ibrutinib in
patients from the RAY study.
Aims: To identify specific mechanisms underlying ibrutinib resistance in MCL,
and to correlate potential genetic signatures with patient response.
Methods: The clinical results of the RAY study are reported elsewhere (Dreyling
2015). Patients were grouped by best ORR+PFS: Durable Responder: com-
plete response or partial response (PR)+PFS ≥4 months; Moderate Clinical
Benefit: PR+PFS <4 months or stable disease; and Primary Resistant Disease.
For mutational analysis, the Durable Responder group was compared with the
Poor/Non-responders group (Moderate Clinical Benefit+Primary Resistant Dis-
ease combined) using Fisher’s exact test for comparisons between the 2
groups. For primary resistance analysis, baseline variant differences between
groups were compared. For acquired resistance analysis, initial samples and
samples obtained at progression after response were compared. Deep
sequencing was performed on DNA from tumor cells (Illumina HiSeq instrument)
using a custom gene panel. Sequences were aligned to hg19 reference
genome, variants were described using SAMtools, and germline filters were
applied to identify possible somatic mutations. All patients provided written
informed consent.
Results: Mutations associated with primary resistance to ibrutinib were iden-
tified in NF-kB signaling pathways, both canonical (e.g., A20) and noncanonical
(e.g., BIRC2). Other mutations were found in epigenetic modifiers and in the
EGFR family. To explore acquired resistance, 34 paired samples (11 ibrutinib;
23 temsirolimus) were analyzed. Two PLCg2 mutations were found in patients
with durable PRs (18.5 and 8.5 months); a CARD11 mutation after PR was
found in 1 patient (after 12 months). Mutations in epigenetic modifiers and alter-
nate NF-kB or PI3K/mTOR pathways were found after a short treatment dura-
tion (<4 months). No primary or acquired Bruton’s tyrosine kinase (BTK) C481S
mutations were detected.
Summary/Conclusions: Mutations in the NF-kB pathway bypassing BTK
appear to be a common mechanism of resistance in this population with MCL.
The similarity between primary and acquired mutations, as well as the lack of
BTK C481S mutations to date, may possibly be explained by the short follow-
up and shorter response duration compared with chronic lymphocytic leukemia.
Some mutations seen in the acquired setting (e.g., CARD11, PLCg2) have
been associated with ibrutinib resistance. Understanding both primary and
acquired resistance patterns is key in order to improve outcomes and define
the populations that benefit from ibrutinib treatment.
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Background: Limited treatment options are available for patients (pts) with rit-
uximab-refractory (R-R) indolent non-Hodgkin lymphoma (iNHL). GADOLIN
(NCT01059630) is an open-label, randomized, phase 3 trial comparing the effi-
cacy and safety of obinutuzumab (GA101; GAZYVA/GAZYVARO; G) plus ben-
damustine (B; G-B) induction, followed by G maintenance, with B standard of
care in this pt group. In the primary analysis (median observation time: 21
months [mo]) of iNHL pts, median Independent-Review Committee (IRC)-
assessed progression-free survival (PFS) was longer in the G-B arm (194 pts;
median not reached) than in the B arm (202 pts; 14.9 mo), with a 45% reduction
in risk of progression or death (HR 0.55; 95% CI 0.40-0.74; p=0.0001). Safety
profiles were comparable.
Aims: To evaluate efficacy and safety in the follicular lymphoma (FL) subset
of GADOLIN pts considered in the primary analysis.
Methods: GADOLIN pts were aged ≥18 years with documented R-R iNHL and
an Eastern Cooperative Oncology Group performance status of 0-2. Pts
received either G 1000mg intravenously (IV) (days [D] 1, 8 and 15 of cycle (C)
1 and D1 of C2-6) plus B 90mg/m2/day IV (D1 and 2 of C1-6) or B monotherapy
(120mg/m2/day IV D1 and 2 of each cycle for up to six cycles); each cycle was
28 days. Following induction, pts in the G-B arm without evidence of progression
received G maintenance (1000mg IV every 2 mo for 2 years or until disease
progression). Endpoints included IRC-assessed PFS (primary), investigator
(INV)-assessed PFS, response and safety. All pts gave informed consent.
Results: 321 (81%) of 396 iNHL pts enrolled had FL (G-B, 155; B, 166). Base-
line characteristics of the FL population were balanced between arms. Median
number of prior therapies was 2. Most pts were refractory to their last prior rit-
uximab (R)-containing regimen (G-B, 94%; B, 93%) and double-refractory to
R and an alkylating agent (G-B, 77%; B, 80%). IRC-assessed end of induction
(EOI) and best overall response were similar in the G-B and B arms (p>0.05
for comparison; Table 1). Median IRC-assessed PFS was not reached in the
G-B arm and was 13.8 mo in the B arm (Figure 1), while median INV-assessed
PFS was more than twice as long in the G-B arm than in the B arm (Table 1);
in both instances, the advantage corresponded to a 52% reduction in risk of
progression or death relative to B (Table 1). Survival data were immature at
the time of analysis. Safety profiles were comparable. Of note, grade 3-5
adverse events (AEs) and grade 5 AEs (fatal outcome) occurred in 65.8% and
5.2% pts in the G-B arm and 58.9% and 6.1% pts in the B arm, respectively.
Table 1.
Parameter                                    FL subpopulation
                                                                      G-B (n=155)                    B (n=166)
Median observation time (range), mo                22.08 (0.4-48.5)            20.27 (0.0-50.0)
PFS (IRC)
Pts with event, n (%)                                   54 (34.8)                    90 (54.2)
Median (mo)                                             Not reached                     13.8
HR [95% CI]; stratified*                                   0.48 [0.34-0.68]
PFS (INV)
Pts with event, n (%)                                   62 (40.0)                   102 (61.4)
Median (mo)                                                   29.2                           13.7
HR [95% CI]; stratified*                0.48 [0.35-0.67]
Response† (IRC)
EOI response (%): overall‡/CR                   70.5/9.4                    62.6/13.5
Best response (%): overall‡/CR                             79.7/15.7                      77.0/19.3
*Stratification factors for FL population were refractory type (R vs R-chemo) and prior therapies
(≤2 vs >2); †During treatment and within 12 mo after start of treatment; ‡Complete response
(CR) or partial response.
Figure 1. Kaplan Meier plot of IRC-assessed PFS in patients with FL. 
Summary/Conclusions: In the FL subset of GADOLIN pts, PFS was signifi-
cantly longer in the G-B arm compared with the B arm, corresponding to a
52% reduction in risk of progression or death. No unexpected safety signals
were identified. G-B is an effective therapy for pts with R-R FL.
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Background: High dose therapy supported by autologous stem cell transplan-
tation (HDT/ASCT) has been a treatment frequently indicated in follicular lym-
phoma (FL) patients and has contributed to modify the natural history of the
disease, however secondary neoplasia is one of the concerns after HDT/ASCT
with a reported incidence very variable among studies due in part to cohort dif-
ferent in terms of age, pre-ASCT treatments, used of total body irradiation
(TBI)-based conditioning regimen or length of follow-up rather than to the pro-
cedure itself.
Aims: To evaluate the cumulative incidence and characteristics of myelodys-
plastic syndromes and acute myeloid leukemia (sMDS/sAML) and solid tumors
after HDT/ASCT in a very long-term follow-up analysis of FL patients.
Methods: A total of 655 FL patients reported to the Spanish GELTAMO registry
and intensified with HDT/ASCT between 1989 and 2007 were analyzed. Base-
line characteristics and therapeutic-related data are listed in the Table 1. Stan-
dardized Incidence Ratios (SIR) were calculated to assess the risk of a second
malignancy by dividing the number of observed second malignancies with the
number of expected sex matched incidence using the 2008 crudes rates in the
Spanish population (M.J Sánchez, Annals oncology 2010).
Table 1. Main clinical Features at Diagnosis and Treatment Variables of
the Series.
Results: At a median follow-up of 12 years from HDT/ASCT and 14.2 years
from diagnosis of FL the median OS were 21.3 years from HDT/ASCT and
22.6 years from the time of FL diagnosis. Of the 645 evaluable patients; 80
(12.5%) developed a second malignancy: solid tumors (38 cases; 47.5%; of
them 5 were skin cancers), sMDS/sAML (34 cases; 42.5%), ALL (2 cases),
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CML (1 case), Hodgkin lymphoma (1 case) and not specified (4 cases). The
accumulated incidence at 5, 10 and 15 years was 1.8%, 3.5% and 4.9% for
solid tumors and 2.6%, 4.3% and 5% for sMDS/sAML, respectively.
sMDS/sAML and solid tumors were documented with a median time of occur-
rence since HDT/ASCT of 4.2 years (0.3-15.5) and 8.3 years (0.5-24.4), respec-
tively. The SIR for second neoplasia was 2.8.Male sex (P=.1) and the use of
BM as stem cell source (P=.1) tended to be associated with an increased num-
ber of second neoplasia. There were no differences according to the use of
anthracycline, fludarabine or rituximab previously to HDT/ASCT, number of
therapy lines before HDT/ASCT, time from diagnosis to HDT/ASCT, status of
the disease at HDT/ASCT or conditioning regimen. Median OS for patients with
second neoplasia is 11.8 years from the time of FL diagnosis, 9.4 years from
ASCT [14.5 y. for solid tumors and 8 y. for sMDS/sAML (P=.01)] and 1.4 years
from the time of diagnosis of second neoplasia [2.7 y. for solid tumors and 1.3
y. for sMDS/sAML (P=.01)], respectively.
Summary/Conclusions: Our results, from the longest follow-up study in FL
including a large number of cases from the rituximab era, indicate that FL
patients undergoing and ASCT are at an increased risk of developing a second
malignancy, however, the incidence is not higher than that reported in other
series without transplantation (Rummel, Lancet 2016; Ardeshna, Lancet 2003).
Low percentage of patients conditioned with TBI and a considerable number of
patients been transplanted soon during the disease, could explain these good
results. Once a secondary neoplasia is diagnosed prognosis is dismal, and
consequently a carefully selection of patients candidates to ASCT is necessary.
For all that, we suggest that, given the favorable survival obtained by
HDT/ASCT makes not evident to what extent incidence of secondary neoplasia
will diminish the benefit of HDT/ASCT in FL.
Myelodysplastic syndromes - Biology
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Background: The development and progression of cancer are shaped by
dynamic alterations of clonal architecture, characterization of which in terms of
gene mutations is essential for the understanding of the pathogenesis of cancer.
However, the clonal architecture in myelodysplastic syndromes (MDS) has
been only inferred from the allelic burden of a limited number of driver mutations
at a single time point. Comprehensive mutation profiling of serial samples has
been performed only for a small number of patients.
Aims: We aimed to delineate the impact of clonal dynamics on disease phe-
notypes, progression to secondary acute myeloid leukemia (sAML), and clinical
outcomes in a large cohort of fully genotyped MDS patients.
Methods: Clonal architecture and dynamics were investigated by whole exome
sequencing (WES) and/or targeted sequencing of 779 patients with MDS and
sAML, of whom 97 were analyzed longitudinally. Combined with published data
sets (N=2,133), the data were also used to interrogate differential roles of driver
mutations in disease progression.
Results: Higher-risk MDS was characterized by a higher number of mutations
with increasing diversity and a larger clone size. The number of cases with het-
erogeneity was significantly higher in sAML compared to lower-risk MDS
(P=0.03). In WES analysis of serial samples, evolution of a new dominant clone
that swept out other subclones was common during disease progression and
frequently accompanied by newly emerging subclones. Leukemic transforma-
tion was heralded by acquisition of new mutations in most cases without clone
sweeping. To clarify the relationship between driver mutations and disease pro-
gression or phenotype, we compared frequencies of major driver mutations
between disease subtypes within a large cohort of patients. In total, data from
samples with lower- (n=1,157) and higher-risk (n=672) MDS, as well as sAML
(n=304), were subjected to analysis of 27 driver genes mutated in more than
2% of the entire cohort. Mutations in genes designated as Type-1 (FLT3,
PTPN11, IDH1, CBL, and NRAS) were significantly enriched in sAML compared
to higher-risk MDS. When compared between higher- and lower-risk MDS, we
observed a skewed enrichment of certain driver mutations in higher-risk MDS,
designated here as Type-2 (TP53, GATA2, RUNX1, IDH2, STAG2, ASXL1, and
NPM1). In longitudinal samples, Type-1 mutations were more likely to be newly
acquired or to increase in clone size (P=1.94×10-4, trend test). In contrast,
more Type-2 and other mutations decreased in their clone size or were even
lost in the second sampling. Patients with Type-1 mutations (Group-I) had a
significantly shorter time to progression to sAML compared to other patients
(hazard ratio (HR)=5.7, 95% confidence interval (CI)=3.4−9.6; P <0.001). Time
to sAML in Group-I patients was also significantly shorter than that in patients
who had Type-2 mutations but lacked Type-1 mutations (Group-II) (HR=3.0,
95% CI=1.7−5.4; P <0.001). Despite the significant difference in the rate of
progression to sAML between patients in Group-I and Group-II, both had a sim-
ilar overall survival. Accordingly, in Group-II patients more deaths occurred
before progression to sAML, compared to Group-I patients.
Summary/Conclusions: Dynamics of clonal architecture strongly correlates
with distinct types of mutations, which are significantly associated with
leukemia-free survival and non-leukemia death, suggesting that screening of
these specific mutations might be useful for the prediction of clinical outcome.
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Background: Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic
Leukaemia (CMML) are haematological disorders that develop in haematopoi-
etic stem or progenitor cells (HSPCs) and are characterised by ineffective
haematopoiesis. 5’-Azacitidine (AZA), a DNA demethylating agent, is the pri-
mary drug for the treatment of high-risk MDS and CMML and response is asso-
ciated with improved survival benefits. However, only half of treated patients
will ever respond to AZA and the molecular basis for poor response is currently
unknown. Additionally, AZA response is rarely sustained and a substantial frac-
tion of responders will eventually relapse.
Aims: We aimed to: 1.) understand the molecular basis for poor response to
AZA, and 2.) characterise the in vivo effect of AZA therapy on dysplastic cells
in responders, as a first step towards understanding eventual relapse.
Methods: We enrolled 18 high-risk MDS and CMML patients on a compas-
sionate access program for AZA in Australia. Bone marrow was collected at
seven different points – before treatment; through 6 cycles of treatment; and
at up to two years after initiation – and we isolated high-purity CD34+ HSPCs
(Figure 1 A). 10 patients had a complete response while 8 were poorer respon-
ders. We performed RNA-seq to query the transcriptomes and deduced the
clonal evolution in the bone marrow in response to AZA therapy by whole
exome-sequencing and single-cell genotyping.
Figure 1.
Results: We hypothesised that primary AZA resistance would be driven by pre-
existing molecular differences between responders and non-responders. Analysis
of the pre-treatment RNA-seq data revealed differential gene expression between
responders and non-responders (Figure 1 B). Pathway analyses of these genes
indicated that cell cycle was relatively up-regulated in responders compared to
non-responders (Figure 1 C). We validated these gene expression differences
in independent patient cohorts. We then adapted a flow cytometry based assay,
amenable to prospective use in a clinical diagnostic setting, to directly detect the
increased quiescence of CD34+ CD38+ haematopoietic progenitors in unsorted
bone marrows of non-responders (Figure 1 D). Finally, to reverse the quiescence
of progenitor cells of non-responders, we developed a stromal co-culture drug
testing platform and discovered that inhibiting integrin-linked signalling combina-
torially with AZA improved the functionality of dysplastic cells (Figure 1 E). To
trace the fate of dysplastic cells upon AZA therapy, we performed whole exome
sequencing of all patients (Figure 1 F). Using the mutations as “molecular bar-
codes”, we deduced the clonal architecture in each individual. We have discov-
ered that although AZA alters the sub-clonal contribution to different lineages,
founder clones are not eliminated and continue to drive hematopoiesis even in
complete responders (Figure 1 G). Lastly, we have also discovered that AZA
response is associated with an up-regulation of inflammation-associated path-
ways in vivo.
Summary/Conclusions: Our findings, across independent cohorts and rele-
vant to both MDS and CMML, have immediate clinical utility not simply to
prospectively identify AZA non-responders but also by suggesting combinatorial
therapies that could improve response. Finally, elucidating the in vivo effects
of AZA therapy lay the foundation for developing more durable treatments.
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Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic dis-
orders characterized by no efficient hematopoiesis and frequent progression
to acute myeloid leukemia (AML). Even in low risk MDS, clonal hematopoiesis
already dominates at diagnosis, and clones found in secondary AML originate
from the MDS stage of disease, highlighting the need to specifically target the
MDS-initiating clone. PF-0449913 is a potent and selective hedgehog pathway
inhibitor that act by binding Smoothened (SMO) and blocking signal transduc-
tion. In xenograft models of human coloirectal and pancreatic cancer, treatment
with PF-04449913 in combination with other anticancer agents reduced the
tumor growth. Furthermore, PF-04449913 demonstrated preliminary antitumor
activity in a phase I trial, when given as monotherapy in patients with several
hematopoietic malignancy. 
Aims: In the present study, we investigated the molecular mechanisms by which
PF-04449913 regulate the self-renewal of MDS-derived iPS cells (iPSCs) in vivo. 
Methods: We generated iPSCs from bone marrow mononuclear cells of two
MDS patients (RAEB1 and RAEB2 by WHO clssification) with complex kary-
otypic abnormalities. Karyotyping analysis revealed that MDS-derived iPSCs
have identical abnormalities to primary MDS cells. We also generated iPSCs
from bone marrow mononuclear cells of normal volunteer as control. To inves-
tigate the effects of PF-04449913 on self-renewal and the relevance as a ther-
apeutic target in MDS initiating cells, NOD/SCID mice were injected sucuta-
neously with MDS-derived iPSCs or normal iPSCs then treated with PF-
04449913 (100 mg/kg; p.o.) from day 10 for 28 days. We also used MDS-L, a
myelodysplastic cell line establised from MDS patient with del(5q) and complex
karyotypic abnormalities for in vitro studies.
Results: Both MDS-derived iPSCs transferred NOD/SCID mice and normal
iPSCs transferred NOD/SCID mice demonstrated the engraftment of
CD34+CD38- positive cells by flow cytometry. However, the treatment with PF-
04449913 reduced the population of CD34+CD38- positive cells in MDS-
derived iPSCs transferred NOD/SCID mice. We isolated human CD45+ cells
from the spleen of mice from each treatment group and injected equivalent
numbers of CD45+ cells into secondary recipients. Following 50 days, all mice
treated with vehicle engrafted with CD34+CD38- positive cells. In contrast,
CD34+CD38- positive cells engraftment was not detected in recipient mice
(n=3) from PF-04449913-treated donors. These results demonstrate the per-
sistent effects of PF-0449913 on long term self-renewing MDS-initiating cells.
We further examined the effects of Nanog pathway modulation on in vitro clono-
genic growth. CD34+CD38- cells from MDS-derived iPSCs transferred
NOD/SCID mice and MDS-L cells were treated with 2 mM of PF-04449913 for
72 hrs, washed free of drugs, and plated in quadruplicate in methylcellulose.
At 14 days, colonies were counted as initial plating. The representative plate
was then washed and cells were re-suspended and re-plated. After an addi-
tional 14 days, colonies were counted as secondary re-plating. Clonogenic
recovery of untreated cells was normalized to 100% and plating results from
all treatment groups were expressed as % control. PF-04449913 had only min-
imum effects on colony formation after initial plating over control cells. However,
upon serial re-plating, secondary colony formations were significantly inhibited
by PF-04449913 (p<0.001). Also reduced expression of Nanog by shRNA also
supressed the secondary colony formations.To identify the mechanisms that
limit the self-renewal of MDS-initiating ells by PF-04449913, NOD/SCID mice
engrafted with CD34+CD38- fractions from MDS-derived iPSCs were treated
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with PF-04449913 (100 mg/kg; p.o.) for 14 days. PF-04449913 induced the
expressions of p21Cip1, cleaved PARP and reduced the expression of BMI-1,
c-Myc, Nanog, and Bcl-XL.
Summary/Conclusions: Our preclinical results indicate that PF-04449913
have potential as an important option for controlling the drug-resistant MDS-
initiating cells. It is expected that the PF-04449913 may become extremely
useful therapeutic interventions in a number of hematological neoplasms,
including MDS, where the persistence of cancer stem cells.
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Background: Mutations in the RNA splicing gene SF3B1 are found in more
than 80% of patients with myelodysplastic syndrome with ring sideroblasts
(MDS-RS), and predict for a stable clinical course and a favourable survival
(Malcovati L. et al., Blood 2015 126(2):233-41). Little is known about the cellular
origin of these mutations or their hierarchy in relation to other somatic mutations. 
Aims: To establish the origin of SF3B1 mutations within the bone marrow (BM)
hematopoietic stem and progenitor cell compartment (HSPC) in MDS-RS.
Methods: We investigated BM mononuclear cells (MNC) from 13 MDS-RS
patients (6 RARS and 7 RCMD-RS) and 4 healthy controls for mutational spec-
trum by targeted sequencing, and quantified HSPC subsets using flow cytom-
etry. Functional analysis of the purified populations was performed in vivo, using
xenotransplantation in NOD scid gamma (NSG) mice to establish repopulating
and self-renewal ability, and ex vivo using clonogenic progenitor assays: colony
forming-unit (CFU) and long-term culture initiating cell (LTC-IC). Hierarchy of
molecularly and functionally distinct stem and progenitors cells was established
using pyrosequencing. 
Results: Screening for recurrently mutated genes in the MNC fractions
revealed mutations in SF3B1 in 12/13 cases, combined with TET2 and
DNMT3A in 4 and 2 patients, respectively. The frequencies of phenotypically
defined MDS-RS HSPC in the BM did not differ from that of normal controls,
whereas pro-B cells were significantly reduced (p<0.005) in MDS-RS. We
tracked back all the mutations identified in the MNC fractions to each purified
MDS-RS stem and progenitor population, and in all LTC-IC and CFU colonies
generated in vitro. Importantly, we identified the SF3B1 mutation at the BM pro-
B level in 5 investigated patients, and also in a smaller fraction, in purified
peripheral blood B-cells from these patients. Analysis of peripheral blood B
cells from the same patients 2-3 years after the first sampling showed an
increase in SF3B1 allelic burden in all cases. Importantly, co-mutations including
DNMT3A and B-COR were not detected in peripheral B cells. This demon-
strates that the origin of SF3B1 mutation arises in the very primitive lymphoid-
myeloid multipotent stem cell compartment. We transplanted purified
hematopoietic stem cells (HSC) and lineage restricted cell populations: CMPs,
GMPs and MEPs from 4 SF3B1 mutated MDS-RS patients into NSG mice; 2
of which also carried TET2 mutations. Engraftment, as defined by
(hCD45+CD19+, hCD45+CD33+CD66b+CD15+ or GPA+CD71+) of all four HSC
samples was detected, while all more mature cell populations failed to engraft.
Importantly, morphological development of ring sideroblasts was observed in
mice transplanted with HSCs from all 4 patients, proving that the self-renewal
potential as well as commitment to the RS erythroid phenotype is restricted to
MDS-RS HSC. 
Summary/Conclusions: Our findings provide evidence of a multipotent stem
cell origin of the SF3B1 mutation in MDS-RS patients and propose the existence
of a mixed B-cell population formed by abnormal cells derived from the MDS-RS
clone and a normal “pre-clonal” population. Stem cell potential and reproduction
of the MDS-RS erythroid phenotype was restricted to MDS-RS stem cells only. 
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Background: Therapy-related myeloid neoplasms (t-MNs) are secondary
malignancies that develop in patients treated with chemotherapy and/or radia-
tion therapy (C/RT). Previously, it was thought that genotoxic stress from C/RT
induced driver mutations in hematopoietic stem cells leading to the development
of t-MNs. However, a recent study suggested that pre-leukemic TP53 mutations
could pre-exist in t-MN patients years before t-MN development. Further, hema-
tological driver mutations have been detected in peripheral blood (PB) from
apparently healthy individuals or patients with solid tumors, a phenomenon
referred to as clonal hematopoiesis of indeterminate potential (CHIP). 
Aims: To test the hypothesis that pre-leukemic driver mutations are detectable in
t-MN patients at the time of primary cancer diagnosis and prior to C/RT exposures. 
Methods: We identified 14 patients with t-MNs who were found to have paired
samples of diagnostic bone marrow (BM) at the time of t-MN diagnosis and PB
obtained after the diagnosis of their primary cancers but prior to C/RT. Targeted
gene sequencing of the 280 leukemia-related genes was performed on the 14
t-MNs diagnostic BM to detect driver mutations. We then assessed presence
of the same driver mutations in the patients’ matched PB samples taken at the
time of primary cancer diagnosis. Because pre-leukemic driver mutations in
the PB samples were expected to have very low variant allele frequency (VAF),
we performed molecular barcoding deep sequencing of 32 genes that were
reported as CHIP-associated mutation. 
Results: Of the 14 t-MN patients, 5 (36%) had t-AML and 9 (64%) had t-MDS.
The median age at primary cancer diagnosis and at t-MNs diagnosis was 62
years (range: 25-74) and 66 years (range: 28-77), respectively. The median
latency from primary cancer to t-MNs was 3 years (range: 1-8). In the t-MN
BM, 3 patients (21%) had normal karyotype and 7 (50%) had del 7q/-7, 4 (29%)
had del 5q/-5 and 5 (36%) had complex karyotypes. Targeted gene sequencing
of t-MN BM (median 289x): revealed 21 canonical hematological driver muta-
tions in 14 t-MNs patients: mutations in TP53 (29%), DNMT3A (21%), TET2
(21%), RUNX1 (21%), IDH2 (14%), SRSF2 (7%), EZH2 (7%), FLT3 (7%),
NRAS (7%), PTPN11 (7%) and GATA2 (7%). Molecular barcoding deep
sequencing of the PB samples (median 3,000x) taken at the time of primary can-
cer diagnosis revealed that pre-leukemic driver mutations were detected in 10
out of 14 (71%) patients. Figure 1 shows the model of clonal evolution from pre-
leukemic driver mutations to t-MN in 3 representative cases. For example, Case
UID6982 had limited stage small cell lung cancer and received concurrent chemo-
radiation therapy with carboplatin and etoposide. He developed t-AML 3 years
after C/RT and was found to have an IDH2 p. R140Q (VAF 25%) and SRSF2
p.P95fs (46%) mutations in the diagnostic BM. His PB samples obtained before
C/RT showed the same IDH2 p.R140Q and SRSF2 p.P95fs mutations with VAF
of 16.4% and 9.8%, respectively. By genes, 75% of TP53, 67% of DNMT3A,
100% of TET2, 67% of RUNX1, 50% of IDH2, 100% of SRSF2, 100% of FLT3,
100% of NRAS, and 100% of PTPN11 mutations were detected as pre-leukemic
driver mutations at time of primary cancer diagnosis. We did not detect EZH2
and GATA2 mutations as pre-leukemic mutations. The median VAF of the detect-
ed pre-leukemic driver mutations was 7.6% (range: 0.5-23%). There was no sta-
tistical difference between patients with and without detectable pre-leukemic
mutations in terms of age at primary cancer diagnosis or latency time to t-MN
development (P=0.73 and 0.54, respectively). 
Figure 1.
Summary/Conclusions: In this study we have demonstrated evidence of
detectable pre-leukemic driver mutations in multiple leukemia driver genes at
time of diagnosis and before therapy of primary cancer in patients whose sub-
sequent t-MNs also harbored identical driver mutations. These data suggest
the potential to develop a risk stratification model based on presence of CHIP
with canonical driver mutations at the time of primary cancer diagnosis. Deter-
mining predictive value of pre-leukemic driver mutations in t-MN development
is currently undergoing.
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New biological markers in MM
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A TARGETED SEQUENCING APPROACH IN MULTIPLE MYELOMA
REVEALS A COMPLEX LANDSCAPE OF GENOMIC LESIONS THAT HAS
IMPLICATIONS FOR PROGNOSIS
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M Fulciniti4, R Szalat4, KC Anderson4, S Minvielle5, M Attal6, P Moreau7,
PC Campbell2, H Avet-Loiseau6, NC Munshi4
1University of Milan, Milan, Italy, 2Wellcome Trust Sanger Institute, Cambridge,
United Kingdom, 3Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,
Italy, 4Dana-Farber Cancer Institute, Boston, United States, 5Université de
Nantes, Nantes, 6Institut Universitaire du Cancer Toulouse, Toulouse, 7CHU
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Background: Next-generation sequencing (NGS) studies have shown that mul-
tiple myeloma is a heterogeneous disease with a complex subclonal architecture
and few recurrently mutated genes. The analysis of smaller regions of interest
in the genome (“targeted studies”) allows interrogation of recurrent genomic
events with reduces complexity of downstream analysis at a lower price. 
Aims: Here, we performed the largest targeted study to date in multiple myelo-
ma to analyze gene mutations, deletions and amplifications, chromosomal
copy number changes and immunoglobulin heavy chain locus (IGH) translo-
cations and correlate results with biological and clinical features. 
Methods: We used Agilent SureSelect cRNA pull down baits to target: 246
genes implicated in myeloma or cancer in general in a mixed gene
discovery/confirmation effort; 2538 single nucleotide polymorphisms to detect
amplifications and deletions at the single-gene and chromosome level; the IGH
locus to detect translocations. We sequenced unmatched DNA from CD138-
purified plasma cells from 418 patients with multiple myeloma at diagnosis, with
a median follow-up of 5.3 years. We sequenced at an average depth of 337x
using Hiseq2000 machines (Illumina Inc.). We applied algorithms developed in-
house to call genomic events, filtering out potential artifacts and germline vari-
ants. We then ranker each event on its likelihood of being “oncogenic” based
on clustering, recurrence and cross-reference with the COSMIC database. 
Results: We identified 2270 gene mutations in 412/418 patients, and of those
688 were oncogenic. 342 patients harbored at least one oncogenic mutation.
215/246 genes showed at lease one likely somatic mutation, but only 106
showed at least one oncogenic mutation. 63% of oncogenic mutations were
accounted for by the top 9 driver genes previously identified (KRAS, NRAS,
TP53, FAM46C, BRAF, DIS3, TRAF3, SP140, IRF4), implying our gene discov-
ery effort did not identify novel mutated genes. We included deletion of tumor
suppressors, amplification of oncogenes, chromosomal copy number changes
and IGH translocations for a total of 76 variables, so that 413/418 patients
showed at least one informative driver genomic event, (median 4/patient). We
investigated pairwise associations between events and found significant corre-
lations, such as TP53 mutations and del(17p), CYLD mutations and del(16),
FAM46C mutations and del(1p), SF3B1 mutations and t(11;14). Hotspots muta-
tions of IRF4 lysine p.123 showed an inverse correlation with a hyperdiploid
karyotype and del(16) as opposed to other missense mutations scattered along
the gene, which has pathogenic implications. Survival was negatively affected
by the cumulative burden of lesions in an almost linear fashion, with median
survival of 10.97 and 4.07 years in patients with <=2 or >=7 lesions respectively,
and this was independent of the nature of the genomic events. Given the het-
erogeneity and complex interplay of the variables we fitted a cox-proportional
hazard model to predict survival. We found that mutations in TP53, amplifications
of MYC, deletions of CYLD, amp(1q), del12p13.31 and del17p13 where the
only significant events, all promoting shorter survival. In particular, TP53 muta-
tions and deletions, often co-occurring, had an additive effect so that carriers of
both showed a dismal survival of 17 months (Figure 1).
Figure 1.
Summary/Conclusions: Due to the complex genomic landscape in MM, a
discovery effort still requires large studies to derive significant associations.
We conclude that a targeted sequencing approach may provide prognostic
models and give insights into myeloma biology. 
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A NEW MULTIPLE MYELOMA CLASSIFICATION SYSTEM THAT
CORRELATES TO DISEASE STAGE AND PROGNOSIS - INDICATION OF
REVERSIBLE PHENOTYPIC PLASTICITY AS A HALLMARK
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Background: Today’s diagnostic tests for multiple myeloma (MM) reflect the
criteria of the updated WHO classification based on biomarkers and clinico-
pathologic heterogeneity.
Aims: To that end, we propose a new biological subtyping of myeloma plasma
cells (mPC) by B-cell subset associated gene signatures (BAGS), from the
normal B-cell hierarchy in the bone marrow (BM). Here we document the prog-
nostic and biological value of subtyping, as shown for DLBCL (JCO 2015 Apr
20; 33:1379).
Methods: We combined FACS and GEP to generate BAGS classifiers for
the normal BM subsets: PreB-I, PreB-II, immature (Im), naive (N), memory
(M) and PC. Construction was based on median-centred probe sets from
the BM data using regularized multinomial regression with six discrete out-
comes representing BAGS, by a total of 55 genes varying from 15-24 per
subtype. Each patient underwent BAGS assignment according to the high-
est predicted probability score above 0.45 or was otherwise unclassified.
The impact of BAGS was analyzed using six clinical cohorts, gathered
across geographical regions, time eras, and sampling methods. The analy-
sis estimated subtype frequencies and included a prognostic meta-analysis
of 926 patients treated with high dose melphalan as first line therapy in 3
prospective trials: UAMS, HOVON65/GMMG-HD4, MRC Myeloma IX data
with the Affymetrix U133 plus 2.0 microarray data available from myeloma
PC samples. To compensate for cohort-wise technical batch effects, each
cohort was median centred and adjusted probe set-wise to have same vari-
ance as the BM data.
Results: Validation of the normal B-cell subset phenotypes. Normalized his-
tograms of the fluorescence intensities (FI) of CD markers based on merged
multiparametric flow cytometry reanalysis of pure sorted populations resulting
from seven independent sorting procedures documented high purity. Principal
component analysis (PCA) of the FI for each sorted cell in all samples docu-
mented specificity. Surface markers, transcription factors, and B-cell differen-
tiation–specific genes were identified through a literature review, and their
expression across subsets was evaluated. The most varying probe sets were
included in an unsupervised hierarchical clustering analysis, supporting the
biological differences. Validation of MM patients subtyping by prognosis. The
resultant tumor assignments exhibited very similar BAGS subtype frequencies,
across 1302 individual MM cases from 4 different cohorts. The 5 BAGS sub-
types of 926 MM cases were significantly associated with overall (P=5.2x10-
8) and progression free (P=1.5x10-6) survival in a meta-analysis of patients in
the 3 clinical trials. The major impact was observed within the PreB-II and M
subtypes conferred with significant increased ISS stage III and inferior prog-
nosis compared to the Im, N and PC subtypes. Cox proportional hazard meta-
analysis showed that the five BAGS subtypes added significant and inde-
pendent prognostic information to the TC classification system and plasma
Beta-2 microglobulin level. In parallel we found significant correlation between
the PreBII subtypes and the proliferation index, risk profiling (P<0.0001) and
Beta-2 microglobulin (P<0.001).
Summary/Conclusions: We have documented patient specific mPC dif-
ferences with prognostic impact in support of reversible phenotypic plas-
ticity in MM. This observation provides a new model for generating insight
into the stages of clonal plasticity associated with oncogenesis and dedif-
ferentiation.
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DEFINING NEW THERAPEUTIC AGENTS THAT TARGET THE ONCOGENIC
TRANSLATION PROGRAM IN MULTIPLE MYELOMA 
S Manier1,2,3,*, D Huynh3, K Salem3, R Ebright3, J Park3, S Glavey3, J Shi3,
A Sacco3, A Roccaro3, J Snyder4, L Brown4, T Facon1, L Whitesell5, J Porco4,
I Ghobrial3
1Department of Hematology, Lille Hospital, 2INSERM U1172, University Lille 2,
Lille, France, 3Medical Oncology, Dana-Farber Cancer Institute, 4Center for
Molecular Discovery, Boston University, Boston, 5Whitehead Institute, Cam-
bridge, United States
Background: Despite significant therapeutic advances, Multiple Myeloma (MM)
remains an incurable hematological malignancy. Therefore, there is a need for
the development of new therapeutic options with novel mechanisms of action
that have not been previously explored in MM. 
Aims: To identify new potential therapies in MM, we screened a library of small
molecules against lymphoid cell lines and defined the mode of action for the
most active class of hits that we found. These compounds act as potent, highly
selective inhibitors of translation initiation and therefore inhibit the oncogenic
translation program of MM.
Methods: A chemically diverse small-molecule drug screen of over 3,000 com-
pounds from the Boston University Center for Molecular Discovery was per-
formed using H929 and NAMALWA cell lines. Follow-up validation and struc-
ture-activity relationship (SAR) studies were performed in several cell lines
including H929, MM1S, MM1R, U266, RPMI and OPM2. RNA sequencing was
performed using the NEBNext kit and Illumina HiSeq 2500. Quantitative pro-
teomic analysis was performed by Tandem Mass Tag (TMT) with mass spec-
trometry (MS). For animal studies, SCID mice were injected with 5x106 MM1S
luc-GFP cells and followed by blood cell count, body weight, bioluminescence
imaging (BLI) and survival.
Results: A primary screen of over 3,000 small-molecules identified 45 com-
pounds with potent activity on H929 and NAMALWA. Further validation of these
hits in 6 cell lines highlighted 3 compounds of the rocaglate class as by far the
most effective. A follow-up SAR screen including 40 rocaglate derivatives iden-
tified a compound called CMLD10509 with an IC50 below 10nM against several
MM cell lines, but no cytotoxicity on human PBMCs, suggesting a useful ther-
apeutic window for this agent in MM. To define the mode of action for
CMLD10509 against MM, we performed RNA-seq on drug- vs DMSO-treated
cell lines. By GSEA analysis, the most enriched pathways were regulators of
transcriptional activation and translation inhibition. To validate these findings
we queried our compound’s signature against the LINCS Cloud database - a
large catalog of gene-expression profiles collected from human cells exposed
to chemical and genetic perturbations - and identified a positive correlation
between our drug signature and translation inhibitors as well as KD of ribosome
subunits. To better define the consequences of CMLD10509-induced translation
inhibition, we performed a quantitative proteomic MS experiment. We identified
7312 proteins of which 54 were significantly down-regulated by CMLD10509
exposure (p<0.05 and FC>2), among them key oncoproteins in MM such as
MYC, MDM2, CCND1, MCL1 and MAF (Figure 1). Strikingly, down-regulated
proteins were strongly associated with KEGG cancer pathways, representing
the oncogenic translation program in MM. Correlation between TMT and RNA-
seq (confirmed by immunoblot and qRT-PCR) validated a purely translational
mechanism as responsible for their depletion in MM cells. Importantly, increased
expression of these same rocaglate-sensitive genes was significantly enriched
in MM patients in several datasets. Finally, CMLD10509 was both active and
well tolerated in a xenograft model of MM (n=10 per group), with significantly
lower BLI counts (p<0.001) and prolonged survival (median OS 35 vs 47 days,
p<0.001).
Figure 1. TMT mass spectometry of NCIH929 treated with CMLD10509 or
vehicle (DMSO). Triplicate analysis, two tailed t-test.
Summary/Conclusions: From a large-scale small molecule screen, we iden-
tified CMLD10509 as a potent compound, which selectively inhibits the trans-
lation initiation and impairs an oncogenic translation program supporting MM
cells that includes MYC, MDM2, CCND1 and MCL1. As proof of concept for
the potential of CMLD10509 as a novel therapeutic strategy, we found it to be
highly active and well tolerated in a mouse model of MM.
S450
PD-1 BLOCKADE ENHANCES THE EFFICACY OF ELOTUZUMAB IN
MOUSE TUMOR MODELS
N Bezman1,*, A Jhatakia1, A Kearney1, T Brender1, M Maurer1, C Sum1,
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Background: Elotuzumab is a humanized monoclonal antibody (mAb) that
binds specifically to human SLAMF7 (hSLAMF7) and has been approved by
the US Food and Drug Administration for use in combination with lenalidomide
and dexamethasone for the treatment of patients with multiple myeloma (MM)
who have received one to three prior therapies. Previous preclinical models
demonstrated that elotuzumab inhibited the growth of SLAMF7-expressing
human myeloma xenografts in immune-compromised mice. These models,
however, lacked adaptive immune cells and therefore could not assess the
mechanism of elotuzumab anti-tumor activity in the setting of a fully intact
immune system.
Aims: To model elotuzumab mechanism of action, alone or in combination with
PD-1 blockade, using human natural killer (NK) cells in vitro and mouse tumor
models in vivo.
Methods: We evaluated elotuzumab-mediated anti-tumor activity alone or in
combination with a mAb to PD-1 using mouse cell lines that stably express
human SLAMF7 (A20-hSLAMF7 and EG7-hSLAMF7). The effect of treatment
on the phenotype and functionality of tumor-infiltrating lymphocytes (TILs) using
flow cytometry and immunohistochemistry was evaluated. In addition, the
effects of elotuzumab on the phenotype of human NK cells isolated from either
healthy donors or patients with MM treated with elotuzumab plus lenalidomide
and dexamethasone was assessed.
Results: A murine IgG2a version of elotuzumab (elotuzumab-g2a) inhibited
growth of hSLAMF7-expressing mouse tumor cells in vivo. Tumor-bearing mice
treated with elotuzumab-g2a, anti-PD-1, or elotuzumab-g2a plus anti-PD-1 had
significantly improved survival over those treated with control IgG2a (Figure 1).
Anti-tumor activity mediated by elotuzumab-g2a required an Fc fragment that
was able to interact with activating Fc receptors, was partially dependent on
both NK cells and CD8+ cells, and synergized with anti-PD-1 treatment. TILs
taken from mice treated with elotuzumab-g2a plus anti-PD-1 had increased
numbers of activated tumor-specific and total CD8+ T cells. Elotuzumab-g2a
and anti-PD-1 combination treatment also promoted NK cell activation and
cytokine and chemokine release within the tumor. In vitro co-cultures of human
NK cells, elotuzumab, and SLAMF7-expressing tumor cell lines led to NK cell
degranulation, upregulation of inflammatory cytokines, and enhanced expression
of activation markers. Similarly, NK cells isolated from bone marrow aspirates
from patients treated with elotuzumab showed an enhanced activation state
compared with NK cells isolated prior to treatment.
Figure 1.
Summary/Conclusions: The combination of the tumor-targeted antibodies
elotuzumab-g2a and anti-PD-1 showed enhanced anti-tumor efficacy in mouse
tumor models. The strong control of tumor growth observed with combination
treatment was due to activation of both adaptive and innate immune cells local-
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ized to the tumor microenvironment. These in vivo findings support the sug-
gested mechanism of action of elotuzumab and PD-1 blockade and provides
rationale for the clinical investigation of elotuzumab and anti-PD-1 combination
therapy in patients with MM.
Study support: Bristol-Myers Squibb.
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THERAPEUTIC IMPACT OF TAK-1 INHIBITION ON TUMOR GROWTH AND
BONE DESTRUCTION IN MYELOMA
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Background: Multiple myeloma (MM) is still incurable with progressive bone
loss. The development of novel therapeutic options yielding better survival out-
comes with bone restoration is urgently needed. We have reported that Pim-2
is overexpressed in MM cells and their surrounding cells, namely bone marrow
stromal cells (BMSCs) and osteoclasts, in bone lesions, and that treatment
with Pim inhibitors markedly suppressed MM tumor growth while preventing
bone destruction in MM-bearing animal models, indicating Pim-2 as an impor-
tant therapeutic target in MM (Leukemia 2011, 2015). We recently found TGF-
β-activated kinase-1 (TAK-1) as an upstream mediator responsible for Pim-2
up-regulation.
Aims: We therefore aimed to clarify the role of TAK-1 in tumor growth and
bone destruction in MM and therapeutic impact of TAK-1 inhibition.
Methods: TAK-1 and Pim-2 expression and TAK-1 phosphorylation was ana-
lyzed by Western blotting. Osteoclastogenic activity was analyzed by TRAP
staining as well as resorptive pit formation. Osteoblastogenesis was estimated
with mineralized nodule formation by MC3T3-E1 preosteoblastic cells. The
TAK-1 inhibitor LLZ1640-2 and TAK-1 siRNA were used to block TAK-1 activa-
tion and reduce TAK-1 expression, respectively. To create MM animal models,
murine 5TGM1 MM cells were inoculated into the tibia in SCID mice.
Results: TAK-1 was constitutively over-expressed and phosphorylated in MM
cells while only marginally in normal peripheral blood mononuclear cells. The
TAK-1 inhibitor LLZ1640-2 dose-dependently suppressed cell growth, and
induced caspase-dependent apoptosis in MM cells. Although TNF-α and IL-6
upregulated Pim-2 expression in MM cells, LLZ1640-2 abolished TNF-α-
induced NF-κB, p38MAPK and ERK activation and IL-6-induced STAT3 acti-
vation in MM cells, leading to Pim-2 suppression. The TAK-1 inhibition also
reduced the transcription factor Sp1 expression upregulated in MM cells.
Because Sp1 induces the expression of various factors responsible for MM
cell growth and survival, Sp1 reduction by the TAK-1 inhibition appears to cause
efficaciously suppression of MM cell survival. LLZ1640-2 as well as TAK-1
knock-down decreased VCAM-1 expression and IL-6 production in BMSCs,
and MM cell adhesion to BMSCs to impair BMSC support of MM cell growth.
Interestingly, phosphorylation of TAK-1 was induced in BMSCs and MC3T3-
E1 preosteoblastic cells by addition of cytokines known as inhibitors of
osteoblastogenesis in MM, including IL-3, IL-7, TNF-α, TGF-β and activinA, as
well as MM cell conditioned media (MMCM), suggesting TAK-1 as a common
mediator to suppress osteoblastogenesis in MM. Furthermore, LLZ1640-2 abol-
ished up-regulation of Pim-2, an inhibitory mediator of osteoblastogenesis, in
BMSCs and MC3T3-E1 cells by MMCM to restore mineralized nodule forma-
tion. Moreover, the TAK-1 inhibition up-regulated in MC3T3-E1 cells phospho-
rylation of Smad1/5 and p38MAPK by BMP-2 while suppressing Smad2/3 phos-
phorylation by TGF-β suggesting potentiation of BMP-2-mediated anabolic sig-
naling. TAK-1 was also up-regulated in osteoclastic lineage cells along with
osteoclastogenesis. Treatment with LLZ1640-2 suppressed the induction of c-
fos and NFATc1 in RAW264.7 preosteoclastic cells as well as their osteoclas-
togenesis by RANK ligand. Finally, treatment with LLZ1640-2 potently sup-
pressed MM growth in murine MM models.
Summary/Conclusions: TAK1 plays a pivotal role in MM tumor growth and
bone destruction in MM. TAK1 may become an efficacious therapeutic target
in MM to suppress tumor burden while restoring bone.
Myeloproliferative neoplasms - Clinical 2
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LONG-TERM OUTCOMES OF RUXOLITINIB (RUX) THERAPY IN PATIENTS
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Background: The JAK1/JAK2 inhibitor RUX has demonstrated rapid and
durable improvements in splenomegaly and symptoms and improved survival
in the two phase 3 COMFORT studies in pts with MF.
Aims: To report final long-term efficacy and safety results after 5 years (y) of
RUX treatment in COMFORT-I.
Methods: In COMFORT-I, 309 pts were randomized (1:1) to RUX or placebo
(PBO). RUX starting dose was based on baseline platelet count (100–200×109/L:
15 mg BID; >200×109/L: 20 mg BID). Pts receiving PBO could crossover to RUX
after the primary analysis (when all pts completed week [wk] 24 and half com-
pleted wk 36) or at any time if they had prespecified worsening of splenomegaly.
The primary endpoint was the proportion of pts achieving ≥35% reduction in
spleen volume (SV) at wk 24. Overall survival (OS) was estimated by Kaplan-
Meier analysis according to randomized treatment (intent-to-treat analysis).
Results: Median follow-up was 268 wk at the time of this analysis. Of 155 pts
randomized to RUX, 43 were still on treatment at the time of study termination.
Of 154 pts randomized to PBO, 111 crossed over to RUX; median time to
crossover was 41.1 wk; 28 were still on treatment at the time of study termina-
tion. At wk 24, pts originally randomized to RUX had a mean SV reduction from
baseline of 31.6%; this response was durable for pts who continued on RUX
with a mean SV reduction of 37.6% at wk 264. At wk 264, 18.5% of pts ran-
domized to RUX had a ≥35% reduction from baseline in spleen volume. Median
duration of spleen response (≥35% SV reduction) was 168.3 wk for RUX
(range, 107.7–NE; n=92 pts). OS favored RUX (HR=0.69; 95% CI: 0.50, 0.96;
P=0.025), with 69 and 82 deaths among pts originally randomized to RUX and
PBO, respectively. Median OS has not been reached for pts in the RUX group.
Median OS was approximately 108 wk for pts randomized to PBO censored at
crossover, and approximately 200 wk for PBO pts. Mean platelet count and
hemoglobin (Hgb) initially decreased through 3 mo. Mean Hgb gradually
increased toward baseline. After wk 24, mean Hgb and platelet count generally
remain stable through 5 y. New onset grade 3 or 4 anemia was 25.2% for the
RUX arm and 26.1% for PBO crossover; grade 3 or 4 thrombocytopenia
occurred in 12.3% and 13.5% of pts, respectively. Notable AEs included herpes
zoster (10.3% and 13.5% of RUX and PBO crossover pts, respectively); basal
cell carcinoma (7.7% and 9.0%, respectively); acute myeloid leukemia (5 pts
in each arm). The rate of leukemic transformation was 0.01 per pt-year for pts
randomized to RUX and 0.02 per pt-year for the PBO crossover pts (Figure 1).
Figure 1.
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Summary/Conclusions: After a median follow-up of 268 wk, the hazard ratio
for OS favored pts randomized to RUX over those randomized to PBO, and SV
reductions were sustained with long-term therapy. Collectively, these data sup-
port the durable efficacy and long-term safety of RUX in pts with MF.
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Background: Polycythemia vera (PV) and essential thrombocythemia (ET)
are myeloproliferative neoplasms (MPN) associated with driving mutations in
JAK2, CALR or MPL genes that can evolve into acute myeloid leukemia (AML).
Older age, abnormal cytogenetics and sequential exposure to cytoreductive
agents have been associated with higher risk of AML. 
Aims: To analyze the influence of the genotype on the risk of myeloid transfor-
mation in patients with PV and ET. In addition, the somatic mutational profile in
paired samples from the chronic and the leukemic phases was studied.
Methods: A total of 1095 patients (PV n=371, ET n=724) were included. The
risk of myeloid transformation according to age, sex, type of disease (PV or
ET), leukocyte count at diagnosis, cytogenetics, cytoreductive treatment, and
genotype (JAK2, CALR, MPL, and triple negative) was evaluated by Cox regres-
sion. Next generation sequencing (NGS) analysis of 66 AML-related genes
was performed in paired samples from the chronic and leukemic phases, when-
ever possible. Supported by grants from the Instituto de Salud Carlos III, Span-
ish Health Ministry: PI13/00557, PI1300393 and PI1300636. 
Results: Median age at MPN diagnosis was 63 years (females: 59%). An
abnormal karyotype was documented in 30 (2.7%) out of 583 evaluable
patients. Genotype was available in 806 patients: 92.5% of PV patients were
JAK2-mutated, whereas 64%, 18%, 3%, and 15% of ET patients were JAK2+,
CALR+, MPL+ or triple negative, respectively. Hydroxyurea plus P32, busulphan
or melphalan was administered in 10% of patients. With a median follow-up of
8 years, 35 cases of AML and 5 cases of myelodysplastic syndrome (MDS)
were diagnosed, resulting in a 10-year probability of myeloid transformation of
3.9%. There were no significant differences in transformation rate according to
MPN type (10-year probability of 4.7% and 3.5% for PV and ET, respectively,
p=0.8). In multivariate analysis, an increased risk of AML/MDS transformation
was observed for patients older than 60 years (HR: 4.3, 95%CI: 1.6-11.6,
p=0.004), with leukocytes >10x109/L (HR: 2.2, 95%CI: 1.01-4.7, p=0.048) and
those treated with hydroxyurea plus leukemogenic agents (HR: 2.5, 95%CI:
1.2-5.4, p=0.02). An abnormal karyotype was associated with an increased risk
of transformation in PV (HR: 5.1, 95%CI: 1.2-22.1, p=0.03) but not in ET. In ET
patients, the 10-year probability of AML/MDS according to genotype was 25%
for MPL+, 6.6% for triple negative, 4.6% for JAK2V617F+, and 0% for CALR+
(p=0.007). When the genotype was included in the multivariate model, the MPL
mutation was an independent risk factor for higher risk of AML/MDS (HR: 6.1,
95%CI: 1.2-30.2, p=0.028), whereas JAK2V617F, CALR or triple negative geno-
types lacked prognostic significance. NGS was performed in 24 post-MPN
AML/MDS samples. Somatic mutations in genes other than JAK2, CALR or
MPL were seen in 20 (83%) patients. Five (21%) patients have one, 7 (29%)
two, 3 (12.5%) three and 5 (21%) four or more additional mutations. Mutational
frequencies were: TP53 42%, TET2 21%, RUNX1 21%, DNMT3A 17%, IDH1/2
17%, SRSF2 12%, ASXL1 12%, SETBP1 8%, SH2B3 8%, and <5% for SF3B1,
NRAS, KRAS, NOTCH1, PTPN11, CBL, NPM and FLT3. At time of submission,
NGS molecular studies were performed in 10 paired samples at PV/ET diag-
nosis and AML/MDS transformation being 52% of the mutations present in both
samples.
Summary/Conclusions: MPL genotype is associated with higher risk of
AML/MDS transformation. Somatic mutations in genes other than JAK2, CALR
or MPL are frequently observed at time of transformation, with 50% of them
being already present at ET/PV diagnosis. TP53 is the gene most frequently
mutated at time of transformation. 
S454
RUXOLITINIB (RUX) REDUCES JAK2V617F ALLELE BURDEN (AB) IN
PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) ENROLLED IN THE
RESPONSE STUDY
AM Vannucchi1,*, S Verstovsek2, P Guglielmelli1, M Griesshammer3, TC Burn4,
A Naim4, D Paranagama4, M Marker5, E Tiecke5, B Gadbaw5, JJ Kiladjian6
1CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms,
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Center, Houston, TX, United States, 3Johannes Wesling Clinic, Minden, Ger-
many, 4Incyte Corporation, Wilmington, DE, 5Novartis Pharmaceuticals Cor-
poration, East Hanover, NJ, United States, 6Hôpital Saint-Louis, Paris, France
Background: The JAK2V617F mutation leads to constitutive activation of
downstream JAK/STAT signaling in pts with PV. In the phase 3 RESPONSE
study evaluating Rux (an oral JAK1/JAK2 inhibitor) vs best available therapy
(BAT) in pts with PV who had an inadequate response to or unacceptable side
effects from hydroxyurea, Rux was superior to BAT in controlling hematocrit,
reducing spleen volume, and improving symptoms. Rux also decreased
JAK2V617F AB steadily over time up to Week 112.
Aims: This follow-up exploratory analysis of the RESPONSE study evaluated
the effect of long-term Rux treatment on JAK2V617F AB in pts with PV.
Methods: 211 pts with the JAK2V617F mutation at Baseline were evaluable
for this analysis. AB was defined as the percent of mutant allele relative to total
(wild-type and mutant). Changes from Baseline in JAK2V617F AB among Rux-
randomized pts and those who crossed over from BAT to Rux were reported
up to Week 208. Baseline AB for the crossover cohort was defined as last
observation before receiving Rux. Complete and partial molecular remission
(CMR, PMR) were defined using the IWG-MRT/ELN consensus criteria. An
exploratory analysis was performed to identify any potential relationship
between reductions in AB and spleen volume.
Results: Pts randomized to Rux (n=104) experienced consistent AB reduction
(mean percent change from Baseline, –12.2%, –18.3%, –22.0%, –30.0%,
–38.1%, –34.9%, and –40.0% at Weeks 32, 56, 80, 112, 144, 176, and 208,
respectively). On average, BAT-randomized pts did not experience AB improve-
ments at Week 32 (mean percent change from Baseline, 1.2%); those who
crossed over to Rux (n=80) had markedly reduced AB over time (–6.3%, –6.7%,
–10.4%, –15.7%, –17.8%, and –13.0% at 32, 56, 80, 112, 144, and 176 weeks
after crossover, respectively). Mean baseline AB for pts who did and did not
have prior interferon (IFN) therapy was as follows: Rux: IFN=72.1%, no
IFN=74.5%; BAT: IFN=88.2%, no IFN=72.0%. All BAT pts who received IFN
(n=13) at randomization crossed over to Rux; mean maximal AB reduction in
evaluable BAT pts receiving IFN was –6.6% before crossover and –25.6% after
crossover. The average maximal percent reductions in AB (median time to max-
imal reduction) in Rux-randomized and Rux crossover arms were –35.9% (25.9
mo) and –21.2% (18.2 mo), respectively (Figure 1). Among evaluable pts, 2/102
(2.0%) Rux-randomized pts achieved CMR at Weeks 143 and 144 vs 1/94
(1.1%) Rux crossover pts at Week 123. Pts who achieved PMR included 33/101
(32.7%) evaluable Rux-randomized pts and 20/92 (21.7%) evaluable Rux
crossover pts, after median times of 112 and 92 weeks, respectively. Seven pts
had ≥90% AB reduction from Baseline (Rux-randomized, n=6; Rux crossover,
n=1). Based on tertiles of maximal AB reduction for the Rux-randomized arm,
there was no relationship between mean maximal change in AB (tertile 1,
–72.2%; tertile 2, –29.1%; tertile 3, –5.7%) and mean PV duration (mo) from
diagnosis (tertile 1, 81.6; tertile 2, 126.2; tertile 3, 105.2). No linear relationship
was observed at last visit between percent change in AB from Baseline and cor-
responding clinical outcomes in terms of spleen volume reduction.
Figure 1.
Summary/Conclusions: Rux treatment (randomized and post-crossover)
reduced JAK2V617F AB in RESPONSE study pts after up to 4 years of treat-
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ment. Some pts may experience molecular responses with Rux treatment
regardless of initiation timing during the disease course or previous IFN treat-
ment. No clear relationship between AB reduction and spleen volume reduction
was observed.
S455
HSC GENETIC HETEROGENEITY DETERMINES CLONAL DYNAMICS IN
PMF
I Triviai1,*, S Zeschke1, V Panagiota2, M Heuser2, C Stocking1, N Kroeger1
1KMT, UKE, Hamburg, 2Hematology, Hemostasis, Oncology and SCT, MHH,
Hannover, Germany
Background: Primary Myelofibrosis (PMF) is a myeloproliferative neoplasm
of stem cell origin, characterized by sequential distinctive waves of aberrant
myeloid differentiation. Atypical erythroid-megakaryocytic progenitors expand
at the initial stages of PMF and perish in the course of PMF development and/or
the expansion of pre-leukemic clones. The continuum of clonal dynamics dom-
inating the chronic phase disease, as exhibited in the variability of divergent
myeloid progeny in PMF progression, reflects the molecular heterogeneity of
malignant HSCs that sustain fluctuations in clone propagation. 
Aims: In our previous work, we described a CD133+ stem cell population cir-
culating in PMF patient peripheral blood, which exhibits multi-lineage differen-
tiation capacity in vivo and in vitro and induces the PMF phenotype in the first
xenotransplantation model of PMF. Single cell analysis of CD133+ patient-
derived HSCs revealed multi-clonal lineage restricted differentiation potential
of the stem cell pool in PMF. The correlation of the molecular burden of indi-
vidual stem cells with their differentiation potential sheds light on the order of
genetic lesions orchestrating the sequence of impaired stem cell function.
Methods: CD133+ HSCs from 100 PMF patients were molecularly character-
ized by whole exon sequencing. Sorted HSC cells were functionally analyzed
at a single cell level for variable myeloid colony formation. 2230 colonies were
phenotypically characterized and isolated. Analysis of the PMF HSC clonogenic
potential indicates that the presence of mutations in the epigenetic regulator
EZH2 correlates with granulo/monocytic differentiation but limited erythroid
colony formation potential (0-0,05%), as determined in three different patient
samples (2 JAK2-V617F+, 1 CALR-fs*+). Transplantation of these patient sam-
ples gave the highest engraftment in our mouse model and in one case,
EZH2muJAK2wt leukemic transformation. 
Results: CD133+ HSC-derived single colony analysis indicated 8 different
genotypic clones of HSC, which exhibit variable granulo/monocytic differenti-
ation capacity in vitro. From a total of 569 formed colonies, 538 were CFU-
GM,-G,-M and 31 BFU-E. PCR analysis of colonies for JAK2-V617F and
Sanger sequencing for EZH2-D265H and EZH2-Y733C mutations indicates
that the presence of JAK2-V617F in hetero- or homozygosity can occur in the
EZH2-D265H background without influencing the granulo/monocytic commit-
ment of these mutated HSCs. Interestingly, the limited BFU-Es that arose con-
tained only single JAK2-V617F mutations in the same patient. Moreover, the
presence of single EZH2-D265H heterozygous clones, single JAK2-V617F
hetero- or homozygous clones, as well as double mutated clones indicate two
independent mutational events affecting the same locus and nucleotide have
occurred in this patient. In view of the overall high frequency of JAK2-V617F
mutations, we predict that the EZH2 mutation was the first mutation in double
mutant clones in this patient. The presence of homozygous EZH2-Y733C muta-
tions in other patients was detected irrespectively of JAK2-V617F mutation
and is correlated with granulocytic-monocytic committed progenitors.
Summary/Conclusions: Our results indicate that mutations in epigenetic reg-
ulators precede the expanding mutations of the chronic phase PMF (JAK2,
CALR). Thus, they confer the genomic instability connected with subsequent
emergence of following mutations and they shape the genomic landscape sup-
porting the expansion of pre-leukemic clones. 
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Background: Recurrent somatic mutations of Calreticulin (CALR) have been
identified in patients harboring myeloproliferative neoplasms; however, their
role in tumorigenesis remains to be elucidated. 
Aims: We aim to elucidate the oncogenic property of mutant CALR and molec-
ular mechanism of its action. 
Methods: To examine whether mutant CALR exhibits oncogenic properties,
its capacity to induce factor-independent growth was examined in a human
megakaryocytic cell line UT-7/TPO that proliferates only in the presence of
thrombopoietin (TPO). The genetic and biochemical interactions between
mutant CALR and TPO receptor c-MPL were examined using a loss-of-function
assay with shRNA and a co-immunoprecipitation assay, respectively. The func-
tional and structural differences between mutant and wild-type CALR were
examined using a domain analysis of CALRs for the c-MPL interaction. Mutant-
CALR activation of c-MPL was determined by examining the phosphorylation
status of c-MPL-downstream molecules using an immunoblot analysis. To
demonstrate this activation process in more physiological circumstances, a
loss-of-function assay for c-MPL was performed in iPS-derived hematopoietic
stem cells that harbor the CALR mutation and exhibit TPO-independent
megakaryopoiesis. 
Results: We found that the expression of mutant, but not wild-type, CALR
induced TPO-independent growth of UT-7/TPO cells. We demonstrated that
c-MPL was required for this cytokine-independent growth. Mutant CALR pref-
erentially associated with c-MPL that is bound to JAK2 over the wild-type pro-
tein. Furthermore, we demonstrated that the mutant-specific C-terminus portion
of CALR interfered with the P-domain of CALR to allow the N-domain to interact
with c-MPL; thus, providing an explanation for the gain-of-function property of
mutant CALR. We showed that mutant CALR induced the phosphorylation of
JAK2 and its downstream signaling molecules in UT-7/TPO cells and that this
induction was blocked when the cells were treated with a JAK2 inhibitor. Finally,
we demonstrated that c-MPL is required for TPO-independent megakary-
opoiesis in iPS-derived hematopoietic stem cells harboring the CALR mutation. 
Summary/Conclusions: These findings imply that mutant CALR activated the
JAK2 downstream pathway via its association with c-MPL. Considering these
results, we propose that mutant CALR promotes the development of myelo-
proliferative neoplasms by activating c-MPL and its downstream pathway. 
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NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1
EPIGENETIC SILENCING IN A AML MOUSE MODEL
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B Del Papa1, D Cecchini1, O Bereshchenko2, T Haferlach3, MP Martelli1,
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Background: Mutations in NPM1 and FLT3-ITD are frequently associated in
human AML and were also reported to induce leukemia in mice. However, the
molecular consequences of this oncogenic cooperation in the development of
AML still remain elusive. 
Aims: We generated an NPM1/Flt3-ITD AML mouse model to address the fol-
lowing issues: i) to characterize the cellular origin of leukemia; ii) to identify the
epigenetic/transcriptional signature in AML pathogenesis; iii) to analyze AML
therapeutic response in vivo; and iv) to validate mouse data in human AML.
Methods: We crossed our NPM1 mutant and Flt3-ITD mice and used: 1) FACS
analysis to study the HSC/progenitor cell compartments in bone marrow (BM);
2) real-time PCR and Western blot analysis to measure GATA1 mRNA and protein
expression; 3) bisulfite conversion followed by DNA sequencing to study methy-
lation; 4) 5-Aza-dC and the FLT3 inhibitor AC220 for treatment experiments.
Results: NPM1/Flt3-ITD double mutated mice progressed to AML recapitulating
features of the human disease. The AML phenotype was preceded by a
preleukemic stage of variable length that inversely correlated with the burden of
the mutant alleles. Pre-leukemic mice displayed leukocytosis (WBC
20.8±18x109/L) and macrocytosis (MCV 58.74±5.6 fl). In NPM1/Flt3-ITD mice,
FACS analysis revealed expansion of multipotent and granulocyte-macrophage
progenitor compartments. Conversely, long-term hematopoietic stem cells and
immature megakaryocytic/erythroid compartments were significantly reduced
as compared to other genotypes combinations. Strikingly, we found that the key
regulator of normal myelo-erythroid differentiation GATA1 was transcriptionally
silenced in NPM1/Flt3-ITD mice. Similarly, AML patients with NPM1/FLT3-ITD
mutations displayed a significantly lower mean GATA1 expression compared to
patients with a different genotype (0.42±0.09 vs 5.3±1.3 respectively, p<0.05).
Genomic bisulfite sequencing of the GATA1 promoter revealed more than
80%±0.12 methylated CpGs in BM cells from double mutated mice as compared
to only 53%±0.22 methylation in other genotypes, thus clearly implicating epi-
genetic changes as the cause of GATA1 transcriptional silencing. In vivo treat-
ment of leukemic mice with the DNA methyltransferase inhibitor 5-aza-deoxy-
cytidine (5-Aza-dC) reactivated GATA1 expression determining the normalization
of leukocytosis and preventing a drop in platelets counts. Strikingly, real-time
PCR analysis revealed a significant 3.45±1.01 upregulation of GATA1 mRNA
levels in BM samples from NPM1/FLT3-ITD mutant AML patients that underwent
5-Aza-dC treatment (p<0.001). Finally, we assessed the sensitivity of NPM1/Flt3-
ITD mice AML to targeted FLT3 inhibition. In vitro treatment with the FLT3 inhibitor
AC220 significantly reduced the viability of BM cells isolated from NPM1/Flt3-
ITD preleukemic or leukemic mice. In vivo, AC220 induced a reduction of WBC
counts accompanied by a partial GATA1 re-expression in peripheral blood cells
without improving mice survival. In a xenotransplant model of human
NPM1/FLT3-ITD AML, the FLT3 inhibitor induced significant reduction in size of
subcutaneous AML tumors with GATA1 upregulation.
Summary/Conclusions: We demonstrated that epigentic modification abro-
gated a GATA1-dependent transcriptional program and represented a prereq-
uisite for NPM1/Flt3-ITD leukemogenesis. Mouse data are further supported
by low GATA1 expression found in human AML samples and in vivo treatments
rescues. Therefore, GATA1 represents a target for new tailored therapies in
AML with NPM1 and FLT3-ITD mutations. 
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FLT3-D835Y AND NPM1C ONCOGENES COOPERATE TO INDUCE AN
AGGRESSIVE MPN IN MICE
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Background: Activating mutations in FLT3 and NPM1 are most common alter-
ations in AML and frequently coincidental. The exon 12 mutation of Npm1
(NPM1c) leads to a mislocalization of the protein from the nucleus to the cyto-
plasm. Two types of mutations are present in FLT3: Tandem duplication of the
juxtamembraneous domain (ITD) and point mutations of the tyrosine kinase
domain (TKD). In murine models, both NPM1c and FLT3-ITD induce an MPN,
while FLT3-TKD leads to a lymphoid disorder. Co-expression of NPM1c and
FLT3-ITD rapidly induces an AML in mice.
Aims: In the present study, we investigated the impact of co-expression of
NPM1c with the TKD mutation FLT3-D835Y in a mouse model.
Methods: For this purpose a heterozygous conditional Npm1c knockin mouse
model was used where Npm1c can be induced via the Mx1Cre-system. Donor
bone marrow was harvested from these mice and cells were retrovirally infected
with the MiG-Flt3-D835Y vector. Infected bone marrow cells were injected into
lethally irradiated C57Bl/6 wt recipient mice. The Npm1c expression was induced
by p(I:C) injection post transplantation resulting in the activation of IFN-α and
thereby Cre recombinase induction under the control of the Mx1 promotor. Control
mice received no p(I:C) injection. Lymphatic/Leukemic organs of moribund mice
were analyzed for lineage-specific cell surface markers by flow cytometry.
Results: Strikingly, Npm1c Flt3-D835Y mice rapidly developed a myeloprolif-
erative neoplasia and succumbed after a median latency of 33 days. In contrast,
Flt3-D835Y Npm wt control mice did not develop a leukemic disease. Detailed
analysis Npm1c Flt3-D835Y mice revealed a high leukemic burden in the
peripheral blood as well as in the bone marrow and a pronounced
splenomegaly. Flow cytometry analysis revealed a myeloid phenotype in the
peripheral blood, spleen and bone marrow of moribund mice, characterized by
a high frequency of FLT3-D835Y+/CD11b+and Gr1+ cells, whereas Flt3-D835Y
control mice showed a normal immune phenotype. Interestingly, immunoblot
analysis of spleen extracts from moribund mice indicated that Flt3-D835Y in
combination with NPM1c induces STAT5 but not STAT3 signaling. These results
suggest that the MPN induction in this model might be due to STAT5 activation.
Previously, it has been shown that the myeloid leukemia of Npm1c Flt3-ITD
mice is retransplantable. To discover whether the myeloid phenotype of NPM1c
Flt3-D835Y mice is retransplantable as well, 1x105 and 1x106 spleen cells of
an Npm1 Flt3-D835Y mouse were injected into sublethally irradiated C57Bl/6
wt recipient mice. Indeed, we were able to show retranplantability of Npm1c
Flt3-TKD disease in the group transplanted with high cell numbers, whereas
the retranplantability was not only partial inducible (15-30% of the mice) in the
group transplanted with lower spleen cell numbers (1x105).
Summary/Conclusions: In summary, our data show that co-expression of
NPM1c and FLT3-D835Y results in the development of a rapidly fatal MPN
whereas FLT3-D835Y-expression alone is not sufficient to cause a myelopro-
liferative disease in C57Bl/6 mice. Moreover, the myeloid phenotype is retrans-
plantable with 1x106 donor spleen cells in C57Bl/6 mice. Interestingly, myelo-
proliferative disease induction might be due to aberrant STAT5 activation by
FLT3-D835Y in the background of NPM1c mutant.
S459
THE RET RECEPTOR TYROSINE KINASE PROMOTES ACUTE MYELOID
LEUKEMIA THROUGH PROTECTION OF FLT3-ITD MUTANTS FROM
AUTOPHAGIC DEGRADATION
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Stem Cell Technology and Experimental Medicine and Division of Stem Cells
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Background: Acute myeloid leukemia (AML) is a heterogeneous disease with
diverse leukemogenic driver lesions. The genetic understanding of AML has
resulted in major improvements in diagnosis, classification, prognostication,
and outcome prediction. However, these insights have not yet translated into
molecular mechanism-based therapies in the majority of cases, because AML
cells are able to rapidly escape attempts at therapeutic targeting such as small-
molecule inhibition of FLT3 internal tandem duplication (ITD) mutants, which
occur in up to 30% of cases and confer a poor prognosis.
Aims: Given the propensity of AML to develop resistance to single-agent small-
molecule therapy, we aimed to identify potential new targets for combinatorial
treatment approaches.
Methods: We performed a series of large-scale RNA interference screens,
using a subgenomic short hairpin RNA (shRNA) library targeting kinases, phos-
phatases, and known cancer-related genes, in a panel of AML cell lines.
Results: We identified that the RET receptor tyrosine kinase (RTK), which has
not previously been implicated in AML pathogenesis, is critical for the viability
and proliferation of cell lines representing various AML subtypes. Validation
experiments demonstrated that depletion of RET by shRNA knockdown or
CRISPR/Cas9-mediated knockout leads to cell cycle arrest in the G0/G1 phase,
increased apoptosis, and reduced clonogenic activity. Moreover, transcriptome
analysis identified elevated RET mRNA levels in 35 of 260 (13.5%) primary
human AML samples. RTK profiling using ELISA-based antibody arrays demon-
strated that RET is highly phosphorylated in RET-dependent AML cell lines.
Analysis of known RET ligand/co-receptor pairs (GDNF/GFRA1, NRTN/GFRA2,
ARTN/GFRA3, PSPN/GFRA4) by quantitative real-time PCR and shRNA knock-
down suggested that RET signaling is facilitated mainly through NRTN/GFRA2
or ARTN/GFRA3. Interrogation of various signaling pathways known to promote
myeloid leukemogenesis showed that RET knockdown resulted in decreased
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phosphorylation of p70S6K (Ser371), S6RP (Ser240/244), and ULK1 (Ser758),
pointing to mTORC1-mediated protein synthesis and/or suppression of
autophagy as important effects of RET signaling in AML cells. Based on recent
data showing that FLT3-ITD mutants can be autophagically degraded (Larrue
et al. Blood 2016), we reasoned that the RET-mTORC1 signaling axis promotes
AML through protection of FLT3-ITD mutants from autophagic degradation. Con-
sistent with this hypothesis, RET knockdown or pharmacologic RET inhibition
with vandetanib and danusertib predominantly affected FLT3-dependent AML
cell lines and were accompanied by upregulation of autophagy and destabiliza-
tion of FLT3, as evidenced by p62 degradation, increased numbers of autophag-
ic vacuoles, and decreased FLT3 protein levels. Finally, we are currently inves-
tigating whether Ret is required for AML development and propagation in vivo
using a murine bone marrow transplantation model.
Summary/Conclusions: Combined, our results indicate that in a proportion
of AML, RET-mTORC1 signaling promotes cell viability and proliferation through
suppression of autophagy, suggesting that targeting RET or, more broadly,
depletion of critical leukemogenic drivers via induction of autophagy may pro-
vide a therapeutic opportunity in this subset of patients.
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A NOVEL EPIGENETIC RESISTANCE MECHANISM TO THE FLT3
INHIBITOR PKC412 INDUCES CROSS-RESISTANCE TO STANDARD
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Background: In acute myeloid leukemia (AML) about 20-30% of patients pos-
sess a FLT3-internal tandem duplication (ITD) associated with a poor prognosis
and a higher propensity for relapse after remission. Tyrosine kinase inhibitors
(TKI) such as PKC412 have been developed for therapy of FLT3-ITD-positive
AMLs. So far, resistance to tyrosine kinase inhibitors has been demonstrated
to occur by point mutations in FLT3 whereas further mechanisms that render
leukemic cells drug resistant remain incompletely understood.
Aims: We utilized a PKC412-resistant model of FLT3-ITD-positive MV4-11
cells to (1) identify novel mechanisms of drug resistance, (2) to analyze cross
resistance to the standard chemotherapeutics cytarabine and daunorubicin
and translate our findings to FLT3-ITD-negative AMLs and (3) to develop strate-
gies to reverse chemoresistance in AML.
Methods: Drug resistance mechanisms were analyzed in vitro by immunohis-
tochemistry, Western blot, shRNA-mediated mRNA knockdown, lentiviral over-
expression, immunoprecipitation, label-free- and SILAC (Stable isotope labeling
by amino acids in cell culture)- mass spectrometry, ChIP-seq and ex-vivo- culture
of patient samples. For in vivo analysis xenograft mouse models were applied. 
Results: We identified loss of the histone methyltransferase EZH2 with sub-
sequent reduction of histone H3K27 trimethylation in PKC412- resistant MV4-
11 cells which led to cross-resistance to cytarabine and daunorubicin. In AML
patients, the absence of EZH2 protein expression was closely associated with
poor overall survival (p=0.008), poor event-free (p=0.005) and poor relapse-
free survival (p=0.047) as analyzed by tissue microarrays. The reduction of
EZH2 protein levels via treatment with H3K27 methyltransferase inhibitors or
lentiviral knockdown was sufficient to induce chemoresistance of Normal Kary-
otype (NK)- AML blasts and cell lines in vitro and in a xenograft mouse model.
The loss of EZH2 in drug resistant MV4-11 cells was regulated by posttransla-
tional mechanisms. Immunoprecipitation of EZH2 revealed a 2.6-fold increased
phosphorylation of residue T487 in resistant cells (p=0.014) and the cyclin-
dependent kinase 1 (CDK1) was associated with EZH2 specifically in resistant
MV4-11. Several ubiquitin-E3-ligases such as TRIM21 were increasingly bound
to EZH2 in resistant compared to sensitive cells resulting in a strong ubiquiti-
nation of EZH2 and subsequent degradation. Pharmacological inhibition of
CDK1 and treatment with the proteasome inhibitor bortezomib, respectively,
increased EZH2 protein and restored drug sensitivity in resistant cells. Func-
tionally, reduction of EZH2 directly induced upregulation of HOX genes and
the drug transporter MRP1, suggesting a stem-cell-like signature to be asso-
ciated with the resistance phenotype, which could be reverted by proteasome
inhibitors. In primary AML samples sensitivity to cytarabine was specifically
increased in samples with elevated EZH2 protein levels upon bortezomib expo-
sure whereas no change was observed in patient samples without EZH2
increase upon bortezomib treatment (p=0.0079, Fisher´s exact test).
Summary/Conclusions: In summary, our findings identify a novel epigenetic
resistance mechanism that can be induced by prolonged exposure to PKC412
or cytotoxic drugs. EZH2 protein restoration by proteasome inhibitors in com-
bination with established therapy approaches may be a promising therapy con-
cept to restore drug sensitivity in AML.
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DAMAGING CHEMOTHERAPY IN LEUKEMIA 
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Background: Relapsed leukemia has a poor survival, which can be attributed
to the relative chemotherapy resistance of this disease entity. While the conse-
quences of chemotherapy resistance are clear, the genetic alterations underlying
resistance remain poorly understood. We recently identified somatic mutations
that are specifically enriched in relapsed leukemia, including a novel loss of func-
tion mutation in the epigenetic regulator SETD2. SETD2 is the only known mam-
malian Histone 3 Lysine (H3K36) trimethyltransferase and its role in DNA mis-
match repair was recently established. In view of the presence of SETD2 muta-
tions in relapsed leukemia, and the role of SETD2 in DNA repair, we hypothesized
that SETD2 plays a role in chemotherapy resistance in relapsed leukemia. 
Aims: To investigate the role of SETD2 loss of function mutations in chemother-
apy resistance and identify therapeutic targets for SETD2 mutant leukemia. 
Methods: We employed two different models to study the role of SETD2 in
chemotherapy resistance, which include an isogenic human leukemia model
engineered with CRISPR-Cas9 and a murine leukemia with Setd2 conditional
knockout and retroviral expression of MLL-AF9. We studied the presence and
mechanism of chemotherapy resistance in both models.
Results: We demonstrate that loss of function SETD2 mutations cause resist-
ance to chemotherapy. The resistance is specific to DNA damaging chemother-
apies, including the commonly used agents 6-thioguanine and cytarabine. In
contrast, no resistance to the non-DNA damaging agent L-asparaginase was
observed. In addition to causing an increase in IC50 values, loss of SETD2
results in a strong competitive advantage in the presence of DNA damaging
agents, mimicking the selective pressure of SETD2 mutant clones during treat-
ment in patients (Figure 1). We further establish that the resistance is caused
by an abrogated DNA damage response as demonstrated by a decreased
phosphorylation of CHK1 and CHK2 and a reduced apoptotic response after
treatment with DNA damaging therapies. In our conditional knockout model,
we show that, in addition to causing a significant acceleration of leukemia,
SETD2 loss causes resistance to cytarabine and doxorubicin treatment in vivo.
Finally, we show that WEE1 inhibition specifically targets SETD2 mutant cells
and re-sensitizes to chemotherapy, hereby providing a treatment option for
SETD2 mutant, chemotherapy resistant leukemia.
Figure 1.
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Summary/Conclusions: While relapsed leukemia is known to be chemother-
apy resistant, the mechanisms of resistance remain poorly understood. This
study is the first to show that loss of function SETD2 mutations confer
chemotherapy resistance in leukemia. In addition, we show that treatment with
a WEE1 inhibitor – which is currently in clinical trials - is able to specifically
target SETD2 mutant leukemia and reverse chemotherapy resistance. Hence,
this study supports a prominent role for loss of function SETD2 mutations in
disease progression and chemotherapy resistance in leukemia, as well as pro-
viding evidence for a potential therapy to treat SETD2 mutant, chemotherapy
resistant leukemia. 
Red blood cells and iron - Clinical
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RESULTS OF TRANSCRANIAL DOPPLER ULTRASOUND SCREENING
FROM THE POST-STOP STUDY
J Kanter1,*, J Kwiatkowski2, J Voeks3, H Fullerton4, E Debenham3, R Adams3
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Background: The Stroke Prevention Trial in Sickle Cell Anemia (STOP) and
Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) estab-
lished that routine transcranial Doppler ultrasound (TCD) screening could iden-
tify children with sickle cell disease (SCD) at high risk of stroke. Furthermore,
these studies demonstrated that patients with abnormal TCD require indefinite
chronic red cell transfusions (CRCT) as standard of care. Thus, annual TCD
screening is recommended from ages 2 to 16 years, with more frequent mon-
itoring if the result is abnormal. Patients with abnormally high TCD who were
started on CRCT had reductions in ischemic strokes compared to patients not
receiving transfusions as shown in several clinical series and analyses utilizing
large hospital databases when comparing rates before and after the publication
of the STOP study in 1998. 
Aims: This study sought to evaluate the outcomes of patients identified with abnor-
mal TCD who had previously participated in the STOP and/or STOP 2 trials.
Methods: Between 1995 and 2005, STOP and STOP 2 (STOP/2) were con-
ducted at 26 sites in the US and Canada. These studies included 3,835 children,
ages 2 to 16 y with SCD type SS or S-beta-0-thalassemia. Participation in
STOP/2 ranged from a single screening TCD to randomization. STOP 2 also
had an observational arm for children on CRCT for abnormal TCD who’s TCD
had not reverted to normal. The Post-STOP study was designed to follow-up
the outcomes of children who participated in one or both trials. 19 of the 26
original study sites participated in Post-STOP, contributing a total of 3,539 (92%)
of the STOP/2 subjects. After exit from STOP/2, these children received TCD
screening and CRCT (or other treatment) according to local practices. Data
abstractors visited each clinical site and obtained retrospective data from
STOP/2 study exit to 2012-2014 (depending on site) including follow-up TCD
and brain imaging results, clinical information, and laboratory results. Two vas-
cular neurologists, blinded to STOP/2 status and prior TCD and neuroimaging
results, reviewed source records to confirm all ischemic and hemorrhagic
strokes, discordant opinions were resolved through discussion. 
Results: The two (STOP and STOP-2) study databases contained unique
records for 3854 children at 26 sites. Nineteen of those original sites participated
in post stop accounting for 3539 subjects (92%). Of these 3539, records of
care at enrolling states were located for 2851 subjects (81% of possible). The
mean age at the start of Post-STOP was 10.5 y and mean duration of follow-
up after exiting STOP/2 was 9.1 y. During the STOP or STOP2 period, 333
(11.7%) patients had an abnormal TCD and 12 patients suffered acute stroke
(included the post-STOP encounters). During the Post-STOP period, an addi-
tional 122 (4.34%) of children where identified with abnormal TCD. Of these
patients identified with abnormal TCD in the Post-STOP period, 25 (20%)
patients suffered an ischemic event only 15 (60%) of which were receiving
appropriate CRCT prevention. An additional 7 patients (5.7%) identified with
abnormal TCD suffered a hemorrhagic event, only 1 of whom was on CRCT
therapy (4 patients were on HU and 2 patients had unknown treatment). The
remaining 90 (74%) patients with abnormal TCD had no reported negative neu-
rologic outcomes despite variations in compliance with CRCT during the post-
stop period (or were lost to follow-up). 
Summary/Conclusions: The Post-STOP study included 81% of the original
STOP and STOP-2 patients. In total, 455 of those patients (16%) were iden-
tified with an abnormal TCD. While many of these patients were continued on
CRCT, many individuals were treated with Hydroxyurea, had no preventative
therapy or were lost to follow-up. Future prospective trials are needed to better
evaluate which patients identified at high risk for stroke by TCD do not require
lifetime CRCT. 
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DOPPLER ULTRASOUND RELIABLY IDENTIFIES SICKLE CELL DISEASE
ADULT PATIENTS WITH INTRACRANIAL VASCULOPATHY
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Background: Stroke is one of the leading causes of death in both children and
adults with sickle-cell disease (SCD) most often related to a specific large-vessel
vasculopathy. Prevention of stroke is based on blood exchange transfusion if
stenosant vasculopathy is confirmed. However magnetic resonance angiography
or angio scanner are not easily available in many AFrican countries instead of
Doppler ultrasound which is the main diagnosis strategy in SCD children. Doppler
ultrasound has never been demontrated to be effecient in SCD adults. 
Aims: The objective of this study was to assess whether Doppler ultrasound
is sensitive and specific to identify SCD adult patients with vasculopathy, com-
pared with magnetic resonance angiography.
Methods: 80 adult SCD patients likely to have brain attempt were referred to
our center for vasculopathy screening. 77 patients could benefit from our pro-
tocol including both a 3T brain MR imaging with a 3D time-of-flight MR angiog-
raphy and a Doppler-Ultrasound examination performed on the same day. 3
patients presented contraindication to MRI.
On MR imaging, patients were categorized according to the grade of the highest
stenosis and to the presence of Moya-Moya. On EchoDoppler-Utrasound
examination, time-averaged mean of the maximum velocity (TAMMx) was
measured and a TAMMx ratio was established using the highest TAMMx value
recorded on one axis, divided by the TAMMx value of the ipsilateral extracranial
internal carotid artery. Presence of Moya-Moya was also recorded.
Results: Among the 38 patients with an intracranial vasculopathy (stenosis
>=50% on MR imaging, presence of an occlusion or Moya-Moya), 33 had a
severe vasculopathy according to EchoDoppler criteria defined as a TAMMx
ratio >=3 (n=5) or presenting an occlusion (n=11) or a Moya-Moya (n=17). Sen-
sitivity and specificity of EchoDoppler to identify patients with >=50% vascu-
lopathy on MRA is respectively of 87%, 90%. Positive and negative predictive
values are respectively of 86% and 87%.
Summary/Conclusions: Doppler ultrasound may be used to identify SCD
adult patients with vasculopathy. 
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CHILDREN WITH SICKLE CELL ANEMIA ON CHRONIC TRANSFUSION
FOR ABNORMAL TRANSCRANIAL DOPPLER VELOCITIES. PATIENT/
SIBLING COMPARISON OF COGNITIVE PERFORMANCES AND
ASSOCIATION WITH NEUROIMAGING DATA
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Background: Patients with sickle cell anemia (SCA) are known to have cog-
nitive deficiency. However, only a comparison with non-SCA siblings allows
true appreciation of the disease impact.
Aims: The aims of the present study were to compare the cognitive perform-
ances of SCA-children on long-term transfusion programs due to a history of
abnormal transcranial Doppler (TCD) velocities with those of their siblings, and
to assess the relation to neuroimaging data.
Methods: Drepagreffe is a French national multicenter prospective trial (AP-
HP, NCT 01340404) involving SCA-children, younger than 15 years of age,
placed on chronic transfusion for abnormal-TCD (TAMMX ≥200 cm/sec), and
comparing the outcome of cerebral vasculopathy following transfusions or
hematopoietic stem cell transplant. We present here, the results of cognitive
testings done at enrollment in SCA-children and non-SCA siblings, and patient
neuroimaging data. The MRI scoring was: 3=territorial, 2=borderzone (cortical
and subcortical), 1=white matter or basal ganglia infarcts, 0 to 3=atrophia, and
MRA scoring was: 1=mild stenosis (25-49%), 2=moderate stenosis (50-74%),
3=severe stenosis (75-99%), 4=occlusion for each artery and 0 to 2 for Moya
presence. Cognitive testing, performed in patients and in siblings when possi-
ble, included WPPSI-3 (3-6 yr), WISC-4 (7-16 yr) or WAIS-3 (>16 yr) scales,
depending on the subject age.
Results: Sixty-seven SCA-children (36F/31M) were included. Seven had a his-
tory of overt stroke. At abnormal-TCD detection and chronic transfusion initiation,
the mean age (SD) was 5.5yr (2.5) and velocities≥200/cm/sec were found in
right/left middle (n=29/22), anterior (n=7/5), internal carotid (n=10/7) and
extracranial internal carotid (n=7/7) arteries, as abnormal velocities were
observed in more than one artery in several patients. At enrollment, following a
mean duration of chronic transfusion of 2.8 years, the mean age was 8.1yr (3.1),
and mean(SD) maximum velocities had significantly decreased from 219 (26)
to 169 (46) cm/s (p<0.001). MRI/MRA data were available in 66/67 patients.
Ischemic lesions were present in 25 patients and 18 of them had silent lesions.
Stenoses were present in 35/66 patients in right/left middle (n=7/10), anterior
(n=11/16), internal carotid (n=7/12) and extracranial internal carotid (n=11/12)
arteries, as stenoses were observed in more than one artery in several patients.
Cognitive testing was obtained in 64/67 patients (parental refusal for 3 patients),
and in 56 siblings (8 were too young for testing). Paired analysis with siblings
showed significant differences in Verbal Comprehension Index (VCI) with a
mean difference of 7.6±14.5 (p<0.001), Processing Speed Index (PSI) 6.3±20.5
(p=0.04), and Full Scale IQ (FSIQ) 7.3±15.0 (p=0.001). Patient cognitive per-
formance indexes were correlated negatively and significantly with the MRI and
MRA scores. After exclusion of the 7 patients with stroke history, significant dif-
ferences were still observed in VCI (p=0.013) and FSIQ (p=0.019), but were
not correlated with the presence of silent cerebral infarcts. 
Summary/Conclusions: SCA-children on transfusions for history of abnormal
cerebral velocities had significantly lower cognitive performances than their
siblings, even in the absence of stroke history. In the no-stroke patients, the
differences observed with their siblings were not correlated with the presence
of silent cerebral infarcts. These data suggest that stroke and silent infarcts
are not the only underlying cause of cognitive deficiency in SCA children. 
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Background: A clinical trial was initiated in April 2015 at Scientific Institute
San Raffaele to evaluate safety and efficacy of autologous hematopoietic stem
cells (HSCs) genetically modified with the GLOBE lentiviral vector for the treat-
ment of transfusion dependent beta thalassemia (TIGET-BTHAL; EudraCT
number 2014-004860-39).
Aims: The financial sponsor is the Italian charity organization Fondazione
Telethon. The manufacture is MolMed S.p.A. The therapeutic potential of
GLOBE was validated in thalassemic mice (Miccio et al., PNAS 2008; Miccio
et al. PlosONE, 2011) and human thalassemic cells (Roselli et al., EMBO
MolMed 2010) showing persistent transgene expression and disease correc-
tion. Preclinical GLP studies included a toxicology and tumorigenicity study in
th3/+ mice and a biodistribution study of human of CD34+ cells in NSG mice
demonstrating safety of the approach.
Methods: The clinical protocol will treat 3 adults followed by 7 minors, with a
staggered enrolment strategy based on evaluation of safety and preliminary
efficacy in adult patients by an independent data safety monitoring board before
inclusion of pediatric subjects. Inclusion criteria: transfusion dependent beta
thalassemia, age 3-65 years, adequate cardiac, renal, hepatic and pulmonary
functions, absence of severe liver or cardiac iron overload, absence of severe
liver fibrosis or cirrhosis. Exclusion criteria include active hepatitis, HIV infection
or a previous allogeneic BMT and for pediatric patients availability of a well
matched donor. The HSC source is mobilized peripheral blood stem cells
(PBSCs) obtained after administration of lenograstim and plerixafor. PBSCs
are transduced after apheresis and kept frozen in 10%DMSO until administra-
tion to the patient. Conditioning: treosulfan and thiotepa for adult and elderly
children (≥8years), busulfan for younger children (age 3-7yrs old). The chosen
route of administration of thawed and washed gene modified cells is
intraosseous in the posterior-superior iliac crests, bilaterally. The aim of
intraosseous infusion is to enhance engraftment and minimize first-pass intra-
venous filter. Autologous lymphocytes (previously cryopreserved from aphere-
sis or phlebotomy) are re-infused at a target dose of 5x10^7 CD3+ cells/kg on
day+3 to speed adaptive immune recovery.
Results: Between May and October 2015 three patients were included. As of
March 2016, one patient is 6 months post gene therapy, one 1.5 months and
one has completed mobilization. Age at enrollment: 31, 35, 35 years. Stem
cell harvest was 30x106 CD34+/kg, 21.3x106 CD34+/kg and 23.5x106
CD34+/kg, respectively. Cell dose of gene modified cells of the 2 treated
patients: 19.4x106 CD34+/kg and 18.4x106 CD34+/kg. Adverse events record-
ed as of March 2016 were mild, reversible and related to the conditioning reg-
imen and transplant procedure. The first patient had a neutrophil engraftment
(>500 ANC/µl) on day+21 and platelet engraftment (>20.000/µl unsupported)
on day+16. The second patient had a neutrophil engraftment on +25 and
platelet engraftment on +21. The first patient treated showed multilineage
engraftment of gene corrected cells with higher levels in erythroid lineage and
received the last red blood cell transfusion 2 months after gene therapy. At 6
months follow up the patient was transfusion-free and conducting a normal
working activity with a haemoglobin of 9.2 g/dL.
Summary/Conclusions: In conclusion, preliminary data on adult patients
showed a good yield of PBSCs, a high number of cells infused, good tolerability
of the procedure overall with reversible adverse events and preliminary positive
efficacy data.
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EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, ON ANEMIA
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Background: Pyruvate kinase (PK) deficiency is a congenital hemolytic ane-
mia caused by deficiency of the glycolytic enzyme red cell PK (PK-R), required
for maintenance of adenosine triphosphate (ATP) in red blood cells. AG-348
is an orally-available, small molecule, allosteric activator of PK-R that activates
wild-type and a range of mutated PK-R enzymes in vitro and increases PK-R
activity and restores ATP levels in red blood cells from patients with PK defi-
ciency ex vivo.
Aims: To describe early data from the ongoing DRIVE PK study
(NCT02476916), an open-label, dose-ranging trial of AG-348 in transfusion-
independent adults with PK deficiency.
Methods: After providing informed consent, patients are randomized to AG-
348 50 mg or 300 mg orally twice daily (BID) for 6 months. Transfusion inde-
pendence is defined as no more than 3 units of red blood cells transfused in
the 12 months preceding first dose and no transfusions in the 4 months pre-
ceding first dose. Patients are followed weekly for Weeks 1–3, then every 3
weeks until Week 12, and then monthly until Week 24. Hormone and iron status
are evaluated at Baseline, Week 12 and End of Study.
Results: As of 15 Jan 2016, 10 patients have received treatment for between
1 and 24 weeks. Adverse events (AEs) have been mild-to-moderate, with nau-
sea (CTCAE Grade 1–2) the most commonly reported AE: 2 out of 5 (40%)
patients in the 50 mg BID arm and 3 out of 5 (60%) patients in the 300 mg BID
arm. No serious AEs have been reported. There have been no dose modifica-
tions for AEs. A single patient has had dose modifications for an increase in
hemoglobin (Hb) above the protocol mandated maximum. Dosing was tem-
porarily interrupted and reduced twice (100 mg BID, then 50 mg BID) and the
patient has since been maintained on 50 mg BID for several weeks. Pharma-
cokinetic data showed exposure in line with expectations from earlier healthy
volunteer studies with AG-348 for both doses. At data cutoff, pharmacodynamic
analysis of 2,3-diphosphoglycerate (2,3-DPG) and ATP was available for 5
patients. Baseline 2,3-DPG levels were elevated in 4 of 5 patients, as expected.
All patients with a Hb response of ≥1.5 g/dL also showed a substantial decrease
in 2,3-DPG levels. Further data are being collected to evaluate relationships
between hematological parameters and pharmacodynamic markers (2,3-DPG
and ATP). Genotype–response relationships are also being assessed.
Summary/Conclusions: Early clinical data from DRIVE-PK indicate that AG-
348 is well tolerated. Data on all patients (n~15–20), including safety, hemato-
logical responses, pharmacodynamic effects and genotype–response relation-
ships will be presented.
Bleeding disorders
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Background: Gene therapy for haemophilia B offers the potential to convert
the disease severity from severe to a mild phenotype through continuous
endogenous production of FIX. Adeno-associated viral (AAV) vectors of
serotypes 2 and 8 (AAV2 and AAV8) containing the human factor IX (hFIX)
gene have been used in previous clinical trials.1-3 A single infusion with AAV8
vector resulted in dose dependent FIX expression for up to 4 years.4 AMT-060
(AAV5-hFIX) consists of an AAV5 vector with an LP1 liver specific promotor,
containing a codon-optimised wild type hFIX gene. A potential advantage of
AAV5 is the lower prevalence of neutralising antibodies compared to other
serotypes.
Aims: This study aims to investigate the safety and efficacy of AMT-060 in
adult patients with severe or moderately severe haemophilia B. 
Methods: This is an open-label, single dose escalating study in patients with
FIX activity ≤1-2% of normal, and a severe bleeding phenotype. Five patients
were enrolled in the first cohort of AMT-060 5×1012 gc/kg and a subsequent 5
patients will be enrolled in the second cohort of 2×1013 gc/kg. Patients receive
AMT-060 via IV infusion over 30 minutes in an in-hospital setting. Safety assess-
ments include treatment related adverse events (AEs) and serious AEs (SAEs).
Efficacy assessments include FIX activity, rFIX usage and annualized bleeding
rates. We report here preliminary results of the 5 patients treated in the first
dose cohort. All patients gave informed consent.
Results: The age of the patients ranged from 35 to 72 years. None of the
patients had pre-existing AAV5 antibodies. Four patients had documented FIX
activity of <1% and one patient had 1.5%. Four patients had documented
haemophiliac arthropathy. All patients were receiving rFIX prophylaxis weekly
or twice-weekly prior to treatment with AMT-060. As expected, all 5 patients
developed anti-AAV5 antibodies in response to study drug. None of the patients
have developed inhibitory antibodies against FIX. Two SAEs have occurred.
One patient had an asymptomatic, mild, transient elevation of ALT (peak level
at week 10, 61 IU/L; upper limit of normal, 40 IU/L) that resolved after rapid
institution of a tapering regimen of prednisolone. Another patient had a self-
resolving febrile episode within the first 24 hours of AMT-060 administration.
During the first 12 weeks post-gene therapy, 4 out of the 5 patients achieved
FIX activity levels that allowed them to discontinue rFIX prophylaxis. FIX activity
and other efficacy outcome measures for a minimum of 30 weeks follow-up of
the 5 patients in the first dose cohort will be presented.
Summary/Conclusions: Treatment of haemophilia B with a single infusion of
AMT-060 was well tolerated, and clinically relevant FIX activity has been achieved
in the first dose cohort, relieving 4 out of 5 patients from rFIX prophylaxis. The
study will continue with enrolment of the second dose cohort as planned.
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RESPONSIVENESS OF HEMOPHILIA B-CAUSING NONSENSE MUTATIONS
TO RIBOSOME READTHROUGH-INDUCING DRUGS STRICTLY DEPENDS
ON THE NUCLEOTIDE AND PROTEIN CONTEXT
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Background: Nonsense mutations, caused by premature termination codons,
are relatively frequent in Haemophilia (>10%) and are considered as “null muta-
tions”. However, they have been found also in moderate/mild Haemophiliacs
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and, as compared with large gene deletions, are associated with lower risk for
developing inhibitors. This observation point to the presence of residual expres-
sion levels arising from “ribosome readthrough” over nonsense triplets, whose
sequence context has an impact on readthrough efficiency, as we have shown
in a very small cohort of Haemophilia B (HB) patients. Drugs inducing
readthrough such as aminoglycosides are proposed as potential therapy.
Aims: To investigate residual secreted and functional levels of factor IX (FIX)
produced by an extended panel of HB nonsense mutations.
Methods: Recombinant FIX (rFIX) nonsense variants were expressed in
HEK293 cells, and secreted and intracellular protein levels, as well as protein
isoforms, were evaluated by ELISA and Western Blotting analysis. Residual
activity was assessed by coagulant assays.
Results: We investigated a panel of F9 mutations (R75X, L103X, R162X,
W240X, R294X, R298X, Y330X, Q370X, R379X, R384X), associated to
severe/moderate HB, representing the vast majority of patients with nonsense
mutations in HB (324 patients out of 467, corresponding to ~70%). Appreciable
levels of secreted FIX were detected for the R162X, W240X, R294X, R298X,
Y330X mutants, with truncated isoforms being the large predominance. Trun-
cated forms for Q370X, R379X and R384X were observed in cell lysates only,
which suggests misfolding and intracellular retention. Noticeably, the full-length
FIX form was appreciable for the R162X variant, indicating the occurrence of
spontaneous readthrough, which was significantly increased by the use of
aminoglycosides. Moreover, aminoglycosides promoted the synthesis of full-
length FIX in the presence of the R75X, Y330X, Q370X, R379X, R384X muta-
tions, not undergoing appreciable spontaneous readthrough. Intriguingly, we
investigated the peculiar W240X nonsense mutation, caused by two different
termination codons, which showed a differential impact of readthrough in restor-
ing the full-length protein depending on the sequence context. Preliminary
coagulant and functional assays revealed that only a few variants were prone
to undergo efficient readthrough in terms of secretion and coagulant function.
Summary/Conclusions: These data demonstrate that nonsense mutations
can be associated to residual FIX levels through a mechanism of “productive”
readthrough. The identification of “leaky” nonsense mutations, and thus of
patients with trace FIX levels and potentially “high responders” to readthrough-
inducing drugs, might help diagnosis and treatment.
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A FUSION PROTEIN OF INTERLEUKIN-4 AND INTERLEUKIN-10
PROTECTS AGAINST BLOOD-INDUCED CARTILAGE DAMAGE IN VITRO
AND IN VIVO
L van Vulpen1,2,*, R Schutgens2, K Coeleveld1, C Steen-Louws3, C Hack3,
J Popov-Celeketic1, S Mastbergen1, F Lafeber1
1Rheumatology & Clinical Immunology, 2Van Creveldkliniek, 3Laboratory for
Translational Immunology (LTI), University Medical Center, Utrecht, Netherlands
Background: Joint damage upon bleeding causes significant morbidity in
patients with hemophilia, and adds to joint degeneration after trauma and major
joint surgery. Interleukin (IL)-4 and IL-10 have been demonstrated to protect
cartilage from blood-induced damage independently. Recently a novel fusion
protein of both cytokines, IL4-10 synerkine, has been developed.
Aims: To evaluate whether IL4-10 synerkine protects against blood-induced
joint damage similarly as the combination of the individual components, both
in vitro as well as in vivo.
Figure 1. Concentration dependent effect of the IL4-10 synerkine.
Methods: In vitro, human cartilage explants were exposed to 50% v/v whole
blood for 4 days and simultaneously to a broad concentration range (0-
100ng/mL) of the IL4-10 synerkine. Effects of 10 ng/mL IL4-10 synerkine were
compared to the same concentrations of the individual cytokines and the com-
bination. Cartilage matrix proteoglycan turnover (proteoglycan synthesis,
release, and content) was assessed after a recovery period of 12 days. More-
over, the influence of IL4-10 synerkine and its individual components on levels
of IL-1β and IL-6 were investigated in a 4 days 50% v/v whole blood culture.
In hemophilia A mice, a joint bleed was introduced on day 0 and 14. Mice were
randomized between intra-articular treatment with synerkine (7pmol), IL-4&IL-
10 (both 7pmol) or PBS on day 0, 2,14 and 16. After 5 weeks, joint damage
was evaluated by the Valentino score for synovitis (hematoxylin and eosin-
stained sections) and the modified OARSI score for cartilage damage (Safranin
O-stained sections).
Results: In vitro, the synerkine prevented blood-induced cartilage damage in a
dose-dependent manner up to normalization already at a concentration of 1
ng/mL (see Figure 1). At 10ng/mL, the synerkine was equally effective as the
combination of the separate cytokines. IL-1β and IL-6 release in whole blood
cultures was suppressed. In vivo, treatment with the synerkine attenuated carti-
lage damage upon joint bleeding (difference between experimental and con-
tralateral joint in synerkine group p=0.201; IL-4&IL-10 p=0.008; PBS p=0.001).
In all groups, synovial inflammation was statistically significantly increased in the
experimental paw, none of the treatments affected this (p<0.005 in all groups).
Summary/Conclusions: The IL4-10 synerkine fully prevented blood-induced
cartilage damage in a human cartilage tissue in vitro model and ameliorated car-
tilage degeneration upon a repeated joint bleed in haemophilic mice when inject-
ed intra-articularly. These data support the need for further investigation of the
potency of the IL4-10 synerkine in the treatment of blood-induced arthropathy.
S470
FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN SEVERE
HEMOPHILIC ANKLE ARTHROPATHY
L Van Vulpen1,*, HC Vogely2, G Roosendaal1, P de Kleijn1, P van Roermund2,
R Schutgens1, S Mastbergen3, F Lafeber3
1Van Creveldkliniek, 2Orthopaedic Surgery, 3Rheumatology & Clinical Immunol-
ogy, University Medical Center, Utrecht, Netherlands
Background: The ankle joint is the most affected joint in youngsters with hemo-
philia. Joint distraction, an effective treatment in ankle osteoarthritis, has the
advantage of preservation of the original joint without compromising subse-
quent conservative surgeries like arthrodesis, if still needed. In three cases
evaluated in retrospect, good clinical and structural efficacy in hemophilic ankle
arthropathy was demonstrated.
Aims: The aim of the current study is to prospectively investigate the clinical
effectiveness of ankle joint distraction in hemophilia.
Methods: Hemophilia patients (n=10; ≥18 and <55 years) were eligible in case
of severe complaints of arthropathy in the tibiotalar joint causing functional lim-
itations, despite analgesics and conservative treatment. Ankle joint distraction
using an Ilizarov external fixator was performed during 10 weeks. Clinical effec-
tiveness was evaluated using standard questionnaires and physical examina-
tion. Functional tests, X-ray and MRI examination were performed at baseline
and 1-year follow-up.
Results: At the moment, a 12 months follow-up is available in 4 patients,
three severe hemophilia A patients and one severe hemophilia B patient.
Age at time of surgery ranged from 21 to 33 years. During distraction, none
of the patients experienced bleeding. Pin tract infection, commonly seen with
external frame use, occurred in 3 patients, and was treated effectively with
oral antibiotics.
Pain (visual analogue scale) decreased from 67 (47-79)mm at inclusion to 27
(7-84)mm at 6 months and 15 (1-43)mm at 12 months follow-up. Functional
limitations, measured by the Haemophilia Activities List and the Ankle
Osteoarthritis Scale, improved in three patients at 6 months, and in all four
patients at 12 months. Functional tests improved considerably in all patients at
1-year follow up (e.g. 6-minutes walking test increased from 497 (434-560) to
621 (560-688) meters). Range of motion of the ankle was slightly decreased
after 6 months due to stiffness of the ankle, but regained at 12 months in all
patients. MRI revealed a decrease in volume of subchondral cysts and bone
edema in all patients, and slight improvement of the joint space width in two
patients (see Figure 1).
Figure 1. Structural improvement after ankle distraction on MRI.
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Summary/Conclusions: This first prospective study investigating the efficacy
of joint distraction in haemophilic ankle arthropathy, showed clear clinical and
structural improvement in all patients at 1 yr follow-up. Although preliminary,
these data indicate that joint distraction may be a promising treatment post-
poning more rigorous surgery like ankle arthrodesis in those patients not ben-
efitting from conservative therapy.
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THALIDOMIDE FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA:
EFFICACY AND SAFETY OF LONG-TERM TREATMENT
R Invernizzi*, F Quaglia, C Klersy, F Pagella, F Chu, E Matti, G Spinozzi,
C Olivieri, R Bastia, C Danesino, M Benazzo, CL Balduini
IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Background: Hereditary hemorrhagic telangiectasia (HHT) is a genetic disease
that leads to multiregional angiodysplasia. Severe recurrent epistaxis is the
most common presentation often leading to severe anemia. In a previous open
label, phase 2, non-randomized, single-centre study, we have shown that low-
dose thalidomide (Thal) was safe and effective in reducing epistaxis in HHT
patients, providing a rapid, long-lasting clinical improvement without serious
adverse events (Lancet Haematol 2015; e465-73). However, the effect of Thal
was not permanent. After the end of therapy, most patients relapsed at various
time points.
Aims: To assess the effects of Thal on the severity of epistaxis in subjects with
HHT who relapse after a first successful treatment with the drug; to evaluate
safety and tolerability. The main purpose of our study is to obtain clinical data
useful for the identification of a regimen for long-term prevention of HHT epis-
taxis by Thal.
Methods: Our study is the extension of a previous clinical trial (THALI-HHT,
EudratCT 2011-004096-36, ClinicalTrials.gov Identifier: NCT01485224). HHT
patients, successfully treated with Thal according to this protocol, may receive
again Thal providing that eligibility criteria are still met and they relapsed at
least 4 weeks after the end of previous therapy. Twenty-nine patients are poten-
tially recruitable. Thal is given orally for 8 weeks at the same dosage that
induced remission (50 or 100 mg/day, off label use). Thal courses may be
repeated at most 3 times; in case of relapse occurring within 4 weeks from the
end of a previous treatment course, Thal is permanently discontinued. Monthly
follow-up evaluates the epistaxis severity according to well defined criteria (Am
J Rhinol Allergy 2009;23:52-58) and the transfusion need, with adverse events
being reported.
Results: Fourteen HHT patients for whom informed consent was obtained, 9
M and 5 F, aged 48-84 years (median 64), with mutations in either ACVRL1 (12
cases) or ENG gene (2 cases) who relapsed at 10-68 weeks (median 32) after
the end of Thal induction therapy, have been retreated so far, 9 patients with
50 mg/day of Thal and 5 patients with 100 mg/day. Eight-week courses of Thal
were effective in 13 (93%) patients with a significant reduction of nose bleeding
and a concomitant increase of hemoglobin levels and decrease of the transfu-
sion need. At a median follow-up of 81 weeks (range 39-117) after the end of
the first course of retreatment, 3 (22%) patients maintained a response, where-
as 10 (71%) relapsed again (median relapse-free survival 28 weeks). Eight
patients were successfully retreated with a second 8-week course of Thal and
5 patients, who relapsed again, with an additional third course. Median relapse-
free survival was 28 weeks after the end of the second course and 24 weeks
after the end of the third course. Only nonserious, grade 1, drug-related adverse
effects, including constipation, drowsiness, and peripheral edema were
observed during Thal courses.
Summary/Conclusions: These preliminary results strongly support the hypoth-
esis that repeated administrations of Thal maintain their efficacy and can be
used for long-term treatment of HHT epistaxis. Recruiting a suitable group of
patients and following them carefully is expected to confirm this suggestion
and contribute to identifying maintenance treatment schedules that permanently
reduce epistaxis.
Supported by Telethon Grant GGP13036.
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DYSREGULATED MIR34A/DIACYLGLYCEROL KINASE Ζ INTERACTION
ENHANCES T-CELL ACTIVATION IN ACQUIRED APLASTIC ANEMIA
Y Sun*, H Li, Q Feng, Y Yu, X Li, J Peng
Qilu hospital of Shandong University, Jinan, China
Background: As a paradigm of bone marrow failure syndrome, acquired aplas-
tic anemia (AA) was thought to be a specific autoimmune disease for the aber-
rant T-cell immune homeostasis. MicroRNAs (miRNAs) down-regulate gene
expression by binding to target messenger RNAs and play important roles in
various immune processes. We screened for differentially expressed miRNAs
in T-lymphocytes of sever AA (SAA) patients by miRNA genechip assays and
found miR34a overexpressed in SAA. MiR34a has been demonstrated to direct-
ly and functionally target diacylglycerol kinase (DGK) ζ to promote T-cell
response. There was no data referred to the role of miR34a or DGKζ in AA.
Aims: To investigate the role of miR34a and DGKζ in T-cell activation in AA.
Methods: Human bone marrow mononuclear cells (BMMCs) were isolated
from 25 SAA patients, 16 moderate AA (MAA) patients and 20 healthy volun-
teers. Affymetrix miRNA genechip assays on CD3+ T-cells purified from BMMCs
of three SAA patients and three healthy controls were undertaken. Then the
relative expression of miR34a and DGKζ in BMMCs from the 41 AA patients
and 20 healthy controls was quantified by real time polymerase chain reaction.
The BMMCs from AA patients were transfected with miR34a inhibitor sponge
in lentivirus and the level of T-cell activation marker CD69 on the transfected
cells was analyzed by flow cytometry. The lymphocytes isolated from lymph
nodes (LN) of wild-type (WT) and miR34a-knockout (KO) mice were labeled
with CFSE and left unstimulated or stimulated with McAbs to CD3 and CD28.
The cell division and the CD69 and CD25 expression was analyzed by flow
cytometry. A murine model of bone marrow failure was created in which LN
cells from WT or miR34a-KO mice (C57/B6 background) were transferred into
CB6F1 mouse recipients preirradiated with 5 Gy total body irradiation. After
euthanasia on Day 12, CD4+,CD8+ and Lin-Sca1+CD117+CD34-(LSKCD34-)
BM cells were analyzed by flow cytometry.
Results: The microarray analysis demonstrated that miR34a expression
increased 2.1-fold in T-cells from SAA patients compared with that in healthy
controls. The significantly higher expression of miR34a was confirmed by PCR
in BMMCs from the 41 AA patients compared with that from the 20 normal con-
trols. The miR34a expression showed a negative correlation with peripheral
blood neutrophil or reticulocyte counts in AA patients, and was higher in SAA
than in MAA groups. The mRNA level of DGKζ in AA patients was much lower
than that in controls, and was negatively correlated with the level of miR34a.
The protein level of CD69 on T-cells transfected with miR34a inhibitor lentivirus
was lower than that on cells transfected with control lentivirus. In murine models,
upon stimulation with McAbs to CD3 and CD28, the CD4+ and CD8+ LN cells
from miR34a-KO mice expressed much lower levels of CD69 and CD25 than
those from WT mice, and proliferated less vigorously than the cells from WT
mice. Consistently, the DGKζ expression in LN cells from miR34a-KO mice
decreased to a less extent after stimulation than that in cells from WT mice. In
vivo, the mouse recipients transferred with miR34a-KO lymphocytes demon-
strated lower mortality on Day12 after irradiation, fewer CD8+ T-cells in BM and
increased BM LSKCD34- cells compaired to those transferred with WT cells.
Summary/Conclusions: The data demonstrated that miR34a/DGKζ was dys-
regulated in AA, which resulted in enhanced T-cell activation and bone marrow
failure. Our study indicated that miR34a/DGKζ played a critical role in T-cell
immunity in AA and might be a new therapeutic target for AA.
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BONE MARROW FAILURE IN PAROXYSMAL NOCTURNAL HEMOGLOB-
ULINURIA IS ASSOCIATED WITH EXPANSION OF ANTIGEN-SELECTED T
CELLS: HIGH-THROUGHPUT EVIDENCE 
E Stalika1,*, K Gemenetzi1, L Gargiulo2, N Maglaveras1,3, I Chouvarda1,3,
K Stamatopoulos1, A Hadzidimitriou1, A Karadimitris2, M Papaioannou2,4
1Institute of Applied Biosciences, CERTH, Thessaloniki, Greece, 2Centre for
Haematology,Department of Medicine, Hammersmith Hospital, Imperial College
London, London, United Kingdom, 3Laboratory of Medical Informatics, Medical
School, 41st Dept Internal Medicine, Hematology Unit, Medical School, Aristotle
University of Thessaloniki, Thessaloniki, Greece
Background: Paroxysmal nocturnal hemoglubinuria (PNH) is an acquired clon-
al disease of hematopoietic stem cells caused by somatic mutation of the PIG-
A gene that is essential for the biosynthesis of the glycolipid molecule glyco-
sylphosphatidylinositol (GPI). The clinical phenotype of PNH consists of hemol-
ysis, thrombophilia and bone marrow failure (BMF). While hemolysis and throm-
bosis are largely due to deficiency of the GPI-linked complement inhibitors, the
pathogenesis of BMF remains unknown. Previous studies have indicated that
CD1d-restricted, GPI-specific T cells are present in PNH patients and might
underlie BMF. Interestingly, these cells display a heavily biased T cell receptor
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repertoire with enrichment for T cell receptor (TR) α chains encoded by the
TRAV21/TRAJ31-1 genes and frequently carrying a distinctive complementar-
ity-determining region 3 (CDR3: AVNNNARLM) combined by TR β chains
encoded by the TRBV19 gene, often with restricted CDR3 as well, strongly
alluding to selection by common (auto)antigen(s).
Aims: Prompted by these findings, here we sought to obtain more evidence
about the nature of the implicated immune response through detailed analysis
of the repertoire of GPI-specific T cell populations.
Methods: Our study included samples from 11 patients and 9 normal donors.
TRAV21 gene rearrangements were RT-PCR amplified on RNA from T cell
subsets sorted from peripheral blood mononuclear cells on the basis of: (i)
expression of CD48, [positive in GPI+ cells] and vice versa; and, (ii) expression
of TR β chains encoded by the TRBV19 gene versus TRBV19 negative. Both
criteria applied to PNH patients, whereas the sole criterion used for normal
donors was TRBV19 expression. PCR products were sequenced on 454 GS
Junior (Roche) platform. Sequences were submitted to IMGT/HighV-QUEST,
and metadata was processed by an in-house bioinformatics pipeline. Since all
studied rearrangements utilized the same TRAV gene, we defined as clono-
types TRA rearrangements with identical TRA joining (TRAJ) gene usage and
amino acid CDR3 sequence.
Results: Overall, significant differences (p<0.05) were identified in PNH
patients vs normal controls for 13 of 50 functional TRAJ genes, the most pro-
nounced concerning the TRAJ39, TRAJ57 and TRAJ58 genes. Similarly, sig-
nificant differences (p<0.05) emerged when comparing the TRAJ gene reper-
toire between T cell subsets in PNH patients. In particular, (i) the TRAJ15 and
TRAJ4 genes were over-represented amongst CD48+ cells; while the TRAJ24
and TRAJ33 were over-represented amongst CD48- cells, (ii) the “GPI-specific”
CDR3 sequence (AVNNNARLM) was identified with higher frequency in CD48+
versus CD48- cells, however it was also present, with statistically significant
lower frequency (p<0.05) amongst healthy donors ; (iii) the frequency of the
“GPI-specific” CDR3 sequence was identified in GPI- positive up to 73.8% and
in GPI-negative T – cell fractions up to 25.6%. When comparing the CDR3
length in i) patients versus healthy individuals, and ii) GPI-positive versus GPI-
negative T cells, we noted a significant (p<0.05) bias to longer CDR3s in
patients vs healthy donors; and, CD48- vs CD48+ cells. Cluster analysis of the
CDR3 sequences of all PNH cases identified 21 different clonotypes that were
shared by PNH patients but not by healthy individuals.
Summary/Conclusions: The present study documents noteworthy restrictions
in the TR repertoire in PNH, indicative of antigen selection. The existence of
clonotypes shared between different patients suggests that common antigen
driven immune responses may be implicated in the pathogenesis of BMF.
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A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNAI
THERAPEUTIC (ALN-CC5) TARGETING COMPLEMENT C5 FOR
TREATMENT OF PNH AND COMPLEMENT-MEDIATED DISEASES:
INTERIM PHASE 1 STUDY RESULTS
A Hill1,*, A Gava2, J Taubel3, J Bush4, A Borodovsky5, N Kawahata5,
H McLean6, CH Soh5, A Partisano5, B Sorensen5, N Najafian5, A Urbano-Ispizua7
1St James’ Institute of Oncology, Leeds Teaching Hospitals, Leeds, United
Kingdom, 2Hospital Clínic of Barcelona, Barcelona, Spain, 3St George’s Uni-
versity of London, London, 4Covance Clinical Research Unit, Leeds, United
Kingdom, 5Alnylam Pharmaceuticals, Cambridge, United States, 6Alnylam
Pharmaceuticals, Uxbridge, United Kingdom, 7Hospital Clinic Barcelona,
IDIBAPS, Institute of Research Josep Carreras, Barcelona, Spain
Background: Uncontrolled complement activation plays a pivotal role in a vari-
ety of disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atyp-
ical hemolytic-uremic syndrome (aHUS). Despite the availability of eculizumab,
treatment challenges, including heterogeneity in clinical response combined
with inter-individual variation in clearance of eculizumab, remain. ALN-CC5 is
a subcutaneous (SC) investigational RNA interference (RNAi) therapeutic tar-
geting complement C5 (C5). 
Aims: The aim of this abstract is to report safety, pharmacodynamics (PD) and
clinical activity of ALN-CC5 in normal healthy volunteers as well as initial results
in patients with PNH.
Methods: A phase 1/2 single-ascending dose (Part A) and multiple-ascending
dose (Part B) study of ALN-CC5 in healthy adult volunteers and patients with
PNH (Part C) is ongoing. Enrollment of several cohorts of healthy volunteers
in both Part A and Part B has been completed. Part C is a 39-week multiple
dose study in patients with PNH. Primary endpoints are safety and tolerability.
Secondary endpoints include: pharmacokinetics (PK), reduction of circulating
C5 and complement activity as measured by CAP/CCP Wieslab ELISA assays
and sheep erythrocyte hemolysis assay as well as reduction in LDH (in PNH
patients). ALN-CC5 is administered SC at a concentration of 200 mg/mL.
Results: Part A enrolled 32 healthy volunteers who were randomized (1:3) to
placebo or a single SC dose of 50, 200, 400, 600 or 900 mg of ALN-CC5. Part
B enrolled 24 healthy volunteers who were randomized (1:3) to placebo or up
to 13 weekly doses of 100, 200, 400 or 600 mg of ALN-CC5. Among the initial
healthy volunteers enrolled, (Part A: n=20; Part B: n=12) ALN-CC5 was con-
sidered generally well tolerated with no serious adverse events (SAEs), study
discontinuations or clinically significant laboratory findings. Preliminary data
showed C5 knockdown up to 99% with nadir residual C5 values as low as 0.6
mcg/mL; complement activity inhibition (CAP & CCP) up to 97% with mean
max inhibition of 95±1% for CAP and 96±0.9% for CCP and reduction of serum
hemolytic activity up to 98% with mean max inhibition of 84±7.6%, suggesting
potentially clinically meaningful complement inhibition following ALN-CC5
administration. Notably, an up to 97.8% knockdown (KD) of serum C5 at day
98 after a single dose in the top dose cohort and up to 98.3% KD at day 112
after five weekly doses in the 200 mg cohort was maintained. Based on these
initial findings, Part C was initiated. In Part C, patients with PNH receive 200
mg weekly doses of ALN-CC5. Updated safety, pharmacodynamics (PD) and
clinical activity for all study participants, will be presented.
Summary/Conclusions: ALN-CC5 was shown to be generally well tolerated,
with no clinically significant, drug-related adverse events to date in healthy vol-
unteers. The PD effects of ALN-CC5 were found to be durable, with clamped
C5 knockdown and complement activity inhibition supporting a less frequent
as well as SC dose regimen. Collectively, these initial results suggest that the
use of a novel RNAi therapeutic targeting C5 is a promising approach for inhibit-
ing complement in PNH, aHUS and other complement-mediated diseases.
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NEXT GENERATION TARGETED SEQUENCING IMPROVED THE PRECISE
DIAGNOSIS OF PEDIATRIC APLASTIC ANEMIA /INHERITED BONE
MARROW FAILURE SYNDROMES
W An*, Y Guo, Y Chen, Y Zou, X Chen, W Yang, L Chang, Y Wan, X Zhu
Pediatric blood diseases center, Institute of Hematology and Blood Diseases
Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Col-
lege, Tianjin, China
Background: Inherited bone marrow failure syndromes (IBMF) is a group of
diseases with heterogeneous clinical and genetic characteristics and overlap-
ping symptoms. Diagnosis of IBMFS depend on classic clinical manifestation
like early onset, physical anomalies associated, family history of cancer and/or
bone marrow history, and abnormal laboratory test including chromosome
breakage testing (MMC and/or DEB), mutation analyses and bone marrow
chromosome analyses. At present, more than 70 pathogenic gene mutations
had been identified. However, in some patients, physical anomalies is absent
or delayed, and were diagnosed as acquired bone marrow failure. Therefore,
precise genetic analysis is very important for establish a specific diagnosis,
predict cancer risk, direct treatment and genetic counseling.
Aims: In this study, we focus on the application of next generation targeted
sequencing in precise diagnosis of pediatric aplastic anemia (AA)/IBMF, and com-
pared the results with clinical manifestation and chromosome breakage testing.
Methods: We designed a targeted capture next generation sequencing (NGS)
assay to test a panel of 417 blood disease genes. Pediatic patients (≤14 year
old) with suspected diagnosis of AA/IBMF were enrolled. Peripheral blood (PB)
was used to genetic analysis and oral epithelia cells or PB from the parents
were used to identify whether the gene mutations were somatic mutations or
not. The results were validated by Sanger sequencing.
Results: We validated the assay using 30 samples with known mutations. The
mean depth for targeted sequencing was 200×, 93.28% of targeted regions
were covered with >10×.288 patients with pediatric IBMF were enrolled includ-
ing 177 subjects were clinically diagnosed as acquired AA, 49 Fanconi anemia
(FA), 26 DBA, 8 DC, 15 SCN, 4 congenital thrombocytopenia, 1 Shwachman-
Diamond syndrome (SDS). Totally, 66 (23.6%) subjects have IBMF related
genetic mutations. In subjects clinically diagnosed as acquired AA, 17 (9.6%)
subjects have IBMF related gene mutations, including 10 subjects finally genet-
ically diagnosed as FA, 3 DC, 2 Epstein syndromes, 1 Wiskott-Aldrich syndrome
(WAS). In subjects clinically diagnosed as FA, 21 (42.1%) have FANC related
gene mutations and 3 (6.9%) have other IBMF related gene mutations. In sub-
jects clinically diagnosed as DC, 7 (85.7%) have telomere related gene muta-
tions. In subjects clinically diagnosed as DBA, 11(37.9%) have ribosomal pro-
tein related gene mutations and 1 FA. In subjects clinically diagnosed as SCN,
5 (33.3%) have SCN-related gene mutations, 1 DC, 1 FA and 1 WHIM syn-
drome, 1 AKT, 1 GFI1 mutation. In subjects clinically diagnosed as congenital
thrombocytopenia, 1 CAMT. In subjects finally genetically diagnosed as AA,
FA or DC, 4.4%, 18.2% and 9.1% have family history of BMF or malignant
blood diseases respectively, and 3.8%, 9.1%, 0% have family history of solid
tumor respectively. In subjects finally genetically diagnosed as AA, FA or DC,
8.8%, 66.75%, 63.3% have physical anomalies respectively. Compared to sub-
jects with AA, subjects with FA or DC are more likely to have physical anomalies
of short stature and development retardation, Cafe au lait spots of the skin and
finger(toe) malformation (24.2% vs 0%, P=0.000; 21.2% vs 1.2%, P=0.021;
36.4% vs.1.2%, P=0.000). Moreover, 8.1% subjects present physical anomalies
before or at the same time with bone marrow failure. In subjects finally diag-
nosed as FA or DC, only 27% and 14% have positive MMC respectively.
Summary/Conclusions: Compared to traditional diagnostic methods, the tar-
geted NGS analysis is economic, convenient, easy to update and very impor-
tant for differential diagnosis, personal treatment and follow-up and genetic
counselling, especially for make differential diagnosis between acquired and
congenital BMF. Moreover, the targeted NGS can be used to make precise
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diagnosis between IBMFs which have overlapping clinical symptoms. In sub-
jects with IBMF, the positive rate of MMC is low. Therefore, further gene muta-
tion analysis is necessary for highly suspicious subjects with IBMF who have
negative result of MMC.
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THREE CASES OF CYCLIC NEUTROPENIA WITH ACQUIRED CSF3R
MUTATIONS, ONE DEVELOPING AML
C Zeidler1,*, M Klimiankou2, S Mellor-Heineke3, E Reinel2, M Uenalan4,
S Kandabarau3, K Welte5, J Skokowa2
1SCNIR, Medical School Hannover, Hannover, 2Department of Hematology,
Oncology, Immunology, Rheumatology and Pulmonology, University Hosppital
Tuebingen, Tuebingen, 3Medical School Hannover, Hannover, Germany, 4Depart-
ment of Experimental Hematology, Medical School Hannover, Hannover, 5Dept
of Pediatrics, University Hosppital Tuebingen, Tuebingen, Germany
Background: We recently reported a 17-year-old female with cyclic neutrope-
nia (CyN) harboring ELANE mutations presenting with cycling hematopoiesis
involving neutrophils, platelets and reticulocytes who developed AML (FAB M2)
(presented at ASH 2015, Blood 126 (23) abstract 885). At the time of AML diag-
nosis, all CSF3R-expressing BM leukemic blasts were positive for the
p.Gln741X mutation. We tested the patient’s BM MNCs, obtained at the time
of leukemia development, for RUNX1 mutations, finding that the RUNX1 muta-
tion p.Asp171Asn was present at an allele frequency of 10%. So far, CSF3R
mutations have been reported in congenital neutropenia patients (CN) only but
never in patients with CyN.
Aims: Our aim was to determine whether other CyN patients harbor CSF3R
mutations.
Methods: We performed deep sequencing of CSF3R in 19 additional CyN
patients.
Results: Out of these 19 patients we identified two additional patients harboring
acquired CSF3R mutations. One CyN patient aged 15.4 years and her sister
inherited the ELANE mutation from their father. Time-course analysis of the
acquisition of CSF3R mutations in this patient showed that 2.6% of the CSF3R
alleles in BM MNCs were obtained at the age of 13 years possessing the
p.Gln749X mutation. After additional 1.5 and 2.4 years, respectively, the mutant
allele frequency increased to 9% and 8%. A third CyN patient, a 7 year old girl,
harboring spontaneous ELANE mutations and revealing typical cycling of neu-
trophils, platelets, and monocytes was treated with G-CSF at a dose of 4.5
µg/kg/day and recently acquired CSF3R mutation (p.Gln739X) in approx. 30%
of the CSF3R allele. The latter two CyN patients have not yet developed AML
or myelodysplastic syndrome (MDS).
Summary/Conclusions: Taken together, these findings suggest that CyN
patients with typical CyN-associated ELANE mutations may also acquire
CSF3R mutations and are therefore at risk for leukemic development. Long-
term data of the Severe Chronic Neutropenia International Registry (SCNIR)
have shown that the risk of acquisition of CSF3R mutations and of myeloid
transformation is low but not absent in patients with CyN compared to patients
with CN. This new knowledge is important for prognostic counseling and long-
term management of ELANE-CyN patients.
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RANDOMIZED PHASE III STUDY OF EARLY RITUXIMAB INTENSIFICATION
IN COMBINATION WITH CHOP14 FOLLOWED BY RITUXIMAB OR NO
MAINTENANCE IN DIFFUSE LARGE B-CELL LYMPHOMA: A
HOVON-NORDIC LYMPHOMA GROUP STUDY
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Background: Rituximab (R)-CHOP is standard treatment for patients with dif-
fuse large B-cell lymphoma (DLBCL). The optimal R dose and schedule is not
known. In a small series of 20 patients serum levels of R, measured during the
R-CHOP-14 regimen in elderly patients with DLBCL increased slowly up to
cycle 5, reaching plateau thereafter (Reiser M, et al. J Clin Oncol 2006). We
hypothesized that R serum levels might be suboptimal, especially early during
treatment, and that the treatment outcome might improve through intensification
of R during the first 4 cycles. In this study designed for both young and elderly
DLBCL patients we compared standard treatment of R-CHOP-14 with the same
regimen combined with 4 extra R administrations during the first 4 cycles.
Patients in complete remission after induction treatment were randomized for
a second time between observation and R maintenance. Here we report the
efficacy and safety results of the first randomization.
Aims: This phase III, open-label randomized study was designed to detect
superior metabolic complete remission rates of early intensification of R com-
bined with CHOP-14+G-CSF versus no intensification of rituximab in patients
with DLBCL of all age groups.
Methods: Patients with previously untreated DLBCL, CD20 positive, stage II-
IV, ages between 18-80 years, were randomized 1:1 between standard R-
CHOP-14 and an experimental arm with R-CHOP-14 combined with extra R
375 mg/m2 IV on day 8 of the first 4 cycles. Prephase treatment of prednisone
100 mg orally for 5 days was mandatory in elderly patients. All patients received
pegfilgrastim 6 mg sc on day 2. All patients underwent restaging after 4 cycles
of therapy and at the end of induction therapy. Response was evaluated using
PET-CT scans according to the Lugano criteria 2014. A Deauville score of ≤3
was considered as a complete response. The primary endpoint of the first ran-
domization was metabolic complete remission rate after induction treatment.
This trial was registered at www.trialregister.nl as NTR1014. All patients gave
written informed consent.
Results: 575 patients were randomized (standard arm 286 patients, experi-
mental arm 289 patients). Median age was 65 years (range, 18-80), 50% of
patients were 66 years or older and 52% were male. The majority of patients
(57%) had a high-intermediate or high aa-IPI score. Baseline patient and dis-
ease characteristics were well balanced between treatment arms. No significant
difference in CR rate was observed between the two treatment arms, standard
arm 84% CR and experimental arm 82% CR (odds ratio=0.83, 95% CI 0.54-
1.28, p=0.40). The observed CR rates in patients ≤or >65 years were identical.
With a median follow-up of 49 months (maximum 90 months), 3- and 5- year
progression free survival (PFS) were 74% and 68% in the standard arm and
71% and 61% in the experimental arm (hazard ratio=1.23, 95% CI 0.92-1.63,
p=0.16). No significant improvement in PFS was noted in subgroups by age
(≤or >65 years) or gender. The frequencies of hematological and non-hemato-
logical adverse events were similar in both treatment arms.
Summary/Conclusions: In patients with DLBCL treated with R-CHOP-14 rit-
uximab intensification early during treatment did not improve the CR rate or
the 3-year PFS. No clinical subgroup benefited from rituximab intensification in
this study.
S478
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Background: Communicating prognosis in a plain language to patients with
diffuse large B-cell lymphoma (DLBCL) and their relatives can be challenging.
Survival of DLBCL patients relative to a matched background population (MBP)
represents a relevant measure of prognosis.
Aims: The purpose of this study was to investigate the post-treatment survival
of DLBCL patients in CR/CRu relative to an MBP and to examine the duration
of CR/CRu needed to obtain similar survival to the MBP.
Methods: This retrospective study utilized the nationwide Danish Lymphoma
Registry (LYFO). We included patients fulfilling the following criteria: a) newly
diagnosed DLBCL in the period 2003-2011, b) ≥15yrs of age at diagnosis, and
c) achieving CR or CRu after 1st line R-CHOP(-like) therapy. Survival curves
were generated using the Kaplan-Meier method and survival of the MBP was
established from lifetime tables.
Results: In total, 1632 Danish DLBCL patients met the inclusion criteria and
the baseline characteristics were similar to that seen in previous studies. The
median follow-up from diagnosis was 85 months. The 5-year OS of the MBP
was superior to that of the DLBCL patients (88% vs 78%, p<0.001). In analyses
restricted to patients in continuous CR/CRu for >2 and 5 years, the OS of DLB-
CL patients remained inferior to that of an MBP (p<0.001 for 2 years; p<0.001
for 5 years). Age-stratified analyses (<50yrs vs ≥50yrs) showed, the OS of
patients <50yrs became identical to that of an MBP after only two years in con-
tinuous CR/CRu (p=0.90). For DLBCL patients ≥50yrs, however, the OS
remained inferior past 5 years of continuous CR/CRu. The OS of DLBCL
patients ≥50 years were still inferior after censoring patients with relapses
(p<0.001) (Figure 1).
Figure 1.
Summary/Conclusions: The OS of DLBCL patients in CR/CRu after R-
CHOP(-like) therapy was inferior to that of an MBP, but the differences were
gradually reduced for patients with durable remission. Interestingly, the OS of
young DLBCL patients (<50yrs) quickly became identical to that of an MBP.
However this was not the case for patients ≥50yrs, even after excluding those
with relapse. This suggests that the residual life expectancy of this subgroup
of patients may be reduced due to late toxicities or other causes not directly
related to DLBCL.
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A BIOCLINICAL PROGNOSTIC MODEL INCORPORATING MYC AND BCL2
PREDICTS OUTCOME TO SALVAGE THERAPY IN RELAPSED/
REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: AN NCIC CTG LY12
CORRELATIVE SCIENCE STUDY
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Background: Less than 50% of patients (pts) with relapsed/refractory diffuse
large B-cell lymphoma (rrDLBCL) achieve long-term event-free (EFS) and over-
all (OS) survival with salvage therapy. Better predictors of outcome are needed
for these pts.
Aims: To determine clinical and molecular predictors of EFS and OS for rrDL-
BCL pts treated with rituximab (R) and either gemcitabine, dexamethasone,
cisplatin (R-GDP) or dexamethasone, cytarabine, cisplatin (R-DHAP) followed
by autologous stem-cell transplantation (ASCT) on the Canadian Cancer Trials
Group LY12 study.
Methods: In total, 91 pts had DLBCL and sufficient histologic material to create
tissue microarrays and undergo immunohistochemical (IHC) testing for CD10,
BCL6, MUM1, FOXP1, LMO2, BCL2, CMYC, P53, pySTAT3 expression. In
addition, 97 formalin-fixed, paraffin-embedded tissue samples underwent gene
expression profiling (GEP) using NanoString to evaluate Cell of Origin (COO)
by the Lymph2Cx assay, as well as BCL2, MYC, P53, STAT3, PDL1 and PD1
expression. Survival analysis was performed using the Kaplan-Meier method
and Cox regression.
Results: COO was not associated with EFS or OS, according to the Hans
IHC algorithm or the Lymph2Cx assay. Expression of py-STAT3 (≥50%), P53
(≥30%), MYC (≥40%), and BCL2 (≥70%) by IHC was found in 7.6%, 19.8%,
36.3%, 63.7%, of patient samples respectively. Expression of MYC was asso-
ciated with lower 3-year (y) EFS rates (10% versus (vs) 42%, p=0.007) and
OS rates (29% vs 56%, p=0.002) compared to MYC- patients. Similarly, 3y
EFS rates were 25% vs 41% (p=0.029) and OS rates were 37% vs 63%
(p=0.020) for BCL2+ vs BCL2- cases, respectively. The 22 pts with IHC-
based dual expressing (DE) lymphomas (MYC+/BCL+) had significantly
worse 3y EFS (0% vs 40%, p=0.0009) and OS rates (20% vs 54%, p=0.0004)
relative to the 69 pts with without DE phenotype. In addition, p53+ vs p53-
lymphomas had 3y EFS rates of 11% vs 36% (p=0.034). STAT3 was not
associated with EFS or OS. Similar to IHC, both MYC and BCL2 expression
using NanoString GEP (>1.5xmean) were significantly associated with inferior
OS and EFS, and no patient who expressed both markers achieved 2y EFS
or OS. For the 82 lymphomas with samples for both IHC and GEP, a concor-
dance rate of 79% was seen for MYC and 57% for BCL2. Expression of PD1
(p=0.03) but not PDL1 (p=0.41) by GEP was associated with inferior EFS. In
multivariate analyses, 4 factors were adversely associated with EFS and OS:
primary refractory DLBCL, elevated serum LDH at relapse, MYC expression
and BCL2 expression (assessed by either IHC or GEP). Using these 4 fac-
tors, a bio-clinical score predicted EFS and OS from initiation of salvage
chemotherapy. Using IHC to assess MYC and BCL2, 3y EFS was 55% for
34 pts with 0-1 factor vs 16% for 53 patients with 2-4 factors (p<0.0001).
Similarly, using GEP to assess MYC and BCL2, the 3y EFS was 46% for 58
pts with 0-1 factor vs 5% for 39 pts with 2-4 factors (p<0.0001, see Figure 1).
The same 4 factor model predicted EFS for the 54 pts who received ASCT:
3y EFS 68% for 0-1 factor vs 34% for 2-4 factors (p=0.013) assessing MYC
and BCL2 by IHC, or 53% for 0-1 factor vs 18% for 2-4 factors (p=0.008)
when assessing MYC/BCL2 by GEP.
Figure 1.
Summary/Conclusions: In conclusion, MYC and BCL2 expression, deter-
mined by IHC or Nanostring GEP, are independent poor prognostic factors for
rrDLBCL, and dual expression predicts dismal prognosis. Combining MYC and
BCL2 expression, primary refractory disease and elevated LDH results in a
robust bio-clinical model strongly associated with EFS and OS for rrDLBCL,
including chemosensitive patients who proceed to ASCT.
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PHASE 1 TRIAL OF CUDC-907, A NOVEL, ORAL DUAL INHIBITOR OF
HDAC AND PI3K: UPDATED ASSESSMENT OF PATIENTS WITH
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Background: Diffuse large B-cell lymphoma (DLBCL), the most common lym-
phoid malignancy in adults, is an aggressive form of non-Hodgkin lymphoma
with significant heterogeneity in terms of gene expression, prognosis and
response to treatment. Certain histone modifications and HDAC expression
patterns have been implicated in the pathobiology of DLBCL and other cancers.
Aberrant PTEN/PI3K/AKT signaling is also frequently observed in a variety of
human cancers including DLBCL, where loss of PTEN and/or activating muta-
tions in PI3K have been shown to inhibit apoptosis and promote tumor cell pro-
liferation. Synergistic anti-tumor effects achieved with HDAC and PI3K inhibitor
combinations in DLBCL xenograft models have provided a strong rationale for
testing a highly potent dual HDAC and PI3K inhibitor, CUDC-907. Significant
anti-tumor effects have been observed across a wide range of DLBCL models
exposed to CUDC-907, including the U2932 ABC DLBCL model that harbors
BCL2 amplification and over-expresses cMYC and BCL6, and the double hit
WSU-DLCL-2 GCB DLBCL model that harbors MYC and BCL2 translocations.
These disease mechanisms and preclinical data have led to testing of CUDC-
907 in an ongoing Phase 1 trial in patients with various hematologic cancers. 
Aims: This study is evaluating the effect of CUDC-907 on treatment-related
toxicity and efficacy in patients with relapsed or refractory (RR) lymphoma and
multiple myeloma (MM). 
Methods: Seventy-five heavily pre-treated patients with RR lymphoma or MM
have received CUDC-907 in 21-day cycles according to once daily (QD), inter-
mittent (BIW or TIW), or five days on/two days off (5/2) dosing schedules.
CUDC-907 was escalated in 30 mg increments such that patients received 30-
60 mg QD, 60-150 mg intermittently, or 60 mg 5/2. Dose expansion investigating
the 60 mg 5/2 dose and schedule as monotherapy and in combination with rit-
uximab is ongoing. To date, a total of 29 patients have been treated with the
5/2 dosing schedule, including 4 patients who were assigned to concomitant
standard of care dosing of rituximab on day 1 of the first 6 cycles of treatment. 
Results: The most common treatment-related adverse events (AEs) were
Grade 1-2 diarrhea (56%; 4% Grade ≥3), fatigue (33%; 4% Grade ≥3), nausea
(29%), thrombocytopenia (27%; 17% Grade ≥3), and neutropenia (12%; 9%
Grade ≥3), with dose limiting toxicities of hyperglycemia (QD and BIW sched-
ules) and diarrhea (QD and TIW schedules). Side effects were reversible and
manageable. The AE profile for patients who received CUDC-907 on the 60
mg 5/2 dosing schedule, including those who received concomitant rituximab,
was commensurate with that of the overall safety population. Among 20
response-evaluable patients with RR DLBCL, 9 (45%) achieved objective
responses (3 CRs and 6 PRs); lasting a median of 2.6 months (range: <1-14+).
Three response evaluable patients were found to overexpress MYC (≥40%)
and BCL2 (≥70%) by IHC, meeting criteria applied to “double-expressor” (DE)
DLBCL. Two of these patients attained objective responses: 1 CR (followed by
autologous stem cell transplant) and 1 PR (lasting 4 months). The third patient
has experienced lengthy disease stabilization (5.7+ months). Interestingly, all
3 CRs observed on this study occurred in patients with MYC gene copy number
gain, including the patient who also had DE DLBCL.
Summary/Conclusions: Signals emerging from preclinical and clinical studies
suggest that patients with DLBCL, including those with MYC-altered and there-
fore particularly aggressive disease, may derive benefit from treatment with
CUDC-907. A Phase 2 trial examining CUDC-907 60 mg 5/2 as monotherapy
and in combination with rituximab in RR MYC-altered DLBCL is currently ongo-
ing. Patients are being enrolled based on locally reported MYC status, defined
as gene translocation or copy number gain by FISH and/or protein expression
≥40% by IHC. Tumoral tissue will be assessed centrally to confirm MYC status
of enrolled patients. Other genetic aberrations, such as BCL2 and BCL6, will
also be evaluated for correlation with clinical outcomes (NCT02674750).
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Background: Non-Hodgkin lymphoma (NHL) is the most prevalent hematologic
malignancy in the US and the fifth most deadly cancer with nearly 19,790
deaths/year in the US. DLBCL is the most common NHL subtype, representing
25-35% of new cases annually. Although five-year survival rates in the first-line
setting range from 30-50%, approximately 1 in 3 of these patients will be refrac-
tory to or relapse post treatment. Diverse therapeutic outcomes are observed
in these patients with relapsed/refractory aggressive DLBCL. The international,
multi-cohort Retrospective Non-Hodgkin Lymphoma Research (SCHOLAR-1)
was designed to study outcomes in patients with refractory DLBCL.
Aims: The aim of SCHOLAR-1 was to retrospectively evaluate response rate
and overall survival in patients with refractory DLBCL to serve as a benchmark
for future clinical trials in this underserved population.
Methods: Eligibility criteria included refractory DLBCL, which was defined as
progressive disease (PD) or stable disease (SD) as best response to
chemotherapy (duration of SD <12 months and at least 4 cycles of first-line or
2 cycles of later line therapy) or relapse ≤12 months after autologous stem cell
transplantation. All patients must have received an anthracycline as part of a
prior regimen. In addition, all patients with CD20-positive disease must have
received prior treatment with an anti-CD20 monoclonal antibody. SCHOLAR-1
included data from 2 phase 3 studies (LYSARC-CORAL and Canadian Cancer
Trials Group (CCTG)-LY.12) and 2 observational cohorts (MD Anderson Cancer
Center [MDACC] and Mayo Clinic/University of Iowa [MC/IA] Specialized Pro-
gram of Research Excellence). Response rates and overall survival were esti-
mated from the time that salvage therapy was initiated.
Results: Among 861 patients with DLBCL, 597 patients with refractory disease
were identified. Response rates ranged from 19% to 36% (complete responses
from 2% to 18%). Median survival was poor, ranging from 4.6 months to 6.9
months across cohorts. Data for each study or cohort are shown in the Table 1.
Table 1.
ASCT, autologous stem cell transplantation; CR, complete response; NA, not applicable (based
on study design); OS, overall survival; PR, partial response; RR, response rate; tx, treatment.
Summary/Conclusions: This is the first study to define patient outcomes for
those with refractory DLBCL in a large group of patients. Outcomes were similar
across cohorts. Our results suggest that patients with refractory, aggressive DLB-
CL represent a homogenous population with a response rate of 20% - 30% and
median overall survival of approximately 6 mos. These consistently poor out-
comes represent a significant unmet need in patients with refractory DLBCL.
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Background: Prognosis of children with acute myeloid leukemia (AML)
improved within the recent decades. Study groups worldwide performed
prospective randomized trials to select more effective and/or less toxic drugs.
Several approaches such very high dosages of cytarabine versus high cumu-
lative dosages of anthracyclins or performance of allogeneic stem cell trans-
plantation (HSCT) versus chemotherapy only led to rather similar results in
terms of event-free (EFS) and overall survival (OS). 
Aims: Therefore we asked if the improvement of survival is dependent from
particular therapy elements identified in randomized trials or rather a correlation
with time. This would implicate that factors such as intensity, supportive care
or risk group stratification have a much higher impact than the selection of a
specific drug. 
Methods: In total, 1873 children (0 to 18 yrs) enrolled to the AML-BFM trials
from 1987 until 2011 were included (excluding Down’s Syndrome and acute
promyeloblastic leukemia). The AML-BFM Study group recruited on popula-
tion-based trials all children with AML from Germany and since 1998 from
Czech Republic, Austria and Switzerland. Outcome data were analyzed not
only per trial but per 2- and 3-year-periods respectively (Kaplan-Meier).
Results: The 5–year EFS and OS (1987 to 2011) increased from 41±3% to
51±2% and 49±3% to 72±2%, respectively. The Table 1 shows EFS and OS of
3 year periods. The comparison to the AML-BFM trial episodes indicate that a
stepwise increase in long-term survival was achieved –according to protocols-
by more intensive chemotherapy from 1987-1997. Analysis of 2 and 3-yr-peri-
ods shows changes within these study protocols dependent on particular ther-
apy elements and amendments (Figure 1). After 1998 the following years rather
show a continuous improvement but only in OS. An increasing gap between
EFS and OS (period 1987-1989: 9%; 2008-2010: 24%) was observed. A rele-
vant and unexpected increase in OS was observed in 2001/02. At this time
point there was no change in first line protocol, but in addition an international
relapse protocol was implemented. The survival after relapse increased from
17±3 up to 44±3%.
Table 1.
3-yr-period                                         [n]                   EFS±SE [%]             OS±SE [%]
1987-1989                                        134                      43±4%                   52±4%
1990-1992                                        161                      39±4%                   47±3%
1993-1995                                        249                      52±3%                   58±3%
1996-1998                                        284                      48±3%                   58±3%
1999-2001                                        250                      50±3%                   64±3%
2002-2004                                        246                      51±3%                   65±3%
2005-2007                                        245                      52±3%                   74±4%
2008-2010                                        232                      46±4%                   70±3%
AML-BFM 87 (1987-1992)                  295                      41±3%                   49±3%
AML-BFM 93 (1993-1997)                  488                      50±2%                   57±2%
AML-BFM 98 (1998-2003)                  465                      49±2%                   63±2%
AML-BFM 2004 (2004-2011)             625                      51±2%                   72±2%
Figure 1.
Summary/Conclusions: Since 1987, several changes influenced AML thera-
py. The intensity of treatment increased until the AML-BFM 98 trial, in supportive
care mainly the general introduction of antimycotics (recommendation 1993)
might be the most relevant change. Since 1995 OS improved continuously
until 2008, whereas EFS did not change significantly. Although, the slightly
reduced relapse rate might suggest that 2nd line treatment becomes more dif-
ficult due to the selection of the more resistant AML, from the data it is clear
that the efficacy of 2nd line therapy improved. 
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MONOSOMAL KARYOTYPE AND TRISOMY 8 ARE POOR PROGNOSTIC
FACTORS IN PEDIATRIC AML: AN AML-BFM 2004 TRIAL REPORT ON
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Background: Conflicting data on poor risk factors in pediatric acute myeloid
leukemia (AML) hamper risk stratification systems and the improvement of
risk-adapted therapeutic strategies.
Aims: We aimed to unravel the prognostic impact of specific chromosomal
aberrations including complex and hypodiploid as well as monosomal kary-
otypes and trisomy 8 in pediatric patients with AML. 
Methods: Karyotypes of a population-based cohort of 643 patients <18 years
with de novo AML treated on the AML-BFM 2004 study protocol (excluding
Down’s Syndrome and patients with t(15;17)/PML-RARA fusion gene) were
analyzed. For cytogenetic definitions see Table 1.
Results: Our analysis revealed overlapping groups of patients with monosomal
(MK+), complex (CK+) or hypodiploid (HK+) karyotypes. Multivariate regression
confirmed MK+ (n=25) as new independent poor risk factor for event-free survival
(EFS) with a reduced EFS of 23±9% (p=0.008), even after exclusion of mono-
somy 7 (MKno-7; n=19; EFS 25±10%, p=0.007). As expected, Monosomy 7 (n=8;
pEFS 13%±12%; p=0.0026) was associated with poor outcome and resistance
to induction chemotherapy. Importantly, after exclusion of MK, patients with CK
did not experience a significantly worse outcome (n=47; 42±7%, p=0.12), while
CK+/MK+ patients did poorly (n=11; EFS 24±14%, p =0.04). Similarly, hypodiploid
karyotype (HK) did not predict worse outcome overall (n=38; EFS 43±8%,
p=0.26). However, after exclusion of HK+ patients with concurrent t(8;21) (n=21;
pEFS 70±10%), the remaining HK+ patients showed very poor prognosis (n=17,
pEFS 9±8%, p=<0.0001). Finally Trisomy 8 without additional cytogenetic aber-
rations was associated with poor outcome (n=16; EFS 25±11%; p=0.009).
Table 1.
                                                             Pts n     5y pEFS   p-value     5ypOS     p-value
                                                               (%)       (SE) % (Logrank)*  (SE)%  (Logrank)*
monosomal karyotype† (MK+)                 25(4)      23(9)     0.0008    43(10)    0.0008
monosomal karyotype†excl. -7                   19(3)      25(10)    0.0066    47(12)    0.0070
MK+/CK+                                                 11(2)      24(14)     0.041     36(15)    0.0013
MK+/CK-                                                  14(2)      21(11)    0.0047    50(13)     0.070
MK+/HK+                                                 11(2)        9(9)     <0.0001   36(15)    0.0031
MK+/HK-                                                  14(2)      34(13)      0.22      49(14)     0.057
hypodiploid karyotype¬ (HK+)                 38 (6)      43(8)       0.26       62(8)       0.27
HK+/MK-                                                  27(4)      57(10)      0.60       73(9)       0.59
complex karyotypes+(CK+)                      58(9)      42(7)       0.12       62(7)       0.30
CK+/MK-                                                  47(7)       47(7)       0.33       68(8)       0.94
*in comparison to other patients with cytogenetic data,+3 or more aberrations, at least one
structural aberration; without favorable genetics; without MLL rearrangement; †Two or more
autosomal monosomies or one autosomal monosomy with at least one structural abnormality.
No favorable cytogenetics (t(15;17)(q22;q21); (t(8;21)(q22;q22); inv(16)(p13q22)/t(16;16)
(p13;q22)); ¬ <46 chromosomes, SE=standard error, pOS=probability of OS, pEFS=probability
of ES.
Summary/Conclusions: Our study identified monosomal karyotype and iso-
lated trisomy 8 for the first time as strong and independent prognostic factors
in a pediatric AML cohort that are associated with poor outcome. In contrast,
complex karyotype alone without MK or hypodiploidy per se does not seem to
confer dismal prognosis. These results have important implications for risk
stratification including the indication for stem cell transplantation and should
be validated in ongoing pediatric trials.
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BASED ON GENETIC DATA AND MINIMAL RESIDUAL DISEASE: RESULTS
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AGE OF 70 YEARS
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Background: Refinement of the AML risk stratification based on genetic data
(cytogenetics and molecular characteristics) and minimal residual disease
(MRD) assessment may optimize the post-remission allocation to consolidation
chemotherapy only or hematopoietic cell transplantation (HCT).
Aims: To evaluate the feasibility and results of an ongoing prospective phase
II trial of intensive chemotherapy followed or not by HCT depending on genetics
of AML and levels of MRD after consolidation.
Methods: Patients 18 to 70 years old with primary AML treated at 15 academic
hospitals between February 2012 and November 2015 were enrolled in the trial.
The number of patients included and the outcomes will be updated on May 1,
2016. Induction consisted of idarubicin 12 mg/m2 days 1-2-3 as intravenous
bolus and cytarabine 200 mg/m2as continuous infusion days 1 to 7. Consolida-
tion courses were the high-dose cytarabine schedule of the CALGB with reduc-
tion of cytarabine from 3 g/m2 to 1.5 g/m2 in patients older than 60 years. The
number of consolidation courses was based on AML risk allocation: three in the
low-risk category (CBF, NPM1mut/FLT3-ITDwild or ratio<0.5, CEBPA biallelic
mutation, all of them with low MRD after consolidation (by flow cytometry and/or
quantitative PCR of the specific transcripts); two in the intermediate risk category
(intermediate cytogenetics without favorable or unfavorable mutations (these
patients subsequently received an autologous or allogeneic transplantation
depending on MRD levels and availability of an HLA matched donor); and one
consolidation followed by mandatory allogeneic transplantation from any stem
cell source available (identical sibling, unrelated, cord blood, haploidentical) in
the high-risk group (adverse genetics and/or MRD persistence on high levels).
Results: In 372 patients enrolled so far, the median age (range) was 55 (18-
70) years and 53% were male. MRC cytogenetic distribution was: CBF AML
12%, intermediate-risk 66% and poor risk 22%. FLT3-ITD was detected in 22%
of 348 cases studied (29% in intermediate risk cytogenetics) group and NPM1
mutation was evident in 57% of patients with a NK.Complete remission (CR)
rate in 365 evaluable patients was 74% (n=272), Induction death occurred in
9% and 19% in patients up to and above 60 years, respectively; 10% of patients
had refractory leukemia in the two age categories. Two hundred forty patients
completed the consolidation phase and were risk allocated; 104 (43%) to the
genetics-MRD favorable category, 73 (30%) to the intermediate and 65 (27%)
to the high-risk group; in the latter, 80% of patients received an allogeneic HCT.
Median follow-up of the surviving patients is 16 months. Overall survival (OS)
of the whole series was 47±3% at 30 months; disease-free survivals at that
time point were 74±5% in the favorable risk group, 44±5% in the intermediate
and 29±7% in the in the high-risk group (Figure 1), due to significantly difference
in the relapse incidence (23%, 41% and 56%, respectively). Remarkably, we
confirmed our previous finding that patients with intermediate-risk MRC cyto-
genetics with NPM1 mutation and FLT3-ITDwild had comparable outcomes to
those with NPM1 mutation and an allelic ratio below 0.5.
Figure 1.
Summary/Conclusions: Risk adapted therapy for primary AML based on
genetics and MRD is feasible in a cooperative group setting. The proportion of
patients in whom the risks of an allogeneic HCT in first CR may be avoided is
higher than 40% when considering not only cytogenetics but also molecular
and MRD information. Allogeneic HCT in high-risk patients was feasible in most
instances but further approaches to decrease relapses such as novel agents
and immune therapies are needed.
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SEQUENTIAL HIGH-DOSE CYTARABINE PLUS IDARUBICIN IMPROVES
REMISSION RATE AND SURVIVAL DURATION IN ADULT ACUTE
MYELOGENOUS LEUKEMIA (AML): RANDOMIZED TRIAL OF THE
NORTHERN ITALY LEUKEMIA GROUP (NILG)
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Background: AML is curable in the fraction of patients who achieve complete
remission (CR) and do not relapse following consolidation or allogeneic stem
cell transplantation (ASCT). Therefore new strategies are continuously devel-
oped to overcome the risk of primary resistant or recurrent disease. 
Aims: In NILG trial 02/06 [ClinicalTrials.gov Identifier: NCT00495287]a sequential
high-dose (SHD) regimen was compared to standard induction, having CR rate
as primary study objective. CR patients were eligible to risk-specific treatment.
Methods: Study patients were stratified by age 60 years and randomized to
ICE (idarubicin 12 mg/m2/d iv. dd1-3, cytarabine 100 mg/m2/bd iv. dd 1-7, etopo-
side 100 mg/m2/d iv. dd1-5) or SHD (cytarabine 2 g [1 g if age >65]/m2/bd iv.
dd 1-2 and 8-9, idarubicin 18 mg/m2/d iv. dd 3 and 10), plus G-CSF from d11.
Postremission consolidation consisted of IC (cycle 2), intermediate-dose cytara-
bine 1 g/m2/bd iv. dd 1-4, with harvest of CD34+ blood stem cells (cycle 3), and
allogeneic SCT if high-risk or second randomization to BUCY2-conditioned
autograft or repetitive HD cycles (cytarabine 2 g/m2/bd iv. dd 1-5 and idarubicin
8 mg/m2/d dd 1-2, cycles 4-6) supported by 1-2 x106/kg CD34+ cells. The high-
risk class was defined by cytogenetics, selected risk factors in intermediate/nor-
mal cytogenetic risk group (FLT3 ITD+, WBC >50, minimally differentiated/
megakaryo-/erythro-blastic,secondary or MDS-related AML), and late CR.
Results were analyzed by treatment intention and, to detect late survival differ-
ences, compared using the Kaplan-Meier estimate with weighted log-rank tests
according to Fleming and Harrington.
Results: Between 2006-2012, 572 patients were enrolled (median age 52
years, range 16-73; 74% high-risk; 286 with comparable characteristics in each
arm). After induction course, CR rate was 69.2% in ICE arm and 81.5% in SHD
arm (P .001), due to lower resistance rate (25.2% vs 11.2%, P <.0001) without
increased mortality (5.6% vs 7.3%, P .39). The benefit was confirmed in high-
risk AML (n=201 vs 218: CR 64.2% vs 77.6%; P .002) and in patients aged ≤60
years with de novo AML (n=190 vs 189: CR 74.2% vs 86.2%; P .003). Overall
CR rate after cycle 2/other salvage was 82.5% vs 86.0% (P .25). SHD increased
the time to neutrophil/platelet recovery (P <.0001), the risk of infections (bac-
terial, P .0001; fungal, P .003) and hepatic, metabolic and cutaneous toxicity
(P <.05), and was associated with longer intercycle intervals (P<.0001), lower
feasibility of cycle 3 (P <.0001) and poorer stem cell mobilization (n=123 vs
93). One-hundred ninety-three patients (41%) had an allograft in CR1 (175
high-risk [96 in ICE arm and 79 in HDS arm] and 18 standard-risk [6 in ICE arm
and 12 in HDS arm]). Median and 5-year overall survival (OS) were 2.14 years
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and 38% in ICE arm compared to 4.51 years and 48% in SHD arm (P .0125),
improving sensibly in the standard-risk subset (5-year OS 55% vs 72%, P
.0068) and patients aged ≤60 years with de novo AML (5-year OS 43% vs
58%; P .0026). Median and 5-year DFS were 1.48 years and 36% compared
to 3.41 years and 48% (P .0030), again improving in the standard-risk subset
(5-year DFS 40% vs 64%; P .0064) and patients aged ≤60 years with de novo
AML (5-year DFS 38% vs 54%; P .0023) (Figure 1).
Figure 1.
Summary/Conclusions: The current SHD schedule, albeit proving more toxic
than standard ICE did not increase the risk of induction death and improved
the CR rate and 5-year OS and DFS results, particularly in patients with stan-
dard-risk AML and aged ≤60 years with de novo AML.
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Background: Outcomes of elderly patients with acute promyelocytic leukemia
(APL) have been reported as less effective than in younger patients because
of lower compliance and higher mortality rate related to toxicity of the treatment.
This fact has led to design the risk-adapted and age-adapted PETHEMA
LPA2005 protocol, in which the anthracycline dose in second consolidation
was reduced with respect to previous protocols.
Aims: This study aims at comparing elderly patients (age ≥60 years old) who
were treated according to PETHEMA LPA2005 schedule and those who were
included in the more intensive previous protocols (LP96&LP99 trials).
Methods: Elderly patients (age equal or greater than 60) who were reported
to the multicenter PETHEMA APL registry, diagnosed with APL and demon-
stration of the t(15;17) or PML/RARA rearrangement were included in this
study. They were excluded if they met any of the following criteria: 1) Eastern
Cooperative Oncology Group (ECOG) performance status at presentation of
more than three, 2) severe medical comorbidities limiting the administration of
chemotherapy in opinion of the treating physician, 3) antecedents of primary
malignancy or previous therapy with leukemogenic agents, and 4) protocol vio-
lation. Elderly patients who received treatment according to the risk and age-
adapted protocol LPA2005 were compared to those included in LPA96&LPA99
protocols.
Results: From November 1996 to November 2014, 389 elderly patients were
reported to PETHEMA APL registry and 268 (69%) were considered as eligible.
Causes of ineligibility were secondary APL (19%), ECOG 4/unfit for intensive
chemotherapy (11%), and protocol violation (1%). Median age of eligible
patients was 67 years (range, 60-84), and the distribution of relapse-risk cat-
egories was low (29%), intermediate (50%), and high (21%). Two-hundred six-
teen out of 268 eligible patients (81%) achieved complete remission and 52
(19%) died during induction treatment due to hemorrhage and infection, mainly.
Leukemic resistance was not observed. Comparing patients according to pro-
tocol, no differences in biological and clinical characteristics at diagnosis were
identified between the LPA96&99 and LPA2005 cohorts. The median follow-
up of patients alive was 62 months (range 2-191). Patients treated with the
less intense schedule (LPA2005 trial) had lower toxicity, with a lower duration
of neutropenia and thrombocytopenia during the second consolidation and
fewer days of hospitalization, resulting in reduced 5-year non-relapse mortality
compared with the LPA96&99 trials (5% vs 18%, P=0.02). At 5 years, patients
treated according to LPA2005 protocol had higher overall survival (74% vs
60%, P=0.02), and higher disease-free survival (87% vs 69%, P=0.009) than 
patients who received LPA96&99 protocols. There were no differences in the
cumulative incidence of relapse between the two groups (P=0.25) (Figure 1).
Figure 1.
Summary/Conclusions: Anthracycline dose reduction during consolidation
for elderly patients with APL treated with the PETHEMA LPA2005 trial resulted
in lower toxicity and non-relapse mortality, while maintaining a high antileukemic
activity.
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Background: Primary central nervous system lymphoma (PCNSL) is a rare
subtype of non-Hodgkin lymphoma, of which approximately 95% are diffuse
large B-cell lymphomas (DLBCLs). However, PCNSL shows very different bio-
logical and clinical characteristics from systemic DLBCL, and our knowledge
about the molecular pathogenesis of PCNSL is still incomplete.
Aims: The purpose of this study is to delineate the entire spectrum of gene
mutations, copy number alterations (CNAs) and structural variants (SVs) in
PCNSL to better understand its pathogenesis.
Methods: We first analyzed paired tumor/normal DNA from 37 PCNSL cases
by whole-exome sequencing (WES). Significantly mutated genes identified by
WES and previously known mutational targets in PCNSL and systemic DLBCL
were further screened for mutations using targeted sequencing in an extended
cohort of PCNSL cases (N=92). CNAs have been also investigated using SNP
array-karyotyping (N =56). Whole-genome sequencing (WGS, N=9) was also
performed to identify the recurrent mutations in non-coding regions and SVs.
Results: The mean number of nonsynonymous mutations identified by WES
was 183 per sample, which was comparable to the figure in systemic DLBCL.
A higher representation of C>T transition involving CpG dinucleotides and
hotspot mutations within the WRCY motif targeted by somatic hypermutations
(SHMs) suggested the involvement of activation-induced cytidine deaminase
(AID) in the pathogenesis of PCNSL. We found 12 genes significantly mutated
in PCNSL (q <0.1), including MYD88, PIM1, HLA-A, TMEM30A, B2M, PRDM1,
UBE2A, HIST1H1C, GRB2 as well as several previously unreported mutational
targets in systemic DLBCL or PCNSL, such as SETD1B, ITPKB, EIF4A2. Copy
number analysis identified recurrent genomic segments affected by focal dele-
tions (N=27) and amplifications (N=10), most of which included driver genes
targeted by recurrent somatic mutations or known targets of focal CNAs such
as CDKN2A and FHIT. Subsequent targeted sequencing finally identified a
total of 107 significantly mutated genes, of which 43 were thought to be targeted
by SHM according to their mutational signature. Most cases with PCNSL (98%)
had mutations and CNAs involving genes that are relevant to constitutive NF-
κB/Toll-like receptor (TLR)/B-cell receptor (BCR) activity, including those in
MYD88, CD79B/A, CARD11, TNFAIP3, GRB2 and ITPKB. Genetic alterations
implicated in escape from immunosurveillance were also frequently identified
in as many as 76% of cases, including mutations of HLA-B, HLA-A, HLA-C,
B2M and CD58 as well as CNAs in 6p21.32 (HLA class II), 1p13.1 (CD58) and
15q15.2 (B2M), suggesting the importance of immune escape in the patho-
genesis of PCNSL. SHMs were observed in most cases (98%), which affected
not only known non-immunoglobulin targets of AID including PIM1, IGLL5 and
BTG2 but also previously unreported genes involved in cell proliferation, apop-
tosis, or B cell development. WGS identified 52 loci in which somatic mutations
were enriched, including 5’-region of BCL6, RHOH, BACH2, genes known to
undergo SHM. Furthermore, breakpoints clusters of SVs included IG loci (IGK,
IGH and IGL), CDKN2A/B as well as known targets of AID, such as BCL6,
BTG2 and PIM1.
Summary/Conclusions: Comprehensive genetic analyses of a large cohort
of PCNSL cases revealed the genetic landscape of PCNSL, which was char-
acterized by constitutive NF-κB/TLR/BCR signaling, escape from immunosur-
veillance, as well as SHMs/SVs caused by AID.
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Background: Mantle cell lymphoma (MCL) ranges from cases with rather indo-
lent clinical behavior to very aggressive tumors with poor survival rates. Aggres-
sive cases seem to be associated with low levels of somatic hypermutation
(SHM) in the Immunoglobulin Heavy Chain (IGHV) gene, and de novo expres-
sion of SOX11. In contrast, indolent MCLs have high levels of IGHV somatic
mutation and lack SOX11. Although many studies have focused on biological
and clinical features of MCL, its methylome remains largely unknown. As recent
studies have suggested a relationship between dynamic methylation during
normal differentiation and neoplastic transformation, we hypothesized that a
similar link exists in MCL. 
Aims: We aimed to explore the DNA methylation landscape in MCL in light of
the methylome in the entire B-cell lineage in order (i) to generate new insights
into the biological and clinical aspects of MCL and (ii) to further understand the
link between the dynamic methylation during normal differentiation and neo-
plastic transformation.
Methods: We generated genome-wide DNA methylation profiles of 86 MCL
samples using the HumanMethylation450 BeadChip and we sequenced the
DNA methylome of two representative MCLs by whole genome bisulfite
sequencing (WGBS). As normal controls, we used samples (n=67 for BeadChip
and n=12 for WGBS) from different B-cell subpopulations (n=10 for BeadChip
and n=6 for WGBS). We applied a principal component analysis and consensus
clustering to define epigenetic MCL subgroups and to determine their normal
counterparts. Furthermore, to tackle the high individual epigenetic variation in
MCL, we compared the DNA methylation profile of each individual MCL to a
fixed reference point, the hematopoietic progenitor cells, and further analyzed
the observed changes in the context of DNA methylation changes observed
during B-cell differentiation. To understand the functional and clinical impact of
DNA methylation changes we have linked our data with histone modification
profiles (chIP-seq), the three-dimensional chromatin structure (4C-seq), the
mutational landscape (whole genome/whole exome sequencing) and clinical
data in MCL. 
Results: First of all, we identified two epigenetic MCL subgroups that carry
epigenetic imprints of pre- versus post-germinal center B cells. 
Secondly, we observed that the majority of individual DNA methylation changes
in MCL also occur during normal B-cell differentiation and that pure tumor-spe-
cific changes are rare; most (89-99%) DNA methylation alterations in MCL are
within or in close proximity to those regions showing dynamic methylation in
normal B cells. Thirdly, several thousand differentially methylated regions in
MCL show differential enhancer-associated histone modifications, including a
region 650 Kb away from SOX11. In SOX11 expressing MCL cells, this distant
region is hypomethylated and shows high contact frequencies with the SOX11
promoter in three-dimensional space, suggesting that we have identified a new
regulatory element of SOX11 in MCL. Lastly, at the clinical level we observed
that epigenetic and genetic changes co-evolve during MCL progression and
that the magnitude of epigenetic changes is associated with overall survival of
MCL patients.
Summary/Conclusions: Our results (i) provide new insights into the cellular
origin, pathogenetic mechanisms and clinical behavior of MCL, (ii) show that
pure tumor-specific DNA methylation changes in MCL are rare and (iii) highlight
that differential methylation in cancer can target potential epigenetic drivers at
distant regulatory elements of key oncogenes.
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Background: The adaptor protein MYD88 is critical to relay activation of Toll-
like receptor signaling to NF-κB activation. MYD88 mutations, particularly the
p.L265P mutation, have been described in numerous distinct B cell malignan-
cies, including diffuse large B cell lymphoma (DLBCL). 29% of activated B cell
(ABC)-type DLBCL, which is characterized by constitutive activation of the NF-
κB pathway, carry the p.L265P mutation. In addition, ABC-DLBCL frequently
displays focal copy number gains affecting BCL2.
Aims: Here, we aimed to investigate the potential role of the Myd88p.L265P
point mutation in lymphomagenesis.
Methods: We generated a novel mouse model (termed Myd88c-p.L252P), in
which Cre-mediated recombination, specifically in B cells, leads to the condi-
tional expression of Myd88p.L252P (the orthologous position of the human
MYD88p.L265P mutation) from the endogenous locus. More precisely, the
endogenous exons 2 to 6 of Myd88 (which consists of 6 exons) were flanked
by loxP-sites. Downstream of the last exon, a second set of exons 2 to 6 was
inserted, harboring the point mutation p.L252P. Cre-mediated recombination
leads to the excision of the endogenous exons 2 to 6 and expression of the
inserted, mutated set of exons. This system very closely mimicks the situation
observed in the clinic, as it allows for the heterozygous expression of
Myd88p.L252P from the endogenous locus.
Results: To assess the functionally of our allele, we generated mouse embry-
onic fibroblasts (MEFs) homozygous for the Myd88c-p.L252P allele, recombined
them in vitro by lentiviral transduction. After puromycin selection, cDNA was
sequenced and only the mutant transcript was detected. Western blotting ver-
ified the expression of this mutant transcript and increased phospho-p65 levels
as a marker for NF-kB activation. We activated our allele B cell-specifically by
crossing it to the Cd19-Cre mouse. The resulting Myd88c-p.L252P;Cd19Cre/wt
animals had a lifespan of around 500 days, significantly shorter than that of
the Cd19Cre/wt control. Magnetic resonance imaging and autopsy showed the
development of splenomegaly and lymphadenopathy starting at around 60
weeks of age. Further histological and immunohistochemical investigation
revealed the existence of lymphoproliferative disease and the sporadic emer-
gence of large B cell lymphoma with an Bcl6-/Mum1+/B220+/Cd138- immuno-
type. Analysis of V(D)J recombination by southern blotting showed clonal pop-
ulations in samples from animals diagnosed with lymphoma by histology. BCL-
2 is highly expressed in most ABC DLBCL cases. To potentially enhance lym-
phomagenesis in our mice, we aimed to combine the Myd88p.L252P mutation
with Bcl-2 overexpression by making use of a newly genrated LSL.BCL2 allele,
where human BCL2 expression is driven by the CAGGs promoter. Indeed, all
Myd88c-p.L252P;LSL.BCL2;Cd19Cre/wt mice die of aggressive large B cell lym-
phoma at a median of 36 weeks. All animals showed splenomegaly and/or
lymphadenopathy, accompanied by infiltration of the liver. Bone marrow involve-
ment was only detected once and was locally restricted, indicating a secondary
lesion. Clonality analysis by southern blot showed oligoclonality, suggesting a
strong oncogenic potential of Myd88p.L252P in combination with BCL2 overex-
pression. Interestingly, lymphoma cells were of a Bcl6-/Mum1+/B220-/Cd138+
immunotype, in accordance with the plasmoblastic morphology that was his-
tologically observed.
Summary/Conclusions: In summary, we generated a mouse model that
enables Cre-mediated expression of Myd88p.L252P from the endogenous locus.
Myd88c-p.L252P;Cd19Cre/wt mice develop and eventually die of lymphoprolifer-
ative disease. The emergence of diffuse large B cell lymphoma (DLBCL) was
observed. Combination of B cell-specific Myd88p.L252P with BCL-2 overexpres-
sion results in the development of an aggressive lymphoma with plasmoblastic
features, most reminiscent of ABC-type DLBCL.
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BET INHIBITORS SUPPRESS PD-L1 TRANSCRIPTION TO ENHANCE
ANTI-TUMOUR IMMUNITY AND IMMUNOTHERAPEUTIC APPROACHES
S Hogg1,2,*, J Shortt3, R Johnstone1,2
1Peter MacCallum Cancer Centre, 2Sir Peter MacCallum Department of Oncol-
ogy, The University of Melbourne, 3School of Clinical Sciences at Monash
Health, Monash University, Melbourne, Australia
Background: Bromodomain and Extra-Terminal (BET) proteins are a highly
conserved family of epigenetic ‘readers’ that recognise and bind acetylated
lysine residues on histones and other proteins to modulate gene expression.
BET proteins are enriched at enhancer regions regulating oncogenic transcrip-
tion and inhibitors (BETi) displace BET proteins from chromatin leading to sup-
pression of oncogenes (e.g. cMYC). BETi elicit a heterogeneous range of
tumour cell responses including apoptosis, growth arrest, differentiation, and
senescence. However, responses to single agent BETi are self-limited in vivo
and drug resistance uniformly emerges in preclinical modelling. As BET-
inhibitors (BETi) are now being clinically evaluated in both haematological and
solid malignancies, the focus is now shifting to the design of effective combi-
nation strategies for phase II studies. 
Aims: BETi have potent anti-inflammatory properties, including chromatin-
independent downregulation of NFkB signalling. However, broader mecha-
nisms of immunomodulation by BETi in the context of anti-tumour responses
remain poorly defined. Having previously discovered NK- and T-cell immunos-
timulatory activity of an acetyllysine mimetic fragment (n-methylpyrrolidone),
we sought to evaluate the immunomodulatory activity of the prototypical thein-
odiazapine BETi, JQ1.
Methods: Utilising the syngeneic model of transplanted Eμ-Myc aggressive
‘Burkitt-like’ lymphoma we first compared the efficacy of JQ1 in wild-type
(immunocompetent) and immunodeficient RAG1-/- or RAG2-/-cγ-/-mice. To inter-
rogate the functional interaction between JQ1 and the immune system, we
profiled changes in tumour cell immunogenicity following drug exposure by
flow cytometry. 
Results: We observed a 50% reduction in the survival advantage conveyed
by JQ1 in mice deficient in T- and/or B-lymphocytes compared to immunocom-
petent controls. Notably, tumour-infiltrating lymphocytes (TILs) and peripheral
blood T-cells from wild-type mice failing JQ1 therapy expressed high levels of
PD-1, suggesting suppression of an endogenous anti-lymphoma immune
response during disease progression. Having previously identified recurrent
copy number amplification of PD-L1 (universally juxtaposed to the Eμ-Myc
transgene), we hypothesised this endogenous host response may be damp-
ened by the PD-L1/PD1 axis and further modulated by JQ1. Strikingly, JQ1
rapidly and potently suppressed PDL1 transcription in Eμ-Myc lymphoma cells
in vitro and in vivo. ChIP assays revealed significantly reduced BRD4 occu-
pancy of the PDL1 promoter/enhancer within 2 hours of JQ1 exposure (with
90% suppression of PD-L1 mRNA levels). shRNA knockdown of BRD4 likewise
downregulated PD-L1 transcription. Moreover, JQ1 treatment suppressed both
constitutive and IFNγ-inducible PD-L1 expression in human myeloma, Burkitt
and Hodgkin cell lines. Finally, treatment of mice bearing Eμ-Myc lymphoma
with JQ1 in combination with a checkpoint inhibitor (anti-PD1) or immune stim-
ulating antibody (anti-4-1BB) was highly synergistic responses despite minimal
single-agent activity of these therapeutic antibodies.
Summary/Conclusions: We suggest that oncogenic PD-L1 transcription
(including IFNγ-induced expression) is directly regulated by BRD4 and can be
suppressed for therapeutic gain by BETi leading to augmented anti-tumour
immunity, particularly in the context of immune checkpoint inhibitors. BETi/anti-
PD1 combination studies should be evaluated in genetically leveraged (e.g.
cMYC positive) aggressive lymphoid malignancy.
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ROLE OF THE MSC-DERIVED EXOSOMAL AND ENDOGENOUS JAK2-
SET/PP2A-Β-CATENIN-MODULATOR MIR-300 IN LEUKEMIC STEM/
PROGENITOR PROLIFERATION AND SURVIVAL IN CML
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Background: Nanostring arrays and RNAseq analysis of total, CD34+,
CD34+CD38- bone marrow (BM) cells from healthy individuals (n=6) and CML
patients (n=16) showed gradual inhibition of miR-300 expression (CML-CPmiR-
300>CML-BCmiR-300). MiR-300 is a human intergenic microRNA predicted to tar-
get multiple components of the BCR-ABL1/JAK2/hnRNPA1/SET/PP2A/β-catenin
pathway that, as reported is essential for survival/self-renewal of leukemic pro-
genitors and quiescent TKI-resistant Ph+ hematopoietic stem cells (HSCs). 
Aims: This work is aimed at understanding the mechanisms regulating miR-
300 in CML and assessing the importance of its downregulation for proliferation,
survival and self-renewal of CML (CP and BC) cells.
Methods: Lentiviral-mediated modulation of miR-300 expression was used in
CML cells and cell lines to assess effect of miR-300 on its mRNA targets, and
on the clonogenic potential, LTC-IC, and number of quiescent leukemic stem
and/or progenitor cells, and on the leukemogenic potential in animal models of
CML. MSC-derived exosomes and conditioned medium, hypoxic/normoxic con-
ditions and BCR-ABL1 inhibition were used to determine the mechanisms of
regulation of miR-300 expression.
Results: MiR-300 transduction in CMLCD34+ cells and BCR-ABL1+ cell lines
decreased JAK2, β-catenin, hnRNPA1 and SET expression and increased
PP2A activity. Targets were confirmed by miR-300 expression in BCR-ABL1+
cells expressing Flag-tagged miR-300-targets lacking or carrying a wild-type
or mutated 3’UTR. Restored miR-300 expression in CMLCD34+cells and/or
BCR-ABL1+ cell lines impaired proliferation and clonogenic potential,
markedly reduced LTC-ICs, and increased TKI sensitivity. Notably, miR-300
expression was inhibited by BCR-ABL1 in proliferating cells. Accordingly,
imatinib restored miR-300 expression in CD34+ dividing progenitors and
BCR-ABL1+ cell lines without altering miR-300 levels in quiescent (CFSEMAX)
CMLCD34+cells (n=3), consistent with the BCR-ABL1 kinase-dependent acti-
vation of the Jak2/SET/PP2A/β-catenin pathway in CML progenitors but not
quiescent Ph+ HSCs. Surprisingly, miR-300 levels were increased in
CD34+CD38- compared to CD34+CD38+ CML cells, and >20-fold higher in
CFSEMAX compared to dividing CMLCD34+cells (n=4). Furthermore, it
appears that forced miR-300 expression decreases engraftment of BCR-
ABL+ cells (32D-BCR-ABL) in immunocompromised mice. Bone marrow
transplant experiments in NSG mice with miR-300-transduced human CD34+
CML-BC cells, and with miR-300-transduced Lin- and LSK cells from SCL-
tTA-BCR-ABL mice are ongoing and will allow us to determine the role of
miR-300 on leukemic HSC engraftment and ability to propagate disease. To
determine whether enhanced miR-300 expression in quiescent cells depends
on cell autonomous events or is induced by the BM microenvironment, we
exposed BCR-ABL+ cells to conditioned medium (CM) of HS-5 or hTERT
mesenchymal stem cells (MSC). CM strongly decreased proliferation,
induced imatinib but not FTY720 (PP2A activator) resistance, increased miR-
300 levels, decreased BCR-ABL1 activity and Jak2 expression but not its
activity, and did not alter b-catenin levels or PP2A activity. Interestingly, miR-
300 was found in MSC-derived exosomes, and its expression increased in
BCR-ABL1+ cells exposed to exosomes. Accordingly, proliferation of CML-
BCCD34+and LAMA-84 cells was strongly reduced upon exposure to MSC-
derived exosomes. These effects were abolished when we used CM from
MSCs transduced with a miR-300 antagomir. Interestingly, culturing of
leukemic cells in hypoxic conditions dramatically induced miR-300 expression
that, in turn, impaired proliferation of primary CD34+ CML cells and BCR-
ABL cell lines.
Summary/Conclusions: Altogether our results indicate that downregulation
of miR-300 appears necessary for the activation of JAK2/SET/PP2A/b-
catenin survival signals in CML progenitors. Conversely, increased miR-
300 levels (endogenous and MSC-derived) seem to be required for HSC
quiescence.
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Background: Tyrosine kinase inhibitor (TKI) has dramatically improved the
outcome of CML, but it could not eliminate leukemia stem cell (LSC). Self-
renewal is a key characteristic for LSC. Emerging evidence indicates that β-
catenin, the Wnt pathway’s central effector molecule, is required for develop-
ment and maintenance of LSC in CML. 
Aims: We hypothesize that the combination of β-catenin and tyrosine kinase
inhibition could represent a promising strategy for preventing the development
of TKI resistance as well as a novel approach in the therapy of BC CML by tar-
geting CML-BC LSC.
Methods: Aided with single-cell mass cytometry analysis and data visualization
with SPADE and viSNE, we investigated the activity of the combination of TKI
with a Wnt/b-catenin signaling modulator C82 in vitro and with the C82 pro-
drug PRI-724 in vivo in a xenograft murine model.
Results: Primary CML-BC cells were stained with multiple cell surface markers
and intracellular survival signaling molecules and subjected to CyTOF analysis.
It revealed that β-catenin expression was high in various CML stem/progenitor
cells and particularly highest in CD34+CD38+CD123+Tim3+ subset. viSNE visu-
alization demonstrated that β-catenin overexpression was associated with high
levels of pCRKL, c-Myc, pAKT, pTyr, pSTAT3, and pSTAT5. Primary CML-BC
cells from were then treated with C82, nilotinib, and both. viSNE visualization
and SPADE tree analysis revealed that C82 and the combined regimen more
significantly decreased various stem/progenitor cells, especially
CD34+CD38+CD123+Tim-3+ cells, which represents for the candidate for CML-
BC LSC. Next, NSG mice engrafted with CML-BCT315Icells were treated with
PRI-724, nilotinib, or the combination. At the end of treatment, cells were col-
lected from the mice and subjected to CyTOF analysis. viSNE visualization
showed that PRI-724 and combination strikingly reduced CD34+b-cateninhigh,
CD34+CD38-, and CD34+CD38+ different CML-BC stem/progenitor subsets.
Furthermore, SPADE tree analysis revealed the combination more profoundly
than PRI-724 alone reduced CD34+CD38-, CD34+CD38+ and Tim-3+GMP pro-
genitor cells in NSG mice, which was confirmed by flow cytometry.Furthermore,
PRI-724 and the combination induced CD11b expression, suggesting PRI-724
and the combination promoted CML-BC stem/progenitor cell differentiation.
Notably, PRI-724 and nilotinib combination significantly inhibited CD44 in
CD34+CD38+CD123high and CD34+CD38+CD123highTim-3high subsets, and
Tim-3 in CD34+CD38+CD123highTim-3high subset, respectively. Finally, PRI-
724 and the combination significantly improved the overall survival of CML-
BC-loaded NSG mice, as compared to control and the nilotinib treatment.
Summary/Conclusions: Collectively, by identifying, tracking and visualization
CML-BC LSC based on CyTOF analysis, our results show that inhibition of β-
catenin effectively targets CML-BC stem/progenitor cells and prolongs survival
of CML-BC-loaded NSG mice, which is further enhanced by combination with
inhibition of Bcr-Abl. 
S493
DYNAMICS OF SOMATIC MUTATIONS COMMONLY DETECTED IN OTHER
MYELOID NEOPLASMS BEYOND THE BCR-ABL GENE REARRANGEMENT
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Background: Chronic myeloid leukemia (CML) is mainly characterized by a
translocation event t(9;22)(q34;q11.2) which fuses the ABL1 gene and the BCR
gene, yielding a bcr-abl onco-protein. Despite remarkable improvement in the
treatment of CML via tyrosine kinase inhibitors (TKIs), a portion of patients
show resistance to these treatments and have a much higher risk of progression
to accelerated phase (AP) or blastic phase (BP) as a result. The survival of
patients who progress to BP is comparable to the pre-TKI era, even with other
salvage treatment modalities such as allogeneic stem cell transplantation. Using
high-throughput sequencing technologies, extensive investigations in other
myeloid malignancies have discovered commonly mutated genes and the bio-
logical pathways they effect. Other than ABL1 kinase domain (KD) mutations,
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very little is known about the origins and dynamics of relevant somatic variants,
as well as their associations with BCR-ABL transcript changes and their clinical
implications on TKI response in CML.
Aims: We aimed to determine whether patterns of mutation acquisition, per-
sistence, and clearance can provide insight into treatment outcomes in CML.
Methods: 100 CML patients were included for deep sequencing targeting 92
genes that are recurrently mutated in other myeloid neoplasms. Treatment fail-
ure was estimated to be 10.2% at 3 years while PFS at 5 years was 91.0%.
The OS at 5 years was 92.6%. Based on ELN criteria, 74 patients were deter-
mined to have optimal response, 18 failed but remained in CP, and 8 had pro-
gressed to accelerated or blast phases. For each patient, samples taken at
the initial diagnosis (prior to TKI therapy) and after TKI treatment, as well as T-
cell samples, were sequenced in this study. 
Results: In total, 64 variants from 32 genes in 37 patients were detected in 300
serial samples from 100 CML patients. ASXL1, ABL1, and TET2 were the 3
genes most frequently mutated (n=9, n=6, and n=6, respectively). Unsupervised
hierarchical clustering of the 51 non-silent mutations across all serial samples
revealed 5 distinct pattern of mutation dynamics throughout the course of CML
(Figure 1). A majority of cases with mutations only had mutations from one pat-
tern. Pattern 1 mutations arise at diagnosis and persist at follow-up. Despite
this, all patients with Pattern 1 mutations were TKI-responsive. Since these
mutations were not cleared in spite of significant reduction of BCR-ABL transcript
level at the time of follow-up, they are likely to be indicative of abnormal and
clonal Ph-negative hematopoiesis that existed prior to Ph-positive clones. Pat-
tern 2 mutations are acquired during TKI treatment. This pattern included a high
portion of ABL1 KD mutations (7/13 mutations in 6 patients). Perhaps unsur-
prisingly, all patients with Pattern 2 mutations failed TKI therapy. Pattern 3 muta-
tions rise at the time of diagnosis and vanish or substantially decrease following
TKI therapy. Patients with these mutations showed mixed patterns of clinical
outcomes. Interestingly, Pattern 3 mutations were frequently within genes asso-
ciated with chromatin modification and DNA methylation, which are epigenetic
regulation pathways (11/17, 64.7%). Patients with Pattern 4 and 5 mutations
showed evidence of preleukemic mutations in CML. Too few cases had these
mutations to assess their association with treatment outcomes.
Figure 1. BCR-ABL level indicated on a log10 percentage scale for both
subplots. Each circle in the left-hand plot represents a variant. Filled cir-
cles indicate TKI treatment failure. The right-hand plot shows patients
without extra mutations. Each dot indicates an individual patient. The
boxes on the right indicate the number of patients within each decade on
TKI response coloured by pattern.
Summary/Conclusions: Overall, this study demonstrates that patterns of
mutation acquisition, persistence, and clearance vary but have a number of
interesting correlations with clinical outcomes. Our data show that mutation
burden often persists despite successful TKI response in CML, particularly in
mutations that are likely in persistent Ph-negative clones, while mutation clear-
ance is not associated with particular outcomes. Patients that acquired new
mutations during treatment all failed TKI therapy. We found evidence of
preleukemic mutations in some CML patients. These patterns show that CML
mutation dynamics following TKI therapy are markedly distinct from other hema-
tologic malignancies. 
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THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN
PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL
B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A,
IN CHRONIC MYELOID LEUKAEMIA
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Molecular & Clinical Cancer Medicine, University of Liverpool, Haematology,
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Background: Protein phosphatase 2A (PP2A) is an important phosphatase
which opposes the deregulated kinase activity that typifies many malignancies.
It comprises a scaffold (A) subunit linked to a catalytic (C) and regulatory (B)
subunit; the latter dictates activity, substrate specificity and intracellular locali-
sation and has 26 isoforms. Of these, B56γ confers a PP2A nuclear localisation
signal, and mutations interfering with its PP2A binding are reported in solid
tumours. We have shown that a high diagnostic level of CIP2A, a key PP2A
inhibitor, is a predictive biomarker of poor outcome in both acute and chronic
myeloid leukaemia (CML), and ~30 studies in non-haematological tumours all
also show a similar association with poor outcome. PP2A is known to dephos-
phorylate MYC at serine 62, thus destabilising it and shortening its half-life.
PP2A also regulates mTORC1, MAPK/ERK, AKT, P53 and NfKB pathways
which are associated with malignancy, but whether CIP2A involvement is direct
or indirect is not understood; furthermore the detailed molecular and biochem-
ical consequences of high CIP2A levels in malignant cells remain elusive.
Aims: We aim to test whether CIP2A binding to PP2A is dependent on which
regulatory subunits are attached in the PP2A heterotrimeric complex. This will
help to explain how CIP2A can mediate some but not all of PP2A’s specific
functions on pathways involved in cancer progression.
Methods: The CML cell line K562 expresses high levels of CIP2A. Its CIP2A
levels and those of MYC, S62 MYC, and PP2A components were assessed by
flow cytometry. Primary CML cells, both mononuclear and CD34+, with either
low or high levels of CIP2A were also studied, after obtaining informed consent.
CML cells and cell-lines were used in fractionation (to seperate into distinct
cellular compartments), western blotting, co-immunoprecipitation and qPCR. 
Results: CIP2A co-immunoprecipitates not only with PR65, the heat repeat
scaffold (A) subunit of PP2A, but also with B56γ, one of the B regulatory sub-
units of PP2A, though not with the alternative B subunits PPP2R4, B56α, B56β,
PPP2R5E or B72/130. In primary CML cells with high CIP2A levels, B56γ
mRNA expression is lower than in either control or CML samples with low
CIP2A levels, to suggest it has an inhibitory effect on B56y protein levels. In
high CIP2A K562 cells, CIP2A is predominantly cytoplasmic, as is B56γ. In
addition, S62 MYC is almost entirely cytoplasmic. CIP2A knockdown by tran-
sient transfection of siRNA will increase the level of B56γ and vice versa, sug-
gesting that expression is negatively correlated.
Summary/Conclusions: These data suggest that CIP2A reduces the active
PP2A-B56γ associated complex and is compatible with the following model: In
normal cells (which have very little CIP2A present) and malignant cells with low
CIP2A, the PP2A scaffold plus C unit complex moves freely around the cell with
full activity, getting access to the nucleus by the nuclear localisation signal
obtained on binding B56γ. CIP2A is at too low a level to interfere with this. Cyto-
plasmic PP2A is also fully active and can thus regulate important cytoplasmic
pathways such as MAPK/Jun which can promote proliferation. If CIP2A is high
(exclusively a feature of some malignant cells), it binds B56γ as part of the
PP2A complex. This results in the specific loss of function performed by the
PP2A-B56γ attached complex. This could be achieved by CIP2A in a number
of ways, including interfering with PP2A- B56γ nuclear transport, by restricting
access of the nuclear localisation signal (NLS) or a direct inhibitory effect on
function (i.e. blocking of the active site). Concurrently, a reduction in B56γ mRNA
is observed. Overall, these effects reduce the amount of PP2A- B56γ phos-
phatase function, leading to deregulation of known pathways that require func-
tional B56γ; these include the P53 tumour suppressor function and MAPK/ERK
in uncontrolled cell proliferation. The effect on S62 MYC may also be affected
by reducing total nuclear levels of PP2A or causing a misbalance of other active
B regulatory subunits that compete to bind PP2A. Thus, high CIP2A results in
a specific deregulation of PP2A function likely to promote clonal progression,
with potential overlap in other haematological malignancies.
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MODELLING PONATINIB RESISTANCE IN BCR-ABL1+ CELL LINES:
IMPLICATIONS FOR PONATINIB THERAPY
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Background: Ponatinib overcomes TKI resistance (imatinib, nilotinib and dasa-
tinib) that develops due to BCR-ABL1 kinase domain (KD) mutations including
T315I. Besides KD mutations, there are several identified TKI resistance mech-
anisms, such as BCR-ABL1 overexpression, regulation of the expression of
TKI transporters, and Bcr-Abl independent Axl kinase overexpression. How-
ever, little is known about the mechanisms that may cause ponatinib resistance.
Here, modes of ponatinib resistance have been investigated in TKI naïve and
pre-treated BCR-ABL1+ cell lines.
Aims: To characterise ponatinib resistance mechanisms in BCR-ABL1+ cell
line models.
Methods: Ponatinib resistance was generated by using four BCR-ABL1+ cell-
lines: 1) K562, 2) K562-DOX (ABCB1 overexpressing variant) 3) K562 DOX-
55D (resistant to 55 nM dasatinib) and 4) K562 T315I (resistant to 200 nM
dasatinib, harbouring the T315I mutation). The average steady state of pona-
tinib plasma concentration in patients is 101 nM for dosage at 45 mg/day.
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Hence, the resistant cells were exposed to increasing concentration of ponatinib
to 100 nM (if higher concentration could not be achieved) or 200 nM, as these
concentrations are close to clinically relevant. Parental ponatinib naïve controls
were maintained in parallel. R indicates ponatinib resistant variants.
Results: Four resistant cell lines were established. All of the four cell lines
were cross-resistant to other TKIs (2000 nM imatinib, 1000 nM nilotinib and
200 nM dasatinib). The two dasatinib pre-treated resistant cell lines developed
BCR-ABL1 KD mutation(s). The level of T315I in the K562 T315I-R line (sur-
vived in 100 nM ponatinib) increased from 44% to 66%, and the expression
level of BCR-ABL1 increased 6-fold compared to the naïve line (p<0.05). The
K562 DOX 55D-R (survived in 200 nM ponatinib) developed compound muta-
tions G250E/E255K (54%). However, KD mutations were not observed in the
cell lines with no prior exposure to TKI. The ponatinib resistance in K562-R
and K562 DOX-R cell lines (both survived in 200 nM ponatinib) were Bcr-Abl
independent: active Bcr-Abl and CrkL (surrogate marker of Bcr-Abl activity)
levels were reduced, while Axl protein and AXL mRNA expression levels were
increased significantly (all p<0.05). After incubation with Axl inhibitors, 1 μM
R428 or 12.5 μM BMS-777607, the K562-R and K562 DOX-R cell lines were
re-sensitised (approximately 50% reduction in viability) to 200 nM ponatinib
while the controls remained resistant to the drug (both p<0.05). Next, retroviral
vector was used to reduce AXL gene expression in the K562-R and K562 DOX-
R cell lines. This AXL gene reduction in the two cell lines resulted in re-sensi-
tisation to 10 nM ponatinib (Figure 1A-B), while controls remained resistant to
200 nM ponatinib. These results suggested that Axl overexpression is critical
for Bcr-Abl independent ponatinib resistance.
Figure 1.
Summary/Conclusions: We show that in the setting of prior-TKI exposure,
BCR-ABL1 KD mutations are likely to cause ponatinib resistance. In the TKI
naïve setting, Bcr-Abl independent modes of resistance may be more likely,
suggesting combination therapeutic approaches may be required in this setting.
In addition, ponatinib resistance are unlikely to be overcome by the use of the
first or second generation TKIs.
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HIGH THROUGHPUT SEQUENCING AS A MEASURE OF EARLY
RESPONSE TO THERAPY IN CHILDHOOD ALL
I Kirsch1,*, B Crossley1, D Williamson2, C Gawad3, B Wood4, M Borowitz5,
M Devidas6, K Maloney6, E Larsen6, N Winick6, P Marin6, S Hunger7, M Loh8,
H Robins9
1Translational Medicine, 2Client Services, Adaptive Biotechnologies, Inc., Seat-
tle, 3Oncology, St. Jude Children’s Research Hospital, Memphis, 4Laboratory
Medicine, University of Washington, Seattle, 5Laboratory Medicine, Johns Hop-
kins University Medical Center, Baltimore, 6Children’s Oncology Group, Uni-
versity of Florida, Gainesville, 7Pediatric Oncology, Children’s Hospital of
Philadelphia, Philadelphia, 8Pediatric Oncology, University of California at San
Francisco, San Francisco, 9Adaptive Biotechnologies, Seattle, United States
Background: Early response to induction chemotherapy has been demon-
strated to be a highly significant prognostic factor in the outcome of children
with acute lymphoblastic leukemia. Multiparametric flow cytometry (mpFC) has
been the routinely used methodology in the US for determination of this
response. New high throughput sequencing (HTS) technologies of rearranged
immune receptor (TCR and Ig) genes have raised the possibility of a more
accurate, sensitive, and standardizable approach to determination of early
response to therapy in ALL patients.
Aims: In this study, we investigated whether the Adaptive Biotechnologies
assay of IgH and TCRG would be able to quantify residual disease at the end
of induction therapy for children with ALL and be of prognostic value with regard
to outcome (event free survival) in these patients.
Methods: The first study involved a total of 480 patients enrolled on Children’s
Oncology Group (COG) clinical trials AALL0331 and AALL0232 for whom mpFC
measurement of residual disease and outcome data are available. A second
study involved samples from 73 patients enrolled in a former Pediatric Oncology
Group trial, POG 9905, who were mpFC negative at d29. For increased statis-
tical power the patients in POG 9905 were selected for analysis so that ~50%
had relapsed disease determined in follow-up monitoring. MpFC was performed
at COG reference laboratories the University of Washington or Johns Hopkins
Hospital as part of the evaluation for MRD. Genomic DNA was extracted from
frozen bone marrow specimens collected at diagnosis and at day 29 post the
start of induction therapy. High throughput sequencing of CDR3 regions of IGH
and TCRG was performed on all samples, with the testing laboratory blinded
to patient outcome. Diagnostic and d29 matched samples from a given patient
were sequenced and dominant clonal CDR3 sequences from diagnosis were
searched for in the corresponding d29 sample. Both the presence and the fre-
quency of the MRD clone relative to the total IGH repertoire and total nucleated
cell population were determined.
Results: The assays defined the dominant clonal sequences in 93% of the
patients. 70% of this subgroup was found to have residual disease present at
d29. Clones from some of the patients demonstrated a single “trackable”
sequence while clones from other patients demonstrated multiple trackable
sequences either within or between the two immune receptor loci being
assessed. 60% of the residual disease detected by HTS was previously report-
ed as MRD negative by mpFC. For “standard risk” patients, 53% were positive
for MRD by HTS and negative by mpFC. With the combined COG data, using
a MRD cutoff of 10-4, HTS was able to define a correlation with event-free sur-
vival (p=0.0003). Furthermore, for the “standard risk” patients, being MRD pos-
itive or negative as determined by the more sensitive HTS assay was also cor-
related with outcome (p=0.02). In addition, a correlation was noted between
poorer outcome and a “germline” or TCRG only (i.e. IgH loci retained in the
germline configuration) genotype (p=0.04). In the second study of patients
enrolled in the POG 9905 trial, the more sensitive HTS cut-off of 10-5was cor-
related with outcome (p=0.0228).
Summary/Conclusions: This is the largest patient cohort studied to date for
which mpFC, HTS, and outcome data are available. This work suggests that
HTS is an accurate and standardized assay whose increased sensitivity com-
pared to mpFC is relevant to determination of patient outcome.
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DURABLE REMISSIONS AFTER MONOTHERAPY WITH CD19-SPECIFIC
CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS IN CHILDREN
AND YOUNG ADULTS WITH RELAPSED/REFRACTORY ALL
S Maude1,*, D Teachey1, S Rheingold1, P Shaw2, R Aplenc1, D Barrett1,
C Barker1, C Callahan1, N Frey2, F Nazimuddin2, S Lacey2, Z Zheng2,
B Levine2, J Melenhorst2, L Motley1, D Porter2, C June2, S Grupp1
1The Children’s Hospital of Philadelphia, 2University of Pennsylvania, Philadel-
phia, United States
Background: Targeted immunotherapy with chimeric antigen receptor (CAR)-
modified T cells can produce potent anti-tumor responses. We previously report-
ed complete remissions (CR) and prolonged persistence in children and adults
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with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with CD19-
specific CAR-modified T cells (CTL019). We now report on outcomes and
longer follow-up of 59 children and young adults with relapsed/refractory ALL
enrolled on the pediatric phase 1/2a trial of CTL019.
Aims: Determine the safety and efficacy of CTL019 in pediatric patients with
relapsed/refractory CD19+ ALL. Determine the safety and efficacy of CTL019
in pediatric patients with a history of CNS involvement of ALL. Assess relapse-
free survival (RFS) and overall survival (OS) after CTL019.
Methods: After informed consent, patient-derived T cells were transduced with
a lentiviral vector encoding a CAR composed of anti-CD19 scFv, CD3z, and 4-
1BB domains, activated/expanded ex vivo with anti-CD3/CD28 beads, and
then infused at a dose of 107 to 108 cells/kg with a transduction efficiency of
2.3-45%. 54/59 patients received lymphodepleting chemotherapy the week pri-
or to cell infusion.
Results: Of 59 patients aged 20mo-24y with CD19+ ALL, 44 had detectable
disease prior to CTL019 cell infusion, while 15 were minimal residual disease
(MRD)-negative. 39 were treated for relapse after prior stem cell transplant
(SCT). 15 patients had CNS disease within a year of infusion. At assessment
1 month after infusion, 55/59 (93%) were in CR. MRD <0.01% by flow cytometry
was achieved in 52 patients. CTL019 cells were detected in the CSF, all patients
achieved CR in the CNS (including 4 patients with CSF blasts detected the
day prior to infusion), and no CNS relapses have been seen. With median fol-
low-up 12 mo (1-43 mo), 34 patients had ongoing CR, with only 6 receiving
subsequent therapy (5 SCT, 1 donor lymphocyte infusion), RFS was 76% (95%
CI, 65-89%) at 6 mo and 55% at 12 mo (95% CI, 42-73%), and OS was 79%
(95% CI, 69-91%) at 12 mo. 20 patients subsequently relapsed, 13 with CD19-
negative disease. CTL019 persistence was accompanied by B cell aplasia,
which continued up to last assessment (1-39 mo) in 24/34 patients with ongoing
CR. Cytokine release syndrome (CRS) was seen in 88% of patients. Severe
CRS requiring hemodynamic or respiratory support occurred in 27%, was asso-
ciated with high disease burden, and was reversed with the anti-IL6R agent
tocilizumab. We could predict development of severe CRS through regression
modeling using IFNγ, sgp130, and IL1RA measured in the first 72h (sensitivity
86%, specificity 89%, AUC 0.93).
Summary/Conclusions: Single-agent CTL019 immunotherapy can induce
potent responses in patients with relapsed/refractory ALL and can control CNS
leukemia. Durable remissions were observed without subsequent SCT. Phase
2 multisite and global registration trials of CTL019 are in progress.
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IMPACT OF DISEASE BURDEN ON LONG-TERM OUTCOME OF
CD19-TARGETED CAR MODIFIED T CELLS IN ADULT PATIENTS WITH
RELAPSED B-ALL
J Park*, I Riviere, X Wang, M Sadelain, R Brentjens
Memorial Sloan-Kettering Cancer Center, New York, United States
Background: We have previously reported high response rates in adult
patients with relapsed or refractory (R/R) B-cell ALL following CD19-targeted
19-28z chimeric antigen receptor (CAR) modified T cells regardless of the dis-
ease burden at the time of T cell infusion. However, the impact of disease bur-
den on toxicity and long-term clinical outcome in patients who received 19-28z
CAR modified T cells has not been examined in detail.
Aims: In order to better understand the association between pre-treatment
disease burden and tolerability and long-term efficacy of 19-28z CAR T cells,
herein we report the result of of a focused analysis from the phase I clinical
trial of 19-28 CAR T cells in adults patients with R/R B-ALL (NCT01044069).
Methods: Adult patients with R/R B-ALL were enrolled to the phase I clinical
trial. All patients underwent bone marrow (BM) biopsy immediately prior to 19-
28z CAR T cell infusion, and were divided into two cohorts based on the blast
% in BM: minimal disease (<5% blasts) vs morphologic disease (≥5% blasts).
Subsequently, patients received lymphodepleting chemotherapy followed by
19-28z CAR T cell infusion. 
Results: Of 46 patients treated, 21 patients had minimal disease and 25
patients had morphologic disease at the time of CAR T cell infusion. Baseline
disease and treatment characteristics were similar between the two cohorts,
except less HSCT in the minimal disease cohort (29 vs 48%). Complete
response (CR) and minimal residual disease-negative CR (MRD-CR) rates
were 91% and 71% in the minimal disease cohort, and 75% and 65% in the
morphologic disease cohort, respectively. Severe cytokine release syndrome
exclusively occurred in patients with morphologic disease (44% vs 0%) but
grade 3/4 neurotoxicity was observed in 14% of patients with minimal disease
vs 40% with morphologic disease. Although overall relapse rates did not differ
between the two cohorts, no relapse or death occurred in the minimal disease
cohort beyond 12 months. At a median follow-up of 12.0 months (range, 1-45),
the estimated 6-month overall survival (OS) rates for all patients in the minimal
disease and morphologic disease cohorts were 73% and 57%, respectively.
Among the patients who achieved MRD-CR, the estimated 6-month OS rates
were 92% for the minimal disease cohort with remissions extending beyond 3
years, and 65% for the morphologic disease cohort. 
Summary/Conclusions: These data confirm the potent anti-tumor efficacy of
19-28z CAR T cells (JCAR015) in adult patients with R/R ALL regardless of
pre-treatment disease burden. Patients with minimal disease appear to have
more favorable toxicity profile and long-term survival rates. These findings sup-
port the use of 19-28z CAR T cells in earlier lines of ALL treatment, such as in
a frontline setting. 
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INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE
LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED
CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR
THERAPY
DJ DeAngelo1,*, EJ Jabbour2, M Stelljes3, M Liedtke4, W Stock5, N Goekbuget6,
G Martinelli7, S O’Brien8, K Wang9, T Wang10, ML Paccagnella10, B Sleight10,
E Vandendries11, AS Advani12, HM Kantarjian2
1Dana-Farber Cancer Institute, Boston, MA, 2University of Texas MD Anderson
Cancer Center, Houston, TX, United States, 3Universitätsklinikum Münster, Mün-
ster, Germany, 4Stanford Cancer Center, Stanford, CA, 5The University of Chica-
go Medicine, Chicago, IL, United States, 6University Hospital Frankfurt, Frankfurt,
Germany, 7University of Bologna, Bologna, Italy, 8University of California, Irvine,
Orange, CA, 9Pfizer Inc, Pearl River, NY, 10Pfizer Inc, Groton, CT, 11Pfizer Inc,
Cambridge, MA, 12Cleveland Clinic Main Campus, Cleveland, OH, United States
Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-
calicheamicin conjugate, showed superior response vs standard care for
relapsed/refractory acute lymphoblastic leukemia (ALL) in the ongoing phase
3 INO-VATE trial.
Aims: To assess the effects of prior therapy on response and toxicities in
patients with relapsed/refractory ALL receiving InO in the phase 3 trial
Methods: Per protocol, intent-to-treat analyses of complete remission [CR]/CR
with incomplete hematologic recovery [CRi] included the first 218 of 326
patients randomized (ITT218). The safety population included 139 patients
who received ≥1 InO dose (max 1.8 mg/m2/cycle [0.8 mg/m2 on day 1; 0.5
mg/m2 on days 8 and 15 of a 21–28 day cycle for ≤6 cycles]). Minimal residual
disease (MRD) negativity was assessed by central flow cytometry (<0.01%).
Data as of October 2, 2014 are presented (trial ongoing). Informed consent
was obtained from all patients.
Results: 109 patients in the ITT218 received InO (CR/CRi rate, 81% [95% CI,
72–88]; MRD negativity rate in responders, 78% [95% CI, 68–87]; median
remission duration [DoR], 4.6 [95% CI, 3.9–5.4] months). 67% and 32% of
patients received InO as salvage (S) 1 and S2 (missing, n=1). For S1 vs S2,
response was numerically higher, MRD-negativity was similar, and DoR was
numerically longer (Table 1). CR/CRi rate was numerically lower for patients
with (n=17) vs without (n=92) prior SCT (77% [95% CI, 50–93] vs 82% [72–
89]). In the safety population, grade ≥3 febrile neutropenia rates were similar
for S1 (n=95) vs S2 (n=43) (both 23%) and for patients with (n=24) vs without
(n=115) prior SCT (29% vs 23%). Any grade hepatobiliary AE rates were sig-
nificantly higher in S2 vs S1 (47% vs 17%; P<0.001) and numerically higher
for patients with vs without prior SCT (42% vs 23%). For S1 vs S2, 36 vs 11
patients had poststudy SCT. Veno-occlusive liver disease (VOD) including post-
SCT VOD occurred in 8% of S1 vs 16% of S2 patients (2 fatal in S1); in 21%
with vs 9% without prior SCT (1 fatal in each cohort).
Table 1.
Summary/Conclusions: InO may provide clinical benefit in patients with
relapsed/refractory ALL for both S1 and S2 therapy; hepatotoxicity risk increas-
es with number of prior therapies and prior SCT.
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EARLY IMMATURE T-ALL AS DETERMINED BY ABSENCE OF BI-ALLELIC
DELETION AT THE TCR GAMMA LOCUS IS NOT AN ADVERSE
PROGNOSTIC FACTOR ON THE MRC UKALL2003 TRIAL
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Background: Despite a marked improvement in the survival of children with
T-cell acute lymphoblastic leukaemia (T-ALL), a significant proportion of patients
will experience refractory disease or relapse. Previous studies using
immunophenotyping and gene expression profiling identified the early T-cell
precursor (ETP) phenotype as a subgroup of T-ALL with an inferior outcome.
However, the diagnosis of ETP by immunophenotyping remains difficult to stan-
dardise, and gene expression profiling on T-ALL cases is not widely utilised.
An alternative marker of immature T-ALL is Absence of Bi-allelic Deletion (ABD)
at the TCRγ locus which has been shown to be associated with a very poor
outcome. It is a marker that can potentially be standardised and assessed in
real time for clinical use. 
Aims: To investigate whether ABD status at the TCRγ locus adds prognostic
information to paediatric T-ALL patients treated on the MRC UKALL2003 trial. 
Methods: After informed consent, diagnostic DNA from 152 paediatric patients
with T-ALL on the UKALL2003 trial was analysed by qPCR to amplify the region
between the most 3’ V region (TRGV11) and the most 5’ J region (TRGJP1) of
the TCRγ locus. Presence of an undeleted sequence in this region would indi-
cate developmental arrest of the thymocyte at an early immature stage prior to
V-J recombination. Patients were assigned to the ABD and non-ABD groups if
fold change was ≥0.5 and <0.25 respectively. The undetermined group (fold
change 0.25-0.5) were excluded from further analysis. Results were validated
using the Illumina CytoSNP-850K array. Overall Survival (OS) and Relapse-
free Survival (RFS) were plotted using Kaplan-Meier survival analysis. Cox
regression and the log rank test were used to compare groups. 
Results: Of 152 patients analysed by qPCR, 23 (15%) had ABD, 110 (72%)
were non-ABD, and 19 (13%) were undetermined. Of the 133 informative
patients, 118 had SNP array data that was consistent with the qPCR findings.
There was no statistical difference in OS by ABD group (HR for ABD 1.34 (0.37–
4.79); p=0.65). RFS was also very similar between the two groups (HR for ABD
1.68 (0.54-5.22); p=0.36) (Fig 1). MRD results were available for 102 patients.
Median MRD levels were higher in the ABD group than the non-ABD group
(2.5% positive cells at day 29 vs 0.02% respectively, p=0.031). The proportion
of patients with indeterminate MRD was also higher in the ABD group (n=13,
57%) than in the non-ABD group (n=18, 19%) (p<0.0001). All eight ABD patients
with high risk MRD received regimen C compared to 29 of 53 (55%) MRD high
risk non-ABD patients (p=0.01). The good OS in ABD patients could not be
attributed to coincidence of a favourable–risk NOTCH/FBXW7 genotype, as
only 9% (2/23) of ABD patients were double mutant as compared to 31%
(34/110) of non-ABD patients (p=0.03) (Figure 1).
Figure 1. Kaplan-Meier curves for OS and RFS for T-ALL patients accord-
ing to ABD status treated on the UKALL2003 trial.
Summary/Conclusions: We found no evidence that the molecular marker
ABD added further prognostic value to the outcome of paediatric patients with
T-ALL treated on the UKALL2003 trial. Therefore escalation of treatment to
more intensive regimens based on ABD status is not justified on this protocol.
Our failure to confirm previous reports of a poor outcome for the ABD patients
could be due to the fact that this trial employed MRD risk directed therapy.
New Compounds in AML Treatment
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PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE
CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS
AGED ≥65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE
FOR INTENSIVE THERAPY
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Background: Volasertib (V) is a potent and selective cell cycle kinase inhibitor
that induces mitotic arrest and apoptosis by targeting polo-like kinase. In a ran-
domized, open label, Phase II trial in patients (pts) with previously untreated AML,
ineligible for intensive therapy, V+LDAC vs LDAC improved remission rate (31%
vs 13%; p=0.052), event-free survival (EFS; HR 0.57 [95% CI 0.35–0.92]) and
overall survival (OS; HR 0.63 [95% CI 0.40–1.00]; Döhner et al., Blood 2014).
Aims: A Phase III trial (NCT01721876) was conducted to confirm the Phase II
results.
Methods: Pts were randomized 2:1 (stratified by ECOG [0/1 vs 2] and type of
AML [de novo vs secondary]) to receive LDAC (20 mg s.c. BID Days 1–10
Q4W) and either V (350 mg; 1-hr iv infusion Days 1 and 15 Q4W) or placebo
(P). The primary analysis was performed after completion of recruitment (Nov
2014) and focused on efficacy in pts randomized ≥5 months before clinical cut-
off. Objective response (OR; complete response [CR]+CR with incomplete
hematological recovery [CRi]; blinded central review) was the primary endpoint,
and OS was the key secondary endpoint. An additional OS analysis was per-
formed in all randomized pts (Nov 2015).
Results: 666 pts were treated (444 V+LDAC; 222 P+LDAC). The primary analy-
sis included 371 pts (246 V+LDAC; 125 P+LDAC); pt characteristics were bal-
anced: median age, 75/75 yrs; secondary AML, 47%/49%; adverse genetics,
32%/32%, respectively. The percentage of pts with OR was not statistically sig-
nificantly higher with V+LDAC vs P+LDAC (25.2% vs 16.8%; Odds ratio 1.66
[95% CI 0.95–2.89; p=0.071]), and thus the primary endpoint was not met. A
negative OS trend was seen for V+LDAC vs P+LDAC (median OS: 4.8 vs 6.5
mos; HR 1.26 [95% CI 0.95–1.67; p=0.113]). Adverse event severity increased
with V+LDAC vs P+LDAC, with fatal infection frequency of 16.6% vs 5.1%, con-
sidered to be the main reason for the negative OS trend. Consequently, the
study was unblinded, and investigators/pts could stop/continue treatment based
on individual benefit-risk evaluations. Additional exploratory analyses were con-
ducted. The protocol allowed doses to be missed or delayed for medical reasons;
this dosing flexibility resulted in differences of overall treatment intensity, and a
better outcome for pts treated in the V+LDAC arm at lower-dose density vs high-
er-dose density was shown. Competing risk modeling of survival endpoints
(events resulting from lack of efficacy or non-tolerability) confirmed the
antileukemic effect of V+LDAC. An additional OS analysis was performed on all
randomized pts from a Nov 2015 snapshot. The HR for OS was 1.06 (95% CI
0.88–1.28; p=0.552); these OS results may be affected by the communication
of primary analysis results, unblinding and subsequent treatment decisions.
Summary/Conclusions: This Phase III trial did not meet the primary endpoint
and did not confirm the promising efficacy results from the randomized Phase
II study. Pts treated with V+LDAC had higher risk for fatal infections compared
with P+LDAC, resulting in a negative OS trend at the primary analysis. Pt man-
agement/medical decision making (dose density) influenced the outcome and
might have been affected by the blinded trial design. Updated results one year
after unblinding show largely overlapping OS for both treatment arms. Com-
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peting risk modeling of survival endpoints confirmed the antileukemic effect of
V+LDAC and supports investigation of modified V doses and schedules to
improve tolerability. The trial is still ongoing; updated/final results will be pre-
sented at the meeting as available.
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37Sarah Cannon Research Institute, Nashville, 38Temple BMT Program, Jeanes
Hospital, Philadelphia, 39Cancer Research And Biostatistics, Seattle, 40Uni-
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Background: CPX-351 is a nano-scale liposomal formulation of 5:1 molar
ratio cytarabine and daunorubicin that exhibits marked efficacy improvements
among poor risk AML patients. A phase III study of CPX-351 vs 7+3 treatment
in older high-risk (e.g. secondary) AML patients is nearing completion
(NCT01696084).
Aims: This report correlates induction response (CR+CRi) with baseline FLT3
ITD/TKD+, NPM1+, and CEBPA+ mutations from the Phase III study.
Methods: Patients 60-75 years of age with t-AML, MDSAML, CMMLAML and de
novo AML with MDS cytogenetic abnormalities were eligible for this open label
randomized study. 153 patients were randomized to CPX-351 (100units/m2, days
1, 3, and 5) and 156 patients to 7+3 (cytarabine 100mg/m2/dayx7 days, daunoru-
bicin 60mg/m2 days 1, 2, and 3) induction. Data for response was reviewed inde-
pendently and in a blinded manner by the study’s hematopathologist. Patients
were assessed at baseline for FLT3, NPM1, and CEBPA mutations.
Results: Mutation status was determined in 278/309 (90%) patients for FLT3
ITD, 275/309 (89%) for FLT3 TKD, 282/309 (91%) for NPM1, and 270/309
(87%) for CEBPA. FLT3 mutations (ITD+ and/or TKD+) were found in 44 (16%)
patients. Mutations occurred in 26 pt (9%) for NPM1, and 15 pt (6%) for CEBPA.
The complete remission data stratified by FLT3 ITD+, FLT3 TKD+, NPM1+,
and CEBPA+ status are presented in the Table 1. Compared to control, CPX-
351 treatment produced higher response rates among all patients (47.7% vs
33.3%), all FLT3 mutated patients (68.2% vs 27.3%, p=0.148), FLT3 ITD+
patients (12/19 (63.2%) vs 3/14 (21.4%)), FLT3 TKD+ patients (5/6 (83.3%) vs
4/11 (36.4%)), and NPM1+ patients (92.3% vs 53.9%). Most FLT3 ITD+ patients
were NPM1- (26/33, 78.8%) with responses in 8/15 (53.3%) CPX-351 vs 2/11
(18.2%) in 7+3 patients. 
Summary/Conclusions: Treatment with CPX-351 appears to be associated
with improved response rates in patients with common AML mutations, includ-
ing those associated with poor outcomes, such as FLT3 ITD mutations. Pre-
liminary findings from cytotoxicity assays using fresh AML patient blasts suggest
that AML blasts exhibiting FLT3 ITD mutations were more sensitive to CPX-
351 than FLT3 WT blasts. Moreover, increased cytotoxicity was associated
with increased uptake of CPX-351 liposomes by AML blasts. While the clinical
findings are based on small patient numbers, the remission data presented
here, combined with the early preclinical data provide a provocative hypothesis
for how CPX-351 might be advantageous for specific types of AML mutations
and provide a rationale for expanded trials of CPX-351, particularly in the FLT3
ITD mutated population, which is expected to respond poorly to conventional
treatment regimens.
Table 1.
                              CR+CRi Rate n (%)
Group:                                       CPX-351 Arm             7+3 Arm                  p-value
All patients                               73/153 (47.7)       52/156 (33.3)
FLT3 mutated (all)                     15/22 (68.2)          6/22 (27.3)               0.0148
FLT3 ITD+/TKD-                            10/16 (62.5)           2/11 (18.2)
FLT3 ITD+/TKD+                             2/3 (66.7)              1/3 (33.3)
FLT3 ITD-/TKD+                              3/3 (100)              3/8 (37.5)
FLT3 ITD+/NPM1-                         8/15 (53.3)            2/11 (18.2)
NPM-1mutated (all)                   12/13 (92.3)          7/13 (53.9)
NPM1+/FLT3 wt                             5/6 (83.3)              6/7 (85.7)
NPM1+/FLT3 mutated                    6/6 (100)              1/5 (20.0)
NPM1+/FLT3 unknown                   1/1 (100)               0/1 (0.0)
CEBPA mutated (all)                   3/11 (27.3)            1/4 (25.0)
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SGN-CD33A IN COMBINATION WITH HYPOMETHYLATING AGENTS: A
NOVEL, WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN
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Background: Many older patients with AML are treated with hypomethylating
agents (HMAs) or other low-intensity therapy (Dombret 2015, Kantarjian 2012).
SGN-CD33A (vadastuximab talirine; 33A) is a CD33-directed antibody conju-
gated to 2 molecules of a pyrrolobenzodiazepine (PBD) dimer. Upon binding,
33A is internalized and transported to the lysosomes where PBD dimer is
released via proteolytic cleavage of the linker, crosslinking DNA, and leading
to cell death. Enhanced cytotoxicity was observed in preclinical studies com-
bining 33A+HMA (azacitidine or decitabine), with HMA priming upregulating
CD33 and increasing incorporation of PBD dimer (Sutherland 2015).
Aims: A combination cohort in a phase 1 study (NCT01902329) was designed
to evaluate the safety, tolerability, pharmacokinetics, and antileukemic activity
of 33A in combination with an HMA.
Methods: Eligible patients (ECOG 0– 1) must have previously untreated CD33-
positive AML, and have declined intensive therapy. 33A (10 mcg/kg) was admin-
istered via outpatient IV every 4 weeks on the last day of HMA (azacitidine or
decitabine [5-day regimen], standard dosing). Patients with clinical benefit could
continue treatment until relapse or unacceptable toxicity. Investigator assess-
ment of response was per IWG criteria; CRi required either platelet count of
≥100,000/µL or neutrophils of ≥1,000/µL (Cheson 2003).
Results: Fifty-three patients (64% male) with a median age of 75 years (range
60 – 87) were treated with the combination therapy. Nineteen patients (36%)
had adverse cytogenetic risk (MRC) and 30 patients (57%) had intermediate
cytogenetic risk. Forty-eight patients (91%) were treatment naïve and 5 patients
(9%) had received prior low-intensity therapy for MDS. At baseline, patients
had a median of 45.9% BM blasts. Patients were on treatment for a median of
15.6 weeks (range 2 – 68) and 27 patients (51%) remain on study treatment;
no DLTs were reported. Grade 3 or higher adverse events (AE) reported in
≥20% of patients were febrile neutropenia (47%), thrombocytopenia (42%),
anemia (34%), and neutropenia (28%). Other common treatment-emergent
AEs regardless of relationship to study treatment were fatigue (55%), nausea
(43%), constipation (38%), decreased appetite (36%), and peripheral edema
(36%). Thirty- and 60-day mortality rates were 2% and 8% respectively with no
treatment-related deaths reported. Thirty-seven of the 49 efficacy evaluable
patients (76%) achieved CR (17), CRi (19), or PR (1), with a median time to
remission of 2 cycles (range 1 – 4); the median relapse-free survival in CR/CRi
patients is currently 6.9 months (range 0+ – 11+). Thirteen of 17 patients (76%)
with adverse cytogenetic risk achieved remission. Of the responding patients,
14 of 33 (42%) achieved MRD negativity by local or central flow cytometry.
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Thirty-seven patients (70%) were alive at the time of this data cut with a median
follow-up of 4.7 months (range 0.5-15.6). Survival trends appear similar in
patients ≥75 years as in patients <75 years.
Summary/Conclusions: The combination of 33A with HMA was well tolerated
and capable of inducing deep and durable remissions. In ~50 treated patients,
activity with the combination appeared greater and occurred more rapidly than
what is historically expected from HMA alone in this patient population. The
observed low early mortality rate and the 76% overall remission rate in AML
patients with poor risk factors are particularly encouraging. A global phase 3
randomized trial of 33A+HMA vs HMA alone is planned for 2016.
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PHASE 1B RESULTS OF IDASANUTLIN+CYTARABINE (ARA-C) IN ACUTE
MYELOID LEUKEMIA (AML) PATIENTS (PTS)
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Background: Idasanutlin is a potent, oral MDM2 antagonist. A Phase 1b study
was conducted to assess the safety and efficacy of idasanutlin+ara-C in
relapsed/refractory (R/R) AML pts.
Aims: The primary endpoint was to identify the maximum tolerated dose and/or
recommended dose and safety profile of idasanutlin+ara-C. Secondary endpoints
included complete remission (CR) rate, complete remission with incomplete
platelet (CRp) or hematologic recovery (CRi), morphologic leukemia free state
(MLFS), composite complete remission (CRc, CR+CRp+CRi) rate, pharmacoki-
netics (PK), and exploratory analyses of predictive/prognostic biomarkers.
Methods: In the dose escalation phase, R/R AML pts or those not considered
candidates for standard induction therapies were treated with escalating doses
of the initial idasanutlin formulation dailyx5 days (d)+ara-C 1 g/m2x6d. After
identification of the recommended dose, an expansion cohort in R/R AML pts
treated with ≤2 prior regimens was enrolled. A bridging arm was added to char-
acterize the safety and PK of a spray dried powder (SDP) formulation of
idasanutlin. CRs were confirmed ≥28d after initial assessment. TP53 mutation
and flow cytometry of MDM2 expression in blasts were assessed as potentially
predictive/prognostic by association with CRc.
Results: A total of 76 pts (1 pt was subsequently identified to have CMML and
not AML) were treated with the combination therapy. Dose escalation patients
(n=23) were treated with 400 mg qd (n=10), 400 mg bid (n=7), or 600 mg bid
(n=6) of idasanutlin with ara-C. While not meeting protocol specified DLT crite-
ria, diarrhea incidence and grade tracked with increasing dose and thus the
recommended dose was 600 mg bid. Twenty-one pts were subsequently treated
in an expansion cohort with 600 mg bid idasanutlin+ara-C. Thirty-two pts were
enrolled in the bridging arm with either 300 mg bid (n=19) or 400 mg bid (n=13)
of SDP idasanutlin+ara-C. Demographics and best responses are noted in the
Table 1. The CR proportion was 25% (19/75 pts); the CRc proportion was 29%
(22/75 pts), and the CR+CRp+CRi+MLFS proportion was 33% (25/75). Patients
with CRc were followed until relapse or until 1 year (yr) from start of therapy;
median duration of response is ~6.4 months (range 1.1 to 11.9 mos). Five pts
remain in CR and continue in the 1 yr follow up period; 4 pts were in CR at the
final visit ~1 yr from start of treatment. PK exhibited Cmax at ~6h, t1/2 of 1d, and
dose proportionality. The SDP formulation doubled relative bioavailability.
MDM2% positivity in CD45dim AML blasts by flow cytometry suggests that
higher levels of MDM2 expression are associated with response (p=0.00049).
TP53 mutation status was not associated but did trend with response (p=0.08)
as predictive/prognostic association derives from negative predictive value of
the small proportion of mutant patients. By contrast, MDM2 protein expression
by flow cytometry displayed pronounced association with CRc when analyses
were restricted to TP53 WT-only patients (p=0.0021).
Summary/Conclusions: Treatment with idasanutlin+ara-C resulted in durable
CRs. Five of the 22 pts who achieved a CRc (23%) proceeded to transplant
following therapy, demonstrating that this combination is a promising therapeutic
option in R/R AML. Biomarker data suggests that identifying pts in which TP53
activity may be therapeutically enhanced may provide for improved outcomes.
A Phase 3 trial is open and accruing.
Table 1.
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PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY
DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA
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Background: Vosaroxin, is a first-in-class anti-cancer quinolone derived (AQD)
DNA topoisomerase II inhibitor currently under evaluation for the treatment of
pts with AML and high-risk MDS.
Aims: To determine the overall response rate including complete response
(CR)+CR without platelet recovery (CRp)+CR with insufficient hematological
recovery (CRi), safety and early mortality of vosaroxin and decitabine in newly
diagnosed older pts with AML. 
Methods: Pts were eligible if they had untreated AML or high-risk MDS (≥10%
blasts), were 60 years of age or older, had adequate performance status (ECOG
≤2) and organ function. In the phase I the first six pts received vosaroxin 90
mg/m2 daily on Days 1 and 4 with decitabine 20 mg/m2 daily for 5 days repeated
in approximately 4 to 5 week intervals for up to 7 cycles. This dose was well
tolerated in the 6 pts. However, due to occurrence of 8 episodes of grade 3/4
mucositis in the subsequent 16 pts the induction dose of vosaroxin was reduced
to 70 mg/m2. 40 subsequent pts received vosaroxin 70mg/m2 in induction.. 
Results: 62 pts (55 AML, 7 high-risk MDS) with a median age of 69 years
(range, 60 - 78) have been enrolled. They included 23 (37%) with diploid, 22
(35%) with adverse, and 17 (27%) pts with miscellaneous cytogenetics. 18
(33%) pts with AML had antecedent hematological disorders (AHD) including
9 (16%) with MDS, 5 (9%) with MDS/MPN, and 1 (2%) with CLL. Four pts with
AHD had received prior therapy including 5-azacytidine (n=1), decitabine (n=1),
ruxolitinib+5-azacytidine (n=1), lenalidomide (n=1). Additionally, 10 (16%) pts
had therapy-related disease. Median bone marrow blast %, median white blood
cell, hemoglobin, & platelet counts were 36% (9-97), 3.6x109/L (0.4 - 57.0), 9.4
g/dL (6.8 - 13.1), and 33x109/L (7 - 333), respectively. All 62 pts were evaluable
for response. The overall response rate was 74% including CR in 31 (50%),
CRp in 10 (16%), and CRi in 5 (8%). Minimal residual disease by 19 color flow-
cytometry was not detectable in 21 of 38 (55%) evaluable responders. The
median number of cycles to response was 1 (1-4). Response by baseline char-
acteristics is shown in Table 1.
Table 1. Response by baseline characteristics.
Parameter                  Category               N      Overall response(CR, CRp, CRi)        CR
Age                            60-74≥75           5012                    74%75%                     52%42%
Cytogenetics                 Diploid               23                         83%                            57%
                         -5/-7/other adverse      22                         64%                            36%
                              Miscellaneous          17                         76%                            59%
MutationStatus           TP53IDH2           1311                    69%91%                     46%82%
                                    IDH1                  9                          33%                            33%
                                     RAS                  11                         64%                            18%
Eleven (18%) pts have proceeded to allogeneic stem cell transplant. The medi-
an follow-up is 11.0 months (2.8 - 27.5). The main therapy related grade ≥3
toxicities were mucositis in 11 (18%) and liver enzyme elevation in 8 (13%) pts.
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The median overall survival (OS) for all pts is 9.8 months. Four-week and 8-
week mortality for all pts were 0 and 13%, respectively. The induction dose of
vosaroxin was 90 mg/m2 in 22 pts and 70 mg/m2 in 40 pts. The lower dose of
vosaroxin was associated with reduced 8-week mortality (8% versus 23%),
similar overall response (75% versus 73%), and improved OS (Figure 1).
Summary/Conclusions: Combination of vosaroxin and decitabine is effective
in older pts with AML and high-risk MDS. The lower dose of vosaroxin 70 mg/m2
on days 1 and 4 is associated with improved outcomes. 
Figure 1. OS with vosaroxin and decitabine compared to historical cohort
of pts treated with single agent decitabine at MDACC.
Myeloproliferative neoplasms - Biology
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GENETIC VARIATION AT HBS1L-MYB AND GFI1B-GTF3C5 INFLUENCES
WHETHER JAK2 V617F MUTATED MPN PRESENT WITH ET OR PV
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Background: Evidence from epidemiological, familial and genetic studies indi-
cate that common, low penetrance variants present in the general population
contribute to the risk of developing MPN and also contribute to the phenotypic
pleiotropy observed in these disorders. In a recent genome wide study we
found that genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predis-
poses to JAK2-unmutated MPN. Furthermore, focused analysis of these four
variants demonstrated that rs9376092 at HBS1L-MYB and the JAK2 46/1 hap-
lotype specifically influence whether JAK2 V617F mutated cases present with
PV or ET. 
Aims: It is likely that variation at other genetic loci influence disease phenotype
in MPN. Our aim was to identify inherited genetic factors on a genome wide
basis that influence whether JAK2 V617F positive MPN patients present with
PV or ET.
Methods: We undertook a two stage genome-wide association study. At stage
1,556 ET and 556 PV patients with JAK2 V617F were genotyped using Illumina
Human OmniExpressExome v1.2 BeadChips. Following standard quality control,
allelic chi-square tests were used to compare ET and PV cases. At stage 2, sig-
nificant SNPs were genotyped in four additional JAK2 V617F-positive ET/PV
cohorts from the UK (n=180), Spain (n=664), Italy (n=547) and Germany (n=74).
The final effect size and significance of SNPs was determined by a fixed effects
meta-analysis. The relationship with disease subtype was determined by com-
parison of either ET or PV cases against healthy controls (stage 1; WTCCC2
n=5200) and linear regression was used to assess the relationship with JAK2
V617F mutation burden following normalisation using Blom transformation. 
Results: After quality control and excluding the p arm of chromosome 9 due to
recurrent aUPD in PV and to a lesser extent in ET, 650,386 SNPs were tested
in 499 ET and 505 PV cases at stage 1. Using a combination of significance,
clustering of significant linked SNPs and functional evidence, 163 SNPs were
tested at stage 2. Meta-analysis of ET versus PV cases identified one SNP,
rs9399137 43kb upstream of HBS1L and 83kb upstream of MYB, that achieved
genome-wide significance (pMETA=2.91x10-9) without heterogeneity between
cohorts (Cochran’s Q test, p=0.31). One additional SNP, rs3011271 16kb down-
stream of GFI1B and 22kb upstream of GTF3C5, with moderate significance for
ET versus PV (pMETA=3.00x10-5) and without heterogeneity between cohorts
(p=0.18) also reached genome-wide significance (pMETA=2.36x10-8) when com-
pared to V617F mutation level. In comparison with healthy controls, the HBS1L-
MYB SNP predisposes to ET (p=2.01x10-6, OR=1.41) while the GFI1B-GTF3C5
SNP predisposes to PV (p=1.66x10-7, OR=1.49). Stratifying PV cases by 9p
aUPD, showed that the association with GFI1B-GTF3C5 is restricted to PV cases
with 9p aUPD (p=1.95x10-11 in cases with aUPD; p=0.67 in cases without aUPD).
We found no evidence that previously reported SNPs at NR3C1 (glucocorticoid
receptor), TET2, ATM, SH2B3, ERCC2 or CHEK2 influenced the development
or phenotype of JAK2 V617F-mutated MPN.
Summary/Conclusions: On a genome wide level (excluding chromosome
9p), we have found that germline variation in the intergenic regions between
HBS1L and MYB exerts the strongest influence on JAK2 V617F mutated MPN
phenotype. In addition, variation between GFI1B and GTF3C5 predisposes to
PV and in particular to cases with high JAK2 V617F mutation burden associated
with 9p aUPD. Our findings indicate a complex interplay between somatic and
germline genetics in MPN, and provides pointers towards the functional basis
of the phenotypic pleiotropy of these disorders.
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TUMOR NECROSIS FACTOR RECEPTOR 2 MAY BE REQUIRED FOR
CLONAL DOMINANCE OF JAK2 V617F MUTANT OVER JAK2 WILDTYPE
CELLS
M Deininger*, W Heaton, A Senina, A Pomicter, J Marvin, S Swierczek, A Eiring,
J Prchal, T O’Hare
University of Utah/Huntsman Cancer Institute, Salt Lake City, United States
Background: The JAK2V617F mutation is detected in large subsets of patients
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with myeloproliferative neoplasms (MPNs). The presence of JAK2V617in a
hematopoietic stem (HSC) or progenitor cell confers a proliferative advantage
over native JAK2 counterparts. Several inflammatory cytokines are elevated in
MPN patients and in murine models of JAK2V617F-driven MPN, including tumor
necrosis factor alpha (TNF-α). We have previously shown that JAK2 kinase
activity regulates TNF-α expression, which in turn imparts a competitive advan-
tage on JAK2V617F expressing cells over their normal counterparts (Fleischman
et al. Blood. 2011;118(24):6392-8).
Aims: 1. To identify the cellular source of TNF-α generation in JAK2V617
expressing hematopoietic cells.
2. To deliniate whether TNFR1 vs TNFR2 mediates TNF effects in MPNs.
Methods: We used FACS/intracellular staining to measure TNF-α expression
in murine and human hematopoietic cells. Blocking antibodies or shRNA knock-
down were used to specifically probe the role of TNFR1 vs TNFR2 for MPN
colony formation. Colonies were genotyped by FACS (GFP) or DNA sequenc-
ing. TNFR1/R2 null hematopoietic cells were used in competitive repopulation
experiments to interogate the functional relevance of TNFR1 vs TNFR2 for
MPN pathogenesis. 
Results: TNF-α was low in unstimulated hematopoietic cells. However, when
cells were treated with lipopolysaccharide (LPS), TNF-α expression was 16-
fold higher in HSCs of MF patients compared to normal controls (p<0.005),
with significant but less pronounced differences in more mature populations. In
a murine model of JAK2V617F driven MPN, where JAK2V617F cells are identified
by GFP, TNF-α expression was 3-fold higher in JAK2V617F-expressing
hematopoietic stem cells (HSCs; GFP+) compared to GFP- controls (p<0.005),
irrespective of LPS stimulation. We initially treated JAK2V617F mice with etan-
ercept, a soluble TNF receptor fusion protein that binds and inactivates TNF-
α, but found that etanercept did not significantly restrain JAK2V617F-associated
WBC or hematocrit increases over a 10-week period, despite suppression of
plasma TNF-α activity. As TNF-α may activate pro-apoptotic (predominantly
through TNFR1) and pro-survival pathways (predominantly through TNFR2),
we reasoned that global (etanercept) blockade of TNF-α may not shift the bal-
ance in favor of normal hematopoiesis. To investigate this we sorted primitive
(Lin-, cKit+) cells from mice with JAK2V617F-induced MPN by TNF receptor
expression. TNFR2+ cells showed significantly increased colony formation com-
pared to TNFR1+ cells, demonstrating that TNFR2 expression is associated
with increased clonogenic potential. Next we treated these primitive cells with
specific antibodies blocking TNFR1 or TNFR2 and assessed colony formation.
Blocking TNFR2 resulted in decreased colony formation, while blocking TNFR1
increased colony formation. Analogous results were seen in CD34+ cells from
MF patients. Additionally in samples heterozygous for JAK2V617F, TNFR2-
blocking antibodies selected JAK2 wild type over V617F mutant colonies. Pre-
liminary results from murine TNFR1 and TNFR2 null models and shRNA knock-
down of TNFR1 and TNFR2 suggest that lack of TNFR2 but not TNFR1 favors
outgrowth of wild type cells.
Summary/Conclusions: Our data suggest that TNF-α generated by primitive
MPN cells promotes their survival through activation of TNFR2, suggesting that
selective inhibition of TNFR2 may shift the equilibrium from MPN toward normal
hematopoiesis and that TNFR2 blockage may be useful to treat MF and other
myeloproliferative neoplasms. 
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THE JAK2V617F MUTATION IS A POTENTIAL TARGET FOR CANCER
IMMUNE THERAPY
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hagen at Roskilde, Roskilde, 2Center for Cancer Immune Therapy, Department
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Background: More than 50% of patients with Philadelphia chromosome neg-
ative chronic myeloproliferative neoplasia (MPN) harbor the JAK2V617F muta-
tion. This is an acquired somatic mutation, and is found exclusively in myeloid
malignancies, rendering it a cancer specific antigen and thus an attractive target
for cancer immune therapy.
Aims: By this study we wish to clarify if the JAK2V617F mutation is recognized
by the immune system, hereby proving the potential of cancer immune therapy
as a whole new treatment modality for the JAK2V617F mutated MPNs.
Methods: We used the database www.syfpeithi.de to identify epitopes in the
mutated JAK2 peptide with high affinity for HLA-A2. We chose the HLA-A2
restricted nonamer peptide JAK201 containing the V617F valine to phenylala-
nine substitution as the most promising candidate. A specific T cell culture was
established from peripheral blood mononuclear cells (PBMCs) from an HLA-
A2 positive healthy donor by stimulating with autologous dendritic cells, JAK201
peptide and cytokine as previously described1. Enzyme Linked ImmunoSPOT
(ELISPOT), intracellular cytokine staining (ICS) and Cr51 cytotoxicity assays
were used to analyze the reactivity of the specific T cells. The T cells were
either stimulated with JAK201 peptide, T2 cells, HLA-A2 or HLA-A3 positive
K562 cells or non-HLA K562 cells. T2 cells are unable to present endogenous
peptides and thus only present exogenous peptide – in our experiments the
JAK201 peptide. The HLA-A2 positive cancer cell lines UKE1 and SET2, which
both harbor the JAK2V617F mutation, were used as target cells for the analyses
of the T cells’ reactivity against JAK2V617F mutated cancer cells.
Results: First we analyzed the capacity of the specific T cells to release TNF-α
and IFN-γ upon stimulation with JAK201 peptide. Release of both cytokines upon
stimulation with JAK201 peptide was confirmed by ELISPOT (Figure 1A and B)
and ICS (data not shown). Next we showed, that the specific T cells were able to
kill T2 cells pulsed with JAK201 peptide (data not shown). K562-A3 cells pulsed
with JAK201 peptide were not killed, whereas K562-A2 cells were killed, demon-
strating that killing by the specific T cells is HLA-A2 restricted (Figure 1D). Next
we wanted to investigate, if stimulation of T cells with cancer cells carrying the
JAK2V617F mutation induces cytokine release and killing of the cancer cells.
We thus stimulated T cells with the HLA-A2 and JAK2V617F positive cancer cell
line UKE1. The JAK201 specific T cells released IFN-γ (Figure 1C) and TNF-α
(data not shown) in response to stimulation with UKE1. The target cells were
stimulated with IFN-γ 48 hours before assaying to increase their antigen presen-
tation, and the T cells showed an enhanced release of IFN-γ upon stimulation
with IFN-γ treated UKE1 cells (Figure 1C). Furthermore, T cells were able to kill
UKE1 cells in a cytotoxicity assay, and in line with the above, we demonstrated
an increased killing of the UKE1 cells after treatment with IFN-γ (Figure 1E). Ini-
tially the HLA-A2 and JAK2V617F positive cancer cell line SET2 was not killed
in a cytotoxicity assay, but after stimulation with IFN-γ, the SET2 cells were readily
killed by the JAK201 specific T cells (data not shown). Finally, transfection with
JAK2V617F siRNA into UKE1 cells abrogated T cell mediated killing, whereas
mock transfected UKE1 cells were killed by the T cells (Figure 1F). By this exper-
iment we demonstrated, that killing of target cells is dependent upon the presence
of the JAK2V617F mutation.
Figure 1.
Summary/Conclusions: By establishing a T cell culture specific for the
JAK2V617F mutation we have shown that the immune system is able to effec-
tively target cells carrying the JAK2V617F mutation. Thus cancer immune ther-
apy in the form of adoptive T cell therapy and/or vaccination could prove to be
new treatment modalities for MPN in the future.
Reference
1. Munir S et al. Cancer Res. 2013;73(6):1764-76.
S509
CALRETICULIN MUTANT PROTEINS INDUCE MEGAKARYOCYTIC
SIGNALING TO TRANSFORM HEMATOPOIETIC CELLS AND UNDERGO
ACCELERATED DEGRADATION AND GOLGI-MEDIATED SECRETION
L Han, C Schubert, J Köhler, M Schemionek, S Isfort, T Brümmendorf,
S Koschmieder, N Chatain*
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Trans-
plantation, University Hospital RWTH Aachen, Aachen, Germany
Background: Somatic calreticulin (CALR), Janus kinase 2 (JAK2) V617F, and
thrombopoietin receptor (MPL) mutations are essentially mutually exclusive in
myeloproliferative neoplasms (MPN), suggesting that they activate common
oncogenic pathways. CALR mutants are confined to MPNs with aberrant
megakaryopoiesis, such as essential thrombocythemia and myelofibrosis.
Recent data showed that MPL is essential for CALR mutant-driven MPN. How-
ever, the characteristics of CALR mutants and their mechanisms of action are
still poorly understood.
Aims: Our study was aimed at the elucidation of MPL-dependent and -inde-
pendent mechanisms of CALR frameshift mutants to drive megakaryocytic dif-
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ferentiation and oncogenic transformation. Furthermore, we investigated the
cause of low cellular protein abundance of the CALR mutants.
Methods: The murine myeloid cell line 32D and human HL60 cells stably
expressing the most frequent CALR mutants (del52 and ins5) were generated
to analyze growth factor-independent growth, as the first steps of cellular trans-
formation, in the presence and absence of MPL expression. Additionally, using
brefeldin A, MG132, and tunicamycin treatment as well as generation of further
mutants (i.e. YFP-fusion proteins), CALR mutant protein degradation and
secretion were examined.
Results: In this report, we demonstrate that the most frequent CALR mutants,
type 1 (del52) and type 2 (ins5), increase critical megakaryocytic transcription
factors such as NF-E2 and GATA1. Interestingly, this occurred in an MPL-inde-
pendent but AKT-dependent fashion, leading to the upregulation of Mpl and
CD41 expression. These effects were also confirmed by the observation of
spontaneous outgrowth of CALR mutant-transduced 32D cells, showing
increased NF-E2, CD41, and Mpl expression as well as constitutive STAT5
activation and response to JAK inhibitor treatment. Interestingly, we found high
cellular levels of mutated CALR and loss of downstream signaling after block-
age of the secretory pathway and protein glycosylation. Hence, we demonstrate
that low CALR mutant protein abundance is a result of accelerated secretion
as well as ubiquitin- and proteasome-independent degradation. CALR mutant
degradation was attenuated by MPL expression.
Summary/Conclusions: Together, our data illustrate how CALR mutants may
initiate abnormal megakaryopoiesis, even in the absence of MPL, by a mech-
anism that most likely involves activated AKT. In addition, our findings show
enhanced secretion, MPL-driven protein stabilization, and importance of Golgi
signaling of the MPL receptor for CALR-mutant mediated transformation.
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EXPRESSION, REGULATION, AND FUNCTIONAL ROLE OF HERMES
ADHESION RECEPTOR CD44 IN NEOPLASTIC MAST CELLS IN
SYSTEMIC MASTOCYTOSIS
N Mueller1,*, D Wicklein2, G Eisenwort1,3, A Boehm1,4, H Herrmann1,3,
G Stefanzl1,3, G Hoermann3,5, WR Sperr1,3, M Arock6, U Schumacher2,
P Valent1,3
1Internal Medicine I, Division of Hematology and Hemostaseology, Medical
University of Vienna, Vienna, Austria, 2Institute of Anatomy and Experimental
Morphology, University Cancer Center, University Medical-Center Hamburg-
Eppendorf, Hamburg, Germany, 3Ludwig Boltzmann Cluster Oncology, Medical
University of Vienna, Vienna, 4Elisabethinen Hospital, Linz, 5Department of
Laboratory Medicine, Medical University of Vienna, Vienna, Austria, 6LBPA
CNRS UMR8113, Ecole Normale Supérieure de Cachan, Paris, France
Background: The Hermes receptor CD44 is a multifunctional adhesion mole-
cule that plays an essential role in the homing and expansion of neoplastic
stem- and progenitor cells in various myeloid malignancies. Although mast
cells (MC) are known to express CD44, little is known about the regulation and
function of this receptor on neoplastic stem cells and MC in patients with sys-
temic mastocytosis (SM).
Aims: The aim of this study was to define the expression and function of CD44
on neoplastic MC.
Methods: CD44 expression on primary neoplastic MC and various human MC
lines was analyzed by immunocytochemistry and flow cytometry.
Results: CD34+/CD38- stem cells, CD34+/CD38+ progenitor cells, and
KIT+/CD34- MC invariably expressed CD44 in all patients with indolent SM
(ISM, 12/12), SM with associated hematologic non-MC-disease (SM-AHNMD,
4/4), aggressive SM (ASM, 3/3), and MC leukemia (MCL, 6/6). In addition, all
human MC lines examined, including HMC-1.1, HMC-1.2, ROSAKITwt, and
ROSAKITD816V, were found to express cytoplasmic CD44 and cell surface
CD44. We next examined the regulation of expression of CD44 in neoplastic
MC. Incubation with the MEK inhibitor RDEA119 (0.1-5 µM) or the STAT5 block-
er pimozide (2.5-10 µM) for 48 hours resulted in a dose-dependent and signif-
icant downregulation of surface expression of CD44 compared to control medi-
um (100%) in all MC lines examined (RDEA119, 2.5 µM: 71±9% surface stain-
ing intensity in HMC-1.1; 82±3% in HMC-1.2, 33±13% in ROSAKITwt, and
31±3% in ROSAKITD816Vcells; pimozide, 7.5 µM: 59±7% surface staining inten-
sity in HMC-1.1; 68±3% in HMC-1.2, 62±16% in ROSAKITwt, and 80±3% in
ROSAKITD816V cells, p<0.05). In contrast, incubation with the demethylating
agents decitabine (0.1-5 µM) or azacitidine (0.1-5 µM) for 96 hours resulted in
a dose-dependent and significant upregulation of CD44 expression compared
to control medium (100%) in all MC lines examined (decitabine, 5 µM; 210±50%
surface staining intensity in HMC-1.1; 282±78% in HMC-1.2, 236±56% in
ROSAKITwt, and 198±55% in ROSAKITD816V cells; azacytidine, 5 µM:
379±103% surface staining intensity in HMC-1.1; 429±105% in HMC-1.2,
412±135% in ROSAKITwt, and 292±136% in ROSAKITD816V cells; p<0.05). We
were also able to detect soluble CD44 in the sera of patients with ISM, SM-
AHNMD, ASM, and MCL as well as in the supernatants of neoplastic MC lines.
In order to define a functional role for CD44 on MC, an in vivo xenotransplan-
tation model using severe combined immunodeficient (SCID) mice, HMC-1.2
cells, and shRNA against CD44, were employed. In this model, the shRNA-
mediated knock-down of CD44 in HMC-1.2 cells was found to lead to reduced
MC expansion, reduced tumor formation, delayed ulceration, and prolonged
survival compared to cells transduced with control shRNA (median survival in
the CD44 shRNA group: 110 days vs 97 days in the control group; p<0.05). In
these experiments, the formation of lung metastasis, quantified by human Alu-
sequence-specific qPCR, was found to be particularly decreased (15-fold) in
the CD44 knock-down group compared to controls.
Summary/Conclusions: CD44 is a relevant MC homing molecule that is
expressed in neoplastic MC as well as in neoplastic stem- and progenitor cells
in advanced SM. Our data also suggest that CD44 may serve as an interesting
new target of therapy in patients with advanced SM.
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TUMOR-SPECIFIC GLYCOSYLATED CD43 IS A NOVEL AND HIGHLY
SPECIFIC TARGET FOR ACUTE MYELOID LEUKEMIA AND
MYELODYSPLASTIC SYNDROME
M Hazenberg1,*, M Gillissen1, M Kedde2, E Yasuda2, G de Jong1, S Levi2,
A Bakker2, P Hensbergen3, T Beaumont2, P van Helden2, H Spits2
1Hematology, AMC, 2AIMM Therapeutics, Amsterdam, 3 Center for Proteomics
and Metabolomics, LUMC, Leiden, Netherlands
Background: Acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) are high-risk diseases with a poor prognosis. Even with intensive treatment
regimens less than 50% of patients can be cured, and for the majority of patients
- those over 65 years of age and/or patients with comorbidities - such intensive
regimens are not feasible. Novel therapeutic approaches such as immunotherapy
directed against a highly specific tumor target are highly needed.
Aims: The aim of our study was to identify novel therapeutic antibodies that
are highly specific for AML and to discover novel tumor-specific antigens, widely
expressed on AML and MDS but not on healthy hematopoietic and non-
hematopoietic cells.
Methods: For this we made use of the oldest human tumor immunology model
with proven efficacy available: an allogeneic HSCT patient with a potent graft
versus AML allo-immune response. From this patient we isolated CD27+ IgG+
memory B lymphocytes and transduced these cells with Bcl-6 and Bcl-xL, there-
by generating pre-plasmablast B cell clones that produce abundant antibodies.
Supernatants of these B cell clones were used to screen for binding to surface
antigens on the AML cell line THP-1. 
Results: We identified an IgG1 antibody, AT14-013, that specifically interacted
with AML cell lines THP-1, MOLM-13, SH-2 and others, and with leukemic blasts
isolated from newly diagnosed AML and MDS patients from our clinic. AT14-
013 did not interact with healthy hematopoietic and non-hematopoietic cells.
This antibody was of donor origin and was antigen experienced as it contained
26/11 somatic hypermutations in the heavy and light chains, respectively. Target
identification using mass spectrometry analysis and epitope mapping strategies
with FLAG-tagged truncated variants of CD43 expressed by THP-1 that we cre-
ated revealed CD43 as the target. CD43 is expressed by all hematopoietic cells,
but AT14-013 targeted a specific, sialylated epitope on CD43 that is uniquely
and widely expressed on all types of AML, as illustrated by its reactivity with
blasts of each of 48 randomly selected AML and MDS patients in our clinic.
AT14-013 induced antibody-dependent cell-mediated cytotoxicity and comple-
ment dependent cytotoxicity of AML cell lines and primary blasts.
Summary/Conclusions: We have identified onco-sialylated CD43 (CD43os)
as a novel tumor-specific target that is widely expressed on AML and MDS
blasts. Antibodies against this target have high potential as therapeutic anti-
bodies, either as a naked antibody or manufactured into an antibody-drug con-
jugate, bispecific T cell engager or CAR (chimeric antigen receptor) T cell.
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THE HIGHLY CLINICAL EFFICACY AND SAFETY OF THE AUTOLOGOUS
ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS IMMUNOTHERAPY
FOR 26 CASES WITH HEAVILY TREATED REFRACTORY B ACUTE
LYMPHOBLASTIC LEUKEMIA
J Pan1,*, J Yang1, B Deng2, X Zhang1, Y Wu2, Y Lin1, C Tong1
1Department of Hematology, 2Department of immunotherapy, Yanda Lu Daopei
Hospital, Langfang, China
Background: the patients with refractory B-ALL are almost incurable by
chemotherapy or allo-HSCT. Many data has demonstrated that anti-19-CART
cell immunotherapy can result in CR and bridge to allo-HSCT for these patients.
Aims: to evaluate the clinical efficacy and safety of the second generation of
anti-CD19-CART cells immunotherapy.
Methods: leukapheresis products from the patients themselves were cultured
in the serum free medium containing antibodies to CD3, CD28, and IL2, IL7,
IL15, IL21, transduced with the lentivirus encoding anti-CD19-CD3ξ-4-1BB
CAR (Figure 1) for 7 days. After leukapheresis, patients received chemotherapy
containing fludarabine 30mg/ m2 per day IV and cyclophosphamide 250mg/
m2 per day IV for 3 days except one patient who had persistent cytopenia. On
day 7 or/and day 8, the cultured CART cells were infused. Between Jun. 31
2015 to Feb. 20 2016, total 26 cases with chemotherapy refractory B-ALL were
treated with CART. After infusion of CART, the patients were followed until die,
or relapse, or at least 15 days. In the included cases, the median age was 9
years old (2-59 years old), the median observation period was 100 days (19-
204 days), and the median prior chemotherapy period was 14 months (1-36
months). 19/26 cases were hematological relapse, with 10/19 complicated
extramedullary relapse, 7/26 cases remained minimal residual disease detected
by flowcytometry (FCM-MRD) over 3 months although by alternative
chemotherapy. Before CART therapy, all patients relapsed during chemotherapy
or hadn’t responded to 1 or more cycles of chemotherapy after relapsed except
one patient suffered from severe infective pneumonia because she carried
inherited immune related gene deficiency (LYST c.6031A>G/p.I2011V gene
mutation) and was intolerated to chemotherapy. Before CART therapy, the
median percentage of blasts in BM was 67% (11.5-96%) in the cases with
hematological relapse, the FCM-MRD were 0.01-1.53% in the MRD+ group.
The median infused total CD19- CAR T cells was 10x104/kg (0.5-140x104/kg),
the median cells transfection efficiency is 19% (1.2- 53.6%), the median cells
viability is 85% (43-99.4%).
Results: On day 16 after CART infusion, 15/19 hematological relapse cases
achieved CR or CRi (83.3%), 14/15 cases achieved CMR (FCM-MRD nega-
tive). 6/7(85.71%) FCM-MRD positive cases achieved CMR (FCM-MRD neg-
ative). During the first month, 1 case died from CRS, 2 cases died from leukemia
progression. 2/16 who have achieved CR and been follow up for ≥60 days
relapsed again, 1 is CD19- relapse. 6/6 cases who have achieved CR and
bridged to allo-HSCT remain CCMR to now with median follow up period 40
days (24-106 days) after allo-HSCT. The median appearance of CRS was at
day 6 (day 1-11), the median CRS grade was 1 (0-5). All MRD+ patients before
CART therapy only developed ≤1 grade of CRS. The IL6 and INFγ elevates in
PB and CSF in all detected patients (n=4).
Figure 1.
Summary/Conclusions: Our anti-CD19-CAR T cells immunotherapy can result
in high CR/CRi /CMR rate (including extramedullary leukemia) and low TRM
for the heavily treated refractory B-ALL, which provide an opportunity to cure
these advanced patients by allo-HSCT. The infused CART number in our
patients is lower than many reports, which can dramatically reduce the cost of
the therapy. The major complication is CRS. CRS grade is associated with the
number of malignant B cells in PB. CD19-relapse has been observed.
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REGENERATION OF WT1 SPECIFIC CTLS UTILIZING IPSC TECHNOLOGY
T Maeda1,2,*, S Nagano1,2, K Masuda1, T Kitawaki2, A Takaori-Kondo2,
H Kawamoto1
1Department of Immunology, Institute for Frontier Medical Science Kyoto Uni-
versity, 2Department of Hematology and Oncology, Graduate School of Medi-
cine, Kyoto University, Kyoto, Japan
Background: Current cancer immunotherapies mainly aim to activate and
expand tumor antigen specific cytotoxic T lymphocytes (CTLs) in vitro or in
vivo, but these methods are not so successuful because of the difficulty in
preparing sufficient number of CTLs. 
Aims: For successful cancer immunotherapy, we are trying to expand tumor
antigen specific cytotoxic T lymphocytes (CTLs) by utilizing the iPS cell tech-
nology. When iPSCs are produced from antigen specific T cells, the rearranged
configurations of T cell receptor (TCR) genes are inherited to the iPSCs, and
when T cells are regenerated from such iPSCs, all of them should come to
express the same TCR as the original one. Therefore it will become possible
to obtain de novo generated tumor specific CTLs almost unlimitedly. In line with
this concept, we have succeeded in regenerating MART-1 specific T cells (Viz-
cardo et al., Cell Stem Cell, 2013).
Methods: We firstly established iPSCs from CTLs specific for WT1, expanded
from healthy volunteers. CD4/8 DP cells were generated by culturing these T-
iPSCs on Op9/DLL1 cells. By stimulating these DP cells by agonist peptide or anti
CD3 Ab, CD8 T cells expressing CD8 alpha-beta heterodimers were formed. They
can be expanded more than ten thousand fold by repeated TCR stimulation.
Results: Regenerated CD8 T cells exhibited very high antigen specific killing
activity comparable to the original CTLs and were able to kill some leukemia
cell lines and primaly leukemia cells which express endogenous WT1 protein
and HLA A2402. In in vivo leukemia treatment model regenerated CD8 T cells
elongated the survival of treated mice.
Summary/Conclusions: We have succeded in regenerating CD8 T cells with
high antigen specific cytotoxic activity. This method could bring about a break-
through in cancer immuno-therapy.
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MESENCHYMAL STROMAL CELLS GENERATED FROM POOLED
MONONUCLEAR CELLS OF MULTIPLE BONE MARROW DONORS AS A
RESCUE THERAPY FOR SEVERE STEROID-REFRACTORY GRAFT
VERSUS HOST DISEASE: A MULTICENTER SURVEY
Z Kuci1,*, H Bönig2, H Kreyenberg1, M Bunos2, A Jauch3, J Janssen3, M Skific4,
K Michel2, B Eising1, G Lucchini5, S Bakhtiar1, J Greil6, P Lang7, O Basu8,
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E Salzmann-Manrique1, E Seifried2, T Klingebiel1, P Bader1, S Kuci1
haematologica | 2016; 101(s1) | 191
Copenhagen, Denmark, June 9 – 12, 2016
1University Hospital Frankfurt, Department for Children and Adolescents, 2Insti-
tute of Transfusion Medicine and German Red Cross Blood Center, Frankfurt
am Main, 3Institute of Human Genetics, University of Heidelberg, Heidelberg,
Germany, 4University Hospital Centre Zagreb, Clinical Department of Transfu-
sion and Transplantation Biology, Zagreb, Croatia, 5Great Ormond Street Hos-
pital, Department of Hematology/Oncology, London, United Kingdom, 6Univer-
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Background: Mesenchymal stromal cells (MSCs) represent a heterogeneous
cell population concerning their proliferative, differentiation and allosuppressive
potential. 
Aims: To circumvent donor-to-donor heterogeneity which may lead to inconsis-
tent results after treatment of acute graft-versus-host disease (aGvHD) with mes-
enchymal stromal cells (MSCs) generated from a single or several individual
donors, we developed a novel approach by generating MSCs from pooled bone
marrow mononuclear cells (BM-MNCs) of eight healthy “third-party” donors. 
Methods: BM-MNCs of 8 healthy “third-party” donors were isolated and frozen
separately in cryobags. After thawing, BM-MNCs of 8 donors were pooled and
cultured for 14 days in DMEM+5% platelet lysate (PL). Generated MSCs were
frozen in 209 cryovials ȧ 1.5x10e6 MSCs, representing the MSC-bank. Several
vials were expanded for 12-14 days in DMEM+10% PL till the end of passage
2 and frozen as MSC-end products (MEPs). These products were evaluated
for proliferative, differentiation and allosuppressive potential as well as genomic
stability. Eighty-one MEPs generated from aliquots of the MSC bank were
administered on a compassionate-use basis after approval of the regulatory
authorities to 26 patients with steroid-refractory acute GvHD at a target dose
of 1-2×106 MSCs/kg BW in 7 transplantation centers.
Results: MEPs exhibited typical MSC phenotype, trilineage differentiation
potential and replicative senescence after 13 passages, as determined by
increased expression of senescence-related markers such as p21 (CDKN1A)
and p16 (CDKN2A). Chromosomal analysis of MEPs demonstrated a normal
karyotype, whereas FISH analysis demonstrated a normal diploid pattern, indi-
cating their genomic stability. Importantly, MEPs exerted a significantly higher
allosuppressive potential than the mean allosuppressive potential of MSCs
generated from the same donors individually. Administration of 81 MEPs to 26
patients with severe steroid-resistant aGvHD in 7 stem cell transplant centers
who were refractory to many lines of treatment, induced a 77% overall response
at the primary endpoint (day 28). Remarkably, although the cohort of patients
was highly challenging (92% grade III/IV and only 8% grade II GvHD), after
treatment with MEPs the overall survival rate at 2 years follow-up was 71±11%
for the entire patient cohort, compared to 51.4±9.0% in GvHD clinical studies,
in which MSCs were derived from single donors.
Summary/Conclusions: To our knowledge this is the first serum-free MSC
bank generated from pooled BM-MNCs of multiple donors as a source for bulk
production of clinical-grade MSCs with a predictable potency. Importantly, clin-
ical data presented in this study demonstrated the in vivo safety and efficacy
of MEPs, which may provide a novel therapeutic tool for the effective treatment
of severe aGVHD.
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GENERATION OF CHIMERIC ANTIGEN RECEPTOR - MODIFIED MEMORY
STEM CELL CD8+ T LYMPHOCYTES FROM NAIVE PRECURSORS BY
MODULATION OF WNT/BETA-CATENIN PATHWAY OR INHIBITION OF
AKT-SIGNALING
A Berger1, I Weber1, S Khan1, M Chiemlewski2, H Abken2, M Theobald1,
UF Hartwig1,*
1III. Dept. of Medicine - Hematology, Internal Oncology & Pneumology, Uni-
versity Medical Center Mainz, Mainz, 2Dept. of Internal Medicine I & Center for
Molecular Medicine, University of Cologne, Cologne, Germany
Background: Adoptive cellular therapy (ACT) of chimeric antigen receptor
(CAR)-reprogrammed T cells has advanced as a personalized and effective
immunotherapy for leukemia and solid tumors. However, ACT, especially to
solid tumors is often hampered by limited T cell engraftment and limited capa-
bility of terminally differentiated, high avidity effector T cells (TEFF) to establish
sustained antitumor immunity. Recently, long-living stem cell memory T cells
(TSCM) with an enhanced capacity for self-renewal and plasticity to differentiate
into central memory (TCM), effector memory (TEM) and TEFF could be shown
to elicit potent antitumor responses, prolonged survival and memory. Moreover,
modulating the Wnt/ß-catenin or PI3K-Akt-mTOR signaling pathways in T cells
using inhibitors of glycogen-sythase-kinase-3β (TWS119) or Akt (inhibitor VIII)
have emerged as promising approaches to block CD8+ effector T cell differen-
tiation and to facilitate the in vitro generation of TSCM and TCM.
Aims: In the present proof of concept study, we therefore investigated the gen-
eration of CD19 CAR expressing CD8+ TSCM from naive CD8+ T lymphocytes
by modulating T-cell differentiation using TWS119 or Akt inhibitor VIII to be
used for ACT.
Methods: Naive CD8+CD45RA+ T cells isolated from PBMC by MACS® were
polyclonally stimulated with CD3/CD28 Dynabeads in the presence of various
cytokines and retrovirally transduced with a second generation CD19 CAR
three days after activation. To promote a TSCM/CM phenotype transduced cells
were either polyclonally restimulated or co-cultured with CD19+ B-ALL
(NALM16) together with TWS119 or Akt inhibitor VIII. CD19 CAR expression
was determined by flow cytometry. IFN-γ ELISPOT and 51chromium-release-
cytotoxicity assays were used to analyze effector functions of CD19 CAR
expressing TSCM and TCM. Adoptive transfer studies of redirected T cells into
NALM-16 engrafted NSG mice were performed to evaluate antileukemic
responses in vivo.
Results: Upon repetitive restimulation and TWS119/Akt inhibitor VIII treatment
we obtained strong expansion of T cells with a TSCM/CM phenotype. In contrast,
this effect was less pronounced by naive T cells cultured in the sole presence
of interleukin (IL)-12 followed by IL-2, IL-7, IL-15, and IL-21, confirming that both
Wnt/ß-catenin and PI3K-Akt-mTOR pathways play a key role in T cell differen-
tiation. In addition, CD8+CD45RA+CD45RO-CD95+CD62L+CCR7+TSCM/CM
showed high expression levels of CD19 CAR, elicited strong IFN-γ release and
cytolytic activity to CD19+ NALM-16 cells when compared to mock transduced
controls. This effect was also seen in CD19 CAR positive total CD8+T cells
although less pronounced. First studies to evaluate the therapeutic efficacy of
CD19-CAR redirected TSCM/CM revealed that upon adoptive transfer of 1-5x106T
cells into NSG mice engrafted with NALM-16 B-ALL significant regression of
leukemia could be observed in spleen and bone marrow. Again, antileukemic
responses were also seen with CD19 CAR transduced TEM and TEFF but
TSCM/CM appeared to be more effective when applied at lower numbers (1 x106
cells/mouse). Further studies are in progress to elucidate the functional proper-
ties of CD19 CAR TSCM/CM in more detail.
Summary/Conclusions: In conclusion, these proof of concept studies demon-
strate that ex vivo generated TSCM/CM redirected to acute leukemia by retroviral
transfer of optimized leukemia- or tumor-reactive CARs may be a promising
approach to improve ACT.
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DISREGULATED MEGAKARYOCYTE MIGRATION AND MATURATION IS
POSSIBLY DUE TO IMPAIRED BONE MARROW SYMPATHETIC
NERVETHROUGH NESTIN+ MESENCHYMAL STEM CELL IN CHRONIC
IMMUNE THROMBOCYTOPENIA
M Wang, LL Xu, JM Zhang, FE Feng, QM Wang, XS Zhao, Y Kong, XY Zhao,
YJ Chang, LP Xu, KY Liu, XJ Huang, XH Zhang*
Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Impaired megakaryocyte maturation and reduced platelet pro-
duction is a most important mechanism responsible for immune thrombocy-
topenia (ITP).Megakaryocyte (MK) maturation in the bone marrow microenvi-
ronment (BMME) is accompanied by increased expression of CXCR4 andits
migration from the endosteal niche to the vascularniche, where MKs intrude
proplatelets into the bone marrow (BM)sinus to release platelets.Thrombopoi-
etin(TPO) is the major physiological regulator of the proliferation and differen-
tiation of MKs,whereas MK migration is regulated by sympathetic nerves and
the chemokine CXCL12, which is mainly produced by nestin+ mesenchymal
stem cells (MSCs) in the BM.There is no information regarding MK migration
or BMME in ITP.
Aims: We sought to investigate the migration and maturation status of MKsin
chronic ITP, to measure the sympathetic nervous response, which regulates
the migration and maturation of MKs, and to assess the variationin nestin+
MSCs, which produce the potent chemokine CXCL12 under the regulation and
protection of sympathetic nerves.
Methods: BM samples were obtained from chronic ITP patients and healthy
haematopoietic stem cell donors.The distribution of MKs, sympathetic nerve
fibres, Schwann cells and nestin+ MSCs in BMME was analysed by immunohis-
tochemistry and/or immunofluorescence, and quantitative analyses were con-
ducted using confocal microscopy. BM nestin+ MSCs were sorted by flowcytom-
etry. The quantity and apoptosis of nestin+ MSCs and the surface markers
CXCR4 and β3-adrenergic receptor (adrb3)on nestin+ MSCs and CXCL12+
nestin+ MSCs were further analysed by flowcytometry.The expression levels of
CXCL12 and adrb3 in nestin+ MSCs wereanalysed by real-time quantitative PCR. 
Results: The percentage of CD41+ MKs adjacent to the CD34+ BM sinus and
CXCR4+CD41+MKs in the BM were both strikingly reduced in chronic ITP
patients compared with normal controls.The concentration of CXCL12 was also
significantly lower in the BM of ITP patients,and the percentage of CD41+ MKs
in the vascular niche and of CXCR4+CD41+MKs correlated with the concen-
tration of BMCXCL12. The percentage of nestin+ MSCs among CD45-CD31-
CD235a- stromal cellsin normal controls was 3.8 times higher than that in chron-
ic ITP patients.Consistently, the percentage of live nestin+ MSCs in normal
controls was also significantly increased, whereas apoptosis of nestin+ MSCs
in ITP patients was significantly increased compared with normal controls. The
proportion of CXCL12+nestin+ MSCs in normal controls was much higher than
that in ITP patients, which was correlated with the concentration of CXCL12 in
the BM.Sympathetic nerve fibres and Schwann cells adjacent todistinctive
nestin+ MSCs and vasculature weremarkedlyreduced in the BMof ITP patients,
andthe neurotransmitternorepinephrine and adrb3 in nestin+ MSCs were both
significantly reduced in ITP patients.
Summary/Conclusions: This isthe first report to describe BMME and
megakaryocyte migration in chronic ITP. Our research suggests that reduced
activity of BM sympathetic nervesis associated with impaired MK migration and
maturation, resulting in reduced plateletproduction. With reducedBM sympa-
thetic nerves innervation, nestin+ MSCs arefunctionally compromised and
reduced due to increased apoptosis, enhancing the dysregulatedmigration and
maturation of MKsvia diminished CXCL12 signalling through CXCR4 on MKs.
Protection of sympathetic nerves that prevent MSCapoptosis may provide a
potentially powerful strategy to promotethrombopoiesis.
S517
FINAL SAFETY AND EFFICACY RESULTS FROM THE EXTEND STUDY:
TREATMENT WITH ELTROMBOPAG (EPAG) IN ADULTS WITH CHRONIC
IMMUNE THROMBOCYTOPENIA (CITP)
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Background: EPAG increased platelets and reduced bleeding in 6-week and
6-month placebo-controlled trials in previously treated cITP patients. Adult
patients with cITP initially enrolled in 4 EPAG studies could continue treatment
in the open-label extension study, EXTEND.
Aims: To present the final long-term safety and efficacy results from EXTEND
(Jun 2006 to Jul 2015).
Methods: EPAG was started at 50 mg and titrated to 25-75 mg/day or less
often, based on platelet counts. Maintenance dosing continued after minimiza-
tion of concomitant ITP medication and optimization of EPAG dosing. Patients
who received 2 years of EPAG and transitioned off due to commercial avail-
ability of EPAG were considered to have completed EXTEND, whether or not
they continued treatment with commercial EPAG.
Results: Of 302 patients enrolled, 67% were females and 38% were splenec-
tomized; 45% (n=135) completed and 55% (n=167) withdrew. The most common
reasons for withdrawal were adverse events (AEs; 14%), patient decision (13%),
lack of efficacy (11%), and other (13%). The overall median duration of exposure
was 2.4 years (range, 2 days to 8.8 years) and mean average daily dose was
50.2 (range, 1-75) mg/day. Median platelet counts increased to 50 Gi/L by Week
2. Overall, 86% (259/302) of patients achieved platelets 50 Gi/L in the absence
of rescue therapy and 61% achieved platelets 50 Gi/L for 50% of on-treatment
assessments; 126/248 (51%) patients maintained continuous platelet counts ≥50
Gi/L for at least 31 weeks (Figure 1). Incidence of bleeding symptoms (WHO
grades 1-4) decreased from baseline (57%; 171/302) to 1 year (16%; 13/80). Pro-
portionately more patients with platelet counts <10 Gi/L had grades 2-4 bleeding
compared with those with higher platelet counts (59% vs ≤40%). Of 101 patients
receiving concomitant ITP treatment at baseline, 34 stopped at least one ITP
medication, and 39 had a sustained reduction or permanently stopped at least
one ITP medication taken at baseline. The most frequently discontinued/reduced
ITP medications were corticosteroids (n=34), danazol (n=5), azathioprine (n=4),
and other (n=1). AEs occurred in 277 (92%) patients. Serious AEs (SAEs) occurred
in 96 (32%) patients, and 24 (8%) patients had SAEs considered possibly drug-
related. Drug-related SAEs occurring in 2 patients were cataracts (n=8), increased
alanine aminotransferase (ALT) (n=4), deep vein thrombosis (n=2), increased
aspartate aminotransferase (n=2), increased bilirubin (n=2), myocardial infarction
(n=2), and pneumonia (n=2). AEs leading to withdrawal occurred in 41 (14%)
patients. 28 (9%) patients experienced SAEs. The most frequent AEs leading to
withdrawal were increased ALT (n=5), increased bilirubin (n=4), cataracts (n=4),
and DVT (n=3). Nineteen patients (6%) reported thromboembolic events (TEEs),
and 37 reported hepatobiliary laboratory abnormalities (HBLAs). Ocular-related
events started on-therapy occurred in 80 (26%) patients; the most frequently
occurring events were cataract (n=28; 9%) and conjunctivitis (n=12; 4%). At base-
line, 192 patients had at least one cataract risk factor.
Figure 1. Maximum continuous weeks of maintaining platelets ≥50 Gi/L
without rescue therapy.
Summary/Conclusions: Sustained platelet increases and reduced bleeding
symptoms were observed in EPAG-treated patients with cITP throughout the
study. Concomitant ITP medications were reduced without requiring rescue
medications. EPAG was well tolerated with exposures 6 years. Monitoring of
HBLA and cataracts is appropriate, even with long-term treatment. Funding:
Study (NCT00351468) is/remains sponsored by GlaxoSmithKline; EPAG is an
asset of Novartis AG as of March 2, 2015.
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IDENTIFYING THE GENETIC BASIS OF RARE BLEEDING AND PLATELET
DISORDERS USING SYSTEMATIC PHENOTYPING AND GENOME
SEQUENCING
E Turro1,2,3,*, S Sivapalaratnam1,2, D Greene1,2,3, W Ouwehand1,2,4
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Background: The majority of rare bleeding, thrombotic and platelet disorders
(BPDs) do not have an identified genetic basis. Whilst whole genomic sequenc-
ing is now an affordable approach, small family sizes, variable penetrance and
phenotypic variability are barriers to identifying the responsible genetic variants.
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We have used a systematic phenotyping approach combined with novel clus-
tering analyses to identify implicated genes and candidate causal mutations
called by next generation sequencing (NGS). 
Aims: Detection of novel genetic causes of BPDs.
Methods: A total of 848/1247 index cases and 78/87 affected relatives have
been sequenced/phenotyped. The Human Phenotype Ontology (HPO) has
been expanded to better capture clinical and laboratory data. Genes known to
harbour variants responsible for BPDs have been screened. New algorithms
have been developed to identify patients with similar phenotypes and a poten-
tially shared genetic basis of disease. 
Results: In 115 cases a definitive or likely genetic explanation has been iden-
tified and in 13 a partial genetic explanation. Four genes harbouring variants
responsible for platelet abnormalities including DIAPH1, SRC and TRPM7 have
been identified. Variants responsible for atypical presentations of previously
known syndromes, including MYH9-related disease and Hermansky-Pudalk
syndrome, have also been identified. Finally, we have shown that large num-
bers of cases are explained by variants in recently reported genes, e.g. 27 by
variants in ACTN1, eight by variants in the 5’UTR of ANKRD26 and two by
variants in STIM1. In total a long list of 45 genes have been identified as har-
bouring variants responsible or possibly responsible for BPDs in our collection
and many are under further investigation. 
Summary/Conclusions: A systematic method of detailed phenotyping and
NGS has formed the basis of screening and clustering analysis. We have iden-
tified genes harbouring variants responsible for BPDs and have confirmed pre-
vious findings. Syndromic phenotypes have been better defined and a large
number of candidate variants remain to be explored. Having used WGS as the
main method of DNA sequencing will now allow these methods to be extended
to regulatory regions of the genome.
S519
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Background: Gaucher disease is caused by deficient activity of lysosomal
acid β-glucosidase, leading to glucosylceramide accumulation in macrophages
and resultant hepatosplenomegaly, pancytopenia, and skeletal disease.
Despite well-characterized symptoms and treatment availability, disease aware-
ness is low. Diagnostic delays are common and can result in irreversible dis-
ease manifestations. As thrombocytopenia, anemia, and splenomegaly are
common in Gaucher patients, hematologists often identify, evaluate, and man-
age the disease. Eliglustat, a substrate reduction therapy, is a first-line oral
treatment for adults with Gaucher disease type 1 (GD1) who have a compatible
CYP2D6 metabolizer phenotype (>90% of patients). 
Aims: Summarize hematologic, bone, and Gaucher biomarker outcomes (chi-
totriosidase and others) in 3 clinical trials of eliglustat in adults with GD1.
Methods: Data were evaluated from 3 Sanofi Genzyme-sponsored trials: Phase
2 in treatment-naïve patients (NCT00358150, N=26); ENGAGE, a randomized,
placebo-controlled Phase 3 trial in treatment-naïve patients (NCT00891202,
N=40); and ENCORE, a Phase 3 imiglucerase-controlled trial in patients previously
stabilized on ≥3 years of enzyme replacement therapy (NCT00943111, N=159).
Results: Primary endpoints were met in all 3 trials (Lukina Blood 2010; Mistry
JAMA 2015; Cox Lancet 2015). In the Phase 2 study after 4 years, mean hemo-
globin increased by 2.3±1.5 g/dL relative to baseline (BL) (BL=11.3±1.5 g/dL),
mean platelet count increased by 95% (BL=69±21x109/L), spleen and liver vol-
umes decreased, and mean lumbar spine bone mineral density went from the
osteopenic to the normal range with corresponding reductions in biomarkers. In
ENGAGE after 18 months, mean hemoglobin levels, platelet counts and spleen
and liver volumes improved in placebo patients switched to eliglustat and contin-
ued to improve in patients continuing on eliglustat, with corresponding improve-
ments in mean bone marrow burden (BMB) score and biomarkers. In former
placebo patients, mean hemoglobin increased by 0.79±0.82 g/dL (BL=12.2±2.0
g/dL), mean platelet count increased by 40%±37 (BL=71.5±25.2x109/L) and mean
BMB score decreased by 0.9 after 9 months on eliglustat. In patients on eliglustat
for 18 months, mean hemoglobin increased by 1.02±0.84 g/dL (BL=12.1±1.8
g/dL), mean platelet count increased by 58%±41 (BL=75±14x109/L), and mean
BMB score decreased by 2.2. In ENCORE after 2 years, stability with respect to
hemoglobin, platelets, spleen, liver, bone, and biomarkers was maintained in for-
mer imiglucerase patients switching to eliglustat and in patients continuing on
eliglustat. In former imiglucerase patients, 100% maintained stable hemoglobin
(mean change: 0.04±0.78 g/dL) and 90% maintained stable platelets after 1 year
of eliglustat (mean change: 1.46±31.7x109/L). In patients continuing on eliglustat,
97% maintained stable hemoglobin (mean change: 0.10±0.77 g/dL) and 94%
maintained stable platelets (mean change: 2.27±17.6x109/L) after 2 years. Mean
bone values, all in the normal range at baseline, remained normal after 1-2 years
of eliglustat. In all 3 trials, eliglustat was generally well tolerated; 90% of patients
overall elected to continue on eliglustat. Most adverse events were non-serious,
considered unrelated to eliglustat, and mild or moderate in severity.
Summary/Conclusions: Long-term use of eliglustat in adults with GD1 was
associated with continued improvements in clinical parameters in previously
untreated patients and clinical stability in patients previously stabilized on
enzyme replacement therapy.
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Background: ITP is an autoimmune disorder with increased platelet destruc-
tion and insufficient platelet production. Romiplostim, a thrombopoietin receptor
agonist, improves ITP outcomes compared with control (placebo or standard
of care). Splenectomy removes a major site of sequestration of antibody-coated
platelets, which might alter responsiveness to romiplostim or increase the risk
of thrombosis or other complications. The efficacy and safety of romiplostim in
splnx versus nonsplnx patients are not fully characterized.
Aims: This analysis evaluated safety and efficacy for splnx vs nonsplnx patients
across 13 completed clinical studies of romiplostim in adults with ITP.
Methods: Data up to June 2014 were pooled. Informed consent was obtained
in each ITP study. Safety was analyzed after ≥1 dose of romiplostim or control.
Adverse event (AE) rates were adjusted for time of exposure. Efficacy included
platelet response (any ≥50x109/L) and sustained platelet response (≥50x109/L
≥9 of 12 consecutive weeks). Four dose-finding studies that employed off-label
doses were excluded from efficacy analyses.
Results: Safety was analyzed for 1111 patients (395 splnx; 716 nonsplnx). At
baseline, splnx (vs nonsplnx) patients had longer median ITP duration (8.7
[95%CI: 7.7, 9.7] vs 1.6 [1.4, 2.0] yr), lower median platelet count (14.0 [12.0,
15.3] vs 19.3 [18.0, 21.0] x109/L), and a higher proportion with >3 prior ITP
treatments (38% [33.2%, 43.0%] vs 12% [9.5%, 14.3%]). Splnx patients used
more rescue medications (263.4 [95%CI: 251.5, 275.7] vs 153.3 [125.3, 138.8]
per 100 pt-yr). Exposure-adjusted AE rates are provided in the Table 1. AE
rates per 100 pt-yr in the control group for both splnx (1861.1 [95%CI: 1616.9,
2132.2]) and nonsplnx (1052.6 [989.3, 1119.0]) patients were higher than in
the respective romiplostim group. Efficacy data were analyzed for 1024 patients
(376 splnx; 648 nonsplnx). Median platelet counts increased with romiplostim
and platelet responses were stable over time in both subgroups. For romi-
plostim, rates of platelet response (≥50x109/L at least once) were 82% (95%CI:
78%, 86%) for splnx and 91% (89%, 93%) for nonsplnx patients (p<.0001),
and rates of sustained platelet response (≥50x109/L ≥9 of 12 consecutive
weeks) were 68% (63%, 72%) and 80% (77%, 83%), respectively (p<.0001).
Table 1. Duration-adjusted AE Rate per 100 pt-yr (95% CI).
                                                   Splnx (702.0 pt-yr)                Nonsplnx (1129.7 pt-yr)
Any AE                                       1226.4 (1200.6, 1252.5)             851.9 (835.0, 869.1)
Hemorrhage AEs                         266.1 (254.2, 278.4)                140.8 (134.0, 147.9)
Infection AEs                              156.7 (147.6, 166.2)                124.8 (118.4, 131.5)
Thrombotic AEs                                 6.3 (4.6, 8.4)                             4.6 (3.4, 6.0)
Reticulin AEs*                                  0.4 (0.2, 7.4)                             0.6 (0.2, 1.3)
Any serious AE                                  68.1 (62.1, 74.5)                      44.1 (40.3, 48.1)
Any fatal AE                                         1.6 (0.8, 2.8)                             2.7 (1.9, 3.9)
Any treatment-related AE                123.1 (115.0, 131.6)                   82.1 (76.9, 87.6)
*AEs reported as bone marrow reticulin fibrosis, myelofibrosis, or reticulin increase across 12
studies; excluded 1 ITP study specifically designed for bone marrow assessment (reported
separately).
Summary/Conclusions: Removing a major site of platelet sequestration
increased neither responsiveness nor toxicity of the thrombopoietin receptor
agonist, romiplostim. In splnx patients, platelet response rates were lower, use
of rescue medications was higher, and exposure-adjusted rates of hemorrhage
AEs and infection AEs were higher. Differences between splnx and nonsplnx
patients in disease duration/severity may have influenced concomitant treat-
ments and safety/efficacy results. In conclusion, romiplostim safety generally
was comparable between splnx and nonsplnx patients and platelet response
rates were high in both populations.
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Background: Both T cell receptor (TCR) and co-signalling molecules are
required for T cell activation. Programmed death 1 molecule (PD-1) triggers an
immune checkpoint and co-inhibitory signalling that leads to peripheral tolerance.
Some PD-1 polymorphisms (SNPs) have been described and associated with
autoimmune disease or cancer predisposition. Monoclonal antibodies target co-
inhibitory molecules enhance the immune response against malignancies.
Aims: Establish the relevance of the PD-1 SNPs on the clinical outcome after
allogeneic-hematopoietic stem cell transplantation (allo-HSCT).
Methods: We accomplished a retrospective analysis of the SNPs PD-1.1G/A
(promoter) and PD-1.3G/A (4 intron) genotypes of the donor in a cohort of 1485
HLA-identical sibling transplants (SIB) from Spanish transplant centers per-
formed between 1991 and 2013. T-cell depleted graft recipes were not included.
PD-1 genotyping determined by allelic discrimination assays and detection sys-
tem Life Technologies on DNA samples obtained from peripheral blood. Written
informed consent was obtained. Statistical cumulative incidence was estimated
for aGVHD, relapse and transplant related mortality (TRM) according to PD-1
donor’s genotype. TRM was defined as death due other causes but relapse.
Overall survival (OS) and relapse-free survival (RFS) were analyzed through
Kaplan Meier method comparing curves by the log-rank test. Multivariate analy-
sis was performed by Cox regression model.
Results: PD-1 allele and haplotype frequencies were comparable to other Cau-
casian populations. The haplotype PD-1.1G/PD-1.3G was the predominant
(86.3%). There were statistical differences on age and gender demographic
features in donors genotyped as PD-1AG or AA. The remaining clinical variables
were comparable between these both genotype groups and between PD-1.3AA
or PD-1.3AG/GG cohorts as well, except for the high proportion of myeloablative
transplants on the last one. The aGVHD grades II-IV cumulative incidence was
higher in recipes receiving grafts from homozygous PD-1.1G (p: 0.027) and
PD-1.3A (p: 0.003) donors. Both genotypes were independent risk factors in
multivariate analysis for grades II-IV aGVHD (p:0.033; HR2.2; 95%CI: 1.1 to
4.8 and p<0.001; HR4.5; 95%CI: 2 to 10.1 respectively). PD-1.3AA remained
as independent risk factors for sever III-IV aGVHD (p<0.001; HR7.22; 95%CI:
2.6 to 19.7). The cumulative incidence for aGVHD grades II-IV was 64% in
patients with “high risk” genotypes (PD-1.1GG/PD1.3AA), 32.6% for PD-
1.1GG/PD-1.3AG or GG genotypes and 18% in those with of at least one A-
allele at PD-1.1 position (p:0.001 and p:0.029). Despite the increased risk of
aGVHD, we did not detect any influence of the PD-1 genotype and the second-
ary clinical endpoints (chronic GVHD, TRM, OS and relapse). We inferred the
relative frequencies of genotypes and haplotypes for CTLA-4/PD-1 combina-
tions so, on 883 donors we found that the most frequent matched observed
(42.6%) involves the A alleles at both CTLA-4 SNPs coexisting with G allele at
PD-1.1 and PD-1.3, without any association between CTLA-4 and PD-1 SNPs.
Summary/Conclusions: PD-1 genotypes carrying with the “high risk” alleles
are independent risk factors for grades III- IV aGVHD. Other genotypes seem
to be protective as it has been describe in other autoimmune mediated dis-
eases. There were no statistically differences with the other clinical endpoints,
suggesting that PD-1 should be relevant in the initial process of allorecognition,
but not on prevention of relapses. These preliminary results should be confirmed
by other studies. Financed by PI11/01690 and PI14/01646 and MTV3/120210.
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Background: Management of patients with grade I acute graft versus host dis-
ease (GvHD) (a skin rash covering less than 15% of the body surface), is a matter
of individual preference: some would treat with steroids, most clinicians would
probably not treat. We hypothesized that treatment of grade I GvHD would sig-
nificantly reduce the proportion of patients progressing to grade II GvHD.
Aims: To test whether steroid treatment of acute GvHD grade I, protects
patients from progressing to grade II GvHD.
Methods: Nine Centers of the Italian Group for Bone Marrow Transplantation
(GITMO), randomized 171 patients with acute grade I skin GvHD, to an obser-
vation arm (n=85) or to a treatment arm (n=86)- prednisolone 1 mg/kg/day for
5 days and then taper and discontinue on day +30. Patients in the observation
arm, could be treated when GvHD grade II developed, at whatever interval
from randomization. The primary end point of the study was progression to
acute GvHD grade II. Secondary end points were: transplant related mortality
(TRM), survival, infections and chronic GvHD.The two groups were balanced
for diagnosis (p=0.9), disease phase (p=0.4) and donor type (p=0.4) The medi-
an age for the observation arm, was borderline higher than the treatment arm
(46 vs 38 years, p=0.08).
Results: The cumulative incidence of progression to acute GvHD grade II, was
50% in the observation and 35% in the treatment arm (p=0.02). This difference
was 58% vs 35%, (p=0.05) for HLA identical siblings (n=70) and 45% vs 36%
for alternative donors (n=101) (p=0.3). Grade III-IV GvHD was diagnosed in 11
observation vs 12 treatment patients (13% vs 14%, p=0.8); the incidence was
comparable in the two arms, also when stratified in HLA identical siblings (17%
vs 18%) or alternative donor grafts (10% vs 11%). Moderate/severe chronic
GvHD was comparable in the two groups (17% vs 19%). Patients in the obser-
vation arm had less bacterial infections (11 vs 23, p=0.05) less CMV reactivation
episodes (66 vs 95, p=0.01), and comparable fungal infections (6 vs 8, p=0.4).
Severe adverse events (SAE) were recorded less frequently in the observation
arm (n=18) than in the treatment arm (n=31)(p=0.1). Cumulative incidence of
transplant related mortality (TRM) was 20% (observation) vs 26% (treatment)
(p=0.2). Relapse related death (RRD) was 25% vs 21%. Actuarial 1 year sur-
vival was 86% (observation) vs 82% (treatment) (p=0.3). Main causes of death
in observation/treatment arms, were as follows : acute GvHD 7% -12%; chronic
GvHD 4%>2%; infection, 6%>11%; and leukemia relapse 21% -17%.
Summary/Conclusions: In conclusion, steroid treatment of grade I GvHD pre-
vents progression to grade II GvHD, however, it does not protect patients
against GvHD grade III-IV, nor against chronic GvHD, and exposes patients to
a higher risk of infections. For this reason there is no beneficial effect on TRM,
relapse related death and survival. Based on this prospective trial, patients with
grade I GvHD should be left untreated, untill GvHD resolves spontaneously or
progresses to grade II.
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Background: We recently conducted a prospective study (NCT01810120)
which showed that haploHSCT after depletion of α/β T cells is a suitable and
effective option for those children in need of an allograft and lacking an imme-
diately available HLA-identical donor. However, recovery of adaptive T-cell
immunity remains suboptimal and some patients experienced either relapse of
the original disease or severe viral infections. 
Aims: In light of these considerations, strategies aimed at accelerating early
recovery of adaptive T-cell immunity are desirable. 
Methods: We designed a phase I/II trial aimed at testing the safety and efficacy
of post-transplant infusion of donor-derived T cells transduced with the new
iC9 suicide gene (BPX-501) in children with either malignant or non-malignant
disorders (NCT02065869); enrollment started in December 2014. Cells are
administered within 14±4 days after haploHSCT. The phase I portion of the trial
consisted of a classical 3+3 design with 3 cohorts, receiving escalating doses
of BPX-501 cells of 2.5x105, 5x105, and 1x106 cells/kg, respectively. Patients
included in the phase II portion received the highest tolerated/recommended
dose identified during the phase I portion of the study. As of February 15th
2016, 13 children with acute leukemia either in first or second complete remis-
sion (CR1/CR2) have been transplanted; 7 were males and 6 were females.
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Median age at HSCT was 6.5 years (range 0.9-16.1); 10 pts had acute lym-
phoblastic leukemia (ALL) and 3 acute myeloid leukemia (AML). All pts trans-
planted in CR1 had either poor cytogenetic/molecular characteristics or high
levels of minimal residual disease (MRD) at the end of induction therapy. All
children received >10x106 CD34+ cells/Kg and <1x105 αβ+ T cells/Kg. A mye-
loablative regimen was given to all children, who also received as prophylaxis
of graft-versus-host disease (GVHD) anti-thymocyte globulin (12 mg/kg over 3
days, from -5 to -3). Rituximab (200 mg/m2) was administered on day -1 to fur-
ther prevent EBV-related lymphoproliferative disorders. No pharmacological
GvHD prophylaxis was employed after HSCT. 
Results: Sustained primary engraftment occurred in all pts. The median time
to infusion of BPX-501 cells was 16 days (range 13-18) after HSCT; median
cell viability was 91% (range 65-97). Only one child developed gut and liver
acute GVHD requiring infusion of AP1903, which controlled the disease. Five
pts experienced skin-only grade I-II acute GVHD, this leading to a cumulative
incidence (CI) of 38%. None of the patients at risk developed chronic GVHD.
No patient died for transplant-related complications. One pt relapsed at 4 month
after HSCT, the CI of disease recurrence being 12%. With a median follow-up
of 6 months (range 3-12), the Kaplan Meier estimate of leukemia-free survival
(LFS) is 88% (95% CI 38.7-98.1) compared to 76.6% (95% CI 65.4-84.5) in
the 77 CR1/CR2 ALL/AML patients included in our previous study (Figure 1).
BPX-501 cells progressively expanded over time after the infusion and are
persisting, contributing to the recovery of adaptive T-cell immunity.
Figure 1.
Summary/Conclusions: These data indicate that the infusion of BPX-501
cells in children with acute leukemia given selectively manipulated haploHSCT
results in the absence of transplantation-related mortality and chronic GVHD.
Although the median observation time is still limited, the CI of disease recur-
rence is promising.
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TRENDS IN THE USE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT
FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
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Background: Indications for hematopoietic stem cell transplantation (HSCT)
for adults with acute lymphoblastic leukemia (ALL) evolve over time and vary
among countries as well as the methodology of the procedures.
Aims: The goal of this study was to assess general trends in the number of
various types of HSCTs performed between years 2001 and 2012 in Europe.
Methods: Data reported to the European Society for Blood and Marrow Trans-
plantation (EBMT) registry were used for this analysis. In addition, we evaluated
HSCT rates with respect to the incidence of ALL in selected European countries.
Results: Altogether, 11602 first allogeneic (n=9938) or autologous (n=1664)
HSCTs were performed in the period 2001-2012. Comparing years 2010-2012
and 2001-2003, the number of alloHSCTs performed in first CR increased by
108%, most prominently for transplantations from unrelated (219%) and mis-
matched related donors (89%). The number of HSCTs from matched sibling
donors increased by 43%, while the number of autoHSCTs decreased by 71%
(Table 1). The increase of the use of alloHSCT, irrespective of the disease
stage, was stronger for Ph-pos (108%) than Ph-neg ALL (21%) while similar
for B- and T-ALL. Among patients aged >55 years, the number of alloHSCT
increased by 386% while among younger adults (18-55 years), by 48%.
Between 2001 and 2003, peripheral blood was used as source of stem cells in
69% cases of alloHSCT, compared to 93% between 2010-2012 (p<0.0001).
The use of bone marrow decreased from 30% to 6%, respectively (p<0.0001).
The proportion of alloHSCT with reduced-intensity conditioning (RIC) increased
from 6% to 19% (p<0.0001). Among myeloablative transplantations, regimens
based on total body irradiation were the preferable option (app. 80% over the
whole study period, p=NS). In contrast, among RIC regimens, the use of
chemotherapy predominated (75% between 2010-2012, p=0.006). In most of
analyzed individual countries, the estimated rates of alloHSCT (no. HSCT per
100 newly diagnosed ALL) for patients in CR1 increased over time. However,
the values for a period 2010-2012 varied strongly, being highest in the Nether-
lands (42.2), followed by the UK (32.3) and France (32.2) while lowest in Russia
(0.8). HSCT rates correlated with socio-economic status of a country as defined
by the Human Development Index (R=0.71, p=0.046).
Table 1. Numbers of HSCT procedures for ALL in first CR by donor type.
Summary/Conclusions: Results of our analysis indicate a continuous trend
for an increased use of alloHSCT for adults with ALL, which may be attributed
to increasing availability of unrelated donors. However, it may also be specu-
lated that the introduction of tyrosine kinase inhibitors allowed higher proportion
of patients with Ph-pos ALL proceeding to transplantation. Finally, the imple-
mentation of RIC regimens contributed to wider use of alloHSCT among older
adults. Limitations of the analysis include any assumptions made regarding
ALL incidence for the specified time period and possible variation in reporting
to the EBMT registry from different countries over time.
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Background: The success of allogeneic stem cell transplantation (HSCT) is
limited by acute graft-versus-host disease (aGvHD), one of the major and life-
limiting complications. A proteomic urine pattern “aGvHD_MS17” capable to
predict aGvHD grade II or more has been developed (Weissinger et al., 2007
and 2014). In 2008 a multicenter, randomized, placebo-controlled, double blind
clinical trial to evaluate the proteomic-based prediction of aGvHD as well as
possibilities of pre-emptive therapy was initiated. Patients after the first allo-
geneic HSCT could be included in this trial. Ten centers in Germany contributed
267 patients to this trial and 90 were randomized according to the positivity of
proteomic urine pattern aGvHD-MS17 to receive either prednisolone or placebo.
To date, data of 210 (89 randomized) patients have been analysed for incidence
of acute GvHD grade II or more and overall survival for the first year post HSCT.
Aims: The aim of this clinical trial was to evaluate the predicitve potential of
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aGvHD_MS17 for the development of aGvHD grade II to IV. In additioan we
analysed the possibility of 2mg/kg body weigth prednisolon for pre-emtptive
therapy of aGvHD diagnosed by the positivity of aGvHD_MS17.
Methods: Urine was collected on days +7, +14, +21,+28, +35, +50 and +80
(all +/-3 days) after allogeneic HSCT frozen, shipped to Hannover and analysed
within 72h as described (Weissinger et al., 2007). Positivity of aGvHD_MS17
was achieved, when the dimensionless classification factor (CF) was +0.1 or
more. Upon positivity of a sample for aGvHD_MS17, patients were randomized
and received either prednisolone (2mg/kg BW for 5 days) or placebo. The
majority of the patients had acute leukaemia prior to transplantation (n=120),
were not in CR/CP (n=126; 60%) and were transplanted from matched (n=184;
84%). One hundred fifty one (71%) received reduced intensity conditioning reg-
imens and the majority (84%; n=177) received immunosuppressive antibodies
as GVHD-prophylaxis prior to transplantation and a calcineurin-inhibitor
(CSA/MTX n=78; CSA/MMF n=93) based GvHD-prophylaxis afterwards.
Results: Prospective and blinded evaluation of aGvHD_MS17 revealed in this
first analysis the correct classification of patients developing aGvHD grade II
or more with a sensitivity of 71.17% and a specificity of 80%. The best CF (cri-
terion) for the prediction of acute GvHD was at 0.16, which is between the pre-
viously published discriminatory CF of 0.2 (Weissinger et al., Blood 2007) and
0.11 (Weissinger et al., Leukemia 2014). The aGvHD-MS17-pattern turns pos-
itive about 7 days (range: 1 to 21) prior to the prior to clinical or biopsy based
diagnosis of aGvHD. Patients in the aGvHD-MS17-positve group developed
aGvHD grades II to IV in 49.5% while 19% of patients with aGvHD-MS17 neg-
ative samples developed acute GvHD grade II to IV. Interestingly,
aGvHD_MS17 positivity between day +5 to +35 indicated pending aGvHD II-
IV very accurately. Pattern-negative patients developed aGvHD II-IV later name-
ly between days +20 and +40. Both groups reach a plateau around day +50.
Patients with aGvHD_MS17-positive samples have a 2.76 fold risk of develop-
ing severe acute GvHD (p<0.0001). In addition, overall survival is significantly
different for patients with samples positive for aGvHD_MS17, 40% of those die
within the 1st year after HSCT (day +80 and +250). In contrast, 90% of patients
who never had aGvHD_MS17-positive samples survive the first year (p
<0.0001).
Summary/Conclusions: Our first analysis of the Pre-GvHD-trial implicates
that aGvHD_MS17 is highly reproducible in the early prediction of aGvHD devel-
opment, especially shortly after HSCT (up to day +25). Additionally, univariate
analysis suggests that aGvHD_MS17 accurately separates patients with high
and low overall survival after allogeneic HSCT.
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IN VIVO ROLE OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID)
EXPRESSION IN THE DEVELOPMENT OF PRECURSOR B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
F Auer1,*, D Ingenhag1, A Martín-Lorenzo2, I Sánchez-García2, A Borkhardt1,
J Hauer1
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ter for Child and Adolescent Health, Heinrich Heine University, Düsseldorf, Ger-
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Background: AID is essential for somatic hypermutation and class switch
recombination in mature B-cells, while its role in precursor B-cells is controver-
sially discussed. Since recently there is in vitro experimental evidence that AID
is upregulated in precursor B-cells after exposure to LPS and contributes to
the clonal evolution of pB-ALL.
Aims: Our rational was to establish an in vivo model to investigate the effect
of AID in precursor B-cells independent of BCR-signaling and/or Rag1 induced
oncogenic alterations. In this study we elucidate its role in vivo using a Rag1-/-
tumor-prone model, which is AID deficient or AID competent. Therefore we are
able to study the relevance of the Aicda gene in a dose dependent manner in
pro-B cells.
Methods: The p19Arf-/-/Rag1-/- mouse model (Hauer et al., 2011) was crossed
back on an AID deficient background (p19Arf/Rag1/AID-/-). Healthy and
leukemic mice were characterized by FACS analysis, immunohistochemistry,
and molecular genetics. Preleukemic pro-B-cells were analyzed for IL7 sensi-
tivity. Three pB-ALL tumors were further subjected to whole exome sequencing
on a HiSeq2500 (Illumina) platform.
Results: P19Arf/Rag1-/- deficient mice develop pB-ALL at an incidence of 26%
with evidence of AID expression. Surprisingly, additional loss of AID in these
mice accelerates the pB-ALL incidence to 96% (43/45, median disease onset
25 weeks). Moreover we show that this effect is AID dose dependent, since
AID heterozygous animals on the same background displayed a significant dis-
ease reduction (83%, 15/18, median disease onset 33 weeks). The leukemias
displayed blast infiltration through spleen and peripheral blood with a cell sur-
face phenotype of CD19+B220+ckit+IgM-CD25- and were able to engraft in sec-
ondary recipients with a phenotype identical to the primary disease. Whole
exome sequencing of murine tumors additionally revealed an accumulation of
recurrent somatic Jak3 mutations (R653H, V670A), highlighting the relevance
of the IL7R signaling in these cells. AID expression was verified in preleukemic
pro-B cells (CD19+B220+ckit+IgM-) of p19Arf/Rag1-/- and P19Arf/Rag1-/-AID+/-
animals by qRT-PCR. The importance of an intact IL7-signaling pathway was
further shown by an increased sensitivity to IL-7 withdrawal in AID deficient
preleukemic pro-B cells of these mice.
Summary/Conclusions: This work provides evidence for an in vivo role of AID
in precursor-B cells and that absent AID expression as well as overexpression
of AID can promote leukemia.
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OF AN INTEGRATED GENETIC RISK SCORE IN PEDIATRIC BCP-ALL
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Background: Pediatric B cell precursor acute lymphoblastic leukemia (BCP-
ALL) is characterized by cytogenetic aberrations and deletions of B cell devel-
opment genes. Patients with cytogenetic aberrations ETV6-RUNX1, high hyper-
diploidy (51-65 chromosomes) and TCF3-PBX1 have a good prognosis, where-
as BCR-ABL1, MLL-rearranged, iAMP21 and haploid/near-triploid BCP-ALLs
have a poor prognosis. Cases without these established chromosomal abnor-
malities are called B-other ALL and have an intermediate prognosis. Within the
B-other group a novel high-risk subtype, BCR-ABL1-like, was discovered based
on similar gene expression to BCR-ABL1-positive BCP-ALL and a similar poor
outcome (Den Boer et al. 2009; Mullighan et al. 2009). Recently, Moorman et
al. developed an integrated genetic risk score combining cytogenetic data and
deletion profile of B cell differentiation genes which was predictive for outcome
of pediatric BCP-ALL patients treated on UK protocols (Moorman et al. 2014).
Aims: We aimed to evaluate the independent prognostic value of the integrated
genetic risk score in B-other and BCR-ABL1-like ALL of a Dutch/German pedi-
atric cohort.
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Methods: This study comprised 170 children with BCP-ALL including 78 pre-
viously described BCR-ABL1-like cases identified by hierarchical clustering
and 92 non-BCR-ABL1-like B-other cases (Van der Veer et al. 2013). Patients
with Down syndrome were excluded because of increased risk for treatment-
related toxicity. Copy number of 8 commonly deleted genes was measured by
the SALSA MLPA kit P335, a ratio <0.75 was considered a deletion. Using the
described MLPA profiles (Moorman et al. 2014) the genetic risk score was
determined for each sample. Briefly, genetic good risk is defined by no deletion
of IKZF1, CDKN2A/B, PAR1, BTG1, EBF1, PAX5, ETV6 or RB1; isolated dele-
tions of ETV6, PAX5 or BTG1; ETV6 deletions with a single additional deletion
of BTG1, PAX5 or CDKN2A/B. Genetic poor risk is defined by any deletion of
IKZF1, PAR1, EBF1 or RB1, and all profiles not mentioned above. Event-free
survival (EFS) was estimated using the actuarial Kaplan-Meier method, survival
data between groups were compared using Cox regression.
Results: Among 170 cases negative for sentinel cytogenetic aberrations, we
identified 126 genetic poor risk and 44 genetic good risk cases. The 5-year
EFS in the genetic poor risk cases was 74% compared with 83% in the genetic
good risk group (p=0.1). Genetic poor risk was more frequent in BCR-ABL1-
like than in B-other (86% vs 64%, Fisher p=0.001). The prognosis of B-
other/genetic poor risk (5-yr EFS 81%, p=0.3) and BCR-ABL1-like/genetic good
risk (5-yr EFS 73%, p=0.3) cases was worse, but not significantly worse, from
that observed for B-other/genetic good risk (5-yr EFS 86%), whereas the BCR-
ABL1-like/genetic poor risk cases had poorer outcome (5-yr EFS 68%, p=0.03;
Figure 1). IKZF1 deletion, known to be associated with poor outcome, occurred
in 54% of BCR-ABL1-like/genetic poor risk and 36% of B-other/genetic poor
risk cases. After removing IKZF1-deleted cases, outcome of the BCR-ABL1-
like/genetic poor risk cases remained poor (5-yr EFS 57%, p=0.01), while out-
come of the B-other/genetic poor risk cases (87%) did not differ from that
observed for B-other/genetic good risk cases (86%). In multivariate analyses
including subtype and genetic risk score, the BCR-ABL1-like subtype was inde-
pendently prognostic in the total group of BCR-ABL1-like and B-other cases
(HR 1.8, p=0.06) and upon exclusion of IKZF1-deleted cases (HR 3.0, p=0.01)
whereas genetic risk score was not independently prognostic of these subtypes.
About 80% of both BCR-ABL1-like and B-other genetic poor risk IKZF1-wild
type cases carried CDKN2A/B and/or PAX5 aberration, however intragenic
amplification of PAX5 was more frequent among BCR-ABL1-like than B-other
genetic poor risk group (16% vs 3%, p=0.08).
Figure 1.
Summary/Conclusions: The genetic risk score developed in the UK identified
a group of BCR-ABL1-like patients at higher risk of treatment failure in a
Dutch/German pediatric BCP-ALL cohort. The outcome of B-other/genetic poor
risk and BCR-ABL1-like/genetic good risk cases showed a trend for a worse
outcome compared with B-other/genetic good risk. The genetic poor risk group
largely overlapped with the BCR-ABL1-like group, and only the latter inde-
pendently predicted for an adverse clinical outcome.
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LEUKEMIA
AM Savino1, J Sarno1, L Trentin2, M Vieri1, G Fazio1, M Bardini1, C Bugarin1,
G Fossati3, K Davis4, G Gaipa1, L Meyer5, G Nolan4, A Biondi1, T te Kronnie6,
C Palmi1, G Cazzaniga1,*
1Centro Ricerca Tettamanti, Fondazione Tettamanti, Monza, 2Department of
Women’s and Children’s Health, University of Padova, Padova, 3Preclinical R&D
Department, Italfarmaco S.p.A., Cinisello Balsamo, Italy, 4Baxter Laboratory in
Stem Cell Biology, Department of Microbiology and Immunology, Department of
Pediatrics, Stanford University, Stanford, United States, 5Department of Pediatrics
and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany, 6Depart-
ment of Women’s and Children’s Health, University ofPadova, Padova, Italy
Background: The cure rate for B Cell Precursor Acute Lymphoblastic Leukemia
(BCP-ALL) approaches 90% with current treatment regimens, however only a
third of patients with relapse are cured. Therefore, there is an urgent need to
focus on subgroups of patients with hallmarks of bad prognosis that could benefit
from novel therapeutic approaches. Alterations of Cytokine Receptor-like Factor
2 (CRLF2), a negative prognostic factor in pediatric BCP-ALL, have been iden-
tified in up to 10% of patients representing half of the high risk Ph-like ALL and
of Down Syndrome-associated BCP-ALL. Rearrangements of CRLF2 resulting
in its overexpression are associated with activating mutations of the JAK-STAT
pathway, causing the hyperactivation of JAK/STAT and PI3K/mTOR signaling.
Inhibition of CRLF2/JAK2 signaling has the potential to become a therapeutic
targeted intervention for this subgroup of poor prognostic patients. Previous stud-
ies have shown that the HDAC inhibitor Givinostat/ITF2357 has potent anti-tumor
activity against JAK2V617F mutated myeloproliferative neoplasms (MPN), for
which it has already a clinic application and established safety profile. 
Aims: We studied the in vitro and in vivo efficacy of Givinostat in cases with
CRLF2 rearrangements. 
Methods: The effect of Givinostat in proliferation and apoptosis was tested on
MHH-CALL4 and MUTZ5 cell lines positive for exon 16 JAK2 mutations and in
patient derived CRLF2-rearranged blasts expanded in xenograft mouse models
(PDX) and co-cultured on OP9 stroma.
Results: Givinostat inhibited proliferation and induced apoptosis of BCP-ALL
CRLF2- rearranged MHH-CALL4 and MUTZ5 cell lines, with IC50 values lower
than those for the SET2 cell line bearing JAK2V617F mutation, both for prolif-
eration (IC50: 0.08±0.05µM vs 0.14±0.03µM) and apoptosis (IC50:
0.17±0.03µM vs 0.22±0.04µM). Consistently, after 72 hours of co-culture on
OP9 stroma, Givinostat (0.2µM) was able to kill up to >90% of PDX cells
(Annexin V/Sytox negative), in contrast with the vehicle-treated samples which
showed 25-60% of blasts still alive after treatment. Moreover, in primary sam-
ples from diagnostic BM, CyTOF analyses showed that CD10+/CRLF2+ blasts
were preferentially killed by the drug whereas the normal residue remained
unaffected. At low doses (0.2 µM), Givinostat downregulated genes of the
JAK/STAT pathway (STAT5A, JAK2, IL7Rα, CRLF2, BCL2L1 and cMYC) and
inhibited the basal and ligand induced signaling, reducing the phoshporylation
of STAT5 in all tested samples (mean fold decrease of pSTAT5: 2.4±0.6). The
down modulation of CRLF2 protein was also observed by flow cytometry (mean
fold decrease 3.55±1.38). Furthermore, Givinostat augmented the effect of
chemotherapy in inhibiting proliferation and inducing apoptosis in CRLF2
rearranged cell lines and in primografts, in vitro. After 72 hours, the combined
treatment reached considerable reduction in viable blasts than single treat-
ments (e.g. 6.3-35.3% viable cells in chemotherapy-treated samples vs 1.4-
4.3% of combination). In vivo, Givinostat significantly reduced engraftment of
human blasts in xenograft models of CRLF2 positive BCP-ALL.
Summary/Conclusions: In conclusion the HDAC inhibitor Givinostat efficiently
kills CRLF2 rearranged leukemia by inhibiting JAK/STAT pathway and syner-
gizes with current chemotherapy. Givinostat may represent a novel and effec-
tive tool, in combination with current chemotherapy, to treat this subsets of ALL
with poor prognosis and chemotherapy-related toxicity. These data strongly
argue for the translation of Givinostat in combination with conventional therapy
into human trials. 
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MEDIATED PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
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1Department of Pediatric Oncology, Hematology and Clinical Immunology, Cen-
ter for Child and Adolescent Health, Heinrich Heine University, Düsseldorf,
Germany, 2Instituto de Biología Molecular y Celular del Cáncer, CSIC/ Univer-
sidad de Salamanca, Salamanca, Spain
Background: Although, the genetic aberration associated with BCR-ABLp190-
positive leukemia is already well characterized, the link between the BCR-
ABLp190 fusion protein and precursor B-cell acute lymphoblastic leukemia (pB-
ALL) development is only insufficiently understood.
Aims: By applying a combination of tyrosine kinase inhibitors (TKI) and
chemotherapy, significant improvements have been made in fighting the poor
prognosis of Ph+ ALL, but there is still no long term survival achieved in 30-
50% of pediatric and adult ALL cases. Thus for the development of individual
disease based treatments, further insights are needed to identify the underlying
mechanism that shape BCR-ABLp190 pB-ALL development.
Methods: We generated a mouse model, restricting BCR-ABLp190 expression
to hematopoietic stem/progenitor cells (HS/PCs), by placing the BCR-ABLp190
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cDNA under the control of the Sca1 promoter (Sca1-BCR-ABLp190). This model
was further crossed back with Pax5+/- mice (Sca1-BCR-ABLp190+Pax5+/-). PB-
ALL tumors of both strains were subjected to whole exome and genome
sequencing (HiSeq2500 - Illumina). Reporter gene assays containing copies
of a CD19 promoter derived high affinity binding site were used to assess the
transcriptional functionality of the detected Pax5 variants.
Results: Here we show that pB-ALL development can be established in mice
(13%, 5 out of 36, starting at 13 months), when BCR-ABLp190 oncogene expres-
sion is restricted to HS/PCs (Sca1-BCR-ABLp190). These leukemias are a phe-
nocopy of the human disease with respect to clinical, pathology and genomic
lesions. All pB-ALLs displayed clonal immature BCR rearrangement and the
cell surface phenotype (CD19-B220+IgM-), suggested a reduction of Pax5 activ-
ity. Therefore, Sca1-BCR-ABLp190+Pax5+/- mice were generated, which almost
exclusively developed pB-ALL (CD19-B220+IgM-Mac1+/-) with shorter latencies
(93%, 27 out of 29, first disease onset at 6 months). In order to identify the sec-
ond hit related to pB-ALL disease we next performed whole exome (n=13) and
whole genome (n=3) sequencing of Sca1-BCR-ABLp190+Pax5+/- tumors, which
further revealed alterations of the remaining wild-type Pax5 allele (6/13 point
mutations; 1/3 deletions). All point mutations were shown to confer reduced
transcriptional Pax5 activity by luciferase assay.
Summary/Conclusions: Thus, we shed further light on Ph+ ALL disease evo-
lution on a molecular level, by presenting first proof that expression of the BCR-
ABLp190 oncogene is not necessary in the leukemic cell, but is sufficient in
HS/PCs to induce pB-ALL. Moreover we show an essential function of Pax5 in
BCR-ABLp190 mediated pB-ALL development.
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THE ROLE OF CNOT3 AND THE ENTIRE CCR4-NOT COMPLEX IN TUMOR
DEVELOPMENT
C Vicente1,*, R Stirparo1, S Demeyer1, R Vandepoel1, O Gielen1, B Hassan1,
T Kureha2, T Yamamoto2, J Cools1
1KU Leuven, Center for Human Genetics and VIB, Center for the Biology of
Disease, Leuven, Belgium, 2Cell Signal Unit, Okinawa Institute of Science and
Technology, Kunigami, Okinawa, Japan
Background: CNOT3 is a subunit of the evolutionary conserved CCR4-NOT
complex, mediating RNA degradation through deadenylation of mRNA. We
recently discovered loss-of-function mutations in CNOT3 in patients with T-cell
acute lymphoblastic leukemia (T-ALL) and CNOT3 has also been found to be
mutated in chronic lymphocytic leukemia. These finding suggests a role for
CNOT3 as tumor suppressor gene. However, the role of CNOT3 in normal and
malignant T-cell development remains largely unknown.
Aims: We used mouse and fly (Drosophila melanogaster) models to investigate
the role of CNOT3/Not3 and other members of the CCR4-NOT complex in nor-
mal T-cell development and in tumor development.
Methods: RNAi mediated down-regulation of Not3 and other subunits of the
CCR4-NOT complex was performed in the fly eye cancer model (based on
NOTCH hyper-activation). In mice, we conditionally deleted Cnot3 in lymphoid
lineage cells by crossing Cnot3fl/fl mice with the CD2-iCre strain.
Results: In the fly model, reduction of Not3 expression resulted in a significant
increase in tumor incidence. The knockdown of other subunits of the CCR4-NOT
complex (Not1, Not2, Twin and Pop2) also enhanced tumor formation, indicating
that the entire complex and its deadenylase activity are required for tumor sup-
pression. Overexpression of Not3 suppressed formation of eye tumors. Gene
expression profiling (RNA-seq) showed that suppression of Not3 expression
leads to the stabilization of a set of transcripts that might support tumor growth
and development. In the mouse, we confirmed that CNOT3 and other subunits
of the CCR4–NOT complex are expressed in normal T-cells during T-cell devel-
opment. A single Cnot3 allele was sufficient to support normal T-cell development.
However, in mice with deletion of both Cnot3 alleles, CD4+ and CD8+ cells were
greatly reduced in spleen, bone marrow and peripheral blood. Analyses of thymi
revealed that cells were blocked at the DN2-DN3 developmental stages. Thus,
CNOT3 is essential for the normal development and differentiation of T cells.
Summary/Conclusions: Our results show that CNOT3 is important for proper
T-cell development and establish the entire CCR4-NOT complex as a tumor
suppressor complex.
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CAPTURE-BASED NEXT GENERATION SEQUENCING (NGS) IDENTIFIES
ALSO RARE IG/TCR REARRANGEMENTS IN ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA PATIENTS
ML Guinea Montalvo1,*, M Paris1, M Tosi1, S Lilliu1, B Peruta1, R Cavagna1,
C Belotti1, P Zanghì1, L Elidi1, S Salmoiraghi1, T Intermesoli1, R Bassan2,
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1Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa
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Background: Minimal Residual Disease (MRD) has been demonstrated as
the most important
prognostic factor in Acute Lymphoblastic Leukemia (ALL). To date, allele-spe-
cific oligonucleotide quantitative PCR (ASO-QPCR) has been considered the
gold standard for MRD analysis. This approach requires the identification of
clonal markers at diagnosis starting from PCR amplification of the most frequent
IG/TCR gene rearrangements. However, in a proportion of cases it fails to iden-
tify clonality and suitable markers for MRD evaluation. Recently, a Next Gen-
eration Sequencing (NGS) approach, similarly based on selected rearrange-
ments amplification, has been described to identify clonal markers at diagnosis
and to monitor MRD in lymphoid malignancies. 
Aims: To apply a novel capture-based NGS approach for the identification of
IG/TCR clonal markers at diagnosis possibly overcoming limits of an ampli-
con-based approach.
Methods: A capture-based NGS panel was designed targeting coding V, D
and J genes in the IG/TCR loci. Libraries were prepared using Nextera Rapid
Capture Enrichment protocol (Illumina) and pair-end sequenced on the MiSeq
platform (v3 chemistry, 2x300bp, Illumina). NGS experiments were performed
on 10 diagnostic bone marrow samples of adult ALL patients (6 B- and 4 T-lin-
eage) already studied for clonality following the EuroMRD guidelines within the
NILG 09/00 clinical trial (ClinicalTrials.gov Id: NCT02067143). We also included
2 Human Umbilical Vein Endothelial Cells (HUVEC) and 2 mesenchimal cord
blood cells as negative controls for IG/TCR rearrangements. NGS data were
analyzed by the Vidjil software (Giraud, Saison et al., BMC Genomics 2014,
http://www.vidjil.org).
Results: In the 10 studied diagnostic samples, capture NGS detected all the
fifty clonal rearrangements previously identified by standard clonality assess-
ment and Sanger sequencing. Only one IGH rearrangement was not revealed
because of low coverage of the V, D and J genes involved in this specific
rearrangement. Furthermore, this novel approach allowed to identify 24 addi-
tional clonalities that were subsequently confirmed: (i) 3 corresponded to low
represented clones that were finally revealed by standard method only after an
additional amplification round and sequencing; (ii) 10 corresponded to oligo-
clonal rearrangements in which Sanger sequencing did not allow the discrimi-
nation of single clones that was only possible thanks to single sequences deriv-
ing from NGS; (iii) 11 were characterized by uncommon V/DJ combination that
were amplified and sequenced only after NGS based oligonucleotide design.
HUVEC and mesenchimal cells capture NGS data analysis did not reveal any
rearrangement in IG/TCR genes.
Summary/Conclusions: Our capture-based NGS approach for IG/TCR loci
allowed to identify known as well as low represented and uncommon rearrange-
ments not previously isolated by conventional methods. This technology offers
the opportunity to identify at diagnosis minor leukemia clones so preventing
unexpected relapse in patients proved negative for major clones. Furthermore,
capture NGS can be of high value in patients with rare rearrangements in which
standard procedures could not identify molecular markers suitable for MRD eval-
uation. In fact these patients could not benefit from a MRD driven treatment. In
the future, we aim to retrospectively apply this technology on samples where
standard clonality assessment failed in order to redefine patients molecular MRD
risk classification and to correlate the new assignment with clinical outcome. 
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MIR-126 DRIVEN LEUKEMIA: A MURINE MODEL TO UNDERSTAND
HUMAN B-ALL PATHOGENESIS
MM Naldini1,2,3,*, C Caserta1,2,3, S Nucera1, G Desantis1, A Cosentino1,2,
J Garcia-Manteiga4, JE Dick5, A Lombardo1, F Ciceri2,6, B Gentner1,7
1San Raffaele Telethon Institute for Gene Therapy, 2Vita Salute San Raffaele
University, Milan, 3Co-First Authors, ., 4Centre for Translational Genomics and
Bioinformatics, Milan, Italy, 5Princess Margaret Cancer Centre, University
Health Network and Dept. of Molecular Genetics, University of Toronto, Toronto,
Canada, 6Hematology and Bone Marrow Transplantation Unit, IRCSS
Ospedale San Raffaele, 7Hematology and Bone Marrow Transplantation Unit,
IRCSS Ospedale San Raffaele, Milan, Italy
Background: Deregulated miR activity can contribute to hematologic malig-
nancy. We have shown that miR-126 regulates HSC quiescence, and its ectopic
expression induces a monoclonal leukemia in mice. By engineering a Doxycy-
cline(doxy)-repressible miR-126 overexpression cassette (Tet.126), we showed
that spontaneous B-ALL development was prevented, and full-blown disease
regressed when miR-126 was turned off.
Aims: We sought to further investigate the mechanism behind miR-126-driven
leukemia in our mouse model and explore its relevance in human B-ALL.
Methods: We performed RNAseq of murine B-ALL blasts before and after turn-
ing miR-126 off. We then functionally validated involved pathways by phos-
phoflow and performed in vivo rescue experiments by lentiviral (LV) overex-
pression of candidate factors. We then transduced human B-ALL blasts with
miR-126 reporters-, knockdown- or overexpressing LVs and transplanted them
into NSG mice for characterization.
Results: Transcripts changing in our murine B-ALL model upon miR-126 with-
drawal clustered into 3 main categories: (1) up-regulation of p53-dependent
pathways and negative cell cycle regulators; (2) induction of B-cell differentiation
genes including the transcription factors Myb, Mafb, Ebf1, Ikzf1/3, Pbx1 and
pre-BCR-type signaling; (3) down-regulation of oncogenic/prosurvival pathways
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typically associated with stem and progenitor cells (Kit, Wnt, Thy1, Jak/Stat,
Bcl2). Further proof of miR-126-dependent activation of Stat5 and Akt path-
ways, two key signaling axes in leukemia, was obtained by phosphoflow analy-
sis. To explore the functional relevance of these pathways in our mouse B-ALL
model, we transduced Tet.126 ALL blasts with LV expressing dominant negative
p53 (GSE56), Ikaros (IK6) or BCRABL (p210), engrafted them in mice and
turned off miR-126 expression by doxy when mice had full-blown leukemia.
Doxy treatment cured mice transplanted with Tet.126 ALL. However, GSE56
delayed early blast clearance, and this effect was further enhanced when com-
bined with IK6 or BCRABL, confirming a relevant role of these pathways in our
model. We are currently knocking out direct miR-126 targets by Crispr/Cas9
technology in B-ALL blasts in order to identify the components that render this
model fully independent from miR-126 expression. To test the relevance of the
model for human B-ALL, we focused on Philadelphia (Ph)+ B-ALL, which share
some of the molecular features encountered in our model. Most patient Ph+B-
ALL expressed to various levels miR-126. To measure biological miR-126 activ-
ity, we transduced primary blasts (n=10 Ph+ALL) with a miR-126 reporter LV
and successfully engrafted 7 of them in NSG mice. In all 7 diseases, we detect-
ed substantial miR-126 activity that was stable and disease-specific over serial
transplantation, suggesting a fine-tuned regulation of miR-126 expression in
B-ALL. We then over-expressed or knocked down miR-126 in primary Ph+B-
ALL. Both perturbations negatively affected engraftment in NSG mice and
increased apoptosis, further confirming that human B-ALL depend on a pre-
cisely set level of miR-126 expression. Interestingly, miR-126 knock-down and
Imatinib treatment showed a less than additive effect on B-ALL burden in the
mice (n=2 different diseases), suggesting that miR-126, at least in part, main-
tains active kinase signaling in human Ph+B-ALL. Our murine miR-126 B-ALL
model shows similarities to Ph+B-ALL. 
Summary/Conclusions: We propose that miR-126 constitutes part of the
armamentarium of B-ALL cells to counteract apoptosis and differentiation there-
by permanently maintaining them in an otherwise unstable progenitor cell state.
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MUTATIONS IN TP53 AND JAK2 GENES ARE ASSOCIATED WITH POOR
PROGNOSIS IN PEDIATRIC AND ADULT PATIENTS WITH B-CELL
PRECURSOR ALL
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ogy, Virgen Blanca Hospital, Leon, 6Hematology, Juan Ramón Jiménez Hos-
pital, Huelva, 7Hematology, Jerez Hospital, Jerez de la Frontera, Cadiz, 8Hema-
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Background: B-cell precursor Acute Lymphoblastic Leukemia (B-ALL) is a
malignancy of lymphoid progenitor B-cells, characterized by a marked hetero-
geneity. The identification of hidden genomic lesions that could be associated
with treatment failure and relapse is still a challenge. 
Aims: To determine the frequency and prognostic impact of mutations in a
panel of genes in both children and adults with B-ALL, treated according to
PETHEMA and SEHOP protocols. 
Methods: The mutational status of TP53, JAK2, PAX5, LEF1, CRLF2 and
IL7R, genes was investigated in 340 newly diagnosed patients with B-ALL,
211 were children while 129 were adults. Mutation analyses were performed
using oligonucleotide primer plates designed as part of the IRON-II collabo-
rative network applying 454 massively parallel amplicon next-generation
sequencing technology (454 Life Sciences, Branford, CT, USA). 19 exons
(E) were sequenced by case: TP53 (E4-E11), JAK2 (E12-E16), PAX5 (E2-
E3), LEF1 (E2-E3), CRLF2 (E6) and IL7R (E5).The variant analysis was per-
formed using Amplicon Variant Analyzer (AVA-Roche 454) and Sequence
Pilot (JSI Medical Systems) software. A cut-off 2% was applied to define vari-
ants. 
Results: A mutation rate of 12.1% (41 of 340) was identified. Eleven (26.8%)
patients with mutations concomitantly harbored 2 or 3 mutations. The muta-
tions were more frequent in adult than in children (20.2% vs 7.1%, p<0.0001).
TP53 was the most frequently mutated gene (4.1%), while mutations in
CRLF2 (2.9%), JAK2 (3.5%), PAX5 (2.4%), IL7R (0.3%) and LEF1 (0.6%)
were less frequent. All mutations observed in the childhood cohort of B-ALL,
were exclusively observed in the subgroup of patients without ETV6-RUNX1
translocation (p=0.045) while in the adults all mutations were exclusively
detected in BCR-ABL1 negative cases (p<0.0001). In the whole cohort of
patients, the presence of mutations in TP53 (TP53mut) (p=0.007) and JAK2
(JAK2mut) (p=0.003) was associated with poor response to frontline therapy.
The univariate survival analysis in whole B-ALL cohort showed that,
CRLF2mut was associated with shorter RFS (p=0.023) and EFS (p=0.027),
JAK2mut with a decreased RFS (p<0.0001) and EFS (p=0.001), while
TP53mut was associated with poorer OS (p<0.0001), RFS (p=0.001) and
EFS (p<0.0001). In the multivariate analysis, TP53mut was an independent
risk factor associated with shorter OS (HR, 3.4; p=0.032). TP53mut (RFS:HR,
3.2; p=0.04 and EFS:HR, 3.2; p=0.04) and JAK2mut (RFS: HR,4.0;p=0.01
and EFS: HR,3.9;p=0.01) were independent markers of poor prognosis for
RFS and EFS respectively. In the group of children with B-ALL, a significantly
shorter OS (p=0.002), RFS (p=0.04), and EFS (p=0.009) was observed in
patients with TP53mut. TP53mut was an independent risk factor associated
with significantly shorter RFS (HR, 4.5; p=0.04). In adult B-ALL patients,
TP53mut was associated with a shorter OS (p=0.02) and RFS (p=0.03), and
JAK2mut was related with poorer RFS (p=0.002) and EFS (p=0.03).The pres-
ence of TP53mut was an independent risk factor associated with significantly
shorter OS (HR, 2.3; p=0.03). Moreover, TP53mut (HR, 5.9; p=0.03) and
JAK2mut (HR, 5.6; p=0.04) retained their independent prognostic significance
in multivariate analysis regarding for RFS.
Summary/Conclusions: The mutations in TP53 and JAK2 genes could be
considered as a novel biomarkers associated with poor prognostic in B-ALL
patients.
Grants: HUS272U13; SACYL-GRS-1112/A/15; RD12/0036/0069, FISPI15/
01471 and PI15/00032 to EFR and Group 61 of Red Cáncer.
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NBN GENE VARIABILITY IS ASSOCIATED WITH INCREASED RISK OF
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Background: NBN gene encodes nibrin which is a part of the MRN complex
responsible for DNA double-strand brakes (DSB) repair. Homozygous mutation
in NBN gene leads to rare autosomal recessive immunodeficiency associated
with chromosomal instability and increased predisposition to lymphoproliferative
disorders, called Nijmegen breakage syndrome (NBS). Although the role of
homozygous deletion (657del5) of NBN gene in ALL development has been
established, the impact of heterozygous variants of NBN gene on clinical course
of childhood ALL remains undefined.
Aims: To determine clinical course and biological features of childhood ALL in
homo- and heterozygous carriers of 657del5 mutation in NBN gene.
Methods: In total, 593 children (median age 6.48±4.64 years, median follow-
up 3.31 years) with newly diagnosed BCP-ALL treated in 15 centers of the Pol-
ish Pediatric Leukemia/Lymphoma Study Group were enrolled in the study. We
detected 657del5 mutation in NBN gene using PCR with fluorescent primer
and capillary electrophoresis. Positive results were subsequently confirmed by
Sanger’s sequencing. Targeted copy number screening of selected 23 loci was
performed on available DNA samples (n=366) using the P335-B2 SALSA MLPA
kit (MRC-Holland, Netherlands). IKZF1 deletions were additionally identified
using multiplex-PCR with breakpoint-specific primers. Survival analysis with
estimation of the probability of overall survival (OS), event-free survival (EFS)
and relapse-free survival (RFS) was performed with respect to cytogenetic and
molecular features of ALL, clinical characteristics at diagnosis (WBC, age, gen-
der, risk group, CNS involvement) as well as response to treatment (steroidore-
sistance and minimal residual disease at day 15).
Results: In total, we identified n=23 patients (3.88%) with 657del5 in NBN gene,
four of them (17.39%) harbouring biallelic deletions (Nijmegen breakage syn-
drome) while the remaining n=19 were heterozygous carriers (82.61%). Carriers
of 657del5 in NBN had shorter EFS compared to wild type patients (median
2.05 years, IQR: 1.52-3.82 years vs 3.16 years, IQR:1.89-4.79 years; p=0.082).
No significant differences in OS were observed. Interestingly, we found that CNS
relapse of BCP-ALL was significantly more frequent in 657del5 carriers as com-
pare to wild-type patients (17.65% vs 1.87%; p=0.002). In the multivariate analy-
sis we found that steroidoresistance (OR=15.82, 95%CI 2.44-102.37, p=0.004)
and being a carrier of 657del5 in NBN (OR=38.46, 95%CI 5.69-259.22, p<0.001)
are independent risk factors increasing the risk of CNS relapse.
Summary/Conclusions: We report for the first time the association between
NBN gene variants and biological and clinical features of childhood ALL. In our
study cohort, carriers of 657del5 in NBN gene who were diagnosed with BCP-
ALL had increased risk of CNS relapse regardless CNS involvement at diag-
nosis. Carriers of 657del5 have worse prognosis (shorter EFS) comparing to
wild-type patients. 
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medical center, Nijmegen, 6Prinsess Máxima Center for Pediatric Oncology,
De Bilt, Netherlands
Background: Despite developments in targeted and whole genome gene
sequencing, the robust detection of all genetic variation, including structural
variants, in and around genes of interest and in an allele-specific manner
remains a challenge. Targeted Locus Amplification (TLA) [de Vree et al., Nature
Biotechnology 2014;32:1019-25] is a strategy to selectively amplify and
sequence entire genes on the basis of the crosslinking of physically proximal
sequences. Unlike other targeted re-sequencing methods, TLA works without
detailed prior locus information, as one or a few primer pairs are sufficient for
sequencing tens to hundreds of kilobases of surrounding DNA. This enables
robust detection of single nucleotide variants, structural variants and gene
fusions in genes of interest.
Aims: We describe the use of TLA and NGS to detect fusion genes and
sequence mutations relevant for stratification of B-cell precursor acute lym-
phoblastic leukemia (BCP-ALL). Genomic profiling of BCP-ALL in the last few
years has substantially extended the number of risk factors that can be used
for risk stratification. However, conventional tests provide incomplete sequence
information and can therefore miss clinically relevant information. In addition
the opportunities TLA presents in the detection of breakpoint sequences prom-
ise to empower breakpoint specific minimal residual disease tests.
Methods: A total of 31 primer sets targeting 19 recurrently affected genes were
designed and multiplexed, including the ‘classical’ players MLL, RUNX1, TCF3,
and IKZF1, the tyrosine kinase genes ABL1, ABL2, PDGFRB, CSF1R, JAK1,
JAK2, JAK3, FLT3, and TYK2, and the cytokine signaling genes CRLF2, EPOR,
IL7R, TSLP, SH2B3, and IL2RB. Primer sets were chosen such that the most
relevant regions were sufficiently covered. Viable cells from 47 selected BCP-
ALL samples were analysed. TLA prep was performed, TLA amplicons were
library prepped using Nextera and sequenced on an Illumina NextSeq.
Results: All 20 rearrangements known to be present in these samples were
detected by TLA, including rearrangements in ETV6-RUNX1 (n=5), MLL (n=2),
TCF3-PBX1 (n=3), CRLF2 (n=3), EBF1-PDGFRB (n=2), BCR-ABL1 (n=1),
RCSD1-ABL2 (n=1), SSBP2-CSF1R (n=1) and iAMP21 (n=2). For 14 of the
fusions sequencing depth was sufficient to extract breakpoint-spanning
sequences directly. For two cases with known JAK2 fusions with an unknown
partner, the fusion gene was identified (TERF2 and BCR), as was the case for
an unknown ABL1 fusion (FOXP1). New fusions were identified in 8 cases, includ-
ing previously described IGH@-EPOR, TCF3-ZNF384, MLL, and CRLF2 fusions,
and novel gene fusion of TCF3-CD163L1 and HDAC9-FLT3. In addition we iden-
tified multiple deletion breakpoints in IKZF1, and sequence mutations in JAK2.
Summary/Conclusions: We conclude that TLA is an effective method for the
reliable detection of sequence mutations and structural variations that are rel-
evant for disease prognosis and/or improved treatment decisions.
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Background: More effective and less toxic therapies are required for the treat-
ment of T-cell acute lymphoblastic leukemia (T-ALL). Recently, we and others
reported promising therapeutic activity for ABT-199, a highly specific inhibitor of
the anti-apoptotic BCL-2 protein, in immature subtypes of human T-ALL. Nev-
ertheless, ABT-199 sensitivity is variable between different T-ALL patient samples
and the emergence of therapy resistance together with the occurrence of dose-
limiting toxicities provides a rationale for the evaluation of ABT-199 as part of
combination therapies. Indeed, previous studies have shown that ABT-199 can
synergize with conventional chemotherapeutic agents in human T-ALL.
Aims: In this study, we aimed to identify novel synergistic drug combinations
with the BH3 mimetic ABT-199 in the context of human T-ALL.
Methods: A drug-screening platform was used to identify promising drug com-
binations of ABT-199 with a panel of 21 drugs, including approved anticancer
drugs and emerging investigational and preclinical compounds, in a panel of
primary T-ALLs. Subsequently, in vitro synergism was analyzed by determina-
tion of the combination index (CI) based on cell viability. Moreover, in vivo drug
treatment assays were performed using xenografts of luciferase-labeled T-ALL
cells. Finally, microarray-based gene expression analysis, RT-qPCR, Western
blot and co-immunoprecipitation assays were used to obtain additional insights
in the molecular mechanisms of drug synergism.
Results: A drug screening in 6 primary human T-ALLs (5 diagnostic and one
relapse specimen) revealed strong anti-leukemic effects for the combination of
ABT-199 with BET bromodomain inhibitors, including JQ1 and OTX-015. In
vitro drug synergism between these molecules was confirmed in a panel of 13
human T-ALL cell lines and the degree of synergism was significantly correlated
with BCL-2 expression levels. Furthermore, in vivo drug treatment experiments
using xenografts of luciferase-positive LOUCY cells confirmed the synergistic
activity of the JQ1/ABT-199 combination therapy as evaluated by biolumines-
cence, percentage of leukemic blasts in blood or bone marrow and spleen size.
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Finally, to better understand the molecular mechanism by which BET bromod-
omain inhibition enhances the anti-leukemic properties of ABT-199, we defined
the transcriptional consequences of JQ1 in synergistic T-ALL cell lines. Notably,
BCL2L11 expression was rapidly induced after short-term JQ1 exposure. As a
result, BET bromodomain inhibition triggered an enhanced binding of BIM to
BCL-2 in synergistic T-ALL cell lines, providing a putative explanation for the
improved therapeutic efficacy of ABT-199 and JQ1 in human T-ALL.
Summary/Conclusions: BET bromodomain inhibition can sensitize BCL-2-
positive human T-ALL to ABT-199 treatment by interfering with the balance of
pro- and anti-apoptotic BCL-2 family members.
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PATIENT-REPORTED OUTCOMES FROM A GLOBAL PHASE 3
RANDOMIZED CONTROLLED TRIAL OF INOTUZUMAB OZOGAMICIN
VERSUS STANDARD CARE FOR RELAPSED/REFRACTORY ACUTE
LYMPHOBLASTIC LEUKEMIA
HM Kantarjian1,*, Y Su2, H Bhattacharyya2, E Yan3, M Shapiro4, JC Cappelleri5
1University of Texas MD Anderson Cancer Center, Houston, TX, 2Pfizer, Inc,
New York, NY, 3Pfizer, Inc, La Jolla, CA, 4Pfizer, Inc, Cambridge, MA, 5Pfizer,
Inc, Groton, CT, United States
Background: Inotuzumab Ozogamicin (InO), an anti-CD22 antibody-
calicheamicin conjugate, has demonstrated superior clinical activity versus
standard care (SC; intensive chemotherapy) for relapsed/refractory acute lym-
phoblastic leukemia (ALL) in the ongoing phase 3 INO-VATE trial (DeAngelo,
European Hematology Society 2015 meeting [abstract: LB2073])
Aims: To assess quality of life (QoL), functioning, and symptoms in patients
with relapsed/refractory ALL receiving InO versus those receiving SC, based
on patient-reported outcomes (PROs) from this phase 3 trial.
Methods: Patients were randomized to InO (max 1.8 mg/m2/cycle [≤6 cycles])
or SC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor,
ara-C+mitoxantrone, or high-dose ara-C [≤4 cycles]) and completed the Euro-
pean Organization for Research and Treatment of Cancer Quality of Life Core
Questionnaire (EORTC QLQ-C30) and EuroQoL 5 Dimensions questionnaire
(EQ-5D) at baseline, day 1 of each cycle, and end of treatment. Treatment dif-
ferences in PRO measures over time were assessed in the intent-to-treat pop-
ulation using longitudinal mixed-effects models with random intercepts and
slopes. Analyses were supportive and no multiplicity adjustments were made.
Informed consent was obtained from all patients.
Results: 141 and 138 patients were randomized to InO or SC; PROs comple-
tion rates were 85% and 64%, respectively. Overall, patients receiving InO
reported numerically better quality of life (QoL), functioning and symptom
scores at each cycle versus SC, with statistically significant differences in least
squares mean Physical and Role Functioning (7.6 and 11.5, respectively;
P<0.02). Mean treatment differences in favor of InO in EQ-VAS, Global Health
Status/QoL, Social Functioning, Dyspnea, Appetite Loss, and Fatigue exceeded
or approached 5 (generally considered the minimally important difference [MID]
to be clinically meaningful), although without statistical significance. Other
dimensions directionally favored InO, except Emotional Functioning, Consti-
pation, and Pain, but none approached MID.
Summary/Conclusions: This is the first time that PROs are reported in a large
randomized controlled trial of ALL. QoL, functioning, and symptoms in
relapsed/refractory ALL patients receiving InO appeared generally better than
those receiving SC. These data support the favorable benefit risk ratio of InO
for relapsed/refractory ALL treatment, with superior clinical efficacy that does
not compromise patients’ QoL.
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DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS,
DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY
SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON
ALL-MB 2008 PROTOCOL
G Tsaur1,2,*, A Druy1,2, A Solodovnikov2,3, A Popov4, T Riger1,2,
T Verzhbitskaya1,2, O Streneva1,2, E Shorikov5, L Saveliev1,2,3, L Fechina1
1Regional Children’s Hospital N 1, 2Research Institute of Medical Cell Tech-
nologies, 3Ural State Medical University, Ekaterinburg, 4Federal Research Insti-
tute of Pediatric Hematology, Oncology and Immunology named after D.
Rogachev, 5Morozov pediatric municipal hospital, Moscow, Russian Federation
Background: Recently A. Moorman et al introduced new stratification strategy
for pediatric B-cell precursor ALL (BCP-ALL) based on cytogenetic risk groups
and copy-number alterations (CNAs) detected by single multiplex ligation probe
amplification (MLPA) kit (Blood. 2014; 124(9):1434-1444).
Aims: To test refined diagnostic strategy on independent cohort of childhood
BCP-ALL enrolled into Russian multicenter trial ALL-MB 2008.
Methods: 142 BCP-ALL patients with median age of 3.1 years (range 1-16
years) were included in the current study based on availability of genomic DNA
obtained at the time of diagnosis. Median of follow-up period was 4.2 years.
Ph-positive ALL was revealed in 2 patients; both of them were allocated into
high risk group (HRG) and included in the study. MRD was evaluated by mul-
ticolor flow cytometry with sensitivity non-less than 0.01%. CNAs were esti-
mated by SALSA MLPA P335 ALL-IKZF1 probemix, all revealed IKZF1 dele-
tions were confirmed by SALSA MLPA P202 IKZF1 (IKAROS) probemix (both
MRC-Holland, The Netherlands). Informed consent was obtained in all cases.
Results: IKZF1 deletions were found in 15 (10.6%) patients, deletions of
CDKN2A/B was detected in 44 (31.0%) cases, BTG1 deletions in 12 (8.4%),
EBF1 in 2 (1.4%), PAX5 in 46 (32.4%), ETV6 in 39 (27.5%), RB1 in 11 (7.7%),
PAR1 region was deleted in 9 (6.3%) cases. Based on cytogenetic risk and
CNA group assessment 111 (78.2%) patients allocated to the genetic good risk
(GGR) group, 31 (21.8%) to the genetic poor risk (GPR) group. Patients
referred to the GGR group had higher EFS than patients in GPR group
(0.89±0.03 vs 0.59±0.11, p=0.002) and lower cumulative incidence of relapse
(CIR) (0.07±0.03 vs 0.39±0.11, p<0.001). Although in multivariate analysis the
relation between genetic risk group stratification and EFS as well as relapse
risk was not statistically significant. While IKZF1 deletions (HR 5.214 (95% CI
2.045-13.292), p=0.001), WBC count at diagnosis more than 50*109/L (HR
3.273 (95% CI 1.264-8.476), p=0.015) and M3 status of bone marrow (BM M3)
at day 15 (HR 2.711 (95% CI 1.612-4.559), p<0.001) were significantly asso-
ciated with decreased EFS. Presence of IKZF1 deletions also led to higher
relapse risk (HR 15.175 (95% CI 3.676-62.643), p<0.001) and it was inde-
pendent of other risk factors. After that we estimated the role of IKZF1 deletions,
solely. Patients with IKZF1 deletions were older (9.7 vs 3.2 years, p=0.007)
and more frequently stratified to HRG (53.3% vs 5.5%, p<0.001) than the 127
cases without IKZF1 deletions. IKZF1 deletions were associated with delayed
blast clearance, assessed by BM M3 status at day 15 (p=0.003), lack of hema-
tological remission at day 36 (p<0.001). As a result, the IKZF1-positive cases
more often had MRD levels ≥10% at day 15 (45.4% vs 12.4%, p=0.014), ≥0.1%
at day 36 (66.7% vs 13.1%, p<0.001) and ≥0.01% at day 85 (41.7% vs 6.6%)
than those with normal status of IKZF1. IKZF1 deletions led to significantly
worse outcome in the whole cohort of patients (EFS 0.30±0.15 vs 0.89±0.03,
p<0.001, CIR 0.67±0.18 vs 0.07±0.02 P<0.001). Additionally, IKZF1 deletions
retained their prognostic significance in different subsets of patients: in the ‘B-
other’ group, in BM M3 as well as in BM M1+M2 groups at day 15, in MRD-
defined risk groups at day 15, day 36 and day 85, in ALL-MB 2008 ImRG
patients, but not in SRG or HRG. Notably, all 2 SRG patients with IKZF1 dele-
tions remained in the first CCR.
Summary/Conclusions: We could not confirm that stratification for genetic
risk groups was independent of other factors. It might be protocol-dependent.
In contrast, IKZF1 deletions led to unfavorable outcome in the whole cohort of
patients, various subgroups and appeared to be MRD-independent.
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LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN
ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL
PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS
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R García-Boyero11, R Guàrdia12, P Barba13, M Amigo14, A Bermúdez15,
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Background: Several studies have reported a poorer prognosis for patients
with Ph-negative, B-cell precursor (BCP) ALL expressing CD20 in ≥20% blasts.
This has led to perform phase II and III studies demonstrating an improvement
in prognosis with the addition of anti-CD20 monoclonal antibodies to the initial
treatment. However, little is known about the prognostic value of CD20 expres-
sion in BCP ALL patients treated according to MRD-oriented protocols.
Aims: To analyze the frequency and prognostic impact of CD20 expression in
adult patients (18 - 59 yr) with Ph-negative, BCP ALL treated with the MRD-
oriented protocols ALL-HR-03 and ALL-HR-11 (for patients with high risk ALL)
and ALL-SR-08 (for patients with standard risk ALL) from the Spanish PETHE-
MA Group.
Methods: Immunophenotypic reports of adult patients with Ph-negative, BCP
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ALL included in the above referred protocols were reviewed. CD20 expression
≥20% was considered to define CD20 positivity (CD20+) as this cut-off level
has been selected in some studies performing treatment with antiCD20 MoAb.
MRD was assessed by multiparameter flow cytometry. High-risk (HR) Ph-neg-
ative, BCP ALL patients were defined according to one of the following criteria:
age (≥30 years), WBC count (>30x109/L) or cytogenetics (11q23/MLL gene
rearrangements), whereas patients lacking all these features were considered
as standard-risk (SR) ALL. HR-ALL patients included in ALL-HR-03 and ALL-
HR-11 protocols received intensive induction and consolidation therapy followed
by allogeneic HSCT if the MRD clearance was poor, whereas SR-ALL cases
received a pediatric-based protocol, allogeneic HSCT being also indicated if
persistent MRD positivity.
Results: Overall 308/362 patients included in the three protocols were evalu-
able for CD20 expression, of whom 111 (36%) were CD20+. Compared with
patients with CD20 level ≤20%, CD20+ cases showed a trend towards lower
WBC count (X[SD] 33[76] vs 46[77]x109/L, P=0.05) and a higher frequency of
common+pre-B phenotypes (107/111 vs 148/197, P<0.001). No differences in
outcomes (CR rate, CIR, DFS and OS) were observed on comparison of CD20+
patients with the other cases, neither for the whole series nor for the different
risk groups (Table 1). Similar results were observed after censoring the follow-
up of patients at the time of HSCT. The lack of prognostic impact was observed
after stratification (cut-off) for age (30 yr.) and WBC count (30x109/L).
Table 1.
Summary/Conclusions: One third of adult patients (18-59 yr) with Ph-nega-
tive, BCP ALL treated with MRD-oriented PETHEMA protocols expressed CD20
≥20%. CD20 expression ≥20% did not show prognostic significance in this
study.
Supported in part with the grants PI10/01417 from Fondo de Investigaciones
Sanitarias and RD12/0036/0029 and RD12/0036/0048 from RTICC, Instituto
de Salud Carlos III and 2014SGR225(GRE), Generalitat de Catalunya and La
Caixa Foundation, Spain.
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PROTEIN PHOSPHATASE 4 REGULATORY SUBUNIT 2 (PPP4R2) IS
RECURRENTLY DELETED IN ACUTE MYELOID LEUKEMIA (AML) AND
REQUIRED FOR EFFICIENT DNA DOUBLE STRAND BREAK REPAIR
JK Herzig1,*, L Bullinger1, A Tasdogan2, FH Heidel3, V Teleanu1, HJ Fehling2,
C Buske4, H Döhner1, K Döhner1, VI Gaidzik1
1Internal Medicine III, University Hospital of Ulm, 2Institute of Immunology, Ulm
University, Ulm, 3Leibniz-Institute for Age Research, Fritz-Lipmann-Institute,
Jena, 4Institute of Experimental Cancer Research, University Hospital of Ulm,
Ulm, Germany
Background: We have previously identified a commonly deleted region (CDR)
at chromosomal band 3p14.1-p13 in cytogenetically normal (CN) and complex
karyotype (CK) AML. This CDR has also been described in solid tumors like
cervix and prostate cancer. Within the CDR, PPP4R2 is one of eight affected
genes. As part of the protein phosphatase 4 (PPP4) complex, PPP4R2 was
shown to be involved in the DNA repair of double-strand breaks (DSBs) by de-
phosphorylation of DNA damage response (DDR) proteins like phosphorylated
histone H2AX (γH2AX) or KRAB-domain associated protein 1 (pKAP1) in
osteosarcoma or cervix carcinoma cells.
Aims: To investigate the role of PPP4R2 in hematopoiesis and leukemogenesis.
Methods: Gene expression of PPP4R2 was analyzed by qRT-PCR in a cohort
of AML patients (pts, n=63), that is 3p CDR within CN-AML (n=10), 3p CDR
within CK-AML (n=26), CN-AML (n=24), CK-AML (n=3), and healthy bone mar-
row (BM) controls (n=8). Lentiviral transduction with PPP4R2-ORF was used
to overexpress (OE) PPP4R2 in the human myeloid leukemic cell line MEG-01
with a homozygous deletion of PPP4R2. Knockdown (KD) of Ppp4r2 was per-
formed by lentiviral delivery of Ppp4r2-shRNA in murine pre-leukemic MLL-
AF9 and normal Lineage negative (Lin-) BM cells. We determined the effects
on proliferation by MTS-Assay, clonogenic growth in methylcellulose, and apop-
tosis and DDR by flow cytometry and Western blot analysis.
Results: Compared to healthy BM, PPP4R2 expression was significantly lower
in AML pts with lowest expression levels in CN-AML 3p CDR cases and CK-
AML 3p CDR cases (p=0.007; p<0.0001, respectively). PPP4R2 OE in MEG-
01 cells considerably reduced proliferation (p=0.007), as well as colony forming
potential (p=0.07). On the other hand, apoptosis caused by DSBs upon ionizing
radiation (IR) was not induced in PPP4R2 OE MEG-01 cells, suggesting a
restoration of DDR. In line, PPP4R2 OE in MEG-01 cells showed a significant
decrease of pKAP1 (S824), reduced γH2AX (S139) [0.5 h post (p.) IR: p=0.01,
p=0.4; 2 h p. IR: p=0.0001, p=0.8, respectively] and less P53 (S15) activation.
Next, we determined loss-of-function effects upon Ppp4r2 KD in murine MLL-
AF9 transformed BM cells. In this leukemia model, Ppp4r2 KD significantly
decreased cell proliferation (p<0.0001) as well as colony forming potential
(p=0.0002), but enhanced repopulating capacity (p=0.04). IR caused enhanced
apoptosis in Ppp4r2 KD cells (48 h p. IR: p=0.009) that was accompanied by
significant accumulation of pKAP1, γH2AX (0.5 h p. IR: p=0.005, p=0.0002; 2
h p. IR: p=0.004, p<0.0001, respectively), and activated P53, indicating consti-
tutive DNA damage and less efficient DNA repair. Furthermore, we assessed
the effect of Ppp4r2 KD in Lin- BM cells. Ppp4r2 KD reduced proliferation
(p=0.3), but not clonogenic growth (p=0.6). In response to IR, Ppp4r2 KD in
Lin- BM cells resulted in a higher amount of apoptotic cells (48 h p. IR: p=0.07),
which was associated with elevated DDR protein pKAP1 and γH2AX levels
(0.5 h p. IR: p=0.02, p=0.6, respectively).
Summary/Conclusions: As candidate gene of a CDR on 3p in AML pts,
PPP4R2 displayed lowest expression in CN-AML with 3p CDR. Furthermore,
we identified PPP4R2 as a critical regulator of DDR in both normal hematopoi-
etic and leukemic cells via deregulation of the PPP4 complex. While impaired
DNA repair and constitutive DNA damage might contribute to the pathogenesis
of AML, further studies are warranted to determine potential additive effects of
PPP4R2 deletion to leukemogenesis.
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PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED
WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR
MYELOPROLIFERATIVE NEOPLASM (MPN) 
S Morin1,*, A Renneville2, A Marceau-Renaut2, M Sebert1, T Braun3, C Bally1,
C Preudhomme2, P Fenaux1, L Adès1
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3Hematology, Hôpital Avicenne-Assistance Publique Hôpitaux de Paris, Paris,
France
Background: Nucleophosmin 1 gene (NPM1) mutations account for 30% of
AML and 50% of cytogenetically normal (CN) AML. NPM1 mutated AML without
FLT3-ITD (NPM 1+FLT3 ITD–) is classified in the favorable risk group. Recent
studies, including from our group, showed that most NPM1+FLT3-ITD–AML
also carry mutations in other genes such as DNMT3A, IDH1, IDH2, TET2 muta-
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tions which may constitute “preleukemic” clones, as suggested by the fact that
those mutations often persist in patients with undetectable NPM1 minimal resid-
ual disease (MRD) after intensive chemotherapy (Peterlin Haematologica 2015,
Corces-Zimmerman PNAS 2014). On the other hand, a recent report showed
that virtually all relapses in NPM1+AML carried NPM1 mutation, arguing against
the fact that relapse can emerge from those preleukemic clones, independently
of the presence of NPM1 mutation (Hills NEJM 2016).
Aims: To better understand the genetic mechanisms underlying disease evolution
in patients with de novo CN NPM1+ FLT3-ITD-AML in complete remission (CR).
Methods: Over a 10-year period, 34 de novo CN NPM1+ FLT3-ITD-AML (medi-
an age 55 years) were treated with intensive chemotherapy at our center, and
32 achieved CR. 12 (37%) remained in hematological CR with undetectable
NPM1-MRD, 14 (44%) relapsed with the same NPM1 mutation, and 6 (19%)
developed MDS or MPN while still in molecular CR for NPM1 (Figure 1A). 12
of the relapsing patients and all 6 patients with MDS or MPN evolution had
sequential molecular analysis using NGS of PCR-amplified exons of a panel
of the 26 genes most frequently mutated in myeloid malignancies.
Results: The 6 patients who developed MDS or MPN with undetectable NPM1-
MRD, after a median of 14 months (range: 4-30), were all aged >55 years, and
included 2 RARS, 2 RCMD, 1 CMML type 1 and 1 primary myelofibrosis (PMF).
In all 6 cases, a “preleukemic” clone with at least 1 mutation in TET2 (n=4),
JAK2 (n=2), ASXL1 (n=1), IDH2 (n=3) or spliceosome genes (SRSF2, SF3B1,
U2AF1, (n=3)) was found at AML diagnosis, and was still present (with stable
or increasing variant allele frequency) at the time of MDS or MPN diagnosis
(Figure 1B). In the 12 relapsing patients, “preleukemic” mutations were also
present at AML diagnosis in 10/12 cases. However, they possibly differed
between the 2 groups: At AML diagnosis, TET2 mutation was identified in 4/6
(66%) patients who developed MDS or MPN, versus 2/12 (16%) patients who
relapsed, p=0.1). Conversely, 8/12 patients who relapsed had mutations in
DNMT3A or IDH1, versus 0/6 patients who developed MDS or MPN (p=0.025).
At AML relapse, mutations co-occurring with NPM1mutation were identical to
those observed at AML diagnosis.
Figure 1.
Summary/Conclusions: Our study suggests that a significant proportion of
patients with de novo NPM1+FLT3-ITD- CN-AML (19% in our series) may sub-
sequently develop MDS or MPN in the absence of NPM1 mutation recurrence,
and that this type of hematological evolution seems to be related to the per-
sistence and expansion of preleukemic clones. The high incidence of such
evolution may be related to the relatively advanced age of our patient cohort,
due to our hospital unit recruitment (mostly elderly AML). Interestingly, in most
patients with AML relapse, preleukemic clones were also observed at AML
diagnosis but with a different mutational pattern, possibly pointing out different
pathophysiological mechanisms. If those findings are confirmed in a larger
number of patients, NPM1+ AML patients may have to be closely followed-up
after CR achievement even when NPM1 MRD remains undetectable, due to
the relatively high risk of MDS or MPN, at least in elderly patients.
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CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARAC-
TERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA
FROM CHRONIC MYELOMONOCYTIC LEUKEMIA
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Background: Little is known about factors contributing to the transformation
of CMML into secondary AML. In the “Austrian Biodatabase for Chronic
Myelomonocytic Leukemia (ABCMML)” we retrospectively and prospectively
collect clinical, biologic and molecular information of patients with CMML from
different centers in a real life setting. Up to now 355 patients have been includ-
ed, cytogenetic data are available in 186 patients, targeted next-generation
sequencing (NGS) data in 138 patients, and in vitro culture data in 120 patients,
respectively.
Aims: Our aim was to characterize the clinical, molecular and biologic features
of patients with CMML who develop AML.
Methods: Clinical, hematological and cytogenetic data were obtained from
patients records. For molecular characterization we used NGS with amplicon-
based target enrichment of 39 CMML associated genes. Only mutations with an
allele burden of 10% or higher were considered positive in this analysis. Since
increased spontaneous myeloid colony formation is an in vitro characteristic of
RAS pathway hyperactivation (Wang et al., Blood 2010) colony-forming units
granulocyte/macrophage (CFU-GM) growth in the absence of exogenous
cytokines was assessed using semisolid cultures as previously described
(Geissler et al., J Exp Med 1996). Transformation into AML was defined as a
blast cell percentage of at least 20% in the peripheral blood and/or bone marrow.
Results: Of the 355 CMML patients studied, we identified 47 who had already
CMML derived AML at the time of inclusion (group A), 80 patients who later
had documented transformation into AML (group B) and 228 patients, in whom
no transformation was recorded (group C).
Characteristics (median values, ranges) [p-values] of CMML patients who
developed AML (group A+B) vs CMML patients without AML (group C) were:
age (years): 70 (34-88) vs 73 (45-92) [0.14]; WBC (G/l): 14.0 (0.7-360) vs 14.2
(1.6-156) [0.818]; hemoglobin (g/dl): 9.8 (6.0-16.7) vs 11.0 (5.1-12.2) [0.000];
platelets (G/l): 89 (5.0-435) vs 90 (2.0-709) [0.435]; PB blasts (%): 14 (0-79)
vs 0 (0-18) [0.000]; LDH (U/l): 294 (106-3685) vs 259 (102-1912) [0.013]; OS
(months): 23.1 vs 38.7 [0.004]; CFU-GM per 105 PBMNC: 333 (0-4533) vs 13
(0-1009) [0.002]; (range in normal individuals 3.5 – 8.5). Thus, CMML patients
who developed AML had a significantly inferior survival, lower hemoglobin val-
ue, higher LDH, and higher spontaneous CFU-GM formation than patients who
did not develop secondary AML. The incidence of RAS pathway mutations in
group A+B (67%; 22/33) was significantly higher than in group C (37%; 39/105),
[p=0.003]. The detailed pattern of mutations in RAS pathway, epigenetic reg-
ulator and spliceosome components in CMML patients who developed AML
(group A+B) is shown in Figure 1.
Figure 1. Mutation status of genes in CMML patients who developed AML.
RAS pathway mutations were found in 15 of 19 (79%) CMML patients in whom
molecular profiles were studied at the time of AML and in 7 of 14 (50%) CMML
patients who later developed AML. The incidence of TET2 mutations was 70%
(23/33) in group A+B which was not significantly different from the incidence in
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group C (63%; 66/105), [p=0.474]. There was also no significant difference in the
incidence of mutations with regard to other epigenetic modulators and to compo-
nents of the spliceosome. Other mutations were rare and were also not significantly
different. The most common cytogenetic abnormalities were+8 (12%), -7/del(7q)
(6%), and –Y (4%), respectively, without significant differences in the two groups.
Summary/Conclusions: Our data show that patients with CMML who trans-
form into AML have an unfavorable prognosis. In the majority of them the trans-
formation process seems to be associated with hyperactivation of the RAS
pathway. In order to improve outcome RAS pathway inhibitors should be studied
in this high risk cohort.
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MOLECULAR CLASSIFICATION AND COMPARATIVE ANALYSIS OF ACUTE
MYELOID LEUKEMIA MULTI-OMICS DATA USING THE INTERACTIVE
HEMAP RESOURCE
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Background: Collections of genome-wide data can facilitate the characteriza-
tion of disease states. The current challenge is to unify pre-existing patient
molecular data to allow i) subtype-specific mechanisms to be distinguished
from common mechanisms that underlie the departure from healthy states and
ii) to evaluate disease contexts for promising drug targets.
Aims: The first goal in this study was to determine the robustness of molecular
stratifications in acute myeloid leukemia (AML) by comparing them across dif-
ferent datasets and clinical annotations. We further focused on characterization
of acute myeloid leukemia (AML) cases with normal or complex karyotypes
and develop methodology for in silico evaluation of drug specificity.
Methods: The unsupervised dimensionality reduction method t-Distributed Sto-
chastic Neighbor Embedding (t-SNE) was used to stratify a heterogeneous col-
lection of 1,713 AML transcriptomes. We developed bioinformatics methodology
for inclusion of new samples and unsupervised discovery of their cytogenetic
type. Additional multi-omics datasets of 99 patients from The Cancer Genome
Atlas were integrated to gain insight into disease biology. In silico screening of
drug target expression was combined with chemical screen data of target speci-
ficity to compare two FLT3 inhibitors that are in ALL and AML clinical trials
(Lestaurtinib and Tandutinib, respectively). A larger collection of 9,544 tran-
scriptomes from 36 hematological malignancies and healthy blood cell type
controls was utilized for this purpose.
Results: The current clinical classification of AML distinguishes between fusion-
gene-positive categories. Unsupervised clustering in the t-SNE space yielded
a performance comparable to that of robust and reproducible classifiers. Fur-
thermore, we found additional clusters using t-SNE maps that corresponded to
a distinct mutational pattern (CEBPA, NPM1 or RUNX1/TP53). CEBPA-mutated
cases were found to exhibit elevated expression of S-adenosylmethionine-
dependent methyltransferase pathway and we could show that this leads to
globally elevated DNA methylation levels genome-wide. Expression patterns
of targets inhibited by Lestauritinib revealed that it has the potential to act on
considerably more genes (in addition to FLT3), of which several targets with
low Kd values are also expressed in normal cell types, thus having potential to
lead to side effects. Comparison of AML and other malignancies showed that
the more specific Tandutinib may also be a promising drug for lymphoma trials,
based on the multiple low Kd targets associated with this disease context.
Summary/Conclusions: Our results revealed molecular phenotypes that distin-
guish normal karyotype AML samples. The generated interactive resource,
Hemap, is available online for investigating the molecular states of hematological
malignancies and expediting therapeutic innovations. The FLT3 inhibitor currently
evaluated in AML clinical trials, Tandutinib showed highly AML-specific expression
profile of its low Kd targets and has potential for drug repositioning in lymphoma.
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Background: The DDX41 gene, encoding a DEAD-box type ATP-dependent
RNA helicase, is rarely but reproducibly mutated in myeloid diseases. The
acquired mutation in DDX41 is highly concentrated at c.G1574A (p.R525H) in
the conserved motif VI located at the C-terminus of the RecA-like helicase core
domain where ATP interacts and is hydrolysed. Therefore, it is likely that the
p.R525H mutation in the DDX41 protein perturbs the ATPase activity in a dom-
inant-negative manner. 
Aims: This study was aimed at elucidating the molecular functions of DDX41
protein and the role of p.R525H DDX41 mutant in leukemogenesis.
Methods: In this study, we first screened for the DDX41 mutation of CD34-positive
tumour cells based on mRNA-sequencing and identified the p.R525H mutation
in three cases among 23 patients. Then we analyzed changes in gene expres-
sions and phenotype of hematopoietic cells transduced with the DDX41 mutant. 
Results: We initially found that the patients harboring the p.R525H DDX41
mutation commonly exhibited AML with peripheral blood cytopenias and low
blast counts, suggesting that the mutation inhibits growth and differentiation of
hematopoietic cells. To address molecular functions of DDX41, we clarified the
localization of DDX41 protein. Ectopically expressed Myc-tagged DDX41 was
mostly nuclear regardless of the p.R525H mutation. In addition, the majority of
the endogenous DDX41 protein was also mostly nuclear. In the nucleus, DDX41
protein was localized both in the nucleoplasm and in the nucleolus, implying
that DDX41 plays a role in the nucleoplasm as well as in the nucleolus. We
then transduced cord blood-derived CD34-positive cells with DDX41 wild type
(WT) or p.R525H. After a 30-day culture, p.R525H cells showed decreased
proliferation compared with WT cells, with a certain ribosomopathy phenotype
as suggested by GSEA analysis. This finding and the highly conserved DEAD-
box type RNA helicase domain of DDX41 led us to speculate that the enzyme
might be involved in the pre-rRNA processing. Northern blot analysis probing
internal spacer (ITS) 1 and 2 of pre-rRNA showed that signals of 47S and 41S
pre-rRNAs were increased, whereas the 21S signal was decreased in THP-1
cells expressing DDX41 p.R525H. Although the precise phase at which DDX41
takes part in the pre-rRNA processing has not been elucidated yet, this series
of experiments suggests a role for DDX41in the trimming of 5’ external spacer
and/or ITS2. Recent studies on ribosomopathies including 5q- syndrome
revealed an activation of the MDM2-p53 pathway in the pathogenesis of the
diseases. Although p53 activation was not evident in the p.R525H DDX41
expressing cells, GSEA instead revealed a negative enrichment of cell cycle-
promoting genes regulated by the RB-E2F axis in p.R525H DDX41 cells. Cell
cycle inhibition through E2F suppression was also detected in patient-derived
samples. In our study, we further found increased RPL5 and RPL11 bound to
MDM2 in p.R525H DDX41 cells. It is likely that the mutant DDX41 increased
free ribosomal proteins that are not incorporated into the 60S ribosome and
that these proteins eventually formed a complex with MDM2, thus the degra-
dation of RB by MDM2 might be compromised.
Summary/Conclusions: In summary, we propose a mechanism of growth defect
in haematopoietic cells triggered by p.R525H DDX41 occurring in the following
order: (i) p.R525H mutant inhibits pre-rRNA processing;, (ii) compromised ribo-
somal biogenesis as a result of impaired rRNA synthesis causes a release of
ribosomal proteins that bind to MDM2; (iii) MDM2-mediated RB degradation is
suppressed, thus eventually activating the RB pathway and resulting in the inhi-
bition of E2F activity. Considering late occurrence of AML in patients harbouring
the mutation, it might require age-dependent epigenetic alterations or other
somatic changes for this mutation to fully transform haematopoietic cells.
P545
WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN
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Background: Myelodysplastic syndrome (MDS) and acute myeloid leukaemia
(AML) are related heterogeneous haematopoietic stem cell clonal disorders
characterised by defective haematopoiesis and premature mortality in many
patients. The majority of MDS and AML cases are sporadic but there are also
rare cases (<5%) where two or more affected individuals are found within the
same family (familial MDS/AML). Familial MDS/AML patients represent a high-
risk population who require unique follow-up and treatment strategies to achieve
cancer risk reduction, prevention and best management. To date, heterozygous
germline mutations in 10 disease genes (ACD, ANKRD26, CEBPA, DDX41,
ETV6, GATA2, RUNX1, SRP72, TERC and TERT) have been associated with
the inherited predisposition in these families, but explain only 50-60% of cases. 
Aims: To identify new germ-line mutations in families with MDS/AML of
unknown aetiology
Methods: Bone marrow or peripheral blood samples were collected from 78
families, where two or more members have been diagnosed with a haemato-
logical disease (AML, MDS, aplastic anaemia or thrombocytopenia) but includ-
ing at least one with MDS or AML. Each index case of these families was tested
for mutation in the 10 known disease genes using deep targeted sequencing.
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Whole exome sequencing (WES) was performed in families with still unknown
aetiology. Exome libraries were prepared using Illumina Nextera reagents and
sequenced on the HiSeq2000. Germline variant calling was performed using
GATK and all functional variants were selected. We used the following criteria
to enrich for genes with pathogenic relevance: (i) recurrent genes (those with
mutations in at least two families); (ii) novel variants or genetic lesions, not
described in dbSNP137, ExAC, HAPMAP or the 1000 Genomes projects; (iii)
functional annotation based on both PolyPhen scores (>0.850) and the Muta-
tionTaster algorithm (disease causing) to assess pathogenicity. 
Results: 46 of the 78 families in our cohort (59%) have mutations in 8 of the
10 known loci (ACD, CEBPA, DDX41, GATA2, RUNX1, SRP72, TERC and
TERT). In 32 families of unknown aetiology, whole exome sequencing (WES)
was performed and a mean of 422 non-synonymous variants were found per
sample. The chosen criteria have allowed us to limit the search to the most rel-
evant germline mutations in our cohort, reducing the number of new candidate
disease genes to nine with shared nonsynonymous variants: ATP13A4,
COL2A1, DNAJC10, GLDC, LRP2, MAN1C1, PDCD4, SEC23B and TFIP11.
Summary/Conclusions: We have identified nine new potential candidate dis-
ease genes in familial MDS/AML. However, a single unifying candidate gene has
not been identified, suggesting genetic heterogeneity. Further studies will estab-
lish which of these can be assigned as true ‘familial MDS/AML’ disease genes.
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Background: Mutations in the nucleophosmin 1 (NPM1) gene are considered
a key event in the pathogenesis of AML. Recently, we gained insights into
clonal architecture and clonal evolution of NPM1 mutated (NPM1mut) AML.
While DNMT3A mutations (DNMT3Amut) showed the highest stability suggest-
ing DNMT3Amut to be an early event in leukemogenesis, we also observed an
increase in genomic complexity at the time of relapse.
Aims: To validate our previous results on clonal evolution in a larger cohort of
NPM1mut AML patients (pts), to define relapse specific mutation patterns as
well as to identify the impact on gene expression.
Methods: Paired samples at diagnosis and relapse from 129 NPM1mut AML
pts were assessed for additional mutations by comprehensive mutation analysis
(FLT3-ITD, FLT3-TKD, DNMT3A, IDH1/2, NRAS, ASXL1, TP53, MLL-PTD).
In addition, AML cases with loss of NPM1mut at the time of relapse and with
persisting NPM1mut were subjected to whole exome sequencing (WES; n=20)
and RNA-Seq was performed on selected paired NPM1mut loss diagnosis and
relapse cases (n=6).
Results: At diagnosis, concurrent gene mutations were found at the following
incidence: FLT3-ITD 32% (40/126), FLT3-TKDmut19% (22/118), DNMT3Amut
69% (78/113), NRASmut 19% (22/117), IDH1mut 21% (26/123) and IDH2mut 18%
(22/118). None of the pts analyzed exhibited a TP53, MLL-PTD or ASXL1 muta-
tion. At relapse, we found a significant shift in the genetic pattern of 74 pts (59%)
with the most frequent changes seen for FLT3-ITD, which was lost in 10 and
newly acquired in 24 pts. Additional changes affected FLT3-TKDmut,
DNMT3Amut, NRASmut, IDH1mut, IDH2mut, ASXL1mut and TP53mut. Notably,
gain of MLL-PTD (n=4) was restricted to pts with loss of NPM1mut at the time of
relapse. Based on these findings we calculated the following stabilities for the
most frequent mutations: FLT3-TKDmut27%, NRASmut45%, FLT3-ITD 75%,
IDH1mut 88% and IDH2mut 90%, and DNMT3Amut 97%, thereby confirming our
previous findings for DNMT3Amut. Similarly, NPM1mut was lost at relapse in 10
pts (8%) of which 9 pts showed a stable DNMT3Amut at relapse. By WES we
could confirm persistence of mutations known to be involved in clonal
hematopoiesis, such as DNMT3A and TET2 mutations. These were usually
seen during all analyzed time points (diagnosis, remission and relapse). Other-
wise, we found distinct mutational patterns at the time of relapse compared to
the time of diagnosis for NPM1mut loss cases, while mutational profiles of cases
without NPM1mut loss at relapse remained more stable. For example, while the
mutational pattern of diagnostic samples showed an enrichment for mutations
affecting MYC signaling, at the time of relapse in NPM1mut loss cases there
was a significant enrichment of mutations in the MAPK signaling cascade. RNA-
Seq for selected diagnosis/relapse pairs further supported a switch in signaling
cascades at the time of relapse in NPM1mut loss pts with differentially expressed
genes being significantly enriched for MAPK signaling genes.
Summary/Conclusions: In total, 59% of NPM1mut AML pts showed clonal evo-
lution at the time of relapse. In accordance with our previous findings,
DNMT3Amut demonstrated the highest stability constituting early events that per-
sist in preleukemic hematopoietic stem cells. While some relapse cases evolve
from clones already forming the tumor bulk at diagnosis, NPM1mut loss relapse
cases possess almost no relationship to the paired diagnosis sample, apart from
preleukemic mutations, and demonstrate a switch in major signaling cascades.
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Background: Chromosome number alteration, aneuploidy, causes unfitness
in eukaryotic cells and is generally not sufficient to induce malignant transfor-
mation. However, it is a hallmark of cancer and 10-15% of acute myeloid
leukemia cases are aneuploid. 
Aims: Aim of the study was to investigate the molecular mechanisms activated
by A-AML cells to tolerate an abnormal chromosome number and overcome
the unfitness barrier, in order to define potential druggable targets.
Methods: We performed whole exome sequencing of 42 aneuploid (A-) AML
(isolated trisomy and monosomy, complex and monosomal karyotype) and 34
euploid (E-) AML (100 bp, paired-end, Illumina platform). Variants were called
by MuTect and Varscan 2.0. Gene expression profiling was obtained from bone
marrow cells of 22 A-AML and 27 E-AML with 80-100% blasts (HTA 2.0,
Affymetrix). Data were analyzed using Transcriptome Analysis Console 3.0
(Affymetrix) and Gene Set Enrichment Analysis (Broad Institute). 
Results: In a cohort of 166 AML patients (80 A-AML and 86 E-AML) treated at
our Institute, aneuploidy was associated with poor overall survival (median sur-
vival: 13 and 26 months in A-AML and E-AML, respectively; p<.01). A-AML
showed reduced expression of RAD50 and ATR compared with E-AML (p<.001),
suggestive of an impaired DNA damage response and checkpoint arrest, despite
normal levels of CHK1 and CHK2 kinases. These defects hampered the activa-
tion of p53, the guardian of ploidy and its transcriptional program, which were
disrupted both at functional and genomic levels. A-AML was not only enriched
for TP53 mutations, which were common in complex and monosomal karyotype
cases and absent in E-AML, but also for genomic lesions targeting p53-related
genes, including those involved in p53 activation (APAK, FATS, PIAS4) and sta-
bility (USP10, DDX31) and known p53 targets (RBM38, DDR1). Overall, 42% A-
AML had a mutation in TP53 or its related genes, compared with 15% E-AML
(p=.01). Moreover, a gene expression signature of p53 downregulation was
enriched in A-AML, irrespective of the mutational status (p<.05). Upregulation of
PLK1 contributed to functional inactivation of p53 in A-AML (p<.01). PLK1 also
forced entry and progression through mitosis in A-AML by cooperating with over-
expression of CDC20 (p<.001), which is sufficient to overcome the spindle-
assembly checkpoint, leading to the formation of daughter cells with an aberrant
chromosome number. The spindle assembly machinery and additional cell cycle-
related genes involved in DNA replication, centrosome dynamics, chromatid
cohesion and chromosome segregation were frequently mutated (p<.05) or
deregulated at transcriptional level (p<.01) in A-AML, suggesting a role in pro-
moting and maintaining genomic instability, which was highlighted by a higher
number of genomic alterations in A-AML. The mutations mostly targeted chro-
matin modifiers, splicing, DNA methylation and signaling genes. In parallel, a
KRAS transcriptional signature was upregulated in A-AML (p<.05), irrespective
of the mutational status, to sustain cell survival and proliferation. 
Summary/Conclusions: We depicted here for the first time the complex
molecular mechanisms promoting and maintaining the aneuploid phenotype
in AML, which include deregulated checkpoint response and cell cycle machin-
ery, inactivated p53 and hyperactivated KRAS pathway. This evidence suggests
that pharmacological reactivation of p53, inhibition of cell cycle checkpoints
and KRAS signaling, which are under investigation, may be valuable thera-
peutic strategies for aggressive A-AML.
GS & AP: equal contribution. Supported by: FP7 NGS-PTL project, ELN, AIL,
AIRC, PRIN, progetto Regione-Università 2010-12 (L. Bolondi).
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IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE
CHROMOTHRIPSIS IS LINKED TO TP53 ALTERATION AND CELL CYCLE
IMPAIRMENT
F Rücker*, A Dolnik, H Kett, R Schlenk, H Döhner, K Döhner, L Bullinger
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Background: The single catastrophic event “chromothripsis”, uncovered by
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genome sequencing, is a phenomenon of genomic instability. It is characterized
by extensive genomic rearrangements reflected by an oscillating pattern of
DNA copy number levels in one or few chromosomes as assessed by e.g. sin-
gle-nucleotide polymorphism (SNP) microarray analysis. The prevalence of
chromothripsis across tumor entities is very heterogeneous, and despite several
studies linking chromothripsis with TP53 alterations, the underlying mechanisms
are still largely unknown. In acute myeloid leukemia (AML), TP53 alterations
(loss and/or mutation) are almost exclusively found in cases with complex kary-
otype (CK-AML).
Aims: Our aim was to gain further insight into the role of chromothripsis in AML.
Methods: We performed integrative analysis using genomic SNP microarray
profiling, global gene expression profiling as well as TP53 mutation screening
in 103 CK-AML and correlated our findings with clinical data of 55 age-adjusted
intensively treated study patients (HD98A, AMLSG 07-04, and AMLSG 06-04).
Results: SNP profiling identified rearrangement patterns consistent with chro-
mothripsis (defined as at least ten switches between two or three copy-number
states on an individual chromosome) in 36 of 103 CK-AML (35%). The most
frequent affected chromosome (chr) was chr 7 (14%) followed by chr 3, 5, 17,
21 (11% each), and 6, 8, 10, 11, and 12 (5% each). Cases with chromothripsis
were characterized by a higher degree of genomic complexity, as measured
by total number of copy number alterations per case (mean±SD 23±10 versus
11±10, P<.0001), and by the association with specific genomic alterations, that
is, monosomy 5 or losses of 5q (-5/5q-) (P=.003), -7/7q- (P=.02), -16/16q-
(P=.009), and the cytogenetic category “monosomal karyotype” (P=.0002).
Genetically, as previously reported chromothripsis was correlated with TP53
alteration (30/36 chromothripsis-positive CK-AML vs 37/67 chromothripsis-neg-
ative CK-AML, P=.005). Clinically, CK-AML patients with chromothripsis were
slightly older (median age, 62 versus 58 years, P=.02) and showed in trend
lower bone marrow blast counts (median 45% versus 80%, P=.07). Whereas
TP53 alteration predicted for lower complete remission (CR) rate (TP53altered
25% vs TP53unaltered CK-AML 68%, P=.005), chromothripsis had no impact on
CR, but predicted for inferior survival; the 2-year estimated survival rates for
chromothripsis-positive and chromothripsis-negative patients were as follows:
event-free survival (EFS), 0% versus 12% (P=.01); relapse-free survival (RFS),
0% versus 35% (P=.06); and overall survival (OS), 0% versus 26% (P=.02),
respectively. Since chromothripsis is associated with TP53 alteration, which is
the most important prognostic factor in CK-AML outweighing all other known
prognostic variables in multivariable analysis, chromothripsis does however
not provide additional independent prognostic information. On the other hand,
gene expression profiling comparing chromothripsis-positive vs –negative
TP53altered CK-AML cases showed a distinct gene signature pointing to mech-
anisms underlying chromothripsis. For example, in addition to TP53 alteration
chromothripsis-positive cases showed a significant deregulation of genes asso-
ciated with genomic instability (e.g. Fanconi anemia pathway genes), mitotic
regulation (e.g. CCNA1) as well as transcriptional regulation (e.g. CEBPA).
Summary/Conclusions: Detailed molecular profiling links chromothripsis to
impaired TP53 in CK-AML and suggests an addition pathogenic basis for the
occurrence of chromothripsis.
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Background: Familial thrombocytopenia 2 (THC2) is a rare autosomal domi-
nant platelet disorder, associated with a predisposition to develop haematolog-
ical malignancies and is caused by different mutations in the ANKRD26 5’ UTR.
This gene is coding for a membrane-associated protein that is predicted to
interact with signaling effectors including cytokine receptors, and that behaves
as a scaffold between different protein partners.
In megakaryocytes (MKs), the mutations in the 5’ UTR eliminates the DNA
binding of two transcription factors, RUNX1 and FLI1, causing the loss of tran-
scriptional repression of ANKRD26 along differentiation; this results in an abnor-
mal expression of the protein in mature megakaryocytes inducing an over-acti-
vation of the TPO/MPL/MAPK signaling pathway responsible for a defect in
platelet formation and explaining the thrombocytopenia.
Aims: To study the mechanisms responsible of the pre-leukemic state, we gen-
erated iPSC lines from isolated CD34+ cells of three patients harbouring three
different ANKRD26 mutations; in addition, they were transduced with a short
hairpin RNA (shRNA) targeting ANKRD26 (shANKRD26).
Methods: The iPSCs were successfully differentiated toward an haematopoietic
fate with a co-culture system (OP9 cells) and a feeder-free system: the derived
MKs showed the same defects observed in patient primary cells, that were res-
cued by the shANKRD26, therefore validating the relevance of the iPSC model. 
Results: Next, we used this model to study the granulo-monocytic (GM) com-
partment: we found an increased expression of ANKRD26 in the GM progenitors
derived from patients iPSC and primary cells, but also an increase in their num-
ber and proliferation. We observed an over-activation of the JAK/STAT, MAPK
and AKT signalling pathways in presence of G-CSF, suggesting a possible inter-
action between ANKRD26 and the G-CSF receptor (CSFR3). Those results
were confirmed in the cell line UT7/G-CSFR. This cell line constitutively overex-
presses ANKRD26, and its knock down by the shRNA markedly decreased pro-
liferation in the presence of G-CSF. In contrast we did not observe any difference
in the proliferation rate in presence of GM-CSF, a feature that suggests a func-
tional link between ANKRD26 and the G-CSFR, but not with the GM-CSF recep-
tor. In addition, we observed a sensible reduction of the proliferation rate of
patients and iPS-derived granulocytic precursors in presence of JAK1/2 inhibitor
(ruxolitinib). We also detected an increase of PIM1 expression, a direct target of
STAT3/5 and a possible mediator of this lineage over-proliferation (Figure 1).
Figure 1.
Summary/Conclusions: In conclusion, this work shows an important role for
ANKRD26 in two different signaling pathways, TPO/MPL and G-CSF/G-CSFR,
the former responsible for the thrombocytopenia, the latter may be implicated
in the pre-leukemic state.
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Background: Several pro-survival proteins promoting resistance to chemother-
apy, such as BCl-2, STAT3,NFκB and AKT,are over-expressed in AML cells,
thus representing the basis for targeted therapies. However, only multi-target
drug strategy may lead to the modulation of the pro-survival protein network,
due to the simultaneous activation of alternative pathways.
Notch signalling is a master developmental pathway that controls tumour cell
survival by interacting with pro-survival proteins, such as β-catenin, BCL-2,
STAT3, NFκB, and AKT, thus representing an ideal target to interfere with all
these pathways in different cancer systems.
We recently showed that Notch inhibition was capable of abrogating microen-
vironment-mediated AML cell chemo-resistance (P550, EHA20); however, little
is known about the mechanism involved. 
Aims: We studied the mechanisms underlying microenvironmental, Notch-
mediated AML chemo-resistance by investigating the contribution of BCl-2,
STAT3, NFκB and AKT. Using in silico and in vitro approaches we analyzed the
expression changes of these proteins in ex-vivo AML cell samples in condition
of pharmacological or genetical Notch down-regulation, as well as in AML cells
either cultured alone or co-cultured with human bone marrow mesenchymal
stromal cells (hBM-MSCs) in presence of chemoterapeutic agents, such as
cytarabine (Ara-C) and Idarabucin.
Methods: Cells were obtained from bone marrow (33) and peripheral blood (22)
samples of AML patients. hBM-MSCs were expanded from bone marrow of 20
healthy donors (BM-MSCs) and 20 AML patients (BM-MSCs*). Gene set enrich-
ment analysis (GSEA) were perform using GEOR tools on AML expression array
of 304 patients previously deposited in Gene Expression Omnibus (GSE10358).
Genetic inhibition of Notch signalling was achieved in AML cell lines (HL-60 and
THP1) by infecting cells with lentiviral particles carrying shRNA for either RBP-
jK or MALM1, two mediators of Notch signaling. Pharmacological Inhibition of
Notch in AML was achieved by using Gamma secretase Inhibitors (GSIs), Notch
transcription factors Inhibitor SAHM1, and combination of Notch blocking anti-
bodies.Ara-C, and idarubicin were added to culture supernatants at different
concentrations. Cell viability was evaluated by Annexin-V/Propidium Iodide (PI).
Protein levels were analyzed by intracellular staining with corresponding fluo-
rophore conjugated antibodies, followed by flow cytometry analysis.
Results: In silico Gene set enrichment analysis and flow cytometry analysis
showed that AML samples highly expressed Notch1, Jagged1, STAT3, NFκ-B
and AKT genes and proteins. Notably, higher levels of Notch1 were found in
patients with poor cytogenetic prognosis, while STAT3, NF-κB and AKT were
uniformly expressed by AML patients. Protein analysis revealed low levels of
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pro-survival proteins AKT, STAT3 and NF-κB in RBP-jk and MALM1 knock-
down cells, as compared to control cells infected with non specific shRNA. We
then verified that genetic (shRNA) and pharmacological inhibition of Notch, by
using either GSIs or Notch receptor blocking antibodies, was capable of sen-
sitizing AML cells, either cultured alone or in presence of hBM-MSCs, to ARA-
C or idarubucine. Additionally, we found that hBM-MSC-dependent induction
of AML chemoresistance was associated to increase of AKT, NF-κB and STAT3
protein levels in AML cells. Similarly, Notch inhibition with GSIs prevented hBM-
MSC-mediated increase of AKT, NF-κB and STAT3, thus restoring sensibility
of AML cells to Idarubucin treatment.
Summary/Conclusions: These results suggest that inhibition of Notch sig-
nalling is sufficient to reduce protein levels of AKT, STAT3 and NF-κB proteins
involved in AML chemoresistance, thus making the pro-survival core network
controlled by Notch a potential target for specific Notch targeted therapies.
Acute myeloid leukemia - Biology 3
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INTEGRATIVE ANALYSIS OF LINCRNA EXPRESSION IN 922 ACUTE
MYELOID LEUKEMIA PATIENTS REVEALS MULTIPLE PROGNOSTIC
GENE SIGNATURES 
D Beck1,2,*, J Thoms1, C Palu1, T Herold3, A Shah1, J Olivier4, L Boelen5,
Y Huang1, D Chacon1, A Brown6, M Babic6, C Hahn6, M Perugini 6, X Zhou7,
B Huntly8, W Berdel9, B Wörmann10, T Büchner9, W Hiddemann3,
S Bohlander11, H Scott6, I Lewis6, R D’Andrea6, J Wong1, J Pimanda1
1Lowy Cancer Research Centre, UNSW Australia, 2Centre for Health Tech-
nologies, UTS Australia, Sydeny, Australia, 3Department of Internal Medicine
III, University Hospital Grosshadern, Munich, Germany, 4School of Mathemat-
ics, UNSW Australia, Sydeny, Australia, 5Medicine, Imperial College London,
London, United Kingdom, 6Centre for Cancer Biology, University of South Aus-
tralia, Adelaide, Australia, 7Comprehensive Cancer Center, Wake Forest Uni-
versity, Winston-Salem, United States, 8Department of Haematology, Cam-
bridge Institute for Medical Research, Cambridge, United Kingdom, 9Medicine,
Hematology and Oncology, University of Münster, Münster, 10Medicine, Hema-
tology, Oncology, Tumor Immunology, Charité - Universitätsmedizin Berlin,
Berlin, Germany, 11Medicine, University of Auckland, Auckland, New Zealand
Background: Acute myeloid leukemia (AML) is a heterogeneous myeloid neo-
plasm that develops in hematopoietic stem and progenitor cells (HSPCs) with
altered ability to self-renew, proliferate and differentiate. The karyotype and
recurrent lesions in NPM1, FLT3-ITD and CEBPA are associated with patient
remission, relapse and survival and have been integrated into AML prognostic
indices such as those developed by the United Kingdom Medical Research
Council (MRC) or the European Leukemia Net (ELN). However, the utility of
these guidelines for clinical decision making has only been validated in the
~40% of patients younger than 60 years (SEER). The human genome consists
of more than three billion nucleotides that encode a relatively small number of
coding (~1.5%) and a larger number of non-coding (~75%) transcripts. The
association between the coding genome and the biology and pathogenesis of
AML and its utility for clinical decision making has been extensively studied.
However, the contributions from the large pool of non-coding RNAs to these
events is largly unknown.
Aims: Long intergenic non-coding RNAs (lincRNA) are emerging as key reg-
ulators of an increasing number of molecular processes and have been shown
to regulate stem cell activity and function during myeloid and lymphoid differ-
entiation, while their role in leukemia is poorly understood. Therefore, we aimed
to: 1. Comprehensively describe and evaluate the expression of lincRNAs in
leukemic cells from widely used, large, clinically annotated AML cohorts, AML
cell lines and in normal hematopoietic stem and progenitor cell subsets. 2.
Develop and validate lincRNA signatures that are robust predictors of patient
survival, not limited to single patient cohorts but significant across multiple
large cohorts, and do not require measurement of large numbers of genes.
Methods: Here we analysed expression profiles of 1664 lincRNAs measured
using three technologies in 922 patients from three independent patient cohorts
including those from the United States of America (The Cancer Genome Atlas),
Netherlands (HOVON), Germany (CALGB) and we sourced a fourth independ-
ent Australian AML dataset to experimentally validate our findings. We also
analysed datasets from the BLUEPRINT epigenome project and the Cancer
Cell Line Encyclopedia to compare our findings to expression profiles in normal
hematopoietic cells and AML cell lines.
Figure 1.
Results: We developed and validated a novel approach to quantify the expres-
sion of 1664 lincRNAs in 736 AML patients from 3 well-characterized patient
cohorts representing the largest resource of lincRNA expression profiles avail-
able in AML. Interrogation of this database (i) reconfirmed previously known
regulatory relationships and uncovered lincRNAs in close proximity to key
haematopoietic genes that showed strong expression correlations across AML
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datasets, identified that distinct lincRNAs expression profiles are (ii) associated
with recognized cytogenetic and mutational subgroups of AML and (iii)
expressed in AML and normal HSPC subsets. We also (iv) identified 48 lincR-
NAs that were significantly correlated with patient outcomes and (v) expression
signatures composed of 2-4 lincRNAs that have prognostic value in addtion to
current clinical risk algorithms based on the assesment of karyotype and muta-
tions in CEBPA, FLT3 and NPM1, (vi) that these signatures can be measured
by RT-PCR and used as a standalone tool or in conjunction with the ELN to
predict survival across multiple AML cohorts, including patients older than 60
years (Figure 1a and b).
Summary/Conclusions: Taken together, this comprehensive analysis of lin-
cRNA expression in multiple AML patient cohorts and in normal hematopoietic
cell subsets not only highlights their value as prognostic markers but also pro-
vides a platform to selectively perturb lincRNAs in leukemic cells.
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ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF
MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE
A Chaturvedi1,*, MM Araujo Cruz1, N Jyotsana1, A Sharma1, R Goparaju1,
A Schwarzer2, K Görlich1, R Schottmann1, EA Struys3, EE Jansen3, C Rohde4,
C Müller-Tidow4, R Geffers5, G Göhring6, A Ganser1, F Thol1, M Heuser1
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tation, 2Institute of Experimental Hematology, Hannover Medical School, Han-
nover, Germany, 3Department of Clinical Chemistry, VU University Medical
Center, Amsterdam, Netherlands, 4Department of Hematology and Oncology,
University of Halle, Halle, 5Genome Analytics Group, Helmholtz Centre for
Infection Research, Braunschweig, 6Institute of Human Genetics, Hannover
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Background: Canonical mutations in IDH1 and IDH2 produce high levels of
the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive
inhibitor of αKG-dependent enzymes and a putative oncometabolite. Almost
all patients with IDH1/2 mutations express high levels of intracellular R-2HG,
while an increase of the S-enantiomer of 2HG has never been described in
AML, glioma, chondrosarcoma or intrahepatic cholangiocarcinoma patients.
Aims: To investigate whether oncometabolites R-2HG and/or S-2HG, have a
causative function in leukemogenesis or instead are rather only biomarkers for
oncogenic IDH.
Methods: We daily administered R-2HG and S-2HG at a dose of 1mg/mouse
in vivo in three independent mouse models (HoxA9, MLL-AF9 and an AML
patient derived xenotransplantation model) containing only wild-type IDH1 and
compared the blood profile, survival, gene expression and differentially methy-
lated regions between the groups.
Results: R-2HG treated mice had significantly higher engraftment levels in
peripheral blood than S-2HG and PBS treated mice. R-2HG treated mice
developed striking leucocytosis, and had declining hemoglobin and platelets
compared to S-2HG or PBS treated mice. Peripheral blood from R-2HG treated
mice revealed significantly more immature and less mature myeloid cells after
treatment than S-2HG, αKG and PBS treated mice. Furthermore, the R-2HG
treated mice died significantly earlier than mice treated with S2HG and PBS
in all three models. A question of current investigation is whether R-2HG alone
is responsible for the transforming effects of mutant IDH or if the mutant protein
contributes additional oncogenic functions. Interestingly, both cohorts,
HoxA9+IDH1mut and HoxA9 treated with R-2HG, developed leukemia, albeit
with different kinetics. Next, we examined whether the faster disease kinetics
of mutant IDH1 compared to R-2HG would be overcome if the R-2HG dose
was increased from 1 to 5 mg R-2HG per day. We observed a dose dependent
increase of R-2HG in bone marrow cells of treated mice, while the dose of 5
mg R-2HG per day even slightly exceeded R-2HG of cells expressing mutant
IDH1. Mice treated with 1 or 5 mg of R-2HG had similar engraftment levels
and died with an identical latency, while IDH1 mut mice died significantly ear-
lier. In gene expression data R-2HG treated cells clustered with IDH1 mut
cells, while IDH1 wt cells clustered with HoxA9 control cells. However, many
genes that were exclusively upregulated in IDH1 mut cells but not in R-2HG
treated cells showed that R-2HG treated cells were at an intermediate stage
between control/IDH1 wt cells and IDH1 mut cells. The differentially methylated
regions (DMRs) between R-2HG treated cells and IDH1 wt cells were well
represented in IDH1 mut cells. However, DMRs between IDH1 mut and IDH1
wt cells were not well represented in R-2HG treated cells and these cells clus-
tered with IDH1 wt and not IDH1 mut cells. The higher number of hyper- and
hypomethylated regions in IDH1 mut cells compared to R-2HG treated cells,
supports an additional function of the mutant protein on transcriptional regu-
lation and DNA methylation beyond the function of the metabolite R-2HG and
can explain the earlier disease onset of IDH1 mut cells compared to R-2HG
treated cells.
Summary/Conclusions: We show that R-2HG, but not S-2HG, is an
oncometabolite that does not require the mutant IDH1 protein to induce hyper-
leukocytosis and to accelerate disease onset in vivo. Thus, circulating R-2HG
acts in a paracrine fashion and can drive the expansion of many different
leukemic and preleukemic clones that may even express wildtype IDH1, and
therefore can be a source of clonal evolution and diversity.
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INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL
AND LEUKEMIC HEMATOPOIESIS
M Dépond1,*, Y Zhang1, L He1, M Wittner1, V Baral1, R Tang2, O Legrand2,
MC Béné3, F Delhommeau2, V Joulin1, F Louache1
1IGR U1170 inserm, villejuif, 2Service d’Hématologie et Thérapie cellulaire,
Hôpital St Antoine, Paris, 3Laboratoire d’Hématologie, Nantes, France
Background: The transcription factor ASCL2 (Achaete Scute-like 2) is involved
in intestinal stem cell biology regulating their stem cell identity while its overex-
pression induces an intestinal hyperplasia. In addition, it is over-expressed in
numerous tumor types. In cancer cells and T follicular cells, it regulates the expres-
sion of CXCR4, a chemokine receptor involved in cell migration, homing and pro-
liferation. Conversely, CXCR4 and Wnt signaling regulates ASCL2 expression
suggesting that CXCR4 and ASCL2 interact to regulate the metastasis formation.
In acute myeloid leukemia (AML), CXCR4 has a predominant role in the regulation
of interaction of cells with their environment and its expression is correlated with
poor prognosis. However, ASCL2 contribution to AML in poorly understood.
Aims: The aim of this study is to elucidate the role of ASCL2 in normal and
leukemic hematopoiesis by analyzing of its expression in AML and normal
hematopoietic progenitors and using different cell line models for the overex-
pression and down regulation.
Methods: To study the function of ASCL2 transcription factor, 135 samples of
AML patients were analyzed for the ASCL2 mRNA level. CXCR4+/+ and
CXCR4-/- murine leukemic cells were generated by expression of MLL-ENL
fusion protein in fetal liver cells for E15 embryos. To examine the effects of loss
of function of ASCL2 on leukemic development, murine leukemic cells were
transduced with shRNA targeting ASCL2 and engrafted to mice. Finally, we
examined the consequences of ASCL2 overexpression by enforcing its expres-
sion using lentivirus transduction in CD34+ progenitor cells.
Results: We first observed that 32% (43/135) of AML samples displayed ASCL2
mRNA expression higher than normal progenitor CD34+ cells from bone mar-
row of control individuals. In addition, the level of ASCL2 mRNA correlates with
poor prognosis AML (p<0,001). Normal hematopoietic cells and progenitors
show a weak expression of ASCL2, except monocytes and NK cells. In murine
leukemic models, we found a high expression of ASCL2 in leukemic stem cells
that is dependent of CXCR4 and correlates with expression of the stem cell
associated genes HOXB4 and HOXB13. Knocking-down ASCL2 by shRNA in
murine leukemic cells induces a sharp decrease in the number of leukemic
cells and delayed leukemic progression in vivo resulting in increased survival
of leukemic mice. Enforced expression of ASCL2 in cord blood CD34+ progen-
itor cells induces a 4-fold decrease in the cloning efficiency in progenitor assays
compared to cells transduced with GFP (p<0,02). Surprisingly, a subset of
ASCL2 transduced cells were able to sustain colony formation in secondary,
third and fourth serial colony assays suggesting that ASCL2 overexpression
has differential effect depending on targeted cells.
Summary/Conclusions: Our results indicate that ASCL2 is overexpressed in
AML. In AML murine models, ASCL2 down regulation delayed leukemic progres-
sion while it may maintains the self-renewal capacity of subsets of cells. Altogether,
our results implicate ASCL2 as an important regulator in AML development and
suggest that ASCL2 expression is associated with aggressiveness of leukemia. 
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DIFFERENTIAL DNA METHYLATION IN CYTOGENETICALLY NORMAL
ACUTE MYELOID LEUKEMIA IS LINKED TO ALTERED GENE EXPRESSION
OF ENHANCER TARGET GENES
Y Qu1,*, L Siggens2, L Cordeddu2, K Ekwall2, S Lehmann1,3, A Lennartsson2
1Center for Hematology and Regenerative Medicine (HERM), 2Department of
Biosciences and Nutrition, Karolinska Institute, Stockholm, 3Department of
Medical Sciences, Hematology Unit,, Uppsala University, Uppsala, Sweden
Background: During normal hematopoiesis, DNA methylation is tightly con-
trolled at regulatory elements. Enhancer methylation patterns can distinguish
both between different cell identities and maturation stages. In our previous
work, we found aberrant DNA methylation in low CpG density regions and in
transcription factor genes in AML patients and that dynamic enhancer methy-
lation during normal granulopoiesis correlate with gene expression pattern.
However, changes of DNA methylation in enhancer regions occur in leukemia
are remaining largely unknown. 
Aims: To study the aberrant DNA methylation of enhancers in AML patients in
correlations to altered chromatin status and putative target gene expressions. 
Methods: In this study a total of 57 cytogenetically normal AML (CN-AML)
patients and 12 FACS sorted bone marrow myeloid samples with four differenti-
ation stages from 3 healthy individuals were used to profile DNA methylation
changes in AML and granulopoiesis using the Illumina 450k array. H3K27ac ChIP
sequencing was performed on 6 CN-AML patients’ mononuclear cell samples
and analyzed together by integrating data of hypersensitivity sites sequencing
(DHSseq) of normal bone marrow CD34+, NB4 and HL60 from ENCODE project
and 5 CN-AML patients from recent published paper. Total enhancers were
obtained from FANTOM5 project and used for analyzing correlation to putative
target genes. Moreover, selected enhancers were edited by CRISPR/Cas9 sys-
tem in order to test the expression change of target genes.
Results: We found a number of hypermethylated and hypomethylated sites in
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AML patients compared to NBM, some of which are specific to AML while
others correspond to changes observed during granulopoesis. In addition a
core set of the changes observed were independent of specific mutations.
Strikingly, the majority of these changes occurred in regulatory regions of the
human genome defined as DNA hypersensitivity (DHS) sites. Hypermethylated
sites show reduced chromatin accessibility and histone acetylation (H3K27ac)
at transcription start sites (TSS) proximal and distal regions from TSS sug-
gesting active promoters and enhancers that are hypermethylated are silenced.
Hypomethylated sites occurred more frequently outside of TSS regions with
only a subset of hypomethylated sites in distal regions from TSS correlated to
increased chromatin accessibility and H3K27ac. To examine if the changes in
DNA methylation at enhancer regions are correlated to altered gene expression
of target genes in AML we focused on differential methylation of enhancers
defined by the FANTOM consortium, which have high confident target gene
predictions. An adverse correlation between enhancer methylation changes
and putative target gene expression levels was found by integrating transcrip-
tome data from RNA sequencing in the AML patients. Moreover, by using
CRISPR/Cas9 system, targeted editing of selected active enhancer elements
in AML cell lines HL60 and KG1a lead to decreased expression of target genes.
Summary/Conclusions: This study demonstrates the relationship between
abnormal DNA methylation and enhancer activation, which correlates with tar-
get gene expression in CN-AML. This suggests that there are unique regulatory
events that occur in CN-AML at enhancer regions, which distinguish AML
patients from NBM and granulopoietic progenitors. Our results suggest that
aberrant DNA hypomethylation at distal regulatory regions in AML can cause
opening up of the chromatin, resulting in abnormal transcriptomic alternation
of the target genes that potentially contribute to leukemogenesis. 
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IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A
TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA
Y Ge*, M Schuster, S Pundhir, F Bagger, N Rapin, B Porse
Finsen Laboratory & Danstem center & BRIC – Biotech Research and Innova-
tion Center, University of Copenhagen, Copenhagen N, Denmark
Background: Acute Myeloid Leukemia (AML) is a heterogeneous collection
of hematological malignancies, which are maintained by a population of so-
called leukemic stem cells (LSCs). LSCs accumulate various genetic and epi-
genetic abnormalities, including aberrations in mRNA splicing. Recent progress
suggests that dysregulation of splicing factors contributes to pathogenesis of
AML, but little is known about the AML-specific dependency on splicing factors
for leukemic cells survival and proliferation.
Aims: The current study uses in vivo shRNA screen approach to identify novel
splicing factors required for leukemia progression.
Methods: We used a mouse model of human CEBPA mutant AML and a splic-
ing factor shRNA library to screen for novel splicing factor genes essential for
AML. Functional study of the best candidate gene RBM25 included in vivo
competitive bone marrow transplantation assay, survival assay and in vitro
colony forming unit assay. In the human leukemic cell line U937, RBM25 knock-
down cells were assessed proliferation, cell cycle and apoptosis by flow cytom-
etry. Splicing events were detected by SpliceR tool based on RNA-sequencing
data on U937 cells carrying RBM25-shRNA or not. 
Results: By in vivo shRNA screen in CEBPA mutant AML mouse model, we
found that splicing factor Rbm25 was important for murine leukemic cells in
vivo and for human leukemic cells in liquid culture. Rbm25 knockdown accel-
erated the growth of leukemic cell after transplantation, and shortened the lifes-
pan of leukemic mice. RBM25 knockdown accelerated proliferation and colony
formation of human leukemic cells U937 by increasing cell cycle progression
and decreasing apoptosis. Using RNA-seq profiling in U937 cells, we identified
368 transcripts that were regulated by RBM25. Particularly, RBM25 knockdown
promoted alternative splicing of BIN1 to produce inactive form that block its
interaction with MYC, thus the oncogenic MYC pathway was activated. More-
over, by accurate RT-qPCR method, we showed RBM25 regulated Bcl-x splic-
ing to affect apoptosis. RBM25 knockdown caused the accumulation of anti-
apoptotic isoform Bcl-xL, and ABT-263 inhibition of Bcl-xL partially reversed
the RBM25-mediated tumor progression.
Summary/Conclusions: This study showed that splicing factor Rbm25 knock-
down can promote proliferation of both murine and human leukemic cells, and
provides detailed mechanistic insights into RBM25-regulated splicing dysreg-
ulation in AML. The newly identified tumor suppressor gene RBM25 has great
therapeutic potential and clinical values as a prognostic factor.
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HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION
AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA
CELLS
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Background: Acute Myeloid Leukemia (AML) are heterogeneous haemato-
logical diseases characterized by a clonal expansion of immature progenitors
and associated with overall poor prognosis. Many aberrant activation of sig-
nalling pathways are found in AML which enhances the proliferation and sur-
vival of leukemic cells. Among them, mTORC1 signalling, which controls protein
translation, autophagy and metabolism, is activated in almost all AML samples.
Metabolic reprogramming is a common phenotype in cancer cells and mainly
occurs through the well-known “Warburg effect» which consists in enhanced
glucose catabolism even in the presence of oxygen. High rate glycolysis pro-
vides tumor cells advantages through rapid production of ATP and intermedi-
ates for the synthesis of nucleotides, amino acids, and lipids.
Aims: We investigated in our present study whether mTORC1 signaling could
drive the metabolic reprogramming of AML cells, especially toward glucose uti-
lization, and if high mTORC1 activity could lead to the sensitivity of leukemic
cells to metabolic targeted therapy.
Methods: We performed analysis in 6 AML cell lines, in primary AML cells
obtained from bone marrow or blood samples of 18 patients at diagnosis and
in normal CD34+ hematopoietic progenitor cells (HPCs). mTOR signalling
was down-regulated with either rapamycin or ShRNAs targeting RAPTOR,
mTOR or RICTOR and mTORC1 activity was up-regulated through TSC2
deletion by CRISPR/Cas9. Glucose flux was analyzed using 13C nuclear mag-
netic resonance.
Results: Using a transcriptomic profiling, we first identified an mTORC1-depen-
dant glucose metabolic signature in AML cells. We also showed that high
mTORC1 activity promoted glycolysis and led to glucose addiction in AML cells.
Indeed, the level of mTORC1 activity determines the sensitivity of AML cells to
glycolysis inhibition: whereas AML cell survival with high mTORC1 activity is
dependent on glucose availability, switch-off mTORC1 activity by pharmaco-
logical (rapamycin) or genetic invalidation (mTOR or RAPTOR knockdown)
leads to glucose-independent cell survival that is mainly sustained by a com-
pensatory increase in mitochondrial oxidative phosphorylation (OXPHOS).
Finally, we observed a high flux of glucose through the pentose phosphate
pathway (PPP) which supports AML cell growth. Indeed, 6-aminonicotinamide
(6-AN), which blocks the activity of the glucose-6-phosphate dehydrogenase
(G6PD), the key limiting enzyme of PPP, induced cytotoxicity against AML cells
in vitro – including in primary samples from AML patients – and in vivo, without
impact on normal hematopoietic progenitor cells.
Summary/Conclusions: Overall, our results demonstrate that high mTORC1
activity creates a specific vulnerability to G6PD inhibition that may work as a
new AML therapy. Given that mTORC1 signaling is deregulated in almost all
AML samples, targeted therapy against G6PD may be beneficial for a broad
range of patients with AML.
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ALVOCIDIB POTENTIATES THE ACTIVITY OF ABT-199 IN NONCLINICAL
MODELS OF ACUTE MYELOID LEUKEMIA
C Whatcott1,*, J Bogenberger2, W Kim1, K Soh1, YS Lee1, P Peterson1,
K Maughan1, A Siddiqui-Jain1, S Weitman1, D Bearss1, S Warner1, R Tibes2
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Background: The BCL-2 inhibitor ABT-199 (or venetoclax) has recently received
FDA breakthrough therapy designation for use in combination with hypomethy-
lating agents (HMAs) in patients with acute myeloid leukemia (AML). Early stage
trials have demonstrated clinical response rates over 70% in combination with
HMAs (azacitidine or decitabine) in previously untreated elderly patients with
AML. Single-agent activity of ABT-199 was modest in AML, and resistance is
developing in combination regimens. One proposed mechanism of resistance is
compensatory up-regulation of other BCL-2 family proteins such as MCL-1, which
plays a general role in resistance to BCL-2 inhibitors. The CDK9 inhibitor, alvo-
cidib, as a component of a sequential regimen with chemotherapy, demonstrated
a superior rate of complete remission in newly diagnosed intermediate and high-
risk AML patients over standard induction chemotherapy in a randomized multi-
center Phase 2 trial. We and others have demonstrated that alvocidib inhibition
of CDK9 can mediate transcriptional repression of anti-apoptotic MCL-1. Further,
we and others have shown that alvocidib can increase pro-apoptotic BIM (a pan
BH3-only protein) in some cells. BIM is known to neutralize all anti-apoptotic
BCL-2 family proteins such as MCL-1 and BCL-2, thus having a similar net effect
on mitochondrial outer membrane permeabilization (MOMP)-induced apoptosis
as MCL-1 down-regulation. Therefore, we hypothesize that alvocidib and ABT-
199 synergize in the treatment of AML by shifting the balance/activity of pro- ver-
sus anti-apoptotic BCL-2 family members in favor of apoptosis induction.
Aims: These studies sought to investigate the nonclinical activity of the com-
bination of alvocidib with ABT-199 in the context of (drug-resistant) AML.
Methods: CellTiter-Glo was used for all cell viability assays interrogating alvo-
cidib and ABT-199 activity in cell lines, following manufacturer’s protocol. RT-
PCR was used to measure mRNA expression of MCL-1 and other markers in
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response to drug treatment. Protein expression was assessed using standard
western blotting techniques. To determine the efficacy of an alvocidib/ABT-199
combination on tumor growth in an in vivo model, multiple xenograft mouse
models, and ex vivo studies with AML patient samples were performed.
Results: In this report, we demonstrate that alvocidib inhibits both mRNA and
protein expression of MCL-1 in a time and concentration-dependent fashion in
a majority of AML cell lines analyzed. Additionally, in a cell line for which alvocidib
did not reduce MCL-1 protein levels (MOLM-13), we observe a potent, dose-
dependent increase in BIM protein after 24 hours of alvocidib treatment. Con-
current treatment of alvocidib with ABT-199 in standard 96-hour assays resulted
in potent, dose-dependent, synergistic reductions of cell viability in ABT-199-
sensitive and resistant cells. ABT-199-sensitive lines, MV4-11 and MOLM-13,
exhibited 5- to 10-fold reduction of ABT-199 EC50 values in the low nM range
when combined with 80 nM alvocidib. Importantly, ABT-199-resistant lines, OCI-
AML3 and THP-1, exhibited at least a 20-fold reduction of ABT-199 EC50 values
from near 1 μM to 10-50 nM, when combined with 80 nM alvocidib. Xenografts
models, as well as ex vivo drug synergy studies with AML patient samples, are
currently under way to interrogate the efficacy of this combination.
Summary/Conclusions: Taken together, our data suggest that the combination
of alvocidib with ABT-199 could be a novel therapeutic regimen in both ABT-
199-sensitive and -resistant AML across a heterogeneous genomic background.
Although reduction of MCL-1 by alvocidib may be associated with synergy in
some cells, other mechanism(s) are operating as well. We conclude that a
CDK9 inhibitor/ABT-199 combination may be a novel approach for the treatment
of AML and warrants further pre-clinical and clinical validation. To this effect,
animal models are underway, as are plans for clinical trials.
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FIRST-IN-CLASS CDK7 INHIBITOR, INDUCES ROBUST APOPTOSIS IN
ACUTE MYELOID LEUKEMIA AND DEMONSTRATES DURABLE IN VIVO
EFFICACY
YJ Choi1,*, S Hu1, N Ke1, Y Ren1, J Lopez1, S Milijovska2, D Orlando2,
D Schmidt3, M Bradley1, K Sprott3, C Fritz1, E Olson1
1Biology, 2Computational Biology, 3Chemistry, Syros Pharmaceuticals, Cam-
bridge, United States
Background: CDK7 acts bi-functionally as a CDK-activating kinase (CAK) con-
trolling proliferation and as a transcriptional kinase phosphorylating the P-CTD-
RNAPol II, thereby driving efficient transcriptional processes. CDK7 has recently
emerged as an attractive gene control target in cancers driven by transcriptional
dependencies and regulated by Super-enhancers (SEs) (Kwiatkowski et al.,
2014; Chipumuro et al., 2014; Christensen 2014; Wang 2015). Acute Myeloid
Leukemias (AML) harbor mutations in genes controlling gene expression, and
as a consequence, are exquisitely sensitive to CDK7 inhibition. Employing our
SE-platform technology we reveal mechanistic insights underlying the vulner-
ability of AML to gene control modulation via selective CDK7 inhibition.
Aims: Evaluate CDK7 as an anti-cancer target in AML, using our covalent,
potent and highly selective CDK7 inhibitor. Investigate the cellular and mech-
anistic consequences of targeting CDK7 in AML underlying their susceptibility
to CDK7-dependent transcriptional control.
Methods: Characterize CDK7 inhibition in vitro and in vivo to evaluate potency
and efficacy in AML cell lines and xenografts (cell line derived xenografts, CDXs
and patient derived xenografts, PDXs). We employ our SE-platform technology
and next-generation sequencing to identify key mechanisms targeted in AML
with our selective CDK7 inhibitor.
Results: Here we report a first-in-class CDK7 inhibitor that covalently targets
a cysteine outside the kinase domain, resulting in sustained, highly selective
inhibition. Syros compound, SY-1365, exhibits significant biochemical potency
(Ki=17±7nM) and selectivity when profiled against >450 other kinases. In a
cancer cell line panel, acute leukemias emerged among the most sensitive to
CDK7 inhibition. Moreover, AML cell lines undergo rapid and robust apoptosis
within 24 hours. This is preceded by >90% CDK7 target engagement and con-
comitant loss of P-CTD-RNAPol II suggesting the primary consequence of tar-
geting CDK7 is the impaired transcriptional activity dependent on CDK7. Further
investigation of the transcriptional consequences of CDK7 inhibition point to a
reliance on key disease relevant transcriptional aberrations including translo-
cations and SE-genes (e.g. MLL fusions, MYB, HOX10A and MYC). Given the
covalent mechanism of SY-1365 and PK profile, we evaluated intermittent treat-
ments in vitro with subsequent washout of free drug to model dosing regimens
in vivo. We demonstrate that brief drug exposures maintain a robust irreversible
apoptotic response in leukemia cells. In contrast, treated non-transformed cells
recover from a transient G2/M arrest followed by re-synthesis of free CDK7
and no apoptosis/cell death. We have extended these findings to in vivo exper-
iments whereby intermittent dosing in AML patient derived xenograft models
(PDX, AM7577) maintains efficacy (reducing human CD45+ leukemia cells to
<1%) with a significant survival advantage. We have established a PD assay
by measuring target engagement of CDK7 both in mouse xenografts and
human PBMCs to support: 1) establishing a PK-PD-efficacy relationship 2)
quantifying target engagement during dose escalation in a Ph1 clinical trial.
Summary/Conclusions: In summary, we describe our first-in-class CDK7
inhibitor, SY-1365 that is potent, highly selective and leads to durable, complete
responses in xenograft models of AML. These data support the rationale for
advancing compounds with this profile toward clinical development.
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IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH
THE ONCOGENIC ACTIVITIES OF STAT5 IN AML
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Background: Among STAT family members, STAT5 has been described to be
the most frequently hyper-activated in a variety of hematopoietic cancers and
solid tumors as a result of deregulated tyrosine kinase signaling. To date, var-
ious tyrosine kinase inhibitors (TKIs) are in the clinic or in clinical trials for treat-
ment of hematopoietic diseases. However, TKI treatment is often accompanied
by resistance development, cytotoxicity as a result of poor kinase selectivity,
as well as cardiovascular toxicity. Bypassing tyrosine kinases through direct
inhibition of STAT5 phosphorylation would be advantageous for therapy devel-
opment especially in the case of STAT5 regulated cancers. Despite essential
roles of STAT5 in solid and hematopoietic cancers, only first generation phar-
macologic STAT5 inhibitors are currently available for clinical development. 
Aims: The tight association of STAT5 activation with transformation and tumor
progression has made STAT5 an attractive molecular target for the development
of novel cancer therapeutics. We therefore aim to identify a selective and spe-
cific inhibitory compound to interfere with STAT5 signaling in hematopoietic
cancers to contribute to the development of a new generation of targeted drugs.
On top, we will support functional studies into the mechanistic details of STAT
gene activation, which holds the potential to develop even more specific and
less toxic compounds for clinical application.
Methods: In collaboration with Prof. Patrick Gunning, University of Toronto, Cana-
da, a library of lead STAT5 inhibitors targeting the SH2 domain has been estab-
lished, which was extensively validated in vitro on AML model cell lines and pri-
mary AML patient samples in regard to their mechanism of binding and action.
Therefore, standard techniques, such as Western Blotting, immunoprecipitation,
Electrophoretic Mobility Shift Assay (EMSA), qRT-PCR, as well as AnnexinV/PI
and PI staining were used. Furthermore, combinatorial effects of the selected
STAT5 inhibitor with a library of >1800 experimental or FDA approved drugs,
especially TKIs, were evaluated using a luminescent cell viability assay.
Results: We identified a small inhibitory molecule, called AC-4-130, which
binds to the SH2 domain of STAT5, subsequently resulting in the disruption of
the reciprocal STAT5-phosphopeptide interactions. The selected compound
efficiently blocked kinase-mediated phosphorylation, dimer formation, nuclear
translocation, DNA binding and STAT5 mediated target gene expression. Fur-
thermore, AC-4-130 led to a cell cycle blockade in G0/G1 and the induction of
apoptosis in the model cell lines used. Studies with human AML patient-derived
samples similarly showed the induction of apoptotic cell death and an encour-
agingly low IC50 of about 1 µM after efficient blockade of STAT5 activation. A
combinatorial drug screen revealed a synergistic effect of AC-4-130 with TKIs,
such as Dasatinib and Sunitinib, as well as with drugs standardly used in the
clinical treatment of AML patients e.g. with the JAK2 inhibitor Ruxolitinib or the
chemotherapeutic agent Clofarabine.
Summary/Conclusions: In summary, our findings indicate that AC-4-130 is a
potent and selective inhibitor of STAT5. This compound provides a lead struc-
ture for further chemical modifications and clinical development, especially in
combination with standard treatment, to improve existing therapies and over-
come resistance development in hematopoietic malignancies.
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IMPAIRED BASE EXCISION REPAIR GLYCOSYLASE/AP ENDONUCLEASE
ACTIVITY CONTRIBUTES TO CYTARABINE RESISTANCE IN ACUTE
MYELOID LEUKEMIA
W Olipitz1,2,*, K Lind2, N Monsberger2, A Katschnig2, A Mangerich3, J Rankl2,
S Hofer2, M Mueller2, E Schulz2, F Quehenberger4, D Schlembach5, C Robier2,
A Woelfler2, A Zebisch2, H Sill2
1Department of Medicine III, LMU Munich, Munich, Germany, 2Division of
Hematology, Medical University of Graz, Graz, Austria, 3Molecular Toxicology,
Department of Biology, University of Konstanz, Konstanz, Germany, 4Institute
of Medical Informatics, Statistics and Documentation, 5Department of Gyne-
cology and Obstetrics, Medical University of Graz, Graz, Austria
Background: Base excision repair (BER) is the primary DNA repair mechanism
dealing with DNA base lesions representing the predominant type of DNA dam-
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age in mammalian cells. Deficiencies in BER initiating enzymes - glycosylases
and AP endonuclease - have been associated with increased genomic insta-
bility and cancer.
Aims: Here we investigated the role of BER in acute myeloid leukemia (AML).
Methods: We determined BER activity in 99 primary AML samples, 34 CD34+
umbilical cord blood cell samples and 27 AML cell lines using the alkaline comet
assay and H2O2 treatment. Oxidative base lesion levels were determined in 10
AML cell lines using a modified version of the Comet assay with bacterial
enzymes Fpg and Endo III as well as using liquid chromatography-coupled tan-
dem mass spectrometry (LC-MS/MS). Using nuclear protein extracts in an
oligonucleotide incision assay, we tested the enzymatic activity of glycosylases
and AP endonuclease. Nuclear protein levels were determined by western blot.
Mutational analysis of BER genes was performed using Sanger sequencing and
sensitivity of AML cells to cytarabine treatment was tested using an MTS assay.
Results: We found DNA strand incision of oxidatively damaged bases signifi-
cantly impaired in primary AML cells as compared to UCB cells (p=0.003) sug-
gesting a deficiency in BER glycosylases and AP endonuclease. In addition,
5/27 AML cell lines showed impaired DNA strand incision activity. We hypothe-
sized that BER deficient cells harbor an increased number of oxidative base
lesions as compared to BER proficient cells. Using a modified comet assay and
LC-MS/MS we were able to show that increased numbers of unrepaired oxida-
tive base lesions were indeed present in glycosylase deficient AML cells (comet
assay: p=0.0001; LC-MS/MS: p=0.03). We then evaluated the activity of oxida-
tive DNA glycosylases/AP endonuclease and found significantly decreased DNA
strand incision activity in BER deficient cells as compared to proficient cells
(p=0.002) further supporting the fact that these enzymes are impaired in BER
deficient cells. Cytarabine is a cornerstone of AML therapy and has recently
been shown to induce oxidative damage. Therefore, we tested for a potential
effect of BER impairment on sensitivity to treatment with increasing concentra-
tions of cyarabine and found that BER deficient cells are less sensitive to cytara-
bine treatment as compared to BER proficient cells (p=0.009). In further explor-
ing the causes of BER deficiency, Sanger sequencing of key BER genes showed
several single nucleotide polymorphisms but no consistent mutational pattern.
However, gene expression profiling revealed decreased expression of nuclear
OGG1 and MUTH1 proteins in BER impaired cells.
Summary/Conclusions: Taken together we found impaired BER in a sub-
stantial number of primary AML samples and AML cell lines potentially con-
tributing to decreased sensitivity to cytarabine treatment.
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DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING
AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA
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Background: TET enzymes are methylcytosine dioxygenases regulating gene
expression by oxidizing methylcytosine. Loss-of-function TET2 mutations are
frequent in myeloid malignancies, but TET3 gene mutations are rare. Thus,
although TET3 has similar function to TET2 and its expression is regulated
during differentiation in hematopoietic tissue, the role of TET3 in the patho-
genesis of these diseases has not previously been addressed.
Aims: The aim of our study was to investigate the role of extensive loss of
hydroxymethylation activities by double inactivation of TET2 and TET3 in acute
myeloid leukemia (AML).
Methods: Relationship of TET2 and TET3 expression in human AML patient
samples was analyzed using the TCGA database. To investigate the coopera-
tive and distinct roles of Tet2 and Tet3, Tet2flox and Tet3flox mice were crossed.
Then, neonates baring double floxed alleles and Mx1-Cre transgene were
injected with pIpC. Genome-wide transcription and methylation profiles in gran-
ulocyte-macrophage progenitor cells (GMPs) from 4-6 weeks old Tet2/Tet3-
null mice were examined by RNA-sequencing and reduced representation
bisulfite sequencing (RRBS). We established primary cell lines from Tet2/Tet3-
null bone marrow in RPMI 1640 with IL-3. Cells were treated with a hypomethy-
lating agent, decitabine and cell viability was measured by WST-8 assay. The
Tet2/Tet3-null cell line was then transduced with human TET2 catalytic domain
(TET2CD) using the pGCDN-IRES-GFP retroviral vector. Recipient mice trans-
planted with bone marrow cells from Tet2/Tet3-null leukemic mice were treated
with 5-azacytidine intraperitoneally.
Results: Human AML showed positive correlation in TET2 and TET3 expres-
sion. Concurrent Tet2/Tet3 deletion induced fully penetrant, lethal AML with a
median survival of 59 days, whereas single deletions of Tet2 or Tet3 were
healthy within the observation period (Figure 1 A). Gene set enrichment analy-
sis revealed that Tet2/Tet3-null GMPs were characterized by enrichment of
several signatures, including interferon response, Stat3 signaling, TNF-α sig-
naling via NF-κB, and p53 pathway. RRBS showed that Tet2/Tet3-null GMPs
showed marked increase of hyper-differentially methylated regions (hyper-
DMRs) compared with Tet2-null, Tet3-null, or wild-type GMPs. Hyper-DMRs
were frequently observed in enhancer regions. Genes hypermethylated (≥20%
difference compared with wild-type GMPs) at enhancers in Tet2/Tet3-null GMPs
showed a significant trend toward downregulation in expression. Lethally irra-
diated syngeneic mice transplanted with bone marrow cells from Tet2/Tet3-
null leukemic mice developed AML within 3 months. Tet2/Tet3-null leukemic
cells were easily propagated in IL-3-containing medium in vitro. Decitabine
inhibited proliferation of Tet2/Tet3-null leukemic cells and upregulated expres-
sion of surface Gr-1 and Mac-1, indicating myeloid differentiation of these cells.
Recipient mice transplanted with the cell line developed AML. Retroviral over-
expression of human TET2 catalytic domain (TET2CD) decreased proliferation
of the cell line in vitro. Mice transplanted with the TET2CD expressing cell line
developed AML at longer latencies compared to those transplanted with the
mock cell line (Figure 1 B). Progression of AML in recipient mice transplanted
with Tet2/Tet3-null leukemic cells was significantly suppressed by the 5-aza-
cytidine treatment (Figure 1 C).
Figure 1.
Summary/Conclusions: Our results suggest that epigenetic dysregulation by
concurrent loss of Tet2 and Tet3 plays important roles in the pathogenesis of
AML. Hypomehtylating drugs may be useful in treating TET-deregulated AML
.
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NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT
AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE:
IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE
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Background: Allogeneic stem cell transplant (allo-SCT) plays the central role
in management of Acute Myeloid Leukaemia (AML). Relapse is the major cause
of treatment failure after allo-SCT but little is known about either molecular pre-
dictors of relapse or the clonal structure of patients with recurrent disease post-
transplant.
Aims: 1) Elucidate whether mutations detected at diagnosis are prognostic for
disease relapse post-allo-SCT. 2) To characterise clonal structure at relapse
following allo-SCT.
Methods: We performed targeted resequencing of 34 AML-associated genes
in 113 adults who underwent allo-SCT for AML. In 30 patients we compared
mutational profiles at diagnosis and at disease relapse post allo-SCT. Libraries
constructed using Fluidigm Access Array were sequenced on a MiSeq platform.
FASTQ files were mapped using a BWA aligner (Stampy) and variant calling
performed using Varscan, GATK and Pindel. Recurrent somatic variants previ-
ously associated with AML were included in the analysis. Novel variants were
validated by Sanger sequencing.
Results: Of the 113 patients studied, 91 (80.5%) had intermediate/ favourable
and 22 (19.5%) adverse risk karyotype. We detected mutations in 102/113
patients with on average 2 mutations per patient at diagnosis. Our cohort was
enriched for samples with mutations in KIT, SRSF2 and TET2 (p<0.05), but
depleted for NPM1 (p<0.05) compared with data from a previously published
cohort of unselected de novo AML (CGARN, 2013). 49 patients relapsed post
allo-SCT. In multivariate analysis mutations in IDH1 and WT1 were significantly
associated with an increased relapsed risk (p=0.03 and p=0.013 respectively).
IDH1 and TP53 mutations were associated with worse relapse-free survival
(p=0.047 and p=0.049 respectively). Additionally, p53 mutations were associated
with reduced overall survival (p=0.027). Molecular characterisation of paired diag-
nosis and relapse samples showed novel mutations in 20/30 patients. 11/20
(55%) had changes in mutation number, with or without cytogenetic change. 9/20
(45%) patients had new mutations at relapse not detected at diagnosis (VAF sen-
sitivity of <0.5%). These included: NRAS (n=2), TET2 (n=3) and DNMT3A, IDH2,
PHF6 and WT1 in single patients. Multiple distinct mutational events occurred in
5/9 patients. In contrast, 5/30 (16%) had no detectable changes in either muta-
tions or karyotype at relapse and 7/27 (26%) had cytogenetic changes only. Inter-
estingly, in 4 patients changes in clonal structure were identified at relapse by
mutational profiling only, with no cytogenetic changes detected. We could deduce
clonal evolution from pre-existing clones by mutation profile in 6 patients; or from
de novo clones with loss of pre-existing clones in 3 patients.
Summary/Conclusions: We identified novel mutations present at diagnosis in
adult AML which appear to be associated with an increased risk of relapse after
allogeneic SCT. The mixed clonal landscape at relapse suggests multiple genetic
mechanisms are likely responsible for relapse. The emergence of novel mutations
at relapse suggests that maintenance strategies using targeted therapies tailored
to the mutational profile at diagnosis may be ineffective. Rather post-transplant
interventions with a broader anti-leukaemic activity, such as donor lymphocyte
infusions, or other immunotherapeutic approaches may be preferable. However,
the emergence of novel mutations at relapse in NRAS, DNMT3A, TET2 and IDH2
suggests that novel therapies targeting RAS and DNA methylation pathways
should be considered. These data, which require validation in a larger cohort,
demonstrate that detailed molecular characterisation has the capacity to both pre-
dict relapse risk post allo-SCT and inform the design of maintenance strategies.
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Background: Allogeneic bone marrow transplantation (BMT) offers the greatest
chance of cure for patients with high-risk acute myeloid leukemia (AML). Persist-
ence of disease or high levels of pre BMT minimal residual disease (MRD) have
been reported to predict relapse risk after BMT. WT1 expression levels and mul-
ticolor flow cytometry (MFC) are the most common tools to evaluate MRD.
Aims: The aim of this study was to analyze the role of pre-BMT combined
MRD assessment as predictor for post-transplant relapse risk and to evaluate
its the predictive value when comparing different stem cell source and condi-
tioning intensity.
Methods: We retrospectively analyzed the outcome of 224 consecutive AML
patients receiving allo-BMT in first or second CR. Pre-BMT marrow samples
were analysed for WT1 expression and MFC as MRD evaluation . Median age
at transplant was 44 years. Disease phase was CR1 in 161 (72%) and CR2 in
63 patients (28%). One hundred sixty-three (73%) received myeloablative con-
ditioning, whereas 61 patients (27%) received reduced intensity conditioning.
Stem cell source was HLA-identical sibling in 79 (35%), haploidentical (HAPLO)
in 59 (27%) and alternative donor in 86 (38%). Median follow-up was 59 months
(95% CI 46.271.8 months). Relapse-free survival (RFS) was calculated from
the time of BMT until last follow-up or documented leukemic relapse. Overall
Survival (OS) was calculated from the time of BMT until death by any cause or
last follow-up. A positive MFC MRD was defined by the presence of no less
than 25 clustered leukemic cells/105total events (threshold of 2.5x10-4residual
leukemic cells) at four-color flow-cytometry. WT1 copy number/Abl copy number
500x104 was used as cut-off value for abnormal WT1 expression.
Results: Relapse occurred in 63 patients (28%). Three-year estimate of RFS
was 68.8% (median not reached). The cumulative incidence of relapse was
significantly affected by occurrence of acute GVHD (lower for grade ≥2, p
<0.05), donor source (lower for HAPLO, p<0.005), MRD status before BMT
measured with any method (p <0.001 for WT1-based MRD, p<0.03 for MFC
based MRD, p<0.0001 for combined MRD). Multivariate RFS analysis revealed
that the combined MRD evaluation was the only independent predictor of RFS
(p <0.001). Specifically, MFC-MRD was the strongest predictor of longer
relapse free survival (p <0.001) since only two relapses occurred in the 24
MFC-MRD negative patients and 3-years RFS was 89.9%. Among MFC-MRD
positive patients, WT1 MRD status stratified the risk of relapse as the 3-years
RFS was 73.3% and 44.4%, respectively, for patients with normal or increase
WT1, p <0.01 (Figure 1). The predictive value of MRD resulted independent
from analyzed variables, however, patients with double positive MRD did slight-
ly better when undergoing HAPLO BMT. Moreover, conditioning intensity did
not affect RFS duration in MFC MRD negative patients. MRD evaluation was
also a strong predictor of long term survival: 3- years OS was 73.5% for MFC
negative and 36.7% for double WT1 and MFC MRD positive patients, respec-
tively (p <0.001). Multivariate OS analysis showed that conditioning intensity
and combined MRD evaluation significantly influenced OS duration (p <0.005
and <0.001, respectively).
Figure 1.
Summary/Conclusions: Pre transplant MRD evaluation by WT1 and MFC on
bone marrow samples is a reliable predictor of relapse risk. Patients with both
negative pre-BMT MRD markers have a significantly longer RFS, while patients
with both positive MRD markers display an higher risk of relapse. MRD prog-
nostic information may improve the choice of the optimal conditioning intensity
and stem cell source. Identifying patients who have an higher risk of relapse
could open the way to apply pre-emptive therapeutic strategies to prevent AML
relapse, from donor lymphocyte infusion to other innovative approaches.
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PROGNOSIS AND TARGETED TREATMENT OF AML WITH DIFFERENT
IDH MUTATIONS COULD BE INFLUENCED BY ADDITIONAL MUTATIONS 
T Alpermann1,*, C Haferlach1, W Kern1, K Perglerová2, M Meggendorfer1,
T Haferlach1
1Munich Leukemia Laboratory, Munich, Germany, 2MLL2, Praha, Czech
Republic
Background: Precision medicine aims at specifically targeting different gene
mutations, e.g. FLT3-ITD (by midostaurin), DNMT3A or TET2 (by hypomethy-
lating agents), IDH1R132 (by IDH304 or AG-120), IDH2 (by AG-221), or IDH1/2
(by AG-881). However, accompanying gene mutations bearing prognostic infor-
mation or also being drugable targets and the cytogenetic background may
need further attention before treatment decisions.
Aims: To investigate the mutation pattern and cytogenetic background of de
novo AML with IDH1R132, IDH2R140, and IDH2R172 mutations.
Methods: 1360 patients (pts) with de novo AML were evaluated at initial diag-
nosis by morphology, cytogenetics and analysed for the three mutation hotspots
IDH1R132, IDH2R140 and IDH2R172. Furthermore, ASXL1, CEBPA, DNMT3A,
FLT3-ITD, FLT3-TKD, MLL-PTD, NPM1, RUNX1, TET2, TP53, and WT1 were
investigated. All pts were treated with intensive standard chemotherapy.
Results: In total, 111/1360 (8%) pts showed an IDH1R132 mutation (mut), 168
(12%) an IDH2R140mut and 35 (3%) an IDH2R172mut. Four of these pts were
mutated in both IDH1R132 and IDH2R140. 50% of IDHmut occurred in FAB
AML M1, 31% were found in AML M2, and 12% in AML M4. In all other FAB
classes less than 5% of the IDHmut occurred or no IDHmut at all (AML M3).
Distribution of the three IDHmut types within the FAB classes was equal. 78%
(238/306) of IDHmut carried a normal karyotype. Most frequently IDHmut pts
were also mutated in NPM1 (51%), followed by DNMT3A (45%), FLT3-ITD
(23%), ASXL1 (17%), RUNX1 (16%), and MLL-PTD (13%). CEBPA, FLT3-
TKD, WT1, and TP53 were rarely mutated in IDHmut pts. Of note, 50% of the
IDHmut pts showed an additional targetable mutation. However, accompanying
aberrations differed between the IDHmut pts: IDH1R132mut pts in 103/107
(96%) showed additional mutations, but in 87/107 (81%) a normal karyotype.
63% of these pts were NPM1mut, 60% showed a DNMT3Amut, 23% a FLT3-
ITD, 10% an ASXL1mut, 10% an MLL-PTD, 9% a RUNX1mut, and only 3% a
TET2mut. IDH2R140mut pts showed in 91% (150/164) of cases additional
mutations, and a normal karyotype in 132/164 (80%) of cases. In comparison
to IDH1R132mut pts they less frequently showed mutations in NPM1 (52%)
and less often in DNMT3A (36%). However, IDH2R140mut pts carried more
often ASXL1mut (24%) and RUNX1mut (17%) compared to IDH1R132mut pts.
26% showed FLT3-ITD, 12% an MLL-PTD, and 2% a TET2mut. Interestingly,
IDH2R172mut pts showed in only 27/35 (77%; p=0.005 compared to combined
other IDHmut) cases mutations and in only 19/35 (54%; p<0.001) a normal
karyotype. Additionally, only 3% of pts showed mutations in NPM1 (p<0.001),
only 11% in FLT3-ITD, but 36% a mutation in DNMT3A, 27% in RUNX1, 27%
an MLL-PTD, 12% in TET2, and 10% in ASXL1. Therefore, the patterns of
accompanying mutations differ significantly between the three IDH mutation
groups, both regarding potential additional treatment targets and adverse risk
markers. Regarding survival IDH2R172mut pts showed a more favorable out-
come (57% 5-yr-survival) compared to IDH1R132 (37%, p=0.049) and
IDH2R140 (37%, p=0.029) mutated pts. A favorable trend was also seen com-
pared to IDH wild type (40%, p=0.067) (Figure 1).
Figure 1. Overall survival according to IDH mutations (mut) and IDH1/2
wildtype (wt) within the intermediate risk group according to the refined
MRC criteria.
Summary/Conclusions: 1) Patients with IDH1 and IDH2 mutations show dif-
ferent aberration patterns; 2) IDH1R132, IDH2R140, and IDH2R172 show dif-
ferent outcomes; 3) treatment decision is challenging as diverse mutations with
distinct targeted treatment options are simultaneously present; 4) IDH2R172
mutated patients might benefit from IDH targeting treatment, but other drugable
targets might be addressed in parallel.
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DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD
RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS
J Marková *, O Fuchs, P Michková, A Kostečka, C Šálek, J Březinová,
P Soukup, J Soukupová Maaloufová, A Vítek, P Cetkovsky, J Schwarz
Institute Hematology and Blood Transfusion, Prague 2, Czech Republic
Background: Patients with normal karyotype and NPM1 mutations lacking
FLT3/ITD (FLT3) as well as those having CEBPA mutations are regarded to
have favorable prognosis according to ELN criteria. However, this classification
does not take into account other aberrations frequently associated with NPM1
and CEBPA, such as DNMT3A or IDH1/2 mutations.
Aims: To test possible impact of DNMT3A, IDH1 and IDH2 mutations on out-
come within the ELN good-risk CEBPA or NPM1 mutated patients.
Methods: Presence of FLT3, DNMT3A, IDH1 and IDH2 mutations was detect-
ed by Sanger sequencing in 115 NPM1 or CEBPA mutated patients with AML
with an intermediate-risk cytogenetics (according to Grimwade et al., 2010)
diagnosed between 2001-2014. Median age at diagnosis was 57.5 years (range
23.7-81.9), the initial median WBC count was 33.1x109/L (range 0.4-303.7). The
male/female ratio was 59/56 and the median of follow-up was 11.6 months.
All patients were treated by remission-inducing regimens and standard post-
remission therapy± allogeneic stem cell transplant.
Results: For analyses, patients were divided into 6 groups: Group A: NPM1+
only (n=22); Group B: NPM1+/FLT3- with DNMT3A and/or IDH1 mutation
(n=25); Group C: NPM1+/FLT3+ regardless of DNMT3A/IDH1 mutations (n=45)
Group D: CEBPA+ only (n=22); Group E: CEBPA+/FLT3- with DNMT3A and/or
IDH1 mutation (n=5); Group F: CEBPA+/FLT3+ regardless of DNMT3A/IDH1
mutations (n=6). FLT3, DNMT3A and/or IDH1 mutations did not significantly
influence the probability of achieving CR in NPM1+ patients. CR was reached
by 18/20 (90.0%) patients within group A, 18/21 (85.7%) in group B and 28/39
(71.8%) in group C. Relapse was detected in only 5/18 (27.8%) group A
patients, in 12/19 (63.2%) in group B and in 19/28 (67.9%) in group C. NPM1
mutated patients with neither FLT3 nor DNMT3A/IDH1 mutations (group A)
had significantly longer EFS (P=0.009) as well as OS (P=0.017; Figure1A)
than group B (DNMT3A and/or IDH1) mutated ones. FLT3, DNMT3A and IDH1
were strongly associated with monoallelic CEBPA mutation. 10/19 patients had
at least one of these aberrations, compared with only 1/13 cases within a bial-
lelic CEBPA mutated ones (P=0.004). Within the CEBPA+ cohort, FLT3 and/or
DNMT3A and/or IDH1 mutations significantly decreased the chance of reaching
CR on the one hand and increased the risk of relapse on the other. Only 7/11
(63.6%) patients within groups E and F (when analysed together) achieved
CR compared with 19/20 (95.0%; P=0.012) cases in group D. 4/7 (57.1%)
patients relapsed within groups E+F and only 3/19 (15.8%, P=0.018) patients
belonging into group D. Presence of FLT3 and/or DNMT3A and/or IDH1 aber-
rations shortened significantly EFS (P=0.009) and OS of CEBPA mutated
patients (P<0.0001). There was no difference between patients within E and F
groups regarding EFS and OS (Figure 1B). IDH2 mutations did not influence
the prognosis of NPM1+ or CEBPA+ patients whatsoever (not shown).
Figure 1. OS in genetic subgroups of NPM1+ (A) and CEBPA+ (B) patients.
Summary/Conclusions: Patients with NPM1 or CEBPA mutations have favor-
able outcome only if they lack FLT3 or DNMT3A/IDH1 mutations. Not only
FLT3 but also DNMT3A and/or IDH1 aberrations significantly shortened both
OS and EFS of these patients. FLT3/ITD, DNMT3A and IDH1 positivity coincide
with monoallelic CEBPA mutation which might be the reason of inferior outcome
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of patients with monoallelic CEBPA mutation as compared to those with biallelic
CEBPA (usually lacking the additional mutations). We infer that only patients
with NPM1 or CEBPA mutation lacking the additional aberrations should not
be transplanted in first CR.
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MUTATIONAL SPECTRUM ANALYSIS BY NEXT GENERATION SEQUENCING
IN ADULT ACUTE MYELOID LEUKEMIA
H Wei1, Y Wang1, D Lin1, B Liu1, C Zhou1, K Liu1, B Gong1, S Wei1, G Zhang1,
X Gong1, Y Liu1, Y Li1, R Gu1, S Qiu1, Y Mi2, J Wang2,*
1Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Med-
ical Sciences & Peking Union Medical College, 2Institute of Hematology and Blood
Diseases Hospital,State Key laboratory of Experimental Hematology,Chinese
Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Background: Based on biological function and prognostic roles of these muta-
tions, acute myeloid leukemia (AML) can be segregated into distinct subgroups.
However, the spectrum of recurring alterations in larger cohorts needs further
exploration and validation. Furthermore, it is not clear what genetic alterations
co-operate with those initiating mutations to induce leukemia.
Aims: To investigate genetic alterations in a large cohort of adult AML and to
explore potential mutations as therapeutic targets, we performed targeted high
throughout NGS of 112 candidates in AML samples from 270 newly diagnosis
patients.
Methods: After informed consent was obtained, 270 patients were investigated
by a custom targeted NGS gene panel, which covered 112 genes associated
with blood diseases. All exons of these genes were sequenced on an Ion Torrent
semiconductor plat form and reads were mapped to NCBI hg19 RefSeq. Vali-
dation runs showed accurate results, with a mean of >97% coverage of the tar-
geted regions at the average depth of 800X. Five genes mutations including
FLT3-ITD, CEBPA, NPM1, CALR, and MPL were also detected by Sanger
sequencing, since they are not accurately detected by NGS. Polymorphisms
annotated in dbSNP 135 were excluded. All putative mutations were compared
against multiple databases (e.g.1000genomes,COSMIC, PolyPhen, SIFT). To
obtain more detailed genetic information, we also analyzed fusion genes includ-
ing AML1-ETO, CBF-MYH11, and MLL translocations by RT-PCR, fluorescence
in situ hybridization(FISH) and karyotype analysis.TP53 gene loss were deter-
mined by FISH, in addition to mutations detected by NGS.
Results: On average approximately three (2.84) genes per patient were mutated,
and 76 (66.1%) of the 112 genes were revealed to be mutated in at least one
patient. The most common gene abnormalities were FLT3 (21.85%), CEBPA
(21.48%), NPM1 (20.37%), AML1-ETO (20.00%), N-RAS(19.36%).Mutation fre-
quencies of CEBPA and N-RAS were higher than those reported in the literatures.
Whereas, mutation frequencies of DNMT3a (10.37%) and IDH2 (1.48%) were
lower. According to the critical initiating step in the pathogenesis of AML, we
grouped the adult AML into 9 groups (Figure 1). Then, we analyzed the co-oper-
ating mutation in these groups. AML1-ETO and CBFb-MYH11 make up CBF (core
binding factor) leukemia. But they had different co-operating mutation constitu-
tions. C-Kit mutations were the most common co-operating mutation for AML1-
ETO. Whereas, N-ras mutations were most frequent one for CBFb-MYH11. N-
ras mutations were common in all of groups, except NPM1 leukemia. N-ras muta-
tions constituted 15% co-operating mutation in AML1-ETO, 44% in CBFb-MYH11,
30% in MLL translocation, 19% in CEBPA double mutation, 18% in secondary
type, and 23% in others. Interestingly, we found 14.81% patients in our cohort
had FAT1 mutations, which was not reported before. And FAT1 mutations could
be found with high frequency in all of groups. FAT1 mutations could be found in
15% AML1-ETO, 19% CBFb-MYH11, 10% MLL translocation, 11% CEBPA double
mutation, 11% NPM1 mutation, 9% in secondary type, and 19% in others.
Figure 1. Adult AML were grouped into 9 groups based on the critical ini-
tiating step in the pathogenesis of AML.
Summary/Conclusions: Adult AML reveals a highly heterogeneous spectrum
of candidate gene mutations. Here we provide an original and comprehensive
overview of recurring mutations in AML. N-ras mutations are common in all
AML entities, except NPM1 leukemia. These mutations have to be validated in
a larger cohort with a focus on clinical implications accompanied by their use
as therapeutic targets.
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NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING 
REATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID
LEUKEMIA
S Kakiuchi1,*, Y Minami2, N Fukushima3, Y Miyata1, Y Mizutani1, H Goto1,
K Kurata4, S Kawamoto1, K Yakushijin1, H Matsuoka1, T Naoe5, H Minami1
1Department of Medical Oncology and Hematology, 2Department of Transfusion
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Hematology and Oncology, Nagoya University Graduate School of Medicine,
Nagoya, 4Department of Hematology and Oncology, Kobe University Hospital,
Kobe, 5National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Background: Cumulative evidence suggests that dormant self-renewing
leukemic stem cells (LSCs) contribute to acute myeloid leukemia (AML) prop-
agation and relapse by evading conventional chemotherapies that target cycling
cells. Therefore, there is a great need to find innovative therapies for AML that
eliminate LSCs by targeting their specific properties. Aberrant activation of the
Hedgehog (Hh) signaling pathway is involved in maintenance of the LSC pop-
ulations in several experimental systems. PF-0444913 (PF-913) is a novel oral
small molecule inhibitor that selectively binds and targets Smoothened (SMO),
a membrane protein regulating the Hh pathway. Treatment with PF-913 has
shown promising results regarding safety, tolerability, and early signs of efficacy
in the early phase study of hematologic malignancies, including AML (Jamieson,
et al. ASH, 2011). However, the detailed mode of action and biomarkers remain
to be elucidated in AML therapy with the Hh pathway inhibitors.
Aims: We examined gene profiling analyses and biomarkers using the pre-
clinical model and clinical samples derived from AML patients during PF-913
therapy to clarify the mode of action and biomarkers in AML therapy with the
Hh pathway inhibitors.
Methods: We used AML cell lines and patient-derived primary AML cells and
bone marrow cells in PF-913 treatment. Using RQ-PCR assays, we examined
the change of gene expressions in the canonical Hh pathway molecules. We
carried out comprehensive gene set enrichment analysis (GSEA), and pathway
analysis during PF-913 treatment both in the pre-clinical experimental systems
and the clinical setting (bone marrow blast-rich mononuclear cells derived from
AML patients during the PF-913 mono-therapy). We also examined cell cycle
analyses using flow-cytometory, immunoblot and immuno-staining assays.
Results: In the immunodeficient NOD/SCID/IL2rgnull(NOG) mouse model and
the ex vivo culturing system of AML cell lines, GSEA revealed that PF-913 treat-
ment induced effects on the self-renewal signatures and the cell-cycling regu-
lations associated with LSC-like properties. Moreover, GSEA revealed that PF-
913 treatment in the clinical setting modulated the LSC-like signature, the cell-
cycling regulation signature, and the chemokine activity signature in the AML
bone marrow cells. Ki-67 immuno-staining of bone marrow derived from AML
patients showed that PF-913 treatment temporarily increased cell-cycling status
during shorter periods of treatment. We also examined the pluripotency factor,
Nanog expression in bone marrow cells derived from AML patients during the
PF-913 therapy, based on the previous report that downstream effectors in the
Hh pathway, GLI1 and GLI2, directly bind to the Nanog promoter and that the
GLI-Nanog axis promotes stemness and growth in several cancers. Change of
Nanog transcripts was closely associated with the GLI-target genes in bone
marrow blast-rich mononuclear cells derived from AML patients during the PF-
913 therapy. Furthermore, by backing to the pre-clinical experimental systems,
Nanog transcript level stringently and significantly decreased during PF-913
treatment. In the same pre-clinical model, immunoblot resulted PF-913 treat-
ment decreased the expression of Nanog protein level, too.
Summary/Conclusions: Gene profiling analyses revealed that treatment with
Hh signaling inhibitor, PF-913 modulates self-renewal and cell-cycling signa-
tures in AML, and Nanog transcript can be a responsive biomarker during the
therapy. Our findings imply that PF-913 treatment can improve AML therapy
through sensitizing dormant LSCs to chemotherapy and overcoming residual
LSC-like diseases in the bone marrow microenvironment.
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A NOVEL NEXT-GENERATION SEQUENCING BASED ASSAY FOR
FLT3/ITD MUTATIONS IS SENSITIVE AND SPECIFIC AND CAN BE USED
TO DETECT MINIMAL RESIDUAL DISEASE IN AML PATIENTS
M Levis1,*, J Miller2, Z Xie3, V McClain3, A Carson3, T Stenzel2
1Oncology, JOHNS HOPKINS UNIVERSITY, Baltimore, 2LabPMM, 3Invivo-
scribe, San Diego, United States
Background: FLT3/ITD mutations are common in AML and confer a poor prog-
nosis. A sensitive, specific assay for the detection of minimal residual disease
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(MRD) in FLT3/ITD AML could guide decisions on transplant or maintenance
therapy. To date, polymerase chain reaction (PCR) based assays for MRD in
FLT3/ITD AML have been hampered by competition from the wild type allele,
limiting the overall sensitivity to approximately 1 cell in 100. While several
groups have reported the development of MRD assays for this disease, none
of these diagnostics have been developed in concert with bioinformatics soft-
ware under a quality system with the intent of being submitted to regulatory
authorities as a harmonized assay available to the international community.
We have developed a sensitive and specific MRD assay for FLT3/ITD mutations
using next-generation sequencing (NGS).
Aims: We report here the development of an assay for FLT3/ITD mutations
using a next-generation sequencing (NGS) platform.
Methods: Exons 14 and 15 are amplified by PCR and the products were detect-
ed by a refined NGS technique developed at Invivoscribe, Inc. Initial validation
was carried out by spiking in fixed amounts of mutant DNA into wild type DNA
to establish a sensitivity equivalent to detection of at least one ITD-containing
cell out of 10,000 with a minimum input of 100,000 cell equivalents of DNA.
Results: We tested a series of 15 bone marrow aspirate samples from patients
previously diagnosed with FLT3/ITD AML. All patients gave informed consent
according to the Declaration of Helsinki. The investigator conducting the MRD
assay was blind to the clinical information about the sample- no information was
provided beforehand regarding the presence or absence of FLT3/ITD mutation,
its length, or the mutant-to-wild type allelic ratio. All patients tested were in
clinical remission by IWG criteria (J. Clin Oncol 2003; 24:4642) and all samples
were derived from the first pull aspirate material used for the clinical confirmation
of that remission. In all samples, both the standard CLIA-certified assay for the
FLT3/ITD mutation (J Mol Diagn 2003; 5:96) as well as standard multi-parameter
flow cytometry (for a leukemia-associated phenotype) were negative for
detectable FLT3 mutations or cells with a leukemia phenotype. The first 4 sam-
ples were from patients who were newly-diagnosed, had just completed induc-
tion therapy, had achieved first CR, and were awaiting consolidation therapy. In
all 4 cases, the FLT3/ITD mutation detected at diagnosis was detected in these
remission samples, with mutation levels ranging from 1.35E-05 to 1.74E-04.
Three samples were from patients who had relapsed and had responded to
salvage therapy, achieving a CR2. In these 3 cases, the original FLT3/ITD length
mutation was detected, with mutation levels ranging from 1.38E-06 to 1.11E-04
mutant ITD reads/total reads. Six samples were from patients who had under-
gone allogeneic transplant in remission. The samples were collected during rou-
tine post-transplant surveillance, 2-5 years after transplant. No mutation was
detected in any of these patients, all 6 of whom are alive and disease free 2.5-
5.5 years after transplant. Finally, 2 samples were from patients who had under-
gone allogeneic transplant for FLT3/ITD AML in first CR. At 2 and 6 months
post-transplant, respectively, bone marrow aspirates from these 2 patients con-
firmed ongoing morphologic remission, with 100% donor chimerism in both the
marrow and the T-cell compartment, and a negative standard assay for FLT3/ITD
mutations. Using DNA from these same time points, the MRD assay detected
FLT3/ITD mutations at levels of 3.67E-03 and 1.04E-04 mutant ITD reads/total
reads, respectively. Both of these patients relapsed with AML carrying the detect-
ed FLT3/ITD mutation within 6 months. 
Summary/Conclusions: This novel MRD assay is specific, and is 2 orders of
magnitude more sensitive than current commercially available assays for
FLT3/ITD mutations. We anticipate that this assay will be broadly available to
the public soon, and will have a significant impact in the clinical management
of this disease. 
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AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST
SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST
LINE ACUTE MYELOID LEUKEMIA TREATMENT
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Background: We have overcome the limitations of 40 years of ex vivo testing
Aims: The aim of this study is to determine the ability of Vivia’s novel test
(based on studying the ex-vivo sensitivity to drugs) to predict the complete
remission (CR) rates after induction chemotherapy with cytarabine (Ara-C) and
idarubicin (Ida) in 1st line AML.
Methods: This has been an observational clinical trial where bone marrow
samples from adult patients diagnosed with de novo AML in Spanish centers
from the PETHEMA group were included. Whole marrow samples maintaining
their Native Environment were incubated for 48h in well plates containing Ara-
C, Ida, or their combination. Pharmacological responses are calculated using
population models. Induction response was assessed according to the Cheson
criteria (2003). Patients attaining a CR/CRi were classified as responders and
the remaining as resistant.
Results: 390 patient samples were used to calculate the dose response (DR)
curves for Ara-C alone, Ida alone, and their synergism. For clinical correlation
we used 142 patients with median 56 years. The strongest clinical predictors
were the Area Under the Curve (AUC) of the DR of Ara-C (P=1.34E-05), and the
AUC of IDA (P=3.9E-05). The GAM models revealed a significant relationship
(RSquare=0.452 and deviance explained=45%) between these predictors and
higher probabilities of post-induction resistance. Figure 1A shows a table illus-
trating the correlation between clinical outcome (columns) and the test predictions
(lines). Using the cut off determined by the GAM models. The test obtain a high
Specificity and Positive Protective Value (95% and 80,77%) and a lower sensitivity
(50%) with a general prediction of a 81,69%. Interestingly, the 5 cases that the
test identify as resistant but were clinically sensitive have high level of minimal
residual disease. On the other hand, the test does not properly identify 21/142
that are clinically resistant and the test predicts as sensitive (bottom left quadrant
right panel). This mismatched subgroup mimics the problems from molecular
markers where a resistant clone present in a minority of leukemic cells cannot
be detected yet drives the patient response. Consistent with this analysis, adding
the cytogenetic risk factor to the ex vivo results, identifying the high risk population
by molecular markers that might be present in a minority of the cells, significantly
improves the correlation; Figure 1B shows the 90% overall correlation achieved
in 117 patient samples adding the cytogenetic risk factor, with a major improve-
ment in the sensitivity from 50% to 72%. Both approaches lead to substantial
improvements in estimated overall survival.
Figure 1. Clinical correlation of the ex vivo test alone (A, left) or adding
the cytogenetic risk factor (B, right).
Summary/Conclusions: This novel test is able to predict the clinical response
to Ida+Ara-C induction with overall correlation and predictive values of 80%,
higher than ever achieved. Considering this result and current clinical response
rate of 66.7% (70% in this study), clear clinical benefits can be achieved with
the use of the test. Adding the cytogenetic risk profile further increase the cor-
relation to 90%. Thus this novel test may be valuable information to guide 1st
line patient therapy
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RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION
AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA
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Background: The rapid evolution of molecular genetics has resulted in a
diverse range of genomic variants that have been variably linked to patient
prognosis in Acute Myeloid Leukaemia (AML). Standard regression analysis
does not adequately address the complex multigene interactions that may pos-
itively or negatively influence individual patient outcome. Recursive partitioning
is an alternative approach that empirically computes and ranks in order of
importance, all possible prognostic combinations to create a stepwise decision
tree resulting in the categorical partitioning of the AML population into sub-
groups of patients with independent prognosis. Through utilizing Random Forest
analysis which repeatedly reforms the decision tree utilizing both subsets of
the data and of the variables to avoid the tendency for over-fitting the data to
the data set enhancing the generalizability of the decision tree. 
Aims: To demonstrate the utility of an algorithmic machine-based learning
approach to define independent prognostic subgroups using cytogenetic and
genomic variants derived from The Cancer Genome Atlas (CGA) analysis of
200 patients with AML. 
Methods: Clinical and mutational data was collected from the CGA AML dataset
with cases limited to an age of <70 years. Exome sequencing data from the
CGA dataset (http://cancergenome.nih.gov) was analysed utilising Integrated
Genomics Viewer (IGV) v2.3 with statistical analysis performed utilising R (R
foundation for statistical computing) v3.2.3 and the rpart (v4.1-10), randomFor-
est (v4.6-12) and randomForestSRC (v2.0.7) modules. The analysis was
restricted to the 20 most commonly identified mutations within the CGA dataset
to exclude uncommon mutations.
Results: The analysis set included 173 patients with complete clinical and genet-
ic information. Of these 143 were aged <70 years. The median overall survival
for the entire cohort was 24 months with a median follow-up of 40.5 months.
Recursive partitioning analysis was performed with a minimum “bucket” size of
8 patients (5% of the total dataset) and a complexity parameter of 0.001 reflective
of the relative complexity acceptable within the model. This resulted in a decision
tree that highlighted the importance of favourable risk karyotype and mutations
affecting TP53, RUNX1, DNMT3A, NPM1 and FLT3-ITD. (Figure 1). In non-
CBF AML a striking adverse prognostic impact was observed for TP53, RUNX1
and DNMT3A mutations, particularly when these were in combination with other
‘driver’ mutations, such as NPM1 and FLT3-ITD. Random Forest Analysis con-
firmed the prognostic importance of these mutations and predicted an error rate
of 37.08% for the predictive model in determining survival for patients within this
dataset, thus predicting a greater than 62% probability of correctly predicting
survival outcome with these factors. CBF-AML and normal karyotype AML neg-
ative for high-risk prognostic molecular markers carried a favourable risk (median
OS NR and 27 months, respectively). Patients with high-risk disease included
those with DNMT3Amut (median OS 11 months), TP53mut (median OS 12
months), RUNX1mut (median OS 11 months) and adverse-risk karyotype (medi-
an OS 12 months). Patients with FLT3-ITD (median OS 24 months) had an inter-
mediate prognosis in the absence of other high-risk markers. CEBPA double
mutants did not appear in the decision tree, likely reflective of the low occurrence
rate of CEBPA mutations in the dataset.
Figure 1.
Summary/Conclusions: Recursive partitioning analysis allows for the formu-
lation of a non-biased analysis tree and highlights the importance of combina-
tions of mutations in determining prognosis for patients with AML. The impact
of mutations affecting TP53, RUNX1 and the combination of mutations affecting
DNMT3A with other driver mutations was prognostically relevant in patients
with intermediate and poor risk karyotype. Confirmation of this decision tree
approach using larger datasets will further refine the accuracy and value of this
novel algorithmic approach for prognostically sub-classifying AML.
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CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF
NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+
AML) PATIENTS WITH INCREASED RISK OF RELAPSE
A Porwit1,2,*, C Hojilla2, M Thomas3, M Sukhai3, S Kamel-Reid2,3, T Zhang4,
A Schuh5, M Minden5
1Pathology, Lund University, Lund, Sweden, 2Pathology, University Health Net-
work, 3Cancer Genomics Program,, Princess Margaret Cancer Center, 4Cancer
Genomics Center, University Health Network, 5Leukemia Program, Princess
Margaret Cancer Center, Toronto, Canada
Background: NPM1 mutated AML has been considered as a subset of AML
patients with relatively good prognosis. However, multiple studies have shown
clinical variability in NPM1 mutated AML.
Aims: Using combined flow cytometry and next generation sequencing (NGS)
data we have sought to identify prognostic factors, which would help in individual
risk-assessment in NPM1+AML. 
Methods: Blasts from 83 NPM1+ AML patients diagnosed Jan 2012 to Aug
2015 at UHN, Toronto, were analyzed. 76 patients received induction treatment,
mostly with daunorubicin 60 mg/m2 for 3 days and cytarabine 100 mg/m2 (age
>60 years) or 200 mg/m2(age <60 years) daily for 7 days. At diagnosis, all cases
were immunophenotyped using a 4-tube, 10-color flow cytometry panel (1).
30x105 cells were analyzed using Navios and Kaluza software (Beckman Coul-
ter). Cases were classified according to 3 immunophenotypic patterns depend-
ing on the degree of monocytic differentiation (1: no monocytic differentiation;
2: a monocytic subset, and 3: predominantly monocytic). FLT3-ITD/TKD and
NPM1 mutations were identified using fragment analysis on an ABI Genetic
Analyzer 3100 /3130 platform. NGS using the TruSight Myeloid Sequencing
Panel (Illumina) was performed in 68 patients. 
Results: Among 83 NPM1+ AML patients, 69 patients had normal karyotype,
10 had cytogenetic abnormalities and 4 failed. 7 patients were excluded from
statistical analysis due to early death. 47 patients achieved complete remission
(CR) and 29 relapsed with 11 subsequent deaths. Average time to relapse from
diagnosis was 10.5 months. Presence of FLT3 ITD mutation (39 pts) and
immunophenotypic marker expression patterns 1-3 were not significantly asso-
ciated with relapse-risk. However, aberrant expression of CD7+ alone or espe-
cially CD34/CD7 co-expression (even in a small subset of leukemic cells) was
significantly associated with relapse-risk, independent of FLT3 ITD or TDK
mutational status. Figure 1 shows examples of CD7 negative case (left), CD7
in a subset of blasts with minimal CD34/CD7 population (middle) and most
blasts CD7/CD34+ (right). CD7+ and CD7- group of patients did not differ sig-
nificantly in clinical characteristics. However, CD56 was more often expressed
in CD7+ patients who relapsed. NGS revealed a heterogeneous mutational
profile of known leukemogenic genes. At diagnosis, 15 aberrations (copy num-
ber alterations (CNAs), n=10; uniparental disomies (UPDs), n=5) were identified
in 25% of patients. None of the studied mutations were significantly associated
with increased relapse risk. Interestingly, PTPN11 mutation showed increased
frequency in the group with CD7 expression but was found mostly in patients
who remained in CR. Otherwise there was no significant association between
NGS results and immunological marker expression patterns. At relapse, 56
genomic alterations (CNAs, n=46; UPDs, n=10) were detected in 55% of
patients indicating an increase in genomic complexity.
Figure 1.
Summary/Conclusions: Expression of CD7 and/or CD34 were associated
with early relapse and/or mortality. The genetic mutational profile of NPM1+
AML is heterogeneous, suggesting that no one specific genetic driver may be
responsible for leukemogenesis and affect prognosis. PTPN11 mutation seems
to be associated with better prognosis in NPM1+ AML.
Reference
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Background: Reports of patients (pts) with therapy-related acute promyelo-
cytic leukemia (t-APL) have increased in recent years (yrs) and retrospective
studies have suggested that their outcomes were similar to those of pts with
de novo APL. More recently, arsenic trioxide (ATO)/all-trans retinoic acid
(ATRA) has been shown to be the most effective therapy in de novo APL
with low/intermediate Sanz score (Lo-Coco F. et al. NEJM, 2013). So far, this
regimen has not been evaluated systematically in t-APL pts. 
Aims: To describe clinical outcome in a large series of t-APL pts and to com-
pare outcomes after treatment with ATO/ATRA with that after chemotherapy
(CTX) and ATRA.
Methods: We retrospectively studied 76 t-APL pts (median age, 59 yrs;
range, 18-80 yrs), treated between 1998 and 2015 within seven study
groups/institutions of the US and Europe. Pts had received i) CTX/ATRA
(n=34; either daunorubicin/idarubicin and ATRA for induction and different
CTXs+ATRA for consolidation), ii) ATO/ATRA (n=19; according to Lo-Coco
F. et al. NEJM, 2013 (n=16) or Burnett AK, et al. Lancet Oncol, 2015 (n=3)),
iii) CTX/ATO/ATRA (n=17; according to Gore SD, et al. JCO, 2010), and
ATRA only (n=6).
Results: In 63 of the 76 t-APL pts, a solid cancer was the primary malig-
nancy, with breast cancer being the most common (n=28), followed by
prostate (n=9), head&neck (n=7) and gastrointestinal cancers (n=6). In five
of the 76 pts, a hematologic neoplasm was the primary malignancy (non-
Hodgkin lymphoma, n=4; Hodgkin lymphoma, n=1). Eight pts had received
cytotoxic treatment for autoimmune/rheumatological diseases. The median
latency period between diagnosis of primary malignancy/disease and occur-
rence of t-APL was 4 yrs (range, 1-27 yrs). Sixty pts were of low/intermediate
Sanz score. The four therapy groups were comparable in all baseline char-
acteristics except for age (p=0.004) and platelet counts (p=0.003); pts treat-
ed with ATRA only were significantly older and had lower platelets. Response
data were available for 74 pts. Complete remission after induction therapy
was achieved in 82% of the CTX/ATRA pts, in 100% of the ATO/ATRA pts,
in 94% of the CTX/ATO/ATRA pts and in 33% of the ATRA pts. Early death
rate for the intensively treated group was 6% (CTX/ATRA, n=3;
CTX/ATO/ATRA, n=1; ATO/ATRA=0) and 50% in the ATRA group. Only two
of the 76 pts relapsed (both of the CTX/ATRA group), both pts were suc-
cessfully salvaged and went on to allogeneic transplant. Ten pts died in
remission (relapse of the prior malignancy, n=5 (CTX/ATRA, n=2, ATRA,
n=2, CTX/ATO/ATRA, n=1); infections, n=2 (CTX/ATRA, n=1 and ATO/ATRA,
n=1); adverse events during treatment, n=2 (CTX/ATRA, n=1 and
ATO/ATRA, n=1); reason unknown, n=1 (CTX/ATRA)). With a median fol-
low-up of 2.4 yrs, the estimated 2-year relapse-free survival was lower in
pts receiving CTX/ATRA (80%; 95%>CI: 66-97%) as compared to pts treated
either with ATO/ATRA (93%; 95%>CI: 82-100%) or CTX/ATO/ATRA (94%;
95%>CI: 83-100%). The estimated 2-year overall survival (OS) rate for pts
receiving CTX/ATRA was again lower (85%, 95%>CI: 73-98%) as compared
to pts treated either with ATO/ATRA or CTX/ATO/ATRA (94%, 95%>CI: 84-
100%, each). Two-year survival was not evaluable for pts treated with ATRA.
Regarding toxicity, there was a trend towards less frequent febrile neutrope-
nia of grade ≥3 in pts treated with ATO/ATRA as compared to CTX/ATRA or
CTX/ATO/ATRA (p=0.06).
Summary/Conclusions: The ATO-based regimen for first line treatment of
t-APL pts was associated with excellent and sustained response rates. These
data demonstrate the important potential of ATO/ATRA in the primary man-
agement of t-APL pts.
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AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN
PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYS-
PLASIA-RELATED CHANGES (MRC) IN AZA-AML-001 PER CENTRAL
REVIEW
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Background: Patients (pts) with AML-MRC are generally older and more likely
to have poor-risk cytogenetics, leading to poor prognosis (Weinberg, Blood,
2009). A subanalysis of the AZA-AML-001 (AZA-AML) trial evaluated safety
and efficacy of AZA vs CCR in 158 pts diagnosed with AML-MRC per local
assessment (Seymour, ASH 2014). Subsequently, AML-MRC classification was
adjudicated centrally according to WHO criteria (Vardiman, Blood, 2009).
Aims: Determine the difference in frequency of AML-MRC classification
between local and central assessments in AZA-AML, and evaluate the treat-
ment (Tx) effects of AZA vs CCR and AZA vs low-dose ara-C (LDAC) in the
centrally confirmed AML-MRC pt cohort.
Methods: Pts aged ≥65 yrs with newly diagnosed AML confirmed by central
review, ECOG PS 0-2, intermediate- or poor-risk cytogenetics, and WBC
≤15x109/L, classified as having AML-MRC per WHO criteriaΔΔ are included in
these analyses. Pre-randomization, the most appropriate of 3 CCR was pres-
elected for each pt: intensive chemotherapy (IC, standard 7+3), LDAC (20mg
SC BID x10d/28d), or best supportive care (BSC) only. Pts were then random-
ized to preselected CCR or AZA (75mg/m2/d x7d/28d). Overall survival (OS)
was compared for AZA vs CCR in all AML-MRC pts, and for AZA vs LDAC in
the LDAC preselection group. Overall response rate (ORR) included complete
remission (CR)+CR with incomplete hematologic recovery (CRi) (IWG 2003).
Results: Upon central review, a much larger pt cohort was identified than based
on local reports. In all, 262/488 pts (54%) fulfilled WHO criteria for AML-MRC:
AZA n=129, CCR n=133 (IC n=24, LDAC n=79, BSC n=30). In the AZA and CCR
arms, respectively, median age was 76 yrs (range 64-90) and 75 yrs (65-87), 51%
and 54% had poor-risk cytogenetics, 27% and 22% had ECOG PS=2, and median
blasts were 65% (27-99) and 70% (26-100). At baseline (BL) only 79 pts (30%)
were reported to have had prior MDS. BL characteristics for LDAC-preselected
AZA and LDAC pts were comparable except for ECOG PS=2 (31% vs 19%,
respectively) and poor-risk cytogenetics (42% vs 58%). Median numbers of Tx
cycles were: AZA 5 (range 1-27), IC 2 (1-3), LDAC 2 (1-22), and BSC 3 (1-9). OS
for all AML-MRC pts was improved with AZA vs CCR (HR 0.74 [95%CI 0.57, 0.97],
P=0.026; Figure 1 A): median OS was 8.9 vs 4.9 months, respectively, and 1-yr
survival rates were 44% vs 27% (Δ17% in favor of AZA). ORR was 25% vs 17%
with AZA vs CCR, respectively (P=0.17). In LDAC-preselected pts, median OS
with AZA vs LDAC was 9.5 vs 4.6 months, respectively (HR 0.77 [0.55, 1.1],
P=0.14; Figure 1 B) and 1-yr survival rates were 45% vs 24% (Δ22% in favor of
AZA). ORR was higher with AZA vs LDAC: 27% vs 14%; P=0.050. Rates of grade
3-4 cytopenias were similar among AZA, IC, and LDAC, except that febrile neu-
tropenia was less frequent with AZA (23%) than with LDAC (33%) or IC (39%).
Figure 1. Median overall survival for patients with AML-MRC.
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Summary/Conclusions: Over one-half of all newly diagnosed AZA-AML pts
met the WHO definition of AML-MRC in central review vs one-third in local
review, suggesting potential under-diagnosis of MRC in the community. This
difference may also reflect challenges in diagnosing dysplasia. MDS and AML
may reflect a continuum of myeloid disease, particularly in this pt population.
Pts with AML with MDS-related changes may respond preferentially to AZA. In
both the locally (Seymour, ASH 2014) and centrally identified AML-MRC
cohorts, AZA provided a clinically meaningful effect with prolonged OS and
improved 1-year survival rates.
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IMPACT OF PHYSICIANS’ CHARACTERISTICS ON DECISION MAKING IN
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Background: Outside clinical trials, therapeutic options offered to elderly acute
myeloid leukemia(AML) patients (pts) are limited. They can be summarized as
intensive chemotherapy (ICT), low-intensity therapy or best supportive care (BSC)
depending on patient- and disease-related prognosis factors. Although scoring
systems have been proposed to rationalize this clinical decision-making, there is
a strong heterogeneity in clinical practice which is still poorly understood. Indeed,
cancer management study mainly focused on the patients’ determinants of care
but very few have assessed the influence of physicians’ characteristics and none
in AML. In behavioral sciences, attitudes towards risk and ambiguity are crucial
psychological traits that may explain medical choices and practices. These char-
acteristics are connected with theoretical models of decision under uncertainty
which can be divided in Expected Utility (EU) and Non-Expected Utility (Non-EU)
models. Choice patterns in decision tasks known as Allais and Ellsberg paradoxes
allow classifying individuals in these two classes of models.
Aims: Our study investigated the impact of physician’s characteristics on their
medical decisions regarding selected clinical vignettes of older AML pts that high-
light distinct and difficult representative situations derived from clinical practice.
Methods: Physicians’ demographical and occupational characteristics were col-
lected through a national cross-sectional web survey among French onco-haema-
tologists. We also assessed their attitude regarding risks by the self-reported
individual willingness to take risks in the daily life on a 0-10 Likert scale (Dohmen
& al, 2011) and the response to the binary lottery choice questions of the Allais
paradox (Kahneman & Tversky, 1979) for identifying respondents conforming to
EU. A last question used two certainty equivalents elicitations (Abdellaoui & al,
2011) in an Ellsberg paradox setting in order to define an index of ambiguity atti-
tudes. The physicians were asked to decide how to treat (ICT, low-intensity ther-
apy or BSC) elderly AML patients presented in clinical vignettes. We present the
results for vignette with highest heterogeneity (cf. Figure 1).
Figure 1. Clinical vignette.
Results: Among the 211 physicians who responded to the survey, the median
age was 42 years old [inter-quartile range (IQR): 32-52], 54% were male, 72.5%
were consultant or professor, 70.6% worked in academic center, 78% were
Hematologists, 61% were involved in AML care in their daily practice. Regarding
Likert scale of willingness to take risk, median was 5 (IQR 4-7). Regarding the
Allais paradox, EU, non-EU and undefined status represented respectively
42.2%, 44.5% and 13.3%. Regarding attitudes towards ambiguity, averse, neu-
tral, seeking and undefined attitudes represented respectively 43.1%, 16.6%,
15.6% and 24.7%. From the clinical vignette we observed that 51.7% choose
ICT, 45% favored low-intensity therapy and 3.3% BSC. Using the elicited treat-
ment recommendation in the vignette as the explained variable, a multivariate
logit model (N=159) on variables identified from the bivariate analyses high-
lighted the following trends: the probability of recommending ICT was 60%
lower for women compared to men (p=0,012). Risk averse respondents tended
to recommend less ICT (p=0,075) as well as EU respondents (p=0.126). Ambi-
guity averse respondents tend to recommend more ICT (p=0,073).
Summary/Conclusions: These preliminary results show that physicians’ atti-
tudes towards risk and ambiguity, i.e. physicians’ non professional character-
istics, may influence their clinical practice when dealing with older AML pts.
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THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE
CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES
CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY
DIAGNOSED ACUTE MYELOID LEUKEMIA
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Background: Young patients affected by non APL-Acute Myeloid Leukemia
(AML) achieve complete remission (CR) using conventional induction
chemotherapy with anthracycline plus cytarabine-based regimens in about 55-
70%. The addition of Gemtuzumab Ozogamicin (GO) as third or fourth drug
demonstrated to improve clinical outcome, in terms of CR rates.
Aims: We retrospectively evaluated and compared the efficacy of different
induction schedules, in terms of CR rates and (OS), administered to two groups
of AML patients. Group 1 (n=139) was treated with a GO (MyFLAI or MyAIE
schedules); group 2 (n=270) received a non-GO based regimen including or
not Fludarabine (FLAI, FLAN, FLAG, 3+7 or DAE).
Methods: From 1997 to 2014, 409 patients with newly diagnosed AML were
treated in 3 Italian Institutions. According to karyotype (performed in 392/409
patients), FLT3 (available for 244/409 patients), and NPM1 mutational status
(available for 157/409 patients), based on the NCCN-2013 risk stratification
criteria, 35.2% of the patients were considered at High Risk (HR) (31.6% and
36.4% in the two groups, respectively) and 7.6% at low risk (LR) (7.8% and
7.0%, respectively).
Results: The complete remission (CR) rate after induction was 81.4% and
70.4% for Group 1 and 2, respectively (p=0.008). Deaths during induction (DDI),
occurring in the first 50 days from 1st line therapy, were 4/139 (2.9%) in Group
1 and 22/270 (8.1%) in Group 2. Patients treated with GO showed a better OS
than patients of Group 2; the 5-years OS in the two groups was 54.01% and
34.9%, respectively, and different according to age (54.0% and 34.9% respec-
tively (p<0.001) in patients <60 years, 30.2% and 13.5% respectively (p=0.001)
in patients >=60 years). Notably, the analysis on subgroup of HR patients
showed a significantly better OS in Group 1 than in Group 2 (p=0.007, 5-year
OS 47.7%; 21.0% respectively) and EFS.
Summary/Conclusions: Our conclusion is that adding GO to any induction
regimen is an independent and strong predictor of better OS and higher CR
rate. Patients with SR and HR AML could therefore benefit from this new
approach to AML front line treatment in terms of OS if compared with other
standard regimens.
Acknowledgements: ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-
12 (L. Bolondi), FP7 NGS-PTL project.
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HOSPITALIZATION FOR TREATMENT-EMERGENT ADVERSE EVENTS
(TEAE) IN OLDER (≥65 YEARS) PATIENTS WITH ACUTE MYELOID
LEUKEMIA (AML) WITH >30% MARROW BLASTS IN THE PHASE 3
AZA-AML-001 STUDY 
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Background: AML treatment (Tx) places an enormous financial burden on
both payers and patients (pts). Hospitalization is the largest cost driver in AML
care (Zeidan, Crit Rev Oncol Hematol, 2015) and AML pts report reduced quality
of life when in hospital (Sekeres, Leukemia, 2004). The AZA-AML-001 (AZA-
AML) study compared azacitidine (AZA) with conventional care regimens (CCR)
in older pts with AML. As previously reported, AZA was associated with lower
incidence rates (IRs) of hospitalization and total days in hospital for TEAEs per
pt-year (pt-yr) of drug exposure vs the combined CCR arm (Dombret, Blood,
2015). AZA-AML had a preselection study design, allowing for comparisons
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between AZA and individual CCR in groups of pts with generally comparable
clinical and prognostic features at entry.
Aims: Compare IRs of hospitalization and days in hospital for TEAEs adjusted
for pt-yrs of exposure within preselection groups.
Methods: Older pts with newly diagnosed AML (>30% bone marrow blasts),
ECOG PS 0-2, intermediate- or poor-risk cytogenetics, and WBC count ≤15x109/L
were eligible. Pre-randomization, all pts were preselected to receive the most
appropriate CCR: low-dose ara-C (LDAC, 20mg SC BID x10 days (d)/28d), inten-
sive chemotherapy (IC, cytarabine 100-200mg/m2 IV x7d+anthracycline IV x3d
induction), or best supportive care (BSC) only. Pts were then randomized to AZA
(75mg/m2x7d/28d) or to CCR and received the preselected Tx. All pts could
receive BSC. Safety-evaluable pts had ≥1 dose of study drug and ≥1 post-baseline
safety assessment. TEAEs were assessed for up to 28 days after the last AZA or
LDAC dose, 70 days after the last IC course, or day of discontinuation for BSC
pts. TEAEs were defined as new or worsening AEs during Tx. To address imbal-
ances in duration of exposure between Tx groups, hospitalization and days in
hospital for TEAEs are normalized for pt-yrs of exposure using aggregate data. 
Results: In all, 471 pts were safety-evaluable (AZA n=236, CCR n=235). Most
pts were preselected to LDAC (n=304; 65%). Baseline characteristics of AZA
and CCR pts within preselection groups were generally comparable. Duration of
exposure (pt-yrs) was longest with AZA in each preselection group (Table 1).
AZA was associated with lower IRs of hospitalization and days in hospital for
TEAEs vs other Tx. IR for number of hospitalizations was not significantly different
between AZA and LDAC or AZA and IC, but was ~55% lower with AZA vs BSC
(relative risk 0.455). Additionally, IRs for days in hospital for a TEAE were lower
with AZA by 6.4 to 22.5 fewer days/pt-yr across preselection groups (Table 1).
Table 1.
Summary/Conclusions: Accounting for drug exposure when reporting safety
outcomes is common in diseases with low mortality rates that require chronic
Tx, but may be increasingly relevant for diseases with a high mortality rate,
such as AML, particularly for drugs like AZA that are given in repeated Tx
cycles. In AZA-AML, incidence rate of hospitalization for a TEAE was >50%
lower with AZA vs BSC, suggesting that older AML patients should be offered
active Tx. AZA was also associated with shorter hospital stays, as evidenced
by fewer days in hospital for TEAEs with AZA vs LDAC, IC, and BSC.
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Background: Acute myeloid leukemia (AML) constitutes a heterogeneous
clonal hematological malignancy characterized by fast accumulation of imma-
ture myeloid cells that are no longer able to differentiate into fully mature blood
cells. AML is the most frequent acute leukemia with more than one quarter of
a million people diagnosed annually worldwide. Only moderate improvement
has been achieved with standard treatment over the last 3-4 decades. Due to
genetic heterogeneity and complexity of the disease with considerable variation
in therapy response and high relapse rate, AML remains a disease with poor
prognosis (median overall survival of 18 months). Hence, there is an urgent
need to improve the existing treatment by identification of novel therapeutic
targets. By comparative gene expression analysis we have identified aberrantly
expressed genes in human AML patient cells as compared to their normal
counterparts purified from bone marrow samples of healthy individuals. One
of these genes, pyruvate dehydrogenase kinase 1 (PDK1), a regulatory meta-
bolic enzyme, has been shown to be upregulated in several subtypes of AML,
and is thought to contribute to the altered energy metabolism exhibited by can-
cer cells known as the Warburg effect or aerobic glycolysis. Hence inhibiting
the activity of PDK1 with small molecule inhibitors provides an interesting novel
therapeutic strategy for the treatment of AML. 
Aims: The aim of this study was to investigate how targeting of PDK1 by small
molecule inhibitors dichloroacetate (DCA) and AZD7545 would affect growth
and survival of t(8;21) AML in a series of in vitro culture experiments. 
Methods: Several different methods were used in order to investigate the role
of PDKs including western blot analysis as well as different functional assays
to show a switch in the glycolytic acitvity. 
Results: The inhibition of PDK1 with DCA was found to reverse the glycolytic
phenotype of cancer cells from glycolysis toward mitochondrial respiration lead-
ing to cell death in human t(8;21) AML cells. Additionally, the combination of
DCA with standard chemotherapy demonstrated a synergistic inhibitory effect.
The novel PDK inhibitor AZD7545 was demonstrated to be a more potent
inhibitor of PDK1 activity than DCA in t(8;21) AML. However, its ability to switch
the Warburg effect is still under investigation. Furthermore in order to establish
the use of DCA and AZD7545 in a preclinical setting, a mouse model mimicking
human t(8;21) AML was used to determine the expression profile of PDK iso-
forms. Here PDK2 and PDK3 expression was identified to be predominantly
important for the glycolytic phenotype. It was also possible to show that DCA
and AZD7545 treatment impaired in vitro colony formation ability of clonogenic
murine t(8;21) AML cells to a higher extent than wild-type mouse cells. 
Summary/Conclusions: Overall, these results indicate that PDKs play an
important role in maintaining the Warburg effect in t(8;21) AML, thus implicating
that inhibition of PDKs with small molecule inhibitors might represent a novel
therapeutic strategy for the treatment of AML patients. 
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HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH
EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE
MYELOID LEUKEMIA PATIENTS
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Background: Homeodomain-only protein homeobox (HOPX) gene encodes
a homeodomain protein and functions as an adaptor protein to mediate tran-
scriptional repression. It was shown to play a role in stemness in intestine, hair
follicles, and pulmonary alveolar cells. HOPX was also reported as a tumor
suppressor gene in lung, colon, esophagus, pancreas, uterus, and stomach
cancers.However, the biological effects of HOPX in hematopoietic malignancies
have not been explored. 
Aims: In this study, we aim to see the clinical and biological relevance of HOPX
expression in acute myeloid leukemia (AML).
Methods: The HOPX gene expression levels were extracted from the mRNA
array data derived from 346 newly diagnosed AML patients in the National Taiwan
University Hospital, and were analyzed for its clinical and biological relevance. 
Results: The 346 patients were divided into two groups based on the median
level of HOPX expression. Patients with higher HOPX expression had signifi-
cantly higher incidences of mutations in RUNX1, ASXL1, IDH2 and DNMT3A,
but lower incidences of NPM1 mutation and CEBPA double mutations. With a
median follow-up of 31.2 months, patients with higher HOPX expression had
a shorter overall survival (OS) compared with those with lower HOPX expres-
sion (P=0.003). In multivariate analyses, higher expression of HOPX still rep-
resented a poor prognostic factor for OS independent of age, WBC counts,
karyotype, FLT3-ITD, CEBPA double mutations and NPM1, MLL-PTD, and
RUNX1 mutation (P=0.018). The results were recapitulated in the two inde-
pendent validation AML patient cohorts. Gene set enrichment analysis (GSEA)
showed enrichment of both hematopoietic stem cell (HSC) and leukemia stem
cell (LSC) signatures in the AML cells with higher HOPX levels (P<0.0005 in
HSC and P=0.004 in LSC), compatible with a role of HOPX in cell stemness.
. Furthermore, the expression of six ATP-binding-cassette (ABC) transporter
molecules that were related to poor prognosis and drug resistance, by pumping
drugs out of AML cells, were significantly higher in the high HOPX group.
Summary/Conclusions: Higher expression of HOPX appeared to be an inde-
pendent unfavorable prognostic factor in our and other AML cohorts. HOPX
expression is highly correlated with stem cell signatures and ABC-related
chemoresistance pathway. These results might at least in part explain the poor
survival in AML patients with high HOPX expression levels.
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Background: Patients with acute myeloid leukemia (AML) and inv(16) or t(8;21)
(CBF-AML) are considered of good prognosis. In consequence, general rec-
ommendation in these patients is not to perform an allogeneic hematopoietic
cell transplantation (alloHCT) in first complete response (CR). However, their
relapse incidence after standard frontline chemotherapy may reach 40%. There-
fore the identification of potential prognostic markers is considered of great
interest in order to improve their current outcome. Among these, KIT mutations,
identified in approximately one third of patients, have been invoked as a poten-
tial relevant prognostic factor in CBF-AML, although their clinical relevance is
currently uncertain.
Aims: Analyze the prognostic impact of KIT mutations in CBF-AML, in a series
of patients treated following CETLAM protocols (AML-03 and AML-12).
Methods: This study analyzed all consecutive patients with primary CBF-AML
enrolled into the AML-03 and AML-12 CETLAM trials for patients up to the age
of 70 years. Induction chemotherapy included idarubicin, intermediate-dose
cytarabine and etoposide. Consolidation treatment consisted of repeated cours-
es of high-dose cytarabine followed in a small fraction of patients of autologous
HCT. Exon 8 KIT mutations were analyzed by PCR amplification and direct
sequencing, whereas exon 17 mutations were analyzed by PCR amplification
and melting curve analysis in a LightCycler.
Results: The series included 143 CBF-AML patients (73♀, 70♂), 71 with
RUNX1/RUNX1T1 and 72 with CBFB/MYH11 rearrangements. Median age
was 42 years (range: 17-71), and median WBC count 14x109/L (range: 1.4-
243x109/L;). Overall, CR rate was 91%, 5-year overall survival (OS) was
75±4%, and leukemia-free survival (LFS) was 69±5%. No differences in OS
or LFS were found between the two CBF-AML groups. KIT mutation studies
were available in 101 patients with the following results: 1) RUNX1/RUNX1T1:
42 patients harboring (76%) wild-type KIT configuration (wt), and 13 (24%)
with mutated KIT (mut); 2)CBFB/MYH11: 32 (70%) wt, and 14 (30%) mut.
Although no differences in OS and LFS were observed between mutant and
wt patients when both CBF-AML groups were analyzed together (Figure 1). In
contrast, KIT mut had impact on outcome in the RUNX1/RUNX1T1 subgroup:
LFS was significantly better in KITwt patients (5 years LFS: 79±7%, vs
53±16%; p=0.043) and cumulative incidence of relapse (CIR) was higher in
the KITmut group (5 years CIR: 12±4%, vs 47±15%; p=0.006). There was a
trend for a worse OS in patients with RUNX1/RUNX1T1 and KITmut (5-year
OS in patients with KITwt was 81±6%, vs 50±16% in KITmut patients;
p=0.068); No differences in CR rate were found depending on presence or
absence of KIT mutations in any CBF-AML subgroup. Multivariate analysis
including age, WBC count, bone marrow blasts and mutational status of KIT,
confirmed the effect of KIT mutations in RUNX1/RUNX1T1 AML in terms of
LFS and CIR (LFS HR=3,5; 95% CI: 1,029-11,961; CIR HR=6,2; 95% CI:
1.534-24.93), but not in OS.
Figure 1.
Summary/Conclusions: In this study, KIT mutations exerted an unfavorable
prognostic effect in patients within the RUNX1-RUNXT1 AML subset, although
the higher relapse risk observed in this AML subgroup did not translate into a
shorter overall survival. The potential benefit of targeted therapies such as KIT
inhibitors on relapse risk reduction deserves to be investigated in this setting.
More data are needed to modify the still valid recommendation of postponing
alloHCT for CBF-AML to more advanced phase of the disease.
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RELATIVE BENEFIT FOR INTENSIVE VERSUSNON-INTENSIVE INDUCTION
THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID
LEUKEMIA (AML) USING A COMPOSITE, AGE-COMORBIDITY-CYTOGE-
NETIC, MODEL
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S Mukherjee4, B Medeiros5, P Shami6, E Pena6, S Wardyn1, J Whitten1,
P Becker2,7, J McCune1,2, S Lee1,2, B Sandmaier1,2, F Appelbaum1,2, E Estey2,7
1Fred Hutchinson Cancer Research Center, 2University of Washington, Seattle,
3Massachusetts General Hospital, Boston, 4Cleveland Clinic Taussig Cancer
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Background: Induction therapy for newly diagnosed AML can be classified as
“more” or “less” intensive. Currently less intensive therapies such as azacitidine
or decitabine (HMA) appear to be increasing in use among patients >65 years,
reflecting concerns about the ability of older patients, who often have various
comorbidities, to tolerate intensive therapy. However, the issue of relative effi-
cacy of intense versus non- intense therapies arises together with the question
about the relative benefit/risk ratios of these options in various populations
defined by age, comorbidities, and disease-related characteristics such as cyto-
genetic and molecular features.
Aims: Our group has designed and validated a new model combining the prog-
nostic effects of age, comorbidity index, and cytogenetic/molecular risks (Blood
2015 126:532). Here, we used this composite model to define distinct prognostic
groups and within each, compared two year mortality rates among patients
with newly-diagnosed AML according to whether they received intensive or
non-intensive therapy at 5 collaborating institutions. Non-intensive therapy prin-
cipally included HMA or low-dose cytarabine, while intensive therapies primarily
consisted of “7+3” or other similar cytotoxic induction regimens.
Methods: We retrospectively collected information regarding comorbidities,
laboratory, and survival data from 1079 patients with newly diagnosed AML
who received therapy at 5 institutions from 2008–2012. Median follow-up of
patients still alive was 30 months.
Results: Patients were ≤49 (29%), 50-59 (25%), 60-69 (26%), and ≥70 (20%)
years old. Cytogenetic-molecular risks were favorable (21%), intermediate I
and II (36%), or unfavorable (43%) per European Leukemia Net classification.
Induction treatments were non-intensive in 18% and intensive in 81% of
patients. Using the composite risk model, 17% of patients had scores of 2-4,
37% scores 5-7, 27% scores 8-10, and 19% scores ≥11. As shown before
(Blood 2015 126:532), hazard ratios (HR) for mortality increased with increasing
scores. Patients with the lowest scores (2-4) almost always received intensive
therapies (98%), and were therefore omitted from the comparison analysis.
Table 1 shows distribution of regimen intensity per patient age groups: the pro-
portion of patients receiving non-intensive therapy increased with increasing
age. Patients with scores 5-7, 8-10, and ≥11 had statistically significantly higher
survival rates when given intensive versus non-intensive therapies (Table 2).
We also looked at outcomes specifically among patients 70-79 years old given
intensive (46%) or non-intensive (54%) therapies. Intensive therapies among
those older patients resulted in statistically significantly higher survival rates at
2-year (27% versus 11%, HR: 0.72, P=0.05, Figure 1).
Table 1. Regimen intensity per patient age groups.
Table 2. Comparisons of hazard ratios (HR) and 2-year rates of survival
between intensive and non-intensive first induction therapies.
Summary/Conclusions: Intensive therapy leads to better long term survival
even in older patients with significant co-morbidities. Early mortality is not
increased in older patients given intensive rather than non-intensive induction
therapy, likely due to improvements in supportive care over time. While we can-
not exclude the effects of selection bias, our model accounted for the principal
covariates associated with outcome. Absent a randomized trial comparing inten-
sive and non- intensive therapies, our results suggest that the former should
be offered to all patients up to the age of 80 regardless of their comorbidity bur-
den. Prospective randomized studies are needed to investigate the role of non-
intensive therapies in older patients in light of their comorbidity burden. Studies
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of physical, cognitive, and social health might further identify groups of patients
for whom non-intensive therapies could yield survival benefit.
Figure 1.
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NOVEL LEUKEMIA STEM CELL-TARGETED THERAPY FOR ACUTE
MYELOID LEUKEMIA BASED ON DUAL INHIBITION OF EZH1/EZH2
I Kitabayashi*, S Fujita1, E Takamatsu1, D Honma2, N Adachi2, I Atsushi3,
K Araki2
1Division of Hematological Malignancy, National Cancer Center Research Insti-
tute, 2Oncology Research Laboratories, Daiichi Sankyo Co., Ltd, 3Department
of Cellular and Molecular Medicine, 1Division of Hematological Malignancy,
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Background: Despite great progress in curing acute leukemia and malignant
lymphoma, survival after relapse remains poor. The essential cause of the
relapse following conventional chemotherapy is a remaining population of drug-
resistant cancer stem cells (CSCs). 
Aims: Thus, selective targeting of LSCs is a promising strategy for preventing
relapse. The polycomb repressive complex 1 (PRC1) and 2 (PRC2) regulate
ubiquitination of histone H2A at lysine 112 (H2AK112) and trimethylation of
histone H3 at lysine 27 (H3K27), respectively. We report here that RING1A/B
and EZH1/2, which are catalytic subunits of PRC1 and PRC2, are essential for
maintenance of CSCs.
Results: We report here that RING1A/B and EZH1/2, which are catalytic sub-
units of PRC1 and PRC2, are essential for maintenance of CSCs. Using Ezh1-
null, Ezh2-conditional and their double knock-out mice, we examined the effects
of genetic deletion of EZH1/2 on AML. and found that double deletion of Ezh1/2
induced cell differentiation and apoptosis more severely than single deletions
in vitro in all subtypes of AML. In AML mice models, deletion of Ezh1/2 induced
differentiation of AML cells and complete remission of AML, which was not
achieved by single deletion of Ezh1 or Ezh2. Interestingly, the number of CSCs,
especially quiescent CSCs, dramatically reduced after deletion of both Ezh1
and Ezh2. However, such strong effects were not observed after deletion of
either Ezh1 or Ezh2. We have developed potent and specific inhibitors against
both EZH1 and EZH2, and found that the EZH1/2 dual inhibitor induced cell
differentiation and apoptosis in most subtypes of AML tested in vitro, but a
selective EZH2 inhibitor did not affect the growth and survival of AML cells.
Oral administration of the EZH1/2 dual inhibitor selectively reduced the number
of CSCs and prolonged the survival of the AML mice. Moreover, combination
of the EZH1/2 dual inhibitor and Ara-C prolonged survival more dramatically.
The dual inhibitor was also effective on treatment of malignant lymphomas in
xenograft models. 
Summary/Conclusions: Taken together, these results strongly suggest that
dual inhibition of EZH1 and EZH2 is a promising therapeutic strategy to erad-
icate CSCs in a wide range of AMLs. Based on these results we have initiated
Phase I clinical trial of the dual inhibitor in malignant lymphoma and we are
preparing for AML.
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IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-
TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY
ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
Y Kovtun*, G Jones, L Harvey, L Rui, C Audette, F Liu, C Bai, A Wilhelm,
NC Yoder, S Adams, VS Goldmacher, R Chari, T Chittenden
ImmunoGen., Inc., Waltham, United States
Background: Targeted delivery of cytotoxic molecules by ADCs recognizing
cancer-specific antigens is a promising therapeutic approach. CD123, the IL-
3 receptor alpha-subunit, is an attractive cancer target implicated in AML cell
survival and proliferation. CD123 is universally expressed on AML blasts, is
differentially expressed on AML stem cells relative to normal hematopoietic
cells, and is associated with aggressive disease. Here, we report the preclinical
evaluation of IMGN632, a novel conjugate of a humanized anti-CD123 antibody
with a payload that alkylates DNA without cross-linking.
Aims: Evaluate the activity of IMGN632 in preclinical AML models
Methods: Anti-CD123 antibodies were generated in mice by immunization with
a cell line expressing human CD123. The number of CD123 antigens per cell,
MDR activity, cell cycle profile and markers of cell death were assessed by
flow cytometry on AML cell lines and primary cells from AML patients. Cytotox-
icity of the ADC was evaluated on AML cell lines after continuous exposure up
to 7 days, and on primary AML patient samples by colony formation after 1-
day exposure. Antitumor activity in vivo was assessed in immuno-deficient
mice bearing human AML xenografts.
Results: We generated a high-affinity anti-CD123 antibody that blocks IL-3-
dependent proliferation of AML cells more effectively than previously reported
antibodies, and binds to a distinct epitope on the CD123 extracellular domain.
The antibody was humanized and engineered so that two cysteine residues
were incorporated into its constant region. The payload, an indolino-benzodi-
azepine dimer containing a mono-imine, was attached to the cysteines via a
peptide linker, yielding the conjugate, IMGN632, with two payload molecules
per antibody. Following internalization of IMGN632 into CD123 expressing cells
the highly cytotoxic payload is released intracellularly. The payload alkylates
DNA leading to cell cycle arrest and apoptosis-mediated cell death. IMGN632
was effective at killing twelve human AML cell lines expressing CD123 levels
comparable to those of AML patients and carrying one or more known poor
prognosis markers for AML (FLT3-ITD, EVI1 overexpression, P53 mutation or
high MDR), generating IC50 values between 0.5 and 120 pM (median 3 pM).
IMGN632 was inactive in CD123-negative cell lines at these concentrations.
Anti-leukemic activity of IMGN632 and gemtuzumab ozogamicin (GO), the
latter once approved for the treatment of relapsed/refractory AML, were com-
pared in vitro in primary AML patient samples (n=15), including four from
relapsed/refractory AML patients and seven with strong MDR activity. GO
demonstrated variable activity killing 90 percent of AML cells at concentrations
between 30 and 30,000 pM (median 1,000 pM). In contrast, IMGN632 was
highly active in all samples killing at 100-fold lower concentrations, IC90 from
3 to 46 pM (median 14 pM). A non-targeted control ADC was inactive at 1,000
pM. In vivo, a single 70 mcg/kg IMGN632 dose resulted in durable complete
responses in 5/6 mice bearing MV4-11 subcutaneous xenografts (FLT3-ITD
AML model). Likewise, a single 240 mcg/kg IMGN632 dose reduced tumor
burden in 6/6 mice bearing Kasumi-3 disseminated xenografts (AML line with
P53 mutation and MDR overexpression). Corresponding payload-matched dos-
es of a non-targeted ADC were inactive. IMGN632 was well tolerated at these
doses. 
Summary/Conclusions: IMGN632 exhibits potent in vitro and in vivo activity
against AML cell lines and patient samples, including those with poor prognostic
markers. These findings support advancing IMGN632 into clinical trials.
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LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL
B-CELL LYMPHOCYTOSIS (MBL)
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N Ioannou2, DF Jelinek4, SL Slager5, NE Kay1, TD Shanafelt1
1Hematology, Mayo Clinic, Rochester, United States, 2King’s College, London,
United Kingdom, 3Immunology, Mayo Clinic, Rochester, 4Immunology, Mayo
Clinic, Scottsdale, 5Health Sciences and Research, Mayo Clinic, Rochester,
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Background: Patients with chronic lymphocytic leukemia (CLL) have significant
abnormalities in the circulating T-cell compartment – including an increase in
the circulating CD8+ T-cells (particularly of the exhausted phenotype), dysreg-
ulated cytokine production, and defective immunological synapse formation
with antigen-presenting cells. It is not known if these defects are also present
in individuals with clinical MBL, a precursor condition to CLL.
Aims: We sought to perform a comprehensive and longitudinal analysis of cir-
culating T-cells in individuals with clinical MBL. 
Methods: Using peripheral blood mononuclear cells of individuals with MBL
stored in the Mayo Clinic Tissue Bank, we performed 8-color flow cytometry to
comprehensively evaluate T-cell subsets (CD4+ and CD8+ naïve, effector,
effector memory and central memory cells). We performed these analyses at
the time of MBL diagnosis and at a second time point (median of 48 months
later) in 18 individuals with MBL. We also evaluated the immunological T-cell
synapse at these two time points. We compared these results to age-matched
healthy adults (n=5) using the Kruskal-Wallis test. The Mayo Clinic IRB
approved this study.
Results: Analyses at MBL diagnosis: No difference in the absolute CD4+
count or major CD4+ subsets were observed between controls and individuals
with MBL at ascertainment. In contrast, the absolute CD8+ count was signifi-
cantly higher in individuals with MBL relative to controls (median 0.5x109/L vs
0.2x109/L; p=0.03), mostly due to higher CD8+ effector memory cells. No dif-
ference in naïve, effector and central memory CD8+ T-cells were observed at
ascertainment. Sequential Studies : After a median follow-up of 48 months, 9
individuals experienced an expansion of the B-cell clone (Group 1, median
absolute lymphocyte count [ALC] increased from 7.5x109/L to 39.0x109/L at
time point 2). In the remaining 9 individuals there was no expansion of the B-
cell clone (Group 2, median ALC was 7.3x109/L at time-point 1 and 8.7x109/L
at time-point 2). Among individuals in Group 1 who had expansion of the B-
cell clone, a statistically significant increase in absolute CD4+ central memory,
CD4+ effector memory, all CD8+ T-cell subsets (naïve, effector, effector mem-
ory and central memory), and exhausted T-cells (CD8+PD1+) was observed
at time-point 2. In contrast, among the 9 MBL individuals in Group 2 who had
no expansion of the B-cell clone, there were no significant differences in the
distribution of CD4+ and CD8+ T-cell subsets at time point 2 compared to MBL
diagnosis. We next analyzed differences in T-cell subsets at the time of MBL
diagnosis between individuals in Group 1 and 2. The absolute CD8+PD1+
count was significantly higher at MBL ascertainment among individuals in
Group 1 compared to those in Group 2 (0.08x109/L vs 0.02x109/L, p=0.01);
suggesting that individuals with a higher proportion of exhausted T-cells at
diagnosis are more likely to experience expansion of the B-cell clone. Immuno-
logical T-cell Synapse Studies: As shown in Figure 1a, immunological T-cell
synapse function was significantly worse in individuals with MBL compared to
age-matched healthy controls. The synapse function also got progressively
worse as the B-cell clone expanded among individuals in Group 1 (Figure 1b).
In contrast, there was no worsening of synapse function in individuals in Group
2 (Figure 1c), suggesting that the decline in the function of T-cells was directly
proportional to an increase in the size of B-cell clone.
Figure 1.
Summary/Conclusions: Consistent with CLL, there is an expansion of CD8+
T-cells in MBL individuals at the time of ascertainment. MBL individuals who
have a higher proportion of exhausted T-cells at diagnosis are more likely to
develop an expansion of the B-cell clone over time. Finally, for the first time we
demonstrate that T-cells from MBL exhibit impaired immune synapse formation
and this functional defect worsens as the size of the B cell clone expands. 
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COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL
PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q
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Background: Chronic lymphocytic leukemia (CLL) with 11q deletion (11q-) has
been associated to a poor prognosis, but the clinical course of patients carrying
this lesion is variable. The minimal deleted region (MDR) includes ATM and can
also include BIRC3, a gene often deleted or mutated in advanced/chemorefrac-
tory CLL. The prognostic implications of BIRC3 disruption in addition to ATM
deletion are not well defined. We have previously conducted a study on BIRC3
gene in 55 untreated 11q- CLL patients using Cytoscan HD array (Affymetrix) for
copy number aberration (CNA) analysis. BIRC3, rarely mutated, was deleted in
82% of cases and the biallelic lesion (D+M) was associated with a marked hyper-
leukocytosis at diagnosis and immediate need of treatment.
Aims: In order to expand these preliminary observations, the study was extend-
ed to an additional cohort of 43 11q- CLL patients using the innovative droplet
digital PCR (ddPCR) technique for BIRC3 CNA.
Methods: Genomic DNA was extracted from peripheral blood samples of 43
untreated 11q- CLL. BIRC3 CNA was performed utilizing the QX200TM Droplet
DigitalTM PCR System (Bio-Rad) that represents a useful tool to screen known
lesions with high accuracy and to provide an absolute quantification of a given
target locus relatively to a reference locus. Data were analyzed using the Quan-
taSoft software and CN value was computed by the ratio between the FAM-tar-
get (BIRC3) and the HEX-reference (KBTBD, centromeric probe on chr 11)
molecule concentrations, times to the number of copies of reference species
in the genome (i.e. [BIRC3]/[KTBD]*2). By a serial dilution experiment of a CLL
case with 95% 11q- by FISH and by preliminary tests on CLL with different
types and amounts of FISH lesions, ddPCR proved capable of identifying a
deletion when present in at least 10% of CLL cells and to confirm FISH results
in 100% of cases. BIRC3 mutations (exons 6-9) were evaluated by Sanger
sequencing. Time-to-first treatment (TFT) was calculated from the date of diag-
nosis to the date of first therapy or last follow-up.
Results: Given the comparable biological and clinical features of both cohorts,
as well as the superimposable TFT (median TFT: 12.3 vs 12 months; p=0.36),
the 98 11q- CLL patients were pooled together. Their baseline characteristics are
reported in Table 1. All patients showed 11q- by FISH (median 70.5%, range 10-
99% of nuclei). BIRC3 was included in the deleted region in 74/98 cases (75.5%)
and was mutated in 7/97 (7.2%), being always deleted on the other allele (D+M).
After a median follow-up of 70.5 months (range 7.4-235.9), 77/91 evaluable
patients have undergone treatment (median TFT 15.6 months, range 0.2-235.9).
BIRC3 deleted cases showed a TFT not significantly different from that of WT
cases. Conversely, BIRC3 D+M lesions was associated with a shorter TFT com-
pared to that of BIRC3 deleted/WT cases (median TFT 2.3 vs 16.3 months,
p<0.0001). Notably, BIRC3 D+M cases had a marked hyperleukocytosis at diag-
nosis significantly different from BIRC3 deleted/WT cases (p<0.0001). Finally,
6/7 cases with BIRC3 D+M required treatment soon after diagnosis.
Table 1. Clinical and biological characteristics of 98 11q- CLL patients.
Summary/Conclusions: Among untreated CLL with 11q-: 1) BIRC3 deletion
represents a common event (75%), whilst the mutation is rare (7%); 2) BIRC3
deletion does not seem to influence TFT of 11q- CLL; 3) BIRC3 D+M is strongly
associated with a short TFT; 4) BIRC3 D+M is mostly associated to an imme-
diate need of treatment and to a marked hyperleukocytosis at diagnosis. ddPCR
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represents a handy tool to screen a known CNA with a good sensitivity and
accuracy, resulting in a cost-effective approach.
P582
CLONAL EVOLUTION IN CLL IS ASSOCIATED WITH AN UNMUTATED
IGHV STATUS, MUTATED TP53 AND SHORTER SURVIVAL
C Haferlach*, S Jeromin, N Nadarajah, M Zenger, W Kern, T Haferlach
Munich Leukemia Laboratory, Munich, Germany
Background: CLL is a clinically heterogeneous with a course ranging from
stable disease for many years to a rather rapid progression requiring treatment.
During recent years several genetic parameters have been identified which
are associated with progression of the disease. Clonal evolution (CE) on the
genetic level is likely to correlate with clinical progression and might be used
as a predictor and thus guide treatment strategies.
Aims: The aim of this study was to evaluate the frequency of clonal evolution
on the cytogenetic level and its association with the IGHV mutation status,
TP53 mutations and clinical outcome.
Methods: 789 CLL cases were selected on the basis that chromosome banding
analysis (CBA) had been performed at least at two time points. The median
age at first evaluation was 72 years (range: 29-95 years). The first time point
of analysis was at primary diagnosis or prior to any treatment in all patients. A
total of 1902 CBA were evaluated. The median number of samples per patient
was 2 (range: 2-9). The time between samples ranged from 1 months to 118
months (median 17 months). In all patients interphase FISH was performed
with probes for 17p13 (TP53), 13q14 (D13S25, D13S319, DLEU), 11q22 (ATM),
the centromeric region of chromosome 12 and t(11;14)(q13;q32) (IGH-CCND1).
In 464 patients both TP53 mutations and IGHV mutation status were evaluated.
For 254 of these patients also clinical follow-up data was available. Median
follow-up was 64 months and 5-year overall survival (OS) was 88.8%.
Results: At first investigation CBA revealed a normal karyotype in 134 (17%)
patients. In cases with an aberrant karyotype the pattern of abnormalities was
typical for CLL. CE was observed in 243/789 patients (31%). The median time
to CE was 30 months (range 1.5-112 months). The most frequent abnormalities
gained during CE observed in >10% of cases were gains of 2p (n=48), 8q
(n=53), 13q (n=35), 17q (n=27) and losses of 6q (n=33), 8p (n=52), 11q (n=40),
13q (n=70), and 17p (n=95). In the total cohort an unmutated IGHV status was
present in 61% of cases and was significantly more frequent in patients with
CE (76.5% vs 59.4%, p<0.001). TP53 mutations were detected in 15% of cases
in the total cohort and were more frequent in patients in whom CE was observed
(25.5% vs 10.2%, p<0.001). In the cohort of patients with clinical follow-up
data, 70 of 87 (80.5%) patients with CE received therapy during the course of
the disease, whereas in patients without CE this was the case in 112/167
(67.1%) (p=0.028). Patients in whom CE was observed had a tendency for
shorter OS as compared to those without (5-year OS 84.8% vs 90.9%, p=0.07).
While no impact of CE was observed in patients with a mutated IGHV status,
in patients with an unmutated IGHV status 5-year OS was 82.8% in cases with
CE compared to 92.1% to those without (p=0.05) (Figure 1).
Figure 1. Pattern of chromosome abnormalities acquired during clonal
evolution: gained regions are depicted in green to the right and lost
regions in red to the left.
Summary/Conclusions: We observed clonal evolution in 31% of CLL patients
who were analyzed during the course of their disease. Loss of 17p, 8p and
13q as well as gain of 8q and 2p were the most frequently gained chromosome
abnormalities. Clonal evolution was associated with TP53 mutations and an
unmutated IGHV status and with inferior OS in particular in patients with an
unmutated IGHV status. The frequency and impact of clonal evolution needs
to be further evaluated in unselected patient cohorts in which chromosome




EPIGENETIC REGULATION OF ROR1 IN CHRONIC LYMPHOCYTIC
LEUKEMIA DEFINES PREFERABLE TARGET FOR COMBINED EPIGENETIC
AND IMMUNE THERAPY
K Skorka1,*, M Karp1, E Zakrzewska1, J Zaleska1, M Zajac1, A Karczmarczyk1,
J Purkot1, W Tomczak2, P Wlasiuk1, D Matosiuk3, K Giannopoulos1,4
1Department of Experimental Hematooncology, 2Department of Hematooncol-
ogy and Bone Marrow Transplantation, 3Department of Synthesis and Tech-
nology of Pharmaceutical Substances, Medical University of Lublin, 43Depart-
ment of Hematooncology, St John’s Cancer Center, Lublin, Poland
Background: Definition of leukemia-associated antigens (LAA) expression
represents a pivotal step towards inventing new and effective immunotherapy
strategies for chronic lymphocytic leukemia (CLL). Expression of LAA could be
epigenetically regulated, influencing thereby immune responses to defined
LAA. In other tumors, 5-azacytydine effectively increased expression of
cancer/testis antigens. Increased expression of LAA under 5’azacytidine expo-
sure might augment immunogenicity of these antigens inducing more effectively
anti-LAA cytotoxic immune response. ROR1 might be a specific neo-antigen
and may serve as a target for immunotherapy. Moreover spontaneous anti-
ROR1 humoral as well as a T cell responses were observed in CLL patients.
Aims: To define effect of 5’azacytidine therapy on expression of LAA and gen-
eration of ROR1-specific T-cell responses in CLL patients towards identification
of preferable target for future combined epigenetic and immunotherapy
approaches in CLL.
Methods: Expressions of ROR1 and other LAA encoded by ACTB, FMOD,
PLIN2, NFXD1, BAGE, CTAG1B, GAGE1 PRM1, WT1, MAGEA1, MAGEA3
and RPSAR in CLL were assessed in 111 CLL patients and 29 HVs using qRT-
PCR. Next, the influence of 5µM 5’azacytidine in 24-hours cell cultures of
mononuclear cells on the LAA expression was analyzed. Expression of genes
encoding LAA were normalized using constitutive gene GAPDH. For functional
experiments we chose ROR1 since it might represent preferable target for
immunotherapy. Mixed lymphocyte peptide cell cultures followed by ELISpot
assays for specific interferon gamma release were performed to determine
influence of 5’azacytidine on generation of the cytotoxic ROR1-specific T-cell
responses in CLL patients and HVs with the expression HLA-A*0201 (as
assessed by flow cytometry).
Results: We found expression of the following genes with the median 1/ΔCt
of: ROR1=0.105, FMOD=0.203; PLIN2:=0.151; NFXD1=0.070; BAGE=0.067,
ACTB=-0.359, RPSAR=0.102 and no expression of the CTAG1B and GAGE1
in all CLL cases. We observed low expression of PRM1 and WT1 in minority
of CLL patients with the median 1/ΔCt of: 0.007 and 0.056 respectively. Higher
RPSAR, FMOD, BAGE expressions in CLL than HV (median 0.102 vs – 0.505,
p<0.001; median 0.203 vs 0.060, p<0.001; median 0.067 vs 0.0001, p<0.001
respectively), and lower expression of PLIN2 in CLL that HV group (median
0.151 vs 0.439) were found. Increased expression of ROR1, RPSAR, FMOD
after exposure to 5’azacytidine was observed. In functional experiments we
found 5’azacytidine led to effective induction of LAA-specific T-cell cytotoxic
responses against peptides encoded by ROR1.
Summary/Conclusions: This study provides the evidence that LAA are dif-
ferentially expressed and regulated in CLL. Although RPSAR, FMOD, BAGE
showed highest expression in CLL as compared to HV, increased expression
of ROR1, RPSAR, FMOD was observed after exposure to 5’azacytidine. More-
over, 5’azacytidine effectively augmented anti-ROR1 cytotoxic T-cell responses.
Therefore we could conclude that preferential immunotherapy could target
ROR1 and its effectiveness could be augmented by the addition of 5’azacytidine
to treatment.
This work was supported by Medical University of Lublin Scientific Grant DS 462.
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COMPLEX KARYOTYPE AS IDENTIFIED BY CHROMOSOME BANDING
ANALYSIS IS ASSOCIATED WITH SHORTER OVERALL SURVIVAL IN CLL
INDEPENDENT OF TP53 ALTERATION AND IGHV MUTATION STATUS
C Haferlach*, S Jeromin, T Alpermann, W Kern, T Haferlach
Munich Leukemia Laboratory, Munich, Germany
Background: In standard CLL routine diagnostics interphase-FISH, TP53 muta-
tion analysis and the evaluation of the IGHV mutation status are performed.
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Since cultivation of CLL cells was improved by stimulation of CLL cells in vitro
with DSP30 and IL2 chromosome banding analysis (CBA) is more often per-
formed in CLL. Rigolin et al. (Blood 2012) demonstrated that CBA adds prognostic
information in CLL patients with “normal” karyotype as determined by interphase-
FISH. Recently, Thompson et al. (Cancer 2015) reported that a complex karyotype
is a stronger predictor than 17p deletion for an inferior outcome in relapsed or
refractory CLL patients treated with ibrutinib-based regimens.
Aims: The aim of this study was to evaluate the impact of complex karyotype
on overall survival (OS) in CLL patients.
Methods: The basis of this study were 1046 CLL cases evaluated at diagnosis
or prior to first therapy. Median age was 67 years (range: 30-89 years). Bone
marrow or blood samples were analyzed by CBA and FISH with probes for
17p13 (TP53), 13q14 (D13S25, D13S319, DLEU), 11q22 (ATM), the centromer-
ic region of chromosome 12 and t(11;14)(q13;q32) (IGH-CCND1). Further, the
TP53 and IGHV mutation status was determined in all patients. Overall survival
was evaluated from time of analysis to death or last follow up. For all patients
follow up data was available with a median follow up of 68 months.
Results: In order to determine the impact of complex karyotype patients were
categorized according to the number of chromosome abnormalities (CA) detect-
ed per case. None, 1, 2, 3, 4 and ≥5 abnormalities were observed in 228
(21.8%), 449 (42.9%), 208 (19.9%), 72 (6.9%), 36 (3.4%), and 53 (5.1%) cases,
respectively. In 46 (4.4%) cases a TP53/17p deletion was identified by FISH
and in 76 (7.3%) TP53 mutations by sequencing. 39 patients carried both a
TP53 deletion and a TP53 mutation, while in 963 (92.1%) no TP53 alterations
were detected. A significant association was observed between the number of
CA and TP53 alterations: 0-2 CA: 5.5%, 3 CA: 11.1%, 4 CA: 13.9%, and ≥5 CA
39.6% (p<0.001). The number of CA was also associated with an unmutated
IGHV status (0-2 CA: 35.9%, 3 CA: 52.8%, 4 CA: 50%, and ≥5 CA 66%
(p<0.001)). In the total cohort OS at 5 years differed significantly according to
the number of CA (0-2 CA: 84.8%, 3 CA: 83.7%, 4 CA: 77.7%, ≥5 CA: 52.6%,
p<0.001). Three different definitions for complex karyotypes were evaluated:
CK3: ≥3 CA, CK4: ≥4 CA, and CK5: ≥5 CA. We tested the impact of complex
karyotype on OS separately in patients with and without TP53 alterations. In
patients without a TP53 alteration OS at 5 years was significantly lower in cases
harboring a complex karyotype than in those without a complex karyotype (CK3:
80.3% vs 86.4%, p=0.03; CK4: 73.6% vs 86.4%, p=0.004; CK5: 66.4% vs
86.3%, p=0.001). Also in patients with TP53 alterations a complex karyotype
was associated with a negative impact on OS (OS at 5 years: CK3: 41.0% vs
59.6%, p=0.01; CK4: 35.7% vs 59.4%, p=0.01; CK5: 31.3% vs 59.1%, p=0.002).
In multivariate Cox regression analysis an independent negative impact on OS
was identified for TP53 deletion (relative risk (RR): 3.1, p=0.001), TP53 mutation
(RR: 1.7, p=0.05), number of chromosome abnormalities (RR: 1.1 per CA,
p=0.006) and unmutated IGHV status (RR: 2.0, p<0.001).
Summary/Conclusions: Although karyotype complexity is associated with
TP53 alterations and an unmutated IGHV status, the number of chromosome
abnormalities as determined by chromosome banding analysis is an independ-
ent negative prognostic parameter in CLL.
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IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPRO-
LIFERATIVE DISORDERS 
A Rawstron1,*, RM de Tute1, J Shingles1, L Gorman1, K Turner1, PA Evans1,
SL Barrans1, SJ O’Connor1, C Burton1, RG Owen1, P Hillmen2
1HMDS, St. James’s Institute of Oncology, 2LICAP, University of Leeds, Leeds,
United Kingdom
Background: The multidisciplinary diagnosis of CD5+ B-lymphoproliferative
disorders (B-LPD) can be challenging because there is significant overlap in
the clinical, cellular/immunophenotypic and molecular features. There is no
pathognomonic molecular abnormality in CLL: deletion of 13q14 is present in
approximately half of CLL cases but is also present in more than 10% of MCL
as well as other B-LPD. The presence of a CCND1/IGH in a monoclonal CD5+
B-LPD indicates a diagnosis of MCL. The MYD88 L265P mutation is a gain-of-
function driver mutation present in the majority of WM/LPL and <5% of CLL
cases. An immunophenotypic scoring system is often used to facilitate differ-
ential diagnosis but markers such as CD200 & ROR1 may permit a more repro-
ducible diagnosis, particularly when considering recently identified signalling
pathway abnormalities.
Aims: To compare immunophenotypic scoring with a diagnostic panel com-
prising CD200 and ROR1 the differential diagnosis of CD5+ B-LPD
Methods: Analysis was performed on 3082 sequential cases (1041 diagnosis,
2041 follow-up) pre-treatment or relapse). Flow cytometry (5x8-CLR tubes with
CD19 & CD20 as a backbone combined with 38 markers including CD5, CD23,
κ, λ, CD79b, CD43, CD200 and ROR1) and morphological evaluation was per-
formed in all cases with immunohistochemistry in 1058/3082; molecular analy-
ses were determined by the clinical details and immunophenotype. The final
diagnosis was determined by a multidisciplinary team review of all the available
data with input from haematopathologists, clinicians, and radiologists. An
immunophenotypic score of 0-5 was calculated separately assigning 1 point
for expression of CD5 or CD23 and 1 point for weak or no expression of CD79b
or sIg or CD20.
Results: A learning set comprising 1172 cases showed ROR1 was expressed
in 97.1% of CLL (639/658), 71.7% of MCL (33/46), 23.1% of HCL (6/26), 21.9%
of WM/LPL/MZL (75/342), 9.5% of DLBL (4/42), and 3.4% of FCL (2/58). The
markers contributing most to the differential diagnosis of CLL vs MCL were
CD20, CD23, and CD200 (specificity 91.3%, 82.6% and 78.3% respectively).
CD23 was expressed in 17.3% (8/46) MCL cases; co-expression of CD200
and CD23 was evident in 8.7% (4/46) MCL cases. The markers contributing
most to the differential diagnosis of CLL vs WM/LPL/MZL were CD20, ROR1,
and CD43 (specificity 83.0%, 78.1% and 70.5% respectively). CD43 and ROR1
were frequently expressed in MCL and so did not help to differentiate CLL vs
MCL. Similarly CD200 was frequently expressed in WM/LPL/MZL (69.9%,
239/342) and did not contribute to the differential diagnosis of CLL vs
WM/LPL/MZL. Overall the protein expression profiles that showed specificity
for differential diagnosis of CLL vs other disorders were CD5, CD23, CD43,
ROR1 and CD200 expression with weak CD20, CD81 and surface immunoglob-
ulin/CD79b expression (Figure 1A). This profile was compared with a scoring
system in a validation set (n=1469): cases scoring 5 included a small proportion
with a CCND1/IGH translocation; cases scoring 4 had a similar incidence of
CCND1/IGH and MYD88 abnormalities as cases with a score of 1-3 (Figure
1B). Cases with a fully characteristic immunophenotype had no detectable
CCND1/IGH translocations; 2/66 had a MYD88 mutation & both had a CD5-
negative MBL in addition to the dominant CLL-phenotype population. Other
CD5+CD23+ cases had a high incidence of CCND1 or MYD88 abnormalities.
Figure 1.
Summary/Conclusions: A scoring system is suboptimal for diagnosis when
additional pathway abnormalities such as MYD88 mutations are taken into
account, particularly if cases with a score of 4 or 3 are included. The detection
of a MYD88 mutation in a case with a characteristic CLL immunophenotype is
frequently associated with the presence of an additional neoplastic non-CLL
B-cell population. This study is limited by the fact that molecular testing was
guided by immunophenotypic analysis and we are currently assessing sequen-
tial cases to determine the incidence CCND1/MYD88 pathway abnormalities
in a larger series of cases with a homogeneous phenotype. However the results
clearly demonstrate that lack of ROR1 expression in a CD5+CD23+ B-LPD is
associated with a high incidence of MYD88 pathway abnormalities; this may
represent a group of disorders with biological features intermediate between
CLL and WM that should be characterised further. 
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REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF
CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC
PROFILE
I Del Giudice1,*, GM Rigolin2, S Raponi1, L Cafforio1, C Ilari1, J Wang3,
M Bordyuh3, A Piciocchi4, M Marinelli1, M Nanni1, M Filetti1, A Bardi2,
E Tammiso2, E Volta2, M Negrini5, E Saccenti2, FR Mauro1, G Gaidano6,
A Guarini1, R Rabadan3, A Cuneo2, R Foà1
1Department of Cellular Biotechnologies and Hematology, Hematology, Sapien-
za University, Rome, 2Section of Hematology, Azienda Ospedaliero-Universi-
taria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy, 3Department of
Biomedical Informatics, Center for Computational Biology and Bioinformatics,
Columbia University, New York, United States, 4GIMEMA Data Center, GIMEMA
Foundation, Rome, 5Laboratory for Technologies of Advanced Therapies (LTTA)
and Department of Morphology, Surgery and Experimental Medicine, University
of Ferrara, Ferrara, 6Division of Hematology, Department of Translational Med-
icine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Background: Chronic lymphocytic leukemia (CLL) patients with isolated dele-
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tion at chromosome 13q (13q-) and devoid of NOTCH1, SF3B1, BIRC3, TP53
clonal mutations represent a very low risk subgroup. Cytogenetics with novel
mitogens has allowed to reveal chromosomal aberrations in regions uncovered
by standard fluorescence in situ hybridization (FISH) in CLL and to identify
novel genetic subgroups with prognostic relevance beyond known gene muta-
tions (Rigolin et al., GCC 2015).
Aims: To identify in CLL patients with a very low risk genetic profile - i.e. 13q-
or normal FISH and devoid of NOTCH1, SF3B1, BIRC3, TP53 mutations -
karyotype (KT)-defined categories using novel mitogens and subclonal TP53
mutations with the aim of further refining the identification at diagnosis of
patients who may never require treatment and with a possible normal life
expectancy.
Methods: A cohort of 106 CLLs with a very low risk genetic profile, as defined
above, was selected from a series of consecutive CLL patients characterized
at diagnosis. FISH and cytogenetics with novel mitogens were performed as
described (Bardi et al., J Biomed Biotechnol 2011). The mutational screening
of NOTCH1, SF3B1, BIRC3 and TP53 was performed by Sanger sequencing.
Subclonal TP53 mutations were identified by ultra-deep sequencing on
Genome Sequencer Junior (Roche-454 Life Sciences) and a dedicated bio-
informatic analysis, as described (Rossi et al., Blood 2014).
Results: The characteristics of CLL with 13q- only (n=62; 58.5%) or normal
FISH (n=44; 41.5%), with no clonal gene mutations, were the following: 69
males, 37 females; median age 64 years (range 27-85); IGHV genes: mutated
72/96 (75%), unmutated 24/96 (25%). KT with novel mitogens was evaluable
in 104/106 cases (98%). Overall, a normal KT was present in 39 cases
(37.5%), 13q- only in 34 (32.7%), 1 or 2 lesions (other than 13q-) in 25 (24%),
≥3 lesions in 6 (5.8%). Complex KT or additional chromosomic lesions were
not associated with the IGHV gene mutation status (37.5% of unmutated vs
30% of mutated cases). In particular, CLL with 13q- only by FISH and no gene
mutations showed additional karyotypic lesions in 25.8% of cases (1-2 addi-
tional lesions in 14, ≥3 lesions in 2); CLL with normal FISH and no gene muta-
tions showed karyotypic lesions in 34% of 42 evaluable cases (1-2 lesions in
11, >3 lesions in 4). After a median follow-up of 42.5 months (range 2.0-102.0),
according to KT, very low risk CLL patients with normal KT/13q- only were
associated with a significantly longer overall survival (OS) (p=0.0004) than
cases with additional lesions/complex KT (Figure 1A). The same stratification
held true even among 13q- (p=0.005) and normal FISH CLL (p=0.03) sub-
groups (Figure 1B). Time-to-first treatment (TFT) was significantly longer for
very-low risk CLL with normal KT/13q- than for cases with additional
lesions/complex KT in the whole series (p<0.0001) and within normal FISH
CLL (p<0.0001). TP53 subclonal mutations were identified only in 3/97 cases
(3%), with a minor allele frequency of 0.015-0.03. All showed normal KT/13q-;
2 cases showed mutated IGHV. All are alive and 2 are still untreated at the
last follow-up.
Figure 1.
Summary/Conclusions: In CLL patients belonging to a very low risk category
by FISH and gene mutations, whilst TP53 subclonal mutations are very rare
and of uncertain significance, KT using novel mitogens further refines the prog-
nostic stratification allowing to identify a subgroup of patients with excellent
long-term prognosis and about 30% of cases with a worse outcome.
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PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA
GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
Z Jaskova1,*, J Malcikova1,2, J Smardova3, Y Brychtova1, M Doubek1, M Trbusek1
1Department of Internal Medicine, Hematology and Oncology, University Hos-
pital Brno and Faculty of Medicine, Masaryk University, 2Center of Molecular
Medicine, Central European Institute of Technology, Masaryk University,
3Department of Pathology, University Hospital Brno and Faculty of Medicine,
Masaryk University, Brno, Czech Republic
Background: TP53 mutations represent the most adverse predictive and prog-
nostic factor in chronic lymphocytic leukemia (CLL). We have previously shown
that missense mutations located in central DNA-binding domain of p53 protein
frequently lead to the accumulation of mutated p53 protein with presumably
oncogenic properties. A small molecule involved in clinical trials, PRIMA-
1MET(Tocris Bioscience), has been declared to be able to change mutated p53
to its wild-type (wt) conformation with rescue of its activity.
Aims: To identify factors correlating with pro-apoptotic activity of PRIMA-1MET
in CLL cells.
Methods: Peripheral blood mononuclear cells from patients with CLL (propor-
tion of leukemic cells >85%) were chosen from the TP53 cohort characterized
by the yeast functional analysis FASAY and direct sequencing. A metabolic
WST-1 assay determined the viability of cells after PRIMA-1MET treatment.
The impact of 48h PRIMA-1MET treatment on p53 protein level was analyzed
by western blot (WB). The induction of pro-apoptotic p53 target genes was
assessed by qRT-PCR. 
Results: Initially, we assessed the effect of PRIMA-1MET on viability of CLL
cells. Both p53-mutated and p53-wt samples (n=12) responded by the clear
concentration-dependent curve of viability within the concentration range 0.5-
4µM; thus indicating that the observed PRIMA-1MET effects on cell viability
were p53-independent among the samples. The PARP1 protein cleavage
observed in most of the tested samples (7 out of 12) confirmed apoptosis as
the principal mechanism of cell death. Using 11 samples and treatment with
2µM and 4µM, we demonstrated that PRIMA-1MET can readily eliminate (n=5)
or partially reduce (n=4) high baseline level of mutated p53 protein. Next, we
analyzed the expression of p53 target genes and detected a pronounced induc-
tion of CDKN1A (p21), GADD45 and PMAIP1 (Noxa) in all analyzed types of
samples: (i) with strong accumulation of mutated-p53 protein, (ii) with null p53
protein resulting from a truncating TP53 mutation, and (iii) in p53-wt samples.
In addition, we observed a prominent inverse correlation between the final via-
bility of CLL cells and PMAIP1 induction after 4µM PRIMA-1MET treatment
(Spearman´s rho=-0.8462; p=0.0005). A similar effect was also noticeable for
the viability of CLL cells and CDKN1A induction (Spearman´s rho=-0.6853;
p=0.0139). In line with these findings, there was also a significant correlation
between PMAIP1 and CDKN1A inductions after 4µM PRIMA-1MET treatment
(Spearman´s rho=0.7413; p=0.0058).
Summary/Conclusions: In CLL cells, the PRIMA-1MET is able to markedly
diminish or even completely eliminate accumulated mutated p53 protein. How-
ever, all accompanying experiments suggest that the observed effects of PRI-
MA-1MET towards apoptosis induction are in fact p53-independent in CLL cells.
Currently, we addressed the question of whether other family members like
the p73 protein can account for the observed effects.
Supported by MUNI/A/1028/2015.
P589
PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR
REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA:
AN ESCCA AND ERIC HARMONISATION PROJECT
A Rawstron*, KA Kreuzer, A Soosapilla, M Spacek, O Stehlikova, P Gambell,
N McIver-Brown, K Psarra, M Arroz, R Milani, J de la Serna, CM Teresa,
O Jaksic, JF Nomdedeu, C Moreno, GM Rigolin, A Cuneo, P Johansen,
HE Johnsen, R Rosenquist, CU Niemann, W Kern, DA Westerman, M Trneny,
SP Mulligan, M Doubek, S Pospisilova, P Hillmen, DG Oscier, M Hallek, P
Ghia, E Montserrat
On behalf of the European Society for Clinical Cell Analysis (ESCCA) & Euro-
pean Research Initiative on CLL (ERIC), Barcelona, Spain
Background: The WHO and iwCLL diagnostic criteria for CLL rely on mor-
phology and immunophenotype based on the co-expression of
CD19/CD5/CD23 on B-cells with weak CD20 and monoclonal immunoglobulin
expression. The current criteria have some limitations affecting reproducibility,
particularly flexibility in marker expression with some centres using a scoring
system that permits absence of CD5 or CD23. Through survey of 154 ERIC
and ESCCA members involved in the diagnosis CLL, a consensus marker
panel was identified, comprising CD19, CD5, CD23, CD20, Kappa and Lambda
as a minimum (i.e. required for a diagnostic panel) with CD43, CD79b, CD81,
CD10, CD200, and ROR1 also recommended for investigation. In addition,
definitions for the expression pattern and performance characteristics of the
proposed markers were developed that could potentially improve reproducibility
of diagnosis across different centres.
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Aims: To determine the feasibility of testing whether the proposed diagnostic
markers meet the required performance characteristics in individual laboratories.
Methods: A gating strategy to identify the expression levels of component
markers on normal peripheral blood lymphocytes was developed and distributed
to participating laboratories who tested it on ten historical cases with polyclonal
B-cells. The median fluorescence intensity for the relevant markers on defined
positive and negative control populations were recorded and returned for central
analysis where the relative signal value was calculated.
Results: Data were returned from 9 participating laboratories. The marker com-
binations used were different in each centre but the results, shown in Table 1,
demonstrate that most centres are using appropriate reagents with acceptable
instrument settings. The performance characteristics for all 6 markers were
met in all 10 cases in 5/9 centres. Suboptimal results were identified for 1 or 2
markers in 3/9 centres. Suboptimal results did not necessarily relate to the
reagent used and the same reagent could have different performance charac-
teristics in different laboratories because overall results were also influenced
by laboratory procedures and instrument settings. 
Summary/Conclusions: Flow-cytometry laboratory performance is influenced
by many factors including the clone, fluorochrome, and manufacturer of each
reagent, the combination and concentration of reagents used as well as the
cytometer instrument settings. Optimising and standardising each component
of the process can be labour-intensive. The relatively simple global approach
developed by ERIC/ESCCA to assess the CLL diagnostic panel is applicable
to a variety of reagent and instrument suppliers and can easily identify potential
problems or confirm acceptable performance in individual laboratories. The
quality assessment of the diagnostic panel is being extended to other markers
including CD43, CD200 and ROR1 with prospective evaluation as part of an
ERIC project to improve the reproducibility of differential diagnosis in CLL.
Table 1.
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THE SYK/JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO
ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA
M Blunt1, R Dobson1, M Larrayoz1, S Wilmore1, A Hayman1, J Parnell1,
L Smith1, A Davies1, P Johnson1, P Conley2, A Pandey2, J Strefford1, M Cragg3,
F Forconi1, F Stevenson1, G Packham1, G Coffey2, A Steele1,*
1Cancer Sciences Unit, University of Southampton, Southampton, United King-
dom, 2Portola Pharmaceuticals, San Francisco, United States, 3University of
Southampton, Southampton, United Kingdom
Background: B cell receptor (BCR) kinase inhibitors such as ibrutinib and ide-
lalisib have proved effective for the treatment of chronic lymphocytic leukaemia
(CLL). However, these inhibitors appear only to suppress the disease without
being curative. A number of patients have developed resistance to ibrutinib fol-
lowing mutation of the BTK or PLCγ2 gene, whilst other patients are unable to
tolerate these drugs due to adverse events or progress whilst on therapy for
unknown reasons. More recently, our group showed that microenvironmental
signals such as IL-4 can partially reverse BCR-kinase inhibition by ibrutinib and
idelalisib restoring αIgM induced ERK phosphorylation and calcium flux. There-
fore, the development of novel drugs that are still effective once other BCR-
kinases inhibitors become ineffective and/or which target signals from the
tumour microenvironment is of utmost importance. Cerdulatinib inhibits both
Syk (a protein pivotal to BCR signalling) and JAK3 (a protein integral for IL-4
signalling). Importantly, targeting Syk was also shown to induce apoptosis in
CLL samples resistance to ibrutinib, identifying Syk inhibition as a promising
strategy to treat these patients. Cerdulatinib is currently in a phase I open label
dose escalation study and is currently demonstrating clinical activity in patients
with relapsed/refractory B cell malignancies including CLL.
Aims: To investigate the dual Syk/Jak inhibitor, cerdulatinib, on CLL cell biology.
Methods: Twenty-four primary CLL samples were treated with cerdulatinib in
the presence or absence of IL-4/CD40L or αIgM and apoptosis assessed using
propidium iodide/Annexin V staining or PARP cleavage. The effect of cerdula-
tinib on BCR and IL-4-induced signalling were assessed by immunoblotting
and flow cytometry.
Results: At plasma concentrations achievable in patients, cerdulatinib induced
apoptosis of CLL cells cultured in vitro in a concentration, time and caspase
dependent manner, with a mean IC50 of 3μM and 1μM at 48hr and 72hr respec-
tively. Cerdulatinib preferentially induced apoptosis of samples with progressive
disease (unmutated IGHV, CD49d+ or ZAP70+) compared to indolent disease
(mutated IGHV, CD49d- or ZAP70-). Cerdulatinib significantly inhibited IL-4
induced phosphorylation of STAT6 and αIgM induced calcium flux and down-
stream signalling via phosphorylation of AKT, ERK and S6 Kinase at concen-
trations ≤300nM. Cerdulatinib induced similar levels of apoptosis irrespective
of pro-survival signalling via IL-4/CD40L or αIgM treatment, suggesting that
this drug may be able to overcome microenvironmental signals and thus target
tumour cells within the lymph nodes. In addition, cerdulatinib inhibited αIgM
and IL-4/CD40L induced expression of pro-survival proteins MCL1 and Bcl-XL.
Next we explored the possibility of augmenting cerdulatinib induced apoptosis
by simultaneous inhibition with the Bcl-2\Bcl-XL inhibitor ABT-199. In vitro in
the presence of IL-4/CD40L, ABT-199 synergised with cerdulatinib to induce
significantly greater cell death than with either agent alone. Finally we evaluated
the effect of cerdulatinib on BCR-induced expression of CCL3 and CCL4 in
CLL cells. Cerdulatinib significantly inhibited CCL3 and CCL4 expression at
concentrations achievable in patients and to a greater extent than observed
with ibrutinib alone.
Summary/Conclusions: Together these data provides the first in vitro support
for the continued use of cerdulatinib in clinical trials for the treatment of CLL as
either a single agent or in combination with other therapies such as ABT-199.
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SAFETY, EFFICACY AND IMMUNE EFFECTS OF VENETOCLAX 400 MG
DAILY IN PATIENTS (PTS) WITH RELAPSED CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)
MA Anderson1,2,3,4,*, AW Roberts1,2,3,4, JF Seymour3,4, JF Gerecitano5,6,
BS Kahl7, TJ Kipps8, JM Pagel9, SD Puvvada10, WG Wierda11, L Gressick12,
M Zhu12, M Dunbar12, B Chyla12, M Verdugo12, SY Kim12, MS Davids13
1Department of Clinical Haematology and BMT, The Royal Melbourne Hospital,
2Division of Cancer and Haematology, The Walter and Eliza Hall Institute of
Medical Research, 3Victorian Comprehensive Cancer Centre, 4Faculty of Med-
icine, University of Melbourne, Parkville, Australia, 5Memorial Sloan-Kettering
Cancer Center, 6Weill Cornell Medical College,, New York, 7Washington Uni-
versity, St. Louis, 8University of California San Diego, San Diego, 9Swedish
Medical Center, Seattle, 10University of Arizona, Tucson, 11University of Texas,
Austin, 12AbbVie, Inc., North Chicago, 13Dana-Farber Cancer Institute, Boston,
United States
Background: Venetoclax (VEN) is an orally bioavailable BCL2 selective
inhibitor. Patients (pts) with relapsed or refractory CLL or small lymphocytic
lymphoma were treated in a phase 1 trial (M12-175, NCT01328626) with doses
ranging from 150-1200 mg/day (Roberts, et al., NEJM 2016).
Aims: Here we report the updated safety and efficacy data in the subset of
CLL pts treated at the recommended phase 2 dose (RP2D) of VEN (400 mg
daily), with a focus on effects on the host immune system.
Methods: 59 CLL pts were enrolled to receive VEN at the RP2D of 400mg/day.
This analysis is restricted to the 57 pts with complete baseline and re-staging
evaluations. Immunophenotyping studies were performed by flow cytometry
on the peripheral blood at local laboratories. 
Results: As of December 1, 2015, the median time on study was 19 months
(range 0.5-44). Pts had a median of 3 prior therapies (range 1-11). The overall
response rate was 81%; 16% achieved complete remission. The 24-month
estimate for progression-free survival was 62% [95% CI=45, 75] and that for
duration of response was 77% [95% CI=58, 98]. The most common treatment
emergent adverse events (AEs) were upper respiratory tract infection (49%),
diarrhea (47%), and neutropenia (44%). Grade ≥3 AEs occurred in 86% of pts,
including 40% with neutropenia, 17.5% with infection, and 13.5% with febrile
neutropenia. 19/25 pts with neutropenia were treated with GCSF; all of them
responded, 2 were also dose-reduced. 8 deaths were reported [Richters trans-
formation (n=4), complications after allogeneic stem cell transplant (n=2), small
bowel obstruction, viral pneumonia (n=1 each)]. Significant reductions were
seen in blood B-cell counts, however, no appreciable reductions were observed
in the mean absolute counts for CD3+ T-cells, CD4+ or CD8+ T-cells, or NK
cells. Similarly, no significant changes were observed in immunoglobulin levels.
Only 11/57 pts experienced Grade ≥3 infection, at the rates of 14% in the first
6 months and 9% for the subsequent time on study.
Summary/Conclusions: VEN at RP2D of 400 mg/day resulted in a high
response rate and durable remissions. While VEN can induce neutropenia,
host T-cell numbers and immunoglobulin levels remained unchanged, and the
risk of Gr ≥3 infection in this relapsed CLL population was low.
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Background: Ibrutinib is an option in patient with relapsed/refractory CLL.
Nevertheless, the median age in the Phase I-III studies is 67 to 71 years, which
does not reflect current practice.
Aims: In France, the data of the ATU (early-access program, n=428 CLL
patients) could be used to analyze the safety (adverse events, AE) and efficacy
of this treatment in patients older than 75 years old (n=150/428).
Methods: Analysis of efficacy and safety data in 71/150 elderly patients (70.4%
male), median age 79 years (75-89 years, 39.4%>80 years) who received the
Ibrutinib treatment for their CLL.
Results: At initiation of treatment, the population had frequent vascular comor-
bidities (hypertension 34%, venous thrombosis 10%, arteritis 7%), heart comor-
bidities (myocardial infarction, 10.3%, arrhythmias 13.4%, valvular disease 4%),
or kidney dysfunction (31.3% with reduced creatinine clearance 30-60ml/min).
As such, they required antiplatelet therapy and/or anticoagulant in 30% and 12%
of cases, respectively. Baseline CLL characteristics included: advanced Binet
stage (stage C 68%), deletion 17p and/or TP53 mutation 53.3%, deletion 11q
21.6%, median of 3 lines of previous treatments (range 1-9). Patients started
ibrutinib at 420mg/d in all but one patient, still 55.7% of patients had a dose
reduction to 280mg/d due to toxicity during the first year of follow-up, after a
median of 8 weeks (range 2-52)). Standard dose was reintroduced in 10/39 pts
after resolution of AE, among which 5/10 had to decrease dose from one level
again. Ibrutinib was definitively stopped in 34% of pts after a median of 5 months
(range 1-16), mainly for AEs (infections 5.6%, cardiac complications 7%, bleed-
ings 11.3%, hematological toxicity), rarely for PD (5.6%). After a median follow-
up of 15.1 months, overall response rate at 12 months (45 evaluable patients)
was 93.4%, including 75.5% partial remission (35,6% with or 40% without lym-
phocytosis). Overall survival (OS) and progression-free survival (PFS) rate at 12
months were 92% and 83%, respectively. At last follow-up (median: 15.1mo),
63.4% of patients were alive on treatment, 15.5% alive without ibrutinib, and
21.1% (15/71) died from: infection (7/15), CLL progression (6/15, 3/6 had proven
Richter transformation), heart disease (2/15). In statistical analysis, the only factor
influencing PFS (HR=6,369; p=0,004) and duration of response (HR=7,052,
P=0,017) but not OS was a previous medical history of arteritis/myocardial
ischemia. As reported from clinical trials, a drug hold>7 days tended to be asso-
ciated with a reduction of the duration of response, but not a dose reduction from
420 to 280mg/d. In this series, estimated median OS was 21 months. Safety
profile was fairly known and manageable: grade 1-2 bleeding (19%), cardiac tox-
icity (7%), diarrhea (24%), myalgia/arthralgia (20%), the frequency of which
decreasing over the first 6 months. On the other hand, ibrutinib was associated
with a risk of hematologic AE and infection (20% of patients experienced infection
of at least grade 2), irrespectively from date of assessment (3, 6 or 12 months).
Summary/Conclusions: In very elderly patients with CLL, Ibrutinib was an
effective strategy requiring nevertheless an adequate management of toxicities,
dose reduction being often efficient.
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Background: In chronic lymphocytic leukemia (CLL), TP53 mutation
(TP53mut), 17p deletion (17p-) or fludarabine-refractoriness are strongly asso-
ciated with resistance to chemotherapy-based treatment and a poor prognosis.
The German and French CLL study groups initiated the CLL2O trial, which
aimed to achieve sufficient response rates and remission duration by combining
the CD52-antibody alemtuzumab with dexamethasone followed either by alem-
tuzumab-maintenance or allogeneic stem cell transplantation. The trial enrolled
only CLL patients refractory to a fludarabine-based regimen (with or without
17p-) or with 17p- (front line or relapsed).
Aims: While incidence and prognostic value of gene mutations have been
extensively evaluated in first-line CLL treatment situations, only scarce data is
available from clinical trials focusing on high risk patients.
Methods: We performed targeted next generation sequencing (tNGS) of eight
recurrently mutated genes (TP53, NOTCH1, SF3B1, ATM, BIRC3, POT1,
FBXW7, MYD88) on baseline samples of 111 CLL2O patients. Statistical analy-
ses were performed by Fisher’s exact test, Kaplan-Meier estimates, and Cox
proportional hazards regression with significance as p<.05 (two-sided).
Results: The full CLL2O cohort (n=131) comprised 17p- frontline (n=42), 17p-
relapsed (n=28) and refractory (with 17p- (n=30) and without 17p- (n=31))
patients. Analyses are reported for the full cohort and for those predefined sub-
sets of the trial. Among all 111 patients with mutation data available, TP53 muta-
tions were detected in 79 (71.2%), NOTCH1 in 32 (28.8%), SF3B1 in 27 (24.3%),
ATM in 24 (21.6%), BIRC3 in 7 (6.3%), POT1 in 4 (3.6%), FBXW7 in 3 (2.7%)
patients and MYD88 in a single (0.9%) patient. There were associations of muta-
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tions with genomic aberrations, e.g. TP53 with 17p- (p<.001), ATM with 11q-
(p=.037), but there was no correlation between TP53mut and other recurrent
mutations. Remarkably, 11 pretreated patients showed 2 to 4 TP53mut, while
only a single untreated patient had two TP53mut. In the full trial cohort, none of
the mutations had a significant impact on response, progression free survival
(PFS) or overall survival (OS). Notably, in patients with 17p-, the incidence of
TP53, SF3B1 and NOTCH1 mutations was similar in treatment naïve (n=37)
and pretreated (n=74) patients and the overall genomic landscape appeared
not markedly different between those cohorts (Figure 1). These findings indicate
that most genomic variants preexist and are not induced by fludarabine-based
chemotherapy in 17p- CLL. Of note, in the 17p- frontline cohort, there was a sig-
nificant association of TP53 wild-type (hazard ratio 0.14; p=.02) and ATMmut
status (hazard ratio 0.16; p=.04) with prolonged PFS. In contrast, within the
refractory and 17p- relapsed subgroup, there was no significant association of
any mutation with outcome. In the F-refractory cohort, when comparing the
groups with (n=26) and without (n=21) 17p-, there was an association of ATMmut
with absence of 17p- (p=.01), but no significant correlation to outcome.
Figure 1.
Summary/Conclusions: In conclusion, within the full trial cohort none of the
recurrent mutations had an impact on outcome in the CLL2O trial. Fludara-
bine-based treatment does not appear to increase the overall complexity of the
genomic landscape of 17p- CLL, but it might increase the number of intraindi-
vidual TP53mut in a given tumor. TP53 is a prognostic factor in previously
untreated, but not in pretreated and refractory patients enrolled within the
CLL2O trial. Of note, in the F-refractory cohort 20/21 (95,2%) patients without
17p- and with TP53 wild-type had at least one other alteration such as 11q-,
NOTCH1mut, ATMmut or SF3B1mut.
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Background: Idelalisib (IDELA) is a first-in-class selective PI3Kδ inhibitor
approved in EU for use in combination with rituximab (R) for patients (pts) with
relapsed CLL; or as first-line CLL treatment in the presence of del(17p) or TP53
mutation (TP53m) in pts unsuitable for chemo-immunotherapy. A post-autho-
rization, pre-national reimbursement early access program (EAP) was initiated
for Australia, Belgium, Greece, Ireland, Spain and UK, for pts without other
therapeutic options and who could not be included in an IDELA clinical trial.
Pts with relapsed/refractory (R/R) CLL/SLL and treatment naïve (TN) CLL/SLL
with del(17p)/TP53m, were eligible for the CLL/SLL cohort. IDELA data outside
clinical trials and in real-world settings is limited.
Aims: This analysis was to characterize baseline demography of pts treated
with IDELA+R in both TN CLL/SLL pts with del(17p)/TP53m and R/R CLL/SLL,
outside of a clinical trial setting. Serious adverse events (SAE) reported are
also presented.
Methods: The EAP enrolled pts from March 2015, analysis data-cut off was 15
January 2016. Available data were collected from de-identified pt registration
data and SAE reports. This analysis summarizes baseline pt characteristics
which were either mandatory or optional on the enrolment form. SAEs were
reported whilst pts were on treatment. The proportion of missing data (unre-
ported or unrecoverable) is also shown in the Table 1.
Results: Median follow up was 133 days (2-315). 170 pts with R/R CLL/SLL
had documented prior treatment regimens (166 with specific treatment and 4
with number of lines only). Most commonly used prior therapies included anti-
CD20 (85.6%), cyclophosphamide (69.3%), fludarabine (56.6%), bendamustine
(43.3%) and prednisolone (40.0%). SAE data collected were consistent with
previous clinical study SAE reporting with SAEs in 37/263 (14.1%) pts. SAEs
included 8 (3.0%) pneumonia, 7 (2.7%) liver test elevations, 5 (1.9%) neutrope-
nia, 5 (1.9%) pneumonitis, 4 (1.5%) skin reactions, 3 (1.1%) diarrhea and 3
(1.1%) febrile neutropenia. 
Table 1.
Summary/Conclusions: This is the largest cohort reported to date for pts with
CLL/SLL treated with IDELA+R, outside of clinical trials. Pts included in the
EAP had similar demographic characteristics to those previously reported in
clinical trials.1 To date, available results indicate an acceptable tolerability profile
of IDELA+R in the real-world setting for pts withTN CLL/SLL and 17p deletion/
TP53m and for pts with R/R CLL/SLL.
Reference
1. Eichhorst B, et al. Ann Oncol 2011; 22(Suppl 6):vi50-vi54.
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Background: TP53 aberrations (deletions and/or mutations, TP53ab) in chron-
ic lymphocytic leukemia (CLL) are associated with dismal clinical outcome and
reduced life expectancy. However, mounting evidence suggests that within cas-
es carrying TP53ab other cytogenetic features may also influence the clinical
outcome. Alterations in chromosome 8, in particular 8p losses (affecting several
regions, from 8p12 to 8p23) and 8q gains (usually involving 8q24, where MYC
is located), are enriched in TP53ab patients and have been proposed as fea-
tures with potential prognostic value within this aggressive group. 
Aims: To assess the prevalence of 8p losses (8p-) and 8q gains (8q+) in CLL
patients with TP53ab, characterize their clinicobiological profile and evaluate
their prognostic value.
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Methods: A total of 101 patients with TP53ab from 17 Spanish and Greek insti-
tutions were included in the study. 8p- and 8q+ were analyzed in peripheral blood
samples by FISH using LPL (8p22) and MYC (8q24) probes (AbbottMolecular)
in 75 and 101 cases, respectively. Clinical and cytogenetic data from patients
with 8p- vs normal 8p (N-8p) and 8q+ vs normal 8q (N-8q) were compared.
Results: A total of 11/75 patients (14.7%) showed 8p- and 18/101 cases
(17.8%) carried 8q+. In 6/75 patients (8%) both abnormalities were concomi-
tant. As for the clinicobiological profile at diagnosis, 8p- and 8q+ cases dis-
played no differences regarding age, Hb/platelet/leucocyte values, as well as
FISH detected abnormalities del(11q), del(13q) and trisomy 12 compared to
cases with normal 8p (N-8p) and normal 8q (N-8q), respectively. However, cas-
es with 8p- exhibited a higher incidence of B symptoms compared to N-8p cas-
es (P=0.039). Interestingly, 8p- cases carried a higher number of 17p-deleted
cells as well as a higher median number of chromosomal alterations detected
by chromosome banding analysis (CBA) (7 vs 3) and, therefore, a higher fre-
quency of complex karyotypes (CK, defined as ≥3 structural/numerical aberra-
tions) compared to N-8p cases (P=0.001, P=0.041 and P=0.006, respectively).
Similarly, cases with 8q+ also showed a higher median number of chromosomal
abnormalities (6.5 vs 2) and higher frequency of CK compared to N-8q cases
(P=0.001 and P=0.002, respectively). Ten-year survival analysis revealed a
significant shorter overall survival (OS) for both 8p- and 8q+ (P=0.002 for 8p-
vs N-8p, and P=0.007 for 8q+ vs N-8q). CK also had a negative impact on OS
(P=0.018) (Figure 1). In multivariate analysis only CK retained independent
significance (P=0.032, HR: 2.5).
Figure 1. Kaplan Meier plots for ten-year OS in patients carrying (A) 8p-,
(B) 8q+ and (C) complex karyotype with 8q+ or N-8q.
Summary/Conclusions: 1. The prevalence of 8p- and 8q+ in this cohort of
CLL patients with TP53ab was 14.7% and 17.8% respectively. 2. The detection
of chromosome 8 abnormalities (8p- and/or 8q+) by FISH in patients with CLL
and TP53ab is associated with karyotype complexity and further deteriorates
outcome. 3. Genomic complexity assessed by CBA negatively impacts on sur-
vival even amongst patients with TP53ab. 4. Validation in large cohorts is
required to elucidate if the observed dismal OS in CLL patients with 8p- and/or
8q+ is due to chromosome 8 alterations per se or by the genomic instability
associated with complex karyotypes.
Acknowledgements: PI11/01621; PI15/00437; RD12/0036/0044, RD12/0036/
0069 FEDER; 2014/SGR585; Fundació La Caixa.
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Background: Ibrutinib (ibr) is the first-in-class, oral, once daily Bruton’s tyrosine
kinase inhibitor EMA-approved for adult patients with CLL with ≥1 prior therapy.
Difference in outcomes with ibr may exist by prior lines of therapy (LoT). Variable
overall survival (OS) after ibr discontinuation (DC) have also been reported.
Aims: To evaluate outcomes with ibr based on prior LoT, and following ibr DC
in patients with CLL.
Methods: We analyzed data from two randomized phase 3 trials of ibr: PCYC-
1115/16 (RESONATE-2) in patients ≥65 years with treatment naïve (TN) CLL;
PCYC-1112 (RESONATE) in previously treated (PT) CLL, excluding patients
with del17p for a more homogenous dataset for analysis. All patients provided
informed consent. Progression-free survival (PFS) and overall response rate
(ORR) were assessed by investigator.
Results: Data from 271 patients were included in this analysis. In TN vs PT
patients, median age was 73 vs 66 years. PT patients had a median of 3 prior
therapies including CD20 antibody (93%), purine analog (87%), or alkylating
agents (93%; bendamustine 41%). Median PFS and OS were not reached
(NR) for TN or PT patients, with 89-92% progression free at 2 years for patients
treated with ibr in 1st- or 2nd-line (Table 1). ORR was high regardless of LoT
(91% in TN, 92% in PT patients). 85% of TN patients and 61% of PT patients
continue ibr treatment. Adverse event (AE) profile was similar for both groups.
Patients receiving ibr in earlier LoT were less likely to DC ibr due to progressive
disease (PD) (Table 1). Median OS post ibr DC is NR for patients who received
ibr in 1st- or 2nd-line (n=23) vs 7-9 months (mo) in 3rd-line and beyond (n=34).
Table 1. Outcomes with Ibrutinib based on prior LoT including outcomes
following discontinuation.
Summary/Conclusions: Treatment with once daily ibr led to favorable PFS
and OS, and high ORR regardless of LoT in patients with CLL. Patients who
received ibr in earlier LOT as 1st- or 2nd-line therapy were less likely to progress
and experienced better post-ibr survival outcomes.
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Background: The phase 3 RESONATE™ trial (NCT01578707) compared ibru-
tinib (ibr) with ofatumumab (ofa) in patients (pts) with previously treated CLL
and not eligible for purine analogue treatment. Ibr showed significantly
improved progression-free survival (PFS; hazard ratio [HR]=0.22; p<0.001)
and 18-month overall survival (OS; adjusted for crossover) (HR=0.35 [0.16-
0.75]) (Diels, ISPOR-EU 2015).
Aims: In the absence of a head-to-head comparison of single-agent ibr with
other frequently used treatments, we investigated the relative efficacy of ibr vs
physician’s choice in R/R CLL pts by comparing pt-level data from RES-
ONATE™ with R/R pts in a real-world setting (the CLLEAR database). The
CLLEAR database holds data on CLL pts from the Czech Republic, collected
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from academic centers. Electronic Medical Records for 450 pts from 3 centers,
collected between 2012 and 2015 were available from this database. 
Methods: Pt-level data from the RESONATE™ trial (ibr, n=195; ofa, n=196)
were compared with data from the CLLEAR database, adjusting for confounding
factors using multivariate statistical modelling. From this database, pts who
received second-line or later line treatment were identified. Longitudinal follow-
up in subsequent treatment lines was available for pts in second (n=87), third
(n=33), fourth (n=15), and subsequent (n=13) lines. In order to account for non-
comparability of ibr pts with the CLLEAR cohort due to lack of randomization,
the statistical approach of a multivariate Cox proportional hazards model was
used to compare PFS and OS between treatments, including line of therapy,
age, gender, disease stage (based on Binet/Rai), and ECOG performance sta-
tus as covariates.
Results: Across all treatment lines, the most frequent treatment regimens used
were FCR or FCR-based treatment (20.9%), alemtuzumab monotherapy
(15.5%), chemotherapy+monoclonal antibodies (14.2%), rituximab monotherapy
(9.5%), corticosteroid only (9%), R-CHOP or R-CHOP–based (6.1%), and BR
(4.7%); the remaining percentages comprised a multitude of various other ther-
apies, each used in less than 4% of pts. Line of therapy, age, gender, disease
stage, and ECOG performance status were all independent risk factors for worse
outcome of PFS and OS. Median age at treatment initiation was 67 years for
both pt cohorts. Median number of prior therapies in RESONATE™ was 3, com-
pared with 1 for CLLEAR. The observed HRs for PFS and OS of ibr vs physi-
cians’ choice from the CLLEAR database were 0.19 (0.13-0.27) and 0.26 (0.17-
0.42). After adjustment for differences in baseline characteristics, HRs improved
to 0.10 (0.06-0.16) for PFS and 0.15 (0.08-0.28) for OS. The impact of adjust-
ment on PFS and OS was mainly driven by differences in number of prior lines
of therapy. Adjusted HRs for PFS and OS of ibr vs FCR-based treatment in the
second line were 0.07 (0.02-0.25) and 0.11 (0.02-0.57), respectively.
Summary/Conclusions: Investigation of clinical outcomes suggests that ibr
administered to pts in the RESONATE™ trial was more effective than physi-
cian’s choice amongst pts from a real-world cohort of Czech pts. PFS and OS
for ibr is improved compared with standard therapies currently available for pts
with R/R CLL. These results are consistent with a previous report from a
Swedish observational study showing superiority of the ibr cohort from RES-
ONATE™ over physicians’ choice (Österborg, ASH 2015) and further support
the growing evidence that ibrutinib significantly improves both PFS and OS vs
current and prior commonly used regimens.
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INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC
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SUBSET #2
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Background: Several population-based studies support the notion that overall
survival (OS) in CLL has improved in recent years. Relevant to this, a turning
point in the management of CLL was the introduction of chemoimmunotherapy,
in particular the fludarabine-cyclophosphamide -rituximab (FCR) regimen, the
first to lead to prolonged OS compared to previous chemotherapy approaches.
However, certain CLL subgroups have proven refractory to chemo(immuno)
therapy, the paradigmatic example being patients harboring aberrations within
the TP53 gene who display resistance to all such approaches. Aside from this,
relatively little is known about the trends in OS over time among other CLL
prognostic subgroups.
Aims: To investigate trends in long-term survival of CLL patients with particular
biomarker profiles treated with chemo(immuno)therapy.
Methods: We evaluated parameters affecting OS within a cohort of 3503
patients treated for CLL with chemo(immuno)therapy in 15 institutions in Europe
and the US. The patient distribution in the present study was as follows: males:
n=2410 (69%), median age at treatment: 63.5 years; CD38 positivity:
n=707/1853 (39%); del(17p): 111/1059 (11%); del(11q): 199/937, 21%; trisomy
12: 133/706, 19%; del(13q): 323/570, (57%); unmutated IGHV genes (U-CLL):
n=2216 (63%); membership in stereotyped subset #2 (IGHV3-21/IGLV3-21):
n=166 (5%). The latter was assessed separately due to representing an aggres-
sive CLL subgroup, independently of IGHV gene somatic hypermutation status.
Patients included in the analysis received primary treatment between May 1980
and July 2013 and were subdivided into two groups: (A) treated before 2006
(n=2092) and; (B) treated in 2006 and after (n=1411). This time-point was cho-
sen due the following implementation of chemoimmunotherapy in clinical prac-
tice after 2005.
Results: The two groups did not differ at diagnosis with regards to gender,
IGHV mutational status, stereotyped subset #2 membership or cytogenetic pro-
file. In contrast, significant differences (p<0.05) were identified concerning:
patient age at time of first treatment (median: 63 for group A vs 64.5 for group
B); CD38 positivity (42% in group A vs 33% in group B, p<0.0001); OS (mea-
sured from the time of diagnosis): 9.5 years in group A vs 17.5 years in group
B (p<0.0001). The superior outcome of patients treated after 2005 (group B)
was evident across subgroups defined by age, gender, IGHV mutational status,
CD38 expression, del(11q), trisomy 12 and del(13q) (p<0.05 for all compar-
isons). In contrast, the OS was not improved after 2005 for cases carrying
del(17p) (median OS: 7 and 5.2 years in groups A and B respectively, p=0.61),
which is not unexpected given the documented low efficacy of
chemo(immuno)therapy amongst patients with such aberrations. Notably, a
similar lack of improvement in OS (median OS: 7 and 9 years in groups A and
B respectively, p=0.14) was identified for cases belonging to stereotyped subset
#2, further highlighting this subset as a particularly aggressive CLL subgroup.
Summary/Conclusions: Advances in chemo(immuno)therapeutic approach-
es in CLL during the last decade have translated into prolonged OS in all prog-
nostic subgroups of the present study except those carrying TP53 abnormal-
ities as expected, but also to those assigned to stereotyped subset #2, that
are generally devoid of such gene aberrations. This latter finding, reported
here for the first time, supports the clinical relevance of B cell receptor IG
stereotypy in CLL and indicates the need for alternative treatment options for
subset #2 patients. 
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Background: Patients (pts) with chronic lymphocytic leukemia (CLL) who
relapse after or become refractory (R/R) to BCR pathway inhibitors have poor
outcomes. Venetoclax (VEN) is a selective, oral BCL-2 inhibitor with significant
activity in R/R CLL.
Aims: Primary endpoints are ORR by iwCLL criteria [week (w) 8, 24, then every
12w] and safety.
Methods: In this ongoing Ph 2 study, pts with CLL R/R to ibrutinib (IBR, Arm
A) or idelalisib (IDE, Arm B) receive VEN 20 mg daily followed by 5-week ramp
up to 400 mg daily. 
Results: 54 pts were enrolled (41 A, 13 B), including 25 refractory to IBR and
6 to IDE; 12 and 6 were intolerant with CLL progression after stopping IBR and
IDE, respectively; 3 in each arm had both IBR and IDE. 54% had >5 prior ther-
apies, 83% had unmutated IGHV, 20% had ALC >100x109, 35% had del(17p),
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and 24% had ≥1 node ≥10 cm. Median time on VEN was 31.9 w (0.6– 52.9)
for Arm A and 23.7 w (5.4–52.9) for Arm B. 8 in Arm A discontinued VEN (4 PD;
1 each respiratory failure, multi-organ failure, death of unknown cause, consent
withdrawal); 2 in Arm B (1 PD, 1 non-response). Efficacy in 48 evaluable pts is
shown in the Table 1. In the refractory subsets, 14/22 Arm A pts and 3/5 Arm B
pts achieved response. 8/27 pts who reached w24 were MRD-negative (10-4)
by flow cytometry in blood (all Arm A: 2 CR, 1 nPR, 4 PR, 1 SD).
Table 1.
Best response in evaluable* pts, n (%)               Arm An=38                    Arm Bn=10
ORR                                                                       23 (61)                           5 (50)
CR                                                                        3 (8)                                 0
PR/nPR                                                          19 (50)/1 (3)                     5 (50)/0
SD                                                                         10 (26)                           4 (40)
PD                                                                           1 (3)                             1 (10)
DC before assessment                                              4 (11)                                0
*3 in each arm are not yet evaluable
Safety was consistent with prior reports. AEs in >20% pts: neutropenia (48%),
diarrhea (37%), nausea (35%), anemia (32%), fatigue (24%), hyperphosphatemia
(20%). Grade 3/4 AEs >10%: neutropenia (39%), thrombocytopenia (22%), ane-
mia (20%), leukopenia (13%), pneumonia (13%). SAEs in ≥2 pts: pneumonia
(9%), febrile neutropenia (7%), increased potassium, multi-organ failure, septic
shock (4% each). 2 pts had laboratory TLS without clinical sequelae.
Summary/Conclusions: In CLL pts R/R to IBR or IDE, VEN monotherapy
showed promising activity, including MRD negativity at 24w, with acceptable
safety. This is the first prospective study to demonstrate efficacy in this poor
prognosis population. Follow-up will assess depth and duration of response.
Chronic myeloid leukemia - Biology
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Background: Although tyrosine kinase inhibitors (TKIs) have significantly
improved the prognosis of chronic myeloid leukemia (CML), the ability of TKIs to
eradicate CML remains uncertain and patients must continue TKI therapy for
indefinite periods. The BCR-ABL1 gene is a strong driver mutation in CML patho-
genesis, and there have been few reports of somatic mutational analysis in CML.
Aims: Our study objective is to identify somatic mutations in newly-diagnosed
chronic-phase of CML (CML-CP) patients who were registered in Japan adult
leukemia study group (JALSG) CML212 study by whole-exome sequensing
(WES).
Methods: The JALSG CML212 study is a multicenter prospective randomized
study to compare the cumulative achievement of CMR for adult de novo CML-
CP (UMIN Clinical Trials Registry, UMIN000007909). Patients were randomly
assigned to receive either dasatinib or nilotinib. Samples from the initial 24
patients enrolled in the study between May 2013 and Jan 2014 were analyzed.
Genomic DNA was extracted from PBMCs at the time of diagnosis. As a
germline control, DNA was obtained from buccal mucosal cells. Whole exome
capture was accomplished by liquid phase hybridization of sonicated genomic
DNA with a mean length of 150–200 bp for the bait cRNA library, which was
synthesized on magnetic beads. The captured targets were subjected to mas-
sive sequencing using HiSeq 2000 sequencing system with the pair end 100
bp read option. Copy number analysis was performed using DNAcopy, in which
the total number of reads covering each bait region and the allele frequency of
heterozygous SNPs detected by WES were used as input data. The mean
coverage of more than 95% of the target sequences was analyzed at an aver-
age depth of more than ×20. The mutations identified by WES were confirmed
by Sanger sequencing and deep sequencing. Single nucleotide variants (SNVs)
were extracted from WES as somatic mutations. All mutations were compared
with published SNP data. Known synonymous SNPs with p values ≥0.001 com-
pared with the valiant allele frequency (VAF) of peripheral blood leukocytes
and oral mucosa by the Fisher’s exact test were excluded from further analysis.
Correlations between the number of mutations and clinical factors were iden-
tified by the Pearson product-moment correlation coefficient using EZR soft-
ware. Gene ontology (GO) analysis was used to evaluate functional enrichment
in GO terms among mutated genes detected by WES.
Results: The median age of the patients was 55 years, 75% were male, and
the mean WBC count at diagnosis was 96000/μL. The median IS-BCR-ABL1
was 57%. 8.3% of patients had additional mutations besides translocation of
(9;22) that were detected by the G-band staining method. We identified 190
somatic mutations on 184 genes other than the BCR-ABL1 fusion gene (median
8, range 1-17). Summary of mutations were shown in Figure 1. TET2 or TET3,
AKT1, and RUNX1 were mutated in one patient each. Especially mutations in
epigenetic regulators, ASXL1, TET2, TET3, KDM1A and MSH6 were mutated
in 5 patients (21%). Two patients had mutations on ASXL1, both were loss of
function mutations and existed within exon 12. Other recurrent mutations were
identified in CLSTN2, COL7A1, CSMD2, and DYSF. By GO analysis, mutated
genes were mostly enriched with cell signaling and cell division pathways. DNA
copy number alterations revealed that 2 out of 24 patients had uniparental dis-
omy (UPD) in chromosomes 1p and 3q, respectively.
Summary/Conclusions: We identified mutations of TET2, TET3, ASXL1,
AKT1, RUNX1, and PRDM9, besides multiple novel recurrent mutations pre-
viously reported in association with hematological malignancies. Further analy-
ses such as the transition of these mutations by deep sequencing are required
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to elucidate associations with therapeutic responses or prognosis, and func-




ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML
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Background: Atypical chronic myeloid leukemia (aCML) is an haematological
neoplasm characterized by a median overall survival of 12.4 months. The stan-
dard treatments for aCML patients are chemotherapeutic drugs. However, these
treatments result inefficient in inducing remission from the pathology. Recently
we demonstrated that the haploinsufficiency of Morgana, an Hsp90 co-chap-
erone, in vivo is sufficient to induce a lethal and transplantable CML-like myeloid
neoplasm characterized by non recurrent cytogenetic abnormalities in the bone
marrow. Morgana is able to bind to and inhibit Rho-kinases, which are emerging
as key oncogenic players in haematological disorders
Aims: Identify fundamental altered pathways in aCML to uncover the biological
basis of the disease and find new therapeutical targets.
Methods: The bone marrow of morgana heterozygous mice and chronic
myeloid leukemia patients has been analyzed extensively by flow cytometry
and immunoistochemestry. Murine and human CML bone marrow cells and in
vitro cellular models (K562 and THP-1 cells) have been tested for sensitivity to
the ROCK inhibitor Fasudil. 
Results: We demonstrated that diseased morgana heterozygous mice show
ROCK hyperactivation in the bone marrow and that inhibition of these kinases
results in apoptosis of morganalow bone marrow leukemic cells without affecting
normal cells survival. Moreover, in THP-1 cells Morgana downregulation
enhances ROCK activity promoting cell proliferation while ROCK inhibition sig-
nificantly reduces the proliferation of these cells. Interestingly, we found that
the Morgana-ROCK pathway is altered in the 16% of Philadelphia-positive CML
patients where ROCK hyperactivation, cooperating with BCR-ABL signalling,
leads to imatinib resistance. In this context, treatment with a ROCK inhibitor
restores the efficacy of imatinib to induce apoptosis. In addition, we found Mor-
gana downregulation and ROCK hyperactivation in the bone marrow of all
aCML patients we tested. 
Summary/Conclusions: Taken together these results point out Morgana as
an oncosuppressor and ROCK as potential therapeutical target for Morganalow
CML patients. 
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Background: The introduction of specific BCR-ABL tyrosine kinase (TK)
inhibitors, especially imatinib mesylate (Gleevec), revolutionized the clinical
treatment of Chronic Myeloid Leukemia (CML). However, in many cases stable
remission cannot be sustained through several escaping mechanisms, such
as mutations in the ABL-kinase (e.g. T315I & M351T). These insights raise an
urgent need to develop alternative treatment strategies. An attractive approach
is targeting Heat Shock Protein 90 (Hsp90), which acts as a molecular chap-
erone and facilitates the folding of several oncogenic proteins including, BCR-
ABL.FDA approved Hsp90 inhibitors are available and show anti tumor activity
but to the best of our knowledge they all target the N terminal domain of Hsp90
and initiate heat shock response (HSR) with severe side effects (Wang &
McAlpine, 2015). Thus C-terminal Hsp90 inhibition can be an attractive
approach in targeting Imatinib resistant CML with low toxicity. We have identified
hotspots in the C-terminal domain of Hsp90 (Ciglia et al., 2014) and designed
several non-peptidic inhibitors, which target Hsp90’s C-terminal dimerization.
Aims: Generation and characterization of novel compounds targeting C termi-
nal dimerization of Hsp90 in vitro and in vivo.
Methods: The specificity of selected inhibitor (DDK88) to Hsp90 was deter-
mined by Hsp90 dependent luciferase refolding assay followed by efficacy
experiments using imatinib sensitive and resistant myeloid leukemic cell lines
in vitro as well as in in vivo Xenograft model.
Results: In the present study, we have extensively characterized a novel and
promising therapeutic compound (DDK88) for patients with Imatinib resistant
CML in vitro and in vivo. DDK88 exhibits anti-proliferative and cytotoxic activity
in several human myeloid leukemic cell line models (e.g. K562 - 5.72±0.31µM,
KCL-22 - 2.74±0.52µM) and induces cell cycle arrest, early differentiation and
inhibits colony formation. DDK88 disrupts Hsp90’s chaperone activity to BCR-
ABL protein. Hence in vitro application of DDK88 revealed down regulation of
BCR-ABL protein expression and its downstream signaling network including,
STAT5a, CRKL, AKT and mTOR proteins. Moreover, imatinib resistant CML
cell lines are equally sensitive to DDK88 (e.g. K-562r - 6.24±0.52 µM, KCL-22r
- 2.86±0.63µM) as compared to imatinib sensitive cells. In the same way,
DDK88 inhibits proliferation and BCR-ABL kinase activity of 3 clinically relevant
imatinib-resistant (~10 µM) BCR-ABL mutant (T315I, M351T & E255K - ~3µM)
cell lines. Notably, unlike clinical inhibitors targeting N-terminal (e.g. AUY922),
DDK88 does not induce HSR, evaluated by protein expression of HSF-1,
Hsp70, Hsp40 and Hsp27. DDK88 has a therapeutic window as its inhibitory
effects on healthy cord blood (CB) derived mononuclear cells (MNCs) and
CD34+ cells were significantly less potent as compared to the human leukemic
cell lines. Furthermore, in-vivo proof of concept studies demonstrate the efficacy
of DDK88 at 0.5 mg/kg in a K-562-Luciferase Xenograft tumor model. DDK88
reduced tumor burden with respect to tumor weight (DDK88 0.2±0.01g vs vehi-
cle 1.26±0.44g (p=0.04)). Immunoblot analysis of tumor samples derived from
DDK88 treated mice revealed the absence of HSR as well as downregulation
of BCR-ABL kinase activity and its associated downstream signaling pathways.
Summary/Conclusions: This study provides in vitro and in vivo characteriza-
tion of a novel anti-Hsp90 compound, which is specific against its C-terminus.
Hence further improvement and testing of DDK88 in pre-clinical studies can be
a promising strategy to target imatinib resistant CML and to avoid HSR.
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Background: Treatment of chronic myelogenous leukemia (CML) with BCR-
ABL tyrosine kinase inhibitors (TKI) achieves high rates of molecular response.
However, BCR-ABL-positive leukemic stem and progenitor cells persist implying
the need for lifelong treatment. Bone marrow stroma plays an important role in
inhibiting apoptosis. Cytokines such as interleukin 3 (IL-3) and
granulocyte/macrophage-colony stimulating factor (GM-CSF) mediate BCR-
ABL-independent survival of progenitor cells via common receptor subunit
CSF2RB. Disruption of the CSF2RB axis by the Janus kinase1/2-inhibitor rux-
olitinib overcomes cytokine-mediated resistance in vitro. We previously demon-
strated upregulation of CSF2RB in BCR-ABL-transformed cells as potential
resistance mechanism, and now provide an indepth molecular and functional
analysis.
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Aims: The aim of this study was to examine the functional and biological rel-
evance of CSF2RB upregulation in BCR-ABL positive leukemia cells in
response to TKI treatment as mechanism by which IL-3 and GM-CSF induce
TKI resistance. 
Methods: Human M07p210 cells were used to study the functional relevance
of CSF2RB-mediated rescue of TKI-treated leukemia cells by siRNA-mediated
knockdown of CSF2RB. Cell proliferation and viability of BCR-ABL positive
CML CD34+ progenitor cells under the influence of nilotinib/ dasatinib and rux-
olitinib were analyzed in vitro. Expression of CSF2RB in M07p210 cells and
BCR-ABL positive CML CD34+ progenitor cells in response to nilotinib and
dasatinib was examined by western blot and RT-PCR. Bone marrow samples
harvested at 3 months on nilotinib therapy were used to study CSF2RB regu-
lation in CML-patients with defined levels of molecular response.
Results: In M07p210 cells and CML CD34+ progenitor cells, BCR-ABL inhibi-
tion with TKIs induces significant upregulation of CSF2RB on protein and
mRNA-level. Moreover, cytokines exert distinct survival signals including STAT5
activation, despite effective BCR-ABL-inhibition in the presence of nilotinib.
Furthermore, selective knockdown of CSF2RB prevents cytokine-mediated cell
survival in nilotinib-treated M07p210 cells. Combination treatment of M07p210
and treatment naïve CML CD34+ progenitor cells with nilotinib/ dasatinib and
ruxolitinib overcomes cytokine-mediated tyrosine kinase inhibitor resistance
as demonstrated by additive growth inhibition in the presence of GM-CSF. Nor-
mal progenitors remain unaffected indicating differential activity. In colony
assays with treatment naïve CML progenitors, combined application of nilotinib/
dasatinib and ruxolitinib significantly diminished granulocyte-monocyte and
erythroid colony formation in the presence of rescuing cytokines. In picked pro-
genitor colonies, mRNA-upregulation of CSF2RB was observed in 2 of 7 nilo-
tinib-treated patient samples. Interestingly, marked upregulation of CSF2RB
was also seen in 2/7 samples exposed to combined treatment. In contrast,
total leukocytes from bone marrow harvested at 3 months after start of nilotinib
treatment in 8 patients shows unidirectional upregulation of CSF2RB mRNA
independently of the molecular response.
Summary/Conclusions: CSF2RB is upregulated in response to nilotinib and
dasatinib in vitro, and in clinical samples derived from nilotinib treated patients.
Marked individual variations of CSF2RB expression in correlation to clinical
outcome can be observed in bone marrow mononuclear progenitors indicating
patient specific cell intrinsic regulation of CSF2RB. In contrast, consistent
CSF2RB upregulation in total bone marrow lysates confirms the bone marrow
cytokine-response counteracting nilotinib treatment most likely governed by
the bone marrow stroma. Efficacy and tolerability of combined BCR-ABL/
Jak1/2-inhibtion with ruxolitinib and nilotinib to target persistent stem cells is
currently investigated in clinical trial NCT02253277.
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Background: Genomic instability in chronic myeloid leukaemia (CML) is report-
ed to be associated with increased reactive oxygen species (ROS). The mito-
chondrial (mt) genome is susceptible to ROS-induced mutations due to oxidative
stress in the mitochondrion and limited DNA repair mechanisms. MtDNA is pres-
ent in multiple copies per cell: homoplasmy indicates that all mtDNA copies in
a cell are identical, whereas coexistence of variant and wild type is referred to
as heteroplasmy. Significant variations in treatment outcome occur despite all
CML patients having the BCR-ABL1 fusion gene. We hypothesized that mtDNA
mutations might reflect high mutational stress and an adverse prognosis. 
Aims: To determine the landscape of somatic mtDNA mutations in CML, and
to determine whether mt mutations are due to oxidative stress.
Methods: The whole mt genome was amplified in two overlapping fragments,
pooled in equimolar concentrations and sent for next generation sequencing.
We studied 27 CML patients at diagnosis (Dx) and follow-up (FU) after 12
months of therapy in the ALLG CML9 trial using up-front imatinib, with selective
switching to nilotinib for sub-optimal molecular response. Patients were select-
ed as good (n=15) or poor (n=12) responders based on achievement of major
molecular response (BCR-ABL1IS ≤0.1%) at 12 months. Mesenchymal stem
cells or hair follicles were used to exclude germline polymorphisms. Compari-
son of technical duplicates was used to establish a 2% cut-off to distinguish
mutations from background sequencing errors.
Results: No indels were found. We identified 73 somatic point mutations in
14/15 (93%) good responder patients, and 14 somatic mutations in 9/12 (75%)
poor responder patients at Dx. Mutations were distributed across the mt
genome with no evident hotspots. The distribution did not differ between good
and poor responders, and did not show the excess of G>T transversions that
is considered characteristic of ROS-induced damage. The number of somatic
mutations per patient was higher in good responders (1-18 per patient; mean
4.87) than in poor responders (mean 4.87 vs 1.17 per patient; p=0.0115) (Figure
1A). There was no correlation between Sokal or EUTOS score and the number
of mutations. All somatic mutations at Dx were heteroplasmic, with the excep-
tion of one patient carrying 10/18 homoplasmic mutations. No difference in the
allele frequency (AF) of mutations was found between good (2.1% -90.8%;
mean 22.1%) and poor responders (3.7%>74.6%; mean 26.4%) (Figure 1B).
Most (85/87) mutations found at diagnosis reverted to homoplasmy in FU sam-
ples. Only two patients had mutations showing persistent heteroplasmy with a
change in the AF. New heteroplasmic mutations were identified in FU samples
in 7/15 (47%) good responder patients, and in 5/12 (42%) poor responders.
The AF of mutations at FU was lower than at Dx (2.1%>40.3%, mean 6.5%;)
(Fig 1B), but was higher than the estimated level of the residual CML clone
(BCR-ABLIS 0%>2.7%; mean 0.46%).
Figure 1.
Summary/Conclusions: MtDNA mutations are common in CML, and identify
clonal diversity both at diagnosis and after imatinib treatment. The pattern of
mtDNA mutations was not consistent with ROS-mediated damage. The pres-
ence of mt mutations was not associated with clinical risk score and had no
prognostic effect. Most mutations found at diagnosis were undetectable at fol-
low-up, consistent with molecular response of the CML clone, but the emer-
gence of heteroplasmy in follow-up might indicate the presence of a non-CML
haematopoietic clone in some patients.
P605
CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN
MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA
D Karamitros1,*, H Morrison2, R Kinstrie2, N Goardon1, RE Clark3, M Copland2,
P Vyas1
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Background: Chronic myeloid leukaemia (CML) is a model of the multistep
processes in cancer. In myeloid malignancies initiating mutation originates in
a haemopoietic stem cell (HSC) to give rise to pre-leukaemic stem cell popu-
lations. After blast transformation, multiple leukemic stem cell (LSC) populations
can be identified. We have shown that CD34+LSC populations were most
closely related to normal progenitor populations but had shared elements of a
normal stem cell expression signature1. In chronic phase (CP)-CML, the
leukaemia-propagating population is the HSC, and the progenitor subpopula-
tions do not have stem cell characteristics. Studies to isolate LSC populations
in BP-CML have been limited, identifying the granulocyte-macrophage progen-
itor subpopulation as a possible LSC source2. Moreover while CP-CML is
dependent on BCR-ABL, the mutations and additional cytogenetic abnormali-
ties underlying disease progression are poorly annotated.
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Aims: In this study we aim to: i)Identify changes in size of immunophenotypic
(IP) compartments in the progression from CP to BP-CML, ii)characterize which
haemopoietic stem/progenitor cell (HSPC) subpopulations of BP-CML patients
contain LSCs iii)understand the clonal structures associated with disease pro-
gression.
Methods: We have performed extensive IP analysis of 14 AP-CML, 4 CP-CML
and 11 BP-CML patients and compared the various HSPCs compartments to
normal bone marrow (BM) (N=3). Furthermore we purified HSPC-like popula-
tions from 5 BP-CML patient samples and performed in vivo xenograft studies
using NSG mice with serial transplantation to identify populations with LSC
potential. Finally multicolor FISH analysis was performed in 3 patient samples
and in engrafted human cells from primary and secondary murine recipients.
Results: Our data conclusively demonstrate that functional LSCs are present
in multiple stem/progenitors populations in myeloid BP-CML,. We have
described the clonal structures in the samples of 3 patients. Sequential acqui-
sition of 17p13 loss or of 17p13loss and isochromosome 17 was seen in patient
samples. More complex clonal structures, with the presence of subclonal atyp-
ical BCR-ABL and 17p13loss were detected after transplantation in NSG mice.
The monitoring of clonal structures in a patient with 2 sequential samples sug-
gested that the clonal architecture is dynamic and can change with progression
of the disease. 
Summary/Conclusions: Our results demonstrate that myeloid BP-CML is a
heterogeneous disorder with variable LSC populations. Further interrogation
of these populations and of clonal hierarchy will identify novel therapeutic tar-
gets of LSC populations.
DK and HM are joint first authors, MC and PV are joint senior authors
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Background: Aurora Kinase (AK) A has a pivotal role in chronic myeloid
leukemia (CML) genomic instability. Its constitutive activation associated with
the BCR-ABL1 TK activity promotes the progression of mitosis irrespective of
the integrity of replicated DNA. Published studies have proven the therapeutic
advantage of AK inhibitors in CML patients either responsive or resistant to
imatinib (IM). Such AK inhibitors potential has been ascribed to their inhibitory
activity on p210 TK activity. 
Aims: In this study, we have focused on the specificity and mechanisms of
action of AKs and Plk inhibitors in the putative LSC compartment (CD34+). 
Methods: The CD34+ hematopoietic cell fraction was investigated for the phos-
phorylation levels of AKA and other pro-survival components of its signalling
pathways: - FoxM1, a proliferation-associated transcription factor implicated in
the advantage of clonal hematopoiesis over the normal counterpart, particularly
in the leukemic stem cell (LSC) compartment, which is not dependent on BCR-
ABL1 tyrosine kinase (TK) for proliferation and survival; - Polo-like kinase 1
(Plk1), a ser-thr kinase involved in M/G1 progression. CD34+ cells were isolated
from bone marrow samples of 10 CML patients at clinical diagnosis by means
of immuno-magnetic selection (miniMACS from Miltenyi Biotec). CD34+ cells
from peripheral blood of healthy donors, pooled to avoid individual differences
were used as normal controls. Informed consent was obtained from all the
patients. RT-PCR (reverse transcriptase-polymerase chain reaction), WB (west-
ern blotting), IP/IB (immunoprecipitation and immunoblotting) were used to
investigate gene expression and protein interactions.
Results: Our results proved a FoxM1 increment associated with IM resistance.
An IM-resistant K562 cell line (LD50 0.37 microM vs 0.026 microM of parental
cells) generated in our lab exhibited FoxM1 over-expression and hyper-phos-
phorylation contingent upon the upstream activation of AKA and Plk1. In fact,
in IM-resistant K562 cells, both Plk1 inhibition by volasertib (1microM) and AKs
inhibition by danusertib (1microM), activated a significant increment of apoptotic
cell death compared to parental cell line. AKA, FoxM1 and Plk1 involvement in
IM resistance was confirmed in mononuclear cell fraction from bone marrow
samples of 3 CML patients who developed IM resistance independent from
BCR-ABL1 point mutations. Interestingly, the putative BCR-ABL1+/CD34+ LSC
compartment, which is neither dependent on BCR-ABL1 TK for proliferation
and survival nor killed by IM and second generation inhibitors, showed a hyper-
phosphorylation of AKA and a consequent overexpression and hyper-activation
of FoxM1 and Plk1. Moreover, clonogenic assays performed by using CD34+
progenitors from 3 CML patients at diagnosis showed that volasertib and
danusertib are capable to reduce the clonogenic potential of the CD34+ com-
partment to a much greater extent compared to 1st and 2nd generation TKIs
(see Table 1). 
Table 1.
LD50                                         PT1                        PT2                        PT3
IMATINIB                                 0.255 M                0.374 M                0.472 M
NILOTINIB                                0.197 M                0.277 M                0.324 M
DASATINIB                               0.269 M                0.311 M                0.295 M
VOLASERTIB                            0.112 M                0.093 M                0.162 M
DANUSERTIB                           0.098 M                0.084 M                0.073 M
Summary/Conclusions: The BCR-ABL1+/CD34+ compartment provides a
sanctuary for disease relapse upon drug withdrawal as well as a putative source
of drug-resistance. We have identified a new signaling pathway involved both
in drug resistance and in CD34+ cell survival. Our data open the route to novel
therapeutic approaches worth exploring in order to overcome drug resistance.
Danusertib and volasertib are in clinical trials in hematologic malignancies.
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PRESENCE OF SOMATIC AND GERMLINE MUTATIONS IN EPIGENETIC
MODIFIERS IN CML-CP
G Nteliopoulos*, A Bazeos, G Gerrard, M Alikian, HE Foong, L Foroni, JF Apperley
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Background: Chronic myeloid leukaemia (CML) originates from a single genet-
ic aberration (BCR-ABL1); however the clinical disease is remarkably hetero-
geneous and the genetic mechanisms of resistance to tyrosine kinase inhibitors
(TKI) are still poorly understood. Recently, we have identified consistent differ-
ences in genome-wide DNA methylation patterns in chronic phase (CP) CML
patients compared to healthy controls, whireas epigenetic modifying enzymes
have been found frequently mutated in other haematological neoplasms.
Aims: The aim of this study is to analyse a panel of mutations in epigenetic
modifiers in CML-CP using Ion Torrent PGM next-generation sequencing. The
panel design was based on gene expression analysis we generated and liter-
ature search. Potential mutations found at diagnosis may be used as novel
prognostic biomarkers for TKI response.
Methods: 52 samples from untreated patients with newly diagnosed CML-CP
(CD34+) who started on imatinib were included in the study, classified as
responders (n=26) /non-responders (n=26) based on BCR-ABL1/ABL ratio at
3 months. As constitutional non-leukaemic DNA, for non-responders we used
DNA from T cells, cultured in vitro for 7 days, and for responders DNA from the
patients in deep molecular remission (whole blood). 14 samples from healthy
donors (CD34+) and 5 samples from CML-BC (blast crisis) were also used. A
custom panel covering the coding region of 71 epigenetic enzymes was
designed.
Results: A mean depth of 273/amplicon was obtained, detecting mutations as
low as 4%. After excluding “bad” variants of low quality, common SNPs with
minor allele frequency (maf) >1%, variants found in healthy controls and intronic
variants, we kept the non-synonymous variants predicted disease causing,
deleterious and damaging by Mutation Taster, PolyPhen-2 and SIFT respec-
tively, and found 104 variants in 46/71 of the genes. However, when constitu-
tional DNA was used as non leukaemic control, we found that only 35 were
CML-related somatic mutations, including missense, nonsense, frameshift/non-
frameshift insertions and splice site variants, present in 25 genes. 26 mutations
were found in non-responders (NR), 13 in responders (R). Interestingly all non-
sense variants (in ASXL1, IKZF1, DNMT3A, EP300) and most insertions (in
ASXL1, WT1), were found only in non-responders. Similarly, nonsense muta-
tions in ASXL1 and IKZF1 were found in 2 CML-BC patients. The frequency of
the mutated allele for most mutations was <10%. Mutations were detected in
the R and NR group in equal proportion (11/26 patients), however, the presence
of ≥2 mutations was more common in NR. In addition, we examined the corre-
lation of presence of mutations with gene expression, detecting a correlation in
some cases, and their influence on overall survival (OS), finding an influence,
especially in the non-responders, more prominent when there were ≥2 muta-
tions. Moreover, we found 69 missense variants that were also present in the
constitutional DNA, with frequency of the mutated allele ~50%, considered as
germline mutations. These variants were present in 32 genes with 39 and 34
variants in NR and R respectively, while there was no difference in the number
of R, NR that carried at least one mutation (both groups 20/26 patients). Specific
variants in RUNX1, TET1, TET2 were found in ≥3 patients.
Summary/Conclusions: The mutation analysis of epigenetic modifiers in CML-
CP identified the presence of somatic mutations, some of which (found only in
NR) can be considered as predictive biomarkers for IM failure, and germline
mutations that may predispose to CML.
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Background: Assessment and monitoring of BCR-ABL1 levels by quantita-
tive PCR (qPCR) is essential for the management of CML patients treated
with TKIs. Currently, up to 30-40% of CML patients treated with TKIs can
achieve a deep molecular response (DMR: BCR-ABL1 ≤0,01% IS), but only
50% maintain a stable Treatment Free Remission (TFR) after discontinuation
of TKIs therapy. qPCR has some intrinsic limitations and it does not appear
to be an optimal assay to select the best candidates to TKIs discontinuation.
Digital PCR (dPCR) can give an absolute quantification of target nucleic acids
by partitioning the PCR reaction mix over a large number of wells, each con-
taining a single copy or no copies of the target region. The number of target
copies originally present in the sample can be calculated from the number of
partitions in which amplification has successfully occurred. The dPCR is
expected to give a better sensitivity and accuracy than qPCR in the assess-
ment of molecular Minimal Residual Disease (MRD) in CML patients treated
with TKIs.
Aims: The aim was to quantify the BCR-ABL1 transcript levels by dPCR in
116 CML patients treated with TKIs (imatinib, nilotinib or dasatinib) and
achieving a major molecular response (MMR or MR3.0) or DMR (MR4.0,
MR4.5and MR5.0). The results obtained by dPCR were compared with the
ones obtained by qPCR.
Methods: The dPCR was performed on a QuantStudio 3D Digital PCR Sys-
tem (Life Technologies) by using a TaqMan-MGB probes targeting the BCR-
ABL1 transcript. The absolute quantities of BCR-ABL1 transcript were
expressed as number of copies/ul. Samples for dPCR testing were obtained
from CML patients treated with TKIs, on time-checks planned for MRD mon-
itoring by standard qPCR performed according to the last International Guide-
lines. The analysis by dPCR and qPCR were performed on 33 cases with
stable MR3.0, 37 cases with stable MR4.0, 34 cases with stable MR4.5, 12
cases with stable MR5.0. Blank samples served as negative controls, while
10 healthy donors served as normal controls. Patients enrolled in the study
gave informed consent.
Results: In patients with MR3.0 the number of BCR-ABL1 copies/ul assessed
by dPCR were significantly higher than those of patients with MR4.0 (0.0002),
MR4.5 (p<0.0001) or MR5.0 (p<0.0001). BCR-ABL1 transcript levels were
detectable by dPCR also in cases (n°=43) resulted undetectable by qPCR.
No linear correlation was found between the BCR-ABL1 copies/ul assessed
by dPCR and the values of BCR-ABL1/ABL1% IS (R=0.196) or the absolute
copy number of BCR-ABL1 transcripts assessed by qPCR (R=0.184). How-
ever, a case by case analysis revealed a linear correlation (R=0.729) only
for the cases with an absolute copy number of BCR-ABL1 transcript >15
assessed by qPCR. One-way ANOVA test revealed a correlation between
dPCR BCR-ABL1 levels and the MR3.0class only. The 84% of deep respon-
ders fell under the value of 0.468 BCR-ABL1 copies/ul indicated by the ROC
analysis as the value below which the patients with lower levels of MRD
might be dissected (specificity=63.64%, sensitivity=84.34%; AUC=0,847).
Summary/Conclusions: The study suggests that dPCR is more accurate
and sensitive than qPCR especially in the patients with DMR and currently
we are conducting a systematic monitoring of MR by dPCR to evaluate its
reliability. Larger and prospective studies are warranted to confirm the higher
sensitivity and accuracy of dPCR and its usefulness to better select the can-
didates for TFR.
Acknowledgments: This work was supported in part by EuropeanLeukemiaNet
(ELN) - European Treatment and Outcome Study (EUTOS) and by Cofin 2009.
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MOLECULAR RESPONSES OF B2A2 BCR-ABL1 TRANSCRIPT ARE
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MC Wang1,*, MC Kuo2,3, TY Chen4, Y Yang5, SP Yeh6, CC Chen7, YC Su8,
PC Hsiao9, MY Lee10, WL Hwang5, CY Kuo1, TH Lin2, LY Shih2,3
1Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, 2Chang Gung
Memorial Hospital at Linkou, 3Chang Gung University, Taoyuan, 4National
Cheng Kung University Hospital, Tainan, 5Taichung Veterans General Hospital,
6China Medical University Hospital, Taichung, 7Chang Gung Memorial Hospital
at Chaiyi, 8Buddhist Dalin Tzu Chi General Hospital, Chaiyi, 9Chung Shan
Medical University Hospital, Taichung, 10Chia-Yi Christian Hospital, Chaiyi, Tai-
wan, ROC
Background: b3a2 (e14a2) and b2a2 (e13a2) are the two major BCR-ABL1
transcripts in CML. The prognostic relevance of the two transcript subtypes
after frontline therapy with tyrosine kinase inhibitor is unclear.
Aims: We aimed to determine the impact of the two BCR-ABL1subtypes on
outcome of CML patients following frontline imatinib therapy.
Methods: BCR-ABL1 transcript subtype was determined in 655 newly diag-
nosed CML-CP patients enrolled in Taiwan CML Study from Jun-2004 to March-
2014. The frequencies of transcript subtypes were 62.4% (n=409) for b3a2,
34.5% (n=226) for b2a2, 1.8% (n=12) for both b3a2 and b2a2, and 1.3% (n=8)
for other rare types. The BCR-ABL1 levels expressed as International scale
(IS) were measured in a central laboratory every 3 months following frontline
imatinib 400mg/d. A comparison of the molecular responses and outcome of
patients between b3a2 and b2a2 transcript subtypes was made.
Results: Of the 635 patients with b3a2 and b2a2 transcripts, there was no dif-
ference in age, gender, WBC count, circulating blast percentage, platelet count,
or Sokal risk score between the two subtypes. At 3 months, BCR-ABL1 IS
≤10% was achieved in 49% of b3a2 patients compared with 42% of b2a2 type
(P=0.114). At 6 months, 19% of b3a2 patients had BCR-ABL1 IS >10% com-
pared with 37% of b2a2 (P <0.0001). At 12 months, 35% of b3a2 type had
BCR-ABL1 IS >1% compared with 46% of b2a2 patients (P=0.027). Patients
with b2a2 transcripts had a slower rate of decline as compared with that of
b3a2 transcripts over the time from 3 months to 7 years after imatinib treatment.
The cumulative incidence of MMR at 2 years in b3a2 and b2a2 patients were
55.6% and 38.2%, respectively (P <0.0001); at 4 years was 71.2% for b3a2
and 59.2% for b2a2 (P <0.0001). The cumulative incidence of MR4.5at 4 years
was 28% and 26.7% for b3a2 and b2a2, respectively (P=0.323); at 6 years
was 42.2% for b3a2 and 41.5% for b2a2 (P=0.323). The median time to MMR
was not different between patients carrying the two transcript types, 14.4
months for b3a2 and 15.5 months for b2a2 (P=0.659). The median time to
MR4.5for b3a2 was 32.6 months and 34.1 months for b2a2 patients (P=0.994).
With a median follow-up of 49.3 months, 30 (4.7%) patients had disease pro-
gression, accelerated phase (n=13) and blast crisis (n=17; 10 myeloid and 7
lymphoid). There was no difference in the occurrence of disease progression
between the two transcript subtypes (3.7% for b3a2 and 6.6% for b2a2,
P=0.117). Lymphoid-blast phase was highly associated with b2a2 transcript
(6/7) compared to b3a2 type (1/7) (P=0.010). The overall survival at 10 years
for b3a2 and b2a2 transcripts were 94.0% and 93.9%, respectively (P=0.635).
The progression-free survival at 10 years was 92.7% for b3a2 and 87.9% for
b2a2 patients (P=0.089).
Summary/Conclusions: Taiwan CML Study demonstrated that patients with
b2a2 transcripts had significant higher failure rates at 6 and 12 months, a lower
cumulative incidence of MMR by 2 and 4 years, a higher frequency of lymphoid
crisis and a trend of inferior progression-free survival as compared to those
with b3a2 patients.
Grant support: XMRPG1A0085 and OMRPG3C0021.
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Background: Dasatinib (DAS) has shown superiority over imatinib in achieving
cytogenetic and molecular responses in chronic phase (CP) CML but with a
different toxicity profile, which may impact on its overall benefit. Reported tox-
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icities from the DASISION trial at 5 years include pleural effusions (PE) (29%),
pulmonary hypertension (PHTN) (5%), and low rates of arterial ischemic events.
While the literature well describes the incidence of these events, the response
to therapy and the impact of subsequent dose modifications on the outcome of
the toxicity have generally not been comprehensively characterised.
Aims: To review the incidence of these side-effects in a snapshot survey of
Australian patients (pts) receiving DAS, either as first or subsequent line of
therapy for CML-CP, with a focus on risk factors and the response of the toxicity
to therapeutic changes.
Methods: Retrospective study of all eligible pts (received DAS for CML-CP
and access to sufficient data) at 17 Australian institutions. Each pt’s history
was tracked in detail to identify any complications potentially attributable to
DAS, and the treatment and outcome of these complications in response to
cessation or alterations in DAS dose or schedule.
Results: 221 pts were evaluable, with a median age at DAS commencement
of 53 years (range 20 – 86) and median starting dose of 100mg (20-140). 51
(23%) received DAS as 1st line therapy, 133 (60%) 2nd line and 37 (17%) 3rd
line. The median follow up from DAS commencement was 27 months (4 –116
months). No side effects were reported in 105 (48%) pts. Of the 116 (52%) pts
with side-effects, the most common side effect was PE, observed in 53 (24%)
pts with a median age of 65 years (41-86 years) and with median time to onset
of 11 months (0.5-59 months). Most (40 pts, 76%) were receiving DAS as 2nd
line therapy. DAS dose at PE onset was 100mg in 37 pts (70%), 140mg in 9
pts (17% PEs; notably 38% of pts on this dose developed PE), 70mg in 4 pts,
80mg in 2 pts and 50mg in 2 pts. The Figure 1 documents outcomes in pts with
PE at 100mg dose with the key findings being a very high risk of recurrence in
the absence of dose reduction and a substantial risk despite dose modifications.
Evaluation of the CML status in these patients 6 months after changes in DAS
dose and schedule is currently underway. Additional management of PE includ-
ed diuretics (79%), thoracocentesis (43%), and steroids (47%). Only 1 of 7 pts
given maintenance low dose steroids developed recurrence. Other side-effects
included Grade 3-4 haemorrhage in 8 pts (4%), 3 of whom had platelets <50
x109/L and fatal intracerebral haemorrhage in a pt with a normal count. Ten
(5%) pts had elevated pulmonary artery pressures meeting criteria for PHTN
(RVSP >36mmHg) [median DAS dose 100mg (100-140)]; all described dysp-
noea, although notably 8 had either concurrent PE or developed PE within 6
months. Of 5 PHTN pts with available follow up data, RVSP normalised in 4
post DAS cessation. The two episodes of peripheral vascular disease requiring
intervention occurred in pts previously treated with nilotininb. There were no
atypical infections apart from one pt with an empyema. Two pts had benign
cervical lymphadenopathy. There were no deaths clearly attributable to DAS.
Side-effects led to permanent DAS cessation in 51 pts (23%).
Figure 1.
Summary/Conclusions: The incidence of common DAS side effects (PE, PHTN)
were similar to those seen in the DASISION study. Other side-effects were uncom-
mon. Age and dose were risk factors for PE. In pts with PE on 100mg, recurrence
was very high in the absence of dose reduction, and was still high despite reduc-
tion but appeared to be reduced by maintenance low dose steroids. These find-
ings support the results of Porrini (ASH 2011) who found DAS at lower doses is
effective in the elderly. With dosing appropriate for age, possibly supported by
titration according to DAS levels and molecular response, severe side effects of
DAS requiring permanent drug cessation are likely to be rare.
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THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE
CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN
PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA
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Background: Drug transporters, such as hOCT1 (SLC22A1) and ABC mem-
bers (ABCB1, ABCG2), have been already shown to play a role in both intra-
cellular and systemic plasma concentrations of imatinib. In particular, our group
showed that the hOCT1 c.480C>G polymorphism conditions higher rates of
adverse events and shorter EFS. Analogously, the ABCB1 polymorphisms have
been related to a worse prognosis, but the item is still debated. 
Aims: Here we address imatinib pharmacodynamics through a mathematical
analysis based on patient’s pharmacogenetic data and gender. All analyses
were conducted in the context of the TIKlet protocol (ClinicalTrials.gov code:
NCT01860456).
Methods: Fifty-three CML patients receiving imatinib, 30 males and 23 females,
were enrolled at the Hematology Unit of Pisa and at the Department of Internal
Medicine of Orbassano (TO), Italy. The following polymorphisms were
assessed: rs72552763 [MI420I], rs12208357 [c.181C>T] and rs683369
[c.480C>G] (hOCT1), rs1128503 [c.1236C>T], rs2032582 [c.2677G>T/A] and
rs1045642 [c.3435C>T] (ABCB1), rs4149117 [c.334G>T] (SLCO1B3). Patients
were grouped according to the absence (wild-type) or the presence (heterozy-
gous or polymorphic homozygous) of at least one polymorphic allele. 
Results: We found that the complete cytogenetic response was in strong rela-
tionship with combinations of hOCT1 [c.480C>G] and ABCB1 [c.3435C>T] poly-
morphisms. Indeed, genotypes identical for both loci (i.e., wild/wild or polymor-
phic/polymorphic) exhibited a longer time to CCyR than those with mixed types
(wild/polymorphic or polymorphic/wild), p-value=0.013. Since the drug tolerability
has a strong incidence on the discontinuation of the therapy, we studied also
whether the onset of toxicities was related to any of the considered variables.
Interestingly, the same combinations of hOCT1 [c.480C>G] and ABCB1
[c.3435C>T] polymorphisms found related to efficacy were found associated
with the maximum grade of toxicity as well, p-value=0.022. In particular, patients
with mixed hOCT1 c.480C>G and ABCB1 c.3435C>T genotypes displayed high-
er levels of toxicity. As ancillary investigation we studied also the time to the
onset of the main toxic effects and we found that the time of manifestation of the
cramp toxicity was shorter in females than in males (5.3 vs 22.6 months) and
the time to manifestation of the edema toxicity was associated with a combination
between gender and ABCB1 c.3435C>T (2.5 vs 16.4 months).
Summary/Conclusions: To the best of our knowledge this study sheds a first
light on the possible role of the combination between hOCT1 [c.480C>G] and
[ABCB1 c.3435C>T] polymorphisms as predictor of both efficacy and toxicity
of the imatinib treatment. 
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Background: Use of 2nd generation tyrosine kinase inhibitors (2G-TKIs) dasa-
tinib (DAS) and nilotinib (NIL) in chronic phase (CP) chronic myeloid leukemia
(CML) patients failing imatinib (IM) result in around 50% of sustained cytoge-
netic response. However, it’s unclear if there’s a significant difference in efficacy
of the two 2G-TKIs, especially in the long-term.
Aims: To compare efficacy of DAS and NIL in CP-CML patients after IM resist-
ance or intolerance.
Methods: We retrospectively analysed 163 CP-CML patients resistant or intol-
erant to IM that received either DAS (n=95) or NIL (n=68) as second-line therapy.
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We compared the characteristics of the two groups at the time of CML diagnosis
and at the time of IM failure, including the cause of switch to 2G-TKI, duration
of IM therapy, IM dose escalation and Hammersmith score to predict the prob-
ability of response to 2G-TKIs. Cytogenetic and molecular responses were eval-
uated according to the ELN recommendations. Time to treatment failure (TTF)
was calculated from the start of 2G-TKI to any of the followings: progression to
accelerated or blastic phase (ABP), death for any cause at any time, treatment
discontinuation for primary or secondary resistance or intolerance. Progression
free survival (PFS) was calculated from the start of 2G-TKI to ABP or death.
Overall survival (OS) was calculated from the start of 2G-TKI to death.
Results: Considering CML characteristic at diagnosis, the DAS and NIL
cohorts were comparable for age, sex and risk score (Sokal and EUTOS).
Median duration of IM therapy was similar (DAS 19 months, NIL 14 months),
but 27/95 patients (28%) had IM dose escalation before DAS compared to
only 9/68 (13%) before NIL (p=0.03). There was a higher rate of switch to
DAS than to NIL for secondary resistance (26/95, 27% vs 7/68, 10%; p=0.01)
while more patients changed from IM to NIL due to intolerance (31/68, 46%,
vs 21/95, 22% for DAS; p=0.002). Rates of primary resistance did not differ
(47/95, 49% for DAS vs 28/68, 41% for NIL; p=0.37), as other causes of switch
(1/95, 1% for DAS vs 2/68, 3% for NIL; p=0.77). Hammersmith score was
almost identical in the two groups. Complete cytogenetic response (CCyR)
was attained in 53/73 (73%) patients not in CCyR at the time of DAS start,
compared to 31/48 (65%) patients not in CCyR at the time of NIL start (p=0.46).
Mean time to attain CCyR was similar (7.1 months for DAS and 5.3 months
for NIL; p=0.30). Major molecular response (MMR) was achieved in 55/89
(65%) patients not in MMR at the time of DAS start and in 39/61 (65%) patients
not in MMR at the time of NIL start (p=0.82). Again, mean time to MMR was
not different in the DAS e NIL cohorts (12.4 vs 8.5 months; p=0.14). With a
median follow-up of 44 months (range 1–124), 5-year TTF was similar for
DAS (65%, 95%CI 52-75%) and NIL (61%, 95%CI 43-74%; p=0.40) [Figure
1a]. Thirty-two of 95 patients (34%) stopped DAS due to toxicity (19/32, 59%),
resistance (11/32, 31%) or other causes (3/32, 10%); 22/68 patients (32%)
interrupted NIL for toxicity (11/22, 50%), resistance (8/22, 36%) or other caus-
es (3/22, 14%), Probability of survival and progression were almost identical,
with a 5-year PFS of 84% (95%CI 68-89%) for DAS and 92% (95%CI 79-
97%) for NIL (p=0.27) [Figure 1b] and a 5-year OS of 89% (95%CI 78-95%)
and 96% (95%CI 85-99%) (p=0.31), respectively.
Figure 1.
Summary/Conclusions: With the limits of a retrospective analysis, our data
suggest similar efficacy of DAS and NIL after IM failure in CP-CML, with high
rates of cytogenetic and molecular responses and excellent long-term survival.
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Background: Most patients (pts) with chronic myeloid leukaemia (CML) on
long-term tyrosine kinase inhibitor (TKI) treatment will achieve a deep molecular
response (commonly defined as MR4.0; BCR-ABL ≤0.01%). Around half of
these pts would remain in treatment-free remission (TFR) if their TKI were
stopped after several years of stable MR4.0 or better. TFR is increasingly
becoming a goal of treatment, yet little has been reported about pt perceptions
of TFR.
Aims: To examine factors that influence expressed willingness to attempt TFR.
Methods: We developed a survey incorporating CML-specific factors (dis-
ease history, treatment toxicity, adherence) and questions relating to per-
ceived susceptibility to relapse and consequences of relapse, benefits of and
barriers to attempting TFR. Verbatim responses to an open-ended question
regarding willingness to attempt TFR were grouped into themes. The survey
incorporated two validated inventories: the Morisky Medication Adherence
scale and the MDAnderson Symptom Inventory for CML TKI toxicity. CML
pts in MR4.0 were eligible if they were taking any approved TKI. Pts were
recruited from around Australia after receiving an invitation letter explaining
the survey.
Results: There were 87 eligible respondents (Table 1). 82% of pts (95% CI
73-90%) indicated that they would be willing to cease TKI under close medical
supervision if their doctor (Dr) thought it appropriate. On a scale of 0-100 (where
100 is extreme willingness) the median score was 69. No demographic or CML-
related (disease duration, TKI) variable in the survey was significantly associ-
ated with the outcome variable. On average, respondents rated their TKI toxicity
severity as 2.3 (SD: 1.7; Range: 0-7) on a 0-10 scale, (where 10 is very severe).
This was positively correlated (r=0.76; p<0.01) with interference of TKI toxicity
in daily life (mean 2.66). Increasing age was positively correlated with TKI tox-
icity severity (r=0.34; p<0.05), but not with interference of toxicity. Neither meas-
ure of TKI toxicity was significantly associated with willingness to stop TKI treat-
ment. Stated treatment adherence was moderate (mean score 6.9/10 [SD: 1.1;
Range: 3.5-8]). Adherence was positively correlated with age (r=0.27; p<0.05),
but not with willingness to attempt TFR. Qualitative responses were related to
willingness (59%); reluctance (34%); and ambivalence or conditional willing-
ness (38%) to attempt TFR. The most frequently cited reasons to stop TKI
included: TKI toxicity, actual (n=21) or potential (n=5); and confidence in the
Dr (n=11) or molecular response (n=8). The leading reason not to stop was
fear of disease progression or TKI resistance (n=7). Some patients believed
that age or comorbidities made them unsuitable to attempt TFR; that TKI treat-
ment was essential to prevent relapse or death; or cited negative experiences
of friends stopping chemotherapy for other cancers. Conditional willingness
was most often related to availability of medical supervision and testing (n=14)
and probability of maintaining TFR (n=7).
Table 1. Patient characteristics.
Summary/Conclusions: Most respondents (82%) would be willing to stop
their TKI with the support and supervision of their Dr. Although TKI toxicity was
the commonest reason to attempt TFR, there was no correlation between
symptom severity and willingness to stop TKI. This might indicate that even
mild TKI toxicity is sufficient motivation for pts to attempt TFR. Potential future
toxicity was also relevant to some patients. Reluctance to stop TKI was often
associated with needs for additional information or misunderstanding of the
current data. Understanding pt motivations and concerns is important if TFR is
to be incorporated into the routine treatment pathway for CML.
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CHRONIC MYELOID LEUKEMIA
AC Gonçalves1,2,3,*, R Alves1,2,3, P Couceiro2, P Rodrigues-Santos2,4,
P Freitas-Tavares5, A Pereira3,6, L Ribeiro5, L Mota-Vieira7,8,9, JM Nascimento
Costa10,11, AB Sarmento-Ribeiro1,2,3,5
1Laboratory of Oncobiology and Hematology and University Clinic of Hematol-
ogy, Faculty of Medicine University of Coimbra, 2Center for Neuroscience and
Cell Biology (CNC), 3Center of Investigation on Environment Genetics and
Oncobiology (CIMAGO), 4Immunology, Faculty of Medicine University of Coim-
bra, 5Clinical Hematology Department, Centro Hospitalar e Universitário de
Coimbra (CHUC), Coimbra, 6Medicine Department, Hospital Distrital da
Figueira da Foz, EPE, Figueira da Foz, 7Molecular Genetics and Pathology
Unit, Hospital of Divino Espírito Santo of Ponta Delgada, EPE, Ponta Delgada,
Azores, 8Azores Genetics Research Group, Instituto Gulbenkian de Ciência,
Oeiras, 9Centre for Biodiversity, Functional and Integrative Genomics, Faculty
of Sciences, University of Lisboa, Lisboa, 10University Clinic of Oncology, Fac-
ulty of Medicine University of Coimbra, 11Oncology Department, Centro Hos-
pitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal
Background: Oxidative stress (OS), resulting from an imbalance between
Reactive Oxygen Species (ROS) production and antioxidant defenses, con-
tributes to cell damage, apoptosis and ineffective hematopoiesis. Chronic
myeloid leukemia (CML) is a clonal neoplastic disease associated with the
reciprocal translocation t(9;22), encoding the BCR-ABL1 oncogene. BCR-ABL
protein induces, among other mechanisms, production of reactive oxygen
species (ROS) by activation of the PI3K pathway, increase glucose metabolism
and mitochondrial dysfunction. The antioxidant enzymes superoxide dismu-
tases (SOD) and catalase (CAT), as well as DNA repair enzymes, such as
OGG1, are important cell defense components against OS. Polymorphisms in
genes that codify these enzymes may contribute to differences in susceptibility
of individuals to oxidative damage, since it can lead to reduced protection
against OS, influencing CML development and therapeutic response.
Aims: In the present study we investigate the influence of polymorphisms in
genes related with oxidative stress (CAT, GPX1, MPO, SOD1, and SOD2) and
DNA repair (OGG1, NEIL1, and XRCC1), and in the transcription factor NFE2L2,
as a prognostic risk marker in CML patients [namely the impact in overall survival
and tyrosine kinase inhibitors (TKIs) response]. Moreover, we also analyzed
their participation in the development of mutations in BCR-ABL1 gene.
Methods: This study enrolled 75 patients diagnosed with CML. The genetic
polymorphisms of CAT (rs1001179), GPX1 (rs1050450), MPO (rs2333227),
SOD1 (rs2070424), SOD2 (rs4880), OGG1 (rs1052133), NEIL1 (rs5745920),
XRCC1 (rs1799782), and NFE2L2 (rs13001694), were assessed by RFLP-
PCR and Tetra-primer-ARMS-PCR. The oxidative stress (reactive oxygen
species/total antioxidant status ratio) and DNA damage (8-hydroxy-2’-
deoxyguanosine) were measured using commercial kits. The statistical analysis
was carried out by variance analysis, χ2 test and Fisher exact test (p<0.05). 
Results: Our results show that SOD2 CC genotype influence the mutation sta-
tus of BCR-ABL1 gene (odds ratio 9.25x, I.C.95% 1.24-18.82; p=0,007), being
the CC genotype also associated with higher oxidative stress levels. On the
other hand, patients with MPO GG and AG genotypes have a high rate of sub-
optimal response to TKIs (odds ratio 4.92x, I.C.95% 1.24-9.10; p=0,043), and
these genotypes were also associated with higher oxidative stress levels. More-
over, the overall survival of CML patients can be influenced by NEIL1 [CML
patients with CT genotype had lower survival (166±5 months) than patients
with CC and TT genotypes (204±6 months; p=0.041)] and NFE2L2 [CML
patients with TT genotype had lower survival (88±7 months) than patients with
CT and TT genotypes (216±8 months; p=0.003)].
Summary/Conclusions: Our results show that genetic polymorphisms in
oxidative stress and DNA repair related genes modulate oxidative stress and
DNA damage levels in CML patients. Moreover, these polymorphisms influence
the prognosis of CML patients, their response to TKI treatment and the devel-
opment of BCR-ABL1 mutations, which suggest their potential as new prog-
nostic and therapeutic biomarkers.
This work was supported by CIMAGO (Project 22/09) and R. Alves is supported
by the FCT fellowship SFRH/BD/51994/2012.
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PRETREATED CP-CML PATIENTS 
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Background: Ponatinib is a potent oral tyrosine kinase inhibitor (TKI) active
against native and mutant forms of BCR-ABL1. It is approved for patients with
refractory CML or Ph+ALL, or with the T315I mutation. Responses at early
landmark time points have been correlated with positive long-term outcomes
in patients treated with other TKIs in the first- and second-line settings. 
Aims: Landmark analyses are limited for populations treated with multiple prior
TKIs. Here, we evaluate the impact of achieving early landmark responses with
ponatinib on 3-year outcomes in heavily pretreated patients in the ongoing
Phase 2 PACE trial (NCT01207440). 
Methods: Molecular responses (International Scale; BCR-ABL ≤0.1% [major
molecular response (MMR)], >0.1–1%, >1%–10% and >10%) and cytogenetic
responses (Ph+ metaphases ≤35% [major cytogenetic response (MCyR)]) at
3, 6 and 12 months and their association with outcomes at 3 years past land-
mark were examined in a post hoc analysis of heavily pretreated patients with
chronic-phase (CP)-CML (n=267). P values were calculated using the log-rank
test. Data cutoff date was 3 August, 2015. All patients gave informed consent. 
Results: Median time from diagnosis was 7 years (range 0.5-27) and median
age was 60 years (range 18-94); 61% of patients had received ≥3 prior TKIs.
At 3, 6, and 12 months, 48%, 62% and 71% of patients, respectively, achieved
MCyR, and 14%, 29% and 39%, respectively, achieved MMR, among patients
evaluable at each landmark. Greater reductions in BCR-ABL1 transcript levels
at most landmark time points were associated with improved PFS and OS at 3
years (Table 1), as was MCyR. Deeper responses at all landmark time points
were also associated with the achievement of MR4.5 over time. 
Table 1. Estimated PFS and OS at 3 years past landmark by BCR-ABL1 level.
Summary/Conclusions: Deep, early reductions in BCR-ABL1 transcripts were
positively associated with long-term survival in this refractory population. These
data support the prognostic value of achieving early landmark cytogenetic and
molecular responses with ponatinib in heavily pretreated patients.
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Background: In BCR-ABL1 tyrosine kinase inhibitor (TKI) treated chronic
phase chronic myeloid leukemia (CP-CML), early molecular response (EMR)
at 3 month is currently identified as being one of the most important prognostic
factors. Sokal risk score and dose intensityduring first 3 months were strongly
associated with achievement of EMR. As dasatinib is a novel, oral tyrosine
kinase inhibitor with improved potency, identification of very early molecular
response (VEMR) would be beneficial.
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Aims: We evaluated the possibility of the VEMR at I month predicting outcomes
in newly diagnosed CP-CML patients treated with dasatinib.
Methods: In this multi-center, observational, open-label study, 102 patients
with CP-CML were enrolled to receive dasatinib at a dose of 100 mg once
daily. The primary end point was complete molecular response (CMR) by 18
months. Secondary end points including molecular response (MR) by 1, 3, 6,
12, 18, 24, 36 month, time to and duration of MMR and CMR, bcr-abl kinetics
by digital PCR, and safety were tested. A receiver operating characteristic
(ROC) curve from molecular data on Day+28 was calculated to predict EMR
and MMR at specific timepoints.
Results: Median age was 49 years (19-81 years) and 61 patients were male.
With median follow-up duration of 17 months (0.9-27.2 months), 92 (90.1%)
out of 102 patients were still on dasatinib treatment and 10 patients discontin-
ued due to disease progression or treatment failure in 3 patients or adverse
events in 4 patients or other causes. The cumulative MMR at 12 months was
65.2%. The cut-off value of BCR-ABL1 transcript on Day+28 calculated by
ROC curve was 40%. Among 92 patients who have available molecular data
of both D+28 and 12 months, fifty nine (64.1%) patients had less than 40% of
BCR-ABL1 transcript (VEMR) on Day+28. In 59 patients who had VEMR, 50
(84.7%) patients achieved MMR at 12 months. However, only 30.3 (10 out of
33 patients) % of patients with no VEMR achieved MMR at 12 month. More
detailed data will be updated at presentation. 
Summary/Conclusions: Our study shows that VEMR at I month can be an
important predictor for further molecular responses as well as long-term out-
come. Therefore it would be helpful to monitor BCR-ABL1 transcript level at 1
month in patients who treated with more potent TKIs. 
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Background: An exploratory, landmark analysis of the randomized phase 3
DASISION trial (NCT NCT00481247) demonstrated improved long-term out-
comes (progression-free survival [PFS] and overall survival [OS]) in newly diag-
nosed CML-CP patients treated with dasatinib or imatinib who achieved BCR-
ABL1 ≤10% vs >10% at 3 months. The early molecular milestone of BCR-
ABL1 ≤10% at 3 months was achieved by a higher proportion of patients on
dasatinib (84%) compared with imatinib (64%). 
Aims: To evaluate the effect of EURO (Hasford) risk score on the achievement
of BCR-ABL1 ≤10% at 3 months and to evaluate long-term efficacy (PFS, OS,
major molecular response [MMR], and MR4.5) in treatment-naïve CML-CP
patients from DASISION. A multivariate analysis was performed to explore the
relationship between the survival of a patient and several explanatory variables
including treatment, gender, ECOG performance status, race, age, smoking
status, and geographical region. 
Methods: In DASISION, patients received dasatinib 100 mg once daily (n=259)
or imatinib 400 mg once daily (n=260). BCR-ABL1 transcript levels were meas-
ured on the International Scale. Patients with a EURO score ≤780 were con-
sidered low risk, >780 to ≤1480 intermediate risk, and >1480 high risk.
Results: Most patients in DASISION were at intermediate risk according to
EURO score (124 [48%] on dasatinib and 123 [47%] on imatinib); 86 patients on
dasatinib and 87 patients on imatinib (33% each arm) were at low risk, and 49
patients on dasatinib and 50 patients on imatinib (19% each arm) were at high
risk. A higher percentage of patients in the dasatinib arm achieved BCR-ABL1
≤10% at 3 months vs the imatinib arm in all risk groups (low: 91% vs 73%; inter-
mediate: 80% vs 66%; high: 83% vs 44%). The largest difference was observed
between those at high risk: 17% of high-risk patients on dasatinib did not achieve
BCR-ABL1 ≤10% at 3 months vs 56% on imatinib. Within each EURO risk score
group, a higher proportion of patients on dasatinib vs imatinib had BCR-ABL1
≤1% at 3 months (low: 56%, 95% confidence interval [45-68%] vs 20% [12-30%];
intermediate: 48% [38-57%] vs 12% [7-20%]; high: 33% [20-48%] vs 5% [1-
16%]). Five-year PFS, OS, MMR, and MR4.5 rates were higher for patients with
BCR-ABL1 ≤10% vs >10% at 3 months in all risk groups (Table 1). Based on
multivariate analysis of OS at 5 years, women were found to be at a lower risk
of death than men (hazard ratio: 0.38, 95% confidence interval: 0.19, 0.75). No
association was found between survival and other explanatory variables.
Summary/Conclusions: In all EURO risk score groups, a higher percentage
of patients on dasatinib achieved BCR-ABL1 ≤10% at 3 months than patients
on imatinib, with the most striking difference in high-risk patients. The proportion
of patients achieving BCR-ABL1 ≤1% at 3 months was higher with dasatinib
vs imatinib, and the 95% confidence intervals for the two treatment arms did
not overlap. Long-term outcomes were superior for patients with BCR-ABL1
≤10% at 3 months across all risk groups. These analyses suggest that dasatinib
should continue to be considered as a first-line therapy for CML-CP patients,
irrespective of EURO risk score.
Table 1.
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RESULTS FROM ENESTFREEDOM: TREATMENT-FREE REMISSION (TFR)
FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH
CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
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Background: Proof of concept for TFR in CML-CP was demonstrated in the
STIM trial, which enrolled pts with sustained deep molecular response (MR)
on long-term imatinib (IM; median duration of 59 mo); ≈ 40% of pts enrolled in
STIM maintained TFR (no loss of deep MR) after stopping IM. Similar results
were observed in subsequent tyrosine kinase inhibitor (TKI) TFR studies,
although differences in design (eg, pt population, monitoring requirements, cri-
teria for reinitiation of therapy) preclude direct comparison of results across
studies. Several studies have shown an association between maintaining TFR
and longer TKI treatment duration. 
Aims: To present results from the single-arm phase 2 ENESTfreedom study
(NCT01784068) evaluating the ability to stop NIL and maintain TFR in pts who
achieved a sustained deep MR on frontline NIL.
Methods: Eligible pts had CML-CP, typical b2a2 and/or b3a2 BCR-ABL1 tran-
scripts, and ≥ 2 y frontline NIL, and had achieved MR4.5 (BCR-ABL1 ≤ 0.0032%
on the International Scale [IS]) on treatment. All pts provided informed consent.
On study, pts continued NIL for 1 y (consolidation phase; RQ-PCR assessments
every 12 wk); pts meeting response criteria during the consolidation phase (no
assessment worse than MR4 [BCR-ABL1IS≤ 0.01%], ≤ 2 assessments between
MR4 and MR4.5, and MR4.5 in the last assessment) were eligible to stop NIL
(TFR phase; RQ-PCR assessments every 4 wk for the first 48 wk). NIL reiniti-
ation (ReRx phase) was triggered by loss of major MR (MMR [BCR-ABL1IS ≤
0.1%]). This analysis was conducted when all pts who entered the TFR phase
had completed 48 wk of TFR, entered the ReRx phase, or discontinued from
the study (data cutoff, 30 Nov 2015).
Results: A total of 215 pts were enrolled and entered the consolidation phase;
190 of these pts stopped NIL and entered the TFR phase. Median age at enroll-
ment was 55 y, and median NIL duration prior to TFR was 43 mo (range, 33-
89 mo). At wk 48 of the TFR phase, 51.6% (95% CI, 44.2-58.9%) of 190 pts
remained in MMR without reinitiation of treatment (primary endpoint), and
47.4% (95% CI, 40.1-54.7%) were in MR4.5 without reinitiation of treatment. A
total of 86 pts lost MMR and reinitiated NIL. Of these 86 pts, 85 pts regained
MMR, and 76 pts regained MR4.5(1 pt discontinued from the study without
regaining MMR [pt decision] 7.1 wk after entering the ReRx phase). The median
time to regain MMR was 7.9 wk. No new safety signals were observed with
NIL treatment. Fewer pts developed adverse events (AEs) in the TFR phase
(65.8%) vs the consolidation phase (83.2%). Myalgia has been reported as
part of an IM withdrawal syndrome in prior studies. Here, in the first 48 wk of
the TFR phase, 47 pts (24.7%; grade 3/4 in 1.1%) stopping NIL reported AEs
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in the musculoskeletal pain grouping (defined as musculoskeletal pain, myalgia,
pain in extremity, arthralgia, bone pain, and/or spinal pain), of whom 32 had no
previous such events. Most of these events occurred early in the TFR phase
(39 pts had an event within the first 24 wk; median duration, 24.0 wk).
Summary/Conclusions: In ENESTfreedom, over 50% of pts remained in TFR
48 wk after stopping NIL, a clinically meaningful rate for pts with a relatively
short duration of NIL therapy (≈ 3.6 y). Among pts who did not remain in TFR,
all who remained on study regained MMR, and most regained MR4.5 with NIL
reinitiation.
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IMPACT OF AZACITIDINE THERAPY ON OVERALL SURVIVAL OF NEWLY
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Background: Treatment of myelodysplastic syndromes (MDS) has undergone
a sweeping change in recent years following the emergence of demethylating
agents such as azacitidine (AZA). However, recently published data establish
a clear need for population-based studies to confirm the findings of clinical
trials in the real-life setting.
Aims: To evaluate the use and outcomes of AZA in higher-risk MDS (HR MDS;
International Prognostic Scoring System [IPSS] Int-2/High-risk) patients (pts)
in a real-life setting.
Methods: The ERASME study is an observational, prospective study of pts with
MDS (WHO 2008 classification). This sub-analysis included only HR MDS pts
who had been chosen for one of the following management therapies at time of
diagnosis: active therapy with AZA or allogeneic hematopoietic cell transplant
preceded by AZA (AZA-HCT). The presence of therapy-related MDS and cyto-
genetic abnormalities was taken into consideration. Overall survival (OS) of these
pts was compared against best supportive care using the Kaplan-Meier and time-
dependent methods.
Results: A total of 150 pts with HR MDS were recruited between January 2013
and August 2015. 113 pts (median age 73.0 years [yrs; interquartile range 66.0-
77.0]; 52% male) were treated with AZA and 37 pts (median age 81.0 yrs [75.0-
85.0]; 57% male) with best supportive care (considered only for survival analy-
sis). Therapy-related MDS was detected in 19% of cases. IPSS score was Int-
2 in 51% of pts and High-risk in 49%. Prognostic cytogenetics was classified as
good in 35% of pts, intermediate in 4%, poor in 22%, and very poor in 27%
(14% were unclassified due to missing metaphase data). The first therapy admin-
istered was AZA for 84 (74%) pts and AZA-HCT for 29 (26%) pts. The main rea-
sons for treatment strategy selection were risk classification (99%), age (80%),
symptomatology (58%), and comorbidities (52%). The median number of AZA
cycles was 4.0 (1.0-7.0), with 41 pts (36%) receiving ≥6 cycles. Most pts were
treated on a 7-day regimen (n=91 [81%]; missing=14%) and a dose of 75 mg/m2
(n=71 [63%]; missing=2%). The most common adverse events (AEs) were
asthenia in 20 pts, pyrexia in 18, constipation in 14, febrile neutropenia in 12,
and neutropenia in 10. AEs led to dose reductions in only 8% of cases. Overall,
median OS for pts treated with AZA on the 7-day regimen at the 75 mg dose vs
pts treated with other regimens was 19.4 months (mos; 12.8-23.2) vs 14.9 mos
(11.8-18.6) (P=not significant [ns]), respectively. Observed OS in pts treated for
≥6 cycles vs those treated for <6 cycles was 20.3 mos (14.2-23.2) vs 14.9 mos
(6.6-not reached [NR]) (P=0.05). OS in pts who did not have comorbidities vs
those who did was 20.3 (7.4-NR) vs 16.6 (12.8-22.2) (P=ns). At last study fol-
low-up (36 months), 53 pts (47%) had died after a median of 7.4 mos (4.2-13.7):
39 (46%) and 14 (48%) pts on AZA and AZA-HCT, respectively. Median OS in
HR MDS pts treated with AZA was higher than in HR MDS pts receiving sup-
portive care: 16.6 mos (13.1–21.7) vs 8.4 mos (5.7-13.0) (P <0.01). Median
time-dependent OS was also higher with AZA than with supportive care: 14.8
mos (12.8-18.7) vs 5.0 mos (2.5-11.6) (P <0.01).
Summary/Conclusions: The findings from this post hoc subanalysis of the
prospective population-based study show that treatment with AZA prolongs OS
in pts with HR MDS in a real-life setting when compared with supportive care.
The results support the hypothesis that OS could be compromised with signifi-
cantly more baseline comorbidities or reduced total dose recommended of AZA.
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Background: Azacitidine (AZA) is effective in high risk MDS, CMML-2 and
low blast count AML patients not suitable for more intensive treatment. Factors
that may influence response to AZA are still under investigation. Bone marrow
fibrosis is a potentially negative prognostic marker on overall survival (OS),
but its clinical significance in this setting of patients remains to be clarified.
Aims: To evaluate efficacy and clinical predictors of OS and overall response
rate (ORR) to AZA in a real life patient cohort. 
Methods: We retrospectively evaluated 94 consecutive patients treated at two
Institutions from June 2009 till February 2016 with AZA subcutaneously (5+2+2
schedule) every 28 days, outside clinical trials. We analyzed data from routine
laboratory analysis, bone marrow histology, morphology and cytogenetics at
diagnosis. Statistical analysis was performed using Student’ t test for continuous
variables, and chi-square test for categorical ones. OS was measured from the
starting of AZA treatment. Median age at diagnosis was 72.5 years (range 39-
90); male to female ratio was 1.7 (58/34). The initial diagnosis according to
WHO 2008 classification were low blast count AML in 15 cases (15.9%), AREB2
in 40 (42.6%), AREB1 in 25 (26.6%) CMML in 5 (5%) and RCUD/RCMD/MDS
NOS in 9 (10%). The International Prognostic Scoring System (IPSS) risk for all
MDS patients was int-2 (N=60) or high (N=20) at the onset of AZA therapy.
Median number of cycles administered was 7 (range 1-44).
Results: Seventy-nine patients (84%) receiving ≥4 cycles of therapy were avail-
able for response evaluation according to International Working Group 2006
criteria. After a median of 6 cycles (4-13), ORR was 47.8% (CR 23.1%, PR
14.1% and SD with hematologic improvement 10.3%), SD was 23.1%, and PD
29.5%. Median OS from the beginning of therapy was 19.9 months (range 4-75
months). AREB-1 and AREB-2 presented a lower OS (11.4 and 19 months)
than AML (22 months) and CMML/RCUD/RCMD/MDS NAS (42 months). As
expected, a statistically significant difference in median OS was observed
between int-2 and high risk (31 versus 15 months respectively, p<0.005). In uni-
variate analysis monocytosis, severe neutropenia, peripheral and marrow blasts
percentage, and bone marrow cellularity did not influenced ORR. IPSS cytoge-
netic risk category (43 favourable, 10 intermediate, 41 poor) did not influence
ORR, but it had an impact on OS that is significantly lower in poor than in inter-
mediate risk (median OS 12 vs 26 months, p=0.05). OS in low risk cytogenetic
category was 31 months. As regards the grade of marrow fibrosis, patients with
MF-0 had significantly lower PD rate than those with any grade of fibrosis (25%
vs 52%, p=0.01). Moreover, ORR was higher in patients with MF-0 versus the
others (48% vs 40%), although not significantly (Figure 1). In our study, patients
with any grade of fibrosis had worse median OS then patients with no fibrosis
(15 months vs 26 months).
Figure 1.
Summary/Conclusions: Our results confirm effectiveness of AZA in patients
with high risk MDS and AML with low marrow blast counts. To the best of our
knowledge, this is the first report showing that bone marrow fibrosis negatively
impacts response to AZA therapy. Further studies are needed to clarify the
clinical significance of marrow fibrosis and its impact on OS and ORR among
patients treated with hypomethylating agents.
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Background: The IPSS and the revised-IPSS were generated with data from
816 and 7,019 patients (pts) of academic centers with a median age of 69 and
71 years (y), respectively. The IPSS should be applied to all MDS-pts to assess
prognosis and define the optimal therapeutic strategy.
Aims: The aim of the current evaluation of the regular care MDS-registry was
to describe the age distribution of MDS in regular care and the meaning of the
IPSS in various classes of age.
Methods: Pts were eligible if a bone marrow (BM) biopsy was performed and
pts have given written informed consent. Basic data and the quarterly course
of the disease were documented in an online registry. Statistical analysis:
Depending on the distributions of each variable frequency tables, means (SD),
medians were calculated overall and stratified by age classes. Corresponding
overall tests were performed (Chisquare, Kruskal-Wallis). Furthermore, survival
was estimated by IPSS and age stratified Kaplan-Meier curves and compared
using a bivariate Cox regression model. 
Results: Between July 2009 and March 2015 (69 months) 1689 pts from 85
institutions mainly outpatient practices, were recruited and eligible. Median age
of 681 (40.3%) women and 1008 (59.7%) men were 74.8y (min-max: 26.5-
94.2). The duration of observation, frequencies of IPSS, need for transfusions
(Tx) prior to diagnosis (d), comorbidities and the Charlson comorbidity index
(CCI) are given in the Table 1. Higher age and IPSS risk were significantly
associated with the risk of death (Figure 1).
Table 1. Age distribution and MDS parameter.
Figure 1. Survival stratified in IPSS and age (classified <=69, 70-74, 75-
79, >=80).
Summary/Conclusions: The median age of MDS pts in the German regular
care registry is higher than that of the cohorts, who generated the IPSS. Further
analysis will clarify the impact of the enhanced rate of comorbidities and need
for transfusion in the 80y+ cohort related to the survival in the low and Int-1
IPSS subgroups.
The MDS-registry is supported by an unrestricted grant from Celgene and
Novartis.
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Background: Since the survival in patients diagnosed with MDS varies from
months to decades, prognostic models are important tools for estimating prog-
nosis and making therapy-related decisions. Several scoring systems for risk
stratification have been developed including the International Prognostic Scoring
System (IPSS), the Revised IPSS (IPSS-R) and the World Health Organization
(WHO) Classification-based Prognostic Scoring System (WPSS). The nationwide
Swedish MDS-register was started in 2009 and includes newly diagnosed patients
with Myelodysplastic syndrome (MDS) and disorders with combined features of
myelodysplastic and myeloproliferative neoplasms (MDS/MPN). All hospitals in
Sweden diagnosing these patients report to the MDS-register, including university
hospitals, county and local hospitals. The completeness against the compulsory
Swedish Cancer Register was 95% for the period under study (2009-2013).
Aims: The aim of this study was to validate and compare IPSS, IPSS-R and
WPSS in a nationwide population-based setting. Furthermore, we present data
on incidence, clinical characteristics at diagnosis and clinical outcomes such
as overall survival and AML-transformation.
Methods: All patients aged 16 years or older diagnosed with MDS 2009-2013
and reported to the MDS-register were included (n=1334). Patients with
MDS/MPN were excluded (n=291). Data included date of diagnosis, age, gen-
der, WHO-diagnosis, laboratory parameters, transfusions-dependency, diag-
nostic procedures including information on bone marrow morphology and cyto-
genetics and information on previous treatment with chemotherapy or irradia-
tion. By means of record linkage, information was obtained from the Swedish
Cause of Death Register and the Swedish AML-register up to December 31,
2014 to calculate overall survival (OS) and transformation to AML. 
Overall and AML-free survival was assessed using the Kaplan-Meier method.
Prognostic scores were calculated for IPSS, IPSS-R and WPSS, respectively.
The prognostic methods were evaluated using Harrell’s concordance (C) index.
The indices were internally validated by bootstrapping with 1000 samples.
Results: The crude yearly incidence of MDS was 3.5 per 100.000 persons.
Median age at diagnosis was 76 years and 58% of the patients were male. At
time of diagnosis, 49% of patients were dependent on red blood cell transfu-
sions. The median OS for the whole population was 2.7 years and time to 25%
AML-transformation was 3.8 years. For 848 (64%) patients data were complete,
enabling risk score assessment for all three systems. The major part of missing
data was attributed to that karyotyping was not performed, mainly in the older
population. Compared to previous register-based studies we found that a larger
proportion of patients had higher risk disease. Risk category in the different
scoring systems, OS and time to 25% AML-transformation are presented in
Table 1. Comparisons between the scoring systems show that all three had
good prognostic power. However, IPSS-R and WPSS had significantly better
prognostic properties compared to IPSS.
Table 1. Clinical outcome and discriminative power on the WPSS, IPSS
and IPSS-R based risk categories.
Summary/Conclusions: To our knowledge, this is the first nationwide popu-
lation based validation of IPSS, IPSS-R and WPSS. While our findings confirm
the prognostic power of all three systems, IPSS-R and WPSS appear to be
slightly more powerful tools for prognostication than IPSS.
P622
EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH
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Background: Myelodysplastic syndromes (MDS) are a heterogenous group of
clonal hematopoietic stem cell disorders characterized by increased risk of
leukemic transformation.Patients evolving into leukemia respond poorly to
chemotherapy and die within a short time. Hence, it is very important to find
detectable marker to predict the probability of leukemic transformation once MDS
has been diagnosed. In our previous study, we establish a nested case-control
study cohort in 435 MDS patients. With whole-genome expression chip, we ana-
lyzed the different gene expression profile of paired MDS patients. A subset of 6
genes was found to distinguish the leukemia group (MDS patients with evolution
to leukemia) and control group (MDS patients without evolution to leukemia).
These 6 genes were TUBB, PSMD1, SLC7A5, ATG3, TUBB2C and TIMM10.
Aims: Based on our previous study on feature genes related to leukemic evo-
lution of myelodysplastic syndrome (MDS), we investigated the differential
expression of TUBB gene in MDS patients with leukemic evolution and that
without evolution. Also, we studied the effect of down-regulation of TUBB gene
on SKM-1 cell line.
Methods: Based on our nested case-control study cohort of MDS patients, we
chose paired patients in 1:1 ratio, according to age, gender, WHO subtype,
IPSS cytogenetic subgroup and follow-up period (≥1 year). We examined TUBB
gene expression changes in paired patients from case group (with evolution)
and control group (without evolution), using quantitative real time PCR. We
used small interfering RNA to down-regulateTUBB gene expression in SKM-1
cell line. The effect of TUBB-siRNA on the growth rate,colony formation per-
centage and the ultrastructure of SKM-1 were tested by CCk-8 kit, flow cytom-
etry, soft agar and transmission electron microscope, respectively.
Results: We chose 11 patients in each group of our MDS nested case-control
study cohort excluding patients underwent gene expression microarray test.
TUBB gene expression of MDS patients in case group were significantly higher
than that in control group (P<0.01).Satisfactory transfection efficiency (>80%)
could be obtained withlipofectamine. Real time PCR showed the down-regu-
lated expression of TUBB after transfection (P<0.05). Growth inhibition of SKM-
1 cell was obvious 24 hours after TUBB-siRNA transfection (P<0.05). The cell-
cycle analysis by flowcytometershowed the percentage of SKM-1 before trans-
fection in S phase was higher than that after transfection. Colony formation
percentage of SKM-1 was inhibited obviously with TUBB-siRNA transfection
(P<0.01). The ultrastructure of SKM-1 cell after transfection exhibit several fea-
tures, such as vacuole in cytoplasm and nuclear fragmentation (Figure 1).
Figure 1.
Summary/Conclusions: TUBB gene expression was significantly higher in
case group than that in control group of our MDS nested case-control study
cohort. Growth and colony formation inhibition are the result of siRNA against
TUBB.Our results indicate that TUBB gene may play a role in evolution of MDS
into acute leukemia. 
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Background: Anemia is one of the most frequent abnormalities detected in
hemograms and it can be the first sign of MDS, especially in the elderly patients.
Diagnosis of MDS when anemia is the only abnormality can be complicated,
so the diagnosis is delayed until the degree of anemia becomes severe (trans-
fusion dependency) and/or other cytopenias/blasts appears. 
Aims: To evaluate the impact of systematically review of all hemograms per-
formed in a hematology department-lab selecting those with anemia and/or
macrocytosis of undetermined significance. In these hemograms selected we
performed a study trying to identify the underlying disease causing anemia. 
Methods: We performed a prospective study within 4 months (Dec/12-Mar/13)
in 3 hematology labs in Spain. Algorithm approach consisted of four steps
(Figure 1). NGS analysis was performed on a MiSeq platform (Illumina) and
IonReporter (Life Technologies) in MDS patients. Target-capture sequencing
was performed across genes previously related to MDS. The statistical analy-
sis was implemented using SPSS v21.0.
Results: From 290 hemograms candidates to MDS screening, 139 final diag-
noses have been made (48%) (Figure 1). The main causes of anemia were
iron deficiency (n=59) and megaloblastic anemia (n=39). A MDS was diagnosed
in 14/25 hematological malignancies (56%). Regarding those MDS patients
(Table 1) median age was 79 years (58-91); 12/14 patients had anemia
[Hb=10,7g/dl] such as isolated cytopenias. All patients had macrocytosis (mean
MCV=104fL). Most of patients (n=10) were low-risk MDS (IPSS-R≤3.5) and were
treated according to guidelines. Table 1: Baseline characteristics of MDS cohort.
Figure 1.
Table 1.
The K700E mutation in SF3B1 was the most frequent (n=6) and was highly
correlated to ring sideroblasts in bone marrow (100% of patients). The median
follow-up MDS patients were 30 months [28-36]. KM estimated 3-year OS was
71%. Regarding impact on survival of mutational status, TP53 and ZRSR2
mutations were associated to poor prognostic and all these patients had died
as compared to the presence of other mutations (SF3B1 or TET2) where all
patients are still alive (p=0.001).
Summary/Conclusions: This prospective approach is a reasonable screening
procedure in the hematological laboratories and will probably allow us to diag-
nose early the more relevant causes of anemia, including MDS, and providing
the appropiate intervention for the patients.
Celgene supported this study. 
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MANAGEMENT OF IRON OVERLOAD WITH DEFERASIROX IN VARIOUS
HEMATOLOGICAL MALIGNANCIES – REAL WORLD EXPERIENCES
FROM THE GERMAN NON-INTERVENTIONAL STUDY EXSEPT
F Nolte1,2,*, C Schumann1, H Nückel3, B Schmidt4, H Hebart5, O Rubanov6,
R Kühn7, S Kreil1,8, G Metzgeroth1,8, C Johr9, S Albrecht9, W Hofmann1,8
1Medical Faculty Mannheim of the University of Heidelberg, Mannheim, 2Inter-
nal Medicine, Hematology and Oncology, St. Hedwig Hospital, Berlin, 3Office-
based Hematology/Oncology specialist, Office-based Hematology/Oncology,
Bochum, 4Office-based Hematology/Oncology, Munich, 5Internal Medicine,
Stauferklinikum Schwaebisch Gmuend, Mutlangen, 6Office-based Hematol-
ogy/Oncology, Hameln, 7Office-based Hematology/Oncology, Oldenburg,
8Hematology and Oncology, University Hospital Mannheim, Mannheim, 9Novar-
tis, Nuremberg, Germany
Background: Iron overload (IO) resulting from chronic transfusion therapy is
common in patients with various hematological disorders and may finally result
in organ failure. Deferasirox is approved for the treatment of iron overload in
patients with transfusion dependence.
Aims: The aim of the study was to evaluate the pattern of use of deferasirox
in the daily routine setting.
Methods: Overall, 420 patients (pts) receiving deferasirox were analyzed
across 107 German office- and hospital-based hematology centers: 280 with
myelodysplastic syndrome (67%), 53 with myeloproliferative disorders (13%),
18 with AML (4%) and 69 with other acquired and inherited anemias (16%).
The study was conducted during 2010-2014 with an ongoing 2-year follow-up
period until the end of 2016. Serum ferritin, liver function parameters, dosing
and adverse events were recorded at baseline and at month 1, 3, 6, 12, 18
and 24 following initiation of deferasirox therapy. Deferasirox was administered
according to the summary of product characteristics and pts with at least 1 fol-
low-up visit were eligible for analysis.
Results: Of a total of 420 pts, 243 were male (58%) and 177 female (42%) with
a median age of 74 yrs., (range 2-93 yrs.). Mean time from first diagnosis of the
hematological malignancy and transfusion therapy to initiation of IO therapy was
3.4 yrs. and 1.8 yrs. respectively. 227 pts (54%) showed a moderate need for
blood transfusions (2-4 units/month) and 107 pts (25%) a mild need for blood
transfusion (<2 units/month) at baseline. Deferasirox effectively reduced mean
iron burden as measured by serum ferritin from 2230 µg/L (±1279 µg/L) at base-
line to 1786 µg/L (±1390 µg/L) at 24 months, respectively. As expected, mean
creatinine clearance decreased from 91 mL/min to 80 mL/min within the first 3
months and remained stable until the end of observation. Median daily dose of
deferasirox at time of initiation was 17 mg/kg (range 2-30 mg/kg); dose adjust-
ments were required in 162 pts (39%). Adverse events (AE) were reported in
364 pts (87%). The most common AEs were gastrointestinal disorders (29%), a
decrease in renal creatinine clearance (22%) and an increase in blood creatinine
(18%), presented as proportion of pts suffering from the AE.
Summary/Conclusions: These findings indicate that chelation therapy with
deferasirox is feasible in treated patients with the capability to reduce iron bur-
den. The safety profile shows no unexpected toxicities. The results of this inter-
im analysis will further contribute to understand the management of IO therapy
with deferasirox in the routine setting. 
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CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY
PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS
DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014
A Dinmohamed1,2,3,*, O Visser4, M Jongen-Lavrencic3, A van de Loosdrecht5
1Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht,
2Public Health, Erasmus University Medical Center, 3Hematology, Erasmus
MC Cancer Institute, Rotterdam, 4Registration, Netherlands Comprehensive
Cancer Organisation (IKNL), Utrecht, 5Hematology, VU University Medical Cen-
ter, Amsterdam, Netherlands
Background: Specific morphological features in the bone marrow (BM)—eg,
type and degree of dysplasia, as well as myeloblasts—constitutes a diagnostic
hallmark of MDS. Careful assessment and subsequent documentation of these
features are necessary to facilitate an accurate classification of MDS according
to the World Health Organization (WHO) classification that was initially pub-
lished in 2001 and updated in 2008.
Aims: In this population-based study, we sought to assess the implementation
of the WHO classification of MDS in daily practice in the Netherlands according
to time and health care region.
Methods: We selected all adult (≥18 years) MDS patients diagnosed between
244 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
2001-2014 (N=8912; median age, 75 years; 59% males and 19% previous
malignancy) from the nationwide Netherlands Cancer Registry (NCR). All MDS
subtypes were recorded in the NCR according to the International Classification
of Diseases for Oncology Third Edition (ICD-O-3) that follows the WHO classi-
fication of MDS and includes: refractory cytopenia with unilineage dysplasia
(RCUD), refractory anemia (RA) with ring sideroblasts (RARS), MDS with iso-
lated del(5q), refractory cytopenia with multilineage dysplasia (RCMD), RA with
excess blasts (RAEB) and MDS not otherwise specified (MDS NOS). The ICD-
O-3 does not have separate codes for RAEB-1 or 2. Univariable and multivari-
able logistic regression models were constructed to identify variables associated
with the diagnosis of MDS NOS. These variables included age at, and year of,
diagnosis, sex, previous malignancy, as well as hospital type (non-academic v
academic) and health care region of diagnosis (8 regions in total).
Results: The proportion of MDS NOS decreased from 58% in 2001 to 13% in
2014 (Figure 1A). There was regional variation noted in the distribution of
MDS NOS (average in 2001-2014, 43%; range 30%>50%; P<0.001), which
eventually leveled off with time (average in 2014, 13%; range 8%>24%;
P=0.385; Figure 1B). Following multivariable logistic regression analysis with
adjustment for variables with P<0.20 in univariable analysis, age per 10 year
increase (odds ratio [OR], 1.18; P<0.001) was associated with having a MDS
NOS diagnosis, whereas year of diagnosis per 1 year increase (OR, 0.87;
P<0.001) and diagnosis in particular health care regions were associated with
a lower odds of MDS NOS.
Figure 1.
Summary/Conclusions: These encouraging population-based results indicate
that the classification of MDS improved markedly over time across all health care
regions in the Netherlands. The reason behind this improvement may be twofold.
First, clinicians, cytomorphologists and pathologists became increasingly aware
with the WHO classification of MDS. This is mainly due to efforts by HOVON to
create awareness for MDS by education and the design of MDS-specific clinical
trials, especially since 2008. Secondly, the registration of MDS subtypes by reg-
istrars of the NCR improved due to better training in recognizing MDS subtypes
in the medical records. Nevertheless, advance age is still associated with the
diagnosis of MDS NOS. It is anticipated that specific morphological features in
the BM will remain central for the classification of MDS in the upcoming revision
of the WHO classification that will be expected in 2016. Therefore, careful analysis
and proper documentation of morphological findings remain crucial to facilitate
an accurate classification of MDS, which, in turn, is needed to accurately inform
patients about their MDS. Well-established population-based registries are useful
instruments to evaluate guideline adherence and registration practice.
P626
LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR
PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC
SYNDROMES
AE DeZern1,*, G Binder2, S Rizvi2, FA Corvino3, SR Arikian3, A Surinach3,
J Lee3, BD Smith1
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Baltimore, MD, 2Celgene Corporation, Summit, NJ, 3Genesis Research, Hobo-
ken, NJ, United States
Background: For patients (pts) with myelodysplastic syndromes (MDS),
dependence upon red blood cell (RBC) transfusions has been long demon-
strated to be a risk factor for progression-free survival. Recent studies have
suggested that higher levels of transfusion burden are associated with worse
prognosis (Chan LSA, et al. Leuk Lymphoma 2014;55:10:2296-2300; Pereira
A, et al. Am J Hematol 2010;86:245-250). The increasing prognostic risk asso-
ciated with more frequent transfusions poses the question of whether costs
also vary with transfusion frequency.
Aims: To assess the costs associated with different levels of transfusion burden
among pts with transfusion-dependent (TD) lower-risk MDS, from a US per-
spective based on claims data.
Methods: Pts were identified from a large US claims database (2008–2013)
by ICD-9 codes for MDS, with the first such code determining the index date.
Pts with ≥12 months pre- and ≥6 months post-index data were included if they
met the criteria of TD post-index, defined as 2 consecutive 8-week periods
each with ≥1 transfusion episode and no interim 56-day period without a trans-
fusion. Pts with ICD-9 codes for high-grade MDS or acute myeloid leukemia at
diagnosis or stem cell transplant anytime were excluded. Transfusion burden
was measured as average days between RBC transfusions during the TD peri-
od. Pts were followed until they no longer met TD criteria or end of data. Total
costs of care (medical and pharmacy) were evaluated in 2015 US dollars from
a payer’s perspective, based on paid claims for initial TD periods and averaged
to determine monthly cost levels. 
Results: 2,645 TD MDS pts met the inclusion criteria; 59% were male and
51% were ≥75 years old. 1,854 (70%) pts averaged ≤28 days between RBC
transfusions during the TD period. When patients were categorized by the aver-
age time between transfusions, those transfused every 2–3 weeks comprised
the largest group (23%) (Figure 1). The principal differences in baseline char-
acteristics for TD pts transfused ≤28 days apart vs TD pts with less frequent
transfusions were sex (60.7% female vs 53.6% male), age (median 74 years
vs 78 years) and prevalence of thrombocytopenia (25.9% vs 16.8%). Average
monthly total cost of care per pt was 53% higher for TD pts transfused ≤28
days apart vs TD pts with less frequent transfusions ($19,497 vs $12,717).
Within the former group, costs were 58% higher among pts who transfused
≤14 days apart compared with those who transfused every 15–28 days
($25,268 vs $16,033). Inpatient services and pharmacy represented 45% and
8% of total monthly TD costs, respectively.
Figure 1. Average time between transfusions during TD period, and asso-
ciated average total monthly cost/patient*.
Summary/Conclusions: The average time between transfusions is heteroge-
neous among TD MDS pts, with 27% having ≤14 days between transfusions
and similar percentages transfused every 2-3 or 3-4 weeks. Pts with more fre-
quent transfusions had higher average monthly total costs. This suggests that
TD pts with higher transfusion burden face greater economic challenges as
well as the established clinical challenges.
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THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION
OF PATIENTS WITH LOWER-RISK MDS
T Knight Asorey*, J Falantes, FJ Márquez Malaver, C Calderón-Cabrera,
R Bernal, R Morales, I Espigado, J Pérez-Simón
Haematology and haemotherapy Service, Hospital Universitario Virgen del
Rocio, Sevilla, Spain
Background: Patients (pts) with Lower-risk Myelodysplastic syndromes (LR-
MDS) defined by having Low or Intermediate-1 IPSS score show a wide prog-
nostic heterogeneity. In addition to age, the presence of comorbidities defined
as other chronic advanced medical diseases, can impact on survival in MDS.
However, the prognostic significance has not been evaluated specifically in the
group of LR-MDS pts.
Aims: To evaluate extra-hematological comorbidities together with classic
hematological parameters in a series of pts with LR disease by IPSS and non-
unfavorable cytogenetic categories by IPSS-R.
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Methods: 232 pts with LR-MDS were retrospectively analyzed between 2000
and 2015. Only pts who received best supportive care with blood transfusion,
erythropoietic stimulating agents and/or just observation if no symptomatic
cytopenias were included. Non-leukemic death (NLD) was analyzed according
to the following variables: age, hematological parameters, IPSS and the MDS-
comorbidity index (MDS-CI. Della Porta MG, et al. Haematol. 2011)
Results: Clinical and baseline characteristics are shown in Table 1. At last
follow-up, 148 pts (64%) had died and 33 pts (14%) progressed to acute
myeloid leukemia. Diabetes requiring treatment and cardiac disease were the
most frequent comorbidities (30% and 29% respectively). Prevalence of
comorbidities was higher in the group of pts aged >65 years (63.3% vs 38.4%;
P=0.04) as well as the number of pts with more than one comorbidity (30.2%
vs 9.6%; P<0.001). After a median follow-up of 60 months (range, 48-71),
median OS for the whole series was 36 months (range, 30-41). In univariate
analysis, the following variables significantly influenced on outcome (P<0.05):
IPSS (low vs int-1), Hb <10 g/dL, platelet <50x10e9/L, BM blasts 5-9%, trans-
fusion dependence (TD), diabetes requiring treatment, cardiac, severe pul-
monary and severe to moderate hepatic disease as defined by MDS-CI. Table
2 shows multivariate analysis. Age did not influence on survival. According to
these data, an assigned weight was applied to each parameter with prognostic
impact for OS. As shown in Figure 1, three sets of patients were categorized
into different risk groups with significantly different risk of NLD (P<0.001):
group 1 (pts with score 0-2; Low-risk group, n=110, 47.5%), group 2 (score 3-
4; intermediate risk group, n=94, 40.5%) and group 3 (score 5-6; high risk,
n=28, 12%). At last follow-up, 51 out of 110 (46.4%) patients in the low risk
group and 69 out of 94 (73.4%) in the intermediate risk group had died from




Summary/Conclusions: This integrated score (clinical and comorbidity) stratifies
patients in 3 groups with significant different risk of NLD. Diabetes and cardiac
diseases are the most prevalent comorbidities. Interestingly, age, when consid-
ered together with clinical parameters and comorbidities, did not influence on
outcome. In summary, this study confirms the importance of comorbidities at
diagnosis, together with other well-known hematological parameters in pts with
LR-MDS and may help to proper define therapeutic strategies in this set of pts.
Bone marrow failure syndromes incl. PNH - Biology 
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STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS
WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELLS TRANSPLANTATION
N Petinati1,*, L Kuzmina2, N Sats1, N Drzie1, N Risinskaya3, A Sudarikov3,
V Vasilieva2, M Drokov2, E Michaylzova2, E Parovichnikova2, V Savchenko2
1Physiology of hematopoiesis lab., 2Bone marrow transplantation, 3Molecular
Hematology, NATIONAL RESEARCH CENTER FOR HEMATOLOGY, Moscow,
Russian Federation
Background: Graft failure following allogeneic hematopoietic cell transplanta-
tion (alloHSCT) may result from rejection by recipient T cell. The changes of
stromal microenvironment (SM) in patients with graft failure were not described.
It was demonstrated that multipotent mesenchymal stromal cells (MSC), the
element of SM, are impaired by allogeneic lymphocytes. It was assumed that
SM in patients with graft failure could be altered.
Aims: The aim of the study was to analyze SM in patients with graft failure and
long-term bone marrow (BM) aplasia.
Methods: A randomized clinical trial (ClinicalTrials.gov NCT01941394) for
acute graft-versus host disease prevention with MSCs has been on-going at
the National Research Center for Hematology. BM MSCs have been developed
individually for each patient from its own donor of HSC. Three patients with
AML and graft failure after alloHSCT (1 from unrelated and 2 from related par-
tially compatible donors) were observed. In an attempt to restore the SM donor
MSCs were injected under local anesthesia in the iliac crest after obtaining
informed consent from the patient. The cells were injected into the bone tissue
in small portions 100-200 mkl through 2 skin punctures, and multiple periosteal
punctures. In 2 patients bone marrow punctures were performed 5 and 3
months after the donors’ MSCs implantation. It was withdrawn by 2-3 ml of
bone marrow from 4 independent punctures from iliac crest of each patient.
Colony-forming units fibroblast (CFU-F) from these BM samples were analyzed
and MSCs were isolated and cultured by standard method.
Results: In 2 patients 2 weeks after MSCs administration their own
hematopoiesis recovered. Analysis of BM MSCs in 5 months after donor MSCs
implantation revealed significant decrease in cumulative MSCs production for
3 passages (1.2±0.2x106) compared with all AML patients after alloHSCT
(4.2±0.6x106) and healthy donors (8.0±2.1x106). The efficiency of cloning,
showing the number of MSCs with proliferative ability in the population, was
also significantly decreased (0.101±0.014) compared with donors (0.34±0.07).
In one patient leukocyte count reached 109/L only in 9 months after donor
MSCs implantation. Analysis of BM samples from this patient after MSCs
implantation revealed decrease of bone marrow cellularity (Table 1) per ml ver-
sus 16.7±0.7x106 in donors. Cumulative MSCs production in this patient was
very low (Table 1) Cloning efficiency was also significantly lower than donors.
Gradually, the total cell production increased and 3 months after the start was
2 times higher than the original and CFU-F concentration in the BM also began
to recover. In 3 and 5 months after MSCs implantation donor MSCs were found
in the bone marrow of 2 patients.
Table 1. Analysis of BM samples of one patient.
Days after         Number of   Number of BM   Cumulative MSC  CFU-F per 106   Efficiency
MSCs               leukocytes   cells/ml, x106      production for        BM cells       of cloning
implantation       per mkl                             4 passaged, x106
77                         100              1±0.16              0.73±0.2
99                         700           2.76±1.02          1.19±0.34               8.0
171                       700           2.32±0.21          1.56±0.38          40.8±15.7     0.25±0.08
Summary/Conclusions: Thus it is possible that graft failure in patients after
alloHSCT is not only connected with the immune response, but with severe
damage of bone marrow stromal cells, which may partly be restored after
administration of the donor MSCs.
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SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLO-
BINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY?
ES Kairemo1,*, AE Armstrong2, H Jarva1,3, S Meri1,3
1Department of Bacteriology and Immunology, University of Helsinki, 2Coagu-
lation Disorder Unit, Helsinki University Central Hospital Comprehensive Can-
cer Center, 3Helsinki University Hospital Laboratory (HUSLAB), Helsinki, Fin-
land
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired syn-
drome characterized by intravascular hemolysis, thrombosis and bone marrow
failure. The disease is caused by a mutation on the PIG-A gene that leads to
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a lack of glycosylphosphatidylinositol (GPI) -anchored complement regulatory
molecules CD55 and CD59 from the surface of a clonal lineage of blood cells.
The diagnosis of PNH is made by analyzing GPI-anchored molecules on blood
cells by flow cytometry. The disease course is often unpredictable and the ther-
apeutic options are limited. While in previous studies spontaneous remissions
have been reported to occur in up to 15-30% of cases, there are no detailed
case reports published of these patients. In particular, it would be important to
distinguish true remissions from other developing disorders, especially from
malignancy.
Aims: Because of the variable clinical course of PNH we wanted to explore
whether true spontaneous remissions occur in PNH in the Finnish patient mate-
rial. A nation-wide study of all patients in Finland since 1995 and an extended
follow-up time (up to 20 years) have allowed a detailed analysis of the course
of the disease in our patients. 
Methods: In a nation-wide project we collected patients from all Health Care
Districts in Finland. The sources of information included the Helsinki University
Central Hospital Laboratory (HUSLAB) databases, flow cytometry analysis of
red blood cells (RBC) and leukocytes, patients’ medical records and a patient
questionnaire. The patients were evaluated until September 2015. An ethical
permission for the study was given by the co-ordinating ethical committee at
the Helsinki University Hospital Health Care District. A research permission
was also obtained from the National Institute of Health and Welfare (Helsinki,
Finland) and the patients gave written informed consents for the study.
Results: In a cohort of 106 Finnish patients with a PNH clone we found six cases
where the clone disappeared or clearly diminished (to a level equal or below
1.5%). Two of the six patients subsequently developed leukemia (acute myeloid
leukemia and chronic myelomonocytic leukemia) while the other four are in clinical
remission. The median time from the diagnosis until the remission was 12.5 years
(range 6-15 years). For the two patients who developed leukemia the diagnosis
was made 26 years and 12 years respectively after the initial PNH diagnosis. For
one of the patients the CD59-deficient cell clone disappeared three years earlier
and for the other one in the same year leukemia was diagnosed. For all patients
the median CD59-deficient RBC clone size was 64% at highest (range 30-
91%). Four of the patients had classic PNH with signs of hemolysis. All of the
patients had underlying aplastic anemia. 
Summary/Conclusions: According to our data spontaneous remissions are
not as frequent as previously described and the disappearance of the PNH cell
clone may have dramatically different outcomes. Nevertheless, true remissions
occur, but the patients need to be carefully followed up for a potential emer-
gence of malignancy. The remission may have an immunological background.
In our cases immunosupressive treatment may have affected the PNH cell
clone or the cell clone could have lost its growth advantage after repopulation
of the bone marrow. Spontaneous remissions provide an interesting topic for
further studies, which could bring along a better understanding of the natural
history of PNH. 
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UNAFFECTED MYELOID DIFFERENTIATION OF IPS CELLS DERIVED
FORM A CYCLIC NEUTROPENIA (CYN) PATIENT WITH ELANE MUTATION
A Zahabi1,*, T Morishima1, R Bernhardt1, K Welte2, J Skokowa1
1Department of Hematology, Oncology, Immunology, Rheumatology and Pul-
monology, 2University Hospital Tübingen, Germany, Tübingen, Germany
Background: Cyclic neutropenia (CyN) is a hematologic disorder in which
blood cell counts particularly granulocytic neutrophils, monocytes, platelets,
and reticulocyte numbers show cycles at appr. 21 day intervals. The majority
of CyN patients (ca 90%) harbor inherited mutations in the ELANE gene. Intrigu-
ingly, same ELANE mutations are present in two different bone marrow failure
syndromes: congenital as well as in cyclic neutropenias. It is unclear how muta-
tion in the same gene cause congenital (CN) or cyclic neutropenia (CyN). The
pathomechanism of cycling hematopoiesis downstream of ELANE mutations
is also unclear. Recent studies using inducible pluripotent stem cells (iPSCs)
derived from severe congenital neutropenia (CN) patients harbouring ELANE
mutations demonstrated markedly diminished granulocytic differentiation of
these cells in vitro (Nayak RC, et al. JCI 2015; Hiramoto T, et al. PNAS 2013).
Interestingly, correction of ELANE gene mutation in iPSCs from a CN patient
using CRISPR/Cas9 technology restored defective granulopoiesis, suggesting
the monogenic origin of the ELANE mutation caused congenital neutropenia
(Nayak RC, et al. JCI 2015). These data suggest that additional gene mutations
or epigenetic defects in combination with mutated ELANE might be responsible
for the pathogenesis of cyclic neutropenia. 
Aims: In the present study we evaluated the in vitro myeloid differentiation of
iPSCs derived from the CyN patient harboring sporadic heterozygous ELANE
mutation (c.761C>G p.W241L), in comparison to iPSCs derived from healthy
individuals. 
Methods: We used embryoid-body (EB)-based protocol of granulocytic differen-
tiation from iPSCs described by N. Lachmann et al. (Stem Cell Reports 2015). 
Results: we found that myeloid differentiation of iPSCs derived from CyN
patient, was comparable to that of healthy individual iPSCs, as revealed by the
analysis of the percentage and absolute numbers of CD45+/CD11b+,
CD45+/CD16+ and CD45+/CD15+ cells as well as by the examinations of the
cell morphology on cytospin preparations. 
Summary/Conclusions: These data suggest that the in vitro hematopoiesis in
CyN is normal as judged by iPSC technology and that in vivo additional humoral
or bone marrow niche components might influence myeloid cell cycling in CyN.
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OUTCOME OF ADOLESCENT AND YOUNG ADULTS WITH ACQUIRED
APLASTIC ANEMIA TREATED WITH IMMUNOSUPPRESSIVE THERAPY IN
COMPARISON WITH CHILDREN AND OLDER ADULTS
A Cabannes-Hamy1,*, N Boissel1, R Peffault De La Tour2, E Lengliné3,
T Leblanc4, E Raffoux3, M Robin2, A Xhaard2, A Baruchel4, G Socié2,
N Dhédin1
1Adolecent and Young adult Hematology, 2Bone Marrow Transplantation Hema-
tology, 3Adult Hematology, Saint Louis Hospital, 4Pediatric Hematology, Robert
Debré Hospital, PARIS, France
Background: Acquired aplastic anemia (AA) is a rare hematological disorder
with a peak of incidence in the Adolescent and Young Adult (AYA) population.
Younger age has been associated with better response after immunosuppres-
sive therapy with anti-thymoglobulin and cyclosporine (ATG-CSA), as well as
better survival. However, no study focused on the specific outcome of AYA
patients so far.
Aims: This retrospective study assessed the impact of age on outcome of AA
after ATG-CSA by comparing AYA with younger and older patients.
Methods: We retrospectively analyzed a cohort of AA patients treated front-
line by the association of ATG (rabbit or horse) and CSA in Saint-Louis Hospital
between January 2000 and June 2013. Patients were divided into three age
groups: children (<15 years), AYA (15-25 years) and adults (>25 years). Eighty-
four consecutive patients were included (29 children, 32 AYA and 23 adults).
Children presented more frequently with very severe AA (55% versus 22% in
AYA and 22% in adults, p=0.023). Time from diagnosis to ATG was longer in
adults (69 days versus 26 in children and 28 in AYA, p=0.007). Children were
more frequently treated with rabbit-ATG (86% versus 59% in AYA and 52% in
adults, p=0.004). Patients were similarly transfused before ATG in the 3 groups.
Rates of transplantation after failure/relapse were similar in these subgroups.
Complete response (CR) was defined as a neutrophil count >1 G/L, a platelet
count >100 G/L and a haemoglobin level >10 g/dl, according to the National
Institutes of Health (NIH) criteria. Partial response (PR) was defined as trans-
fusion independence with a neutrophil count >0.5 G/L, but not meeting the
blood count criteria for CR.
Results: The overall response rate at 6 months was 48% in children, 69% in
AYA and 30% in adults, and 76%, 78% and 49% respectively at 5 years. In
multivariate analysis, along with the use of horse ATG (OR=3.398, p=0.045),
age remained associated with better response rate. Thus, in comparison with
AYA patients, the 6-month response rate was lower in adults (OR=0.179,
p=0.008) and similar in children (OR=0.609 p=0.386). The 5-year relapse rate
was 20.7%, with no impact of age. The only relapse risk factor identified was
higher baseline lymphocytes count (OR=1.939, p=0.011). Twenty seven
patients (12 children, 6 AYA and 9 adults) underwent allogeneic hematopoietic
stem cell transplantation (HSCT), 4 from an HLA-identical sibling donor (adults
over 40 years), 18 from an unrelated donor and 5 from cord blood. They were
referred to HSCT after failure (16), relapse (8) or clonal evolution (3). With a
median follow-up of 5.4 years, the 5-year overall survival (OS) was 86.5%.
After censoring at the time of HSCT, the 5-year OS was 95.9%. Eleven patients
died, all in failure/relapse after ATG-CSA, including 8 after HSCT (5 from infec-
tion, 2 from GVHD and 1 from graft failure). Adults over 25 years had shorter
survival than AYA (HR=4.984, p=0.049) and showed a trend toward worse sur-
vival than children (HR=3.311, p=0.092). However, in multivariate analysis,
younger age did not impact OS. The predictive factors associated with improved
survival were a lower baseline lymphocytes count (HR=4.696, p=0.015), a lower
baseline neutrophils count (HR=4.735, p=0.045), a higher baseline reticulocytes
count (HR=0.897, p=0.023) and a shorter time from diagnosis to ATG
(HR=7.341, p=0.001) (these 4 factors analyzed as continuous variables), as
well as a better 6-month response rate (HR=0.008, p=0.015).
Summary/Conclusions: Response rate of AYA population treated with ATG-
CSA for AA is similar to children’s and better than adult’s one. However, younger
age has no influence on OS or relapse.
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A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495,
A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC
PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
JM Johnston1,*, A Ricardo1, M Arata1, J Lickliter2, SJ DeMarco1, R Fahrner1,
RP Hammer1, B Newstat1, D Roychowdhury1, S Tobe1, D Winslow1, D Treco1
1Ra Pharmaceuticals, Cambridge, United States, 2Nucleus Network, Mel-
bourne, Australia
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired,
clonal hematopoietic stem cell disorder caused by a deficiency in glycosylphos-
phatidylinositol (GPI)-linked proteins on cell surfaces. Patients with mutations
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in the phosphatidylinositol glycan class A gene are unable to produce functional,
protective, GPI-linked proteins, resulting in the accumulation of specific com-
plement proteins on the surface of red blood cells (RBCs) and subsequent
RBC lysis by the membrane attack complex (MAC). Inhibition of complement
activation at the level of complement C5 is a clinically validated approach for
the treatment of PNH. RA101495, a synthetic macrocyclic peptide, binds to
C5 at a unique site not targeted by currently available therapies, and alloster-
ically inhibits C5 cleavage into C5a and C5b, preventing production of a key
component of the MAC. RA101495 also inhibits the assembly of MAC by block-
ing the interaction between C5b and C6.
Aims: A Phase 1 single-ascending-dose clinical pharmacology study in healthy
human volunteers designed to evaluate the safety, tolerability, pharmacokinetics
and pharmacodynamics of RA101495 following subcutaneous (SC) injection.
Methods: The study was randomized, double-blinded, and placebo (PBO)-
controlled with 4 SC single-ascending-dose cohorts housed in a clinical phar-
macology unit for 3 days. After obtaining written informed consent, all subjects
received 1 dose of RA101495 on Day 1. Four subjects (2 RA101495 and 2
PBO) were administered the lowest dose level (0.05 mg/kg) and 6 subjects
per cohort (4 RA101495 and 2 PBO) were sequentially administered the 3
higher dose levels (0.1, 0.2, and 0.4 mg/kg). Safety was assessed by intensive
clinical monitoring, and frequent blood samples were obtained for determination
of RA101495 concentrations by liquid chromatography/high resolution mass
spectroscopy and ability to inhibit complement-mediated RBC lysis in an ex
vivo antibody-sensitized sheep erythrocyte hemolysis assay. All subjects
received prophylaxis for N. meningitides infection with ciprofloxacin and, for
the highest dose, vaccination as well.
Results: A total of 22 subjects were enrolled into the study (14 RA101495 and
8 PBO). Plasma concentrations of a single SC injection showed linear dose-
dependent exposure across all dose levels. Preliminary results show that at
the maximum plasma concentration, the percent inhibition of hemolysis com-
pared to baseline reached ≥90% for the 0.1, 0.2, and 0.4 mg/kg dose cohorts
and 60% for the lowest dose (0.05 mg/kg) cohort. Suppression of hemolysis of
up to 4 days (further time points are being analyzed) was observed for the 0.1,
0.2, and 0.4 mg/kg dose ohorts. Notably, a single injection of 0.4 mg/kg resulted
in ≥90% suppression of hemolysis for at least 4 days. The only safety finding
noted was mild cutaneous injection site erythema in 3 of 6 subjects on the
highest dose (data are still blinded); there was no associated pain, tenderness,
swelling, or induration and all events resolved rapidly following dosing. 
Summary/Conclusions: RA101495 is a novel synthetic macrocyclic peptide
inhibitor of C5-mediated hemolysis that is being developed as an alternative to
intravenous monoclonal antibody therapy for the treatment of PNH. RA101495,
currently being investigated for daily at-home SC self-administration, shows a
rapid onset of activity, and appears to be safe and well tolerated. These preliminary
data suggest low daily doses will achieve steady-state levels suitable for ≥90%
suppression of hemolysis, and that once-weekly dosing should be achievable.
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THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF
RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC
ANEMIA (AA) PATIENTS.
E Nevill1,*, B Dalal2, S Narayanan1, H Donna1, M Power1, D Sanford1,
D Forrest1, S Nantel1, M Barnett1, Y Abou Mourad1, A Gerrie1, K Song1,
C Toze1, R Broady1, H Sutherland1, T Nevill1
1Division of Hematology, Leukemia/BMT Program of BC, 2Division of
Hematopathology, Vancouver General Hospital, Vancouver, Canada
Background: Immunosuppressive therapy (IST) is effective in improving the
hematologic cytopenias in 65-75% of patients (pts) with aplastic anemia (Young
NS, Blood, 2006). A clone of hematopoietic cells deficient in glycosylphos-
phatidylinsoitol membrane protein anchors - a PNH clone - can be seen in
~50% of AA (pts) (Socie G, Sem Hematol, 2000). The presence of a PNH clone
in AA may predict for a favourable response to IST (Sugimori, Blood, 2006)
although this remains controversial (Scheinberg, Br J Haemtol, 2009). The
development of high-resolution PNH flow cytometric testing may be a mitigating
factor explaining interstudy variability.
Aims: To determine whether the presence or the size of a PNH clone in AA pts
affects the rate or degree of response to standard IST at a regional/provinical
referral centre.
Methods: A retrospective chart and computer data base review was performed
on all AA pts >age 16 years (yrs) referred to Vancouver General Hospital (VGH)
between January 2008 and October 2015 for treatment with IST. Bone marrow
pathology was centrally reviewed and all pts had metaphase cytogenetic analy-
sis performed to exclude a clonal abnormality. PNH flow cytometry was done
at VGH on the red cells, granulocytes and monocytes of all pts using an anti-
body panel that included FLAER, CD55 and/or CD59. IST was uniform during
the study period and consisted of Cyclosporine (CSA) 2.5 mg/kg p.o. b.i.d.,
ATGAM 40 mg/kg/d IVx4 and IV Methylprednisolone 1 mg/kg/dx10 with a 10-
day taper. CSA doses were adjusted to maintain whole blood trough CSA levels
of 200-300 ug/L for a 12-month period followed by tapering based uoon hema-
tologic tolerance. Severity of AA and criteria for response to IST were as pre-
viously published (Marsh J, Br J Haematol, 2009). Statistical comparisons were
performed using the Fisher’s exact test and differences in group medians were
assessed with the Mann Whitney U test.
Results: During the 8-year study period, 57 pts with AA received IST at VGH;
2 pts died within 2 weeks of commencing treatment and 55 pts were evaluable
for response. There were 28 males (M) and 27 females (F) with median age of
56 yrs (range 17-74). AA was very severe in 7 pts, severe in 28 pts and non-
severe in 20 pts. Response to IST was seen in 39 pts (70.1%) - partial response
(PR) in 26 pts (47.3%) and complete response (CR) in 13 pts (23.6%). Ten pts
received a second cycle of ATGAM or rabbit ATG (Thymoglobulin), 3 pts for
recurrent AA following CSA taper (all responded) and 7 pts for initial non-
response (no responses at 12 mos). A PNH clone was found at diagnsois in
29 pts (52.7%; PNH+) with median clone size 0.9% (range 0.1% - 87%). M/F
ratio was 0.7 in PNH+ pts and 1.6 in pts without a PNH clone (PNH-) (p=0.18).
Median age was similar in the PNH+ (51 yrs) and PNH- (57 yrs) groups (p=0.49)
but was significantly younger in PNH+ pts with clone size >1%, n=14 (33.5 yrs;
p=0.04). Rate and degree of response to IST was similar in PNH+ pts (65.5%;
20.7% CR) and PNH- pts (76.9%; 26.9% CR) (p=0.38) and the size of the PNH
clone did not influence the response rate. Kinetics of response to IST did differ
notably between PNH+ and PNH- pts (Table 1).
Table 1.
                                3 mos                     6 mos                    12 mos                   24 mos
PNH+ (n=29)             51.7%                    62.1%                    65.5%                    65.5%
PNH- (n=26)              42.3%                    53.8%                    53.8%                    76.9%
All of the PNH+ responders achieved ≥PR by 12 months while 6/20 of the
PNH- pts reached PR/CR between 12 and 24 mos (p=0.02). On serial testing,
PNH clone size increased >10% in 3 pts (10%) and decreased by >10% in 2
pts (7%). Five pts in the PNH- group (19%) developed a persistent PNH clone
on follow-up. With a median follow-up of 44 mos, 49 of 55 evaluable pts remain
alive; 4 PNH+ pts and 2 PNH- pts have died.
Summary/Conclusions: IST is associated with a 70% response rate in AA
pts. The presence of a PNH clone and the size of a PNH clone does not predict
the degree or rate of response to IST. However, the kinetics of response differs
between PNH+ and PNH- pts. PNH- pts may take longer to achieve response
criteria with 20-25% of pts responding during the seond year of IST.
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A CLINICAL SIGNIFICANCE AND TIME-DEPENDENT CHANGE OF PNH
CLONE SIZE IN PATIENTS WITH BONE BARROW FAILURE SYNDROME:
JAPANESE MULTI-CENTRE PROSPECTIVE STUDY
Y Shirasugi1,2,*, C Sugimori2,3, H Noji2,4, T Shichishima2,4,5, N Obara2,6,
S Chiba2,6, H Ninomiya2,7, Y Nakamura1,2, K Ando1,2, Y Yonemura2,8,
T Kawaguchi2,9, K Hosokawa2,10, Y Ueda2,11, JI Nishimura2,12, Y Kanakura2,12,
S Nakao2,13
1Hematology and Oncology, Tokai University School of Medicine, Isehara,
2Japan PNH Study Group, Tokyo, 3Hematology, Ishikawa Prefectural Central
Hospital, Kanazawa, 4Cardiology and Hematology, Fukushima Medical Uni-
versity, 5Fukushima Research Institute of Environment and Medicine, Fukushi-
ma, 6Hematology, 7Medical Sciences, University of Tsukuba, Tsukuba, 8Trans-
fusion Medicine and Cell Therapy, Kumamoto University Hospital, 9Kumamoto
University Graduate School of Medical Sciences, Kumamoto, Japan, 10Hema-
tology Branch, National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, United States, 11Hematology and Oncology, Osaka Univer-
sity Graduate School of Medicine, 12Hematology and Oncology, Osaka Uni-
versity Graduate School of Medicine, Suita, 13Cellular Transplantation Biology,
Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
Background: In patients with bone marrow failure (BMF) syndromes, including
aplastic anemia (AA) or low-risk types of myelodysplastic syndrome (MDS), a
small population of GPI-AP-deficient blood cells (PNH-type cells) is often
detectable through high-resolution flow cytometry. Some studies have shown
that BMF patients with PNH-type cells have a favorable response to immuno-
suppressive therapy (IST), compared to BMF patients lacking PNH-type cells.
Aims: We conducted a multi-centre prospective observational investigation in
Japan, the OPTIMA study, to determine the clinical significance and time
dependent change of PNH clone size in BMF patients.
Methods: From July 2011, we recruited patients who were diagnosed with
BMF syndromes. The primary endpoint was to determine the prevalence of
increased PNH-type cells in BMF syndromes and to clarify the clinical signifi-
cance of the presence and quantitative changes of these cells with regard to
clinical features. Six university laboratories across Japan were assigned as
regional analyzing centres and the percentage of PNH-type cells was measured
by high-resolution flow cytometry, originally established in Kanazawa University.
Cross validations were conducted twice per year at each regional centre to
minimize inter-laboratory variations in detection sensitivities, cutoff values, and
other variables. The liquid FLAER method (≥0.003%) and cocktail method
(≥0.005%) with CD55 and CD59 antibodies were used for the detection of
PNH-type granulocytes and erythrocytes.
Results: Between July 2011 and July 2015, 2411 patients were enrolled in the
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study, and we analyzed 2299 patients who were eligible for this interim analysis.
Based on high-resolution flow cytometry, 784 (34.1%) patients had ≥0.005%
PNH-type erythrocytes and ≥0.003% PNH-type granulocytes; for each disease
subset PNH-type cells were found in 73/73 (100%) patients with PNH, 377/716
(52.7%) with AA, 110/622 (17.7%) with MDS, 182/655 (27.8%) with undiagnosed
BMF, and 42/233 (18%) with suspected PNH. Overall, 186 (8.1%) patients had
≥1% of both PNH-type erythrocytes and granulocytes: 69 (94.5%) patients with
PNH, 69 (9.6%) with AA, 22 (3.5%) with MDS, 10 (1.5%) with undiagnosed BMF
syndromes and 16 (6.9%) with suspected PNH. With regard to the WHO classi-
fication of MDS subtypes, 20.1% (58/288) of patients with RCMD, 17.5% (28/160)
with RCUD, and 40% (2/5) with del (5q) MDS possessed PNH-type cells; no
patients with RARS (n=27) or RAEB (n=63) had PNH-type cells. At 3-year fol-
low-up, a total of 86 (3.7%) patients were able to be evaluated for time-dependent
changes of PNH-type cells. Seventy-six of the 86 (11 with PNH, 48 with AA, 11
with MDS, 4 with undiagnosed BMF syndromes, and 2 with suspected PNH)
patients had PNH-type cells at enrollment. In four of the 76 patients, PNH-type
cells became undetectable at 3-years; 3 of the 4 patients had AA and the other
had MDS; all but one AA patient received IST and achieved partial or complete
response to the treatment. PNH-type cells were not detected at 3 years in 10
patients who did not show PNH type cells at enrollment.
Summary/Conclusions: PNH-type cells were detected in 52.7% of patients
with AA and 17.7% of patients with low-risk types of MDS, but were not detected
in any of RARS and RAEB patients. The results of the nation-wide study con-
firmed our previous finding that the presence of increased PNH-type cells rep-
resents a benign nature of bone marrow failure.
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HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION: A VALID ALTERNATIVE OPTION FOR PATIENTS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
F Chen*, D Wu, X Tang, M Miao, C Fu, H Qiu, S Xue, X Ma, Z Jin
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: In the era of Eculizumab, indentifying patients with PNH who may
benefit from allogeneic stem cell transplantation(SCT) is challenging, especially
for those who have no HLA-matched donors. Several recent studies have shown
that HLA-haploidentical SCT for patients with hematological malignancy can
achieved comparable outcomes with HLA-identical sibling transplantation. There
are very few reports on the use of HLA-haploidentical SCT for PNH. 
Aims: The aim of the present study was to assess the long-term clinical out-
come of HLA-haploidentical SCT in patients with PNH.
Methods: Total of 12 PNH patients received HLA-haploidentical SCT between
Oct 2010 and Oct 2015 at our institution. The patients were aged 8 to 54(median
22.5 years). The median interval from the diagnosis to transplantation was 5
months (range 2-180). Of the 12 HLA-haploidentical donors, 6 were siblings, 2
fathers, 2 mothers, 1 son and 1 daughter. 11 patients received myeloablative
conditioning regimen consisting of busulfan, cyclophosphamide and ATG (anti-
thymocyte globulin), 1 patient who underwent salvage HLA-haploidentical SCT
after the graft failure of double umbilical cord blood transplantation received con-
ditioning including reduced-intensity total body irradiation, cyclophosphomide and
ATG. G-CSF-mobilized bone marrow and peripheral blood stem cells were trans-
planted as graft. Prophylaxis for graft-versus-host disease(GVHD) consisted of
cyclosporine or tacrolimus+mycophenolate mofetil+short-term methotrexate.
Results: All 12 patients were engrafted successfully. The median time of neu-
trophils (ANC) reached to 0.5×109/L and platelets (PLT) reached to 20×109/L
were 12 (range 11-26) days and 15 (range 11-120) days, respectively. 2 patients
developed grade II acute GVHD, 2 patients developed limited chronic GVHD.
After a median follow-up time of 16.5 (range 2.0-40.0) months, the 3-year OS
probability was 77.8±13.9%. 2 patients died of treatment-related mortality,
including severe pulmonary infection (n=1) and transplant-associated throm-
botic microangiopathy (n=1),respectively. No patients were documented to have
a recurrence of PNH clone after SCT.
Summary/Conclusions: This study showed that long-term outcomes of HLA-
haploidentical SCT in patients with PNH were comparable to that of HLA-
matched donor SCT (the 3-year OS probability was 80.5±10.2%, P=0.02) at
our institution. HLA- haploidentical SCT should be considered as a valid alter-
native therapeutic option for PNH patients without HLA-matched donors.
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GENE MUTATIONS IN INHERITED BONE MARROW FAILURE SYNDROME
REVEALED BY NEXT GENERATION SEQUENCING: COMPARISON WITH
CHROMOSOME BREAKAGE TEST
DS Lee1, SN Park2,*, KO Im2, JA Kim1, HS Park1, SM Hwang3
1Dept of Laboratory Medicine, 2department of tumor cell biology, Seoul National
University College of Medicine, Seoul, 3Dept of Laboratory Medicine, Seoul
National University College of Medicine, Bundang, Korea, Republic Of
Background: Inherited bone marrow failure syndrome (IBMFS) is character-
ized by cytopenias, congenital physical abnormalities, and predisposition to
malignancy. Fanconi Anemia (FA) is the most frequent cause among IBMFS
and chromosome breakage test is routinely performed to diagnose FA, while
gene tests for FA is not easily accessible due to large sized and multiple
involved genes. We performed whole genome sequencing and compared the
gene mutation with the results of chromosome breakage test.
Aims: The aim of our study was 1) to investigate the incidence of FA showing
positive results for CBT among patients diagnosed with AA, and 2) to investigate
the frequency of the gene mutations which are related to IBMFS in patients with
AA. We collected the DNA of 16 patients who were suspected for the diagnosis
of IBMFS and performed whole genome sequencing. For specimen in whom we
could not acquire consent for genetic testing and research, we retrospectively
rescored the results of CBT according to 3 different diagnostic criteria for FA.
Methods: In 16 patients with childhood Aplastic Anemia(AA), whole genome
sequencing was performed in context with chromosome breakage test with mit-
omycin C and diepoxybutane. Additionally, the results of 67 consecutive chromo-
some breakage tests from 57 patients under suspicion of FA were retrospectively
rescored based on widely used 3 different scoring systems and compared the
concordance rate among the results of 3 different scoring systems.
Results: Mutation variants related with IBMFS were detected in 68.8% (11/16
patients); RPS19 and RPS24 in 2 patient, BLM in 2 patient and FA genes (FAN-
CA, FANCD1, FANCG, FANCJ, FANCM, FANCN, FANCO) in 9 patients. Inher-
ited predisposition to myeloid leukemia related genes (MSH6, ATR, MPL) were
detected in 18.7% (3/16 patients). Coexisting somatic mutations of oncogene
(MAP3K1) was detected in 1 patients among 9 patients with FANC mutation
(11.1%, 1/9 FA patients). Among 9 patients with FA gene mutations, 2 patients
showed positive results for chromosome breakage test and the other 7 patients
showed negative results for chromosome breakage test. Concordance rate
among 3 different scoring systems for chromosome breakage test was 91.2%
(52/57 patients) (Table 1).
Table 1.
Summary/Conclusions: Whole genome revealed high frequency (68.8%) of
IBMFS related genes in childhood aplastic anemia, suggesting that molecular
testing is requisite for diagnosis of IBMFS. Considering that chromosome break-
age test detected only 22.2% of FA patients who were confirmed by molecular
test and significant portion of patients who showed positive chromosome break-
age test did not harbor FA gene mutation, significance of chromosome breakage
test for FA must be reconsidered.
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PROSPECTIVE STUDY ON THE USE OF PEGFILGRASTIM IN CHILDREN
WITH SEVERE CONGENITAL NEUTROPENIA
F Fioredda1,*, T Lanza1, F Gallicola1, M Lanciotti1, E Mastrodicasa2, S Signa1,
S Zanardi3, M Calvillo1, C Dufour1
1Haematology Unit, IRCCS Istituto Giannina Gaslini, Genova, 2Pediatric Oncol-
ogy Haematology Unit, S Maria della Misericordia Hospital, Perugia, 3Biosta-
tistic and Epidemiology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background: Granulocyte-ColonyStimulating Factor (G-CSF), has radically
changed the prognosis of Severe Congenital Neutropenia (SCN) patients who
are at risk of lethal infections.The compliance to daily subcutaneous injections
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is sometime scarce thus affecting the efficacy of treatment.The peghilated
form of filgrastim (PEG) due to its long half-life should enable the frequency
of injections.
Aims: To describe the efficacy, safety and PK profile of PEG in children affected
with SCN.
Methods: SCN pediatric patients treated with G-CSF scarcely compliant to
daily injections, were considered eligible to the study. After 72 hours wash out,
PEG was administered at starting dose of 100 g/kg at an interval not shorter
than 4 days; subsequent injections aimed to mantain median absolute neu-
trophil count (ANC) between 1000-5000/cmm and to control infections. Bone
marrow morphology, cytogenetics, G-CSFR mutation analysis, abdomen ultra-
sound scan, and bone density assessment by dual energy X-ray absorptiometry
(DEXA) were performed at baseline and then yearly. Blood count, biochemical
parameters, serum concentration of pegfilgrastim (ELISA,Quantikine HS, R
and D System, Inc, MN) were frequently evaluated within the first six months
and afterward 3-4 times/year. Evaluation of QoL up by Short Form Health Sur-
vey questionnaire (SF-36) was performed at the beginning and at the end of
the follow-up. Infectious load was calculated by infectious ratio (IR) which con-
siders the number of documented infections over the period at risk/patient,
normalized by 1000.
Results: From July 2006 to Oct 2015, 5 SCN patients (3males) diagnosed at
a median age of 2 months (0-18) entered in the study. Four patients were
ELANE and one HAX-1 mutated. G-CSF was given for a median of 36 months
(0,23-89) and at a median dose of 7.5g/kg (5-25 g/day) before PEG. Median
age at enrollment was 50 months (7-110) and median duration of PEG was 46
months (7-111). The median PEG dose was 60g/kg (50-100) given every 7-12
days. ANC rose from a median of 1000/cmm in G-CSF to 1515/cmm in PEG
(p=ns). IR dropped from 9.5 in G-CSF to 5.5 in PEG (p=ns).Otitis, otomastoditis
and skin abscesses were the most frequent type of infections seen during
PEG.When PEG was given every 7-8 vs every 9-12 days ANC significantly
increased (1283/cmm) over G-CSF phase (670/cmm; p=0.002). Also IR further
declined with the more frequent PEG schedule (IR 6 vs 3.5; p=ns). The QoL
questionnaire showed a marked overall improvement (100%) particularly in
physical and mental performances and a relevant reduction of physical
pain.PEG was never interrupted because of side effects.Biochemical parame-
ters remained in the normal ranges, spleen size did not increase and in one
patient osteoporosis developed. In the same patient a mutation of G-CSF
receptor appeared after 4 years of PEG then disappeared. Peak serum con-
centration of PEG was achieved after 72 hr from administration, levels then
declined to those of the washout phase (Pre-PEG) on day 7.
Summary/Conclusions: PEG was able to rise neutrophils and to protect
patient toward severe infections enabling a better quality of life withoutside
effects. PK data are probably in keeping with low risk of overexposure. Larger
study and longer follow up are needed to confirm these findings.
Novel targets for MM
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IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS
RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER
LENALIDOMIDE-DEXAMETHASONE THERAPY
A Bolomsky1,*, E Müldür1, V Fritz1, D Heintel1, M Wilheim2, N Zojer1, W Hübl2,
H Ludwig1
1Wilhelminen Cancer Research Institute, Department of Internal Medicine I,
Wilhelminenspital, 2Department of Laboratory Medicine, Wilhelminenspital,
Vienna, Austria
Background: The identification of cereblon, ikaros and aiolos as central part-
ners and targets of immunomodulatory drugs (IMiDs) represents a milestone
in our understanding of the mechanisms of actions of these agents. However,
although we and others noted a significant association between the expression
of these molecules and response or survival, methods for a valid stratification
of patients to IMiD-based therapies are still missing.
Aims: In the current study, we analysed IKAROS protein expression by using
multicolour flow cytometry in myeloma cells as well as distinct cell subsets of
the bone marrow microenvironment for its potential as predictive and/or prog-
nostic marker for IMiD-based therapies.
Methods: IKAROS protein levels were analysed in stored BM samples of 16
MM patients before initiation of treatment with lenalidomide-dexamethasone.
Cells were thawed, restored overnight and stained for CD3/CD38/CD45/
CD56/CD138/HLA-DR or CD3/CD4/CD8/CD14/CD19/CD34/CD45. Intracellu-
lar staining of IKAROS (or the corresponding isotype control) was performed
according to the BD Transcription Factor Buffer Set protocol. Live/dead cells
were discriminated using BD Fixable Viability Stain 520. Analyses were per-
formed on a FACS Canto II.
Results: IKAROS protein expression was detected in all cell subtypes analysed,
including MM cells, B-lymphocytes, T-lymphocyte subsets (CD3+CD4+,
CD3+CD8+, CD3+CD4+CD8+, CD3+CD4-CD8-), NK cells, monocytes and
CD34+ cells. No association was observed between IKAROS protein levels and
response. However, we detected a significant correlation of IKAROS protein lev-
els and overall survival (OS) for the percentage of IKAROS positive B-lympho-
cytes (R=0.61, P=0.012) and CD3+CD8+ T cells (R=0.50, P=0.047). Similarly,
IKAROS median fluorescence intensities (MFI) of CD3+ T lymphocytes (R=0.55,
P=0.027), CD3+CD8+ T cells (R=0.53, P=0.035) as well as monocytes (R=0.55,
P=0.029) significantly correlated with OS. No association was found between
OS and the percentage of IKAROS positive MM cells (R=0.10 P=0.70) or MFI of
MM cells (R=0.12, P=0.65). Univariate Cox regression analysis confirmed the
association with survival for the percentage of IKAROS positive B-lymphocytes
(P=0.014) and the MFI of CD3+ (P=0.029) and CD3+CD8+ (P=0.05) T lympho-
cytes as well as monocytes (P=0.017). When we stratified patients according to
high or low IKAROS expression (cutoff=mean) in distinct cell subtypes we were
able to define different prognostic subgroups. In particular, a higher percentage
of IKAROS positive cells were associated with better outcome for B-lymphocytes
(median OS 82.3 vs 33.6 months, P=0.01) and CD3+CD8+ T lymphocytes (medi-
an OS 82.3 vs 31.8 months, P=0.05). Again, no association was observed
between the percentage of IKAROS positive MM cells and OS (median OS 35.6
vs 45.3 months, P=0.43).
Summary/Conclusions: In conclusion, our results demonstrate a significant
association between IKAROS protein levels in bone marrow CD3+CD8+ T lym-
phocytes, B-cells and monocytes with overall survival. In contrast, no associ-
ation was noted between IKAROS expression in myeloma cells and OS. This
suggests that the activity of IMiDs is mainly mediated via IKAROS expression
in bone marrow immune cells, which therefore could serve as prognostic marker
for patients assigned to IMiD containing regimens. Based on these initial
results, prospective analysis of IKAROS protein expression in an enlarged
patient cohort is in progress.
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CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA
MICROENVIRONMENT
K Beider1,*, V Voevoda1, H Bitner1, E Rosenberg1, O Ostrovsky1,
E Ribakovsky1, M Leiba1, A Shimoni1, M Koren-Michowitz1, M Abraham2,
A Peled2, A Nagler1
1Bone Marrow Transplantation, Sheba Medical Center, Ramat-Gan, 2Goldyne
Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel
Background: Chemokine and cytokine network plays an important role in mul-
tiple myeloma (MM) pathogenesis. Studying the underlying mechanisms may
help to identify new therapeutic targets to treat MM. Here we reveal B-cell
chemo-attractant CXCL13 (BCA-1) being novel factor expressed in the tumor
microenvironment of MM, supporting osteoclastogenesis and being associated
with extramedullary progression.
Aims: To characterize the expression of CXCL13 and define its functional
sequel in the MM milieu.
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Methods: We utilized our recently established in vivo xenograft model of BM-
disseminated human myeloma (using engineered CXCR4-expressing
RPMI8226 cells), as well as analysis of MM cell lines, stromal components and
primary samples from patients (pts) with MM.
Results: Evaluation of the cytokines in sera of MM-inoculated mice in comparison
to control mice detected increased levels of the CXCL13 chemokine being the
highest factor among the broad panel analyzed. Elevated mCXCL13 was also
detected in bone marrow (BM) samples from the MM-bearing mice, and correlated
with induced expression of murine factors associated with osteoclast (OC) acti-
vation (RANKL, NFATc, GPNMB, CTSK, OSCAR). IHC analysis of MM-occupied
murine BM revealed myeloid cells being the main source of increased mCXCL13,
while human RPMI8226 cells in murine BM milieu also expressed detectable lev-
els of hCXCL13. In addition, hCXCL13 mRNA was found to be expressed by
MM cell lines (n=8), BM stromal cell lines and peripheral-blood generated Mф.
Strong induction of CXCL13 expression in both MM and stromal cells was detect-
ed upon their co-culture. Furthermore, CXCL13 expression in BMSCs and Mф
was significantly induced following RANKL treatment; in turn, addition of CXCL13
up-regulated RANKL levels, demonstrating a positive regulation loop between
CXCL13 and RANKL. Functional tests revealed the ability of CXCL13 to induce
in vitro formation of TRAP+ OCs, while CXCL13 neutralizing antibodies blocked
this effect. Furthermore, CXCL13 neutralization markedly decreased RANKL
expression in BMSCs. Of note, CXCR5, cognate CXCL13 receptor, was
expressed predominantly by stromal and myeloid cells, suggesting the paracrine
effects of MM-generated CXCL13. Mechanistically, we found that TGFβ signaling
was involved in CXCL13 induction in both MM and stromal cells. Addition of TGFβ
receptor kinase inhibitor SB-431542 interfered with the activation triggered by
the interaction between MM cells and stromal components and prevented the
increase in CXCL13 expression. Finally, we evaluated the presence of hCXCL13
in primary MM samples. CXCL13 transcript was detected in BM aspirates from
MM pts (n=20), its expression was significantly upregulated upon co-culture with
BM stromal cells and correlated with expression of osteoclastogenic factors,
including RANKL and MT1-MMP, an important component of OC fusion machin-
ery. In addition, plasma level of CXCL13 was significantly higher in MM pts (n=44)
(148 pg/ml±136) in comparison to normal individuals (n=9) (19 pg/ml±7.6)
(p<0.001). Furthermore, IHC analysis of BM biopsies from MM pts (n=7) and
plasmacytoma samples (n=6) demonstrated the expression of CXCL13 in malig-
nant plasma cells. Importantly, CXCL13 showed markedly increased expression
within plasmacytoma tissues, suggesting that elevated CXCL13 levels may be
associated with extramedullary disease (Figure 1).
Figure 1.
Summary/Conclusions: Altogether, our data define a previously unrecog-
nized role of CXCL13 in MM, unravel its involvement in the osteoclastogenic
process and suggest CXCL13 as potential novel target for the diagnosis and
treatment of MM.
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MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVI-
RONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID
DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING
AND MULTIPLE MYELOMA PATIENTS
C Giallongo1, D Tibullo1,*, NL Parrinello1, P La Cava1, G Camiolo1, G D’Amante1,
N Caporarello2, C Conticello1, CD Anfuso2, A Romano1, F Di Raimondo1
1Division of Hematology, azienda ospedaliera universitaria policlinico vittorio
emanuele, 2Dept. of Biomedical and Biotechnological Sciences, School of Med-
icine, University of Catania, Catania, Italy
Background: A well-recognized feature of multiple myeloma (MM) is the inti-
mate relationship between plasma cells (PC) and BM microenvironment, which
is mainly composed of mesenchymal stromal cells (MSC), endothelial cells,
immune cells and extracellular matrix. Granulocytic-Myeloid-derived suppressor
cells (G-MDSC) accumulate in the tumor microenvironment during tumor devel-
opment. MDSC promote tumor growth and invasion, immunosuppression and
host immune evasion by suppressing lymphocyte activation and antigen recog-
nition. Even though it has been demonstrated that G-MDSC are increased in
MM microenvironment, the role of MSC in promoting immunosuppressive
microenvironment through activation of G-MDSC remains unexplored.
Aims: Analyzing MSC from MGUS, Smoldering myeloma (SMM) and MM
patients in promoting tumor microenvironment transformation.
Methods: Human peripheral blood mononucleated cells (PBMC) isolated from
healthy subjects (HS) were cultured alone, with HS- (n=8), MGUS- (n=6), SMM-
(n=4) or MM-MSC (n=12, 8 patients at diagnosis and 4 relapsed) at 1:100 ratio.
After one week, PBMC were collected. G-MDSC were isolated using anti-
CD66b magnetic microbeads and the phenotype (CD11b+CD33+CD14-
HLADR-) was confirmed by cytofluorimetric analysis. Immunosuppression was
analyzed after incubation with autologous T cells CFSE+ stimulated by phyto-
haemagglutinin (PHA-P).
Results: G-MDSC educated by SMM- and MM-MSC co-cultures (MSCed-G-
MDSC) exhibited suppressive effect with a reduction of T cell proliferation
(p<0.001) compared to G-MDSC control (isolated from PBMC cultured in medi-
um alone). Notably, neither MDSC control nor HS- or MGUS-MSCed-G-MDSC
showed suppressive ability. Before incubation with T cells, the expression of
immunomodulatory factors was investigated by real-time PCR in SMM- and
MM-MSCed-G-MDSC compared to MGUS-MSCed-G-MDSC. SMM- and MM-
MSCed-G-MDSC up-regulated Arg1 (56.4±18.2 and 24.9±13, p<0.001), NOS2
(82±35 and 21±18, p<0.001), TNFα (10±3 and 45.7±28.8, p<0.05) and CEBPA
(90±23 and 65±19, p<0.001), a transcription factor promoting suppressive phe-
notype. Adding Bortezomib (5 nM) to co-culture of SMM- and MM-MSC with
PBMC, isolated G-MDSC lost immunosuppressive ability. Analysis of MM-MSC
from 4 patients revaluated after 3 bortezomib-based therapy followed by autol-
ogous stem cell transplantation showed that their immunological dysfunction
was reverted after therapy. Since it has been reported that neutrophils can
acquire monocytic characteristics in response to inflammatory signals, G-MDSC
control and MSCed-G-MDSC were plated onto dentine disks (DDs) for 3 days.
A significant digestive activity was observed only in DDs with MM-MSCed-G-
MDSC (p=0.002) and was lost by MM-MSCed-G-MDSC isolated from co-culture
with Bortezomib. Moreover, compared to MGUS-MSCed-G-MDSC, SMM- and
MM-MSCed-G-MDSC up-regulated PROK2 expression (5.2±1.2 and 7.6±2,
p<0.05), a chemotactic and pro-angiogenic factor. Investigating effect on angio-
genesis in vitro, MM-MSCed-G-MDSC induced tube formation. On the contrary,
this effect was not observed in the condition with MM-MSCed-G-MDSC isolated
from co-culture with Bortezomib.
Summary/Conclusions: MSC from SMM and MM but not MGUS patients are
able to activate G-MDSC favoring indirectly transformation of microenvironment
in a “tumor” milieu with consequent immune escape and PC growth and survival.
Their immunological dysfunction can be reverted by bortezomib exposure.
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TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH
& SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT
A Bolomsky1,*, K Schlangen2, W Schreiner2, N Zojer1, H Ludwig1
1Wilhelminen Cancer Research Institute, Department of Internal Medicine I,
Wilhelminenspital, 2Center for Medical Statistics, Informatics and Intelligent
Systems, Medical University of Vienna, Vienna, Austria
Background: The polycomb complex protein BMI-1 was previously reported
to be overexpressed in multiple myeloma (MM) and silencing of BMI-1 was
shown to impair the proliferation and survival of MM cells. However, therapeutic
agents specifically targeting BMI-1 are not available so far.
Aims: Here we investigated PTC-209, a novel transcriptional repressor of BMI-
1, for its activity in MM.
Methods: BMI-1 expression was analysed by using publically available gene
expression (GEP) data. The anti-MM activity of PTC-209 was examined by via-
bility testing, cell cycle analysis, annexin V and 7-AAD staining, quantification
of cleaved PARP, JC-1 as well as colony formation assays. Gene and protein
expression was studied by quantitative PCR and flow cytometry, respectively.
The impact of PTC-209 on osteoclast, osteoblast and tube formation was
analysed in vitro by using cell type specific differentiation assays.
Results: Overexpression of BMI-1 in MGUS, SMM and MM patients was con-
firmed by using publically available GEP-datasets. Of note, BMI-1 expression
was further increased at relapse which translated into significantly shorter over-
all survival in relapsed/refractory patients treated with bortezomib or dexam-
ethasone (median OS 22.2 months vs 13.7 months, P=0.003).
Treatment with PTC-209 induced downregulation of BMI-1 protein levels and sig-
nificantly impaired viability of all HMCLs analysed with IC50 values <2 µM in 6 of
8 MM cell lines (range: 0.21-5.68 µM). Mechanistically, PTC-209 led to an accu-
mulation of MM cells in the G1 phase of the cell cycle and induced apoptosis.
The latter was confirmed by annexin V/7-AAD staining, detection of cleaved
PARP and depolarization of the mitochondrial membrane. These alterations were
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observed in conjunction with the deregulation of central myeloma genes, such
as downregulation of CCND1 (up to 0.67±0.04 fold reduction, P<0.001), MYC
(up to 0.50±0.07 fold reduction, P<0.001) as well as upregulation of p21 (up to
3.4±0.4 fold increase, P<0.001), p27 (up to 2.1±0.6 fold increase, P=0.03) and
NOXA (up to 3.6±1.2 fold increase, P=0.009). In addition, PTC-209 significantly
reduced the number and size of colonies formed by myeloma cells in colony for-
mation assays (OPM-2: 215±50 vs 105±12 colonies with PTC-209 at 1 µM,
P=0.005; KMS-12-BM: 59±12 vs 17±3, P<0.001). PTC-209 likewise decreased
the survival propagating effects of IGF-1 and IL-6. In co-culture with BMSCs,
PTC-209 was found to uphold its anti-MM activity and enhanced the activity of
pomalidomide and carfilzomib. Additive and synergistic drug activities of PTC-
209 and pomalidomide/carfilzomib were confirmed in six MM cell lines. Analysing
the impact of PTC-209 on cells of the myeloma microenvironment demonstrated
a significant reduction of in vitro osteoclast and tube formation. No signs of TRAP-
positive osteoclasts as well as a significantly decrease of total tube length
(P=0.005) were observed with PTC-209 at 1 µM. Unfortunately, PTC-209 dis-
played a likewise negative impact on the formation of osteoblasts (68±4% reduc-
tion in alkaline phosphatase activity with PTC209 at 1 µM, P<0.001). However,
this was associated with a significant induction of DKK1 expression upon PTC-
209 treatment and concurrent treatment with an anti-DKK1 antibody was found
to overcome (43±6% vs 21±12% decrease in ALP activity, P=0.02), at least in
part, the osteoblast inhibitory properties of PTC-209.
Summary/Conclusions: In conclusion, we confirmed overexpression of BMI-1
in MM highlighting its role as attractive drug-target and reveal therapeutic target-
ing of BMI-1 by PTC-209 as a promising novel therapeutic intervention for MM.
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LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON
LYMPHOCYTES IN MYELOMA PATIENTS
S L Danhof*, M Schreder, L Rasche, S Strifler, S Knop, T Gogishvili, H Einsele1,
M Hudecek
University Hospital Würzburg, Würzburg, Germany
Background: Lenalidomide (Len) has become an integral component of mul-
tiple myeloma (MM) therapy with its tumoricidal and immunomodulatory effects,
the latter being of particular interest in continuous treatment. However, the pre-
cise mode of action and the consequences of Len on lymphocyte subset com-
position and function are still incompletely understood.
Aims: Here, we analyzed the composition and PD-1 expression of lymphocytes
from MM patients undergoing Len maintenance (LenMT) and compared those
to the respective parameters in control groups of MM patients (at primary diag-
nosis/PDX, at relapse/RD or in complete remission/CR; according to IMWG
criteria) and healthy donors.
Methods: We performed multi-parameter FACS analysis on peripheral blood
(PB) of 71 MM patients to identify CD4+ and CD8+ naïve (45RA+62L+), central
(45RO+62L+) and effector (45RO+62L-) memory T cells, B cells (CD19+), NK
cells (CD3-CD56+), NKT cells (CD3+CD56+) and γ/δ T cells (γ/δ TCR+) and
their PD-1 surface expression. Corresponding bone marrow (BM) samples
from the same individuals were equally analyzed for lymphocytic PD-1 surface
expression when available (n=15). Analysis was performed in the following
subgroups of patients: at PDX (15), at RD (12), in sustained CR without recent
anti-MM therapy (18) and during LenMT (20). The fifth subgroup comprised
patients without exposure to Len and a disease burden that was comparable
to the cohort of patients during LenMT who were not in CR (6). All patients pro-
vided written informed consent according to the local regulatory boards.
Results: At PDX, absolute numbers of lymphocytes were found within the nor-
mal ranges for T, B and NK cells, while the administration of LenMT significantly
reduced CD3+ T cells counts. This was predominantly due to a loss of CD4+
naïve T cells (p=0.004), whereas CD8+ naïve T cells and the entire central
and effector memory T cell compartments were largely preserved. B cell counts
were highest in the CR group, with an approximately fourfold increase in regard
to the LenMT group. Absolute numbers of NK cells were significantly higher in
patients undergoing LenMT as compared to all other previously treated MM
patients. Analyzing PD-1 surface expression, we found highest levels on CD3+
T cells, no matter whether the lymphocytes were of BM or PB origin. We further
observed increased PD-1 expression on all PB lymphocytes from patients with
active MM disease (PDX, RD), whereas optimal disease control (CR) brought
PD-1 expression down to ranges observed in healthy donors. Similarly, the
LenMT cohort displayed lower PD-1 levels than patients with active disease,
which was most pronounced for CD8+ T cells. In order to rule out the influence
of disease burden on PD-1 levels, we compared patient cohorts with equivalent
residual BM and serological disease burden with and without exposure to Len
and found a significant reduction of PD-1 surface expression on CD8+ T cells
during LenMT (p=0.038). Longitudinal data of PD-1 levels before, during and
after LenMT further confirmed this observation.
Summary/Conclusions: Our data show that LenMT modulates lymphocyte
subset composition in MM patients, underlining its potent immunomodulatory
capacity. Furthermore, this first in vivo observation of low PD-1 expression lev-
els associated with LenMT suggests a potential for combined use of Len with
novel therapeutic approaches, such as chimeric antigen receptor modified T
cells or bispecific T cell engaging antibodies. Whether additional checkpoint
blockade might further enhance anti-MM efficacy of Len by decoupling the PD-
1/PD-L1 axis will have to be studied in future clinical trials.
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CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS
E Kryukova1,2, L Brozova3, L Besse4, K Growkova1,2,5, L Sedlarikova6,
J Nekvindova7, J Filipova1,2,5, Z Kufova1,2,6, T Sevcikova1,2,5, L Zahradova1,
J Jarkovsky3, S Sevcikova6, F Kryukov1,2,*, R Hajek1,2,6
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Hospital Ostrava, 2Faculty of Medicine, University of Ostrava, Ostrava, 3Insti-
tute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University,
Brno, Czech Republic, 4Department of Hematology/Oncology, Cantonal Hos-
pital St. Gallen, St Gallen, Switzerland, 5Department of Biology and Ecology,
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sity, Brno, 7Institute of Clinical Biochemistry and Diagnostics, University Hos-
pital Hradec Kralove, Hradec Kralove, Czech Republic
Background: Circulating serum microRNAs (miRNAs) are emerging biomark-
ers in cancer as well as a minimally invasive diagnostic solution due to their
high stability and association with the disease. Previously, circulating miRNAs
with diagnostic and prognostic potential in a broad range of monoclonal gam-
mopathies have been described. Nevertheless, circulating miRNAs profile in
immunoglobulin light chain amyloidosis (ALA) is still not elucidated. ALA is a
plasma cell dyscrasia characterized by deposition of amyloid fibrils in various
organs and tissues, derived from monoclonal immunoglobulin light chains (LC),
leading to organ dysfunction.
Aims: To reveal ALA specific profile of circulating miRNAs
Methods: MiRNAs profiling using TaqMan Low Density Arrays was used to
find differently expressed miRNAs between 15 ALA, 6 MGUS, 10 MM patients
and 11 healthy donors (HD). Data normalization was performed using geometric
mean of three most stably expressed miRNAs (miR-126, miR-24, miR-484).
Kruskal-Wallis and Mann-Whitney U test were used to define significance.
Receiver operating characteristic (ROC) analysis of chosen miRNAs was per-
formed to describe their predictive potential.
Results: In general, 50 miRNAs were differentially expressed in ALA compared
to MM, MGUS and HD (p<0.05) and 12 of them have met significance criteria
after Bonferroni correction (p<0.0004). Based on high specificity and sensitivity
values (≥80%), five miRNAs were defined to have prognostic value: miR-21, miR-
25, miR-328, miR-451, miR-134 (Figure 1). Additionally, in ALA samples, four fol-
lowing miRNAs were detected as significantly overrepresented compared to the
rest of tested cohorts: miR-134 (sensitivity 93.3% and specificity 81.5%, p=0.0005),
miR-133a (sensitivity 73.3% and specificity 74.5%, p=0.0052), miR-342 (sensitivity
100% and specificity 59.3%, p=0.0001) and let-7b (sensitivity 66.7% and specificity
77.8%, p=0.0044) (Figure 1). We suppose that these overrepresented miRNAs
could have a biological relevance in ALA pathobiology. Serum miR-134 and miR-
133a were described as markers of acute coronary syndrome (Gacoń et al., 2015);
let-7b was found to be serum marker for primary IgA nephropathy (Serino et al.,
2015), while serum miR-342 was described as a biomarker for the diagnosis of
Alzheimer’s disease (Tan et al., 2014). It is postulated that extracellular amyloid
beta (Aβ) deposits are the fundamental cause of this disease. This finding raises
the intriguing possibility that all amyloid diseases, irrespective of the nature of the
amyloid forming protein, share common biomarkers.
Figure 1.
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Summary/Conclusions: This study identified five serum miRNAs with a
potential to distinguish ALA patients from MM, MGUS and healthy donors
with high sensitivity and specificity. Moreover, we described increased level
of miR-134, miR-133a and let-7b that could serve as biomarkers of end-organ
damage in ALA patients. Level of serum miR-342 can be suggested as a
potential amyloid-specific biomarker and needs to be validated on the other
amyloid diseases.
Acknowledgments: This work was supported by the Ministry of Health (15-
29667A), Institutional Development Plan of University of Ostrava (IRP201550)
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PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1
ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE
MYELOMA
K Gish1,*, H Kim1, R Power1, M Fox1, J Hickson2, T McGonigal2, D Chao1,
M Sho1, H Singh1, E Tarcsa3, W Gao2, L Loberg2, C Allan1, C Becker2,
R Duffy1, R Nath1, D Afar1
1AbbVie Biotherapeutics, Redwood City, 2AbbVie, North Chicago, 3AbbVie
Bioresearch Center, Worcester, United States
Background: ABBV-838 is an antibody-drug conjugate (ADC) directed against
CS1 (SLAMF7/CD319), a cell-surface glycoprotein that is expressed with high
levels and prevalence on multiple myeloma (MM) cells, with normal expression
limited to leukocyte subsets (including plasma cells, NK cells, and activated
monocytes).  This ADC uses monomethyl auristatin E (MMAE) with a cathep-
sin-cleavable linker, and it binds to a unique epitope on CS1.
Aims: We evaluated the preclinical anti-tumor activity and toxicology of ABBV
838, with a goal to enable Phase 1 clinical development of this novel anti-
CS1 ADC.
Methods: Tumor efficacy studies of ABBV-838 monotherapy and in combination
with standard-of-care agents were conducted in mouse xenograft models. Tol-
erability studies were conducted in rodents and non-human primates (NHP),
and the IND-enabling toxicology studies were conducted in NHP.
Results: ABBV-838 showed significant antitumor activity and induced complete
tumor regressions in mouse models using human myeloma xenografts, including
disseminated bone marrow models (OPM-2 and LP-1). Enhanced efficacy was
observed when a sub-optimal dose of ABBV-838 was combined with standard-
of-care agents such as bortezomib and pomalidomide. Tumor regressions were
also observed in xenograft-bearing mice that were pretreated for two weeks with
bortezomib, then switched to treatment with ABBV-838 alone, or pomalidomide
plus ABBV-838. To optimize efficacy and to minimize safety issues, an additional
process step was used to isolate ABBV-838 product containing primarily two
MMAE molecules per antibody (identified as E2). Efficacy and tolerability studies
were conducted to compare different drug-to-antibody ratios (DAR) and distribu-
tions of loading; the greatest therapeutic index (maximum tolerated dose/minimum
effective dose) observed in non-clinical studies was achieved with E2-enriched
ADC. In a GLP-compliant toxicology study, primary toxicities of ABBV-838 were
typical of other MMAE-based ADCs and consisted of bone marrow toxicity and
lymphocyte decreases in lymphoid tissues, and were mostly resolved or consis-
tent with a regenerative response at the end of a 3-week recovery period. A sin-
gle-dose no-observed-adverse-effect level (NOAEL) was established in cynomol-
gus monkey at 12 mg/kg (1340 µg/m² of conjugated MMAE), which is the equiv-
alent conjugated MMAE dose for the single-dose max non-lethal dose of 6 mg/kg
as published for brentuximab vedotin (Figure 1).
Figure 1.
Summary/Conclusions: Targeting myeloma cells via the CS1 protein with
ABBV-838 results in potent preclinical anti-tumor activity as a monotherapy,
and in combination with multiple approved therapies, with complete tumor
regressions against multiple xenograft models of myeloma. ABBV-838 is cur-
rently being investigated in a Phase 1 first-in-human safety study.
Disclosures: All authors are employees of AbbVie. The design, study conduct,
and financial support for this research were provided by AbbVie. AbbVie par-
ticipated in the interpretation of data, review, and approval of the publication. 
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SOLUBLE BCMA BINDS ITS LIGAND BAFF AND PREVENTS NORMAL
ANTIBODY PRODUCTION IN MULTIPLE MYELOMA PATIENTS
J Berenson*, E Sanchez, M Li, G Tang, C Wang, H Chen
Institute for Myeloma & Bone Cancer Research, West Hollywood, United States
Background: A hallmark of multiple myeloma (MM) is the low levels of uninvolved
immunoglobulin (Ig) levels. B-cell maturation antigen (BCMA) is a receptor expressed
in mature non-malignant and malignant B lymphocytes, including plasma cells. We
previously demonstrated that BCMA is present in the serum of MM patients and that
its levels predict overall survival (Sanchez et al. Br J Haematol 2012).
Aims: We hypothesized that soluble BCMA binds BAFF, preventing normal
plasma cell development and antibody production in MM patients.
Methods: BCMA-Fc and control Ig were obtained (R&D Systems). Human
BCMA and mouse BAFF, IgG, IgA and IgM were measured with ELISA (R&D
Systems & Bethyl). Human IgA and IgG levels were determined using neph-
elometry (Immage 800, Beckman Coulter). Hevylite Assays (Binding Site) were
used to quantify the levels of heavy0light chain isoform pairs.
Results: hBCMA-mBAFF complexes were detected with an ELISA at high lev-
els in plasma of SCID mice with human MM xenografts; these mice showed
reduced levels of free BAFF. rhBCMA or control Ig-Fc (100 µg) was injected
into immune competent C57 Bl or Balb/c mice, and resulted in decreases in
IgA, IgG and IgA levels. Decreases in IgA levels were observed when compared
to baseline levels on days 4 and 6 (P=0.0031 and P=0.0064, respectively),,
and the controls (P=0.0087 and P=0.0221). Mouse IgG levels also showed a
reduction compared to baseline (P=0.0023), the Ig-Fc (P=0.0014) and the con-
trol (P=0.0129). IgM levels showed similar decreases when compared to the
untreated (P=0.0001) and Ig-Fc (P=0.0088) groups. MM patients’ serum con-
tainBCMA-BAFF complexes, and showed reduced free BAFF levels compared
to controls (P=0.0004). Raji B-cells were then incubated with serum from a
healthy subject (0.02 µg/ml BCMA) of a MM patient with serum containing high
levels of BCMA (0.75 µg/ml) or low levels of BCMA (0.02 µg/ml) or rhBCMA-Fc
(3.0 µg/ml) in the presence of rhBAFF (500 ng/ml). Serum from the MM patient
with high BCMA and rhBCMA decreased rhBAFF binding by 71% (from 96.8 to
25.6%) and 74% (from 96.8 to 22.9%), respectively, whereas serum from the
healthy subject and MM patient with low BCMA did not affect BAFF binding.
Using antoher human B-cell line (TB94), serum containing high BCMA and
rhBCMA decreased rhBAFF detection on these cells from 94% to 62.1% and
from 98.6% to 48.7%, respectively. Given the reduction in BAFF binding to B-
cells and reduction in serum free BAFF levels in MM patients, we determined
whether the relationship of serum BCMA levels to uninvloved Ig levels in MM
pts. Serum BCMA levels inversely correlated with uninvolved IgG in IgA MM
(n=134) and uninvolved IgA in IgG MM (n=313, P <0.0001). Using Hevylite
Assay, similar results were observed in BCMA levels compared to uninvolved
IgG isoforms in both pts with involved IgG lambda (n=62, P=0.0006) and IgG
kappa (n=117, P <0.0001).
Summary/Conclusions: We demonstrate BCMA-BAFF complexes in MM
xenografts resulting in reduced BAFF levels, and administration of rhBCMA to
normal mice leads to marked reductions in antibody levels. We also show these
complexes in MM patients, resulting in reduced serum free BAFF levels which
prevent this ligand from binding B-cells. As a consequence, serum BCMA levels
inversely correlate with uninvolved Ig levels in MM pts. Thus, the lack of normal
antibody production in MM pts results in part from corculating BCMA binding
its ligands, preventing production of normal antibody-producing cells.
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DIFFERENTIAL EFFECTS OF ELOTUZUMAB (ANTI-SLAMF7) AND
ANTI-CD38 MONOCLONAL ANTIBODIES IN PRECLINICAL MODELS
N Bezman1,*, A Kearney1, P PVK1, A Jhatakia1, T Brender1, M Maurer1,
K Henning1, T Pazina2, K Campbell2, A Cohen3, R Graziano1, M Robbins1
1Bristol-Myers Squibb, Princeton, 2Fox Chase Cancer Center, 3University of
Pennsylvania, Philadelphia, United States
Background: Monoclonal antibodies (mAbs) have recently presented a new
treatment paradigm for patients with multiple myeloma (MM). Two such approach-
es, anti-SLAMF7 antibody (elotuzumab) and anti-CD38 antibodies (daratumumab
and SAR650984), were primarily developed based on the rationale of high expres-
sion of target protein on myeloma cells. Expression of these protein targets
(SLAMF7 and CD38), however, is not limited to tumor cells and is also found on
cells of the innate and adaptive immune systems. Non-tumor-targeted effects
mediated by these mAbs may not only contribute to the overall anti-tumor
response, but may also provide the rationale for new combination regimens. 
Aims: To further define the mechanism of action of elotuzumab and anti-CD38
mAbs on immune cell subsets.
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Methods: The effect of elotuzumab and anti-CD38 mAbs on antibody-depen-
dent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity,
and natural killer (NK) and T-cell activation was assessed. Surrogate antibodies
of daratumumab (daratumumab-s) and SAR650984 (SAR650984-s) were gen-
erated on the basis of protein sequences, as published in their corresponding
patent families, and were expressed as recombinant hIgG1 for in-vitro studies
with human cells or mIgG2a for in-vivo mouse tumor studies. Mutant versions
of mAbs that eliminated Fc:FcγR binding were also generated to assess the
contribution of FcR binding for mAb efficacy in preclinical models.
Results: SLAMF7 and CD38 were highly expressed on myeloma cells. In vitro,
elotuzumab and anti-CD38 mAbs were equally potent in inducing ADCC of
MM1S cells, whereas only daratumumab-s was able to fix complement.
SLAMF7 and CD38 were also highly expressed on human NK cells. In a co-
culture of myeloma cells and NK cells, elotuzumab induced more pronounced
NK-cell activation than did daratumumab-s. SLAMF7 and CD38 were differen-
tially expressed on T-cell subsets: SLAMF7 expression was highest on CD8+T
cells and memory subsets, whereas CD38 expression was highest on naïve
cells. While both SLAMF7 and CD38 levels were induced following anti-CD3
stimulation, neither elotuzumab nor anti-CD38 mAbs mediated ADCC towards
activated T cells. Elotuzumab and anti-CD38 mAbs, however, led to inhibition
of cytokine production by naïve T cells isolated from healthy donors, and these
effects were reversed in the presence of lenalidomide. Ongoing studies are
characterizing the effects of elotuzumab and anti-CD38 mAbs on T cells from
bone marrow aspirates from patients with MM.
Summary/Conclusions: Elotuzumab enhanced activation of NK cells in vitro,
whereas anti-CD38 mAbs were cytolytic against NK cells. Engagement of both
targets on myeloma cells led to similar augmentation of ADCC. SLAMF7 and
CD38 engagement on T cells may also have non-overlapping effects based
on the differential expression of these proteins between naïve and memory
subsets, which may inform the rationale for future clinical use.
Funding: Bristol-Myers Squibb. Medical writing assistance: M Thomas, Caudex,
funded by Bristol-Myers Squibb
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NRF2 ACTIVITY IN BONE MARROW MESENCHYMAL STROMAL CELL
PROTECTS MULTIPLE MYELOMA FROM CARFILZOMIB AND
BORTEZOMIB INDUCED CELL DEATH
Y Sun1,*, L Zaitseva1, K Bowles1,2, S Rushworth1
1Department of Molecular Haematology, Norwich Medical school, University
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Hospitals NHS Trust, Norwich, United Kingdom
Background: Bone marrow mesenchymal stromal cells (BM-MSC) interact
with multiple myeloma (MM) cells and modify their viability and drug sensi-
tivity. Recent studies identify various oncogenic pathways which are involved
in modulating the BM-MSC/MM cell microenvironment. The transcription fac-
tor NRF2 is a key regulator for the maintenance of intra-cellular redox home-
ostasis and is negatively regulated by proteasome degradation through its
inhibitor KEAP1. NRF2 pathways have been shown to contribute to the malig-
nant phenotypes of several cancers through effects on proliferation and drug
sensitivity. 
Aims: To determine if NRF2 signalling in BM-MSCs affects the redox home-
ostasis of MM and promotes survival and resistance to proteasome inhibitors.
Methods: Primary human MM and BM-MSC cells were obtained under UK
ethical approval (LREC ref 07/H0310/146). Transwell co-culture system was
used to characterize the MM-BMSC interactions. NRF2 protein expression and
its target genes were examined by Western blotting and qRT-PCR. CellTiter-
Glo luminescent cell viability assay and apoptosis assay (PI/ Annexin V staining
by flow cytometry) were performed. Lentiviral mediated shRNA knockdown
(KD) of NRF2 in the BM-MSC.
Results: To study the cell-cell communications between BM-MSC and MM
cells we established a co-culture system using primary MM derived from
patients BM and the equivalent stromal cells. We also used MM cell lines.
NRF2 was found to be highly expressed in primary BM-MSC derived from
patients with MM. We found that both bortezomib and carfilzomib further
increased NRF2 activity in both primary MM cells and BM-MSC. In addition
treatment with proteasome inhibitors enhanced NRF2 target gene expression
as measured by qRT-PCR and Western blotting. We showed that BM-MSC
protect MM from bortezomib and carfilzomib induced cell death. Next we
knocked down NRF2 (NRF2-KD) in both MM and BM-MSC and then performed
a co-culture with and without bortezomib and carfilzomib. We found that BM-
MSC derived NRF2 was essential for MM protection from bortezomib and carfil-
zomib induced cell death in-vitro.
Summary/Conclusions: NRF2 driven cytoprotective responses are activated
in BM-MSC and MM by bortezomib and carfilzomib. Furthermore, NRF2-KD in
BM-MSC reverses MM resistance to bortezomib and carfilzomib. This highlights
the importance of NRF2 in regulating MM drug resistance within the bone mar-
row microenvironment through independent actions in both the tumour and the
non-malignant stromal cells which support it.
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PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF
ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND
DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-
AND-REFRACTORY MULTIPLE MYELOMA
S Madan1,*, D Atanackovic2, J Supko3, D Tamang4, SS Jones4, C Wheeler4,
NS Trede4, L Anderson5
1University of Texas Health Science Center, San Antonio, 2Huntsman Cancer
Institute at University of Utah, Salt Lake City, 3Massachusetts General Hospital,
4Acetylon Pharmaceuticals Inc., Boston, 5University of Texas Southwestern
Medical Center, Dallas, United States
Background: Ricolinostat (ACY-1215), a liquid, selective HDAC6 inhibitor,
potently synergizes with bortezomib (Btz), lenalidomide (Len) and pomalidomide
(Pom) in models of multiple myeloma (MM) (Quayle Blood 2013). Pan-HDAC
inhibitors are active in MM in combination with Btz and Len, but toxicities (throm-
bocytopenia, fatigue, and GI events) limit dosing exposure. By contrast, ricolino-
stat is well tolerated in clinical studies as monotherapy (Raje Blood 2012) and in
combination with Btz/dexamethasone (Dex) (Vogl, Blood 2015), Len/Dex (Yee,
Blood 2015) and Pom/Dex (Raje, Blood 2015) and acts synergistically even in
refractory patients. ACE-MM-104 is a dose-escalation study of an alternative liq-
uid formulation (ALF) of ricolinostat at a concentration of 10 mg/mL in combination
with Pom/Dex in patients with relapsed or relapsed-and-refractory MM (RRMM).
This formulation has an improved excipient profile over earlier formulations.
Aims: Determine safety, tolerability and preliminary efficacy of ricolinostat ALF
in combination with Pom/Dex.
Methods: Dose escalation of ricolinostat ALF was in combination with Pom (4
mg) for 21/28 day cycle and weekly Dex (40 mg). Patients (pts) had measurable
disease, ≥2 prior therapies including ≥2 cycles of Len and proteasome inhibitor
and relapsed or RRMM. Adequate bone marrow, hepatic and renal function
were required. Pts with non-secretory MM, prior Pom or HDAC inhibitor therapy
were excluded. Blood samples were obtained for PK and pharmacodynamics
(PD) assessment of acetylated tubulin and histones. Starting dose of 120 mg
BID was based on preclinical data and experience with ricolinostat in either 20
or 12 mg/mL formulations currently used in clinical trials. Median age was 64
years and median number of prior regimens was 2 (1-4). Ten pts were refractory
to prior therapies (8 to Dex, 6 to Btz, 6 to Len, and 2 to both BTz and Len).
Results: Dose escalation comprised 16 pts. No DLTs were observed in the
first 4 pts dosed at 120 mg ricolinostat BID. Emerging data with the 12 mg/mL
formulation suggested that BID dosing was less well tolerated. Therefore, sub-
sequent pts were dosed on a QD schedule: 4 at 120 mg, and 8 at 180 mg. Tox-
icities were mostly low grade and treatment was tolerated at QD dosing of
21/28 day cycles. Common toxicities of safety-evaluable pts (n=15) included
fatigue (60%), URI, pruritus, dyspnea, dizziness (27% each), diarrhea, consti-
pation, nausea (20% each). Grade 3/4 related toxicities included neutropenia
(5 pts, 33%), anemia (27%), febrile neutropenia and neutropenia (20%). Few
TEAEs were attributed to study drug. One DLT (neutropenia) was observed at
180 mg QD. Cohort expansion to 6 pts showed no further DLT. PK/PD demon-
strates selective inhibition of HDAC6 vs HDAC1,2,3 at therapeutic doses. PK
shows 120 mg of ricolinostat ALF and 160 mg in the 12 or 20 mg/mL formula-
tions achieved equivalent exposure which did not increase with increased dos-
ing. Hence, the 180 mg QD schedule was declared the highest dose level test-
ed. There was no evidence of ricolinostat accumulation or drug-drug interaction
with Pom. With a median F/U of 7 cycles for the 11 response-evaluable patients
there were 6 ≥PR and DCR was 82%.
Summary/Conclusions: Ricolinostat ALF is well-tolerated in combination with
Pom/Dex at doses up to 180 mg QD without major toxicities. This formulation
of ricolinostat is used in ongoing clinical studies in combination with paclitaxel
and abraxane to treat solid tumors.
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DEVELOPMENT OF A PREDICTIVE MODEL TO IDENTIFY PATIENTS WITH
MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANT
AT RISK FOR SEVERE INFECTIONS USING DATA FROM THE FIRST TRIAL
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ogy, Bologna University School of Medicine, Bologna, Italy, 11Universitair Zieken-
254 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
huis Antwerpen, Edegem, Belgium, 12Hospital 12 de Octubre, Madrid, Spain,
13Centre Hospitalier Yves Le Foll, Saint-Brieuc, France, 14Gachon University Gil
Hospital, Incheon, Korea, Republic Of, 15Service des Maladies du Sang, Hôpital
Claude Huriez, Lille, 16Quinten, Paris, France, 17Celgene International Sàrl,
Boudry, Switzerland, 18YGM Consult, Quinten, Paris, France
Background: Patients (pts) with multiple myeloma (MM) have an increased
risk of infections due to toxicities of therapy, immunosuppression by the under-
lying disease, comorbidities, and old age (Nucci & Anaissie, Clin Infect Dis,
2009). Furthermore, MM demonstrates a low immune response to prophylactic
vaccination and to both viral and bacterial infections, highlighting the need for
preventative or early treatment measures (Karlsson et al., Clin Vaccine
Immunol, 2011; Blimark et al., Haematologica, 2015). The pivotal, phase 3
FIRST trial compared lenalidomide plus low-dose dexamethasone (Rd) to mel-
phalan, prednisone, and thalidomide (MPT) in transplant-ineligible pts with new-
ly diagnosed MM (NDMM).
Aims: To identify factors predictive of infections in the first 4 months of the
FIRST trial and develop an infection risk scoring system.
Methods: In the FIRST trial, pts were randomized 1:1:1 to receive Rd until dis-
ease progression (Rd continuous), Rd for 18 cycles (Rd18), or MPT. For this
analysis, data from the Rd continuous and Rd18 arms were pooled. Demo-
graphics, medical history, and baseline characteristics including co-medications
were analyzed to identify risk factors of treatment emergent (TE) grade ≥3
infection during the first 4 months. Pts with both progression-free survival ≤4
months and no TE grade ≥3 infection within the first 4 months were excluded.
A subgroup discovery algorithm was used to identify univariate prognostic fac-
tors associated to high or low risk of infection. The most clinically and biologically
relevant variables were used in a multivariate logistic regression model with an
iterative variable selection process. Pts with missing data on at least one input
variable were excluded from the model (n=9). From the resulting predictive
model, a scoring system was developed by allocating -2 to 2 points to factors
of low or high risk based on their influence in the model. The cumulative score
classified pts into high (2 to 5 points) or low (-3 to 1 points) infection risk groups.
Results: Of the 1623 pts enrolled in the FIRST trial, 340 pts had TE grade ≥3
infections, and 56.2% of these 340 pts had their first infection in the first 4
months (Figure 1A). Risk of infection was similar regardless of therapeutic arm
(P=.53). Risk factors were assessed in 1378 pts and the final model retained
4 variables: (Eastern Cooperative Oncology Group [ECOG] performance status,
serum β2-microglobulin [Sβ2M], lactate dehydrogenase [LDH], and hemoglo-
bin) that independently associate with TE grade ≥3 infections occurring in the
first 4 months (Figure 1B). The high- and low-risk groups defined by the scoring
system were associated with significantly different rate of TE grade ≥3 infections
during the first 4 months (24% and 7%, respectively).
Figure 1.
Summary/Conclusions: The risk scoring system described here can identify
pts at risk for infections during the first 4 months of treatment and may be used
to implement risk-adapted strategies for the treatment or prevention of infections.
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OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF
BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL
CHROMOSOMAL CHANGES
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A Jauch1, J Hillengass1
1University Hospital of Heidelberg, 2German Cancer Research Center, Heidel-
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Background: Deletion 17p13, del(17p), is associated with poor outcome in
patients with multiple myeloma (MM) but some patients show long-term survival.
Aims: With the current study we intended to identify prognostic factors for sur-
vival in patients with del(17p). Analyzed factors included baseline characteris-
tics, treatment modalities and additional chromosomal aberrations.
Methods: Between 05/2002 and 10/2015 total of 4906 interphase FISH (iFISH)
studies have been performed in patients with plasma cell diseases at the Uni-
versity Hospital of Heidelberg, Germany. We identified 110 patients with
del(17p) in newly diagnosed, symptomatic MM according to CRAB criteria of
the International Myeloma Working Group. FISH was performed on CD138-
purified plasma cells using probes for: 1q21, 5p15, 5q35, 8p21, 9q34, 11q23,
13q14.3, 15q22, 17p13 and 19q13, translocations t(11;14), t(4;14) and t(14;16).
Hyperdiploidy (HD) was assessed by the score of Wuilleme et al. (gains of at
least two of the chromosomes 5, 9 and 15). Survival times were estimated with
the Kaplan-Meier method and compared using log-rank test. Multivariable Cox
regression analysis was performed to assess impact of baseline characteristics,
treatment modalities and additional cytogenetic abnormalities on outcome.
Results: Age >65 years (n=42, 38%) was associated with adverse outcome
(PFS: 13 vs 26 months, p=0.001; OS: 21 vs 56 months, p<0.001) as well as
higher ISS score (ISS I/II/III PFS: 35/ 20/ 16 months, p=0.02; OS: 72/ 71/ 27
months, p=0.004) and elevated baseline LDH (PFS: 14 vs 26 months, p<0.001;
OS: 18 vs 53 months, p=0.001). Patients with subclonal (10-60% of plasma
cells, n=47, 42.7%) del(17p) had longer PFS than patients with del(17p) in a
major >60% of plasma cells (26 vs 19 months, p=0.03). Additional gain of 1q21
(n=41, 37.3%) was associated with shorter PFS (17 vs 25 months, p=0.01, Fig-
ure 1A). Hyperdiploidy (n=36, 37.9%) did not ameliorate impact of del (17p)
(Figure 1B), but gain 19q13 (n=41, 37.6%) predicted longer PFS (30 vs 18
months, p=0.01) and OS (50 vs 29 months, p=0.01, Figure 1C). Multivariate
analysis in transplant eligible patients (≤65 years, n=68, 61.8%) revealed better
survival for patients treated with upfront autologous transplantation (hazard
ratio, [95% confidence interval]: 0.15 [0.04, 0.58], p=0.006) and a trend for
better survival for bortezomib induction therapy (0.35 [0.11, 1.08], p=0.07).
Application of maintenance therapy was associated with better survival in trans-
plant-eligible patients (0.3 [0.09, 0.99], p=0.05).
Figure 1.
Summary/Conclusions: We demonstrate heterogeneous outcome of patients
with del(17p) according to baseline characteristics and treatment. 19q13 should
be included in routine FISH panel, since gains were associated with better sur-
vival. Bortezomib-based induction therapy followed by autologous stem cell
transplantation and maintenance therapy might be the best treatment option
for patients with del(17p).
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CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA
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Background: For decades, diagnosis and therapy for multiple myeloma has
been guided by sequential measurements of monoclonal immunoglobulin (M-
protein) as a marker for total tumor mass. However, the increasing availability
of mutation specific drugs and insight into the complex genetic architecture of
cancer raises a need for disease monitoring at the clonal and mutational levels.
Circulating tumor DNA (ctDNA) has shown promise to this end in solid tumors,
but its biology and dynamics over time are poorly understood and only prelim-
inary reports are available for myeloma.
Aims: To evaluate the properties of ctDNA as a tumor marker in myeloma by
comparison with M-protein levels and sequential whole exome sequencing
(WES) of bone marrow plasma cells.
Methods: We measured ctDNA levels in stored Serum (n=278), EDTA-plasma
(n=8) and citrate-plasma (n=2) samples from 22 patients by digital droplet (dd)
PCR. Target mutations for each patient had been previously identified by WES
or PCR of bone marrow plasma cells and were mainly in the NRAS, KRAS and
BRAF genes. Blood samples were processed and frozen at -80° C within 1.5
hours of acquisition and then stored for a median of 5 years (range 0-23) before
DNA isolation. Fragment length analysis by Bioanalyzer 2100 (Agilent tech-
nologies) was performed to ensure sample quality. DdPCR was performed
using the QX100/200-system with Prime PCR mutation detection assays
according to manufacturer’s instructions (BioRad). Samples were called muta-
tion-positive if they contained more than 1 single-positive mutant droplet, yield-
ing a specificity of 98.4% based on control experiments.
Results: There was no correlation between sample storage time and the quantity
of amplifiable DNA, and fragment length analysis revealed the presence of cir-
culating DNA in 30 representative samples. Mutation levels in 6 time-matched
serum and EDTA-plasma samples were similar. Taken together, these observa-
tions validate our material. Known tumor mutations were detected by ddPCR of
ctDNA in all 14 patients analyzed at diagnosis and in 11/12 patients with relapsed
disease. Compared with the average 55% sensitivity in early stage solid tumors
by similar methods, newly diagnosed myeloma behaves like an advanced solid
tumor with regards to ctDNA. Mutated allele frequency measured by WES of
bone marrow plasma cells correlated with the level of ctDNA at the same time
(Spearman´s rho=0.507, p=0.003). Furthermore, we detected two mutations in
ctDNA that were not present in time-matched bone marrow aspirates, indicating
that a single bone marrow aspirate may not be representative with respect to the
heterogeneity of the tumor. We found a striking co-variation between ctDNA and
M-protein for periods up to seven years in 9 out of 11 patients where sequential
samples were available. In many cases, ctDNA reacted more rapidly to changes
in tumor mass compared to M-protein although this could not be systematically
assessed in a retrospective material. Peak mutation levels in ctDNA started out
low at diagnosis and gradually increased with each relapse in 7 out of 9 patients.
This observation was particular evident in three patients where ctDNA levels
increased to around 400 times diagnostic levels at the end of the disease course
as illustrated by patient 292 (Figure 1). Interestingly, in this patient we also
observed increasing levels of ctDNA immediately following the initiation of effec-
tive chemotherapy, including a previously undetectable IRF4 mutation.
Figure 1. Co-variation of serum mutations and M-protein in patient 292.
Summary/Conclusions: We show that ctDNA is a marker for tumor mass in
myeloma, as evidenced by the co-variation with M-protein. The good perform-
ance of ctDNA in this study, despite long storage time and sub-optimal samples
(serum rather than EDTA-plasma), adds to its robustness as a tumor marker.
Our data suggest that myeloma is particularly suited for using ctDNA to access
the tumor genome, as tumor mutations can be detected in almost all patients.
Increased ctDNA-levels immediately following the initiation of effective therapy
may be exploited for very early evaluation of treatment response and to
increase the sensitivity of ctDNA analysis.
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WITH WALDENSTRÖM’S MACROGLOBULINEMIA (WM): UPDATED
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Background: Single-agent ibrutinib, a once-daily oral inhibitor of Bruton’s tyro-
sine kinase (BTK), demonstrated durable responses in previously treated
patients (pts) with WM (Treon, N Engl J Med. 2015), leading to its FDA and EU
approval in WM. MYD88 L265P is a commonly identified mutation in pts with
WM; the resulting mutated protein signals through interleukin-1 receptor-asso-
ciated kinase 1 and BTK, leading to constitutive activation of the NF-κB pathway
(Yang, Blood. 2013). Ibrutinib attenuates the MYD88-BTK interaction, thus
blocking BTK-dependent downstream signaling and inducing apoptosis of WM
cells (Treon, N Engl J Med. 2012).
Aims: To evaluate the efficacy and safety of single-agent ibrutinib in WM pts
considered refractory to their last rituximab-containing therapy (defined as
relapse at <12 months or failure to achieve at least a minor response).
Methods: After informed consent, pts with confirmed diagnosis of WM, sympto-
matic disease requiring treatment (Kyle, 2003), refractory to rituximab, hemoglo-
bin ≥8 g/dL, IgM ≥0.5g/dL, platelets ≥50,000 cells/mm3, absolute neutrophil count
≥750 cells/mm3, adequate hepatic function, and ECOG ≤2 received oral ibrutinib
420 mg daily until progression or unacceptable toxicity. Pts with central nervous
system involvement, clinically significant cardiovascular disease, known bleeding
disorder, treatment for WM ≤30 days prior to first dose were excluded. Primary
endpoints were PFS, ORR, hemoglobin improvement, and OS.
Results: Baseline characteristics are shown in the Table 1 (N=31). Common
reasons for treatment initiation were fatigue unrelieved by rest (74%), constitu-
tional symptoms (42%), anemia (42%), and lymphadenopathy (23%); 4 pts start-
ed therapy due to peripheral neuropathy. Most recent therapies included
monotherapy (32%), combination therapy without antibody (29%), and combi-
nation therapy with antibody (39%). At a median follow-up of 12.7 months, ORR
was 84%, with a major response rate (MRR; defined as ≥PR) of 68%, and the
estimated 1-year PFS rate was 93%. Initial analysis of 23 baseline samples iden-
tified MYD88MUT/CXCR4WT in 16 pts and MYD88MUT/CXCR4WHIM in 6 pts. The
ORR and MRR were 88% vs 83% and 75% vs 83%, respectively. One of the 23
pts had MYD88WT/CXCR4WT and achieved a best response of stable disease.
Four of 5 pts were able to discontinue required plasmapheresis for disease control
at the end of cycle 1. Baseline median hemoglobin of 10.3 g/dL increased to
11.4 g/dL after 1 cycle and reached 12.8 g/dL at Week 49. Median IgM of 3830
mg/dL declined by >50% after 1 cycle, with continued improvement over time
(median 920 mg/dL at Week 49). Any-grade adverse events (AEs; >15%) includ-
ed diarrhea (42%); upper respiratory tract infections, hypertension, increased
tendency to bruise (23% each); nausea, thrombocytopenia, neutropenia (19%
each); and pyrexia, arthralgia, back pain (16% each). Common grade ≥3 AEs
included neutropenia (13%), hypertension (10%), anemia and diarrhea (6%
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each). All pts with Grade ≥3 cytopenias had received at least 4 prior therapies.
Serious AEs occurred in 9 (29%) pts. Four (13%) pts had dose reductions. Four
pts discontinued ibrutinib—2 pts due to progressive disease and 2 due to an AE
(gastrointestinal AL amyloidosis and diarrhea). Overall, 87% continue on ibrutinib,
with no events of IgM flare, atrial fibrillation or major bleeding (Figure 1).
Table 1. Baseline characteristics.
Figure 1. Kaplan-Meier analysis of PFS (all treated patients).
Summary/Conclusions: Single-agent ibrutinib is highly active in this heavily
pretreated rituximab-refractory WM population, with a high ORR and manage-
able safety profile consistent with previous studies.
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Background: The combination of an immunomodulatory drug with the protea-
some inhibitor (PI) bortezomib (BORT) and low-dose dexamethasone (LoDEX)
has demonstrated preclinical synergy and considerable clinical activity in
relapsed and refractory multiple myeloma (RRMM) (Mitsiades et al., Blood,
2002;99:4525-30; Richardson et al., Blood, 2014;123:1461-9). Treatment (Tx)
with pomalidomide (POM)+LoDEX has been shown to delay disease progres-
sion and extend survival in patients (pts) with myeloma previously treated with
lenalidomide (LEN) and BORT (Richardson et al., Blood, 2014;123:1826-32;
San Miguel et al., Lancet Oncol, 2013;14:1055-66). Preliminary results of MM-
005 showed that POM+BORT+LoDEX (PVd) was effective and well tolerated
in LEN-refractory and BORT-exposed pts. Previously, subcutaneous (SC)
BORT demonstrated non-inferiority to intravenous (IV) BORT and an improved
safety profile in pts with RRMM (Moreau et al., Lancet Oncol, 2011;12:431-40).
Thus, MM-005 included a cohort that received PVd with SC BORT. 
Aims: To identify the optimal dose of PVd for a phase 3 trial in pts with RRMM,
to assess the efficacy and safety of PVd, and to evaluate SC administration of
BORT within the PVd regimen. 
Methods: Pts must have provided informed consent and received 1-4 lines of
prior Tx, with ≥2 consecutive cycles of LEN plus a PI. Pts had to be PI exposed
and refractory to LEN but not to BORT. A 3+3 design with 21-day cycles was
used to determine the maximum tolerated dose (MTD). In cycles 1-8, dose-
escalation cohorts received POM (1-4 mg/day on days 1-14), IV or SC BORT
(1-1.3 mg/m2 on days 1, 4, 8, and 11), and LoDEX (20 mg/day, or 10 mg/day
for pts aged >75 years, on days 1, 2, 4, 5, 8, 9, 11, and 12) until progressive
disease (PD) or unacceptable adverse event (AE). After cycle 8, BORT was
given on days 1 and 8, and LoDEX was given on days 1, 2, 8, and 9. The pri-
mary endpoint was MTD. 
Results: Of the 34 pts enrolled, 59% were male, and median age was 58.5
years (range, 36-76 years). The median number of prior anti-myeloma Tx lines
was 2 (range, 1-4). All pts were refractory to LEN, and all were exposed to prior
PI (97% received prior BORT and 6% received prior ixazomib). All pts discon-
tinued Tx, mostly due to PD (n=23) but none due to Tx-related AEs. No dose-
limiting toxicities were reported in the dose-escalation cohorts or at the maxi-
mum planned dose (MPD) of POM 4 mg, BORT 1.3 mg/m2, and LoDEX 20 mg
(10 mg for pts aged >75 years). The median number of Tx cycles received was
9 (range, 2-36) for all pts and, in the MPD cohorts, was 11 (range, 2-19) with
IV BORT (n=10) vs 8 (range, 3-15) with SC BORT (n=12). The overall response
rate (≥partial response [PR]) for all pts was 65% (n=22), with 2 complete
responses (CRs), 1 stringent CR, 11 very good PRs, and 8 PRs; median dura-
tion of response was 7.4 months. All pts achieved at least stable disease. In
the MPD cohorts, grade 3/4 AEs were more frequent with IV BORT vs SC
BORT (90% vs 75%), including neutropenia (80% vs 25%), thrombocytopenia
(40% vs 17%), and pneumonia (30% vs 8%). There were no reports of grade
3/4 peripheral neuropathy (PN) or deep vein thrombosis (DVT).
Summary/Conclusions: PVd was highly effective in pts with LEN-refractory
and PI-exposed myeloma. PVd was well tolerated, with no grade 3/4 PN or
DVT and no Tx discontinuation due to Tx-related AE. AEs were generally less
frequent with SC vs IV BORT. Thus, the favorable tolerability and efficacy of
PVd, a potential new therapeutic option in pts with RRMM, is being further eval-
uated in a large phase 3 trial (MM-007).
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Background: Cancer pts present with a highly heterogeneous health status and
today treatment choices are numerous. Therefore, careful assessment of indi-
viduals’ condition is relevant. Moreover, in order to define best tolerable treatment
options, novel metrics for non-disease variables are needed. Albeit impairment
in the Karnofsky Performance Status (KPS), Activities of Daily Living (IADL or
ADL) and quality of life (QoL) are predictive for outcome in cancer pts, the prog-
nostic variables within a defined and prospectively assessed battery of established
functional tests have rarely been meticulously assessed in MM.
Aims: Our aim is to establish a prospective comorbidity and functional geriatric
assessment (CF-GA) to more objectively rate fitness and pts’ biological age,
rather than the chronological age alone in MM. We assessed a battery of defined
tests in German DSMM study centers in newly diagnosed (ND) MM pts.
Methods: This trial of DSMM centers performed a thorough, prospective comor-
bidity and functional geriatric assessment (CF-GA) in consecutive ND MM pts.
This GA was performed prior to initiation of anti-myeloma treatment and reflect-
ed pts’ baseline health status. The CF-GA included the IADL, ADL, Timed Up
and Go Test (TUGT), malnutrition, pain, rating of fitness, SF12-QoL and geriatric
depression scale (GDS). Moreover, established comorbidity (CM) scores,
namely: ß2MG/eGFR (EJH 2009;83:519-27), Kaplan Feinstein (KF),
Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), Charlson
Comorbidity Index (CCI), initial-Myeloma Comorbidity Index (I-MCI) and
revised-MCI (R-MCI) were assessed. The CF-GA was performed as a screening
tool to assess pt fitness as well as to predict survival and toxicities. The trial
protocol was approved by the ethics committees of the Freiburg University. All
patients provided written informed consent and all procedures were conducted
in accordance with the Declaration of Helsinki, the International Conference on
Harmonization and Guidelines for Good Clinical Practice.
Results: Characteristics of a total of 238 pts, currently included in this CF-GA,
were typical for tertiary centers with a median age of 62 years (27-84) and 94%
with symptomatic disease: the median hemoglobin was 11.0g/dl (5-17), eGFR
72ml/min/1.73qm (7-163), ß2-MG 3.8mg/l (0.8-38.4) and BM infiltration 40%
(0-95). The baseline frailty assessment revealed a median KPS of 80% (30-
100) and physicians’- and patients’-scored fitness was rated with 3 (1-6). Medi-
an functional results for the IADL were 8 (1-8), for the ADL 5 (2-6), for pain 2
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(0-10), for malnutrition 4 (0-14) and for cognitive deficiency via Mini Mental
State Examination (MMSE) 28 (15-30). The median GDS was 2 (0-13) and
TUGT 10 (4-80). Median CM scores were substantially different with an I-MCI
of 1 (0-3), ß2MG/eGFR of 1 (0-2), KF of 1 (0-3), CCI of 2 (0-8), HCT-CI of 2 (0-
8) and R-MCI of 4 (0-9). In age subgroups >60 and >70 years, mean R-MCI
and IMWG did increase the most and much lesser with HCT-CI and KF use,
confirming the latter’s lesser usefulness in MM (Figure 1). According to our
current results in 238 pts, highly relevant CF-GA-tools in MM are the TUGT, R-
MCI and IMWG score. Since any CF-GA is time-consuming, we have created
a web account that allows easy and prompt assessment of the R-MCI
(https://myelomacomorbidityindex.org) within 1-2 minutes.
Figure 1. Mean results in different comorbidity indices in age groups.
Summary/Conclusions: To the best of our knowledge, this is the first prospec-
tive multicenter GA that accumulates most valuable MM-specific disease risks,
frailty tests and comorbidity scores. Our current results in 238 pts showed that
the most relevant and compromised parameter in MM are: KPS, renal function,
osteolyses, pain, malnutrition, TUGT, frailty, ADL and fitness, whereas lung
function, MMSE, GDS, ADL seem less informative nor substantially impaired.
As combined CM test, most discriminative are the R-MCI and IMWG that reveal
intermediate and unfit pts and increase with age, whereas almost all pts via
HCT-CI and KF appeared fit. Most predictive CF-GA tools should be included
in future clinical trials.
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Background: Pending the availability of second generation new drugs in clin-
ical practice, currently patients with MM who relapse after induction therapy
can be treated with bortezomib or lenalidomide-based combinations besides
up front therapy. However, the impact of the different therapy sequences induc-
tion-first salvage therapy on PFS2 is not well known and even less it has been
defined which is the most appropriate therapy sequence according to cytoge-
netic risk at diagnosis.
Aims: To analyze the impact on PFS2 of the therapeutic sequence induction-first
salvage therapy in patients who were enrolled up front in 2 prospective trials (VMP
vs VMPT-VT, MPR vs Mel-200) stratified according to cytogenetic risk by FISH.
Methods: Among patients included in the above prospective trials, 366/523
(70%) had available FISH analysis at diagnosis. One hundred and eight
patients (29.5%) were classified at high cytogenetic risk (HR), defined by the
presence of t(4;14) and/or del17p, whereas all the remaining 258 patients were
considered as having a standard risk (SR). Overall, 45 patients (12%) were
retreated with the same agent used up front (R-group), 94 (26%) received
bortezomib as induction and lenalidomide at first relapse (B-L group), 159
(43.5%) received lenalidomide up-front followed by bortezomib at first relapse
(L-B group) and 68 patients (18.5%) underwent bortezomib up-front followed
by chemotherapy or thalidomide (B-suboptimal group).
Results: Both in HR (PFS2=22 months) and in SR group (PFS2=28 months),
B-suboptimal sequence resulted in a significantly shorter PFS2 compared with
all others treatment groups. Among patients receiving B-L sequence, HR
patients had a PFS2 comparable with that of SR group (PFS2=42 vs 58
months; p=0.138). On the contrary, in the group treated with L-B sequence,
adverse cytogenetics resulted in a significant shorter PFS2 if compared with
SR group (PFS2=39 vs 48 months; p=0.061). Similar findings were observed
in the R-group in which PFS2 of HR and SR patients was 39 and 64 months,
respectively (p=0.008). Considering HR patients, no significant difference in
term of PFS2 was seen between R-group and B-L group whereas PFS2 of L-
B group resulted significantly shorter compared both with R-group (p=0.029)
and B-L group (p=0.043).
Summary/Conclusions: The choice of appropriate therapy up-front and in
first relapse is of utmost importance to maximize PFS2 in patients with MM.
Cytogenetic risk should be take into account in this regard since outcome of
patients with standard cytogenetic risk features seems to be not affected by
therapy sequences whereas, patients with high-risk features, had a better out-
come only if Bortezomib was used upfront.
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Background: For patients (pts) with multiple myeloma (MM), older age and
the presence of comorbidities have been associated with a poorer prognosis.
A frailty scale was recently described that categorized pts with MM as fit, inter-
mediate, or frail based on age, comorbidities, and physical and cognitive func-
tioning (Palumbo et al., Blood, 2015). The frailty score was a predictor of death
and toxicity. The pivotal phase 3 FIRST trial showed that treatment with
lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd
continuous) prolonged progression-free survival (PFS) and overall survival
(OS) vs melphalan, prednisone, and thalidomide (MPT) in transplant-ineligible
pts with newly diagnosed MM (NDMM).
Aims: To examine the outcomes in pts in FIRST based on frailty score severity.
Methods: Pts in the FIRST trial provided informed written consent and were
randomized to receive Rd continuous, Rd for 18 cycles (Rd18), or MPT. An
algorithm based on the previously described frailty scale was used to categorize
pts into 3 severity groups: fit, intermediate, and frail. Baseline pt characteristics
included in the algorithm were age, Charlson Comorbidity Index score, and
self-care and usual activities from the EQ-5D questionnaire (as proxies for the
Activities of Daily Living and Instrumental Activities of Daily Living scales). Pts
missing data on ≥1 variable were excluded (n=106). This analysis evaluated
PFS and OS outcomes between treatment arms within each severity group
using a data cutoff of March 3, 2014.
Figure 1.
Results: Of 1623 total pts, 1517 were included in the analysis, and the majority
of these pts were frail compared with fit or intermediate (54% vs 17% vs 30%,
respectively). Breakdowns based on severity group were similar across treat-
ment arms (Figure 1A). Compared with fit or intermediate pts, frail pts were
older and had higher Eastern Cooperative Oncology Group performance status
scores, higher International Staging System (ISS) stage, higher lactate dehy-
drogenase levels, and worse renal function. OS was improved in fit vs frail pts
(hazard ratio [HR], 0.42; P <.0001) and intermediate vs frail pts (HR, 0.62; P
<.0001). Treatment with Rd continuous prolonged PFS and OS compared with
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MPT for all severity groups (Figure 1B). Rd continuous reduced the risk of pro-
gression or death vs MPT by 44%, 39%, and 22% in fit, intermediate, and frail
groups, respectively. Fit pts had a lower risk of grade 3 or higher (grade 3+)
non-hematologic adverse events (AEs) compared with frail pts (HR, 0.77;
P=.0021). The risk of grade 3+ hematologic AEs was similar for all levels of
frailty. Pts treated with Rd continuous had a similar risk of grade 3+ non-hema-
tologic AEs compared with those treated with MPT for all severity groups. The
risk of grade 3+ hematologic AEs was lower with Rd continuous than with MPT
in the fit, intermediate, and frail groups. Pts within each severity group were
further divided based on ISS stage: fit pts were subdivided into stage I vs II/III
and intermediate and frail pts into stage I/II vs III. Combining ISS stage with
frailty classification further improved prognostic assessment of pts within each
severity group for both PFS and OS.
Summary/Conclusions: This analysis of the FIRST trial population supports
the use of the frailty scale for predicting risk of death in pts with NDMM. PFS
and OS benefits were seen with Rd continuous vs MPT across all levels of
frailty, with the greatest benefits seen in fit pts. These data support the use of
continuous therapy with Rd as a standard of care for pts with transplant-ineli-
gible NDMM.
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Background: Geriatric assessment (GA) collects data related to the medical,
psychosocial and functional capabilities of the elderly patients, and provides
tools for treatment and care decisions. Based on data from patients who par-
ticipated in clinical trials, a “Frailty score” was developed by the IMWG, by using
a simplified GA with 3 tools (Katz Activity of Daily Living (ADL), the Lawton
Instrumental Activity of Daily Living (IADL) and the Charlson Comorbidity Index
(CCI)) (Palumbo et al., Blood 2015). 
Aims: To prospectively evaluate different GA tools and comorbidity indices in
consecutive, unselected, “Real-World”, patients >65 years.
Methods: The following tools were used: G8 geriatric assessment screening tool
(G8-GAS), VES-13, GDS, Katz ADL, Lawton IADL, MMSE, KPS (%), ECOG PS,
number of falls in the past 1 & 6 months, lower-extremity function and disability
in elderly tool, nutritional assessment tools (DETERMINE and Mini Nutritional
Assessment), social support score, cognition evaluation tools (MMSE), Geriatric
Depression Scale and comorbidity indices (CCI, CIRS-G, ACE-27 tool). 
Results: Since January 2012, 144 consecutive patients >65 years diagnosed
with symptomatic MM in the Department of Clinical Therapeutics, University of
Athens, had a GA. The median age was 76 years (range 66-92); 55% were
males; 26% had ISS-1, 24% ISS-2 and 50% ISS-3 and 19% (of 121 with avail-
able) had high risk cytogenetics (del17p or t(4;14)) while 22% had eGFR<30
ml/min/1.73 m2. Treatment was IMiDs-based in 47% (thalidomide in 13% and
lenalidomide in 34%) and proteasome inhibitor-based in 53%. PR or better was
achieved by 78% of evaluable patients. Two year overall survival (OS) was
71%. Advanced age was associated with shorter OS and risk of early death
(<3 months) (early death rates were 3%, 8% and 20% for patients ≤70 vs 71-
80 vs >80 years). ISS stage was associated with OS (p=0.004) but not high
risk cytogenetics (p=0.714) or different types of primary therapy (p=0.593).
Per the IMWG “frailty score”, 29% were fit, 17% intermediately fit and 54% frail
with 2-year OS of 77%, 81% and 62% respectively. The distribution in frailty
scores was different than that of patients in the IMWG cohort (39%, 31% &
30%), probably because our patients were unselected and older. Several dif-
ferent GA tools showed prognostic significance in univariate analysis, such as
the number of falls in the past 6 months (p=0.002), lower extremity function
(p=0.014), mini nutritional assessment (p=0.014), G8-GAS (p<0.001), KPS
<50% (p<0.001), ECOG PS >2 (p=0.04) and MMSE (p=0.024). There was an
association of early death with KPS ≤50% (p=0.003), ECOG PS >2 (p=0.05),
Geriatric depression score (p=0.018) and G8-GAS score (p=0.015). IMWG
“frailty score” was not associated with early death. In multivariate analysis,
which included ISS and age, the number of falls in the past 6 months (HR: 4.7,
p=0.007) and the score of the G8-GAS tool (HR: 4.7, p=0.004) were independ-
ent factors for survival. Addition of cytogenetics did not improve the multivariate
model. IMWG “frailty score” in a multivariate analysis, which included ISS stage,
did not have independent statistical significance for OS. 
Summary/Conclusions: In elderly myeloma patients, GA with G8-GAS tool
provides prognostic information related to the risk of early death and overall
survival, independently from disease characteristics and the treatment type.
GA can be simple and provides a strong tool which may be useful for prognos-
tication and treatment decisions in elderly patients.
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Background: The introduction of new treatment modalities have changed sig-
nificantly the perspective of multiple myeloma (MM) patients. The factors that
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are associated with inferior treatment response and possible drug-resistance
are currently in the focus of investigation. 
Aims: The aim of the study was to analyze the prognostic significance of CRBN
expression in MM patients ineligible for autologous stem cell transplantation
(ASCT).
Methods: The study included 92 newly diagnosed MM patients (median age
67 years, range 35-80 years; 44 male/48 female) with following distribution:
IgG myeloma had 55 patients (59.8%), IgA 18 (19.6%), light chains 16 (17.4%),
and IgD 2 patients (2.2%). Advanced III clinical stage (CS, Durie&Salmon) had
68 patients (73.9%), II 18 (19.6%), and 6 (6.5%) had symptomatic I CS. Of 92
patients, 24 (26.1%) had ISS score 1, 28 (30.4%) ISS 2 and 40 (43.5%) ISS 3.
Elevated LDH level was present in 18/92 patients (19.6%). High risk chromo-
somal abnormalities (CA, iFISH): t(4; 14), del(17p), were detected in 14 patients
(15.2%). Renal impairment existed in 16 patients (17.4%). The CRBN expres-
sion was analyzed on the samples of bone marrow aspirate by RT-PCR
method. All patients were treated with novel agents within three-drug combi-
nations with alkylating agents (melphalan or cyclophosphamide) and corticos-
teroids (dexamethasone or prednisolone). Thalidomide based combinations
were applied in 77 patients (83.7%) while 15 patients (16.3%) were treated
with bortezomib based combinations. The patients were ASCT ineligible due
to the age, high comorbidity index, progressive disease or personal attitude. 
Results: Overall treatment response (CR/VGPR/PR/MR) was achieved in 77
patients (83.7%). Median CRBN expression for patients with CR, VGPR, PR,
MR and PD, in the group treated with thalidomide- or bortezomib based com-
binations, was 3.13, 2.65, 2.08, 1.85 and 0.97 respectively; and 2.63, 3.00,
3.04, and 1.35, respectively. Treatment response correlated with high CRBN
expression (p=0.011), mainly in the group treated with thalidomide based com-
binations (p=0.013), while in the group treated with bortezomib based combi-
nations such correlation was not found (p=0.665). The most discriminative cut-
off value of CRBN expression selected by the ROC analysis was 1.39 (sensi-
tivity 41% and specificity 81.8%, AUC value 0.643, 95% CI 0.502–0.785,
p=0.05). Low CRBN expression (≤1.39) had 22/92 patients (23.9%), 19/77 of
thalidomide group (24.7%), and 3/15 (20%) of bortezomib group. The presence
of high risk CA wasn’t associated with lower CRBN expression (p=0.35).
Patients with low CRBN expression (≤1.39), treated with thalidomide based
combinations, had significantly shorter progression free survival (PFS) com-
pared to patients with high CRBN expression (median of PFS 22 months vs
median not reached, Log Rank=5.70, p=0.017). In this group, low CRBN
expression wasn’t associated with inferior OS (Log Rank=2.93, p=0.087).
Regarding bortezomib treated patients, there wasn’t observed impact of CRBN
expression neither on PFS (Log Rank=0.063, p=0.80), nor on OS (Log
Rank=0.036, p=0.85). Among significant variables (ISS, LDH, CA, and CRBN),
Cox regression analysis has confirmed that low CRBN expression has the
most significant prognostic influence on PFS (HR, 3.5; 1.40-8.77; p=0.008) in
patients treated with thalidomide based combinations. 
Summary/Conclusions: Indicating possible suboptimal treatment outcome,
the level of CRBN expression may represent additional prognostic tool in per-
sonalized treatment approach to individual myeloma patient. 
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Background: Subcutaneous (SC) delivery of bortezomib (BTZ) has been
shown non-inferior to intravenous (IV) delivery in terms of efficacy while offer-
ing improved safety (Moreau, et al. Lancet Oncol 2011;12:431-40). The phase
3 ENDEAVOR study demonstrated a significant improvement in progression-
free survival (PFS) for carfilzomib and dexamethasone (Kd) vs IV/SC BTZ
and dexamethasone (Vd) in patients with relapsed or refractory multiple
myeloma (RRMM) (Dimopoulos, et al. Lancet Oncol 2016;17:27-38). Cur-
rently, most BTZ use in MM is SC, and most relapsed MM patients had prior
exposure to BTZ.
Aims: We present results of a subset analysis of the efficacy and safety of Kd
vs SC Vd in the ENDEAVOR study consistent with current standard of care;
the effect of prior exposure to BTZ was also investigated.
Methods: After providing informed consent, patients with RRMM (1-3 lines of
therapy) were randomized 1:1 to Kd or Vd. The analysis compared Kd patients
who had selected SC BTZ delivery pre-randomization if randomized to Vd arm
with Vd patients who used SC BTZ. Kd arm received carfilzomib (30-min IV infu-
sion) on days 1, 2, 8, 9, 15, and 16 (20 mg/m2 on days 1 and 2 of cycle 1; 56
mg/m2 thereafter) and dexamethasone (d) 20 mg on days 1, 2, 8, 9, 15, 16, 22,
and 23 of a 28-day cycle. Vd arm received BTZ 1.3 mg/m2 on days 1, 4, 8 and 11
and d (20 mg) on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-day cycle. The primary
endpoint was PFS. Secondary endpoints included overall survival (OS), overall
response rate (ORR), rate of grade ≥2 peripheral neuropathy (PN), and safety. 
Results: A total of 929 patients were randomized to Kd (n=464) or Vd (n=465); of
these, 360 Vd patients received SC BTZ. Among 464 Kd patients, 356 patients
selected SC route of BTZ administration if randomized to Vd arm. Median PFS
has not been reached for Kd but was 9.5 months (mo) for Vd patients treated with
SC BTZ (hazard ratio [HR]: 0.58; 95% confidence interval [CI], 0.46–0.72). Median
PFS for Kd vs SC Vd was 13.4 mo vs 8.4 mo for patients with prior BTZ exposure
(HR: 0.66; 95% CI, 0.50–0.87). Median OS has not been reached for Kd but was
24.3 mo for SC Vd (HR: 0.75; CI, 0.53–1.08). ORR was 76.1% (Kd) vs 64.4%
(SC Vd), and 70.4% (Kd) vs 62.1% (SC Vd) for patients with prior BTZ use. Grade
≥2 PN rates were 6.5% (Kd) vs 33.3% (SC Vd), and 6.2% (Kd) vs 29.1% (SC Vd)
for patients with prior BTZ. Grade ≥3 adverse events (AEs) were 74.4% (Kd) vs
67.5% (SC Vd), and 71.8% (Kd) vs 64.5% (SC Vd) for patients with prior BTZ.
Results are shown in Table 1. Figure 1 shows Kaplan‒Meier PFS curves.
Table 1. Outcomes
                                                                                        Prior BTZ 
                                  Kd (n=356)     SC Vd (n=360)          Kd (n=196)    SC Vd (n=203)
Median PFS, mo             Not reached              9.5                        13.4                  8.4
HR for Kd vs           0.58                       0.66
SC Vd (95% CI) (0.46–0.72)            (0.50–0.87)
ORR, % (95% CI)                 76.1                   64.4                       70.4                 62.1
                                    (71.3–80.4)        (59.3–69.4)            (63.5–76.7)      (55.0–68.8)
Grade ≥2 PN rate, %             6.5                    33.3                        6.2                  29.1
Odds ratio (95% CI) 0.139                   0.160
                    (0.09–0.22)         (0.08–0.31)
Grade ≥3 AEsa, %                74.4                   67.5                       71.8                 64.5
aSafety population was 355 (Kd) and 360 (SC Vd), and 195 (Kd) and 203 (SC Vd) in the prior
BTZ group.
Figure 1. Kaplan-Meier PFS curves.
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Summary/Conclusions: Treatment with Kd led to prolonged progression-free sur-
vival vs Vd patients who were administered SC BTZ. The use of Kd also led to
higher response rates, a trend for prolonged OS, and lower rate of grade ≥2 PN vs
SC Vd. In patients with prior BTZ exposure, Kd treatment resulted in longer PFS,
greater ORR, and decreased PN vs SC Vd. These results suggest that Kd has a
favorable benefit-risk profile and delivers superior efficacy and improved clinical
outcomes compared with SC Vd for RRMM regardless of prior BTZ treatment.
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Background: In the double-blind, placebo-controlled, phase 3 TOURMALINE-
MM1 study (NCT01564537) in 722 patients with relapsed/refractory multiple
myeloma (RRMM) following at least one prior therapy, IRd was associated with
a significant improvement in PFS vs placebo-Rd (HR 0.742, p=0.012), together
with limited additional toxicity (Moreau et al., ASH 2015). Data from this study
led to approval by the US FDA of ixazomib, in combination with Rd, in this setting. 
Aims: Despite recent advances in treatment, no quality-of-life (QoL) data are
available from double-blind, randomized, placebo-controlled studies in RRMM.
A secondary endpoint of TOURMALINE-MM1 was to assess patient-reported
QoL using the EORTC Quality of Life Questionnaire (EORTC QLQ-C30) and
MM-specific MY-20 module.
Methods: Patients with RRMM were randomized 1:1 to receive IRd or place-
bo-Rd (ixazomib 4 mg or matching placebo on days 1, 8, and 15, plus lenalido-
mide 25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and
22, in 28-day cycles) until disease progression or unacceptable toxicity. Patients
completed the EORTC QLQ-C30 and MY-20 questionnaires at screening, the
start of cycles 1 and 2 and every other cycle, the end of treatment, and every
4 weeks until progression.
Results: Over a median follow-up of 23 months, QoL was maintained from
baseline with both treatment regimens. Mean EORTC QLQ-C30 global health
status scores for the intent-to-treat population were similar for the IRd vs place-
bo-Rd arms, suggesting the addition of ixazomib did not impact QoL (Figure 1).
For the EORTC QLQ-C30 functioning scales, linear mixed model analysis of
least squares (LS) mean change from baseline showed similar results over time
for the IRd and placebo-Rd arms: 0.4 vs -1.3 for physical, -1.3 vs -3.0 for role,
1.0 vs -1.6 for emotional (p<0.05), -3.5 vs -5.7 for social, and -4.2 vs -4.6 for
cognitive functioning scales (higher values indicate better functioning). For the
physical, emotional, and social scales, significantly higher mean scores (p<0.05)
were seen in the IRd vs placebo-Rd arm at several time points, suggesting
better QoL with IRd. In line with the limited additional toxicity seen with IRd vs
placebo-Rd (74%/47% vs 69%/49% of pts had grade ≥3 adverse events
[AEs]/serious AEs), EORTC QLQ-C30 symptom scale scores were similar for
IRd vs placebo-Rd, LS mean change from baseline was 1.8 vs 4.2 for appetite
loss, 3.5 vs 5.1 for constipation, 14.5 vs 10.4 (p<0.05) for diarrhea, 1.0 vs 2.0
for dyspnea, -0.3 vs 0.9 for financial difficulties, 0.4 vs 2.4 for fatigue,1.1 vs 0.5
for insomnia, 1.6 vs 0.6 for nausea/vomiting, and -2.8 vs -2.3 for pain scales
(lower scores indicate lower symptom burden). Diarrhea (which was mostly
grade ≤2) did not appear to impact patient perception of overall QoL. Consistent
results were also seen with the MY-20 measure: LS mean change from baseline
in the IRd vs placebo-Rd arms was -3.3 vs -4.3 for body image, 8.1 vs 4.9 for
future perspective (p<0.05) (higher scores indicate better QoL), -5.8 vs -5.5 for
disease symptoms, and 3.8 vs 3.4 for side effects of treatment (lower scores
indicate lower symptom burden). Post-hoc analyses showed that, in both arms,
changes in global health status and several functioning and symptom scores
were significantly correlated with response to treatment.
Summary/Conclusions: In the double-blind, placebo-controlled, phase 3
TOURMALINE-MM1 study in patients with RRMM, patient-reported QoL was
maintained with the addition of ixazomib to Rd, which also provided a significant
clinical benefit, thus improving patient outcome. 
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Background: Carfilzomib, an irreversible proteasome inhibitor, is approved as
a single agent and in combination with dexamethasone in the United States
(US) for the treatment of relapsed/refractory and relapsed multiple myeloma
(MM), respectively and in the US and Europe in combination with lenalidomide
(LEN)/dexamethasone for the treatment of relapsed MM. The approved
dose/schedule of carfilzomib is a twice-weekly, 10-min intravenous (IV) infusion
on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle (starting dose: 20mg/m2 [cycle
1: days 1 and 2], escalating to 27mg/m2 thereafter).
Aims: A phase 1/2 study (CHAMPION-1; NCT01677858) to determine the max-
imum tolerated dose (MTD) of carfilzomib (phase 1), the overall response rate
(ORR [≥partial response]) (phase 2) and safety of once-weekly carfilzomib with
dexamethasone (Cd) in patients with relapsed or refractory MM.
Methods: Patients with relapsed or refractory MM (1-3 prior lines of therapy)
received carfilzomib (30-min IV infusion) on days 1, 8, and 15 every 28 days.
Phase 1: patients received carfilzomib 20mg/m2 on day 1 of cycle 1 followed
by 45, 56, 70, or 88 mg/m2 beginning day 8 of cycle 1 in successive dose-level
cohorts until the MTD was reached (using a standard 3+3 dose-escalation
scheme). All patients received dexamethasone 40mg (IV or oral) days 1, 8, 15,
and 22 (cycles 1-8); dexamethasone was omitted on day 22 cycles ≥9. Phase
2: patients received carfilzomib 20mg/m2 on cycle 1, day 1, escalating to the
MTD for subsequent doses. Dexamethasone was given as previously. Cd was
administered until unacceptable toxicity or disease progression. Blood samples
were collected for pharmacokinetic and pharmacodynamic analyses.
Results: Patients with relapsed or refractory MM (1-3 prior lines of therapy)
received carfilzomib (30-min IV infusion) on days 1, 8, and 15 every 28 days.
Phase 1: patients received carfilzomib 20mg/m2 on day 1 of cycle 1 followed by
45, 56, 70, or 88 mg/m2 beginning day 8 of cycle 1 in successive dose-level
cohorts until the MTD was reached (using a standard 3+3 dose-escalation
scheme). All patients received dexamethasone 40mg (IV or oral) days 1, 8, 15,
and 22 (cycles 1-8); dexamethasone was omitted on day 22 cycles ≥9. Phase 2:
patients received carfilzomib 20mg/m2 on cycle 1, day 1, escalating to the MTD
for subsequent doses. Dexamethasone was given as previously. Cd was admin-
istered until unacceptable toxicity or disease progression. Blood samples were
collected for pharmacokinetic and pharmacodynamic analyses (Table 1).
Table 1. Adverse events in any grade occurring in ≥20% of patients and
grade ≥3 adverse events occurring in ≥5% of patients treated at the carfil-
zomib MTD.
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Summary/Conclusions: Once-weekly carfilzomib (70 mg/m2) with dexam-
ethasone for patients with relapsed or refractory MM has an acceptable safety
and tolerability profile with promising efficacy. The dose and schedule of carfil-
zomib used in this study (20/70mg/m2) is currently being compared with the
regulatory-approved carfilzomib dose and schedule (20/27mg/m2 twice-weekly)
in an ongoing phase 3, superiority study (ARROW; NCT02412878).
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Background: Over the past decade, numerous drug therapies have emerged
for the treatment (Tx) of multiple myeloma (MM). However, eventually all
patients (pts) relapse or progress with heterogeneous clinical pattern (Alegre
et al., Haematologica, 2002). According to the International Myeloma Workshop
Consensus Panel (IMWCP; Rajkumar et al., Blood, 2011), salvage Tx for MM
relapse should begin at symptomatic clinical relapse (clinR) and earlier at
asymptomatic biological relapse (BR) when paraprotein increases significantly.
In the case of asymptomatic BR/progression, rescue Tx could be delayed in a
subset of pts (Fernández de Larrea et al., Bone Marrow Transplant, 2014),
particularly in low-risk pts with stable M-protein and hemoglobin. Progressive
increases of M-spike in blood and/or urine could lead to rescue Tx, even in the
absence of clinical symptoms, to avoid complications (e.g., renal failure, plas-
macytomas, or hypercalcemia).
Aims: This Spanish observational prospective Registry aims to describe MM
relapse patterns, comparing the impact in terms of time to progression (TTP)
on Tx decisions (starting Tx at BR [TxBR] vs delaying Tx until clinR progression
[TxClinR]).
Methods: Adult pts with MM who received 1 or 2 lines of Tx and had achieved
≥partial response (PR) to the last Tx and were in (or prior to) BR according to
the IMWCP(Rajkumar et al., Blood, 2011)were included. 41 Spanish sites are
participating, with 410 pts registered. Data recorded included, among others,
demographic, relapse clinical characteristics, TTP, and time from BR to clinR
(TTP-ClinR). All pts provided their informed written consent.
Figure 1. Time from biological relapse to clinical relapse, months.
Results: The cohort evaluated 184 pts (97 male/87 female; mean age of 68.7
years [SD, 10.7]). Heavy chain isotypes were IgG κ (39.0%), IgG λ (23.6%),
IgA κ (14.3%), IgA λ (9.9%), IgM λ (1.1%) and IgD λ (0.5%). Prognostic stage
at diagnosis according to the ISS was II (28.0%), I (26.9%), and III (24.7%).
47.8% of pts had received autologous stem cell transplant. In 49 pts with avail-
able cytogenetic data, 31 (63.3%) were standard-risk and 18 (36.7%) were
high-risk. First-line Tx was based mostly on bortezomib (74.4%). After first-line
Tx, pts achieved stringent complete response (17.9%), complete response
(27.4%), very good partial response (29.6%), or PR (25.1%). Median follow-
up was 8.5 months. After BR, 100 pts (55.2%) started Tx (lenalidomide, 68.4%;
bortezomib, 28.9%) at BR (65% with significant paraprotein relapse), while Tx
was delayed until clinR in 81 (44.8%) pts. Overall median time to progression
from BR to clinR (the primary objective) was 22.8 months (95% CI, 17.7-not
estimable [NE]). A statistically significant difference was found between Tx
groups, median TTP-ClinR was 14.2 months (95% CI, 11.5-18.0) for TxClinR
pts and NE for TxBR pts (P <.0001; Figure 1). Additional details regarding pat-
tern of BR will be presented.
Summary/Conclusions: Although longer follow-up is needed, in this updated
preliminary cohort of pts with MM BR, we found that starting Tx at BR delays
the time to clinical relapse, suggesting that pts may benefit from early Tx after
first or second relapse. 
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Background: Single-agent carfilzomib has demonstrated activity in patients
with relapsed and refractory multiple myeloma with high-risk cytogenetic abnor-
malities. In the phase 3 study (NCT01080391; N=792 patients) carfilzomib,
lenalidomide and dexamethasone (KRd) significantly improved progression-
free survival (PFS) versus lenalidomide and dexamethasone (Rd) in patients
with relapsed multiple myeloma (RMM).
Aims: A pre-planned subgroup analysis of the efficacy and safety of KRd versus
Rd according to patients’ baseline cytogenetic risk status.
Methods: Adult patients with RMM who had received 1-3 prior lines of therapy
were randomized (1:1) to receive KRd or Rd in 28-day cycles. Patients in the
KRd arm received carfilzomib as a 10-minute IV infusion on days 1, 2, 8, 9, 15,
and 16 (cycle 1, 20mg/m2 on days 1 and 2; escalated to target 27mg/m2 there-
after) during cycles 1-12. For cycles 13-18, carfilzomib was omitted on days 8
and 9 and discontinued after 18 cycles. Lenalidomide 25mg was administered
days 1-21 and dexamethasone 40mg days 1, 8, 15, and 22. The primary end
point was PFS; secondary end points included overall survival, overall response
rate (ORR), duration of response (DOR), health-related quality of life and safety.
The high-risk group was defined as patients with the genetic subtype t(4;14)
or t(14;16) or deletion 17p in ≥60% of plasma cells (as assessed using fluores-
cence in situ hybridization). The standard-risk group consisted of all other
patients with known baseline cytogenetics.
Results: A total of 396 patients were randomized to each arm. For patients with
known baseline cytogenetics, risk status was similar across treatment arms (high-
risk: KRd, 24.6%; Rd, 23.4%; standard-risk: KRd, 75.4%; Rd, 76.6%). Efficacy
outcomes by cytogenetic risk status are presented in the Table 1. In the high-risk
group (n=100), median PFS was 23.1 months (95% confidence interval [CI]:
12.5–24.2) for KRd vs 13.9 months (95% CI: 9.5–16.7) for Rd (hazard ratio [HR]:
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0.639; 95% CI: 0.369–1.106). In the standard-risk group (n=317), median PFS
was 29.6 months (95% CI: 24.1–not estimable) and 19.5 months (95% CI: 14.8–
26.0), respectively (HR: 0.657; 95% CI: 0.480–0.901). In the high-risk group,
ORRs were 79.2% (KRd) vs 59.6% (Rd) and in the standard-risk group, 91.2%
(KRd) vs 73.5% (Rd). In the high-risk group, rates of grade ≥3 adverse events
were 89.1% (KRd) vs 78.4% (Rd) and in the standard-risk group 85.6% (KRd) vs
84.5% (Rd).
Table 1. Efficacy outcomes and AEs of interest by baseline cytogenetic
risk status.
Summary/Conclusions: In patients with high-risk cytogenetics, treatment with
KRd improved median PFS by 9 months versus Rd (median PFS of nearly 2
years vs 13.9 months). KRd was also associated with a 10-month improvement
in median PFS vs Rd in patients with standard-risk cytogenetics. Treatment
with KRd resulted in higher response rates, greater depth of response and a
longer DOR versus Rd, regardless of patients’ baseline cytogenetic risk status.
The triplet regimen of KRd had a favorable benefit–risk profile in patients with
RMM and improved outcomes in patients with high-risk disease.
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Background: In ENDEAVOR (NCT01568866; N=929), carfilzomib plus dex-
amethasone (Cd) was superior to bortezomib/dexamethasone (Bd), with a 2-
fold improvement in median PFS (18.7 vs 9.4 months; HR=0.53; 95% CI, 0.44,
0.65; p<.0001) in patients with RMM.
Aims: To evaluate change from baseline in left ventricular ejection function
(LVEF), right ventricular (RV) function and pulmonary artery systolic pressure
(PASP) via echocardiogram (ECHO) in a subset of patients from the ENDEAV-
OR study.
Methods: Adults with RMM (1-3 prior regimens) with a LVEF ≥40% and no evi-
dence of New York Heart Association class III or IV symptomatic heart failure
(HF), symptomatic ischemia, uncontrolled arrhythmias or recent myocardial
infarction within 4 months before randomization. Patients received either carfil-
zomib (30-min IV infusion on days [D] 1, 2, 8, 9, 15, 16 [20 mg/m2 on D1, 2 of
cycle 1; 56 mg/m2 thereafter]) and dexamethasone (20mg on D1, 2, 8, 9, 15,
16, 22, 23 of a 28-day cycle) or bortezomib (1.3 mg/m2; IV or SC on D1, 4, 8,
11) and dexamethasone (20mg on D1, 2, 4, 5, 8, 9, 11, 12 of a 21-day cycle).
All eligible patients were assessed at baseline and every 12 weeks on D1 of
treatment cycles and at the end-of-treatment visit (using 2D transthoracic
ECHO). ECHOs were centrally read. An independent cardiac events adjudica-
tion committee (CEAC) reviewed results in conjunction with adverse events
(AEs) to assess clinical significance. Primary endpoint was reduction (≥10%
absolute decrease from baseline in patients with LVEF ≤55% or a reduction
<45% for patients with baseline LVEF >55%) or no change in LVEF (≤24 weeks
from baseline).
Results: A total of 151 patients (Cd: 75; Bd: 76) were included in this substudy;
74 in each arm were evaluable for safety. More patients in the Cd arm (versus
the Bd arm) were aged ≥75 years (21.3% vs 14.5%), had prior cardiac-related
medical history (26.7% vs 14.5%) and received drugs for obstructive airway
disorders (28.0% vs 17.1%). Patients in the Cd arm had a higher incidence of
HF reported as an AE vs Bd (10.8% [n=8] vs 4.1% [n=3]), consistent with the
overall safety population (8.2% vs 2.9%). History of cardiac disorders was asso-
ciated with an elevated (not significant) risk of HF (3/8 Cd pts; 0/3 Bd pts).
Patients receiving Cd had a higher incidence of hypertension (HTN) versus
those treated with Bd (20.3% vs 8.1%). Twenty-three patients (15.2%) discon-
tinued treatment due to AEs); 8 due to non-fatal cardiac-related AEs (6 Cd [2
due to LV dysfunction, and 1 each due to HF, decreased EF, pulmonary
embolism, and ischemic stroke] and 2 Bd [1 each due to decreased EF and RV
failure]). Only 1 patient (Bd) had significant LVEF reduction as defined within
the first 24 weeks. Six patients had a significant LVEF reduction at any time
during the study (Cd: 3; Bd: 3). All but 1 had resolution to normal LVEF. CEAC
evaluation found 14 patients (Cd: 8; Bd: 6) had on-study CEAC-defined clinically
meaningful changes in ECHOs; 11/14 (79%) did not meet the ECHO criteria
for decreased LVEF. The CEAC reported more Cd patients (vs Vd) had evi-
dence of HF (n=4 vs n=0) or pulmonary HTN (n=4 vs n=1) (Figure 1).
Figure 1. Left ventricular ejection fraction (LVEF) by week.
Summary/Conclusions: In the overall and cardiac substudy, HF and pul-
monary HTN events occurred more frequently with Cd vs Vd although ECHO-
detected significant decline in LVEF was low on both treatment arms and with
similar frequency. The substudy found limited utility for serial screening with
ECHOs to mitigate cardiac risk for unselected patients receiving carfilzomib.
Alternative surveillance strategies are needed to detect early cardiotoxicity and
prevent treatment interruption or discontinuation.
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PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND
STANDARD-RISK CYTOGENETICS
M Binder1,*, SV Rajkumar2, RP Ketterling3, A Dispenzieri2, MQ Lacy2, MA Gertz2,
FK Buadi2, SR Hayman2, YL Hwa2, SR Zeldenrust2, JA Lust2, SJ Russell2,
N Leung2,4, P Kapoor2, RS Go2, WI Gonsalves2, RA Kyle2, SK Kumar2
1Department of Internal Medicine, 2Division of Hematology, 3Department of
Laboratory Medicine and Pathology, 4Division of Nephrology and Hypertension,
Mayo Clinic, Rochester, United States
Background: Cytogenetic evaluation using fluorescence in situ hybridization
(FISH) at the time of diagnosis is essential for initial risk stratification and the
employment of risk-adapted treatment strategies in multiple myeloma. Despite
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the absence of cytogenetic high-risk abnormalities a subset of patients does
experience poor overall survival.
Aims: To identify demographic, clinical, and cytogenetic characteristics asso-
ciated with poor three-year overall survival in patients with standard-risk cyto-
genetics.
Methods: We studied 514 patients who were diagnosed with multiple myeloma
between January 2004 and December 2015 at Mayo Clinic Rochester and
underwent FISH evaluation within six months of diagnosis. Patients with high-
risk cytogenetics and those who were lost to follow-up within three years were
excluded. High-risk cytogenetics were defined as the presence of del(17p),
t(4;14), t(14;16), or t(14;20). Bone marrow aspirates were evaluated for dele-
tions, monosomies, trisomies, and tetrasomies using chromosome- or cen-
tromere-specific FISH probes. IGH rearrangements were evaluated using an
IGH break-apart probe and evaluating up to five potential partners (FGFR3,
CCND1, CCND3, MAF, and MAFB). Multivariable-adjusted logistic regression
models were used to assess the associations between the parameters of inter-
est and three-year overall survival.
Results: The median age at diagnosis was 65 years (31-95), 316 (62%) of the
patients were male. The median overall survival was 6.4 years (5.5-7.7) for the
entire cohort (n=514), 9.2 years (8.3-10.4) for those who survived at least three
years (n=361, 70%), and 1.2 year (1.0-1.5) for those who did not survive three
years after diagnosis (n=153, 30%). The factors associated with poor three-
year overall survival are summarized in Table 1.
Table 1. Factors associated with poor three-year overall survival (n=514).
Parameter                                Value                                  OR (95% CI)                p
Age                        Older than 65 years at diagnosis            2.80 (1.80-4.36)         <0.001
Plasma cells            Less than 20% in bone marrow             2.00 (1.12-3.60)          0.020
Karyotype                   Hyperdiploid clone present                0.51 (0.33-0.79)          0.003
The model was adjusted for sex, β2-microglobulin, and albumin at diagnosis.
Summary/Conclusions: Patients with multiple myeloma and standard-risk
cytogenetics are a heterogeneous group. One third of the patients are experi-
encing less than three years of overall survival after diagnosis. Advanced age,
extent of bone marrow involvement, and specific clonal abnormalities were
associated with poor three-year overall survival. These findings emphasize the
importance of further risk stratification and the need for reliable predictors of
poor clinical outcomes in this patient population.
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CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON
IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND
ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE
M Jawhar1, N Naumann1, J Schwaab1, C Dietz1, J Casper2, TA Dang3, L Dietze4,
K Döhner5, A Hänel6, B Lathan7, H Link8, S Lotfti9, S Mielke10, V Luber10,
O Maywald11, L Müller12, U Platzbecker13, O Prümmer14, H Thomssen15,
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HELIOS Klinikum Berlin-Buch, Berlin, 19II. Medizinische Klinik, Universität-
sklinikum Schleswig-Holstein, Kiel, 20MLL, Münchner Leukämielabor,
München, Germany, 21Wessex Regional Genetics Laboratory, Salisbury,
22Faculty of Medicine, University of Southampton, Southampton, United King-
dom
Background: A distinct subcategory of the WHO 2008 classification of myeloid
neoplasms comprises myeloid/lymphoid neoplasms with eosinophilia (MLN-
eo) and rearrangements of PDGFRA, PDGFRB or FGFR1. Patients with
PDGFRA or PDGFRB fusion genes are exquisitely sensitive to imatinib.
Aims: We sought to evaluate the clinical characteristics and long-term outcome
on imatinib in MLN-eo patients (pts) with PDGFRB fusion genes.
Methods: Within the “German Registry on Disorders of Eosinophils and Mast
Cells” 22 MLN-eo pts with PDGFRB fusion genese were retrospectively
analysed.
Results: Fifteen different fusion genes were identified; three partner genes
were recurrent (ETV6, n=5; CDCC88C, n=3; H4, n=2). Median age was 49
years (range 20-80) with a striking male predominance (20/22, 91%). Signif-
icant eosinophilia ≥0.5x109/l and ≥1.5x109/l was present in 15/19 (79%) and
11/19 (58%) pts, respectively, monocytosis >1.0x109/l (median 0.5x109/l,
range 0-89) was seen in 5/15 pts (33%). Splenomegaly was observed in
12/15 (80%) pts, organ involvement in 5/22 (23%) pts including cytologically
or histologically confirmed infiltration of pleura (n=2), central nervous system
(n=1), endo-/myocard (n=1), liver (n=1) and skin (n=1). Five pts were initially
diagnosed in blast phase (BP): myeloid BP (n=1), extramedullary myeloid
sarcoma (n=1), T-cell lymphoblastic lymphoma (n=2) and B-cell acute lym-
phoblastic leukemia (n=1). Four pts (chronic phase, CP, n=2; BP, n=2) pre-
sented with a complex karyotype. All 17 CP pts were treated with imatinib
(400mg/d, n=12, 71%; 100 mg/d, n=5, 29%) and achieved complete hema-
tologic remission (CHR); no primary resistance was observed. Complete
cytogenetic remission was achieved in 10/11 (91%) evaluated pts after medi-
an 11 months (range 3-34) and complete molecular remission (CMR), as
detected by negative nested RT-PCR, in 10/12 pts (83%) after median 23
months (range 8-110). Imatinib was reduced from 400 mg/d to 100mg/d in
7/12 pts and to 3x100mg/week in two pts. After a median treatment of 7 years
(range 0-11), 15/17 pts are alive. One CP patient with a complex karyotype
achieved a CHR for 13 months but no cytogenetic remission and died due to
progressive disease. The second CP patient died because of comorbidity
while in CHR. One patient in BP with secondary T-cell lymphoma received
intensive chemotherapy followed by imatinib and died due to comorbidity at
month 27, while the second patient is alive on imatinib monotherapy 97
months after diagnosis. Three pts (complex karyotype, n=2) received an allo-
geneic stem cell transplantation (SCT) after intensive chemotherapy or a
short course of imatinib median 3 months (range 1-7) after diagnosis. Two
pts were re-exposed to imatinib because of residual disease. Two pts are
alive 3 and 42 months after SCT, respectively. The third patient died due to
progressive leptomeningeal involvement while in CHR on imatinib 9 months
after SCT. Overall, 4/22 pts (18%) have died (BP, n=2; CP, n=2) due to comor-
bidity while in remission (n=2) or progressive disease (n=2). Of note, 3 of
these 4 pts had an additional complex karyotype at diagnosis. 
Summary/Conclusions: We here confirm known and report several new clin-
ical and genetic characteristics in pts with MLN-eo and PDGFRB fusion genes:
i) significant male predominance, ii) significant eosinophilia is not present in all
pts (in contrast to FIP1L1-PDGFRA, but similar to FGFR1 fusion genes), iii)
264 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
except splenomegaly, organ involvement/dysfunction is rather uncommon, iv)
pts can present in BP of myeloid or lymphoid origin, v) an additional complex
karyotype may be associated with adverse prognosis, vi) in CP, no primary
resistance to imatinib was observed and vii) pts can be treated with imatinib
100mg/d.
P667
THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN
IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION
ML Randi1,*, M Ruggeri2, I Bertozzi1, I Nichele2, G Biagetti1, E Cosi1, F Fabris1
1Dept of Medicine - DIMED, University of Padua, Padova, 2Hematology, San
Bortolo Hospital, Vicenza, Italy
Background: Absolute erythrocytosis is a relatively rare finding in the clinical
practice, characterized by persistently raised hemoglobin (Hb) and hematocrit
(Ht) levels. The most extensively studied form of absolute erythrocytosis is
Polycythemia Vera (PV), a primary neoplastic disease characterized by the
presence of JAK2 mutations, risk of vascular complications and of evolution in
myelofibrosis or acute leukemia. Secondary erythrocytosis are represented by
rare congenital diseases (due to EPO-receptor or oxygen sensing pathway
genes mutation), acquired forms, [erythropoietin (EPO)-mediated] or idiopathic
erythrocytosis (IE) an absolute and isolated polyglobulia, without any definite
cause, not JAK2 mutations, not EPO-mediated. These patients are rarely
observed in clinical practice, thus few is known regarding their clinical charac-
teristics, natural history and best management.
Aims: In this work, we report clinical features of a large cohort of patients with
IE focusing on their thrombotic risk compared with a cohort of patients with PV. 
Methods: We report 145 patients with IE (not carrying any JAK2 mutation nor
affected by congenital/familial or secondary erythrocytosis) studied between
1980 and 2015 in two centers of Venetian region Italy. As controls we used
145 patients with PV all carrying JAK2 mutations, diagnosed in the same peri-
od and matched for Ht values. All patients were treated with phlebotomies, to
maintain Ht below 45%. In all these patients, we collected disease-relevant
parameters, including blood count at diagnosis and major events during fol-
low-up. Statistical analysis was performed by using the Mann-Whitney test,
the χ2 test or Fisher’s exact test and the Kaplan-Meier method.
Results: Results are summarized in the following Table 1.
Table 1.
                                                                  IE                        PV                      p
Patients, n                                                    145                      145                      -
Males, n (%)                                            127 (87.6)            83 (57.2)             <0.001
Median age at diagnosis, years            56.5 (21.2-75.8)  61.7 (30.3-81.9)        0.006
(Percentile range, 5th to 95th)
Median Follow up, years                        6.6 (0.3-23.2)      7.4 (0.3-22.1)            n.s.
(Percentile range, 5th to 95th)
Median WBC, x109/L                              7.2 (5-11.9)        8.7 (5.7-17.3)         <0.001
(Percentile range, 5th to 95th)
Median Hb, g/L                                    179 (164-195)     175 (149-213)          0.03
(Percentile range, 5th to 95th)
Median Ht, %                                      52.8 (48.3-57.8)  53.1 (46.2-66.2)          n.s.
(Percentile range, 5th to 95th)
Median plts count, x109/L                    217 (132-320)     485 (209-882)        <0.001
(Percentile range, 5th to 95th)
Patients with at least                                 21 (14.5)             39 (26.9)               0.01
a thrombosis, n (%)
During follow-up, 15 patients with IE (10.3%) and 27 with PV (18.6%) experi-
enced at least a thrombotic complication (p=0.04), with a dramatically different
Thrombosis Free survival (p=0.005). Arterial thromboses were 13 among
patients with IE and 12 in patients with PV. The thrombotic incidence rate was
3% patients/year in PV and 1.5% patients/year in IE (IRR=2).
Summary/Conclusions: IE, is a poorer studied disease. The clinical picture
(i.e. vascular complications during follow-up and final outcomes) are not fully
investigated. PV, a well-studied disease, has an estimated cumulative throm-
bosis rate of about 4% patients/year not different than our finding in the pres-
ent cohort. In this study, we demonstrate that patients with IE develop fewer
thrombotic complications than patients with PV. However, IE, in spite of a
stringent program of phlebotomy, absence of leukocytosis and/or thrombo-
cytosis, maintain higher thrombosis rate (1.5% patients/year) when compared
to general population (around 0.8% persons/year). The present data suggest
that IE has an increased thrombotic risk even if lower than PV, showing that
the rheological alteration due to high Ht play a relevant role even in the
absence of a clonal disease. Moreover, taking into account that most cardio-
vascular complications are represented by arterial thrombosis, prophylaxis
with aspirin should be considered, in absence of contraindications.
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AZACITIDINE IN THE TREATMENT OF PH- MYELOPROLIFERATIVE
NEOPLASMS IN BLASTIC PHASE: THE EXPERIENCE OF GRUPPO
LAZIALE FOR THE STUDY OF PH- SMPC
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Background: Prognosis of patients with myeloproliferative neoplasms (MPN)
developing blast phase (MPN-BP) is very poor. Median overall survival (OS) of
these patients is about 2-3 months and nowadays no drug can induce a durable
complete response (CR) in patients who are not candidate to Bone Marrow
Transplantation (BMT).
Aims: We retrospectively evaluated 27 patients (M/F 19/8, median age 62.5
years, range 30.8-80.6) with MPN-BP according to international criteria treated
with azacytidine (AZA) in the last 7 years, to highlight the role of AZA in this
subset. Data were obtained from database of Gruppo Laziale for the study of
Ph- SMPC.
Methods: Primitive MPN diagnosis was Essential Thrombocythemia in 9 cases,
Primary Myelofibrosis in 9, Polycythemia Vera in 5 and MPN-U in 4; the JAK-
2 V617F mutation was present in 17/25 patients tested (68%); all but 2 patients
received a previous treatment during chronic myeloproliferative phase [18
patients with Hydroxyurea (HU) alone, 1 with HU and Anagrelide, 4 with HU
and Pipobroman, 1 with Melphalan followed by allo-BMT, 1 with Pipobroman
alone]. Median time from diagnosis to BP evolution was 59.6 months (range 1-
312). All patients were treated with 5-AZA at the dosage of 75 mg/m2: as to the
schedule, 24 patients received a 7-day schedule and 3 patients a 5-day sched-
ule every 28 days. At the time of evolution, median WBC value was 12.8x106/L
(range 2.2-89.5 X 106/L), median Hb level 9.8 g/dl (range 6.6-12.7 gr%) and
median PLT value 183.5x106/L (range 9-846x106/L).
Results: Two pts were too early (only 1 cycle still performed) while 8/25 evalu-
able pts (32%) achieved a CR after a median time of 5 months (range 3-12)
from AZA start, 2 pts (8%) had a partial response (PR), 4 pts (16%) had an
hematological improvement (HI), with a 56% global response rate: the remain-
ing 11 pts (44%) had no response (9 pts had a disease progression and 2 died
early after AZA initiation from pulmonary fungal infection and respiratory failure
respectively). The median OS from BP evolution of the whole cohort was 9.9
months (95% CI 7.0-12.8): the median OS of responding pts (CR+PR+HI) was
18.6 months (95% CI 8.4-28.8) compared with 4.9 months (95% CI 0.9-8.8) of
resistant pts (p<0.001).
Summary/Conclusions: Our data confirm the relative efficacy and safety of
AZA compared to historical controls in this group of patients with otherwise dis-
mal prognosis, underlining the possible achievement of long-lasting responses
in a sizeable portion of them.
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COMPARISON OF GENOMIC DNA-BASED VS MESSENGER RNA-BASED
KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES
BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS
T Kristensen1,*, S Broesby-Olsen2, H Vestergaard3, C Bindslev-Jensen2,
MB Møller1
1Department of Pathology, 2Department of Dermatology and Allergy Centre,
3Department of Hematology, Odense University Hospital, Odense C, Denmark
Background: Mastocytosis is a heterogeneous group of diseases character-
ized by growth and accumulation of neoplastic mast cells (MCs). Mastocytosis
often represents a diagnostic challenge. The vast majority of adults with mas-
tocytosis carry the activating somatic KIT D816V mutation. Recent advances
in KIT D816V mutation analysis allow detection of the mutation in peripheral
blood (PB) in most patients. Mutation analysis of PB is therefore increasingly
used for screening in suspected mastocytosis. A very high sensitivity is needed
to produce clinical meaningful diagnostic yields in indolent SM (ISM) in both
PB and bone marrow (BM) aspirate. KIT D816V mutation analysis may be
based on genomic DNA (gDNA) or the expressed messenger RNA (mRNA).
Depending on KIT gene expression levels of the D816V-positive cells, mRNA-
based analysis is potentially more sensitive than gDNA-based analysis. How-
ever, very limited experimental evidence comparing these two approaches
presently exists.
Aims: To systemically compare gDNA-based and mRNA-based KIT D816V
mutation analysis of PB and BM aspirate in SM patients to determine the optimal
technical approach.
Methods: In 82 SM patients (76 ISM (including 3 BMM and 4 SSM) and 6 SM-
AHNMD), gDNA-based and mRNA-based KIT D816V mutation analysis of PB
was performed. In 65 patients, BM aspirate was also analyzed.
A highly sensitive KIT D816V mutation-specific qPCR assay was used for both
gDNA-based and mRNA-based analysis. Importantly, gDNA-based analysis
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was performed with gDNA from 50.000 cells per reaction and mRNA-based
analysis was performed with cDNA from mRNA from 50.000 cells, thus allowing
non-biased comparison of the two approaches.
Results: In mRNA-based analysis, PB from 24 of the 82 patients (29%) fulfilled
criteria of positivity. In gDNA-based analysis, 77 of the 82 (94%) samples tested
D816V-positive, thus demonstrating a higher diagnostic yield with gDNA in PB
samples (chi2-test: P<0.001). The gDNA-based D816V-positive allele burden was
significantly higher in PB samples that tested positive in the mRNA-based analysis
compared to samples that tested negative in mRNA-based analysis (median
allele burden 2.8% vs 0.051%; Mann-Whitney U-test: P<0.001). In BM aspirate,
64 of 65 samples tested D816V-positive in mRNA-based analysis, whereas all
65 samples tested positive in gDNA-based analysis (chi2-test: P=0.32). While
the diagnostic yield was thereby high in BM aspirates in both gDNA-based and
mRNA-based analysis, the confidence of mRNA-based results was significantly
higher than gDNA-based in samples with low mutation levels as calculated from
the absolute threshold cycle (Ct) values of the qPCR analysis.
Summary/Conclusions: Previous studies performing KIT D816V mutation
analysis of PB in ISM have reported highly different diagnostic yields. The
reported differences may be explained by several factors. However, our direct
comparison of mRNA-based and gDNA-based analysis indicate that the differ-
ence in mRNA-based and gDNA-based analysis is a major determinant of diag-
nostic yield in PB. Previous inconsistencies are therefore likely to be primarily
explained by this parameter. We conclude that gDNA-based KIT D816V muta-
tion analysis should always be preferred over mRNA-based in PB in ISM. In
addition, mRNA-based KIT D816V mutation analysis may have added value
in BM aspirates if gDNA-based analysis produces a borderline or weakly pos-
itive result, or test unexpectedly negative.
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3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE
SWEDISH MPN REGISTRY
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Background: Newly diagnosed patients with Philadelphia chromosome neg-
ative myeloproliferative neoplasms (MPN) are included in the Swedish MPN
Registry since 2008.
Aims: The aim was to report incidence, blood values, earlier vascular compli-
cations and planned treatment in newly diagnosed MPN patients.
Methods: From January 2008 through December 2014 a total of 3167 were
registered. The diagnosing clinics report age, gender, blood values, earlier vas-
cular complications and planned treatment. Registration of cancers is manda-
tory. About 95% of MPN were reported to the registry at the time of analysis.
Results: Polycythemia vera (PV) was diagnosed in 1105, essential thrombo-
cythemia (ET) in 1285, myelofibrosis (MF) in 440 and MPN unclassified 337
patients. The annual incidence per 100,000 inhabitants for PV was 1.7, for ET
1.9, for MF 0.66 and for MPN unclassified 0.53. The median age at diagnosis
was lowest for ET, 68 years, for PV was 69 years, for MF and MPN unclassified
70 years. In PV and MPN unclassified the proportion of men and women were
equal, in ET there was a female predominance (58%), whereas 55% of the MF
patients were male. The blood values at diagnosis are presented in Table 1. 
Table 1.
The prevalence of vascular complications prior to MPN diagnosis was highest
for the PV, ET and MPN unclassified, 37%, 35% and 34% respectively. The
MF patients had significantly lower prevalence, 26% (p<0.001 compared with
PV and ET, p=0.018 compared with MPN unclassified). The time from a previ-
ous vascular event to diagnosis was not reported in the registry. The majority
of complications were thromboembolic; 32% of PV patients, 30% of ET patients,
28% of MPN unclassified patients and 20% of MF patients. The corresponding
frequencies for hemorrhagic events were 5%, 5%, 8% and 7%, respectively.
The most frequent vascular events were of cerebral, cardiac and deep vein
thrombosis/pulmonary embolism. ET patients with reported vascular compli-
cations had a significantly lower hemoglobin and hematocrit (p=0.002 and
p=0.005, respectively) and higher WBC count (p=0.031), whereas the platelet
concentration was comparable in patients with or without recorded complica-
tion. JAK2 V617F mutation was present in 71% of ET patients with vascular
complications prior to diagnosis, compared to 60% of the patients without com-
plications (p<0.001). Also, the PV patients with earlier reported vascular events
had a significantly higher mean age, lower hemoglobin and hematocrit at diag-
nosis compared to patients without vascular complications (p<0.001, respec-
tively). Myelosuppressive treatment was planned in 66.6% of the ET patients
compared to about 50% of the patients with PV, MF and MPN unclassified
(p<0.001, respectively). Phlebotomy treatment was planned in 82% of the PV
patients. Transfusion was planned to be given to 16% and EPO to 13% of the
MF patients. ASA prophylaxis was recorded for about 60% of the PV and ET
patients, compared to about 30% of the MF and MPN unclassified patients.
Summary/Conclusions: ET and PV were the most common MPN entities,
40% and 35% respectively. JAK2 V617F mutation was present in 98% of PV
patients and in 57-64% in the other MPN etities. Reported vascular complica-
tions prior to diagnosis were common, especially in PV, ET and MPN unclas-
sified. The majority of events were thromboembolic.
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Background: Thrombosis represents the main complication in Philadelphia neg-
ative myeloproliferative neoplasms (Ph-MPN). It is supposed that inappropriate
activation of leukocytes and platelets with their mutual interaction represents an
important mechanism of thrombosis tendency in these diseases. The role of cir-
culating leukocyte-platelet (Le-Plt) aggregates as risk factor for thrombosis in
Ph-MPN has been investigated so far in retrospective studies which included
significant proportion of patients (pts) on antiplatelet or cytoreductive therapy.
Aims: The aim of our prospective study was to investigate the predictive value
of circulating neutrophyle-platelet (Neu-Plt) and monocyte-platelet (Mo-Plt)
aggregates as well as soluble selectins for occurence of thromboembolic events
in pts with Ph-MPN.
Methods: The study included 95 consecutive pts with de novo Ph-MPN (39
polycythemia vera, 27 essential thrombocythemia, and 29 primary myelofibro-
sis), diagnosed according to WHO criteria. All analysis were performed after
diagnosis, and before the start of antiplatelet or cytoreductive therapy. Flow
cytometric analysis of Le-Plt aggregates was performed on whole blood sam-
ples anticoagulated with EDTA/CTAD. Le-Plt aggregates were estimated as a
fraction (%) of CD42b+CD61+ neutrophyles and monocytes. The plasma levels
of E-, L-, and P-selectins were determined by enzyme immunoassay. All arterial
and venous thrombotic events, except microcirculatory disturbances, were
recorded during mean follow-up period of about 3.25 years after diagnosis.
Results: During the follow-up thromboembolic complications occurred in 12.6%
Ph-MPN pts (arterial in 9.4%, venous in 3.2%), with mean time to thromboembolic
event of 39 months. The overall incidence rate of main thrombotic events in
whole group of Ph-MPN during the follow-up was 4.36 per 100 pts-years. The
levels of Neu-Plt (26.7% vs 22.4%) and Mo-Plt (17.8% vs 12.3%) aggregates
did not differ significantly between groups of pts with and without thrombosis.
Using multivariate COX proportional hazard regression model, it was proved that
Mo-Plt aggregates represent independent predictive factor for thrombosis devel-
opment (HR=1.561, 95% CI: 1.007-2.420, p=0.046). Frequency of HTA was sig-
nificantly higher in group of Ph-MPN pts with thrombosis compared to those with-
out thrombosis (p<0.05), and multivariate COX proportional hazard regression
model confirmed that interaction between Mo-Plt aggregates and HTA may be
additive (HR=1.975, 95%CI: 1.215-3.212, p=0.006). The level of soluble P-
selectin was significantly higher in group of Ph-MPN pts with thrombosis than in
group of pts without thrombosis (346.89 ng/ml vs 286.39 ng/ml, p=0.034), but
has not been proved as a predictive risk factor for occurrence of thrombosis
(COX proportional hazard regression model). The levels of E- and L-selectin did
not differ significantly between Ph-MPN groups, according to the presence of
thrombosis.
Summary/Conclusions: This is the first prospective study investigating pre-
dictive role of Le-Plt interactions on occurence of thromboembolic complication
in Ph-MPN. Among several investigated parameters, only increased level of
Mo-Plt aggregates was shown as independent predictive risk factor for devel-
opment of thromboembolic complications. Concomitant presence of HTA further
strengthens predictive role of Mo-Plt aggregates. Since the reduction of throm-
botic risk is a primary goal of therapy in Ph-MPN, special attention should be
paid to the treatment of HTA.
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Background: Response to ruxolitinib (RUX), the only JAK1/2 inhibitor com-
mercially available for the treatment of Myelofibrosis (MF) may vary among
patients (pts) and is largely unpredictable at therapy start. Due to the lack of
predictors of response, pts’ selection is based on clinical needs.
Aims: To evaluate the impact of pre-treatment clinical/laboratory factors, as
well as RUX dose, on response to RUX in a cohort of “real-life” MF pts.
Methods: A multicenter observational study on WHO-defined MF was con-
ducted in 11 Italian Hematology Centers. Data were extracted from an electronic
database that included retrospective data on pts treated before January 2015.
Response to RUX was evaluated according to IWG-MRT criteria.
Results: Between June 2011 and June 2015, 266 pts with PMF (140
pts,52.6%), or PET-MF (51,19.2%) or PPV-MF (75,28.2%) were treated with
RUX in participating Centers. At diagnosis, baseline characteristics were (medi-
an): age, 64.2 y (range, 26-86); ≥65 y, 45.5%; male, 58%; hemoglobin (Hb),
11.5 g/dL (5-17.7); Hb <10 g/dL, 27.4%; PLT, 356×109/L (30-1110); PLT
<100×109/L, 5.2%; spleen enlargement, 87.5% (spleen length ≥10cm: 40.6%);
constitutional symptoms, 48.8%. Molecular analysis was performed on 215 pts
(81%) and was positive in 90% (JAK2V617F), 7% (CALR), 1% (MPLW515K/L);
2% (triple negative). Karyotype was abnormal in 43 (30%) out of 145 evaluable
pts (unfavorable: 9%). Median follow-up from MF diagnosis was 4 yr (0.5-29.6)
and median RUX exposure was 22 mos (3-54). Overall, 92 out of 232 (39.7%)
pts with spleen ≥5cm achieved a spleen response at any time during RUX ther-
apy (Table 1).
Table 1. Patients characteristics at RUX start.
At 3 and 6 mos, the response was achieved by 28.1% and 31% of evaluable
pts, respectively. In univariate analysis, pre-treatment factors negatively corre-
lating with spleen response were: transfusion dependence, platelet count
≤200x109/l, spleen palpable ≥10 cm below costal margin, grade 3 marrow fibro-
sis and interval between MF diagnosis and RUX start ≥2y. Also, the rate of
spleen response significantly correlated with RUX starting dose, with 18.5%,
33.8% and 47.7% of responses observed in pts treated with 5mg BID, 15mg
BID and 20mg BID, respectively (p=0.008). Also, spleen response correlated
with the average RUX dose in the first 12 wks, with pts treated with doses ≥10
mg BID having better response rates (44.4% vs 25.4% in pts treated with ≤10
mg BID, p=0.01). Three variables remained significant in multivariate regression
logistic analysis: large splenomegaly (HR:2.01, 95%CI:1.1-3.1;p=0.015), time
between MF diagnosis ≥2y (HR:1.8, 95%CI:1.0-3.2;p=0.037) and median RUX
dose ≤10mg BID in the first 12 wks (HR:2.29, 95%CI:1.1-4.3;p=0.02).Overall,
178 pts out of 217 symptomatic patients (82%) had a symptom response. Fac-
tors associated with worse responses were: grade 3 marrow fibrosis (p=0.035),
transfusion dependency (p=0.001) and RUX titrated dose ≤10 mg BID
(p=0.014). In multivariate analysis, symptom response rate correlated only with
RUX titrated dose (HR:2.4, 95%CI:1.1-4.9,p=0.016). Neither spleen or symp-
toms response significantly correlated with survival.
Summary/Conclusions: In the real-life setting, IWG-MRT-defined spleen and
symptoms response rates were observed in 40% and 70% of pts, respectively.
Among pre-treatment features, large splenomegaly and a delay in treatment start
≥2 yrs from diagnosis identified pts with lower spleen response rates. Additionally,
median titrated doses ≤10mg BID significantly correlated with poorer spleen and
symptoms responses. Overall, these data point out the role of an early treatment
in order to achieve better therapeutic results. Also, since drug-induced anemia
was not significantly associated with RUX doses, the study supports the impor-
tance to start and maintain over time the maximum tolerated RUX dose.
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Background: Splanchnic vein thrombosis (SVT) is strongly associated with
myeloproliferative neoplasms (MPN) such as Polycythemia Vera (PV), Essential
Thrombocythemia (ET), Myelofibrosis (MF). This association was established
when routine molecular analysis of JAK2 V6176F mutation was introduced as
a diagnostic assessment for MPN. Up to 50% of Budd-Chiari syndrome and
30% of extraepathic thrombosis are associated with the presence of JAK2
V617F mutation. However, 30% of these patients do not meet the WHO criteria
for the diagnosis of PV, ET or MF. 
Aims: The study aims to compare and contrast the pathophysiological and
genotypic features of JAK2 V617F positive SVT patients with those meeting
the standard diagnostic criteria for MPN. 
Methods: We conducted a retrospective single centre study of 43 patients with
JAK2 V617F positive SVT at the Queen Elizabeth Hospital NHS Trust to doc-
ument the clinical and haematological features of these patients at presentation,
their long-term outcome and their JAK2 mutational status and allele burden by
quantitative digital droplet PCR. 
Results: SVT occurred before MPN was diagnosed according to WHO criteria
in 28 out of 43 patients, and in 3 patients a thrombotic event at a different site
occurred before onset of MPN. Within this cohort 18 patients were females and
13 were males. The mean age at diagnosis of SVT/ thrombotic event was 35
years (range 22-67). During follow-up 10 patients developed PV (3 female, 7
males), 7 patients developed ET (3 females, 4 males), 9 patients developed U-
MPN (7 females, 2 males), 5 patients did not develop a recognisable MPN at
their last follow-up. The median hemoglobin at SVT diagnosis was 14.05 g/dL
in females and 14.85 g/dL in males, the median WBC was 9.1x109/L, the median
platelet count at SVT diagnosis was 266x109/L. These values would not have
met the WHO diagnostic criteria for ET, PV or MF at diagnosis. In this study we
considered JAK2 mutational burden in the range of 0-25% as low, 26-74% as
intermediate and >75% as high (AM Vannucchi et al.). In our cohort, the median
JAK2 mutational burden was in the lower range with a median allele burden of
17% (range 0.6-81%). The median JAK2 mutational burden in the patients diag-
nosed with SVT without developing MPN at their last follow up had a median
allele burden of 14% (range 9.9-22%), which is lower than the mutational burden
found in PV and PMF (26-50%) and similar to ET (0-22%).
Summary/Conclusions: JAK2 V617+ SVT constitute an early but distinct MPN
subtype presenting with young age, unremarkable haematolgical parameters
and low JAK2 V617F allele burden. 
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Background: Increased angiogenesis in BCR-ABL1 negative myeloprolifera-
tive neoplasms (MPNs) has been recognized but its connection with clinical
and molecular markers needs to be defined.
Aims: The aim of our study was to (1) asses bone marrow (BM) angiogenesis
measured by microvessel density (MVD) using two different monoclonal anti-
bodies CD34 and CD105; (2) analyze correlation of MVD with plasma angiogenic
factors including vascular endothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF) and Interelukin-8 (IL-8); (3) examine the possible associa-
tion of MVD with clinical, laboratory, morphological and molecular markers.
Methods: We examined serum and BM specimens from 90 patients with MPNs
(30 polycythemia vera (PV), 30 primary myelofibrosis (PMF), 30 essential
thrombocythemia (ET)) at the time of diagnosis. Ten age-matched patients
without hematological disorder were used as controls. MVD was analysed by
immunohistochemistry “hotspot” method while serum angiogenic factors VEGF,
bFGF and IL-8 were tested by Elisa immunoassay. Mutation analysis of JAK2-
V617F, CALR exon 9 was analyzed by DNA sequencing and allelic PCR.
Results: MVD was significantly increased (CD34=37.6±17.6; CD105=30.8±15.3)
in whole MPN cohort compared to controls (CD34=19.8±12; CD105=11.7±24.4).
MVD was highest in PMF (CD34=44.5±20.3; CD105=38.4±16.9) followed PV
(CD34=43.2±15.8; CD105=31.7±13.4) then ET (CD34=26.6±8.9;
CD105=24.7±11). Correlation between MVD and plasma angiogenic factors was
found in all cases. MVD was significantly increased in patients with JAK2-V617F
mutation and correlated with JAK2 mutant allele burden (CD34-MVD: ρ=0.491,
p<0.001; and CD105-MVD: ρ=0.276, p=0.02) but regarding CALR mutation no
significant MVD differences were detected in whole cohort. MVD analyzed by
both antibodies correlated with leukocyte count, serum lactate dehydrogenase,
hepatomegaly, and splenomegaly. BM fibrosis was significantly associated with
CD34-MVD (p=0.002), CD105-MVD (p=0.008), IL-8 (p=0.001) and JAK2 mutant
allele burden (p=0.013). JAK2 homozygote status had positive predictive value
(100%) for BM fibrosis. Patients with prefibrotic PMF (CD34-MVD=39.1±13.4,
CD105-MVD=37.1±14.4) had significantly higher MVD then patients with ET
(CD34-MVD=26.6±8.9; CD105-MVD=24.7±11) (p<0.001).
Summary/Conclusions: This study highlights the strong correlation of MVD
with plasma angiogenic factors, JAK2 mutant allele burden and BM fibrosis in
MPNs. We identified specific angiogenic factors, which correlated with BM
fibrosis. According to our results, we could recommend MVD to be additional
histopathological marker to distinguish ET from prefibrotic PMF.
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Background: The most frequently reported AEs leading to treatment discon-
tinuation with anagrelide (Agrylin®, Shire) were headache, diarrhea, edema,
palpitations, and abdominal pain. Of the 942 subjects treated with anagrelide
for a mean duration of approximately 65 wks, 161 (17%) were discontinued
due to AEs or abnormal laboratory test results (PI, Agrylin). These effects may
be attributable to anagrelide’s inhibitory effects on human PDE3. Modification
of the PK profile of anagrelide to reduce peak plasma levels while maintaining
therapeutic blood levels may offer a means to retain platelet lowering activity
while reducing potential side-effects. In the Phase 1 HV study, BIO-ANA101,
2 such novel controlled release formulations of anagrelide (CR and IR/CR)
were compared with the EU marketed formulation (Xagrid®, Shire) in a single
dose cross-over study at a dose of 0.5 mg. The CR formulation demonstrated
Cmax/AUC0-inf values that were 23%/72% of Xagrid’s, respectively leading to
the development program of anagrelide CR (GALE-401).
Aims: Characterize the safety profile of GALE-401 in HV and MPN subjects.
Methods: To date, 98 HV and 18 MPN subjects have been enrolled among 5
Phase 1 clinical trials (BIO-ANA101, 102, 103, 104, 105) and a Phase 2 single
arm, open label pilot study (NCT02125318) of GALE-401, respectively. All stud-
ies were conducted in accordance with ICH Guidelines and GCP principles.
Safety events were compared across HV vs MPN subjects treated with GALE-
401 compared to historical Agrylin published data.
Results: In the HV studies, single and multiple doses of GALE-401 were safe
and well tolerated and there were no clinically relevant changes in vital signs,
ECGs, and safety laboratory parameters other than a reduction in platelet
counts. The most frequent TEAEs reported included headache, pain in extrem-
ities or back, palpitations and gastrointestinal disturbances. In particular, in BIO-
ANA105, with 20 subjects randomized to receive either GALE-401 or Agrylin
(0.5 mg BID for 7d) after which they were washed out for a minimum of 21d and
received the alternative drug product for an equal period, the overall AEs con-
sidered by the Investigator to be related to treatment were observed [GALE-
401 (7 events/6 subjects) vs Agrylin (12 events/8 subjects)]. With the exception
of GI disorders (15%, GALE-401 vs 10.5%, Agrylin), the incidence of TEAEs
across SOCs was higher during Agrylin treatment compared to GALE-401 treat-
ment. In the Phase 2 MPN study, subjects treated with GALE-401 exhibited
fewer of the more common AEs associated with Agrylin (cardiac; general; gas-
trointestinal; respiratory, thoracic, and mediastinal; skin and subcutaneous tis-
sue; nervous system) or equivalent (musculoskeletal and connective tissue)
AEs associated with Agrylin. Some of the less common AEs of Agrylin were
comparatively more frequent for GALE-401 (vascular; hepatobiliary; blood and
lymphatic). Additionally, fewer moderate to severe (Grade 3/4) AEs and fewer
AEs per patient (2.3 vs 3.3) were observed with GALE-401 vs Agrylin, respec-
tively. Further, based on treatment discontinuation due to an AE, 5 subjects who
were previously intolerant to Agrylin (because of AEs) have continued their treat-
ment with GALE-401. Overall, 3 of these 5 subjects were on study for a longer
duration [mean time on study, 106d, (47–196d)] compared to their experience
with Agrylin prior to enrollment into the Phase 2 study (~7d). Two subjects (40%)
have remained in the study and have been able to continue their treatment with
GALE-401 for 15 and 22m, respectively. Given this information, GALE-401
seems to confer an improved overall safety profile and potentially offers patients
improved tolerability compared to the licensed product.
Summary/Conclusions: Across HV and MPN subjects, GALE-401 consis-
tently demonstrated a well-tolerated safety profile. Moreover, in a small subset
of subjects enrolled in the Phase 2 MPN pilot study, some previously treated
Agrylin intolerant subjects, demonstrated a continued prolonged clinical benefit
with GALE-401. A randomized trial comparing Agrylin vs GALE-401 is needed,
alternatively or together with a trial evaluating Agrylin intolerant subjects is
warranted.
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Background: Adult T-cell leukemia/lymphoma (ATL) is an aggressive periph-
eral T-cell neoplasm associated with human T-cell leukemia virus type-1 retro-
virus. ATL includes a heterogeneous group of patients with regard to patholog-
ical and clinical features as well as prognosis, suggesting the presence of
underlying molecular pathogenesis that can account for such heterogeneity
among patients. Recently, through an integrated molecular analysis of a large
cohort of ATL cases, we delineated the complete registry of genetic alterations
in ATL. 
Aims: We sought to analyze possible associations between these genetic/epi-
genetic lesions and clinical/pathological phenotypes in a large set of ATL
patients, especially focusing on the impact of mutations and copy number alter-
ations (CNAs) on clinical outcome.
Methods: We investigated a total of 361 ATL samples, including acute (n=192),
lymphoma (n=66), chronic (n=89), and smoldering (n=14) subtypes, for recur-
rent mutations and CNAs, and assessed their impact on disease phenotypes
and prognosis. 
Results: Aggressive (acute and lymphoma) subtypes were characterized by a
higher number of mutations and focal amplifications/deletions, hyperploid status,
and CIMP phenotype, compared with indolent (chronic and smoldering) tumors.
Two mutations (TP53 and IRF4) and eight focal deletions involving 1p13 (CD58),
6p21 (HLA-B), 9p21 (CDKN2A), 10p11 (CCDC7), 13q32 (GPR183), 16q23
(WWOX), 17p13 (TP53), and 19q13 (CEBPA), were more common in aggressive
ATL than in indolent ATL. In contrast, showing a similar mutational distribution to
those found in large granular lymphocytic leukemia, STAT3 mutations were char-
acteristic of indolent diseases. Next, we examined the impact of mutations and
CNAs on prognosis among 215 ATL cases, for which survival data were available.
Multivariate analysis revealed that disease subtype (aggressive vs indolent) was
the most significant predictor of clinical outcome in ATL. Subsequent multivariate
analysis showed that within the patients with aggressive ATL, older age (≥70
years), CCR4 mutations, and 9p24 amplification were independently associated
with an inferior outcome. Based on the number of the risk factors, patients with
aggressive ATL were classified into three categories showing marked difference
in 3-year overall survival (OS) (P <0.001): those with no (OS, 32%), one (18%),
and two or more risk factors (0%). Among patients with indolent ATL, we found
IRF4 and TP53 mutations, 9p24 amplification, and deletions in 9p21 and 10p11
were significantly associated with worse prognosis. Interestingly, these alterations,
except for 9p24 amplification, were more frequently found in aggressive ATL.
More importantly, based on these risk factors, the patients with indolent ATL can
be classified into two major categories showing marked difference in clinical out-
comes: patients with no risk factors (OS, 89%) and those with one or more risk
factors (OS, 21%) (P <0.001, HR=16.8, 95% CI:5.4-52.5), suggesting that patients
with indolent ATL harboring a genetic feature of the aggressive subtypes might
represent a genetically and biologically distinct subset, which should be better
treated as having an aggressive disease.
Summary/Conclusions: Through comprehensive genetic profiling, we demon-
strated that the known subtypes of ATL can be further classified into molecularly
distinct subsets characterized by discrete sets of genetic alterations and sub-
stantially different prognosis. Our results suggest that genetic profiling can
improve the prediction of prognosis in ATL patients and better guide therapy.
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Background: hnRNP K is a versatile molecule that regulates numerous critical
cellular process, such as transcription and translation. Recently, we demon-
strated that alterations in hnRNP K expression can drive hematological malig-
nancies. Additionally, using reverse phase protein array (RPPA) analyses, we
discovered that hnRNP K overexpression correlates with increased c-Myc levels
and activation of putative c-Myc targets in patients with hematological malig-
nancies. Likewise, RT-PCR analysis revealed that HNRNPK is overexpressed
in specific subsets of lymphoma patients. These findings could explain an alter-
native mechanism by which c-Myc is overexpressed in lymphoma patients with-
out c-Myc alteration.
Aims: The aim of this work is understand the oncogenic potential of hnRNP K
and evaluate its role in driving c-Myc-dependent lymphomas that do not harbor
MYC translocations.
Methods: To directly examine the impact of hnRNP K overexpression on lym-
phomagenesis, we generated a transgenic mouse model that specifically over-
expresses hnRNP K in the B-cell compartment (Eµ-Hnrnpk). Phenotypes were
characterized by cytokine analyses, CBC, and flow cytometry of serum, blood,
and bone marrow. Livers, lymph nodes, spleens, and thymi were measured
and molecularly investigated through qRT-PCR, immunohistochemistry, and
western blot analyses. Molecular mechanisms were validated using ChIP- and
RIP-assays. Malignant lymphoma cells from Eµ-Hnrnpk mice were examined
for sensitivity to bromodomain inhibitors in vitro and in vivo assays.
Results: Eµ-Hnrnpk mice overexpressed hnRNP K in the B-cell compartment
in multiple transgenic lines resulting in a highly penetrant lymphoma phenotype
marked by a significant reduction in survival, enlargement of hematopoietic tis-
sues, and dissemination into distant organs (Figure 1A-B). Eµ-Hnrnpk mice
also display a significant increase in immature lymphoblasts that were trans-
plantable and reproduced the aggressive lymphomas observed in the donor
mice (Figure 1C). Together, these results indicate that hnRNP K is an oncogene
when overexpressed. Molecularly, we observed a direct correlation between
hnRNP K overexpression and elevated c-Myc levels in tissues from transgenic
mouse (Figure 1D), as well as in  transfected cell lines. RIP analysis demon-
strated a directly interaction and causal relationship between hnRNP K over-
expression and translation of the Myc transcript. In addition to the hnRNP K-
mediated activation of the c-Myc pathway, pro-lymphoid cytokines such as IL-
9 and CXCL-1 were also elevated in the sera of Eµ-hnRNP K mice, resulting
in the overexpression/activation of the JAK-STAT pathway. c-Myc is currently
an “undruggable target.” However, the discovery of small molecules that inhibit
the function of Bromodomain and extra terminal (BET) family members (e.g.
JQ1) have shown efficacy in disrupting c-Myc activities. Using JQ1 and BRD4-
Protac (Arvinas®) in in vitro and in vivo studies, we demonstrate that lymphoma
cells from Eµ-Hnrnpk mice have a significant reduction of viability in vitro with
both compounds. Furthermore, engraftment studies using NSG mice showed
that JQ1 treatment reduced the percent of engrafted cells compared to mice
treated with vehicle alone.
Figure 1.
Summary/Conclusions: We demonstrate for the first time that hnRNP K is a
bona fide oncogene with the capacity to drive c-Myc dependent lymphomas.
Given our observations that hnRNP K is overexpressed in patients lymphoma,
these results suggest that hnRNP K represents a potential biomarker to select
patients for target therapies that inhibit c-Myc in the absence of MYC translo-
cations or gene amplifications.
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GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN
FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE
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United Kingdom, 3Inserm U197 Laboratoire d’hematologie, CHU Rennes,
Rennes, France, 4Cancer Sciences Unit, Cancer Research UK Centre,
Southampton, 5Evolution and Cancer Laboratory, Barts Cancer Institute, Lon-
don, United Kingdom
Background: Follicular lymphoma (FL) is an incurable B-cell malignancy char-
acterised by advanced disease and a heterogeneous clinical course. Recent
temporal analyses of the genetic changes in these tumours suggest that each
disease episode evolves from a putative lymphoma-propagating population.
These studies have relied on profiling ‘single’ FL biopsies over several time
points, however, multi-site sampling in solid cancers has demonstrated pro-
found intra-tumour heterogeneity. Whether such patterns are seen in FL has
not been examined, with their presence likely to complicate precision medicine
based initiatives of these lymphomas in the future. 
Aims: To measure the extent of genetic diversity in FL by profiling spatially-
separated biopsies.
Methods: Eighteen tumour samples from several tissue sources (lymph node,
LN; bone marrow, BM; skin, spleen, ascites or pleural effusion) were collected
from 7 FL patients (SP1-7) representing 9 distinct episodes of disease (diagnosis
(5); progression (2), transformation (2)). FL B-cells and normal T-cells were
enriched by fluorescence activated cell sorting (FACS) in the majority of cases.
Whole exome sequencing (WES) was performed on tumour and germ-line DNA
from all patients (mean coverage 142x). Somatic variants, acquired uniparental
disomy (aUPD), copy number alterations (CNAs) were defined using established
bioinformatics tools. Variant allele frequencies (VAFs) were used to define the
clonal architecture. Validation of variants and CNAs were completed by targeted
deep sequencing using the Fluidigm-Miseq platform (>1000x) and multiplex lig-
ation-dependent probe amplification (MLPA) respectively.
Results: Amongst the 18 tumours, we identified a mean of 63 non-synonymous
somatic variants (range 34-128). Together with BCL2-IGH translocations, muta-
tions in CREBBP (7/7) and KMT2D (6/7) were shared and clonally represented
in all spatially-related samples supporting their roles as early “drivers” of FL. Out-
side of these 3 aberrations, there was widespread intra-tumour heterogeneity
with discordance of variants across spatially-separated sites ranging from 3% -
47%. While these site-specific or private mutations included genes recurrently
mutated in FL (TNFRSF14, RRAGC, TNFAIP3), there was variegation in VAFs
at predominantly subclonal levels, alluding to their acquisition at different evolu-
tionary time points. In SP2, we observed differential (sub) clonal selection with
the p.Y641S EZH2 mutation preferentially expanded in the LN compared to the
corresponding BM, whereas the reverse was the case with a p.R400Q ATP6V1B2
mutation (Figure 1). This dichotomy in mutation preference suggests that the
local microenvironment may impact on the fitness of a particular mutation. CNA
analyses mirrored mutational patterns with both shared 16p aUPD (encompass-
ing the locus of CREBBP) in 5 of 7 cases but also site-specific alterations
observed in 4 of 7 cases. Overall, the extent of spatial heterogeneity was highest
at histological transformation with >30% of mutations discordant across biopsies
and included mutations in TNFAIP3 (SP3) and CCND3 (SP4).
Figure 1.
Summary/Conclusions: We demonstrate spatial genomic heterogeneity is
prevalent in FL and is more pronounced at transformation. The existence and
diversity of site-specific aberrations suggests that a single biopsy can capture
some but not all of the clonal complexities in a patient’s lymphoma at a given
time-point. These spatial variations need to be considered in biomarker-led
clinical studies.
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Background: Recent studies on mutation discoveries have identified an ever
growing long list of potential pathogenic mutations in diffuse large B-cell lym-
phoma (DLBCL). There are also remarkable variations in the spectrum and
frequency of somatic mutations identified among different studies with only a
few genes showing mutations in >10% of cases. It is imperative to validate the
incidence of the recurrent mutations and investigate their inter-relationship and
potential correlation with lymphoma molecular subtype in a large cohort of well
documented DLBCL, and explore their potential value in prognosis and treat-
ment stratification. The REMoDL-B trial utilised GEP (gene expression profiling)
to stratify patients with newly diagnosed DLBCL (n=1132) for the addition of
bortezomib to R-CHOP, based on the hypothesis that this agent may selectively
improve the outcome of ABC-DLBCL, thus providing an excellent opportunity
for validation of potential genetic biomarkers. 
Aims: 1) to investigate the incidence of recurrent mutations, their inter-rela-
tionship and distribution according to COO molecular subtype in the REMoDL-
B trial; 2) to access the potential value of these genetic changes, together with
other clinicopathological and molecular parameters, in disease prognosis and
treatment stratification. 
Methods: In the first phase of the study, mutation screening was performed
for 19 genes involving the NF-kB pathway (CD79A, CD79B, CARD11,
TNFRSF11A, MYD88, TNFAIP3, TRAF3), plasma cell differentiation (PRDM1),
apoptosis regulation (TP53, FAS, DDX3X), antigen presentation and recogni-
tion (B2M, CD58), and histone modifiers (CREBBP, EP300, EZH2, MLL2,
MEF2B, KDM2B). Mutation in these genes was screened in duplicate by Flu-
idigm multiplex-PCR and Illumina sequencing using DNA samples extracted
from formalin-fixed paraffin-embedded (FFPE) diagnostic biopsies (Wang et
al. JMD 2015). Mutation data was correlated with COO molecular subtype,
which was determined by Illumina WG-DASLTM GEP using RNA samples from
FFPE diagnostic biopsies (Care et al., PLOS ONE 2013). 
Results: To date, mutation data was obtained in 240 cases of DLBCL including
121 cases of GCB-DLBCL, 72 cases of ABC-DLBCL and 47 cases of unclassi-
fied. Among the 19 genes investigated, 5 genes showed a significant difference
in their mutation frequencies between ABC and GCB-DLBCL, with CD79B (13%
in ABC, 4% in GCB, p=0.04) and MYD88 (32% in ABC, 5% in GCB, p=7x10-7)
mutations significantly enriched in ABC-DLBCL, while EZH2 (27% in GCB, 0%
in ABC, p=1x10-6), MLL2 (16% in GCB, 6% in ABC, p=0.04) and CBP (24% in
GCB, 3% in ABC, p=7x10-5) mutations significantly enriched in GCB-DLBCL. In
general, there was a tendency of mutual exclusion among gene mutations in
the NF-kB pathway, apoptosis regulation, and to a lesser extent in histone mod-
ifiers. By grouping genes according to their molecular function, mutations in the
NF-kB pathway (51% in ABC, 29% in GCB, p=0.002) were also significantly
enriched in ABC-DLBCL, while mutations in histone modifiers (57% in GCB,
21% in ABC, p=1x10-6) were significantly enriched in GCB-DLBCL. Interestingly,
there was a significant association in the mutations between the NF-kB pathway
and plasma cell differentiation programme (p=0.02). 
Summary/Conclusions: The data collected so far confirm the association
between mutations in individual genes or molecular pathways, and DLBCL
molecular subtype. Ongoing investigations to expand both the number of cases
and the list of the genes for mutation analysis are in progress. 
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ADHESION MOLECULE JAM-C: A POTENTIAL TARGET FOR MANTLE
CELL LYMPHOMA THERAPEUTICS
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Background: Junctional adhesion molecule C (JAM-C), a member of the JAM
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family is expressed by endothelial cells, platelets, NK cells, B lymphocytes and
some B-cell lymphoma subtypes, in particular mantle cell lymphoma (MCL).
MCL constitutes 3-10% of all malignant non-Hodgkin B cell lymphomas and
the median survival of patients remains only 4-5 years, despite recent drug
developments. We have shown previously, that blocking JAM-C using poly-
clonal antibodies inhibited B cell homing to lymphoid organs and decreased
lymphoma engraftment in a NOD/SCID mouse model. 
Aims: Homing of malignant B-cells to bone marrow and secondary lymphoid
organs is of critical importance for lymphoma spread and growth. The aim of
the current work was to develop and to test monoclonal antibodies with JAM-
C blocking activities for potential therapeutic use in the clinics. 
Methods: Monoclonal antibodies (mAb’s) were generated by classic hybridoma
technology and tested for binding to JAM-C. mAb’s with highest affinity were
selected and tested in vitro and in our NOD/SCID mouse model. For in vitro
studies, B-cells from peripheral blood of healthy donors and of lymphoma
patients were activated with interleukins and CD40L, with or without mAb’s,
then phosphorylation of intracellular kinases, proliferation, cell cycle status and
JAM-C expression were assessed. For in vivo studies, primary B cells and
Jeko-1 cells (MCL cell line) were injected i.v. into NOD/SCID mice and homing
and engraftment of cells to lymphoid organs were studied in mice treated with
mAb’s compared to non-treated animals.
Results: From six different mAb’s generated, one mAb H225, significantly
reduced proliferation of normal and malignant JAM-C pos B-cells in vitro by
30 and 35%, respectively. This reduction was found to be paralleled by a
decrease in the phosphorylation of ERK1/2 by 20%, whereas the phospho-
rylation of other signaling kinases remained unchanged (Akt, JNK, p38 and
STAT5). In mice injected with primary B cells incubated with mAb H225,
homing to bone marrow, spleen and lymph nodes was significantly
decreased by 50%, 60% and 40%, respectively. Treatment of mice with H225
for two weeks starting several days after injection of Jeko-1 cells, resulted
in drastically reduced lymphoma cell numbers in spleen, liver, bone marrow
and lymph nodes (decrease of 100%, 99%, 95% and 100%, respectively),
compared to control mice. Lymphoma cells recovered from treated mice
showed decreased proliferation kinetics (34% decrease) compared to cells
from non-treated animals. 
Summary/Conclusions: Our results show that mAb H225 effectively blocks
homing of lymphoma B cells to supportive lymphoid organs and decreases
lymphoma engraftment in bone marrow, spleen, and lymph nodes. Addition-
ally, we show for the first time an inhibitory effect of JAM-C blocking on B
cell proliferation. Targeting JAM-C could therefore constitute a new thera-
peutic strategy for the treatment of B cell lymphomas expressing JAM-C, in
particular MCL. 
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ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL
LYMPHOMA BUT DO NOT IMPACT PATIENTS’ SURVIVAL
A Marečková1,*, J Malcikova1,2, N Tom2, K Pal2, D Salek1, S Pospisilova1,2,
M Trbusek1
1Department of Internal Medicine-Hematology and Oncology, University Hos-
pital Brno, 2Center of Molecular Medicine, CEITEC, Masaryk University, Brno,
Czech Republic
Background: Mantle cell lymphoma (MCL) represents 5-10% of non-
Hodgkin’s lymphomas and is characterized by aggressive clinical course with
median survival reaching only 3-5 years. Mutations in the TP53 tumor sup-
pressor gene detected in approximately 20% of patients negatively influence
overall survival (OS). In addition, ATM kinase, the upstream p53 activator,
was described to be mutated in up to 56% of MCL patients; however, the
data about clinical impact of this aberration is still limited.
Aims: To explore the ATM mutations frequency in our MCL patients’ cohort
and to assess their impact on OS.
Methods: Samples from predominantly (85%) untreated patients containing
at least 5% of malignant cells according to flow cytometry were selected for
NGS analysis. Amplicon-based targeted sequencing using an in-house
methodology was done on MiSeq instrument (Illumina). Whole coding regions
and splicing sites of ATM and TP53 genes were analyzed (ATM: exons 4-65,
TP53: exons 2-11). Final data was processed by CLC Genomic Workbench
software. The median coverage was 4212 reads and a cut-off for the variant
allele frequency (VAF) was set at 1%. Functional impact of detected variant
was assessed using dbSNP, COSMIC, and HGMD mutation databases. All
detected presumably pathogenic alterations were verified either by Sanger
sequencing (mutations above 20% VAF) or by repeated NGS analysis (muta-
tions under 20% VAF). The 11q and 17p loci deletions were analyzed using
MLPA technology in samples containing >30% of malignant cells.
Results: Samples from 78 MCL patients were analyzed using the targeted
NGS. ATM mutations were identified in 41/78 patients (53%). In total, 57
mutations were disclosed with 12 patients carrying two mutations and 2
patients even three ATM mutations. Truncating variants represented 42% of
all mutations. The analysis of germline status performed in 16 patients with
available DNA from remission period showed the germline origin in one case
(mutation c.3939_3940del). The MLPA analysis was performed in 33/78
patients and showed ATM locus deletion in 16 cases (48%). A majority of
ATM-mutated patients (70%) carried accompanying allelic deletion, while all
remaining ATM-affected patients manifested two or three ATM mutations;
presumably on opposite alleles. Only two patients carried isolated 11q dele-
tion. To reliably assess a clinical impact of ATM mutations, the known impact
of TP53 gene aberration must have been set aside; therefore the TP53 gene
status was analyzed as well. TP53 mutations were identified in 18/78 patients
(23%). Besides that, four patients carried isolated 17p deletion. In line with
presumably common ATM/p53 activity in one biological pathway, concurrent
mutations in both genes were rare occurring in 3 patients. The OS analysis
then unambiguously showed a negative impact of TP53 defects but not of
ATM mutations (P=0.02 and P=0.74, respectively) with the median OS being
81 months in ATM-mutated patients, 49 months in TP53-defective group and
“not reached” in ATM/TP53 wt patients.
Summary/Conclusions: Although ATM mutations represent the second most
frequent genetic abnormality in MCL besides cyclin D1 translocation t(11;14),
their impact on survival seems absent. This is in a striking contrast to TP53
defects, which significantly deteriorate overall survival of MCL patients.
Supported by grants H2020 692298, MEYS LQ1601, TAO TE0200005 and
MZO AZV 15-31834A, 15-30015A, MUNI/A/1028/2015.
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Background: Mantle cell lymphoma (MCL), is a distinct lymphoma subtype
with an aggressive clinical course and a median survival of 3-5 years. New
emerging strategies include especially inhibitors of the B-cell receptor path-
way (BTK, PI3K, Akt, mTOR) which is constitutively activated in MCL and
plays a critical role in tumor growth and survival. 
Aims: In the present study we investigated different PI3K-Inhibitors (Copan-
lisib, Pictilisib, AS-605240, duvelisib, A66, idelalisib and TGX-221) targeting
different isoforms (PI3Kα/δ, PI3Kγ/α, PI3Kγ, PI3Kγ/δ, PI3Kα, PI3Kδ and
PI3Kß) in MCL. 
Methods: MCL cell lines (Z-138, Mino-1, Granta-519, Jeko-1, Rec-1, Maver-
1) were exposed to different PI3K-Inhibitors (Copanlisib, Pictilisib, AS-605240,
IPI-145, A66, idelalisib and TGX-221; 0,3125-5µM) with or without murine feed-
er layer (M210B4). The effect of drugs was evaluated by cell count (trypan-
blue staining), cell metabolism (WST-assay or ONE-GloTM Luciferase assay
for luciferized MCL cell lines), cell cycle (FACS) and apoptosis (Annexin V PE/7-
AAD staining). Subsequently, combinations with other inhibitors of the
PI3K/mTOR pathway were analysed. Proteome Profiler phospho-kinase anti-
body array as well as Western blot analyses were performed after exposure to
the various PI3K inhibitors and correlated to the sensitivity of cell lines. Finally,
the effects of drug combination were confirmed in primary patient samples.
Results: The most efficient PI3K inhibitor (tested at 5µM) was Copanlisib
(PI3Kα/δ) with a median reduction of cell proliferation of 77% (57.5%>89.4%)
followed by the dual isoform inhibitor Pictilisib (PI3Kγ/α) reaching a median
reduction of cell proliferation rate of 60% (47%>72.5%). For the single PI3K
isoform inhibitors AS-605240 (PI3Kγ) was the most efficient reaching a medi-
an reduction of cell proliferation of 26% (8.2%>49.7%). Comparison of single
isoform inhibition to combined inhibition of the different isoforms in MCL cell
lines confirmed the superiority of the combined inhibition of all four isoforms
to inhibition of three by 7,2%, to two by 19,2% and to single by 33,7%. Inter-
estingly triple combinations including targeting of the α-and γ-isoforms were
almost as efficient as inhibition of all 4 isoforms. In addition reduction of cell
proliferation of dual-PI3K-Inhibitors (Pictilisib and Copanlisib) were higher
(60% and 77%) than combinations of single isoform inhibitors (AS-605240
and A66: 34%; A66 and idelalisib: 36%; respectively). In primary patient sam-
ples copanlisib revealed the highest cytotoxicity followed by duvelisib, idelal-
isib, TGX221 and A66 (80.9%; 62.5%; 48.7%; 50% and 40.5%, respectively,
5µM). The differential impact of single and multiple PI3K isoform inhibition on
phospho kinases suggests that concurrent phosphorylation inhibition of p53,
Akt, p70S6 Kinase, RSK1/2/3, STAT3, c-Jun, eNOS, WNK1, Pyk2 and PLCγ-
1 is responsible for increased biological activity to multiple PI3K-isoform inhi-
bition. The observation that inhibitors of different isoforms of PI3K result in
different protein phosphorylation patterns supports the hypothesis that the
PI3K isoforms act on different downstream signaling pathways. Additional
data on the influence of microenvironment on the different PI3K-Isoform
inhibitors will be presented. 
Summary/Conclusions: Based on the comprehensive analysis of PI3K inhi-
bition, inhibition of multiple isoforms of PI3K appears to be most efficient in
MCL. Thereby the superiority of combined PI3K-isoform inhibition vs selective
single isoform inhibition leads to the assumption that each PI3K-isoform reg-
ulates different downstream pathways. In addition, the modulating effect of
the murine feeder layer confirms that the microenvironment plays a critical
role for the mode of action of inhibitors of the B-cell receptor pathway. 
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Background: Recent studies have described the landscape of recurrently
mutated genes in mantle cell lymphoma (MCL). However, with the exception
of TP53, little is known about the clinical relevance of these mutations.
Aims: Thus, we performed deep sequencing analysis of a MCL gene panel in the
prospective series of patients enrolled in the FIL-MCL0208 phase III trial (EudraCT-
Number: 2009-012807-25, high-dose immunochemotherapy followed by autolo-
gous transplantation for untreated, advanced stage <65 years MCL patients).
Methods: The mutational study included a subgroup of patients with availability
of tumor DNA. A specifically designed, targeted resequencing gene panel,
including coding exons and splice sites (genes: ATM, BIRC3, CCND1, KMT2D,
TP53, TRAF2, WHSC1, NOTCH1) was analyzed in tumor DNA from baseline
bone marrow CD19+ purified MCL cells and, for comparative purposes to filter
out polymorphisms, in the paired normal genomic DNA (available in 55% of
cases) using a TruSeq Custom Amplicon target enrichment system followed
by deep next generation sequencing (Illumina, median depth of coverage
2356x). Variants represented in >10% of the alleles were called with VarScan2
with the somatic function when the paired germline DNA was available. For
patients lacking germline DNA, a bioinformatic pipeline including a number of
stringent filters was applied to protect against the misclassification of polymor-
phisms as somatic variants. Primary endpoint of the analysis was progression
free survival (PFS) and clinical data were retrieved at the time of the first,
planned, interim analysis (as of May, 2015).
Results: Out of the 300 enrolled patients, 174 were evaluable for the mutational
study (median age: 57 years, range 35-66; males 75%). The MIPI was interme-
diate or high-risk in 39% of patients, the Ki67 ≥30% in 44%, and blastoid histology
occurred in 9%. Patients not included in the study, due to unavailable tumor DNA
(n=124) showed superimposable clinical features, except from a lower stage IV
rate (79% vs 91%, p=0.003), as expected. At the first planned interim analysis,
median follow-up of alive patients was 26 months. At 2-years, 79% of patients
were progression free and 91% alive (Cortelazzo et al. EHA 2015). Overall, at
least one mutation was detected in 114/174 cases (66%), including mutations of
ATM in 43% of cases, WHSC1 in 16%, CCND1 in 13%, KMT2D in 12%, TP53
in 8%, NOTCH1 in 8%, BIRC3 in 5% and TRAF2 in 1%. By univariate analysis,
mutations of TP53 (2y PFS 42% vs 83%; p<0.0001) and KMT2D (2-years PFS
69% vs 81%; p=0.008) associated with a significantly shorter PFS. By multivariate
analysis, mutations of TP53 (HR: 5.3) and KMT2D (HR: 2) associated with an
increase of the hazard of progression. By recursive partitioning analysis, three
MCL subgroups were hierarchically classified (Figure 1). 
Figure 1.
The high-risk category (TP53 +/- KMT2D mutation, 7% of patients) showed a 2y
PFS of 42%, the intermediate risk (KMT2D mutation without TP53 mutation,
10%) showed a 2y PFS of 75%, while the low-risk (no TP53, no KMT2D muta-
tions, 83%) had a 2y PFS of 83%. The low number of events so far recorded
prevented any analysis on overall survival.
Summary/Conclusions: Though limited by the short follow-up, our data show
that: i) the combination of TP53 and KMT2D mutations predicts a shorter PFS
in younger MCL patients receiving high-dose therapy; ii) intensive chemother-
apy does not overcome the negative prognostic impact of TP53 mutations; and
iii) KMT2D mutations may represent a novel genetic biomarker in MCL.
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Background: The PI3K pathway is known to contribute to B-cell non-Hodgkin
lymphoma (NHL) cell survival by regulation of cell cycle, apoptosis, proliferation,
differentiation, homing and retention. The PI3K p110 subunit constitutes the
catalytic domain of class I PI3Ks and exists as four isoforms. p110-δ isoform
is primarily expressed in cells of hematopoietic origin and constitutes a key
component of the BCR pathway. Idelalisib (IDELA/GS-1101/CAL-101) is a first-
in-class PI3Kδ selective inhibitor that is approved for the treatment of relapsed
chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma (FL),
and small lymphocytic lymphoma. The mechanisms of IDELA sensitivity and
resistance remain to be fully elucidated. 
Aims: Characterization of the cellular and molecular effects of IDELA in an in
vitro model utilizing a primary FL coculture system with follicular dendritic cells
(FDC) or M2-polarized macrophages (M2).
Methods: FL primary cells from lymph node (LN) biopsies were co-cultured
(24-72h)with the FDC cell line HK or M2 generated from M-CSF activated mono-
cytes from peripheral blood of normal donors. Viability of FL cells was assessed
by flow cytometry (AnnexinV/7-AAD). B cells were isolated using CD20 magnetic
beads, RNA extracted and subjected to Gene Expression Profiling (GEP). Sig-
nificant pathways were identified by Gene Set Enrichment Analysis (GSEA).
Results: In the absence of accompanying cells, IDELA (100-500nM) induced a
moderate cytotoxic effect in FL cells (n=10). FDC or M2 co-cultures increased
FL cell viability up to 2-fold. IDELA was also able to reduce this pro-survival effect
of FDC or M2, highlighting its impact on lymphoma-microenvironment interactions
(Figure 1A). To characterize the molecular mechanisms of these observations,
FL primary cells (n=5) were cultured either alone,with FDC or M2, and treated
with 500nM IDELA for 48h. GSEA indicated that both FDC and M2 induced the
transcription of genes related to B-cell receptor (BCR) and CD40 signaling path-
ways, together with Germinal Center program and BLIMP-targets. IDELA signif-
icantly (FDR<0.05) reduced the engagement of these transcriptional pathways.
Additionally, FDC promoted the transcriptional activation in FL cells of gene sets
related to angiogenesis, trans-endothelial migration, extracellular matrix (ECM)
adhesion and integrin signaling. IDELA was able to counteract this gene upreg-
ulation in a subset of patients and preliminary functional experiments validated
that IDELA abrogates ECM adhesion (Figure 1B) and VEGF-A secretion (Figure
1C). However, IDELA was inefficient at blocking the secretion of the macrophage
attractant CCL-2, the matrix metalloproteinase MMP-2 and the pro-inflammatory
cytokines IL-6 and IL-8. In FL-M2 co-culture, GSEA showed that M2 activated
the transcriptional activation in FL cells of gene sets that were not sensitive to
IDELA treatment, such as Toll-like receptor (TLR) and CCR5 signaling pathways.
Moreover, the matrix metalloproteinase MMP-9 was highly elevated in FL-M2
co-culture and was not modulated by IDELA exposure.
Figure 1.
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Summary/Conclusions: We have characterized the impact of IDELA on FL
cells and their crosstalk with two immune populations (FDC and M2
macrophages) present in the LN which are associated with poor prognosis.
These results suggest that although IDELA targets several important B-cell
pathways (BCR, CD40, angiogenesis, trans-endothelial migration, ECM adhe-
sion), other pathways related to pro-inflammatory immune response and cell
disseminationare not affected.
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MIR-34A PREVENTS LUNG INJURY IN BLEOMYCIN INDUCED PULMONARY
FIBROSIS
R Bulvik1,*, S Wallach-Dayan1, S bulvik2, R breuer1
1Lung Biology Laboratory, Hadassah hebrew university medical center,
jerusalem, 2Hematology department, Laniado hospital, Netanya, Israel
Background: Bleomycin is a critical component in the treatment of Hodgkins
disease however its major side effect, namely lung fibrosis prevents its use in
certain subgroups, especially elderly patients. Prevention of this life threatening
side effect could potentially increase the cure rate in this disease. A prominent
feature of fibrotic lungs is the development of inflammation leading to accumu-
lation of abnormal myofibroblast populations resistant to death receptor-induced
apoptosis. We have previously shown that this resistance is mediated by the
expression of cellular FLICE-Inhibitory Protein (c-FLIP). In this work we study
the regulation of c-FLIP expression by miR-34a.
Aims: To assess the critical role of miR-34a on FLIP expression during in-vivo
bleomycin-induced fibrosis.
Methods: Lung fibrosis was induced using a well-established model of
Bleomycin- and control saline-treated C57BL/6 and miR-34 knock-out (KO) mice.
Fibrosis was measured by histological H&E semi morphological index (SMI)
score, bronco-alveolar-lavage (BAL) cytological ratio and by Collagen abun-
dance using Sircoll-collagen kit. miR-34KO and C57BL/6 myofibroblasts were
isolated from day 0/14/28 and day 56 of the model. qPCR and Western blot
assays were used to analyze level of miR-34A and FLIP. Furthermore, isolated
myofibroblasts were transfected with miR-34 overexpression lentiviral-vector vs
scrambled vector and levels of FLIP were measured. Apoptosis was induced in
miR-34 over-expressed myofibroblasts co-cultured with T-cells and the apoptosis
ratio was measured by caspase-3 cleavage and annexin-v staining.
Results: In-silico DIANA prediction tools found FLIP among the top 10th putative
genes with an 85% probability to be targeted by miR-34a. in-vitro we detected
an inverse correlation between RNA levels of miR-34a and FLIP in myofibrob-
lasts isolated from Bleomycin- and saline-treated mice; saline-treated Lung-
myofibroblasts isolated from day 14 express high levels of miR-34a and low
levels of FLIP while Bleomycin-treated mice lung-myofibroblasts isolated from
day 14 (when fibrosis severity is at its highest) show low levels of miR-34a
expression and high levels of FLIP (FLIP: 0.98±0.3 vs 3.5±1.2 ; miR-34a:
1.03±0.1 vs 0.48±0.07, respectively. p<0.05). The same pattern as Bleomycin-
treated myofibroblasts is seen in miR-34 KO untreated myofibroblast; low levels
of miR-34a and high levels of FLIP. Restoration of MiR-34a into miR-34KO
naive myofibroblasts reduced FLIP levels back to a normal state as opposed
to scrambled control counterparts. Moreover, miR-34a over-expression
regained myofibroblast susceptibility to apoptosis when cocultured with T-cells.
In-vivo, both Bleomycin treated C57BL/6 and miR-34KO groups show high lev-
els of FLIP and severe fibrosis on day 14 compared to healthy saline treated
groups. However, while C57BL/6 Bleomycin treated mice recover from fibrosis
on day 28, the miR-34KO Bleomycin treated mice continue to express high
FLIP levels and persistent fibrosis.
Summary/Conclusions: miR-34a is an important regulator of FLIP expression
and is effective in attenuation of Bleomycin lung fibrosis progression. Maintain-
ing high levels of miR-34a in Hodgkins disease patients treated with Bleomycin
may prevent lung fibrosis.
Indolent Non-Hodgkin lymphoma - Long-term
and outcome
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INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90
IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR
REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE
CELL LYMPHOMA
K Hatake1,*, R Kanzaki2, Y Yabuuchi2, O Kataoka2, S Nagai2, Y Asaeda2
1The Cancer Institute Hospital, 2Mundipharma K.K., Tokyo, Japan
Background: Yttrium-90 ibritumomab tiuxetan (90Y-IT) is a radiolabeled anti-
CD20 monoclonal antibody approved in Japan since 2008 for use in relapsed
or refractory (R/R) indolent B-cell non-Hodgkin lymphoma (NHL) or mantle cell
lymphoma (MCL). Here we present data from its real world use in Japanese
patients (pts) after marketing authorization. 
Aims: To evaluate safety and efficacy of 90Y-IT in Japanese pts with R/R B-cell
NHL or MCL in usual clinical settings.
Methods: This is a prospective study of consecutive clinical cases collected
from 63 institutions across Japan. Pts were enrolled between Aug, 2008 and
May, 2010. The data cut-off was Aug 27, 2015. Adverse events were assessed
for intent-to-treat population. Efficacy was analyzed during standard observation
period according to IWC 1999 and followed annually for outcomes and sec-
ondary malignancy. 
Results: Safety was evaluated for 413 pts enrolled. Median age was 61 (range
31-87) with 77.2% follicular lymphoma and 12.1% MCL according to WHO clas-
sification. 97.3% of pts were performance status 0 - 1 with Ann Arbor staging I,
II, III and IV ranging 10.9%, 22.5%, 35.4% and 29.8% respectively. Median
number of previous treatments were 3 (range 1 - 22). Of the 409 pts who
received 90Y-IT, 315 received 14.8 MBq/kg (0.4 mCi/kg) and 89 received 11.1
MBq/kg (0.3 mCi/kg). Adverse drug reactions (ADRs) were reported in 373 pts
(90.3%). There was no difference observed in the incidence rate of ADRs across
patients demographics. The most common ADRs were hematotoxicities
(88.6%): thrombocytopenia (75.5%), leukopenia (57.6%) and neutropenia
(35.6%). Infection was reported in 45 cases (10.9%), with most common being
herpes zoster 10 (2.4%), nasopharyngitis 6 (1.5%) and bronchitis 5 (1.2%).
Secondary malignancy was reported in 13 pts, including 9 myelodysplastic syn-
drome and 2 acute myeloid leukemia. Of 409 pts, 59 were excluded from the
efficacy analysis data set due to unavailable best response, off-label use, or
90Y-IT not being administered. The overall response rate (ORR) in 354 evalu-
able pts was 76.8% [95% CI: 72.1 to 81.1%] and complete response (CR) rate
was 47.7% [95% CI: 42.4 to 53.1%]. ORR and CR for those receiving 2 or less
prior regimens were 86.0% [95% CI: 79.6 to 91.0%] and 56.1% [95% CI: 47.9
to 64.0%] respectively, while ORR and CR for those receiving more than 2 prior
regimens were 69.3% [95% CI: 62.2 to 75.8%: p=0.0003] and 40.7% [95% CI:
33.7 to 48.1%: p=0.005] respectively.
Summary/Conclusions: The interim analysis of this surveillance confirms 90Y-
IT is a tolerable and efficacious treatment option for pts with R/R B-cell NHL or
MCL in Japan, demonstrating good benefit-risk balance consistent with the cur-
rently available international and Japanese data. (NCT01448928)
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PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE
LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE
OUTCOME BETWEEN FL AND DLBCL
L Magnano1,*, O Balagué2, I Dlouhy1, J Rovira1, K Karube3, A Rivas1,
B Gonzalez2, A Martinez-Trillos1, A Martinez2, J Delgado1, E Gine1, N Villamor4,
E Campo2, A Lopez-Guillermo1
1Hematology, 2Pathology, Hospital Clinic de Barcelona, Barcelona, Spain,
34Department of Pathology and Cell Biology, University of the Ryukyus, Nishi-
hara, Japan, 4Hematopathology Unit, Pathology Department, Hospital Clinic
de Barcelona, Barcelona, Spain
Background: Whereas histologic transformation to DLBCL during the follow-
up of FL determines a poor outcome, it is not clear the prognostic impact of the
presence of a DLBCL component (FL/DLBCL) in the diagnostic biopsy of
patients with FL.
Aims: to analyze the clinical characteristics, treatment, response, progression
free survival (PFS) and overall survival (OS) of patients diagnosed with FL/DLB-
CL in comparison with FL or DLBCL patients. 
Methods: 877 patients diagnosed either FL or DLBCL between 2002 and 2015 in
a single institution were included in the study. The distribution was as follow: FL,
369 cases (161 M/208 F; median age, 59 years), DLBCL, 508 cases (274 M/234
F; median age, 65 years). The main clinical, biological features and outcome were
analyzed. All biopsies of FL/DLBCL patients were reviewed in order to quantify
the DLBCL component. NOTCH1 mutations were assessed in 195 cases. 
Results: 41 patients showed a DLBCL component ranging from 5% to 95%
(median: 50%). Patients with FL/DLBCL showed more frequently than DLBCL
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cases, ambulatory performance status, absence of B symptoms, primary nodal
origin, advanced stage and low risk IPI with these features being closer to those
of FL patients (p<0.01 in all cases). On the contrary, FL/DLBCL patients had an
intermediate position between FL and DLBCL cases regarding bone marrow
infiltration, anemia and serum LDH levels. All FL/DLBCL patients were treated
as aggressive lymphoma (R-CHOP). Response and outcome of the patients
according to the histology are listed in the Table 1. Of note, the proportion of pri-
mary refractoriness in FL/DLBCL patients was significantly higher than in FL
and similar than that of DLBCL patients. In Figure 1, PFS and OS of the 3 groups
are plotted. No significant differences were seen according to the degree of
DLBCL component. In a multivariable analysis with FL patients (including
FL/DLBCL, B2 microglobulin and FLIPI), FLIPI demonstrated to be significant
for OS (p<0.001). NOTCH1 were more frequently mutated in FL/DLBCL (11%)
in comparison with FL (2%) or DLBCL patients (1.5%) (p=0.06).
Table 1. Response and outcome of the patients according to the histology.
Characteristics                               FL (n=328)        FL/DLBCL(n=41)      DLBCL(n=508)
                                                         n (%)                      n (%)                      n (%)
Response to therapy                                                                                           
CR                                                  216; 75                   26; 65                   343; 69
PR                                                   58 (20)                    6 (15)                     40 (8)
Failure                                              14 (5)                    8 (20)*                  116 (23)
Relapse/progression                          100 (31)                  15 (37)                  224 (44)
PFS-5 years (95% CI)                      65% (59-71)           56% (40-72)           50% (45-55)
OS-5 years (95% CI)                        85% (81-89)           73% (57-89)           63% (59-67)
* p<0.05 with FL.
Figure 1.
Summary/Conclusions: FL patients with a component of DLBCL showed an
intermediate outcome between FL and DLBCL. These patients may represent
a different group of FL that warrants further biological studies.
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DISTINCT INCREASING TREND AND BIRTH-COHORT EFFECT OF
FOLLICULAR LYMPHOMA INCIDENCE IN TAIWAN: EPIDEMIOLOGICAL
ANALYSES AND IMPLICATIONS
SJ Wu1,*, CJ Chiang2,3, JYC Chen2,3, WC Lo2,3, CT Lin1, MS Lai2,3
1National Taiwan University Hospital, 2Graduate Institute of Epidemiology and
Preventive Medicine, College of Public Health, National Taiwan University, 3Tai-
wan Cancer Registry, Taipei, Taiwan, ROC
Background: Follicular lymphoma (FL) is much less prevalent in Asia than in
the West. However, the recent reports have shown that the relative rate of FL
among all lymphoma subtypes is increasing in Taiwan as well as in other Asian
populations. Since lifestyle and environmental factors have been proposed to
be associated with the risk of FL, it is of interests whether the Westernized
lifestyle and environmental alternations that are increasingly affecting Tai-
wanese may have an important impact on this change.
Aims: The study is aimed at drawing the epidemiological pictures of FL in both
Taiwan and the US and dissecting the individual factors contributing to the epi-
demiological differences between these two areas. The comparison of the epi-
demiological characteristics of FL between Taiwan and the West may help clar-
ify the factors relevant to the development of this disease.
Methods: The relevant epidemiological data of FL during 1993-2012 for Tai-
wanese were obtained from the Taiwan National Cancer Registry Database,
and the corresponding data of Caucasian Americans, the Surveillance, Epi-
demiology, and End Results (SEER) Program Research Data. Age-specific
incidence rates of FL were plotted by calendar year at diagnosis and by birth-
cohort for both populations. The individual effects of time-period and birth-
cohort on the incidence trends were evaluated with the age-period-cohort analy-
sis. Patients’ outcomes, represented by 5-year relative survivals (RS) between
1990 and 2009, were calculated for outcome comparisons.
Results: The age-standardized incidence rate of FL for the Taiwanese was
continuously increasing during the 20-year period while that for Caucasian
Americans remained steady (Figure 1). The age-specific incidence rates for
Taiwanese were much lower than those for Caucasian Americans for all age
group. The estimations of the average annual percentage changes (AAPC) of
incidences were significantly positive for all age groups in Taiwan, indicating a
consistently increasing incidence trend in all age groups, whereas the AAPC
for Caucasian Americans were small and without a consistent pattern. Com-
parisons of the age-specific incidences in representative birth cohorts demon-
strated that for Caucasian Americans, there were almost no differences in the
incidences between earlier and later birth cohorts; but for the Taiwanese, the
incidence was higher for every later birth cohort in every given age group. With
the age-period-cohort modeling approach to dissect the individual effects con-
tributing to this distinct incidence trend, a much stronger birth-cohort effect was
identified for the Taiwanese but not for Caucasian Americans. In regard of the
outcomes, the 5-year RS in Taiwan and the US were both improving. However,
patients’ RS in Taiwan during this period were steadily 10~15% inferior to that
in the US in both younger and older patients.
Figure 1.
Summary/Conclusions: Despite the much lower incidence, there is a distinct
increasing trend of FL in Taiwan; underlying this increasing trend is a strong
birth-cohort effect, suggesting that changes in life style may be an important
factor for the difference in incidence trend between the East and the West and
providing an evidence of associations between environmental factors and the
development of FL. The improved RS in both areas implies that therapeutic
advances are changing the clinical course of FL, but the stable RS gap between
Taiwanese and American patients indicates that the genetic background is
affecting FL patients’ outcomes.
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LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY
IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON
TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE
II INITIAL STUDY
M Kesavan*, JH Turner, AD McQuillan
School of Medicine and Pharmacology, University of Western Australia, Perth,
Australia
Background: Follicular lymphoma (FL) is the second most common non-
hodgkin lymphoma (NHL) in Western countries. The decision to treat is gener-
ally based on the disease grade and presence of GELF criteria. Standard rit-
uximab chemotherapy regimens improved progression free survival (PFS) but
have not translated into an improvement in overall survival (OS). Conventional
therapy has a risk of myelotoxicity including myelodysplastic syndrome (MDS).
Our phase II INITIAL clinical trial was the first to report significant efficacy of
first-line 131I-rituximab outpatient therapy in advanced symptomatic FL. To allay
concerns regarding long-term toxicity we report the incidence and nature of
both short and long-term myelotoxicity over 10 years of follow up. An update
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of the TTNT and long-term survival outcomes of our INITIAL experience of
front-line 131I-RIT for follicular lymphoma is also reported.
Aims: We report the toxicity, time-to-next-treatment (TTNT) and survival out-
comes after a decade of follow-up of the original phase II INITIAL study patient
cohort treated with Iodine-131-rituximab radioimmunotherapy (131I-RIT).
Methods: We reviewed the 68 patients in the original prospective phase II INI-
TIAL study commenced April 2006. Standard eligibility criteria were applied;
baseline entry myeloid function required platelets >70x109/L, neutrophils
>1x109/L and hemoglobin >100g/L. All patients met GELF criteria for treatment.
Therapy comprised 375mg/m2 rituximab at weekly intervals for 4 weeks. Stan-
dard maintenance rituximab was then given. Individual dosimetry was per-
formed using tracer 250Mbq 131I-rituximab whole body SPECT/CT. A prescribed
radiation absorbed dose to the whole body was fixed at 0.75Gy and each patient
received an individual administered activity for therapy based upon this dose.
Patients were monitored with weekly blood counts during the first 8 weeks and
reviewed at regular intervals thereafter.
Results: No patient was lost to follow up. All patients were treated at the fixed
radiation dose of 0.75Gy to whole body. Of 68 patients, 5 were excluded from
toxicity analysis due to insufficient data. All patients were included in the OS
and TTNT assessments. Median age at enrollment was 60 years (37 females
and 31 males) with median follow-up of 70 months. No patient required hospital
admission for management of bleeding, sepsis or any other complication.
Myelotoxicity of grade 3/4 (CTCAE) during the first 8 weeks of therapy occurred
in 23 patients (36%); 6 with grade 3/4 thrombocytopenia, 14 with grade 3/4
neutropenia and 3 patients with concurrent grade 3/4 thrombocytopenia and
neutropenia. Grade 3/4 myelotoxicity manifested as a nadir of platelets at week
4 and of neutrophils at week 6. Resolution was essentially complete by week
8. No significant hemoglobin reduction was seen. On multivariate analysis bone
marrow involvement was independently associated with development of acute
thrombocytopenia (p=<0.01). No significant long-term myelotoxicity was
observed. There was no instance of MDS or acute leukemia. Deauville criteria
were fulfilled for complete response (CR) based on 18F-FDG PET/CT at 3
months follow up in 56 patients (82%). Mean TTNT was 97 months (95 months
for FLIPI 0/1, 104 months for FLIPI 2 and 83 months for FLIPI >3). Mean OS
was 107 months (94 months for FLIPI 0/1, 109 months FLIPI 2 and 99 months
for FLIPI >3). There was no statistically significant difference between groups
for TTNT or OS. Achievement of CR at 3-month follow-up 18F-FDG PET/CT
was predictive of long-term survival (relative risk=0.36 in contrast to 2.8 for
patients not achieving CR) (Figure 1).
Figure 1.
Summary/Conclusions: First-line131I-RIT for advanced FL is safe and effec-
tive. Long-term follow-up of 131I-RIT of advanced FL demonstrates durable
response without toxicity. Myelosuppression is modest and self-limited.
Deauville criteria at 3-month 18F-FDG PET/CT are predictive of TTNT and OS.
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LONG TERM OUTCOMES IN PRIMARY OCULAR ADNEXAL MUCOSA-
ASSOCIATED LYMPHOID TISSUE LYMPHOMAS (POAML): A LARGE
SINGLE INSTITUTE COHORT STUDY
A Desai1,*, MG Joag2, L Lekakis1, D Tse2, A Markoe3, IS Lossos1
1Hematology/Oncology, Sylvester Comprehensive Cancer Center, University
of Miami, 2Ophthalmology, Bascom Palmer Eye Institute, University of Miami,
3Radiation Oncology, Sylvester Comprehensive Cancer Center, University of
Miami, Miami, United States
Background: POAML are rare malignant proliferations affecting the orbit,
lacrimal gland, eyelids and conjunctiva, accounting for 35%– 80% of the Primary
Ocular Adnexal Lymphoma (POAL) cases. We present the outcomes of the
largest single institute study on 182 POAML patients followed for a medium of
63.5 (range 1-387) months. 
Aims: To report natural history and identify clinical parameters associated with
POAML relapses/progression.
Methods: A retrospective study of 182 patients with POAML diagnosed or treat-
ed between January 1984 and December 2015, based on the tumor registry at
the University of Miami Sylvester Comprehensive Cancer Center. Information
on demographics, medical history, anatomic location, International Prognostic
Index (IPI), laboratory/imaging data, stage, treatment and response, details on
relapse and management, progression free survival (PFS), time to progression
(TTP) and overall survival (OS) was extracted. Kaplan-Meier survival curves
were constructed and analyzed by the log rank test with JMP® statistical dis-
covery software.
Results: Of the analyzed 182 patients with POAML, 145 (79.6%) presented in
Ann-Arbor stage I and 30 (16.4%) in stage II-IV disease. Median age at diagnosis
was 72 years (range, 7-92 years). Patients with lacrimal POAML tended to pres-
ent at a younger age (median 49.5 years) compared to those with orbital (median
65 years) (p=0.002) and conjunctival POAML (median 62 years) (p=0.05). Over-
all, 147 of 174 (84.4%) treated patients achieved a complete response (CR)
after first-line therapy. In 98 patients with stage I disease who received initial
radiation therapy (RT), CR was more commonly observed in patients treated
with radiation dose ≥30.6 Gy compared to patients receiving lower RT doses
(p=0.04). Similarly, there was also statistically significant difference between
these groups in 5 and 10-year PFS (p<0.0001), but no difference in OS. Overall,
the long-term local control was achieved in 14 (70%) patients treated with RT
<30.6 Gy and 69 (88%) patients treated with RT ≥30.6 Gy (p=0.04). In patients
treated with RT for stage I disease 5(4.5%) developed CNS relapses with sig-
nificantly higher relapses (3/5) in the group receiving <30.6 Gy (p=0.04). Among
174 patients with available follow up data, 36(20.6%) relapsed/progressed and
in 147 who achieved a CR after first-line treatment, 5-year and 10-year relapse
rates were 23.7% and 43.3%, respectively. Transformation to diffuse large B-
cell lymphoma was diagnosed in 7 (4%) and accounted for 7/36 (19.4%) pro-
gressions/relapses, leading to death in 2 patients. Median OS for all patients
was 250 months (95% CI: 222-upper limit not reached), median PFS was 134
months (95% CI: 87-198) and the median time to progression was 198 months
(95% CI:109-upper limit not reached). Kaplan-Meier estimates for the FFP for
all 174 patients at 1, 5, and 10 years after completion of initial treatment were
92.7% (95% CI: 87.6%-95.8%), 73.8% (95% CI: 65.8%-80.4%), and 60% (95%
CI: 49%-70%), respectively. On univariate analysis, age >60 years, radiation
dose, bilateral ocular involvement at presentation and advanced stage were sig-
nificantly associated with shorter PFS (p=0.006, p=0.0001, p=0.002 and
p=0.0001 respectively) Multivariate analysis showed that age >60 years
(HR=2.44) and RT<30.6 Gy (HR=4.17) were the only factors associated with
shorter PFS (p=0.01 and p=0.0003, respectively).
Summary/Conclusions: Patients with POAML have CNS relapses in 2.8%
and transform to DLBCL in 4% of cases. RT at doses ≥30.6 Gy are associated
with better local control; fewer local, CNS and distant relapses and longer PFS.
Early stage POAML do well with localized RT for stage I disease but demon-
strate long-term constant risk for relapse. 
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EARLY TRANSFORMATION IN LOW-GRADE LYMPHOMAS AND ITS
ADVERSE PROGNOSTIC SIGNIFICANCE ON SURVIVAL 
LM Juárez Salcedo1,2,*, P Griffin2, J Sandoval-Sus2, C Bello2, B Shah2, E Ayala2,
MA Kharfan-Dabaja2, P Chervenick2, EM Sotomayor3, L Sokol2, JC Chavez2
1Haematology Department, Principe de Asturias University Hospital, Alcalá de
Henares, Spain, 2Department of Malignant Hematology, Moffitt Cancer Center,
Tampa, 3Hematology/Oncology, George Washington University, Washington
D.C, United States
Background: Transformed lymphoma (TL) is a very heterogeneous condition
that usually represents the final stage of low grade non-Hodgkin’s lymphomas
(LG-NHL) progression. It is commonly associated with poor survival. Previously,
we reported the prognostic impact of the Revised International Prognostic Index
(R-IPI) and National Comprehensive Cancer Network-IPI scores at histologic
transformation in survival (Tsao et al., ASH 2013 and Griffin et al., ASH 2014).
Here we investigate the impact of early transformation in TL. 
Aims: To determine if early transformation of LG-NHL has a prognostic impact
in high-risk TL.
Methods: Patients with a biopsy proven diagnosis of TL from LG-NHL between
January 2001 and December 2014 that were treated at Moffitt Cancer Center
were identified using the Total Cancer Care Database. High risk TL was defined
based on an R-IPI over 3 points and NCCN-IPI over 3 points. Early transfor-
mation was empirically defined as the evidence of aggressive transformation
within 24 months (TT24) from LG-NHL diagnosis. Overall survival (OS) was
calculated from the date of transformation, estimated by the Kaplan-Meier
method (K-M), and compared using the Log-rank test. Predictors of survival
were assessed using Cox proportional hazards model, and multivariate analy-
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ses of significant factors were assessed by backward step elimination for vari-
ables with a p<0.05.
Results: A total of 149 patients with transformed DLBCL were identified. The
median age at transformation was 58 years (range 21–89), the M/F ratio was
1.4. The most common type of LG-NHL was follicular lymphoma (75.8%). At TL,
B-symptoms were present in 30%, stage III/IV in 64.4%, elevated LDH in 55.2%,
serum albumin (SA) less or equal than 3,7 g/dL in 28% of patients. Forty-five
percent and 44.6% had IPI score ≥3 and NCCN-IPI score ≥3, respectively. The
most common treatment regimen at time of transformation was R-CHOP (61%)
then by R-ICE (12.7%). The median OS was 6.4 years (95% CI, 5.48-7.49). The
5 and 10-years OS were 54% and 33% respectively. Patients with NCCN-IPI
and R-IPI ≥3 were associated with poor survival (median OS of 4.2 years,
p=0.024; and 3.76 years, p<0.001, respectively). SA ≤3.7 g/dL was predictive for
inferior OS (3.5 y vs 8.6 y, p=0.04). TT24 was associated with poor outcomes
(OS 3.3 vs 6.1 y, p=0.008) (Figure 1). Multivariate analysis showed that TT24
(HR 4.13, p=0.042), NCCN-IPI >3 (HR 3.16, p=0.075) and IPI ≥3 (HR 3.47,
p=0.063)were statistically significant for shorter OS. The impact of TT24 was
particularly significant in high risk TL (NCCN-IPI >3 and/or IPI ≥3) with very poor
outcomes (OS 1.7 vs 4.4 y, p=0.038 and 1.3 vs 4.4 y, p <0.001; respectively).
Figure 1. OS by early transformation (TTT24).
Summary/Conclusions: Early time of transformation (TT24) to a more aggres-
sive lymphoma is predictive of shorter OS in patients with TL, especially in
cases of high risk TL, defined by the R-IPI and/or NCCN-IPI scores. New strate-
gies in prospective studies based on TT24 are warranted for patients with TL.
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OFATUMOMAB FOR THE TREATMENT OF EXTRANODAL MARGINAL
ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID
TISSUE (MALT LYMPHOMA): THE O-MA1 STUDY
B Kiesewetter1,*, O Neuper1, ME Mayerhoefer2, W Dolak3, J Lukas4, M Raderer1
1Dept. of Medicine I/Clin. Div. of Oncology, 2Dept. of Radiology, 3Dept. of Med-
icine III/Clin. Div of Gastroenterology and Hepatology, 4Dept. of Ophthalmology,
Medical University Vienna, Vienna, Austria
Background: To date there is no defined treatment standard for Helicobacter
pylori (HP)-eradication refractory, extragastric or advanced mucosa-associated
lymphoid tissue lymphoma (MALT lymphoma). Immuno-/chemotherapy combi-
nations have been successfully tested in this setting, however, due to the indolent
course of this disease less toxic approaches are warranted. Rituximab-monother-
apy has been tested for MALT lymphoma and has shown symptomatic activity
but a relatively low rate of durable remissions. Based on data generated in other
B-cell malignancies second-generation compound ofatumumab (OFA) appears
to be an attractive agent for the treatment of MALT lymphoma.
Aims: The primary endpoint of this trial was to evaluate the capacity and safety
of OFA to induce objective responses in patients with HP-eradication refractory
or extragastric MALT lymphoma
Methods: The O-MA1 study was a single-center phase II study. In case of HP-
positive MALT lymphoma a minimum of 12 months follow-up after successful
HP-eradication was required. OFA monotherapy was given at four weekly dos-
es (1000mg i.v., weeks 1,2,3,4) followed by four doses at two-month intervals,
starting at week 8. Restaging was performed at weeks 12, 24 and at end of
treatment. To date, the planned number of 16 patients has been included and
the study is closed to recruitment.
Results: The median age at treatment start was 69 years with an absolute
range of 38 to 85 years. Five of 16 patients (31%) had primary gastric MALT
lymphoma while the remaining 11 (69%) presented with extragastric manifes-
tations including lymphoma of the ocular adnexa (n=6), the lung (n=1), the
bladder (n=1), the liver (n=1), the breast (n=1) and bilateral lymphoma of the
parotid glands (n=1). In terms of staging 12 patients (75%) had localized lym-
phoma i.e. stage I or II according to Ann Arbor, and four patients (25%) dis-
seminated disease i.e. stage IV. All patients had an ECOG performance status
below two, but a total of nine patients (56%) had more than four significant
comorbidities. IPI-Score was 0 - 1 in 12 patients (75%) and 2 - 3 in four patients
(25%). A total of eight patients (50%) had been pretreated including five patients
(31%) with prior immuno- or chemotherapy. Median time from last treatment to
the first dose of OFA in pretreated patients was 8.9 months (range; 4.5-59). At
the time of this analysis all patients had at least one restaging and were thus
evaluable for response. Twelve of 16 patients showed an objective response
for an overall response rate of 75%. The complete remission rate was 50%
(8/16), while 25% had a partial remission (4/16) and 25% disease stabilization
(4/16) as best response. However, one patient with gastric lymphoma and com-
plete remission at first and second restaging had a focal gastric relapse at final
assessment. This patient is currently asymptomatic and no salvage treatment
has been indicated so far. The median time to best response was 3.3 months
(range; 2.5-10). Tolerability of treatment was excellent with no related adverse
events greater CTCAE grade I except infusion reaction grade I/II in 13/16
patients (81%) during the first OFA-application, which could be easily handled
with steroids or antihistamines and did usually not reoccur in the following.
However, one patient was taken off-study due to unrelated prolonged hospital-
ization for erysipelas but was still evaluable for response as this was after the
fourth application of OFA. No relevant grade III or IV hematologic adverse
events have occurred. To date at a median follow-up time of 16.2 months
(range; 3.9-28.2) 14 of 16 patients have finished treatment with no further
relapse or progress, while two patients are on treatment. More mature data
will be presented at the meeting.
Summary/Conclusions: This is the very first study to evaluate OFA as a
chemotherapy-free approach for the treatment of MALT lymphoma. With 16/16
planned patients recruited we report a response rate of 75% and a disease
stabilization rate of 94%. Toxicities were negligible even in elderly patients with
significant comorbidities.
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BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP AS FIRST-LINE
TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN’S LYMPHOMA:
EVIDENCE FROM A MULTICENTER, RETROSPECTIVE STUDY
P Mondello1,*, N Steiner2, W Willenbacher2, I Wasle2, F Zaja3, R Zambello4,
A Visentin4, E Mauro5, S Ferrero6, P Ghione6, V Pitini7, S Cuzzocrea8, M Mian9
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Background: The optimal first line treatment for advanced low-grade non-
Hodgkin lymphomas (LG-NHL) is still highly debated. Recently, the StiL and
the BRIGHT trials showed that the combination of rituximab and bendamustine
(R-B) is non-inferior to rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP) with a better toxicity profile. 
Aims: Utilizing a retrospective analysis, we compared the efficacy and safety
of both regimens in clinical practice. 
Methods: From November 1995 to January 2014, 263 LG-NHL patients treated
with either R-B or R-CHOP were retrospectively assessed in 7 European cancer
centers. 
Results: Ninety patients were treated with R-B and 173 with R-CHOP. Overall
response rate was 94% and 92% for the R-B and the R-CHOP group, respec-
tively. The percentage of complete response was similar for both groups (63%
vs 66% with R-B and R-CHOP, respectively; p=0.8). R-B was better tolerated
and less toxic than R-CHOP. The median follow-up was 6.8 and 5.9 years for
the R-CHOP and the R-B group, respectively. Overall, no difference in pro-
gression free survival (PFS) (108 months vs 110 months; p=0.1) was observed
in the R-B group compared to the R-CHOP cohort. However, R-B significantly
prolonged PFS in FL patients (152 and 132 months in the R-B and R-CHOP
group, respectively; p=0.05). 
Summary/Conclusions: We confirm that the R-B regimen administered in
patients with LG-NHL is an effective and less toxic therapeutic option than R-
CHOP in clinical practice. In addition, we suggest R-B as the treatment of
choice for FL patients due to the long-term disease control achieved. 
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FINAL RESULTS OF IHC ANALYSIS AND PROGNOSTIC FACTORS IN POST
TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID
ORGAN TRANSPLANTATION
Z Nooruddin1, Z Pan1, L Gross2, D Weitzenkamp2, D Pollyea1, J Gutman1,
W Robinson1, C Smith 1, J Schowinsky1, B Haverkos1, E Purev1, D Sherbenou1,
R Rabinovitch 1, D Ney 1, CT Jordan 1, M Kamdar1,*
1Blood Cancer and BMT, 2Dept of Biostatistics, University of Colorado Denver,
Denver, United States
Background: Post Transplant Lymphoproliferative Disorder (PTLD) represents
one of the most fatal complications following solid organ transplants (SOT). A
multicenter analysis in 2010 reported a 3yr overall survival (OS) of 62%. In
2014 a single institutional study reported an improved median OS of 8 years
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in the rituximab era. Clinical studies have attempted to subdivide post transplant
diffuse large B cell lymphomas (PT-DLBCL) into immunophenotypic subgroups
with most reviews demonstrating a higher incidence of activated B-cell (ABC)
subtype. Because of the rarity of PTLD, insight into disease development and
progression is currently limited
Aims: Our preliminary analysis of data on 52 patients (pts) was presented at
the American Society of Hematology meeting in 2015 (Abstract 1443). We here-
by present our final analysis on a larger cohort of 86 pts with PTLD treated at
the University of Colorado over a 25-year period.
Methods: This retrospective analysis focused on 86 adult SOT pts who were
treated for PTLD at our institution between Jan 1989 to April 2015.
Results: 86 pts were evaluated. The median age at transplantation was 49.5 yrs
(5-74 yrs). Median time from SOT to PTLD was 37 months (1.4-499).The most
common transplanted organ included kidney (40%), liver (38%), lung (13%) and
heart (9%). Grafted organ was involved with lymphoma in 25% pts. 62% were
male, 36% had Stage III-IV, 60% were EBV positive, 16% had bone marrow
involvement, 19% had CNS involvement and 30% had extranodal Disease. 31%
pts had early PTLD (<12mnths of SOT) and 69% pts had late PTLD(>12mnths
of SOT). 77% pts with early PTLD and 49% of pts with late PTLD were EBV pos-
itive. Of the 86 patients, 75 pts (87%) had monomorphic histology. Amongst
monomorphic PTLD 48 pts (64%) had DLBCL, 9% had Burkitt Lymphoma, 12%
had CNS lymphoma, 1% had plasmablastic lymphoma, 1% had NK/T cell lym-
phoma, 3% had hodgkins lymphoma and 5% had plasma cell neoplasm. 88%
pts were CD20 positive, 67% had elevated LDH and 50% had an IPI >1. 85%
were on >1 immunosuppressive agent (ImSx) with a median ImSx treatment (Rx)
duration of 3 years. Interestingly 80% of pts with CNS lymphoma were on
mycophenolate mofetil ImSx. 86% of pts with Burkitt lymphoma had undergone
liver transplantation. All Pts with CNS Lymphoma were recipients of kidney trans-
plantation. Initial Rx included reduction in ImSx in 80% pts, rituximab monotherapy
in 27% pts, rituximab +chemotherapy in 31% pts and chemotherapy alone in
11%pts. 63 of 86 patients were assessable for response. 90% achieved a com-
plete remission after first line therapy while 17% were refractory to front line ther-
apy. 9 out of 63 pts(14%) pts relapsed. IHC staining utilizing the Hans Algorithm
was applied on 32 of 48 samples with DLBCL. ABC subtype was identified in
75% (24/32 samples) and GCB (germinal center B-cell) subtype in 25% (8/32)
samples. Median overall survival was 133 months (11yrs). On univariate analysis
ABC DLBCL subtype (HR 0.28, 95% CI 0.085-0.970, p=0.03) was associated
with improved survival. Graft organ involvement with PTLD and CNS disease
showed a trend to poor survival. EBV positivity, Polymorphic PTLD and Early
PTLD showed a trend toward improved survival. Rituximab containing therapy
(Monotherapy or with Chemotherapy) was better than non-Rituximab therapy
(HR 0.6 P=0.3). Rituximab plus Chemotherapy had worse outcomes than Ritux-
imab monotherapy (HR 2.06) (Figure 1).
Figure 1. Product-limit survival estimates. With number of subjects at risk.
Summary/Conclusions: In this consecutive series of PTLD after SOT from a
single institution over a 25 year period we noted a 3yr OS of 81% and a 5yr OS
of 76%. ABC subtype was associated with improved survival whereas graft
organ involvement and CNS disease was associated with a trend to poor out-
comes. Rituximab based therapy was associated with improved outcomes. In
one of the first ever-reported data in PT-DLBCL cases we were able to demon-
strate a higher incidence and an improved survival with ABC DLBCL subtype
compared to GC DLBCL. The reason for this is not fully understood and merits
further evaluation in larger pt cohorts.
Aggressive Non-Hodgkin lymphoma - Clinical
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IMPROVED OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH PRIMARY
CENTRAL NERVOUS SYSTEM LYMPHOMA WITH PRESERVATION OF
COGNITIVE FUNCTION
S Kassam1,*, A Costello2, V Potter1, P Patten1, D Yallop1, S Devereux1,
R Marcus1
1Haematology, 2Neuropsychology, King’s College Hospital, London, United
Kingdom
Background: Outcome for patients with primary central nervous system lym-
phoma (PCNSL) have improved with the use of high-dose (HD) methotrexate-
based (MXT) regimens but relapses are frequent. To prevent relapse, consol-
idation of first response is desirable, the main options being whole-brain radio-
therapy (WBRT) or high-dose chemotherapy (HDC) and autologous stem cell
transplant (ASCT). Our centre has favoured the latter given the high incidence
of neurotoxicity with WBRT.
Aims: To retrospectively review the outcomes for patients with PCNSL treated
with HDC and ASCT and report analysis of prospective neurocognitive assess-
ments.
Methods: 63 patients were diagnosed with PCNSL between 2008 and 2015.
The median age at diagnosis was 60 years (range 27-80; 37 male). 21 patients
went on to receive HDT-ASCT with BCNU-thiotepa conditioning. A proportion
of these patients also had prospective neurocognitive assessment. 5 cognitive
domains were assessed: intellectual, memory, language, perception and exec-
utive functions. All employed tests have published, validated normative data.
Raw test scores were converted into age adjusted standard scores and com-
pared with published normative values.
Results: 49/63 patients (78%), ≤70 years and hence suitable for HDC-ASCT,
were treated with HD-MXT based regimens. 23 (47%) had a response i.e. com-
plete response (CR) or partial response (PR) to first-line treatment and 14/23
proceeded to HDC-ASCT. 15/26 patients who did not have a response to HD-
MTX went on to receive second line treatment (6 radiotherapy, 7 chemotherapy)
and, of these, 7 achieved a response (CR/PR) of whom 4 proceeded to HDC-
ASCT. 9/23 patients that initially responded to HD-MXT but did not proceed to
HDC-ASCT all relapsed. 5 received further treatment (2 chemotherapy and 3
radiotherapy) and of these, 3 proceeded to HDC-ASCT in second response.
Overall, 21 patients received HDC-ASCT, median age 54 years (range 26-68;
15 male). Histology was DLBCL in 19, mantle cell lymphoma in 1 and ALK+
anaplastic large cell lymphoma in 1. For all 63 patients, the median follow-up
is 8.3 months (0-92 months) and 36 patients (57%) have died, all except one
from lymphoma. The median first remission duration is 10 months (1-71) and
median overall survival (OS) 8.7 months. For the 21 patients receiving HDC-
ASCT, the median follow-up is 26 months (11-92) and the median progressive
free survival and OS has not been reached (Figure 1). 6/21 (29%) have
relapsed; 2 with systemic lymphoma. 5 have died; 4 from lymphoma and 1
treatment-related (hepatitis E infection). 9 patients had neurocognitive assess-
ments at baseline (pre- ASCT) and 1 year post ASCT (6 of whom had under-
gone baseline assessment) and 7 patients at 2 years post ASCT (3 of whom
had undergone both baseline assessment and 1 year post ASCT). Intellectual,
language and perceptual functions were preserved over the 2 year period.
However, some patients displayed impairment in memory and executive func-
tion at baseline. While no deterioration in executive functions was demonstrated
over the 2 year period, there was a suggestion of mild decline in aspects of
verbal recall memory at 1 year post ASCT (paired t-tests of mean score on list
learning at 1 year follow-up significantly below baseline mean score, p=0.021).
Figure 1.
Summary/Conclusions: In this unselected group of patients, the outcome for
PCNSL remains poor. However, for those patients that respond to induction
regimens and are fit enough to receive HDC-ASCT, prolonged disease control
can be achieved with relative preservation of neurocognitive function. 
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LENALIDOMIDE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B
CELL LYMPHOMA: IS IT A VALID TREATMENT OPTION?
P Mondello1,*, N Steiner2, W Willenbacher2, S Ferrero3, A Marabese4, V Pitini1,
S Cuzzocrea5, M Mian4
1Human Pathology, University of Messina, Messina, Italy, 2Internal Medicine
V: Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria,
3Molecular Biotechnologies and Health Sciences, University of Torino, Torino,
4Hematology & CBMT, Ospedale di Bolzano, Bolzano, 5Chemical, Biological,
Pharmaceutical and Environmental Sciences, University of Messina, Messina,
Italy
Background: Diffuse large B cell lymphoma (DLBCL) is the most frequent
aggressive non-Hodgkin lymphoma (NHL) in the western country. Despite its
typical morphology, DLBCL is characterized by molecular heterogeneity, which
can be classified by gene expression profiling (GEP) in two main subgroups
based on the cell of origin, namely germinal center B cell (GCB) and activated
B-cell. However, GEP is not routinely performed, which is why immunohisto-
chemistry (IHC) is commonly used for designating these two subtypes. Because
of the addiction to different oncogenic driver pathways, each subtype differs in
response to drugs, leading to a distinct prognosis. In particular, the cure rate
of ABC is only 40% after standard immunochemotherapy, hence novel thera-
peutic approaches are urgently needed. Prospective randomized studies
regarding the use of lenalidomide in relapsed/refractory (R/R) DLBCL have
demonstrated efficacy and feasibility of this immunomodulatory agent.
Aims: Up to now, data evaluating this drug in clinical practice are lacking.
Therefore, we assessed its toxicity and efficacy in the largest R/R DLBCL real-
life cohort carried out up to now.
Methods: From January 2006 to January 2015, 123 consecutive patients
affected by R/R DLBCL who underwent lenalidomide monotherapy were ret-
rospectively assessed in 3 European cancer centers.
Results: All patients received a starting dose of either 15 mg/day or 25 mg/day
of lenalidomide. Response to treatment differed significantly between the two
IHC subgroups: patients with non-GCB DLBCL achieved a complete remission
(CR) in 32% and a partial remission (PR) in 33% compared to 0% and 3% in
the GCB group (p<0.0001 and p=0.001). Toxicity was limited and reversible.
The median follow-up was 4.5 years (range 2-108 months). The median dura-
tion of response was 4 months (range 1-10 months) and 15 months (5-23
months) in GCB and non-GCB DLBCL, respectively (p<0.001). Patients receiv-
ing the 25 mg daily of lenalidomide had an overall superior outcome compared
to those who underwent the 15 mg regimen, namely 21% achieved a CR and
23% a PR compared to 0% and 8% (p=0.007 and 0.05). Also median duration
of response varied significantly between both dosing groups (10 vs 4 months;
p=0.03). Overall, the median progression free survival was 34 months (range
2-108 months), ranging between 37 and 30 months according to the non-
GCB and GCB DLBCL group (p<0.0001) and between 24 and 34 months
(p=0.002) according to the higher or lower lenalidomide dosing. However,
overall survival was similar between the different subgroups (38 vs 41 months
in non-GCB and GCB DLBCL, p=0.2; 38 vs 42 months in 15 and 25 mg/die,
p=0.4). 
Summary/Conclusions: In this real-life setting, we demonstrated that lenalido-
mide is a valid treatment option for R/R DLBCL with only limited and reversible
toxicity. As expected, lenalidomide is more efficient in patients with non-GCB
DLBCL, but responses were also observed in the other subgroup, which is
why it can be considered also for GCB DLBCL. If clinically feasible, the 25mg
dosing should be preferred.
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NONPEGHYLATED LIPOSOMAL DOXORUBICIN AS A COMPONENT OF
R-CHOP IS EFFECTIVE AND SAFE IN THE TREATMENT OF A CARDIAC
HIGH-RISK AND ELDERLY LYMPHOMA PATIENTS
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Background: Doxorubicin is the most effective single agent in the treatment
of non Hodgkin’s lymphoma (NHL). Its use is limited for the cardiac toxicity
particular in elderly patients (pts) and in pts with history of cardiac disease.
Liposomal doxorubicin has been proven to reduce cordiotoxicity.
Aims: The aim of this retrospective study was to evaluate in real life in a high-
risk population the use of nonpeghylated liposomal doxorubicin (NPLD) in term
of efficacy and cardiac events.
Methods: 965 consecutive pts treated with R-COMP (doxorubicin was sub-
stituited with NPLD, Myocet) were collected from 32 Italian Hematologic Cen-
ters. After the evaluation of pts’ records 16 were excluded, so the final analy-
sis was conducted on 937 pts. Median age was 73 (range 26-92), the reasons
for use of NPLD were: age (449 pts), cardiac disease (340 pts), uncontrolled
hypertension (123 pts), other reasons (55 pts). According to clinicians eval-
uation 48% of pts would not have used standard doxorubicin for different sit-
uations (age, cardiomiopathy, previous use of doxorubicin, uncontrolled
hypertension). 115 pts showed at diagnosis a LVFS <50% (in 108 pts this
data was not reported). 5083 cycles were infused and 841 pts (90%) per-
formed 4 or more cycles according to the therapeutical program. 462 pts
(49%) were over 74 years, 66% of pts had stage III or IV, 95% were DLBCL.
Results: Overall 678 pts (72%) obtained a complete remission (CR) and 116
experienced a relapse. CR rate was not significantly different between the
52% of pts which could be able to use standard doxorubicin (76%) and the
48% of pts which would not have used doxorubicin (70%). During treatment
98 pts (11%) presented a cardiac toxic event in particular: 29 heart failure,
29 severe cardiac arrhythmia, 15 myocardial infarction, 4 atrial fibrillation, 3
cardiac arrest and 18 other mild cardiac complications. No statistical differ-
ences was reported between pts with normal FEVS or less tha 50% according
to this cardiac toxic events. After a median period of observation of 32
months, 651 pts are alive and the overall survival (OS) was 72%. OS was
significantly superior in pts considered eventually elegible to standard dox-
orubicin in comparison with other not elegible 79% vs 70% (p .001). 282 pts
were death and 4 were lost to follow-up. The causes of death: 181 due to
lymphoma progression, 37 due to complications other than cardiac, 15 due
to cardiac complications, 12 due to second neoplasm and in 41 the cause
was not known. After a median observaton period of 23 months PFS was
58%. Either in univariate or in multivariate OS and PFS were not significantly
affected by age or cardiac disease.
Summary/Conclusions: In conclusion NPLD introduced in R-CHOP is effec-
tive and safe in a cardiac high-risk population and in a negatively selected
group of pts. Moreover the use of this NPLD permitted that about half of our
population have had the opportunity to receive the best available treatment. 
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METHYLATION OF CELL-FREE CIRCULATING DNA IN PLASMA
PREDICTS POOR OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA
LS Kristensen1,*, JW Hansen1, SS Kristensen1, D Tholstrup1, LBS Harsløf 1,
OB Pedersen2, PDN Brown1, K Grønbæk1
1Department of Hematology, Rigshopitalet, Copenhagen N, 2Klinisk Immunol-
ogisk Afdeling, Næstved Sygehus, Næstved, Denmark
Background: The prognostic value of aberrant DNA methylation of cell-free
circulating DNA in plasma has not previously been evaluated in diffuse large
B-cell lymphoma (DLBCL). 
Aims: The aim of this study was to investigate if aberrant promoter DNA
methylation can be detected in plasma from DLBCL patients and to evaluate
this as a prognostic marker. Furthermore, we wanted to follow possible
changes in methylation levels during treatment. 
Methods: Seventy-four patients were enrolled in the study, of which 59
received rituximab and CHOP-like chemotherapy. Plasma samples were col-
lected from all patients at the time of diagnosis and from 14 healthy individuals
used as controls. In addition, plasma samples were collected during and after
treatment for surviving patients. In total, 158 plasma samples were analyzed
for DNA methylation in the promoter regions of DAPK (DAPK1), DBC1,
MIR34A, and MIR34B/C using pyrosequencing. 
Results: Aberrant methylation levels at the time of diagnosis were detected
in 19, 16, 8, and 10% of the DLBCL plasma samples for DAPK1, DBC1,
MIR34A and MIR34B/C, respectively. DAPK1 methylation levels were signif-
icantly correlated with DBC1 and MIR34B/C methylation levels (P<0.001).
For the entire cohort five-year overall survival (OS) rates were significantly
lower in the groups carrying aberrant DAPK1 (P=0.004) and DBC1 methyla-
tion (P=0.044), respectively. Multivariate analysis identified DAPK1 as an
independent prognostic factor for OS with a hazard ratio of 5.1 (95% CI: 1.9-
13.4, P=0.001). Patients with DAPK1 methylated cell-free circulating DNA at
time of diagnosis, who became long term survivors, lost the aberrant methy-
lation almost immediately after treatment initiation. Conversely, patients that
regained or maintained aberrant DAPK1 methylation died soon thereafter.
Summary/Conclusions: Aberrant promoter methylation of cell-free circulat-
ing DNA can be detected in plasma from DLBCL patients, and DAPK1 methy-
lation is an independent prognostic marker that may also be used to assess
treatment response.
278 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
P699
REAL-WORLD EXPERIENCE OF IBRUTINIB IN >700 PATIENTS WITH
MANTLE-CELL LYMPHOMA: DATA FROM A GLOBAL NAMED PATIENT
PROGRAM
S Rule1,*, J Diels2, N Healy3, W Iraqi4, J Aschan5, M Wildgust6
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& Modeling, Beerse, Belgium, 3Janssen-Cilag EMEA Medical Affairs, Dublin,
Ireland, 4Janssen Pharmaceuticals, Paris, France, 5Janssen-Cilag EMEA Med-
ical Affairs, Sollentuna, Sweden, 6Janssen Research & Development, Raritan,
United States
Background: A global named patient program (NPP) was opened in numerous
countries worldwide in order to allow access to ibrutinib for eligible patients
with relapsed/refractory mantle-cell lymphoma (MCL) prior to approval in those
countries. This program provides real-world data on estimated outcomes with
ibrutinib across a large, global MCL population.
Aims: To use real-world data from the ibrutinib MCL NPP to investigate whether
treatment benefits reported in randomized clinical trials are reflected in out-
comes observed in clinical practice.
Methods: In an analysis of ibrutinib ordering/reordering, we estimated patient
time on treatment, in order to provide a conservative approximation of progres-
sion-free survival (PFS) using Kaplan-Meier analysis and Cox proportional haz-
ard regression. Reordering data were censored at the date of last ibrutinib sup-
ply or resupply (ibrutinib was resupplied every 1-3 months depending on stage
of the NPP). Patients transferring to commercial ibrutinib after approval were
censored at the time of NPP closure in their country.
Results: In total, 715 patients with MCL from 26 countries enrolled in the NPP
were included in this analysis; median age was 70 years, and 76.1% were
male. After 12 months, 52.3% (95% CI, 43.5-60.4%) of the global population
remained on treatment. This estimate is similar to the 12-month time on treat-
ment (57.6% [95% CI, 48.9-65.3%]) and PFS (58.0% [95% CI, 49.3-65.7%])
rates observed in the phase 3 RAY (MCL3001) study of ibrutinib for
relapsed/refractory MCL (inclusion criteria were similar for the MCL NPP and
RAY). Moreover, Kaplan-Meier curves for time on treatment for the global MCL
NPP population and the RAYstudy population were not statistically different
(Figure 1; MCL NPP versus RAY: HR, 1.14 [95% CI, 0.83-1.54]). Limited base-
line demographic information collected at NPP enrollment allowed an explo-
ration of time on treatment via multivariate analysis (Figure 2).
Figure 1. Time on treatment for Global MCL NPP population versus RAY.
Figure 2. Multivariate analysis of time on treatment.
Timing of MCL diagnosis was the only independently significant variable in the
multivariate analysis, with time on treatment being longer in patients diagnosed
with MCL within the last 2 years. Of note, in this analysis, neither refractory dis-
ease (defined as no response to prior therapy [ie, stable disease or progres-
sion]), advanced disease (involvement of the bone marrow, extranodal sites,
or both), relapsed disease, nor prior response with the previous therapy addi-
tionally impacted time on treatment. In total, 168 patients (23.5%) discontinued
treatment during the observation period, the most common reasons being death
(10.8%), disease progression (7.3%), and AEs (1.3%).
Summary/Conclusions: Although NPP data are based on physician declara-
tions and are unmonitored, this analysis provides a real-world estimate of time
on treatment, which can be considered a conservative proxy for PFS. The esti-
mates, determined from a large, global MCL population, were similar to those
for the RAY study, which suggests that results observed in MCL clinical trials
with ibrutinib are reproducible in clinical practice.
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A SPECIFIC SIGNATURE IN LYMPH NODE BIOPSIES OF PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PREDICTS CENTRAL
NERVOUS SYSTEM (CNS) INVOLVEMENT
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Background: The infiltration of immunoprivileged sites, including the central
nervous system, either at diagnosis or at relapse, confers an ominous outcome
to the patients with DLBCL. A specific gene expression profiling (GEP) has
been identified for primary CNS lymphomas (pCNSL). Similarly, GEP studies
could help in selecting DLBCL patients with high risk for CNS infiltration. 
Aims: To identify a GEP “CNS signature” in the lymph nodes of patients with
DLBCL that can predict CNS involvement.
Methods: GEP analysis (Affymetrix HG-U219) was performed in 11 cases of
DLBCL patients with CNS infiltration (3 cases at diagnosis and 8 during the fol-
low up). The control group consisted of 27 DLBCL, not otherwise specified,
without extranodal involvement, that showed no CNS infiltration during follow
up. No case of transformed or immunodeficiency -related DLBCL was included
in the control group. Lymph node samples at diagnosis were used in both
groups. Differential gene expression between the two subgroups was analyzed
using the Limma package (bioconductor.org, R version 3.2.0), and biological
pathways assignment was performed by Gene set enrichment analysis (GSEA)
using custom gene sets related to B cell biology, canonical pathways (C2CP)
and transcription factor (C3TFT) public databases.
Results: Our analysis (log fold change >1,5 and P<0.05) identified 25 upreg-
ulated genes in the CNS group (Figure 1), including SRRM2, SRSF5 and
TRA2A (involved in splicing), EVL (cell motility), MKI67 and TRIB2 (associated
with brain metastasis in other cancers) and BCL6 (associated with pCNSL);
and 11 downregulated genes, including LSP1 (implicated in transendothelial
migration of leukocytes). Pathway analysis with GSEA (False discovery rate
(FDR) <0.05 and Normalized enrichment score (NES) >1.8) revealed that the
CNS group showed an overrepresentation of signaling pathways related to: 1)
extracellular matrix molecules, migration (FAK) and adhesion-related pathways
(integrins), 2) angiogenesis, 3) cell proliferation (E2F) and 4) NOTCH (Table
1). Immunohistochemistry analyses to validate these findings are ongoing.
Table 1.
Pathway name                                                          Number of genes    NES     FDR q-val
ECM-migration adhesión patwhays
NABA_BASEMENT_MEMBRANES                                            40                2.5       <0.001
PID_INTEGRIN1_PATHWAY                                                      66               2.21      <0.001
KEGG_ECM_RECEPTOR_INTERACTION                                     83               2.18      <0.001
KEGG_FOCAL_ADHESION                                                      197              2.15      <0.001
NABA_COLLAGENS                                                                43               2.08       0.001
PID_AVB3_INTEGRIN_PATHWAY                                              75               2.07       0.001
PID_FAK_PATHWAY                                                                 59               1.93       0.006
Angiogenesis
REACTOME_SIGNALING_BY_PDGF                                         118              1.89       0.008
PID_LYMPH_ANGIOGENESIS_PATHWAY                                   25               1.89       0.008
PID_VEGFR1_2_PATHWAY                                                      69               1.87        0.01
Cell cycle
V$E2F_Q4                                                                           230              1.97      <0.001
NOTCH pathway
REACTOME_SIGNALING_BY_NOTCH                                       100              1.96       0.004
REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING     42               1.98       0.004
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Figure 1.
Summary/Conclusions: The CNS signature identified in our study at diagnosis
could represent a specific feature of DLBCL patients with high risk for CNS
involvement. If confirmed, these findings could better guide initial treatment of
these patients to improve their outcome.
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DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: REAL LIFE
ANALYSIS OF PATIENTS WITH REFRACTORY DISEASE OR RELAPSE
B Arboe*, JS Gørløv, P Brown
Department of Hematology, Copenhagen Uiversity Hospital, Rigshospitalet,
Copenhagen, Denmark
Background: The addition of Rituximab as part of first line treatment for diffuse
large B- cell lymphoma (DLBCL) has improved outcome. However, in the case
of refractory disease or relapse, high dose chemotherapy with autologous stem
cell transplant (ASCT) is regarded the only curative option. 
Aims: To analyze treatment and outcome for patients with DLBCL with primary
refractory or relapsed disease in the Rituximab Era.
Methods: Patients diagnosed with de novo DLBCL in the period 2000-2013
were identified in the Danish National Lymphoma Registry. Patients not
responding to first line treatment or who subsequent developed relapse were
included. Patients with primary CNS lymphoma were excluded. Survival analy-
sis was performed according to the Kaplan Meier method and compared by
log-rank tests. Survival time was measured from date of relapse to death or
censored at the time of analysis.
Results: A total of 5203 patients were diagnosed with DLBCL in the study peri-
od. Median age was 68 years, and 56% were male. In 4842 patients a first line
treatment was started. 3295 patients were treated with Rituximab containing
treatment. 2852 (86%) achieved partial remission or better after first line ther-
apy, however 443 (14%) had primary refractory disease, and 446 (14%)
patients developed relapse (CNS involvement n=90, other lymphoma subtype
n=68). The median overall survival was 8.8 years. Of the 731 patients with
either primary refractory or relapsed disease, 330 received a second line treat-
ment; 242 received salvage therapy, of these 89 patients completed ASCT.
After 2 years, 46 patients receiving ASCT were still alive. Intention to treat
analyses reveals significantly better outcome for patients with relapsed dis-
eased treated with salvage strategy compared to those treated with palliative
strategy (p=0.03). However, no difference was seen for the patients with primary
refractory disease (p=0.3), Figure 1. As expected, patients with primary refrac-
tory disease not receiving ASCT had a dismal survival compared to patients
with later relapse (p=0.003), but no significant difference was found in the group
receiving ASCT. For the 1547 patients not treated with Rituximab, 1143 (73%)
achieved partial remission or better, however 404 (27%) had primary refractory
disease, and 344 (22%) developed relapse (CNS involvement n=37, other lym-
phoma subtype n=32). The median overall survival was 2.3 years. Of the 681
patients with primary refractory or relapsed disease, a total of 150 patients
received second line treatment, 113 patients received salvage therapy and of
them 37 patients also received ASCT. After 2 years, 28 patients receiving ASCT
were still alive. Of the patients not receiving ASCT, 41 patients were still alive
after 2 years. In both groups, patients with primary refractory disease had dis-
mal survival compared to patients with later relapse (p=0.007 vs p=0.03).
Figure 1. Survival for patients with primary refractory disease (A) and
relapsed disease (B) based on intention to treat analyses.
Summary/Conclusions: The addition of Rituximab has significantly improved
outcome after first line treatment for DLBCL, and the incidence of relapse has
decreased. In the relapse setting, salvage with ASCT has been the standard
second line treatment for DLBCL for over 20 years, but only 38% of the patients
treated with salvage strategy did actually receive ASCT. Intention to treat analy-
ses show, that patients intended to receive ASCT have significantly better out-
come, but patients not being eligible for ASCT actually had a 2 year survival of
31%. This shows that patients with relapse of DLBCL do have a chance to sur-
vive although not being eligible for ASCT.
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CENTRAL NERVOUS SYSTEM INTERNATIONAL PROGNOSTIC INDEX IN
DIFFUSE LARGE B-CELL LYMPHOMA
N Tomita1,2,*, M Yokoyama1,3,4, W Yamamoto5, R Watanabe6, Y Shimazu7,
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hama City University Medical Center, Yokohama, 20Hematology and Rheuma-
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tology, Nihon University School of Medicine, Tokyo, 21Internal Medicine, Sasebo
City General Hospital, Sasebo, 22Hematology and Oncology, Nagoya University
Graduate School of Medicine, Nagoya, 23Hematology, Tokyo Medical and Den-
tal University, Tokyo, 24Hematology/Immunology, Fujisawa City Hospital, Fuji-
sawa, 25Pathology Project for Molecular Targets, Cancer Institute Japanese
Foundation for Cancer Research, Tokyo, Japan
Background: The central nervous system (CNS) is a sanctuary for lymphoma
cells. Once CNS involvement in lymphoma occurs, it is almost fatal. CNS
involvement is thought to be a rare but important complication in the lymphoma’s
clinical course. We previously demonstrated that the involvement of the breast,
adrenal gland, and/or bone was an independent risk factor for CNS involvement
based on clinical data in 1,221 patients with diffuse large B-cell lymphoma
(DLBCL) treated with R-CHOP (Cancer Sci 2012). Afterward, several groups
proposed a new prognostic model consisting of 6 factors, including the 5 risk
factors in the International Prognostic Index, and involvement of kidney/adrenal
gland, predicting the risk of secondary CNS involvement (Schmitz N, et al.
2013, Savage KJ, et al. 2014, and El-Galaly, et al. 2015).
Aims: To validate the usefulness of this prognostic index using our previously
fixed data in DLBCL patients who did not receive any CNS prophylaxis.
Methods: Clinical data of untreated, de novo DLBCL patients were collected
in 2010 from 47 institutions in Japan. Included patients had been treated with
R-CHOP therapy as the primary treatment between 2003 and 2006. Clinical
data collected were the presence or absence of 26 extranodal sites including
the kidney and adrenal gland, along with factors including age, sex, clinical
stage, serum lactate dehydrogenase (LDH) level, performance status (PS),
bulky mass, and B symptoms. Patients who received any CNS prophylaxis
were excluded. Patients with primary CNS involvement or with distinct forms
of DLBCL, such as intravascular lymphoma, primary effusion lymphoma, and
primary mediastinal large Bcell lymphoma were also excluded.
Results: A total of 1,220 CD20-positive DLBCL patients with complete infor-
mation related to risk factors were available (data from 1 patient was withdrawn
due to an error in one of the items mentioned). Patient characteristics were as
follows: 62% were aged >60 years, 55% had elevated LDH, 46% had advanced
stage disease, 21% had PS >1, 20% had >1 extranodal sites, and 4% (n=51)
had kidney/adrenal involvement. With a median follow-up of 48 months in living
patients, 82 (6.7%) cases of CNS involvements were observed. More than half
of the CNS involvement was the parenchymal type (53.7%), followed by the
leptomeningeal type (31.7%) and both (14.6%). Systemic (except for CNS)
lymphoma status at CNS involvement was as follows: 38 (46%) patients were
in the first complete remission (CR), 8 (10%) patients were in the second or
more CR, and 36 (44%) patients were in non-CR. The median time interval
between the initiation of therapy and CNS involvement was 9 months. In the
51 patients with kidney/adrenal involvement, 9 (18%) developed CNS involve-
ment. According to sum of the above-mentioned 6 factors, patients were cate-
gorized into 3 CNS-risk categories of 0-1 (n=483, 40%), 2-3 (n=504, 41%), and
4-6 (n=233, 19%), which represented low-, intermediate-, and high-risk groups,
respectively. The cumulative incidence of CNS involvement at 2 years was
1.4% for low-risk, 5.9% for intermediate-risk, and 12.9% for high-risk patients,
respectively (Figure 1).
Figure 1. Cumulative risk of CNS involvement according to CNS-IPI.
Summary/Conclusions: The prognostic model for CNS involvement (CNS-
IPI) was useful in a DLBCL patient cohort treated with R-CHOP and without
any CNS prophylaxis.
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BETTER PROGNOSTICATIONS WITH INTERIM PET/CT RESPONSES
BASED ON METABOLIC TUMOR VOLUME COMPARED TO VISUAL AND
SUV-BASED ASSESSMENTS IN THE PATIENTS WITH DLBCL WITH
EXTRANODAL INVOLVEMENTS
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DH Yang4
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Background: 18F-FDG PET is currently used in diffuse large B-cell lymphoma
(DLBCL) for staging and evaluation of therapeutic efficacy at various time
points. Nevertheless, the predictive value of interim PET/CT (iPET/CT) has not
been consistent throughout the studies. Particularly, iPET/CT assessment in
patients with multifocal, non-contiguous involvement at extranodal (EN) sites
may result in a false determination of prognosis due to tracer uptake of inflam-
matory or physiologic anatomic sites.
Aims: The purpose of this study is to investigate the predictive accuracy of
iPET/CT response based on visual, quantitative SUV-based and MTV-based
assessment in patients with DLBCL and EN involvements.
Methods: iPET/CT responses for 163 patients with newly diagnosed DLBCL
and EN involvements were investigated retrospectively. iPET/CT responses
were based on the visual, SUV-based and MTV-based assessments. The
assessment of PET/CT was performed at the time of diagnosis, at the third or
fourth cycles and at the completion of R-CHOP. For visual assessment, the
five-point scale (5-PS) based on the Deauville criteria was used and graded as
negative (grade 1-3) or positive (grade 4-5) by comparison with initial PET/CT
scan. Second, the quantitative analysis of 18F-FDG uptake changes was based
on the percentage of SUVmax reduction (ΔSUVmax) and the rates of reduction
in the metabolic tumor volume (ΔMTV2.5) between initial and interim PET/CT
scans. The cutoff point of ΔSUVmax was 65.7% and that of ΔMTV2.5 was
99.3% based on previous reports.
Results: Median age was 61 years (range 18-83 years) and 88 patients
(54.0%) in advanced disease (III/IV). Patients were classified according to the
IPI risk with 95 patients (58.3%) being classified as low or low-intermediate
and 68 patients (41.7%) as high-intermediate or high risk. Number of extranodal
site(s) were 1 site in 102 patients (62.6%), 2 sites in 39 (23.9), 3 sites in 18
(11.0), and 4 sites in 4 (2.5%). iPET/CT responses based on visual analysis
were classified into grade 1-3 in 99 patients (60.7%) and grade 4-5 in 64
(39.3%), and based on SUV-based, classified into higher the cutoff of ΔSUVmax
(>65.7%) in 140 patients (85.9%) and lower (<65.7%) in 23 patients (14.1%),
respectively. Among the patients with MTV2.5 data (n=110), higher ΔMTV2.5
(>99.3%) was observed in 81 patients (73.6%) and lower ΔMTV2.5 (<99.3%)
in 29 (26.4%). On visual assessment, iPET/CT-positive patients had no differ-
ence of relapse rates (28.3±5.4%) compared to those of iPET/CT-negative
patients (23.1±4.5%) (p=0.419). Among the patients with 5-PS grade 4-5, higher
the optimal cutoff of ΔSUVmax (>67.5%) and ΔMTV2.5 (>67.5%) were achieved
in 46 patients (71.9%) and 18 (22.2%). The 5-year overall survival (OS) rates
and progression free survival (PFS) rates were 75.6±3.8% vs 60.6±11.7%
(p=0.056), and 77.9±3.7% vs 55.9±12.1% (p=0.007) depending on the cutoff
of ΔSUVmax, respectively. Based on the cutoff of ΔMTV2.5, the 5-year OS
rates were 77.1±4.8% and 61.9±9.1% (p=0.046), and the 5-year PFS rates
were 80.2±4.6% and 64.4±9.0% (p=0.020). In the multivariate analysis, age at
diagnosis, ECOG PS 2-4, EN involvement >1 site, and lower ΔMTV2.5
(<99.3%) were unfavorable factors for predicting PFS and OS.
Summary/Conclusions: The MTV2.5-based assessments in iPET/CT could
have significant potential as a prognostic predictor of PFS and OS than visual
assessment or SUVmax reduction in patients with EN involvements. However,
the visual assessments have the limitations to predict long-term outcomes with
high false positive rates at EN involvements. The quantitative SUV-based
assessments in iPET/CT were significant prognostic predictor of PFS and OS,
especially in the patients with 1 EN site involvement. However, the visual
assessments have the limitations to predict long-term outcomes with high false
positive rates at EN involvements.
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DETECTION OF BONE MARROW INVOLVEMENT OF DLBCL - COMPARISON
OF PET-CT AND BONE MARROW BIOPSY
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Background: In malignant lymphoma, bone marrow involvement is considered
as clinical stage IV, which adversely affects International Prognostic Index.
Detecting bone marrow lesion is therefore important in staging of malignant
lymphoma. Bone marrow biopsy (BMB) has been a classical method to detect
bone marrow infiltration. Recently, positron emission tomography combined
with computed tomography (PET-CT) became a routine tool in staging of malig-
nant lymphoma. Especially, in diffuse large B cell lymphoma (DLBCL), PET-CT
shows high sensitivity of detecting viable nodal and extra-nodal lesions.
Aims: The aim of this retrospective study is to evaluate the diagnostic accuracy
of PET-CT in detecting bone marrow infiltration in patients with newly diagnosed
DLBCL.
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Methods: We collected data from all patients who were newly diagnosed with
DLBCL from January 2005 to October 2015 at Yokohama City University Hos-
pital, and Yokohama City University Medical Center. Patients with DLBCL who
underwent both PET-CT and BMB prior to the initiation of treatments were
finally included in the analysis. Bone marrow biopsy: Results of unilateral BMB
of posterior iliac crest were collected from written reports. BMB specimens
were evaluated by hemato-pathologists of each institution. The presence of
lymphoma cells in the bone marrow was based on morphological and immuno-
histochemical findings. PET-CT analysis: Written reports were used to collect
PET-CT data. Interpretation of images was made by radiologists of each insti-
tution where PET-CT scans were performed. Bone marrow involvement in PET-
CT was defined as greater intensity of FDG uptake in the bone marrow than
those in liver. This study was approved by the Internal Review Board of Yoko-
hama City University Graduate School of Medicine.
Results: In total, 430 patients were newly diagnosed with DLBCL from January
2005 to October 2015. Of 430 patients, 254 underwent both PET-CT and BMB
before treatment who were evaluated in the further analysis. Median age at
diagnosis was 68 years (range: 21-93). Four patients were diagnosed with
intravascular lymphoma, and 4 with primary mediastinal large B cell lymphoma.
All other patients were diagnosed with DLBCL, not otherwise specified (NOS).
Bone marrow FDG uptake was elevated according to the defined criteria in 23
patients (9%), while the infiltration of lymphoma cells in the bone marrow was
detected by BMB in 26 patients (10%). Of 23 patients with elevated PET uptake
in the bone marrow, 6 (32%) patients were diagnosed as negative for bone
marrow infiltration by BMB. Among the 6 patients who were positive for PET-
CT and negative for BMB, the pattern of FDG uptake in the bone marrow was
focal in 3, diffuse in 1, and unknown in 2 (Figure 1). The patient with diffusely
increased bone marrow FDG uptake had chronic myelogenous leukemia prior
to diagnosis of DLBCL. Among the 26 patients positive for BMB, bone marrow
FDG uptake was increased in 17 (65%). The remaining 9 BMB positive patients
were negative for PET-CT. Of 17 patients positive for both BMB and PET-CT,
the pattern of FDG uptake in the bone marrow was diffuse in 8, focal in 5, and
unknown in 4.
Figure 1. Study flow diagram, and comparison between PET-CT and bone
marrow biopsy in detection of bone marrow involvement.
Summary/Conclusions: In conclusion, our study revealed that significant
number of patients showed discrepancy between the results of PET-CT and
BMB in detecting bone marrow involvement of lymphoma cell. Although PET-
CT is highly sensitive tool for detecting viable lymphoma cells and is commonly
used for staging in routine practice, our data indicated that PET-CT still cannot
replace BMB for identifying lymphoma cells in the bone marrow.
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PILLAR-2: PHASE 3 STUDY OF ADJUVANT EVEROLIMUS VERSUS
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COMBINED CHEMOTHERAPY
F Cavalli1,*, K Tobinai2, L Rigacci3, T Lin4, T Ikeda5, A Vanazzi6, M Hino7,
Y Shi8, J Mayer9, LJ Costa10, CD Bermudez Silva11, J Zhu12, D Belada13,
K Bouabdallah14, JG Kattan15, C Wu16, J Fan16, AL Louveau17, M Voi16,
TE Witzig18
1Oncology Institute of Southern Switzerland, Bellinzon, Switzerland, 2Depart-
ment of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3Hema-
tology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy,
4Cancer Center Sun Yat Sen University, Guangzhou, China, 5Division of Hema-
tology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka,
Japan, 6Division of Clinical Haemato-Oncology, Istituto Europeo di Oncologia,
Milan, Italy, 7Department of Clinical Hematology and Diagnostics, Osaka Uni-
versity Graduate School of Medicine, Osaka, Japan, 8Department of Medical
Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Med-
ical Sciences & Peking Union Medical College, Beijing, China, 9University Hos-
pital Brno, Brno, Czech Republic, 10University of Alabama, Birmhingham, Unit-
ed States, 11Instituto Nacional de Cancerologia, Bogota, Colombia, 12Beijing
Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Bei-
jing, China, 13Fourth Department of Internal Medicine - Hematology, Charles
University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic,
14Department of Haematology, CHU Haut-Lévèque, Bordeaux, France, 15Hotel
Dieu De France University Hospital, Beirut, Lebanon, 16Novartis Oncology,
Novartis Pharmaceuticals Corporation, East Hanover, United States, 17Novartis
Pharma, Paris, France, 18Mayo Clinic, Rochester, United States
Background: The high-risk of relapse in patients (pts) with diffuse large B-cell
lymphoma (DLBCL) who achieved a complete response (CR) to first-line ritux-
imab-based chemotherapy (R-chemo) highlights the need for effective treat-
ments to improve outcomes.
Aims: The phase 3 PILLAR-2 (NCT00790036) study aimed to reduce DLBCL
relapse after 1 year of adjuvant everolimus (EVE) treatment to poor-risk patients
(International Prognostic Index [IPI] ≥3) who had achieved a CR with R-chemo.
Methods: Pts with histologically confirmed stage III/IV poor-risk (IPI ≥3) DLBLC
who had a PET/CT-confirmed CR to first-line R-chemo were randomized 1:1
to EVE 10 mg/day or placebo (PBO) for 1 year or until disease relapse, unac-
ceptable toxicity, or death. The primary endpoint was disease-free survival
(DFS) by local assessment using revised IWRC. Secondary endpoints were
overall survival (OS), lymphoma-specific survival (LSS), and safety.
Results: Enrolled pts (N=742) were randomly assigned to EVE (n=372) or PBO
(n=370). Among randomized pts, 48% in the EVE arm and 67% in the PBO arm
completed study treatment per protocol. The main reasons for discontinuation
were AEs (EVE, 30%; PBO, 12%) and relapsed disease (EVE, 7%; PBO, 13%).
Median follow-up was 50.4 months (range, 24.0–76.9 months). Overall, 47% of
pts were ≥65 years, 50% were men, and 42% had an IPI of 4+5. In the primary
analysis DFS was not significantly different between EVE and PBO (Log-rank
p=0.276). The 2-year DFS rates (95% CI) were 78% (73-82%) with EVE and
77% (72-81%) with PBO. The 2-year OS rates were 91% with EVE and 88%
with PBO (Hazard Ratio [HR], 0.75; 95% CI: 0.51-1.10). Results of exploratory
subgroup analyses showed a trend favoring EVE over PBO for both DFS and
OS in pts with IPI 4+5, in males, and in pts <65 years of age (Table 1). There
was also a trend favoring EVE over PBO for LSS (Table 1). Common grade 3/4
AEs with >3% difference for EVE vs PBO included neutropenia, stomatitis, CD4
lymphocytes decreased, lymphopenia and anemia. During study treatment, 5
pts in the EVE arm and 2 pts in the PBO arm died.
Table 1.
Summary/Conclusions: Adjuvant EVE for 1 year did not improve DFS in poor-
risk pts with DLBCL who achieved a CR after R-chemo. Trends favoring adju-
vant EVE for DFS and OS in selected pt subgroups and for LSS in the overall
population suggest that EVE may provide anti-lymphoma activity in poor-risk
DLBCL that warrants further investigation.
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Background: Acute graft versus host disease (aGVHD) remains a life-threat-
ening complication and substantially reduces efficacy of allo-HSCT. In particular,
the outcome of patients with severe steroid-refractory aGVHD continues to be
poor. Administration of Mesenchymal Stromal Cells (MSC) has been reported
by others and us as an interesting treatment option. However, variability in
products and the inability to link surrogate markers of the product to clinical
efficacy could prove to be a major threat in daily clinical practice.
Aims: Evaluate the impact of MSC donors as well as donor properties such as
age on the outcomes clinical response and overall survival.
Methods: We evaluated the impact of individual donors as well as donor prop-
erties such as age on clinical response in a cohort of 102 patients with grade
II-IV steroid refractory aGVHD treated with bone marrow derived MSC from
third party non-HLA matched donors. Primary outcome measures were one
year overall survival (OS) and response of GVHD. Cox proportial hazards mod-
els, competing risk analyses (Gray’s test) and Kaplan Meier estimates were
used for analyzing response and OS respectively.
Results: 102 patients received in total 299 MSC infusions derived from 10 dif-
ferent BM donors. Median number of infusions was 3 (range 1-4). 75,5% of
patients received all MSC infusions from the same donor, 20,6% with MSC
from 2 donors and 3,9% with MSC from 3 different donors. Two donors were
used to treat 28,4% and 43,1% of patients respectively. When testing impact
on one year OS of an individual product no differences between patients treated
with either the 2 main contributing donors or the patients treated with the ‘other’
MSC donors could be observed. However, when donor age was used to cluster
cohorts (donor age <and >10 years) differences were observed (Figure 1) with
a survival benefit for patients treated with young donors. Competing risk analy-
sis also revealed a significant benefit for patients only treated with young
donors. Furthermore in multivariate analysis, MSC donor age remained pre-
dictive for OS (HR 2,00, p-value 0,025).
Figure 1. One year overall survival estimation by means of Kaplan Meier
depending on age of MSC donor used.
Summary/Conclusions: In our cohort of 102 patients with steroid refractory
acute GVHD that were treated with MSC we observed differences in both
achieving complete resolution of GVHD symptoms as in OS. Patients only treat-
ed with MSC derived from very young bone marrow donors (<10 years old)
had significantly better resolution of GVHD symptoms as well as an improved
OS. These findings may have implications for both future as well as currently
ongoing clinical trials with MSC.
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CHRONIC GRAFT-VERSUS-HOST-DISEASE AND B-CELL RECONSTITUTION
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
V Wiegering1,*, K Haas2, M Frietsch3, W Matthias1, PG Schlegel1, M Eyrich1
1Pediatric stem cell transplant program, University Children’s Hospital, 2Depart-
ment of Biometry, University Medical Center, 3stem cell laboratory, University
Children’s Hospital, Wuerzburg, Germany
Background: Hematopoetic stem cell transplantation (HSCT) is an established
therapy for many pediatric hematological diseases. Besides relapse, chronic
GvHD (cGvHD) is the most important determinant of posttransplant morbidity
and mortality. Although the precise mechanisms underlying cGvHD are not
completely understood so far, convincing evidence suggests an important con-
tribution of B-cells in cGvHD pathophysiology. Multiple studies in adult cGvHD
patients have described altered patterns of B-cell reconstitution.
Aims: Since data on B-cell reconstitution and cGvHD in children, who generally
show different kinetics of immune reconstitution than adults, are lacking so far,
we wanted to investigate this relationship in a purely pediatric cohort of
alloHSCT recipients.
Methods: First, in a retrospective cohort of 104 pediatric alloHSCT recipients
transplanted between 2005 and 2013, we analyzed 2151 flow cytometric
immune profiles. To identify differences in lymphocyte distribution in children
with and without GvHD over time we applied hierarchial linear analysis. Second,
in a prospective cohort of 74 children, we investigated more closely the distri-
bution of B-cell subsets, cytokine production in B- and T-cells, serum cytokine
levels including BAFF, autoantibody production and apoptosis resistance of
peripheral B-cells.
Results: In the first retrospective cohort, median age was 8.9±7.0 years. Inci-
dence of cGvHD was 15%, median time to onset was 132±198days. In a uni-
variate analysis, risk factors for cGvHD were: a history of previous aGvHD,
radiation-based conditioning and a donor-host sex mismatch. As expected,
relapse rate was significantly lower in cGvHD patients. Hierarchial linear analy-
sis showed that children later experiencing cGvHD had elevated T-cell frequen-
cies during the first 180 days (63±17 vs 45±23% CD3+ in children with vs
without cGvHD, resp.). In contrast, B-cells were significantly lower in cGvHD
children once cGvHD had occurred. Interestingly, reconstitution of naïve T-cells
was delayed but not abrogated in children with cGvHD, reaching a mean of
44±17% of naïve T-cells in the CD4+ compartment after 2 years postHSCT
(compared to 58±15% in children without GvHD). A more detailed analysis of
B-cell subsets in the prospective cohort revealed that the lower number of B-
cells in cGvHD children were due to a defect in naïve B-cell regeneration. Mem-
ory and CD24++CD38++ transitional B cells were expanded. We detected
autoantibodies (mainly ANAs) in 88% of cGvhD children, compared to 13% in
children without cGvHD. In approx. 50% of cGvHD children these autoantibod-
ies became negative after 2 years postHSCT. Apoptosis resistance is a mech-
anism also operational in pediatric cGvHD, as B-cells from cGvHD children
showed reduced rates of apoptosis after 48h in culture, a phenomenon that
could be induced by exogenous BAFF in a dose dependent way. In contrast to
what has been reported in adults, serum BAFF levels were not elevated con-
tinuously during cGvHD, but progressively declined over time. A detailed analy-
sis of bone marrow B-cell precursor subsets has been performed, which is cur-
rently under biometrical evaluation.
Summary/Conclusions: Our data represent the first large and comprehensive
data set on B-cell reconstitution and cGvHD in a purely pediatric cohort. We
confirm patterns of B-cell dysbalance which have been described in adult
cGvHD patients before. However, other features such as the preserved thymic
reconstitution despite cGvHD and the rapid decline of BAFF and autoantibodies
are in contrast to previous reports. Thus, the higher regenerative capacity of
children seems to have a significant impact on the disturbed B-cell homeostasis
in cGvHD.
P707
A NOVEL QUANTITATIVE PCR APPROACH TARGETING INSERTION/
DELETION POLYMORPHISMS (INDEL-PCR) FOR CHIMERISM QUANTIFICATION:
FINALLY HIGH SENSITIVITY AND QUANTIFICATION CAPACITY TOGETHER
A Navarro-Bailón1,*, C Martínez-Laperche1, D Carbonell1, E Buces1,
M González-Rivera2, M Bastos1, P Balsalobre12, M Kwon1, D Serrano1,
J Anguita1, J Gayoso1, JL Díez-Martín1, I Buño1
1Haematology, Hospital General Universitario Gregorio Marañón, 2Instituto de
Investigación Sanitaria Gregorio Marañón, Madrid, Spain
Background: Post-hematopoietic stem cell transplantation (SCT) chimerism
monitoring is important to assess engraftment, anticipate relapse and provide
information on the development of graft versus host disease, facilitating thera-
peutic intervention.
Aims: The aim of this study was to test the technical efficacy and clinical utility
of a novel quantitative PCR approach targeting insertion/deletion polymor-
phisms (indel-PCR).
Methods: This study included 157 samples (81 bone marrow, 60 peripheral
blood (PB), 11 T-cells, 2 myeloid cells, 2 CD34-cells, 1 NK-cells purified using
immunomagnetic technology) of 24 patients who underwent SCT for haemato-
haematologica | 2016; 101(s1) | 283
Copenhagen, Denmark, June 9 – 12, 2016
logical malignancies. Additionally, 2 sets of 11 artificial mixtures were created
using PB leukocytes of two healthy subjects (a male and a female) with known
percentages of male leukocytes (putative recipient): 100, 75, 50, 25, 10, 5, 3,
1, 0.1, 0.01, 0. Chimerism analysis was performed by the gold-standard STR-
PCR (AmpFlSTR SGM Plus®, Life Technologies, USA) and by indel-PCR (Men-
type® DIPscreen, Mentype® DIPquant, Biotype, Germany). Concordance
between both methods was calculated with SPSS using intraclass correlation
coefficient.
Results: The number of informative loci identified with indel-PCR (>3/patient)
was higher than with STR-PCR for all patients. Concordance between both
methods for the 157 patient samples and 11 artificial mixtures was “very good”
(intraclass correlation coefficient=0.96). Of note, analysis of artificial mixtures
provides evidence of significantly (≥2 logs) higher sensitivity by indel-PCR
(0.01%) than by STR-PCR (1%, Figure 1). Moreover, indel-PCR shows
unprecedented quantification capacity (Figure 1). Out of the 168 samples ana-
lyzed, 32 were positive and 15 negative by both methods, while 121 were pos-
itive only by indel-PCR (95% with <1% recipient). Clinical outcome and
chimerism dynamics of 24 patients are described in Figure 1, data of 4 of them
were censored (engraftment failure, disease progression, insufficient number
of samples). All the samples presented complete donor chimerism by STR-
PCR. Of the 9 patients who showed stable or decreasing percentage of recip-
ient cells, only one (11%) presented extramedulary relapse. Of the 11 patients
who presented increasing percentage of recipient cells in one determination,
relapse occurred in 5 patients (45%, 3/6 patients who did not have further
determinations, 2/4 who showed stable or decreasing recipient cell percentage,
and 0/1 patient who presented increasing recipient cells in subsequent deter-
minations).
Figure 1. Analysis or artificial mixtures.
Summary/Conclusions: This novel indel-PCR is a simple and accurate tech-
nique that, in comparison with the current gold standard STR-PCR, shows very
good concordance and provides higher rates of informative loci per patient, as
well as unprecedented combined sensitivity and quantification capacity. Such
features allow minutely monitoring chimerism dynamics and might improve clin-
ical management of transplanted patients, specially predicting relapse in those
patients who do not have a molecular marker available for disease follow up.
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A NEW APPROACH OF DUAL-SCT WITH UNMANIPULATED HAPLO-
IDENTICAL GRAFT AND UNRELATED CORD BLOOD IN PATIENTS WITH
HEMATOLOGICAL DISORDERS
J Chen*, Y Xu, S Chen, X Wang, Y Wang, S Ma, A Sun, H Qiu, Y Han, X Tang,
C Fu, F Chen, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Dual-SCT with T-cell depleted haplo-identical graft and cord
blood (CB) has developed in recent years, which revealed a promising out-
come. In China, graft manipulation is seldom performed, so we proposed an
alternative dual-SCT strategy with unmanipulated haplo-identical graft co-infus-
ing with unrelated CB unit, and published an encouraging outcome based on
preliminary results.
Aims: Here we reported the recent updates of this prospective study.
Methods: This is an on-going prospective study approved by local Ethics Com-
mittee. The main inclusion and exclusion criteria are: (1) definitely diagnosed
as hematological disorders; (2) with an indication of allo-SCT; (3) without an
available matched related or unrelated donor. Myeloablative conditioning of
either modified Bu/Cy regimen or modified TBI/Cy regimen was applied. Selec-
tion of donor, conditioning, GVHD prophylaxis and supporting care follows the
principles described previously. In order to identify the superiority of dual-SCT,
data of patients receiving haplo-identical donor transplantation in the same
time frame were analyzed as parallel control in this report.
Results: From January 2011 through December 2014, 219 patients were
recruited in this study including patients with AML (29%), ALL (38%), MDS
(10%), SAA (10%) and other diseases. The median age was 26 (15-60) years
old. The median counts of MNC was 10.5×108/Kg in haplo-identical graft and
1.83×107/Kg in cord blood unit, respectively. Only 4 patients achieved stable
engraftment of CB unit. Univariate analysis in the study cohort suggested that
lower MNC count (less than 12×108/Kg) in haplo-identical graft was related to
a significantly lower Grade II-IV aGVHD incidence (P=0.041), lower TRM
(P=0.008) and better survival (P=0.007). Comparing with 5/6 or 6/6 matched
CB unit, 4/6 matched CB unit resulted in higher TRM with a statistical signifi-
cance (P=0.023), and lower OS with marginal significance (P=0.071). Parallel
control group contains 176 patients with roughly comparable baseline char-
acteristics. In the comparison analysis, 2-year TRM was 14.9±3.0% versus
29.4±5.4% for dual-SCT and haplo-SCT (P=0.003), and 2-year relapse inci-
dence was 14.8±3.5% versus 23.3%±4.4% (P=0.011), respectively. Finally,
better 2-year OS (81.5±3.1% versus 64.4±4.2%, P<0.001) and PFS
(79.1±3.0% versus 58.9±4.1%, P<0.001) were observed in dual-SCT group
compared to haplo-SCT. No difference of GVHD incidence was identified
between two groups (Figure 1).
Figure 1.
Summary/Conclusions: Our report showed promising outcomes of dual-SCT
with unmanipulated haplo-identical graft and unrelated CB unit. Lower MNC
count in haplo-identical graft and 5-6/6 matched CB unit were related to a better
prognosis after dual-SCT. Efficacy of this approach merits further confirmation
by longer follow-up, and moreover, by well designed randomized clinical trials.
Besides, probable mechanisms and interactions between stem cells needs to
be explored. 
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RECIPIENT CCR5 GENETIC VARIATION PREDICTS TRANSPLANT
OUTCOMES AFTER HLA-MATCHED UNRELATED DONOR BONE
MARROW TRANSPLANTATION
T Horio1,*, S Mizuno1, M Mizutani1, K Uchino 1, I Hanamura1, JL Espinoza2,
K Matsuo3, M Onizuka4, K Kashiwase5, Y Morishima6, T Fukuda7, Y Kodera8,
N Doki9, K Miyamura10, M Takehiko11, A Takami1
1Hematology, Aichi Medical University School of Medicine, Nagakute, 2Hema-
tology, Kanazawa University Graduate School of Medical Science, Kanazawa,
3Hematology, Aichi Cancer Center Research Institute, Nagoya, 4Hematology,
Tokai University School of Medicine, Isehara, 5Hematology, Japanese Red
Cross Kanto-Koshinetsu Block Blood Center, Tokyo, 6Hematology, Aichi Cancer
Center Research Institute, Nagoya, 7Hematology, National Cancer Center Hos-
pital, Tokyo, 8Hematology, Aichi Medical University, Nagoya, 9Hematology,
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hos-
pital, Tokyo, 10Hematology, Japanese Red Cross Nagoya First Hospital,
Nagoya, 11Hematology, Keio University School of Medicine, Tokyo, Japan
Background: The chemokine receptor CCR5, mainly expressed on
macrophages, dendritic cells, memory T cells, and the endothelium, plays roles
in the adaptive immune response by enhancing the production of antigen-spe-
cific T cells through directing CD8+ T cells to sites of CD4+ T cells and dendritic
interactions. Its genetic variant (rs1800023, -2086 A>G), which resides in the
promoter region, has been reported to be associated with susceptibility to var-
ious infectious diseases, including HIV infection.
Aims: To investigate the impact of CCR5 genetic variation on transplant out-
comes of HLA-matched unrelated donor bone marrow transplantation (BMT).
Methods: CCR5 genotyping was performed on 333 patients with hematologic
malignancies who underwent BMT through the Japan Marrow Donor Program
between January 2006 and December 2009 and their HLA-matched unrelated
donors, and its association with the transplant outcomes was retrospectively
examined.
Results: The genotype frequencies of A/A, A/G, and G/G were 34%, 49% and
17% in the recipients and 35%, 50% and 15% in the donors (P=0.93), respec-
tively. The recipient A/A genotype was associated with a significantly better
overall survival (OS) than the recipient A/G or G/G genotype (69% vs 43%,
P=0.04; Figure 1A). A multivariate analysis showed that the recipient A/A geno-
type has a significantly advantage regarding the OS (hazard ratio [HR], 0.53;
95% confidence interval [CI], 0.30-0.93; P=0.03) and the relapse rate (HR,
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0.45; 95% confidence interval [CI], 0.21-0.97; P=0.04). These effects were not
seen according to the donor CCR5 genotype.
Summary/Conclusions: These results suggest an association between the
recipient CCR5 genotype and the OS and relapse rate after unrelated BMT.
Genotyping for the CCR5 rs1800023 polymorphism could therefore be useful
in predicting the prognoses and risk-adapted management of transplanted
patients and may offer novel therapeutic insights to induce the graft-versus-
tumor effect effectively.
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PRESUMABLY FALSE POSITIVE MINIMAL RESIDUAL DISEASE (MRD)
QPCR RESULTS AFTER ALLOGENEIC SCT UNCOVERED BY NEXT
GENERATION SEQUENCING (NGS)
M Kotrova1,*, K Muzikova1, VHJ van der Velden2, P Sedlacek3, J Stary3,
JJ van Dongen2, M Bruggemann4, J Trka1, E Fronkova1
1CLIP, Department of Pediatric Haematology and Oncology, 2nd Faculty of
Medicine, Charles University and University Hospital Motol, Prague, Czech
Republic, 2Department of Immunology, Erasmus MC, Rotterdam, Netherlands,
3Department of Pediatric Haematology and Oncology, 2nd Faculty of Medicine,
Charles University and University Hospital Motol, Prague, Czech Republic,
4Second Medical Department, University Hospital Schleswig-Holstein, Campus
Kiel, Kiel, Germany
Background: MRD detection using qPCR for IG/TR rearrangements has been
succesfully used in pediatric acute lymphoblastic leukemia (ALL) patients already
for two decades and risk-adapted therapy based on its results has proven to be
highly beneficial. Also MRD after allogeneic stem cell transplantation (SCT) in
relapsed pediatric ALL has been shown to predict subsequent relapse and post-
transplant MRD values have been used for guiding therapeutic interventions. We
have previously shown that MRD detection by qPCR for clonal IG/TR rearrange-
ments can yield false positive results in patients after SCT caused by massive
regeneration of B-cells (Fronkova, Bone Marrow Transplantation, 2008), despite
following strict EuroMRD guidelines for defining the MRD positivity (van der
Velden, Leukemia, 2007). From our previous work (Kotrova, Blood, 2015), we
know that NGS and qPCR have comparable sensitivity for MRD detection. We
hypothesized that NGS of IG/TR rearrangements can distinguish between false
and real positivities and can also identify the source of false positive results.
Aims: To detect MRD by NGS in our pediatric BCP-ALL cases after allogeneic
SCT, who had at least one low-positive (not quantifiable) qPCR MRD result
and remained in complete remission. No therapy intensification was imple-
mented in these patients, except for one of them, who received DLI.
Methods: Sequencing libraries were prepared from 500ng of bone marrow DNA
via a two-round PCR: in the first round rearranged IGH or TRG genes were ampli-
fied using universal primers. In the second round products from the first round
were flanked by sequencing adaptors and sample-specific barcodes. Libraries
were sequenced on Ion Torrent PGM sequencer using the Hi-Q chemistry. For
detection of clonal leukemia-specific IG/TR rearrangements we used our in-house
bioinformatic algorithm. We sequenced 30 qPCR positive (not quantifiable) post-
transplant samples from 18 patients (16 patients carrying 24 IGH and 2 patients
carrying 3 TRG qPCR targets) who remained in complete remission after SCT
with a median follow-up of 10.4 years (range 1.8-15.5). One low-positive post-
transplant sample from patient who later developed CNS relapse was added as
positive control. The median coverage was 500,000 reads/sample.
Results: Besides the positive control patient, only 2 of 30 (7%) follow-up sam-
ples were found to be MRD-positive, defined as the presence of leukemia-spe-
cific sequence(s) as identified at diagnosis in the follow-up samples. One of
the positive samples belonged to patient with the shortest follow-up and unclear
outcome so far (1.8 years). To find the cause of false positive qPCR results we
searched for matches of the clone-specific qPCR primers sequences from sam-
ples which were qPCR positive and NGS negative in all resulting fastq files.
For all primers, similar sequences (with maximally 2 mismatches) were found
in fastq files from different patients, thus likely explaining false positivities by
qPCR analysis.
Summary/Conclusions: Our results indicate that in this specific situation of
massive regeneration post-transplant qPCR can detect false positive results,
despite high degree of standardization and strict rules for defining positivity.
Next generation sequencing of IG/TR rearrangements can solve this problem,
because it provides the sequence of the entire CDR3 region of all rearrange-
ments in the sample, and therefore allows specific identification of the leukemia-
specific sequence. 
Support: NPU I LO1604, GACR P302/12/G101, GAUK 394214, 00064203 (Min-
istry of Health, Czech Republic), AZV 16-32568A.
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PRE-EMPTIVE THERAPY WITH IFN-Α-2B FOR ACUTE LEUKEMIA PATIENTS
WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT
A Wang, F Chen, X Ma, A Sun, X Zhu, H Qiu, Z Jin, S Xue, D Wu, X Tang*
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Relapse still remains the most frequent cause of treatment failure
and mortality. According to the data of CIBMTR, relapse has become the leading
cause of death following allo-HSCT. The high risk patients with more advanced
disease, have a relapse rate of 40–80%.Therefore, prevention and treatment
of relapse post allo-HSCT is the most likely approach to improve survival of
these patients. It is well known that IFN-α had been widely used in the field of
antitumor. Recently it is shown that IFN-α also play an important role in immune
modulation to enhance the effect of GVL.
Aims: In order to investigate the role of IFN-α in the field of prevention and
treatment of acute leukemia relapse post allo-HSCT.
Methods: We dynamically monitored the minimal residual disease of 986 AL
patients who underwent allo-HSCT from January 1, 2006 to March 31, 2014 in
our hospital. There were 98 patients who presented increasing tendency of
MRD and were enrolled in this study and preemptive treatment were performed
once a relapse tendency was detected. pre-emptive therapy was given as long
as one of the following conditions were met: 1. 3–5% bone marrow blasts; 2.
MRD ≥1×10-3; 3. Positive specific fusion gene detection or WT-1 gene copy
number >200 copies/10,000 abl copies; 4. DC ≤90% detected by short tandem
repeat (STR) technology; or 5. More than two listed conditions were met.Among
them, 31 patients received IFN-α-2b pre-emptive therapy, and 67 patients
received non-IFN-α-2b therapy such as: withdraw immunosupressant, tradi-
tional DLI or DC-CIK immunotherapy. 
Results: There were no significant differences in disease characteristics
between two groups. For the 31 patients who received IFN-α-2b pre-emptive
therapy (IFN group), the median time of IFN-α treatment was 60 days (range:
5–720 days), Twenty five patients had response to the treatment without pro-
gressing to hematological relapse (response rate 80.6%); 3 patients had stable
disease (SD) after IFN treatment; 3 patients had no response and eventually
progressed to hematological relapse. Regarding 67 patients who received non-
IFN-α-2b therapy(non IFN group), 22 patients had response to the treatment
(RR 32.8%), 45 patients failed to the treatment and progressed to hematological
relapse at a median time of 35 (range: 6–940) days, There was significant dif-
ference of RR between two group(P=0.000). 31 patients of IFN group tolerate
well and no patient terminated therapy due to side effects. During the treatment
of IFN, 18 patients(58.1%) developed GVHD: 6 patients (19.4%) with aGVHD
and 14 (45.2%) with limited cGVHD. The median follow-up time was 21 (4.5-
78.5) months. 22 of 31 cases of IFN group maintained disease-free survival.
The 5-year overall survival rate (OS) and the leukemia-free survival rate (LFS)
of IFN group were 47.0%±13.9% and 38.7%±13.1% respectively. However, the
5-yr OS and LFS of non IFN group were 14.5%±10.7% and12.5%±9.4% respec-
tively. The difference were significantly (P=0.000,P=0.002 respectively).
Patients with GVHD had significantly better response than patients without
GVHD (88.9% vs 53.8%, P=0.043, P <0.05). 
Summary/Conclusions: IFN-α-2b pre-emptive therapy can effectively prevent
high-risk patients with relapsing tendencies for disease progression post allo-
HSCT. Further large-scale investigation is warranted.
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A STUDY OF RHTPO IN COMBINATION WITH CHEMOTHERAPY AND
G-CSF FOR PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IN
PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA
H Bai1,*, J Zhu1, C Wang1, S Hao2, J Hu3, S Zou4
1Department of haematology, Shanghai general hospital, Shanghai, China,
2Department of haematology, Shanghai Jiaotong University Affiliated Xinhua
Hospital, Shanghai, China, 3Department of haematology, Shanghai Jiaotong
University Affiliated Ruijing Hospital, Shanghai, China, 4Department of haema-
tology, Fudan University Affiliated Zhongshan Hospital, Shanghai, Shanghai,
China
Background: High dose chemotherapy followed by autologous stem cell trans-
plant (ASCT) is the standard treatment for relapsed non–Hodgkin lymphoma
patients who are still chemotherapy–sensitive. Unfortunately, collection of an
adequate number of hematopoietic stem cells can be difficult in these patients,
as they usually have received multiple prior cytotoxic regimens. Studys have
shown recombinant human thrombopoietin(rhTPO) improved mobilization of
peripheral blood progenitor cells in patients with breast cancer.Data on mobi-
lization efficacy in patients with lymphoma are, however, still limited.
Aims: To assess the efficacy and safety of rhTPO in combination with
chemotherapy and granulocyte colony–stimulating factor(G–CSF) for peripheral
blood progenitor cell mobilization in patients with relapsed Non–Hodgkin lym-
phoma.
Methods: A total of 79 patients were included in this prospective multi–center
randomized controlled clinical study. After administration of mobilizing regimens
(CTX 2.5⁄m2d1–2+VP16 200mg⁄m2d1), patients were randomized to TPO+G–
CSF (TPO group,n =40) or G–CSF (control group, n=39). Seven point five
μg⁄kg⁄d of G–CSF and 15000U⁄d rhTPO were subcutaneously administered
from day 2 after chemotherapy and until the stem cell collection was completed.
PBPCs were collected by daily leukapheresis when the white blood cell count
reached ≥10×109⁄L; leukapheresis was continued until acquisition of a target
dose of ≥5×106 CD34+ cells⁄kg. Mobilized PBPCs were transplanted into
patients after additional high–dose chemotherapy with cyclophosphamide, car-
mustine, and etoposide (CBV). The primary endpoint was CD34+ cell yield.
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Secondary endpoints included proportion of target and minimum mobilization,
time of neutrophil and platelet engraftment, number of platelet transfusions,and
adverse events.
Results: Addition of rhTPO significantly improved total CD34+ cell yield (8.56
vs 4.84×106⁄kg, P<0.01). In TPO group, higher percentages of patients
achieved the minimum yield of CD34+>2×106⁄kg (100% vs 86%; P<0.05) as
well as the target yield of CD34+>5×106⁄kg (72.9% vs 41.3%; P<0.05).No
side effects associated with TPO were observed. The median time to neu-
trophil engraftment was the same in both groups (12 days). No differences
in platelet engraftment(12.3 vs 14.1 days), number of platelet transfusions
(3.2 vs 4.4), days of fever (4.6 vs 3.3) were seen between TPO and control
groups, respectively.
Summary/Conclusions: These results indicate that rhTPO safely and effec-
tively enhance mobilization of PBPCs with chemotherapy and G–CSF in
patients with relapsed Non–Hodgkin lymphoma.
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A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND
GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION
AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM
CELL TRANSPLANTATION
F Loeff, JF Falkenburg, L Hageman, S Veld, M van de Meent, S Halkes, I Jedema*
Hematology, Leiden University Medical Center, Leiden, Netherlands
Background: Alemtuzumab, a monoclonal antibody targeting the glycophos-
phatidylinositol (GPI)-anchored CD52 protein, is used for in vivo and/or in vitro
T-cell depletion before allogeneic stem cell transplantation (alloSCT) to reduce
the risk of graft rejection and graft-versus-host disease. Following profound
lymphodepletion, we observed a rapid recovery of T-cell numbers early after
transplantation, despite presence of lytic circulating levels of residual alem-
tuzumab. In the majority of patients, a substantial portion of these T-cells com-
pletely lacked CD52 membrane expression, explaining why these cells escaped
alemtuzumab-induced cytotoxicity.
Aims: To further characterize the CD52 negative T cells arising after alem-
tuzumab-based T cell depleted alloSCT and to unravel the mechanism under-
lying the loss of CD52 membrane expression.
Methods: To study the functionality of the CD52 negative T cells, these cells
were isolated by flowcytometric cell sorting from peripheral blood (PB) samples
taken with informed consent from patients within 6 months after alloSCT. Pres-
ence of the GPI anchor was determined using a fluorescently labeled GPI-specific
aerolysing FLAER. CD52 positive T cells were similarly isolated as control cells.
For specific experiments, CD52 negative virus-specific T cells were isolated
based on staining with specific peptide/HLA tetramers. Functional activity was
tested in cytokine release assay and cytotoxicity assays. To investigate whether
absence of CD52 expression was the result of loss of CD52 gene expression,
mRNA expression analysis was performed on the CD52 negative T cells.
Results: Cytokine production and cytotoxicity assays showed that the CD52-
negative T-cells which were present early after alloSCT contain functional virus-
specific T-cells with lytic capacity comparable to their CD52+ counterparts.
mRNA expression analysis revealed similar levels of CD52 expression in CD52-
negative and CD52+ cells. Since CD52 is tethered to the membrane via the
GPI-anchor, we analyzed whether loss of CD52 membrane expression resulted
from loss of GPI-anchor expression by flowcytometry using counterstaining
with the GPI-specific aearolysin FLAER. This analysis revealed that loss of
CD52 expression on post-transplant T-cells generally resulted from loss of GPI-
anchor expression. Gene expression analysis of the 26 genes that comprise
the GPI-anchor biosynthesis pathway revealed no overall loss of expression
for any of these genes. Since loss of GPI-anchor expression in paroxysmal
nocturnal hemoglobinuria (PNH) and aplastic anemia has been described to
be often the result of mutations in PIGA, we performed mutation analysis on
CD52/GPI-negative (CD4+ n=53, CD8+ n=12) and CD52/GPI-positive (CD4+
n=8, CD8+ n=7) T-cell clones isolated from 3 patients after alloSCT. mRNA
was isolated from each clone followed by Sanger sequencing of the PIGA cod-
ing region. We were able to detect mutations in 42/53 CD4+ and in 10/12 CD8+
CD52/GPI-negative clones. None of the individual mutations was found more
than twice within clones from the same recipient, demonstrating a highly poly-
clonal mutational landscape. In CD52/GPI-positive clones no mutations in the
PIGA coding region were found. To investigate whether these mutations in
PIGA were sufficient to induce loss of GPI-anchor expression, we retrovirally
transduced 35 CD52/GPI-negative CD4+ T-cell clones with constructs encoding
wtPIGA. Restored GPI-anchor expression and coinciding CD52 membrane
expression was observed in all 35 clones upon transduction with PIGA, but
not with empty vector.
Summary/Conclusions: We conclude that loss of CD52 membrane expres-
sion in T-cells isolated early after alemtuzumab-based T-cell depleted alloSCT
is the result of various mutations in the PIGA gene and consequential loss of
GPI-anchor expression. We showed that these CD52-negative populations
contain functional virus-specific T-cells and may therefore be essential in
immune protection early after transplantation.
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WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK
PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE
COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED
BY ALLO-HSCT
J Cao, X Shi, L Ge, A Sun, X Zhu, H Qiu, Z Jin, M Miao, C Fu, X Ma, F Chen,
S Xue, Y Han, M Xue, X Mao, D Wu, X Tang*
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is the only curative treatment options to hematologic malignancies. However,
majority of patients with refractory or resistant hematologic malignancies can
not achieve remission before transplantation. It is necessary to design a safe
and affective conditioning regimen to reduce the tumor burden, improve the
remission rate, decrease the transplantation related mortality and improve dis-
ease-free survival in patients with advanced acute myloid leukemia(AML) and
myelodysplastic syndrom(MDS). One of the promising drugs of epigenetics is
decitabine (DAC), which has a significant effect on a variety of hematologic
malignancies including MDS and advanced AML. Furthermore, decitabine can
not only up-modulate the tumor-associated antigen express on surface of
leukemia cells to increase graft-versus-leukemia (GVL) effect but also can
reduce the incidence of graft-versus-host disease (GVHD) by increase the
number of regulatory T Cells (Tregs).
Aims: This clinical study will investigate the security and efficacy of conditioning
regimen containing low-dose decitabine combined with modified BUCY regimen
for advanced AML/MDS patients, explore the role of immunomodulatory activity
post transplantation and compared this regimen with conventional modified
BUCY regimen. 
Methods: Between January 2012 and March 2015, a total of 156 patients were
enrolled in this study. In which, there were 46 patients who received a condi-
tioning regimen of low-dose DAC (DAC group) and a modified BUCY
regimen(Con group) followed by allo-HSCT, and the second cohort consisted
of 110 who only received a modified BUCY regimen.Comparing the baseline
of two groups, there were no significant difference except there were more
advanced stage patients in DAC group(63% vs 32.7%,p=0.007) A modified
BUCY conditioning regimen include semustine (250 mg/m2/d) for 1 d(-10d),
cytarabine (2 g/m2 q12 h) for 2 d (-9 d to -8 d), busulfan (0.8 mg/kg/6 h) for 3
d (-7 d to -5 d), and cyclophosphamide (1.8 g/m2/d) for 2 d (-4 d to -3 d). Mean-
while, patients in the DAC group received the DAC treatment for 3 to 4 d with
a total of 100 mg/m2before modified BUCY regimen.
Results: In the DAC group, all patients engrafted successfully, including 29/46
(63%) non-remission (NR) patients. However, there were seven patients pre-
sented graft failure in Con group.The median time of neutrophil and platelet
recovery in two groups were 12 (10-21) vs 12 d (range: 10-23 d)(p and 13 (10-
35) days vs 14 d (range: 9-40 d) respectively.There were no significant differ-
ences between two groups. The transplantation-related mortality (TRM) rate
was 0% vs 16.4%(p=0.004) for DAC group and Con group. The median follow-
up were 200(20-985)d and 177.5(3-1093)d. The cumulative rate of aGVHD and
cGVHD were 26.7% vs 46.8%(p=0.034) and 68.4% vs 70.7% (p=0.598) respec-
tively. The cumulative relapse rate was 26.5% and 37.8%(p=0.706)respectively.
The estimated 2-year overall survival (2yr-OS) and 2 year disease-free survival
(2yr-DFS) rate were 76.6% vs 51.2%(p=0.01) and 63.3% vs 41.4%(p=0.046)
respectively. Furtheremore, for the patients who were in advanced stage before
transplant, the The estimated 2yr-OS and 2yr-DFS rate were 77.3% vs
44.8%(p=0.009) and 66.5% vs 46.7%(p=0.031) respectively. 
Summary/Conclusions: 1. Low-dose decitabine combined with modified
BUCY is a safe and effective conditioning regimen for high-risk patients with
AML/MDS with low toxicity and well tolerance.All patients of DAC group engraft-
ed and transplantation-related mortality (TRM) rate was 0.
2. 100% NR patients of DAC group achieved complete remission with full donor
chimerism at d30. 3.Comparing with Con group, DAC group patients had rala-
tive lower incidence of aGVHD and TRM but relative higher estimated 2-yr OS
and DFS, especially for advanced stage patients.
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ELEVATED EXPRESSION OF TIM-3 ON CD8 T CELLS CORRELATES WITH
CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC STEM CELL
TRANSPLANTATION
X Li, B Yang, L Xu, L Bin, X Wu*, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: T-cell immunoglobulin and mucin domain-containing molecule 3
(Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion in
virus infections. However, the role of Tim-3 in the pathogenesis of early
cytomegalovirus (CMV) reactivation after allogeneic stem cell transplantation
(allo-HSCT) is not well understood. 
Aims: In this study, we aimed to investigate the role of Tim-3 during CMV infec-
tion after allo-HSCT. 
Methods: We detected 33 patients and 10 healthy controls in this study. Collected
peripheral blood (PB) of patients 30 days, 60 days, 90 days after allo-HSCT who
were neither aGVHD nor suffered from other virus infection, such as HBV, HIV,
EBV, et al. Plasma samples were assessed for CMV-DNA by PCR, (Peripheral
blood mononuclear cells) PBMCs were isolated for flow cytometry to detect Tim-
3 expression on CD8+ T cells, apoptosis of Tim-3- and Tim-3+ T cells (Annexin
V, AV) and IFN-γ secreted by Tim-3- and Tim-3+ T cells.
Results: The rate of CMV reactivation was 51.5% (17/33) of all the patients.
Hence we divided them into three groups: CMV positive group, CMV negative
group, healthy control group. An elevated frequency of Tim-3+CD8+ cells was
observed in transplanted patients compared to healthy controls, and in trans-
planted patients, the Tim-3 expression on CD8+ T cells was significantly higher
in CMV positive patients than CMV negative cases (7.048±3.060% for healthy
controls, 15.55±6.314% for CMV negative patients, and 38.98±17.50% for CMV
positive patients, P<0.05). The frequency of Tim-3-expression T cells correlates
with viral load in CMV reactivation. After effective antivirus treatment and CMV
became negative, the frequency of Tim-3+CD8+ T cells was decreased. IFN-γ
secreted by Tim-3-CD8+ T cell was significantly higher than that produced by
Tim-3+CD8+ T cells in each group (P<0.05). In healthy controls, the apoptosis
of Tim-3+CD8+ T lymphocytes were significantly increased than that of Tim-3-
CD8+ counterparts (2.926±0.654% vs 1.546±0.411%, P=0.001), while in allo-
HSCT patients, there were no differences in apoptosis between Tim-3+CD8+
and Tim-3-CD8+ T lymphocyte (2.069±1.720% vs 1.632±0.789% in CMV neg-
ative group, 2.274±1.185% vs 1.871±0.265% in CMV positive group, P>0.05).
Summary/Conclusions: Tim-3 expression on T cells results in the changes of
T cell function and level of apoptosis, and closely correlated with CMV infection
after allo-HSCT.
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INTERFERON-GAMMA GENE POLYMORPHISM ASSOCIATE WITH
MORTALITY AND GRAFT-VERSUS-HOST DISEASE SEVERITY IN
HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION
MV Palau Nagore1,*, M Berro2, J Bestach1, C Foncuberta3, A Vitriu3, G Remaggi4,
J Martinez Rolon4, G Jaimovich5, A Requejo5, K Padros6, MB Rodriguez6,
G Kusminsky2, I Larripa1, C Belli1
1Departamento de Genética Hematologica, Instituto de Investigaciones Med-
icas (IMEX/CONICET) - Academia Nacional de Medicina, Buenos Aires,
2Unidad de Trasplante Hematopoyetico, Hospital Universitario Austral, Pilar,
3Unidad de Trasplante Hematopoyetico, Instituto Alexander Fleming, 4Unidad
de Trasplante Hematopoyetico, FUNDALEU, 5Unidad de Trasplante
Hematopoyetico, 6PRICAI, Fundacion Favaloro, Buenos Aires, Argentina
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
with sibling donors is a life-saving intervention for patients with hematological
malignancies. It is recognized that numerous genetic factors in patient and
donor, including polymorphic variants of cytokine encoding genes, have been
reported that contribute to the outcome of the procedure. Interferon gamma
(IFNy) plays a central role in innate and adaptive immunity. IFNG gene has a
regulatory element in its first intron that includes a microsatellite CA repeat
which CA12 variant is associated with an increased production. Up to date
there are few published data on the association between this polymorphism
and allo-HSCT related complications performed in small series. 
Aims: To evaluate the presence of the microsatellite polymorphism +875 (CA)n
IFNG and its relationship with response and/or complications related to allo-
HSCT.
Methods: Two hundred and twenty two (222) patient/donor pairs who under-
went a sibling donor HSCT in our centers were genotyped for the presence of
+875 (CA)n IFNG (rs3138557) variants. Transplants took place between
01/2000 and 03/2015 with a median follow up of 4.4 years.
Results: Median age of recipients was 33 years, being 90% ≥16 years old and
58% male. Prevalent diagnoses were acute myeloid leukemia 29%, acute lym-
phoid leukemia 23%, lymphoproliferative disorders 13%, and myelodysplastic
syndrome 12%; 45% were in early stage of the disease. Myeloablative condi-
tioning regimens were used in 59% and the prevalent source for stem cells was
peripheral blood in 90% of patients. Genotypes distribution was 22%
CA12/CA12, 41% CA12/CAno12 and 37% CAno12/CAno12 for recipients, and
17%, 54% and 29% for donors, respectively (Chi2 test p=0.011). When patients
with genotype CAno12/CAno12, associated with low expression, were compared
against the rest of genotypes, we observed that these patients developed less
acute graft versus host disease (aGVHD) grades II-IV (21% vs 37%, Fischer
exact test p=0.053), grades III-IV (6% vs 15%, p=0.071), chronic GVHD (26%
vs 41%, p=0.029), and a later myeloid engraftment (≥15 days: 54% vs 26%, p
<0.001). Moreover, this group had a significant reduction in overall survival (OS)
(1-5 years, 69-40% vs 71-56%, Kaplan-Meier, log-rank, p=0.03), disease free
survival (DFS 1-5 years, 54-40% vs 65-49%, log-rank, p=0.07) due to a higher
relapse rate (1-5 years, 37-45% vs 22-32%, Gray’s Test, cumulative incidence
p=0.02), The predictive value was sustained (OS 59-31% vs 69-54%, p=0.05)
and Relapse rate (38-45% vs 22-32%, p=0.01) when the cohort of patients that
receive a non-myeloablative conditioning was analyzed separately.
Summary/Conclusions: The study of the polymorphism +875 (CA)n IFNG
would be useful to identify patients with differential behavior towards allo-HSCT
with sibling donors. While it is necessary to confirm our results in a larger series,
genotype associated with a lower expression of IFNγ would be associated with
less GVHD, later engraftment and shorter overall survival that could be related
to a higher relapse rate, especially in those patients who received reduced-
intensity conditioning regimens.
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CLINICAL OUTCOME AND IMMUNE RECONSTITUTION IN α/β T-CELL
DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION FROM
MATCHED RELATED AND UNRELATED DONORS
M De Witte1,*, A Janssen2, G Fleurke1, L Timmerman2, E Spierings2, I Slaper3,
J Kuball1,2
1Hematology, 2Laboratorium of Translational Immunology, 3Cell Therapy Facil-
ity, University Medical Center Utrecht, Utrecht, Netherlands
Background: The outcome of allo-SCT in patients with hematological malig-
nancies is still hampered by GVHD and relapse. Specific depletion of αβ T-
cells is proposed to result in a decreased incidence of aGVHD, whereas the
remaining innate cells such as NK cells and γδT cells may provide control of
infected and transformed cells the first months post SCT. This strategy has
been pioneered in haploindentical transplantation with encouraging results.
Within this study, we extend αβT- cell depleted allo-SCT to patients with a
matched related and unrelated donor. 
Aims: The primary aim is to develop an allogeneic SCT protocol with a low
incidence of aGVHD without an increased incidence of infections or relapse to
serve as a platform for post-allo interventions such as a pre-emptive DLI or
transfer of genetically modified T cells.
Methods: 55 Patients with hematological malignancies (including AML, ALL,
MM, NHL, MPN) who received an αβT-cell depleted allo-SCT of a HLA matched
sibling (MRD) or HLA matched (9 or 10/10) unrelated donor (MUD) were
analysed. αβT-cell reduction was performed by negative selection with anti-
αβTCR antibodies in combination with magnetic microbeads, using the auto-
mated CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). The
maximal contamination with αβT-cells was 5x105/kg. The conditioning regimen
consisted of: ATG (Genzyme®) 6 mg/m2+fludarabine 120 mg/m2+busilvex
AUC=90. Part of the patients received mycophenolic acid as GVHD prophylaxis
for 28 days. Patients were retrospectively analyzed for clinical parameters
including immune reconstitution, engraftment, infections, GVHD, relapse, NRM
and OS and compared to an historical control cohort of recipients of T cell
replete allo-SCT. A retrospective cohort of recipients of T cell replete allografts
was used for comparison. In addition in a subset of patients NGS of the TCRβ
chain was performed using the Illumina/MiSeq sequencing platform after iso-
lation of diverse immune subsets within the αβT-cell repertoire.
Results: αβT-cell depletion with anti-αβTCR antibodies resulted in a 4.1 (1.7-
5.2) log depletion of αβT cells and a recovery of 77% (43-98%) of the CD34+
cells. The median contamination with αβT-cells was 16x103/kg (0.8x103/kg -
200x103/kg) and infused number of CD34+ cells were 6.8x106/kg (1.2 x106/kg
– 10.4x106/kg). The combination of ATG/fludarabine/busilvex was well tolerated
with hematological recovery within 3 weeks. Primary engraftment (chimerism
>95%) was observed in all patients (n=55). Immune reconstitution primarily
consisted of NK cells. In addition, γδT cells were detectable at normal numbers
the first half year post SCT, whereas the adaptive immune repertoire showed
a delayed reconstitution. The incidence of CMV infections was 54% in patients
after αβT cell depleted allo-SCT without MMF, 23% in patients after αβT cell
depleted allo-SCT with MMF and 38% in T cell replete allo-SCT control cohort.
The incidence of EBV infections was 30,8%; 9,5% and 8,7% respectively. The
incidence of aGVHD >grade II within 100 days in patients of a αβT-cell depleted
allo-SCT was 0%. During this short time of follow-up (1-20 months) we observed
no significant differences in EFS, NRM and OS as compared to historical control
cohorts. With NGS of the TCRβ repertoire, a surprising diversity was observed
in defined immune subsets ranging from clonal expansion of regulatory T cells
to broad repertoires in effector memory cells.
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Summary/Conclusions: Here we present the clinical outcome of a large
cohort (n=55) of patients having received an αβT-cell depleted allograft of
MRD/MUD. We observe a swift reconstitution of innate cells (NK cells and γδT-
cells) the first 6 months post transplantation, followed by a subsequent recon-
stitution of the adaptive immune repertoire. The incidence of severe aGVHD
was 0%, without a significant increase in infections or relapse shortly post allo-
SCT. These results will be confirmed during extended follow-up and in a
planned prospective multicenter study. 
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BASELINE LABORATORY VARIABLES SERVE AS POTENT PREDICTORS
OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
RELATED MORTALITY
R Shouval1,*, J Fein2, N Shem-Tov1, I Danylesko1, R Yerushalmi1, R Mehr3,
G Shafaf Lavy3, S Hassid3, A Shouval4, R Unger3, A Shimoni1, A Nagler1
1Hematology and Bone Marrow Transplantation, Sheba Medical Center, Tel-
HaShomer, Ramat- Gan, 2Sackler School of Medicine, Tel-Aviv University, Tel-
Aviv, 3The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan Uni-
versity, Ramat- Gan, 4Internal Medicine “F”, Tel Aviv Sourasky Medical Center,
Tel-Aviv, Israel
Background: Prognostic models for allogeneic hematopoietic stem cell trans-
plantation (HSCT) outcomes have traditionally relied on physician-evaluated
parameters, subject to interpretation. Furthermore, despite availability of com-
prehensive electronic medical data, their use has been limited by standard sta-
tistical techniques, requiring subjective pre-selection of variables prior to con-
struction of prediction models.
Aims: Using Random Survival Forests (RSF), a machine learning (ML) algo-
rithm, we sought to estimate predictive importance of a wide array of clinical
and laboratory variables, including many not often assessed, in predicting
HSCT related mortality (TRM). ML is a subfield of artificial intelligence, com-
monly applied in complex data scenarios.
Methods: We retrospectively analyzed a cohort of patients undergoing allo-
geneic HSCT in a single center. Patients’ clinical data were crossed with labo-
ratory data from institutional electronic medical records at baseline admission
for transplantation. A total of 33 variables, mostly laboratory based (v=23), were
included. An RSF model for TRM, with relapse as a competing event, was con-
structed and variable importance was extracted. Partial dependence plots were
used to graphically explore the risk-adjusted relationship between predictors
and TRM. Top RSF predictors were introduced into a Cox regression model,
and cumulative incidence (CIn) was compared across individual variables.
Results: A cohort of 965 patients with a median age of 53 (16 -76) were ana-
lyzed. Indications for transplant were mostly hematologic malignancies mainly
AML and MDS. The majority of patients received myeloablative conditioning
(58%) and graft-versus-host-disease (GvHD) prophylaxis with cyclosporine
and methotrexate (76%). Median follow-up time was 6.4 years. The top 15
predictors selected by RSF are presented in Figure 1a. TRM is strongly pre-
dicted by pre HSCT albumin, GvHD prophylaxis and estimated creatinine
clearance, whereas these factors are less predictive of relapse. Partial
dependence plotting uncovered non-linear relationships between TRM CIn
and creatinine clearance (Figure 1b) and serum albumin. Seven of the top 10
RSF predictors were confirmed by a Cox regression model (Table 1) and TRM
CIn plots (Figure 1c).
Table 1.
Variable                                                                            Hazard ratio              p-value
GvHD Prophylaxis                            MTX vs MMF                          1.32                    0.0180
                                                    - vs Other                          0.734
HLA mis-match                               0 vs 1                                  2.356                   0.0001
Diagnosis                                       AML vs ALL                           0.934                   0.0085
                                                    - vs MDS/MPD                  1.404
                                                    - vs Lymphoma                 2.157
                                                    - vs Other                          1.676
Albumin (g/dl)                               >3.7 vs <3.7                        1.708                   0.0002
Creatinine clearance (mL/min)        >60 vs <60                         1.694                   0.0007
Age                                                <20 vs 20-40                      1.442                   0.0085
                                                    - vs >40                           2.225
Alk Phos (IU/I)                               <120 vs >120                     1.461                   0.0073
Summary/Conclusions: Using a novel methodology across a comprehensive
landscape of HSCT patient characteristics, we identified key predictors of TRM.
Variables such as creatinine clearance and albumin display a strong non-linear
relationship with the primary outcome-TRM, while TRM is linearly dependent
on alkaline phosphatase. Some elements considered in existing prognostic
scoring systems, such as hepatocellular transaminases, were not predictive.
Taken together, these findings provide a new framework for evaluating trans-
plantation risk in a data-rich environment, and reveal simple and objective
determinants of transplant-related mortality.
Figure 1.
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CYTOMEGALOVIRUS INDUCES STRONG ANTILEUKEMIC EFFECT IN
ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING SIBLING HSCT
WITHOUT ATG-CONTAINING REGIMEN
H Qiu*, X Bao, S Xue, X Hu, X Ma, F Chen, X Wu, S Chen, A Sun, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: A considerable number of studies have demonstrated that
cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell
transplantation (Allo-HSCT) could enforce graft-versus leukemia (GVL) effect
in acute myeloid leukemia (AML) patients. However, the use of antithymocyte
globulin (ATG) as part of graft-versus-host disease (GVHD) prophylaxis may
dampen this beneficial effect of CMV replication. 
Aims: The purpose of this study is to investigate whether the ATG or non-ATG
containing regimens can all benefit from this GVL effect.
Methods: In this context, we retrospectively analyzed the effect of CMV reac-
tivation on relapse, survival and prognosis in a total of 227 AML patients who
received a myeloablative (MA) conditioning regimen at a single research center
between January 2010 and April 2013.
Results: Of these 227 patients, 110 cases received non-ATG-containing reg-
imens and 117 cases received ATG-containing regimens. CMV reactivation
occurred in 45 patients (41%) among non-ATG regimen -months, a lower risk
of cumulative relapse incidence associated with CMV reactivation was
observed in non-ATG group in multivariate analyses (OR 0.28, 95% CI 0.10-
0.79; P=0.016). However, CMV reactivation after transplantation did not signif-
icantly decrease the cumulative incidence of relapse in our ATG group (OR
0.28, 95% CI 0.10-0.79; P=0.016).
Summary/Conclusions: Collectively, our results demonstrate that in AML
patients following sibling HSCT, the CMV-induced beneficial effect on relapse
occurs only in the MA regimens containing no ATG, although ATG promotes
CMV reactivation. the cumulative incidence of relapse in our ATG group (OR
0.28, 95% CI 0.10-0.79; P=0.016).
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COMPARING TIME-DEPENDENT PREDICTIVE PERFORMANCE OF
ALLOGENEIC HSCT RISK SCORING SYSTEMS
J Fein1,*, R Shouval2, N Shem-Tov2, I Danylesko2, R Yerushalmi2, A Shouval3,
A Shimoni2, A Nagler2
1Sackler School of Medicine, Tel Aviv University, Tel Aviv, 2Hematology and
Bone Marrow Transplantation, Sheba Medical Center, Tel Ha-Shomer, Ramat-
Gan, 3Internal Medicine “F”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background: The European Bone Marrow Transplant (EBMT) score and
Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) predominate
in the assessment of risk of allogeneic hematopoietic stem cell transplantation
(HSCT)-related mortality. Though validated, both scores have been shown to
fluctuate in predictive capacity between different patient populations.
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Aims: To evaluate and compare the long-term performance of the EBMT and
HCT-CI scores across typical transplant indications.
Methods: This is a retrospective analysis of a cohort of patients from a single
center. EBMT and HCT-CI scores were calculated for the entire cohort. Cox
regression modeling, with scores as covariates, was used to assess the prob-
ability of overall survival (OS) as well as treatment-related mortality (TRM) with
relapse as a competing risk. Score performance in predicting each outcome at
multiple time-points was compared, using receiver operating characteristics to
determine time-dependent areas under the curve (AUC). AUC measures the
ability of a model to differentiate between those who do and do not experience
the outcome event on a scale of 0.5 (no better than random chance) to 1 (perfect
discrimination). Performance was further compared within specific subgroups.
Results: A cohort of 845 patients, with a median age of 52 (16 - 76), was
assessed. Indications for transplant were primarily acute leukemia and
myelodysplastic syndrome. EBMT scores reflected a normal distribution; 50%,
25%, 12% and 14% of patients had HCT-CI scores of 0, 1, 2 and 3 or greater,
respectively. The majority of patients had advanced disease (45.0%) and
received myeloablative conditioning (67.7%). Median follow-up was 6.2 years.
Patients with early or intermediate disease had a median survival >4 years;
those with advanced disease had only 0.5 year. Increasing scores correspond-
ed to distinct and increasing risk of TRM (Figure 1a, b), Table 1). Neither score
predicted relapse. Predictive performance, measured by AUC, was time-depen-
dent. While in the first 2 years post-HSCT the EBMT score showed significantly
greater discrimination, the scores subsequently converged. This was seen both
in the entire population and within subgroups such as disease status and con-
ditioning regimen.
Table 1.
             Risk score   % patients   TRM HR (95% CI)       p        OS HR (95% CI)        p
EBMT            0-2            19.4%                   1
                     1
                     3             22.2%       1.59 (0.96-2.63)    0.071    1.29 (0.82-2.02)    0.270
                     4             23.9%       1.86 (1.15-3.00)    0.010             1.76             0.011
                     5             24.1%       2.55 (1.61-4.05)   <0.001   2.25 (1.46-3.47)   <0.001
                   6-7            13.0%       3.87 (2.40-6.26)   <0.001   2.62 (1.66-4.14)   <0.001
HCT-CI            0             49.9%                   1                                         1
                     1             24.7%       1.36 (0.97-1.89)    0.072    1.28 (1.03-1.59)    0.025
                     2             12.4%       1.54 (1.05-2.27)    0.028    1.39 (1.07-1.80)    0.014
                    ≥3            14.4%       2.09 (1.48-2.96)   <0.001   1.72 (1.36-2.17)   <0.001
Figure 1.
Summary/Conclusions: In an allogeneic HSCT cohort with median follow-up
time >6 years, predictive performance of the EBMT score is greater than that
of HCT-CI in the first two years after transplantation. The HCT-CI score steadily
improves until performances converge. The different components of the two
prognostic models may account for the HCT-CI score’s improving effectiveness
over time: the EBMT score reflects primarily static features of the patient and
procedure at time of transplantation; the HCT-CI score includes factors subject
to subsequent improvement or deterioration. Altogether, both models provide
stepwise risk estimation, however individual clinical prediction remains elusive
due to limited discrimination (i.e. AUC).
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PROPHYLACTIC DLI VS NO DLI FOR REFRACTORY ACUTE LEUKEMIA
UNDERGOING ALLO-HSCT WITH SEQUENTIAL INTENSIFIED
CONDITIONING
Q Liu1,*, L Xuan1, Z Fan1, Y Zhang1, H Zhou1, F Huang1, D Nie2, D Lin3,
J Sun1, Y Xiao4
1Department of Hematology, Nanfang Hospital, Southern Medical University,
2Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Uni-
versity, 3Department of Hematology, the Third Affiliated Hospital, Sun Yat-Sen
University, 4Department of Hematology, Guangzhou General Hospital of
Guangzhou Military Command, Guangzhou, China
Background: The major obstacle is leukemia relapse for refractory leukemia
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). We
previously introduced a strategy of sequential intensified conditioning and early
rapid immunosupressant withdrawal for refractory leukemia undergoing allo-HSCT,
with 5-year overall survival (OS) and 3-year relapse rate of 44.6% and 33.3%.
Aims: To reduce leukemia relapse, prophylactic donor lymphocyte infusion
(DLI) was administered based on our historical strategy. 
Methods: We conducted a prospective multi-center study to assess the efficacy
of the new strategy for refractory advanced acute leukemia. Sequential intensiﬁed
conditioning regimen was: ﬂudarabine (30 mg/m2/day, -10 to -6 days)+cytarabine
(2.0 g/m2/day, -10 to -6 days) plus total body irradiation (4.5 Gy/day, -5, -4
days)+cyclophosphamide (60 mg/kg/ day, -3, -2 days)+etoposide (15 mg/kg/day,
-3, -2 days). Immunosupressant was withdrawn by 10%/week in patients without
acute graft-versus-host disease (aGVHD) by day +30 post-transplantation. For
patients without grade II/>II aGVHD by day +60 post-transplantation, DLI was
administered at a median dose of 1.0×108mononuclear cells/kg if donor lympho-
cytes were available. DLI was given once to all patients regardless of minimal
residual disease (MRD), and was then administered based on GVHD and MRD
status. If patients were MRD negative, DLI was not given again; if patients were
MRD positive and without GVHD, DLI was given monthly until GVHD occurred
or MRD became negative or for a total of four times.
Results: A total of 153 patients with refractory advanced acute leukemia under-
going allo-HSCT from January 2009 to June 2014 were enrolled. All patients
achieved hematopoietic reconstitution except for two who died of infection and
two who died of RRT within 2 weeks post-transplantation. At the time of neu-
trophil reconstitution, all 149 evaluable patients achieved complete remission.
The incidence and mortality of regimen-related toxicities were 100.0% and
1.3%. The 5-year overall and disease-free survival post-transplantation were
51.1%±5.7% and 49.2%±5.3%. The 5-year relapse rate and non-relapse mor-
tality (NRM) were 27.3%±4.4% and 29.7%±5.3%. According to the availability
of donor lymphocytes and the criteria for DLI, 144 patients surviving day +60
were divided into two groups (80 DLI versus 64 non-DLI). The relapse rate was
less and OS was better in patients receiving DLI than in those not receiving
DLI (22.7% vs 33.9%, P=0.048; 58.1% vs 54.9%, P=0.043). NRM was similar
between DLI and non-DLI groups (P=0.104). Multivariate analysis revealed
that lower bone marrow blasts on day 0, DLI and chronic GVHD were associ-
ated with less relapse and better OS.
Summary/Conclusions: The strategy of sequential intensified conditioning
followed by early immunosupressant withdrawal and DLI could reduce relapse
of refractory acute leukemia after allo-HSCT and improve survival.
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THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM
FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPEND-
ENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
T Suwabe1,*, Y Shibasaki2, T Katagiri1, S Miyakoshi1, H Kobayashi1, K Fuse1,
T Ushiki1, N Sato3, T Yano3, T Kuroha3, S Hashimoto3, M Narita1, H Sone1,
T Furukawa3, M Masuko2
1Department of Hematology, Endocrinology and Metabolism, Niigata University
Faculty of Medicine, 2Division of Stem Cell Transplantation, Niigata University
Hospital, Niigata, 3Department of Hematology, Nagaoka Red Cross Hospital,
Nagaoka, Japan
Background: Although the Hematopoietic Cell Transplantation-specific Comor-
bidity Index (HCT-CI) and Comorbidity-age index are useful tools for pre-trans-
plant risk assessments in allogenic hematopoietic stem cell transplantation (allo
HSCT), c-statistic estimates for non-relapse mortality (NRM) and overall survival
(OS) of them are reported to be about 0.65. Therefore, a new index rather than
the HCT-CI which can predict more reliably outcomes is required to aid bedside
decision making.
Aims: The purpose of this study was to create a new risk index based on three
biomarkers, which are pre-transplant serum ferritin (SF), albumin (Alb), and C-
reactive protein (CRP), to predict NRM and OS after allo HSCT.
Methods: We analyzed 198 adult patients who underwent allo HSCT between
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2005 and 2014 at our facilities in this study, including 96 with acute myeloge-
nous leukemia, 47 with acute lymphoblastic leukemia, 26 with myelodysplastic
syndrome, 4 with myeloproliferative neoplasms, 3 with chronic myeloid
leukemia, 5 with adult T-cell leukemia/lymphoma, 1 with mixed lineage
leukemia, 4 with aplastic anemia, 2 with chronic active Epstein-Barr virus infec-
tion and 10 with malignant lymphoma. Median age of patients was 52.5 years
(range: 16-67). A total of 57 patients received related stem cell transplantations,
82 received unrelated stem cell transplantations, and 59 received cord blood
transplantations. In addition, myeloablative and non-myeloablative conditioning
regimens were administered to 114 and 84 patients, respectively. The 70
patients with non-remission acute leukemia/lymphoma or refractory anemia
with excess blasts were categorized as having a high disease status, and the
others were categorized as having a standard disease status. We scored the
pre-transplant risk index using biomarkers (Biomarker index: Bio-I) which was
calculated to be assigned a 1 point for >2000ng/ml of SF, <3.4mg/dl of Alb and
>1.5mg/dl of CRP respectively. We divided patients into three risk groups using
Bio-I, low (score 0, N=138), intermediate (score 1-2, N=49) and high (score 3,
N=11). We evaluated the utility of the Bio-I as an index for predicting post-
transplant outcomes.
Results: Median pre-transplant SF was 4894ng/ml (range: 8-35185 ng/ml),
Alb was 3.65g/dl (range: 2.1-5.2g/dl) and CRP was 0.16mg/dl (range: 0.01-
17.9mg/dl). The Bio-I exhibited sufficient c-statistic estimates for NRM (0.613)
and OS (0.662) at 1 year. These values were similar to those reported for the
HCT-CI. In univariate analysis, the Bio-I was successfully used to stratify the
patients into three risk groups in NRM (p=0.001) and OS (p<0.001). In multi-
variate analysis adjusted for the HCT-CI and disease status, the high-risk Bio-
I group was found to be an independent poor prognostic factor for NRM (hazard
ratio (HR): 5.16, p<0.001). Furthermore, intermediate- and high-risk groups
were shown to be independent poor prognostic factors for OS (intermediate:
HR 1.67, p=0.034, high: HR 4.39, p<0.001). In addition, we created a compre-
hensive scoring system for OS which was calculated to be assigned each point
(Bio-I low: 0, intermediate: 1, high: 2, HCT-CI 0-2: 0, ≥3: 1 and disease status
standard: 0, high: 1). This comprehensive scoring system displayed a higher
c-statistic estimate for OS than the HCT-CI at 1 year (0.754).
Summary/Conclusions: The Bio-I, which is based on SF, Alb, and CRP levels,
is a useful tool for risk assessment before allo-HSCT because it is easy to cal-
culate, exhibits sufficient sensitivity, can be used to stratify patients into three
clear risk groups, and acts as an independent (including from the HCT-CI) risk
factor for predicting post-transplant outcomes.
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HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH
ACQUIRED SEVERE APLASTIC ANEMIA
L Xu*, S Zuo, X Zhang, F Wang, X Mo, T Han, W Han, Y Chen, Y Zhang,
J Wang, Y Wang, C Yan, Y Sun, X Huang
Peking University Institute of Hematology, Peking University People’s Hospital,
Xicheng district,Beijing, China
Background: Matched sibling donor hematopoietic stem cell transplantation
(MSD HSCT) is the upfront therapy for children with acquired severe aplastic
anemia (SAA), but MSD is not available for most patients. The technique of
haploidentical HSCT (haplo-HSCT) for SAA has been improved according to
exciting results reported recently, although it is recommended to pediatric SAA
patients after failure to at least 2 courses of IST based on ATG in current guide-
lines.
Aims: To study that who will benefit from haplo-HSCT most.
Methods: 52 SAA patients younger than 18 years received haplo-HSCT con-
secutively between February 2007 and November 2015 in our center. All the
patients received haplo-HSCT with the protocol of using G-CSF primed bone
marrow plus G-CSF-mobilized peripheral blood stem cells without in vitro T
cell depletion. The conditioning regimen included BU(08.mg/kg q6hrsx2d),
CY(50mg/kgx4d) and rATG(2.5mg/kg/dx4d). CsA, MMF and short-time MTX
were used for GVHD prophylaxis.In 23 newly diagnosed patients, haplo-HSCT
was administered as the upfront therapy and in the other 29 refractory patients,
it was administered as non-upfront therapy. 
Results: 51 patients achieved primary engraftment except one child died of
regimen related toxicity on the day +1. Graft failure occurred on 3 patients (two
was rejection and the other one was secondary poor graft function). The cumu-
lative incidence (CI) of aGVHD grade II-IV and grade III-IV was 39.2±0.5% and
13.7±0.2%, respectively. The CI of cGVHD was 34.2±0.5%. The 3-year OS
and FFS was 84.5±5.0% and 82.7±5.2% with a median follow-up time of 744.5d
(100-3294) for surviving patients. ECOG was the only predictor of OS and fail-
ure free survival (FFS).The OS, FFS, aGVHD, cGVHD have no significant dif-
ference between the upfront therapy group and the non-upfront therapy group. 
Summary/Conclusions: Both newly diagnosed and refractory pediatric SAA
patients could benefit from haplo-HSCT, especially for the children with good
general condition. Considering the excellent outcome, haplo-HSCT might be
considered to be alternative therapy for pediatric SAA patients without MSD in
selected centers. Further studies are needed to confirm this result in prospec-
tive trials.
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COMPARISON BETWEEN FLUDARABINE PLUS BUSULFAN AND
FLUDARABINE PLUS MELPHALAN CONDITIONING REGIMENS BEFORE
SINGLE-UNIT CORD BLOOD TRANSPLANTATION FOR ADULT ACUTE
MYELOID LEUKEMIA PATIENTS
J Aoki1,*, M Tanaka1, H Kanamori1, N Uchida2, K Nishiwaki3, A Yonezawa4,
B Saito5, H Kobayashi6, T Eto7, M Takanashi8, T Ichinohe9, Y Atsuta10,11,
A Takami12, S Yano13
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ment of Internal Medicine, Jikei University School of Medicine, Kashiwa Hos-
pital, Kashiwa, 4Kokura Memorial Hospital, Kitakyushu, 5Showa University
School of Medicine, Tokyo, 6Nagano Red Cross Hospital, Nagano,
7Hamanomachi Hospital, Fukuoka, 8Japanese Red Cross Society, Tokyo,
9Hiroshima University Hospital, Hiroshima, 10Japanese Data Center for
Hematopoietic Cell Transplantation, 11Nagoya University Graduate School of
Medicine, Nagoya, 12Aichi Medical University, Aichi, 13Jikei University School
of Medicine, Tokyo, Japan
Background: In recent year, reduced intensity conditioning (RIC) is developed
and increasingly used in allogeneic hematopoietic stem cell transplantation (allo-
HSCT) for acute myeloid leukemia (AML) patients. Fludarabine plus busulfan
(FB) and fludarabine plus melphalan (FM) are widely used RIC regimens. A pre-
vious study reported FB and FM provide comparable survival after allo-HSCT
from HLA matched siblings for AML patients. However, outcomes of cord blood
transplantation (CBT) following FB or FM are unknown in AML patients. 
Aims: We conducted a nationwide retrospective study to compare FM and FB
in AML patients who underwent CBT. 
Methods: Clinical data were collected from the registry database of the Japan
Society for Hematopoietic Cell Transplantation. The selection criteria included
AML (excluding acute promyelocytic leukemia), aged 16 years or older, first
transplantation, single-unit CBT (HLA 4-6/6 match) between January 2003 and
December 2013, FB (fludarabine 120-180 mg/m2, busulfan 8mg/kg (or intra-
venous injection in equivalent doses) and TBI 2-4Gy) or FM (fludarabine 120-
180 mg/m2, melphalan 80 mg/m2 and TBI 2-4Gy). We compared outcomes
(overall survival (OS), relapse, non-relapse mortality (NRM) and hematopoietic
recovery) after CBT following FB or FM.
OS was estimated by the Kaplan-Meier method and was compared using a
log-rank test. Relapse and NRM were considered competing risk events for
each other and were compared using Gray’s test. The cumulative neutrophil
and platelet recoveries were also estimated and compared by Gray’s test con-
sidering death without these events as a competing risk. In a multivariate analy-
sis, the Cox proportional hazard model and Fine-Gray methods were used for
OS and cumulative incidence of relapse, NRM and hematopoietic recovery
respectively, using the following variables: age, gender, disease status, cyto-
genetic risk category, HLA disparity, nucleated cell dose, donor-recipient gender
mismatch, ABO mismatch, and transplantation year.
Results: Of the 412 patients, 122 patients (29.6%) received FB and 290
patients (70.4%) received FM. Median age were 61 (20-78) and 60.5 (17-82)
years old, respectively (P=0.66). Higher proportion of FM patients received
HLA 6/6 matched CBT (P=0.03) and 4Gy TBI (P=0.002). There was no differ-
ence in other factors. Three-years OS (34.0% and 33.7%, P=0.81) relapse
(34.9% and 36.3%, P=0.93), NRM (33.4% and 33.4%, P=0.89), 30-days neu-
trophil engraftment (63.1% and 67.2%, P=0.39) and 60-days platelet engraft-
ment (45.1% and 50.0%, P=0.33) were not significantly different between FB
and FM. In multivariate analysis, FB and FM showed similar OS (HR, 0.96;
P=0.78), relapse (HR, 0.98; P=0.91), NRM (HR, 1.03; P=0.88), neutrophil
engraftment (HR, 1.09; P=0.51) and platelet engraftment (HR, 1.18; P=0.31).
Summary/Conclusions: The current study showed FB and FM provide similar
outcomes of CBT for AML patients.
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MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE
GUIDED SEQUENTIAL CHEMOTHERAPY PLUS DONOR LYMPHOCYTE
INFUSION COULD IMPROVE SURVIVAL OF PATIENTS WITH ACUTE
LEUKEMIA WHO RELAPSED AFTER ALLO-HSCT
CH Yan1,*, Y Wang2, XD Mo3, XH Zhang4, LP Xu 4, KY Liu4, XJ Huang4
1Peking University People’s Hospital, Peking University Institute of Hematology,
2 Peking University Institute of Hematology, Peking University People’s Hospi-
tal, Bejing, 3Peking University People’s Hospital, Peking University Institute of
Hematology, 4Peking University Institute of Hematology, Peking University Peo-
ple’s Hospital, Beijing, China
Background: Allogeneic hematopoietic cell transplantation (allo-HSCT) is an
effective therapy for acute leukemia, but relapse remains a major problem. Our
recently article confirmed that chemotherapy plus DLI was superior to
chemotherapy alone in patients with acute leukemia who relapsed after allo-
HSCT, but the disease-free-survival (DFS) was only 20% at 2 years post-DLI
and the cumulative risk of re-relapse was nearly 60% at 2 years post-DLI.
Some articles have confirmed that chronic graft-versus-host disease (GVHD)
post-DLI was a favorable prognostic factor for DFS. Besides, minimal residual
290 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
disease (MRD) identified by multi-parameter flow cytometry (FCM) and real-
time quantitative polymerase chain reaction (RQ-PCR) could represent
leukemic load and predict relapse.
Aims: To perform a prospective study and investigate the impact of MRD and
GVHD guided sequential chemotherapy plus DLI on re-relapse and DFS in
patients with acute leukemia who relapsed after HSCT.
Methods: From January 1, 2013 to February 28, 2015, consecutive 70 patients
with acute leukemia who relapsed after allo-HSCT and received chemotherapy
plus DLI to treat relapse were enrolled in this study and were defined as study
group. When patients relapsed after allo-HSCT, induction chemotherapy plus
DLI would be given firstly, and then, if patients achieved complete remission
(CR), sequential chemotherapy plus DLI would be given based on the state of
MRD and GVHD post-DLI. Besides, from January 1, 2000 to December 31,
2008, 54 patients with acute leukemia who relapsed after allo-HSCT only
received induction chemotherapy plus DLI to control relapse and were defined
as historical group.
Results: In study group, cumulative risk of re-relapse, overall survival (OS)
and disease-free survival (DFS) at 1-year post-DLI was 45.7%, 56.9% and
50.0%, respectively. As well, multivariate analysis suggested that no chronic
GVHD post-DLI (P=0.019, HR=5.093) and persistent MRD-positive state post-
DLI (P<0.0001, HR=14.178) were unfavorable factors for re-relapse. Further-
more, based on the risk factors, 70 patients were further stratified into low-risk
group, intermediate-risk group and high-risk group. Cumulative risk of re-relapse
was significantly lower, DFS and OS were significantly better in low-risk group
than that in other two groups (re-relapse: 22.3% vs 80.0% vs 92.5%, P<0.0001;
DFS: 75.1% vs 0.0% vs 0.0%, P<0.0001 and OS: 94.7% vs 60.0% vs 0.0%,
P<0.0001). Besides, compared with historical group, cumulative risk of re-
relapse was significantly lower, DFS and OS were significantly better in study
group (re-relapse: 45.7% vs 70.4%, P<0.0001; DFS: 50.0% vs 24.1%,
P<0.0001 and OS: 56.9% vs 29.6%, P<0.0001).
Summary/Conclusions: These data suggest that based on the state of MRD
and GVHD post-DLI, sequential chemotherapy plus DLI could improve out-
comes of patients with acute leukemia who relapsed after allo-HSCT.
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TERMINAL NK CELL MATURATION IS CONTROLLED BY CONCERTED
ACTIONS OF T-BET AND ZEB2 
S Goossens1,*, M van Helden1, C Daussy2, B Lambrecht1, T Walzer2, G Berx1
1Inflammation Research Center, VIB, Ghent University, Ghent, Belgium, 2CIRI,
Université de Lyon, Lyon, France
Background: ZEB2 is a Zinc finger E-box binding transcription factor known
to control epithelial-to-mesenchymal transition during development and disease.
We recently have demonstrated that it is as well essential in multiple hematopoi-
etic lineage differentiation decisions and for hematopoietic stem/progenitor
migration.
Aims: We found that the Zeb2 is the most highly induced transcription factor
during NK cell maturation. The aim of this project was to elucidate the role of
Zeb2 in NK cells.
Methods: Using conditional loss and gain-of function mouse models we gen-
erated a cohort of mouse models with graded expression levels of Zeb2 specif-
ically in the NK cell lineage.
Results: Targeted deletion of Zeb2 resulted in impaired NK cell maturation,
survival and exit from the bone marrow. NK cell function was preserved but
mice lacking Zeb2 in NK cells were more susceptible to B16 melanoma lung
metastases. Reciprocally, ectopic expression of Zeb2 resulted in a higher
frequency of mature NK cells in all organs. Moreover, the immature pheno-
type of Zeb2 null NK cells closely resembled that of Tbx2 null NK cells. This
was due both to a dependence of Zeb2 expression on T-bet and to a prob-
able cooperation of these factors in gene regulation. Transgenic expression
of Zeb2 in Tbx21 null NK cells partially restored a normal maturation, estab-
lishing that timely induction of Zeb2 by T-bet is an essential event during NK
cell differentiation. Finally, this novel transcriptional cascade could also oper-
ate in human as T-bet and Zeb2 are similarly regulated in mouse and human
NK cells.
Summary/Conclusions: Here, we demonstrate that Zeb2 is essential to pro-
mote terminal NK cell maturation and that it functions downstream of T-bet.
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BIFURCATION INTO HEMATOPOIETIC STEM CELL TYPES IS DEPENDENT
UPON THE DEVELOPMENTAL SIGNALING MOLECULES
M Crisan1,2,*, P Solaimani Kartalaei2, CS Vink3, T Yamada-Inagawa2, A Neagu2,
S Karkanpouna2, K Bollerot2, C Purini2, W van Ijcken4, R van der Linden2,
SMC de Sousa Lopes5, R Monteiro5, C Mummery5, E Dzierzak2,3
1BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh,
United Kingdom, 2Cell Biology, Erasmus MC Stem Cell Institute, Rotterdam,
Netherlands, 3Centre for Inflammation Research, University of Edinburgh, Edin-
burgh, United Kingdom, 4Centre for Biomics, Erasmus MC, Rotterdam, 5Depart-
ment of Anatomy and Embryology, Leiden University Medical Centre, Leiden,
Netherlands
Background: All hematopoietic stem cells (HSC) are not alike. Clonal HSC
transplantations and refined cell sorting based on HSC surface markers or
reporters or responsiveness to signalling pathways have identified HSC sub-
types with different functional properties. HSC subtype behaviours include pre-
ferred/biased lineage output following transplantation. The source of this HSC
heterogeneity has yet to be identified. Since bone morphogenetic protein (BMP)
affects the development of HSCs while they are generated, HSC subtypes may
be differentially controlled by the BMP signaling pathway. However, the canon-
ical BMP pathway is dispensable in the fetal liver and adult bone marrow, tissues
where HSCs migrate during development. 
Aims: Investigate whether HSC subtypes are programmed intrinsically during
the developmental emergence of HSCs and/or whether their heterogeneity is
determined by extrinsic factors encountered in different developmental
hematopoietic tissues.
Methods: We examined whether HSCs in the embryo, fetus and adult are
directly responsive to BMP signaling and the relationship of BMP signaling to
HSC heterogeneity. To this objective, we used the BRE GFP transgenic reporter
mouse model. GFP is expressed in BRE–GFP mice when BMP and the BMP
receptor signal through Smad1/5 to activate transcription from the BRE
sequence. GFP expression denotes BMP activation at the moment of cell obser-
vation/isolation and does not represent previous BMP activation history.
Prospectively isolated cell types based on GFP expression and/or specific
marker combinations were further transplanted into irradiated recipients or ana-
lyzed by RNA sequencing.
Results: We show that BMP signalling directly regulates HSCs as they are
first generated in the aorta-gonad-mesonephros (AGM) region. However, in
expansion conditions upon explant culture, we find that the AGM harbors two
types of adult-repopulating HSCs: One type is BMP-activated and the other is
a non-BMP-activated HSC type that is indirectly controlled by Hedgehog sig-
nalling through the VEGF pathway. Importantly, the two types of HSCs are
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also found in the murine fetal liver and adult bone marrow in vivo. Clonal trans-
plantation demonstrates that they have distinct haematopoietic lineage out-
puts. Transcriptomic analyses show that the two HSC types differ in intrinsic
genetic programs, thus supporting a role for the developmental signalling
pathways in the regulation of HSC heterogeneity and lineage output.
Summary/Conclusions: Our results reveal that the bifurcation in HSC types
take place from early embryonic stages and suggest that their development
is dependent upon the signalling molecules in the microenvironment they
reside. Our findings provide insight into the molecular control mechanisms
that define HSC types and have important implications for reprogramming
cells to HSC fate and treatments targeting distinct HSC types.
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LACK OF MIR-127 DOWN-REGULATION IN THE TRANSITION FROM
HEMATOPOIETIC STEM CELLS TO MULTI-POTENT PROGENITORS
LEADS TO PANCYTOPENIA AND DEFECTIVE SELF-RENEWAL 
L Crisafulli1,2, S Muggeo1,2, P Uva3, L Susani1,2, M Cleary4, P Vezzoni1,2,
B Gentner5,6,7, F Ficara1,8,*
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Background: The ability of balancing self-renewal and differentiation is a key
hallmark of somatic stem cells; however, the molecular pathways underlying
this regulation are not completely understood, including any role for micro-
RNAs (miRNAs). To identify miRNAs involved in the maintenance of
hematopoietic stem cells (HSCs) identity we employed Pbx1-conditional
knockout (KO) mice. Pbx1 is a homeobox transcription factor that positively
regulates HSC quiescence. Its absence in post-natal HSCs causes a prema-
ture myeloid differentiation and an excessive proliferation that ultimately leads
to their exhaustion, indicating a profound self-renewal defect [1]. Moreover,
Pbx1maintains proto-oncogenic transcriptional pathways involved in myelo-
proliferative disorders [2].
Aims: Our aim was to assess if miRNAs contribute to regulate the balance
between self-renewal and differentiation in HSCs, which is malfunctioning in
myeloproliferative disorders and/or leukemia. 
Methods: To achieve our aim we employed Pbx1-conditional KO mice, whose
stem cells display a profound self-renewal defect. We reasoned that miRNA
profiling of Pbx1-null HSCs, which are defective in their main functions, would
lead to uncover miRNAs playing a role in HSC biology. Therefore, TaqMan-
based miRNA profiling of HSCs and of their immediate downstream progeny
of multi-potent progenitors (MPPs) from wt and Pbx1-conditional KO mice was
performed. The expression of the most differentially expressed (DE) miRNAs
was validated through independent real time PCR analysis, and was assessed
in additional BM cell populations. Finally, we performed in vivo functional studies
through lentiviral-mediated over-expression in primary murine bone marrow
(BM) cells followed by transplantation in irradiated recipient mice.
Results: Unsupervised hierarchical clustering indicates a clear distinction
between HSCs and MPPs at the level of miRNA expression, in accordance
with the hypothesis that miRNAs contribute to regulate the first transition step
in the adult hematopoietic development. Within each group, Pbx1-null and wt
cells cluster separately, suggesting that Pbx1 directly or indirectly might reg-
ulate the expression of miRNAs involved in HSC self-renewal. Importantly,
we found a group of miRNAs that are concordantly DE both in the physiological
HSC-to-MPP transition and in Pbx1-null HSCs compared to wt HSCs. Among
this list, miR-127 is the most DE. Its level of expression is comparable to that
of other miRNAs previously associated to HSCs. However, it is the only one
whose down-regulation occurs at the first transition from HSCs to MPPs, and
that is strongly HSC-specific, since it is not re-expressed further down in the
hematopoietic hierarchy within the BM. Interestingly, it is up-regulated in
CD34+ cells from chronic myeloid leukemia patients. Lack of miR-127 down-
regulation in Lineage- (Lin-) cells, achieved through lentiviral-mediated con-
stitutive expression, led to their in vivo competitive disadvantage over un-
transduced Lin- cells in long-term transplantation assays, and to a self-renewal
defect as assessed in secondary recipients. In addition, transduced Lin- cells
transplanted in the absence of competition gave rise to pancytopenia.
Summary/Conclusions: A tight regulation of miR-127 is crucial to maintain
HSC functions.
Funding: AIRC-Fondazione Cariplo (TRIDEO#15822); MIUR (FIRB#RBAP
11H2R9).
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NAMPT-NAD+-SIRT2 PATHWAY-TRIGGERED DEACETYLATION OF LMO2
PROTEIN IS INDISPENSABLE IN THE EARLY HEMATOPOIESIS THROUGH
COMPLETE TAL1 COMPLEX FORMATION
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Background: Nicotinamide phosphoribosyltransferase (NAMPT) is known as a
rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide
(NAD+) and supplies NAD+ to sirtuins (SIRTs) that require NAD+ to activate their
protein deacetylase functions. We already reported that NAMPT-NAD+-SIRT1
pathway is essential for granulopoiesis (Skokowa J, et al. Nat Med. 2009).
Aims: To analyze the roles of NAMPT-NAD+-SIRT pathway in early
hematopoiesis and elucidate new molecular mechanisms.
Methods: We used human induced pluripotent stem (iPS) cells model and a
serum- and feeder-free monolayer hematopoietic differentiation system. We
added NAMPT- or SIRT-inhibitors to the cells and analyzed hematopoietic dif-
ferentiation.
Results: First of all, we cultured iPS cells in the presence or absence of the spe-
cific inhibitor of NAMPT, FK866. Interestingly, we found marked reduction of
VEGFR2+CD34+ early hematopoietic progenitor cells at day 6 of differentiation
by inhibition of NAMPT. As a results of qRT-PCR results which shows SIRT2
mRNA expression is increasing in this differentiation stage, we tested SIRT2
specific inhibitor AC93253 and found that inhibition of SIRT2 also significantly
suppressed differentiation into VEGFR2+CD34+ early hematopoietic progenitor
fraction. Furthermore, the emergence of CD43+ hematopoietic progenitor cells
and colony forming ability at day 13 was completely suppressed by inhibition of
SIRT2. These results indicate that NAMPT-NAD+-SIRT2 signaling is needed for
early hematopoiesis. To evaluate downstream targets of NAMPT-NAD+-SIRT2,
we analyzed mRNA and protein expressions of well-known early hematopoietic
genes (GATA2, RUNX1, LMO2, and TAL1) in differentiated iPS cells on day 6
and found that both of them in these factors were not down-regulated by NAMPT
or SIRT2 inhibition. With the idea of post-transcriptional modifications, we tested
protein-protein interaction between SIRT2 and these candidate proteins in these
cells using Duolink technique. We found that RUNX1, LMO2 and TAL1 proteins
interact with SIRT2 protein. To identify the target of SIRT2-triggered deacetylation,
we quantified and compared the Duolink signals from total- and acetylated- can-
didate proteins in the cells treated or not with SIRT2 inhibitor using flow cytometry.
This analysis revealed that only LMO2 is deacetylated by SIRT2. LMO2 is known
as a component of TAL1 complex, which consist of LMO2, TAL1, LDB1, E47
and GATA1/2 proteins and has transcriptional activity as a complex on
hematopoiesis-specific target genes. Interestingly, mRNA expression levels of
all these target genes were markedly downregulated by inhibition of NAMPT or
SIRT2. Next, we predicted possible acetylated lysine residue in LMO2 protein
and found K74 and K78 as strong candidates. We made LMO2 protein expres-
sion constructs containing acetylation- (KQ) and deacetylation- (KR) mimic
mutants at these lysine residues and compared LMO2-LDB1 interaction between
WT and mutant LMO2 constructs by co-immunoprecipitation. This experiment
revealed that KQ-mutant had impaired interaction with LDB1 protein in compar-
ison to WT and KR-mutant LMO2. These results indicate that deacetylation of
LMO2 protein by SIRT2 is required for the interaction between LMO2 and LDB1
proteins.
Summary/Conclusions: NAMPT-NAD+-SIRT2 pathway plays an indispensa-
ble role in the early hematopoiesis by deacetylation of LMO2 protein which
enables the interaction between LMO2 and LDB1 proteins and complete TAL1
complex formation.
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B LYMPHOPOIESIS IS DEPENDENT ON TRANSCRIPTION FACTOR ERG
E Søndergaard1,2,3,*, M Rehn1,2,3, KJ Knudsen1,2,3, MS Hasemann1,2,3,
A Rauch4, J Jendholm1,2,3, S Mandrup4, B Porse1,2,3
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of Copenhagen, 2Biotech Research and Innovation Centre (BRIC), 3Danish
Stem Cell Centre (DanStem), Faculty of Health Sciences, University of Copen-
hagen, DK-2200 Copenhagen N, 4Department of Biochemistry and Molecular
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Background: B lymphopoiesis is a process that has been extensively studied
for decades, which has led to the discovery of several transcription factors that
are indispensible for the formation of B-cells.
The transcription factor ERG has previously been shown to influence
hematopoietic stem cells and various cancers. However, its role in B-cell devel-
opment is, thus far, largely uncharacterized.
Aims: To characterize the role of the transcription factor ERG in the develop-
ment of B lymphocytes with particular emphasis on elucidating underlying tran-
scriptional mechanisms.
Methods: We have created an Ergfl/fl:CD2iCre mouse model, in which the
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DNA-binding domain of Erg is deleted exclusively in the lymphoid cells render-
ing the transcription factor non-functional in this cell compartment.
Phenotypic characterization of the knock-out mouse was done using a combi-
nation of flow cytometry and in vitro differentiation assays.
To elucidate the mechanisms behind the influence of ERG on B lymphopoiesis,
we have examined gene expression changes in B cell progenitors following its
deletion using a microarray-based approach. For examination of changes at
the chromosomal level, we are using ATAC-sequencing, which assesses chro-
matin accessibility.
Results: The lymphoid-specific knock-out of Erg leads to a dramatic loss of B-
cells, which can be detected as a decline in the number of mature B-cells in the
peripheral lymphoid organs. In the bone marrow, a substantial reduction in B-
cell progenitors is seen already at an early progenitor stage with the cell loss
becoming gradually worse throughout differentiation. These findings are reca-
pitulated in ex vivo experiments.
The loss of B-cells can partly be ascribed to changes in the propensity of B cell
progenitors to undergo apoptosis and proliferation.
Accordingly, gene expression analyses show a reduced expression of cell cycle-
related genes in the B-cell progenitors. Furthermore, we see a deregulation of
genes associated with B-cell differentiation.
On the chromosomal level, the deficiency of ERG leads to marked changes in
genome-wide DNA accessibility in the B-cell progenitors.
Summary/Conclusions: We have identified ERG to be of central importance
for the development of B-cells. Loss of ERG in the lymphoid cell compartment
leads to a severe reduction in B-cells, which can be detected already at an
early progenitor stage. The deficiency of ERG leads to changes in key cell
properties, gene expression and genome-wide chromosomal accessibility.
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EXPRESSION OF BCL2, BUT NOT STAT5 SIGNALING, RESCUES
LYMPHOPOIESIS IN THE ABSENCE OF HHEX
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Background: The transcription factor Hhex (Hematopoietically-expressed
homeobox gene) is important for the development of definitive hematopoietic
progenitors and B-lymphocytes during embryogenesis. We have previously
shown that Hhex is essential for adult lymphoid development, with its absence
resulting in a severe defect stemming from a block in Common Lymphoid Pro-
genitor (CLP) differentiation. This block was characterised by cell cycle arrest
of B cell progenitors, as well as apoptosis and defective Stat5 phosphorylation
in response to IL-7.
Aims: The aim of this study is to determine the roles of apoptosis and defective
Stat5 signaling in the lymphoid developmental failure caused by loss of Hhex.
Methods: To investigate the pathways mediating this developmental block we
have crossed Mx-Cre inducible conditional Hhex knock-out mice with transgenic
mice expressing Bcl2 or constitutively active Stat5. We employed steady-state
flow cytometric cell phenotyping, competitive bone marrow transplantation and
in vitro differentiation experiments to assess lymphoid development. In addition,
B-cell function was assessed by in vitro proliferation assays of splenic B-cells.
Results: We found that overexpression of Bcl2 rescued B-cell development in
the absence of Hhex, as well as restoring the development of T, B and natural
killer (NK) lineages during in vitro differentiation and in vivo transplantation
experiments. In contrast, constitutively active Stat5 failed to rescue lymphoid
development in vitro or in vivo in the absence of Hhex. Further analysis of
Hhex-null, Bcl2-transgenic B-cells in vitro demonstrated that they were capable
of proliferation, indicating that these rescued B-cells were functional.
Summary/Conclusions: These results indicate that Bcl2 expression can over-
come the lymphoid deficiencies observed in the absence of Hhex, suggesting
that the primary role of this transcription factor is to promote survival of lymphoid
progenitors during early lymphoid development.
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ANAMORSIN IS ESSENTIAL FOR B-CELL TERMINAL DIFFERENTIATION
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Background: Anamorsin (AM, also called CIAPIN1) is a cell death-defying fac-
tor, which we have cloned as a molecule that conferred resistance to apoptosis
induced by growth factor deprivation. AM-deficient mice die during late gesta-
tion, and AM KO embryos are anemic and very small compared to wild-type
embryos (J Exp Med 2004; 199: 581–592), suggesting that AM is essential for
embryo growth and hematopoiesis. The embryonic lethality of AM KO mice
impedes detailed analysis of the roles of AM. AM is important in Fe-S cluster
protein biogenesis (BBRC 2011; 408: 329–333), which is indispensable in many
biological processes, suggesting that AM may be required for critical biological
pathways. 
Aims: To overcome the embryonic lethality of AM KO, here we generated AM
conditional KO (AMflox/flox) mice. The Cre-loxP system enabled cell type-specific
genetic modification. Since we previously reported AM overexpression in ~30%
of B-cell-type malignant lymphoma, here we focused on the role of AM in B-cell
development. 
Methods: We generated and analyzed CD19-Cre/AMflox/flox mice, with AM
deleted specifically in CD19+B cells (from Pro-B cells to mature peripheral B
cells in B-cell development). B-cell development progresses through the pro-
B-cell, pre-B-cell and immature-B-cell stages in BM and then exit from BM to
spleen, where they pass through transitional stages; transitional type 1 (T1)
and transitional type 2 (T2), and mature to either follicular B cells or marginal
zone B cells.
Results: Compared with control CD19-Cre mice, CD19-Cre/AMflox/flox mice
exhibited fewer B220+B cells in the spleen (40.8±2.6% vs 56.8±3.8%, P<0.001),
peripheral blood (23.2±2.5% vs 51.0±4.4%, P<0.001), and LN (8±2.3% vs
31.7±1.0%, P<0.001). To further examine how AM deficiency impacted B-cell dif-
ferentiation, BM and spleen cells were categorized into B-cell subsets—from
hematopoietic stem cells to mature follicular and marginal zone B cells—based
on marker expression patterns using flow cytometry. Compared to control mice,
CD19-Cre/AMflox/flox mice showed significantly fewer follicular type I (FO-I) cells
(B220+, AA4.1−, sIgMlow, CD23+, sIgD+), which are the most matured follicular B
cells in the spleen (7.9±0.1% vs 15.1±1.0%, P<0.01). Immunohistochemistry
using monoclonal anti-B220 antibody in formalin-fixed paraffin-embedded spleen
sections showed smaller B-cell follicles in CD19-Cre/AMflox/flox mice. Since AM
was originally isolated as an anti-apoptotic molecule, spleen cells were treated
with FITC-conjugated annexin V to determine the percentage of apoptotic cells,
revealing greater apoptotic cell accumulation in CD19-Cre/AMflox/flox mice com-
pared to controls (30.0±4.4% vs 19.8±1.3%, P<0.05). This suggested that follic-
ular B cell development was blocked by increased apoptosis in the CD19-
Cre/AMflox/flox mice. Furthermore, CD19-Cre/AMflox/flox mice lacked splenic
CD19+B220−/low cells, which display a plasmablast phenotype. 
Summary/Conclusions: Although AM expression was consistent throughout
the differentiation stages of CD19+ B cells, AM deficiency predominantly affect-
ed terminal differentiation of B cells, especially from T2 to FO-I. Immature B
cells mature through transient T2 B cells into follicular or marginal zone B cells,
and their follicular versus marginal zone fate partly depends on the strength of
BCR signaling. Reduced numbers of FO-I B cells and CD19+B220−/low cells in
the spleen are also reported in mice with defects in Bruton’s tyrosine kinase
(BTK), which is activated in downstream of BCR signaling. The phenotypic sim-
ilarity between Btk-deficient mice and our CD19-Cre/AMflox/flox mice suggests
that AM may affect B-cell development through the BCR-BTK pathway. Overall,
our present results show that AM plays essential roles in B-cell terminal differ-
entiation, suggesting the potential involvement of some Fe-S cluster proteins
in B-cell terminal differentiation. Moreover, our novel AMflox/flox mice will enable
further investigation of the functions of AM and the related Fe-S cluster proteins
in various organs.
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DOWNREGULATION OF CD44 FUNCTIONALLY DEFINES HUMAN T-CELL
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Background: T-cell development in the thymus is a complex process that
depends on sequential transcriptional and epigenetic events that induce T-cell
lineage commitment and simultaneously suppress alternative cell fates. Human
T-cell development is less well studied than its murine counterpart due to the
lack of genetic tools and the difficulty of obtaining cells and tissues. However,
recent technological advances have enabled the identification of the transcrip-
tional landscape of differentiating human thymocytes. Research has focused
on mimicking the thymus environment in in vitro T-cell differentiation cultures
starting from hematopoietic stem/progenitor cells (HSCs) derived from human
cord blood or bone marrow.
Aims: We aimed to compare in vitro T-cell differentiation at the level of gene
expression with gene expression of in vivo murine and human early T-cell devel-
opment. Recapitulation of gene expression at the correct stage of differentiation
would validate this model beyond the level of surface markers that are commonly
used to identify sequential differentiation stages in vitro and in vivo, and helps
identify novel markers that delineate specific stages and commitment points.
Methods: We have utilized the OP9-DL1 in vitro co-culture system to gradually
differentiate CD34+ HSCs from umbilical cord blood into the T-cell lineage.
HSCs in this co-culture will recapitulate in vivo T-cell development as measured
by incremental acquisition of surface markers CD7, CD5, CD1a, CD4, and
CD8. We investigated and compared gene expression profiles of 11 human T-
cell differentiation subsets collected by FACS sorting at 5 different time-points.
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We determined the TCRβ rearrangement status and functionally defined T-cell
commitment of several human early thymocyte subsets.
Results: The changes in gene expression of subsequent early T-cell develop-
mental stages closely resemble those of human and murine in vivo thymocyte
subsets, validating the OP9-DL1 co-culture as a true representative of in vivo
human T-cell development. These analyses let us to define a gene signature
that distinguishes pre- and post- αβ T-cell commitment. We searched for various
candidate surface markers that could pinpoint the exact transition from pre- to
post-T-cell committed human thymocytes; both in human thymocytes in vivo
as well as in differentiating cells in vitro, loss of CD44 marks T-cell commitment
in early CD7+CD5+ cells, before the acquisition of CD1a surface expression.
The CD44-CD1a- post-committed thymocytes have initiated in frame TCR
rearrangements and have completely lost the capacity to develop into myeloid,
B- and NK-cells, unlike uncommitted CD44+CD1a- thymocytes.
Summary/Conclusions: The gene expression profiles of 11 human in vitro T-
cell differentiation subsets closely resemble those of early T-cell development
of murine and human thymocytes. Therefore, the OP9-DL1 co-culture closely
mimics in vivo T-cell development. Moreover, this model has enabled us to
pinpoint human αβ T-cell commitment using CD44. In conclusion, loss of CD44
represents a previously unrecognized stage that defines the earliest committed
T-cell population in the human thymus.
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Background: Knowledge about the differences and similarities between nor-
mal hematopoietic stem and progenitor cells (HSPCs) and their malignant
counterparts is an essential prerequisite for the development of novel thera-
peutic approaches for the treatment of hematologic diseases such as acute
myeloid leukemia (AML). We recently identified the adhesion G-protein coupled
receptor 56 (GPR56) as novel leukemia stem cell marker in AML. While GPR56
has been attributed a role in homing and endothelial to hematopoietic stem
cell transition in mice and zebrafish its functional role in human primary HSPCs
has not been fully characterized yet.
Aims: Here we set out to determine the functional role of GPR56 expression
for normal HSPC function in the human hematopoietic system.
Methods: We knocked down GPR56 via lentiviral shRNA vectors in cord blood
(CB) CD34+ cells. Gene knockdown was confirmed by FACS analysis upon
lentiviral transduction prior to subjecting the cells to in vitro and in vivo assays.
GFP+ cells were sorted into methylcellulose and colony formation potential
was determined after 12 days. Furthermore, cells were injected in NSG mice
and bone marrow was analyzed for total and lineage specific human engraft-
ment at 4, 8, and 20 weeks post transplantation. RNA-Sequencing (RNA-Seq)
was performed in CB CD34+ cells 3 days post infection to determine differences
in gene expression.
Results: We observed a rapid decrease in the fraction of GFP+ cells infected
with two different shRNA vectors against GPR56, but not when infected with
shLuciferase control vector. Furthermore, colony formation capacity of CD34+
cord blood cells was severely impaired upon knockdown (KD) of GPR56 with
greater reduction in the more immature GEMM and BFU-E colonies compared
to G- and M-colonies. Moreover, we found that the repopulating potential of
CB CD34+ cells was significantly impaired in cells with near complete KD of
GPR56. Accordingly, we observed an inverse correlation between the level of
GPR56 KD and contribution of GFP+ cells to engraftment. In addition, we
observed significant differences in the lympho-myeloid-lineage-ratio to the dis-
advantage of the lymphoid lineage when harvesting human cells from mouse
bone marrow 20 weeks post transplantation of GPR56 KD HSCs compared to
controls. RNA-Seq of CB CD34+ cells upon GPR56 KD vs controls revealed
enrichment for several GO terms connected to the regulation of hematopoiesis,
apoptosis, and survival.
Summary/Conclusions: Together, our findings indicate that GPR56 is not
only involved in survival and proliferation, but also in the maintenance of the
multipotent undifferentiated state of human HSPCs.
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Background: Aplastic anemia (AA) is a bone marrow failure disorder in which
the microenvironment seems to play a role.
Mesenchymal stromal cells (MSC) have been investigated in AA for their essen-
tial function in bone marrow microenvironment. However, there are limited and
controversial in vitro studies characterizing patient-derived MSC. Therefore, in
vivo models would be tremendously useful to better understand the effective
role of the stromal compartment in AA niche. Indeed, the establishment of sim-
plified haematopoietic stem cell niche models potentially allows to recapitulate
haematopoietic and stromal defects and to dissect the functional role of different
cell populations involved in the development of specific diseases.
Aims: Using our recently described in vivo model which accurately mimics the
miniature of a bone/bone marrow organ, we aim to investigate the role of MSC
in AA reproducing pathological microenvironment and testing their ability to
support haematopoiesis (Serafini et al., 2014).
Methods: We isolated MSC from 7 newly diagnosed AA pediatric patients (AA-
MSC) and 7 age-matched healthy donors (HD-MSC), after informed consent
according to institutionally approved protocols. MSC cultures were character-
ized by evaluating clonogenicity, cell growth, immunophenotype, and differen-
tiation potential in vitro. Additionally, we analyzed immunohistologically and
functionally the haematopoietic and stromal compartment of the ossicles
obtained after the in vivo implant of chondrogenic pellets derived from MSC of
both groups.
Results: AA-MSC displayed morphology, phenotypic profile, proliferation and
in vitro differentiation capacities similar to their normal counterparts, albeit exhib-
ited a lower colony forming efficiency. Moreover, we showed that AA-MSC main-
tain the capacity to establish in vivo an ossicle constituted by cortical bone filled
with normal host-derived haematopoiesis. Immunohistochemistry analysis of
the haematopoietic tissue in the intertrabecular space within the ossicles
revealed the presence of murine macrophages, myeloid cells, megakaryocytes,
red blood cells and osteoclasts in similar proportion in normal and patient-derived
sections. Moreover, within the AA ossicle-derived marrows, it was possible to
determine the presence of haematopoietic clonogenic progenitors and quantify
the same number of cells belonging to the erythroid, myeloid and megakary-
ocytic lineages as their normal counterparts. Also the human stromal compart-
ment of the ossicles originated from AA-MSC and HD-MSC resulted similar. A
comparable amount and disposition of adipose marrow was observed in AA
ossicles and in controls. Ossicles derived from both sources of MSC prepara-
tions similarly presented osteoblasts lining the osseous trabeculae, bone marrow
interstitial fibrosis, reticulin deposition and iron storages.
Summary/Conclusions: This is the first study which addresses the in vivo
ability of AA-MSC to support haematopoiesis. Using our in vivo model, we have
been able to demonstrate that AA-MSC generate normal ossicles characterised
by cortical bone, marrow cavity, donor-derived marrow stroma, and host-
derived haematopoietic tissue. Further studies are needed to expand this inves-
tigation to a larger cohort of patients, in order to understand if these observa-
tions could be confirmed in MSC preparations derived from AA patients of dif-
ferent age and/or disease classification. Moreover, this work demonstrates that
our experimental system could be suitable to model in vivo haemopoietic dis-
eases and paves the way for studies on AA and other disorders.
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FUNCTION IN HUMANS
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Background: Human blood production releases around 1011 cells per day into
circulation. These originate from a minute population of haematopoietic stem
cells, which differentiate towards mature cells by the clonal expansion of pro-
genitor cells, following lineages of increasingly restricted fate. The molecules
and pathways involved in lineage choice have been studied in great detail, but
our understanding of the networks of proteins controlling cell fating is partial. 
Aims: We sought to identify genetic variants controlling iron metabolism,
haemotopoeisis, blood cell differentiation and blood cell clearance by a hypoth-
esis free genomewide study; the largest population association analysis of
blood cell traits to date.
Methods: We studied 36 haematological traits (measuring the properties of
reticulocytes, red cells, platelets and the white cell subtypes) derived from the
full blood counts of 173,480 individuals of European ancestry, selected from the
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UK Biobank and INTERVAL cohorts. We analysed 29.5 million genetic variants
(many of which were rare, with minor allele frequencies as low as 0.01%), imput-
ed from genotypes measured using the UK Biobank Affymetrix Axiom array. 
Results: We identified 182,105 variants significantly associated with at least
one trait and could explain these associations using 1,652 distinct sentinel vari-
ants, 148 of which corresponded to previously reported GWAS hits, validating
almost all the blood trait associations known for European populations. The
associations of the remaining 1,504 sentinel variants were novel, augmenting
the number of known associations by over 10-fold. Remarkably, we identified
270 rare and 258 low-frequency variants (allele frequency <1% and 1-5%
respectively), and 44 “high impact” variants with additive allelic effects of more
than 0.5 phenotypic standard deviations.
Summary/Conclusions: Almost three quarters of the associated variants are
in the non-coding part of the genome with a striking enrichment in DNAse-I
hypersensitivity sites with an enhancer signature. Gene sets containing asso-
ciations were enriched in haematological pathways, genes implicated in rare
blood and immune disorders, and genes predisposing to human complex dis-
ease, confirming the importance of our results for the understanding of
haematopoietic processes and pathogenesis.
P737
EFFICIENT GENOME EDITING OF MOUSE HEMATOPOIETIC CELLS
USING CRISPR/CAS9 TECHNOLOGY
E Sarrou1,*, B Gibson2, K Keeshan1
1Institute of Cancer Sciences, University of Glasgow, 2Department of Haema-
tology, Royal Hospital for Sick Children, Glasgow, United Kingdom
Background: A number of techniques have been used to study hematopoietic
malignancies including viral overexpression of human oncogenes, RNA inter-
ference (RNAi) and transgenic animals. Each of these have their caveats for
cell specific targeting, particularly RNAi approaches that are characterised by
incomplete genetic inactivation without changing the genetic code. Genome
editing technologies, including clustered regularly-interspaced short palindromic
repeats (CRISPR), have been used to stably modulate the genome of several
model organisms. The genome engineering of hematopoietic cells is compli-
cated mainly due to the low efficiency of the non-viral delivery methods.
Aims: To generate efficient and stable genome edited murine hematopoietic
models using CRISPR/Cas9 technology.
Methods: Two different guideRNAs (gRNAs) targeting either Mcm6 (gRNA5
and 8) or Sirt1 (gRNA3 and 9) were designed and cloned into the pL-
CRISPR.EFS.GFP lentiviral vector. These genes were chosen as they are
involved in hematopoietic progenitor and stem cell (HSPC) properties. GFP+
32D Cl3 mouse hematopoietic cells were FACS sorted at day 5 post-transduc-
tion. Knockout efficiency was confirmed by both western blotting and qRT-PCR.
Functional analysis was performed by the SURVEYOR assay and Sanger
sequencing. Murine HSPCs were isolated from 5FU treated C57BL/6 mice
(CD45.2+), transduced with the most efficient gRNA for either Sirt1 or Mcm6
and injected into B6.SJL mice. Engraftment was measured by FACS analysis
of blood sampling at 4 weeks post-transplant.
Results: CRISPR/Cas9 efficiency was first tested on the mouse 32D cell line
in vitro. Decreased protein and mRNA levels of Sirt1 were detected in 32D
GFP+ bulk population transduced with gRNA9 (32D+gRNA9) at day 5 which
was not evident with gRNA3. SURVEYOR assay revealed that Cas9-mediated
cleavage efficiency was higher in 32D+gRNA9 cells (16.3% indels) compared
to 32D+gRNA3 cells (12.5% indels). 32D+gRNA9 cells were further expanded
and FACS sorted for single clones. 5/20 clones showed complete absence of
Sirt1 at the protein level (25% of Cas9 efficiency). Efficient clones were further
used for genotype analysis by Sanger sequencing to confirm the type of indels.
On the other hand, we saw complete absence of Mcm6 protein expression in
32D GFP+ bulk cells transduced with gRNA5 or gRNA8, and >2-4-fold mRNA
reduction was observed when transduced with gRNA5 and 8, respectively. Our
CRISPR/Cas9 system was further tested in vivo using primary cells. Murine
CD45.2+ HSPCs were isolated, transduced with equal viral titre of empty vector,
Mcm6-gRNA8 or Sirt1-gRNA9 and transplanted into CD45.1+ mice. Blood sam-
pling revealed high levels of engraftment as determined by CD45.2% and
CRISPR transduction efficiency determined by the GFP levels at 4 weeks post-
transplant. Our results show that CD45.2+GFP+ cells engrafted at 4 weeks
showing effective CRISPR/Cas9 mediated transduction and transplantation of
Mcm6 and Sirt1 knockout primary HSPCs. 
Summary/Conclusions: In this study we successfully generated in vitro and
in vivo CRISPR/Cas9 models for efficient genome editing on hematopoietic
cells. Our findings demonstrate a complete gene knockout in vitro but with vari-
able Cas9-mediated cleavage which was further confirmed by our clonal analy-
sis. This suggests that Cas9 function might depend on both the targeted gene
and/or the gRNA. Also, transduction of HSPCs was sufficient to ensure engraft-
ment of GFP+ cells. Long-term serial analysis will be further conducted to
ensure stable expression and test Cas9-mediated cleavage in vivo.
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Background: Erythropoiesis is a complex process starting from pluripotent
medullary progenitors and leading to the production of enucleated erythrocytes.
Several transcriptomic analyses of erythroid differentiation have been published
to better understand the molecular mechanisms of erythropoiesis. However, it
is now clearly established that the proteome cannot simply be deduced from
the transcriptome and that post transcriptomic modifications are responsible
for a large part of the proteome variations. Consequently, a direct proteomic
analysis of the erythroid differentiation is required to accurately assess the
modifications that occur during this process.
Aims: Our goal was to provide a deep analysis of the proteome evolution of
human erythroid cells during their differentiation, from the BFU-E up to the
orthochromatic erythroblast, and a quantitative analysis of the repartition of the
proteins between the pyrenocyte and the reticulocyte after enucleation. The
absolute quantification of proteins will be determined rather than their relative
evolution all along the differentiation process.
Methods: We used CD34+ cord blood progenitors and an optimized cell culture
method allowing the production of highly synchronized cell populations of ery-
throid cells at various differentiation stages. Cellular populations from erythroid
progenitors up to reticulocytes were submitted to mass spectrometry label-free
analysis. To analyze the repartition of proteins after enucleation, pyrenocytes
and reticulocytes were sorted by FACS. Equal numbers of reticulocytes and
pyrenocytes were analyzed by mass spectrometry after iTRAQ labelling.
Results: Our analysis led to the absolute quantification, as protein copy number
per cell, of more than 6100 proteins involved in many various biological process
throughout the erythroid differentiation, with a false discovery rate of less than
1%. The range of quantified protein expression extended to around 7 logs.
Absolute quantification was validated by several ways including the comparison
of calculated values with those already published for several proteins and the
classical differentiation markers expression pattern. All erythroid transcription
factors were quantified. A comparison between mRNA and protein expression
showed only a modest correlation as usual. Interestingly, this analysis revealed
proteins with unexpected expression in erythroid differentiation such as
optineurin, an autophagy inducer, or phospho1, a phosphatase involved in bone
mineralization, which increased along differentiation, or leptin receptor, known
to activate JAK2 and STAT5, which peaked at the proE/BasoI stage. Further-
more, the absolute quantification allows the calculation of protein ratio of differ-
ent complexes. Regarding to segregation of proteins between reticulocytes and
pyrenocytes, our study allowed the quantitative repartition of 1300 proteins.
Flow cytometry imaging was used to calculate the cell surface area and the
cytoplasmic volumes of pyrenocytes and reticulocytes allowing to determine
whether a protein segregates passively or whether it is actively sorted. This
method revealed proteins with unexpected localization and the active segre-
gation of several proteins including most erythrocyte-specific membrane pro-
teins which actively segregate with reticulocytes.
Summary/Conclusions: All these results significantly increase our knowledge
of the protein expression pattern during erythropoiesis and should constitute a
valuable data base for subsequent studies regarding both physiological and
disordered erythropoiesis. A similar analysis is currently ongoing on murine
erythroid differentiation to compare human and murine erythroid proteomes.
P739
AN IMBALANCE BETWEEN PLASMA ANNEXIN-A5 AND
PHOSPHATIDYLSERINE EXPRESSION IN ERYTHROCYTES PROMOTES
VASCULAR INJURY DURING SICKLE CELL DISEASE
S Sadoudi1,*, S Le Jeune2, P Bonnin3, D Charue1, C Boulanger1, O Blanc-Brude1
1’ParCC’ Paris Cardiovascular Center - UMRs970, INSERM, Université Paris-
Descartes, AP-HP, Paris, 2Arterial Hypertension, Avicenne hospital, AP-HP,
Bobigny, 3Vascular explorations, Lariboisière hospital, AP-HP, INSERM, Uni-
versité Paris-Descartes, Paris, France
Background: Chronic hemolytic anemia, including Sickle Cell Disease (SCD) is
characterized by painful vaso-occlusive crises (VOC), vascular injury, red blood
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cell (RBC) aggregation and vesiculation, and intravascular hemolysis. At steady
state, RBC release hemoglobin, heme and microparticles (MP) in plasma. This
increases again during VOC. Stressed RBC and the MP they release express
phosphatidylserine (PS) at their surface and contain cytotoxic heme, with dele-
terious impact on endothelial cells and vascular function. On the other hand,
annexin-A5 is an intracellular protein that associates with membranes during cell
stress and can be found in plasma. Annexin-A5 acts as a PS inhibitor, neutralizing
PS-mediated effects of stressed cells and MP, and is generally thought to be an
anti-inflammatory and anti-thrombotic protective agent.
Aims: We aimed to determine whether PS expression in red blood cells and
MP in SCD is counterbalanced by annexin binding, and whether annexin-A5
in particular is modulated during vaso-occlusions. More specifically, we wanted
to assess whether the plasma levels of annexin-A5 were all consumed during
vaso-occlusions, or whether some annexin-A5 remained bioavailable for new
interactions.
Methods: 1) We collected plasma and erythrocytes from a cohort of SCD
patients during steady state or VOC, and matched controls. We studied plasma
MP, plasma annexin-A5 levels and erythrocyte and MP expression of PS. 2)
We designed a novel ELISA-based assay to capture PS+ MP with an anti-
annexin-A5 antibody. It quantified annexin-A5-covered MP in plasma, but also
estimated ligand-free functional annexin-A5. We characterized plasma MP by
FACS with labeling of ligand-free PS with annexin-A5 and anti-CD235a, and
size by NTA (50-1500 nm). 3) We tested recombinant annexin-A5 to block ROS
production induced by SCD MP in cultured endothelial cells. 4) We used a
model of hypoxia-induced vaso-occlusion in transgenic mice with SCD and
tested PS neutralization in vivo with recombinant annexin-A5.
Results: In controls, RBC displayed little labeling with exogenous annexin-A5
by FACS. ELISA revealed that MP were few and covered with endogenous
annexin-A5. Moreover, some annexin-A5 remained bioavailable in plasma. In
SCD, plasma levels of annexin-A5 were increased, and MP levels were increased
significantly, materializing hemolysis as expected. Surprisingly, SCD RBC and
plasma MP all showed increased PS expression, as mean fluorescence intensi-
ties (MFI) by FACS. Hence, SCD RBC and MP bore more ‘free’ PS at their sur-
face, available to exogenous annexin-A5 binding. In acute stage VOC, MP levels
were increased even further and bore cytotoxic heme. RBC PS externalization
increased even further in intensity, and we still found virtually no ligand-free
annexin-A5 in plasma. In vitro, recombinant annexin-A5 inhibited the pro-oxidant
effects of SCD MP on cultured endothelial cells. In vivo, recombinant annexin-
A5 released vaso-occlusions triggered by hypoxia in transgenic mice with SCD,
characterized by echo-Doppler measurements of renal perfusion.
Summary/Conclusions: We concluded that the equilibrium between PS
expression and annexin-A5 is compromised in SCD. Endogenous plasma
anenxin-A5 appears to be entirely consumed by excess PS externalization,
unable to quench new bouts of PS expression during hemolysis, and insufficient
to neutralize the high levels of PS+ MP produced by stressed RBC. In SCD,
the therapeutic use of recombinant annexin-A5 may thus help compensate the
imbalance between PS+ MP and annexin-A5.
P740
STAPHYLOCOCCUS AUREUS PROTEIN ISDH INHIBITS THE CD163
PATHWAY FOR HAPTOGLOBIN-FACILITATED HEMOGLOBIN SCAVENGING
KL Madsen1,*, K Stødkilde2, C Dickson3, A Etzerodt2, JH Graversen1, D Gell3,
CBF Andersen2, SK Moestrup1
1Department of Cancer and Inflammation Research, University of Southern
Denmark, Odense C, 2Department of Biomedicine, Aarhus University, Aarhus,
Denmark, 3School of Medicine, University of Tasmania, Hobart, Australia
Background: Hemolysis induced by bacterial α-toxin is a common complica-
tion in septic infections with Staphylococcus aureus and other bacteria, which
utilize heme as a source for exogenous iron. The S. aureus uptake of heme
occurs by a sophisticated heme-extraction mechanism that involves proteins
from the iron-regulated surface determinant (Isd) system. Sequestration of
heme from the hemoglobin-haptoglobin (Hb-Hp) complex is initiated by binding
of Hb-Hp to the Isd protein H (IsdH). IsdH contains three the near-iron trans-
porter (NEAT) domains; N1 and N2 anchors to hemoglobin, while the third
NEAT domain N3 extracts heme. Normally, Hb-Hp is rapidly scavenged by the
macrophage receptor CD163. However, since IsdH bind Hb-Hp close to the
binding site of CD163, IsdH can potentially interfere with the uptake.
Aims: The objective of this study was to test the effects of recombinant IsdH
on Hb-Hp binding to CD163 and cellular uptake.
Methods: To study effects of IsdH, recombinantly expressed full-length
IsdHN1N2N3 and two truncated variants of IsdHN1 and IsdHN2N3 were used.
Endocytotic uptake of fluorescently labelled Hb-Hp by CD163-expressing Chi-
nese hamster ovary (CHO) cells in presence of IsdH was evaluated by confocal
microscopy and image-cytometry. Binding kinetics of IsdH was further charac-
terized by SPR analysis.
Results: Our present data show that the high-affinity binding of IsdH to Hb-Hp
strongly inhibits concomitant binding to and uptake by the human macrophage
receptor CD163. Full-length IsdHN1N2N3 showed the strongest inhibition of Hb-
Hp uptake in CD163 expressing CHO cells and displayed the highest overall
affinity for binding to Hb-Hp compared to the truncated versions. The single
domain, IsdHN1, which is not directly involved in the heme extraction, was also
a potent inhibitor of both CD163 binding and endocytosis of Hb-Hp (Figure 1).
Figure 1.
Summary/Conclusions: Inhibition of the CD163 uptake of Hb-Hp could benefit
the bacterium by keeping hemoglobin accessible a source of iron. Furthermore,
dampening of the CD163-mediated hemoglobin degradation pathway, which
converts the pro-inflammatory hemoglobin to anti-inflammatory metabolites,
may further spark a septic inflammation supporting bacterial growth. Finally, it
may skew the diagnostic negative correlation between hemolytic activity and
the plasma concentration of haptoglobin. We suggest that inhibition of CD163-
mediated Hb-Hp uptake is an additional function of IsdH.
P741
BODY IRON STATUS HAS A LARGER IMPACT ON UTILIZATION EFFICIENCY
OF DIETARY IRON FOR ERYTHROPOIESIS THAN ERYTHROPOIETIC
STIMULATION
Y Matsuo-Tezuka*, Y Shimonaka
Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura,
Japan
Background: In a previous study, we demonstrated that dietary iron uptake
and mobilization of stored iron are both up-regulated through suppression of
serum hepcidin levels during erythropoietic stimulation by administration of
Epoetin beta pegol (C.E.R.A.), a long-acting erythropoiesis-stimulating agent.
It was also demonstrated that up-regulation of ferroportin (FPN) in reticuloen-
dothelial macrophages and up-regulation of divalent metal transporter 1 (DMT1)
and FPN in enterocytes are followed by hepcidin suppression. To determine
the contribution of dietary iron for erythropoiesis under iron intervening condi-
tions and erythropoietic stimulation, we labeled dietary iron with stable iron iso-
tope 57Fe and assessed it by inductively coupled plasma mass spectrometry
(ICP-MS). By using them, we demonstrated that the utilization of dietary iron
for erythropoiesis was increased under erythropoietic stimulation and
decreased under iron loading. However, it is not elucidated which intervention
has stronger impact on the utilization efficiency of dietary iron for erythropoiesis.
Aims: In this study, we compared the impact of body iron status and erythro-
poietic stimulation on the utilization efficiency of dietary iron for erythropoiesis.
Methods: To assess dietary iron-derived hemoglobin synthesis, a diet con-
taining 200 ppm of 57Fe instead of natural iron (57Fe-diet) was used. A diet
containing 200 ppm of natural iron (native Fe diet) was used as a control.
C57BL/6NCrl mice were fed the native Fe diet and were intravenously admin-
istered 0.2 or 0.4 mg/mouse of iron-dextran (iron-loading condition) or dextran
(control). Five days after iron loading, the diet was switched to the 57Fe-diet
immediately after intravenous injection of 2 or 10 µg/kg of C.E.R.A. or vehicle.
On 10 days after C.E.R.A. treatment, mice were euthanized by exsanguination
under anesthesia with isoflurane, and hemoglobin levels were measured. To
quantify dietary iron-derived hemoglobin synthesis, the content of hemoglobin
containing 57Fe (57Fe-hemoglobin) was measured by ICP-MS. The utilization
efficiency of dietary iron for erythropoiesis was assessed as a ratio of 57Fe-
hemoglobin to hemoglobin levels.
Results: On 10 days after C.E.R.A. administration, hemoglobin levels were
increased in C.E.R.A. 10 µg/kg-treated groups compared with vehicle-treated
groups, as well as 57Fe-hemoglobin levels. On the other hand, iron-loading
did not affect hemoglobin levels. However, 57Fe-hemoglobin levels were
decreased in the iron-dextran 0.4 mg/mouse-treated groups as well as in the
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iron-dextran 0.2 mg/mouse-treated groups under steady-state erythropoiesis.
The utilization efficiency of dietary iron for erythropoiesis was significantly low-
ered in iron-dextran 0.4 mg/mouse-treated groups compared with dextran-treat-
ed group, whereas the utilization efficiency of dietary iron for erythropoiesis
was not significantly different between vehicle- and C.E.R.A.-treated groups.
Summary/Conclusions: In the previous study, we demonstrated that both ery-
thropoietic stimulation and iron intervention influenced the dietary iron utilization
for erythropoiesis. Furthermore, in the present study, we demonstrated that
iron intervention, in spite of mild iron loading conditions which did not affect the
hemoglobin levels, reduced the utilization efficiency of dietary iron for erythro-
poiesis and it had larger effect than erythropoietic stimulation. It suggested that
iron loading could potentially drop the utilization efficiency of dietary iron for
erythropoiesis and therefore it is important to optimize the iron replacement
therapy for renal anemia patients.
P742
AG-519 IS A POTENT ACTIVATOR OF MUTANT PYRUVATE KINASE
ASSOCIATED WITH HEMOLYTIC ANEMIA
J Hixon1,*, PA Kosinski1, M Clasquin1, K Johnson1, J Popovici-Muller1, B Zahler2,
G Cianchetta1, L Silverman1, L Dang1, C Kung1
1Agios Pharmaceuticals, Inc., Cambridge, 2PharmD Consulting, LLC, Penning-
ton, United States
Background: Pyruvate kinase (PK) deficiency is an autosomal recessive enzy-
mopathy that is the most common cause of hereditary nonspherocytic hemolytic
anemia. PK deficiency is a rare disease characterized by a life-long chronic
hemolysis with severe co-morbidities. It is hypothesized that mutations in PK
result in insufficient energy production, in the form of adenosine triphosphate
(ATP), to maintain red cell membrane homeostasis, leading to chronic hemol-
ysis. Treatment is generally palliative, focusing on the resultant anemia, and
there are no approved drugs that directly target mutated PK. AG-519 is an
orally available, allosteric activator of the red cell isoform of PK (PK-R). AG-
519 is currently in a randomized, double-blind, phase 1 study in healthy volun-
teers (NCT02630927), with the objective of identifying a safe and pharmaco-
dynamically active dose and schedule to be used in subsequent clinical studies
in subjects with PK deficiency.
Aims: We describe the mechanism of action and cellular effects of AG-519 in in
vitro and ex vivo settings on mutant PK-R proteins associated with PK deficiency.
Methods: Mutant PK-R enzymes were expressed in E. coli and the kinetic param-
eters of the purified enzymes were evaluated in the presence or absence of AG-
519. For thermostability studies, mutant enzymes were pre-incubated with control
or AG-519 and then subjected to elevated temperature (53°C) followed by assess-
ment of residual activity over time. Peripheral blood was obtained from patients
with PK deficiency and the red cells were incubated with AG-519 for up to 24 h,
followed by assessment of PK-R activity and ATP levels.
Results: We demonstrate that AG-519 can potently activate a spectrum of recom-
binantly-expressed PK-R mutant proteins associated with PK deficiency. All tested
mutant enzymes exhibited at least 2-fold activation compared to baseline. The
binding of AG-519 attenuated the thermostability defect of several mutant alleles
of PK-R, including the commonly observed R510Q mutant, which had a half-life
of ~2% of that of wild-type PK-R when incubated at 53°C. Pre-incubation of the
R510Q protein with AG-519 restored the half-life to that of the wild-type enzyme.
PK-deficient red cells are characterized by changes in metabolism associated
with defective glycolysis, including a deficiency in ATP. PK-deficient red cells from
several patients with distinct compound heterozygous PK-R mutations exposed
to AG-519 ex vivo had increased PK-R enzyme activity (up to 4-fold over control)
and increased ATP levels (up to 100% over control). These experiments demon-
strate that AG-519 can effectively activate mutant PK-R within patient red cells.
In these ex vivo settings, ATP levels in AG-519-treated cells can reach levels that
are typical of normal, non-PK-deficient red cells (Figure 1).
Figure 1.
Summary/Conclusions: These data support the hypothesis that drug inter-
vention with AG-519 may restore glycolytic pathway activity and normalize red
cell metabolism in vivo. This therapeutic approach may be an effective way to
correct the underlying pathology of PK deficiency and, importantly, provide clin-
ical benefit to patients.
P743
REDPLEX: A TARGETED NEXT GENERATION SEQUENCING-BASED
DIAGNOSIS FOR PATIENTS WITH HEREDITARY HEMOLYTIC ANEMIAS
R Russo*, I Andolfo, F Manna, A Gambale, P Pignataro, G De Rosa, A Iolascon
Molecular Medicine and Medical Biotechnologies, University “Federico II”,
CEINGE - Biotecnologie Avanzate, Naples, Italy
Background: Mutations in more than 30 genes cause hereditary hemolytic
anemias (HHA), a highly heterogeneous group of rare anemias characterized
by complex and often unexplained genotype-phenotype correlations. In the
group of HHA are included: (1) hyporegenerative anemias (HA), as congenital
dyserythropoietic anemias (CDA); (2) hemolytic anemias due to red cell mem-
brane defects (HAMD), as hereditary spherocytosis (HS) and hereditary stom-
atocytosis (HST). Although the workflow to diagnose these conditions is a nor-
mal clinical practice, differential diagnosis, classification, and patient stratifica-
tion among HHA are often very difficult. Indeed, the variety of unspecific and
overlapping phenotypes often hampers a correct clinical management of the
patients. Beyond achieving a definitive diagnosis, knowing the genetic basis of
these patients can be valuable also for guiding treatment.
Next generation sequencing (NGS) refers to non-Sanger-based high-through-
put DNA sequencing technologies. This technology plays a major role either in
disease gene discovery or in clinical use for establishing a genetic diagnosis.
Particularly, the major current application of NGS in diagnostics is through tar-
geted (t)-NGS, in which a selected fraction of genes is sequenced.
Aims: The main aim of our study is the development of a fast, accurate, reliable
and cost effective diagnostic tool for HHA based on t-NGS.
Methods: In order to assess the reliability of this diagnostic method we created
a t-NGS gene panel, named RedPlex, composed by 34 loci causative or can-
didates of HHA. In silico design of RedPlex was performed by Agilent Sure
Design web tool. For each locus, all predicted exons and 100 flanking
nucleotides were always included in the electronic design. Sequence length
was set at 150×2 nucleotides, and the predicted target size amounted to 538
regions (239.764 kb). Targeted enrichment was performed on 44 patients by
HaloPlex Target Enrichment System (Agilent Technologies). High-throughput
sequencing was performed by Illumina NextSeq 500. SureCall software (Agilent
Technologies) was used for bioinformatic and computational analyses. All
focused variants were confirmed by Sanger sequencing and by the analysis of
inheritance pattern.
Results: RedPlex panel showed high sensitivity and specificity. It was able to
capture at least 99.4% of 538 exons with high and uniform coverage. Indeed,
approximately 97.0% and 90.0% of regions were covered by at least 100 and
200 reads, respectively.
Several non-synonymous variants of unknown significance were identified in
the largest genes. However, we were able to obtain a conclusive diagnosis in
32 out 44 patients with ambiguous phenotypes; instead, 12 patients remained
undiagnosed. We also identified some patients showing multiple disease-asso-
ciated variants suggesting complex inheritance.
Summary/Conclusions: NGS studies have identified a greater-than-expected
number of genetic variations in the human genome. This suggested that existing
clinical monogenic testing systematically can miss very relevant information.
Our analyses demonstrated that RedPlex represents a reliable diagnostic tool
for HHA patients. Indeed, it resulted to be a robust platform that overcomes for
power, costs, speed, sensitivity and specificity the gene-by-gene strategy. More-
over, this approach also allowed the identification of “polygenic” conditions, i.e.
patients in which the phenotypic variability could be explained by the presence
of modifier variants associated to causative mutations.
P744
SOLUBLE FAS AND FAS LEGEND LEVELS IN YOUNG PATIENTS WITH
SICKLE CELL DISEASE: ROLE IN NEPHROPATHY AND
CARDIOPULMONARY COMPLICATIONS
A Adly1,*, E ismail2, N Gamal1
1Pediatrics, 2Clinical Pathology, Ain Shams University, Cairo, Egypt
Background: Sickle cell disease (SCD) is characterized by chronic inflamma-
tion due to ischemic tissue damage, accentuated during acute complications.
Fas and its ligand (FasL) are members of tumor necrosis factor receptor super-
family and a major pathway for induction of apoptosis. Fas/FasL interactions
may be related to augmentation of inflammatory response. 
Aims: We assessed the levels of sFas and sFasL in 35 children and adoles-
cents with SCD compared with 35 healthy controls in relation to hemolysis,
iron overload, sickle vasculopathy including kidney disease. 
Methods: SCD patients, in steady state, asymptomatic for heart disease and
pulmonary hypertension were studied. All patients were subjected to detailed
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medical history and thorough clinical examination with special emphasis on
disease duration, history of sickling crisis, acute chest syndrome, stroke, evi-
dence of pulmonary or cardiac disease, spleen status, transfusion hsitory and
hydroxyurea/chelation therapy. Serum ferritin, urinary albumin creatinine ratio
(UACR), high-sensitivity C-reactive protein (hs-CRP) and soluble Fas/FasL
(sFas/FasL) levels were assessed. Screening for pulmonary hypertension and
cardiovascular abnormalities was performed by the noninvasive echocardio-
grapghy to evaluate left ventricular function, pulmonary artery pressure, tricus-
pid regurgitant jet velocity (TRV). A TRV ≥2.5 m/s was used as a proxy for
patients at risk for pulmonary hypertension.
Results: A total of 20% of patients were splenectomized, 31.4% had pulmonary
hypertension and 14.3% had heart disease. Nephropathy was found in 54.3% of
patients sFas and sFas/sFasL ratio were significantly higher in SCD patients
compared with the control group (p<0.001) while sFasL was significantly lower
in patients (p=0.022). sFas/sFasL ratio was significantly higher in patients com-
pared with controls and in patients with pulmonary hypertension, nephropathy
and those who had history of frequent sickling crisis or serum ferritin ≥2500
(p<0.001). SCD patients treated with hydroxyurea had lower sFas/sFasL ratio
than untreated patients. sFas/sFasL ratio was positively correlated to transfusion
index, white blood cells, hs-CRP, serum ferritin and UACR. Multiple linear regres-
sion analysis showed that WBCs and serum ferritin (p<0.001) were independently
related to sFas/sFasL ratio in patients with SCD. The cutoff value of sFas/sFasL
at 8.75pg/mL could differentiate SCD patients with and without nephropathy while
the cutoff value at 22pg/mL could differentiate SCD patients with and without
pulmonary hypertension risk with high sensitivity and specificity.
Summary/Conclusions: sFas/sFasL ratio may be considered as a marker for
vascular dysfunction in SCD patients and is related to inflammation, iron over-
load and albuminuria level. Thus, it may be a reliable method to assess renal
impairment in SCD. Our findings could be of pathophysiological importance,
because they provide evidence that diminishing inflammation in general, and
perhaps the levels of sFas in particular, may have a role to play in altering SCD
related-vasculopathy.
P745
ELEVATED PLASMA ASYMMETRIC DIMETHYLARGININE LEVELS IN
CHILDREN WITH BETA-THALASSEMIA MAJOR MAY BE AN EARLY
MARKER FOR ENDOTHELIAL DYSFUNCTION
O Gursel1,*, S Tapan2, E Sertoglu2, E Taşcılar3, I Eker1, T İleri4, Z Uysal4,
E Kurekci1
1Department of Pediatric Hematology, 2Department of Biochemisty, 3Depart-
ment of Pediatric Endocrinology, GULHANE MILITARY MEDICAL ACADEMY
AND MEDICAL FACULTY, 4Department of Pediatric Hematology, Ankara Uni-
versity Medical Faculty, Ankara, Turkey
Background: Thalassemia, resulting from defects in the production of alpha-
and beta-globin chains of hemoglobin, is the most common form of inherited
anemia all over the world, as well as in Turkey. Beta-thalassemia major requires
regular blood transfusions to maintain an adequate supply of hemoglobin and
sustain life, and patients suffer from the long-term consequences of iron over-
load which may lead to various complications, including damage of parenchy-
mal organs and cardiovascular system. In vitro studies have revealed that iron-
loading has been linked with endothelial dysfunction due to peroxidative tissue
injury resulting from blood transfusions, circulating cholesterol oxidation prod-
ucts, and possibly coronary artery disease. Asymmetric dimethylarginine
(ADMA) is an early marker for endothelial dysfunction and also regarded as
an independent predictor of future cardiovascular events. In addition, endothe-
lial adhesion molecules [soluble intercellular adhesion molecule-1 (sICAM-1),
soluble vascular cell adhesion molecule-1 (sVCAM-1) and P-selectin] are also
considered as early endothelial dysfunction markers, and there is scarce data
that highlights the significance and role of these molecules in endothelial dys-
function development in pediatric beta-thalassemia major patients. 
Aims: Based on all these informations, in the present study we aimed to assess
circulating levels of ADMA between patients with beta-thalassemia major and
control group and determine its correlation with markers of endothelial adhesion
molecules (sICAM-1, sVCAM-1 and P-selectin), and Pentraxin-3 as prognostic
factors for vascular risk stratification and subclinical atherosclerosis.
Methods: A total of 31 children with beta-thalassemia major aged between 4-16
year old (study group) and 36 age and gender matched healthy controls were
enrolled in the study. Fasting blood samples were obtained from the antecubital
vein. The samples for the measurement of sICAM-1, s-VCAM-1, P-selectin, Pen-
traxin-3 and ADMA were centrifuged for 15 min at 2000 g, aliquoted, and imme-
diately frozen at -80 oC until analysis. Plasma ADMA was measured along with
soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhe-
sion molecule-1 (sICAM-1), P-selectin, and Pentraxin-3. Circulating levels of
sICAM-1, s-VCAM-1, P-selectin, Pentraxin-3 and ADMA were determined with
commercially available ELISA kits (ADMA were by Immunodiagnostic Systems,
Boldon, UK; Pentraxin-3 was by R&D Systems, USA; sICAM-1, s-VCAM-1 and
P-selectin were by eBioscience, San Diego, CA, USA).
Results: Age, gender and body mass index were similar in two groups. The
beta-thalassemia major patients had significantly higher serum ferritin, sICAM-
1, s-VCAM-1 and ADMA levels than controls (p <0.001 for ferritin, s-VCAM-1,
ADMA; and p =0.003 for sICAM-1, respectively). There was a significant pos-
itive correlation between ADMA and ferritin, VCAM-1 and ICAM-1 levels while
a negative correlation was noted between ADMA and BMI, and Hb concentra-
tions (p <0.001 for Hb, ferritin, VCAM-1; p =0.031 for BMI; and p =0.001 for
ICAM-1). On the other hand, there was no significant correlation between
ADMA and age, WBC count, platelet count, serum P-selectin and Pentraxin-3
measurements (p >0.05).
Summary/Conclusions: In conclusion, as far as we know, this is the first study
evaluating ADMA and endothelial adhesion molecules together in children with
beta-thalassemia major and this makes the results of our study more meaningful
compared to previous studies. These findings support the hypothesis that a seri-
ous degree of endothelial activation and damage underlie the pathophysiology
of beta-thalassemia major and endothelial dysfunction may participate in the pro-
gression of common complications encountered in these subjects.
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A NATION-WIDE POPULATION STUDY OF REFERENCE INTERVAL FOR
HEMOGLOBIN LEVEL
J Yang1, YJ Kim2,*, TS Park3, JM Byun4, J Yoo5, T Youk6
1Ongjin Public Health Center, Incheon, 2School of Medicine, 3Kyung Hee Uni-
versity, 4Internal Medicine, Seoul National University Hospital, Seoul, 5National
Health Insurance Service Ilsan Hospital, Goyang, 6Department of Statistics,
Korea University, Seoul, Korea, Republic Of
Background: Attempts to define the ‘norm’ for hemoglobin level have pro-
posed different reference intervals depending on influential factors such as
age, sex, pregnancy, altitude and ethnicity. Changes in life style and public
health affect those factors and reference intervals require an update accord-
ingly.
Aims: Reference interval for hemoglobin can be variable and an obstacle for
this problem is the absence of large database that enables exclusion of indi-
viduals that are not ‘normal’. Here we attempt to provide an update of refer-
ence interval regarding age and sex groups based on large national database,
which so far is the largest used for establishing a reference interval of hemo-
globin level. 
Methods: The National Health Insurance (NHI) program is a government-
operated mandatory health insurance program of Republic of Korea, providing
general health screening once every two years. Participation rate of general
health screening of NHI is steadily increasing, reaching 74.8% of registered
individuals in 2014. Between the period of January 2009 and December 2013,
total of 6,759,566 individuals and their hemoglobin value were analyzed after
applying the exclusion criteria. The exclusion criteria were in brief, a) diag-
nosed diseases; respiratory diseases including tuberculosis, hypertension,
obesity, anemia, diabetes mellitus, dyslipidemia, hepatitis, nephrotic diseases,
b) life style; smoking, alcohol consumption and c) physiologic conditions;
pregnancy. Questionnaire used for general health screening is available
online (http://minwon.nhis.or.kr/exam/i/file/english_n.pdf). Reference intervals
were based on median value and 2.5~97.5 percentile. Data were categorized
by sex and age group by 10 years. All statistical analyses in this study were
done using SAS v9.4 (SAS Institute Inc., Cary, NC, USA).
Results: Reference intervals for each respective groups are shown in Figure
1. The data included threefold more women than men, as men were much
more excluded by smoking and alcohol consumption criteria. The reference
interval for whole population using median (2.5~97.5 percentile) was
14.8(12.5~16.8) g/dL in men and 12.8(10.6~14.7) g/dL in women. Men had
higher median hemoglobin level of 2g/dL than women at the age group of
40s, which the difference has decreased thereafter. Hemoglobin level
decreased along with increasing age, as expected.
Figure 1.
Summary/Conclusions: Establishing a reference interval requires consider-
ation of many variables other than age, sex, geographic location and ethnicity
such as standardization of methods. Laboratory standardization is well estab-
lished in Republic of Korea and this reference interval of hemoglobin level using
large national database is capable of accurately representing this specific pop-
ulation. An updated reference interval will improve diagnostic orientation and
decisions for therapy.
P747
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE
FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK
M Griffin1,*, C Couzens2, W Ingram2, R Karim2, M Koh3, M Layton4, K Lowndes5,
M McMullin6, P Medd7, L Mitchell8, L Morgan2, S Narayanan9, I Neilly10,
M Nikolousis11, J Ros12, N Sharma6, A Hill1
1Hematology, Leeds teaching hospitals, Leeds, 2Hematology, University Hospital
of Wales, Cardiff, 3Hematology, St Georges Hosptial and Medical School, 4Hema-
tology, Hammersmith hospitals, London, 5Hematology, Hampshire Hospitals NHS
foundation trust, Winchester, 6Hematology, Centre for cancer research and cell
biology, Belfast, 7Hematology, Plymouth Hospitals NHS trust, Plymouth, 8Hema-
tology, NHS Lanarkshire, Lanarkshire, 9Hematology, University hospital
Southampton, Southampton, 10Hematology, Northumbria healthcare trust,
Northumbria, 11Hematology, Heart of England NSH trust, Birmingham, 12Hema-
tology, St Georges Hospital and Medical School, London, United Kingdom
Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired
clonal stem cell disorder with an associated complement mediated morbidity
and mortality. International flow cytometry guidelines recommend PNH screen-
ing in ‘at risk’ patients. These include patients with bone marrow failure syn-
dromes; Intravascular hemolysis; unexplained hemolysis with iron deficiency,
oesophageal spasm, thrombocytopenia or granulocytopenia; unusual throm-
bosis with unexplained cytopenia or hemolysis; or other acquired direct coomb’s
test negative hemolytic anaemias. 
Aims: The aim of this retrospective audit is to determine application of the
International flow cytometry guidelines in UK practice. 
Methods: The UK PNH network members (hematologists with an interest in
PNH) provided anonymised data for analysis. PNH screens analysed from Jan-
uary 2014 to December 2014 were included.
Results: 1579 PNH screens were assessed (53% male; mean age 53 yrs), of
which 9.4% were positive. Screening indications included aplastic anaemia (AA)
(5.3%) of which 40% were positive, cytopenias (36.7%) of which 11% were pos-
itive, thrombosis (28%) of which 2% were positive, haemolysis (5.7%) of which
12% were positive, MDS (0.4%) of which 6% were positive, and other reasons
(6.9%) with 6% positive. 257 (16%) screens had no clinical details provided. PNH
clone size varied with the majority less than 1% (53%). 22% had a clone size of
1-10%, and 12% had a clone of 10-50%. 18 (12%) had a clone of more than
50%, of these 5 were screened for haemolysis, 7 cytopenias, 4 no clinical details,
1 thrombosis and 1 AA. 377 patients with repeat testing were assessed, 91% of
whom had a known PNH clone. The majority had clinical PNH (218), of whom
25% had evolved from preceding AA and 3% from MDS. 
Summary/Conclusions: This is the largest audit of PNH screening requests
from UK centres. It’s reassuring that recommendations are adhered to with
very few patients screened inappropriately. 40% of AA patients had a PNH
clone in keeping with current evidence. The subgroup analysis highlights the
importance of PNH clone monitoring in patients with underlying bone marrow
disorders, as they may subsequently develop clinical PNH and require treat-
ment. Ongoing education is essential for the screening and monitoring for this
rare but potentially fatal disease. 
Disclosure: Alexion UK provided funding to support the UK PNH network
meetings.
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DIAGNOSTIC VALUES FOR IRON DEFICIENCY ANEMIA IN CHILDREN
AND WOMEN USING SERUM HEPCIDIN AND ZINC PROTOPORPHYRIN
(ZPP) 
G Kanuri*, D Chichula, S Majumdar, J P Rao, A Shet
Hematology Research Unit, St. Johns Research Institute, Bangalore, India
Background: Iron deficiency with or without anemia is a major health problem,
affecting more than 2 billion people worldwide. Widely used tests e.g. serum
ferritin and sTfR are confounded by inflammation and erythropoietic activity
respectively. Serum hepcidin and ZPP are potentially useful biomarkers in the
diagnosis of iron deficiency (ID) and iron deficiency anemia (IDA). However,
diagnostic values for iron deficiency anemia from participants in resource limited
settings are not available. 
Aims: We determined the optimal cutoff values, sensitivity and specificity of
these two biomarkers in children and their mothers in a low middle income set-
ting where both conditions are highly prevalent.
Methods: Healthy rural community dwelling children aged 12-59 months and
their mothers from randomly selected villages in a province of South India were
prospectively enrolled after obtaining informed consent. Participants were cat-
egorized biochemically into healthy, ID and IDA groups based on previously
published criteria. Serum hepcidin concentration was quantified by enzyme
immunoassay kit (PenninsulaLabs) according to the manufacturer’s protocol.
Washed red cells were used to measure ZPP in triplicate using a hematofluo-
rometer (AvivBiomedical). Receiver operator characteristics were performed
using the sTfR/log Ferritin index as a gold standard and optimized using the
Youden index.
Results: The demographic characteristics, hematological and biochemical
parameters of the different study groups are shown in Table 1. Mean hemoglo-
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bin was significantly lower in IDA compared to healthy or ID subjects (p<0.001).
In children, a serum hepcidin cut off value ≤13ng/mL diagnosed IDA with 92%
sensitivity and 87% specificity (area under ROC curve (AUCROC): 0.972
(95%CI,0.939-0.990)) and a cutoff value ≤23ng/mL detected ID with 71% sen-
sitivity and 80% specificity (AUCROC:0.768 (95% CI,0.703-0.824)). In women,
serum hepcidin cutoff value ≤4.5ng/mL diagnosed IDA with 97% sensitivity and
92% specificity (AUCROC:0.975 (95% CI, 0.956-0.994)) and cutoff value of
≤7.4ng/mL had 90% sensitivity and 69% specificity (AUCROC: 0.792(95%
CI,0.694-0.890)) to diagnose ID. Similarly, ZPP in children at a cutoff value of
≥83 µmole/mole heme diagnosed IDA with 94% sensitivity and 84% specificity
(AUCROC: 0.941 (95%CI,0.90-0.97)). In women, ZPP at a cutoff value ≥123
µmole/mole heme diagnosed IDA with 98% sensitivity and 69% specificity
(AUCROC: 0.894 (95% CI,0.848-0.939)). In both women and children, the
AUCROC for ZPP to diagnose ID was less than 0.5.
Table1. Hematological and biochemical parameters.*Median (Interquartile
range); ap<0.05 compared with respective healthy subjects, bp<0.05 com-
pared with respective ID subjects.
Summary/Conclusions: Cutoff values for diagnostic markers hepcdin and
ZPP to diagnose IDA in two high risk groups provide guidance for practitioners
in limited resource settings. Serum hepcidin has higher sensitivity and speci-
ficity to diagnose IDA than ID. ZPP may diagnose IDA with higher sensitivity
and specificity, it is a technically simple, rapid, and cheap point of care test to
detect IDA in both practice and community settings.
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UTILITY OF RED CELL INDICES TO DIAGNOSE IRON DEFICIENCY IN
RURAL INDIAN CHILDREN 
S Majumdar*, G Kanuri, A Shet
Hematology Research Unit, St Johns Research Institute, Bangalore, India
Background: The prevalence of anemia in Indian children aged 6-59 months
is high (56%) with 62% cases attributable to iron deficiency. However, this con-
dition is underdiagnosed in India, in part due to unavailability of diagnostic tests
for iron deficiency anemia (IDA) in rural settings. Red cell distribution width
(RDW) appears to be sensitive in the diagnosis of iron deficiency and values
>14.3% was found to predict iron deficiency in anemic toddlers. RDW meas-
urements are provided routinely while measuring complete blood counts and
are operator independent. Thus, we investigated the potential of RDW as a
point of care test to diagnose iron deficiency anemia.
Aims: To determine utility and establish cutoff values for RDW to diagnose
IDA in rural Indian children
Methods: Healthy community dwelling children aged 1-5 years living in ran-
domly selected villages in a South Indian province provided a venous blood
sample. A complete blood count inclusive of RDW was performed using a field
based automated cell counter. Serum ferritin (SF) and Ferritin Index (FI) were
measured at the central laboratory. Subjects were classified into healthy (HL);
iron deficient (ID) and iron deficiency anemia (IDA) as shown in Table 1.The
coefficient of variation in red cell size (RDW-CV) was expressed as a percent-
age. Receiver’s operator characteristics (ROC) were performed to examine
the sensitivity and specificity of RDW CV when compared with a gold standard
SF to diagnose ID or IDA and optimized using Youden index.
Results: Majority of the children in this study had ID (66%) or IDA (27%) with
only a small portion of the population that demonstrating normal ferritin values.
Baseline demographic, hematological and biochemical parameters of children
enrolled in the study are tabulated (Table 1). 
Table 1: Demographic, hematological and biochemical characteristics in
HL,ID and IDA
                       Baseline characteristicsMarker
                                    Age*(y)     Hb* (g/dl)    MCV*(fl)           SF **              RDW*
                                                                                                (ng/ml)
HL (n=44)                     3.4±0.85     11.8±0.58    76.9±3.2      35.2 (32-41)     13.4%±1.1
(Hb >11g/dl andSF >30ng/ml)
ID (n=466)                    3.1±0.90     11.9±0.69    75.3±4.3    11.8 (7.8-16.6)   13.9%±1.4
(Hb >11g/dl and SF <30ng/ml)
IDA (n=192)                  2.4±0.90      9.8±0.82     66.6±6.0      4.3 (3.1-6.9)     16.7%±2.1
(Hb <11g/dl and
SF <12ng/ml or FI >1.03)
*Mean±SD; **Median+IQR.
Mean RDW CV was found to be significantly higher in IDA (16.7%) compared to
HL (13.4%) and ID (13.9%) (p <0.001). IDA was diagnosed at cutoff of RDW
>14.6% with 90% sensitivity and 84.9% specificity (AUCROC: 0.94, 95%CI 0.89-
0.97) (Figure 1). However, RDW >13.5% detected iron deficiency with only low
sensitivity (65.9%) and specificity (55.9%) (AUCROC :0.63, 95%CI 0.52-0.71).
Those subjects with an RDW >14.6% were more likely to have iron deficiency
(OR 6.9, 95%CI 2.4-19.6, p value 0.003).
Figure 1. Receiver operator characteristic curve to predict ID anaemic
children.
Summary/Conclusions: In a rural population of children, with a very high
prevalence of ID and IDA, we found that an RDW CV value >14.6% diagnosed
IDA with 90% sensitivity and 85% specificity. Use of this RDW cut off value
could guide primary health care decisions regarding iron supplementation in
rural children with ID/IDA.
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GROWTH AND DEVELOPMENT DURING A 5-YEAR OBSERVATIONAL
STUDY OF IRON CHELATION THERAPY WITH DEFERASIROX IN PEDIATRIC
PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS (ENTRUST)
E Vichinsky1,*, A El Beshlawy2, A Alzoebie3, A Kamdem4, S Koussa5,
T Chotsampancharoen6, A Bruederle7, G Gilotti8, J Han8, M Elalfy9
1Children’s Hospital & Research Center, Oakland, United States, 2Cairo Uni-
versity, Cairo, Egypt, 3Sheikh Khalifa Medical City, Abu Dhabi, United Arab
Emirates, 4Centre Hospitalier Intercommunal, Créteil, France, 5Chronic Care
Center, Hazmieh, Lebanon, 6Songklanagarind Hospital, Songkhla, Thailand,
7Novartis Pharma AG, Basel, Switzerland, 8Novartis Pharmaceuticals, East
Hanover, United States, 9Ain Shams University, Cairo, Egypt
Background: Regular transfusion and iron chelation therapy (ICT) are often
indicated for pediatric patients (pts) with chronic anemias such as β thalassemia
major (βTM), sickle cell disease (SCD) and Diamond–Blackfan anemia (DBA).
Delayed growth and development can occur as a result of iron overload, indi-
cating optimal management of iron loading is required. Growth retardation has
also been reported in young patients (<3 yrs) receiving intensive ICT with DFO
(de Virgillis S et al. J Pediatr 1998) and thus regular monitoring of growth is
essential. In a 5 yr clinical trial of deferasirox in βTM pediatric patients (2–<16
yrs), growth and development progressed normally (Cappellini MD et al. Blood
2011). Here we report growth and development during deferasirox treatment
in real-life clinical practice in young pts with transfusional hemosiderosis from
the 5-yr multinational, observational ENTRUST study.
Aims: To assess growth and development during long-term deferasirox treat-
ment in an unselected population of transfusion-dependent children with chron-
ic iron overload.
Methods: Over 5 yrs, pts with transfusional iron overload aged 2-<6 yrs at enroll-
ment received deferasirox in accordance with local (country-specific) prescribing
information. An initial deferasirox dose of 10-30 mg/kg body weight was recom-
mended and adjusted based on serum ferritin (SF), therapeutic goals, tolerability
and changes in pt weight. Parents/guardians provided written, informed consent.
Pt height and weight were recorded at baseline and end of each year and mean
annual growth velocity was calculated for pts on treatment; data were analyzed
by geographical region (Europe, Americas, Middle East/Africa, Asia).
Results: In total, 267 pts (mean age at study entry 3.2 yrs; 52.1% male) with
βTM (n=176, 65.9%), SCD (n=52, 19.5%), DBA (n=12, 4.5%) and other ane-
mias (n=27, 10.1%) were enrolled and received ≥1 deferasirox dose. Most pts
(n=172; 64.4%) received an average blood intake >7 mL/kg/month. Median
SF level decreased from 1702 ng/mL at baseline to 1127 ng/mL after 5 yrs.
Overall, mean deferasirox dose increased from a planned starting dose of
26.2±5.9 mg/kg/day to a final actual dose of 28.6±7.7 mg/kg/day. Actual aver-
age dose was generally aligned with weight; however, initially deferasirox doses
received were suboptimal to manage iron intake and dose adjustments based
on weight gain were delayed. Mean growth velocity was 4.86–5.95 cm/yr in
male and 5.44–6.08 cm/yr in female pts (Table 1), which is in line with public
growth curves for children aged 2-≤11 yrs; as observed across all geographical
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regions. Mean weight increased steadily over time (Table 1) in line with mean
growth velocity. Median serum creatinine increased steadily over time (28.0
μmol/L at baseline to 39.4 μmol/L) in line with median height, and by association
with increasing muscle mass. One patient with βTM experienced an adverse
event of below normal height that was not suspected to be drug-related.
Table 1. Growth velocity, height, and weight during treatment with
deferasirox in male and female patients aged 2-<6 years at baseline.
Summary/Conclusions: In accordance with previous deferasirox trials, this
long-term, ‘real-life’ safety study in young pediatric pts with transfusional iron
overload showed expected growth velocities and weight gain for a prepubertal
population across all geographical regions. Careful monitoring of pts and appro-
priate weight-based adjustment of deferasirox dose ensures effective manage-
ment of long-term ICT and control of transfusional iron loading.
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SEARCH AND YOU SHALL FIND – VARIANT HEMOCHROMATOSIS GENE
MUTATIONS AS A CAUSE OF HYPERFERRITINEMIA IN BLOOD DONORS
AH Laursen1,*, K Magnussen2, L Friis-Hansen3, JL Marott4, T van Overeem
Hansen3, OW Bjerrum1
1Department of Haematology, 2Centre for Donor Hemoglobin and Iron, 3Depart-
ment of Genomic Medicine, Rigshospitalet, 4The Copenhagen City Heart Study,
Frederiksberg Hospital, Copenhagen, Denmark
Background: Blood donors in the capital region of Denmark undergo frequent
ferritin measurements to prevent blood donation-related depletion of iron storages.
Somewhat surprisingly, some patients actually demonstrate hyperferritinemia,
despite regular blood donations. Hyperferritinemia is often the result of inflamma-
tory conditions or liver diseases, but hereditary hemochromatosis (HH) is also a
frequent cause of elevated serum ferritin concentrations. HH is in most cases an
autosomal recessive genetic disorder characterized by mutations in different genes
related to iron metabolism. HH is associated with an increase in intestinal iron
absorption and excessive iron deposition in variant tissues (e.g. liver, heart and
endocrine glands) with risk of concomitant organ dysfunction. The primary HH
gene defect is a missense mutation (C282Y) in the HFE gene and C282Y homozy-
gosity is by far the most frequent genotype in HH. However, several different HFE
genotypes can also lead to HH. Furthermore, non-HFE phenotypic HH with iron
overload can result from other genetic defects in proteins related to iron metabo-
lism, including mutations affecting hepcidin (HAMP), ferroportin 1 (SLC40A1),
hemojuvelin (HFE2) and transferrin receptor 2 (TFR2) gene expression.
Aims: The purpose of our study was to explore the relevance of extensive HH
mutational analyses in a selected population of healthy Danish blood donors
with hyperferritinemia.
Methods: 49 consecutive donors (f=6, m=43) were included prospectively from
the Capital Regional Blood Center. Inclusion criteria were either a single ferritin
value above 1000µg/L or repeated hyperferritinemia with at least one value
above 500µg/L. Included donors were evaluated with a full physical examina-
tion, a medical history and extensive biochemical investigations, including a
complete blood count, parameters of iron metabolism and relevant organ func-
tion tests. Genetic testing was carried out by next generation sequencing using
a hemochromatosis gene panel including mutational status of the HFE gene,
the HFE2 gene, the HAMP gene, the SLC40A1 gene and the TFR2 gene.
Results: 40 of 49 donors were mutation positive, combining for a total of 67
mutations. 18 patients had 1 mutation, 18 patients had 2 mutations, 3 patients
had 3 mutations and 1 patient had 4 mutations. Interestingly, there were only
11 patients with C282Y homozygosity. Thus, of the 40 mutation positive donors,
29 had phenotypic evidence of HH, albeit with a more atypical HH genotype.
An overview of the mutational frequencies is shown in Figure 1. 
Summary/Conclusions: Our view on the genetic background of HH is constantly
expanding due to the documentation of several different genotypes resulting in
phenotypic HH. Screening of blood donors with hyperferritinemia could be a
straightforward way of identifying individuals with a high probability of HH since
iron overload in healthy blood donors adherent to the blood donor program could
be suggestive of significant malfunction of iron metabolism. Although standard
genetic testing for C282Y mutational status is available at a relatively low-cost, it
obvioulsy does not account for the genotypic variations in HH pathogenesis.
Thus, a more complete genetic workup should be considered in order to improve
HH diagnostic testing in individuals with unexplained hyperferritinemia.
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A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY,
TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF
AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN
HEALTHY SUBJECTS
A Barbier1,*, J Cutie2, G Connor1, E Merica1, C Kung1, K Le1, H Yang1,
PA Kosinski1, L Silverman1, ZJ Yuan1, S Agresta1, M Cohen3
1Agios Pharmaceuticals Inc., Cambridge, 2Viola Medica, Lexington, 3MBC
Pharma Solutions, Newtown, United States
Background: Pyruvate kinase (PK) deficiency is an inborn error of metabolism
affecting children and adults that results in lifelong hemolytic anemia, and is
associated with serious long-term comorbidities such as poor growth and devel-
opment in children and chronic iron overload in adults. PK deficiency is caused
by a functional deficiency of the red blood cell isoform of PK (PK-R). As a result
of this defect in glycolysis, levels of 2,3-diphosphoglycerate (2,3-DPG) in the
blood are elevated and adenosine triphosphate (ATP) levels are low. AG-348,
an orally available allosteric activator of PK-R currently being tested in a phase
2 clinical trial in adult patients with PK deficiency (NCT02476916), has been
shown to increase ATP and decrease the levels of 2,3-DPG in healthy volun-
teers. A drug discovery effort aimed at eliminating the aromatase inhibitory
activity observed with AG-348 resulted in the identification of AG-519.
Aims: AG-519 is currently in a randomized, double-blind, phase 1 study in
healthy volunteers (NCT02630927), with the objective of identifying a safe and
pharmacodynamically active dose and schedule to be used in subsequent clin-
ical studies in subjects with PK deficiency. Here we report the single ascending
dose phase of this study.
Methods: Healthy men and women (non-childbearing potential) aged 18–60
years and providing informed consent are eligible. Four dose levels (from 50
mg to up to 1250 mg) will be explored sequentially, starting with the lowest
dose. At each dose level, 8 subjects will be enrolled and randomized to receive
a single oral dose of AG-519 (n=6) or placebo (n=2), with an option to enroll 2
additional dose cohorts (n=8 each) to assess alternative single dose levels.
Safety assessments include adverse events (AEs), vital signs, electrocardio-
gram and clinical laboratory parameters. Serial blood samples will be drawn to
measure plasma AG-519 concentrations and whole blood 2,3-DPG and ATP
concentrations for pharmacokinetic and pharmacodynamic assessments.
Results: Eight subjects have been enrolled at 50 mg and a further 8 subjects
enrolled at 250 mg to date. Blinded safety reviews indicated no safety concerns
in healthy volunteers receiving a single dose of AG-519 given as 50 mg or 250
mg, or placebo. Plasma AG-519 exposure was dose-dependent, with low to mod-
erate variability in the pharmacokinetic parameters of AG-519. Investigation of
the pharmacodynamic effects of AG-519 after a single dose indicated that there
was a substantial dose-dependent decrease in blood 2,3-DPG concentration
(Figure 1). There was no effect on blood ATP concentration, indicating that ATP
change requires more than one dose, as observed in the single ascending dose
study for AG-348. Based on these encouraging results, single dose escalation is
ongoing, and the multiple ascending dose component has been initiated, with
dose escalation proceeding in order to determine maximal tolerated dose and/or
optimally effective dose and effects on sex hormones. Further data from the
single ascending dose and multiple ascending dose cohorts will be presented.
Figure 1. Actual and change from baseline concentration-time profiles of
2,3-DPG in blood following a single dose of AG-519 (n=6 for 50 mg and
250 mg, n=4 for placebo. 
Summary/Conclusions: AG-519 is well tolerated, with exposure-dependent
decreases in 2,3-DPG concentrations when given as a single daily dose in healthy
subjects. Fourteen day dosing results from this trial will further inform the potential
for AG-519 as a second potential molecule for the treatment of PK deficiency.
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ANALYSIS OF MOLECULAR MECHANISMS OF DOMINANT-INTERFERING
FAS MUTATIONS
D Schäfer1,*, S Nabhani1, C Schipp1, L Loizou2, PT Oommen1, HJ Laws1,
B Fleckenstein3, A Borkhardt1, P Stepensky4, U Fischer1
1Department of Pediatric Oncology, Hematology and Clinical Immunology, Uni-
versity Clinic of the Heinrich Heine University, Düsseldorf, Germany, 2Arch-
bishop Makarios III Hospital, Nicosia, Cyprus, 3Department of Clinical and
Molecular Virology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlan-
gen, Germany, 4Department of Pediatric Hematology-Oncology, Hadassah
Hebrew University Medical Center, Jerusalem, Israel
Background: The autoimmune lymphoproliferative syndrome (ALPS) is clini-
cally characterized by lymphadenopathy, hepatosplenomegaly, autoimmunity,
hypergammaglobulinemia, and an increased number of CD3+TCRαβ+CD4-
CD8- double-negative T (DNT) cells. Defects in the FAS signaling pathway
lead to impairment of lymphocyte apoptosis and hence to accumulation of acti-
vated and autoreactive lymphocytes. In approximately 70% of ALPS cases,
mutations in the trimeric FAS receptor have been identified (classified as ALPS-
FAS). Most ALPS patients harbor heterozygous dominant interfering mutations
with in part unclear mechanisms.
Aims: To better understand the pathogenesis of ALPS-FAS and the molecular
mechanisms of dominant-interfering FAS mutations we tried to identify and to
functionally analyze novel FAS mutations in a cohort of 35 patients with an
ALPS-like clinical phenotype.
Methods: DNA was isolated from blood of 35 patients with an ALPS-like clinical
phenotype using standard methods and FAS was subjected to Sanger
sequencing and compared to the annotated wildtype sequence. Activated and
expanded T cells were stimulated with recombinant FAS ligand, staurosporine
or were left untreated and apoptosis was measured by Annexin V-FITC/PI
staining via flow cytometry. Immunophenotyping was carried out by flow cytom-
etry. Immortalized T cell lines were generated using Herpes virus saimirii.
Results: We identified six patients with heterozygous FAS mutations. Five
mutations were novel (p.R102C, p.R250G, p.NVQ266-268KQT, p.W281L,
p.Q283K), one was a known splice site mutation frequently found in ALPS
patients (p.E218MfsX*4). One mutation affected the extracellular domain of
the receptor (p.R102C), the others occurred in the death domain. All patients
with FAS mutations fulfilled the two required ALPS diagnostic criteria: 1) chronic
(>6 months), nonmalignant, noninfectious lymphadenopathy or splenomegaly
or both and 2) elevated DNT cells (≥1.5% of total lymphocytes). Secondary
diagnostic criteria were also fulfilled: all patients had a typical ALPS
immunophenotype and impaired FAS signaling led to resistance of primary
patient T cells to FAS ligand-mediated apoptosis. All six patients can be clas-
sified as ALPS-FAS cases.
Summary/Conclusions: With heterozygous FAS mutations, statistically one
in eight FAS trimers is made of wildtype proteins only. This is a mechanism by
which the FAS signaling in ALPS patients is impaired. Among the identified
FAS mutations was a known splice site mutation leading to skipping of exon 8,
frameshift and premature termination in exon 9. This mutation abrogates recruit-
ment of the adapter molecule FADD to the receptor. The R250G mutation is
novel, but other amino acid exchanges (Q,P,L or termination) have been
described at this site. By analogy, p.R250G should reduce binding of FADD.
Reported structural analyses indicate that p.Q283K also dominantly interferes
with FADD recruitment. Two further mutations affected the death domain and
may interfere with binding of proteins via death domain interaction (p.W281L
and p.NVQ266-268KQT). The latter mutation resulted from six consecutive
missense mutations leading to the exchange of three amino acids. To our
knowledge, six consecutive missense mutations have not been described for
ALPS patients or in general. One patient harbored a mutation in the extracel-
lular domain of the receptor (p.R102C). This may lead to a wrong formation of
a cystin-bridge. Further analysis of FAS mutations regarding their structure
and functional impact are performed and will be reported.
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UNSMAKING PRIMARY IMMUNE DEFICIENCIES IN EARLY-ONSET EVANS
SYNDROME USING IMMUNOPHENOTYPING AND NGS: TOWARDS A
CLINICAL AND GENETIC CLASSIFICATION
N Aladjidi1,*, C Picard2, H Fernandes3, Y Bertrand4, V Barlogis5, M Pasquet6,
E Levy7, F Mazingue8, C Guitton9, A Magerus10, T Leblanc11, G Leverger12,
A Fischer13, F Rieux-Laucat7
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versity Hospital of Bordeaux, Bordeaux, 2Paris Descartes-Sorbonne Paris Cité
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Immunology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assis-
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unit/CEREVANCE/CIC1401, Inserm CICP, University Hospital of Bordeaux,
Bordeaux, 4Pediatrics, Institut d’Hématologie et d’Oncologie Pédiatrique, Lyon,
5Pediatric Hémato-Oncology Unit, La Timone Hospital, Marseille, 6Pediatric
Hémato-Oncology Unit, Universitary Hospital, Toulouse, 7INSERM UMR 1163,
Laboratory of Immunogenetics of Pediatric Autoimmunity /aris Descartes-Sor-
bonne Paris Cité University, Insitut Imagine, Paris, 8Pediatric Hémato-Oncology
Unit, universitary Hospital, Lille, 9Pediatrics, Hospital, Le Kremlin Bicêtre,
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nity /Paris Descartes-Sorbonne Paris Cité University, Insitut Imagine, 11Pedi-
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nit, Armand Trousseau Hospital, 13Paris Descartes-Sorbonne Paris Cité Uni-
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Background: Evans syndrome (ES) is a rare autoimmune disorder in children
with generally unknown aetiology at onset. In France, a collaborative immuno-
pediatric network recently presented comprehensive data on a large series of
156 non selected childhood ES (OBS’CEREVANCE cohort): 70% of the cases
were suspected to be secondary to potential immune defects.
Aims: This prospective study reports the genetically identified primitive immune
deficiencies (PID) in those 156 non selected children with ES.
Methods: Complete data from birth to last follow-upare registered in real-time.
Relevant immune events are defined, leading to the subgroup of suspected
secondary ES: lymphoproliferation, systemic or organ-specific auto-immunity,
hypogammaglobulinemia, non microbial pulmonary, digestive or neurological
diseases. Etiological investigations at the initial diagnosis were consistent with
national guidelines and repeated during the follow-up. Complete immunophe-
notyping was performed in laboratories of the national CEREDIH network. All
the children underwent screening for autoimmune lymphoproliferative syn-
drome (ALPS). Functional and genetic studies (Sanger sequencing or NGS)
were mainly addressed to the French CEDI reference laboratory, Necker, Paris
and to the INSERM unit 1163, Institut IMAGINE, Paris.
Results: In January 2016, 156 children from 26 centres diagnosed between
1981 and 2014 with ES were analysed. The median age at initial cytopenia
was 5.4 (0.2-17.2) years old. The median follow-up from ES diagnosis was 6.5
years (0.1-28.8). 14 children had aetiologies that might explain the autoimmune
cytopenia (13 pediatric systemic lupus erythematosus (pSLE), and one 22q11.4
deletion). Lymphoproliferation at presentation led to the exploration of apoptosis
pathways in 55 patients and to ALPS biomarkers in most patients. Six patients
(11% of the tested patients) had an apoptosis defect, related to a germ line
FAS mutation (ALPS-FAS) in 5 cases (9%) and to a somatic KRAS mutation
in 1 case. A genetic search (Sanger sequencing or NGS) has been performed
on 43 patients with clinical relevant criteria. A monogenic defect was found
after the ES diagnosis in 8 patients: 2 STAT3 gain of function mutations, 4
CTLA4 deficiencies, 2 LRBA deficiencies. In the 35 other patients, genetics
studies are ongoing. ES was thus secondary to pSLE in 13 patients (8.3%) or
to an identified PID in 15 patients (9.6%). In 52% of the patients in the present
cohort, and even in apparently primary cases (chronic isolated bi-cytopenia),
ES could be related to an as yet unidentified genetic defect.
Summary/Conclusions: At the present time, in this cohort, a PID could be
identified in 10% of ES patients. This proportion will certainly grow up in a near
future following this genetic strategy based on well characterized clinical and
immunological features. More specific therapies (mTOR inhibitors in ALPS
patients, or CTLA4-targeted therapies in CTLA4 and LRBA deficient patients)
can already be proposed. The current challenges are therefore to rapidly com-
plete this genetic approach and to further define new candidate genes, to iden-
tify additional targeted therapies. 
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MRI SKELETAL MANIFESTATIONS IN GAUCHER DISEASE: UTILITY OF
SPANISH-MRI (S-MRI) SCORE AT DIAGNOSIS AND FOLLOW-UP
M Andrade-Campos1,*, E Valero-Tena2, P Irun1, P Alfonso1, P Giraldo3,
M Roca-Espiau 4
1Translational Research Unit, IIS-Aragon. CIBERER., 2Rheumatology, HCU-
LB., Translational Research Unit, IIS-Aragon, 3Translational Research Unit,
IIS-Aragon. CIBERER. FEETEG., 4Dra. Roca Image Diagnostic Center, Inter-
national Skeletal Society, Zaragoza, Spain
Background: Gaucher disease (GD), the most prevalent lysosomal storage
disorder is characterized by multisystem involvement, secondary to the accu-
mulation of glucosyil-ceramide in the reticule-endothelial system. Bone disease,
is on of the most frequent manifestations, it’s caused by several factors: derived
cell accumulation, vascular events and cytokine release – chronic inflammatory
state. MRI has demonstrated to be the gold standard for assesses bone
involvement, including bone infiltration, bone crisis, infarcts and avascular
necrosis; others like vertebral collapses secondary to infiltration-osteopenia
and osteoporosis are also common. The Spanish-MRI score (S-MRI), described
by Roca et al. in 2006 is a semi quantitative tool combining the assessment of
the bone marrow burden (infiltration), (BMB) in vertebra, pelvis and femurs (0-
12 points), with the presence of bone vascular events (4 points for every lesion).
Despite the value of S-MRI to assess the initial involvement of GD patients,
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their value during follow up is also remarkable. The MRI was incorporated in
our unit since 1993 for routinely evaluation.
Aims: To analyses our experience with MRI bone-assessment in our unit, espe-
cially focus on the role of S-MRI at diagnosis, follow-up and identification of
bone lesions. 
Methods: All patients included in the Spanish Registry of Gaucher disease
had signed an inform consent for the management of the information relative
to the disease. A total of 131 patients have been evaluated by MRI in the radio-
diagnostic center of the unit, following the same protocol and by the same radi-
ologist specialized in muscle-skeletal MRI, summarizing ~340 MRI studies. 
Results: From 131 patients, in 64 (49.6%) was part of the initial assessment
previous to start any therapy, 63(48.1%) were under enzymatic replacement
therapy (ERT) and 4 under substrate reduction therapy (SRT). Mean age: 37.5
y (13-74), M/F: 70/61, type 1 GD: 124, type 3 GD: 7. The genotype
N370S/L444P was the most frequent (37.1%). At first MRI 104 (79.4%) present
at least one lesion related with GD, mean S-MRI: 11.6 (2-28) points, mean
BMB 7.1 (0-12) points, vascular complications was presents in 67 (64.4%)
patients and 44 (33.8%) presents lesions not related with GD. During follow-up
62 (47.3%) patients were evaluated sequentially. A reduction in the BMB scored
by S-MRI was observed after 5 years of therapy (Figure 1). 14 patients on ther-
apy (12 ERT and 2 SRT) and one without therapy present a vascular event,
mean time on therapy (8.4 y; 1.5-16). Of them, three cases registered a bone
crisis in small feet bones (two in calcaneus, scaphoids); two cases developed
multiple foci lesions in lower limbs, mainly in tibia after severe infections. Into
the not previously GD-related lesions we want to highlight the presence of
hemangiomas in vertebra in 11 (8.4%), discopathies in 27 (20.6%) patients,
two cases with neuronopathic-like arthropathy without manifestations of periph-
eral neuropathy but with severe bone involvement and 3 patients with bone
alterations that lead a neoplasm diagnosis.
Figure 1. Evolution of BMB after 5 years on MRI follow-up (62 patients).
Summary/Conclusions: The bone disease is the most important issue in type 1
Gaucher disease patients, the most debilitating alterations have been identified
since the description of the disease, despite the bone related MRI lesions, there
were many findings registered. It’s difficult to say if GD predispose to others man-
ifestations like here described. In our experience, MRI assessment permits to opti-
mize the follow-up of the patients on therapy and identified early complications.
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SEVUPARIN DEMONSTRATES BINDING TO KEY ADHESION RECEPTORS
INVOLVED IN PATHOGENESIS OF SICKLE CELL DISEASE 
M Lindgren1,*, R Brock2
1SCD, Dilaforette AB, Stockholm, Sweden, 2Dept. of Biochemistry, Radboud
University Nijmegen Medical Centre, Nijmegen, Netherlands
Background: Sevuparin is a novel drug candidate with potential as therapeutic
agent for patients with sickle cell disease (SCD). Sevuparin has an anti-adhesive
mechanism of action and is currently studied in a clinical phase II study in SCD
patients hospitalized for acute painful vaso-occlusive crisis (VOC). Sevuparin’s
anti-adhesive effects have previously been demonstrated in both in vitro and in
vivo models. SCD is the most common haemoglobinopathy, affecting millions of
people worldwide. A single point mutation in the β-globin gene results in synthesis
of abnormal sickle haemoglobin (HbS), which polymerizes and causes sickling
of red blood cell (RBC) under hypoxic conditions. RBCs containing predomi-
nantly HbS (SS-RBCs) also demonstrate an adhesive phenotype, where degree
of adhesiveness correlates with frequency of vaso-occlusive events in SCD
patients. The pathogenesis of VOC involves decreased blood flow caused by
microvascular obstructions from the adhesion between the different blood cells
and the vessel endothelium as well as endothelial cell activation. The abnormal
adhesion has been studied and several key adhesion proteins identified;
Selectins are involved in the initial attachment of cells to the vessel wall. More
firm binding is exerted via the integrins, such as thrombospondin (TSP), von
Willebrand Factor (vWf) and fibronectin (FN). Among the selectins, P-selectin is
the most extensively studied adhesion receptor in SCD, contributing to SS-RBC
adhesion and vaso-occlusion both in vitro and in vivo. Blocking P-selectin has
demonstrated improvement in blood flow. However, both E-selectin and L-
selectin have been indicated to be involved as well. E-selectin is upregulated
during inflammatory processes and participates in adhesion between white blood
cells. L-selectin contributes to lymphocyte and neutrophil trafficking and is
cleaved from leukocytes during cell activation. Several other, non-membrane
bound proteins, such as FN, vWF and TSP, have been shown in pre-clinical
model systems to contribute by serving as anchoring or bridging proteins
between the blood cells and the activated endothelium in SCD.
Aims: To determine the binding characteristics of sevuparin with key adhesion
proteins known to be involved in SCD vaso-occlusion and thereby provide evi-
dence of the multiple anti-adhesive properties at a molecular level for this new
investigational treatment.
Methods: The binding characteristics were determined by Fluorescence Cor-
relation Spectroscopy (FCS). Pharmacokinetic studies were performed in mice.
Results: Dissociation constants were determined by FCS, using a competitive
titration approach. Kd for the key adhesion proteins was determined to
0.49±0.38µM for P-selectin, 4.48 µM for E-selectin, 0.45±0.43µM for L-selectin,
2.25±0.34µM for Fibronectin, 0.48±0.34µM for von Willebrand Factor and
0.42±0.18µM for Thrombospondin. To understand which of the interactions would
be relevant in the clinical setting, a pharmacokinetic study was performed in
mice. From this, the target plasma concentration of 2.5 µM was calculated.
Applying the target plasma concentration to the Kd values reported above, sevu-
parin would bind to the adhesion proteins P-selectin, L-selectin, vWF and TSP
while the interaction with FN and E-selectin would be limited. Figure 1. Illustration
of possible multimodal mechanism of sevuparin action. The Figure 1 demon-
strates the potential interactions between sickle blood cells and the blood vessel
wall endothelium.
Figure 1.
Summary/Conclusions: Binding experiments with isolated adhesion receptors
suggest that multiple interactions contribute to the anti-adhesive effect demon-
strated in vitro and in vivo with sevuparin. Sevuparin shows significant binding
to P-selectin, L-selectin, vWF and TSP, but a weaker binding to FN and E-
selectin. An illustration of the potential multimodal mechanism of sevuparin
action can be found in Figure 1.
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GLUTATHIONE S TRANSFERASE GENE POLYMORPHISMS AND THE
RISK OF CNS COMPLICATIONS OF SICKLE CELL DISEASE IN EGYPTIAN
PATIENTS
H Ellithy1,*, S Yousry2, G Shaheen2
1Internal Medicine- Hematology Unit, 2Clinical Pathology Departement, Kasr
Al-Ainy School of Medicine- Cairo University, Cairo, Egypt
Background: Sickle cell disease (SCD) is characterized by multisystem com-
plications with marked variability in disease severity between individuals. Clin-
ical manifestations of SCD are mainly resulted from sickling of Hb S, which is
augmented by oxidative stress. The glutathione system plays an important role
in scavenging the products of intracellular oxidation, so protects Hb S from oxi-
dation, minimizing manifestations of SCD. SCD patients with genetically defec-
tive glutathione system due to glutathione S transferases (GSTs) gene poly-
morphisms, are expected to develop sever forms of SCD.
Aims: Exploring the possible association of the GST gene polymorphisms
(GSTM1, GSTT1 and GSTP1) and the severity of manifestations of SCD in
Egyptian patients, as the GST gene polymorphisms may be considered as a
critical genetic modifier in SCD patients.
Methods: We studied the frequency of the GSTs (GSTM1, GSTT1 and GSTP1)
genes polymorphisms in 100 Egyptian adult SCD patients and 80 age-and sex-
matched controls, GSTM1 and GSTT1 gene polymorphisms were examined
by multiplex polymerase chain reaction (PCR) with using a housekeeping B
globin gene as internal control. A polymerase chain reaction-restriction fragment
length polymorphism assay [PCR-RFLP] was used to detect GSTP1 polymor-
phism. We studied the association between the GSTs gene polymorphisms in
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the SCD patients, and the risk of developing severe clinical manifestations,
including CNS complications in the form of transient ischemic attacks (TIAs)
and strokes, avascular necrosis (AVN) of the head of femur (diagnosed by MRI
of the hip), and renal injury by estimation of Albumin /creatinine ratio (A/C ratio).
Results: Among our study population, GSTM1, GSTT1 and GSTP1 genotypes
distribution was similar between SCD patients and controls. CNS complications
were observed in 66.7% of the SCD patients, 33.3% of the patients had no
history of CNS complication. AVN of the head of femur was observed in 61.5%
of the patients, while 38.5% of the patients had no previous AVN of the head
of femur. The A/C ratio was ranging from 0.01 to 4, mean=0.5±0.6 and median
=0.3. The GSTM1 null genotype was significantly associated with CNS com-
plications (P value=0.03), it was also associated with AVN of the head of the
femur (Odd ratio=7) and raised A/C ratio (mean=0.6±0.82 vs 0.49±0.42 for null
genotype and non-null genotype respectively), however it was not of statistical
significance (P-Value=0.2 and 0.8 respectively). GSTT1 null genotype was also
associated with CNS complication (Odd ratio=5.1), AVN of the head of femur
(Odd ratio=4.2), and raised A/C ratio (mean=0.55±0.65 vs 0.49±0.44 for null
genotype and non-null genotype respectively), however it was not statistically
significant (P-Value=0.4, 0.5 and 0.9 respectively). Non wild GSTP1 polymor-
phisms (Homozygous and heterozygous) were not associated with sever clin-
ical manifestations of SCD in the form of CNS complications, AVN of the head
of the femur and A/C ratio (P value=0.5, 0.6 and 0.8 respectively). 
Summary/Conclusions: As GSTM1 and GSTP1 null genotypes were associ-
ated with unfavorable clinical outcomes, GST gene polymorphisms may be
used as a genetic marker, of a predictive value for defining patients at risk of
developing sever SCD complications, due to impaired anti-oxidative defense
mechanism. Patients with GSTM1 and GSTP1 null genotypes may get benefits
of using prophylactic treatments aimed at reduction of oxidative stress to protect
them against severe complications. However, further studies on a large scale
including different ethnicities are required to prove our observation. 
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LUSPATERCEPT INCREASES HEMOGLOBIN, REDUCES LIVER IRON
CONCENTRATION, AND IMPROVES QUALITY OF LIFE IN NON-TRANS-
FUSION DEPENDENT ADULTS WITH BETA-THALASSEMIA
A Piga1,*, S Perrotta2, A Melpignano3, C Borgna-Pignatti4, MR Gamberini4,
E Voskaridou5, V Caruso6, P Ricchi7, A Pietrangelo8, X Zhang9, D Wilson9,
A Bellevue9, A Laadem10, M Sherman9, K Attie9
1Turin University, Turin, 2Second University of Naples, Naples, 3Ospedale “A
Perrino”, Brindisi, 4University of Ferrara, Ferrara, Italy, 5Laiko General Hospital,
Athens, Greece, 6Garibaldi Hospital, Catania, 7AORN “A. Cardarelli”, Naples,
8CEMEF, Medicina 2, Modena, Italy, 9Acceleron Pharma, Cambridge, MA,
10Celgene Corporation, Summit, NJ, United States
Background: Luspatercept (ACE-536), a fusion protein containing a modified
activin receptor type IIB, is being developed for the treatment of β-thalassemia.
Luspatercept binds to GDF11 and other ligands in the TGF-β superfamily to
promote late-stage erythroid differentiation. Luspatercept corrected the effects
of ineffective erythropoiesis in a thalassemia mouse model (Suragani R, Blood
2014) and was well tolerated and increased hemoglobin (Hgb) in a phase 1
clinical study (Attie K, Am J Hematol 2014).
Aims: This is an ongoing, phase 2, multicenter, open-label, dose-finding study
followed by a long-term extension study to evaluate the effects of luspatercept
in adults with β-thalassemia, including a subgroup that was non-transfusion
dependent (NTD, <4 Units RBC/8 wk). Endpoints included Hgb, liver iron con-
centration (LIC) by MRI, safety, and patient-reported quality of life question-
naires (FACT-An, SF-36).
Methods: Inclusion criteria included age ≥18 yr and Hgb <10 g/dL (NTD pts).
Luspatercept was administered SC every 3 wks for up to 5 doses in the dose-
ranging study (completed) with a 2-month follow-up unless enrolled directly
into a 2-year extension study (ongoing). Six sequential cohorts (n=35 total)
were treated at escalating doses from 0.2 to 1.25 mg/kg. An additional expan-
sion cohort (n=29) was treated with a starting dose of 0.8 mg/kg with escalation
up to 1.25 mg/kg. Of the 64 patients treated in the dose-ranging study (including
34 NTD), 51 were enrolled in the extension study.
Results: Data (as of 25 Sept 2015) were evaluable for 31 of 34 patients who
were NTD. Median age was 37 yr, ranging from 20 to 61 yr, and 68% had prior
splenectomy. Median Hgb was 8.4 g/dL (range 6.5-9.6 g/dL) and mean (±SD)
LIC was 5.6±3.8 mg/g dw. 12 patients were receiving iron chelation therapy
(ICT) at baseline. Mean increase in Hgb was greater in patients treated with
0.8-1.25 mg/kg than in patients treated with 0.2-0.6 mg/kg. Of the patients
treated in the longer-term extension study, 11/17 (65%) achieved a ≥1.0 g/dL
increase in mean Hgb over any 12-week period, and 8/17 (47%) increased by
≥1.5 g/dL. 5/14 (36%) patients with baseline LIC ≥5 mg/g dw had a mean
decrease in LIC ≥2 mg/g dw (mean decrease 3.2 mg/g dw, 32.1%) over the
16-week base study period. 14/14 (100%) patients with baseline LIC <5 mg/g
dw maintained LIC <5 mg/g dw. Four NTD patients with long-term, persistent
leg ulcers experienced complete or partial healing with luspatercept treatment.
Increases in the FACT-An anemia subscale and the SF-36 physical component
summary (PCS) at Week 24 (n=15, last observation carried forward) correlated
with Hgb increases (p<0.05). Luspatercept was generally well tolerated, with
no related serious adverse events reported to date. Adverse events in the NTD
subgroup were mostly mild-moderate and the most frequent related adverse
events (≥3 patients) were bone pain, headache, musculoskeletal pain, myalgia,
and arthralgia.
Summary/Conclusions: Luspatercept treatment was well-tolerated and led
to increased hemoglobin levels, decreased LIC, and improved quality of life in
NTD adults with β-thalassemia. The increase in hemoglobin correlated with
improvement in QOL anemia symptom score. These changes represent a sig-
nificant reduction in disease burden reflected in improved patient quality of life
for patients with NTD β-thalassemia; further studies in this population are
planned.
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AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) AND
ALPS-RELATED SYNDROME (ARS). DIFFERENCES ON CLINICAL AND
BIOLOGICAL FEATURES AND TREATMENT RESPONSE: A SINGLE
CENTER EXPERIENCE.
F Fioredda1,*, E Palmisani1, C Micalizzi1, M Calvillo1, F Pierri1, F Tucci1,
I Olivieri1, M Mazzoni1, P Terranova1, I Caviglia2, C Dufour1, M Miano1
1Haematology Unit, 2Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini,
Genova, Italy
Background: ALPS is a rare, inherited disorder of the immune system due to
defective Fas mediated-apoptosis, characterized by lymphoproliferation, autoim-
munity and frequently cytopenias. Immunological/autoimmune disorders with an
ALPS phenotype but not completely fitting ALPS full diagnostic criteria, are fre-
quently seen by heamatologists and often represent a therapeutic challenge. 
Aims: is to describe clinical and biological features and treatment response of
a cohort of ALPS and ARS patients seen at our Centre.
Methods: patients with ALPS and ARS treated at the our Centre from January
2001 to December 2015, were considered eligible to the study. ALPS was
defined according to the revised diagnostic criteria established by a work shop
in 2009. ARS has been arbitrarily defined by the presence of i) cytopenia+at
least one “Required Criteria” or one “Primary Additional Criteria” or b) two
“Required criteria”+one Secondary Additional Criteria. Anagraphical, clinical,
biochemical data were collected for each patient. Response to immunosup-
pression was defined partial or complete according to a melioration/resolution
of cytopenia or other symptoms. 
Results: 90patients (49 males, 41 females) whose median age at diagnosis
was 10 yrs (0-39.8) with ALPS (37) or ARS (53) were evaluated. Lymphopro-
liferation was present in 71% (64/90)patients and consisted of isolated lym-
phoadenopathy (31%>28/90-), isolated splenomegaly (54%>49/90), or both
(19%>17/90). Lymphoadenopathy was more frequent (49%)in ALPS than in
ARS (19%; p<0.01) and so was splenomegaly (84% in ALPS vs 34% in ARS
patients, (p<0.01). The median percentage of Double Negative T-cells/total
lymphocytes was and again was higher in ALPS 2.6% (0.6-14.8) over ARS
(2.2% 0.6-19.5) (p<0.01). Cytopenia was present in 80% subjects; of these
32% (26) were ALPS and 64% (46) ARS (p=0.05) and involved one (62%) or
more cell lineages (38%). Isolated thrombocytopenia was significantly more
frequent in ARS (79%) vs ALPS (21%)(p=0.01), while neutropenia (52%) and
hemolytic anemia (44%) were more represented in ALPS vs ARS (p=0.03 and
=0.01 respectively). Trilinear cytopenia was present almost exclusively in ALPS
(86%) vs ARS (14%) (p<0.01). Vitamin B12 values above1500 ng/l and autoim-
mune symptoms were more frequent in ALPS than in ARS (p=0.02 and p<0.01).
Fourteen out of 89 patients (16%)did not need any treatment. Of the remaining
75, 14 (19%) responded to steroids and/or immunoglobulin, while
61(81%)required a second/third line therapy. Of these 61, 41 (67%) received
MycophenolateMofetil (MMF) which resulted in a partial/complete response in
70%. Response rate was 78% in ALPS and 61% in ARS (p=ns). Twenty eight
of 61 (46%) received Sirolimus, including 15 patients who had previously failed
MMF treatment. Partial/complete response was seen 92% of ALPS and in 77%
of ARS patients (p=ns).
Summary/Conclusions: Lymphoprolipheration and autoimmune symptoms
characterizes mainly ALPS, while cytopenia is a peculiarity of ARS. Isolated
thrombocytopenia is more frequent in ARS patients, while neutropenia/
haemolytic anemia or trilinear cytopenia is more typical of ALPS. MMF and
Sirolimus represent a valid option for the treatment of ALPS and ARS being
effective in more than ¾ of the cohort thus sparing steroids. The definition of
the genetic profiles of these patients might enable treatments tailored on the
different pathogenic mechanisms.
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INCREASED LEVELS OF CIRCULATING IMMATURE GRANULOCYTES IN
SEPSIS HAVE A SIGNIFICANT IMPACT ON SURVIVAL: RESULTS OF THE
FRENCH MULTICENTRIC SEPTIFLUX 2 STUDY
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Background: In industrialized countries, overall survival of sepsis is 27%, and
each year, as many patients die of sepsis as of heart attack. In the first hours of
sepsis, increased percentage of band cells and late immature granulocytes (Imm
Gran), the cytologic equivalent of CD10dim and CD16dim immature granulocytes,
has long been described. Recently, we suggested in a proof-of-concept mono-
centric study that Imm Gran CD10dim and CD16dim quantification by flow cytom-
etry may have a prognostic interest in septic patients. We also showed that this
cell compartment contains myeloid derived suppressor cells (MDSCs). 
Aims: Here we demonstrate prospectively that the prognostic value of this the
CD10dim and/or CD16dim granulocyte counts in a multicentric study including
12 centers and 781 patients.
Methods: Prospectively, between November 2013 and June 2015, all patients
admitted for less than 24 hours in 12 french hospitals for Sepsis, severe Sepsis
or septic shock were eligible. A blood count and a eight colors cytometry staining
(CD64/CD10/CD14/CD16/CD24/CD11b/CD3/CD45) were performed to quan-
tify CD3 cells, CD64+ granulocytes, CD10dim and CD16dim immature granu-
locytes, monocytes and although the inflammatory monocytes (CD16+). The
intensity of CD10 and CD16 was also compared (mean, mode, CV).
Results: 1062 patients were screened and 281 excluded mainly due to uncon-
firmed infection. 781 were analyzed. Patients were segregated in 3 groups
regarding the severity of sepsis: 343 Sepsis (67+/-75 years), 192 severe sepsis
(67+/-67 years) and 246 with septic shock (65+/-15 years). In each group we
have followed the clinical deterioration (8%, 12% and 9%) at 48 hours and the
mortality rate (0%, 1% and 9%) respectively. Corresponding to the emergence
of CD16dim Imm Gran, an increased CV of CD16 expression (CV=52, p<0.01)
was found in deteriorating patients compared to patients with a stable or
improved condition at 48 hours (CV=44.2, p<0.01). At day 0, the absolute count
of Imm Gran was 2 G/L vs 4.7 G/L (p<0.01) in patients who survived or not at
day 7, and 1.9 G/L vs 4.6 G/L at day 30 (p<0.01). The proportion of Imm Gran
was 19.8% vs 66.4% (p<0.01) in patients who survived or not at day 7, and
19.1% vs 55.2% at day 30 (p<0.01). Thus, both absolute count and proportion
of Imm Gran had a negative prognostic value on mortality at day 7 and 30. A
CD3 lymphopenia had also a significant impact on survival, 0.5 G/L vs 0.3 G/L
(p<0.01) at day 7 and 0.6 G/L vs 0.4 G/L (p<0.01) at day 30.
Summary/Conclusions: These results demonstrate in a multicentric manner
on a very large prospective cohort of patients that increased levels of CD10dim
and CD16dim Imm Gran, as quantified by daily routine flow cytometry in hospital
laboratories, have a strong pejorative prognosis value on survival at day 7 and
30 in Sepsis. Early Sepsis management being known to prevent deterioration
of patients, we strongly suggest that setting up the precise quantification of
immature granulocytes by flow cytometry could benefit to septic patients with
a tailored specific management. 
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SEQUENCING FOR THE MOLECULAR DIAGNOSTIC OF INHERITED
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Background: Molecular testing of Inherited bleeding coagulation disorders
(IBCDs) not only offers confirmation of diagnosis, but also aids in genetic coun-
seling, prenatal diagnosis and in certain cases genotype–phenotype correla-
tions are important for predicting the clinical course of the disease and to allow
tailor-made follow up of individuals. Until recently, genotyping has been mainly
performed by Sanger sequencing, a technique known to be time consuming
and expensive. Currently, Next-Generation Sequencing (NGS) offers a new
potential approach that enables the simultaneous investigation of multiple genes
at manageable cost.
Aims: To analyze the applicability of a 31-gene NGS panel in the molecular
diagnosis of patients with IBCDs.
Methods: We enrolled a total of 30 patients (19 males and 11 females; median
age, 20 years, ranging from 1 to 61 years old), with previously confirmed coag-
ulation factor deficiencies. IBCDs genotype was studied using NGS technology.
A custom target enrichment library was designed to capture thirty-one genes
known to be associated with IBCDs. Probes were generated for 343 targets to
cover 103.3 kb regions (all exons and flanking regions) of these genes. Sanger
sequencing was performed to validate all causative variants identified by NGS.
Results: The use of this 31-gene panel approach allowed us to identify the
causative variants of the IBCDs in all patients. Overall, thirty pathogenic variants
were found (five hypodysfibrinogenemias, five von Willebrand disease, three
FVII deficiencies, one FV, FX, FXII, FXIII, Prekallykrein deificiency, each other,
two FXI deficiencies, eight Hemophliia A and 2 Hemophilia B), including eight
novel mutations affecting F8, FGA, FGG, F11, F10, F5 and VWF genes and
twenty-two previously reported variants were detected. Most of them, 27 were
missense/nonsense and 3 were frameshift changes due to microdeletions.
NGS and Sanger sequencing were 100% concordant (Table 1).
Table 1.
Summary/Conclusions: Inherited coagulation disorders could be successfully
molecularly characterized by using our 31-gene Next Generation DNA Sequenc-
ing panel. This approach allowed the diagnosis of the disease at a molecular
level in all patients, and the identification of novel genetic variants in 26% of the
cases included. Our results demonstrate that this approach could be an accurate,
reproducible, and reliable tool in the rapid genetic diagnosis of IBCDs. 
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Background: Molecular diagnosis should be performed for all patients with
hemophilia A (HA) and/or B (HB), highlighting any excess risk of inhibitor devel-
opment associated with specific mutations, and enabling carrier testing for
female relatives and prenatal or possible pre-implantation genetic diagnosis
or to distinguish von Willebrand disease (VWD). Currently, Next-Generation
Sequencing (NGS) offers a powerful approach that enables the simultaneous
exploration of exons, introns and regulatory regions of various genes. 
Aims: To evaluate the usefulness of a molecular diagnostic algorithm for hemo-
philia A and B based on NGS to analyze full-length F8, F9 and VWF genes.
Methods: Overall of 100 DNA samples were analyzed. Ninety-five unrelated
hemophilic patients (HA=78 and HB=17) and 5 females for her hemophilia car-
riers’ status in whom the index case were unknown. Our molecular algorithm
first step catalogues severe HA patients carrying intron 22 or intron 1 inversions
detected by long range PCR. In a second step, severe HA patients without
previous alterations as well as rest of different types of FVIII or FIX deficiency
and female carriers were considered for NGS studies. (Figure 1). Whole regions
(exonic, flanking, regulatory and intronic) were sequenced by the NGS enrich-
ment target. In those patients without pathogenic variants, multiplex ligation-
dependent probe amplification (MLPA) was performed. 
Results: In the global analyses, genotyped were identified in 94 out of 100 sam-
ples (94%). Fourteen novel variants were detected. Only in 6 mild HA patients,
pathogenic variants were not found. All severe HA patients (n=20) were geno-
typed. In 11 of them, IVS22 were confirmed (55%). None IVS1 was found. In the
remaining 7 out of 8 patients (IVS22 and IVS1 negative), genetic variants were
found by NGS analyses and it allowed us to detect 3 nonsense, 2 microdeletion,
1 duplication and 1 missense pathogenic variant. MLPA approach reached a
complex mutation (gross deletion and duplication) in the last severe HA patient.
Most of HA patients included were mild/moderate phenotype (n=54 and n=4;
75%). In 52 out of 58 patients (90%), missense pathogenic variants were found.
In 5 of them, a new accurate diagnose was established due to detection of path-
ogenic VWF variants: one case with a VWD type 2N, one carrier of VWD type
2N and 3 cases of VWD type 1. In the remaining 6 cases, intronic variants are
being analyzed. About HB patients, genotype was confirmed in all patients (n=17).
All variants were missense except one nonsense variant. Most of them (n=10;
63%) affected to the catalytic domain. About hemophilia carrier status, 5 females
were included because their index cases were not known. Three pathogenic
variants were confirmed in F8 gene (IVS-22, p.Arg427* and c.5374-19delT; IVS-
16), in three of them. In the remaining two symptomatic females (mild FVIII defi-
ciency), a pathogenic variant (c.2561G>A; p.Arg854Gln) in exon 20 of VWF gene
was found. Accordingly, a new type 2N-VWD diagnose was established.
Figure 1.
Summary/Conclusions: The use of this molecular-algorithm approach allowed
us to identify the causative variants of the HA and HB patients, correctly rede-
fine VWD and to establish the status of female carriers.
Pfizer supported this study.
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MUTATIONS IN FVIII A DOMAIN
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Background: Significant discrepancy between one-stage clotting assay (FVI-
II:C1) and chromogenic method (FVIII:CR) for FVIII activity measurement is
common in mild haemophilia A (HA) patients. Different missense mutations
are identified in families with discrepant HA. Such mutations are located mainly
within exons encoding C2 and A2 domains of FVIII. Missense mutations in A2
domain can cause instability of molecule leading to reduced FVIII:CR. The dif-
ferences in FVIII levels may lead to an incorrect biochemical phenotype and
diagnosis of haemophilia. The global haemostasis tests may represent an
option for better prediction of the mild HA clinical phenotype.
Aims: Genetic background was determined in patients with discrepant FVIII
activity in Slovenian patients with mild haemophilia A. The structural elements
in FVIII molecule were characterised. Further specific and global coagulant
assays were investigated to determine their usefulness.
Methods: F8 gene mutations were determined with Sanger sequencing and
analyzed with in silico methods. FVIII activity tests were performed with one
stage clotting assay (APTT-SP reagent and FVIII deficient plasma, both Instru-
mentation laboratory-IL, USA) on ACL TOP 500 instrument (IL, USA) and chro-
mogenic assay (Electachrome Factor VIII, IL, USA) using spectrofotometric
manual method (Multiskan EX, Thermolabsystem, Finland). FVIII antigen (FVI-
II:Ag) was determined with Asseracgrom FVIII:Ag kit (Stago, France). APTT
wave clot analysis was performed on ACL TOP 500 instrument and thromboe-
lastometry on ROTEM®delta instrument (Pentapharm GmbH, Germany).
Results: Twelve patients from 7 families presented with FVIII:C1 measurement
significantly higher than those obtained with FVIII:CR method. FVIII activity ratio
range was from 2.6-4.2. The p.Ser308Leu variant in A1 domain (previously
described) was identified in seven patients. All of them had reduced FVIII:C1
ranged from 21 to 48% and normal FVIII:Ag ranged from 52 to 112%. Three
novel missense variants clustered in A2 domain (p.Val670Phe, p.Tyr683His,
p.Asp685Gly) were associated with fourfold discrepancy. Four patients with those
variants had FVIII:Ag from 26 to 62% however, they would be classified as having
moderate form of HA using FVIII:CR method. All three genetic variants are located
at the interface between A2 and A3 domain (Figure 1). APTT was normal in 5
patients carrying the p.Ser308Leu variant. The wave clot analysis shows that
92% of our patients demonstrated normal acceleration of APTT reaction (max2
parameter) in the contrast with nondiscrepant HA, where max2 is normal in only
17% (data not shown). For INTEM test of ROTEM analysis, clotting time has
sensitivity of 42%. Clinical data classified all our patients as mild haemophiliacs
with bleeding episodes provoked only by surgical interventions or trauma.
Figure 1. Close-up view of the FVIII A2 (orange) – A3 (magenta) domain
interface. Amino acids at position 670, 683 and 685 contribute to FVIII
interdomain.
Summary/Conclusions: Three novel genetic variants were described causing
a discrepant biochemical phenotype of HA. The nature and position of variants
are strongly associated with phenotype and contribute to the FVIII molecule
instability. High results of FVIII:Ag showed that the endogenous synthesis and
secretion of FVIII is less affected. The APTT test could be in normal range in
discrepant patients, however, wave clot analysis shows good differentiation
between discrepant and nondiscrepant patients and could provide additional
information in managing HA. ROTEM poorly discriminates between normal
individuals and mild HA patients and the method is unlikely to be helpful in dis-
crepant HA identification. One-stage and chromogenic method should be used
in diagnostics of non-severe HA to avoid the misdiagnosis and to complement
the genetic findings.
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Background: The ‘Willebrand in the Netherlands’ study group has previously
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published that almost a quarter of patients with moderate and severe Von Wille-
brand disease (VWD) reported joint bleeds. Those bleeds had a negative impact
on health related quality of life and joint integrity, according to patient-reported
and retrospective medical file data. However, besides that, little information is
available for VWD patients on the prevalence and severity of arthropathy and
its influence on joint function and daily life activities.
Aims: To assess the prevalence and severity of arthropathy and its impact on
joint function and daily life in moderate and severe VWD patients (trial number
NTR 4548). 
Methods: Dutch patients with moderate and severe VWD (VWF activity<30
IU/dL and <10 IU/dL, respectively) and documented treatment for at least
one joint bleed were invited to participate. The same number of controls (mod-
erate and severe VWD patients without joint bleed treatment) were selected
and matched for age (±2 years), gender and FVIII level (±10%). A single
experienced physiotherapist conducted the Haemophilia Joint Health Score
(HJHS, 0-124). X-rays were made from all joints with prior bleeds, contralat-
eral joints and one control joint. One radiologist scored the X-rays according
to Pettersson (PS, 0-13 per joint). Arthropathy was defined as a clinical HJHS
score ≥3 or PS>0. All participants completed the Haemophilia Activity List
(HAL, 0-100) questionnaire. The Visual Analogue Score (VAS, 0-10 cm) was
used to assess joint pain. 
Results: 48 patients and 48 controls were included, 60% males, mean age 46
years (range 18-80). Mean FVIII levels were 26 IU/dL in the patients and 31
IU/dL in the controls (p=0.19). More patients had type 3 VWD (19/48 vs 3/48
controls). In the control group of patients without documentation on joint bleed
treatment, 14/48 patients did report one or more joint bleeds but none of them
more than five. In contrast, 56% of the 48 patients had more than five joint
bleeds. Arthropathy occurred in 37/48 (77%) patients and 35/48 (73%) controls
(p=0.51). Overall, arthropathy occurred in both severe (47/64) and moderate
VWD (25/32) and in all three VWD types (22/28 type 1; 30/46 type 2; 20/22
type 3). The median HJHS was significantly higher in the patients compared to
the controls (5 vs 1.5, p<0.01, maximum score 47 vs 29). PS>3 occurred in 2
controls compared to 12 patients (p<0.01) and overall most in type 3 VWD
patients (9/22 type 3 vs 3/46 type 2 vs 2/28 type 1). The total HAL score as well
as the scores on the three separate HAL components were significantly lower
for the 48 patients compared to the controls (median scores HAL Sum: 88 vs
100, p<0.01; Upper Extremity Activities: 93 vs 100, p=0.01, Basic Lower Extrem-
ity Activities: 87 vs 100, p<0.01; Complex Lower Extremity Activities: 80 vs 100,
p<0.01). Clinically relevant joint pain (mean VAS score >3) was reported by 17
patients and 9 controls (p=0.07). 
Summary/Conclusions: Arthropathy, according to our stringent definition, was
seen in 77% of patients with moderate and severe VWD treated for joint bleeds.
Notably, arthropathy was also found in 73% of matched control VWD patients
without joint bleed treatment. Joint function and –integrity in the VWD patients
treated for joint bleeds was affected, consistent with higher HJHS and joint X-
rays scores. These patients experienced a significant impact on daily life activ-
ities (HAL, both upper and lower extremities) and 35% also reported clinically
relevant joint pain (VAS). 
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Background: Inherited bleeding, thrombotic and platelet disorders (BPDs) are
rare diseases affecting approximately 300 individuals per million births. With
the exception of haemophilia and von Willebrand disease patients, a molecular
analysis for BPD patients is often unavailable. Many specialised tests are usu-
ally required to reach a putative diagnosis and they are typically performed in
a slow, step-wise manner to control costs. The results of these tests may be
used to prioritise genes for Sanger sequencing if a genetic diagnosis is required.
This approach causes significant delays and a conclusive molecular diagnosis
is often never reached, which can compromise treatment and impede rapid
identification of affected relatives. 
Aims: Our aim was to design a platform through which accurate and rapid test-
ing of inherited BPDs would be possible.
Methods: We designed a high-throughput sequencing (HTS) platform targeting
all 87 known BPD disease genes. The platform can call single nucleotide variants,
short insertions/deletions and large copy number variants (though not inversions),
which are subjected to automated filtering for diagnostic prioritisation.
Results: We sequenced 159 and 141 samples respectively from individuals
with and without previously known causal variants. Among the latter group, 61
cases had phenotypes strongly indicative of a particular molecular aetiology
while the remainder had an aetiology that was a priori highly uncertain. All the
previously detected variants were recapitulated and, when the aetiology was
suspected but unknown, a molecular diagnosis was reached in 56 of 61 cases. 
Summary/Conclusions: The ThromboGenomics platform provides a compre-
hensive and affordable DNA-based test to diagnose patients suspected of having
a known inherited BPD thereby significantly reducing the current diagnostic delay.
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Background: CD72 is considered to be an important B cell co-receptor for its
prominent role in immune regulation. Previous studies show that CD40 signals
play a more important role in mechanism of primary immune thrombocytopenia
(ITP) by activating B cell and inducing B-cell growth with Ig secretion. NF-κB
activation is a pivotal pathway in CD40 signaling. However, the effect of CD72
on B cells activated by CD40 in ITP remains unknown.
Aims: This study aimed to explore the effect of CD72 on B cell activation
through CD40 in ITP.
Methods: Activation-associated surface markers (CD80, CD86 and CD40), the
proliferation, apoptosis, plasmablasts and platelet-associated IgG were ana-
lyzed by flow cytometry in patients with active ITP and health controls. In cul-
tures vitro, peripheral blood mononuclear cells (PBMCs) were stimulated by
anti-CD40 in the presence or absence of CD40L, IL-4 and IL-21, autologous
platelets. Production of IgG and IgM in the culture supernatants was determined
by enzyme-linked immunosorbent assay. The levels of NF-κB P65 and IκBα
mRNA were assessed by real-time quantitative polymerase chain reaction.
Results: Our data showed that CD40 expression was significantly decreased
on CD19+ B cells after CD72 ligation in ITP patients compared to controls. The
higher levels of activation markers CD80, CD86 on CD19+ B cell stimulated by
anti-CD40 was reduced by anti-CD72 in ITP patients and controls. CD40 stimu-
lation significantly promoted the survival of CD19+ B cells, and reduced the apop-
tosis of CD19+ B cells in ITP patients compared to that observed in controls.
CD72 ligation corrected the effect of CD40 stimulation on apoptosis and prolifer-
ation of B cells. The CD40-mediated the differentiation of B cells into plasmablasts
was blocked by CD72 ligation in ITP patients and controls. However, the role of
CD72 on B cell differentiation was stronger in ITP patients than in controls. CD72
ligation had only a minor effect on reducing platelet-associated IgG in ITP patients.
Following stimulation with anti-CD40 and IL-21, synthesis of IgM by B cell was
diminished in the presence of anti-CD72, whereas the IgG levels were barely
reduced. The reduced ratio had no difference in ITP patients and controls.CD72
signaling significantly reduces NF-κB P65 and IκBα expression at the mRNA lev-
els in PBMCs activated by anti-CD40 in ITP patients compared to controls.
Summary/Conclusions: These findings indicate that CD72 is a key molecule
in regulating B cell activation, proliferation, apoptosis and antibody secretion
mediated by CD40 signaling in ITP patients.Thus, CD72 may be involved in
the pathogenesis of ITP and antagonizing CD72 could be a novel strategy for
the therapy of ITP.
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Background: Bruton’s tyrosine kinase (BTK) is expressed in platelets (PLTs)
and mediates collagen-induced aggregation of PLTs. TEC, a member of the
TEC family kinases, is also expressed in human and mouse PLTs. Studies in
PLTs from BTK-deficient X-linked agammaglobulinemia patients (Quek 1998;
Lipsky 2015), and BTK and/or TEC KO mice suggest that the 2 kinases likely
possess redundant functions in collagen-induced aggregation; however, BTK
is thought to play a more dominant role than TEC, as BTK deficiency alone
reduces robust aggregation at lower collagen concentrations (Atkinson 2003).
Ibrutinib (ibr) is a once-daily, first-in-class, covalent inhibitor of BTK approved
for various B-cell malignancies. Additional BTK inhibitors (BTKis) have been
evaluated in clinical trials, with bleeding as a common adverse event (AE)
observed not only for ibr but also for ONO-4059 (Walter 2016), ACP-196 (Byrd
2016), and BGB-3111 (Tam, ASH 2015). Early-phase clinical data reported to
date for these follow-on molecules have been limited due to small patient num-
bers and minimal follow-up, where ACP-196 and ONO-4059 had bleeding
events of petechiae and contusion among the most common AEs (hematoma
was also frequently reported with ONO), and BGB similarly had a 33% bleeding
rate. These compounds are potent BTKis with additional activity against TEC;
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therefore, inhibition of BTK or both BTK and TEC may contribute to bleeding.
Aims: This study investigated how ibr and other clinical-stage BTKis, with a
focus on selectivity over TEC, impact PLT function and their potential implication
in bleeding events in patients on BTKi therapy.
Methods: On-target potency and selectivity of BTKis over TEC were investi-
gated with recombinant enzymes using 3 different assays: LabChip® MSA,
TR-FRET, and 33P HotSpot activity. Cell activity was tested in human whole
blood for BCR activation and in PLTs by light transmission aggregometry (LTA).
The activity of BTKis was also evaluated by measuring cellular TEC phospho-
rylation levels in the presence of BTKis.
Results: Ibr had potency of approximately 1 nM or below with 0.7- to 11-fold
selectivity for BTK over TEC in all 3 biochemical assays. ACP-196 had variable
potency (3-135 nM) towards BTK; however, the selectivity profiles against TEC
were similar to ibr, with <3-fold differences in the ratios (Table 1). Ibr, ACP-196,
and ONO-4059 had IC50s 20-40 nM in BCR assays, but in LTA with PLTs from
healthy human donors, a 3-fold difference was observed compared with ibr (Fig-
ure 1). However, this difference in patients with CLL, in whom ACP-196 is admin-
istered twice daily, plasma Cmax levels were approximately 1-2 μM, 3- to 5-fold
higher than those after ibr (0.2-0.4 μM) in CLL patients (Table 2). Moreover, inhi-
bition of TEC phosphorylation in PLTs was similar between ibr and ACP-196.
Table 1. Recombinant kinase assays.
Figure 1. Platelet aggregation after ibrutinib or ACP-196 treatment.
Table 2. Pharmacokinetic parameters.
Summary/Conclusions: BTKis tested did not show a definitive selectivity
advantage against TEC in enzymatic or cellular phosphorylation assays. When
compared at the clinically and pharmacologically relevant plasma concentra-
tions, both ACP-196 and ibr had similar effects on PLT aggregation. These
results appear consistent with clinical data on bleeding events for both ACP-
196 (Byrd 2016) and ibr (Byrd 2014). Only double-blinded placebo-controlled
studies can address the potential risks and benefits of these subtle differences.
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Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare inherited
abnormality characterized by systemic vascular dilatation resulting in arteri-
ovenous fusion including hepatic vascular malformations (HVaMs) with the risk
of bleeding events. Due to current efforts to sub-classify a high risk group of
asymptomatic patients with HVaMs on the one side and the experienced ben-
efits of bevacizumab on the other side, cost-effective screening of HHT patients
for hepatic involvement become more and more attractive. 
Aims: To analyze HVaMs in a group of patients (n=18) applying CEUS and
adding quantitative time intensity curve analysis (TIC analysis).
Methods: US/CEUS imaging data of 18 patients (2 men/16 women; mean age
59.4±12.1y; range, 21-83y) diagnosed with HHT in the Ear-Nose-Throat (ENT)
department of the University Hospital of Regensburg between Jan 2015 and Jan
2016 were retrospectively analyzed with a high-end US scanner. SonoVue 1.0-
2.4 ml was applied i.v. as contrast agent. Findings on B-Mode, color coded Doppler
sonography (CCDS) and Power Doppler (PD) were analyzed in respect of sug-
gested sonographic grading and staging criteria and by considering the “color
spots”. In order to perform TIC analysis eight regions of interest (ROIs) with a
diameter of 5 mm were placed in the perfused hepatic artery, portal vein, shunt
region and hepatic parenchyma, two ROIs per region. For quantitative investiga-
tion, the area under the curve (AUC) and time to peak (TTP) was considered.
Results: HVaMs could be identified in all patients, being localized particularly
in the central area, segment 8 and the left lobe of the liver. All patients showed
dilated hepatic artery (mean diameter 11,5 mm). Another major Caselitz criteria
“intrahepatic arterial hypervascularization” was found in only 61,1% of the
cases, while minor criteria “tortuous course of the extrahepatic artery” was
described in 83,3%. The other 3 minor criteria (Vmax and RI hepatic artery;
Vmax portal vein) were on average somewhat above the norm. Altogether, in
only 55,6% of our patients the two major criteria were positive, while 16,7%
did not reach diagnostic criteria for HVaMs. Buonamico reported higher sen-
sitivity for “color spots” compared to Caselitz criteria, but 27,8% of our patients
showed no spots at all. With regard to sonographic staging by Buscarini L.
and grading criteria by Buscarini E., stage III and grade 3 could be demon-
strated most frequent (~ 40%). We found arterioportal HVaMs in more than
half of the patients (61,1%), however always in combination with arteriovenous
malformations. In 16,7% even portovenous malformations were associated.
HVaMs with early hyperenhancement during the arterial phase could be
demonstrated by CEUS in all patients. Significant lowest TTP and highest
AUC were detected in the hepatic artery and highest TTP and lowest AUC in
the hepatic parenchyma and the portal vein. TTP and AUC values of the shunt
region were between those of hepatic artery and portal vein. US/CEUS cov-
ered all subtle patterns and proved more accurate in diagnosis of challenging
lesions like high-flow angiomas when compared to MRI, CT or angiography
(Figure 1).
Figure 1.
Summary/Conclusions: For the first time we analyzed CEUS findings of a
group of 18 HHT patients regarding macro- and microcirculation. Our data
demonstrate significant differences in TTP and AUC values in the four selected
regions: hepatic artery, shunt region, portal vein and hepatic parenchyma.
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Background: Complications from chronic HCV infection remain a major cause
of morbidity and mortality among individuals with IBLD, including those with
hemophilia (HEM), beta thalassemia (BTHAL), von Willebrand disease (VWD),
and sickle cell anemia (SCA). Inability to tolerate ribavirin and frequent comor-
bidities have limited HCV treatment options in these patients. The efficacy and
safety of a once-daily, fixed-dose combination of EBR 50 mg (NS5A inhibitor)
and GZR 100 mg (NS3/4A protease inhibitor) has been demonstrated in a
broad population of HCV-infected patients and supported evaluation in the
IBLD population.
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Aims: To assess the safety and efficacy of EBR/GZR in patients with HCV
infection and SCA, BTHAL, or HEM/VWD.
Methods: C-EDGE-IBLD is a double-blind, placebo-controlled study that ran-
domized treatment-naïve and peg-interferon/ribavirin treatment-experienced
(TE) HCV genotype (GT)1, 4, or 6-infected patients in a 2:1 ratio to either an
immediate-treatment group (ITG; 12 weeks of EBR/GZR) or deferred-treatment
group (DTG; 12 weeks of placebo followed by EBR/GZR). Randomization was
stratified according to cirrhosis status and IBLD group, defined as 1) HEM (A
or B) or VWD, 2) BTHAL, or 3) SCA. The primary endpoints for this study were
proportion of patients in the ITG who achieved an SVR12 (HCV RNA <15 IU/mL
12 weeks after study treatment completion) and a comparison of the safety
and tolerability of EBR/GZR in the ITG relative to placebo treatment in the DTG.
All patients provided written informed consent.
Results: Mean age was 44 years; 75% male; 18% black; 40% GT1a; 44%
GT1b; 11% GT4; 26% cirrhotic; 50% TE; 6% HIV/HCV co-infected; 43%
HEM/VWD; 38% BTHAL; 18% SCA. SVR12 was achieved by 93.5% (100/107)
patients receiving EBR/GZR in the ITG. Of the 7 patients who failed to attain
SVR12, 6 patients relapsed and 1 patient discontinued treatment early with
noncompliance and did not participate further in the study. SVR12 was high in
all blood disorder groups (Table 1). There were 3 (2.9%) patients with serious
adverse events (SAEs) (1 drug-related, 2 related to IBLD) in the ITG with no
discontinuations due to safety events. In the DTG, 1 patient discontinued due
to AEs and 1 withdrew consent; 6/52 (11.5%) had SAEs (1 drug-related, 3 relat-
ed to IBLD). No patient in either arm prematurely discontinued from the trial
due to worsening of underlying IBLD. There was 1 hepatic event of clinical
interest (alanine aminotransferase >3× baseline and >100 U/L) in each arm. 
Table 1. SVR12 in the ITG (full analysis set population).
Summary/Conclusions: EBR/GZR is well tolerated and effective in patients
with HCV GT1, 4, or 6 with or without cirrhosis with IBLD.
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DOES HIGH HISTONE LEVEL LEAD US TO DETERMINE COAGULOPATHY
EARLY AFTER TRAUMA IN PEDIATRIC PATIENTS?
E Ulusoy1, M Duman1, A Çağlar1, T Küme2, A Er1, F Akgül1, H Çitlenbik1,
D Yılmaz1, H Oren3,*
1Pediatric Emergency Care, 2Biochemistry, 3Pediatric Hematology, Dokuz Eylül
University Faculty of Medicine, Izmir, Turkey
Background: Acute traumatic coagulopathy occurs after trauma with impair-
ment of hemostasis and activation of fibrinolysis. Some endogenous materials
may take role on this failure of coagulation system. Extracellular histone is one
of the molecules taking attention recently. 
Aims: This study investigated the association between plasma histone com-
plexed DNA fragments (hcDNA) and coagulation abnormalities in pediatric trau-
ma patients.
Methods: This case control study conducted in pediatric patients with multipl
trauma or isolated brain injury. Fifty trauma patients and 30 healthy controls
were enrolled. Demographic data, anatomic injury characteristics, coagulation
parameters, computerized tomography findings, trauma and thrombosis scores
were recorded. Venous blood samples for hcDNA were collected into two hours
after injury and assessed by enzyme linked immunosorbent assay. 
Results: Eighteen patients had isolated brain injury, 32 patients had multiple
trauma. Twenty seven patients had mild, 11 patients had moderate and 12
patients had severe trauma according to Glasgow Coma Scale. Although no
patient had overt disseminated intravascular coagulation, 13 patients had acute
coagulopathy of trauma shock (ACoTS). Plasma hcDNA levels were signifi-
cantly higher in trauma patients than healthy controls (0.474 AU and 0.145 AU,
respectively). There was an association between plasma hcDNA levels and
trauma severity according to Glasgow Coma Scale, Pediatric Trauma Score,
Injury Severity Score. AcoTS patients had higher plasma histone levels than
without AcoTS (0.703 AU and 0.398 AU; respectively). Plasma hcDNA levels
were significantly correlated with the International Society of Thrombosis and
Hemostasis score, length of intensive care unit stay, prothrombin time, D- dimer
levels, and also there were negative correlations with fibrinogene levels and
pediatric trauma scores.
Summary/Conclusions: This study indicated for the first time that hcDNA lev-
els increase in pediatric trauma patients associated with coagulopathy. Further
studies are needed to clarify the role of high hcDNA levels in determining the
functional significance of these changes in disseminated intravascular coagu-
lation and predicting mortality.
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AAV-MEDIATED GENE THERAPY FOR HEMOPHILIA B-EXPRESSION AT
THERAPEUTIC LEVELS WITH LOW VECTOR DOSES
KA High1, L George2, S Sullivan3,*, A Luk1, T Urich1, J Teitel4, A Cuker5,
F Wright1, Y Chen1, D Hui1, K Wachtel1, A Galvao6, LE McMillan7, D Takefman1,
ME Carr8, L Couto1, X Anguela1
1Spark Therapeutics, 2Pediatrics, Children’s Hospital of Philadelphia, Philadel-
phia, 3University of Mississippi Medical Center, Jackson, 4St. Michael’s Hospital,
Toronto, 5Perelman School of Medicine of the University of Pennsylvania, 6The
Children’s Hospital of Philadelphia, Philadelphia, 7The University of Mississippi
Medical Center, Jackson, 8Pfizer, Philadelphia, United States
Background: Published data from Nathwani et al. (NEJM 2014) demonstrated
long-term expression of Factor IX in men with hemophilia B infused with an
AAV8 vector expressing wild-type Factor IX. However, levels of expression
ranged from 1.4%>2.2% normal at the lowest dose (2 x 1011 vector genomes
[vg]/kg body weight) to 2.9-7.2% normal at the highest dose (2 x 1012vg/kg).
Moreover, 4/6 subjects infused at the highest dose required a course of pred-
nisolone to reduce rising transaminases associated with the highest dose (but
not observed at the lower doses of 2 x 1011 or 6 x 1011 vg/kg). Data from a nat-
ural history study of patients with hemophilia by den Uijl et al. suggest that cir-
culating levels of ~12% are required to eliminate spontaneous joint bleeds
(Haemophilia 2011). 
Aims: We sought to develop a high specific activity vector that would drive
therapeutic levels of FIX activity at doses low enough to avoid the need for
immunomodulation with steroids.
Methods: We developed a vector containing: 1) a novel bioengineered AAV
capsid with tropism for liver; and 2) a Factor IX expression cassette that carries
a strong liver-specific promoter driving the expression of FIX Padua (R338L).
The Padua variant shows an ~8-fold increase in specific activity compared to
wild-type FIX (Simioni et al., NEJM 2009). Based on studies in non-human pri-
mates, we predicted that therapeutic FIX activity levels, >10%, would be
attained at doses as low as 5 x 1011 vg/kg. We further predicted that the ability
to observe therapeutic levels of FIX activity at lower doses of vector would limit
potential need for a course of immunomodulation with steroids. 
Results: Here we report data on the first three subjects with severe hemophilia
B infused with this novel vector. The first two subjects, ages 23 and 18 respec-
tively, had no prior history of liver disease, while the third, age 47, had a history
of HCV infection but had cleared spontaneously. These subjects had been
screened for neutralizing antibodies to the novel AAV capsid and found to be
negative. Subjects were infused intravenously with SPK-FIX at a dose of 5 x
1011 vg/kg over a period of ~1 hour. FIX activity levels (shown in Figure 1) in
the first two subjects have plateaued at 28% and 30% respectively at 18 and 7
weeks post infusion, while subject #3 is currently at 16% 3 weeks after infusion.
Subject #3 treated himself with an extended half-life product for a suspected
ankle bleed 2 days after vector infusion; other than this there have been no
other factor infusions and no bleeds in the 28 cumulative weeks of observation.
There have been no transaminase elevations higher than 1.5 times upper limit
of normal, and steroids have not been administered to any subjects thus far.
ELISPOTs were used to monitor T cell responses to AAV and to FIX in all sub-
jects and have shown no or very low responses. Of note, the time course of
rise in Factor IX levels to a plateau level has been remarkably consistent among
the three subjects to date.
Figure 1.
Summary/Conclusions: Conclusion/Summary: We report the first clinical
results using a novel bioengineered AAV capsid expressing a high specific
activity FIX transgene. This has led to plateau FIX activity levels of 28% and
30% in the first two subjects infused, with no factor use since vector infusion.
The development of a vector that can direct high level clotting factor expression
at low doses, so that immunosuppression is not required, represents an impor-
tant goal for liver-directed gene therapy.
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RECOMBINANT THROMBOMODULIN AMELIORATES HEMATOLOGICAL
MALIGNANCY-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION
MORE PROMPTLY THAN CONVENTIONAL THERAPY WITHOUT CAUSING
SEVERE HEMORRHAGIC EVENTS
N Kurita,*, Y Yokoyama, H Muto, T Kato, M Sakata-Yanagimoto, N Obara,
Y Hasegawa, S Chiba
Department of Hematology, University of Tsukuba, Tsukuba, Japan
Background: Disseminated intravascular coagulation (DIC) is a lethal compli-
cation in patients with hematological malignancies. Although standard therapy
against DIC remains to be established, soluble recombinant thrombomodulin
(rTM), which serves as a receptor for thrombin, has been developed as a prom-
ising anti-DIC agent. However, the position of rTM needs to be determined in
the treatment of DIC associated with hematological malignancy.
Aims: We retrospectively compared outcome of hematological malignancy-
related DIC treated with rTM or other conventional anticoagulant therapies in
order to clarify the effectiveness of rTM.
Methods: Consecutive DIC episodes of 217 in 195 patients with hematological
malignancies (AML except for APL, 69; APL, 26; ALL, 27; NHL, 44; myeloma,
12; CML, 7; other; 10) hospitalized between January 2004 and Dec 2015 in
University of Tsukuba Hospital were analyzed using medical records. Diagnosis
of DIC was based on the DIC scoring system proposed in the Japanese Ministry
of Health and Labor Welfare criteria (Kobayashi et al., Bibl Haematol 1983).
DIC was induced by hematological malignancy itself (h-DIC) or severe infection
secondary to hematological malignancy (i-DIC) in 140 and 77 episodes, respec-
tively. In 125 episodes, 380 units/kg/day of rTM was administered intravenously
from the onset of DIC for median of 6 (range, 1-41) days. Other DIC episodes
were treated with conventional anticoagulant therapies (low molecular weight
heparin, 65; gabexate mesilate, 16; other anticoagulants, 11) for median of 11
(range, 1-30) days. Every anticoagulant therapy was accompanied by treatment
for DIC-causing disease. We compared recovery time from DIC (the day when
the DIC score was decreased to 5 or less), overall survival, and severe hem-
orrhagic events related to the treatment, between rTM- and conventional anti-
coagulant-treated groups.
Results: Bleeding tendency was documented in 63 DIC episodes at the onset.
In h-DIC, recovery from DIC was significantly more prompt in rTM-treated
group than conventional therapy group with the recovery rates of 55% (95%
CI: 43-65) and 32% (95% CI: 21-44), respectively at day 7 after the therapy
initiation (P=0.03, Figure 1). By contrast, recovery from i-DIC was significantly
worse than that from h-DIC, and was not influenced by anticoagulant thera-
pies; recovery rates from i-DIC at day 7 were 23% (95% CI: 13-36) in the
rTM-treated group and 33% (95% CI: 17-50) in the conventional therapy group
(P=0.6). Day 60 overall survival rates in h-DIC were 81% (95% CI: 69- 88)
and 79% (95% CI: 65 - 88) in the rTM-treated and conventional therapy
groups. In i-DIC, on the other hand, 35% (95% CI: 21-49) and 38% (95% CI:
32 - 55) survived with the rTM and conventional therapies, respectively. Severe
hemorrhagic events that led to discontinuation of anticoagulant therapy was
significantly less in the rTM-treated group (3%; 95% CI, 0-7) compared with
that in the conventional therapy group (15%; 95% CI: 5-23; P=0.02).
Figure 1. Recovery from h-DIC.
Summary/Conclusions: The recovery from h-DIC treated with rTM was more
prompt compared to that with conventional anticoagulant therapy, although
survival was not influenced by the therapy. We emphasize that rTM can be an
effective anti-DIC agent without causing adverse hemorrhagic events even in
DIC cases with preexisting bleeding tendency. However, the outcome was still
significantly worse in i-DIC secondary to hematological malignancies even after
introduction of rTM. Further development of anticoagulant therapy is required
particularly for the control of i-DIC.
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EXTRACELLULAR HISTONES ENHANCE FACTOR XA MEDIATED
PROTHROMBIN ACTIVATION WITHOUT PHOSPHOLIPID REQUIREMENT
Y Sahraoui1,*, S Abrams1, D Su1, Y Alhamdi1, J Foley2, G Wang1, CH Toh1,3
1Institute of Infection and Global Health, University of Liverpool, Liverpool,
2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hos-
pital, London, 3Roald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool
University Hospital, Liverpool, United Kingdom
Background: Thrombin generation in vivo is central to coagulation activation
and its dysregulation is pivotal to the development of disseminated intravascular
coagulation (DIC) and multiple organ failure (MOF). Typically, thrombin is gen-
erated when the prothrombinase complex, composed of activated factor X
(FXa), activated co-factor V (FVa) and phospholipids, cleaves prothrombin in
the presence of calcium. Whilst histones form the basis of chromatin within
cells, circulating histones released after extensive cellular injury are significantly
elevated in critically ill patients with associations to enhanced thrombin gener-
ation. However, the underlying pathophysiological mechanism remains to be
fully elucidated.
Aims: To characterise the mechanistic role of elevated extracellular histones
in enhancing thrombin generation in critical illness.
Methods: Histone-prothrombin interactions were determined by binding
assays. Thrombin generation was evaluated by in vitro prothrombin cleavage
and thrombin generation assays.
Results: Here, we demonstrate that extracellular histones promote thrombin
generation by acting as a co-factor to FXa. Unlike FVa which requires a phos-
pholipid surface to form functional prothrombinase complexes, histones can
substitute for FVa in the absence of phospholipids. The addition of histones to
FV-/- deficient plasma restored thrombin generation, suggesting that histones
can bypass FVa to induce thrombin generation. Mechanistically, histones direct-
ly bind to prothrombin (H3 [Kd=6.8x10-7 M] and H4 [Kd=7.0x10-7 M]), to facil-
itate FXa-induced prothrombin cleavage and thrombin generation (H4
[12.25±1.25 fold] and H3 [8.82±0.67 fold]). FXa levels are the limiting factor of
histone-enhanced thrombin generation since this process was inhibited in FX-
/- plasma unless exogenous FXa was added. Specifically, using either heparin
or specific anti-histone antibodies to block histones, histone-prothrombin inter-
actions, prothrombin cleavage and subsequent thrombin generation were sig-
nificantly reduced. 
Summary/Conclusions: This novel role for extracellular histones in increasing
thrombin generation, independent of FVa, may offer insight into the underlying
pathological mechanism for systemic dissemination of thrombin generation in
critical illness. Importantly, it identifies circulating histones as a potential target
for therapeutic intervention in reducing the development of DIC and subsequent
MOF in critical illness.
P773
PHORBOL 12-MYRISTATE-13-ACETATE INDUCES VON WILLEBRAND
FACTOR PROPEPTIDE RELEASE FROM ENDOTHELIAL CELLS FROM 2
DISTINCT COMPARTMENTS
R Bierings1,2,*, L Knipe1, N Hellen1,3, I Conte1,4, T Carter1,4
1The Francis Crick Institute, London, United Kingdom, 2Plasma Proteins, San-
quin Research, Amsterdam, Netherlands, 3National Heart and Lung Institute,
Imperial College, 4Cardiovascular and Cell Science Research Institute, St.
George’s University, London, United Kingdom
Background: Von Willebrand factor (VWF) and its propeptide (VWFpp) are
stored for secretion within specialized endothelial secretory organelles called
Weibel-Palade bodies (WPBs). Release of their content into the vascular lumen
through a process called exocytosis enables the endothelium to actively par-
ticipate in the arrest of bleeding and to slow down and direct leukocytes to
areas of inflammation. WPBs undergo exocytosis upon stimulation with ago-
nists that elevate intracellular free Ca2+ ([Ca2+]i) or cAMP concentrations. 
Aims: Phorbol 12-myristate-13-acetate (PMA) is also a potent VWF secreta-
gogue, and it is generally assumed that PMA-evoked VWF secretion arises solely
from WPB exocytosis (the VWF storage compartment). Here we present evidence
that PMA activated VWF release comprises an early (0-15 minutes) and a late
(>15 minutes) component that originate from distinct intracellular compartments. 
Methods: Using live cell imaging of WPB exocytosis in endothelial cells
expressing fluorescently tagged WPB probes we have characterized PMA-
evoked VWF secretion. 
Results: A significant fraction of the early phase of PMA-evoked VWF secretion
from human endothelial cells arises from a cycloheximide (CHX)-sensitive (i.e.,
nascent or non-storage) compartment: stimulation for 15 minutes with either
PMA (100 ng/ml) or histamine (100 μM) caused similar amounts of VWF secre-
tion. However, prior inhibition of protein synthesis (10 μM CHX for 24 hours)
reduced PMA-evoked secretion by ~70% while histamine-evoked secretion was
unaffected. Optical analysis of live cells expressing VWFpp-EGFP targeted to
WPBs showed that the first 15 minutes of histamine stimulation was associated
with exocytosis of 41.4±4.0% (mean±sem, n=12) of fluorescent WPBs, com-
pared to 8.4±2.1% (n=11) for PMA. The latter was independent of WPB matu-
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ration state and for both stimuli, the percentage of fluorescent WPB exocytotic
events was unaffected by CHX treatment. This suggests that the early phase of
PMA-evoked VWF release originates from a compartment other than WPBs.
Since VWFpp is proteolytically cleaved from proVWF in the trans-Golgi network
(TGN), we focused on this compartment as the potential source of early PMA-
evoked secretion. Phospholipase D (PLD) is a key enzyme regulating trafficking
from the TGN. Inhibition of PLD with the pan-PLD inhibitor FIPI resulted in a
reduction in the early phase of PMA-evoked VWFpp secretion, similar to that
seen with CHX, although at later times VWFpp secretion was unaffected. Pre-
incubation (10 minutes) with PMA (100 ng/ml) produced a profound shift in the
Ca2+-sensitivity of VWF secretion, to close to resting levels. 
Summary/Conclusions: Together the data suggest that at early times PMA
causes VWF release predominantly from a non-WPB compartment, most likely
the TGN, while at later times WPB exocytosis accounts for the majority of
secreted VWF. The slow onset in PMA-evoked WPB exocytosis could reflect a
time-dependent shift in the Ca2+-sensitivity of exocytosis. Our data help clarify
the mechanisms by which PMA induces VWF secretion in endothelial cells,
and highlight the need for care when interpreting PMA-evoked secretion data
in terms of the underlying mechanisms regulating WPB exocytosis. 
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NEWLY DIAGNOSED PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH
ENHANCED TF PATHWAY ACTIVATION, THROMBIN GENERATION AND
INCREASED CONCENTRATION OF PROCOAGULANT MICROPARTICLES
D Fotiou1, F Zagouri1, TN Sergentanis1, K Stametelopoulos1, T Psaltopoulou1,
E Kastritis1, E Terpos1, I Efmorfiadis2,3, A Rousseau3, P Van Dreden4,
I Elalamy2,3, AK Larsen3, MA Dimopoulos1,5, G Gerotziafas2,3,*
1Department of Clinical Therapeutics, National and Kapodistrian University of
Athens, School of Medicine, Athens, Greece, Athens, Greece, 2Service d’Hé-
matologie Biologique, Hôpital Tenon, Hôpitaux Universitaires de l’Est Parisien,
Assistance Publique Hôpitaux de Paris, 3Cancer Biology and Therapeutics,
INSERM U938, Institut Universitaire de Cancérologie (IUC), Université Pierre
et Marie Curie (UPMC), Sorbonne Universities, Paris, France. Faculté de
Médecine Pierre et Marie Curie, Paris, 4Clinical Research Department, Diag-
nostica Stago, Gennevilliers, France, 5School of Medicine, Kapodistrian Uni-
versity of Athens, Athens, Greece
Background: Multiple myeloma (MM) and other plasma cell dyscrasias (PCD)
as well as the associated immunomodulatory treatments are linked to increased
risk of venous thromboembolism (VTE). The identification of patients at VTE risk
and the optimization of VTE prevention is an unmet medical need. Elaboration of
a risk assessment model (RAM) specific for patients with PCD, which includes
biomarkers of hypercoagulability, could improve the management of VTE risk.
Aims: We conducted a longitudinal observational study, to explore the rela-
tionship of MM with cellular and plasma hypercoagulability aiming to identify
the most relevant biomarkers for use in a RAM for VTE in combination with
clinical risk factors. 
Methods: Newly diagnosed patients with PCD (n=186) were recruited from
July 2014 to Dec 2015; including 27 with monoclonal gammopathy of undeter-
mined significance (MGUS), 40 with asymptomatic multiple myeloma (AMM),
79 with multiple myeloma (MM), 30 with AL-amyloidosis, 8 with Waldenstrom’s
Macroglobulinemia (WM) and 2 with solitary plasmacytoma. They were com-
pared against 30 healthy age and sex-matched individuals (CG). A systematic
compression ultrasound was performed at baseline and at 6-12 months. Blood
samples were obtained at diagnosis and at 6-12 months (n=89). Samples of
platelet-poor plasma were assessed for thrombin generation (TG) with PPP-
Reagent® (TF 5pM and 4 μM phospholipids), P-selectin, D-dimers (D-Di), acti-
vated FVII (FVIIa), Tissue Factor (TFa), fibrin monomers (FM), and procoagu-
lant phospholipid-dependent clotting time (Procag-PPL). The upper and lower
normal limits (UNL and LNL) were calculated by the mean±2SD.
Results: Median age was 67 years (37-89) and 49% of the population was
male. Median time to follow up was 7 months (1-12 months). Among MM cases
(n=79) symptomatic VTE rate was 10% (n=8) and mortality rate 7.5%. The
events included 2 central venous catheter thromboses, 1 Pulmonary
Embolism, 2 Deep vein thromboses, 2 superficial vein thromboses and 1
mesenteric vein thrombosis. Cases had significantly shorter PPL-ct, higher
FTa and DDi, TG (increased Peak), heparanase and P-selectin compared to
controls (p<0.001). Along the MGUS- AMM- MM continuum, D-Di concentration
(p<0.0001), FM concentration (p<0.05), lag time (p<0.027) and MRI were high-
est in MM patients. Sixty percent of MM patients had Procoag-PPL: below the
LNL, in 63% TFa levels were above the UNL, and 31% had MRI lower than
LNL. After 6 months of treatment, FTa, DDi, MRI, peak thrombin and P-selectin
levels decreased (p<0.05) and TM and ATIII levels increased (p<0.05). 
Summary/Conclusions: In patients with PCD, increased procoagulant
microparticles of cellular origin is a generalized phenomenon. In addition,
patients with MM, are at high risk of VTE and present with significant TF path-
way activation and increased TG. A significant fraction, but not all, of the patients
present strong signs of plasma hypercoagulability. The finding of high inter-
individual variability of TG underlines the heterogeneity of blood coagulation
alterations in PCD patients. The data of the prospective part of this study will
allow validation of the clinical significance of this finding.
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ROLE OF ROTATIONAL THROMBELASTOMETRY (ROTEM®) IN RAPID
ESTIMATION OF RIVAROXABAN DRUG LEVEL
H Chuah1,2,*, D Pepperell2, M Leahy1, T Dixon3, A Mukhtar4,5, M Kesavan2,6,
J Ling7, D Sankhesara7, P Brownell7, S P’ng2
1Haematology Department, Royal Perth Hospital, Perth, 2Haemophilia and
Haemostasis Centre, Fiona Stanley Hospital, 3PathWest Laboratory Medicine,
Fiona Stanley Hospital Network, Murdoch, 4Centre for Population Health
Research, Curtin University, Bentley, 5Western Australia Country Health Serv-
ice, Department of Health, Perth, 6University of Western Australia, Crawley,
7Fiona Stanley Hospital, Murdoch, Australia
Background: Rivaroxaban, a direct factor Xa inhibitor, allows the use of fixed
dosing schemes and eliminates the need for routine coagulation monitoring.
However, rapid assessment of the degree of rivaroxaban anticoagulation is
required in certain scenarios, e.g. major haemorrhage, before thrombolysis or
urgent surgery. Clinically significant Rivaroxaban drug levels have been pro-
posed between 30-50ng/mL using a calibrated anti-Xa assay, but the turnaround
time for the test is slow. Therefore, rapidly available results using a point-of-
care haemostasis test like ROTEM® might be beneficial in these scenarios. 
Aims: The aim of this study was to evaluate the role of conventional rotational
thrombelastometry (ROTEM®) and modified low tissue factor activated ROTEM®
(LowTF-ROTEM®) in estimating rivaroxaban drug level in in-vivo setting.
Methods: In this multicenter study, we analysed 77 patients receiving Rivarox-
aban for therapeutic indications including treatment of venous thromboem-
bolism, long-term prevention of recurrent venous thromboembolism and stroke
prevention in non-valvular atrial fibrillation. Patients’ citrated whole blood sam-
ples were tested on the ROTEM® delta analyser using commercially prepared
EXTEM reagent according to manufacturer’s instructions. Modified low tissue
factor ROTEM® test was also performed, using a recombinant tissue factor
reagent (Siemen’s INNOVIN), used at a dilution of 1:1000 of the normal working
concentration used for INR testing. Patients’ Rivaroxaban levels (ng/mL) were
determined in citrated platelet poor plasma by analysis on the Stago STA-R
Evolution analyser, using a chromogenic anti-Xa method (Diagnostica Stago
Liquid anti-Xa), paired with specific Rivaroxaban calibrators and controls (Diag-
nostica Stago).
Results: The relationship between ROTEM® clotting time (CT) and Rivaroxaban
level is of moderate strength (R2=0.461). Based on this relationship, we are 95%
confident that for ROTEM® CT of 61 seconds or less, Rivaroxaban level will be
less than 50 ng/ml. For prediction of clinically significant Rivaroxaban levels of
>50ng/mL, ROTEM® CT has a positive predictive value of 81% and negative
predictive value of 100%. The relationship between LowTF -ROTEM® clotting
time (CT) and Rivaroxaban level is of a low strength (R2=0.142) (Figure 1). 
Figure 1.
Summary/Conclusions: ROTEM®, a point-of-care test, has utility in excluding
clinically significant Rivaroxaban level, which may be critical for patients requir-
ing urgent surgery or thrombolysis.
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PLATELET DERIVED MICROPARTICLES, AGGREGATES AND MARKERS
OF IMMUNE ACTIVATION AND DISEASE PROGRESSION IN HIV INFECTED
TREATMENT NAIVE ASYMPTOMATIC INDIVIDUALS
B Nkambule1,*, G Davison2, H Ipp3
1Laboratory Medicine and Medical Science, University of Kwazulu-Natal, Dur-
ban, 2Biomedical Science, Cape Peninsula University of Technology, Bellville,
3Pathology, Stellenbosch University, Cape Town, South Africa
Background: Chronic immune activation in human immunodeficiency virus
(HIV) infection induces activation of leucocytes and platelets, resulting in the
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formation of microparticles (MPs). Platelet microparticles (PMPs) are prothrom-
botic and have been described in inflammatory disease. Increased levels of
platelet aggregation have been reported in HIV. PMP levels may be a more
sensitive marker of platelet activation, compared to surface CD62P expression
on activated platelets.
Aims: We aimed at measuring MPs, PMPs and platelet aggregates in HIV
infected individuals, using flow cytometry based whole blood assay. Optimised
to ensure artefactual platelet activation is kept minimal by omitting any cen-
trifugation and platelet isolation steps. Moreover, we aimed at evaluating asso-
ciations between MPs, PMPs, platelet aggregates and markers of immune acti-
vation and disease progression in asymptomatic treatment naïve HIV infected
individuals.
Methods: Forty-Eight (48) antiretroviral therapy (ART) naïve HIV infected and
40 uninfected individuals were recruited in a clinic in Cape Town. Microparticles
(MPs), Platelet microparticles (PMPs), platelet aggregates and platelet P-
selectin CD62P were measured using flow cytometry. These were then corre-
lated with CD4 count, viral load and %CD38 on CD4+ T cells.
Results: HIV infected individuals showed increased levels of median platelet
%CD62P 2.93[1.23-12.88] vs control 1.15[0.19-3.59]; circulating MPs HIV
group median 1.7[0.95-2.83] vs 1.12[0.63-1.57] Control group, p=0.0160; levels
PMPs median %PMPs 26.64[11.33-36.62] vs control 20.02[18.08-26.08],
p=0.0133. In the HIV group, levels of activated platelets correlated with; platelet
aggregates (r=0.5530, p=0.011); activated PMPs (r=0.594, p=0.007). Baseline
%platelet aggregates were similar between the groups. However the platelet
aggregates in the HIV group showed increased levels of activation, platelet
aggregates median %CD62P 14.10[5.49-39.94] vs 0.17[0-10.99] control group,
p=0.0097. The HIV group showed increased levels of immune activation, medi-
an %CD38 on CD8+ cells 24.03[15.76-43.92] vs control 9.23[6.8-12.96],
p<0.0001. In the HIV group levels of %CD38+ CD8+ T cells correlated with;
%PMPs (r=0.4730, p=0.0196), %MPs (r=0.4386, p=0.025) and %PLT aggre-
gates (r=0.321, p=0.135). In the HIV group %MP showed no correlation with;
CD4+T cell count (r=-0.026, p=0.894); Viral load (r=0.207, p=0.355). %PMPs
also showed no correlation with Viral load (r=0.152, p=0.511), CD4+ T cell
count (r=0.-0.361, p=0.07).
Summary/Conclusions: We describe an optimized whole blood flow cytom-
etry based assay for the evaluation of circulating MPs, PMPs and levels of
activated platelets and aggregates. That mimics the In vivo physiological envi-
ronment of MPs. Furthermore we report on increased levels of circulating MPs
and PMPs in HIV infected asymptomatic individuals. We also describe




INCIDENCE OF PERIPHERAL CIRCULATING CELLS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA PHENOTYPE A FIRST EPISODE OF
CEREBRAL SINUS VEIN THROMBOSIS: RESULTS FROM A PROSPECTIVE
MULTICENTER STUDY
M Napolitano1,*, RC Santoro2, G Sottilotta3, NL Parrinello4, G Rizzo4, A Triolo4,
R Lombardo4, E Di Francesco4, F Gagliano5, F Daniele6, S Raso1, G Tarantino1,
S siragusa1, F Di Raimondo7, G Giuffrida4
1Haemostasis and Thrombosis Center, Università di Palermo, Palermo, 2Centro
Emofilia Emostasi e Trombosi Dipartimento di Emato-Oncologia, General Hos-
pital “Pugliese Ciaccio”, Catanzaro, 3Haemostasi and Thrombosis Center,
Ospedale “Bianchi-Melacrino-Morelli, Cosenza, 4Haematology department,
Ospedale “Ferrarotto”, Catania, 5Haemostasis and Thrombosis Center, Ospdeale
“Di Cristina”, Palermo, 6Haemostasis and Thrombosis Center, General hospital,
Cosenza, 7Haematology Department, University of Catania, Palermo, Italy
Background: Paroxysmal nocturnal hemoglobinuria (PNH) clones have been
rarely observed in association with atypical site venous thrombosis, mainly of
the splanchnic veins, in absence of a known PNH diagnosis. 
Aims: Primary aim of the current study was to evaluate the incidence of PNH
clones in patients with a first episode of thrombosis localized at the cerebral
sinus veins (CVT). Patients without known PNH were tested for PNH clone by
high-sensitivity flow cytometric analysis on peripheral blood at CVT diagnosis. 
Methods: All the enrolled patients had an objectively confirmed first episode
of CVT. At enrollment, an accurate personal and familial clinical history was
taken and a complete determination of known inherited and acquired risk fac-
tors for venous thromboembolism was performed. At CVT diagnosis, patients
were assayed for PNH clone on peripheral blood at their enrolling institutions.
In case of a positive PNH clone determination, a second sample was centrally
assayed at the laboratory of the Study Coordinating Center at “ Ospedale Fer-
rarotto”, Catania. All PNH clone assays were performed using a high-sensitivity
multiparameter flow cytometric analysis able to identify an abnormal population
of >0.01% PNH cells. Enrolled patients underwent standard anticoagulant treat-
ment for CVT and a two years clinical follow-up after diagnosis. If any sign or
symptom of venous thrombosis recurrences occurred, a PNH clone was tested
again. Descriptive statistic was adopted for the purpose of this study. The study
was conducted in accordance with the Declaration of Helsinki and Ethics Com-
mittee approval was obtained at each enrolling center. Data were collected in
a dedicate database 
Results: Seventy seven subjects were enrolled (40 Females, 37 males; mean
age: 41 years, range 19-87). Anticoagulant treatment was administered for a
mean of six months (range:4-13 months); warfarin was administered in 64.9%
of patients, Low Molecular Weight Heparin in 35.2% of patients. Adverse events
related to anticoagulant therapy were not reported. CVT was associated with
factor V Leiden gene mutation at heterozygous state in 5 patients (6.5%), FII
(G20210A) gene mutation at heterozygous state in 6 patients (7.8%), JAK2
V6167F in 2 (2.5%) patients, Protein S deficiency in one case (1.2%), Lupus
Anticoagulant and anti-phospholipid antibodies in five cases (6.5%), combined
inherited and acquired risk factors in 3 cases (3.8%), recent surgery in 10.2%,
oral contraceptives in 6.4% and pregnancy in 3.8% cases. Among screened
patients, 38 (49.3%) did not have any of the known risk factor for venous throm-
boembolism. The incidence of PNH clones observed in our cohort was of 2.5%.
PNH clones were detected in 2 cases: in one patient a small one (size 0.08%)
was not further confirmed at the centralized determination, while in another
case a clear demonstrable clone (size 1.5%) was confirmed on two consecutive
independent determinations. The patient (a 27 years old Caucasian female)
had a positive familial history of venous thromboembolism and an otherwise
unremarkable personal thrombophilia screening, in absence of any symptom
or other laboratory sign of PNH. Two venous thrombosis recurrences occurred
at two years follow-up, both cases without any evidence of PNH clones. 
Summary/Conclusions: Testing for PNH can be taken into account as part of
the standard etiology-screening in atypical site venous thrombosis.However,
at the present it is not clear whether detection of relatively small PNH clone, in
absence of other signs and symptoms suggestive for PNH, may suggest spe-
cific therapy beyond anticoagulation.
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REGULATION OF WEIBEL-PALADE BODY EXOCYTOSIS FROM
ENDOTHELIAL CELLS BY SYNTAXIN-3 AND STXBP5 CONTAINING
SNARE COMPLEXES
M Schillemans1, D van Breevoort1, M Hofman1, M Wahedi1, A Gangaev1,
H Meems1, M van den Biggelaar1, R Adam2, H Janssen3, S Meijer1, J Voorberg1,
R Bierings1,*
1Plasma Proteins, Sanquin Research, Amsterdam, Netherlands, 2Pediatric
Gastroenterology, University Medical Centre, Mannheim, Germany, 3Cell Biol-
ogy, Netherlands Cancer Institute, Amsterdam, Netherlands
Background: Immediate release of a pre-stored cocktail of hemostatic, inflam-
matory and angiogenic mediators from endothelial secretory organelles,
Weibel-Palade bodies (WPBs), forms the first line of defense of the vessel wall
in response to vascular trauma. By releasing Von Willebrand factor (VWF), the
main component of WPBs, the endothelium actively participates in the arrest
of bleeding. This process also directs leukocytes to sites of inflammation. Dys-
regulation of VWF levels is associated with cardiovascular disease or can result
in a bleeding tendency, such as Von Willebrand disease. Several components
that are critical for regulated WPB exocytosis have been identified, including
the small GTPase Rab27A and its effector Slp4-a, but the mechanism remains
unclear. We have previously identified syntaxin binding protein 1 (STXBP1) as
an endogenous Slp4-a binding partner involved in WPB release, along with
the SNARE protein syntaxin-3.
Aims: In this study we investigated the possible role of syntaxin-3 in WPB traf-
ficking and exocytosis. 
Methods: The subcellular location of syntaxin-3 in endothelial cells was char-
acterized using immunocytochemistry and density gradient ultracentrifugation.
Iterative interactomics was performed to map the interacting proteome of syn-
taxin-3 and STXBP5.
Results: Interestingly, we found that the t-SNARE syntaxin-3 was primarily
associated with WPBs. To further explore its role in WPB biology we mapped
the endothelial interactome of syntaxin-3 through an unbiased label-free mass
spectrometry approach. Among its interaction partners are various SNAREs
and associated proteins such as syntaxin binding proteins 2 and 5 (STXBP2/5),
N-ethylmaleimide-sensitive factor (NSF), SNAP23 and α-SNAP, suggesting
we successfully pulled down a SNARE complex and its regulatory machinery
that are involved in exocytosis. Taking forward one of the candidate, STXBP5,
we found that silencing of STXBP5 expression using siRNA potentiated ago-
nist-induced VWF release from endothelial cells, which suggests it acts as a
negative regulator of WPB exocytosis. We narrowed down the inhibitory role
of STXBP5 to the C-terminal Vamp-like domain (VLD), which interacts with
syntaxins and attenuates histamine-induced VWF secretion upon lentiviral
expression in endothelial cells. To further investigate the role of syntaxin-3 in
endothelial cells we isolated blood outgrowth endothelial cells (BOECs) of a
patient suffering from variant microvillous inclusion disease (MVID), a severe
gastrointestinal disorder, caused by a homozygous mutation in STX3 that leads
to complete syntaxin-3 deficiency. WPBs of MVID BOECs are entirely devoid
of syntaxin-3, display immature WPB morphology and have a reduced secre-
tory potential when challenged with histamine.
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Summary/Conclusions: Our data show that WPB exocytosis is regulated by
a complex interplay between the WPB-associated SNARE syntaxin-3 and
STXBP5.
Quality of life, palliative care, ethics
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COMPARISON OF QUALITY OF LIFE BETWEEN LONG-TERM SURVIVORS
OF INDOLENT AND AGGRESSIVE LYMPHOMA: RESULTS OF A SINGLE
CENTER PROSPECTIVE COHORT STUDY
SJ Kim1,*, WS Kim1, J Cho2, D Kang2
1Medicine, 2Health Sciences and Technology, Samsung Medical Center, Seoul,
Korea, Republic Of
Background: Lymphoma is a basically curable disorder by chemotherapy and
or radiotherapy. As clinical features and treatment outcomes are different
according to subtypes of lymphoma, the various treatment strategies have been
applied from intensified treatment such as high-dose chemotherapy followed
by autologous stem cell transplantation to observation without any treatment.
Thus, patients experience different treatments based on the nature of their dis-
eases so-called indolent and aggressive lymphomas. However, there is limited
ata about the health-related quality of life of long-term survivors of indolent and
aggressive lymphoma. 
Aims: The primary objective is to evaluate the health-related quality of life at
diagnosis and after treatment in long-term survivors of indolent and aggressive
lymphomas. The secondary objective is to evaluate psychosocial wellbeing in
long-term survivors such as fear of recurrence, social support and spiritual well-
being.
Methods: Patients were diagnosed with Hodgkin and non-Hodgkin lymphoma
according to the diagnostic criteria of the World Health Organization between
2008 and 2011. Patients were enrolled into the Samsung Medical Center
Prospective Cohort Study (NCT#01877109) and their health-related quality of
life was assessed by the EORTC QLQ-C30. The follow-up evaluation of the
health-related quality of life was done with long-term survivors in 2014. The
quality of life at the time of diagnosis was compared with that of patients at the
time of long-term follow-up, and they were compared according to indolent and
aggressive lymphomas. 
Results: Among 953 patients registered in the cohort study, 642 alive patients
were requested to conduct the follow-up survey about their health-related
quality of life. As we failed to get response from 242 patients due to refusal
to respond, follow-up loss, and incomplete survey, we analyzed 400 patients’
health-related quality of life and psychosocial wellbeing. 305 patients were
diagnosed with aggressive lymphoma such as diffuse large B-cell and periph-
eral T-cell lymphoma whereas 95 patients were diagnosed with indolent lym-
phoma such as follicular and marginal zone lymphoma. The socioeconomic
characteristics such as age, marital status, monthly family income, education
and working status were not significantly different between indolent and
aggressive lymphomas. Although the baseline health-related quality of life
was significantly better in patients with indolent lymphoma that aggressive
lymphoma, the follow-up survey showed the improvement of quality of life in
patients with aggressive lymphoma. However, several aspects of psychoso-
cial wellbeing such as fear of recurrence, social support, happiness, satis-
faction and life purpose were impaired in patients with indolent and aggressive
lymphoma (Figure 1).
Figure 1.
Summary/Conclusions: The health-related quality of life could be recovered
in long-term survivors with indolent and aggressive lymphoma after treatment.
However, a majority of long-term survivors still suffer from impaired psychosocial
wellbeing, especially fear of recurrence. Thus, more education about disease
course and support for psychosocial wellbeing could be helpful for long-term
survivors with lymphoma.
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IMPACT OF IRON DEFICIENCY ON QUALITY OF LIFE AND WORK
CAPACITY OF WOMEN 
L Caramelo1,*, A Mezzacasa2, D Mansour3
1Global Communications and Public Affairs, 2Global Medical Affairs, Vifor Phar-
ma, Glattbrugg, Switzerland, 3 Sexual Health, Newcastle upon Tyne Hospitals
NHS Foundation Trust, New Croft Centre, Newcastle upon Tyne, United King-
dom
Background: The most severe stage of iron deficiency (ID), iron deficiency
anemia (IDA)is a global problem, with the greatest prevalence among women
and children.1 IDA has been shown to negatively impact on cognitive perform-
ance and ability to concentrate and can result in fatigue.1
Aims: This survey aimed to gain an understanding of the awareness, preva-
lence and perceptions of ID/IDA within a European population.
Methods: An online, quantitative survey was carried out across Europe
between in July and August 2015. The survey included respondents from the
UK, France, Germany, Spain, Italy, Portugal and Sweden. In general the ques-
tionnaire was designed to take only 5 minutes. Respondents who reported a
confirmed diagnosis of ID/IDA at some point in their lives completed a more in-
depth questionnaire taking approximately 20 minutes. 
Results: A total of 10,272 people completed the survey, with 7,025 aware of
ID or IDA, and 934 of those having had a confirmed diagnosis of ID or IDA at
some point in their lives.The awareness and prevalence of iron deficiency are
higher amongst women than men (14% women vs 4% men). In general prac-
tice, heavy menstrual bleeding (HMB) is recognized as the primary cause of
ID/IDA in women.2 This was reflected in public perception, with 59% associating
heavy periods or menstruation as the main cause of ID/IDA in women, and
50% of women ranking it among the top 5 causes. Results from the survey
show that 28% of patients suffer from HMB in addition to their ID/IDA. The first
symptom experienced most frequently was tiredness/fatigue, which was also
the main driver for patients to seek medical help (54% reported it as their
reason for visiting an HCP). On average, people experienced symptoms for
2.5 years before visiting a doctor. 63% of all patients felt that their ID/IDA had
a negative impact on their ability to concentrate, affecting a greater proportion
of women than men (64% of female vs 55% of male patients). Concern over
skin pallor was also greater for women (49% of female patients vs 36% of male
felt their ID/IDA made them look ill). Patients reported that their ID/IDA had the
greatest impact on their personal well-being (79% citing a slight or severe neg-
ative impact). The second most significant impact was on working life, affecting
49% of patients. 
Summary/Conclusions: This survey highlights the greater impact of ID/IDA
among women than men, reflected in awareness, prevalence and effect on
concentration and working life. Recent epidemiological studies suggest that
the gender gap for anemia (primarily caused by ID) is widening further.1
References
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IRON DEFICIENCY: UNDERSTANDING PERCEPTIONS OF SUFFERERS
AND THE GENERAL PUBLIC
L Caramelo1,*, A Mezzacasa2, NJ Kassebaum3
1Global Communications and Public Affairs, 2Global Medical Affairs, Vifor Phar-
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Background: Iron deficiency anaemia (IDA) is the third-leading specific cause
of global years lived with disability, impacting large portions of the global and
European populations,1 despite the availability of simple, effective treatment.
Aims: This survey aimed to gain an understanding of the level of awareness
of iron deficiency (ID) and/or IDA amongst the general population, as well as
perceptions of the disease and its symptoms. 
Methods: A quantitative, online survey across Europe, UK, France, Germany,
Spain, Italy, Portugal and Sweden was conducted in the period July 21st- August
21st, 2015. Approximately 1,000 participants from each nation, and represen-
tative of the population aged 18 years or over, were surveyed.
Results: A total of 10,272 people completed the survey, with 7,025 aware of
ID or IDA and 934 of those reported having had a confirmed diagnosis of ID or
IDA at some point in their lives. Tiredness/fatigue was the symptom most
strongly associated with iron deficiency and IDA, followed by paleness. How-
ever, 36% of respondents who were aware of ID/IDA only knew the name and
could not identify causes or symptoms. The main symptom leading patients to
present to their General Practitioner (GP) was fatigue/tiredness (54%). 21% of
patients did not experience symptoms before their diagnosis. In patients who
experienced symptoms, these appeared an average of 9 months before they
visited their GP, with a further 6 months required to receive a confirmed diag-
nosis. Despite having been diagnosed with ID/IDA, 11% of patients have never
received a prescription for their ID/IDA. Patients felt that the most significant
impact of their ID/IDA was on their personal well-being (79%), with 49% report-
ing a negative impact on their working life. 
Summary/Conclusions: This survey revealed only low-level awareness of
ID/IDA within the general European population. There is also a long delay
between the appearance of symptoms and an appropriate diagnosis, despite
the significant impact ID/IDA has on a patient’s work and quality of life.
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CIRS COMORBIDITY SCORE IS USEFUL FOR TREATMENT CHOICE AND
PREDICT TREATMENT OUTCOME IN ELDERLY PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES
J Poisson1, N Carnel1, T Guerekobaya1, F Plassart2, B Poujol3, P Genet1,
A Andreoli1, A Al Jijakli1, Ta Botin Lopez1, L Mesbah1, L Sutton1, D Chaoui1,*
1Hematology, 2Pharmacy, 3Geriatric, Centre Hospitalier Victor Dupouy, Argen-
teuil, France
Background: The Cumulative Illness Rating Scale (CIRS) seems to be a reli-
able tool for the evaluation of the burden of comorbidity in elderly cancer
patients (Extermann M, J Clin Oncol 1998). CIRS score is widely used in chron-
ic lymphocytic leukemia clinical trials to identify fit and unfit patients and influ-
ence therapeutic decision-making. 
Aims: The aim of our study was to evaluate CIRS impact in elderly patients
with other hematological diseases treated in real life.
Methods: This was a longitudinal, prospective, monocentric study. We focused
on patients aged 70 or older who received their first cycle of chemotherapy
between September 1st 2014 and August 31th 2015. We recorded the multidis-
ciplinary treatment decision taken: curative, symptomatic and palliative treat-
ment. Geriatric tools recorded (G8 score, CIRS score, sheet A SEGA (Short
Emergency Geriatric Assessment) frailty score, ADL, IADL) were not used dur-
ing treatment decision. The first course of chemotherapy was considered as
the standard dose. We analyzed during the following chemotherapy courses:
dose reduction, chemotherapy delaying, early discontinuation. Impact of geri-
atric tools especially CIRS comorbidity score, SEGA frailty score on treatment
choice (palliative versus curative treatment) was performed in all patients
included in our study (n=141). Analysis of CIRS and other geriatric tools impact
on treatment chemotherapy adaptation was performed in 118 patients (exclu-
sion of palliative and symptomatic treatments). 
Results: during the one year period analysis, 141 patients >70 years old (70-
95) were discussed during our weekly multidisciplinary meeting. Average age
was 80. The most frequent hematological diseases were distributed as follow:
NHL (32%), multiple myeloma (29%), CLL (13%) and MDS (8%). Twenty one
percent of patients and 18% were assigned to Bendamustine and Bortezomib
based chemotherapy. Other chemotherapy regimens included (CHOP and
CHOP like treatment +/- rituximab (10%), 5-azacytidine (8%), IMID (8%). Pal-
liative and symptomatic treatments decisions were taken in 11 and 12 patients
respectively. At diagnosis, the median scheet A SEGA score was 6 (0-18) indi-
cating that the subjects included were mostly not frail. Median CIRS total rate
excluding hematological malignancy was 6 (0-18). High CIRS score (median
10) and SEGA score (median 12) were significantly associated with palliative
treatment, p=0,001 and p=0,01 respectively. Regarding patients assigned to
curative approach, treatment was prematurely stopped in 32% of patients,
dose reduction in 30% and chemotherapy was delayed in 18%. Only 33% did
not experienced one of these events. CIRS grade 3 or 4 and CIRS score >6
were strongly associated with early chemotherapy discontinuation (p=0,0014
and 0,0008), respectively. In contrast no impact was observed regarding
chemotherapy delaying or dose reduction. SEGA score was not associated
with early discontinuation, nor dose reduction and chemotherapy delaying.
Summary/Conclusions: CIRS score and SEGA score could be helpful in treat-
ment choice. Palliative treatment could be the best approach in patients with
CIRS score >10 and or SEGA score >12. Patients CIRS score more than 6 are
at higher risk of early chemotherapy discontinuation. A special attention is
required for these patients to avoid such events. Reason of early discontinua-
tion and impact on response will be presented at the EHA meeting.
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THE RELATIVE BURDEN OF AL AMYLOIDOSIS ON HEALTH-RELATED
QUALITY OF LIFE
M Bayliss1, MK White1, KL McCausland1, S Guthrie2,*
1Optum, Lincoln, RI, 2Prothena Biosciences Inc, South San Francisco, CA,
United States
Background: The SF-36v2® Health Survey (SF-36v2) is a widely used general
patient-reported outcome survey that can describe and quantify the impact of
disease and its treatment on health-related quality of life (HRQoL). Light chain
(AL) amyloidosis is a rare disease characterized by misfolded amyloid protein
deposits in tissues and vital organs, and little is known about the burden of AL
amyloidosis on HRQoL.
Aims: To compare the HRQoL profile of patients with AL amyloidosis and key
patient subgroups to a general US population (USP) sample. 
Methods: The SF-36v2 was administered in an online, cross-sectional study
of adults (≥18 years of age) with self-reported AL amyloidosis (n=341). The
SF-36v2 measures eight domain scales (physical functioning (PF), role limita-
tions due to physical health problems (RP), bodily pain (BP), general health
(GH), vitality (VT), social functioning (SF), role limitations due to emotional
health problems (RE), and mental health (MH)) and two component summary
measures: physical (PCS) and mental (MCS). Analysis of variance was used
to compare the norm-based SF-36v2 scores from patients with AL amyloidosis
to samples representing the USP. The USP sample size ranged from 4,024 –
4,036 for specific SF-36v2 scores. The USP data were adjusted to the age and
gender distribution of the patient sample using separate ordinary least-squares
regression models, with each SF-36v2 scale or summary score as a dependent
variable. Using the same method, we evaluated the burden of two key sub-
groups: 1) patients with recent diagnosis (within the past year) (n=52); and 2)
patients with cardiac involvement (n=178).
Results: Relative to USP norms, HRQoL of patients with AL amyloidosis is
significantly worse on scores from all eight SF-36v2 domain scales and both
summary measures (p <0.05 for all). The largest decrement was in GH, where
the AL amyloidosis patient mean was a full standard deviation worse than the
USP (39.3 vs 49.0, respectively, Cohen’s d -0.654; p <0.001). Large decrements
(more than a half standard deviation) also were seen in PF (24.5 vs 36.9), RP
(40.5 vs 47.6), VT (44.5 vs 50.2), SF (43.6 vs 49.6), and PCS (40.7 vs 46.7).
Subgroup analysis showed that, relative to the USP, patients (1) recently diag-
nosed with AL amyloidosis and (2) with cardiac involvement had large decre-
ments in each of the SF-36v2 domain scales and both summary measures (p
<0.05 for all). The largest decrements for each subgroup, relative to USP, were:
• Recently diagnosed: All scores except BP were at least a half standard devi-
ation lower than USP, with three domain scores at least one standard deviation
lower (RP, GH, SF).• Cardiac involvement: Four domain scores and one sum-
mary measure score were at least a half standard deviation lower than USP
(PF, RP, GH, VT, and PCS).
Summary/Conclusions: Results indicate that AL amyloidosis patients have
broad HRQoL deficits across all areas of physical and mental functioning com-
pared to the general USP, with greater impact evident among key AL amyloi-
dosis subgroups – in particular, patients diagnosed within the past 12 months.
Understanding the burden of AL amyloidosis can help physicians identify ancil-
lary treatments and services that may ease their burden and ultimately improve
patients’ HRQoL.
Study supported by: Prothena Biosciences Inc.
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OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA
IN A LARGE COHORT INSIDE A PHASE 1 CLINIC DEPARTMENT
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L Haddag-Miliani4, J Arfi-Rouche4, J Lazarovici3, D Ghez3, W Rahali3,
C Falet3, V Vergé5, C Bonnet1, F Bigot1, JC Soria1, V Clayette6, V Ribrag3, J
Bosq5
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biopathology departement, 6Research and Translationnal Laboratory, Gustave
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Background: Treating relapsed/refractory lymphoma remains a challenge.
While phase 1 trials classically aim to determine the recommended phase 2
dose (RP2D), the search of anti-tumor activity is increasingly evaluated.
Aims: We aimed to assess the tolerance and efficacy of phase 1 trial and to
determine a simple scoring system to identify patients who will prematurely
discontinue phase 1 studies (before six weeks), in a large cohort of patients
with relapsed/refractory (r/r) lymphoma.
Methods: Data from 137 consecutive patients with refractory/r lymphoma treat-
ed within a panel of 22 phase 1 trials were collected, between 2008 and 2016.
At inclusion, median age was 66 years [range: 23-86]. Lymphoma histological
patient’s types were: 79 (55%) aggressive non-Hodgkin lymphoma (59 diffuse
large B-cell lymphoma, 6 T-cell lymphoma and 14 Mantle cell lymphoma), 40
(29%) indolent non-Hodgkin lymphoma and 18 (13%) Hodgkin lymphoma. The
predefined Gustave Roussy (GR) score combined two simple variables, PS
and baseline serum albumin (+1 if PS=0, +1 if albumin≤35g/l).
Results: Grade 3 or 4 adverse events related to study drug were experienced
by 39/137 (28%) patients, in 27/39 (69%) during first cycle and in 12/39 (31%)
after first cycle. Dose-limiting toxicity was seen in 12/137 (9%) of patients. Any
toxic death was recorded. With a median follow-up of 13 [0.3-85] months, medi-
an OS and progression free survival (PFS) were respectively 22 (CI95%: 17-
38) and 4 (CI95%: 2-5) months. Best overall response rate Cheson 2007 analy-
sis shown overall response rate and disease control rate at 30% and 63%,
respectively. Median overall survival was better in responder (undefined) com-
pare to disease controllers (31 months) and non-responder patients (12 months)
(p=0.0003). At inclusion WHO performance status (PS) >0, baseline albumin
≤35 g/l and baseline LDH ≥250 UI/L were significantly associated with poorer
OS. Patients with a GR score=0 experienced significantly better OS compared
to patients with a score=1 and a score=2 (37 months vs 17 months vs 9 months;
p=0.007). A premature study discontinuation was recorded in 46/137 patients
(34%). The GR score distinguishes patients most likely to remain on study for
more than 6 weeks. A molecular portrait was performing in 40 patients to
improve the patient orientation in the trials.
Figure 1.
Summary/Conclusions: The three parameters WHO performance status (PS)
>0, baseline albumin ≤35 g/l and baseline LDH ≥250 UI/L are associated with
OS and premature withdrew of study and could serve as a basis to better select
patient in hematological phase 1 trials. Survival was dramatically better in
responder’s patients, pledging to accelerate the search for efficacy signals from
phase 1.
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QUALITY OF LIFE IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC
LEUKEMIA: CHILDREN’S AND PARENTS’ PERCEPTION
S Sarı1, D Kızmazoğlu1, M Evim Sezgin2, A Kantarcıoğlu2, Ö Tüfekçi1,
B Baytan2, S Yılmaz Bengoa1, A Meral Güneş2, H Oren1,*
1Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, Izmir, 2Pedi-
atric Hematology, Uludağ University Faculty of Medicine, Bursa, Turkey
Background: Improved outcome and predicted long survival for children with
acute lymphoblastic leukemia (ALL) make the early and efficient therapy, quality
of life, and psychosocial intervention more important. It is well known that quality
of life is negatively affected in ALL survivors who are cured.
Aims: The aim of this study is to investigate the social, physical, emotional,
family, and functional factors that may affect the quality of life in children with
ALL to find out how we can support their lives after treatment to provide better
quality of life in our country. 
Methods: The study population consisted of 46 children who were diagnosed
with ALL and had been treated at both centers with ALL-BFM 95 chemotherapy
protocol. We included children who had been completed therapy at least two
years ago and were 7-17 years-old. The control group consisted their siblings
at closest age and gender. The sociodemographic data of patients were record-
ed from hospital files. Patients and their siblings were evaluated with KINDL
questionnaire for measuring health-related quality of life in children and ado-
lescents. The perception of child about quality of life also evaluated by the
parents.
Results: No significant differences could be found among life quality scores
with respect to variables as gender, therapy type, risk group, time after the end
of therapy, income status, and having chronic illness. Mean quality of life scores
of patients were as follows: Physical well-being 75.27±19.9, emotional well-
being 76.77±16, social functioning 79.21±18, family 82.74±19.7, self-esteem
60.73±24.4, and school 63.99±19.3. Mean quality of life scores of siblings
(between 7-17 years) were as follows: Physical well-being 61.36±20.12, emo-
tional well-being 85.22±11.27, social functioning 86.36±15, family 79.54±27.96,
self-esteem 69.88±24.97, and school 64.20±14.54. Total mean quality of life
score of patients and siblings were 73.12±13.4 and 74.43±11.28, respectively.
Mean quality of life scores of parents questionnaires were as follows: Physical
well-being 78.06±20.80, emotional well-being 77.13±15.76, social functioning
81.38±14.64, family 82.74±15.74, self-esteem 71.28±19.44, and school
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63.70±14.60; total mean quality of life score was 75.51±11.60. When we inves-
tigated the questionnaires of patients and parents, we found that the self-
esteem scores of the patients were significantly lower than the parents evalu-
ation (p=0.037); we found no correlation in school subscales between patients’
and parents’ evaluation. There was good positive correlation between physical
well-being, emotional well-being, and social functioning. When the results of
patients and their siblings were compared, mean physical well-being scores of
siblings were lower than the patients (p=0.049). 
Summary/Conclusions: The quality of life scores of 7-17 years-old ALL sur-
vivors were not affected by gender, therapy type, risk group, time after the end
of therapy, income status, and having chronic illness. Physical well-being scores
were higher in patients than their siblings. Our findings demonstrated that the
parent evaluated self-esteem and school scores differed from their child; we
think that the parents should follow-up their children more closely for their self-
esteem development and school performances. 
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HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN LONGITUDINAL
STUDIES INCLUDING MULTIPLE MYELOMA PATIENTS: A CRITICAL
REVIEW OF INTERPRETING CHANGES OF SCORES OBTAINED BY
EORTC QLQ-C30
L Kongsgaard Nielsen1,*, M Jarden2, CL Andersen3, H Frederiksen4,
N Abildgaard1
1Odense University Hospital, Department of Haematology, HFE-X, Odense,
2University Hospitals Center for Health Research (UCSF) and Center for Inte-
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3Roskilde University Hospital, Department of Haematology, Roskilde, 4Odense
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Background: Multiple myeloma (MM) patients report more symptoms and
more severe symptoms than patients with other hematological malignancies,
resulting in reduced health-related quality of life (HRQoL). The goal of MM
treatment and care is to prolong progression free survival and overall survival,
and to reduce symptoms with least possible side effects to therapy. Because
survival is improving in MM patients there is increasing focus on HRQoL. 
Aims: The aim of the review is to evaluate longitudinal studies including MM
patients according to minimal important difference (MID) for physical function,
global QoL, fatigue and/or pain, according to the two available guidelines by
Cocks (Eur J Cancer 2012, 48:1713-21) and Kvam (Eur J Haematol 2010,
84:345-53).
Methods: A literature search was performed 14 December 2015 in PubMed
and Embase and 29 December 2015 in PsycINFO and CINAHL. Publications
with longitudinal follow-up using EORTC QLQ-C30 for HRQoL measurement of
physical function, global QoL, fatigue or pain were included, if the mean score
at baseline and minimum one follow-up time point were presented in the text, a
table or a figure, or the change in mean score from baseline over a given time
point was specified. Publications concerning patients with mixed hematological
diagnoses were excluded, if the results were not presented for MM patients
separately. Articles in other languages than English were excluded.
Results: A total of 25 publications were identified, which relates to 15 primary
and 5 relapse studies, one population-based and one mixed population study.
Evaluation of change in score concluded by guidelines of Cocks compared to
Kvam, showed diversity in the interpretation of changes of HRQoL scores over
time. Large improvement (only possible for pain) and medium improvement in
one or more of the evaluated HRQoL parameters were only achieved in studies
including newly diagnosed MM patients. During primary treatment with autol-
ogous hematopoietic stem cell transplantation (ASCT), temporary large dete-
riorations are seen, but three months after ASCT equalization occurs with even
large improvements in physical function, global QoL, fatigue and pain. In the
studies of MM patients undergoing relapsed treatment regimes, no MID or vari-
able degrees of deteriorations are generally documented. Only two relapse
studies documented improvement during relapse treatment, which both were
for pain, one with small and one with medium improvement. The population-
based study demonstrated deterioration in global QoL, fatigue and pain at one
year follow-up.
Summary/Conclusions: Several longitudinal studies of changes in HRQoL
scores during MM treatments have been published over the last two decades,
and guidelines for interpreting HRQoL changes with thresholds of MID have
been developed. In return, these methods are not definite, and further research
is required. It is still unresolved, which is the optimal duration between the two
measuring points for interpretation of MID and possible different thresholds for
MID in younger vs frail patients, and in newly vs relapsed MM patients, respec-
tively. Based on our review, it is clear that improvements in HRQoL are far
more likely during treatment of newly diagnosed patients compared to relapsed
patients. Whether this is due to the trajectory of the MM disease, differences
in the type and/or efficacy of anti-myeloma regimens used in the primary or
relapsed settings, or individual factors such as comorbidity or response shift/cal-
ibration, should be in focus in future studies.
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on novel agents
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CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF
IMMUNOCOMPROMISED AND NON IMMUNOCOMPROMISED
PLASMABLASTIC LYMPHOMA PATIENTS: ANALYSIS OF 135 PATIENTS
TREATED IN THE LYSA GROUP
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Lille, 11Department of biopathology, CHRU Toulouse, Toulouse, 12Department
of biopathology, Assistance Publique des Hopitaux de Paris, Saint Antoine hos-
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Background: Plasmablastic lymphoma (PBL), initially described in 1997 in the
oral cavity of HIV positive patients, is now recognized as a distinct aggressive
and rare entity of diffuse large B-cells lymphoma by the World Health Organization
classification. Others cases have been reported since the original description,
both in immunocompromised and immunocompetent patients. However, these
latter are largely derived from case reports or small series, and PBL remains a
diagnostic and therapeutic challenge with an aggressive clinical course.
Aims: The aim of this study was to specify the clinical, biological, pathological
features and outcome of patients with PBL.
Methods: The clinical, biological, pathological features and outcome of a cohort
including 135 patients with PBL diagnosed after 2000 in the LYSA centers were
reported and analyzed.
Results: The median age was 58 years, with a male predominance. The cohort
was divided into 56 HIV-positive patients, 17 post-transplant patients, and 62
non immunocompromised patients including 11 patients with local or systemic
inflammatory disease, 13 patients with history of cancer and 31 elderly patients.
Despite PBL in immunocompetent patients has already been described in the
literature, this study highlights that this subtype of patients finally presents some
degree of immunodepression, confirming a strong relationship between immun-
odeficiency and PBL. The most frequent primary involved site was the oral cav-
ity in 19% of cases. Immunophenotype showed CD138 positivity in 88% of cas-
es and CD20 negativity in 90% of cases. EBER expression was observed in
62% of cases. Chemotherapy was administered to 108 of 135 patients, with a
complete response rate of 55%. The use of rituximab, combined with
chemotherapy, seems to be interesting with a trend towards improved complete
response rate and event free survival. The median overall survival was 32
months. In the multivariate prognostic analysis, International Prognostic Index
score, chemotherapy and complete response rate were associated with survival
benefit. HIV positive status showed better overall survival when compared with
HIV negative status, but only in univariate analysis.
Summary/Conclusions: This cohort, the largest reported to date, lead to a
better understanding and increase the spectrum of knowledge on PBL. However
specific guidelines to clarify all the treatment options are lacking, and may
improve the poor prognosis of this rare disease.
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SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND
INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF
SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY
NON-HODGKIN’S LYMPHOMA
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Background: There is a high unmet medical need for new efficacious and tol-
erable regimens for patients with relapsed or refractory (R-R) non-Hodgkin’s
lymphoma (NHL). CD19 is expressed by most B-cell NHLs; in contrast to other
targets, CD19 expression is maintained at a stable level during the course of
the disease. MOR208, an Fc-engineered, humanized monoclonal CD19 anti-
body demonstrates activity in certain leukemia and lymphoma model systems
through enhanced antigen-dependent cell-mediated cytotoxicity and antigen-
dependent cell-mediated phagocytosis. A phase I study showed MOR208 to
be safe and well-tolerated with encouraging single-agent activity in patients
with chronic lymphocytic leukemia. Therefore MOR208 may have clinical use
as a new therapeutic agent in this setting.
Aims: This analysis focused on the preliminary efficacy and safety of MOR208
in diffuse large B-cell lymphoma (DLBCL) and indolent (i) NHL cohorts. The
primary endpoint was investigator assessed overall response rate (ORR).
Methods: This is an open-label, multicenter, phase IIa study of MOR208 in R-
R NHL patients progressing after at least one prior rituximab-containing therapy.
Patients were enrolled into 4 cohorts of aggressive (DLBCL and mantle cell lym-
phoma) and iNHLs (follicular lymphoma and other iNHLs). Patients received
single-agent MOR208, 12 mg/kg IV, weekly, for 8 weeks (2 cycles); treatment
could continue for 4 additional weeks in patients with at least stable disease
after 2 cycles. MOR208 maintenance could be given (every 2 or 4 weeks) until
progression in patients with complete (CR) or partial response (PR) at 12 weeks.
Results: In total, 92 patients were enrolled including 35 (38%) with DLBCL and
45 (49%) with iNHL. ORR was 26% in DLBCL (9/35 patients; 2 CRs and 7 PRs),
and 27% in iNHL (12/45 patients; 5 CRs and 7 PRs). In evaluable patients (those
who completed at least 2 cycles and had a response assessment) the ORR
was 36% in DLBCL (25 evaluable patients), and 30% in iNHL (40 evaluable
patients), respectively. Median duration of response was 13.7 months for DLBCL
patients (1.2-26, 3 ongoing and >20 months in remission) and 8.4 months for
iNHL patients (2.5-20.3, 6 ongoing, including 1 patient >20.3 months in remis-
sion). In DLBCL responders, 5/9 were rituximab-refractory (either no response
or response lasting<6 months to a previous rituximab-containing therapy), of
which 2 patients had a response duration of >19.8 months and 1 patient of >1
year under MOR208 treatment. The incidence of grade ≥3 hematologic treatment
emergent adverse events was low (DLBCL: 9/35, 26%; iNHL: 4/45, 9%), includ-
ing neutropenia, anemia and thrombocytopenia in 14%, 9% and 6% of DLBCL
patients and 4%, 0% and 0% of iNHL patients. Infusion-related reactions were
seen in 3/35 (9%) and 4/45 (9%) patients in the DLBCL and iNHL cohorts, all of
grade 1-2 except for one grade 4 dyspnea. There were no treatment-related
deaths and no trend towards late toxicity.
Summary/Conclusions: Single-agent MOR208 was associated with a prom-
ising ORR including CRs and long-lasting responses in both DLBCL and iNHL,
including in patients with rituximab-refractory disease. These efficacy data, and
the excellent safety and tolerability profile of MOR208 further justify the devel-
opment of MOR208 as part of a combination therapy in B-cell malignancies.
S790
HAPLOTRANSPLANTS VERSUS HLA-IDENTICAL DONOR (HID) FOR
ALLOGENEIC STEM-CELL TRANSPLANTATION (ALLOSCT) IN REFRACTORY
NON-HODGKIN LYMPHOMA (NHL)
H Huang*, D Wu
Soochow University, Suzhou, China
Background: AlloSCT is an effective therapeutic option for patients with refrac-
tory lymphoma. However, the donor source is the biggest problem for alloSCT.
The feasibility of haploSCT has dramatically expanded the donor pool, making
allogeneic transplantation available for the vast majority of patients, especially
for patients with rapidly progressing disease in whom unrelated donor search
cannot be awaited.
Aims: In this study, we aim to compare outcome of haplotransplants with con-
ventional related and matched unrelated donor transplants for refractory
relapsed or high risk NHL.
Methods: Seventy-eight patients who had undergone alloSCT between January
2006 and October 2015 in our center were analyzed retrospectively. The median
age was 30 years (range, 12 to 58 years). The histological subtypes included dif-
fuse large B cell lymphoma (13), mantle cell lymphoma (3), Burkett’s lymphoma
(1), B-cell lymphoblastic lymphoma (8), other type mature B cell lymphoma (10),
T-cell lymphoblastic lymphoma (18), peripheral T cell lymphoma (18) and NK/T
cell lymphoma (7). Bone marrow was involved in 65 patients, 9 patients had
experienced treatment failure with prior autologous SCT. All of the patients
received a myeloablative conditioning regimen which is TBI/Cy or Bu/Cy. 33
patients received Haplo Donors, 45 patients received HID, including sibling and
matched unrelated donors. Before alloSCT, 49 patients were in CR, 12 patients
were in PR, 18 patients were in NR. Primary refractory or progression was more
common in the HAPLO group (p=0.001), other variables were balanced.
Results: Seventy-eight patients were engrafted successfully and all patients
achieved full donor chimerism. There is no difference for hematopoietic recovery
between two groups. In HAPLO group, the median time of neutrophils and
platelets recovery were 12 days (range, 9d to 15d) and 17 days (range, 11d to
60d). In HID group, the median time of neutrophils and platelets recovery were
11 days (range, 9d to 16d) and 17days (range, 12d to 45d), respectively. After
transplantation, 75 patients acquired complete response, another 3 patients
acquired partial response. In HAPLO group, 6 patients had recurrent disease,
and 5 patients died from transplantation-related (TRM) including infection and
other organ failure at 1-year. In HID group, 6 patients had recurrent disease
and 8 patients died of TRM. The median follow-up duration was 23 months
(range, 2-139) in HAPLO group, 29 months (range, 2-139) in HID group. Among
HAPLO and HID recipients, the 3-year progress free survival rate was 56.8%
and 60.0% (P =0.45), respectively; overall survival rate was 58.9% and 62.1%
(P=0.48), respectively; the 3-year cumulative incidences of relapse were 48.4%
and 47.7% (P =0.36), and those of the 2-year-non-relapse-mortality were 25.2%
and 27.8% (P =0.86), respectively. The cumulative incidences of grade 3–4
acute GVHD were 28.4% (95% CI =7.2-28.1%) and 20.5% (95% CI =5.7–
22.2%)(P =0.43), respectively. Univariate analysis showed that disease status
before alloSCT may be a factor affecting OS and PFS (p=0.001).
Figure 1.
Summary/Conclusions: This retrospective study showed haploSCT resulted
in similar clinical efficacy compared to HID in patients with refractory/relapsed
or high risk lymphoma. Importantly, TRM and acute GVHD were acceptable
without obvious difference between two groups. HaploSCT provides a chance
of long-term disease control even for patients without HID.
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UPDATED RESULTS FROM ZUMA-1: A PHASE 1-2 MULTICENTER STUDY
EVALUATING THE SAFETY AND EFFICACY OF KTE-C19 (ANTI-CD19 CAR
T CELLS) IN REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN
LYMPHOMA (NHL)
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Background: Non-Hodgkin lymphoma (NHL) is the most prevalent hemato-
logic malignancy in the US and the 5th most deadly cancer with nearly 19,790
deaths/year. Diffuse large B-cell lymphoma (DLBCL) is the most common NHL
subtype, representing 25-35% of new cases annually. Approximately 1 in 3
patients treated in the first line will be refractory to treatment or relapse post-
treatment and represent a significant unmet medical need. Patients with
relapsed/refractory B-cell malignancies demonstrated durable remissions when
treated with CD28/CD3zeta anti-CD19 CAR T cells at the National Cancer
Institute (NCI) (Kochenderfer, JCO 2015; NCT00924326). KTE-C19 includes
the same CAR construct as that used in the NCI trial, but is centrally manufac-
tured in a streamlined 6- to 8-day process. Updated data from the phase 1
portion of the ZUMA-1 clinical trial are reported.
Aims: The primary goal was to determine the safety of KTE-C19. Secondary
aims included evaluation of overall response rate, duration of response, blood
concentrations of CAR T cells, and serum cytokine levels.
Methods: Patients with relapsed/refractory aggressive B-cell NHL were treated
with a single target dose of 2 × 106 anti-CD19 CAR T cells (KTE-C19)/kg fol-
lowing a fixed dose of cyclophosphamide/fludarabine conditioning chemother-
apy. Key inclusion criteria were ECOG 0-1 and chemo-refractory disease, which
was defined as progressive or stable disease as best response to last line of
therapy or disease progression ≤12 months after autologous stem cell trans-
plantation. All patients provided informed consent.
Results: Seven patients received KTE-C19 as of January 15, 2016. A previ-
ously reported dose-limiting toxicity of grade 4 cytokine release syndrome and
neurotoxicity occurred in one patient. All other grade ≥2 cytokine release syn-
drome and neurotoxicity adverse events resolved within one month. There
were no other adverse events due to KTE-C19 after one month post-dosing.
The overall response rate was 71%, with a complete response rate of 57%.
Ongoing complete responses of 3 to 6+ months were present in 3 patients
who previously demonstrated disease progression within 6 months of autolo-
gous stem cell transplantation. Levels of CAR T cells peaked within 2 weeks
and remained detectable 1 to 6+ months after infusion. Updated results will be
presented.
Summary/Conclusions: Additional follow up of patients enrolled in the ZUMA-
1 trial demonstrated durable complete remissions after a single dose of KTE-
C19, with no new KTE-C19-related adverse events. The KTE-C19 regimen
and central, streamlined manufacturing process were safe and feasible for
future studies. The phase 2 portion of the ZUMA-1 clinical trial (NCT02348216)
is ongoing.
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LOW-DOSE CHEMOTHERAPY FOLLOWED BY ANTI-CD19 CHIMERIC
ANTIGEN RECEPTOR (CAR) T CELLS INDUCES REMISSIONS IN
PATIENTS WITH ADVANCED LYMPHOMA
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A Xue3, T Feldman4, JW Friedberg5, MJ Roschewski6, S Feldman2, L McIntyre2,
MA Toomey2, SA Rosenberg2
1Experimental Transplantation and Immunology Branch, National Cancer Insti-
tute (NCI), National Institutes of Health (NIH), 2Surgery Branch, NCI, NIH,
Bethesda, 3Kite Pharma, Inc., Santa Monica, 4Lyphoma Division, John Theurer
Cancer Center, Hackensack University Medical Center, Hackensack, 5Univer-
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Background: Non-Hodgkin lymphoma (NHL) is the most common hematologic
malignancy in the US and the 5th deadliest cancer with almost 20,000 deaths
per year. Anti-CD19 CAR T cells achieve durable remissions in patients with
relapsed/refractory B-cell malignancies. Pre-treatment with chemotherapy
allows depletion of recipient leukocytes, which improves the anti-cancer effects
of adoptively transferred T cells. Increased serum concentrations of interleukin
(IL)-15 is believed to contribute to this beneficial effect of chemotherapy. We
(Kochenderfer et al. Journal of Clinical Oncology, 2015) and others previously
reported effects of high-dose chemotherapy administered before anti-CD19
CAR T-cell therapy. We now report the effects of low-dose conditioning
chemotherapy followed by anti-CD19 CAR T-cell infusion.
Aims: The main goals of the study were to evaluate efficacy and safety of low-
dose conditioning chemotherapy followed by anti-CD19 CAR T cell therapy in
patients with advanced lymphomas.
Methods: Twenty-two patients with advanced lymphoma were included in the
study. Eighteen patients were treated with cyclophosphamide 300 mg/m2 daily
for 3 days; the remaining 4 patients received cyclophosphamide 500 mg/m2
on this same schedule. Fludarabine 30 mg/m2 was provided to all patients on
the same schedule and days as cyclophosphamide. A single dose of CAR T
cells was administered 2 days after chemotherapy was completed. CAR T cell
concentrations and cytokine levels were examined in blood samples collected
from patients. Informed consent was received from all patients.
Results: Among 19 patients with diffuse large B-cell lymphoma of various sub-
types, 8 demonstrated complete response, 5 partial response, 2 stable disease,
and 4 progressive disease. A complete response was also noted in one patient
with mantle cell lymphoma. Two patients with follicular lymphoma both obtained
complete response. Duration of response ranged from 1 to 20 months, with 10
remissions that remain ongoing. All but 4 patients had either chemo-refractory
lymphoma or relapsed lymphoma following autologous stem cell transplanta-
tion. Neurological toxicities were the most commonly observed adverse events.
Fever and hypotension were also observed. The median peak blood CAR+
cell concentration was 47/μL (range 4-1217/μL), with higher levels found in
patients who demonstrated complete or partial response than in those with
stable or progressive disease. The mean serum IL-15 level was 4 pg/mL prior
to administration of conditioning chemotherapy and 32 pg/mL after chemother-
apy (P<0.0001).
Summary/Conclusions: Low-dose conditioning chemotherapy followed by
anti-CD19 CAR T cells induced remissions in patients with advanced B-cell
lymphomas.
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CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH
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Background: Classical Hodgkin lymphoma (cHL) is characterized by Hodgkin
Reed–Sternberg cells, which contain genetic aberrations at 9p24.1 leading to
overexpression of the programmed death receptor-1 (PD-1) ligands PD-L1 and
PD-L2. Thus, cHL may be uniquely sensitive to PD-1 blockade. Nivolumab
(Nivo) is a fully human IgG4 immune checkpoint inhibitor antibody targeting
PD-1 that showed promising results in a phase 1b study (NCT01592370) in
patients (pts) with relapsed/refractory cHL (Ansell SM et al. NEJM
2015;372:311-9) who currently have limited treatment options.
Aims: This study, Cohort B of the phase 2 Checkmate 205 study
(NCT02181738), evaluated the efficacy and safety of nivo in pts with cHL who
had received brentuximab vedotin (BV) after failed autologous stem cell trans-
plantation (ASCT).
Methods: Nivo was given at 3 mg/kg IV every 2 weeks (wk). Response was
assessed using 2007 IWG criteria, by both an independent radiologic review
committee (IRRC) and investigators (Inv). The primary endpoint was IRRC-
assessed objective response rate (ORR). Quality of life was assessed by EQ-
5D VAS (0–100 scale) and EORTC QLQ-C30. Written informed consent was
obtained for all pts. Results of the primary ORR analysis after approximately 6
months (mo) minimum follow-up are reported.
Figure 1. Best change from baseline in target lesions for all response-
evaluable patients (IRRC assessment).
Results: Among 80 pts enrolled and treated, the main characteristics included
median (range) age, 37 years (18–72) and median (range), 4 prior regimens
(3–15). 33 pts enrolled from Europe; 47 were from the US or Canada. At data
cut-off (October 2015), 51 pts (64%) remained on therapy. Of 29 pts (36%)
who discontinued, the most common reason was disease progression (n=13).
Only 4 pts discontinued due to an AE. 90% of pts had drug-related AEs, includ-
ing 25% Grade 3–4 AEs and 1% Grade 5 (multi-organ failure). The most com-
mon drug-related AEs were fatigue (25%), infusion reaction (20%), and rash
(16%). The most common serious AEs were pyrexia, tumor progression,
arrhythmia, infusion reaction, septic meningitis, and pneumonia (≤4% each).
Most common immune-mediated AEs were hypothyroidism/thyroiditis (14%),
rash (10%), and hypersensitivity (6%). All 6 pts who stopped nivo and received
subsequent stem cell transplant were alive at data cut-off. After median (range)
follow-up of 8.9 mo (1.9–11.7), IRRC ORR (95% CI) was 66% (54.8%, 76.4%);
CR and PR rates were 8.8% (3.6%, 17.2%) and 57.5% (45.9%, 68.5%), respec-
tively. Almost all pts had some degree of tumor regression (Figure). All but one
responder had tumor reduction of ≥50% from baseline; the other had response
determined by negative FDG-PET scan. In 43 pts who had no response (SD
or PD) to BV, nivo treatment resulted in IRRC ORR of 72% (31/43). Median
(range) time to response was 2.1 mo (1.6–5.7). Inv ORR (95% CI) was 73%
(61.4%, 81.9%); CR and PR rates were 27.5% (18.1%, 38.6%) and 45.0%
(33.8%, 56.5%), respectively. At data cut-off, 62% (33/53) of IRRC responders
remained in response. IRRC 6-mo PFS was 77%; OS was 99%. Mean EQ-5D
VAS score increased over time, from 62 at baseline to 80 at Wk 33, with a clin-
ically meaningful improvement in health state by Wk 9 (>7-point change).
EORTC QLQ-C30 findings suggested a trend towards improvement in func-
tional, symptom, and global health scores.
Summary/Conclusions: In pts with cHL who progressed following ASCT and
BV, nivo is associated with a high response rate, long-lasting responses, and
an acceptable safety profile. PFS and OS are encouraging in this heavily pre-
treated population. Patient reported outcomes suggest improvement in quality
of life while on nivo treatment.
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MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/
REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087
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Background: Patients with cHL who relapse after autologous stem cell trans-
plantation (ASCT) or progress after brentuximab vedotin (BV) have a poor prog-
nosis. In cHL, nearly universal 9p24.1 amplification, as well as less likely mech-
anisms such as Epstein-Barr virus infection and chromosomal rearrangements,
induce PD-L1 and PD-L2 expression on the tumor cell surface, suggesting that
cHL may have a genetically determined dependence on the PD-1 pathway.
Pembrolizumab is a humanized monoclonal antibody against PD-1 that blocks
interaction with PD-L1 and PD-L2. In the phase 1b KEYNOTE-013 study, pem-
brolizumab demonstrated high antitumor activity (objective response rate [ORR]
of 65%) in heavily pretreated patients with cHL. KEYNOTE-087 is a phase 2
study designed to further evaluate the clinical activity of pembrolizumab in this
patient population.
Aims: To determine the ORR, safety, and tolerability of pembrolizumab in
patients with R/R cHL.
Methods: KEYNOTE-087 (NCT02453594) is a multicenter, single-arm, multi-
cohort phase 2 study designed to evaluate the clinical activity of pembrolizum-
ab in 3 cohorts: R/R cHL after ASCT and subsequent BV therapy (cohort 1);
ineligible for ASCT due to chemo-resistance (no response to salvage
chemotherapy) and BV therapy failure (cohort 2); and R/R cHL after ASCT
but not treated with BV after ASCT (cohort 3). Patients received pembrolizum-
ab at a fixed dose of 200 mg intravenously every 3 weeks. Primary end point
was ORR, with response assessed every 12 weeks according to Revised
Response Criteria for Malignant Lymphomas. A prespecified interim analysis,
based on investigator-assessed response, was performed after 30 patients in
cohorts 1 and 2 reached the first response assessment. Informed consent
was obtained for all patients.
Results: At the time of data cutoff (Feb 1, 2016), 60 patients were evaluable
for cohorts 1 and 2. Median (range) age was 36 (19 - 64) years in cohort 1 and
33 (20 - 71) in cohort 2. 35% had primary refractory disease (no response to
frontline therapy), 67% received ≥4 prior lines of therapy, and by design 100%
failed prior BV. ORR among 30 patients in cohort 1 was 70% (95% CI, 51% -
85%). 6 patients (20%) achieved complete response (CR; residual mass per-
mitted if PET negative), 15 (50%) partial response (PR), and 6 (20%) stable
disease as best response. ORR among 30 patients in cohort 2 was 80% (95%
CI, 61% - 92%). 8 patients (27%) achieved CR, 16 (53%) PR, and 4 (13%) sta-
ble disease as best response. With a median of 6 treatment cycles, the most
common treatment-related AEs (TRAEs) were pyrexia (13%), diarrhea (8%),
and fatigue, platelet count decrease, dry skin, and cough (7% each). There
were 7 grade 3 TRAEs in 3 patients: neutropenia, colitis, diarrhea, cytokine
release syndrome, herpes zoster infection, increased amylase, and lichen
planus; and only 1 grade 4 TRAE, increased lipase. There were no treatment-
related deaths.
Summary/Conclusions: PD-1 blockade with pembrolizumab shows frequent
responses in heavily pretreated patients with cHL. Of note, pembrolizumab
provided a high ORR (80%) in patients who were not candidates for ASCT and
failed previous BV therapy. Cohort 3 continues accrual and interim analysis
results will be presented.
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VERY LATE RELAPSE >5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN
LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP
HD7-HD12 TRIALS
PJ Bröckelmann*, H Görgen, C Kohnhorst, M Fuchs, P Borchmann, A Engert
Department I of Internal Medicine and German Hodgkin Study Group (GHSG),
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Background: Patients who are free of Hodgkin lymphoma (HL) for >5 years
after first diagnosis are usually considered cured. Nevertheless, late relapses
occur and biology, clinical characteristics, therapeutic approaches and prog-
nosis are currently poorly understood.
Aims: Our study hence aimed at a comprehensive analysis of very late relapse
(VLR) of HL.
Methods: We retrospectively analyzed 5149 patients of the GHSG HD7-HD12
trials, who were observed and relapse-free for >5 years after first diagnosis to
estimate the incidence of VLR of HL. Cumulative incidence of VLR was calcu-
lated with death without preceding relapse considered as competing risk and
compared between groups using Gray’s test. To investigate, whether VLR can
be considered as new cases of HL, standardized incidence ratio (SIR) was
estimated using age- and sex-specific reference values for the German popu-
lation. Overall survival (OS) was estimated according to Kaplan-Meier from
first diagnosis to death from any cause. Additionally, OS from date of relapse
was estimated for patients with VLR and compared with a group of 487 patients
from the respective trials having early relapse (≤5 years from first diagnosis).
Patient characteristics and therapy at relapse were analyzed descriptively.
Results: With a median observation time of 10.3 years, a total of 169 relapses
>5 years after first diagnosis were observed. In patients relapse-free for >5 years,
cumulative incidences at 10, 15 and 20 years rose in a linear fashion and were
2.8%, 5.1% and 8.6%, respectively, with an SIR of 97.1 (95% CI: 83.0-112.9).
VLR were more frequently observed in patients with early-stage favorable than
early-stage unfavorable or advanced-stage disease at first diagnosis (15-year
cumulative incidence 8.0% vs 4.4% and 4.2%, respectively, p<0.001). OS was
significantly worse in patients with VLR when compared to non-relapse survivors
(10-year OS: 95.9% vs 88.5%, HR: 2.4, 95% CI: 1.7-3.4, log-rank p<0.001).
Compared to patients with early relapse, fewer patients with VLR were treated
with autologous stem-cell transplantation (ASCT, 35% vs 49%). Instead, they
often received polychemotherapies such as BEACOPP (18% vs 13%) or ABVD
(15% vs 11%). Compared to early relapse, we observed superior OS after VLR
(HR: 0.5, 95% CI: 0.3-0.8, p<0.01) after adjustment for type of therapy and risk
group at first diagnosis. In addition, relapse characteristics, changes in histologic
subtype and risk factors for VLR will be presented.
Summary/Conclusions: Besides therapy-associated side effects, survivors
after initially successful HL-therapy are at a 100-fold increased risk of re-occur-
rence of disease compared to German reference values. After modern risk-
adapted treatment strategies especially in early-stage favorable HL, thorough
regular follow-up is hence needed for timely detection. With adequate treat-
ment, prognosis of VLR seems favorable when compared to early relapses.
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Background: Patients with relapsed/refractory (RR) Hodgkin lymphoma (HL)
have a very poor prognosis. Allogeneic stem cell transplantation (allo-HCT)
has been used in this setting with controversial results.
Aims: Aim of our study is to investigate the role of allo-HCT in RR HL.
Methods: This study reported on 69 patients with RR HL, median age 34
(range, 18 - 64), consecutively transplanted between 2000 and 2015 in 3 trans-
plant center in Northwest Italy. Coordinator of the project was the Division of
Hematology of the University of Torino. Patients were heavily pre-treated with
a median of 4 therapy lines (range, 2 - 6). Sixty-four patients (93%) received
previous high-dose chemotherapy and autologous transplantation. At the time
of allo-HCT, 52 patients (75%) were at least in partial remission (PR) and were
defined responsive. The remaining 16 patients (23%) had progressive disease
(non-responsive). The disease status of 1 patient was not available. Brentux-
imab Vedotin (BV) was given as bridge to transplant in 11 patients. Moreover,
7 patients received BV after allo-HCT as salvage. The majority of patients
underwent reduced intensity allo-HCT, 64 patients (93%). Donors were HLA-
matched unrelated in 39 cases (57%), HLA-matched siblings in 28 cases
(41%), HLA-haploidentical in 2 cases (3%). The stem cells source was periph-
eral blood in 61 patients (88%), bone marrow in 7 patients (10%) and cord
blood in 1 patient (1%).
Results: Overall, 32 patients (46%) have died at the time of last contact, includ-
ing 20 patients who had relapsed. This resulted in a median overall survival
(OS) [Figure 1], and relapse-free survival (RFS) of 5.1 years (range, 0 - 13.8),
and 1.3 years (range, 0-12.6), respectively. Median follow-up among the 37
survivors was 7.2 years (range, 0.1-13.8). The 5-year cumulative incidence of
treatment related mortality (TRM) and relapse were 17.7% and 43.4%, respec-
tively. As expected, patients younger than 35 had a lower 5-year TRM com-
pared to older patients (8.7% versus 27.1%). The day-100 cumulative incidence
of grades II-IV acute graft-versus-host disease (GvHD) was 36.7% (60 evalu-
able patients). Only 8 patients had grade III disease. No grade IV acute GvHD
was reported. The cumulative incidence of limited or extensive chronic GvHD
was 45.6% (57 evaluable patients). The 5-year estimated of RFS was signifi-
cantly higher in responsive compared to non-responsive patients, 46.9% versus
12.5%, respectively, p= 0.009. There was a trend to improved 5-year OS in
responsive patients, 54.6% versus 37.5%, respectively, p= 0.19. The RFS
advantage of responsive patients was confirmed by multivariable Cox regres-
sion (HR= 3, 95% CI 1.4 - 6.4, p= 0.005). The 5-year relapse incidence was
35.3% and 68.8% in responsive and non-responsive patients, respectively.
Eleven patients received BV as bridge to allo-HCT for a median of 6 cycles.
Only 3 patients failed to achieved at least PR. Then, BV was used as salvage
for post-alloHCT relapse in 7 patients. All patients achieved at least PR. None
of patients treated with BV had unexpected toxicity or GVHD worsening.
Figure 1.
Summary/Conclusions: Allo-HCT is a feasible and effective option for RR
HL. In our series, the disease status at HCT was the main predictor of out-
comes, primarily relapse. Furthermore, BV showed efficacy as a bridge to allo-
HCT as well as post allo-HCT rescue.
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PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/
REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA:
KEYNOTE-013
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Background: Primary mediastinal large B-cell lymphoma (PMBCL) frequently
exhibits 9p24.1 alterations, leading to overexpression of the PD-1 ligands, PD-
L1 and PD-L2. This provides a possible mechanism of immune evasion and
suggests that PMBCL could have a genetically determined vulnerability to PD-
1 blockade. Pembrolizumab is a humanized monoclonal antibody that blocks
the interaction between PD-1 and its ligands. Pembrolizumab has already
demonstrated robust antitumor activity in advanced solid tumors and in classical
Hodgkin lymphoma. KEYNOTE-013 (NCT01953692) is a multicenter, multico-
hort phase 1b study designed to evaluate the safety and preliminary efficacy
of pembrolizumab in patients with hematologic malignancies. Preliminary
results of the PMBCL cohort of KEYNOTE-013 are reported.
Aims: To determine the safety, tolerability, and antitumor activity of pem-
brolizumab in patients with relapsed/refractory (R/R) PMBCL.
Methods: Patients with R/R disease who have relapsed after or are ineligible
for autologous stem cell transplantation (ASCT) received pembrolizumab IV
10 mg/kg Q2W or 200 mg Q3W for up to 2 years or until confirmed disease
progression or unacceptable toxicity. Primary end points were safety and ORR.
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Response was evaluated using computed tomography (CT) and positron emis-
sion tomography (PET) at weeks 6 and 12, and every 8 weeks thereafter, using
IHP 2007 criteria. Other end points included complete remission rate and dura-
tion of response (DOR). Informed consent was obtained for all patients.
Results: As of February 1, 2016, 16 patients were enrolled and treated in this
cohort. The first 11 patients received pembrolizumab 10 mg/kg every 2 weeks;
the next 5 patients received a fixed dose of 200 mg every 3 weeks, which has
demonstrated equivalence based on PK/PD studies. Median age was 30 years
(range, 22-62), 44% had ≥4 prior lines of therapy, 31% had prior ASCT, and
75% had prior radiation. 10 patients (62%) experienced treatment-related AEs,
most commonly grade 1-2 decreased appetite, diarrhea, fatigue, hypothy-
roidism, nausea, and pyrexia (2 patients each). Only 1 patient experienced a
grade 3 treatment-related AE (neutropenia), and there were no grade 4 treat-
ment-related AEs or treatment-related deaths. 4 patients experienced serious
AEs, including grade 3 pneumonia in 3 patients and grade 3 cough in 1 patient;
all were unrelated to study drug. No patients discontinued for toxicity. Among
the 16 treated patients, the median follow-up was 5.0 months (range, 0.8-22
months) and the objective response rate (ORR) was 37.5% (6/16), with 1 patient
(6.25%) achieving a complete remission and 5 patients (31.25%) achieving a
partial response. One subject discontinued treatment based on clinical pro-
gression before the first assessment and was considered a non-responder.
The median DOR has not been reached (range, 0.03+-17+ months), with 5
responses ongoing at the time of data cutoff. 9 have discontinued treatment: 5
because of progressive disease based on imaging, 3 because of clinical pro-
gressive disease, and 1 because of physician decision.
Summary/Conclusions: The preliminary results of KEYNOTE-013 indicate
that PD-1 blockade with pembrolizumab is associated with a tolerable safety
profile and a promising response rate in heavily pretreated patients with R/R
PMBCL. These patients often have a very poor outcome with conventional ther-
apy, justifying further studies of pembrolizumab in this population.
ALL Biology - Transcriptional dysregulation
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Background: Next generation sequencing technologies have drawn attention
to the analysis of genetic alterations across different cancer genomes. Precur-
sor leukemias are unique in that they often harbor structural variations (SV)
and have relatively few mutations. Instead, the maturing lymphoid cells are vul-
nerable to off-target effects downstream of the recombination activating genes
(RAG) and activation-induced deaminase (AID, encoded by the AICDA gene)
activity that is required for immune gene rearrangement.
Aims: Earlier in vitro studies on DNA binding and genome-wide binding profiles
of RAGs have shed light on the mechanisms how this complex is recruited to
DNA; however these studies have been carried out using normal cells or mouse
models that limit their integration with patient WGS data. More recently, a func-
tional role of transcription in genomic instability has begun to emerge: AID can
generate off-target DNA breaks at loci that harbor highly active enhancers and
display convergent transcription (transcription from both strands) in lymphomas.
The present study represents a systematic investigation of SVs detected in
acute pre-B-cell leukemia (pre-B-ALL) in the context of global transcriptional
activity in leukemic cells.
Methods: RNA polymerases engaged into primary transcription across the
genome can be measured using Global-Run-On sequencing (GRO-seq). There-
fore, this method is ideally suited to distinguish features of transcription at SV
sites. Transcriptional activity was assayed using GRO-seq from ALL cells rep-
resenting seven different pre-B-ALL cytogenetic subtypes, and jointly analyzed
with public WGS data from the ETV6-RUNX1 (51 cases), high hyperdiploid (16
cases), hypodiploid (20 cases) and MLL-rearranged (22 cases at diagnosis
and 2 relapses) subtypes of precursor B-ALL. Pre-B-ALL patient expression
profiles (N=1,382), B-lymphoid cell chromatin conformation capture (HiC), RNA
polymerase ChIP-seq and DNAse hypersensitivity (DNAse-seq) data were used
as additional data.
Results: The active transcriptional profiles from ALL patients revealed striking
similarity at SV sites to AID off-target lesions reported in lymphomas. Based on
pre-B-ALL transcriptomes, high AICDA levels were particularly prevalent in
sample clusters that corresponded to high-risk ALL cases and 62% were cyto-
genetically classified to the subtype “other”. The highest level of AICDA expres-
sion was presented by a relapsed ALL case with high expression already at
diagnosis. SV with RAG recognition motifs (RSS motif) also associated strongly
with features of transcriptional activity. We could show that elevated levels of
convergent transcription that typically occurs at intragenic enhancers positively
correlated with detected R-loop levels (needed for AID recruitment) and number
of RNA polymerase stalling events at breakpoints. The wide stalling regions
identified correlated with highly accessible DNA regions. Accordinly, RNA poly-
merase stalling sites detected at TSS regions with breakpoints harboring the
RAG recognition motif were significantly wider than stalling sites found at TSS
regions with no breakpoints, indicating that RNA polymerase stalling could
mediate RAG access to its cleavage sites.
Summary/Conclusions: The results support a model in which transcriptional
features (convergence of transcription and Pol2 stalling), through altering
access to DNA, could act to guide secondary DNA lesions and therefore
leukemia progression. Our results position RAG among complexes involved in
transcription-coupled genomic instability. Moreover, we present evidence of
expression of AICDA in high-risk / cytogenetic class “other” pre-B-ALL cases.
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Background: T-cell acute lymphoblastic leukemia (T-ALL) results from the
leukemic transformation of thymic cell precursors caused by a multistep patho-
genesis involving numerous genetic and epigenetic abnormalities. They are
characterized by high relapse rates and poor prognosis, calling for the search
of novel therapeutic options. T lymphocytes differentiate in the thymus accord-
ing to a highly orchestrated process involving developmental checkpoints.
Among these, negative selection is a major process by which thymocytes rec-
ognizing self-Major Histocompatibility complex with high affinity are eliminated
by TCR-mediated apoptosis.
Aims: In this study, we hypothesized that tissue homeostatic regulators may
be amenable to reactivation in tumor cells. We inferred that experimentally
chronic/persistent induced TCR signaling in T-ALL could initiate a molecular
program similar to negative selection of thymic T-cell progenitors and induce
cell death.
Methods: We used the transgenic Marilyn TCR-HY in a human T-ALL cell line
(ALL-SIL) and in a mouse model of TEL-JAK2-induced T-ALL, to test TCR acti-
vation by its cognate peptide/MHC. We evaluated chronic/persistent TCR acti-
vation by anti-CD3ε monoclonal antibody in vitro (in TCR-HY ALL-SIL and in a
panel of 36 primary T-ALL patients cases) and in vivo (in TJK2/CD3ε+ and
TJK2/CD3ε- mouse T-ALL model and in xenotransplanted mice with 7 human
T-ALL).
Results: Using the Marilyn TCR-HY transgene, we showed that TCR activation
by its cognate peptide/MHC induced apoptosis in vitro (ALL-SIL TLX+ cell line)
and dramatically impaired development/maintenance of leukemias in vivo
(murine TEL-JAK2-induced T-ALL) exclusively in DBY-expressing male mice.
Anti-CD3ε monoclonal antibody stimulation mimicked high affinity self-pep-
tide/MHC-induced TCR signaling (human OKT3; murine, 145-2C11): this led
to massive leukemic cell death and remarkably induced a gene expression
program similar to thymic negative selection. In addition, in vitro stimulation of
CD3/TCR complex with an anti-CD3ε antibody resulted in cell death of primary
CD3/TCR-expressing T-ALL (n=36) regardless their underlying oncogenetic
characteristics. Keeping with this, in vivo treatment by anti-CD3ε monoclonal
antibody prevented from the emergence of the leukemic process in several
TCR+ T-ALL murine models, whereas it had virtually no impact on the survival
of mice engrafted with murine CD3ε-/- T-ALL cells. Importantly, anti-CD3ε treat-
ment hampered leukemogenesis in xenotransplanted mice with human
TCR/CD3+ T-ALL (n=7) in both preventative and curative settings.
Summary/Conclusions: In our study, we found that reactivation in T-ALL
blasts of the lineage-specific checkpoint control normally set by TCR signaling
during T-cell development, displays anti-tumoral functions. Importantly, despite
the multiple and complex oncogenic mechanisms driving T-ALL, this TCR-
dependent checkpoint remains switchable to induce massive tumor cell apop-
tosis. These data provide a strong rationale for targeted therapy based on anti-
CD3 treatment of TCR-expressing T-ALL patients and demonstrate that
endogenous developmental checkpoint pathways are amenable to therapeutic
intervention in cancer cells.
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Background: T-cell acute lymphoblastic leukemias (T-ALLs) are aggressive
hematologic tumors that result from the malignant transformation of T-cell pro-
genitors. Due to intensified chemotherapy, the prognosis of T-ALL has gradually
improved. Nevertheless, this clinical improvement is most pronounced in pedi-
atric treatment protocols, whereas adult patients more often present with pri-
mary resistant or relapsed disease. 
Aims: Our Aim is to develop new mouse models that mimic oncogenic lesions
identified in human disease. These mouse models are critically required to fur-
ther enhance our knowledge on the molecular mechanisms that drive T-cell
leukemogenesis. Moreover, they serve as important pre-clinical models to eval-
uate new therapeutic strategies for the treatment of human T-ALL.
Methods: Here, we generated a fast method for embryonic stem cell (ESC)
targeting and mouse chimera production. We constructed gateway-compatible
vectors that allow tailor-made targeting vector design, including conditional
expression of a transgene combined with an eGFP/luciferase reporter from
the ROSA26(R26)-promoter or from (inducible) exogenous promoters. The
final targeting vector is recombination-mediated cassette exchange (RMCE)-
compatible and can be inserted in a genetically engineered R26-locus via
RMCE. Correct integration of the incoming construct reactivates the NeoR
gene and results in up to 100% ESC targeting efficiencies. 
Results: Using our technology, we generated R26-based conditional knock-in
mouse models for putative oncogenes that have previously been implicated in
T-ALL disease biology. More specifically, the MYB leucine zipper transcription
factor is aberrantly activated in a subset of T-ALL patients through T-cell recep-
tor driven translocations (t(6;7)(q23;q34)) or genomic duplications of the MYB
locus itself. Moreover, Myb was found to be crucial for the initiation of oncogenic
superenhancers in T-ALL. In addition, another subset of T-ALLs show specific
TCR-mediated translocations that drive aberrant expression of the cell cycle
regulator Cyclin D2 (CCND2). To study the in vivo roles of cMyb and Ccnd2 in
the pathogenesis of T-ALL, we used the above-mentioned genomic engineering
technology to generate cMyb and Ccnd2 conditional knockin mouse models.
These animals were crossed with Lck-Cre mice to obtain T-cell specific expres-
sion of the oncogenes of interest at moderate pathophysiological relevant lev-
els. Currently, we are monitoring tumor development in T-cell specific homozy-
gous knockin mice. In addition, Myb and Ccnd2 transgenic animals are crossed
into a Pten null background to accelerate disease onset. Preliminary data
shows that T-cell specific Ccnd2 overexpression cooperates with Pten loss to
decrease T-ALL latency.
Figure 1.
Summary/Conclusions: All together, we have used a fast genomic engineer-
ing pipeline to develop new and pathophysiological relevant conditional over-
expression mouse models for human T-ALL.
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ACTIVATED JAK-STAT SIGNALING COOPERATES WITH HOXA9 AND
DRIVES LEUKEMIA DEVELOPMENT
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Background: The JAK-STAT signaling pathway is critical for the normal devel-
opment and proliferation of hematopoietic cells. Mutations in JAK1 or JAK3
occur within ~20% of T-cell acute lymphoblastic leukemia (T-ALL) cases and
have also been described in other malignancies. We have previously shown
that JAK3 mutations are able to transform hematopoietic cells in vitro and
cause long latency T-ALL in a mouse model.
Aims: To determine mutations which are significantly associated with ectopic
activation of the JAK-STAT signaling pathway and determine whether they
cooperate in leukemia development in vivo. 
Methods: Targeted-resequencing of 115 genes across 155 diagnostic T-ALL
samples and qPCR on patient derived xenograft (PDX) samples was used to
evaluate candidate genes significantly associated with mutations within the
JAK-STAT5 pathway. Oncogenic cooperation and transformation to cytokine
independent growth was evaluated using primary hematopoietic progenitor
cells ex vivo. In vivo leukemia cooperation was assayed using a modified bone
marrow transplant assay using either wild type or CD4-Cre donor mice in con-
junction with either a retroviral vector for constitutive expression in all
hematopoietic lineages or a novel antiparallel lox66/71 retroviral vector for
restricted expression within developing T-cells. 
Results: Mutations in JAK3 were found to frequently co-occur with HOXA clus-
ter rearrangement and our qPCR analysis of PDX samples identified HOXA9
as the most upregulated HOXA gene in cases with mutant JAK3. Constitutive
expression of the JAK3(M511I) mutant together with HOXA9 transformed
murine hematopoietic progenitors to cytokine independent growth ex vivo, while
JAK3 mutant or HOXA9 alone did not transform cells ex vivo. To model the
possible cooperation of JAK3(M511I) and HOXA9 in vivo we initially used the
bone marrow transplant model with constitutive expression of JAK3(M511I)
and HOXA9. This led to the rapid development of a mixed myeloid-lymphoid
leukemia in vivo (median survival=82 days) compared to JAK3(M511I) alone
(median survival=164 days) or HOXA9 alone (no disease). To study the coop-
eration during T-ALL development specifically, we modified the bone marrow
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transplant model by using a novel inducible retroviral vector in combination
with CD2-Cre or CD4-Cre donor bone marrow cells so that JAK3(M511I) and
HOXA9 expression is delayed to lymphoid progenitors or T-cells. All models
confirmed a clear cooperation between JAK3(M511I) and HOXA9, and ChIP-
seq, ATAC-seq, and RNA-seq on the leukemic cells confirmed cooperation at
the transcriptional level between STAT5 (downstream of JAK3) and HOXA9
Summary/Conclusions: JAK3 mutations and ectopic expression of HOXA9
cooperate to transform hematopoietic cells and cause rapid leukemia develop-
ment in vivo.
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BET INHIBITOR AS A NOVEL THERAPEUTIC APPROACH FOR THE
TREATMENT OF MLL-REARRANGED INFANT ACUTE LEUKEMIA
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Background: Despite the improvements in the field of pediatric leukemia
achieved in the last decades, some groups of patients still suffer from a low
cure rate. Acute lymphoblastic leukemia occurring in infants carrying the MLL
gene translocation (MLL+ infant ALL) has an overall poor outcome due to drug
resistance and high relapse rate. Numerous studies have shown that the per-
turbation of the chromatin structure and the transcriptional deregulation induced
by the MLL translocation represent the main mechanism of leukemogenesis.
Therefore, new therapeutic strategies targeting the chromatin structure and/or
the recruitment of the transcriptional complex represent nowadays the most
promising approaches.
Aims: In this study we aimed to investigate the effect of Bromodomain and
Extra Terminal (BET) inhibition by using the inhibitor I-BET151. BET is a family
of adaptor proteins, including BRD2, BRD3 and BRD4, which bind to the acety-
lated residues of the histone core, and function as epigenetic readers.
Methods: The anti-leukemic effects of I-BET151 administration was tested in
vivo in a mouse model of human MLL+ infant ALL. A human MLL+ cell line or
primary samples derived from infant patients were transplanted into immuned-
eficient mice, in order to recapitulate the disease in vivo. Subsequently, the
animals were treated with I-BET151 or with the vehicle only, via intraperitoneal
injection. Additionally, the biological mechanism of the compound was further
elucidated at the molecular lever, both in vitro using several human MLL+ ALL
cell lines, as well as ex vivo in patients-derived xenograft (PDX) samples from
mice.
Results: Herein we observed that I-BET151 administration reduces the engraft-
ment and the disease burden of MLL+ infant ALL in vivo and prolongs the sur-
vival in mice. Importantly, the anti-leukemic effect of I-BET151 was also con-
firmed in a “curative setting” experiment, where the treatment was started when
the leukemia was already consolidated in mice. Furthermore we elucidated the
biological mechanism of the compound and demonstrated that I-BET151 is
able to block cell proliferation (G0/G1-phase arrest) and induce apoptosis
through the downregulation of known BRD4 target genes (i.e. c-MYC, BCL2
and CDK6) and the impairment of the IL7Ra/STAT5 signaling pathway. More-
over, the analysis of transcriptional profile changes of PDX samples exposed
to I-BET151 ex vivo allowed us to identify a specific “I-BET core signature” of
genes deregulated upon treatment and belonging to the BRD4 and HOXA gene
network. The function of these newly identified genes and their potential role in
MLL leukemogenesis is currently under investigation. Finally, we have observed
that I-BET151 in combination with HDAC inhibitors is even more efficient com-
pared to the single therapy, as these two compounds have a synergic activity.
Summary/Conclusions: Taken together our data show that I-BET151, alone
or in combination with HDAC inhibitors, exerts a potent anti-leukemic effect on
MLL+ infant ALL. Notably, our study demonstrated for the first time the efficacy
of I-BET151 in primary patients’ samples. In conclusion, given the aggressive-
ness of the disease and the lack of a cure for infant patients with MLL leukemia,
this study is extremely novel and particularly relevant in the field of hematology,
as I-BET151 may represent in the future a promising novel approach for the
treatment of this high-risk leukemia.
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TARGETING CHROMATIN REGULATORS INHIBITS LEUKEMOGENIC
GENE EXPRESSION IN NPM1 MUTANT LEUKEMIA
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GS Vassiliou5, T Hoshii2, SA Armstrong2
1III. Department of Medicine, University Medical Center, Johannes Gutenberg
University Mainz, Mainz, Germany, 2Cancer Biology and Genetics Program,
Memorial Sloan Kettering Cancer Center, New York, 3Dana Farber Cancer
Institute, Harvard Medical School, Boston, 4Antitumor Assessment Facility,
Memorial Sloan Kettering Cancer Center, New York, United States, 5Wellcome
Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
Background: Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3
are frequently highly expressed and mutated in acute myeloid leukemia (AML).
Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in
the NPM1 gene (NPM1mut), and FLT3 is concomitantly mutated in ~50% of
these cases. Little is known how these cells maintain aberrant gene expression.
Since specific chromatin regulatory complexes control HOX expression in nor-
mal hematopoiesis and in leukemias expressing an oncogenic MLL-fusion pro-
tein, we hypothesized that they might also regulate HOX expression in other
settings, and that inhibition of HOX and FLT3 expression would produce an
antiproliferative effect in NPM1mut AML.
Aims: To investigate dependencies of NPM1mut AML on MLL and DOT1L com-
plexes and to delineate their potential role in control of leukemogenic gene
expression.
Methods: CRISPR-Cas9 genome editing across exons encoding specific pro-
tein domains was used in a negative selection screen to assess potential
dependencies of NPM1mut AML on specific MLL protein domains, and this con-
cept was extended with inhibitors of the menin-MLL interaction (MI2-2 and
MI503). Dependencies on DOT1L were explored using the inhibitor EPZ4777.
In vitro and in vivo target validation was performed in two conditional murine
knock-in models (Npm1CA/+FLt3ITD/+; Npm1CA/+RosaSB/+) and in a dissemi-
nated human xenograft model of Npm1mut AML.
Results: Using a CRISPR-Cas9 negative selection screen, we discovered
the menin binding site of MLL as a dependency in NPM1mut OCI-AML3 cells,
a region critically involved in chromatin binding of the MLL complex. We next
sought to assess treatment effects of MI2-2 and MI503 and observed dramatic
suppression of HOX and MEIS1 expression, differentiation induction, and
profound growth inhibition in human OCI-AML3 cells and murine Npm1mut
AMLs. Of interest, ectopic expression of Meis1, Hoxb4, or Hoxa9-Meis1 res-
cued the antiproliferative effects of menin-MLL inhibition. In vivo MI503 treat-
ment of leukemic OCI-AML3 xenografts resulted in profound HOX and MEIS1
suppression, significant reduction of leukemia burden, and in a significant
survival advantage of both, human xenografts and secondarily transplanted
Npm1CA/+RosaSB/+ mice compared to vehicle controls. As MEIS1 was most
dramatically suppressed across all three models, we determined drug effects
on FLT3 expression, a reported target gene of MEIS1 and found consistent
suppression of FLT3 to almost undetectable levels. MI503 treatment depleted
menin and H3K4me3 on HOX and MEIS1 loci. We also observed a significant
decrease of H3K79me2 at those loci, pointing to a potential role for DOT1L,
the sole H3K79 methyltransferase. Treatment with EPZ4777 resulted in HOX,
MEIS1, and FLT3 down regulation, cell growth inhibition, and profound dif-
ferentiation of NPM1mut AML blasts just as we found with inhibition of the
menin-MLL interaction. Next, we investigated effects of combinatorial menin-
MLL and DOT1L inhibition and found superior suppression of HOX and FLT3
expression, dramatically more pronounced differentiation, and synergistic
growth inhibition. Combinatorial drug treatment further reduced leukemia ini-
tiating potential of NPM1mut AML cells dramatically compared to single drug
treatment in vivo.
Summary/Conclusions: MLL and DOT1L are chromatin regulators that control
HOX, MEIS1 and FLT3 expression in NPM1mut AML. Combinatorial small-mol-
ecule inhibition has synergistic on target activity and represents a potential
therapeutic opportunity that should soon be ready for clinical assessment.
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Background: Acute myeloid leukemias (AML) with CEBPA mutations define
a provisional entity in the WHO 2008 classification. Patients with biallelic CEB-
PA (CEBPAbi) mutations comprising N-terminal frameshift and C-terminal in
frame mutations (hereafter termed typical CEBPAbi AML) characteristically
present a normal karyotype and have a favorable clinical outcome. In contrast,
characteristics of samples with other combinations of mutations (atypical CEB-
PAbi AML) are less well established.
Aims: Using the RNA-sequencing data from 415 primary AMLs in Leucegene
cohort, we aimed to refine the transcriptomic and mutational landscape of 14
CEBPAbi AML samples (7 typical and 7 atypical) present in this collection, and
to interrogate the novel mutations identified in this subgroup in a targeted chem-
ical inhibitor screen.
Methods: We performed RNA-sequencing, comparative transcriptomic analy-
sis, mutation detection, cell culture and chemical screening using the methods
previously reported (Lavallée et al, Nature Genetics, 2015).
Results: The 7 typical CEBPAbi specimens are best characterized by 95 dif-
ferentially expressed genes. Using this gene expression profile (GEP), we
next performed a principal component analysis and determined that 4/7 atyp-
ical CEBPAbi samples clustered with typical CEBPAbi (hereafter termed
GEP+), while 3/7 atypical CEBPAbi samples did not (GEP-). Identification of
low HOXA9 expression alone was sufficient to discriminate between GEP+
and GEP- atypical CEBPA AML (>300 fold median HOXA9 expression ratios).
In our cohort of CEBPAbi AML we identified 23 mutated genes, including the
previously reported mutations in WT1 and GATA2 in 3/14 (21% each). The
most frequent mutations in CEBPAbi AML was the activating CSF3R T618I
mutation present in 29% (4/14) of this subgroup compared to only 3/401
CSF3R mutated samples in other AML subtypes (p<0.0001). CSF3R encodes
the granulocyte colony stimulating factor receptor (G-CSFR) and is a direct
target of CEBPA, suggesting a selective pressure for acquisition of these
mutations in CEBPAbi AML cells. Interestingly, an additional mutation in G-
CSFR pathway (STAT5B N642H) was present in a fifth CEBPAbi AML sample.
Considering the high frequency of CSF3R mutations in CEBPAbi AML we
conducted a targeted chemical screen employing a collection of compounds
(n=11) enriched for JAK inhibitors. Inhibitors were tested in a dose response
assays using CEBPAbi (n=14) and control normal karyotype CEBPA wild-
type (NK CEBPAwt, n=14) primary AML cells. Results showed that all CSF3R
T618I mutated samples were sensitive to JAK inhibitors (e.g. median ruxoli-
tinib IC50=66nM (range: 48 - 94)). Most interestingly, CEBPAbi GEP+ samples
(n=11), irrespective of their CSF3R mutation status, were uniformly and sig-
nificantly more sensitive than NK CEBPAwt specimens to JAK inhibitors (e.g.
ruxolitinib median IC50: 62 vs 181 nM, p=0.01), but not to other inhibitors
such as dasatinib or sorafenib, or to cytotoxic agents daunorubicin and
cytarabine. This may suggest that networks upstream of JAK-STAT are aber-
rantly activated in a majority of these specimens. In contrast, CEBPAbi GEP-
were less sensitive to JAK inhibitors (e.g. ruxolitinib median IC50: 285, range:
48 to >10,000 nM), with the exception of a single sample carrying CSF3R
T618I mutation. These results indicate that the transcriptionally distinct CEB-
PAbi GEP- AML are also distinguishable from CEBPAbi GEP+ AML in their
responses to various chemical compounds.
Summary/Conclusions: Our study reports a novel co-occurrence of mutations
within the CEBPA/CSF3R pathway in CEBPAbi AML and reveals a uniform
sensitivity to JAK inhibitors in the transcriptionally uniform CEBPAbi GEP+ AML
cells. Altogether, it paves the way to personalized clinical trials repositioning
JAK inhibitors for CEBPAbi AML.
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Background: Acute myeloid leukemia (AML) is a fatal disease that is charac-
terized by a rapid expansion of myeloid leukemic blasts with impaired differen-
tiation that accumulate in the bone marrow. Because the prognosis for AML is
poor and the treatment for most AML subgroups has remained similar for almost
four decades, demand is strong for new types of therapies in this disorder. It is
thought that one of the major obstacles in successfully treating AML is to effi-
ciently target the AML cells with leukemia-initiating capacity, which often evade
standard chemotherapy treatments, leading to disease relapse.
Aims: The aim of this project has been to characterize Toll-like receptor 1
(TLR1) as a therapeutic target on primitive AML cells. 
Methods: A murine AML model driven by retroviral MLL-AF9 fusion expression
was used for the mouse studies. Flow cytometry was used to measure Tlr1
expression, for cell cycle analysis, and to measure activated AKT and NFκB.
For studies of human AML, MLL-AF9 transformed cord blood cells were used,
and also AML patient samples. Global gene expression profiling was performed
using RNA-sequencing.
Results: In search for candidate therapeutic cell surface targets in AML, we
here identified TLR1 as upregulated in primitive AML cells relative to corre-
sponding normal bone marrow cells. Stimulating primitive leukemic cells with
Pam3CSK4, a Tlr1/Tlr2 agonist, resulted in an increase in actively cycling cells
and cell expansion. Morphologic analysis and enhanced CD11b expression
indicated rapid myeloid differentiation of the cells. Moreover, Pam3CSK4
strongly suppressed their leukemia-initiating capacity as assessed in ex vivo
treatment experiments followed by transplantations into sublethally irradiated
recipient mice. In contrast, ex vivo Pam3CSK4-stimulation of normal
hematopoietic stem and progenitor cells only mildly suppressed their long-term
repopulating ability in competitive transplants. In human leukemia, Pam3CSK4-
stimulation of MLL-AF9-transformed cord blood cells pushed them into differ-
entiation and eradicated their colony-forming capacity accompanied by AKT
and NFκB activation. In AML patient samples, Pam3CSK4 caused cell differ-
entiation, evidenced by morphological changes consistent with macrophage
outgrowth and an increase in CD15-expressing cells, whereas minor effects
were observed in normal bone marrow cells. The Pam3CSK4-induced differ-
entiation showed strong correlated (r=0.98) with the level of TLR1 expression
in AML CD34+CD38- cells. Hence, our data suggest that AML patients with
high TLR1 expression would be more susceptible to treatments targeting TLR1.
Summary/Conclusions: In summary, these findings demonstrate that TLR1
is upregulated in primitive AML cells and that agonistic targeting of the
TLR1/TLR2 complex forces AML cells into differentiation, revealing a new puta-
tive strategy for therapeutically differentiating AML cells.
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Background: One of the major goals in AML research is to identify key char-
acteristics of leukemic stem cells (LSCs) in patients with AML. Gene expression
profiling in functionally validated primary AML LSCs has established a gene
signature, which consists of 42 genes associated with LSC properties and infe-
rior treatment outcome in patients with AML (Eppert et al., Nature Medicine
2011). Among these 42 genes the G-protein coupled receptor 56 (GPR56) was
highly expressed in the LSC enriched fraction compared to the CD34-negative
leukemic bulk.
Aims: The aim of this study was to determine the functional role of Gpr56 in
AML and to test its accessibility for antibody-mediated targeting of human AML
LSCs.
Methods: For this retrovirally engineered overexpression of Gpr56 and the
murine bone marrow transplantation model was used. For analyses in the
human system NSG xenografting was employed. 
Results: 43 clinically and molecularly annotated AML samples of different
genotypes were analysed by RQ-PCR, confirming high expression in NPM1c
mutated AML and lower expression in the CBF INV16 AML subtype with a
4.7fold difference between the two genotypes. Of note, expression of GPR56
was highest in normal CD34+ hematopoietic stem and progenitor cells, indi-
cating that there is substantial, but not aberrantly high GPR56 expression in
human AML cells. To test whether expression levels of GPR56 correlated with
treatment outcome, microarray based GPR56 expression of 423 clinically and
molecularly annotated newly diagnosed patients treated in two independent
prospective clinical trials was correlated with event free and overall survival:
when the median expression level of GPR56 was taken as cut-off, high GPR56
expression was associated with inferior event free and overall survival in the
total cohort of patients (n=423) as well as in the patients with normal karyotype
(n=184) Functional relevance of GPR56 expression was validated in mice, in
which co-expression of Gpr56 and Hoxa9 induced leukemia in transplanted
mice after a median time of 148 days post transplantation (range 93-264) in
contrast to the Hoxa9 and Gpr56 controls, which did not develop any signs of
disease in the observation period of up to 380 days post transplant. Vice versa,
the onset of leukemia was significantly delayed by shRNA-mediated knock-
down of GPR56 in Hoxa9/Meis1 transduced cells when transplanted into mice.
Overexpression of Gpr56 grossly changed the molecular phenotype of Hoxa9
transduced cells affecting pathways involved in G-coupled protein receptors
and associated intracellular signaling. As GPR56 is part of the LSC signature
in human AML, associated with inferior prognosis and as we had shown that
GPR56 in collaboration with the oncogene Hoxa9 contributes to myeloid leuke-
mogenesis, it was tested whether antibody-mediated blockage of the surface
receptor GPR56 impairs leukemic engraftment in the NSG mouse model.
Blockage of GPR56 with a monoclonal naked antibody significantly impaired
engraftment into NSG mice. Importantly, also FLT3-ITD3+ NPM1c- primary
patient samples showed an up to 68% decrease in BM engraftment at 12 weeks
(p<0.04).
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Summary/Conclusions: Taken together, these data demonstrate that high
expression of GPR56 is able to contribute to AML development and characterize
the GPR56 as a potential novel target for antibody-mediated anti-leukemic
strategies.
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SUPER-ENHANCER ANALYSIS DEFINES NOVEL AML AND MDS SUB-TYPES
SENSITIVE TO SY-1425, A POTENT AND SELECTIVE RARA AGONIST
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Background: Super-enhancers (SEs) are exceptionally large, highly active
chromatin regions that are densely occupied by transcription factors. They have
been implicated in directing gene expression programs that define cell identity
and also regulate oncogenes critical to the pathogenesis of cancer. One such
target, the retinoic acid receptor alpha (RARα) was identified by the asymmetric
distribution of its enhancer in a cohort of 60 non-APL AML patient samples pro-
filed by our gene control platform.
Aims: This study sought to characterize the relationship between a RARA
super-enhancer and response to SY-1425, a potent and selective RARα ago-
nist, in AML patient samples, cell lines, and mouse models. MDS patient sam-
ples were also tested for comparable RARA enhancer levels and elevated bio-
marker.
Methods: ChIP-seq and RNA-seq were used to study the presence of SEs
and correlated mRNA in patient samples. ChIP-seq, RNA-seq, and expression
arrays were used in AML cell lines for the same profiling in addition to charac-
terization of the transcriptional and chromatin level response to SY-1425. The
effect of SY-1425 was studied in proliferation assays for AML cell lines and in
patient-derived murine xenograft models of AML.
Results: The presence of a SE at the RARA gene locus was found to predict
anti-proliferative sensitivity to the potent, selective RARα agonist, SY-1425,
both in vitro and in vivo. SY-1425 is a clinical stage RARα agonist with greater
potency, selectivity, and improved PK over the pan-RAR agonist, ATRA. SY-
1425 is not susceptible to auto-induced metabolism and markedly inhibited
growth of RARA SE-selected patient-derived murine xenograft models in which
ATRA had no significant benefit. Normal bone marrow blast cells have low
levels of RARA enhancer activity. However, the formation of the SE at the RARA
gene locus drives RARα transcription in excess of endogenous ligand level,
favoring the unliganded, repressive state of the transcription factor that leads
to myeloid differentiation block. SY-1425 treatment of SE-containing AML cells
strongly induces activation of these formerly repressed genes, halting prolifer-
ation and promoting differentiation. To examine transcriptional response to SY-
1425, ChIP-seq for enhancer (H3K27ac) and RARα binding was paired with
mRNA profiling before and after treatment. Following treatment, loci with strong
RARα peaks showed increased acetylation and there was formation of new
enhancers where little acetylation was previously observed, consistent with
RARα serving as a repressor when unliganded and as a transcriptional activator
with SY-1425 bound. Moreover, the genes near the SY-1425-induced enhancers
are found to be strongly upregulated. This effect is exemplified by enhancer
and mRNA upregulation of TGM2, a canonical ATRA differentiation response
gene in APL. This mechanism is similar to PML-RARα differentiation blockade
and SY-1425-induced gene expression changes are very similar to those
observed with retinoid treatment of APL cells. In addition to AML, a sub-popu-
lation of MDS patient samples also contain elevated levels of RARA SE and
associated biomarker, suggesting the potential utility of SY-1425 in this closely
related disease. Furthermore, ChIP-seq analysis has established that SEs exist
in MDS which are comparable to those in RARA SE-driven AML.
Summary/Conclusions: In summary, our gene control platform has identified
novel subsets of non-APL AML and MDS patients who may respond to the
selective RARa agonist, SY-1425. Based on these findings, a phase 2 clinical
investigation of SY-1425 in AML and MDS patients, using an SE-derived bio-
marker to enrich for patients likely to respond, is planned for later this year.
Treatment in specific AML subgroups
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HIGHER DOSE DAUNORUBICIN APPEARS BENEFICIAL IN PATIENTS
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Background: The use of anthracycline and ara-C has been standard induction
therapy for Acute Myeloid Leukaemia for at least 30 years. Several trials have
compared 90mg/m2 of daunorubicin with 45mg/m2 and found benefit either
overall or in subgroups. In the NCRI AML17 trial we compared 90mg/m2 with
the more commonly used control arm of 60mg/m2 in the first course of
chemotherapy. Our preliminary findings showed no benefit for increasing the
dose of daunorubicin, with increased early mortality (Burnett et al, Blood
2015,125, 3878).However, follow-up was short at only 14.8 months, and there
was a suggestion of heterogeneity, with FLT3-ITD mutant patients potentially
benefitting. We present here an updated analysis with a median follow up of
28 months.
Aims: To establish whether high dose daunorubicin in induction therapy for
AML patients predominantly aged 18-60 years improved survival overall or in
any cytogenetic or genetic subgroup.
Methods: Between 09/2011 and 10/2013, 1206 patients were randomised in
1:1 to daunorubicin 90mg/m2 or 60mg/m2 (d1,3,5) in course 1, then 50mg/ m2
(d1,3,5) in course 2, with Ara-C 100mg/m2 12-hourly d1-10 (course 1) and d1-
8 (course 2). The median age was 53yrs (16-72); 54% were male; 84% had de
novo AML, 10% secondary, and 6% high risk MDS; median presenting WBC
was 8.5 (0.3-430); 10% had favourable cytogenetics; 72% intermediate and
18% adverse.
Results: Overall, 60-day mortality remained higher with DA90 (10% vs 5%,
p=0.002), and 3-year overall survival did not differ (50% vs 47%, p=0.7) sug-
gesting that no overall survival benefit has emerged for DA90. However, analy-
sis stratified by FLT3-ITD showed significant heterogeneity (p=0.02). In ITD
WT patients, DA90 did not improve outcome (51% vs 49%, p=0.3), but in ITD
mutant patients a survival significant benefit (54% vs 34%, p=0.03) has
emerged with longer follow up. 60-day mortality was not different (7% vs 6%,
p=0.8). Although numbers were small the benefit appeared greater with higher
allelic ratio (p=0.01 for trend). We did not observe a benefit related to age,
cytogenetic group, NPM1 mutation status, nor in patients with a FLT3 TKD
mutation.
Figure 1.
Summary/Conclusions: These results indicate a potential role for higher doses
of daunorubicin in patients with FLT3-ITD mutations. Such therapy could com-
plement the use of FLT3-inhibitors, but its delivery is dependent on early knowl-
edge of mutation status or possibly delivery of the escalated dose in the second
course of induction therapy.
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Background: Somatic mutations affecting isocitrate dehydrogenase 1 (IDH1)
or 2 (IDH2) genes are found in 15% to 20% of patients (pts) with acute myeloid
leukemia (AML). The incidence of these mutations increases with age, which
is mainly attributed to IDH2 mutations. The mutated enzymes emerge as prom-
ising therapeutic targets given their abnormal function to produce the
oncometabolite 2-hydroxyglutarate. First selective inhibitors of mutant IDH1
and IDH2 proteins are in early clinical development, however, it is currently
unknown how results from single-agent inhibitor therapy compare to those of
conventional salvage therapy.
Aims: The primary objective of this study was to assess the outcome of patients
with refractory or relapsed AML with IDH1/2 mutations.
Methods: A total of 2825 adults with AML [median age: 55 years (yrs), range
18-84 yrs] who entered eight prospective first-line AMLSG trials of intensive
conventional induction and consolidation therapy were included in the study.
Refractory disease (RD) was defined as failure to achieve complete remission
(CR) after two cycles of induction. Mutational status of IDH1 and IDH2 was
assessed at the time of initial diagnosis using a combination of denaturing-
high-performance liquid chromatography followed by direct DNA-sequencing.
Results: Overall, IDH1/2 mutations were identified in 530 (18.8%) of 2825 pts;
IDH1 mutations in 7.5% (212/2822) and IDH2 mutations in 11.5% (326/2825)
of pts; 8 pts had a mutation in both IDH1 and IDH2. All but one IDH1 mutation
involved codon R132. Among the IDH2 mutated cases, IDH2R140 and IDH2R172
mutations were detected in 246 (75%) and 75 (23%) pts, respectively; there
were 5 cases with IDH2 mutations involving other codons. In IDH1/2 mutated
AML the CR rate after induction therapy was 62% (327/530) (IDH1: 64%; IDH2:
61%). A total of 138 pts, including those who only received one induction cycle,
were refractory to the primary induction; among the pts receiving two induction
cycles 82 had RD (IDH1, n=31; IDH2, n=50; IDH1+IDH2, n=1). Two hundred
and eight IDH1/2 mutated pts relapsed (IDH1, n=112; IDH2, n=92; IDH1+IDH2,
n=4). Median overall survival (OS) in pts with RD (measured from the date of
RD) and relapse (RE; measured from the time of RE) was 1.03 yrs and 0.79
yr, respectively; in IDH1 mutated AML 0.53 yr and 0.63 yr, respectively, and in
IDH2 mutated AML 1.22 yrs and 1.09 yrs, respectively. The median OS in all
IDH1/2 mutated pts with RD/RE was 0.81 yr; pts with IDH2 mutations had a
longer (P=.003) survival, which was mainly attributed to the cases carrying
IDH2R172 mutations. Of the 82 pts with RD, 39 (48%) received allogeneic
hematopoietic-cell transplantation (alloHCT); the median survival time with allo-
HCT was 1.80 yrs compared to 0.53 yr in those who did not undergo alloHCT.
Of the 208 relapsed patients, 153 received intensive chemotherapy or alloHCT,
and 89 (58%) of the 153 pts subsequently achieved a CR/CRi. Seventy-four
relapsed pts received alloHCT. Median survival after relapse of pts receiving
alloHCT was 1.50 yrs compared to 0.63 yr in those not receiving an alloHCT.
Summary/Conclusions: IDH1/2 mutations represent a frequent (in this study
~19%) molecular alteration in AML. A substantial proportion of AML pts with
IDH1/2 mutations have RD or relapse. Median survival with conventional sal-
vage treatment in these pts was 0.81 yr, with IDH2 mutated pts and those
receiving alloHCT having significantly longer survival. Our results represent a
benchmark for clinical trials evaluating IDH inhibitors in this clinical setting.
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Background: Aberrant expression levels of mRNA and microRNA (miR) tran-
scripts have been shown to associate with clinical outcome of cytogenetically
normal acute myeloid leukemia (CN-AML) patients (pts). Recently, long non-
coding RNA (lncRNA) expression was found to be an independent prognostic
marker in older CN-AML pts (Garzon et al. PNAS 2014;111:18679-84). How-
ever, the prognostic value and biological implications of lncRNA expression in
younger CN-AML patients are unknown.
Aims: The aims were to determine whether lncRNA expression is associated
with clinical features, recurrent mutations and prognosis of younger CN-AML
patients, and to obtain biological insights into the function of lncRNAs in this
disease setting.
Methods: We performed whole transcriptome profiling (RNA-seq) in 377
younger (<60 years) de novo CN-AML adult pts and investigated the associa-
tions of lncRNA expression with recurrent, prognostically-relevant gene muta-
tions and clinical features. All patients were treated on frontline Alliance/Cancer
and Leukemia Group B (CALGB) protocols. Analysis of gene mutations was
performed using targeted amplicon sequencing (NPM1, DNMT3A, TET2, WT1,
FLT3-TKD, IDH2, IDH1, RUNX1 and ASXL1) and Sanger sequencing (FLT3-
ITD, double CEBPA). Small RNA sequencing was performed for miR profiling.
The 377 patients were randomly divided into a training set for exploratory analy-
ses (n=263) and a validation set (n=114).
Results: We derived gene mutation-related lncRNA signatures in the training
set and tested their accuracy in detecting the pts’ mutational status in the val-
idation set. Of the mutations tested, only double CEBPA mutations, NPM1
mutations and FLT3-ITD associated with distinct lncRNA signatures. These
signatures were able to predict mutated or wild-type gene status in the valida-
tion set with high accuracy (sensitivity and specificity >72% in all cases). Using
the training set, we identified 24 lncRNAs associated with event-free survival
(P<10-6). A small number of these lncRNAs associated with prognostic gene
mutations (1 with FLT3-ITD, 4 with double CEBPA mutations). Linear combi-
nation of the weighted expression values of the 24 lncRNAs yielded a prog-
nostic lncRNA score. Using the median value as a cut-off, the lncRNA score
divided the training set into two groups with very different prognoses; pts with
high lncRNA scores had shorter disease-free (DFS, P<.001) and overall sur-
vival (OS, P<.001) than pts with low lncRNA scores. In the validation set, pts
with high lncRNA scores were more likely to have higher white blood cell counts
(P=.009), FLT3-ITD (P=.007) and high miR-155 expression (P<.001) at diag-
nosis. There was no significant difference in complete remission rates between
pts with high and low lncRNA scores (84% v 89%). After a median follow-up of
6.2 years, pts with high lncRNA scores had shorter DFS (P<.001; 5-year DFS,
17% v 51%) and OS (P=.002; 5-year OS, 26% v 52%) than those with low
lncRNA scores. In multivariable analyses, the association of high lncRNA score
with shorter DFS (HR: 2.16, P=.01) and OS (HR: 1.75, P=.04) remained sig-
nificant after adjusting for other covariates. We also correlated the lncRNA
score with mRNA and miR expression and identified several oncogenes (FOSB,
JUN, ETS2, SRC, RET) and cell-cycle regulators (PLK2, PLK3), which were
highly expressed in pts with high lncRNA scores. Gene Ontology analysis
revealed enrichment for genes implicated in apoptosis, programmed cell death
and inflammation in the high lncRNA score pts. Similarly, miRs that associate
with aggressive malignant phenotype (e.g., miR-155, miR-500, miR-362) were
overexpressed in pts with high lncRNA scores.
Summary/Conclusions: We conclude that lncRNA profiling provides mean-
ingful prognostic information and identifies potentially targetable oncogenic
pathways in younger CN-AML adult pts.
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Background: Treatment options for AML in patients (pts) >60 years (y) include
intensive chemotherapy (IC) and/or azacitidine (AZA). Yet, AZA and IC need
not automatically be mutually exclusive. 
Aims: In the multicenter DRKS00004519 (RAS-AZIC) study of the East Ger-
man Study Group (OSHO), first-line treatment with AZA followed by AZA or IC
in pts >60 y with AML was evaluated. Data of a planned interim analysis per
protocol of the first 40 consecutive pts are presented. 
Methods: Patients >60 y with newly diagnosed AML and eligible for IC were
included irrespective of white blood count (WBC). In the phase I part of the
trial, safety of upfront AZA (75 mg/m2/day s.c.) for 7 days followed by IC (mitox-
antrone 10 mg/ m²/day on day (d) 1-3 and cytarabine 1g/ m²/BID on d 1, 3, 5,
7) on d 17 was established through a 3+3 design. In the multicenter phase II
part (figure), upfront AZA was sequentially followed by AZA or IC based on d
15 bone marrow (BM) blast count (<45 versus ≥45%) and CR, CRi on d 56 pre-
viously identified as early predictors for long-term response to AZA in AML (Al-
Ali et al., Leuk Lymph 2012). The primary endpoint was response (OR) [CR,
CRi, and PR] at d 90 according to the International Working Group criteria.
Safety, OS, and TRM were main secondary end points. On the basis of an opti-
mal two-stage design (Simon, Control Clin Trials 1989), an expected OR of
61% at the end of the trial was estimated. Thus, in an intention-to-treat analysis,
if ≤19 of the first 40 pts did not achieve the primary endpoint, protocol treatment
would be considered inferior to standard IC. The trial is supervised by an inde-
pendent Data Monitoring Committee. Adverse events (AEs) are reported
according to the NCI CTCAE 4.03. All pts gave written informed consent.
Results: The median age of the 40 pts was 70y (55% males). de novo AML
was present in 63% of pts. Median BM blasts and WBC were 39% and
6.7x109/L respectively. Cytogenetics was high- in 29% and intermediate-risk in
71% (normal cytogenetics 50%) of 38 pts. FLT3 and NPM1 were mutated in
11% and 17% of 36 pts respectively. All pts received the upfront AZA. 37 (92.5%)
pts received protocol assigned treatment based on BM blasts on d 15 (54%
continued with AZA; 46% received IC). Overall, in the 33 (82.5%) pts who con-
tinued therapy per protocol until d90, an OR was achieved in 27 (82%) pts
[CR/CRi (n=17/7); PR (n=3)]. In the intention-to-treat cohort (n=40), this repre-
sents an OR of 67.5% [CR/CRi (60%); PR (7.5%)] with AZA+one IC cycle
(n=28) or two IC cycles (n=3). TRM on d 30 and d 90 was 0% and 5% respec-
tively. After a median follow-up of 202 days, OS for the entire cohort was 84.5%.
OS for responding pts was 95.5%. Except for one patient, upfront AZA was not
complicated by leukocytosis even in pts with WBC >15x109/L and was generally
well tolerated. Constipation grade 1+2 was the most frequently reported AE
under AZA (45%). Overall, the most frequent grade 3+4 non-hematologic AE
was infection [11 times in 31 IC-cycles (35%); 7 times in 60 AZA-cycles (12%)].
Figure 1.
Summary/Conclusions: These data imply that sequential epigenetic therapy
and intensive chemotherapy in elderly pts with AML in an individualized
response-based approach is feasible with a very low treatment-related mortality
and yields responses that are at least comparable to those achieved after
repeated cycles of standard chemotherapy. The final results of this trial will
substantiate these data and scrutinize the impact of this approach on long-
term survival.
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RESULTS FROM ONGOING PHASE 2 REGISTRATION STUDY OF SL-401
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Background: SL-401 is a novel targeted therapy directed to the interleukin-3
receptor (IL-3R; CD123). IL-3R is overexpressed by many hematologic cancers,
including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid
leukemia (AML), myeloproliferative neoplasms (MPN) and multiple myeloma.
In a prior Phase 1/2 trial, SL-401 demonstrated clinical activity, including multiple
complete responses (CRs), in patients with BPDCN, a highly aggressive malig-
nancy of unmet medical need and poor prognosis. Building on this prior expe-
rience, we report herein updated efficacy and safety data from our ongoing SL-
401 registration trial in BPDCN.
Aims: This Phase 2 trial is a single-arm, open-label, two-stage study consisting
of a lead-in dose escalation (stage 1) and subsequent expansion stage (stage
2) designed to generate safety and efficacy data to support potential registration
in BPDCN.
Methods: In stage 1, pts with BPDCN or relapsed/refractory (r/r) AML received
SL-401 as a daily IV infusion for up to 5 days (7, 9, 12 or 16 µg/kg/day) every
21 days. In stage 2, pts with BPDCN receive SL-401 at the optimal stage 1
dose and schedule. Response criteria include assessment of skin by modified
severity weighted assessment tool (mSWAT), and bone marrow, lymph node
and viscera by standard measures. Clinical CR (CRc) is defined as no
detectable disease in bone marrow, lymph nodes or viscera with microscopic-
only skin disease.
Results: At data cut-off (1/20/16), 48 pts (18 BPDCN; 30 r/r AML) were treated
with SL-401. 18 BPDCN pts (9+9 in stages 1&2) received SL-401 (7 µg/kg,
n=3 [stage 1]; 12 µg/kg, n=15 [6+9 in stages 1&2]); median age 70 yrs (range
45-82 and 1 compassionate use pt age 15); data on 30 r/r AML pts (14+16 in
stages 1&2) to be reported separately. Most common treatment-related AEs
(all grades) are transient transaminase elevation (57%) and hypoalbuminemia
(40%). Transient thrombocytopenia was also noted (15%). Two stage 1 pts had
capillary leak syndrome (CLS): gr 5 (7 µg/kg) and gr 4 (12 µg/kg). Safety pre-
cautions were developed and successfully implemented to minimize risk of
severe CLS. Since adoption, severe CLS has not been observed at doses up
to 12 µg/kg. No cumulative side effects were observed over multiple cycles. In
stage 1, 12 µg/kg was the maximum tested and recommended stage 2 dose
for BPDCN and MTD in r/r AML; MTD was not reached in BPDCN. An 87%
(13/15) overall response rate (ORR) was observed in 15 evaluable BPDCN
pts, with marked disease reductions in skin, bone marrow, lymph node and vis-
cera. A 100% (10/10) ORR was observed in evaluable first-line BPDCN pts,
with 90% (9/10) of pts achieving CR (n=7) or CRc (n=2). A 100% (8/8) ORR
was observed in evaluable first-line BPDCN pts treated at the optimal dose (12
μg/kg), and all 8 pts achieved either CR (n=6) or CRc (n=2). 6 of the 8 pts
either remain on SL-401 in CR (n=4; duration ongoing at 3+ to 8+ cycles) or
were bridged to stem cell transplant (n=2; 1 CR, 1 CRc after 7, 4 cycles). 
Summary/Conclusions: SL-401 demonstrated robust single-agent activity in
BPDCN, including 100% ORR in first-line, and 87% in all-lines, with multiple
CRs; response duration data are maturing and encouraging. This trial
(NCT02113982) is designed to support registration in BPDCN and updated
data will be presented. SL-401 is also being developed in additional IL-3R/
CD123+ hematologic malignancies, including AML in CR with minimal residual
disease and high-risk MPN.
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Background: Ricolinostat (Rico, ACY-1215), an oral selective HDAC6
inhibitor, is well tolerated as monotherapy (Raje Blood 2012) and demon-
strates potent synergistic activity with lenalidomide (Len) and pomalidomide
(Pom) in preclinical models (Quayle Blood 2013). Pan-HDAC inhibitors vorino-
stat and panobinostat are active in MM in combo with bortezomib (Btz) and
Len, but toxicities limit dosing and treatment exposure, with resulting dimin-
ished efficacy. Rico selectively targets HDAC6 while retaining reduced and
tolerable levels of HDAC1, 2, 3 inhibition that down-regulates expression of
critical transcription factors regulating cancer cell proliferation, such as c-Myc
and IRF4.
Aims: This trial explored activity of Rico in combo with Pom and dexametha-
sone (Dex) in a population comparable to both the MM-002 and MM-003 trials
for Pom/Dex (Richardson Blood 2015; San Miguel Lancet Oncol 2013). At the
primary endpoint of PFS in MM-003, the ORR was 16.6% at 18.1 wks med
follow-up, and was 31% at 10 mos. In our trial, 7 pts were treated and no
DLTs were observed in Phase 1b (Raje Blood 2015), and Phase 2 results are
now presented.
Methods: Pts had measurable paraprotein, adequate BM reserve and hepatic
function with CrCl ≥45 mL/min. Refractory disease was defined as progression
on or within 60 days of last therapy (RRMM). Pts with non-secretory MM, prior
Pom or HDAC inhibitor therapy were excluded. Blood samples were obtained
for PK/PD assessment of acetylated tubulin and histones. A sample size of
66 was determined to be adequate to detect an ORR of 44% against a histor-
ical rate of 29%.
Results: Phase 2 opened at a dose of 160 mg BID, with a predetermined
SRC review to occur after 6 pts had completed 1 cycle of therapy. No DLTs
were observed with 160 mg BID dosing; however, diarrhea or fatigue leading
to dose reductions prompted SRC recommendation for QD dosing in ongoing
Phase 2 to maintain maximum therapeutic exposure. Enrollment was closed
in Nov 2015 after 96 pts were enrolled in Phase 2. Med age was 67 (39-87)
yrs and med number of prior regimens was 2 (2-7). 93% were refractory to
Len, 64% were refractory to Btz, and 49% were refractory to both Len and Btz
as defined in the entry criteria. Treatment was very well tolerated and common
toxicities were predominantly low grade and included neutropenia (44%),
fatigue (39%), anemia (30%), diarrhea (28%), thrombocytopenia (19%) and
upper respiratory tract infection (16%). Important related grade 3/4 toxicities
included neutropenia (22%), thrombocytopenia (7%), anemia (5%), diarrhea
(4%), and fatigue (3%). Serious related adverse events reported included
bradycardia (n=1), bronchitis (n=1), chronic cardiac failure (n=1), dehydration
(n=1), dyspnea (n=1), febrile neutropenia (n=1), general physical health dete-
rioration (n=1), hypoxia (n=1), pneumonia (n=2), renal failure (n=1), and throm-
bocytopenia (n=1). PK/PD relationship demonstrates selective inhibition of
HDAC6 (increasing acetylated tubulin) vs nonselective HDAC inhibition
(increasing acetylated histones) at therapeutic doses. There was no evidence
of Rico accumulation or drug-drug interaction with Pom. 84 efficacy evaluable
pts at 4 mos med follow-up demonstrated: PR or better (ORR) of 36%, MR or
better (clinical benefit rate, CBR) of 52%, SD or better (disease control rate,
DCR) of 89%, med PFS of 5.5 mos, and med DOR of 9 mos. Of these pts, 51
were enrolled at least 6 mos prior to the data cut, with a 5 mos med follow-up
and demonstrated an ORR of 47%, CBR of 63%, DCR of 90%, med PFS of
7 mos, and med DOR of 13 mos. This compares favorably to the MM-003 trial
of 16.6% ORR at time of primary PFS analysis (med follow-up of 18.1 wks)
and ORR of 31% (10 mos med follow-up), as well as similar data from MM -
002, with efficacy data continuing to mature.
Summary/Conclusions: These results establish proof of concept and demon-
strate that the addition of ricolinostat (a potent oral selective HDAC6 inhibitor)
to Pom/Dex is an active regimen in RRMM, leading to superior and durable
responses compared to the historical experience with Pom/Dex alone in
RRMM.
S814
PHASE 1 STUDY OF VENETOCLAX MONOTHERAPY FOR RELAPSED/
REFRACTORY MULTIPLE MYELOMA
S Kumar1,*, R Vij2, JL Kaufman3, J Mikhael4, T Facon5, B Pegourie6,
L Benboubker7, C Gasparetto8, M Amiot9, P Moreau9, S Diehl10, S Alzate10,
J Ross10, M Dunbar10, M Zhu10, S Agarwal10, J Leverson10, P Maciag10,
M Verdugo10, C Touzeau9
1Mayo Clinic, Rochester, 2Washington University School of Medicine, St. Louis,
3Winship Cancer institute of Emory University, Atlanta, 4Mayo Clinic Arizona,
Phoenix, United States, 5CHRU Lille, Hopital Huriez, Lille, 6CHU Grenoble, La
Tronche, 7CHRU Tours, Saint-Avertin, France, 8Duke University, Hematologic
Malignancies & Cellular Therapy, Durham, United States, 9CHU de Nantes,
Hotel Dieu-HME, Nantes, France, 10AbbVie, Inc., North Chicago, United States
Background: The anti-apoptotic protein BCL-2 has been implicated in the sur-
vival of multiple myeloma (MM) cells. Venetoclax (VEN) is an oral, highly selec-
tive BCL-2 inhibitor, which induces cell death in MM cell lines and primary sam-
ples, particularly those with t(11;14), and a high BCL-2 and low BCL-XL profile.
Aims: The objectives of the study are to evaluate safety, PK, recommended
phase two dose, and preliminary efficacy of VEN monotherapy in
relapsed/refractory (R/R) MM.
Methods: After 2-week dose-ramp-up, VEN was given daily at 300, 600, 900, or
1200 mg in dose escalation cohorts and 1200 mg in the safety expansion cohort.
Results: As of 9/17/15, 48 patients were enrolled: 30 in the dose escalation
and 18 in the safety expansion. Median age was 65 and 28 patients had ISS
stage II/III. Median (range) number of prior therapies was 5 (1–15), and 45
patients had prior bortezomib (32 refractory), 46 lenalidomide (37 refractory),
and 40 had SCT. 18 patients had t(11;14)-positive MM. Adverse events (AEs)
in ≥30% of patients were diarrhea (40%), nausea (40%), and thrombocytopenia
(31%). Grade 3/4 AEs in ≥10% were thrombocytopenia (29%), anemia and
neutropenia (17% each). SAEs in ≥2 patients were sepsis (n=3), cough, malig-
nant neoplasm progression, and pyrexia (2 each). Median (range) time on VEN
was 1.9 (0.2–13.8) months. 33 (69%) patients discontinued (DC): 26 related to
disease progression, 4 due to AEs (worsening shortness of breath,
hypokalemia, nausea, lung disorder), 2 withdrew consent, 1 due to death (brain
hemorrhage following injury). 5 deaths occurred (3 disease progression, 1 brain
hemorrhage, 1 lung disorder). 2 DLTs were seen at 600 mg (cohort was expand-
ed): epigastric pain,and nausea with abdominal pain. Steady state mean Cmax
and AUC24 were ~dose proportional at all doses except 900 mg (n=21). 43 of
48 patients were evaluable for efficacy (Table). In the patients with complete
responses, these were maintained for 9.7 (600 mg) and 9.0 months (900 mg,
ongoing). Very good partial responses were reported for 3 patients, all in the
1200 mg dose cohort.
Table 1.
*Patient has translocation of chromosome 14 with unknown partner
Summary/Conclusions: Venetoclax monotherapy has a tolerable safety profile
in R/R MM. Preliminary efficacy, including complete responses, and very good
partial responses, support venetoclax single agent activity in this population,
primarily in patients with MM harboring the t(11;14) chromosomal translocation.
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A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF ELOTUZUMAB
MONOTHERAPY IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE
MYELOMA
P Richardson1, E Wong2, K Stockerl-Goldstein3, C Rosenbaum4, M Dhodapkar5,
YM Jou6, M Lynch6, M Robbins6, E Bleickardt6, S Jagannath7,*
1Dana-Farber Cancer Institute, Boston, 2VA Connecticut Healthcare System,
West Haven, 3Washington University, St. Louis, 4University of Chicago Medi-
cine, Chicago, 5Yale University, New Haven, 6Bristol-Myers Squibb, Princeton,
7Mount Sinai Medical Center, New York, United States
Background: Smoldering multiple myeloma (SMM) is an asymptomatic pre-
cursor of active multiple myeloma (MM), with no approved therapies. Patients
(pts) with MM have compromised natural killer (NK) cell function; during early
disease, pts may have better immune activity. Elotuzumab is an IgG1 immunos-
timulatory antibody targeted against SLAMF7, a glycoprotein expressed by
myeloma and NK cells.1 Progression from SMM to MM, and association
between NK cell status and tumor burden, is incompletely understood. SMM
provides a disease setting to assess elotuzumab monotherapy in less immune
compromised pts.
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Aims: To explore the association between baseline (BL) CD56dim NK cells in
bone marrow and maximal change in serum M protein (measure of tumor bur-
den) in pts with high-risk SMM treated with elotuzumab. Efficacy and safety of
elotuzumab monotherapy were also assessed. 
Methods: Pts with high-risk SMM participated in this Ph 2, open-label study
(NCT01441973). High risk was defined as serum M protein ≥3 g/dL and bone
marrow plasma cells (BMPCs) ≥10% (criteria 1); serum M protein 1–3 g/dL,
BMPCs ≥10%, and an abnormal free light chain (FLC) ratio (<0.125 or >8.0)
(criteria 2); or urine M protein >200 mg/24 h, BMPC ≥10%, and an abnormal
FLC (≤0.125 or ≥8.0; criteria 3).2 Two high-risk cohorts, enrolled serially, were
examined to explore different dosing schedules: pts in cohort 1 (C1) received
elotuzumab 20 mg/kg IV in 28-day cycles (cycle 1: Days 1 and 8; cycle 2+:
once monthly); in cohort 2 (C2), pts received elotuzumab 10 mg/kg IV in 28-
day cycles (cycles 1 and 2: wkly; cycle 3+: twice monthly). Tumor response
was assessed every 4 wks. Pts received elotuzumab until disease progression
per modified International Myeloma Working Group (IMWG) criteria (including
progressive disease or progression to symptomatic active myeloma). Primary
endpoint was association between BL percent of bone marrow CD56dim NK
cells (CD45+/CD3-/CD56dim/CD16+) and maximal change in serum M protein.
Secondary endpoints were progression-free survival (PFS) and overall
response rate (ORR). Safety was an exploratory endpoint. Informed written
consent was obtained for all pts.
Results: 31 pts were treated (C1, n=15; C2, n=16). Across both cohorts, 32%
of pts met criteria 1 for high-risk SMM, 61% met criteria 2, 13% met criteria 3.
At data cut-off (January 26, 2016), 27% and 38% of pts from C1 and C2, respec-
tively, were still on treatment. Main reason for discontinuation was disease pro-
gression (C1, 47%; C2, 31%). A clear association between BL percent CD56dim
cells and maximal change in serum M protein (p=0.779) and between BL
CD56dim cells and response (≥minimal response; p=0.988) was not established.
PFS and ORR are reported (Table). AEs were reported in all pts in both cohorts.
No grade 5 AEs were reported. Most common AEs of any grade were upper
respiratory tract infection (C1, 53%; C2, 63%) and fatigue (C1, 47%; C2, 38%).
Infusion reactions were reported in 13% of pts; all grade 1–2. SAEs were report-
ed in 53% of pts in C1 and 44% in C2.
Table 1. Progression-free survival and overall response rate.
Summary/Conclusions: An association between BL percent CD56dim NK cells
in bone marrow and changes in serum M protein with elotuzumab treatment
was not established. Elotuzumab monotherapy may delay SMM progression
to MM, as most pts achieved a best overall response of SD or MR, with ≥MR
in 29% of pts, including PR in 10%, and favorable PFS. Treatment was generally
well tolerated; the AE profile was consistent with prior elotuzumab experience.
Funding: BMS. Medical writing: S Addison, Caudex, funded by BMS.
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DELETION OF CDKN2C DRIVES THE PROGNOSTIC IMPACT OF DELETION
1P IN MULTIPLE MYELOMA
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Background: Survival in multiple myeloma is highly variable and predicting
high risk behaviour is key for implementation of risk-adapted therapies. Ulti-
mately, drivers of high risk myeloma need to be identified and directly targeted
to turn risk markers into predictive markers for precision medicine.
Aims: To identify the prognostic impact of different genetic lesions affecting
chromosome 1p.
Methods: CD138 immunomagnetically selected bone marrow tumour material
of 1,036 newly diagnosed myeloma patients enrolled in the NCRI Myeloma XI
trial were studied. The trial investigated CTD vs CRD induction therapy as well
as lenalidomide maintenance vs no maintenance and enrolled both young and
fit patients who received intensive chemotherapy (n=598 in this analysis), as
well as elderly and less fit patients (n=438) who were treated on the non-inten-
sive arm. Cases were molecularly profiled using a combination of MLPA and
qRT-PCR (Boyle EM, et al. Gen Chrom Canc 2015; Kaiser MF, et al. Leukemia
2014). These high-throughput methods run on standard molecular biology
equipment and allow for robust parallel assessment of multiple genetic lesions
in one molecular reaction, including different lesions at chromosome 1p.
Results: Of the 1,036 patients, 10% carried deletion of CDKN2C at 1p32, 18%
deletion DPYP (1p21.3), 15% deletion COL11A1 (1p21.1) and 25% deletion
FAM46C (1p12), consistent with previous reports. In 7% CDKN2C and
COL11A1 co-occurred and also in 7% CDKN2C and FAM46C co-segregated.
In 8% of COL11A1 and 18% of FAM46C deleted cases CDKN2C copy number
was normal. Only CDKN2C was affected by recurrent homozygous deletions,
which was seen in 2% of cases. Deletion of CDKN2C (1p32) was associated
with inferior outcome in the 598 intensively treated, younger patients with medi-
an progression free survival (PFS) of 21.8 vs 33.8 months (P=0.028) and 24-
months median overall survival (OS) of 80% vs 88% (P=0.003). Deletion of
CDKN2C was not associated with shorter survival in the elderly group of
patients. Deletions of DPYP, COL11A1 and FAM46C were not associated with
shorter PFS in the intensively treated group. Deletion of COL11A1 was asso-
ciated with inferior OS (P=0.02). However, this was dependent on co-occur-
rence of deletion CDKN2C and was not significant when looking at cases with
isolated COL11A1 deletion (P=0.6). No significant impact of deletion FAM46C
on outcome was observed. 
Summary/Conclusions: Deletion of chromosome 1p is an established risk
factor in intensively treated patients. Our analysis suggests that CDKN2C at
1p32, rather than DPYP (1p21.3), COL11A1 (1p21.1) or FAM46C (1q12) is the
relevant gene conferring poor prognosis. This has important implications for
the potential development of therapeutic strategies for del(1p) myeloma.
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CARDIAC UPTAKE IN AL AMYLOIDOSIS OF 99MTC-DPD AS A NOVEL
MARKER OF POOR PROGNOSIS IN SYSTEMIC AL AMYLOIDOSIS
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Background: The prognosis and outcomes in systemic AL amyloidosis are
determined by cardiac involvement. The standard method for assessing degree
of cardiac impairment in AL amyloidosis has relied on cardiac biomarkers like
NT-proBNP and cardiac troponin-T. However, these markers are not specific
for cardiac amyloidosis and other factors like renal failure or fluid overload may
affect the levels and limit their utility in determining the prognosis. Thus far, no
imaging modality has accurately predicted outcomes in AL amyloidosis. In
recent years, the role of bone scintigraphy tracers like technetium-99m-labelled
3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) has been evalu-
ated. They are very sensitive in non-AL amyloidosis. The utility of 99mTc-DPD
scintigraphy in AL amyloidosis has not been studied.
Aims: We report here in a series of 189 patients in which cardiac uptake using
99mTc-DPD scintigraphy is a marker of very poor outcome in AL amyloidosis.
Methods: All patients who underwent 99mTc-DPD scintigraphy with a confirmed
diagnosis of AL amyloidosis were identified from the database of the UK Nation-
al Amyloidosis Centre. 189 patients with systemic AL cardiac amyloidosis had
99mTc-DPD scans at diagnosis from June 2010-November 2015. All patients
also had a full protocolized amyloid assessment including cardiac biomarkers,
haematology, biochemistry, echocardiography and SAP scintigraphy. All
patients are followed up every 3-6 months for prospective protocolized follow
up. The characteristics of patients with a positive scan were compared with
those patients in whom the scan did not show cardiac uptake. The survival out-
comes were assessed by the method of Kaplan and Meier. Cox regression
was used to determine univariate and multivariate variables impacting survival.
Results: A total of 189 patients were identified. 114 (60%) had no cardiac
uptake on 99mTc-DPD scans (DPD-negative) and 75 (40%) had cardiac uptake
on 99mTc-DPD scans (DPD-positive); 57 (76%) had grade 1 cardiac uptake, 13
(17%) had grade 2 and 5 (7%) grade 3. There was no significant difference
between the DPD-positives and DPD-negatives in terms of NYHA class I/II ver-
sus III/IV (64% and 36% in the DPD-positives vs 67% and 33% in the DPD-
negatives, p=0.75); Mayo staging 1/2 vs 3 (17% and 83% vs 25% and 75%,
p=0.20); supine systolic blood pressure (112 vs 116, p=0.26). The echocardio-
graphic parameters were also similar in the positive and negative groups: LVEF
(50% vs 55%, p=0.1); mean LV wall (15mm vs 15mm, p=0.39); e/e’ (18 vs 17,
p=0.58). Organ involvement did not show a significant difference between the
DPD-positives and DPD-negatives (renal: 52% vs 48%, p=0.66; autonomic
nervous system: 20% vs 14%, p=0.32). The serum free light chains showed no
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significant difference (median dFLC 343mg/L vs 316mg/L, p=0.40). However,
the cardiac biomarkers were significantly greater in the DPD-positives com-
pared to the DPD-negatives: N-terminal fragment of brain natriuretic peptide
(NT-proBNP) (8296 ng/L vs 4411 ng/L, p=0.005) and high sensitivity troponin
(hsTNT) (113 ug/L vs 83 ug/L, p=0.001). The overall median survival of the
whole cohort was 7 months (95% CI 3 to 11 months). In the DPD-positive group
the median survival was 4.3 months compared to 11.8 months in those with
cardiac involvement by conventional criteria but DPD-negative (p=0.045). On
univariate analysis factors impacting survival were: cardiac involvement, Mayo
disease stage, presenting dFLC levels, NT-proBNP, hsTNT and cardiac uptake
on 99mTc-DPD scintigraphy. Multivariate models will be presented.
Summary/Conclusions: 99mTc-DPD scintigraphy is a useful imaging modality
in cardiac AL amyloidosis showing cardiac uptake in 40% of patients with car-
diac involvement by conventional criteria. Patients with positive scans for car-
diac uptake have significantly higher NT-proBNP and hsTNT compared to those
with negative scans. Cardiac uptake on 99mTc-DPD scan is associated with
very poor outcomes. We believe that uptake on a 99mTc-DPD scan shows
advanced cardiac disease independent of all other markers of cardiac involve-
ment in AL amyloidosis. These findings suggest that 99mTc-DPD scintigraphy
should be considered as a simple baseline prognostic investigation in all
patients with cardiac AL amyloidosis.
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PRETRANSPLANT ANTI-CCR4 ANTIBODY AGAINST ADULT T CELL
LEUKEMIA/LYMPHOMA WAS ASSOCIATED WITH SIGNIFICANTLY
INCREASED RISKS OF SEVERE/STEROID-REFRACTORY GVHD,
NON-RELAPSE MORTALITY AND OVERALL MORTALITY
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Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is one important treatment option for patients with aggressive adult T cell
leukemia/lymphoma (ATLL). Mogamulizumab (anti-CCR4 monoclonal antibody;
Mog) was recently approved as a treatment for ATLL. There are major concerns
regarding the possible adverse effects of pretransplant Mog, as Mog depletes
regulatory T cells (Tregs) for several months. 
Aims: Here, we aimed to assess the impact of pretransplant Mog on the clinical
outcomes after allo-HSCT.
Methods: We included 996 allo-HSCT recipients aged 70 years old or younger
with aggressive ATLL who were diagnosed between 2000 to 2013, and received
intensive chemotherapy using multiple chemotherapeutic drugs as first-line
therapy. Before allo-HSCT, 82 patients received Mog with a median interval 45
days from the last Mog to allo-HSCT.
Results: Pretransplant Mog was associated with an increased risk of grade
III-IV acute GVHD (30.9% vs 17.2%, P<0.01) and refractoriness to systemic
steroid for acute GVHD (48.9% vs 23.5%, P<0.01). The cumulative incidence
of 1-year non-relapse mortality was significantly higher in patients with pre-
transplant Mog compared to those without Mog (43.7% vs 25.1%, P<0.01).
The probability of 1-year overall survival was also significantly inferior in patients
with pretransplant Mog compared to those without Mog (49.4% vs 32.3%,
P<0.01). In particular, use of Mog with intervals<50 days to allo-HSCT was
associated with a dismal clinical outcome.
Summary/Conclusions: Our study clearly showed that pretransplant Mog sig-
nificantly worsened the clinical outcome, which strongly supports the important
relevance of Tregs in allo-HSCT in humans as in animal models. In clinical
practice, Mog should be cautiously used for patients with ATLL who are eligible
for allo-HSCT.
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REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR ADULT DE NOVO ACUTE
LYMPHOBLASTIC LEUKEMIA: A PROSPECTIVE STUDY FROM THE
UKALL14 TRIAL (ISRCTN 66541317)
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Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT)
is a potentially curable treatment modality for adults with acute lymphoblastic
leukaemia (ALL) with significant improvement in overall survival (OS) and
reduction in relapse incidence. However, in the donor versus no donor analysis
of the UKALL12/E2993 trial in adult ALL, the OS benefit did not extend to older
patients in whom myeloablative allogeneic hematopoietic cell transplant related
mortality (TRM) was 35% at 2 years and outweighed the reduction in relapse
risk. To address this elevated TRM, reduced intensity conditioning (RIC) has
been introduced. In our current UK National Cancer Research Institute
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UKALL14 study all patients ≥41 years in CR, regardless of Philadelphia (Ph+)
status and other high risk factors, are considered “high risk” and recommended
a RIC alloHSCT with a matched sibling (sib) or matched unrelated donor (MUD)
after a 2 course induction and high dose methotrexate.
Aims: The primary endpoint is event free survival (EFS). We report here the
early outcome of 120 patients with at least day 100 follow up (FU) who received
RIC alloHSCT on UKALL14 trial.
Methods: Standard reduced intensity conditioning was with fludarabine
30mg/m2 d -6 to -2, melphalan 140 mg/m2 d -2 and alemtuzumab 30mg d -2 to-
1 (MUD) or d-1 (sib). Graft versus host disease (GVHD) prophylaxis was
ciclosporin A only. A small group of patients did not receive the standard condi-
tioning protocol. Multilineage chimerism (MC) and minimal residual disease
(MRD) were assessed 3 monthly post alloHSCT. Escalating doses of donor lym-
phocyte infusions (DLI) were given for T-cell mixed chimerism or MRD, starting
dose 1 x 106 CD3 cells/kg, escalating by half log increments every 3 months.
Results: Five hundred and ninety seven patients were registered on the trial
to date, 173 were registered for a RIC alloHSCT, 122 have completed the trans-
plant, 120 of whom have sufficient follow up to report. Median age was 51 years
(range 29 to 64). Donor was sib in 39 and MUD in 81 patients, respectively.
Median WBC at diagnosis was 8.7 x 109/L (0.6-557.23). 57 of 106 (54%) evalu-
able patients had high-risk cytogenetics, 31 (26%) were Ph+. 18 of 74 (24%)
with MRD data were MRD +ve pre-alloHSCT. Post-alloHSCT, myeloid engraft-
ment occurred in 111 patients at a median of 14 days, 9 had missing data. No
graft failures were reported. Acute graft versus host disease (GVHD) occurred
at grade 1 in 34 patients (28%) and grade 2-3 in 12 patients (10%). 47 patients
developed chronic GVHD (40% of 117 patients surviving beyond D100), 20
limited and 27 extensive. Of 15 patients who suffered transplant-related mor-
tality (TRM), 8 died of infection (one post-transplant lymphoproliferative dis-
ease). Other causes of TRM included organ toxicity (2) and GVHD (2). TRM
was not associated with age or donor type. 27 patients relapsed at a median
time of 230 days (range 97-1034) with a relapse risk of 27.5% (18.9-38.1) at
22 months post alloHSCT. Of those, 16 (of 25 with data) had high-risk cytoge-
netics (EFS, p=0.11) and 10 (of 19 with data) were MRD +ve pre-alloHSCT
(EFS, HR 2.41, p=0.025). 37 patients in total received 84 DLI (median maximum
dose 1 x 106 CD3 cells/kg) including 20 for mixed chimerism, 6 for rising MRD
and 9 for both. 5 patients (14%) developed post-DLI GVHD at grade 1 (n=4)
and grade 2 (n=1). Serial MC data is available for 43 patients. By 6 months
post transplant, 34 out of 43 patients (79%) achieved full donor total peripheral
blood chimerism whereas only 15 (35%) achieved full donor chimerism in the
T-cell compartment. With longer follow up, 26 patients (60%) achieved full donor
T-Cell chimerism (median 9 months), 10 after receiving DLI (38%). Figure 1
shows Kaplan Meier curves of OS 66.3% (55.0-75.5, 95% CI) and EFS 59.4%
(48.6-68.7) at 22 months (median follow-up).
Figure 1.
Summary/Conclusions: This is early follow up from the first prospective data of
RIC alloHSCT in older adults with ALL from a large, multicenter trial and the early
results are promising. Severe GVHD and TRM were relatively low leading to a
higher EFS than expected for this age group, however, longer follow up is needed.
T-cell mixed chimerism was common at first MC assessment but early data indicate
that conversion to full donor chimerism is achievable and safe with DLI. The impact
of mixed chimerism and pre-emptive DLI on relapse remain to be evaluated.
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HIGH EXPRESSION OF THE STEM CELL MARKER GPR56 IS ASSOCIATED
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Background: In acute myeloid leukemia (AML) leukemia initiating cells (LICs)
are believed to exist within the CD34+/CD38- cell compartment. Recently, the
G protein-coupled receptor 56 (GPR56) was shown to define a novel LIC com-
partment independent of the CD34+/CD38- phenotype. LICs are assumed to
be responsible for AML maintenance & relapse & may be less immunogenic
than AML bulk cells. Hematopoietic stem cell transplantation (HSCT) is a con-
solidating approach mainly based on immunological graft-versus-leukemia
(GvL) effects & its therapeutic success is associated with the elimination of
AML LICs by GvL effects.
Aims: To evaluate the clinical relevance of aberrant GPR56 expression in the con-
text of the CD34+/CD38- burden at diagnosis in AML patients (pts) receiving HSCT.
Methods: We analyzed 148 AML pts (median age 61, range 14-75 years [y])
for whom diagnostic bone marrow aspirate material was available & who
received a non-myeloablative (3x30mg Fludarabine+2Gy total body irradiation
[TBI]) or myeloablative (2x60mg Cyclophosphamide+12Gy TBI) HSCT in 1st
(69%) or 2nd (19%) complete remission (CR) or in CR with incomplete periph-
eral recovery (12%). At diagnosis, the mutation (mut) status of CEBPA, NPM1,
presence of FLT3-ITD & expression levels of BAALC & EVI1 were evaluated.
For 68 pts RUNX1mut status was available. The CD34+/CD38- burden & com-
mon surface markers expressions were determined by flow cytometry. A 5%
cut-off defined pts with a high & low CD34+/CD38- burden. GPR56 was meas-
ured by qRT-PCR, normalized to ABL1 & the median normalized gene expres-
sion was used to define high & low expressers. Median follow up was 4.9y.
Results: European LeukemiaNet (ELN) classification was 24% favorable, 24%
intermediate-I, 17% intermediate-II, 28% adverse & 7% unknown. At diagnosis
high GPR56 expressers had lower white blood cell counts (P=.04), were less
likely to have de novo AML (P=.02), core-binding factor AML (P=.01), to be
NPM1mut (P=.02) & were more likely to have a del7 (P=.004), to be RUNX1mut
(P=.09) by trend, to be EVI1 positive (P=.04) & to have higher BAALC (P<.001)
expression. BM blasts in the high GPR56 group were less likely to be positive
for myeloid markers (CD33, P=.009; CD38, P=.04; CD64, P=.04; CD15,
P=.002; CD65, P=.001) & the pan-leukocyte marker CD45 (P=.03) & more
likely to be positive for T-cell (CD7, P=.03; by trend CD2, P=.1), thrombocytic
& erythroid (CD61, P=.005; Glykophorin A, P=.003) & immature (by trend CD34,
P=.07) markers. High GPR56 expression was associated with high
CD34+/CD38- cell burden at diagnosis (P=.002) & with a higher cumulative
incidence of relapse (CIR, P=.04, Figure 1A) in AML pts receiving HSCT. Since
GPR56 defined a novel LIC compartment independent of the CD34+/CD38-
phenotype, we analyzed the impact of aberrant GPR56 expression in the low
CD34+/CD38- burden pts. Similar clinical, cytogenetic & molecular associations
were observed as in the entire set of pts. In the low CD34+/CD38- burden
group, high GPR56 expression identified a group of AML pts with a higher CIR
as compared to pts with low GPR56 expression (P=.05, Figure 1B).
Figure 1.
Summary/Conclusions: High GPR56 expression was associated with a higher
relapse rate & worse outcome predictors. Among pts with low CD34+/CD38-
burden high GPR56 expression defined a subgroup with higher CIR after HSCT
possibly due to an independent GPR56-defined LIC population. HSCT-associ-
ated therapeutic GvL effects might be insufficient to control the disease in pts
with high LIC burden defined by the CD34+/CD38-phenotype & GPR56 expres-
sion status at diagnosis.
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Background: The feasibility of cord blood transplantation (CBT) in adults is
limited by the relatively low number of hematopoietic stem/progenitor cells con-
tained in one single CB unit. The infusion of two CB units from different partially
HLA-matched donors (double CBT) is frequently performed in patients who
lack a sufficiently rich single CB unit. In patients given CBT following myeloab-
lative conditioning, previous studies have demonstrated that, although double
CBT extended the use of CBT for patients lacking a single unit with adequate
cells (>2.5 x 107 total nucleated cells (TNC)/kg), it failed to improve engraftment
and outcomes.
Aims: Here we investigated whether these observations remained true in the
setting of reduced-intensity conditioning (RIC) CBT.
Methods: Inclusion criteria included adult (>18 yrs) patients, acute myeloid
leukemia (AML) or acute lymphoblastic leukemia (ALL), complete remission
(CR) at the time of transplantation, first single (with a cryopreserved TNC >2.5
x 10E7/kg) or double CBT between 2004 and 2014, and RIC conditioning.
Results: Data from 534 patients with AML (n=408) or ALL (n=126) receiving a
first single (n=172) or double (n=362) CBT were included in the analyses. In
comparison to patients transplanted with a single CB, double CB recipients
had a shorter follow-up (34 vs 54 months, P=0.0005), were more frequently
male (56 vs 41%, P=0.002), received more frequently a conditioning combining
TBI, cyclophosphamide and Flu (TCF regimen, 83 vs 66%, P<0.001), and
received less frequently ATG (16% vs 37%, P<0.001). In univariate analysis,
in comparison to patients transplanted with a single CB, double CB recipients
had a suggestion for a higher incidence of grade II-IV acute GVHD (36 vs 28%,
P=0.08) but a similar incidence of neutrophil engraftment (83 vs 77%, P=0.3).
Further, at 3-year, in comparison to single CB recipients, double CB recipients
had a similar incidence of chronic GVHD (36 vs 28%, P= 0.17), a similar inci-
dence of relapse (32 vs 35%, P=0.4), a similar incidence of nonrelapse mortality
(22 vs 29%, P=0.17) but a better OS (51 vs 41%, P=0.03) and LFS (46 vs
36%, P=0.06) (Figure 1). In multivariate analyses OS (HR=0.8, 95% CI 0.7-
1.1, P=0.20) and LFS (HR=0.8, 95% CI 0.6-1.1, P=0.17) were no longer sig-
nificantly better in double CB than in single CB recipients, although there
remained a trend in that direction.
Figure 1. Unadjusted CBT outcomes in patients transplanted following
RIC with a single or a double CB.
Summary/Conclusions: These data suggest that LFS and OS are not different
for double than single UCB with an adequate TNC dose in the RIC setting. These
observations should serve as basis for future prospective randomized studies.
S822
DONOR AND RECIPIENT TOLL-LIKE RECEPTOR 1 VARIATIONS COMPARABLY
PREDICT TRANSPLANT-RELATED MORTALITY AFTER UNRELATED BONE
MARROW TRANSPLANTATION
K Uchino1,*, S Mizuno1, M Mizutani1, T Horio1, I Hanamura1, JL Espinoza2,
K Matsuo3, M Onizuka4, K Kashiwase5, Y Morishima6, T Fukuda7, Y Kodera8,
N Doki9, N Doki9, K Miyamura10, T Mori11, A Takami1
1Division of Hematology, Department of Internal Medicine, Aichi Medical Uni-
versity School of Medicine, Nagakute, 2Cellular Transplantation Biology,
Kanazawa University Graduate School of Medical Science, Kanazawa, 3Divi-
sion of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya,
4Department of Hematology and Oncology, Tokai University School of Medi-
cine, Isehara, 5Japanese Red Cross Kanto-Koshinetsu Block Blood Cente,
Tokyo, 6Division of Epidemiology and Prevention, Aichi Cancer Center
Research Institute, Aichi, 7Hematopoietic Stem Cell Transplantation Unit,
National Cancer Center Hospital, Tokyo, 8epartment of Promotion for Blood
and Marrow Transplantation, Aichi Medical University, Nagakute, 9Hematology
Division, Tokyo Metropolitan Cancer and Infectious Diseases Center
Komagome Hospital, Tokyo, 10Department of Hematology, Japanese Red
Cross Nagoya First Hospital, Nagoya, 11Division of Hematology, Department
of Medicine, Keio University School of Medicine, Tokyo, Japan
Background: Toll-like receptor 1 (TLR1), the most ubiquitous among the TLR
family, plays an essential role in the innate immunity system through initiating
the production of inflammatory cytokines. Its genetic variant (rs5743551, -7202
A>G), which resides in the promoter region, has been reported to be associated
with susceptibility to various infectious diseases and the mortality and morbidity.
Aims: To investigate the impact of TLR1 variation on transplant outcomes of
bone marrow transplantation (BMT).
Methods: TLR1 genotyping was performed on 333 patients who underwent
unrelated HLA-matched BMT for hematologic malignancies through the Japan
Marrow Donor Program between May 2006 and April 2009 and their donors,
and its association with the transplant outcomes was retrospectively examined.
Results: The genotype frequencies of A/A, A/G, and G/G were 10%, 39% and
50% in the recipients and 11%, 36% and 51% in the donors (P=0.82), respec-
tively. The A/A genotype vs A/G or G/G genotype both in the donors (37% vs.
18%, respectively; P=0.0042) and the recipients (39% vs 17%, respectively;
P=0.021) was associated with a significantly higher 3-year transplant-related
mortality (TRM). The A/A genotype in the donors (hazard ratio [HR], 3.4; 95%
confidence interval [CI], 1.6-7.2; P=0.0017) and the recipients (HR, 2.6; 95%
CI, 1.3-5.4; P=0.0093 ) remained statistically significant in the multivariate analy-
sis for 3-year TRM.
Figure 1.
Summary/Conclusions: These results suggest an association of the donor
and recipient TLR1 A/A genotype with increased TRM after unrelated BMT. An
analysis of the TLR1 genotype could therefore be useful for selecting the donor,
managing patients in a risk-adapted manner, and creating therapeutic strate-
gies to prevent TRM after hematopoietic stem cell transplantation.
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PLATELET PROPERTIES IN A PATIENT WITH STORMORKEN SYNDROME
(STIM1 MUTATION) - ADHESION RECEPTOR LEVELS, CALCIUM HOMEOSTASIS
AND PHOSPHATIDYLSERINE EXPOSURE
KD Cummins1,*, EE Gardiner2, J McFadyen1,2, RK Andrews2, J Jing2,
P McCarthy3, MM Ryan4, CA McLean5, SM Jane1,2
1Department of Haematology, The Alfred Hospital, 2The Australian Centre for
Blood Diseases, Monash University, 3The Ronald Sawyers Haemophilia Centre,
The Alfred Hospital, 4Department of Neurology and Murdoch Children’s
Research Institute, Royal Children’s Hospital, 5Anatomical Pathology, The
Alfred Hospital, Melbourne, Australia
Background: Stormorken syndrome is a rare monogenic disorder, recently
attributed to a gain-of-function mutation of the stromal interaction molecule 1
(STIM1) gene, which is involved in calcium homeostasis. While this syndrome
is associated with macrothrombocytopenia and a bleeding phenotype of vari-
able severity, the pathophysiology underlying the platelet abnormalities is not
fully described.
Aims: Evaluate parameters in platelets from a patient with Stormorken syn-
drome and assess the value of platelet flow cytometry in aiding differential diag-
nosis of Stormorken syndrome in patients with bleeding not fully explained by
macrothrombocytopenia.
Methods: The presence of a p.R304W mutation in STIM1 exon 7 was con-
firmed after a Stormorken syndrome-like phenotype was recognised in a 21-
year old male with long-standing thrombocytopenia, hyposplenism, pupillary
miosis and tubular aggregate myopathy. Citrated blood was analysed by flow
cytometry for platelet adhesion receptor levels, intracellular calcium levels (both
at rest and flux in response to agonists, using Fluo-3-AM), microparticles and
platelet phosphatidylserine (PS) exposure (annexin-V binding). Testing on two
occasions compared samples from the patient, his unaffected mother, and
healthy donors. 
Results: Flow cytometry of platelet-rich plasma from the patient confirmed the
morphological finding of macrothrombocytopenia, with altered forward and side
scatter properties, and also increased numbers of CD41-positive microparticles.
In comparison with the control samples, levels of metalloproteinase-sensitive
adhesion receptors GPVI and GPIbα were present at the lowest end of normal
ranges. The ratio of GPIbα:CD41 was significantly reduced, indicating that
GPIbα receptor density was independent of mean platelet volume. Levels of
sGPVI were within the normal range suggesting that aberrant metallopro-
teinase-mediated shedding was not responsible for reduction in GPVI levels.
Resting intracellular calcium levels were elevated ~5-fold, and calcium flux in
response to ionophore was significantly enhanced. Resting platelet PS expo-
sure was at the upper end of the normal range. 
Table 1.
Summary/Conclusions: Using flow cytometry, platelets from a patient with a
confirmed gain-of-function mutation of STIM1 demonstrated altered physical
properties, reduced adhesion receptor levels, enhanced PS exposure, signifi-
cantly increased intracellular calcium at rest and an exaggerated calcium flux
response to platelet agonists. Blood samples contained elevated levels of
platelet-derived microparticles. Flow cytometric analyses of Stormorken syn-
drome platelets demonstrate reproducible abnormalities, which begin to inform
the structural and functional differences in platelets that may contribute to the
bleeding phenotype of this rare monogenic disorder, in particular with regards
to surface receptor expression and calcium homeostasis.
S824
IMPAIRED FUNCTION OF MESENCHYMAL STEM CELLS FROM IMMUNE
THROMBOCYTOPENIA PATIENTS IN INDUCING REGULATORY DENDRITIC
CELL DIFFERENTIATION VIA NOTCH2/JAGGED-1 SIGNALLING PATHWAY
LL Xu, JM Zhang, QM Wang, Y Kong, YJ Chang, XS Zhao, XY Zhao, M Lv,
LP Xu, KY Liu, XJ Huang, XH Zhang*
Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Immune thrombocytopenia(ITP) is characterized by platelet
destruction and megakaryocyte dysfunction due to the breakdown of self-tol-
erance. Mesenchymal stem cells(MSCs) play a pivotal role in immune toler-
ance. Bone marrow MSCs(BMMSCs) residing in bone marrow stroma
(BMS)have been shown to induce regulatory dendritic cell(regDC) differentiation
from CD34+ haematopoietic progenitor cells (HPCs). MSCs from ITP patients
(ITP-MSCs) exhibit increased senescence and apoptosis, but whether ITP-
MSCs have an impaired ability to instruct regDCs remains unknown. Notch is
a major factor mediating the interaction between HPCs and BMS.BMS has
been reported to prevent the terminal differentiation of DCs through the Notch
ligand Jagged-1. Moreover, Jagged-1 has been shown to be involved in the
immunosuppressive effects of MSCs on T cells and DCs. It has shown that
Notch signalling is important for the modulation of MSCs.
Aims: To investigate whether ITP-MSCs displayed impaired function in inducing
regulatory dendritic cell differentiation via notch2/jagged-1 signalling pathway.
Methods: CD34+HPCs were differentiated in the absence or presence of ITP-
MSCs or control-MSCs, and then immature DCs were harvested and induced to
mature with LPS in the absence of MSCs. MGG staining, flow cytometry and
ELISA were performed to characterize the DCs. Mature DCs were then cocultured
with CD4+T cells, and proliferation, differentiation, and the anergic and regulatory
features of T cells were assessed by flow cytometry. The differential expression
of notch receptors, notch intracellular domain(NICD),hes-1, and Jagged-1, was
assessed by RT-PCR, flow cytometry and western blot analysis.NICD2-express-
ing lentivirus,Notch2-targeting shRNA lentivirus, exogenous Jagged-1, and anti-
Jagged-1 Ab were used to analyse the underlying mechanism(s).
Results: ITP-MSCs showed impaired function in inhibiting morphological and
phenotypic development, proliferation, interleukin-12(IL-12) secretion, and in
enhancing endocytosis and interleukin-10(IL-10) production of DCs. DCs that
were differentiated in the presence of ITP-MSCs(ITP-MSC-DCs) exhibited a
dramatically impaired ability to inhibit allogeneic CD4+ T cell proliferation and
to change Th2 polarization. The ITP-MSC-DCs had a deficient capacity to
induce anergic and regulatory T cells. Jagged-1 expression and Notch2 sig-
nalling pathway activation were down-regulated in ITP-MSCs. The application
of exogenous Jagged-1 and anti-Jagged-1 Ab revealed an involvement of
Jagged-1 in the development of regDCs. And NICD2 overexpression of ITP-
MSCs displayed elevated Jagged-1 expression and an enhanced ability to
induce regDCs, which was suppressed after treatment with anti-Jagged-1 Ab.
The attenuated function of control-MSCs following Notch2 knockdown was
reversed by exogenous Jagged-1. Thus, the Notch2 signalling pathway may
modulate regDC differentiation in a Jagged-1-dependent manner. Following
pre-treatment with aspirin, both ITP-MSCs and control-MSCs exhibited an up-
regulation of the Notch2/Jagged-1 signalling pathway and an enhanced ability
to induce regDCs.
Summary/Conclusions: ITP-MSCs show defects in the induction of regDC
development, which may play a role in the pathogenesis of ITP. The
Notch2/Jagged-1 signalling pathway is involved in the impaired function of ITP-
MSCs, and agents targeting this pathway may have great potential for the treat-
ment of ITP.
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NOVEL RARE VARIANTS IN EXON 4 OF GP6 HAVE LARGE EFFECTS ON
GPVI EXPRESSION AND PLATELET FUNCTION
S Jansen1,2, W Ouwehand1,2,3, S Sivapalaratnam1,2,*
1Haematology, University of Cambridge, 2NHS Blood and Transplant, Cam-
bridge, 3Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Background: One of the initial steps in primary haemostasis is the binding of
collagen by the GPVI signalling receptor on platelets. We have an interest in
genetic variation in GP6 with an effect on expression and function. Platelets
from GPVI-deficient patients are not activated by collagen, but do not show
any severe bleeding phenotype. Therefore the GPVI receptor is a promising
target for chronic anti-thrombotic treatment. Common variants in the GP6 gene
are known to influence GPVI expression, but they only account for 16% of the
observed variation seen in large cohort studies.
Aims: We hypothesized that a large proportion of the variation would be explained
by rare variants in GP6 with a greater effect on expression and function.
Methods: The study was performed in the Cambridge Platelet Function cohort
of 1500 health consented volunteers. GPVI function and expression was deter-
mined by flow cytometry and levels confirmed by Western blotting and ELISA.
We planned on Sanger sequencing GP6 and FCER1G in the extreme cases
with combined function and expression defects of GPVI. Where possible pedi-
grees of index cases with rare and functionally relevant GP6 variants, were
recruited. Site-directed mutagenesis was performed to introduce individual
identified variants and final plasmids verified by Sanger sequencing to test the
functionality of the variants. The effect of the variants on thrombus formation
was determined by the van Kruchten methodology.
Results: We identified two outlier individuals with approximately 50% reduction
in GPVI expression levels and reduced functional responses. Sequencing in
one of the individuals, identified a rare G/A variant at position 584 in the GP6
coding sequence, causing a serine to asparagine substitution at residue 195
(S195N). This variant had a frequency of 0.011% in 72.590 Caucasian individ-
uals of the ExAC database. Sequencing of the second individual and their 4
pedigree members revealed a pattern consistent with the inheritance of a novel
rare C/A variant at position 580 in the GP6 coding sequence, encoding a proline
to threonine substitution at residue 194 (P194T). This variant was unobserved
in the ExAC database. Both the S195N and P194T variants occur in a key
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structural motif of the second immunoglobulin-like domain of the receptor. In
cell lines the S195N variant resulted in no expression of GPVI, whereas P194T
did have expression. Both variants did effect thrombus formation in flowing
whole blood over collagen-coated surfaces.
Summary/Conclusions: We have used a combination of platelet GPVI expres-
sion and function phenotypes, combined with sequencing of outliers, to identify
rare variants with large effect on the native configuration of the cellular receptor
and thereby its function and expression.
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LONG-TERM RISK OF CARDIOVASCULAR EVENTS FOLLOWING
SPLENECTOMY-A DANISH POPULATION-BASED COHORT STUDY
M Rørholt1,*, W Ghanima2, D Farkas3, H Toft Sørensen3, M Nørgaard3
1Pediatrics, 2Haematology & Research, Østfold Hospital trust, Sarpsborg, Nor-
way, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus,
Denmark
Background: The most frequent medical indications for splenectomy are
hematological disorders and although, splenectomy has been used for decades
to treat various medical and surgical conditions, it is known to be associated
with various short and long term complications. An increased risk of venous
thromboembolism following splenectomy is well documented while data on
long-term risk of cardiovascular events following splenectomy are scarce.
Aims: This study aimed to assess risk of acute myocardial infarction (MI), pul-
monary arterial hypertension (PAH), and stroke following splenectomy among
patients splenectomised for a variety of indications compared with the risks in
the general population and to determine whether these events were related to
the procedure or to the underlying pathology by comparing the risk among
patients who underwent splenectomy with that among non-splenectomised
patients with similar medical conditions.
Methods: We used population-based medical databases to identify patients
splenectomised in Denmark during 1996-2012, and constructed an age- and
sex-matched general population comparison cohort and a disease-matched
comparison cohort. We classified splenectomised patients into 8 subgroups
based on the underlying indication for splenectomy: (1) traumatic rupture of
the spleen; (2) idiopathic thrombocytopenic purpura (ITP); (3) unspecified
thrombocytopenia; (4) hematopoietic cancer; (5) hereditary haemolytic
anaemia; (6) abdominal cancer; (7) splenomegaly/other splenic diseases; (8)
no indication recorded. We computed 5-year cumulative incidence rates (treat-
ing death as a competing event) and adjusted hazard ratios (aHRs) with cor-
responding 95% confidence intervals (CIs) of MI, PAH, and stroke for the 3
cohorts. We controlled for age, sex, and pre-existing chronic obstructive pul-
monary disease, obesity, pulmonary embolism and heart failure.
Results: We identified 5,306 splenectomised, 53,060 population comparisons
and 11,651 disease-matched comparisons. The most frequent indications for
splenectomy were traumatic rupture (19.5%), abdominal cancers (16.6%),
hematopoietic cancers (7.9%), and ITP (7.1%). Within 5 years of follow-up
(table), 1.28% of splenectomised patients had MI compared with 1.75% in the
general population, yet corresponding aHR was 1.26 (95%CI 1.02-1.55). The
5-year cumulative incidence of PAH was 0.33% among splenectomised and
0.16% [aHR 3.28(95%CI 1.93-5.58)] in the general population, and for stroke
3.34% versus 2.62% [aHR 2.05(95%CI 1.78-2.36)]. When comparing the
splenectomised cohort with the disease-matched cohort, only stroke-risk was
elevated, occurring in 2.99% of the splenectomised versus 2.32% in disease-
matched [aHR 1.49(95% CI 1.23-1.81)].
Table 1.
Summary/Conclusions: The higher risk of stroke in splenectomised compared
with the disease-matched and the general population indicates that splenec-
tomy increases the risk of stroke. Risk of MI and PAH was not higher in splenec-
tomised patients than in disease-matched comparisons, indicating that the
higher risk in splenectomised patients compared with the general population
can largely be explained by the underlying indication.
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QUANTIFICATION OF IGG ANTI-ADAMTS13 ANTIBODY LEVEL CAN PREDICT
THE LIKELIHOOD OF MORTALITY IN ACUTE THROMBOTIC
THROMBOCYTOPENIC PURPURA
F Alwan1,2,*, K Langley2, S McGuckin1, M Thomas1,2, JP Westwood1,2, M Scully1,2
1Department of Haematology, University College London Hospital, 2Haemosta-
sis Research Unit, University College London, London, United Kingdom
Background: Acute Idiopathic Thrombotic Thrombocytopenic Purpura (TTP)
is a life threatening disorder caused by inhibition of the Von Willebrand factor
cleaving protein ADAMTS13 by acquired antibodies, usually of the IgG sub-
class. Its prevalence has been estimated at four to six cases per million per
year and is characterized by hemolytic anemia, thrombocytopenia, fever, neu-
rological symptoms and renal dysfunction. Untreated, mortality has been doc-
umented at 90% but even with treatment, it remains around 15-20%. Plasma
Exchange (PEX) is the mainstay of treatment but immunosuppressive/
immunomodulatory therapy is often also required. Since January 2009, the
United Kingdom TTP registry has been collecting information on all acute pre-
sentations of TTP across the country. In addition to testing for ADAMTS13
activity, confirmation of the presence of Anti-ADAMTS 13 IgG antibodies forms
part of the initial work up.
Aims: A retrospective review to evaluate whether the presenting IgG
ADAMTS13 antibody level can predict the likelihood of mortality in acute pre-
sentations of TTP.
Methods: 360 acute events were identified from the registry involving 314
patients treated in 63 hospitals. Only acquired TTP was considered with all
cases of congenital TTP excluded. Acute TTP was defined as ADAMTS13 pro-
tease activity below 10% (FRETS vWF-73 assay, NR: 60-120%) or between
10-20% with a detectable IgG ADAMTS13 antibody present. Acute events were
then stratified into groups depending on the presenting IgG ADAMTS13 anti-
body level (0-29%, 30-59%, 60-89%, >90%).
Results: Of the events identified, 68% of those involved were female with a
median age of 46 (range 5-90 years) and a median ADAMTS13 at diagnosis
of<5% (range<5%-57%). There was no statistically significant difference when
considering these factors between the subgroups. 40 deaths were noted in
total, accounting for 11.1% of all events. There was a statistically significant
increase in mortality in patients with a presenting IgG ADAMTS13 antibody
level above 30% compared to those with a level below 30% (p=0.0023). Sub-
group analysis of those presenting with an IgG ADAMTS13 antibody level
above 30% found no significant difference in mortality if the level was 30-59%,
60-89% or above 90% (p=0.83).
Summary/Conclusions: There is an increased risk of mortality seen in patients
with acute TTP and a presenting IgG ADAMTS13 antibody level above 30%.
Such patients should be considered for more aggressive treatment from initial
diagnosis. Mortality does not appear to increase with further increases in the
antibody level.
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MASITINIB FOR THE TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT
AND SMOLDERING SYSTEMIC MASTOCYTOSIS: A RANDOMIZED,
PLACEBO-CONTROLLED, INTERNATIONAL, PHASE 3 STUDY
O Hermine1,2,3,*, MO Chandesris4, C Bulai Livideanu5, C Paul5, G Guillet6,
E Jassem7, M Niedoszytko7, S Barete8, S Verstovsek9, C Grattan10,
G Damaj11, D Canioni12, S Fraitag13, L Lhermitte14,15, S Georgin Lavialle16,
LB Afrin17, J Agopian3,18,19, K Hanssens3,18,19, JP Kinet3,20, C Auclair3,21,
C Mansfield3, A Moussy3, P Dubreuil3,18,19,22, O Lortholary23,24,25
1University of Paris Descartes, Institut Imagine INSERM U1163, 2CNRS
ERL8654, Centre de Reference des Mastocytoses, 3AB Science, 4Department
of Haematology, Necker Children’s Hospital, Assistance Publique-Hôpitaux de
Paris (APHP), Paris, 5Paul Sabatier University, Department of Dermatology,
Mastocytosis Competence Center, Hôpital Larrey, Toulouse, 6Department of
Dermatology, CHU Poitiers, University Hospital, Poitiers, France, 7Department
of Allergology, Medical University of Gdansk, Gdansk, Poland, 8Sorbonne Uni-
versités, UPMC Paris 6, Assistance publique-Hôpitaux de Paris, Département
de dermatologie et allergologie, Hôpital Tenon, Centre de référence des mas-
tocytoses, Paris, France, 9Hanns A. Pielenz Clinical Research Center for Myelo-
proliferative Neoplasms, Department of Leukemia, MD Anderson Cancer Cen-
ter, Houston, Texas, United States, 10Department of Dermatology, Norfolk &
Norwich University Hospital, Norwich, United Kingdom, 11Centre Hospitalier
Universitaire, Amiens, 12Pathology Department, Université Paris Descartes,
Paris Sorbonne Cité, Faculté de Médecine & APHP Necker-Enfants Malades,
13Pathology Department, Hôpital Necker-Enfants Malades, APHP, 14Université
Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut
National de Recherche Médicale (INSERM) U1151, 15Laboratory of Onco-
Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker
Enfants Malades, 16Service de médecine interne, Hôpital Tenon, Université
Pierre et Marie Curie, DHU I2B, Paris, France, 17- Division of Hematology,
Oncology & Transplantation, University of Minnesota, Minneapolis, Minnesota,
United States, 18Inserm U1068, CRCM (Signaling, Hematopoiesis and Mech-
anism of Oncogenesis); Institut Paoli-Calmettes, Aix-Marseille Université,
CNRS, UMR7258, Marseille, 19Centre de Référence des Mastocytoses, Hôpital
Necker-Enfants-Malades, Université Paris Descartes, Sorbonne Paris Cité,
Paris, France, 20Department of Pathology, Harvard Medical School and Beth
Israel Deaconess Medical Center, Boston, MA, United States, 21Laboratoire
de Biologie et Pharmacologie appliqué, CNRS UMR 8113, Ecole Normale
Supérieure de Cachan, Université Paris Saclay, Cachan, 22Inserm, la Ligue
Nationale Contre le Cancer (Equipe labelliseé), 23Department of Infectious Dis-
eases and Tropical Medicine, AP-HP, Necker-Enfants Malades University Hos-
pital, 24Centre d’Infectiologie Necker-Pasteur, Paris, France; Paris Descartes
University, Sorbonne Paris Cité, 25Paris Descartes University, Sorbonne Paris
Cité, Paris, France
Background: Indolent systemic mastocytosis (ISM) and smoldering systemic
mastocytosis (SSM) are life-long conditions associated with a significant reduc-
tion in quality-of-life. Masitinib (AB1010) is a selective oral tyrosine kinase
inhibitor targeting wild-type KIT (WT-KIT), LYN and FYN. Masitinib does not
inhibit KIT-D816V mutated mast cells (MC) but does target normal MCs. This
is in part via dual inhibition of LYN and FYN modulating MC degranulation in a
KIT-independent manner, and secondly by greatly reducing the normal MC bur-
den through inhibition of WT-KIT.
Aims: To assess the efficacy and safety of masitinib (6 mg/kg/day over 24-
weeks with a possible extension period) against placebo in severely sympto-
matic ISM/ISM patients (pt) who were unresponsive to optimized symptomatic
treatments.
Methods: Severely symptomatic ISM/SSM pts were defined as having at least
one baseline symptom among: pruritus score ≥9, number of flushes/week ≥8,
Hamilton rating scale for depression score ≥19, or Fatigue Impact Scale (FIS)
total score ≥75. Treatment-effect was tested using repeated measures method-
ology for rare diseases via the generalized estimating equation (GEE) model
in a modified intention-to-treat (mITT) population. Response was defined as a
≥75% improvement from baseline for any one of the aforementioned severe
symptoms. Primary endpoint (4R75%) was cumulative response (timeframe
W8-W24) in at least one severe baseline symptom. Long-term analysis was
performed over the timeframe of W8-W96. Secondary endpoints included out-
comes related to safety, patient-reported symptomatic endpoints and objective
endpoints representative of MC activity or burden.
Results: A total of 135 pts were enrolled. Masitinib showed a significant
improvement over placebo in its primary endpoint, 18.7% vs 7.4%, respectively,
odds ratio of 3.6 (95%CI 1.2-10.8, P=0.008). Masitinib sustained a significant
4R75% response over the long-term with odds ratio of 3.5 (95%CI 1.3-9.7,
P=0.016). This result was corroborated by statistically significant outcomes in
various sensitivity and secondary analyses. For example, at W24 the mean
change of tryptase level relative to baseline in pts with baseline tryptase level
>20µg/L was a decrease of 18.0% in the masitinib arm vs an increase of 2.2%
in the placebo arm, i.e. an absolute difference of 20.2% (P<0.001). The
response of urticaria pigmentosa to masitinib was also statistically significant
when compared with placebo (P=0.02), an observation supported by abolition
of Darier’s sign (P=0.02). Toxicities were predominantly gastrointestinal or skin
events, consistent with masitinib’s known safety adverse events (AE) profile
and typically manageable via dose reduction. Severe AE reported with a >4%
difference between treatment-arms were diarrhea (9.8%), rash (5.7%), and
asthenia (4.1%). The most frequent serious AEs in the masitinib arm were diar-
rhea (4.3%) and urticaria (2.9%). There were no deaths or life-threatening AEs
in the masitinib arm. Long-term safety assessment revealed comparable inci-
dence of AEs between treatment-arms.
Summary/Conclusions: Masitinib generated a significant therapeutic benefit
across a diverse range of symptoms in pts with severely symptomatic ISM/SSM
who were unresponsive to optimized symptomatic treatments. Moreover, the
response criterion of ≥75% improvement in at least one severe baseline symp-
tom constitutes a clinically meaningful effect. Data from the study’s extension
period showed that masitinib was capable of maintaining remission of symp-
toms for over 2 years. This is an important observation given that ISM and
SSM are a life-long conditions requiring chronic management. Masitinib was
associated with increased frequency of AEs during the first 6 months of treat-
ment, although no toxicities were life-threatening, and over the long-term the
incidence of AEs was similar between masitinib and placebo. In summary,
masitinib has shown a positive benefit/risk ratio and may be an important future
treatment option for severely symptomatic ISM/SSM pts.
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STAT3 GAIN-OF-FUNCTION MUTATIONS CAUSE AUTOIMMUNE
LYMPHOPROLIFERATIVE SYNDROME LIKE DISEASE BY DYSREGULATING
EXPRESSION OF FAS AND BCL2 PROTEINS AND CAN BE THERAPEUTICALLY
TARGETED BY BH3 MIMETICS
S Nabhani1, H Miskin2, C Schipp1, C Levin3, T Dujovny3, A Koren3, D Harlev2,
S Revel-Vilk4, M Gombert1, S Ginzel1,5, A Borkhardt1, P Stepensky4, U Fischer1,*
1Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine-
University Duesseldorf, Duesseldorf, Germany, 2Pediatric Hematology Unit,
Shaare Zedek Medical Center, Jerusalem, 3Pediatric Hematology Unit, Emek
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Background: Autoimmune Lymphoproliferative Syndrome (ALPS) like disease
is typically characterized by lymphadenopathy, hepatosplenomegaly, autoim-
mune cytopenias and an elevated number of double negative T cells (DNT
cells, CD3+, TCRα/β+, CD4-, CD8-). 70% of patients suffering from classical
ALPS harbor germline or somatic mutations in genes involved in the apoptotic
FAS death receptor signaling pathway (FAS, FASLG or CASP10). For about
30% of ALPS or ALPS-like patients the genetic cause is unknown.
Aims: The objective of this study was to identify novel gene candidates under-
lying ALPS like disease of unknown genetic cause and to test potential targeted
therapeutic approaches.
Methods: 30 patients with clinical ALPS like symptoms, but without classical
mutations were analyzed by whole-exome sequencing. Candidate genes were
identified using an in-house developed bioinformatic analysis pipeline for gene
prioritization. Candidate mutations were validated by Sanger sequencing. Their
impact on Fas signaling and apoptosis was studied and potential therapeutic
approaches tested.
Results: We identified two patients with de novo germline mutations (p.R278H,
p.M394T) of the Signal Transducer And Activator Of Transcription 3 (STAT3).
Elevated levels of phosphorylated STAT3 (pSTAT3-Tyr705) indicated constitu-
tive activation of STAT3. Patient 1 presented with Coombs positive hemolytic
anemia, thrombocytopenia, generalized progressive, non-infectious, non-malig-
nant lymphadenopathy and splenomegaly at the age of nine. Immunopheno-
typing revealed increased numbers of DNT cells (20% in peripheral blood) and
over time the patient developed panhypogammaglobulinemia. Patient 2 pre-
sented with early-onset insulin dependent diabetes mellitus and non-infectious,
non-malignant lymphadenopathy, splenomegaly, thrombocytopenia, neutrope-
nia and mild anemia. DNT cells and immunoglobulin levels were normal. We
could demonstrate that constitutive activation of STAT3 led to decreased FAS
expression on primary patient T cells and to reduced FAS ligand induced apop-
tosis similar to the effect of FAS mutations in classical ALPS. Therapeutic tar-
geting of STAT3 is challenging and so far none of the developed STAT3
inhibitors has been approved for clinical use. To determine alternative targets
we analyzed STAT3 signaling in primary and transformed lymphocytes of the
patients. STAT3 gain-of-function mutations led to increased expression of
STAT3 target genes, including SOCS3 and key anti-apoptotic factors of the
BCL2 family of proteins (BCL-2, BCL-XL), whereas expression of pro-apoptotic
factors (BAX, BAK) was decreased. Consistently, patient cells were resistant
to cell death induced by stimuli (e.g. IL-21, staurosporine) mediating cell death
via the BCL2 protein family. Treatment with a STAT3-specific inhibitor (S3I-201)
normalized the expression of these factors and rescued the apoptotic response.
Cells harboring STAT3 mutations were significantly more sensitive than normal
cells to death induced by the BH3 mimetic inhibitor ABT-737 that targets BCL2,
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BCL-XL and BCL-W providing proof-of-concept evidence and indicating a novel
therapeutic option.
Summary/Conclusions: We report here on dominant STAT3 gain-of-function
mutations that caused clinical phenotypes similar to ALPS like disease. We
demonstrated that constitutive active STAT3 caused decreased FAS expression
and a skewed balance of pro- and antiapoptotic BCL-2 factors resulting in
apoptosis evasion that may be therapeutically targeted by BH3 mimetics.
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PRECLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF
AG-519, AN ALLOSTERIC PYRUVATE KINASE-R ACTIVATOR
Y Chen, R Nagaraja, K Le, PA Kosinski, G Histen, C Kung, H Kim, C Prakash,
L Dang, J Popovici-Muller, J Hixon, L Silverman, S Biller, H Yang*
1Agios Pharmaceuticals Inc., Cambridge, United States
Background: Pyruvate kinase (PK) deficiency is a rare genetic disease caus-
ing chronic hemolytic anemia. Symptoms vary in severity and include
splenomegaly, iron overload and jaundice, and current treatments are support-
ive only. PK deficiency is caused by mutations in the red blood cell (RBC) iso-
form of PK (PK-R), a key enzyme in RBC glycolysis. Functional PK-R deficiency
leads to increases in the upstream metabolite 2,3-diphosphoglycerate (2,3-
DPG) and decreases in the product adenosine triphosphate (ATP) in blood.
Small molecule activation of mutant PK-R could restore the glycolytic pathway,
and decrease hemolysis, leading to patient benefit. AG-519 is an orally avail-
able allosteric activator of both mutant and wild type PK-R currently in clinical
development.
Aims: To explore the pharmacokinetic/pharmacodynamic (PK/PD) relation-
ships of AG-519 with PK-R activity, ATP and 2,3-DPG in wild type PK-R mice,
and to use data from animal studies to project the pharmacokinetic profile and
efficacious dose of AG-519 in humans.
Methods: In vitro intrinsic clearance (CLint) was calculated in microsomes and
hepatocytes from all species tested. In vivo PK/PD was analyzed in PK-R wild
type C57/BL6 female mice. AG-519 or vehicle was given orally as a single
dose, or for 5 and 13 twice-daily (BID) doses, at 1, 10, 50 and 150mg/kg. Blood
or plasma concentrations of AG-519, ATP and 2,3-DPG were measured at 0,
3, 6, 12, 24, 36, 48 and 72 h following the last dose by liquid chromatography
with tandem mass spectrometry, with PK-R activity measured by colorimetric
assessment of the reaction rate in blood cell lysates. For in vivo pharmacoki-
netic profiling of AG-519 in Sprague Dawley rats, Beagle dogs and cynomolgus
monkeys, clearance (CL), volume of distribution at a steady state (Vss), termi-
nal half-life (t½), and oral bioavailability (F) were calculated. The human profile
was predicted by allometric scaling with correction factors.
Results: AG-519 showed moderate CL (1.13-2.51L/h/kg), moderate Vss (2.08-
6.44L/kg), moderate to long t½ (6.3-9.8h), rapid absorption (Tmax ≤1.2h) and
moderate oral bioavailability (6.9-19.5% with suspension formulation) in mouse,
rat, dog and monkey. There was good in vitro to in vivo correlation in the CL
estimates across species. In mouse PK/PD studies, dose-dependent increases
in blood ATP levels were observed after 5 and 13 BID doses, but not after a
single dose. In addition, dose-dependent decreases in 2,3-DPG were observed
following both single and multiple doses of AG-519. There were dose-depen-
dent increases in blood PK-R activity after single and multiple AG-519 doses.
The AG-519 exposure to biomarker response (2,3-DPG, ATP and PK-R activity)
relationship was described by an Emax model. With the projections of an effec-
tive t½ (4.1-7.1h), CL (0.414L/h/kg), Vss (2.95L/kg), and F (22.5%) in humans,
twice-daily dosing of 111mg (range 62-134mg) of AG-519 in humans is antici-
pated to achieve the EAUC90(0-12h) (the exposure required to achieve 90% of
maximal effect on all three biomarkers) of 421 h•ng/mL.
Summary/Conclusions: AG-519 showed a favorable pharmacokinetic profile
in several animal species, allowing prediction of its profile in humans. This,
along with the clear PK/PD relationship established in the mouse model demon-
strating activation of PK-R, allowed prediction of the AG-519 efficacious dose
in humans. These data supported the decision to bring AG-519 into a phase 1
healthy volunteer study (NCT02630927).
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HAPLO-IDENTICAL TRANSPLANTATION FOR ACQUIRED SEVERE
APLASTIC ANEMIA IN A MULTI-CENTER PROSPECTIVE STUDY
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Background: Severe aplastic anemia (SAA) is a life-threatening disorder for
which allogeneic hematopoietic stem cell transplantation (HSCT) is the avail-
able curative approach. Haplo-identical donor (HID) as an alternative source,
should be considered in the absence of matched related or unrelated donor
after failing to respond to immunosuppressive therapy (IST). Obvious superi-
ority arises from the immediate availability of a suitable haplo-identical donor
for most patients within appropriate time-frame. However, initial outcomes of
HID for SAA were far from satisfactory owing to poor engraftment, refractory
graft-versus-host disease (GVHD) and delayed immune reconstitution.
Several small-sample studies using various approaches of haplo-identical
transplantation revealed the mixed success, with short-term survival rates
reaching 67%>100% and graft failure rates ranging from 0% to 25%. However,
the recent reports of haplo-identical transplantation for SAA are rather hetero-
geneous and almost all series are limited by small numbers of patients.
Aims: To further prove the therapeutic effect of haplo-identical SCT in the treat-
ment of SAA, we conducted a prospective multi-center study using uniform
protocol, and compared outcomes of haploidentical SCT with those of all con-
temporaneous transplantation from MRD.
Methods: This was a disease-specific, multicenter, prospective study. All eli-
gible patients treated at 11 participating institutions were included. Patients
were administered with BU/CY+ATG conditioning regimen, G-BM combined
with peripheral blood stem cells without in vitro T-cell depletion and a combi-
nation of CsA, MTX and MMF as graft-versus-host disease (GVHD) prophy-
laxis. The primary endpoint was engraftment. Various outcomes of HID were
compared with those of contemporaneous transplantation from matched related
donors (MRD).
Results: For patients receiving HID-SCT, all cases surviving for more than 28
days achieved donor myeloid engraftment. The median time for myeloid
engraftment was 12 (range, 9-25) and for platelet was 15 (range, 7-101) days
with a cumulative platelet engraftment incidence of 94.1±0.1%. With a median
follow up of 18.3 (3.0-43.6) months and when compared with MRD, HID recip-
ients had more cumulative incidence of grade II-IV acute GVHD (aGVHD;
33.7% vs 4.2%, P<0.001), more chronic GVHD (cGVHD; 22.4% vs 6.6%,
P=0.014) at 1 year, but similar grade III-IV aGVHD (7.9% vs 2.1%, P=0.157),
3-year estimated overall survival (OS, 89.0% vs 91.0%, P=0.555) and 3-year
estimated failure free survival (FFS, 86.8% vs 80.3%, P=0.659). Multivariate
analysis showed no significant difference in primary engraftment and survival
outcomes between two cohorts. 
Summary/Conclusions: Haplo-identical transplantation using our protocol was
proved to be an effective and safe choice in SAA patients who failed previous
IST. It could be recommended for those who lack a MRD as higher priority.
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SUCCESSFUL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TEN
PATIENTS WITH SEVERE CONGENITAL NEUTROPENIA USING AN
INTENSIVE IMMUNOMYELOSUPPRESSIVE CONDITIONING REGIMEN:
THE RESULTS OF A SINGLE INSTITUTE
Y Mizoguchi*, S Karakawa, T Doi, M Shimomura, K Tomioka, S Sakata,
A Furue, I Chijimatsu, S Okada, M Miki, H Kawaguchi, M Kobayashi
Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sci-
ences, Hiroshima, Japan
Background: Severe congenital neutropenia (SCN) is a rare heterogeneous
genetic disorder categorized as a bone marrow failure syndrome. The main
clinical feature of patients with SCN is recurrent bacterial infections from early
infancy due to severe chronic neutropenia. Majority of SCN patients have ben-
efitted by the treatment with granulocyte colony-stimulating factor (G-CSF).
However, patients on long-term G-CSF therapy have a relative risk of devel-
oping myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The
only curable treatment for SCN patients is hematopoietic stem cell transplan-
tation (HSCT). Recently, HSCT with reduced intensity conditioning (RIC) reg-
imens have been applied to the treatment for SCN patients prior to malignant
transformation. However, the optimal conditions of HSCT for SCN patients
have not been established. 
Aims: In this study, we conducted bone marrow cell transplantations (BMT) in
ten patients with SCN using an immunomyelosuppressive conditioning regimen
to minimize early and late transplant-related morbidity in Hiroshima University
Hospital. 
Methods: A total of eleven HSCT procedures were performed in ten patients
with SCN from 2009 to 2015. Four of ten patients had experienced the engraft-
ment failure of initial HSCT and three of them were referred to our hospital for
re-transplantation. Nine of ten patients (90%) had a heterozygous mutation in
the ELANE gene. Bone marrow cells (BM) were obtained from five HLA-
matched related (MRD), three HLA-matched unrelated (MUD), and three HLA-
mismatched unrelated (7/8) donors (MMUD), respectively. Conditioning regi-
men consisted of fludarabine (125 mg/m2), cyclophosphamide (140 mg/m2),
melpharan (90 mg/m2), and total body irradiation (3.6 Gy). Antithymocyte glob-
ulin (ATG, 10–12 mg/kg) was also administered, but two patients from MRD
did not receive ATG, and one patient from MUD received low-dose ATG (i.e.,
2.5 mg/kg instead of 10–12 mg/kg). Short-term methotrexate and tacrolimus
were administered for the prophylaxis of graft-versus-host disease (GVHD).
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Results: Engraftment of neutrophils was observed within post-transplant 24
days in all but 1 case who developed graft failure. This case, who had under-
gone initial HSCT with MUD-derived bone marrow using our conditioning reg-
imen with low-dose ATG (2.5mg/kg), was rescued by second HSCT with BM
from another MUD receiving the same conditioning regimen with a 12mg/kg of
ATG. Two patients received HSCT from HLA-matched related donor developed
stable mixed chimerism without neutropenia in peripheral blood. Although one
patient who received donor lymphocyte infusion due to mixed chimerism devel-
oped acute GVHD grade II and limited chronic GVHD, the others did not devel-
op severe GVHD (acute GVHD gradeII-III 9%, chronic GVHD 9% respectively).
All patients are alive for 6 months to 8 years after HSCT with no signs of severe
infections or transplantation-related morbidity.
Summary/Conclusions: Our results demonstrate that BMT together with a
sufficient immunosuppressive conditioning regimen may be a feasible and effec-
tive treatment for SCN patients, irrespective of initial engraftment failure. The
excellent results in our cohort suggest that indications for proceeding to HSCT
could be extended to patients without malignant transformation. The further
analyses of accumulated cases are necessary to assess the efficacy, safety,
and less late adverse effects related to HSCT including fertility. 
Transfusion medicine
S833
RED CELL ALLOIMMUNISATION RISK IN PATIENTS WITH DIFFERENT
TYPES OF INFECTIONS
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Background: Red cell alloantigen exposure can lead to antibody associated
morbidity. A valid alloimmunisation prediction score will support identification
of high-risk patients, consequently followed by offering them extended matched
red cell products. Murine models have suggested inflammation as an important
modulator of the humoral response towards red cell antigens.
Aims: We set out to quantify the alloimmunisation risk of various types of infec-
tions in humans.
Methods: We performed a multicenter case-control study in a source population
of patients who received their first and subsequent red cell transfusions during
an eight year follow-up period. Cases, defined as patients developing a first trans-
fusion-induced red cell alloantibody, were each compared with two randomly
sampled controls, defined as non-alloimmunised patients receiving at least the
same number of red cell units. Logistic regression analysis, stratifying for potential
confounders, was used to evaluate the association between red cell alloimmuni-
sation and the presence of various types of infections during a 5-week ‘alloim-
munisation risk period’. Tissue-invasive bacterial infections were defined as
‘severe’ or ‘mild’ according to the expected induced systemic inflammatory
response accompanying the type of infection. Bacteremiae were subclassified
into Gram-positive or Gram-negative bacteremiae according to the causative
microorganism. Viraemia and disseminated viral zoster infections were defined
as ‘disseminated viral infections’, hereby contrasting local viral infections.
Results: Within a cohort of 24,063 newly transfused patients, 505 cases and
1,010 matched controls received a median of eight (interquartile range 4-16)
red cell transfusions. During the risk period, 159 cases (31.5%) and 314 controls
(31.1%) were diagnosed with at least one infectious episode. Alloimmunisation
incidences increased upon red cell antigen exposure during severe, but not
mild, bacterial infections (adjusted relative risk (RR) 1.34 with 95% confidence
interval (CI) 0.97-1.85; figure). RRs were further pronounced when these bac-
terial infections were accompanied with long-lasting fever (RR 3.06, CI 1.57-
5.96). Disseminated viral disorders demonstrated a RR of 2.41 (CI 0.89-6.53,
figure). Surprisingly, bacteraemia with Gram-negative, but not with Gram-pos-
itive, microorganisms, coincided with a 2-fold reduction in alloimmunisation
incidences (RR 0.58, CI 0.13-1.14, figure 1). Fungal infections, as well as ele-
vated CRP values, and (level of) leucocytosis were not associated with red cell
alloimmunisation.
Figure 1.
Summary/Conclusions: Our findings corroborate animal studies suggesting
that red cell transfusions in a setting of severe bacterial or viral infections
increase the risk of alloimmunisation, contrasting Gram-negative bacteraemia
which substantially reduce alloantibody formation. Data on recent or existing
infections should thus be incorporated into an alloimmunisation prediction score,
enabling selecting high-risk patients who will benefit most from extended
matched red cell transfusions.
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THE USE OF PEGYLATED CARBOXYHEMOGLOBIN BOVINE IN PATIENTS
FOR WHOM BLOOD IS NOT AN OPTION
A Abuchowski, R Jubin*, J Berryman, R Prince
Prolong Pharmaceuticals, South Plainfield, United States
Background: Severe hypoxia due to low hemoglobin (Hb) levels causes sig-
nificant morbidity and mortality. This is of great concern for patients who cannot
receive blood transfusions due to personal (i.e., Jehovah’s Witness) or medical
(i.e., hyperhemolysis) reasons, or simply due to the lack of availability. PEGy-
lated-carboxyhemoglobin (PEG-HbCO; SANGUINATE™) is a novel therapeutic
agent designed to release carbon monoxide to reduce vascular inflammation
and then transfer oxygen to hypoxic tissue and cells. PEG-HbCO has been
used in 24 patients under the USA emergency Investigational New Drug (eIND)
program. A retrospective analysis of these patients was performed.
Aims: Perform post-hoc analysis of clinical findings; their relationship to indi-
vidual patient diagnosis/associated comorbidities and PEG-HbCO intervention.
Methods: 23 patients with hemoglobin levels under 5 g/dL and 1 sickle cell dis-
ease patient with Hb of 8.7 were determined to be near death or at serious risk
of severe morbidity and were treated with PEG-HbCO. Applications included
AML, sickle cell disease (SCD) comorbidities, trauma and hemorrhagic shock.
Patients ranged in age from 19 to 61. A unit of PEG-HbCO consists of 500 mL
(40 mg/mL). Total doses ranged from 1 unit up to 8 units given over 9 days.
Results: No serious adverse events associated with PEG-HbCO were reported.
All patients provided with timely emergency treatment with PEG-HbCO were
reported by the investigator to show clear signs of improved mental function that
was temporally associated with infusion of PEG-HbCO despite continuing low Hb
levels. Improvements in cerebrovascular oximetry, cerebral blood flow, pulmonary
infiltrates, renal function and serum biochemistry (bilirubin, liver function, LDH)
were reported in various patients. A SCD patient with acute chest syndrome
showed clearing of pulmonary infiltrate within 24 hours of PEG-HbCO infusion.
Nine of eleven (81%) severely anemic patients showed improvement upon admin-
istration of PEG-HbCO, defined by an initial improvement in mental alertness and
culminating in hospital discharge (excluding trauma patients with ISS score ≥25).
Summary/Conclusions: The varied results seen in these critical care patients
represent preliminary evidence of substantial improvement in clinically signifi-
cant endpoints used by the clinicians to assess response to treatment in the
urgent care setting. Most important is the evidence of response despite no
immediate improvement in the hemoglobin level which, if left untreated, may
have lead many of these patients to significant morbidity and potential mortality.
While severe anemia persisted for most of these patients, it appears that the
life-threatening hypoxia did not. There is a significant unmet medical need to
treat hypoxia in patients for whom blood is not an option. PEG-HbCO is under
development for the treatment of the life-threatening effects of acute severe
anemia (Hb ≤5 g/dL) in patients who cannot receive red blood cell transfusions.
PEG-HbCO is also in clinical development for the treatment of SCD comor-
bidities, delayed graft function following renal transplantation and reduction of
delayed cerebral ischemia following subarachnoid hemorrhage.
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INTRODUCTION OF A PREOPERATIVE ANAEMIA CLINIC IMPROVES
PERI-OPERATIVE TRANSFUSION USE
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Background: Preoperative anaemia is a potentially modifiable risk factor for
perioperative morbidity and mortality. Strategies for anaemia correction have
been outlined by the UK Joint Blood and Transplant Professional Advisory
Committee, the 2015 NICE (National Institute of Clinical Excellence) guidelines
for blood transfusion and a guideline by the British Committee for Standards
in Haematology. Here we present the results of a pilot study, where we intro-
duced a preoperative clinic aimed at correcting treatable anaemia without
delaying cardiac surgery at Papworth hospital, UK.
Aims: The aims of this study were to evaluate whether introduction of a pre-
operative anaemic clinic improves patient blood management or clinical out-
come following major cardiac surgery.
Methods: All patients listed for major cardiac surgery between May to Decem-
ber 2015, Papworth Hospital, UK were screened for anaemia at surgical pre
assessment clinic. 107 patients with a haemoglobin <130g/l (males) and
<120g/l (females) were recruited and underwent further testing for ferritin, vita-
min B12, plasma folate, creatinine and TSH. Patients were then reviewed at
clinic by a consultant haematologist, who decided upon appropriate anaemia
management. 25 patients with a ferritin level<100g/L received 1g of Ferinject®
(Fe-Carboximaltose) as a single dose infusion up to 6 weeks preoperatively.
For another 23 patients the above ferritin criterion was met, but for a variety of
reasons preoperative iron could not be administered. 4 patients received oral
iron. The remaining patients were advised to commence B12, folate or combi-
nations thereof or proceeded to surgery in the absence of a treatable cause of
anaemia. We collected information on blood products administered, total hos-
pital stay, intensive care stay and mortality. Data were compared to a previously
published historic control group of anaemia patients undergoing cardiac surgery
(n=165;Pap60) and compared by t-test.
Results: Patients assessed in the preoperative anaemia clinic received signifi-
cantly less red cell transfusion than patients proceeding directly to surgery in the
Pap60 study (2.2±3.2 units vs 3.9±4.0 units; mean±S.D., p=0.027) and had sig-
nificantly shorter hospital stay (12.9±10.6 days vs 16.0±9.9 days; mean±S.D.,
p<0.01). However there was no difference in transfusion use or hospital stay
between iron treated and non-iron treated, low ferritin patient subgroups, nor
were these significantly different in comparison to the whole anaemia clinic cohort.
Figure 1.
Summary/Conclusions: In conclusion, we have found that our preoperative
anaemia clinic improves overall patient blood management in the peri-operative
period with a reduction in blood transfusion usage. However intravenous iron
when given in the context of major cardiac surgery seems to have no additional
benefit in this pilot study.
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Background: Luspatercept (ACE-536), a fusion protein containing a modified
activin receptor type IIB, is being developed for the treatment of β-thalassemia.
Luspatercept binds to GDF11 and other ligands in the TGF-β superfamily to
promote late-stage erythroid differentiation. Luspatercept corrected the effects
of ineffective erythropoiesis in a thalassemia mouse model (Suragani R, Blood
2014) and was well tolerated and increased hemoglobin in a phase 1 clinical
study (Attie K, Am J Hematol 2014).
Aims: This is an ongoing, phase 2, multicenter, open-label, dose-finding study
followed by a long-term extension study to evaluate the effects of luspatercept in
adults with β-thalassemia, including a subgroup on regular transfusions (≥4 units
RBC/8 weeks). Endpoints included RBC transfusion burden (units/12 weeks),
liver iron concentration (LIC) by MRI, safety, and quality of life questionnaires.
Methods: Inclusion criteria included age ≥18 yr and genetic confirmation of β-
thalassemia. Luspatercept was administered SC every 3 wks for up to 5 doses
in the dose-ranging study (completed) with a 2-month follow-up unless enrolled
directly into a 2-year extension study (ongoing). Six sequential cohorts (n=35
total) were treated at escalating doses from 0.2 to 1.25 mg/kg. An additional
expansion cohort (n=29) was treated with a starting dose of 0.8 mg/kg with
escalation up to 1.25 mg/kg. Of the 64 patients (pts) treated in the dose-ranging
study (including 30 pts regularly transfused), 51 enrolled in the extension study.
RBC transfusions during the study were administered based on each patient’s
usual pre-transfusion hemoglobin threshold.
Results: Data (as of 25 Sept 2015) were evaluable for 28 of 30 pts on regular
RBC transfusions. Median age was 37.5 yr, ranging from 21 to 54 yr, and 57.1%
had prior splenectomy. At baseline, median transfusion burden was 8 units/12
weeks (range 4-18 units). Mean (±SD) LIC was 4.5±4.6 mg/g dw. 27 pts were
on iron chelation therapy (ICT) at baseline. 21/28 (75%) pts achieved ≥33%
decrease and 16/28 (57%) achieved ≥50% decrease in transfusion burden
over any 12-week period compared with the 12 weeks prior to treatment (mean
decrease was 56% in 23 pts with at least 12 weeks on study). 4/8 (50%) pts
with baseline LIC ≥5 mg/g dw had a decrease in LIC ≥2 mg/g dw (mean
decrease 3.1 mg/g dw, 35.1%) during the 16-week base study; 14/14 (100%)
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pts with baseline LIC<5 mg/g dw maintained LIC<5 mg/g dw. Luspatercept was
generally well tolerated, with no related serious adverse events reported to
date. Adverse events in this regularly transfused subgroup were mostly mild-
moderate and the most frequent related adverse events (≥4 pts) were bone
pain, myalgia, arthralgia, headache, asthenia, and musculoskeletal pain.
Summary/Conclusions: Luspatercept treatment was well-tolerated and led
to decreased RBC transfusion requirements in regularly transfused patients
with β-thalassemia. The decrease in RBC transfusions correlated with decreas-
es in liver iron concentration. These changes represent a significant reduction
in disease burden for regularly transfused patients with β-thalassemia. A Phase
3 study of luspatercept in adults who require regular RBC transfusions due to
β-thalassemia is ongoing (BELIEVE study; clinicaltrials.gov NCT02604433).
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Background: Childhood autoimmune hemolytic anemia (AIHA) requires in 30-
50% of cases immunosuppressive therapy for steroid resistance or prolonged
dependence. Although there are no pediatric guidelines for the second line
strategy, in small retrospective studies or rare controlled studies, rituximab
appears to be indicated.
Aims: This prospective observational national study reports the practice, effi-
ciency and tolerance of rituximab in non-selected children with isolated AIHA
or AIHA in context of Evans syndrome (AIHA/ES).
Methods: For this study, all children under 18 years old, living in France, who
had been treated, by rituximab for an AIHA, whatever the context was, between
January 1, 2000 and December 31, 2012, registered in the OBS’CEREVANCE
cohort, were included. The end point for analysis was December 31, 2013,
ensuring more than 1 year’s follow-up for each patient. Response criteria were
defined, relapse free survival (RFS) curves were provided, and tolerance was
assessed from patient’s medical records.
Results: Sixty one children with AIHA were given rituximab, 375 mg/m²/dose
for a median of 4 weekly doses. All patients had previously received steroids,
26 had received one to four supplementary line of treatment. The median age
at rituximab initiation was 8.5 [0.3; 17.6] years. The median delay from diagnosis
to rituximab was 9.9 [0.2; 153.1] months. With a median follow-up of 4 years
(0.3 - 11) from rituximab initiation, 46 patients responded (75%), 40 complete
response (CR) and 6 partial response (PR). 20 patients (43%) relapsed in a
median delay of 10.8 (1.7-57.6) months after treatment by rituximab The pro-
portion of relapses among responder patients was significantly lower in patient
who were treated early after diagnosis (p=0.03). In all children rituximab allowed
decrease of steroid therapy. Compared to AIHA/ES, in isolated AIHA, the pro-
portion of CR was significantly higher (74% vs 54%, p=0.02), and RFS was
significantly higher (p=0.04). Ten patients were aged less than one year at rit-
uximab initiation. In this subgroup, the median time between diagnosis and rit-
uximab initiation was 1.6 months, shorter than 12 months in the rest of the
cohort (p=0.006). Seven patients responded (70%), 6 CR and RFS was 71%.
Two children presented allergic reactions. No case of progressive multifocal
leuco-encephalopathy was observed. A total of 40 children received IVIg
replacement, whose duration was temporary in 31 and prolonged in 9. Five
patients died and among them one severe sepsis associated with agranulocy-
tosis could be reliable to rituximab therapy.
Summary/Conclusions: In our hands, in this large series of childhood AIHA,
rituximab was a valuable second line treatment, allowing steroid withdrawal in
60-70% of cases, with 30% long term responders, even in infants, mainly in
isolated AIHA and when it was precociously used. Two serious concerns on
safety are abrupt severe neutropenia, and prolonged hypogammaglobulinemia:
adequate screening of underlying primitive immune deficiency before treatment
is mandatory.
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Background: CD22 is expressed in most (>90%) cases of B-cell acute lym-
phoblastic leukemia (ALL) and is an attractive target for the treatment of B-cell
malignancies. Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody
conjugated to calicheamicin, has demonstrated significantly superior response
vs standard care (SC) in the first 218 randomized patients with relapsed/refrac-
tory (R/R) ALL in the phase 3 INO-VATE trial (data presented previously, DeAn-
gelo, European Hematology Association [EHA] 2015 meeting [LB2073]).
Aims: To assess overall survival (OS) and progression free survival (PFS) of
adults with R/R ALL receiving InO vs SC
Methods: In this ongoing global, 2-arm, randomized phase 3 trial
(NCT01564784), patients with R/R ALL (including ~15% of patients in each
arm with Philadelphia-positive ALL) due to receive salvage (S) 1 or 2 therapy
were randomized to InO (starting dose 1.8 mg/m2/cycle [0.8 mg/m2 on day 1;
0.5 mg/m2 on days 8 and 15 of a 21-28 day cycle (≤6 cycles)]) or SC (either
fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor [FLAG],
ara-C plus mitoxantrone, or high-dose ara-C). Study was designed with two
primary endpoints: 1) OS and 2) complete remission (CR)/CR with incomplete
hematologic recovery (CRi) assessed in first 218 patients randomized (results
previously presented). Overall study-wise type-I error was controlled by splitting
1-sided α to 0.0125 for each endpoint. Safety was assessed in all patients who
received ≥1 dose of study drug. Per protocol, the final OS analysis was to occur
upon observing ~248 events; 252 events (122 with InO and 130 with SC) were
observed on March 8, 2016; data as of this date are presented.
Results: The ITT analysis population included 326 patients with both arms
being well balanced for baseline stratification factors. The OS hazard ratio (HR)
between InO and SC was 0.77 (97.5% CI, 0.58-1.03) with 1-sided P=0.0203
and median OS 7.7 [95% CI, 6.0-9.2] vs 6.7 [95% CI, 4.9-8.3] months. The
second primary objective of demonstrating a statistically significant improve-
ment in final OS with InO vs SC was not met at prespecified significance level
of 0.0104. The 2-year OS rate for InO vs SC was 23% (95% CI, 16-30%) vs
10% (95% CI, 5-16%). It was noted, however, that the OS departed from the
proportional hazards assumption. Given this, a restricted mean survival time
(RMST) analysis was applied and showed: mean OS was 13.9 months for InO
vs 9.9 months for SC, a difference that met statistical significance. PFS was
significantly longer with InO vs SC (HR, 0.45 [97.5% CI, 0.34-0.61]; 1-sided P
Summary/Conclusions: Compared with SC, InO provided evidence of longer
OS and significantly prolonged PFS in adult patients with R/R ALL.
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Background: Antiplatelet therapy use at time of intracerebral haemorrhage
(ICH) is associated with higher mortality. Reduction of haematoma growth using
platelet transfusion might improve outcome.
Aims: To investigate whether platelet transfusion improves outcome compared
to standard care at three months in people with spontaneous ICH taking
antiplatelet therapy.
Methods: This was a multicentre prospective, randomised, open, blinded-end-
point (PROBE) parallel group trial, conducted at 60 hospitals in The Nether-
lands, Scotland and France. We enrolled patients with spontaneous supraten-
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torial ICH aged ≥18 years using antiplatelet therapy for ≥7 days preceding ICH,
if Glasgow Coma Scale was ≥8. Participants were randomised (1:1, with a
secure web-based system using permuted blocks, stratified by study centre
and type of antiplatelet therapy) to receive either platelet transfusion (interven-
tion) within six hours of start of symptoms and 90 minutes of diagnostic brain
imaging, or standard care without platelet transfusion (comparator). The primary
outcome was modified Rankin Scale (mRS) score assessed blinded to treat-
ment allocation at three months after ICH. PATCH was registered with the
Netherlands trial register (NTR1303). 
Results: Between February 2009 and October 2015, 97 participants were ran-
domised to platelet transfusion and 93 to standard care. Mean age with stan-
dard deviation was 74.0, 10.2 years in the interventional and 73.5, 11.2 years
in the comparator group. The odds of death or dependence at three months
were higher after platelet transfusion compared to standard care (adjusted
common OR 2·05, 95% CI 1·18 to 3·56), with no evidence of treatment effect
modification in sub-groups of interest. Platelet transfusion did not reduce ICH
growth at 24 hours.
Summary/Conclusions: Platelet transfusion seems inferior to standard care
for people using antiplatelet therapy before ICH.
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Background: Mainly regarded as actors of primary hemostasis, human
platelets are also capable of directly interact and internalize, by endocytosis,
the human immunodeficiency virus (HIV)-1 in vitro. Although patients with
acquired immunodeficiency syndrome can present thrombocytopenia and, as
we showed earlier, when highly viremic, present HIV-containing platelets, the
in vivo relevance of virus endocytosis by platelets and its role in HIV patho-
genesis remain to be elucidated. We speculate that HIV enclosed within
platelets can be sheltered from host immune system response and transported,
by circulating platelets, to macrophages from different tissues, where the virus
can establish viral reservoirs.
Aims: We therefore investigated whether HIV-1-containing platelets could be
internalized by macrophages, triggering productive infection and possibly estab-
lishing a viral reservoir vectored by platelets.
Methods: To approach the question, we obtained platelet-enriched plasma
(PRP) from seropositive patients (n=40) treated or not with highly active anti-
retroviral therapy (HAART) and established a flow cytometry/confocal
microscopy method to: i) quantify the amount of HIV-1-containing platelets
present in HIV-1 seropositive patient PRP ; and ii) observe the interaction of
HIV-1-containing platelets from patient PRP with human peripheral blood mono-
cyte-derived macrophages (M0) in vitro, and determine qualitatively and quan-
titatively the distribution of the virus.
Figure 1.
Results: Here, we show that HIV is consistently retrieved within platelets of
HIV-infected patients. These patients with detectable HIV-1-containing platelets
had lower numbers of CD4+ (< 300/ul) and total T lymphocytes in the blood
when compared with patients lacking detectable HIV-1 in platelets. In contrast,
detection of HIV-1-containing platelets was not correlated to patient viral load,
treatment or thrombocytopenia. This suggests that HIV-1 can also circulate,
sheltered within platelets, in the blood of patients with undetected cell-free
virus and unaltered platelet count. When incubated for 2 hours with M0 in vitro,
platelets derived from patient PRP interacted rapidly with M0, either being inter-
nalized by M0 or remaining attached to M0 surface (figure). Viral p24/p55 cap-
sid antigens were detected within M0 after the interaction period. The higher
the number of HIV-1-containing platelets detected in PRP (detected by flow
cytometry), the higher the number of HIV-1-containing platelets interacting with
M0 (detected morphologically). The amount of HIV-1-containing platelets asso-
ciated to macrophages correlated negatively with patients CD4+ and total T
lymphocytes numbers, highlighting that association of HIV-1-containing
platelets with M0 could occur in vivo in patients with bad prognosis.
Summary/Conclusions: Although the outcome of HIV-1 retention by platelets
and a platelet mediated-immunity during viral infection are still under investi-
gation, this study demonstrates that HIV-1 can circulate in the bloodstream of
seropositive, HAART-treated patients with undetected blood viral load using
platelets as carriers, and that macrophages internalize HIV-1-containing
platelets derived from these patients. The results highlight an alternative path-
way, via platelets, for viral dissemination to tissue macrophages. Considering
that inhibitors of platelet function have been employed for the treatment of dif-
ferent diseases, the study contributes to reveal a novel and promising thera-
peutical target for blocking HIV-1 spread and establishment of viral reservoirs.
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Background: Daratumumab (D), a human anti-CD38 IgGκ monoclonal anti-
body, induces deep and durable responses with a favorable safety profile in
patients with relapsed or refractory multiple myeloma (RRMM). We report a
pre-specified interim analysis of the first randomised controlled study of dara-
tumumab (CASTOR; NCT02136134).
Aims: To compare the efficacy and safety of daratumumab plus bortezomib
(V) and dexamethasone (d) versus Vd alone in patients with RRMM in a phase
3 study.
Methods: Patients who received ≥1 prior line of therapy were randomised (1:1)
to 8 cycles (q3w) of Vd (bortezomib: 1.3 mg/m2 subcutaneously on Days 1, 4,
8, 11; dexamethasone: 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, 12) with or
without daratumumab (16 mg/kg intravenously qw in Cycles 1-3, Day 1 of
Cycles 4-8, then q4w until progression). The primary endpoint was progres-
sion-free survival (PFS).
Results: 498 patients (DVd, 251; Vd, 247) were randomised. Baseline demo-
graphics and disease characteristics were well balanced. Patients received a
median of 2 prior lines of therapy (range 1-10). 66% received prior bortezomib;
76% received prior immunomodulatory drug (IMiD); 48% received prior pro-
teasome inhibitor (PI) and IMiD; 33% were IMiD-refractory; and 32% were
refractory to last line of prior therapy. With a median follow-up of 7.4 months,
daratumumab significantly improved median PFS (61% reduction in the risk of
progression/death) for DVd versus Vd (Figure 1). Addition of daratumumab to
Vd also significantly delayed median time to disease progression (TTP) versus
Vd (not reached [NR] vs 7.3 mo; hazard ratio, 0.30; 95% confidence interval,
0.21-0.43; P <0.0001). Daratumumab significantly increased overall response
rate (ORR; 83% vs 63%, P <0.0001), in addition to doubling the rates of very
good partial responses (VGPR) or better (59% vs 29%, P <0.0001) and com-
plete responses (CR) or better (19% vs 9%, P = 0.0012) for DVd versus Vd,
respectively. The median duration of response was NR for DVd versus 7.9
months for Vd. All planned sensitivity analyses demonstrated that DVd was
better than Vd, which was consistent with the results from the primary analysis.
In addition, pre-specified subgroup analyses on PFS demonstrated that the
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treatment effect of DVd over Vd was consistent across all selected subgroups.
Most common (>25%) treatment-emergent adverse events (TEAEs; DVd/Vd)
were thrombocytopenia (59%/44%), peripheral sensory neuropathy (47%/
38%), diarrhoea (32%/22%) and anaemia (26%/31%). Most common grade
3/4 TEAEs (>10%) were thrombocytopenia (45%/33%), anaemia (14%/16%),
neutropenia (13%/4%). 7%/9% (DVd/Vd) of patients discontinued due to a
TEAE. Daratumumab-associated infusion-related reactions (IRR; 45% of
patients) mostly occurred during the first infusion (98% of patients with IRR);
most were grade 1/2 (grade 3/4, 9%/0%).
Figure 1.
Summary/Conclusions: Daratumumab significantly improved PFS, TTP, and
ORR in combination with Vd versus Vd alone. DVd doubled rates of both VGPR
or better and stringent CR/CR versus Vd alone. Safety of DVd is consistent
with the known safety profile of daratumumab and Vd. The addition of daratu-
mumab to Vd should be considered a new standard of care for patients with
RRMM currently receiving Vd alone.
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Background: Cold agglutinin disease (CAD) is a difficult to treat autoimmune
haemolytic anemia in which IgM antibodies bind to erythrocytes at low temper-
ature and fix complement. This complement deposition opsonizes erythrocytes
which undergo extravascular haemolysis in the liver.
Aims: Based on preclinical studies (Shi et al., 2014 Blood), we hypothesized
that TNT009, an antibody directed against complement component C1s, could
stop haemolysis in CAD patients.
Methods: This represents an interim analysis of a first-in-human trial, where
we have included four female CAD patients. Patients received a test dose of
10 mg/kg TNT009, followed by a full dose of 60mg/kg 1-4 days later, and three
additional weekly doses of 60 mg/kg.
Results: All infusions were well tolerated without premedication and without
relevant adverse effects. Out of four patients, three had been transfusion-
dependent either previously (one patient within the last year) or recently (2
patients within 14 days of their enrolment into the trial). These three patients
unequivocally responded immediately to TNT009 infusion, and are described
below. TNT009 blocked the classical pathway of complement as demonstrated
by an immediate drop in CH50 and rise in C4. TNT009 rapidly abrogated
extravascular haemolysis, normalizing bilirubin levels in all three patients from
a median of 1.7mg/dL (range: 1.6-2.6) to 0.7mg/dL (0.6-0.7) within 24 hours.
Infusion of TNT009 immediately decreased the destruction of reticulocytes
which rose from 131 (103-140) to 185 (175-286) x10E9/L within 24h. Hapto-
globin levels normalized within one week and confirmed the complete halt of
haemolysis. Haemoglobin levels rose from a median haemoglobin of 7.5g/dL
(range: 6.8-8.3) before the test dose by 1.6 g/dL (1.1-1.6) within the first week,
and completely normalised (>12 g/dL Hb by end of study in two patients; one
patient still under observation) within 5-6 weeks. Normalisation of these param-
eters corresponded to complete remission of CAD-induced haemolysis. The
time course of all these changes was highly significant (Friedman ANOVA
p<0.001). Haemolysis recurred when effective drug levels were completely
cleared from the circulation about 4 weeks after the last dose of TNT009. Re-
exposure to TNT009 in a named patient programme recapitulated the immedi-
ate onset of effect, and the rapid and complete stop of haemolysis in these
patients. The only patient who did not respond to TNT009 was suffering from
secondary CAD and had a 70% bone marrow infiltration with chronic lympho-
cytic leukaemia accompanied by CLL-driven severe hypocomplementaemia.
Figure 1: Early changes within one week after TNT009 infusion (60mg/kg) in
the three responders. Individual patients are depicted by the same symbols
throughout. Haptoglobin is slightly offset for better visibility of similar values.
Figure 1.
Summary/Conclusions: TNT009 has an immediate onset of action, and
showed remarkable and unprecedented efficacy in CAD patients in need of
treatment. The three responding patients became transfusion independent
while on TNT009. The results are encouraging and instrumental in planning for
upcoming pivotal studies.
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Background: Daratumumab (D), a human anti-CD38 IgGκ monoclonal anti-
body, was associated with rapid, deep, and durable responses and a favorable
safety profile when combined with lenalidomide and dexamethasone (Rd) in a
phase 1/2 study of relapsed or relapsed and refractory multiple myeloma pts
(Plesner T, et al. ASH 2015, Abs. 507).
Aims: To compare the efficacy and safety of D in combination with Rd vs Rd
alone in pts with RRMM in a randomised, open-label, multicenter, phase 3
study (POLLUX; NCT02076009).
Methods: Pts who received at least 1 prior line of therapy for myeloma were
randomised (1:1) to R 25 mg orally on Days 1-21 of each 28-day cycle and d
40mg weekly, with or without D (16mg/kg qw for 8 weeks, q2w for 16 weeks,
then q4w until progression). The primary endpoint is progression-free survival
(PFS). Secondary endpoints are time to progression (TTP), overall response
rate (ORR), rate of very good partial response (VGPR) or better, minimal resid-
ual disease-negative rate, overall survival (OS), duration of response, time to
response, and safety.
Figure 1.
Results: 569 pts were randomised. Median age of pts was 65 years old. Pts
received a median of 1 prior line of therapy (range 1-11), with 19% of pts with
≥3 prior lines of therapy. Eighty-six percent received a prior PI, and 55%
received prior IMiD, including 18% prior R, with 44% having received both a PI
and an IMiD; 27% were refractory to the last line of prior therapy, 18% were PI
refractory, and none were R refractory. After a median follow-up of 13.5 months,
D significantly improved median PFS (63% reduction in the risk of
progression/death) for DRd vs Rd (Figure 1). Addition of D to Rd significantly
delayed TTP vs Rd (not reached [NR] vs estimated median of 18.4 mo; hazard
ratio, 0.34; 95% CI, 0.23-0.48; P<0.0001). D significantly increased ORR (93%
vs 76%, P<0.0001) and rates of VGPR or better (76% vs 44%, P<0.0001) and
complete response (CR) or better (43% vs 19%, P<0.0001) for DRd vs Rd,
respectively. The median duration of response was NR for DRd vs 17.4 months
for Rd. All preplanned sensitivity analyses were consistent with results from
the primary analysis. Pre-specified subgroup analyses of PFS demonstrated
that the treatment effect of DRd over Rd was consistent across all pre-specified
subgroups. The most common (<25%) TEAEs (DRd/Rd) were neutropenia
(59%/43%), diarrhea (43%/25%), fatigue (35%28%), upper respiratory tract
infection (32%/21%), anemia (31%/35%), constipation (29%/25%), cough
(29%/13%), thrombocytopenia (27%/27%), and muscle spasms (26%/19%).
Most common grade 3/4 TEAEs (>10%) were neutropenia (52%/37%), throm-
bocytopenia (13%/14%), and anemia (12%/20%). The rate of Grade 3/4 infec-
tions/infestations was 28% in the DRd group and 23% in the Rd group and the
most common Grade 3/4 infections/infestations TEAE (≥5%) was pneumonia
(8%/8%). Similar rates of treatment discontinuation due to TEAEs were
observed (7%/8%). D-associated infusion-related reactions (IRR; 48% of pts)
mostly were grade 1/2 (grade 3/4, 5%/0%); most (92% of IRRs) occurred during
the first infusion.
Summary/Conclusion: DRd was superior to Rd alone. A significant reduction
in the risk of disease progression/death was demonstrated with DRd vs Rd.
DRd induced deep and durable responses, including doubling stringent CR/CR
rates and significantly increasing the rate of VGPR or better vs Rd alone. DRd
was associated with a manageable safety profile consistent with the known
safety profile of D and Rd. The combination of D and Rd potentially represents
a new standard of care for pts with >1 prior treatment.
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IMPROVING NELARABINE EFFICACY IN REFRACTORY/RELAPSED
T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY TARGETING ABERRANT
PI3K/MTOR SIGNALING
F Chiarini1,*, A Lonetti2, A Cappellini3, A Bertaina4, F Locatelli4, F Melchionda5,
A Pession5, AM Martelli2
1Institute of Molecular Genetics, Rizzoli Orthopedic Institute, Bologna, National
Research Council, 2Department of Biomedical and Neuromotor Sciences, Uni-
versity of Bologna, Bologna, 3Department of Human Social and Health Sci-
ences, University of Cassino, Cassino, 4Department of Pediatric Hematology
and Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, 5Pediatric
Oncology and Hematology Unit “Lalla Seràgnoli”, S. Orsola-Malpighi Hospital,
University of Bologna, Bologna, Italy
Background: The introduction of novel chemotherapy protocols has improved
the outcome of T-cell acute lymphoblastic leukemia (T-ALL) patients, but refrac-
tory and/or relapsing disease remains a major concern. In this context, a major
contribution was provided by the introduction of the nucleoside analogs and in
particular nelarabine, approved for salvage treatment of refractory/relapsed T-
ALL patients.
Aims: A serious nelarabine drawback is that it induces a dose-dependent neu-
rotoxicity. To improve nelarabine efficacy, it is essential to study its molecular
targets, testing selective inhibitors of such targets, to be administered in com-
bination with nelarabine, allowing for a lower dosage of the chemotherapeutic.
Methods: Human T-ALL cell lines (HBP-ALL, DND41, Jurkat, MOLT-4,
MOLT16, CEM, CEM-R drug-resistant, ALL-SIL, Loucy, HSB2, Peer, PF382,
P12-ICHIKAWA) and primary T-ALL refractory/relapsed lymphoblasts from
patients were incubated with increasing concentrations of nelarabine alone or
combinated with PI3K/mTOR inhibitors for cell viability assays and absolute
cell counting by flow cytometry. Flow cytometry was also performed to analyze
apoptosis and for phenotyping analyses. Protein expression was evaluated by
Western Blot. ENT1/ENT2 gene expression was measured by quantitative real
time PCR in T-ALL settings.
Results: We examined cell viability of cell lines and primary T-ALL
refractory/relapsed cells. Cell viability assays indicated the presence of T-ALL
cell lines sensitive to nelarabine (IC50<5µM) and others which displayed higher
IC50 (>15µM). The most resistant cell line (IC50>300µM) was Loucy, which is
representative of ETP-ALL, a T-ALL subtype with a very poor prognosis. Nelara-
bine sensitive cells showed a significant increase of apoptotic cells after 48h
treatment with 2-5 µM nelarabine, as demonstrated by flow cytometric analyses
of stained with AnnexinV FITC/PI cells and western blot analyses of caspases
8, 9, 3, and PARP. In contrast, resistant T-ALL cells were not perturbated. It has
been reported that the levels of expression of ENT 1/2 nucleoside transporters
were related to in vitro nelarabine sensitivity of T-ALL cell lines and primary sam-
ples. The expression of ENT1/2 transporters could be also dependent on inter-
actions between leukemic cells and tumor microenvironment. No significant dif-
ferences in ENT1/2 mRNA levels between samples sensitive or resistant to
nelarabine were seen. Modulation of ENT1/2 gene expression was not related
to nelarabine treatment, even if in some cases the co-culture with human stromal
cells HS-5, which mimic the bone marrow microenvironment, partially supported
cell survival. Upregulated phosphoinositide 3-kinase (PI3K)/mammalian target
of rapamycin (mTOR) signaling is a common feature of T-ALL, where it portends
a poorer prognosis by influencing leukemic cell proliferation, survival, and drug-
resistance. We analyzed the effects of nelarabine on the phosphorylation status
of key components of the PI3K/mTOR pathway in T-ALL settings. Sensitive T-
ALL cells showed a strong decrease in the phosphorylation of Ser473 p-Akt and
Ser235/236 p-S6 ribosomal protein (S6RP). In contrast, resistant cells treated
with nelarabine alone, showed a hyperactivation of PI3K/mTOR and MEK/ERK
signaling pathways. The combination of nelarabine with the pan PI3K inhibitors
ZSTK474 or BKM120 was synergistic in reducing cell viability and in inducing
strong apoptosis in all the resistant cell lines and in relapsed T-ALL patient sam-
ples with upregulated PI3K/mTOR signaling.
Summary/Conclusions: Nelarabine combined with PI3K inhibitors efficiently
reduced cell viability and induced apoptosis in T-ALL settings, allowing for a
lower dosage of nelarabine and therefore, synergizing with conventional thera-
pies in relapsed/refractory T-ALL patients with upregulation of PI3K signaling.
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ROLE OF G9A AND EPIGENETIC CHANGES IN LEUKEMIA CELL MIGRATION
AND THEIR REGULATION BY VLA4 INTEGRIN
J Redondo-Muñoz1,*, X Zhang2, P Whang3, P Cook4, E Zindy1, CJ Williams5,
TA Jowitt6, AS MacDonald4
1Wellcome Trust Centre for Cell-Matrix Research, 2University of Manchester,
3CRUK Manchester Institute, 4Manchester Collaborative Centre for Inflamma-
tion Research, 5Materials Science Centre, 6Wellcome Trust Centre for Cell
Matrix Research, University of Manchester, Manchester, United Kingdom
Background: T-Acute Lymphoblastic Leukemia (T-ALL) originates from neo-
plastic T cell precursors in the thymus. Usually, T-ALL cells have to migrate
from the thymus into other tissues, where residual cells might persist after treat-
ments. The nuclear deformability of these tumor cells, and the signals from the
cell receptors called integrins are critical to allow cancer cells to squeeze and
cross physical barriers. Epigenetics, a novel cancer hallmark that comprises
histone modification, histone variants and DNA modifications, leads a new drug
generation to prime cancer cells to death. But some epigenetic changes, such
as H3K9me3, have been linked with cancer invasion, and might have additional
functions leading cancer progression.
Aims: The objective of this study was to explore how epigenetic changes
induced by the integrin VLA4/α4β1 control, in a transcriptional independent
manner, the nuclear deformability and infiltration of ALL cells.
Methods: Human T (Jurkat) leukemia cell lines, and normal primary T cells
were cultured in suspension or on integrin ligands for different times and the
levels of H3K9me3 were determined. Nuclear deformability was evaluated
using several biophysical techniques, such as Atomic Force Microscopy. To
identify the molecular mechanism induced by α4β1 integrin, and how this would
be relevant for T-ALL cell migration, different biochemical and cell biology meth-
ods were performed.
Results: We showed that acute lymphoblastic leukemia (ALL) cells cultured
on VCAM1 or Fibronectin (ligands of α4β1 integrin) presented higher levels of
H3K9me3 than cells in suspension. We confirmed that ALL cells were more
sensitive to this effect than normal T-cells. We determined that G9a, a histone
methyltransferase, localized at the nuclear envelope and was responsible for
H3K9 methylation when T-ALL cells were cultured on VCAM1. We used stable
Jurkat cells depleted for G9a to demonstrate that H3K9 methylation contributed
to the nuclear stiffness and the ability of ALL cells to migrate in response to
chemotaxis and in 2D and 3D environments.
Summary/Conclusions: Our results reveal novel functions for G9a in modu-
lating ALL migration, which might contribute to tumor cell dissemination and
leukaemia progression.
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DYNAMICS OF EARLY RESPONSE TO TREATMENT OF CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA IS ASSOCIATED WITH GENE
DEFECTS
A Pastorczak1,*, L Sedek2, M Braun1, J Taha1, E Polakowska1, M Bartlomiejczyk1,
A Sonsala2, J Madzio1, W Fendler1, E Ulinska3, M Matysiak3, K Derwich4,
M Lejman5, J Kowalczyk5, A Koltan6, B Kazanowska7, T Szczepanski2,
W Mlynarski1
1Department of Pediatrics, Oncology, Hematology and Diabetology, Medical
University of Lodz, Lodz, 2Department of Pediatric Haematology and Oncology,
Medical University of Silesia, Zabrze, 3Department of Paediatric Haematology
and Oncology, Medical University of Warsaw, Warsaw, 4Department of Pediatric
Haematology, Oncology and Transplantology, University of Medical Sciences,
Poznan, 5Department of Paediatric Haematology and Oncology, Medical Uni-
versity of Lublin, Lublin, 6Department of Pediatric Haematology and Oncology,
Collegium Medicum, Bydgoszcz, 7Department of Pediatric Haematology, Oncol-
ogy and Transplantology, Medical University of Wroclaw, Wroclaw, Poland
Background: Genetic abnormalities such as BCR-ABL1 translocations, MLL
and CRLF2 rearrangements and IKZF1 deletions influence blast clearance dur-
ing induction phase of childhood B-cell precursor ALL (BCP-ALL). Minimal resid-
ual disease (MRD) at different time-points of the induction protocol reflects
chemosensitivity and may provide information about resistance of leukemic
cells to cytotoxic drugs.
Aims: We investigated early response to treatment at three time-points of
induction protocol (days 8, day 15 and 33) in patients with childhood ALL with
respect to genetic abnormalities.
Methods: 481 children (median age 4.33 yrs), with newly diagnosed BCP-ALL
treated between 02-2009 and 08-2015 with the ALL-IC BFM09 protocol in cen-
ters of the Polish Pediatric Leukemia/Lymphoma Study Group were enrolled
into analysis. Targeted copy number screening was performed on available
DNA samples (n=457) using the P335-B2 SALSA MLPA kit (MRC-Holland,
Netherlands). IKZF1 deletions were confirmed with breakpoint-specific multi-
plex-PCR. CRLF2 protein expression on leukemic cells was determined by
flow cytometry (FCM). Steroid resistance was defined as the presence of ≥1000
leukemic cells/µl of peripheral blood after 7 days of steroid therapy. MRD was
measured at day 15 (MRD15) and day 33 (MRD33) of induction therapy using
8-color flow cytometry. Chemosensitivity of leukemic cells to L-asparaginase,
antracyclines and steroids was tested in vitro using an MTT assay (n=27).
Results: The frequency of cytogenetic abnormalities and microdeletions in
selected genes were as follow: BCR-ABL1 fusion n=11 (2.4%), MLL rearrange-
ments n=24 (5.2%), IKZF1del n=96 (20%), PAX5 del n=100 (22%), PAR1 del
n= 42 (10%), CDKN2A del n=128 (28%), CDKN2B del (26%), BTG1 del n=39
(8.5%), ETV6 del n=101 (22%), EBF1 del n=21 (4.5%), RB1 del n=30 (6.5%).
TLSPR expression was observed in 6% of patients (22/358). Poor steroid
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response was present in 42 cases (42/452=9.3%) and was not associated (all
p>0.15) with any of the analyzed genetic factors. Median MRD15 and MRD33
were 5.67% and 0.01% respectively. In univariate analysis median MRD level
at day 15 was significantly higher among patients with BCR-ABL1 fusion
[12.69(2.5-37.78)% vs 0.31(0.03–3.28)% p=6x10-4], IKZF1del [1.005(0.072-
12.54)% vs 0.3(0.03-2.7)%, p=4x10-4] and ETV6del [0.6(0.075-6.615)% vs
0.32(0.029-3.94)%, p=0.02]. Also median MRD level at day 33 was elevated
in patients with BCR-ABL1 fusion [0.03(0.0001-0.08)% vs 1x10-4(0.0001-
0.005)%, p=0.02] and in patients with IKZF1 deletion [1x10-4(0.0001-0.05)%
vs 1x10-4(0.0001-0.003)%, p=0.02]. Multivariate analysis of MRD15, MRD33
and ΔMRD was done for variables with univariate significance of p<0.15
(log10WBC, age at diagnosis, sex, poor steroid response, hypodiploidy, MLL
rearrangements, BCR-ABL1 fusion, IKZF1 del, ETV6 del, EBF1 del, PAR1 del).
A mixed effects model was used to evaluate intraindividual changes of MRD15
and MRD33 and factored in genetic covariates. The following variables were
significant for MRD15 and MRD33 timepoints: log10WBC (β=0.28, p=1x10-7)
and (β=0.09, p=0.05), age at diagnosis (β=0.22, p=1x10-7) and (β=0.23,
p=1x10-6), IKZF1 del (β=0.14, p=1x10-3) and (β=0.08, p=0.08), respectively.
Additionally the following variables were significantly associated with the
absolute difference of MRD between MRD33 and MRD15: logWBC (β=-0.15,
p=4x10-4), steroid resistance (β=-0.38, p=1x10-6), IKZF1 del (β=-0.19, p=2x10-
2), and PAR1 del (β=-0.13, p=3x10-3). MTT confirmed increased resistance to
asparaginase of IKZF1 del positive blasts (p=0.01).
Summary/Conclusions: Poorer blast clearance during induction protocol in
ALL patients harboring IKZF1 deletions may result partly from chemoresistance
to L-ASP, which was noted for the first time in both clinical and in vitro settings.
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THE WEE1 INHIBITION DEEPLY SENSITIZES ACUTE LYMPHOBLASTIC
LEUKEMIA CELL LINES AND PRIMARY CELLS TO THE CYTOTOXIC
EFFECT OF DIFFERENT ANTINEOPLASTIC COMPOUNDS
A Ghelli Luserna Di Rorà1,*, I Iacobucci1, N Beeharry2, C Papayannidis1,
E Imbrogno1, V Robustelli1, A Ferrari1, V Guadagnuolo1, M Cavo1, G Martinelli1,
TJ Yen2
1Department of Hematology and Medical Sciences “L. and A. Seràgnoli,
Bologna, Italy, 2Cancer Biology Program, Fox Chase Cancer Center, Philadel-
phia, United States
Background: Although the efficacy of Checkpoint kinase inhibitors have been
established in different kind of tumors, only few studies have been performed
in order to evaluate their effectiveness on hematological disorders. The Wee1,
ATR/Chk1 and ATM/Chk2 pathways are involved in cell cycle regulation, DNA
damages response and DNA repair. Wee1 is a checkpoint kinase, involved
mainly in the regulation of G2/M transition through the phosphorylation of both
Cyclin-dependent kinase 1 (CDK1) and 2 (CDK2). 
Aims: In this study we evaluated the in vitro/ex vivo efficacy of a Wee1 inhibitor,
MK-1775, in single agent and in combination on Acute Lymphoblastic Leukemia
(ALL) cell lines and primary samples.
Methods: A panel B-/T-ALL cell lines and different primary cells isolated from
adult ALL patients were treated in single agent or in combination with different
compound (nucleoside analogue, Clofarabine; tyrosine kinase inhibitor, Bosu-
tinib; Chk1/Chk2 inhibitor, PF-00477736) and then was evaluated the reduction
of the cell viability (MTS reagent), the reduction of the proliferation(Trypan blue
exclusion dye assay), cell cycle modification (Propidium iodide staining), induc-
tion of apoptosis (Annexin V/Pi staining), protein modification (Western blot)
and protein expression modification (Prime PCR plate).
Results: MK-1775 deeply reduced the cell viability in a dose and time-depen-
dent manner in all the treated cell lines. The reduction of both cell viability and
proliferation were associated with the increment of apoptosis and the activation
of different DNA damage markers (gH2AX and Parp-1), confirming the cyto-
toxicity of MK-1775 in single agent. We hypothesized that targeting Chk1, a
kinase upstream, of Wee1, would be more effective in reducing cell proliferation.
Indeed, the concomitant inhibition of Chk1 and Wee1 kinases, using the PF-
0477736 in combination with MK-1775, synergized in the reduction of the cell
viability, inhibition of the proliferation index and induction of apoptosis. We
undertook further studies to understand the chemo-sensitizer activity of the
compound, thus MK-1775 was combined with different drugs (Clofarabine,
Bosutinib Authentic, Bos, and a particular isomer of Bosutinib, Bos-I).The com-
bination between MK-1775 and clofarabine showed an additive effect in terms
of reduction of the cell viability and induction of apoptosis. Finally the Wee1
inhibitor was combined with the tyrosine kinase inhibitors Bos and Bos-I. Both
isomers in combination with MK-1775 showed an additive effect in term of
reduction of the cell viability and induction of apoptosis. The cytotoxic effect of
Bos-I was stronger on the Philadelphia-negative cell lines in comparison to the
positive counterpart. Western blot analysis highlighted that this compound, but
not the Bos, interfered with the Chk1/Chk2 and Wee1 pathway. The results
found on the different cell lines were confirmed also on primary leukemic cells.
Summary/Conclusions: In our opinion the results of this study identify the
Wee1 kinase as a promising target for the treatment of ALL. As monotherapy
the inhibition of Wee1 increases the genetic instability of leukemic cells, pro-
moting cell death caused by progressive addition of DNA damages. As chemo-
sensitazer agent, the MK-1775 inhibits the DNA damage response pathway,
increasing the cytotoxicity of different compounds. Supported by ELN, AIL,
AIRC, progetto Regione-Università 2010-12 (L. Bolondi), FP7 NGS-PTL project.
Martinelli G. & YenT.J. equal contribution
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CHARACTERISATION OF JAK3 KINASE DOMAIN MUTANTS
S Degryse1,2,*, M Vanden Bempt1,2, S Demeyer1,2, K Jacobs1,2, E Geerdens1,2,
J Cools1,2, CE de Bock1,2
1Center for the Biology of Disease, VIB, 2Center for Human Genetics, KU Leu-
ven, Leuven, Belgium
Background: Janus kinase 1 (JAK1) and JAK3 are cytosolic tyrosine kinases
that are required for cytokine receptor signaling. Recent studies have identified
both JAK1 and JAK3 mutations in ALL, AML and lymphoma. JAK3 is mutated
in 16% of T-ALL cases. The maojority of these mutations are found within the
pseudokinase and kinase domains of JAK3.
Aims: To determine the transforming mechanism of newly identified JAK3
kinase domain mutants L875H, P906S and E958K and to characterize their
sensitivity to various JAK inhibitors.
Methods: We studied six JAK3 mutations, two pseudokinase (M511I and
R657Q) and four kinase domain (L857Q, L875H, P906S and E958K) mutants.
We expressed these proteins in Ba/F3 (proB-cell) and ex vivo cultured primary
mouse T-cells. CRISPR/Cas9 genome editing was used to generate common
gamma chain (Il2rg) and Jak1 knock out cells.
Results: All six JAK3 mutants were able to transform Ba/F3 cells to growth
factor independent growth. The JAK3 L857Q and L875H mutants were able to
transform the Ba/F3 cells in the absence of Jak1 or Il2rg, indicating that these
two kinase domain mutants do not require binding to a cytokine receptor and
do not require Jak1 as a signaling partner. In contrast, the JAK3 M511I, R657Q,
P906S and E958K mutants required the presence of Jak1 and Il2rg. Moreover,
the growth of these four JAK3 mutants was decreased by overexpression of
wild type JAK3 showing that the JAK3 mutants compete with wild type Jak3
for binding to the receptor. Using a proT-cell model, the two JAK3 kinase
domain mutants L857Q and L875H showed increased transformation to
cytokine independent growth compared to the remaining JAK3 mutants. We
next determined the sensitivity of the cells transformed by the JAK3 mutants
to either JAK3 selective inhibitors (tofacitinib and decernotinib) or JAK1 selec-
tive inhibitors (ruxolitinib and baricitinib). Decernotinib was able to inhibit all
JAK3 mutants. While tofacitinib was able to inhibit most JAK3 mutants, the
L875H mutant was resistant to this compound. Whilst the JAK1 selective
inhibitors were able to inhibit the JAK3 M511I, R657Q, P906S and E958K, they
were not able to inhibit the JAK3 L857Q and L875H mutants that were shown
to transform cells independently of JAK1.
Summary/Conclusions: The majority of JAK3 mutant proteins require binding
to a cytokine receptor complex for full activation and transformation of cells to
cytokine independent growth and are sensitive to JAK1 selective inhibition. All
data indicated that the transforming mechanism of the two kinase domain
mutants L857Q and L875H differ from the other JAK3 mutants. They can acti-
vate downstream signaling independent of the receptor complex and are not
sensitive to JAK1 selective inhibition. In addition, the L857H mutants show a
high tolerance for the JAK inhibitor tofacitinib.
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IDELALISIB SENSITIVITY AND MECHANISMS OF DISEASE PROGRESSION
IN RELAPSED TCF3-PBX1 ACUTE LYMPHOBLASTIC LEUKEMIA
S Eldfors1,*, H Kuusanmäki1, M Kontro2, MM Majumder1, A Parsons1,
H Edgren3, T Pemovska1, O Kallioniemi1, K Wennerberg1, N Gökbuget4,
T Burmeister5, K Porkka2, C Heckman1
1Institute for Molecular Medicine Finland, University of Helsinki, 2Hematology
Research Unit Helsinki, University of Helsinki and Helsinki University Central
Hospital Cancer Center, 3Medisapiens Ltd., Helsinki, Finland, 4Department of
Medicine II, Goethe University, Frankfurt, 5Department of Hematology, Oncol-
ogy and Tumorimmunology, Charité Universtätsmedizin Berlin, Berlin, Ger-
many
Background: TCF3-PBX1 (E2A-PBX1) is a recurrent gene fusion in B cell
precursor lymphoblastic leukemia (BCP-ALL) resulting from translocation
t(1;19)(q23;p13). The majority of human TCF3-PBX1 BCP-ALLs are pre-B-cell
receptor positive. TCF3-PBX1 BCP-ALL patients typically respond to
chemotherapy; however, many relapse and subsequently develop resistant
disease with few effective treatment options. Mechanisms driving disease pro-
gression and therapy resistance have not been studied previously in TCF3-
PBX1 BCP-ALL.
Aims: Here, we aimed to identify novel options for treating TCF3-PBX1 BCP-
ALL by profiling leukemic cells from a 25-year-old male who relapsed after
chemotherapy and allogeneic bone marrow transplant. In addition, we sought
to identify molecular mechanisms underlying disease pathogenesis and pro-
gression.
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Methods: Bone marrow (BM) aspirates and a skin biopsy were collected from
the index patient at diagnosis and relapse. The sensitivity of BM mononuclear
cells was assessed against a library of 302 investigational and approved anti-
neoplastic drugs. To understand molecular mechanisms underlying the patho-
genesis and progression of the disease, we performed in-depth molecular pro-
filing of the patient samples. Exome sequencing was used to identify somatic
mutations and copy number aberrations at diagnosis and relapse, while RNA
sequencing was performed to identify aberrant gene expression. Drug classes
effective at inhibiting the viability of the patient cells were further investigated
using TCF3-PBX1+ BCP-ALL and control cell lines that lacked the fusion.
Results: Drug sensitivity testing showed that leukemic blasts from relapse
samples of the index patient were sensitive to several classes of targeted drugs.
Among the most effective was idelalisib, inhibitor of phosphatidylinositide 3-
kinase delta (p110δ) and approved as a second line treatment for CLL and fol-
licular lymphoma. Testing of two relapse samples from the index patient (668_1
and 668_4), positive control CLL and healthy controls showed that the index
BCP-ALL and CLL cells were similarly sensitive to idelalisib (Figure 1a). To
determine whether idelalisib sensitivity is common to all BCP-ALLs, we tested
the sensitivity of TCF3-PBX1 positive (n=3) and negative (n=3) BCP-ALL cell
lines. Two TCF3-PBX1+ cells lines were sensitive while all negative cell lines
were resistant (Figure 1b). The TCF3-PBX1+ 697 cell line had a mutation to
NRAS, likely resulting in RAS pathway activation and altering sensitivity to ide-
lalisib. Idelalisib sensitivity of TCF3-PBX1+ BCP-ALL cells was further support-
ed by evidence showing TCF3-PBX1 directly regulates expression of PIK3CD,
the gene encoding p110δ. RNA sequencing of the relapse samples showed
high CXCR4 expression, which was not observed in a cohort of diagnostic
phase TCF3-PBX1 BCP-ALLs (N=15). CXCR4 mediates interactions with
CXL12 expressing BM stromal cells and has been implicated in contact medi-
ated drug resistance. Idelalisib inhibits CXCR4 signaling providing a rationale
for using this drug to counter drug resistance. The index patient’s leukemia
acquired mutations to both TP53 alleles at relapse. In addition, the patient’s
leukemic cells had an MTOR mutation, which was associated with high sensi-
tivity to mTOR inhibitors, which has not been observed before in TCF3-PBX1
BCP-ALL.
Figure 1.
Summary/Conclusions: Our results suggest idelalisib is a promising treatment
option for patients with TCF3-PBX1 BCP-ALL, while other drugs could be useful
depending on the genetic context of individual patients.
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INFANT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA SHOWS CHARACTERISTIC
GENETIC FEATURES COMPARED TO CHILDHOOD CASES
J Hoell1,*, M Dörrenberg1, A Klötgen1, M Gerzmehle2, W Wössmann3, M Stanulla4,
A Borkhardt1
1Department of Pediatric Oncology, Hematology and Clinical Immunology, Hein-
rich Heine University Duesseldorf, Duesseldorf, 2ALL BFM Trial center, University
Hospital Schleswig-Holstein, Kiel, 3Department of Pediatric Hematology and
Oncology, University Hospital Gießen and Marburg, Gießen, 4Pediatric Hema-
tology and Oncology, Hannover Medical School, Hannover, Germany
Background: Survival rates of infants (<1 year of age) diagnosed with acute
lymphoblastic leukemia (ALL) remain poor with a 4-year event free survival of
47% (Interfant-99). Beside their often highly aggressive initial clinical presen-
tation, these patients usually do not respond well to current therapies. For rea-
sons not yet understood, nearly all of those patients present with B cell-ALL
with T cell-ALL remaining an absolute rarity in infants.
Aims: Given its rarity, the biology of infant T-ALL is not understood. Also, it is
not clear whether it presents a distinct disease compared to T-ALL diagnosed
in later childhood. The aim of our present study therefore was to identify the
landscape of genetic alterations of infant T-ALL by whole-exome sequencing
(WES), transcriptome and microRNA sequencing.
Methods: We analyzed a total of three infant T-ALL patients and six childhood
T-ALL patients as comparison. All sequencing was performed on a HiSeq 2500
(Illumina). Obtained sequence reads were aligned to the human reference
genome. Resulting variation calls were annotated by Variant Effect Predictor.
MuTect and VarScan2 were employed for identification of somatic nucleotide
variations (SNVs). Correlation analyses based on public databases for miR-
NA-mRNA targeting were performed to reveal miRNA-mRNA pairs expressed
in a negative correlation fashion.
Results: In total, 4504 genes had SNVs in any of the three infant patients, 1305
were recurrent in at least two and 557 in all three infant patients. We did not
detect any SNVs in Notch1, however, we found SNVs in Notch2 and Notch3. On
transcriptome level, 676 genes were differentially expressed (│logFC│ ≥1,
FDR<0.05) between the patient groups. Out of these genes, 194 were downreg-
ulated in infants and 482 were upregulated when compared to childhood cases.
The hierarchical clustering of these significantly differentially expressed genes
clearly separated the two patient groups. To analyze the differences between
infant and childhood T-ALL samples on an epigenetic level, we performed miRNA
sequencing and found 55 miRNAs which were differentially expressed between
infant and childhood cases. Correlation analysis for differentially expressed miR-
NA-mRNA target pairs revealed 34 miRNA-mRNA pairs (Spearman’s Rho ≤ -
0.6, FDR ≤0.05). Pathway analyses (Ingenuity Pathway Analysis/IPA, Qiagen)
showed 51 pathways which were differentially regulated between infant and child-
hood patients (p-value<0.05). Most perturbed pathways fell into categories with
functions in the immune system or were cancer-related, including differentiation,
proliferation, apoptosis or cell survival signaling. Examples include ERK5 and
TLR signaling. Both toll-like-receptors 2 (TLR2) and 4 (TLR4) were predicted to
be inhibited by IPA leading to an aberrant expression of their downstream targets.
TLR2 was not significantly downregulated in T-ALL infant samples with a logFC
of -1.21 (FDR=0.5), because of variant expressions within the groups. However,
one infant case showing a slightly higher expression of TLR2 was carrying an
SNV in its coding sequence leading to a missense variant. Several TLR2 targets
including SELP, ITGA2B, IL1B, CXCL8 and CD86 were significantly downregu-
lated in infant compared to childhood T-ALL samples.
Summary/Conclusions: Our analyses on exome, transcriptome and miRnome
level suggests that infant T-ALL has distinct disease features compared to child-
hood T-ALL. Differences were observed on both transcriptomic and epigenetic
level. Moreover, we describe several differentially expressed pathways including
ERK5 and TLR signaling pathways.
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IDENTIFICATION OF THE GENOMIC AND TRANSCRIPTOMIC CHANGES
CORRELATED WITH THE EX VIVO RESISTANCE TO DAUNORUBICIN AND
DOXORUBICIN IN PEDIATRIC ACUTE LEUKEMIAS
J Laskowska1,2,*, J Szczepanek1,2, A Tretyn1,2, J Styczyński3
1Centre for Modern Interdisciplinary Technologies, 2Department of Plant Phys-
iology and Biotechnology, Nicolaus Copernicus University, 3Department of Pedi-
atric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus Uni-
versity, Torun, Poland
Background: Drug resistances in leukemias correlates with numerous genomic
and transcriptomic changes, but the significant majority is still unidentified.
Daunorubicin (DNR) and doxorubicin (DOX) are chemotherapeutics of the
anthracycline family frequently used in acute leukemias (AL) treatment.
Aims: The objective of the experiment was to identify changes on the genome
and transcriptome level and compare them with ex vivo resistance to DNR and
DOX in pediatric patients with acute lymphoblastic (ALL) or myeloblastic (AML)
leukemia.
Methods: In order to determine the ex vivo drug resistance profiles to DOX
and DNR, MTT cytotoxicity assay was performed on mononuclear cells from
155 patients with ALL or AML. Gene expression profiles (51 patients with ALL,
16 with AML) were prepared on the basis of cRNA hybridization to oligonu-
cleotide arrays of the human genome (Affymetrix). CGH array profiles, (34
patients with ALL, 12 with AML) were prepared on the basis of gDNA hybridiza-
tion to oligonucleotide arrays of the human genome (Agilent). Data were ana-
lyzed using bioinformatics tools (Partek GS, GeneSpring, Feature Extraction,
CytoGenomics) and data bases (UCSC Genome Browser, GeneCards, Pan-
therDB). Validation of array results was performed by RT-qPCR with the use of
UPL probes for 20 genes comparing to 4 reference genes. The relative expres-
sion was calculated by Pfaffl method of quantification in REST-2009 (Qiagen).
Results: Ontological analysis of selected genes in transcriptomic profiles
revealed, that hydrolases were mostly overexpressed in lymphoblasts resistant
to DNR and DOX, but contrarily hydrolases showed differential expression level
in AML cells resistant to DNR. Moreover, in both leukemic blasts resistant to
DNR, chemokines were overexpressed. Additionally, in myeloblasts resistant
to DNR, genes involved in transcription from RNA polymerase II promoter were
downregulated, in ALL cells resistant to DOX-overexpressed, and in ALL blasts
resistant to DNR genes showed differential expression. On the basis of
achieved aCGH results, we singled out a couple of recurrent genomic changes
identified among children with AL. Amp8p12-p11.21 is statistically significant
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rearrangement in resistant DNR profile, additionally del9p21.3 and
amp22q11.22 are in resistant DOX profile. In blasts sensitive to DNR, we also
identified del5q32-35.3, amp14q32.33, del15q11.1-11.2 and del21.11.2-p11.1.
What is more, the results of relative expression analysis of candidate and ref-
erence genes are presented in Table 1.
Table 1. Microarray and qPCR expression level analysis for all valifated
genes.
Summary/Conclusions: The multidimensional analyses revealed, that resist-
ance to DNR and DOX are the result of recurrent genomic and transcriptomic
changes in leukemic blasts. We presume, that chromosome aberrations
del9p21.3 and amp22q11.22 may associate with resistance to DOX, and
amp8p12-p11.21 with lack of sensitivity to DNR and DOX. Additionally, basing
on the Real-Time PCR results, we selected presumable target genes, such as
ANXA1, ARAP1, FGR, HK3, SERP1, ITGAM, DUSP2, RETN, ITGB2 in DOX
and IDA profiles. All of them were overexpressed. Interestingly, CASP1 was
unique target gene in DOX resistant profile and PCDH9 in DNR resistant profile.
Overexpression of CASP1 may influence on immune response in leukemia.
Furthermore, the decreased expression level of cadherins (such as PCDH9)
may have impact on the interactions of hematopoietic progenitors and bone
marrow stromal cells, resulting breakdown of adhesive mechanisms and
enhancement of cell proliferation. This study was supported by Grant from the
National Science Centre No. DEC-2011/03/D/NZ5/05749.
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SLOWER EARLY RESPONSE TO TREATMENT AND DISTINCT EXPRESSION
PROFILE OF CHILDHOOD HIGH HYPERDIPLOID ACUTE LYMPHOBLASTIC
LEUKAEMIA WITH DNA INDEX<1.16
M Zaliova1, L Hovorkova1, M Vaskova1, O Hrusak1, J Stary2, J Zuna1,*
1CLIP, Dept. of Paediatric Haematology and Oncology, 2Dept. of Paediatric
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Background: Acute lymphoblastic leukaemias (ALL) with 51-67 chromosomes
in leukaemic cells are defined as high-hyperdiploid (HHD). Besides the number
of chromosomes, the hyperdiploid ALL can be determined also by DNA index
(DNAi; established by flow cytometry), representing ratio of DNA content in
leukaemic vs normal diploid cells. In childhood, HHD leukaemias comprise 25-
30% of all cases, typically arise from B lymphocyte precursors and are generally
associated with good prognosis. However, several studies show heterogeneity
in HHD-ALL and suggest that the favourable prognosis is associated rather with
cases presenting with higher ploidy defined by DNAi >=1.16 or with a presence
of specific single or combined trisomies. Thus, cases with DNA index >=1.16
and<1.6 are often considered as “typical” high hyperdiploid ALLs while leukemias
with >50 chromosomes and DNA index<1.16 are only rarely studied separately.
Aims: In this study we analysed childhood HHD-ALL patients divided into
groups with lower (<1.16) and higher (>=1.16) DNAi to reveal biological and
clinical differences between the two subgroups.
Methods: Eighty-nine childhood HHD-ALL patients were analysed by single
nucleotide polymorphism array to determine extra chromosomes and to corre-
late the data with DNA content established by flow cytometry. Moreover, we
analysed treatment response, presence of secondary aberrations, mutations
in Ras pathway genes (NRAS, KRAS, FLT3, PTPN11) and also gene expres-
sion profile (GEP) to reveal possible differences between the two subgroups.
Results: Our results show that vast majority of cases with 51 to 54 chromo-
somes have DNAi between 1.1 and 1.16 and cases with 55 and more chromo-
somes have usually DNAi >=1.16. The groups with lower and higher DNAi
have distinct response to early treatment - the better response of the group
with higher DNAi is probably associated with specific chromosomal gains (tri-
somy of chromosome 10 or combined with trisomies 4 and/or 17) highly
enriched in the group with higher DNAi. Moreover, patients with lower and high-
er DNAi show distinct GEP in unsupervised clustering analysis; importantly,
analysis of the differentially expressed genes and number of its genomic copies
suggests, that gene dosage effect probably does not play a driving role in the
different behaviour of the two HHD-ALL subgroups.
Summary/Conclusions: The distinct GEP suggests that cytogenetically
defined HHD-ALL is in fact composed of two biologically distinguishable sub-
groups. These differences should be taken into account when defining ALL
with excellent prognosis; if treatment deintensification is considered for child-
hood HHD ALL, only cases with DNAi >=1.16 and gain of chromosome 10 plus
chromosomes 4 and/or 17 should be taken into account. Support: The study
was supported by grants from Ministry of Health, Czech Republic: IGA
NT/14350-3 and project 00064203 (UH Motol).
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DIFFERENT PROGNOSTIC ROLE OF RECURRENT COPY NUMBER
ABERRATIONS IN B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
WITHOUT RECURRENT FUSION GENES IN 3 CONSECUTIVE AGE
COHORTS
M Messina1,*, S Chiaretti1, AL Fedullo1, A Piciocchi2, MC Puzzolo1, S Grammatico1,
V Apicella1, G Te Kronnie3, M Vignetti2, AM Testi1, A Vitale1, A Guarini1, R Foà1
1Hematology, Department of Cellular Biotechnology and Hematology, Sapienza
University, 2GIMEMA Data Center, Rome, 3Department of Women and Child
Health, University of Padova, Padua, Italy
Background: In B-lineage acute lymphoblastic leukemia negative (B-NEG
ALL) for recurrent fusion genes (BCR-ABL1, MLL-rearrangements, TCF3-
PBX1, ETV6-RUNX1), the most common copy number aberrations (CNAs) -
i.e. IKZF1, PAX5, EBF1, BTG1, CDKN2A, RB1, CRLF2 deletions - increase
with age progression (Messina et al, 2016). While the prognostic role of IKZF1
deletion (ΔIKZF1) has been extensively studied, novel data on the potential
role of other CNAs are currently emerging. With the number of novel prognostic
markers increasing exponentially, ALL risk assessment is becoming complex;
thus, it is crucial to provide a simplified, integrated predictor, possibly adjusted
for age-cohort.
Aims: 1) To correlate the most common CNAs with the clinico-biological fea-
tures of B-NEG ALL patients; 2) to assess their prognostic role; 3) to evaluate
whether their impact on outcome varies across age-cohorts.
Methods: CNAs of the above mentioned genes were studied by Multiplex Lig-
ation-dependent Probe Amplification (Salsa MLPA P335 ALL-IKZF1 kit, MRC-
Holland) in 157 B-NEG ALL, including 56 adults, 56 adolescents/young adults
(AYA) and 45 children. CNAs were correlated with age, gender, Hb levels, white
blood cell (WBC) and platelets counts, and with RAS and JAK/STAT pathway
mutations. The impact of CNAs on disease free survival (DFS) was analyzed.
Results: Overall, 46.6% of children, 82.4% of AYA and 87.5% of adults, carried
at least 1 CNA. In particular, deletions of IKZF1 were detected in 41.4%, of
CDKN2A in 36.9%, of PAX5 in 25.5%, of ETV6 in 17.8%, of EBF1 in 12.1%
and of BTG1 in 10.2% of patients, with IKZF1, CDKN2A, PAX5 and BTG1 dele-
tions being significantly more frequent in adults and AYA than in children, as
already mentioned. EBF1 and CDKN2A-deleted patients had a significantly
higher WBC count. BTG1 deletions occurred exclusively in males (p=0.002).
Furthermore, JAK/STAT mutations were significantly associated with EBF1
(p=0.033) and CDKN2A deletions (p=0.026). Survival analyses on the whole
cohort with clinical data available (N=133) showed that CDKN2A-deleted
patients had a significantly worse DFS than CDKN2A-WT cases at 5 years
(39.7% vs 64.1%, p=0.005); EBF1-deleted patients also had a significantly
poorer DFS than EBF1-WT cases (33.3% vs 60.1%, p=0.003). A trend towards
a worse DFS was observed for BTG1-deleted cases, with its negative impact
being more evident when considering only AYA (30% vs 61.4%, p=0.095).
CDKN2A and EBF1 deletions retained their negative impact on DFS also when
considering the adult cohort only. Indeed, CDKN2A-deleted had a shorter DFS
than CDKN2A-WT cases (12.8% vs 54%, p=0.03); similarly, DFS of EBF1-
deleted was inferior than EBF1-WT cases (0% vs 38.3, p=0.002); a trend was
observed combining adults with AYA, while no impact was found in children. At
variance, a trend towards a better DFS for ETV6-deleted vs ETV6-WT cases
was observed (100% vs 65%, p=0.065) in children, recalling the favorable
prognostic impact of ETV6-RUNX1. In the present cohort, the role of ΔIKZF1
remains controversial: nevertheless, by combining adults and AYA, patients
harboring ΔIKZF1-only or no CNAs had a trend towards a longer DFS than the
remaining cases (62.6% vs 39.1%, p=0.068).
Summary/Conclusions: Besides the heterogeneous distribution, we also
found a different impact on prognosis of CNAs across age cohorts, with
CDKN2A and EBF1 deletions influencing adult patients’ outcome and BTG1
negatively impacting on AYA survival; notably, these lesions did not impact on
the outcome of childhood ALL. These findings indicate that, apart from the
mutational status, risk assessment of ALL should also include the evaluation
of selected CNAs.
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CALCINEURIN COMPLEX ISOLATED FROM T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA (T-ALL) CELLS IDENTIFIES NEW SIGNALING PATHWAYS
WHOSE INHIBITION SYNERGIZE WITH CALCINEURIN INHIBITION TO
PROMOTE T-ALL CELL DEATH
V Tosello1, V Saccomani2, J Yu3, F Bordin2, A Amadori2, E Piovan2,*
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Background: Calcineurin (Cn) is a calcium activated protein phosphatase,
composed of a catalytic subunit (PPP3CA) and a regulatory subunit (PPP3CB).
It is critically involved in calcium signaling in diverse cells and is involved in
many aspects of normal T cell physiology, however the role of Cn and/or its
downstream targets in leukemogenesis are still ill-defined.
Aims: Available evidence shows that Nuclear Factor of Activated T cells (NFAT)
transcription factors are mediators of Cn action in different cancers. However,
it is possible that NFAT factors are not the only targets of Cn in leukemogenesis,
as Cn can dephosphorylate other factors possibly relevant to its oncogenic
properties. Aim of this study was to identify putative downstream targets/effec-
tors involved in the pro-oncogenic activity of Cn in T-cell acute lymphoblastic
leukemia (T-ALL), evaluate if the interactors are enriched in cellular signaling
pathways relevant for T-ALL pathogenesis and if novel drug combinations can
be proposed to enhance the efficacy of chemotherapeutic drugs and/or reduce
the side effects of clinically relevant immunosuppressive drugs targeting Cn.
Methods: In order to identify putative downstream targets/effectors involved in
the pro-oncogenic activity of Cn in T-ALL we used tandem affinity chromatogra-
phy, followed by mass spectrometry (MS) to purify novel Cn-interacting partners.
Novel interactions were validated by immunoprecipitation following transient
overexpression in 293T cells or as native interactions in T-ALL cells. Drug syn-
ergisms using relevant drug combinations were evaluated through the execution
of cell viability assays (bioluminescent method and annexin V-PI staining). Effects
of Cn activity modulation on cellular signaling pathways found to be enriched in
our MS list were evaluated by western blotting and flow cytometry.
Results: We identified numerous PPP3CA interactors, including proteins impli-
cated in leukemia pathobiology such as NPM1, BCL11B, GSK3b and KDM1.
The identified Cn-interacting proteins were found to be part of diverse cellular
signaling pathways including eIF2 signaling, cell cycle control of chromosomal
replication, mammalian target of Rapamycin (mTOR) signaling and 14-3-3
mediated signaling. Interestingly, modulation of Cn activity (by inhibitors and
activators) lead to alterations in the identified signaling pathways including
PI3K-AKT-mTOR signaling and eIF2 signaling. In addition, jointly targeting path-
ways enriched in our Cn complex (such as PI3K-mTOR signaling, cell cycle
control of chromosomal replication mediated by topoisomerase II) together with
Cn unveiled novel synergistic pro-apoptotic drug combinations.
Summary/Conclusions: The signaling pathways reported here will contribute
to identify novel drug combinations which could enhance the efficacy of
chemotherapeutic drugs and/or reduce the side effects of clinically relevant
immunosuppressive drugs targeting Cn.
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OVEREXPRESSION OF PTP4A3 IN ETV6-RUNX1 ACUTE LEUKEMIA
T Grönroos1,*, S Teppo1, J Mehtonen2, S Laukkanen1, T Liuksiala1,3, M Nykter3,4,
M Heinäniemi2, O Lohi1
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ical Technology, University of Tampere, 4Department of Signal Processing,
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Background: Acute leukemia is the most common cancer in childhood. The
ETV6-RUNX1 (E/R) fusion gene is present in 25% of childhood precursor B
cell acute lymphoblastic leukemia (pB-ALL). E/R fusion is acquired in utero by
a translocation between chromosomes 12 and 21 (t[12,21][p13;q22]). Translo-
cation creates an aberrant fusion transcription factor which induces genome-
wide repression of regulatory sequences and gene transcripts. The family of
protein tyrosine phosphatase 4A (PTP4A) proteins are phosphatases with dual
specificity. The family consists of three closely related members (PTP4A1-3)
and they participate in a wide range of cellular activities, including cell prolifer-
ation, migration and invasion. Kinases and phosphatases have an intricate
relationship in balancing intracellular signalling activity, and this balance is often
deregulated in malignancies.
Aims: There are indications that members of the PTP4A family are involved in
pathogenesis of various hematological malignancies. This motivated us to
investigate the role of PTP4A3 in acute lymphoblastic leukemias by using gene
expression data on patient samples, bioinformatic analyses and experimental
manipulation of cell lines.
Methods: We investigated expression of members of PTP4A family across
acute and chronic leukemias, cell lines and healthy cells of hematopoietic origin
in a large collection of patient samples assayed by Affymetrix HU2.0 microarray
and retrieved from GEO database. After normalization and manual curation, a
two-dimensional “leukemia-map” was generated by t-SNE to visualize the data.
We used experimental manipulation of cell lines to validate our findings from
the “leukemia-map”.
Results: PTP4A3 showed markedly increased expression among pre-B-ALL
and decreased expression in acute myeloid leukemias, chronic leukemias and
healthy cells. In further scrutiny, strong expression of PTP4A3 coincided with
the E/R subtype of pB-ALL, showing approximately four-fold higher expression
as compared to other pB-ALL leukemias (p=5.449805e-50). To validate the
finding, two more patient data sets were retrieved to confirm the higher expres-
sion of PTP4A3 in the E/R subtype. In agreement, induction of E/R fusion in
Nalm-6 cells increased the level of PTP4A3 mRNA. At primary transcript level,
as assayed by global nuclear run-on sequencing (GRO-seq), the decrease of
PTP4A3 expression after E/R knockdown was evident. Further, we identified a
number of potential E/R binding sites upstream of PTP4A3 gene. Inhibition of
PTP4A3 phosphatase activity in E/R positive REH cells was better tolerated as
compared to other tested ALL cells.
Summary/Conclusions: We show that expression of PTP4A3 is markedly
upregulated in the E/R subtype of acute pB-ALL. Our data hint that PTP4A3
expression is regulated by the E/R fusion itself, suggesting further studies on
the surrounding regulatory elements. The potential role of PTP4A3 inhibitors
will be further evaluated in combination with the known anti-leukemic drugs.
E850
DROPLET DIGITAL PCR ANALYSIS FOR DIAGNOSIS AND MINIMAL
RESIDUAL DISEASE MONITORING IN ADULT PH+ ACUTE LYMPHOBLASTIC
LEUKEMIA
F Albano*, N Coccaro, A Zagaria, L Anelli, G Tota, P Orsini, C Brunetti, L Impera,
A Minervini, CF Minervini, C Cumbo, P Casieri, E Parciante, D Pastore,
P Carluccio, G Specchia
Hematology - University of Bari, Bari, Italy
Background: BCR-ABL1 tyrosine kinase inhibitors (TKIs) are considered an
important component of treatment for adult patients affected by Philadelphia-
positive (Ph+) acute lymphoblastic leukemia (ALL). In fact, recent studies report-
ed that treating Ph+ ALL with the combination of imatinib and multi-agent
chemotherapy improved the overall outcome. Currently, no data are available
on the impact of TKIs on minimal residual disease (MRD) in Ph+ ALL. In fact,
although the real-time quantitative PCR (RQ-PCR) method, usually employed
for monitoring the BCR-ABL1 residual transcript, is sensitive and easy to per-
form, it lacks a full standardization and international quality validation.
Aims: Here, we describe a highly sensitive and reproducible droplet digital
PCR (ddPCR) test to monitor BCR-ABL1 transcript level in Ph+ ALL. The aim
of the study is to demonstrate that ddPCR represents a sensitive and rapid
method for both diagnosis and MRD monitoring of Ph+ ALL patients.
Methods: BCR-ABL1 expression analysis by ddPCR was performed in twen-
ty-two newly diagnosed adult Ph+ ALL patients. The diagnosis was confirmed
by qualitative RT-PCR specific for the BCR-ABL1 p190 fusion gene detection.
ddPCR experiments were successfully performed in all twenty-two patients at
the onset; several follow-up points were evaluated in thirteen patients. ddPCR
experiments were performed using primers and probes specific for BCR-ABL1
p190. GUSB was used as control gene. Fifty ng and 750 ng of cDNA templates
were used for the onset and for the post-treatment samples, respectively. To
increase the limit of detection (LOD), three replicates were run for the post-
treatment samples. ddPCR experiments were performed by Bio-Rad’s QX200
system and ddPCR data were analyzed with QuantaSoft analysis software
(version 1.7.4). Target concentration was expressed as BCR-ABL1 copies/mg.
Results: First, we defined the LOD of the BCR-ABL1 p190 ddPCR system, a
10-fold dilution series (100, 10-1, 10-2, 10-3, 10-4, and 10-5) of a pool of p190
positive patients using a diluent-pool of healthy volunteers. This analysis
showed remarkable linearity, trueness, and precision down to 10-5. After con-
verting to log-log scale, linear regression showed no concentration-dependent
bias, and R2 equaled 0.996. Because the negative samples showed no back-
ground, even the detection of a single droplet per well was considered a positive
result. The median concentration of the BCR-ABL1 transcript at the onset was
233.8 (min 3.24-max 1744) x 103 BCR-ABL1 copies/mg. Concerning the analy-
sis of follow-up samples, among the thirty-four points that were negative to
qualitative nested RT-PCR, twenty-three (68%) resulted to be positive by
ddPCR analysis, with a median concentration of 44.95 (min 0.27-max 573.3)
BCR-ABL1 copies/mg. Follow-up points that were negative in ddPCR remained
negative even when the experiments were repeated increasing the depth of
the analysis, evaluating a total quantity of 4.5 micrograms of RNA.
Summary/Conclusions: This study indicates that, as compared to RQ-PCR,
ddPCR increases the depth of the quantitative analysis of BCR-ABL1 p190
fusion transcript by allowing the evaluation of larger amounts of RNA. Moreover,
our preliminary data revealed that the amount of the BCR-ABL1 fusion transcript
at diagnosis is heterogeneous and that the ddPCR is much more sensitive than
nested qualitative RT-PCR analysis, as the 68% of samples negative to nested
PCR during the follow-up resulted to be positive by ddPCR. Therefore, we sug-
gest that ddPCR represents a precise, sensitive and rapid method for both
diagnosis and MRD monitoring of Ph+ ALL patients.
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ABNORMAL EXPRESSION OF THE CYSTEINE AND GLYCINE-RICH
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Background: Cysteine and glycine-rich protein 2(CSRP2) is a member of the
CSRP family of genes, encoding a group of LIM domain proteins, which may be
involved in regulatory processes important for development and cellular differ-
entiation. It has been reported that determination of CSRP2 protein level had a
significant meaning for cardiovascular and respiratory diseases. In view of the
important function of CSRP2 in cell growth and differention, CSRP2 may also
have a role in carcinogenesis. However, the expression of CSRP2 has not been
explored in leukemia, especially in B-cell acute lymphoblastic leukemia (ALL).
Aims: The purpose of this study was to investigate the expression of human
CSRP2 messenger RNA in B-cell acute lymphoblastic leukemia by real-time
fluorescent quantitative reverse transcription-polymerase chain reaction assay. 
Methods: A real-time quantitative RT-PCR based on TaqMan fluorescence
methodology was used to quantify the CSRP2 mRNA copy number in the bone
marrow cells from patients with leukemia and in 11 human leukemic cell lines.
Normal marrow samples from the allogeneic stem cell transplantation donors
were served as control. Informed consent was obtained for every marrow sam-
ple.
Results: Expression levels of the CSRP2 gene in leukemic cell lines, leukemia
patients and normal donor marrow are shown in Figure 1. These results showed
that the relative levels of CSRP2 gene expression in marrow from the 212 newly
diagnosed B-cell ALL was signiﬁcantly higher than those of marrow from the 43
healthy donors(p<0.01). No statistical significant difference was observed in 18
newly diagnosed T-cell ALL, 73 AML and 43 healthy donors (p’s >0.05), but it
was higher in SupB15, BV-173 cells from B-cell ALL cell lines than in other cells
from AML or T-cell ALL cell lines. Focusing on B-cell ALL patients, the median
level of CSRP2 in 212 newly diagnosed patients was 42.13%(range 0-740.55%),
while the median level in 290 treated patients who achieved CR decreased to
0.55%(range 0-21.21%). However, in 17 refractory patients and 22 relapsed
patients, the median level was 60.83%(range 2.89-548.47%) and 43.17%(range
0.08-346.81%), respectively. In newly diagnosed B-cell ALL, 8 patients with
MLL-AF4 translocation showed higher CSRP2 expression levels compared with
124 patients without this translocation(p<0.01). Figure1.Expression levels of
CSRP2 in leukemic cell lines, leukemia patients and normal donor marrow. HD
denotes healthy donors; De nove denotes newly diagnosed; CR denotes com-
plete remission; Horizontal lines represent median CSRP2 expression for each
group.* indicates p<0.05 compared with HD; & indicates p<0.05 compared with
De novo B-cell ALL; # indicates p<0.05 compared with CR B-cell ALL.
Figure 1.
Summary/Conclusions: These ﬁndings suggest that abnormal expression of
CSRP2 in leukemia may be involved in the pathomechanism of B-cell ALL.
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IL7R OVEREXPRESSION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL): PROGNOSTIC IMPLICATIONS IN B-LINEAGE ALL WITHOUT
RECURRENT FUSION TRANSCRIPTS
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and Medical Studies, University of Torino, Torino, Italy
Background: The IL7 receptor alpha chain (IL7R) heterodimerizes either with
the IL2RG to form the IL7 receptor or with CRLF2 to form the receptor for the
thymic stromal lymphopoietin (TSLP) both in T and B-cells. Signaling from
these receptors activates the JAK/STAT pathway that is frequently altered both
in T- and B-lineage acute lymphoblastic leukemia (ALL), due to mutations of
its members. Among them, IL7R mutations are relatively common in adult B-
ALL without recurrent transcripts (B-NEG) and in T-ALL. In a cohort of adult
ALL previously studied by gene expression profiling (GEP) we observed that
IL7R expression levels were variable, with a considerable number of B-NEG
and T-ALL cases overexpressing it, thus suggesting that its deregulation may
rely on different mechanisms.
Aims: To evaluate the clinical relevance of IL7R expression levels in adult B-
NEG and T-ALL, we correlated the levels of IL7R expression with patients’ out-
come and analyzed the transcription profile of IL7R-high cases.
Methods: IL7R expression levels were inferred from previously performed GEP
studies (Affymetrix) of adult ALL, including 78 B-NEG and 68 T-ALL. Martingale
residual analysis was used to select the optimal IL7R cut-off, which was com-
puted separately for these two groups. Differences in survival curves of IL7R-
high and IL7R-low were calculated by the log-rank test. GEP of IL7R-high was
analyzed and correlated with the molecular and immunophenotypic features.
Screening of the JAK/STAT genes recurrently mutated was performed by Sanger
in 66/78 B-NEG (IL7R, CRLF2, JAK2) and 38/68 T-ALL (IL7R, JAK1/3, STAT5B).
Results: IL7R expression levels were extremely heterogeneous both in B-
NEG (mean 656.9, range 43.8-3000) and in T-ALL (mean 1047 range 58.9-
5874). Martingale residual analysis provided a cut-off of 500 for B-NEG and
1000 for T-ALL. By using these cut-points, 47% of B-NEG and 41% of T-ALL
cases were defined as IL7R-high. In B-NEG, correlation between IL7R expres-
sion levels and outcome showed that IL7R-high cases had a significantly short-
er OS at 4 years than IL7R-low (31% vs 62%, p=0.04). Similarly, in T-ALL a
trend towards a poorer OS was observed in IL7R-high patients than IL7R-low
(27% vs 40%, p=0.2). The comparison of IL7R-high and IL7R-low by supervised
GEP analysis identified a set of differentially expressed genes both in B-NEG
(157 genes) and T-ALL (208 genes); only 11 transcripts overlapped. Indeed,
functional annotation analysis of upregulated genes in IL7R-high highlighted
an enrichment of JAK/STAT, Wnt and ErbB signaling members in B-NEG cases
and of JAK/STAT and Notch pathway members in T-ALL, suggesting the
involvement of different downstream cascades. As per the associations with
other biological features, IL7R levels were significantly lower in TAL1 cluster
than in other subgroups (p=0.005). Notably, we observed a significant associ-
ation between IL7R high expression and JAK/STAT pathway mutations both in
B-NEG and T-ALL (p=0.001 and 0.03, respectively), thus indicating that IL7R-
high might be a marker of an underlying JAK/STAT mutation.
Summary/Conclusions: Overall, our findings indicate that IL7R altered
expression may represent a novel prognostic marker in B-NEG cases and, to
a lesser extent, in T-ALL. Given the different GEP observed between IL7R-
high B-NEG and IL7R-high T-ALL, it is intriguing to speculate that IL7R dereg-
ulation may activate different pathways. Furthermore, IL7R overexpression
should prompt the investigation of JAK/STAT mutations both in B-NEG and T-
ALL. However, given the overall incidence of JAK/STAT mutations it is likely
that IL7R overexpression might be also sustained by other mechanisms that
are currently under investigation.
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NEGATIVE PRE TRANSPLANT MINIMAL RESIDUAL DISEASE, ASSESSED
BY FLOW CYTOMETRY, IMPROVES OUTCOME IN ADULT ACUTE
LYMPHOBLASTIC LEUKEMIA, ESPECIALLY IF CLEARENCE IS ACHIEVED
EARLY DURING INDUCTION
M Gambella1,*, F Guolo1, P Minetto1, D Guardo1, E Coviello1, N Bisso1,
N Di Felice1, A Kunkl2, F Ballerini1, M Clavio1, M Miglino1, RM Lemoli1, M Gobbi1
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2Service of Flow Cytometry, IRCCS AOU San Martino-IST, Genoa, Italy
Background: With the introduction of pediatric-inspired induction regimen,
prognosis of adult acute lymphoblastic leukemia (ALL) has substantially
improved, leading to an increased assessment of minimal residual disease
(MRD) during all induction course and a progressive use of MRD-driven ther-
apeutic approach. In most modern pediatric protocols, persistence of MRD dur-
ing the first courses of induction therapy is an adverse prognostic factor and
constitutes a strong indication for early allogeneic bone marrow transplantation
(BMT). However, it remains unclear if an effort towards MRD eradication should
be attempted before BMT, as relatively few data are available on outcome of
MRD positive adult ALL patients.
Aims: The aim of this study was to analyze the role of pre-BMT MRD assess-
ment as predictor for the post-transplant relapse risk and to evaluate the impact
of day 33 MRD status in pre-BMT MRD negative patients.
Methods: We retrospectively analyzed the outcome of 53 consecutive ALL
patients receiving allo-BMT, with available pre-BMT multicolour flow cytometry
(MFC) MRD assessment. Median age at transplant was 30 years. Disease
phase was CR1 in 20 (38%), CR2 in 17 (32%), and CR3 in 14 patients (30%).
Thirty-five patients (66%) had B lineage ALL, whereas 18 (34%) had T-ALL.
Relapse-free survival (RFS) was calculated from the time of transplantation
until last follow-up or documented leukemic relapse. Overall Survival (OS) was
calculated from the time of transplantation until death by any cause or last fol-
low-up. Median follow up was 62 months.
A positive MFC MRD was defined by the presence of no less than 25 clustered
leukemic cells/105 total events (threshold of2.5x10-4 residual leukemic cells) at
four-color flow-cytometry.
Results: Relapse occurred in 30 patients (57%). Three-year RFS was 42.2%
(median 10 months). The probability of relapse was significantly affected by
disease status at BMT (CR1 vs CR2 or p<0.001), karyotype (p<0.03) and MFC
MRD (both day 33 and pre-BMT, p<0.03). Pre-BMT MFC-MRD was a strong
predictor of longer relapse free survival: 5 relapses occurred in the 17 MFC-
MRD negative patients and 3-years RFS was 69.4% (median not reached),
compared to 25 relapses observed in 36 MFC MRD positive patients, with a 3-
year RFS of 29.4% (median 5 months). Multivariate analysis revealed that MFC
MRD and disease status at transplantation were significant predictors of RFS
duration (p<0.001 and p<0.05, respectively). Eleven patients with pre-BMT
MRD negative had available day +33 assessment. Two relapses were observed
among the 3 day 33 MRD positive patients (66%), compared to three relapses
among 8 day 33 MFC MRD negative patients (37%). MRD evaluation was a
strong predictor of long term survival, as 3- years OS was 65% for MFC MRD
negative compared to 49.8% for MFC MRD positive patients (p<0.05).
Summary/Conclusions: Pre transplant MFC MRD evaluation is a feasible and
reliable predictor of relapse risk in adults ALL patients. Patients with positive
MFC MRD have a very high relapse risk and a poor outcome after BMT.
Although small numbers prevented us to drive conclusion, persistence of MRD
at day 33 seems to confer a worse prognosis in pre-BMT MRD patients. In the
era of targeted therapy, at least for B-ALL, persistence of MRD after induction
could be an indication for innovative approach, such as attempts of MRD erad-
ication using recently developed immunoconjugated monoclonal anti-CD-22
antibodies or anti-CD3/anti-CD-19 bispecific antibodies.
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MOLECULAR DETECTION OF ALL IN THE PERIPHERAL BLOOD IS MORE
SENSITIVE THAN FLOW CYTOMETRIC ANALYSIS OF THE BONE
MARROW IN PATIENTS WITH TREATMENT-RELATED HYPOCELLULARITY
I Kirsch1,*, H Smithers2, O Finney2, B Crossley1, M Jensen2, R Gardner2
1Translational Medicine, Adaptive Biotechnologies, 2Pediatric Oncology, Seattle
Children’s Hospital, Seattle, United States
Background: Minimal residual disease detection (MRD) is an important tool
for early detection and monitoring relapse. Traditionally, bone marrow is col-
lected and analyzed by flow cytometry (FC) to evaluate MRD status in acute
lymphoblastic leukemia patients (ALL). More recently, highly sensitive molecular
methods such as high throughput sequencing (HTS) allow for more sensitive
detection of MRD below 1 in 10-5. Although the bone marrow is considered to
be more representative of leukemic burden than sampling the blood, bone mar-
row collection is more invasive, traumatic, and costly than peripheral blood
draws and therefore is performed only at specified and limited intervals. Paired
bone marrow and blood samples from ALL patients can be assessed and com-
pared for MRD at different time points in therapy.
Aims: In this study, we analyzed paired blood and bone marrow samples from
the Adaptive Biotechnologies assay of IgH and TCRG in order to determine
whether HTS performed on a peripheral blood sample is as informative as HTS
and FC on a bone marrow sample in the assessment of MRD.
Methods: ALL patients enrolled in the Seattle Children’s Pediatric Leukemia
Adoptive Therapy (PLAT-02) trial undergo MRD assessment pre and post CD19
CAR T cell infusion by FC of the bone marrow. We have used high throughput
sequencing (HTS) in paired blood and bone marrow samples from these
patients. Samples taken prior to therapy evaluate the complete B cell repertoire
and detect any dominant sequences which may be used for subsequent track-
ing. Samples taken at intervals during therapy assess the levels of MRD up to
63 days post-infusion.
Results: We have obtained 38 paired bone marrow and peripheral blood sam-
ples to date. We have observed a significant correlation in both the frequency
of total reads and the number of malignant cells per million in paired peripheral
blood and bone marrow samples by HTS. Of these, 26/38 (68%) of bone mar-
row samples were determined either aparticulate or hypocellular. Importantly,
8/14 (57%) of patients who were MRD negative in the bone marrow by FC
were MRD positive in the blood by HTS. While it may only be true of patients
receiving this particular form of treatment, there were some samples assayed
by immunosequencing in which peripheral blood was a more sensitive measure
of tumor burden than simultaneously acquired bone marrow. These data sug-
gest, that, in cases where the bone marrow is hypocellular or aparticulate,
peripheral blood samples evaluated by HTS are more sensitive than traditional
flow cytometric analysis in the bone marrow for detection of MRD.
Summary/Conclusions: The impact of B cell aplasia may be important in
increasing the sensitivity of HTS in the detection of MRD. The ability to detect
an ALL B cell clone in the blood through HTS has many clinical implications;
blood can be sampled more often, is less of a burden to patients, and can pro-
vide earlier prediction of relapse.
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DE-ESCALATION OF INTENSITY DID NOT AFFECT THE LONG-TERM OUT-
COME NEITHER IN T-ALL NOR IN BCP-ALL IF NON-INTERRUPTIVE
TREATMENT IS APPLIED: RESULTS OF THE RUSSIAN ALL STUDY
GROUP
E Parovichnikova1,*, V Troitaskaya1, A Sokolov1, G Kliasova1, L Kuzmina1,
S Kravchenko1, E Gribanova1, S Bondarenko2, O Baranova3, Z Akhmerzaeva1,
O Gavrilina1, G Baskhaeva1, T Obukhova1, M Rusinov1, S Kulikov1, E Zinina4,
M Grishunina5, E Zotina6, T Kaporskaya7, L Gavrilova8, V Savchenko1
1National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, 2Research institution of children oncology, hema-
tology and transplantology, Saint Petersburg, 3Russian Cancer Research Cen-
ter, Moscow, 4Regional clinical hospital, Surgut, 5Regional clinical hospital,
Nizhnii Novgorod, 6Regional clinical hospital, Kirov, 7Regional clinical hospital,
Irkutsk, 8Regional clinical hospital, Saransk, Russian Federation
Background: More aggressive pediatric-like protocols and high portion of allo-
geneic HSCT are now a standard approach to treatment in adult acute lym-
phoblastic leukemia (ALL). Here we report the results of the adult (15-55 yy)
Ph-negative ALL protocol based on the different approach: de-escalated but
non-interruptive treatment with low numbers of allo-HSCT. The study is regis-
tered on the ClinicalTrials.gov public site; NCT01193933.
Aims: To assess non-intensive and non-interruptive approach to ALL treatment.
Methods: The ALL-2009 is based on: (1) the replacement of prednisolone (Pdn)
60mg/m2 with dexamethazone (Dexa) 10mg/m2 if blast cells are ≥25% in b/m
after prephase (7d); (2) de-intensified but non-interruptive 5 months induction/con-
solidation treatment (5 wks Pdn/Dexa with 3 instead of 4 Dauno/Vncr pulses, 4
weeks of 6MP with 5 L-asp, 2 instead of 4 ARA-C blocks, 1 instead of 2 Cph
injections during induction; induction-like 3 consolidations for 3wks, 2wks, 4wks
–continuously without intervals), followed by (3) 2 late (at 6 mo) intensifications–
with 1 day HD MTX (1,5 g/m2)and with 1 d HD ARA-C (2 g/m2), both with L-asp
and 3 d dexa and (4) 2-yrs continuous 6MP/MTX maintenance with doses mod-
ification according to myelosuppression with monthly 3-days dexa/vncr/L-asp
pulses (∑ L-asp=590.000IU/m2). The protocol was identical for all risk groups.
For T-ALL patients auto-HSCT after non-myeloablative BEAM conditioning fol-
lowed by the protocol maintenance was an option as late consolidation. Allo-
HSCT was indicated only for extremely high-risk BCP-ALL (t(4;11), L>100). No
central MRD monitoring was performed. Since Apr 2009 till Feb 2016, 298 Ph-
negative ALL pts with a median age 28 years (15-55), f/m 137/161 were recruited.
In 6 pts phenotype was unknown, B-lineage ALL was diagnosed in - 62,4%
(n=182), T-lineage ALL-36,6% (n=107), biphenotypic -1% (n=3). In BCP-ALL 31
patients (n=17%) were not qualified by the risk in the data-base; 72,8% (n=110)
were in the high risk (HR) group (WBC ≥30; EGIL BI, LDH >2N; late CR; t(4;11)-
positive). In T-ALL 7 patients (n=8%) were not qualified by the risk in the data-
base; 76% (n=76) were in the high risk (HR) group (WBC ≥100; EGIL TI/II,TIV,
LDH >2N; late CR). The analysis was performed in february 2016.
Results: CR rate in 284 available for analysis pts was 86,7% (n=246), induction
death occurred in 9,1% (n=26), resistance was registered in 4,2% (n=12). Late
haematologica | 2016; 101(s1) | 349
Copenhagen, Denmark, June 9 – 12, 2016
responders constituted 13,1% (n=20) in BCP-ALL and 28,9% (n=24) in T-ALL.
In 89 CR T-ALL pts 35 auto-HSCT were performed at a median of 5,8 mo of
CR. Allogeneic BMT was performed only in 18 of 256 patients who survived
induction (7,0%). Totally 49 pts (19,9%) had relapsed. At 60 mo OS for the
whole cohort constituted-58,9% (BCP-ALL -53,3%, T-ALL-67,5%), DFS-64.9%
(BCP-ALL-56,2%, T-ALL-79,5%), relapse probability (RP)-25% (BCP-ALL -
30,6%, T-ALL-15,8%). In a univariate analysis among various risk factors (age<
≥30y, initial risk group, WBC, LDH, immunophenotype, late response >35d)
age (≥30 y) for BCP-ALL became statistically significant for OS and RP, WBC
for DFS and RP, risk group for DFS, LDH for RP, t(4;11) for OS, DFS and RP.
In T-ALL in a univariate analysis only LDH was significant for OS. In a multi-
variate analysis no common risk factors were significant non in T-ALL, nor in
BCP-ALL.
Summary/Conclusions: Our data demonstrate that the de-escalation of inten-
sity but constant non-interruptive treatment is rather effective in adult ALL pro-
ducing more than 50% OS in BCP-ALL and 65% in T-ALL. We believe that this
approach, without intensive highly myelosuppressive consolidation courses
and high portion of allogeneic HSCT may become an alternative and repro-
ducible approach in adult Ph-negative ALL, though we have to stress that the
compliance of the pts to the protocol should be very strict. 
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SERIAL MONITORING OF BCR-ABL BY REAL-TIME POLYMERASE CHAIN
REACTION IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE
ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH IMATINIB
S Lim1,*, YD Joo1, BS Sohn2
1Internal Medicine, Haeundae Paik Hospital/Inje University College of Medicine,
Busan, 2Internal Medicine, Sannggye Paik Hospital, Inje University College of
Medicine, Seoul, Korea, Republic Of
Background: The positive impact of imatinib on treatment outcome in patients
with Philadelphia Chromosome-Positive (Ph+) acute lymphoblastic leukemia
(ALL) is well known, and the kinetics of the BCR-ABL transcript correlated with
the patient’s clinical course. 
Aims: The aim of this study was to evaluate the relationship between imatinib
dose intensity and molecular response of BCR-ABL.
Methods: Imatinib (600 mg/day orally) was administered continuously with
combination chemotherapy, starting from eighth day of remission induction
treatment, then through 5 courses of consolidation or until allogeneic
hematopoietic cell transplantation (HCT). Patients who were not transplanted
were maintained on imatinib for 2 years. Molecular response monitoring was
performed at the central lab with quantitative RT-PCR assays for peripheral
blood or bone marrow BCR-ABL RNA in serial; at the time of diagnosis, at
hematologic complete remission (HCR), and every 3 months thereafter. The
molecular response was defined as complete (MCR) if the BCR-ABL/G6PDH
ratio was less than 1x10-5.
Table 1.
Results: Between October 2005 and February 2009, total 87 patients, aged
16-71 years, with newly diagnosed Ph+ALL were enrolled. With median follow-
up of 5 years among survivors (range: 2.6-8.9 years). At the time of diagnosis,
the BCR-ABL transcript amount showed no correlation with WBC count and
peripheral blast percent. Eighty-two patients (94%) achieved HCR at a median
25 days (range, 14-69 days) and 45 patients (57.7%) of 78 evaluable patients
achieved MCR at the same time. Within three months after induction treatment,
59 patients (67.8%) achieved molecular complete remission. Total MCR rate
was 88.5% during the entire study period and the median time from treatment
to MCR was 54 days (range, 13-384 days). Among these 77 MCR patients, 32
experienced molecular recurrence which was defined as BCR-ABL transcript
positive conversion from 1x105. On subsequent follow-up, regardless of allo-
geneic HCT, 24 additional patients achieved MCR at 3 to 9 months. Of 54
patients who underwent allogeneic HCT while in first CR, with quantitative PCR
being performed at a median 2.1 months (range, 0.1-4.0 months) prior to allo-
geneic HCT, 43 (80%) showed BCR-ABL transcript amount below 1x105. After
allogeneic HCT, 49 of 50 evaluated patients (98%) achieved MCR. Median time
of MCR duration was 13 months (range, 0.9-60.3 months) and median molecular
relapse-free survival was 28 months. Patients with loss of MCR at any time had
a higher cumulative incidence of leukemia relapse and a lower relapse-free sur-
vival (RFS). Thirty two patients who lost of MCR had significantly inferior RFS
(P<0.0001) and OS (P=0.001) then 41 who maintained MCR. MCR achievement
within 3 months after remission induction was significant predictor of RFS
(P=0.004) and OS (P=0.003). In univariate analyses, the duration of MCR was
affected by using G-CSF during remission induction (P=0.0046), initial dose
intensity of imatinib within 7 weeks (P=0.001), ≥90% vs<90%, total imatinib
dose intensity during whole study period, and allogeneic HCT (P=0.002). Mul-
tivariate analyses after adjusting the Cox model was described in Table 1.
Summary/Conclusions: Prospective assessment of the extent of molecular
response and imatinib dose intensity during imatinib-based treatment and post-
allogenic HCT is likely to be useful in identifying subgroups of Ph+ALL patients
at a high risk of relapse and we will be able to apply the risk-adapted or minimal
residual disease based therapeutic approaches for Ph+ALL patients.
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KPT-8602 IS A SECOND-GENERATION XPO1 INHIBITOR WITH IMPROVED
IN VIVO TOLERABILITY AND POTENT IN VIVO ACTIVITY AGAINST ACUTE
LYMPHOBLASTIC LEUKEMIA
J De Bie1,*, J Neggers2, A Dagklis1, T Vercruysse2, O Gielen1, E Baloglu3,
W Senapedis3, S Shacham3, Y Landesman3, A Uyttebroeck4, N Boeckx5,
J Cools1, D Daelemans2
1Center for human genetics, KU Leuven - VIB, 2Rega Institute for Medical
Research, KU Leuven, Leuven, Belgium, 3Karyopharm Therapeutics, Newton
MA, United States, 4Pediatric Haematology and Oncology, 5Laboratory Medi-
cine, University Hospitals Leuven, Leuven, Belgium
Background: Human exportin-1 (XPO1) is a transport protein that exports a
wide variety of different cargo proteins from the nucleus to the cytoplasm.
Selective Inhibitor of Nuclear Export (SINETM) compounds block the formation
of the XPO1-cargo complex leading to accumulation of tumor suppressors in
the nucleus and show potent anti-cancer activity. Selinexor (KPT-330) is cur-
rently in Phase-II/IIb clinical trials for treatment of both hematologic and solid
tumors, while KPT-8602 is in Phase 1/2 clinical trials for treatment of relapsed
refractory multiple myeloma. 
Aims: We investigated the in vitro and in vivo activity of KPT-8602, a second-
generation clinical stage XPO1 inhibitor with improved tolerability, against acute
lymphoblastic leukemia (ALL).
Methods: We performed co-localization experiments and a phenotypic reporter
assay to evaluate the anti-XPO1 activity of KPT-8602. We cultured 5 T-ALL
and 3 B-ALL cell lines with different concentrations of the drug and assessed
cell viability after 72h exposure. CRISPR/Cas genome editing was used to
mutate XPO1 in ALL cell lines. For the in vivo experiments, NSG mice were
injected with a T-ALL patient derived xenograft (PDX) sample, and animals
were treated with KPT-8602 10mg/kg or placebo once a day by oral gavage
for 3 weeks. Mice were bled weekly to measure the total white blood cell count
and number of human leukemic cells.
Results: KPT-8602 strongly inhibited XPO1-cargo interaction as well as XPO1-
dependent nuclear export at nanomolar concentrations and induced potent
cytotoxicity on T-ALL and B-ALL cell lines in vitro (EC50 values ranging from
25 to 140 nM). To determine the drug-target specificity, we used CRISPR/Cas
mediated genome editing to introduce XPO1 mutations that prevented KPT-
8602 binding and resulted in loss of inhibitory activity, indicating that the inhibito-
ry effects of KPT-8602 are completely dependent on XPO1 inhibition. Daily
oral treatment with KPT-8602 could block leukemic expansion in mice engrafted
with a JAK3 mutant T-ALL at an early stage of disease development. Also when
KPT-8602 treatment was initiated at day 28 after injection (when more than
5% of human leukemic cells were detected in the blood), we observed a sig-
nificant reduction of leukemia cell numbers, without affecting normal erythro-
poiesis. KPT-8602 treatment during 3 weeks led to prolonged survival of the
animals, compared to placebo treated animals (p=0.0041).
Summary/Conclusions: KPT-8602 is a highly specific second-generation
XPO1 inhibitor with potent anti-ALL activity both in vitro and in vivo. It displays
better tolerability compared to selinexor, which allows for daily dosing and war-
rants further evaluation of this new drug in patients.
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DETAILED CHARACTERIZATION OF LAIP PROFILE AND HETEROGENEITY
AT TIME OF DIAGNOSIS PREDICTS MINIMAL RESIDUAL DISEASE IN
B-CELL PRECURSOR ALL
S Modvig1,*, NF Øbro1, S Rosthøj2, GW Jürgensen1, K Schmiegelow3,4,
HV Marquart1
1Department of Clinical Immunology, Copenhagen University Hospital Rigshos-
pitalet, 2Section of Biostatistics, University of Copenhagen, 3Department of
Pediatric and Adolescent Medicine, Copenhagen University Hospital Rigshos-
pitalet, 4Institute of Clinical Medicine, Faculty of Health and Medical Scences,
University of Copenhagen, Copenhagen, Denmark
Background: Early and accurate risk stratification in B-cell precursor acute
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lymphoblastic leukemia (BCP-ALL) is essential for individualized treatment
strategies in order to improve prognosis and lower treatment associated toxicity.
Leukemia-associated immunophenotype (LAIP) heterogeneity is common at
time of diagnosis (Øbro et al, Leukemia, 2011) yet current immunophenotyping
methods do not include heterogeneity. Furthermore, studies of the LAIP prog-
nostic value have not shown consistent results.
Aims: To characterize in detail the LAIP and the frequency of immunopheno-
typically distinct subpopulations by flow cytometry at time of diagnosis and to
evaluate their prognostic value for end-of-induction minimal residual disease
(MRD) in BCP-ALL.
Methods: Flow cytometry data from time of diagnosis was re-evaluated retro-
spectively in 125 patients with BCP-ALL consecutively diagnosed between
October 2011 and June 2015 and treated according to the NOPHO ALL 2008
protocol. The expression of intracellular and surface B-lineage markers (CD45,
CD19, CD34, CD38, CD10, CD20, CD22, nTDT, cyCD79a, and cyCD22) and
cross-lineage expressed markers (CD123, CD66c, CD133, CD13, CD33, and
CD15) was scored as negative, positive dim, positive (normal) or positive bright,
and broad or bimodal expression was registered. Corresponding normal pop-
ulations in unaffected bone marrow samples were used as reference (method-
ological details will be presented). Groups were compared by the Mann-Whitney
U test. The prognostic potential of LAIP expression was assessed in a multiple
regression model with end-of-induction flow-MRD as outcome adjusting for
age, WBC at diagnosis, cytogenetic group (high risk comprised hypodiploid,
MLL, and iAMP21, non-high risk comprised t(12;21), hyperdiploid, t(1;19),
dic(9;20), and no cytogenetic aberration) and NOPHO diagnostic treatment
regime (high/standard risk).
Results: Distinct immunophenotypic subpopulations defined by bimodal
expression of one or more markers were observed in 66 patients (53%), with
nine patients (7%) having three or more subpopulations. The most frequently
bimodal marker was CD34, displaying bimodality in 37 patients (30%). In
patients with a homogeneous expression of CD34 we found higher end-of-
induction flow-MRD in patients with CD34 positive blasts compared with CD34
negative (p=0.0008, figure 1). Accordingly, in patients with bimodal expression
of CD34 we assessed the expression level of the dominant blast subpopulation
and found that patients with a CD34 positive dominant blast subpopulation dis-
played higher end-of-induction MRD (p=0.0095, figure 1). When including all
patients (CD34 homogeneous negative/dim/normal/bright and heterogeneous
predominantly negative/positive) in an adjusted multiple regression model, we
confirmed the prognostic value of CD34 score on MRD (p=0.0003). Since risk
stratification of patients without identified cytogenetic aberrations is more diffi-
cult, we analyzed this subgroup separately, and found that CD34 expression is
an independent predictor of high MRD (p=0.0074, multiple regression, n=37)
in this group as well.
Figure 1. Flow-MRD in patients according to CD34 expression. Lines rep-
resent median values. -: negative, +: positive dim, ++: positive (normal),
+++: positive bright.
Summary/Conclusions: Detailed characterization of the CD34 expression
level of blasts and immunophenotypically distinct subpopulations seems to
bring valuable information on BCP-ALL prognosis regardless of age, WBC and
cytogenetic findings. Detailed and standardized LAIP characterization is a read-
ily accessible prognostic tool and could potentially be taken into consideration
in future risk evaluations of BCP-ALL patients.
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PHASE I STUDY OF MOXETUMOMAB PASUDOTOX IN ADULT PATIENTS
WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC
LEUKEMIA
F Ravandi1,*, J Cortes1, D Thomas1, M Rytting1, N Daver1, M Konopleva1,
P Kebriaei1, W Wierda1, C DiNardo1, C Bivins1, D McCue2, S Pierce1,
A Richie1, H Kantarjian1
1Leukemia, 2Pharmacy, University of Texas - MD Anderson Cancer Center,
Houston, United States
Background: Moxetumomab pasudotox (MP), previously known as HA22 or
CAT-8015, is a recombinant immunotoxin composed of the Fv fragment of a
humanized IgG4 anti-CD22 monoclonal antibody fused to a 38-kDa truncated
fragment of Pseudomonas exotoxin A. CD22 is expressed on the surface of
blasts in over 90% of patients with precursor B-acute lymphoblastic leukemia
(ALL) as well as in other lymphoid neoplasms and is an attractive target for
monoclonal antibody-based therapy. MP and its predecessor compound, BL22
have been investigated for the treatment of patients with relapsed hairy cell
leukemia (HCL) as well pediatric patients with relapsed B-ALL and have demon-
strated promising activity.
Aims: This single center, phase I study was conducted to determine the max-
imum tolerated dose and potential efficacy of MP in adult patients with relapsed
and/or refractory B-ALL.
Methods: Patients were eligible if they were 18 years or older, with previously
treated B-ALL (either relapsed after having achieved prior response or refractory
to prior therapy) and had adequate performance status and organ function with
bilirubin ≤1.5mg/dL, liver enzymes ≤2 x upper limit of normal (ULN) and crea-
tinine ≤2mg/dL. Patients with cardiac ejection fraction less than 40%, active
hepatitis or HIV infection, history of microangiopathic hemolysis, symptomatic
CNS involvement, recent prior therapy (including systemic chemotherapy in
the past 14 days, monoclonal antibodies in the past month, or allogeneic stem
cell transplant in the past 100 days) were excluded. Dose escalation in the
phase I portion of the study was based on a standard 3+3 design starting at a
dose of MP 30µg/kg every other day (qod) for 6 doses with subsequent dose
levels at 40 and 50µg/kg qod for 6 doses and 50µg/kg qod for 10 doses. All
patients received appropriate premedication with hydroxyzine, ranitidine, cor-
ticosteroids and acetaminophen and were monitored for toxicity including pre-
viously identified risks of capillary leak syndrome and hemolytic uremic syn-
drome (HUS). All other supportive managements was based on standard insti-
tutional practice.
Results: Between December 2013 and September 2015, 16 patients with
relapsed or refractory B-ALL were treated on this trial. Median age of the
patients was 30 years (range, 18-67 years). Median number of prior therapies
was 3 (range, 1-6). 4 patients had a prior allogeneic stem cell transplant and 3
had prior therapy with inotuzumab ozogamycin. 10 patients were refractory to
their last prior therapy and 6 had relapsed from prior therapy (duration of prior
CR less than 6 months in 2 and greater than 6 months in 4). Performance
status was 0 in 2, 1 in 10 and 2 in 4 patients. Four patients had normal karyotype
and 10 complex cytogenetic abnormalities which included t(4;11) in 1 patient.
Another patient had t(1;19) and one patient had miscellaneous abnormality.
CD22 expression was detected in all patients including 50-69% expression in
4, 70-89% expression in 4, and ≥90% expression in 8. The median number of
courses of MP administered was 1 (range, 1-4) with 6 patients treated at 30
µg/kg, 4 patients at 40 µg/kg, and 6 patients at 50 µg/kg x 6 doses. The final
dose regimen of 100 µg/kg x 10 doses was not studied due to early termination
of the study. Only one DLT (grade 3 HUS) occurred at 50 µg/kg x 6 dose level;
however, the study was terminated because the 10-dose schedule was not tol-
erated in a parallel pediatric trial. One patient with 5 prior regimens achieved a
complete response (CR) which lasted 2.5 months. No other responses by stan-
dard criteria were reported. Non-hematological toxicity of grade 3/4 included
reversible capillary leak syndrome (CLS) in 1 patient, weight gain in 2, ascites
in 1, tumor lysis syndrome (TLS) in 1, elevation of liver enzymes in 3, and HUS
in 1 patient. Grade 2 adverse events including CLS, edema and elevation of
liver enzymes were noted in another 5 patients. No deaths directly attributable
to therapy were reported.
Summary/Conclusions: MP at the doses studied in this trial is feasible and
can produce response in patients with multiply relapsed B-ALL. The recom-
mended dose for phase II trials is 50µg/kg qod x 6 doses.
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INTENSIVE VS. SEMI-INTENSIVE CHEMOTHERAPY IN OLDER ADULTS
(55-65 YR) WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE
LYMPHOBLASTIC LEUKEMIA
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Hematology, Hospital Central de Asturias, Oviedo, 13Clinical Hematology, Hos-
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Background: Treatment of older adults (55-65 yr.) with ALL is difficult to stan-
dardize. The election between intensive vs semi-intensive therapy is frequently
based on physician and/or patient preferences. Specific analyses of outcomes
according to the intensity of the therapy in this age group are scarce.
Aims: To analyze and compare the baseline characteristics, the results of treat-
ment and the outcomes of older adults (55-65yr.) with Ph-negative ALL included
in intensive high-risk (HR) protocols (ALL03 and ALL11, J Clin Oncol 2014;
32:1595-604, Blood 2015; 126: 1333) vs semi-intensive protocols (ALLOLD07,
Leuk Res 2016; 41: 12-20) from the Spanish PETHEMA Group.
Methods: The main clinical and hematologic data, as well as the response to
therapy and outcome of older adults (55-65 yr.) with Ph-negative ALL treated
intensively or semi-intensively according to the PETHEMA protocols were ana-
lyzed and compared. Intensive protocols (ALL03 and ALL11) included intensive
induction and consolidation therapy followed by allogeneic HSCT according to
MRD clearance. Semi-intensive protocol (ALLOLD07) includes non-intensive
induction chemotherapy with non-genotoxic drugs, followed by semi-intensive
consolidation and standard maintenance therapy (EWALL backbone); allo-
geneic HSCT with RIC regimen was allowed in fit patients in CR1 according to
physician’s criteria.
Results: From 2003 to 2015, 46 patients were treated intensively vs 32 treated
semi-intensively. Except for age (intensive: 58[55-65] yr. vs semi-intenive: 61
[56-65], p=0.01), the main clinical and hematological characteristics at baseline
were comparable in the two groups. Death in induction and relapse rate were
higher in the semi-intensive group, with a trend for a lower CR duration in this
group. However, the OS probability was not significantly different in the two
groups (Table 1). The rate of HSCT realization in CR1 was low in both groups
(8% vs 5%).
Table 1.
Summary/Conclusions: This study confirms the poor prognosis of older adults
(55-65 yr.) with Ph-negative ALL, regardless of the intensity of the therapy. The
low rate of HSCT in CR1 in this age group and a high rate of death in consol-
idation in patients treated intensively are of note. The trend for a significantly
better CR duration in patients treated intensively did not translate into improved
OS. Better therapies are needed in this age group of Ph-negative ALL patients.
Supported in part with the grants PI10/01417 from Fondo de Investigaciones
Sanitarias and RD12/0036/0029 from RTICC, Instituto Carlos III and
2014SGR225(GRE), Generalitat de Catalunya, Spain, and a grant from “La
Caixa” Foundation.
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FLOW CYTOMETRY OF CEREBROSPINAL FLUID IN CHILDREN WITH
ACUTE LYMPHOBLASTIC LEUKEMIA AT DIAGNOSIS AND RELAPSE
M Gabelli*, B Buldini, S Disarò, A Zangrando, S Francescato, P Scarparo,
B Michielotto, E Bortoloso, MC Putti, G Basso
Clinica di Oncoematologia Pediatrica, Università degli Studi di Padova, Padova,
Italy
Background: Acute lymphoblastic leukemia (ALL) may involve central nervous
system (CNS) in 3-6% of pediatric patients. Cytology (CC) of cerebrospinal
fluid (CSF) is currently used to define CNS infiltration, although sensitivity and
specificity are low. Flow cytometry (FC) can identify blasts in CSF samples
that are negative for cytology with higher sensitivity and specificity. The fre-
quency and the significance of this occult cerebrospinal involvement in children
with ALL is still not clear.
Aims: We explored the feasibility of CSF flow cytometric analysis at each lum-
bar puncture during therapy in primary and relapsed ALL. Moreover, we studied
prospectively its clinical significance in comparison with cytology and cell count.
Methods: We included children (aged 1-18 years) with Philadelphia negative
ALL and with ALL isolated marrow relapse diagnosed from 12.09.2013 to
31.01.2016 at our Institution, after informed consent acquisition. Treatment
schedule and definition of CSF involvement were as per AIEOP-BFM ALL2009
Protocol. At each point of intrathecal therapy, CSF was collected and analyzed
within 24 hours by an automated cell counter, by cytology and 8-color flow
cytometry (B or T lineage panel). A tiny cluster of events with immunophenotype
compatible with blasts at diagnosis was considered positive by FC (FC+).
Results: 784 samples from 76 patients with de novo ALL and 92 samples from
13 children with marrow relapse were considered. Median follow up was 14
months (1-28,5 months). At diagnosis 4 T-ALL patients (5%) presented CNS
involvement (CNS3): 3 with positive cytology (CC+) and positive FC, 1 with cranial
nerve palsy (CC-/FC-). Other 3 patients (pB-ALL) had positive cytology but<5
cell/µl (CNS2): 2 were FC+, 1 FC- (normal T and B cells). 25/76 children (33%)
with no CNS leukemia (CNS1) resulted FC+: 3 T-ALL, 22 pB-ALL. 9/25 (36%)
CNS1/FC+ patients were high risk (MRD based stratification). FC persisted pos-
itive at day 15 in 2 CNS3/FC+ patients, in 1 CNS2/FC+ and in 2 patients that
were positive only by FC at diagnosis. Among patients who were FC+ at diagno-
sis, we found other isolated FC+ samples at subsequent time points: 2 during
induction, 4 during consolidation. Moreover, during reinduction a child CNS3/FC+
at diagnosis presented other 3 samples FC+/CC-. Even children who had neg-
ative CSF by flow cytometry at diagnosis presented isolated FC+ samples at
later time points: 1 during induction, 6 during consolidation. One child (CNS1/FC-
at diagnosis) died for infection, one patient (CNS1/FC+ at diagnosis) presented
early marrow relapse, the remaining 74 are alive in complete remission (4/74
after hematopoietic stem cell transplantation). Among 13 patients with isolated
marrow ALL relapse, 7 (54%) had FC+ CSF at presentation. 4/7 had a second
relapse (2 CNS relapse, 2 BM relapse), 3 died. Among 6 FC- patients, 1 had a
second marrow relapse, 1 died of transplant related mortality, 1 showed disease
progression and 3 are alive and in complete remission.
Summary/Conclusions: Flow Cytometry of CSF is a simple, rapid and cheap
method that is able to identify blasts with high sensibility and specificity, allowing
the detection of occult CNS infiltration. Our preliminary data suggest that FC
CSF positivity may be a risk factor for BM and CNS relapse in children. A longer
follow up and a larger group of patients are needed to confirm these findings
in ALL at diagnosis and relapse.
E862
USE OF VOXEL-BASED MORPHOMETRY TO DETECT CEREBRAL VOLUMES
ABNORMALITIES IN LONG TERM SURVIVORS OF CHILDHOOD ACUTE
LYMPHOBLASTIC LEUKEMIA
G Aloj1,*, G Pastorino2, F Mazio3, N Di Paolo3, MP Riccio4, A D’Amico3,
C Bravaccio2, R Cuccurullo1, R Parasole1, V Poggi1
1Pediatric Hemato-Oncology Department, Santobono-Pausilipon Children’s
Hospital, 2Child Neuropsychiatry Unit, Traslational Medical Science Depart-
ment, 3Neuroradiology Unit, Advanced Biomedical Science Department, “Fed-
erico II” University, 4Child Neuropsychiatry Unit, Mental and Fisical Health and
Preventive medicine Department, Second University of Naples, Naples, Italy
Background: Improvements in therapeutic strategies of pediatric Acute Lym-
phoblastic Leukemia(ALL) over the last decades have highly increased survival
rates; consequently, there is a growing population of ALL Long Term
Survivors(ALL-LTS). Treatment protocols include Central Nervous System
directed Chemotherapy(CT) associated, in selected patients, to Cranial Irradi-
ation(CI). These treatments appear able to determine neurocognitive late effects
in ALL-LTS. The anatomical and molecular basis of these alterations are still
largely unknown, and neuroimaging studies, such as automated whole brain
segmentation of MRI images through Voxel-Based Morphometry(VBM), may
be helpful in their understanding. Aim of this study was to better define neu-
roanatomic regions involved in neurocognitive impairment of a population of
ALL-LTS, and to evaluate possible relationships of these abnormalities with type
of therapy.
Aims: The primary objective was to detect the neuroanatomical alterations in
ALL-LTS who received either CT alone or in combination with CI during child-
hood. Secondary objective was to assess the neurocognitive performance in
the same two groups of LTS.
Methods: In this cross-sectional, controlled study, twentysix ALL-LTS were
recruited from the ALL-LTS cohort of patients followed up in the Hemato-Oncol-
ogy Department of Santobono-Pausilipon Children’s Hospital of Naples. Thir-
teen subjects received CT and CI (group A) while thirteen received CT alone
(group B). All signed written informed consent. The two groups were matched
for age, sex, ethnicity, education, number of right-handed and left-handed sub-
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jects, use of glasses, age at ALL diagnosis, years since therapy-discontinuation
and type of therapeutic protocol used. People who underwent HSCT and
relapsed subjects were excluded. Imaging were collected using a 3T Siemens
Scanner. VBM analyses were conducted on MPRAGE T1 3D images in Statis-
tical Parametric Mapping 8. Analyses of brain volumes were performed as glob-
al Gray Matter(GM), White Matter(WM) and Cerebro Spinal Fluid(CSF) volumes
and as regional voxel-by-voxel analyses. Neurocognitive performance was
assessed through the Wechsler Adult Intelligence Scale-Revised(WAIS-R) for
over 16 years and through the Wechsler Intelligence Scale for Children 4th Edi-
tion(WISC-4th) for age 9-16 years. d2-R test and Wisconsin Card Sorting
Test(WCST) were used to assess respectively attention and concentration abil-
ities and executive function. A two sample t-test was employed for all the
between group comparisons.
Results: Absolute volumes of GM, WM and CSF segments of group A vs group
B did not differ significantly. Group A showed significantly smaller volumes than
group B in superior frontal gyrus, posterior medial frontal gyrus, paracentral
lobule, inferior parietal lobule, precuneus, temporal medial gyrus, parahip-
pocampal gyrus, medial and posterior cingulate cortex. Significant differences
between groups were found for intelligence, performance, attention and mem-
ory measures of WAIS-R. No significant differences were observed for WISC-
4th, d2-R and WCST, but in both groups, working memory, processing speed,
concentration and attention were worse than population norm.
Summary/Conclusions: In our study some neuroanatomic structures showed
smaller volumes in ALL-LTS treated with CT in combination with CI than in
those treated with CT alone. These findings could be related to specific neu-
rocognitive alterations observed in these subjects, and represent an initial
attempt in elucidating their anatomical basis. Further studies on more extensive
pediatric series are needed to confirm our observations.
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HYPER-CVAD COMPARED TO BFM-LIKE CHEMOTHERAPY FOR THE
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA. A
RETROSPECTIVE SINGLE CENTER ANALYSIS
I El Dika1, R massoud2, M charafeddine1, R mahfouz3, M kharfan-dabaja4,
A bazarbachi2, J Elcheikh2,*
1AUBMC, beirut, Lebanon, 2transplantation, 3pathology, AUBMC, beirut,
Lebanon, 4moffitt, tampa, United States
Background: Multiple induction regimens have been developed for adult
patients with acute lymphoblastic leukemia (ALL). However, there have been
no prospective randomized trials that directly compare these regimens.
Aims: In this report, we retrospectively evaluated the outcome of 62 adult ALL
patients treated with hyper-CVAD (n=38) and the (i.e. Berlin-Frankfurt-Munster,
n=24) BFM-like protocols at the American university of Beirut medical center,
Lebanon; between November 2000 and december 2015. Feasibility of allo-
geneic stem cell transplantation (allo-SCT) for those patients, in terms of effi-
cacy and tolerability was also evaluated.
Methods: The median age was 38 years in the hyper-CVAD group and 20
years in the BFM-like group with a male/female ratio of 50/50 and 54/46, respec-
tively. The majority of cases were B cell in origin (89% in the hyper-CVAD group
and 79% in the BFM-like group). Thirteen patients (34%) vs only 2 patients
(8%) were positive for Philadelphia chromosome (Ph+) in both groups respec-
tively, (p= 0.0744). Eight patients received imatinib (7 vs 1) and five patients
received dasatinib (4 vs1) in the first and second group respectively. Other 2
patients received imatinib than dasatinib in the hyper-CVAD group only.The
disease risk score was high in 76% of patients in the hyper-CVAD group vs
33% of patients the BFM-like group (p=0.119).
Figure 1.
Results: The median follow-up time was 29 months. Fifteen patients (39%)
and ten patients (42%) underwent allo-SCT in the hyper-CVAD and BFM-like
group respectively. At the last follow up 28 patients (74%) were in complete
remission (CR) in the first group vs 18 patients (75%) in the second group. Of
those, 20 patients (53%) vs 11 patients (46%) were MRD-negative at the last
follow up respectively. The 5-year survival rate was similar in hyper-CVAD group
compared to the BFM-like group (63 vs 62%, p= 0.808) (Figure 1). The 5 years
disease free survival (DFS) rate was 29% compared to 28% in the BFM-like
group, (p= 0.435) (Figure 2). Both chemotherapies were well tolerated. None
of the patients died from drug related toxicity.
Summary/Conclusions: Despite the older age and more patients with high
risk category and Ph+ in the hyper-CVAD group, this difference was not trans-
lated into a difference in outcome between the 2 groups. The hyper-CVAD reg-
imen seems to be feasible for adult patients with ALL in terms of tolerability and
efficacy. There is still a need for large, prospective, randomized studies in order
to establish the best chemotherapy protocols for adult ALL patients.
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BFM REGIMEN OFFERS SIMILAR EVENT FREE SURVIVAL COMPARED
TO HYPERCVAD BUT WITH LESS TOXICITY IN ADOLESCENTS AND
YOUNG PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
A Vega*, E Pacheco, C Fuentes, L Aguilar, C borjas, B rubio, O garces
Hematology, IMSS, Guadalajara, Mexico
Background: The experience to adapt pediatric protocols to adolescents and
young adults (AYA) with acute lymphoblastic leukemia (ALL) is improving.
Although there is still concern that toxicity may occur.
Aims: We present two groups of AYA treated with an adult protocol (hypercvad)
and BFM developed for children. The study aimed to compare event free sur-
vival (EFS) and toxicity in both regimens.
Methods: Patients aged ≥16 and ≤40 between 2008-2015. BFM consisted of
8 blocks. Induction with vcr, pdn, asp, daunorubicine (dau) and intrathecal
therapy (IT). Consolidation with ciclophosphamide (cfm), mercaptopurine (mp),
cytarabine (cyt), vcr, asp and IT. CNS prophylaxis with methotrexate (mtx),
followed by interim maintenance (im) combining vcr, mtx and asp. The other
4 blocks composed by delayed intensification (di) x 2 with vcr, dau, pdn, asp,
cfm, mp, cyt, vcr and one im and di (as in induction). Hypercvad was prescribed
with the addition of IT to each one of the 8 arms. Maintenance consisted of
POMP for 2 years, and in some, combined with etoposide or anthracycline
plus IT for 6 months. Rituximab (mab) was allowed at discretion if CD 20+.
Ph+ cases received imatinib. Radiotherapy was permitted for mediastinal
tumor. Patients changed the initial regimen if non hematological toxicity
occurred during induction or by preference and registered in the regimen they
continued. Variables analyzed: age (±30), WBC (≥30000 B and ≥100000 T),
cytogenetic (t9;22 [ph+] and complex karyotypes), lineage, CD20, and aberrant
markers. Relapse and death in CR due to toxicity were censored for the EFS
analysis. Toxicity counted as one event in each block/arm (only ≥3 grade) or
if admission or transfusion needed. Death during induction was excluded from
the toxicity analysis.
Table 1. Toxicities. *Two similar blocks were added together.
Results: Fifty eight cases were treated. Median was 24 years (16-40). WBC
was 15400 (0.6-632000). Twelve patients had karyotype and five were high
risk (four ph+). Sixteen cases (33%) classified as high risk. Three cases had
CNS disease. Fifty one (88%) cases were B and 48% CD 20+ (ten received
mab). Seventeen had aberrant markers. Mediastinal tumor was observed in
four T cell cases. The EFS of the whole group at 3 years was 30%. Forty five
(78%) patients received induction with BFM with 8 deaths (17.7%), and thirteen
(22%) with hypercvad with 2 deaths (15.3%). Median follow up was 12 months
(1-72) with twenty one individuals in CR. Fourteen (29%) patients changed
treatment, thirteen in the BFM group, 4 for pancreatitis and 9 by preference
and one due to toxicity in the hypercvad group. Thirty three patients were
included in BFM and twenty five in hypercvad. The EFS at three years was
32% for BFM and 28% for hypercvad p=.6. There were seventeen relapses
(BFM 8 hypercvad 9) and ten deaths in CR due to toxicity (BFM 3 hypercvad
7). Toxic deaths in BFM were infectious in one and CNS toxicity in two. All
toxic deaths in hypercvad were infectious Table 1. None of the variables had
statistical difference. More toxic deaths occurred during the even courses and
nearly 80% required admission for neutropenia and blood support (compared
to a close 30% of the odd courses) in the hypercvad protocol. For the BFM,
most admissions happened during consolidation (28%). The other blocks had
less toxicity, although neurotoxicity occurred during maintenance. Mucositis
presented barely in both groups. Coagulopathy and hepatitis rarely appeared
with asp.
Summary/Conclusions: Both regimens had similar EFS but hypercvad had
more deaths in CR due to myelotoxicity and more blood support and admission
to the hospital. Severe non-myelotoxic events were uncommon.
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PATTERN OF CNS RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA
BCR-ABL POSITIVE, THE IMPORTANCE OF CHARACTERIZATION OF
ABL1 MUTATIONS IN CEREBROSPINAL FLUID
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Central de Asturias, Oviedo, 14Hospital Joan XXIII, Tarragona, 15Hospital del
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Málaga, 18Hospital Fuenlabrada, Fuenlabrada (Madrid), 19ICO-Hospital Josep
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Background: He incidence of central nervous system (CNS) relapse among
patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) is 8-17%.
Although tyrosine-kinase inhibitors (TKI), especially imatinib, are included in
the first-line treatment in these patients, their concentration in CNS is too low
to effectively prevent CNS relapse, making CNS prophylaxis mandatory.
Aims: To study the frequency, predictors and evolution of BCR-ABL positive
ALL patients with CNS relapse in two consecutive clinical trials of the PETHE-
MA group using imatinib and chemotherapy. As secondary objective we pro-
posed the introduction of a new method for the study of variants of uncertain
significance (VUS) in kinase domain of the BCR-ABL from cDNA of cere-
brospinal fluid (CSF) blasts, in order to adapt the TKI used in relapse according
to the clonal evolution from bone marrow (BM) to CSF cells.
Methods: It has been reviewed data of CNS relapse of patients included in
two consecutive clinical PETHEMA trials (PETHEMA-LAL-PH-2008 and
PETHEMA-LAL-OPH-2007), for treatment of BCR-ABL- Ph+ ALL patients. In
two patients with combined BM and CSF we analyzed the BCR-ABL mutations
at diagnosis and at relapse in both sites. Kinase domain of cDNA was amplified
in two steps by nested PCR in the samples of BM at diagnosis and BM or CSF
at relapse, covering the whole kinase domain from residues Gly227 to Gly514.
Further enzymatic fragmentation of the domain yielded ~200 bp of small frag-
ments. Ion Torrent ultra deep-sequencing of the resulting fragments allowed
us to evaluate the variants of the chimeric protein.
Results: A total of 138 ALL BCR/ABL positive patients were analyzed and 128
reached complete remission, 30 of them have relapsed (13 [43%] involving
CNS [isolated or combined], 16 [53%] BM and 1 in unknown site). The overall
survival probability at 2 years was 69% for the “CNS Relapse” group (IC95%:
44-94%; p=0.067) and 44% for the “Not CNS Relapse” group (IC95%: 20-68%;
p=0.067, Figure 1a). In a multivariable analysis any clinical variable was asso-
ciated with CNS relapse probability. In two of the CNS and BM relapsed patients
we have performed massive sequencing experiments of ABL1 Kinase domain
mutational status. In the first patient ultra-deep NGS of BM samples at diag-
nosis and at relapse did not show VUS or pathogenic variants, but the CSF
study at relapse confirmed the variant c.1159 T>A, p.L387M. The same study
in the second patient also found the same pathogenic variant only in CSF blast
cells (Figure 1b), whereas, the VUS c.733 A>G, p.K245E was found only in
the BM sample at diagnosis.
Figure 1.
Summary/Conclusions: In BCR-ABL ALL patients treated with imatinib and
chemotherapy CNS relapse was a significant feature, despite CNS prophylaxis,
In our series we did not find any clinical variable predicting CNS relapse. We
have found the pathogenic variant p.L387M in CSF blasts of two patients with
combined CNS and BM recurrence, this variant not being found in BM samples
at diagnosis or at relapse. These mutations were sensitive to other TKIs with
better penetration to CSF. Based on these results, a mutational study of the
kinase domain of the BCR-ABL in blast cells obtained from CSF, should also
be integrated in the mutation study of these patients in order to select the TKI
according to the clonal evolution from BM to CSF cells.
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PROGNOSTIC IMPACT OF COPY NUMBER ALTERATIONS IN A SERIES
OF PEDIATRIC PATIENTS WITH DE NOVO B-CELL PRECURSOR ACUTE
LYMPHOBLASTIC LEUKEMIA IN A SINGLE CENTER
M Trabazo Del Castillo1,*, S Rives2,3, N Vega-Garcia1, R Malatesta1, C Estella1,
A Català2,3, M Torrebadell1,3, R Berrueco2,3, A Ruiz-LLobet2, L Calvente1,
A Alonso-Saladrigues1, M Mesegué1, M Solsona1, M Camós1,3
1Hematology Laboratory, 2Pediatric Hematology. Department of Hematology
and Oncology, Hospital Sant Joan de Déu, University of Barcelona, Esplugues
de Llobregat, 3Centro de Investigación Biomédica en Red de Enfermedades
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Background: Gene copy number alterations (CNAs) have been recently pro-
posed as variables for risk stratification in acute lymphoblastic leukemia (ALL).
However, their use in clinical practice is controversial, as their prognostic impact
could depend on the applied therapeutical protocol and the interaction with
other clinical and biological variables. 
Aims: To analyze the prognostic impact of CNAs in a series of pediatric patients
with B-cell precursor ALL (pre-B ALL) treated in a single center.
Methods: Pediatric patients (0-18 years) with pre-B ALL, diagnosed between
1999 and 2015 and homogeneously treated according to consecutive protocols
of the Spanish Hematology and Oncology Pediatric Society (SEHOP) Cooperative
Group (SHOP-99, SHOP-2005, SEHOP-PETHEMA 2013). CNAs were studied
by MLPA technique with SALSA-P335 kit (MRC-Holland) and Coffalyser software.
Results: We included 55 patients with a median age of 4.7 years (range 1.1-
14.9), 56% males. Only one patient had central nervous system infiltration.
Median WBC count was 8.4x109/L (range 1.1-296.9). All cytogenetic subtypes
were represented. We observed the presence of CNAs in 29 patients (53%),
including 17 (31%) cases with one CNA, 8 (15%) patients with 2 CNAs and 4
(7.5%) patients with ≥3 CNAs. The most frequent CNAs were deletions of
CDKN2A/B, observed in 12 patients (22%), followed by ETV6 deletions in 11
cases (20%) and IKZF1 deletions in 9 cases (16%); also, we observed deletions
of PAX5 in 7 cases (13%), of BTG1 in 4 patients (7%), of RB1 in 2 cases (4%),
JAK2 deletions in one case and CRLF2 alterations (PAR region) in one case.
IKZF1 deletions were more frequently observed in BCR-ABL1 rearranged cases
and in patients with B-other subtype (cases with absence of main cytogenetic
categories), and ETV6 deletions predominated in cases with ETV6-RUNX1
rearrangement. Among those patients with more than one CNA, IKZF1 was the
gene most frequently involved (IKZF1plus, 7 cases). The presence of CNAs
was significantly correlated to older age (p=0.006), hyperleukocytosis >20x109/L
(p=0.018) and high levels of minimal residual disease (MRD>10%) at day 15 of
induction, assessed by flow cytometry (p=0.012). A higher number of CNAs (≥2)
was found in boys (p=0.026). Noticeably, the patient with CNS infiltration har-
bored 3 CNAs. IKZF1 deletions were associated with high hyperleukocytosis
(>100x109/L, p=0.001), older age (p=0.001), high NCI risk (p=0.008) and high
MRD levels at day 15 (p<0.0001). We found the same associations for
IKZF1plus. CDKN2A/B deletions showed a trend to high WBC count
(>100x109/L, p=0.051) and presence of MRD at the end of induction
(MRD>0.01%, p=0.082). We found no significant associations for ETV6 or PAX5
deletions. After a median follow up 2.6 years (0.3-11.9) all patients are alive and
3 patients relapsed, with an event free survival (EFS) at 5 years of 87±7%. The
presence of ≥2 CNAs correlated to worse EFS (64±16% vs 100%, p=0.043).
Summary/Conclusions: in our series, the presence of CNAs, mainly IKZF1
deletions, were associated with poor prognostic factors like older age, high
WBC count and high levels of MRD at early timepoints. We are currently
expanding our series to confirm our results. GRANTS: PI12/2417, PN I+D+I,
ISCIII (SGE, FIS), CIBERER, Fundación AECC, Fundación Sandra Ibarra,
Fundación Cris contra el cáncer & “Força Miquel”, “Candela” & “Mua” projects.
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COMBINED BLINATUMOMAB + DASATINIB/IBRUTINIB THERAPY OF
RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS-
ANTILEUKEMIC EFFECT ON THE T-HELPER AND T-REGULATORY CELLS
REDUCTION BACKGROUND
A Sokolov*, E Parovichnikova, V Troitskaya, I Galtseva, M Firsova, J Davidova,
N Kapranov, V Savchenko
National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, Russian Federation
Background: Blinatumomab, bispecific anti-CD3/CD19 monoclonal antibody,
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is effective as monotherapy in the treatment of relapsed/refractory acute lym-
phoblastic leukemia (R/R-ALL), but long term results could be improved. T-reg-
ulatory (T-reg) and T-helper cells can inhibit effector T-cells used by blinatu-
momab. Tyrosine-kinase inhibitors (TKI) could be used in the treatment of both
Ph-positive (Ph+) and Ph-negative (Ph-) ALL as pre-B-cell receptor signaling
inhibitors.
Aims: To study T-cell subpopulations kinetics in R/R-ALL patients during com-
bined blinatumomab+TKI treatment of relapsed ALL patients.
Methods: Two relapsed ALL patients (1 bone marrow Ph+ relapseand 1
extramedullary extraperitoneal with severe abdominal pain Ph- relapse)were
treated with blinatumomab 28 mcg/day by continuous infusion 4 weeks cycles
with 2 weeks intervals (3 cycles in Ph+ relapse and 2 cycles in Ph- patients).
Dasatinib 140 mg/day started In Ph+ patient from the 3rd week of the first bli-
natumomab cycle and further continuously. Ibrutinib 560 mg/day started in Ph-
patient from the 4th week of the first blinatumomab. T-cell subpopulations of
the peripheral blood (T-helper, cytotoxic, T-reg, NK) were studied by flow cytom-
etry every week during the whole treatment period. Blinatumomab was provided
by Amgen sponsored Expanded Access Program.
Results: The Ph+ ALL patient treated by blinatumomab+dasatinib combination
had pleural effusions and nonspecific lung infiltration fully regressed after 2
weeks dasatinib interruption. In that patient the second molecular remission
was obtained after the second blinatumomab cycle+dasatinib treatment. In Ph-
ALL patient the abdominal pain fully regressed and tumor size slightly
decreased after the first blinatumomab cycle+ibrutinib. T-cell subpopulations
study revealed only T-helper (lowered from 0,437 to 0,111x10*9/L in Ph+ ALL
pt and was decreased to 0,112-0,111x10*9/L in Ph- ALL pt) and T-reg cell (was
decreased to 0,006-0,002x10*9/L in Ph+ pt and lowered from 0,009 to
0,006x10*9/L in Ph- ALL pt) pools reduction. Absolute counts of cytotoxic T
cells and NK cells remained within the normal reference values in both patients.
Summary/Conclusions: The correlation of the efficacy of blinatumomab treat-
ment that uses effector cells in antileukemic effect against relapsed ALL with
T-helper and T-reg pools reduction possibly indicates an overcoming the neg-
ative influence of those T-cell subpopulations. TKIs may act in synergy with bli-
natumomab during their concomitant use.
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LOW EXPRESSION OF LYMPHOID ENHANCER-BINDING FACTOR-1
(LEF1) ASSOCIATES WITH POOR PROGNOSTIC FACTORS IN PEDIATRIC
ACUTE LEUKEMIA
R Malatesta1,*, N Vega-Garcia1, C Estella1, S Rives2,3, M Torrebadell1,3,
A Català2,3, R Berrueco2,3, A Ruiz-Llobet2, L Calvente1, M Trabazo1,
A Alonso-Saladrigues1, M Mesegué1, M Solsona1, M Camós1,3
1Hematology Laboratory, 2Pediatric Hematology. Department of Hematology
and Oncology, Hospital Sant Joan de Déu, University of Barcelona, Esplugues
de Llobregat, 3Centro de Investigación Biomédica en Red de Enfermedades
Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
Background: LEF1 expression has been described in different types of leukemia,
but its prognostic impact remains controversial. In adult patients with acute lym-
phoblastic leukemia (ALL), LEF1 overexpression correlates to high-risk factors
(hyperleukocytosis, BCR-ABL1 rearrangement and complex karyotype). In con-
trast, overexpression of LEF1 is a favorable prognostic factor in childhood ALL
and in acute myeloblastic leukemia (AML), both in adults and children.
Aims: to analyze the prognostic impact of LEF1 expression in a series of pedi-
atric patients diagnosed with acute leukemia in a single center. 
Methods: we included pediatric patients (0-18 years) with de novo acute
leukemia, treated according to consecutive protocols of the Spanish Hematol-
ogy and Oncology Pediatric Society from 2003 to 2015. mRNA expression lev-
els of LEF1 were assayed by quantitative PCR and analyzed with the 2-DDCt
method, with non-neoplastic samples used as controls for the relative quantifi-
cation. Patients were grouped into quartiles (Q1-Q4) according to LEF1 expres-
sion level: LEF1high (Q4) and LEF1low (Q1-Q3). Correlations with clinical and
biological variables and survival analysis were performed with non-parametric,
chi-square and Kaplan-Meier tests and log-rank comparison for subgroups.
Results: we analyzed 104 patients, with a median age of 4.7 years (0-17.4),
including 61 boys (59%). Sixty-two patients (60%) had B-cell precursor ALL (all
main cytogenetic subtypes represented), 22 patients (21%) had T-cell ALL and
20 cases AML (19%). Our AML series was enriched in infants: the median age
was 2.7 (0.08-15.96), included 5 infants (25%) and 8 MLL rearranged cases
(40%). Median expression level of LEF1 was 6.44 (0-461), and differed signif-
icantly according to lineage (21.6 (0.1-461) in B-ALL; 4.7 (0.01-79.3) in T-ALL
and 0.18 (0-13.5) in AML, p<0.0001). In the whole series of patients, LEF1low
expression was observed predominantly in infants and in patients with MLL
rearrangement (p=0.043 and p=0.011, respectively). In addition, a trend to
hyperleukocytosis was observed in patients with LEF1low (p=0.06). After a medi-
an follow-up of 4.3 years (0.06-14.96), 14 patients died and 13 relapsed. The
overall survival (OS) at 5 years was 94±3% in B-ALL patients, 80±9% in T-ALL
and 63±11% in AML patients, p=0.001. In B-ALL subgroup of patients, low
expression of LEF1 was again significantly correlated to infant cases (p=0.025).
Interestingly, in T-ALL patients we observed different findings: those cases with
high expression of LEF1 associated with older age (p=0.025) and worse event
free survival (EFS, 61±15% vs 100%, p=0.02), although the number of patients
is low and our results must be taken with caution. Despite the number of patients
precluded the finding of statistical significance, in AML cases we observed, as
in the whole series of patients, a correlation between LEF1low and age<1 year,
MLL rearrangement and higher WBC count (p=0.08, p=0.055 and p=0.072,
respectively).
Summary/Conclusions: in our series of pediatric patients, low LEF1 expres-
sion levels in B-ALL and AML patients correlated to adverse prognostic factors,
such as age<1 year, MLL rearrangement and hyperleukocytosis. A larger num-
ber of patients is needed to confirm our results. GRANTS: PI12/2417, PN I+D+I,
ISCIII (SGE, FIS), CIBERER, Fundación AECC, Fundación Sandra Ibarra, Fun-
dación Cris contra el cáncer & “Força Miquel”, “Candela” & “Mua” projects.
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CHARACTERISTICS OF PONATINIB THERAPY FOR PHILADELPHIA-POSITIVE
ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) PATIENTS IN
REAL-WORLD CLINICAL PRACTICE COMPARED TO THE PACE TRIAL
M Mauro1,*, LJ McGarry2, M Yang2, S Lustgarten2, H Huang2
1Memorial Sloan Kettering Cancer Center, New York, NY, 2ARIAD Pharmaceu-
ticals, Inc., Cambridge, MA, United States
Background: The pivotal phase 2 PACE trial (NCT01207440) studied the use
of ponatinib in adult patients with refractory Ph+ ALL and formed the basis of
the approval of ponatinib. Prescribing data tracked by the specialty pharmacy
exclusively responsible for distribution of ponatinib in the US are available from
Jan 2014 onward.
Aims: To compare the PACE clinical trial data vs real-world pharmacy data, in
order to examine similarities and differences between patient characteristics,
regimens and duration of therapy evolving over time.
Methods: We compared PACE data, which enrolled patients Sep 2010 - Oct
2011 (all providing informed consent) to real-world data for Ph+ ALL patients start-
ing ponatinib treatment Jan 2014 - Dec 2015. Real-world data source includes
referring physicians, pharmacy intake forms and dispensing records. Data on co-
prescribing were available for a small subset of patients. Patient characteristics
and dosing were compared using non-parametric tests; average daily dose was
calculated, including therapy gaps as “zero” dose. Duration of therapy was
assessed using Kaplan-Meier techniques and proportional hazard regression.
Results: PACE enrolled 32 Ph+ ALL patients; 274 US real-world Ph+ ALL
patients started treatment with ponatinib over a 2-year period. Demographic
characteristics of PACE vs real-world patients, including age (median 61.5 vs
55.5 years; p=0.589) were similar. Most PACE patients were in their 3rd line of
TKI therapy or later (19% 2nd, 44% 3rd and 38% 4th) while most real-world
patients appear to be in earlier lines of TKI (29% no prior TKI reported, 32%
2nd line, 24% 3rd, and 15% 4th) (p<0.001). All PACE patients received 45
mg/day of ponatinib as their initial dose; in the real-world, 50% of patients
initially received 45 mg/day of ponatinib, 41% received 30 mg/day and 9% 15
mg/day. Average dose was higher in PACE vs real-world (39.1 vs 27.3 mg/day;
p<0.001). PACE only permitted monotherapy ponatinib whereas combination
therapy appears to be used in a portion of real-world practice. Median time on
therapy was 2.7 months in PACE vs 5.5 months in real-world patients (p=0.004),
and nearly 50% of real-world patients remained on therapy after 6 months,
vs<20% in PACE (Table).
Table 1.
Summary/Conclusions: Real-world Ph+ ALL patients appear to be demo-
graphically similar to those enrolled in PACE, but there is evidence of ponatinib
use earlier (less prior TKI treatment) in real-world patients. Starting dose in real-
world reflects 50%<45 mg daily and subsequent lower dose intensity. Median
duration of therapy was significantly longer for real-world patients than for PACE,
with nearly one-half of real-world patients remaining on therapy at 6 months.
Longer median duration of therapy may be related to lower dose intensity, use
in earlier therapy lines, and use of combination therapy in real-world clinical
practice. Further study of real-world use of ponatinib in Ph+ ALL is needed.
E870
RISK FACTORS IN PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA: A COLLABORATIVE STUDY OF THE BIOLOGICAL COMMITTEE
OF THE LEUKEMIA GROUP OF THE SPANISH HEMATOLOGY AND
ONCOLOGY PEDIATRIC SOCIETY
N Vega-García1,*, M Torrebadell1,2, A Jiménez-Velasco3, M Ortega4, L Abad5,
M Pratcorona6, L Muñoz7, R Malatesta1, L Calvente1, A Català2,8, R Berrueco2,8,
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A Ruiz-Llobet8, C Estella1, M Trabazo1, A Alonso-Saladrigues1, M Mesegué 1,
A Pascual9, Á Lassaletta10, I Badell11, S Pisa12, MR Velasco13, JL Dapena14,
S Rives2,15, M Ramírez-Orellana10, M Camós1,2
1Hematology Laboratory, Hospital Sant Joan de Déu, Barcelona, 2Centro de
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto
de Salud Carlos III, Madrid, 3Hematology and Hemotherapy Laboratory, Hos-
pital Carlos Haya, Málaga, 4Cytogenetics Unit Hematology Department, Hos-
pital Vall d’Hebron, Barcelona, 5Hematology Laboratory, Hospital Niño Jesús,
Madrid, 6Hematology Laboratory, Hospital de la Santa Creu i Sant Pau,
Barcelona, 7Hematology Laboratory, Hospital Parc Taulí, Sabadell, 8Pediatric
Hematology, Department of Hematology and Oncology, Hospital Sant Joan de
Déu, Barcelona, 9Hematology Department, Hospital Carlos Haya, Málaga,
10Hematology and Oncology Department, Hospital Niño Jesús, Madrid, 11Pedi-
atric Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona,
12Pediatric Hematology Department, Hospital Parc Taulí, Sabadell, 13Hema-
tology Department, Hospital Virgen de la Salud, Toledo, 14Pediatric Hematology
and Oncology Department, Hospital Vall d’Hebron, 15Pediatric Hematology
and Oncology Department, Hospital Sant Joan de Déu, Barcelona, Spain
Background: Useful biomarkers for risk stratification in pediatric T-ALL are
still needed. Several biological variables have been proposed as new prog-
nostic biomarkers, including NOTCH1, FBXW7, PTEN & RAS mutations,
expression of myeloid antigens and presence of copy number alterations
(CNAs) of certain genes, but published results are controversial. 
Aims: To analyze the prognostic impact of mutations, CNAs and myeloid anti-
gens expression in a series of 56 pediatric T-ALL patients.
Methods: Pediatric patients (0-18 years) diagnosed with T-ALL, treated accord-
ing to SEHOP (Spanish Hematology and Oncology Pediatric Society) and
PETHEMA Cooperative Groups from 2001 to 2015. Mutations of NOTCH1,
FBXW7, PTEN, NRAS & KRAS were screened by Sanger sequencing. CNAs
were studied by MLPA technique with SALSA-P383 T-ALL kit (MRC-Holland)
and Coffalyser software.
Results: Median age was 7 years (range, 0.3-15.4 years), 72% males. Central
nervous system infiltration was present in 3 cases. Median WBC count was
56x109/L (range, 1.1-588). Twenty-four cases showed a cortical phenotype
and 3 were classified as early T-cell precursor leukemia. Myeloid antigen
expression (CD13 and/or CD33) was observed in 5 cases (14%). Twenty-three
(41%) cases harbored NOTCH1 mutations, including 18 single NOTCH1 muta-
tions (NOTCH1single) and 5 cases with more than one mutation, located in dif-
ferent domains (NOTCH1double). FBXW7 was mutated in 9 cases (16%) and
NRAS in 5 (9%). Overall, we observed NOTCH1/FBXW7 mutations in 28 cases
(50%). Six cases harbored PTEN abnormalities (mutations and/or deletions).
Thirty-one of 41 analyzed cases (76%) showed ≥1 CNAs: CDKN2A/B deletions
were the most frequent (28 cases, 60%) and were homozygous in 17 cases
(CDKN2A/Bhomo). We also observed LEF1 deletions (n=4), MYB duplications
(n=4), CASP8AP2 deletions (n=4), and deletions (n=2) and duplications (n=1)
of EZH2 gene. NUP214/ABL fusion gene was detected in 2 cases.
CDKN2A/Bhomo was associated with higher WBC count (p=0.04). After a medi-
an follow-up of 4 years (range, 0.09-14.24), 10 patients relapsed and 12 died.
The 5 years overall survival (OS) was 70±8%. All patients achieved morpho-
logical complete remission (CR) after induction. Minimal residual disease levels
(≥0.01%) were detected by flow cytometry in 8 cases (28%). Five patients
underwent allogeneic stem cell transplantation. The univariate analysis showed
a better OS for patients with cortical phenotype (90±7% vs 50±20%, p=0.035)
and a worse OS for CDKN2A/Bhomo (44±16% vs 78±10%, p=0.048) and muta-
tions in FBXW7, NRAS or PTEN abnormalities (FBXW7mut/NRASmut/PTENabn)
(50±14% vs 78±8%, p=0.027). In the multivariate analysis, CDKN2A/Bhomo
and FBXW7mut/NRASmut/PTENabn retained their statistical significance (HR
5.5, p=0.013 and HR 6.4, p=0.006, respectively). For event free survival (EFS),
hyperleukocytosis >200x109/L and FBXW7mut/NRASmut/PTENabn independ-
ently predicted a worse outcome (HR 5.3, p=0.034 and HR 8.9, p=0.007,
respectively).
Summary/Conclusions: In our series, the presence of FBXW7mut/
NRASmut/PTENabn predicted a worse OS and EFS, and the homozygous dele-
tion of CDKN2A/B genes were independently associated with an inferior OS.
Larger series of patients are needed to confirm our results. GRANTS:
PI12/2417, PN I+D+I, ISCIII (SGE, FIS), CIBERER, AMPILE, Fundación AECC,
Asociación Pablo Ugarte, Fundación Uno entre cienmil, Fundación Sandra
Ibarra, Fundación Cris contra el cáncer, “Força Miquel”, “Candela” & “Mua”
projects.
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MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS)
INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMİA (ALL): PRE AND
POST TRANSPLANT
P Ataca Atilla*, E Atilla, S Civriz Bozdag, S Kocak Toprak, P Topcuoglu,
O Arslan, H Akan, M Beksac, O Ilhan, G Gurman, M Ozcan
Ankara University School of Medicine Department of Hematology, ANKARA,
Turkey
Background: The CNS is most common extramedullary site of involvement in
ALL occurs in 4% to 8% of patients under chemotherapy. Allogeneic hematopoi-
etic stem cell transplantation (Allo-HSCT) has emerged the curative treatment
of ALL. The data how and which patients respond to CNS involvement treat-
ment in pre and post transplant period remain limited.
Aims: The objectives of this study is to examine the management and out-
comes of CNS involvement in pre and posttransplant period.
Methods: This single-center retrospective analysis included 137 ALL patients
who underwent Allo-HSCT at Ankara University School of Medicine between
2005 and 2015. CNS involvement/relapse included 1 or more of the following
criterias: evidence of leukemic blasts in the cerebrospinal fluid (CSF), cranial
nerve palsy or contrast-enhancing brain or spinal mass on imaging.
Results: Pretransplant CNS involvement was diagnoesed in 7 (5%) patients
whereas posttransplant CNS relapse was detected in 12 (9%) patients. The
patient characteristics are shown in table. All induction regimens included pro-
phylactic intrathecal chemotherapy (Methotrexate, ARA-C). None of the
patients with pre-transplant involvement had post-transplant CNS relapse. Iso-
lated CNS relapse was detected in 4 (33%) post-transplant patients. Median
time to CNS relapse from Allo-HSCT was 8 months (range, 1-28). Twp pre-
transplant (29%) and two post-transplant (16%) CNS involvement patients
received reduced intensity conditioning. TBI based conditioning was prefered
in 6 pre-transplant (86%) and 7 (58%) post-transplant CNS involvement
patients. Peripheral blood was the stem cell source for 17 patients wheras two
pre-transplant CNS involvement patients had received bone marrow from their
matched relatives. None of the patients received CNS-directed prophylactic
therapy after transplantation. All of the pre-transplant involvement patients were
died due to disease relapse post-transplant. Two patients who received HDT
and RT were alive in post-transplant CNS relapse group.
Table 1.
Summary/Conclusions: The prognosis is poor in CNS relapse detected in
ALL patients posttransplant or pretransplant period. HDC and RT seems the
most effective treatment strategy.
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NOVEL DYNAMIN2 MUTATION IN ADULT T-CELL ACUTE LYMPHOBLASTIC
LEUKEMIA
Z Ge1,*, M Li2, G Zhao1, N Jin1, B Chen1, MD Yu3, J Li2, S Dovat4, C Song4
1Hematology, Zhongda Hospital, Southeast University Medical School, 2Hema-
tology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Chi-
na, 3Sydney Kimmel Medical College at Thomas Jefferson University, Philadel-
phia, 4Pediatrics, Pennsylvania State University Medical College, Hershey,
United States
Background: Dynamin 2 (DNM2), a GTPase is essential for intracellular vesi-
cle formation and trafficking, cytokinesis, and receptor endocytosis. Recently
DNM2 genetic mutations are identified in a subtype of T-cell acute lymphoblas-
tic leukaemia (T-ALL) termed “early T-cell precursor” (ETP) ALL that comprises
up to 15% of T-ALL, and is associated with treatment failure. However, study
on DNM2 genetic mutations in adult ALL is rare.
Aims: To characterize the novel DNM2 mutations in Chinese adult T-ALL
patients.
Methods: Bone marrow (BM) samples from 42 newly diagnosed T-ALL patients
[31 male with median age 26 (16-62), 11 female with median age 29 (19-60)]
were collected between July 2010 and December 2014 at the First Affiliated
Hospital of Nanjing Medical University. The diagnosis of ALL was made accord-
ing to the morphologic, immunophenotypic, cytogenetic and molecular criteria
of WHO Diagnosis and Classification of ALL (2008). All the patients provided
their written informed consent in accordance with the Declaration of Helsinki
before enrollment in the study. The study was approved by the Institutional
Review Board of the Nanjing Medical University. We performed mutational
analyses of DNM2 exons 2-22. Exons in NOTCH1, FBXW7, PHF6, PTEN,
JAK1 and IL-7R were also screened. Conventional cytogenetic analysis was
performed at the time of diagnosis, using unstimulated short-term cultures
according to the recommendations of the International System for Human Cyto-
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genetic Nomenclature (ISCN). For each sample, at least 20 BM metaphase
cells were analyzed. Immunophenotypic analyses were performed by flow
cytometry on fresh BM samples. The cell-surface antigen was defined positive
when fluorescence intensity of at least 20% of cells exceeded fluorescence of
negative control.
Results: DNM2 mutations were identified in 4 of 42 T-ALL patients (9.5%). All
the four cases were point mutations (c.1081C>T, c.1453T>C, c.1609G>A and
c. 1801C>T), which is located in exon 8, 13, 16 and 18. In the four identified
mutations, one is nonsense mutation and three are missense mutations. All of
the four mutations were lead to amino acid changes (R361X, Y485H, G537S
and R601W). The R361X and Y485H are located in middle(MID) domain, while
G537S and R601W in pleckstrin homology(PH) domain of DNM2. Interestingly,
we found that the four patients with DNM2 mutations co-existed with NOTCH1
mutations, 3 of the 4 cases co-existed with two NOTCH1 mutations (point muta-
tions and / or indel mutations), which were located in NOTCH1 exon 26, 27
and 34. Moreover, 3 of the 4 patients with DNM2 mutations were also con-
comitant with PHF6 mutations which were located in PHF6 exon 4, 5 and 8.
The clinical characteristics of the patients with DNM2 mutations were further
analyzed. It showed that one patient relapsed, one patient had initial high WBC,
and two patients had complex karyotype. Importantly, the days for reaching
the complete remission after induction chemotherapy were over 4 weeks for all
these patients. These data indicated that the patients with DNM2 mutations in
this cohort of adult T-ALL had poor prognosis.
Summary/Conclusions: We identified 4 novel DNM2 mutations and the co-
existence of mutations in NOTCH1/PHF6 in adult T-ALL patients. We also
observed the association of DNM2 mutations with poor prognosis. Our finding
suggested the DNM2 mutations may be involved in the oncogenesis of T-ALL.
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LONG-TERM OUTCOME OF RELAPSED ADULT PHILADELPHIA
CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA TREATED
WITH CONTINUOUS IMATINIB PLUS COMBINATION CHEMOTHERAPY
S Lim1,*, YD Joo1, JH Lee2, JH Lee2, DY Kim2, BS Sohn3, KH Lee2, IH Kim1
1Internal Medicine, Haeundae Paik Hospital/Inje University College of Medicine,
Busan, 2Internal Medicine, Aasan Medical Center, University of Ulsan, College
of Medicine, 3Internal Medicine, Sanggey Paik Hospital, Inje University College
of Medicine, Seoul, Korea, Republic Of
Background: Treatment outcome with conventional salvage therapy in
relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+
ALL) is poor and is often associated with significant morbidity. Tyrosine kinase
inhibitors (TKI) have changed strategy of Ph+ ALL therapy and improved prog-
nosis of the disease. However, despite the progress associated with TKI therapy
for Ph+ ALL, the maintaining remission remains the major challenge.
Aims: We assessed the long-term outcome of relapsed adult Ph+ ALL patients
treated with continuous imatinib plus combination chemotherapy.
Methods: Imatinib (600 mg/day orally) was administered continuously with
combination chemotherapy, starting from eighth day of remission induction
treatment, then through 5 courses of consolidation or until allogeneic
hematopoietic cell transplantation (HCT). Patients who were not transplanted
were maintained on imatinib for 2 years.
Figure 1.
Results: Between October 2005 and February 2009, total 87 patients, aged
16-71 years, with newly diagnosed Ph+ALL were enrolled. With median follow-
up of 5 years among survivors (range: 2.6-8.9 years) and data was frozen up
in May 2015. After remission induction, 82 patients (94%) achieved complete
remission (CR). Among these patient, 44 patients (54%) experienced leukemia
relapse and median time of leukemia relapse-free survival was 13.9 months
(range, 0.4-89.5 months). Sites of relapse were bone marrow (79.5%), central
nervous system (CNS) (9.1%), lymph nodes (6.8%), testis (2.3%) and pancreas
(2.3%), respectively. Sixteen patients (36.4%) relapsed during consolidation
treatment, 23 patients (52.3%) relapsed after allogeneic hematopoietic cell
transplantation (HCT), and five patients (11.4%) relapsed during maintenance
treatment after completion of five consolidation. The relapse rate within one
year from CR was 45.5% in total patients and that within one year in patients
underwent allogeneic HCT in first CR was 25.0%. Salvage treatments of
relapsed Ph+ ALL were combination chemotherapy in 13 patients (29.5%), ima-
tinib in 6 (13.6%), imatinib plus combination chemotherapy in 6 (13.6%), dasa-
tinib in 8 (18.2%), dasatinib plus combination chemotherapy in 5 (11.4%),
intrathecal methotrexate in 4 (9.1%) who relapsed in CNS, and to stop immuno-
suppressant therapy in one who underwent allogeneic HCT. One relapsed
patient did not receive treatment due to poor performance state and died of
leukemia recurrence. Patients treated with dasatinib±combination chemother-
apy were demonstrated a longer survival compared with patients treated with
combination chemotherapy without dasatinib (P=0.026). Dasatinib treatment
had a tendency of superiority in survival but there was no statistical significance.
Nineteen patients (43.2%) among evaluable 43 patients treated salvage therapy
achieved a second CR. Two patients of them were received allogeneic HCT
after achieving second CR. Eleven patients in twelve evaluable patients who
achieved a second CR experienced a second relapse. The median time of sur-
vival was 21.3 months (range, 4.4-72.2 months). The causes of death of them
were leukemia recurrence (89.2%), and infection (10.8%).
Summary/Conclusions: Inclusion of dasatinib into transplantation strategy
allows obtaining sustained remission even in patients relapsed after imatinib
treatment.
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HEMATOPOIETIC STEM CELLS CAN BE SEPARATED FROM LEUKEMIC
CELLS IN A SUBGROUP OF ACUTE LYMPHOBLASTIC LEUKEMIA
PATIENTS
W Wang1,2, E Foerner2, L Manta2, E Buss2, A Jauch3, V Eckstein2, P Wuchter2,
AD Ho2, C Lutz2,*
1Department of Oncology, Nanjing Medical University Affiliated Wuxi Second
Hospital, Nanjing, China, 2Departement of Medicine V, University Hospital of
Heidelberg, 3Institute of Human Genetics, University of Heidelberg, Heidelberg,
Germany
Background: Aldehyde dehydrogenase (ALDH) activity which is involved in
the metabolism of intracellular aldehydes has been demonstrated to function
as a marker for stem cell activity in various tissues including the hematological
system. In combination with CD34-positivity and CD38-negativity high ALDH
activity (CD34+CD38-ALDH+) has been shown to be a reliable tool for the sep-
aration of hematopoietic stem cells (HSC) from leukemic cells in a subgroup of
patients with acute myeloid leukemia (AML). In B-cell acute lymphoblastic
leukemia (B-ALL) successful separation of normal HSC has so far been limited
to a subgroup of patients. These isolations were mostly guided by CD19-neg-
ativity in combination with the CD34+CD38- phenotype. However, in some cases
leukemia initiating cells were also detectable in the pool of CD19- cells indicating
that better isolation strategies are necessary.
Aims: In this study we sought to investigate the value of ALDH-activity for the
isolation of HSC from leukemic cells in adult B-ALL.
Methods: Between 2011 and 2015 bone marrow (BM) aspirates of 15 ALL
patients were collected after written informed consent and stratified in ALDH-
numerous (≥1.9% ALDH+ cells) and ALDH-rare (<1.9% ALDH+ cells) cases.
The cut-off value of 1,9% was determined by the amount of ALDH+ cells in
healthy bone marrow controls. HSC candidates (CD34+CD38-ALDH+) and var-
ious subpopulations were analyzed for the presence of clonal marker and func-
tionally tested in in vitro assays.
Results: In ALDH-rare B-ALL clonal-marker negative HSC could be reliably
separated by the CD34+CD38-ALDH+ phenotype, whereas this separation was
not possible in ALDH-numerous B-ALL. Functional assays confirmed the HSC-
potential of isolated cells and showed increased long- and short-term colony-
initiating activity. Further analysis showed that in ALDH-rare ALL HSC-potential
was uniformly restricted to CD19- cells. However, addition of ALDH-activity was
necessary to further enrich for HSC-activity as CD34+CD38-CD19-ALDH- cells
contained no colony forming potential.
Summary/Conclusions: In summary, we provide a method to separate func-
tionally normal HSC from leukemic cells in a subgroup of B-ALL patients that
can be identified by their overall low percentage of cells with high ALDH-activity.
This protocol thereby allows comparative analyses of patient matched HSC
and leukemic cells in order to improve the understanding of leukemic evolution
in adult B-ALL.
E875
DOES TIMING OF CENTRAL VENOUS LINE REPLACEMENT MATTER
DURING INDUCTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA?
E Ataseven*, D Kızmazoğlu, Ö Tüfekçi, F Demir Yenigürbüz, S Yılmaz Bengoa,
H Oren
Department of Pediatric Hematology and Oncology, Dokuz Eylul University
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Background: The use of central venous lines (CVL) in children with acute
lymphoblastic leukemia (ALL) provides comfortable administration of intensive
chemotherapy and blood sampling. The optimal time for insertion of CVL in
patients with ALL is controversial.
Aims: The aim of this study is to define the frequency of CVL related compli-
cations and also to analyse the frequency of cases of catheter related infection
and thrombosis in relation to timing of CVL replacement.
Methods: We reviewed the records of 52 pediatric ALL patients with CVL treat-
ed during a 10-year period. Demographics, preoperative blood counts, type of
central line, time of CVL replacement, CVL related complications, and blood
counts during complications were all noted. All the data were collected from
those with the first catheter use. 
Results: Fifty two pediatric ALL patients (29 male, 23 female) with a median
age of 6,1 years were included in the study. Most of the patients (92.3%) had
an internal line (port). CVL was replaced before treatment day 15 (early) in
twenty six patients (50%) and after 15 days (late) in 26 patients (50%). Systemic
infections occurred in 24 patients (46.2%). Regarding the infection rates, no
difference was found between early and late CVL replacement (p=0.09). Most
of the infections (68%) were due to coagulase negative Staphylococcus aureus.
The median absolute neutrophil count during infections was 150/mm3 (0/mm3
to 17,700/mm3). There were three patients with thrombosis and no difference
was found between early and late insertion of CVL replacement groups
(p=0.35). Other catheter related complications was recorded in seven patients
(leakage in one patient, accidental removal of line in one patient, line rupture
in one patient, and line occlusion in four patients). CVLs had to be removed in
seventeen patients (32.7%) before the end of chemotherapy protocol due to
various reasons (catheter related infections in six patients, local skin infections
in four patients, and other catheter related complications in seven patients). 
Summary/Conclusions: The present study showed no relation between the
timing of catheter replacement and occurrence of infection and thrombosis.
Our results suggest CVLs can be replaced safely at the time of diagnosis or
early period of treatment to provide a comfortable administration of chemother-
apy and to decrease painful blood samplings.
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TYROSINE KINASE INHIBITORS IN PHILADELPHIA-CHROMOSOME
POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REAL CLINICAL
PRACTICE
F Folber1,*, J Machal2, S Hrabovsky1, J Mayer1, M Doubek1
1Department of Internal Medicine, Hematology and Oncology, University Hos-
pital Brno, 2Faculty of Medicine, Masaryk University, Brno, Czech Republic
Background: Adult patients with Philadelphia-chromosome positive acute lym-
phoblastic leukemia (Ph+ ALL) are at high risk of relapse. Allogeneic stem cell
transplantation still remains the treatment of choice in spite of the major benefit
brought by adding tyrosine kinase inhibitors (TKIs) to the standard chemother-
apy. On the other side, TKIs also bear several side effects and some of them
require significant dose reductions.
Aims: The aim of this analysis was to focus on treatment strategies in unse-
lected adult Ph+ ALL patients in real clinical practice and how TKI dose reduc-
tion may influence their outcomes.
Methods: All adult patients diagnosed with Ph+ ALL and treated with TKIs at
our centre between 2005 and 2015 were included into this retrospective analy-
sis. We describe baseline features, treatment options and outcomes. The data
were analysed for response and relapse rates and factors affecting survival.
Results: A total number of 41 consecutive patients aged 19 to 82 years (median
58) at the time of diagnosis of Ph+ ALL were included. Leukocyte count was
1.8 to 296 x 109/L (median 20) at presentation. Most commonly observed were
common-B immunophenotype (73%) and p190 bcr-abl transcript (63%). Thir-
teen (32%) patients were treated according to pediatric-based intensive proto-
col, 13 (32%) using a reduced-toxicity protocol, and 15 (37%) in a palliative
approach. An allogeneic transplant was performed in 17 (41%) patients. Thir-
ty-three (85%) patients achieved a complete remission (CR) and 56% of them
achieved a complete molecular response (CMR). First line TKI was imatinib in
all patients, with a median daily dose of 600mg. In 18 (44%) patients the dose
had to be reduced to 400, 300 or 200mg due to side effects (haematological
36%, oedemas 32%, gastrointestinal 16%, skin rash 4%). Sixteen (46%)
patients in CR eventually relapsed and only 6 (38%) achieved a second CR.
Second line TKI was dasatinib (12; 75%) or 800mg imatinib (3; 19%). Dasatinib
was given at a median daily dose of 140mg but in a much broader range (35
to 140 mg). This dose was further decreased in 10 (83%) patients, while most
common non-haematological side effects were gastrointestinal (17%), oede-
mas (13%) and effusion (4%). Five (83%) of these patients in CR2 experienced
a second relapse. During the follow-up with a median of 12 months (range 1
to 103 months), 27 (66%) patients died; fifteen (56%) of infection, 11 (41%) of
disease progression and one (4%) of a secondary malignancy. Fourteen (34%)
patients are still alive in complete remission. Five-year overall survival (OS) in
the whole cohort was 30%. The survival was not influenced by leukocyte count,
immunophenotype nor the type of the bcr-abl transcript. The statistically sig-
nificant risk factors for longer OS were: age under 55 (5-year OS 57% vs 8%,
p<0.01), CR (37% vs 0%, p<0.01), CMR (54% vs 0%, p<0.01), allogeneic
transplant (58% vs 8%, p<0.01) and relapse (67% vs 0%, p=0.01). In non-
transplanted patients with imatinib dose reduction the survival was not inferior
compared to patients without a reduction. Surprisingly, these patients were
surviving even longer (2-year OS 38% with a reduction vs 8% without, p<0.01).
Whether this finding represents a clinically significant phenomenon or is a mere
coincidence remains a question for further investigation.
Summary/Conclusions: Adult patients with Ph+ ALL form a distinct subgroup
with a very variable prognosis. The best treatment outcome can be reached in
younger patients who undergo allogeneic transplant in first haematologic and
molecular remission. According to our analysis, imatinib dose reduction due to
side effects is not associated with inferior survival. (Supported by Czech
Leukemia Study Group-for Life.).
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PREDICTIVE VALUE OF IG/TR AND BCR/ABL1 PCR-BASED MINIMAL
RESIDUAL DISEASE MONITORING IN PH+ PEDIATRIC ALL TREATED
WITH IMATINIB IN THE ESPHALL STUDY
G Cazzaniga1,*, P De Lorenzo2, J Alten3, S Roettgers4, J Hancock5, V Saha6,
A Castor7, H Madsen8, V Gandemer9, H Cavé10, V Leoni1, G Ferrari1,
R Pieters11, V van der Velden12, J Stary13, J Zuna13, G Escherich14, U zur Stadt14,
M Aricò15, V Conter1, M Schrappe3, MG Valsecchi2, A Biondi1
1AIEOP, 2EsPhALL Trial Data Center, University of Milano-Bicocca, Monza,
Italy, 3BFM-G, Kiel, 4BFM-G, Giessen, Germany, 5CCLG, Bristol, 6CCLG, Man-
chester, United Kingdom, 7NOPHO, Lund, Sweden, 8NOPHO, Copenhagen,
Denmark, 9FRALLE and EORTC, Rennes, 10FRALLE and EORTC, Paris,
France, 11DCOG, Utrecht, 12DCOG, Rotterdam, Netherlands, 13CPH, Prague,
Czech Republic, 14COALL, Hamburg, Germany, 15AIEOP, Ragusa, Italy
Background: Several studies showed that minimal residual disease (MRD)
detection is a strong independent prognostic factor in childhood acute lym-
phoblastic leukemia (ALL) including Ph+ ALL treated with conventional
chemotherapy. Very few data and of difficult interpretation are available on the
predictive value of early MRD response in Ph+ ALL treated with tyrosine kinase
inhibitors (TKI)s.
Aims: MRD was detected by real-time quantitative PCR of rearranged
immunoglobulin/T-cell receptor (IG/TR) genes and/or BCR/ABL1 fusion tran-
script in the EsPhALL study to investigate its predictive value in patients treated
with imatinib.
Methods: In the EsPhALL study, after induction therapy, patients received
BFM high risk ALL therapy; imatinib was given intermittently during the intensive
treatment phases for a total of 18 weeks or less, usually 10 weeks, if patients
underwent hematopoietic stem cell transplantation (HSCT), indicated for large
majority of patients. MRD on the bone marrow (BM) was monitored as an ancil-
lary study after induction therapy (TP1), consolidation Phase IB (TP2), HR
Block1 (TP3), HR Block2 (TP4), HR Block3, first and second reinduction, and
at end of therapy. Quantitative PCR analysis was performed and interpreted
according to Euro-MRD network guidelines for both IG/TR and BCR/ABL1.
Results: MRD negativity increases progressively, both by IG/TR (from 10% at
TP1 to 57% at TP4) and by BCR/ABL1 (from 13% at TP1 to 30% at TP4). Con-
versely, the proportion of patients with highly positive MRD by IG/TR decreases
from 78% at TP1 to 14% at TP4 and by BCR/ABL1, from 80% at TP1 to 57%
only at TP4. The minority of patients IG/TR MRD negative at TP1 (N=9, 10%)
had a very favorable outcome with no relapses, whereas patients with high or
low MRD positivity had a similarly high 5-year cumulative incidence of relapse
(CIR) (SE) of 35.2 (5.9) and 36.4 (15.4), respectively. Achieving MRD negativity
at TP2 is also associated with low risk of relapse (5-year CIR (SE) 14.3 (9.8)),
whereas achieving negativity only at TP3 or TP4 is associated with a CIR of
36.4 (15.5) and 42.9 (21.6), respectively, similar to that of patients with low or
high positivity at any time-point. BCR/ABL1 MRD negativity (although based
on small numbers) at TP1 or TP2 is reached less frequently compared with
IG/TR MRD, but is associated with a similar very low risk of relapse (one relapse
in 8 patients MRD negative at TP1), while patients with low or high positivity
have instead a high risk of relapse, again similar to that observed for positive
IG/TR MRD. The overall concordance between the two methods is 69%; for
patients with positive MRD by both techniques, the estimated mean differences
of BCR/ABL1 versus IG/TR results were significantly different from zero, and
were consistent according to different TPs with significantly higher positivity by
BCR/ABL1. There are also rare cases consistently negative by IG/TR and pos-
itive by BCR/ABL1 with a very favorable outcome.
Summary/Conclusions: MRD negativity by IG/TR is obtained more frequently
than by BCR/ABL1 and it is highly predictive of a very favorable outcome and
the earlier the negativity, the better the prognosis. Further investigations are
needed to understand the biology in cases with discordant results, and in par-
ticular of those negative by IG/TR and positive by BCR/ABL1. The role of MRD
in patients treated continuously with TKI inhibitors and without HSCT needs to
be explored in current studies.
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OUTCOME OF PATIENTS WITH HIGH RISK ACUTE LYMPHOBLASTIC
LEUKEMIA IN HAPLOID-MATCHED VS SIBLING-MATCHED ALLOGENEIC
STEM CELL TRANSPLANTATION
H Yan, L Tan, L Gao, C Zhang, Y Liu, L Gao, P Kong, H Liu, X Zhang*
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Background: The efficacy of allogeneic stem cell transplantation in patients
with high risk acute lymphoblastic leukemia (ALL) is unclea, and the relevant
prognostic factors are not well-known.
Aims: To explore the efficacy of allogeneic stem cell transplantation in patients
with high risk acute lymphoblastic leukemia (ALL) and investigate its relevant
prognostic factors
Methods: A total of 69 patients with ALL who were treated with allo-HSCT in
our hospital from July 2007 to August 2013, all patients were followed up more
than two years. They were divided into haploid-matched (haploidentical allo-
geneic stem cell transplantation) group (n=42) and sibling-matched(HLA sib-
ling-matched allogeneic stem cell transplantation) group (n= 27). Clinical char-
acteristics of two groups were retrospectively analyzed.Survival date were ana-
lyzed by the Kaplan-Meier method and the prognostic factors were analyzed
with the COX regression model.
Results: 2 years over-all survival(OS) is 63.4% in haploid-matched group,
53.9% in sibling-matched group, difference was not statistically significant
(P=0.197); and 2 year LFS(leukemia-free survival) is 59.4% and 53.7% in hap-
loid-matched group and sibling-matched group respectively,difference was not
statistically significant(P=0.17). 2 years RR(relapse rate) of sibling-matched
group(39.5%) is higher than that of haploid-matched group(19.5%) (P=0.014).
In hematopoietic reconstruction, Neutrophils reconstruction of the haploid-
matched group later than sibling-matched group(P=0.002), and platelet recon-
struction in two group is similar(P=0.072). Grade I-II aGVHD(acute graft-ver-
sus-host disease) in haploid-matched group is higher than sibling-matched
group (P=0.008), then grade III-IV aGVHD and chronic GVHD are similar
(P=0.726, P=0.81 respectively) in two group. We collected the early(six months)
infection after HSCT, infection rate of haploid-matched group is higher than
sibling-matched group(P=0.02). 2 year NRM(non-relapse mortality) rate of sib-
ling-matched group is 11.1%, NRM rate of haploid-matched group is 26.2%,
the difference was not statistically significant (P=0.519). The Cox regression
analysis showed that disease status before transplant (not CR1) were main
risk factors affecting LFS of patients(P=0.001), relative risks is 7.581. limtited
GVHD (P=0.013) and shorter time from first diagnosed to transplantation
(P=0.012) is protective factors,relative risks is 0.178 and 0.688 respectively.
Summary/Conclusions: In high-risk patients with ALL ,haploid-matched and
sibling-matched HSCT are similar in total outcome. haploid-matched donor can
be suitable source of allogeneic stem cell transplantation.
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EXPLORE THE INNER RELATION AMONG THE MORPHOLOGY,
IMMUNOPHENOTYPIC, MOLECULAR GENETIC FEATURES IN MIXED
PHENOTYPE ACUTE LEUKEMIA
P Wang1, XJ Deng1, SH Liu1, C Zhang, X Qiang1, HY Zhang1, Y Gou1, WC
Yang1, XG Peng2,*
1Department of Hematology, Xinqiao Hospital, Third Military Medical University,
Chongqing, 2Department of Hematology, Xinqiao Hospital, Third Military Med-
ical University, Chongqing, China
Background: The mixed phenotype acute leukemia(MPAL) is rare leukemia.
The biology of MPAL is unclear.
Aims: To analyze and explore the inner relation among the Morphology,
immunophenotypic, cytogenetic, molecular genetic features and prognosis of MPAL.
Methods: MICM classification by morphology and cytochemistry, flow cyto-
metric immunophenotyping,conventional cytogenetic,fluorescence in situ
hybridization (FISH) and/or molecular genetic, was used to relrospectively study
2575 patients with AL from January 2008 to March 2015.
Results: The results showed that 30(1.16%) cases were diagnosed as
MPAL,fulfilling WHO 2008 criteria. 13 cases of 30 MPALs’Leukemia cells pre-
sented the same kind of morphological characteristics,leukemia cells of the
other 17 cases has two different morphological characteristics(The two kinds
of cells were more than double in volume I. Maxicell: around 16 to 25 um, mor-
phological characteristics similar to myeloid myeloblast and/or monoblast, POX
positive II. Cellule:around 8 to 12 um,morphological characteristics similar to
lymphocytes,but is not a classic myeloblast,monoblast or lymphoblast, Cyto-
plasm pseudopodia,burr shape change,drag the caudate,containing A particle
or not, folded or irregular nuclei). Based on FAB criteria,12(40%) patients
showed AML morphologies, mainly M1 and M5,the dominant subtype. 6(20%)
patients were classified ALL,7(23.3%) patients were classified hybrid acute
leukemia(HAL). The remaining 5(16.7%) cases resisted classification by mor-
phology and were categorized as acute undifferentiated leukemia. Immunophe-
notyping data showed that 16 of 30 cases(53.3%) had combined B-lymphoid+myeloid
immunophenotype(B+My),12(40%) combined T-lymphoid+myeloid immunopheno-
type(T+My), 1(3.33%) B+T- lymphoid immunophenotype (B+T), and in the remain-
ing 1(3.33%) cases there was evidence of trilineage concomitant expression
[myeloid, B, and T lymphoid(My+B+T)]. In addition, there are 1/16 cases of MY+B
with T-lineage marker CD7+ not as trilineage. There were high expression of
stem/progenitor cell markers CD123,CD34,CD38 and HLA-DR in MPAL;with
the positive rate of 100%,93.3%,90% and 92.6%,respectively. A total of 11
(36.7%) had Ph chromosome and/or BCR-ABL fusion gene by FISH and/or
RT-PCR. Median WBC of peripheral blood was 149x109/L ranging between
1.46x109/L and 797x109/L.Compared with Ph-MPAL,it has statistical signifi-
cance that combined B+My immunophenotype(P=0.001) and the peripheral
blood was found to be immature granulocytes (promyelocytic, myelocyte and
metagranulocyte) by smears for morphology (P=0.002), at the positive rate of
90.9%(10 of 11 cases) in Ph+MPALs. 7 cases of HAL by morphology associated
with the BCR-ABL fusion gene(P=0.01),and these appeared as combined B+My
immunophenotype. 22 of 30 patients were treated with at least 2 cycles of
chemical drugs,with the complete response(CR) rate of 59.1%(13/22). This
study found In these 30 cases of MPALs, according to our set of morphological
classification scheme the ALL often appeared as combined B+My immunophe-
notype that was diagnosed by morphology;the combined T+My immunophe-
notype cases usually showed AML by morphological classification. While
myeloid and lymphoid blast cells were simutalously seen in BM, high leukocyte
and high immature granulocytes were seen in PB, and with B+My immunophe-
notype, it often hint MPAL with Ph chromosome or BCR-ABL fusion gene.
Summary/Conclusions: MPAL is a set of heterogeneous disease that origi-
nated in the stage of pluripotent stem cell and have directional differentiation
potential,mainly presents the characteristic of myeloid differentiation.
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LPS STIMULATION INDUCES ROS FORMATION, APOPTOSIS, DNA
DAMAGE AND OXIDATION OF CYSTEINE RESIDUES IN FLT3-ITD POSITIVE
CELL LINES RESULTING IN FLT3-TYROSINE KINASE INHIBITOR
RESISTANCE
C Mueller1,*, T Schnoeder1, L Simeoni2, F Heidel1, C Thurm2, B Schraven2,
T Fischer1
1Department of Hematology and Oncology, 2Institute of Molecular and Clinical
Immunology, University Clinic Magdeburg, Magdeburg, Germany
Background: Recurrent infections are associated with an increased incidence
in the development of malignancies, including acute myeloid leukemia (AML).
Inflammatory events directly induce formation of reactive oxygen species (ROS)
and cause DNA damage, protein and lipid oxidation. In case of recurrent infec-
tions, bacterial peptides, like LPS, can lead to ROS induction. In particular,
cysteine residues of proteins can directly be oxidized by ROS causing either
loss or gain of function. However, it is still unclear how inflammatory events
can induce these protein oxidation and to what extent the oxidation of cysteine
residues in a subset of AML, the FLT3-ITD positive AML, causes a change of
biological behavior.
Aims: The goal of our study was to characterize the role of LPS-induced oxida-
tive stress in murine and human FLT3-ITD positive cell lines to identify respon-
sible FLT3-ITD- and TLR related signaling pathways. To adress stress-induced
cysteine oxidation of the FLT3-kinase, we generated cysteine-to-alanine
mutants in murine myeloid 32D cells (FLT3-WT and FLT3-ITD) and investigated
the induction of ROS formation, proliferation, cell cycle distribution and the
response to TKI treatment (AC220, PKC412).
Methods: 32D cells stably transduced with either FLT3-WT or FLT3-ITD and
human FLT3-ITD positive MV4,11 were stimulated with LPS (5-50 ng/ml) for
2h and with 10 ng/ml LPS for different time-points (0-90 min), respectively.
ROS formation (H2DCFDA method) and activation of FLT3-ITD and TLR-related
signaling pathways were analyzed by immunoblotting. To analyze effects of
chronic inflammation, FLT3-WT and FLT3-ITD positive cells were kept in culture
for 12 days with repeated LPS stimulation (10 ng/ml every 48h). To address
the role of cysteine oxidation within the FLT3-kinase, we mutated highly con-
served cysteine residues C474 (extracellular domain) and C925 (intracellular
domain) to alanine by site-directed mutagenesis and performed a retroviral
transduction of 32D cells with the respective constructs. Subsequently, cysteine
mutants were characterized for proliferation (MTT), ROS formation and their
sensitivity to TKI treatment (AC220, PKC412; 5 to 50 nM, respectively) in com-
parison to standard FLT3-ITD mutant. 
Results: LPS stimulation resulted in an increased time- and dose-dependent
ROS induction in FLT3-ITD positive cells compared to WT cells (100ng/ml LPS
for 2h: 6-fold). In addition, LPS stimulation resulted in a stronger activation of
FLT3-ITD- and TLR-related signaling pathways in ITD-positive cells (Stat5, Akt,
Erk, NFB). Long-term LPS stimulation over 12 days induced an enhanced
ROS formation, apoptosis and accumulation of H2AX in both FLT3-WT, as
well as in FLT3-ITD positive cells. To address the role of cysteine oxidation, we
generated stable cysteine-to-alanine-mutants. However, the FLT3-ITD C925A
mutation (intracelullar domain) resulted in an increase of ROS formation com-
pared to the FLT3-ITD C474A mutation (extracellular domain; 25% increase).
Furthermore, the C925A mutation resulted in a significant decrease in apoptosis
after TKI treatment compared to non-mutated FLT3-ITD and the FLT3-ITD
C474A mutant (AC220 50nM: 25%; PKC412 50nM: 40%). In addition, FLT3-
ITD C925A mutant showed a reduced decrease in phosphorylation of Stat5
and Akt after short-term (1h) TKI treatment (AC220: 50, 100 nM; PKC412 10,
100nM) compared to non-mutated and FLT3-ITD C474A mutants.
Summary/Conclusions: Our study demonstrates that inflammatory events,
like LPS stimulation, induce ROS formation, apoptosis and DNA damage in
FLT3-WT and FLT3-ITD positive cells. This might lead to genetic instability and
induction of critical mutations, e.g. within FLT3 kinase. Additionally, we could
show that cysteine oxidation within the intracellular domain of FLT3-ITD resulted
in a resistance to TKI treatment.
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ANALYSIS OF SNORNA EXPRESSION AND FUNCTION IN ACUTE MYELOID
LEUKEMIA
F Zhou1, C Pauli1, Y Liu1, D Gerloff1,*, C Rohde1, M Köhn2, D Misiak2,
S Hüttelmaier2, C Müller-Tidow1
1Department of Internal Medicine IV, Hematology and Oncology, University
Hospital Halle, 2Section for Molecular Cell Biology, Institute of Molecular Med-
icine, Martin-Luther-University Halle, Halle, Germany
Background: Small nucleolar RNAs (snoRNAs) belong to the group of non-
protein-coding RNAs with distinct functions in ribosomal RNA (rRNA) modifi-
cation. snoRNAs are divided into the two major classes: box C/D and box
H/ACA snoRNAs. SnoRNAs assembly with small nucleolar ribonucleoproteins
(RNPs) and guide those snoRNPs to the rRNA, where they catalyze rRNA
modifications. C/D box snoRNAs are involved in 2-O-methylation, whereas
H/ACA snoRNAs guide pseudouridylation. Recent studies showed that snoR-
NAs play a role in cancerogenesis. Hence, we analyzed snoRNAs expression
and function in leukemogenesis.
Aims: Investigation of snoRNA expression pattern and function in acute
myeloid leukemia. 
Methods: To understand the role of snoRNAs in leukemia, we analyzed the
snoRNA expression pattern of 63 AML patients at time of diagnosis. Additionally
we analyzed snoRNA expression patterns in AML1-ETO or Myc transduced
lin- mouse bone marrow cells. Librarys for small RNA (40-200 nt) specific next
generation sequencing (NGS) were prepared with TruSeq Small RNASample
Prep Kit. NGS was performed on an Illumina HiScanSQ, using 50 cycles of
single read sequencing. For functional analysis of single snoRNAs, we per-
formed single Knockouts of 6 snoRNAs (SNORD14D, SNORD34, SNORD35A,
SNORD43, SNORD53 and SNORD104) in Kasumi and MV4-11 cells using
CRISPR/Cas9 technology. Mutations in the genomic sequence were confirmed
by Sanger sequencing. Subsequently, expression of snoRNAs was analyzed
by qRT-PCR. To analyze the effect of snoRNA knockout on colony formation
ability of mutated cells, we embedded 300 cells/well in methylcellulose.
Colonies were counted after 7-10 days.
Results: Next generation sequencing data revealed 229 C/D box snoRNAs
and 90 H/ACA box snoRNAs were expressed in one or more patient samples.
In further analyses, we compared clinical data and snoRNA expression pattern.
SnoRNA expression patterns were associated with specific risk groups. High
levels of snoRNA expression associated with intermediate molecular risk (269
snoRNAs, p≤0.05) and a poor response to chemotherapy (101 snoRNAs,
p≤0.05). Further, we could show that snoRNAs are higher expressed in AML
patient samples with NPM1 wildtype (124 snoRNAs, p≤0.05). Transduction of
the oncogenes AML1-ETO9a or Myc to normal lin- mouse bone marrow cells
induced an increased overall snoRNA expression. We found 93 snoRNAs
downregulated and 88 upregulated during ATRA induced differentiation of HL60
cells. The functionally analyzed snoRNAs SNORD14D, SNORD34,
SNORD35A, SNORD43 and SNORD53 were downregulated. CRISPR/Cas9
induced knockouts for SNORD14D, SNORD34, SNORD35A or SNORD43 sig-
nificantly inhibited colony formation of Kasumi-1 cells. Also, loss of SNORD14D
or SNORD35A decreased colony formation potential of MV4;11 cells. Loss of
SNORD34, SNORD35A, SNORD43 and SNORD104 resulted in a significant
reduction of 2´-O-methylation on the respective rRNA modification sides (28S
U2824, 28S C4506, 18S C1703 and 28S C1327).
Summary/Conclusions: SnoRNA expression profiles are altered in specific
AML subtypes. Further, we identified a functional relevance of snoRNAs in cell
growth of leukemic cells.
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PERSISTENCE AND EXPANSION OF HEMATOPOIETIC CLONES IN POST
CHEMOTHERAPY AML ASSESED BY TARGET SEQUENCING
D Soriano1,*, L Rai2, T Boneva2, C Grace2, S Mackinnon3, P Kottatidis1,
E Nacheva2,3
1Haematology, Royal Free NHS Trust, 2Haematology, Health Services Labo-
ratories, 3Haematology, University College London, London, United Kingdom
Background: Gene variance screening has demonstrated the persistence of
pre-leukemic hematopoietic stem cells (HSC) in AML patients during complete
morphological remission (CR) (Corces-Zimmerman et al, Proc Natl Acad. 2014
and Terrence et al, Blood. 2015) but very little is known about their gene profile,
dynamics and/or clinical associations. 
Aims: Assess the dynamics of the gene variance profile and its clinical corre-
lation in 20 AML patients who achieved CR after chemotherapy treatment. 
Methods: Bone marrows samples from 18 de novo AML and 2 secondary AML
patients were analysed at diagnosis and monitored for 2 to 34 months post
chemotherapy initiation. 19 patients received induction/re-induction chemother-
apy including both cytarabine and an anthracycline or purine analog, 1 patient
received a non intensive chemotherapy consisting of a low dose cytarabine
(LDAC) composed regimen. Targeted exon sequencing of 54 genes was carried
out using a commercial panel (Illumina TruSight, myeloid panel) with exons
fully covered for 17 genes, while a set of specific exonic locations targeted in
the other 37 genes. Non-synonymous gene variances with a minimum of 500
reads and ≥5% frequency were reported. Variants were identified using Illumina
bio-informatics pipeline augmented by COSMIC, SNP library (dbSNP137),
OMIM, 1000 genomes and published data.
Results: Of the 20 patients analysed, 15 patients showed persistence of clonal
haematopoiesis with some gene variances reported as ‘polymorphic’ and ‘tol-
erated’, considered to represent CHIP (Genovese et al., N Engl J Med 2014;
McKerrell et al., Cell Reports 2015; Steensma et al., Blood 2015). None of the
AML ‘driver type’ variances seen at diagnosis were detected in the CR samples.
Certain variances (in order of frequency) in DNMT3A, TET2, CBLB, ASXL1,
ZRSR2, SRSF2, BCORL1, CEBPA, CUX1, CARL, ETV6, CBLC, ABL1 and
HRAS genes were found to form three distinct patterns in CR: a) expansion of
novel variances concurrent to the persistent diagnostic gene profile (10/20), b)
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persistence of unique variances seen at diagnosis without novel additions (9/20)
and c) no gene variances present after chemotherapy (1/20). Two out of 10
patients from group (a) relapsed during the follow up period with reappearance
of the initial FLT3_ITD bearing clone or occurrence of a novel IDH1 variance
(p.R132C) respectively, while the rest remained in CR. Interestingly, a patient
with a missense TP53 variance (Protein var: NP_000537.3: p.Cys238Tyr) at
diagnosis had a clearance of this TP53 AML clone after being treated with
LDAC composed regimen.
Summary/Conclusions: We report an expansion of hematopoietic clonal pop-
ulations in 10 out of 20 patients analysed by target next generation sequencing.
These results indicate that cell populations harbouring unique age related vari-
ances may have a competitive survival advantage after chemotherapy although
the clinical importance this phenomenon requires further investigations. Acci-
dentally we came across a promising treatment with LDAC and aminopeptidase
inhibitor for unfit AML patients harbouring the classical TP53 mutation. Our
findings are in alignment with recent studies showing persistence of clonal
haemopoiesis in AML during CR, which warrants the need to monitor residual
disease using appropriate gene panel.
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IDENTIFICATION OF NOVEL PUTATIVE SNORNAS IN AML PATIENT
SAMPLES
D Gerloff1,*, C Rohde1, F Zhou1, C Pauli1, M Köhn2, D Misiak2, KK Knut Krohn3,
S Hüttelmaier2, C Müller-Tidow1
1Department of Internal Medicine IV, Hematology and Oncology, University
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Research, University of Leipzig, Leipzig, Germany
Background: Small nucleolar RNAs (snoRNAs) are a large group of non-cod-
ing RNAs. Mostly snoRNAs are located in introns of host genes. They are highly
abundant in eukaryotes and are divided into two major families, box C/D and
box H/ACA snoRNAs, based of common sequence motifs and structural fea-
tures. The box C/D snoRNAs carry the conserved boxes C (RUGAUGA,
R=purine) and D (CUGA) near their 5’ and 3’ ends, respectively. The H/ACA
box snoRNAs consist of two hairpins and two short single-stranded regions,
which contain the H box (ANANNA) and the ACA box. snoRNAs guide small
nucleolar ribonucleoproteins (snoRNPs) to complementary regions of ribosomal
(rRNA) or small nuclear RNAs (snRNA), where the snoRNP complexes catalyze
ribosomal modifications. Recent studies showed the relevance of snoRNAs for
the pathogenesis of cancer.
Aims: Identification and analysis of unknown snoRNAs in AML.
Methods: To understand the role of snoRNAs in leukemogenesis, we analyzed
the snoRNA expression pattern of 63 AML patients, registered in a recent clinical
trial (ClinicalTrials.gov NCT00915252). RNA was isolated with Qiagen
miRNeasy Kit. Librarys for small RNA specific next generation sequencing
(NGS) were prepared with TruSeq Small RNASample Prep Kit and size sepa-
ration of 40-200 nucleotides. NGS was performed on an Illumina HiScanSQ,
using 50 cycles of single read sequencing. Sequencing data were processed
with Cutadapt, mapped with Bowtie 2 to the human genome (hg19). Abundant
regions were detected with Bedtools genomeCoverageBed and were annotated
using snoRNABase (LBME), DASHR, UCSC snoRNA and repeatmasker track.
For further analysis reads of discovered regions were calculated as reads per
million (RPM). Regions without annotation were analyzed for C/D box motifs to
discover putative C/D box snoRNAs.
Results: Next generation sequencing data revealed that 229 of the 269 known
C/D box snoRNAs (85%) were expressed in one or more patient samples. For
the H/ACA box snoRNAs we could identify 90 of 112 (80%). In addition we
found 1396 mapped regions, which could not be annotated as known small
noncoding RNAs. In silico analysis identified 90 putative C/D box snoRNAs. All
of these putative snoRNAs contain the box C/D motifs and were mostly located
in introns of known genes. In further analysis we compared clinical data and
snoRNA expression pattern. Here we found that expression of the known snoR-
NAs clustered with specific risk groups. High levels of snoRNA expression are
associated with intermediate molecular risk grouped patients (269 snoRNAs,
p≤0.05) and a poor response to chemotherapy (101 snoRNAs, p≤0.05). Like-
wise, increased expression of putative snoRNAs was found in patients with an
intermediate molecular risk (51 snoRNAs, p≤0.05) and in patients with a bad
response to chemotherapy (20 snoRNAs, p≤0.05). To investigate putative snoR-
NAs during myeloid differentiation we treated HL60 cells with 1µM all-tran-
sretinoic acid (ATRA) and analyzed their expression (d0 vs d6). In the HL60
cells we could recover 83 putative snoRNAs out of 90 we found in the patient
samples. The data show that 45 putative snoRNAs were downregulated (<0.7)
while 17 putative snoRNAs were upregulated (>1.3) during myeloid differenti-
ation. To analyze the binding of 8 putative snoRNA candidates to the snRNP
complex we performed NOP58 and FBL specific RNA immunoprecipitation
(RIP) in Kasumi-1 cells. Here, we could show an enriched binding of 2 putative
snoRNAs to FBL and NOP58.
Summary/Conclusions: In summary, our data show that snoRNAs may con-
tribute to neoplastic transformation. Further we identified novel unknown snoR-
NAs, which will be further analyzed.
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INHIBITION OF CXCR4 BY THE HIGH AFFINITY ANTAGONIST BL-8040 IN
AML DOWNREGULATES BCL-2 THROUGH REGULATION OF MIR-15A/16-1
EXPRESSION
M Abraham1,*, S Klein2, B Bulvik3, H Wald1, O Eizenberg1, D Holam2, L Weiss2,
K Beider4, O Wald2, S Bulvik5, A Avigdor4, O Benjamini4, E Galun2, A Nagler4,
Y Pereg6, A Peled2
1Biokine Therapeutics, Biokine Therapeutics Ltd, Rehovot, 2Goldyne Savad
Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, 3Biokine
Therapeutics, Weizman Science Park, Rehovot, 4Hematology Division, Chaim
Sheba Medical Center, Tel-Aviv, 5Hematology Department, Laniado Hospital,
Netanya, 6BioLineRx Ltd, BioLineRx Ltd, Tel-Aviv, Israel
Background: Acute Myeloid Leukemia (AML) is a heterogeneous group of dis-
eases characterized by uncontrolled proliferation and survival of hematopoietic
stem and progenitor cells. The chemokine CXCL12 and its receptor CXCR4
are key players in the retention of AML blasts in the protective bone marrow
(BM) microenvironment. The CXCL12/CXCR4 axis is also critical for the survival
and maintenance of AML blasts in their stemness state. CXCR4 overexpression
is associated with poor prognosis in AML patients. Signaling activated through
CXCR4 was shown to be detrimental by increasing survival of tumor cells and
promoting resistance to therapy.
Aims: We have studied the effect of the CXCR4-antagonist, BL-8040 on the
survival of human AML blasts and investigated the molecular mechanism by
which inhibition of CXCR4 signaling leads to leukemia cell death. 
Methods: Human AML cell line and human primary AML samples were used for
in vitro studies. The in-vivo effect of BL-8040 was tested using MV4-11, U-937,
THP-1 and human primary AML cells engrafted in NOD scid gamma (NSG) mice.
Results: We found that the human AML cells MV4-11, THP-1, U-937, and
human primary AML cells express high levels of CXCR4. The CXCR4 antago-
nist, BL-8040 was found to induce apoptosis of the tested AML cells in-vitro
and in-vivo. Survival of tested AML cells was found to be dependent on BCL-2
as demonstrated by the ability of the BCL-2 inhibitor, ABT-199 to induce dose
dependent apoptosis in vitro. Interestingly, treatment of AML cells with BL-8040
reduced the expression of BCL-2 together with inhibition of the ERK signaling
pathway. BL-8040 dependent reduction in BCL-2 expression was associated
with increased expression of miR-15a/16-1. In addition to BCL-2, increased
expression of miR-15a/16-1 reduced the expression of MCL-1 and cyclin D, its
other target genes. Interestingly, these effects were not observed following
stimulation with the CXCR4 antagonist, AMD3100. In support of these results
overexpression of miR-15a/16-1 in AML cells was shown to induce their apop-
tosis. In the MV4-11 in-vivo AML model, when BL-8040 was administrated for
7 constitutive days we observed decreased number of AML cells accompanied
with apoptosis in BM, Spleen and blood. Following one or two injections of BL-
8040 apoptosis of AML blasts was observed together with upregulation of miR-
15a/16-1 and decrease of BCL-2, only in the spleen. Importantly, Human AML
cells engrafted to the spleen expressed lower levels of BCL-2 as compared to
AML cells in the BM suggesting that the BM required prolonged inhibition in
order to overcome the high levels of BCL-2 in this microenvironment.
Summary/Conclusions: Our results demonstrate that CXCR4 signaling reg-
ulates the expression of miR-15a/16-1 and their target genes BCL-2, MCL-1
and cyclin-D1. Furthermore, these results indicate that the CXCR4 antagonist,
BL-8040 may tip the balance toward cell death by down- regulating survival
signals through miR-15a/16-1 pathway and inhibition of the ERK signaling cas-
cade in AML cells.
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AML ORCHESTRATES MITOCHONDRIAL METABOLISM IN BONE MARROW
MESENCHYMAL STROMAL CELLS THROUGH AN INCREASE OF PGC-1Α
C Marlein1,*, L Zaitseva1, K Bowles1,2, S Rushworth1
1Department of Molecular Haematology, University of East Anglia, 2Department
of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich,
United Kingdom
Background: Acute Myeloid Leukaemia (AML) is biologically a heterogeneous
disease which results from defects in haematopoiesis, characterised by the
accumulation of haematopoietic myeloid cells in the bone marrow. Although
there have been advances in the treatment of the disease, AML remains incur-
able for at least 80% of patients. It has been shown that AML cells have an
increased mitochondrial mass and higher levels of oxidative phosphorylation
(OXPHOS) compared to normal CD34+ cells, suggesting a dependency of
OXPHOS for AML survival. Little is known about the mitochondrial activity of
bone marrow mesenchymal stromal cells (BM-MSC), which provide a support-
ive environment for AML cells in the bone marrow.
Aims: Therefore the aim of this study is to determine if there is an increase in
mitochondrial respiration in BM-MSCs from AML patients (AML BM-MSCs)
compared to non-AML patients (normal BM-MSCs) and to understand how the
difference is regulated.
Methods: Primary AML blasts were obtained from patient bone marrow. Pri-
mary AML and normal BM-MSCs were isolated from patients bone marrow,
with informed consent and under approval from the UK National Research
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Ethics Service (LRCEref07/H0310/146), using adherence. BM-MSC were char-
acterised using flow cytometry for expression of CD90+, CD73+, CD105+ and
CD45-. Mitochondrial respiration and glycolysis rates were measured using
the Seahorse XF24 extracellular flux analyser. RT-qPCR and western blotting
were used to determine peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α) expression and regulation. Lentiviral mediated
knockdown was also used.
Results: Our results show that AML BM-MSCs have an increased ATP pro-
duction after 3 days compared to normal BM-MSCs. AML BM-MSCs also show
an increased oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR) compared to normal BM-MSCs. This demonstrates not only an
increase in mitochondrial respiration but also increased glycolysis, which cor-
relates with the increased ATP production of the AML BM-MSCs compared to
normal BM-MSCs. Mitochondrial respiration and glycolysis increase in AML
BM-MSCs after co-culture with primary AML cells. This suggests that exposure
to AML cells cause the increased mitochondrial respiration and glycolysis
observed in the AML BM-MSCs. There is differential expression of PGC-1α
mRNA and protein in AML BM-MSCs after co-culture with AML cells, suggesting
regulation of mitochondrial respiration through PGC-1α.
Summary/Conclusions: These results provide evidence of an increased mito-
chondrial respiration and glycolysis in the AML BM-MSCs compared to the nor-
mal BM-MSCs and that the difference is orchestrated by the AML cells. In addi-
tion this difference is regulated through PGC-1α, the master regulator of mito-
chondrial biogenesis. We hypothesise that therapeutic intervention targeting
mitochondrial activity in the AML micro-environment would make AML more
susceptible to current treatment regimes.
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PML-RARΑ REGULATES AKT THROUGH HSP90 INHIBITION IN APL
BLASTS
N Noguera1,2,*, ML Piredda1,2, G Gaur1,2, M Divona1, G Catalano1, MT Voso1,
F Lo_Coco1,2
1Biomedicine and Prevention, Tor Vergata University, 2Neuro-Oncohematology,
Santa Lucia Foundation, Rome, Italy
Background: HSP90s are molecular chaperons required for conformational sta-
bilization and trafficking of over 400 documented client proteins involved in cell
growth, maturation and apoptosis. The HSP90β isoform is constant ubiquitously,
whereas α/α1 isoforms are inducible, prone to increase in stress conditions.
Functional Hsp90 is required for the stability of the AKT, serine - threonine kinase,
which is phosphorylated in response to growth factor stimulation. Activated AKT
migrates transducing the signal to over 130 substrates in the cytoplasm and
nucleus playing a crucial regulatory role in cell differentiation, cell cycle, tran-
scription, translation, metabolism and apoptosis. In acute myeloid leukemia (AML)
higher levels of HSP90s have been associated with poor prognosis.
Aims: The aim of this work is to comprehensively analyze the involvement of
HSP90 in pathogenesis of APL.
Methods: Seventeen APL and 22 unselected AML patients were analyzed
by quantitative PCR to measure HSP 90 mRNA expression levels. HSP90
protein levels were also analysed in 21 AML and 20 APL cases using Western
Blot. In addition, HSP90 protein levels were studied in: I) PR9 cells, a Zn
inducible PML/RARA cell line; II) APL patient primary blasts and PML/RARA
expressing NB4 cells after treatment with ATRA. ChIP-qPCR was used to
scan HSP90 regulatory sequences for the presence of PML-RARα protein.
AKT mRNA and protein levels were analysed in 16 APL and 10 AML patients.
AKT mRNA and AKT phosphorylation levels were studied in PR9 cells line
plus Zn and in NB4 cells treated with 17AAG, ATRA or both. AKT half-life
and ubiquitinilation levels were study using Hek293T cells transfected with
PML-RARα. Localization of Hsp90 and AKT were analysed using a Confocal
microscopy in PR9 cells line plus Zn.
Results: We observed a significantly lower expression of HSP90 and AKT in
primary APLs, as compared to other AMLs. In vitro treatment of the NB4 cell
line with ATRA upregulated HSP90s and AKT protein levels. Inhibition of HSP90
function by the 17 AAG inhibitor induced a decline of AKT and nullified the
effect of ATRA indicating that HSP90 action is necessary for AKT stability. Using
an inducible PML/RARα model (PR9 cell line) we observed a decline of HSP90
mRNA and protein starting at 2/4 hours, corresponding to the expression peak
of the hybrid protein. AKT protein, but not mRNA, declined to 30% at 24 hours.
Using confocal microscopy we observed the translocation to the cytoplasm of
co-localized HSP90 and AKT proteins, 8 hours after PML/RARα induction. In
Hek293T cells transfected with PML-RARα we observed ubiquitination and
down-regulation of AKT. ChIP assays showed the binding of PML-RARα to the
HSP90-α and β promoter regions, resulting in downregulation of expression,
effect reverted by ATRA. We further detected an increase in acetylation of the
DNA promoter region of the two isoforms of HSP90 after treatment of NB4
cells with ATRA, suggesting that PML-RARα inhibits HSP90s expression at
the transcriptional level probably through recruitment of the HDAC-repressor
complex NCOR. 
Summary/Conclusions: In summary, repression of HSP90 expression by
PML/RARA is associated in APL cells with loss of specific function in controlling
AKT protein phosphorylation, intracellular trafficking and stability.
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RUNX1-MUTATED AML SHOW A HIGH FREQUENCY OF TRISOMY 8 AND
TRISOMY 13 AND ARE ASSOCIATED WITH MUTATIONS IN ASXL1 AND
COMPONENTS OF THE RNA-SPLICING MACHINERY
A Stengel1,*, W Kern1, M Meggendorfer1, K Perglerovà2, T Haferlach1,
C Haferlach1
1MLL, Munich Leukemia Laboratory GmbH, Munich, Germany, 2MLL2, Praha,
Czech Republic
Background: Mutations in RUNX1 have been reported in 5 to 20% of AML. A
detailed cytogenetic and molecular genetic analysis of RUNX1-mutated AML
has not been performed yet.
Aims: 1. Comprehensive cytogenetic and molecular genetic characterization
of AML with RUNX1 mutations. 2. Analysis of potential impact of the respective
markers on prognosis.
Methods: The cohort comprised 140 cases of AML with RUNX1 mutations (95
male, 45 female). Median age was 67 years (range: 18-87 years). All patients
were investigated using chromosome banding analysis (CBA). Mutation analy-
ses by amplicon sequencing were performed for ASXL1, BCOR, CBL, CEBPA,
DNMT3A, ETV6, EZH2, FLT3-ITD, FLT3-TKD, GATA2, IDH1, IDH2, KIT, KRAS,
MLL-PTD, NPM, NRAS, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1 and
WT1. Variants of unknown significance were excluded from statistical analysis.
Results: CBA revealed a normal karyotype in 83/140 (59%) and an aberrant
karyotype in 57/140 (41%) of patients: 37 (27%) cases harbored trisomies, 20
cases (14%) showed other aberrations. In more detail, +8 was detected in 17
cases (12%), followed by +13 (11 cases, 8%), +11 (4 cases, 3%) and +14 (4
cases, 3%). No other recurrent abnormalities were observed. A complex kary-
otype (>3 abnormalities) was not detected. The highest mutation frequency
was observed for ASXL1 (42%), followed by SRSF2 (36%), BCOR (21%),
FLT3-ITD (18%), TET2 (18%), IDH2 (17%) and U2AF1 (16%). Mutation fre-
quencies >5% were also detected for DNMT3A (14%), MLL-PTD (14%), NRAS
(13%), WT1 (12%), IDH1 (9%), SF3B1 (9%) and CEBPA (5%). Thus, mutations
in genes coding for components of the RNA-splicing machinery were detected
in 89 patients (64%). No CEBPA double mutations were identified. Totally,
sequencing revealed 463 mutations in addition to RUNX1 (mean number of
additional mutations per patient: 3). In detail, 3 patients (2%) showed no, 18
(13%) one, 44 (31%) two, 43 (31%) three, 22 (16%) four, 9 (6%) five and 1
(1%) six concomitant mutations. Thus, in 98% of patients at least one molecular
mutation additional to RUNX1 was observed. Correlation analyses between
cytogenetic and molecular genetic markers revealed a strong association of
trisomies with mutations in splicing factor genes (spliceosome mutations in
patients with vs without trisomies: 33/37 (89%) vs 55/103 (53%), p<0.001).
Additionally, cases with +8 correlated with ASXL1 mutations (ASXL1mut in
patients with vs without +8: 11/17 (65%) vs 45/122 (37%), p=0.036). An asso-
ciation was revealed for a normal karyotype (NK) with mutations in FLT3-ITD
(with NK: 20/83 (24%) with FLT3-ITD; without NK: 5/57 (9%) with FLT3-ITD,
p=0.024). In the total cohort, median overall survival (OS) was 29 months. An
aberrant karyotype had no influence on OS. However, mutations in U2AF1 and
NRAS both were associated with a significantly shorter OS (median OS, for
U2AF1 mutated vs unmutated, 21 vs 33 months; p=0.039; for NRAS mutated
vs unmutated, 12 vs 31 months, p=0.026) and in patients with ≥3 accompanying
mutations (≥3 vs<3 mutations, 20 vs 57 months, p=0.002).
Summary/Conclusions: RUNX1-mutated AML show a NK or specific cytoge-
netic abnormalities (+8 or +13) and a lack of a complex karyotype. Moreover,
they depict a typical pattern of additional molecular mutations with a high fre-
quency of ASXL1 mutations and mutations in spliceosome genes (especially
SRSF2 and U2AF1), which according to Lindsley et al. (Blood 2015) is specific
for secondary AML. Further, no entity-defining genetic abnormalities were
observed. Thus, RUNX1-mutated AML might qualify for a separate entity.
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REACTIVE OXYGEN SPECIES (ROS) MODULATES SENSITIVITY TO
FLT3-TYROSINE KINASE INHIBITORS IN MURINE AND HUMAN FLT3-ITD
POSITIVE AML CELL LINES
C Mueller1,*, L Simeoni2, F Heidel1, B Schraven2, T Fischer1
1Department of Hematology and Oncology, 2Institute for Molecular and Clinic
Immunology, University Clinic Magdeburg, Magdeburg, Germany
Background: FLT3-ITD positive acute myeloid leukemia (AML) is character-
ized by an increased concentration of intracellular ROS and high extracellular
concentrations of hydrogen peroxide (H2O2). Increased ROS levels regulate
numerous cellular processes, such as cell cycle, apoptosis, metabolism and
drug resistance. Interestingly, in leukemia driven by other oncogenes (e.g. Bcr-
Abl) it has been described that modulation of ROS may improve the response
to selective tyrosine kinase inhibitor (TKI) treatment. Some pathways, including
STAT5/NOX4, have been reported to induce high ROS levels in FLT3-ITD-pos-
itive AML. However, it is unclear how FLT3-ITD positive AML cells modulate
their cellular functions and/or drug resistance by auto-/paracrine ROS species.
In addition, in leukemia driven by other oncogenes (e.g. Bcr-Abl) it has been
described that modulation of ROS may improve the response to selective tyro-
sine kinase inhibitor (TKI) treatment.
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Aims: Our goal was to identify the auto-/paracrine effects of hydrogen peroxide
on proliferation and cell cycle progression in FLT3-ITD positive murine and
human cell lines. In addition, we aimed to characterize the effects of H2O2 mod-
ulation with respect to the sensitivity to TKI treatement as a possible resist-
ance-inducing factor.
Methods: Murine (32D, BaF3) and human (MOLM-13, MV4-11) FLT3-ITD pos-
itive cell lines were analyzed for intracellular ROS levels using H2DCFD, extra-
cellular H2O2 concentration and activities of the scavenging enzymes SOD1,
SOD2, catalase, and glutathione peroxidase (GPx). For the analysis of the role
of extracellular H2O2, cells were incubated directly with H2O2 (10 µM) for 2h and
assayed for the activation of FLT3-ITD-dependent signaling pathways (STAT5,
Akt and Erk) using immunoblotting. For the analysis of the effects of H2O2-gen-
erating enzyme glucose oxidase and of the H2O2-degrading enzyme catalase,
cells were cultured for 48h and assayed for proliferation (MTT) and cell cycle
progression (PI). Furthermore, the effect of extracellular H2O2 concentration on
TKI treatment (AC220, PKC412; each 5 to 50 nM) was analyzed by FACS.
Results: Stimulation of FLT3-ITD positive cells using H2O2 resulted in a strongly
increased time-dependent activation of FLT3-ITD-associated signaling path-
ways (STAT5, Akt, Erk) as compared to untreated cells. This difference was
more pronounced in ITD-positive cells in comparison to WT cells particularly
for AKT activation. In addition, stimulation with H2O2 also increased the activities
of SOD1/2 and catalase. The long-term increase in extracellular H2O2 concen-
tration was mimicked experimentally by addition of glucose oxidase to the cul-
ture medium (0.75 U/ml). Interestingly, this resulted in enhanced proliferation
and cell cycle progression, whereas cultivation with catalase led to decreased
proliferation and cell cycle arrest. Combined treatment with catalase and TKIs
(AC220, PKC412; 5 and 10 nM, respectively) resulted in a significantly higher
rate of apoptosis. Of note, the response to both TKIs was significantly reduced
when glucose oxidase (0.75 U/ml) was added to the medium. The decrease in
apoptosis was associated with stabilization of the mitochondrial potential (TMRE
assay), stable expression of the anti-apoptotic proteins Mcl-1 and Bcl-XL, and
a reduced cleavage of caspase 3 and caspase 8.
Summary/Conclusions: Our results strongly suggest that H2O2 acts as an
auto-/paracrine stimulator of proliferation and cell cycle progression in FLT3-
ITD positive cells. Furthermore, we could characterize H2O2 as a regulatory
element with respect to TKI sensitivity. Our results indicate that combined inhi-
bition of FLT3-ITD and H2O2 reducing agents/enzymes, like catalase, may have
potential clinical application in treatment of FLT3-ITD positive AML patients.
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COMBINING DOT1L INHIBITOR EPZ-5676 WITH SORAFENIB TO TREAT
MLL-REARRANGED (MLL-R) PEDIATRIC ACUTE MYELOID LEUKEAMIA
(AML)
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Background: About 20% of the childhood AML present MLL gene transloca-
tions, that are associated with a very poor prognosis. That is why there is a
strong interest in developing novel therapeutic strategies for these patients. As
DOT1L is responsible for H3K79 methylation and is associated with MLL-r
leukemogenesis, DOT1L inhibitors entered in clinical trials as promising treat-
ments. MLL-r AML also showed an overexpression of FLT3 receptor tyrosine
kinase. Therefore, FLT3 inhibitors, such as the multi-tyrosine kinase inhibitor
Sorafenib, demonstrated encouraging efficacy in AML.
Aims: To investigate the efficacy of a combination treatment using DOT1L
inhibitor EPZ-5676 and Sorafenib to treat MLL-r AML.
Methods: MLL-r (MOLM13, NOMO1, THP1) and non MLL-r (OCI-AML3, HL60
and U937 harboring CALM-AF10 translocation) AML cell lines, and MLL-r primary
samples from pediatric AML patients were used. Flow cytometry analyses were
performed to assess absolute cell counting and apoptosis (AnnexinV FITC/PI
staining). Protein expression and H3K79 methylation were quantified by Western
blot. mRNA expression was studied by quantitative Real-Time PCR (Q-PCR).
Results: Firstly, the specific effects of DOT1L inhibition were examined in AML
cell lines treated with increasing concentrations of EPZ-5676, up to 18 days.
Cell growth was significantly inhibited after at least 8 days of treatment in
MOLM13 and NOMO1 cells, but time-dependent apoptosis occurred only in
MOLM13, thus suggesting that DOT1L inhibition alone might not be able to
induce cytotoxicity. Whereas no effects were observed in HL60, U937 (non
MLL-r), or THP1 (MLL-r) cells, both cell growth impairment and apoptosis were
detected in non MLL-r OCI-AML3 cells, so that the impact of DOT1L inhibition
could not exclusively rely on MLL rearrangements. Repression of DOT1L
occurred since the 4th day of treatment, as demonstrated by the complete loss
of H3K79me2. To further explore the consequence of this phenomenon, both
MLL targets and key component of signaling pathways involved in AML survival
(i.e. PI3K, FLT3 and MAPK) were investigated in cells treated with 1 uM EPZ-
5676, up to 28 days. Gene expression of HOXA9, MEIS1, FLT3 and CDK6
protein (MLL target) decreased in all cell lines, whereas STAT5 and c-Myc
mRNAs, along with STAT5 protein expression, were downregulated only in
MLL-r cells. Furthermore, in MOLM13 and NOMO1 cells p-Erk was strongly
reduced. Finally, p-Akt slightly decreased in nearly every case, whereas a strong
induction in p-S6RP was observed only in U937 cells after prolonged treatment,
suggesting the possible involvement of PI3K pathway in drug resistance mech-
anisms. To increase the benefit of DOT1L inhibition, both AML cell lines and
MLL-r primary samples were pretreated with increasing concentration of EPZ-
5676 for 4/8 days, following 24/48h treatment with Sorafenib. This combination
resulted in a synergistic effect in nearly all cases. Importantly, EPZ-5676 pre-
treatment increased Sorafenib-induced cell growth inhibition in EPZ-5676
refractory cells HL60, U937 and THP1. Moreover, in primary AML samples both
EPZ-5676 and Sorafenib showed a limited effect as single agent, whereas their
combination induced a drastic increase of apoptosis.
Summary/Conclusions: These results demonstrated that the single adminis-
tration of EPZ-5676 has a limited antileukemic activity, which is not restricted
to MLL-r AMLs. However, the combination of EPZ-5676 with Sorafenib revealed
a synergistic effect in both MLL-r and non MLL-r AMLs, paving the way to inno-
vative and more effective treatments for pediatric AML patients.
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WHOLE EXOME SEQUENCING IDENTIFIES NOVEL MUTATIONS IN
RELAPSED OR REFRACTORY ACUTE PROMYELOCYTIC LEUKAEMIA
(APL) UNRESPONSIVE TO ORAL ARSENIC TRIOXIDE
HS Gill1,*, HW Ip2, J Li3, RLH Yim1, G Panagiotou3, AYH Leung1, YL Kwong1
1Department of Medicine, 2Department of Pathology, 3School of Biological Sci-
ences, The University of Hong Kong, Hong Kong, Hong Kong
Background: Arsenic trioxide (As2O3)-based regimens induce remissions in
>90% of relapsed APL. Further relapses after As2O3-induced remissions por-
tend a poor prognosis. With the use of As2O3 in frontline treatment of APL,
relapses in patients previously treated with As2O3 resulting in arsenic resistance
is an emerging clinical problem. There is a paucity of information on the molec-
ular mechanisms of As2O3-resistance.
Aims: To determine mutations associated with As2O3-resistance with whole
exome sequencing (WES). 
Methods: Seven patients with prior As2O3 treatment, who had ≥2 subsequent
relapses occurring during or refractory to As2O3 treatment, were assigned to
the discovery cohort. Serial bone marrow (BM) samples that were arsenic-
sensitive (taken before treatment in a relapse responding to As2O3) and
arsenic-resistant (obtained in subsequent relapses refractory to As2O3) under-
went WES the illumina HiSeq 1500 platform at an average depth of 100X.
Exome data were analysed utilizing bioinformatic pipeline programs designed
to identify single nucleotide variants (SNVs) that were present either only or
at increased frequencies in the resistant samples. The functional significance
of non-synonymous missense mutations was evaluated using SIFT, Polyphen2
and FATHMM programs. Putative SNVs were confirmed by Sanger sequenc-
ing. Confirmed SNVs were tested in arsenic-resistant BM samples obtained
from a validation cohort of 22 relapsed patients previously salvaged with
As2O3, who had subsequent As2O3-refractory relapse again. Clinicopathologic
features, karyotype, FLT3 and PML-RARA mutations were determined in the
validation cohort.
Results: In the discovery cohort, serial WES showed following confirmed SNVs
of potential functional significance showed increased allele frequency during
As2O3-resistance: NOTCH2, FOXD4L5, KCNJ11/18, MADCAL1, CBR3, NSD1,
FLG1, CCCDC179, SIGLEC11, ROBO4, CISD2, WT1, PTCH1, KMT2D and
MED17. PML B2 domain mutations were not seen. The frequencies of the
mutations were validated in a cohort of 22 patients with relapsed or refractory
APL following oral As2O3-based treatment. The recruited patients comprised
14 men and 8 women with a median age of 44.5 (range:24-76) years at relapse.
1 (5%) patient had microgranular variant of APL while 2 patients (9%) had ther-
apy-related APL. Additional karyotypic abnormalities were seen in 3 (14%)
patients.14 patients (64%) had central nervous system (CNS) involvement at
relapse. Internal tandem duplication of FLT3 (FLT3-ITD) was detected in 7
(32%) patients. The following recurrent mutations were found in As2O3-refrac-
tory relapse BM samples: NOTCH2 (n=17, 77%), FOXD4L5 (n=22, 100%),
KCNJ11/18 (n=14, 64%), MADCAM1 (n=15, 68%), CBR3 (n=17, 77%), NSD1
(n=17, 77%), FLG1 (n=20, 91%), CCCDC179 (n=7, 32%), SIGLEC11 (n=5,
23%), ROBO4 (n=3, 14%), CISD2 (n=3, 14%), WT1 (n=1, 5%), PTCH1(n=1,
5%), KMT2D (n=1, 5%) and MED17 (n=6, 27%).
Summary/Conclusions: Mechanisms other than PML B2 domain mutations
may account for As2O3 resistance. Novel genes regulating the cell signaling
and apoptotic pathways, cellular proliferation, histone modification, DNA repair
and angiogenesis were frequently mutated in As2O3-refractory APL. Further
functional validation on the role of these mutations in conferring As2O3 resist-
ance is required.
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MOLECULAR LANDSCAPE OF PRIMARY AND RELAPSED ACUTE
PROMYELOCYTIC LEUKEMIA
A Fasan1,*, C Haferlach1, K Perglerová2, W Kern1, T Haferlach1
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1MLL Munich Leukemia Laboratory, Munich, Germany, 2MLL2 s.r.o., Praha,
Czech Republic
Background: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12)/
PML-RARA accounts for ~5% of adult AML. Two therapeutic agents, ATRA
and arsenic trioxide (ATO), induce differentiation of promyelocytes in vivo result-
ing in complete remission. However, some patients still relapse after ATO-
ATRA based treatments and the mechanisms associated with resistance to
these agents are still poorly understood.
Aims: The evaluation of the mutational spectrum of APL both at initial diagnosis
and relapse.
Methods: We analyzed a cohort of 124 de novo APL cases including 14 cases
who showed hematologic or molecular relapse. All patients (pts) were proven
to have t(15;17)(q22;q12)/PML-RARA by chromosome banding analysis (CBA)
(n=114), fluorescence in situ hybridization (n=120) and/or RT-PCR (n=124).
69 pts were male and 55 pts were female with a median age of 47 years (range:
16-84 years). All 124 samples were analyzed by next generation sequencing
(NGS) using a 24-gene panel targeting ASXL1, CBL, CSF3R, DNMT3A,
ETNK1, ETV6, EZH2, FLT3-TKD, GATA2, IDH1, IDH2, KIT, KRAS, NPM1,
NRAS, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1 and
ZRSR2. FLT3-ITD was analyzed by gene scan. Relapse samples were
screened for mutations within the PML-RARA fusion transcript by direct Sanger
sequencing.
Results: Using standard CBA, additional cytogenetic aberrations were
observed in 44/114 pts (27%). The most frequent secondary chromosome aber-
ration was +8 (14/44; 32%). Using NGS 77/124 pts (62%) had at least one
mutation (mut) in addition to PML-RARA, 17/77 (22%) had ≥2 additional mut
(maximum: four). Most common were mutations in FLT3 (FLT3-ITD: 47/124,
38%, FLT3-TKD: 15/124; 12%) and WT1 (13/124, 10%). Mutations in other
genes (ASXL1, CBL, DNMT3A, ETV6, KRAS, NRAS, RUNX1, SF3B1 and
TET2) were found in less than 10% of cases, respectively. Comparing the initial
mutational pattern of pts who relapsed during the course of disease with those
staying in molecular remission revealed no difference in concomitant molecular
mutations. Solely the percentage of pts with concomitant mutations was higher
in the relapse group (79% vs 60%; n.s.). Survival analysis revealed no influence
of concomitant mutations in individual genes on prognosis. Also the amount of
additional mutations had no prognostic impact. In selected cases (n=14/124),
we compared changes in the patterns of genetic lesions between initial diag-
nosis and relapse. In 8/14 (57%) pts the initial mutation pattern changed at
relapse. Mutations gained at relapse were WT1 (2/14, 14%) followed by
DNMT3A, ETV6, FLT3-TKD, RUNX1 and TP53 (each 1/14, 7%). Loss of muta-
tions was observed in FLT3-TKD, WT1 (each 2/14, 14%) as well as in ASXL1,
FLT3-ITD and NRAS (each 1/14, 7%). In 4/14 relapsed pts (29%), mutations
within the PML-RARA fusion transcript were detected. In none of the cases
these mutations were detectable at initial diagnosis and thus all were acquired
mutations. Missense mutations in the ligand binding domain of RARA were
detected in 3 relapsed pts (p.Arg272Gln, p.Arg276Trp and p.Ser287Leu). In
one relapsed APL pt, a mutation in the B2 domain of PML was observed
(p.Ala216His). All mutations occurred in post-ATRA-relapse.
Summary/Conclusions: 1) 62% of APL cases carry additional molecular muta-
tions. 2) The most frequent additional molecular mutation is FLT3-ITD (38%)
followed by FLT3-TKD mutations (12%) and mutations in WT1 (10%). 3) In
57% of relapsed APL the molecular mutation pattern changes. 4) Acquired
mutations within the PML-RARA fusion transcript are detected in 29% of
relapsed APL patients.
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ACTIVATION OF NRF2 IN BONE MARROW MESENCHYMAL STROMAL
CELLS MEDIATES SURVIVAL AND CHEMOTHERAPY RESISTANCE IN
ACUTE MYELOID LEUKAEMIA BLASTS
N Loughran*, A Abdul-Aziz, M Shafat, K Bowles, S Rushworth
Department of Molecular Haematology, University of East Anglia, Norwich,
United Kingdom
Background: The bone marrow microenvironment and the cells with in it play
a critical role in acute myeloid leukaemia. NRF2 regulates a range of cytopro-
tective transcriptional responses and acts as a master regulator of oxidative
and electrophilic stress. We have previously shown that NRF2 forms part of a
major cell survival pathway in protecting the AML blasts from chemotherapy
induced apoptosis. Here we hypothesise that NRF2 also functions to regulate
pro-survival factors in Bone Marrow - Mesenchymal Stromal Cells (BM-MSC)
from patients with AML and investigate whether targeting NRF2 in the BM-
MSC could enhance the efficacy of cytotoxic chemotherapy in AML.
Aims: In this study we aim to characterise the NRF2 signalling pathway in the
BM-MSC and investigate how NRF2 signalling regulates oxidative stress in
BM-MSC-AML niche.
Methods: Primary AML blasts and BM-MSC were isolated from AML patients
following informed consent and under approval from the UK National Research
Ethics Service (LRCEref07/H0310/146). Cytarabine, daunorubicin and hydro-
gen peroxide (H2O2) were used to induce NRF2 activation in AML blasts and
BM-MSC. Annexin V/PI staining was used to determine apoptosis of treated
cells. N-acetyl cysteine (NAC) was used to determine the role of glutathione.
Cell-Titer Glo assay was performed to determine cell viability. Dichlorofluores-
cein-H DCFDA (DCF) dye was used to determine levels of reactive oxygen
species (ROS). Western blot analysis was used to determine NRF2 expression
in drug treated samples.
Results: Results show that AML blasts have increased survival in vitro when
co-cultured with BM-MSC. Co-culture with BM-MSC was also shown to confer
protection to AML blasts in the presence of daunorubicin, cytarabine and H2O2.
Lower levels of ROS were observed in the AML blasts after BM-MSC co-culture,
as determined by DCF fluorescence. NRF2 in BM-MSC was found to be acti-
vated by daunorubicin and cytarabine, as depicted by an increased expression
of NRF2 in the nucleus after drug treatment. Moreover depletion of NRF2 in the
BM-MSC reduced the protection conferred to the AML cells by the BM-MSC in
response to daunorubicin, cytarabine and H2O2. Furthermore, the addition of
NAC was shown to decrease AML blast apoptosis in culture in these assays.
Summary/Conclusions: These results demonstrate that NRF2 is induced in
the non-malignant BM-MSC in response to chemotherapy with the functional
consequence of promoting survival in neighbouring AML blasts. We propose
targeting the actions of NRF2 in the stromal cells as a novel strategy to increase
the tumour cytotoxicity of current drugs used to treat patients with AML.
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MICRORNAS HSA-LET-7A AND MIR-142-3P IN T CELLS IN PATIENTS
PRESENTING WITH ACUTE MYELOID LEUKAEMIA-A MEANS OF REPAIRING
TUMOUR-INDUCED T CELL DEFECTS?
R Petty1,*, X Zhang2, C Ivan2, G Calin2, J Gribben1, R Le Dieu1
1Haemato-oncology, QMUL, London, United Kingdom, 2Experimental Thera-
peutics, The University of Texas MD Anderson Cancer Center, Houston, United
States
Background: Our previous work has shown that the absolute number of T
cells is increased in the peripheral blood of patients presenting with Acute
Myeloid Leukaemia (AML). These T cells can form conjugates with tumour
cells but subsequent immune synapse formation and recruitment of down-
stream signalling molecules is inhibited. We found an altered T cell gene
expression profile indicative of aberrant TCR signalling and T cell activation
patterns suggesting a blunted immune response. We now hypothesize that a
means by which these alterations in T cell gene expression are effected is via
modulation of microRNA (miRNA) expression.
Aims: To define miRNA deregulation in peripheral blood T cell populations in
patients presenting with AML compared to healthy age-matched individuals.
Methods: In a pilot study, CD4 and CD8 T cells were isolated from stored
peripheral blood samples taken from AML patients at diagnosis and pre-treat-
ment (n=3) and age/sex matched healthy volunteers (n=3) by FACS (average
purity 98%). All AML patients had intermediate cytogenetic risk. Total RNA was
hybridised to custom small RNA microarrays (MD Anderson) containing probes
for 18694 human miRNA and 30945 other non-coding RNA species. Duplicate
normalized probe intensities were averaged and differentially expressed small
RNA were determined by LIMMA (linear models for microarray data) taking a
FDR p>0.05 and fold change of +/- 1.5. Unsupervised hierarchical clustering
and principle component analysis (PCA) were performed in R studio V3.2.2.
Supervised clustering was conducted in Cluster V3.0 and Treeview V1.1.6r4.
Identification of targeted mRNA was performed using miRTarBase (www.mir-
tarbase.mbc.nctu.edu.tw/).
Table 1.
Results: Hierarchical clustering and PCA of all samples, rather than differen-
tiating samples by T cell population, differentiated AML from healthy controls
illustrating that miRNA expression in T cells is altered by the presence of AML
blasts. Supervised clustering demonstrated 39 miRNA were differentially
expressed in AML CD4 T cells - 27 down-regulated, 12 up-regulated and 71
miRNA were differentially expressed in AML CD8 T cells - 41 down-regulated,
30 up-regulated. A number of these miRNA have already been shown to have
a role in T cell proliferation and cellular migration. To validate this list, this
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dataset was correlated with our previously generated mRNA dataset (indepen-
dent patient and control cohort) (see Figure). Crucially, this demonstrates 2
independent datasets showing coordinated deregulation of genes critical to T
cell function. In both CD4 and CD8 cells, up-regulated genes are involved in T
cell differentiation and activation (EIF2CA and KRAS) but also paradoxically in
inhibition of cytokine production (STAT3 and ZEB1 in CD8 cells and SOCS3
and ZEB1 in CD4 cells) supporting our previous hypothesis of aberrant T cell
activation in AML. Two candidate miRNAs whose expression may induce the
observed T cell defects are hsa-let-7a-5p and miR-142-3p. Hsa-let-7a-5p is
down-regulated in both CD4 and CD8 cells and has recognised functions in
the regulation of T cell proliferation via CDK6 and MYC as well as in Th2 dif-
ferentiation. miR-142-3p is down-regulated in CD4 cells and its reduced expres-
sion inhibits T cell proliferation via HOX10A.
Summary/Conclusions: These data support the hypothesis that T cell miRNA
expression is altered by the presence of AML blasts. This microRNA dataset
has been validated against an independent mRNA dataset. Potential miRNA of
interest are hsa-let-7a-5p and miR-142-3p as they have fundamental roles in
normal T cell function. These findings will now be examined in a larger cohort.
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TP-1287, AN ORAL PRODRUG OF THE CYCLIN-DEPENDENT KINASE-9
INHIBITOR ALVOCIDIB
W Kim, K Soh, YS Lee, P Peterson, K Maugham, C Whatcott*, S Weitman,
S Warner, D Bearss, A Siddiqui-Jain
Tolero Pharmaceuticals, Inc., Lehi, United States
Background: Alvocidib is a potent inhibitor of cyclin-dependent kinase-9
(CDK9) and induces apoptosis in cancer cells by reducing the expression of
short-lived, anti-apoptotic protein such as MCL-1. Alvocidib, used in combination
with cytarabine and mitoxantrone, is currently in a Phase II clinical trial in
younger relapsed/refractory acute myeloid leukemia (AML) patients to evaluate
the utility of a patient selection biomarker, dependent on MCL-1. Patients with
AML that have a high dependence on MCL-1 are considered more likely to
benefit from the alvocidib-containing regimen. Alvocidib is currently delivered
by intravenous infusion which, although an effective delivery strategy, does not
allow for chronic dosing and scheduling. An oral form or formulation of alvocidib
could greatly expand the utility of the drug in combination with other targeted
agents by allowing for more prolonged exposure. Alvocidib is highly permeable
in CACO-2 monolayers and is soluble at acidic pH’s but solubility is strikingly
reduced at neutral or basic conditions, which might hamper the development
of an oral formulation.
Aims: We hypothesized that a phosphate prodrug of alvocidib would improve
solubility under neutral or basic conditions and enable the efficient systemic
delivery of alvocidib via oral administration. We planned to investigate the effi-
cacy of an orally delivered phosphate prodrug using various treatment sched-
ules in AML mouse xenograft models.
Methods: We synthesized TP-1287, a phosphate prodrug of alvocidib, in three
steps from the parent compound. The solubility of TP-1287, was determined at
various pH’s, in water. Pharmacokinetic studies were conducted in mice and
efficacy was evaluated in AML xenograft mouse models using various dose
levels and schedules. MCL-1 was evaluated as a pharmacodynamic biomarker
in tumors from xenografted mice, following treatment with TP-1287.
Results: TP-1287 was found to be highly soluble under acidic, neutral, and
basic conditions (1.52 mg/mL at pH 2.2; 1.81 mg/mL at pH 4.5; 9.48 mg/mL at
pH 6.8 and 9.31 mg/mL at pH 8.7) compared to alvocidib (4.38 mg/mL at pH
2.2; 1.25 mg/mL at pH 4.5; 0.02 mg/mL at pH 6.8 and 0.02 mg/mL at pH 8.7).
Pharmacokinetics studies in mice showed that TP-1287 was efficiently con-
verted to the parent alvocidib (Cmax=1922.7 ng/ml, t1/2=4.4 hr) with high oral
bioavailability (%F >100%, compared to intravenous alvocidib). TP-1287
demonstrated significant anti-tumor efficacy in an AML mouse xenograft model
and produced a more than two-fold inhibition of the pharmacodynamic bio-
marker MCL-1 in xenografted tumors, demonstrating a wide, 75-fold therapeutic
dosing window.
Summary/Conclusions: The phosphate prodrug of alvocidib, TP-1287, is high-
ly soluble over a broader pH range than alvocidib and is efficiently metabolized
to the parent compound in vivo. Tumor xenograft models and pharmacodynamic
studies indicate that oral delivery of TP-1287 is efficacious in mice. Based on
these results, we anticipate moving TP-1287, as an orally delivered CDK9
inhibitor, into a forthcoming clinical trial.
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POST-INDUCTION MINIMAL RESIDUAL DISEASE ASSESSMENT BY BOTH
MULTIPARAMETER FLOW CYTOMETRY AND RT-PCR PREDICTS
OUTCOME IN ACUTE MYELOID LEUKEMIA
C Bories1,*, F Dumezy2, O Nibourel2, G Fouquet1, EM Boyle1, A Willaume1,
V Deken-Delannoy3, B Quesnel1, C Preudhomme2, C Berthon1
1Service des Maladies du Sang, 2Hématologie cellulaire, CHRU Lille, 3Unité
de biostatistique, MRRC, Lille, France
Background: Minimal residual disease (MRD) assessment is essential during
the follow-up of patients with acute myeloid leukemia (AML). Although it is not
yet decisional, except in acute promyelocytic leukemia (APL), its evaluation by
RT-PCR in AML has already shown a significant impact on survival in AML.
Multiparameter Flow Cytometry (MFC) offers another option to monitor MRD,
especially for acute leukemias that lack molecular markers. Furthermore, results
can be obtained in a shorter timeframes, which could be of great use in the
management of AML patients.
Aims: We aim to study MRD assessment by MFC and/or RT-PCR after induc-
tion therapy for AML and its impact on outcome.
Methods: Patients were retrospectively included from a database of 182
patients that had at least one MRD assessment for AML during their follow-up
from 2005 to 2013. Patients that were diagnosed with AML, who received inten-
sive chemotherapy, that obtained cytologic complete remission after one or
two courses of induction-therapy, and that had their initial follow-up in our center
were included. Exclusion criteria included APL patients. MRD was assessed
by MFC based on leukemia-associated immunophenotype present at diagnosis,
including cross-lineage markers and maturation asynchronies. RT-PCR-based
MRD was evaluated by quantification of WT1 or NPM1 expression in either
blood or bone marrow samples. MRD data were extracted between post-induc-
tion hematologic recovery and first consolidation for further analysis. Concor-
dance between MFC and RT-PCR was evaluated for patients who had an MRD
evaluation by both methods at the same time. Overall survival (OS) and relapse
free survival (RFS) were estimated according to MRD status. OS and RFS
were also evaluated after censoring data at the time of stem cell transplant.
Results: 128 patients were eligible. Median age at diagnosis was 52 (range:
16-73). 36 patients had an initial leucocytosis superior to 50G/L. ELN prognostic
groups were represented as follow: 36%, 27%, 22% and 15% of patients were
classified in the favourable, intermediate-1, intermediate-2 and unfavourable
groups respectively. De novo AML represented 118 out of the 128 patients. 60
patients underwent an allograft, 35 at first remission. 111 patients presented at
least one MRD assessment, of whom 75 (68%) by MFC and 84 (76%) by RT-
PCR (84 on WT1 and 26 on NPM1 expression). Concordance between both
methods was relatively good since results were consistent with both methods
for 35 of 44 samples. Interestingly, discordant samples were found in both ways
- negative MCF-MRD with positive RT-PCR-MRD or positive MCF-MRD with
negative RT-PCR-MRD.The median follow-up was 53 months. 3 years-OS was
61%. 65 patients (51%) relapsed during their follow-up. 3-years RFS was 42%.
Patients with negative MRD (either by MCF or RT-PCR) had a better 3-years
OS (68% versus 41%, p=0.002) and RFS (51% versus 27%, p=0.0045) than
patients with positive MRD. Censoring data at the time of stem cell transplant
did not impact the significativity of the results. For patients with only RT-PCR
MRD assessment, the benefit of negative MRD was also significant on OS
(p=0.0027) and RFS (p=0.0005). Considering only patients with MCF MRD
assessment (75 patients), MRD had no significative impact on RFS (p=0.09)
and OS (p=0.52).
Summary/Conclusions: As previously reported, we found that RT-PCR
assessment of MRD is associated with OS and RFS in patients with AML. How-
ever only few studies have compared monitoring of MRD by both MCF and
RT-PCR at post-induction time. We found a relatively good concordance
between both methods. Moreover we showed that using MCF in addition to RT
PCR for MRD assessment increased the number of patient that could be mon-
itored at post induction time and was still correlated with outcome.
E893
PHARMACOLOGICAL INHIBITION OF THE PI3K/AKT/MTOR AND NF-KB
CANCER PROMOTING PATHWAYS FOR TARGETED TREATMENT OF
ACUTE MYELOID LEUKEMIA PATIENTS
AG Deslauriers1,2,*, K Reckzeh1,2, A Mosbech1,2, KD Rasmussen2,3,
K Helin2,3,4, K Theilgaard-Mönch1,2,5
1Finsen Laboratory, 2Biotech Research and Innovation Center (Bric), 3Centre
for Epigenetics, 4The Danish Stem Cell Centre (DanStem), Copenhagen, Den-
mark, 5Haematology, Lund University Hospital, Lund, Sweden
Background: Acute myeloid leukemia (AML) develops as a consequence of
genetic aberrations in hematopoietic stem and progenitor cells causing a dif-
ferentiation impairment and an accumulation of AML blast cells in the bone
marrow. This results in bone marrow failure as well as depletion of normal blood
cells. Standard treatment remains initial high-dose chemotherapy (anthracy-
cline/cytarabine) and subsequent consolidation therapy (allogeneic transplan-
tation), however AML patients retain a poor median 5-year survival rate, thus
there is a need for more effective treatment modalities. Furthermore, due to
the tremendous genetic and epigenetic heterogeneity of leukemia, it becomes
important to define more personalized treatment schemes. One of the most
common genetic aberration in AML is the translocation t(8;21), which forms the
fusion protein and core-binding transcriptional repressor AML-ETO encoded
by the fusion oncogene RUNX1-RUNX1T1. Using our bioinformatics screening
of microarray gene expression datasets, aberrant signaling of the phosphatidyli-
nositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin complex 1
(mTORC1) and NF-kB pathways, involved in proliferation and survival advan-
tages, has been identified as a causative agent of malignant transformation in
t(8:21) AML patients.
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Aims: The aim of this study was to use gene expression signatures associated
with the t(8;21) AML subtype in order to define specific targets and evaluate
the anti-leukemic activity of selected small molecule inhibitors against these
targets, in a personalized treatment strategy. More specifically, the objective
was to determine if a combinatorial treatment targeting the PI3K/Akt/mTOR
and NF-kB pathways can block leukemic cell proliferation compared to normal
cells, using a t(8;21)/TET2-/- AML model. AML-ETO has been shown not to be
sufficient to induce leukemia and is often associated with other dominant neg-
ative mutations acquired in early progenitors, such as TET2, a methylcytosine
dioxygenase, which is represented by our murine model.
Methods: The small molecule inhibitors GDC-0941, NVP-BEZ235, IKK-16,
and BAY 11-7082, were used to investigate their effects on cellular proliferation
in assays supporting clonogenic growth. For this, GFP+-sorted murine
t(8;21)/TET2-/- cells and normal wild type bone marrow cells were plated in
semi-solid methylcellulose, in parallel. Colony formation was evaluated after
treatment with the inhibitors, either individually or in combination. Furthermore,
pathway blockade was evaluated using specific biomarkers, protein phospho-
rylation and transcription factor translocation.
Results: In our study, we demonstrate that the small molecule inhibitors inac-
tivated their respective targeted pathways, seen through specific biomarker
analysis, and inhibited cellular growth and survival of the human t(8;21)
leukemic cell line Kasumi-1. Furthermore, the in vitro assays supporting clono-
genic growth of our murine t(8;21)/TET2-/- AML cells showed that the small
molecule inhibitors hindered colony formation in a dose dependent manner,
while combinatorial inhibition of PI3K/Akt/mTOR and NF-kB showed synergistic
inhibition.
Summary/Conclusions: This study demonstrates that dual targeted therapy
against the PI3K/mTOR axis and NF-kB signalling, may represent a novel ther-
apeutic modality for t(8;21) AML. It also showed that identification of specific driv-
ers of AML subtypes can be targeted in a personalized fashion, which could
potentially be used in combination with standard chemotherapeutic regimens in
order to reduce patient relapse and adapt treatment depending on AML subtype.
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NPM1 MUTATION AND FLT3/ITD IN A DOUBLE TRANSGENIC ZEBRAFISH
RECAPITULATES FEATURES OF HUMAN ACUTE MYELOID LEUKEMIA
JW Lu1,*, HA Hou2, MS Hsieh1, HF Tien2, LI Lin1,3
1Department of Clinical Laboratory Sciences and Medical Biotechnology,
National Taiwan University, 2Department of Internal Medicine, 3Laboratory Med-
icine, National Taiwan University Hospital, Taipei, Taiwan, ROC
Background: Acute myeloid leukemia (AML) is a clonal hematologic malig-
nancy that shows great variability with regard to pathogenesis and treatment
outcomes. One of the most common mutations associated with AML involves
the class III receptor tyrosine kinase, FMS-like tyrosine kinase 3 (FLT3), which
plays an important role in hematopoiesis. Constitutively activated FLT3 occur-
ring as internal tandem duplication (ITD) within the juxtamembrane domain is
observed in 20-25% of AML patients and refers to the poorest response to cur-
rent standard treatment. FLT3-ITD mutant was reported to be a driver mutation
in myeloid leukemogenesis. Zebrafish, sharing similar leukocyte compartment
with human beings, recently emerged as a promising animal model for studying
diseases and for drug discovery. 
Aims: To establish a transgenic FLT3-ITD zebrafish line, and further explore
their characteristics, on which future drug screening may be developed.
Methods: We established a transgenic zebrafish that is able to express human
FLT3-ITD or NPM1-Mut under the control of a myeloid-specific promoter (5.3
kb spi-1). Specifically, we generated two constructs, referred to as spi1: FLT3-
ITD-2A-EGFP/CG2 and spi1:NPM1-Mut-PA/CG2, respectively. 
Results: Cytological analysis of kidney marrow (KM) and peripheral blood (PB)
smears prepared from wildtype and FLT3-ITD zebrafish were examined at 4,
6 and 9 months. In comparison with wild type fish, the KM from some spi1:FLT3-
ITD-2A-EGFP/CG2 6- and 9-month old transgenic zebrafish had a greater
number of myeloid progenitors and an excess of blast cells with focal aggre-
gation. Hematoxylin and eosin (H&E) staining of the 6 month-old FLT3-ITD
transgenic fish kidney showed mild effacement and distortion of kidney structure
as well as increased infiltration of myeloid cells. Further morphological analysis
of cytospin marrow showed that AB-wild type fish possessed the normal com-
plement of haematological cells, whereas 2 out of 6 spi1:FLT3-ITD-2A-
EGFP/CG2 zebrafish had an abnormal number of myeloid progenitors and
decreased synthesis of erythroid cells at 9 month-old. Finally, leukoerythrob-
lastosis was observed in PB. It is well recognized that the NPM1 and FLT3-
ITD mutations occur concurrently in AML patients, and the combined genotype
that results from this (NPM1/FLT3-ITD) is the most powerful indicator of AML
prognosis. To better delineate the two-hit model in zebrafish, we also generated
FLT3-ITD/NPM1-Mut double transgenic mutants. In so doing, we found that
FLT3-ITD and NPM1-Mut synergistically promoted myeloid blasts and the
expansion of precursor cells in zebrafish as young as six months. Flow cyto-
metric analysis and Liu’s stains of the KM and PB smears from 6-month old
FLT3-ITD/NPM1-Mut transgenic fish revealed myeloid hyperplasia with pre-
dominance of blast cells and depletion of erythroid series in KM, whereas
immature blast cells were able to progressively infiltrate the KM and circulate
into the PB. Taken above, we suggested that FLT3-ITD and NPM1-Mut syner-
gistically promoted myeloid blasts and the expansion of precursor cells in
zebrafish.
Summary/Conclusions: In conclusion, FLT3-ITD as a common FLT3 mutation
in AML patients could results in expanded myelopoiesis with poor differentiation
in adult zebrafish. These transgenic fish could potentially provide a valuable
platform to investigate leukemogenesis and screen drugs in the near future.
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THE MIR-128A/LIN28A AXIS REGULATES MYELOMONOCYTIC
DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA
L De Luca1,*, S Trino1, I Laurenzana1, V Grieco2, G Bianchino2, V Campia3,
F D’Alessio4, LR Francesco1, C Antonella1, V Simeon1, O Villani5, D Cilloni3,
L Del Vecchio4,6, P Musto7
1Laboratory of Preclinical and Translational Research, 2Laboratory of Clinical
Research and Advanced Diagnostics, IRCCS-Referral Cancer Center of Basil-
icata (CROB), Rionero in Vulture, 3Department of Clinical and Biological Sci-
ences, University of Turin, Orbassano, 4Biotecnologie Avanzate s.c.a r.l.,
CEINGE, Naples, 5Department of Onco-Hematology, IRCCS-Referral Cancer
Center of Basilicata (CROB), Rionero in Vulture, 6Dipartimento di Medicina
Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico
II, Naples, 7Scientific Direction, IRCCS-Referral Cancer Center of Basilicata
(CROB), Rionero in Vulture, Italy
Background: Acute myeloid leukemia (AML) is a heterogeneous neoplastic
disorder of hematopoietic progenitors. Lin28 is a conserved RNA-binding pro-
tein playing an important role in cancer stem cells. Ectopic expression of Lin28
reprograms hematopoietic progenitor cells from adult bone marrow (BM),
endowing them to mediate multi-lineage reconstitution which resembles fetal
hemotopoiesis. It has been reported the existence of reciprocal regulatory loops
between Lin28 and mir-128. In particular, this miRNA is expressed in early
hematopoietic progenitor cells preventing the differentiation of all hematopoietic
lineages. Moreover, increased expression of mir-128 was associated with high-
risk molecular features of AML.
Aims: Since Lin28 and its mir-128 seem to be important regulators of
hematopoiesis, it could be interesting to study their involvement in the induction
and maintenance of AML.
Methods: We analyzed, by qRT-PCR, Lin28A and mir-128 expression levels
in 37 AML patients, AML cell lines and 13 healthy donors. Lin28 protein expres-
sion was evaluated by cytofluorimetric analysis in myeloid and lymphoid pre-
cursors of 10 BM healthy subjects and in 9 AML leukemic cells (LC). Overex-
pression of Lin28A or silencing of miR-128 were obtained in OCI-AML3 cell
line for 24-48 h. Moreover, OCI-AML3 and ME1 cells were treated with PMA
for 24, 48 and 72h. Cells were collected and used to perform cell cycle assay,
apoptosis assay, caspase 3/7 assay, cytofluorimetric analysis of Lin28A,
CD11b, CD45 and CD14, western blot for Lin28A and p21 and qRT-PCR for
EGR2 and ZFP36.
Results: Real Time PCR data indicated a down-regulation of Lin28A in AML
patients (p<0.001) and cell lines (p<0.05) as compared with controls. To confirm
this data, we also analyzed its protein expression in AML LC compared with
normal myeloid precursors, showing a significant down-regulation (p<0.01).
Furthermore, our data showed an up-regulation of Lin28A in normal myeloid
precursors with respect to lymphoid (p<0.001) and erithroid ones (p<0.01).
The over-expression of Lin28A in OCI-AML3 induced myeloid differentiation;
in fact, we observed a significant increased of CD11b (p<0.05), CD14 (p<0.05),
EGR2 (p<0.05) and ZFP36 (p<0.01). We also observed a significant block of
cell cycle in S phase (p<0.05), an increased expression of p21 protein and the
induction of apoptosis (p<0.001). To confirm the involvement of Lin28A in
myeloid differentiation of LC, we treated AML cells with PMA. As expected, we
observed an increase of myeloid markers (CD11b p<0.05, CD14 p<0.05, EGR2
p<0.01, ZFP36 p<0.01) and also a significant overexpression of Lin28A
(p<0.05). Moreover, PMA treatment confirmed a significant block of cell cycle
in G2 phase (p<0.01), an increased expression of p21 and the induction of
caspase-dependent apoptosis (p<0.01). Literature data indicate that miR-128
regulate Lin28A; in fact, we demonstrated by qRT-PCR its up-regulation in
AML patients (p<0.05) and cell lines (p<0.01). Furthermore, its silencing in
OCI-AML3 induced a significant increase of Lin28A, p21 and myeloid markers
as EGR2 and ZFP36 (p<0.001), confirming their involvement in myeloid differ-
entiation and in cell cycle arrest.
Summary/Conclusions: Our data indicate mir-128/Lin28A axis as a potential
regulator of myeloid differentiation, suggesting its involvement in AML devel-
opment.
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DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN
ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
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Background: In the study carried out by The Cancer Genome Atlas Research
Network (TCGA), 99% of patients with acute myeloid leukemia (AML) presented
at list one mutation over 23 genes (NPM1, FLT3, ASXL1, BCOR, CEBPA,
DNMT3A, EZH2, IDH1, IDH2, KDM6A, KIT, KRAS, NRAS, PTPN11, RAD21,
RUNX1, STAG2, SMC1A, SMC3, TET2, TP53, U2AF1 and WT1). However,
there are not studies focused on these 23 genes to evaluate their incidence
and clinical role within independent cohorts of patients lacking chromosomal
aberrations, which represents nearly 50% of patients (NKAML).
Aims: To establish the frequency and prognostic influence of mutations and
their interactions in the 23 genes designated by TCGA study in the context of
other prognostic clinical and molecular markers in a cohort of de novo NKAML
patients.
Methods: The study includes 112 adult patients with de novo AML (excluding
acute promyelocytic leukemia) with normal karyotype. Available DNA sample at
diagnosis was the only limiting criterion. DNA samples from Hospital Universitari
i Politècnic La Fe were provided by Biobank La Fe. We carried out targeted gene
sequencing (Ion Torrent Proton System–Life Technologies) using a 23 genes
custom panel including all coding regions (NPM1, FLT3, ASXL1, BCOR, CEBPA,
DNMT3A, EZH2, IDH1, IDH2, KDM6A, KIT, KRAS, NRAS, PTPN11, RAD21,
RUNX1, STAG2, SMC1A, SMC3, TET2, TP53, U2AF1 and WT1). Selected vari-
ants were annotated using IonReporter® Software for clinical reporting. Non-
pathogenic variants were filtered out by excluding synonymous, intronic and poly-
morphic variants (major allele frequency (MAF) ≥0,01 and/or included in dbSNP).
FLT3-ITD mutations were assessed as previously reported1.
Results: After filtering procedure we identified a total of 314 high-confidence
variants, with an average of 3 mutations per sample, (range 0-7). Mutations in
at least one of the genes were found in 103 out of 112 patients (95%). The
most commonly mutated genes were DNMT3A (n= 43, 39%), NPM1 (n= 37,
33%), FLT3-ITD (n=33, 29%), IDH (n=31, 28%), TET2 (n=30, 27%), RUNX1
(n=19, 17%), ASXL1 (n=17, 15%), KDM6A (n=14, 13%), WT1 (n=11, 15%) and
PTPN11 (n= 9, 12%). Of the 112 samples, 91% contained at least one mutation
in one of eight categories defined according to biologic function with a putative
role in AML pathogenesis: DNA-methylation–related (71%), encoding nucle-
ophosmin (NPM1) (33%), activated signalling (37%), chromatin-modifying
(27%), myeloid transcription-factor (25%), cohesin-complex (20%), tumor sup-
pressor (16%), and spliceosome-complex (U2AF1)(4%). In addition, we iden-
tified a strong pattern of mutual exclusivity between ASXL1 mutations and three
other genes, in an independently manner, U2AF1 (P=0.011), TET2 (P=0.032)
and DNMT3A (P=0.03). In addition, we found a significant co-occurrence
between mutations in DNMT3A and NPM1, (P=0.001) and TET2 and IDH2 or
NRAS (P=0.004; P=0.039, respectively). In univariate analyses, NKAML
patients carrying indels in TET2 or in ASXL1 showed a significantly worse out-
come (5-year OS, wt34% vs. mut 7%, P=0.025; 5-year OS, wt 30% vs. mut
12%, P=0.001, respectively). Further results will be presented in the meeting
Summary/Conclusions: Over 23 genes described by TCGA, 91% de novo
NKAML patients showed at least one mutation. The most frequently mutated
functional category was DNA-methylation (71%), which might trigger the
process of leukemogenesis in NKAML. This work was supported by: Fundación
Española de Hematología (FEHH), PI12/01047, RD12/0036/0014,
PIE13/00046, PI13/01640, PI13/02387, PT13/0010/0026, PI14/01649 and
PROMETEOII/2014/025.
Reference
1. Moreno I, et al. Haematologica 2003;88 1: 19-24.
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CD97 EXPRESSION MEDIATES MIGRATION AND ADHESION OF FLT3-ITD
POSITIVE ACUTE MYELOID LEUKEMIA CELLS AND MODULATES THE
BONE MARROW STROMAL MICROENVIRONMENT
M Wobus1,*, M Kräter1, A Jacobi2, O Otto2, U Oelschlägel1, M Bornhäuser1
1University Hospital Dresden, 2Biotec, TU Dresden, Dresden, Germany
Background: Bone marrow niches are specialized microenvironments that
facilitate homing and survival of normal hematopoietic stem and progenitor
cells (HSPCs) as well as leukemic stem cells (LCSs). Targeting the niche is a
new strategy to eliminate persistent and drug-resistant LSCs. However, defined
mechanisms mediating interactions of acute myeloid leukemia (AML) cells with
the microenvironment remain largely unexplored. We have recently demon-
strated that expression of the adhesion GPCR CD97 is elevated in blasts of
FLT3-ITD positive AML patients.
Aims: Here, we investigated the underlying mechanisms in more detail and
the impact on mesenchymal stromal cells (MSCs) as a main cellular component
of the bone marrow niche in vitro.
Methods: FLT3-ITD MV4-11 and FLT3 wildtype OCI-AML3 AML cells were
used for the in vitro experiments. CD97 knock-down was achieved by lentiviral
transduction of plko1.6/shRNACD97. Primary MSCs were isolated from bone
marrow aspirates of healthy donors and co-cultured with AML cell lines in direct
or indirect manner. Expression analyses were carried out by flow cytometry
and Western blot. Trans-well migration was analysed in a Boyden chamber
assay and the deformation capacity of the AML cells was investigated by real-
time deformability cytometry (RT-DC).
Results: CD97 knock-down by lentiviral transduction of plko1.6/shRNACD97
in MV4-11 leukemic cells caused inhibited trans-well migration towards FCS
and LPA which is at least in part Rho-ROCK pathway dependent. Adhesion to
a stromal layer was significantly decreased within two days and immunoblotting
revealed inhibited Akt phosphorylation in the CD97 knock-down cells. The
expression of the lysophosphatidic acid (LPA) receptor correlated with CD97
levels in FLT3-ITD MV4-11 but not in FLT3 wildtype OCI-AML3 cells indicating
a physical interaction of these receptors. Changes in size as well as the defor-
mation capacity after retroviral transduction of leukemic cells suggested effects
on actin-myosin cytoskeleton dynamics. In the second part of the study, we
tested the impact of leukemic cells and their CD97 expression on the MSC
phenotype. FACS analysis was performed after three days of MSC incubation
with leukemic cell lines or their conditioned medium, respectively. Interestingly,
CD90 and CD146 expression levels were increased by about 50% after cocul-
ture with MV4-11 wildtype cells but declined to the basic level after incubation
with CD97 knock-down cells. In contrast, the expression levels of CD73 were
increased by MV4-11 and even further elevated by CD97 knock-down cells.
Comparable results were observed after MSC culture with conditioned medium
of MV4-11 cells.
Summary/Conclusions: In summary, our data suggest a modulation of the bone
marrow microenvironment by FLT3-ITD positive leukemic cells expressing CD97
in association with LPA receptor rendering it a potential new theragnostic target.
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REPOSITIONING OF QUINACRINE FOR TREATMENT OF ACUTE
MYELOID LEUKEMIA - SYNERGIES AND IN VIVO EFFECTS
A Eriksson1,*, M Gustafsson1, M Fryknäs1, J Gullbo2, P Nygren2, M Höglund1,
R Larsson1
1Department of Medical Sciences, 2Department of Immunology, Genetics and
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Background: We have previously reported that quinacrine, formerly extensively
used as an antimalarial drug, may have repositioning potential for treatment of
acute myeloid leukemia (AML)1.
Aims: The aim of this study was to further evaluate the potential of quinacrine
for a clinical trial in AML by investigating its possible synergistic effect with other
antileukemic compounds as well as evaluating its efficacy in vivo in a mouse
model.
Methods: Cytotoxic activity of quinacrine in combination with one of 9 different
drugs (daunorubicin, cytarabine, azacitidine, decitabine, sorafenib, gel-
danamycin, All-Trans Retinoic Acid (ATRA), vorinostat, and arsenic trioxide) in
AML cell lines was evaluated using the fluorometric microculture cytotoxicity
assay (FMCA). Assessment of combinatorial effects and possible synergy was
performed using conventional Bliss independence analysis based on results
from all combinations of 4 different concentrations (including zero concentration)
of each drug. Activity of quinacrine in vivo was investigated in a model with AML-
PS cells injected intravenously in female SCID mice (at Accelera S.r.l). After two
days, groups of ten mice were randomized to treatment with quinacrine or vehicle
control. Quinacrine was administered by oral gavage at the dose of 100 mg/kg
three times a week for two consecutive weeks; control animals were treated
with vehicle (iv) only (twice a week for two weeks). Mice were monitored daily
for mortality and clinical signs, body weights were evaluated twice a week. Blood
aliquots were collected on days 30 and 31 to determine the percentage of cir-
culating leukemic cells by FACS analysis. BD Cellquest software was used for
data collection and analysis. Median survival time (MST) was calculated and
the log-rank test was used to evaluate the statistical significance of differences
between the control group vs. the quinacrine-treated group.
Figure 1.
Results: In the in vitro drug combination analysis, several promising synergies
were observed after studying duplicated experiments, for instance when com-
bining quinacrine with geldanamycin, ATRA, cytarabine, hypomethylating
agents or sorafenib. In the AML mouse model, evaluation of circulating leukemic
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cells detected in blood samples (in percent of white blood cells) showed 72%
human tumor cells in the control mice, whereas in mice treated with quinacrine,
this was only 2.2%. In agreement with these data, the MST of control mice
was 34 days whereas it was 46 days in quinacrine-treated mice (p<0.0001). At
the tested dose, quinacrine did not decrease the body weight of treated mice.
Summary/Conclusions: These results strengthen the repositioning potential
for quinacrine in AML, suggesting in vivo efficacy as well as promising synergies
in combination with different agents, including geldanamycin, conventional
chemotherapeutics as well as the hypomethylating agent azacitidine. These
results provide further support for evaluation of the anti-leukemic effect of
quinacrine in a clinical trial in AML.
Reference
1. Eriksson A, Osterroos A, Hassan S, et al. Drug screen in patient cells
    suggests quinacrine to be repositioned for treatment of acute myeloid
    leukemia. Blood cancer journal 2015; 5: e307.
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PRIMARY ACUTE MYELOID LEUKEMIA CELLS WITH OVEREXPRESSION
OF EVI-1 ARE SENSITIVE TO ALL TRANS RETINOIC ACID
HJ Verhagen, MA Smit, A Rutten, F Denkers, PJ Poddighe, PA Merle,
M Maarse, JJ Janssen, GJ Ossenkoppele, L Smit*
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Background: Acute Myeloid leukemia (AML) is a heterogeneous myeloid pro-
liferative disease that can be classified based on morphology, cytogenetics,
molecular aberrations, gene expression and methylation profiles. Aberrant
expression of the transcriptional regulator ecotropic viral integration site-1 (EVI-
1) occurs in ~10% of adult AML patients and is associated with particularly
aggressive disease and a very poor outcome. Up to 95% of EVI-1 positive
patients have an overall survival of less than 1 year. Therefore, there is an
urgent need for novel treatment strategies to improve the survival of EVI-1
positive AML patients. For decades, most AML patients, including the group
with EVI-1 overexpression, are treated with a chemotherapy combination con-
sisting of cytarabine-arabinoside and an anthracycline. Importantly, EVI-1-pos-
itive AML patients have an very poor initial response to this currently used com-
bination chemotherapy; 39% of EVI-1 positive patients do not achieve a com-
plete remission after induction therapy as compared to 18% of patients in the
other AML subgroups. To date, only a few alternative treatments have shown
to be slightly more effective than this combination of chemotherapeutics. The
exception to this is the treatment of acute promyelocytic leukemia (APL)
patients with all trans retinoic acid (ATRA). ATRA treatment has significantly
increased the survival chances for APL patients and has turned APL from a
poor prognostic leukemia into a curable disease.
Aims: As treatment of APL patients with ATRA is very successful, we sought
to determine the response to ATRA of EVI-1 positive AML patients.
Methods: Here we investigated the response of EVI-1 positive AML to ATRA
(n=14) and compared this to the response of EVI-1 negative AML cases (n=7).
We studied the effect of treatment with ATRA on myeloid blast differentiation,
clonogenic capacity and on the in vitro and in vivo survival of AML cells.
Results: Like induction of CD11b expression on APL cells, we observed
increased CD11b expression on the cell membrane of 69% of EVI-1-positive
AML cases (9/13) after 7 days of incubation with ATRA. In contrast, EVI-1 neg-
ative AML cases had no induction of differentiation after ATRA treatment. In
several of the EVI-1 positive AML cases, treatment with ATRA induces apop-
tosis of the leukemic blasts. Moreover, pre-incubation of patient EVI-1-positive
AML cells with ATRA results in enhanced sensitivity to doxorubicin. Besides
low complete remission rates after initial treatment, the extreme poor prognosis
of EVI-1-positive patients is because of high relapse rates. This relapse is due
to chemotherapy resistant leukemic progenitors or leukemic stem cells (LSC).
Eradication of these LSC is crucial to improve the outcome of EVI-1-positive
patients. We observed a significant reduction in colony forming capacity of
leukemic progenitors/stem cells in primary AML after treatment with ATRA but
most importantly we demonstrated that in vivo ATRA treatment of primary EVI-
1 positive AML cases leads to a significant reduction in leukemic engraftment
in the bone marrow and spleen (Figure 1).
Figure 1.
Summary/Conclusions: This study is the first to show that a considerable part
of the primary EVI-1 positive AML patient samples are sensitive to ATRA treatment,
suggesting that combining ATRA with conventional chemotherapy might be a
promising treatment strategy for this poor prognostic subgroup of AML patients.
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GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM
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Background: Although recurrent chromosomal alterations are the main diag-
nostic and prognostic markers in acute myeloid leukemia (AML) at the time of
diagnosis, nearly 50% of patients have an apparently normal karyotype
(NKAML), displaying an intermediate risk for survival and relapse. SNP array
(SNP-A) allow us to study variations in the number of copies (CNV) and regions
of loss of heterozygozity (LOH) in myeloid neoplasms. Using systematically
matched germline samples might ascertain the somatic nature of each lesion.
Aims: To establish the role that may play some cryptic abnormalities present
in NKAML patients through the frequency, recurrence and any possible clinical
association of CNVs and LOHs.
Methods: A total of 218 de novo NKAML patients were analyzed. Among them,
25 patients were enrolled in the consecutive multicenter PETHEMA trials at
the Hospital Universitari i Politècnic La Fe and Hospital 12 de Octubre, with
available DNA sample at diagnosis and at complete molecular remission were
selected for this study. DNA from Hospital Universitari i Politècnic La Fe were
provided by Biobank La Fe. We expanded the cohort with other AML series
with publicly available SNP-A data to a total of 181 cases (n=49 del TCGA,a
n=53 de Kronke J, et al.,b n=30 de Tadayuki A, et al.c y n=49 Koren-Michowitz
M, et al.d). Samples were genotyped using Human CytoScan HD (n=37) and
Genome-Wide Human SNP 6.0 (n=181) according to manufacturer’s protocol
(Affymetrix Santa Clara, C.A., U.S.A.). DNA copy number and paired LOH
analyses were performed using the Genotyping Console and the Chromosome
Analyses Suite (ChAS) software (Affymetrix). Filters applied for segment Copy
Number Abnormalities (CNA) detection were ≥20 consecutive markers in a
region of at least 100Kb, and for regions of Copy Neutral Loss of Heterozygocity
(CN-LOH), ≥100 markers in at least 500Kb. All abnormalities found in the remis-
sion sample were ruled out and assume as non-somatic. Besides, every poten-
tial abnormality was checked in the Database of Genomic Variants (http://pro-
jects.tcag.ca/variation). Size, position, and location of genes were identified
with UCSC Genome Browser (http://genome.ucsc.edu/). The human reference
sequence used for alignment was the GRCh37/hg19assembly
Results: A total of 304 abnormalities were found as an acquired event in 143
NKAML patients (66%), resulting in 2.1 abnormalities/case. These consisted
of 151 heterozygous deletions, 99duplications and 54 CN-LOH. Cryptic chro-
mosomal aberrations were more frequents in chr 1, 2, 5, 6, 7, 11, 13, 16 and
19. The most common CN-LOH was in 13q (being FLT3 involved in all them),
1p y 7p. In 19p (chr19:1-16300000) we detected more deletions, while in chr
1, 4, 5 and 20 more insertions. Likewise, patients harbored cryptic aberrations
(mainly deletions or CN-LOH) involving KMT2A,(n=5), RAD21 (n=4), RUNX1
(n=4), ETV6 (n=3), EZH2 (n=3), WT1 (n=3), PTPN11 (n=2), TET2 (n=2), U2AF1
(n=2), IDH1 (n=1) and NPM1 (n=1). Further results will be presented.
Summary/Conclusions: This study has delineated recurrent abnormalities
that may act as driver event and could explain leukemogenesis in up to 66%
of NKAML cases. This work was supported by the following grants: Fundación
Española de Hematología (FEHH).
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A NON-FUCOSYLATED FULLY HUMAN MONOCLONAL ANTIBODY
AGAINST IL-3RΑ, KHK2823, SHOWS PROMISING PHARMACOLOGICAL
CHARACTERISTICS IN NONCLINICAL STUDIES
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Background: Human interleukin-3 receptor alpha (IL-3Rα, CD123) is highly
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expressed in myeloid malignancies, including acute myeloid leukemia (AML)
and myelodysplastic syndrome (MDS), and is considered to be an attractive
target molecule for antibody targeting. We generated KHK2823, a non-fucosy-
lated fully human IgG1 monoclonal antibody against human IL-3Rα, which is
armed with ADCC-enhancing POTELLIGENT® technology.
Aims: KHK2823 is currently in Phase 1 study in the United Kingdom to inves-
tigate safety and efficacy on AML and MDS patients (NCT02181699). Here,
we describe nonclinical profiles and binding characteristics of KHK2823 as a
potential therapeutics against AML and other myeloid malignancies.
Methods: Binding profiles of KHK2823 were analyzed by primary cells derived
from patients in AML, MDS and B-ALL, and cell lines by using flow cytometry.
Epitopes were analyzed by overexpressing IL-3Rα-GM-CSF-R chimeric pro-
teins on 293F cells. Antibody-dependent cellular cytotoxicity was measured by
51Chromium release assay using AML cells as target and peripheral blood
mononuclear cells as effector Effects of IL-3 signal were assessed by using IL-
3-dependent TF-1 cell line. Nude rats subcutaneously transplanted with MOLM-
13 cells and cynomolgus monkeys were used for evaluating pharmacological
activities in vivo.
Results: KHK2823 bound to various hematological malignant cells and
leukemic stem cells, including AML, MDS and B-ALL. ADCC assay showed
high antibody-dependent cellular cytotoxic activity in patients’ malignant cells.
A IL-3Rα antibody 7G3 but not KHK2823 inhibited the growth of TF-1, a IL-3-
dependent cell line, in the presence of human IL-3 in vitro, suggesting that
KHK2823 does not interfere IL-3R to bind IL-3. For further characterization of
KHK2823, we screened epitopes of IL-3Rα antibodies. Three dimensional struc-
ture of IL-3Rα protein was predicted from the homology modeling of IL-4Rα
protein (PDB: 3BPNC). Three structural domains of the extracellular region of
IL-3Rα, designated as A-, B- and C- domains from the N-terminal, were pre-
dicted and replaced by GM-CSFRα. For further precise epitope analyses, six
regions with 7-amino acid in IL-3Rα were substituted to the equivalent regions
of GM-CSFRα protein. The analyses showed that KHK2823 recognizes the
epitope distant from the critical region for IL-3 signals. The data coincided with
that KHK2823, in contrast to 7G3 antibody, did not interfere with the binding of
IL-3 to IL-3R. The epitope analysis also unraveled that KHK2823 but not 7G3
could recognize a isoform of IL-3Rα without A-domain predicted in public data-
base. Several in vivo studies were conducted to evaluate the nonclinical profile
of KHK2823. The nude rat xenograft model showed pharmacological effects.
The pharmacodynamics and the toxicology profiles of KHK2823 were assessed
in cynomolgus monkeys administered by i.v. infusion, once weekly for 4 weeks.
KHK2823 was found to be well tolerated in the monkey study at a maximum
dose of 100 mg/kg. IL-3Rα-positive cells in the peripheral blood were depleted
in all the KHK2823-administered monkeys tested.
Summary/Conclusions: The anti-IL-3Rα antibody KHK2823 possesses prom-
ising pharmacological and toxicological profiles analyzed on the animal studies
and in vitro studies, and recognizes the distinctive epitope, which does not
interfere with the IL-3 signals and also does not lose recognition to the isoform.
These data suggest that KHK2823 might possess safer and more efficacious
characteristics to show promising profiles in the future.
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HETEROTYPIC SIGNALLING BETWEEN BONE MARROW STROMAL
CELLS AND BLASTS PROVIDES INSIGHT INTO THE CELLULAR
COMMUNICATION IN ACUTE MYELOID LEUKAEMIA
A Dokal*, J Gribben, P Cutillas
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University
of London, London, United Kingdom
Background: The bone marrow stromal microenvironment (BMSM) has a well-
established role in the pathophysiology of acute myeloid leukaemia (AML). This
is demonstrated by primary AML blasts dependence on stromal conditioned
media to survive in culture. Although it is clear that there are components of
the stromal secretome that augment AML blast survival, we are currently only
aware of a fraction of these factors and the precise dynamics of the stromal-
blast interactions are not fully understood. In this study we were interested in
dissecting the secretome and identifying novel secreted proteins that may con-
tribute to AML cell survival outside of the current understanding (e.g. SDF-1).
Aims: The ultimate aim of this project is to determine proteins secreted by AML
and bone marrow stromal cells that may mediate communication between AML
blasts and the stromal environment. Further, we wanted to identify secreted
proteins in AML cells harbouring different karyotypes to understand how these
cells illicit heterotypic activation or inhibition of signalling pathways in cells
across the different AML-subtypes.
Methods: To assess the feasibility of this approach, the secretome of 4 human
AML cell lines and 1 mouse bone marrow stromal cell line were characterised
by harvesting the conditioned media from each cell line individually and in co-
culture (9 conditions) in triplicate (n=3). The secretomes were then purified from
the conditioned media before undergoing global quantitative proteomic analysis
using Liquid Chromatography Tandem Mass Spectrometry. MASCOT searches
against both mouse and human proteomes allowed for discrimination between
the stromal and AML proteins during bioinformatic analysis. In parallel the viability
of these cell populations was recorded using a Beckman Coulter Vi-Cell cell via-
bility analyser, functionally assessing the supportive capabilities of the BMSM
after the AML cells were subjected to 24 hours of serum starvation.
Results: Secretomic analysis of the chemical crosstalk identified 520 bone
marrow stromal proteins (including Osteopontin, Fibronectin, ECM proteins)
and 293 AML blast proteins that satisfied identification criteria across the sam-
ples. 98 of such proteins have known functions as cytokines/growth factors.
Analysis of the stromal secretome revealed a set of 20 stromal proteins whose
secretion was modulated as a result of AML-stromal co-culture. These putative
extracellular signalling proteins have known roles in cell adhesion, migration or
microenvironment remodelling. In addition, the modulations in the composition
of the AML secretome are suggestive of reactive crosstalk with the BMSM lead-
ing to stromal cell complicity. Finally, we display how serum starvation only
leads to a drop in viability for AML cells cultured in isolation. It appears the
BMSM is able to maintain if not increase basal AML cell viability under the
same conditions. These findings are complimented by the reduction in extra-
cellular markers of stress in the co-cultured secretomes. 
Summary/Conclusions: This proteomic approach has allowed for the identi-
fication of a panel of proteins secreted by the stromal cells that can affect cell
signalling and therefore behaviour of AML blast cells. Interestingly there are a
number of novel signalling proteins secreted by the blasts that are indicative of
orchestrating the BMSM. Analysis is now underway to fully map the progression
of signalling in AML blasts that is initiated by the binding of these stromal sig-
nalling proteins. When complete this study will provide insight as to how the
stromal microenvironment helps propagate leukaemic blasts across the different
AML-subtypes.
E903
ONO-5390556 AS POTENTIAL TARGETED THERAPY FOR ACUTE
MYELOID LEUKAEMIA WITH ETV6-NTRK3 FUSION GENE
R Kozaki*, T Yoshizawa, R Fujikawa, H Kato, N Goto
Oncology research laboratories, ONO Pharmaceuticals, Osaka, Japan
Background: Chromosomal rearrangements that target NTRK1, NTRK2 and
NTRK3 are rare but recurrent abnormalities observed in some types of cancer.
Fusion variants for each NTRK gene have been described in cancers that give
rise to constitutive activation of kinase domains that are believe to drive the
oncogenic process. Translocation of NTRK3 and Ets family transcription factor
6 (ETV6), ETV6-NTRK3 appears with the greatest frequency across many can-
cer types, including acute myeloid leukaemia (AML), radiation-associated thy-
roid cancer, high grade gliomas, ductal carcinoma, fibrosarcomas, congenital
mesoblastic nephroma and secretory breast carcinoma. Patients bearing ETV6-
NTRK3 show resistant to chemotherapy, indicating that targeting active NTRK
may be effective in the treatment of patients with this fusion.
Aims: ONO-5390556 is a highly potent and selective NTRK inhibitor with an
IC50 in the sub-nmol/L range. We have examined the activity of ONO-5390556
against ETV6-NTRK3 bearing cell line, IMS-M2 models both in vitro and in vivo.
Methods: Response was assessed by oral administration of ONO-5390556
once daily for 26 days in mice bearing IMS-M2 cells that were subcutaneously
injected into female SCID mice. To investigate the regulation of signaling path-
ways by ONO-5390556 in IMS-M2 cells, western blotting was performed.
Results: IMS-M2 cell lines showed reduced proliferation (IC50: 0.8 nmol/L)
compared with Ba/F3 cells (IC50 not reached at 1000 nmol/L). In the IMS-M2
xenograft model, tumour growth inhibition at the final treatment day was 62.7%
in the 0.6 mg/kg treatment group and 100% both in the 2 mg/kg and 6 mg/kg
treatment groups respectively (All treatment groups: P<0.001 v.s. Vehicle). The
treatment of ONO-5390556 was well tolerated in IMS-M2 bearing SCID mice
with no body weight loss. Western blotting demonstrated a dose-dependent
reduction in phosphorylation of the NTRK and the downstream signaling of
NTRK pathway, ERK, AKT and PLCg1.
Summary/Conclusions: The dramatic and sustained response to NTRK inhi-
bition in IMS-M2 cells provides a rationale for the mechanisms underlying the
response. Our in vivo study therefore demonstrate that ONO-5390556 has sig-
nificant activity against cells containing NTRK rearrangement and shows prom-
ise for the treatment of patients with ETV6-NTRK3 fusion gene positive AML.
E904
ASSESSMENT OF THE ALLELIC RATIO OF DNMT3A R882 MUTATIONS IN
ACUTE MYELOID LEUKEMIA BY DIGITAL DROPLET PCR
J Grimm*, T Dick, M Bill, M Jentzsch, J Schulz, L Schmalbrock, L Bonifacio,
M Knyrim, K Schubert, M Cross, W Pönisch, V Vucinic, G Behre, GN Franke,
D Niederwieser, S Schwind
Hematology and Oncology, University of Leipzig, Leipzig, Germany
Background: In acute myeloid leukemia (AML) the allelic ratio (AR) of internal
tandem duplication in the FLT3 gene (FLT3-ITD) has been shown to impact clin-
ical outcomes. DNMT3A mutations (mut) occur in approximately 20% of AML
patients (pts) & the majority is found in amino acid R882. These mut arise early
in leukemogenesis & their presence is associated with worse prognosis in some
AML subgroups. To date the biological & clinical impact of DNMT3Amut AR has
not been investigated. Simultaneous absolute quantification of mut & wild type
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(wt) copies with the highly sensitive & specific digital droplet PCR (ddPCR) may
represent an excellent tool for DNMT3A R882mut AR assessment.
Aims: To evaluate the feasibility of DNMT3A R882mut AR assessment by
ddPCR at diagnosis & during disease course in AML pts.
Methods: AML pts treated at our institution between 2000 & 2015 with DNMT3A
R882H or R882C mut & eligible diagnostic (n=33) &/or follow-up material (n=20)
were analyzed by ddPCR. cDNA was applied to a duplex assay measuring
DNMT3Amut & wt simultaneously. Absolute copy numbers of DNMT3Amut/
DNMT3Awt defined the AR. Samples with an AR<0.0001 or<3 positive droplets
were rated negative according to the manufacturer’s recommendations. Mut in
NPM1, CEPBA & presence of FLT3-ITD & -TKD were assessed at diagnosis. For
pts receiving hematopoietic stem cell transplantation (HSCT) data on bone marrow
chimerism at day 28 & 56 after HSCT were collected.
Results: 35 pts (median age 63 years [y], range 29-87y) were identified to
have a DNMT3A R882H (71.4%) or R882Cmut (28.6%). All mut were deter-
mined to be heterozygous by visual inspection of the Sanger sequence traces.
At diagnosis 31.4% of the AML pts had a DNMT3A R882mut AR>1 (median
AR 0.92, range 0.0002-2.3). Pts with an AR>1 had more often secondary AML
by trend (36.4% vs 8.3%, P=.06), were less frequently NPM1mut (18.2% vs
65.2%, P=.03), had fewer platelets by trend (P=.08) & more blasts in peripheral
blood (P=.04). A DNMT3A R882mut AR>1 at diagnosis associated with shorter
overall survival (Figure 1A, P=.005). 27 pts received HSCT with 15 having
available samples pre-HSCT. DNMT3A R882mut AR declined in all pts pre-
HSCT (AR range 0-0.57, median 0.14; median AR reduction 67.3%, range
30.6-100%, P<.001). The majority of patients remained DNMT3A R882mut
positive (86.7%) pre-HSCT. At day 28 after HSCT five pts had material available
to assess DNMT3A R882mut AR. Four pts were positive for DNMT3A R882mut
(AR range 0.0001-0.51) of whom three experienced relapse. One patient was
negative for DNMT3A R882mut at day 28 & is in continuous remission. Figure
1B displays an exemplary AR course of one patient who experienced relapse
after HSCT. Notably, the DNMT3A R882mut AR increased by two log-levels
between day 28 & 56 after HSCT while the bone marrow total chimerism
remained at 100%.
Figure 1.
Summary/Conclusions: ddPCR is a feasible method to assess DNMT3Amut
AR during disease course. In spite of the limited number of pts, our data suggest
that the DNMT3A R882mut AR at diagnosis may associate with biological &
clinical features & outcome of AML pts. DNMT3A R882mut AR may be useful
for monitoring minimal residual disease (MRD) after HSCT. Assessment of
DNMT3A R882mut AR by ddPCR will be included in future clinical trials to val-
idate its prognostic impact & its feasibility as MRD marker after HSCT in AML.
E905
USE OF NGS MULTIGENIC PANEL IN MOLECULAR DIAGNOSTIC OF
MYELOID MALIGNANCIES TO STRATIFY PATIENTS FOR PERSONALIZED
THERAPIES
E Franchini1,*, E Zuffa1, A Padella1, G Simonetti1, M Manfrini1, MA Laginestra1,
G Motta1, C Baldazzi1, GF Prisinzano1, C Venturi1, MT Bochicchio1, N Testoni1,
C Papayannidis1, G Marconi1, M Perricone1, E Ottaviani2, G Martinelli1
1Seragnoli Institute,Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna, 2S. Orsola-Malpighi Hospital, Hematology
Unit, Bologna, Italy
Background: In the last years, next generation sequencing (NGS) technology
resulted to be a new effective strategy in identifying genetic aberrations in
myeloid neoplasms. Molecular mutation information became essential for bio-
logical subclassification, risk stratification and therapeutic decisions; the muta-
tional status of several genes became important for understanding the complex
interactions among different pathways in leukemogenesis.
Aims: Characterization of myeloid neoplasms using a multigenic panel of NGS
sequencing in order to identify important alterations in a shorter time than tra-
ditional molecular methods and with a higher sensitivity. This will be helpful in
a prematurely detection of small clones, important for monitoring disease pro-
gression and the inclusion in target therapy protocols.
Methods: We performed 15 runs with the TruSight Myeloid Panel of Illumina,
for a total of 118 patients analyzed at diagnosis: 95 AML/sAML, 15 MPN, 3
CML, 3 MDS and 2 CMML. 25 patients (21,2%) had a normal karyotype, 25
(21,2%) presented one or two alterations, 26 (22%) had a complex karyotype,
while for 42 patients (35,6%) no information about the karyotype was available.
The panel is a next-generation sequencing platform to screen somatic variants
in 54 genes relevant in myeloid diseases: 15 full genes (exons only) and onco-
genic hotspots of 39 additional genes, for a total of 568 amplicons.
Results: The output data were then analyzed with the Illumina’s software Vari-
ant Studio and the results were filtered by a coverage of minimum depth of
500 and allele frequency >3%. Variants already classified as SNP were
removed. Only non-synonymous mutation were considered. The mean cover-
age was 3662 with a mean of 24 alterations per patient. 57,5%, 3.9% and
38.6% of the alterations had a Variant Allele frequency (VAF)<10%, between
10-30% and >30%, respectively. Three patients resulted wild-type, while 10
patients carried only one mutation. The most mutated genes were ASXL1,
BCOR, TET2, BCORL1, KDM6A, STAG2, DNMT3A, NOTCH1, ATRX, EZH2,
RAD21, TP53, ETV6 (p<1e-05). We also detected 66 short deletions and 11
short insertions (max length 23 bp and 25 bp respectively). Then we proceeded
with the validation of the mutations >10% of NPM1, DNMT3A, TP53, FLT3,
JAK2, MPL, SETBP1, IDH1 and IDH2 with conventional molecular methods
available in our laboratory (Sanger Sequencing and dPCR) and all the 145
mutations were confirmed. We also validated the alterations<10% of CEBPa,
TP53, RUNX1, IDH1, IDH2, CALR and FLT3 with the Roche GS Junior 454
and we obtained >90% of concordance. Moreover 18 AML samples were also
analyzed by WES and 97,5% of the mutations were confirmed.
Figure 1.
Summary/Conclusions: These data suggest that a NGS multigenic panel is
an effective strategy in myeloid neoplasms characterization and stratification
in light of the development of novel personalized therapies (IDH-inhibitors:
AG120 and AG221, MEK-inhibitors: GDC-0973, JAK-inibitors: Ruxolitinib and
FLT3-inhibitors: Sorafenib, Midostaurin, AC220, ASP2215). Moreover, this
approach is cheaper and time-saving and can also reveal alterations with a
higher sensitivity than conventional methods. For this reason, we think that
this approach could be strongly recommended for all new diagnosis/relapse
myeloid neoplasm in order to obtain a more complete and premature charac-
terization of the disease that will give advantages in term of therapeutic
approach and OS of the patients. Akcnowledgments: work supported by ELN,
AIL, AIRC, Progetto Regione-Università 2010-12 (L.Bolondi), FP7 NGS-PTL
project, Illumina inc.
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BIOLOGICAL MARKERS OF RELAPSE IN ELDERLY PATIENTS WITH AML
IN CR AFTER INDUCTION-CONSOLIDATION CHEMOTHERAPY AND
MAINTENANCE WITH 5-AZACITIDINE
M Cuzzola1,*, C Alati2, P Di Bartolomeo3, P Salutari3, A Candoni4, E Simeone4,
A Cortelezzi5, A Freyrie5, F Di Raimondo6, V Calafiore6, P Niscola7, D Capelli8,
G Irrera9, C Rigolino1, MC Cannatà1, A Marino2, A De Angelis2, F Ronco2,
EN Oliva2
1CTMO Laboratory, 2Hematology Division, A.O. Bianchi-Melacrino-Morelli,
Reggio Calabria, 3U.O. di Ematologia Clinica, Ospedale Civile Spirito Santo,
Pescara, 4Centro trapianti e terapie cellulari, clinica ematologica, A.O. Univer-
sitaria di Udine, Udine, 5Haematology Unit, Fondazione IRCCS Ca’ Granda,
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Ospedale Maggiore Policlinico and University of Milan, Milano, 6Divisione Clin-
icizzata di Ematologia, Ospedale Ferrarotto, Catania, 7Divisione Ematologia,
Ospedale Sant’Eugenio, Roma, 8Clinica di ematologia, Ospedlae Umberto I di
Ancona, Ancona, 9CTMO, A.O. Bianchi-Melacrino-Morelli, Reggio Calabria,
Italy
Background: Acute myeloid leukemia (AML) is biologically complex due to the
continuously evolving clonal architecture that marks remission and relapse.
Though biological targeted therapeutics are changing clinical practice, there is
still a lack of epigenetic markers of prognosis.
Aims: To identify biomarkers of relapse in elderly patients with AML in CR after
conventional induction (“3+7”) and consolidation chemotherapy.
Methods: In a phase III, prospective, randomized, open-label, multicenter
trial, designed to assess the efficacy of post-remission treatment with 5-Azac-
itidine versus best supportive care (BSC), patients are included if: they are
>60 years of age; have newly diagnosed “de novo” AML or evolving from
myelodysplastic syndrome; >30% bone marrow blasts; no contraindications
for intensive chemotherapy; and an ECOG performance status<3. Induction
chemotherapy consists of two courses of “3+7” (Daunorubicin 40 mg/m2 daily
days 1-3 and cytarabine 100 mg/m2 daily continuous IV infusion days 1-7).
Patients in complete remission (CR) receive consolidation therapy (cytarabine
800 mg/m2 3 hour infusion bid days 1-3) after which they are randomized 1:1
to receive BSC or 5-Azacitidine maintenance therapy up to 4 years and six
months until AML relapse. Bone marrow (BM) samples were obtained from
patients at diagnosis before treatment and at CR before randomization.
Genomic DNA was obtained from BM mononuclear cells. Prognostic somatic
mutations were evaluated by the Human Hematopoietic Neoplasm qBiomarker
Somatic Mutation PCR Array (QUIAGEN) that includes DNA sequence muta-
tion assays designed to detect the most frequent, functionally verified, and
biologically significant mutations in human hematopoietic neoplasms, such
as: FLT3, NPM1, IDH1, IDH2, CEBPA, KIT, KRAS, WT1, ASXL1, EZH2,
DNMT3A and TP53. Various univariate logistic regression models were con-
structed. Each model included the treatment allocation, the dichotomous vari-
able, “Relapse Yes/No” as the dependent variable, and each somatic mutation
(mutated/wild-type) as independent variables. The median time to relapse will
be estimated by the Kaplan Meier method.
Results: At interim analysis, 31 patients (14 males), mean age 69 SD±6 years
achieved a CR and were randomized to receive BSC (N=13) or 5-Azacitidine
(N= 18). At the time of the present report, 21 of the 31 patients have relapsed
(10 in BSC arm, 11 in 5-Azacitidine arm), while the remaining 10 are alive in
CR. Median time to relapse was 296 days, 95% CI 73 -519. Amongst biomark-
ers assessed, only TP53 (NM_000546 p179Y) at diagnosis was associated
with AML relapse (p=0.007, Table 1A). Specifically, 15 out of 17 patients with
mutated TP53 at diagnosis relapsed compared to 6 out of 14 patients with wild-
type TP53. Of the latter 6 patients, 4 were on 5-Azacitidine. Finally, we built a
logistic regression model adjusting the TP53 variable for the effect of the ran-
dom allocation, which did not represent a confounder for relapse. Median time
to relapse in TP53 mutant patients was 147 days, 95% CI 51-242 versus 389
days, 95% CI 353-425.in TP53 wild-type patients (p=0.022, Figure 1).
Table 1.
Figure 1.
Summary/Conclusions: The presence of TP53 mutation at diagnosis in elderly
“fit” patients with AML undergoing induction-consolidation chemotherapy seems
to confer an independent adverse clinical course which is not abrogated by
post-remission treatment.
E907
PATTERNS OF INTERACTION BETWEEN MULTIPOTENT MESENCHYMAL
STROMA CELLS (MSC) AND ACUTE MYELOID LEUKEMIA (AML) CELLS
IN VITRO AND IN VIVO
R Schelker*, G Müller, C Hart, S Klatt, A Kratzer, W Herr, J Grassinger
Department of Internal Medicine III, Hematology & Oncology, University Hospital
of Regensburg, Regensburg, Germany
Background: MSC are a key factor within the bone marrow (BM) niche by reg-
ulating hematopoietic stem cells (HSC) within the endosteal and perivascular
region. Moreover, MSC are suspected to support the aberrant hematopoiesis
in a similar manner.
Aims: In our study we sought to investigate the effect of MSC on AML cells in
vitro and in vivo.
Methods: MSC from AML patients (LD) and donors without BM disorder (BD)
were obtained from BM aspirates. Phenotypic and functional criteria of MSC
were tested subsequently. Liquid culture assays were performed from LD and
BD samples to compare expansion capacity. Co-cultures of AML cells (LC) on
MSC were initiated and compared to those on mouse fibroblasts (MS5). Addi-
tionally, the effect of blocking CXCR4 and TGF-b1 on proliferation of LC was
tested in these co-cultures with and without cytarabine supplementation. Ultra-
structural intercellular communication of MSC and LC was investigated by elec-
tron microscopy (ECM). Gene expression profiles of cultured LD-MSC vs BD-
MSC were established by using Affimetrix gene chip. Finally, homing and engraft-
ment of MSC, LC and combinations thereof in NSG mice were investigated.
Results: MSC were successfully harvested from BM aspirates and showed a
typical differentiation pattern and surface marker profile. LD-MSC showed sig-
nificant decreased expansion capacity compared to BD-MSC. Co-culture of LC
on MSC resulted in a higher proliferation than on MS5. Blocking TGF-b1 but
not CXCR4 increased proliferation of LC and enhanced chemo-sensitivity
towards cytarabine. ECM analysis showed no evidence for junctional bridging
between LC and MSC. Gene analysis revealed a marked overexpression of
stanniocalcin-1 (STC-1) in LD-MSC compared to BD-MSC. mRNA and western
blot analysis as well as ELISA and immunohistological findings confirmed this
observation. In vivo experiments emphasized that HSC and LC exhibited sig-
nificant higher homing efficiency than MSC, the latter being mainly trapped
within the lung. Mice treated (transplanted) with MSC showed decreased cytara-
bine sensibility as compared to control mice without MSC.
Figure 1.
Summary/Conclusions: MSC derived from patients with AML show distinct dif-
ferences to MSC from BD. MSC support LC in vitro and in vivo. TGF-b1, CXCR4
and STC-1 signaling may play an important role within the leukemic niche.
E908
THE ROLE OF THE NUCELOPHOSMIN-1 SPLICE VARIANT R2 IN ACUTE
MYELOID LEUKEMIA DEVELOPMENT
M Zajac1,*, J Zaleska1, G Stasiak1, O Jankowska-Lecka2, T Gromek2,
M Soroka-Wojtaszko2, A Szudy-Szczyrek2, B Sokolowska2, M Hus2, L Bullinger3,
K Giannopoulos1,4
1Department of Experimental Hematooncology, 2Department of Hematooncol-
ogy and Bone Marrow Transplantation Unit, Medical University of Lublin, Lublin,
Poland, 3Department of Internal Medicine III, University of Ulm, Ulm, Germany,
4Department of Hematology, St. John’s Cancer Center, Lublin, Poland
Background: A close cytogenetic and molecular analogy between de novo
MDS and AML of elderly people indicates a common pathogenic mechanism
for these conditions. The frequent mutations of the splicing machinery in MDS
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suggest that alternative splicing of certain molecules of the crucial signaling
pathways might drive progression to AML. Recently, we found that high expres-
sion of the NPM1 splice variant R2 may provide prognostic value for CN-AML
patients.
Aims: Assuming the common origin of MDS and AML we aimed to characterize
the NPM1 R2 splice variant expression in groups with MDS, sAML and AML
patients. Moreover, NPM1 stabilizes the ARF and interacts with the tumor sup-
pressor p53, regulates the increase in stability and transcriptional activation of
p53, thus contributing to modulating growth-suppressive pathways. Therefore,
we characterized expression pattern of ARF, MDM2, TP53 genes with addi-
tional downstream molecules (p21, miR-34a) in AML, s-AML and MDS patients.
Methods: For 128 samples (58 AML, 62 MDS and 8 samples with sAML)
expression levels of NPM1 R2, ARF, MDM2, TP53 and p21 were assessed by
qRT-PCR. We also measured expression levels of miR-34a, miR-34b and miR-
34c in CD33+ cells from 20 AML patients samples. To investigate whether R2
might disrupt localization of the NPM1 wild type protein, we used constructs
with GFP-tagged NPM1-R2 and NPM1-wt under cytomegalovirus promotor to
transfect WI-38 fibroblasts and performed immunohistochemistry analysis for
NPM1 in 23 AML bone marrow smears.
Results: The expression of NPM1 R2 was significantly higher in AML, s-AML
and MDS groups compared to HVs (median 0.023 vs 0.005, p<0.001, 0.025
vs 0.005, p<0.001 and 0.017 vs 0.005, p<0.001, respectively). NPM1 R2 pos-
itively correlated with TP53 expression in AML (r=0.77, p<0.001) and MDS
(r=0.68, p<0.001). We observed elevated expression of miR-34c in HVs group
compared to AML (0.11 vs 0.07, p<0,001). No differences were found in
miR34a, miR-34b and miR-34c expression between groups with high or low
R2 expression. Transfections analyses showed that GFP-tagged NPM1-R2
was detected in nucleoplasm, whereas the GFP-NPMwt was detected in the
nucleoli. However, the IHC stainings for AML samples revealed that in cases
with high R2 expression we were able to determine a cytoplasmic localization
of NPM1 even in the absence of its concomitant mutation. Therefore, we pro-
vide further evidence that the cytoplasmic localization of NPM1 might depend
not only on its mutational status, but might be influenced by the distribution of
its splice variants.
Summary/Conclusions: In our study we found that the expression levels of
R2 were elevated in AML, sAML and MDS groups compared to HVs suggesting
that R2 might play a role in the process of the tumorigenesis not only in AML
cases but also in early stages of development of this disease. As the NPM1
R2 splice variant represents a truncated form of NPM1 gene, our transfections
analyses confirmed that this isoform mostly localizes in the nucleoplasm, and
thus might also have a biological impact in the malignant cells by interaction
with other proteins. Moreover, strong positive correlation between R2 and TP53
expression was found in AML and MDS groups suggesting biological link
between these transcripts. In summary, the expression of NPM1 R2 might be
of biological importance for AML as well as for sAML and MDS patients. This
work was supported by National Centre for Science Grant HARMONIA (UMO-
2013/10/M/NZ5/00313).
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THE ROLE OF ADENOSINE DEAMINASE AND DNA METHYLATION IN
ACUTE MYELOID LEUKEMIA
N Tekin1,2,*, K Behrens2, M Ziegler2, K Mills3, H Ozdag4, RA Padua5, C Stocking2
1Department of Viral Transformation, 2Retroviral Pathogenesis, Heinrich-Pette
Institute Leibniz Institute for Experimental Virology, Hamburg, Germany, 3Cen-
tre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast,
United Kingdom, 4Biotechnology Institute, Ankara University, Ankara, Turkey,
5Institut Universitairé d’Hématologie, Inserm Unit 1131, Université Paris VII,
Hôpital Saint-Louis, Paris, France
Background: Genes coding for epigenetic regulators are frequently mutated
in acute myelogenous leukemia (AML). As epigenetic marks are reversible,
drugs that target these events may have an important impact on AML survival
rates. The objective of this study is to investigate the importance of a metabolic
enzyme, Adenosine Deaminase(ADA), whose gene is upregulated by abnormal
DNA methylation during AML induction. Analysis of the mouse microarray gene
expression data showed that the ADA gene is highly upregulated in
NRASD12/BCL2 MDS mouse models, which was validated by Q-PCR (Tekin
and Padua, unpublished data). If the expression of different subtypes of AML
samples is assessed, ADA levels are highest in the subgroup carrying inv(16)
or t(8;21) chromosomal translocations. Notably, these subgroups of patients
also have a conserved DNA methylation pattern (Figueroa et al. 2010).
Aims: Based on the observations, the following hypothesis has been formu-
lated and was tested using human AML cells: Is ADA a key enzyme regulating
the hypermethylation status in AML and contributing to disease progression?
Methods: To address the hypotheses, two approaches were taken: 1) To
silence the ADA gene using shRNAs against ADA and to investigate its impact
on DNA methylation 2) To overexpress ADA using a lentiviral vector expressing
the ADA cDNA, and similarly investigate altered DNA methylation patterns. In
initial experiments, three human cell lines were chosen: ME-1 AML cells car-
rying the inv(16), Kasumi-1 AML cells with t(8;21) and K562 t(9;22) cells, which
was used as a control group. The cell lines were manipulated to overexpress
or repress ADA by transduction with lentiviral vectors. As a control and com-
parison, azacitidine (AZA), a powerful demethylation agent, was also used.
After transduction with lentiviral vectors and treating with AZA, RNA and DNA
were extracted and proteins were purified. To investigate if inhibiting ADA mim-
ics the effect of AZA, DNA methylation levels of Kasumi cells were measured
by gene expression of the specific genes (CDKN1A, ITGA2B, LY86). Bisulphite
conversions of the DNA samples were carried on for the evaluation of the
methylation status for the future studies.
Results: ADA protein levels were determined via western blot to ensure the
success of the ADA gene manipulation by lentiviral transduction. Expression
of ADA and two related genes encoding downstream enzymes from the methy-
lation pathway DNA methyltransferase 1 (DNMT1) and S-adenosylhomocys-
teine hydrolase (SAHH) were investigated by Q-PCR. ADA gene expression
levels do not impact on SAHH and DNMT1 gene transcription, but we con-
cluded that it does impact at the protein level. Interestingly, an inverse corre-
lation between ADA and DNMT1 protein levels were determined between the
cell lines. While ME-1 cell line has the highest ADA level and lowest DNMT1
level, K562 showed the highest DNMT1 levels with lowest ADA protein levels.
In Kasumi cells a correlation between the expressions of methylated genes
and ADA silencing was observed, which was similar to that observed upon
AZA treatment. While AZA treatment resulted in >20 fold increase in the expres-
sion of methylated genes, silencing ADA increased the expression of methy-
lated genes >2,5-10 fold.
Summary/Conclusions: The analysis of this study showed that silencing ADA
can partly mimic the effect of AZA. To confirm the impact of ADA levels on DNA
methylation, global gene analysis using bisulfite converted DNA samples, fol-
lowed by promotor array or sequencing will be performed.
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NEW DELETION OF JAK2 DETECTED BY SNP ARRAY IN ACUTE
MYELOID LEUKEMIA: A ROLE IN OVERALL SURVIVAL
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Center for Molecular Medicine of the Austrian Academy of Sciences, 4Research
Center for Molecular Medicine of the Austrian Academy of Sciences, Wien,
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Background: In Acute Myeloid Leukemia (AML), a hematologic malignancy
that originates in hematopoietic stem and myeloid progenitor cells, there is a
strong need to develop new diagnostic and therapeutic options. Age and kary-
otype have been recognized as the most prominent prognostic factors in AML
patients. Novel array-based technique-single-nucleotide polymorphism (SNP)
microarray can detect cytogenetic lesions involve mostly structural alterations
with losses or gains of chromosomic material. Those chromosomic abnormal-
ities are predictive of response and are very important to define therapeutic
strategies. SNP microarray can detect copy-neutral loss of heterozygosity (CN-
LOH), which plays a role in oncogenesis by duplicating oncogenes, inhibiting
tumor suppressors, and stimulating improper epigenetic programming.
Aims: Our objective is to evaluate the prognostic impact of these genetic alter-
ations on clinical outcome.
Methods: We analyzed 310 AML patients (pts): 218 performed by SNP Array
6.0 (Affymetrix) and 92 performed by Cytoscan HD Array(Affymetrix) and also
by Next Generation Sequencing (NGS)-WES HiSeq 2000 (Illumina). SNP Array
data were analyzed by Nexus Copy Number™ v7.5 (BioDiscovery).
Table 1.
Results: The median age of our cohort of pts was of 52 years and they had a
median age at diagnosis of 51,3 years with a female/male ratio of 51% and
49%. Copy Number Alterations (CNAs) were detected in all patients affecting
all the chromosomes, in particular our cohort of pts present a percentage of
CNA, divided as follow: 42% of UPD (Uniparental Disomy), 19% of Copy Num-
ber (CN) gain, 39% of CN loss. By SNP array analysis we found that several
genes were preferentially deleted, for example ADAM3A (62,2% pts), TP53
(15% pts), HRAS (8,6% pts), ETV6 (7,8% pts) and JAK2 (7% pts), while genes
preferentially involved in amplifications are: FLT3 (42,5% pts), KIT (36,5% pts),
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KRAS (34,2% pts) and SIRPB1 (32,5% pts). We focused on a particular het-
erozygosis loss of JAK2, detected in 8% of pts, which goes from 5,049,001bp
to 5,140,230p, involving the second tyrosine-kinase domain (figure 1). We
showed that the group of patients which present this deletion had an overall
survival rate better than the group with an amplification of the gene (p-val-
ue<0,01). None CN loss in this region of JAK2 had been described in
hematopoietic tissue before.
Summary/Conclusions: By SNP arrays we have identified CNAs involving
important cancer genes in AML and we showed that a new deletion in JAK2
may play a role in the overall survival. Future prospectives will be to confirm
and correlate other cancer genes aberrations and mutations with the prognosis
of AML, in order to identify new biomarkers relevant for the disease.
Acknowledgement: ELN, AIL, AIRC, PRIN, progetto Regione-Università 2010-
12(L. Bolondi),FP7 NGS-PTL project.
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PROTEOMIC ANALYSIS OF RELAPSE AML IDENTIFIES OPPORTUNITIES
FOR THERAPEUTIC INTERVENTION IN INDIVIDUAL PATIENTS
D Britton*, P Casado, V Rajeeve, E Wilkes, R Smith, J Fitzgibbon, J Gribben,
P Cutillas
Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London,
London, United Kingdom
Background: A poor outcome in patients with acute myeloid leukaemia (AML)
is usually related to chemorefractory disease or relapse after an initial response.
Standard therapy generally includes days 1-3 daunorubicin (D) and days 1-7
cytarabine (A) followed by several similar courses should complete remission
be achieved. Resistance of AML blasts to such treatment can be attributed to
the activity of pro-survival enzymes, some of which can be inhibited by phar-
macological inhibitors, therefore could potentially be repurposed for relapsed
AML in a case by case basis. However, finding the right inhibitor for the right
patient presents a challenge due to the plethora of possible causes of resistance
in each case. Liquid chromatography – tandem mass spectrometry (LC-MS/MS)
proteomics is a powerful discovery technology enabling quantification of global
protein expression and enzymatic activity in samples. Hence this approach
may be an effective way to identify suitable drug targets in biopsies and better
understand the biochemistry of cells following chemotherapy. 
Aims: Our primary aim was to identify biochemical pathways modulated in
AML blasts and cell lines as a result of treatment with standard chemotherapy.
We also aimed to test pharmaceutical alternatives to personalise AML treatment
following thorough investigation into the expression and activity of protein drug
targets in AML blasts and cell lines before and after chemotherapy. 
Methods: We used LC-MS/MS proteomics and phosphoproteomics to inves-
tigate global protein expression and kinase activity in 19 matched diagnosis
and relapse AML biopsies, as well as in 3 AML cell lines before and after
chemotherapy. Briefly, we collected frozen biopsy specimens from Barts and
the London tissue bank. After thawing the AML blasts were incubated in FBS
containing media for 2 hr at 37oC. Cell lines (HL60, MV411 and p31Fuj) were
treated±D and/or A (2, 6, or 24 hr). After incubation, cells were centrifuged and
washed in PBS, then proteins extracted in urea lysis buffer. For proteomics,
proteins were digested with trypsin, and resulting peptides analysed directly by
LC-MS/MS. For phosphoproteomics, phosphorylated peptides were first
enriched using TiO2 prior to analysis. Commercial (Mascot) and in-house
(Pescal, KSEA) software were utilised to identify and quantify proteins, deter-
mine kinase activities and investigate intracellular signalling. Cell Viability of
blasts±treatments were recorded using the Guava ViaCount Reagent and
Cytometer.
Results: On average we identified >3000 proteins and >9,000 phosphorylation
sites per sample. We observed that AML blasts showed high expression and
activity of enzymes involved in DNA repair (e.g. PARP1, ATR and PRKDC) at
diagnosis and several increased significantly after relapse (e.g. PLK3 and
APEX1). Pro-survival signalling pathways and those regulating apoptosis and
metabolism were also modulated after relapse but these were patient specific.
AML cell lines were more sensitive to D than A. HL60s were most sensitive
while p31Fuj cells were least sensitive. Chemotherapy induced significant
increase in activity of ATM, ATR, PRKDC and CHEK2. Simultaneous inhibition
of ATM and ATR significantly reduced cell viability±A. 
Summary/Conclusions: We identified the most abundant and active protein
drug targets in AML primary samples and cell lines. Treating AML cell lines with
chemotherapy uncovered biochemical pathways involved in DNA repair and
survival that determined sensitivity or resistance to these drugs. Proteins sig-
nificantly modulated in expression and activity after relapse include those
involved in DNA repair and pro-survival but these were patient specific, sug-
gesting that targeted therapies will have to be personalized.
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IDENTIFICATION OF A NOVEL RNA GIANT NUCLEAR BODY IN MYELOID
LEUKEMIA
H Zhou*, R Xu
Department of Hematology, Key Laboratory of Cancer Prevention and Inter-
vention, China National Ministry of Education, Second Affiliated Hospital, School
of Medicine, Zhejiang University, Hangzhou, China
Background: Constitutive synthesis of oncogenic mRNAs is essential for main-
taining the uncontrolled growth of myeloid cells. However, little is known about
how these mRNAs are exported from the nucleus to the cytoplasm. Cancer
cells, unlike normal cells that only divide a finite number of times before they
enter into a state of growth arrest or die, are able to maintain uncontrolled pro-
liferation. The cell nucleus, which houses much of the genome and the machin-
ery needed for its replication, maintenance, and expression, is crucial for the
survival and proliferation of cells. However, no nuclear bodies have been defin-
itively linked to the uncontrolled proliferation of cancer cells so far. EIF4E
nuclear bodies were initially reported two decade ago and thought to be involved
in the exporting of nuclear mRNAs associated with cell proliferation. studies
have shown a positive correlation between increased eIF4E phosphorylation
and cancer cell proliferation as well as tumorigenesis. Consistently, highly phos-
phorylated eIF4E (p-eIF4E) was frequently observed in a variety of human can-
cers. Therefore, we hypothesized that cancer-associated nuclear bodies as
detected by p-eIF4E antibody may exist in the nuclei of cancer cells.
Aims: To identify the putative cancer-associated nuclear body, we initially
stained two human leukemia cell lines KG-1 (acute myeloid leukemia, AML) by
immunofluorescence staining with antibodies against phosphorylated eIF4E
(p-eIF4E) or total eIF4E (t-eIF4E); To reveal the morphology and structure fea-
tures of GNB; To determine whether RNA-GNB abundance was associated
with the hyperproliferative phenotype in human cancer.
Methods: Cell lines and culture. Myeloid cell lines were used in this
study.Hematopoietic malignant cells were cultured in RPMI-1640 supplemented
with 10% fetal calf serum (FCS) at 37°C in a 95% air, 5% CO2 umidified incu-
bator. Normal human blood samples and human leukemia cell samples. Normal
blood cells and primary leukemia cell samples were isolated from healthy vol-
unteers or leukemia patients with their informed consent in accordance with
the Declaration of Helsinki. All experiments were approved by the ethics com-
mittee of Hangzhou First People’s Hospital. Immunofluorescence staining. Cells
were fixed with freshly prepared 3.7% paraformaldehyde in PBS (pH 7.2) for
20 min at room temperature on slides. Cells were then blocked and permeabi-
lized with PBS containing 10% FBS and 0.1% Tween-20 for 30 min at room
temperature. Staining of cells with primary antibodies was performed overnight
at 4°C, and then with a FITC or rhodamine-conjugated secondary antibodies
for 1 h at room temperature. After three washes with PBS, the slides were
mounted in Vectashield with DAPI and sealed. Immunopurification of GNBs
from leukemia cells. GNBs were purified from leukemia cells as centrifugation
at 2,000 rpm for 5 minutes at 4°C. After washed three times with PBS, cells
were resuspended in PBS containing protease inhibitors and transferred to a
7 mL Dounce tissue homogenizer for dounce homogenization. The homoge-
nized suspension was collected for removing intact cells and undisrupted nuclei
by centrifugation at 1,000 rpm for 5 minutes at 4°C. Separation of GNBs from
nucleoli on the cell nuclei. Cells were collected by centrifugation at 2500 rpm
for 5 minutes at 4°C. After removing the supernatant, the cell pellet was lysated
with 0.5ml of buffer A for 5min and then centrifuged at 700 rpm, 5min at 4°C.
The supernatant was carefully removed and the nuclei were washed with 1.5ml
of Buffer A without NP40 by centrifugation at 700 rpm, 5min at 4°C. 
Results: We report the identification of a RNA giant nuclear body (RNA-GNB)
that is abundant in acute myeloid cells but rare in normal cells. The RNA-GNB
contains a RNA core surrounded by a protein shell. We identify 782 proteins from
acute myeloid-associated RNA-GNBs, 40% of which are involved in the nuclear
mRNA trafficking. RNA-GNB is required for cell proliferation, and its abundance
is positively associated with tumor burden and outcome of therapies.
Figure 1.
Summary/Conclusions: Our studies have identified RNA-GNB as a potential
nuclear mRNA trafficking organelle. Further studies will be required to charac-
terize the components of proteins and mRNAs in RNA-GNB and reveal their
functions. This will help elucidate how RNA-GNBs form and regulate the uncon-
trolled proliferation of cancer cells.
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PHASE 1B/2 STUDY OF VENETOCLAX WITH LOW-DOSE CYTARABINE
IN TREATMENT-NAÏVE PATIENTS AGED ≥65 YEARS WITH ACUTE
MYELOGENOUS LEUKEMIA
TL Lin1, S Strickland2, W Fiedler3, RB Walter4, JZ Hou5, GJ Roboz6, A Enjeti7,8,
KM Fakouhi9, DE Darden9, M Dunbar9, M Zhu9, J Hayslip9, AH Wei10,*
1University of Kansas Medical Center, Kansas City, 2Vanderbilt-Ingram Cancer
Center, Nashville, United States, 3Hubertus Wald University Cancer Center,
University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4Univer-
sity of Washington, Seattle, 5University of Pittsburgh Medical Center (UPMC)
Cancer Center, Pittsburgh, 6Weill Cornell Medical College, New York, United
States, 7Calvary Mater Hospital Newcastle, Waratah, 8NSW and School of
Medicine and Public Health, University of Newcastle, Callaghan, Australia,
9AbbVie, Inc., North Chicago, United States, 10The Alfred Hospital and Monash
University, Melbourne, Australia
Background: Treatment options for older patients (pts) with acute myeloge-
nous leukemia (AML) unfit for intensive chemotherapy are limited. Expected
complete remission rates for low-dose cytarabine (LDAC) are about 10% in
this population. Targeting the pro-survival molecule BCL-2 has demonstrated
clinical efficacy as a therapeutic strategy in various hematologic malignancies.
Venetoclax (VEN), a selective BCL-2 inhibitor, shows synergy with cytarabine
in several AML cell lines and primary samples.
Aims: The primary objectives of the study include evaluating the safety of VEN
administered with LDAC and preliminary estimates of efficacy.
Methods: This is a non-randomized, open-label phase 1/2 dose-escalation/
expansion study of VEN+LDAC, in treatment-naïve AML pts ≥65 years not eli-
gible for intensive chemotherapy. Pts receive oral VEN once daily (QD) on days
1-28 and subcutaneous LDAC 20mg/m2 QD on days 1‒10 of each 28-day cycle.
VEN dose escalation follows a 3+3 design; dose-limiting toxicities (DLTs: grade
4 toxicity, platelet count <25,000/μL, or absolute neutrophil count <500/μL within
14 days of last VEN dose) are assessed during cycle 1, up to day 42.
Results: As of Oct 1 2015, 18 pts (66.7% male; median age 74 years) have
received LDAC+VEN in the phase 1 portion (VEN 600 mg target dose [n=8];
VEN 800 mg target dose [n=10]). Median time on study is 127.5 (range 30‒272)
days; 9 pts (50%) remain on study. DLTs of Grade 4 thrombocytopenia lasting
>42 days without evidence of residual leukemia occurred in 2 pts in the VEN
800 mg dose group. The recommended phase 2 dose is 600 mg. Adverse
events (AEs; ≥30% prevalence) were nausea (77.8%), anemia (55.6%), febrile
neutropenia, neutropenia, fatigue (each 38.9%), vomiting, diarrhea and
hypokalemia (each 33.3%). The most common serious AE was febrile neu-
tropenia (33.3%). No clinically significant tumor lysis syndrome was observed.
The overall response rate in phase 1 was 44% (complete remission, n=4; com-
plete remission without complete marrow recovery, n=4; resistant disease, n=8;
death before evaluation, n=2).
Summary/Conclusions: Initial findings suggest that VEN+LDAC has accept-
able tolerability and promising clinical activity in older, treatment-naïve AML
pts. Available phase 2 updates will be presented.
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CLINICAL OUTCOME AND EFFECT OF ALLO-SCT IN ADULT PATIENTS
WITH DE NOVO OR AML-RELATED MYELOID SARCOMA. RESULTS
FROM AN ITALIAN MULTICENTER SURVEY
D Lazzarotto1,*, A Candoni1, C Filì1, F Forghieri2, L Pagano3, G Spinosa4,
A Busca5, E Borlenghi6, L Melillo7, F Mosna8, F Lessi9, ME Zannier1, E Simeone1,
R Fanin1
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Foggia, Foggia, 5Division of Oncology, Hematology and Stem Cell Transplan-
tation, University of Torino, Torino, 6Division of Hematology, Spedali Civili di
Brescia, Brescia, 7Division of Hematology, IRCCS San Giovanni Rotondo, San
Giovanni Rotondo, 8Division of Hematology, Hospital of Treviso, Treviso, 9Divi-
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Background: Myeloid Sarcoma (MS) is a rare hematologic myeloid neoplasm
that can involve any site of the body. It can occur as isolated “de novo”
extramedullary form or it can be associated with an acute myeloid leukemia
(AML), a chronic myeloproliferative neoplasm (MPN) or a myelodysplastic syn-
drome (MDS) at onset or at relapse (secondary MS).
Aims: The rarity of MS does not enable prospective clinical trials and therefore
a specific multicenter register can be very useful for the clinical and biological
studies of this rare disease.
Methods: We report the clinical characteristics and outcome of 53 histologically
confirmed MS, diagnosed and treated in 9 Italian Hematological Centers in the
last 10 years (2005-2015).
Results: The median age of these patients (pts) was 47 years (range 15-82)
and 30 (56.6%) were male. There were 9/53 de novo extramedullary MS, 24/53
primary AML-related MS and 20/53 were secondary MS (the median time to
the onset of MS from the previous haematologic disease was 34.5 months,
range 4–94). Histologic and biologic data are available in all cases. The most
common extramedullary anatomic sites of disease were: skin, lymph nodes,
soft tissues, bone and testis. Treatment: 46/53 pts (86.8%) underwent a pro-
gram of intensive chemotherapy (combined with radiotherapy in 16/46 cases)
including FLAI, HDAC-IDA, HyperCVAD and MEC schemes, with a CR Rate
of 43.5% (20/46). Twenty-four (52.2%) pts underwent Allo-SCT, 9 from an HLA-
identical sibling donor, 2 from an haploidentical donor and 13 from a MUD.
The median OS of the whole population (53 pts) was 16.7 months with no dif-
ferences between de novo extramedullary MS and AML-related MS (p=0.71).
The OS probability at 5 yrs was 33,8%. The survival was significantly better in
the pts that underwent an intensive therapeutic program (median OS: 18.3
mths vs 5.4 mths, P=0,006). Furthermore, among the intensively treated pts,
the survival was better in those pts that underwent Allo-SCT (median OS not
reached vs 10.6 mths, P=0,001), in pts with de novo or primary MS (median
OS 20.4 mths vs 10.6 mths of the secondary MS, P=0,012) and in the pts that
achieved a CR after induction chemotherapy (median OS not reached vs 14.6
mths, P=0,07) without differences between de novo extramedullary MS and
AML-related MS (p=0.76). In multivariate analysis, Allo-SCT and Response to
Induction therapy, were the only significant variables in predicting survival
(P=0,002 and P=0,037, respectively). The median post-transplant OS of the
Allo-SCT recipients was not reached after a median follow-up of 17.5 months
and we observe a survival advantage in the patients who achieved a pre-trans-
plant CR (P=0,042) and in the patients who developed a chronic GvHD after
Allo-SCT (P=0,065).
Summary/Conclusions: The pts with isolated MS result to have a similar
unfavourable outcome than the patients with AML-related MS. These data out-
line the need of underwent an intensive therapeutic program that includes Allo-
SCT, whenever possible, both in isolated extramedullary MS and in AML-related
MS. The outcome after Allo-SCT is positively influenced by the development
of chronic GvHD suggesting a Graft versus MS effect.
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OVEREXPRESSION OF ADAM28 ENHANCES ACUTE MYELOID
LEUKEMIC CELL MIGRATION AND INCREASES THE GROWTH OF
XENOGRAFT TUMOURS IN MICE
XH Zhang*, CC Wang, JM Zhang, Q Jiang, H Jiang, J Lu, YJ Chang, XS Zhao,
XY Zhao, LP Xu, KY Liu, XJ Huang
Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Acute myeloid leukemia(AML) is fatal as a result of primaryre-
fractoriness, relapse, or treatment-related mortality. Cytogenetics is the most
powerful predictor of prognosis in AML, and integrating additional genetic data
may further improve predictive capabilities. A disintegrin and metalloproteinases
(ADAMs) are involved in various biological events, including cell adhesion, cell
fusion, membrane protein shedding, and proteolysis.Our previous study has
demonstrated that the expression level of ADAM28 is significantly elevated in
relapsed ALL patients and is regulated via a PI3K/Akt signalling pathway.We
hypothesized that overexpression of ADAM28 might contribute to invasion and
metastasis in adult AML, promoting thetumourigenicity potential andproliferation
of AML cells.
Aims: To investigate whether overexpression of ADAM28 was associated with
relapse in de novo AML patients, we performed this prospective clinical study
and explored the functions and regulation of ADAM28 overexpression in vitro.
Methods: The mRNA expression of ADAMs in the bone marrow of de novo
AMLpatients was measured by qPCR. ADAM28 expression levels in BM, serum
and cerebrospinal fluid were also measured. Twenty-three healthy donors as
controls and 200 AML patientswere included in our group. The cumulative inci-
dence of relapse (CIR),overall survival (OS) and event-free survival (EFS) after
a 3-year follow-up were used to evaluate prognosis.Primary AML cells and dif-
ferent AML cell lines were cultured to examine the expression of ADAM28 in
vitro. ADAM28-specific cDNA and siRNA were designed and established.
Leukemic cell migration was measured using modified Boydenchambers.A
nude mouse model was established to measure the effect of ADAM28 on thetu-
mourigenicity of leukemic cells in vivo. The expression of Ki-67 and PCNA was
detected to measure proliferation.
Results: In general, mRNA expression of ADAM28 displayed the most signif-
icant differences between patients and healthy donors among the ADAMs
detected.The expression of ADAM28 was significantly increased in AML
patients compared with healthy donors. Patients suffering relapse exhibited
significantly higher expression levels of ADAM28 compared with those who
remained in complete remission. Patients with CNSL also demonstrated sig-
nificantly increased ADAM28 expression in the CSF and serum compared with
non-CNSL patients. The Kaplan-Meier survival curve showed that EFS was
shorter andCIR was higher in patients with high expression levels of
ADAM28.The results showed that age, karyotype and ADAM28 level are inde-
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pendent risk factors for OS and EFS.In vitro, the expression of ADAM28 was
relatively higher in primary blast cells and SHI-1 cells, which were selected for-
subsequentprocedures. Overexpression of ADAM28 promoted the proliferation
and invasiveness of SHI-1 cells and primary blast cells transfected with
ADAM28 cDNA; in contrast, knockdown of ADAM28 expression inhibitedpro-
liferation and invasiveness.Following subcutaneous injection into nude
mice,ADAM28 knock-down cells displayed an inhibited tumourigenicity poten-
tial, whereas ADAM28-overexpressingcells presented largerxenograft tumours.
Summary/Conclusions: Our findingsdemonstrate that overexpression of
ADAM28 in AML patients is correlated to relapse; patients with higher levels of
ADAM28 have a higher CIR. Overexpression of ADAM28 can enhance cell
proliferation and migration, as well as tumourigenicity. These data suggest that
ADAM28 may be a novel biomarker for predicting the prognosis of AML, poten-
tially providing a new therapeutic target.
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PROLONGED SURVIVAL IS ACHIEVABLE FOR A QUARTER OF PATIENTS
IN PRIMARY INDUCTION FAILURE FOR ACUTE MYELOID LEUKEMIA, BUT
DOES NOT RELY ON REPEATED SALVAGE THERAPY-A MONOCENTRIC
RETROSPECTIVE STUDY
MP Ledoux*, C Fohrer-Sonntag, C Simand, B Merle, S Natarajan-Amé,
LM Fornecker, B Lioure
Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background: Response to first induction chemotherapy is a strong prognostic
factor in patients with newly diagnosed acute myeloid leukemia (AML) eligible
for intensive treatment. Primary induction failure (PIF) leads to an escalation of
therapeutic means, the benefit of which remains controversial.
Aims: Allogeneic hematopoietic stem cell transplantation (HSCT) appears to
be the most appropriate consolidation treatment to lower relapse risk but deter-
mining its best timing is still a challenge: disease-free (DFS) and overall sur-
vivals (OS) are known to be better if allogeneic HSCT is done in complete
remission (CR), but earlier transplant is usually associated with a better out-
come. These two conditions seem to pull in opposite directions in PIF AML.
Methods: We therefore conducted a retrospective monocentric study analyzing
the outcome of all adult patients with newly diagnosed AML in Strasbourg Uni-
versity Hospital between 2002 and 2014 and failing to achieve remission after
first induction.
Results: Of 704 AML patients, 394 (56.0%) received intensive chemotherapy,
and 90 (22.8%) were considered PIF. Sixty-three of these patients (70.0%)
received further intensive treatment, enabling a median OS of 418 days, com-
pared to 65 days for patients on palliative care and 253 days for patients receiv-
ing hypomethylating agents only (p<0.001). Salvage chemotherapy led to CR
in 40% of patients, and those having received an allogeneic HSCT while still
on CR reached a median OS of 2068 days, with a three-year survival of 57.4%.
Patients in CR after salvage therapy but who were not subsequently trans-
planted had a median OS of only 551 days. Patients receiving more than one
salvage chemotherapy before being transplanted had a median OS of 418
days, compared with 467 days for patients who were transplanted while refrac-
tory without or after only one salvage therapy (p=0.7). Among the 23 patients
still refractory at transplantation, allogeneic HSCT eventually led to remission
in 20 patients (87%), but with a high subsequent relapse rate. Allogeneic HSCT
in refractory patients led to a median OS of 467 days, with three-year survival
reaching 25.6%. On the whole, the three-year survival rate of the 38 patients
who received an allogeneic HSCT was 39.5% compared with 2% for the 52
patients who did not undergo transplantation.
Summary/Conclusions: Continuing intensive treatment of AML after primary
induction failure is still the better therapeutic option in terms of survival for fit
patients: we have observed that it can result in prolonged survival, and perhaps
cure, for roughly a quarter of them, supporting this approach. However, con-
sidering our data, receiving more than one salvage chemotherapy doesn’t
appear to lead to a better outcome and may impair the rate of allogeneic HSCT.
This might eventually affect the outcome of refractory patients, since allogeneic
HSCT is a crucial step in their management. Although survival is consistently
lower for patients lacking CR, allogeneic HSCT for refractory patients still offers
prolonged survival to a significant proportion of PIF AML patients in spite of
their initial dismal prognosis.
E915
IMPACT OF SINGLE NUCLEOTIDE POLYMORPHISMS OF ABCB1 GENE UPON
THE EFFECTIVENESS AND TOXICITY OF INDUCTION CHEMOTHERAPY
IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
JE Megías-Vericat1,*, P Montesinos2, MJ Herrero1, F Moscardó2, V Bosó1,
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Investigación Sanitaria La Fe, 4Pharmacogenetic Unit, Medicament Clinical
Area, 5Pharmacogenetic Unit, Medicament Clinical Area; Clinical Pharmacology
Unit; and Pharmacology Department, Medicine Faculty, Valencia University,
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Background: The intake of anthracyclines in blast cells could be affected by
efflux pumps of ABC family.
Aims: Previous studies suggested that single nucleotide polymorphisms
(SNPs) of ABCB1 may influence anthracycline effectiveness in acute myeloid
leukemia (AML) induction therapy, although their impact in induction death and
anthracycline-related organ toxicity.
Methods: The SNPs of ABCB1 gene (rs1128503, rs1045642, rs2032582 and
haplotype) were evaluated in 225 adult patients at initial diagnosis from AML
using a Sequenom (iPLEX) mass spectrometry–based multiplex genotyping
assay (Sequenom, San Diego, CA). All patients received induction chemother-
apy consisting of idarubicin plus cytarabine (PETHEMA-LMA 99, 2007 and
2010 trials). Efficacy of first induction cycle was evaluated comparing complete
remission (CR) vs partial remission (PR) or resistance, excluding these patients
dying during induction. Induction death was defined as patients dying during
induction against CR, excluding these patients with PR or resistance. Based
on WHO grading scale, toxicities were grouped as binary variables (grade 0-1
vs grade 2-4). The grade of toxicity assigned to an organ group was the max-
imum grade of all the specific toxicities within that group. Genotypes were stud-
ied with a co-dominant model. Association between variables was assessed
using linear and logistic regression adjusting for age, gender, cytogenetic risk,
ECOG, leukocyte and platelet count, hemoglobin, creatinine, bilirubin, albumin
and LDH level at diagnosis (R® version 3.1.2).
Results: The median age of patients was 51.1 years (16-78 years). There were
no statistically significant differences in CR. Nevertheless, induction death was
associated to ABCB1 triple variant haplotype (40.0% vs 17.2%; OR: 0.2; 95%CI:
0.05-0.8; P=0.017). Besides, the ABCB1 triple variant haplotype was related to
more nephrotoxicity than the other genotypes (OR: 3.6; 95%CI: 1.3-10.4;
p=0.016). The variant alleles of ABCB1 rs1128503, rs2032582 and recessive
haplotype were also related to hepatotoxicity (OR: 6.9; 95%CI: 2.2-21.2; p= 0.001;
OR: 2.9; 95%CI: 1.01-8.1; p=0.049; OR: 6.0; 95%CI: 2.1-16.3; p<0.001; respec-
tively). Regarding hematologic toxicity, time to neutropenia recovery was delayed
with variant allele of ABCB1 rs2032582 (OR: 3.0; 95%CI: 1.1-10.1; P=0.047).
Summary/Conclusions: The variant alleles of ABCB1 polymorphisms have
been related to lower anthraclycline clearance and higher tissue exposure. This
could be the reason of the higher toxicity and induction death observed. This
study shows a prognostic impact of ABCB1 polymorphisms in adult AML
patients regarding induction chemotherapy toxicity. Further studies with larger
population are needed to validate these associations, which could be useful
biomarkers in clinical practice. Study supported by grants from the “Instituto
Carlos III” (PIE13/00046), “Instituto Investigación Sanitaria La Fe” (2013/0331)
and the Cooperative Research Thematic Network (RTICC), Grant
RD12/0036/014 (ISCIII & ERDF). Samples have been managed by the La Fe
Biobank, licensed as required by Spanish Royal Decree 1716/2011 of 18
November (Ref.: PT13 / 0010/0026).
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CLEARANCE OF NPM1 MUTATION AT FIRST COMPLETE REMISSION
AFTER INDUCTION THERAPY DID NOT PREDICT THE SURVIVAL IN
FAVORABLE RISK GROUP WITH NORMAL KARYOTYPE ACUTE
MYELOID LEUKEMIA
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Background: The presence of minimal residual disease is known to be an
independent prognostic factor for the duration of remission and survival in acute
myeloid leukemia (AML). However, since AML has a molecular heterogeneity,
the routine assessment of minimal residual disease (MRD) has not been adopt-
ed in the current practice of patients with AML.
Aims: Herein, we evaluated the NPM1 mutation as a marker of MRD at first
complete remission (CR) after induction therapy in normal karyotype AML (NK-
AML) with favorable molecular risk group.
Methods: A total of 413 patients were included in the present study who met
the following eligibility criteria: 1) age ≥15 years; 2) a diagnosis of NK-AML
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confirmed by conventional cytogenetic analysis; 3) treatment with induction
chemotherapy using a standard protocol (a 3-day course of anthracycline with
a 7-day course of cytosine arabinoside). Analysis of NPM1 mutations were
performed using targeted resequencing by SureSelect capture and Illumina
platform technology. The 184 patients (44.6%) showed NPM1 mutation at diag-
nosis and, 99 patients were NPM1 mutated and FLT3-ITD negative (favorable
molecular risk by ELN). We have focused on the prognostic impact of NPM1
MRD esp. in the group with favorable risk by ELN risk classification. The 52
out of 99 favorable risk patients were available the analysis of NPM1 mutations
at CR samples.
Results: In 52 patients, 37 patients (71.2%) were negative (NPM1MRD-) and,
15 patients (28.8%) persistently observed the NPM1 mutations (NPM1MRD+)
in CR samples. There was no difference in variant allele frequencies of NPM1
mutations at diagnosis between NPM1MRD- vs NPM1MRD+ (32.7% [range, 6.85-
43.9] vs 36.8% [range, 25.0-48.7], p=0.168). There was no difference in gender
(p=0.754) or age (p=0.545). However, WBC count in NPM1MRD- group (median:
15.3 x 10^9/L, range: 0.9-142.0) was lower than in the NPM1MRD+ group (medi-
an: 81.1 x 10^9/L, range: 1.7-224.6.0), (p=0.014). In 15 out of 52 patients
received allogeneic stem cell transplantation (SCT), there was no difference of
proportion of patients receiving allotransplant between NPM1MRD- vs
NPM1MRD+ group (21.7% vs.20.0%, p=0.897). In the survival analysis accord-
ing to the MRD of NPM1 mutation, there was no difference between NPM1MRD-
vs NPM1MRD+ group in terms of 5-year overall survival (OS) (NPM1MRD- vs
NPM1MRD+, 66.1% vs.72.7%, p=0.699) and 5-year event free survival (EFS)
(NPM1MRD- vs NPM1MRD+, 57.1% vs.61.1%, p=0.596). There was no differ-
ence in relapse risk at 5-year (NPM1MRD- vs NPM1MRD+, 36.4% vs.32.2%,
p=0.509). Regardless of clearance of NPM1 mutations, allogeneic SCT sub-
stantially reduced the relapse risk (p=0.007). However, allogeneic SCT did not
confer to overall survival benefit due to higher non-relapse mortality (p=0.046).
Summary/Conclusions: In this cohort, clearance of NPM1 mutation at first
CR in favorable risk group of NK-AML was not replicated as a prognostic marker
to predict the survivals or relapse risk. Even in patients with NPM1 positive at
first CR in favorable molecular risk group, the most of patients demonstrated
long term survival even with consolidation chemotherapy without allogeneic
transplantation. To clarify the role of clearance of NPM1 mutations, further
analysis after consolidative therapy will be needed.
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VALIDATING THE PATIENT’S “FITNESS” CRITERIA PROPOSED TO
GUIDE TREATMENT DECISION IN ELDERLY AML: A MULTICENTER
STUDY ON A SERIES OF 699 PATIENTS BY THE NETWORK “RETE EMA-
TOLOGICA LOMBARDA”
E Borlenghi1, C Pagani1,*, C Basilico2, M Bernardi3, R Cairoli4, A Cortelezzi5,
M Davia6, A Ferrario2, N Fracchiolla5, L Marbello4, C Messina3, A Santoro7,
E Todisco7, M Turrini8, P Zappasodi6, C Cattaneo1, C Lamorgese1, G Rossi1
1Hematology, ASST Spedali Civili, Brescia, 2Hematology, ASST dei Sette Laghi,
Presidio di Varese Osp Circolo Fondazione Macchi, Varese, 3Hematology and
BMT Unit, San Raffaele Scientific Institute, 4Hematology, ASST Grande
Ospedale Metropolitano Niguarda, 5Hematology, Ca Granda Ospedale Mag-
giore Policlinico, Milano, 6Hematology, Policlinico San Matteo, Pavia, 7Hema-
tology, Istituto Clinico Humanitas-Cancer Center, Rozzano (Mi), 8Hematology,
Ospedale Valduce, Como, Italy
Background: Treatment of elderly patients (pts) with acute myeloid leukemia
(AML), is still controversial. In 2013 an Italian panel of experts proposed a set
of objective criteria to define pts fit or unfit to conventional intensive chemother-
apy (iCT) or non intensive therapy (niT) (Ferrara et al, Leukemia, 2013). Since
such criteria derived from experts opinion, they need to be validated in the clin-
ical setting to become an useful tool for therapy decision making.
Aims: Fitness criteria were applied to a population-based series of pts with
AML (not M3), to retrospectively evaluate their actual applicability, their con-
cordance with the treatment actually given, and the outcome of pts according
to “fitness”, leukemia biology and treatment.
Methods: We evaluated 699 pts aged >65 y, diagnosed between 2008 and
2015, at 8 Centres of the Hematological Network of Lombardy (REL). AML was
de novo in 419 pts and therapy-related or secondary to myeloid neoplasms (s-
AML) in 280 pts; median age was 74 (range 65-96). The categorization accord-
ing to “fitness” criteria was carried out retrospectively by physicians who had
followed pts and through medical files. Pts were defined as fit to iCT (FIT),
unfit to iCT (UNFIT), or unfit even to niT (FRAIL). ELN prognostic criteria could
be applied to 117 (27.9%) de novo AML [12.2% favorable-risk (fav) (CBF 4.6%),
32.5% intermediate-1 (int1), 14.2% intermediate-2 (int2), and 36.4% adverse
(adv) risk]. Karyotype (K) was adverse (ELN) in 193 (36%) of 537 evaluable
AML. According to physicians decision, 274 pts (39.2%) received iCT, 134 pts
(19.2%) niT, including low-dose ara-c, hypomethylating agents or experimental
non-myelotoxic drugs, and 291 pts (41.6%) best supportive care (BSC).
Results: Fitness criteria were not applicable in 13 pts (1.9%), because of insuf-
ficient data. Among 686 evaluable pts, 292 (42.5%) were FIT, 289 (42.1%) UNFIT,
and 105 (15.3%) FRAIL. Median age was 69, 78 and 76 y, respectively
(p<0.0001). Median overall survival (OS) of FIT, UNFIT and FRAIL pts was 10.9,
4.2 and 1.8 months (m), respectively (p=0.000) (Figure 1). According to ELN
risk, median OS was 17.5, 14.1, 8.0, 9.8 m, in fav, int1, int2 and adv risk de novo
AML, respectively (p 0.008). Median OS was 12.6 and 5.9 m in not-adv and adv
K, respectively (p 0.002).Overall concordance between “fitness criteria” and the
treatment actually received by pts was 79.4% (76% in FIT, 82.7% in UNFIT and
80% in FRAIL pts). There was a significant interaction between disease biology
and treatment actually given. FIT pts receiving niT had a higher proportion of
adv K (66%) than pts receiving iCT (19%). In FIT pts median OS was best with
iCT, being significantly longer than in pts actually “undertreated” (11.6 m with iCT
vs 7.6 m with niT or BSC; p 0.006). In UNFIT pts median OS was 8.7, 9.2, 2.5 m
with iCT, niT and BSC, respectively. It was significantly worse in patients actually
“undertreated” with BSC only (p 0.0001), but “overtreating“ UNFIT pts with iCT
did not improve OS. Among FRAIL pts, “overtreatment” using niT didn’t improve
OS compared to BSC (2.9 vs 1.5 m, p:ns).
Figure 1.
Summary/Conclusions: The “fitness criteria” proposed were easily applicable
even retrospectively and in a multicenter setting. Overall concordance between
“fitness criteria” and treatment actually received by pts was high (79.4%). Fitness
was significantly related to patient’s survival. The “fitness criteria” could correctly
identify patients most likely to benefit from different treatment intensities or BSC.
Knowing biologic risk profile may further refine treatment decisions.
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CLINICAL CHARACTERISTICS AND OUTCOME OF PEDIATRIC ACUTE
MYELOID LEUKEMIA WITH DEL(5Q): A REPORT FROM THE JAPANESE
PEDIATRIC LEUKEMIA/LYMPHOMA STUDY GROUP
A Kinoshita1,*, T Taki2, Y Hayashi3, H Miyachi4, H Matsushita4, M Yabe5,
D Tomizawa6, H Takahashi7, A Tawa8, K Horibe9, T Taga10, S Adachi11
1Pediatrics, St Marianna University School of Medicine, Kawasaki, 2Molecular
Diagnosis, Kyoto Prefuctural University of Medicine, Kyoto, 3Pediatric hema-
tology/oncology, Gumma Children’s Hospital, Maebashi, 4Laboratory Medicine,
Tokai University School of Medicine, 5Laboratory Medicine, Tokai University of
Medicine, Isehara, 6Children’s Cancer Center, Natinal Center of child health
and development, 7pediatrics, Toho University, Tokyo, 8Pediatrics, Natinal Hos-
pital Organaization, Osaka Medical Center, Osaka, 9Clinical Research Center,
Natinal Hospital Organaization, Nagoya, Nagoya, 10Pediatrics, Shiga Unversity
of Medical Science, Ohtsu, 11Human Health Science, Kyoto University, Kyoto,
Japan
Background: Deletion of chromosome 5q (5q-) confer a poor prognosis in
adults with acute myeloid leukemia (AML) and associated with higher white
blood cell count at diagnosis. However, since this chromosomal abnormality is
rare in pediatric patients with AML, the clinical characteristics and prognostic
significance are not clear. 
Aims: To clarify AML with 5q- in terms of hematological and clinical character-
istics, and prognosis. 
Methods: Between November 2006 and December 2010, 485 consecutive
patients aged<18 years with suspected AML excluding acute promyelocytic
leukemia, Down syndrome, secondary AML, myeloid/natural killer cell leukemia,
and myeloid sarcoma were registered in AML-05 conducted by the Japanese
Pediatric Leukemia/Lymphoma Study Group. The diagnosis according to the
2008 WHO classification was determined centrally by integrating morphologic,
cytogenetic, immunologic, molecular and clinical parameters. We stratified
patients after the second induction course to either of the three risk groups
according to the cytogenetics and FLT3-ITD status at diagnosis and the
response to induction chemotherapy. Allogeneic hematopoietic transplantation
(HSCT) was planned for the patients allocated for the high risk group including
5q- after the third or fourth chemotherapy course.
Results: Of the 485 patients registered, 32 patients were excluded because
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of misdiagnosis or refusal by the guardians. Of the 453 eligible patients, a total
of 11 patients (2.4%) were identified as AML with 5q-. The table 1 shows cyto-
genetic data for the 5q- patients. All patients with 5q- had unrelated chromoso-
mal abnormalities >3 and were therefore diagnosed as AML with myelodyspla-
sia-related changes. Median age at diagnosis was 1.9 years (range, 0.2-13.8)
and median WBC count at presentation was 28.1×109/l(range, 2.1-50.7). Any
significant differences were seen in age and WBC count compared to those
without 5q-. Of the 11 patients, 7 (64%) had a complete response (CR) to induc-
tion chemotherapy. Of the 4 patients with induction failure, 2 were treated with
HSCT and were alive. Of the 7 patients achieving CR, bone marrow relapse
was recognized in 5, 2 of whom were alive after HSCT. Excluding patients with
core binding factor leukemia, the 3-year event-free survival for patients with
5q- was significantly lower than for those without 5q- (18% versus 56%,
P=0.02). However, the 3-year overall survival was not significantly different
between patients with 5q- and those without 5q- (54% versus 70%, P=0.07).
Table 1.
Summary/Conclusions: Our study suggests that AML with 5q- has a poor
prognosis, but that intensive therapy including HSCT may improve outcome in
children with AML with 5q-.
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DOSE ESCALATION STUDY OF CRENOLANIB IN COMBINATION WITH
HIGH DOSE CYTARABINE/IDARUBICIN SALVAGE CHEMOTHERAPY IN
MULTIPLY RELAPSED FLT3 POSITIVE AML
J Cortes1,*, F Ravandi1, G Garcia-Manero1, T Kadia1, G Borthakur1, M Konopleva1,
N Daver1, N Pemmaraju1, E Jabbour1, Z Estrov1, T Phung2, V Urity2,
A Uchida2, J Paradela1, M Andreef1, H Kantarjian1
1The University of Texas MD Anderson Cancer Center, Houston, 2Arog Phar-
maceuticals Inc, Dallas, United States
Background: FLT3 inhibitors usually provide transient clinical benefit to patients
with FLT3-mutated AML. FLT3 inhibitor-based combination therapy has been
suggested to enhance such benefit. Crenolanib is a novel, type I, oral pan-
FLT3 inhibitor with high single-agent activity against multiply relapsed FLT3-
ITD and tyrosine kinase domain (TKD) mutant AML. We here report interim
data from a Phase I trial to evaluate the safety and efficacy of salvage therapy
with high dose cytarabine/idarubicin followed by crenolanib in multiply relapsed
FLT3+ve AML.
Aims: Dose escalation study to determine the maximum tolerated dose (MTD)
of crenolanib when combined with high dose cytarabine+idarubicin.
Methods: Pts >18y with refractory/relapsed FLT3 ITD and/or TKD+ve AML are
eligible. Pts receive salvage therapy with high dose cytarabine (1.5 g/m2/day
over 3 hours for 4d or for 3d if >60y) along with idarubicin (12 mg/m2 for 3d).
Daily crenolanib starts from d5 and is continued until 72hrs prior to next
chemotherapy regimen. The starting dose cohort of crenolanib is 60 mg TID
and is then escalated in subsequent cohorts to 80 mg TID and 100 mg TID. Pts
may receive consolidation with cytarabine (750mg/m2 for 3d) and idarubicin (8
mg/m2 for 2d) followed by daily crenolanib. Crenolanib may be administered
for maintenance for up to 365 days.
Table 1.
Results: To date, 11 pts (10 males, 1 female) have been enrolled with a median
age of 43 (range 19-70). Pts were heavily pre-treated with a median of 3 prior
systemic treatments (range: 1-9). 8/11 pts had received prior investigation
agents including 6 with prior FLT3 inhibitors. Three pts had undergone allo-
geneic SCT. Besides FLT3, multiple other leukemia associated mutations were
present at baseline: NPM1 (40%), DNMT3A (40%), WT1 (30%), TET2 (30%),
NRAS/KRAS (30%), IDH2 (20%), NOTCH1 (20%), MLL (20%), RUNX1 (10%),
ASXL1 (10%) and EZH2 (10%). All 3 pts treated with cytarabine/idarubicin fol-
lowed by crenolanib 60 mg TID tolerated the regimen well with no DLTs. Two
achieved a CR (including one who became FLT3 negative after reinduction).
Both these patients have undergone an allo SCT. 5 pts received cytarabine/
idarubicin followed by crenolanib 80 mg TID. One of the three evaluable pts in
this cohort achieved a CRi and has undergone SCT. The patient with ETP-ALL
had no response. No pt required dose reduction in the 80mg TID cohort. All 3
pts in crenolanib 100mg TID cohort have now completed cytarabine/idarubicin
salvage and are receiving crenolanib (but are too early for assessment of
response).
Summary/Conclusions: Crenolanib can be safely administered with
HiDAC/idarubicin salvage chemotherapy in multiply relapsed AML. 3 patients
have achieved a CR/CRi which allowed them to be bridged to an allo SCT.
Accrual to this trial will continue at the crenolanib 100 mg TID dose.
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QUANTIFICATION OF COMMON AND RARE NPM1 SUBTYPES USING A
SINGLE MASSIVELY MULTIPLEX DIGITAL PCR ASSAY FOR MINIMAL
RESIDUAL DISEASE IN AML
N Mencia Trinchant*, Y Hu, F Ali, ML Guzman, GJ Roboz, DC Hassane
Weill Cornell Medicine, New York, United States
Background: Acute myeloid leukemia (AML) is a fatal disease with poor out-
comes. Despite initial remissions, most patients relapse and ultimately succumb
to their disease. The presence of minimal residual disease (MRD) in patients
has been shown to be predictive of relapse and thus is likely to better inform
therapeutic decision-making. Improved assessment methods are therefore
urgently needed. Molecular assessment of MRD has been accomplished using
a number of markers including NPM1 mutations (NPM1mut). The vast majority
of NPM1 mutations are four nucleotide insertions in exon 12, the most common
of which is type A (c.860_863dupTCTG), found in approximately 75% of NPM1
mutated AML patients. The remaining patients often have rarer subtypes with
differing and often patient-specific insertion polymorphisms with over 50 such
polymorphisms being reported. Currently, real time quantitative PCR (RQ-PCR)
is used to assess mutant NPM1 percentages. However, RQ-PCR requires cus-
tom assays and development of plasmid standards tailored to each subtype.
RQ-PCR assays have been adapted to digital PCR (dPCR) to eliminate the
need for plasmid standards, but custom primers and/or probes are still needed.
Moreover, in diagnostic cases where NPM1mut diagnosis is made by capillary
electrophoresis without sequencing, subtype information is absent and MRD
cannot be assessed reliably with standard approaches. To overcome these
obstacles, we demonstrate a massively multiplex dPCR assay that operates
on >95% of NPM1 polymorphisms without requiring prior knowledge of the spe-
cific polymorphism and is robust to NPM1 evolution and mixtures of NPM1
mutant clones.
Aims: To determine if a single assay can consistently quantify NPM1mut per-
centages in a manner that is robust to NPM1 subtype.
Methods: AML samples and synthetic reference standards with varying NPM1
mutations were quantified as NPM1 mutant copies per ABL1 copies
(NPM1mut/ABL1). Subtype-specific assays were compared to massively mul-
tiplexed dPCR assay. Agreement between NPM1mut/ABL1 measurements was
assessed in parallel using both methods.
Results: NPM1 mutant copies were quantified using massively multiplexed
dPCR assay alongside subtype-specific assays. The massively parallel dPCR
assay demonstrated excellent correlation with subtype-specific assays (r >0.95;
Pearson’s correlation), including rare subtypes such as NPM1-DD1. We addi-
tionally assessed mixtures of subtypes alongside standard assays. In such
mixtures, our massively multiplexed assay correctly ascertained NPM1mut/
ABL1 ratios whereas standard subtype-specific assays underestimated
NPM1mut/ABL1 ratios, demonstrating the robustness and accuracy of this
assay in samples with mixtures of NPM1 mutants. Sensitivity was comparable
with standard subtype-specific assays without cross-reactivity to wild-type
NPM1.
Summary/Conclusions: Massively multiplexed dPCR inexpensively allows a
single assay to detect the vast majority of NPM1 mutations both common and
rare. The quantification is largely impervious to NPM1 evolution/polyclonality
and greatly diminishes the need for subtype-specific assays with custom primer
sets and plasmid standards. It is therefore a useful strategy for the follow up of
AML patients diagnosed with NPM1mut AML in MRD assessment.
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A SIMPLE 3-GENE MOLECULAR SCORE RETAINS HIGH PROGNOSTIC
VALUE IN NON HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA TREATED
WITH AIDA 2000 PROTOCOL: A RETROSPECTIVE STUDY FROM A
REGIONAL REGISTER
D Guardo*, F Guolo, P Minetto, E Coviello, M Gambella, G Rivoli, N Colombo,
M Miglino, F Ballerini, M Clavio, RM Lemoli, M Gobbi
Chair of Hematology, Departement of Internal Medicine (DiMI), University of
Genoa, IRCCS AOU San Martino IST, Genoa, Italy
Background: Non high risk acute promyelocytic leukemia (APL) patients, as
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defined by WBC count at diagnosis, have nowadays a very good prognosis
when treated with ATRA plus chemotherapy based protocols, with high rate of
complete molecular remission after consolidation therapy. However, a small
portion of patients (roughly 10%) will eventually relapse, despite the achieve-
ment of molecular CR. In the past years, some groups showed that relapse
risk could be predicted by testing for some gene alterations, such as FLT3-
ITD, or by break point cluster region (BCR) analysis. However, those results
were not confirmed in prospective trials.
Aims: We recently showed that a simple gene-expression panel including WT1
and BAALC expression levels analysis has high prognostic value in MDS
patients. The aim of the present study was to evaluate if the application of a
similar panel to APL patients at diagnosis could be predictive of relapse risk
and survival.
Methods: We retrospectively applied a simple 3 gene based molecular panel
including WT1 and BAALC expression levels at diagnosis, FLT3-ITD mutational
status (molecular profile), alongside with BCR analysis, to a cohort of de novo 66
non high-risk acute promyelocytic leukemia patients, treated in our institution
between January 1st 2004 to June 30th 2015. All patients have been treated
according to the Italian age-adapted AIDA protocol. Median age was 47 years
(range 16-88), 17 patients were older than 60 years. Median follow up was 58
months. BCR analysis was available in all patients, 43 patients showed BCR1/2,
whereas 23 patients had BCR3 (35%). Molecular profile was available in 44/66
patients (66%). Cut-off values for WT1 (25000/Abl x 10-4) and BAALC (450/Abl
x 10-4) were arbitrary chosen after pre-analysis and comparison with our published
data. Seven patients had FLT3-ITD mutation (17%), 18 (45%) patients had high
WT1 expression levels and BAALC was overexpressed in 9 (23%) patients.
Results: Sixty-three patients survived induction, all of them achieved CR.
Among patients who had completed the whole therapeutic program at the time
of the analysis 2 showed molecular persistence of disease and therefore
received further therapy achieving molecular CR. Ten patients experienced
disease relapse (15%). Pre-analysis showed that FLT3-ITD, not over-
expressed WT1 levels, high BAALC levels but not the presence of BCR3 were
associated with higher relapse risk. None of the molecular alterations reached
statistical significance if taken alone. Therefore a molecular score including
those 3 genes was built: 18 patients had no risk factor, 20 had one risk factor
and 6 had two risk factors. Relapse risk was influenced only by the presence
of at least one molecular risk factor (p<0.05). Disease free survival (DFS) dura-
tion was significantly higher in patients who had no molecular risk factor when
compared to patients with at least one (3-years DFS of 100% and 85%, respec-
tively, p<0.05). Overall survival (OS) analysis led to similar results: patients
with no molecular risk factors had a very good outcome when compared to
patients with at least one alteration (3-years OS of 100% and 79% respectively,
p<0.03). Furthermore, we observed that both in DFS and OS analysis, the
presence of two molecular factors leads to a worse outcome compared to the
presence of only one alteration (p<0.05).
Figure 1.
Summary/Conclusions: Even in a small cohort, we demonstrate how a simple
molecular profile, including FLT3-ITD and levels of expression of BAALC and
WT1 could identify a subset of standard APL patients at higher risk of relapse.
Sub-stratification of patients could allow us to recognize patients who may take
benefit from an intensified consolidation therapy, as it is currently applied to
high risk patients, in order to reduce risk of relapse.
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ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS (≥70 YRS):
SEMI-INTENSIVE INDUCTION AND CONSOLIDATION WITH MAINTE-
NANCE TREATMENT (1-YR) IN OUTPATIENT BASIS
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Background: The results of AML treatment in patients’ ≥70 years are disap-
pointing. Finding tolerable and efficacious treatments remains a major chal-
lenge. Intermediate dose cytarabine schedules in combination with other drugs
allow treating patients in an outpatient basis. 
Aims: The CETLAM04LAM70 semi-intensive protocol (Eur J Haematol.
2015;95:576-82) aimed to achieve a significant proportion of durable remissions
in elderly (≥70 years) patients with AML based on reduction of the toxicity of
full dose cytarabine. Despite this, toxicity and deaths in consolidation were of
concern. In the current protocol (CETLAM11LAM70) intensive consolidations
were substituted by 1 year of 5-azacitidine treatment. The aim of this study
was to evaluate the tolerability and efficacy of the CETLAM11LAM70 protocol
and to compare the outcomes with those from CETLAM04LAM70 protocol. 
Methods: Eligible patients: 70 years of age or older with a newly diagnosed
AML excluding t(15;17), biphenotypic leukemia with t(9;22) or blast crisis of
chronic myeloid leukemia, ECOG 0-3 and able to attend weekly hospital visits
at baseline. Treatment regimen: Induction-1 with FAG (fludarabine 25 mg/m2
PO days 2-5, cytarabine 100 mg/m2 SC days 2-8, filgrastim 300µg SC days 1-
8), induction-2 or consolidation with IAG (idarubicin 20 mg/m2 PO days 2-4,
cytarabine 100 mg/m2 SC days 2-8, filgrastim 300µg SC days 1-8) followed by
12 courses of AZA (5-azacitidine 75 mg/m2 SC days 1-5 every 28 days). The
main differences with the CETLAM04LAM70 protocol were the cytarabine dose
(200 mg/m2 vs 100 mg/m2), the number induction/consolidation cycles and the
12 months maintenance.
Results: From January 2011 to June 2015, 44 patients were included (target
50 patients). Median age 74[70;87] years, 23 males (52%). AML characteristics:
poor-risk cytogenetics 15 (34%), trilineage dysplasia 14/42 (33%), FLT3 ITD
6/33 (18%), mutation of NPM1 9/31 (29%). Outcomes: induction-related deaths
8 (18%), overall response to induction-1 26 (59%)(11/44 CR and 15/44 PR),
consolidation-related deaths 3 (12%) and deaths during AZA treatment 2 (14%).
Fourteen patients (32%) completed the scheduled treatment. The 1 and 2-yr
(95%CI) OS, DFS and response duration are summarized in Table 1. Toxicities:
Median duration of thrombocytopenia (<20x109/L) and neutropenia (<1x109/L)
were 3 weeks (range 1-6) without differences between induction and consoli-
dation. Fever in induction was observed in 30 patients (68%) and 34 (77%)
were hospitalized; the median hospital stay was 15 days (1-45). Ten patients
(23%) during induction and 8 (31%) during consolidation could be managed
completely as outpatients. No toxicities grade >2 were observed during azac-
itidine treatment. No differences in OS, CR duration and DFS were observed
on comparison of the two protocols (Table 1).
Table 1.
Summary/Conclusions: The CETLAM11LAM70 protocol for elderly AML
patients ≥70 years is tolerable, feasible and effective with reasonable response
and induction mortality rates. Despite azaciditine was less toxic than previous
consolidation strategies, the modification of the protocol did not help to improve
OS. Supported: grants PI10/01417 and PI14/00450 from FIS, RD12/0036/0029
from Instituto Carlos III and 2014SGR225(GRE) from Generalitat de Catalunya,
Spain.
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COMBINATION OF RNA- AND EXOME-SEQUENCING EFFICIENTLY
ELIMINATES FALSE-POSITIVE SOMATIC POINT MUTATIONS AND
INDELS-EXEMPLIFIED BY CASES OF CN-AML
L Herborg, MC Hansen*, A Roug, P Hokland
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
Background: Thorough annotation as a means of detecting highly relevant
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mutations, and aberrated genes, is becoming more feasible as the evidence of
biological pathways underlying malignant transformation compiles. However,
there is a continuous risk of misinterpretating both true and false positive obser-
vations, which is closely coupled to the sheer number of observations in NGS
projects. Thus, there is still a need to find ways to efficiently filter data ab initio,
with little knowledge added from disease aetiology and other clinical findings
in order to gain new insights.
Aims: We aimed at finding an efficient method to pinpoint true positive and
known causal mutations, decreasing the need of downstream interpretation of
variants to a minimum. 
Methods: DNA and RNA were extracted from lysated bone marrow aspirate to
a mean concentration of 35 ng/µl for both groups and 20 samples in total (Fig.).
In order to streamline the alignment and variant calling workflow, we imple-
mented CLC Biomedical Workbench (Qiagen, Aarhus, DK) to keep all datapro-
cessing in one simple workflow. Only regions covered by the Nextera Rapid
Capture Exome kit (Illumina, CA, USA) were included and common variants
excluded (dbSNP, NCBI, MD, USA). Alternative GATK and MuTect de facto
standard workflow was used to survey the quality of CLC Biomedical Work-
bench alignment and single nucleotide variant (SNV) detection.
Results: Exome sequencing yielded an average of 9.1*10^7 sequence reads
with read lengths of 100 and over 99% mapped in each sample. The combina-
tion of whole exome and RNA sequencing efficiently reduced the number of
detected mutations to a median number of 6 [3, 21] somatic nucleotide variants
(see figure). 6 new mutations, reported to be mutated in at least one other case
of haematological neoplasms (COSMIC, Wellcome Trust, Sanger Institute,
Cambridge, UK), i.e. not detected by routine laboratory assays at the depart-
ment. Detection of NPM1 mutations confirmed results from Sanger sequencing,
but were found in one additional sample. Likewise, IDH1 census mutation con-
firmed positive lab results, one additional mutation previously undetected and
added IDH2 mutation. CLC Biomedical Workbench did not prove successful in
detecting FLT3 internal tandem repeats. The cytogenical status was confirmed
by assessment of allelic frequencies from NGS (not shown).
Figure 1.
Summary/Conclusions: Removal of the substantial number of false positives
and irrelevant mutations are a high-priority issues when performing NGS. As CLC
Biomedical Workbench, and other tools such as VarScan2, generally detects a
large number of somatic variants in raw comparison of paired samples it is crucial
to apply stringent and optimal filtering. We show that the inclusion of RNA
sequencing in the workflow, not only provides information on malignant expression
profiles excluded here, but importantly help to capture the, often very few somatic
mutations of myeloid leukaemia. As signature indels, such as found in NPM1,
TET2 and FLT3, are important drivers the practicality of DNA-RNA combination
is evident, as we demonstrate here-with the exception of FLT3-ITD aberration,
which was not detected properly. This small research study not only shows how
careful the large number of variants from NGS must be approached-it is also in
agreement with previously reported relatively low number of somatic mutations,
concluded by several studies. Although we use remission samples in both cases
for added stringency, a clinical practical counterpart would be the combination of
RNA and DNA malignant sample and skin biopsy or sorted control, DNA only, in
whole exome or even targeted panel sequencing.
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A BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM-LIKE
PHENOTYPE IDENTIFIES A SUBGROUP OF NPM1-MUTATED AML
PATIENTS WITH WORSE PROGNOSIS
P Minetto1,*, F Guolo1, A Kunkl2, L Giannoni1, N Bisso1, D Guardo1, F Ballerini1,
M Miglino1, M Clavio1, RM Lemoli1, M Gobbi1
1Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, 2Service of Flow Cytometry, IRCSS AOU San Martino-IST, Genoa, Italy
Background: NPM1-mutated acute myeloid leukemia (NPM1-mut AML) is con-
sidered by WHO classification of myeloid neoplasms a distinct entity, repre-
senting about 30% of de novo AML in adults. Isolated NPM1 mutations display
a strong positive prognostic value since they are associated with high complete
response rate to induction therapies, reduced relapse risk and increased overall
survival. A certain degree of clinical heterogeneity is however evident among
NPM1-mut patients. The prognostic relevance of NPM1-mut AML immunophe-
notype (IF) is unclear. NPM1-mut blasts are usually CD34 negative, CD33 and
CD13 positive. “Myeloid IF” or “monocytic IF” can be distinct by the expression
of monocytic antigens as HLA-DR, CD64, CD14, CD11b.
Aims: The aim of the present study was to identify leukemia-associated
immunophenotypes (LAIP) in a cohort of previously untreated NPM1-mut AML
patients and to possibly disclose the prognostic role of antigens-expression
patterns.
Methods: We retrospectively evaluated a cohort of 38 young, de novo NPM1-
mut AML patients who have been intensively treated in our institution between
2006 and 2014. All patients were treated with a fludarabine containing induction.
Multi-color immunophenotypic analysis is routinely performed in our centre by
analysing erythrocyte-lysed whole BM blasts collected at diagnosis to identify
relevant antigen aberration patterns and the pathological leukaemia phenotype
for future minimal residual disease assessment.
Results: By citofluorimetric analysis three different subgroup of patients could
be identified: 16/38 patients displayed a myeloid IF [CD33/CD13/CD38/
CD117/MPO (+), CD16/ CD123 (-)]; 7/38 patients displayed a moncytic IF
[CD33/CD64/cyLys/CD11b/CD15 (+) with 3/7 patients CD13+]; the third group
included 10 patients who displayed a “myelo-monocytic IF” [CD33/CD13/CD38/
CD117/MPO/CD64/cLys/CD11b/CD15 (+)]. Differently from what reported, in
our experience HLA-DR displayed a heterogeneous expression and was not
associated with monocytic differentiation. No statistically significant differences
in relapse free survival (RFS) and overall survival (OS) were detectable among
the three groups. FLT3-ITD mutation incidence was significantly higher in the
monocytic group, however this did not translate in a worse outcome; as well,
the expression of CD34 did not negatively affect RFS and OS. Interestingly we
found that a peculiar immunophenotype CD56/CD123/CD4 (+) was recurrent
in 6 patients, it was not significantly associated with one of the previously
described cytofluorimetric subgroups, and was significantly associated with
worse disease free survival (p<0.01, Fig. 1). Since these markers represent
part of the typical immunophenotypic pattern of blastic plasmacytoid dendritic
cell-neoplasm (BPDCN) we called this phenotype “BPDCN-like”. BPDCN-like
phenotype was not significantly associated with the concomitant presence of
FLT3-ITD mutation; moreover, median values of WT1 m-RNA expression levels
were significantly lower in this subgroup of patients in comparison with the
whole cohort of patients (2200 WT1/ABL copies vs 16090 WT1/ABL, p<0.05).
Figure 1.
Summary/Conclusions: We found a peculiar BPDCN-like immunophenotype
among NPM-1 mut AML patients associated with significantly worse outcome.
The biological explanation of this finding is not clear; further gene-expression
profiling studies could contribute do understand our findings. We explained the
lack of negative prognostic impact from FLT3-ITD mutation as consequence of
the intensive fludarabine containing-induction.
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MFC -MRD ASSESSMENT MAY DRIVE POST INDUCTION CONSOLIDATION
IN INTERMEDIATE RISK AML. IS IT TIME FOR MRD-DRIVEN DECISION
MAKING?
P Minetto*, F Guolo, D Guardo, G Pastori, N Colombo, F Ballerini, M Miglino,
M Clavio, RM Lemoli, M Gobbi
Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCSS AOU San Martino-IST, Genoa, Italy
Background: Since the induction therapy for acute myeloid leukemia (AML)
has not changed in the last decades the optimization of post remissional ther-
apeutic strategies is fundamental to improve patients outcome. Allogeneic
haematologica | 2016; 101(s1) | 379
Copenhagen, Denmark, June 9 – 12, 2016
hematopoietic stem cell transplantation (BMT) offers the greatest chance of
cure for most AML patients, however in the heterogeneous group of interme-
diate cytogenetic risk (int-risk) patients who achieve complete remission (CR)
after induction courses, the role of BMT in 1st CR is not well defined.
Aims: The aim of the present study was to evaluate the prognostic role of min-
imal residual disease (MRD) assessment through multiparameter flow cytom-
etry (MFC-MRD) after 1st and 2nd induction courses in int-risk patients under-
going or not BMT in 1st CR.
Methods: Fifty-five consecutive int-risk AML patients, according to MRC clas-
sification, achieving CR after induction therapy, with available post induction
MFC-MRD evaluation were retrospectively included in this study. All patients
were uniformly treated with a fludarabine-containing induction. Median age
was 49 years. BMT in 1st CR was scheduled if an HLA identical sibling donor
or, for selected patients, if an haploidentical donor was available. The remaining
34 patients proceeded to high dose cytarabine consolidation and underwent
BMT in 2nd CR from any donor if available (6 patients). A positive MFC MRD
was defined by the presence of no less than 25 clustered leukemic cells/105
total events at four-color flow-cytometry. Twenty-three and 30 patients achieved
MFC MRD negativity after one or two induction cycles, respectively. Median
follow up was 44 months. Relapse-free survival (RFS) was calculated from the
time of diagnosis until last follow-up or documented leukemic relapse.
Results: Fifty-five consecutive int-risk AML patients, according to MRC clas-
sification, achieving CR after induction therapy, with available post induction
MFC-MRD evaluation were retrospectively included in this study. All patients
were uniformly treated with a fludarabine-containing induction. Median age
was 49 years. BMT in 1st CR was scheduled if an HLA identical sibling donor
or, for selected patients, if an haploidentical donor was available. The remaining
34 patients proceeded to high dose cytarabine consolidation and underwent
BMT in 2nd CR from any donor if available (6 patients). A positive MFC MRD
was defined by the presence of no less than 25 clustered leukemic cells/105
total events at four-color flow-cytometry. Twenty-three and 30 patients achieved
MFC MRD negativity after one or two induction cycles, respectively. Median
follow up was 44 months. Relapse-free survival (RFS) was calculated from the
time of diagnosis until last follow-up or documented leukemic relapse.
Table 1.
Summary/Conclusions: MFC-MRD assessment after induction therapy is a
strong predictor of relapse risk and could improve risk stratification for inter-
mediate patients. A deeper evaluation of MRD through MFC may overcome
morphologic CR assessment becoming a powerful tool to delineate the thera-





ZYGODACTYLY IS STRONGLY ASSOCIATED WITH ACUTE MYELOID
LEUKAEMIA
A Niblock1,*, O mcconville2, MF McMullin1, P Morrison3
1Haematology, 2Podiatry, 3Genetics, Belfast city Hospital, Belfast, United Kingdom
Background: Zygodactyly is a subtype of syndactyly characteristed by bilateral
partial cutaneous webbing of the second and third toes without hand involve-
ment. It is a failure in separation of developing toes during organogenesis. The
incidence of zygodactyly is approximately 4 in 10,000 men and males are
affected twice as frequently as females1. In Northern Ireland there are 3.3 per
100,000 new cases of Acute Myeloid Leukaemia (AML) each year2. Podiatry
assessment of two haematology ward patients with AML confirmed zygodactyly.
Given its relatively low incidence in the general population we decided to
inspect all our inpatients.
Aims: To assess if there is a correlation between patients with zygodactyly
and the development of acute leukaemia.
Methods: On the 18th January 2016, all the inpatients with acute leukaemia
were examined by a physician and a podiatrist for presence or absence of
zygodactyly. There were 17 patients in total (7 male, 10 female). 
Results: 14 out of 17 had partial or full zygodactyly and AML (figure 1). In the
unaffected group one patient had Acute Lymphoblastic Leukaemia (ALL), two
had AML (one of whom had Acute pro-myelocytic leukaemia). This ward based
observational case series interestingly shows a higher frequency of Zygodactyly
amongst patients with AML. It also demonstrated no particular sex predomi-
nance which one usually attributes to Zygodactyly. This raises the question of
way subtle 2nd/3rd toe syndactyly is higher amongst patients with acute
myeloid leukaemia?
Figure 1.
Summary/Conclusions: It is not unusual for physical abnormalities to be asso-
ciated with an increased risk of developing AML. Congenital bone marrow fail-
ure syndromes demonstrate multisystemic abnormalities and a risk of AML in
later life. Diamond Blackfan anaemia has physical abnormalities (~50%) includ-
ing webbed neck, malformed thumbs and 5% develop AML. Over 50% of Fan-
coni anaemia cases have skeletal abnormalities especially the radial ray - 10-
20% develop Myelodysplastic syndrome/AML over a 13 year period. Dysker-
atosis Congenita is characteristed by the association of dyskeratotic nails and
bone marrow failure with a signifcant increase in AML3. Case reports show
these syndromes are occasionally diagnosed in the 3rd and 4th decades as
clinical features are occasionally subtle. AML arises from genetic alterations in
a stem or progenitor cell that result inuncontrolled growth. The hematopoietic
microenvironment has been implicated in the pathogenesis of hematologic
malignancies. Hematopoietic stem cells live in a highly specialized complex
microenvironment, known as a niche4. The structures common to bone marrow
environment and cutaneous tissues could help explain the link between phys-
ical abnormalities and the risk of AML. Zygodactyly subtype 1 (ZD1) has been
linked to chromosome 3p21.31 so genes in this region may be associated with
AML or may modify the niche. Further studies are needed to determine the
exact causes of this interesting finding.
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CLINICAL DECISION SUPPORT SYSTEM (CDSS) BASED ON PATHWAYS
CONSTRAINED SOMATIC MUTATIONAL DATA INTEGRATION IN ACUTE
MYELOID LEUKEMIA PERSONALIZED MEDICINE
M Manfrini*, V Guadagnuolo, C Papayannidis, G Simonetti, A Padella, S Paolini,
MC Abbenante, S Parisi, C Sartor, MC Fontana, E Ottaviani, G Martinelli
DIMES, Institute of Hematology, University of Bologna, Bologna, Italy
Background: Personalized medicine will strengthen the prognosis and provide
better, patient-specific drug identification. This type of clinical approach is based
on high throughput analysis technology available today. Cancer could benefit
from targeted therapy because of high number and heterogeneity of DNA alter-
ations. Acute Myeloid Leukemia (AML) is characterized by several type of
known point mutations and chromosomal aberration. Massive parallel sequenc-
ing showed that a number of new discovered single nucleotide variants (SNV)
could affect patients survival time and drug resistance. In this clinical settings
next generation sequencing (NGS) is becoming a useful tool to investigate
patients genome giving a detailed picture of which mutations occurred and
hence an improved diagnosis.
Aims: To exploit these informations for prognosis and personalized therapies
there is the need of easily available tools for clinicians. We propose a statistical
model learned from data provided by NGS technology, patients cytogenetics
predictive risk and clinical outcomes, which could be useful to predict drug
sensitivity and prognosis for new diagnosed patients.
Methods: DNA from a cohort of 65 AML patients from S. Orsola University Hos-
pital, Bologna, Italy, were analyzed by Whole Exome Sequencing (WES). Dif-
ferent computational tools were assembled in an in-house pipeline in order to
achieve an optimal detection lowering false positive rate. Briefly, pre-processing
was carried out following GATK guidelines and re-calibrated alignment files
were analyzed by MUTECT and VARSCAN2 algorithms in order to detect single
nucleotide variants (SNV) and indels. An additional AML dataset containing
WES data from 200 AML patients were downloaded from TCGA database in
order to collect somatic variants and clinical data. A training set (60 percent of
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cases) was built stratifying patients by age and sex in order to maintain the pro-
portion of the original entire dataset. Other 30 percent of cases were employed
as testing set. SNV for each patients were mapped to Reactome and Pathways
Commomns. Binary matrix factorization was applied to the patients/pathways
matrix in order to find pathways signatures capable to cluster patients. To model
pathways constrained mutational data toward event free survival or drug resist-
ance we employed a generalized linear model with binary outcome, including
also cytogenetics risk and presence/absence of cancer genes driver mutations
from AML biomedical literature. Regression model was applied with 10-fold cross
validation to find statistically significant explanatory variables.
Results: Whole exome sequencing detected 4783 somatic mutations of which
2441 labeled as non-silent. Non-silent mutations were mapped to pathways
databases and binary matrix factorization. Five pathways signatures were
obtained allowing clustering of patients in three groups. Recurrent driver genes
involved in AML onset were found with different frequencies in patients and
included in the model. Regression analysis provided a model which allow clas-
sification of patients in responder/non-responder to standard chemotherapy
and toward event free survival.
Summary/Conclusions: In the complex task of interpreting NGS data collected
from AML patients, this tool could be useful to guide clinician in the selection of
a standard therapy versus experimental therapy: when poor prognosis or drug
resistance is more likely associated with patients mutational data, latter could
be preferable.
Acknowledgements: ELN, AIL, AIRC, PRIN, Progetto Regione-Università 2010-
12 (L. Bolondi), FP7 NGS-PTL project.
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MOLECULAR RESPONSE IN ACUTE MYELOID LEUKEMIA WITH WT1
OVEREXPRESSION HAS A STRONG PROGNOSTIC IMPACT IN PATIENS
TREATED WITH CHEMOTHERAPY ONLY AND/OR UNDERGOING
ALLOGENEIC STEM CELL TRANSPLANTATION
C Salek*, R Petrbokova, M Kouba, J Mertova, P Soukup, V Valkova, H Hajkova,
J Polak, P Cetkovsky
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Background: WT1 is a leukemia associated antigen whose expression may be
used as an alternative marker for minimal residual disease (MRD) monitoring in
acute myeloid leukemia (AML) mainly in patients lacking a specific molecular target.
Aims: To evaluate the prognostic impact of WT1 expression at diagnosis and
during therapy.
Methods: The cohort comprised 84 subjects (median age 52 yrs, range 21-66
yrs; median follow up 1.9 yrs, range 0.6-7.1 yrs) treated from 2008 to 2014
who had overexpressed WT1 gene at diagnosis and attained hematological
remission after up to 2 induction cycles of chemotherapy. Consolidation
chemotherapy consisted of 3-4 cycles of chemotherapy or allogeneic
hematopoetic stem cell transplantation (HSCT), depending on cytogenetic and
molecular characteristics and response to the first induction cycle. WT1 expres-
sion was quantified using a standardized method according to the recommen-
dations of European LeukemiaNet. Upper normal limit of WT1 expression was
defined as ≤50 copies WT1/104 copies of reference gene ABL in peripheral
blood. Only patients with WT1 overexpression >500 copies/104 ABL at diag-
nosis were suitable for MRD monitoring. Molecular response (MR) was defined
as a decrease of WT1 expression<50 copies/104 ABL.
Results: Patients with WT1 expression at diagnosis >500 and ≤5000 copies
WT1/104 ABL had 3yr OS 70% and EFS 40%, whereas those with >5000 copies
had 3yr OS 50% and EFS 25%, respectively (p=0.036 for OS and 0.030 for
EFS). Failure to reach MR was a strong prognostic factor for survival in an
overal cohort (3yr OS 63% vs 27%, p<0.001; 3yr EFS 38% vs 0%, p<0.001),
in patients treated with chemotherapy only (3yr OS 66% vs 34%, p=0.002; 3yr
EFS 31% vs 0%, p=0.009) as well as in patients undergoing HSCT in first com-
plete remission (3yr OS 70% vs 30%, p=0.009; 3yr EFS 62% vs 12%, p<0.001).
Median time to MR was 3.0 months (95%CI 2.8-3.1) and was not dependent
on the level of pre-treatment WT1 expression. Reaching MR before start of
consolidation therapy was not signicant (3yr OS 67% vs 51%; p=0.089). Of 43
WT1 positive patients at that timepoint, 33 (77%) reached MR by further therapy
(chemotherapy or HSCT). Of 27 patients who were WT1 positive before con-
solidation I and received another consolidation cycle, 22 (81%) reached MR
after consolidation II. There was no significant difference in survival between
patients never reaching MR and those with molecular relapse. In a multivariate
analysis, the level of WT1 expression at diagnosis and ability to reach MR were
significant prognostic factors for OS and EFS. In addition, performing HSCT as
part of first line therapy was another positive prognostic factor for EFS only.
WT1 expression before HSCT was the only significant marker for OS and EFS
in transplanted patients.
Summary/Conclusions: The level of WT1 expression at diagnosis correlates
with survival. Monitoring of WT1 expression is a sensitive tool for MRD moni-
toring in patiens with WT1 overexpression at diagnosis. Failure to reach MR is
a potent predictor of relapse. These patients could profit from further intensifi-
cation of the therapy.
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CHARACTERIZATION OF PATIENTS WITH RELAPSED OR REFRACTORY
AML IN CONTINUED FOLLOW-UP AFTER TREATMENT WITH VOSAROXIN/
CYTARABINE VS PLACEBO/CYTARABINE IN THE VALOR TRIAL
A Pigneux1,*, F Ravandi2, EK Ritchie3, JE Lancet4, MD Craig5, HA Horst6,
J Maertens7, HG Derigs8, M Heuser9, A Wei10, D Hogge11, R Clark12, R Ward13,
JA Smith13, AR Craig13, RK Stuart14
1Université de Bordeaux, CHU de Bordeaux, Bordeaux, France, 2University of
Texas MD Anderson Cancer Center, Houston, TX, 3Weill Cornell Medical Cen-
ter, New York, NY, 4Moffitt Cancer Center, Tampa, FL, 5West Virginia University,
Morgantown, WV, United States, 6Klinik fuer Innere Medizin II, University Hos-
pital Schleswig-Holstein, Kiel, Germany, 7Universitair Ziekenhuis, Leuven, Bel-
gium, 8Klinikum Frankfurt Main, Frankfurt, 9Hannover Medical School, Han-
nover, Germany, 10The Alfred Hospital and Monash University, Medborne, VIC,
Australia, 11Vancouver General Hospital, Vancouver, BC, Canada, 12Royal Liv-
erpool University Hospital, Liverpool, United Kingdom, 13Sunesis Pharmaceu-
ticals, Inc., South San Francisco, CA, 14Hollings Cancer Center, Medical Uni-
versity of South Carolina, Charleston, SC, United States
Background: Patients with relapsed/refractory (R/R) AML have a median over-
all survival (OS) less than 1 year. In the phase 3 VALOR trial, vosaroxin/cytara-
bine prolonged median OS in patients with R/R AML by 1.4 months vs
placebo/cytarabine (7.5 vs 6.1 months; HR=0.87 [95% CI 0.73-1.02]; P=0.061).
Of 711 enrolled patients, 134 (19%) were alive in follow-up at the primary analy-
sis. After the primary analysis, ongoing patients were followed for survival.
Aims: To characterize patients who continue to be followed for survival in the
VALOR trial.
Methods: In VALOR, patients with R/R AML were randomized 1:1 to receive
cytarabine (1 g/m2 IV over 2 h, d 1-5) plus either vosaroxin (90 mg/m2 IV over
10 min d 1, 4; 70 mg/m2 in subsequent cycles) or placebo.
Results: As of Jan 22, 2016, 83 patients (12%) were alive in follow-up: 46/356
(13%) in the vosaroxin/cytarabine arm and 37/355 (10%) in the placebo/cytara-
bine arm. Median follow-up in these patients was 40 months (range 28-60).
Patient characteristics are presented (Table); a higher proportion of patients
were ≥60 years in the vosaroxin/cytarabine arm (50% vs 27% with
placebo/cytarabine). Most achieved complete remission (CR) on study (70%
with vosaroxin/cytarabine; 51% with placebo/cytarabine); over half maintained
CR at database lock (59% with vosaroxin/cytarabine; 49% with placebo/cytara-
bine). Nearly all received subsequent therapy (93% with vosaroxin/cytarabine;
100% with placebo/cytarabine). Most patients on vosaroxin/cytarabine (85%)
and all patients on placebo/cytarabine received posttreatment stem cell trans-
plantation (SCT). Seven patients in the vosaroxin/cytarabine arm did not under-
go SCT; all were ≥60 years of age. Median follow-up in these 7 patients was
33 months (range 31-48).
Table 1. Baseline characteristics of ongoing patients.
Summary/Conclusions: A small proportion of patients with R/R AML continue
to be followed for survival in VALOR. Typically, these patients achieved CR fol-
lowed by SCT; however, some patients ≥60 years treated with vosaroxin/cytara-
bine achieved long-term survival without SCT.
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DETECTION OF BASOPHIL-ASSOCIATED IMMUNOPHENOTYPIC
FEATURES OF ACUTE PROMYELOCYTIC LEUKEMIA BLAST CELLS AT
DIAGNOSIS IS ASSOCIATED TO A HIGHER AND MORE SEVERE
BLEEDING DIATHESIS
S Matarraz1,*, V Guerri1, E Colado2, C Chillón3, M Gonzalez3, B Vidriales3,
C Salvador4, V van der Velden5, T Caballero6, O Gutierrez7, L Gutierrez1,
A Mayado1, S Barrena1, A López8, A Yeguas Bermejo9, I Martín Rubio9,
G García-Donas10, JA García-Erce11, J van Dongen12, A Orfao1
1Medicine, Centro de Investigación del Cáncer (IBMCC, CSIC-USAL) and
IBSAL, Salamanca, 2Hematology, Hospital Universitario Central de Asturias,
A.G.C. Laboratorio de Medicina, Oviedo, 3Hematology, Hospital Universitario
de Salamanca, Salamanca, 4Hematology, Hospital Miguel Servet, Zaragoza,
Spain, Zaragoza, Spain, 5Immunology, Erasmus MC, University Medical Center
Rotterdam, Rotterdam, Rotterdam, Netherlands, 6Hematology, F.E.A de Hema-
tología y Hemoterapia, Hospital Universitario Virgen del Rocio, Sevilla, 7Hema-
tology, Hospital Rio Hortega, Valladolid, 8Medicine, Hospital Universitario Cen-
tral de Asturias, A.G.C. Laboratorio de Medicina, Salamanca, 9Hematology,
Hospital Universitario de Getafe, Madrid, 10Hematology, Hospital Juan Ramón
Jiménez, Huelva, 11Hematology, Hospital San Jorge, Huesca, 12Immunology,
Erasmus MC, University Medical Center Rotterdam, Rotterdam, Rotterdam,
Spain
Background: The introduction of induction therapy with all-trans retinoic acid
and anthracycline-based chemotherapy in acute promyelocytic leukemia (APL)
have translated into complete remission in most patients. However, severe
hemorrhage manifestations at diagnosis and/or during induction therapy lead
to early death in 10-15% of patients, which is currently a major focus of research
in APL.
Aims: Here we performed an extensive immunophenotypic characterization
of blast cells from APL and investigated the potential association between their
differential phenotypic profiles and the bleeding diathesis depicted at baseline.
Methods: A total of 133 bone marrow samples from newly-diagnosed APL
patients were immunophenotypically characterized. In all cases, 8-color flow
cytometry was performed for in depth characterization of APL blast cells and
residual hematopoietic cell compartments using the EuroFlow AML/MDS panel.
The relatioship between the bleeding diathesis and the immunophenotypic fea-
tures of blast cells at diagnosis could be studied in 86 APL cases.
Results: The multiparameter immunophenotypic characterization of marrow
APL blast cells revealed that these patientes systematically depict (among 100%
of their leukemic cells) CyMPO+/++, CD33+/hi, and CD123+/hi expression, togeth-
er with CD15-/low CD117+, CD71+ and CD9+, while lacking the myelomonocytic
maturing-associated markers CD16, CD10 and CD300e, as well as the expres-
sion of CD105, NG2 (7.1), CD25 and the megakaryocytic lineage-associated
markers CD41, CD61, CD42a, CD42b. Other (aberrant) phenotypes were typ-
ically found in APL although at lower frequency, including CD64low (55/59 cases;
93%), HLA-DR- (72/78; 92%), CD13+/++ (56/61; 92%) and CD38+ (47/55; 86%),
followed by CD4low (30/58 cases; 52%), CD203c+ (40/92; 44%), CD34+ (23/78;
30%), the cross-lineage expression of CD7 (14/47; 30%), asynchronous reac-
tivity for CD35 (14/52; 27%) and CD22 (8/52; 15%) and ectopic CD56 (9/60
cases; 15%). The expression of several other markers was rather exceptional
in APL blast cells, including, CD19 (7/58 cases; 12%), CD79a (6/57; 10%),
CD14, NuTdT (3/54; 5%), CD11b (2/59; 3%) and CD36 (2/61; 1%). Of note,
from all analyzed markers the expression vs lack of CD203c showed the
strongest association with bleeding manifestations at diagnosis (90% vs 10%
of APL cases; p<0.001), followed by CD7 (89% vs 11%; p=0.03), CyCD79a (0%
vs 100%; p=0.05) and a similar trend for the expression of CD34 by blast cells
(74% vs 26%; p=0.06). Furthermore, APL cases with severe bleeding at diag-
nosis depicted a significantly higher frequency of CD203 expression by blast
cells, as compared to those with mild and absent bleeding symptoms at baseline
(80% vs 46% and 10%, respectively; p<0.001). A similar association was respec-
tively found for the expression of CD7 by blast cells (75% vs 31% and 7%;
p=0.02) and cytoplasmic CD79a (33% vs 18% and 0%; p=0.05).
Summary/Conclusions: The presence of basophil differentiation features in
marrow APL blast cells, as depicted by their expression of CD203c and/or
CD22, and to a lower extent also of certain cross-lineage antigen expression
markers (CD7 and/or CD79a) is associated to a higher frequency and severity
of bleeding symptoms at diagnosis, which might point to the need of adapted
therapy protocols particularly in these cases.
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ASSESSMENT OF BAALC AND MN1 GENE EXPRESSION LEVEL COULD
CONTRIBUTE TO IMPROVED PROGNOSTIC STRATIFICATION OF THE
AML-NK PATIENTS
I Marjanovic1,*, T Karan-Djurasevic1, J Kostic1, T Kostic1, M Virijevic2, I Djunic2,
N Suvajdzic Vukovic2,3, D Tomin2,3, S Pavlovic1, N Tosic1
1laboratory for Molecular Biomedicine, Institute of Molecular Genetics and
Genetic Engineering, University of Belgrade, Serbia, 2Clinic of Hematology,
Clinical Center of Serbia, 3School of Medicine University of Belgrade, Belgrade,
Serbia
Background: There is a constant need for the introduction of new molecular
markers in AML-NK group of patients in order to ensure more precise risk strat-
ification. The latest attempt was the inclusion of expression level changes of
some genes, like BAALC (brain and acute leukemia, cytoplasmic) and MN1
(meningioma 1). MN1 is an oncoprotein found to function as transcription coac-
tivator, while the BAALC function is not yet clearly defined. Both of the genes
are highly expressed in hematopoietic progenitor cells and are down-regulated
during differentiation.
Aims: Aim of this study was to evaluate the BAALC and MN1 gene expression
levels in de novo AML-NK patients, and to investigate association with other
molecular and clinical data.
Methods: Fresh bone marrow (BM) samples were collected from 111 AML-NK
patients at diagnosis (62 male, 49 female, median age 54 years, range 19-78).
Relative quantification analysis of BAALC and MN1 expression level was per-
formed by RQ-PCR methodology, using comparative ddCt method with healthy
controls as calibrator.
Results: The median expression level of BAALC and MN1 among patients
was 1.55 (0.01-4246.00) and 1.59 (0.00-67.74), while the levels detected
among healthy controls was 1.00 (0.65-3.63) and 1.00 (0.40-2.53), respectively.
The existence of a positive correlation between BAALC and MN1 expression
was detected (r=0.693). Using median value of gene expression levels among
healthy individuals plus 3xSD as a cut-off value, we found that 42 patients
(38%) expressed BAALC gene, while 43 patients (39%) expressed MN1. Nei-
ther BAALC+ nor MN1+ status, had any association with usual clinical charac-
teristics. The BAALC+/ MN1+ status was not associated with the presence of
FLT3 and IDH1/IDH2 mutations, but exhibited strong correlation with NPM1wt
status (p<0.001). Only 2/42 BAALC+ and 2/43 MN1+ patients were found to
have NPM1 mutations. When among BAALC+ and MN1+ patients median
expression level of adequate gene was introduced as a cut-off value, patients
were divided into BAALChigh/BAALClow (21/21) and MN1high/MN1low (21/22)
patients. NPM1 mutations could not be found in none of the high expressing
group of patients (BAALChigh or MN1high), FLT3-ITD could be detected in only
four patients, and therefore the most frequent were the patients with so called
FLT3-ITD/NPM1 double negative status. Compared to MN1low group, MN1high
patients tend to have lover CR rate (41% vs 59%; p=0.227), and it was con-
firmed in the survival analyses where MN1high patients had lower DFS (12
months vs 30 months; p=0.319) and also shorter OS (5 months vs 20 months;
p=0.069). Similar findings were detected for BAALChigh patients who, in com-
parison with BAALClow patients, had a tendency to lower CR (42% vs 58%)
and resistant disease (67% vs 33%). In survival analyses BAALChigh patients
had lower DFS (12 months vs 18 months; p=0.261) and OS (5 months vs 8
months; p=0.196).
Summary/Conclusions: In our cohort of AML-NK patients, overexpression of
either BAALC or MN1 is a factor of poor prognosis. This finding could especially
contribute to an improved risk stratification among FLT3-ITD/NPM1 double
negative patients lacking a reliable prognostic marker.
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ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AND NORMAL
KARYOTYPE HAVE A FAVOURABLE OUTCOME AFTER INTENSIVE
THERAPEUTIC PROGRAMS
M S Bernardi1,*, M Carrabba1, C Messina1, L Seghezzi2, A Forcina1, E Sala1,
F Pavesi1, L Vago1, B Gentner1, R Milani3, C Corti1, J Peccatori1, F Lorentino1,
F Ciceri1
1Onco-Haematology, 2Laboratory Medicine-Cytogenetics, 3Laboratory Medi-
cine-Cytomorphology, San Raffaele Scientific Institute, Milano, Italy
Background: Outcome of AML patients (pts) older than 60 years is poor
because of unfavourable disease characteristics; comorbidities frequently tailor
under-powered treatment. When standard induction is given to elderly pts the
complete remission (CR) rate is around 55%, median overall survival (OS)
after intensive post-remission treatments, such as high dose cytarabine (HDAC)
or haematopoietic stem cells transplantation, autologous (AUTO) or allogeneic
(ALLO), is about 6 months. Cytogenetic is the principal prognostic factor influ-
encing CR and survival.
Aims: Retrospective evaluation of data from AML pts ≥60 yrs of age who
received an intensive treatment program at our Institute.
Methods: Period 2/2001 to 11/2015, 111 pts. Criteria for pts selection: PS
(ECOG) ≤2, renal and hepatic parameters within normal ranges or<2 times
normal values, no active infections and cardiac ejection fraction >50%.
Results: Median pts age was 68 (60-80). Diagnosis: secondary AML or AML
with multilineage dysplasia in 64 cases (6 therapy-related), de novo AML in 47
cases. Cytogenetics: favourable (FAV) 4 cases, adverse (ADV) 15 (complex
11), intermediate (INT) 81, 57 of them were normal karytotype (NK), not evalu-
able (NE) 11 cases. Molecular analysis (56 pts): 10 NPM1 mut, 9 CEBPA mut,
7 FLT3ITD, 1 FLT3TKD, 1 RUNX1-RUNX1T1, 1 JAK2 mut, 27 negative. Overall,
79 pts (71%) obtained the CR after standard induction chemotherapy (CHT),
cumulative incidence (CI) of post-induction treatment related mortality (TRM)
was 7.5±4%, median OS was 386 days (12-4725), and 3y OS from diagnosis
29.6±9%, median DFS was 297 days (12-3704), and 3y DFS from diagnosis
20.2±8%. We compared the outcomes of 57 NK pts with 50 INT, UNFAV and
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NE pts analysed together (noNK). CR rate after induction: 84% (48 pts) and
54% (27 pts) for NK and noNK pts, respectively, p=0.0008. Post-remission treat-
ments (74 pts): 47 NK pts received HDAC in 16 cases, AUTO in 16, ALLO in 9
and CHT in 6, 27 noNK pts received HDAC in 14 cases, AUTO in 4, ALLO in 8
and CHT in 1. CI of post-remission treatment TRM was 13±7% (10 pts, 6 NK
and 4 noNK), mostly after ALLO (6 pts). 3y relapse incidence: 55.8±15% for NK,
68.7±15% for noNK, p=0.282. Survival probability of NK pts was significatively
higher than no-NK pts: 3y OS from diagnosis was 36.6±12% for NK (median
614 days), 19.4±10% for noNK (median 284 days), p=0.0006, 3y DFS from
diagnosis was 27.5±11% for NK (median 453 days), 10.9±7% for noNK (median
219 days), p=0.002. Notably, age did not influence the outcomes: in particular,
3y OS from diagnosis was 46.5±15% if age<70 (median 795 days), and
22.3±13% if age ≥70 (median 467 days), p=0.246. Survival of NK pts remained
significatively better than no-NK excluding from the analysis cases with FAV and
ADV molecular abnormalities (p=0.0037 for OS, p=0.0013 for DFS).
Summary/Conclusions: Intensive approaches proved feasible in our pts and
prolonged survival was observed for several of them. In particular, NK pts
showed a survival advantage due to better CR rate after induction and a longer
survival free from events, suggesting a higher chemosensitivity of leukemic
blasts in absence of cytogenetic abnormalities. Molecular abnormalities and
age did not significatively influence the outcome of NK pts. We conclude that
absence of cytogenetic abnormalities per se probably defines in the elderly a
AML subtype with favourable prognosis. Anyway, strategies to prevent disease
relapse also in these pts should be explored.
E934
THE HOMOZYGOUS TP53 P72R SNP IS ASSOCIATED WITH NON-FAVORABLE
CYTOGENETIC RISK GROUPS IN ACUTE MYELOID LEUKEMIA
E Schulz1,*, K Lind1, W Renner2, BS Petersen3, C Dill4, S Hofer1, R Lal1,
F Quehenberger5, F Stölzel4, H Sill1
1Department of Internal Medicine, Division of Hematology, 2Clinical Institute of
Medical and Chemical Laboratory Diagnostics, Medical University of Graz,
Graz, Austria, 3Institute of Clinical Molecular Biology, Christian-Albrechts-Uni-
versity, Kiel, 4Department of Internal Medicine I, University Hospital Dresden,
Dresden, Germany, 5Institute for Medical Informatics, Statistics and Documen-
tation, Medical University of Graz, Graz, Austria
Background: Previous results about a possible predisposition for acute myeloid
leukemia (AML) in individuals with the TP53 P72R SNP are conflicting.
Aims: We tested the hypothesis that the risk for AML development is increased
in P72R carriers and that this SNP also influences survival of these patients.
Methods: We performed a case control study of 215 AML patients from Graz,
Austria, and Dresden, Germany, and of 3759 controls from Graz and Kiel, Ger-
many. Genotyping was accomplished with constitutional DNA using the TaqMan
assay and direct sequencing. The presence of an Hardy-Weinberg equilibrium
and the homogeneity of case and control genotypes as well as cytogenetic risk
groups according to European LeukemiaNet were tested by the chi-squared test.
Survival analyses according to different genotypes stratified for treatment centers
were performed by the Kaplan-Meier method and the Wald-test of cox regression.
The likelihood ratio test was used to assess the additive model of single alleles.
Results: Genotypes of cases and controls were in Hardy-Weinberg equilibrium
(AMLs P=0.192, controls P=0.325; df=1). There was no difference in the geno-
type distributions between AML patients (PP n=20, PR n=78, RR n=117) and
controls (PP n=249, PR n=1482, RR n=2028; P=0.262; df=2). This was also
true for the recessive model PP/PR versus RR (P=0.949; df=1). Survival analy-
ses of patients who received at least 3+7 induction therapy showed a trend for
better overall survival (OS) in the combined group of patients with the PP/PR
genotypes (HR=0.70, 95% CI, 0.46-1.1, P=0.091) whereas no difference was
present between all three genotype groups. The additive model of Arginine
alleles showed a trend for decreased survival (PP>PR>RR; 72R, HR=1.40,
95% CI, 0.99-1.90, P=0.061). There was no association with relapse free sur-
vival. Analyses of clinical parameters of all patients showed a significantly dif-
ferent distribution of cytogenetic risk groups with decrease of favorable cyto-
genetics in patients with the RR genotype (PP/PR, 15/90 [16.7%]; RR 6/112
[5.4%]; P=0.0171; df=1).
Summary/Conclusions: There is no association of the P72R genotype with AML
development in this study. The RR genotype shows a trend for lower OS and a
statistically significant association with non-favorable cytogenetic risk groups.
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FLAG-IDA REGIMEN AS SALVAGE THERAPY IN REFRACTORY/
RELAPSED AML PATIENTS: A SINGLE-CENTER EXPERIENCE
M Delia*, D Pastore, P Carluccio, C Pasciolla, C Bitetti, A Franco, L Anelli,
A Mestice, F Albano, G Specchia
Hematology - University of Bari, Bari, Italy
Background: Although treatment outcome in acute myeloid leukemia (AML)
adult patient has improved over the past decade, relapse still occurs in up to
50-70% of cases. Furthermore, 15-30% of patients fail to achieve complete
remission (CR) because of treatment-resistance. The management of primary
refractory and/or relapsed disease remains challenging for clinicians. Although
several different chemotherapy combinations are currently administered in
refractory/relapsed AML patients, the prognosis is still poor, with a complete
remission rate ranging from 30% to 40%.
Aims: In our study, we reviewed the outcome of 116 refractory and/or relapsed
AML patients who underwent salvage therapy with the FLAG-Ida regimen
between 2005 and 2015 at our institution. The study aim was to determine the
efficacy of the FLAG-Ida regimen in order to clarify which variables (WHO PS,
LDH, bone marrow, peripheral blood blasts and platelets counts, white blood
cells (WBC), PMN, molecular-cytogentic risk, duration of response and relapsed
or refractory disease), present before starting FLAG-Ida treatment, might have
an impact both on CR and on overall survival (OS).
Methods: We analyzed 116 consecutive adult patients (56 males, 60 females;
median age 48 years, range 17-72) with newly diagnosed acute myeloid
leukemia refractory to standard induction regimens or relapsed after CR, who
received the FLAG-Ida protocol as salvage therapy between January 2005 and
December 2015. Sixty-eight of the 116 patients (58%) were in first relapse,
forty-seven patients (42%) were refractory to conventional chemotherapy. Medi-
an WBC count before salvage therapy was 10.1 x109/l (range 0.56-88). Median
bone marrow and peripheral blasts counts were 52 and 20%, respectively;
median platelets count was 91x10e3/uL. According to the FAB classification,
14 patients had M0, 5 M1, 53 M2, 16 M4, 22 M5, 4 M6, 2 had Biphenotype
Acute Leukemia. According to molecular-cytogenetic risk stratification 51(44%),
44 (38%) and 21 (18%) patients belonged to poor, intermediate and good risk
group, respectively.
Results: Sixty-nine of 116 patients (59%) achieved complete remission (CR);
forty-seven 41%) patients were refractory to the salvage therapy. In multivariable
analysis, variables with positive impact on response rate were lower WBC counts
(<10e3/uL, p=0.0047), higher platlets counts (>50x10e3/ul, p=0.046), molecu-
lar-cytogenetic risk (p=0.032), duration of response in relapsed AML (p=0.006)
and relapsed rather than primary refractory disease (p=0.042), respectively.
Median OS was 17 months (m). Cox regression analysis confirmed that both
higher platlets counts, p=0.002 (17 (>50x10e3/ul) vs 11 m (<50x10e37uL), log
Rank, p=0.05) and relapsed disease, p=0.041 (23 (relapsed) vs 17 m (refracto-
ry), Gehan-Breslow, p=0.021) correlated with better survival. Of note, molecu-
lar-cytogenetic risk evaluated before starting treatment was associated with CR,
while no correlation was found with OS in multivariate model.
Summary/Conclusions: Our data seem to confirm the value of FLAG-Ida in
relapsed AML rather than refractory disease, and may suggest its best usage
as bridge-therapy in patients awaiting allotransplantation.
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DECITABINE COMBINED WITH HAAG AS INDUCTION CHEMOTHERAPY
FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
X Tang*, W Cui, Z Jin, J Cao, D Guo, A Sun, X Zhu, H Qiu, C Fu, Y Han,
C Ruan, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Treatment of newly diagnosed acute myeloid leukemia (AML)
remains challenging. Several host- and disease-related factors contribute to
poor outcome in elderly patients or high risk patients with AML, including med-
ical comorbidities, physical frailty, and increased incidence of poor-risk biologic
features. Indicating an urgent need for alternative treatment strategies improv-
ing clinical outcome for these patients. It is confirmed that Decitabine has the
synergistic reaction with daunomycin or cytarabine. Therefore, we investigated
whether Decitabine combined with HAAG regimen might also be effective for
the newly diagnosed of AML patients. 
Aims: To evaluate the efficacy and toxicity of DAC combined with HAAG regi-
men as an induction therapy for newly diagnosed AML patients as well as com-
pared with standard IA(IDA 12mg/m2/d*3d) regimen.
Methods: 130 patients with AML were newly diagnosed in our center bewteen
January 2014 and December 2015.The median age was 4211-82 years.
Among them,49 cases received DAC+HAAG regimen(DAC 20mg/m2/d*5d
combined with low dose of homoharringtonine 1mg/m2/d*7-14d, cytarabine
subcutaneously 10mg/m2/q12h*7-14d, aclarubicin 10mg/d*4-8d and G-CSF
priming). The other 81 patients received standard IA regimen (idarubicin
12mg/m2/d*3d and cytarabine 100mg/m2/d*7d).The outcomes of all the patients
after one cycle of chemotherapy were evaluated.
Results: 1.The complete remission(CR) rate of DAC+HAAG group was supe-
rior than that of IA group(81.6% vs 74.5%, P=0.517), but with no statistically
significant. While the overall response rate (ORR) of DAC+HAAG group was
similar wiht IA group(87.8% vs 88.7%, P=0.786). 2. Median overall survival
(OS) from the starting of DAC+HAAG chemotherapy and IA were 6.5(2-20)
months and 8.5(0.5-25) months (P=0.384). Meanwhile, the estimated one-year
survival of DAC+HAAG and IA group were 55.8%±8.9 and 77.9%±5.4% respec-
tively (P=0.089).3. The survival of DAC+HAAG were not more prior than IA,
but we found that the ages of DAC+HAAG were statistically older than the IA
group(P=0.00). However, in DAC+HAAG group, there were 14 elderly (≥60
years old) that not any one in IA group(P=0.000). The CR rate of the old cases
was 64.3% and the estimated 1-year survival was 73.4%±13.4%. 4. Treatment
related mortality (TRM) was found in 1 case in DAC+HAAG group compared
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with 2 cases in IA group. All patients presented cytopenias of grade 4. There
were no differences on the recovery time of ANC ≥0.5*109/L,HB≥70g/L and
PLT≥20*109/L after induction chemotherapy (P=0.969,0.392,0.225). 5. The
incidence of adverse events including fever, nausea and vomiting, diarrhea
were lower in DAC+HAAG group(P=0.024,0.024 and 0.028). While the hap-
pened of infection,bleeding,cardiovascular impact, liver dysfunction and renal
insufficiency were similar. 6.For the two group, lower blast percentage as diag-
nosed were significantly associated with a higher OS rate (P=0.000 and
P=0.000).
Summary/Conclusions: DAC+HAAG regimen as an induction chemotherapy
for newly diagnosed AML patients could better effectively reduce tumor burden
than IA regimen(no statistical significance) with mild toxicity. For naïve AML
patients, DAC combined with HAAG regimen may be an optimal choice, espe-
cially for patients who cannot tolerate high dose of chemotherapy.
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AGE FACTOR ON REMISSION INDUCTION THERAPY FOR ADULT ACUTE
MYELOID LEUKEMIA
H Kim1,*, HJ Kim2, YH Min3, DS Hong4, HJ Kim5, J Park6, HJ Shin7, WS Lee8,
Y Park9, SK Park10
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sun Hospital, Hwasun, 3Yonsei University College of Medicine, 4Soon Chun
Hyang university Hospital, 5St. Marry Seoul Hospital, Catholic University of
Korea, Seoul, 6Gachon University Gil Hospital, Incheon, 7School of Medicine,
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Busan Paik Hospital, Busan, 9Korea University School of Medicine, Seoul,
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Background: Therapeutic goal for acute myeloid leukemia (AML) is the cure
and usually it can be achieved by intensive chemotherapy. One of the most
important factors to choose remission induction therapy is the patient’s age. 
Aims: We evaluated the impact of age on remission induction therapy for AML.
Methods: The Korean Society of Hematology AML/MDS Working Party built
the adult AML registry. The registry collected 14 year or older patients; however
this analysis included only 18 years or older patients as adult AML.
Figure 1.
Results: Total 3041 cases were collected in the registry and 3008 adult AML
patients were included in this analysis. Enrolled number of patients were pre-
sented in Figure 1A. Risk groups based on karyotype showed strikingly different
tendency among age groups. Poor risk group had a tendency of slight increase
as patients were getting older (21-34%). However more dramatic change was
decreasing better risk group instead of increasing intermediate risk group as
ages increased (Figure 1B). Performing induction chemotherapy was similar
below 60 years ago (89-94%), however it droped to 76% in age 60-70y, 46% in
age 70-80y and only 41% in age older than 80y (Figure 1C). We selected 1935
patients who were older than 17y and not acute promyelocytic leukemia and
received induction chemotherapy and known induction responses. The complete
remission (CR) rates were decreasing as ages increased: 89.5% in age under
20y; 79% in 20-30y; 75% in 30-40y; 76% in 40-50y; 73% in 50-60y; 63% in 60-
70y; 58% in 70-80y; 29% in 80y or older patients. When the analysis was focused
on patients who had received cytababine-idarubicin (AI) or cytarabine-daunoru-
bicin (AD) induction chemotherapy (n=1377), the CR rates were following: 86%
in age under 20y; 77% in 20-30y; 75% in 30-40y; 76% in 40-50y; 73% in 50-60y;
68% in 60-70y; 62% in 70-80y; 50% in 80y or older patients. When analyzing the
population according to risk group, the CR rates were similar in better risk group;
92.9% in age under 20y; 100% in 20-30y; 88.6% in 30-40y; 89.2% in 40-50y;
81.6% in 50-60y; 72.2% in 60-70y; 100% in 70-80y patients. In intermediate risk
group, the CR rates were 84.6% in age under 20y; 78.9% in 20-30y; 74.1% in
30-40y; 79.4% in 40-50y; 77.6% in 50-60y; 74% in 60-70y; 59.5% in 70-80y;
66.7% in 80y or older patients. CR rates were dramatically dropped in elderly
age with poor risk karyotypes; 77.8% in age under 20y; 66.7% in 20-30y; 70.9%
in 30-40y; 59.7% in 40-50y; 61.6% in 50-60y; 54.5% in 60-70y; 44.4% in 70-80y;
0% in 80y or older patients. There was no difference of CR rate between AI and
AD (p=0.542): p=0.685 in 30-40y; p=0.713 in 40-50y; p=0.452 in 50-60y; p=0.813
in 60-70y; p=1.000 in 70-80y; p=1.000 in age older than 80y. However there was
significant higher CR rate among AI regimen in under 30y (p=0.033).
Summary/Conclusions: Age clearly impacts on outcome of induction
chemotherapy. CR rates were similar in favorable risk group in all age groups.
However CR rates of unfavorable risk group dramatically droped in elderly
patients. There was no clear difference between AI and AD induction in terms
of CR rates. Poor outcome in elderly AML can be resulted mainly from poor
risk characteristics.
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DEFINING FRAILTY OF ELDERLY PATIENTS WITH ACUTE MYELOID
LEUKEMIA AT DIAGNOSIS
S Aydin1, E Audisio1, S D’Ardia1, B Allione1, B Nicolino1,*, A Busca2, CM Dellacasa2,
A Evangelista3, G Ciccone3, U Vitolo1
1Oncology and Hematology, 2Oncology and Hematology, Stem Cell Transplant
Center, 3Unit of Cancer Epidemiology, CPO Piemonte, AOU Città della Salute
e della Scienza di Torino, University of Turin, Turin, Italy
Background: Acute myeloid leukemia (AML) is a disease of older adults, with
a median age at diagnosis over 65 years. Evaluation of disease-related and
patients specific factors in the context of clinic decision making has therefore
been largely subjective. Several studies demonstrated improved survival for
older patients receiving intensive induction chemotherapy compared to those
receiving supportive care alone. Defining this subset of patients who are not
eligible or ”not fit” for intensive chemotherapy involves a great deal of subjec-
tivity. Criteria yet have to be standardized across or within institutions.
Aims: Aim of this study was to investigate the validity of three validation scores
for distinction of patient fitness at diagnosis in parallel to physician evaluation.
Further patient outcome according the respective evaluation was compared.
Methods: A total of 69 clinically and molecularly well characterized consecutive
elderly (>60 years) patients with newly diagnosed AML were treated from 2012
to 2015 according to age, performance status and co-morbidities in a single
hematology center. Therapy response was defined according to ELN criteria.
Therapy intensity decision was based on an initial haematologist evaluation fol-
lowed by discussion in an interdisciplinary board. In parallel, the local geriatric
G8 screening tool, the HCT-CI comorbidity score and the AML score proposed
by the German Acute Myeloid Leukemia Cooperative Group, predicting proba-
bility of complete remission (CR) and early death (ED) were performed. Overall
survival from diagnosis was compared between groups using the Cox model.
Results: Thirty-three patients (47,8%) were evaluated “fit” by the medical board
and treated by intensive chemotherapy, whereas 26 patients (37,7%) under-
went semi-intensive/experimental therapy and 10 patients (14,4%) received
best supportive care. A total of 21 patients (31,4%) achieved a complete remis-
sion after induction chemotherapy, whereas 49% patients (25%) were non
responders and 13 (19,4%) died. Overall, the median survival time was 5,2
months (95% CI 3,5-8,3). Primary physician care evaluation was able to define
in a statistically significant manner a “fit” from an “unfit” patient. Median survival
time from the “fit” patients was 8,3 moths (95%CI 6,1-11,2) compared to the
“unfit” evaluated patients with 2,9 months (95%CI 1,3-4,4), p=0,004. Parallel
evaluation of patients fitness using the G8, HCT-CI and AML scores discrimi-
nated significantly “fit” from “unfit” patients considering median survival time,
p=0,001, p=0,032 and 0,021, respectively. The ability of the frailty scores on
the prediction of fitness classification compared to the physician evaluation
was analyzed by calculating the area under the curve (AUC) using a logistic
regression model. In this approach an AUC of 1,0 denotes perfect prediction
whereas and AUC of 0,5 is analogous to a coin flip. With this regard the AUC
for the G8 Score was 0,73, whereas the HCT-CI was 0,72 and the AML score
ED 0,78 and the AML CR 0,79 in the present cohort.
Summary/Conclusions: In conclusion, in the present cohort the applied frailty
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scores at diagnosis correlated significantly regarding median overall survival.
These results may encourage a following larger multi-centre analysis in order
to verify the statistic power of the performed analysis.
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GENOTYPIC AND PHENOTYPIC CLONAL EVOLUTION IN RELAPSED
FAVORABLE-ACUTE MYELOID LEUKEMIA PATIENTS
C Martinez Losada1,*, J Serrano1, N Noguera2, E Garza2, L Borgia2, L Piredda2,
S Lavorgna2, T Ottone2, F Lo Coco2, J Sanchez-García1
1Hospital Reina Sofia, Cordoba, Spain, 2Tor Vergata University, Rome, Italy
Background: Despite high rates of cure with standard chemotherapy in
patients with favourable-risk acute myeloid leukemia (AML) according to Euro-
pean Leukemia Net (ELN) classification, some patients will eventually relapse.
It is currently unclear whether leukaemia relapse is due to intrinsic chemo resist-
ance or to clonal evolution with acquisition of new driver mutations and clonal
selection 
Aims: Characterization of phenotypic and genotypic features at relapse com-
pared to diagnosis in patients with molecular/cytogenetic favourable-risk AML
presenting relapse after achieving complete remission (CR).
Methods: Retrospective study of 13 molecular/cytogenetic low risk AML
patients (Non-M3) (CBF 3 NPM1 10) according to ELN classification criteria
from Tor Vergata Hospital (Rome) and Reina Sofia Hospital (Córdoba). They
were treated with intensive chemotherapy achieving CR and relapsed after a
median of 12.2 months (4.4-255.9) (Table 1). NRAS, KRAS, DNMT3A, IDH1,
IDH2 and TP53 genes were analyzed in marrow samples obtained at relapse
by Sanger Sequencing using ABI 3130® Genetic Analyzer (Applied Biosystems
Inc., Foster City, CA). When a mutation was found, the diagnosis sample for
this mutation was screened using Sanger Sequencing also. A complete phe-
notypic profile was carried out using multiparametric flow cytometry with 3-
laser FACSCanto II in both diagnosis and relapse samples. Additionally, all
mutations were tested at diagnosis in 7 patients with favourable-risk AML
achieving continuous CR (non-relapsing patients)
Results: In non-relapsing patients, only a case with IDH1 mutation (R132H)
was found. When analyzing relapse-diagnosis paired samples in 13 AML
patients, three patterns of clonal evolution were found: Group A (8 patients):
Genotypic (G) and phenotypic (P) persistence of the main clone. Two patients
presented a mutation in DNMT3A gene: R882H mutation and
c.2705_2706delTC (p.F902fs) mutation (not described so far) respectively. Both
mutations were found in diagnosis and relapse samples and phenotypic profile
remained unchanged. Group B (2 patients): Phenotypic profile evolution but
no changes in genotype. One patient harboured a mutation in DNMT3A gene
(R882H) in both diagnosis and relapse samples. Many importants phenotypic
changes were observed: In diagnosis sample, CD65+, CD19-, CD15+, CD117+,
DR+, CD56LOW, CD7-, CD13+, CD2+, CD11b+, CD14-, CD38+, CD34+,
CD33+ were expressed in the main leukemic clone. In the relapse sample,
CD15, DR, CD56, CD2 and CD11b not expressed. Group C: 3 patients pre-
sented phenotypic and genotypic clonal evolution. The mutations were detected
in relapse but not in diagnosis samples: i) D876Y mutation in DNMT3A gene
(not described so far), accompanied with phenotypic profile changes with acqui-
sition of CD34 and CD117 and loss of CD15. ii) R140Q mutation in IDH2 gene
and G105 mutation in IDH1 gene with a phenotypic evolution with acquisition
of CD34 and loss of a suclone CD56 +. iii) G105 in IDH1 gene with a phenotypic
evolution with increased of CD33 and acquisition of CD15. These mutations
were studied by NGS in the diagnosis samples. IDH mutations were present in
both patients, while DNMT3A gene remained wild type.
Table 1.
Summary/Conclusions: i). Driver mutations are found more frequently in
patients with favourable-risk AML who relapse compared to those with sustained
CR. ii). 3 patterns of relapse were detected: A). No P changes/G (N=8); B). P
Changes/No G (N=2). C). P changes/G (N=3). These results highlight the impor-
tance of clonal evolution at relapse in favourable-risk AML patients. 
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DNMT3A MUTATIONS IN ACUTE MYELOID LEUKAEMIA WITH INTERME-
DIATE-RISK KARYOTYPE - INCIDENCE AND CORRLEATION WITH OTHER
GENE MUTATIONS
GF How*, SJ Khoo, LT Tan, C Chuah
Haematology, Singapore General Hospital, Singapore, Singapore
Background: Acute myeloid leukaemia is an aggressive heterogeneous
haematopoietic disease. It is characterized by an increased proliferation of
haematopoietic progenitor cells that have lost the ability to differentiate. In the
last 15 years, major advances have been made in the disease with the discov-
ery of many genetic abnormalities affecting cell proliferation, differentiation,
apoptosis or cell cycle regulation. Some of these molecular markers confer
good prognosis while others have been found to be adverse prognostic factors.
Of the molecular markers, DNMT3A (DNA N-methyltransferase 3A) gene muta-
tion is found to be an independent poor prognostic marker in most studies.
Aims: In this study, we evaluated the mutation status of DNMT3A in AML
patients with intermediate-risk cytogenetics, in particular, those with normal
karyotype. The incidence of DNMT3A mutations was correlated with the muta-
tion status of other genes like FLT3, NPM1, IDH1 and IDH2 which were also
determined.
Methods: For the detection of DNMT3A mutations, exon 26 of the gene was
PCR amplified and direct sequencing of the amplicons was performed to detect
mutation hotspots in this exon in a cohort of 93 patients.
Table 1.
Results: A total of 16(17%) patients were identified with R822 mutations in
DNMT3A exon 26. R882H was the predominant mutation in these patients
(n=10) while the remaining 6 had R822C. Of these 16 patients, 14 (87.5%) of
them were also NPM1-mutated while 9 had FLT3/ITDs as well. The close asso-
ciation of DNMT3A mutations with NPM1 mutations was significant (p=0.048)
while that with FLT3/ITDs was not quite statistically significant (and p=0.084).
IDH mutations were detected in only 3 patients with R882 mutations (IDH1
R132H, n=1; IDH2 R140Q, n=2). The relation between DNMT3A mutations
and other patient characteristics were determined by the Mann Whitney U test
(continuous variables) and the Fisher exact test (categorical variables) (details
in Table 1). The platelet counts were significantly higher in the DNMT3A -positive
patients than in the patients without DNMT3A mutation (p=0.0125). DNMT3A
mutations were also significantly enriched in patients with the FAB M5 subtype
(12/22, 55%, p=<0.0001). Other clinical parameters showed no significant dif-
ference between the DNMT3A-positive group and the wild type group. Inter-
estingly, in a patient who was separately investigated, FLT3/ITDmut, NPM1mut
and DNMT3A R882C were detected at diagnosis but while FLT3/ITD was not
detected on follow-up at relapse, an IDH2 R140Q was observed. The R882C
status, however, remained unchanged. Previous larger study series have
demonstrated the stability of DNMT3A during the course of disease.
Summary/Conclusions: Within the normal karyotype and other intermediate
risk AMLs, we did not observe any significant correlation of DNMT3A mutations
with white blood cell counts, FLT3/ITD or IDH mutations, contrary to what was
observed in other studies which involved AMLs across all cytogenetic risk groups.
We hope the findings from this preliminary study would help improve our under-
standing of the association of DNMT3A mutations with other gene mutations in
intermediate risk AMLs. Further work is needed to investigate the significance
of the DNMT3A exon 26 mutations, in particular, the R882 mutations, as a prog-
nostic predictor and the role of screening of these mutations for further risk-
stratification of intermediate risk AMLs, particularly in normal karyotype AML.
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CLINICAL CHARACTERISTICS OF ACUTE MYELOID LEUKEMIA PATIENTS
FROM REGIONS CONTAMINATED BY DEPLETED URANIUM: 20 YEAR
ANALYSIS
L Mehinovic1, A Kozaric1,*, A Dizdarevic2, S Kurtovic2
1Pathology, Cytology, and Human Genetics, 2Hematology, Clinical Center of
the University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Background: During the war in Bosnia (1992-1995), ammunition with depleted
uranium was used in several regions, including the town of Hadzici, where the
United Nations have measured high concentrations of depleted uranium several
years after the war. Depleted uranium (DU), a radioactive heavy metal, is used
in military ammunition. Studies have shown the potential health risks of con-
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tamination by DU by wounding, ingestion, and inhalation. In vivo and in vitro
experiments showed the carcinogenic potential of DU by neoplastic transfor-
mation of human and mouse cells, leading to the development of myeloid neo-
plasms. It is assumed that the DU exposure induces genomic stability leading
to carcinogenesis.
Aims: Increased numbers of patients with blood cancers in DU stricken area
was noted by hematologists, so we systematically analyzed hematological
patients from this region in the last 20 years, from 01.01.1996.-31.12.2015. 
Methods: We systematically analyzed hematological patients from two region
in the last 20 years, from 01.01.1996.-31.12.2015. One region had high con-
centrations of DU (Hadzici) and the other region (ilijas) was used as a control.
Both regions have the same population size and same access to tertiary health
care. Patient data was collected including age at diagnosis, sex, address, blood
parameters, cytogenetics, therapy, and survival. 
Results: In the 20 year analyzed period from 01.01.1996–31.12.2015, we
found 717 patients with hematological conditions (437 from DU-stricken town
vs 280 from control town). There were 74 patients with myeloid malignancies
(54 vs 20), 55 patients with non Hodgkin lymphoma (26 vs 29), 21 patients
with Hodgkin lymphoma (9 vs 12), and 6 patients with ALL (4 vs 2). Among the
myeloid neoplasms, CML showed 6 fold increase in DU-stricken area and AML
showed 3 fold increase. The median age at diagnosis for AML patients was 41
vs 73, and for CML patients was 62 vs 53. Male to female ratio was for AML
0.5 vs 1, and for CML 1 vs 7. For AML patients, 22% vs 67% of patients achived
complete remission after first treatment. The median duration of remission was
10.5 v 17.5 months. OS at 24 months was 22% vs 50%.
Summary/Conclusions: Clinical parameters showed more severe course of
acute myeloid leukemia patients in DU stricken area compared to the control
and international data. Further investigation is needed to elucidate the possible
causes of stark increase in myeloid neoplasms in Hadzici area.
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COMPARISON OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION TO INTENSIVE CONSOLIDATION CHEMOTHERAPY
AND MONITORING MINIMAL RESIDUAL DISEASE IN CORE BINDING
FACTOR ACUTE MYELOID LEUKEMIA
HK Kim*, S Park, JH Jang, SJ Kim, WS Kim, K Kim, CW Jung
Division of Hematology-Oncology, Department of medicine, Samsung medical
center, Seoul, Korea, Republic Of
Background: One third of patients with core binding factor (CBF) acute myeloid
leukemia (AML) relapse and disease relapse is most common cause of treat-
ment failure. For detecting relapse, quantitative RT-PCR of AML1-ETO or CBFB-
MYH11 fusion transcript is used to evaluate minimal residual disease (MRD).
Aims: The purpose of this study was to compare the clinical outcome of post-
remission therapy between autologous peripheral stem cell transplantation
(ASCT) and intensive consolidation chemotherapy in CBF AML patients and
to assess MRD in patients who accomplished first CR(CR1) after induction
chemotherapy using quantitative RT-PCR of AML1-ETO transcript.
Methods: We retrospectively analyzed adult patients who diagnosed with CBF
AML between March 1996 and July 2014, and achieved CR1 after induction
chemotherapy at Samsung Medical Center. The patients were divided into two
groups who received ASCT or 3 to 4 cycles of intensive consolidation chemother-
apy as post-remission therapy. In addition, we also investigated the impact of
MRD after induction chemotherapy using quantitative RT-PCR of AML1-ETO
for patient with t(8;21). AML1-ETO transripts were normalized to ABL.
Figure 1.
Results: We identified 65 patients (Male=33, Female=32; t(8;21)=45,
inv(16)=20) and the median age at diagnosis was 42 years(range 18-64). 26
patients (40%) received ASCT as postremission therapy and 40 patients were
treated with 3 to 4 cycles of intensive chemotherapy. The ASCT group showed
a better 5-year relapse free survival (RFS) rate (50.5% vs 67.0%, p=0.381)
and similar 5-year overall survival (OS) rate (59.5% vs 66.6%, p=0.743) during
median follow-up 96 months. The median value of AML1-ETO mRNA levels in
bone marrow was higher in relapsed patients with t(8;21) than non-relapsed
patients (425.79 vs 3.29, per ABL x 103, p=0.045). We determined cutoff for
MRD as the median value of AML1-ETO transcript of all patients with t(8;21),
3.39 per ABL x 103. The 5-year RFS rates in the patients without and with MRD
were 87.5% and 68.6%, respectively. (p=0.391).
Summary/Conclusions: This study demonstrated that ASCT as postremission
therapy showed a better RFS than chemotherapy alone in patients with CBF
AML, monitoring minimal residual disease by AML1-ETO mRNA levels as sur-
rogate marker of patients with t(8;21) in CR1 was beneficial.
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PROGNOSTIC IMPLICATIONS OF THE IDH1 SINGLE NUCLEOTIDE
POLYMORPHISM RS11554137 IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA
E Petrova*, I Martynkevich, L Polushkina, L Martynenko, M Ivanova, N Cybakova,
E Kleina, E Shabanova, A Chechetkin, K Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Saint-Petersburg, Russian Federation
Background: Several studies have shown that synonymous single nucleotide
polymorphisms directly impact gene function through various translational or
post-translational mechanisms, such as altering mRNA binding, protein folding,
the spliceosome, mRNA stability, or expression in general. Mutations in 132
codon of IDH1 gene are quite frequent event in acute myeloid leukemia (AML).
Also, approximately 10% of AML patients were detected to have polymorphism
rs11554137 in the 4th exon of IDH1 gene. Data concerning the impact on prog-
nosis of polymorphism rs11554137 is still controversial.
Aims: To investigate the frequency and prognostic value of polymorphism
rs11554137 in IDH1 gene, its combination with clinical hematological features
and karyotype variant in AML pts.
Methods: The study included 112 pts with AML (median age - 55 years). In
103 pts (92.0%) was verified de novo AML and in 9 (8.0%) - secondary AML
from preceding MDS or lymphoma. Cytogenetic analysis was performed on G-
differentially stained chromosomes, so pts were divided into 4 groups: with
normal karyotype (NK) - 52 (46.4%), favorable karyotype - 9 (8.0%), unfavor-
able karyotype - 16 (14.3%), with other chromosomal abnormalities - 35
(31.3%) pts. Screening of IDH1 gene aberrations was performed by real-time
PCR with further analysis of melting curves.
Results: Polymorphism rs11554137 in IDH1 gene was detected in 7.1% (8
out of 112) of pts with AML. Distribution of pts with AML, depending on the
morphological variants showed that polymorphism rs11554137 was more com-
mon in pts with M4 variant (5 of 20, p=0.005). All pts with polymorphism
rs11554137 had de novo AML. The median age of pts with polymorphism
rs11554137 (58 years) was significantly higher than in pts without it (55 years)
(p=0.005). There was no significant differences when the number of white blood
cells and platelets in PB, blasts in BM in pts with and without polymorphism
rs11554137 was compared. Slightly more often polymorphism rs11554137 in
IDH1 gene occured in pts with NK (5 of 8 pts; p=0.334), 3 pts with polymorphism
had unfavorable karyotype. None of the pts with favorable karyotype was
detected to have polymorphism rs11554137. All pts with polymorphism
rs11554137 in IDH1 gene were screened for mutations in FLT3, NPM1, NRAS,
CKIT and DNMT3A genes. Only in 2 pts polymorphism rs11554137 in IDH1
gene was met singly. In the remaining pts (6 of 8) polymorphism rs11554137
was found simultaneously with mutations in other genes: DNMT3A+, FLT3-
TKD+, NPM1+, FLT3-ITD+/DNMT3A+, FLT3-ITD+/FLT3-TKD+/DNMT3A+ and
in 2 pts polymorphism rs11554137 was detected in combination with FLT3-
ITD. We also investigated the prognostic value of polymorphism rs11554137
in IDH1 gene. Comparative analysis of median overall and relapse free survival
in pts with and without polymorphism showed significant differences: 5.8
months and 12.8 months (p=0.046) and 4.2 months and 9.5 months (p=0.004)
respectively.
Summary/Conclusions: Polymorphism rs11554137 in IDH1 gene is quite fre-
quent event in pts with AML. It is usually associated with M4 variant of AML
and higher median age as compared with pts without polymorphism. Significant
prognostic potential of polymorphism rs11554137 in IDH1 gene allows to con-
sider it as an unfavorable marker correlated with a high risk of relapse and
poorer survival. Synonymous polymorphisms represent a special category of
molecular aberrations that should be considered in the diagnosis and prognosis
of AML pts.
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FRONT-LINE CENTRAL VASCULAR ACCESS DEVICES IN ACUTE
LEUKEMIAS – PERIPHERALLY INSERTED CENTRAL CATHETER (PICC)
VERSUS TRADITIONAL CENTRAL VENOUS CATHETER(CVC): A PHASE
IV RANDOMIZED TRIAL (NCT02405728)
C Cerchione*, M Di Perna, R Della Pepa, N Pugliese, V Caprioli, C Frieri,
F Pane, M Picardi
Hematology, Ematologia e Trapianto/AU Federico II, Napoli, Italy
Background: The use of PICC as an alternative to other CVC devices, partic-
ularly for prolonged infusions of cytotoxic agents, blood products and/or other
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supportive therapy, is becoming very frequent in cancer patients. PICCs are
easier to insert, and associated to a lower rate of complications than traditional
CVC. However, in the setting of high-risk patients with acute leukemia there is
limited information on the feasibility and safety of PICC as primary vascular access
device. Our Hematology Department is conducting a Phase IV randomized trial.
We compare PICC versus traditional CVC as front-line venous access device in
patients with acute leukemias undergoing remission induction chemotherapy.
This trial is registered on ClinicalTrials.gov, number NCT02405728 (ongoing).
Aims: Primary endpoint is the occurrence of catheter-related bloodstream infec-
tions and/or catheter-related thrombosis. Secondary endpoints are the occur-
rence of other complications, such as pneumothorax or catheter occlusion, and
patient quality of life. Questionnaire covering functional status, sleep and
hygiene disturbance had been given to assess patients’quality of life.
Methods: From April 2015 to February 2016, 152 patients with acute leukemia
planned for remission induction chemotherapy were randomly assigned (1:1)
to PICC (Arm A) or traditional CVC (Arm B). Inclusion Criteria were: age >18
years, suspected survival >4 weeks, and need of central venous access device
(long-term; >4 weeks). While exclusion criteria were ongoing uncontrolled sys-
temic infection, presence of significant thrombosis/stenosis in arm or central
veins, and inability to communicate and/or to sign informed consent. All inser-
tions were followed by chest X-ray.
Results: 152 patients (130 AML, 22 ALL), median age 47 years (13-82), were
randomized in the two arms. In Arm A, 76 PICCs were inserted in 76 hemato-
logical patients (median age 51.5 years, r.19-82, 17 females, 59 males) suffering
from acute myeloid leukemia (AML: 70) or acute lymphoblastic leukemia (ALL:
6). Double lumen PICCs (5 Fr) were inserted in 70 patients, single lumen PICCs
(4 Fr) were inserted in 5 patients, and triple lumen PICC (6Fr) was inserted in
1 patient. 68 PICCs were inserted in the right basilica vein, 5 PICCs were insert-
ed in the left basilica vein and 3 PICCs were inserted in the left brachial vein.
In Arm B, 76 traditional CVCs were inserted in other 76 hematological patients
(44 males, 32 females) suffering from AML (60) or ALL (16). 45 CVCs were
inserted in subclavian vein and 31 CVCs were inserted in jugular vein. Overall,
the median duration of in situ catheter placement was 5 months. In the arm A,
median duration of device was 6 months (r. 12-8), catheter-related thrombosis
occurred in 8 patients (6 basilica vein, 2 brachial vein) and catheter-related
bloodstream infections in 4 patients (2 methicillin-resistant, 1 coagulase-nega-
tive, 1 staphylococci). In the arm B, median duration of device was 3 months
(r. 5-10), 20 cases of catheter-related thrombosis (7 subclavian vein, 13 jugular
vein) and 15 cases of catheter-related bloodstream infections (3 methicillin-
resistant, 2 coagulase-negative, 4 staphylococci, 6 enterobacteriaceae) were
observed. Thus, PICCs were significantly associated with fewer major compli-
cations compared with traditional CVC (catheter-related thrombosis: 10.5% in
the arm A vs. 26% in the arm B, P=0.01 by χ2 test; catheter-related bloodstream
infections: 5% in the arm A vs. 19% in the arm B, P=0.007 by χ2 test).
Table 1.
Summary/Conclusion: The preliminary observations of this ongoing Phase
IV randomized study, focusing on front-line use of central venous access device,
suggest that the use of PICC represents an advance in terms of decrease of
complication rate and improve of quality of life for patients with acute leukemia.
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EFFICACY AND SAFETY OF ETOPOSIDE IN COMBINATION WITH G-CSF,
LOW-DOSE CYTARABINE AND ACLARUBICIN IN NEWLY DIAGNOSED
ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
L Gao1, YM Feng1, HJ Yan1, YQ Zhang2, C Zhang, L Gao1, PY Kong1, Y Liu1,
LD Zhu3, YJ Zeng1, J Rao1, Y Su4, TH Yang5, SB Wang6, HM Li7, SF Lou8,
X Zhang1,*
1Department of Hematology, Xinqiao Hospital, Third Military Medical University,
2Department of Health Statistics, 3Department of Hematology, Collage of Mili-
tary Preventive Medicine, Third Military Medical University, Chongqing, 4Depart-
ment of Hematology, General Hospital of Chengdu Military Region of
PLA,Sichuan, Chengdu, 5Department of Hematology, Yunnan Provincial Peo-
ples Hospital, Yunnan, 6Department of Hematology, General Hospital of Kun-
ming Military Region of PLA, Yunnan, 7Department of Hematology, Yunnan
Medical College, Kunmin, 8Department of Hematology, Second Affiliated Hos-
pital, Chongqing Medical University, Chongqing, China
Background: Chemotherapy for elderly patients with acute myeloid leukemia
(AML) is still a great challenge. Although 50% AML patients could achieve com-
plete remission (CR) after intensive 3+7 regimen, treatment-related toxicities
(TRT) appeared particularly prominent in elderly patients. In 2013, a multi-
center randomized controlled trial in southwestern China confirmed that 71.1%
refractory or relapsed AML achieved CR after received etoposide combine with
low-dose CAG (E-CAG) regimen, and TRT was low, with no mortality. 
Aims: This prospective phase II, open label, randomized controlled study was
designed to assess the efficacy and safety of E-CAG induction treatment for
elderly patients with newly diagnosed AML.
Methods: The effect of E-CAG on the rate of CR was the main study end-
point. The median survival time and the toxicity of the E-CAG regimen were
also evaluated. 
Results: After induction chemotherapy, patients with E-CAG regimen had a
similar CR rate than did patients who received DA regimen (55.1% vs 48.9%,
P=0.158). The tolerability profiles of E-CAG regimen appeared better than DA
regimen. Especially, gastrointestinal reaction and III-IV bone marrow suppres-
sion. The median survival time was extended for 4 months in E-CAG group
(14.3 months vs 10.3 months, P=0.042). The two-year OS probability in E-CAG
group and DA group was 24.2% and 11.3%, perspectively. 
Summary/Conclusion: The E-CAG regimen seems promising and offers lower
toxicity for the treatment of elderly patients with AML, and expected to become
a bridge for non-myeloablative stem cell transplantation.
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OUTCOMES WITH RITUXIMAB MONOTHERAPY VERSUS R-CHOP IN
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE ARISING AFTER
SOLID ORGAN TRANSPLANT: A UNITED KINGDOM MULTICENTRE
STUDY
D Burns1,2,*, C Klesham3, YA Hodgson4, L Fredrick5, J Haughton6, M Lannon7,
H Hussein7, C Byrne8, C McNamara3, B Vydianath9, A Lennard7, R Johnson6,
J Wright5, C Fox4, K Cwynarski3, S Chaganti2
1Institute of Cancer and Genomic Sciences, University of Birmingham, 2Centre
for Clinical Haematology, University Hospital Birmingham, Birmingham,
3Department of Haematology, Royal Free Hospital, London, 4Centre for Clinical
Haematology, Nottingham University Hospital, Nottingham, 5Department of
Haematology, Sheffield Teaching Hospitals, Sheffield, 6Department of Haema-
tology, St James’s Institute of Oncology, Leeds, 7Department of Haematology,
Freeman Hospital, Newcastle upon Tyne, 8Department of Renal Medicine, Not-
tingham University Hospital, Nottingham, 9Department of Pathology, University
Hospital Birmingham, Birmingham, United Kingdom
Background: Post-transplant lymphoproliferative disease (PTLD) remains an
important complication of solid organ transplantation (SOT). There is currently
a lack of data to guide selection between Rituximab monotherapy (R-mono)
and R-CHOP as options for frontline therapy of B-cell PTLD.
Aims: To report outcomes and prognostic factors for patients with B-cell PTLD
arising after SOT, comparing R-mono vs R-CHOP as initial therapy.
Methods: This retrospective study included adult patients from 6 centres in
the United Kingdom diagnosed with biopsy-proven PTLD between 2000-2013.
Median follow-up was 4 years 2 months.
Results: Of 116 cases of PTLD identified, 100 were categorised as B-cell
PTLD and were included in this analysis. Histological subtypes were 67 DLBCL,
23 polymorphic and 10 B-cell PTLD otherwise unspecified. There were 62
renal, 30 liver, 7 cardiothoracic and 1 pancreatic transplant recipients. Median
age at diagnosis was 48 years (range 16-84 years) and 65% of patients were
male. Early onset disease, presenting ≤1 year after transplant, comprised 15%
of cases. EBV-association was noted in 55/78 (71%) of evaluated cases and
this was related to early onset disease (X2 p=0.004). Initial therapy was R-
mono in 26/100 (26%) and R-CHOP in 45/100 (45%). Use of R-CHOP was
associated with monomorphic histology (OR 18.3, p=0.001), ≥2 extranodal
sites (OR 4.5, p=0.03), late onset disease (OR 6.2, p=0.01) and lack of EBV
association (OR 0.08, p=0.002). Of patients treated with R-mono, 25/26 (96%)
completed at least 4 infusions of Rituximab 375 mg/m2 weekly, with no treat-
ment-related deaths. Of those treated with R-CHOP, 33/45 (73%) completed
at least 6 cycles, although there were 4 treatment-related deaths. The overall
response rate for R-mono was 20/26 (77%; 14 CR, 6 PR, 5 NR and 1 undeter-
mined) compared to 36/45 (80%; 30 CR, 6 PR, 5 NR and 4 undetermined) for
R-CHOP. Amongst patients treated with R-mono, 17/26 (65%) had no further
therapy and remained disease free with median follow-up of 44 months; 6 other
patients received R-CHOP for consolidation of response or relapsed/refractory
disease. Overall survival (OS) was 71% and 61% at 3 years for R-mono and
R-CHOP respectively (p=0.40; Figure 1A). Amongst all patients with B-cell
PTLD, significant baseline predictors of inferior OS were age ≥50 years (HR
3.8, p<0.001), ECOG PS ≥2 (HR 1.9, p=0.04), elevated LDH (HR 2.0, p=0.08
borderline), stage ≥2 disease (HR 2.5, p=0.01) and ≥2 extranodal sites (HR
1.8, p=0.08 borderline). Overall response to R-mono or R-CHOP was also
highly predictive of OS (HR 0.16, p=0.0001). B symptoms, onset time, extran-
odal disease, histology and EBV-association were not predictive. In multivariate
testing, age ≥50 years (HR 5.3, p=0.0001) and advanced stage (HR 2.2, p=0.06
borderline) remained significant. Applying a 4 point modified prognostic index
(comprising age ≥50 years, stage ≥2 disease, ECOG PS ≥2 and elevated LDH)
to patients treated with R-mono or R-CHOP, those with low risk disease (0-1
points) had significantly improved survival compared to those with high risk
disease (≥2 points), with 3 year OS of 87% vs 51% (p=0.001; Figure 1B).
Amongst patients with high risk disease, 13 treated with R-mono had an inferior
complete response rate compared to 21 treated with R-CHOP (23% vs 67%;
OR 0.15, p=0.02), although a survival difference was not detected.
Figure 1.
Summary/Conclusions: We report outcomes for R-mono vs R-CHOP as initial
therapy for PTLD arising after SOT. R-mono may deliver inferior response rates
for patients with high risk disease. Using a modified prognostic index we identify
a subset of patients with poor outcome for whom novel therapeutic strategies
are required.
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EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE OF ADVANCED
STAGE: NKEA (NEXT-GENERATION THERAPY FOR NK/T-CELL
LYMPHOMA IN EAST ASIA) PROJECT
R Suzuki1,*, M Yamaguchi2, M Oguchi3, N Asano4, N Tomita5, J Amaki6,
T Ando7, N Niitsu8, N Sekiguchi9, J Takizawa10, K Miyazaki2, N Katayama2
1Cancer Center, Shimane University, Izumo, 2Hematology, Mie University, Tsu,
3Radiation Oncology, Japanese Foundation for Cancer Research Cancer Insti-
tute Hospital, Tokyo, 4Molecular Diagnostics, Nagano Prefectural Suzaka Hos-
pital, Suzaka, 5Hematology, Yokohama City University, Yokohama, 6Hematol-
ogy, Tokai University, Isehara, 7Hematology, Saga University, Saga, 8Hema-
tology, Saitama Medical University, Moroyama, 9Hematology, Shinshu Univer-
sity, Matsumoto, 10Hematology, Niigata University, Niigata, Japan
Background: Treatment of extranodal NK/T-cell lymphoma, nasal type (ENKL)
has proceeded and evolved. Concurrent chemoradiotherapy with platinum-con-
taining regimen and L-asparaginase based chemotherapy such as SMILE
(steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) are the cur-
rent standard for limited- and advanced-stage ENKL, respectively. However,
there are no large-scale study which analyzed the data of patients in general
practice.
Aims: To understand the recent conditions of ENKL, we conducted a survey
for new-generation therapy for NK/T-cell lymphoma in East Asia (NKEA).
Patients with advanced-stage were analyzed in this study.
Methods: This cooperative study by hemato-oncologists and radiation oncol-
ogists in Japan (UMIN000015491) retrospectively analyzed data from patients
with ENKL who were diagnosed between 2000 and 2013.
Results: Data of 358 patients with ENKL of all clinical stage were collected
from 31 institutes. A total of 102 patients were in advanced stage (4 with stage
III and 98 with stage IV). There were 64 males and 38 females. The median
age was 59 years, ranging from 18 to 86 years old. A total of 27 patients were
initially treated with CHOP-type regimen, 33 patients with DeVIC-type, and 30
patients with SMILE-type regimen, but 12 patients did not receive any
chemotherapy. In total, 23 patients received additional radiotherapy (RT). The
median dose of RT was 48 Gy. Thirty patients received hematopoietic stem
cell transplantation (SCT, 10 autologous and 20 allogeneic). Patients who were
initially treated with SMILE-type treatment more received SCT (50% vs 26%
with CHOP-type or 24% with DeVIC-type). The overall response rate was 67%
for SMILE-type, 45% for DeVIC-type, and 33% for CHOP-type regimens. The
5-year overall survival (OS) rate was 25% with a median follow-up of 5.8 yrs,
and the 5-year progression free survival (PFS) rate of 17%. OS of patients
who received SMILE-type, CHOP-type, and DeVIC-type regimen was 39%,
28%, and 19%, respectively (P=0.04). addition of RT did not affect the progno-
sis of advanced ENKL (5-year OS: 24% for patients without RT and 26% for
patients with RT). Prognosis of patients who received SCT was better than
those who did not (5-year OS: 55% vs 12%). The type of SCT (autologous vs
allogeneic) did not affect the prognosis (5-year OS: 40% for autologous vs
62% for allogeneic). The international Korean Prognostic Indexes were not
prognostic (P=0.54 and 0.30, respectively), but the PINK (Prognostic Index for
NK) score was prognostic (P=0.03).
Figure 1.
Summary/Conclusions: The efficacy of SMILE-type chemotherapy for
advanced ENKL was shown in this study, although there remains several lim-
itations of retrospective nature. A novel prognostic index of PINK successfully
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predicted the prognosis. The prognosis of advanced-stage ENKL has improved
as compared with that in the previous-era, but further betterments are required.
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VALIDATION OF NCCN INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI)
FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). THE ADDITION OF
Β2MICROGLOBULIN RESULTED IN GELTAMO-IPI THAT IS MORE
ACCURATE
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Background: The NCCN International Prognostic Index (NCCN-IPI) for
patients with DLBCL treated in the rituximab era showed enhanced discrimina-
tion in the original study, when compared to IPI. However, in our previous study
(ASH 2015 #3955) it failed to identify patients with a real poor outcome. 
Aims: In the present study we explore the prognostic effect of adding new fac-
tors to the variables of NCCN-IPI in a large series of patients.
Methods: This nation-wide retrospective study includes a final database of 1848
patients with de novo DLBCL diagnosed in 20 Spanish centers within the Grupo
Español de Linfomas/ Transplante de Médula Osea (GELTAMO) network treated
with standard chemotherapy and rituximab. To study the improvement of the prog-
nostic effect of adding three new variables, normalized high serum β2 microglobulin
(β2mcg), primary extranodal involvement and treatments more intense than R-
CHOP, to the NCCN-IPI variables, the series was split in two cohorts. The training
cohort (1230 patients) was used to develop a prognostic model using Cox regres-
sion models for Overall Survival and the final model was validated in an independ-
ent validation cohort (618 patients). The Kaplan Meyer method and log-rank test
were used for OS and comparison of curves. The prognostic effect of this score
was compared with NCCN-IPI and IPI with the reclassification calibration statistics
(a modification of Hosmer–Lemeshow goodness of fit).
Results: The COX regression model in the training cohort, showed that distinct
extranodal involvement (as included in NCCN-IPI), primary extranodal lymphoma
and intense treatment achieved no significance. The final model included the
rest of the variables, with points according with the hazard ratios: age (<65/0
pts; ≥65-79/1 pt; ≥80/2 pts), PS(0-1/0 pts ; 2/1 pt ;≥2/2 pts), high LDH, Stage III-
IV and high β2mcg, with 1 point each, resulting in a score (GELTAMO-IPI) with
a maximum of 7 points that separated significantly four risk groups: LR (0 points),
LIR (1-3 pts), HIR (4 pts), HR (≥5) with significantly different 5-yOS that was
subsequently confirmed in the validation cohort. Using all the patients in the
series with available data (n=1672), GELTAMO-IPI discriminates better (5-yOS
rates of LR: 93%, LIR 79%, HIR 66%, HR 39%) than NCCN-IPI (93%, 83%,
67%, 49%, respectively) and IPI (88%, 77%, 68%, 51%, respectively); both
NCCN-IPI and IPI failed to identify a population with a 5-yOS substantially lower
that 50%. Similar results were obtained for 5-yFFS. In the reclassification cali-
bration statistics GELTAMO-IPI was more accurate than NCCN-IPI and IPI.
Figure 1.
Summary/Conclusions: GELTAMO-IPI including β2mcg along all the variables
of NCCN-IPI (excluding selective extranodal involvement) is more accurate than
NCCN-IPI and IPI for the prognosis of DLBCL. Additionally, it can be used in pri-
mary nodal and extranodal lymphoma and in patients with intense treatment
and, most important, identifies a poor prognostic group with 5y-OS of 39%.
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Background: Central Nervous System (CNS) relapse of Diffuse Large B-cell
Lymphoma (DLBCL) is associated with a poor prognosis. CNS prophylaxis is
administered to patients deemed to be at high risk of CNS relapse but the indi-
cations for prophylaxis are not standardized. The German High-Grade Non-
Hodgkin Lymphoma Study Group (DSHNHL) recently proposed a new 6-factor
prognostic model incorporating the 5 International Prognostic Index (IPI) factors
in addition to kidney/adrenal gland involvement to determine the risk of CNS
relapse in patients with aggressive B-cell lymphoma. This model stratified
patients into 3 risk groups: low [0-1 factors, 2 yr CNS relapse risk=0.6% (95%
CI 0.0-1.2)]; intermediate [2-3 factors, 2 yr CNS relapse risk=3.4% (95% CI
2.2-4.6)] and high risk [4-6 factors, 2 yr CNS relapse risk=10.2% (95% CI 6.3-
14.1)] (Schmitz et al, Lugano 2013); which was subsequently validated in an
independent cohort of R-CHOP-treated patients with DLBCL at the British
Columbia Cancer Agency (BCCA) (Savage et al, ASH 2014).
Aims: In this analysis we applied the DSHNHL prognostic model to the UK
NCRI prospective R-CHOP-14 v 21 trial cohort to determine if similar risk groups
could be identified.
Methods: The randomised phase III UK R-CHOP-14 vs 21 trial assessed rit-
uximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP)
given 2 weekly versus 3 weekly in 1080 DLBCL patients accrued between
2005-2008 (Cunningham et al, 2013). Administration of CNS prophylaxis was
at the discretion of investigators but recommended for patients with involvement
of bone marrow, peripheral blood, nasal/paranasal sinuses, orbit and testis
(12.5mg intrathecal methotrexate (IT MTX) for the first 3 cycles of treatment or
according to local guidelines). Details of CNS prophylaxis were retrospectively
collected from participating sites using case report forms.
Figure 1.
Results: With a median follow-up of 6.5 years the incidence of CNS relapse in
our cohort was 1.7% (18/1,080). 17.3% (170/982) of patients in the R-CHOP-
14 vs 21 trial received CNS prophylaxis: IT MTX=94.0%, high-dose intravenous
MTX=1.3%, prophylaxis type unknown=4.5%. We have previously reported
that the incidence of CNS relapse for patients receiving prophylaxis was 3.5%
which may suggest some benefit of this therapy (Gleeson et al, ASH 2014).
The 6-factor DSHNHL model stratified patients into 3 risk groups for CNS
relapse at 2 years: low (0-1 factors)=0%; intermediate (2-3 factors)=1.0% (95%
CI 0.2-1.8) and high risk (4-6 factors)=4.6% (95% CI 1.5-7.7) [Figure 1]. Patients
developing CNS relapse (n=18) were divided into the following DSHNHL risk
groups: low n=1/313, intermediate n=7/563 and high-risk n=10/204. The pro-
portion of patients receiving CNS prophylaxis was 15.3%, 14.2% and 31.4%
for low, intermediate and high-risk groups respectively.
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Summary/Conclusions: The overall incidence of CNS relapse within the R-
CHOP-14 vs 21 trial cohort was low (1.7%). The DSHNHL model identified 3
risk groups for CNS relapse at 2 years in the R-CHOP-14 vs 21 cohort, with
patients in the high-risk group demonstrating a 2-year incidence of CNS relapse
of 4.6%. We observed a lower rate of CNS relapse than that reported by both
the DSHNHL and BCCA groups. This may have been influenced by population
differences, as the DSHNHL cohort included patients with aggressive B-cell
non-Hodgkin lymphoma and the BCCA cohort is a population-based dataset.
In addition the proportion of patients receiving CNS prophylaxis may have dif-
fered between patient cohorts.
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Background: Prognosis of diffuse large B-cell lymphoma (DLBCL) has
improved with the advent of Rituximab. However, there is increasing evidence
that treatment of patients with relapsed and refractory disease is challenging.
Aims: The purpose of this trial is to evaluate the safety, tolerability and efficacy
of the combination of the mTOR inhibitor Temsirolimus and a standard salvage
regimen (R-DHAP) in patients with relapsed or refractory DLBCL.
Methods: This is a prospective, multicenter, phase II, open-label study. Patients
with relapsed or refractory DLBCL with a maximum of two prior treatment lines
were eligible. The STORM regimen consisted of Rituximab 375mg/m2 (day 2)
and DHAP (Dexamethasone 40mg day 3-6, Cisplatine 100mg/m2 day 3, Cytara-
bine 2x2g/m2 day 4) with Temsirolimus added on day 1 and 8 of a 21 d cycle,
with 2-4 cycles planned. In part I, dose levels for the mTOR inhibitor Temsirolimus
from 25, 50, 75 and 100 mg were predefined. Based on the observed toxicity
profile, the independent data safety committee recommended a Temsirolimus
dose of 25mg given on day 1 and 8 for the part II extension cohort of the trial.
Results: In part I of this clinical trial 15 patients were included - 8 patients in
the 25 mg cohort and 7 patients in the 50 mg cohort. Median age was 70 (range
49-76) years and median number of prior regimen was 1. Two DLTs (one
venous thrombosis in the 25 mg cohort, one esophagus infection in the 50 mg
cohort) were observed. The most frequent non-hematologic side effects were
nausea (9 pts, 60%), epistaxis (7 pts, 47%), fatigue (6 pts, 40%), increased
ALT (6 pts, 40%) and increased creatinine (6 pts, 40%). Frequent grade 3/4
events (n>2) in both cohorts (25mg|50mg) included leukopenia (11 pts, 73% -
with a mean duration of 4.4 days | 6.7 days), thrombocytopenia (11 pts, 73% -
with a mean duration of 4.6 days | 11.9 days), lymphopenia (6pts, 40%), anemia
(5 pts, 33%), neutropenia (3 pts, 20%), renal failure (3 pts, 20%) and infections
(4 pts, 27%, bladder infection, esophagus infection, central venous access
infection, soft tissue infection, mucositis). All but one evaluable patient respond-
ed (10/11 pts, 91%), with two CRs and one CRu (27%). Four patients could
not be evaluated for response at the time of the first report. After a median
follow up of 12 (range 5-22) months, no relapse had been documented (1 pt
lost to follow up); since then, progression of disease has occurred in three
patients and led to these patients’ death. However, only for one of these patients
participation in the study ended prematurely because of progressive disease
under therapy, while the other two had already dropped out due to adverse
events. As far as the extension cohort of part II is concerned, preliminary data
of 17 patients are reported below. Median age was 61 (range 42-74) and medi-
an number of prior regimen was one. Out of these 17 patient data sets, two
could not be evaluated for response. The response rate of the remaining 15
patients was 87% (13/15 pts). Two therapy-related deaths occurred (one patient
died from sepsis during neutropenia, another from cerebral bleeding, both
events occurring after cycle 3). After a median follow up of 7 months for the
total study population, median PFS and OS have not been reached.
Summary/Conclusions: Temsirolimus can be safely added to DHAP and Rit-
uximab with promising activity. This conclusion drawn from part I of the study
has been confirmed by the preliminary data of part II. Recruitment of the part
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Background: Prognostic factors (PFs) have not been extensively studied in
PMLBCL and prognostic models specifically applicable to this entity have not
been developed, mainly due to its rarity. R-CHOP provides very good results
in PMLBCL, minimizing failure rates. High IPI and serous effusions emerged
as adverse prognostic factors in 181 Japanese patients treated with
RCHOP±RT (selected among broader population with heterogenous treat-
ment), while serous effusions, B-symptoms and age were identified in 96
RCHOP±RT-treated patients in a 2012 abstract from Vancouver. Given that
more intensive chemotherapy (R-da-EPOCH) might be better than R-CHOP,
the applicability of various PFs needs to be urgently evaluated in the Rituximab
era in order to define subgroups of patients at high risk for treatment failure
and death.
Aims: The identification of PFs for the outcome of patients with PMLBCL treat-
ed with RCHOP± RT.
Methods: 213 patients with PMLBCL were treated in a multicenter setting with
RCHOP±RT (usually 6-8 cycles). The following potential prognostic factors
were evaluated: Age (median 31; range 17-82; >60 years only 4%), gender
(female 64%), B-symptoms, stage III/IV, infradiaphragmatic disease, extranodal
involvement (either stage IV or stage E), pleuritis, pericarditis, performance
status (PS) ≥2, LDH levels, anemia, leukocytosis ≥10x109/L, ESR ≥30mm/h,
albumin <4g/dL, bulky disease (≥10cm), age-adjusted IPI (aaIPI; ≥2 in 21%).
A modified version of aaIPI was also analyzed, attributing 1 point to either stage
III/IV or E-disease instead of stage III/IV only (aaIPI-mod). 
Results: With 52 failures recorded (51 within 17 months from diagnosis), the
3-year freedom from progression (FFP) was 75%. With 24 deaths recorded
(excluding 2 unrelated deaths), the 5-year overall survival (OS) was 87%.
aaIPI≥2 identified a minority of patients (21%) with a 5-year FFP of 64% vs
79% for those with aaIPI 0-1 (p=0.04) and 5-year OS of 76% vs 91%
(p=0.0095). The aaIPI-mod was more effective in predicting the outcome and
indentified a larger poor prognostic group (41% of total): The 5-year FFP was
61% vs 86% for those with aaIPI-mod 0-1 (p<0.0001), while 5-year OS was
75% vs 97% (p<0.0001). Many of the examined variables had a significant
(p<0.05) or borderline (p<0.15) association with both FFP and OS (extranodal
disease, LDH, PS, abdominal disease, bulky disease, serous effusions, ane-
mia). In multivariate analysis of FFP, extranodal involvement and bulky disease
were independent PFs (p=0.006 and p=0.04). None, 1 or 2 of these factors
were present in 29%, 42% and 30% of the patients. FFP at 5 years was effec-
tively predicted being 88%, 79% and 59% for patients with 0, 1 or 2 PFs respec-
tively, while 5-year disease specific survival was 100%, 91% and 72%.
Summary/Conclusions: In the largest patient series reported so far,
RCHOP±RT provided satisfactory results in PMLBCL with long-term FFS of
75% and excellent OS of 87%. The aaIPI was moderately predictive of the out-
come but a modified version performed better. Either the aaIPI-mod or the com-
bination of extranodal involvement and bulky disease defined a subgroup com-
prising ~40% and ~30% of patients respectively with a ~40% risk of failure and
≥25% risk of death, who might be suitable for trials of treatment intensification.
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Background: Recent studies show that the risk of VTE in Non Hodgkin Lym-
phoma (NHL) patients (pts) is similar to that observed in high risk solid tumors
(i.e. pancreatic, ovarian cancer). VTE in NHL occurs in most cases within 3
months from diagnosis and can have substantial impact on treatment delivery
and outcome as well as on quality of life. However few data are available on
potential predictors.
Aims: To better clarify the epidemiology of early (within 6 months from treatment
start) VTE in NHL pts we conducted a pooled data analysis of 12 clinical trials
from FIL. Our analysis included basic demographic features, lymphoma-related
characteristics as well as the Khorana score KS (based on histology, body mass
index BMI, platelets count PLTs, white blood cells count WBC and hemoglobin
values Hb) which is extensively used in solid tumors to predict VTE risk.
Methods: From Jan. 2010 to Dec. 2014 all pts with B-cell NHL enrolled in
prospective clinical trials from FIL for frontline treatment were included. For 9
studies the study period included the entire trial population. The analysis was
conducted based on CRFs as well as pharmacovigilance reports. VTE definition
and grading was stated according to standard criteria of toxicity (CTCAE V4.0).
Cumulative incidence of VTE from study enrollment was estimated using the
method described by Gooley et al. accounting for death from any causes as a
competing risk. The Fine & Gray survival model was used to identify predictors
of VTE among NHL pts. Factors predicting the grade of VTE were investigated
using an ordinal logistic regression model. This pooled data analysis was
approved by local IRB.
Results: Overall, 1717 pts belonging to 12 studies were evaluated. 8 studies
were phase I/II or II (25% of pts) and 4 phase III (75% of pts). M/F ratio was
1.41, median age was 57 (IQ range IQR 49-66). Histologies were: diffuse large
B-cell lymphoma DLCL-B 34%, follicular lymphoma FL 41%, mantle cell lym-
phoma MCL 18%, other 6%. Median BMI was 25 (IQR 22-28). Median Hb, WBC
and PLTs counts were 13g/dl (IQR 11.5-14.2), 7,1x10^9/l (IQR 5.6-10.3) and
224x10^9/l (IQR 169-298) respectively. In 1189 pts was assessed KS: 58% low
risk, 30% intermediate risk, 12% high risk. Human erytropoetin support was
given to 9% of pts. All pts received Rituximab. Planned therapeutic programs
included autologous stem cells transplantation in 27% of pts, conventional
chemotherapy in 67% and conventional chemotherapy plus lenalidomide in 6%.
Overall 59 any grade VTE episodes occurred in 51 pts (2.9%), including 21
grade III-IV VTEs (18 pts). None was fatal. Median time from study enrollment
to VTE was 63 days (IQR: 35-110). Considering death as a competitive event
the 6 months cumulative incidence of VTE was 2,2% (95%IC: 1.1-3.3) in low
risk, 4.5% (95%IC: 2.3-6.7) in intermediate and 6.6% (95%IC: 2.4-10.8) in high
risk KS (p=0.012). KS was predictive also for grade III-IV VTEs as they were
0,7% (95%IC:0.1-1.4) in low risk and 2% (95%IC:0.8-3.3) in intermediate-high
risk (p=0.048). Results were similar also after excluding lenalidomide containing
studies. Fine and Gray multivariate analysis, adjusted for age and stage, showed
that KS (intermediate risk adjHR=1.96; 95%IC: 0.84-4.56 and high risk
adjHR=3.81; 95%IC: 1.51-9.58) and DLCL-B histotype (adjHR=2.58; 95%IC:
1.01-6.55) were independently associated to an increased risk of VTE. Moreover
an ordinal logistical regression model indicated that the increase of 1 point in
the KS resulted in an increased risk of VTE (OR=1.85; 95%CI: 1.23-2.79).
Figure 1.
Summary/Conclusions: Our results suggest that DLCL-B hystotype and KS
are predictors of VTE in NHL. The latter might become a simple and effective
tool to assess the risk of VTE in NHL. Prospective validation including also pts
not eligible for clinical trials is needed.
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Background: Prognosis and treatment options for patients with diffuse large
B-cell lymphoma (DLBCL) has for the last 20 years been conveyed on the basis
of The International Prognostic Index (IPI). Improving IPI by adding biomarkers
is, however, an ongoing discipline. The National Comprehensive Cancer Net-
work IPI (NCCN-IPI) adds to the classical IPI factors more refined age and lac-
tate dehydrogenase (LDH) strata and weighs extranodal disease according to
the involvement or not of high risk organs such as bone marrow, CNS, liver/GI
tract or lung. The NCCN-IPI was derived and validated on two cohorts with a
mean age of 57- and 62-years, respectively, i.e. slightly younger than one would
expect in a population-based DLBCL cohort. In Denmark, the universal health-
care system is tax funded and free of charge for all inhabitants ensuring a broad
coverage of high quality healthcare. For lymphoma, a national group elaborate
management guidelines and a prospective collection of patient-related data
stored in the group’s database (LYFO).
Aims: i) To validate the NCCN-IPI in a population-based cohort of de-novo
DLBCL patients treated with anthracycline-based chemotherapy; (ii) to analyze,
in a multivariate model, whether adding information on pre-therapeutic hemo-
globin level improves on the ability of the NCCN-IPI to predict outcome.
Methods: All patients were diagnosed with de novo DLBCL between 2000 and
2012 and treated with anthracycline-based chemotherapy with or without ritux-
imab (R). Patients with indolent- or composite lymphoma were excluded, as
were patients with primary CNS-lymphoma. Clinical data were obtained from
LYFO and biochemical data were retrieved partly from LYFO and from hospital
laboratories. Data on vital status were obtained from the Danish Civil Registra-
tion System. Patients were followed from the date of biopsy until death or the
end of study (December 10, 2015). Overall survival was described using
Kaplan-Meier curves according to NCCN-IPI, treatment and hemoglobin values.
Univariate and multivariate analysis were performed using Cox proportional
hazard model including NCCN-IPI group, anemia and treatment as covariates
with mutual adjustment. Anemia was defined as hemoglobin<7.3 mmol/l l for
women and<8.3 mmol/l for men. The proportional hazard assumption was eval-
uated graphically using log-log plots. The study was approved by the Danish
Data Protection Agency (no. 1-16-02-562-13).
Results: A total of 3654 patients fulfilled the inclusion criteria and had a median
follow-up of 1888 days. Median age was 65 years (range 15-98), 2033 (56%)
were men, 2081 (57%) had Ann Arbor stage III-IV, and 712 (19%) had a per-
formance score ≥2. The pre-therapeutic LDH ratio (measured vs max reference
value) was >1 in 2225 (61%). Anemia was present in 1784 (49%) patients. The
NCCN-IPI separated our cohort in low (8%), low intermediate (35%), high inter-
mediate (39%), and high risk (18%) patients. For R-chemo treated patients,
the four NCCN-IPI risk groups (low, low-intermediate, high-intermediate, high)
revealed 5-year OS values of 0.96 (CI95%, 0.92-0.98), 0.81 (CI95% 0.77-0.83),
0.60 (CI95% 0.56-0.63), and 0.30 (CI95% 0.26-0.37), respectively (Figure 1A).
When hemoglobin level was added to the model it showed a significant impact
on OS for both intermediate risk groups. Estimated 5 year overall survival in
anemic vs non anemic patients with high-intermediate risk NCCN-IPI was 0.53
(95%CI 0.48-0.58) and 0.69 (95%CI 0.63-0.73) (Figure 1 B) and for low-inter-
mediate 0.74 (95%CI 0.68-0.79) and 0.84 (95%CI 0.80-0.87). Patients with
anemia as defined had a HR of 2.46 (95%CI 2.08-2.90).). After adjusting for
NCCN-IPI factors, the HR remained significant (1.51; 95%CI 1.29-1.83).
Figure 1.
Summary/Conclusions: In a population-based cohort of de novo DLBCL
patients, we found that pre-therapeutic anemia was present in 49% of the
patients and had independent prognostic impact also when adjusted for NCCN-
IPI risk factors, and stratified for rituximab treatment. The adverse prognostic
value of pretherapeutic anemia was independent of gender and age strata. Our
patient cohort was older than the ones of the original NCCN-IPI publications
(median age 65 yrs vs 54 yrs), which probably explains the difference in the
proportion of high-risk patients (18% in our cohort vs 8% and 14% in the two
original NCCN-IPI cohorts).
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ROUTINE IMAGING FOR PERIPHERAL T-CELL LYMPHOMA IN FIRST
COMPLETE REMISSION DOES NOT IMPROVE SURVIVAL: A DANISH
SWEDISH POPULATION-BASED STUDY
H Cederleuf1,*, L Hjort Jakobsen2,3, F Ellin4, P de Nully Brown5, T Stauffer Larsen6,
M Boegsted2,3, T Relander1, M Jerkeman1, TC El-Galaly2,3
1Department of Oncology, Skåne University Hospital, Lund, Sweden, 2Depart-
ment of Hematology, Aalborg University Hospital, 3Department of Clinical Med-
icine, Aalborg University, Aalborg, Denmark, 4Department of Internal Medicine,
Kalmar County Hospital, Kalmar, Sweden, 5Department of Hematology,
Rigshospitalet, Copenhagen University Hospital, Copenhagen, 6Department
of Hematology, Odense University Hospital, Odense, Denmark
Background: Routine surveillance imaging plays a limited role in detecting
lymphoma relapse and a recent Danish-Swedish study showed that imaging-
based follow-up practice was not associated with better outcome for diffuse
large B-cell lymphoma (DLBCL) patients.
Aims: Using a similar approach, we evaluated the outcome of Danish and
Swedish patients with nodal peripheral T-cell lymphoma (PTCL) in first CR for
whom traditions for routine imaging have been different.
Methods: Patients from the Danish and Swedish lymphoma registries were
selected by the following criteria: a) newly diagnosed nodal PTCL from 2007
to 2012, b) age ≥18 years, and c) CR after CHOP or CHOEP therapy with or
without consolidating high-dose therapy (HDT). Follow-up for Swedish patients
included symptom assessment, clinical examinations and blood tests at 3- to
4-month intervals for 2 years, with longer intervals later in follow-up. The nation-
al Swedish guidelines only recommended imaging when relapse was clinically
suspected. Follow-up for Danish patients was similar but included routine imag-
ing, usually computed tomography (CT) every 6 months for 2 years and at
some centers annual CT from the 3rd till the 5th year of follow-up as well.
Results: In total, 109 Danish patients and 123 Swedish patients with nodal
PTCLs were included. PTCL not otherwise specified (NOS) was diagnosed in
95 patients, anaplastic large cell lymphoma (ALCL) in 88 patients, and angioim-
munoblastic T-cell lymphoma (AITL) in 49 patients and with similar subtype
frequencies for Danish and Swedish patients. The baseline demographic char-
acteristics were also fully comparable between Danish and Swedish patients
(Table 1). The OS estimates for Danish and Swedish patients in CR following
frontline therapy were similar for all patients (P=0.6, Fig 1) and in PTCL subtype
specific analyses. The most important adverse predictor of OS following CR
was age >60 (Hazard Ratio [HR], 3.73; 95% CI, 2.08 to 6.66, P<0.01). The 2-
year probability of relapse was similar for Danish and Swedish patients (25%;
95% CI 16-33% vs 29%; 95% CI 19-38%, P=0.53). The post-relapse OS was
similar for Danish and Swedish patients overall (P=0.8) and in PTCL subtype
specific analyses.
Table 1. Demographic and clinicopathological information on Danish and
Swedish patients with nodal PTCL.
Figure 1.
Summary/Conclusions: Relapse following frontline treatment for PTCL is typ-
ically associated with a poor prognosis and an imaging based follow-up practice
did not translate into better survival for Danish patients. Thus, a follow-up strat-
egy without routine surveillance imaging appears safe and equally effective to
a FU strategy with imaging for patients with nodal PTCL in first CR.
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REAL-TIME CELL-OF-ORIGIN SUBTYPE IDENTIFICATION BY GENE
EXPRESSION PROFILE IN THE PHASE 3 ROBUST TRIAL OF
LENALIDOMIDE+R-CHOP VS PLACEBO+R-CHOP IN PREVIOUSLY
UNTREATED ABC-TYPE DLBCL
U Vitolo1,*, A Chiappella1, TE Witzig2, M Spina3, RD Gascoyne4, L Zhang5,
J Flament5, J Repici5, E Conlin5, K Delissio5, GS Nowakowski2
1Division of Hematology, Città della Salute e della Scienza Hospital and Uni-
versity, Torino, Italy, 2Division of Hematology, Mayo Clinic, Rochester, United
States, 3Division of Medical Oncology, National Cancer Institute, Aviano, Italy,
4Pathology and Lymphoid Cancer Research, British Columbia Cancer Agency,
Vancouver, BC, Canada, 5Celgene Corporation, Summit, United States
Background: Gene expression profiling (GEP) represents a gold standard in
identifying patients with activated B-cell–like (ABC) DLBCL, a subtype associ-
ated with inferior outcomes. Until recently, real-time identification of patients
with ABC DLBCL as an integrated biomarker and inclusion criterion was not
feasible due to technology limitations. The randomized, double-blind, global
phase 3 ROBUST study (NCT02285062) compares lenalidomide+R-CHOP
(R2-CHOP) with placebo+R-CHOP in patients with previously untreated ABC-
type DLBCL with participating sites in Asia, Australia, Europe, New Zealand,
and North America.
Aims: Explore the real-world feasibility of GEP screening to determine DLBCL
cell of origin (COO) in a global phase 3 study and quantify turnaround time
and the percentage of screened patients having ABC-subtype DLBCL.
Methods: ROBUST methods have been described (Nowakowski, ASCO 2015).
Patients must provide written informed consent. A key entry criterion is previously
untreated, histologically confirmed ABC-type CD20+ DLBCL. Formalin-fixed
paraffin-embedded excisional/surgical or core needle biopsy samples (Storhoff,
Blood 2015) are analyzed by central pathology using the NanoString Lymphoma
Subtyping Test (LST; Wallden, JCO 2015), based on the Lymph2Cx GEP assay
(Scott, Blood 2014). Turnaround time is defined as number of days between
central pathology sample receipt and results being provided to the study site.
Results: As of 11 Jan 2016, 357 patients were screened for ROBUST using
the LST. Samples were analyzed in 2 central pathology labs in the US and UK.
COO was ABC and non-ABC in 118 (33%) and 212 (59%), respectively. 27
patients (8%) had samples that could not be processed for technical reasons
(incorrect/insufficient slides or blocks, or low tissue RNA concentration and/or
purity). Mean turnaround time was 2.25 days (range, 0-9). 86 patients have
met all inclusion criteria and were enrolled in ROBUST.
Summary/Conclusions: Real-time COO assessment is feasible in a multi-
center, global phase 3 DLBCL study with short turnaround time. The percentage
of patients with ABC-type DLBCL was similar to that reported in the literature.
Our findings have important implications for the design and size estimation of
both current and future studies in newly diagnosed DLBCL utilizing COO as a
biomarker, promising a significant step forward in precision medicine. Updated
results will be presented.
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MYD88 (L265P) MUTATION IS ASSOCIATED WITH AN UNFAVORABLE
OUTCOME OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
K Hattori1,*, M Sakata-Yanagimoto1,2, Y Okoshi2,3,4, Y Goshima5, S Yanagimoto6,
R Nakamoto-Matsubara1, T Sato7, M Noguchi7, S Takano8, E Ishikawa8,
T Yamamoto8, A Matsumura8, S Chiba1,2
1Hematology, Graduate School of Comprehensive Human Sciences, 2Hema-
tology, Faculty of Medicine, University of Tsukuba, 3Ibaraki Clinical Education
and Training Center, University of Tsukuba Hospital, Tsukuba, 4Hematology,
Ibaraki Prefectural Central Hospital, Ibaraki, 5School of Medicine, University of
Tsukuba, Tsukuba, 6Division for Health Service Promotion, The University of
Tokyo, Bunkyo-ku, Tokyo, 7Pathology, Faculty of Medicine, 8Neurosurgery,
Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background: Primary central nervous system lymphomas (PCNSL) typically
show an immunophenotype resembling that of activated B-cell-like diffuse large
B-cell lymphoma (ABC-DLBCL). Somatic mutations in MyD88, CD79B, and
CARD11 were shown to activate the NFκB signaling pathway in ABC-DLBCL.
These mutations are reported to be strongly over-represented in PCNSL.
Nonetheless, clinical relevance of these mutations remains unclear. On the
other hand, the several specific clinical parameters, such as MSKCC and
IELSG prognostic score systems, were reported to predict the treatment out-
come of PCNSL patients. Recently advanced genetic knowledge, however, is
not incorporated in any of these proposals.
Aims: We conducted this study to elucidate the impact of gene mutations on
clinical outcome of PCNSL.
Methods: We analyzed 42 immuno-competent patients suffering from newly
diagnosed PCNSL who were aged over 60 years, or aged 55-60 years if they
had poor performance status, and in whom enough material for DNA extraction
was available. They were treated with modified version of the EORTC protocol,
consisted of systemic administration of intermediate-dose methotrexate (MTX),
lomustine, procarbazine, and methylprednisolone, and intrathecal chemother-
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apy with MTX and cytarabine (Taoka K., et al., Int J Hematol 2010; Lee SY., et
al., Oncol Res Treat 2014), at the University of Tsukuba Hospital between
March, 2005 and May, 2015. Targeted deep sequencing was performed by
using Ion Ampliseq technology for 12 genes, including MyD88, CD79B, PIM1,
TBL1XR1, BTG2, PRDM1, TNFAIP3, CARD11, B2M, TOX, TMEM30A, and
PRKCD. All candidate mutations were validated by genomic PCR followed by
Sanger sequencing. Overall survival (OS) and progression-free survival (PFS)
were estimated using the Kaplan-Meier method, and compared by the peto-
peto generalized Wilcoxon test.
Results: At least one mutation was detected in 38/42 cases (90.4%). Frequen-
cies of mutations of 12 genes were similar to those of the previous reports
(MyD88, 79%; CD79B, 52%; PIM1, 69%; TBL1XR1, 24%; BTG2, 29%; PRDM1,
24%; TNFAIP3, 12%; CARD11, 19%; B2M, 11.9%; TOX, 11.9%; TMEM30A,
4.8%; PRKCD, 4.8%). The median follow-up time was 26 months (range, 1-105
months), with OS at 3 years of 46% and PFS at 3 years of 26%. By univariate
analysis, age >75 (P=0.0105) and altered mentation (P=0.0202) were signiﬁ-
cantly associated with inferior OS. Regarding PFS, CrCl >90 (P=0.0286) and
altered mentation (P=0.0473) were signiﬁcant factors. In addition, MyD88 L265P
mutation showed a tendency to be associated with inferior OS and PFS, although
statistically non-significant (OS: P=0.127, PFS: P=0.0872, Figure1). When
adjusted to a multivariate Cox regression analysis, MyD88 L265P mutation
remained as a signiﬁcant risk factor for death (hazard ratio (HR), 2.9; 95% conﬁ-
dence interval (CI), 1.0–8.3, P=0.0470), together with altered mentation (HR,
4.7; 95% CI, 1.5-14.7, P=0.0072). Regarding PFS, only MYD88 L265P mutation
(P=0.0303) was signiﬁcantly associated with a higher risk of progression.
Summary/Conclusions: This is the first study that provides evidence that eld-
erly PCNSL patients with MyD88 L265P mutation show an unfavorable prog-
nosis. Given that MyD88 L265P mutation was reported to be also associated
with an unfavorable outcome of DLBCL, not otherwise specified and cutaneous
DLBCL of leg type, dysregulated cellular program by this mutation may be an
important determinant for the prognosis of DLBCL in general. These findings
open new perspectives in the utility of MyD88 L265P mutation in the clinical
sequencing settings of PCNSL.
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SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB ADMINISTRATION
IN FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR
LYMPHOMA: PREFMAB STUDY OF PATIENT PREFERENCE AND
SATISFACTION IN 19 COUNTRIES
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S Osborne6, R Smith6, A Grigg7
1University Hospital Giessen and Marburg, Giessen, Germany, 2Seoul National
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Background: A subcutaneous (SC) formulation of rituximab has been devel-
oped with comparable clinical activity to rituximab intravenous (IV), but a shorter
administration time (~5 min vs 1.5-6 hrs). The SC administration route has
been shown to reduce healthcare resource burden and has potential to reduce
patient treatment burden compared with rituximab IV. In PrefMab, patients pre-
ferred rituximab SC over IV when given with chemotherapy, and reported higher
levels of convenience and satisfaction with the rituximab SC administration
route. However, in a large, international study, regional differences in patient
preference due to local variations in clinical practice or culture may not be clear
in the overall data.
Aims: To evaluate country-specific patient preference and satisfaction with rit-
uximab SC vs IV.
Methods: PrefMab (NCT01724021) is a randomized, open-label, crossover
phase 3b study. Patients were aged 18-80 years and had: previously untreated
CD20+ diffuse large B-cell lymphoma (DLBCL; international prognostic index
[IPI] 1-4 or 0 with bulky disease) or follicular lymphoma (FL; FLIPI grade 1-3a);
at least 1 bi-dimensionally measurable lesion ≥1.5cm at its largest dimension;
and ECOG performance status ≤3. All patients gave informed consent. Patients
received 8 cycles of rituximab according to 2 schedules: 1 cycle rituximab IV
(375mg/m2) and 3 cycles rituximab SC (1400mg) then 4 cycles rituximab IV; or
4 cycles rituximab IV (375mg/m2) then 4 cycles rituximab SC (1400mg).
Patients also received 6-8 cycles of chemotherapy (CHOP [cyclophosphamide,
doxorubicin, vincristine, prednisone], CVP [cyclophosphamide, vincristine, pred-
nisone], or bendamustine as per standard local practice). A Patient Preference
Questionnaire (PPQ) was completed at cycles 6 and 8. A Rituximab Adminis-
tration Satisfaction Questionnaire (RASQ) was completed at cycles 4 and 8;
domains were scored 0 (least)-100 (best). The current analysis included coun-
tries with data for ≥10 patients.
Results: At the primary data cut-off (January 19, 2015), 743 patients had been
randomized to treatment in 32 countries. The median age was 60 years, most
patients had DLBCL (63% vs 37% FL) and baseline characteristics were balanced
between arms. Nineteen countries (listed in Figure) with data available for ≥10
patients were eligible for and included in the analysis. At cycle 8, most patients
preferred rituximab SC to IV, with the median score ranging from 60-100% (Fig-
ure); similar results were seen at cycle 6. Preference was not substantially impact-
ed by underlying disease. Patient satisfaction was higher for the SC administration
route. Compared with the IV route, median RASQ scores were ≥10 points higher
for SC in: 0/19 countries in the physical impact domain; 8/19 countries in the psy-
chological impact domain; 16/19 countries in the impact on activities of daily living
domain; 15/19 countries in the convenience domain; and 14/19 countries in the
satisfaction domain. In 18/19 countries most patients (>70%) thought the time
taken to administer rituximab SC was “just right”, although 53% of patients in
Brazil felt it was “too short”. In all countries, most patients (>50%) felt they had
“more than enough time” to discuss their illness with their nurse and/or doctor,
regardless of administration route, although in Germany, Brazil and Canada >50%
patients felt the SC route impacted on this time.
Figure 1.
Summary/Conclusions: Patient preference and satisfaction was higher with
rituximab SC vs IV, and did not vary substantially by the country in which treat-
ment was received.
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EXTRACORPOREAL PHOTOPHERESIS: SAFE AND EFFECTIVE FOR THE
TREATMENT OF MYCOSIS FUNGOIDES
E Atilla1,*, P Ataca Atilla1, S Civriz Bozdag1, SK Toprak1, BN Akay2, H Sanli2,
P Topcuoglu1, H Akan1, G Gurman1, O Ilhan1
1Ankara University School of Medicine Department of Hematology, 2Ankara
University School of Medicine Department of Dermatology, Ankara, Turkey
Background: Primary cutaneous T-cell lymphomas (CTCL) are second most
common extranodal non-Hodgkin lymphoma with an yearly incidence of 0.45
per 100,000 person. The treatment of mycosis fungoides (MF), the most fre-
quent CTCL, is determined by disease extent, prognostic factors and patient
characteristics. Extracorporeal Photopheresis (ECP) was approved by the US
Food and Drug Administiration for the palliative treatment of MF since 1988.
Aims: The aim of this study is to analyze the clinical activity, toxicities, response
and outcome rates of ECP; compare with combination therapies in the treatment
of patients with MF.
Methods: We retrospectively included 50 MF patients who have diagnosed at
our center. ECP was given empirically in cycles of 2 consecutive days in every
2 to 4 weeks at any time during their follow-up.
Table 1.
Results: The patient characteristics is shown in table. Treatments prior to ECP
were; topical retinoids (bexarotene), topical corticosteroids, phototherapy
(PUVA), Narrowband ultraviolet B light (NBUVB), Interferons, Metotrexate
(MTX), CHOP (cyclophosphamide, daunorubicin, vincristine, prednisolone).
ECP is combined with gemcitabine, PUVA, MTX, Bexaroten, IFN or Vorinostat
up to patient characteristics. Overall response rate (ORR) was 42% (21/50)
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with median time to response 11 months (range, 3-48 months). 15 of the
responded patients (71%) were in stage III and IV at diagnosis. 10 of the
responders (48%) had 3 or over treatment lines prior to ECP. 29 patient had
not responded (58%) and 3 patients underwent (6%) allogeneic hematopoietic
stem cell transplantation during follow-up. 8 patients (16%) had adverse events
related with ECP; catheter related infection, headache, fever, shivering, nausea.
Overall survival (OS) rate for 50 patients were 72 months (range, 3-211). The
number of cycles in ECP responder patients were 32, and 44 for non-respon-
ders. Stage 3 and 4 patients had received average of 31 cycles compared to
55 cycles in stage 1 and 2 patients (P=0.006). The increased number of ECP
is not correlated with the response (P=0.203). There were no statistically dif-
ference in OS in early stage vs late stage patients (77 vs 69 months, P=0.077).
Time to response in early stage disease were 14 months and 8 months with
late stage disease (P=0.267). Combined treatment with ECP statistically had
improved OS (84 months vs 62 months, P=0.005).
Summary/Conclusions: The overall survival has improved in combined treat-
ment with ECP patients. ECP may be a preferred treatment alternative due to
low risk of adverse events. There is a conflicting data on treatment schedule
and continuation. Prospective controlled clinical trials which are conducted on
same ECP protocol and duration will better document the efficacy of this ther-
apeutic modality.
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R-DA-EPOCH WITHOUT RADIOTHERAPY IN PRIMARY MEDIASTINAL
LYMPHOMA PATIENTS RESULTS IN SIMILAR OUTCOME IN COMPARISON
WITH A HISTORICAL COHORT TREATED WITH RADIOTHERAPY BASED
REGIMENS
A Guidetti1,2,*, L Devizzi1, L Pappalettera1, G Perrone1, A Mussetti1, N Cieri1,
L Pettine1, L Farina1, A Dodero1, P Corradini1,2
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and Hemato-Oncology, University of Milano, Milano, Italy
Background: Historically, patients with Primary Mediastinal B Cell Lymphoma
(PMBCL) have been treated with chemotherapy according to R-CHOP or R-
VACOP-B regimen followed by radiotherapy with favorable outcome. Omission
of radiotherapy in treatment of PMBCL represents a challenge due to the long-
term toxicity observed in young people affected by this disease. Recently, Rit-
uximab Dose Adjusted EPOCH (R-DA-EPOCH) regimen based on continuous
drugs infusion not followed by radiotherapy demontrated to be an attractive
alternative treatment for these patients.
Aims: We retropsectively compared the outcome of R-DA-EPOCH without
radiotherapy with R-CHOP, R-VACOP-B or high dose sequential therapy fol-
lowed by radiotherapy in newly diagnosed PMBCL patients treated at Istituto
Nazionale dei Tumori in Milano from 2002.
Methods: Clinical, laboratory and imaging data of patients with PMBCL at diag-
nosis have been retrospectively collected and analyzed for clinical characteris-
tics, response rate, progression free survival (PFS) and overall survival (OS).
Results: Overall, 67 newly diagnosed PMBCL patients have been treated
between 2002 and 2016, 26 patients treated after September 2009 received 6
cycles of R-DA-EPOCH (R-DA-EPOCH group), whereas from 2002 to 2009,
31 patients received 6 cycles of R-CHOP (n=15), 12 weeks of R-VACOP-B
(n=13) or high dose sequential therapy supplemented with rituximab (n=3), fol-
lowed by radiotherapy (RT group). Ten patients treated without Rituximab were
excluded from this analysis. Median age at diagnosis was 30 years in both
groups (range, 18-61 and 21-55). With the exception of an higher proportion of
stage III/IV patients in RT group (42% vs 11%) (p=0.01), other clinical charac-
teristics were similar: extranodal disease in 11% and 35%, elevated LDH in 65%
and 48% and presence of bulky disease (diameter >10 cm) in 77% and 68% of
patients in R-DA-EPOCH and RT group respectively (p=ns). Eighteen patients
(69%) completed R-DA-EPOCH without radiotherapy, 4 patients received radio-
therapy because of residual disease at PET (Deauville Score 4), whereas 4
patients progressed. No patients relapsed after a median follow-up of 21 months
(range, 3–79). In RT group, 24 patients (77%) completed the treatment with
radiotherapy whereas 7 (22%) patients experienced disease progression before
radiotherapy. Overall, 6 patients (19%) relapsed after a median of 7 months
(range, 4-19). Eight out of 13 relapsed and refractory patients underwent autol-
ogous transplant and 5 of them are in complete remission. Median follow-up for
RT patients was 73 months (range, 5-155). One patient developed a secondary
malignancy 3 years after R-VACOP-B, whereas until today no secondary tumors
have been observed among R-DA-EPOCH patients. 3-yrs OS and PFS for the
whole population were 80% and 66%. In R-DA-EPOCH group 3-yrs PFS was
82% and in RT group was 57% (p=0.07); 3-yrs OS was 88% and 76% in R-DA-
EPOCH and RT group, respectively (p=ns). 3-yrs PFS was 46%, 76% and 82%
in R-CHOP, R-VACOP-B and R-DA-EPOCH (p=0.02), whereas 3-yrs OS was
62%, 92% and 88% in the three subgroups respectively (p=ns).
Summary/Conclusions: Omitting radiotherapy is feasible in patients treated
with R-DA-EPOCH regimen. At the present, no significative differences in PFS
and OS have been observed when R-DA-EPOCH patients are compared with
a retrospective cohort treated with chemotherapy and radiotherapy. A longer
follow-up of R-DA-EPOCH patients could assess significativity of the slighty
advantage observed in term of PFS and will allow a proper assessment of long-
term toxicity.
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COMPARISON OF BONE MARROW ASPIRATE FLOW CYTOMETRY AND
TREPHINE IMMUNOHISTOCHEMISTRY IN STAGING OF PATIENTS WITH
LYMPHOMA
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Background: Accurate staging of lymphoma is essential for guiding manage-
ment and predicting outcome. Bone marrow biopsies are performed as part of
routine staging for patients with lymphoma and immunohistochemistry on the
trephine biopsy is considered the gold standard. Multiparameter Flow Cytom-
etry (MFC) is increasingly sensitive at detecting small clonal B-cell populations
and abnormal T-cell phenotypes on bone marrow aspirate samples but it is not
clear that this adds additional clinically relevant information.
Aims: To compare results of MFC on bone marrow aspirates with immunohis-
tochemistry on trephine biopsies for patients with T- and B-cell lymphomas to
assess whether MFC is of additional clinical utility.
Methods: Results of lymphoma staging marrows received by the King’s Col-
lege Hospital Haematological Malignancy Diagnostic Centre between June
2014 and June 2015 were retrospectively reviewed. All aspirate samples had
MFC performed using the following antibodies; CD19, CD5, CD4, CD8, CD2,
CD20, CD23, CD10, CD79b, CD49d, CD38, FMC7, kappa and lambda.
Results: 117 patient samples were received. The lymphoma diagnoses includ-
ed diffuse large B-cell lymphoma (DLBCL; n=63), follicular lymphoma (FL;
n=29), primary central nervous system lymphoma (n=9), marginal zone lym-
phoma (n=6), high grade transformation of low grade lymphoma (n=4), mantle
cell lymphoma (n=2), post-transplant lymphoproliferative disorder (n=2) and T-
cell lymphoma (n=2). The concordance rate between trephine histology and
MFC was 86.3% (n=101). Both were negative in 89 cases (76.1%) and positive
in 12 cases (10.3%). Three cases (2.6%) were detected by MFC alone but not
apparent on the trephine histology. The diagnoses in these cases included pri-
mary central nervous system lymphoma (3% CD5-/CD10- clonal B-cells; n=1),
mantle cell lymphoma (2% clonal B-cells; n=1) and DLBCL (4% CD5-/CD10-
clonal B-cells; n=1). In these three cases the clinical management was not
altered by knowledge of the MFC results. Ten cases (8.5%) were histologically
positive but negative by MFC. The diagnoses in these cases were FL (n=4),
DLBCL (n=2), T-cell lymphoma (n=1) and FL transformed to DLBCL (n=3).
There were three cases (2.6%) with suboptimal trephines. One of which was
a case of DLBCL in which MFC was positive (5% CD5-/CD10- clonal B cells). 
Summary/Conclusions: As reported in other series, the concordance between
multiparameter flow cytometry and the trephine biopsy is high. Rarely, MFC
can detect low-level bone marrow involvement not detected by immunohisto-
chemistry. However, these results are unlikely to alter clinical management. In
resource stretched health care systems, MFC on lymphoma staging marrows
may not be justified. 
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EVALUATION OF THE NEW PROGNOSTIC SCORE IN HIV RELATED NON
HODGKIN LYMPHOMA. EXPERIENCE IN UNIVERSITY HOSPITAL SON
ESPASES
S Ruiz1,*, L Garcia1, L Bento1, MD Bea2, F Serra3, I Herráez1, M Garcia1,
R Del Campo3, J Bargay3, A Sampol1, A Gutierrez1
1Hematology, 2Microbiology, Hospital Universitario Son Espases, 3Hematology,
Hospital Son Llàtzer, Palma de Mallorca, Spain
Background: The use of the International Prognostic Index (IPI) in aggressive
lymphoma is widespread in the context of HIV infection. However recently it
has been reported a new index tailored to patients infected with human immun-
odeficiency virus (HIV) which takes into account the characteristics of immuno-
suppression, viral load and evolutionary status of HIV infection: the AIDS-relat-
ed lymphoma International Prognostic Index (ARL- IPI). 
Aims: To evaluate this new index inside the Balearic Lymphoma Group in com-
parison with other prognostic scores used in aggressive lymphomas.
Methods: We identified all aggressive lymphomas diagnosed between 2002
and 2015 based on the records of the Service of Pathology contrasted with
their HIV status. After that, the characteristics of their HIV infection (CD4 counts,
viral load and AIDS-defining illness) with the main prognostic factors, treatment
and evolution of the lymphoma were subsequently collected. Survival analysis
was performed using Kaplan - Meier curves with the log -rank test.
Results: Table 1 shows main characteristics of the patients (n=50). Median
age was 41 years, most with advanced disease (84% Ann Arbor (AA) stage III-
IV) and poor prognosis factors: 70% a-IPI >1 and 71% TS>2. Seventy-two per-
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cent of cases had a prior history of AIDS; while 46% had CD4 counts lower
than 200 / microL and 54% VIH viral loads higher than 10000 copies/mL. ARL-
IPI showed 26%, 42% and 26% of patients respectively in the low, intermediate
and high risk subgroups. Overall response (p=0.002) and CR rates (p=0.012)
were significantly different in these three risk subgroups: respectively low risk
(92% and 77%), intermediate risk (74% and 65%) and high risk (31% and 23%).
Median follow-up was 53 (0-167) months. PFS and OS at 4 years was 53%
and 51%, respectively. Univaried survival analysis showed several factors sig-
nificantly associated to worse PFS (ECOG PS>1, p=0.001; III-IV AA stage,
p=0.018; a-IPI 2-3, p=0.01; R-IPI 1-2 or 3-5, p=0.029; TS>2, p=0.006; interme-
diate and high ARL, p=0.002 and lower CD4 count, p=0.019) and OS (ECOG
PS>1, p<0.001; bulky disease, p=0.043; a-IPI 2-3, p=0.041; intermediate and
high ARL-IPI, p=0.001 and lower CD4 count, p=0.001) (Image 1).
Table 1.
Figure 1.
Summary/Conclusions: In our study ARL-IPI showed a very good definition
of prognostic groups in terms of response and survival. Interestingly, ARL-IPI
identifies a high risk subgroup with a very poor prognosis. Our results validate
the usefulness of this new prognostic index in the HIV population with aggres-
sive lymphoma.
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SERUM IL-10 LEVEL PREDICTS POOR PROGNOSIS IN PATIENTS WITH
ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: RESULTS OF A SINGLE
CENTER COHORT STUDY
SJ Kim1,*, JS Ham2, KJ Ryu3, YH Ko4, WS Kim1, SH Kim5
1Medicine, 2Samsung Medical Center, 3Samsung Biomedical Research Insti-
tute, 4Pathology, 5Laboratory Medicine, Samsung Medical Center, Seoul,
Korea, Republic Of
Background: Angioimmunoblastic T-cell lymphoma (AITL) is derived from T-
follicular helper cell, and tumor cells are often outnumbered by admixed reactive
inflammatory cells. Accordingly, the secretion of various cytokines and their
interaction with tumor microenvironment has been more studied compared to
other subtypes of PTCL. Interleukin-10 (IL-10) is one of T-helper cell-associated
cytokine and promotes M2 macrophage inhibiting the anti-tumor action of non-
neoplastic T-cells. Thus, serum IL-10 level might be associated with treatment
outcome of AITL patients.
Aims: The primary objective is to evaluate whether serum IL-10 level at diag-
nosis could predict survival outcome of AITL patients. The secondary objectives
are the comparison of serum cytokine profiles according to subtypes of PTCL
and their interaction with clinical and laboratory features.
Methods: Patients were from two prospective cohort studies of our institution:
the first study (NCT#00822731) and the second study (NCT#01877109).
Patients were diagnosed with AITL, peripheral T-cell lymphoma, not otherwise
specified (PTCL-NOS), ALK-negative and positive anaplastic large cell lym-
phoma (ALCL) between September 2008 and December 2014 according to
the pathology criteria of the World Health Organization. Serum samples at diag-
nosis after we obtained written informed consent were collected and stored at
-80°C until analysis. Procarta cytokine profiling kit (Panomics, CA, USA) with
Bio-Plex Cytokine Assay System (Bio-Rad Laboratories, Herucules, CA, USA)
was used to measure different cytokines, including IL-2, IL-4, IL-5, IL-10, IL-
12, IL-13, and interferon-γ. Survival status and disease status were updated in
February, 2016.
Results: A total of 97 patients were analyzed: AITL (n=37), PTCL-NOS (n=40),
ALK-negative ALCL (n=11), and ALK-positive ALCL (n=9). All patients were
treated with CHOP (cyclophosphamide, doxorubicin, vincristine and pred-
nisone) or CHOP-like regimens after diagnosis. The response to the first-line
treatment was as follows: complete response (n=64), partial response (n=11),
and progressive disease (n=22). With the median follow-up of 42 months, 58
patients experienced relapse, progression, or any kinds of death, and 44
patients died. The 3-year overall survival of AITL patients (66%) was superior
to that of PTCL-NOS (43%) and inferior to ALK-positive ALCL (75%) in consis-
tent with previous reports. Among measured cytokines, serum levels of IL-10
and IL-12 were significantly higher in AITL patients than other subtypes
(P<0.05), and other cytokines did not show any significant association with
subtypes. The cutoff for serum IL-10 and IL-12 was determined by the ROC
curve, and high serum IL-10 (>1.845 pg/mL) was significantly associated with
poor overall survival (P=0.012, figure). All patients with high serum IL-10
showed disease progression after CHOP chemotherapy. This association was
only found in AITL patients not other subtypes. In addition, other cytokines
including IL-4,5, and 12 did not show a significant association with survival out-
comes in AITL patients as well as other subtypes.
Figure 1.
Summary/Conclusions: Serum IL-10 level at diagnosis might be a useful bio-
marker for predicting survival outcome in patients with AITL. Our findings should
be confirmed by a future study with larger population.
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REDUCED RCHOP FOR ELDERLY PATIENTS WITH DLBCL
L Vidal1,*, S Lando1, I Vaxman1, P Raanani1, R Gurion1, A Gafter-Gvili2
1Davidoff Cancer Center, Hematology, 2Internal Medicine A, Rabin Medical
Center, Petah Tikva, Israel
Background: RCHOP regimen is considered the standard of care for patients
with diffuse large B-cell lymphoma (DLBCL). Elderly patients often have comor-
bidities, worse performance status, less hematologic reserve and are more
prone to changes in pharmacokinetics, which lead to higher rates of toxicity.
Therefore it was suggested that elderly patients should be treated with reduced
intensity RCHOP regimen. Very few studies examined regimens of reduced
intensity RCHOP.
Aims: To evaluate the effect of dose reduction of RCHOP on survival, disease
control and toxicity in patients 70 years or older with DLBCL.
Methods: We performed a retrospective cohort study including patients with
DLBCL treated with RCHOP at the Rabin Medical Center between the years
2004-2014. We excluded patients with transformation or CNS involvement. We
collected age, sex, performance status (PS), B symptoms, bone marrow
involvement, number of extranodal involvement sites, Ann Arbor stage, inter-
national prognostic index (IPI), bulky disease, Charlson comorbidity index
(Charlson), hemoglobin (Hb), LDH, neutrophil, lymphocyte, monocyte, and
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platelet count, creatinine, albumin, CRP, cardiac ejection function, RCHOP
dose (for each drug separately) and treatment date, response, and survival.
We defined full, standard dose (SD) as 90% and above of standard adriamycin
dose, and reduced dose (RD) as less than 90% in the first cycle. OS was com-
pared using Kaplan-Meier survival analysis. Variables potentially associated
with mortality were entered into a Cox regression multivariate analysis.
Results: 140 patients were eligible. Median dose reduction was by 88%. Median
age was 80 years in the RD group, and 76 years in SD group (p<0.001). Patients
in the RD group were older, had a worse PS, and a higher IPI and Ki67, and
lower albumin, Hb, and lymphocyte count. There were no differences between
the groups regarding sex, B symptoms, bone marrow involvement, number of
extranodal involvement sites, stage, bulky disease, Charlson, LDH, neutrophil,
monocyte, and platelet count, creatinine, and CRP. 3% of patients had cardiac
ejection function<45%. Patients treated with RD RCHOP had statistically sig-
nificant lower risk of achieving complete response (CR) (HR for in a univariate
model of OS RD group (HR 2.53, 95% CI 1.57-4.07, p=0.0001), older age,
advanced stage, more than 1 extranodal site involvement, performance status
more than 1, higher IPI, lower albumin and Hb levels had negative prognostic
effect on survival. In multivariate model 1 including age, sex, Charlson, and Hb
the negative effect of RD treatment remained statistically significant compared
to SD (HR 1.93, 95% CI 1.18-3.15, p=0.01) as well as age and Hb. In model 2
including treatment group, age, sex, PS, IPI, LDH, and albumin there was a
trend towards worse survival with RD RCHOP compared to SD (HR 1.64, 95%
CI 0.96-2.82, p=0.069). Age, sex, IPI, and albumin remained prognostic in this
model. There was no statistically difference in the rate of any infection between
the groups (p=0.623). Patients treated with RD RCHOP were hospitalized more
than patients treated with SD RCHOP (median 4 vs 1 day, respectively).
Summary/Conclusions: Based on retrospective data, dose reduction of adri-
amycin in the first cycle of R-CHOP may reduce the chance to achieve CR and
impair OS. This should be further evaluated in randomized trials. We will further
explore the effect of dose intensity and density in all cycles of RCHOP on PFS
and OS.
E963
A PREDICTIVE SCORE FOR CNS DISSEMINATION AND ITS EFFECT ON
CNS PROPHYLAXIS IN A MONO-INSTITUTIONAL SERIES OF 242
PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED
IN THE RITUXIMAB ERA
AJ Ferreri1,*, T Calimeri1, C Cecchetti1, A Vignati1, M Foppoli1, L Scarfò1,
M Sassone1, M Ponzoni2, F Caligaris-Cappio1
1Department of OncoHematology, 2Pathology Unit, San Raffaele Scientific
Institute, Milan, Italy
Background: CNS dissemination is a lethal event in DLBCL. Early detection
and effective CNS prophylaxis may reduce related mortality. However, risk pre-
dictors reported in the rituximab era exhibits a low diagnostic sensitivity and
the most effective prophylaxis remains to be defined.
Aims: We analysed these two unmet clinical needs in a retrospective series
of 242 pts with DLBCL treated in the rituximab era.
Methods: Consecutive HIV-neg adults with DLBCL without CNS involvement
treated with R-CHOP or similar were considered. CNS, mediastinal and leg-
type DLBCL, high-grade transformed lymphomas and pts registered in prospec-
tive trials were excluded. Following institutional guidelines, no DLBCL pt diag-
nosed before 2007 received CNS prophylaxis; after 2007, CNS prophylaxis,
consisting of 3-4 cycles of methotrexate 3 g/m2±intrathecal liposomal cytarabine
(IT) was indicated in pts with high CNS recurrence risk. IT was delivered one
dose per R-CHOP course, and methotrexate was delivered after R-CHOP treat-
ment. CNS dissemination risk was defined by involvement of the testis,
kidney/adrenal, spine, skull, paranasal sinuses, orbit, and/or breast or by the
simultaneous presence of advanced stage and high serum LDH. In the present
study, CNS dissemination risk was defined as low in pts without involvement
of high-risk extranodal organs and with an International Prognostic Index (IPI)
of 0-3; intermediate in pts without involvement of high-risk extranodal organs
and with an IPI of 4-5; and high in pts with involvement of above-mentioned
high-risk extranodal organs and with any IPI.
Results: 242 pts were analysed (median age 66, range 18-89). According to
the proposed model, CNS dissemination risk was low in 148 (61%) pts, inter-
mediate in 29 (12%) and high in 65 (27%). Pts with low and intermediate risk
were managed without prophylaxis, whereas this strategy was indicated in 45
high-risk pts: 35 pts received intravenous±IT chemotherapy, 10 pts receive
only IT chemotherapy due to MTHFR polymorphisms, comorbidity or old age.
CNS prophylaxis was well tolerated; unexpected toxicity and interruptions due
to toxicity were not recorded. At a median follow-up of 51 months (12-171), 11
(4.5%) pts experienced CNS relapse: in the brain parenchyma in 6 cases, in
the meninges in the others. CNS relapse rate was<1% (1/148) in low-risk pts,
10% (3/29) in intermediate-risk, and 11% (7/65) in high-risk pts. Eight of these
pts died of CNS progressive lymphoma after 7-37 months (median 12). In the
high-risk subgroup, CNS relapse rate was 25% (5/20) in pts who did not receive
CNS prophylaxis, 20% (2/10) in pts treated IT chemotherapy alone and 0%
(0/35) in pts who received intravenous±IT chemotherapy (p=0.004). Overall,
18 high-risk pts experienced relapse, and CNS was the most commonly
involved site (7/18). Moreover, the addition of intravenous CNS prophylaxis
was associated with a significantly improved PFS (3-yr: 80% vs 42%; p=0.001)
and OS (3-yr: 86% vs 43%; p=0.00007).
Summary/Conclusions: With all the limitations of a retrospective series, this
study suggest that pts with DLBCL and involvement of certain extranodal
organs and/or high IPI should receive CNS prophylaxis with intravenous high-
dose methotrexate and IT liposomal cytarabine. This strategy shows a relevant
effect on survival of high-risk pts as CNS is a common relapse site, associated
with a high mortality.
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A PHASE I STUDY IN T CELL LYMPHOMA PATIENTS TREATED WITH
ANTI-CD70 SIMPLE ANTIBODY™ ARGX-110
JM Michot1,*, M Maerevoet2, P Aftimos2, S Rottey3, C Rolfo4, F Offner3,
L Van Rompaey5, M Moshir5, H de Haard5, K Silence5, M Bagot6, P Pauwels7,
K Zwaenepoel7, A Awada2, D Bron2, V Ribrag1
1Hematology, Gustave Roussy Institute, Villejuif, France, 2Hematology, Jules
Bordet Institut, Bruxelles, 3Hematology, Ghent University Hospital, Ghent, Bel-
gium, 4Hematology, Universitair Ziekenhuis Antwerpen, Antwerpen, Bahrain,
5arGEN-X BVBA, Ghent, Belgium, 6Dermatology, Saint Louis APHP, Paris,
France, 7Hematology, Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium
Background: CD70 is a cell surface marker transiently expressed on activated
B, T cells and dendritic cells. The interaction via its receptor CD27 results in
survival, proliferation and lymphocyte differentiation. In a large number of solid
tumours types, CD70 is overexpressed but without receptor co-expression. As
overexpression of CD70 is paralleled by high expression of its receptor CD27
in TCL, the CD70/CD27 axis appears critical for proliferation and survival of
malignant cells in T-cell lymphoma.
Aims: ARGX-110 is a novel glycoengineered monoclonal antibody targeting
CD70 and blocking CD27 signaling, leading to a direct mode of action lysing
CD70+ tumor cells (via CDC, ADCP and enhanced ADCC) and indirect anti-
tumor restoring immune surveillance.
Methods: (NCT01813539) A phase I trial was initiated with ARGX-110, dose
escalated to investigate safety, clinical pharmacology and determine the RP2D,
in refractory or relapsed solid tumors and hematological malignancies on
patients with CD70+tumors (defined by IHC >10%+). ARGX-110 was given to
65 patients at doses from 0.1 to 10 mg/kg intravenously every 3W.
Results: Preclinical data: Immunohistochemistry on TCL patient samples con-
firmed overexpression of CD70 (>10% CD70+ tumor cells) in 40/73 PTCL
(55%) and 15/21 CTCL (71%) samples. Serum soluble CD27 levels were ele-
vated in TCL patients compared to healthy subjects (670±1096 vs 192±44
IU/ml, respectively, p= 0.0062). Phase 1 heme results: Nine patients received
ARGX-110 for a TCL. Histological TCL types were 3 Cutaneous TCL (CTCL)
and 6 Peripheral TCL (PTCL). ARGX-110 was well tolerated with no grade >3
adverse events related to the study drug. A clinical and/or biological response
was observed in 4/9 of T-cell Lymphoma patients; CTCL (n=3) and PTCL-AITL
(n=1) patients. Response consisted in 2 patients with CTCL Sezary syndrome
(treated at 0.1 and 10 mg/kg, respectively) in a >90% reduction in the circulating
malignant clone, with a clinical partial response in the skin in one patient. The
other patient with CTCL TFH lymphoma (treated at 5 mg/kg) achieved a PR.
One patient with PTCL with Angioimmunoblastic T-cell Lymphoma (AITL)
reached a PR (5 mg/kg dose) and had a resolution of lymphoma associated
auto-immune hemolytic anemia.
Summary/Conclusions: In the TCL patients treated with ARGX-110, a signal
of clinical and/or biological anti-tumor activity was observed. These preliminary
results support further investigation of ARGX-110 in TCL.
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DOUBLE PROTEIN LYMPHOMA PATIENTS OF THE NON-GCB
SUBTYPE HAVE AN INFERIOR PROGNOSIS WHEN TREATED WITH
CHEMOIMMUNOTHERAPY
K Troppan1,*, C Beham2, H Greinix1, A Deutsch3, P Neumeister1
1Hematology, Internal Medicine, 2Pathology, 3Internal Medicine, Graz, Austria
Background: Diffuse large B-cell lymphoma (DLBCL) can be stratified by cell
of origin (COO) derivation into the prognostically favorable germinal center B-
cell (GCB)–like and unfavorable activated B-cell (ABC) or non-GCB-like subtype
based on gene expression signatures or immunohistochemical determination.
Double-hit lymphoma (DHL) were identified as a subgroup of aggressive lym-
phomas with both MYC and BCL2 gene rearrangements, characterised by a
rapidly progressing clinical course and short survival. Recently, DLBCL patients
with an immunohistochemical coexpression of MYC and BCL2 also demon-
strated inferior prognosis suggesting that concurrent expression of MYC/BCL2,
termed double-protein-expression lymphoma (DPL), rather than cell-of-origin
classification, is a better predictor of prognosis in patients treated with R-CHOP.
Aims: We determined the frequency of DPL in a large single center cohort of
DLBCL uniformely treated with R-CHOP and evaluated patients’ outcome in con-
trast to “standard” DLBCL not exhibiting concurrent expression of MYC/BCL2.
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Figure 1.
Methods: We evaluated retrospectively the appearance of DPL in 440 patients
with DLBCL, consecutively diagnosed and treated between 2004 and 2014 at
our institution. To determine the double-hit score, immunohistochemistry for c-
MYC and BCL2 was performed on diagnostic samples. Furthermore, the Choi
algorithm was used to subclassify samples by cell-of-origin. On the basis of
immunohistochemical MYC and BCL2 expression, a double-hit score (DHS)
was assigned to all patients with DLBCL. The DHS-2 group was defined by
high expression of both MYC and BCL2 protein.
Results: A GCB subtype was found in 162 patients, whereas 223 samples
were classified as non-GCB subtype. For 55 patients, no classification accord-
ing to cell-of-origin could be performed. Of 440 DLBCL, 289 patients were
evaluable, 58 of them showed a double-hit score of 0, 168 patients had a DHS
of 1, and 63 a DHS of 2, respectively. Twenty-one of 76 patients with a DHS of
2 could be classified as GCB, whereas 42 patients exhibited a non-GCB sub-
type. Using Kaplan-Meier curves and log-rank tests, we could demonstrate a
significant inferior outcome for DLBCL patients with the non-GCB subtype as
compared to the GCB subtype (, p<0.001). Further, DPL patients had also a
shorter overall survival (OS) (p=0.05). Combining the cell-of-origin classification
with the DHS, we were able to further discriminate a subgroup of patients with
an even worse clinical outcome to standard treatment (median OS 81 vs 44
months, p<0.001) (Figure 1).
Summary/Conclusions: In this large single center cohort, we could demon-
strate a significant negative effect on OS for DLBCL patients coexpressing
MYC and BCL2. We could further define a particular subgroup of patients within
the non-GCB cohort demonstrating double hit positivity (DHS of 2) that is asso-
ciated with a particular short survival. These non-GCB-, DHS positive DLBCL
patients are candidates for novel therapeutic strategies.
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A CLINICO-PATHOLOGIC AND IMMUNOHISTOCHEMICAL ANALYSIS OF
ORAL AND EXTRA-ORAL PLASMABLASTIC LYMPHOMA IN SOUTH
AFRICA
S Meer1,*, Y Perner2, P Willem3
1Faculty of Health Sciences, Department of Oral Pathology, 2Faculty of Health
Sciences, Department of Anatomical Pathology, 3Faculty of Health Sciences,
Department of Hematology and Molecular Medicine, University of the Witwa-
tersrand, Johannesburg, South Africa
Background: Plasmablastic lymphomas (PBLs) are a group of aggressive
non-Hodgkin lymphomas originally described to be exclusive to the oral cavity
in patients with immunodeficiency. This group of uncommon lymphomas, which
shows morphologic, phenotypic and molecular features of terminally differen-
tiated B-cells is increasingly being described in many extra-oral sites as well,
in both HIV and non-HIV infected patients. Data relating to age, gender, HIV
status and immunophenotypic profile have been published in case reports,
case series and systemic reviews. To date there are no data on extra-oral PBLs
in South Africa where HIV is higly endemic. We present a series of 101 oral
(55) and extra-oral (45) PBLs which forms the largest global series described
to date in a region of Africa where HIV is endemic.
Aims: To characterize the clinical, morphological and immunological features of
oral and extra-oral plasmablastic lymphomas in a defined South African population.
Methods: This is a retrospective study on archival cases of extra-oral and oral
PBLs diagnosed over the period 2006 to 2015 in the Department of Anatomical
Pathology, University of the Witwatersrand, Johannesburg, South Africa. Clinical
parameters analyzed included patients age, gender, HIV status and site of
tumor presentation. Each case was reviewed histologically to confirm the diag-
nosis and assessed immunohistochemically with CD45 (LCA), CD20, CD79a,
PAX5, CD138, MUM1, BLIMP1, VS38c, Ki-67, BCL6, CD10, and HHV8 using
standard immunohistochemistry protocols. The presence of EBV-encoded early
nuclear RNAs (EBER1 and EBER2) was assessed by chromogenic in-situ
hybridization. Ethical clearance was obtained from the University of the Witwa-
tersrand human research ethics committee.
Results: Forty-six patients were diagnosed with extra-oral PBLs and 55
patients with oral PBLs. These included all adult patients, except for one case
of a nine-year old child. The age ranged from 9 to 59 years (mean:35.5; medi-
an:35) for extra-oral cases and 22 to 78 years for oral PBLs (mean:41.1; medi-
an:41). Of the 18 and 34 patients with extra-oral and oral PBLS with known
HIV status, 17 (95%) and 33 (97%) patients respectively were infected with
HIV. None of the patients had systemic disease at presentation. The overall
male:female ratio was 1.9:1 (67 males and 34 females), with 66% of PBLs
occurring in males. The male:female ratio for extra-oral and oral PBLs was
1.4:1 (27 males (59%) and 19 females) and 2.7:1 (40 (73%) males and 15
females) respectively. The anus was the favoured extra-oral site of presentation
(13 of 46 cases, 28%), followed by soft tissue (11 of 46 cases, 24%). The
favoured oral site for PBL was the maxilla (16 of 55 cases, 29%) followed by
the palate (11 of 55 cases; 20%). The histomorphology in both oral and extra-
oral PBLs was similar showing both plasmablastic and plasmacytic features.
The immunohistochemical profile of all PBLs in the study recapitulated that
found for both oral and extra-oral PBL in the literature, except for CD45 (leuco-
cyte common antigen), which signalled positively in a higher percentage of cas-
es. Overall 73 of 80 cases (91%) were positive for CD45; 36 of 42 extra-oral
cases (85.7%) and 37 of 38 oral cases (97%). The positive membrane signal
for CD45 was of variable intensity, between 5 and 100% of tumor cells. EBV
was positive by in-situ hybridization in 71 of 74 cases (96%), i.e. in 37 of 40
(93%) extra-oral cases and all 34 oral PBLs (100%).
Summary/Conclusions: Extra-oral PBL was identical to its oral counterpart in
gender and age distribution, HIV status, morphological appearances,
immunophenotypic profile and association with EBV. The high association with
EBV as assessed by in-situ hybridization studies mirrors that of extra-oral and
oral PBLs reported in the literature. A peculiarity observed within this case
cohort was the high level of expression of CD45. This has been reported to be
of low or near absent in most cases of PBL, as defined by the WHO 2008 and
recorded in the literature. Although the HIV status was only known for approx-
imately half of these cases, HIV associated PBL manifested as a single disease
in both oral and extra-oral forms, and should be regarded as the same tumor.
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A NGS IGK ASSAY FOR THE DETECTION OF CLONALITY AND THE
MONITORING OF MINIMAL RESIDUAL DISEASE
Z Xie1,*, K Hutt1, J Panganiban1, W Huang1, S Zheng1, D Duong1, A Jacobsen1,
G Pawlowsky2, J Thorne1, M Arcila3, J Miller1, T Stenzel1
1Invivoscribe, San Diego, United States, 2LabPMM, Martinseried, Germany,
3Memorial Sloan-Kettering Cancer Center, New York, United States
Background: During B-cell development, functional immunoglobulin genes
are assembled from individual V, D, and J gene segments to generate V-D-J
combinations of length and sequence that are unique for each cell. Rearrange-
ments within IGH occur first, followed by IGK. In addition to V-D-J rearrange-
ment, the IGK Kde locus can rearrange to Vk gene and to an isolated RSS in
the Jk-Ck intron (INTR). Leukemia and lymphomas originating from the malig-
nant transformation of individual lymphoid cells generally share one or more of
these cell specific or “clonal” gene rearrangements. Assays that identify clonal
lymphocyte populations in clinical specimens are used on a routine basis to
assist in the diagnosis of lymphoproliferative disease. The clinical relevance of
minimal residual disease (MRD) detection in lymphoproliferative disease has
been demonstrated by many studies. However, allele-specific primers are
required for the qPCR-based MRD monitoring. The emergence of cost-effective,
next-generation sequencing (NGS) platforms and development with associated
bioinformatics tools have resulted in powerful new approaches for clonality
detection and MRD monitoring without the requirement of allele-specific
designs.
Aims: To establish an IGK NGS assay that, combined with an IGH NGS assay,
will increase the chance of identifying clonal populations and provide easy
tracking of identified clonal population for MRD in lymphoid malignancies.
Methods: Genomic DNA from cell line, peripheral blood, bone marrow aspi-
rates, and FFPE were tested for IGK rearrangements using the LymphoTrack®
IGK MiSeq® Assay (Invivoscribe Inc., San Diego, USA). The IGK libraries were
run individually or in combination with IGH and or TRG libraries. The sequencing
data was analyzed using LymphoTrack® bioinformatics software, which per-
forms the separation of IGK, IGH, and TRG data as necessary, and generates
frequency distributions and identifies the rearranged DNA sequences for each
target. Total of 198 peripheral blood samples were also tested by the capillary
electrophoresis (CE) based IdentiClone® IGK assay.
Results: Data generated with the IGK NGS assay and bioinformatics software
identified clonality and corresponding DNA sequences of IGK Vk-Jk, Vk-Kde,
and INTR-Kde gene rearrangements. Excellent linearity of the IGK NGS assay
was obtained from contrived cell line DNA in the range of 2.5-20% when running
individually (R2=0.9897) or in combination with IGH and TRG assays
(R2=0.9905). The concordance between the 198 samples tested by IGK NGS
and CE assays was 77%. There were 43 samples indentified to be clonal out
of 198 samples tested by both IGK and IGH NGS assays. Among those sam-
ples, 31 and 25 samples were clonal for IGK and IGH, respectively, and 18
samples were clonal for both IGK and IGH. It was demonstrated that the NGS
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assay allows for easy tracking of clonal populations at the sensitivity of 10-4 or
at even lower limits of dectection, provided sufficient amount of DNA is tested.
Summary/Conclusions: A comprehensive assay has been developed for the
MiSeq® platform that identifies clonal IGK rearrangements and the associated
specific DNA sequences. The IGK assay, in combination with the IGH assay,
increased the detection of clonality by 72% comparing to IGH alone. The assay
can be used both to detect clonality and monitor the identified clonal populations
in MRD.
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DE NOVO TRANSFORMED FOLICULAR LYMPHOMA. OUTCOMES AND
ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION
M Alcoceba*, S Alonso, L Magnano, M García-Álvarez, M Andrade,
G Rodríguez, S Mercadal, JM Sancho, A Salar, R Arranz, MJ Terol,
A Rodríguez, S González de Villambrosia, L López, S Monsalvo, S Novelli,
E de Cabo, MS Infante, E Pardal, M Canales, M González, A Martín,
A López-Guillermo, MD Caballero
Hematologia, Spanish Group of Lymphoma and Autologous Stem Cell Trans-
plantation (GELTAMO), Spain
Background: The role of histologic transformation (HT) on survival of follicular
lymphoma (FL) in the rituximab era has been recently analyzed in several stud-
ies. However, there is no information about the outcome of patients with simul-
taneous presence of FL and diffuse large B cell lymphoma (DLBCL) in the
same initial diagnostic biopsy (de novo transformed FL; dn-tFL).
Aims: We examined clinical characteristics, survival following transformation
(SFT) and impact of intensive regimens (including ASCT) in a group of patients
diagnosed of dn-tFL, and compared them with a group of FL patients who
developed HT (tFL).
Methods: We recruited 1809 patient candidates from a retrospective series in
18 centres from the Spanish Group of Lymphoma and Autologous Stem Cell
Transplantation (GELTAMO). Of them, 75 patients were diagnosed of dn-tFL,
and the other 1734 of FL grade 1-3a, from which 106 developed HT. Treatment
at HT consisted in rituximab containing regimens.
Results: Clinical variables were not significantly different between tFL and dn-
tFL. 5-year SFT was significantly higher in dn-tFL as compared to tFL patients
(75% vs. 25%, p<0.0001; Figure 1A). Variables influencing 5-year SFT in dn-
tFL were complete response (CR) to front line therapy (90% vs. 41%, p<0.001;
Figure 1B), and low-risk FLIPI score (100% vs 58%, p=0.018). In the multivari-
ate analysis, only CR to front line therapy (HR 6.5, 95% CI: 2.0-20.7) had an
independent influence on 5-year SFT. In the conventional tFL comparison
cohort, achievement of CR (47% vs 5%, p<0.001; Figure 1B), but not low-risk
FLIPI (40% vs. 27%, p=0.2) influenced 5-year SFT. A total of 19 dn-tFL patients
did not achieve CR to first-line therapy, and received salvage therapy, which
was followed by ASCT as consolidation therapy only in 4 cases. 5-year SFT in
the ASCT group was higher (67% vs. 42%, p=0.07). However, these groups
were not comparable since patients receiving ASCT were significantly younger
than those not receiving ASCT (median 54 years vs. 71 years, p=0.031).
Figure 1.
Summary/Conclusions: De novo tFL patients have better SFT than patients
that develop HT after FL diagnosis. Although differences are evident in terms
of general SFT, both groups are characterized by a decisive influence of therapy
response in SFT. Interestingly, although FLIPI score is not the standard index
to evaluate aggressive lymphoma, it accurately stratified composite FL+DLBCL
and not the conventional tFL. In our series, ASCT shows a potential benefit as
a rescue therapy in those dn-tFL patients not responding to first-line treatment.
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LOW EXPRESSION OF MIR-155 IN VINCRISTINE RESISTANT DIFFUSE
LARGE B-CELL LYMPHOMA
H Due1,2,*, A Amanda Schönherz1, L Bechmann Krogh3, J Støve Bødker1,
A Schmitz1, R Froberg Brøndum1, H Erik Johnsen1, M Bøgsted1,
J Giehm Mikkelsen3, A Stidsholt Roug4, K Dybkær1
1Department of Hematology, Aalborg University Hospital, Denmark, Aalborg,
2Clinical Medicine, Aarhus University, 3Department of Biomedicine, Aarhus
University, 4Department of Hematology, Aarhus University Hospital, Aarhus,
Denmark
Background: Vincristine is a key chemotherapeutic drug of first line therapy
R-CHOP in Diffuse Large B-cell Lymphoma (DLBCL). The clinical course for
DLBCL patients has great variability and an unfavorable outcome is observed
in more than 40% of cases due to intrinsic or acquired treatment resistance.
Accordingly, identification of molecular resistance mechanisms and early pre-
diction of drug specific resistance is an urgent clinical need. 
Aims: This study investigates the potential of miRNAs as predictive biomarkers of
vincristine resistance and the involvement of miRNAs in the resistance mechanisms.
Methods: Systematic vincristine dose-response screen was performed on 12
DLBCL cell lines to identify 50% growth inhibition dose (GI50) for the individual
cell lines. Ranking of GI50 allowed trichotomisation into groups of drug specific
sensitive (n=3), intermediate (n=6), or resistant (n=3) cell lines. Based on global
miRNA expression profiles of each cell line in untreated condition, class com-
parison was performed and 13 differentially expressed miRNAs were identified
between sensitive and resistant cell lines (fold-change>׀2׀, p-value<0.05).
Especially, miR-155 showed significant association between low expression
and increased vincristine resistance having 33.5 fold decreased expression in
resistant cell lines (p=0.0005). Based on gene expression profiles, 66 DLBCL
patients biopsied at time of diagnosis were classified into the prognostic molec-
ular subclasses ABC/GCB and B-cell associated gene signatures (BAGS),
reflecting naturally occurring B-cell subsets of naïve, centroblast, centrocyte,
memory, and plasmablast cells as cell of origin. Additionally, resistance gene
signature (REGS) for vincristine was assigned to the clinical samples giving
each case a likelihood of predicted response to vincristine. Expression levels
of miR-155 were determined in the DLBCL samples by RT-qPCR.
Results: A significantly higher expression of miR-155 was observed in the
prognostic adverse ABC subclass compared to GCB (n=66, p-value=0.0373)
indicating miR-155 as an unfavorable marker. However, using BAGS classifi-
cation clinical samples assigned into the prognostic favorable centrocyte sub-
class had higher miR-155 expression compared to the prognostic adverse cen-
troblast subclass (n=59, p-value=0.003). Observations further supported when
BAGS classification was stratified into ABC and GCB subclasses. Within the
GCB subclass centrocyte DLBCL cases had significantly higher miR-155
expression compared to centroblast cases (n=27, p=0.0223). Within the ABC
subclass no difference between the BAGS subclasses was detectable. Thus,
using the prognostic BAGS classification system within the GCB subclass low
miR-155 expression is an unfavorable marker. REGS stratification of clinical
samples did not show significant miR-155 expression differences between
REGS classes. However, assigning REGS to ABC and GCB subclasses, sep-
arately, a significant difference between low miR-155 expression and vincristine
resistance was observed within the GCB subclass (n=27, p-value=0.051) but
not within the ABC subclass (n=26, p-value=0.99). This supports the in vitro
observations of low miR-155 expression and vincristine resistance within the
GCB subclass.
Summary/Conclusions: In conclusion, we observed different miR-155 expres-
sion patterns between ABC and GCB subclasses. Moreover, a significant asso-
ciation between low miR-155 expression and vincristine resistance was demon-
strated within GCB assigned cases. To unravel the biological mechanism deter-
mining miR-155 impact on vincristine resistance functional studies including
expression manipulation in DLBCL cells with lentiviral vector system are ongoing.
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RITUXIMAB AND HIGH DOSE CYTARABINE WITH AUTOLOGOUS
TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
S Burrows1,*, D Tucker1, G Naylor2, K Wardrope3, S Bolam4, P McKay3,
A Forbes2, S Rule1
1Haematology, Derriford Hospital, Plymouth Hospitals Trust, Plymouth,
2Haematology, Royal Cornwall Hospital, Truro, 3Haematology, Gartnavel Gen-
eral Hospital, Glasgow, 4Haematology, Musgrove Park Hospital, Taunton, Unit-
ed Kingdom
Background: Mantle cell lymphoma (MCL) is an aggressive and incurable
form of non-Hodgkin lymphoma (NHL), typically presenting at a late stage,
often with extra nodal involvement, and with a preponderance for older males.
Front-line therapy incorporating rituximab and high-dose cytarabine (R-HDAC),
often in combination with other drugs or alternating with another regimen, fol-
lowed by autograft in first response is standard of care for younger, fitter
patients. Reported overall response rates (ORR) and progression free survival
(PFS) are typically 70-90% and 50-60% respectively.
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Aims: To explore the tolerability and efficacy of rituximab and single-agent R-
HDAC prior to autologous stem-cell transplant in patients with untreated MCL.
Methods: We studied 45 unselected, transplant eligible patients with MCL treat-
ed upfront with R-HDAC alone across four UK centres between February 2010
and August 2015. The median age was 60, the majority were male (84%), and
the majority had advanced disease (91% Stage III/IV). None had central nerv-
ous system (CNS) involvement at presentation. All patients received at least
one cycle of R-HDAC. The median number of cycles of R-HDAC given was 5,
and 89% received at least three cycles. Only two patients stopped R-HDAC
therapy early due to toxicity; one due to PJP pneumonia after the first cycle
who was stepped down to Bendamustine based treatment, and one due to
severe sepsis after the second cycle who stopped therapy at this point having
already achieved a partial response. One further patient completed five cycles
of R-HDAC but was felt unfit for autograft at that point.
Results: Nine patients (20%) progressed on R-HDAC, of whom only three
(33%) achieved a remission with second line therapy, two of whom subse-
quently died of progressive disease. In total 31 patients (69%) have now under-
gone transplantation; 28 (62%) received an autograft (the majority BEAM con-
ditioned), two had an allogeneic transplant and one a syngeneic transplant.
Two patients are currently completing R-HDAC treatment and will undergo
BEAM autograft thereafter. Transplant related mortality was within expected
limits, with one patient dying as a result of sepsis due to BEAM autograft toxicity.
Median duration of follow up of the entire cohort was 38 months. Overall
response rate for R-HDAC with or without transplantation was 35/45 (78%),
with most patients achieving a complete remission (CR) (n=30, 67%). Median
OS and PFS were not reached. The OS at 4yrs is 78% (18/23); and PFS at
4yrs is 61% (14/23). Eight patients relapsed after achieving CR1 with HDAC
+/- transplantation, five (63%) have subsequently achieved a second remission.
The most commonly employed strategies amongst patients who required sub-
sequent treatment were Ibrutinib (47%), Bortezomib (35%), CHOP (29%) and
Bendamustine (17%) based therapies. CNS involvement was seen at
relapse/progression in four cases.
Figure 1.
Summary/Conclusions: This study confirms that induction with R-HDAC, con-
solidated with stem cell transplantation where appropriate, is a safe and effec-
tive upfront treatment strategy in MCL, and compares favourably with other
induction regimens in terms of toxicity and duration of response. By avoiding
the use of other agents as part of upfront treatment excess toxicity is avoided.
Using R-HDAC upfront also leaves a greater range of therapies available for
use at subsequent relapse, with good remission rates after second line therapy
shown in this study. However, direct comparison with other upfront treatment
strategies has not been made, and a prospective randomised controlled trial is
needed.
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TREATMENT OF INITIAL CENTRAL NERVOUS SYSTEM INVOLVEMENT
IN SYSTEMIC AGGRESSIVE LYMPHOMA WITH HIGH DOSE METHOTREXATE
AND R-CHOP
M Nijland1,*, A Jansen2, J Doorduijn3, R Enting4, J Bromberg5, H Kluin-Nelemans1
1Hematology, University Medical Center Gronigen, Groningen, 2Neurology,
Canisius-Wilhelmina Hospital, Nijmegen, 3Hematology, Erasmus University
Medical Center Rottedam, Rotterdam, 4Neurology, University Medical Center
Gronigen, Groningen, 5Neurology, Erasmus University Medical Center Rot-
tedam, Rotterdam, Netherlands
Background: Central nervous system (CNS) involvement in systemic aggres-
sive B-cell non Hodgkin lymphomas (B-NHL) at initial diagnosis is uncommon.
Two recent studies suggest a beneficial effect of intensive chemotherapy fol-
lowed by autologous stem cell transplantation (ASCT) for these patients, but
since ASCT was only offered to patients in complete remission optimal treat-
ment remains unclear.
Aims: We investigated the outcome of patients with concomitant systemic and
CNS B-NHL (sCNS B-NHL) at diagnosis treated with high dose methotrexate
(HD-MTX) and R-CHOP, but no ASCT.
Methods: We performed a retrospective cohort study of patients with sCNS B-
NHL at diagnosis identified from the electronical databases of 2 referral centers
in the Netherlands. Patients had histological proven aggressive B-NHL and stage
4 disease according to Ann Arbor classification with concomitant parynchymal
CNS involvement. Patients were treated according to one of two regimens: either
6 alternating cycles of HD-MTX and R-CHOP, or four cycles of HD-MTX followed
by 6 cycles of R-CHOP. In the latter MTX was part of the MBVP regimen which
also includes teniposide (VP16) and carmustine (BCNU). Primary endpoints
were progression free survival (PFS) and overall survival (OS).
Figure 1. Overall and progression free survival.
Results: From 2001-2015 21 patients with sCNS B-NHL were identified. Medi-
an follow-up was 28 months. Characteristics at diagnosis: median age 54 years
(range 19-71); WHO performance ≥2: 33%; IPI-score 0-1: 9%, 2-3: 66%, 4-5:
25%. Histological B-NHL types: diffuse large B-cell lymphoma: 66%; iatrogenic
immunodeficiency B-NHL: 14%; transformed marginal zone lymphoma: 10%;
intravascular B-NHL: 10%. Systemic organ involvement: testicular: 44% of
patients at risk; breast: 17% of patients at risk; bone: 38%; kidney: 19%. Con-
comitant spinal fluid localization occured in 43% of patients. Fifteen out of 21
patients completed therapy as planned. The median number of MTX cycles at
a dose of 3 g/m2 was 4 (range 1-8). Sixty-two percent of patients also received
intrathecal MTX. The median number of R-CHOP cycles was 6 (range 0-8).
Whole brain radiotherapy was given to 33% of patients in partial remission.
Besides the additional VP16 and BCNU in patients treated with MBVP, there
was no difference between the two regimens. 3-year PFS and OS for the entire
cohort were 45% (95%CI 34-56%) and 49% (95%CI 38-60%) respectively. The
treatment related mortality (TRM) was 24% (5/21). No significant difference in
OS was found between the two regimens (HR OS 1.25, 95%CI 0.38-4.2 p
0.72). The 3 patients with IPI-score 0-1 were alive at the last control, whereas
all 4 patients with IPI-score 4-5 died within 2 years after diagnosis. There were
6 relapses (28%): 2 systemic, 2 in CNS, and 2 both systemic and in CNS.
Summary/Conclusions: In this second largest cohort described to date, the
outcome of patients with sCNS B-NHL treated with HD-MTX and R-CHOP was
comparable to that of more intensive regimens. Prospective studies are needed
to define the optimal treatment for these patients.
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FEASIBILITY AND EFFICACY OF DHAOX REGIMEN AS SALVAGE AND
MOBILIZING THERAPY IN RELAPSED /REFRACTORY LYMPHOMAS
E Coviello*, L Giannoni, G Pastori, L Mitscheunig, D Avenoso, P Minetto,
F Guolo, M Miglino, M Clavio, RM Lemoli, G Marco, F Ballerini
Chair of Hematology, Department of Internal Medicine (DiMI), University of
Genoa, IRCCS AOU San Martino-IST, Genoa, Italy
Background: As already known, cisplatinum containing regimens for the man-
agement of relapsed-refractory lymphomas are complicated by different
adverse events, mainly renal impairment. Since 2004 we used oxaliplatinum
instead of cisplatinum, in association with cytarabine and dexamethasone
(DHAOX). 
Aims: The aim of the present study was to perform a retrospective analysis on
feasibility and efficacy of this salvage regimen in patients with R/R lymphomas.
Methods: We retrospectively analyzed the outcome of 83 patients with R/R
lymphomas who received DHAOX regimen from October 2004 to January 2016.
The median age was 59 (22-79) and the median follow up is 56 months. Our
series includes 41 patients with Diffuse Large B cell Lymphoma (DLBCL, 49%),
10 with Hodgkin Lymphoma (HL, 12%), 13 with Mantle Cell Lymphoma
(MCL,16%), 15 with Indolent Lymphomas (18%), 4 with Peripheral T cell Lym-
phoma (5%). DHAOX schedule contains dexamethasone (40 mg/die on days
1-4), oxaliplatinum (130 mg/sqm on day 1) and cytarabine (2 g/sqm bid on day
2). In the majority of patients DHAOX was used as second line therapy. All
patients received prophylactic G-CSF to reduce neutropenia. We analyzed
overall survival (OS) and relapse free survival (RFS) in the whole cohort and
then in DLBCL and HL patients. We evaluated haematological and non haema-
tological adverse events (AEs).
Results: Non haematological AEs of grade >2 were observed in 27 patients
(33%). The most frequent were: oral mucositis and other gastrointestinal events
(6 patients, 8%), FUO (17 patients, 21%), sepsis (3 patients, 4%), paresthesias
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(5 patients, 6%), and other different AEs in 4 patients (gout, atrial fibrillation,
hypocalcemia and pleural effusion). 13 patients (16%) needed transfusional
support. No patients experienced renal impairment. In 39 patients DHAOX reg-
imen was utilized as mobilizing therapy to collect CD34+ cells for autologous
stem cell transplantation (ASCT). In 32/40 patients (83%) more than 4x106
CD34+ cells/kg were collected following G-CSF stimulation (5 mcg/Kg/die from
day 5), in 1 patient associated with plerixafor. Median OS was 84 months. The
projected OS at 12, 24, 36 months was 74.5%, 64.3% and 54.5%, respectively.
Forty-one patients with DLBCL have been treated (median age 55 yy, range
22-79), 33 in second line (81%), 8 in third or subsequent line (19%). CR was
obtained in 22 cases (60%), PR in 4 cases (11%). Eleven patients did not
respond (29%). ORR was 71%. The median OS was 33 months and the pro-
jected OS at 12, 24 and 36 months was 66.3%, 57.9%, 45.5% respectively.
Ten patients with HL were treated (median age 44, range 28-74), 7 in second
or third line (70%), 3 in fourth or subsequent lines (30%). CR and PR were
obtained in 3 (30%) and 1 patients (10%), respectively. ORR was 40%. Con-
sidering only patients in second or third line, the ORR was 29%. Stem cell har-
vest was attempted in 2 patients, reaching the stem cell goal in both cases.
The median OS was 84 months. The projected OS at 12, 24 e 36 months was
88.9%, 77.8%, 66.7% respectively.
Figure 1.
Summary/Conclusions: DHAOX regimen was generally well tolerated, with
acceptable toxicity profile and no documented significant renal impairment. By
reducing days of hospitalization and the need of supportive care, we obtained
a significant saving of economic resources despite the higher cost of oxaliplat-
inum. Stem cell mobilization with DHAOX resulted feasible and a successful
apheresis was achieved in most patients. In conclusion, DHAOX regimen
showed a good efficacy and a safe profile in the setting of relapsed/refractory
non Hodgkin Lymphomas, mainly DLBCL; on the contrary, we experienced
poor results in relapsed/refractory HL, suggesting that other schedules might




OUTCOMES OF 34 PRIMARY BREAST DIFFUSE LARGE B-CELL
LYMPHOMA IN RITUXIMAB ERA AT A SINGLE INSTITUTION
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1Hematology/Oncology, 2Division of Pathology, 3Pathology Project for Molec-
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Background: Primary breast lymphoma (PBL) is a rare subtype of lymphoma
accounting for 1 to 2% of extra-nodal lymphomas with the most subtype of dif-
fuse large B cell lymphoma (DLBCL), thus the data of pathology and outcome
is limited.
Aims: To elucidate the clinicopathological features and the outcomes including
incidence of central nervous system (CNS) relapse in Rituximab-era.
Methods: Data were collected on patients with PBL diagnosed between Jan-
uary 1992 and 2016 at the Cancer Institute Hospital of JFCR, retrospectively.
Patients with stage III and IV were excluded. Female DLBCL with stage I / II
were also collected as a control in the matched case-control study.
Results: A total of 34 patients; 9 treated with CHOP-like regimens (CHOP group),
10 treated with rituximab-CHOP (R-CHOP group), and 15 treated with R-CHOP
and intrathecal (IT) prophylaxis, were analyzed. Median age was 57 years. All
patients were female with 21 patients (70.5%) of presenting with right breast
tumor. Non-GC type defined by Hans algorithm had a higher proportion of 14 out
of 24 analyzable patients (58.3%) without poor prognostic value. In comparison
with early stage DLBCL treated with R-CHOP with or without IT prophylaxis
except for breast, younger age (57 years v.s. 66 years) and higher CNS relapse
rate (8.8% v.s. 0%) had significant difference between two groups. Then 1: 3
pair-matched case-control study limited in patients with stage I / II, female, and
rituximab use, adjusted with age was carried out. Non-GC had higher rate in
PBL than early stage DLBCL (66.7% v.s.44.4%), however, with no significant dif-
ference. On survival analysis with a median follow-up of 63months, PBL did not
have poor prognosis with a 3-y-PFS (89.2% vs 90.2%, p=0.55) and 3-y-OS
(90.0% vs 94.5%, p=0.87). Among patients with PBL, after a median follow-up
of 47.5 months (range 1-286 months), the 3-year Progression free survival (PFS)
and overall survival (OS) according to three groups; CHOP group, R-CHOP
group, and IT+R-CHOP group were 55.6%, 80%, and 100% (p=0.058), and
55.6%, 80%, and 100% (p=0.06), respectively. CNS relapse had occurred in 3
out of 34 patients: all were stage II, one in CHOP group and two in R-CHOP
group. Notably IT+ R-CHOP group had no relapse to date.
Figure 1.
Summary/Conclusions: PBL patients are younger than early stage DLBCL,
and still considered as a high-risk for CNS relapse in Rituximab era. Neverthe-
less, IT added to R-CHOP potentially improve outcomes including CNS relapse. 
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PATIENTS WITH PRIMARY CNS LYMPHOMA OR PRIMARY TESTICULAR
DIFFUSE LARGE B-CELL LYMPHOMA HAVE AN INFERIOR PROGNOSIS
WHEN CO-EXPRESSING C-MYC AND BCL2
K troppan1,*, C Beham2, H Greinix1, A Deutsch1, P Neumeister1
1Hematology, Internal Medicine, 2Pathology, Graz, Austria
Background: Primary central nervous system lymphomas (PCNSLs) and pri-
mary testicular lymphomas (PTLs) are extranodal diffuse large B-cell lym-
phomas (DLBCLs) exhibiting a similar genetic signature and are characterised
by an inferior response to current treatment regimens. DLBCL can be stratified
by cell of origin (COO) derivation into the prognostically favorable germinal
center B-cell (GCB)-like and the unfavorable activated B-cell (ABC) or non-
GCB-like subtype based on gene expression signatures or immunohistochem-
ical determination. The majority of PCNSL or PTL lymphoma derives from the
non-GCB subtype. Recently, DLBCL patients with an immunohistochemical
co-expression of c-MYC and BCL2 demonstrated inferior prognosis suggesting
that concurrent expression of MYC/BCL2, termed double-protein-expression
lymphoma (DPL), is a predictor of prognosis. Up to now there are no data,
investigating the impact of DHL in patients with PCNSL or PTL.
Aims: We determined the frequency of DPL in a single center cohort of PCNSL
or PTL and evaluated patients’ outcome in contrast to “standard” DLBCL not
exhibiting concurrent expression of MYC/BCL2.
Figure 1.
Methods: We evaluated retrospectively the appearance of DPL in 42 patients
with CNS or testicular DLBCL, consecutively diagnosed and treated between
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2004 and 2014 at our institution. To determine the double-hit score, immuno-
histochemistry for c-MYC and BCL2 was performed on diagnostic samples.
Furthermore, the Choi algorithm was used to subclassify samples by cell-of-
origin. On the basis of immunohistochemical c-MYC and BCL2 expression, a
double-hit score (DHS) was assigned to all patients with DLBCL. The DHS-2
group was defined by high expression of both MYC and BCL2 protein.
Results: Except for 3 samples, all patients were classified as non-GCB sub-
type. For 7 patients, no classification according to cell-of-origin could be per-
formed. Of 42 primary extranodal DLBCL (PCNSL, n=28, PTL, n= 14), 29
patients were evaluable, 5 of them showed a double-hit score of 0, 11 patients
had a DHS of 1, and 13 a DHS of 2, respectively. Using Kaplan-Meier curves
and log-rank tests, probably due to small sample size, we could not demonstrate
a significant different outcome for PCNSL or PTL patients with the non-GCB
subtype as compared to the GCB subtype (p=0.74). However, we could clearly
demonstrate a significant impaired outcome for patients with DHS of 2 (OS 61
versus 7 months, p=0.01) (Figure 1). Particularly, for patients with non-GCB
subtype, we were able to further discriminate a subgroup of patients with an
even worse clinical outcome to standard treatment (p=0.007).
Summary/Conclusions: In this single center cohort, we could demonstrate a
significant negative effect on OS for PCNSL or testicular large cell lymphoma
patients co-expressing MYC and BCL2. We could further define a subgroup of
patients within the non-GCB cohort demonstrating double hit positivity (DHS of
2) that is associated with a particular short survival. These non-GCB-, DHS
positive DLBCL patients are candidates for novel therapeutic strategies.
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CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN DIFFUSE LARGE
B-CELL LYMPHOMA. A SINGLE CENTER ANALYSIS OF THE RISK FACTORS
AND THE IMPACT OF CNS PROPHYLAXIS IN THE RITUXIMAB ERA
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F Robin1, M Martelli1
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tology, Sapienza University, Rome, Italy, Rome, 2Hematology, Arcispedale San-
ta Maria Nuova-IRCCS, Reggio Emilia, Italy
Background: Central nervous system (CNS) relapse is a serious and generally
fatal complication of diffuse large B-cell lymphoma (DLBCL) occurring in almost
5-7% of patients in the pre-rituximab era. The median time from diagnosis to
detection of CNS disease is less than 1 year, suggesting that seeding in the
CNS occurs early in the course of disease, with the exception of primary testis
lymphoma in which it can occur up to 10 years after diagnosis. Up to date,
there is no general consensus on how to define high-risk patients and what is
the optimal CNS prophylaxis. The addition of rituximab to CHOP chemotherapy
(RCHOP) has improved the clinical outcome of DLBCL. Nevertheless, the
impact of rituximab on the incidence of CNS complications is still unclear.
Aims: This retrospective study aimed to analyze the predictive factors of CNS
relapse and the impact of CNS prophylaxis in DLBCL patients treated at our
Institute over a 12-years period.
Methods: We collected 393 patients with DLBCL diagnosed between 2002
and 2014. The patients with all stage of disease, regardless of the IPI score,
were eligible and all received RCHOP every 14 or 21 days for at least 4/6
cycles. Patients with HIV or CNS involvement at diagnosis were excluded. Pro-
phylaxis with intrathecal methotrexate (IT-MTX) was administered in patients
with a high risk of CNS relapse according to the Italian Society of Hematology’s
guidelines. The diagnosis of CNS relapse was based on CT/MRI assessment
and/or cerebrospinal fluid cytology.
Results: The median age was 58 years (IQR 47-68), 54% were males; 212/393
patients (54%) had stage III-IV, a bone marrow (BM) involvement was found in
51/393 patients (13%), while 49 (12%) had an involvement of more than 1
extranodal site, testis involvement was in 20/393 patients (5%). B symptoms
were experienced by 100/393 patients (25%) and an elevated LDH was present
in 115/393 patients (29%). According to the IPI score, 197/393 patients (50%)
had a IPI<2 and 196/393 (50%) a IPI>2. Twelve/393 patients (3%) experienced
a CNS relapse: 7 of them had a brain mass, 2 had a leptomeningeal involve-
ment and 3 had both.CNS prophylaxis was carried out in 81/393 patients (21%):
27 with a IPI<2 and 54 (67%) with a IPI≥2. In the low risk group, only 1 patient
with a primary testis involvement developed a CNS relapse 26 months from
diagnosis, despite prophylaxis. In the high risk group according to IPI, 11
patients experienced a CNS relapse; only 4 of them had received IT-MTX[R1].
At univariate analysis: gender (p=0.029), advanced stage (p=0.004), PS>2
(p=0.009), presence of B symptoms (p=0.000), elevated LDH (p=0.006),
involvement of >1 extranodal sites (p=0.000), BM involvement plus elevated
LDH (p=0.003), testis localization (p=0.019) and IPI>=2 (p=0.000) were asso-
ciated with an increased risk of CNS relapse. At multivariate analysis, only
PS>2 (p=0.031, 95%CI: 0.009-0.189), testis involvement (p=0.001, 95%CI:
0.048-0.2) and BM involvement plus elevated LDH (p=0.016, 95%CI: 0.021-
0.2) were predictive factors of high risk of CNS relapse. The 2-year overall sur-
vival of the CNS relapsed patients was 9%, with a median follow-up of 8 months
from diagnosis (IQR 4-28).
Summary/Conclusions: CNS relapse remains a fatal event for patients with
DLBCL even in the rituximab era. Poor PS, testis and BM involvement combined
with elevated LDH represent the most important prognostic factors for CNS
relapse. In our experience, single IT-MTX prophylaxis did not reduced CNS.
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SURVIVAL IMPACT OF SERUM ALBUMIN (SA) IN PATIENTS WITH
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RELATED
NON-HODGKIN’S LYMPHOMAS
J Clara1,2,*, S Dalia3, B Shah2, C Bello2, P Chervenick2, LM Juarez Salcedo2,
MA Kharfan-Dabaja2, L Sokol2, E Sotomayor4, J Chavez2
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2Malignant Hematology, Moffitt Cancer Center, Tampa, 3Hematology/Oncology,
Mercy Clinic, Joplin, 4Hematology/Oncology, George Washington University,
Washington D.C., United States
Background: Despite effective combination antiretroviral therapy for HIV, there
is still increased incidence of Acquired Immunodeficiency Syndrome (AIDS)
related Non-Hodgkin lymphomas (NHLs). AIDS related NHLs represent a chal-
lenge for the practicing oncologist. Prognostic factors have been shown to be
useful to risk stratify the disease. 
Aims: Here we examine potential prognostic indicators that may improve the
performance of current prognostic systems in AIDS related NHLs.
Methods: Patients with HIV associated aggressive B-cell NHL were identified
between 2001- 2014 at Moffitt Cancer Center. Patients with and primary central
nervous system lymphoma were excluded. Clinical data including CD4 count,
HIV viral load (VL) and opportunistic infections (OI) were included. Survival
curves analyzed using the Kaplan Meier method and statistical significance
was assessed using the log-rank test. A p<0.05 was considered statistically
significant.
Results: A total of 85 patients were included. The male:female ratio was 6.7.
Median age was 44.3 years (range 25-65). The median time from HIV to NHL
diagnosis was 29 months (0-284). Seventy-eight percent presented with stage
III/IV disease. The Eastern Cooperative Oncology Group performance (ECOG)
status was >1 in 62%. The most common histologies were Diffuse Large B Cell
Lymphoma (DLBCL) and Burkitt’s lymphoma with 49 and 34%, respectively.
Bulky disease was present in 27.3%, elevated LDH in 61.5%, and CD4
count<100/mL at diagnosis in 29.5% patients. The mean Hb, SA and CD4 count
were 3.6 g/dL, 11.8 g/dL and 205.9 k/uL, respectively. A serum albumin (SA)<3.7
g/dL and Hb<10 g/dl were present in 33% and 23.2% of patients, respectively.
Forty-six percent had had cART at time of diagnosis. The cohort’s median OS
was 5.9 years. KM curves showed poor median OS with SA<3.7 g/dl (OS=3.9
y, p=0.021), Hb<10 g/dl (0.7 y, p= 0.001) and OI (OS= 1.0 y, p=0.018), There
was a trend with worse OS with NCCN-IPI score >3 (OS=1.1 y, p= 0.165). MV
analysis showed that SA<3.7 retained statistical significance (HR: 2.45, CI:
1.03-5.84, p=0.042).
Figure 1.
Summary/Conclusions: New prognostic scoring systems have improved the
risk stratification of AIDS-related lymphomas (Barta el al, Haematologica 2014).
SA<3.7 is associated with worse OS in this study. SA could improve the strat-
ification of AIDS related lymphomas in the cART era. A validation of the role of
SA should be performed in larger cohorts.
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OUTCOME FOR PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA
TREATED WITH GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT
RITUXIMAB
V Dhanapal1,*, M Gunasekara1, L Chia1, P Patten2, R Marcus2, S Devereux2,
D Yallop2, D Wrench3, P Fields3, C De lord2, S Bowcock2, S Kassam2
1Haematology, Medway Maritime Hospital, Kent, 2Haematology, Kings College
Hospital, 3Haematology, Guys & St Thomas Hospital, London, United Kingdom
Background: Relapsed/refractory aggressive lymphoma remains challenging
to treat. There is no standard salvage chemotherapy regimen. Studies suggest
that the outpatient combination of Gemcitabine, Oxaliplatin (Gem-Ox) with Rit-
uximab (R) achieves similar response rates (RR) with less toxicity than intensive
inpatient regimens1.
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Aims: To review outcomes for patients with refractory/relapsed aggressive
lymphoma treated with Gem/Ox+/-R.
Methods: This retrospective study analysed clinical data on patients with
relapsed/refractory aggressive lymphoma treated with Gem/Ox with or without
R between 2010 and 2015 at 3 teaching hospitals in London, UK. The treatment
schedule was Gemcitabine 1000mg/m2 and Oxaliplatin 100mg/m2 +/- Ritux-
imab 375 mg/m2 on day 1 and repeated every 15 days for up to 8 cycles.
Results: 44 patients, 26 male, with a median age of 66 years (range 22-83)
were included. 30 (68%) patients had DLBCL; 27 had received prior R. 6 had
T-cell lymphoma, 3 Hodgkin lymphoma and 5 had high grade transformation
of low grade B-cell lymphoma. The median number of prior treatments was 1
(range 1-6). 7 patients had received an autologous transplant, 1 of whom had
also received an allogeneic transplant. Remission duration (RD) to the prior
treatment regimen was<12 months in 26 (59%) patients. 26 (75%) patients
received R with Gem-Ox. The median number of cycles received was 4 (range
1-6). Response was assessed by CT scan in 19 PET/CT in 19, MRI in 2 and
by clinical evaluation in 4. The overall response was 43% (n=19) with a com-
plete response (CR) of 29% (n=13). CR was achieved in 11/18 (61%) patients
with a prior RD ≥12 months compared to 2/26 (8%) patients whose prior RD
was<12 months (p=0.0002). 27/44 (61%) patients were transplant eligible, 7
of whom had received a prior autologous transplant. The overall response in
transplant eligible patients was 44% (n=12) 8/27 (30%) went on to receive a
stem cell transplant; 4 autologous and 4 allogeneic transplants. At a median
follow up of 6 months (range 0.5-33), the median overall survival (OS) is 8
months. For the 19 responding patients the median RD has not been reached.
Median OS was significantly better in patients who had had a ≥12 month
response to their prior treatment regimen; 13 vs 4.5 months, p=0.02 (Fig 1).
Toxicity data were available for 36 patients. 17(47%) patients experienced
grade 3/4 haematological toxicity. 8 (22%) had at least one febrile episode
requiring hospitalisation. There were 4 (11%) grade 3/4 non-haematological
toxicities, including diarrhoea, vomiting, peripheral neuropathy and bowel per-
foration. Dose reductions were required in 5 patients. 33 (75%) patients have
died, 26 (60%) from lymphoma. Other causes of death include 1 old age, 2
post transplant graft vs host disease, 1 treatment-related sepsis 3 unknown.
Figure 1.
Summary/Conclusions: In this study of ‘real world’ patients, Gem-Ox+/-R is
a well-tolerated, outpatient regimen achieving good response rates in patients
with chemo-responsive disease. Responses are comparable to more toxic,
inpatient, platinum-based regimens. It can also successfully bridge patients to
stem cell transplantation. Best responses are achieved in patients who have
had a prior remission of at least 1 year.
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DOSE-ADJUSTED ETOPOSIDE-PREDNISONE-VINCRISTINE-CYCLOPHOS-
PHAMIDE-DOXORUBICIN-RITUXIMAB (DA-EPOCH-R) FOR PRIMARY
MEDIASTINAL B-CELL LYMPHOMA (PMBCL) AND OTHER VERY
HIGH-RISK OR ADVANCED LYMPHOMAS
F Carobolante1,*, AM Scattolin1, P Viero1, M Dozzo1, R Sancetta1, A Pascarella1,
F Dei Rossi2, A Dorigo3, P Donisi4, R Bassan1
1Hematology, 2Nuclear Medicine, 3Pharmacy, Ospedale dell’Angelo and SS.
Giovanni e Paolo, Venezia Mestre, 4Pathology, Ospedale SS. Giovanni e Paolo,
Venezia, Italy
Background: Dose-adjusted etoposide, prednisone, vincristine, cyclophos-
phamide, doxorubicin and rituximab (DA-EPOCH-R) is highly effective in PMB-
CL (Wilson W et al. NEJM 2013;368:1408) and is adopted in very aggressive
lymphomas with encouraging results. While it is commonly used in US, expe-
rience in European countries is limited.
Aims: DA-EPOCH-R was used at Venice hospitals to treat adult patients with
PMBCL and aggressive lymphoma variants associated with a poor response
to R-CHOP. 
Methods: DA–EPOCH-R consists of 6-8 cycles q21d with escalating doses of
etoposide, cyclophosphamide and doxorubicin. Etoposide, vincristine (fixed
dose 0.4mg/m2/d) and doxorubicin are given by continuous IV infusion over
96 hours (dd 1-4). Drug level 1 is with etoposide 50, doxorubicin 10 and
cyclophosphamide (d5) 750mg/m2/d. A 20% dose escalation after each cycle
and up to level 6 is prescribed to patients who do not develop a neutropenia
<500/µl. The dose is reduced by 20% if neutropenia lasts >1 week or platelets
fall <25.000/µl. Concomitant drugs are prednisone 60mg/m2/bd (dd 1-5), ritux-
imab 375mg/m2 d1, and G-CSF from d6. Complete remission (CR, CRu [uncon-
firmed]) is defined according to standard criteria and PET/CT assessment after
a minimum of 4 cycles.
Results: Thirty-three patients were treated between august 2013 and january
2016. Twenty-eight patients were treated frontline for PMBCL (n=14), non-
GCB/highly proliferative (Ki67 ≥80%) diffuse large B-cell lymphoma (DLBCL)
(n=5), double-hit DLBCL (n=6), plasmablastic lymphoma (n=2, one without R),
and EBV+ lymphomatoid granulomatosis (n=1). Five patients were treated at
salvage after 1-2 prior lines for DLBCL (n=3), Burkitt lymphoma (n=1) and
Hodgkin disease (n=1, without R). Median patient age was 57.5 years (range
17-74 years), 61% were male, 73% had ECOG PS >1, 64% had stage III-IV
disease and 58% had intermediate-high/high IPI. Altogether, the 33 patients
received 158 courses, without change in dose level in 5 salvage patients. Twen-
ty-six of 28 untreated patients had 2 or more cycles and are evaluable for dose
level increments. Dose level could not be increased in 8 patients (31%),
reached level 2 in 5 (19%), level 3 in 7 (27%), level 4 in 5 (19%), level 5 in 1
(4%) and level 6 in none. Toxicity consisted of severe neutropenia and throm-
bocytopenia in 67% and 10% of the cycles, respectively, neutropenic fever with
admission to hospital (n=5, 15%), vincristine-related neuropathy (n=3, 9%),
and thromboembolism (n=3, 9%). Due to poor clinical conditions, treatment
was stopped after cycle 1 in a DLBCL patient (aged 65) with concurrent lung
cancer, and switched to R-CHOP after 2 and 4 cycles in 2 patients (aged 74
and 61, respectively) with double-hit DLBCL, both remaining well and alive.
Twenty-five patients completing 4 courses with PET/CT-based restaging are
evaluable for response (Table). CR and ORR rate was high in patients treated
frontline, particularly in PMBCL (ORR and PFS 100%). Response rate was
appreciable in double-hit and very aggressive lymphomas as well, but was
instead poor in patients treated at salvage.
Table 1.
Summary/Conclusions: DA-EPOCH-R proved globally feasible and safe in
this aged patient population, and highly active in PMBCL as observed in the
original study. The small patient number and the limited follow-up period do
not allow definite conclusions, although the regimen would be useful in PMBCL
(avoiding mediastinal irradiation) and potentially useful in very aggressive B-
cell lymphomas at risk of failing standard R-CHOP therapy.
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ELDERLY AGE IS NOT EXCLUSION FACTOR FOR INTENSIVE THERAPY
BY SCHEME R-DA-EPOCH/R-HMA FOR PATIENTS WITH UNTREATED
HIGH-GRADE DIFFUSE LARGE B-CELL LYMPHOMA
O Gavrilina1,*, E Zvonkov1, E Parovichnikova1, V Troitskaya1, N Gabeeva1,
L Kuzmina1, I Toropova2, V Lapin2, V Kanin3, A Gubkin4, S Kulikov1,
V Savchenko1
1National Research Center for Hematology, Moscow, 2Regional hospital,
Yaroslavl, 3Regional oncology center, Khabarovsk, 4Clinical hospital named
N.A. Semashko, Moscow, Russian Federation
Background: Median of age for patients with diffuse large B-cell lymphoma
(DLBCL) is 60. Approximately 50% of DLBCL are defined as high-grade by IPI
and these forms are characterized by aggressive course and poor response to
standard chemotherapy (CT). High-dose methotrexate courses, as example
Hyper-CVAD/HMA or mNHL-BFM-90 protocols are applied for patients with
high risk DLBCL. But for elder patients this approach usually is not employed
due to the extreme toxicity. Addition of R-HMA to R-DA-EPOCH favourably
changes the outcome in patients with untreated high-grade diffuse large B-cell
lymphoma [ASH 2015 # 2708].
Aims: To evaluate the efficacy and toxicity of R-DA-EPOCH/R-HMA protocol in
patients with untreated high-grade diffuse large B-cell lymphoma depending on age.
Methods: 35 untreated DLBCL patients from 4 centers were enrolled in a
prospective study between August 2013 - Jan 2016; stage II-IV; ECOG 0-3;
median age 55 years (27-76); age ≥60y/<60y 50%/50%; M/F 60%/40%; IPI:
63% high-intermediate and 37% high risk; 20% with bone marrow involvement.
All patients underwent 4-8 courses (2-4 cycles) of chemotherapy: R-DA-
EPOCH (standard dose and scheme), R-HMA (R 375 mg/m2 d1, MTX 1000
mg/m2 24 hours d 2, AraC 3000 mg/m2 q 12 hrs d 3-4). For patients older than
60 year dose of R-HMA was reduced (R 375 mg/m2 d1, MTX 500 mg/m2 24
hours d 2, AraC 1000 mg/m2 q 12 hrs d 3-4) and R-EPOCH were applied with-
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out dose adjusted. In 4 cases of DLBCL with bone marrow involvement BEAM
conditioning and autologous stem cell transplantation were applied.
Figure 1.
Results: The median follow-up is 16 months (3-31). There was no mortality
associated with toxicity. The main non-hematological toxicities of R-HMA were
infections (mucositis, pneumonia, sepsis, enteropathy) grades 1-2 and 3-4 in
90% and 10%, respectively. Hematological toxicity grade 4 for less than 4 days
we observed only after courses R-HMA. Complete remission (CR) was
achieved in 31 (88,6%) patients. In group of young patients we observed 2 pro-
gressions of the disease after first cycle of chemotherapy, 2 cases with partial
remission after 2-3 cycles and following progression of disease. There are three
failures in patients older than 60 years: two relapses (after 5 and 13 month CR)
and one death after 7 month CR by reasons not related with DLBCL. With a
median follow 16 months overall and event-free survival of 35 patients consti-
tuted 81,6% and 78,2%, respectively. There is no difference in elderly and
young groups: OS was 93,3% vs 71,4% (p=0,2), EFS was 77,8% in both. So
the combination of R-DA-EPOCH/R-HMA may be considered as optimal inten-
sive approach in elder patients.
Summary/Conclusions: The R-DA-EPOCH/R-HMA protocol demonstrated
acceptable toxicity and high efficacy in patients with high-grade DLBCL. This
protocol has shown optimistic results in the elderly patients and it could be rec-
ommended for further investigation in that group.
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FREQUENCY AND CLINICAL IMPLICATIONS OF SOX11 EXPRESSION IN
BURKITT LYMPHOMA
T Wästerlid1,*, L Nordström2, M Pedersen3, P Nørgaard3, AO Gang4, P Brown5,
M Jerkeman1, S Ek2
1Department of Oncology, Lund University and Skåne University Hospital,
2Department of Immunotechnology, CREATE Health, Lund University, Lund,
Sweden, 3Department of Pathology, Herlev University Hospital, Herlev, 4Depart-
ment of Hematology, Herlev University Hospital, 5Department of Hematology,
Rigshospitalet, Copenhagen, Denmark
Background: The transcription factor SOX11 is normally expressed during
embryogenesis in humans. Several studies have shown that SOX11 is aber-
rantly expressed in various types of haematopoetic and solid malignancies,
and appears to affect clinicopathological characteristics. In mantle cell lym-
phoma, SOX11 serves as a diagnostic antigen and has been shown to be asso-
ciated with superior outcome (Nordström et al. British Journal of Haematology
2014), although its role as a prognostic indicator remains controversial. In chron-
ic lymphocytic leukemia, SOX11 was associated with inferior overall survival
(Roisman et al. Tumor Biol 2015), whereas SOX11 expression correlated with
superior outcome in epithelial ovarian cancer (Sernbo et al. BMC Cancer 2011).
Various possible target genes and transcriptional programs have been identi-
fied, by which SOX11 may exert both repressive, and exaggerative, functions
on proliferation (Kuo et al. Oncogene 2015, Vegliante et al. Blood 2013). In
Burkitt lymphoma (BL), two small series have reported expression of SOX11 in
30-50% of cases (Mozos et al. Haematologica 2009, Dictor et al. Haematologica
2009). As of yet, no study has been performed specifically to evaluate the impli-
cation of SOX11 expression in BL.
Aims: The aim of this study was to investigate the frequency of SOX11 positive
BL cases in a larger joint cohort from Denmark and Sweden, and correlate its
expression to clinical and pathological parameters.
Methods: 45 BL cases were collected from Sweden and Denmark. Samples
were analyzed for expression of SOX11 and other immunohistochemical mark-
ers. Clinical data were obtained from the Danish Lymphoma Database (LYFO)
and the Swedish Lymphoma Registry. Additionally, 9 pediatric BL cases were
analyzed for SOX11 expression, but with no clinical data available.
Results: In the adult study population, 14/45 (31%) expressed nuclear staining
of SOX11. The SOX11 positive subgroup had a higher median age (53 compared
to 41), as well as a larger proportion with elevated LDH. Other prognostic factors
were equally distributed between the groups. Although a similar proportion of
patients received high-intensive chemotherapy in both subgroups, 3 (21%)
received no treatment in the SOX11 positive cohort. There was no significant dif-
ference in immunohistochemical characteristics between SOX11 positive and
negative cases. Five-year overall survival (OS) in the SOX11 positive group was
57%, compared to 77% in the SOX11 negative cohort. When adjusting for treat-
ment and and prognostic factors in multivariable analysis, no significant difference
in outcome was seen between groups (hazard ratio: 1.5, 95% confidence interval:
0.3-6.3, p=0.6). In the pediatric cohort, 5/9 (56%) expressed SOX11.
Summary/Conclusions: SOX11 expression was found in a minority of BL cas-
es, and was associated with higher age in the adult BL cohort. In contrast to
SOX11 expression in other malignancies, SOX11 expression showed no sig-
nificant impact on outcome, in our study, when adjusting for prognostic factors
and treatment.
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LONG-TERM FOLLOW-UP OF PRIMARY GASTRIC DIFFUSE LARGE
B-CELL LYMPHOMA TREATED WITH MNHL-BFM-90
E Zvonkov*, N Gabeeva, A Morozova, O Gavrilina, A Sidorova, D Koroleva,
A Kovrigina, E Parovichnikova, V Savchenko
National Research Center for Hematology, Moscow, Russian Federation
Background: R-CHOP chemotherapy can induce favorable result for local-
ized-stage primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients.
But the presence of adverse factors (AF) and advanced stage decrease the
efficacy of this therapy: 3-year progression-free survival (PFS) and overall sur-
vival (OS) are 43% and 64% respectively. The optimal treatment strategy for
this pts still remains unknown. 
Aims: Efficacy and safety assessment of the modified chemotherapy protocol
NHL-BFM-90 (m NHL-BFM-90) in the treatment of the PG-DLBCL with AF. 
Methods: Forty previously untreated pts with PG-DLBCL underwent m NHL-
BFM-90 treatment between January 2004 and December 2015; mean age 47
years (range 37-72); age ≥60 years 9 pts (22,5%); M\F=23\17; stage >I 27 pts
(68%); all pts had one or more AF. None of the patients received surgical treatment
before chemotherapy and no consolidation radiotherapy. NHL-BFM-90 program
(2 courses A and 2 courses B) was modified for PG-DLBCL in the following way:
doxorubicin (50mg\m2) was added on the third day of course A. Twenty one
(52%) pts received rituximab on day 0 prior to each course of therapy.
Results: The overall response rate (ORR) was 100%. Complete remission was
achieved in 38 (95%) pts. From 2 pts with partial remission one died from pro-
gression of disease, one received salvage therapy. With a median follow-up of 74
months (range 3-146) disease-free and overall survival of 40 pts constituted 87,5%
and 92,5%, respectively. All but one treatment failure belonged to the group without
rituximab. Hematologic toxicity of grade 3 and 4 was observed in 80% of pts.
Severe complications became the reason for subsequent switch to CHOP therapy
after 2 courses in 6 cases. There was no treatment-related mortality.
Summary/Conclusions: The mNHL-BFM-90 demonstrated acceptable toxicity
and high efficacy in patients with PG-DLBCL with AF. 
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PRIMARY BONE MARROW LYMPHOMA: A HEMATOLOGICAL EMERGENCY
IN ADULTS WITH FEVER OF UNKNOWN ORIGIN
HY Wang1,*, CF Yang2, TJ Chiou3, SH Yang4, JP Gau1, YB Yu1, PM Chen1,
CH Tzeng1, CY Tsai5, HC Hsu6, FD Wang7, JH Liu1, LT Hsiao1
1Division of Hematology and Oncology, Department of Medicine, 2Department
of Pathology and Laboratory Medicine, 3Division of Transfusion Medicine,
Department of Medicine, Taipei Veterans General Hospital, Taipei, 4Division of
Oncology and Hematology, Department of Medicine, National Yang-Ming Uni-
versity Hospital, Ilan, 5Division of Allergy, Immunology, and Rheumatology,
Department of Medicine, 6Division of General Medicine, Department of Medi-
cine, 7Division of Infectious Disease, Department of Medicine, Taipei Veterans
General Hospital, Taipei, Taiwan, ROC
Background: Primary bone marrow lymphoma (PBML) denotes non-Hodgkin
lymphoma (NHL) arising primarily in the bone marrow (BM) without any lym-
phadenopathy. It is often masked by prolonged fever leading to delayed diag-
nosis and notorious for various definitions adopted by previous studies.
Aims: This study aimed to lighten clinical panorama of PBML and to identify
potentially warning parameters of PBML.
Methods: Two cohorts of PBML patients were enrolled. Cohort I consisted of
163 PBML cases from 16 case series and 23 case reports for meta-analysis of
clinical characteristics. Cohort II comprised 221 adults with fever of unknown
origin (FUO) from Taipei Veterans General Hospital who underwent a BM study,
and 52 cases of them were finally diagnosed of NHLs, including 26 PBML cas-
es. The latter cohort was used to identify warning parameters of PBML by com-
paring data upon admission between all FUO patients with and without a sub-
sequent PBML diagnosis.
Results: In cohort I, PBML had heterogenous histology and could be clinically
separated into two distinct entities: lymphoma limited entirely to the BM, liver,
and/or spleen (i.e. BLS-type, n=79), and isolated BM lymphoma (i.e. IBM-type,
n=84). Two third (67%) of PBML patients initially manifested with fever, and
one third (31%) complicated with hemophagocytic lymphohistiocytosis (HLH).
The BLS-type cases were mainly reported from the countries in Eastern Asia,
more often presented as FUO and HLH at diagnosis, and suffered from a poorer
prognosis (median overall survival of BLS-type vs IBM type=272 vs 580 days,
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P<0.001). For 26 PBML patients of the cohort II, 89% were classified as BLS-
type; median overall survival revealed dismal 9 days, with 54% having early
mortality within 30 days. Compared to non-PBML NHL in the cohort II, PBML
is an independent risk factor of both early mortality and overall survival. Among
221 FUO adults in cohort II, 4 warning parameters able to alert underlying
PBML were independently identified, including serum alkaline phosphate >2×
UNL, serum immunoglobulin G<0.67× UNL, cytopenia ≥2 lineages, and leuco-
erythroblastosis in the peripheral blood.
Table 1. Univariate and multivariate analyses of warning parameters for
primary bone marrow lymphoma in 221 adults with fever of unknown ori-
gin.
Figure 1.
Summary/Conclusions: As a particular clinical phenotype of NHL, PBML is
often masked by prolonged fever and should be regarded as a hematological
emergency when approaching patients with FUO. Our study provided additional
diagnostic clues to early recognize FUO adults with underlying PBML.
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CHEMOTHERAPY OF 40 PRIMARY MEDIASTINAL B-CELL LYMPHOMA
PATIENTS
J Mangasarova1,*, A Magomedova1, A Misyurina1,2, E Nesterova1, L Gorenkova1,
A Gilenko1, E Baryakh3, V Vorobiev3, S Kravchenko1
1National Research Center for Hematology, 2LLC “GeneTechnology”, 3State
clinical hospital N°52, Moscow, Russian Federation
Background: Primary mediastinal B-cell lymphoma (PMBCL) amounts from
0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women.
All relapses in PMBCL occur as early events. Taking into account unfavorable
prognosis in case of relapse or progression of PMBCL (2-year overall survival
(OS) is about 15% [Kurvilla J., 2008]), it’s necessary to achieve a complete
remission (CR) in first line treatment.
Aims: To evaluate an efficacy of R-DA-EPOCH therapy+R-DHAP№2 and
autologous peripheral blood stem cell transplantation (autoSCT) with BEAM
conditioning regimen in treatment of PMBCL pts.
Methods: In 40 pts (14 males, 26 females) diagnosis of PMBCL was estab-
lished according to WHO criteria. All pts had stage II of disease according to
Ann Arbor classification. Median age of pts was 27 years old (from 19 to 67
years old). Increased LDH concentration was revealed in 34 from 40 (85%)
pts. Bulky mediastinal disease was in 31/40 (77.5%) pts. In case of CR after 6
courses according to computer tomography and PET scanning treatment was
completed. In case of PR pts underwent 2 R-DHAP courses with autoSCT
(BEAM conditioning regimen). All cases of treatment failure occurred till one
year of observation. Kaplan-Meier method was used to calculate OS and OFS.
Results: After 6 R-DA-EPOCH therapy CR was achieved in 32/40 (80%) pts,
8/40 (20%) pts had PR and underwent 2 R-DHAP courses followed by auto-
SCT (BEAM). 2- OFS and OS was 96% and 100%. Early relapse occurred in
1/40 (2,5%) patient. Median follow up was 20 months (3-32). 
Summary/Conclusions: R-DA-EPOCH allows getting high efficacy of primary
mediastinal B-cell lymphoma therapy. Although future analysis will show distant
results of R-DA-EPOCH chemotherapy. Taking into account unfavorable prog-
nosis in case of relapse or progression of PMBCL autoSCT in first line therapy
might have benefit in patients with partial remission after R-DA-EPOCH.
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VITREORETINAL LYMPHOMA: A DESCRIPTIVE STUDY OF A VERY RARE
OCCURRENCE FROM A SINGLE INSTITUTION IN ITALY
A Ferrari1,*, L Cimino2, F Ilariucci1, A Fama1, I Alvarez1, A Ruffini1, CC Chan3,
S Luminari1, F Merli1
1Ematologia, Dipartimento Oncologico e Tecnologie avanzate, 2Oculistica, Chirur-
gia Generale e Specialistiche, Arcispedale Santa Maria Nuova-IRCCS, Reggio
Emilia, Italy, 3Section on Immunopathology, Laboratory of Immunology, National
Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
Background: The vitreoretinal lymphoma is a rare subset of primary central
nervous system lymphoma (PCNSL) with a poor prognosis. Because of its
rarity and the difficult of collecting tumor simples, this entity remains poorly
understood and the optimal management is still unknow.
Aims: to describe a single insitution experience with Vitreoretinal lymphomas.
Methods: The 2011-2015 archives of the hematology and oftalmology units of
the Reggio Emilia Hospital Lymphoma were searched for cases with vitreoreti-
nal lymphoma. Cases were classified as primary vitreoretinal lymphoma (PVRL)
of systemic lymphomas with concurrent Vitreoretinal involvement (CVRL). We
defined stage IE as mono or bilateral involvement of the vitreum. We provide
a complete description of pathological, clinical, and therapeutic findings.
Results: We identified 7 patients with either PVRL (3) or with CVRL (4). Four
patient were female, the median age at diagnosis was 62 years (range 45-74),
three had a stage IE and four a stage IVA. All patients were HIV negative.
Among the 4 CVRL 2 patients showed brain involvement, one patient nodal
involvement, one patient gastric involvement. All patients were initially referred
with ocular symptoms mimicking uveitis. The median time between the onset
of the ocular symptoms and the lymphoma diagnosis was 13 months (range
2-30 months). All patients underwent a diagnostic vitrectomy. The cytopatho-
logical analysis was positive in five cases and uncertain in two cases (CVRL).
The immunoistochemical analysis showed atypical CD20+ lymphocytes in three
cases. Vitreous supernatant was submitted for IL-10 and IL-6 measurement
by ELISA using the IL-10 to IL-6 ratio as a diagnostic marker. Elevation of IL-
10 levels and IL-10:IL-6 ratio greather than 1 was found in all cases. Molecular
analysis of the specimens detected IgH gene rearrangements in 4 cases.
Notably the three PCR negative samples displayed a sharp unbalanced IL-
10:IL-6 ratio and atypical CD20+ lymphoid large cells. Cerebral Spine Fluid
(CSF) analysis was negative in all patients. All patients were treated as CNS
lymphomas and received combined high-dose systemic chemotherapy with
Rituximab, High dose ARA-C and High dose Methotrexate, and intravitreal
methotrexate iniection (Intravitreal methotrexate 400 microg/0,1 ml twice weekly
for 4 weeks, once weekly for 8 weeks, and then once montly for 9 months for
a total of 25 injection). All 7 patients achieved a complete remission (CR) at
the end of therapy. Four patients underwent autologous stem cell transplant
(ASCT) in first remission.m The median observation period was 16 months
(range, 2-48 months). All patients were alive at this time point except for one
patient who relapsed four months after ASCT and died one month later.
Summary/Conclusions: This single center retrospective series highlights the
insidious onset of both PVRL and CVRL and the difficulties in diagnosing this
particularly rare lymphoma occurrence.
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RCHOP VS -CHOP CHOP IN DIFFUSE LARGE CELL FOLLICULAR
EPIDEMIOLOGICAL OF PATIENTS WITH LYMPHOMA LYMPHOMA TREATED
IN CARACAS, VENZUELA FOR 14 YEARS
A Muller*
Hematology, Clinica El Avila, Caracas, Venezuela
Background: Few epidemiological Venezuelan Lymphoma patients data are
found in the literature to compare survival and the current standard treatment
with chemoinmunotheraphy with Lymphoma patients from developed countries.
Aims: The purpose of this paper is to present epidemiological data of patients
with lymphoma treated by the Commission of lymphoma IOH and some private
clinics in Caracas during the past 14 years and compare the efficacy of treat-
ment of RCHOP vs CHOP
Methods: Materials and Methods A total of 1812 patients with lymphoma, of
which 1214 were classified as non-Hodgkin lymphoma and 598 as Hodgkin’s
lymphoma were treated, and of these 1117 patients with lymphoma were stud-
ied from the pto epidemiologically between 1996- 2010 Lymphoma diagnosis
was made based on clinical history, X-rays, CT, lymph and tissue biopsy
(depending on the case), immunohistochemistry studies when required.
Results: Results Patients with lymphoma were classified into Hodgkin and non-
Hodgkin 390 cases 827 cases. Hodgkin’s lymphoma (HL) is subclassified in
Nodular Sclerosis 62.6%, 27.7% mixed cellularity, lymphocyte-predominant
4.3% 5.4% Depletion Lymphocytic The age and sex of the patients were Nodular
Sclerosis: 32.45 years (18-65), 129 female and 115 male, Mixed cellularity: 22.3
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years (18-56), 37 female and 72 male, predominantly lymphocytic 22.6 years
(18-67), 6 female and 11 male, depletion Lymphocytic 22 years (20-42) female
and 15 maleThe stages were stage I: 5,5%, stage II: 44%, stage III: 31.1% stage
IV: 19.4%.HL patients were treated with different chemotherapy protocols:
MOPP, ABVD, STANDFORD V, HYBRID, COPP / ABVD, COPP / EBVD, BEA-
COPP and in some cases radiotherapyNon Hodgkin Lymphomas were subclas-
sified by 36.4% Diffuse Large Cell, Follicular 24.1%, 10% Maltoma, 5.5% of
peripheral blood cells, 3% mantle cell lymphoma, 20.8% other types of lym-
phoma such as mycosis Mycosis, immunoblastic Anaplastic, Lymphoblastic,
Burkitt, Cutaneous B cell 45% of patients with follicular lymphoma had a high
score FLIPI and 60% of diffuse large cell lymphoma had a high intermediate
score with high-risk prognostic factors and only 15% of these were low-risk DLB-
CLNHL were treated with different protocols according to the year of admission
and stage of CHOP disease, CHOP Bleo, MACOB B, ATT, Hyper-CVAD, CHOP
MTX and from 2005 to 2010 55 patients were treated with R-CHOP and year
1999-2004 29 patients were treated with CHOP resulting overall survival in DLB-
CL with RCHOP 92.1% vs 67.9% and 89.5% LF vs 50%, event-free survival of
90% DLBCL with RCHOP CHOP vs 44% (p 0.002) and LF with CHOP vs 89.8
RCHOP age influenced patient survival (p 0.56). Other variables such as sex,
type of lymphoma, stage had no impact on the EFS.
Summary/Conclusions: Conclusion: 1117 patients with lymphoma were studied
retrospectively. Patients were classified in 34.9% and 65.1% non -Hodgkin lym-
phoma. The most common subtype of LH was nodular sclerosis (62.57%) and
was more common in women and young adults of mixed cellularity HL was the
second most common and the prevalence in lymphocytes and lymphocyte deple-
tion constituted only 6.8% and 8 7%% the most common was the NHL diffuse
large cell and the second Follicular NHL. The Venezuelan population is made up
of a mixture of different indigenous races, Caucasian, Negroid, but it seems that
this disease follows the same patterns reported in other populations Overall sur-
vival, event-free survival of DLBCL and LF was statistically significant in favor of
RCHOP, which should be the treatment of choice in these pathologies.
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IS THAT MALE GENDER AN ADVERSE RISK FACTOR ONLY IN YOUNG
PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
T Faiza1,*, B SALAH1, D malika1, G yamina1, S mohamed1, T mohamed el
habri2, B mohamed2, A fatma zohra1
1Hematology, 2Radiology, central hospital of the army, ALGER, Algeria
Background: The International Prognostic Index (IPI) is the most important
clinical tool for determining prognosis in diffuse large B-cell lymphoma (DLBCL).
It incorporates ﬁve adverse risk factors: age above 60 years; Ann Arbor stage
III or IV; elevated serumnlactate dehydrogenase (S-LDH); Eastern Cooperative
Oncology Group (ECOG) performance status of 2 or higher; and involvement
of two or mor extranodal sites. GUSTAF HEDSTRÖM was published in Acta
Oncologica (in April 2015), one of the largest population-based studies of DLB-
CL presented (7166 patients were included), he found male gender to be a sig-
niﬁcant adverse risk factor compared to fertile women, without msurvival differ-
ences between genders in the older sub-population. According Nurith H, the
reduced rate of NHL among females may be explained by direct effects of
estrogens on lymphoma cell proliferation or by its effect on anti-tumor immune
response: the influence of sex hormones on lymphoid malignancies has been
the subject of clinical and in vitro research. Epidemiological studies highlighting
the association between sex hormones and NHL have provided some clues.
Lee and colleagues reported that an increasing number of pregnancies and
live births is associated with a decreasing trend in the risk of DLBCL.
Aims: The primary objective of this study was to analyze the impact of gender
on age in patients with newly diagnosed DLBCL.This retrospective study includ-
ed 95 patients with diffuse large B cell lymphoma who were treated the Medical
Hematology Department, HCA during the time period from 2000 to 2015.
Methods: We conducted a retrospective cohort study of all DLBCL patients
diagnosed between 2000 and 2015, to evaluate the impact of gender for survival
from DLBCL. Survival curves n were estimated according to the Kaplan-Meier
method and associated log rank, a Cox model was used to evaluate the prog-
nostic impact of clinical risk factors (age<vs≥52 y, ECOG≤VS>2, stage I-II vs
III-IV, LDH normal vs high, extranodal sites, IPI (0-5), IPI-a (0-3).
Results: In total, 95 patients were included for analysis, clinical caracteristics
of our patients are summarized in Table I. Data collected were: year of diagno-
sis, age, gender, Ann Arbor stage, ECOG performance status, extranodal sites,
S-LDH, IPI, age adjusted IPI (aaIPI). When patients older (52 years or older),
or younger than 52 years, were analysed separately, the same risk factors
remained no significant. Sex was not found to be signiﬁcantly correlated with
adverse outcome in univariate analysis according to the Kaplan-Meier method
and associated log rank tests: women have a comparable overall survival to
that of men in the same age group (75% vs 88,5% ; P=0,332). nIn a relative
survival multifactorial model adjusted for stage, ECOG performance status,
serum lactate dehydrogenase and two or more extranodal sites, male gender
was not found to be an adverse risk factor for patients younger than 52 years
(RR 0.893, 95% CI 0.641-1.244). However, the impact of the above-mentioned
prognostic factors was significantly correlated with age. In effect, using multiple
regression Cox model, we found that Ann Arbor stage III and IV, as well as
extranodal involvement of two or more sites, IPI are correlated to worse out-
come, with 0.024 vs 0.087, 0.009 vs 0.844, 0.0001 vs 0.687 respectively, P (for
age ≥vs<52 years), see Figure 1-6.
Table 1.
Summary/Conclusions: our study clearly demonstrates the impact of age on
the survival of patients with LGDB, however gender does not appear to influ-
ence patient outcomes.
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Bleeding disorders (congenital and acquired)
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INCIDENTAL FINDINGS BY TARGETED EXOME SEQUENCING USED TO
DIAGNOSE RARE INHERITED BLEEDING DISORDERS-PATIENT’S
CHOICES ON INFORMATION AND OUTCOME
EB Leinoe1,*, M Rossing2, O Østrup2, P Kampmann1, N G Andersson3,
E Zetterberg3
1Haematology, 2Center for Genomic Medicine, Rigshospitalet University Hos-
pital, Copenhagen, Denmark, 3Coagulation Unit, University Hospital Skaane,
Malmoe, Sweden
Background: Whole exome sequencing (WES) has the ability to identify
numerous mutations within a genome, many of which are not related to the
phenotype in question, but they may have clinical ramifications. Incidental find-
ings (IF) are pathogenic alterations in genes, that are not apparently relevant
to the diagnostic situation, for which, the sequencing was intended. Scientific
and ethics boards recommend, that the informed consent process ensures,
that patients understand the possibility that IF will be detected and indicate
which (if any) information on IF, they wish to receive. We have implemented
WES to diagnose patients with inherited bleeding disorders. Our exome
sequencing panel for bleeding disorders only examines specific genes, but
with the additional use of search terms (thrombocytopenia, thrombocytopathia
and bleeding) incidental findings may occur. Mutations associated with inherited
thrombocytopenia may also be associated with haematological cancers. No
previous study has described the outcome of IF in this diagnostic setting.
Aims: To examine patient`s choice on information regarding IF and to report
the rate of IF.
Methods: Patients were examined by ISTH-BAT score and standard coagula-
tion testing. Prior to WES analysis, patients were given oral and written infor-
mation concerning the risk and possible seriousness of IF. The pretest infor-
mation on IF included risk of detecting mutations associated with cancer or
brain disease. Patients from Copenhagen were asked to make a pretest written
choice of whether they wanted information on: A. All genetic results of clinical
significance, including IF. B. No information on IF. C. Provision of IF with known
clinical significance and the possibility of treatment or prevention of disease.
Patients from Malmoe were asked to make a pretest written choice of whether
they wanted information on: A. All genetic results of clinical significance, includ-
ing IF. B. No information on IF. The Illumina HiSeq 2500 platform was used for
targeted exome sequencing. Sequencing was performed on the HiSeq 2500
as paired end (PE) sequencing, 2x101 bases, resulting in approximately 100
M PE reads. Variants were called with a minimum of 10x coverage and exported
as.vcf format with approximately 220,000 variants prior to upload in Ingenuity
Variant Analysis (Qiagen). Common SNPs were subtracted. 
Results: A total of 91 genes associated with bleeding were examined in 107
patients from Copenhagen and 37 patients from Malmoe. The following IF were
made: 1. A heterozygous variant in Telomerase reverse transcriptase (TERT)
(His412Tyr) in a 34-year female with macro-thrombocytopenia. The variant had
previously been reported to be associated with reduced telomerase activity,
dyskeratosis congenital and aplastic anemia. A telomer analysis performed by
an outside lab, showed that leukocytes did not have short telomeres or low
telomerase enzymatic activity. It was concluded, that the variant was a non-
pathogenic polymorphism and the patient informed correspondently. 2. A het-
erozygous missense mutation in SERPINC1 (Pro73Leu) in a 40-year female
without thrombosis. It was previously described as a founder mutation in the
Finnish population, associated with type II antithrombin (AT) deficiency and
increased risk of thrombosis. Her AT III level was normal; no additional function
testing was done. It was concluded that due to her haemorrhagic diathesis,
she was not at high risk of thrombosis and informed correspondently. 3. A het-
erozygous GATA2 mutation (Pro41Ala) previously associated with myelodys-
plasia and skin cancer in a 36-year female. Several relatives had a history of
skin cancer and her aunt had leukemia. She was informed of the increased
risk of skin and haematological cancer, offered regular follow-up and advised
on skin protection.
Figure 1.
Summary/Conclusions: IF were discovered in 3/148 (2%). In two separate
cohorts of patients from Copenhagen and Malmoe, the choices on information
were comparable. Ninety-nine patients (66%) wanted information on all genetic
results and 7 patients (5%) declined all information regarding IF. The remaining
42 patients (29%) did either not make a choice or only wanted information,
when a disease could be treated or prevented. Targeted exome sequencing of
rare inherited bleeding disorders may disclose IF with major impact and/or
require additional consultation/validation by an external laboratory or expert. It
is of outmost importance that patients understand the consequences of IF,
before giving informed consent to WES:
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HEMORRHAGIC EVENTS AND PRIMARY HEMOSTASIS DISORDERS
DURING TREATMENT WITH IBRUTINIB
N Acedo, J Loscertales, B Aguado*, Y Paz, E Jiménez-Barral, S Rodrigo,
S Almero, I Santamaría, A Alegre
Hematology, Hospital Universitario de La Princesa, Madrid, Spain
Background: Ibrutinib is a first-in-class Bruton kinase inhibitor (BTK) registered
for the treatment of Chronic Lymphocytic Leukemia (CLL), mantle cell lym-
phoma (MCL) and Waldenström Macroglobulinemia (WM). Increased risk of
bleeding events are associated with ibrutinib, mostly grade ≤2. Probable mech-
anism for this risk could be the role of BTK in platelet activation via GPIb, GPVI
and FVW.
Aims: To present our experience regarding hemorrhagic events and hemosta-
sis tests alterations in CLL patients (pts) treated with ibrutinib.
Methods: 10 pts with relapsed CLL were started on ibrutinib between decem-
ber/2012 and march/2016. Median age was 69 years (range: 42-83 years). 8
of them were male. Median exposure to the drug was 17 months (range 1-
38). After 9 to 36 months from initiation of treatment (median 22 months) 6/10
were thoroughly interviewed about personal history of bleeding events and the
following laboratory work was performed: factor VIII level, FvW antigen and
activity, platelet function analysis (PFA-100TM) with ADP and epinephrine, and
aggregation studies with collagen, ADP and arachidonic acid (AA). Along this
tests all patients had blood counts with platelets more than 100 x 10e9/L. 
Results: 2 out of 10 pts had bleeding events (grade 1 or 2), consisting in spon-
taneous bruising, in the first weeks of treatment. 4 pts underwent minor invasive
procedures with no complications, withholding the drug at least 3 days before
and after. 2 pts were on concomitant antiplatelet (1) or anticoagulant (1, LMWH,
due to AF) and had no bleeding events. All pts tested (6/6) had normal or
slightly elevated levels of F VIII, FvW:Ag and FvW:ristocetin cofactor activity.
2 pts had abnormal PFA-100TM and abnormal aggregations with every agonist.
One case had normal PFA-100 TM while aggregations with collagen and AA
were mildly altered.
Summary/Conclusions: Our limited experience shows a moderate risk of
minor bleedings consisting with a platelet disfunction. Despite the fact that we
have no baseline tests done, alterations in primary hemostasis tests, including
PFA-100TM and specially aggregometry could be expected early on after expo-
sure to ibrutinib.
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REGULATION OF CD72 EXPRESSION ON CD19+CD27+ MEMORY B CELL
BY CD40L IN PRIMARY IMMUNE THROMBOCYTOPENIA
M Lyu*, Y Li, Y Hao, C Lyu, W Liu, S Wang, Y Guan, H Li, R Yang
Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of
Medical Sciences And Peking Union Medical College, Tianjin, China
Background: CD72, a co-receptor of B cell receptor, regulates B cell activation
and is involved in B cell-related autoimmune diseases. Despite the knowledge
that expression of CD72 on peripheral B cell is aberrant in patients with some
autoimmune diseases, it is uncertain whether this aberrant expression is
restricted to specific B cell subsets in primary immune thrombocytopenia (ITP).
Furthermore, the mechanisms that regulate CD72 expression on peripheral B
cell in ITP are unknown.
Aims: This study aimed to examine CD72 expression on subsets of B cells
and uncover the regulatory mechanisms of CD72 expression on peripheral B
cell in ITP.
Methods: Frequencies of B cell subsets and expression of CD72 and CD40L
were determined by flow cytometry in patients with active ITP, patients in remis-
sion and health controls. To activate B cells, the following reagents were added
at the initiation of culture in vitro, anti-IgM, CD40L, LPS. The following cytokines
were used to evaluate their effect on CD72 expression: interleukin-4 (IL-4), IL-
10, IL-21, B-cell-activating factors (BAFF). The level of CD72 mRNA was
assessed by real-time PCR. The concentration of plasma CD40L was meas-
ured by ELISA. Specific anti-platelet autoantibodies were measured by the
Pak Auto method.
Results: Patients with active ITP had a significantly higher frequency of CD19+B
cells, CD19+CD27+ memory B cell and lower frequency of CD19+CD27- naive
B cells than did controls and patients in remission. The mean fluorescence inten-
sity of CD72 on circulating B subcells is upregulated in active ITP patients com-
pared to that recorded in controls and patients in remission. In active ITP
patients, the expression of CD72 on CD19+ CD27+B cells was inversely corre-
406 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
lated with platelet counts, but there is no difference among groups with different
age and gender. Patients with anti-platelet autoantibodies had significantly higher
expression of CD72 on CD19+CD27+B cells. In vitro, analysis of B cell activation
revealed that the CD40L could induce CD72 significant upregulation on B cells
and CD19+CD27+ B cells both in patients and controls. The mRNA levels of
CD72 in peripheral blood mononuclear cells activated by CD40L were increased.
When used in combination with CD40L, IL-10 and BAFF further enhanced the
expression of CD72 on CD19+CD27+B cell, whereas IL-21 reduced CD72
upregulation. CD40L expression on CD4 T cells and plasma CD40L levels were
significantly higher in active ITP patients compared to controls. Significant
increases in plasma CD40L were correlated with CD72 expression on
CD19+CD27+ B cell in ITP patients.
Summary/Conclusions: These data provide evidence that active ITP patients
have higher CD72 expression on increased CD19+CD27+ memory B cells,
which is associated with platelet counts and autoantibody. Soluble higher
CD40L found in active ITP patients might contribute to the increased levels of
CD72 on CD19+CD27+ B cell.
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THROMBIN GENERATION AND WHOLE BLOOD VISCOELASTIC ASSAYS
IN THE MONITORING OF HAEMOPHILIA WITH INHIBITORS
M Serban1,*, E Ursu1, L Cernat2, D Poenaru3, J Patrascu3, C Jinca3, W Schramm4,
S Talpos3, S Arghirescu3
1Hemato-oncology, 2Laboratory, Emergency Children’s Hospital “Louis Tur-
canu”, European Haemophilia Center, 3University of Medicine and Pharmacy
“Victor Babes”, Timisoara, Romania, 4“Ludwig-Maximilians” University,
München, Germany
Background: During the past decade numerous studies using thrombin gen-
eration (TGA) and viscoelastic tests (TEG) have been introduced in clinical lab-
oratories, looking for a new perspective on monitoring patients with severe
haemophilia complicated with inhibitors.
Aims: We attempted to obtain a more reliable image on global hemostasis of
patients with haemophilia A (HA) and high titre inhibitors treated with bypassing
agents (BPAs) by using these two new laboratory tools, TGA and TEG.
Methods: Seven persons with HA and high titre inhibitors treated with by pass-
ing agents during 12 bleeding episodes, 5 of them in invasive surgical conditions
have been evaluated. Reaction time (R), kynetics (K) and maximal amplitude
(MA) on thrombelastograph System 5000, and lag time, peak, time to peak
(ttpeak), endogenous thrombin potential (ETP), start tail and velocity index
have been the focused parameters, interpreted also in connection with the clin-
ical outcomes. The same procedure was performed on 15 healthy volunteer
control group.
Results: While traditional coagulometric assay failed giving information on the
global hemostatic potential, TEG displayed significantly prolonged R and K
(p<0.01), with prompt improvement after BPAs administration. The thrombo-
gram revealed also significantly low values (p<0.001) for peak and velocity
index and prolonged time to peak and start tail, also, with significant (p<0.01)
long lasting (more than 4 hours) improvement after BPAs administration.
Summary/Conclusions: In our modest experience, the combined use of TEG
and TGA has been a useful source for surrogate markers, able providing more
informative and reliable data on the impact of BPAs on the hemostatic results
in an attempt of a more safe and effective personalised therapy in haemophilia
complicated with inhibitors.
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ACQUIRED HAEMOPHILIA: A MALAYSIAN OUTLOOK
V Selvaratnam1,*, J Suriar1, T Sen Mui1, O Tee Chuan1, C Kian Meng1, J Sathar2
1Haematology, 2Hospital Ampang, Malaysia, Selangor, Malaysia
Background: Acquired Factor VIII inhibitor is a very rare bleeding condition due
to the spontaneous development of autoantibodies directed against factor VIII.
Aims: To identify at the demographics, presenting features and bleeding char-
acteristics of patients with Acquired Hemophilia referred to the Haematology
Unit at Ampang General Hospital, over a 10 year period. 
Methods: The list of patients with acquired factor VIII inhibitor who were treated
from June 2005 to May 2015 was identified and their case notes were then
retrieved from the medical records of the hospital.
Results: Between 2005 and 2015, 28 patients from Kuala Lumpur were diag-
nosed with acquired factor VIII inhibitors. The population of Kuala Lumpur is
1,501,800 (Population Statistics 2003) giving an incidence of 1.8 cases
/million/year.The patient demographics are shown in Table 1.Ten patients (36%)
had an underlying associated disease. One was postpartum with history of
psoriasis, two had systemic lupus erythematosus, three with bullous pem-
phigoid, two with thyroid disease, one rheumatoid arthritis and one with a malig-
nant lung nodule. In the remaining 18 patients (64%) were idiopathic. All patients
had abnormal bleeding with a total of 54 haemorrhagic episodes. 14 patients
had life or limb threatening bleeding: postpartum haemorrhage, iliopsoas
haematoma, compartment syndrome, arterial puncture, gastrointestinal bleed
and intracranial bleed.
Table 1. Demographics of patients with acquired FVIII inhibitor.
Table 2. Sites of Haemorrhages on Presentation.
Summary/Conclusions: Over a 10-year period we treated 28 patients with
acquired hemophilia with an estimated incidence of 1.8/million/year. The median
age of was 58.5 years, with a male preponderance(57%). It was associated
with an underlying disease in 36% of cases. Life or limb threatening haemor-
rhages were seen in 50% of patients. Factor VIII level and inhibitor titre at pres-
entation did not predict severity of bleeding.Mortality rate was 15%; all patients
died of complications related to bleeding and treatment. It is important to rec-
ognize and diagnose this disorder, as appropriate treatment will give a favorable
outcome; failing which it can be fatal.
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CONTRIBUTION OF HEMODILUTION, FIBRINOLYSIS, ACIDOSIS, AND
HYPOTHERMIA TO DERANGEMENT OF CLOT FORMATION IN THE IN VITRO
MODEL OF TRAUMA-INDUCED COAGULOPATHY
I Budnik1,*, B Shenkman2, U Martinowitz2
1Department of Pathophysiology, Sechenov First Moscow State Medical Uni-
versity, Moscow, Russian Federation, 2National Hemophilia Center and Institute
of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel
Background: Trauma-induced coagulopathy (TIC) develops often after major
trauma and may be diagnosed before any therapeutic intervention is provided.
Pathophysiology of TIC includes tissue injury and severe hypoperfusion which
cause endothelial activation of the protein C pathway and release of tissue plas-
minogen activator (tPA) resulting in systemic anticoagulation and hyperfibrinol-
ysis. Subsequent hemodilution due to massive transfusions as well as hypother-
mia and acidosis exacerbate the hemostatic derangement and may lead to
uncontrollable postoperative hemorrhage in severely traumatized patients.
Aims: To investigate the relative contribution of hemodilution, fibrinolysis, acidosis,
and hypothermia to the derangement of clot formation in the in vitro TIC model.
Methods: The study was approved by the local research ethics committee.
Citrated venous blood was obtained from adult healthy volunteers who signed
an informed consent form. The in vitro TIC model included hemodilution com-
bined with hyperfibrinolysis, acidosis, and hypothermia. Hemodilution (40%)
was produced by mixing the blood with TRIS/saline solution. Fibrinolysis was
induced by treating the blood with 165 ng/mL tPA. Acidosis (pH 7.0–7.1) was
produced by treating the blood with 1.2 mg/mL lactic acid. Hypothermia (31°C)
was achieved by setting the appropriate temperature while running the test.
Intact blood tested at 37°C served as control. Clot formation was evaluated
using rotational thromboelastometry (ROTEM) device (Pentapharm, Germany).
Clotting time (CT, s), maximum clot firmness (MCF, mm) and lysis onset time
(LOT, s) were measured using the EXTEM test with 1:50 pre-diluted reagent
and presented as Mean±SD.
Results: In control, CT was 349±66 s, and none of the factors (hemodilution alone
or in combination with tPA-induced fibrinolysis, hypothermia, and/or acidosis)
affected this parameter. In control, MCF was 64±3 mm. Hemodilution reduced
MCF to 54±4 mm (P<0.001 vs control). Combination of hemodilution and hypother-
mia produced the same effect. Combination of hemodilution and hyperfibrinolysis
reduced MCF to 46±7 mm (P<0.001 vs hemodilution alone). Combination of
hemodilution, hypothermia, and hyperfibrinolysis had the greatest inhibitory effect
on MCF reducing it to 38±8 mm (P<0.001 vs combination of hemodilution and
hyperfibrinolysis). Acidosis did not modify the effect of the other factors on MCF.
No clot lysis was observed in control. Hemodilution did not lead to clot lysis unless
hyperfibrinolysis was induced; in these conditions, LOT was 1766±324 s. When
additionally combined with hypothermia, LOT was prolonged to 2380±530 s
(P<0.001). Acidosis had no effect on LOT at either blood temperature.
Summary/Conclusions: Differential effect of TIC constituents on clot formation
is revealed. Latent processes that precede clot formation (CT) were not affected
by any of the factors studied. Clot strength (MCF) was reduced in the presence
of hemodilution, further reduced if combined with hyperfibrinolysis, and maxi-
mally reduced if additionally combined with hypothermia. tPA-initiated clot lysis
was delayed by hypothermia. Acidosis had no effect on clot formation. The
data presented may be helpful to better understanding the pathogenesis of TIC
and elaboration of individually-tailored treatment strategy.
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DIRECT ORAL ANTICOAGULANTS THERAPY AFTER INTRACRANIAL
HAEMORRHAGE WHILE ON VITAMIN K ANTAGONISTS
E Gómez, P García-Ramirez, A Zabalza*, M Redondo, I Quispe, P Arregui,
MC Montoya, M Alvarellos, DP Millacoy, MJ Paloma
Servicio de Hematología, Complejo Hospitalario de Navarra, Pamplona, Spain
Background: Restarting antithrombotic therapy after an intracranial haemor-
rhage while on vitamin K antagonists (VKA-ICH) treatment is challenging in
many cases. When cardioembolic risk is high (CHADS2-Vasc ≥3) antithrom-
botic therapy should be offered to these patients. The lower rate of intracranial
bleeding of direct oral anticoagulants (DOACs) compared to warfarin reported
in recent phase III randomized trials for patients diagnosed of non valvular
atrial fibrillation (NVAF), probably make these drugs a safer option to treat
VKA-ICH patients.
Aims: The objective of this retrospective, observational study is to evaluate the
efficacy and safety of restarting oral anticoagulation treatment with DOACs in
NVAF patients with a high cardioembolic risk and a previous VKA-ICH episode.
Methods: From October 2012 until January 2016 a total of 23 patients at the
Complejo Hospitalario de Navarra were treated with DOACs after a VKA-ICH
episode while on treatment with the VKA acenocoumarol (sintrom®). We analysed
the following variables: INR on admission, the time in the therapeutic range (TTR),
the rate of spontaneous or posttraumatic ICH, the use of reversal drugs on admis-
sion, the median days to restart oral anticoagulation, and the cumulative incidence
of a second ICH following the restart of anticoagulation treatment.
Results: 23 patients with intracranial hemorrhage during treatment with VKA
restart anticoagulation with a DOAC at our institution. The median age was 78
(68-89), 56.5% were male. All patients had been treated with a VKA antagonist
for NVAF with a median CHADS2VASc score of 4 (2-7) and a median HASBLED
of 3 (1-5). The mayority of ICH events ocurred spontaneously (65.2%). In con-
trast, 34.8% ICH occurred after trauma. Only one patient in our cohort had a
lobar ICH. International normalized ratio (INR) on admission was infratherapetic
in 26% (n=6), therapeutic in 52.2% (n=12) and supratherapetic in 21.7% (n=5).
The mayority of cases were managed at the Emergency room with non activated
prothrombin complex concentrate (PCC) (73.9%) as reversal agent with a medi-
an dose of 24.6 UI/kg (9.68-37.5) in combination with 10 intravenous mg of vita-
min K. (Table 1). The median days to restart oral anticoagulation with a DOACs
after an ICH was 42 (4-521). 17.4% rivaroxaban (n=5), 4.3% dabigatran (n=1)
and 73.9% apixaban (n=17). With a median follow up of 32.88 months (3-88.58)
the cumulative incidence of a second ICH was 7.1% (standard error 6.9%). Only
2 patients in our cohort had recurrent spontaneous ICH, one under rivaroxaban
15 mg once daily and a second one while on apixaban 2.5 mg bid, at 19 and 43
months after restarting DOACs, respectively. No thromboembolic event was
recorded during the follow up in our cohort. (Table 2).
Tables.
Summary/Conclusions: The use of direct oral anticoagulants after an ICH is
a safe option for long-term anticoagulation treatment in patients with non-valvu-
lar atrial fibrillation at high risk of ischaemic stroke. However, further studies
are required to assess longer-term efficacy and safety of DOAC after an ICH.
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BEVACIZUMAB AS TREATMENT IN REFRACTORY HEREDITARY
HAEMORRHAGIC TELANGIECTASIA
E Castillo1,*, J Prada-Arismendy2
1Unidad de Oncología y Hematología, Hospital Manuel Uribe Ángel, 2Grupo
de Investigación e Innovación Biomédica, Instituto Tecnológico Metropolitano,
Medellin, Colombia
Background: Hereditary Hemorrhagic Telangiectasia (HHT) is a dominantly
inherited vascular disorder characterized by recurrent epistaxis, cutaneous
telangiectases and visceral arteriovenous malformations (AVMs) that affect
many organs: lungs, gastrointestinal tract, liver and brain. Diagnosis is definitive
if at least 3 of the following are fulfilled: spontaneous and recurrent epistaxis,
telangiectasia, family history and visceral lesions. Although the disease is highly
penetrant, during the first years of life, only 50% of individuals have symptoms.
Although 80% of patients have gastric or small bowel telangiectases, only 25-
30% of patients develops symptomatic gastrointestinal bleeding. Treatment of
these patients is based on iron therapy and secondary use of medications such
as Hormone Replacement Therapy, antifibrinolytic, tamoxifen, interferon,
sirolimus and endoscopic cauterization. There are few clinical studies that clar-
ifies therapeutic measures in these patients, and that is why the best available
scientific evidence is based on case reports.
Aims: This is the case of a patient with refractory HHT, who presented severe
gastrointestinal bleeding, which was successfully treated with Bevacizumab 
Methods: A 67 year-old man with history of Chronic Obstructive Pulmonary
Disease, hypertension, diabetes mellitus, hypothyroidism, right-sided heart fail-
ure and HHT which was diagnosed 11 years ago. HHT was initially character-
ized by epistaxis, skin telangiectases and occasional events of gastrointestinal
bleeding. The patient had received repeated nasal and esophagogastric cau-
terizations, but there was scarce response and it was necessary recurring
blood transfusions. Diagnosis was confirmed, and multiple palate, esophagus,
stomach and duodenum bleeding angiodysplasias were found. Laboratory tests
demonstrated iron deficiency and anemia. The patient was on parenteral iron
supplementation every week, without obtaining any benefit.
Results: The patient was admitted every week in emergency service with hem-
orrhagic shock (Hemoblobin (Hb) levels between 3.5 to 6 g/dL), receiving
between 3-4 blood units every week. The patient received oral thalidomide 200
mg/day during 2 months with no benefit, persisting low Hb levels despite numer-
ous transfusions, and he was diagnosed with hepatic and pulmonary AVMs.
Bevacizumab was initiated 5 mg/kg every 14 days for 6 doses. Hb rose to14
g/dl during the first week of treatment and it has been stable since then, the
patient has been independent of blood transfusions for 8 months, decreasing
hepatomegaly and right heart failure.
Summary/Conclusions: Bevacizumab is a humanized recombinant monoclonal
antibody against VEGF, which plays an important role in angiogenesis. It inhibits
endothelial cell proliferation thus preventing vessel growth and causing regression
of existing vessels. HHT is characterized by high serum and tissue levels of
VEGF, that is why Bevacizumab is a reasonable agent to consider for the treat-
ment of HHT. To our knowledge, this is one of the first cases reported of intractable
HHT with gastro-intestinal hemorrhage efficiently treated using bevacizumab.
Some cases of epistaxis with anemia successfully treated with bevacizumab has
been reported. Others works have reported that administration of bevacizumab
in patients with HHT associated with severe hepatic AVMs and high cardiac out-
put, was associated with reversal of high-output cardiac failure related to hepatic
shunting. Nevertheless, longer follow-up studies are necessary to determine the
duration of HHT efficacy and whether maintenance therapy is required.
E996
PREDICTION OF INHIBITORS IN UKRAINIAN HAEMOPHILIA PATIENTS
O Stasyshyn*
Surgery, SI “Institute of blood pathology and transfusion medicine of UNAMS”,
Lviv, Ukraine
Background: Replacement therapy in hemophilia patients (pts) is complicated
by the factor VIII (IX) inhibitors among 30% of hemophilia A pts and 3-5% of
hemophilia B pts. The treatment of bleeding and elimination of inhibitors is
complicated, costly and not always successful. 
Aims: To develop a simple score that stratifies hemophilia pts according to
their risk of developing inhibitors.
Methods: 135 pts with hemophilia A and B was divided into two groups: I -74
pts with inhibitor and II –61 pts without inhibitor. We analyzed 16 risk factors to
develop inhibitor: type of hemophilia (A or B), severity, age, age at diagnosis,
hereditary or sporadic, family history of inhibitors, intensive treatment at initial
treatment- days of exposure (ED) /1 episode), age at first exposure to FVIII/IX,
reason for first treatment with FVIII, FVIII/IX product type, prophylaxis or “on
demand” treatment, factor concentrate switching, significant and life-threatening
bleeding localization; surgery: I-urgent or selective; II - major or minor, the
purulent complications. To examine the relationship between risk factors and
the likelihood of inhibitor development, we used regression models of discrete
choice. Specifically, we estimate the range of one factor binomial choice models
to study the individual effects of each factor on the probability of inhibitor devel-
opment. In addition, we analyze the joint impact of risk factors using multiple
logit regression that allows to explore the effects and importance of each factor,
controlling for the presence of other factors. Adequacy of logit models was
conducted using chi-square test, and the significance of regression coefficients
was based on Student Wald statistics. Finally, we calculated the theoretical
values  of probability of an inhibitor development for each patient and ranges
(95% CI) of predicted risk of inhibitor development in pts with the value of the
dependent variable “yes” and “no”.
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Results: The first model includes the following factors: age, clotting factor con-
centrate switching, FVIII/IX product type, purulent complications and the number
of ED / 1 episode of bleeding. At 5% significance level, the type of surgery
(minor/major) as well as positive “inhibitory” history are added. At the 10% sig-
nificance level, the model additionally contains a variable characterizing the
urgency of surgery (urgent or planned). In this approach, the factors that deter-
mine the type of hemophilia, age, diagnosis and life-threatening bleeding are
not significant and therefore, we do not include them in the final multivariate
regression. The number ED / 1 episode has the highest impact on the probability
of inhibitor development: if it increases, the likelihood of inhibitor development
increases by 27%. For patients who changed the type of concentrates, the like-
lihood of inhibitor development increases by 23%. The effect of the FVIII/IX
product type, the age and the type of the surgery - is negative and significant,
while purulent complications and “inhibitory” history result in the increase in
the likelihood of inhibitor development by 21% and 12%, respectively. This mul-
tivariate logit model allows to predict the likelihood of developing an inhibitor
for a pts based on the information about the values of each of these factors.
Summary/Conclusions: According to our model, the factors associated with
treatment have the highest impact on the probability of inhibitor development.
Based on the results, reducing the frequency of inhibitors can be achieved by
changing the approaches to the treatment of pts with hemophilia.
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ACQUIRED ISOLATED PROTHROMBIN DEFICIENY IN A PATIENT WITH
FOLLICULAR LYMPHOMA SUCCESSFULLY TREATED WITH
IMMUNOCHEMOTHERAPY
K Müller1,*, G Eiling1, C Schröder1, B Oldenkott1, E Langer2, KM Derwahl1,
F Nolte1,3
1Internal Medicine, St. Hedwig Hospital, 2Laboratory Berlin, Charité Vivantes
GmbH, Berlin, 3Medical Faculty Mannheim of the University of Heidelberg,
Mannheim, Germany
Background: Acquired haemophilia is rare bleeding disorder, that is caused
by autoantibodies against clotting factors. Approximately 50% of cases are
associated with either malignancies, autoimmune diseases or pregnancy,
respectively. However, half of the cases remain idiopathic. While in the vast
majority autoantibodies are directed against factor VIII leading to acquired
haemophilia A, acquired prothrombin (factor II) deficiency is a rare event and
information on treatment outcome is scarce.
Aims: Here we report on a case of a patient with follicular lymphoma and an
acquired isolated prothrombin deficiency suffering from severe bleeding com-
plications, who was successfully treated with immunochemotherapy.
Methods: A 73-year old female patient was diagnosed with a grade I-II asymp-
tomatic follicular lymphoma stage IV (intermediate risk according to FLIPI) in
July 2015. In November 2015 the patient was admitted to our hospital due to
macro haematuria and pain in the distal right thigh. The patient did not remem-
ber any trauma but MRI showed an intramuscular haematoma. Laboratory test-
ing revealed decreased Quick values (32%) and a prolonged activated partial
thromboplastin time (aPTT: 64 sec.) as compared to August 2015 (Quick 100%;
aPTT 26 sec.) Since the patient received no anticoagulant treatment and diet-
related vitamin K deficiency could be ruled out, single factor analyses were
performed and showed an isolated prothrombin deficiency, which was con-
firmed by repeated analyses. Lupus anticoagulants were negative, as were
analyses with regard to von-Willebrand-Jürgens syndrome. Moreover, the
patient developed a haemoglobin relevant gastrointestinal bleeding with gas-
troscopy showing a diffuse bleeding in the fundus reflecting the haemorrhagic
diathesis due to the coagulopathy. The patient received repetitive prothrombin
substitution with prothrombin complex concentrates leading to transient stabi-
lization of the coagulation system. Eventually she was subjected to successful
surgical revision of the muscular haematoma. Although inhibitory antibodies
were not detectable we assumed an association of the coagulopathy with the
concomitant FCL and initiated an immunochemotherapy with rituximab and
bendamustine in December 2015.
Figure 1.
Results: Repetitive evaluation of coagulation parameters and prothrombin
activity showed a successive improvement of the respective parameters after
the first cycle of treatment (Figure 1). Since December 2015 no prothrombin
substitution was necessary and prothrombin activity increased from 18% in
November 2015 to 52% by January 2016. Currently, the patient has no signs
of haemorrhage or relapse of the coagulopathy with continuous improvement
of the global coagulation parameters.
Summary/Conclusions: Although rare events, isolated clotting factor deficien-
cies should be considered in cases of unexplained coagulopathy in patients
with malignancy in general and malignant lymphoma in particular. Treatment
of the underlying lymphoma by immunochemotherapy can reverse the
haemophilic state in patients with NHL.
E998
THE BLEEDING SPECTRUM OF 21 EGYPTIAN PATIENTS SUFFERING
FROM CONGENITAL AFIBRINOGENAEMIA: A 10-YEAR RETROSPECTIVE
STUDY
M Abdelwahab1,*, A Casini2
1Pediatric Hematology, Cairo University Pediatric Hospital, Cairo, Egypt, 2Uni-
versity Hospitals and Faculty of Medicine of Geneva, Switzerland, Geneva,
Switzerland
Background: Congenital afibrinogenaemia has an estimated prevalence of
one in 1,000000. The afibrinogenemic patients’ phenotype is mainly charac-
terised by bleeding but thromboses, bone pain and delayed wound healing
have also been reported
Aims: To describe the phenotypic spectrum and bleeding incidence of an Egypt-
ian afibrinogenaemic cohort
Methods: All patients with a confirmed congenital afibrinogenaemia (based on
fibrinogen levels and genotype) were included. Patients were followed regularly
every 1-12 months over a period of 1 to 10 years. All bleeding episodes and
fibrinogen replacements were recorded.
Results: Twenty-one patients (13 males, 8 females) with a mean age of 12.9
years from 15 consanguineous families were included.They were followed for
a median period of 9 years.The bleeding phenotype was characterized by umbil-
ical bleeding (65%), oral bleeding and epistaxis (45%), central nervous system
haemorrhage (25%), joint bleeds (25%), hematochezia (10%), peritoneal bleed-
ing (10%), hematuria (5%), spinal hemorrhage (5%), muscle bleeds (5%). Most
women in child bearing period reported menorrhagia (75%). In addition, 15%
of patients experienced a delayed wound healing and all had post-traumatic
bleeding. Half of patients (57%) had atypical bleeds in the form of spontaneous
unexplained severe bone pain in forearms and lower limbs, relieved by fibrino-
gen replacement. Overall, the incidence of severe bleeding varied from 1 to 5
bleeds/pt/years although one patient had weekly hemorrhages. No patients
had arterial or venous thrombosis. All patients were on demand therapy but
one with recurrent cerebral bleeding on biweekly prophylaxis. Replacement
fibrinogen included cryoprecipitate 15-20 mg/kg/d for mild to moderate bleeds
and 30mg/kg/12-24 hours for severe/serious bleeds for a period ranging from
1-5 days.
Summary/Conclusions: Our cohort showed a wide phenotypic spectrum with
high prevalence of cerebral bleeding. The absence of thrombosis is possibly
explained by the young age of patients. We confirmed that bone pain is a fre-
quent complication of afibrinogenaemia. Optimal management of this symptom
require further investigations.
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HEALTH RELATED QUALITY OF LIFE IN GREEK CHILDREN WITH
HAEMOPHILIA AND THEIR CAREGIVERS
A Papagianni1,*, M Economou1, A Teli1, H Platokouki2, H Pergantou2,
D Niakas3, A Varaklioti3,4
11rst Pediatric Department, Ippokration General Hospital, Aristotle University
of Thessaloniki, Thessaloniki, 2Haemostasis Unit, Haemophilia Centre, “Aghia
Sophia” Childrens’ Hospital, Athens, 3Faculty of Social Sciences, Hellenic Open
University, Patras, 4Blood Center and National Centre for Congenital Bleeding
Disorders, Laiko General Hospital, Athens, Greece
Background: Health-related Quality of Life(HRQoL) has become an important
outcome in every day clinical practice.
Aims: The aim of the study was the assessment of health-related quality of life
(HRQoL) in children with haemophilia and their caregivers in Greece, using a
disease-specific questionnaire and the investigation of demographic and clinical
factors that affect their HRQoL.
Methods: The study was conducted in two national pediatric haemophilia cen-
ters, in Thessaloniki and Athens [and included 45 children and their parents]
The Greek version of the Hemophilia-Specific Quality of Life Index (Haemo-
QoL) questionnaire was administered to 45 pediatric patients aged 4 to 16
years and their parents. The latter filled in a questionnaire with demographic
data (child’s and parent’s age, residence, number of siblings-whether sick or
not, marital status, education level, employment) and clinical data of the patient,
namely type of haemophilia, severity, presence or history of inhibitor, type of
treatment, number of haemarthrosis over last 12 months, presence of chronic
pain). Statistical analysis of the results was performed using SPSS 19.0.
Results: Overall, patients and caregivers had a mean age of 10.46±4.3 and
39.51±7.4 years respectively. 86.7% of patients had haemophilia A and 77.8%
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were on prophylaxis treatment. HRQoL scores were found to be widely below
40 for children and below 50 for their caregivers in all dimensions. “Family”
and “Treatment” had the highest scores (mean scores 57.7 and 46.2 respec-
tively), suggesting reduced quality of life in these dimensions in age group 4-
7. The most impaired domain of Haemo-QoL in age group 8-12 was “Perceived
Support” (mean score 40.63), while the older children were more impaired in
“Family” and “Treatment”, but much less so than the younger ones (mean
scores 36.1 in both domains). The least impaired dimensions were “Self-view”,
“Other people” and “Relationships” among the three groups. Cronbach’s alpha
coefficient was assessed for every subscale and in total, suggesting
sufficient/very good internal consistency reliability of the Greek version of
Haemo-QoL. Among Haemo-QoL subscales, “Perceived Support” in age group
8-12 and “Sports/School” and “Relationships” in the adolescent group were
found strongly associated with the number of haemarthrosis over the previous
12 months.
Summary/Conclusions: The use of a disease specific QoL tool showed that
children and their caregivers report a relatively good quality of life, with “family”
and “treatment” being the most impaired especially in the younger age group.
The number of haemarthrosis over the previous year is a clinical characteristic
which impairs some of the aspects of quality of life, especially in the adolescent
group. These data are important for the future planning of treatment regimens
as well as the psychological support of patients and their families.
E1000
ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH IMMUNE
THROMBOCYTOPENIC PURPURA
S Sahinkaya, H Tokgoz*, U Caliskan
Pediatric Hematology and Oncology, Necmettin Erbakan University Meram
Medical Faculty, Konya, Turkey
Background: Presence of antiphospholipid antibodies (APAs) has been
observed in children with immune thrombocytopenic purpura (ITP), but their
role for the outcome of disease is controversial.
Aims: The aim of this study was to evaluate the relation between APAs and
the clinical course, labarotory findings, response to treatment and prognosis
of ITP in childhood. 
Methods: The cross-sectional study included to patients with newly diagnosed
ITP aged between 0-18 years, in the period of time between March 2014 and
March 2015, at our centre. Clinical and laboratory findings, medical treatments,
and the course of the diseases were recorded for all patients. At the time of
diagnosis, anti-phospholipid antibodies including lupus anticoagulant, anticar-
diolipin antibodies (aCL), anti-beta-2 glycoprotein I antibodies were studied.
The patients who have positive results for APAs at diagnosis were examined
again for APAs at 12th week of follow-up period.
Results: Forty children (21 (52.5%) females and 19 (47.5%) males) with newly
diagnosed with ITP were enrolled the study. APA levels were positive at 12
patients (30%) at the time of diagnosis. Among the APA positive patients, only
one patient had all of three APAs, one patient had both aCL IgM and LA, 10
patients had single positive results for APAs (figure 1). Among APA positive
patients, the positivity of anti beta 2 glycoprotein I, aCL and LA were 58.3%,
16.7%, and 8.3% respectively. After 12 week, only 3 of these 20 cases were
still positive for APA. One of them was positive both LA and anti beta 2 glyco-
protein I, and two of them were positive for anti beta 2 glycoprotein I IgG. There
was not a significant difference between APA positiveness (at the time of diag-
nosis and control) and gender groups, platelet counts, IgG levels or course of
disease. At the time of diagnosis, mean age of APA positive patients was sig-
nificantly higher than in APA negative patients (p<0.05). According to age inter-
val; there was three patients aged between 0-1 year and none of them were
APA positive. At the time of diagnosis, APA positiveness was found in 7 of 28
(25%) patients aged between1-9 years, and 5 of 9 patients (55.5%) aged
between 9-18 years. There was no relationship between APAs and treatment
response or outcome of disease.
Figure 1.
Summary/Conclusions: Unlike in adults, pediatric studies about APAs and
ITP are limited. APAs may be present in children with ITP. It may be related to
underlying viral infections or idiopathic, and more common in adolescence.
The persistence of APAs may contribute to thrombotic complications in the
future. More comprehensive studies are needed to determine the relationship
between APAs and İTP.
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FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN WITH
BLEEDING
P Zharkov*, I Demina, M Panteleev
Federal Research Clinical Centre Of Pediatric Hematology Oncology And
Immunology N.A. D. Rogachev, Moscow, Russian Federation
Background: Diagnosis in a bleeding child without thrombocytopenia or clot-
ting factor deficiency is always challenging. In these cases using a platelet flow
cytometry (PFC) method might be helpful because it can detect several glyco-
protein deficiencies on platelet surface and confirm the diagnosis of platelet
dysfunction. Here we present a case series of patients with bleeding due dif-
ferent platelet disorders, established by a modification of PFC method-func-
tional platelet activity analysis (FPAA).
Aims: to asses the role of a modification of platelet flow cytometry (PFC)
method-functional platelet activity analysis (FPAA) in children with bleeding.
Methods: 32 patients (1-17 yo) with mild to severe bleeding without von Wille-
brand disease, factor XIII deficiency, or other coagulopathy were included.
Whole blood platelets were studied by FC either in native or activated with col-
lagen-related peptide (0.18 µg/ml) and thrombin receptor activating peptide
(12.5 µM). Fluorescencently labeled antibodies against CD42b, CD61 and
PAC-1, phosphatidylserine (PS) and CD62p were used; dense granule (DG)
release was studied using loading with mepacrine.
Results: After FPAA from 32 children 2 pts were excluded because of normal
results and 1 because of preanalytical issues. From those 29, 4 pts were diag-
nosed with CD61 deficiency, and 25-with different granule defects. Isolated defi-
ciency or mobilization defect of dense and alpha granules was found in 9 and 4
children, respectively. Combined storage pool deficiency/mobilization defect
(CSPD/MD) was diagnosed in 8, while we found 1 combination of CSPD/MD
and PAC-1 deficiency, and 3 combinations of CSPD/MD and PS deficiency.
Summary/Conclusions: Different platelet disorders could be found in up to
93,5% of patients with bleeding without clotting factor deficiency. Most of the
alterations include storage alpha/dense granule pool deficiency/mobilization
defect or CSPD/MD.
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SAFETY AND EFFICACY OF B-DOMAIN DELETED 3RD GENERATION
RECOMBINANT FACTOR VIII (GREENGENE FTM) IN KOREAN PATIENTS
WITH HAEMOPHILIA A: DATA FROM A POST-MARKETING SURVEILLANCE
STUDY
SK Kim1,*, SK Park2, KY You3, TJ Hwang3, YM Choi4
1Dept. of Pediatrics, Inha University Hospital, Incheon, 2Dept. of Pediatrics,
Ulsan University Hospital, Ulsan, 3Dept. of Pediatrics, 4Internal Medicine, Korea
Hemophilia Foundation, Seoul, Korea, Republic Of
Background: New B-domain deleted 3rd generation recombinant factor VIII
(GreenGene FTM, beroctocog alfa) was launched in 2010. 
Aims: This clinical trial evaluated the safety and efficacy of GreenGene FTM
in patients with haemophilia A over a period of 12 months. 
Methods: From July 2010 to July 2014, a total 136 hemophilia A patients were
enrolled in the post marketing surveillance (PMS) study and were analyzed for
safety of the drug. Among them, 114 patients were analyzed for efficacy. Sub-
jects with differing haemophilia A severities and medical histories were monitored
during 12 months of prophylactic and/or on-demand therapy. Efficacy was rated
by their doctors with 4 scales as excellent, good, moderate, or no effect.
Results: Among 135 evaluable subjects, 85 (63.0%) had severe haemophilia,
35 (25.9%) had moderate haemophilia and 15 (11.1%) had mild haemophilia.
Excellent/good efficacy rate was 91.3% for hemostasis and 89.4% for hemor-
rhage prevention. Twelve subjects reported 13 adverse drug reactions (ADRs),
which were recovered without sequelae. The frequent ADRs were gastrointesti-
nal disorders, nervous system, vascular disorders and general disorders. In 113
previously treated patients (PTP), two patients (1.8%) developed inhibitors after
intensive FVIII treatment for surgery and hematuria, respectively.
Summary/Conclusions: The results of this PMS study support that Green-
Gene FTM is safe and efficacious in the treatment and prevention of patients
with hemophilia A. The results of this study are consistent with the previously
published GreenGene FTM studies.
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FACTOR XI DEFICIENCY IN PREGNANCY: THREE CASE REPORTS
A Poz1, M Turello2, A Bertone2, G Barillari2,*
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Background: Management of pregnant women with factor XI deficiency (F11D)
poses a challenge to the clinician because of both the variabile uterine bleeding
during labor and the risk associated with factor replacement. Hemoleven® is a
factor eleven (FXI) concentrate processed by deep filtration and ion exchange
chtomatography, with double viral inactivation performed using solvent deter-
gent and nanofiltration. It represents a good treatment for protecting against
bleeding, but the potential risk of thrombosis shoul be considered.
Aims: We present the cases of three women with F11D and a history of bleed-
ings, where the efficacy and safety of Hemoleven® treatment was assessed
during pregnancy and labor.
Methods: During labor, the drug was administered together with tranexamic acid.
Results: In case 1 the woman was diagnosed as F11D when she was 10, with
a plasma FXI level less than 1% and an omozygote phenotype. The 34 year
old primagravidae had an uneventful pregnancy, and she was admitted at 39+1
weeks of gestation. When cutting the umbelical cord, antihaemorragic prophy-
laxis was performed with 1 g of tranexamic acid, intravenously injected, and
1000 UI of Hemoleven. 1 g of tranexamic acid was then administered every 8
hours, from the first to the eighth day post-partum, while 1000 UI of Hemoleven
were given during the second and the fifth day post-partum.In case 2, a 26
year old primagravidae had an uneventful pregnancy, but she was admitted at
38+4 weeks of gestation due to a very big condylomatosis. She was diagnosed
as F11D at the age of 17, with a plasma FXI level of 42% and an heterozygote
phenotype. Despite FXI level, she had an hemorragic phenotype. Caesaren
section was planned and performed at the day of admission, in general anes-
thesia. 30 minutes before the delivery started, 1000 UI of Hemoleven were
infused, and 1 g of tranexamic acid was administered intravenously ad the
beginning of the procedure. After caesarean section, 1 g of tranexamic acid
was given every 8 hour till the seventh day.In case 3, a 36 year old woman had
an uneventful second pregnancy, and she was admitted at 39 weeks of gesta-
tion. She was diagnosed as F11D at the age of 31, with a plasma FXI level of
30%. Vaginal delivery was induced with oxitocin. After umbelical cord excision,
1000 UI of Hemoleven were infused and 1 g of tranexamic acid was given intra-
venously. Subsequently, 1 g of tranexamic acid was then administered every 8
hours, from the first to the seventh day post-partum.
Summary/Conclusions: Neither post-partum haemorragy nor thrombotic
events were evident in all the three cases, thus confirming safety and efficacy
of clotting factor eleven concentrate. Hemoleven® dose and duration of treat-
men was alway carefully decided before delivery, with a management plan
shared between haemostasis experts, obstetrics, and the patients. Considering
our experience, the benefit/risk ratio of Hemoleven® should be weighted and
management tailored to each individual patient.
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SERUM CYTOKINE AND CHEMOKINE LEVELS IN CHILDREN WITH
IMMUNE THROMBOCYTOPENIA
A Komitopoulou1,*, A Bartzeliotou2, E Pergantou1, I Farakla2, I Papassotiriou2,
H Platokouki1
1Hemophilia Center and Hemostasis Unit, 2Department of Clinical Biochemistry,
Aghia Sophia Children’s Hospital, Athens, Greece
Background: Immune thrombocytopenia (ITP) is an acquired immune disorder
derived from disruption of platelet production and removal from blood circula-
tion, usually as a consequence of autoantibody and cytotoxic T-lymphocyte
development against them, which ultimately results to the phagocytosis of the
trapped platelets from monocytes. Onset of ITP in children is often triggered by
viral infections, infectious diseases or vaccination. In pediatric patients with
ITP, as in adults, impaired immunity by deregulation of the balance of Th1/Th2
(T-helper) and of Tregs (regulatory T cells) is referred. The cytokines which are
secreted by activated lymphocytes control the immune system either by stim-
ulating or inhibiting the activity of cells but simultaneously they are involved in
the production of antiplatelet antibodies or other cytokines and/or chemokines.
Aims: The aim of our study was to determine the serum levels of specific Th
cytokines and chemokines in children with ITP and to correlate them with clinical
parameters.
Methods: The group of patients consisted of 18 children with ITP (8 male,10
female) of a mean age at investigation 5.46 years. ITP was chronic in 6/18 chil-
dren, while acute/persistent was in 12/18 (duration of thrombocytopenia>12
or<12 months, respectively). None but one patient had received any treatment
during the last 3 months. The control group was constituted by 37 children of
preschool age. Serum levels of cytokines IL-1a, TNF-a, IL-1b, IL-10, IL-12p40,
hsIL-6 and chemokines of macrophages such as IL-8 (CXCL8) and MCP-1
(CCL2) were measured in patients and controls using the cytokine-chemokine-
MAP technology which is a bead based multiplex assay using the Luminex.
Inform consent was obtained from the parents of both groups.
Results: There was no significant difference in the concentrations of IL-1a, Il-
1b, IL-10, IL12p40 and the chemokine IL-8 among the two groups, except of
the concentration of TNF-a which was found quite lower among patients and
controls. Furthermore, only the levels of TNF-a differed remarkably between
children with acute/persistent compared to children with chronic ITP (p<0.05).
A significant reduction of hsIL-6 (1.0±0.2 vs 1.6±0.2pg/mL, p<0.05) and MCP-
1 (252.7±20.0 vs 408.5±22.2pg/mL, p<0.001) was noticed in children with ITP.
Summary/Conclusions: The current study did not seem to confirm the hypoth-
esis of the overall increase of proinflammatory cytokines in children with ITP.
The higher values of TNF-a in the initial phase of the disease could be inter-
preted as a response to inflammation. The finding of the dramatically reduced
chemotactic protein MCP-1 (CCL2), possibly reveals deficient response in the
ability to control inflammation, a conclusion reinforced by a recent study in
murine models of human ITP1. The exact role of various cytokines/chemokines
in the deregulation of the immune system, sush as occurs in autoimmune dis-
eases, remains to be investigated, particularly in children which are often on
inflammatory process. Well-designed studies with a larger number of children
with ITP and larger subsets of patients at different stages of the disease, as
well, which will investigate a wider range of cytokines, may provide useful
answers in the future.
Reference
1. Leontyev et al. Transfusion, 2014; 54:2871.
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COMBINED DEFICIENCY OF FACTOR V AND VIII CAUSED BY TWO NOVEL
MUTATIONS AT MCFD2 GENE
Q Li*, R Zhou
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical
School, Nanjing, China
Background: Combined deficiency of coagulation factor V and VIII (F5F8D) is
a rare autosomal recessive disorder characterized by a mild-to-moderate bleed-
ing tendency with the reduction of the two factors in plasma. Mutations in
LMAN1 and MCFD2 gene account for all F5F8D patients.
Aims: To identify the molecular mutation causing F5F8D in a Chinese pedigree.
Methods: The activated partial thromboplastin time(APTT), prothrombin time
(PT) and coagulate activities of coagulation factors of the proband and her par-
ents were detected for diagnosis. PCR was used to amplify the exons and
intron/exon boundaries of LMAN1 and MCFD2 genes . The amplicons were
sequenced directly and aligned with software chromas 2.
Results: The proband’s APTT, PT, FV:C and FVIII:C was 75s, 17s, 9.9% and
5.9%, respectively, while those parameters of her parents were all within the
normal range. Sequencing the 13 exons of the LMAN1 gene and 4 exons of the
MCFD2 gene from the patient revealed two novel missense mutations. The first
one was a heterozygous mutation: g.35T>A, causing the Leu12Glu in exon2 of
MCFD2. The second one was a homozygous mutation: g.398A>T, leading to
the Asp133Val in exon 4 of MCFD2. The two mutations Leu12Glu and Asp133Val
were identified in the compound heterozygous state in her parents.
Summary/Conclusion: The two novel mutations might be the molecular patho-
logical mechanism causing F5F8D in this pedigree.
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FALSE HOMOZYGOUS HLA GENOTYPING RESULTS DUE TO LOSS OF
HETEROZYGOSITY IN ACQUIRED APLASTIC ANAEMIA
B Heyrman*, A De Becker, S Verheyden, C Demanet
UZ Brussel, Brussels, Belgium
Background: The pathogenesis of acquired aplastic anaemia is driven by T
cell-mediated destruction of hematopoietic progenitors. Clonal evolution is
known to occur in around 70% of patients. This includes around 12% with loss
of heterozygosity (LOH) of chromosome 6p, involving the human leukocyte
antigen (HLA) locus. Loss or down-regulation of HLA class I antigens is a way
to escape cytotoxic T-cell surveillance. LOH can appear even without previous
therapy. In acquired aplastic anaemia it is well studied as a biological phenom-
enon. LOH appears to have no impact on the course of the disease nor does
it predict response to treatment, as results are contradictory in this matter. 
Aims: The aim of this case report is to draw attention on possible false HLA
genotyping in acquired aplastic anaemia prior to allogeneic hematopoietic stem
cell transplantation. 
Methods: Repeated HLA genotyping was performed on peripheral blood using
flow multiplex DNA typing and sequence-based typing.
Results: We report false HLA genotyping results due to loss of heterozygosity
in a 59-year-old female patient of Caucasian origin, presenting with very severe
aplastic anaemia. At diagnosis we obtained heterozygous results (A*24, A*33,
B*07, B*14, C*07, C*08, DRB1*13, DRB1*15, DQB1*03, DQB1*06). Bone mar-
row karyotype was normal. After treatment with rabbit anti-thymocyte
globulin+cyclosporine, not reaching a partial response at 6 months, we repeat-
ed HLA genotyping in order to search for an unrelated donor, because there
was no HLA compatible sibling. This time we obtained homozygous results
(A*24:02, B*07:02, C*07:02, DQ*06:02,DR*15.01). Repeated testing confirmed
loss of HLA genotype heterozygosity. New bone marrow karyotype didn’t show
alterations in chromosome 6. Monosomy 7 was found, compatible with devel-
opment of high risk myelodysplastic syndrome-associated cytogenetic abnor-
malities.
Summary/Conclusions: When homozygous HLA genotype results are
obtained in acquired aplastic anemia, confirmatory testing on other somatic
cells (eg. buccal swab) is needed to avoid hematopoietic stem cell transplan-
tation with an unmatched donor.
E1006
PREVALANCE OF CHROMOSALLY-INTEGRATED HERPESVIRUS 6 IN
PATIENTS WITH APLASTIC ANEMIA
M Bakker1,*, C Van Leer-Buter2, M Nijland1
1Hematology, 2Microbiology, University Medical Center Groningen (UMCG),
Groningen, Netherlands
Background: Aplastic anemia (AA) is a rare heterogeneous bone marrow fail-
ure syndrome. It is hypothesized that in most cases AA is an immune-mediated
disease. One third of patients, especially those who do not respond to immuno-
suppressive therapy, have shortening of telomeres in there leucocytes. Muta-
tions in genes responsible for telomere repair proteins are present in some of
these patients. Human herpesvirus 6 is one of the herpesviruses which estab-
lish latent infection. It is shown that reactivation of latent HHV-6 can have direct
suppressive effects on hematopoietic progenitors which can be the cause of
bone marrow suppression after hematopoietic stemcell transplantation. Besides
latent infection, HHV-6 can integrate in the human DNA at the telomeric region
which results in germ-line transmission of the HHV-6 genome. Chromosomally
integrated HHV-6 (ciHHV-6) can be found in less than 1% of the population.
Aims: We performed an exploratory study to investigate the prevalence of ciH-
HV-6 in patients with AA in order to determine whether ciHHV-6 represents a
risk factor for developing AA. 
Methods: Between 2008 and 2015 101 patients were treated for AA at the
University Medical Center Groningen in The Netherlands. Whole blood samples
of 53 of these patients that were initially used for clinical purposes were avail-
able for analysis by quantitative PCR (qPCR) for the presence of HHV-6 DNA.
Results: Of the 53 samples 11 patients had detectable HHV-6 DNA. Ten
patients had a low HHV-6 viral load with median concentration of 1.9x102
copies/ml (range 1.2x106-2.3x104 copies/ml). One patient had a high viral load
with 5.2x106 copies/ml suggestive of ciHHV-6. Viral chromosomal integration
was subsequently proved by demonstrating HHV-6 DNA in hair follicles of this
patient. In our cohort the prevalence of ciHHV-6 was 1.9%, which is not above
the expected incidence of the general population.
Summary/Conclusions: The prevalence of ciHHV-6 in patients with AA is sim-
ilar to that of the general population. It is therefore unlikely that ciHHV-6 is a
risk factor for AA.
Bone marrow failure syndromes incl.
PNH - Clinical
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PROSPECTIVE MULTICENTRIC EVALUATION OF THE CURRENT MEDICAL
INDICATION FOR PAROXYSMAL NOCTURAL HEMOGLOBINURIA
DIAGNOSTIC SCREENING
M Morado1, M Perez-Andres2, A Freire Sandes3, E Colado4, D Subira5,
P Isusi6, MS Noya7, MB Vidriales8, A Sempere9, JA Diaz10, A Minguela11,
B Alvarez12, C Serrano13, T Caballero14, MDLM Rey15, A Perez-Corral16,
MC Fernandez Jimenez17, E Magro18, A Lemes19, C Benavente20, H Bañas21,
J Merino22, C Castejon23, O Gutierrez24, P Rabasa25, M Vescovi Gonçalves26,
A Orfao27,*
1Serv Hematologia, Hosp La Paz, Madrid, 2Cancer Research Centre (IBMCC,
CSIC-USAL), Institute of Biomedical Research of Salamanca (IBSAL), and
Cytometry Service (NUCLEUS) and Department of Medicine, Univ. Salamanca,
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Group, Sao Paulo, Brazil, 4Serv Hematologia, Hosp Central Asturias, Oviedo,
5Serv Hematologia, Hosp. Univ. Guadalajara, Guadalajara, 6Serv Hematologia,
Hosp Univ. Basurto, Bilbao, 7Serv Hematologia, Hosp Univ. A Coruña, A
Coruña, 8Serv Hematologia, Hosp Univ. Salamanca, Salamanca, 9Serv Hema-
tologia, Hosp La Fe, Valencia, 10Serv Hematologia, Hosp Univ. Santiago de
Compostela, Santiago de Compostela, 11Serv Inmunologia, Hosp. Virgen de
la Arrixaca e Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia,
12Serv Hematologia, Lab Central CAM, 13Serv Inmunologia, Fundacion
Jimenez Diaz, Madrid, 14Serv Hematologia, Hosp. Univ. Virgen del Rocio,
Sevilla, 15Lab Unificado Donosti, Hosp Donosti, San Sebastian, 16Hosp. Gre-
gorio Marañon, Madrid, 17Serv Hematologia, Compl. Hosp de Toledo, Toledo,
18Serv Hematologia, Hosp. Univ. Principe de Asturias, Alcala de Henares,
19Serv Hematologia, Hosp. Univ. Dr. Negrin, Las Palmas de GC, 20Serv Hema-
tologia, Hosp. Clínico San Carlos, Madrid, 21Serv Hematologia, Hosp San
Pedro de Alcantara, Caceres, 22Serv Inmunologia, Clínica Universitaria de
Navarra, Pamplona, 23Balague Center, Hospitalet de Llobregat, 24Serv Hema-
tologia, Hosp. Rio Hortega, Valladolid, 25Serv Hematologia, Hosp San Pedro,
Logroño, Spain, 26Fleury Group, Sao Paulo, Brazil, 27Cancer Research Centre
(IBMCC, CSIC-USAL), Institute of Biomedical Research of Salamanca (IBSAL),
and Cytometry Service (NUCLEUS) and Department of Medicine, University
of Salamanca, Salamanca, Spain
Background: Although consensus guidelines have been proposed in 2010 for
the diagnostic screening of paroxysmal nocturnal hemoglobinuria (PNH) by
flow cytometry (FCM), so far no study has investigated the efficiency of such
medical indications in multicentric vs. reference laboratory settings.
Aims: To evaluated the efficiency of the current consensus medical indications
for diagnostic screening of PNH by FCM
Methods: Overall, information about 3,938 samples from an identical number
of individuals prospectively submitted between January 2011 and December
2014 for diagnostic screening of PNH by flow cytometry was collected at 24
flow cytometry laboratories in Spain which participate in the PNH-External
Quality Assurance Program of the Iberian Society of Cytometry (1,718 samples)
plus one reference laboratory in Sao Paulo, Brazil (2,220 samples). The fol-
lowing GPI-associated markers were analyzed: FLAER (analyzed in 87% of
the cases), CD14 (98%), CD16 (37%), CD24 (93%), and/or CD157 (5%). In
those cases with GPI-deficient mature neutrophils and monocytes, expression
of CD59 (100% of cases) was also analyzed on red blood cells.
Results: Overall, diagnostic screening based on consensus medical indications
was highly efficient (567 PNH+/3,938 screened cases; 14% PNH+ samples)
both in the multicenter setting in Spain (10%) and reference laboratory in Brazil
(16%). Although GPI-deficient cells were found within all age groups, a signifi-
cantly higher frequency of PNH+ cases was observed among the screened PB
samples from individuals ≤40 years vs. older cases (18% vs. 11%; p<0.001)
Estimated annual incidence of new PNH cases was be of ≈2.5 cases/million
individuals per year. When patients with previously diagnosed hematological
associated disorders (mostly AA and MDS) were excluded from the analysis,
the annual incidence of PNH was of 0.6 cases per million individuals per year.
The highest frequency of PNH+ cases was observed among patients screened
because of bone marrow (BM) failure syndrome (33%), particularly among those
with mainly aplastic anemia (243/541; 45%) and to a less extent also myelodys-
plastic syndrome (26/266; 10%). Among the other individuals studied, the most
efficient medical indications for PNH screening included: hemoglobinuria (35/73;
48%), unexplained cytopenias including anemia (88/393; 22%), non-immune
hemolytic anemia (71/382; 19%), and thrombosis associated to (non-hemolytic)
anemia and/or another cytopenia (10/73; 14%). PNH+ cases was less commonly
observed among patients with chronic myeloproliferative neoplasms (1/21;
4.8%), unexplained cytopenias in the absence of anemia (39/772; 5.1%) or
unspecified anemia (17/468; 3.6%). In contrast, only a minor fraction of the
patients who had been submitted for PNH testing because of unexplained throm-
bosis in the absence of cytopenia were positive (3/800; 0.4%).
Summary/Conclusions: In summary, our results demonstrate that the current
medical indications for PNH screening by FCM are highly efficient, although
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improved screening algorithms are needed for patients presenting with throm-
bosis and normal blood cell counts.
E1008
POSSIBLE RISK FACTORS FOR THROMBOSIS IN CHINESE PATIENTS
WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Z Long*, Y Du, B Han
Department of Hematology, Peking union medical college, Beijing, China
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease
caused by an acquired mutation of the X-linked PIGA gene on the hematopoietic
stem cell. The most common cause of morbidity and mortality in PNH is throm-
bosis, but the exact mechanisms involved in thrombus formation are still
unknown, and predisposing factors for thrombosis in PNH patients have yet to
be defined.
Aims: To identify high risk factors and susceptibility genes leading to thrombotic
formation in PNH.
Methods: Totally, 95 patients with PNH diagnosed between 2009 and 2015
were enrolled in the study. Clinical data like sex, age, hemoglobin level, reticular
cell percentage, white blood cell and platelet count, LDH level, CD59- and
FLAER-granulocytes percentage, thrombophilia risk factors like level of protein
C, protein S, antithrombin III, APC resistance, blood fat, phospholipid antibody
were evaluated. Samples from patients were genotyped for the reported 28
alleles in 21 genes including MTHFR, PROC, PROS, F2, F5, prothrombin and
other genes which are reported as high risk factors for venous thromboem-
bolism (VTE) by polymerase chain reaction fragment length polymorphism
methods (PCR-RFLP). 
Results: Of the 95 PNH patients, 19 (20%) patients had at least 1 episode of
thrombotic event. Only 3 patients had arterial thrombosis and 16 patients had
venous thrombosis. The medium age of patients with thrombosis was 42-year-
old, similar to those without (42-year-old, p=0.9947). Male: female ratio was
1.71 in thrombosis group, 1.17 in non-thrombosis group (p=0.6072). Patients
with thrombosis had the same disease pattern compared to those without.
Although there was no difference in level of hemoglobin (p=0.2512), white blood
cell count (p=0.4681), platelet count(p=0.6185), reticular cell count
(p=0.6296)and LDH level (p=0.4511) between patients with thrombosis and
those without, patients with thrombosis showed higher percentage of CD59-
granulocytes (p=0.038)and FLAER- granulocytes (p=0.036) compared to those
without. The routine thrombophilia screening tests did not show any difference
either between PNH patients and normal controls, or between patients with or
without thrombosis. Patients with the TC genotype (rs2519093 in the ABO
gene) were approximately 18.5 folds prone to thrombus formation than those
with the CC genotype (p<0.0001). In addition, the T allele was found to be a
significant risk factor for thrombosis (OR 6.447, 95%CI 2.815-14.76, p<0.0001).
No association was detected between other SNPs and risk to thrombosis.
Summary/Conclusions: Compared with non-thrombotic patients, PNH throm-
botic patients have similar clinical features except that they have bigger PNH
clone. And for the first time, our results suggested that the rs2519093 in the
ABO gene confers risk to thrombosis in PNH. Therefore, rs2519093 polymor-
phism may represent a potential genetic biomarker in PNH patients for throm-
bus formation.
E1009
POLYMORPHISM OF THE COMPLEMENT RECEPTOR 1 GENE IN CHINESE
PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Y Du, Z Long, J Zhuang, M Chen, B Han*
Department of Hematology, Peking union medical college, Beijing, China
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired genet-
ic disorder of the bone marrow, eculizumab is an effective monoclonal antibody
inhibits terminal complement activation through block the distal complement path-
way, but the hematologic response to eculizumab is variable. Previous report
showed patients with PNH who have rare allele (L) of the complement receptor
1 (CR1) gene, either heterozygotes (H/L) or homozygotes (L/L), displayed more
sub-optimal responder to eculizumab compared with common allele (H/H).
Aims: We investigate polymorphism of the CR1 gene in Chinese patients with
PNH in order to determine its potential impact on eculizumab efficiency. 
Methods: DNA was extracted from peripheral blood mononuclear cells from
95 Chinese patients with PNH. Rs2274567 and rs3811381 in CR1 gene were
genotyped by polymerase chain reaction fragment length polymorphism meth-
ods (PCR-RFLP). Hemolysis factors including hemoglobin level and LDH level
were investigated and thrombotic percentage was evaluated between different
genotypes.
Results: Of the 95 patients, frequencies of the rare rs2274567 allele (12%) is
much lower than Caucasian PNH population previous reported (31%,
P<0.0001), and rare allele frequencies of rs3811381 is also significantly lower
(12% vs 29%, P<0.0001) in Chinese patients. 72(76%) patients were H/H, while
23 (24%) patients were H/L genotype for rs2274567 polymorphism. There were
no difference between the two genotypes in hemoglobin level (83.7g/L vs
72.8g/L, p=0.0917) and LDH level (1312U/L vs 1022U/L, p=0.2682). As for the
rs3811381 genotype, there were 71 (75%), 22 (23%) and 2 (2.1%) patients
with H/H, H/L, L/L genotype separately. There was no difference among the
different genotype groups in the hemoglobin level (83.2g/L, 74.8g/L and 75.5g/L,
respectively, p=0.4278) and LDH level (1312U/L, 997U/L,1233U/L, respectively,
p=0.5171), either. Although not significantly, the thrombotic percentage tent to
increase from H/H to H/L (17% to 30%, p=0.2288) for rs2274567 polymorphism
and H/H to H/L to L/L genotype (17%, 27%, 50%, respectively, p=0.3201) for
rs3811381 genotype.
Summary/Conclusions: Very rare H/L or L/L genotype of CR1 was found in
Chinese people with PNH. Frequencies of Chinese rare alleles in CR1 gene
were significantly lower than that of Caucasian population, which may indicate
a favorable response to eculizumab treatment. No difference of hemoglobin
level or hemolysis was found among different genotype groups, but the per-
centage of thrombosis seemed to increase from H/H, H/L to L/L.
E1010
EPIDEMIOLOGIC OVERVIEW OF CONGENITAL DYSERYTHROPOIETIC
ANEMIA-UPDATED DATA FROM THE GERMAN CDA REGISTRY
M Bommer1,*, R Javorniczky1, U Keppler2, K Holzwarth2, R Leichtle2, F Theis2
1Hematology, Oncology and Infectious diseases, Alb-Fils Kliniken Göppingen,
Göppingen, 2Hematology, Oncology, Rheumatology and Infectious diseases,
University of Ulm, Ulm, Germany
Background: Congenital dyserythropoietic anemia is a very rare hereditary
disorder, leading to ineffective hematopoiesis, anemia and secondary
hemochromatosis. According to the classification of Heimpel and Wendt (1968)
at least four subtypes (CDA I-III, CDA variant) can be distinguished. Diagnosis
is based upon morphological examination of blood and bone marrow. Genetic
testing can confirm the diagnosis in many cases: CDA I-CDAN1, C15ORF41;
CDA II - SEC23B; CDA III-KIF23; variant-KLF 1, GATA-1. Familial cases are
autosomal recessive (CDA I, CDA II), autosomal dominant (CDA III) or variable
(CDA variant).
Aims: The aim of this study was to analyze the prevalence of this very rare
inherited anemia.
Methods: The German CDA registry was initiated in 1990 by Heimpel and
coworkers and includes cases from all over the world. All patients known to the
study group since 1967 have been documented. Data analysis is based upon
an ACCESS database. Diagnosis was confirmed using the criteria published
previously by Heimpel and Anselstetter (2003). From a minority of patients results
from genetic testing are available. We analyzed the prevalence of CDA-subtypes
in different continents. CDA IV is summarized within the CDA variant group.
Results: At the reporting date (13.02.2016) a total of 989 cases from 811 fam-
ilies were registered. Geographical analysis shows 751 patients are registered
in Europe, 90 in America, 21 in Oceania (Australia, New Zeeland), 57 in
Africa/near east (including Israel) and 70 in Asia. The most frequent subtype is
CDA II, followed by CDA I. Most cases are reported in Italy, Spain, Great-Britain,
Germany and Israel (data not shown). Detailed information is given in table 1.
Table 1.
Summary/Conclusions: Prevalence of congenital dyserythropoietic anemia
in the different countries is very heterogeneous, reflecting the rarity and the
lack of awareness of the disease. Nevertheless the diagnosis is under reported
due to numerous cases with only mild symptoms misdiagnosed as myelodys-
plastic syndrome or unclassified hemolytic anemia.
E1011
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) SCREENING IN
PATIENTS WITH UNEXPLAINED ANEMIA: A SINGLE INSTITUTION
EXPERIENCE
J England1,*, B Dalal2, H Leitch3
1Internal Medicine, University of British Columbia, 2Division of Laboratory
Hematology, Vancouver General Hospital, 3Hematology, St. Paul’s Hospital,
Vancouver, Canada
Background: Referral to hematology for work up and management of anemia
is common. Paroxysmal nocturnal hematoglobinuria (PNH) is a clonal disorder
in which cells deficient in glycosylphosphatidyl inositol (GPI) anchor are lysed
by complement. PNH can present with direct antiglobulin test (DAT) negative
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hemolysis, thrombosis, unexplained cytopenias, and iron deficiency secondary
to ongoing hemolysis. Evaluation for PNH clones is recommended for patients
with DAT negative hemolysis or cytopenias that remain unexplained after thor-
ough work up. PNH screening is important to identify patients who could benefit
from eculizumab therapy, which improves quality of life and overall survival
while reducing hemolysis, transfusion requirement, and thrombosis. 
Aims: This study sought to evaluate how frequently patients with unexplained
anemia were being screened for PNH. 
Methods: The study looked at patients with unexplained anemia referred to
hematology at St. Paul’s Hospital between 2010 and 2015. Demographic infor-
mation, clinical features (including history of arterial/venous blood clots and
history of red blood cell [RBC] transfusion), and list of key investigations such
as bone marrow biopsy (BMBx) were collected for each patient. Baseline lab-
oratory data relevant to hemolysis were obtained including lactate dehydroge-
nase (LDH), bilirubin, reticulocyte count, haptoglobin, and DAT testing. Flow
cytometry for expression of FLAER, CD24, CD14, and CD59 on neutrophils,
monocytes, and RBC was used as high resolution testing of PNH.
Results: A total of 540 patients were included in the study. The study group
was comprised of those with anemia not yet diagnosed (NYD, n=318, including
9 with DAT negative hemolysis and 92 with unexplained iron deficiency despite
endoscopic gastrointestinal investigation), pancytopenia NYD (n=49), and ane-
mia of chronic disease (n=173). Of these patients 112 (20.7%) underwent BMBx,
48 (8.9%) had a history of RBC transfusion, and 24 (4.4%) had prior thrombosis.
For hemolysis investigations, 445 (82.4%) patients had testing done for LDH,
459 (85.0%) for total bilirubin, 425 (78.7%) had reticulocyte counts, and 219
(40.6%) patients had haptoglobin levels done. A total of 131 (24.2%) patients
had a suggestion of possible hemolysis based on these measurements. PNH
testing was done in 56 (10.4%) patients, corresponding to 12.3% of anemia
NYD, 44% of DAT-negative hemolysis, 21.7% of unexplained iron deficiency,
20.4% of pancytopenia NYD, and 4.0% of anemia of chronic disease. One
patient with anemia NYD had a positive PNH screen with a small (0.017%)
detectable clone of uncertain significance. Compared to those who did not
undergo PNH testing, those who were screened for PNH were more likely to
have a history of thrombosis (16.1% vs 3.1%, p=0.0003), underwent BMBx
(44.6% vs 18.0%, p=0.0001), received RBC transfusions (21.4% vs 7.4%,
p=0.0018),and to have elevated reticulocytes (26.8% vs 7.6%, p=0.0001), LDH
(25.0% vs 12.2%, p=0.0126), and low haptoglobin (21.4% vs 2.9%, p=0.0001).
Summary/Conclusions: Anemia is a common referral to hematology, but initial
investigations may not uncover a cause. Although hemolytic parameters are
evaluated in most patients with unexplained anemia, PNH is tested for only in
a minority of cases (10.4%) despite potential indicators of hemolysis in 24.2%
of those with unexplained anemia. As effective therapy for PNH is now avail-
able, increased screening could identify patients who would benefit from treat-
ment and should be considered.
E1012
EFFICACY AND SAFETY OF DEFIBROTIDE FOR TREATMENT OF HEPATIC
VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) IN ADULT AND PEDIATRIC PATIENTS FOLLOWING
CHEMOTHERAPY
N Kernan1, P Richardson2,*, A Smith3, B Triplett4, S Grupp5, J Antin6,
L Lehmann7, Y Messinger8, W Liang9, R Hume9, A Hannah9, R Soiffer6
1Pediatric BMT Service, Memorial Sloan Kettering Cancer Center, New York,
2Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy,
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Med-
ical School, Boston, 3Division of Pediatric Blood and Marrow Transplantation,
University of Minnesota, Minneapolis, 4Bone Marrow Transplantation and Cel-
lular Therapy, St. Jude Children’s Research Hospital, Memphis, 5Pediatric
Oncology, The Children’s Hospital of Philadelphia, Philadelphia, 6Stem
Cell/Bone Marrow Transplantation Program, Division of Hematologic Malig-
nancy, Department of Medical Oncology, Dana-Farber Cancer Institute, 7Center
for Stem Cell Transplantation, Division of Hematologic Malignancy, Department
of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School,
Boston, 8Cancer and Blood Disorders Program, Children’s Minnesota, Min-
nesota, 9Jazz Pharmaceuticals, Palo Alto, United States
Background: Veno-occlusive disease/sinusoidal obstruction syndrome
(VOD/SOS) is typically thought of as an unpredictable and potentially life-threat-
ening complication of hematopoietic stem cell transplantation (HSCT) conditioning,
but also may occur following primary chemotherapy (CT) without HSCT. Severe
hepatic VOD/SOS (associated with multi-organ dysfunction [MOD]) may be asso-
ciated with >80% mortality. Endothelial cell (EC) damage is a critical pathophysi-
ologic factor; preclinical data suggest that defibrotide (DF) stabilizes ECs with
direct, as well as EC-mediated, restoration of the thrombo-fibrinolytic balance. DF
is approved in the European Union for treatment of severe hepatic VOD/SOS in
adult and pediatric patients post-HSCT. In the United States (US), a new drug
application was accepted for priority review in 2015. DF has been available in the
US on an investigational basis via a treatment protocol (T-IND) study.
Aims: To assess the efficacy of DF for treatment of VOD/SOS in pediatric and
adult subgroups following primary CT with MOD or without MOD (off-label),
from the T-IND program.
Methods: Eligibility for the T-IND program initially required VOD/SOS diag-
nosed by Baltimore criteria, with MOD, following HSCT. The protocol was
amended to include patients with VOD/SOS without MOD, following CT, or as
diagnosed by modified Seattle criteria (using a 5% weight gain threshold). All
patients provided informed consent and received open-label defibrotide as a
2-hour intravenous infusion at 6.25 mg/kg every 6 hours (25 mg/kg/day) for a
recommended ≥21 days. Survival at Day+100 following CT was measured
using Kaplan-Meier (KM) estimates.
Results: Among 857 T-IND patients with VOD/SOS who received ≥1 dose of
DF as of April 18, 2015, 101 (11.8%) had undergone primary CT (without
HSCT), of whom 54.5% were male, 66.3% were white, and median (range)
age was 7.0 (0, 69.0) years. This group included 81 (80.2%) pediatric patients
(aged ≤16 years; 59 [72.8%] aged 2–11 years) and 19 (18.8%) adults (aged
>16 years) (age not available for 1 patient); 48 (47.5%) patients had MOD (40
[49.4%] pediatric patients and 8 [42.1%] adults), and 52 (51.5%) did not have
MOD (41 [50.6%] pediatric patients and 11 [57.9%] adults). For all patients
and for the subset without MOD, the most commonly used chemotherapy
agents included vincristine, cytarabine, and cyclophosphamide. KM-estimated
Day+100 survival is reported in the Table. Overall, 62 (61.4%) patients reported
≥1 adverse event (AE), including 22 (21.8%) with AEs judged at least possibly
related to DF, most commonly (≥3.0%) hypotension (4.0%) and nausea (3.0%).
Two deaths (pleural hemorrhage and pulmonary hemorrhage plus hypotension)
were possibly related to DF.
Table 1.
Summary/Conclusions: KM-estimated survival rates at Day+100 post-CT for
patients treated with DF were 81% in pediatric patients and 63% in adults,
which were clinically encouraging findings. As has been observed in post-
HSCT patients, pediatric patients may have higher survival rates than adults
post-CT. DF was generally well tolerated in this study and had a safety profile
consistent with previous studies. Support: Jazz Pharmaceuticals
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ALXN1210, A LONG-ACTING C5 INHIBITOR, RESULTS IN RAPID AND
SUSTAINED REDUCTION OF LDH WITH A MONTHLY DOSING INTERVAL
IN PATIENTS WITH PNH: PRELIMINARY DATA FROM A DOSE-ESCALATION
STUDY
JW Lee1,*, E Bachman2, R Aguzzi2, JH Jang3, JS Kim4, ST Rottinghaus2,
L Shafner2, J Szer5
1The Catholic University of Korea, Seoul, Korea, Republic Of, 2Alexion Phar-
maceuticals, Inc., New Haven, CT, United States, 3Samsung Medical Center,
4Yonsei University College of Medicine, Seoul, Korea, Republic Of, 5Royal
Melbourne Hospital, Melbourne, Australia
Background: ALXN1210, a rationally designed humanized monoclonal anti-
body to C5, was engineered for an extended duration of complement inhibition.
A previous study in healthy volunteers showed immediate, complete, and sus-
tained inhibition of C5. The half-life (t½) of ALXN1210 was >30 days-substantially
longer than eculizumab-which facilitates an extended dosing interval of ≥1mo.
Aims: ALXN1210-PNH-103 is a Phase 1b, multicenter, open-label, intrapatient
dose-escalation study (NCT02598583), evaluating the safety, tolerability, and
efficacy of 2 IV maintenance dosing regimens of ALXN1210 in patients (pts)
with paroxysmal nocturnal hemoglobinuria (PNH) never treated with a com-
plement inhibitor.
Methods: In this interim analysis, 2 cohorts of pts ≥18 y were investigated: pts
in Cohort 1 (C1) received either 400- or 600-mg induction doses followed by a
900-mg maintenance dose q4w; pts in Cohort 2 (C2) received 600- and 900-
mg induction doses, followed by an 1800-mg maintenance dose q4w. The pri-
mary objective was to assess safety and tolerability of ALXN1210. The primary
efficacy outcome was change in lactate dehydrogenase (LDH) level. Other
endpoints included change in blood transfusions and in hematologic parame-
ters related to PNH.
Results: A total of 13 pts consented and enrolled (Table). Median duration of
exposure was 3.7 mo for C1 (n=6) and 1.8 mo for C2 (n=7). All pts showed
rapid reductions in LDH levels, which were observed at the first evaluable time
point (day 8). Decreases in LDH were sustained over 4-mo dose intervals, as
shown by mean reductions from baseline in LDH of 85.6% in C1 on day 113
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and 83.8% in C2 on day 57, the latest evaluable time points (Figure). Among 5
pts with ≥1 transfusion in the year before treatment (2 in C1, 3 in C2), only 1
patient (in C1, who had received 12 units of packed red blood cells in the prior
6 mo) received a transfusion (2 units) while on ALXN1210. Multiple doses of
ALXN1210 resulted in no serious adverse events (SAEs), no infusion site reac-
tions, and no drug discontinuations or AEs leading to withdrawals. The most
common treatment-emergent AE (TEAE) was headache (2 pts). Investigators
judged 69% of TEAEs to be unrelated to treatment. All related AEs resolved
with ongoing ALXN1210 treatment.
Table 1. Baseline demographics and disease characteristics.
Figure 1. Mean (SD) LDH values over time, by cohort.
Summary/Conclusions: ALXN1210-PNH-103 is the first study to demonstrate
safety and efficacy of ALXN1210 in pts with PNH. ALXN1210 treatment resulted
in rapid reductions in LDH levels in 100% of pts, which were sustained through
2-4 monthly dosing intervals, consistent with the extended t½ of ALXN1210.
There was a notable decrease in the need for blood transfusions. These pre-
liminary LDH data suggest that rapid, complete, and sustained complement
inhibition with ALXN1210 results in highly effective blockade of intravascular
hemolysis. A Phase 2 study examining monthly and longer dosing intervals of
ALXN1210 is ongoing.
LB2248
12 WEEKS SAFETY AND EFFICACY RESULTS OF A NOVEL C5 INHIBITOR
COVERSIN IN PNH WITH RESISTANCE TO ECULIZUMAB DUE TO
COMPLEMENT C5 POLYMORPHISM
S Langemeijer1,*, W Weston Davies2, M Nunn2, JI Nishimura3, Y Kanakura3,
N Blijlevens1, M Nijziel1, P Muus1
1Radboud University Medical Center, Nijmegen, Netherlands, 2Akari Thera-
peutics Plc, London, United Kingdom, 3Osaka University Graduate School of
Medicine, Osaka, Japan
Background: Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare acquired
life-threatening disease characterized by complement induced haemolysis and
its sequelae and a high incidence of thrombosis. The monoclonal antibody
eculizumab binds to C5 and prevents its activation and cleavage into C5a and
C5b and is an established treatment for PNH and aHUS. However, for patients
with the rare amino acid polymorphism p.Arg885His or pArg885Ser, which inter-
feres with the binding and efficacy of eculizumab (Nishimura et al, 2014, Lange-
meijer et al, 2015), there is still no effective treatment. A new small protein com-
plement inhibitor named Coversin is in Phase 1-2 clinical development. Cover-
sin also prevents cleavage and activation of C5 but binds to C5 at different site
than eculizumab. In vitro Coversin inhibits C5 activation in both wild type C5
and C5 with a polymorphism at the Eculizumab binding site. Coversin studies
in healthy volunteers proved safe and demonstrated inhibition of terminal com-
plement activation.
Aims: We report pharmacokinetics (PK), pharmacodynamics (PD), safety and
preliminary efficacy data of the novel C5 inhibitor Coversin in a severely
haemolytic PNH patient with a C5 polymorphism. 
Methods: Coversin was administered by s.c. injection at an ablating dose of
0.57 mg/kg on day 1, followed by a maintenance dose of 0.14 mg/kg per day
thereafter. Peripheral blood samples were drawn for PK/PD. Protocol specified
doubling of the dose and /or shortening of the dose interval were allowed on
the basis of clinical symptoms and CH50 levels to achieve adequate and sus-
tained complement inhibition.
Results: The patient is a 30 year old male with PNH, (granulocyte clone size:
90%) and severe haemolysis (LDH 3 to 17 x UNL), transient renal failure,
extreme fatigue and symptoms of muscle dystonia and no history of thrombosis.
He remained severely haemolytic during eculizumab treatment despite adequate
drug levels and no antidrug antibodies. Other causes of haemolysis were exclud-
ed. The patient was shown to have a p.Arg885Ser polymorphism rendering him
resistant to eculizumab therapy. There was a good initial response to an ablating
dose of 0.57mg/kg Coversin with CH50 levels decreasing below 8 U Eq/ml,
which is the lower limit of qualification of the ELISA assay. Clinical symptoms
and laboratory markers of haemolysis improved during the maintenance treat-
ment of 0.14mg/kg every 24 hours. However, 6 days into the treatment, the
patient again experienced haemolysis-associated symptoms with dark urine
hours before the next s.c. injection and no further decrease of his LDH. The
same occurred after doubling of the dose to 0.29 mg/kg per day. Dividing the
dose into 0.14 mg/kg injections Q 12 hours resulted in stable complement inhi-
bition with CH50 levels <8 U Eq/ml and no breakthrough symptoms. The LDH
decreased to approximately 1.5xUNL. For the first time since he was diagnosed
with PNH in 2009 the patient feels well with no symptoms of fatigue and no
muscle dystonia. There have been no further haemolytic episodes. Twelve
weeks after start of treatment, our patient did not have any drug-related adverse
events, except occasional local and transient irritation at the injection site.
Summary/Conclusions: Over a period of 12 weeks Coversin has proven safe
and effective in the first PNH patient treated with the drug.
LB2249
A PHASE 1 MULTIPLE-DOSE CLINICAL STUDY OF RA101495, A
SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE
INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
JM Johnston1,*, A Ricardo1, M Arata1, J Lickliter2, SJ DeMarco1, R Fahrner1,
RP Hammer1, B Newstat1, D Roychowdhury1, S Tobe1, D Winslow1, D Treco1
1Ra Pharmaceuticals, Cambridge, United States, 2Nucleus Network, Mel-
bourne, Australia
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired,
clonal hematopoietic stem cell disorder caused by a deficiency in glycosylphos-
phatidylinositol (GPI)-linked proteins on cell surfaces. Patients with mutations
in the phosphatidylinositol glycan class A gene are unable to produce functional,
protective, GPI-linked proteins, resulting in the accumulation of specific com-
plement proteins on the surface of red blood cells (RBCs) and subsequent
RBC lysis by the membrane attack complex (MAC). Inhibition of complement
activation at the level of complement C5 is a clinically validated approach for
the treatment of PNH. RA101495, a synthetic macrocyclic peptide, binds to C5
at a unique site not targeted by currently available therapies and allosterically
inhibits C5 cleavage into C5a and C5b, preventing production of a key compo-
nent of the MAC. RA101495 also inhibits the assembly of MAC by blocking the
interaction between C5b and C6.
Aims: A Phase 1 multiple-dose clinical pharmacology study in healthy human
volunteers designed to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of RA101495 following once daily subcutaneous (SC) injec-
tions over 7 days.
Methods: The study was single-center (Australia), randomized, double-blinded,
and placebo (PBO)-controlled. After obtaining written informed consent, all sub-
jects received daily SC doses of 0.2 mg/kg RA101495 or matching PBO for 7
days while housed in a clinical pharmacology unit. Safety was assessed by
intensive clinical monitoring, and daily blood samples were obtained at -15 min-
utes, 3 hours, and 6 hours relative to each day’s dose for determination of
RA101495 concentrations by liquid chromatography/high resolution mass spec-
troscopy and ability to inhibit complement-mediated RBC lysis in an ex vivo
antibody-sensitized sheep erythrocyte hemolysis assay. All subjects received
prophylaxis for N. meningitides infection with ciprofloxacin and vaccination.
Results: A total of 6 subjects were enrolled into the study (4 RA101495 and 2
PBO). Plasma concentrations showed a steadily increasing exposure over the
7 days of dosing in the 4 RA101495-treated subjects (see Figure). From these
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data, the half-life of RA101495 appears to be 7 days. Preliminary results show
that, for the subjects with measurable plasma levels of RA101495, the mean
percent inhibition of hemolysis compared to baseline reached ≥95% beginning
at the first time point, 3 hours after dosing on Day 1, and continued throughout
the 7 days of dosing; all individual subjects showed ≥90% reduction of hemol-
ysis at all time points (Figure). The only safety finding noted was mild cutaneous
injection site erythema in 2 of the 4 RA101495-treated subjects; there was no
associated pain, tenderness, swelling, or induration and all events resolved
rapidly following dosing.
Figure 1.
Summary/Conclusions: RA101495 is a novel synthetic macrocyclic peptide
inhibitor of C5-mediated hemolysis that is being developed as an alternative to
intravenous monoclonal antibody therapy for the treatment of PNH. RA101495,
currently being investigated for daily at-home SC self-administration, shows a
rapid onset of activity, and appears to be safe and well tolerated. These pre-
liminary data suggest low daily doses will achieve steady-state levels suitable
for complete and sustained inhibition of complement and suppression of hemol-
ysis, and, given the long half-life, that once-weekly dosing is possible.
LB2250
AN ORALLY ADMINISTERED SMALL MOLECULE FACTOR D INHIBITOR
(ACH-4471) FOR TREATMENT OF PNH AND COMPLEMENT DISEASES:
PRELIMINARY PHASE 1 RESULTS IN HEALTHY VOLUNTEERS
RB Ellis-Pegler1,*, C Schwabe1, I Ajari2, H Robison2, R Sorensen2, J Lahey2,
W Yang2, M Huang2, J Hui2, H Kocinsky2, M Geffner2, D Apelian2
1Auckland Clinical Studies Ltd, Aukland, New Zealand, 2Achillion Pharmaceu-
ticals, Inc, New Haven, United States
Background: ACH-4471 is a novel, small molecule complement factor D (fD)
inhibitor; to our knowledge, this represents the first clinical data reported for an
oral inhibitor of this target. ACH-4471 prevents cleavage of complement factor
B into Ba and Bb in the alternative pathway of the complement cascade, leading
to blockade of C3 convertase production. Hence, unlike C5 inhibitors, ACH-
4471 also prevents C3 fragment deposition on PNH cells and may confer a
pharmacological advantage by protecting PNH cells from both intravascular
and extravascular hemolysis.
Aims: To assess the safety and tolerability of single ascending oral doses of
ACH-4471 in healthy volunteers and to evaluate its pharmacokinetic (PK) and
pharmacodynamic (PD) profile and PK/PD relationship as measured by the
serum AP activity ex vivo.
Methods: In this Phase 1a study, ACH-4471 was given as a single oral dose
to healthy volunteers. Dose group 1 enrolled 6 active and 6 placebo subjects,
while subsequent groups enrolled 6 active and 2 placebo subjects each. Each
group was studied for 28 days after dosing. Active treatment subjects in the
first 2 groups received 200 and 600mg ACH-4471 QD, respectively. Inhibition
of serum AP activity was evaluated using the AP Wieslab assay, which tests
ACH-4471 under stringent conditions in the presence of bacterial endotoxin
(LPS), a potent AP activator. To date, 20 subjects (Groups 1 and 2) have been
dosed and evaluated (19 males, 1 female) with a median age of 23.9 years
(range 21.0 - 54.2). For both groups, all subjects were followed for AEs/SAEs
through the last scheduled visit at Day 28. Blood samples were collected at
predefined time points from Days 1 to 4 to determine plasma concentrations
of ACH-4471.
Results: There have been no drug-related SAEs, TEAEs leading to study dis-
continuation, or study-drug related Grade 3/4 TEAEs. PK data indicate that
peak plasma concentrations (Cmax) are achieved by 1 to 2.5 hours after a
single 200- or 600-mg dose, with the majority of exposure (measured as AUC)
occurring over the first 24 hours. The terminal phase begins 16 hours after
dosing and the mean terminal half-life is approximately 9 hours. PD data from
the ex vivo evaluation of serum AP activity indicate rapid and nearly complete
inhibition of AP activity after single 200- or 600-mg doses. Mean plasma con-
centrations of ACH-4471 necessary to achieve >80% or >90% AP inhibition
were approximately 180 and 230ng/mL, respectively. Simulations indicate that
these steady-state Ctrough levels could be maintained by twice daily (BID) dos-
ing with the current capsule formulation; ongoing formulation development
efforts may allow for once daily dosing. Plasma Bb concentration, an in vivo
biomarker for the inhibition of fD activity by ACH-4471, decreased dose-depen-
dently with a nadir 9 hours after dosing and a gradual recovery to original levels
by 48 hours. Taken together, these results indicate that administration of ACH-
4471 results in potent inhibition of AP activity.
Summary/Conclusions: ACH-4471 was well-tolerated at the single dose lev-
els examined to date with no safety trends. PD results indicate that ACH-4471
potently inhibits AP activity. PK modeling predicts that the current formulation
of ACH-4471 will provide sustained suppression of AP activity with BID dosing,
and future formulations may be effective with QD dosing. A
14-day multiple ascending dose study of ACH-4471 is planned to start in
2Q2016.
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THE PI3K DELTA SELECTIVE INHIBITOR, IDELALISIB, MODULATES
CYTOKINE PRODUCTION IN INNATE IMMUNE CELLS STIMULATED
THROUGH TOLL-LIKE RECEPTORS
L Grosmaire, A Yahiaoui, S Tannheimer*
Gilead Sciences, Inc., Foster City, United States
Background: Idelalisib (IDELA) is an oral, selective PI3Kd inhibitor approved
for the treatment of relapsed chronic lymphocytic leukemia (CLL). A subset of
patients develop severe diarrhea/colitis which requires interruption of IDELA
therapy and in some instances, corticosteroid treatment (Coutre et al., Leuk
Lymphoma, 2015). Toll-like receptors (TLR) play a critical role in innate immunity
by detecting pathogen associated molecular patterns (PAMPs). Responses to
signaling through TLR drive not only an immediate innate cell response to
pathogens, but also enable cells of the innate immune system to shape an adap-
tive immune response. PI3Kd has been shown to modulate signal transduction
through TLR4 and TLR1/2 in murine bone marrow derived dendritic cells (Aksoy
et al., Nat Imm, 2012). Additionally, PI3Kd has been shown to modulate TLR2,
TLR4, TLR5, and TLR9 signaling in murine bone marrow derived macrophages
(Plevy et al., Gastroenterology, 2010). Mice with a targeted inactivating mutation
in the p110d subunit of PI3Kd spontaneously develop colitis at 8 weeks of age,
and bone marrow macrophages from these mice secreted significantly more
inflammatory cytokines (Plevy et al., Gastroenterology, 2010).
Aims: Evaluate the effects of clinically relevant concentrations of IDELA on
TLR signaling in human monocyte derived macrophages (MDMs) as a potential
mechanism contributing to clinically observed adverse events.
Methods: We utilized MDMs skewed to either a M1 or M2 phenotype by culture
for six days in GM-CSF or M-CSF, respectively. MDMs stimulated with a TLR1/2
(PAM3CSK4), TLR4 (LPS), or TLR5 (flagellin) agonist in the presence of clini-
cally relevant concentrations of IDELA were examined for cytokine production
at early and late time points (MesoScale Discovery). Additionally, nCounter
Human Inflammation Kit V2 (NanoString) was used to assess the effects on
gene expression and Peggy Sue (Protein Simple) was used to analyze changes
in protein expression on MDMs. 
Results: Cytokine analysis revealed that both MDM1 and MDM2 cells produced
inflammatory IL-12p40 when stimulated with TLR agonists. However, IL-12p40
production by MDM2 cells when stimulated with TLR1/2, TLR4 or TLR5 agonists
was significantly increased in the presence of IDELA (Fig. 1A). Inflammatory
cytokine upregulation was not seen in MDM1 cells. MDM2 cells produced
immunosuppressive IL-10 in response to TLR1/2, TLR4 or TLR5 agonist stim-
ulation. The IL-10 production was inhibited in the presence of IDELA (Fig. 1B).
MDM1 cells produced little to no IL-10 in this context. IDELA exerted a differ-
ential effect on gene expression in MDM2 versus MDM1 cells. CXCR2 ligands
were upregulated in MDM2 cells in the presence of IDELA plus TLR agonists
to a much greater extent than MDM1 cells, while the anti-inflammatory IL-1RA
was downregulated.
Figure 1.
Summary/Conclusions: The immunological challenge of the mucosal envi-
ronment of the intestine is maintaining a balance between a tolerogenic state
with the commensal microbiota and an ability to aggressively respond to poten-
tial pathogens. Under normal conditions, TLR signaling by enteric bacteria is
protective (Rakoff-Nahoum et al., Cell, 2004). Here we show that IDELA mod-
ulates TLR signaling in MDMs, resulting in MDM2 cells producing higher
amounts of inflammatory cytokines, and less immunosuppressive IL-10. This
dysregulation of the tolerogenic cytokine balance and subsequent perturbations
of the innate/adaptive immune system is consistent with proinflammatory
cytokine imbalance which may result in colitis in PI3Kd deficient animal models. 
E1014
MUTATIONS IN SF3B1 GENE ARE SELECTED INDEPENDENTLY ON
ATM/TP53 STATUS AND REDUCE THE TIME TO FIRST TREATMENT IN
CLL PATIENTS
M Hlozkova*, J Figulova, V Navrkalova, J Malcikova, J Smardova, N Tom,
Y Brychtova, M Doubek, J Mayer, S Pospisilova, M Trbusek
University Hospital Brno and Faculty of Medicine, Masaryk University, Brno,
Brno, Czech Republic
Background: Significant proportion of chronic lymphocytic leukemia (CLL)
patients manifests abnormalities in the DNA damage response pathway (DDR)
through defects in TP53 or ATM gene. Interestingly, recurrent mutations in splic-
ing factor 3 subunit b1 (SF3B1) have also been shown to partially impair DDR
in CLL patients. Whilst ATM dysfunction seems to typically occur early in CLL
pathogenesis, mutations in TP53 and SF3B1 have been reported to be mostly
subclonal events originating later during the disease course.
Aims: (a) to assess whether SF3B1 mutations’ occurrence associates with
adverse genetic lesions in TP53 and ATM genes, (b) to determine the impact
of all three types of defects on time to first treatment (TTFT) and overall survival
(OS), and (c) to analyze changes in ATM and SF3B1 mutation status during
the disease course.
Methods: We used the yeast functional analysis FASAY coupled to Sanger
sequencing for the identification of TP53 mutations (analyzing thus exons 4-
10), the next generation sequencing (NGS) on MiSeq instrument (Illumina) for
the whole ATM gene screening (62 coding exons with splicing sites), and direct
Sanger sequencing for the analysis of mutational hot-spot exons 14-16 in
SF3B1 gene. The median coverage in the NGS analysis was ~4000 reads,
and we set up a uniform sensitivity of 10% for all three methodologies.
Results: We analyzed unfavorable cohort of 205 patients consisting predom-
inantly (86%) of IGHV unmutated patients, with 64% of the patients being treat-
ment-naïve. The TP53 dysfunction was identified in 53/205 patients (26%),
while both ATM and SF3B1 mutations occurred in 49/205 cases (24%). In line
with the expectations, we observed the frequent co-occurrence of ATM muta-
tions with del(11q) (P˂0.001), and the strong mutual exclusivity of ATM and
TP53 mutations (co-occurring in only one patient). By contrast, there was no
significant association or mutual exclusivity between SF3B1 mutations´ pres-
ence and ATM or TP53 mutational status, neither among untreated patients
nor in the whole cohort. For the TTFT and OS analyses, we firstly employed a
hierarchical classification of TP53 and ATM mutations and did not consider
SF3B1 mutational status; in addition, we limited this analysis to only IGHV
unmutated patients. Compared to TP53-wt/ATM-wt patients having median of
18 months (m), the TTFT was apparently reduced in both TP53-mutated (6 m;
P=0.002) and ATM-mutated patients (7 m). However, the latter group exhibited
heterogeneous impact of mutations leading to only non-significant TTFT reduc-
tion (P=0.130). The OS analysis then showed a prominent (P˂0.001) negative
impact of TP53 mutations (38 m) and a borderline significance of ATM mutations
(67 m; P=0.058) compared to wt patients (90 m). As a sub-analysis, we
assessed the effect of single SF3B1 mutations: these led to reduced TTFT (11
m; P=0.029 compared to 18 m in wt patients), while did not show an impact on
OS. The analysis of ATM and SF3B1 throughout the disease course involving
at least one relapse then disclosed that (a) 27/28 repeatedly analyzed ATM
mutations (median time between analyses 40 m) and (b) 29/30 analyzed SF3B1
mutations (33 m) were identified in both samplings. In addition, 7 out of 72
repeatedly analyzed SF3B1-wt samples showed a new mutation in this gene. 
Summary/Conclusions: Mutations in SF3B1 occur regardless of the ATM/p53
pathway dysfunction in CLL and can be selected by therapy. Their presence
results in early therapy need but not in shorter survival. Supported by projects
no. 65269705, TA0 TE02000058 and MUNI/A/1028/2015.
E1015
BIOLOGICAL AND CLINICAL FEATURES OF IMMUNOSUPPRESSIVE
THERAPY IN PATIENTS AFFECTED BY LARGE GRANULAR LYMPHOCYTE
LEUKEMIA
A Teramo1,2,*, M Leoncin1,2, G Barilà1,2, G Calabretto1,2, C Ercolin1,2,
A Cabrelle2, E Boscaro1, S Teolato1, E Pagnin1, M Facco1,2, L Trentin1,2,
G Semenzato1,2, R Zambello1,2
1Department of Medicine, Hematology and Clinical Immunology Branch, Uni-
versity School of Medicine, 2Venetian Institute of Molecular Medicine (VIMM),
Padua, Italy
Background: Large Granular Lymphocyte Leukemia (LGLL) is a rare and het-
erogeneous lymphoproliferative disorder characterized by the chronic proliferation
of clonal Large Granular Lymphocytes (LGLs) with cytotoxic activity. Recently,
activating STAT3 mutations have been discovered in 30-40% of T-LGLL patients.
The treatment of LGLL is based on immunosuppressive drugs, such as
Methotrexate (MTX), Cyclophosphamide (CTX) and Cyclosporin A (CyA), used
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at low doses. These therapies have limited efficacy and the Overall Response
Rate (ORR) is near 50%. Furthermore, in vitro studies on the molecular effects
of these drugs on leukemic lymphocytes are not available in the literature and
the biological rational of LGLL treatment has yet not been investigated.
Aims: The aim of this study was to analyze the in vivo efficacy of treatment on
a cohort of patients referred to the Hematology Unit at Padua University. In
addition, we performed in vitro study of the molecular effect of these drugs on
pathological LGLs in order to better understand their efficacy/specificity, in par-
ticular considering their effect on STAT3 pathway.
Methods: Clinical characteristics and treatment response were collected from
17 LGLL patients. For in vitro analysis a cohort accounting 35 patients was
studied. Cell cultures of patients’ peripheral blood mononuclear cells (PBMCs)
were set up with CTX (5µM), CyA (10µM) or MTX (100µM). On collected culture
cells apoptosis by Annexin V assay and phosphorylation of STAT3 by Western
Blot were investigated.
Results: Clinical results demonstrated that ORR for each drug ranged from
35.7% to 57.1%, CTX treatment showing the higher ORR independently from
the therapy line. Fifteen out of the 17 treated patients were STAT3 mutated,
indicating a strong correlation between STAT3 mutation and symptomatic dis-
ease. Interestingly, consistent with literature data, patients carrying Y640F
STAT3 mutation showed a better ORR on MTX treatment as compared with
patients with different STAT3 mutation (66% versus 14.2%). In vitro, CTX and
CyA showed a strong increase of LGL apoptosis, leading to the complete dis-
appearance of LGL clone within 3-6 days of culture. Anyway, concerning the
specificity of the killing leukemic LGL cells, while sparing non leukemic PBMCs,
our data showed that both CTX and CyA were also partially toxic for non-LGLs
population. As regards MTX treatment, no increase of apoptosis was revealed,
but, interestingly, we observed that MTX induced apoptosis when LGL were
stimulated to proliferate by IL-15, suggesting a predominant effect on activated
cells. Considering the key role of STAT3 activation in leukemic LGL survival,
we observed a decrease of STAT3 phosphorylation levels only after CyA treat-
ment. Finally, adding autologous plasma (10%) to cell culture the cytotoxic
effect of drugs was partially reduced (~50%), suggesting that plasma might
contain cytokines preserving LGL survival.
Summary/Conclusions: In summary, CTX showed a good efficacy in vivo
and in vitro, even if in this last setting the compound did not exhibit a good LGL
specificity. MTX might be more efficient when LGLs are proliferating and when
LGLs carry activating mutations, even if it does not affect STAT3 activation.
Finally, we demonstrated that CyA expresses its cytotoxic effect through a
mechanism that down-modulates STAT3 activation. Our results contribute to
get insights into the molecular mechanisms of immunosuppressive drugs used
in LGLL treatment and suggest that STAT3 mutation/activation might represent
a suitable target for therapy.
E1016
CD49D IS A BETTER PREDICTOR OF OVERALL SURVIVAL THAN THE
NOVEL RECURRENT MUTATIONS IN CHRONIC LYMPHOCYTIC
LEUKEMIA: RESULTS FROM AN ITALIAN MULTI-CENTER COHORT
M Dal Bo1, P Bulian1, R Bomben1, A Zucchetto1, FM Rossi1, F Pozzo1, E Tissino1,
D Benedetti1, T Bittolo1, P Nanni1, I Cattarossi1, E Zaina1, H Chivilò1,
M Degan1, F Zaja2, G Pozzato3, A Chiarenza4, F Di Raimondo4,
MI Del Principe5, G Del Poeta5, D Rossi6, G Gaidano7, V Gattei1,*
1Clinical and Experimental Onco-Ematology Unit, Centro di Riferimento Onco-
logico, I.R.C.C.S., Aviano, 2Clinica Ematologica, Centro Trapianti e Terapie Cel-
lulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Miseri-
cordia, Udine, 3Department of Internal Medicine and Hematology, Maggiore
General Hospital, University of Trieste, Trieste, 4Division of Hematology, Fer-
rarotto Hospital, Catania, 5Division of Hematology, S. Eugenio Hospital and Uni-
versity of Tor Vergata, Rome, 6Division of Hematology-Department of Transla-
tional Medicine –, 7Division of Hematology-Department of Translational Medicine
–, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
Background: CD49d, the alpha-chain of VLA-4 integrin, was identified among
the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia
(CLL), along with IGHV status and the 17p deletion (Bulian et al, JCO, 2014).
In addition to TP53, the clinical relevance of mutations of NOTCH1, SF3B1
and BIRC3 recently emerged.
Aims: To test the clinical relevance of CD49d in subgroups defined by
NOTCH1, SF3B1, BIRC3 alterations.
Methods: The cohort was of 778 unselected CLL (treated cases, n=356, median
follow-up 80 months with 173 deaths), all characterized for CD49d expression
(CD49dhigh, ≥30% positive cells by flow cytometry, n=229), IGHV status (unmu-
tated, UM, n=262), karyotype abnormalities (5% cut-off, 13q-, n=308; +12,
n=103; 11q-, n=64), at diagnosis, along with TP53 mutations/deletions (here-
inafter, disruption, n=84, including 58 17p-), NOTCH1 mutations (n=81), SF3B1
mutations (n=54), BIRC3 disruption (n=59). Recurrent mutations were investi-
gated by Sanger sequencing before therapy (at diagnosis in 65% of cases).
Results: i) CD49dhigh associated with age ≥65 years (p=0.0001), Rai stage ≥I
(p<0.0001), UM IGHV status (p>0.0001), absence of 13q- (p=0.0001), pres-
ence of +12 (p<0.0001), NOTCH1 mutations (p<0.0001). ii) By univariate analy-
sis, CD49dhigh had impact as OS predictor (hazard ratio/confidence interval,
HR/CI=2.62/1.94-3.54; p<0.0001). In multivariate analysis, CD49dhigh was con-
firmed as independent prognosticator (HR/CI=1.88/1.36-2.60, p<0.0001), along
with age≥65 years (HR/CI=3.90/2.68-5.67), Rai stage ≥I (HR/CI=1.80/1.30-
2.51, p=0.0005), UM IGHV (HR/CI=1.84/1.31-2.60, p=0.0005), 11q-
(HR/CI=2.21/1.39-3.51, p=0.0008), TP53 disruption (HR/CI=3.65/2.15-5.30,
p<0.0001), NOTCH1 mutations (HR/CI=1.79/1.17-2.73, p=0.0068). Conversely,
+12, SF3B1 mutations, BIRC3 disruption were all excluded from the final model.
iii) The variable importance (VIMP) of biological markers as OS predictors was
evaluated by a random forests approach. CD49d (VIMP=0.0410) was ranked
among the most important OS predictors, followed by IGHV status
(VIMP=0.0388), TP53 disruption (VIMP=0.0352) and NOTCH1 mutations
(VIMP=0.0168); conversely, SF3B1 mutations (VIMP=0.0002) and BIRC3 dis-
ruption (VIMP=-0.0024) had no importance as OS predictors. iv) Post-treatment
survival was evaluated to explore the impact of prognosticators as therapy
response predictors. CD49dhigh, UM IGHV, TP53 disruption but not NOTCH1
mutations were able to split cases into groups with significant different treatment
responses (see Figure). This observation was confirmed by multivariate analy-
sis where CD49dhigh (HR/CI=1.55/1.08-2.23, p=0.0192), UM IGHV
(HR/CI=1.70/1.17-2.49, p=0.0060), TP53 disruption (HR/CI=2.67/1.79-4.00,
p<0.0001) were maintained and NOTCH1 mutations were excluded. iv) In Rai
stage 0 cases (n=389), CD49dhigh had impact as Time-to-First-Treatment pre-
dictor (HR/CI, 2.68/1.78-4.05, p<0.0001) by univariate analysis. In multivariate
analysis, CD49dhigh again emerged as independent prognosticator
(HR/CI=1.61/1.01-2.56, p=0.0442), along with UM IGHV (HR=2.66/1.72-4.12,
p<0.0001), +12 (HR/CI=3.36/2.00-5.62, p<0.0001), TP53 disruption
(HR/CI=1.97/1.03-3.78, p=0.0419), BIRC3 disruption (HR/CI=2.70/1.24-5.89,
p=0.0127), whereas age, NOTCH1 mutations, 13q-, 11q-, were excluded.
Figure 1.
Summary/Conclusions: CD49d, along with IGHV status, is the most powerful
independent negative OS prognosticator in CLL also when NOTCH1, SF3B1,
BIRC3 alterations were evaluated. CD49d, IGHV status and TP53 disruption
may also have a role as therapy response predictors.
E1017
COMBINED SYK AND JAK INHIBITION BY CERDULATINIB INDUCES
APOPTOSIS IN CLL AND OVERCOMES RESISTANCE TO IBRUTINIB
A Guo1, P Lu1, G Coffey2, P Conley2, A Pandey2, L Wang1,*
1University of Chicago, Chicago, 2Portola Pharmaceuticals, S. San Francisco,
United States
Background: Despite recent advances in the treatment of chronic lymphocytic
leukemia, robust and durable complete responses enabling extended periods
of time off-therapy are not achieved. One possible reason for this may be
explained pre-clinically; agents like ibrutinib and idelalisib induce cell cycle
arrest, but not apoptosis, in CLL cells treated in vitro. Consistently, when cells
from ibrutinib-treated patients are analyzed, no significant apoptosis is seen
even after 3 months of therapy. CLL tumor cells receive growth and survival
signals from not only the BCR, but also a variety of cytokine receptors which
primarily utilize Janus kinases (JAK) to initiate the signaling cascade, culmi-
nating in the upregulation of BCL2 family members and preventing apoptosis.
We have therefore been exploring the utility of combining BCR pathway sup-
pression via SYK with JAK/STAT pathway suppression using a novel small
molecule inhibitor, cerdulatinib. Cerdulatinib is a selective and potent inhibitor
of SYK, JAK1, JAK3, and TYK2, currently in a phase I dose escalation study
in patients with B cell malignancies.
Aims: The aim of these studies was to determine the anti-tumor activity of cer-
dulatinib in primary CLL co-cultures as well as molecular correlates of response. 
Methods: Using a repository of previously-banked viable CLL primary tumors
(n=60), we evaluated cell death in the presence of cerdulatinib on stromal cell
supported CLL cultures. Viability assays were performed by evaluating PARP
cleavage and propidium iodide uptake. Western blotting or FACS analysis was
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used to determine cerdulatinib-impact on survival signaling networks and BCL2
family expression.
Results: In general, tumor specimens were sensitive to cerdulatinib, especially
in cases with poor prognosis (e.g. mutation status, ZAP70 expression, cytoge-
netics). Importantly, sensitive tumor cells actually underwent apoptosis, which
was not observed in direct comparisons with ibrutinib. The mechanism of apop-
tosis induction was demonstrated by western blotting to be cerdulatinib-induced
down-regulation of MCL-1, which was associated with induction of tumor PARP
cleavage. Apoptosis was induced by this agent irrespective of co-culture with
known survival factors, including different stromal cell lines, or media supple-
mentation with IL4, CD40 ligand, anti-IgM, or a combination of the three. Cer-
dulatinib anti-tumor activity significantly correlated with inhibition of pAKT S473
and pERK T202/Y204 within the tumor cells, and was associated with
decreased BCR, JAK/STAT, and NF-kB pathway activation. Moreover, primary
CLL samples resistant to ibrutinib remained sensitive to cerdulatinib. 
Summary/Conclusions: The data suggest an alternate mechanism by which
apoptosis may be induced in CLL, and provide a justification to continue clinical
studies with cerdulatinb in this disease. Cerdulatinib has the potential to deliver
a higher rate of complete responses in CLL, as well as provide another thera-
peutic option for patients who either did not respond to or relapsed on ibrutinib. 
E1018
DNA REPLICATION CONTROL MECHANISMS INVOLVED IN
CHEMORESISTANCE OF CHRONIC LYMPHOCYTIC LEUKEMIA
G Srdana1,2,*, P Montilla-Perez1,2, A Bradbury3, L Berquet1, L Yseabert1,2,4,
G Laurent1,4, A Quillet-Mary1,2, JS Hoffmann1,2
1UMR 1037 INSERM Université Paul Sabatier ERL 5294 CNRS, Cancer
Research Center of Toulouse, 2Laboratory of Excellence Toulouse Cancer
LABEX TOUCAN, Toulouse, France, 3Newcastle University, Newcastle, United
Kingdom, 4Departement of Hematology, Institute Universitaire du Cancer,
Toulouse, France
Background: Chronic lymphocytic leukemia (CLL), the most common leukemia
in the Western hemisphere, is characterized by clonal expansion of B lympho-
cytes co-expressing CD5 and CD19 that arise from the lymph nodes and accu-
mulate in patient’s peripheral blood and bone marrow. Historically, standard
first line treatment of CLL patients has been based on a DNA targeting agent,
cyclophosphamide, nucleoside analogue, fludarabine and an anti-CD20 anti-
body, rituximab. Although the chemotherapeutic regime results in high rate of
complete response, majority of CLL patients, nevertheless, relapse.
Aims: CLL genomes are characterized by, both, chromosome aberrations affect-
ing the karyotypic integrity and elevated frequencies of nucleotide point mutations.
Altered DNA replication, repair and recombination (3R) mechanisms may account
for chromosomal instability and mutator phenotype that propels the development
of chemoresistance towards genotoxic therapies. Here, we aimed to determine
the expression of 3R genes and decipher their functional role in CLL.
Methods: For this purpose we assessed complete 3R gene expression profiles
in 140 peripheral blood (PB) samples obtained from clinically annotated CLL
patients and correlated the obtained data with patients’ clinical outcomes. Next,
in order to investigate the DNA replisome of the cycling CLL cells, we used an
in vitro approach based on interleukin-2 (IL-2) and CpG-oligonucleotide stimu-
lation to obtain proliferative primary patient leukemic cells. To determine the
chemotherapeutic implication of the 3R gene of interest (GOI), we performed
drug sensitivity screens in presence of fludarabine on two CLL cell lines estab-
lished successively from the same patient that differed in the expression of the
3R GOI. Also, we used a mouse embryonic fibroblast (MEF) cell line and its
heterozygous and homozygous knock-outs for the 3R GOI to confirm the
obtained results. We characterized chemoresistance profiles using cellular via-
bility screens, cell cycle and DNA synthesis analysis. In order to decipher the
molecular basis of chemoresistance driven by our 3R GOI, we used drugs that
partially recapitulate the mechanism of action (MOA) of fludarabine, namely,
hydroxyurea (HU), an inhibitor of the ribonucleotide reductase (RNR) and
aphidicolin, an inhibitor of replicative DNA polymerases.
Results: Our qRT-PCR data revealed deregulated expression of several 3R
genes among which, alternative DNA polymerase nu (POLN). Interestingly, we
observed that relatively high expression of POLN correlates with a shorter pro-
gression free survival (PFS) in patients that received the chemotherapeutic
treatment. In addition, in vitro proliferation assays showed that primary CLL
lymphocytes that were stimulated to enter the cell cycle and divide, exclusively
upregulated POLN. Drug screens in two independent cellular models showed
that upregulation of POLN contributed to fludarabine chemoresistance in terms
of cellular viability and sustained DNA synthesis. Our chemoresistance data
demonstrated that, unlike POLN knock-out cells, POLN expressing cells are
able to continue synthesizing DNA in presence of fludarabine. These results
support observed clinical correlation between POLN expression and PFS. In
terms of the molecular mechanism of POLN driven chemoresistance, differential
DNA synthesis profiles obtained in presence of fludarabine were recapitulated
when cells were treated with hydroxyurea but not aphidicolin.
Summary/Conclusions: Finally, our data reveal deregulated expression of 3R
genes in CLL, among which that of a specialized DNA polymerase nu (POLN).
We show that POLN overexpression correlates with worse clinical outcome in
CLL patients upon receiving therapy. Moreover, our in vitro results clearly show
that upregulation of POLN observed in cycling CLL cells can drive fludarabine
chemoresistance. In conclusion, we propose that, on the molecular level, POLN
contributes to chemoresistance by sustaining the DNA synthesis and preserving
cellular viability in presence of a low dNTP pool imposed by fludarabine.
E1019
ARSENICTRIOXIDE REGULATES CHRONIC LYMPHOCYTIC LEUKEMIA
PROLIFERATION BY TARGETING XPO1/SURVIVIN PATHWAY SIGNALLING
XH Zhang1,*, R Feng2, JM Zhang1, SM Yang1, Q Jiang1, H Jiang1, J Lu1,
YZ Qin1, LP Xu1, KY Liu1, XJ Huang1
1Peking University Institute of Hematology, Peking University People’s Hospital,
2Departments of Hematology, Beijing Hospital, Beijing, China
Background: Chronic lymphocytic leukaemia(CLL) is characterized by the pro-
gressive accumulation of clonal mature B-cells in the blood, bone marrow, and
lymphoid organs and by a highly variable clinical course. Elevated expression
of exportin 1 (XPO1/CRM1) has been reported in CLL and correlated with a
poor prognosis and resistance to therapy. Inhibition of XPO1 can result in CLL
cell death in vitro and increased survival in a CLL mouse model. The efficacy of
XPO1 inhibitor for the treatment of diffuse malignant peritoneal mesothelioma
may rely on interference with the function of survivin. Our previous work showed
that arsenic trioxide(As2O3) induced apoptosis in a CLL cell linetogether with
up-regulation of p53 and down-regulation of survivin. Taken together, these find-
ings raise the question of whetherAs2O3 might inhibit CLL by inducing apoptosis
via the suppression of XPO1/survivin pathway signalling.
Aims: We sought to investigate whether XPO1/survivin pathway signalling
might be involved in the anti-CLL effect induced by As2O3.
Methods: The expression of XPO1 in the MEC1 cell line and primary peripheral
blood cells from CLL patients was assessed by qPCR and compared with the
expression in purified peripheral normal B-cells. XPO1 siRNA was used to knock-
down XPO1 expression in MEC1 cells. XPO1 plasmid transfection was used to
overexpress XPO1. Thesurvival and apoptosis rates of MEC1 cells induced by
As2O3were determinedby 7-AAD,Annexin V-PI and caspase3/7 analysis. The
expression of various genes associated with apoptosis, including Bax, PUMA,
survivin, BCL-2, BCL-x and XIAP, were assessed by real-time PCR.XPO1 normal
and XPO1 knockdown MEC1 cells were inoculated intravenously
intoNOD/scid/γcnull(NSG) mice to establish a human leukaemia xenograft model.
We assessed tumour characteristics, including organ infiltration, apoptosis, and-
expression of survivin, ki67 and XPO1, as well as survival in our xenograft model.
Next, we used this model to study the effects of As2O3 in vivo.
Results: XPO1 was expressed in the MEC1 cell line and in CLL patients.
Expression data suggested that XPO1 was up-regulated inCLL patients com-
pared with normal controls. As2O3 could inhibit the proliferation and induced
apoptosis in MEC1 cells, and it down-regulated the expression of XPO1 and
survivin in MEC1 cells.XPO1 suppressed by As2O3was associated with
enhanced mRNA expression of the pro-apoptotic genes Bax, PUMA and survivin,
and suppression of the anti-apoptotic genes BCL-2, BCL-x and XIAP.Overex-
pression of XPO1 in MEC1 decreased As2O3 -induced apoptosis.Inhibition of
XPO1 by selinexorin MEC1 cellsresulted in increasedAs2O3 -induced apopto-
sis.Furthermore, siRNA knockdown of XPO1 strongly impaired in vivo engraft-
ment of MEC1 cells following transplantation in NSG mice, conferring a survival
benefit compared with mice transplanted with control cells.As2O3 could inhibit
tumour growth and significantly increased the survival of mice bearing MEC1-
derived xenografts by inhibiting XPO1 and survivin.
Summary/Conclusions: This is the first report to demonstrate thatAs2O3can
induce apoptosis and inhibit proliferation in CLL. The mechanistic effect of As2O3
on CLLresults from the down-regulation of XPO1/survivin pathway signalling.
E1020
IBRUTINIB STIMULATES IL-10 SECRETION BY NLCS, MEDIATING A
PARTIAL PROTECTION OF CLL CELLS FROM APOPTOSIS
S Fiorcari1,*, R Maffei1, V Audrito2, S Martinelli1, E ten Hacken3, P Zucchini1,
C Quadrelli1, S Benatti1, L Potenza1, M Luppi1, JA Burger3, S Deaglio2,
R Marasca1
1Department of Medical and Surgical Sciences, University of Modena and Reg-
gio Emilia, Modena, 2Department of Medical Sciences, University of Turin and
Human Genetics Foundation, Turin, Italy, 3Department of Leukemia, MD Ander-
son Cancer Center, Houston, United States
Background: In lymphatic tissues, CLL cells establish intimate contact with
accessory cells, such as nurse-like cells (NLCs). NLCs have a pivotal role in
CLL clone maintenance and support CLL cell survival, proliferation and protec-
tion from drug-induced apoptosis. Ibrutinib is a potent inhibitor of Btk kinase,
able to counteract the pro-survival effects in CLL cells provided by microenvi-
ronment. A peculiar effect of ibrutinib includes reduced retention and homing of
CLL cells to tissue compartments and a mobilization from microenvironmental
niches into the peripheral blood.
Aims: Here, we investigated the biological effects and mechanism mediated
by ibrutinib on CLL- NLCs crosstalk.
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Methods: CLL-PBMCs were cultured in complete medium for 12 days and
then treated with 1µM ibrutinib. NLC phenotype was analyzed upon ibrutinib
exposure. IL-10 production was tested by real time PCR and CSA in NLCs.
CD19+ CLL cells viability and analysis of signaling pathways in presence of IL-
10 stimulation were evaluated after treatment with ibrutinib.
Results: First, we found that CLL cells cultured without NLCs are more sensi-
tive to ibrutinib-induced apoptosis if compared to CLL cultured with NLCs.
Indeed ibrutinib does not completely hamper the protective effect mediated by
NLCs on leukemic cells when both CLL and NLCs are exposed to the drug
(p<0.05 at 24h, 48h and 72h). Among the plethora of factors potentially involved
in CLL desensitization to ibrutinib effect, NLCs were characterized by a strong
up-regulation of IL10 and NAMPT known to be involved in CLL protection from
apoptosis (p<0.05). We focused our attention on IL-10 and we demonstrated
that treatment with ibrutinib for 24h improves NLCs secretion of IL-10. CD19+
CLL cells stimulated with IL-10 in a dose escalation experiment (from 0.1 ng/ml
to 100 ng/ml) show good protection from apoptosis at different doses at different
time-points. We then analyzed the ability of ibrutinib to abrogate the pro-survival
signal induced by IL10 stimulation (1 ng/ml) in CD19+ CLL cells after 24-48h
of culture. Ibrutinib does not completely antagonize the ability of IL-10 to protect
CLL cells from apoptosis and to activate pSTAT3 and pERK signaling pathways.
In accordance, ibrutinib is able to potentiate the immunosuppressive and per-
missive profile of NLCs stimulating the expression of CD163, CD206 and the
activation of pSTAT6 with a concomitant inhibition of pSTAT1.
Summary/Conclusions: The ability of ibrutinib to effectively disrupt the
crosstalk between CLL cells and NLCs is still unclear. Our data demonstrate
that ibrutinib may also target NLCs, potentiating their permissive features
through the secretion of unwanted survival factors such as IL-10.
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LEUKEMIC CELL/MICROENVIRONMENT INTERACTIONS IN CHRONIC
LYMPHOCYTIC LEUKEMIA: ROLE OF JAK2/STAT3 AXIS IN THE
SURVIVAL OF NEOPLASTIC CLONE
F Severin1,2,*, F Fezzato1,2, V Martini1,2, V Trimarco1,2, F Raggi1,2, L Martinello1,
A Visentin1,2, E Scomazzon1, M Facco1,2, G Semenzato1,2, L Trentin1,2
1Department of Medicine, Hematology and Clinical Immunology Branch, Uni-
versity of Padua, 2VIMM (Venetian Institute of Molecular Medicine), Padova,
Italy
Background: Chronic Lymphocytic Leukemia (CLL) is characterized by the
accumulation of mature clonal CD19+/CD5+/CD23+ B lymphocytes in periph-
eral blood, bone marrow, and lymphoid tissues. Despite their in vivo prolonged
lifespan due to intrinsic defects, CLL leukemic cells rapidly undergo sponta-
neous apoptosis in vitro, highlighting the need of extrinsic signals delivered by
the microenvironment. Several molecules, including those released by mes-
enchymal stromal cells (MSCs), signal through JAK (Janus Kinases)/STAT
(Signal Transducers and Activators of Transcription) pathways. Constitutive
activation of JAKs and STATs occurs at very high frequency in various
hematopoietic malignancies and solid tumors. STAT3 tyrosine (Tyr) phospho-
rylation at residue 705 is known to be critical for the activation of JAK2/STAT3
pro-survival signaling, while the role of STAT3 Serine (Ser) phosphorylation at
residue 727 has not yet been well described. In CLL, STAT3 is constitutively
phosphorylated at Ser727 with respect to normal B lymphocytes, but the phos-
phorylation status at Tyr705 still remains unresolved.
Aims: We are aimed to evaluate JAK2/STAT3 pathway involvement in leukemic
B cell survival and to study the cross-talk between JAK/STAT and BCR/Lyn
axes. With the identification of new targets implicated in this cross-talk, and
through the analysis of leukemic cell resistance to drug-induced apoptosis, we
plan to counteract the favorable pro-leukemic cell stimuli.
Methods: B cells were collected from 34 controls and 76 CLL patients. Purified
cells (2x106 cells/ml) were cultured, with/without mesenchymal stromal cells
(MSCs), and treated with AG490 (10, 50 and 100μM) and Stattic (5, 7.5, and
10μM), specific inhibitors of JAK2 and STAT3 respectively, for 24, 48 and 72h.
STAT3 expression and phosphorylation were evaluated by Western Blotting
(WB) and Flow Cytometry (FC), and its localization was analyzed by confocal
microscopy and subcellular fractionation. CLL and normal B cell viability was
tested by FC with Annexin V/PI test. Lyn and SHP-1 phosphorylation was
assessed by WB.
Results: We demonstrated that STAT3 is overexpressed in malignant B cells
(Student’s t test, p<0.001) and the protein is higher phosphorylated at Tyr705
with respect to the normal counterpart (Student’s t test, p<0.05), thus showing
its constitutive activation in CLL. We also found that the in vitro incubation of
leukemic B cells with AG490 and Stattic, specific inhibitors of JAK2 and STAT3,
respectively, induces a dose-dependent apoptosis of CLL B cells. We demon-
strated that these inhibitors are able to induce apoptosis in CLL B cells reverting
the resistance to cytotoxic agents induced by the MSCs, bypassing the provided
pro-survival stimuli. In addition to JAK2/STAT3 inhibition, we showed that
AG490 treatment on CLL cells can mediate the activation of SHP-1, decreasing
its phosphorylation at Ser591, thus leading to inactivation of Lyn protein, by
de-phosphorylation in its active site at Tyr396. Lyn, a Tyr-kinase, and SHP-1,
a Tyr-phosphatase, are both involved in the prolonged lifespan of neoplastic
CLL cells.
Summary/Conclusions: Bypassing the pro-survival stimuli provided by the
tumor microenvironment, the ability of AG490 and Stattic to induce apoptosis
in leukemic B cells, represents a starting point for the development of new
therapeutic strategies in CLL. These findings also provide new insights on the
cross-talk between JAK/STAT and BCR/Lyn axes in CLL.
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LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN
CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE
G L Eagle1,*, J Zhuang1, R Jenkins2, N Kitteringham2, M Oates1, K Park2,
A Schuh3, S Devereux4, P Hillmen5, A Pettitt1
1Department of Molecular & Clinical Cancer Medicine, 2MRC Centre for Drug
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of Liverpool, Liverpool, 3Department of Oncology, University of Oxford, Oxford,
4Department of Haematological Medicine, Kings College Hospital NHS Foun-
dation Trust, London, 5Faculty of Medicine and Health, University of Leeds,
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Background: Chronic Lymphocytic Leukaemia (CLL) is notable for its clinical
variability, suggesting a role for precision medicine. Attempts at understanding
the biological basis of this variability have mainly focussed on genomic alter-
ations and gene expression at the mRNA level. However, the molecular basis
of CLL variability remains incompletely understood. We speculate that this is
because the clinical phenotype is ultimately determined by gene expression at
the protein level. We have therefore embarked on a global proteomic study of
a large number of CLL trial samples for which whole genome sequencing data
will be available through the Genomics England Ltd (GEL) CLL Pilot Project.
We anticipate that our study will bridge the gap in our understanding between
genotype and clinical phenotype.
Aims: Recently developed mass spectrometric approaches to highly parallel,
label-free protein quantification provide a new opportunity to develop diagnostic,
prognostic and predictive biomarkers. SWATH (Sequential Windowed Acqui-
sition of all THeoretical fragments) is a data-independent approach which gen-
erates a mass spectral library of fragment ions from all detectable peptide pre-
cursors. The composite MS/MS spectra are deconvoluted by alignment with a
high quality and exhaustive, tissue specific database, whereupon patient sam-
ples may be stratified based on the quantitative expression profile of thousands
of proteins. Here, we describe generation of a CLL-specific protein database
that will provide a permanent reference source for all future trial samples, as
indicated in Figure 1.
Methods: Protein extracts were prepared from CLL cells from 14 individual
patients in various stages of the disease. Lysates were pooled and digested
before being subjected to cation exchange chromatography. Forty fractions were
delivered into a TripleTOF 6600 mass spectrometer (SCIEX) via an Eksigent
nanoLC 415 system (SCIEX). Data dependent acquisition was performed using
25 MS/MS per cycle to optimise for quality and 30 MS/MS per cycle to optimise
for coverage, and the combined data were searched using ProteinPilot 5.0 (SCI-
EX) against the SwissProt database (Nov 2015, 20,193 human entries). Proteins
lying within a 1% global false discovery rate were included in the database.
Results: The new CLL-specific database contains 7773 proteins. The database
covers 50% of all human UniProtKB/SwissProt entries which have evidence at
the protein level. Pathway analysis of B cell receptor (BCR) signalling based
on the GeneGo pathway maps in the MetaCore database (version 6.14, build
61508; Thomson Reuters) showed that this CLL database covers over 87% of
the proteins involved in BCR signalling. The quality of the database entries is
further underlined by high representation in the Human Genome database
(20,814 entries) in aspect of Gene Ontology biological processes and molecular
functions, as determined by PANTHER over-representation tests.
Figure 1.
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Summary/Conclusions: Our global protein expression database for CLL cells
is thus the most complete database of its type. By combining advanced com-
putational biology to relate protein expression to whole genome sequencing
data, the database will provide a framework for elucidating the effect of genomic
alterations on protein expression. The construction of this comprehensive CLL
database also provides the platform for applying SWATH/MS-based analysis
of individual patient samples to identify novel drug targets and predictive bio-
markers of disease progression and treatment response.
E1023
THE IMPACT OF THE TUMOUR MICROENVIRONMENT ON B-CELL
RECEPTOR (BCR) EXPRESSION AND SIGNALLING IN CHRONIC
LYMPHOCYTIC LEUKAEMIA (CLL)
R Dobson*, M Blunt, M Aguilar-Hernandez, M Larrayoz-Ilundain, L Smith,
J Strefford, M Cragg, F Forconi, F Stevenson, G Packham, A Steele
University of Southampton, Southampton, United Kingdom
Background: Chronic lymphocytic leukaemia (CLL) is thought to be driven fol-
lowing antigen engagement of the B cell receptor (BCR). This has been high-
lighted further by the BCR Kinase inhibitors Ibrutinib and Idelalisib, which have
proved instrumental in the treatment of CLL. However, these inhibitors appear
to only suppress the disease without being curative. A number of patients have
developed resistance to ibrutinib following mutation of the BTK or PLCγ2 gene,
whilst other patients are unable to tolerate these drugs due to adverse events
or progress whilst on therapy for unknown reasons. B-cell activating factor
(BAFF) and interleukin-4 (IL-4) are known to increase CLL cell viability in vitro,
and are thought to be present within CLL lymph nodes. Therefore we have
investigated the role of BAFF and IL-4 in regulating BCR signalling in CLL cells
and promoting resistance to ibrutinib and idelalisib.
Aims: To understand how IL-4 and BAFF regulate BCR pathway inhibition by
ibrutinib and idelalisib. 
Methods: Experiments were carried out using primary CLL cells. All isolates
used contained >85% CD19+CD5+ cells. Protein expression was evaluated by
flow cytometry or immunoblotting and signalling capacity was detected by cal-
cium flux analysis in response to soluble αIgM by flow cytometry. Cell viability
was assessed using annexin v/propidium iodide staining. 
Results: As previously shown CLL cells treated with BAFF (500 ng/ml) or IL-4
(10 ng/ml) only for 48h significantly protected against basal apoptosis. This
anti-apoptotic effect was further augmented when cells were treated with BAFF
and IL-4 in combination. CLL cells treated in vitro with ibrutinib and idelalisib
induced approximately 24.3% and 28.8% apoptosis respectively following treat-
ment for 48h. However, apoptosis induced by the BCR-kinase inhibitors was
reversed following pre-treatment with IL-4 or BAFF. CLL cells incubated in vitro
with IL-4 for 24h significantly augmented sIgM expression and αIgM induced
phosphorylated ERK and calcium flux. These IL-4 induced effects on sIgM
expression were more prominent in Unmutated(U)-CLL samples, and could be
reversed using the JAK3 inhibitor tofacitinib (CP-690550). Whilst, IL-4 had little
effect on sIgD. Interestingly pre-treating CLL cells with IL-4 significantly reversed
the ability of ibrutinib (1 µM) and idelalisib (1 µM) to inhibit αIgM-mediated sig-
nalling at 24h. In contrast BAFF treatment showed no clear effect on sIgM
expression and downstream signalling. However, in a proportion of CLL sam-
ples treated simultaneously with BAFF and IL-4, BAFF reduced IL-4 specific
increases in sIgM augmentation. Next we pre-treated CLL cells with tofacitinib
(10 µM) for 1 hr prior to IL-4 treatment. Tofacitinib significantly reversed the
effects observed with IL-4 and restored the ability of ibrutinib and idelalisib to
inhibit αIgM induced signalling. This effect was specific to the inhibition of IL-4
since tofacitinib (≤10 µM) did not induce CLL cell death. Finally we showed
that BAFF, and IL-4 to a greater extent, resulted in an increase in miRNA155
expression which has previously been shown to be associated with more pro-
gressive disease and enhanced BCR signalling.
Summary/Conclusions: Our data suggests that IL-4 augments sIgM recovery
and down-stream signalling in CLL, which may compromise the effectiveness
of BCR kinase inhibitors. However these effects were not observed for BAFF.
Furthermore, co-treatment of BCR-kinase inhibitors in combination with tofac-
itinib may indicate a promising treatment strategy for the treatment of CLL.
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INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN
CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY
FROM P53 STATUS
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Background: Standard immune-chemotherapy allows to achieve 60-70%
response rate in CLL patients, but complete remission remains uncommon.
Unsatisfactory therapeutic options still exist for higher risk groups, and in par-
ticular those harboring TP53 mutations or deletion.
Aims: We propose USP7, a known de-ubiquitinase with multiple roles in cellular
homeostasis, as a potential therapeutic target in CLL.
Methods: Primary CLL cells were enriched in CD19+ fraction using the Milteny
anti-CD19 kit and were used to investigate USP7 levels. P5091 (USP7 inhibitor)
efficacy was tested in CLL cell lines and patients. Proliferation and apoptosis
were evaluated respectively with CTG technology and Annexin V-FITC/Propid-
ium PE detection by flow cytometry. The specificity of the USP7 inhibitor was
verified with a pool of 5 different siRNAs able to efficiently silence USP7.
Results: Our data show that the de-ubiquitinase USP7 is aberrantly expressed
in CLL. In particular, USP7 is over-expressed in about 70% of CLL CD19+ lym-
phocytes, both at the mRNA and protein levels. We also analyzed USP7 expres-
sion levels in an expansion cohort of a publicly available CLL patients (n=217)
and 12 normal samples, where USP7 was over-expressed in CLL when com-
pared to normal samples (****p<0.0001). We proved that USP7 is regulated at
post-transcriptional level by miR-338-3p and functionally activated by Casein
Kinase 2 (CK2) through phosphorylation at serine 18 residue. USP7 inhibition by
P5091 as well as by specific siRNA, induces cell growth arrest and apoptosis
mediated by the restoration of the nuclear pool of PTEN. Notably in primary CLL
cells, P5091 treatment strongly promoted apoptosis. Moreover, USP7 inhibitor
treatment of primary CLL was associated with increases ubiquitination of endoge-
nous PTEN and consequently PTEN relocalization into the nucleus. Strikingly,
TP53 deleted CLL samples and cells lines were equally subject to P5091 apop-
tosis induction, confirming that the USP7 inhibitor acts in a p53 independent man-
ner. These data showed potent activity of P5091 against primary CLL.
Summary/Conclusions: We demonstrate the efficacy of a small molecule
inhibitor of USP7, P5091, in vitro in cell lines and ex vivo in primary CLL samples
in a P53-independent manner. Our preclinical study therefore, supports the
evaluation of USP7 inhibitor as a potential CLL therapy.
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DIRECT AND INDIRECT MODULATION OF MACROPHAGES IN THE
TUMOR MICROENVIRONMENT UPON GENOTOXIC STRESS ALTERS
PHAGOCYTIC FUNCTION
D Vorholt*, T Erlikh, N Nickel, M Hallek, C Pallasch
Department I for Internal Medicine, Centre for Integrative Oncology CIO, Uni-
versity Hospital of Cologne, Cologne, Germany
Background: Resistance against chemotherapy is a central problem in the
current treatment of B cell malignancies. Up until now, little is known about the
impact of the tumor microenvironment on therapeutic outcome. This microen-
vironment consists of many different kinds of cells varying between tumors,
significantly manipulating malignancy and enabling relapses after treatment.
Macrophages are present in the microenvironment of most tumors-designated
as tumor associated macrophages (TAM)-and are often correlated to a poor
prognosis. We postulate that macrophages and their reprogramming are an
essential element in the malignant progression of tumors and their response to
DNA damage as occurring in chemotherapeutic treatment and are a promising
target to improve therapy response.
Aims: We aim to define the functional characteristics of macrophages in their
cross talk with malignant B cells and characterize their role for disease pro-
gression and antitumor therapy. Our particular interest lies on the investigation
of the functional mechanistic and kinetics underlying macrophage repolarisa-
tion. Here, we intend to identify key regulators and their upstream signaling
pathways by focusing on the DNA damage pathway.
Methods: To assess macrophage leukemia cell interaction we established in
vitro and ex vivo co-cultures of macrophages and leukemic cells, specifically
investigating macrophage antibody dependent cellular phagocytic (ADCP)
capacities. Leukemic cell clearance and macrophage phenotype characteriza-
tion are determined by flow cytometry. We addressed both primary CLL patient
cells as well as humanized mouse model of BCL2/MYC double hit lymphoma.
Results: Functionally we prove that low dose application of the in vitro equivalent
of Cyclophosphamide, Mafosfamide significantly increases the phagocytic func-
tion of macrophages. Besides this direct effect on macrophages, a combination
of cyclophosphamide and alemtuzumab was demonstrated to induce a
macrophage based increase in tumor clearance by cytokine secretion of stressed
malignant B cells. Here, we could determine IL10 as an inducer of increased
phagocytosis in tumor associated macrophages. Moreover we show that IL10
modulates differentiation of macrophages which strongly increases their ADCP
compared to classical M1/M2 differentiated macrophages. Analyzing the func-
tional contribution of the DNA-damage pathway we could identify pronounced
secretion of IL10 in p53-deficient leukemia cells. We show in vitro that the DNA
damage pathway plays an important role in the ASAP mechanism as a down
regulation of various DNA damage key players in the leukemic cells diminishes
the stimulating effect of Cyclophosphamide and antibody combinations.
Summary/Conclusions: Repolarisation of macrophages towards increased
phagocytosis is essential in immunochemotherapies. We demonstrate that the
DNA damage pathway is important for this stimulating effect and that the mech-
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anism involves a complex interplay between macrophages and leukemic cells.
The DNA damage of the genotoxic chemotherapy is increasing the phagocy-
tosis activity of the macrophages directly as well as indirect by a cytokine
secreted from stressed leukemic cells.
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NF-ΚB INDUCES IL-6-MEDIATED STAT3-PHOSPHORYLATION IN CLL
CELLS
U Rozovski1,2,*, D Harris2, P Li2, Z Liu2, A Ferrajoli2, J Burger2, P Thompson2,
N Jain2, W Wierda2, M Keating2, Z Estrov2
1Hematology, Beilinson Hospital, Petach Tikva, Israel, 2Leukemia, MD Ander-
son Cancer Center, Houston, United States
Background: In CLL cells STAT3 is constitutively phosphorylated on serine
727 residues whereas phosphorylation of STAT3 on tyrosine 705 residues cells
is inducible. Cytokines, such as IL-6, or IgM antibodies that activate CLL cells’
BCR, induce tyrosine phosphorylated (p) STAT3. However, while IL-6 induces
tyrosine pSTAT3 within 15 minutes, IgM induces pSTAT3 within 2-4 hours. The
reason for the delayed IgM-induced phosphorylation is unknown. Like STAT3,
the transcription factor NF-κB is constitutively activated in CLL cells and stim-
ulation of the BCR further activates NF-κB. Whether BCR stimulation upsurges
NF-κB’s transcriptional activity. Specificallhas not been elucidated.In CLL cells
STAT3 is constitutively phosphorylated on serine 727 residues whereas phos-
phorylation of STAT3 on tyrosine 705 residues cells is inducible. Cytokines,
such as IL-6, or IgM antibodies that activate CLL cells’ BCR, induce tyrosine
phosphorylated (p) STAT3. However, while IL-6 induces tyrosine pSTAT3 within
15 minutes, IgM induces pSTAT3 within 2-4 hours. The reason for the delayed
IgM-induced phosphorylation is unknown. Like STAT3, the transcription factor
NF-κB is constitutively activated in CLL cells and stimulation of the BCR further
activates NF-κB. Whether BCR stimulation upsurges NF-κB’s transcriptional
activity. Specificallhas not been elucidated.
Aims: 1) To describe the BCR dependent, NF-κB-mediated gene expression
profile of CLL cells. 2) To confirm our hypothesis that prolonged stimulation
with IgM antibodies induces tyrosine pSTAT3 via NF-κB-mediated induction of
IL-6 in CLL cells.
Methods: We incubated peripheral blood CLL cells in the presence or absence
of IgM antibodies or IL-6, and harvested the cells at different time points. Total
RNA was extracted using TRIzol, cDNA was synthesized with Super Script
First synthesis System for RT-PCR, and NF-κB-target gene expression was
quantified using RT-PCR. To measure the levels of tyrosine pSTAT3 we used
flow cytometry and to assess binding of NF-κB (p65) to DNA we utilized an
electromobility shift assay (EMSA) using an NF-κB-binding site labelled DNA
probe.
Results: To study the transcriptional activity of NF-κB we used a PCR array
that profiles the expression of 83 NF-κB-target genes. To reduce the ‘noise’
from stochastic variability in gene expression we first identified a core of genes
that are expressed in cells from all patients’ samples. To that aim we ranked
the Ct values in each array and considered all genes that were amplified earlier
than the cycle in the 75th percentile. Using this approach we identified 35 genes
(42% of genes represented in the array) that were amplified in all 6 patients’
samples. Annotation analysis revealed that the key pathways common to these
35 genes included ‘Positive regulation of the NF-κB cascade’, ‘Inflammation’
and ‘Negative regulation of apoptosis’. Applying stringent criteria we identified
5 genes common to all cases that were amplified prior to the cycle representing
the 25th percentile. Most amplified genes detected in all samples prior to stim-
ulation (28/35, 80%) were also detected after 4 h of IgM stimulation, confirming
that NF-κB is constitutively activated in CLL cells. However, 19 addition genes
(19/83, 23% of the genes in the array) were detected in all IgM-stimulated but
not in unstimulated cells. Remarkably, IL-6 was detected in all cases only after
IgM stimulation. Furthermore, observed an IgM-induced time-dependent incre-
ment in IL-6 and IL-8, suggesting that IL-6 expression is dependent on stimu-
lation of the BCR. Indeed IL-6 neutralizing antibodies significantly reduced the
levels of tyrosine pSTAT3 in CLL cells incubated for 18 h with IgM antibodies.
In addition, EMSA of CLL cells from 4 different patients showed that stimulation
of the BCR with IgM antibodies increased the binding of NF-κB to DNA in a
time-dependent manner. Furthermore, the JAK2 inhibitor Ruxolitinib attenuated
the NF-κB-DNA binding, suggesting that 2-4 hour exposure to IgM antibodies
induces activation of NF-κB, a process mediated in part by IL-6 that activates
the JAK2/STAT3 pathway. 
Summary/Conclusions: It has been well established that the BCR of CLL
cells is stimulated in the bone marrow and lymph nodes. However, whereas
the immediate effects of BCR stimulation have been excessively studied, the
successive effect of BCR stimulation is poorly understood. We found that stim-
ulation of the BCR induces tyrosine phosphorylation of STAT3 via NF-κB-medi-
ated induction of IL-6, a process that requires protracted BCR stimulation.
Although NF-κB is constitutively activated in CLL cells, continuous activation
of the BCR further activates NF-κB. These findings suggest that agents, such
as Ruxolitinib, that inhibit the successive effects of the BCR activation, would
become effective therapeutic agents in CLL.
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DIFFERENTIAL EXPRESSION PROFILE OF H/ACA RIBONUCLEOPROTEIN
COMPONENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
P Dos Santos1,*, J Panero1, C Stanganelli2, V Palau Nagore1, R Bezares3,
I Slavutsky 1
1Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Exper-
imental-CONICET-Academia Nacional de Medicina, 2División Patología Molec-
ular, Instituto de Investigaciones Hematológicas-Academia Nacional de Med-
icina, 3Servicio de Hematología, Hospital Teodoro Alvarez, Buenos Aires,
Argentina
Background: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous
disease. Telomere dysfunction has been proposed as an emerging prognostic
factor in this pathology. Telomeres are essential to maintain chromosomal
integrity and genome stability. They progressively shorten with repeated cell
division, leading to telomere dysfunction and contributing to tumorigenesis.
Telomerase is a ribonucleoprotein complex containing an internal RNA template
(TERC) and a catalytic protein with telomere-specific reverse transcriptase
activity (TERT). The human TERC gene consists of three major domains;
among them the H/ACA domain is essential for telomere biogenesis. H/ACA
ribonucleoprotein (RNP) complex is composed of four evolutionary conserved
proteins, including dyskerin (DKC1), NOP10, NHP2 and GAR1. The first three
proteins form a core trimer that directly binds to H/ACA RNAs. They are inter-
dependent upon each other for stability and also regulate stability of the bound
RNAs. GAR1 binds only to DKC1 and is needed for proper functioning of the
H/ACA RNPs, but its absence does not reduce stability of the RNA.
Aims: In this study, we have evaluated the expression profile of the H/ACA
RNP complex: DKC1, NOP10, NHP2 and GAR1, as well as TERT and TERC
mRNA levels, in patients with CLL. Results were correlated with telomere length
(TL), genetic alterations, mutational status of IGHV (immunoglobulin heavy chain
variable region) genes, and clinico-pathological characteristics of the disease.
Methods: The study was performed on mononuclear cells isolated on a Ficoll-
Paque Plus density gradient from peripheral blood samples of 60 patients with
CLL at diagnosis (34 males; mean age: 66.8 years; range: 44-88 years) and
14 normal controls. All individuals gave their informed consent and the study
was approved by the local Ethics Committee. Gene expression and absolute
TL measurement was carried out by real-time quantitative PCR. IGHV gene
rearrangements and mutational status were analyzed by RT-PCR and bi-direc-
tional sequencing. Cytogenetic and FISH analysis were also performed.
Results: Gene expression analysis showed increased mRNA levels of TERT,
NHP2 and GAR1, as well as decreased expression of TERC, DKC1 and
NOP10 in CLL patients compared to controls (p=0.043). A significant correlation
between GAR1-NHP2, GAR1-NOP10 and NOP10-NHP2 transcription levels
(p=0.0001) was detected, supporting a strong interaction among them. Patients
with short TL had higher expression of TERT (p=0.033) and DKC1 (p=0.02)
than those with long telomeres. The analysis taking into account cytogenetic
and FISH alterations showed higher mRNA levels of GAR1 and NHP2 in
patients with two or more anomalies (p=0.02) compared to those with no/one
alteration. An upregulation of TERT, TERC, GAR1 and NOP10 expression in
unmutated IGHV CLL patients was also observed. No association between
gene expression and clinical parameters was found. However, a tendency to
a short treatment free survival in patients with increased TERT expression was
detected.
Summary/Conclusions: Our findings show a global modification in the expres-
sion of telomere associated genes in CLL, being, to our knowledge, the first
analysis of TERC, NOP10, NHP2 and GAR1 in this pathology. Their association
with higher number of genetic alterations and unmutated IGHV mutational sta-
tus suggests a role for these telomere-associated genes in genomic instability
and telomere dysfunction in CLL.
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REDOX SIGNALING HYPERSENSITIVITY DISTINGUISHES CHRONIC
LYMPHOCYTIC LEUKEMIA PATIENTS WITH FAVORABLE PROGNOSIS
C Cavallini1, O Perbellini2, R Chignola1, M Cordani1, E Zoratti1, E Mimiola1,
C Laudanna1, M Donadelli1, G Pizzolo1, MT Scupoli1,*
1University of Verona, Verona, 2San Bortolo Hospital, Vicenza, Italy
Background: Chronic lymphocytic leukemia (CLL) patients exhibit a variable
clinical course, with some patients having indolent disease and others experi-
encing a more accelerated course, treatment resistance and dismal outcome.
The B-cell receptor (BCR) signaling is a key determinant of heterogeneous
clinical behavior of CLL and is a target for therapeutic interventions. Endoge-
nously produced H2O2 is thought to fine tune the level of BCR signaling by
reversibly inhibiting phosphatases. However, relatively little is known about
how CLL cells sense and respond to such redox cues.
Aims: In this study, we used phospho-specific flow cytometry to compare BCR
signaling responses to H2O2 in prognostic groups of CLL patients.
Methods: The phosphorylation levels of five proteins downstream of the BCR
signaling, namely SYK, NF-κB p65, ERK1/2, p38 and JNK, were analyzed at
the single-cell level in 26 CLL cell samples using phospho-specific flow cytom-
422 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
etry. In accordance with the Declaration of Helsinki, all patients provided written
informed consent for the collection and use of their samples for research pur-
poses. The local Ethics Committee (Comitato Etico per la Sperimentazione,
AOUI) approved sample collection. Protein phosphorylation was measured in
the basal condition and following stimulation with H2O2. Circulating B cells from
healthy individuals were analyzed as controls. The two-sample Wilcoxon’s rank
sum test was used to compare protein phosphorylation in groups of patients.
Time to first treatment (TTFT) was calculated from the date of diagnosis to the
date of initial therapy. TTFT curves estimated using the Kaplan- Meier method
for the respective groups of patients were compared using the log-rank test.
Results: In CLL cells, stimulation with H2O2 induced a statistically significant
increase in phosphorylation of all analyzed signaling proteins with the exception
of SYK. Moreover, the extents of responses to H2O2 were significantly higher
in CLL than normal B cells for all signaling proteins but SYK. Comparison of
H2O2 signaling response in prognostic groups of patients defined by IGHV
mutational status, CD38 or ZAP-70 expression, showed that median phospho-
rylation response of ERK1/2 to H2O2 was significantly higher in the patient sub-
set defined by the mutated IGHV status (M-CLL) (P=0.031). No significant cor-
relations were observed between H2O2 responsiveness of BCR signaling pro-
teins and ZAP-70 or CD38 expression. Kaplan-Meier curves showed statistically
significant slower progression (longer time to first treatment, TTFT) in patients
with higher p-ERK1/2 and p-NF-B p65 responses to H2O2, indicating that
lower responsiveness of these signaling proteins to H2O2 correlated with more
rapid progression [median TTFT was 41.6 and 115 months for patients with
lower and higher NK-kB p65 responsiveness to H2O2, respectively (log-rank
test P=0.0011); median TTFT was 38.7 and 117.0 months for patients with
lower and higher ERK1/2 responsiveness to H2O2, respectively (log-rank test
P=0.0008)] (Figure 1). Interestingly, the ability of H2O2 responsiveness signaling
to define prognostic groups is comparable to that of IGHV mutational status
(log-rank test P=0.0003).
Figure 1.
Summary/Conclusions: This study reveals that a novel H2O2 signaling
response distinguishes a prognostic group of CLL patients with favorable prog-
nosis. Specifically, higher H2O2 responsiveness of ERK1/2 or NF-kB is predic-
tive of longer TTFT, thus highlighting ERK and NF-kB as biologically and clini-
cally relevant signaling nodes in CLL.
Funding. This study was funded by Fondazione Cassa di Risparmio di Verona,
Vicenza, Belluno e Ancona and Associazione Italiana Ricerca sul Cancro
(AIRC) (grant #6599).
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OFATUMUMAB AND LENALIDOMIDE PREFERENTIALLY INHIBIT B-CELL
RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
WITH MUTATED IGHV
C Cavallini*, E Guardalben, A Ambrosetti, D Veneri, G Pizzolo, MT Scupoli
University of Verona, Verona, Italy
Background: Lenalidomide has clinical activity in chronic lymphocytic leukemia
(CLL) patients exerting pleiotropic activity on the immune system. The combi-
nation of lenalidomide with the anti-CD20 monoclonal antibody ofatumumab
induces durable responses in patients with relapsed/refractory CLL. In addition
to cell- and complement-mediated B-cell depletion induced by anti-CD20 anti-
bodies and to immunomodulatory activity of lenalidomide, both drugs have
been shown to directly inhibit survival and proliferation of malignant B cells.
Signal transduction mediated by the B-cell receptor (BCR) promotes CLL sur-
vival and proliferation and is considered a key determinant of CLL clinical behav-
ior and target for therapeutic interventions. However, the hypothesis that ofa-
tumumab and lenalidomide could target BCR signal transduction has never
been examined in CLL.
Aims: In this study, we used phospho-specific flow cytometry to investigate
the direct effects of lenalidomide and ofatumumab on BCR signaling in CLL
cells from different prognostic groups of treatment-naive patients.
Methods: The phosphorylation levels of four proteins downstream of the BCR
signaling, namely SYK, ERK1/2, PLC-γ, and NF-κB p65, were analyzed at the
single-cell level in 9 CLL cell samples treated in vitro with single-agent ofatu-
mumab, single-agent lenalidomide or their combination, using phospho-specific
flow cytometry. Phosphorylation was measured in the basal condition and fol-
lowing BCR stimulation with anti-IgM, resulting in overall 576 signal readouts.
The repeated measures Anova with Dunnett’s multiple comparison test was
used to compare drug effects on protein phosphorylation.
Results: Ofatumumab and lenalidomide induced different effects in ex-vivo
CLL cells with different prognostic features as defined by the IGHV mutational
status. In the IGHV-mutated (M) subset, treatment with ofatumumab, alone or
in combination with lenalidomide, induced a significant reduction of SYK and
ERK1/2 basal phosphorylation. Remarkably, in the same CLL group, lenalido-
mide significantly inhibited ERK1/2 basal phosphorylation. On the contrary, in
the patient group defined by unmutated IGHV status (UM), treatment with ofa-
tumumab and lenalidomide induced no significant changes in basal phospho-
rylation of BCR proteins. As expected, BCR stimulation with anti-IgM antibodies
induced a signaling response in CLL cells that was statistically significant for
ERK1/2, PLC-γ, and NF-κB p65. In the M subset, treatment with ofatumumab,
alone or in combination with lenalidomide, significantly inhibited the anti-IgM
signaling response of SYK and ERK1/2. Interestingly, lenalidomide significantly
reduced the anti-IgM-induced signaling response of SYK. In contrast, in the
UM CLL subset, ofatumumab and lenalidomide induced no significant changes
in anti-IgM responses of BCR proteins.
Summary/Conclusions: This study suggests that ofatumumab and lenalido-
mide can influence the BCR signaling in the basal state as well as under stim-
ulation, with differential effects in distinct prognostic subsets of CLL. Although
a study on a larger patient set is needed to extend and confirm these results,
overall they indicate that ofatumumab and lenalidomide can inhibit BCR sig-
naling in the M subset of CLL whilst have no significant effect in UM CLL, poten-
tially contributing to the capacity of these drugs to differentially inhibit disease-
progression in patients with CLL.
Funding. This study was funded by Fondazione Cassa di Risparmio di Verona,
Vicenza, Belluno e Ancona and AIRC (grant #6599).
Acknowledgments. We thank GSK and Celgene for providing ofatumumab and
lenalidomide.
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DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND,
IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION
AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL
IN MUTATED IGHV SUBSET
L Poppova1,2,*, P Janovska3, K Plevova1,2, L Radova2, H Plesingerova1,2,
M Borsky1, J Kotaskova1,2, B Kantorova1,2, M Hlozkova1, J Figulova1, Y Brychtova1,
M Doubek1,2, A Kozubik3,4, S Pospisilova1,2, S Pavlova1,2, V Bryja3,4
1Center of Molecular Biology and Gene Therapy, Department of Internal Med-
icine–Hematology and Oncology, University Hospital Brno and Medical Faculty,
2CEITEC - Central European Institute of Technology, 3Institute of Experimental
Biology, Faculty of Science, Masaryk University, 4Department of Cytokinetics,
Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno,
Czech Republic
Background: Wnt ligands drive several distinct pathways-the best explored
are Wnt/β-catenin (canonical) and Wnt/Planar Cell Polarity (PCP) pathways.
We have shown recently that ROR-1 driven Wnt-5a-activated WNT/PCP path-
way controls migratory properties of chronic lymphocytic leukemia (CLL) cells
and WNT5A positivity correlates with aggressive CLL (Janovska et al., Clin
Cancer Res 2016). Several reports suggested that the canonical Wnt/β-catenin
pathway, known to drive malignant transformation of multiple cell types, also
participates on CLL pathogenesis. This was based on the high expression of
canonical Wnt ligands and LEF1, and mutations in Wnt pathway genes. There
is, however, a lack of direct evidence showing that CLL cells can respond to
canonical Wnt ligands by activating β-catenin-dependent transcription. On the
other hand, the observation that WNT3, encoding for the canonical Wnt ligand,
is among the most up-regulated genes, supports the role of Wnt/β-catenin path-
way in CLL.
Aims: To clarify the role of Wnt/β-catenin pathway in CLL by (1) detailed analy-
sis of WNT3 expression and (2) cell-line based study of the ligand-induced
pathway activation.
Methods: B-cells from CLL patients and non-malignant controls were negatively
separated with RossetteSep (StemCell) or MACS kits (Miltenyi Biotec). WNT3
mRNA expression was analyzed with quantitative RT-PCR using TaqMan Gene
Expression Assays (Applied Biosystems). The WNT3 expression was correlated
with clinical and biological parameters. Survival analyses were performed using
Kaplan-Meier curves, Cox regression model and log-rank test; cut-off was
assessed in CutOff Finder web application. Wnt/β-catenin pathway activity was
analyzed by the SuperTopFlash reporter system (Promega).
Results: By analyzing 137 previously untreated patients we confirmed that
WNT3 gene is strongly overexpressed in CLL compared to normal B-cells
(P=0.0001) and that its level is higher in patients with mutated IGHV (M-CLL;
P=0.047). Further, we identified low WNT3 level as a strong independent marker
indicating shorter treatment-free survival (TFS) in M-CLL (P<0.0002). Time
course analysis in 86 patients revealed that WNT3 declines with disease pro-
gression in a significant proportion of patients (decrease in 37%, increase in
4% of patients; P<0.0001), namely in a disease activity onset in untreated M-
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CLL and in a disease recurrence after therapy in patients with unmutated IGHV
(U-CLL). Functional tests showed that selected lymphoid cell lines (CLL-derived
MEC1 and ROR1-positive REC1) failed to respond to the ligand-induced acti-
vation of the Wnt/β-catenin pathway while bone marrow stromal cells M210B4
were able to transduce a signal to TCF/LEF-dependent transcription.
Figure 1.
Summary/Conclusions: Our results show that despite WNT3 overexpression
in CLL cells, its high levels are not associated to aggressive CLL. On the con-
trary, low WNT3 independently identifies patients with short TFS in M-CLL and
WNT3 level decrease accompanies disease evolution in a significant proportion
of patients. The data indicate that the Wnt/β-catenin pathway plays a more com-
plex role in CLL pathogenesis than previously anticipated, opening a hypothesis
that Wnt-3 ligand might be associated to early steps in CLL pathogenesis pos-
sibly via mediating interaction with the cells in the microenvironment.
Supported by grants Ministry of Health of Czech Republic AZV 15-29793A,
15-30015A, 15-31834A, Ministry of Education CEITEC2020 (LQ1601),
Masaryk University MUNI/A/1028/2015, EU Horizon 2020 No 692298.
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INNATE LYMPHOID CELLS ARE EXPANDED AND FUNCTIONALLY
ALTERED IN CHRONIC LYMPHOCYTIC LEUKEMIA
I De Weerdt1,2,*, V van Hoeven2, JM Munneke2, S Terpstra1,2, T Hofland1,2,
MD Hazenberg2, AP Kater2,3
1Experimental Immunology, 2Hematology, Academic Medical Center, 3Lym-
phoma and Myeloma Center Amsterdam, Amsterdam, Netherlands
Background: Both innate and adaptive immune cells markedly affect CLL
cells, yet recent findings also highlight reciprocal stimulation of immune cells
by clonal B cells. Multi-directional signals derived from a triad formed by malig-
nant cells, lymphocytes and innate immune cells could therefore critically con-
tribute to shaping a supportive environment for the malignant clone. Elucidation
of the immune disturbances and tumor microenvironment in CLL is essential
for improving therapeutic possibilities and treatment of the CLL immunodefi-
ciency. At the crossroad of innate and adaptive immunity, innate lymphoid cells
(ILCs) have recently entered the stage as key players in the initial immune
response and tumor surveillance. ILCs have lymphoid morphology but lack
rearranged antigen receptors. In addition to NK cells, the ILC family consists
of 3 non-cytotoxic groups, mirroring T helper subsets. Group 1 ILCs produce
IFN-γ, whereas group 2 ILCs secrete IL-5 and IL-13. Group 3 ILCs produce IL-
22 and IL-17, and are subdivided based on the expression of the natural cyto-
toxicity receptor NKp44. The role of ILC in CLL has not yet been clarified.
Aims: The aim of this study is to investigate the frequency and functionality of
ILCs in CLL patients.
Methods: ILCs, defined as lineage-CD127+CD161+ lymphocytes, were measured
by flow cytometry in 21 untreated CLL patients and 8 age-matched healthy controls
(HCs). We studied functionality of ILCs through measuring cytokine production
by flow cytometry upon PMA/ionomycin stimulation in CLL patients (n=6) and HCs
(n=6). To assess function after cytokine activation, proliferation and cytokine pro-
duction was measured in ILC subgroups in 4 CLL patients and 3 HCs.
Results: The number of ILCs in the peripheral blood is significantly increased
in CLL patients. Moreover, the ILC count correlates with the absolute leukocyte
count in CLL patients, suggesting a rise in ILCs with disease progression. The
absolute counts of both ILC1s and NKp44- ILC3s are significantly elevated in
comparison to HCs. The activation status of ILCs, as measured by CD69 expres-
sion, is similar in CLL patients and HCs. Next, we compared the functionality of
ILCs from CLL patients and HCs by measuring cytokine production. TNF-α pro-
duction is significantly reduced in CLL patients, yet IFN-γ production is compa-
rable between CLL patients and HCs. The production of type 2 (IL-13) and type
3 (IL-22) cytokine production by ILCs in CLL patients is similar to that in HCs.
Finally, we investigated whether functional differences remained present upon
cytokine activation. In parallel with direct cytokine measurements in the total
ILC pool, cultured ILC1s from CLL patients produce less TNF-α, while IFN-γ
production by cultured ILC1s was not affected. ILC1s from CLL patients tend to
expand slower than their healthy equivalents, although the difference was not
statistically significant. In contrast with ILC1s, the expansion and production of
IL-17A and IL-22 of NKp44- ILC3s was not affected upon cytokine activation.
Summary/Conclusions: Taken together, we demonstrate that in patients with
CLL, ILC homeostasis is disturbed. ILCs are expanded in CLL patients and
their absolute numbers correlate with disease stage. In addition, ILC1 function
is impaired which persists upon cytokine activation. These observations are in
line with NK cell alterations and may represent a bystander effect, or reflect
functional involvement of ILCs in CLL pathobiology. The extent to which ILCs
affect disease progression and therapeutic response is yet to be identified.
E1032
IN VITRO EVALUATION OF BORTEZOMIB MOLECULAR EFFECTS IN
LARGE GRANULAR LYMPHOCYTE LEUKEMIA
G Calabretto1,2,*, A Teramo1,2, G Barilà1,2, C Ercolin1,2, M Leoncin1,
A Cabrelle2, E Boscaro1, S Teolato1, E Pagnin1, M Facco1,2, L Trentin1,2,
G Semenzato1,2, R Zambello1,2
1Department of Medicine, Hematology and Clinical Immunology Branch, Univer-
sity School of Medicine, 2Venetian Institute of Molecular Medicine, Padua, Italy
Background: Large Granular Lymphocyte Leukemia (LGLL) is a chronic lym-
phoproliferative disorder characterized by clonal expansion of Large Granular
Lymphocytes (LGLs) with cytotoxic activity. LGLs proliferation is maintained
through the activation of several survival signaling pathways. Among these,
one of the most important deregulated pathway is the JAK/STAT axis. STAT3
activation, mediated by IL-6 signaling or activating STAT3 mutations, promotes
LGLs survival by inducing several anti-apoptotic genes transcription and rep-
resents a hallmark of this disease. Nowadays, LGLL therapy is based on
immunosuppressive drugs, such as Methotrexate (MTX), Cyclophosphamide
(CTX) and Cyclosporine A (CyA), showing however only a partial efficacy with
an Overall Response Rate (ORR) of about 50-60%. Bortezomib (Bz), the first
FDA-approved proteasome inhibitor used in Multiple Myeloma (MM) therapy,
is not an approved treatment opportunity for LGLL, but the rare co-association
of LGLL with MM offered the opportunity to retrospectively investigate the effect
of this drug on leukemic LGLs. The literature reports that patients diagnosed
with both LGLL and MM showed a decrease in the LGLs count after Bz treat-
ment, suggesting that this drug may have an effect on inhibiting the LGL clone.
Aims: The aim of this study is to investigate the in vitro effects of Bz on PBMCs
from LGLL patients, in order to understand its molecular mechanism of action
in reducing the LGL clone.
Methods: Peripheral blood mononuclear cells (PBMCs) of 20 LGLL patients
(8 out of 20 characterized by STAT3 mutations), isolated through Ficoll density
centrifugation, were cultured and treated with Bz (5.2 nM) for 24 or 48 hours.
Real Time-PCR, western blot (WB) assays and immunofluorescence assay
were performed to analyze mRNA and protein expression. Cell apoptosis was
evaluated by Flow cytometry, using Annexin V staining.
Results: We analyzed IL-6 mRNA expression levels in patients-derived PBMCs
by Real Time-PCR. Our results demonstrated that IL-6 gene expression sig-
nificantly decreases in Bz-treated cells, as compared to a not treated condition
(p<0.01). The transcriptional data were supported by immunofluorescence
assay, showing that this cytokine is mainly produced by the monocyte/
macrophage lineage and that its expression is reduced after Bz treatment. To
investigate the Bz effect on IL-6-induced JAK/STAT pathway, we performed
WB analysis to evaluate STAT3 activation by measuring pSTAT3 Tyr705. Our
results showed that pSTAT3 Tyr705 levels strongly decrease in Bz-treated con-
dition, irrespective to the presence of STAT3 mutations. This pattern strictly
differs from untreated PBMCs, in which STAT3 remains over-activated. Then,
by Real Time-PCR and WB assays, we analyzed the expression of STAT3
downstream targets, focusing on the anti-apoptotic MCL-1 and BCL-2 gene
expression. Our results demonstrated a significant reduction of the expression
levels of both these genes following Bz treatment (p<0.01). Finally, we evalu-
ated Bz effect on cell survival by Annexin V staining. Our results showed a sig-
nificant time-dependent increase in LGL apoptosis after Bz treatment, as com-
pared to a not treated condition. Moreover, we observed that this drug is highly
specific in inducing leukemic LGLs apoptosis, not affecting the other PBMCs.
Summary/Conclusions: Our results provide evidence that Bortezomib might
represent a new intriguing therapeutic option to be added to the immunosup-
pressive drugs already used in LGLL therapy.
E1033
A SHARP CONTRAST IN FUNCTIONALITY BETWEEN EBV- AND
CMV-SPECIFIC CD8+ T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
T Hofland1,2,*, I de Weerdt1,2, S Endstra1,2, EB Remmerswaal2,3, IJ ten Berge2,3,
AP Kater1,4, SH Tonino1,4
1Hematology, 2Experimental Immunology, 3Renal Transplant Unit, Academic
Medical Center Amsterdam, 4Lymphoma & Myeloma Center Amsterdam, Ams-
terdam, Netherlands
Background: Chronic lymphocytic leukemia (CLL) is characterized by a tumor
induced T-cell dysfunction, which leads to impaired cytotoxicity, which is probably
caused by an inability to form immune synapses and increased expression of
exhaustion markers. However, we recently found that CMV-specific CD8+ T-cells
from CLL patients are functionally intact when compared to age-matched healthy
424 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
controls (HC). This finding challenges the concept of a global T-cell dysfunction
in CLL. Whether intact functionality of CMV-specific T-cells is a rare exception or
whether T-cell functionality is indeed more heterogeneous is currently unknown.
Acquired T-cell dysfunction in CLL needs to be better understood in order to
improve anti-tumor immunotherapies that rely on T-cell mediated effects.
Aims: To analyze T-cell function heterogeneity in CLL, we studied the
immunophenotype and functionality of CD8+ T-cells specific for Epstein-Barr-
virus (EBV), another widely common chronic latent viral infection.
Methods: EBV-specific CD8+ T-cells were analyzed using EBV tetramers and
14-color flow cytometry in 45 untreated CLL patients and 23 age-matched HC.
We studied T-cell differentiation, expression of exhaustion markers (PD-1,
CD244 and CD160), functional markers and homing markers. To study the
functionality of EBV-specific CD8+ T-cells, we determined cytokine production
and polyfunctionality after stimulation with EBV-derived peptides. Furthermore,
we analyzed ex vivo cytotoxicity of EBV-specific CD8+ T-cells.
Results: We found that, when compared to HC, EBV-specific T-cells in CLL
patients are further differentiated with a significantly smaller percentage of “ear-
ly” effector memory cells (also called EM1; CLL=39.6% vs HC=57.68%). These
results are mirrored by the expression pattern of the transcription factors T-bet
and Eomes; 25.79% of EBV-specific T-cells of CLL patients display a T-bethigh-
Eomeshigh phenotype vs 17.44% in HC, again pointing to an increased differ-
entiation state. In comparison with HC, EBV-specific T-cells in CLL patients
show higher expression of exhaustion markers CD244 and CD160, but not PD-
1. However, there were no significant differences in granzyme B and K expres-
sion, suggesting an unaltered cytotoxic potential. On a functional level, no dif-
ferences between CLL and HC were found with respect to production of the
cytokines TNFα, IFNγ, IL-2 and MIP-1β and degranulation (measured as
CD107a+ cells) of EBV-specific T-cells after peptide stimulation. Polyfunction-
ality of EBV-specific T-cells of CLL patients was comparable with HC. Surpris-
ingly, we found that EBV-specific T-cells of CLL patients display significantly
less direct cytotoxic capacity compared to HC in an ex vivo killing assay (mean
specific lysis of target cells CLL=6,83% vs HC=32,4%), indicating a functional
impairment despite normal differentiation and cytokine production. We are cur-
rently performing experiments to study immune synapse formation of EBV-spe-
cific T-cells (which we will be able to present during the EHA meeting) to deter-
mine involvement of the immune synapse in this acquired defect.
Summary/Conclusions: Taken together, we conclude that EBV-specific T-
cells show signs of functional impairment and are, in contrast to CMV-specific
T-cells, not able to evade CLL induced T-cell dysfunction. In depth studies on
differences in T-cell mediated viral responses in the context of CLL will yield
important clues to develop strategies to overcome T-cell dysfunction in this dis-
ease.
E1034
IDENTIFICATION OF A STRUCTURALLY NOVEL BTK MUTATION THAT
DRIVES IBRUTINIB RESISTANCE IN CLL BUT NOT RICHTER
TRANSFORMATION
YL Wang1,*, S Sharma1, N Galanina2
1Pathology, 2Medicine, University of Chicago, Chicago, United States
Background: Ibrutinib (ibr), a first-in-class Bruton tyrosine kinase (BTK)
inhibitor, has demonstrated high response rates in both relapsed/refractory and
treatment naïve chronic lymphocytic leukemia (CLL). However, about 25% of
patients discontinue ibrutinib therapy at a median follow-up of 20 months and
many patients discontinue the treatment due to leukemia progression or Richter
transformation. Mutations affecting the C481 residue of BTK disrupt ibrutinib
binding and have been characterized by us and others as the most common
mechanism of ibrutinib resistance. In addition, BTK mutations have been found
in several Richter-transformed patients treated with ibr. In these patients, it is
not clear whether BTK mutations are related to Richter transformation or ibr
treatment or both.
Aims: As the use of ibr becomes more prevalent in CLL and other types of
non-Hodgkin lymphoma (NHL), more patients are expected to develop resist-
ance. Thus, a complete understanding of the mechanisms of ibr resistance is
important for the development of strategies to prevent and treat ibrutinib resist-
ance.
Methods: Serial samples were collected from a Richter transformed CLL patient
who were treated with ibrutinib, responded and then relapsed. The samples
were analyzed using Onco1K, a 1,200-gene next-gen sequencing panel with
an average sequencing depth of 420x. The uncovered novel mutation was then
validated with Sanger sequencing and characterized with structural modeling.
The role of the mutation was further functionally defined with cell transfection
followed by assays for cell-proliferation, BrdU-incorporation, and intracellular
B-cell receptor signaling.
Results: A structurally novel mutation of Bruton tyrosine kinase was identified
which was associated with CLL relapse but not Richter transformation. Func-
tionally, cells carrying the mutant BTK show resistance to ibrutinib at both cel-
lular and molecular levels to a similar extent as BTKC481S. 
Summary/Conclusions: Our study lends further insight into the diverse mech-
anisms of ibrutinib resistance that has important implications for the develop-
ment of next-generation BTK inhibitors as well as mutation detection in relapsed
patients.
E1035
CHECKPOINT KINASE 1 INHIBITION POTENTIATES APOPTOSIS AND
INFLICTS MITOTIC FAILURE IN CLL-DERIVED MEC-1 CELL LINE
J Zemanova1,*, O Hylse2, J Collakova3, P Vesely3, A Oltova1, K Paruch2,
M Trbusek1
1Department of Internal Medicine-Hematology and Oncology, University Hos-
pital Brno and Faculty of Medicine, Masaryk University, 2Center of Biomolecular
and Cellular Engineering, International Clinical Research Center, St. Anne’s
University Hospital, 3Central European Institute of Technology, Brno University
of Technology, Brno, Czech Republic
Background: Treatment options for patients with TP53-mutated lymphoid
tumors are very limited. In chronic lymphocytic leukemia (CLL), TP53 defects
were not surmounted by chemoimmunotherapy regimens functioning in other
patients, and also remain challenging for innovative small-molecule inhibitors
of B-cell receptor signaling. Recently, the inhibition of ataxia-telangiectasia
mutated and Rad-3 related (ATR) kinase operating in the DNA damage
response (DDR) pathway has been identified as a potential alternative thera-
peutic strategy in CLL. ATR is a key molecule activating the DDR pathway
through phosphorylation of checkpoint kinase 1 (Chk1) upon recognition of
DNA damage.
Aims: (1) to test the Chk1 inhibition potential for sensitizing TP53-mutated
CLL-derived MEC-1 and MEC-2 cell lines to nucleoside analogs (NAs) fludara-
bine, cytarabine and gemcitabine, and (2) to analyze appropriate cell death
mechanisms in MEC-1 cells.
Methods: We used highly specific Chk1 inhibitor SCH900776 and measured
(a) overall cell viability using a metabolic WST-1 assay, (b) DNA double strand
breaks (DSBs) accumulation using pS139 detection on H2AX (γ-H2AX), and
(c) apoptosis and cell cycle profile using annexin-V/PI and DNA content staining,
respectively. In case of fludarabine, we also analyzed structure of mitotic chro-
mosomes and employed a cell-live imaging for direct cell death monitoring.
Results: The MEC-1 cell line was significantly (P<0.01; two-way ANOVA) sen-
sitized to all three NAs using 200 nM SCH900776, as evidenced by 72 h cell
cultivation and concentration-dependent curves of viability. Interestingly, the seri-
al sister cell line MEC-2 established from the same patient one year later com-
pletely lost the Chk1 inhibition-mediated sensitization to fludarabine. Analyzing
further cell death mechanisms in MEC-1 cells, we observed that SCH900776
greatly facilitated γ-H2AX accumulation in the co-treatments with all three NAs
and in all tested time intervals (4, 14, 24, and 48 h). Accordingly, apoptosis was
clearly augmented in the co-treatments compared to single agent treatments
with NAs. In the cell cycle analysis, an increase of sub-G1 (apoptotic) fraction
in the co-treatments with Chk1 inhibitor resulted in all three NAs from diminished
post-G1 populations (S and G2/M). The cytogenetic analysis for the co-treatment
of SCH900776 with fludarabine disclosed a substantially reduced mitotic index
(0.6% compared to 15.8% in control), and severe chromosome pulverization in
cells undergoing mitosis (detected in 42% of analyzed mitotic cells). By contrast,
this pulverization was only occasionally observed in single agent treatment with
fludarabine (4%) and never present in control untreated MEC-1 cells. The cell-
live imaging then disclosed several abnormal features during mitosis including
(a) hardly recognizable metaphase plate, (b) inner cell mass asymmetric division
between daughter cells, (c) accelerated time course of division process involving
approximately 14 minutes (compared to 22 minutes in untreated cells), and (d)
signs of apoptosis such as membrane blebbing.
Summary/Conclusions: The intrinsic resistance of TP53-mutated CLL cells
to NAs can be significantly surmounted by Chk1 inhibition leading to cell cycle
checkpoints abrogation and augmented DNA damage. Further testing of clinical
candidate SCH900776 and other specific Chk1 inhibitors in CLL is justified and
particularly appropriate among TP53 mutated patients.
Supported by grant 15-33999A (MH CR), project MUNI/A/1028/2015, grant
CZ.1.05/1.1.00/02.0123 (MEYS CR), and project CEITEC 2020 (LQ1601).
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PROGNOSTIC SIGNIFICANCE OF SIGNAL TRANSDUCER AND ACTIVATOR
OF TRANSCRIPTION 5 AND 5B EXPRESSION IN EPSTEIN-BARR VIRUS
POSITIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
P Diamantopoulos1,*, M Sofotasiou1, Z Georgoussi2, N Giannakopoulou1,
V Papadopoulou1, A Galanopoulos3, E Kodandreopoulou1, P Zervakis1, P Pallaki2,
F Kalala1, MC Kyrtsonis1, A Dimitrakopoulou4, T Vassilakopoulos1,
M Angelopoulou1, N Spanakis1, NA Viniou1
11st Department of Internal Medicine, Hematology Unit, Laikon General Hospi-
tal, National and Kapodistrian University of Athens, 2Laboratory of Cellular Sig-
naling and Molecular Pharmacology, Institute of Bioscience and Applications,
National Center for Scientific Research “Demokritos”, 3Department of Clinical
Hematology, G. Gennimatas District General Hospital, 4Department of Immunol-
ogy and Histocompatibility, Laikon General Hospital, Athens, Greece
Background: Signal Transducer and Activator of Transcription (STAT) proteins
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are cytosolic transcription factors that, upon activation, dimerize and migrate
to the nucleus to control gene expression. Among them, STAT5 consists of
two isoforms (STAT5A and STAT5B) that are 90% identical and are encoded
by two adjacent genes on 17q11.2. Aberrant STAT5 activity has been linked to
tumorigenesis, and the implication of STAT5 in leukemias and lymphomas that
are correlated to viruses has been long speculated. EBV-related lymphoma-
genesis has not been thoroughly studied in correlation to the JAK-STAT path-
way, although there are in vitro data supporting a constitutive activation of
STATs in EBV positive lymphoma cell lines.
Aims: We investigated the expression of total STAT5 and STAT5b in patients
with Chronic Lymphocytic Leukemia (CLL) in correlation to the presence of
Epstein-Barr Virus (EBV) and Latent Membrane Protein 1 (LMP1).
Methods: Peripheral blood samples from patients with CLL and healthy blood
donors were obtained. EBV DNA quantification was performed by real time
PCR using the EBV R-gene Quantification Complete kit (bioMérieux, Paris,
France). A conventional Real time PCR was used for the detection of LMP1-
mRNA and LMP1 expression was verified by ELISA (LMP1 detection kit,
MYBiosource, San Diego, CA, USA). Western-blotting was performed for
STAT5 and STAT5B in protein extracts. The secondary antibodies used were
Affinity Purified Antibody Peroxidase Labeled Goat anti-Rabbit and anti-Mouse
IgG (H-L) (Kirkegaard & Perry Laboratories, USA). Gel Pro Analyzer 4 was
used to analyze the results. IBM SPSS statistics, v19.0 (IBM Corporation, NY,
USA) was used for the statistical analysis of the results.
Figure 1.
Table 1. Correlation of EBV and LMP1 status with the expression of STAT5
and STAT5b.
*Pearson’s chi-square test, 2-sided p
Results: Sixty-three (63) patients with CLL and immunophenotypical com-
firmed disease by peripheral blood at the time of sample collection were includ-
ed in the study. The vast majority of the patients (81%) were treatment naïve,
and the clinical stage according to the Binet staging system was: stage A 42.9%,
B, 34.9%, and C 22.2%. Total STAT5 was expressed in 38 patients (60.3%)
and STAT5b was expressed in patients only (18, 28.6%) but not in healthy sub-
jects. Its expression was correlated to the detection of EBV (77.3% versus
51.2%, p=0.006) and the expression of LMP1 (58.3% versus 21.6%, p=0.011),
(detailed results in Table 1). The expression of STAT5b and the presence of
EBV and LMP1 were strongly negatively correlated to the overall survival (OS)
of the patients (p=0.011, 0.015, 0.006 respectively). Double positive (for EBV
and STAT5b) patients had the lowest OS (p=0.013), (Figure 1).
Summary/Conclusions: This is the first report of a survival disadvantage of
EBV positivity in CLL, and the first correlation of STAT5b to OS. Moreover,
double positivity (for EBV and STAT5b) was correlated to a worse prognosis,
while double negative patients had the highest OS. The correlation of STAT5/5b
expression with the presence of the virus and OS defines a subgroup of patients
that may benefit from treatment with anti-STAT agents.
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EX VIVO LYMPH NODE NATIVE MICROENVIRONMENT ASSAY SHOWS
NOVEL ANTIPROLIFERATIVE ACTIVITY FOR IDELALISIB AND IBRUTINIB
ON CLL CELLS
J Ballesteros1,*, L Scarfo2, M Mattsson3, A Xochelli4, P Ranghetti2, D Primo1,
A Robles1, J Gorrochategui1, J Martinez Lopez5, J de la Serna5, M Gonzalez6,
V Munugalavadla7, S Tannheimer7, R Rosenquist3, K Stamatopoulos4, P Ghia2
1Vivia Biotech, Tres Cantos, Spain, 2Universita Vita-Salute San Raffaele and
Ospedale San Raffaele, Milan, Italy, 3Uppsala University, Uppsala, Sweden,
4Center for Research and Technology Hellas, Thessaloniki, Greece, 5Hospital
12 de Octubre, Madrid, 6Hospital Clinico Universitario de Salamanca, Sala-
manca, Spain, 7Gilead Sciences, Foster City, CA, United States
Background: Survival and proliferation of chronic lymphocytic leukemia (CLL)
cells is favored by the essential role of the tumor microenvironment (TME) that is
similarly responsible at least in part for disease progression and drug resistance.
Aims: We planned to evaluate and predict the efficacy of therapeutic com-
pounds in vivo, by reproducing in a co-culture system the different microenvi-
ronmental components that enable B cells to survive and proliferate, mimicking
in particular the lymph node microenvironment where most of the crucial events
of the pathogenesis of CLL occur.
Methods: To this purpose, cryopreserved peripheral blood (PB) mononuclear
cells from CLL patients in need of treatment were tested with the Exvitech®
proprietary automated flow cytometry-based platform. Different components
have been evaluated to reproduce the ME and induce proliferation and survival
of CLL cells: (i) 3 backbone stimulations: CD40L+CpG, CD40L+IL21, CpG+IL2;
(ii) “Native Environment”, defined as the plasma & erythrocyte/granulocyte frac-
tion of a Ficoll gradient: (iii) the stroma cell line H5S, added at different ratios
(1:10 or 1:100); (iv) both human and bovine fetal serum (at 10 or 20% total vol-
ume); (v) stimulatory B cell factors, including IL-21, soluble CD40L, BAFF, and
B cell receptor stimulation (anti-IG).
Results: Of all the described combinations, the addition of CpG+IL2, HS5 (at
1:100 ratio), human serum 10%, and “native environment” from PB of CLL
samples (pooled samples to prevent interpatient variability) were the best to
promote CLL proliferation (30±3%) and viability (60±5%). We then tested dose
responses of the novel BCR inhibitors, idelalisib (PI3kδ inhibitor) and ibrutininb
(BTK inhibitor) in 29 and 25 cryopreserved progressive CLL samples, respec-
tively (Figure) and showed that resting CLL cells were virtually unaffected by
either drug (EC50 of 12,5µM and 28.3µM), suggesting a limited direct pro-apop-
totic activity of the drugs. In contrast, marked inhibition of proliferation was
observed (EC50 of 30 nM and 550 nM, respectively) in the presence of either
inhibitor, leaving only a median of 5% CLL cells that continued proliferating
even at the highest doses.
Figure 1.
Summary/Conclusions: We here report a novel ex vivo assay that incorpo-
rates TME stimuli thus more accurately simulating in vivo interactions and
enabling high-throughput pharmacological characterization in more physiolog-
ical conditions. This assay demonstrated a previously unreported anti-prolifer-
ative activity for both idelalisib and ibrutinib that may explain the efficacy of
both drugs in patients.
E1038
THE RETINOID DRUG ACITRETIN UPREGULATES CD38 EXPRESSION IN
CHRONIC LYMPHOCYTIC LEUKEMIA AND MEC-1 CELLS AND REDUCES
CELL HOMING TOWARDS THE CHEMOKINE CXCL12: POTENTIAL FOR
EXPLOITATION IN THERAPY
S Elsir Mohammed1,*, J Quinn2, P Thornton1, B Hennessy3, S Bergin2,
S Napolitano2, P Murphy1
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Background: CD38 expression is a robust prognostic indicator in Chronic Lym-
phocytic Leukemia(CLL) and has gained importance among the repertoire of mark-
ers utilised to aid management decisions in CLL. The CD38 molecule is also
attracting interest as a mark for targeted therapies, namely anti-CD38 monoclonal
antibody treatment. Retinoids modulate CD38 expression due to the presence of
the Retinoic Acid Response Element (RARE) DNA sequence in intron 1 of the
CD38 gene. Several studies have investigated this effect in myeloid malignancies
however little is known about retinoid effect on lymphoid malignancies.
Aims: In this study we demonstrate that the retinoic acid derivative, acitretin,
upregulates the expression of CD38 on the MEC-1 cell line and on primary
CLL cells from CD38 positive patients. We propose that by doing so, acitretin
may render these cells more susceptible to the actions of anti CD38 monoclonal
antibody drugs and thus have a potential role as an adjunct to such therapies.
We also show that acitretin reduces CLL cell homing in response to the
chemokine CXCL12, therefore potentially preventing cells from reaching the
micro environment niche and may as a result, lead to shortened survival. 
Methods: Ethical approval for the study was obtained from the ethical commit-
tee in Beaumont University Hospital. Peripheral blood samples were collected
from 32 patients with a confirmed diagnosis of CLL and who had given written
informed consent. MEC-1 cells were obtained from DSMZ, Germany. MEC-1
cells and cells from five CD38 negative and five CD38 positive patients were
treated with 10µM acitretin for 24 and 72 hours. CD38 expression was meas-
ured by flow cytometric analysis at baseline and at the different time points.
Results are expressed as fold difference in Mean Fluorescence Intensity (MFI)
in treated versus untreated cells. Migration assays were performed using 2x106
cells per well incubated with either 10µM acitretin or media, overnight in 1%FBS.
Cells were subsequently transferred to chamber inserts overlying 10%FBS
media containing 200ng/ml CXCL12 in all wells, except negative controls. Cells
were allowed to migrate for 4hrs. Migration was calculated as percentage of
cells in lower chamber to upper chamber. 
Results: CD38 expression in MEC-1 cells was significantly upregulated in cells
incubated with 10µM acitretin for 72 hours, (6.89 fold higher expression in
acitretin treated cells compared to controls, n=3,**p=0.00075). In primary cells
derived from patient samples that had CD38 expression ≥9% at baseline,
acitretin produced an increase in CD38 expression that was 2.25 fold higher
compared to untreated cells(n=5,* p=.022). However, in primary cells from
patient samples with CD38 expression<9% at baseline, the effect of acitretin
was only 1.53 higher CD38 expression in cells treated with 10µM acitretin at
72 hours. Significant modulation of CD38 expression in these cells was only
achieved in the cells treated with 50µM acitretin for 72 hours (*p=.022). In cell
migration, acitretin treatment resulted in a significant reduction in CLL cell hom-
ing toward CXCL12 in 14 out of 17 patient samples. Mean relative migration
was reduced from 23.5% to 11.9% of input cells (11.6% reduction, **p=.00018,
n=14, mean +/- SEM).These were cell samples from a varied group of patients
that included 8(54%) from previously treated, relapsed patients and 6(43%)
treatment naïve patient samples. 
Summary/Conclusions: CD38 expression is significantly unregulated by
acitretin in CLL cells expressing CD38 at baseline. We suggest this would prove
advantageous in the setting of anti-CD38 monoclonal antibody therapy through
improving efficacy of this drug, and should be studied further in CLL. Acitretin
also reduced the homing ability of CLL cells towards the chemoattractant
CXCL12, the mechanism and potential therapeutic implications of which needs
to be further explored.
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ARRAY CGH ANALYSIS REVEALS DELETION OF CHROMOSOME 22Q11
IN CLL WITH NORMAL KARYOTYPE AND NO FISH ALTERATIONS
F Mestichelli*, A Dalsass, S Ferretti, E Camaioni, M Angelini, S Mei, V Pezzoni,
F Travaglini, E Troiani, S Angelini, P Galieni
U.O.C Ematologia, Ospedale Mazzoni, Ascoli Piceno, ASCOLI PICENO, Italy
Background: Genomic aberrations have increasingly gained importance as
prognostic markers in B-cell chronic lymphocytic leukemia (CLL). Recently, a
number of additional studies have been completed that clearly demonstrate
the feasibility of using array comparative genomic Hybridization (a-CGH) as a
clinical tool to identify genomic alterations of prognostic importance in CLL.
Aims: aCGH is able to identify a significant percentage of genomic abnormal-
ities that escapes conventional cytogenetics and CLL FISH panel due to the
limitations of these methods. 
Methods: Using Oligonuckleotide-based array CGH (CytoChip 4x180K-Illumina)
we detected copy number changes in the tumor genomes of 23 CLL cases at
diagnosis, with normal karyotype e no FISH alterations. The cytogenetic study
was performed on nuclei and metaphases after stimulation with a combination
of CpG-oligonucleotide DSP30 and interleukin 2 (IL-2). In Chromosome Banding
Analysis (CBA) we analyzed a minimum of 20 metaphases for each patient.
Interphase FISH was performed using a comprehensive set of commercially
available probes, as follows: P53 (TP53)Deletion (17p13), ATM Deletion (11q22),
D13S25 Deletion (13q14.3), MYB Deletion (6q23)[Cytocell], CEP-12 (Chromo-
some 12) [Abbott], XL IGH plus Break Apart Probe [MetaSystems]. A minimum
of 100–200 interphase nuclei were evaluated per probe for each patient.
Results: A total of 21 of the 23 (91%) cases were successfully analyzed by
Oligonuckleotide-based array CGH. We observed a submicroscopic deletion
of chromosome 22q11, as the sole anomaly in 4/21 cases (19%). Patients with
loss 22q11 showed progression disease, and the median Time to Treatment
(TT) was 64.2 months (range 24.6 - 83.1 months). Loss 22q11 ranged in size
from 0.68Mb-0.28Mb. The minimally deleted region included the ZNF280A,
ZNF280B, GGTLC2, and PRAME genes. Moreover this genomic change had
not been detected by standard cytogenetic and/or FISH analyses. Gunn et al.
suggest that the incidence of 22q11 deletions was second only to loss of the
13q14 region, found in approximately 50% of CLL cases; few and divergent
data were reported in literature regarding prognostic impact of this genomic
abnormality in CLL.
Summary/Conclusions: Our results showed that submicroscopic 22q11 dele-
tion is potentially significant genomic aberration in CLL and this alteration is
being missed by the current routine techniques. Moreover, increasing the num-
ber of cases to analyze we can confirm the data obtained and to correlate the
alteration observed to the clinical course.
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EXPRESSION OF FCGAMMARIIB PREDICTS TIME TO TREATMENT IN
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
R Bosch1,2,*, EP Vicente1,2, A Mora1,2, G Ferrer3, R Damle3, S Gorlatov4,
K Rai5, E Montserrat6, J Nomdedeu7, L Blanco7, M Pratcorona7, J Delgado6,
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Hospital Clínic, IDIBAPS, 7Laboratory of Hematology, Hospital de la Santa
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Background: The Fcγ receptor IIb (FcγRIIb) is a low-affinity Fcγ receptor that
negatively regulates B-cell receptor (BCR) function in normal B-cells. In chronic
lymphocytic leukemia (CLL) cells, FcγRIIb may exert this inhibitory effect when
colligated with the BCR. Since CLL cells are activated in vivo, the clinical impact
of FcγRIIb expression in this malignancy is worth of being investigated.
Aims: The aims of this study were to: (1) analyze the basal expression of
FcγRIIb on CLL cells and normal B-cells; (2) investigate the relationship
between FcγRIIb and well-known prognostic markers; and (3) explore the prog-
nostic impact of FcγRIIb on clinical outcome of patients with CLL.
Methods: The study population included 174 patients with active CLL and 34
healthy donors. The median age at diagnosis was 66 years (34-88) and follow-
up was 8.0 years (0-38.7). FcγRIIb expression was determined by flow cytom-
etry using an Alexa488-conjugated mAb specific for human FcγRIIb within the
following combinations: FcγRIIb/CD38/CD19/CD5 and FcγRIIb/CD49d/
CD19/CD5. Results were expressed as the ratio between the MFI for FcγRIIb
and the MFI for the corresponding isotype (MFIR). The Fisher’s exact test and
the Mann-Whitney U test were used for comparisons between groups. Kaplan–
Meier survival and Cox regression analysis were performed to evaluate the
correlation of FcγRIIb expression with clinical outcome. Best cut-offs for time
to treatment (TTT) were determined by ROC curves.
Results: Both CD5+CD19+ leukemic cells and CD19+ normal B-cells
expressed FcγRIIb, with no significant differences in MFIR between the popu-
lations [median MFIR: 46.4 (8.3-153.4) vs 49.4 (30.8-73.2), p=0.812]. FcγRIIb
expression, however, was highly heterogeneous among CLL samples, with
4.5% showing very high expression (outliers). Within clones from the same
patient, FcγRIIb MFIR was higher on CD38+ or CD49d+ cells than on CD38-
or CD49d- cells, respectively (p<0.01). Eighty-one percent (142/174) of patients
showed high (MFIR>30.8) and 19% had low FcγRIIb expression (MFIR<30.8).
We did not find any association between FcγRIIb expression and well-known
prognostic markers except CD49d (p=0.025). However, the correlation between
FcγRIIb and CD49d expression was very weak (κ=0.085) showing concordance
in only 39.7% of cases. At the time of analysis, 52 patients (29.9%) had required
therapy. Patients with low FcγRIIb expression had a significantly shorter TTT
than those with high FcγRIIb expression (median 46.07 vs 62.7 months; log-
rank p<0.028). In univariate analysis, other prognostic parameters, such as
clinical stage, serum B2M, elevated LDH, ZAP70, CD38 and CD49d expres-
sion, IGHV mutational status, cytogenetics, and mutations of NOTCH1 and
SF3B1 significantly correlated with shorter TTT (p<0.01). In a multivariate analy-
sis incorporating FcγRIIb expression, ZAP70, CD38 and CD49d expression,
IGHV mutational status, cytogenetics, and mutations of NOTCH1 and SF3B1,
only low FcγRIIb expression (HR 2.66, 95%CI 1.22-5.80, p=0.014), unmutated
IGHV (HR 3.02, 95%CI 1.30-7.02, p=0.010), and mutated SF3B1 (HR 11.27,
95% CI 2.82-45.12, p=0.001) and NOTCH1 (HR 4.79, 95%CI 1.31-17.48,
p=0.018) retained prognostic significance for shorter TTT.
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Summary/Conclusions: FcγRIIb expression can predict time to treatment in
CLL, underlying a key role of the receptor in the progression of this malignancy.
These results encourage further investigation to characterize the mechanisms
by which FcγRIIb controls CLL cell activation and to uncover the relationship
of FcγRIIb with other molecules, particularly CD49d.
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FYN INHIBITOR INDUCES APOPTOSIS IN NK LEUKEMIA CELLS
I Laurenzana1,*, A Caivano1, L De Luca1, S Trino1, F La Rocca1, V Simeon1,
C Tintori2, F D’Alessio3, A Traficante4, M Maietti4, A Teramo5, R Zambello5,
G Semenzato5, S Schenone6, M Botta2, P Musto7, L Del Vecchio3,8
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Center of Basilicata, Rionero in Vulture (PZ), 2Department of Biotechnology,
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zate s.c.a.r.l., CEINGE, Napoli (NA), 4Unit of Clinical Pathology, IRCCS Referral
Cancer Center of Basilicata, Rionero in Vulture (PZ), 5Department of Medicine
Hematology and Clinical Immunology, Padua University School of Medicine,
Padova, 6Department of Pharmacy, University of Genoa, Genova, 7Scientific
Direction, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ),
8Department of Molecular Medicine and Medical Biotechnologies, University
of Naples, Napoli (NA), Italy
Background: Fyn protein, a member of Src-family kinase, has different bio-
logical functions including growth factor/cytokine receptor, T and B-cell receptor
and integrin-mediated signaling, cell-cell adhesion, mitosis, differentiation of
natural killer (NK) cells. Some studies show its involvement in hematologic
malignancies. However, the tissue-specific pattern of Fyn mRNA expression
indicate that it is more expressed in NK and T cells respect to other human tis-
sues. NK cell neoplasms are a rare and heterogeneous group of disorders
characterized by increased proliferation of cytotoxic NK cells. They include
aggressive NK leukemia (ANKL) and chronic lymphoproliferative disorder of
NK cells (NK-CLPD). ANKL has a fulminant clinical course frequently resulting
in death within two months; NK-CLPD is typically indolent. Since no standard
therapies for immature NK cell neoplasms have been established so far, new
therapeutic options are needed. Tintori et al. found a new Fyn inhibitor by a
structure-based drug design protocol followed by hit-to-lead optimization. The
4c pyrazolo[3,4-d]pyrimidine compound showed antiproliferative activity against
different cancer cell lines.
Aims: The aim of this study was to determine the effect of 4c compound in NK
leukemic cells.
Methods: Fyn mRNA level was evaluated in peripheral blood mononuclear
cells (PBMC) from 10 healthy controls (HC) and 8 NK-CLPD patients by qRT-
PCR; protein level was evaluated in PBMC from 3 HC and 3 NK-CLPD and in
2 ANKL cell lines (KHYG1 and NK92) by western blotting (WB). The 4c com-
pound was tested in a time course MTS assay at increasing concentrations on
HC-PBMC, KHYG1 and NK92. KHYG1 were treated with 4c at 4µM for 24h to
evaluate apoptosis and cell cycle by cytometric analysis, as well as gene
expression profile by Illumina HiScanSQ. Fyn immunoprecipitation and pro-
teome profile arrays of apoptosis and phospho-kinase were also performed.
Expression of procaspase3, active caspase3, P70 and Akt was validated by
WB. 4c compound was tested also in 3 NK-CLPD e 1 ANKL patients. Cell via-
bility was assessed by trypan blue dye count method and apoptosis was verified
by cytometric analysis.
Results: qRT-PCR data showed a significant overexpression of Fyn level in
PBMC of NK-CLPD patients compared to HC. Protein level was highest in NK-
CLPD patients (p<0.001) and NK cell lines (p<0.0001) respect to HC. To verify
the effect of 4c compound, we treated KHYG1 and NK92 with different con-
centrations, showing a reduction of cell viability (EC50= 4µM and 14µM respec-
tively at 24h); on the contrary, there was no effect on HC-PBMC. Moreover,
this treatment induced a significant caspase3 dependent apoptosis (p<0.01)
and G2/M cell cycle arrest. Gene expression analysis of 4c treated or not
KHYG1 identified 455 down-regulated and 326 up-regulated genes, most of
which involved in cell death function, thus confirming the apoptosis data. To
corroborate Fyn inhibition by 4c treatment, we detected a reduction of its phos-
phorylation and we also observed a decrease of phospho-Akt and phospho-
P70, two proteins involved in apoptotic process and cell proliferation. Interest-
ingly, 4c treatment reduced cell viability and activated caspase3 dependent
apoptosis (p<0.05) in 3 NK-CLPD and 1 ANKL patients.
Summary/Conclusions: In this study we demonstrated a higher Fyn expres-
sion in NK leukemia patients compared to healthy controls. We also demon-
strated an apoptotic effect of pyrazolo[3,4-d]pyrimidine 4c compound on NK
leukemia cells and we provided in vitro preliminary evidences that Fyn is its
possible cellular target.
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RETROTRANSPOSONS SHAPED NON-REDUNDANT CLLU1 GENE MODULES
S Papamichos1,*, D Margaritis1, E Spanoudakis1, A Christoforidou1,
Z Bezirgiannidou1, G Koutra2, E Lamprianidou1, I Kotsianidis1
1Department of Haematology, Democritus University of Thrace Medical School,
Alexandroupolis, 2Cardiac Intensive Care Unit, General Hospital of Kavala,
Kavala, Greece
Background: CLLU1 was originally identified as a gene differentiating IgVH-
unmutated (IgVH-UM) and IgVH-mutated (IgVH-M) chronic lymphocytic leukemia
(CLL) and is now appreciated to represent a potent predictor of overall survival
of CLL patients. Whilst CLLU1 is located in a genomic region that is highly
expressed in both germinal center B cells and CLL cells, indicating an open-
chromatin structure, its transcription is highly restricted. CLLU1 expression is
markedly high in IgVH-UM CLL, low in IgVH-M CLL and negligible in normal B-
cell subpopulations or any other hematological specimens tested. Alternative
splicing of the CLLU1 gene generates 7 transcript variants. Previous studies
revealed a powerful linear relation between the expression levels of all the vari-
ants, signifying that transcription is orchestrated by a common promoter located
upstream of exon 1. Accordingly, it was deduced that (epi)genetic aberrations,
occurring during leukemogenesis, could trigger the inordinate activation of this
promoter. DNA methylation microarray analysis identified CLLU1 to present low-
er methylation levels in IgVH-UM CLL cases compared to IgVH-M CLL cases
and to normal B-cells. It was shown that the larger proportion of methylated
sites occupied CLLU1 gene body, while a strong correlation between CLLU1
body hypomethylation and gene expression was also established. Transposable
elements (TEs) carry a markedly high density of CG dinucleotides and remain
heavily methylated in normal cells. Aberrations in DNA methylation marks could
allow for TEs to exert a significant impact on host gene expression. For example,
long terminal repeats (LTRs) of endogenous retroviruses (ERVs) contain tran-
scription regulatory elements that, in the sense orientation, are functional and
could initiate transcription of adjacent human genes.
Aims: Document that non-redundant CLLU1 gene modules were evolutionary
provided by TEs. Provide a rationale for the intriguing transcriptional profile of
the gene.
Methods: CLLU1 genomic sequence was downloaded from the NCBI Gene
database and scanned for the presence of integrated TEs by RepeatMasker.
EMBOSS Cpgplot was used to identify genomic regions of unusual CG com-
position located within CLLU1 body. PROMO Version 3.0.2 software, employing
version 8.3 of TRANSFAC database, was used to evaluate transcription factor
(TF) binding affinity of the region spanning 150 nucleotides (nts) upstream and
downstream of CLLU1 transcriptional start site (TSS), assumed to include
important transcription regulatory elements. CLLU1 locus syntenic alignments
of numerous mammals were downloaded from the UCSC Genome Browser
Database. Phylogenetic and molecular evolutionary analyses were conducted
using MEGA version 6.
Results: CLLU1 exon 1 is located within a region reported from RepeatMasker
to match a sense orientation MLT2B1 LTR, of the ERV-L family. The LTR
extends 109 nts upstream of CLLU1 TSS. CLLU1 start codon was evolutionarily
provided by a MIR element. CLLU1 polyadenylation signal was also provided
by a MIR element. CLLU1 body contains CG-rich genomic content. EMBOSS
Cpgplot analysis identified a CpG island in the gene body, which, however, is
an AluY element of unusually high CG composition than a bona fide CpG island.
Of note is the high Observed/Expected CG ratio within and adjacent to CLLU1
coding DNA sequence. The region spanning 150 nts upstream and downstream
of CLLU1 TSS includes a plethora of high-affinity TF binding sites. Analysis
identified multiple binding sites for TFs known to play a major role in CLL patho-
genesis, namely PAX5, the NF-κB subunit RELA, IRF1 and ELK1. Binding
motifs for known oncoproteins (JUN, MYB) as well as for XBP1, a potent TF
factor in B cells, were also detected. Of note, XBP1 is known to immensely
enhance the transcription of HTLV-I exogenous retrovirus. Phylogenetic analy-
sis revealed that a 4 bp genomic deletion allowed the generation of an ELK1
binding site exclusively in the Hominid genome. Because the DNA sequence
adjacent to the site presents null variation between Hominids and also because
this genomic region includes no common single nucleotide polymorphisms in
human, we assume the occurrence of a selective sweep fostering the creation
of the motif.
Summary/Conclusions: Non-redundant CLLU1 gene modules were provided
by TEs thereby remain heavily methylated in normal cells and become sus-
ceptible to increased hypomethylation during leukemogenesis. This finding
provides a mechanistic link between high CLLU1 expression and poor clinical
outcome prognostication since CLLU1 body hypomethylation occurs predom-
inantly in IgVH-UM CLL cases. - In the Eμ-TCL1 transgenic mouse model,
whilst TCL1 mice are expected to develop an IgVH-UM CLL-like disease phe-
notype at around 11 month, hypomethylation of TEs occurs as early as in 7-
months-old mice. In addition, DNA methylation levels remain relatively stable
over time among IgVH-UM CLL cases, not affected by treatment. The above,
combined with our findings, provide a rationale for CLLU1 expression repre-
senting an inherent and constant feature of a particular CLL clone.
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AMONG CLL PATIENTS WITH MULTIPLE FISH ABNORMALITIES, 13Q AND
11Q DELETIONS ENTAIL THE COMMONEST COMBINATION IN CONTRAST
TO 11Q AND 17P DELETIONS, BEING THE COMBINATION WITH WORSE
OUTCOME
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Background: Fluorescence in-situ hybridization (FISH) defines a hierarchy of
genetic changes that predicts survival in CLL. However, multiple abnormalities
(MA) may also occur and little is known about its distribution and clinical impact.
Aims: To assess the frequency and clinical outcome of 245 patients with CLL
and MA detected by FISH in a database containing clinical and biological data.
Methods: Cases with more than one FISH abnormality were retrieved from
the database. FISH abnormalities included in the routine CLL FISH panel (13q-,
11q-, 17p- and +12) were taken into account.
Results: MA were detected in 245 out of 1743 CLL cases (14%). FISH studies
were performed at diagnosis (FISH-d) in 154 cases (61%), and during disease
evolution (FISH-e) in 91 cases (38%). Among the 91 cases from the group of
FISH-e, 26 cases (11%) had a prior FISH without MA, and 39 cases (16%) had
received treatment for CLL before FISH. The most frequent associations in the
group of FISH-d were the combinations of 13q- with 11q- observed in 52 cases
(33.8%), followed by 13q- with 17p- (37 cases, 24%), and 13q- with +12 (28
cases, 18.8%). By contrast, in the group of FISH-e 13q- and 17p- were the most
prevalent partners (28 cases, 31%) followed by 13q- and 11q- (25 cases, 27%)
and +12 and 17p- (12 cases, 13%). More than 2 abnormalities were observed
in a low proportion of cases: 17 (11%) in the group of FISH-d, and 7 (7.6%) in
the group of FISH-e. Interestingly, most of them included 17p- (14/17 FISH-d;
6/7 FISH-e). The weirdest combination was 11q- and 17p-, only observed in 5
cases (3.2%) in the group FISH-d and 2 cases (2.1%) in the group FISH-e.
Globally, 17p- was found in more cases during disease evolution (48 cases,
52%) than at the moment of diagnosis (66 cases, 42%). Moreover 17p- appeared
as the major clone in a very low proportion of cases in both groups, whereas
13q- or +12 where observed more frequently as the major clone, suggesting
13q- or +12 as early events, in contrast with 17p-. Overall survival (OS) and
time to first therapy (TTFT) were analyzed in the group of FISH-d, being respec-
tively 68 months, and 25 months, for the whole series. The combination of 13q-
and 11q- showed the larger OS (75 months), while CLL with 13q- and 17p-
showed the shorter OS (37 months). Moreover the presence of 17p- was asso-
ciated with a shorter OS (63 m vs 75 m, p=0.02). Regarding TTFT, CLL with
13q- and +12 showed a median TTFT of 53 months while the CLLs with 17p-
and 11q- only had 4 months of TTFT (p=0.017) (Figure 1).
Figure 1.
Summary/Conclusions: MA were observed in 14% of CLL cases, representing
a heterogeneous group. The distribution among combinations was unequal.
The combinations of 13q- with 11q- and 17p- were the most frequent associa-
tions, in contrast to 11q- and 17p-, observed in a minority of the cases. 17p-
often occurred during disease evolution involving minority clones. MA entailed
poor prognosis when emerged at diagnosis, probably due to the high incidence
of bad prognosis aberrations such as 17p- and 11q-. On behalf of Grupo
Español de Leucemia Linfática Crónica (GELLC) and Grupo Cooperativo
Español de Citogenética Hematológica (GCECGH).
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FUNCTIONAL ROLE OF PI3K-DELTA IN MALIGNANT B CELLS
L Neumann*, E Göckeritz, M Hallek, G Krause
Dept. I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Background: Among catalytic PI3K subunit isoforms, p110-δ is highly and
selectively expressed in malignant compared to other cell types and involved
in B cell receptor (BCR) signaling. Idelalisib, which specifically targets p110-δ,
shows clinical efficacy e.g. for the treatment of chronic lymphocytic leukemia
(CLL), but only modest direct cytotoxicity against malignant B cells in vitro. 
Aims: To elucidate the mechanism of action of idelalisib and to dissect the con-
tributions of p110-δ to both cell autonomous functions as well as interactions
with the tumor micro-environment, engineered inhibitor-resistant p110-δ
mutants were employed as chemical genetic tools. In addition cell line models
expressing such mutants might anticipate a potential type of clinically acquired
resistance. 
Methods: According to structural alignment with known inhibitor-resistant p110-
α mutants, p110-δ-I777M and –I825V were generated by site-directed muta-
genesis as potentially inhibitor-resistant mutants. Inhibitor resistance was
assessed by comparing phospho-Akt levels after inhibitor treatment in retrovi-
rally transduced cell lines expressing wild type or mutant p110-δ. Transductants
of the murine fibroblast cell line NIH3T3 were assessed for anchorage-inde-
pendent growth and saturation density as markers of oncogenic transformation.
The emphasis of our chemical genetic evaluation was on malignant B cells and
employed the human Burkitt lymphoma and murine pre-B cell lines Ramos and
BaF/3. Chemokine levels in culture supernatants were determined by enzyme-
linked immunosorbent assay, while chemotaxis to CXCL12 was examined in
trans-well migration assays.
Results: The murine fibroblast cell line NIH 3T3, which lacks endogenous
p110-δ expression and sensitivity to idelalisib, gained sensitivity to idelalisib
concentrations above 1 µM upon over-expression of p110-δ with regard to
phosphorylation of Akt at serine 473. According to pAkt levels, the I777M muta-
tion in p110-δ partly reversed the sensitivity to idelalisib of NIH 3T3 cells
expressing p110-δ. Moreover expression of p110-δ-I777M increased the
anchorage-independent growth and the saturation density of NIH3T3 cells. In
Ramos and Baf-3 cells, which endogenously express p110-δ, additional expres-
sion of p110-δ-I777M led to markedly increased Akt phosphorylation and to
resistance against 10-100 nM idelalisib. Expression of p110-δ-I777M rescued
the secretion of the chemokine CCL-3 by Ramos cells upon stimulation of the
B-cell receptor from inhibition by idelalisib. Chemotaxis of Baf-3 cells to the
chemokine CXCL-12 was reconstituted by expression of p110-δ-I777M in the
presence of inhibitory concentrations of idelalisib.
Summary/Conclusions: The novel engineered p110-δ-I777M mutant showed
an unexpected gain of function and mediated resistance against idelalisib that
can be exploited for the chemical genetic evaluation of p110-δ function. In
malignant B cell lines, p110-δ was less involved in cell autonomous functions
than in their interactions with the micro-environment, exemplified by chemokine
secretion and migration.
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ACTIVATION INDUCED DEAMINASE SPLICE VARIANTS EXPRESSED IN
B CELL LEUKEMIA AND LYMPHOMA DO NOT RETAIN THEIR CATALYTIC
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Š Pospíšilová1,2
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Philadelphia, United States
Background: Activation induced deaminase (AID) is essential for enhancing
antibody affinity and effector functions in B cells during secondary immune
response. It induces somatic hypermutation (SHM) and class switch recombi-
nation (CSR) in the immunoglobulin (Ig) genes. AID is a potent mutator -SHM
frequency in the Ig genes is a million times higher than the frequency of spon-
taneous mutagenesis (10-3 -10-4 mutations/ cell/ generation). AID studies per-
formed in mouse models have shown a correlation between AID activity and
genomic instability. AID is aberrantly expressed in various B lymphoid malig-
nancies and also in some solid tumors. 
Aims: In this project, we set out to investigate the function of four alternatively
spliced AID variants that differ from the full-length protein in the C terminal
domain. These variants are present in an increased proportion in chronic lym-
phocytic leukemia (CLL), Ph-positive acute lymphoblastic leukemia (Ph-positive
ALL) and mantle cell lymphoma (MCL).
Methods: Individual AID splice variants were cloned from peripheral blood CLL
cells into an HA-tagged retroviral vector. Mature B cells purified from AID knock-
out spleens were stimulated with lipopolysaccharide and interleukin-4 and sub-
sequently infected with retroviruses carrying individual AID splice variants. Cells
were cultured ex vivo for a total of 4 or 5 days and then assessed for CSR to
IgG1 by flow-cytometry or sorted based on high GFP expression marking the
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infected cells. The level of SHM in the Ig switch region Sm was assessed by
ultra-deep next generation sequencing. The amount of double strand breaks
in the Ig Sm was quantified by ligation-mediated PCR and hybridization with
an Sm probe.
Results: While full-length AID induced CSR, SHM and double strand breaks
in the Ig genes, alternatively spliced AID variants behaved as catalytically inac-
tive in all performed functional assays. Immunoblotting with an anti-HA antibody
revealed that AID splice variants had lower protein expression compared to
full-length AID. It is a well-established fact in the AID field that in most situations,
AID levels correlate with its activity. Therefore, lower expression of alternatively
spliced AID variants might have contributed to their loss-of function in our model
system.
Summary/Conclusions: Alternatively spliced AID transcripts were previously
shown to be expressed in CLL, Ph-positive ALL and MCL. We hypothesized
that alternative splicing might modulate their activity and consequently change
AID deamination levels in the Ig genes or its targeting in the whole genome.
Results of AID splice variant analysis done in AID knockout mouse B cells stim-
ulated ex vivo indicated their loss of function. Therefore, the role of alternatively
spliced AID expressed in B-lymphoid leukemia and lymphoma remains unclear,
and their function is to be further analyzed using human cell lines derived from
B-cell malignancies.
This work was supported by project No.3SGA5792 financed from the SoMoPro
II Programme that has acquired a financial grant from the People Programme
(Marie Curie Action) of the Seventh Framework Programme of EU according
to the REA Grant Agreement No. 291782 and was further co-financed by the
South-Moravian Region. This publication reflects only the author’s views and
the Union is not liable for any use that may be made of the information con-
tained therein.
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CHROMOSOMAL GAINS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A
RARE EVENT ASSOCIATED WITH A DISMAL PROGNOSIS
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Background: Hyperdiploidy is a common cytogenetic alteration in some hema-
tological diseases such as B acute lymphoblastic leukemia or multiple myelo-
ma, with prognostic value. However, the presence of chromosomal gains other
tan trisomy 12 (+12) in chronic lymphocytic leukemia (CLL) has scarcely been
reported before.
Aims: The aim of this study was to analyze, by FISH, the frequency and prog-
nostic implications of chromosomal gains in CLL.
Methods: A retrospective review of 1,359 consecutive cases diagnosed with
CLL referred for FISH analysis to a unique institution, between 2004 and 2012,
was carried out. Chromosomal gains were considered when a gain of at least
3 out of the 5 FISH probes used (11q22/ATM, 12q13, 13q34, 14q34/IGH, and
17p13/TP53) was observed. In addition, Next Generation Sequencing analysis
was carried out to investigate the mutational status of TP53 (exons 4–11) gene.
Table 1.
Results: 8 cases with chromosomal gains were identified out of the 1,359 CLL
patients (0.59%), referred for FISH studies. One case was excluded from the
analysis due to inadequate follow-up. Five cases (cases nº 3-7) presented
chromosomal gains at diagnosis; the other two (case nº 1 and 2) during disease
evolution and after having received treatment with chlorambucil. Four patients
(57%) were female, and the median age at diagnosis was 74 years (range 63-
86). The median white blood cell count at the time of diagnosis was 16 x 109/L
(range, 7-67). No significant anemia or thrombocytopenia were detected in any
case at diagnosis. It is noteworthy that the immunophenotype of three out of
the seven cases suggested the diagnosis of atypical CLL. Serum LDH and
β2microglobulin levels at diagnosis were high in 57% (4/7) and 29% of the cas-
es (2/7), respectively. Three out of seven (43%) patients presented with
splenomegaly and hepatomegaly, and 29% with more than three enlarged
lymph node regions. The presence of B symptoms was detected in 29% of the
cases. Of note, at the time of diagnosis most cases were classified as early
stages according to Binet classification (stage A 57%; stage B 29%; stage C
14%). IGHV mutation status was available in 57% of the cases being all of
them classified as unmutated pattern. Besides chromosomal gains, additional
chromosomal abnormalities were detected in 57% of the patients including:
17p- (2 cases), 11q- and IGH alteration (1 case), and 13q- and IGH deletion
(1case). Detailed FISH results are shown in Table I. Only one patient (case nº
7) showed a missense TP53 mutation (c.613T>G; p.Y205D) with a mutational
burden of 95%. This variation was previously described as a mutation in the
COSMIC database (COSM43844). This TP53 mutated case did not show 17p
deletion. Six patients (86%) required treatment during follow-up with a median
TTFT of 1.4 months (CI95%, 0.8-1.9). Most treated patients (4/6, 66%) required
two or more chemotherapy therapies (median 3, range: 1-4), due to refractori-
ness or relapse. Median duration of response to first line treatment was 7
months (0-36). With a median follow-up of 66 months (6-115), 5 patients have
died due to: disease progression (3 cases), infection (1 case), and cardiovas-
cular disease (1 case). Median OS from the time of diagnosis was 66 months
(CI95%, 0-174), and from the time of chromosomal gains acquisition was 20
months (CI95%, 16-24).
Summary/Conclusions: Chromosomal gains are a rare event in CLL. Our
results also suggest that the presence of chromosomal gains involves poor
prognosis in these patients.
This work was supported by grants from the Spanish Fondo de Investigaciones
Sanitarias FIS 09/01543, PI15/01471.
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S Bossio1,*, L De Stefano2, F Storino2, N Caruso3, A Palummo2, G Iaquinta2,
G Cutrona4, M Gentile3, E Vigna3, M Ferrarini5, A Neri6, F Fais4, P Tassone7,
AG Recchia2, F Morabito8
1Unità di Ricerca Biotecnologica, Azienda Sanitaria Provinciale, Aprigliano (CS)
and A.O. of Cosenza, Cosenza, Italy, 2Unità di Ricerca Biotecnologica, Azienda
Sanitaria Provinciale, Aprigliano and Hematology Unit, Department of Onco-
hematology, Aprigliano (CS), 3Hematology Unit, Department of Onco-hema-
tology, A.O. of Cosenza, Cosenza, 4IRCCS, 5IRCSS Scientific Division, AOU
S. Martino-IST, Genova, 6Centro di Ricerca per lo Studio delle Leucemie, Fon-
dazione IRCCS, Università di Milano, Milano, 7University of Magna Graecia
and Cancer Center, Catanzaro, 8Hematology Unit, Department of Onco-hema-
tology, Azienda Sanitaria Provinciale, Aprigliano and Hematology Unit, Depart-
ment of Onco-hematology, Cosenza, Italy
Background: The proteomic approach is essential in the multi-disciplinary
field of hematological research. Previously, using MALDI-TOF analysis we
identified Tβ4, a G-actin sequestering protein involved in the regeneration of
injured tissues and cell migration, as a downregulated protein in CLL patients,
also confirmed by an independent GEP analysis comparing B-CLL cells and
normal controls.
Aims: Here, using 2DE proteomic analysis we evaluated differential protein
expression patterns after treatment with exogenous Tβ4 and/or Len, which has
been shown to improve immune dysfunction in CLL by repairing actin poly-
merization and rapid signaling at the immunological synapse. We investigated
whether purified B-CLL cells having high/low Tβ4 expression respond differently
to migratory stimuli such as CXCL12/SDF1α.
Methods: Purified B-CLL lymphocytes were isolated from untreated Binet stage
A CLL patients prospectively enrolled atdiagnosis (O-CLL1 clinicaltrial.gov iden-
tifier NCT00917540) and healthy controls. N=93 patients were evaluated for
Tβ4 expression by Flow cytometry (FC, medianRFI=15.06, IQR:6.9–28.8).For
migration assays, SDF1α (100nM) as chemoattractantwas used to determine
the CLL migration index. B-CLL cells from two patient samples havinglow or
highTβ4expression were pre-treated with Len (5mM) and then with Tβ4
(100nM)for 2DE analysis.
Results: CLL samples with the lowest Tβ4 expression (n=12) also had higher
F-actin levels as evaluated by FC than normal controls (n=7) in a sample cohort
(n=93). FC assessed Tβ4 expression in B-lymphocytes in CLL patients (n=93)
vs controls (n=7). Tβ4RFIvalues showed Tβ4 expression was heterogeneous
(Tβ4RFI=1.3–152.05;medianRFI=15.06) compared to controls (Tβ4RFI=3.4–
70.9;medianRFI=38.3). Baseline F-actin expression is also influenced by dif-
ferent levels of Tβ4 expression: CLL CD19+CD5+ samples with Tβ4highalso
had higher G-actin expression, with a lower F/G-ratio, and conversely Tβ4low
samples, there wasa higher expression of F-actin, with a higher F/G-ratio
(n=14), also confirmed by FC experiments. CD19+CD5+ CLL cells express
high levels of functional CXCR4/CD184,which facilitates CLL cell migration
beneath stromal cells. B-CLL strongly responded to the migratory stimulus
SDF-1α. Furthermore, migration induced by SDF1α increased in CLL cells after
Len (0.5 µM) treatment. Conversely, the CLL with Tβ4low was more responsive
to Len inhibition, resulting in a reduction in migratory potential towards SDF1α.
Purified B-CLL lysates (n=2) were analyzed by 2DE analysis. Protein profile
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analysis showed a number of protein spots ranging from 18 to 60kDa that were
differentially expressed with respect to cells exhibiting Tβ4low/high expression.
More importantly, treatment with Len or following Tβ4 replenishment also
changed protein expression in function of the endogenous Tβ4
Summary/Conclusions: Our preliminary qualitative analysis suggests that the
proteomic profile of CLL samples exhibiting higher or low Tβ4 levels also cor-
respond to groups of proteins with a differential protein expression. Moreover,
in the presence of Tβ4 or Len, or Tβ4/Len combination these proteins may
respond with a strong inhibition or up-regulation of the expression of other pro-
teins. Here,we show that 2DE evaluation of CLL profiles may be useful to iden-
tify changes in expression profiles of CLL proteins following treatment with dif-
ferent agents. These differences may translate into functional differences such
as cell migration and cytoskeletal dynamics in the malignant clone.Special
thanks to Celegene Corp and AIRC-CARICAL Regional Grant 16695.
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A COMPARATIVE STUDY ON THE EFFECTS OF NUTLIN-3A IN B-CLL
CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH AND WITHOUT 17P
DELETION
M Reiter, S Schnabl, M Hilgarth, E Ponath, R Hubmann, D Demirtas, C Zielinski,
U Jäger, M Shehata*
Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Background: The p53-MDM2 interaction is emerging as a promising thera-
peutic target in chronic lymphocytic leukemia (CLL). It is well known that MDM2
oncoprotein inhibits the function of wild-type p53 by its degradation and that
MDM2 inhibitors are mainly effective in CLL cases with wild type p53. However,
there is no substantial data on the effect of MDM2 inhibitors on CLL cells with
p53 mutation or 17p deletion (17p-).
Aims: The aim of this work is to have a deeper insight into the effect MDM2
inhibitor Nutlin-3a on CLL cells obtained from patients with or without 17p dele-
tion under standard suspension culture conditions and in a microenvironment
model using co-cultures of CLL cells with primary bone marrow stromal cells
(BMSC). This includes evaluating the effect of Nutli-3a on cell viability, induction
of apoptosis and the regulation of key p53 downstream targets.
Methods: Peripheral blood mononuclear cells (PBMC) were obtained from 25
B-CLL patients with (n=7) and without (n=18) 17p deletion and exposed to Nut-
lin-3a under suspension or co-culture conditions for 2-3 days. Dose and time
kinetics were also performed and cell viability was evaluated by MTT assay.
Induction of apoptosis was assessed by AnnexinV/propidium iodide (PI) staining
and FACS analysis. In parallel, a selective effect of Nutlin-3a on CLL cells, T-
cells and monocytes was investigated using specific markers for B cells (CD19),
T-cells (CD3) and monocytes (CD14) in combination with PI. In addition, the
effect of Nutlin-3a on the key p53 downstream targets involved in the regulation
of apoptosis (MDM2, Bax, PUMA, Noxa and Mcl-1), cell cycle regulation (p21)
or DNA repair (PARP) was assessed by Western blotting and RT-PCR.
Results: In vitro treatment with Nutlin-3a induced cell killing in CLL cells from
patients with and without 17p deletion as demonstrated by MTT assays. The
effect of the inhibitor was relatively higher on the samples from patients with
wild-type 17p at low concentrations (0,5µM to 1µM) compared to patients with
17p deletion. However, at higher concentrations (1-10µM), Nutlin-3a showed a
remarkable effect on both groups. A similar pro-apoptotic response to Nutlin-
3a was detected by FACS analysis experiments where Nutlin-3a induced 2,5
fold increase in apoptosis rate in patients without 17p deletion compared to 1,6
fold increase in apoptosis in patients with 17p deletion. The pro-apoptotic effect
of Nutlin-3a was comparable under suspension and co-culture conditions and
was higher in CLL (CD19+) cells compared to T-cells and monocytes. Consis-
tent with the increase in apoptosis rates, Nutlin-3a treatment induced the
expression of p53 downstream target p21 mRNA and this was associated with
PARP cleavage in both patient groups.
Summary/Conclusions: These data confirm the beneficial effect of Nutlin-3a
in CLL and further suggest that MDM2 inhibitors might be effective in 17p wild-
type and 17p deleted patients depending on the concentration of Nutlin-3a.
Therefore, the clinical relevance of these data deserves further investigations.
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DNA-DEPENDENT TRANSCRIPTIONAL REGULATORY GENES WERE
HYPOMETHYLATED IN KOREAN CHRONIC LYMPHOCYTIC LEUKEMIA-A
METHYLCPG BINDING DOMAIN NGS STUDY
YK Lee1,*, M Kim1, EJ Lee1, HJ Kim2, DY Zang2, HY Kim2, E Lee1
1Department of Laboratory Medicine, 2Department of Internal Medicine, Hallym
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Background: Chronic Lymphocytic Leukemia (CLL) is the most common
leukemia in Western countries, but it is very rare and shows relatively poor
prognosis in Asian countries including Korea. 
Aims: To investigate the differences in the pathobiology of Korean CLL, we
analyzed the methylation profile and the expected affected pathways using the
methylCpG binding domain NGS (MBD-seq).
Methods: Bone marrow aspirate of 9 CLLs and 5 control individuals were used
for MBD-seq using MethylMiner Methylated DNA Enrichment Kit and Illumina
Hi-Seq 2000. Differentially methylated regions (DMRs) were determined by fil-
tering for each regions associated with |log2FC|≥1 and exact test p-val-
ues<0.05. Hierarchical clustering analysis, gene-enrichment and functional
annotation analysis was performed.
Results: Pair-wise correlation coefficient matrix showed a high similarity was
observed among either CLL group or control group, but not between the CLL
group and the control group. Among 79,612 tested regions regarding to 18,434
genes with CpG islands, CLL group showed 2,078 DMRs (780 genes)-1,083
hypermethylated regions (350 genes) vs 995 hypomethylated regions (430
genes). In CpG islands analysis, the DMR profiling clearly separated CLL group
from control group. The most frequently hypermethylated genes included
ANKRD20A2, CHERP, PRPF38A, C1orf123, FKTN, TRAFD1, SH3D21,
MGAT1, NECAB3 and UCKL1. Gene ontology analysis showed genes related
with protein localization, cellular macromolecule localization and protein trans-
port were hypermethylated. The most frequently hypomethylated genes includ-
ed CBX4, OSR2, LMX1B TNRC18, ICAM5, GATA6, CDX2, NR3C2, STK3 and
HOXB8. Gene ontology analysis showed genes related DNA dependent tran-
scriptional regulation and RNA metabolic process regulation were hypomethy-
lated. Pathway analysis showed genes related pathways in cancer or hedgehog
signaling pathway were hypomethylated.
Summary/Conclusions: We performed the whole genome methylation profile
analysis using NGS MBD-seq in Korean CLL for the first time. Our result demon-
strated that Korean CLL has a distinct methylation profile. Genes related with
protein localization, cellular macromolecule localization and protein transport
were hypermethylated, and genes related DNA dependent transcriptional reg-
ulation and RNA metabolic process regulation were hypomethylated. Cancer
pathway and hedgehog signaling pathway could be overexpressed due to
hypomethylation in relevant genes. 
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INCREASED EXPRESSION OF PIM2 GENE IS ASSOCIATED WITH POOR
PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
K Kapelko-Slowik1,*, D Urbaniak-Kujda1, J Dybko1, D Wolowiec1, B Jazwiec1,
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Background: PIM2 gene belongs to PIM family, which encodes serine/threo-
nine kinases involved in cell survival and apoptosis. PIM2 gene is implicated in
many neoplasms including solid tumors and acute myeloid leukemia. The rela-
tion between expression of PIM2 gene and course of chronic lymphocytic
leukemia`s (CLL) as well as outcome has not been fully defined.
Aims: The aim of the study was to evaluate the role of PIM2 gene as a marker
for CLL malignancy and the importance of PIM2 gene expression as a prog-
nostic factor in CLL.
Methods: Sixty-seven patients, 35 females and 32 males, aged 49-90 years
(median age was 66 years) with de novo CLL were enrolled in the study. Thir-
ty-two patients reached complete remission (CR). Bone marrow samples were
collected in all patients at the time of diagnosis, whereas only samples with
monoclonal lymphoid cells for more than 80% of total cellularity were assessed.
In 16 patients bone marrow in CR phase was examined. The control group
consisted of 14 healthy individuals. The expression of PIM2 gene was analyzed
by Taq Man RQ-PCR assay and PIM2 protein was detected by Western blot.
All statistical analyses were performed using Statistica software.
Results: Median PIM2 gene expression in CLL patients was significantly higher
than in control group. CLL patients with high expression levels of PIM2 gene
(above the median) had significantly shorter progression free survival (PFS)
than patients with low PIM2 expression (p=0.001). In addition, it was found that
patients who achieved CR, had significantly lower expression of PIM2 gene
than patients with no CR (p=0.002). Importantly, elevated PIM2 gene expression
assessed initially, was restored to normal level in all patients in CR. Moreover,
the overexpression of the PIM2 kinase was detected in CLL patients in contrast
to controls. PIM2 expression in correlation to CLL Rai stages was evaluated
also and it was noted that PIM2 expression in stages IV and III was higher than
in both stages I and II (p=0.002). Moreover, CLL patients with rapid lymphocyte
doubling time (LDT) (<12 months) shown higher PIM2 expression than patients
with lower LDT (≥12 months), p=0.003. Positive correlation between PIM2 gene
expression and the percentage of malignant lymphocytes with ZAP70 expres-
sion was found (r2=0.3214 p=0.01).
Summary/Conclusions: We showed that increased expression of PIM2 gene
in CLL cells is associated with poor prognosis and resistance to chemotherapy
in CLL patients.
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RECOVERY OF TUMOUR SUPPRESSOR FUNCTION OF NOTCH3 BY AN
ASPERGILLUM DERIVED MYCOTOXIN IN CHRONIC LYMPHOCYTIC
LEUKAEMIA (CLL)
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Background: Deregulation of NOTCH2 signalling is critically involved in CLL
leukemogenesis. We have recently shown that CLL cells are less sensitive to
γ-secretase inhibitors (GSI) indicative for the expression of constitutively active
NOTCH2 forms which do not depend on γ-secretase for processing and func-
tion. In contrast, targeting CLL cells with the Aspergillum derived NOTCH2
transactivation inhibitor gliotoxin efficiently induced apoptosis in the leukemic
cells by a mechanism which appeared to involve the induction of NOTCH3.
Aims: To gain deeper insight into the function of NOTCH3 in CLL cells, we
analysed NOTCH3 expression in relation to spontaneous and gliotoxin induced
apoptosis and tested the effect of NOTCH3 inhibition on CLL cell viability.
Methods: The NOTCH3 gene was inhibited by GSI (RO4929097) or by siRNA
mediated gene silencing. Apoptosis was calculated as the sum of PI-/AnxV+
(early apoptosis) and PI+/AnxV+ (late apoptosis) cells. The expression of
NOTCH and apoptosis related genes was monitored by RT-PCR and FACS
analysis.
Results: Results showed that inhibition of NOTCH2 signaling by gliotoxin led
to the concomitant induction of NOTCH3 signalling as indicated by the induced
co-expression of NOTCH3 and its ligands JAG2 (in unstimulated CLL cells) or
DLL1 (in PMA activated CLL cells) at the mRNA level. Gliotoxin induced a
tumour suppressive NOTCH3 signalling signature as demonstrated by the
induction of the apoptosis regulating NOTCH3 target genes HEY1, NR4A1,
and CDKN1A (p21) in the pre-apoptotic phase. In contrast, the anti-apoptotic
genes NOTCH2, FCER2 (CD23), and AKT1 were inhibited by gliotoxin. We
then tested the effect of gliotoxin and GSI on induction of apoptosis. Gliotoxin
induced apoptosis in CLL cells (mean %±SD: 85±10% versus 13±5%), while
GSI (RO4929097) mediated NOTCH3 inhibition was associated with a
decrease in spontaneous (7±3% versus 13±5%) and gliotoxin induced apop-
tosis (51±7% versus 85±10%) in the leukemic cells. To directly confirm that
NOTCH3 has a pro-apoptotic role in CLL, we silenced NOTCH3 by RNA inter-
ference. After 3 days in culture, NOTCH3 siRNA decreased the apoptotic effect
of gliotoxin leading to a 3.5-fold increase in the percentage of living CLL cells.
Inhibition of NOTCH3 by siRNA was also associated with an increased surface
expression of CD23, a downstream target of NOTCH2. These data show that
the inhibition of NOTCH3 may lead to the upregulation of NOTCH2/CD23 axis
and resistance to apoptosis. This reciprocal regulation of NOTCH2 and
NOTCH3 together with their opposite effects on cell viability strongly suggests
that these two NOTCH receptors have different roles in the regulation of the
viability of CLL cells. Interestingly, NOTCH3 mRNA could be detected in
patients with early stage of the disease (Rai 0-II) but not in Rai III-IV. Thus, in
CLL cells, constitutive active NOTCH2 signalling might suppress pro-apoptotic
NOTCH3 signalling enabling the expansion of the malignant clone particularly
in advanced stages of the disease.
Summary/Conclusions: In summary, these novel data indicate that selective
targeting oncogenic NOTCH2 might recover a pro-apoptotic NOTCH3 activity
which should be considered in the design of therapies aimed to target the
NOTCH pathway in CLL cells. Moreover, this data points for the first time to a
tumour suppressive function for NOTCH3 in CLL.
Chronic lymphocytic leukemia and related
disorders - Clinical
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SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED
STUDY INCLUDING 13,034 PATIENTS DIAGNOSED IN 1982-2013 IN
SWEDEN
V Steingrímsson1,*, SH Lund2, PW Dickman3, C Weibull3, M Björkholm4,
O Landgren5, SY Kristinsson1,4
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Background: Chronic lymphocytic leukemia (CLL) is the most common
leukemia in Western countries with a median age between 65-74 years at diag-
nosis. In clinical trials on CLL treatment, elderly patients with comorbidities
have been heavily underrepresented and therefore population-based studies
on survival are important to estimate effects of newer treatment on survival.
Few observational studies on survival in CLL have been conducted and they
have not been consistent in showing improved survival. 
Aims: To evaluate the effect of the introduction of new drugs on survival in
CLL patients, we conducted a population-based study in CLL patients diag-
nosed in Sweden from 1982 until 2013, with follow-up through 2014.
Methods: Information on CLL patients diagnosed between January 1, 1982 and
December 31, 2013 was retrieved from the well-established Swedish Cancer
Registry. The registry has been validated with regards to CLL and has a diagnostic
accuracy of more than 90%. Relative survival ratios (RSR) and excess hazard
ratios (EHR) were used for estimating the impact on patient survival.
Results: Between January 1, 1982 and December 31, 2013, a total of 13,034
CLL patients were reported to the Swedish Cancer Registry. Age was a signif-
icant predictor of survival reflected in reflected in EHRs of 1.48 (95% confidence
interval (CI) 1.21-1.81), 2.69 (2.22-3.27) and 5.37 (4.33-6.66) for age groups
51-65, 66-80, and >81 years, respectively, compared to the reference interval
of<50 years. Similar results were obtained when comparing 1-, 5- and 10-year
survival between age groups. Males had a significantly increased excess risk
of death compared to females (EHR=2.12, 95%, CI 1.93-2.34) and worse 1-,
5-, 10- and 15-year RSR. A significantly increased excess risk of death was
observed in CLL patients diagnosed in the calendar period 1993-2002 com-
pared to 2003-2013 (EHR=1.36; 95% CI 1.22-1.51). Furthermore, a significantly
improved 5- and 10-year RSR was observed comparing CLL patients diag-
nosed 2003-2013 (5-year RSR 0.81, 95% CI 0.79-0.82 and 10-year RSR 0.61,
0.58-0.65) to 1993-2002 (0.75, 0.73-0.77 and 0.54, 0.51-0.56, respectively.
When stratified by age groups, the excess risk of death was significantly higher
in 1993-2002 compared to 2003-2013 in age groups<50, 51-65 and 66-80
years old, with EHR 2.87 (95% CI 1.52-5.42), 1.56 (1.26-1.93) and 1.25 (1.08-
2.13), respectively. However, it was non-significant in patients 81 years and
older (EHR=1.23, 95% CI 0.96-1.58). In age groups<50 and 51-65 years the
5-year survival was significantly better when calendar period 1993-2002 was
compared to 2003-2013 (Figure). The 5-year RSR in age group<50 years old
was 0.84 (95% CI 0.79-0.90) in 1993-2002 vs 0.99 (95% CI 0.97-1.01) in 2003-
2013 and in the age group 51-65 years the RSR was 0.84 (0.81-0.86) in 1993-
2003 vs 0.91 (0.89-0.93) in 2003-2013. The difference in 5-year RSR was non-
significant in older age groups.
Figure 1.
Summary/Conclusions: We have in this large population-based study, includ-
ing more than 13,000 patients with CLL, shown improvement in survival of CLL
patients in the last decade and the difference is most apparent in younger
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patients. Younger patients are in general healthier and less likely to have comor-
bidities. Based on our results we conclude that risk stratification is likely to ben-
efit older patients for better selection of those patients that can receive intensive
treatment. Furthermore, a more significant improvement in overall survival in
elderly patients might be obtained with the introduction of a more targeted ther-
apy with less side effects.
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IDELALISIB IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB
IMPROVES OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/
REFRACTORY CLL: INTERIM RESULTS OF A PHASE 3 RANDOMIZED
DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
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Background: Patients (pts) with relapsed/refractory CLL and adverse prog-
nostic features (e.g., del17p/TP53mut) respond poorly to standard treatment.
Here we present results of a pre-specified subgroup analysis of OS and ORR
from an ongoing randomized double-blind placebo-controlled study (Clinical-
Trials.gov ID: NCT01569295).
Aims: To demonstrate an improvement in OS and ORR in pts on idelalisib
(IDELA) in combination with bendamustine/rituximab vs bendamustine/ritux-
imab alone in pts with relapsed/refractory CLL and in a pre-specified pt popu-
lation with adverse risk features.
Methods: Between June 2012 and August 2014, 416 pts with relapsed/refrac-
tory CLL from 180 centers in North America, Australia, New Zealand, and
Europe were enrolled in this ongoing study. After informed consent, eligible pts
were randomized 1:1 to idelalisib 150 mg BID (207 pts) or matching placebo
(209 pts). All pts received bendamustine 70 mg/m2 on days 1 & 2 and rituximab
375 mg/m2 day 1 of cycle 1 and 500 mg/m2 D1 cycles 2 to 6. A cycle of the reg-
imen was Q28 days. Study treatment continued until disease progression,
death, intolerable toxicity, or withdrawn consent. Stratification performed by an
independent laboratory was by del17p, TP53 mutations, or mutated IGHV, and
clinically by refractory (progression<6 months from completion of prior therapy)
or relapsed (progression at least 6 months from completion of prior therapy)
disease. Median follow-up at the time of this report was 12 months. The primary
endpoint of PFS defined by standard criteria was adjudicated by an IRC. Overall
survival and ORR were secondary endpoints. Crossover was not permitted at
the time of CLL disease progression.
Results: Median overall survival was not reached in either arm; there was a
statistically significant improvement in overall survival, after the pre-specified
multiplicity adjustment, in the idelalisib arm (HR=0.55; 95% CI: 0.36, 0.86;
P=0.008 [stratified]). As of 15 June 2015, there were 34 deaths in the idelalisib
arm and 51 deaths in the placebo arm. An improvement in ORR was observed
on the idelalisib vs placebo arm in all adverse-risk categories evaluated (Table).
Table 1.
Summary/Conclusions: Idelalisib in combination with bendamustine and rit-
uximab is superior to bendamustine and rituximab alone, reducing the risk of
death and disease progression, and increasing progression-free and overall
survival. Overall response rate was also increased on the idelalisib arm. These
results were consistent across pts with adverse-risk features. The safety profile
was consistent with prior reported studies. This trial provides further evidence
for the improved outcomes for idelalisib-based therapy in pts with relapsed/
refractory CLL. This regimen represents an important new treatment option for
the management of relapsed/refractory CLL, further establishing the role of
idelalisib in this setting.
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Background: The oral BTK inhibitor ibrutinib is effective and well-tolerated for
patients (pts) with relapsed/refractory (R/R) CLL and MCL; however, the rate of
complete remission (CR) is low, and response duration is limited in MCL and in
CLL with del(17p) or complex cytogenetics. TGR-1202 is a 2nd generation oral
PI3K-delta specific inhibitor with promising efficacy and tolerability. We hypoth-
esized that dual BCR pathway blockade would be tolerable and efficacious.
Aims: The primary aim of this open-label, phase I/Ib investigator-initiated mul-
ticenter trial is to determine the RP2D (recommended phase 2 dose) and the
safety/tolerability of TGR-1202 plus ibrutinib in pts with R/R CLL or MCL. Sec-
ondary aims are to assess efficacy including response rates, duration of
response, and PFS/OS.
Methods: Pts received continuous simultaneous daily oral dosing of ibrutinib
(420 mg CLL, 560 mg MCL) and TGR-1202, starting at 400 mg daily and esca-
lating in a standard 3+3 design from 600 to 800 mg. The DLT observation period
was the first 28 day cycle, with CLL and MCL pts evaluated in separate cohorts.
Pts continue until progression or unacceptable toxicity. Eligibility criteria include:
≥1 prior therapy, requiring treatment by IW-CLL criteria, ECOG PS ≤2, and ade-
quate hematologic and organ function. Prior BTK or PI3K inhibitors were
allowed. CTCAE v4 and IW-CLL criteria were used to evaluate toxicity and effi-
cacy, with response evaluations after 2 mo., every 3 mo. up to 1 year, and
every 6 mo. thereafter.
Results: As of 25 Feb 2016, 20 pts were enrolled, 10 CLL, 10 MCL. The median
age at enrollment was 66 yrs. (range 48-83). The median number of prior thera-
pies was 2 for CLL (range 1-6, including 2 with prior ibrutinib and 2 with prior
PI3Ki) and 3 for MCL (range 2-5, including 2 with prior ibrutinib). Two CLL pts
had del(17p), 2 had del (11q), and 7/10 (70%) had unmutated IGHV. The phase
I portion in both diseases is now complete. Hematologic toxicities in CLL: neu-
tropenia (37.5%, all gr 3-4), thrombocytopenia (25%, all gr 1), and anemia (37.5%,
all gr 1/2). All grade non-hematologic toxicities occurring in >25% of CLL pts:
diarrhea and nausea (37.5% each, all gr 1). There were no DLTs, and SAEs
included gr 3 atrial fibrillation, gr 3 lipase elevation, and gr 3 CNS infection. The
RP2D of TGR-1202 was 800 mg. Hematologic toxicities in MCL: neutropenia
(37.5%, 12.5% gr 4), thrombocytopenia (50%, 12.5% gr 3), and anemia (37.5%,
12.5% gr 3). All grade non-hematologic toxicities occurring in >25% of MCL pts:
diarrhea (75% [62.5% gr 1, 12.5% gr 2]), fatigue (50%, all gr 1/2), and 37.5%
each for nausea (all gr 1/2) and transaminitis, dizziness, hypocalcemia (all gr 1).
There were no DLTs, and SAEs included gr 3 hypophosphatemia in 2 pts and 1
pt with gr 3 amylase / gr 4 lipase elevation. The RP2D of TGR-1202 was 800 mg.
There were no gr 3/4 bleeding events in either cohort. 6/9 (68%) of CLL pts
achieved response, including 1 CR and 5 PR or PR-L. 4/7 (57%) of MCL pts who
have reached the first response evaluation achieved response (all PR).
Summary/Conclusions: We report to our knowledge the first clinical data on
combined delta-PI3K and BTK inhibition in B cell malignancies. TGR-1202 plus
ibrutinib is well-tolerated in pts with R/R CLL and MCL, with no DLTs observed to
date. The RP2D of TGR-1202 for both CLL and MCL was 800 mg daily. Preliminary
efficacy data suggest a high response rate in both diseases, and phase Ib expan-
sion cohorts at 800mg are now accruing in this ongoing study (NCT 02268851).
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CLINICAL EPIDEMIOLOGY OF CLL AND CYTOGENETIC ABNORMALITIES:
ASSOCIATION OF UNIQUE EPIDEMIOLOGIC EXPOSURES WITH 17P OR
11Q DELETION IN NEWLY-DIAGNOSED CLL
JM Foran1,*, MM O’Byrne2, AA Chanan-Khan1, JF Leis3, NE Kay4,
DL Van Dyke5, JR Cerhan2, TD Shanafelt4, SL Slager2
1Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Jack-
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sonville, 2Department of Health Sciences Research, Mayo Clinic, Rochester,
3Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center,
Phoenix, 4Division of Hematology, 5Cytogenetics Laboratory, Mayo Clinic,
Rochester, United States
Background: Clinical epidemiologic exposures associated with risk of devel-
oping CLL have been described in large case-control studies, including allergy,
some autoimmune diseases, obesity, medical and family history, and some
occupational exposures including rural/farm habitat. However, it is not known
whether specific exposures are associated with a unique disease phenotype,
and specifically whether risk factors for development of CLL are themselves
associated with adverse cytogenetic profile by FISH, namely del(11q) and
del(17p).
Aims: Primary Aim: To determine whether common clinical epidemiologic expo-
sures associated with development of CLL are associated with a unique cyto-
genetic profile as determined by FISH at the time of diagnosis, and specifically
which CLL risk factors are associated with adverse FISH profile [del(11q) and
del(17p), either alone or in combination with other abnormalities]
Methods: We used cases from the Mayo Clinic Case-Control Study of Lym-
phoma, annotated with molecular markers from the Mayo Clinic CLL database
to evaluate associations of medical history, lifestyle, family history, and farming
history in a case-only study of the risk 17p or 11q deletion in CLL patients.
Newly diagnosed CLL patients were enrolled between 2002 and 2012, and
weight was patient-reported from 2 years prior to diagnosis. Unconditional
logistic regression was used to estimate Odds Ratios (ORs) and 95% Confi-
dence Intervals (CI) for risk adverse FISH profile (11q or 17p deletion). A sig-
nificance level of 5% was used to determine statistical significance. 
Results: We included n=683 patients, of whom n=100 had 11q or 17p dele-
tions. Results of the analysis are noted in the Table.
We observed a significant association of rheumatoid arthritis with adverse FISH
profile (11q or 17p deletion) at diagnosis (OR=2.49, 95% CI 1.06-5.86,
p=0.037). In contrast, we observed a significant inverse relationship of any
Allergy (Food, Plant, Animal, Insect, Dust, Mold) (OR=0.59, 95% CI 0.36-0.96,
p=0.035) and of Atopy (OR 0.63, 95% CI 0.40-0.99, p=0.045) with adverse
FISH profile. Other common exposures including obesity, smoking, and farm
exposures were not associated with high risk FISH profile. Similarly, family his-
tory was also not associated with an adverse FISH profile, consistent with ear-
lier reports.
Table 1.
Summary/Conclusions: Some clinical epidemiologic risk factors (allergy,
atopy and rheumatoid arthritis) associated with the development of CLL are
themselves significantly associated with specific disease-related cytogenetic
abnormalities as determined by FISH profile at diagnosis. This suggests that
some CLL risk factors may be associated with a unique clinical and genetic
phenotype, which may influence disease biology and prognosis after diagnosis.
Specific exposures that appear to mediate disease risk through alternate path-
ways of immune stimulation (i.e. allergy and atopy vs rheumatoid arthritis) are
associated with a significantly different cytogenetic risk profile at diagnosis,
suggesting that they likely have unique mechanisms of leukemogenesis. Fur-
ther studies are ongoing to determine the impact of CLL epidemiologic risk
factors on clinical outcome in association with other clinical and biological prog-
nostic factors at diagnosis.
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ASSESSING TIME TO FIRST TREATMENT IN EARLY CLL: A COMPARATIVE
PERFORMANCE ANALYSIS OF FIVE PROGNOSTIC MODELS WITH
INCLUSION OF CLL-IPI
S Molica1,*, D Giannarelli2, M Gentile3, R Mirabelli1, L Levato1, F Morabito3
1Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro,
2Biostatistic Unit, IRCCS Regina Elena, Roma, 3hematology-Oncology, Azien-
da Ospedaliera Annunziata, Cosenza, Italy
Background: Recent research in CLL focused on the development of prog-
nostic scores which assemble in a same model different prognostic markers.
However, analyses comparing the performances of these models are lacking.
Aims: In a prospective patient cohort we evaluated the capability of four recent-
ly proposed prognostic models in CLL (i.e., 2007 MDACC score, GCLLSG
score, 2011 MDACC score,O-CLL1 score) to predict time to first treatment
(TTFT). Results were compared with those obtained using the CLL-IPI.
Methods: Newly diagnosed Binet stage A patients (n=337) from several Italian
Institutions prospectively enrolled into the O-CLL1 protocol (clinicaltrial.gov
identifier: 115 NCT00917540) form the basis of this analysis.
Results: The Harrell’s c values which indicate the discriminatory power of the
models (higher is better) were better for 2011 MDACC score (c-index, 0.71)
and the O-CLL1 score (c-index,0.75) which were generated looking at TTFT
as endpoint and combine clinical, biological and genetic markers. The same
applied with GCLLSG (c-index,0.70) score and CLL-IPI (c-index, 0.70) even
though they were originally developed with overall survival as main end pont.
Finally, a c-statistic below 0.70 which is the threshold necessary to have value
at the individual patient level was observed with 2007 MDACC score (c-index,
0.65) which was designed to assess overall survival as end point and did not
incorporate major genetic factors. A global view of performances of different
scores was also provided by the area under the receiver operating character-
istic (ROC) curve figures considered an alternative measure of discrimination
(Figure 1). Furthermore, the time-dependent ROC analysis which is an exten-
sion of ROC curves demonstrated that for early time points (<24 months) scores
provided limited ability in distinguishing patients with different TTFT. In contrast,
for late time points (≥24 months after diagnosis), the predictive accuracy of
TTFT was higher for models including both clinical and genetic variables (i.e.,
O-CLL1, CLL-IPI,2011 MDACC score, GCLLSG score) in comparison with
models which included only clinical variables (i.e., 2007 MDACC score). Finally,
values of Aikaike information criterion (AIC) which indicates the goodness of
the fit (lower is better) were better for the O-CLL1 score (AIC, 810) and worse
for 2007 MDACC score (AIC, 851). In between there were the GCLLSG score
(AIC, 837), the CLL-IPI (AIC, 841) and the 2011 MDACC score (AIC, 844),
respectively.
Figure 1.
Summary/Conclusions: Although different with respect to either the endpoints
for which they were generated (i.e., OS versus TTFT) or the prognostic factors
considered (i.e., only clinical versus clinical and genetic) all models used in
this validation analysis worked in predicting TTFT. Results of AIC and Harrell’s
c value demonstrated that the predictive accuracy of TTFT was higher for mod-
els including both clinical and genetic variables (i.e., CLL-01, CLL-IPI,2011
MDACC score, GCLLSG score). 
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BCL6 ABNORMALITIES ON FLUORESCENCE IN SITU HYBRIDIZATION
ARE ASSOCIATED WITH EARLY AGE AT DIAGNOSIS, KARYOTYPIC
COMPLEXITY, AND AGGRESSIVE DISEASE IN CHRONIC LYMPHOCYTIC
LEUKEMIA
P Eulitt*, Q Zhao, A Ruppert, L Abruzzo, C Coombes, A Gordon, J Jones,
F Awan, J Blachly, L Andritsos, J Byrd, N Heerema, J Woyach
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Background: The clinical course of CLL is variable but can be predicted in
part by recurrent cytogenetic abnormalities. BCL6 functions as a transcriptional
repressor during germinal center formation, and alteration of 3q27 has been
well characterized in some B cell malignancies. However, the incidence and
significance of BCL6 abnormalities in CLL is unknown.
Aims: We aimed to determine the incidence and clinical significance of BCL6
abnormalities in CLL by analyzing a large database of CLL patients. We then aimed
to analyze subsets of patients enrolled in clinical trials to determine the signficance
of primary BCL6 abnormalities compared to acquired BCL6 abnormalities.
Methods: Between 10/2007 and 6/2014, 1811 patients (pts) with CLL at our
institution underwent FISH which included a probe for 3q27. Clinical and molec-
ular data were reviewed for pts with rearrangements or extra copies of BCL6.
Data were also obtained from pts participating in 4 sequential clinical trials of
ibrutinib, and characteristics of pts with and without pre-treatment BCL6 abnor-
malities were compared.
Results: 152 pts (8.4%) were found to have an abnormality of BCL6 at any
time during their clinical course. Clinical and cytogenetic characteristics are
summarized below. BCL6 abnormalities were present prior to first therapy in
28 pts, suggesting a primary abnormality. These pts had an early age at diag-
nosis (62.5 years), short time from diagnosis to first treatment (median 23.6
months), and relatively low 5-year survival (estimated at 62.9%). Pts with BCL6
abnormalities were likely to have complex karyotype and other high risk abnor-
malities including MYC rearrangement/copy gains and del(17p). Comparing
pts with and without BCL6 abnormalities undergoing similar therapy, those with
BCL6 abnormalities were more likely to have complex karyotype (p=0.0007),
MYC abnormalities (p<0.0001), and del(17p) (p<0.0001).
Table 1.
Summary/Conclusions: BCL6 abnormalities are associated with other high
risk markers in CLL, and these pts have early age at diagnosis, short time to
first therapy, and relatively short survival. These data suggest that BCL6 FISH
abnormalities may be an important biomarker in CLL. Work to further charac-
terize the biologic basis for these findings is ongoing.
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VERY YOUNG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
HAVE LOWER INCIDENCE OF ADVERSE CYTOGENETICS AND
IMPROVED OVERALL SURVIVAL: 10-YEAR EXPERIENCE FROM
MEMORIAL SLOAN KETTERING CANCER CENTER
B Getta1,*, S Devlin2, J Park1, M Tallman1, E Berman1
1Leukemia Service, 2Department of Epidemiology and Biostatistics, Memorial
Sloan Kettering Cancer Center, New York, United States
Background: Young pts, arbitrarily defined as ≤ age 40, comprise a very small
fraction of patients with CLL. Risk factors and outcomes in this young age group
are not well described. 
Aims: To compare biologic disease factors and clinical outcomes between
patients age ≤40 with those >40.
Methods: Young pts were arbitrarily defined as ≤40 at diagnosis. Pts from the
MSKCC CLL database diagnosed between 1/1/2005 and12/31/2015 were
included. Two control CLL pts age >40 were matched to each patient ≤40 and
served as controls. Matching was based on diagnosis year (+/- 2 yrs) and the
time from diagnosis to the first MSKCC visit (+/- 2 yrs). Patient and disease
characteristics were compared using Fisher’s exact test. Cox regression analy-
sis accounting for the matched pairs was used to estimate overall survival,
time-to-first and –second treatment, and duration of first response. Survivor
curves were estimated using Kaplan-Meier methods. The National Cancer Insti-
tute Surveillance, Epidemiology and End Results (SEER) database was used
to compare the overall survival of pts ≤40 years with those >40 diagnosed
between 1990-2005. Statistical analysis was performed using the R statistical
package. The project was approved by the MSKCC institutional review board.
Results: 71/3455 (2.1%) pts in the MSKCC database were < age 40. Charac-
teristics of the two groups are shown in Table 1. Significant differences included:
initial WBC, presence of B symptoms, B2M and adverse cytogenetics. Second
malignancies occurred more frequently in pts >40. There were 6 cases of
Richter’s transformation (RT) to DLBCL in each group, one case of histologically
‘accelerated CLL’ in each group and two cases of transformation to Hodgkin
lymphoma in the group >40. DLBCL with TP53 mutation/del17p was seen in
1/6 pts ≤40 and 3/6 in >40 group. DLBCL was the initial indication for CLL ther-
apy in 5/6 young pts who had RT, 3 of whom presented concurrently with CLL
and RT. No pt >age 40 presented with CLL and DLBCL. There was no difference
in the incidence of autoimmune complications in the two groups and no differ-
ence in the incidence of hematologic or solid organ malignancy in 1st or 2nd
degree family members. The median follow-up of the MSKCC pts ≤40 was 54
months (1-313) and those >40 was 48 months (0-271). 48% of pts in each
group required treatment. The time to first therapy and duration of response
following 1st and 2nd line therapy were similar (Table 1). Six pts ≤40 (8.5%) and
2 pts >40 (1.4%) underwent allo-BMT (p=0.018). There were 4 deaths in pts
≤40 (5.6%) and 18 deaths in pts >40 (12.7%). Seven of the 22 deaths were
unrelated to CLL (Table 1); and 6 of these were due to secondary malignancies.
The estimated OS at 8 years was 0.97% in the group<40 and 86% in the group
>40 (p=0.053) (Fig 1A). Lastly, in order to compare our results with a larger
database, we evaluated young pts in the SEER database. There were 29,822
CLL pts of whom 279 were ≤40 (0.94%). The median OS in SEER cohort for
pts age ≤40 was not reached, and in those age>40 was 6.9 years (95% CI 6.8-
7.0),(p<0.001) (Fig 1B).
Figure 1.
Summary/Conclusions: A very small fraction of pts with CLL are diagnosed
before the age of 40. These data suggest: a lower incidence of adverse cyto-
genetics at diagnosis, equivalent treatment response, and a higher incidence
of RT that was not associated with del17p. MSKCC and SEER data suggest




CD49D EXPRESSION IS ASSOCIATED WITH DEVELOPMENT OF
LYMPHADENOPATHY IN PATIENTS WITH MONOCLONAL B-CELL
LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
P Strati1,*, K Chaffee1, S Achenbach1, S Slager1, T Call1, N Kay1, W Ding1,
S Parikh1, D Jelinek2, C Hanson1, T Shanafelt1
1Mayo Clinic, ROCHESTER, 2Mayo Clinic, Scottsdale, United States
Background: CLL clinical presentation is very heterogeneous, including lym-
phadenopathy, organomegaly, and cytopenias. The biologic factors which deter-
mine these differences in clinical manifestation are poorly understood. CD49d
is a surface integrin expressed on CLL lymphocytes that facilitates interactions
between CLL B-cells and stromal cells in the microenvironment. Although case
series suggest high expression of CD49d in CLL patients may be associated
with presentation with lymphadenopathy, these series are small and nearly all
the information to date is cross-sectional. 
Aims: We used the Mayo Clinic CLL database to prospectively evaluate the
association between CD49d expression and subsequent development of lym-
phadenopathy in a cohort of patients with newly diagnosed MBL and CLL Rai
stage 0.
Methods: All patients seen at our center between 08/2001 and 12/2015 and
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who had pre-treatment CD49d testing available within 1 year of the date of
diagnosis were included in the study. CD49d was considered positive if ≥30%
of cells expressed CD49d (JCO 32:897). Time to development of lym-
phadenopathy was defined as time from diagnosis to appearance of palpable
lymph nodes; in the absence of development of lymphadenopathy, patients
were censored at date of first therapy or last follow-up. The Kaplan-Meier plots
display time to development of lymphadenopathy.
Results: The study included 720 individuals, 333 with MBL and 387 with Rai
stage 0 CLL. Among these patients, CD49d was positive in 34.5% of those
with MBL and in 19.4% of patients with CLL Rai stage 0 (p<0.001). The medi-
an% of clonal B-cells expressing CD49d at diagnosis was 12% (interquartile
range [IQR] 5%>59%) in individuals with MBL and 3.7% (IQR, 2%>14%) in
patients with Rai stage 0 (p<0.001). Fourty-four (15%) patients with MBL and
82 (21%) patients with CLL Rai 0 subsequently developed palpable lym-
phadenopathy during the course of follow-up (median follow-up= 3.4 years).
CD49d positivity at baseline was also associated with shorter time to develop-
ment of lymphadenopathy both in patients with MBL (p=0.048) and CLL Rai 0
(p<0.001; Figure 1).
Figure 1.
Summary/Conclusions: CD49d expression identifies a cohort of MBL and
Rai 0 CLL patients whose clinical course may be dominated by development
of lymphadenopathy as opposed to bone marrow infiltration and cytopenias.
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IMPACT OF THE APOPTOTIC REGULATOR DRAK2 IN CHRONIC
LYMPHOCYTIC LEUKEMIA
C Ciardullo1, E Willmore2, P Zhou2, V Rand2, C Harrison2, A Hall2, J Eswaran2,
M Soundararajan1,*
1Faculty of Health and Life Sciences, Northumbria university, 2NICR, Newcastle
University, Newcastle upon Tyne, United Kingdom
Background: In chronic lymphocytic leukaemia (CLL), the impaired balance
between the pro-apoptotic and anti-apoptotic stimuli is involved in chemore-
fractoriness and clinical outcome. The low proliferation rate indicates that one
of the primary mechanisms during disease development may be apoptotic fail-
ure. The apoptotic pathways and CLL proliferation is controlled by a variety of
regulator molecules including various protein kinases. DRAK2 belongs to the
Death-associated protein kinase (DAPK) family sharing 52% homology with
DAP kinase 1 (DAPK1), a heritable predisposing factor in CLL. DRAK2 is
expressed exclusively in lymphoid tissue while drak2−/− mice showed five-fold
decrease in spleen germinal center compared to their wild-type littermates
resulting from increased B-cell apoptosis. Further according to recent studies
DRAK2 has been shown to control cell proliferation through its interaction with
TβR1 thereby downregulating the smad2/3 mediated signalling. 
Aims: The aim of this investigation is to understand the impact of one of the
major apoptotic regulators, Death-Associated Protein Kinase-Related 2
(DRAK2) in CLL and its relationship to two distinct cellular networks a) involving
TGF-β and b) Zap70-RhoH mediated signalling pathway in CLL
Methods: In our study, we have analyzed 102 CLL samples using TaqMan
quantitative real-time PCR (qPCR) and calculated the relative expression by
the 2-ΔΔCt method. A ROC curve was generated to identify the optimal diag-
nostic cut-off. DRAK2 expression was then split at this cut-off and the resulting
dichotomous variable was included in a survival analysis. 
Results: The DRAK2 mRNA expression ranges from 0.16 to 9.26. Interestingly,
DRAK2 low-expressing patients showed significantly shorter survival than
DRAK2 high-expressing patients (p=0.003). The low expression of DRAK2 is
also identified as an adverse prognostic factor within the 13q deleted CLL
patients. When we studied the relationship between DRAK2 and critical prog-
nostic factors such as ZAP70 and its interaction partner RhoH, an atypical
GTPase which influences the development of CLL, mRNA level of RhoH had
no impact on overall survival in our cohort but discovered positive correlation
(Pearson’s r=0.36, p=0.00002) between DRAK2 and RhoH mRNA expression
levels. Further based on the recent literature, which suggests negative feed-
back loop regulation between DRAK2 and Transforming growth factor β Recep-
tor I, controlling TGF-β/Smads signalling in solid tumours, we measured the
TGFBR1 mRNA expression and found a positive correlation between DRAK2
and TGFBR1 expression (Pearson’s r=0.446, p=0.000003).
Summary/Conclusions: Together, our data show for the first time an associ-
ation between DRAK2 expression and CLL poor prognosis and suggest the
possibility of novel TGF-β/DRAK2 apoptotic signalling regulation in CLL. More-
over Zap70-RhoH mediated regulatory mechanism of DRAK2 remains rather
complex that needs to be further investigated.
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THE PROGNOSTIC SIGNIFICANCE OF PROLYMPHOCYTES IN CLL AND
CORRELATION WITH MOLECULAR MARKERS IN THE LRF CLL4 TRIAL
D Catovsky1,*, M Else1, E Matutes1, R Morilla1, J Strefford2, D Oscier3
1Molecular Pathology, The Institute of Cancer Research, London, 2Faculty of
Medicine, University of Southampton, Southampton, 3Molecular Pathology,
Royal Bournemouth Hospital, Bournemouth, United Kingdom
Background: An increase in the percentage and number of circulating pro-
lymphocytes in CLL has been associated with strong expression of surface
immunoglobulin (SmIg), trisomy 12 and a poor outcome (Melo et al, Br J
Haematol 1986;63:377 & 1987;65:23; Que et al, Blood 1993;82:571).
Aims: This study re-examines the biological and clinical significance of
increased peripheral blood prolymphocytes in patients entered into the ran-
domised UK LRF CLL4 trial. It also investigates the associations between
increased prolymphocytes and a comprehensive array of biomarkers.
Methods: 777 previously untreated patients were randomised between 1999
and 2004 to receive either chlorambucil or fludarabine, alone or in combination
with cyclophosphamide. Median follow-up for overall survival (OS) was 11.8
(range 10.2-15.9) years. The proportion of prolymphocytes was assessed at
trial entry in 508 patients.
Results: 270 patients (53%) had <5% prolymphocytes, 167 (33%) had 5-9%,
60 (12%) had 10-14% and 11 (2%) had =>15% prolymphocytes. We confirmed
the association of increased prolymphocytes (=>10%) with strong SmIg expres-
sion and trisomy 12. In multivariate analysis =>10% prolymphocytes was inde-
pendently associated with NOTCH1 mutations, absence of 13q deletion, high
CD38 expression and unmutated IGHV genes:
Table 1.
Increased prolymphocytes (=>10%) were associated with a shorter progres-
sion-free survival (HR 1.50 [95%CI: 1.16-1.93], p=0.002) and OS (HR 1.99
[95%CI 1.53-2.59], p<0.0001; Figure 1). An absolute prolymphocyte count
>=15x109/L was also associated with longer OS (HR 1.53 [95%CI 1.15-2.04],
p=0.004). =>10% prolymphocytes was an independent predictor of OS when
the multivariate model included the significant variables age, disease stage,
11q and 13q deletion and TP53 del/mut together with any one of the following,
each included separately: IGHV mutational status, B2M, CD38, Zap70 or
CLLU1 expression, mutations on NOTCH1 or SF3B1, or telomere length. When
all the significant variables were included together,% prolymphocytes was not
an independent predictor of OS. Deaths due to Richter’s syndrome were more
common amongst patients who had =>10% prolymphocytes at trial entry (9/71,
13%) vs those with<10% prolymphocytes (8/437, 2%; p<0.0001).
Figure 1. Overall survival by <10% vs =>10% prolymphocytes.
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Summary/Conclusions: Our data support the routine examination of blood
films in CLL and suggest that a finding of an increased proportion of prolym-
phocytes may be a trigger for a further evaluation of clinical and laboratory fea-
tures of progressive disease.
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ITALIAN VALIDATION OF THE INTERNATIONAL PROGNOSTIC INDEX FOR
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL-IPI) AND
COMPARISON WITH MDACC PROGNOSTIC INDEX: ANALYSIS OF 620
CASES
M Gentile1,*, FR Mauro2, D Rossi3, I Vincelli4, S Molica5, G Cutrona6,
G Tripepi7, A Pitino8, M Gori8, AG Recchia9, S Bossio9, A Neri10, M Ferrarini11,
G Gaidano12, R Foà13, F Morabito9,14
1UOC Ematologia di Cosenza, Cosenza, 2Department of Cellular Biotechnolo-
gies and Hematology, Hematology Sapienza University, Rome, Italy, 3Oncology
Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona,
Switzerland, 4UOC Ematologia di Reggio Calabria, Italy, Reggio Calabria,
5Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, 6SS
Molecular Diagnostics IRCCS S. Martino-IST, Genova, 7Consiglio Nazionale
delle Ricerche, Istituto di Fisiologia Clinica, Reggio Calabria, 8IFC-CNR, UOS
di Roma, Rome, 9Biotechnology Research Unit, AO/ASP di Cosenza, Aprigliano
(CS), 10Department of Clinical Sciences and Community Health, University of
Milano and Hematology CTMO, Foundation IRCCS Ca’ Granda Ospedale Mag-
giore Policlinico, Milano, 11Direzione Scientifica IRCCS, San Martino IST, Gen-
ova, 12Division of Hematology, Department of Translational Medicine, Amedeo
Avogadro University of Eastern Piedmont, Novara, 13Hematology Sapienza Uni-
versity, 14UOC Ematologia di Cosenza, Rome, Italy
Background: In the last two decades, a plethora of clinical, serological and
biological markers have been identified that are significantly associated with
the prognosis of chronic lymphocytic leukemia (CLL) patients. Recent research
has focused on the development of scoring systems capable of integrating the
major prognostic parameters. A recent international collaboration proposed an
international prognostic index (CLL-IPI) built on clinical, serological, and bio-
logical parameters (TP53 deletion and/or mutation, IGHV mutational status,
β2M, clinical stage, and age) universally applicable to previously untreated CLL
patients to predict overall survival (OS).
Aims: We performed a validation of the CLL-IPI in an independent series of
Italian patients. Furthermore, we compared this tool with the prognostic index
proposed by the MDACC CLL group in 2007.
Methods: Databases from 4 Italian centers including roughly 3000 newly diag-
nosed CLL patients were used to evaluate the validity and reproducibility of the
CLL-IPI. Baseline data regarding age, Binet stage, IGHV mutational status,
β2M and TP53 status, using only del17p, were available for 620 cases. The
parameters for the calculation of the MDACC score were also available in these
patients. The CLL-IPI and the MDACC score were calculated using the methods
proposed. The accuracy of the prognostic models was assessed by the Harrell
C index (an index of discrimination), the explained variation in mortality (an
index combining calibration and discrimination), and the Akaike information cri-
terion (AIC, an index comparing two non-nested prognostic models). The lower
the AIC, the higher the prognostic accuracy of a predictive model.
Results: The median age of the 620 patients was 65 years (range 27-92) with
55.1% males. The majority of patients had Binet stage A (81.9%) and 366 cases
(58.7%) had Rai stage 0. All 5 parameters of the CLL-IPI were found to be
independently associated with survival in this study cohort (age >65 years: HR
5.48, P<0.0001; Binet B/C stage: HR 2.17, P<0.0001; β2M>3.5 mg/L: HR 1.99,
P=0.001; IGHV unmutated: HR 1.82, P=0.002; TP53 deleted: HR 2.84,
P<0.0001). According to the CLL-IPI, 57.1% of patients were classified as low-
, 23.3% as intermediate-, 14.9% as high-, and 4.7% as very high-risk. The 5-
year OS probabilities were: 93.5% for low-risk, 83.2% for intermediate-risk,
68.6% for high-risk, and 35.1% for very high-risk cases (P<0.0001; Harrell C
index=73%; P<0.001). The prognostic index risk category remained a predictor
of survival when analysis was limited to Rai stage 0 (P<0.0001). Subsequently,
we compared the CLL-IPI with the MDACC prognostic index score in our cohort.
The Harrell C index of the MDACC score was 70% (P<0.001), similar to the
CLL-IPI (73%). The AIC showed the superiority of the CLL-IPI compared to the
MDACC score in predicting OS (CLL-IPI, AIC=1372.007 versus MDACC score,
AIC=1383.364). Accordingly, the explained variation in mortality provided by
the CLL-IPI was 29% (P<0.001), a figure higher than that due to the MDACC
score (26%, P<0.001), indicating that the CLL-IPI had a higher prognostic accu-
racy for mortality compared to that of MDACC score.
Summary/Conclusions: Our results confirm the validity of the CLL-IPI to predict
survival among patients with previously untreated CLL. Moreover, we have demon-
strated that the CLL-IPI which combines clinical and serological data with biological
parameters has a higher accuracy for predicting prognosis of CLL patients than
the MDACC score, a model built only on clinical and laboratory markers.
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IDELALISIB PLUS AN ANTI-CD20 ANTIBODY IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE HBV CORE ANTIBODY
POSITIVE: SIMILAR PATTERNS OF LIVER TEST ABNORMALITIES
T Robak1,*, AD Zelenetz2, A Mato3, JA Jones4, JM Pagel5, JC Barrientos6,
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Background: Increased hepatitis B virus (HBV) reactivation risk has been
reported in patients (pts) undergoing treatment with anti-CD20 therapies, includ-
ing rituximab (R) and ofatumumab (O).1 Reactivation can also occur after HBV
surface antigen (HBsAg) loss, especially in immuno-compromised pts.2,3 A high
rate of reactivation has been reported in such pts receiving an anti-CD20 anti-
body+chemotherapy.4 The incidence of transaminase elevation in CLL pts who
are core antibody positive (anti-HBc+)/ HBsAg-/HBV PCR- and receiving anti-
CD20+kinase inhibitors including idelalisib (IDELA) has not been reported.
Aims: The objective of this analysis was to characterize the patterns of changes
in liver tests in pts with CLL and anti-HBc+/ HBsAg-/HBV PCR- and receiving
IDELA+anti-CD20.
Methods: The patterns of changes in liver tests were analyzed among 477 pts
with relapsed/refractory (R/R) CLL treated with IDELA+R vs placebo+R
(NCT01539512) or IDELA+O vs O (NCT01659021). Pts with anti-HBc+/HBsAg-
were enrolled only if they were HBV PCR- by quantitative PCR (qPCR). Pts
who were anti-HBc+/HBsAg- at screening were monitored for potential HBV
reactivation (manifested as detectable HBV DNA by qPCR).
Results: During the study period beginning May 2012, 283 pts received
IDELA+anti-CD20 therapy (110 IDELA+R; 173 IDELA+O) and 194 pts received
anti-CD20 monotherapy (108 R; 86 O). Of 477 pts analyzed, 390 pts were anti-
HBc-/HBsAg- (86 IDELA+R; 152 IDELA+O; 79 R; 73 O); 85 pts were anti-
HBc+/HBsAg-/HBV PCR- (24 IDELA+R; 21 IDELA+O; 28 R; 12 O); 2 pts had
missing data (1 R; 1 O). Of the 85 pts who were anti-HBc+, 3 had a prior history
of HBV infection and 41 (22/45 on IDELA+anti-CD20 and 19/40 on anti-CD20)
had received IV immunoglobulin (IVIG) before screening for treatment of
hypogammaglobulinemia; 5 pts on IDELA+anti-CD20 and 3 on anti-CD20
received anti-HBV prophylaxis on-study. In the subgroup analysis, no significant
difference in liver test abnormalities was detected between anti-HBc+/HBsAg-
and anti-HBc-/HBsAg- subgroups in pts receiving IDELA+anti-CD20 or anti-
CD20 monotherapy (table).
Table 1.
Summary/Conclusions: Prior exposure to Hep B does not appear to be a risk
factor associated with liver test abnormalities in pts treated with IDELA+anti-
CD20.
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SECONDARY CANCERS, MAJOR INFECTIONS AND AUTOIMMUNE
DISEASES OCCUR IN DIFFERENT SUBSETS OF PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA
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Background: Chronic lymphocytic leukemia (CLL), the most common leukemia
in western country, is still an incurable disease and the most relevant complications
are major infections (MI), second cancers (SC) and autoimmune diseases (AD).
Aims: The aim of this study was to define the prevalence, risk factors and the
evaluation of the impact of MI, SC and AD on the survival of CLL patients
Methods: We retrospectively analyzed clinical and biological data from 795
patients referred to Hematology and Clinical Immunology Unit of Padua Uni-
versity hospital. MI, were defined as those infective events that required in
patients management or the use of intravenous antibiotics. SC comprised all
other malignancies; while low and high-grade dysplasia were excluded. AD
included all autoimmune and immune-mediate diseases. FISH analysis
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(n=598), CD38 expression (n=656), IGHV mutations (n=507) and TP53 abnor-
malities (n=527, account for TP53 deletion and mutation) were evaluated
according to international guidelines. Statistical analyses were performed with
Fisher exact test, Chi-square test, Log-rank test, Kaplan-Meier method and
Cox model. Overall survival was calculated from the date of diagnosis to death
(event) or last available follow-up (censored).
Results: With a median follow-up of almost 100 months, thirty-four percent of
patients developed at least one complication among MI, SC and AD with 95%
of them being occurred after CLL diagnosis (Figure 1A). Ninety-eight patients
experienced 138 MI, among which pneumonia (65%), septic shock (13%) and
deep tissue abscess (10%) were the most common. 120 patients reported 187
SC; skin cancer (32%), colon cancer (16%) and other-hematological malig-
nancies (14%) resulted to be the most common SC. Eighty patients were diag-
nosed with 103 AD, the most common of which resulted to be hematological
(41%), rheumatologic (17%) and thyroid-related diseases (16%). We observed
that only 0.9% of the cohort developed all the complications and that 1.4%
experienced both SC and AD, 1.8% both MI and AD, and 3.9% both MI and
SC during the follow-up period (Figure 1B). These data suggest a low proba-
bility to develop two or three complications and, as shown in Figure 1C, they
seem to occur in a mutually exclusively manner. MI were found with a higher
prevalence in males, in previously treated patients and in those with high-risk
cytogenetic by FISH and TP53 abnormalities. SC resulted to be more common
in male, in advance Rai and Binet stages at diagnosis, in previously treated
patients, in high-risk FISH and TP53 abnormalities. AD were more common in
female, in advance stage disease and in patients with 11q. No associations
were found between specific treatments. The estimated median time to SC
and MI development were 20 and 21 years, respectively; while it was not
reached for AD. After 20 years from the diagnosis SC, MI and AD occurred in
48%, 42% and 29% of patients, respectively. Kaplan-Meyer analysis showed
that patients who developed a MI had the worst prognosis whereas those with
AD had the best; in fact medians overall survival were 14.14 and 17.16 years
form MI and SC groups, while it was not reached for AD and all others patients
not included in the three groups. These data were confirmed in multivariate
analyses; MI and SC have a negative impact on the overall survival among
with TP53 abnormalities and IGHV mutations (HR 2.04, 1.50, 2.25 and 3.70,
respectively).
Figure 1.
Summary/Conclusions: We herein provide evidence for the existence of clin-
ical subsets with different predispositions to develop major infections or sec-
ondary cancers or autoimmune diseases, with significant impact of the survival
of CLL patients.
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Background: A frequent feature of chronic lymphocytic leukemia (CLL) is pro-
gressive hypogammaglobulinemia that can affect one or more immunoglobulin
(IG) subclasses.
Aims: To report the incidence of hypogammaglobulinemia in a large series of
patients with CLL and explore associations with various clinical and biological
markers.
Methods: Study group included 502 CLL patients with the following character-
istics: median age: 65 years; males/females: 326/176; Binet stage A: 330/417
(79%), unmutated IGHV genes (U-CLL): 177/502 cases (35.2%); CD38 expres-
sion: 68/390 cases (17.4%); clonotypic IG of the MD or G isotype: 295 (78%)
and 53 (14%) cases, respectively; isolated del(13q): 73/208 (35%); trisomy 12:
21/207 (10.1%); del(11q): 21/210 (10%); del(17p): 13/216 (6%); NOTCH1
del7544-45/p.P2514Rfs*4: 12/259 (4.6%).Within our cohort, we identified cases
belonging to one of three different, major subsets with stereotyped B-cell recep-
tor IG (BcR IG), namely: (1) subset #1 (clan I IGHV genes/IGKV1(D)-39): U-
CLL, clinically aggressive, n=12; (2) subset #2 (IGHV3-21/IGLV3-21), mixed
IGHV mutational status, noted clinical aggressiveness, n=6; and, (3) subset
#4, mutated IGHV4-34/IGKV2-30 BcR IG, clinically indolent, n=14.
Results: At diagnosis, decreased IG serum levels in at least one subclass
were identified in 283/502 patients (56.3%), as follows: (i) decreased IgM,
224/502 cases (44.6%); (ii) decreased IgG, 105/502 cases (21%); (iii)
decreased IgA, 131/502 cases (26%). In 54/502 cases (10.7%), all serum IG
subclasses were decreased. Among cases with hypogammaglobulinemia, 114
(40.2%) and 31 (11%) exhibited isolated IgM and IgA subclass deficiency,
respectively; isolated IgG decrease, was relatively rare (13 cases, 4.6%). Iso-
lated IgA deficiency was significantly (p<0.05) more frequent amongst females,
patients with advanced clinical stage (Binet B/C, Rai III/IV) and those with
NOTCH1 mutations (p=0.01) compared to isolated IgM deficiency. Notably, all
stereotyped subset #2 cases showed low levels of at least one serum subclass,
while in 2/6 such cases, all three IG subclasses (IgA, IgM, IgG) were affected.
No statistically significant differences were identified between patients with nor-
mal serum IG levels versus those with hypogammaglobulinemia regarding age,
gender, disease burden at diagnosis, IGHV gene mutational status, CD38
expression, cytogenetic aberrations, NOTCH1 mutations and the incidence of
a second malignancy. With a median follow up of 5 years, 192/413 cases
[46.5%] received treatment. Patients with hypogammaglobulinemia exhibited
increased need for treatment compared to those with normal serum IGs
(124/234 vs 68/179 respectively, p=0.002). IgG and IgA deficiency were corre-
lated with shorter time-to-first-treatment (TTFT) while none of the decreased
IG subclasses impacted on overall survival (OS). In multivariate analysis for
TTFT, IgG and IgA deficiency did not retain independent significance, with
advanced clinical stage, U-CLL, del(11q) and del(17p) remaining as independ-
ent adverse factors.
Summary/Conclusions: In conclusion, abnormalities of serum IGs at diagno-
sis are detected in CLL patients with heterogeneous clinicobiological profiles,
including different disease burden at diagnosis, cytogenetic aberrations and
IGHV gene mutational status. However, certain observations reported herein,
in particular the high incidence of hypogammaglobulinemia in subset #2 and
the association of NOTCH1 mutations with IgA subclass deficiency, open novel
possibilities for unraveling the implicated pathophysiological mechanisms.
E1066
THE ASSOCIATION OF DYSLIPIDEMIA WITH CHRONIC LYMPHOCYTIC
LEUKEMIA: A POPULATION-BASED STUDY
L Mozessohn1,*, C Earle2, D Spaner1, S Cheng2, M Kumar2, R Buckstein1
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Background: Metabolic syndrome (MetS) is a risk factor for the development
of cancer. In addition, pre-clinical data suggest that chronic lymphocytic leukemia
(CLL) cells are dependent on adipocytes and fatty acids for growth and that
aberrant lipid metabolism is an important pathogenic mechanism in CLL.
Aims: Our objective was to determine whether patients with CLL have a higher
incidence of MetS prior to their CLL diagnosis compared to those without CLL
and to determine the impact of lipid-lowering medications on survival.
Methods: We conducted a population-based retrospective cohort study in
Ontario, Canada using administrative databases of adults ≥66 years old to
compare the prevalence of MetS and its components (diabetes, dyslipidemia,
hypertension) before a diagnosis of CLL compared to age and sex-matched
controls without CLL. Logistic regression was used to study the association
between MetS and its components to CLL. The Kaplan-Meier method and Cox
Regression were used to investigate survival.
Results: We identified 2124 persons with CLL and 7935 controls from January
1, 2000 to December 31, 2005 with follow-up until death or March 31, 2014.
The median follow-up was 10.7 years (95% CI, 10.5 to 10.9). Overall, the mean
age was 75.6 years and 42.1% were female, 20.2% had diabetes, 35.8% had
hypertension, 17.6% had dyslipidemia and 28.0% received lipid-lowering med-
ications prior to a diagnosis of CLL. In multivariable analysis, dyslipidemia (OR
1.34, 95% CI 1.17 to 1.54) and hypertension (OR 1.20, 95% CI 1.07 to 1.34)
were associated with the development of CLL, whereas MetS and diabetes
alone were not. On univariable survival analysis, dyslipidemia in CLL patients
was associated with a significantly worse overall survival, however, not on mul-
tivariable analysis (HR 1.06, 95% CI 0.91 to 1.23). In comparison, lipid-lowering
medication use at any time was associated with a significantly improved overall
survival on univariable (see Figure) and multivariable analysis (HR 0.55, 95%
CI 0.49 to 0.63) as was female sex (HR 0.66, 95% CI 0.59 to 0.75) and fewer
comorbidities (HR 0.72, 95% CI 0.59 to 0.89). Advanced age (HR 1.08, 95%
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CI 1.06 to 1.09) and diabetes (HR 1.31, 95% CI 1.14 to 1.50) were associated
with a significantly worse overall survival.
Figure 1.
Summary/Conclusions: We demonstrate an association between dyslipi-
demia and the development of CLL, supporting pre-clinical data. Furthermore,
the relationship is independent of metabolic syndrome and diabetes. Lipid-low-
ering medications appear to confer a survival advantage in CLL. Prospective
studies are needed to confirm these results and test their potential application
to intervention strategies.
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Background: Lymphocytosis is a known effect of B-cell receptor (BCR) tar-
geted therapies used to treat CLL and SLL, including idelalisib (IDELA). IDELA
is a selective oral PI3Kδ inhibitor which inhibits multiple signaling pathways,
including those downstream of the B-cell receptor, CXCR4, and CXCR5. Per
updated response criteria (Hallek M, el al. Blood. 2012;119:5348; Cheson B, et
al. J Clin Oncol. 2012;30:2820-2822.), drug-induced lymphocytosis alone
should not interfere with the time of designation of a partial response (PR) and
is not considered progressive disease (PD) in the absence of other signs or
symptoms of progression.
Aims: This post hoc analysis characterized the patterns of lymphocytosis
observed in patients (pts) with CLL/SLL treated with IDELA-based regimens,
and evaluated the effect of lymphocytosis on safety and efficacy.
Methods: Pts from 4 studies (2 phase 1, 1 phase 2 and 1 phase 3) who
received IDELA dosed at 100 or 150 mg BID were included in this analysis. Pts
were grouped by disease status (treatment-naïve vs relapsed/refractory) and
treatment regimen (IDELA-monotherapy vs IDELA in combination with
chemotherapy, an anti-CD20 mAb [anti-CD20], or both. Chemotherapeutic
agents included chlorambucil, bendamustine, or fludarabine. Anti-CD20 mAbs
included rituximab or ofatumumab. Absolute lymphocyte counts (ALC) were
measured throughout each study to calculate peak ALC, time to peak ALC,
and time to 50% reduction from baseline ALC. To evaluate the effect of lym-
phocytosis on safety, grade ≥3 treatment-emergent adverse events (TEAEs)
and TEAEs of interest (leukostasis, blood viscosity abnormalities, central nerv-
ous system hemorrhage, and disseminated intravascular coagulation) were
summarized in pts with ALC >200 K/µl at any time during IDELA treatment. To
evaluate the effect of lymphocytosis on efficacy, median progression-free sur-
vival (PFS) was analyzed in pts receiving IDELA monotherapy for
relapsed/refractory CLL (phase 1 study) and treatment-naive CLL/SLL (phase
2 study) stratified by ALC reduction from baseline (≥50% [yes or no]).
Results: The analysis population included 352 pts (105 treatment-naïve; 247
relapsed/refractory), 63 on IDELA monotherapy and 289 on IDELA combination
regimens. 68% of pts experienced a post-baseline increase in ALC, including
83% of pts on IDELA monotherapy and 50% of pts on combinations. Time to
peak was 2-4 weeks across groups. 73% of pts achieved a 50% reduction from
baseline ALC, including 33% of pts on IDELA monotherapy and 82% of pts on
combinations. Median time to 50% reduction from baseline ALC was longest
for pts with relapsed/refractory CLL/SLL on IDELA monotherapy (15 wks) and
shortest for pts with relapsed/refractory CLL on IDELA+chemotherapy+anti-
CD20 (2 wks). The safety analysis included 31/352 pts (9%) with ALC >200
K/µl at any time on IDELA treatment, with a maximum reported ALC of 447
K/µl. Of these 31 pts, Grade 3/4 TEAEs were reported in 8 (26%) during the
time when ALC >200 K/µl. No pt with signs or symptoms of hyperleukocytosis
was identified. The efficacy analysis included 63 pts (41 treatment-naïve; 22
relapsed/refractory) on IDELA-monotherapy. The median PFS was similar for
pts with or without a ≥50% reduction from baseline ALC (Table).
Table 1. PFS by achievement of ≥50% reduction from baseline ALC.
Summary/Conclusions: Addition of anti-CD20 and/or chemotherapy to IDELA
abrogated the transient lymphocytosis seen with IDELA-monotherapy, regard-
less of disease status. Consistent with the updated response criteria, lympho-
cytosis does not appear to impact the efficacy of IDELA in this pt population.
Lymphocytosis also did not predispose pts to severe or unexpected AEs.
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Background: Ibrutinib is a selective and covalent inhibitor of Bruton’s tyrosine
kinase approved for chronic lymphocytic leukemia (CLL). Outcome and burden
of adverse events of specific therapy reported in clinical trials may differ from
routine clinical practice due to selection bias and different monitoring. 
Aims: The aim of this observational study of Polish Adult Leukemia Study
Group (PALG) was to prospectively assess the efficacy and toxicity of ibrutinib
monotherapy in relapsed/refractory CLL patients treated within the ibrutinib
compassionate use named patient program (NPP) in Poland.
Methods: Patients were eligible for ibrutinib compassionate use NPP if they
met all following criteria a) relapsed or refractory CLL, b) active CLL/SLL requir-
ing treatment, c) a minimum of 1 prior line of chemotherapy. Data on treatment
outcome and complications were anonymously collected using electronic CRFs.
Results: This report is based on data obtained for 163 patients (158 with CLL
and 5 with SLL) treated in 15 hematology centers participating in the observa-
tional study of PALG. There were 91 male and 72 female patients with median
age 63 (range 40-84). Fifty-two patients (32.5%) had advanced disease (III or
IV Rai stage) at diagnosis. Median number of chemotherapy lines prior to ibru-
tinib was 3 (range 1-10). FISH cytogenetics at inclusion to NPP was conducted
in 96 (60%) patients, and it revealed del17p in 30 patients (19%). The median
follow-up time was 9.2 months (range 0.4-22.2 months). Overall response rate
(complete remissions, partial remissions or partial remissions with lymphocyto-
sis) was 73%. Median progression free survival and overall survival (OS) had
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not been reached with 24 deaths recorded during the time of observation. The
estimated probability of 12-months OS was 0.83 (95%CI: 0.75-0.88) that
appears inferior to 0.90 reported in RESONATE clinical trial (Byrd et al, NEJM
2014). Among parameters analyzed as potential prognostic factors, the
advanced clinical stage (Rai III and IV) was associated with inferior OS, with
estimated 12-months survival of 0.72 (95%CI: 0.577-0.826) (Fig 1A). Interest-
ingly, no negative influence of del17p regarding OS was detected (Fig 1B).
Regarding ibrutinib toxicity grade 3 or 4 side effects occurred in 43 patients
(27%). Infections of any grade were diagnosed in 57 patients (36%), while atrial
fibrillation of any grade was seen in 14 patients (8.8%). Thirty-three patients
(20.2%) required ibrutinib dose reductions, mainly due to infections or hemato-
logical toxicity. Interestingly, in RESONATE trial with similar follow up time (medi-
an 9.4 months) ibrutinib dose reduction was reported only for 4% of patients.
Figure 1.
Summary/Conclusions: This large analysis of refractory/relapsed CLL
patients treated with ibrutinib monotherapy in real-world clinical practice shows
satisfactory treatment results, however, patients’ outcome appears inferior as
compared to that observed in the clinical trial. This difference could be partially
due to relatively frequent ibrutinib dose reductions and treatment interruptions
observed in this patient cohort. Furthermore, our report confirms efficacy of
ibrutinib in relapsed/refractory CLL patients with del17p, but also shows that
advanced CLL stage at diagnosis retains its prognostic value.
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SF3B1 MUTATIONS, IGHV MUTATION STATUS AND ABNORMALITIES
DETECTED BY GENOMIC ARRAYS DETERMINE PROGNOSIS IN CLL
WITH NORMAL KARYOTYPE
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1University of Catania, Division of Haematology, Catania, Italy, 2MLL, Munich
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Background: Normal karyotype (NK) CLL accounts for 15-20% of all CLL cas-
es and confers per se an intermediate risk. Our group reported a higher SF3B1
mutation (mut) rate compared to other cytogenetic subgroups and only one
third of patients showed unmutated IGHV status (IGHVu). Furthermore, we
previously demonstrated that array-based comparative genomic hybridization
(aCGH) technology could detect cryptic abnormalities in 19% of NK CLL.
Aims: To further characterize CLL with normal karyotype and identify prognostic
parameters.
Methods: We selected 164 patients with NK and CLL cells percentage >15%
(16% of total CLL cohort). Chromosome banding analysis yielded normal kary-
otypes. FISH analyses, performed with probes for 17p13 (TP53), 13q14
(D13S25, D13S319, DLEU), 11q22 (ATM), centromere region of chromosome
12, t(11;14)(q13;q32)(IGH-CCND1), 6q21 and IGH rearrangements, did not
reveal any abnormalities. aCGH was performed with SurePrint G3 ISCA
CGH+SNP Microarray (Agilent, Waldbronn, Germany). IGHV status, mutational
analysis by DNA sequencing for SF3B1, NOTCH1 and TP53 and information
on time to treatment (TTT) were available for all patients. White blood cell (WBC)
count was available for 153/164 patients.
Results: Median follow-up was 5.6 years and 10-year OS was 75%. Median age
was 63 years (range, 34 to 83) and 93/164 (54%) were male. Median WBC count
was 36,500/mL (range, 3,300 to 463,000). Cases with CLL cells ≤5000/μL had
nodal presentation. By flow cytometry, median% CLL cells was 52% (range, 16%
to 94%). Cut-off for CD38 and ZAP70 positivity was 30% and 20%, respectively.
34 patients (20%) showed CD38 positivity and 61 (36%) ZAP70 positivity. By
aCGH, we detected 68 copy number abnormalities (CNA) in 37 patients (22%).
Majority (24/37; 65%) had 1 CNA, 9 patients (24%) showed 2 CNA and 4 (11%)
more than 2 CNA. IGHVu was present in 52/164 (32%) cases. SF3B1 was mutat-
ed in 26/164 (16%), NOTCH1 in 12 (7%) and TP53 in 7(4%). Univariate Cox
analysis for TTT showed adverse impact for: WBC (HR:1.05 per 10,000/μL
increase; 95%CI 1.02-1.09; p=0.001);% CLL cells (HR:1.3 per 10% increase;
95%CI 1.16-1.5; p<0.001); CD38 positivity (HR:2.7; 95%CI 1.5-5; p=0.001); ≥2
CNA (HR:3.6; 95%CI 1.6-8.1; p=0.002); SF3B1mut (HR:2.3; 95%CI 1.2-4.5
p=0.013); IGHVu (HR:4.8; 95%CI 2.6-8.7; p<0.001). Detection of any CNA, ZAP70
positivity, TP53mut and NOTCH1mut did not relate with TTT. In multivariate analy-
sis,% CLL cells (HR:1.2 per 10% increase; 95%CI 1.04-1.4; p=0.015), ≥2 CNA
(HR:2.9; 95%CI 1.2-7.012; p=0.015), SF3B1mut (HR:2.3; 95%CI 1.16-4.5;
p=0.016) and IGHVu (HR:4.3; 95%CI 2.1-8.4; p<0.001) retained their prognostic
value. Therefore, we clustered patients into 3 groups (figure 1; table 1). Patients
without risk factors (#0) showed the best outcome (median TTT not reached);
patients with 1 risk factor (#1) had a median TTT of 6.5 years; patients with at
least two risk factors (#2) showed a median TTT of 6 months (p<0.001).
Table 1. Cluster groups according to prognostic factors.
Figure 1.
Summary/Conclusions: Through the evaluation of IGHV mutational status,
SF3B1 and aCGH, we identified CLL patients with normal karyotype at the
highest risk for need of treatment.
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A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED
TRIALS FOR THE TREATMENT OF RELAPSED OR REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA
J Thompson1,*, M Bibby2, A Gara2, J Quigley3, S Sciuto4, R Perard5, V Leblond6
1Epidemiology, ICON plc, Abingdon, United Kingdom, 2Epidemiology, ICON
plc, Vancouver, Canada, 3Health Economics, ICON plc, Abingdon, 4Gilead Sci-
ences, UK Ltd., 5Gilead Sciences, Europe Ltd., Uxbridge, United Kingdom,
6Hematology, Hôpital Pitié-Salpêtrière, Paris, France
Background: Treatment of Chronic Lymphocytic Leukemia (CLL) by
chemotherapy is not curative, and patients receive multiple chemotherapy lines
in an attempt to manage their disease along the years. Due to cumulative tox-
icity or resistance, treatment options following first-line therapy quickly become
limited and new treatment options are needed. Idelalisib is a novel oral inhibitor
of PK13K delta for the treatment of relapsed/refractory (R/R) CLL. This study
reviewed randomized controlled trials (RCTs) of idelalisib and treatment options
in the management of R/R CLL.
Aims: To review the efficacy and safety of idelalisib relative to other commonly
used treatments for R/R CLL.
Methods: A systematic literature review was conducted to identify articles eval-
uating idelalisib (Id), ibrutinib (Ib), alemtuzumab (A), fludarabine (F), rituximab (R),
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ofatumumab (O), bendamustine (B), cyclophosphamide (C), methylprednisolone
(Mp), chlorambucil (Ch), lenalidomide (L), doxorubicin (D), vincristine (V), pred-
nisone (P), CHOP, and CVP as single agents or in combination, in adult patients
with R/R CLL. Searches were conducted in the following literature databases:
EMBASE, MEDLINE, MEDLINE In-Process and CENTRAL. Conference abstracts
from ESMO, ASCO, EHA and ASH 2012–2015 were also searched. Screening
was carried out independently by two reviewers. English language RCTs reporting
overall, complete or partial response, stable or progressive disease, overall survival
(OS), progression-free survival (PFS) or safety were included.
Results: Of 2222 potential studies, 29 full papers were screened, eight of which
were included in the final review. Nineteen conference abstracts were also
included. Overall, data from 14 unique RCTs were included in the final analysis
(Table 1). Three RCTs included Id; in combination with R, or O, or BR. The
other 11 studies identified are outlined in table 1. Only eight studies reported
baseline genetic characteristics. The included studies were heterogeneous with
regards to CLL stage, cytogenetics, and prior lines of therapy; all of which are
recognised as treatment modifiers. The median duration of progression-free
survival (PFS) between treatment arms was available for nine studies and
ranged from 5.5 months (R) to 30.6 months (FCR). Across all studies, the great-
est difference in the median duration of PFS between treatment arms was 13
months (IdR vs R; hazard ratio= 0.15; 95% CI 0.09-0.24). The Median duration
of PFS in treatment arms that contained Id ranged from 16.3 months (IdO) to
23.1 months (IdBR). Median OS was reported in 11 studies and ranged from
16.7 months (O) to not reached.
Table 1.
Summary/Conclusions: This systematic literature review suggests that ide-
lalisib (in combination with BR, O and R) is an acceptable alternative treatment
compared to interventions currently used in clinical practice for R/R CLL
patients.
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PREVALENCE OF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) AND
LOW FREQUENCY MUTATIONS IN CLL & MONOCLONAL B LYMPHOCYTOSIS:
A MAYO CLINIC EXOME SEQUENCING COHORT STUDY
JM Foran1,*, YW Asmann2, SJ Achenbach3, KG Chaffee3, DR O’Brien3,
TG Call4, NE Kay4, JR Cerhan3, TD Shanafelt4, SL Slager3
1Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center,
2Health Sciences Research, Mayo Clinic Florida, Jacksonville, 3Health Sciences
Research, 4Division of Hematology, Mayo Clinic, Rochester, United States
Background: ARCH refers to somatically acquired single-nucleotide variants
(SNV’s) and small indels in DNA involving hematologic (and non-hematologic)
genes (most commonly DNMT3A, TET2, ASXL1 & PPM1D) detected by whole-
exome sequencing (WES) in peripheral blood in unaffected individuals. The
incidence of ARCH increases with age and is asociated with an 11-fold increase
in the risk of hematologic malignancy including leukemia. However, the contri-
bution of ARCH to the development of CLL, the hematologic malignancy with
highest prevalence, is unknown. Furthermore, the frequency and clinical impact
of ARCH-associated and other non-ARCH low frequency mutations is unknown
in CLL. We therefore sought to understand the contibution and frequency of
ARCH and other low frequency mutations in a cohort of patients with CLL and
monoclonal B-lymphocytosis (MBL, an established precursor state with
increased risk of CLL development) who have undergone WES.
Aims: To determine the prevalence of ARCH and non-ARCH low frequency
mutations and their association with clinical risk factors in a cohort of unaffected
(UA) and affected individuals with CLL & MBL using peripheral blood WES.
Methods: Bioinformatic analysis was performed using raw data (BAM and
FASTQ files) from WES performed in a cohort of 445 patients, comprised of
CLL (n=160), MBL (n=73), and unaffected individuals (UA, n=212). Samples
were prepared using the Agilent V2 Exome Capture Kit, and in some cases pre-
pared using the Agilent V4 Exome Capture Kit. WES alignment was performed
with Novoalign within GGPS and recalibrated and realigned with GATK. Pileup
files were obtained from the recalibrated and realigned BAM files, and identifi-
cation of clonal and sub-clonal variants performed using DV-Boosting method
and Q value of 0.05 as cut off. Consistent with previous evaluation of ARCH,
“non-functional” variants were filtered out (synonymous, UTR, intron, etc.). In
addition, variants with an Alternative Allele Frequeny (AAF) ≥0.05 in European
or Caucasian populations of HapMap, 1000G, and ESP6500 were filtered out
as “polymorphisms” and not included as mutations. Remaining variants were
categorized as “disruptive” and “non-synonymous” (NS) variants in accordance
with previous publications. Disruptive SNV’s included those with Start/Stop
codon and at splice sites. Because of the inclusion of “affected” individuals in
this analysis who may have subclinical clonal disease variants, we defined the
“non-inherited” variants more conservatively as those with<40% of the AAF.
Results: The frequency of detectable mutations is noted in Figure. In almost
all cases the AAF was ≤10%. Based on previous population-based studies, we
anticipated a rate of disruptive (Disrupt) and NS ARCH mutations for the cohort
of 445 patients (noted in Table). We did not detect ARCH mutations in any CLL
or UA patient, and in total detected DNMT3A and ASXL1 mutations each in 2
MBL patients. We detected non-ARCH low AAF disruptive somatic mutations
in other genes in 12 CLL and 11 MBL patients, respectively, including in 4 Tier
1 cancer genes (JAK2, FGFR3, MLH1 & STK11) occurring in 3 patients each
with CLL and MBL. No mutations were detected in UA population in this analy-
sis. To determine if low AAF mutations were associated with any unique CLL
clinical characteristics, we compared frequencies among the subset of CLL
patients. Among those with available Rai stage, CLL patients with a detectable
low AAF mutation appeared to be more likely to have advanced (stage III/IV)
disease at diagnosis (25%) compared with those without a mutations (2.3%)
(p=0.03), but there was no difference in early stage disease (Stage 0: 75% vs
67.7%; and Stage I/II: 0% vs 31.1%, respectively) (p=0.13). There was no dif-
ference in age at diagnosis or gender.
Table 1.
Figure 1.
Summary/Conclusions: ARCH appears to be a very infrequent event in CLL,
and therefore is unlikely to constitute a major risk factor for CLL development.
Low AAF non-ARCH mutations are detectable in some patients with CLL (7.5%
in this analysis), including in some Tier 1 cancer genes, and may be associated
with advanced stage disease at diagnosis, although this is based on a limited
number of observations and will require prospective confirmation. These results
suggest an important role for Deep Sequencing in advanced CLL focusing on
Tier 1 cancer genes.
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PERFORMANCE STATUS AND COMORBIDITY AFFECT SURVIVAL IN
ELDERLY PATIENTS WITH CLL AFTER LOW DOSE ALEMTUZUMAB
COMBINED WITH CHEMOTHERAPY: RESULTS FROM THE HOVON68 TRIAL
F Vojdeman1,*, M van’t Veer2, G Tjønnfjord3, M Itälä-Remes4, E Kimby5,
A Polliack6, KL Wu7, J Doorduijn8, W Alemayehu9, S Wittebol10, T Kozak11,
J Walewski12, M Abrahamse-Testroote9, M van Oers13, C Geisler1
1Hematology, Rigshospitalet, Copenhagen, Denmark, 2Hematology, Leiden
University Meidcal Centre, Leiden, Netherlands, 3Hematology, Oslo University
Hospital and Institute of Clinical Medicine, Oslo, Norway, 4Hematology, Turku
Central Hospital, Turku, Finland, 5Hematology, Dept. of Medicine at Huddinge,
Karolinska Institutet, Stockholm, Sweden, 6Hematology, Hassadeh University
Hospital, Hebrew, Israel, 7Hematology, Stuivenberg Hospital, Antwerpen, Bel-
gium, 8Hematology, Erasmus MC Cancer Center, 9HOVON Data Centre, Rot-
terdam, 10Internal Medicine, Gelderse Vallei, Amersfoot, Netherlands, 11Hema-
tology, Charles University Hospital Kralovske Vinohrady, Prague, Czech Repub-
lic, 12Lymphiod Malignancies, Maria Sklodowska-Curie Memorial Institue and
Oncology Centre, Warszaw, Poland, 13Hematology, Academish Medish Cen-
trum, Amsterdam, Netherlands
Background: In CLL, chemo-immunotherapy is the standard of care. Until
recently fludarabine and cyclophosphamide (FC) has been considered the
chemotherapy of choice in fit patients irrespective of age. However, ageing
results in a decline in organ function and immune competence resulting in high-
er susceptibility to the toxicity of chemotherapy, while FC+Rituximab resulted
in more infections when compared to Bendamustine+Rituximab, also in the
elderly (Eichhorst et al. 2014). Furthermore, in the HOVON68 CLL trial, patients
above 65 years of age had no survival benefit from the addition of low-dose
alemtuzumab to FC in contrast to younger patients (Geisler et al. 2014).
Aims: Here we address the issue of why elderly patients with CLL did not ben-
efit from the addition of low-dose alemtuzumab to FC, using a 5 year update
of the HOVON68 trial.
Methods: 272 patients from the HOVON68 trial were included in this study. All
data were collected from the HOVON database, updated as of February 2015,
to reach a median follow-up period of 61 months. Baseline characteristics, causes
of death, comorbidities, organ related adverse events, infections, and lymphocyte
counts during treatment and the follow-up period were extracted as variables.
The statistical analyses included survival- and competing risk analysis using uni-
variate and multivariate cox regression performed in STATA version 13.1. P-val-
ues were two-sided and considered as statistically significant if below 0.05.
Figure 1.
Results: The addition of alemtuzumab to FC (FCA) improved overall survival
from a median of 77 months to median not yet reached (log rank P=0.049) in
the 5 year update of the HOVON68 trial. In addition, we confirmed that elderly
patients aged 65 to 75 of age had no improvement in OS (p=0.38). Overall 40%
(110/272) of patients died in the follow-up period. Excluding deaths related to
allogeneic transplant (n=10), 44% (44/100) died from CLL-related causes. The
elderly patients who received FCA had close to a significantly higher non-CLL
related death rate compared to all others (p=0.05). Infections accounted for
almost half (46.4%) of all non-CLL related causes of death. However, among
FCA treated patients, non-CLL related deaths in the elderly were primarily due
to secondary cancer or cardiovascular disease (10/14, 71%). At trial entry, most
of the comorbidity in the elderly was cardiovascular (23/37, 62%) including
hypertension, atrial fibrillation, history of transient cerebral ischemia, or ischemic
heart disease. The comorbidities were balanced between the treatment arms.
In the elderly, performance status (PS)>0, del(17p), β2microglobulin≥3.5mg/dL,
opportunistic infection, and comorbidity>0 (Figure 1) were significantly associ-
ated with non-CLL related mortality by univariate Cox regression using compet-
ing risk analysis. By multivariate analysis of factors found to be significant on
univariate analysis, only PS>0 (HR 5.25 [1.88-14.63], p=0.002), del(17p) (HR
4.47 [1.35-14.81], p=0.014), and comorbidity (HR 5.4 [1.66-15.33], p=0.004)
remained independently significant. No interactions were found between the
three significant variables with treatment arm, or between PS and comorbidity.
Summary/Conclusions: FCA induced more non-CLL and non-infection related
deaths in elderly patients compared to younger patients with biological high
risk CLL in the HOVON68 trial. Both PS and comorbidity had a significant
impact on non-CLL related mortality in the elderly after treatment with FC or
FCA.
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OUR APPROACH TO HAIRY CELL LEUKEMIA (HCL): 31 YEARS OF
EXPERIENCE
P Ataca Atilla*, E Atilla, S Civriz Bozdag, M Kurt Yuksel, S Kocak Toprak, P
Topcuoglu, O Arslan, M Ozcan, H Akan, M Beksac, O Ilhan, G Gurman
Ankara University School of Medicine Department of Hematology, Ankara,
Turkey
Background: HCL is a rare chronic lymphoid malignancy generates from
mature B cells. The frequency is 2% in all leukemia and diagnosed mostly in
middle ages. Patients response to purine analogues treatment.
Aims: In this study our aim is to present our HCL patients with demographic
features, treatment modalities and responses. 
Methods: 38 HCL patients who were diagnosed and treated at Ankara Univer-
sity Department of Hematology between 1984 and 2015 were retrospectively
evaluated. Ki-square test and student t test were used in comparison. P<0.05
was considered statistically significant.
Results: Median age of patients were 38 (range, 31-79). 29 of patients (76%)
were male. The average leucocyte, hemoglobin, platelet, lactate dehydroge-
nase (LDH) levels and the spleen size at diagnosis were as follows: 5,1 x
10^9/L (range, 1,5-20), 12,4 g/dl (range, 9-17,5), 118x10^9/L (range,15-300),
179 IU (range,107-394), 155 mm (range,110-290). BRAF mutation could be
evaluated in one patient and revealed as positive. 8 patients (21%) underwent
splenectomy prior to chemotherapy. All patients received cladribine (0.1mg/kg,
7 days) as a first line treatment; 8 patients (21%) had two courses for remission.
11 patients (30%) had treatment related febrile neutropenia, 2 patients (0.05%)
had transient skin rash after infusion. 7 patients (18%) had a relapse and 1
patients received pentostatin (4mg/m^2, 1 dose every 2 weeks, 6 months), 6
patients were retreated with the first line treatment and achieved complete
response. The overall survival was 67 months, respectively. Leucocyte, hemo-
globin, platelet levels were lower, LDH levels were higher and spleen size was
increased in patients with relapse however no statistical difference were detect-
ed.The patients with splenectomy had improved survival compared to patients
without splenectomy (107 vs 292 months, P=0.04) (Figure).
Figure 1. Splenectomy had increased overall survival.
Summary/Conclusions: We detected 18% relapse rate in our series and all
patients were followed in remisson after second line purine analogue treatment.
Splenectomy has improved overall survival and possibly still has a role to play
in HCL therapy. Generally, HCL is a chronic disease with a favorable prognosis. 
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ARRAY COMPARATIVE GENOMIC HYBRIDIZATION HAS PROGNOSTIC
VALUE IN CHRONIC LYMPHOCYTIC LEUKEMIA BEYOND STANDARD
FLUORESCENCE IN SITU HYBRIDIZATION
B Beaton1,*, J Howard-Reeves2, D Brazma2, K Mokretar2, T Boneva2, C Hockings3,
F Sillito1, E Phillips4, L Blake5, C Grace2, K Cwynarski1, EP Nacheva2
1Hematology, Royal Free NHS Foundation Trust, 2OncoCytogenetics Labora-
tory, Health Services Laboratories LLP Royal Free London site, 3Hematology,
Barnet and Chase Farm NHS Hospitals Trust, 4Hematology, The Whittington
Hospital NHS Trust, 5Hematology, North Middlesex University Hospital NHS
Trust, London, United Kingdom
Background: Chronic lymphocytic leukemia (CLL) has significant clinical het-
erogeneity. Fluorescence in situ hybridization (FISH) is an integral component
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of current risk stratification models, with poor prognosis associated with dele-
tions of 11q and 17p and good prognosis with deletions at 13q. In addition to
identification of clinically significant clonal aberrations by FISH, array compar-
ative genomic hybridization (aCGH) offers a high resolution assessment of
genetic imbalance.
Aims: To demonstrate prognostically significant features using aCGH beyond
that shown by FISH alone.
Methods: Consent for genomic investigation on excess material was given by
91 patients (67 diagnostic, 19 post-treatment, 5 relapse) from 5 referral centres.
Diagnosis was confirmed by standard morphology, immunophenotype and FISH
and/or karyotype. FISH was performed using commercial probes (Abbott Molec-
ular, UK and Cytocell, UK). aCGH was performed on DNA extracted from either
peripheral blood, bone marrow aspirate, stored frozen cells or post-culture fixed
chromosome preparations using a standard 8 x 60K Agilent array platform
(SurePrint G3 Human CGH Microarray Kit, G4450A). Additional FISH analysis
was performed to address questions raised by the microarray results when
necessary. Clinical data was collected retrospectively.
Results: Of 91 patients (males 73.4%, females 26.6%), data regarding treat-
ment was available for 67 (73.6%). Of these, 54 (80.5%) required chemotherapy
treatment. Of those treated, median time to treatment (TTT) was 34 months
(range: 0-264 months). Median time from diagnosis to end of follow-up in the
untreated group was 74 months (range: 30-432 months). The known prognostic
markers assessed demonstrated: diagnostic lymphocyte count >30 x109/l
(73.3%); CD38 positive (48.3%); ZAP70 positive (46.5%); IGHV unmutated
(43.9%); β-2 microglobulin elevated (40%). Elevated lymphocyte count and
ZAP70 positivity were statistically significant between treated and untreated
groups with p values of 0.023 and 0.0043, respectively. The other markers
showed trends towards a difference between treated and untreated groups,
but did not have a p value<0.05. There was a strong inverse relationship (see
Figure 1) between TTT and total genomic aberrations (TGA) observed in the
treated group (p=0.0014). Using a cut-off of 2Mb, aCGH was able to delineate
between small deletions (<2Mb) and large deletions (>2Mb) at chromosome
13q14.1. This difference cannot be delineated by standard FISH probes. Inter-
estingly, of the untreated group, 7/13 (53.8%) had a small deletion, while 0/13
had a large deletion detected, compared with the treated group where 10/54
(18.5%) had a small deletion, while 16/54 (29.6%) had a large deletion. The
difference here, where large deletions are seen in only the treated group, sug-
gests the large deletions are associated with more aggressive disease. Another
interesting observation was that by using aCGH, deletions involving Mitogen-
Activated Protein Kinase Kinase 4 (MAP2K4) found at chromosome 17p, which
has not yet been described in CLL, was observed in 5 patients, all in the treated
group. Three of the 5 were associated with Tumor Protein P53 (TP53) found
by FISH.
Figure 1. Relationship between Total Genomic Aberrations (TGA) and
Time to Treatment (TTT).
Summary/Conclusions: The correlation between aCGH and clinical data
demonstrates the utility of aCGH beyond that of standard FISH. Increased TGA
is significantly associated with shorter TTT from diagnosis. Detecting the dif-
ference between a deletion of 13q14.1 involving >2Mb (large) compared
with<2Mb (small) by aCGH, which cannot be differentiated by standard FISH
probes, may be useful in predicting patients that will need to be treated.
MAP2K4 may be an important marker in CLL in predicting patients that may
need treatment, but will need further investigation.
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RISK FACTORS AND PROFILE OF INFECTIONS ON IBRUTINIB THERAPY
OUTSIDE CLINICAL TRIALS: A SINGLE CENTER EXPERIENCE OF 68
PATIENTS
C Protin1,*, K Paricaud2, F Despas3, G Martin-Blondel2, L Ysebaert1
1Hematology, IUC Toulouse-Oncopole, 2Infectious diseases, CHU Purpan,
3Pharmacology, Faculté de Médecine de Toulouse, Toulouse, France
Background: Ibrutinib is a first in class oral inhibitor of Bruton’s Tyrosin Kinase,
a protein critical for the B-cell receptor signaling cascade, but with significant
activity also against NK, T cell, and macrophage signaling pathway downstream
other receptors. High response rates in relapse/refractory chronic lymphoid
leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s disease have
granted ibrutinib a global market approval in these lymphomas. In the context
of various clinical trials, investigators reported 24% of grade ≥3 infections, more
frequently bacterial. 
Aims: In this study, we aimed to assess in “real life” the profile of infections
related to this targeted therapy, and identify risk factors.
Methods: Between March 01, 2014 and January 15, 2016, we included all
patients starting ibrutinib (and exposed for >1 month), referred to the Toulouse
University Hospital Cancer Center (IUC-Toulouse Oncopole).
Results: We enrolled 68 patients with a median age of 69.7 years, 76.5% of
the patients with CLL and 23.5% with MCL. Forty-three infectious adverse
events (IAE) occurred in 30/68 patients (44.1%), including 18/43 (41,9%) grade
1-2, 21/43 (48,8%) grade 3-4 and 4/43 (9,3%) grade 5. Median time to IAE
onset was 2,9±1,7 months, 33/43 (76,7%) being observed the first 6 months of
therapy, suggesting recovery of the normal immune system with CLL improve-
ment. Among 43 IEA, 23 were of unknown origin (treated with wide spectrum
antibiotics, most therefore of bacterial origin), and 20 IAE were documented:
13 bacterial (including 2 Campylobacter jejunii and 3 Pseudomonas aerugi-
nosa), 5 fungal (2 invasive aspergillosis, 1 mucormycosis, 1 pneumocystosis
and 1 disseminated cryptococcosis) and 2 viral (hepatitis E virus reactivations).
In accordance with published results from clinical trials (Maddocks et al., JAMA
Oncol 2015), PFS was significantly shorter in those patients with onset of any
grade IAE during the first 3 months of therapy (median PFS 8mo vs NR,
p=0.02), or with onset of severe IAE grade ≥3 (median PFS 10mo vs NR,
p=0.02). The baseline characteristics of the patients were well balanced
between the two study groups (infected and non infected) regarding comor-
bidities, history of previous infections, number of previous lines of therapy (medi-
an of 3), or primary prophylaxis (cotrimoxazole+/-valaciclovir: 40% of patients
with IAE vs 50% of patients without). There was no clinical or biological param-
eter before commencing ibrutinib correlated to IAE risk (median neutrophil and
lymphocyte count, CD4/8 T lymphocyte count and gammaglobulin levels). How-
ever, peak lymphocytosis induced by ibrutinib at month 1 and 2 was correlated
to IAE risk (median 126843/ml vs 69409/ml after 1 month, 100238/ml vs
63485/ml after 2 months, Mann-Whitney test p<0,05 for both).
Summary/Conclusions: In this real-life practice series, 44% of patients have
developed IAE of which 50% were severe (grade ≥3) including 13% fungal
infection. As compared to clinical trials, we confirmed the significant correlation
of early-onset IAE with PFS, and that IEA risk decreases with time (even after
3 months), without disappearing over time (10% IAE occuring >6 months). Inter-
estingly, and consistent with an improvement of normal immune responses
linked to the desinfiltration of lymph nodes/spleen/bone marrow, ibrutinib-
induced lymphocytosis was associated with a lower incidence of infection. 
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IMPACT OF ANTI-CD20 ANTIBODIES ON THE INCIDENCE OF SECONDARY
CANCERS IN PATIENTS TREATED FOR CHRONIC LYMPHOCYTIC
LEUKEMIA
S Guidez1,*, H Demarquette2, M Nudel2, C Le Grand2, C Herbaux2, T Facon2,
B Cazin2, F Morschhauser2
1Hématologie et thérapies cellulaires, CHU de Poitiers, POITIERS, 2Service
des maladies du sang, CHRU de Lille, LILLE, France
Background: An increased incidence of second primary malignancies (SPM)
is described in chronic lymphocytic leukemia (CLL). Current hypothesis to
explain this phenomenon mainly relies on immunosuppression conferred by
both CLL itself and CLL treatment. The imputability of fludarabine has been
long recognized but the risk associated with monoclonal antibodies, especially
rituximab recently shown to improve overall survival in CLL when combined
with fludarabine and cyclophosphamide (FC), remains unknown.
Aims: The objective of this study was to investigate the impact of anti-CD20
antibodies on the incidence of secondary cancers in patiens treated for chronic
lymphocytic leukemia.
Methods: We conducted a retrospective study of the incidence of secondary
cancers in 1255 CLL patients diagnosed since 1980 in the University Hospital
of Lille to better characterize the possible risk of SPM associated with rituximab.
Results: Of 1255 patients, 651 (52%) received therapy including rituximab
(38%), FC (26.7%), F alone (22.4%), chlorambucil (27.5%), alemtuzumab
(15.5%) and bendamustine (9.3%). Rituximab was given either in combination
with FC (27.5%), other chemotherapy (2.6%) or as a single-agent (3.5%). There
was no significant difference in terms of age (58 versus 62 years), gender,
Binet stage, cytogenetic abnormalities and number of regimen received
between patients treated with or without rituximab. Median follow-up was 6
years for all patients (range 2-23), 4.8 years (range, 2-8) since initiation of ther-
apy for patients treated without rituximab and 3.6 years (range, 0.2-11) for
patients who received rituximab. Median overall survival (OS) was 18 years for
patients treated with R-chemotherapy versus 11 years for patients treated with
chemotherapy alone (p<0,001). Of 1255 patients, 21.5% were diagnosed with
SPM. The incidence of SPM was 17.1% in patients who did not receive treat-
ment compared to 10% in those treated. Among treated patients, the incidence
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of SPM was significantly higher (19% v 2%) in patients who received rituximab
(p<0.001). SPM incidence was increased after R-FC (24.4%), FC (10.5%) com-
pared to other regimen (p<0,001). Most frequent SPM were skin (25%)-and
urologic cancers (23%). Median onset of SPM was 5 years (range, 2-20) with-
out rituximab and 2 years (range, 1-7) with rituximab.
Summary/Conclusions: In this large single center retrospective study, we
found an earlier and significantly increased incidence of SPM, mainly skin can-
cers, in CLL patients treated with R-chemotherapy compared to those given
chemotherapy alone. It remains to be determined whether this increased SPM
incidence is a due to a direct toxicity of rituximab or merely a collateral conse-
quence of improved OS observed after rituximab.
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BACH2 AND BCL6 COOPERATIVELY FUNCTION AS TUMOUR
SUPPRESSORS IN CLL
C Ciardullo1, E Willmore2, A Enshaei2, P Zhou2, V Rand2, M Soundararajan1,
A Hall2, C Harrison2, J Eswaran2,*
1Applied Sciences, Northumbria University, 2Northern Institute for Cancer
Research, Newcastle upon Tyne, United Kingdom
Background: Chronic lymphocytic leukemia (CLL) is the most common
leukemia in adults in the Western World. Aberrant germinal center (GC) reac-
tions could be a triggering factor in CLL, potentially contributing to its patho-
genesis. The transcriptional repressors BCL6 (B-Cell CLL/Lymphoma 6) and
BACH2 (BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor
2) are crucial regulators of GC B-cell fate. The double heterozygous Bcl6-/+
Bach2-/+ mice exhibit profound reduction in GC formation in response to T-cell
dependent antigen immunization. In GC B cells, the stability of BACH2 protein
is regulated by BCL6 and 30% of BACH2 DNA binding sites overlap with BCL6
binding sites. Both proteins are upregulated and interaction between BACH2
and BCL6 represses transcription of PRDM1 (PR Domain Containing 1, With
ZNF Domain), a key driver of plasma cell differentiation.
Aims: The aim of the study is to determine the role of these two critical GC B-
cells regulators, BCL6 and BACH2 in CLL and investigate whether there is a
functional collaboration between them in CLL using a patient sample cohort
comprising 102 patients.
Methods: We have analyzed 102 CLL samples using TaqMan quantitative
real-time PCR (qPCR) and calculated the relative expression by the 2–ΔΔCt
method. A ROC curve was generated to identify the optimal diagnostic cut-off.
The expression was then split at this cut-off and the resulting dichotomous
variable was included in a survival analysis.
Results: We observed different levels of BCL6 and BACH2 expression
throughout the CLL cases analysed. Median RQ (Relative Quantity) was 32.47
(range 4.04-153.29) for BCL6 and 232.62 (range 16.50-1132.30) for BACH2.
Interestingly, CLL cases expressing low levels of BCL6 and BACH2 mRNA
had significantly shorter overall survival (OS) than high BCL6 and BACH2-
expressing samples. Moreover, the low expression of BACH2 and BCL6 specif-
ically decreased OS of CLL patients with mutated IgVH and 11q and 13q dele-
tions. BACH2 mRNA expression negatively correlates to the expression of
CD38 (Pearson Correlation coefficient=-.418, p=.011), a poor prognostic factor
in CLL. Finally, we identified a positive correlation between BCL6 and BACH2
expression (Pearson correlation coefficient =.335, p=.001), suggesting that
these two factors could act synergistically in CLL. We also assessed the impact
of BACH2 expression in combination with other variables that are known to be
relevant for CLL prognosis (age and 17p deletion) and we identified a prog-
nostic index (PI=2.6). According to this model, patients with a PI<= 2.6 have a
shorter OS compared to patients with a PI >2.6 (p=0.004). 
Summary/Conclusions: Taken together, our study shows the prognostic role
of BCL6 and BACH2 in CLL and the possibility of increased B cell receptor sig-
nalling due to the lack of Bcl6 and BACH2.
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IMPORTANCE OF PHARMACIST CONSULTATION TO PREDICT EARLY
TOXICITIES WITH IBRUTINIB AND IDELALISIB: A SURVEY FROM 119
PATIENTS TREATED IN A SINGLE INSTITUTION
C Vinson1, E Degui1, E Delmas2, C Protin2, V Pelagatti-Charrade1, S Perriat1,
F Despas3, G Laurent2, L Ysebaert2,*
1Pharmacy, 2Hematology, IUC Toulouse-Oncopole, 3Pharmacology, Faculté
de Médecine de Toulouse, Toulouse, France
Background: Ibrutinib (IB) and idelalisib (ID) have changed treatment para-
digms in the management of R/R B-cell malignancies but their safety profile in
the real-world setting is ill-defined. 
Aims: Here, we report on the impact of drug-drug interactions (DDI) on early
toxicity in a series of 119 patients (28 prospectively, 91 retrospectively evalu-
ated) with CLL, mantle cell (MCL) and follicular lymphoma (FL), treated outside
the context of clinical trials.
Methods: Consecutive IB/ID pts who initiated therapy off-protocol at Institut
Universitaire du Cancer (IUC) Toulouse-Oncopole from Apr2014 to Dec2015
were included (given they had been exposed to drug at least 1mo). A medica-
tion review for potential DDI was performed by a clinical pharmacist on all files.
Baseline characteristics, concomitant medications (COMED), and toxicities
were recorded. Toxicity at month 1 (TOXM1) was defined by any grade 3-4, or
grade 2 but leading to dose reductions due to impact on quality of life (always
on patients’ demand).
Results: 67 IB pts (52 CLL, 12 MCL) and 52 ID pts (39 CLL, 13 FL) were
assessed (all with a median of 3 previous lines of therapy). Ibrutinib: median
age was 68.6y, with a median number of 3.6 COMED (range 0-14, 30% with
COMED>5, defining polypharmacy). Fifty-five% were taking substrates of
CYP3A4/Pgp, 21% inhibitors of Pgp, 16% and 25% inhibitors of CYP2D6 and
3A4, respectively. No dose reduction was allowed at the initiation of therapy.
TOXM1 was reported in 22/67 pts (32.8%), with only 5/22 grade 3-4 toxicities,
and 17/22 grade 2 impacting QoL (mostly cramps, diarrhea, dyspepsia, rash).
TOXM1 was not correlated to type of lymphoma, previous therapies, gender,
age, COMED>5, but correlated statistically to Pgp inhibitors (52.4% vs 23.9%,
p=0.02) or CYP3A4 inhibitors (57% vs 26.4%, p=0.03) concomitant drug intake,
as could be expected from pharmacokinetics profile of ibrutinib. PFS was not
impacted by dose reduction. Idelalisib: median age was 74y, with a median
number of 4.2 COMED (range 0-12, 41% with COMED>5). Sixty-five% were
taking substrates of CYP3A4/Pgp, 36% inhibitors of Pgp, 0% and 25% inhibitors
of CYP2D6 and 3A4, respectively. TOXM1 was reported in 15/52 pts (28.8%),
but due exclusively to grade 3-4 events: neutropenia (23%), mucositis (4%),
diarrhea/transaminitis (2% each). TOXM1 was not correlated to type of lym-
phoma, age, number or type of COMED, but to female gender (50% vs 14%,
p=0.01). Aldehyde oxydase activity (the main pathway of ID metabolism) is
poorly defined in humans, but reduced in female rats. When looking at the first
3 mo of ID therapy, women had an increased frequency of neutropenic (39%
vs 14.44%) and diarrhea (16.7% vs 2.9%) events of any grade, but less
transaminitis events(5.5% vs 9%), as compared to men. TOXM1 led to dose
reductions after a month of ID in 44.5% and 11.2% of female/male pts, respec-
tively (impacting PFS). At 6mo follow-up, 38.5% of patients were still on therapy
(most discontinuations due to grade 3-4 AE).
Summary/Conclusions: DDI were found to impact early toxicities with IB but
not with ID, emphasizing the urgent need of better PK/toxicity evaluation for
both drugs in real-life practice. Such prospective evaluation is just starting in
our institution (protocol PK-E3i) to better monitor plasma levels (and adequately
adapt drug dosage), and better support patients’ compliance in the long-term. 
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IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): IMPACT OF THE
YOU&I™ PATIENT SUPPORT PROGRAM ON TREATMENT ADHERENCE
A Peters1,*, J Wiernikowski2, S Barker3, M Mahler4, S Luker5, J Connors6
1University of Alberta, Edmonton, 2Juravinski Hospital and Cancer Centre,
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Agency Centre for Lymphoid Cancer, Vancouver, Canada
Background: Oral therapies for cancer can present several advantages over
intravenous drugs, including greater flexibility and convenience for the patient
and reduced healthcare costs. However, for treatment to be effective, a high
degree of adherence must be maintained. Prior studies have shown a range
of non-adherence to long-term oral anticancer therapy, with adherence rates
varying considerably with patient characteristics. Consequences of low adher-
ence can include increased healthcare costs and inferior patient outcomes,
including decreased time to relapse and decreased survival. The YOU&i™
Patient Support Program (PSP) supports patients with reimbursement services
and provides patients and their physicians with a comprehensive nurse-coach-
ing program in an effort to encourage treatment adherence.
Aims: To examine patient satisfaction and adherence to ibrutinib within the
YOU&i™ PSP.
Methods: Using evidence-based literature reviews and global/local market
research, barriers to treatment adherence were identified. These included a
lack of disease/treatment education, high financial burden, negative psychoso-
cial/motivational factors, poor medication routine-building, and suboptimal
patient:physician communication. Each patient’s risk for non-adherence was
calculated using the Morisky Medication Adherence Scale© score and the total
number of barriers identified at initial assessment, and the frequency of nurse-
coaching calls was adjusted accordingly. Patients were categorized as “adher-
ent” if they had ≥85% compliance (obtained refills within 4 days of expected
refill date) and as “discontinued” if ibrutinib was not dispensed for ≥3 months,
if the patient was confirmed as discontinued prior to ibrutinib not being dis-
pensed for ≥3 months, or if the patient was confirmed as deceased. All other
patients were categorized as “partially adherent”. Patient questionnaires were
used to gauge satisfaction with the YOU&i™ PSP.
Results: As of January 19, 2016, a total of 903 CLL patients were enrolled in
the PSP; 87% of patients opted in for nurse coaching. Most patients (58%)
had received 1-2 prior lines of therapy. At 9 months from treatment initiation,
81% of patients who received nurse coaching vs 59% of those who did not
were categorized as “adherent” (excludes patients who discontinued due to
disease progression or death). Similarly, only 7% of those who received nurse
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coaching vs 23% of those who did not were discontinued from ibrutinib for rea-
sons other than disease progression or death. In the overall PSP population,
17% discontinued the program; among the patients discontinuing, the most
common reason was death (49%). Overall, 91% of patients reported that they
were satisfied/very satisfied with the PSP, with 87% likely to recommend the
program. Furthermore, 78% reported that the PSP was very helpful in support-
ing their adherence to ibrutinib.
Summary/Conclusions: Although there is an inherent potential for self-selec-
tion bias, these results from the YOU&i™ PSP suggest that nurse coaching
may contribute to improved patient adherence to oral anticancer treatment. In
the YOU&i™ PSP, nurse coaching appeared to also be associated with
decreased treatment discontinuation. This program, or similar supportive pro-
grams, may be helpful in assisting patients in maintaining adherence to treat-
ment with ibrutinib.
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INCIDENCE OF AND RISK FACTORS FOR MAJOR HEMORRHAGE IN US
VETERANS ADMINISTRATION PATIENTS WITH NEWLY DIAGNOSED
CHRONIC LYMPHOCYTIC LEUKEMIA
P Georgantopolous1,*, H Yang2, M Cai2, L Norris3
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olina Center of Economic Excellence for Medication Safety, the South Carolina
College of Pharmacy, University of South Carolina, Arnold School of Public
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Background: Patients with chronic lymphocytic leukemia (CLL) have an
increased risk for major hemorrhage (MH) compared to the age- and gender-
matched general population (Gifkins et al, Blood, 2015). However, the specific
risk factors associated with bleeding among patients with CLL are not well
established.
Aims: Our objective was to estimate the incidence of MH among patients newly
diagnosed with CLL receiving care at US Veterans Administration (VA) health-
care facilities and to identify risk factors associated with MH in these patients.
Methods: Patients diagnosed with CLL from 1999 through 2013 were identified
using ICD-9 codes from VA electronic medical records. Those with<6 months of
VA care before CLL diagnosis were excluded from analysis to capture a newly
diagnosed patient cohort. Follow-up was from initial CLL diagnosis until death,
12/31/2013, or MH onset, whichever occurred first. We defined an MH event as
a diagnosis code of bleeding in a critical area or organ or bleeding that was
treated with blood transfusion within 7 days. We calculated the incidence rate
of MH after CLL diagnosis. Potential risk factors included demographic charac-
teristics and selected medical history based on ICD-9 codes within 6 months
before the first CLL diagnostic code. We performed univariate comparisons and
a backward stepwise Cox proportional hazards regression analysis.
Results: Of the 24,581 veterans with newly diagnosed CLL, 24,166 (98.3%)
were male, 20,464 (83.3%) were white; median age at diagnosis was 72.0 years;
2,013 (8.2%) experienced MH after CLL diagnosis, with a median time of 2.6
years between diagnosis and MH event. The incidence of MH was 16.4 per
1,000 person-years (95% CI, 15.7-17.1/1000). Statistically significant (P<0.05)
risk factors for MH were (HR; 95% CI) history of MH (4.0; 3.4-4.7), anemia (2.6;
2.0-3.4), stroke (2.0; 1.2-3.5), male (2.0; 1.3-3.0), African American (1.7 vs white
race; 1.5-2.0), uncontrolled hypertension (1.7; 1.3-2.2), atrial fibrillation (1.5; 1.2-
1.7), CAD (1.3; 1.1-1.4), and age >75 years (1.1 vs<65 years; 1.0-1.3).
Summary/Conclusions: The incidence of MH in newly diagnosed CLL patients
was 16.4 per 1,000 person-years. Risk factors most strongly associated with
MH after CLL diagnosis are history of MH, anemia, stroke, and being male.
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MALE GENDER IS ASSOCIATED WITH AN IMPAIRED OVERALL AND
PROGRESSION FREE SURVIVAL IN PATIENTS WITH PROGNOSTIC LOW
RISK CHRONIC LYMPHOCYTIC LEUKEMIA
C Da Cunha-Bang1,*, C Geisler2, L Enggaard3, C Poulsen4, P Brown2, H Frederiksen5,
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Background: Recently the new International Prognostic Index for Chronic Lym-
phocytic Leukemia (CLL) patients (CLL-IPI) was developed (Bahlo J, et al: The
International Prognostic Index For Patients With Chronic Lymphocytic
Leukaemia (CLL-IPI). ICML, Lugano, 2015). The index does not include gender
as a weighted factor. However, previous analyses of Danish CLL patients indi-
cate gender specific variations in Overall Survival (da Cunha-Bang C, et al:
Improved Survival for Patients with CLL in the Era of Combination Chemoim-
munotherapy - a Danish Population Based Study. Blood 126:1740-1740, 2015).
Aims: To analyze gender-specific outcome for patients following diagnosis with
CLL for different CLL-IPI risk groups based on the Danish CLL-database.
Methods: All patients diagnosed with CLL in Denmark were registered and
prospectively followed in the Danish National CLL database (2008-2015). The
present analysis included all patients for whom all five factors included in the
CLL-IPI score were registered (del(17p/TP53, IGHV mutation status, beta-2-
microglobulin, Binet/Rai stage, age). Overall survival (OS), treatment free sur-
vival (TFS) and progression free survival (PFS) were calculated using Kaplan
Meier and multivariate Cox regression models adjusted for relevant confounders.
Results: In total, 1541 patients were included. Analyzing the entire population,
no difference in OS was found based on gender. However, analysis of the 1314
(778 (59%) male, 536 (41%) female) patients from the low and intermediate risk
CLL-IPI score groups showed an impaired OS ((Hazard ratio (HR (95%CI)) for
death; 1.7 (1.2-2.3) P=0.002)) for male versus female patients. No variation in
TFS was found. However, following treatment male patients had a significantly
impaired PFS (HR for progression; 3.0 (1.5-6.2) P=0.003)) versus female patients.
Summary/Conclusions: Male CLL patients in low and intermediate CLL-IPI
risk groups have a higher risk of dying than their female counterparts. The
increased risk of dying from non-CLL related causes for male patients may
explain this difference, which is overruled by the increased risk of dying from
CLL among high and very high CLL-IPI risk groups. Following CLL treatment
the gender disadvantage is apparently accentuated. Focus on reducing pre-
treatment risk factors for male CLL patients may improve survival in this popu-
lation. Further analyses of cause of death following treatment in male CLL
patients are warranted.
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BENDAMUSTINE PLUS RITUXIMAB IN 65 YEAR AND ABOVE UNTREATED
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
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M Ballesteros10, I Jarque11, J Ochoa Grullon12, R Iglesias1, M Estevez1,
R de Oña1, E Prieto13, A Diaz-Lopez14, P Baltasar15
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Background: Frontline Chemoimmunotherapy with Bendamustine and Ritux-
imab (BR) in Previously Untreated and Physically Fit Patients (pts) with
Advanced Chronic Lymphocytic Leukemia (CLL) has been compared against
the standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) and sug-
gested as an option for elderly pts (Eichhorst el al ASH 2014). There is a lack
of data regarding BR as CLL front line in routine clinical practice.
Aims: The aim of this study is to evaluate the toxic profile and effectiveness of
BR as front line in 65 yr and above CLL patients in daily practice and to identify
risk factors.
Methods: We performed the analysis of the 65yr and above patients included
in the MDA-LLC-2015-02 study, which consisted of a retrospective study CLL
patients from 12 Spanish sites treated with BR as front line (B 90 mg/m2 days
1 and 2 every 28 days and R 375 mg/m2 on day 1 of the first cycle and 500
mg/m2 on day 1 of the other cycles). We evaluate effectives as IWCLL, toxicity
as CTCAE v4.0 of NCI, overall survival (OS) and progression free survival
(PFS) (Kaplan-Meier). This study has been approved by the Spanish Medicines
Agency AEMPS.
Results: Sixty two (male 46 pt/female 16 pt) out of 85 pt included in MDA-LLC-
2015-02 study were 65 or older, median age 72 (65-84). Risk factors as follows,
ECOG≥2: 6 pt, high LDH: 25 pt, high β2 microglobulin: 50 pt, Binet C: 22 pt,
Creatinine >1.3 mg/dL: 8 pt. Toxicity: A total of 316 cycles were administered,
median 6 per patient, grade 4 neutropenia: 9pt, hospitalization do adverse
events 13 pt, all febrile neutropenia. No cases of treatment related mortality.
Efficacy: ORR 90.2%, with a median follow up 36 months 19 pt required second
line therapy and 10 pt died, 2 because of progression. Median OS 56 months
and median PFS 45 months (3 year OS 85.5%). ECOG≥2 (p0.002, p0.008)
and grade 4 neutropenia (p0.017, p0.006) predict OS and PFS. High LDH, high
β2 microglobulin, Binet C, Creatinine >1.3 mg/dL, trisomy 12, del11q, del13q
did not predict OS neither PFS.
Summary/Conclusions: This results confirms BR as an effective (ORR 90.2%
and PFS 45 months) and safe (no cases of treatment related mortality) as first
lines for 65 year old and above CLL patients.
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PHASE 1 FINAL RESULTS AND PHASE 2A DOSE SELECTION FOR
CERDULATINIB (PRT062070) A DUAL SYK/JAK INHIBITOR IN PATIENTS
WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
P Hamlin1,*, I Flinn2, N Wagner-Johnston3, J Burger4, G Michelson, A Pandey5,
M Birrell5, G Coffey5, J Leeds5, A Sabalvaro-Torres5, Y Kim5, J Curnutte5,
M Patel6
1Memorial Sloan Kettering Cancer Center, New York, 2Sarah Cannon Research
Institute, Nashville, 3Johns Hopkins University, Baltimore, 4MD Anderson Can-
cer Center, Houston, 5Portola Pharmaceuticals Inc, South San Francisco,
6Florida Cancer Specialists, Sarasota, United States
Background: Subsets of B cell lymphomas demonstrate a reliance on B-cell
antigen receptor (BCR) and/or cytokine JAK/STAT signaling for survival. SYK
is upstream of BTK, PI3Kδ, and PLCγ2 on the BCR pathway, making it a poten-
tial therapeutic target. Additional survival mechanisms are mediated by
cytokine-induced JAK/STAT pathways, derived from the tumor or tumor infil-
trating leukocytes, which leads to upregulation of BCL2 family members. In
pre-clinical tumor models, cerdulatinib induces apoptosis in a genetically
diverse panel of cell lines and primary B cell tumors in the 1 to 2 µM range.
Aims: The primary aim of the study was to establish the maximum tolerated
dose of cerdulatinib.
Methods: This is a 3+3 dose escalation study with 28-day cycles. Once daily
(QD; up to 100 mg) and twice daily (BID; up to 45 mg) dosing was evaluated.
Pharmacokinetics (PK), pharmacodynamics (PD), and safety were monitored,
as well as an initial assessment of efficacy. Clinical response was assessed by
standard criteria. Potency and specificity for SYK and JAK pathway inhibition
were measured in whole blood assays by monitoring signaling responses fol-
lowing ligation of the BCR and receptors for IL2, IL4, IL6, and GM-CSF. Serum
markers of inflammation were also measured.
Results: 43 patients with CLL/SLL or B-cell NHL were enrolled on the com-
pleted phase 1. Median age is 67 years (range 23-85) and median prior ther-
apies is 3 (range 1-8). Treatment related AEs ≥ grade 3 occurring in 2 or more
patients with daily dosing were: fatigue (n=5), anemia and neutropenia (n=3
each), and abdominal pain, neutrophil count decrease, and pneumonia (n=2
each). A number of these events occurred in the setting of progressive disease.
The highest overall exposure was achieved at the 45 mg BID dose, in which 2
DLTs occurred: grade 3 pancreatitis and grade 3 fatigue. Enrollment to this
dose was discontinued, and the phase 2a dose was selected. In review of the
40-100 mg QD doses, the average SS Cmin and Cmax concentrations plateaued
at 0.70±0.20 and 1.38±0.23 µM, respectively. QD dosing of 40-100 mg resulted
in 50 to 100% (SS Cmin to Cmax) inhibition of SYK and JAK signaling in periph-
eral blood, and significant inhibition of serum markers of inflammation. The
extent of inhibition of SYK and JAK signaling as well as inhibition of serum
markers of inflammation significantly correlated with tumor response. While
the PK is suitable for QD dosing with a t1/2 of 12-16 hours and a 2:1 peak-
trough ratio, the pH dependent low solubility of cerdulatinib limited dissolution,
and physiologic modeling suggested that BID dosing would increase overall
exposure. This was accomplished with the 45 mg BID dose, where complete
inhibition of SYK and JAK at SS Cmin (~1.5 µM) in peripheral blood assays
was observed, consistent with an approximate doubling in exposure. Partial
responses in phase 1 were observed in 5 heavily pretreated patients with CLL,
FL, and transformed DLBCL at doses ranging from 30-65 mg QD. Two PRs
were observed in the 45 mg BID dose group, one in a patient with FL and
another with CLL. Responses typically occurred after 2 cycles of treatment.
Multiple patients have demonstrated nodal reductions and maintained clinical
benefit for over a year. Based on the PK/AE profile, there appeared to be higher
grades of adverse events at SS Cmin of 1.25 µM or greater. PK modeling indi-
cated a dose of 35 mg BID would yield a SS Cmin of 1.02 µM and a SS Cave of
1.16 µM, which is predicted to be tolerable, efficacious, and achieve complete
inhibition of SYK and JAK in peripheral blood. 35 mg BID was therefore select-
ed as the phase 2a dose.
Summary/Conclusion: Cerdulatinib demonstrates clinical activity in heavily
pretreated patients with CLL/B-cell NHL and is generally well tolerated. BID
dosing has overcome the previous plateau in exposure and has enhanced PD
effects. A phase 2a study is now open for CLL/SLL, FL/other indolent NHL and
aggressive B-cell NHL at a dose of 35 mg BID.
Chronic myeloid leukemia - Biology
E1083
ABERRANT MECHANISMS OF TELOMERE MAINTENANCE IN CHRONIC
MYELOID LEUKEMIA - THE POTENTIAL ROLE OF POT1
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Background: As in most cancers, a reduction in the telomere length is one of
the features of chronic myeloid leukaemia (CML) and telomere shortening is
correlated with disease progression from the chronic phase (CML-CP) to the
blastic phase (CML-BP). Targeted therapy in CML with tyrosine kinase inhibitors
(TKIs), such as imatinib, gives long-lasting remission in the majority of patients.
However, significant proportion of patients may develop resistance and
progress to advanced phases with limited therapeutic options. Majority of stud-
ies are focused on monitoring the telomere length during the progression of
the disease. However the precise role of telomere-associated proteins, includ-
ing shelterin complex in BCR/ABL1-mediated genomic instability in CML pro-
gression and resistance to TKIs have not been fully elucidated.
Aims: The aim of our study was to determine the role of the members of the
shelterin complex in aberrant telomere maintenance mechanisms in CML pro-
gression with special focus on POT1.
Methods: We employed human BCR-ABL1-positive cells (K562), and BCR-
ABL1-negative cells (HL60), as well as CD34+ primary cells isolated from periph-
eral blood leukocytes of CML patients at various stages of the disease (chronic
phase, chronic phase TKI-resistant and blastic phase). Blood samples were
taken after informed consent. The components of telomere complex were stud-
ied at the mRNA level (RT-qPCR) and protein level (Western blotting). The activ-
ity of telomerase was measured using ELISA. The mean TRF length was meas-
ured using the TeloTAGGG telomere length assay and individual telomere length
using primed in-situ labelling technique. Global DNA damage was assessed
using comet assay. ROS and RNS were analysed using fluorogenic probes.
Results: Initially, we confirmed with Southern blotting that the telomere short-
ening was positively correlated with CML progression (CML-CP in comparison
to CML-BP). However, in samples from CD34+ CML-CP TKI-resistant patients
in comparison to CML-CP patients, an increase in telomere length was
observed. Dynamic changes in telomere length were neither associated with
expression of TERT/TERC nor with enzymatic activity of telomerase in the
course of the disease. Therefore, we decided to examine the potential role of
shelterin complex in telomere maintenance in disease progression looking at
the expression pattern of selected members of telomeric complex. We found
that the expression of POT1 was significantly upregulated in CML-BP as com-
pared to CML-CP (Fig.1). Moreover, expression of POT1 was positively corre-
lated with BCR-ABL1 expression. To verify the hypothesis that telomeres are
elongated in TKI-resistant cells, imatinib-resistant K562 cells were used. We
showed that telomeres in the resistant cells were significantly longer which
was associated with differential expression of shelterin complex members,
including POT1. These findings suggest that actual telomere length in disease
progression may change in biphasic mode and may include initial telomere
lengthening (possibly by alternative telomere lengthening mechanisms) in TKI-
resistant cells. We also found that the changes in telomere length in TKI-resis-
tant cells were accompanied by the genomic changes at chromosome level
and oxidative/nitrosative stress
Figure 1.
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Summary/Conclusions: In conclusion, we postulate that abnormal expression
of members of the shelterin complex, such as POT1, may be responsible for
aberrant telomere maintenance mechanisms in CML cells and may play role in
genomic instability associated with CML progression as well as the clonal selec-
tion and resistance to TKIs.
E1084
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS
PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRON-
IC MYELOID LEUKEMIA
C Giallongo*, NL Parrinello, D Tibullo, P La Cava, A Romano, G Camiolo,
G D’Amante, F Stagno, P Vigneri, GA Palumbo, F Di Raimondo
Division of Hematology, azienda ospedaliera universitaria policlinico vittorio
emanuele, Catania, Italy
Background: Recently, we and another group demonstrated that Myeloid sup-
pressor cells play an important role of immune escape in chronic myeloid
leukemia (CML) patients.
Aims: Investigating the effect of the tyrosine kinase inhibitors (TKI) therapy on
MDSC and possible correlation with clinical response.
Methods: CML patients at diagnosis (n=30) and during TKI treatment (n=43) were
enrolled in this study. Eighteen patients were treated with imatinib (IM), 13 with nilo-
tinib (NIL) and 12 with dasatinib (DAS). MDSCs were also analyzed in peripheral
blood of 20 healthy donors (HD). Granulocytic MDSCs (G-MDSCs) were identified
as CD11b+CD33+CD14-HLADR- cells while monocytic MDSCs (M-MDSCs) as
CD14+HLADR by cytofluorimetric analysis. Their immunosuppressive activity was
tested through incubation with autologous CFSE+T cells. Exosomes were isolated
from CML serum at diagnosis (n=5) by sequential ultracentrifugation.
Results: G-MDSCs and M-MDSCs percentages in CML patients were greater
than HD (respectively 82.5±9.6% vs 56.2±5.4% and 33.6±19% vs 5.9±4%,
p<0.0001). Both isolated subpopulations showed expression of BCR/ABL and
were able to inhibit T cells proliferation in comparison to positive control (from
48±7.6% to 25±5% for G-MDSC, p=0.0057 and 16.7±0.6% for M-MDSC,
p<0.0001). No suppressive effect was observed in co-cultures with G-MDSC
and M-MDSC obtained from HD. In addition, M-MDSC percentage correlated
with BCR/ABL transcript levels in patients at diagnosis (r=0.579, p=0.0004).
Evaluating the effect of TKI therapy on MDSC levels, we found that both IM, NIL
and DAS induced a significant reduction of G-MDSC percentage at 6 months
(from 82.5±9.6% to 55±17.3% after IM, to 60.9±9% after NIL and to 48.7±13%
after DAS, p<0.0001) and 12 months (61.2±9.7% after IM, 61.4±6.7% after NIL
and 33.4±14% after DAS, p<0.0001) of treatment. The levels of M-MDSCs sig-
nificantly decreased only after DAS therapy (from 33.6±19% to 6.8±12.6% at 6
months, p=0.014 and 11.4±12.3% at 12 months, p=0.008). M-MDSC reduction
was also present but did not reach statistical significance after IM treatment
(22.2±24.5% and 22.3±21.7% respectively at 6 and 12 months) and after NIL
therapy (21±19.9% and 17.4±16.3% at 6 and 12 months) with a great variability
among patients. Subsequently, correlation of MDSC with clinical response to
TKI therapy was investigated. We found that in DAS, but not in IM or NIL treated
patients, a correlation between percentage of Major Molecular Response (MMR)
and number of persistent M-MDSCs was found. A significant difference was cal-
culated comparing M-MDSC levels in the MMR group (n=6) versus no MMR
(n=6) at 12 months (p=0.008). To evaluate if leukemic cells are able to expand
MDSC releasing soluble factors or exosomes, we incubated monocytes obtained
from HD with sera or exosomes from CML patients at diagnosis or healthy sub-
jects. M-MDSCs percentage significantly increased only in conditions with CML
serum (29±13%; p=0.0006) or exosomes (8±2.8%; p=0.01). No effect was
observed on G-MDSC percentage.
Summary/Conclusions: Therapy with TKI reduces the percentage of MDSCs
and levels of the monocytic subset correlates with MMR value in patients treated
with dasatinib, suggesting their importance in clinical investigation as prognostic
factor. Moreover, our data suggest the possible development in CML patients
of a circuit primed by tumor cells that, through the release of soluble factors
and exosomes, are able to expand M-MDSCs, creating an immunotolerant
environment that results in T cell anergy and facilitates tumor growth.
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THE USE OF THE EAC PRIMERS IN DIGITAL PCR FOR MONITORING
MINIMAL RESIDUAL DISEASE IN CML RESULTS IN A SHIFT BETWEEN
MOLECULAR RESPONSE GROUPS.
J Maier 1, GN Franke 1, M Cross 1, K Wildenberger 1, F Giles 2, O Frank 3, A
Hochhaus 4, C Dietz 5, MC Müller 6, D Niederwieser 7,*, T Lange 8
1Abteilung Hämatologie, Internistische Onkologie, Universität Leipzig, Leipzig,
Germany, 2Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, United
States, 3Novartis Pharma GmbH, Nürnberg, 4Jena University Hospital, Jena,
5Universität Heidelberg, 6Institute for Hematology and Oncology (IHO GmbH),
Mannheim, 7Universität Leipzig, Leipzig, 8Asklepios Klinikum Weißenfels,
Weißenfels, Germany
Background: Digital PCR (dPCR) generates an absolute read out that is largely
robust to variations in PCR efficiency and should reduce the requirement for
standardisation by laboratory-specific conversion factors.
Aims: The aim of this study was to compare the results of dPCR to qPCR
(quantitative PCR) in blinded samples from two independent laboratories with
respect to the observed rates of molecular response (MR) in CML patients (pts)
having undergone 18 months of nilotinib treatment in the ENEST1st trial (Clin-
icalTrials.gov:NCT01061177).
Methods: A total of 230 cDNA samples from CML pts with e13 or e14/a2 BCR-
ABL fusion genes who were treated within the ENEST1st trial between 2012 and
2013 were analysed in Leipzig (L, n=75) or Mannheim (M, n=155) with qPCR.
BCR-ABL levels were determined relative to those of ABL and standardization
was achieved using plasmid DNA. Both labs are accredited by the European
Treatment and Outcome Study (EUTOS) collaboration. The cDNA samples were
blinded for the qPCR results and re-analysed in L with a duplex dPCR using a
QX200 Droplet Digital PCR System (BIO-RAD). In line with the manufacturer’s
recommendations, duplicate samples yielding a minimum of 3 positive droplets
from the 12-19.000 routinely analysed droplets were scored as positive. Depth
of MR was scored using the EUTOS definitions used in the ENEST1st trial.
Results: A previous comparison between dPCR and qPCR showed significant
differences in the distribution of the molecular response (MR) categories
(p=0.02) with more residual disease (RD) measured by dPCR. In detail, signif-
icantly fewer patients achieved deep molecular responses (MR4 to MR5) by
dPCR (p=0.035). Of the 230 samples analysed by the two methods, 58%
(n=134) were classified in the same MR category, while 11% (n=25) skipped to
classes with less RD and 31% (n=71) moved to classes with more RD by dPCR,
mostly over a range of 1-2 classes. ABL copies in non-concordant samples
were median 1.1 fold higher by dPCR than by qPCR, while BCR-ABL transcripts
were 3 fold higher by dPCR in 56/71 samples analysed, resulting in significantly
more patients having more RD by dPCR. Experimental tests of the sensitivity
between 0.25 and 25 BCR-ABL copies showed a LOQ (limit of quantitation) of
3 positive droplets in duplicates (cut-off 3). Interestingly, application of the lab-
oratory-specific qPCR conversion factor to the dPCR data (cut-off 3) independ-
ently reduced the difference in distribution categories between the qPCR and
dPCR to below significance (Table 1).
Table 1. Distribution of MR classes.
Summary/Conclusions: The use of M-BCR-ABL primers according to the
EAC (Europe Against Cancer) protocol in dPCR with a cut-off of 3 droplets
results in a shift of molecular response categories towards more minimal RD
by dPCR than by qPCR. This difference is reduced to below significance by
application of the laboratory specific qPCR conversion factor to the dPCR data.
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PRE-EXISTING SOMATIC MUTATIONS IN GENES COMMONLY MUTATED
IN MYELOID MALIGNANCIES (RUNX1, DNMT3A, ASXL1) MAY CONFER
BAD PROGNOSIS IN CHRONIC MYELOID LEUKEMIA
M M Machnicki1,2,*, I Solarska1,3, M Zawada4, P Stawinski5, R Ploski5,
I Seferynska3, T Sacha6, T Skorski7, T Stoklosa1
1Department of Immunology, Centre of Biostructure Research, 2Postgraduate
School of Molecular Medicine, Medical University of Warsaw, 3Department of
Diagnostic Hematology, Institute of Hematology and Transfusion Medicine,
Warsaw, 4Department of Hematology Diagnostics, The University Hospital,
Krakow, 5Department of Medical Genetics, Medical University of Warsaw, War-
saw, 6Department of Hematology, Jagiellonian University, Krakow, Poland,
7Department of Microbiology and Immunology, Fels Institute of Cancer
Research and Molecular Biology, Temple University School of Medicine,
Philadelphia, PA, United States
Background: Chronic Myeloid Leukemia is readily manageable disease for
majority of patients. However, a subset of patients either never achieve or lose
response to tyrosine kinase inhibitors (TKIs) and progress from chronic (CML-
CP) to blastic phase (CML-BP). The genetic basis of this transition remains
only partially understood, particularly when loss of TKI sensitivity cannot be
attributed solely to BCR-ABL1 mutations.
Aims: We sought to determine the genetic background of CML progression in
patients who experienced TKI treatment failure not associated with BCR-ABL1
mutations using targeted enrichment and next-generation sequencing strategy.
Methods: Sequential DNA samples were collected from 9 patients who were
diagnosed in CML-CP and progressed to CML-BP (8 myeloid, 1 lymphoid).
SeqCapEZ Choice (NimbleGen) enrichment was used to capture coding
sequences of 952 genes (7Mb) implicated in human cancer (with focus on
hematological malignancies), followed by high-throughput sequencing on Illu-
mina HiSeq 1500 (>90% ge20, >100x mean coverage).
Results: In 7 patients we observed variants in RUNX1, DNMT3A, ASLX1,
PTPN11 and IDH1 genes (table), all of which were considered as damaging
and located in previously known hotspots (except for novel DNMT3A mutations).
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Almost all variants could be detected at CML-CP at varying allele frequency,
thus preceding diagnosis of CML progression.
Table 1.
Summary/Conclusions: Our results suggest that in rare, refractory CML cases
mutations in genes frequently mutated in myeloid neoplasms might cause or
contribute to an aggressive CML phenotype. Early detection of such genetic
lesions might be important for patients who will not achieve remission with cur-
rently available standard treatment regimens and who should be considered
as high-risk patients.
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EVOLUTION OF RUNX1 AND ASXL1 MUTATIONS DURING THE
PROGRESSION OF CHRONIC MYELOID LEUKEMIA TO MYELOID BLAST
PHASE: AN ANALYSIS OF 52 MATCHED PAIRED SAMPLES AT BOTH
INITIAL DIAGNOSIS AND BLAST PHASE
HW Kao1,2,*, MC Kuo1,2, PN Wang1, P Dunn1,2, JH Wu1, CL Lai1, TH Lin1,
LY Shih1,2
1Chang Gung Memorial Hospital at Linkou, 2Chang Gung University, Taoyuan,
Taiwan, ROC
Background: Before imatinib era, most patients with Ph-positive chronic
myeloid leukemia (CML) diagnosed at chronic phase (CP) or accelerated phase
(AP) will transform to blast phase (BP) compared with a small number of
patients receiving imatinib therapy. The biology of CML-BP is still largely
unknown. Data from direct comparison of matched samples between both diag-
nosis and BP was limited.
Aims: We aimed to determine the role of RUNX1 and ASXL1 mutations in addi-
tion to BCR-ABL1 kinase domain (ABL1-KD) mutations during the progression
of CML in a larger cohort of matched paired samples in CP/AP and myeloid BP.
Methods: Bone marrow samples from 52 patients with CML at initial diagnosis
(47 CP and 5 AP) and myeloid BP transformation were enrolled. Nineteen
patients received imatinib therapy before BP transformation (group A) and the
remaining 33 patients had not been treated with imatinib (group B). Semi-nest-
ed polymerase chain reaction (PCR) assay followed by denaturing high-per-
formance liquid chromatography and/or direct sequencing was used to detect
ABL1-KD mutations. RUNX1 (exons 3-8) and ASXL1 (exon 12) mutations were
analyzed by PCR-based assays and direct sequencing. Patients with ABL1-
KD, RUNX1, or ASXL1 mutations in myeloid BP were subjected to the analyses
of the corresponding genes in the matched diagnosis samples. Pyrosequencing
was used to measure the mutant levels.
Results: The median age of patients at the time of CML diagnosis was 45 (16-
84) years. The median time from CP/AP to myeloid BP was 26 (1.9-162.9)
months. Eight (42.1%, 8/19) of group A patients had ABL1-KD mutations at BP
compared with none in group B patients (P=0.0003). None of the 8 patients
carrying ABL1-KD mutations at BP had ABL1-KD mutations detected in the
diagnostic samples. Ten (19.2%, 10/52) patients in myeloid BP had RUNX1
mutations, but none of them had RUNX1 mutation in the corresponding diag-
nostic samples. Only one of the 10 patients with RUNX1 mutations in myeloid
BP had ABL1-KD mutations. Two patients (10.5%, 2/19) acquired RUNX1
mutations at BP in group A compared with 24.2% (8/33) in group B (P=0.227).
ASXL1 mutation was detected in 6 (11.8%, 6/51) samples in myeloid BP, of
which only one was positive for ASXL1 mutation in the diagnostic sample which
was in AP. All the 5 patients who acquired ASXL1 mutations did not have ABL1-
KD mutation in myeloid BP. Acquisition of ASXL1 mutations in myeloid BP was
0% (0/18) and 18.2% (6/33) in group A and group B, respectively (P=0.054).
Together, 3 patients had co-existence of RUNX1 and ASXL1 mutations at
myeloid BP. Emergence of ABL1-KD mutations did not significantly affect the
acquisition of RUNX1 or ASXL1 mutations during myeloid BP transformation.
Summary/Conclusions: RUNX1, ASXL1 or ABL1-KD mutations were not
detected in CML patients at initial diagnosis except one who presented with AP.
Acquisition of RUNX1 and/or ASXL1 mutations occurred in 25.5% (13/51) of
patients during myeloid BP transformation. ABL1-KD mutations only occurred in
patients treated with Imatinib, and ASXL1 mutations were prone to develop in
patients not treated with Imatinib. (Grant support: XMRPG360366 and
OMRPG3C0021).
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NEXT-GENERATION SEQUENCING OF AMPLIFIED DNA FRAGMENTS
WITH LENGTH POLYMORPHISMS ASSOCIATED WITH CHRONIC
MYELOID LEUKEMIA REVEALED POLYMORPHISMS IN REPETITIVE ELE-
MENTS AND CANCER RISK LOCI
J Koblihova1,*, K Srutova1,2, M Jaruskova1,2, H Klamova1, K Machova Polakova1,2
1Institute of Hematology and Blood Transfusion, 2Institute of Clinical and Exper-
imental Hematology, First Faculty of Medicine, Charles University, Prague,
Czech Republic
Background: A genetic predisposition and molecular mechanisms of chronic
myeloid leukemia development (CML) and of resistance to the treatment with
tyrosine kinase inhibitors (TKI) is the matter of the research worldwide. High-
throughput techniques such as next generation sequencing (NGS) enable
whole-genome analysis per each individual, however, often with limitations in
a large volume of obtained data requiring extensive bioinformatics analysis.
Aims: We created an approach to scan the individual CML genomes using the
combination of highly reproducible amplified fragment length polymorphism
(AFLP) analysis and of NGS in order to identify polymorphic loci associated
with CML or response to imatinib (IM).
Methods: AFLP was performed on 65 CML patients treated with IM first line
(39 pts with optimal response; 26 pts with IM failure) and 30 healthy donors;
for confirmatory analysis next 30 controls were added. The median age of
patients was 55 years (range 18-84). AFLP analyses were performed using
MseI and EcoRI endonucleases and commercially available kits and protocols.
Fragmentation was run on ABI PRISM 3130 sequencer. The lengths of DNA
fragments were analyzed with GeneMapper. DNA fragment frequency among
CML patients and controls were analyzed by the exact binomial test. Nine
selected DNA fragments were further characterized by NGS and the obtained
data were evaluated using NextGENe. Polymorphisms in identified DNA frag-
ments were confirmed by Sanger sequencing.
Results: AFLP generated 3912 AFLP markers/DNA fragments with diverse
distribution among CML patients and healthy controls. Among them 199 were
significantly associated with CML and 5 with IM response. Using NGS, we
characterized 7 loci associated with CML and 2 with response to IM. In
CAC_ACC_25, we confirmed SNP rs113864098 (C/T) resulting in an introduc-
tion of EcoRI restriction site. The locus is on chromosome 1 and is a part of
L1MC1 and AluSz repetition. The significantly higher frequency of rs113864098-
T allele was found in the patient cohort (60%) in comparison to healthy donors
(13%) (P=0.016). SNP rs7906704 (G/T) was confirmed in the CAT_ACC_54
fragment localized on chromosome 10 between NRAP and CASP7 genes
resulting in the introduction of MseI restriction site in this locus. The frequency
of minor rs7906704-T allele was significantly higher in CML patients (38%;
P=0.04) in comparison to healthy controls. This SNP was found to be involved
in apoptosis pathway in pancreatic tumorigenesis (Li et al., 2012). Further, we
identified DNA fragment CTT_ACA_57, which was significantly frequently pres-
ent in patients with optimal response to IM (65%) in comparison to patients
with IM failure (19%) (P=0.03). The fragment is a part of satellite sequence
ALR/Alpha occurring in centromeric regions with the highest frequency on chro-
mosome 5. Wide evidence of small genomic aberrations of ALR/Alpha was
found in chronic lymphocytic leukemia (Kim et al., 2010). 
Summary/Conclusions: In this work, we applied whole-genome fragmentation
analysis to identify DNA polymorphisms associated with CML and response to
IM and subsequently confirmed these potential novel DNA markers by geno-
typing. Up to now, we identified and confirmed 2 SNPs significantly associated
with CML and 1 repetitive element polymorphism associated with response to
IM. We assume identification of more genomic markers associated with CML
and suppose potential use of AFLP/NGS combinational approach as the alter-
native to whole-genome sequencing.
Supported by Ministry of Health of CZ grant IGA NT11555 and project
00023736.
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DROPLET DIGITAL PCR IMPROVE MINIMAL RESIDUAL DISEASE DETECTION
IN >35% OF SAMPLES COMPARING TO RQ-PCR
M Andrade-Campos1,*, P Alfonso1, L Lopez de Frutos2, G Soro3, P Giraldo1
1Translational Research Unit, IIS-Aragon. CIBERER., 2Translational Research
Unit, IIS-Aragon., 3Research Nurse, IIS-Aragon, Zaragoza, Spain
Background: The gold standard for BCR-ABL quantification in chronic myeloid
leukemia patients (CML) is the real time quantitative polymerase chain reaction
(RQ-PCR), this technique has a limited sensibility to MR4.0 or MR4.5 in the
majority of laboratories. Several discontinuation studies in chronic phase CML
(CP-CML) patients reveal that both, the achievement a deeper response and
a long time in this response seem the main factors for good outcomes. The
droplet digital PCR (ddPCR) had shows more sensitivity to detect minimal
amounts of BCR-ABL transcripts in patients with undetectable BCR-ABL tran-
scripts by RQ-PCR, leading an opportunity to investigation in this field.
Aims: To evaluate the usefulness of the ddPCR in detect the presence of BCR-
ABL transcripts in CP-CML patients under TKI therapy, compared with RQ-PCR.
Methods: Between August-2013 to Mar 2015, a total of 112 samples from 34
CP-CML patients under TKI therapy were analyzed. The blood samples were
obtained in EDTA for RQ-PCR and in TempusTM tube for RNA isolation. The
RQ-PCR was performed following the current recommendations. The RNA was
obtained from peripheral blood using TempusTM Spin RNA isolation kit accord-
ing manufacturer recommendations. The analysis by ddPCR for each sample
was done using 5 μg of RNA obtained using One-step kit and processed in
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Qx100 Droplet Digital PCR, Biorad; using primers and probes described by
Gabert et al., 2003, the results were analyzed using QuantaLife Biorad software
and expressed in absolute number of BCR-ABL copies and positive droplets.
Samples were processed per triplicate (3 wells). Positive samples: were con-
sidered when the sum of ≥3 positive droplets in minimum of 24,000 droplets. 
Results: From the 112 samples analyzed by RQ-PCR, 69 (61.6%) were neg-
ative and 43 (38.4%) were positive. According molecular response the distri-
bution by international scale (MR) and number of transcripts (NT). Table 1. The
ddPCR analysis reveals that 65 (58.0%) of the samples were positive, median
of positive droplets: 22.5 (3-35,529). Median BCR-ABL NT: 41.5 (5.5-11,129.3).
For samples with a negative result by RQ-PCR (n=69), in 44 (63.7%) the analy-
sis by ddPCR confirmed the negativity of the sample, however in 25 (36.2%)
there were positivity in 3 or more droplets (median 4, 3-25), with a median NT
9.9 (5.5-44.7) copies. Table 1 exposed also the relation between the MR by
RQ-PCR and the positivity by ddPCR. However if the threshold is settled in
two positive droplets with a minimum of 3.5 NT, the number of positive samples
increase to 38 (55.1%), with a median NT: 8.1 (3.6-44.7). There was a correla-
tion in the number of copies between both techniques, but with a significant
increase in the amount of NT copies.
Table 1.
Summary/Conclusions: The ddPCR offer a new way to assess CP-CML
patients, in special for patients with MR4.0 or undetectable molecular response
by RQ-PCR, and would offer a more secure alternative to select patient for dis-
continuation trials. In our cohort, at least an improving of 36% on identification
of samples with presence of minimal residual disease has been founded. The
use of this technique to monitoring and select patients for discontinuation trials
is warranted.
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DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR
PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION
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Background: Treatment-free remission is a major goal in CML. Nowadays it
is possible to safely discontinue imatinib but it is still not clear which patient (pt)
will relapse. High sensitivity techniques like droplet digital (dd)PCR may help
to discriminate pts who still present a significant amount of disease despite
being in MR4 by standard real-time quantitative PCR (RQ-PCR). 
Aims: To evaluate the capability of ddPCR to predict relapse after imatinib dis-
continuation in CML pts with stable MR4 by RQ-PCR.
Methods: Total RNA was extracted at different time-points from 19 pts in stable
MR4 for two years before discontinuation of imatinib. ddPCR was carried out
in triplicate using 200 ng of cDNA for each replicates and droplets were ana-
lyzed by QX100™ droplet reader (Bio-Rad) using the DigiDrop P210 Master
Mix Kit (Bioclarma). All results were expressed according to the new recom-
mendations [Cross, Leukemia 2015].The Wilcoxon test was used for the com-
parison of the total ABL medians; the Agreement Coefficient of the 2 methods
was calculated with Cohen’s K test; Logistic Regression was used to assess
the relationship between the probability of relapse and disease level by RQ-
PCR and ddPCR. 
Results: A total of 48 samples were retrospectively analyzed by RQ-PCR and
ddPCR. All pts discontinued imatinib; 8/19 pts had to restart treatment for loss
of MMR/MR4 after a median of 5.3 mos (2.2-8.5). A difference between ddPCR
and RQ-PCR median total ABL copies (p<0.001) was found with the following
medians (ranges): 46290 (8420-124600) and 93060 (25440-210000) for RQ-
PCR and ddPCR respectively. A difference between ddPCR and RQ-PCR medi-
an total BCR-ABL1/ABL1% (p<0.001) was found: 0 (0-0.09); and 0.0009 (0-
0.015) for RQ-PCR and ddPCR respectively. Sixteen pts had >2 evaluations,
3 had an evaluation between 14 and 18.5 mos before discontinuation. 6 pts
had an evaluation at -12 mos (+/-0.81), 10 at -9 mos(+/-1.3), 14 at -6 mos(+/-0.9),
15 at -3 mos(+/-1.2), considering as time “0” the date of discontinuation. At
time -12, only 1pt resulted BCR-ABL1 positive by both methods, 1 by ddPCR
only and 0 by RQ-PCR only (K0.6, moderate agreement, p 0.13). At time -9, 3
pts resulted BCR-ABL1 positive by both methods, 6 by ddPCR only and none
by RQ-PCR only (K=0.1, slight agreement, p 0.34). At time -6, 3 pts resulted
BCR-ABL1 positive by both methods, 5 pts by ddPCR only and none by RQ-
PCR only, (K=0.3, fair agreement, p 0.08). At time -3, none resulted BCR-ABL1
positive by both methods, 4 pts were positive by ddPCR only and 1 by RQ-
PCR only (K=-0.1, no agreement, p 0.62). Over one year of molecular follow-
up before discontinuation, for negative values obtained measuring BCR-ABL1
by RQ-PCR the probability of relapse was equal to about 50% (45%, Figure 1),
i.e. the capability of RQ-PCR of detecting relapse was basically same as ran-
dom being almost constant for all the positive values of BCR-ABL1. On the
contrary the probability of a relapse for negative values of BCR-ABL1 by ddPCR
was about 30% and it grew up linearly at increasing level of transcript, achieving
a probability of 69% when BCR-ABL1/ABL1% was equal to 0.008%. The dif-
ference between RQ-PCR and ddPCR in predicting the probability of relapse
was statistically significant (p 0.02).
Figure 1.
Summary/Conclusions: Despite the small number of cases, our results con-
firm that the ddPCR is more sensitive than RQ-PCR for low levels of disease.
Molecular follow-up by ddPCR at several time-points before discontinuation
may have a prognostic value for predicting relapse, and this is worthy to be
tested prospectively and in larger cohorts of pts.
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PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) DOWNREGULATION ON
REGULATORY T CELLS DURING TYROSINE KINASE INHIBITOR THERAPY
IN CHRONIC MYELOID LEUKEMIA
P Rodrigues Santos1,2,*, J Almeida1, P Couceiro1, V Alves2, L Ruzickova3,
P Freitas-Tavares3, M Santos-Rosa2
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Background: Programmed death-1 (PD-1) receptor and its ligands (PD-L1
and PD-L2) are involved in attenuating tumor immunity and facilitating tumor
progression. PD-1, PD-L1 and PD-L2 therapeutic blocking agents have been
reported to have significant antitumor effects. In chronic myeloid leukemia
(CML), the expression of this receptor and its ligands is not fully characterized
for the different subsets of cells of the immune system in which their expression
is found constitutively or post-induction. 
Aims: In this study, we analyzed the expression of PD-1 and its ligands on regu-
latory T cells (Tregs) in chronic phase CML patients to understand the mechanisms
underlying suppressor effects that inhibit the anti-leukemia immune response.
Methods: Peripheral blood samples from chronic phase CML patients (n=50)
under Interferon-alpha 2b (IFN-α 2b), imatinib, dasatinb, nilotinib, bosutinib and
ponatinib therapy were analyzed by multi-parametric flow cytometry for the
characterization of regulatory T cells and surface expression of PD-1. Buffy
coats (n=13) from healthy blood donors were used as control. Cytokines and
chemokines were evaluated in a 34-plex panel by xMAP technology
(Luminex®). Gene expression analysis and miRNA profiling were also per-
formed for these samples.
Results: PD-1 Tregs were found significantly decreased (p<0.0001) in CML
patients and down-regulation of this receptor was also observed (p<0.01).
Naïve and memory Treg subsets were equally affected. No significant alter-
ations were observed for PD-L1 and PD-L2 ligands. Although TGF-β and IL-10
production were not significantly altered by down-regulation of PD-1 in Tregs,
the overall effect of tyrosine kinase inhibitor (TKI) therapy suggests a negative
impact in these cells concerning the anti-leukemic immune response.
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Summary/Conclusions: Regulatory T cells represent a major population of
suppressors in the immune response against leukemia. Down-regulation of
PD-1 receptor in Tregs during chronic phase CML reinforces the notion that
discontinuation of treatment must be carefully evaluated beforehand, since
these suppressor cells could permit the proliferation of existent residual
leukemic cells.
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SINGLE NUCLEOTIDE POLYMORPHISMS IN DRUG-RELATED GENES
ARE ASSOCIATED WITH RESISTANCE OR TOXICITY TO IMATINIB IN
CHRONIC MYELOID LEUKAEMIA
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Background: Imatinib (IM) induces apoptosis in BCR-ABL1 positive cell lines
and is extensively used to treat patients with newly diagnosed Philadelphia chro-
mosome-positive Chronic Myeloid Leukaemia (Ph+CML). However, about 20%
of Ph+CML patients fail to achieve optimal response, and a substantial propor-
tion develop intolerance or toxicity. Amplification and overexpression of the BCR-
ABL1 gene, BCR-ABL1 kinase domain point mutations and genetic variability
(as genetic polymorphisms), among others, may explain IM resistance.
Aims: To assess the association between single-nucleotide polymorphisms
(SNP) in drug-related genes and IM resistance or toxicity in CML patients. 
Methods: In a pilot study with 45 Ph+CML patients treated with IM from three
Spanish centers, we tested 1936 SNPs in 225 drug-related genes using the
Affymetrix Drug Metabolism Enzymes and Transporters (DMET) microarray.
Response criteria were assessed according to ELN2009 or ELN2013 guide-
lines. Relevant toxicity to IM was defined as the need for switching to another
tyrosine kinase inhibitor (TKI). SNPs significantly associated with response or
toxicity to IM treatment were validated in an independent group of 105 Ph+CML
patients from 8 Spanish centers. Informed consent (according to the Declara-
tion of Helsinki) was obtained from all patients. Validation genotyping was per-
formed using Fluidigm 96.96 Dynamic Array with BioMark HD Systems (Flu-
idigm Corp., CA). Data were analysed by the BioMark SNP Genotyping Analy-
sis software to obtain genotype calls. Candidate SNPs were primarily evaluated
for adequacy of Hardy-Weinber Equilibrium (HWE) using the Chi-square test.
For the association study, the SNPassoc package from R was used (PMID:
17267436, www.r-project.com).
Results: In this pilot study we found 76 SNPs to be significantly associated with
response or toxicity to IM treatment. In the validation cohort, 5/76 SNPs and 2/76
SNPs were related to IM resistance or toxicity, respectively (Table 1). Patients
carrying at least one variant allele for CYP2C8 (C), UGT2A2 (A), CYP19A1 (T),
ABCC3 (A) and CYP2C8 (A) were significantly associated with IM treatment fail-
ure. In the same way, AC-AA genotypes in CYP19A1 and CT-TT genotypes in
CYP11B1 were significantly associated with lower risk of IM-toxicity.
Table 1. Significant SNPs related to IM resistance or toxicity (Log-Additive
Model).
Summary/Conclusions: The SNPs found in the present study allow the iden-
tification of CML patients at risk to develop IM resistance or toxicity, suggesting
that a second generation TKI should be offered to these patients as first line
therapy. Furthermore, our results suggest that SNP analysis may be included
in clinical practice as a predictive tool for response and toxicity at diagnosis of
CML patients.
Acknowledgements: This study was supported by an unrestricted grant from
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DIFFERENT SETS OF GENES WERE ASSOCIATED TO THE MOLECULAR
RESPONSE AFTER 3 AND 6 MONTHS OF FIRST-LINE NILOTINIB TREATMENT
BY MICROARRAY OF CD34+/LIN- CELLS OF CHRONIC PHASE CML
PATIENTS AT DIAGNOSIS
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Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative
disorder and the biomolecular mechanisms of CML response to tyrosine kinase
inhibitors are not fully defined.
Aims: Thirty chronic phase CML patients were investigated at diagnosis and
at 3, 6 and 12 months of first-line nilotinib treatment and optimal response was
achieved at 3, 6 and 12 months after nilotinib in all the 30 patients (figure 1).
We established cut off values of molecular response (MR) to define groups of
patients, and to explore differences of gene expression profiles (GEP) between
patients at diagnosis based on the MR achieved after 3, 6 and 12 months of
nilotinib, respectively.
Methods: Cut off values were: 1% IS at 3 months of nilotinib, 0.1% IS at 6
months of nilotinib, and 0.01% IS at 12 months of nilotinib. We divided patients
into 2 groups based on MR values of each patient at 3 months of nilotinib:
group A (n=24) with MR≤1.0% IS and group B (n=6) with MR>1% IS. At 6
months of nilotinib, patients were divided into: group C (n=22) with MR≤0.1%
IS and group D (n=8) with MR>0.1% IS. At 12 months of nilotinib, patients were
divided into: group E (n=18) with MR≤0.01% IS and group F (n=12) with
MR>0.01% IS. GEP on the selected bone marrow (BM) CD34+/lin- cells of 30
patients at diagnosis was performed using Affymetrix-GeneChip-HTA 2.0. RMA
was used for preprocessing data. SAMR and GSEA detected differentially
expressed genes and pathways associated with the different groups, respec-
tively. MTC was performed using the FDR with a threshold 0.05 for SAMR and
0.25 for GSEA.
Figure 1.
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Results: GSEA identified significant differences in the transcriptional signature
between group A and group B associated with the MR at 3 months as well as
between group C and group D in respect to the MR at 6 months of nilotinib.
Based on the MR at 3 months, Reactome-pathways-“P130-cascade” and
“GRB2-SOS-linkage-to-MAPK-signaling-for-integrins” were significantly upreg-
ulated in group A. FGA, FGB, FGG, APBB1IP, ITGA2B and CRK genes con-
tributed to call the pathways upregulated. From literature data, nilotinib inhibits
BCR-ABL1 mediated phosphorilation of CKRL which acts in the CML
hematopoietic stem cells in diverse signaling pathways playing an apoptotic
role in CML. CRK was overexpressed in patients with a better MR≤1% IS at 3
months of nilotinib. Aminoacid-and-amine-transport-across-the-plasma-mem-
brane-pathway was significantly overexpressed, whereas “lipid metabolism”
was significantly downregulated (AKR1C1, ANGPTL3) in group A compared to
group B, respectively. Based on the MR at 6 months, “positive-regulation-of-
cytokine secretion” and “interleukin1-secretion” were significantly upregulated
in group C compared to group D, involving PYCARD8, NLRP2, NLRC4, NLRP3
and CARD8 genes. PYCARD and CARD8 promote caspase-mediated-apop-
tosis processes involving the recruitment of recognition receptors: NLRP2,
NLRP3 and NLRC4.
Summary/Conclusions: The study showed that MAPK-signaling-for-integrins
and amine-transport-across-the-plasma-membrane were significantly overex-
pressed in CML patients with MR≤1.0% IS while lipid metabolism was signifi-
cantly underexpressed in CML patients with MR≤1.0% IS after 3 months of
nilotinib. Positive-regulation-of- cytokine-secretion-and-interleukin1-secretion
was significantly overexpressed in CML patients who achieved MR≤0.1 IS after
6 months of nilotinib. In summary, distinct sets of genes involved in apoptosis
were differentially expressed in 30 CML patients at diagnosis based on the MR
at 3 and at 6 months of first-line nilotinib treatment.
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Background: Imatinib is highly effective in the treatment of chronic myeloid
leukemia (CML). Up to 30% of CML patients treated with Imatinib as a first-line
therapy experience treatment failure. The response rate varies within different
stages of the disease. Besides other mechanisms of resistance such as muta-
tions in the Bcr-Abl1 fusion gene, the transport of Imatinib into its target cells
has been proposed to be crucial for its effectiveness. As an organic cation,
Imatinib has to be actively translocated across the cell membrane. Though
some studies suggested a critical role of the organic cation transporter 1 (OCT1)
in regulating Imatinib efficacy, other studies could not confirm these findings.
Although OCT1 is generally capable to transport Imatinib, it might have minor
relevance under clinical conditions. We recently demonstrated that the multidrug
and toxin extrusion protein 1 (MATE1) accepts Imatinib as a substrate.
Aims: In this study, we focused on transporters, which are relevant for Imatinib
uptake and investigated their expression pattern in PBMCs and if they con-
tribute to Imatinib uptake and expression in samples from CML patients or CML
cell lines.
Methods: We used PBMC from 6 healthy volunteers and transporter expres-
sion profile was analyzed by qPCR and intracellular Imatinib accumulation was
quantified by HPLC-UV using stably transfected HEK cells. To assess Imatinib
dependent biologic effects on MATE1 expression, activity of bcr-Abl1 protein
was detected by Western blot analysis using anti-phospho ABL and GAPDH
antibody. To address the clinical significance of MATE1 on the Imatinib therapy
in CML, we evaluated the clonal growth of the immortalized CML cell line K562
cells stably transduced with shRNA against MATE1 in methylcellulose medium
supplemented with Imatinib.
Results: The results showed that Imatinib uptake was significantly increased
in OCT1, OCT2- and MATE1 expressing HEK-cells. We found that the transport
via MATE1 is clinically highly relevant as represented by a remarkably high
quotient for therapy regimes. This is supported by qPCR expression of MATE1
in 31 patients with Bcr-Abl1 major transcript (p210) positive CML.The mRNA
expression of potential Imatinib transporters in PBMC of healthy volunteers as
well as in K562 cells showed that in both cell types OCT1, OCT2 and MATE1
were detected at similar levels comparable to the Imatinib uptake rate into these
cells. Inhibitor studies showed that MATE1 plays an important role in Imatinib
accumulation. In patients, Imatinib non-responders showed a significantly lower
MATE1 expression than Imatinib responders and we found a correlation
between MATE1 transporter expression and clinical response to Imatinib treat-
ment, suggesting that MATE1 might enable to predict whether CML patients
are likely to respond to Imatinib therapy.
Summary/Conclusions: Thus, we identify MATE1 as the main transporter for
the Imatinib dependent therapeutic response of CML patients.
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TRANSPOSON-MEDIATED GENERATION OF BCR-ABL1-EXPRESSING
TRANSGENIC CELL LINES FOR FAST AND UNBIASED SENSITIVITY
TESTING OF TYROSINE KINASE INHIBITORS
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Background: Point mutations in the ABL1 kinase domain are an important
mechanism of resistance to tyrosine kinase inhibitors (TKI) in BCR-ABL1-pos-
itive and, as recently shown, BCR-ABL1-like leukemias. The cell line Ba/F3
lentivirally transduced with mutant BCR-ABL1 constructs is widely used for in
vitro sensitivity testing and response prediction to tyrosine kinase inhibitors.
The transposon-based Sleeping Beauty system presented offers several advan-
tages over lentiviral transduction including the absence of biosafety issues,
faster generation of transgenic cell lines, and greater efficacy in introducing
large gene constructs. Nevertheless, both methods can mediate multiple inser-
tions in the genome.
Aims: Establish a method for enrichment of virtually pure cell fractions carrying
single insertions of the gene construct to permit unbiased in vitro testing of
drug resistance.
Methods: Transposon-mediated gene transfer, flow soritng, FISH, RQ-PCR,
qPCR, immunoblotting, survival assays
Results: We showed that multiple BCR-ABL1 insertions result in elevated IC50
levels for individual TKIs, thus overestimating the actual resistance of mutant
subclones. The establishment of a flow-sorting-based fractionation of BCR-
ABL1-transformed Ba/F3 cells has enabled us to enrich for cells carrying sin-
gle-site insertions, as demonstrated by FISH analysis and real time PCR. Frac-
tions of unselected Ba/F3 cells not only showed a greater number of BCR-
ABL1 hybridization signals, higher expression levels of BCR-ABL1, and
increased activation of BCR-ABL1 downstream signaling, but also revealed
higher IC50 values for the TKIs tested.
Figure 1.
Summary/Conclusions: The generation of multiple gene construct insertions
in Ba/F3 cells by lentiviral- or transposon-mediated transfer has not been report-
ed previously as a relevant problem in the context of in vitro drug sensitivity
testing. Our data demonstrate that targeted flow-sorting of low-fluorescent
Ba/F3-BCR-ABL1 cells facilitates enrichment of virtually pure cell fractions car-
rying single insertions of the gene construct. Employment of this selection step
is highly recommended to permit unbiased in vitro testing of drug resistance.
The clinical relevance of our observations has far reaching consequences
beyond Ph+ neoplasia. The rapidly increasing number of reports on BCR-ABL1-
like leukemias involving a variety of activated kinases highlights the relevance
of TKI-based treatment and in vitro prediction of sensitivity to these agents.
Appropriate modeling of mutant kinases inserted at single sites into Ba/F3 cells,
as presented in this report, is therefore of paramount importance for reliable
prediction of treatment responses to kinase inhibitors.
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THE PROLIFERATIVE ACTIVITY OF THE BONE MARROW CELLS
INVESTIGATED IN VITRO CELL CULTURE OF PATIENTS WITH CHRONIC
MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
T Perekhrestenko*, I Sviezhentseva1, D Bilko1, N Tretiiak2, I Dyagil
1Centre for Molecular and Cell Research , National University of “Kyiv-Mohyla
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Background: The mechanisms of CML progression were postulated based on
in vitro modeling even before they were detected in the clinical practice. CML
haematologica | 2016; 101(s1) | 451
Copenhagen, Denmark, June 9 – 12, 2016
progression can be driven by different mechanisms on tissue, cell, chromoso-
mal and molecular level. Recent in vitro studies of CML bone marrow cells also
suggest that disease progression can be caused by functional changes in pool
of more matured hematopoietic progenitor cells rather than in population of
HSCs. Such evolution of HPCs during CML progression can be identified by
changes in their clonogenic potential during cultivation in semi-solid agar.
Aims: To analyze the changes in functional properties of HSCs and HPCs,
such as ability to form cell aggregates during cultivation in CFU assay with fur-
ther evaluation of cell composition of individually picked-up cell aggregates,
with respect of correlation with CML progression in each individual patient. 
Methods: Totally 51 samples of bone marrow were analyzed from patients
with CML in chronic phase, who were treated with TKI, Imatinib. CFU-assay:
Mononuclear fraction was separated from bone marrow aspirates by centrifu-
gation over Ficoll-Hypaque gradient. All results were expressed as the mean
number obtained from quadruplicate cultures. Clones of > 40 cells were count-
ed as colony forming units granulocyte monocyte (CFU-GM) and those with 5
- 40 cells as cluster forming units (ClFU).
Results: CFU assay indicated that there was a significant (p < 0.05) difference
in clonogenic potential (number of CFU-GM and ClFU) between groups of
patients with different response to the therapy. CFU numbers were lower in
group of patients with optimal response to the TKI therapy (mean value of
25.54±4.6) and for patients with TKI treatment failure (26.00±9.70) when com-
pared to CFU numbers for groups of patients before TKI treatment
(70.40±22.51) and patients with suboptimal response to TKI treatment
(72.37±15.32). Significant decline (p < 0.05) was also indicated for mean num-
bers of ClFU for group of patients with optimal response for TKI (24.05±6.75)
when compared to groups of patients with suboptimal response to TKI
(49.94±7.89), but also for group of patients with TKI treatment failure
(51.17±9.22). The mean number of ClFU for patients before TKI treatment was
41.80±9.78 and was not significantly different from other groups (p > 0.05). As
to colony to cluster ratio our results showed, that there is a correlation (ρ =
0.67) between CCR index and number of bone marrow cells with Ph-chromo-
some. To have a possibility of identification of cells, composing aggregates
obtained in CFU assay, a positive correlation was also found between numbers
of colonies, formed during cultivation in CFU assay and level of CD34+ cells
in bone marrow (ρ = 0.46) and between number of clusters and CD33+ cells
of bone marrow (ρ = 0.76). To evaluate changes in the differentiation potential
of HSCs and HPCs that can be related to pathologic process of CML, we
picked-up individual cells aggregates, formed during in vitro CFU assay of
bone marrow mononuclear cells of CML patients. Cells, composing those
aggregates were analyzed with calculation of maturation index (MI) for each
individual sample. It was indicated, that MI correlates with level of bone marrow
cells, containing Ph-chromosome. CFU assay is one of the standard methods
used to identify functional properties of HSCs and HPCs of bone marrow. Our
data indicated alteration of clonogenic activity of bone marrow hemopoietic
cells for patients with different response to TKI treatment. Thus, CFU and ClFU
numbers were increased in case of examination of bone marrow of patients
before TKI treatment, so as for patients with suboptimal response and TKI
treatment failure. 
Summary/Conclusions: In summary, obtained results suggest that different
mechanisms (BCR-ABL dependent and independent) may be involved in CML
progression process in the same time. Disease prognosis should be preferably
carried out on an individual basis.
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IMPLEMENTING A CERTIFIED PLASMID REFERENCE MATERIAL FOR
COPY NUMBER CALIBRATION DEMONSTRATES GOOD REPORTING
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Background: Development of a quantitative BCR-ABL monitoring assay with
sensitivity down to 4.5 logs below baseline (MR4.5) is important for patients
being considered for tyrosine kinase inhibitor (TKI) discontinuation, and it is
essential to ensure that variability in testing methodologies across laboratories
is tightly controlled. Through analytical and clinical evaluations, Xpert BCR-
ABL Ultra, an automated cartridge-based real-time qPCR BCR-ABL monitoring
assay, has demonstrated sensitivity reaching MR4.5, and every production lot
of cartridges is assigned a unique conversion factor assuring substantial align-
ment to the WHO International Scale (IS).
Aims: Here we describe the implementation of a certified plasmid reference
material (IRMM_ERM-AD623 BCR-ABL Calibrator) for the standardization of
BCR-ABL mRNA quantification through copy number calibration to ensure suf-
ficient BCR-ABL and ABL copies are present to support the MR4.5 sensitivity
claim for Xpert BCR-ABL Ultra.
Methods: To establish the correlation between Cycle threshold (Ct) reporting
and copy number for BCR-ABL and ABL, and to understand the assay sensi-
tivity limit in terms of relative copy number, the IRMM plasmid was used in a
titration study involving three independent BCR-ABL Ultra assay lots. Based
on the titration study, a copy number calibration curve was derived and used
to estimate the copy number for BCR-ABL and ABL in analytical studies previ-
ously performed for CE registration, including the Linearity/Dynamic range,
Analytical LoD and Clinical LoD studies.
Results: The results demonstrate that a linear detection range between 1x106
copies down to 3 copies was achieved with 5 copies being detected in 24 out of
24 replicates and determined as the Limit of Detection (LoD) for both BCR-ABL
and ABL. The overall ABL copy number present in clinical samples in each study
was at least 5-10 times the required minimal ABL copy number of ≥32,000 to
support a claim of MR4.5 and ≥100,000 for MR5.0. This is explained by the fact
that 4ml whole blood is used to prepare the sample lysate and an aliquot of which
equivalent to 0.6ml whole blood is then processed completely in a fully automated
and integrated GeneXpert system for nucleic acid extraction, target amplification,
and quantification, resulting in improved target recovery. The%ratio of the derived
BCR-ABL and ABL copy numbers was further calculated and compared to the
original assay lot-specific%reporting (IS) per WHO calibration, revealing an un-
biased correlation between%BCR-ABL/ABL (Copy number) and%BCR-ABL/ABL
(IS) across the range 100% to 0.001% (IS). To validate the assay performance,
Xpert BCR-ABL Ultra was further evaluated in field studies compared to three
independent laboratory developed tests (LDTs) previously calibrated with the
IRMM plasmid using either ABL or GUSB as control genes, demonstrating a cor-
relation of >0.91, covering samples in the range 100% - 0.001% (IS).
Summary/Conclusions: These studies, using two different calibration systems
(WHO/IS and IRMM/Copy number) and two different control genes (ABL and
GUSB), carried out in four independent research labs, demonstrate, for the
first time, good reporting correlation between%BCR-ABL/ABL (IS) and%BCR-
ABL and ABL (Copy number) in Xpert BCR-ABL Ultra. Furthermore, these data
demonstrate that from a typical clinical specimen, the BCR-ABL Ultra assay
captures more than enough ABL copies to support a sensitivity claim of MR4.5.
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Background: A recent meta-analysis demonstrated that 3 of the new genera-
tion BCR-ABL tyrosine kinase inhibitors (TKIs) (i.e. dasatinib, nilotinib and pona-
tinib) are associated with an enhancement of major molecular response without
improving the overall survival at one year in patients with PH+ chronic myeloid
leukaemia (CML) compared with imatinib. This study also highlighted their asso-
ciation with an increased risk of vascular occlusive events compared with ima-
tinib but distinction between arterial of venous events was not assessed. 
Aims: To perform a meta-analysis on the risk of arterial and venous occlusive
events in patients with Ph+ CML treated with new generation BCR-ABL TKIs
in randomized clinical trials (RCTs).
Methods: The literature search (data lock point: November 26, 2015) was con-
ducted according to a registered protocol (PROSPERO 2014:CRD420140
14147). All RCTs comparing a new generation BCR-ABL TKI versus imatinib in
patients with Ph+ CML were included. Two independent investigators were
responsible of the screening, the review and the extraction of the data using
standard forms. The meta-analysis was performed using a random (REM) and
a fixed (FEM) effect model according to the characteristics of the included stud-
ies. ORs with 95% CIs were computed using the Peto method. Statistical het-
erogeneity was quantified using the I2 value, and publication bias was assessed
by funnel plots.
Results: Among the 400 abstracts identified, 12 studies fulfilled the established
criteria and were included in the statistical analysis. Overall, 4.47% (99/2,217)
of patients developed arterial occlusive events with new generation BCR-ABL
TKIs compared with 0.80% (15/1,884) with imatinib (REM ORPETO: 3.46;
95%CI: 2.35 to 5.10). Ponatinib (REM ORPETO: 3.26; 95%CI: 1.12 to 9.50),
nilotinib (REM ORPETO: 3.60; 95%CI: 2.21 to 5.86) and dasatinib (REM
ORPETO: 3.32; 95%CI: 1.37 to 8.01) are associated with higher risk of arterial
occlusive events than imatinib. No significant difference was found with bosu-
tinib. Venous occlusive events occur in only 0.86% (13/2,217) of patients treated
with new generation TKIs and in 0.16% (3/1,884) of imatinib-treated patients.
Overall, new generation TKIs increase the rate of venous occlusive events
(REM ORPETO: 2.85; 95%CI: 1.04 to 7.78) but stratifications by treatment pro-
vided nonsignificant results. Funnel plots demonstrate no evidences of publi-
cation bias, and the I2 statistic specifies no heterogeneity among studies. Lim-
itations of this meta-analysis include the absence of a time-to-event analysis
and the inconsistent report of cardiovascular events in the literature. However,
the use of a clinical trial register aimed to decrease this heterogeneity. 
Summary/Conclusions: The increased risk of vascular occlusive events asso-
ciated with new generation BCR-ABL TKIs is mainly driven by thrombotic events
occurring at the arterial side. Additional investigations are required to assess
the underlying pathophysiological mechanisms and provide appropriate risk
minimization measures.
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Background: CML is a clonal disorder characterized by the presence of the
Philadelphia (Ph) chromosome which encodes for the bcr-abl tyrosine-kinase
(TK). Target therapy with the TK inhibitor (TKI) imatinib (IM) has greatly
improved outcome in CML; however, only a minority of responsive pts can dis-
continue treatment without relapsing in the short term and even less pts can be
considered free of disease. This data probably relates to persistence of quies-
cent CD34+Ph+ stem cells (SC) whose persistence has been documented
even among pts in optimal response (Bocchia et al, 2008). Compared to IM,
faster and deeper responses in CP-CML pts can be achieved with the second
generation TKI Nilotinib (NIL); however, only preliminary data are available on
NIL potential to eradicate Ph+ SC. Moreover, in vitro studies (Corbin AS, et al
2011; Hamilton A, et al 2012) suggest that CD34+Ph+SC may not be sensitive
to TKI-mediated Bcr/Abl inhibition. However, in vivo data (Defina et al, 2012)
have shown that, compared to IM treated pts, residual leukemic SC are very
rarely detected among NIL treated pts in CCyR even after short-term NIL ther-
apy and even if duration of treatment is shorter for NIL compared to IM treated
pts (median 39 vs 22 mos). At present, no clear evidence of TKI effect on the
leukemic SC clearance is available.
Aims: On behalf of the Rete Ematologica Lombarda (REL), the PhilosoPhi34
protocol (EudraCT: 2012-005062-34), an open label, single arm, phase II study,
was designed to investigate the efficacy of NIL 300 mg BID in BM CD34+/lin-
Ph+cells clearance at 3, 6 (primary objective) and12 months of treatment in
newly diagnosed CP-CML pts.
Methods: Enrolled pts’ BM cells were collected and stored at diagnosis and at
3,6 and 12 mos of treatment. CD34+/lin- cells were purified using a Diamond
CD34 Isolation Kit Miltenyi (97% of purity). FISH analysis of selected unstimu-
lated CD34+/lin- cells was performed according to standard method; consider-
ing the low sensitivity of the test, at least 200 nuclei were examined in order to
define the test as negative. This phase II study was designed according to the
A’Hern single stage design, where, at 6 mos, we assumed a proportion defining
a poor response as PP=0.10, and the proportion defining a good response as
PG=0.30, PA being the proportion of responders.The study required 41 subjects
to decide, with a power of 95%, whether PA ≤0.10 or PA ≥0.30. To have 41
evaluable, 87 pts had to be enrolled, considering 80% of them being fully
analysed and 60% of these reaching CCyR (according to ENESTnd data).
Results: Enrolment of 87 pts was completed by June 2015; the database hasn’t
been locked yet. At present, FISH analysis on CD34+/lin- cells at 6 mos of
treatment is evaluable for 68 of 75 pts with a documented CCyR; 7 negative
tests were not evaluable since less than 200 nuclei were analysed. Only 5/68
(7,3%) evaluable FISH tested positive. Results at 3 and 12 mos are as follows:
8/58 (13,8%) and 0/46 (0%) evaluable FISH respectively tested positive (7 and
6 negative test excluded respectively). Sokal score did not predict for FISH
positive results at any time point.
Summary/Conclusions: These results strongly point to a role for NIL 300 mg
BID in fast clearance of BM CD34+/lin-Ph+ cells in a high proportion of treated
pts. In view of the potential clinical relevance of our data, the protocol was
amended in order to revise our FISH data using a test with higher sensibility
and specificity, i.e.: the gDNA PCR. These results might give insight into a pos-
sible correlation with depth and stability of molecular response.
We acknowledge all REL Colleagues for their collaboration and Novartis SpA
for the partial financial support to the study.
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Background: Prognostic significance of molecular response fluctuation in the
long-term outcome during imatinib treatment in chronic phase chronic myeloid
leukemia (CP-CML) patients have not been so far reported in details.
Aims: Aim of our study was to correlate, over a median follow-up period of 7
years, how instability of molecular response can affect overall survival (OS)
and failure-free survival (FFS).
Methods: A series of 208 patients treated with imatinib first-line was retrospec-
tively analysed. There were 144 males and 94 females, median age was 57.7
years. According to the IS, we considered as MR3 a BCR-ABL/ABL ratio of
≤0.1%, as MR4 a ratio ≤0.01% and as MR4.5 a ratio ≤0.0032%; stable response
was defined as a response that persisted over 3 consecutive RQ-PCR tests,
whereas fluctuation, was defined as the alternation of a test that reached or
was below the threshold ratio according to IS and the consecutive was above
the threshold. We considered OS the time elapsed from diagnosis to death for
any cause, and FFS the timespan that follows therapy without signs of recur-
rence (loss of hematologic and/or cytogenetic response, acquisition of clonal
cytogenetic abnormalities or mutations).
Results: At a median follow-up of 7 years, overall incidence of MR3 was 64.4%:
during the course of treatment, 17 patients (11.6%) had a fluctuation above
and then below the cut-off of 0.1%. Of these 17 patients, 13 (76%) lost the
response and 3 subsequently developed secondary resistance (17.6%) with
an estimated FFS of 82.4% and an OS of 94.6% at 7 years. Considering the
threshold of MR3, of the remaining 117 patients that never had a fluctuation
and maintained a stable response over time, only 3 (2.5%) subsequently lost
the response and developed secondary resistance with an estimated FFS of
93.2% (p=0.02) and OS of 94% (p=ns). All patients were analysed for mutational
screening according to Sanger sequencing analysis: only two patients were
found to develop a mutation of the ABL1 kinase domain, in particular 1 patient
a E255K and 1 patient a M351T. Cumulative incidence of MR4 was 51% and
of MR4.5 was 34.6%, obtained after a median time of 3.8 and 5.4 years, respec-
tively. Overall, 7 patients (6.5%) showed a fluctuation of MR4 response and 4
subsequently lost the response. None of these patients showed secondary
resistance or acquired mutations in the ABL kinase domain and main reason
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for loss of response was confirmed to be low adherence to long-term treatment.
Eighteen patients (25%) showed an unstable MR4.5, but none of them devel-
oped secondary resistance or progressed to blast phase. Considering the
threshold of MR4, fluctuation of molecular burden was associated to FFS of
100% and to OS of 98.2% as compared to patients with stable response that
had a FFS of 99.4% and OS of 97.8%, without any statistical significance.
Summary/Conclusions: Our results showed that unstable MR3 was indeed
associated to an increased probability to develop resistance, whereas long-
term fluctuation of deeper molecular response (MR4-4.5) did not influence the
long-term outcome of CML patients treated with imatinib.
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Background: The clinical significance of BCR-ABL transcript type in the tyro-
sine kinase inhibitors (TKI) era has recently been debated. However, few data
concerning the impact of different BCR-ABL transcripts on early response
dynamics in chronic phase-chronic myeloid leukemia (CP-CML) patients treat-
ed with standard dose imatinib (IM) have been reported.
Aims: To evaluate the probability of optimal response at early timepoints,
according to different p210 BCR-ABL1 transcripts, in a real life population of
CML-CP patients treated with standard dose front-line imatinib.
Methods: 93 CP-CML patients treated with IM 400 mg daily, diagnosed from
2010 to 2015 were retrospectively analyzed. The type of BCR-ABL1 transcript
was determined by multiplex RT-PCR at diagnosis. Molecular monitoring was
performed with quantitative RT-PCR and results were expressed in Interna-
tional Scale (IS) values. Optimal, warning and failure categories were analyzed
according to the 2013 ELN recommendations. Frequencies were compared
by chi-squared test (χ2) or Fisher’s exact test. Progression-free survival (PFS)
was calculated from the start of IM to ABP or death. Overall survival (OS) was
calculated from the start of IM to death.
Table 1. Response rates at 3, 6 and 12 months according to BCR-ABL
trascript type.
Figure 1.
Results: Patients with b3a2, b2a2, b3a2/b2a2 BCR-ABL transcript were 44.1%,
36.6% and 19.4%, respectively. The cohorts were comparable for age, sex
and risk score (both Sokal and Eutos). Forty-three patients (46.2%) moved to
second generation TKI (2GTKI), 24 (55.8%) due to primary or acquired cyto-
genetic or molecular resistance, 19 (44.2%) for intolerance. Rates of optimal
vs non optimal response at 3 months were different between b3a2 vs b2a2 vs
coexpressed transcript groups (75.8% vs 62.2% vs 100% respectively,
p=0.018). Interestingly, all failures at 3 months were observed in the b2a2
group (Table 1). At 6 months, optimal responses were documented in 80% vs
48.3% vs 78.6% of b3a2, b2a2 and b3a2/b2a2 group, respectively (p=0.027);
60% of warnings and 75% of failures were associated to b2a2 transcript. At 12
months timepoint, major molecular response (MMR) rate was significantly dif-
ferent between transcripts (81.8% vs 47.8% vs 78.6% respectively, p=0.03).
52% of treatment changes within 12 months, either for resistance or intolerance,
were observed in the b2a2 group. Differences in early response did not trans-
late into inferior cumulative incidence of complete cytogenetic response (CCyR)
(93.9% vs 82.1% vs 83.3% respectively, p=0.30) or different time to CCyR
achievement. Patients with b3a2 and b3a2/b2a2 transcript had comparable
rates of cumulative MMR (81.8% and 88.9%, respectively), superior to b2a2
patients (66.7%, p=0.12) with a significantly faster time to MMR achievement,
either on IM treatment or with sequential IM+2GTKI approach (Figure 1A).
Notably, among optimal responders at 3 months, MMR was obtained signifi-
cantly later by patients with b2a2 transcript (Figure 1B). Long term outcomes
(PFS, OS) were not affected by transcript type.
Summary/Conclusions: This retrospective analysis suggest a different kinet-
ics of early optimal response achievement based on transcript type, with inferior
rates in patients expressing b2a2. However, this difference did not translate
into unfavourable clinical outcome. Longer time to MMR among optimal respon-
ders presenting with b2a2 could partially account for the negative impact of
this transcript type on stable deep molecular response, previously observed
by our group.
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Background: Chronic myeloid leukemia (CML) is the result of t(9;22) balanced
translocation and/or presence of BCR-ABL1 fusion gene. Usually CML presents
with marked leukocytosis and only in rare cases CML can present at the diag-
nosis with an isolated and marked thrombocytosis, defined as platelet count
>1000x109/L. There are no data on the optimal treatment of these subcategories
of “theoretically high risk” patients in the era of tyrosine kinase inhibitors (TKIs).
Aims: To identify a specific subset of CML chronic phase patients with extreme
thrombocytosis (platelet count >1000x109/L) at diagnosis and to assess clinical
outcomes: overall survival, progression free survival and cumulative response
in terms of CCyR and/or MMR at 12 and 24 months
Methods: Data were collected and evaluated through the analysis of 1591
CML CP patients registered in 16 Italian Haematological Departments from
January 2002 to December 2015
Results: The incidence of extreme thrombocytosis at diagnosis was 5,4%
(87/1591). Median age was 59 years (range 18-87), F/M 63/24. Median spleen
size below the costal margin was 0 cm (range 0-15), and liver size below the
costal margin was 0 cm (range 0-3). Median white blood cell count was
31.600x106/microl(range 6.340-390.000), median haemoglobin level was 11,8
g/dl (range 7,7-16,3), and median platelet count was 1466x109/L. (range 1054-
4720). Sokal score was low in 6 patients (6,8%), intermediate in 23 (26,4%)
and high in 55 (63,2%). Hasford score was low in 17 patients (22%), interme-
diate in 22 (28,6%) and high in 38(49,42%) out of 77 evaluable cases. Coag-
ulation tests were available in 59/87 (67,8%), and aPTT was abnormal in only
three patients (5%). Bleeding time test was available only in 5 patients and
was prolonged in all of them (median value 41 sec1”). Iron assessment was
reported in 56 out of 87 patients and was consistent with iron deficiency in 7
patients (12,5%); assessment of the, JAK2V617F mutation was performed in
43 (49,4%) patients. At diagnosis, 9 out of 87 (10.3%) patients showed haemor-
ragic or thrombotic complications, with only 3 of grade >2 according to the
NCI-CTC.In order to reduce severe thrombocytosis, 73/87 patients (83%)
received hydroxyurea before starting TKI and in two patients thrombocyta-
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pheresis was reported[s1]. As first line TKI 63/87 (72,4%) patients received
imatinib, 16 (18,4%) dasatinib and 8 (9,2%) nilotinib.Seventy-seven out of 87
patients were evaluable after 12 months of treatment, and 67 of 77 (87%)
obtained cCyR or major molecular response (MMR). Sixty-seven patients were
evaluable at 24 months of treatment and 51 out of 67 (76,1%) were in cCyR
and/or MMR. After a median follow-up of 66 months (range 3-179), 81/87
(93,1%) patients are still alive. Six patients (6,9%) died: two from myocardial
infarction, three from concomitant neoplasia, and one from GvHD.Nine (10,3%)
patients developed primary resistance to imatinib and they were shifted to the
second line. Eight additional patients developed secondary resistance, mainly
after imatinib
Summary/Conclusions: The incidence of extreme thrombocytosis in CML
chronic phase is rare;this subset of patients shows the following peculiarities:
predominance of female sex, high or intermediate risk score with a favourable
outcome in terms of both cumulative response rate and survival, low incidence
of thrombotic/haemorragic risk[s1]. Due to the inclusion of patients prior to the
acquisition of JAK2 V617F in the differential diagnosis of thrombocytosis, only
half of the patients were assessed for this mutation
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Background: Since 2012, the dynamics of early molecular response to tyrosine
kinase inhibitor (TKI) treatment is being considered a very useful prognostic
factor for further outcome of chronic myeloid leukemia (CML) patients. Two
ways of determining dynamics of response are being used: BCR-ABL1 tran-
script level at 3rd month of the therapy and individual transcript reduction rate,
expressed as BCR-ABL1 halving time (HT).
Aims: The goal of this analysis was to determine whether BCR-ABL1 transcript
level at third month or BCR-ABL1 HT is more useful for predicting the molecular
responses. Another aim was to perform the analysis using GUSb as a reference
gene, which should provide more accurate results for high BCR-ABL1 transcript
level samples.
Methods: The analyzed group consisted of 96 patients diagnosed with CML in
Faculty of Hematology and Bone Marrow Transplantation at Poznań Medical
University, who were monitored and treated according to ELN recommenda-
tions. The BCR-ABL1 transcript level assessment was performed using an in-
house method with GUSb as a reference gene. The method is being validated
on a regular basis in the reference laboratory in Adelaide, and in 2014 was
positively validated for MR4.5 assesment (ELN/EUTOS performance evalua-
tion). Statistical analysis was made using Statistica 10. All analyses were per-
formed only in patients with full clinical documentation, non-degraded pre-treat-
ment sample and at least 3 years of follow up. The Kaplan-Meier analyses of
MMR, MR4 and MR4.5 were performed for groups divided by BCR-ABL1 halv-
ing values (5-40 days interval). The frequencies of molecular responses in 12th,
24th and 36th month of therapy were aggregated in tables and the graphs show-
ing MMR, MR4 and MR4.5 in selected time points depending on HT cut-off val-
ues were plotted.
Figure 1.
Results: The BCR-ABL1 transcript level at 3rd month was proven to have a
limited prognostic value. The values greater than 10% and lower than 1% have
significant prognostic implications; the interval between 1 and 10% (49% of our
patients) does not predict any molecular outcome. On the other hand, the BCR-
ABL1 HT of 15 days was proven to be a great predictor of MMR, MR4 and
MR4.5. 91,5% of patients with HT shorter than 15 days achieved MMR by 12th
month of treatment (100% by 24th and 36th month). In case of deep molecular
responses, 61,1% achieved MR4 after a year of treatment (83,3% by 24th and
94,4% by 36th month) and 33,3% MR4.5 after twelve months of TKI therapy
(80,5% by 24th and 83,7% by 36th month). The molecular outcome of patients
with BCR-ABL1 HT greater than 15 days was significantly worse: 31,8%, 61,7%
and 69,4% had MMR by 12th, 24th and 36th month of therapy, respectively.
Moreover, the frequency of deep molecular responses was also significantly
lower: 9,1%, 36,5% and 41,4% for MR4 and 4,5%, 16% and 28,8% for MR4.5,
respectively.
Summary/Conclusions: Our results confirmed that the use of GUSb as a ref-
erence gene allows precise evaluation of transcript level at the beginning of
the treatment and probably increases the prognostic value of BCR-ABL1 HT.
The BCR-ABL1 HT below 15 days is an accurate predictor of molecular
response for TKI treated CML patients. The response to the therapy is so good
that the surrogate endpoint such as MMR is achieved by vast majority of them,
regardless of the initial response dynamics. The BCR-ABL1 HT greater than
15 days also predicts significantly lower molecular response rates, especially
MR4 and MR4.5. It is worth pointing out that the proposed BCR-ABL1 HT cut-
off is applicable to the entire group of patients and allows for early identification
of potential non-responders.
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Background: BCR-ABL1 measurement by RT-qPCR is integral to both the diag-
nosis and monitoring of Chronic Myeloid Leukaemia (CML), and has been central
to the remarkable improvement in patient outcomes seen in this disease. As an
ISO 17043 accredited international provider of External Quality Assessment
(EQA)/Proficiency Testing (PT) in this area, UK NEQAS for Leucocyte Immunophe-
notyping (UKNEQAS LI) has a unique perspective on the evolving field of BCR-
ABL1 testing in CML by having access to participants’ technical data.
Aims: To assess the impact of technical standardisation and the development
of the International Scale (IS) on the accuracy of BCR-ABL1 testing, by review-
ing our EQA trial data.
Methods: We analysed all trial data submitted to UKNEQAS LI that could be
meaninfully compared between 2007 and 2015 (16 trial issues, 32 samples).
In order to normalise the log normal EQA data, and allow the application of
parametric statistics, a constant was applied to all participant data before log10
transformation. Robust statistics were used to assess variation, including the
exclusion of outliers as per Algorithm A from ISO 5725-5. Whilst variation was
calculated using log transformed data, where a meaningful data midpoint was
required, medians were used because log transformed means (geometric
means) are difficult to interpret and back transforming log transformed means
is not recommended as it leads to underestimation.
Results: Comparison of participant results identified considerable variability at
high and low levels of disease, including current and proposed therapeutically
important levels. Despite rapid adoption of the IS by laboratories, and the fact
that we have shown lower standard deviations in our IS data sets when compared
to our unconverted data sets, suggestive of decreased variability, a statistically
significant difference in variation between our unconverted and IS data sets could
not be proven. We found that different methods of converting to the IS are pro-
ducing consistently different median results within UKNEQAS LI IS data sets.
Figure 1.
Summary/Conclusions: To allow better quantification of ‘Early’ and ‘Deep’
Molecular Response to fully realise the benefits of improved treatment regimens
our data suggests that further refinement of RT-qPCR protocols, or perhaps a
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switch to new technologies such as droplet digital PCR, will be required. The
finding that different methods of converting to the IS are producing consistently
different median results suggests the need for a review of the process of con-
verting to the IS.
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Background: Imatinib (IM) has been the standard of care for chronic phase
(CP) chronic myeloid leukemia (CML). Recent studies have demonstrated that
BCR-ABL1 transcript levels at 3 and 6-month of front-line therapy is a useful
predictor of long-term outcomes. Neelakantan et al(Blood 2013; 121:2739-42).
found that the prognostic value of the 3-month early molecular response (EMR)
could be improved by combining the 3- and 6-month results, but suggested
that the 3-month EMR had superior prognostic value than the 6-month EMR
so early interventions could be determined based on the 3-month result. How-
ever, prognostic value of very early molecular response (VEMR) have not been
fully defined.
Aims: In this study, predictive value of BCR-ABL1IS at 1 month after front-line
therapy for an achieving MMR at 12 months was evaluated. In addition, the differ-
ence of prognostic role of VEMR in IM group and 2G TKI group were compared.
Methods: With a data cut-off date of 20 Feb 2016, among 223 newly diagnosed
CP CML patients who received IM (N=127) and 2G TKI (N=96) treatment and
had molecular data at 1 month, 98 patients in IM group and 65 patients in 2G
TKI group with at least 1 year of follow-up and available RQ-PCR at 12 months
were included. Based on receiver operating characteristic (ROC) curve analy-
sis, the predictive cutoffs of BCL-ABL1 transcripts at 1 month for achieving
MMR at 12 months in IM group and 2G TKI group were evaluated. All RQ-PCR
were tested with at least 4.5-log sensitivity in the central laboratory (Catholic
Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea).
Results: A total of 163 patients (101 men and 62 women) were analyzed. With
a median age of 44 years (range, 18-81 years), the distribution of low, interme-
diate, and high Sokal risk scores were 41%, 39%, 20%. 36 (37%) of 98 patients
in IM group and 46 (71%) of 65 patients in 2G TKI group achieved MMR at 12
months of front-line treatment. The predictive cutoffs of BCR-ABL1IS level at 1
month for achieving MMR at 12 months were 42.57% (sensitivity 66.67%,
specificity 56.45%, AUC 0.585(0.481-0.684), P=0.1617)and 38.41% (sensitivity
84.78%, specificity 89.47%, AUC 0.846(0.734-0.923), P=0.0001)in IM group
and 2G TKI group, respectively based on ROC curve analysis. In IM group,
24(47%) of 51 patients with ≤42% and 12(25%) of 47 patients with >42%
achieved 12-month MMR respectively (P=0.027). In 2G TKI group, 39(95%) of
41 patients with ≤38% and 7(30%) of 24 patients with >38% achieved 12-
month MMR respectively (P<0.001).
Summary/Conclusions: Our results demonstrated that VEMR is a predictor
for an achieving 12-month MMR in both IM-group and 2G TKI group. Specially,
38.4% cutoff in 2G TKI group showed higher sensitivity and specificity, com-
pared with those of IM group.
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Background: Ponatinib (PON) induces high response rates in heavily pre-
treated CML patients (pts) failing TKIs. A substantial proportion of pts on PON
[17% by 3 years, J. Cortes, Haematologica 2015] experience severe arterial
thrombotic events (ATE). The impact in the real-life setting of this recently
licensed agent is unknown yet.
Aims: We analyzed the French PON compassionate use program (19/04/2012-
30/09/2013) to evaluate outcomes in the real-life setting.
Methods: Multicenter observational retrospective study to examine safety and
efficacy of PON in CML failing TKIs, benefiting from the national PON compas-
sionate use program. Data collection followed the regulations of observational
studies in France. Pts were analyzed in intention-to-treat. Molecular biology
tests were expressed as BCR-ABL/ABL (%IS) in all centers. Standard clinical
data, cardiovascular risk factors (CVRF), onset of any CV events (before and
during PON treatment) and metabolic biological parameters were captured.
Results: 48 patient records were collected in CP, 5 in AP and 6 in BC. We
focused our analysis on CP pts only. There were 24 (50%) males, median age
of 53 (18-76) years at CML diagnosis and 60 (20-82) years at PON initiation.
Sokal scores were high in 15 (31%), intermediate in 17 (35%), low in 6 (12%)
and unknown in 10 (22%) pts. Fifteen pts (31%) were treated for hypertension,
2 were diabetic, 11 (23%) had dyslipidemia (all on statins), tobacco abuse was
present in 19 (39%) pts (1 unknown) and 21 (44%) pts had some pre-existing
cardiovascular risk factors (CVRF) in total prior to PON. Median weight was 66
(50-107) kg, and BMI was 24 (17.85-43) kg/m2. Fifteen (31%) pts (3 unknown)
were on anti-aggregants or anti-coagulants (AAG/C) before PON. Two pts had
nilotinib, 4 dasatinib and all other pts had imatinib first-line for a median of 22
(2-132) months, 25 (52%) dasatinib and 20 (42)% nilotinib for 14 (0.5-64)
months, as second-line, 4 pts developed a T315I mutation after imatinib only;
29 (60%) had received all 3 TKIs prior to PON. At PON initiation, 11 (23%) har-
bored a T315I mutation, 9 (19%) other mutation(s), 24 (50%) none (3 not done).
The trigger for PON was resistance in 34 (71%) pts, intolerance in 11 (23%)
pts and both in 3 (6%) pts. Pts were initiated at a median of 45 (15-45) mg
daily after a median of 73.5 (17-217) months of disease duration. The median
follow-up was 26.5 (2-42) months since PON initiation, and 102.5 (27-230)
months since diagnosis. Median time on PON was 19 (0.13-41.79) months.
Eight pts died, 6 of disease progression, 1 of myocardial infarction and 1 of
PAOD-related complications. The probability of OS was 81.5 (70.5-94)% at 36
months (Fig. 1a) with no influence of the presence of mutations or reason for
PON prescription. Overall, the cumulative incidence of MMR was 55 (35-73)%
at 18 months. Seven (14.5%) pts had hematologic AEs imposing transient PON
withhold, and 19 (40%) diverse grade 1-2 non-hematologic, non-CV AEs (pan-
creatic, hepatic, skin toxicities, no grade 3-4). Significant CV AEs (including
hypertension) occurred in 29 (60%) pts after a median of 5.8 (0.1-25.4) months
of PON (Fig 1b), in 11 pts without CVRF. Eight thrombotic events occurred (3
heart strokes, 2 brain strokes, 1 PAOD, 2 DVT). Of note, 3 thrombotic AEs
occurred on AAG/C. Lipids and HbA1c do not seem to be modified on PON. At
last follow-up 22 (46%) pts are still on PON.
Figure 1.
Summary/Conclusions: In this real-life setting, CP-CML patients resistant or
intolerant to previous TKIs, PON still displayed strong efficacy, ATEs represent
the main adverse factor observed.
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IMATINIB FIRST-LINE WITH SWITCH TO 2ND GENERATION TYROSINE
KINASE INHIBITORS IN CASE OF FAILURE OR TOXICITY: REAL-LIFE
DATA FROM A POPULATION-BASED REGISTRY OF BCR-ABL1+CML
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Background: The main academic-and company-sponsored studies of the treat-
ment of CML with TKIs focus on the results achieved with only one TKI, in sin-
gle-arm trials or in randomized trials comparing two TKIs as first line treatment.
After the discontinuation of the study drug, few data on further treatments are
collected. In real life and in many countries, for several years imatinib has been
used as first-line treatment, but nilotinib and dasatinib have been available and
used as second-line therapy.
Aims: To investigate the response and the outcome on first-line imatinib, with
switch to 2nd generation tyrosine kinase inhibitors (TKIs) in case of failure or
toxicity, in BCR-ABL1+ chronic myeloid leukemia (CML) patients enrolled in a
population-based registry (real-life setting).
Methods: From a cohort of 337 consecutive, unselected, newly diagnosed,
adult, chronic phase, Ph+, BCR-ABL1+, CML patients who were registered
according to population-based criteria in two Italian Regions (Emilia-Romagna
and Sicily) between 2008 and 2012, we identified 236 patients who were treated
with imatinib 400 mg once daily in first-line. The decision to switch to second-
line treatment was up to the Local Investigator (no predefined criteria) Defini-
tions: major molecular response (MMR): BCR-ABL1IS ratio<0.1%; MR4.0: BCR-
ABL1IS ratio<0.01% with >10,000 ABL1 copies; failure and suboptimal
response: according to 2009 European LeukemiaNet (ELN) criteria; progres-
sion: transformation to advanced phases according to ELN criteria; leukemia-
related death (LRD): death after progression.
Results: Sokal risk distribution was 29% low, 47% intermediate, and 24% high.
Median age was 60 years at diagnosis and 64 years at last analysis, with a
median follow up of 4 years. 145 patients (61%) received only imatinib, 57
(24%) were switched to 2nd generation TKIs for failure, and 34 (14%) were
switched to 2nd generation TKIs (n=31) or to Hydroxyurea (n=3) for toxicity.
The median time to switch was 20 months for failure and 8 months for toxicity.
After the switch, the molecular response improved of 1 to 3 logs in 57% of
patients. Molecular responses and outcomes are shown in the Table. Eleven
patients (5%) progressed to blast phase, and all of them died, but one. The 5-
year leukemia-related survival was 95%. The 5-year overall survival was 89%,
with 6% of patients dying in major molecular remission or in chronic phase,
without any evidence of progression. Noticeably, 48% of living patients had
achieved MR 4.0 (BCR-ABL 1 ≤0.01% IS) by 4 years (including first- and sec-
ond-line treatment).
Table 1.
Summary/Conclusions: A policy of imatinib first-line with switch to 2nd gen-
eration TKIs for failure or toxicity, as recommended by European LeukemiaNet
2009, in an unselected (median age 60 years) cohort of patients registered
according to population-based criteria showed a high efficacy.
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THE ALTERATION OF IMMUNOPROFILE DURING DASATINIB TREATMENT
IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE
OBSERVATIONAL STUDY
M Kuno*, H Nakamae, T Katayama, M Nishimoto, Y Hayashi, A Hirose, M Nakamae,
Y Nakashima, H Koh, T Nakane, M Hino
Hematology, Graduate School of Medicine, Osaka City University, Osaka,
Japan
Background: Some chronic myeloid leukemia (CML) patients treated with
dasatinib develop lymphocytosis with an expansion of large granular lympho-
cytes (LGLs) and natural killer (NK) cells. The lymphocytosis is known to be
related to a better response to dasatinib therapy and survival. However, it has
been not elucidated whether increased lymphocytes harbor an effective
immunological and/or anti-tumor activity.
Aims: The aims of this prospective study were 1) to evaluate changes of NK-
cell reactivity and soluble factors and 2) immune cell counts by dasatinib therapy
in treatment naive CML patients and those who were treated with dasatinib
beyond the first line therapy.
Methods: Thirty patients with CML in chronic phase who started tyrosine kinase
inhibitor (TKI) as the first-line treatment or switched to the other TKI were enrolled
in this study between September 2010 and December 2013 at our institute. TKIs
were; dasatinib (as first line n=7, beyond first line n=12), imatinib (as first line
n=3), nilotinib (as first line n=2, beyond first line n=6). We analyzed peripheral
blood samples collected from patients at enrollment, 1, 3, 6 and 12 months after
the initiation of treatment to determine cell counts, lymphocyte subset (such as
NK cells, NK-LGLs, T-LGLs and regulatory T cells) immunophenotyping by flow
cytometry, NK cell activity and plasma levels of 27 soluble factors.
Results: The number of lymphocytes, NK cells, T-LGLs and NK-LGLs signifi-
cantly increased in patients treated with dasatinib (all P<0.01). NK cell activity
at effector to target (E: T) ratios of 10: 1 and 20: 1 significantly elevated in
patients with dasatinib as the first-line treatment (P<0.01) and beyond first-line
treatment (P<0.01). The levels of NK cell activity at diagnosis were below the
normal level in all treatment naive CML patients and elevated above the normal
level at 12 months after the dasatinib therapy in more than half of the patients.
In addition, NK cell activity was significantly negatively correlated with BCR-
ABL mRNA transcript levels in the dasatinib group (r= -0.304, P=0.011) but not
in patients treated with imatinib or nilotinib. A significant association was found
between the numbers of T-LGL before and 3 months (P<0.01), and before and
6 months after dasatinib therapy (P<0.01). There were no significant change in
counts of any immune cell in patients receiving imatinib or nilotinib. Furthermore,
we could not determine a type of chemokine or cytokine associated with lym-
phocytosis induced by the dasatinib treatment.
Summary/Conclusions: Dasatinib might increase the numbers of LGL and
enhance NK-cell cytotoxicity in vivo. Dasatinib might restore the function of
exhausted cytotoxic lymphocytes present already at the time of CML diagnosis.
Increase in LGL counts was strongly correlated with the number of LGL before
dasatinib therapy. We speculated that the number of LGL present before dasa-
tinib therapy is potentially a prognostic factor.
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PLA FLOW; A FLOW CYTOMETRY-BASED ASSAY FOR DETECTION OF
BCR-ABL FUSION PROTEIN IN BLOOD CELLS FROM CML PATIENTS
L Löf1,*, U Olsson-Strömberg2, U Landegren1, M Kamali-Moghaddam1
1Departement of Immunolgy, Genetics and Pathology, Uppsala University,
2Department of Medical Science, Division of Hematology, Uppsala, Sweden
Background: Chronic myeloid leukemia (CML) is currently diagnosed using
RT-PCR and/or FISH to reveal the presence of the fusion mRNA transcripts for
BCR-ABL, or of the characteristic Philadelphia chromosome. RT-PCR is also
used to monitor the effects of treatment by sensitively measuring transcripts
representing minimal residual disease (MRD). It has not been possibly to use
flow cytometry to identify the neoplastic cells but such a method would be help-
ful in the workflow of a hematopathology lab. The PLA flow could provide a
strong complement to the powerful RT-PCR method used today, with the advan-
tages of flow cytometry.
Figure 1. Blood samples from 47 CML patients analyzed for BCR-ABL
positive cells, using FlowPLA (y-axis) and routine analysis of the BCR-
ABL transcript using RT-PCR (x-axis) and compared. Pearson correlation
coefficient was performed.
Aims: We have now developed a method that successfully detects and enumer-
ates cells harboring the fusion protein BCR-ABL by flow cytometry in CML patients.
Methods: The method, PLAflow, uses the in situ proximity ligation assay (PLA)
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(Söderberg et al 2006, Leuchowius et al 2009), where two antibodies target
the BCR and the ABL part, respectively, of the fusion protein. The antibodies
are equipped with DNA oligonucleotides that-when brought in proximity-guide
the formation of a circular DNA molecule as a template for localized DNA ampli-
fication through rolling circle amplification (RCA). Each RCA-product is then
labeled with around 1,500 fluorophore-coupled DNA oligonucleotides, allowing
cells to be detected by flow cytometry. Using this method we analyzed blood
samples from CML patients and compared it to the routine RT-PCR analysis.
Results: The method that was proven to be very sensitive, enable us to detect
very low number of cells harboring BCR-ABL in patient samples.
Summary/Conclusions: The PLA flow is a senstive and robust method that
could provide a strong complement to the powerful RT-PCR method used
today, both at diagnosis and monitoring MRD. Since the PLA flow method is
developed for flow cytometry, and now also adapted for CyTOF, all the advan-
tages with multiparametric analysis can be achieved simultaneously. This
allows monitoring of patients using their own cytogenetic signatures, both at
diagnosis, and during the MRD monitoring. By investigating which cell popu-
lations are expressing the BCR-ABL fusion protein, the method may provide
tools to identifying patients responding to a specific treatment.
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COMPARISON OF PACE CLINICAL TRIAL VS REAL-WORLD PONATINIB
PRESCRIBING AND DURATION OF THERAPY IN CHRONIC-PHASE
CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS
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Background: Ponatinib demonstrated efficacy in patients with highly-resistant
CP-CML in the pivotal phase 2 PACE trial (NCT01207440). Introduced to the
US market in Dec’12, ponatinib was reintroduced in Jan’14 after an 11-week
withdrawal to review data on vascular occlusive events and revise US pre-
scribing information. In the US, ponatinib is available exclusively through a
specialty pharmacy that maintains real-world prescribing data for all US patients
treated with ponatinib since Jan’14.
Aims: Comparison of real-world pharmacy data to PACE trial data for patients
with CP-CML, to identify any differences in duration of therapy due to potential
noncompliance or availability of alternative therapies.
Methods: Data from patients with CP-CML enrolled Sep’10-Oct’11 into the
PACE trial (all providing informed consent) were compared to real-world data
for CP-CML patients starting ponatinib Jan’14-Dec’15. Real-world data source
includes referring physicians, pharmacy intake forms and dispensing records.
Patient characteristics and dosing were compared overall and by line of therapy
using non-parametric tests; average dose was calculated, including therapy
gaps as “zero” dose. Duration of therapy was assessed using Kaplan-Meier
techniques and log-rank tests.
Results: PACE enrolled 270 CP-CML patients; 333 US real-world CP-CML
patients started treatment over the 2-year period. PACE patients were older
(median 60 vs 55 years; p=0.004). Comparing PACE to 258 real-world patients
with known line of therapy, 7% PACE vs 16% real-world were in 2nd line, 36%
vs 28% 3rd line and 57% vs 56% ≥4th line (p=0.084). All PACE patients
received 45 mg/day as the initial dose of ponatinib; in real-world ponatinib use,
48% of patients initially received 45 mg/day, 30% 30 mg/day, and 22% 15
mg/day; however, average ponatinib dose was similar in PACE vs real-world
(2nd line: 29.4 vs 29.0 mg/day; 3rd line: 26.0 vs 25.9 mg/day; ≥4th line: 26.4
vs 26.9 mg/day; all p>0.05.) Duration of therapy was similar in 2nd line and
≥4th line patients in PACE vs real-world, but longer in PACE vs real-world for
3rd line patients (Table).
Table 1.
Summary/Conclusions: Real-world CP-CML ponatinib patients are younger
but otherwise similar to PACE patients. Real-world data suggests an increase
in earlier (second) line ponatinib use and >50% of initial ponatinb dosing is
below 45 mg/day. As expected, the real-world duration of therapy is somewhat
shorter than in PACE; however, the majority of real-world ponatinib patients
across all lines of therapy were on therapy for >1.5 years.
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PATIENT-REPORTED OUTCOMES FROM AN OPEN-LABEL SAFETY AND
EFFICACY STUDY OF BOSUTINIB IN PHILADELPHIA CHROMOSOME
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Background: Bosutinib (BOS) is a tyrosine kinase inhibitor indicated for the
treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
(CML) in adult patients with resistance or intolerance to prior therapy. A 5-year
update of the safety and efficacy results from a phase 1/2 study of BOS for
Ph+ leukemia resistant/intolerant to prior tyrosine kinase inhibitors (clinicaltri-
als.gov: NCT00261846) has recently been conducted.
Aims: To assess the long-term health-related quality of life (HRQoL), function-
ing, and symptoms in patients with chronic phase CML following imatinib resist-
ance or intolerance (chronic phase second line; CP2L) or resistance or intol-
erance to imatinib plus dasatinib and/or nilotinib (chronic phase third line;
CP3L), based on patient-reported outcomes (PROs) from this trial.
Methods: Patients received a starting dose of BOS 500 mg/day and completed
the EuroQoL 5 Dimensions (EQ-5D) and the Functional Assessment of Cancer
Therapy-Leukemia (FACT-Leu) questionnaires at screening; weeks 4, 8, and
12; every 12 weeks thereafter; and at the end of treatment visit. Mean and
95% CIs were reported. Informed consent was obtained from all patients. The
PRO results at 5 years are presented.
Results: A total of 284 patients were enrolled in the CP2L population and 119
patients in the CP3L population. At treatment completion, EQ-5D completion
rates were 67.6% and 65.5% in the CP2L and CP3L populations, respectively;
FACT-Leu completion rates were 65.7% and 64.7% in the CP2L and CP3L
populations, respectively. At baseline, the mean EQ-5D utility score was 0.83
in the CP2L population and 0.80 in the CP3L population. Mean (95% CI)
changes from baseline in EQ-5D utility scores ranged from -0.04 (-0.13 to 0.06)
to 0.12 (0.03-0.21) in the CP2L population and from -0.05 (-0.16 to 0.07) to
0.01 (-0.15 to 0.16) in the CP3L population. At baseline, the mean EQ-5D visual
analog scale (VAS) score was 71.3 in the CP2L population and 72.6 in the
CP3L population. Mean (95% CI) changes from baseline in EQ-5D VAS scores
ranged from 0 (95% CI not available) to 30.17 (-86.96 to 147.29) in the CP2L
population and from -2.64 (-6.14 to 0.85) to 19.69 (-5.30 to 44.68) in the CP3L
population. At treatment completion, most patients reported “no problems” on
all of the 5 dimensions of the EQ-5D health state profiles (Table 1). At baseline,
the mean FACT-General (FACT-G) Total Score and FACT-Leu Total Score were
81.0 and 133.2, respectively, in the CP2L population and 80.8 and 132.5,
respectively, in the CP3L population. In the CP2L population, mean (95% CI)
changes from baseline in FACT-G Total Score (minimally important difference:
3-7 points) and FACT-Leu Total Score (minimally important difference: 6-12
points) ranged from -1.02 (-2.41 to 0.36) to 9.87 (0.94-18.80) and -4.66 (-14.81
to 5.48) to 17.34 (6.33−28.36), respectively. In the CP3L population, mean
(95% CI) changes from baseline in FACT-G Total Score and FACT-Leu Total
Score ranged from -2.74 (-5.09 to -0.39) to 9.50 (95% CI not available) and
-3.05 (-6.84 to 0.73) to 7.22 (-3.40 to 17.85), respectively.
Table 1.
Summary/Conclusions: These findings are of considerable importance to
patients and physicians and indicate, for the patients who remained in the
study, that HRQoL was largely maintained with BOS during the 5-year study
duration in both second line and third line patients with Ph+ CML with resistance
or intolerance to prior therapy.
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PRELIMINARY FINDINGS FROM A CHART REVIEW OF LOWER DOSING
OF PONATINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
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Background: Ponatinib is approved for adult patients with refractory CML or
Ph+ ALL and those with the T315I mutation. Current prescribing information
recommends a starting dose of 45 mg/day, with consideration of lower doses
in patients with selected comorbidities, to manage adverse events, and for
patients who achieve response. Post hoc dose-response analyses from the
registrational PACE trial suggest lower doses of ponatinib may mitigate safety
risk while maintaining response; however, outcomes of patients with lower dos-
es have not been evaluated in clinical practice.
Aims: Characterize response and adverse events of special interest (AESI) in
real-world CML patients treated with ponatinib doses ≤45mg/day.
Methods: We conducted a chart review of adult (aged ≥18 years) US CML
patients receiving ponatinib. Patients were required to have ≥6 months of fol-
low-up from first dose; however, no minimum ponatinib exposure was required.
Data were abstracted from 6 months prior to first dose (“baseline”) through
date of chart review, death or loss to follow up. Baseline characteristics, treat-
ment response and AESI (including arterial occlusive events [AOEs] and venous
thromboembolic events) are reported overall and by average daily dose ≤30
mg (“low dose”) and >30 mg (“standard dose”), calculated including therapy
gaps as “zero” dose.
Results: Preliminary analysis of 35 patients from 9 US sites found patients did
not differ significantly by dosage group in baseline age, CML phase, time since
diagnosis or prior therapy lines; however, fewer low dose patients had no
response at start of ponatinib therapy (Table). Significantly more low dose
patients had hyperlipidemia at baseline (p=0.027), and there was a trend toward
more history of myocardial infarction (MI), coronary artery disease and revas-
cularization among low dose patients (all p=0.070). Low dose patients had
nominally more baseline risk factors or prior events compared to standard dose
patients (Table). Median time on therapy was 11 vs 12 months for low dose vs
standard dose patients, respectively (p=0.336), and dose reduction was com-
mon (73% vs 60%; p=0.411). Best response of major molecular response
(MMR) or better was reported in 40% of low dose patients and 25% of standard
dose (p=0.344); major cytogenetic response (MCyR) or better in 53% vs 45%
(p=0.625), and major hematologic response (MaHR) or better in 80% and 65%
of low vs standard dose, respectively (p=0.331). AESIs reported in ≥2 patients
were: venous recanalization (n=8), mesenteric artery stent insert (n=6), cerebral
small vessel ischemic disease (n=6), MI (n=3), increased troponin (n=3), cardiac
arrest (n=2), creatine phosphokinase (n=2). There was no statistically significant
difference in AESIs between groups; however, a trend toward more AOEs in
patients with lower average doses (p=0.076) was noted, perhaps due to patient
selection or post-event dose reduction. Power to detect differences was limited
by sample size; further analysis of correlation between baseline risk factors
and outcomes is ongoing.
Table 1.
Summary/Conclusions: Preliminary data suggest that in clinical practice,
response is similar among CML patients treated with low and standard dose
ponatinib. Patients with selected risk factors or history of prior event received
lower average doses, and the trend toward greater number of AOEs in the low
dose group suggests that AOEs may be correlated more with risk than dose.
Additional data are needed to fully characterize outcomes of patients treated
with ponatinib at doses lower than the currently recommended 45 mg/day. 
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IMPACT OF IMATINIB PHARMACOKINETICS ON HEALTH RELATED
QUALITY OF LIFE AND ADVERSE EVENTS IN PATIENTS WITH CHRONIC
MYELOID LEUKEMIA
J Cao1,*, J Allen1, B Chowbay2, C Chuah3
1Duke-NUS Medical School, 2National Cancer Centre Singapore, 3Department
of Haematology, Singapore General Hospital, Singapore, Singapore
Background: Imatinib has improved survival of chronic myeloid leukemia
(CML) patients considerably. However, many patients suffer persistent, low-
grade adverse events (AEs) and have relatively inferior health-related quality
of life (HRQOL). This impairment is in part ascribed to low grade AEs, which is
experienced by a large proportion of patients. Studies have demonstrated that
imatinib pharmacokinetics may correlate with imatinib-related AEs but none
investigated the impact on HRQOL.
Aims: To determine the correlation of imatinib pharmacokinetics with HRQOL,
incidence and severity of AEs.
Methods: A prospective cross-sectional study of 70 chronic phase CML patients
at Singapore General Hospital was performed. All patients were on imatinib for
at least 6 months. Blood samples for imatinib pharmacokinetic analysis were
taken at 0 (pre-dose, trough) and 2 hours (peak) after imatinib administration
and analyzed via high performance liquid chromatography. Oral clearance was
calculated using: Cloral=(D/2t)/Css, where D=dose (mg), t=dosing interval (hr),
and Css=steady state imatinib concentration (ng/ml). AEs and HRQOL were
measured using M.D. Anderson Symptom Inventory Chronic Myeloid Leukemia
Module (MDASI-CML), which was filled up within 48 hours of imatinib pharma-
cokinetic sampling. MDASI-CML is a multi-symptom patient-reported outcome
comprising of 20 symptom items (13 core MDASI items, 7 CML-specific symptom
items) and 6 HRQOL interference items. Higher scores indicate more severe
AEs and worse HRQOL. Clinical responses was determined based on European
LeukemiaNet 2013 guidelines. The study was approved by the institutional
review board and all participants were required to sign informed consent.
Results: Median daily dose of imatinib was 400mg and the median imatinib
trough concentration, peak concentration and clearance were 1365 ng/ml, 2372
ng/ml and 5.74 L/hr respectively. Impairment in at least one of the six HRQOL
life activities was experienced by 65.7% of patients while 91.4% of patients
experienced at least one AE. Higher HRQOL scores significantly correlated
with higher imatinib trough (r=0.274; p=0.021) and slower clearance (r=-0.331;
p=0.005) but not with imatinib peak concentrations. Median HRQOL score was
significantly higher in the trough Q4 group compared to the Q1 group (1.50 vs
0.17; p=0.034) and was significantly lower in the clearance Q4 group compared
to the Q1 group (0.17 vs 1.50; p=0.010) (see Figure 1). Higher imatinib trough
and slower clearance also correlated with increased patient-rated incidence of
AEs (r=0.238; p=0.045 and r=-0.278; p=0.020 respectively) and increased
severity of AEs (r=0.248; p=0.037 and r=-0.315; p=0.008 respectively), but not
with clinical response.
Figure 1.
Summary/Conclusions: Higher imatinib trough levels and slower clearance
of imatinib are associated with poorer HRQOL, higher incidence and increased
severity of AEs. Dose adjustment using imatinib trough levels may be beneficial
in reducing AEs and improving HRQOL.
E1112
CMREGISTRY: AN OBSERVATIONAL, MULTI CENTER, PROSPECTIVE
FOLLOW-UP REGISTRY OF PATIENTS WITH CHRONIC PHASE CML WITH
A HIGH PROBABILITY OF OBTAINING A STABLE DEEP MOLECULAR
RESPONSE >CMR4 (IS)
F Capdevila1, E Olavarria2,*, M Perez Encinas3, R de Paz Arias4, RM Ayala Diaz5,
N Garcia Omeña6, F Ferrer Marin7, G Bautista Carrascosa8, V Conesa Garcia9,
JL Steegmann10, OBOTGED Leucemia Mieloide Cronica (GELMC)11
1NavarraBiomed, Fundacion Miguel Servet, Pamplona, Spain, 2Haematology,
Hammersmith Hospital, London, United Kingdom, 3Hospital Clínico Universi-
tario, Santiago, 4Hospital La Paz, 5Hospital 12 de Octubre, Madrid, 6Hospital
Virgen de la Salud, Toledo, 7Hospital Morales Meseguer, Murcia, 8Hospital Uni-
versitario Puerta de Hierro, Madrid, 9Hospital General Universitario de Elche,
Elche, 10Hematologia, Hospital de la Princesa, 11GELMC, Madrid, Spain
Background: Since the advent of Tyrosine Kinase Inhibitors (TKI), many
patients diagnosed with Chronic Myeloid Leukemia (CML) in chronic phase
could achieve a deep molecular response, defined as at least a 4-log reduction
in the bcr-abl transcripts when measured by a standardized PCR on the Inter-
national Scale (IS). These patients are expected to maintain their molecular
response even after discontinuation of their TKI treatment. Several on-going
clinical trials are exploring the best way of stopping TKI therapy and evaluating
the patient and disease characteristics that could predict long term disease
control without treatment.
Aims: The aim of CMRegistry is to collect clinical data and molecular informa-
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tion in the international scale for CML patients in Spain that have achieved a
series of cytogenetic or molecular responses at different time points to any of
the tyrosine kinase inhibitors currently available in Spain in order to monitor
their progress and the achievement of a stable deep molecular response >MR4
(IS). These data may be used to identify patients that would be candidates for
inclusion in future discontinuation studies or combination studies with other
compounds.
Methods: This is an observational, multi-center, prospective study open to all
CML patients that are receiving treatment with any of the tyrosine kinase
inhibitors currently available in Spain and are likely to achieve (or have already
achieved) a deep molecular response (>MR4 (IS)). This likelihood of achieving
>MR4 is defined for the purposes of the study as a bcr-abl/abl ratio of: 1) ≤1%
at 3 months from start of TKI therapy; 2) ≤0.1% at 6 months from start of TKI
therapy; or 3) ≤0.01% any time point during treatment. Clinical data have been
collected using a specific CRF created exclusively for this study. All data were
registered in an anonymous manner. The BCR-ABL ratios in the IS have been
provided by standardized labs in Spain.
Results: From June 2014 to January 2016 a total of 732 patients were regis-
tered in the study. Median age was 55 years (18-78) and 440 patients were
male. The Sokal risk groups were as follows: 254 patients low risk, 230 inter-
mediate risk and 97 high risk. Hasford (Euro) risk stratification showed 223
patients low risk, 225 intermediate and 136 high risk. Eutos classification yield-
ed 341 patients in the low risk and 220 in the high risk categories. The majority
of patients received treatment with Imatinib (409 patients), Dasatinib (82
patients) or Nilotinib (122 patients). Of note, 5 patients received Bosutinib, 1
patient Ponatinib and 4 patients were treated with Interferon. So far 722 patients
remain alive. 10 patients have died, mostly of non-CML related conditions such
as Carcinoma (3 patients), Cerebral Hemorrhage, Ischemic heart disease, res-
piratory failure and sepsis (1 patient each). Interestingly, 2 patients developed
progression of their CML to Accelerated phase and blast crisis (1 patient each).
At present, 104 patients (14%) have achieved a MR4 and 70 (10%) patients a
MR5, while 176 patients (24%) have obtained a complete molecular remission
(undetectable bcr-abl transcripts with a sensitivity of at least 10-5).
Summary/Conclusions: In summary, a large number of CML patients have
been identified in Spain in a prospective study as having a promising molecular
response that would predict for a sustained deep molecular remission. A sig-
nificant proportion of these patients has already achieved a complete molecular
remission and would be potential candidates for discontinuation studies.
E1113
BCR-ABL1 MONITORING ON THE IS USING AN ANALYTICALY AND
CLINICALLY VALIDATED MULTIPLEX ASSAY DIRECTLY ALIGNED TO THE
WHO PRIMARY STANDARDS
J Brown*, I Beldorth, W Laosinchai-Wolf, M Fahey, J Hedges, A Ruskin,
B Andruss
Asuragen, Austin, United States
Background: Detection of BCR-ABL1 e13a2/e14a2 fusion transcripts (major
breakpoint, M-BCR) of t(9;22) is important in studying tumor burden in CML.
The International Scale (IS) was established to standardize the reporting of
these transcripts against a common baseline. As newer TKI therapies create
deeper responses, analytical sensitivity has become a critical topic in investi-
gations into TKI discontinuation, where researchers require an assay that con-
fidently calls molecular responses of ≥4.5 logs below baseline (0.0032%IS or
MR4.5). This has led to various reporting formats as a patient achieves deep
response over time, creating a non-contiguous language of monitoring: base-
line, 10%IS, 1%IS, MMR, MR4, and MR4.5.
Aims: We describe the analytical and clinical validation of a multiplex assay
system reporting continuous MR values via automated software analysis, clin-
ical accuracy at MR3, analytical sensitivity of MR4.7, and direct traceability to
the WHO Primary BCR-ABL1 reference materials without requiring establish-
ment and revalidation of a conversion factor.
Methods: We developed reagents for RT-qPCR, both steps performed on the
ABI 7500 Fast Dx. Armored RNA Quant® (ARQ) technology was employed to
generate a blend of nuclease-resistant BCR-ABL1 and ABL1 RNA transcripts
to calibrate and control the system. A single four-point standard curve using
ARQ blends mimics the WHO Primary BCR-ABL1 reference materials and
accounts for the relative batch run-specific efficiency of the RT step. cDNA
generation and qPCR were optimized, including allowance of high mass of
nucleic acid without inhibition. Residual clinical RNAs were tested to estimate
LOD at minimum RNA input. Software was developed, including a floating,
traceable logic algorithm to ensure that sufficient ABL1 was detected to protect
this LOD. A multi-center clinical outcome study was conducted at 3 clinical lab-
oratories to validate clinical monitoring. Performance was assessed by event-
free survival (EFS) at 32-40 months against test results at 12-18 months on
TKI as estimated by the Kaplan Meier survival function. A total of 139 samples
from 98 patients were enrolled at 2 clinical sites.
Results: We surpassed the desired analytical sensitivity: 1680 measurements
were generated across 28 levels and yielded an LOD estimate of 95% positivity
by probit analysis of MR4.74 (0.0018%IS). LOQ was similar. Despite deep
analytical sensitivity, this system maintains analytical specificity (non-leukemic
and non-CML leukemic specimens were true negative). Linearity was observed
from at least MR0.3 (50%IS) to MR4.7 (0.002%IS). Single-site precision includ-
ed lot, instrument, operator, and run, and was verified as SD ≤0.13 for MR val-
ues ≤3.7. Multi-site precision included site, instrument, operator, and day, and
was verified as SD ≤0.10 for MR values ≤3.7. Traceability to the higher order
WHO standards was demonstrated. In the clinical study, the difference in EFS
between.
Summary/Conclusions: The BCR-ABL1 test improves workflow with its
streamlined reagent formulation, multiplex assay format, and automated soft-
ware analysis. It facilitates assessment on the IS without conversion (through
integrated ARQ materials traceable to the WHO Primary), reports results on a
continuous scale (as both MR and%IS values), and generates results sufficient
for studies in deep molecular responses. Further, it is clinically validated to
predict EFS outcomes at the MR3 level.
E1114
RESULTS OF OBSERVATION WITHOUT TREATMENT IN CHRONIC
MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE
WHO STOPPED THERAPY DUE TO PREGNANCY, ADVERSE EVENTS OR
BY OWN CONSIDERATION
E Chelysheva1,*, A Turkina1, V Shuvaev2, G Gusarova1, A Bykova1,
O Shukhov1, M Vakhrusheva1, A Abdullaev1, M Fominykh2, A Sudarikov1,
I Martynkevich2, K Abdulkadyrov2
1Scientivic Advisory Department of Chemotherapy of Myeloproliferative disor-
ders, Federal State Funded Institution National Research Center for Hematol-
ogy of the Ministry of HealthCare of the Russian Federation, Moscow, 2Russian
Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russ-
ian Federation
Background: A possibility of observation without treatment in chronic myeloid
leukemia (CML) patients is important as the long-term survival on tyrosine
kinase inhibitors (TKI) therapy is excellent and a significant proportion of
patients (pts) may achieve a deep molecular response (DMR).
Aims: To evaluate the results of observation without TKI treatment in CML
patients with DMR who stopped therapy for different reasons.
Methods: Sixty-one CML pts with DMR were observed after TKI cessation.
Fifty-nine pts had chronic phase, 2 pts had accelerated phase of CML at initial
diagnosis. Sokal risk groups ratio low/intermediate/high was 65%/20%/15%.
Male/female ratio was 15/46. Median (Me) age at TKI cessation was 37 years
(range 22-76). The reasons for TKI discontinuation were: 1) adverse events
(AE) of TKI (n=28), 2) self-made decisions of pts or TKI absence (n=15), 3)
pregnancy (n=18). Imatinib and second generation TKI (TKI2) were used in
40(66%) and 21(34%) of pts respectively. Twenty-three (38%) pts were pre-
treated with interferon prior to TKI. Me treatment duration before TKI discon-
tinuation was 72 months (range 6-159 months). BCR-ABL transcript level was
assessed by quantitative Real-time polymerase chain reaction according to
international scale (IS). DMR was considered for at least molecular response
4 log (МR4) or BCR-ABL<0,01%. TKI were resumed after loss of major molec-
ular response (MMR) or BCR-ABL>0,1%. For pregnant pts therapy was
resumed at BCR-ABL level>1% if it happened during pregnancy and at BCR-
ABL level>0,1% if it happened after delivery. МR4 duration >2 years was in 45
(74%) of pts. We evaluated survival probability without MMR loss, terms of
MMR loss and BCR-ABL level at MMR loss.
Figure 1. Survival without MMR loss after TKI discontinuation.
Results: Ме follow-up after TKI discontinuation was 31 month (range 4-99
months). MMR was lost in 28 (46%) pts, TKI were restarted in all of them. Ме
time of MMR loss was 5 months (range 1-22 months). MMR loss happened
within 6 and 12 months after TKI cessation in 20(33%) and in 5(8%) of pts
respectively. In 3(5%) pts MMR loss was at 13,21 and 22 months. No hema-
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tologic relapses were observed. At the time of MMR loss BCR-ABL level ranged
from 0,11% to 13%. In 6 pts TKI were restarted without MMR loss by physician’s
decision at BCR-ABL level 0-0,082%. Two pts with DMR died due to concomi-
tant diseases. Twenty-five (41%) pts continued to be treatment free under mon-
itoring for Me 20 months (range 4-93 months), including 4 women without MMR
loss after delivery. The probability of survival without MMR loss after TKI ces-
sation at 6, 12 and 24 months was 67%, 57% and 49% respectively. For preg-
nancy group the probability of survival without MMR loss after TKI cessation at
6, 12 and 24 months was 67%, 32% and 37% respectively. No significant dif-
ference with pts in whom TKI were stopped for other reasons was found
(p=0,46, figure 1). No MMR loss was observed after 24 months of TKI discon-
tinuation neither in patients who stopped TKI due to pregnancy nor in those
who stopped treatment for other reasons.
Summary/Conclusions: Approximately half of CML patients with DMR had a
possibility to keep MMR within one year after TKI cessation. MMR loss mostly
occurred within first 6 months after TKI discontinuation. No MMR loss was
marked after 24 months of treatment free observation. Pregnancy in CML
patients with DMR did not influence on the ability to maintain MMR after TKI
cessation. A safe treatment free observation in CML patients who stop TKI may
be warranted only with accompanying regular BCR-ABL level monitoring.
E1115
CONCURRENT OPTIMAL MOLECULAR AND CYTOGENETIC RESPONSES
AT BOTH 3 AND 6 MONTHS PREDICT A HIGHER PROBABILITY OF MR4.5
ACHIEVEMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
TREATED WITH IMATINIB
YZ Qin1,*, Q Jiang1, YY Lai1, H Jiang1, XS Zhao1, YR Liu1, XJ Huang1,2
1Peking University People’s Hospital, Peking University Institute of Hematology,
2Peking-Tsinghua Center for Life Sciences, Beijing, China
Background: Tyrosine kinase inhibitors (TKIs) have become the first line treat-
ment of chronic myeloid leukemia (CML). Because early molecular and cyto-
genetic responses have been demonstrated to strongly predict long-term out-
comes, the 2013 European LeukemiaNet (ELN) recommends that the patient
early response should be defined by both molecular and cytogenetic tests to
optimally direct the selection of subsequent treatments. The rapid achievement
of a deep molecular response has become the treatment goal, therefore, the
impact of the combination of early responses on it needs to be investigated.
Aims: We tried to evaluate the impact of the combined molecular and cytoge-
netic responses at 3 and 6 months on the achievement of molecular response
of 4.5 (MR4.5) in imatinib treated CML patients.
Methods: A total of 228 newly diagnosed chronic phase CML patients treated
with imatinib were included. At 3 and 6 months, they all were detected BCR-
ABL transcript levels by real-time quantitative polymerase chain reaction (RQ-
PCR) using peripheral blood samples, and performed karyotyping by standard
G-banding techniques. Patients were grouped into 3-month and 6-month molec-
ular optimal cytogenetic optimal (MOCO), molecular optimal cytogenetic warn-
ing (MOCW), molecular warning cytogenetic optimal (MWCO), molecular warn-
ing cytogenetic warning (MWCW) and failure groups according to the 2013
ELN recommendation. BCR-ABLIS (BCR-ABL levels according to the interna-
tional scale) was serial followed up for molecular response evaluation.
Figure 1.
Results: The median follow-up time was 27 months (range 8-94). For 3 months,
both MOCW and MWCO patients had 3-year MR4.5 rates similar to those of
MWCW and failure patients (8.3% [95% confidence interval (CI), 0-70.5%], 0,
0 and 0, all P>0.05), and they all were significantly lower than that of MOCO
patients (35.5% [95% CI, 23.2-48.0%]; P=0.0047, 0.0057, 0.0089 and 0.0081,
respectively). Similarly, for 6 months, both MOCW and MWCO patients had 3-
year MR4.5 rates similar to those of MWCW and failure patients (5.6% [95%
CI, 0-66.6%], 20.0% [95% CI, 0.2-67.0%], 0 and 0, all P>0.05), and they were
all significantly lower than that of MOCO patients (41.6% [95% CI, 29.2-53.5%];
P=0.025, 0.021, 0.0005 and 0.0010, respectively). Next, responses at 3 and 6
months were combined. Three-month MOCO/6-month non-MOCO, 3-month
non-MOCO/6-month MOCO and 3-month non-MOCO/6-month non-MOCO
patients had similar 3-year MR4.5 rates (9.4% [95% CI, 0-56.5%], 0 and 4.2%
[95% CI, 0-64.0%], P>0.05), and they were all significantly lower than that of
3-month MOCO/6-month MOCO patients (45.4% [95%CI, 32.9-57.1%];
P=0.0024, 0.0073 and<0.0001). This patient group also had significantly higher
3-year event-free survival (EFS) and progression-free survival rates (PFS) than
those of patients with non-MOCO at 3 and/or 6 months (P<0.0001 and 0.0065)
and had a significantly higher 3-year MR4.5 rate than that of patients with a 3-
month/6-month molecularly optimal response but not a cytogenetically optimal
response at 3 and/or 6 months (including 3-month MOCO/6-month MOCW, 3-
month MOCW/6-month MOCO and 3-month MOCW/6-month MOCW, 5.0%
[95%CI, 0-65.6%], P=0.0028).
Summary/Conclusions: The combination of early molecular and cytogenetic
responses better predicts a deep molecular response in CML patients treated
with imatinib. Concurrent optimal molecular and cytogenetic responses at both
3 and 6 months are associated with MR4.5 achievement.
Grant support The Nature Science Foundation of China (81370637 and
81570130) and the Beijing Municipal Science and Technology Program
(Z131100004013026 and Z141100000214011).
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TELOMERE LENGTH SHORTENING IS ASSOCIATED WITH TREATMENT
FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS
G Caocci1,*, M Greco1, G Delogu2, C Secchi2,3, B Martino4, C Labate4,
E Abruzzese5, MM Trawinska5, S Galimberti6, F Orru1, C Fozza7, C Gambacorti
Passerini8, F Galimi2,3, G La Nasa1
1Hematology, Department of Medical Sciences, University of Cagliari, Cagliari,
2Department of Biomedical Sciences, 3Istituto Nazionale Biostrutture e Biosis-
temi, University of Sassari, Sassari, 4Division of Hematology, Ospedali Riuniti,
Reggio Calabria, 5Hematology, S. Eugenio Hospital, University of Tor Vergata,
Rome, 6Department of Clinical and Experimental Medicine, Section of Hema-
tology, University of Pisa, Pisa, 7Department of Clinical and Experimental Med-
icine, University of Sassari, Sassari, 8Department of Internal Medicine, Univer-
sity of Milano Bicocca, Monza, Italy
Background: Telomere biology has been more extensively studied in chronic
myeloid leukemia (CML) than in any other blood cancer. Shorter telomeres
have been associated to disease progression, poor prognosis, higher Hasford
score and acquisition of further cytogenetic aberrations. So far, there are no
studies investigating the possible influence of telomeres on treatment-free
remission (TFR) after discontinuation of therapy with tyrosine kinase inhibitors
(TKIs).
Aims: The aim of the present study was to investigate whether telomere length
was associated with durable TFR in a cohort of CML patients after discontinu-
ation of treatment with imatinib.
Methods: Thirty-two chronic-phase CML patients discontinued TKI treatment
after achieving complete molecular remission (MR4). All patients were treated
with imatinib. Two patients underwent second-line TKI (nilotinib) following
molecular relapse. Telomere length analysis was performed as described by
Cawthon (2002) using a quantitative PCR (q-PCR). The Relative Telomere
Length (RTL) was determined as the Telomere (T) to Single copy gene (36B4)
(S) ratio (T/S) normalized to a reference sample (K-562 DNA). Peripheral blood
samples were also collected from 32 age- and sex-matched healthy controls.
Age corrected RTL (acRTL) represented the difference in telomere length
between patients and age- and sex-matched controls.
Figure 1.
Results: Complete molecular remission (CMR) was achieved after a mean of
26 months of imatinib (range 3-93). TKI treatment was discontinued after a
mean of 84 months from the start of treatment (range 24-143). The median fol-
low-up after discontinuation was 30 months (range 18-60). Thirteen patients
(41%) showed loss of CMR. All relapsed patients regained CMR after restarting
treatment with TKIs. The 36-month cumulative probability of TFR was 59.4%.
RTL was assessed at a mean of 32 months from discontinuation in TFR patients
and at a mean of 23 months after relapse in others. The median value of acRTL
in the CML cohort was 0.09 (range -0.26, +0.86). The Mann-Whitney U test
haematologica | 2016; 101(s1) | 461
Copenhagen, Denmark, June 9 – 12, 2016
showed shorter acRTL in TFR patients compared to patients with molecular
relapse (mean±SD = 0.01±0.14 vs 0.20±0.21; p=0.01). Patients were stratified
according to the median value of acRTL ≤0.09. TFR was significantly higher in
CML patients with acRTL ≤0.09 in comparison to those with longer telomeres
(78.9% vs 30.8%, p=0.002) (Figure 1).
Summary/Conclusions: Achievement of biological recovery through control
or eradication of CML stem cells might depend on their proliferative potential
in relation to telomere length. Age (a parameter directly proportional to telomere
shortening and senescence) has recently been reported as a predictive factor
for molecular relapse in CML patients who discontinue imatinib. CML cells
would escape senescence through up-regulation of telomerase, restoring
telomere length. In our study cohort, TFR patients showed significantly shorter
acRTL than patients who presented molecular relapse. It can be postulated
that quiescent CML stem cells harboring longer telomeres possibly escape
senescence mechanisms and maintain a proliferative potential after discontin-
uation of imatinib treatment. To avoid such tumor escape mechanisms, anti-
telomerase treatment strategies after TKI discontinuation would seem to be a
reasonable proposal.
Gene therapy, cellular immunotherapy
and vaccination
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THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING
FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL
S Theurich1,2,*, J Iltgen2, K Wennhold2, M Garcia Marquez2, S Rothschild2,
B Schneider1, U Holtick1, M Thelen2, C Scheid1, HJ Becker1,2, H Schlösser2,
S Reuter2, A Shimabukuro Vornhagen1,2, M von Bergwelt-Baildon1,2
1Department I of Internal Medicine, Hematology & Oncology, 2Cologne Inter-
ventional Immunology (CII), University Hospital Cologne, Köln, Germany
Background: B lymphocytes not only balance the physiologic immune
response but can also be involved in a variety of immune pathologies. Besides
their traditional function as antibody producing plasma cells, it has been shown
that B cells, upon activation, can develop into professional antigen-presenting
cells (APCs) which mediate further cellular immune responses. Moreover,
cytokines modulate B cell activation via the Janus kinase - signal transducer
and activator of transcription (JAK-STAT) pathway. Inhibition of the JAK-STAT
pathway has been introduced into clinical practice with the specific JAK1/2
inhibitor ruxolitinib. Approved for the treatment of JAK2 mutated myeloprolifer-
ative diseases, ruxolitinib has also shown to alleviate immune mediated symp-
toms such as fatigue and night sweat. Also in steroid-refractive graft-versus-
host disease, ruxolitinib has shown activity.
Aims: Given the broad employment of JAK-STAT signaling in immune respons-
es and the suggested clinical benefits of ruxolitinib mediated JAK1/2 inhibition
in immune pathologies, we analyzed if such “off-target” effects can also mediate
B cell activation.
Methods: Primary human B cells from healthy donors as well as from ruxolitinib
treated patients were used for in vitro analyses. Here, CD40ligand mediated
B-cell activation was applied as a well established model for T-cell dependent
B-cell activation. Morphologic, phenotypic and functional changes were ana-
lyzed by 10-color flow cytometry. Cell metabolism was analyzed via extracellular
flux changes (Seahorse Bio.).
Results: We found that ruxolitinib treatment significantly suppressed CD40L
induced B-cell activation. These alterations became manifest in a reduced cell
size and less homotypic cluster formation as well as in a reduced expression
of co-stimulatory (CD80, CD86) and HLA-class-II molecules. On a functional
level, JAK1/2 inhibition significantly reduced the ability of CD40L activated B
cells to induce T-cell activation in a mixed allogeneic lymphocyte reaction. As
a mechanism of action we found that ruxolitinib reduced glycolysis and the gly-
colytic capacity of activated B cells. Vice versa, inhibition of glycolysis via 2-
deoxyglucose could recapitulate the ruxolitinib induced phenotype. Finally, data
from ruxolitinib treated patients suggest that similar alterations of B cells also
occur in vivo.
Summary/Conclusions: Taken together, our data suggest that ruxolitinib has
important effects on B-cell activation which might contribute to its previously
reported immunosuppressive features. Furthermore, we show that ruxolitinib
can modulate APC-features of activated human B cells via glycolysis.
E1117
INTRA-BONE DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH
HEMATOLOGIC MALIGNANCIES RELAPSING POST ALLOHSCT
A Lange1,2,*, M Mordak-Domagala2, J Bochenska2, E Kocwin2, H Pakos2,
M Krydel2, A Borowik2, E Jaskula1,2
1L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Acad-
emy of Sciences, 2Lower Silesian Center for Cellular Transplantation with
National Bone Marrow Donor Registry, Wroclaw, Poland
Background: Donor Lymphocyte Infusion (DLI) is effective in a proportion of
patients with leukaemia relapsing post alloHSCT. This effect is over-paid by a
high risk of severe aGvHD. Ikehara and Frassoni showed the efficacy of the
intra-bone (IB) marrow hematopoietic stem cell transplantation associates with
a prompt hematopoietic reconstitution and a low risk of aGvHD in animal exper-
iments and in human setting, respectively. Recurrence and GvHD are major
causes of treatment failure post alloHSCT.
Aims: In this study we evaluated a novel technique for relapse treatment in
which donor lymphocytes are directly injected into the patient’s bone marrow
cavity. This study was approved by the local ethic committee.
Methods: Four patients: 3 with AML (2 alloSIB: 50 years old, female, normal
karyotype; 22 years, male 7q31 del., CNS lesions post trauma; and one allo-
MUD: 25 years, male FLT3 ITD), and one with CLL, 64 years old male, TP53
del, chronic EBV infection. FLT3 ITD AML case relapsed 9 months, other AML
cases 2 and 3 yrs and CLL patient 7 years post alloHSCT. The salvage
chemotherapy included FLAG for FLT3 ITD case, anti-CD20 MoAb for CLL
case, two other AML cases received DLI upfront. All received IB DLI (according
to the escalating dose regimen starting from 10E6 for the first and 10E7 for the
second and usually 5 times 10E7 CD3+ lymphocytes for the third dose [cells/kg
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body weight]). The intervals between IB DLI in 3 patients varied from 1 to 2
months being longer in one AML case in which between IB DLI 5’ azacitidine
was administrated. The cells for DLI were obtained from the primary PBPC
transplant material in alloMUD AML case and from unstimulated PBPC in
alloSIB and in two AML cases as well as in one CLL case. The cells were inject-
ed directly to the bone marrow cavity under local anaesthesia and a low molec-
ular Heparin prophylaxis.
Results: 1) At 30 check points post IB DLI the marrow and blood lymphocyte
profile was investigated in 4 patients. We found the prevalence of CD8+ cells
proportions in the marrow over those in the blood (median: 24.3% vs 23.8%,
p<0.004) but in particular the prevalence of CD279+ lymphocytes (16.3% vs
9.5%, p<0.001) and those CD8+CD279+ (6.5% vs 3.2%, p<0.001). 2) In CLL
cases there was a drop in the count of blood lymphocytes, cellularity of the
marrow also decreased and the patient was haematologically stable. The exam-
ination 8 months after the last DLI revealed 3300/µl CD5+CD19+ lymphocytes
in the blood. The level which was also seen soon after the completion of the IB
DLI treatment. 3) AML FLT3 ITD patients responding well to the FLAG salvage
therapy followed by IB DLI is leukaemia free 3 months after the relapse, two
other cases were stable haematologically (ECOG1) but an increase in the pro-
portions of myeloblasts from 23% to 34% seen during 7 and 6 months of obser-
vation time which included IB DLI treatment prompted us to perform the second
transplantation in one case (uncomplicated) and to schedule the second trans-
plant in the other case.
Summary/Conclusions: 1) The observation of four patients they completed
IB DLI suggests that it is safe procedure and GvHD was not observed. 2) The
anti-leukemic effect was seen in CLL case and a stabilization of the
haematopoiesis was seen in two patients receiving IB DLI being not in remis-
sion. AML FLT3 ITD positive case relapsing soon after transplant responded to
the FLAG regimen followed by IB DLI. 3) The higher proportions of
CD8+CD279+ lymphocytes in the marrow as compared to the blood suggest
the presence in the marrow the cells actively involved in the surveillance of
leukaemia.
Supported by INNOMED/I/1/NCBR/2014 grant.
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INTERLEUKIN-2-PRIMED NAÏVE CD8 T CELLS AS A POTENTIAL REMEDY
FOR OVERCOMING TUMOR-DERIVED IMMUNOSUPPRESSION IN TUMOR
MICROENVIRONMENT
DH Yang1,*, SS Lee1, SY Song2, JS Ahn1, SH Jung1, HJ Kim1, JJ Lee1, YR Do3
1Hematology, 2Thoracic and Cardiovascular Surgery, CHONNAM NATIONAL
UNIVERSITY HWASUN HOSPITAL, Jeollanam-do, 3Hematology, Dongsan
Medical Center, Daegu, Korea, Republic Of
Background: CD8 T cells have cytotoxic effector functions upon antigen stim-
ulation and receive considerable attention for adoptive immunotherapy against
cancer. Despite of their potential implication, however, conventional approaches
using in vitro expanded CD8 T cells have not been successful so far, mostly
due to lack of functionality with cellular exhaustion.
Aims: In this study, we therefore investigated the phenotypic and functional
differences among in vitro activated CD8 T cells of three different sources,
namely naïve, memory and tumor-infiltrating lymphocytes (TILs) of human and
mice, for better understanding mechanisms behind potent effector functions
and overcoming limitations of the current approaches. 
Methods: Effector T cell populations were activated from CD8+ naïve, memory
T cells, and CD8+ TILs obtained from cancer tissue (Teff N, Teff M, and re-stim-
ulated TILs, respectively). Individual effectors were analyzed for functional dif-
ference and cytotoxicity. In murine model, we also checked the same methods
for the phenotypes of T cell exhaustion and tumor challenging test using EG7-
EL4 cell line (expressing the OVAp) in adoptively transferred OT-1, thy1.1 Teff
N, Teff M and activated TILs T to C57BL6 mice.
Results: In vitro stimulation of human naïve, memory, and TIL CD8+ T cells
using typical anti-CD3/CD28 antibodies were able to generate phenotypically
homogenous populations of CD62LloCD44hiOX40hiCD27hi cells. Notably, pro-
liferation and total yield after the in vitro expansion were far greater in NTeff
cells than for MTeff and TILeff cells, which was well correlated with the enhanced
telomere length of NTeff cells compared to the latter two populations. In line
with the longer telomere length, NTeff cells exhibited significantly less amounts
of T cell exhaustion markers, PD-1, CTLA-4 and KLRG-1, than those of MTeff
and TILeff cells, and moreover, acquired distinct expression patterns of mem-
ory-promoting transcription factors, with T-bet and Eomes being highly induced
in a rapid, sustainable manner. With regard to tumor-induced immune-suppres-
sion, interestingly, NTeff cells appeared to have lower expression of Foxp1, a
transcription factor promoting T cell quiescence, and were refractory to apop-
tosis upon TGF-β conditioning, implying a better survival potential. As with in
vitro stimulated human T cells, in vitro priming of murine naïve CD8 T cells
using high doses of IL2 were also found to be effective for generating potent
effector cells that can exert tumor-specific cytotoxic activity.
Summary/Conclusions: Of CD8 T cell pools that are different in their activation
states, naïve cells other than pre-existing effector/memory and TIL cells were better
poised to develop into potent effector cells after in vitro stimulation, which provide
an implication for rational design of adoptive immunotherapy against cancer.
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SYNERGISTIC KILLING EFFECT OF A NOVEL TRIPLE-REGULATED
ONCOLYTIC ADENOVIRUS CARRYING PROGRAMMED CELL DEATH 5
GENE AND DAUNORUBICIN ON HUMAN LEUKEMIC CELLS
QM Yao1, J Zhou1, Y Chang1, JL Li1, YZ Wang1, QJ Qian2, HP Wu2, LF Li2,
YH Chen1, XJ Huang1, GR Ruan1,*
1Institute of Hematology, Peking University People’s Hospital, Beijing, 2Laboratory
of Viral and Gene Therapy, Second Military Medical University, Shanghai, China
Background: The expression levels of programmed cell death 5 (PDCD5) are
down-regulated in many malignancies. A novel triple-regulated conditionally
replicating adenoviruses (CRAd) carrying PDCD5 gene expression cassette,
SG611-PDCD5, alone could inhibit tumor growth in vitro and in vivo and protect
selectively the normal cells.
Aims: The purpose of this study was to investigate the synergistic killing effect
of SG611-PDCD5 and low-dose daunorubicin (DNR) on human leukemic cells
in vitro and in vivo.
Methods: The antitumor efﬁcacy was characterized in several leukemic cell
lines in vitro and in xenograft models of human leukemic cell line in nude mice.
A panel of leukemic cells was treated with different concentrations of DNR
alone or in combination with different multiplicities of infection (MOI) of SG611-
PDCD5. The cell viability was determined by using CCK-8 assay. Apoptosis
was detected in whole living cells using flow cytometry or in parafﬁn-embedded
tumor tissues using the TUNEL kit.
Results: Combined SG611-PDCD5 and low-dose DNR showed synergetic
effects in inhibiting the proliferation of human leukemic cell lines K562, MEG-
01, KG-1a and TF-1. Synergistic effects in inducing apoptosis were observed
both in K562 cells in vitro and in tumor tissues from xenograft models of K562
cells in nude mice. In K562 cells, the apoptotic percentages of SG611-PDCD5
at an MOI of 240 pfu/cell in combination with 0.12 ug/ml DNR were 72.5%, sig-
nificant higher than that of SG611-PDCD5 alone (49.4%) or DNR alone (16.7%).
TUNEL assay showed significantly more apoptotic cells in the SG611-PDCD5
plus DNR group than in SG611-PDCD5 group or in DNR group (25.0, 12.5 and
7.8 apoptotic cells/field, respectively, P<0.05). As shown in vivo experiment
(Figure1), the tumor sizes were signiﬁcantly decreased in combined treatment
group on days 8 and 10 after treatment than those in DNR alone and SG611-
PDCD5 alone (all P<0.05). Tumor sizes in the control, DNR, SG611-PDCD5
and DNR plus SG611-PDCD5 groups were 175.9±82.5, 80.9±42.8, 51.6±17.4,
and 27.6±11.9 mm3 on day 10, respectively.
Figure 1.
Summary/Conclusions: Combined treatment of SG611-PDCD5 and DNR
achieves synergistic effects in inhibiting human leukemic cell growth in vitro
and in vivo. This study may lead to development of new strategies for effective
leukemia treatment with a potential reduction in systemic toxicity.
E1120
TRIPLE-REGULATED ONCOLYTIC ADENOVIRUS-MEDIATED VSTM1
OVEREXPRESSION EXHIBITS POTENT ANTITUMOR ACTIVITY ON
COMMON HUMAN LEUKEMIC CELL LINES
J Zhou1, QM Yao1, JL Li1, Y Chang1, T Li2, WL Han2, QJ Qian3, HP Wu3,
LF Li3, XJ Huang1, GR Ruan1,*
1Institute of Hematology, Peking University People’s Hospital, 2Department of
Immunology, Peking University Center for Human Disease Genomics, Beijing,
3Laboratory of Viral and Gene Therapy, Second Military Medical University,
Shanghai, China
Background: VSTM1 (V-set and transmembrane domain-containing 1), as a
potential myeloid differentiation antigen gene, is downregulated in bone marrow
cells from myeloid leukemia patients. Restoration of VSTM1 expression inhib-
ited myeloid leukemia cells’ growth. VSTM1 might provide a potential target for
the diagnosis and treatment of leukemia.
Aims: The purpose of this study was to construct a triple-regulated oncolytic
adenovirus carrying VSTM1 gene expression cassette, SG611-VSTM1, and to
explore its antitumor efﬁcacy on human leukemic cell lines.
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Methods: In SG611-VSTM1, the E1a gene with a deletion of 24 nucleotides
within CR2 region was controlled under the human telomerase reverse tran-
scriptase promoter, the E1b gene expression was directed by the hypoxia
response element, whereas the VSTM1 gene was controlled by the
cytomegalovirus promoter. The insertion and orientation of all recombined plas-
mids were confirmed by restriction enzyme digestion and polymerase chain
reaction (PCR). The relative VSTM1 expression level in human leukemic cell
line K562 after infection with SG611-VSTM1 was detected by real-time quan-
titative PCR (RQ-PCR) and western blot. The tumor-selective replication of
this virus and its antitumor efﬁcacy were characterized in several leukemic cell
lines with different multiplicities of infection (MOI) in vitro. Cell viability was
detected by using Cell Counting Kit-8 (CCK-8). Cell apoptosis was analyzed
by flow cytometry (FCM).
Results: A triple-regulated oncolytic adenovirus carrying VSTM1 gene expres-
sion assette, SG611-VSTM1, was completed and confirmed. VSTM1, hTERTp,
HRE, skeleton and fiber 11 of recombinant adenovirus SG611-VSTM1 were
successfully amplified. SG611-VSTM1 expressed VSTM1 with high efficiency
in leukemic cells as compared with SG611 (P<0. 001). The expression level of
VSTM1 increased gradually along with the increase of MOI. In CCK-8 assay,
the cell viabilities were decreased gradually along with the increase of MOI in
leukemic cells with SG611-VSTM1 in comparison with SG611, while the cell
viabilities were maintained a relatively higher level in the normal cell lines BJ
(about 50%) and L-02 (about 60%) with SG611-VSTM1. Similarly, the proapop-
totic effect of SG611-VSTM1 on leukemic cells was superior to SG611. In K562
cells at 48 h after infection (Fig.1), the apoptotic percentage of SG611-VSTM1
at a MOI of 40 and 160 pfu/cell were 19.3% and 70.9%, significantly higher
than that of SG611 (11.0% and 46.6%), respectively.
Figure 1. Apoptosis of K562 cells infected with SG611-VSTM1 or SG611.
A: at 48 h after infection; B: at 72 h after infection. The apoptotic percent-
age was increased gradually along with the increase of MOI and infection
time prolonging, especially in the group treated with SG611-VSTM1.
Summary/Conclusions: It is concluded that the triple-regulated adenovirus
of SG611-VSTM1 containing the VSTM1 has been successfully established
with high VSTM1 expression level in leukemic cells. SG611-VSTM1 holds an
increase of anticancer efﬁcacy and might be an improvement of the safety as
a new anticancer agent.
E1121
COMBINED ISOLATION OF MULTI ANTIGEN SPECIFIC T CELL PRODUCTS
CONTAINING NAÏVE AND/OR MEMORY VIRUS-SPECIFIC T CELLS AND
T CELLS SPECIFIC FOR TUMOR ASSOCIATED AND MINOR
HISTOCOMPATIBILITY ANTIGENS
M Roex1, J Matamoros Luna1, L Hageman1, E van Egmond1, S Veld1, E van Liempt1,
C Hoogstraten1, L Germeroth2, P van Balen1, S Halkes1, JF Falkenburg1,
I Jedema1,*
1Hematology, LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, Netherlands,
2Juno Therapeutics, Goettingen, Germany
Background: T cell depleted allogeneic stem cell transplantation (aIIoSCT)
followed by a donor lymphocyte infusion (DLI) is a potential curative treatment
for patients with hematological malignancies. However, between the aIIoSCT
and the DLI patients are vulnerable to viral infections and disease relapses.
Within a clinical phase I/II study in the EU FP7 program T-control we isolate
and adoptively transfer multi-antigen specific T-cell products to prevent these
complications. Therefore, we isolate donor T-cells directed against HLA-A1,
A2, A24, B7, and/or B8-restricted peptides of CMV, EBV and Adenovirus and
HLA-A2-restricted peptides from the tumor-associated antigens (TAA) NY-eso,
WT-1, RHAMM, PRAME and proteinase 3, and the minor histocompatibility
antigen (MiHA) HA-1h. Due to the relatively high precursor frequency of virus-
specific T cells in seropositive donors, memory virus-specific T cells can be
easily isolated.
Aims: To investigate the presence and functional activity of the specificities
with a very low precursor frequency, e.g. TAA and MiHA specific T cells, and
virus specific T cells from seronegative donors.
Methods: HLA-A2, B7, and/or B8-positive CMV seronegative donors (n=5)
and EBV seronegative donors (n=2) were selected for isolation of CMV, EBV
and AdV-specific T cells. From 4 HLA-A2 positive donors TAA and MiHA specific
T cells were isolated. The reversible HLA/peptide streptamer and magnetic
nanobead technique (Juno) was used for the isolation out of 1-2*10^9 donor
PBMC, using all relevant streptamers according to the HLA-type of the donor.
The positive fractions were non-specifically expanded using PHA, IL-2 and
allogeneic feeder cells. The presence of the different specificities was assessed
10-14 days after the isolation by tetramer staining. To confirm the presence of
the invisible very low frequency T cell specificities, subsequent enrichment and
expansion rounds were performed until populations were visible. Specificities
that were present in a frequency >1% were clonally expanded and tested for
their functional potential.
Results: After 2 or 3 enrichment and expansion rounds, we were able to demon-
strate specific T cell populations for 6 CMV specificities from 4 seronegative
donors (pp65 A2 NLV (3x), pp65 B7 TPR, 1E-1 A2 VLE, 1E-1 B8 QIK) and 4
EBV specificities from 2 seronegative donors (BMLF-1 A2 GLC, EBNA-3a B7
RPP (2x), BZLF-1 B8 RAK). The CD8/tetramer positive clones from two CMV
specificities (pp65 A2 NLV and pp65 B7 TPR) and one EBV specificity (EBNA-
3a B7 RPP) were tested for antigen specific reactivity measured by cytokine
release (IFN-gamma and GM-CSF) after 24 hours of stimulation with TAP defi-
cient T2 cells and/or allogeneic EBV-LCL exogenously loaded with the relevant
peptide. This analysis revealed the presence of clones of high avidity recognizing
up to 10^-9M peptide on T2 cells and 10^-8M peptide on allogeneic EBV-LCL.
Besides this, all mentioned TAA and MiHA specificities could be isolated from
all four HLA-A2 positive donors after 2 to 4 enrichment and expansion rounds,
and comprised clones with a range of different functional avidities.
Summary/Conclusions: In conclusion, the HLA/peptide streptamer technology
allows the simultaneous isolation of multi antigen specific T cell products con-
taining not only highly frequent virus-specific memory T cells, but also EBV and/or
CMV specific T cells from the naïve T cell repertoire of seronegative donors, as
well as TAA and MiHA specific T cells with differential functional avidities.
E1122
THE IGE REPERTOIRE IN HEALTHY, NON-ALLERGIC INDIVIDUALS: IMPLICATIONS
FOR EFFICIENT ALLERGEN DESENSITATION IMMUNOTHERAPY
M Koning*, I Trollmann, M Griffioen, H Veelken
Department of Hematology, Leiden University Medical Center, Leiden, Nether-
lands
Background: Type I allergic disease is a hypersensitivity reaction mediated
by allergen-specific IgE. Allergen desensitation immunotherapy consists of
serial injections of increasing doses of the allergen. A possible mechanism for
the restriction of the severity of type I allergy by desensitation is the induction
of allergen-specific neutralizing antibodies of non-IgE isotype. It is unclear
whether allergen-specific IgG clones in desensitised individuals have been
recruited form the naive repertoire or from pre-existing clones from which the
IgE clones originated. The largest reported IgE repertoire from a single person
comprises 32 immunoglobulin sequences. 
Aims: To characterise the IgE repertoire in healthy donors in-depth by an unbi-
ased approach. 
Methods: Peripheral blood CD19+ cells from six healthy donors were isolated
by magnetic bead separation and divided into aliquots of 2x106 cells. For each
donor, mRNA was amplified from 5 aliquots by ARTISAN PCR, an anchored
RT-PCR primed on constant immunoglobulin regions and employing a tem-
plate-switching reverse transcriptase. ARTISAN PCR was performed in parallel
to obtain IgE, IgG, and IgM libraries. PacBio sequencing of the resulting 15
amplicon libraries per donor yielded a median of 284 (range: 100-743) full-
length sequences/aliquot and 27500 sequences in total. 
Results: A median of 261 (range: 175-358) unique IgE sequences were
obtained per donor. 9.1-61.8% of individual IgE sequences were represented in
≥2 aliquots of the same donor. In contrast, 1.4-7.8% IgM and 5.7-16.3% IgG
sequences, respectively, were represented in multiple aliquots. 29 unique VDJ
sequences were identified in both IgM and IgG compartments. All IgE sequences
were strictly restricted to their isotype. Somatic mutation loads per sequence
differed significantly between IgE (median: 5.6%), IgM (0.3%), and IgG (8.3%).
Intraclonal sequence diversity in IgE clones was predominantly due to silent
framework region mutations. IGHV3-11, IGHV3-9, and the IGHV3 family were
significantly overrepresented in IgE compared to IgM/IgG. IGHV3-30, IGHV3-
33, IGHV4-59, and IGHV2, 4, 5, and 6 families were underrepresented.
Summary/Conclusions: These data provide a reference for investigations of
the IgE repertoire in allergy and parasitology. In healthy donors, the peripheral
IgE repertoire is less diverse than IgM/IgG, displays a strong IGHV bias, and
carries an intermediate mutation load without evidence for ongoing affinity mat-
uration. IgE and IgG/IgM repertoires apparently do not overlap. The lack of
overlap between IgE sequences and expanded IgG clones, as well as the high-
er mutation load of the latter, suggest that most IgE sequences have undergone
class switch recombination directly from IgM, rather than from class-switched
expanded IgG clones as intermediates. These findings suggest that desensi-
tisation strategies should focus on recruiting novel allergen-specific cells from
the naïve B-cell compartment, rather than attempting to activate and expand
existing IgG-expressing B cells that belong to the same B-cell clone and have
the identical antigen specificity as the allergy-causing B-cells that have under-
gone alternative or subsequent class switching to IgE.
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THE EFFECTS OF VARIOUS BLOOD PROTEINS ON THE ZETA POTENTIAL
OF POLYMER NANOPARTICLES AND PROTEIN CORONA FORMATION:
AN ANALYSIS BY TUNABLE RESISTIVE PULSE SENSING
E Blundell1, M Healey1, E Holton1, M Sivakumaran2, M Platt1,*
1Chemistry, Loughborough University, Loughborough, 2Haematology, Peter-
borough City Hospital, Peterborough, United Kingdom
Background: Nanoparticles are increasingly used as delivery vehicles for tar-
geted drug delivery, gene delivery, imaging and theranostics. Upon introduction
of nanoparticles into biological fluids such as blood, the particles interact with
the constituents of the environment, in particular with proteins. The interaction
of nanoparticles with the proteins leads to formation of a protein-corona and
change in the surface charge of the particles. These changes significantly affect
the pharmacokinetic, pharmacodynamic and toxicological properties of the
nanoparticles. Tunable Resistive Pulse Sensing (TRPS) technology, based on
Coulter principle, enables particle-by-particle measurement of the size and zeta
potential of nanoparticles during their passage through a tunable pore (Lang-
muir (2016) 32,1082-1090.
Aims: To ascertain the effects of three predominant proteins in blood, namely
albumin, immunoglobulin and fibrinogen, in biologically relevant concentrations
on the zeta potential of carboxylated polymer nanoparticles (CPNPs) in saline,
serum and plasma at room temperature and 37oC using TRPS
Methods: The particle size and zeta potential of carboxylated polymer nanopar-
ticles were studied in phosphate buffered saline, albumin (40g/l), immunoglob-
ulin (20g/l), fibrinogen (4g/l), normal human serum and normal human plasma
at room temperature and 37oC using TRPS (qNano, Izon Sciences, Oxford,
UK). The kinetics of the protein corona reorientation for particles initially placed
into serum and then adding 5%(V/V) plasma was then studied by monitoring
changes in size and zeta potential of the particles using qNano.
Results: We observed a significant difference in distributions and zeta values
between room temperature and 37oC assay. The effect was protein dependent,
and the largest difference between the two temperatures was recorded for the
γ-globulin protein where the mean zeta potential changed from -16.7 mV to -
9.0 mV for 25 and 37 oC, respectively. This method was further applied to mon-
itor particles placed into serum and/or plasma. A temperature dependent
change was again observed with serum showing a 4.9 mV difference in zeta
potential between samples incubated at 25oC and 37oC, this shift was larger
than that observed for samples in plasma (0.4 mV). Finally we monitored the
kinetics of the corona reorientation for particles initially placed into serum and
then adding 5%(V/V) plasma.
Summary/Conclusions: The technology presented offers an interesting insight
into protein corona structure and kinetics of formation measured in biologically
relevant solutions i.e. high protein, high salt levels and its particle-by-particle
analysis gives a measure of the distribution of particle zeta potential that may
offer a better understanding of the behaviour of nanoparticles used for
drug/gene delivery in blood.
Hematopoiesis, stem cells and microenvironment
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EXPANDING THE KNOWLEDGE OF BLOOD TRANSCRIPTOME: CIRCULAR
RNAS IN HEMATOPOIESIS
A Bonizzato1,*, E Gaffo2, S Bortoluzzi2, G te Kronnie1
1Women and Children’s Health, 2Molecular Medicine, University of Padova,
Padova, Italy
Background: Circular RNAs (circRNAs) are a class of covalently closed RNA
molecules generated by back-splicing joining exons in a non-collinear way. cir-
cRNAs have been found throughout the tree of life and are conserved in mam-
mals. As reported circRNAs may decoy miRNAs thus de-repressing miRNA
targets and regulating cellular processes and may interact with RNA-binding
proteins and other RNAs. High stability and complex cell type- and differentia-
tion-specific expression patterns make circRNAs promising disease biomarkers.
In cancer circRNAs are highly relevant since they associate with cancer miR-
NAs and regulate cancer-related pathways. Moreover, specific circRNAs exhibit
anti-cancer effects, whereas others discriminate malignant cells from healthy
ones. Recent studies demonstrated that the circRNA number and expression
level in normal blood is reproducible and higher than in other tissues and incip-
ient observations detected circRNAs in B-ALL.
Aims: We aim to detect, discover and characterize circRNAs expressed during
hematopoiesis in order to expand the knowledge of transcriptome complexity
and variations in normal differentiation to set the basis for circRNA studies in
hematologic malignancies.
Methods: CircRNA detection grounds on identification of RNA-seq reads that
contain a back-splice junction. Different programs rely on slightly different
approaches, such as using a pre-compiled dataset of all possible exons of each
gene coupled in reverse order, or by de novo identifying the back-splice junction
from signals in the alignment data coupled with signals of canonical splicing.
Combining the output of at least two programs increases the accuracy of true
circRNA detection, as suggested by recent literature. Poly-A enriched RNA-seq
data of eight cell populations of the hematopoietic tree (Figure 1A) were collected
(HSC, MPP, CMP, CLP, GMP, MEP, MK, EB cells; three biological replicates per
cell type; ID: EGAS00001000284, by Chen L et al., 2014, Science).
Results: A bioinformatics pipeline for detection and analysis of cirRNAs from
RNA-seq data was set up that brings together published circRNA detection
tools (CIRI, find_circ and testrealign.x) and custom made scripts, with a modular
design expandable to novel programs. Preliminary analyses performed with
CIRI allowed us to detect 11,079 putative circRNAs expressed during
hematopoiesis, of which 41% are exonic, 42% are intronic and 17% fall in
regions annotated as intergenic (Figure 1B). Expressed circRNAs are associ-
ated to 4,317 known genes, 58% of which produce only one circRNA, whereas
837 (19%) genes produce two different circular isoforms each, and 959 (22%)
even more than three isoforms. The large majority (87.5%) of circRNAs was
detected only in one cell type, and in each cell population on average 15% of
the total detected circRNAs is present. We identified 20 circRNAs expressed
in all cell stages (Figure 1C) and defined several patterns of circRNAs that are
up or down regulated in less differentiated cells compared to more mature
stages (e.g. HSC vs CMP), specifically in the lymphoid compared with the
myeloid branch of the tree (CMP vs CLP) and, through the myeloid lineage,
from CMP to more and terminally differentiated cells.
Figure 1.
Summary/Conclusions: Recent studies have unveiled a great potential of cir-
cRNAs in hematology. Our results, although preliminary, confirm that a high
number of circRNAs are expressed during hematopoietic cell differentiation.
We identified circRNAs expressed by all cell stages in the dataset, and several
expression patterns that seem to be specific of stem cells, of differentiated
cells, or of cellular lineages. We plan to conduct additional RNA-seq data analy-
ses with different approaches to enrich the set of detected circRNAs in true
positive hits, in order to validate them, to confirm some of the more striking
expression variations observed and to predict functions and interactions of
expressed circRNAs.
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THE APC/C COACTIVATOR CDH1 CONTROLS MAINTENANCE OF THE
HEMATOPOIETIC STEM CELL POOL IN VIVO
S Kreutmair*, D Ewerth, A Gengenbacher, J Duyster, R Waesch, AL Illert
Hematology, Oncology and Stem Cell Transplantation, University medical cen-
ter Freiburg, Freiburg, Germany
Background: Cdh1 is a co-activator of the anaphase-promoting complex
(APC/C) and highly active during G1 to target cell cycle proteins for proteasomal
degradation thereby regulating cell proliferation. Recently, evidence accumu-
lates, that Cdh1 may play a role in proliferation, self-renewal and multilineage
differentiation of hematopoietic stem cells (HSCs).
Aims: Our objective was to examine the functional role of Cdh1 in the
hematopoietic compartment in vivo.
Methods: We used a murine transplantation model in combination with target-
ed genetic RNAi approach for Cdh1 deletion in a competitive transplantation
(TX) assay. Therefore, 5-FU enriched murine bone marrow cells (BMCs) were
lineage depleted and retrovirally infected either with pLMPmiRCtrl or pLMP-
miRCDH1. Primary BMCs and equal proportions of stem and progenitor cells
with significant Cdh1 knockdown were transplanted in competition with non-
infected wildtype BMCs into lethally irradiated wildtype recipients.
Results: Peripheral blood (PB) chimerism of recipient mice revealed a signif-
icant higher ratio of EGFP+ leukocytes in recipients of pLMPmiRCDH1 BMCs
compared to controls (p=0.009). Moreover, spleen and BM chimerism showed
significantly enhanced repopulation of Cdh1 knockdown cells at week 3 com-
pared to pLMPmiRCtrl BMC recipients (p=0.004). Furthermore, Cdh1 knock-
down leads to a significant decrease of apoptotic cells compared to control
BMCs. Additionally, a highly significant decrease in the Sub-G1 cell population
in Cdh1 knockdown BMC recipients confirms enhanced viability of Cdh1 knock-
down cells. In contrast to apoptosis alterations, no obvious difference in cell
cycling could be monitored between sorted EGFP+ pLMPmiRCtrl or
pLMPmiRCDH1 infected BMCs of recipient mice 3 and 8 weeks after TX by
dynamic 2-dimensional EdU/FxCycle violet assays. Interestingly, the difference
in chimerism vanished during the course of the TX assay. To evaluate differ-
ences in the repopulation capacity of Cdh1 knockdown and control BMCs in
transplanted animals, FACS analysis were performed and showed a significant
reduction of LK- (lineage-, cKit+, Sca1-) and LSK- (lineage-, cKit+, Sca1+) cell
frequency within pLMPmiRCDH1 BMC recipient mice compared to controls at
the end of TX indicating that Cdh1 knockdown leads to an initial increase in
repopulation capacity followed by exhaustion of hematopoietic stem and pro-
genitor cells in a competing situation. To examine whether Cdh1 modulates
lineage differentiation of HSCs we performed FACS analyses and detected a
significantly higher proportion of B-cells in recipient mice transplanted with
pLMPmiRCDH1 BMCs compared to control animals. Analyses of the myeloid
compartment displayed differences with reduced levels of granulocytes as well
as monocytes in the PB of Cdh1 knockdown transplanted BMCs compared to
the pLMPmiRCtrl group. T-cells were not affected significantly by Cdh1 knock-
down, at least in this short transplantation setting.
Summary/Conclusions: Taken together, Cdh1 knockdown leads to enhanced
viability as a consequence of less susceptibility to apoptosis in vitro and in vivo,
suggesting that Cdh1 plays an important role in maintaining the stem cell num-
bers within the HSC pool. Furthermore, Cdh1 knockdown regulates lineage dif-
ferentiation in favor to the B-cell differentiation, whereas the myeloid lineage is
repressed in Cdh1 knockdown cells in competitive transplantation experiments.
E1126
THE TRANSCRIPTION FACTOR C/EBPG IS RESPONSIBLE FOR RAPID
PRODUCTION OF NEUTROPHILS DURING EMERGENCY GRANULOPOIESIS
M Kardosova1,*, P Zjablovskaja1, T Brdicka2, D G. Tenen3,4, M Alberich-Jorda1
1Laboratory of Hematooncology, 2Laboratory of Leukocyte Signalling, Institute
of Molecular Genetics, Prague, Czech Republic, 3Cancer Science Institute of
Singapore, National University of Singapore, Singapore, Singapore, 4Harvard
Stem Cell Institute, Harvard University, Boston, United States
Background: CCAAT/enhancer binding protein γ (C/EBPγ) is a member of the
C/EBP family of myeloid transcription factors, which are known as master regu-
lators of hematopoiesis. Recently, it has been shown that increased C/EBPγ lev-
els contribute to the block of neutrophilic differentiation in acute myeloid leukemias
characterized by C/EBPα hypermethylation. Hovewer, the function of C/EBPγ in
normal and stress-induced hematopoiesis remains largely unknown.
Aims: In this study we investigate the role of C/EBPγ in hematopoiesis both in
steady-state and under stress conditions.
Methods: We generated a C/EBPγ conditional knockout murine model, which
allows tissue and time specific excision of C/EBPγ. These mice were crossed
to Vav-1Cre deleter strain to excise C/EBPγ specifically in the hematopoietic
system from early embryonic stages. We employed C/EBPγ f/f Vav-1Cre- and
C/EBPγ f/f Vav-1Cre+ mice, refered here as wt and C/EBPγ ko respectively.
First, frequency of distinct hematopoietic lineages in bone marrow, spleen, and
blood of C/EBPγ ko mice was determined by flow cytometry. Next, to elucidate
whether C/EBPγ is necessary for stress induced granulopoiesis, in vivo admin-
istration of different stimuli, including lipopolysacharide (LPS), granulocyte
colony-stimulating factor (G-CSF) and Candida albicans, was used to model
bacteria- or candidemia-induced emergency granulopoiesis. Mice were sacri-
fied and examined 24 hours after infection since we focused on early phases
of granulopoiesis. Differential cell counting and flow cytometric analysis were
performed to assess whether C/EBPγ is involved in demand-accelerated neu-
trophilic production.
Results: Mice lacking C/EBPγ within the hematopoietic system presented par-
tially reduced levels of blood neutrophils (wt 1.438x106/ml -/+ 0.114 vs CEBPγ
ko 0.988x106/ml -/+ 0.078, p=0.0021), although this reduction did not result in
any signs of sickness. Analysis of other cell populations, including progenitors
and hematopoietic stem cells, did not reveal further differences between wt
and C/EBPγ ko mice. These data suggest that hematopoietic-specific genetic
ablation of C/EBPγ is not critical for steady-state hematopoiesis. Since C/EBPγ
forms heterodimers with another C/EBP member, C/EBPβ, we determined
whether C/EBPγ can modulate the function of this transcription factor. C/EBPβ
is critical for emergency granulopoiesis, and therefore we investigated whether
the absence of C/EBPγ would affect this process. Deletion of C/EBPγ did not
compromise the ability of the hematopoietic system to respond to G-CSF or
LPS, since flow cytometric analysis revealed similar hematopoietic response
in C/EBPγ ko mice in comparison to wt control animals. Interestingly, C/EBPγ
ko mice showed reduced numbers of blood neutrophils during early phases of
candidemia (wt 2.44x106/ml +/- 0.78, vs CEBPγ ko 1.55x106/ml +/- 0.59,
p=0.031). In addition, the distribution of different developmental stages within
the neutrophilic compartment in bone marrow was perturbed, leading to the
accumulation of more immature granulocytic populations and reduced percent-
age of mature neutrophils. Altogether, these results indicate that C/EBPγ pro-
motes accelarated neutrophilic production during early phases of emergency
granulopoiesis upon Candida stimulation.
Summary/Conclusions: Taken together, our data unravel C/EBPγ as a player
in the expansion of granulocytes during early phases of candidemia-induced
emergency granulopoiesis. On the other hand, C/EBPγ appears to be dispen-





TELOMERASE MRNA IN T CELL LEUKEMIA CELL LINE (JURKAT)
DERIVED EXOSOMES TRANSFORMS NONMALIGNANT FIBROBLASTS
INTO TELOMERASE POSITIVE CELLS
O Uziel1, A Gutkin1, E Beery1, J Nordenberg1, M Pinchasi1, H Goldvaser2,
S Henick1, M Goldberg3, M Lahav4,*
1FMRC, Beilinson Hospital and Tel Aviv University, 2Institute of Oncology,
Davidoff Cancer Center Beilinson Hospital, Petah-Tikva, 3Department of Genet-
ics, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem,
4FMRC, 5Institute of Hematology, Davidoff Cancer Center Beilinson Hospital
and Tel Aviv University, Petah-Tikva, Israel
Background: Exosomes are small (30-100nm) vesicles secreted from all cell
types serving as inter- cell communicators by affecting biological processes in
“recipient” cells upon their uptake. Telomerase is transcriptionally repressed in
non malignant somatic cells thus enabling cellular senescence caused by
telomere shortening. Telomerase activation is a hallmark of cancer cells pro-
viding them with endless replicative potential. Telomerase activation is associ-
ated also with other major cellular changes such as resistance to DNA damage,
protection from apoptosis and others. We demonstrate that hTERT mRNA is
transferred via exosomes from Jurkat cells into telomerase negative primary
fibroblasts. The mRNA is translated into active telomerase causing several
major changes in those cells. These findings have potential implications for
tumor cells-microenvironment interactions.
Aims: To assess the presence of hTERT mRNA, the transcript of the enzyme
telomerase, in exosomes secreted from Jurkat cells; to study the possible
effects of this transcript on the phenotype of fibroblasts cells upon exposure to
exosomal hTERT mRNA.
Methods: Exosomes were isolated by exosome isolation kit (exoquick). Real
time PCR was performed to assess the hTERT mRNA levels in exosomes and
in the cells. Verification of exosome isolation and telomerase levels were esti-
mated by Western blotting. Telomerase activity was assessed by Real time
PCR based TRAP assay. Cellular proliferation and senescence status were
assessed by Trypan blue exclusion and b-Galactosidase activity assays,
respectively. Nuclear morphology was visualized after DAPI staining. DNA
damage response was evaluated by counting gH2AX foci accumulation fol-
lowing phleomycin insult.
Results: The current study demonstrates for the first time that hTERT mRNA,
the transcript of the enzyme telomerase, is shuttled from “donor” cancer cells
via exosomes into “recipient” telomerase negative fibroblasts, where it is trans-
lated into a fully active enzyme. All tested cells secreted exosomal hTERT
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mRNA in accordance with the endogenous levels of their hTERT mRNA and
telomerase activity. A non-cancer fibroblasts cell line in which telomerase was
ectopically expressed secreted relatively high levels of exosomal hTERT mRNA
as well. A similar ex-vivo shuttle of exosomal hTERT mRNA isolated from the
serum of a patient with pancreatic cancer into primary fibroblasts was demon-
strated as well. Telomerase activity induced phenotypic changes in the recipient
fibroblasts including extension of life span and postponing senescence. In addi-
tion, telomerase activity protected the fibroblasts from DNA damage induced
by Phleomycin and also protected from apoptosis, indicating that telomerase
extracurricular activities are also manifested in the recipient cells.
Summary/Conclusions: The shuttle of telomerase from cancer cells into
fibroblasts and the induction of these changes may contribute to the formation
of cancer associated fibroblasts representing a unique aspect of the cross talk
between tumors and their microenvironment. These processes bear a thera-
peutic potential targets and as such serve as a promising research avenue.
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PERIPHERAL BLOOD LEUKOCYTE TELOMERE LENGTH AND RISK OF
INFECTIOUS DISEASE: A PROSPECTIVE STUDY OF 75,919 INDIVIDUALS
FROM THE GENERAL POPULATION
J Helby1,2,3,*, BG Nordestgaard1,2,3,4, T Benfield3,5, SE Bojesen1,2,3,4
1Department of Clinical Biochemistry, 2The Copenhagen General Population
Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev,
3Faculty of Health and Medical Sciences, University of Copenhagen, 4The
Copenhagen City Heart Study, Bispebjerg and Frederiksberg Hospital, Copen-
hagen, 5Department of Infectious Diseases, Hvidovre Hospital, Copenhagen
University Hospital, Hvidovre, Denmark
Background: In the general population, older age is associated with short
leukocyte telomere length and with high risk of infections. In a recent study of
allogeneic hematopoietic cell transplantation for severe aplastic anemia, long
donor leukocyte telomere length was associated with improved long-term sur-
vival in the recipients. These findings suggest that leukocyte telomere length
could possibly be a marker of overall immune competence. However, previous
studies examining this hypothesis among individuals from the general popula-
tion have produced conflicting results.
Aims: We tested the hypothesis that short telomere length in leukocytes is
associated with high risk of infectious disease hospitalization.
Methods: Peripheral blood leukocyte telomere length was measured using
quantitative polymerase chain reaction in 75,919 individuals from the general
population. The participants were followed for up to 23 years.
Results: During follow-up, 9671 individuals were hospitalized due to infections.
Short telomere length was associated with high risk of any infection (hazard
ratio 1.05 per 1000 base pair shorter telomeres; 95% confidence interval 1.03-
1.08), pneumonia (1.08;1.04-1.12) and endocarditis (1.32;1.06-1.66) after
adjustment for other infectious disease risk factors. Telomere length was not
associated with risk of skin infection, urinary tract infection, sepsis, diarrhoeal
disease, meningitis or other infections.
Summary/Conclusions: Short leukocyte telomere length was associated with
high risk of any infection, pneumonia and endocarditis. These findings indicate
that leucocyte telomere length may be a marker of immune competence among
individuals from the general population. Further studies are needed to determine
whether risk of infections in allogeneic hematopoietic cell transplant recipients can
be reduced by considering donor leukocyte telomere length when selecting donors.
E1130
ABNORMAL EXPRESSION OF PYRUVATE KINASE M2 IN MYELOID
DENDRITIC CELLS OF THE PATIENTS WITH SEVERE APLASTIC ANEMIA
S Zonghong*, C Liu, M Zheng, W Qi, R Fu, H Wang, Y Wu
Department of Hematology, General Hospital of Tianjin Medical University, Tian-
jin, China
Background: Severe aplastic anemia (SAA) is a hematologic disease charac-
terized by pancytopenia with severe bone marrow failure. dendritic cells was
found to be an antigen-presenting cell (APC) with a most powerful function.Our
previous studies have demonstrated that activated myeloid dendritic cells
(mDCs) increased in the bone marrow of SAA patients, which could accelerate
the polarization of Th1 from Th0 cells, and then initiate the cellular immunity
which played an important role in the primary stage of the immune response.
Aims: We further analyzed the protein components of mDC in SAA and
explored the possible pathogen that activated mDC.
Methods: Basing on our previous research, we further analyzed the protein com-
ponents of mDC in SAA as well as normal control, furtherly we applied both FACS
western and qRT - PCR technology from a perspective of mRNA and protein to
validate our discovery.to explored the possible reason that activated mDC.
Results: After 7 days of culture, the purity of mDC cells was more than 90%
determined by flow cytometry. Results revealed that expression of pyruvate
kinase M2(PKM2) were enhanced in mDCs from SAA patients at an early stage
of the onset. Concurrently, the level of PKM2 in mDC of SAA patients
(59.1±15.8)% was conspicuously higher than that in normal control
(32.7±20.2)% at the protein level. We measured the levels of mRNA of PKM2
genes in our patient samples and identified significantly higher expression of
PKM2 in the SAA untreated group (1.50±0.84) relative to the recovering group
(0.81±0.24) and the control group (0.32±0.11, p<0.05). In addition, a similar
phenomenon was seen by Western blot. As expected, the percentage of PKM2
in mDCs of SAA patients appeared to be strongly correlated with proliferous
degree of bone marrow. The percentage of PKM2 in mDCs in patients with
SAA was positively correlated with the proportion of reticulocytes absolute neu-
trophil counts and quantity of mDCs in peripheral blood. Additionally, the ratio
of CD4+ T-helper lymphocytes to CD8+ T-suppressor lymphocytes (TH/S) was
correlated with the percentage of PKM2 in mDCs. However, no significant dif-
ference in platelet counts was detected in SAA patients.
Figure 1. The purity of mDC cells was more than 90% determined by flow
cytometry.
Summary/Conclusions: These findings demonstrated that dysregulation of
PKM2 expression and activation in mDCs might exert an impact on the immune
status of SAA patients by enhancing the cellular function of mDC.
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ANALYSIS OF T CELL SUBSETS IN G-CSF PRIMED BONE MARROW FOR
ALLOGENEIC STEM CELL TRANSPLANTATION AND ITS ASSOCIATION
WITH CHRONIC GVHD INCIDENCE
MM Rivera Franco1,*, D Gomez Martin2, C Balderas Delgado1, J Merayo Chalico2,
JC Alcocer Varela2, E Leon Rodriguez1
1Hematology-Oncology, 2Rheumatology, Instituto Nacional de Ciencias Med-
icas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico
Background: There is a subset of T cells which modulate the immune system,
maintain tolerance to self-antigens, and abrogate autoimmune disease, called
regulatory T cells (Tregs). These cells generally suppress or downregulate
induction and proliferation of effector T cells. Regulatory T cells come in many
forms with the most well-understood being those that express CD4, CD25, and
Foxp3 (CD4+CD25+ regulatory T cells). Mouse models of bone marrow trans-
plantation as well as some clinical trials, have shown that the administration of
Tregs in combination with the harvested bone marrow prevent and decrease
graft-versus-host-disease (GVHD) and facilitate engraftment. At our institution
the population transplanted with G-CSF primed bone marrow, has a lower inci-
dence of chronic GVHD compared to those transplanted with peripheral blood
and not primed bone marrow. Some microenvironment characteristics of this
hematopoietic stem cells (HSC) source remain unknown, as well as the quan-
titative profile of different T cell subsets in patients who develop chronic GVHD
and those who do not.
Figure 1.
Aims: To analyze the characteristics of G-CSF primed bone marrow, identifying
different T cell subsets, such as Th1, Th2, Th17, and Tregs. in 29 donor sam-
ples, between patients who developed chronic GVHD and those who did not.
Methods: A prospective analysis was performed in 29 G-CSF primed bone
marrow samples from donors from 1999 to 2012. Mononuclear cells were
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defrosted, counted, and viability was assessed by trypan blue exclusion After
a 24 hour resting time (RPMI), mononuclear cells were stimulated with PMA
(50 ng/ml) for 48 hours and cells were harvested and stained for FACS analysis.
Supernatants were collected and measured by Cytometric Bead Array. From
each sample, one million mononuclear cells were permeabilized, fixed, and
stained with CD4-FITC, IL17A-PE, IFN-γ APC, and IL-4 PECy7, and were ana-
lyzed by FACS. All samples were obtained in a BD LSR Fortessa cytometer
and analyzed with the Flow-Jo software. Patients (recipients) demographic
and clinical data were analyzed with support of the software SPSS v.21.
Results: GVHD incidence was reported as following: Ten patients (34.5%) devel-
oped chronic GVHD (10% extensive, and 90% limited), and 16 patients did not
present either. There was no difference in TH1 and TH2 numbers between both
groups, but mononuclear cells from donors of patients who developed chronic
GVHD had a higher percentage of Th17 cells (0.99% vs 0.44%, p<0.001), as
well as decreased Tregs (0.91% vs 2.00%, p<0.001), compared to those who
did not developed GVHD. It was not possible to relate T cell subsets with chronic
GVHD severity since only one patient developed extensive disease.
Summary/Conclusions: With the usage of G-CSF primed bone marrow as a
source of HSC, the incidence of chronic GVHD at our institution was 34.5%.
Patients who develop chronic GVHD are characterized by a pro inflammatory
response with a higher percentage of Th17 cells, as well as a decreased sup-
pressive response characterized by reduced Tregs levels. The low incidence
of chronic GVHD show that G-CSF primed bone marrow is an excellent source
for allogeneic HSC transplantations, and would be useful to compare its lym-
phocyte subset profile and cytokines levels with other HSC sources.
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DYSFUNCTION OF BONE MARROW ENDOTHELIAL PROGENITOR
CELLS FROM SUBJECTS WITH POOR GRAFT FUNCTION FOLLOWING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN
BE IMPROVED BY ATORVASTATIN
M Shi*, Y Kong, Y Song, X Huang
Peking University Institute of Hematology, Beijing, China
Background: Poor graft function (PGF) is a serious complication after allo-
geneic hematopoietic stem cell transplantation (allo-HSCT) and the mecha-
nisms are poorly understood. Murine studies suggest that endothelial progenitor
cells (EPCs) are preferential supporting cells for hematopoietic stem cells
(HSCs) in the bone marrow (BM) microenvironment. Our previous prospective
nested case-control study suggested that a lower frequency of EPCs, which
represent a key cellular component of the BM microenvironment, was an inde-
pendent risk factor for the occurrence of poor graft function after allo-HSCT.
However, the functional role of bone marrow EPCs in the subjects with poor
graft function has never been reported. Moreover, approaches for improving
the dysfunction of bone marrow EPCs in subjects with PGF are lacking. Ator-
vastatin has been reported to improve the mobilization and function of circu-
lating EPCs in a number of diseases, such as heart disease, diabetes, ischemic
stroke and others. Nevertheless, no previous studies have focused on the roles
of atorvastatin on bone marrow-derived EPCs in subjects with poor graft func-
tion following allo-HSCT.
Aims: In this study, we evaluated the function of bone marrow EPCs in subjects
with poor graft function post-allotransplant. Moreover, we investigated whether
atorvastatin could enhance the number and function of bone marrow EPCs
derived from subjects with poor graft function in vitro.
Methods: Three cohorts were included: subjects with poor graft function
(N=15), subjects with good graft function (N=15), defined as persistent suc-
cessful engraftment after allotransplant, and transplant donors as normal con-
trols (N=15). Atorvastatin (0.5nM,5nM,500nM) was administrated to the bone
marrow EPCs in subjects with poor graft function cultured for 7 days. The num-
ber and functions ofCD34(+)/CD133(+)/KDR(+)EPCs were evaluated by flow
cytometry, cell counting, DiI-Ac-LDL and FITC-lectin-UEA-1 double staining,
migration, tube formation test and apoptosis. Reactive Oxygen Species (ROS)
level was evaluated by flow cytometry and DCFH-DA staining. Cell proliferation
was determined by cell counting kit-8 assay. Protein expression for p-p38,p38,
p-akt, akt was measured by flow cytometry and western blots.
Results: Dysfunctional bone marrow EPCs, which were characterized by
decreased migration and angiogenesis and higher levels of reactive oxygen
species and apoptosis, were found in subjects with poor graft function following
allo-HSCT. The phospho-p38 expression was significantly elevated in subject with
poor graft function but all groups showed similar intracellular levels of phospho-
Akt. Furthermore, bone morrow EPCs derived from subjects with poor graft func-
tion were enhanced both quantitatively and functionally by 500nM atorvastatin
treatment in culture on day 7 through down-regulation of the p38 MAPK pathway.
Summary/Conclusions: In summary, the current study is, to our knowledge,
the first to demonstrate the dysfunctions of bone marrow EPCs in the bone
marrow microenvironment of subjects with poor graft function following allo-
HSCT. Moreover, atorvastatin treatment in vitro quantitatively and functionally
improved the bone morrow EPCs derived from subjects with poor graft function
through down-regulation of the p38 MAPK pathway. Our results indicate that
atorvastatin represents a promising therapeutic approach for repairing the
impaired EPCs in subjects with poor graft function post-allotransplant.
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MULTIPOTENT PROGENITOR CELLS AND ACQUIREMENT OF HEMATOPOIETIC
CAPACITY IN THE BONE MARROW OF XENOPUS LAEVIS
Y Tanizaki1,*, Y Mochizuki2, T Aiso1, T Kato1,2
1Faculty of Education and Integrated Arts and Sciences, 2Integrative Bioscience
and Biomedical Engineering, Graduate School of Advanced Science and Engi-
neering, Waseda University, Shinjuku, Japan
Background: Hematopoietic stem cells (HSCs) are characterized by their
capacity for long-term repopulation and multilineage differentiation upon
cytokine stimulation. Thrombopoietin (TPO) is one of the key regulators of HSC
maintenance and platelet production. Previously, we cloned Xenopus laevis
(X. laevis) TPO (xlTPO) and demonstrated that differentiation and proliferation
in thrombocyte progenitors and hematopoietic progenitors are regulated by
xlTPO. Unlike that of mammals, bone marrow (BM) of X. laevis is filled with
adipose cells, and blood cells are mainly produced in the liver. However, func-
tional contribution of fatty marrow for hematopoiesis is unclear, and multipotent
hematopoietic progenitor is not yet identified in X. laevis.
Aims: In this study, we attempted to identify multipotent hematopoietic cells
and evaluate the ability of hematopoiesis in fatty marrow in X. laevis. 
Methods: The suspension cells in X. laevis were cultured in semi-solid culture
system in the presence of xlTPO. Laparotomy was performed in X. laevis under
anesthesia with MS222. The left liver was resected, and cultured with xlTPO
for 24 days. The cultured cells were labeled by PKH26 and autologously trans-
planted by intracardiac injection. After 30 days, the X. laevis were killed and
their right liver was analyzed by FACS. PKH26 labelled cultured cells were
also injected into the blastocoels of X. laevis embryos at stage 8, which have
no immune system. After 3 days, the labeled cells were analyzed by fluores-
cence microscope. For low-temperature exposure, cage containing X. laevis
were transferred to an incubator set at 5°C for 12 days. For micro-computerized
tomography (mCT) analysis, X. laevis were restrained in polystyrene foam
restrainers, and the femurs were imaged by three-dimensional X-ray CT scan.
Results: Hepatic colonies stimulated by xlTPO could be cultured for more than
3 months, during which the cell number reached 1 × 106, indicating that the
cells divided at least 20 times. These colonies expressed erythrocyte-, throm-
bocyte-, leukocyte-, and HSC-specific markers. Moreover, these cells differen-
tiated to thrombocytes and leukocytes in the presence of splenic-conditioned
media. Liver cells obtained by partial hepatic resection were cultured in the
semi-solid culture system in presence of xlTPO, and cells labeled with PKH26
were autologously transplanted. After 30 days, PKH26-positive cells were
detected in the sinusoids of liver and spleen. Flow cytometric analysis showed
that the PKH26-positive cells displayed low forward (FSC) and side (SSC)
scatter and had thin-layered cytoplasm and round nuclei, which are typical fea-
tures of mammalian HSCs. These results indicated that xlTPO regulates pro-
liferation of hematopoietic progenitors, which can be engrafted and differenti-
ated to multiple lineages. To enrich multipotent hematopoietic cells, we gener-
ated anti-xlMPl monoclonal antibodies and showed that anti-thrombocyte anti-
body (T12)-/xlMpl+/FSClow population was enriched in high nuclear/cytoplasm
ratio-hematopoietic progenitors, and the ratio of these cells to all hepatic cells
was 0.28%. Surprisingly, T12-/xlMpl+/FSClow cells were identified in the liver,
spleen, and BM in normal state. Although BM in X. laevis comprises mostly of
adipocytes, large colonies induced by xlTPO were identified in the BM. The
protein expression patterns in these cells overlapped with those in colonies
derived from the liver, demonstrating that multipotent hematopoietic progenitors
were localized in the BM. To explore the hematopoietic capacity in the BM, X.
laevis were exposed to 5°C, which led to pancytopenia. After exposure to low
temperature for 12 days, the numbers of erythrocyte and multipotent progeni-
tors were increased. mCT revealed that femoral bone density was higher than
that before exposure to 5°C, indicating change in the BM microenvironment.
Summary/Conclusions: In conclusion, multipotent hematopoietic progenitors
in X. laevis are enriched in T12-/Mpl+/FSClow cells and these cells are mainly
localized in the liver and BM. These findings suggested that T12-/Mpl+/FSClow
cells in BM is dormant, and changes in the BM microenvironment by low-tem-
perature stimulation induced proliferation of hematopoietic progenitors.
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BONE MARROW STROMAL CELLS FUNCTIONAL CHARACTERISTICS
STUDY IN RECIPIENTS BEFORE ALLO-BMT
N Tcvetkov, I Barkhatov*, E Davydova, A Shakirova, D Romaniuk, O Smykova,
A Borovkova, O Slesarchuk, L Zubarovskaya, B Afanasyev
R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and
Transplantation, First Pavlov Saint Petersburg State Medical University,
St.Petersburg, Russian Federation
Background: The role of the stromal microenvironment in hematopoietic stem
cell transplantation (HSCT) is based on nonlineage-specific effects on prolifer-
ation and differentiation of HSCs. Deficient graft functioning observed in some
cases necessitates development of functional tests for the stromal cells, in
order to provide clinical indications for co-transplanting of hematopoietic and
bone marrow stromal cells (BMSC), and evaluable introduction of alternative
therapeutic approaches.
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Aims: The aim of this study was to investigate the role of bone marrow stromal
cells in the course of donor marrow cells engraftment and their significance in
post-transplant complications.
Methods: The study included clinical observation of the post-transplant course in
ten patients with acute myeloid leukemia (AML) and 7 healthy donors. Bone mar-
row nucleated cells were selectively harvested two weeks prior to BMT, followed
by monolayer culture in alpha-MEM culture medium with 20% fetal bovine serum.
Upon growth of fibroblast-like cell colonies (CFU-F), their hematopoiesis-supporting
activity was determined in the agar-drop/liquid culture system, as well as their dif-
ferentiating ability along adipogenic and osteogenic pathways. We have also ana-
lyzed the relative expression of selectin and CXCR4 genes in these cells.
Results: When comparing functional characteristics of BMSC from healthy
donors and AML patients, an increased hemostimulatory activity of the latter
was noted, as reflected by an increase in large and small CFU-GM numbers
(p<0.02). In addition, an increase in differentiation along adipogenic and
osteogenic pathways was observed in AML patients (p=0.03). Moreover, the
number of CFU-Fs, capable for adipogenic differentiation was inversely corre-
lated with platelet recovery time (p=0.05). In contrast, higher numbers of
osteogenic colonies in culture were associated with an increased time to leuko-
cyte lineage recovery (p=0.05). When analyzing gene expression in BMSC pop-
ulation, a decreased expression of the CXCR4 gene responsible for the homing
effect, with age of the patient’s (p=0.05) was noted. The selectin gene expression
in BMSC was higher by AML patients as compared to healthy donors.
Summary/Conclusions: Stromal cells derived from the patients’ bone marrow
exhibit higher proliferative activity and marked expression of molecules medi-
ating HSC homing, as compared with a group of healthy donors. That finding
could be explained by affection of stromal cells by previous chemotherapy and
myelosuppression. BMSC from AML patients taken before bone marrow trans-
plantation are characterized by a more pronounced capacity to osteogenic and
adipogenic differentiation than those from healthy donors. Increased adipogenic
differentiation ability of the BMSCs is associated with a more rapid recovery of
hematopoiesis.
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G-CSF TREATMENT IN VIVO INDUCES BONE MARROW RELEASE OF
PD-L1 POSITIVE MYELOID DERIVED SUPPRESSIVE CELLS
E Lereclus1,*, X Lafarge2, M Donnard3, S vigouroux4, P Turlure5, A Assal2,
J Feuillard1, Z Ivanovic2, R Jeannet1
1UMR CNRS 7276, CBRS, Limoges, 2EFSAL, Bordeaux, 3CHU Limoges, Limo-
ges, 4Hematologie, CHU Bordeaux, Bordeaux, 5Hematologie, CHU Limoges,
Limoges, France
Background: For its two main adverse effects which engage the vital progno-
sis, graft versus host disease (GVHD) and graft versus leukemia (GVL), tuning
the immune system is the major challenge for successful cure of the patient
who benefits from Hematopoietic Stem Cell (HSC) transplantation. Myeloid
derived suppressor cells (MDSCs) are supposed to be an immature leukocyte
subset composed of granulocytic cells (GrMDSC) and monocytic cells (MoMD-
SC). They are well described in different pathologies such as cancer, burns
and sepsis. Few publications suggest that G-CSF induces bone marrow release
of myeloid derived suppressive cells (MDSCs). But, phenotypically, it is hardly
possible to distinguish them from other myeloid precursors with the classical
lineage markers. Recently, immunosuppressive action of MDSCs was reported
to be due to the PD-L1 molecule that renders these cells able to kill T-cells
through the PD-1/ PD-L1 axis.
Aims: Using PD-L1 as an additional marker, the aim of this study was to quan-
tify MDSCs subsets (GrMDSC and MoMDSC) before and after G-CSF treat-
ment as well as in bone marrow of donors prior Hematopoietic Stem Cell (HSC)
transplantation. 
Methods: Recruitment of donors was done in two hospitals university centers
(Bordeaux and Limoges, France).We analyzed 10 samples of peripheral blood
(PB) before and 17 after G-CSF treatment, 27 samples of cells collected after
apheresis (PSC) and 5 samples of bone marrow (BM) as control. We meas-
ured the rate of GrMDSC (CD45+ Lin- CD11b+ CD14- CD33+ CD16- HLA-DR-
PD-L1+) and MoMDSC (CD45+ CD11b+ CD14+ CD33+ CD16- HLA-DR- PD-
L1+) in BM, PB and PSC sample by flow cytometry. Percentage and absolute
counts CD34 and CD3 positive cells in G-CSF treated donors have been also
collected. Differences between groups were tested for significance with the
Student t-test.
Results: White blood cell count was 5.09 +/- 2.55 G/L and 45.77 +/- 25.5 G/L
before and after G-CSF treatment. Levels of PD-L1+ HLA DR- MoMDSCs and
CD33+ Lin- PDL1+ GrMDSCs were 0.0013 +/- 0.0027 G/L (0.023% +/- 0.042%)
and 0.058 +/-0.048 G/L (1.15% +/- 0.91%) in PB before and were 0.078 +/-
0.085 G/L (0.21% +/- 0.25%) and 12.31 +/- 6.52 G/L (28% +/- 13.3%) after G-
CSF treatment (p=0.002 and<10-4 respectively). Percentages of MoMDSCs
and GrMDSCs with PDL1 expression in bone marrow were 0.0033% +/-
0.0071% and 0.84% +/- 1.21%. Apheresis treatment was associated with
enrichment in PDL1+ MoMDCs but with a loss of PDL1+GrMDSCs. Neverthe-
less, when compared to bone marrow, percentages and total numbers of both
PDL1+ MoMDSC and GrMDSC in apheresis products were still much higher
than in bone marrow (p<0.0001 and p=0.0006). There was no correlation
between levels of CD34+ stem cells, CD3+ or CD19+ lymphocytes and MDSCs
after G-CSF treatment.
Summary/Conclusions: In this study we have shown that PDL1+ MDSCs
were virtually absent in normal bone marrow and that G-CSF treatment induced
a strong MDSC production. We have also demonstrated that, compared to PB,
the product of apheresis was even more enriched in MoMDSC but was partially
depleted in GrMDSC. These results point a major difference between bone
marrow HSCs and PSCs in terms of immunomodulation capacities of the
engraftment product.
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ALTERATIONS OF BONE MARROW MICROENVIRONMENT IN PATIENTS
WITH HEMATOLOGICAL DISORDERS AT THE DIAGNOSIS AND DURING
THE TREATMENT
T Sorokina1,*, I Shipounova2, A Bigildeev2, N Petinaty2, N Drize2, L Kuzmina1,
E Parovichnikova1, V Savchenko3
1Bone Marrow Transplantation, 2Physiology of Hematopoiesis Lab, 3National
Research Center for Hematology, Moscow, Russian Federation
Background: Bone marrow (BM) microenvironment is involved in the initiation
and propagation of normal hematopoiesis and hematological diseases.
Leukemia and chemotherapy affect hematopoietic and stromal precursor cells.
Multipotent mesenchymal stromal cells (MMSCs) are the essential element of
hematopoietic microenvironment.
Aims: The study aimed to characterize MMSCs and their more differentiated
progeny CFU-F derived from the BM of the patients with hematological disor-
ders at diagnosis and during the treatment.
Methods: 74 newly diagnosed cases (33 AML, 21 ALL, 20 CML) were involved
in the study after informed consent. BM was aspirated prior to treatment (time-
point 0) and at days 37, 100 and 180 since the beginning of treatment of acute
leukemia and +3, +6 and +12 months for CML (time-points 1-3). MMSCs were
cultured in aMEM with 10% fetal calf serum. Time to P0 and cumulative MMSC
production after 3 passages were evaluated and CFU-F concentration was ana-
lyzed. The relative expression level (REL) of genes was measured by TaqMan
RQ-PCR. As a control MMSCs and CFU-Fs from 88 healthy donors were used.
Table 1.
Results: Time needed to reach P0 reflects the quantity of MMSC in the BM
sample. The time to P0 in control group was 13.7±0.3 days. Its elongation in
acute leukemia cultures at the time of the diagnosis (table) suggested the reduc-
tion of MMSC number probably due to leukemic expansion, while the longer
time to P0 at time-points 2 and 3 could be explained by the therapy influence.
In CML cultures time to P0 was significantly longer during the whole observation
period due to the continuous therapy and maintaining disease. Cumulative
MMSC production in control group was 7.1±1 x 106 cells. In patients with AML
it was 1/3 of the donor’s at the disease manifestation with no difference at time-
points 1-3, indicating the impaired proliferative abilities of MMSC at the AML
manifestation. Cumulative MMSC production in patients with ALL and CML
didn’t differ from donor’s. BM blast count did not correlate with MMSC produc-
tion. CFU-F concentration in the BM of acute leukemia patients was significantly
lower than donor’s (25.4±3.1 per 106 cells) at the time-point 0 with no difference
at time-points 1-3. CFU-F concentration in the BM of CML patients was also
nearly 40% lower than in control group at the time-point 0 with its following
restoration at time-point 1 and subsequent drop (up to 5 fold lower) at time-
point 3, reflecting the long-lasting lesion of CFU-Fs during the course of the
disease. Gene expression analysis of MMSC from all patients revealed signif-
icant decrease in REL of VEGF and SOX9 genes at the disease manifestation
that did not restore after the treatment. The REL of LIF was significantly
increased at the disease manifestation, reflecting the efforts of MMSCs to inhibit
leukemic proliferation. REL of PDGFRB and IL6 increased during the treatment.
The treatment lead to the downregulation of FGF2, TGFB1 and 2. As FGF2
and TGFB inhibit the differentiation of MMSCs, their downregulation may refer
to the effectiveness of therapy. In MMSCs from acute leukemia patients the
ICAM and SPP1 genes were downregulated at all points, reflecting the mech-
anism of the blocking of MMSCs migration and differentiation during the stress
conditions. The influence of chemotherapy lead to decrease in REL of SDF1,
IL8, VCAM, IL1b1R1, JAG1, IGF1, FGFR1 and 2.
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Summary/Conclusions: The study supports the major influence of leukemic
cells and chemotherapy on the BM microenvironment. The two types of studied
precursors are affected differently. Future studies are needed to evaluate the
role of MMSCs in leukemia pathogenesis.
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COMPARISON OF MOLECULAR AND FUNCTIONAL PROFILES OF
WHARTON’S JELLY AND BONE MARROW MESENCHYMAL STEM CELLS
A Batsali1,2, C Pontikoglou1,*, E Kouvidi1, A Damianaki1, F Papadogiannis1,
I Liapis1, H Papadaki1
1Department of Hematology, 2Graduate Program, University of Crete School
of Medicine, Heraklion, Greece, Heraklion, Crete, Greece
Background: We have previously shown that ex vivo expanded human mes-
enchymal stem/stromal cells (MSCs) derived from the Wharton’s jelly (WJ) of
the umbilical cord exhibit increased proliferative capacity and reduced differ-
entiation potential to adipocytes and osteocytes, compared to bone marrow
(BM) derived-MSCs. This altered differentiation capacity has been attributed,
at least in part due to reduced expression of Wnt antagonist sFRP4 (a promoter
of adipogenesis) and WNT-induced secreted protein-1 (a regulator of osteo-
genesis in WJ-MSCs), thereby supporting the contribution of WNT-pathways
in human MSC biology (Batsali A et al.,Blood 2014:124,21).
Aims: In order to extent the comparative study between BM and WJ-MSCs
we seek to estimate the telomere length of cultured MSCs and analyze the
cell-cycle signaling pathway. Moreover, we aim to investigate the capacity of
WJ-MSCs to support the growth of hematopoietic stem cells (HSCs).
Methods: MSCs were isolated and expanded from healthy donors’ BM aspirates
(n=15) and from the WJ of full-term neonates (n=15) after written informed con-
sent. MSCs were in vitro expanded and re-seeded for a total of 10 passages and
were verified phenotypically by flow cytometry. The expression of 84 genes related
to cell-cycle signaling pathway was assessed using a PCR array (Fold Change
(FC) =2-ΔΔCt). DNA was isolated from culture expanded MSCs (at P2, P6 and
P10) and telomere length was measured by means of real-time-PCR using β-glo-
bin as control. Telomere length is proportional to the relative telomere/single-copy-
gene ratio, T/S= 2-ΔCt (ΔCt= Cttelomere - Ctβ-globin). Levels of human hematopoietic
associated cytokines (Flt-3 ligand/G-CSF/GM-CSF/SDF-1a) were measured by
means of enzyme-linked-immunosorbent assay, from supernatants of MSC cul-
tures (from P2, P6 and P10). MSC hematopoietic supportive capacity was eval-
uated in two-week co-cultures with allogeneic BM or UC-blood CD34+ cells.
Results: Culture-expanded cells from both WJ and BM displayed typical mor-
phological and immunophenotypic MSC characteristics and were able to differ-
entiate into osteoblasts and adipocytes. Regarding the cell-cycle signaling path-
way many genes essential for mitosis and genome stability were up-regulated
in WJ-MSCs, such as ATM (FC=4.04), CCND2 (FC=4.55), AURKB (FC=3.15)
and MKI67 (FC=2.86), while the anti-apoptotic gene BCL2 was down-regulated
(FC=4.07). Moreover the relative telomere length of WJ-MSCs was higher com-
paring with BM-MSCs through all passages, with a significant difference in P2
(p=0.032). The expression of hematopoietic associated cytokine Flt-3 ligand,
an important cytokine for development of several hematopoietic populations,
was expressed in both MSC-sources. G-CSF and GM-CSF, growth factors of
HSCs involved in the production of granulocytes, macrophages and dendritic
cells, were significantly up-regulated in WJ-supernatants but were almost absent
in BM-cultures (p<0.001). The regulator of migration, adherence and engraft-
ment of HSCs, SDF-1a, was significantly overexpressed in BM-supernatants
through cultivation (p<0.05). Nevertheless, WJ-MSCs seemed not to support
CD34+ cell growth as evidenced by the numbers of total colony-forming units
(CFUs), at least in the current experimental setting.
Summary/Conclusions: Collectively, our results suggest that WJ-MSC pop-
ulation exhibit greater proliferation potential and decreased apoptosis, longer
telomeric length and higher genome stability. The observed differences of CFUs
in the co-culture systems could be attributed to the differences in cytokines
secreted by WJ and BM-MSCs. Our results point out that WJ- and BM-MSCs
exhibit unique characteristics and therefore the appropriate source should be
selected for a specific clinical application.
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IMPACT OF LEUKEMIA STEM CELLS PHENOTYPE EXPRESSION ON
RESPONSE TO INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA
PATIENTS
F Albeldawi1,*, S Al-Mudallal2
1Hematopathology, Iraqi Ministry of Health, Balad, 2Hematopathology, Al-
Nahrain University, Baghdad, Iraq
Background: Laboratory data suggest that acute myeloid leukemia AML orig-
inates from a rare population of cells, termed leukemic stem cells (LSCs) or
leukemia-initiating cells, which are capable of self-renewal, proliferation and
differentiation into malignant blasts. There’s a universal agreement that LSCs
lie within the CD34+ compartment of hemopoietic cells and most of leukemic
stem cells express the interleukin-3 alpha chain receptor, CD123 and lack
CD38. The standard model of leukemogenesis posits the stepwise acquisition
of genetic mutations in a susceptible cell and its progeny, leading to the devel-
opment of an autonomous clone that expands enough to cause a clinical syn-
drome. The genetic events occur in susceptible cells that are either hemopoietic
stem cells or its progeny. The resultant leukemic cell has the properties of a
stem cell in terms of self-renewal, but with persistent uncontrolled division and
resistance to chemotherapy. This leukemia stem cell theory has been proved
by proliferation of proposed leukemic stem cell after its injection into lethally
irradiated mice. This finding inspired scientists and researchers to explore new
fields for leukemia treatments because with the current regimes, the relapse
rate is high and death frequently happens due to treatment failure or conse-
quences of bone marrow blast invasion. In the same perspective, researchers
began to assess the prognostic value of leukemic stem cells at diagnosis and
to weigh its significance with other known prognostic factors of AML.
Aims: This study aimed to estimate the expression of LSC phenotype in AML
patients and to correlate it with response to induction therapy.
Methods: A cohort of 41 patients older than 15 years with newly diagnosed de
novo AML were enrolled in this study. They were obtained from the National
center of hematology in Baghdad and Baghdad teaching hospital between
February and July 2013. The expression of CD34, CD38 and CD123 was
assessed by multi-color flow cytometry. LSC positive (LSC+) samples must
express CD34 and CD123 and lack the expression of CD38 in >1% of cells.
French American British (FAB) classification system was used in this study.
After four weeks of induction therapy; three groups were found: those who
reached the complete morphological remission (CR), those who failed to reach
CR and those who died before assessment of morphological remission. The
last two groups were merged for statistical purposes. All statistical operations
were done by Microsoft excel 2010 and SPSS programs. The p-value for sig-
nificance was calculated from Chi square test and Fisher Exact test for 2X2
contingency tables when the Chi square test was not applicable. The percent-
age of LSCs was calculated as the percentage of cells in CD34+CD123+ quad-
rant X the percentage of CD38- cells X the blast% of the individual patient 
Results: The mean expression of CD34+CD38-CD123+ cells at diagnosis was
3.85+7.14 (mean+SD), range=0% to 42.05%, median=2.15%. A cut off value
of 1.0% was designed to separate two groups of patients; those with LSCs of
less than or equal to 1.0% and those with more than 1.0%. In the first group
(LSCs<1.0%), the CR rate was 53.33%, while it was 34.61% in the second
group. Percentage of cases who sustained NR was 46.67% in the first group
and 65.39% in the second age group. Regarding gender, LSC+ male patients
were more (70.83%) than LSC+ females (52.94%). Patients with a low (<1%)
percentage of CD123+CD34+ cells had a CR rate of 50% and an NR rate of
50%. On the other side, in patients who had a higher expression (>1%) of
CD123+CD34+ cells, the CR rate was less (7 of 21, 33.33%) and NR was
higher than the other group (14 of 21, 66.67%).
Summary/Conclusions: 1. LSCs were expressed in 63.41% of AML cases
and were distributed among FAB subtypes without preference to any FAB sub-
type. 2. The expression of LSC phenotype was associated with poor response
to induction therapy in AML patients.
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VASCULAR ENDOTHELIAL CELL-RELATING MOLECULES EXPRESSED
IN AN ADULT HUMAN DERMAL FIBROBLAST WHEN CULTURED WITH
INTERLEUKIN-1-BETA
R Sumiyoshi*, T Matsuo, T Yamamoto, K Matsumoto, J Ooi, N Shirafuji
1Department of Hematology/Oncology, Teikyo University School of Medicine,
Tokyo, Japan
Background: We previously reported that when an adult human dermal fibroblast
(HDF) was cultured with interleukin (IL)-1-beta (b), vascular endothelial growth
factor (VEGF)-A, erythropoietin (EPO), anti-human VEGF-C antibody (Ab) and
anti-human tumor necrosis factor (TNF)-alpha (a) Ab, hematopoiesis-related
genes expressed; however, culturing cells were morphologically fibroblasts (56th
ASH). We also reported that hemogenic endothelium-relating molecules
expressed in HDF with poly (I:C) culture and an electrical stimulation (44th ISEH).
Aims: In this report we observed the biological effects of IL-1-b to HDF for up
to one month-culture.
Methods: HDF was cultured with CELRENA medium, used for induced pluripo-
tent stem (iPS) cell-culture, on 0.1% gelatin-coated plate (porcine skin). Cul-
tures were added with recombinant human IL-1-b for up to four weeks with
splitting each one week. Morphological changes and the expression of vascular
endothelial cell-related genes, and hematopoiesis-related ones were observed.
Results: When HDF was cultured with IL-1-b, CD31, CD34, and CD41 mole-
cules expressed for two weeks’ culture, which are vascular endothelial cell-
markers. Also, VEGF-receptor type-1, and -2, and VE-cadherin expressed sig-
nificantly. Morphologically, HDF was changed to an endothelial cell. When HDF
was further cultured, blast cells were attached to an endothelial cell, and SCL,
and GATA-2 molecule expressed significantly. 
Summary/Conclusions: Recent reports reveal that a kind of vascular endothe-
lial cells, hemogenic endothelium, can be converted into a hematopoietic cell.
We identified that IL-1-b worked an important role in vascular endothelial cell-
formation.
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EXOSOMES SECRETED BY STROMAL CELLS CONTRIBUTE TO THE
HEMATOPOIETIC STEM CELL NICHE
G Stik1,*, S Crequit2, J Durant2, L Petit3, P Charbord3, T Jaffredo1, C Durand2
1CNRS, 2UPMC, 3INSERM, Paris, France
Background: Hematopoietic stem cells (HSCs) are identified by their ability to
self-renew and to differentiate into all blood cell lineages. In vivo, hematopoietic
stem/progenitor cells (HSPCs) are in close association with stromal cells that
constitute a supportive microenvironment also called niche. Recently, exosomes
that are small microvesicles enclosed by a lipid bilayer and enriched in cyto-
plasmic proteins, mRNAs, microRNAs, have emerged as major communication
mediators between cells. However, their implication in the cross-talk between
HSCs and stromal cells is still largely unknown.
Aims: This study aims to assess the existence and the functionality of stromal
cell-derived exosomes in the HSPC support.
Methods: To address this issue, we used two murine stromal cell lines derived
from the fetal liver and with differing capacity to maintain HSPCs ex vivo as
revealed by repopulation assay and long-term cultures. AFT024 (AFT) harbors
a potent HSPC supporting capacity in vitro whereas BFC012 (BFC) is non sup-
portive. For each cell line, the exosome fractions were isolated from culture
supernatant by ultra-centrifugation. Electron microscopy, western blot, and flow
cytometry were performed to characterize the exosomal fraction isolated. Using
PKH67 staining we analyze the uptake of exosomes after co-culture with Lin-
Sca1+ cKit+ (LSK) cells, total bone marrow or after in vivo injection. Clonogenic
assay and FACS analysis were performed after co-culture of LSK cells with
exosomes to assay their biological effect. High-throughput sequencing was
realized to explore the molecular signature followed by several bioinformatic
analyses. Finally, RNA transfer from exosomes to recipient cells was analyzed
by qPCR. 
Results: Electron microscopy performed on stromal cells showed multivesicular
bodies containing exosomes. Additional electron microscopy, FACS and west-
ern blot analyses performed on the fraction isolated by ultracentrifugation
revealed that both AFT and BFC stromal cells secrete exosomes. We then
investigate if these exosomes could be taken up by HSPCs. Interestingly, using
PKH67 stained exosomes, we demonstrated that bone marrow Lin-Sca-1+c-
kit+ (LSK) cells preferentially uptake AFT-derived exosomes. This observation
might be related to the different tetraspanin compositions of AFT and BFC
derived exosomes as observed by flow cytometry. Furthermore, in vitro and in
vivo assays showed that AFT exosomes specifically target hematopoietic
CD45+ cells. We then showed an increase in cell viability and clonogenic poten-
tial when LSK cells were exposed to AFT-derived exosomes for 96 hours in
cytokine-free medium as compared to controls. Moreover, cultures with AFT-
derived exosomes exhibited a 3.5 fold increase in the number of LSK cells as
compared to untreated conditions. We then used high-throughput sequencing
to explore the molecular signatures of AFT and BFC derived exosomes, as
well as their cells of origin. We identified a list of 324 mRNAs and 23 microRNAs
specifically expressed in exosomes and correlated to the HSPC support. Gene
ontology analysis revealed that the apoptotic regulation, cell survival and pro-
liferation pathways were significantly enriched in the AFT-derived exosomal
signature. In addition, we showed the transfer of mRNAs involved in these
pathways from the AFT-exosomes to the LSK recipient cells. Together with our
observation of a decrease in the LSK apoptotic cells after co-culture with AFT-
derived exosomes, these data suggest that exosomes released by AFT cells
may protect HSPCs from apoptosis. 
Summary/Conclusions: Collectively, our results revealed an important role
for exosomes in the HSPC supporting capacity of stromal cells. This work pro-
vides new insights in our understanding of the molecular and cellular mecha-
nisms involved in the cross-talk between HSPCs and their niches. It may also
have interesting applications in regenerative medicine, regarding the ex vivo
manipulation of HSCs in stromal-free conditions for cell therapy.
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HUMAN UMBILICAL CORD BLOOD STROMAL CELLS PROMOTE
HEMATOPOIETIC RECONSTITUTION AND REDUCE GVHD BY AFFECTING
THE TH CELL SUBSETS IN HAPLOIDENTICAL-HSCT
Y Liu, SJ Yang, C Zhang, Q Wen, X Zhang*
Department of Hematology, Xinqiao Hospital, The Third Military Medical Uni-
versity, Chongqing, China
Background: Microenviroment palys very important role in the regulation of
graft-versus-host desease (GVHD).
Aims: To investigate the effect of human cord blood–derived stromal cells
(hUCBDSCs) combined with haploidentical-hematopoietic stem cell transplan-
tation (haplo-HSCT) on GVHD and hematopoietic reconstitution of severe bone
marrow radiation disease.
Methods: The hybrids F1 generation mice were taken 8.0Gy of 60Coγ ray total
body irradiation (TBI). Haploidentical-HSCT were taken after TBI. Grouping:
mBMSC (mouse bone marrow-derived stromal cells) + HSC(Hematopoietic stem
cells) group, hUCBDSCs + HSC group, HSC group and the control group (saline
group). Peripheral blood were taken at 0,3,7,10,14,21,28d days respectively
after transplantation to count WBC, RBC, Hb, PLT. Bone marrow, liver, spleen,
intestine and skin were collected and paraffin-embedded after transplantation
at each point to observe pathologic changes. The changes of body weight, pos-
tural, activity, hair, toilet and survival were observed after transplantation at each
point. Cell colony culture were taken at 7,14,21d after transplantation. IL-2, IL-
4, IL-10, IL-12, IL-17, IL-21, IL-22, IL- 23, IL-33, TGF-β, IFN-α and IFN-γ in
serum were detected by ELISA at 0,7,14,21d after transplantation.
Results: All mice in control group died at 9d to 11d after TBI. The hemogram
began to recover at 7d in hUCBDSCs + HSC group and mBMSC + HSC group
after transplantation which was earlier than that in HSC group (10d). Cell colony
of CFU-E, CFU-GM, CFU-GEMM and CFU-G in hUCBDSCs + HSC group was
more than mBMSC + HSC group (p <0.05). And mBMSC + HSC group was
more than HSC group (p <0.05). The death rate of hUCBDSCs + HSC group
and mBMSC + HSC group were (20.00±5.00)% and (21.67±12.58)% which
were lower than (38.33±7.64) % in HSC group (p <0.05). The GVHD of hUCBD-
SCs + HSC group was not obviously which was better than HSC group. There
were no significant differences of IL-12, IL-17 and IL-23 in each group. IL-2,
IFN-γ expression were increased after transplantation, which is higher in HSC
group than hUCBDSCs group(p <0.05); IL-10 expression in the peripheral blood
were decreased in each group after transplantation. The recovery of IL-10 in
hUCBDSCs + HSC group was faster than HSC group (p <0.05). TGF-β expres-
sion were increased faster in hUCBDSCs + HSC group than the other two
groups(p <0.05) which was the same as TNF -α.
Summary/Conclusions: HUCBDSCs promote hematopoietic reconstitution
and reduce the incidence of GVHD in severe bone marrow radiation disease
in vivo. The main mechanism of this may be associated with the decrease of
Th1 cells and increase of Th2 cells expression.
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THYROID DISEASES IN LYMPHOMA SURVIVORS
MP Simula1,*, AM Mamusa1, S Usai1, A Oppo2, S Mariotti2, E Angelucci1
1Struttura Complessa di Ematologia e Centro Trapianti. Ospedale Oncologico
di Riferimento Regionale. Cagliari, Italia, AOB Cagliari, 2UOC Endocrinologia
e Diabetologia Centro Studio per la prevenzione e la terapia delle malattie
della tiroide, Università di Cagliari, Cagliari, Italy
Background: Improvements in the treatment of both Hodgkin’s (HL) and non
Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long
term survivors. However this patient’s population is at high risk of developing
late therapy related complications that can negatively affect their survival and
quality of life. In this report we focus on thyroid diseases.
Aims: In our institution the HL and aggressive nHL long term survivors are fol-
lowed up in a dedicated clinic since September 2014. Here we report prelimi-
nary data on thyropathies.
Methods: We have reviewed our lymphoma survivors database
Results: We have analyzed data regarding 469 consecutive patients coming
in our clinic from 15 September 2014 to 18 February 2016, 247 were affected
by HL and 222 by nHL. Two hundred thirty three were females, 236 males;
median age at diagnosis was 29 years for HL (range 13-84), 48 years for nHL
(range 12-83); median age at last observation in the follow up clinic was 50
years for HL (range 21-89) and 62 years for nHL (range 24-88). The median
duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL
(range 5-37). One hundred eight patients (23%) experienced thyroid disorders;
they were 85 females (79%) and 23 males (11%), 77 have been treated for HL
(71%) and 31(29%) for nHL. Thyroid diseases observed in our patients were:
hypothyroidisms in 54, autoimmune thyroiditis in 24, nodules in 10, goiters in
10,carcinomas in 8, hyperthyroidism in 2 (table1). Thirteen of these patients
had thyroid exeresis after thyroid disease diagnosis (table2). Regarding the
previous therapies in thyroid disease patients: mediastinal and/or neck radio-
therapy has been administered to 83 (77%) of patients and chemotherapy in
99 (92%). The median time between diagnosis of lymphoma and diagnosis of
thyroid problems was 10 years (range 0-33). Thirty four of these disorders
(31%), including one carcinoma, have been detected during planned controls
(hormonal dosage and echotomography) in absence of symptoms.
Table 1. Type of thyroid disorders in our lymphoma survivor patients.
Table 2. Causes of thyroidectomy.
Summary/Conclusions: In our Department we described a high number of
cases of thyroid disorders in the lymphoma survivors population. These were
more common in females, as in general population, and in previous HL, prob-
ably because of higher rate of radiotherapy received in the treatment of HL
compared to nHL. Almost a third of these disorders were found by tests done
for early diagnosis of late complications in asymptomatic patients. These results





PROGNOSTIC RELEVANCE OF SERUM FERRITIN LEVELS IN HODGKIN
LYMPHOMA (HL) UNDER TREATMENT WITH ABVD OR EQUIVALENT
REGIMENS WITH OR WITHOUT RADIOTHERAPY (RT)
TP Vassilakopoulos1,*, MN Dimopoulou1, M Arapaki1, MP Siakantaris2, G Boutsikas1,
E Variami2, JV Asimakopoulos1, M Dimou3, MC Kyrtsonis3, X Yiakoumis4,
M Moschogiannis4, G Dryllis1, T Giannikos1, M Efstathopoulou1, E Konstantinou1,
I Stergiou1, T Tzenou3, T Iliakis3, G Gainarou1, V Telonis1, KA Petevi1, K Zervakis2,
E Pessach3, P Tsirkinidis5, NA Viniou2, V Komninaka1, P Tsaftaridis1, E Plata1,
S Sachanas4, GA Pangalis4, P Panayiotidis3, K Konstantopoulos1,
MK Angelopoulou1
1Department of Hematology, National and Kapodistrian University of Athens,
21st Department of Internal Medicine, National and Kapodistrian University of
Athens, 31st Propedeutic Department of Internal Medicine, National and
Kapodistrian University of Athens, Laikon General Hospital, 4Department of
Hematology, Athens Medical Center, 5Department of Hematology, 401 Army
General Hospital, Athens, Greece
Background: Cytokine-driven inflammatory processes dominate the clinical
and laboratory expression of HL, especially in advanced stages. Serum ferritin
(SF) levels increase in the context of “acute phase reaction” along with fibrino-
gen, ESR, cerulloplasmin, haptoglobins etc. Although SF elevations are a well
known feature of HL, their prognostic significance has not been adequately
evaluated. Recently, Fernandes-Alvarez et al reported that elevated SF levels
(>350 μg/L) were an independent prognostic factor in 173 optimally treated
patients with classical HL (Leuk Lymphoma 2015).
Aims: To evaluate the prognostic significance of SF levels in a large series of
patients with HL treated with ABVD or similar chemotherapy with or without
radiotherapy (ABVD±RT).
Methods: We evaluated 309 pts with HL, treated with ABVD or equivalents
(±RT), who had available data for SF levels. Median age was 33 yrs (15-87),
54% of patients were male, 34% had B-symptoms, 17% had stage IV disease,
50% had advanced stage (IB,IIB,III,IV), 33% had IPS ≥3, 67% nodular sclerosis
histology and 19% mixed cellularity. Failure-free survival (FFS) was defined as
time between treatment initiation and toxic death, failure to achieve remission
requiring switch to salvage therapy, relapse after remission or last follow-up;
deaths in remission of unrelated causes were not counted as events.
Results: Median follow-up of currently alive patients was 41 months. The medi-
an SF levels were 149 μg/L (range 6.6-6709.0, interquartile range; IQR 63.9-
316.5). As expected, SF levels were lower in females than males (medians
70.6 vs 240.2, p<0.001). Increased SF levels were highly correlated (p<0.001)
with older age, advanced stage, increased IPS and markers of systemic dis-
turbance (B-symptoms, anemia, ESR, CRP, low serum albumin), as well as
with beta2-microglobulin, elevated serum LDH (p=0.01) and mixed cellularity
(p=0.01 compared to nodular sclerosis). However, there was no correlation
with leukocytosis or lymphocytopenia. At a cutoff of 150 μg/L (almost the medi-
an), the 5-year FFS was 85% vs 67% for patients with lower and higher SF
levels (p=0.0005). If a gender-based median cutoff was adopted (high levels
above the median of each gender), the results were similar (84% vs 68%,
p=0.0006). At the published cutoff of 350 μg/L only 21% of patients had high
SF levels and the difference in the outcome was less pronounced (79% vs
64%; p=0.01). In both early (ΙΑ/ΙΙΑ) and advanced (IB, IIB-IV) stages, SF ≥150
μg/L provided an 8-9% absolute difference in 5-year FFS, which was not how-
ever statistically significant (p=0.18 and p=0.16). In multivariate analysis, SF
≥150 μg/L was an independent prognostic factor (p=0.04; HR=1.79) along with
advanced stage (p<0.001; HR=2.66), when adjusted for B-symptoms, anemia,
LDH and gender. Further adjustment for CRP or ESR did not result to any
meaningful alteration of the magnitude of the HR. However, the significance of
SF became marginal if stage IV was used instead of “advanced stage”. In mod-
els containing SF levels, B-symptoms and IPS, SF displaced IPS.
Summary/Conclusions: Elevated SF levels may be an independent prognos-
tic factor in HL treated with ABVD or equivalent regimens±RT after adjustment
for other important variables, including B-symptoms, anemia, ESR and CRP.
However, larger patient series are needed in order to extract safe conclusions
and determine the optimal cutoff.
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INFRADIAPHRAGMATIC HODGKIN LYMPHOMA: A LARGE SERIE OF
PATIENTS AT THE ERA OF TEP-CT. A PARTICULAR SUBSET OF HL?
C Rossi1,*, M mounier2, P brice3, H ghesquières4, V safar4, E nicolas-virelizier5,
C sebban5, A stamatoullas-bastard6, M alcantara6, A chauchet7, E reboursière8,
L filiattre-legras9, A perrot9, G salles4, B Coiffier4, O Casasnovas1
1Hematology, CHU Dijon, Dijon, 2Registre des hémopathies malignes de côte
d’or, Université de Bourgogne, Dijon Cedex, 3Hematology, CHU Paris St louis
LAriboisière F Widal, Paris, 4Hematology, CHLS, Pierre Bénite, 5hematology,
CLB, Lyon, 6hematology, Centre henri Becquerel, Rouen, 7Hematology, CHU
besançon, Besançon, 8hematology, CHU caen, Caen, 9hematology, CHU NAN-
CY, NANCY, France
Background: Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts for 3-
11% of adult cases of stage I-II Hodgkin Lymphoma. The strategy of treatment
has been improved and standardized along the last decades in most clinical
subsets of HL, while it remains heterogeneous in IDHL these patients being
often excluded from clinical trial. Moreover, in previous studies focused on
IDHL, the patients were not staged by PET-CT and the risk was considered
localized stages as advanced.
Aims: Thus, this study aimed to include PET staged patients by comparing
with PET non staged patients for demographic, clinical and biological data the
outcome of these patients.
Methods: The clinical, biological data at baseline, the details of treatment and
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outcome of patients with a first diagnosis of stage I-II of IDHL were retrospec-
tively collected in 8 french departments of hematology. During the same period,
patients with a positive HIV serology and those treated with radiotherapy alone
were excluded. Also, we reported only the patients treated with ABVD regimen
of chemotherapy.
Results: From 1986 to 2014, 100 patients were included whose 65 of them
staged with PET. The characteristics between patients staged with or without
PET-CT were significantly different for age (higher median for PET staged, 53
years vs 47 years, p=0.041), ESR (higher median for PET non staged; 27 vs
58mm, p= 0.044), haemoglobin (lower for PET non staged, 13.6 vs 12.8g/dL,
p=0.0267) and frequence of central adenopathy involvement (60% vs 80%,
p=0.042). Indeed, the following analyses were made in each group separately
in univariate and after adjustment with these four parameters. In the PET-staged
patients group, which were considered as real pure infra-diaphragmatic, the
median of follow-up was 3.8 years. At five years, the PFS was 78% (IC95%
0.64-0.87) and OS was 88% (IC95% 0.73-0.95). Thirteen relapses occurred
(20%) whose eleven (16%) in the five-years after diagnosis, and five died (8%),
3 from HL progression and 2 from toxicity of chemotherapy. In univariate
ananalysis, bulky mass at baseline (p=0.03) and the chemo-radiotherapy com-
bination (p=0.024) influenced the PFS and only bulky mass and the combination
of treatment remained significant (p=0.008) and at the limit of statistical signi-
ficativity (p=0.069) in the modelisation analysis, respectively.
Summary/Conclusions: This multicenter retrospective study including PET-
staged patients, considered as pure IDHL, shows clinical and biological specific
characteristics, which confirm that PET was very useful for management of
these patients. Thus, IDHL could be identify as a subset of HL, in particular of
elderly HL. The chemo-radiotherapy combination seemed be related to a better
PFS in these patients.
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RESULTS AND OUTCOME WITH ABVD-PLATINE PROTOCOL IN HODGKIN
LYMPHOMA WITH BULKY MEDIASTINAL INVOLVEMENT
RM Hamladji*, F Belhadri, M Benakli, R Belhadj, N Abdennebi, F Tensaout,
A Talbi, S Akhrouf, R Ahmed Nacer
Hematology-Bone Marrow Transplantation Department. Pierre and Marie Curie
Center, Algiers, Algeria
Background: Mediastinal lymph node involvement can be large in 50-60% of
Hodgkin lymphoma (HD) wich may be discovered on imaging in asymptomatic
patients (pts) or pts with respiratory signs or chest pain. Bulky form is defined
as a mediastinal mass exceeding one third of the maximum transverse thoracic
diameter on standard chest X-Ray at the level of 5th and 6th thoracic verte-
bra=mediastinal tumor ratio (MDR) ≥35.
Aims: We report the results of 179 HD with bulky mediastinal treated by ABVD-
Platine protocol.
Methods: Over a period of 9 years (2004-2012), 341 pts / 674 (50,6%) with
HD had mediastinal involvement with bulky’s one in 200 (58,6%), median
MTR=0,43 (0 -35- 0,80) among them 179 were treated with ABVD-P: median
age 25 years (11-64), sex ratio 1,03. The most frequent revealing symptom
was lymphadenopathy (51%), fonctionnal respiratory signs (23%) and superior
cava vein syndrome in 5 pts. The histopathologic patterns are nodular sclerosis
(65%), mixed cellularity (28%) lymphocyte depleted 06 pts or predominant 1 pt
and unclassified 5 pts. The clinical Ann Arbor staging was stage II: 53%, stage
III 32% and stade IV 15%. According to prognostic score GHSG (German
Hodgkin Lymphoma Study Group): 18 pts (10%) were in intermediate stage
and 161 (90%) in advanced stage. The protocol treatment is ABVD with platine
30 mg/m2 D2, D3 and D16, D17) monthly: 3 cycles for stage II, 4 for stage III
and IV. After chemotherapy (CT), 122 pts received radiotherapy (RT), 24 pts
high dose CT (HDC) with autologous stem cell transplantation(ASCT) and 25
pts were followed after CT alone. At december 2015, the median follow-up is
98 months (39-143).
Results: After CT, 177pts / 179 are evaluable, the overall response (OR) is
96,6% with 32,2% in complete remission (CR) and 64,4% partial remission
(PR),6 pts are in failure treatment. At term follow-up 158 pts are alive, among
them 155 CR, 3 relapse and 19 died. The overall (OS) and event free (EFS)
actuarial survival are 90% and 83% respectively at 8 years. Among the 171 pts
in response after CT: 122 pts with CT-RT, 24 pts with CT-ASCT and 25 pts fol-
lowed after CT alone, the OS were 94,8%, 71,6%, 77,4% respectively and EFS
93,8%,46,8% and 49,7%.
Summary/Conclusions: The protocol ABVD-Platine in HD with bulky medi-
astinal involvement allowed good results in association with RT better than in
association with CT-ASCT (p<0,001), but no with CT alone (p=0,08) on OS.
Concerning EFS the association CT-RT is better than CT-ASCT and CT alone
p<10-8).
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ADDITION OF ABSOLUTE LYMPHOCYTES/MONOCYTES RATIO
IMPROVES THE STANDARD PROGNOSTIC SCORES FOR ADVANCED
AND LOCALIZED HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD
+/- RADIOTHERAPY
I Herráez Balanzat1,*, L Bento de Miguel1, L García Maño1, J Martinez Serra2,
F Mestre Mestre3, R Ramos Asensio4, P López Perezagua5, J Daumal Domenech3,
S Ruiz de Gracia1, A Sampol Mayol1, A Gutierrez Garcia1
1Hematology, 2Molecular Biology, 3Nuclear Medicine, 4Pathology, 5Radiology,
Hospital Son Espases, Palma de Mallorca, Spain
Background: Hodgkin lymphoma (HL) is a lymphoproliferative malignancy
constituted by a few malignant cells (Reed-Sternberg cells) surrounded by an
inflammatory microenvironment. The amount of monocytes infiltrating HL is a
known prognostic factor but its study implies immunohistochemistry. Lymphope-
nia is a recognized adverse prognostic factor included in the International Prog-
nostic Score (IPS). In the last years the clinical value of the absolute lympho-
cytes/monocytes ratio (LMR) has been reported as an alternative way to con-
sider previous prognostic factors.
Aims: We aim to evaluate the combination of the absolute lymphocytes/mono-
cytes ratio with the standard prognostic scores for advanced (IPS) and localized
(GHSG) HL in order to improve definition of prognosis.
Methods: We retrospectively selected from the Pathology and Pharmacy reg-
istries of Son Espases University Hospital those patients with HL homogenously
treated with ABVD +/- radiotherapy (RT). All standard prognostic factors were
obtained from the records included in IPS and GHSG prognostic scores, as
well as the absolute value of lymphocytes and monocytes. COR curves were
used to determine the cutoff value for the LMR. IPS and GHSG scores were
combined with LMR as follows: IPS 0-2=0; IPS>2=1; GHSG 0=0; GHSG>0=1;
LMR≤cutoff=1; LMR>cutoff=0. LMR-IPS and LMR-GHSG were the sum of IPS
or GHSG with LMR previous values (ranging from 0 to 2). Survival analysis
was performed using Kaplan-Meier curves with the Log-rank test. 
Results: From January 1990 to June 2015, 124 patients fulfilled inclusion cri-
teria. Median age was 37 years (15-75), 62% males, 48% Ann Arbor (AA) stage
III-IV, 13% with ECOG performance status >1, 53% with IPS >2. Median LMR
was 2.19 (0.2-7.7). Response was as follows: 105 (87%) achieved complete
response (CR), 2 (2%) partial response (PR) and 17 (12%) stable disease or
progression (SD/P). Using COR curves we set the cutoff for LMR in 1.56.
Response rate, CR and SD/P were significantly better in patients with LMR
>1.56: respectively 95% vs 72%, 94% vs 69% and 5% vs 29% (p=0.001); as
well as patients younger than 45 (p=0.024) and 60 (p=0.003) years, with ECOG
0-1 (p=0.001), LMR-GHSG 0 (p=0.037) and LMR-IPS 0-1 (p=0.007). Univariate
survival analysis showed several factors significantly influencing OS: age,
ECOG PS, GHSG and IPS, ALC, AMC, LMR, LMR-IPS and LMR-GHSG (Figure
1). PFS was significantly influenced by age, AA stage, ECOG PS, IPS, LMR
and LMR-IPS (Figure 1). In multivariate analysis for early HL age >45 (HR 13.1;
p<0.001), ECOG PS>1 (HR 9.7; p=0.034) and LMR-GHSG>0 (HR 19.8;
p=0.045) (Figure 1) where independent predictors of worse OS while in
advanced HL only remained independent age>45 (HR 4.8; p=0.028) and LMR-
IPS 2 (HR 14; p=0.041). In the PFS multivariate analysis only LMR-IPS showed
to be an independent adverse prognostic factor both for the whole group (HR
4.5; p<0.001) and the advance HL patients (HR 3.5; p=0.013).
Figure 1.
Summary/Conclusions: Addition of absolute LMR improved the ability of IPS
and GHSG scores in identifying HL patients with worse responses and survival
after standard ABVD +/- RT. Particularly, LMR-IPS was able to identify a high
risk subgroup of patients with a 5y-PFS of 48% inside the patients with IPS>2.
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BRENTUXIMAB VEDOTIN-BENDAMUSTINE COMBINATION FOR HODGKIN
LYMPHOMA: EXPERIMENT WITH 8 PATIENTS
C Carola1,*, S Dennetiere2, P Votte1, JP Marolleau1, B Royer1
1CHU Amiens, Amiens, 2CH Compiegne, Compiegne, France
Background: Optimal treatment for patients (pts) with heavily pretreated
Hodgkin lymphoma (HL) is controversial. Long term outcomes from autologous
stem cell transplant (ASCT) in relapsed/refractory (R/R) HL are significantly
better in pts achieving complete remission (CR) from salvage chemotherapy
prior to ASCT. Brentuximab vedotin and bendamustine are highly active, as
single agents, for pts with R/R HL and have manageable safety profile. Bren-
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tuximab is an antiCD30 monoclonal antibody conjugated to monomethyl auris-
tatin E. Patients in CR after Brentuximab, particularly young pts and low risk
early stage disease, did not necessarily benefit additional consolidative therapy
(ASCT or allograft). Elsewhere, Brentuximab consolidation following ASCT
should be proposed for pts with primary refractory disease, early relapse, or
extra nodal disease.
Aims: To point brentuximab-bendamustine combination efficiency and safety
for R/R HL pts.
Methods: We retrospectively analyzed 8 HL pts in 2 centers, treated with
90mg/m2 bendamustine on days 1 and 2, and 1.8mg/kg brentuximab on day
1, every 3 weeks. Six pts were R/R (including 1 post ASCT), 1 in partial
response post chemotherapy and 1 in first line (contraindication to chemother-
apy, heart and respiratory failures).
Table 1.
Results: Median follow-up was 12 months [3-36] from beginning of treatment.
Median chemotherapy treatment was 4 courses [2-6]. Four pts were in CR, 3
in nearly CR, 1 refractory. Three pts underwent subsequently ASCT (2 where
in CR and 1 in nCR): 1 of them had brentuximab maintenance and 1 relapsed
post ASCT. One other pt in nCR beneficiated from reduced intensity-condition-
ing allograft. All pts remained alive at follow-up. This combination was well tol-
erated, without grade 3-4 toxicities: 2 pts had grade 1 anemia, 1 of them grade
2 neutropenia.
Summary/Conclusions: This regimen represents a promising approach to
optimize response rate prior to ASCT or allograft in pts with R/R HL. It could
also be proposed to frail pts as frontline treatment.
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HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS OF SURVIVAL
AND TREATMENT RELATED TOXICITIES OF A COHORT OF PATIENTS
DIAGNOSED BETWEEN 2005-2015
G Bras1,*, M Alpoim1, P Soares2, L Osório2, R Pinto1, F Príncipe1,
J Guimarães1
1Serviço de Hematologia Clínica, 2Serviço de Radioterapia, Centro Hospitalar
de São João, Porto, Portugal
Background: Hodgkin Lymphoma is highly sensitive to chemotherapy and
radiotherapy. Treatment related toxicity is a major concern and have a negative
impact on quality of life and overall survival of these patients.
Aims: To evaluate chemotherapy and radiotherapy attributable toxicity in a
cohort of Hodgkin Lymphoma survivors.
Methods: We performed a retrospective analysis of a Hodgkin Lymphoma
cohort diagnosed and treated in a Portuguese tertiary hospital centre, from
2005 to 2015. The toxicities assessed were: secondary neoplasia, infertility,
thyroid, cardiac, pulmonary, cerebrovascular and neuropsychiatric disorders.
Results: From 2005 to 2015, 151 patients were diagnosed and received first
treatment at our centre. 87 (56,7%) patients were male. At diagnosis, the medi-
an age was 34 (18-88) years. Prevalence of HIV infection was 9,9% (n=15).
Among 151 patients, 138 (91,4%) were treated with a curative intention: 12
(8,6%) had early-stage favourable disease; 39 (28,2%) early-stage
unfavourable; 87 (63%) advanced stage. As first line approach, 81 (58,7%)
were treated with chemotherapy alone and 57 (37,7%) with combined
chemotherapy and radiotherapy. The ABVD protocol was the chemotherapy
regimen in 122 (88,4%) patients, followed by BEACOPP in 7 (5,1%). Radio-
therapy was performed in 60 (41,7%) patients, with Involved Field protocol in
59. Overall Response Rate after first line treatment was 92% for early-stage
favourable, 86% for early-stage unfavourable, 71% for advanced-stage. Autol-
ogous Transplantation was performed in 17 patients (12,3%), all in context of
relapse or refractory disease. The 5-year Overall Survival was 86,3%. Among
patients diagnosed throughout reproductive age, 10,4% (n=10) underwent
gamete cryopreservation, while 24,4% (n=10) of females in fertile age under-
went on GnRH agonists for ovarian protection. The overall incidence of reported
treatment attributable toxicities was 57% (n=86). Pulmonary and neuropsychi-
atric disorders were the most commonly reported, 25,8% (n=39) and 29,8%
(n=45), respectively. Pulmonary complications developed independently of pre-
vious thoracic radiotherapy exposure (p>0,05). Other reported toxicities were:
infertility in 1% (n=1) of individuals in reproductive age; secondary neoplasia
in 4,6% (n=7) with median presentation after diagnosis of 36 months; thyroid
disorders in 7,9% (n=12), of which 75% (n=9) were exposed to cervical radio-
therapy; cardiac complications in 4,6% (n=7), the majority (n=5) was not
exposed to mediastinal radiotherapy; cerebrovascular disease developed in
3,3% (n=5).
Summary/Conclusions: In our cohort of Hodgkin Lymphoma survivors,
chemotherapy and radiotherapy attributable toxicities had a significant preva-
lence. The short follow-up period and the lack of a fully applied surveillance
protocol might be the reason for the lower prevalence of toxicities observed in
this cohort, in comparison with the most relevant published studies. The devel-
opment of surveillance protocols for detection of short and long-term toxicities
are of major importance to understand their true impact in overall survival and
quality of life of Hodgkin Lymphoma survivors.
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BENDAMUSTINE-BRENTUXIMAB COMBINATION IS EFFECTIVE AND
HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF
REFRACTORY AND RELAPSED HODGKIN LYMPHOMA
C Cerchione*, M Di Perna, N Pugliese, R Della Pepa, M Raimondo, F Pane,
M Picardi
Hematology, Ematologia e Trapianto/AU Federico II, Napoli, Italy
Background: The management of patients with refractory or relapsed Hodkin
lymphoma (HL), expecially if after autologous stem cell transplantation (ASCT)
remains controversial. Bendamustine has demonstrated efficacy in several
lymphoproliferative disorders but limited data are available regarding the sched-
ule in patients with HL, in particular its dosage and the possibile combinations
for a synergistic effect. Brentuximab Vedotin is a CD30-directed antibody-drug
conjugate, currently approved for the treatment of relapsed or refractory
Hodgkin lymphoma (HL), as single-agent at the dose of 1.8 mg/kg.
Aims: The objective of this phase II study was to evaluate efficacy and safety
of salvage cytotoxic regimens in patients with refractory and/or relapsed HL.
Three different schedules were evaluated.
Methods: From May 2011 to February 2016, 24 patients (13 M/11 F) (Table 1)
with a median age of 32.5 years (range 16-73) received a salvage regimen
after failure of ASCT. Patients were by chance assigned to one of these three
arms : Standard dose Bendamustine (90 mg/sqm) days 1, 2 + DHAP x 3 cycles
(Arm A), brentuximab single agent 1.8 mg/kg x 4-8 cycles (Arm B), High dose
Bendamustine (120 mg/sqm, days 1, 2) + brentuximab 1.8 mg/kg (day 3) x 4-
6 cycles (Arm C). Each cycle was repeated every 28 days and growth factor
support was sistemically administered, in association with antimicrobial pro-
phylaxis. The treatment efficacy in each group was evaluated according to
Revised Response Criteria for Malignant Lymphoma. Any adverse event
occurred was recorded and classified for type and grade using NCI-CTCAE
criteria (v 4.0).
Results: In arm A, which included 10 patients, the overall response ratio was
40%, with 4 complete remission (CR) and 6 progressive disease (PD). Extra-
hematological toxicities were grade 3 thrombocytopenia in 4 patients and bone
marrow aplasia in 1 patient. In arm B, which included 6 patients, the overall
response ratio was 66%, with 4 CR and 2 PR. Extra-hematological toxicities
were grade 3 neuropathy in 1 patient, hematological toxicity was grade 2 neu-
tropenia in 2 patients. In arm C, which included 8 patients, the overall response
ratio was 100%, with 8 complete remission (CR) and then SCT (4 autologous
and 4 haploidentical-SCT) with persistence of complete remission in all
patients. Median overall survival was 32.2 months (r. 27-44) and median pro-
gression free survival 15.3 months (r. 9-18.4). Extra-hematological toxicities
were increase of transaminase in 2 patients and CMV reactivation in 2 patients,
treated successfully with valgangiclovir. Hematological toxicity was grade 3
thrombocytopenia in 2 patients.
Table 1.
Summary/Conclusions: High dose Bendamustine plus Brentuximab has
shown significant efficacy in a particular severe setting of heavily pretreated
patients, and it could be considered as a bridge to allogenic BMT.
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UPDATES ON EFFICACY AND SAFETY OF DOSE-DENSE AND
DOSE-INTENSE (DD-DI) ABVD AS FRONTLINE THERAPY OF ADVANCED
CLASSICAL HODGKIN LYMPHOMA (HL)
S De Lorenzo1,*, M Barone1, F Rivellini1, V Belsito1, M Langella1, V Maglione1,
P De Prisco1, AP Campana1, C Ingenito1, L Sparano2, AM D’Arco1
1UOC Oncoematologia, 2UO Anatomia Patologica, PO "A. Tortora", Pagani
(SA), Italy
Background: The optimal therapeutic upfront strategy in advanced classic HL
hasn’t yet been standardized. In recent years, the scientific community has giv-
en greater attention to the concept of dose-intensity and several studies demon-
strated that intensifying therapy through dose-escalation of drugs and shorten-
ing cycle intervals yields best results than standard ABVD. However, the best
frontline approach is still debated and the dispute remains between 2 strategies:
1)The “first hit principle” followed by dose reduction in early responders, 2) The
“standard dose” followed by the “second hit” in poor responders.
Aims: Based on the promising results of our recent experience (D’Arco et al,
2015) and of a phase II trial of DD-DI ABVD in advanced HL (Russo et al, 2014)
we expanded our previous series and updated follow-up to confirm our findings.
Methods: We treated in frontline, 22 consecutive cases of advanced HL with
the ABVD DD-DI protocol (Russo et al, 2014), between June 2011 and December
2015. The drugs were given on days 1 and 11, at the doses of standard ABVD
except for doxorubicin (escalated to 35 mg/m2, in the first 4 of 6 cycles). Cycles
were administered every 21 days plus granulocyte-colony stimulating growth
factors. Patients received prophylaxis with cotrimoxazole and lamivudine (as
required).
Results: 22 patients were treated in frontline. The median age was 43 years
(range: 23-67) and unfavourable risk factors such as erytrocyte sedimentation
rate>50 mm/h, ≥3 nodal areas, International Prognostic Score≥3 were present
in 68%, 77%, 59% of patients, respectively. All patients completed the planned
six courses of therapy without dose reductions or delay. Toxicities were: grade
III-IV neutropenia and anemia (9%). Other relevant toxicities were: grade 2
mucocutaneous changes (23%) consisting of skin rash, skin hyperpigmentation
and nail alterations, grade 2 transaminases elevation (14%), grade 2 and 3
vomiting (27%) and grade 2 fatigue (18%). We didn’t observe severe or pro-
longed infections or acute/delayed cardiac or pulmonary toxicities. The overall
response rate (ORR) was 100%, complete response (CR) were 91%, partial
response (PR) were 9%. In patients with bulky disease, 83% achieved CR at
the end of treatment. Positron emission tomography (PET) after 2 and 4 cycles
was negative in 68% and 91% patients, respectively. Only 2 patients were in
PR at the end of cycle 6 and underwent to consolidation treatment: 1) Radio-
therapy (RT); 2) High-dose therapy followed by autologous stem cell transplan-
tation (ASCT), improving PR, then salvage with brentuximab vedotin, reaching
CR. At a median follow-up of 31.5 months (range: 4-53), all patients were alive
and in continuous CR and the median progression free survival (mPFS) hasn’t
been reached.
Summary/Conclusions: On a larger series, we confirm the safety and feasi-
bility of ABVDDD-DI, in the context of “real life” clinical practice. This intensified
schedule seems to be promising in increasing the efficacy of standard ABVD,
in the subset of advanced, high risk HL, in frontline therapy. Our results reinforce
the critical role of dose-intensity to achieve CR and probably to reduce the
need for salvage therapy followed by ASCT. Probably, the role of RT may be
limited to patients with positive PET disease sites, at the end of treatment, as
already demonstrated for BEACOPPescalated in the same context (Engert et
al, 2012). Finally, even with a longer median follow-up (31.5 months), mPFS
hasn’t yet been reached and relevant toxicities haven’t been highlighted. 
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HIGH THROUGHPUT TCR SEQUENCING PROVIDES ADDED VALUE IN
THE DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA
I Kirsch1,*, R Watanabe2, D Williamson3, J O’Malley4, LL Scott2, C Elco5,
J Teague2, A Gehad2, E Lowry2, N LeBoeuf2, J Krueger6, H Robins7, T Kupper2,
R Clarke2
1Translational Medicine, Adaptive Biotechnologies, Seattle, 2Dermatology,
Brigham and Women’s Hospital, Boston, 3Client Services, Adaptive Biotech-
nologies, Seattle, 4Pathology, Brigham and Women’s Hospital, Boston, 5Pathol-
ogy, Brown University, Providence, 6Dermatology, Rockefeller University, New
York, 7Adaptive Biotechnologies, Seattle, United States
Background: Diagnosis of early-stage CTCL can be challenging because skin
lesions contain a mixture of both diverse benign and clonal malignant T cells.
High throughput sequencing (HTS) of the TCR gamma (TCRG) and TCR beta
(TCRB) CDR3 regions is a technique that provides comprehensive analysis of
the total repertoire of T cell clones in a specimen, the breadth of repertoire
diversity, and an exact quantitation of individual T cell clone
Aims: We investigated whether the Adaptive Biotechnologies multiplex PCR
and high throughput sequencing assays of TCRB and TCRG could discriminate
between benign and malignant T-cell skin dyscrasias
Methods: We analyzed skin biopsies from 46 patients with histopathologically
and clinically (based on presentation, history, and course) labelled CTCL (over
80% Stage I or Stage II), 23 patients with psoriasis, 11 eczematous dermatitis,
10 allergic dermatitis, and 6 with normal skin findings.
Results: The TCRB and TCRG assays were able to define the dominant clonal
sequences in every CTCL case and to distinguish likely gamma/delta from
alpha/beta lymphoma. Using the fraction of the top two TCRG sequences as a
fraction of the total nucleated cell population defined a cut off of approximately
1/1000 above which the biopsy was highly specific for malignant disease and
below which the assay approached 100% specificity for non-malignant disease.
The discrimination afforded by reference to the per cent comprised by the top
two TCRG sequences of all TCRG sequences generated from the sample (most
comparable to data generated by TCR PCR) was not nearly as robust. TCR
PCR failed to provide relevant categorization in approximately 30% of the same
CTCL cases. This approach also was able to identify low level presence of
CTCL-correlated clones in systemic circulation and to distinguish subsequent
inflammatory reactions from disease recurrence. Analysis of CTCL TCRG genes
was consistent with CTCL being a malignancy derived from mature T cells.
Summary/Conclusions: Multiplex PCR and high throughput sequencing of
TCRG and TCRB loci in suspect skin lesions was able to impact and add value
to the diagnosis and monitoring of patients with early stage cutaneous T-cell
lymphoma.
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SENSITIVITY OF ULTRASOUND-GUIDED 16 G CORE-NEEDLE CUTTING
BIOPSY AND EXCISIONAL BIOPSY FOR THE CHARACTERIZATION OF
LYMPHADENOPATHIES IN PATIENTS WITH SUSPECTED LYMPHOMA: A
RANDOMIZED SUPERIORITY TRIAL
N Pugliese1,*, M Di Perna1, I Cozzolino2, G Ciancia2, V Varone2, R Della Pepa1,
C Cerchione1, F Cacace1, F Pane1, M Picardi1
1Hematology, 2University of Naples Federico II, Naples, Italy
Background: The performance of lymph node excisional biopsy requires vali-
dation. Although fine-needle aspiration under image guidance offers an alterna-
tive to open biopsies, its sensitivity in lymphoma diagnosis is still a matter of
debate. New approaches to imaging-guided methods are needed. The intro-
duction of new generation ultrasonographic devices (particularly effective in pre-
dicting the malignant status of lymphadenopathies), and progress in tissue sam-
pling with needles with cutting edge of adequate diameter (particularly effective
in providing architectural information of the core of nodal lesion) have enabled
to obtain enough tissue for a definitive diagnosis (according to the WHO Clas-
sification) by mini-invasive procedures, without the need of excisional biopsy.
Aims: The primary endpoint was to demonstrate the superiority in terms of
sensitivity in detecting malignancy of ultrasound (US)-guided core-needle cut-
ting biopsy (CNCB) compared with standard excisional biopsy of lym-
phoadenopathies suspected for lymphoma. Secondary endpoints were: speci-
ficity, positive predictive value (PPV), negative predictive value (NPV), compli-
cation rate related to each diagnostic procedures and relative cost analysis.
Methods: From January 2009 to December 2015, in this single centre trial,
patients having lymphoadenopathies with clinical suspicion of lymphoma were
randomly assigned (1:1) to either US-guided CNCB or standard excisional biop-
sy. In the US-guided group, patients underwent baseline US exploration of all
superficial lymph node areas and any abnormal lymph node underwent pow-
er-Doppler study to select the site of CNCB. The CNCB were all performed
using a 16 gauge modified Menghini-type needle 150 mm in length with auto-
matic aspiration (Biomol HS-Hospital). The selection of lymph node in the exci-
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sional biopsy (standard) group was suggested by the physical examination (at
surgeon’s discretion).
Results: Overall, 372 patients were randomized into two well-matched arms.
Histology showed a malignancies in 93% (172/185) of patients in the US-guided
group (lymphoma, 151 patients; carcinoma, 21 patients) and in 80% (149/187)
of patients in the standard group (lymphoma, 122 patients; carcinoma, 27
patients). During the follow-up of the patients with lymph nodes reported as
being reactive, 19 of 38 patients in the standard group were rebiopsied and
were found to have lymphoma or carcinoma at the subsequent lymph node
histology, whereas three of the six patients in the US-guided group requiring a
second biopsy were found to be positive for lymphoma diagnosis. Thus, sen-
sitivity in detecting malignancy was higher in the US-guided group compared
with the standard group (172/175 [98%] vs 149/168 [89%]; p=.0003), demon-
strating the superiority of US-guided CNCB in reaching a definitive histopatho-
logical diagnosis for malignancies. Biopsy provided false-negative results for
malignancy in 10.2% of patients affected by lymphoma in the standard group
and 1.6% in the US-guided group (p=.0005). Furthermore, US-guided CNCB
showed higher NPV than traditional biopsy, 80% (12/15) vs 50% (19/38; p=.04),
respectively. No differences were found in terms of specificity and PPV between
the two diagnostic techniques, by the time that no false positive were detected
in both groups. Estimated cost per diagnosed with traditional biopsy was 11-
fold higher compared with US-guided CNB group (p<.0001). Overall complica-
tion rate was significantly higher in patients who received excisional biopsy
(78%) than in patients who underwent US-guided CNCB (15%), p<.0001.
Summary/Conclusions: US-guided CNCB has proven to be a quick, safe,
and efficient technique and has radically altered the diagnostic strategy of
enlarged lymph nodes at our institution, avoiding unnecessary lymph node
excisions.
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MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE
VS INVESTIGATOR’S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY
MANTLE CELL LYMPHOMA
L Arcaini1,2,*, S Rule3, T Lamy4, J Walewski5, D Belada6, J Mayer7, J Radford8,
W Jurczak9, F Morschhauser10, J Alexeeva11, T Biyukov12, M Patturajan13,
ML Casadebaig Bravo12, M Trněný14
1Department of Molecular Medicine, University of Pavia, 2Department of Hema-
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Background: Although most patients with mantle cell lymphoma (MCL)
respond to initial therapy, relapses are common and lead to increasingly shorter
remissions. Lenalidomide, an IMiD® immunomodulatory agent with direct and
immune-mediated mechanisms of action, has demonstrated efficacy and safety
in relapsed/refractory (R/R) MCL in multiple studies, including heavily pretreated
patients.
Aims: Evaluate results after an additional 1 year of follow-up after primary
analysis for the randomized MCL-002 (SPRINT) study comparing lenalidomide
vs investigator’s choice (IC) monotherapy in R/R MCL patients.
Methods: MCL-002 is a multicenter, open-label study in MCL patients who had
1-3 relapses or failed prior therapy (including an alkylating agent and an anthra-
cycline, and/or cytarabine, and/or fludarabine [± rituximab]) and were ineligible
for intensified chemotherapy or stem cell transplantation (NCT00875667). Upon
informed consent, oral lenalidomide was initiated at 25 mg/day on days 1-21 of
28-day cycles until disease progression or as tolerated. IC treatment included
single-agent rituximab, gemcitabine, fludarabine, chlorambucil, or cytarabine.
The primary endpoint was progression-free survival (PFS, central review per
modified 1999 IWG criteria); secondary endpoints included ORR, time to
response, OS, and safety. Post-primary analysis (07March2014) all subsequent
analyses are based on investigator’s assessment.
Results: 254 patients were randomized 2:1 to lenalidomide (n=170) or IC
(n=84). As of the current data cut-off of March 7, 2015, 21 (12%) patients remain
on lenalidomide and 2 (2%) patients on IC. With an additional 1 year of follow-
up from the primary analysis (median 21.0 month follow-up [range, 0.02-69.6]),
the median PFS by investigator assessment continues to show improvement
for lenalidomide over IC (8.6 vs 5.4 months, respectively), with an HR=0.67
(95% CI, 0.48-0.89; sequential log-rank P=0.012). Response rates showed a
similar trend with an ORR of 46% vs 23% (P<0.001) and CR/CRu of 12% vs
8% (P=0.336) for lenalidomide vs IC, respectively. Median time to best response
was 5.9 vs 13.1 months and median OS was 27.8 vs 21.1 months. Among the
safety population (250 patients receiving ≥1 dose of study drug), 68% of
lenalidomide and 40% of IC patients with ≥1 adverse event (AE) had dose
reductions/interruptions, in part due to a longer duration of lenalidomide treat-
ment and strict dose modification requirements. At a median time of 2.9 months
(range, 0.7-37.8) from randomization, 39 patients (46%) crossed over from IC
to lenalidomide. The most common grade 3/4 AEs were neutropenia (45% for
lenalidomide vs 34%% for IC, without increased risk of infection), thrombocy-
topenia (20% vs 28%), anemia (9% vs 7%), and leukopenia (8% vs 11%). Non-
hematologic AEs with lenalidomide were primarily grade 1/2. Any-grade tumor
flare reaction was observed in 10% of lenalidomide patients (2% grade ≥3),
and 1 patient in each arm experienced tumor lysis syndrome. Invasive second
primary malignancies were identified in 4% of lenalidomide and 5% of IC
patients.
Summary/Conclusions: Lenalidomide continues to show significantly
improved PFS and ORR by investigator assessment compared with IC in
patients with R/R MCL, which was similar to previous central review. The con-
sistent safety profile of lenalidomide partly reflected longer treatment exposure;
AEs were manageable with dose modifications or supportive therapy. Overall,
long-term follow-up of the MCL-002 trial confirms the improved efficacy of
lenalidomide relative to IC monotherapy in patients with R/R MCL.
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CENTRE EXPERIENCE
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Background: Addition of the anti CD20 monoclonal antibody, rituximab, to
chemotherapy regimens for the treatment of B cell non Hodgkin lymphomas
has been standard practice in the UK since 2003. The initial licence for ritux-
imab was for intravenous (IV) administration. Subcutaneous (SC) rituximab
was granted marketing authorisation in March 2014. Administration of IV ritux-
imab takes between 90 and 270 minutes depending on a number of factors
including the chemotherapy regimen used and the number of doses a patient
has already received. SC rituximab takes 5-10 minutes to give. Prior to July
2014 80% of rituximab doses given at University Hospital of Wales (UHW)
were prepared by our in house pharmacy staff and 20% of doses were bought
in ready prepared bags, to allow flexibility in chemotherapy scheduling. SC rit-
uximab is given as a standard dose for all patients and can be made up by
nursing staff in the chemotherapy day unit.
Aims: To investigate cost savings and reduction in chair times for patients
treated with chemotherapy regimens containing SC rituximab therapy com-
pared to IV rituximab therapy in a single centre in the UK. Infusion related
adverse events were also recorded for the study period.
Methods: Following local governance approval, the UHW department of
haematology switched from IV to SC rituximab in July 2014. The policy change
only applied to patients with a diagnosis of diffuse large B cell lymphoma (DLB-
CL) or follicular lymphoma (FL) receiving treatment with R-CHOP, R-CVP or
R-bendamustine chemotherapy regimens plus any maintenance doses. All dis-
pensed SC doses of rituximab were retrospectively identified from our phar-
macy system in 2015. The actual cost of the SC doses was compared to pro-
jected drug costs and staff time for doses given IV with 20% pre prepared drug
being bought in as prior to 2014. The chemotherapy day unit audited chair time
for the same patient group receiving rituximab containing regimens during a
12 month period in 2013 prior to the change in practice and another 12 month
period in 2015 post the changes. Patient notes were retrospectively audited
for the same 2 time periods in 2013 and 2015 to record documented compli-
cations of rituximab administration.
Results: 92 patients with DLBCL or FL were treated in 2015, receiving a total
of 372 doses of SC rituximab. The annual drug cost savings were estimated at
£20K. The reduced time spent by pharmacy staff in the aseptic unit was esti-
mated at 160 hours annually. The chemotherapy administration time audit
showed that prior to the policy change, average administration times were as
follows: R-CHOP 260 minutes (mins), R-CVP 135 mins, R-bendamustine 180
mins and maintenance rituximab 150 mins. Post July 2014 the average admin-
istration times were as follows: R-CHOP 130 mins, R-CVP 50 mins, R-Ben-
damustine 45 mins and maintenance rituximab 11 mins. This reduction in treat-
ment administration translated into a saving of chair times of 842 hours in 12
months (approximately 72 hrs per month) (Fig 1). Retrospective review of
patient notes did not show any increase in adverse events relating to SC ritux-
imab administration. 
Summary/Conclusions: The introduction of SC rituximab at the UHW resulted
in reduced drug costs, reduced staff time in drug preparation and significant
reductions in chemotherapy chair time for patients with no evidence of an
increase in adverse events relating to drug administration. These savings have
freed resources to allow for other therapies to be accommodated into the exist-
ing service.
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Background: Patients with relapsed/refractory mantle cell lymphoma (R/R
MCL) show poor overall survival (OS) after experiencing failure to
immunochemotherapy and other treatment regimens, including bortezomib.
Lenalidomide is an IMiD® immunomodulatory agent with direct and immune-
mediated mechanisms of action that has demonstrated safety and efficacy
(including meaningful disease stabilization rates) in multiple studies of R/R
MCL.
Aims: Post hoc analysis of lenalidomide-treated patients from the MCL-001
and MCL-002 studies to determine the survival benefit based on response sta-
tus (focusing on patients with stable disease [SD]) at landmark points in time.
Methods: Patients receiving oral lenalidomide 25 mg/day on days 1-21 of each
28-day cycle until disease progression or as tolerated were evaluated from 2
phase II studies: MCL-001 (post-bortezomib failure) and MCL-002 (randomized
vs investigator’s choice monotherapy). Patients provided informed consent for
each study. Kaplan-Meier methods and unadjusted Cox regression models
were used to support the landmark analyses at the start of cycles 3, 5, and 7.
Survival data for patients with SD were compared with those with progressive
disease (PD) or those responding with at least a partial response (PR) for each
time point. Data cutoff for MCL-001 was March 20, 2013 and for MCL-002 was
March 7, 2015.
Results: 304 patients who received lenalidomide in MCL-001 (n=134) and
MCL-002 (n=170) were included in the analysis. At baseline, patients had a
median age of 68.0 years (66% were ≥65 years of age), 76% were male, 91%
had stage III/IV MCL at diagnosis, and 52% had high tumor burden. Patients
had received a median of 2 prior lines of antilymphoma therapy (range, 1-10);
48% were refractory (≤SD) to their last therapy. Baseline demographics and
characteristics were similar for patients with ≥PR, SD, and PD. Response status
at each cycle is shown in Table 1, with no response data for 24% of patients at
cycle 3 due to early discontinuation, censoring or response being outside the
time point window. Median OS in months by response group at cycle 3 was
28.5 for ≥PR, 34.0 for SD, and 11.3 for PD; at cycle 5: 45.3 for ≥PR, 34.7 for
SD, and 13.4 for PD; and at cycle 7: not reached for ≥PR, 37.5 for SD, and
17.4 for PD. At all three time points, there was no significant difference in OS
for patients with ≥PR vs SD, whereas the median OS for patients with SD was
significantly prolonged vs PD. It is important to note that the SD and PD groups
had a small number of patients at the later cycles.
Table 1. Response status and OS at cycles 3, 5 and 7.
Summary/Conclusions: Landmark analyses for lenalidomide-treated R/R
MCL patients with SD at cycles 3, 5, and 7 had OS comparable to patients who
achieved ≥PR. Overall, these data show that R/R MCL patients with either SD
or ≥PR at these time points have significantly improved long-term outcomes
compared to those with PD.
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Background: Follicular lymphoma (FL) is the most common indolent non-
Hodgkin Lymphoma. Treatment of stage I disease is usually radiation monother-
apy, but debate over the role of additional chemo-immunotherapy exists. Most
of the data on treatment and prognosis are based on retrospective historical
cohorts before PET-CT was introduced into routine staging procedures. In these
previous cohorts, 5 year freedom from treatment failure (FFTF) was 60-80%
and the 5 year overall survival (OS) was 80-93%. 
Aims: The current study assessed the outcome of patients diagnosed with
stage I FL who were treated with radiotherapy with or without rituximab, in the
PET-CT era.
Methods: Patients diagnosed with stage I FL based on PET-CT and bone mar-
row biopsy (BMB), who were treated with involved field radiotherapy between
2002-2015, were retrospectively reviewed in this multi-center study. Patients
were treated with either radiation monotherapy or radiotherapy and rituximab. 
Results: Ninety one patients from 9 centers were identified. The median age
at diagnosis was 60 years (range: 31-93) years. FLIPI score was compatible
with a low risk disease (0 or 1) in 93% and with an intermediate risk (FLIPI =2)
in 7% of the patients. Forty eight percent of the patients had FL Grade 1,
39%>Grade 2 and 13% -Grade 3a FL, with 30% presenting with an extra-nodal
disease. Median radiation dose was 30.2 (18-50) Gy. Most patients were treated
with radiation monotherapy (71 patients, 78%), additional rituximab was admin-
istered to 20 patients (22%). Within a median follow-up of 57 months, the 5
year FFTF and OS survival rates were 76% and 97% respectively (Figure 1).
Twenty one percent of the patients (n=19) experienced relapse; most relapses
(n=14) were outside the radiation field. An intermediate risk FLIPI score was
the only independent significant factor for a shorter FFTF [HR=2.3, 95% CI=
1.096 - 4.89, p=0.028].Radiation dose or adjuvant rituximab therapy did not
significantly affect outcome.
Figure 1. Outcome of patients with FL stage I, determined by PET.
Summary/Conclusions: Our findings show that staging with PET-CT and BMB
of stage I FL may result in improved FFTF and OS in patients treated with radio-
therapy compared to historical cohorts, possibly due to better identification of a
true stage I disease. The distant nature of recurrences suggests that occult dis-
tant disease foci, not diagnosed even by PET-CT, are still possible.
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Background: Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin
lymphoma (iNHL) are B-cell malignancies associated with neutropenia, anemia
and thrombocytopenia. Although the etiology of cytopenia is not well understood,
bone marrow leukemia/lymphoma cell infiltrates are thought to contribute. Ide-
lalisib (IDELA) is a selective, first-in-class oral PI3Kδ inhibitor. In preclinical stud-
ies, IDELA selectively targeted malignant B cells with minimal toxicity to non-
malignant B cells and other hematopoietic cell types. In clinical studies evalu-
ating IDELA in B-cell malignancies, hematologic responses across all 3 lineages
were observed in a majority of patients (pts) with baseline (BL) cytopenias.
Aims: The objective of this post hoc analysis was to evaluate hemogram
changes in pts with relapsed or refractory (R/R) CLL or iNHL treated with IDELA
in 2 pivotal studies.
Methods: In phase 3 Study 116, frail pts with CLL were randomized to receive
rituximab (R) in combination with IDELA 150 mg BID or placebo (PBO). In
phase 2 Study 101-09 (NCT01282424), pts with iNHL received IDELA
monotherapy 150 mg BID. Trial inclusion criteria allowed enrollment of pts with
BL cytopenias of any grade (CLL) or grade ˂3 (iNHL). Hematologic profiles for
pts were categorized as normal or abnormal (any grade of cytopenia) at BL
and assessed while on treatment. Supportive care utilization was assessed by
use of blood product transfusions, hematopoietic growth factors, and immuno-
suppressant therapies. Treatment-emergent de novo autoimmune cytopenias
(AIC) and/or worsening of pre-existing AIC were summarized. All analyses
excluded pts from the iNHL study with PD at the first assessment to avoid con-
founding by underlying uncontrolled disease.
Results: A total of 345 pts participated in these trials. The overall response
rates for IDELA-treated patients in the CLL and iNHL studies were 84% and
58%, respectively. For pts with CLL on IDL+R (n=110), BL cytopenias (grade
≥1) included anemia (76%), thrombocytopenia (62%), and neutropenia (34%).
For pts with iNHL on IDELA-monotherapy (n=115), BL cytopenias included ane-
mia (50%), thrombocytopenia (36%), and neutropenia (24%). In patients with a
normal hemogram at BL, median hematologic values remained unchanged over
time with IDELA treatment. In patients with BL cytopenia, IDELA treatment was
associated with improved Hgb and platelet counts and a reduction in supportive
care utilization for anemia, thrombocytopenia, and neutropenia. For pts with
CLL, median peak values for Hgb (24% above BL) and platelets (120% above
BL) were observed within 6 months of IDELA initiation. For pts with iNHL, median
peak values for Hgb (20% above BL) and platelets (64% above BL) were
observed within 3 months of IDELA initiation. ANC remained stable over time in
IDELA-treated pts with CLL and increased in pts with iNHL; a reduction in G-
CSF utilization was observed for pts with CLL or iNHL and BL cytopenias while
on treatment with IDELA. A history of AIC was reported in 6.4% and 16.4% of
pts with CLL on IDELA+R and PBO+R, respectively. As of the data cutoff, no pt
had experienced treatment-emergent AIC and/or worsening of pre-existing AIC.
Figure 1.
Summary/Conclusions: This analysis indicates improved cytopenia in 2 line-
ages for pts with R/R CLL and iNHL treated with IDELA. Thus, pre-existing
cytopenias, including those due to advanced disease, myelosuppression from
prior chemotherapy, and AIC, do not by themselves preclude treatment with
IDELA.
Studies included in this analysis: 101-09: NCT01282424; GS-US-312-0116:
NCT01539512
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Background: Ofatumumab is a novel anti-CD20 monoclonal antibody which
has been approved for the treatment of chronic lymphocytic leukemia, but lim-
ited data exist for patients with Waldenström’s macroglobulinemia (WM). Ofa-
tumumab targets CD20 in a different epitope than rituximab and may also have
a more favorable profile regarding infusion related reactions since, in contrast
to rituximab, it is a human and not chimeric antibody. Fludarabine with
cyclophosphamide (FC) is a very effective treatment when combined with rit-
uximab (FCR) in patients with relapsed or refractory WM. 
Aims: to evaluate the combination of ofatumumab with FC (OFC) in sympto-
matic patients with relapsed or refractory WM requiring therapy
Methods: This is a phase 2 single center trial. Treatment consisted of four
cycles of the OFC combination. A single dose of 100 mg of ofatumumab was
given I.V. on day 1 of the first cycle followed by 1000 mg on day 8. Fludarabine
25 mg/m2 and cyclophosphamide 250 mg/m2 were given intravenously for 3
consecutive days every 28 days for 4 cycles, followed by ofatumumab (1000
mg) in cycles 2 to 4. Primary end point was overall response rate (complete
(CR)+very good (VGPR)+partial (PR)+minor (MR) response) and secondary
endpoints included safety and toxicity, occurrence of “IgM flare”, duration of
response, progression free and overall survival 
Results: From 2013 until 2014, twelve patients were treated with OFC; 75%
and 17% were high and intermediate risk per the International Prognostic Scoring
System for WM. All patients had previously been exposed to rituximab and 4
(33%) were refractory to the last course of rituximab, while 4 (33%) had previously
received bortezomib. On intent to treat, 11/12 (92%) patients responded (17%
VGPR, 67% PR and 8% MR). Median time to first response (≥MR) was 2.2
months and median time to ≥PR was 8.5 months. In 11 (92%) patients a contin-
uing decrease of IgM levels has been observed and at 6 months post OFC com-
pletion 6 (50%) patients have improved their response from MR to PR or VGPR.
“IgM flare” was not observed. All patients completed the planned 4 cycles of
treatment. Infusion related reactions occurred in only one patient (grade 2) who
had a history of severe rituximab intolerance, during the day 8 dosing (1000 mg);
the patient completed the full schedule without further reactions. After a median
follow-up of 23 months, patients have progressed or died and the median pro-
gression-free survival is 21 months. The 2-year duration of response for patients
with ≥PR is 70%, and 2-year survival is 83%. Neutropenia grade 3 occurred in
67% and grade 4 in 25% of patients. One patient experienced neutropenic fever
and the dose of FC was reduced according to the protocol.
Summary/Conclusions: OFC is a rapidly acting combination, inducing high
response rates, including deep and durable responses in heavily pretreated
WM patients, even in those refractory to rituximab and/or bortezomib. Ofatu-
mumab is well tolerated with low incidence of infusion related reactions, and
although the combination has myelotoxicity, it is manageable. 
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Background: Follicular lymphoma (FL) is highly associated with the molecular
rearrangement BCL2/IGH. Although BCL2/IGH has been studied many times,
its real clinical value remains still matter of debates. 
Aims: In our work, we focused on the mutual relationship between molecular
levels of BCL2/IGH measured in peripheral blood (PB) and clinical course of FL.
Methods: We performed qualitative and quantitative testing of BCL2/IGH by
nested and real-time PCR in FL patients (grade 1-3B). PB samples were tested
before the start of therapy (or watch and wait period, 12.8% cases), during
treatment and during follow up at the time of routine clinical controls. According
to mutual correlation of clinical course FL and molecular activity in PB, we
divided patients into five groups (A, B, C, D, E): Group A included patients in a
long-term molecular and clinical remission. Group B was defined by long-term
remission with sporadic molecular activity. Group C included patients with con-
cordant clinical and molecular remission and progression. Group D included
patients with discordant clinical and molecular activity; there are two subgroups:
1) DM defined as evident molecular positivity in lasting clinical remission, and
2) DR defined by a clinically evident relapse in lasting molecular remission.
Group E includes non-evaluable patients with the initial molecular negativity in
PB, patients without treatment (watch and wait) and patients with lack of sam-
ples. Groups A and B with lasting molecular and clinical remissions brought no
correlation information, the only informative population is represented by sub-
groups C and D.
Results: Totally, 187 patients with initial BCL2/IGH positivity were included,
median of molecular follow up was 4.7 ys (range 1.1-14.8 ys) and median clin-
ical follow up 5.3 ys (range 0.4-18.4ys); systemic treatment (chemotherapy or
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immunochemotherapy) was administered in 173/187 (92.5%) cases. There
were 83 men (44%) with median age of 57 ys (range 28-79 ys), clinical stage
III-IV was determined in 144/187 (77%) patients. Median number of PCR sam-
ples per patient was 15 (range 3-67). There were 60 (32.2%) patients in group
A, 16 (8.7%) pts in group B, 39 (20.8%) pts in group C, 26 pts (13.9%) in group
D and 46 (24.6%) pts in group E. Groups C and D (65 pts) gave a relevant cor-
relation information only; the proportion of discordant cases was 26/65 (40%)
pts. As mentioned, group D was divided into two subgroups: DR group (clinical
relapse in molecular remission) with 19 (10.2%) patients, 17/19 (89.5%) patients
remain alive with median overall survival (OS) of 8.5 ys. DM subgroup (mole-
cular activity in lasting clinical remission) consisting of 7 pts, all of them remain
alive with median OS of 12.1 ys. Interestingly, 10/39 (25.6%) patients sub-
scribed into group C died (median OS 4.5 ys; 7 cases with confirmed death
due to FL progression), compared to 2/26 died patients from group D (7.7%, 1
died probably due to progression only) with median OS of 8.8 ys (p 0.067).
Summary/Conclusions: Based on our results, molecular activity of BCL2/IGH
in blood does not correlate sufficiently with clinical activity of FL in about 40%
cases. However, patients with correlating molecular activity in their clinical
relapses seem to have a tendency to a worse prognosis with more deaths relat-
ed to FL and shorter overall survival. We can speculate, that release bcl2/IGH+
cells into PB mirrors the real aggressiveness of FL.
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Background: Follicular lymphoma (FL) is an indolent lymphoma with an excel-
lent prognosis. With the incorporation of chemoimmunotherapy, more than 70%
of the patients survive at 10 years. The clinical significance of FL histologic
grading according to the WHO Classification into grades 1/2 and grades 3A
and 3B is still a matter of debate.
Aims: To study the clinical and laboratory characteristics of grade 3A and 3B
FL compared to grades 1 and 2 and to explore whether higher grades are asso-
ciated with a worse outcome.
Methods: We retrospectively studied all patients with FL diagnosed and treated
in a single University Hematology Unit between 2001 and 2015.
Table 1. Patients’ Characteristics (N=53)9 (103-556).
Results: Among 200 consecutive patients with FL with a median follow-up of
76 months (0.1-186), 53 patients with grade 3 FL were identified (47 with grade
3A and 6 with grade 3B). Patients’ characteristics are shown in the table. The
comparison between grade 3 and grades 1 and 2 patients revealed the following
significant differences: Grade 3 cases had more frequently Ki-67>30%
(p<0.0001), CD10 negativity (p=0.009), high LDH levels (p=0.009) and lympho-
cytopenia <0.8/μL (p=0.05). FLIPI score and bulky disease did not differ signif-
icantly. There was a trend that did not reach statistical significance for male gen-
der, localized stage and absence of bone marrow involvement to be more fre-
quent in grade 3 compared to grades 1/2. Treatment also differed significantly
between the two groups (p<0.0001): 60% of grade 3 patients were treated with
Rituximab (R)-CHOP, while 52% of grade 1/2 patients were treated with R-alky-
lators (chlorambucil or CVP). The outcome of grade 3 patients was not inferior:
10-year PFS was 64% vs 55.6% and 10-year OS was 83.7% vs 84.4% for grade
3 and grade 1/2 patients, respectively. Moreover, a plateau in the survival curves
of grade 3 patients was observed in contrast to a constantly relapsing course of
grades 1 and 2 cases. Among the 53 patients with grade 3, prognostic factor
analysis revealed that Ki-67, age, gender, stage, LDH, bulk and FLIPI score did
not have any significance for outcome, while there was a trend for superior PFS
for R-CHOP treated patients (p=0.08) with a 10-year PFS of 67.3% vs 31.3%
for patients treated with other modalities. However, overall survival did not differ
between aggressive and low intensity treatment strategies. Of note, stage and
FLIPI were well balanced between the two groups.
Summary/Conclusions: Grade 3 FL patients show more frequently high Ki-
67 expression, CD10 negativity, elevated LDH and lymphocytopenia compared
with lower grade FL patients. However, the long-term outcome of grade 3 FL is
equally favorable with plateaus in the survival curves. 
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THE IMPROVING OUTCOME OF NON-HODGKIN LYMPHOMA (NHL)
WITHIN 15 YEARS PERIOD-REAL WORLD DATA OF NATIONAL-WIDE
LYMPHOMA PROJECT
M Trneny1,*, V Campr2, A Janikova3, D Belada4, V Prochazka5, H Mocikova6,
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S Vokurka12, D Adamova13, R Bar14, D Starostka15, M Chodacka16,
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Kralove, 5University Hospital Olomouc, Olomouc, 6University Hospital
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Background: Non-Hodgkin’s lymphomas (NHL) represent the most common
hematologic cancer with increasing incidence over the years. Number of clinical
trials demonstrated improved outcome of different NHL subtypes, the national-
wide studies describing real world data are however limited. Lymphoma Project
established by Czech Lymphoma Study Group (LP-CLSG) in 1999 is focused
on prospective collection of NHL patients data since that time. 
Aims: The aim of this study is to analyze key data of patients diagnosed and
entered into this project during the period 1999-2014. 
Methods: The data National Cancer Registry (NCR) were used for incidence
and mortality population based figures. Web based utility was developed for
LP-CLSG, each center (17 with >50 pts.) is responsible for entering the data of
consecutive newly diagnosed lymphoma patients, the central data office is
responsible for validation of data. Pathology review were performed in dedicated
reference centers. The project is approved by ECs. 
Results: The NHL incidence and mortality resp. has been observed to increase
from 6.1 and 3.6 resp. in 1981 to 10.8 and 6.0 resp. in 2001 and to 13.5 and
5.3 (decrease) per 100,000 resp. in 2011 (data from population based NCR).
Altogether 11 828 patients were recorded in the specific Lymphoma Project in
the period 1999-2014, 10 333 with B or T-cell NHL had the reference center
pathology review and were included into the analysis. More than 2/3 of all newly
diagnosed cases in Czech republic is covered by the project. There were 4187
(40.5%) DLBCL pts., 1969 (19.5%) FL, 885 (8.6%) MZL, 857 (8.3%) MCL, 393
(3.8%) SLL and 1252 (12.5%) other or unclassified B-NHL pts. T-NHL cohort
consisted of 283 (2.7%) PTC NOS pts., 198 (1.9%) ALCL and 309 (3,0%) other
T-NHL. There was no trend for increase or decrease of any NHL subtype during
the observation period. The median age at the diagnosis was 62 (17-97) and
there were similar proportion of men (51.2%) and women (48.8%). Altogether
9,718 had sufficient data for therapy and survival. The median OS for B-NHL
and T-NHL was 13.0 and 3.4 y resp. The median OS for B-NHL patients treated
with chemotherapy (CHT) and rituximab-chemotherapy (R-CHT) were 8.7 and
not reached resp. with probability death risk reduction (DRR) of 36% (HR 0.64
p<0.0001). It was mainly due to DLBCL outcome improvement with median
OS 5.9 years for CHT group vs unreached for R-CHT group, with DRR of 44%
(HR 0.56, 95%CI; 0.44-0.57, p<0.0001). The OS was significantly improved by
rituximab addition to chemotherapy in FL with HR 0.76 (95%CI; 0.59-0.92, p-
0.012), MCL with HR 0.67 (95%CI; 0.49-0.82, p<0.001), SLL with HR 0.60
(95%CI;0.40-0.85, p<0.01), MZL did not show rituximab benefit in this analysis.
The significant OS improvement in all NHL diagnosed in current period (2009-
2014) was observed compared to period 15 years ago (1999-2002) with DRR
by 14% (HR 0.86, 95%CI; 0.74-0.91, p<0.001) This is mainly due to the B-NHL
outcome improvement with HR 0.87 (95%CI;0.75-0.92, p<0.005), there was
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trend for T-NHL outcome improvement (HR 0.82) but it was not significant (p
0.20).
Summary/Conclusions: The analysis of the large national-wide population
has revealed: 1. The lymphoma incidence is more than doubled during last 30
years whereas the mortality started decrease since 2001 after rituximab intro-
duction. 2. The significant NHL outcome improvement in B-NHL mainly due to
rituximab addition with HR 0.56 for DLBCL, 0.76 for FL, 0.67 for MCL and 0.60
for SLL. Other factors could however play the role since 3. There is insignificant
trend for outcome improvement of T-NHL as well. 4. The lymphoma project
allows the detailed subanalysis of different lymphoma subtypes and different
therapeutic approaches, which will be presented.
Supported by grant: AZV CR 16-31092A.
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THE IMPACT OF FDG PET-CT IN THE STAGING OF FOLLICULAR LYMPHOMA,
A SINGLE CENTRE EXPERIENCE
R Fernandez-Alvarez1,*, A Rubio-Castro1, M Sorigue2, A Fernandez-Rubio1,
E Gonzalez-Garcia1, C Fernandez-Alvarez1, JM Sancho2
1Hematology, Hospital Cabueñes, Gijon, 2Hematology, Institut Català d’On-
cologia, Hospital Germans Trias i Pujol, Badalona, Spain
Background: 18-F-fluorodeoxyglucose positron emission tomography-CT
(FDG PET-CT) is now the recommended imaging technique for staging and
response assessment in follicular lymphoma (FL) (Cheson et al. 2014). How-
ever, the relevance of FDG PET-CT in the staging of FL is not well established,
apart from selected cases for specific purposes (accurate assessment of stage
I and for guidance of biopsy when transformation is suspected). PET scanning
is readily available at our centre and it is often included as part of standard
staging procedures in FL patients (pts).
Aims: We aimed to investigate the value of FDG PET-CT scans in the staging
of FL pts in routine clinical practice.
Methods: Retrospective study of pts with grade 1-3a FL who had undergone
conventional staging workup (contrast-enhanced CT and bone marrow biopsy
[BMB]) along with FDG PET-CT at our centre. Pts with concurrent diagnosis of
diffuse large B cell lymphoma were excluded. We compared the disease extent
based on conventional investigations with the incorporation of PET to staging.
Results: A total of 55 pts (female - 29, male - 26) were included, with a median
age of 64 years (range, 33-82). Forty-eight pts (87%) were staged at the time
of initial diagnosis, whereas 7 pts (13%) had received prior treatment and were
staged at relapse. By conventional staging, 42 pts (76%) had advanced stage
(III/IV) and 20 pts (36%) had high-risk FLIPI score. GELF criteria were met in
37 pts (67%). Following staging procedures, 49 pts (89%) received treatment
with diverse regimens, while 6 pts (11%) were managed expectantly. Patho-
logical uptake was detected for all FDG PET-CT scans. The median SUVmax
of most FDG avid lesions was 9.04 (range, 2.8-37.5). However SUVmax was
not correlated with the histological grade. PET identified a higher number of
nodal areas than CT scan in 29 pts (53%). Furthermore, 25 pts (45%) showed
“new” extranodal lesions not seen on CT. Overall, PET revealed 71 additional
nodal areas (+31%) and 28 extranodal lesions not visualized by CT (+127%)..
Bone marrow involvement was reported in 19 pts on PET, compared to only
one case on CT. The uptake pattern was focal in 12 cases (9 multiple, 3 single)
and diffuse in 7 cases. In 5 cases (4 focal, 1 diffuse) BMB showed no infiltration.
No guided biopsies were performed to explore these discordant cases. How-
ever, focal lesions resolved after treatment in all pts, supporting the presence
of disease pretherapy. The sensitivity, specificity, positive and negative preditive
value of FDG PET-CT with respect to BMB was 50.0%, 81.5%, 73.7% and
61.1% respectively. PET also detected five splenic involvements not seen on
CT. Among 13 pts initially classified as localized stage (I/II) by conventional
staging, 5 pts (representing 38%) were found to have stage IV using FDG PET-
CT, due to bone lesions on PET. Overall, the incorporation of PET led to a
change in Ann Arbor stage in 8 pts (14%), all of them were up-staged. As antic-
ipated, the FLIPI distribution was modified when PET was taken into account:
five pts (9%) were re-classified as high risk group on the basis of higher number
of nodal areas and/or more advanced stage on PET. 
Summary/Conclusions: FDG PET-CT identifies a greater extent of nodal and
extranodal disease in FL compared with conventional CT, accounting for an
improved stage accuracy. The addition of PET leads to stage migration in a
proportion of pts, where it has the potential to modify therapy decisions.
Whether this additional information provided by PET improves prognostic strat-
ification remains to be determined.
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RITUXIMAB MAINTENANCE IMPROVED PROGRESSION-FREE SURVIVAL
AND REDUCED THE INCIDENCE OF TRANSFORMATION IN PATIENTS
WITH FOLLICULAR LYMPHOMA
Y Kusano*, Y Terui, M Yokoyama, K Ueda, N Nishimura, Y Mishima, T Gunji,
H Nitta, N Inoue, A Takahashi, N Tsuyama, K Takeuchi, K Hatake
Cancer Institute Hospital of Japanese Foundaton for Cancer Research, Tokyo,
Japan
Background: Follicular lymphoma (FL) is incurable disease even in rituximab
era. Continuous exposure by anti-CD20 antibody after the induction therapy
was considered to improve prognosis of patients with FL. Several phase II and
III trials demonstrated that progression-free survival (PFS) is upgraded by rit-
uximab maintenance. Transformed FL is known as rare but has a negative
impact on prognosis of FL patients. It has not been known the relationship
between rituximab maintenance and the incident rate of transformation.
Aims: We analyzed our data to clarify the efficacy and safety of rituximab main-
tenance in FL patients and to verify whether rituximab maintenance is associ-
ated with the incidence of transformed FL.
Methods: We retrospectively analyzed patients aged over 18 who were diag-
nosed with previous untreated FL grade 1, 2, and 3a in single cancer institute
hospital from 2005. Chemo-sensitive patients had given four weekly rituximab
infusions every 6 months for two years if we had informed consent. Basically,
R-CVP was used except when FL had a feature of (i) bulky disease (≥7 cm),
(ii) maximum of standardized uptake value ≥10 measured by PET scan, and
(iii) clinical aggressive manifestations. The primary efficacy endpoint is the inci-
dence of transformation during rituximab maintenance phase. Secondary end-
points are the 5-year PFS, time to next treatment (TNT), and overall survival
(OS) and adverse events (AEs) during maintenance phase. Estimates of sur-
vival were analyzed by using log rank test and by Cox hazard model. Analysis
of contingency table was done by Fisher’s exact test.
Results: A total of 217 patients achieved at least stable disease by R-CVP/R-
CHOP. Overall 217, 162 received maintenance group and 49 were observed
after induction therapy. Baseline characteristics of both groups were similar
except R-CHOP ratio. At the median follow-up of 68.4 months, 5-year PFS
was 78.4% (95%CI: 70.0-84.9) in the maintenance group and 38.8% (95%CI:
16.2-43.3) in the observation group (P<0.0001). Five-year TNT was 70.6%
(95%CI: 71.2-86.0) in the maintenance group and 47.6% (95%CI: 22.9-50.9)
in the observation group (P<0.0001). The 5-year OS was 95.3% (95%CI: 89.5-
97.9) in the maintenance group and 94.8% (95%CI: 71.2-92.7) in the observa-
tion group (P=0.96). Backward stepwise selection method in Cox hazard model
demonstrated four factors that had a positive impact on PFS independently:
rituximab maintenance (HR: 0.34, 95%CI: 0.19-0.61; P<0.01); non-bulky dis-
ease (HR: 0.41, 95%CI: 0.22-0.76; P<0.01); no transformation (HR: 0.41,
95%CI: 0.22-0.65; P<0.01); and β2 microglobulin<2 (HR: 0.33, 95%CI: 0.19-
0.59; P<0.01). On the other hand, 27 patients experienced transformation after
R-CVP/R-CHOP. Of 27, 7 (4.7%) in the maintenance group and 16 (28%) in
the observation group were transformed (Figure, P<0.01), whereas 7 (3.4%)
in the R-CVP group and 16 (6.6%) in the R-CHOP group were transformed
(P<0.01). Additionally, rituximab maintenance reduced the incidence of trans-
formed FL regardless of induction therapy. In the R-CVP group, the incidence
of transformation was 0.67% in the maintenance arm versus 4% in the obser-
vation arm, (P<0.01), while in R-CHOP group, that was 10.7% in the mainte-
nance arm versus 17.9% in the observation arm (P=0.23). The most common
AE was infusion reaction (13%). One patient quit maintenance at the first cycles
due to severe infusion reaction.
Figure 1. Rituximab maintenance reduced the incidence of transformed
FL.
Summary/Conclusions: Rituximab maintenance was beneficial for only PFS
at the median follow-up of 5 years. However, rituximab maintenance diminished
the incidence of transformed FL significantly and tolerate.
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CLONE-SPECIFIC IGH PLASMIDS AS AN ALTERNATIVE STANDARD FOR
ASSESSMENT OF MINIMAL RESIDUAL DISEASE BY REAL-TIME
QUANTITATIVE PCR IN FOLLICULAR LYMPHOMA
T Laubenstein*, M Kneba, C Pott
Klinik für Innere Medizin II, Universitätsklinikum Schleswig-Holstein, Kiel, Kiel,
Germany
Background: Development of novel treatment options, led to improved clinical
outcome in follicular lymphoma (FL). Additionally sensitive diagnostic tools
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have been established, able to detect low amounts of malignant cells, so-called
minimal residual disease (MRD). Real-time quantitative pcr (RQ-PCR) using
the t(14;18) as a molecular target is beeing broadly applied in FL. In cases with
no PCR-detectable t(14;18), clonal rearrangements of the immunoglobulin
genes (IGH) can be used, limited by the required information of lymphoma infil-
tration in the diagnostic sample, which is not regularly available due to nodal
disease character. Cloned IGH-plasmids as an external standard for RQ-PCR
could be a useful alternative.
Aims: This study investigated, whether RQ-PCR using clone-specific IGH-plas-
mids as standards for quantitative MRD-assessment in FL, is an accurate, repro-
ducible and feasible alternative if no t(14;18) is available as a PCR-target.
Methods: IGH-rearrangements of a b-cell-lymphoma cell-line and 24 FL
patients, amplified by FR1-IGH-PCR, were sequenced for identification of the
clone-specific VDJ-region. Allel specific oligonucleotides were designed to the
CDR3- and the FR3-region as reverse/ forward primers for RQ-PCR. Antisense
consensus probes fitting to the FR3-region were used if possible, otherwise
ASO-probes were designed. The IGH-rearrangements were cloned into plas-
mids and serial dilutions were performed for the cell-line and each patient to
serve as external standards for RQ-PCR. Initially a serial dilution of cell-line
DNA containing known IGH-copies was quantified by the plasmid-standard.
Subsequently amplification characteristics of the IGH-plasmids of 24 FL patients
were compared to each other and to relative genomic DNA (gDNA)-standards.
Finally MRD-levels of follow-up samples, determined by using IGH-plasmid-
and t(14;18)-cell-line- or IGH-gDNA-standards were compared.
Results: IGH-copies of a cell-line sample could be quantified accurately using
IGH-plasmid-standards (median deviation: 6,9%, SD: 3,9%, corr. coefficient:
0,999). IGH-plasmid-standard-curves of the 24 patients indicated high con-
formity referring to slope (median: -3,39; SD: 0,08), correllation coefficient
(median: 0,998; SD: 0,001), efficacy (median: 0,97; SD: 0,03), sensitivity (medi-
an: 10-5) and specificity (median: 5x10-5). Compared to gDNA- plasmid-stan-
dards showed comparable sensitivity (median: 10-5 vs 1,25*x10-5; SD: 1,2x10-
5 vs 2,69x10-5) and a superior specificity (median: 5x10-5 vs 1,41x10-4; SD:
2,5x10-5 vs 2,19x10-4). Moreover a significant superiority of the plasmid-stan-
dards was seen regarding to slope (median: -3,39 vs -3,67; SD: 0,08 vs 0,18;
p: 0,008), correlation coefficient (median: 0,998 vs 0,990; SD: 0,001 vs 0,011;
p: 0,009), and efficiency (median: 0,97 vs 0,87; SD: 0,03 vs 0,06; p: 0,008). In
a final step patient follow-up samples were quantified by different strategies,
using clone-specific IGH-plasmids vs IGH-gDNA or t(14;18)-cell-line-DNA
respectively (total of 126 comparisons). In 92/126 (73,0%) of these comparisons
Δmrd-level was<0,5 log-steps, in 21/126 (16,7%) within 0,5-1 log-steps, in
4/126 (3,2%) within 1-2 log-steps. Only in 9/126 (7,2%) cases Δmrd-level was
>2 log-steps.
Summary/Conclusions: Quantitative MRD-assessment in FL using clone-/
patient-specific IGH-plasmids as external standards for RQ-PCR, represents
an accurate, reproducible and feasible strategy and can therefore be used in
cases with no pcr-detectable t(14;18).
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IS LIMITED STAGE FOLLICULAR LYMPHOMA (FL) A TRULY CURABLE
DISEASE? A RETROSPECTIVE ANALYSIS ON 79 PATIENTS
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Background: Limited stage I/II FL is considered potentially curable in contrast
to advanced stage (III/IV) disease. The most widely accepted treatment strategy
is local radiotherapy (RT), occasionally followed by rituximab (R) monotherapy.
However, studies specifically focusing on localized FL are limited. 
Aims: To study the clinical and laboratory characteristics of limited stage FL
and explore long-term outcomes. 
Methods: We retrospectively studied all patients with FL diagnosed and treated
in a single University Hematology Unit between 2001 and 2015 and stage I/II
cases were recorded. 
Results: Among 200 consecutive patients (median follow-up 76 months), 79
patients with limited stages were identified: 55 stage I and 24 stage II. Treatment
differed according to histologic grade (p=0.002): RT±R was used in 53% of
grade 1/2 histologies, whereas R-CHOP was administered in 54% of grade 3
cases. 5-and 10-year progression free survival (PFS) was 61% and 45%,
respectively, while the corresponding values for overall survival (OS) were 94%
and 90%. A plateau in the PFS curve was observed beyond 8 years. Disease
bulk was identified as a borderline significant factor for PFS (p=0.09): Patients
with bulky disease had a 5- and 10-year PFS of 43% and 29% vs 65% and
49% for those with non-bulky disease. The comparison of limited vs advanced
disease stage revealed no significant differences regarding histologic grade,
gender, age and bulk. FLIPI differed significantly, as expected (p<0.0001): 91%
of limited stage patients had a low FLIPI score, whereas 78% of advanced
stage ones had intermediate and high FLIPI scores. LDH was elevated in 5.3%
of localized and 17.5% of advanced disease (p=0.01). There was a trend for
higher Ki-67 in limited stages (p=0.07). Treatment also differed significantly, as
expected (p<0.0001): 44% of limited stage patients were treated with RT±R vs
0.8% of advanced stage ones, whereas systemic chemotherapy was used in
53% and 92% of localized and advanced stage FL patients, respectively.
Despite treatment heterogeneity, PFS and OS did not differ significantly
between limited and advanced stage disease. However, there was a trend for
superior OS in localized disease patients beyond 5 years (figure).
Figure 1.
Summary/Conclusions: Although limited stage FL is considered as a poten-
tially curable disease, the present retrospective analysis revealed a relapsing
pattern, similar to the one observed in advanced disease for the initial years of
follow-up. However, beyond 8 years, survival curves are suggestive of a
plateau, a finding that should be further confirmed. OS is excellent with 90% of
the patients being alive at 10 years. The optimal treatment for this group of
patients needs further investigation.
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SINGLE CENTER EXPERIENCE OF 90Y-IBRITUMOMAB TIUXETAN IN THE
OLDER POPULATION WITH NON-HODGKIN LYMPHOMA
V Agrawal*, J Castillo, K Raup, T Girton, S Collins, J Brady, J Vadakara,
S Khan
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Background: 90Y-Ibritumomab tiuxetan (90Y-IT) as radioimmunotherapy in the
treatment of B-cell non-Hodgkin lymphoma (NHL) has been approved for con-
solidation and salvage treatment of follicular and indolent lymphoma. It has
also been studied in the treatment of diffuse large B-cell and mantle cell lym-
phoma. Toxicities primarily include myelosuppression with a risk of treatment-
associated myelodysplastic syndrome (MDS).
Aims: To evaluate the toxicity and treatment benefit of 90Y-IT administered to
patients for consolidation and salvage treatment of non-Hodgkin lymphoma.
Methods: Retrospective cohort analysis of patients with B-cell NHL who
received 90Y-IT from 2010 to 2015 at Geisinger Medical Center. 90Y-IT was
administered according to recommended dosing guidelines and cytopenia was
monitored at routine intervals.
Results: Sixty-five patients with NHL received 90Y-IT at median age of 68 years
(range 32-91), 32 (49.2%) patients were male, and 36 (55.8%) were older than
65 years of age. Thirty patients (46.1%) had aggressive NHL and 37 (56.9%)
had stage III/IV disease. Twenty-nine (44.6%) patients received >1 line of treat-
ment prior to 90Y-IT therapy and 62 (97%) received Rituximab based regimens.
No patient received fludarabine based therapy. Prior to administration of 90Y-
IT, the median bone marrow involvement was 0%, median platelet count was
183 x 109/L, median hemoglobin count was 12.7 g/dL, and median absolute
neutrophil count was 3.8 x 109/L. The median follow-up period was 16 months
(range 4-68). The overall response rate was 89.2% with a PR-to-CR conversion
rate of 36%. The response rate was 54.5% in the salvage setting. The median
PFS and OS were 12 and 15 months, respectively. There was no significant
difference in PFS and OS between patients younger and older than 65 years
of age or between patients in CR and not in CR at the time of 90Y-IT. Patients
on Rituximab maintenance after 90Y-IT treatment (n=14, 21.5%) had PFS and
OS improvement (p<0.0001), with median PFS and OS of 45.5 and 48 months,
respectively. In the population without Rituximab maintenance (n=51, 78.4%),
the median PFS and OS were 10 and 13 months respectively. Patients not in
CR at the time of 90Y-IT were found to be responsive to Rituximab maintenance:
PFS improved from median 10.0 to 48.0 months (p<0.0001) and OS improved
from median 14.0 to 53.0 months (p=0.0003). Among patients with grade 3/4
hematologic toxicities, 6 patients required blood transfusion, 4 needed platelet
transfusion, and 17 (26.1%) received pegfilgastrim. One patient required hos-
pitalization for febrile neutropenia. Seven patients relapsed after 90Y-IT and
one patient (1.5%) developed MDS (del 5q, del 20q) 54 months after treatment.
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There were 9 deaths (six were secondary to progressive lymphoma or
chemotherapy-related neutropenic sepsis).
Summary/Conclusions: This is one of the largest reported single-center expe-
rience of 90Y-IT administered to a predominantly elderly population with B-NHL
in the United States. This study demonstrates the safety and feasibility of 90Y-
IT in the elderly population with manageable toxicity and similar outcomes
between patients younger and older than 65 years of age. Furthermore, treat-
ment with 90Y-IT did not negatively impact continued sensitivity and benefit
from Rituximab maintenance.
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DISEASE SURVEILLANCE AND LONG-TERM OUTCOME OF PATIENTS
WITH MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
INVOLVING THE STOMACH: A RETROSPECTIVE MULTICENTRE STUDY
OF 49 PATIENTS IN FIRST REMISSION
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Background: Gastric MALT lymphoma is a rare subtype of non-Hodgkin lym-
phoma with an indolent disease course. Treatment options span from simple
eradication of Helicobacter Pylori with or without radiotherapy for patients with
localized gastric MALT lymphoma to systemic, typically mild chemotherapy
regimens and/or rituximab, for patients with non-localized disease. Complete
remissions (CR) are often achieved, but relapses occur.
Aims: i) to analyze the relapse patterns and the efficacy of routine gastroscopy
for patients with gastric MALT lymphoma in first remission, and ii) report the long-
term outcomes of these patients relative to a matched background population.
Methods: We conducted a retrospective study of patients with localized and
non-localized gastric MALT lymphoma from six Danish hematology centers
between 2000 and 2012. Patients were identified from queries in the Danish
Lymphoma registry (LYFO) and consecutive adult patients (>15 years) in CR
or CRu were included in the study. Local investigators reviewed medical records
and collected information regarding gastroscopic examinations, relapse (includ-
ing relapse detection method and relapse histology), and cause of death. Gas-
troscopies were categorized as routine if prescribed to a patient in clinical
remissions and clinical if prescribed to a patient with relapse suspicious symp-
toms/findings. Data collection was compliant with national regulations.
Results: In total, 49 patients with gastric MALT lymphomas stage I-IV and in
CR or CRu following first line treatment were included. Median age was 64
years (range 25-87) and male:female ratio was 1.1. During a median FU of
88.8 months, seven patients relapsed and 14 patients died. The five-year PFS
and OS estimates were 73% (95% CI 61-88) and 89% (95% CI 80-99), respec-
tively (Figure 1). The OS of a matched background population was not different
from the MALT lymphoma (P=0.94, standardized mortality ratio, Figure 1). Dur-
ing follow-up, the 49 patients received 100 routine endoscopies (mean 2 range
0-6) and 15 clinical endoscopies. In four patients (8%), routine gastroscopy
detected preclinical MALT relapse or another cancer at an asymptomatic stage
(adenocarcinoma). Thus, 4/100 routine endoscopies (4%, 95% CI 1-10%) con-
tributed significantly to detection of relapse or other malignancy. These findings
resulted in chemotherapy for 2/4, helicobacter eradication with antibiotics for
1/4 and surgery for 1/4 (adenocarcinoma). A single MALT lymphoma relapse
was detected as a result of patient reported symptoms. Thus, 1/15 (7%, 95%
CI 0-32%) of the gastroscopies performed in response to clinical
symptoms/findings confirmed relapse. A case of adenocarcinoma localized in
the stomach was found 28 months after first MALT lymphoma diagnosis, but
transformation to high-grade lymphoma was not reported for any patients. Of
note, no deaths were related to progressive MALT lymphoma in this cohort of
49 patients.
Figure 1.
Summary/Conclusions: This study confirms the very indolent nature of gastric
MALT lymphoma with survival not statistically significantly different from the
background population. Preclinical relapse detection has not been shown to
improve outcome in gastric MALT lymphoma and asymptomatic relapse can
be managed with a watch-and-wait strategy in selected patients. In this context,
the yield of routine endoscopy is limited. However, one case of adenocarcinoma
was detected at an early stage by routine endoscopy.
E1165
PRE-DOSING WITH UNLABELLED ANTIBODY SIGNIFICANTLY INCREAS-
ES THE PHARMACOKINETIC EXPOSURE BUT PROTECTS AGAINST
MYELOSUPPRESSION OF 177LU-LILOTOMAB IN NON-HODGKIN B-CELL
LYMPHOMA PATIENTS
A Kolstad1,*, U Madsbu1, C Stokke2, T Bach-Gansmo1, A Muftuler Løndalen1,
JE Holtedahl2, ME Revheim3, Ø Bruland1, J Dahle4, L Baylor Curtis4,
Å Åse Østengen4, H Heyerdahl4, S Turner4, N Bolstad3, R Hartvig Larsen5,
S Spetalen3, M Erlanson6, S Nygaard Rudå1, H Holte1
1Oslo University Hospital, Radiumhospitalet, 2The Intervention Centre, Oslo
Univeristy Hospital, 3Olso University Hospital, 4Nordic Nanovector, 5Sciencons,
Oslo, Norway, 6Norrland University Hospital, Umeå, Sweden
Background: 177Lu-lilotomab (177Lu-DOTA-HH1; BetalutinTM) is a novel
CD37-binding murine IgG1 antibody (HH1) labelled with the beta-emitter
lutetium-177, in a ready-to-use formulation currently in Phase 1/2 clinical devel-
opment for the treatment of non-Hodgkin`s lymphoma (NHL). Pre-dosing with
unlabelled antibody is routinely given with radio-immunotherapies for NHL.
Aims: This pharmacokinetic (PK) sub-study in NHL patients (pts) was designed
to determine the PK profile of 177Lu-lilotomab and to compare the PK profile
with and without pre-dosing with unlabelled HH1.
Methods: Pts with relapsed incurable indolent NHL and with platelet counts
≥150 x109/L were eligible for inclusion in the study. Pts received rituximab (375
mg/m2) on day 1 and 8 to deplete normal B cells. On day 29 pre-dosing with
50 mg HH1 was administered before the single dose of 177Lu-lilotomab in 9
pts. The remaining 4 pts received 177Lu-lilotomab without HH1 pre-dosing.
Activity of 177Lu-lilotomab administered after the pre-dose of HH1 were 10, 15
and 20 MBq/kg vs 10 and 15 MBq/kg without HH1. PK samples were collected
at 0 and 5 minutes, then after 1, 2, and 20 hours and further 2, 3, 4, 7, 14 and
21 days post-177Lu-lilotomab administration. Urine samples were also collect-
ed. Response was assessed by FDG PET/CT scans.
Results: A total of 13 pts, 12 with follicular lymphoma and 1 with mantle cell
lymphoma, were enrolled into this sub-study and either received pre-dosing
with HH1 (n=9) or without HH1 (n=4). The number of prior therapies ranged
from 1 to 7, median body weight was 91.5kg (range: 67-118kg). A total of 153
blood samples were collected. As expected, the median AUC0-∞ increased with
increasing activity of 177Lu-lilotomab irrespective of pre-dosing (range: 3830.7
to 15226.48 h*kBq/mL). There was an increase in median activity-adjusted
AUC0-∞ (675.51 vs 421.11 h*kBq/mL/(MBq/kg); p<0.001) in pts with pre-dosing
compared to no HH1 pre-dosing and a decrease in the volume of distribution
Vz (10.48L vs 17.56L) and clearance rate Cl (126 v 227 mL/h). The median
activity-adjusted Cmax (6.6 vs 6.9 kBq/mL/(MBq/kg)) and T1/2 (53.3 vs 51.6 h)
were similar with and without HH1 pre-dosing. The most common toxicities
observed were haematological which were all reversible and manageable. With
HH1 pre-dosing all Grade 4 thrombocytopenia and neutropenia were reported
by pts with a 177Lu-lilotomab AUC0-∞ >13415 h*kBq/mL (n=3), compared with
>6147 h*kBq/mL (n=2) without pre-dosing. In addition grade 3 thrombocytope-
nia was reported by one pt with an AUC of 11730 h*kBq/mL with pre-dosing
compared to one pt with an AUC of 4913 h*kBq/mL without HH1. The overall
tumor response rate observed in the 12 evaluable pts in the PK sub-study was
67% (one pt had a transformed lesion at 3 months and is excluded from the
efficacy analysis). Five pts with pre-dosing achieved CR or PR and had an
AUC of >6976 h*kBq/mL. Without HH1 pre-dosing a PR was observed in 3
pts, with AUCs of 3830, 4913 and 6195 h*kBq/mL.
Summary/Conclusions: Pre-dosing with unlabelled antibody (HH1) increases
the activity-adjusted AUC and decreases the volume of distribution and clear-
ance rate of 177Lu-lilotomab in NHL pts. Despite the increase in AUC resulting
from pre-dosing with HH1 the incidence of haematological AEs was reduced
compared with no HH1 pre-dosing, suggesting a protective effect of HH1
against the myelosuppression of 177Lu-lilotomab. Further optimisation of the
pre-dosing of 177Lu-lilotomab may lead to greater increases in AUC, and/or
improvement in the side-effect profile.
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FOLLICULAR LYMPHOMAS ARE CURABLE DISEASES. DATA FROM A
RETROSPECTIVE STUDY ON 133 PATIENTS WITH AT LEAST 10 YEARS
OF OBSERVATION
S Kovalchuk*, L Rigacci, F Lancia, B Puccini, G Benelli, L Mannelli, M Novo,
A Bosi
Haematology, AOU Careggi, Firenze, Italy
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Background: Follicular lymphomas are usually defined as incurable diseases
with a natural history characterized by continuous relapses. This study was
launched to evaluate how many patients, after a long observation period, do
not relapse or do not experience a new treatment.
Aims: The aim of the study was to identify which clinical characteristics or ther-
apeutical approaches are associated with this cohort of favourable patients.
Methods: All patients with histologically confirmed diagnosis of follicular lym-
phomas grade I-II or IIIa were selected from our data base starting from January
2000 untill December 2004 in such a way to have at least 10 years of obser-
vation for alive patients. We considered patients obtaining at least a partial
response and we divided patients in two cohorts, cohort 1 with patients relapsed
or progressed and cohort 2 with patients never relapsed or progressed.
Results: One hundred and fourthy-six patients were diagnosed and treated at
our Institution. Thirteen patients were excluded from the analysis, 8 lost to the
follow-up and 5 did not obtained at least a partial remission. Finally 133 patients
were analysed for the study. The median age at diagnosis was 61 years (range
30-87). Stage I-II in 47 patients, III-IV in 86. Bone marrow biopsy was positive
in 87 patients, FLIPI 0-1 in 35, FLIPI 2 in 43, FLIPI 3 in 40 and FLIPI 4 in 15
patients. According to treatment 96 patients were treated with antracycline con-
taining regimens, 24 with fludarabine containing regimens and 13 were observed
or treated with radiotherapy. Rituximab was used in 92 patients, as sequential
treatment in 70 or chemotherapy combined in 22; 41 patients did not use ritux-
imab. We analysed cohort 1 (85 patients) and cohort 2 (48 patients) and the
statistically significant differences between the two cohorts were: elderly patients
(p 0.05), symptomatic patients (p 0.05), FLIPI and FLIPI2 high score (p 0.005),
lack of complete remission (p 0.0000) all observed in cohort 1. The overall sur-
vival with a median period of observation of 127 months (range 2-196) was 71%,
considering the two groups the overall survival in cohort 1 was 62% with a medi-
an of 142 months and it was 94% in cohort 2 with median not reached. In uni-
variate analysis normal value of beta2 microglobulin (p 0.05) and the use of rit-
uximab (p 0.01) were associated with a better overall survival; in multivariate
analysis treatment with rituximab manteined a statistically significance.
Summary/Conclusions: In conclusion this retrospective monocentric study
confirms that about one third of follicular lymphoma patients could be considered
cured particularly if rituximab was used in the treatment. At the present time all
patients with follicular lymphoma are treated with combined immuno-chemother-
apy, moreover after induction therapy patients are started with manteinance.
We can therefore hope for the future in an improvement of survival results.
Infectious diseases, supportive care
E1167
IMPACT OF AZACITIDINE TREATMENT ON INFECTIONS IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROMES
AND MYELODYSPLASTIC/MYELOPROLIFERATIVE SYNDROMES
C Villegas*, S Ortiz, K Javier, S Costa, D Ivars, R Collado, M Lopez, L Irene, M
Roig, M Sanchez, P Perez, M Orero
Hematologia, Hospital General Universitario, Valencia, Spain
Background: It has been described in previous studies a benefit on infection
rate in azacitidine (AZA) treated patients. However, the characteristics of infec-
tious episodes in patients with AZA or best supportive care (BSC) were not
described in detail.
Aims: We decided to analyze the impact of AZA treatment on the risk of infec-
tion, the characteristics of the infectious episodes and outcome in our patients
with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and
myelodysplastic/myeloproliferative syndromes (SMD/MPS).
Methods: Infections were assessed by reviewing medical records of our depart-
ment´s database of patients treated with AZA from January 2006 to November
2015. A cohort of matched control patients treated with BSC (two controls for
each patient) based on World Health Organization (WHO) subtype, neutrophil
count and IPSS-R risk was selected. We took only on account infection´s
episodes which required hospitalization.
Results: We included 138 patients, 92 received BSC and 46 treated with AZA
at standard schedule (75mg/m2/day 7 days every 28). The median follow up
for both groups was 10 months. In the AZA group, 8/46 patients (17.4%)
had<0.5x109/L neutrophils at diagnosis and 6/44 (13.6%) at four months, with
no significant increase in neutropenia incidence (p=0.773). However, In the
BSC group, 7/92 (7.6%) patients had<0,5x109/L neutrophils at diagnosis and
16/77 (20.8%) at four months, with a significant increase in the incidence of
neutropenia. (p=0.022). The percentage of patients free of infection in AZA
group was higher than BSC group. The median of infectious episodes per year
was 1.17 in AZA group (CI 95% 0.44-1.90) and 3.08 in BSC group (CI 95%
1.56-4.60) (p=0.004).The days of hospitalization/year due to infection was 20.59
(CI95% 3.91-37.27) in the AZA group and 39.90 (CI 95% 21.63-58.18) in the
BSC (p=0.003). The cumulative incidence of first infection, with death as com-
petitive risk, was higher in BSC group than in AZA group; with a cumulative
incidence at 12 months of 0.40 (CI 0.26-0.54) and 0.54 (CI 0.43-0.63) in the
AZA and BSC group respectively (Grays´s test p=0.0195). In the AZA group 4
(18.2%) episodes were fatal and in the BSC group 24 (23.3%) (P=0.78). Mul-
tivariant logistical regression shows that only AZA treatment (HR 0.25 p=0.001
CI 0.12-0.55) and absolute neutrophil count (ANC) >0.5X109/L (HR 0.28
p=0.049 CI 0.08–1.03) showed an independent prognostic value. Age, comor-
bidities and WHO subtype were excluded by the test.
Table 1. Baseline characteristics of patients and number of infections.
Summary/Conclusions: Azacitidine treated patients had less risk of infection,
showed with cumulative incidence, less infectious episodes per year and less
days of hospitalization per year. However, the outcome of infection episodes
was similar in both groups. The higher incidence of infections in BSC group
could be explained by the mayor progression to severe neutropenia.
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CLINIC RISK FACTORS OF REFRACTORY CMV REACTIVATION FOLLOWING
ALLOGENEIC AHSCT: A SINGLE-CENTER STUDY IN CHINA
H Qiu*, X Bao, S Xue, Y Xu, X Ma, F Chen, X Hu, Z Zhu, S Chen, A Sun, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Cytomegalovirus (CMV) reactivation remains the main cause of
viral complications after allogeneic hematopoietic stem cell transplantation
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(aHSCT). Especially, CMV with gene mutations against antiviral drugs could
lead to high mortality rate.
Aims: The purpose of this study is to explore the risk factors and outcome for
CMV reactivation and CMV refractory to antiviral chemotherapy after aHSCT.
Methods: CMV reactivation occurred in 282 of 685 (41.2%) patients treated
with myeloablative conditioning regimen. Among the patients with CMV reac-
tivation, 84 of 282 (29.8%) cases developed refractory CMV reactivation (RCR),
and 37 of 282 (13.1%) cases progressed into CMV diseases.
Results: Patients with RCR have a higher cumulative incidence of CMV dis-
eases (26.2% versus 7.6%, P<0.001). Seventy nine of 84 cases (94.0%) devel-
oped RCR before 100 days after aHSCT (5 cases with PP65 detection only).
The copy number of CMV-DNA more than doubled compared to its initial base-
line in 42 of 74 (56.8%) cases after 2 weeks of antiviral therapy, whereas 32
cases did not have a double increase above baseline. CMV disease developed
in 15 of 42 (35.7%) and 3 of 32 (9.4%) (P=0.011) cases in these two groups.
The copy number of CMV-DNA increased at least 5 times above baseline in 24
of 74 (32.4%) patients, and among these 24 patients, 8 of 24 (33.3%) cases
developed CMV disease. Among patients who do not have a 5-fold increase of
CMV-DNA copy number, 10 of 50 (20.0%) patients developed CMV disease
(P=0.232). Both univariate and multivariate analysis demonstrated that the risk
of CMV reactivation and RCR increased in patients from HLA-haploidentical
donor and matched unrelated donor, or without using peripheral blood (PB) as
stem cell source. The multivariate analysis revealed that patients who developed
acute graft-versus-host disease (aGVHD) ≥grade 2 have increased risk of devel-
oping CMV reactivation, whereas RCR occurred more frequently in those with
total body irradiation-containing regimens and a high dosage methylpred-
nisolone (MP) for aGVHD treatment. The prevalence of RCR is three and six
times higher in patients who received MP 1-2mg/kg daily(P=0.024) and ≥2mg/kg
daily(P=0.001), with an odds ratio (OR) of 2.74 and 6.03 respectively.
Summary/Conclusions: High dosage corticosteroids treatment is associated
with incidence of RCR during the early phase after aHSCT.
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INFECTIOUS CHARACTERISTICS AND LONG-TERM OUTCOME IN
OBESE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
MJ Li1,*, HH Chang2, YL Yang3, MY Lu2, PL Shao4, CM Fu1, AK Chou1,
YL Liu5, KH Lin2, LM Huang2, DT Lin3, ST Jou2
1Pediatrics, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu,
2Pediatrics, 3Laboratory Medicine, National Taiwan University Hospital, Taipei,
4Laboratory Medicine, National Taiwan University Hospital Hsin-Chu Branch,
Hsinchu, 5Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan, ROC
Background: Obese patients were reported to have poorer prognosis in pedi-
atric acute lymphoblastic leukemia (ALL), however, the association with infec-
tion during chemotherapy was seldom reported.
Aims: To evaluate the difference of infectious characteristics and long-term
outcome between obese and non-obese patients.
Methods: Total 252 newly diagnosed pediatric ALL patients from 1997 to 2012
at National Taiwan University Hospital treated by Taiwan Pediatric Oncology
Group (TPOG) protocol were retrospectively reviewed. The fever event was
classified into fever of unknown focus, clinically documented infection and
microbiologically documented infection (MDI). Infectious sites were recorded
by location: upper respiratory (EENT), lower respiratory (LRI), blood stream
(BSI), genitourinary tract (GU), gastrointestinal tract, skin or soft tissue, central
nervous system and others. Multivariate analysis for risk factors of infectious
complications was evaluated by Poisson regression with incidence rate ratio
(IRR) and 95% confidence interval (CI).
Table 1. Subgroup Univariate Poisson Regression Analysis in Obese vs
Non-obese Patients.
*No case in this subgroup. LRI-MDI, lower respiratory infection with pathogen; SR, standard
risk; HR, high risk; VHR, very high risk.
Results: Total 219 patients (86.9%) had fever with mean 2.74 episodes per
person. Obese patients (n=38) harbored more MDI, GU and LRI with pathogen
infections than non-obese patients (IRR=1.349, 2.228 and 2.014; 95%
CI=1.109-1.642, 1.558-3.187 and 1.22-3.326; and p=0.003,<0.001 and 0.006,
respectively). Subgroup analysis revealed the IRR in obese patients was higher
in female and younger age patients (Table). The pathogen characteristics in
obese patients included more Gram negative pathogen both in blood stream
(29% vs 14%, p=0.029) and GU tract (32% vs 10%, p=0.001). Klebsiella spp.
bacteremia was higher in obese patients (11% vs 3%, p=0.047). Overall prog-
nosis analysis showed obese patients had more relapsed rate (42.1 vs 22.4%,
p=0.012) but the mortality rate was not different (36.8 vs 23.4%, p=0.063). The
10-year event-free survival was also lower in obese patients (54±8% vs.72±3%,
p=0.002, figure).
Figure 1.
Summary/Conclusions: Obesity was a potential risk factor in infectious com-
plications in pediatric acute lymphoblastic leukemia patients, especially in
microbiologically documented infection and genitourinary tract infection.
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ANTIBIOTICS VERSUS G-CSFS VERSUS A COMBINATION OF BOTH TO
PREVENT INFECTIOUS COMPLICATIONS AND DEATHS IN CANCER
PATIENTS RECEIVING CHEMOTHERAPY: PRELIMINARY RESULTS OF A
NETWORK META-ANALYSIS
N Skoetz1,*, O Blank1, L Buetikofer2, I Monsef3, A Engert4, JJ Vehreschild4
1Department I of Internal Medicine, Cochrane Hematological Malignancies
Group, University Hospital of Cologne, Cologne, Germany, 2Department of
Clinical Research, University of Bern, Bern, Switzerland, 3Cochrane Haema-
tological Malignancies; Department I Of Internal Medicine, 4Department I Of
Internal Medicine, University Hospital of Cologne, Cologne, Germany
Background: Cancer patients receiving chemotherapy are at an increased
risk for infectious complications, which represent the most relevant treatment-
related causes of death (2 to 21%). The risk of infection is dependent on the
duration and intensity of treatment-induced neutropenia and often results in a
reduction of the dose of chemotherapy. Uncertainty exists on the achievable
degree of infection prevention and whether granulocyte colony stimulating fac-
tors (G-CSF), antibiotics or both should be administered.
Aims: The aims of this systematic review and network meta-analysis are to
evaluate the benefits and risks of infection prophylaxis with antibiotics, G-CSF,
or a combination of both in cancer patients receiving chemotherapy at risk for
febrile neutropenia.
Methods: We developed sensitive search strategies for CENTRAL, MEDLINE,
and conference proceedings (search date 12/2015). Study selection and data
extraction:Randomized controlled trials evaluating infection prophylaxis with
antibiotics, G-CSF or both in cancer patients at risk for febrile neutropenia.
Only trials were included which clearly stated whether all patients received
antibiotics or G-CSF in addition to the evaluated prophylaxis. Two authors inde-
pendently assessed studies for eligibility, extracted data and assessed quality
of trials. The primary outcome was mortality during the study. Secondary out-
comes included infection related mortality, severe infection rate, rate of febrile
neutropenia and adverse events. Data synthesis: Effect measures were odds
ratios (OR). Direct comparisons within trials were combined with indirect evi-
dence by using a Bayesian random-effects model. This project was funded by
the Federal Ministry of Education and Research, grant number: 01KG1209.
Figure 1.
Results: A total of 63 studies were identified, including 11838 patients. Only
one study with 40 patients carried out a direct comparison of G-CSF versus
antibiotics. Of all studies comparing antibiotics to no antibiotics, only 2 were
from 2010 or later. The results of the direct comparisons found an advantage
in terms of reduced rate of febrile neutropenia for those trials evaluating G-
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CSF, both in the studies using G-CSF versus placebo (OR 0.37; 95% CI 0.12
to 0.86) and in those evaluating G-CSF plus antibiotics versus antibiotics alone
(OR 0.45; 95% CI 0.24 to 0.74). However, there is no evidence for a difference
for the outcomes mortality during the study, infection-related mortality and
severe infection rate between the various preventive options. Network meta-
analyses show that the combination of G-CSF and antibiotics has the highest
probability to be the best for all the observed outcomes (see figure 1). Between-
trial heterogeneity was considerable for the outcomes febrile neutropenia and
severe infections, potentially due to various definitions (tau 1.08 and 0.97,
respectively) and negligible for the other two outcomes (tau 0.42 and 0.18
respectively). The endpoint adverse events was very rarely and inconsistently
reported, so no overall statement is possible.
Summary/Conclusions: The currently available direct evidence does not show
any difference in terms of mortality for the various prophylactic options. The
evidence from the network meta-analyses shows an advantage if G-CSF is
administered in conjunction with antibiotics compared to placebo, antibiotics or
G-CSF alone. Most evidence on antibiotic prophylaxis stems from studies older
than 10 years, i.e. before the ongoing pandemic of multi-resistant gram-nega-
tives and vancomycin-resistant enterococci. Further studies with clearly defined
inclusion and exclusion criteria (risk of febrile neutropenia) and endpoints (e.g.
definition of febrile neutropenia) are necessary in order to properly compare
the various prophylactic options and to obtain valid results.
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METRONOMIC FIRST-LINE ANTIBIOTICS FOR FEBRILE NEUTROPENIA-IMPACT
ON ECOLOGY AND MORTALITY IN PATIENTS TREATED FOR HAEMATOLOGIC
MALIGNANCIES
GC Wong1,*, LKS Donato1, AL Tan2, S Kalimuddin3, W Lee4, MRT de Guzman1,
BH Tan3
1Department of Haematology, 2Department of Pathology, 3Department of Infec-
tious Diseases, 4Department of Pharmacy, Singapore General Hospital, Sin-
gapore, Singapore
Background: Rising antibiotic resistance threatens to limit our choices for empir-
ical and definitive treatment of febrile neutropenia (FN). Reports suggest that
increasing antibiotic heterogeneity might be associated with a decline in resist-
ance. In our hospital’s Haematology unit, cefepime (CEF) was recommended as
the first-line empirical antibiotic in FN. Rising drug resistance and the potential
usefulness of increasing antibiotic diversity led us to re-consider our approach.
Aims: To introduce antibiotic heterogeneity by alternating use of first-line antibi-
otics and to determine the impact of this on ecology and mortality of patients
treated for haematological malignancies.
Methods: From mid-2013, a new FN guideline was implemented. Neutropenic
patients who developed fever on odd dates of the month would be given
Piperacillin Tazobactam (PTZ) and on even dates, a combination of Cefepime
and Amikacin, post blood cultures. This is termed as “metronomic 1st line
antibiotics”. If fever persists after 48 hours, physicians could continue on the
same antibiotics, or add vancomycin or switch to meropenem (MER). To
assess the impact of this change, we collected the following data for the years
2012 and 2014: rates of bacteremia (including rates of bacteremia caused by
carbapenem-resistant organisms), Methicillin Resistant Staphilococcus Aureus
(MRSA) acquisition, Vancomycin Resistant Enterococcus (VRE) acquisition,
mortality. We also calculated the defined daily doses (DDD) of CEF, PTZ, and
MER for 2012 and 2014. This study was approved by the Institution Review
Board.
Results: In 2012, 1183 patients were admitted 2012 times; in 2014, 1112 patients
were admitted 1843 times. Males formed 54.5% and 55.7% of the patients in
2012 and 2014 respectively. The following were similar (p>0.5) in the 2 years:
mean and median ages of the patients, number of new patients with acute myeloid
leukemia (AML) and acute lymphocytic leukemia (ALL) who started on
chemotherapy, spread of discharge diagnoses (AML, ALL, myeloma, lymphoma).
Rate (DDD/1000 days) of CEF use fell (p<0.001) and rate of PTZ use rose
(p<0.001) in 2014. Rate of MER use was unchanged. Bacteremia rates were
unchanged. Rates of acquisition of MRSA and VRE were unchanged. Rates of
CEF-resistant, and of PTZ-resistant E. coli, Klebsiella spp, and P. aeruginosa
isolated from blood cultures were similar in the 2 years. The rate of carbapenem-
resistant P. aeruginosa was 12.7% in 2012 and 17.5% in 2014 (p=0.6). Mortality
among bacteremic patients was 24% in 2012, 14% in 2014 (p=0.001).
Summary/Conclusions: We conclude that “metronomic 1st line antibiotics”
introduced an element of antibiotic heterogeneity. This was not associated with
an increase in the rate of isolation of resistant organisms. It is possible that the
increased use of PTZ was associated with a lower mortality.
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ORAL GENTAMICIN THERAPY FOR CARBAPENEM-RESISTENT KLEBSIELLA
PNEUMONIAE INFECTIONS IN HEMATOLOGIC PATIENTS: A SINGLE
CENTER EXPERIENCE
F Simonetti1,*, S Fortunato2, M Rousseau3, C Tascini2, F Menichetti2,
A Stefanelli1, E Baccelli1, C Vettori4, M Petrini3
1Hematology Unit, Versilia Hospital - Tuscany, Italy, Lido di Camaiore, 2Infec-
tious Disease Unit, 3Hematology Unit, Pisa Hospital, Pisa, 4Infectious Disease
Unit, Versilia Hospital - Tuscany, Italy, Lido di Camaiore, Italy
Background: The worldwide spread of carbapenem-resistant Klebsiella pneu-
moniae (KPC-Kp) is nowadays a health threat worldwide. KPC-Kp mortality
infections range from 18 to 48% and depend on the type of therapy adminis-
tered; mono vs combo therapy. This result may be due to delayed time to active
therapy, pharmacologic limitations of available treatment options, and the fact
that patients with KPC-Kp infections tend to be critically ill. Patients with hema-
tologic malignancies and hematopoietic stem cell transplant recipients are more
vulnerable to Carbapenemase-resistant Enterobacteriaceae (CRE) because
of chemotherapy-induced gastrointestinal mucositis, prolonged hospitalizations
and neutropenia, and frequent use of broad-spectrum antibacterial agents.
Mortality in these patients might be as high as 85%.
Aims: The aim of our study was to test he efficacy of oral gentamicin in gut decon-
tamination from KPC-Kp in hematologic patients, in view of immunosuppressive
therapy, stem cell transplantation or to prevent sepsis after chemotherapy.
Methods: We performed a prospective study in an Italian Hematology Unit to
quantify the efficacy of gentamicin gut decontamination from KPC-Kp in hema-
tologic patient with and without concomitant infection. We considered eligible
all patient with rectal swab culture positive for KPC-Kp with hematologic disease
and those patients were administered oral gentamicin (80 mg four times daily)
for 7 to 25 days, having stopped the therapy three days after the proved decon-
tamination. Rectal swab cultures were performed at the time of hospital admis-
sion and every 3 days thereafter. 
Results: Fourteen patients with a hematologic disease and concomitant KPC-
Kp positive rectal swab culture were enrolled in the study; only one was resistant
to gentamycin. The patients were 5 female and 9 male, with a mean age of
68.5 years (range 39-80 years). Concomitant systemic associated therapy
(CSAT) was administered to 4/14 patients due to systemic infections. The
enrolled patients were treated with oral gentamicin for 7 to 25 days and the
overall decontamination rate in the entire study population administered oral
gentamicin was 71% (10/14). Only two patients took gentamicin for more than
15 days. Four patients were not decolonized by gentamicin oral therapy: one
of these was the patient harbouring gentamicin-resistant strain and 3 patients
have CSAT. One out of this 4 patients died for KPC-Kp sepsis. At 1 month of
follow-up, no one KPC-Kp re-infection was documented. The decontamination
rate was 90% (9/10) in patients receiving oral gentamicin only, versus 25%
(1/4) in those also treated with CSAT. No new gentamicin-resistant KPC-Kp
strain was isolated during oral gentamycin therapy. 
Summary/Conclusions: The KPC-Kp infection are associated with high mor-
tality and morbidity, especially in Intensive Care Units and hematologic patients;
prevention of KPC-Kp infection is the first provision to implement, followed by
the screening for gut colonization and eventually gut decolonization. In our
experience the decontaminations rate in the entire population was 71% and
90% considering the patients receiving oral gentamicin only. Although the small
number of patients analyzed in this study, our results were similar to others
suggesting that the selective pressure of CSAT on gut microbiota may favor
the persistent carriage of KPC-Kp, thereby contributing on the higher failure
rates observed versus monotherapy. Therefore, the selective oral decontami-
nation therapy of KPC-Kp with oral gentamicin is safe and possibly effective.
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CLINICAL SIGNIFICANCE OF SERUM HEME OXYGENASE 1 IN PATIENTS
WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
D Wang*, J Wang, L Duan, T Tian, H Qiu
Department of Hematology, First Affiliated Hospital of Nanjing Medical University
(Jiangsu Province Hospital), Nanjing, China
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare, threaten-
ing-life clinical syndrome, caused by cytokines storm due to provoked, uncon-
trolled proliferation and over activation of lymphocytes and macrophages. sHLH
in adults is an etiologically heterogeneous entity that has been associated with
infections, autoimmune disorders, and haematological malignancies, mainly
with non-hodgkin lymphoma. Clinically, these disorders feature fever,
hepatosplenomegaly, severe cytopenias, activated macrophages in hematopoi-
etic organs. Biochemical abnormalities include hypofibrinogenemia, hyper-
triglyceridemia, and increased levels of soluble interleukin-2 receptor (sCD25),
serum ferritin(SF), and a large number of inflammatory other cytokines. Heme
oxygenase 1 (HO-1) is an inducible stress-response enzyme and it is also an
rate-limitting enzyme that degrades heme to biliverdin, carbon monoxide (CO)
and free iron in mammalian cells. Biliverdin and CO gain particular interest
because of mediating most of anti-inflammatory, antioxidant and anti-apoptotic
effects of HO-1. HO-1 can be induced by various stressors such as oxidative
stress, inflammatory cytokine, heavy metals and ultraviolet irradiation. HO-1 is
constitutively expressed in peripheral monocytes and organ-localized
macrophages such as hepatic kupffer cells and splenic macrophages. These
facts suggest that HO-1 plays a key role in regulation of the inflammatory
response in physiological and pathological conditions. Recently, there are accu-
mulating evidences that increased serum HO-1 level is related to macrophage
activation. Herein, we measured serum HO-1 levels in sHLH patients and ana-
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lyzed the relationship of serum HO-1 with other biological markers of sHLH.
The results show that serum HO-1 is a novel marker to evaluating severity and
activity of sHLH. In addition, serum HO-1 may be an indicator using in differ-
entiating autoimmune-associated hemophagocytic lymphohistiocytosis (AHLH)
from other underline etiologies of sHLH.
Aims: To investigate the levels and clinical significance of heme oxygenase 1
(HO-1) in patients with secondary hemophagocytic lymphohistiocytosis (sHLH).
Methods: Serum HO-1 levels were determined by using enzyme linked
immunosorbent assays (ELISA) in 43 sHLH patients and 12 healthy contrlols.
Clinically relevant laboratory values, including white blood cell (WBC), hemo-
globin (HB), platelet (PLT), serum ferritin (SF), albuminin (ALB), alanine transam-
inase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH),
fibrinogen (FIB), blood sedimentation rate (ESR), triglyceride (TG), soluble inter-
leukin-2 receptor (sCD25) and C reactive protein (CRP) were collected.
Results: (1) Serum HO-1 levels of the newly diagnosed group were found to
be significantly higher than that of the healthy control group (P =0.001). (2)
Serum HO-1 levels of the newly diagnosed AHLH (autoimmune-associated
HLH) were significantly higher than those in patients with IHLH (infection-asso-
ciated HLH), LHLH (lymphoma-associated HLH) and healthy controls (P<0.05);
(3) The serum HO-1 levels of the clinical remission group were significantly
lower than that of the newly diagnosed group (P<0.05);(4) Serum HO-1 levels
in newly diagnosed sHLH patients positively correlated with SF (r=0.582,
P<0.001), and negatively with ALB (r=-0.308, P=0.045); (5) The receiver oper-
ating characteristic curves (ROC) for serum HO-1 levels of patients with sHLH
and healthy controls produced a cutoff value at 520.4ng/mL, with its sensitivity
and specificity being 90.7% and 100%, respectively. In addition, an optimal
cutoff value for HO-1 was 2922.3ng/mL, and Its sensitivity and specificity were
100% and 99.2%, in patients with AHLH and non-AHLH (LHLH+IHLH), sepa-
rately. Another ROC for SF levels of patients with AHLH and non-
AHLH(IHLH+LHLH) yielded an optimal cutoff value of 1189.0 ng/mL and its
sensitivity and specificity were 85.7% and 55.5%, respectively.
Summary/Conclusions: Serum HO-1 levels are clinically significant in disease
diagnosis, differential diagnosis, evaluating disease activity and treatment out-
comes in patients with sHLH.
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RESPIRATORY VIRAL INFECTIONS IN HEMATOLOGIC PATIENTS IN OUR
ENVIRONMENT. A RETROSPECTIVE STUDY
R Cidre Lopez*, A Nieto Vazquez, A Santamaria Lopez, MDLA Fernandez Fernandez,
MDC Albo Lopez
Hematology, Hospital Álvaro Cunqueiro, Vigo, Spain
Background: Respiratory viral infections are an important cause of morbidity
and mortality in immunocompromised hosts. Hematology patients are espe-
cially susceptible due to their underlying disease and the treatments they
receive. Rhinovirus, Influenza, Parainfluenza and RSV are some of the most
frequent agents. Molecular diagnostic techniques have improved over time,
providing fast and accurate results.
Aims: Analize the characteristics of viral respiratory infections in our patients.
Methods: A retrospective, descriptive study including 237 hematologic patients
from the University Hospital Complex of Vigo with suspected respiratory viral
infection for a period of two years (May 2013-May 2015). We collected 401
PCR samples of respiratory viruses in nasopharyngeal swab and BAL, focusing
on the following data: demographic characteristics, underlying disease, comor-
bidities, symptoms, diagnostic tests, treatment and clinical evolution.
Results: 122 male patients and 115 female, with a median age of 64 years old
(range 4-89). 88 underwent HSCT-46 autologous, 42 allogeneic (35 HLA iden-
tical, 6 haploidentical and 1 cord blood). 61’5% of the samples were positive for
one or more respiratory viruses (63’9% in transplant patients vs 59’8% in non-
transplant). 89’4% were positive in nasopharyngeal samples, 4’7% in BAL and
5’9% in both. Causal agents are shown in Table 2. 17% of samples were positive
for more than one virus, and 15’4% had microbiologic evidence of infection by
a different type of microorganism. 30’5% of the infections were considered noso-
comial. Concerning those with an infection acquired in the community, 59’6%
patients required hospitalization due to the respiratory illness. The symptoms
referred by our patients are shown in table 1. 61’4% of the demonstrated viral
infections were associated with lymphopenia. Hypogammaglobulinemia was
observed in 57%. 30’3% presented comorbidities associated with an increased
risk of respiratory infection (underlying heart or lung disease, smoking, HIV pos-
itivity, DM or other tumors). Radiologic findings: 50’8% showed a normal X-ray
chest image or nonspecific findings, 11’4% pneumonic consolidation and 6’5%
signs of atypical infection. 42 patients underwent a bronchoscopy. 12 obtained
concordant results with nasopharyngeal samples. 10 patients with a negative
nasopharyngeal swab had a viral identification in the BAL. We had an isolated
case with different results in each sample (a RSV was found in the nasopharyn-
geal swab and a coronavirus in the BAL). In 8 patients we found other microor-
ganisms (bacteria, fungus). Influenza virus infections were treated with
oseltamivir. CMV infections in transplant recipients received immunoglobulins
and ganciclovir. 28% of the RSV were treated with immunoglobulins and rib-
avirin. In most patients the outcome was good. 5 patients died, in 4 of them the
respiratory infection was the main cause of death.
Table 1.
Table 2.
Summary/Conclusions: Our study confirms that viral respiratory infections
are a common cause of morbidity in hematologic patients, even though related
mortality was low. The most common symptoms were those of upper airway
involvement. 44% of the patients remained afebrile during the course of infec-
tion. The presence of other comorbidities, lymphopenia and/or hypogamma-
globulinemia seemed to be related with these infections. Although we didn’t
find an increased rate of infection in transplant recipient patients, it seems that
several microorganisms coinfections are more common in this group. Molecular
techniques like PCR have replaced previous diagnostic procedures (like virus
cultures), demonstrating a higher sensibility. Given the high rate of nosocomial
infections, we would like to highlight the importance of vaccinating staff and
family, and isolation measures in patients with suspected respiratory infections
transmitted by droplets or contact.
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PHASE 1 SUMMARY OF ANF-RHO, A NOVEL PEG-MODIFIED FILGRASTIM
INVESTIGATIONAL PRODUCT WITH SUPERIOR PK/PD PROPERTIES
THAT MAY PROVIDE IMPROVED CONTROL OF NEUTROPENIA DURING
DOSE-DENSE CHEMOTHERAPY
R Jubin*, A Abuchowski, D Byczkowski, H Misra, P Buontempo
Prolong Pharmaceuticals, South Plainfield, United States
Background: Anti-Neutropenia Factor - Rho (ANF-RHO) is a new longer acting
granulocyte-colony stimulating factor (G-CSF) consisting of a novel pegylated
version of recombinant human G-CSF protein. ANF-RHO has distinct biophys-
ical and biological properties that produce an improved pharmacokinetic (PK)
and pharmacodynamic (PD) profile as compared to either filgrastim (Neu-
pogen®) or PEGfilgrastim (Neulasta®). ANF-RHO is not a biosimilar drug prod-
uct.
Aims: A Phase 1 clinical study was conducted in healthy volunteers to assess
safety and tolerability of ANF-RHO as well as its PK and PD profile.
Methods: The ANF-RHO cohort dosage levels ranged from 5 to50 μg/kg and
were compared against both active (PEGfilgrastim) and placebo (saline) com-
parators. Subcutaneous, single dose treatment with ANF-RHO in ascending dos-
es or PEGfilgrastim at the standard of care dosage (fixed, 6mg) were compared
in a randomized, controlled, double-blind study that included peripheral blood
absolute neutrophil counts (ANC) and CD34+ stem cell analytical assessments.
Results: Phase 1 clinical safety results were unremarkable, with no severe
adverse events in any cohorts. The ANF-RHO PK/PD results in this Phase 1
study were similar to preclinical findings. PK and PD results (ANC and CD34+)
were markedly prolonged in the ANF-RHO treatment groups even at the lowest
dose. Mean ANC counts for all ANF-RHO treated subjects showed Cmax at 6-
7 days, in contrast to 1-2 days for PEGfilgrastim treated subjects. The peak
blood levels of ANF-RHO were significantly lower than PEGfilgrastim at all levels
tested. Moreover, assessment of the ANC - AUC revealed that ANF-RHO at10
μg/kg was equivalent to PEGfilgrastim at 100 μg/kg, demonstrating an approx-
imately 10-fold potency improvement over PEGfilgrastim in healthy volunteers,
with a longer duration of effect of almost two weeks. Peripheral blood CD34+
levels also yielded similar results. ANF-RHO-induced neutrophil counts
increased in a stable and prolonged manner following treatment, followed by a
slow gradual decline, in contrast to PEGfilgrastim that showed a rapid ANC
spike (2 days) and decrease to baseline within 7 days following administration.
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Summary/Conclusions: The unique PK/PD of ANF-RHO suggests that a sig-
nificantly lower dosage may achieve sustained neutrophil levels sufficient to
mitigate neutropenia - specifically during the high-risk 7-day period following
dose-dense myelosuppressive chemotherapy. Additionally, the sustained and
elevated CD34+ counts suggest ANF-RHO may also have applications in stem
cell mobilization. The lower effective dosages would be anticipated to reduce
the incidence of leukocytosis. Collectively, the increased potency and prolonged
pharmacodynamics of ANF-RHO should provide more effective management
of hematological malignancies when treating patients at high risk for neutrope-
nia and difficult to mobilize patients or when performing dose-intensification in
advanced stage cancer patients.
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INVASIVE PULMONARY ASPERGILLOSIS IN ALLOGENEIC BONE
MARROW RECIPIENTS WITH Β- THALASSAEMIA MAJOR OR SICKLE
CELL DISEASE: INCIDENCE AND RISK FACTORS
K Paciaroni1,*, G DeAngelis1, C Gallucci1, M Ribersani1, M Marziali1, A Isgrò1,
J Gaziev1, L Sarmati2, L Dori2, P Sodani1, G Lucarelli1
1International Centre for Transplantation in Thalassemia and Sickle Cell
Anaemia, Mediterranean Institute of Haematology, 2Clinical Infectious Disease,
Tor Vergata University, Rome, Italy, Rome, Italy
Background: Invasive Pulmonary Aspergillosis (IPA) is a devastating oppor-
tunistic infection and remains a significant cause of morbidity and mortality in
allogeneic Haematopoietic Stem Cell Transplantation (HSCT) recipients. IPA
has been well characterized in adults and in the setting of oncological transplant.
No data are available regarding IPA in patients with β- globin gene disorders
undergoing bone marrow transplant (BMT).
Aims: To evaluate the incidence and the outcome of IPA among BMT recipients
with β-Thalassaemia Major or Sicke cell Anaemia (SCA).
Methods: We evaluated the occurrence, the clinical setting and the clinical
outcome of IPA in pediatric patients affected by Thalassaemia major or SCA
transplanted at our institution.
Results: A total of 292 consecutive patients (median age 11,6, range 1,9-28
years) with β- globin gene disorders who underwent BMT (232 HLA-identical,
related donor; 54 haplotype-identical donor and 4 matched, unrelated donor)
were studied. Overall, the incidence of proven or probable IPA was 2.73% (8
out of 292 cases). The median time to onset IPA infection after transplantation
was 68 days (range, 13-183 days). In particular, in 5 cases (50%) IPA were
diagnosed in the late phase after transplant (day >60) and in 3 cases (50%)
were diagnosed during the post-BMT neutropenic period before engraftment.
All grade of Graft-versus-host-disease (GVHD) was present in 4 (50.0%) of 8
patients with IPA, compared with 97 (37,7%) of 284 patients without fungal
infection (P=n.s.). Among 8 cases with IPA an alternative donor (matched unre-
lated or haplotype-identical) was used in 5 patients (62.5%) compared with 55
cases (19.3%) of 284 recipients without IPA (P=0.003). The infection remained
confined in the lung in 7 (87.5%) of 8 IPA cases, in 2 cases surgical intervention
was adopted in addition to the adequate systemic anti-fungal medical therapy;
only in 1 case the infection was multifocal with CSN involvement. The overall
mortality rate for IPA was 0.7% (2 of 292 patients) whereas the IPA attributable
mortality rate observed in our population was 25% (2 of 8 cases).
Summary/Conclusions: Our data show that in a population affected by β- glo-
bin gene disorders who undergoing allogeneic BMT, the IPA rarely develop
(2,7%) and the overall mortality (0.7%) and the IPA attributable mortality rate
(25%) is markedly lower then the one observed in the setting of haematological
malignancies. In our cohort, a significant risk factor for IPA was the alternative
donor.
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EARLY AND RAPID INCREMENT OF CRP AND IL-8 LEVELS TOGETHER
WITH FASTER AND DEEPER DECLINING OF LEUKOCYTES PREDICT FOR
TYPHLITIS DEVELOPMENT IN TREATED AML PATIENTS
L Span1,*, G Dijkstra2, E Vellenga1, G Huls1
1Hematology, 2Gastro-enterology, UMCG, Groningen, Netherlands
Background: Neutropenic enterocolitis (NE) or typhlitis is an important and
severe complication in patients with acute myeloid leukemia (AML) receiving
intensive chemotherapy.
Aims: In this study we evaluated serum C-reactive protein (CRP), interleukin
(IL)-8, fecal calprotectin, and oral mucositis score as possible time-dependent
predictors of developing NE.
Methods: Adult patients with AML treated with intensive chemotherapy (with
cytarabine) were included. Serum IL-8 and CRP levels were measured daily
during 14 days after cessation of chemotherapy, as well as calprotectin in the
stool. Oral mucositis was also scored daily. Furthermore, CT scan of the
abdomen at day 21 was performed to objectively define patients with NE. 
Results: In total, 34 patients were included and 11 episodes of NE were diag-
nosed. All patients with NE received conservative treatment and only one
patient with NE died because of refractory Enterococcus faecium sepsis. From
day 5 onward (after cessation of chemotherapy), median IL-8 and CRP levels
increased more rapidly to significantly higher levels in patients with NE, whereas
white blood cell (WBC) counts decreased faster to significantly lower levels as
compared to the non-NE patients. Oral mucositis score and fecal calprotectin
levels failed to be different in both groups. Cytarabine dose was of no influence.
As was corrected for bacteraemia, no differences were seen between both
groups.
Summary/Conclusions: Pattern recognition of early and rapidly increasing
IL-8 and CRP levels with significantly lower WBC counts after cessation of
chemotherapy can identify AML patients developing NE. Early recognition of
developing NE can potentially decrease the high mortality rate (25-50%) of this
complication.
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PRESEPSIN (SOLUBLE CD14 SUBTYPE) IS ELEVATED IN FEBRILE
NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCY:
USEFULNESS AS ONE ANOTHER BIOMAKER
N Sugawara1,*, T Oyake1, T Masuda2, M Asahi1, Y Suzuki1, Y Okano1,
Y Fujishima1, Y Aoki1, S Kowata1, S Ito3, Y Ishida1
1Hematology and Oncology, Internal Medicine, 2Critical Care Medicine, 3Med-
ical Oncology, Iwate Medical University School of Medicine, Morioka, Japan
Background: ebrile neutropenia (FN) is often observed in patients with hema-
tological malignancy (HEM). Most of causes are bacterial infections in these
FN, and many cases respond to empirical antibiotic therapy including an anti-
pseudomonas b-lactam agent. Otherwise, it is often difficult to specify the focus
and pathogen of infection in FN patients. Presepsin (Pre-SEP) is a subtype of
soluble CD14, which is a receptor for lipopolysaccharide (LPS)/LPS-binding
protein complexes and is expressed on the myelo-monocytic cell surface.
Recently, it has been shown to be a useful biomarker for assessing the severity
of sepsis and has come into use in the field of critical care medicine. However,
little is known about the biological characteristics of Pre-SEP in FN patients.
Aims: To clarify the usefulness of new biomarker Pre-SEP in the setting of
neutropenia, we performed analyses to determine the clinical relevance of Pre-
SEP in the diagnosis of bacteremia or other infectious complications as a bio-
marker for FN patients after or during chemotherapy in HEM. 
Methods: We measured the plasma concentration of Pre-SEP, procalcitonin
(PCT) and C-reactive protein (CRP) at Day0, 2, 4, 7, 14 and 21 after the onset
of FN, and compared them to those of non-febrile neutropenic patients. Fur-
thermore we reviewed other clinical data including bacterial examination and
clinical courses, and evaluated the utility of Pre-SEP as biomarker of FN. 
Results: The 65 hospitalized FN patients with HEM (AML 16, ALL 12, MDS 14,
NHL 13, MM 8, and ATL 2) were treated by IDSA guideline and administered
antibacterial or antifungal agents, and the clinical data including Pre-SEP were
evaluated. Pre-SEP (Day 0, 2, 4, 7, 14 and 21) was elevated (447 pg/ml (141-
2204), 494 pg/ml (151-1975), 344 pg/ml (164-1264), 312 pg/ml (116-1512),
319 pg/ml (86-1512), 278 pg/ml (129-1425), p<0.05, respectively, cut off value:
314 pg/ml) compared to those in non-febrile neutropenic patients (196 pg/ml
(97.5-453): median (range), respectively). Otherwise, PCT (Day 0, 2, 4, 7, 14
and 21) was also elevated (0.12 ng/ml (0.04-3.40), 0.13 ng/ml (0.05-1.60), 0.11
ng/ml (0.04-3.54), 0.08 ng/ml (0.03-8.21), 0.11 ng/ml (0.02-2.64), 0.36 ng/ml
(0.10-7.75), p<0.05, respectively, cut off value: 0.05 ng/ml) compared to those
in non-febrile neutropenic patients (0.175 ng/ml (0.06-1.91): median (range),
respectively), and CRP (Day 0, 2, 4, 7, 14 and 21) was also elevated (5.07
mg/dl (0.19-27.83), 3.19 mg/dl (0.30-20.54), 2.26 mg/dl (0.15-34.01), 1.33 mg/dl
(0.10-29.48), 0.28 mg/dl (0.10-22.49), 0.36 mg/dl (0.10-7.75), p<0.05, respec-
tively, cut off value: 0.3 mg/dl) compared to those in non-febrile neutropenic
patients (0.625 mg/dl (0.11-8.72): median (range), respectively). There was no
relation between Pre-SEP value and bacterial examination data including blood
cultures. Almost FN cases responded empirical antibacterial therapy, and ele-
vated Pre-SEP, PCT and CRP values decreased again accompanied by defer-
vescence. However, some cases of persistent remarkably elevated Pre-SEP
cases ware observed, and these cases had very poor prognosis. The 5 of 9
cases with remarkably high Pre-SEP value (>1000 pg/ml) at both day7 and 14,
or both day14 and 21 were dead by severe infection related events within 4
weeks, otherwise all other 56 cases than the above recovered from infection
events and survived (p<0.05, respectively).
Summary/Conclusions: These data suggested that Pre-SEP is elevated due
to active infection events in FN patients in spite of conditions being remarkably
decreased neutrophil and monocyte. Pre-SEP is useful as a biomarker of infec-
tion in FN patients, as well as PCT or CRP.
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INVASIVE ASPEGILLOSIS IN PATIENTS WITH ACUTE LEUKEMIAS: PROGNOSTIC
VALUE OF LABORATORY BIOMARKERS DEFINING HIGH RISK PATIENTS
A Vidovic1,*, V Arsic Arsenijevic2, M Virijevic3, D Tomin1, N Suvajdzic Vukovic1,
I Djunic1, M Mitrovic1, P Tojic4, D Marinkovic4, B Mihaljevic1
1Clinical Center of Serbia, Medical Faculty of Belgrade, Clinic of Hematology,
2Medical Faculty, University of Belgrade, Medical Mycology Reference Labo-
ratory, Institute of Microbiology and Immunology, 3Clinical Center of Serbia,
Clinic of Hematology, 4University of Belgrade, Medical Faculty, Belgrade, Serbia
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Background: Invasive fungal diseases, especially invasive aspergillosis (IA)
are the major cause of morbidity and mortality in patients with acute leukemias.
Detection of early laboratory biomarkers: galactomannan (GM) and anti-
Aspergillus antibodies IgM and IgG (Anti-A IgM, IgG) contributes to early recog-
nition, as well as to the monitoring during aspergillosis treatment.
Aims: The aim of study was to evaluate clinical utility and prognostic value of
“non- culture” methods: GM assay and anti-A (IgM and IgG) antibodies for early
diagnosis of aspergillosis in patients with acute leukemias.
Methods: The study included 102 patients, 80 pts with AML and 22 pts with
ALL (52 male/50 female, median age 51 years, range 19-73 years) hospitalized
in the Clinic of Hematology during period of time from January 2012 until
December 2015. All pts were treated with intensive chemotherapy according
to the regimens recommended for the treatment AML and ALL, consequently
developing febrile neutropenia, with median duration of 12 days (7-23days).
Serum GM level were measured twice a weekly using the Platelia Aspergillus
enzime immunoassay (EIA) kit (Biorad, France), applying the cutoff value of
0,5 as positivity. Anti-A IgM/anti-A IgG were measured using commercial tests
(Serion ELISA classis, Virion/Serion, Germany). The concentration of antibod-
ies above 12U/ml was considered as positive finding. In all patients routine
radiological (high resolution CT scaning) was performed, as well as the biolog-
ical monitoring consisted of hematological, biochemical and cytopathological
tests. Median time of follow-up was 294 days (range 15-1300 days) and treat-
ment outcome was assesed on the 100. day of follow-up. Statistical analysis
was performed using IBM SPSS Statistics version 21.0.
Results: In analyzed group of 102 patients, there were 20 possible, 54 probable
and 4 proven cases of IA, while in the last 24 pts were detected only positive
GM or anti-A IgM/anti-A IgG. During 100 days of follow-up, 39 patients died
while 63 patients had survival longer than 100 days. GM index, as well as the
anti-A (IgM and IgG) antibodies, was defined as ratio of total number of positive
findings and total number of performed tests. Predictive value of GM index
was maintained after Cox regression adjustment. In multivariate analysis, GM
index was an independent survival predictor (p=0.012). Anti-A IgM and anti –
A IgG were not statisticaly significant predictor of survival (p=0,224 and
p=0,987).
Summary/Conclusions: The GM assay is a useful tool for monitoring IA in
patients with acute leukemias. Persistent GM positivity is associated with death
and treatment failure, whereas a successful outcome is associated with GM
negativity. Diagnostic and prognostic value of level of anti-Aspergillus antibod-
ies is not documented and more studies, with more patients, are needed to
define better the role of these biomarkers.
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HEPATITIS B IMMUNE STATUS IN CHILDREN TREATED FOR ACUTE
LYMPHOBLASTIC LEUKEMIA
Y El Chazli1,*, H Hassab1, M Salama1, W El Gendy2
1Department of Pediatrics, 2Department of Clinical Pathology, Faculty of Med-
icine, Alexandria University, Alexandria, Egypt
Background: Hepatitis B virus (HBV) infection occurs worldwide, with the high-
est HBsAg carrier rates found in developing countries, where infection is
expected to occur in infancy and childhood. Immunization with hepatitis B vac-
cine is the most effective way of preventing HBV infection and its conse-
quences, especially in endemic areas. Hepatitis B vaccines are highly immuno-
genic, inducing a protective anti-HBs antibody titer (≥10 mIU/mL), in more than
95% of healthy children and young adult. Partial or complete loss of protective
antibody titers against vaccine preventable diseases makes leukemic children
more susceptible to infections. Hemato-oncological patients are considered at
risk for either acute acquired HBV infection or HBV reactivation.
Aims: evaluate the immune status to HB vaccine in children treated for acute
lymphoblastic leukemia (ALL) after completion of chemotherapy and determine
factors affecting anti-HBs titer in those children.
Methods: We evaluated HBV immune status among 76 children who have
been treated for ALL, 43 males and 33 females, their age ranged from 4.9 to
16.3 years with a mean of 11.19 years. They were consecutively recruited from
the hematology oncology clinic at Alexandria University Children’s Hospital.
One hundred healthy children were also included as controls, 51 males and
49 females, age ranged from two to 12 years with a mean of 7 years. All have
been previously vaccinated with 3 doses of hepatitis B vaccine at 2, 4 and 6
months of age. Anti-HBs titer was assessed in all leukemic children and controls
by ELISA, and concentrations<10.0 mIU/mL were considered negative for anti-
HBs (non-immune).
Results: Significantly more leukemic children were non-immune (51.3%) com-
pared to only (15%) in the control group, (p<.0001). Moreover, mean anti-HBs
titer in normal children was significantly higher than in leukemic children, (61.57
vs 42.79 mIU/mL, p=.038). When comparing immune and non-immune
leukemic children according to age at diagnosis of leukemia, it was significantly
higher in non-immune than in immune ones, (6±2.9 vs 4.6±1.9 respectively,
p=.017). Using logistic regression analysis, both previous chemotherapy and
age were identified as independent variables affecting immunity to HB vaccine,
(p=.032, p=.001 respectively). An equation resulted from this analysis to predict
the probability of non-immune status: Y=-3.589+[0.928×disease status]+
[0.243×age (years)], where disease status is entered as “0” if normal child and
as “1” if child has been previously treated for leukemia. The diagnostic per-
formance of the new equation using Receiver Operating Characteristic (ROC)
curve analysis was fair to good tool in discrimination between immune and
non-immune children, (AUC=0.782, 95% CI 0.713-0.851, p<.0001). Children
with value of ≤0.286 will be considered immune with negative predictive value
of 86%. On the other hand, children having a value >0.656, are considered to
be non-immune with a positive predictive value of 78.9%.
Summary/Conclusions: Several variables affect immunity of children to HB
vaccine. Chemotherapy affects immunity to HB vaccine in children treated for
ALL regardless the type of leukemia, the intensity of the protocol used for treat-
ment, and the post chemotherapy interval. A novel equation was developed to
predict non-immune state to HBV in children using both his age and his disease
status thus help taking a decision concerning revaccination of these patients
with minimal costs and time consumption.
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IMPACT OF RESPIRATORY VIRUSES IN IMMUNOCOMPROMISED
PEDIATRIC HEMATOLOGY PATIENTS
M Rompola1,*, S Kinsey1, F Azzuni2, E Kane3, E Roman3, A Hale4, B James5
1Leeds Institute of Cancer and Pathology, University of Leeds, 2Pediatric Infec-
tious Disease, Leeds General Infirmary, Leeds, 3Department of Health Sci-
ences, University of York, York, 4Department of Virology, 5Pediatric hematology,
Leeds General Infirmary, Leeds, United Kingdom
Background: Respiratory viral infections are very common in children. Children
immunocompromised (IC) by treatment for haematological malignancies or fol-
lowing stem cell transplant (SCT) are at increased risk, although the morbidity
and mortality are not well understood.
Aims: To assess the impact of respiratory viruses in IC pediatric hematology
patients aged 0-18 analysed by diagnosis, intensity of treatment, rates of admis-
sion, Pediatric Intensive Care Unit (PICU) and outcomes, including the effect
of influenza H1N1 pandemic (swine flu).
Methods: Retrospective review of PCR positive viral isolates of respiratory
secretions of children with hematological diseases or post SCT, sent between
Jan 2009-Dec 2014. Review of patient records with regards to concurrent neu-
tropenia, blood culture growth, admission, PICU and outcome.
Results: 952 specimens from respiratory secretions were sent, 465 were pos-
itive (48.8%), with total 528 viral isolates (63 specimens had multiple isolates)
representing 171 patients. 232/465 (50%) were from nose swabs; 134/465
(29%) were nose and throat swabs; 71 /465 (15%) were throat swabs; 9/465
(1.9%) were from bronchio-alveolar lavage. Patients: 141 acute leukemias (AL),
27 SCT, 3 other haematological diseases. 96 boys, 75 girls. Mean age at diag-
nosis: 4.9 years. Mean age at sample: 6 years. Viral isolates overall: Of the
total 528 viral isolates the majority, 52%, were rhinovirus, 14.2% Respiratory
Syncitial Virus (RSV), 6.8% parainfluenza 3, 4.6% adenovirus, 4.6% parain-
fluenza 1, 4.2% metapneumovirus, 3.6% parainfluenza 4, 3.4% influenza B and
3.4% H1N1. 385/465 (83%) positive swabs were from AL patients (mean age
at sample 6 years) 70/465 (15%) from SCT patients (mean age at sample 6.8
years) and 10/465 from patients with other disorders (mean age at sample 1.7
years). Treatment intensity: positive results in AL patients occurred at the fol-
lowing phases of treatment 10/385 induction; 164/385 at other phases of treat-
ment; 211/385 in maintenance. In the UK males with ALL are treated for 3 years
(compared with 2 years for girls). Of the total of 211 positive samples taken in
maintenance, 42 (20%) were from boys in their 3rd year of treatment and resulted
in 24 admissions. H1N1 was solated from 18 patients associated with 14 admis-
sions. 1 PICU and subsequent death. Mean age at sample 8.18. 10 maintenance
AL, 6 other phases AL and 2 SCT. (4 mixed isolates: 2 rhinovirus, 1 parainfluenza
1 and 1 RSV.) Overall, 301 admissions at the time of respiratory viral isolate. Of
the 528 viral isolates, 64.7% during admission (mean age 5.7 years). 32.6%
with concurrent neutropenia and only 1.9% with blood culture growth. 10 patients
required PICU during their admission, 8 of which were all/partly attributed to the
respiratory virus. 4 patients were in AL induction (1 died with RSV and parain-
fluenza 4). 1 in AL consolidation. 1 with relapsed ALL who died with rhinovirus
and metapneumovirus. 2 were SCT patients (1 died with rhinovirus).
Summary/Conclusions: There was a surprisingly high (48.8%) positive rate
in the respiratory secretion samples. 64.7% of positive viral isolates coincided
with admission. Respiratory viruses are a cause of significant morbidity, includ-
ing hospital admission and mortality. 38% of patients admitted to PICU all or
partly as a consequence of a respiratory virus; 3 patients died. Rhinovirus,
often dismissed as irrelevant, was present in 75% patients admitted to PICU
and 33% PICU deaths. Although the data reflects a time of H1N1 outbreak: it
was isolated in few patients, however 78% of patients with H1N1 isolate
required admission and 1 patient died.
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VORICONAZOLE AS PRIMARY PROPHYLAXIS OF FUNGAL INFECTIONS
IN HIGH-RISK HEMATOLOGIC PATIENTS: NO NEED FOR EMPIRICAL
ANTI-FUNGAL THERAPY
A Zabalza1,2,*, C Mansilla2, M Ciaurriz2, L Beloki2, M Lachen2, E Perez-Valder-
rama2, A Gorosquieta1, M Rodriguez-Calvillo1, N Ramirez2, E Olavarria3
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1Hematology, Complejo Hospitalario de Navarra, 2Oncohematology Research
Group, Navarrabiomed-Miguel Servet Foundation, Pamplona, Spain, 3Hema-
tology, Hammersmith Hospital-Imperial College Healthcare, London, United
Kingdom
Background: Invasive fungal infections (IFI), predominantly aspergillosis and
candidiasis, remain an important cause of morbidity and mortality following
high-dose chemotherapy and allogeneic stem cell transplantation (alloSCT).
Aims: The primary endpoint of this study was to analysed the efficacy and
safety of voriconazole primary antifungal prophylaxis in combination with a pre-
emptive antifungal strategy in high-risk hematologic patients.
Methods: This is a retrospective, observational and non-interventional study
conducted from March 2009 until February 2012 at the Complejo Hospitalario
de Navarra. Patients could receive voriconazole prophylaxis at different periods
of time in the course of their disease if they were at high-risk of IFI: following
intensive chemotherapy (n=24), allogeneic stem cell transplantation (n=43) or
receiving high-dose corticosteroids treatment for chronic graft versus host dis-
ease (n=11). If patients developed prolonged unresponsive fever after 5 days
of broad-spectrum antibacterials and/or galactomannan antigen was positive,
a high-resolution computed tomography (CT) was performed. If new pulmonary
infiltrates were present, a bronchoscopy with BAL was performed. Only patients
with abnormal CT findings, positive fungal isolates on BAL or positive GM anti-
gen started on pre-emptive antifungal treatment and changed their anti-fungal
treatment to liposomal amphotericin B or an equinocandin. Otherwise, patients
remained on voriconazole prophylaxis despite continuing fever. The cumulative
incidence (CI) of proven/probable IFI, pre-emptive antifungal treatment and
adverse events were estimated by Kaplan-Meier survival curves.
Results: A total of 78 prophylactic voriconazole periods were analysed in a
total of 44 hematologic patients. Only one patient developed a proven/probable
IFI (a breakthrough candidemia) in the allogeneic stem cell transplantation
group. No patient developed proven/probable IFI in the chemotherapy neither
in the chronic graft versus host disease group. The cumulative incidence of
pre-emptive antifungal treatment was 12.5% and 12.3% for the chemotherapy
and the allogeneic stem cell transplantation respectively. The most frequent
adverse event was hepatic toxicity with a cumulative incidence of 10.7%, 25.8%
and 27.3% in the chemotherapy, the allogeneic stem cell transplantation and
the chronic graft versus host disease respectively. No hepatic failure was reg-
istered and hepatic toxicity was reversible after drug discontinuation or transient
interruption.
Summary/Conclusions: Voriconazole is a safe and an effective antifungal
agent for prophylaxis of IFI in high-risk hematologic patients with a success
rate of 97.4% provided that frequent liver monitoring and short intermittent inter-
ruptions are performed. Voriconazole prophylaxis allows for strategies with no
empirical use of systemic anti-fungals.
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RANDOMISED COMPARISON OF PALONOSETRON AND ONDANSETRON
BOTH COMBINED WITH DEXAMETHASONE IN PREVENTION OF EMESIS
IN LYMPHOMA PATIENTS RECEIVING MODERATELY EMETOGENIC
REGIMEN BENDAMUSTINE AND RITUXIMAB
V Ptushkin1,*, N Sharkunov2, S Mayorova2, M Pankrashkina2, E Nikitin2
1Hematology Department, 2Outpatient department for Hematology Oncology
and Chemotherapy, S.P.Botkin’s city hospital, Moscow, Russian Federation
Background: Palonosetron is a highly selective, second-generation 5-HT3
receptor antagonist with a prolonged half-life (40 hours) which makes it attrac-
tive in prevention of delayed nausea and vomiting. Bendamustine, a moderately
emetogenic cytostatic drug is becoming increasingly used in treatment of lym-
phoid malignancies.
Aims: A randomized comparison of palonosetron and ondansetron both com-
bined with dexamethasone in prevention of chemotherapy induced nausea and
vomiting (CINV) in adult patients, receiving bendamustine and rituximab
chemoimmunotherapy.
Methods: Data of 1st interim analysis are presented. The study included 23
patients with median age of 67 years (range 31 - 82 yrs), 13 males and 10
females. The patients did not received chemotherapy at least 6 months prior to
inclusion. Ten patients had follicular lymphoma, 8-chronic lymphocytic leukemia,
6-marginal zone and other types of indolent lymphomas. The BR regimen con-
sisted of rituximab 375 mg/m2 on day 1 and bendamustine 90 mg/m2 on days
1 and 2. Patients were randomly assigned to receive either a single intravenous
bolus dose of palonosetron (0, 25 mg) on day 1 or ondansetron (8 mg on days
1 and 2 of each cycle) along with dexamethasone 30 min before administration
of chemotherapy. CINV was assessed during 1st cycle of chemotherapy using
MASCC Antiemesis Tool. Frequency and severity of acute (within 24 hours)
and delayed (24-120 hours) emetogenic reactions were registered. 
Results: Eleven patients received palonosetron and 12 ondansetron. Groups
were comparable with regard to emetogenic risk factors including sex, age,
kinetosis and alcohol use. Complete response (no emetic episodes and no res-
cue therapy) in acute phase was observed in 100% of patients receiving
palonisetron and in 10/12 (83%) of patients receiving ondansetron. Complete
response in delayed phase was achieved in all patients in palonosetron group
and in 11/12 (92%) in ondansetron group. Complete protection (no emetic
episodes, no rescue therapy, and no significant nausea [Likert scale 2 or less])
in acute phase was achieved in 10/11 (91%) patients in palonosetron group
and in 5/12 (41%) in ondansetron group. In delayed phase complete protection
of CINV was reported by 10/11 (91%) of patients receiving palonosetron and
6/12 (50%) of patients receiving ondansetron.
Summary/Conclusions: The frequency of delayed nausea in patients, receiv-
ing bendamustine is probably underestimated. Prevention of bendamustine
induced nausea and vomiting with palonosetron merits further investigation.
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EFFICACY AND SAFETY OF MICAFUNGIN ON THE MANAGEMENT OF
INVASIVE FUNGAL INFECTIONS AMONG PATIENTS WITH HEMATOLOG-
ICAL MALIGNANCIES AT TERTIARY HOSPITALS IN GREECE- THE
ASPIRE STUDY
M Kotsopoulou1,*, G Vassilopoulos G2, K Anargyrou3, A Spyridonidis4,
I Baltadakis5, HA Papadaki6, M Angelopoulou7, MC Kyrtsonis7, V Pappa8,
K Liakou9, M Tzanetakou9, A Georgopali9, N Anagnostopoulos10
1Metaxa Cancer Hospital, Pireus, 2University General Hospital of Larissa, Laris-
sa, 3Hematology Clinic, 251 General Air Force Hospital, Athens, 4University
General Hospital of Patras, Patras, 5General Hospital of Athens “Euaggelismos,
Athens, 6University General Hospital of Heraklion, Heraklion, 7General Hospital
of Athens “Laikon”, 8Second Department of Internal Medicine and Research
Institute, “Attikon”, University General Hospital, Athens, 9Medical Affairs, Astel-
las Pharmaceuticals AEBE, Attica, 10General Hospital of Athens “G. Genni-
matas”, Athens, Greece
Background: Immunocompromised patients, especially those with cancer or
underling hematological malignancies and patients who undergo hematopoietic
stem cell transplantation (HSCT), are at high risk for invasive fungal infections,
which are often life threatening. Echinocandins are recommended as first -line
treatment for the management of invasive candidiasis/candidemia from the
recent ESCMID guidelines. However, there are relatively limited data for the
daily clinical practice regarding the use of micafungin at hematological settings
in Greece.
Aims: The aim of the study was to evaluate the efficacy and safety of micafun-
gin administration in standard clinical practice among patients with hematolog-
ical malignancies, including patients who underwent HSCT.
Methods: This was a multicenter, non interventional, prospective cohort study
conducted in 10 research sites in Greece. Adult hospitalized patients with hema-
tological malignancies, including recipients of HSCT, were enrolled in the study
between 29 Jun 2013 and 31 Mar 2014. Eligible patients were intended to
receive micafungin which was prescribed as per standard clinical practice
according to its label, while their assignment to a particular therapeutic strategy
was not decided in advance by the protocol. The observational study period
lasted until clinical outcome was recorded. Patients were classified according to
their clinical presentation at baseline using the revised EORTC criteria (2008).
Results: A total of 143 patients were enrolled. Of them, 122 patients had a
hematological malignancy (85.3%), 4 underwent HSCT (2.8%) and 17 had
hematological malignancy and HSCT (11.9%). Acute myelogenous leukemia
(n=58, 40.6%) was the most common hematological disorder, while just over
half of these patients were newly diagnosed (51%). Of the 21 patients in the
HSCT group, 12 underwent autologous and 9 allogeneic HSCT. On treatment
initiation, 78 patients had fever (54.5%) and 85 patients had neutropenia
(59.4%) respectively, while 58 patients had previous febrile episodes(40.6%).
In addition, 112 patients had received systemic antibiotics (78.3%), 64 patients
had received corticosteroids (44.8%) and 69 patients other immunosuppressive
agents (48.3%) as prior treatment. At baseline, 74 patients of the study received
micafungin as prophylaxis while 69 received treatment for possible (52), prob-
able (12) and proven (5) fungal infection. Micafungin was administered as
monotherapy in 97.6% of patients and as first line treatment in 75.5% of
patients, while the mean duration of micafungin administration was 14.2 days
(14.1 days for prophylaxis and 14.3 days for treatment). The success rates of
micafungin were comparable for prophylaxis, possible and proven treatment
strategies (90.5% vs 96.2% vs 100% respectively), while for probable treatment
strategy was 75%. It is worth noting that in the latest group, treatment was con-
sidered as success in 9 patients, as failure in one patient and in two patients
treatment definition as success or failure was not available. Treatment success
was defined by the Investigators based on the EORTC/MSG criteria and their
judgment as applied for daily clinical decision-making. 26 patients (18.2%) dis-
continued micafungin mainly due to limited availability of therapy at study sites,
patient discharge or safety events not related to the study treatment. In total,
30 adverse events were reported throughout the study, including 8 Serious
Adverse Events (deaths) that were not related to micafungin and 22 cases of
special situations. One case of lack of efficacy was reported.
Summary/Conclusions: Micafungin was effective and well tolerated in patients
with hematological malignancies, including patients who underwent HSCT. To
this end, micafungin appears to be a valuable treatment option for the man-
agement of fungal infections in hematological settings.
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ANTIRETROVIRAL THERAPY AND CHEMOTHERAPY IN PATIENTS WITH
HIV INFECTION AND HAEMATOLOGICAL DISEASE - TOXICITY ASSESSMENT
P Sousa e Santos1,*, E Viegas2, F Mousinho1, T Baptista3, A Reichert1,
AP Gomes1, F Falcão4, F Lima1
1Clinical Hematology, 2 Pharmacy Department, Hospital de São Francisco
Xavier, 3Infeciology and Tropical Medicine, Hospital de Egas Moniz, 4 Phar-
macy Department, Faculty of Pharmacy, iMed.ULisboa Research Institute for
Medicine, Universidade de Lisboa, Hospital de São Francisco Xavier, Lisboa,
Portugal
Background: Haematological malignancies, especially lymphoproliferative dis-
eases, are a common manifestation of infection with human immunodeficiency
virus (HIV). With highly active antiretroviral therapy (HAART) the survival of
infected patients with hematologic disease has increased, and in most cases,
overlapping the general population. Concomitant use of HAART and
chemotherapy (CT) has been advocated for enhancing the immune response.
Aims: Characterization of toxicity associated with the concomitant use of
HAART and CT and its impact on prognosis.
Methods: Descriptive, observational, retrospective study to evaluate patients
with haematological malignancies associated with HIV infection and under
HAART during CT, admitted between January 2011 and August 2015. The data
was analysed using SPSS V17.0 program.
Results: We evaluated 24 patients, 19 males. The median age was 45.5 years
(27-61). 22 patients had HIV-1, 1 patient HIV-2 and 1 patient co-infected with
HIV-1 and HIV-2. All patients were on ARVT, 47.8% with regimens based on
two nucleoside reverse transcriptase inhibitors (NRTI) and boosted protease
inhibitor (PI/ r) and 34.8% with 2 NRTI-based regimens and integrase inhibitor
(II). The most common diagnosis was Burkitt’s lymphoma (29.2%), followed
by diffuse large B-cell lymphoma (25%) and Hodgkin Disease (16.7%). The
CD4 cell count was below 250cells/ mcL in 10 patients and none had negative
viral load at the start of CT. We documented 120 complications, most infectious
(50.8%). Organ toxicity was revealed in 11 patients, of which 35% had renal
and 20% liver toxicity. Of the 7 patients who experienced renal toxicity, 6 were
treated with regimens containing tenofovir. Of the 4 patients who experienced
liver toxicity, 2 were treated with PI/ r and 2 with II. It was necessary to suspend
HAART in 5 patients. The scheme has been changed in two. The median of
administered chemotherapy cycles was 4 (1-8) with an overall response rate
of 77.8% (n=14), 50% (n=9) complete response, 27.8% (n=5) partial response,
4 patients were refractory, and the remaining (n=6) were not evaluated. The
overall survival at 2 years was 36.4% (4/11).
Summary/Conclusions: The use of HAART associated with CT is not absent
of toxicities, sometimes forcing its suspension. The new generation of anti-
retroviral drugs, with less pharmacokinetic interactions with antineoplastic
drugs, seems to contribute to better compliance with HAART. The impact of
this association should continue to be evaluated in further studies with larger
samples.
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RE-EVALUATING THE IMPACT OF INVASIVE ASPERGILLOSIS ON THE
PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS
MP Ledoux1,*, N Baati1, F Danion1, E Toussaint1, V Letscher-Bru2,
LM Fornecker1, R Herbrecht1
1Hematology, 2Mycology, Hôpitaux Universitaires de Strasbourg, Strasbourg,
France
Background: Invasive aspergillosis (IA) is a common complication of neu-
tropenic and immunocompromised status occuring during acute myeloid
leukemia (AML) management. Its prognosis has long been dismal, causing an
important additional mortality in hematology patients. However, both diagnostic
procedures and therapeutics have much improved, through galactomannan
dosing, high resolution CT-scan and voriconazole avaibility.
Aims: We intended to assess frequency and prognostic impact of IA in a recent
cohort of patients receiving high dose chemotherapy for AML.
Methods: We have therefore conducted a monocentric retrospective obser-
vational study on all consecutive patients diagnosed with an AML between
2008 and 2012 in Strasbourg University Hospital.
Results: Among 285 patients diagnosed with AML between 2008 and 2012 in
our hospital, 154 received an intensive chemotherapy, with at least one induc-
tion course. Among them, 46 patients (29,9%) have been diagnosed with IA (2
proven IA, 25 probable IA, 19 possible IA). Twenty-eight (18,2%) of these infec-
tions occured following the first induction course (2 proven IA, 17 probable IA,
9 possible IA). Both groups of patients, whether they had an IA or not, had
similar hematological prognosis as assessed by ELN scoring. Almost all IA
patients (44, i.e. 96%) received voriconazole as a treatment. At the closing of
our analysis, 17 patients diagnosed with an IA were still alive, with a follow-up
ranging from 32 months to 93 months (median 64 months). The overall survival
(OS) analysis of these patients showed no significant difference compared to
patients without IA (p=0.94). Five-year survival of the two groups was respec-
tively 40,6% and 41%.
Summary/Conclusions: With an incidence of IA close to recent data concern-
ing patients treated for AML, our monocentric retrospective study on long-term
survival of AML and IA patients shows no significant difference in terms of over-
all survival. These encouraging results shall now be confirmed on a larger
cohort to conclude that the impact of IA on the prognosis of AML patients has
been controlled in the era of diagnostic and therapeutic improvement.
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PRIMARY ANTIFUNGAL PROPHYLAXIS (PAP) WITH MICAFUNGIN AT THE
DOSE 50MG PER DAY IN ADULT PATIENTS WITH ACUTE LYMPHOBLAS-
TIC LEUKAEMIA (ALL) DURING INDUCTION CHEMOTHERAPY: THE
“REAL-LIFE” EVALUATION
T Kabut1,*, F Folber1, C Salek2, J Prochazkova1, M Rolencova1, I Kocmanova3,
M Kouba2, B Weinbergerova1, P Cetkovsky2, J Mayer1, Z Racil1
1Dept. of Internal Medicine - Hematology and Oncology, Masaryk University
and University Hospital Brno, Brno, 2Institute of Hematology and Blood Trans-
fusion, Prague, 3Dept. of Clinical Microbiology, University Hospital Brno, Brno,
Czech Republic
Background: Invasive fungal diseases (IFDs) during treatment of acute
leukaemias are associated with a high morbidity and mortality. While in patients
with acute myelogenous leukaemia PAP during induction treatment is well
established (mainly with posaconazole), standardized PAP in patients with ALL
is lacking. The major obstacle represents the risk of interactions of mould active
azoles with chemotherapy agents during the intensive treatment of ALL. Thus
the choice of PAP in these patients is difficult and they frequently remain without
mould active PAP.
Aims: Evaluation of the efficacy and safety of micafungin PAP (dose 50mg/day)
in adult patients with ALL during the induction chemotherapy.
Methods: A retrospective analysis of patients with ALL (or T-lymphoblastic lym-
phoma or Burkitt’s leukaemia/lymphoma) treated with intensive ALL (or ALL-
like) protocols in 2 tertiary care haematological centres in the Czech Republic
receiving PAP with micafungin. Patients received micafungin (50 mg/day) from
the start of induction chemotherapy till the neutrophils recovery. EORTC/MSG
2008 criteria for IFD diagnosis were used. CCTCAE v 4.0 criteria were used
for evaluation of safety of PAP.
Results: Forty- nine patients received micafungin PAP 50 mg/day during induc-
tion chemotherapy of ALL between 2012 and 2015. ALL-CELL 2012 Junior
protocol was used in 39 patients, GMALL B-ALL/NHL 2002 protocol in 3
patients and ALL-CELL 2012 elderly or EWALL Elderly protocol in 7 patients.
The mean length of micafungin prophylaxis was 22 days (2-80 days). Antifungal
prophylaxis failed in 2/49 (4.1%) patients, who developed IFD. Both patients
developed proven IFD, no episode of probable IFD occurred. Both patients
with proven IFD were successfully treated with combination of antifungal
agents. One proven IFD had a form of invasive pulmonary aspergillosis (his-
tologically proven and confirmed by PCR identification, culture negative) and
occurred only early after the initiation of PAP (day 4). Second proven IFD rep-
resented disseminated Geotrichum capitatum infection (blood culture, liver and
spleen) with MIC 32 μg/ml for echinocandins. Apart from the 2 IFD episodes,
10/49 (20.4%) patients developed pulmonary infiltrates-3/49 (6.1%) specific
for IFD based on EORTC/MSG 2008 criteria (without any microbiological cri-
teria and thus fulfilling criteria for possible IFD) and 7/49 (14.3%) non-specific
pulmonary infiltrates.
Empirical antifungal therapy was initiated in 10/49 patients (20.4%). As an
empirical therapy micafungin at dose 100mg/day was used in 8/10 patients,
voriconazole in 1/10 patients and lipid based amphotericin B in 1/10 patient.
All 49/49 (100%) patients developed liver function test (LFT) elevation at least
grade 1-2. However 63% patients had pre-existing liver test elevations. None
of these LFT elevations were concluded as probably or definitely associated
with micafungin and none required an interruption of micafungin prophylaxis.
Summary/Conclusions: Our real-life data proved efficacy of micafungin 50
mg/day as PAP in this population of patients at high risk of IFD, but also at high
risk of drug-drug interactions. Only 2 (4.1%) patients developed breakthrough
IFD, however in 1 case in a very early stage of PAP. The elevation of LFTs rep-
resented a major limitation of the prophylaxis, but was most likely associated
with a therapy of ALL and did not require an interruption of micafungin PAP.
Echinocandine-based PAP could represent a safe option for prophylaxis of this
difficult to treat population of patients with ALL.
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COMPARISON OF DE-ESCALATION AND NON-DE-ESCALATION EMPIRICAL
THERAPY FOR CONTROLLING INFECTION IN PATIENTS WITH SEVERE
APLASTIC ANEMIA TREATED WITH ANTITHYMOCYTE GLOBULIN
R Fu*, T Chen, G Wang, J Song, L Li, H Liu, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Aplastic anemia (AA) is a bone marrow failure syndrome, fea-
turing pancytopenia, characterized by the reduction in hematopoietic stem and
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progenitor cells.combined immunosuppressive therapy (IST) with antithymocyte
globulin (ATG) and cyclosporine A (CsA) is a standard first-line treatment for
SAA.However, neutropenia caused by SAA and the immunosuppressive effect
of ATG could increase the risk of infections.
Aims: To compare De-escalation and Non-de-escalation Empirical Therapy for
Controlling Infection in Patients with Severe Aplastic Anemia Treated with
Antithymocyte Globulin.
Methods: We compared the efficacy of de-escalation and non-de-escalation
empirical therapy for controlling microbiological culture-confirmed infections in
87 patients with severe aplastic anemia (SAA) treated with antithymocyte glob-
ulin (ATG) from 2006 to 2015 in our center.
Results: The response rate at 7 days and 30 days in de-escalation group was
significantly higher than that in non-de-escalation group (60.32% vs 25.00%,
p=0.003)(79.37% vs 58.33%, p=0.047). After anti-infection treatment, more
patients’ absolute neutrophil count(ANC) increased in de-escalation group than
that in non-de-escalation (76.19% vs 45.83%, p=0.007), though no significant
difference of ANC was found between two groups. Patients in de-escalation
group had better survival outcome at 90 days (p=0.003). In de-escalation group,
the response rate of patients with granulocyte transfusions at 7 days was higher
than that of patients without granulocyte transfusions (78.26% vs 50%,
p=0.027).
Summary/Conclusions: We concluded that early administration of broad-spec-
trum antibiotics pending the results of microbiological cultures combined with a
commitment to change to narrow-spectrum antibiotics should be recommended
for controlling infections in SAA patients treated with ATG and granulocyte trans-
fusions might be an adjunctive therapy to improve the response rate.
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A RETROSPECTIVE ANALYSIS ABOUT STENOTROPHOMONAS
MALTOPHILIA SEPSIS IN PATIENTS WITH HEMATOLOGICAL MALIGNAN-
CY: A SINGLE CENTER STUDY FOR 12 YEARS
M Asahi1,*, T Oyake1, N Sugawara1, Y Suzuki1, Y Okano1, Y Fujishima1,
Y Aoki1, S Kowata1, S Ito2, Y Ishida1
1Hematology and Oncology, Internal Medicine, 2Medical Oncology, Iwate Med-
ical University School of Medicine, Morioka, Japan
Background: Febrile neutropenia (FN) is often observed in hematological
malignancy. Most of FN cases are infections by various causative agents rarely
including antibiotic-resistant bacteria or low virulent bacilli. Stenotrophomonas
maltophiria (SM) is a low virulent bacillus widely existing in the environment, a
causative agent of opportunistic infection and a rare pathogenic bacteria in FN.
Recently, some cases of sepsis by SM were reported in FN with hematological
malignancy, and most of them had often very poor prognosis.
Aims: To clarify the prognosis of SM sepsis in FN patients of hematological
malignancy, we should perform the surveillance of SM infections sufficiently. 
Methods: We reviewed all blood culture data from our single institute from
2004 to 2015, and evaluated retrospectively clinical data of sepsis cases by
SM in FN of hematological malignancy.
Results: Total 3490 events of blood cultures (BC) were performed just before
the first line antibiotic agent administration was started for FN patients in the
Hematology-Oncology unit of our institute from 2004 to 2015. In the 16.4% of
these BC events, some kinds of bacteria or fungus were detected. The fre-
quency of BC positive cases for SM were rarely observed in 2.3% of all BC
events, and total 15 cases of SM sepsis were diagnosed. The primary diagnosis
of hematological disease in those SM sepsis cases were NHL(N=5), AML(N=4),
ALL(N=5) and CML(N=1), and almost all of these disease were relapse or
refractory cases with many treatments for long duration. SMs detected in 15
cases were widely resistant to many antibiotic agents. Fourteen cases died of
MOF, and 9 cases died within 7 days after the finding of BC in spite of intensive
care including administration of sensitive antibiotic therapies.
Summary/Conclusions: The prognosis of SM sepsis in patients with hemato-
logical disease was extremely poor. Surveillance for SM infection in high-risk
patients is essential, and rapid administrations of appropriate antibiotics should
be considered.
Myelodysplastic syndromes - Biology
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RIGOSERTIB (RIGO) COMBINED WITH AZACITIDINE (AZA) IN VITRO &
CLINICAL: MODULATES EPIGENETIC EVENTS AND OVERCOMES
CLINICAL RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN
MYELODYSPLASTIC SYNDROMES (MDS)
P Chaurasia, F Isoda, T Novy, J Ross, SC Navada, EP Demakos,
R Odchimar-Reissig, EP Reddy, LR Silverman*
Cahn School of Medicine, Mount Sinai, New York, United States
Background: MDS is a challenging disease to treat due to intricate complex-
ities at the genetic, molecular and epigenetic levels. Epigenetic based therapy
with the HMA, AZA is the standard of care for patients (pts) with MDS with high-
er-risk disease. Treatment alters the natural history of MDS with increased sur-
vival, reduced risk of transformation to AML and improved hematopoiesis. How-
ever, all pts ultimately fail treatment due to either primary or secondary resist-
ance. Initial results of an ongoing Phase I/II study of AZA combined with RIGO,
an allosteric “ras mimetic” that binds to the Ras Binding Domain impacting
pathways including ras, raf and PI3 Kinase, in pts with MDS demonstrated an
overall response rate of 77%; and 64% in pts following HMA failure (Navada et
al ASH 2015).
Aims: 1) To determine the in vitro effects of rigosertib alone and in combination
with azacitidine on epigenetic signaling in MDS and AML cell lines and on
patient samples treated with the combination in vivo.
Methods: We investigated the in vitro effects of RIGO alone or in combination
on two cell lines: AML (BW90), MDS (MDS-L) and patient samples on global
histone post-translational modifications (PTMs) including including methylation
(H3K4me3, H3K4me2, H3K27me3, and H3K27me2) and acetylation (H3K9ac,
& H3K18ac) levels.
Results: In vitro effects of RIGO alone or in combination on two cell lines: AML
(BW90), MDS (MDS-L) altered global histone post-translational modifications
(PTMs) including methylation (H3K4me3, H3K4me2, H3K27me3, and
H3K27me2) and acetylation (H3K9ac, & H3K18ac) levels associated with tran-
scriptional activation or repression in both cell lines, but effects were more pro-
nounced in combination with AZA. Furthermore, Q-PCR studies demonstrated
that individual treatment of BW90 and MDS-L with RIGO or sequential treatment
with AZA (AZA/RIGO or RIGO/AZA) altered the class I, IIa, IIb, and IV histone
deacetylases (HDACs), DNA methyl transferases (DNMT1, 3a and 3b) and
chromatin remodeler (KDM2a, SET1, JMJD3 and LRWD1) transcript marks in
cellular context suggesting that RIGO potentially acts as a chromatin modifying
agent (CMA), in both cell lines. Treatment with RIGO either alone or combined
with AZA differentially governed cellular proliferation, cell cycle arrest, apoptosis,
histone PTMs, altered expression of cell cycle related proteins, and inactivation
of the PI3/AKT signaling pathway in a cell specific manner. Similar effects were
seen on patient samples. We further investigated the in vivo effects of RIGO
combined with AZA on pt bone marrow samples obtained prior to and after one
cycle of RIGO and AZA. Interestingly, the histone PTMs, HDACs and chromatin
remodelers were significantly altered in the pts BM with increased apoptosis
after AZA/RIGO treatment.
Summary/Conclusions: RIGO combined with AZA can govern epigenetic
mechanisms and overcome clinical resistance to AZA in MDS pts. RIGO poten-
tially functions as a CMA, in combination with AZA and significantly modifies
global histone repression and activation marks suggesting that the combination
may overcome AZA resistance through epigenetic remodeling of chromatin
structure. Additional studies are underway.
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PREVALENCE AND DYNAMICS OF LEUKEMIA-ASSOCIATED MUTATIONS
IN ELDERLY INDIVIDUALS WITHOUT HEMATOLOGIC DISORDERS
T Ernst1,*, J Rinke1, V Müller1, A Waldau1, D Midic1, F Pester2, J Landschulze2,
L Rudolph3, A Hochhaus1
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Background: Aging of the hematopoietic system is accompanied by an
increased incidence of myeloid disorders such as myeloproliferative neoplasms
(MPN), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Recent data indicates that aberrations in the aged hematopoietic stem cell
(HSC) compartment lead to maintenance or expansion of myeloid cells, while
the number of lymphoid progenitors stagnates or declines. HSCs may be par-
ticularly predisposed to acquiring genetic aberrations since they are the only
persistent cells of the blood system. Such mutations may provide enhanced
survival, proliferation and self-renewal capabilities, and lead to the propagation
of a cell clone.
Aims: Clonal hematopoiesis is frequently observed in elderly people and may
represent a premalignant condition. Clonal HSCs acquiring additional mutations
may then transform to cancer cells and give rise to a number of myeloid disor-
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ders and leukemia. Evidence suggests that genetic alterations found in patients
with myeloid malignancies may also be causative for induction of clonal
hematopoiesis. Given these circumstances, discrimination between age-asso-
ciated and leukemia-associated mutations is of major clinical importance, with
potential applications in future prevention, therapy and prognosis.
Methods: In order to investigate the prevalence and dynamics of genetic alter-
ations among elderly individuals without hematologic/oncologic disorders, geno-
typing of the 30 most commonly mutated leukemia-associated genes was per-
formed. For this purpose peripheral blood DNA and buccal cells from a cohort
of 50 elderly people (29 women; median age 84 years; range 80-90 years) were
collected and analyzed by targeted deep next-generation sequencing (NGS).
All mutations were validated in separate runs using genomic DNA isolated from
leukocytes and buccal cells to confirm the somatic origin of mutations.
Results: A total of 16 somatic mutations in leukemia-associated genes were
identified in 13 of 50 (26%) hematologically normal elderly individuals. One
subject presented with two, another subject with three different mutations. Ten
of 16 mutations (63%) affected epigenetic modifier genes (DNMT3A, n=8;
TET2, n=1; IDH2, n=1). Four somatic mutations affected genes involved in the
RNA splicing machinery (SRSF2, n=2; SF3B1, n=1; U2AF1, n=1). Mutations
in TP53 and NRAS were identified in two individuals. All but one mutation were
missense mutations with cytosine to thymine transitions being the most com-
mon base pair change (n=7). Mutations occurred at low variant allele frequen-
cies (VAF) with a median of 11.7% (range: 1.0% to 30.7%) indicating that muta-
tions were presented in only a subset of blood cells. During a 2-year follow-up
observation two subjects with mutations in splicing factor genes died, one sub-
ject with an SF3B1 mutation developed pancreatic cancer, the other subject
harbored a U2AF1 mutation and died due to a stroke. All other individuals with
mutations are alive without any evidence for a hematologic or oncologic disor-
der. Mutation kinetics remained virtually stable over two years as measured by
targeted NGS (median VAF 13.1%, range 1.0% to 35.3%).
Summary/Conclusions: These findings indicate that the appearance of low-
level clones with mutations in epigenetic regulator genes and the RNA splicing
machinery is a common age-associated phenomenon which may represent a
premalignant condition in the development of hematologic cancers and may
also predispose to other aging associated disorders. The question why these
subclones are selected in the elderly but apparently enter a stage of clonal
size stability without further selection in healthy elderly in contrast to patients
with myeloid disorders is of particular interest and needs further investigation.
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FLOW CYTOMETRIC RESPONSE MONITORING IN MDS WITH DEL(5Q)
USING A SIMPLE 5-PARAMETER-SCORE-A TWO-CENTER-EXPERIANCE
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Dresden, Germany, 2VU University Medical Center Amsterdam, Amsterdam,
Netherlands
Background: Recently, we have established a 5-parameter flow cytometry
(FCM)-based score allowing for a precise prediction a deletion (5q) in therapy
naïve MDS patients (pts.).
Aims: The aim of this prospective study was to test, whether this FCM-based
profiling is at least equal to the cytogenetics/FISH-based del(5q) detection for
monitoring response to treatment.
Methods: Overall, 164 FCM investigations were performed in 39 pts. with MDS
and del(5q) (IPSS-R very low/low: n=17, int: n=9, high/very high n=13) including
27 pts. with isolated del(5q) or one additional cytogenetic abnormality. The
majority of analyses were performed in pts. receiving lenalidomide or azacitidine
(n=17 and n=15 pts.), or in pts. receiving chemotherapy and/or allogeneic trans-
plantation (n=3), or growth factors (n=4). The del(5q)-FCM-score includes the
following 5 parameters: myeloid progenitors (myPC >2%)=3 points, CD45 MFI
ratio (lymphocytes: myPC ≤7.0)=10, SSC ratio (granulocytes: lympho-
cytes<6.0)=2, CD71 (≤20%) on granulocytes=1.5, and female gender=1.5; a
score ≥15.0 indicates the presence of del(5q). A standardized FCM (lyse-stain-
wash) and cytogenetics/FISH were performed according to ELN guidelines at
the TU of Dresden and VUMC of Amsterdam.
Results: Before therapy, in 56 cytogenetic/FISH analyses in 39 MDS pts. a
del(5q) was detectable. In 48/56 (86%) FCM measurements, performed in par-
allel, a del(5q) could be predicted using the del(5q)-FCM-score. A complete
cytogenetic response (CCR) was detectable in 17 pts. (41 different evaluations).
Remarkably, all determined del(5q)-FCM-scores matched the above mentioned
CCR (sensitivity=100%). Otherwise, in 32 pts. (69 different evaluations) del(5q)
was still detectable by cytogenetics/FISH, which was accompanied by a match-
ing del(5q)-FCM-score in 58 measurements (specificity=84%). Next, we focused
on those pts. who presented with a typical del(5q)-FCM-score before therapy
(32 pts.; 49 measurements; median score=16.5). Again, all 31 cytogenetic eval-
uations, resulting in a CCR, showed a matching del(5q)-FCM-score (sensitivi-
ty=100%; median score=13.0). On the other side, 52 of the 54 analyses (96%)
without CCR showed a properly high del(5q)-FCM-score (median score=16.5).
Furthermore, we compared cytogenetics/FISH and del(5q)-FCM-score with
additional methods for response monitoring as cytomorphology, two well estab-
lished diagnostic FCM scores: FCSS (flow cytometry scoring system; Wells et
al. Blood 2003) and the diagnostic score (Ogata et al. Haematologica 2012), as
well as the assessment of hematological improvement (HI). Thus, cytomorphol-
ogy and FCSS, analyzing dyspoiesis of multiple cell lineages, showed a CR or
disappearance of a MDS typical FCSS in only around half of all investigations
being in cytogenetic CR (sensitivity: 48% and 58%), but those two methods
revealed a high specificity (100% and 96%). On the other side, the analysis of
HI was highly sensitive (90%) but not specific (56%). Finally, the use of the 4-
parameter Ogata score ended up with a nearly as high sensitivity (90%) and
specificity (87%) as cytogenetics/FISH and the del(5q)-FCM-score.
Summary/Conclusions: Flow cytometry-based detection of a del(5q)-specific
immunophenotype is feasible and can serve as a rapid tool for response mon-
itoring during treatment with disease-modifying drugs. At the moment, we val-
idate the FCM-scores in a larger multicentric study within the iMDS-Flow work-
ing group of the ELNet evaluating if response prediction by FCM might result
in a better separation of the patients’ survival.
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ABT-199 EFFECTIVELY INDUCES APOPTOSIS IN HIGH-RISK MDS
PROGENITOR CELLS IRRESPECTIVE OF PROGNOSTICALLY ADVERSE
MUTATIONS OF TP53, EZH2, RUNX1, AND ASXL1
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Background: Myelodysplastic Syndromes (MDS) is a group of heterogeneous
diseases with a broad spectrum of clinical outcomes. As we could recently
show, the BCL-2 selective inhibitor ABT-199 effectively induces apoptosis in
leukemic progenitors, as well as in blast cells of patients with high-risk MDS
and secondary acute myeloid leukemia (sAML), while the healthy progenitor
cell population was only marginally affected. As current therapeutic strategies
such as Azacytidine have only a short response duration alternative regimes
are urgently needed. Classification systems such as the International Prog-
nostic Scoring System (IPSS) help to estimate the overall survival and the risk
of developing a sAML. Disease-related molecular abnormalities are not incor-
porated in these scoring systems at the moment. However mutations of TP53,
EZH2, RUNX1, and ASXL1 have been shown to identify patients with a shorter
survival than predicted by the IPSS.
Aims: We were interested in analyzing whether ABT-199 could overcome
resistance to apoptosis in high-risk MDS/sAML despite prognostically adverse
mutations in TP53, EZH2, RUNX1, and ASXL1. 
Methods: Purified bone marrow mononuclear cells (BMMNC) were treated
with 1µM ABT-199 or a soluble control (DMSO) for 72h in vitro. Apoptosis was
analyzed by flow cytometry after staining for 7-AAD, Annexin V, and CD34 as
a progenitor marker. The long-term effect was investigated by colony formation
assay. Mutational analysis was performed by Sanger sequencing at a certified
laboratory (Munich Leukemia Laboratory). In total, seven healthy bone marrow
samples and 38 MDS/sAML bone marrow samples (20 patients with proven
wildtype alleles for TP53, EZH2, RUNX1, and ASXL1 as well as 18 patients
with mutations in at least one of the indicated genes) were investigated.
Figure 1. FICOLL-purified CD34+ BMMNC were treated for 72h with 1µM
ABT-199 or a vehicle control (DMSO). Apoptosis was measured by flow
cytometry. Each circle represents the ratio of viable cells after ABT-199
treatment to viable cells after sole vehicle treatment. Student’s t-test
showed no significant difference between mutated and not mutated sam-
ples within one risk group. When compared with healthy controls, we
found that induction of apoptosis was significantly increased in the
stem/progenitor population from IPSS-classified patients with interme-
diate-risk 1 and 2 MDS, high-risk MDS, and sAML.
Results: Prognostically bad molecular genetics including mutations of TP53,
EZH2, RUNX1, and ASXL1 did not affect the response to ABT-199 treatment
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in MDS progenitor cells. No difference in the induction of apoptosis was seen
between mutated and not mutated samples. As expected, the effect of ABT-
199 correlated with MDS disease progression to elevated clinical risk groups.
In addition, the long-term effect of BCL-2 inhibition could be analyzed in three
patients of the high-risk MDS/sAML group with proven mutations by colony for-
mation assays. Here we show that ABT-199 effectively killed colony-forming
stem/progenitor cells from patient samples of the high-risk MDS/sAML sub-
group.
Summary/Conclusions: We conclude that ABT-199 is a promising drug for
patients with high-risk MDS/sAML irrespective of prognostically adverse muta-
tions of TP53, EZH2, RUNX1, and ASXL1.
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Background: Myelodysplastic syndromes (MDS) are a group of hematopoietic
stem cell disorders at high risk of developing acute myeloid leukemia (AML).
Both disorders are characterized by the accumulation of a wide variety of genetic
and epigenetic aberrations in hematopoietic progenitor cells, resulting in altered
cell growth and differentiation. However, the molecular mechanisms underlying
the evolution of MDS to more aggressive stages remain to be discerned.
Aims: To analyze common deregulated genes and gene pathways, which may
potentially be associated with the progression of the disease.
Methods: A multi-platform genome-wide expression profiling was carried out
in a series of 73 patients with normal cytogenetics and 17 controls with non-
malignant disorders. Two platforms for gene expression analysis were used:
the Human Exon 1.0 ST (test group) and the Human Genome U133 Plus 2.0
(validation group) (Affymetrix). The study was based on the analysis of gene
expression changes occurring from non-malignant bone marrow conditions
through different stages of MDS and towards AML. Two-steps analysis was
carried out: (1) Identifying genes which expression levels evolved following an
increasing/decreasing trend during the progression of the disease (Normal,
Low-Risk MDS, High-Risk MDS and AML); (2) Identifying common expression
patterns among the groups of genes with increasing/decreasing trends. At the
end, only the genes that appeared deregulated in common with the two plat-
forms were considered.
Results: This methodological approach allowed us to identify common genes
and gene pathways that were progressively up-/down-regulated in the transition
from non-malignant bone marrow conditions to early MDS stages (Low-Risk
MDS), which also remained progressively deregulated during the progression
towards advanced MDS (High-Risk MDS) and AML. These genes were classi-
fied in 4 major patterns: Pattern 1, MDS/AML-up, included a set of 83 genes
that began to be up-regulated in Low-Risk MDS and remained progressively
altered during the progression towards High-Risk MDS, with the maximum in
AML (NPM1, MYST1, RPL22, RPS6); Pattern 3, AML-up, consisted of 26 pro-
gressively up-regulated genes showing the biggest change in their expression
level in the transition from High-Risk MDS to AML (HOXA9, MEIS1, FLT3). By
contrast, patterns 2 (70 genes) and 4 (32 genes), MDS/AML-down and AML-
down, respectively, included those genes that were progressively down-regu-
lated during the evolution of the disease, showing the minimum levels in AML
(CEACAM3, CRISP3, CAMP, MMP9). These common and dynamically dereg-
ulated genes implicated in the progression of the disease were related to key
cellular functions of known relevance in MDS. Thus, apoptosis, DNA damage
response, ribosome and translation pathways, and chromatin assembly were
progressively up-regulated as the disease progressed, since early MDS stages,
while the immune response showed an increasing down-regulation. In addition,
the transition from advanced MDS to AML would be characterized by a marked
up-regulation of cell proliferation and a differentiation arrest.
Summary/Conclusions: The present study demonstrated the presence of a
progressive deregulation of several cellular functions, with common deregulated
genes, in the transition from non-malignant bone marrow conditions through
early and advanced MDS to AML. This evolution seems to occur in an orches-
trated way, involving common deregulated functional pathways.
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BONE HOMEOSTASIS IS SIGNIFICANTLY ALTERED IN A MYELODYSPLASTIC
SYNDROME MOUSE MODEL
H Weidner1,*, M Rauner2, E Bulycheva1, C Khandanpour3, M Bornhäuser1, LC
Hofbauer2,4, U Platzbecker1,4
1Department of Medicine I, Technical University Dresden, 2Division of
Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Tech-
nical University Dresden, Dresden, 3Department of Hematology, West German
Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen,
4German Cancer Consortium (DKTK), partner site Dresden and German Can-
cer Research Center (DKFZ), Heidelberg, Germany
Background: Myelodysplastic syndromes (MDS) are diseases of the elderly
characterized by an ineffective hematopoiesis leading to cytopenias. Increasing
evidence suggests a role of the bone microenvironment in influencing the devel-
opment and progression of MDS. However, the underlying mechanisms are
not fully understood. NUP98-HOXD13 (NHD13) mice develop MDS-like symp-
toms at an age of 6 months, including anemia and an increased number of
blasts in the bone marrow. Thus, it is a suitable model to study bone home-
ostasis in the setting of MDS.
Aims: Here, we assessed bone homeostasis in NHD13 mice before (2 months
of age) and after (6 months of age) the onset of MDS.
Methods: Micro-computed tomography was performed using the femurs of 2-
and 6-month-old male NHD13 and wild-type mice. Bone samples were then
histologically stained for the osteoclast marker tartrate-resistant acid phos-
phatase (TRAP). The bone formation rate was assessed using dual calcein
labeling. In addition, serum was analyzed by ELISAs to assess the bone
turnover markers C-terminal telopeptide of type I collagen (CTX-I) and procol-
lagen type I propeptide (P1NP).
Results: At 2 months of age NHD13 mice had not yet developed any cytopenia.
Nevertheless, there was already an apparent alteration of bone homeostasis.
The trabecular bone volume (BV/TV) [-26%; P<.05] and trabecular number
(Tb.N) [-20%; P<.01] were reduced in the femurs of NHD13 compared to wild-
type mice. Serum markers indicated an increased bone turnover in NHD13
mice [P1NP 4-fold, P<.01; +17% CTX). At the age of 6 months the NHD13
mice had developed anemia indicated by a reduced hematocrit, -17%, P<.001.
BV/TV in these mice was unchanged when compared with those of wild-type
mice. Of interest, the number of trabeculae was reduced in the 6-month-old
NHD13 mice [-15%; P<.001] whereas their thickness was increased [+18%;
P<.01], suggesting increased osteoblast activity. In fact, histology indicated an
increase in the osteoblast surface in the femurs from NHD13 by 10% [P<.01]
and also the bone formation marker P1NP was elevated in the serum by 54%
[P<.05] compared to wild-type mice. Although NHD13 mice had a lower osteo-
clast-covered surface on the bone [-78%; P<.01], the bone resorption marker
CTX-I was increased by 32% [P<.05].
Summary/Conclusions: NHD13 mice show an altered bone homeostasis,
which is characterized by a high bone turnover. This is in line with an abnormal
interaction of dysplastic hematopoietic cells with the bone compartment.
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Background: Chronic myelomonocytic leukemia (CMML) is a subset of
myelodysplastic/myeloproliferative neoplasms (MDS/MPN), which are morpho-
logically distinct from myelodysplastic syndromes (MDS). Nevertheless, CMML
and MDS share several genetic defects and dysplastic features. Moreover,
CMML can evolve from MDS, designated as secondary CMML (sCMML). The
molecular characteristics of sCMML, which are distinct from those of primary
CMML, remain to be elucidated.
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Aims: By comparing the genetic/cytogenetic abnormalities between sCMML and
other myeloid malignancies, we clarify the molecular pathogenesis of sCMML.
Methods: A total of 601 cases with different myeloid neoplasms, including de
novo CMML (n=89), sCMML (n=26), MDS (n=348), and secondary AML (sAML)
(n=138) were subjected to the analysis, combining the genotyping data from our
cohort and publicly available datasets. Serial samples were available for 7 cases.
Results: In the de novo CMML cohort, the most frequently mutated genes
included TET2 (40%), SRSF2 (30%), ASXL1 (24%), RUNX1 (16%), CBL (11%),
EZH2 (11%), ZRSR2 (11%), and KRAS (10%), which, combined, accounted
for 74% of the CMML cases. In the sCMML cohort, by contrast, RUNX1 (32%),
TET2 (32%), ASXL1 (24%), SF3B1 (24%), and SETBP1 (20%) represented
common genetic alterations, together with -7/del(7q) (43%), complex karyotype
(38%), and del(5q) (24%). In multivariate analysis comparing the spectrum of
mutations between sCMML and de novo CMML, SF3B1, and RUNX1 mutations
were enriched in sCMML patients. In patients with sCMML, SF3B1 mutations
supposed to be acquired prior to RUNX1 mutations based on the comparison
of their variant allele frequencies. Most likely, SF3B1 mutations were acquired
as founder events in the MDS phase and RUNX1 mutations occurred during
sCMML evolution. However, RUNX1 mutations were not always identified in
patients with sCMML, suggesting that other causes are also related to sCMML
evolution. To further identify genetic lesions specifically associated with CMML
evolution, we compared the spectrum of mutations between sCMML and MDS.
Multivariate analysis revealed that mutations in SETBP1, RUNX1, TET2, and
NRAS, del(5q), and -7/del(7q) were significantly and independently associated
with sCMML. Then we divided de novo CMML cases into 2 categories; Type-
1 with ≥2 of these lesions (n=13) and Type-2 with<2 (n=54). Patients with Type-
1 CMML had a significantly shorter overall survival compared to Type-2 disease
(HR=3.73, 95%CI 1.78-7.79, P<0.001). Serial sample analysis revealed that
mutations in SETBP1, RUNX1, and NRAS, and del(7q) tended to be newly
acquired during evolution to sCMML. However, the lesions extracted in the
comparison between sCMML and MDS were also detected in our cohort of
sAML; -7/del(7q) (23%), del(5q) (20%), mutations in SETBP1 (4%), RUNX1
(19%), TET2 (22%), and NRAS (7%). To investigate what lesions are really
characteristic to sCMML evolution from MDS, we compared the frequencies of
genetic lesions between sCMML and sAML. We found SF3B1, SETBP1,
NRAS, and RUNX1 mutations, as well as complex karyotype, and -7/del(7q)
were significantly enriched in sCMML, which largely overlapped with the lesions
associated with evolution from MDS to sCMML.
Figure 1.
Summary/Conclusions: In this study, a novel set of lesions associated with
sCMML evolution (SETBP1, RUNX1, TET2, and NRAS mutations, del(5q), and
-7/del(7q)) was identified and shown to be able to stratify de novo CMML into
clinically distinct subgroups. By genotyping serial samples and comparing
genetic lesions between sCMML and sAML, this set of lesions was thought to
be characteristic to sCMML evolution. Our study demonstrated that specific
genetic events might play an important role in sCMML evolution from MDS.
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MYELOID MALIGNANCIES (FPD/AML)
F Majidi1,*, N Rahner2, S Braunstein3, S Martino1, J Kaivers1, M Wulfert1,
U Germing1, R Haas1, N Gattermann1
1Hematology/Oncology, 2Human Genetics, 3Pathology, Heinrich-Heine-Uni-
versity, Düsseldorf, Germany
Background: A patient with acute myeloid leukemia (AML) secondary to MDS
and a strong family history of thrombocytopenia and myelodysplastic syn-
dromes was referred to our clinic for evaluation of the possible hereditary nature
of myeloid malignancies in the family.
Aims: To identify novel myeloid malignancy-predisposing mutations and con-
tribute to a better understanding of biological processes involved in the devel-
opment of myelodysplasia, also in cases of sporadic MDS.
Methods: Whole exome sequencing was performed on DNA from peripheral
blood of 3 family members with myelodysplasia, one of whom developed AML.
Sanger sequencing was used to determine the frequency of the identified muta-
tions in 13 family members as well as 36 sporadic cases of MDS. Correspon-
ding protein expression was evaluated by immunohistochemistry. Structural
modelling using Pymol software was performed to estimate the probable impact
of mutations on the three-dimensional structure of the corresponding proteins.
Using site-directed mutagenesis we have recently created plasmids carrying
the identified mutations, which will allow us to further evaluate their functional
consequences.
Results: Two confirmed missense mutations were identified by whole exome
sequencing. They affect SCAPER (S-phase cyclin A-associated protein in the
endoplasmic reticulum) and RPRD1A (regulator of nuclear pre-mRNA domain-
containing protein 1A). The SCAPER E342K and RPRD1A I143T mutations
were detected by Sanger sequencing in 9 and 10 out of 13 family members,
respectively. Molecular modelling showed that both mutations can significantly
change the three-dimensional structures of the corresponding proteins. In one
of the mutated cases where bone marrow biopsy material was available, both
SCAPER and RPRD1A showed high protein expression in the cytoplasm and
nucleus. We sequenced the SCAPER and RPRD1A mutation site in 36 patients
with sporadic MDS, all of whom showed the wild type sequence. However,
when protein expression of SCAPER and RPRD1A was evaluated immune -
histochemically on a tissue microarray including core biopsies from 45 patients
with MDS, both proteins showed marked heterogeneity of expression level
among patients. Lack of RPRD1A expression was associated with significantly
shorter overall survival (24 vs 50 months, p<0.03, HR=2.2), independent of
the revised international prognostic scoring system (IPSS). Patients with high
expression of SCAPER showed longer median survival than patients with low
expression (50 vs 28 months) but the difference did not reach statistical signif-
icance. Interestingly, despite strong interindividual heterogeneity, there was
strong intraindividual correlation of protein expression between SCAPER and
RPRD1A (r=0.818, p<0.0001).
Summary/Conclusions: Molecular modelling convinced us that these two
non-conservative mutations cause significant changes in three-dimensional
structure of both SCAPER and RPRD1A proteins, which may lead to altered
affinity to their main binding partners, i.e. Cyclin A and RNA polymerase 2,
respectively. Our findings suggest that SCAPER and RPRD1A should be includ-
ed among the genes to be analysed in cases of familial thrombocytopenia with
propensity for myeloid malignancies. Furthermore, strong heterogeneity of
SCAPER and RPRD1A protein expression among patients with sporadic MDS,
together with the prognostic impact of protein expression, suggests that both
genes may play a role in MDS pathogenesis. Mutation analysis covering the
full length of SCAPER and RPRD1A genes, as well as analysis of the epigenetic
status of both genes may reveal further insight.
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REAL-TIME DEFORMABILITY CYTOMETRY (RT-DC) AS NOVEL DIAGNOSTIC
TOOL IN MYELODYSPLASTIC SYNDROMES
E Bulycheva1,*, O Otto2, M Herbig2, H Weidner1, U Baschant3, S Herold1,
A Jacobi2, M Kramer1, M Stiehler4, M Bornhäuser1, C Thiede1, L Hofbauer3,5,
J Guck 2, U Platzbecker 1 5
1Medical Department I, University Hospital Carl Gustav Carus Dresden,
2Biotechnology Center, Technical University Dresden, 3Medical Department
III, 4University Center for Orthopaedics and Trauma Surgery, University Hospital
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berg, Germany
Background: Myelodysplastic syndromes (MDS) are a group of disorders,
which are often difficult to differentiate from reactive and toxic conditions caus-
ing cytopenia. Contractility and cytoskeletal structure of hematopoietic stem
cells in MDS are known to differ from the healthy counterparts. Thus, detection
of the cells with abnormal mechanical properties could be a promising diag-
nostic procedure for patients with potential MDS.
Aims: Therefore we aimed to evaluate if real-time deformability cytometry (RT-
DC) can be a reliable diagnostic and prognostic tool for MDS patients, as well
as to clarify molecular factors, which are associated with differential cell
deformability.
Methods: We analyzed MACS-separated CD34+ cells from 19 patients with
MDS (median age at BM sampling 65 years [range, 44-87]; m/f=13/6) and 8
age-matched healthy donors (62 years [range, 43-83]; m/f=3/5). Mechanical
characterization was carried out using RT-DC at three flow rates according to
previously described protocol (Otto O. et al., Nat Methods, 2015). With this
technology, single cells are flowed through a microfluidic channel constriction
and deformed without contact by shear stress. Statistical significance was
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assessed by 2-sided Kolmogorov-Smirnov test. Changes in cell cycle were
evaluated by flow cytometry using propidium iodide staining. Molecular alter-
ations were evaluated by targeted resequencing on a MiSEQ instrument using
an amplicon assay (True Sight Myeloid Panel, Illumina) which covers 54 genes
or gene hotspots related to myeloid neoplasms. Cytogenetic analysis was per-
formed in all MDS patients. Overall survival (OS) was estimated using Cox pro-
portionate regression models.
Results: Mean deformability for CD34+ cells of MDS patients was significantly
lower than in control cells (0.0241 vs 0.0272, accordingly, p=0.018). MDS
CD34+ cells underwent significantly less mitosis (2.4% vs 17.4%, p=0.002),
arresting mostly in G1 phase (91.5% vs 66.7%, p<0.001). CD34+ сells from
patients with mutations in RAS-pathway tended to be more deformable, where-
as RUNX1-mutated cells appeared stiffer. Cytogenetics had no influence on
mechanical properties. The deformability appears to be predictive for the OS
starting from time of BM sampling, as 1-year OS in patients with more
deformable cells (>median) was 72.9% vs 37.0% in patients with less
deformable cells.
Summary/Conclusions: RT-DC provides a novel tool to reveal substantial dif-
ferences in mechanical properties of CD34+ cells of MDS patients compared
to healthy donors. This might allow incorporating this technique into diagnostic
approaches of MDS patients.
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SPATIAL INTERACTION OF CYTOGENETIC AND MOLECULAR MUTATIONS
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Background: In myelodysplastic syndromes (MDS), several frequent molecular
mutations affect the same chromosomal regions as common cytogenetic muta-
tions. These regions are potential targets of total loss of function of cancer-pro-
tective genes or could be involved in gain of function of oncogenes. Both alleles
could be simultaneously affected by two different mutation types, one allele by
a molecular mutation and the second allele by a cytogenetic mutation (deletion,
copy number neutral loss of heterozygosity (CN-LOH) and others). Up to now
the impact of biallelic mutations composed by a molecular and a cytogenetic
mutation on leukemogenesis is unknown in MDS.
Aims: The aim of our study was to identify and to characterize such biallelic
mutations (composed by a molecular and a cytogenetic mutation) to delineate
the frequency and the potential clinical significance in MDS.
Methods: We included 209 patients in our analysis: 144 proven MDS, 27 sus-
pected MDS with typical genetic aberrations, 9 myelodysplastic/myeloprolifer-
ative neoplasms (MSD/MPN), and 29 secondary acute myeloid leukemias
(sAML) after MDS. Molecular analysis was done by Sanger sequencing includ-
ing up to 17 of the most frequently mutated genes in MDS. The basis of cyto-
genetic analysis was conventional chromosome banding that was complement-
ed by interphase fluorescence in situ hybridization (FISH), multicolor FISH
and/or molecular karyotyping (SNP array analysis).
Results: Overall, genetic mutations were detected in 84.7% of patients. Cyto-
genetics identified mutations in 46.9% and sequencing revealed mutations in
70.8% of patients. In 20 patients (9.6%) a molecular mutation was located in a
chromosomal region that was in addition affected by a cytogenetic aberration
(assumed to affect the second allele). Such biallelic mutations were more fre-
quent in MDS-RAEB (9/51, 18%), MDS/MPN (2/9, 22%), and sAML (5/29,
17%), but rarer in low-risk MDS (4/93, 4%). The highest frequency of such bial-
lelic mutations was detected in patients with CBL mutations: 2/3 CBL mutations
were located within a CN-LOH of 11q. Furthermore, 4/11 patients with EZH2
mutations had a cytogenetic 7q aberration (2x deletion, 2x CN-LOH), 4/13
patients with TP53 mutations additionally showed cytogenetic loss of 17p. We
detected two patients with a SRSF2 mutation and a simultaneous isochromo-
some iso(17q) that results in gain of 17q. Other molecular mutations involved
in such biallelic mutations were: SRSF2 (1x CN-LOH), TET2 (2x loss, 1x CN-
LOH), DNMT3A (2x CN-LOH), and RUNX1 (2x CN-LOH).
Summary/Conclusions: Biallelic mutations composed by a molecular and a
cytogenetic mutation affecting the same chromosomal region were recurrently
identified in sAML and MDS/MPN in our study but were detected also in low-
risk MDS albeit at lower frequency. Co-occurrence of molecular and cytogenetic
lesions affecting e.g. TP53/7q, EZH2/7q or CBL/11q suggests individual path-
omechanisms resulting in homozygous loss of function of potential tumor sup-
pressor genes. The co-occurrence of activating SRSF2 mutations and iso(17q)
or CN-LOH of 17q might have an oncogenic effect. Biallelic mutations could be
indicative for a regional genetic instability promoting disease progression.
According to the two-hit hypothesis such “composed” biallelic mutations might
arise stepwise. Therefore, they could refer to previous genetic evolution and
consequently to advanced stages of the disease. Sixteen of the 20 biallelic
mutations identified in our study affected patients with high-risk MDS or sAML.
Thus, patients with biallelic mutations due to a molecular and a cytogenetic
mutation in parallel could be at high risk for further progression of the disease.
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MONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS (MO-MDSC)
EXPANSION AND PROGRESSION IN MYELODYSPLASTIC SYNDROMES
F Hernández Mohedo*, P Montes Ramos, S Maroto Gallego, A Cruz Díaz,
E Espinosa de los Monteros, M Jurado Chacón, F Ruiz Cabello, P Jiménez Gámiz
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Background: Myeloid Derived Suppressor Cells” (MDSC) are a heterogeneous
population of inmature myeloid cells constituent of bone marrow microenviron-
ment, whose expansion hampers the host anti-tumor immune response. They
can play a pathogenetic role in the development of ineffective hematopoiesis
in myelodysplastic síndromes (MDS), and contribute to progression to acute
myeloid leukemia (AML), through inmunotolerance and as a cellular effectors
that suppress hematopoiesis. The mechanisms that determine the evolution to
AML are not entirely clarified although, a role of the immune response has been
suggested. In this sense, the bone marrow microenvironment expansion of
suppressor cells of monocytic origin (Mo-MDSC) and T cell inmunosupressive
efector (Tregs) can contribute to tumor progression.
Aims: Our aim has been to investigate a possible role of the myeloid supressor
cells of monocytic origin (CD14+HLA-DRlow/-) and Tregs in the development of
ineffective hematopoiesis in myelodysplastic síndromes (MDS), that may con-
tribute to the development and progression to acute myeloid leukemia (AML)
of MDS. 
Methods: We performed a prospective analysis of a group of 31 patients with
MDS and AML evolved from MDS and a control group of 40 healthy subjects.
It was analyzed by multiparametric flow cytometry techniques to study the pres-
ence of MDSC-Mo (CD14+HLA-DRlow/-) cells and CD34+blasts, in peripheral
blood and bone marrow in both MDS patients and control cases. The mono-
clonal antibodies marked with their respective fluorochromes were: CD45-V500,
CD3-V450,. CD4-PER, CD8-APH- 7, CD19-PE-CY7, CD56-PE-CY7, CD127-
APC, CD34-APC, CD64-FICT, DR- V450, CD25-PE-CY7, CD14-PE and CD64-
FICT and anti DR-V450.The clinical and biological profile of MDS and control
group has analyzed with statistical software IBM SPSS.19.
Results: In the 31 peripheral blood samples of patients with MDS and AML
evolved from MDS, the WHO-2008 diagnostic classification was: RCUD(4),
RCMD(8), RARS and RCMD-RS(2), RAEB-1(3), RAEB-2(6), MMCL-1(5) and
AML evolved from MDS (3). We observed a positive correlation between MDSC
cells with phenotype CD14+ HLA-DRlow/- and CD34+blasts in peripheral blood
(p=0,001). In addition, the frequency of expression of CD14+ HLA-DRlow/- cells,
was significantly elevated in MDS patients as compared to the control cases
(26,52+/-5,47 vs 6,66+/-1,06; p=0,014). No significant results were obtained in
bone marrow for the studied subpopulations. With regard to WHO classification,
we observed a higher value of MDSC in RAEB-2 and AML vs other MDS, almost
statisticaly significant (45,40+/-12,70 vs 18,80+/-5,04; p=0.055). The analysis
of prognostic scoring system IPSS y IPSS-R shows higher incidence of Mo-
MDSC in High risk IPSS (High+Int-2 vs Int-1 and Low risk) (59,55+/-14,14 vs
15,12+/-3,61; p=0.004) and High risk IPSS-R (Very High, High and Int vs Low
and very low risk)(37,06+/-7,99 vs 9,49+/-4,05; p=0.006). Increase frequency of
Mo- MDSCs was also linked to poor and intermediate cytogenetic risks (59,55+/-
14,14 vs 15,10+/-3,94; Poor and Int vs Good and Very good; p=0.006).
Summary/Conclusions: The expansion of cells with MDSCs phenotype of
monocytic origin can suppose a higher risk in myelodysplastic syndromes trans-
formation, favouring the immune escape, which may be important for under-
stand the pathogenesis of high-risk MDS and with poor cytogenetic risks. The
good correlation between myeloid supressor cells of monocytic origin
(CD14+HLA-DRlow/-) and CD34+blasts in peripheral blood, allows monitoring
of patients with MDS.
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ABERRANT METHYLATION OF PROMOTER REGIONS OF SOX7,
P15INK4B AND WNT PATHWAY ANTAGONIST GENES IN PATIENTS WITH
MYELODYSPLASTIC SYNDROMES
I Kostroma1,*, S Gritsaev1, Z Sidorova2, S Kapustin2, A Chechetkin1
1hematological clinic, 2biochemical laboratory, Russian Institute of Hematology
and Blood Transfusion, St.Petersburg, Russian Federation
Background: Epigenetic aberrations, including hypermethylation of CpG
islands in tumor-suppressor genes, are supposed to be a key mechanism of
myelodysplastic syndrome (MDS) development.
Aims: To find out the association between methylation status of SOX7,
p15INK4b, SFRP1, SFRP4 and SFRP5 genes and some hematological features
and overall survival (OS).
Methods: The data of 46 MDS patients with median age of 67.5 years were
analyzed. MDS was diagnosed according to WHO classification. Methylation-
specific PCR was used to study the methylation status.
Results: Aberrant methylation of ≥1 genes was found in 43 patients (93.5%).
The most frequently findings were SOX7 (84.8%), SFRP1 (71.7%) and p15INK4b
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(54.3%) genes methylation. Methylation of 1, 2, 3, 4 and 5 genes simultane-
ously was detected in 10.9%, 28.3%, 26.1%, 19.6% and 8.7% of patients,
respectively. There was no any difference in the number of patients with SFRP1,
SFRP4, SOX7 and p15INK4b methylation in the groups with different bone mar-
row blasts counts. Methylation of SFRP5 gene was more frequently seen in
patients with refractory anemia with excess of blasts (RAEB): 43.5% vs 13.0%
in patients without excess of blasts; OR=5.1, 95%CI: 1.2-22.3, p=0.047. The
patients without excess of blasts were characterized by methylation of 0-1
genes: 26.1% vs 8.7% of RAEB patients, although the difference was not sig-
nificant. At the same time, there was the tendency to increase of the number
of cases with 3-5 methylated genes in patients with 10-19% blasts compared
to patients with 5-9% blasts. In the whole MDS group, there was no any cor-
relation between the number of methylated genes and patient’s age, number
of bone marrow blasts or karyotype. Increased number of methylated genes
did not influence on the OS.
Summary/Conclusions: MDS progression is associated with enhancement
of epigenetic disturbances leading to increase of the number of methylated
genes, in particular, SFRP5
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Background: Not only clinical experience, but also numerous experimental
and animal-modell studies demonstrated that iron overload (IO) negatively
impacts on survival outcomes in patients suffering from myelodysplastic syn-
dromes (MDS). However, the molecular mechanisms of IO induced genetic
damage have neither been sufficiently demonstrated nor been fully understood.
Aims: We aimed to investigate the association between IO, measured as
serum ferritin (SF) as suitable surrogate marker, and genetic instability, con-
sidered to be a main factor responsible for MDS progression to secondary
acute myeloid leukemia (sAML).
Methods: We included 55 patients (median age 74 years, 62% males). The
majority (n=50) had different MDS subtypes, 5 patients had myelodysplastic/
myeloproliferative neoplasms (MSD/MPN). The patients were divided into two
subgroups with normal and elevated SF levels, using 275 µg/l as cut-off for
elevated SF. 26 patients showed normal SF levels (median: 65 µg/l, range: 8-
256 µg/l), while 29 patients showed elevated SF levels (median: 1150 µg/l,
range: 283-3872 µg/l). Various parameters for genetic instability were analyzed
and statistically compared between the two subgroups with normal and ele-
vated SF: a) molecular karyotyping (SNP array analysis) to determine the total
genomic alterations (TGA) size, b) immunofluorescent determination of γH2AX-
foci for quantifying DNA double-strand breaks (DSB) in CD34+ peripheral blood
(PB) cells, c) telomere length (TL) of PB granulocytes and lymphocytes, and
d) plasma nitric oxide metabolites as markers for oxidative stress.
Results: Subsequent analyses revealed a positive correlation of SF levels and
bone marrow blast counts. Thus, all further analyses were adjusted by a logistic
regression model for unevenly distributed blast counts. PB nitric oxide metabo-
lites did not correlate with SF level (N=33 patients with available data). Iron
overload measured by SF showed a significant correlation with the number of
γH2AX-foci per CD34+ PB cell (r=0.481, p=0.039). The median number of
γH2AX-foci per CD34+ PB cells was significantly highlower in 8 patients with
normal SF as compared to 10 patients with elevated SF level (1.9 vs 5.7
γH2AX-foci/CD34+ cell (adjusted p=0.050). TGA size was positively correlating
with SF levels (r=0.397, p=0.026) and with marrow blast counts (r=0.381,
p=0.077). TGA size was higher in 28 patients with elevated SF (median: 34
Mbp, range: 0-248 Mbp) as compared to 23 patients with normal SF (median:
0 Mbp, range: 0-155 Mbp, adjusted p>0.5). Telomere length and IO showed a
significant negative correlation (r=-0.497, p=0.002). TL in granulocytes was
significantly reduced in 13 patients with elevated SF (median: -1.61 kb, range:
-4.06-1.31) as compared to 13 patients with normal SF levels (median: 0.48
kb, range: -3.13-5.32 kb, adjusted p=0.024). In contrast, lymphocyte TL was
not influenced by the SF level.
Summary/Conclusions: In this study, IO was significantly associated with
numerous markers of genetic instability. Elevated SF levels were promoting
the TGA size, spontaneous nuclear damage assessed by γH2AX-foci and
replicative stress (TL) in granulocytes representing the myeloid compartment,
whereas the lymphocyte compartment remained uninfluenced by IO. These
findings further support the assumption of IO being closely related to leukemic
transformation in MDS. Our results contribute to explain the association of IO
and disease progression found in several studies. Whether these results may
have consequences for diagnostics and therapeutic decision-making in patients
with MDS remains to be further investigated.
E1203
CONVENTIONAL CYTOGENETICS, ACGH, AND PCR AS INTEGRATED
WORKUP FOR A CORRECT DIAGNOSIS OF MDS
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Background: Conventional cytogenetics continues to have a fundamental role
in the classification and risk scoring of myelodysplastic syndromes (MDS).
Nevertheless, non-informative karyotypes represent up to 20% of cases. Some
different molecular methods, such as FISH, aCGH or mutational analysis, could
detect new abnormalities and improve the correct subtyping of MDS patients. 
Aims: The aim of the study was to adopt an integrated diagnostic work-up for
better characterizing MDS patients.
Methods: We analyzed 61 patients (71% male, with a median age of 74 years).
According to the WHO classification, 33% were affected by multilineage refrac-
tory cytopenias, 12% by refractory anemia, 15% by refractory anemia with ring
sideroblasts, 21% by refractory anemia with excess of blasts, 3% by 5q- syn-
drome, and 12% by chronic myelo-monocytic leukemia; 67% of patients were
at low/intermediate-1 IPSS risk. All patients were assessed by conventional
cytogenetics, FISH for chromosomes 5, 7, 8, PDGFRalpha and beta rearrange-
ments, aCGH, and PCR for ASXL1, EZH2, TP53, and TET2 mutations. WT1
and RPS14 gene expression levels were also measured by quantitative PCR.
Results: In our series, conventional cytogenetics analysis failed in only 12%
of cases: indeed, the sampling for this analysis was the first one during the
bone marrow aspiration. Overall, 39% of patients showed at least one chro-
mosomal aberration, with complex karyotypes in 7% of cases. FISH allowed
to correctly classify two cases as affected by the 5q- syndrome and one as
affected by deletion of chromosome 7; two patients carried PDGFRbeta
rearrangement; these abnormalities had not been detected by the conventional
cytogenetics.
The aGCH allowed to detect chromosomal aberrations in 38% of cases: aCGH
detected 10 “new” mutated cases in respect of the conventional cytogenetics,
including alterations of the ETV6 and GATA2 genes; After the mutational analy-
ses, 28% of patients resulted mutated, with highest frequency for TP53 (mutat-
ed in the 16% of the overall series). Eight of these TP53-mutated patients
showed normal karyotype, and resulted wild-type by FISH and aCGH. Four
low/intermediate-1 risk patients (8%) showed the ASXL1 gene mutation. Two
cases showed the TET2 mutation. The statistical analysis confirmed the prog-
nostic role of poor cytogenetics either on overall survival (OS) or progression-
free-survival (PFS). Also deletions detected by aCGH resulted to play a nega-
tive prognostic impact on OS. WT1 and RPS14 gene expression was assessed:
over-expression of WT1 was found in one third of all patients, while 70%
showed RPS14 values lower than those measured in healthy donors. Statistical
analysis showed that the WT1 over-expression had statistical significance on
survival, also in multivariate analysis.
Summary/Conclusions: Our study supports the feasibility and the utility of
the introduction in the routinary workup of MDS of FISH and aCGH, in order to
better stratify MDS patients and correctly design ab initio a patient-tailored
treatment.
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TRANSFORMATION FROM MDS WITH ISOLATED DEL(5Q) HARBORING
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Background: Although myelodysplastic syndromes (MDS) with isolated del(5q)
represents a favorable prognosis, the presence of TP53 mutation has been
associated with transformation to secondary AML (sAML) accompanied by the
emergence of a complex karyotype (CK). The demethylating agent azacitidine
(AZA) is currently the standard therapy for patients with high-risk MDS. How-
ever, some reports showed AZA treatment cannot improve survival in high-risk
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MDS and sAML patients with TP53 mutations, in spite of response to AZA. The
molecular mechanisms in the acquisition of resistance to AZA in TP53 mutated
cases has not been completely understood.
Aims: To clarify the molecular mechanisms underlying disease progression
and the acquisition of chemo-resistance in MDS, we delineated clonal evolution
during disease course using high throughput sequencing of serial samples.
Methods: The 77-year-old female patient was diagnosed with MDS with iso-
lated del(5q). She then received lenalidomide (LEN), but progressed to sAML
with CK involving -7. She received AZA with LEN and then achieved temporarily
marrow CR (blast<5%). Although she received same therapies, she relapsed
and died of progressive leukemia. Genomic DNA was collected at four stages
(RAEB-1, sAML, remission, and relapse) on informed consent. We performed
whole exome sequencing (WES) and PCR amplicon based target deep
sequencing by NGS (Illumina HiSeq 2500). Copy number alterations (CNA)
were analyzed based on the read number and allelic imbalances were estimat-
ed from allele frequency of heterozygous SNPs.
Results: The mean coverage of WES and target deep sequencing was 209
times and 67073 times, respectively. We detected 15 somatic single nucleotide
variants (SNV) and 2 frameshift/insertions in 17 genes. We identified the TP53
Y102C and NF1 T676fs as putative driver mutations. As the TP53 Y102C was
the most abundant mutation identified in all stages, could represent the founding
mutation. On the other hand, NF1 T676fs was rapidly enriched in the relapse.
Next we delineated a model of clonal evolution using the proportion of SNV and
CNA. Although CK with -7 was acquired during disease progression in this case,
interestingly, deleted allele of chromosome 7 was different between sAML and
relapse phase. In other words, two distinct clones characterized by deletion of
different allele (-7A/-7B) existed after sAML, and clonal competition occurred
during disease progression and having therapy.(Figure) The sAML stage was
characterized by a founding clone harboring TP53 mutation and del(5q), major
clone containing -7A and sub-clone with -7B. del(11p) was acquired in -7A clone
and became dominant, but in remission the clone with del(11p) was extinct. On
the other hand, clonal evolution took place on -7B clone, which acquired NF1
mutation, del(17p) encompassing TP53, and del(17q) including NF1. Finally,
the evolved clone from -7B obtained chemo-resistance and contributed to
relapse and also -7A clone flared up with deleted NF1.
Figure 1. The proportion of -7 on each allele durng disease course.
Summary/Conclusions: To analysis serial samples during disease progres-
sion discloses that two distinct clone harboring chromosomal aberration on
each allele competed with each other by selective pressure of therapy. These
observations uncovered the complicated clonal architecture with the accumu-
lations of genetic abnormality.
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ACTIVATE UNIQUE AND COMMON TRANSCRIPTIONAL PATHWAYS THAT
INCLUDE POTENTIAL NOVEL MARKERS OF RESPONSE
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Background: Myelodysplastic syndrome (MDS) and acute myeloid leukaemia
(AML) patients have poor tolerability of standard chemotherapies and an unmet
need for novel therapeutic approaches. Epigenetic silencing of genes can occur
via hypermethylation or the recruitment of histone deacetylases (HDACs), with
these changes being reversible making them prime targets for therapy. Agents
that inhibit DNA methylation have proven successful in the treatment of haema-
tological malignancies and have shown promise by increasing the tolerability
for MDS and AML patients, however the underlying mechanism of action
remains to be fully elucidated. 
Aims: In this report, we have studied the molecular and cellular consequences
of treating AML and MDS derived cell lines with Azacitidine as a single agent
as well as performing a small meta-analysis comparing Azacitidine an
Decitabine gene expression with the intention of finding potential rational com-
bination partners.
Methods: LINE-1 pyrosequencing was used to measure global methylation
levels and western blotting used as a measure of protein expression. Cytospins
were performed and slides were stained with Wright-Giemsa to assess the
morphological effect on OCI-AML3 and SKM-1 cells. Gene expression profiling
was performed using Affymetrix U133 plus 2.0 arrays and results were analysed
using Partek Genomics Suite. CHI3L1 methylation was determined using
pyrosequencing with primers designed against the promoter, intron and exon.
Survival analysis examined TGCA dataset of 183 clinically annotated adult cas-
es of de novo AML, whilst the local dataset consisted of 228 clinically annotated
cases of MDS and AML. 
Results: Azacitidine decreased viability and LINE-1 DNA methylation with a
concomitant reduction in DNMT1 protein expression. Morphological assess-
ment of treated OCI-AML3 and SKM-1 cells displayed an increase the propor-
tion of macrophage cells-indicative of an induction of differentiation. Gene
expression profiling using Affymetrix U133 plus 2.0 arrays identified 173 dif-
ferentially expressed probesets following treatment with pathway analysis
using DAVID identifying the immune system and an inflammatory response,
which was also observed with network analysis using STRING. Overlap with
Decitabine gene expression analysis highlighted 138 probesets that were com-
mon to both drugs and supported the role of the immune system in response
to demethylating agents including S100A8/A9, HLA and CHI3L1. CHI3L1 was
up-regulated with both agents and an increase in gene expression correlated
to a loss of promoter, intron and exon DNA methylation. Survival analysis in
locally and publically available datasets of stratified AML patients recognised
that CHI3L1 could be used as a potential marker of response in patients with
good cytogenetics (p=<0.02) compared to those in other subtypes (intermedi-
ate - ns; poor-ns).
Summary/Conclusions: These analyses give further insight into the mecha-
nism of action of both Azacitidine and Decitabine in AML/MDS cell lines by
identifying molecular gene and pathway targets that may be primed for novel
therapeutic combinations for the treatment of elderly patients with AML or high
risk MDS.
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INTEGRATED ANALYSIS OF BOTH BIOLOGICAL AND MOLECULAR
EFFECTS OF THE EPIGENETIC MODIFYING AGENT ROMIDEPSIN IN
MDS/AML
K Clarke1,*, F Liberante1, S McDade2, C Young1, A Thompson1, K Mills1
1Blood Cancer Research Group, CCRCB, 2Functional Genomics Group, CCR-
CB, Queen’s University Belfast, Belfast, United Kingdom
Background: Myelodysplastic syndrome (MDS) patients have poor tolerability
of standard chemotherapies and an unmet need for novel therapeutic approach-
es. Epigenetic silencing of genes can occur via the recruitment of histone
deacetylases (HDACs) with these changes being reversible, making them prime
targets for therapy. Agents that inhibit HDACs (HDACi) have proven successful
in certain malignancies and have shown promise by increasing the tolerability
for MDS patients
Aims: In this report, we aimed to study the molecular and cellular conse-
quences of treating AML and MDS derived cell lines with Romidepsin as a
single agent, which could ultimately provide a rationale for combination thera-
py.
Methods: Cell Titre Glo® was used to measure viability, alongside HDAC Glo®
assay to quantitate HDAC activity. Western blotting was performed to determine
protein expression levels and flow cytometry using propidium iodide staining
was used to measure cell cycle. Affymetrix U133 plus 2.0 arrays were used for
gene expression analysis in conjunction with DAVID and STRING for pathway
and network analysis. The Illumina Next-Seq 500 was used in-house to perform
ChIP-Seq experiments. 
Results: Preliminary analysis identified a candidate dose, time and cell line to
be carried forward for gene expression profiling and ChIP-Seq analysis based
on the ability of Romidepsin to affect proliferation, HDAC activity, acetylation
and cell cycle. Microarray analysis indicated that 484 probesets were signifi-
cantly (p<0.05) up-regulated compared to only 3 down-regulated after 24 hour
treatment with 1.5 nM Romidepsin. Pathway and network analysis, using
STRING and DAVID identified that ROS, inflammation and activation of mito-
chondrial stress pathways were associated with Romidepsin treatment.
Matched samples from Romidepsin treated, and untreated SKM-1 cells were
used for ChIP-Seq analysis of H3K9ac, H3K9me and H3K9me3 chromatin
marks which provided information on positional enrichment and enabled an
integrated transcriptomic-epigenetic mapping approach, thus identifying specific
Romidepsin-induced gene-expression networks. Overlap of differential enrich-
ment of each of the aforementioned marks with the microarray data has high-
lighted that increases in acetylation share the highest degree of overlap with
gene expression.
Summary/Conclusions: These analyses give further insight into the mode of
action of Romidepsin by identifying molecular gene and pathway targets that
haematologica | 2016; 101(s1) | 497
Copenhagen, Denmark, June 9 – 12, 2016
may be primed for novel therapeutic combinations for the treatment of elderly
patients with AML or high risk MDS.
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THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY
HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE
ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS
CASES
D Singhal1,2,3,*, S Moore4, M Kutyna2, R Chhetri2, LA Wee2, J Gray5, S Nath3,6,
N Wickham7, CH Hui7, D Ross8, P Bardy1,2,3, LB To1,2,3, I Lewis1,2,3,9,
D Hiwase1
1Haematology, The Royal Adelaide Hospital, 2Haematology, SA Pathology,
3Faculty of Medicine, University of Adelaide, 4Genetics & Molecular Pathology,
SA Pathology, Adelaide, 5Haematology-Oncology, The Queen Elizabeth Hos-
pital, Woodville South, 6Haematology, Adelaide Haematology, Ashford,
7Haematology, Adelaide Cancer Centre, Kurralta Park, 8Flinders Medical Cen-
tre, Bedford Park, 9Haematology, South Australian Health and Medical
Research Institute, Adelaide, Australia
Background: Therapy-related myeloid neoplasms (T-MN) are well-known com-
plication of prior cytotoxic/radiation therapy for malignancies and auto-immune
diseases and are associated with poor survival compared to de novo MDS
cases;most probably due to higher rate of poor cytogenetic in T-MN cases.
Poor prognosis of T-MN cases following prior cytotoxic chemotherapy (CT)
exposure is well established, however, there is ongoing debate about the prog-
nosis of radiotherapy (RT) only associated T-MN cases.
Aims: This study compares the prognosis of T-MN cases following CT, RT and
de novo MDS cases enrolled in the South Australian MDS (SA-MDS) Registry.
Methods: Demographic, clinical, cytogenetic and laboratory data on 744 de-
novo and 148 T-MN patients were analysed. Survivals between the groups
were compared by using log-rank test and were plotted using Kaplan Meier
curve. Categorical variables were compared by using Chi-square test.
Table 1. Distribution of cytogenetic categories in de-novo &T-MN patients
according to IPSS, R-IPSS and prior treatment type.
Figure 1.
Results: Median age of T-MN and de novo MDS was 71 (20-91) and 73 years
(19-98). Most frequent primary diseases (PD) were lymphoproliferative dis-
eases (n=56, 38%) and prostate cancer (n=22, 15%). Sixty-four (43%) patients
had received CT only, 34 (23%) patients RT only, and 48 (32%) patients
received both CT and RT for PD. 29(20%) patients received autologous stem
cell transplant for their PD. During follow up, 42(28%) patients developed T-
AML, while 104 (70%) developed T-MDS. The median time between cytotoxic
treatment and t-MN diagnosis was 38.5months for RT only (range 0.9-123)
and 31.9months (range 0.2-216.2) for CT(±RT) patients, respectively. As shown
in table 1 and Fig1A, poor risk cytogenetic cases were significantly higher in T-
MN cases treated with CT compared to cases treated with RT alone and de
novo MDS cases (52% vs 25% vs 13% respectively; P<0.0001). Similarly, 47%
CT(±RT)patients had R-IPSS defined poor and very poor cytogenetics com-
pared to 35% of RT only and 13% of de-novo MDS/AML patients (P=<0.0001).
Overall, 40(27%) of T-MN patients received disease modifying therapy (Induc-
tion CT, Hypomethylating agents, low dose Ara-C, and Allogeneic transplant).
Within the T-MN group (144 patients), T-MDS patients had significantly better
median survival than T-AML (14.7 vs 5.0 months, P<0.0001)(Fig 1B). T-MN
patients who received prior RT only had worse median survival than de-novo
patients but better than T-MN patients receiving prior CT (±RT) (9.7 vs 27.9 vs
41.3 months; p=0.001)(Fig 1C). Further, within the individual IPSS cytogenetic
risk category, T-MN consistently had poor median survival than de-novo
patients (Fig.1D) regardless of the type of prior therapy(p=0.001).
Summary/Conclusions: T-MN patients receiving prior CT(± RT) have poorer
survival compared to RT only & de novo MDS patients. Contrary to the pub-
lished literature (Nardi et al JCO 2012), our data suggest that the incidence of
adverse cytogenetics is higher in T-MN patients who received prior RT com-
pared to de-novo patients. T-MN patients have consistently poor survival than
de-novo patients even when matched for IPSS cytogenetic categories.
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POLY [ADP-RIBOSE] POLYMERASE 1 (PARP-1) EXPRESSION IS CORRELAT-
ED TO THE TYPE OF MYELODYSPLASTIC SYNDROME ACCORDING TO
BOTH WHO CLASSIFICATION AND IPSS SCORE
P Diamantopoulos1,*, P Zervakis1, M Sofotasiou1, K Zervakis1, A Symeonidis2,
E Kodandreopoulou1, A Galanopoulos3, V Pappa4, I Kotsianidis5, G Christopoulou2,
V Papadopoulou 1, NA Viniou1
11st Department of Internal Medicine, Hematology Unit, Laikon General Hos-
pital, National and Kapodistrian University of Athens, Athens, 2Department of
Internal Medicine, University Hospital of Patras, Patras, 3Department of Clinical
Hematology, G. Gennimatas District General Hospital, 4Hematology Division,
Second Department of Internal Medicine, Attikon General Hospital, National
and Kapodistrian University of Athens, Athens, 5Department of Hematology,
University Hospital of Alexandroupolis, Alexandroupolis, Greece
Background: Poly [ADP-ribose] polymerase 1 (PARP-1) has a central role in
the repair of single-stranded DNA breaks, thus protecting the cell from genomic
instability. Overexpression of PARP1 may lead a cell to apoptotic or necrotic
death, thus defining the cell’s fate. Genetic defects are important in the patho-
genesis of myelodysplastic syndromes (MDS) and the role of PARP1 in the
apoptotic pathways seems to be promising, since new agents targeting PARP1
are available. PARP1 expression has never been studied in MDS.
Aims: Our aim was to detect PARP1 mRNA in bone marrow samples of
patients with MDS and investigate its correlations to the hematologic and prog-
nostic characteristics of the patients.
Methods: Bone marrow samples were collected from patients with MDS. Quan-
tification of PARP1 mRNA was performed by a SYBR-green based PCR, per-
formed on BIORADCFX96 (BIORAD) and the results were expressed in cor-
relation to those of the housekeeping gene of beta actin. Statistical correlations
were carried out using IBM SPSS statistics, version 19.0.
Results: Fifty three (53) patients with MDS were included in the study. The
basic demographic and hematologic characteristics of the patients are shown
in the Table. The vast majority of the patients (92.5%) were treatment naïve.
The median PARP1 mRNA levels were 0.0259 (range 0.0003-0.6410) and
showed a statistically significant correlation to the type of MDS (according to
the WHO classification) (p=0.016) and to the IPSS score (p=0.001) (detailed
results in Table). The lowest levels were observed in patients with RA (0.0053
vs 0.1477 for non-RA patients, p= 0.016), as well as in patients with low and
intermediate 1 IPSS score (0.0107 vs 0.1831, p=0.01) that had almost 20 times
lower PARP1 mRNA levels than patients with intermediate 2 and high risk
MDS.
Table 1. Patients’ characteristics and results.
* hypomethylating agent
† Independent Samples Kruskal-Wallis Test, 2-sided p
‡ based on only 2 samples
Summary/Conclusions: The correlation of higher levels of PARP1 mRNA with
higher risk MDS has never been reported in the past. This correlation, if con-
firmed by larger studies, may render PARP1 a prognostic factor for patients
with MDS. Moreover, this result can lay the basis for the design of clinical trials
evaluating the use of PARP1 inhibitors in patients with higher risk MDS.
498 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
E1209
NEXT GENERATION SEQUENCING IN HIGH RISK MYELODYSPLASTIC
SYNDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA PATIENTS
TREATED WITH AZACITIDINE ACCORDING TO HIGH RISK MDS 2009
PROTOCOL FROM CETLAM GROUP
M Cabezón1,*, J Bargay2, B Xicoy1, O García3, M Tormo4, L Palomo3, S Marcé1,
D Valcárcel5, C Pedro6, MJ Jiménez1, J Grau1, J Borràs2, R Guàrdia7,
S Brunet8, JM Martí9, A Garcia10, E Feliu1, F Millá1, L Zamora1
1ICO Badalona- Hospital Germans Trias i Pujol. Institut de Recerca contra la
leucèmia Josep Carreras., Badalona, 2Hospital Son Llàtzer, Palma de Mallorca,
3Institut de Recerca Contra la Leucèmia Josep Carreras. Campus ICO-Ger-
mans Trias i Pujol., Badalona, 4Hospital Clínico de Valencia, Valencia, 5Hospital
Vall d’Hebrón, 6Hospital del Mar, Barcelona, 7ICO Girona- Hospital Josep True-
ta, Girona, 8Hospital de Sant Pau, Barcelona, 9Hospital Mútua de Terrassa,
Terrassa, 10Hospital Arnau de Vilanova, Lleida, Spain
Background: Risk-adapted treatment strategy is currently used in myelodys-
plastic syndromes (MDS). Hypomethylating agents have introduced a new per-
spective in the therapeutic approach of higher risk MDS, azanucleosides being
the standard of care for most patients with this disease. The application of next
generation sequencing (NGS) technologies to study MDS has identified several
recurrently mutated genes involved in RNA splicing, DNA methylation, chro-
matin modification, transcription, DNA repair control, cohesin function, RAS
pathway and DNA replication. Even though there is a significant overlap
between the commonly mutated genes in MDS with those found in AML, muta-
tion status is not widely used to select MDS treatment.
Aims: The aim of this study is to identify the mutational status at diagnosis of
MDS and secondary AML (sAML) patients treated with azacitidine to evaluate
if it could help to discriminate which patients will respond from those who will
not and its correlation with clinic-biological data.
Methods: A preliminary prospective study was performed on 39 patients with
MDS and sAML (14 RAEB-2, 9 RAEB-1, 5 RCMD, 1 RCMD-RS, 1 RARS and 9
sAML). Genomic DNA was obtained from bone marrow at diagnosis. SeqCap
EZ and KAPA Library Preparation Kit (Roche) reagents have been used to gen-
erate libraries and enrich DNA of 83 genes implicated in myeloid neoplasm. The
customized panel has been analyzed in MiSeq Illumina platform with 150bp
paired-end reads. NGS data were analyzed using Illumina MiSeq Reporter and
Variant Studio softwares. In 21 patients a CD3+ matched control study was done,
in order to distinguish between somatic and germline variants. Data from treat-
ment response and overall survival (OS) has been collected from all patients.
Results: The mean depth of targeted resequencing per base was 779-fold.
After filtering all the variations obtained for quality, biological consequence and
discard the known SNPs, we obtained 116 variations with a mean of 3 variants
per sample. The average of alterations detected in each cytological category
can be observed in Table 1.
Table 1. Average of abnormalities according to cytological category.
The most frequent altered genes have been TP53 (48.7%), TET2 (20.5%) and
DNMT3A (20.5%). Statistical analysis confirmed that TP53 alterations are asso-
ciated with complex karyotype (p<0.001) and with the very high IPSS-R risk
category (p=0.002). On the other hand, mutations of RNA splicing machinery
(SRSF2, U2AF1, SF3B1 or ZRSR2) and variations in cohesion complex
(STAG2, RAD21 or SMC3) are associated with non-complex karyotype
(p=0.022 and p=0.02) and alterations in SRSF2 are rarely detected in very high
IPSS-R risk category (p=0.007). In our series we have not observed the impact
of TET2 mutations in treatment response. Survival analysis showed that the
presence of variants in TP53 correlated with shorter OS (9.2 vs 19.2; p=0.008).
Alterations in SRSF2 and mutations in cohesion complex are associated with
longer OS (median not reached vs 10.4; p=0.025 and median not reached vs
10.4; p=0.048).
Summary/Conclusions: NGS technique is a good tool to study mutational
profile in MDS and sAML. Patients with sAML and RAEB-2 present more vari-
ations than patients with RAEB-1 or RCMD. The most affected genes match
with those described in the literature for high risk MDS. Alterations in TP53 and
SRSF2 genes seem to be good markers to predict the outcome.
Acknowledgements: Instituto de Salud Carlos III, Spain (PI 11/02519).
E1210
MOLECULAR ALTERATIONS ASSOCIATED WITH PROGRESSION OF
MYELODYSPLASTIC SYNDROMES TO SECONDARY CHRONIC
MYELOMONOCYTIC LEUKEMIA
A Valencia1,*, A Sanna1, E Masala1, B Francesca1, A Gozzini1, E Contini2,
F Torricelli2, B Przychodzen3, J Maciejewski3, A Bosi1, V Santini1
1Experimental and Clinical Medicine, University of Florence, 2AOU Careggi,
Firenze, Italy, 3Department of Translational Hematology & Oncology Research,
Cleveland Clinic, Cleveland, United States
Background: Myelodysplastic syndromes (MDS) are heterogeneous disorders
characterized by ineffective hematopoiesis and risk of progression to acute
myeloid leukemia. However, MDS may progress to clearly myeloproliferative
neoplasms. Some reports have demonstrated that de novo MDS patients can
transform to secondary chronic myelomonocytic leukemia (CMML) independ-
ently of the presence of relative monocytosis (>10%) at initial diagnosis of MDS
(Rigolin et al, Haematologica 1997; Wang et al, Am J Clin Pathol 2006). Clinical
parameters and cytogenetic alterations failed to correlate with probability to
develop this type of progression.
Aims: The knowledge of the mechanisms at the basis of proliferative-non
leukemic progression could help define the prognosis of this group of MDS
patients. We postulated that specific acquired somatic mutations could be asso-
ciated with the transformation from MDS to secondary CMML.
Methods: Seven IPSS lower risk MDS patients (pts) that progressed to CMML
were included in the study. The mutational profile was characterized using a
TruSeq Custom Amplicon panel (Illumina) targeting the 57 recurrently mutated
genes in myeloid malignancies. Around 250 ng of genomic DNA extracted from
mononuclear cells obtained at diagnosis (MDS phase) and at progression
(CMML phase) were used to prepare sequencing libraries following the Illumina
standard protocol. Samples were run on an Illumina MiSeq and variants were
annotated by ANNOVAR. Detected variants were distilled on the basis of their
exonic function, allele frequency, the presence in variants databases, and sev-
eral prediction scores.
Results: At diagnosis, 2 pts had RA and 6 pts had RCMD and at progression
5 pts presented a CMML-1 and 2 pts a CMML-2 (mean time to progression: 20
months). The total WBC count in the CMML phase was significantly higher than
that of the MDS phase (mean, 24.4×109/L vs 4.04×109/L; P= 0.03). The mean
hemoglobin level, platelet count, and blast count were not different between
the MDS and CMML phases. In both phases, 3 pts presented a normal kary-
otype, 1 case a monosomy 7, 1 patient a trisomy 8 and 1 patient a trisomy 14.
Only 1 patient presented a new trisomy 8 at progression. The most frequently
mutated genes at MDS diagnosis were TET2 and ASXL1 (mutated in 7 and 6
pts, respectively). Only two pts presented new mutations in the progression
CMML sample: one patient in the SETBP1 gene and the other one in the
DNMT3A gene. The mutational profiling of these 7 MDS pts at diagnosis (group
1) was compared with that of a second cohort of 40 low-intermediate1 MDS
pts (group 2) that did not progress (mean follow up: 25 months) (Figure 1). The
number of mutations was higher in group 1 (100% pts presented >3 mutations)
than group 2 (80% of pts presented 0-2 mutations). The most commonly mutat-
ed genes differed between the two groups: ASXL1 (100%) and TET2 (86%) in
group 1, while in group 2 were SF3B1 (25%) and TET2 (22%). In order to study
the role of ASXL1 and TET2 mutations in the progression we compared variant
allele frequency (VAF) data: VAF of ASXL1 was significantly higher in CMML
than in MDS phase (38 vs 21; P=0.02), while VAF of TET2 did not shown dif-
ferences.
Figure 1.
Summary/Conclusions: This analysis of the rare type of progression from
frank low risk MDS to MDS/MPN suggests that number of somatic mutations
and presence of ASXL1 mutations during the MDS phase is an important factor
correlated with/predictive of proliferative-non leukemic progression. Increase
in VAF of ASXL1 seems also important in determining progression.
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COST CHANGES ASSOCIATED WITH ACHIEVING TRANSFUSION
INDEPENDENCE (TI) IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES (MDS)
AE DeZern1,*, G Binder2, S Rizvi2, FA Corvino3, SR Arikian3, A Surinach3, J
Lee3, BD Smith1
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,
Baltimore, MD, 2Celgene Corporation, Summit, NJ, 3Genesis Research, Hobo-
ken, NJ, United States
Background: Given the bone marrow failure characteristic of the disease,
patients with MDS are often dependent upon red blood cell (RBC) transfusions.
Guidelines from the European Society of Medical Oncology note that chronic
RBC transfusions are associated with chronic anemia, leading to excess mor-
bidity, and cannot completely resolve impaired quality of life. This transfusion
dependence (TD) has been shown to be a risk factor for progression, and
achieving TI is an important treatment objective.
Aims: To evaluate MDS cost patterns associated with initial periods in which
patients were TD, and subsequent periods of TI.
Methods: Patients were identified from a large US claims database (2008–
2013) by ICD-9 codes for MDS; the index date was the earlier of ≥1 inpatient
or ≥2 outpatient claims. Patients with medical and pharmacy (Rx) coverage for
≥12 months pre- and ≥6 months post-index were included. TD was defined as
≥2 consecutive 8-week periods with ≥1 transfusion each and no interim 56-
day period without transfusion; TI was defined as 8 subsequent transfusion-
free weeks. Patients with high-risk MDS or acute myeloid leukemia at diagnosis
were excluded. TD patients were followed until they no longer met TD criteria
or end of data. Patients who subsequently became TI were followed until they
returned to TD or end of data. Total costs of care were based on paid claims
and reported for 24 months post-onset of TD or TI.
Results: 13,741 MDS patients met the inclusion criteria regardless of transfusion
needs; 2,645 (19%) were TD and 1,378 (52%) subsequently became TI. Median
TD duration was 7.5 months. Age, prior treatment, baseline anemia, del(5q)
mutation, and comorbidities were similar for TD patients who did and did not
subsequently achieve TI. The average total cost of care (medical+Rx) was lower
for TI than for TD patients ($8,138 vs $16,640 per patient-month) (Figure 1). TI
patients had 54% lower monthly medical costs ($7,004 vs $15,289) largely due
to differences in inpatient costs ($2,353 vs $7,056). Monthly Rx costs for TI
patients were 16% lower than for TD patients ($1,134 vs $1,351). Over time,
monthly costs for TI patients declined 50% from initial levels; TD patient costs
declined 27%.
Figure 1.
Summary/Conclusions: Patients who are TD incur significant total costs of
≥$16,000/month. For patients who subsequently achieved TI, monthly costs
were halved from TD costs and continued to decline over time. This suggests
that treatment of TD patients offers the potential for a return to TI, resulting in
economic benefit as well as clinical improvement.
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FERRITINE LEVEL AND PERFORMANCE STATUS ARE SIGNIFICATIVE
PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN LOWER-RISK MDS
PATIENTS GRUPO ARGENTINO DE ESTUDIO DE LOS SINDROMES
MIELODISPLASICOS
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gia Htal Carlos G Durand, 8Hematologia, Hospital Tornu, 9Hematologia,
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Background: Myelodysplastic syndromes (MSD) are a heterogeneous group
of clonal haematopoietic stem cell malignancies characterized by defects in
haematopoietic cell maduration/differentiation. According to the original IPSS,
the majority of patients are classified within low or intermediate-I (lower) risk
with a survival of >3.5 years. However, a large diversity exists within these
patients varying in several characteristics at diagnosis. Up to 10% evolve to
AML and 50% succumb as a result of the severity of cytopenias. The WPSS,
MD Anderson (MDA) and IPSS-R recognized some IPSS limitations. The use
of these systems has improved survival prediction but their usefulness is not
clear in lower risk patients. Also, the inclusion of non-classical variables, as
ferritine level or performance status, is also in debate.
Aims: To analyze the usefulness of risk stratification to predict survival and
evolution to AML in lower risk patients. And, to test whether non classical vari-
ables are independent prognostic variables in these patients.
Methods: This is a retrospective study of 566 patients from the Registro
Argentino de Enfermedades Hematologicas (RAEH), Sociedad Argentina de
Hematologia, diagnosed between 2007 and 2015, last up-date Jan 2016. Out
of the registry, 328 (57.9%) were selected and evaluated according to the IPSS
criteria, excluding those with secondary MDS and with proliferative CMML.
WPSS (both the one including transfusion dependence and with hemoglobin
levels according to gender), MDA and the specific for Low Risk (MDA-LR), and
IPSS-R systems were applied. Univariate (Kaplan-Meier and Long-rank) and
multivariate (Cox regression) analysis were performed to evaluate survival and
evolution to AML.
Results: The selected 328 lower risk patients showed a median age of 72.5
years, 54.6% were male and 17.7% showed a performance status ≥2. With a
median follow-up of 25.4 months, 86 (26.2%) died and 38 (11.6%) evolved to
AML. Gender, ferritine level (<170, 170-350, >350 mg/ML) and all variables
grouped according to different evaluated systems were significant predictive
variables for prognosis. Table 1 shows the distribution of patients according to
all evaluated systems and their respective median survival and time to evolution
to AML. It also depicts that all systems were useful to predict outcome. The
IPSS-R sustained its independence for both survival [p<0.001, exp(B) 1.676]
and evolution to AML [p<0.001, exp(B) 2.544]. Also the classic MDA was useful
for survival [p<0.001, exp(B) 1.987] and both WPSS for evolution to AML
[p<0.001 and 0.02, exp(B) 2.281 and 0.554, respectively including either trf or
Hb]. As the IPSS-R was the only system that sustained its independence to
predict both survival and evolution to AML, all variables not included were ana-
lyzed in a multivariate model. Performance status and ferritine level were sig-
nificative predictive parameters in the model to predict survival [p<0.001 and
p=0.012, exp(B) 1.807 and 1.455]. However, any variable showed an inde-
pendent prognostic impact for evolution to AML besides the IPSS-R.
Table 1. Univariate analysis of variables of prognostic factors for survival
and evolution to AML.
Summary/Conclusions: WPSS, MDA, MDA-LR and IPSS-R systems allowed
us to identify subgroups of patients (11.5%-26.2%) that shift to worse prognosis
categories in lower risk-IPSS patients. IPSS-R sustained its independence to
predict both survival and evolution to AML, while the MDA did it for survival
and the WPSS for leukemic evolution. Performance status and ferritine level
were significative independent prognostic factors to predict survival along with
the IPSS-R in lower risk patients.
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CHARACTERIZATION OF TREATMENT PATTERNS AND OUTCOMES IN
PATIENTS WITH MYELODYSPLASTIC SYNDROMES: ANALYSIS OF
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Background: Myelodysplastic syndromes (MDS) constitute a heterogeneous
form of blood cancer that primarily affects the elderly, and are characterized by
anemia and other cytopenias as well as a high risk of transformation to acute
myeloid leukemia (AML). Treatment, which is selected based on the Interna-
tional Prognostic Scoring System (IPSS), presence of cytopenia, and the pres-
ence of 5q deletion (del[5q] MDS), may include supportive care (eg, whole-
blood and/or platelet transfusion), erythropoiesis-stimulating agents (ESA),
hypomethylating agents, and lenalidomide for del(5q) MDS.
Aims: To characterize the burden of disease, treatment patterns, and outcomes
of MDS patients using a large US database.
Methods: Optum’s integrated claims and Electronic Medical Record database
(“Optum Database”) was retrospectively analyzed to identify adult patients with
an index diagnosis of MDS between 2006 and 2014; to ensure index diagnosis,
only patients with 365 days of retrospective data preceding the index diagnosis
were included. Patients with baseline AML and patients younger than 18 years
of age were excluded. MDS in patients was categorized as low-grade (ICD 9
code 238.72: Refractory anemia [RA], Refractory anemia with excess blasts-1
[RAEB-1], Refractory anemia with ringed sideroblasts [RARS], Refractory
cytopenia with multilineage dysplasia [RCMD], Refractory cytopenia with mul-
tilineage dysplasia and ringed sideroblasts [RCMD-RS]), high-grade (ICD 9
code 238.73, which includes Refractory Anemia with Excess Blasts [RAEB] II),
del(5q) (ICD 9 code: 238.74), or unspecified (ICD 9 code: 238.75) based on
the earliest recorded ICD-9 diagnosis code based on French-American-British
classification. Demographics and clinical outcomes were analyzed by descrip-
tive summary. Treatment patterns were summarized by grouping treatments
as “lenalidomide,” “azacitidine,” “decitabine,” “imatinib,” “chemotherapies,”
“ESA,” and “others.” Kaplan-Meier survival analysis was performed to define
progression to AML.
Results: Of 10,465 MDS patients in the Optum Database, 8493 met the inclu-
sion criteria and were evaluated over a median follow-up of 2.3 years; MDS
was categorized as low-grade in 2136 (25.2%), high-grade in 367 (4.3%),
del(5q) in 198 (2.3%), and unspecified in 5792 (68.2%) patients. Across all
MDS categories, mean age at diagnosis was 70 to 72 years, 77% of patients
were aged ≥65 years, roughly half were male, and the majority were white and
non-Hispanic. In the overall cohort, 40% received ≥1 prescribed agent (46% in
low-grade, 61% in high-grade, 42% in del[5q], and 36% in unspecified MDS).
The most commonly used regimens were epoetin-alfa or darbepoetin in both
low-grade and unspecified, hypomethylating agents (decitabine or azacitidine)
in high-grade, and lenalidomide in del(5q) MDS (Table). In the overall cohort,
500 (5.9%) MDS patients progressed to AML, including 103 (4.8%) patients
with low-grade and 78 (21.3%) with high-grade MDS. In the overall cohort, 38%
of patients who received ≥1 regimen and 13% of patients without prescribed
treatment went on to have a blood transfusion (Table).
Table 1. Demographics and treatment of patients with MDS in optum data-
base.
Summary/Conclusions: Despite the variety of agents available, a significant
proportion of MDS patients across all categories did not receive any treatment,
and many received only supportive care. Rates of transformation to AML and
transfusion dependence are consistent with published estimates.
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MINIMAL RESIDUAL DISEASE MONITORING AND PREEMPTIVE
IMMUNOTHERAPY IN MYELODYSPLASTIC SYNDROME AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
XD Mo1,*, YZ Qin2, XH Zhang2, LP Xu2, Y Wang2, CH Yan2, H Chen2,
YH Chen2, W Han2, FR Wang2, JZ Wang2, KY Liu2, XJ Huang2
1Peking University People’s Hospital, 2Institute of Hematology, Beijing, China
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is
one of the most effective treatments for high-risk myelodysplastic syndromes
(MDS). Although allogeneic HSCT has advanced significantly, post-transplant
relapse remains an important cause of transplant failure. The presence of min-
imal residual disease (MRD) after HSCT can indicate impending relapse.
Aims: This study investigated the efficacy of MRD monitoring and MRD-direct-
ed preemptive immunotherapy in high-risk MDS patients who received allo-
geneic HSCT.
Methods: MRD assessment consisted of Wilms’ tumor gene 1 (WT1) detection
with PCR and leukemia-associated immunophenotypic pattern examination
with multiparameter flow cytometry (FCM).
Results: Post-HSCT, 31 patients were positive for WT1, and 8, for FCM; pos-
itivity for WT1 (18.6% vs 6.1%, P=0.040) or FCM (62.5% vs 3.6%, P<0.001)
indicated a higher 2-year relapse rate. Twenty-one patients met our combined
criteria for MRD, and the presence of MRD was associated with a higher 2-
year relapse rate (27.3% vs 4.5%, P=0.003). Thirty-one patients showed pos-
itive results for preferentially expressed antigen of melanoma (PRAME) after
HSCT, which indicated a higher 2-year relapse rate (19.3% vs 6.2%, P=0.035).
In patients positive for both PRAME and MRD, the relapse rate was 60%
despite preemptive immunotherapy. Multivariate analysis confirmed the asso-
ciation between the increased relapse rate and positivity for both PRAME and
MRD (hazard ratio=42.8, P=0.001). 
Summary/Conclusions: MRD monitoring predicted relapse in high-risk MDS
post-HSCT patients, and PRAME- and MRD-positive patients did not benefit
from preemptive immunotherapy.
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PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC
SYNDROMES
SY Wang1,*, Y Lin2, Y Zheng2, ZC Wang2
1Department of Hematology, Fujian Institute of Hematology, Fujian Medical
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versity, Fuzhou, China
Background: Although additional sex comb-like 1 (ASXL1) gene mutations have
long been reported in Myelodyspastic Syndromes (MDS) and Chronic Myelomono-
cytic Leukemia (CMML), the prognostic significance has been controversial.
Aims: Perform a meta-analysis to study impact of ASXL1 mutations on patients
with MDS and CMML.
Methods: The identified articles were retrieved from some common databases.
We extracted hazard ratios (HRs) for overall survival (OS) and leukemic-free
survival (LFS) and P value of some clinical parameters, which compared AXSL1
mutations and those without from the available studies. Each individual HR
and P value was used to calculate the pooled HR and P value.
Results: 6 studies covering 1689 patients were selected for this meta-analysis.
The pooled HRs for OS and LFS were 1.45(95%CI, 1.24-1.70) and 2.20(95%CI,
1.53-3.17), respectively. When considering CMML patients alone the HR for
OS was 1.50(95%CI, 1.18-1.90). Additional, ASXL1 mutations were more fre-
quently found in male (P=0.008), older (P=0.019) and patients with lower
platelets (P=0.009) or hemoglobin level (P=0.0015) and associated with other
mutations such as EZH2, IDH1/2, RUNX1 and TET2. 
Summary/Conclusions: ASXL1 mutations were associated with poor prog-
nosis in MDS, which may contribute to risk stratification and prognostic assess-
ment in the disease. 
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CIRCULATING CLONAL CELLS ARE PLENTYFUL IN PERIPHERAL
BLOOD OF PATIENTS WITH MYELODYSPLASTIC SYNDROME: A
COMPARISON OF THE PERCENTAGE OF CLONAL CELLS IN PB AND BM
BY FLUORESCENT IN SITU HYBRIDIZATION
KO Im1, DS Lee2,*, SN Park1, SM Hwang3, JA Kim2, SM Kim4, Q Kim1
1department of tumor cell biology, 2Dept of Laboratory Medicine, Seoul National
University College of Medicine, Seoul, 3Dept of Laboratory Medicine, 4depart-
ment of tumor cell biology, Seoul National University College of Medicine, Bun-
dang, Korea, Republic Of
Background: Treatment response of MDS is determined by peripheral blood
hemogram, bone marrow blast%, and cytogenetic results in BM. For the deter-
mination of treatment response, invasive BM study is required. We questioned
whether the malignant cells are circulating or not in PB of patiens with MDS.
We compared the percentage of clonal cells determined by fluorescent in situ
hybridization (FISH) between PB and BM. If clonal cells are present in PB,
monitoring of treatment response could be more easily accessible.
Aims: We aimed to investigate whether interphase fluorescence in situ
hybridization (iFISH) clone size in peripheral blood correlate with bone marrow. 
Methods: A tailored FISH panel (-5/5q-, -7/7q-, +8, -20/20q-, and +1/1q+) based
on reported cytogenetic changes in Korean MDS patients, was performed in
98 patients with MDS at initial diagnosis. We performed corresponding FISH
on peripheral blood in 28 patients in whom aberrant FISH results were observed
in BM. The FISH probes used in the study were LSI EGR1 SpectrumOrange
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(5q31)/D5S23, D5S721 SpectrumGreen (5p15.2), LSI D7S522 SpectrumOr-
ange (7q31)/CEP7 SpectrumGreen, CEP8 SpectrumGreen, LSI D20S108
SpectrumOrange (20q12) and LSI Trisomy 1q (1q25) SpectrumGreen
(Abbott,Downers Grove, IL, USA). 
Results: Among 98 patients diagnosed with MDS at initial diagnosis, 56.1%
(55/98 patients) showed positive result by 5 kinds of FISH probes. In 82.1% of
patients (23/28 patients), clonal cells was detectable in PB and the mean per-
centage was 30.4% (range from 2.5% to 80.0%). The proportion of FISH-pos-
itive cells in PB was lower compared with the those in BM, and the mean per-
cent difference between BM and PB was 30.5% (range from -11.2% to 45.0%).
The proportion of FISH-positive cells in PB was lower compared with the those
in BM, and the mean percent difference between BM and PB was 30.5% (range
from -11.2% to 45.0%). However, the correlation of percentage value was high
between PB and BM (r2=0.85); trisomy 8 (r2=0.85), 5q deletion (r2=0.85), 1q
gain (r2=0.85) and 20q deletion (r2=0.85). In 3 patients with disease progres-
sion, percentage of clonal cells showed signficant interval change.
Summary/Conclusions: Our results suggest FISH monitoring of peripheral
blood can be used as a potential candidate for monitoring tool of treatment
response in MDS.
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TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED
LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT
DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS
STIMULATING AGENTS
A Almeida1,*, P Fenaux2, G Garcia-Manero3, A Giagounidis4, S Goldberg5,
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6Charles University General Hospital, 1st Department of Medicine, Prague,
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poration, Summit, NJ, United States, 11AOU Careggi, University of Florence,
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Background: In the phase 3 MDS-005 study of lenalidomide (LEN) in RBC
transfusion-dependent lower-risk non-del(5q) myelodysplastic syndromes
(MDS) patients (pts) ineligible for or refractory to erythropoiesis-stimulating
agents (ESAs), a significantly higher proportion of LEN-treated pts achieved
RBC transfusion independence ≥8 weeks vs placebo (P<0.001). 
Aims: To describe the frequency, timing, and management of treatment-emer-
gent adverse events (TEAEs) in pts from MDS-005.
Methods: AEs of all 160 pts randomized to LEN who received ≥1 dose were
reported per NCI-CTCAE v3.0.
Results: Median duration of LEN treatment was 164 days (range 7–1,158).
Grade (G)1/2 and G3/4 TEAEs were reported in 96.9% and 86.3% of pts,
respectively. The most common G3/4 TEAEs were neutropenia (61.9%), throm-
bocytopenia (35.6%), anemia (5.6%), pneumonia (5.6%); G3/4 deep vein throm-
bosis (DVT) occurred in 1.9%. G3/4 neutropenia and thrombocytopenia gener-
ally occurred in cycles 1–4. The most common G1/2 TEAEs were diarrhea
(42.5%), constipation (22.5%), asthenia (21.9%), rash (21.3%), fatigue (20.6%),
peripheral edema (20.6%). TEAEs led to 54.4% dose interruptions, 6.3% dose
reductions, and 42.5% dose interruptions with subsequent reduction. Median
time to first dose interruption or reduction was 57 days (range 6–504). The most
common reasons for dose reduction following interruption were neutropenia
(25.0%) and thrombocytopenia (16.3%); 1.9% of pts due to rash. TEAEs led to
LEN discontinuation in 31.9% of pts; the most common reasons were thrombo-
cytopenia (8.8%), neutropenia (4.4%), DVT (1.9%). In this short follow-up period,
no increased incidence of AML or secondary primary malignancies was seen.
Summary/Conclusions: LEN has a predictable and manageable TEAE profile
in this pt population. Diarrhea was the most common G1/2 TEAE; G1/2 TEAEs
generally did not require dose reduction or discontinuation. The most common
G3/4 TEAEs were neutropenia and thrombocytopenia; these occurred early
and, in the majority of pts, reverted with dose reductions or interruptions, avoid-
ing the need for discontinuation. The timing and characterization of TEAEs
highlights the importance of frequent monitoring at the start of therapy.
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IMPACT OF PREVIOUS TRANSFUSION AND COMORBIDITIES IN THE
IPSS-R FOR OVERALL SURVIVAL
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Background: Myelodisplastic sindromes(MDS)are heterogeneus clonal hema-
tological disorders, with different clinical outcome.The revised international
prognostic score system(IPSS-R)showed improvement prognostic power as
compared to IPSS. Disease and patient related factors not considered in IPSS-
R are emerging as relevant for prognosis of individual patients with MDS.
Aims: This is a retropective cohort study to validate the IPSS-R and evaluate
the impact of new variables in a MDS patients serie, wondering if adds any
prognostic survival prediction at diagnosis.
Methods: Data from 339 patients diagnosed with MDS in 11 hospitals sited in
Galicia, Spain from January 1,2007 to december 31,2011. End of the follow-
up time was december 18,2012. The patients were registered in the central
area citogenetic database and were reclassified according to 2008 WHO Cri-
teria. Data of 30 patients with secondary MDS were included and CMML or
AML diagnosys were excluded. Patients treatment was heterogeneous (con-
servative, supportive treatment, chemotherapy, IMIDs, hypometilant agents,
BMT and others). The study was approved by the regional ethical committee.
Results: Population: 44% females and 56% males. Median age: 78 years
(range 29-100). Median follow-up time: 1,7 years. Median survival time: 3,5
years. According to 2008 WHO classification: 14% CRDU, 11% RARS, 31%
RCMD, 8% RCDMSA, 8% MDS(del5q), 12% RAEB-1, 12% RAEB-2,1% U-
MDS. Included 1% fibrotic and 2% hipoplastic MDS. According IPSS, patients
were classified as low risk: 43%, (median survival-MS-: 5 years), intermediate-
1:37% (MS: 3,2 years), intermediate-2:16% and high risk: 4% (MS:5, 3.2, 1
and 0.3 years respectively). According IPSS-R: low IPSS risk patients were
shifted to very low,low and intermediate risk (43%,53% and 4%. MS not
reached, 4.4 and 3.6 years respectively).Intermediate-1 patients spread into
very low(5%), low(54%),intermediate(31%), high, and very high risk (8% and
1%, MS:1 and 0.6 year). Intermediate-2 IPSS patients were classified into inter-
mediate (26%), high (46%) and very high(28%) risk.High risk IPSS patients
were staged in very high IPSS-R risk. The 3 and 5 year ROC survival curves
and AUC was better for the IPSS-R than the IPSS(p<0.001)but not at 1 year.
We studied 4 new variables at diagnosis to improve the survival prognostic
IPSS-R prediction. Ferritin and LDH serum levels, comorbidities (measured by
MDS-CI index)and previous RBC transfusión (at least two RBC in the 4 previ-
ous months).Univariate analisys not showed statistical significance for the
serum LDH.The multivariate analisys didn´t it for serum ferritin levels.Data
available for 327 patients for previous transfusion showed 46 individuals trans-
fused (14%).Risk stratification according MDS-CI: 339 patients: 41% low
risk,43% intermediate risk,16% high risk. The most frecuent observed comor-
bidities were: cardiac disease (35%), other tumour (15%) pulmonary (14%),
renal (9%), hepatic (2%). ROC curves and AUC at 1,3 and 5 years showed
better survival prediction power for IPSS-R if we added the two last variables
individually and increase if we add the two variables simultaneously(p<0.001).
Figure 1.
Summary/Conclusions: IPSS-R provides pronostic power for OS compared
to IPSS but not includes emerging relevant clinical events. Comorbidities exert
a negative impact in life expectancy on MDS patients.Intrinsic MDS characterys-
tics like anemia can worse patients sickness.Previous transfusion can reflect
more aggressive disease or late diagnosis.Late iron develop has a negative
impact in morbidity/mortality.Our study showed that adds the two variables
improve the IPSS-R prognostic power for OS and helps in clinical decisión mak-
ing.
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ANALYSIS OF P53 EXPRESSION BY IMMUNOHISTOCHEMISTRY AS AN
ADDITIONAL PROGNOSTIC TOOL IN PATIENTS WITH MYELODYSPLASTIC
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Background: Somatic mutations in TP53 have been shown to be associated
with aggressive disease, resistance to therapy and poor survival in many can-
cers including haematological neoplasms. The incidence of TP53 mutations in
Myelodysplastic Syndromes (MDS) is low (5-15%) compared to other malig-
nancies but may be associated with adverse outcomes. Consistent correlations
of up to 96% between TP53 mutation by conventional sequencing and demon-
stration of p53 expression by immunohistochemistry (IHC) has been demon-
strated by prior studies.
Aims: We assessed p53 expression by IHC on marrow trephine samples of
246 MDS patients to correlate the p53 expression with their clinical character-
istics and outcomes.
Methods: IHC for p53 expression on marrow trephines of 246 MDS patients
diagnosed between 2003 and 2014 in a single centre were analysed using DO-
7 monoclonal antibody. Clinical information and overall survival including trans-
formation to acute myeloid leukaemia (AML) were obtained from clinical notes
and patient information systems. P53 expression was determined by assessing
1000 haematopoietic cells under high magnification and scored using a Modi-
fied Quick Scoring System.
Results: Thirty nine patients (16%) were positive for p53 expression and 207
patients (84%) were negative. P53 positive patients showed greater degree of
peripheral cytopenias and higher marrow blasts. None of the patients with WHO
subgroups of RARS, RCMD-RS or MDS 5q syndromes were p53 positive. P53
expression was positive in 5% of RA, 5% of RCMD, 18% of RAEB-1, 8% of
RAEB-2 and 15% of MDS/MPN including CMML. P53 expression was signifi-
cantly higher (51%) in patients with t-MDS (N=39). P53 positive patients showed
a higher incidence of complex karyotype with ≥3 abnormalities (58%) and sin-
gle/double abnormalities (40%). Only 7% of p53 positive patients had a normal
karyotype. This is reflected by a higher proportion of patients with Int-2 and
high risk IPSS (57% vs 14%) and with high and very high IPSS-R (53% vs
14%) in p53 positive patients compared to p53 negative patients. The median
overall survival of p53 positive patients was 14 months compared to 33 months
in p53 negative patients (p=0.000). The rate of AML transformation was 16%
in p53 positive patients compared to 8% in p53 negative patients and the time
to development of AML from MDS was shorter in p53 positive patients (9 months
vs 20 months).
Figure 1.
Summary/Conclusions: Positive p53 expression of 16% in the MDS patients
in this study reflected the incidence of p53 mutation published by prior studies.
Positive p53 expression by IHC correlates with higher blast count, adverse
WHO subgroup, complex karyotype, higher IPSS and IPSS-R, poor overall sur-
vival and increased risk of AML transformation. Analysis of p53 expression by
IHC is a reproducible, rapid and inexpensive method and is a useful adjunctive
prognostic tool in clinical practice.
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A PROGNOSTIC SCORING MODEL FOR PATIENTS TREATED WITH
AZACITIDINE FOR MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID
LEUKEMIAS
K Sato1,*, J Inamura1, N Tsukada1, K Sato2, T Hosoki1
1Department of Hematology/Oncology, 2Department of Pathology, Asahikawa
Kosei Hospital, Asahikawa, Japan
Background: Azacitidine (AZA) is widely used in clinical practice for patients
with higher-risk myelodysplastic syndromes (MDS), as well as a proportion of
patients with acute myeloid leukemia (AML). However, the predictive factors of
a poor outcome in AZA-treated patients with MDS or AML have not been fully
evaluated.
Aims: To clarify the risk factors (RFs) for patient survival, we retrospectively
analyzed data of patients treated with AZA for MDS/AML.
Methods: We analyzed the clinical backgrounds, treatments, responses (hema-
tological improvement: HI), survival, and prognostic factors of 31 patients with
MDS/AML (MDS=24, AML with myelodysplasia-related changes=7) who were
treated with AZA at our institute from 2011 to 2015. Expression of p53 protein
in bone marrow cells (BMCs) was assessed immunohistochemically using a
monoclonal mouse anti-human p53 protein antibody (Clone DO-7); p53 protein
overexpression was defined as positivity in >50% of immunoreactive blasts.
Overall survival (OS) was estimated from AZA treatment initiation via Kaplan-
Meier analysis and compared with a log-rank test. RFs associated with OS
were evaluated using a univariate (chi-squared test) or multivariate analysis
(Cox proportional hazards model).
Results: The patients included 24 men and 7 women with a median age of 73
(range: 44-89) years. One, 10, 9, and 11 patients belonged to the low, intermediate
(int)-1, int-2, and high-risk International Prognostic Scoring System (IPSS) groups,
respectively; 2, 11, 6, and 12 belonged to the low, intermediate, high (H) or very
high (VH) revised IPSS (IPSS-R) groups, respectively. Complex karyotypes (CKs)
and p53 protein overexpression were observed in BMCs from 9 and 7 patients,
respectively. Patients received a median of 6 (range: 1-43) AZA cycles at a median
interval of 35 (range: 28-56) days. Eighteen (58%) patients exhibited HI, and 14
(45%) died from disease progression. The estimated 4-year OS of all patients
was 36.4%. RFs associated with OS in a univariate analysis were CKs
(p=0.0079), p53 protein overexpression in BMCs (p=0.0309), high C-reactive
protein level (p=0.0018), serum ferritin >500 ng/ml (p=0.0291), no HI (p=0.0018),
blood transfusion dependency (p=0.0039), and IPSS-R H/VH risk group
(p=0.0484). Multivariate analysis identified p53 protein overexpression in BMCs
(hazard ratio [HR]=10.2, p=0.0366) and serum ferritin >500 ng/ml (HR=10.1,
p=0.0113) as independent RFs for OS. Two OS risk groups were defined accord-
ing to scores from these risk factors: low risk (0) and high risk (1-2). The OS
curves of AZA-treated patients with MDS/AML were significantly stratified into 2
risk groups using our scoring model (p<0.0001, Figure 1).
Figure 1. Overall survival for patients with MDS/AML treated with azaciti-
dine according to our prognostic scoring model.
Summary/Conclusions: We demonstrated clear OS stratification of AZA-treat-
ed patients with MDS/AML into 2 risk groups according to our proposed scoring
model using two risk factors, p53 protein overexpression and hyperferritinemia.
Although further verification via prospective analysis is needed, these findings
may provide valuable information for prognostic predictions of AZA-treated
patients with MDS/AML.
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THE IMPORTANCE OF IMMUNOPHENOTYPING OF HEMOPOIETIC
PRECURSORS IN THE DIAGNOSIS OF CHILDHOOD MDS
I Lorand-Metze1,*, AF Oliveira2, A Tanzini3, LF Lopes2, K Metze4
1Internal Medicine, University of Campinas, Campinas, 2Pediatrics, 3Pathology,
Cancer Hospital Barretos, Barretos, 4Pathology, University of Campinas, Camp-
inas, Brazil
Background: immunophenotyping of BM hemopoietic precursors has been
recognized as useful ancillary technique to confirm the diagnosis of adult MDS.
In children, few data about its utility are available.
Aims: to analyze retrospectively the immunophenotypic features of bone mar-
row (BM) cells at diagnosis of patients registered in the Brazilian Pediatric
Cooperative Group of Myelodysplastic Syndromes (2012-2015).
Methods: diagnosis of the patients was based on clinical data, peripheral blood
(PB) counts, BM cytology and histology and cytogenetics. Deficiency anemias,
autoimmune diseases and viral infections were excluded, as well as patients
with Down’s syndrome. Classification was made by the WHO Pediatric Classi-
fication. Four pediatric deficiency anemias were used as controls. Immunophe-
notyping was made by an 8 color platform to evaluate myelomonocytic matu-
ration and progenitor populations according to the recommendations of the
European LeukemiaNet.
Results: 32 patients (RCC=6 cases; RAEB/-t=13 cases; JMML=13 cases) and
4 controls (deficiency anemias) were analyzed. Median age: controls=20
months, RCC=66 months, RAEB/-t=68 months and JMML=29 months. The
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median number of abnormalities in myeloid maturation was 1.5 (0-4); 3 (0-6)
and 3 (1-5) respectively. The median number of abnormalities in CD34+ cells
were 2 (1-3); 2.5 (1-6) and 3 (1-5) respectively. So, the total number of pheno-
typic alterations was 4 (1-6); 3 (2-11) and 6 (2-9) respectively. The percentage
of CD34+/CD117+/CD13+ cells was 0.5% (0.1-2.8); 3.7% (0.5-8.6) and 4.2%
(0.3-10.1) respectively, compared to 1.1% (0.7-1.6) of the control cases. Aber-
rant cross-lineage antigen expressions in myeloid progenitors were found in
63% of the cases of JMML, in 45% of RAEB/RAEB-t but in none of the RCCs.
Hematogones type I (CD34+/CD19+/CD10+) were decreased in all groups:
0.28% (0-2.4); 0.5% (0-6.4) and 0.03% (0-0.6) respectively, compared with the
controls: 2.1% (0.9-3.2). The same occurred in%CD34- /CD19+/CD10+ cells:
1.6% (0-15.5); 0.8% (0-6.2) and 0.02% (0.-2.1) respectively, compared with
the controls: 12.0 (3.9-12.9). T lymphocytes were markedly decreased only in
patients with JMML. In a discriminant analysis, a model containing age of the
patient, percentage of CD34+/CD117+/CD13+ cells, hematogones type I, T lym-
phocytes and total number of phenotypic alterations were able to classify cor-
rectly 81% of the patients.
Summary/Conclusions: in childhood MDS, alterations in myeloid precursors
and CD34+ myeloid progenitors presented similar changes as in adult MDS.
However, the alterations in B cell precursors and T lymphocytes were more
pronounced, even in very young children. Phenotypic abnormalities in JMML
were more similar to those of RAEB, regardless of the number of BM blasts
counted in cytology or any feature of PB counts.
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FAVORABLE OUTCOMES WITH TUMOR BURDEN REDUCTION WITH
HYPOMETHYLATING AGENTS BEFORE ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLNATATION FOR PATIENTS WITH HIGHER RISK
MYELODYSPLASTIC SYNDROME
SW Park1,*, JY Kim2, YJ Lee2, SK Sohn2, JS Ahn3, HJ Kim3, HJ Shin4,
WS Lee5, SM Lee5, YD Joo6, H Kim7, HS Lee8, YS Kim8, YY Cho9, JH Moon2
1hemato-oncology, Busan National University Hospital, Busan, 2Kyungbook
University hospital, Daegu, 3Chonnam National University Hwasun Hospital,
Hwasun, 4Busan National University Hospital, 5Inje University Busan Baik Hos-
pital, 6Inje University Haewoondae Baik Hospital, Busan, 7Ulsan University
Hospital, Ulsan, 8Kosin University Gosper Hospital, Busan, 9Daegu Catholic
University Medical Center, Daegu, Korea, Republic Of
Background: The use of hypomythylating agents (HMA) have improved the
outcomes of myelodysplastic syndrome (MDS) in terms of hematologic
improvement and long-term survival. HMA treatment while awaiting allogeneic
hematopoietic cell transplantation (allo-HCT) or as a purpose of cytoreduction
for higher risk MDS can be an attractive option with the hope of successful
cytoreduction before allo-SCT. However, the role of induction response or
cytoreduction for the patients with higher risk myelodysplastic syndrome (MDS)
is not yet clearly defined.
Aims: In this sutdy, the clinical significance of tumor burden and transition of IPSS
risk group for transplant eligible patients with higher risk MDS were evaluated.
Methods: The data of 79 transplant eligible patients (<65 years old) diagnosed
with higher-risk MDS from Jan 1992 to Mar 2013 and received HMA as frontline
therapy were retrospectively analyzed. To evaluate the effects of the tumor
burden on treatment outcomes, treatment response (responder vs non-respon-
der), IPSS risk group after HMA treatment, transition of IPSS risk group, and
blast percentage in bone marrow after HMA treatment were evaluated.
Results: Among 79 patients, 30 patients (38.0%) performed allo-HCT (HCT
group) and 49 patiens (62.0%) treated with HMA without allo-HCT (non-HCT
group). Median follow-up duration was 778 days (range 143-2921 days) and
375 days (range 7-6561 days) in HCT group and non-HCT group, respectively
(p=0.001). Three-year overall survival (OS) rate was significantly higher with
HCT group (47.0±12.1%) than non-HCT group (19.6±7.0%, p<0.001), which
confirmes the the role of allo-HCT for patients with higher risk MDS. For HCT
group, the short duration until allo-HCT showed a better outcomes as regards
OS (p=0.035). In the multivariage analysis, blast percentage ≥10% in bone
marrow (HR 2.569, 95% CI 1.116-5.916, p=0.027) and IPSS higher risk prior
to allo-HCT (HR 5.371, 95% CI 1.886-15.291, p=0.002) were found to be sig-
nificantly correlated with the OS. However, IPSS transition did not affect the
long-term outcomes (HR 0.703, 95% CI 0.079-6.285, p=0.752).
Summary/Conclusions: To predict the clinical outcomes of patients with high-
er risk MDS, the optimal time for tumor burden evaluation is prior to allo-HCT
than at the time of initial diagnosis. For those with lower blasts in the BM or
lower IPSS risk group were related with favorable OS. However, as early per-
formance of allo-HCT was associated with favorable OS and IPSS transition
did not affect the OS, it may not be resonable to delay allo-HCT to achieve bet-
ter response to HMA for those who are planning to allo-HCT.
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DISCONTINUATION OF HYPOMETHYLATING AGENT, DOES IT BRING
REDUCED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED
MYELODYSPLASTIC SYNDROME?
HS Lee1,*, YS Kim1, JH Moon2, HJ Kim3, JW Cheong4, DY Jo5, H Kim6,
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6Internal medicine, University of Ulsan College of Medicine, Ulsan, 7Internal
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11Internal medicine, Konkuk University Medical Center, Seoul, 12Internal med-
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Background: The myelodysplastic syndromes (MDSs) are a heterogeneous
collection of clonal hematopoietic malignancies that primarily affect the elderly
and are characterized by bone marrow failure, dysplasia. In previous study,
prolonged treatment duration could have contributed to survival benefit.
Although treatment with HMA undoubtedly prolongs survival in patients who
have poor prognosis, there are still a significant proportion of patients with
MDS who do not respond to therapy with HMA and patients who lose response
or progress on therapy. However, in clinical practice, it is difficult to continue
treatment of HMA because of problems such as toxicities, poor economics,
comorbidities and compliance etc. For those reasons, discontinuation of HMA
before disease progression often happen in clinical setting.
Aims: So there are some questions about survival in MDS patients treated
with HMA in real clinical practice. Are there any differences of survival in patients
with MDS received HMA between treatment failure and discontinuation of HMA
?. And what factors will be helpful to predict survival in both patients group ?.
Methods: The medical records of 246 patients were collected retrospectively
from fourteen university hospitals in South Korea between January 2001 and
October 2013. All included patients had been newly diagnosed to MDS and
they were treated with HMA as front line therapy and they were treated contin-
uously at least 4 cycles. Patients divided two groups into treatment failure
group who discontinued HMA treatment due to disease progression and dis-
continuation of HMA group who stopped HMA treatment because of other cause
without disease progression. The treatment free survival (TFS) was defined
duration from the end date of HMA therapy to the date of disease progression,
relapse, or death from any causes.
Results: The median age of the patients was 68 years. (range 24-92 years)
and the male to female ratio was 1.9:1.0. The percentage of lower than 5% of
bone marrow myeloblast was 37.9% in treatment failure group, 62.1% in dis-
continuation group (p=0.015). Patients who found lower risk IPSS or WPSS
were documented in discontinuation group more than those in treatment failure
group (p=0.050 or 0.005). The median TFS was 4.7 months (range 2.4-7.0)
and the median OS was 34.8 months (range 28.4-41.2). In multivariate analysis,
treatment failure of HMA is independent risk factor for shorter TFS (RR:5.996,
95% C.I. 3.684-9.757, p<0.001). Age of more than 65 years, bone marrow
myeloblast of more than 5%, poor cytogenetics, platelet counts of less than 50
x 103/uL, higher risk of WPSS and IPSS-R, median number of HMA cycles of
less than 7 cycles and treatment failure of HMA were independent risk factors
for shorter OS. Especially, The 3-year TFS and OS were 0.0% vs 40.7%,
(p<0.001) and 29.7% vs 60.2% (p<0.001) in treatment failure group vs discon-
tinuation of HMA group, respectively. However, in univariate and multivariate
analysis, higher risk of WPSS was independent risk factor for shorter TFS and
higher risk of WPSS and median number of HMA of less than 7 cycles were
independent risk factors for shorter OS in only discontinuation of HMA group.
Figure 1.
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Summary/Conclusions: Patients who discontinued HMA without disease pro-
gression showed prolonged survival than those who failed HMA treatment in
real clinical practice. Especially, lower risk of WPSS and more number of per-
formed cycles of HMA may be helpful to predict TFS and OS in patients who
discontinued HMA because of other causes such as toxicities, economics or
compliance etc.
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HETEROGENEITY IN CYTOGENETIC AND CLINICAL FEATURES OF
PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q
G Papaioannou, A Athanasiadou, E Gavriilaki*, Z Bousiou, M Iskas,
M Papathanasiou, N Stavroyianni, I Sakellari, A Anagnostopoulos
Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece
Background: Deletion 5q [del(5q)] represents a distinct cytogenetic abnormal-
ity in patients with myelodysplastic syndrome (MDS). Although isolated del5q
has been linked with favorable prognosis, the role of additional cytogenetic
aberrations has not been clearly defined yet.
Aims: We aimed to study patients with MDS del (5q) in terms of cytogenetic
and clinical features, as well as treatment outcomes.
Methods: We retrospectively analyzed data from 408 patients (pts) diagnosed
with MDS and partial or complete deletion of the long arm of chromosome 5 in
our centre from 2007 to 2014. All patients were studied by karyotyping and
received standard of care by their treating physicians.
Results: Among 408 MDS pts, del(5q) was detected in 32 (7.8%). Isolated del5q
was found in 7/32 (21%). Additional cytogenetic abnormalities were detected in
25/32 pts: chromosomal translocations of 1q, 11q and 20q and deletion of chro-
mosomes 7, 17 and 18. Clinical data were available for 20/32 pts: 17 males: 3
females with a median age of 69.7 at diagnosis. MDS was de novo in 15 pts,
post polycythemia vera in 2 pts and treatment-related in 3 pts (post chemother-
apy±autologous transplant for Hogdkin lymphoma in 2 pts and for multiple myelo-
ma in 1 pt). At diagnosis, median bone marrow blasts were 6% (range 0-19%).
In the peripheral blood, median Hb levels were 8.7g/dl (8-11.7), white blood cell
count 4.2K/μl (1.85-2.65) and platelets 131K/μL (26-330). No evidence of throm-
bocytocis was found. Cytogenetics revealed del(5q) as an isolated abnormality
in 3/20 (15%) pts and additional abnormalities in the rest 17/20 (85%) pts.
Patients with an isolated del (5q) presented no disease progression and 2/3 are
alive in complete remission. One patient with isolated del (5q) succumbed from
other causes. According to the IPSS (International Prognostic Scoring System),
6/20 (30%) pts were diagnosed as low and intermediate-1 risk; whereas, 6 pts
were classified as intermediate -2 and 8 pts as high-risk. Lenalidomide treatment
was initiated in 4 pts among which, 3 had additional cytogenetic abnormalities
and classified as intermediate -1 (2 pts) and intermediate -2 (1 pt) risk. Median
overall survival in pts treated with lenalidomide was 28 months (3-32) compared
to 10 months (1-2) in pts not treated with lenalidomide. Other treatment options
were: azacytidine (5 pts classified as high and 2 as intermediate -2 risk), ery-
thropoietin (2 pts classified as intermediate -1 risk), low dose cytarabine (2 pts
classified as intermediate -2 and high risk int-2) and hydroxyurea (1 pt classified
as high risk). Allogeneic hematopoietic cell transplantation was performed in
two pts with intermediate -2 risk according to IPSS.
Summary/Conclusions: Our study confirms that del(5q) as an isolated cyto-
genetic abnormality is rather rare in patients with MDS compared to del(5q)
additional cytogenetic aberrations. Although the majority of additional cytoge-
netic abnormalities have been traditionally considered non high-risk, our find-
ings link additional cytogenetic abnormalities with higher risk stratification and
worse clinical outcomes.
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VALUE OF THE MULTIPARAMETRIC FLOW CYTOMETRY IN LOW RISK
MYELODYSPLASTIC SYNDROMES AND TYPE I CHRONIC MYELOMONOCYTIC
LEUKEMIA
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Background: Heterogeneity in Low Risk Myelodysplastic Syndromes (MDS)
and Type I Chronic Myelomonocytic Leukemia (CMML) is very remarkable and
demands a maximum expertise to establish the diagnosis and prognosis. Mul-
tiparametric Flow Cytometry (MFC) should allow physicians to systematize and
standardize this assessment.
Aims: To analyze, by using MFC, the value of the immunophenotypic changes
in Low Risk MDS and type I CMML patients.
Methods: This retrospective study included low risk MDS and type I CMML
adult patients (pts) at diagnosis, and used FAB, WHO, and IPSS classifications.
An eight-color MFC and a specific MDS panel validated by Euroflow with Infini-
cyt® program were applied. Granulocytic maturation is classified into 3 groups
according to precise stops or blocking maturation observed in myeloblasts (Mbl)
(stage 1), in promyelocytes (Pro) and metamyelocytes (MT) (stage 2), and with-
out any blocking or Neutrophil (N) (stage 3):
             Stage 1 (Mbl)                     Stage 2 (Pro+MT)                 Stage 3 (N)
  >3,5% or >2,8% + >Stage 2         >48% with < stage I        >58,5% with < stage 2
Blasts (CD34), erythroid, monocyte (Mo), and mast cells count (≥0,04), aber-
rance and blocking maturation were taken into account. Peripheral cytopenia,
cytogenetic, AML progression, and mortality rate were also studied. Informed
consent was obtained.
Results: Sixty-six pts with low risk primary MDS (n=49) and CMML (n=17)
were assessed. Median age 71 (R 21-89), male/female gender: 37/29, WHO
classification: RCMDRS (1), RCMD (37), 5q- (2), RARS (1), RA (4), RAEB-1
(5) and type I CMML (17). AML progression: 15%; mortality rate: 30%, and
causes of death: infections (35%), AML (40%), comorbidities (20%) and sec-
ond tumor (5%). Sixty-two pts were evaluable for blocking granulocytic matu-
ration and were divided into 3 groups: stage 1 (20), stage 2 (16) and stage 3
(26). Stage 1: (20 pts), 31.3% (CD34+ 1.92; range: 0.14-6.59), overall survival:
34 months (median), p=0,001 and, stage 2 and 3 were p=ns. Progression to
AML was similar among all groups (p=ns). CMML patients had an increased
blocking maturation in promonocyte stage (p=0,05), but not showed difference
in mature monocytes (p=ns). Excluding CMML pts, we found that immature
monocyte group (<56%) was significantly associated with thrombocytopenia
(p=0,038), without any incidence over other cytopenia and cytogenetic abnor-
malities (p=ns). The overall survival was decreased with mast cells count ≥0.04
(with a median of 34 months; p=0.04), independently of the staging maturation
group. Erythroid Aberrancies did not show higher transfusion requirement rate
(p=0,5).
Summary/Conclusions: MFC in low risk MDS and type I CMML proved to be
objective and reproducible by standards. Immature monocyte in MDS group
correlated with thrombocytopenia (p=0,038). Short overall survival was asso-
ciated with high mast cells count (p=0.04) and early granulocyte stages blocking
maturation (p=0,001).
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СLINICAL AND HEMATOLOGICAL FEATURES OF PRIMARY MYELODYSPLASTIC
SYNDROMES IN ADULTS AND CHILDREN
N Klimkovich1,*, O Krasko2
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Background: Myelodysplastic syndromes (MDS) are included into a hetero-
geneous group of clonal blood diseases characterized by peripheral cytopenias,
dysplastic features of hematopoietic precursors, progressive deterioration and
a high risk of transformation into leukemia. MDS occur in several versions that
differ in frequency of appearance, the duration of the course and the probability
of transformation into acute leukemia. There are differences in the structure of
MDS variants in patients of different age. This is the basis for the discussion of
clinical and hematological characteristics of primary MDS and systematization
of the results.
Aims: Analysis of the clinical and laboratory characteristics of patients with pri-
mary MDS, depending on age.
Methods: The study included 162 (144 adults and 18 children) with primary
MDS patients aged from 1.5 to 60 years (median age 49 years, adults, children
- 8 years). The material of the study were clinical and medical history, peripheral
blood (PC) and bone marrow (BM). Clinical criteria for inclusion of patients in
the study: a verified diagnosis of MDS, setting variant of the disease in accor-
dance with the criteria of the WHO classification of myeloid neoplasms (2008),
written informed consent for inclusion in the study. The calculations are per-
formed in the R version 3.1.3 statistical package.
Results: Primary MDS have a features of clinical - hematological manifestations
in the age groups under 18 years, 18-39 years and 40-60 years, with the result
that appears different variants of structure (p=0.028) and by IPSS risk cate-
gories (p=0.001). IPSS demonstrates a high prognostic significance in adult
patients (p<0.001), in contrast to pediatric MDS (p=0.110). Most cases of MDS
in children have been the normocytic anemia (MCV 86,5 (73... 103) fl). While
MDS for adults, irrespective of age, a feature of dysplasia is macrocytosis (MCV
101,5 (83.. 123) fl), p<0.001. In children occur the hypocellularity BM in 22.2%.
Adult patients have this characteristic in 2.8% of the age group of 18-39 years
and there is no group in the 40-60 years of age (p<0.001). Erythroid hyperplasia
BM and availability of microforms megakaryocytes BM are frequent signs of
MDS in adults (72.2% and 94.4% in the age group 18-39 years, 62% and 92.6%
in the age group 40-60 years, respectively). In children occur this feature only
22.2% and 66.7% of cases (p<0,001 and p= 0.002, respectively). Many young
granulocytes in BM biopsy (p=0.022) and BM stroma fibrosis (p=0.036) more
common in MDS in the age group 40-60 years compared to patients under 18
years and 18-39 years. A normal karyotype was detected in 71.8% of adults
and 77.8% of children with MDS. In adult patients with MDS with increasing
age decreases the frequency of normal karyotype with an increase in the num-
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ber of unbalanced and complex aberrations. Children with MDS were observed
with the same frequency the isolated and complex cytogenetic damage.
Summary/Conclusions: Patients with MDS of different age groups (children
18-40 years and 40-60 years) have variable manifestations of MDS, which is
determined by the structure of variants, frequency of cytogenetic and dysplastic
abnormalities BM cells, the intensity of the progression. Childhood MDS is a
separate group of disease with features of clinical and hematological manifes-
tations different from adults, which makes the feasibility of its version in the
classification.
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IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC
SYNDROME (MDS) BY FLOW CYTOMETRY?
E Atilla1,*, P Ataca Atilla1, O Turedi2, S Civriz Bozdag1, S Kocak Toprak1,
H Akan1, M Beksac1, O Arslan1, P Topcuoglu1, M Ozcan1, O Ilhan1, HI Ruhi2,
G Gurman1, K Dalva1
1Ankara University School of Medicine Department of Hematology, 2Ankara
University School of Medicine Department of Genetics, Ankara, Turkey
Background: World Health Organization (WHO) classifies myelodysplastic
syndromes due to patolological hallmark of marrow dysplasia. Flow cytometry
immunophenotyping has a crucial role in diagnosis and management of hema-
tological malignancies. Ogata et al. demostrated a simple flow cytometry (FCM)
score which helped to establish the diagnosis of MDS in patients without spe-
cific markers of marrow dysplasia.
Aims: Our aim in this study is to evaluate the patients who had biopsied for
diagnosis of MDS in 2015, confirm with pathology and restage them with FCM-
score at Ankara University School of Medicine Department of Hematology.
Methods:: From 386 patients presented with cytopenias, 78 (20%) was mor-
phologically diagnosed with MDS. Four parameters were combined in a regres-
sion model in FCM score; increased myeloblast-related cluster size, decreased
B-progenitor related cluster size, aberrant CD45 expression and reduced gran-
ulocyte side scatter. All MDS diagnosed patients were reevaluated with FCM
score. The diagnosis of MDS was formulated in the case that the value of the
FCM-score was 2 or more. Chi-squared test was used for categorical vari-
ables.
Results: Median age of 78 patients was 62 (range, 18-90), 49 (62%) of them
was male. Patient characteristics were shown in table. Totally 44 patients (56%)
from 78 patients had FCM-score 2 or more. Patients with MDS without specific
markers of marrow dysplasia (such as ring sideroblasts and/or clonal chromo-
somal abnormalities) were 34% of FCM score positive population. In MDS
patients high FCM score (3 or 4) was found to be significantly associated with
transfusion dependency (P=0.021) and resulting in higher WPSS risk
(P=0.002).
Table 1.
Summary/Conclusions: FCM score can be a new tool for low risk MDS
patients without specific markers of marrow dysplasia.
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CLINICAL CHARACTERISTICS OF PATIENTS WITH MYELOID NEOPLASMS
FROM REGIONS CONTAMINATED BY DEPLETED URANIUM: 20 YEAR
ANALYSIS
A Kozaric1,*, L Mehinovic1, S Kurtovic2, A Dizdarevic2
1Pathology, Cytology and Human Genetics, 2Hematology, Clinical Center of
The University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Background: Depleted uranium (DU), a radioactive heavy metal, is used in
military ammunition. It emits alpha particles and has the half life of 4.5 billion
years. Studies have shown the potential health risks of contamination by DU by
wounding, ingestion, and inhalation. In vivo and in vitro experiments showed
the carcinogenic potential of DU by neoplastic transformation of human and
mouse cells, leading to the development of myeloid neoplasms. It is assumed
that the DU exposure induces genomic stability leading to carcinogenesis. Dur-
ing the war in Bosnia, DU ammunition was used in several towns, including the
town of Hadzici. United Nations have measured the concentrations of depleted
uranium and showed a significant increase in the municipality of Hadzici.
Aims: Increased numbers of patients with blood cancers was observed by
hematologists in DU-stricken area, so we systematically analyzed hematolog-
ical patients from this region in the last 20 years, from 01.01.1996.-31.12.2015. 
Methods: Two regions were analyzed: DU stricken and a control region. As a
control region, patients from a town with the same population number were
used. Patient data from 01.01.1996.-31.12.2015 was collected including age at
diagnosis, sex, address, blood parameters, cytogenetics, therapy, and survival.
Results: In the 20 year analyzed period from 01.01.1996–31.12.2015, we
found 717 patients with hematological conditions (437 from DU-stricken town
vs 280 from control town). There were 74 patients with myeloid malignancies
(54 vs 20), 55 patients with non Hodgkin lymphoma (26 vs 29), 21 patients
with Hodgkin lymphoma (9 vs 12), and 6 patients with ALL (4 vs 2). Among the
myeloid neoplasms, MDS showed a 6 fold change. The median age at diag-
nosis for MDS patients was 50 vs 65. Male to female ratio was MDS 0.5 vs 1.
Median age at diagnosis was 50 in DU-stricken area vs 65 in control region.
Patients from the DU area showed the trends towards higher IPSS-R score
(50% of patients had intermediate and 17% had very high score) compared to
the control and international data. 
Summary/Conclusions: Clinical parameters showed more severe course of
myeloid malignancies in DU stricken area compared to the control and inter-
natinal data. Further investigation is needed to elucidate the possible causes
of stark increase in myeloid neoplasms in DU stricken area.
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CLINICAL AND LABORATORIAL CHARACTERISTICS OF A COHORT OF
PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ERYTHROID
HYPERPLASIA
Y Yu, A Sun*, S Chen, Q Wang, T Zhang, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Myelodysplastic syndrome (MDS) is a clonal disease of
hematopoietic stem cells, which is a clinically and biologically heterogeneous
group of disorders associated with ineffective hematopoiesis, abnormal differ-
entiation, and cytopenias. Approximately one third of MDS patients progress
to secondary acute myeloid leukemia (sAML). Erythroid hyperplasia is very
common in MDS patients, the proportion of erythroid was frequently more than
thirty percent,even fifty percent, compared to ten percent to forty percent in
normal bone marrow. The Erythroid hyperplasia is characterized with relatively
or absolutely increase in the number of erythroid precursor cells, erythroid
maturity curve shifts to the left, increase in early/late erythrocyte ratio, propa-
gation of erythroid blasts and erythroid precursor cells. Erythroid hyperplasia
is an important characteristic of MDS, however, there is still a lack of a related
study of erythroid hyperplasia’s significance in MDS.
Aims: To investigate the clinical and laboratorial characteristics of patients with
myelodysplastic Syndrome (MDS) and erythroid hyperplasia.
Methods: We defined MDS patients whose bone marrow was hypercellular,
the proportion of erythroid was more than fifty percent, and the ratio of mature
erythrocytes and nucleated erythrocytes was no more than 20 as MDS patients
with erythroid hyperplasia.(MDS-E). The retrospective analysis comprised 102
patients with MDS-E from the first affiliated hospital of Suzhou university. We
analyzed their clinical characteristics, karyotype, and the effect of erythroid
hyperplasia on their prognosis. 
Results: 48 of 102(47%)MDS-E patients had a variety of cytogenetic abnor-
malities. The most frequent involved chromosomes were chromosomes
8(39.5% of all abnormal karyotypes), chromosomes 7(23%), followed by chro-
mosomes 1(16.7%) and 20(16.7%). Survival analysis showed that the level of
hemoglobin make a influence on prognosis. The overall survival(OS) of MDS-
E patients with the level of hemoglobin more than 70 g/L was longer than that
of patients whose hemoglobin concentration was less than 70 g/L(P<0.001).
Hematopoietic stem cell transplantation (HSCT) could improve OS of MDS-E
patients(P<0.001). In the chemotherapy group, MDS-E patients receiving
chemotherapy including Decitabine had superior OS over those who were not
treated with Decitabine.(P=0.014).
Summary/Conclusions: MDS-E patients have their own unique biological
features compared with other MDS patients. The level of hemoglobin concen-
tration and erythroid hyperplasia in bone marrow can affect MDS-E patients’
prognosis. The using of Decitabine in chemotherapy and HSCT can improve
OS of MDS-E patients.
506 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
E1230
TP53 GENE MUTATIONS IMPACT ON OVERALL SURVIVAL OF PATIENTS
TREATED WITH LOW-DOSE CLOFARABINE AS A SECOND LINE THERAPY
DUE TO THEIR RESISTANCE TO AZACITIDINE
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A Stamatoullas5, F Dreyfus6, B Samey7, L Ades7, N Vey4, H Dombret3,
C Preudhomme2, P Fenaux7, C Gardin1
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Henri Becquerel, Rouen, 6Cochin Hospital University Paris V, 7Hematology
Seniors, Saint Louis Hospital University Paris VII, Paris, France
Background: Patients with higher risk Myelodysplastic Syndromes (IPSS-INT2
and High; HR-MDS) failing treatment with hypomethylating agents (azacitidine
and decitabine; HMA) have a very poor outcome with a median survival of 5
months. No standard treatment is defined in this setting. We have recently con-
ducted a dose escalation trial of clofarabine, at a starting daily dose of 5 mg/m2,
among patients with HR-MDS or AML evolving from MDS if failing prior azaci-
tidine therapy (NCT01063257; Braun et al., ASH 2011). Among MDS/AML asso-
ciated mutations, TP53 gene mutations confer a poor patients overall survival
and a short response duration to HMA (Takahashi et al., Oncotarget 2016).
Aims: We analyzed these MDS/AML mutations in respect to drug response
and overall survival in this second line therapy trial.
Methods: Twenty-seven patients with a median age of 71 years (62-90) were
included after informed consent from December 2009 to July 2012. All were
due to receive clofarabine at a dose ranging from 5 to 10/m2 either for 5 con-
secutive days or 5 doses over 10 days, for a maximum of 8 cycles. All study
patients were analyzed by next generation sequencing for evidence of muta-
tions in the following genes: TET2, ASXL1, RUNX1, DNMT3a, TP53, IDH1/2,
NRAS/KRAS, CBL, ETV6, EZH2, FLT3-ITD, NPM, JAK2, MPL515, PTPN11,
SETBP1, SF3B1, SRSF2, U2AF1 and ZRSR2. Gene mutations identified by
NGS were checked by Sanger sequencing if necessary.
Results: Twenty patients (74%) had HR-MDS including 1 patient with Chronic
Myelomonocytic Leukemia-2 and 7 (26%) patients had AML evolving from MDS
(16F/11M). Fifteen (56%) patients had adverse karyotype including 9 patients
with complex cytogenetics. Among 8 (29%) patients, a TP53 mutation could be
detected, which was isolated in 4 cases and associated with a complex kary-
otype in 7/8 cases. Distribution of the other gene mutations detected in this
cohort were as follows: ASXL1 (26%), DNMT3a (22%), RUNX1 (15%), TET2
(15%), SRSF2 (15%), U2AF1 (11%), SF3B1 (11%), EZH2 (7%), IDH2 (7%),
ETV6 (7%), NRAS (3.5%), ZRSR2 (3.5%), FLT3-ITD (3.5%), PTPN11 (3.5%)
and SETBP1 (3.5%). Four (15%) patients had no gene mutation detected, 8
(29%) patients had 2 and 6 (22%) patients had at least 3 or more mutations
detected. Only the detection of TP53 mutations had a significant impact on
overall survival with a median survival of 4.7 versus 8.4 months of TP53 mutated
patients and unmutated patients respectively (p=0.0022). The two other most
frequent mutations of the ASXL1 and DNMT3a genes in this population, did no
impact overall survival even among patients unmutated for TP53. As expected,
adverse karyotype was significantly associated with shorter overall survival (8
months versus 4.4 months; p=0.017). When excluding patiens with TP53 muta-
tions, survival of patients with unfavorable cytogenetics was not significantly
shorter when compared to patients with intermediate or favorable cytogenetics
(7.2 months versus 10.9 months; p=0.31). Eight (32%) of 25 patients evaluable
for response achieved response according to IWG 2006 criteria after 1 or 2
cycles of clofarabine (1 CR, 4 mCR+HI, 2 mCR and 1 HI) and 10 (40%) patients
had stable disease. Overall survival was 11.1 months (CI 0.68-3.9) versus 6.7
months (CI 0.25-1.46) in responders and non-responders to clofarabine respec-
tively (p=0.18). In this phase I low-dose clofarabine trial, TP53 mutations were
detected among 7/19 non-responders and 1/8 responding patients (p=0.36) to
clofarabine. Interestingly, 6 of the 8 patients mutated for TP53 had obtained a
prior response to azacitidine before relapse. Mutations of ASXL1 (p=0.63) and
DNMT3a (p=1) had no impact on response to clofarabine.
Summary/Conclusions: Presence of TP53 mutations, detected here in about
50% of patients with an unfavorable karyotype, appears to be the most powerful
adverse prognostic factor for overall survival in this MDS/AML population select-
ed by its resistance to azacitidine.
E1231
REPORT ON OUTCOME OF HYPOMETHYLATING THERAPY WITH ANALYSIS
ON PROGNOSTIC VALUE OF REVISED-INTERNATIONAL PROGNOSTIC
SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
OF LOWER-RISK BASED ON IPSS
Y Lee1, J Moon2, J Yoon1, J Kim1,*, S Sohn1
1Hematology, Kyungpook National University Hospital, 2Hematology, Kyung-
pook national university of hospital, Daegu, Korea, Republic Of
Background: The outcome of patients with lower risk myelodysplastic syn-
dromes (LR-MDS) by International Prognostic Scoring System (IPSS) is very
various and sometimes poorer than expected.
Aims: We retrospectively evaluated the prognostic value of revised-Interna-
tional Prognostic Scoring System (IPSS-R) in accordance with Hypomethylating
therapy (HMT) response for precise prognostication.
Methods: The treatment outcome of 236 patients with IPSS LR-MDS who
received HMT in the Korean MDS Working Party was retrospectively evaluated.
The patients were reclassified to very low/low (VL/L), intermediate (INT), and
high (H) risk groups by IPSS-R.
Results: According to the HMT response, 3 year overall survival (OS) did not
differ between response group (43.4±0.8%) and stable group (Fig 1. 53.6±0.6%,
p=0. 672). Although 25 patients (38.4%) out of 65 responders had a benefit to
continued HMT with a median 14 cycles, H risk group was only 2 patients.
Among 27 patients (41.5%) progressed to secondary failure, H risk group was
most common. Indeed, 42 patients (20.8%) out of 236 patients with LR-MDS
had changed to H risk group based on IPSS-R. Median OS was 63.8 months
(range, 32.6-95 months) in VL/L, 35 months (range, 24.2-45.9 months) in INT,
and 22.3 months (range, 16.6-27.9 months) in H risk group, respectively (Fig-
2. p<0.001). Transformation to AML was 8 patients (8.8%) in VL/L, 12 (12.7%)
in INT, and 10 (23.8%) in H risk group (p=0.049). On multivariate analysis, the
following factors were associated with survival: age ≥65 (HR= 1.731, p=0.023),
ECOG ≥2 (HR= 4.997, p<0.001), H risk group by IPSS-R (HR=3.054, 95%
CI=1.714-5.441, p<0.001), blast ≥5% (HR= 2.070, p=0.035), P/VP cytogenetic
risk by IPSS-R (HR= 4.501, p=0.006) and transformation to AML (HR=2.208,
p=0.007).
Figure 1.
Summary/Conclusions: If patients with LR-MDS are included in the H risk by
IPSS-R, they should be considered early allo-HCT regardless of current benefits
from HMT. Prospective study will be needed to establish the therapeutic strate-
gies in MDS patients with Low-risk by IPSS including optimal timing of allo-
geneic transplantation and the continuing HMT.
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SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING
AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND
CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS 
J Davila Valls1,*, M Sanchez Barba2, M Lopez Pavia1, E Such1, T Bernal1,
E Luño1, F Ramos1, M Calabuig1, H Pomares1, B Gonzalez1, B Merchan1,
E Barranco1, R Sancho Tello1, M Callejas1, MJ Requena1, MJ Jimenez1,
M Pedreño1, A Medina1, AI Vicente1, A Campeny1, M Cortes Sansa1, C Pedro1,
JF Falantes1, MJ Arilla1, A Barez1, R Garcia1, MJ Arcos1, V Gomez1, C Muñoz1,
C Cervero1, J Casaño1, R de Paz1, L Amigo1, A Insunza1, JA Muñoz1,
MT Cedena1, M Gomez1, P Font1, R del Campo1, C Fernandez Lago1,
JA Gonzalez Hurtado1, MD Linares Latorre1, A Mora Casado1, M Vahi1,
L Benlloch3, GF Sanz1, MC Del Cañizo Fernandez-Roldan1, M Diez Campelo1
1GESMD, Valencia, 2Departamento de Estadística, Universidad de Salamanca,
Salamanca, 3Hospital Universitario de La Fe, Valencia, Spain
Background: Myelodisplastic syndromes (MDS) are heterogeneous diseases
in old patients. These patients show very often comorbidities that could
decrease the overall survival and the quality of life. Erythropoietic-stimulating
agents (ESAs) are the most used treatment for low risk MDS with anemia and
are available in almost all centers from the smallest ones to the big reference
centers. The impact of the presence of comorbidities and the size of center
where the treatment is administered on treatment response has not been still
analyzed.
Aims: The main endpoint was to evaluate the impact of comorbidities on the
response to ESAs treatment. The secondary endpoint was to evaluate if the
size of the hospital where this treatment is administered influences on it. 
Methods: Data from 530 patients with low or intermediate-1 risk MDS (accord-
ing to FAB and WHO criteria) who received treatments with ESAs were recorded
in SPRESAS. 458 of these patients had data available at diagnosis of MDS
regarding comorbidities. These were classified as relevant (diabetes mellitus,
atrial fibrillation, thromboembolic disease and renal impairement) and less rel-
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evant (arterial hypertension, others). Data from the size of the center where
the treatment was administered were available in all the patients. Centers were
distributed in levels according to the number of beds available: centers above
1000 beds were considered “level 1” centers, between 500 and 1000 as “level
2” and below 500 beds as “level 3”. Response was evaluated according IWG
2006 criteria.
Results: 370 patients (80.8%) had at least one comorbidity, but when only rel-
evant comorbidities were analyzed, only 252 patients (55.0%) presented at
least one comorbidity (table 1). The presence of one comorbidity relevant or
not did not show any impact on the overall response to ESAs (HR=1.441; p=
0.138 for one comorbidity; HR=1.278; p=0.223 for one relevant comorbidity).
However, curiously, the presence of two or more comorbidities was associated
with statistically significant better response to ESAs (68.9% response in patients
with two or more comorbidities vs 64.2% in patients with less than two comor-
bidities; HR=3.014; p=0.004), the only difference between both groups was
ferritine level while other variables with impact on response were similar in
both groups (PB and BM blasts, Hb level, cytogenetics, transfusion depend-
ency, IPSS and EPO level). Additionally, the presence of two or more relevant
comorbidities was also associated with a better response (75.2% response in
patients with two or more relevant comorbidities vs 64.0% in patients with less
than two relevant comorbidities; HR= 4.126; p=0.001). These 2 groups were
different regarding ferritine and EPO level. When the impact of the different
comorbidities was studied, only hypertension showed influence on the overall
response rate: patients with hypertension had statistically significant better
response to ESAs (72.7%) than those who did not have hypertension (61.5%);
p=0.015, both groups had similar characteristics regarding variables with impact
on response. Regarding center size, 213 patients (40.2%) were treated in “level
1”; 174 (32.8%) in “level 2” and 143 (27.0%) in “level 3” centers. When the
center level was analyzed we could verify that patients who were treated in the
smallest “level 3” centers had a statistically significant higher overall response
rate to ESAs (81.7%) when compared with “level 2” patients (66.0%) and “level
1” patients (52.8%), HR=3.995; p<0.001; there were less patients in transfusion
dependence in “level 3” centers than in the others while other characteristics
were similar in the 3 groups. No differences were observed regarding duration
of ESAs response (p=0.098).
Table 1. Comorbidities distribution.
Summary/Conclusions: The present study shows that ESA treatment should
not be avoided in patients with lower risk MDS with comorbidities, as response
rates are similar to those of patients without. Patients treated in the smallest
centers had the best response rates to ESA.
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IMPACT OF PREVIOUS TRANSFUSION AND COMORBIDITIES IN THE
IPSS-R FOR OVERALL SURVIVAL
DV Nicolás1,*, G Teresa2, G Francisco3, A Manuel4, G Lorena5, A Olga5,
G Hermitas6, S Sandra7, F Angeles8, R Rafael9, L Inés9, G Agustín9, M Carmen10,
U Carlos11, B Jose Luis1
1Haematology, Hospital Clínico Universitario. Santiago de Compostela, 2Cito-
genetics, Fundación Xenómica, Santiago de Compostela, 3Statistics, Hospital
Clínico Universitario, Santiago de Compostela, 4Haematology, Hospital Comar-
cal de Valdeorras, O Barco de Valdeorras, 5Haematology, Hospital Xeral-Calde,
Lugo, 6Haematology, Hospital Comarcal de Monforte, Monforte de Lemos,
7Haematology, Hospital Meixoeiro, Vigo, 8Haematology, CHUVI, Vigo, 9Haema-
tology, CHOP, Pontevedra, 10Haematology, Hospital Arquitecto Marcide, Ferrol,
11Haematology, CHOU, Orense, Spain
Background: Myelodisplastic sindromes(MDS) are heterogeneus clonal hema-
tological disorders, with different clinical outcome. The revised international
prognostic score system (IPSS-R) showed improvement prognostic power as
compared to IPSS. Disease and patient related factors not considered in IPSS-
R are emerging as relevant for prognosis of individual patients with MDS.
Aims: This is a retropective cohort study to validate the IPSS-R and evaluate
the impact of new variables in a MDS patients serie, wondering if adds any
prognostic survival prediction at diagnosis.
Methods: Data from 339 patients diagnosed with MDS in 11 hospitals located
in Galicia, Spain from January 1,2007 to december 31,2011. End of the follow-
up time was december 18,2012. The patients were registered in the central
area citogenetic database and were reclassified according to 2008 WHO Cri-
teria. Data of 30 patients with secondary MDS were included and CMML or
AML diagnosys were excluded. Patients treatment was heterogeneous (con-
servative,supportive treatment, chemotherapy, IMIDs, hypometilant agents,
BMT and others). The study was approved by the regional ethical committee.
Results: Population: 44% females and 56% males. Median age: 78 years
(range 29-100). Median follow-up time: 1,7 years. Median survival time: 3,5
years. According to 2008 WHO classification: 14%CRDU, 11%RARS, 31%
RCMD, 8% RCDMSA, 8% MDS (del5q), 12% RAEB-1, 12% RAEB-2,1% U-
MDS. Included 1% fibrotic and 2% hipoplastic MDS. According IPSS, patients
were classified as low risk: 43%,(median survival-MS-: 5 years), intermediate-
1:37% (MS:3,2 years), intermediate-2:16% and high risk: 4%(MS:5, 3.2, 1 and
0.3 years respectively). According IPSS-R: low IPSS risk patients were shifted
to very low, low and intermediate risk (43%, 53% and 4%. MS not reached, 4.4
and 3.6 years respectively). Intermediate-1 patients spread into very low (5%),
low(54%), intermediate(31%), high, and very high risk(8% and 1%, MS:1 and
0.6 year). Intermediate-2 IPSS patients were classified into intermediate (26%),
high (46%) and very high(28%)risk. High risk IPSS patients were staged in
very high IPSS-R risk. The 3 and 5 year ROC survival curves and AUC was
better for the IPSS-R than the IPSS(p<0.001)but not at 1 year. We studied 4
new variables at diagnosis to improve the survival prognostic IPSS-R predic-
tion. Ferritin and LDH serum levels, comorbidities (measured by MDS-CI
index)and previous RBC transfusión (at least two RBC in the 4 previous
months).Univariate analisys not showed statistical significance for the serum
LDH.The multivariate analisys didn´t it for serum ferritin levels.Data available
for 327 patients for previous transfusion showed 46 individuals transfused
(14%).Risk stratification according MDS-CI: 339 patients:41%low risk,43%
intermediate risk,16% high risk. The most frecuent observed comorbidities
were: cardiac disease (35%), other tumour (15%) pulmonary (14%), renal (9%),
hepatic (2%). ROC curves and AUC at 1,3 and 5 years showed better survival
prediction power for IPSS-R if we added the two last variables individually and
increase if we add the two variables simultaneously(p<0.001).
Figure 1.
Summary/Conclusions: IPSS-R provides pronostic power for OS compared
to IPSS but not includes emerging relevant clinical events. Comorbidities exert
a negative impact in life expectancy on MDS patients.Intrinsic MDS charac-
terystics like anemia can worse patients sickness.Previous transfusion can
reflect more aggressive disease or late diagnosis.Late iron develop has a neg-
ative impact in morbidity/mortality.Our study showed that adds the two variables
improve the IPSS-R prognostic power for OS and helps in clinical decisión
making.
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THE EFFECT OF MESENCHYMAL STEM CELLS DERIVED FROM DIFFER-
ENT SOURCES IN COMBINATION WITH HAPLOIDENTICAL HSCT IN THE
TREATMENT OF BONE MARROW TYPE RADIATION SICKNESS
YH Jia, SJ Yang, X Zhang*
Department of Hematology, Xinqiao Hospital, The Third Military Medical Uni-
versity, Chongqing, China
Background: Mesenchymal stem cells (MSCs) in the microenvironment can
come from different origins and exhibit a diversity of properties. However,
source-dependent and donor-dependent differences in MSCs properties,
including their clinical application are still largely disputed.
Aims: To investigate the effect of the transplantation of mesenchymal stem
cells (MSC) derived from different sources in combination with hematopoietic
stem cells (HSC) in the treatment of bone marrow type radiation sickness.
Methods: 100 mice (CB6F1(H-2b×d)) were hybrids of C57BL/6 (H-2b) and
BABL/C (H-2d), 8 weeks old, weight 18g-22g ,and were divided into 5 groups
after 8.5Gy total body irradiation (TBI) of 60Coγray, according to a completely
randomized design, irradiation group (n=20), HSC transplantation group
(n=20), human umbilical cord blood MSCs (HucbMSCs) and HSC cotrans-
plantation group (n=20), bone marrow MSCs (BMMSCs) and HSC cotrans-
plantation group (n=20), dermal MSCs (DMSCs) and HSC cotransplantation
group (n=20). The clinical manifestation of mice were observed after trans-
508 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
plantation. The survival rate, pathological changes of BM, and other indicators
were tested.
Results: Hair back , decreased activity, diarrhea and weight loss appeared at
three days after irradiation. At the 11th day, all mice in irradiation group died
while the amount of eating and drinking increased and body weight began to
recover in the transplantation group. The clinical manifestation score of GVHD
in cotransplantation group was lower than that in single transplantation. At 28th
day after irradiation, the survival rate of mice in HucbMSCs group was
95%,which were 85%, 80% and 70% in BMMSCs group, DMSC group and
transplantation group respectively. The hematopoietic reconstitution taperoffed
in cotransplantation group, transplantation group, HucbMSCs group, BMMSCs
group, and DMSCs group. The lowest value of hemogram were appear at 3-
7d of WBC, 7-10d of PLT, and 10-14d of RBC after transplantation. The patho-
logical change and the colony formation ability of BM were consistent with the
change in hemogram.
Summary/Conclusions: MSCs could promote hematopoietic reconstitution
and reduce GVHD effect in bone marrow type radiation sickness. HucbMSCs
has better application prospect than others in bone marrow type radiation sick-
ness.
Myeloma and other monoclonal
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IN MULTIPLE MYELOMA THERE ARE TWO SUBSETS OF
IMMUNOSUPPRESSIVE POLYMORPHONUCLEAR NEUTROPHILS WITH
INCREASED LEVELS OF ARGINASE
A Romano1,*, V Simeon2, NL Parrinello1, C Giallongo1, P La Cava1, C Conticello1,
ML Consoli3, M Parisi1, D Tibullo1, P Musto2, F Di Raimondo1
1Division of Hematology, University of Catania, Catania, 2Laboratory of Pre-
clinical and Translational Research, CROB Referral Cancer Center of Basilicata,
Rionero in Vulture, 3Division of Hematology, Ospedale Ferrarotto, Catania, Italy
Background: Multiple Myeloma (MM) is a plasma cell malignancy with a well
documented immune dysfunction. Development of MM is associated with accu-
mulation of Myeloid-Derived suppressor cells (MDSC), mostly represented by
pathologically activated relatively immature polymorphonuclear neutrophils (G-
MDSC). Our previous work showed that also mature polymorphonuclear neu-
trophils (PMN) are activated and immunosuppressive in MM.
Aims: We hypothesized that two populations of polymorphonuclear neutrophils
are present in MM, with differential distribution after a Ficoll separation and dif-
ferential immunosuppressive activity
Methods: Using oligonucleotide microarrays we first evaluated the gene
expression profile (GEP) of PMN at the steady state in 10 MM, 5 MGUS and 8
healthy subjects matched for sex and age, identifying Arg-1 as the first gene
differentially expressed in MM versus healthy PMN. Thus, we validated Arg-1
by RT-PCR, immunohistochemistry and circulating levels in serum by ELISA in
a series of 60 newly-diagnosed MM patients, 30 MGUS and 30 healthy subjects
in both G-MDSC and PMN. Finally, we tested the immunosuppressive proper-
ties of G-MDSC (isolated by CD66b+ immunomagnetic beads in the upper
Ficoll layer) and PMN (sorted from the lower Ficoll layer) isolated from the
same MGUS or MM patients, through functional assays, based on in vitro co-
culture with T-lymphocytes from healthy subjects.
Results: MM-PMN exhibit an increased expression of ARG-1 compared to
MGUS and healthy subjects (25.5 vs 6.2 vs 1 fold changes in gene expression,
p=0.003), confirmed by functional assay of enzymatic activity of ARG-1, posi-
tively correlated with advanced disease. In MM patients, increased levels of
ARG-1 were positively associated with advanced bone disease and
unfavourable cytogenetics. Circulating Arg-1 in serum was higher in MM than
MGUS and healthy subjects (183.6±21.9 versus 88.3±15.6 versus 98.8±11.4
ng/ml, p=0.0022). In MM patients there was a progressive increase from ISS
stage I through III (p=0.003). Immunostaining showed that Arg-1 was increased
in MM versus healthy subjects, but higher levels were evident in G-MDSC than
PMN. Moreover, only in MM-G-MDSC Arg-1 was evident at the nuclear level,
while in PMN Arg-1 had an exclusive cytoplasmic localization. This differential
distribution of Arg-1 was functionally evident, since G-MDSC were more
immunosuppressive than PMN. Indeed, after 72 hours of co-culture with T-cells
obtained from healthy donors in presence of mitogen stimulation (PHA), MM-
PMN were able to reduce T-cell proliferation at both tested 1:2 and 1:8 ratios
(respectively 38.3±2.6% and 14.3±0.6%, p<0.0001), while MGUS-PMN induced
a partial inhibition only at the 1:8 (25.4±4.3%, p=0.002). This effect was partially
reverted with the treatment of 200 μM nor-NOHA, an Arg-1 inhibitor, since within
first 24 hours T-cell proliferation increased in presence of MM-PMN (14.3±0.6
versus 24.5±1.3%, p<0.0001) and MGUS-PMN (25.4±4.3 versus 31.6±2.3%,
p<0.0001). MM-G-MDSC were more immunosuppressive than their MM-PMN
counterpart, since at 72 hours T-cell proliferation was 22.3±1.6% and 8.4±0.5%
(p<0.0001) at 1:2 and 1.8 ratio respectively.
Summary/Conclusions: Polymorphonuclear neutrophils in MM are immuno-
suppressive, but distinguished in two main subpopulations, at different stages
of maturation, based on the expression of Arg-1 and grains distribution, to target
in order to improve the effects of the immunochemotherapy.
E1234
RESISTANCE TO PROTEASOME INHIBITORS IS MEDIATED BY A OVER
ACTIVATION OF THE UPR AND THE DNA DAMAGE RESPONSE IN A
PRECLINICAL MODEL OF MM
S Hernández García, L González Méndez, D Quwaider, N Puig, EM Algarín,
AA López Iglesias, L San Segundo, M Martín Sánchez, T Paíno, AB Herrero,
I Misiewicz-Krzeminska, MV Mateos, NC Gutiérrez, M Garayoa, EM Ocio*
Complejo Asistencial Universitario de Salamanca (IBSAL) y Centro de Investi-
gación del Cáncer (IBMCC-CSIC). Universidad de Salamanca, Salamanca, Spain
Background: MM is still considered incurable partly due to the development
of resistance.
Aims: We have developed a cellular model of resistance to proteasome
inhibitors to investigate the underlying mechanisms.
Methods: Cells sensitive to proteasome inhibitors (MM1S, MM1R, RPMI-8226)
were continuously exposed to increasing concentrations of bortezomib until
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development of resistance. Viability was analyzed by MTT. Activity of different
subunits of the proteasome was analyzed with Proteasome-Glo™ Assay Kit
and presence of unfolded proteins with ProteoStat® Aggresome Detection Kit.
Western-Blot, flow cytometry and qRT-PCR were also used.
Results: The development of acquired resistance to bortezomib in three cell
lines was assessed by MTT assay with IC50 (nM) of 2.5 vs >100; 6.7 vs 78.5
and 21.2 vs >100 for the sensitive vs the resistant counterpart in MM1S, MM1R
and RPMI at 24 hours. Interestingly, cells were also resistant to other protea-
some inhibitors such as carfilzomib, oprozomib or ixazomib, indicating a class-
effect resistance. In absence of bortezomib treatment, resistant cells presented
a lower activity of the different subunits of the proteasome compared to the sen-
sitive counterpart by 52% for caspase-like (C-L); 54% for trypsin-like (T-L) and
42% for chemotrypsin-like (CT-L) activities. This was even lower in case of
MM1R (26%, 25% and 12%) and RPMI-8226 (21%, 40% and 23%) resistant
cells. This inhibition led to an accumulation of unfolded proteins in the resistant
MM1S cells as compared with their sensitive counterpart (96% vs 45%). More-
over, the concentration of bortezomib required to inhibit the proteasome was
around 20-fold higher in the resistant than in the sensitive MM1S cells (x23;
x21 and x27 for the C-L, T-L and CT-L activities). Finally, and most importantly,
even with doses of bortezomib achieving a complete inhibition of the three sub-
units, resistant cells were viable, indicating they were not dependent on the pro-
teasome and had developed alternative mechanisms of survival. In this context,
resistant cells significantly upregulated the pro-survival chaperone BIP/GRP78,
a critical sensor of the ER stress. This upregulation activated the three main
arms of the unfolded protein response (UPR): increased levels of p-IRE1, ATF-
6 and activation of PERK as observed through phosphorylation of its down-
stream substrate EIFα. A sequelae of the activation of the UPR is the transcrip-
tional activation of chaperones, and, accordingly, there was increased expres-
sion of HSP-40 and, particularly, HSP-70 (but not HSP-90) in resistant cells.
The ER stress also induced a DNA damage response with an increase in pH2Ax
in resistant cells and a subsequent upregulation of p53 protein levels. Moreover,
the increase in p-IRE-1 induced the nuclear translocation of NFkB, where it
could exert its pro-survival and transcriptional function. In fact, we also observed
an increase in the anti-apoptotic proteins Bcl-2, Bcl-xL, Mcl-1 and XIAP, some
of them known substrates of NFkB. Interestingly, these resistant cells had an
increased sensitivity to Pifithrin, a Hsp-70 and p53 inhibitor (6 hours Pifithrin
treatment induced 69% vs 26% apoptosis in resistant vs sensitive cells).
Summary/Conclusions: We have demonstrated some of the mechanisms
associated with resistance to proteasome inhibitors: activation of the UPR (with
subsequent upregulation of the chaperone system), DNA damage response and
NFkB signaling with increased levels of antiapoptotic Bcl-2 family members.
This work was supported by ISCIII-FIS PI15/00067 and /02156 and GRS
1175/A/15.
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DEREGULATION OF A-TO-I RNA EDITING IS FUNCTIONALLY AND
CLINICALLY RELEVANT IN MULTIPLE MYELOMA
PJ Teoh1,*, TH Chung1, H Yang1, L Chen1,2, WJ Chng1,3,4
1Cancer Science Institute of Singapore, 2Department of Anatomy, Yong Loo
Lin School of Medicine, 3Department of Medicine, Yong Loo Lin School of Med-
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National University Cancer Institute, Singapore, Singapore
Background: Multiple myeloma (MM) is a plasma cell neoplasm that remains
high risk and incurable despite its therapeutic advancement. Adenosine-to-Ino-
sine (A-to-I) RNA editing is a highly conserved post-transcriptional mechanism
involving sequence alterations at the RNA but not the DNA level, mediated by
ADAR family proteins (ADAR1, ADAR2 and ADAR3). RNA editing can result
in recoding of the proteome, modification of mRNA stability and alteration in
the miRNA biogenesis. In line with its physiological importance, an aberrant
RNA editing activity has been implicated in various human cancers. However,
the relationship between dysregulated RNA editing and the pathogenesis of
MM remains elusive. Importantly, chromosome 1q21 which harbours the
ADAR1 locus is amplified in more than 35% of MM, and this chromosomal
abnormality is a poor prognostic marker. Considering the co-occupancy of other
genes in 1q21, it is unknown if ADAR1 is an important driver gene.
Aims: We aim to define the RNA editome landscape of MM and to characterize
the critical function of a disrupted editome in driving myelomagenesis. We
would also like to delineate if ADAR1 is a critical gene in 1q21.
Methods: To establish the clinical significance of ADARs in MM, we analysed
the publicly available myeloma datasets. Primary patient samples and human
myeloma cell lines (HMCLs) were used as our study models. The level of
ADARs was modulated through the highly-efficient lentivirus system. System-
atic high-throughput RNA-sequencing is employed to investigate the genome-
wide RNA editing status before and after ADAR1 knockdown and overexpres-
sion. The functional effects of differential ADARs expression were examined
through cell viability (CTG), cell cycle (PI staining) and colony formation
(Methocult semi-solid medium) assays.
Results: Comparing with normal plasma cells, MM samples showed a severely
disrupted ADAR1:ADAR2 expression ratio, in which an overexpression of ADAR1
and downregulation of ADAR2 were observed. In correlation, we identified that
there was a close association between 1q21 amplification and ADAR1 expression
level, which consistently increases along the disease progression route, i.e. from
normal plasma to MGUS, SMM and finally MM. Furthermore, analysis based on
the disease subtypes revealed that the 4p16 and MAF subtypes (high-risk prog-
nostic groups) displayed significantly higher ADAR1 expression than other
groups, signifying its role in conferring an aggressive disease nature. More impor-
tantly, patients with high ADAR1 and low ADAR2 expression demonstrated a
poorer overall survival. At the physiological level, knocking down and overex-
pressing ADAR1 in HMCLs affects the global editing events, as detected by
RNA-sequencing. Gene specific validation demonstrated a differential degree of
A-to-I conversion of bona fide ADAR targets, depending on the ADAR1 expres-
sion level. In vitro analysis implicated that both ADAR1 and ADAR2 can func-
tionally affect MM growth and survival, whereby, ADAR1 behaves like an onco-
gene and ADAR2 displayed tumor suppressor properties. When the stable cell
lines were treated with velcade, ADAR1-knockdown cells showed increased sen-
sitivity while ADAR2-silenced cells were more resistant to the drug.
Summary/Conclusions: Considering that RNA editing is a widespread
occurence in the human genome (85%), its biological significance in MM cannot
be undermined. Our study unveils a potential novel role of ADAR-mediated-A-
to-I-editing in conferring myelomagenesis. The functional relevance of ADAR1
and ADAR2 denotes that the RNA editing activity is clinically important and
may represent an important therapeutic target for MM. Further characterization
of the direct mechanisms of A-to-I editing will provide critical knowledge on
whether this event would provide an extra layer of epigenetic deregulation to
MM, leading to a worse disease prognosis.
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TARGETING PROTEIN KINASE CK1A IN THE BONE MARROW MICROEN-
VIRONMENT: A NEW POSSIBLE THERAPEUTIC APPROACH FOR MULTIPLE
MYELOMA THERAPY?
M Carrino1,2,*, S Manni1,2, S Canovas Nunes1,2, P Macaccaro1,2, K Gianesin1,2,
L Quotti Tubi1,2, A Cabrelle1, G Semenzato1,2, F Piazza1,2
1Venetian Institute of Molecular Medicine, 2Department of Medicine (DIMED),
Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy
Background: Multiple myeloma (MM) is an incurable blood tumor arising from
plasma cells. This malignancy is characterized by a multistep pathogenesis
during which plasma cells progressively accumulate in the bone marrow (BM)
and in the late stages of the disease spread to the peripheral blood and other
tissues. Contacts between MM cells and the surrounding hematopoietic and
non-hematopoietic (stromal) cells activate paracrine and autocrine intercellular
loops, which support tumor cell growth and provide a protective niche against
cytotoxic agents. Despite significant improvements in the overall survival over
the last years, patients frequently develop resistance to many chemotherapeu-
tic agents, therefore new curative strategies are urgently needed. Protein
Kinase CK1α (CK1α) is a Ser/Thr kinase that we found overexpressed in a
fraction of MM patients and cell lines. It is essential for the regulation of BM
microenvironment dependent pathways (such as WNT/β-catenin and
PI3K/AKT) important for plasma cell survival, suggesting a possible function
of CK1α in the microenvironment dependent progression of this disease.
Aims: We aimed at evaluating whether or not CK1α inactivation in MM plasma
cells could overcome the BM microenvironment protection, affecting cells
growth and proliferation by impinging on survival signaling pathways associated
to chemotherapeutic resistance. We also aimed to outline whether CK1α inac-
tivation in the BM microenvironment context, could potentiate the therapeutic
effect of drugs approved for the treatment of MM, such as Bortezomib.
Methods: Patient derived plasma cells and the BM microenvironment depend-
ent MM cell lines INA-6 and SaMMi (a patient derived MM cell line, newly gen-
erated in our laboratory) were used. A model of BM microenvironment was
established colturing MM cells with HS-5 stromal cells or with BM stromal cells
(BMSC) from MM patients. RNA interference for CK1α was obtained through
the generation of IPTG inducible MM clones. CK1 inhibition was obtained with
D4476. Apoptosis was investigated with AnnexinV/PI staining and FACS analy-
sis. CK1α downstream pathways were analyzed by WB.
Results: We found that CK1 inhibition caused apoptosis of MM cell lines and
patient derived plasma cells. The presence of a defensive BM microenviron-
ment did not protect MM cells from D4476-induced cell death. These results
were confirmed also by RNA interference using siRNAs targeting the α isoform
of CK1. We investigated also the effects of CK1α inactivation on the microen-
vironment-dependent prosurvival pathways WNT/β-catenin and PI3K/AKT and
found a proteasome independent reduction of both β-catenin and AKT proteins
expression. Furthermore CK1α inhibition enhanced Bortezomib induced cyto-
toxicity not only on plasma cells grown alone, but also on cells co-cultured with
protective stromal cells.
Summary/Conclusions: Our results indicate that by impinging on critical
microenvironment dependent survival pathways, CK1α inactivation leads to
MM cell apoptosis and empowers Bortezomib induced cytotoxicity, overcoming
stromal cell dependent protection and resistance to chemotherapeutic agents.
These results might predict a possible use of CK1α inhibitors in the clinical
setting as a new therapeutic approach for MM therapy.
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RHOU GTPASE: A NOVEL POTENTIAL TARGET TO DISRUPT MULTIPLE
MYELOMA PLASMA CELL INTERACTION WITH PROTECTIVE BONE
MARROW NICHES
S Canovas Nunes1,2,*, M Carrino1,2, E Mandato1,2, L Quotti Tubi1,2, F Zaffino1,2,
S Manni1,2, G Semenzato1,2, F Piazza1,2
1Department of Medicine (DIMED), Hematology and Clinical Immunology Branch,
University of Padua, 2Venetian Institute of Molecular Medicine, Padua, Italy
Background: Bone marrow stromal cell (BMSC)-produced soluble factors, like
the IL-6 cytokine, may impinge on Multiple Myeloma (MM) intracellular signaling
and cytoskeletal properties, protecting it from cytotoxic agents. Rho GTPases,
in their active GTP-bound state, interact with effector proteins in order to control
cytoskeleton remodeling, cell adhesion and polarization, and other essential
processes for cell-cell interaction. The atypical Rho protein Wrch-1/RhoU dis-
plays spontaneous activation and is normally expressed at low levels in various
tissues and organs. This protein might mediate the effects of the IL6R/STAT3
signaling in inducing filopodium formation and stress fiber dissolution, both crit-
ical steps in promoting cell motility. While typical Rho proteins (that share sig-
nificant sequence homology with RhoU) as Cdc42 and Rac-1 have an estab-
lished role in cancer, very little is known on RhoU in tumorigenesis, in particular
in hematologic malignancies.
Aims: Since the IL6R/STAT3 signaling is of great importance in MM malignancy,
we have endeavored to study RhoU expression in normal versus MM plasma
cells. We also focused on understanding its localization and cellular function in
these cells. Lastly, we aimed at unraveling the mechanisms through which
RhoU expression is regulated in MM cells in the context of bone marrow (BM)
microenvironment.
Methods: Malignant plasma cells were isolated from BM extracts or peripheral
blood of MM patients using a magnetic CD138 positive selection kit. Normal B
cells were purified using a magnetic human B cell isolation kit. mRNA expres-
sion was analyzed by qRT-PCR for MM cell lines, MM patients and normal B
cells from healthy donors. Fluorescence microscopy was performed using Zeiss
LSM 700 microscope and the following antibodies were used for staining: Phal-
loidin 594, rabbit anti-RhoU, goat anti nucleolin, anti-rabbit Alexa fluor 488,
anti-goat Alexa fluor 594 and DAPI. STATTIC was used for STAT3 inhibition
and the IL-6 cytokine was used to stimulate the IL-6R. Migration assays were
set-up using 5mm transwells with standard controls, cell count was done by 3
minutes reads in FACS Canto.
Results: Here we provide data showing that RhoU is overexpressed in BMSC-
dependent MM cells, but not in malignant plasma cells from the peripheral
blood of Plasma Cell Leukemia (PCL) patients. We also demonstrate that its
expression was positively modulated to the same extent by BMSC conditioned
media and by IL-6, a major growth factor for MM cells. In MM cell lines, a block-
ade in STAT3 activation inhibited RhoU mRNA transcription in a dose dependent
manner, and caused a clear impairment in migration/motility capacity of these
cells. Interestingly, we observed an unexpected subcellular localization for this
protein in the nucleolus of BMSC-dependent MM cells, which could be inde-
pendent from STAT3 regulation.
Figure 1.
Summary/Conclusions: RhoU GTPase is widely overexpressed in malignant
plasma cells from BM extracts of MM patients but not in cells purified from the
peripheral blood of PCL patients. Its expression is positively modulated by IL-
6 stimulus through the activation of STAT3 transcription factor. We describe for
the first time a localization of this G protein in the nucleolus of MM cells. These
results put to light the pleiotropic features that RhoU could display in this malig-
nancy. We firmly believe that RhoU might be important in MM pathogenesis
and could become a suitable target to disrupt the MM plasma cell interaction
with protective BM niches.
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DEREGULATION OF MAJOR DNA REPAIR MECHANISMS CORRELATES
WITH CLINICAL OUTCOME OF ANTI-MYELOMA THERAPY. THE BENEFICIAL
EFFECT OF DNA REPAIR INHIBITION
M Gkotzamanidou1,*, E Terpos2, NC Munshi1, MA Dimopoulos2, VL Souliotis3
1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School,
Boston, United States, 2Department of Clinical Therapeutics, University of
Athens School of Medicine, University of Athens School of Medicine, 33Institute
of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research
Foundation, Athens, Greece
Background: Deregulation of DNA repair pathways in malignant plasma cells
mediates onset of disease and survival. The precise nature of dysregulated
DNA repair and how it improves multiple myeloma (MM) cells survival or is co-
opted during antitumor therapy is as yet unexplored and requires extensive
study. If fully understood, DNA repair dysregulations could be exploited to selec-
tively kill MM cells by targeting the remaining repair pathways that are critical
for their survival.
Aims: We investigated the mechanistic basis for the link between DNA repair
efficiency and response to anti-myeloma therapy.
Methods: We evaluated major DNA repair mechanisms [nucleotide excision
repair (NER), interstrand cross-links repair (ICL/R), double-strand breaks repair
(DSB/R)] in MM cell lines (melphalan-sensitive, RPMI8226; melphalan-resis-
tant, LR5), peripheral blood mononuclear cells (PBMCs) from 25 healthy con-
trols (HC; 14M/11F, median age 58 years), as well as bone marrow plasma
cells (BMPCs) and PBMCs from 15 newly diagnosed MM patients (8M/7F;
median age 61 years), responders (≥PR, n=9) and non-responders (
Results: Following ex vivo melphalan treatment, responders’ primary cells
(both BMPCs and PBMCs) showed significantly slower rates of NER and
DSB/R compared to non-responders (P=0.0015). Similar rates of ICL/R were
found in primary cells from all individuals. Moreover, apoptotic rates of the pri-
mary cells were inversely correlated with individual DNA repair efficiencies,
being significantly higher in responders’ cells compared to non-responders
ones (P=0.0015). In line with these data, RPMI8226 cells showed slower rates
of NER and DSB/R, but not ICL/R, and higher apoptotic rates than LR5 cells.
Interestingly, co-treatment of all types of cells with DSB/R inhibitors significantly
reduced the rates of DSB/R and increased melphalan sensitivity of the cells.
Moreover, in untreated PBMCs from MM patients, we found an inverse corre-
lation between the local chromatin condensation and the repair capacity of the
cells. Particularly, we observed a progressive, significant increase in the loose-
ness of the local chromatin structure, from HC to MM patients, with responders
showing more condensed chromatin structure compared to non-responders
(all P<0.05). Finally, microarray analyses of untreated PBMCs from MM patients
consistently point to an altered expression of several DNA damage response-
related genes in MM patients compared to HC. Particularly, responders’ PBMCs
showed upregulation of ATR, CHEK2, XPA, XRCC1 and CHEK2 genes and
downregulation of ATM, MPG, UNG, CDKN1A and CDC25C compared to non-
responders (in all cases, fold changes between groups were >2, P<0.001),
suggesting that perturbation in the molecular components of DDR/R pathways
also plays an important role in the therapeutic action of genotoxic drugs.
Summary/Conclusions: Responders to melphalan therapy are characterized
by lower efficiencies of NER and DSB/R mechanisms resulting in higher accu-
mulation of the extremely cytotoxic ICLs and DSBs lesions which in turn, triggers
the induction of the apoptotic pathway. Moreover, the potentiation of melphalan
cytotoxicity by DSB/R inhibition offers a promising strategy toward improvement
of existing regimens.
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BAX ACTIVATION IS A POTENTIAL BIOMARKER OF RESPONSE TO
FILANESIB (ARRY-520) ALONE AND IN COMBINATION WITH POMALIDOMIDE
AND DEXAMETHASONE
S Hernández García1, L González Méndez1, L San Segundo1, M Martín Sánchez1,
I Misiewicz-Krzeminska1, AA López Iglesias1, EM Algarín1, T Paíno1,
M Garayoa1, BJ Tunquist2, NC Gutiérrez1, MV Mateos1, EM Ocio1,*
1Complejo Asistencial Universitario de Salamanca (IBSAL) y Centro de Inves-
tigación del Cáncer (IBMCC-CSIC). Universidad de Salamanca, Salamanca,
Spain, 2Array Biopharma, Boulder, Colorado, United States
Background: Pomalidomide in combination with dexamethasone (PD) has
demonstrated activity in refractory MM patients, but novel combinations are
needed to improve its efficacy. In this context, the kinesin spindle protein (KSP)
inhibitor, filanesib (Arry-520), has demonstrated clinical anti-myeloma effect
and previous data from our group and others have demonstrated the preclinical
synergy of pomalidomide with dexamethasone and filanesib (PDF) what set
the stage for the recently activated clinical trial POMDEFIL being run by the
Spanish MM group investigating this combination in relapsed MM patients.
Aims: In this abstract, we gained insights into the mechanism of the combina-
tion and aimed at identifying potential biomarkers that could predict response.
Methods: MM cells were transiently transfected with non-targeting control short
interfering RNA (NT-SiRNA), Bax siRNA ON TARGET plus SMART pool siRNA
using the cell line Nucleofector Kit V. In vitro action was evaluated in MM cells by
Annexin V staining using flow cytometry. The mechanism of action was analyzed
by Western Blot, immunohistochemistry and immunofluorescence techniques.
Results: All 11 MM cell lines tested were sensitive to filanesib and sensitivity to
this agent correlated with basal levels of Bax and Bax/Mcl-1 protein ratio. Sub-
cellular fractionation of MM1S cells indicated that filanesib triggered translocation
of Bax from the cytoplasm to the mitochondria after 24 and 48 hours, and its sub-
sequent cleavage into the very potent proapoptotic 18 kDa fragment. A simulta-
neous decrease in the levels of Mcl-1 was observed. Knock-down of Bax in MM1S
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by using small interfering RNA decreased the sensitivity of these cells to filanesib,
as treatment with 10 nM for 24 hours induced apoptosis in only 26% of the siR-
NA-Bax cells as compared with 50% in the non-targeted cells (as compared with
58% vs 61% for bortezomib, used as a control for this experiment). Next, we
evaluated changes of Bax protein levels in comparison with others in MM1S cells
after treatment with vehicle, F, PD and PDF treatments. The levels of the proapop-
totic protein, Bax, were significantly increased in both cytosolic and mitochondrial
fractions with PDF treatment, as assessed by Western blotting after 12 or 48
hours of treatment. Of note, this event preceded the initiation of the apoptosis
process as evaluated by cleavage of PARP and annexin V staining. Moreover,
total cellular antiapoptotic protein Mcl-1 levels declined with the combination,
although less than with F treatment and no significant changes occurred in the
mitochondrial and cytosolic compartments by western blot. These results were
confirmed in vivo in a model of subcutaneous plasmacytoma in tumors with big
plasmacytomas, that after two days of treatment with vehicle, PD, F or PDF were
sacrificed and tumors were fixed, paraffin-embedded and stained with anti-Bax
and counterstained with haematoxilin for analyses. In vivo treatment with PDF
also induced a clear increase in Bax that was mainly present in cells with aberrant
monopolar spindles (a hallmark of the KSP inhibition induced by filanesib) and
with an increase of apoptosis evaluated by TUNEL (p<0.001).
Summary/Conclusions: Bax protein is specific involved in the response to
filanesib in monotherapy and plays a significant role in the synergy of its com-
bination with pomalidomide and dexamethasone, being one of the earlier
events observed. Therefore, Bax protein could be a potential biomarker of
response to filanesib and also this synergistic combination.
This work was funded in part by the company Array BioPharma.
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COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE
I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF
MULTIPLE MYELOMA
K Maclachlan1,2,*, A Cuddihy1, N Hein3, S Harrison2, R Hannan1,2,3,4,5,6,7
1Research Division, Peter MacCallum Cancer Centre, 2Sir Peter MacCallum
Department of Oncology, University of Melbourne, Melbourne, 3Department of
Cancer Biology and Therapeutics, Australian National University, Canberra,
4Department of Biochemistry and Molecular Biology, Monash University,
5Department of Biochemistry and Molecular Biology, University of Melbourne,
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Background: Ribosome biogenesis is dysregulated in malignancy, which is
thought to contribute to cellular transformation and proliferation. Selective targeting
of RNA polymerase I (Pol I), the enzyme responsible for transcribing the ribosomal
RNA genes, with the novel small molecule inhibitor CX-5461 (Drygin et al., Cancer
Res 2011) induces cell death using both p53-dependent and -independent path-
ways in both haematological and solid tumours. In a murine model of B-cell lym-
phoma, treatment with CX-5461 significantly increased survival (Bywater et al.,
Cancer Cell) and the drug is now in early stage clinical trials.
Aims: To determine the efficacy of CX-5461 in the treatment of multiple myeloma
(MM), both alone and in combination with standard and emerging MM therapies.
Methods: A panel of human myeloma cell lines (HMCLs) were treated with CX-
5461 prior to measuring proliferation, cell death and cell cycle distribution. Western
blots were performed at serial time points for markers of DNA damage signalling
and cell cycle control. CX-5461 was tested in combination with a variety of ther-
apeutic agents that have demonstrated clinical or preclinical efficacy against MM.
Results: Testing CX-5461 against our panel of HMCLs reveals a wide range
of sensitivity to Pol I inhibition. Our data show that sensitivity to CX-5461 is not
solely dependent on proliferation rate or p53 status. Treatment of HMCLs with
CX-5461 leads to a rapid increase in total and serine-15-phosphorylated p53
protein levels, in line with published data in other malignancies. Interestingly,
CX-5461 induced phosphorylation of the checkpoint proteins Chk1 and Chk2,
even in mutant p53 expressing cell lines, suggesting activation of p53-inde-
pendent cell cycle checkpoints. The combination of CX-5461 with drugs having
differing mechanisms of action shows increased inhibition of proliferation and
induction of cell death compared to single agents alone. Increased efficacy is
seen in combination with dexamethasone, everolimus, JQ1, ABT-199 and
dinaciclib, with the most dramatic results being seen when CX-5461 is com-
bined with bortezomib, carfilzomib or panobinostat.
Summary/Conclusions: Combination drug therapy is necessary to delay
acquired drug resistance to single therapeutic agents and increase overall sur-
vival. Our data suggest that the novel Pol I inhibitor CX-5461 can be combined
with a broad spectrum of agents, with bortezomib, carfilzomib and panobinostat
showing the most promise.
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CHARACTERIZATION OF A PERK KINASE INHIBITOR WITH ANTI-MYELO-
MA ACTIVITY
T Bagratuni*, E Kastritis, N Mavrianou, C Liacos, E Terpos, M Dimopoulos
National And Kapodistrian University of Athens, Athens, Greece
Background: Due to the immunoglobulin production, multiple myeloma (MM)
plasma cells are dependent on the unfolded protein response process (UPR),
which controls protein production and ensures its proper translation and folding.
A study by Michallet et al (2011) showed that knockdown of one of the three
well-known arms of the UPR, PERK (protein kinase R (PKR)-like ER kinase)
in MM cells resulted in autophagic cell death. This outcome indicated the impor-
tant role of PERK activation for the metabolic shift of plasma cell to myeloma
cell but also its ability to impede the apoptotic effect. 
Aims: In this study we used a small ATP competitive molecular inhibitor,
GSK2606414, that acts by targeting PERK enzyme activity in its inactive DFG
conformation at the ATP-binding region, while displaying ≥385 fold selectivity
over c-kit, Aurora B, BRK and many other kinases. 
Methods: mRNA expression of PERK, CHOP and ATF4 in MM patients and
cell lines was determined by real-time PCR. To deterine the effects of
GSK2606414 on MM cell proliferation and apoptosis WST1 proliferation assay
Annexin-PI staining was used respectively. To determine the effects of
GSK2606414 in key genes of the UPR, UPR RT2 profiler PCR array was used.
Results: We initially screened 25 CD138+ MM patients and 6 human myeloma
cell lines (HMCLs) for PERK mRNA expression. Our results showed that PERK
mRNA is highly expressed in almost all patients (5-10 fold higher than the
mean PERK expression of HMCLs). To test the effect of GSK2606414 on the
proliferation of MM cells, 4 HMCLs were treated with different doses of
GSK2606414 at two time points (24 and 48 hours). Treatment of cells with 3-
30μM GSK2606414 resulted in a dose-dependent inhibition of cell proliferation
in all HMCLs ranging for 20-95% reduction of proliferative activity, thus, indi-
cating the dependency of these cells on PERK activity. Treatment with
GSK2606414 at 20μM in H929 and L363 HMCLs for 24 hours resulted 25%
and 15% increase in apoptotic cells by Annexin-PI staining respectively com-
pared to the untreated cells. However, the most important finding was a signif-
icant synergistic effect of GSK2606414 with bortezomib in these cells. Specif-
ically when H929 and L363 cells were treated with 5nM bortezomib in combi-
nation with 20μM GSK2606414, synergistic effect was seen where apoptotic
cells reached 99% and 77% respectively, compared to bortezomib-treated cells
(87% and 42% respectively). To determine the gene target effects of
GSK2606414, ATF4 and CHOP mRNA expression levels were determined in
H929 cell line after 24 hour of treatment. Treatment with GSK2606414 alone
did not alter the expression levels of CHOP but reduced more than 50% the
expression levels of ATF4. When combined with bortezomib CHOP and ATF4
levels were reduced 20% and 60% respectively while treatment with bortezomib
alone increased the levels of CHOP and ATF4 by 50-100%. H929 and L363,
were pre-treated with GSK2606414 and then subjected to ER stress conditions
by treatment with tunicamycin (TM). In the presence of exogeneous UPR induc-
ers, such as TM, GSK2656157 had a significant effect on the expression of
the above genes at much lower IC50 range (≤100 nM) suggesting the in a more
active UPR (sustained ER stress) the effects are more pronounced. Thus, the
combination of GSK2606414 with bortezomib may inhibit one of the mecha-
nisms of MM cells to escape ER stress induced by bortezomib. To determine
the effects of the GSK2606414 on myeloma cells, a UPR RT2 Profiler PCR
array containing 84 key genes for the UPR pathway, was used in order to
screen for differentially expressed genes between treated and non-treated
cells. Results of this array will be presented at the meeting.
Summary/Conclusions: In conclusion, given the on-target pharmacological
effects of PERK inhibitor on MM, development of PERK inhibitors may offer a
therapeutic advantage that would affect MM pathogenesis and treatment.
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EXPLORING THE BONE MARROW NICHE IN MULTIPLE MYELOMA USING
AN ADHESION-INDEPENDENT THREE-DIMENSIONAL CO-CULTURE
MODEL
JM Waldschmidt1,*, D Wider1, S Müller1, C Klein1, AR Thomsen2, M Follo1,
G Herget3, N Südkamp3, J Duyster1, R Wäsch1, M Engelhardt1
1Department of Hematology and Oncology, 2Department of Radiation Oncol-
ogy, 3Department of Orthopedics and Trauma Surgery, University Medical Cen-
ter Freiburg, Freiburg i. Brsg., Germany
Background: The interaction between malignant plasma cells and their bone
marrow (BM) niche is crucial for MM pathogenesis. The BM niche provides a
specific tumor microenvironment which leads to quiescence, drug resistance
and ultimately progression of myeloma. We and others have previously
observed that reduced sensitivity to bortezomib, pomalidomide or vorinostat in
the presence of BM stromal cells (BMSCs) can be restored by adding the adhe-
sion inhibitors AMD3100 and NOX-A12. However, little is known about the
mechanisms of how the MM niche mediates protection.
Aims: Our focus was to develop a novel bone-derived in vitro 3D co-culture
platform and assess the cellular composition and function of the BM niche by
studying the effects of niche cell subfractions on MM growth. 
Methods: An adhesion-independent three-dimensional co-culture model was
used to mimic the BM niche. This model consisted of an agarose matrix inter-
layer containing 100 microwells/cm² (Fig.1A). Each microwell was 1.5mm in
depth and permeable for oxygen and cytokines, but not for BMSCs (Fig.1B).
U266, RPMI-8226, OPM-2 and primary BM patient (pt) cells were utilized with
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and without (w/o) HS-5 vs M210B4 stroma support (Fig.1C.a+b: stroma-support
effect and pt characteristics). Analyses included trypan blue, Annexin/PI, MTT,
FACS, cell cycle analyses and H2B-mCherry/cytochrome c-GFP assays (Udi,
BJH 2013). To examine the effect of distinct BM niche cell populations on MM
growth, niche cell subsets from C57BL6J mice were acquired, digested and
FACS-sorted to collect cell subfractions of mesenchymal stem and progenitor
cells (MSPC), endothelial cells, osteoblasts, premature CD146+ MSPCs (PαS)
and CXCL12-abundant reticular cells (CaRs; Fig.1C.d).
Results: Human MM cell lines (MMCLs) and pt samples were cultured with 1,
10 or 100 cells/microwell, showing a growth advantage with vs w/o stroma sup-
port. Pt samples after 7 days (d) of culture benefitted from both murine M210-
B4 and human HS-5 co-culture (Fig.1C.a). Expression of the chemokine
CXCL12 and its corresponding receptor CXCR4 in U266 cells decreased after
7d with stroma support, thereby reflecting the dynamic regulation of the
CXCL12-CXCR4 axis in vitro (Fig.1C.c). FACS-sorting of murine bone and BM
cells led to valid subset separation, illustrated by a multipolar morphology of
CD31+ endothelial cells and CD31-, CD45-, Sca1+ MSPCs with fibroblast-like
bipolar appearance (Fig.1C.e), whereas PαS cells remained undifferentiated
and positive for CD146. We observed that C57BL6J-derived murine cells dif-
fered in terms of their growth support for OPM-2 cells after 6d of co-culture:
MSPCs from murine BM were more beneficial than those derived from murine
bone (Fig.1C.f). BM-MSPCs also induced stronger support than premature
MSPCs and CXCL12-abundant reticular cells, commonly considered as crucial
mediators of adhesion in the murine niche. Current analyses focus on the gen-
eration of BM cell subsets from both MM pts and non-MM pts, thus overcoming
the limitation of using C57BL6J mice.
Figure 1.
Summary/Conclusions: We present a 3D culture model which reflects stromal
protection for MM cells and may prove more reliable for ex-vivo drug screening
and longitudinal studies. Assessment of the cellular composition of the MM
niche in comparison to the normal BM microenvironment will help to better
understand and selectively target stroma-mediated protection in MM.
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ACTIVATION OF TOLL-LIKE RECEPTOR 4 PROMOTES MULTIPLE MYELOMA
CELL GROWTH AND SURVIVAL THROUGH UPR PATHWAY AND IN A
CASPASE-DEPENDENT MANNER
T Bagratuni*, E Kastritis, C Liacos, E Eleutherakis-Papaiakovou, N Kanellias,
E Terpos, M Dimopoulos
National And Kapodistrian University Of Athens, Athens, Greece
Background: Toll-like receptor family (TLR) of receptors is an essential part of
innate immunity. Expression and function of TLRs in Multiple Myeloma (MM) has
recently become the focus of several studies and although the regulatory role of
TLRs in MM plasma cells has been reported, the molecular mechanism remains
unclear. During infection, human immune cells sense the presence of invading
pathogens through TLRs which then activate transcriptional programs that orches-
trate adaptive responses and induce the endoplasmic reticulum (ER) unfolded
protein response (UPR) to accommodate essential protein translation. Studies
have shown that prolonged ER stress occurs in response to microbes and specif-
ically when cells are exposed to lipopolysaccharide (LPS), a TLR4 activator. The
prolonged stress, possibly arising from a massive increase in protein synthesis,
has shown to suppress CHOP, an apoptosis biomarker, in ER-stressed
macrophages, while low levels of CHOP expression promote B cell survival.
Aims: The aim of our study was to investigate TLR4 signaling in myeloma cells
and to explore possible implications with endoplasmic reticulum unfolded pro-
tein response as a potential mechanism of drug resistance. 
Methods: mRNA expression of TLR4 and CHOP a in MM patients and cell
lines was determined by real-time PCR. To deterine the effects of LPS on MM
cell proliferation and apoptosis WST1 proliferation assay and Annexin-PI stain-
ing was used respectively. Protein expression of CHOP, ATF4, peIF2a, NFkB
and caspases was assesed by immunoblotting analysis.Bottom of Form
Results: We found that TLR4 mRNA is expressed at increased levels (2-10
fold) both in human myeloma cell lines (HMCL) and primary cells. To investigate
whether TLR4 signaling may suppress CHOP expression during sustained
UPR response JJN3 and U266 cells, were pre-treated with LPS (5 ug/mL) and
then subjected to ER stress conditions with a typical ER stressor, tunicamycin
(TM). We found that ER stress-induced CHOP expression was suppressed by
prior engagement of TLR4, by LPS pre-treatment. To test the relevance of these
results, pre-treated LPS and TM samples were also subjected to Annexin-PI
staining to determine the amount of apoptosis. As expected, pre-treated LPS
HMCLs exposed to TM had almost 30% lower Annexin-FITC stained cells com-
pared to the TM-stressed cells only. Thus, downregulation of CHOP by TLR4
ligands may confer resistance to apoptotic stimuli and promote the growth and
survival of MM cells. To determine the potential therapeutic impact of TLR4
signaling in myeloma, we evaluated the activity of bortezomib in LPS pre-treated
above cell lines.LPS pre-treatment partially abrogated the efficacy of bortezomib
in these cell lines by decreasing its anti-proliferative effects compared to the
non-LPS-pretreated cell lines as tested by the WST1 assay. In addition extract
of cells were immunoblotted for CHOP protein expression. Pre-treatment of
MM cells with low dose LPS selectively suppressed CHOP in bortezomib treat-
ed cells compared to the non-LPS treated cells. CHOP suppression was also
accompanied with suppression of PERK, ATF4 and peiF2a, protein expression.
In order to determine whether the escape from the apoptotic pathway which
was achieved by LPS was preceded in caspase-dependent manner, the protein
expression of caspase-8 and caspase-9 was explored upon treatment with
LPS. Indeed, LPS stimulation was able to partially inhibit caspase-8 and cas-
pase-9 expression in bortezomib-induced JJN3 cells. Furthemore pretreatment
of LPS was able to completely abort NFκB inhibition induced by bortezomib.
Then, we examined the impact bortezomib therapy on TLR4 and CHOP mRNA
expression in primary tumors cells, collected before and at day 7 after borte-
zomib-based therapy from 6 myeloma patients. In 5 out of 6 cases TLR4 expres-
sion was significantly up-regulated and was accompanied with a coupled down-
regulation of CHOP mRNA expression. 
Summary/Conclusions: In conclusion, our data suggest that the TLR4 sig-
naling pathway might provide a translational control pathway which disables
cells to undergo the programmed cell death by apoptosis via CHOP branch.
Further exploration of this pathway is needed to establish its role as a potential
mechanism of drug resistance of MM cells which may direct future development
of novel therapeutic targets.
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LONG NON-CODING RNA MALAT1 WAS ASSOCIATED WITH PROGRESSION
OF MULTIPLE MYELOMA AND INDUCED BY CELLULAR STRESS
H Handa1,*, Y Kuroda2, K Kimura2, A Yamane1, Y Masuda2, T Kasamatsu2,
T Saitoh2, K Tahara1, N Kobayashi1, H Shimizu3, N Tsukamoto3, A Yokohama4,
T Mitsui1, T Ishizaki1, H Koiso1, M Takizawa1, H Murakami2
1Department of Medicine and Clinical Science, 2Graduate School of Health
Science, 3Oncology Center, 4Blood Transfusion Service, Gunma University,
Maebashi, Japan
Background: Recent transcriptome-wide analyses have revealed an over-
whelming amount of transcribed but not translated non-coding RNAs capable
of influencing diverse cellular processes such as proliferation, apoptosis, and
motility. Long non-coding RNA (lnc RNAs), which are commonly defined as
transcripts >200 nt in length, have emerged as a class of key regulatory RNA.
LncRNAs are deregulated in diverse human cancers and associated with dis-
ease progression; however little is available in multiple myeloma (MM). 
Aims: To elucidate the role of lnc RNA in MM, we studied expression pattern of
several well-known lnc RNAs in plasma cells of MM, MGUS and plasmacytoma,
and function in MM cell lines in vitro. Moreover, to reveal the distinct lnc RNA
signature more comprehensively, we performed next generation sequencing
based RNA sequencing, which is potentially able to discover novel lnc RNAs.
Methods: Purified CD138+ plasma cells from bone marrow (BM) mononuclear
cells obtained from 110 of MM patients, 48 of MGUS patients, 19 of control BM
and 5 of extramedullary disease (EMD) are subjected to the study after obtain-
ing informed consent. The expression levels of lnc RNAs were determined by
RQ-PCR. RNase H-activating LNA™ GapmeR antisense oligonucleotides were
used to knockdown lnc RNA in vitro in MM cell lines. The cell lines were treated
with bortezomib, MG132, doxorubicin to evaluate the effects of cytotoxic stress
for the lnc RNA expression. RNA sequencing was performed with Illumina
NextSeq 500. This study was approved by IRB of Gunma University Hospital
under Declaration of Helsinki.
Results: We found significant higher level of MALAT1 expression in BM plasma
cells of MM compared to MGUS and control (control vs MM, p<0.001; control
vs MGUS, p=0.01; MGUS vs MM, p<0.001). MALAT1 expression in EMD was
higher by 140 fold than BM MM cells. MALAT1 expression was higher in MM
with t(4;14) and del 17p (p=0.049, p=0.03), but was not different among ISS
(p=0.87). Higher MALAT1 expression is associated shorter progression free
survival (p<0.05), and tendency of shorter overall survival (p=0.09). MM cell
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lines KMS12PE, OPM2, KMS11 treated with bortezomib showed elevated
MALAT1 expression by 4.3 -21.8 fold and ANRIL by 2.2-4.7 fold. Cytotoxic
drug doxorubicin also elevated both lnc RNAs in the cell lines. MALAT1 knock-
down by GapmeR did not affect cell proliferation. The reported cell motility
genes HMMR, CTHRC1 and ROD1 did not alter in MALAT1 knockdown MM
cell lines, but RNA sequencing revealed the changes of many gene expres-
sions. Finally, RNA sequencing of MM, MGUS and EMD samples revealed dis-
tinct lnc RNA expression signature as well as protein coding genes.
Summary/Conclusions: Significant upregulations of lnc RNAs MALAT1 might
be associated with MM progression. Given that MALAT1 is associated with
lung cancer metastasis, MALAT1 might be strongly associated with EMD for-
mation. Genotoxic and ER stress induced by therapeutic drugs might upregu-
late MALAT1 leading extramedullary extension. Revealing distinct lnc RNA sig-
nature of MM is current important issue to clarify molecular mechanisms under-
lying MM progression and to development novel therapies.
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COMBINATION OF T(4;14), DEL(17P13), DEL(1P32) AND 1Q21 GAIN FISH
PROBES IDENTIFIES CLONAL HETEROGENEITY AND ENHANCES
DETECTION OF ADVERSE CYTOGENETIC PROFILES IN 233 NEWLY
DIAGNOSED MULTIPLE MYELOMA
T Smol1,*, A Dufour2, S Tricot3, M Wemeau4, L Stalnikiewicz5, F Bernardi6,
T Christine2, A Daudignon1
1Service d’Hématologie-Immunologie-Cytogénétique, CH Valenciennes, Valen-
ciennes, 2Laboratoire de Cytogénétique Hématologique, CH Versailles, Le
Chesnay, 3Service d’Hématologie Clinique, CH Valenciennes, Valenciennes,
4Service d’Hématologie Clinique, CH Arras, Arras, 5Service d’Hématologie
Clinique, CH Lens, Lens, 6Laboratoire de Biologie, CH Douai, Douai, France
Background: Cytogenetic analyses play a leading part in the risk stratification
of MM due to the prognostic and therapeutic impacts of cytogenetic abnormal-
ities. However, with a metaphase cytogenetic approach only 35% of patients
present abnormal karyotypes, often associated with an advanced stage of the
disease. Practice guidelines now recommend interphase fluorescence in-situ
hybridization (FISH) on isolated CD138-expressing plasma cells (PC) as the
initial cytogenetic analysis for MM. The most pertinent markers target the dele-
tion of 17p13 (TP53 deletion) and the t(4;14)(p16;q32) FGFR3-IGH transloca-
tion, and partial aneuploidies of chromosome 1 (1q21 gain and 1p32 deletion)
are retained as more relevant additional markers.
Aims: Our aim was to fix the FISH combination of del(17p13), t(4;14), 1q21
gain and del(1p32) in a prospective study of 233 newly diagnosed MM with an
analysis of the association between abnormalities and the number of clones.
Methods: Between January 2013 and August 2015, 233 BM samples were
collected from 233 patients during diagnostic at the Cytogenetic Laboratories
in Valenciennes General Hospital, and Versailles General Hospital. The insti-
tutional ethics committee approved the study. PC were enriched from BM
mononuclear cells, using a magnetic cell sorting CD138 MicroBeads kit (Mil-
tenyi Biotec; BergischGlabach, Germany). The FISH panel included
TP53/CEP17 probe (Amplitech, Compiègne, France), 1p32/CDKN2C-FAF1-
1q21/CKS1B probe (Amplitech), t(4;14)(p16;q32) probe (MetaSystems,
Altlussheim, Germany), and IGH break-apart probe (MetaSystems). Technical
thresholds were determined for each probe using isolated CD138-expressing
PC from patients without MM, on the basis of the same method as patients
with MM. Thresholds were assessed after counting 200 cells for each negative
sample, and established by “mean+3 DS” calculation.
Results: Cytogenetic abnormalities were identified in 79.0% of cases, with
one or more adverse abnormalities in 51.9%. We observed a del(17p13) in
15.0%, a t(4;14) translocation in 11.5%, a 1q21 gain in 37.8%, and a del(1p32)
in 8.7% of patients with statistically significant associations between 1q21 gain
and t(4;14) (p=0.001), and del(1p32) and del(17p13) (p=0.01). Adding
1p32/1q21 FISH probe has enabled us to identify one or more adverse abnor-
malities in 39.0% of patients with absence of TP53 deletion or t(4;14). Clonal
heterogeneity was observed in 51.1% of cases. Adverse abnormalities were
significantly more frequent when the number of clones was greater than or
equal to 2, with a frequency of 85.1% against 45.6% when 1 single clone was
identified (p<0.0001). We observed a greater number of MM with 1q21 gain
when clonal heterogeneity was present (≥2 clones): 81.6% versus 18.4% when
1 single clone was identified (p<0.0001). In the case of marked clonal hetero-
geneity (≥3 clones), a higher involvement of del(1p32) was found with a fre-
quency of 28.0% against 5.8% when only 2 related clones were present
(p=0.002). In the subgroup t(4;14)+/1q21+ with 2 or more identified clones
(n=14), 1q21 gain was found to be significantly more often present in the minor
clone compared to the clone with t(4;14) (10/14) (p=0.01).
Summary/Conclusions: We were able to identify adverse abnormalities or
derivative anomalies, and related clones or clonal evolution by FISH analysis.
We confirm the presence of clonal heterogeneity and accumulation of adverse
abnormalities in the first diagnostic analysis. The prognostic impact of these
parameters should be evaluated, and could be included in cytogenetic classi-
fications.
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EXPRESSION OF HUMAN CRBN SENSITIZES MOUSE MULTIPLE MYELOMA
CELLS TO LENALIDOMIDE
D Serdar1,*, S Köpff1, E Fink2, BL Ebert2, J Krönke1
1University Hospital of Ulm, Ulm, Germany, 2Brigham and Women’s Hospital,
Boston, United States
Background: The immunomodulatory drugs (IMiDs) lenalidomide, thalidomide,
and pomalidomide are highly active in the treatment of multiple myeloma. We
and others have shown that IMiDs inhibit growth of multiple myeloma cells by
inducing ubiquitination and degradation of the lymphoid transcription factors
Ikaros (IKZF1) and Aiolos (IKZF3) by the cereblon (CRBN) E3 ubiquitin ligase.
Recently, we identified another lenalidomide-induced substrate of the CRBN
E3 ligase, Casein Kinase 1A1 (CK1α), the degradation of which is responsible
for lenalidomide’s activity in del(5q) myelodysplastic syndrome. However, in
contrast to human cells, mouse cells are resistant to lenalidomide-induced
degradation of CK1α due to a single amino acid change in the mouse CRBN
(mCRBN) protein at position 391 (valine in human CRBN (hCRBN)), isoleucine
in mCRBN) that can be overcome by expression of the human variant.
Aims: To determine whether expression of hCRBN and mCrbnI391V sensitizes
mouse multiple myeloma cells to lenalidomide.
Methods: We studied the mouse multiple myeloma cell line MOPC-315.BM that
has been previously shown to induce multiple myeloma in BALB/c mice after
transplantation. The different CRBN forms were expressed by retroviral vectors.
Results: Western blot analyses showed that MOPC-315.BM multiple myeloma
cells had high protein levels of IKZF1 and IKZF3 as compared to non-myeloma
mouse cells such as Ba/F3 pro-B cells and myeloblast-like 32D cells. However,
lenalidomide treatment of MOPC-315.BM neither induced degradation of IKZF1
and IKZF3 nor had an impact on proliferation. Using retroviral transduction we
expressed mCrbn, hCRBN, and mCrbnI391V in MOPC-315.BM cells. After
lenalidomide treatment, we observed effective degradation of IKZF1 and IKZF3
proteins by western blot analysis in hCRBN and mCrbnI391V expressing MOPC-
315.BM cells but not in those expressing mCrbn or empty vector. Immunopre-
cipitation analysis revealed that in the presence of lenalidomide IKZF3 bound
to hCRBN and mCrbnI391V but not mCRBN, indicating that the isoleucine pres-
ent in mCRBN at position 391 prevents direct interaction with IKZF3. Next, we
examined the effect of expressing different CRBN forms on drug sensitivity of
MOPC315.BM cells. As in the parental cells, mCrbn-expressing cells were
insensitive to lenalidomide. In contrast, lenalidomide inhibited proliferation of
hCRBN and mCrbnI391V expressing cells in a dose-dependent fashion. Similar
results were obtained for pomalidomide and thalidomide. Expression of a dom-
inant negative IKZF3 isoform that inactivates IKZF3 and IKZF1 inhibited pro-
liferation of MOPC315.BM cells, demonstrating that these cells depend on both
transcription factors as their human counterparts. Expression of hCRBN and
mCrbnI391V did not sensitize Ba/F3 or 32D cells to lenalidomide, demonstrating
the multiple myeloma-specific effect of IMiDs. In MOPC315.BM cells, expres-
sion of hCRBN or mCrbnI391V had no effect on the sensitivity of other potent
anti-multiple myeloma drugs including bortezomib and dexamethasone, con-
firming the specific role of CRBN as a drug target for IMiDs.
Summary/Conclusions: These results demonstrate that mouse multiple myelo-
ma cells can be specifically sensitized to IMiDs by expression of hCRBN or mCrb-
nI391V and provide a basis for further development of in vivo models for IMiDs.
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INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACIS) ON THE
EXPRESSION OF ADHESION MOLECULES AND MODERN TARGET
STRUCTURES IN MULTIPLE MYELOMA (MM)
S Müller1,*, J Senger2, J Waldschmidt1, D Wider1, A Thomsen3, G Ihorst4,
J Duyster1, M Hug5, M Jung2, R Wäsch1, M Engelhardt1
1Hematology & Oncology, Medical Center University of Freiburg, 2Pharmaceu-
tical Science, Albert-Ludwigs-University, 3Radiation Oncology, 4Clinical Trials
Unit, 5Pharmacy, Medical Center University of Freiburg, Freiburg, Germany
Background: During the last decades the vital role of the bone marrow (BM)
niche was increasingly explored to elucidate the progression and drug resist-
ance in multiple myeloma (MM), this leading to advances of treatment strategies
to modulate the interaction between malignant plasma cells (PCs) and the
microenvironment. Small molecules (IMiDs, plerixafor, NOX-A12) and biologi-
cals (elotuzumab, daratumumab, indatuximab) have been developed and are
in pre- and clinical use.
Aims: We assessed the influence of histone deacetylase inhibitors (HDACis)
on the BM niche. For this purpose various HDACis were assessed alone and
in combination with antimyeloma agents in a novel 3-dimensional (3D) co-cul-
ture, to predict most rational combination use targeting both PCs and BM niche.
Methods: To best mimic the microenvironment, whilst ensuring easy handling,
we have established an agarose matrix-based 3D coculture model, suitable for
high-throughput screening. The cells are seeded in conical microwells and their
proliferation, viability and apoptosis are assessed. These properties are com-
pared both in presence or absence of stroma and to 2D cultures. Cells are incu-
bated with HDACis, their synergisms with established antimyeloma drugs and
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stroma effects upon the treatment can be visualized via flow-cytometry and via-
bility assays. The expression profile of relevant surface molecules (CXCR4,
CD38, SLAM-F7, CD138) in primary MM cells and MM cell lines (MMCLs) are
determined using fluorescent labeled antibodies and flow-cytometry.
Results: Inside the microcavities of the agarose matrices, PCs indeed formed
3D cell clusters and showed a similar cell proliferation rate compared to 2D
cultures. Cell growth and expression pattern of surface proteins were influenced
by the presence of BM stroma cells (BMSCs), leading to a decrease in CXCR4
but persistence of CD138 expression. Our current results suggest evident dif-
ferences concerning growth and treatment response in our 3D versus 2D culture
systems, which we currently further validate using HDACi as a novel substance
class in MM within this easy to use culture system. Therein, the novel selective
HDAC-6 inhibitor JS28 was selected from more than 20 hydroxamic acid
derivates due to trypsin-dependent in vitro HDAC-inhibition assay results, with
an IC50 of 59nM and a both 200-fold selectivity for HDAC 6 and HDAC 8 as
compared to HDAC 1, respectively. The effect on target could be demonstrated
in 2 different cell lines (HeLa and HL30) via western blot, quantifying a higher
amount of acetylated tubulin, which is mainly degraded via HDAC 6 and con-
sequently an evident marker for HDAC 6 activity. The phenotypic HDACi effect
was determined with assessment in 2 MMCLs U266 and RPMI 8226: treatment
of U266 and RPMI cells were performed with use of panobinostat or JS28 for
48 hours, either alone or combined with bortezomib, to test synergism. 2, 4
and 6nM bortezomib were combined with same ratios of both HDACi panobi-
nostat with 2, 4 and 6nM or JS28 with 20, 40 and 60µM. The calculated com-
bination indices (CI) in both MMCLs were <1 (=synergistic) within a range of
approximately EC40 to EC55 for both combined panobinostat/bortezomib and
JS28/bortezomib treatment schedules.
Figure 1.
Summary/Conclusions: Our current data underline the importance of accurate
3D co-culture models to mimic in vivo proliferation and drug resistance and to
predict later clinical treatment success more effectively. So far, there is insuffi-
cient data that conclusively unravel the complex interactions between HDACis,
their different subtype selectivity and the rapidly increasing number of treatment
options in MM. In this context, our ongoing investigations will focus on cytokine
secretion patterns, expression of adhesion molecules, their targeting and their
alteration by HDACis.
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HEME OXYGENASE 1 (HO-1) PROTECTS MYELOMA CELLS AGAINST
BORTEZOMIB THROUGH NUCLEAR TRANSLOCATION AND REGULATION
OF ER STRESS AND AUTOPHAGY PROTEINS
D Tibullo1,*, I Barbagallo2, C Giallongo1, G Camiolo1, G D’Amante1, P La Cava1,
NL Parrinello1, A Romano1, C Conticello1, S Saccone3, MV Brundo3, L Vanella2,
G Li Volti4, F Di Raimondo1
1Division of Hematology, azienda ospedaliera universitaria policlinico vittorio
emanuele, 2Department of Drug Science, Biochemistry Section, 3Department
of Biological, Geological and Environmental Sciences, 4Department of Biomed-
icine and Biotechnologies, University of Catania, Catania, Italy
Background: Despite recent advances in proteasome inhibitor and
immunomodulatory drug-based therapies, MM remains largely incurable, pri-
marily owing to acquired resistance. HO-1 is a cytoprotective microsomal
enzyme that catalyzes the degradation of heme. We have recently shown that
the protective effect of HO-1 on drug-induced cytotoxicity in leukemic cells does
not involve its enzymatic byproducts, but rather its nuclear translocation fol-
lowing proteolytic cleavage. It has been recently described that Bortezomib
(BTZ) is able to increase HO-1 expression.
Aims: We investigated about the role of BTZ-induced HO-1 in MM cell lines
(U266, SKM-M1).
Methods: Cell Proliferation was performed by ATPlite one step assay
(Perkinelmer) and using flow cytometry Annexin V/ iodure propidio. ROS for-
mation was evaluated by flow cytometry. Endoplasmic reticulum (ER) associ-
ated proteins, autophagy-related proteins and HO-1 protein were evaluated by
western blot assay. The fluorescent images were obtained using a Confocal
Laser Scanning Microscopy (CLSM, Zeiss LSM700, Milan, Italy).
Results: As expected, we observed that Btz (15 nM) induced apoptosis after
24h (p<0.001). Flow cytometric analysis revealed increased levels of ROS after
1h (p<0.0001) of treatment with a peak after 3h (p<0.001). Btz was able to
induce a significant increase in HO-1 mRNA levels after 3h (p<0.0001) of treat-
ment with a maximum peak after 6h (p<0.0001). Since HO-1 is one of the major
endoplasmic reticulum (ER) associated heme protein, we analyzed the ability
of BTZ to induce ER stress. BTZ was able to induce the expression of ER
stress proteins (Bip, IRE1α, Ero1, PERK and CHOP) in MM cells after 6h
(p<0.001) with a peak after 24h (p<0.0001). Moreover, we observed that BTZ
was able to induce autophagy-related genes such as ATFG5 and BENC1 in
U266 cell lines. Silencing HO-1 using siRNA, we observed reduction of proteins
described above indicating that induction of ER stress and then autophagy
pathways by BTZ is HO-1 mediated. Furthermore, by confocal microscope we
observed that HO-1 localized both in the cytoplasm and in the nucleus of MM
cells. Interestingly, blockage of nuclear translocation by E64, a selective inhibitor
of the protein cleavage, induced MM cells to become more sensitive to BTZ
(p<0.001). No change in cell viability was observed inhibiting HO-1 enzymatic
activity by using TIN (zync protoporphirin, 10 uM). Since nuclear HO-1 it has
been reported to be a regulator of DNA repair activities, we also explored its
role in genomic instability of MM cells. Using the cytochinesis-block micronu-
cleus (CBMN) assay, we observed that pre-treatment of U266 with E64 for 24h
led to a significant reduction of the percentage of micronuclei (p<0.01) and
nucleolasmic bridges (p<0.05) observed in binucleated cells. Next, we evalu-
ated U266 ability to activate G2/M checkpoint after UV damage using CBPI
(cytochinesis block proliferation index) assay. The percentage of monucleated
cells (G2/M checkpoint activated) was higher in cells pre-treated with E64 than
control (p<0.05).
Summary/Conclusions: Our data suggest that BTZ-induction of HO-1 is prob-
ably linked to the activation ER stress and autophagy pathway by BTZ through
HO-1 activation. HO-1 nuclear translocation may be involved in MM BTZ resist-
ance. In addition, nuclear HO-1 may be involved in genomic instability of MM cells.
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ANTI-MYELOMA EFFECT OF CANNABINOIDS
V Barbado1, M Medrano1, T Caballero-Velazquez2, I Alvarez-Laderas1,
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Background: It is well studied the antiproliferative and proapoptotic effects of
cannabinoids in neoplasias of the central nervous system, where the cannabi-
noid receptor type 1 (CB1) exhibits the highest levels of expression. In contrast,
the cannabinoid receptor type 2 (CB) is found also exclusively in the hematopoi-
etic and immune system. Despite this, the potential effect of cannabinoids on
hematologic malignancies has been poorly determined.
Aims: Our purpose is to investigate the anti-tumor effect, both in vitro and in
vivo, of different cannabinoids in multiple myeloma (MM) and know the main
signaling pathways implicated in the effect of cannabinoids.
Methods: We evaluated the effect of five cannabinoid compounds in cell via-
bility of six different human multiple myeloma cell lines, primary myeloma plas-
ma cells and healthy primary cells from patients and donors. We studied the
involvement of the main signaling pathways in the effect of cannabinoid as well
as the expression of capases and some proteins of family Bcl-2 and also of the
SPT enzyme by Western-blot. We used selective antagonists of cannabinoid
receptors to know if the effect antiproliferative of tested cannabinoids is medi-
ated by CB2. The role of ceramide was examined by immunohistochemistry
and by pharmacological inhibition of the synthesis route. In addition we evalu-
ated the synergism of the combination of cannabinoids with antimyeloma
agents, such as dexamethasone and melphalan. Finally, we evaluated the
effect of cannabinoids in MM xenograft models.
Results: We demonstrate that cannabinoids induce a selective apoptosis in
myeloma cell lines and in primary malignant plasma cells from MM patients,
without affecting the viability of normal cells from healthy donors, including
hematopoietic stem cells. This antiproliferative effect is mediated by activation
of caspases, mainly caspase 2, and is partially prevented by a pan-caspase
inhibitor. Cannabinoid-induced apoptosis was correlated with an increased
expression of Bax and Bak and a decrease of Bcl-xL and Mcl-1. In addition,
cannabinoid treatment induced a biphasic response of Akt/PKB and significantly
increased the levels of ceramide in MM cells. Remarkably, the blockade of
ceramide synthesis prevented cannabinoid-induced apoptosis, indicating that
ceramides play a key role in the pro-apoptotic effect of cannabinoids in MM
cells. Furthermore, blockage of the cannabinoid receptor CB2 also inhibited
cannabinoid induced apoptosis. Cannabinoid WIN-55 enhanced the antimyelo-
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ma activity of dexamethasone and melphalan overcoming resistance to mel-
phalan in vitro. Finally, administration of cannabinoid WIN-55 to plasmacy-
toma-bearing mice significantly suppressed tumor growth in vivo.
Summary/Conclusions: Our findings suggest that cannabinoids induce a
selective apoptosis in tumor cells without adverse effects and thus they may
be considered as potential therapeutic agents in the treatment of multiple
myeloma.
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BONE MARROW ADIPOCYTES PROMOTE MYELOMA CELL PROLIFERATION
THROUGH INTERLEUKIN-6 SIGNALLING
AM Katumba1,*, MS Shafat1, KM Bowles1,2, SA Rushworth1
1Department of Molecular Haematology, Norwich Medical School, University
of East Anglia, 2Department of Haematology, Norfolk and Norwich University
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Background: Multiple myeloma (MM) is a malignancy characterised by the
proliferation of monoclonal plasma cells within the bone marrow (BM) and its
progression crucially involves support from the BM microenvironment. The BM
microenvironment consists of many cell types not directly involved in
haematopoiesis including the adipocyte, which accounts for over 50% of the
older adults BM by volume. Adipocytes are known to promote the growth and
survival of breast, ovarian and prostate cancers. Subsequently, we hypothe-
sised that BM adipocytes could play a role in mediating MM cell survival and
proliferation.
Aims: To investigate the role of BM adipocytes in regulating the survival and
proliferation of MM cells.
Methods: Primary myeloma cells and MM cell lines were cultured on patient
derived adipocytes which were obtained following informed consent under
approval from the UK National Research Ethics Service (LRCEref07/
H0310/146). MM cell proliferation was determined using flow cytometry cell
count and BrdU uptake while cell survival was determined by annexin V/PI
staining. Immunocytochemistry using a lipid specific dye and nuclear staining
was performed to determine free fatty acid (FFA) transfer between adipocytes
and MM cells with and without the inhibitor acipimox. ß-oxidation rates in MM
cells were determined by Seahorse XF analysis using palmitate and etomoxir.
PCR and cytokine analysis was used to determine the levels of interleukin-6
(IL-6) and other factors. 
Results: We report that BM adipocytes promote MM cell survival and prolifer-
ation. BrdU analysis and annexin V/PI staining revealed that adipocyte/MM
cell co-culture led to increased MM cell proliferation and decreased MM cell
apoptosis compared to MM cells cultured alone. Furthermore, MM cells cultured
on adipocytes induced adipocyte lipolysis and initiated lipid transfer from
adipocytes to MM cells. This process was inhibited by acipimox. In addition,
MM cell/adipocyte co-culture also led to increased MM cell β-oxidation rates
indicating that MM cells use BM adipocyte derived FFAs to produce ATP. Fur-
thermore, pharmacological inhibition of ß-oxidation using etomoxir led to a sig-
nificant decrease in survival and proliferation of MM cells. PCR and cytokine
analysis identified an increased expression of IL-6 in MM cells co-cultured with
adipocytes. Further analysis revealed that IL-6 derived from myeloma cells
induced the breakdown of triglycerides into FFAs (lipolysis) in BM adipocytes. 
Summary/Conclusions: Results indicate that adipocytes provide energy to
MM cells in the form of FFAs for survival and growth in vitro. Moreover, we found
that the signal which induces adipocyte lipolysis is myeloma derived IL-6.
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RETROSPECTIVE STUDY OF PARAPROTEINEMIA PREVALENCE AND
DEVELOPMENT OF HEMATOLOGICAL MALIGNANCIES IN HBSAG
POSITIVE VERSUS HBSAG NEGATIVE PATIENTS
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Background: Hepatitis B virus is lymphotropic and persists in peripheral blood
mononuclear cells for years after active infection. In chronic infection, persistent
antigenic stimulation of lymphocytes occurs. Whether these effects of the virus
on B cells increase the risk of paraproteinemia and its progression is unknown. 
Aims: We proposed to compare HBsAg+ versus HBsAg negative patients
identified in the same time frame for prevalence of paraproteins and risk of
development of hematological malignancy (HM).
Methods: Adults in Montefiore Medical Center with a HBsAg test between Jan
1st 2001 and Dec 31st 2011 were identified. Those with a positive serum protein
electrophoresis (SPEP) test were included. SPEP results were classified into
faint (F-SPEP) and discrete (D-SPEP). Demographics, results of Hepatitis C
and HIV serology were obtained. Cancer registry data were reviewed for a
diagnosis of biopsy confirmed HM.
Results: 216,522 patients were tested for HBsAg. 3,177 were positive. 346 of
3,177 HBsAg+ (10.9%) had an SPEP test. 66 of 346 (19%) had a +SPEP. 15
(4.5%) had a D-SPEP and 51 (14.5%) had a F-SPEP. Of the 213,345 HBsAg-
, 21,291 (9.9%) had a SPEP. 2,226 of 21,291 (10.5%) were SPEP+. 739 (3.3%)
had a D-SPEP and 1487 (7.2%) had a F-SPEP. HBsAg+ patients were more
likely to be SPEP+ than HBsAg-. (19% vs 10.5%, p<0.0001). Patients with
+SPEP among HBsAg+ and HBsAg- were compared. (Table 1) HBsAg+
SPEP+ patients were more likely to be male (69.7% vs 47.9%, p<0.001), more
likely tested for HIV (OR:3.7, 95% CI: 2.1-6.4) and to be HIV positive (OR:2.3,
95% CI: 1.3-4.1). HBsAg+ SPEP+ patients were 6.7 times more likely to have
a HM compared to HBsAg- SPEP+ patients. (OR: 6.7, 95% CI 3.5-12.7) The
types of HM identified in the groups is described in Table 2.
Table 1. HBsAg- SPEP+ versus HBsAg+ SPEP+ patients.
Table 2. Malignancies in HBsAg+ and HBsAg- patients with +SPEP.
Summary/Conclusions: Our study shows that paraproteinemia is more preva-
lent in HBsAg+ patients, and HBsAg+SPEP+ patients are at a greater risk of
developing HM compared to HBsAg- SPEP- Virus dependent B cell proliferation
may be involved in Hepatitis B lymphomagenesis and paraproteins may be a
marker. Modest frequency of HIV testing in our retrospective cohort is a signif-
icant limitation.
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PROTEOMIC SIGNATURE PREDICTING COMPLETE RESPONSE TO PAD
IN REFRACTORY MULTIPLE MYELOMA PATIENTS QUALIFIED FOR
AUTOPBSCT AND VD CONSOLIDATION-MULTICENTER, POLISH MYELOMA
CONSORTIUM 001 STUDY
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tology, St John’s Cancer Center, Lublin, 8Department of Hematology and Bone
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Background: Despite the new drugs introduced to multiple myeloma (MM)
treatment the disease remains incurable due to increasing resistance to therapy.
Understanding biology of disease and identification of biomarkers of resistance
is a key research challenge and may enable the individualization of treatment.
Aims: We aimed to identify biomarkers and signaling pathways differing plasma
cells (PCs) of patients (pts) with refractory/relapsed MM (RRMM) who achieved
complete response (CR) after PAD (bortezomib, adriamycin, dexamethasone)
from those with lower response. All the patients were qualified to undergo a
high dose melphalan and a VD (bortezomib, dexamethasone) consolidation
afterwards.
Methods: Comparative proteome analysis was performed on purified by pos-
itive selection (EasySep), pretreatment PCs from pts, who were refractory to
the first line (CTD) and qualified for PAD chemotherapy followed by high dose
melphalan and 2 cycles of VD consolidation according to standard recommen-
dations of Polish Myeloma Group. Treatment response was assessed using
IMWG criteria. PCs acquired from pre-treatment bone marrow after obtaining
informed consent from pts (IRB# 434/14 UMP) were lysed and protein was
isolated. Proteins from each patient were analyzed using two different, inde-
pendent proteomic methods: Isobaric Tag for Relative and Absolute Quantita-
tion iTRAQ (4-plex) and Label Free-based (LF) proteomic approach. Peptides
were analyzed using Q-Exactive hybrid quadrupole-Orbitrap mass spectrom-
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eter coupled to the chromatograph Dionex 3000 Ultimate nanoLC (Thermo Sci-
entific). Proteins which accumulation in the analyzed subgroups differed by at
least 50% in both methods (iTRAQ and LF) were considered to differentiate.
The dysregulated proteins were subjected to REACTOME and PANTHER bioin-
formatic tools for identifying enriched signaling pathways and networks. 
Results: As of January 31th 2016 30/45 (66%) pts (median age: 60 (38-74))
received 6 planned PAD. Treatment was interrupted due to toxicity for 8 pts
(G3 neuropathy, G2 infection) and disease progression (PD) (7 pts - 15%).
After PAD 8 pts achieved CR (17%), 14 VGPR (30%), 14 PR (30%) and 9 - PD
(20%). 4 pts died due to PD during PAD. Transplantation was so far performed
in 12 pts and consolidation planned 3 months after autoPBSCT in - 7. Proteomic
analysis was performed on PCs from 28 pts. Out of 499 proteins identified
(FDR<1%), 56 showed significant differences in accumulation between patients,
who, after treatment with PAD, achieved CR and patients with worse response.
Accumulation of 13 proteins was up-regulated in resistant patients, among
them thioredoxin domain-containing protein 5 (TXNDC5), proteasome activator
complex subunit 2 (PSMA2) and peroxiredoxin-5 whereas relative abundance
of 42 proteins were down-regulated in resistant patients. Among the latter were
vimentin, annexin A1. Based on the log of p-value from Fisher’s test and number
of identified differential proteins, the most affected pathways constitute: pro-
teasome pathway, apoptosis and programmed cell death, signalling by Rho
GTPases, detoxification of ROS and activation of DNA fragmentation factor
and apoptosis induced DNA fragmentation. 
Summary/Conclusions: We indicated pathways involved in resistance to
investigated regimen in RRMM and confirmed our previous finding in newly
diagnosed MM and RRMM (Dytfeld BJH 2015, ASH 2015). We pointed signif-
icant biomarkers of resistance and potential therapeutic targets as basis for
individualized MM therapy. 
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NOTCH PATHWAY AND INTELEUKIN-6 COOPERATE TO SUPPORT
MULTIPLE MYELOMA CELL PROLIFERATION
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Background: Multiple myeloma (MM) is a malignant plasma cells (PC) disorder
characterized by PCs accumulation in the bone marrow (BM) and a close interac-
tion between PCs and the surrounding microenvironment. Infact, BM stromal cells
(BMSCs) sustain the survival and proliferation of tumor cells through adhesion
molecules and the production of several cytokines, especially interleukin-6 (IL6).
At the initial stage, MM cells strictly depend on IL6 produced by BMSCs and during
disease progression may acquire independence and/or the ability to produce
autonomously this cytokine. The Notch pathway is highly conserved and plays a
crucial role in cell-fate decision, tissue patterning and morphogenesis. Recent evi-
dences suggest a key role of Notch pathway in MM progression, by its ability to
positive regulate cell proliferation, drug resistance and BM infiltration through the
overexpression of both receptors (Notch1 and 2) and ligands (Jag1 and 2).
Aims: We investigated the cooperation between the Notch pathway and IL6
signaling in the promotion of MM cells proliferation. Particularly, we analyzed
how Notch upregulation during MM progression may support tumor cells growth.
Moreover, we evaluate if it could promote the activation of an IL6 autocrine
loop in MM and favor IL6 paracrine production by the surrounding BMSCs.
Methods: Notch signaling modulation was induced in MM cell lines and primary
MM cells as follows: upregulation by 5μg/mL soluble Jag1; down-regulation by
50μM DAPT or Jag1-2 RNA interference. qPCR was performed using SYBR
Green. Absolute cells count and evaluation of IL6 protein expression was
achieved by flow cytometry. Immunohistochemistry (IHC) for Hes6, IL6 and Ig
light chain was performed on BM biopsies at different stages of MM.
Results: Gene expression profiling (GEP) analysis evidenced the upregulation
of Jag1 and Hes5 (Notch transcriptional target) in MM and pPCL (primary plas-
ma cell leukemia) cases compared to normal controls, and the overexpression
of Notch2, Hes5 and Hes6 in the worst prognosis, MAF-traslocated MM
patients. These data support the hypothesis that over-expression of Notch path-
way members correlate with progression or high-risk MM. Notch activity was
modulated in MM cell lines, allowing us to demonstrate that the dysregulation
of Notch signal can substitute IL6 stimulation. Infact, Notch activation in IL6-
dependent cells may stimulate their proliferation in the absence of the cytokine.
On the opposite, upon Notch blockade, IL6-indipendent cells became depend-
ent on IL6 for their growth. Notch pathway is also able to support MM cells pro-
liferation through the promotion of an IL6 autonomous production. Indeed, IL6
expression in U266 cells depends upon Notch signaling and IHC study con-
firmed an association between Notch activation and IL6 immunoreactivity in
MM cells. Since the most important source of IL6 are BMSCs, we focused our
attention on the interaction between MM cells and the surrounding niche. We
showed, by IHC staining, that MM cells induced IL6 expression in the nearby
BMSCs. By co-culture systems, we demonstrated that MM cell-derived Jag lig-
ands are able to activate Notch pathway in BMSCs, promoting IL6 secretion
and MM cell proliferation, whereas Notch inhibition reverts this effect. Our
results were further confirmed in ex-vivo co-cultures of MM cells and BMSCs,
collected from patients.
Summary/Conclusions: Notch signaling in MM cells and in surrounding
BMSCs promotes MM cell growth by boosting IL6 production. These results
support the rationale for a Notch-directed approach in MM and suggest that
Jag ligands may be promising molecular targets in MM therapy.
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INTEGRATIVE ANALYSIS OF DNA COPY NUMBER, DNA METHYLATION
AND GENE EXPRESSION IN MULTIPLE MYELOMA REVEALS
ALTERATIONS RELATED TO RELAPSE
P Krzeminski1,*, L Corchete1, A Martín1, LLC López-Corral1, E Fermiñán2,
E García2, JL García3, J Hernández-Rivas1, R García-Sanz1, J San Miguel4,
N Gutiérrez1
1Hematologia, Hospital Universitario. IBSAL, IBMCC (USAL-CSIC), 2Genomica
y Proteomica, 3Hematology, Centro de Investigación del Cáncer-IBMCC
(USAL-CSIC), Salamanca, 4Clínica Universidad de Navarra, Centro de Inves-
tigaciones Médicas Aplicadas (CIMA), Pamplona, Spain
Background: Multiple myeloma (MM) remains incurable despite the introduc-
tion of novel agents and a relapsing course is observed in the majority of
patients. Although the development of genomic technologies has greatly
improved our understanding of MM pathogenesis, the mechanisms underlying
relapse have been less investigated.
Aims: To investigate the genomic changes generated in the transition of myelo-
ma cells from diagnosis to relapse, analyzing DNA imbalances, methylation,
and transcriptomic modifications.
Methods: Twenty patients with symptomatic newly diagnosed MM were includ-
ed in the study. Paired bone marrow (BM) samples were obtained at diagnosis
and relapse in all the patients. A CD138 positive PC isolation using the
AutoMACs automated separation system was carried out in all the BM samples
(purity was above 90%). Genome-wide detection of CNA was carried out using
the standard Affymetrix CytoScan 750k assay protocol (Affymetrix); DNA methy-
lation was assessed using the “Human DNA Methylation 3x720K CpG Island
Plus RefSeq Promoter Array” according to standard procedures by NimbleGen
Systems, and gene expression profiling was performed by means of the Human
Gene 1.0 ST Array (Affymetrix).
Results: Overall, the acquisition of abnormalities at relapse was much more
frequent than the lost of lesions present at diagnosis, and DNA losses were
significantly more frequent at relapse than in diagnosis samples. Interestingly,
copy number abnormalities involving more than 100 Mb of DNA at relapse sig-
nificantly impact the gene expression of these samples, provoking a particular
deregulation of IL-8 pathway. On the contrary, no relevant modifications of gene
expression were observed in those samples with less than 100 Mb affected by
chromosomal changes. Although different statistical approaches were used to
uncover genes whose abnormal expression at relapse was regulated by DNA
methylation, only two genes significantly deregulated in relapse samples
(SORL1 and GLT1D1) showed a negative methylation-expression correlation.
A deeper analysis demonstrated that DNA methylation was involved in regula-
tion of SORL1 expression in MM. Finally, relevant changes in gene expression
observed in relapse samples, such us downregulation of CD27 and P2RY8,
were not apparently preceded by alterations in corresponding DNA.
Summary/Conclusions: Cross-platform integration of three different microar-
rays data revealed that genomic heterogeneity of MM already described at
diagnosis is subject to change at relapse, both at the DNA and RNA level. This
study, also, showed a limited effect of DNA methylation changes observed at
relapse on the transcriptome of myeloma cells.
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DETAILED FISH PROFILING OF MULTIPLE MYELOMA PATIENTS IDENTIFIES
A GROUP OF PATIENTS WITH ONLY SECONDARY CHROMOSOMAL
ABERRATIONS
M Pantic*, I Bartsch, A Heumüller, R Claus, J Waldschmidt, A Zober, SM Dold,
D Pfeifer, J Rawluk, J Duyster, R Wäsch, M Engelhardt
Hematology, Oncology and Stem Cell Transplantation, University Medical Cen-
ter, Freiburg, Germany
Background: Using targeted fluorescence in situ hybridization (FISH) analyses
of plasma cells, chromosomal aberrations are identified in more than 90% of
patients (pts) with multiple myeloma (MM). It is postulated that early oncogen-
esis in MM is driven by two different (almost) exclusive genetic events: hyper-
diploidy (HYP) and IGH translocations (IGH-R), and that clonal evolution occurs
with acquisition of secondary aberrations (SA). Recent studies showed that
some pts have both types of aberrations (IGH-R+HYP) and that myeloma
relapses are sometimes related to clones quite different to those at diagnosis.
However, the characteristics of MM pts with secondary aberrations only (SA)
have not being extensively studied.
Aims: Our aim was to detect MM pts with SA and to analyze if these pts show dif-
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ferent biological and clinical characteristics than MM pts with primary aberrations.
Methods: We performed FISH on CD138+ plasma cells of 163 MM pts con-
secutively diagnosed in our department since 2012. We used an extensive
FISH panel to analyze five IGH-translocations, five different trisomies and five
probes labeling recurrent secondary aberrations. Ten patients were analyzed
by targeted next-generation sequencing (NGS) technology using the Agilent
HaloPlex library preparation approach. Genes bearing hotspots for mutations
in hematological malignancies were included in the sequencing panel.
Results: Chromosomal (chr) aberrations were detected in 98% (160/163) and
hyperdiploidy was the most frequent primary aberration in 59% (94/160), IGH-
R occurred in 29% (47/160) and SA in 12% (19/160) of MM pts. Overlapping
IGH-R and HYP was found in three pts with HYP proceeding the developing
of t(4;14), in line with recent publications (1,2). In comparison to all MM pts
those with SA showed higher frequencies of IgA MM isotypes (6/19) and light
chain-only MM (6/19). Moreover, they showed more aggressive MM with ISS3
in 74% (14/19) of pts at the time of analysis. 13q14 was the most frequent
chromosomal locus involved in almost all pts (18/19) with equally distribution
of deletion 13q14 (9/18) and monosomy 13 (9/18). Gain 1q21 was the second
most frequent aberration present in even 68% (13/19) of SA pts. Deletion 1p32,
cMYC and 14q32 (IGH)-abnormalities were discovered in 21% (4/19), 21%
(4/19) and 26% (5/19), respectively. A total of 53 chr aberrations were detected
in 19 MM pts with SA showing a high level of chr complexity compared to all
MM pts. Interestingly, two of the analyzed pts, one with three SA and one with
six, did not show additional mutations via NGS technology.
Summary/Conclusions: Our results reveal a progressive MM cell type with
as yet unknown initiating oncogenetic events, but highly activated mechanisms
of clonal proliferation. Moreover they raise two questions, 1. whether pts without
detectable primary genetic events, but with occurrence of unfavorable and
high-risk secondary cytogenetic lesions represent a distinct MM subgroup and
2. how these pts should be best assessed and treated. Using NGS technology
in a large MM pt cohort should allow to gain more insight in the pathogenesis
of this subgroup of MM pts.
References
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Background: Multiple myeloma (MM) is the second most common hematolog-
ical malignancy in the world. It is characterized by increasing rate of various
genetic mutations and dysregulated pathways. This work aims to find out if this
observed dysregulation may be partly caused by a subgroup of non-coding RNAs,
the so-called long non-coding RNA molecules (lncRNA). These molecules are
over 200 nt long, primarily localized in the nucleus, and it seems increasingly
obvious that lncRNAs play a crucial role in human diseases including cancer.
Aims: The goal of this study was to identify a disease-specific cellular lncRNA
signature using a cohort of MM patients in comparison to healthy donors.
Methods: Fifty CD138+ samples obtained from newly diagnosed MM patients
and healthy donors (HD) were evaluated for this study. Screening analysis of
83 lncRNA was performed on 6 MM patients and 6 HD using RT2 lncRNA PCR
Array-Human lncRNA Finder (Qiagen). Significantly deregulated lncRNAs
between MM vs HD were validated by qPCR using relative quantification
approach 2-ΔCt on a larger cohort of patients and HD. Receiver Operating Char-
acteristic (ROC) analysis was used to calculate specificity and sensitivity of
each lncRNA. P values<0.05 were considered significant.
Results: RT2 lncRNA PCR Array profiling revealed 27 deregulated lncRNAs
(all p<0.01) between MM patients and HD. ZFAS1, UCA1, BDNF-AS, NEAT1
and FAS-AS1 expression levels were further verified on a bigger cohort of MM
and HD samples. UCA1 was significantly down-regulated (p<0.0001), NEAT1
and BDNF-AS were up-regulated in MM samples when compared with HD
(both p<0.00000001). To discriminate MM from HD, receiver operating char-
acteristic (ROC) curve was calculated. It revealed sensitivity of 100% and speci-
ficity of 100%, and area under curve (AUC)=1.000 for NEAT1 and BDNF-AS
lncRNA expression and sensitivity of 95.24% and specificity of 75%, and area
under curve (AUC)=0.905 for UCA1 expression levels. We suppose that these
dysregulated lncRNAs could have a biological relevance in MM since BDNF-
AS is an antisense RNA for BDNF, a significant stimulating factor of osteoclasts
in MM, NEAT1 and UCA1 were described as dysregulated in several types of
cancer, including hematological malignancies.
Summary/Conclusions: Altogether, our first observations demonstrate that
cellular lncRNA UCA1, NEAT1 and BDNF-AS may be involved in pathophysio-
logical processes occurring in MM cells and prompt further studies in this field.
Grant support: AZV 15-29508A
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NEXT GENERATION FLOW CYTOMETRY IS A RELIABLE TECHNIQUE
FOR DETECTING MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
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LONG TERM REMISSION
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Background: 4-6 colours flow cytometry has been validated in the past years
as a powerful and feasible technique able to detect MRD in multiple myeloma
patients thus furnishing a clinical and prognostic tool to the physician. Although
its applicability and specificity can be high, it requires good quality bone marrow
aspirate and expert and trained personnel for the analysis. However, recent
results have confirmed that 4-6 colours flow-MRD has a lower sensitivity than
molecular techniques such as allele-specific oligonucleotyde (ASO)-PCR and
next generation sequencing (NGS). Recently, two 8 colours tubes panel devel-
oped by the EuroFlow Consortium showed to be able to detect MRD with an
increased sensitivity and to be applicable as standardized method.
Aims: Complete remission (CR) is a prerequisite for long term responses, pro-
gression free survivals, and ultimately overall survivals and cure, but while many
studies have looked at MRD status soon after autologous or allogeneic stem
cell transplantation with flow or molecular techniques, little is known about long
term remission patients (>5-10 years) and in particular if more sensitive tech-
niques such as NGF or NGS can still detect minimal disease in those patients.
Methods: We tested the feasibility of NGF-MRD to CR MM patients with a
lyse-wash-and-stain sample preparation protocol, staining an high numbers of
bone marrow (BM) cells (≥2x106 cells/tube) with 2-tubes optimized 8-colours
antibody panel, (OneFlow PCST e PCD BD Biosciences) for accurate identifi-
cation of BM plasma cells (PCs) and discrimination between phenotypically
aberrant (aPC) and normal PC (nPC). Patients with a CR/stringent CR were
tested for MRD in BM and peripheral blood samples. Patients with 5-10 years
of remission duration were analysed as well as patients with 2 to 4 years of
remission. Clinical characteristics will be reported as well as treatment received.
Results: Applicability was 100% of patients studied. A preliminary result on
the first 20 patients analysed showed an MRD+status in 12/20 patients prede-
fined as CR. In particular, 2/20 patients did show residual disease also in the
PB. Interestingly when studying patients with >5 years CR status, 1/5 did show
an MRD+. A plan to analyse patients in CR is ongoing within the Tuscan Group
of Multiple Myeloma (GTMM). The target is to test NGF-MRD in >100 CR
patients comparing different treatments (auto vs chemo, vs new agents), age
(<65 years vs >65 years), CR duration (<5 ys vs >5 ys).
Summary/Conclusions: Next generation flow is able to detect minimal resid-
ual disease in approximately 60% of predefined CR patients. The sensitivity
can be quite comparable to the molecular techniques, but with an applicability
largely superior. Patients with long term CR seem to have more chances to be
MRD negative, although these findings nee to be demonstrated in a large
cohort of patients. To confirm these data a study is currently ongoing of the
GTMM and results will be presented.
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Background: Monoclonal gammopathy of unknown significance (MGUS) is a
precursor condition that precedes multiple myeloma (MM). Bone disease is a
major manifestation of MM, and includes osteolytic lesions, fractures, and osteo-
porosis. Previous population-based studies have shown that individuals with
MGUS have an increased risk of fractures, although the mechanism behind this
increased risk remains unknown. Furthermore, these studies have been performed
on clinically established cohorts with a risk of bias due to underlying comorbidity.
Aims: Our aim was to analyze bone mineral density (BMD), bone volume, and
risk of fractures among individuals with MGUS in a screened population.
Methods: We performed a screening for MGUS in the Age Gene/Environment
Susceptibility Reykjavik study (AGES-Reykjavik) cohort, consisting of 5,764
elderly Icelandic men and women. Through serum protein electrophoresis and
free light chain analyses, 300 individuals with MGUS (159 men and 141
women) and 52 individuals with light chain MGUS (LC-MGUS; 35 men and 18
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women) were identified. Quantitative computerized tomography (QCT) was
performed in the lumbar spine (L1/L2), hip and mid-femoral shaft to evaluate
cortical, trabecular and integral BMD as well as bone geometry in all individuals.
Analysis of variance and Tukey’s honest significance test were used to compare
individuals with MGUS and LC-MGUS with others. Hospital records with Inter-
national Classification of Diseases were used to record fractures from the indi-
viduals’ enrollment into the study with a mean follow up time of 6.9 years. Cox
proportional hazard models were used to compare risk of fractures in MGUS
and others. Results were adjusted for age and sex.
Results: No difference was found in BMD between subjects with MGUS and
others at the spine (Table 1; mean for MGUS (MMGUS)=0.197 mg/cm3, mean
for others (Mothers)=0.194 mg/cm3, p=0.21) or total hip (MMGUS=0.239 mg/cm3,
Mothers=0.237 mg/cm3, p=0.22). Volumetric measurements showed that indi-
viduals with MGUS had a statistically significant increase in bone volume com-
pared to others in the lumbar spine (MMGUS=41.5 cm3, Mothers=39.7 cm3,
p<0.001) and total hip (MMGUS=106.3 cm3, Mothers=100.1 cm3, p<0.001). A
significant difference was found in bone volume in total hip in MGUS men, com-
pared to other men (MMGUS=123.6 cm3, Mothers=119.3 cm3, p=0.04). Overall,
the risk of fractures was not increased in individuals with MGUS as compared
to others (hazard ratio (HR): 1.19; 95% confidence interval (CI): 0.94-1.50).
Men with MGUS had a significantly increased risk of fractures, compared to
other men (HR: 1.49; 95% CI: 1.05-2.12).
Table 1.
Summary/Conclusions: Our results from a screened population show that
individuals with MGUS do not have a decreased BMD at the lumbar spine or
hip. Surprisingly, however, we find that bone volume is increased in individuals
with MGUS, especially in men, who also have an increased risk of fractures.
This suggests an effect of MGUS on bone metabolism in men that is not noted
in women, probably as a result of other stronger risk factors in women. Further
reaserch is needed to explain the increased bone volume in men with MGUS.
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Background: Multiple myeloma (MM) remains a predominantly incurable
malignancy despite high-dose chemotherapy, autologous stem cell transplants
and novel agents. Nonetheless, proteasome inhibitors (PI) such Bortezomib
(Bz) have been effective in treating the disease to date. The 26S proteasome
inhibitor indirectly targets the unfolded protein response (UPR) by inhibiting
proteasomal degradation of ubiquitinated paraprotein, subsequently leading to
the lethal accumulation of paraprotein within the cell. Initial treatment is effective,
however most patients eventually develop resistance to the drug. The mecha-
nism of resistance is still unknown, though one possible mechanism contributing
to Bz resistance could be chaperone-mediated autophagy (CMA). Upregulated
in a number of tumours, CMA specifically targets and degrades soluble cytosolic
proteins. It is therefore likely that this pathway could be an alternative stress
management pathway in Bz resistance. 
Aims: We aimed to assess CMA in sensitive and resistant MM, and its role in
alleviating ER stress in bortezomib resistance. 
Methods: QPCR, western blotting, cell viability assays, ER imaging and shRNA
assays were performed to assess the role and importance of UPR and
autophagy in Bz resistant MM, and was correlated to Bz sensitivity.
Results: Molecularly and morphologically, we identified reduced UPR activity
as a result of increasing Bz resistance in both resistant MM patients and in
resistant KMS11 cells. We further identified that the chaperone-mediated
autophagy (CMA) marker, LAMP2A, was highly expressed in resistant cells com-
pared to sensitive cells in cell lines and patients. CMA activity was also seen to
increase in 4 different MM cell lines under various levels of ER induced stress,
strongly suggesting the pathways importance in ER stress management. Upon
further investigation, preliminary data has also shown that macroautophagy may
provide as a compensatory mechanism in cells with impaired CMA.
Summary/Conclusions: CMA is upregulated in Bz resistant MM and functions
as a compensatory stress mechanism in alleviating ER stress in cells with
reduced UPR activity. Partial inhibition of the pathway subsequently results in
the activation of macroautophagy. To effectively treat MM and potentially over-
come Bz resistance, new therapies targeting autophagy are required.
haematologica | 2016; 101(s1) | 519
Copenhagen, Denmark, June 9 – 12, 2016
Myeloma and other monoclonal
gammopathies - Clinical
E1260
CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD)
IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS:
INITIAL RESULTS OF A PHASE 1 STUDY
S Bringhen1,*, P Musto2, F Gay1, N Giuliani2, AM Liberati2, C Pautasso1,
E Ponticelli1, L De Paoli2, R Zambello2, G Ciccone3, AM Carella2, M Boccadoro1,
P Sonneveld4, A Palumbo1
1Myeloma Unit, Division of Hematology, University of Torino, Torino, 2Italian
Multiple Myeloma Network, GIMEMA, 3Unit of Clinical Epidemiology, Azienda
Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO
Piemonte, Torino, Italy, 4Department of Hematology, Erasmus Medical Center,
Rotterdam, Netherlands
Background: The combination of carfilzomib at the dose 20/36 mg/m2,
cyclophosphamide and dexamethasone has been demonstrated to be well toler-
ated and highly effective (Bringhen S. et al, Blood 2014; 124:63-9). A further dose
escalation could improve clinical efficacy. Herein we present initial results of the
dose-escalation phase 1 portion of a multicenter, phase 1/2 study evaluating the
safety and the efficacy of the combination KCyd in elderly NDMM patients (pts).
Aims: The primary objective was to determine the maximum tolerated dose.
The secondary objectives were to determine the safety and the efficacy of
KCyd, including response rate, time to progression, progression free survival,
time to next therapy and overall survival. ated results will be presented.
Methods: Newly diagnosed pts not eligible for autologous stem cell transplan-
tation due to age or co-morbidities were eligible. Carfilzomib was administered
intravenously on days 1,2,8,9,15,16, cyclophosphamide was administered oral-
ly on days 1,8,15 and dexamethasone was administered orally once weekly.
Dose-escalation used a standard 3+3 schema with dose-limiting toxicities
(DLTs) assessed during cycle 1. All pts received carfilzomib at 20 mg/m2 on
days 1 and 2 of cycle 1. Beginning on day 8 of cycle 1, carfilzomib was esca-
lated in 3 successive dose levels from 45 to 70 mg/m2 in combination with the
standard doses of cyclophosphamide 300 mg/m2 and dexamethasone 40 mg.
KCyd induction was administered for 9 28-day cycles. Adverse events (AEs)
were graded by NCI-CTCAE v4. Response was assessed according to the
modified International Uniform Response Criteria.
Results: Between June 2014 and March 2015, 9 pts were enrolled in the com-
pleted phase 1 dose-escalation portion of the study. Median age was 74 years
(range 67-82), 44% had ISS stage III, 67% had unfavorable FISH profile [t(4;14)
or t (14;16) or del17p or amp1]. No DLTs were observed in the 3 pts of cohort
1, with carfilzomib at 45 mg/m2. In cohort 2 carfilzomib was escalated to 56
mg/m2 and 1/6 pt had a DLT with acute kidney injury. Therefore, the MTD of
carfilzomib was established at 56 mg/m2. Drug-related AEs occurring in >20%
of pts included anaemia (56%), fever (44%), thrombocytopenia (33%), diar-
rhoea (33%), vomiting (33%), infections (33%), hypertension (33%), heart fail-
ure (22%), acute kidney injury (22%). Grade 3 AEs occurring in >10% of pts
included anaemia (22%), infections (22%), acute kidney injury (22%) and heart
failure (11%). Only 1 grade 4 AE was reported (thrombocytopenia). Six pts
completed induction treatment, 2 pts discontinued treatment due to AEs and 1
pt due to pt decision. After a median follow-up of 14.2 months, 2 pts achieved
a complete response (CR), 4 pts a very good partial response (VGPR) and 3
pts a partial response (PR), for an overall response rate of 100%, at least
VGPR of 66% and at least CR of 22%. No progressive disease or death
occurred during induction.
Summary/Conclusions: The MTD of carfilzomib was established at 56 mg/m2.
KCyd combination given to untreated, symptomatic, elderly pts with myeloma
is well tolerated and highly effective with an overall response rate of 100%,
including a CR rate of 22%. Enrollment in the phase 2 portion of the study is
ongoing and updated results will be presented.
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AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE
MYELOMA (PREAMBLE): PRELIMINARY REPORT ON PROGRESSION-FREE
SURVIVAL
D Kuter1, G Cook2, H Goldschmidt3, D Cella4, T Zyczynski5,*, C Davis5,
S Popov6, R Vij7
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Background: Multiple myeloma (MM) is associated with significant disease
burden, and long-term prognosis is poor, with relapse almost inevitable.
Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have
improved patient outcomes; however, data on real-world clinical effectiveness
of these available treatments are limited. 
Aims: PREAMBLE (Prospective REsearch Assessment in multiple Myeloma:
an oBservationaL Evaluation; NCT01838512) is an ongoing, international,
prospective, observational cohort study to improve understanding of the real-
world outcomes of IMiDs, PIs, and combination therapy in relapsed/refractory
MM (RRMM). Here we report preliminary progression-free survival (PFS) data.
Methods: Patients with RRMM (≥1 prior therapy) who initiated treatment with
an IMiD, PI, or IMiD+PI within 90 days before or 30 days after study enrollment
were eligible. Data were analyzed using a Cox proportional hazard regression
model that included patient demographics, baseline disease characteristics,
and MM treatment-related variables as covariates.
Results: At the time of data cut-off (December 7, 2015), data were available
for 764 patients and median duration of follow-up was 15 months. The median
age of patients was 68 years and 55% were male. Of the 764 patients, 368
(48%) were receiving an IMiD (81% of whom were receiving lenalidomide,
n=297), 347 (45%) were receiving a PI (80% of whom were receiving borte-
zomib, n=278), and 49 (6%) were receiving an IMiD+PI (59% of whom were
receiving lenalidomide/bortezomib, n=29). Most patients (n=325; 43%) had 1
prior line of therapy, 203 (27%) had 2 prior lines, 111 (15%) had 3 prior lines,
and 123 (16%) had >3. The majority of patients had relapsed MM (n=599,
78%). 161 (21%) patients were refractory to their last line of treatment; 260
(34%) patients discontinued 1 prior line of therapy due to progression, 61 (8%)
discontinued 2 prior lines due to progression, and 25 (3%) discontinued >2
prior lines. 40% of patients had International Staging System (ISS) stage III
disease. Median PFS was 9.26 months (95% CI 8.21–10.12); 1-year PFS rate
was 40.9% and 2-year PFS rate was 19.7%. Approximately half of the patients
(50.7%) were estimated to respond to treatment before then progressing. At 2
years, all patients in this analysis had either responded to treatment or pro-
gressed without response. Median (95% CI) duration of response was 14.2
(10.87–16.39) months and was longer for patients receiving an IMiD versus a
PI (16.4 [11.73–not estimable] months vs 10.9 [7.13–14.69] months). Number
of lines of therapy discontinued due to progression was most strongly associ-
ated with higher rates of progression/death (Figure; HR p<0.001 for all com-
parisons). Other factors associated with higher rates of progression or death
were number of prior lines of therapy (2 vs 1, HR 1.38, p=0.016; 3 vs 1, HR
1.48, p=0.012; >3 vs 1, HR 1.63, p<0.001) and ISS stage at study entry (III vs
I, HR 1.45, p=0.032).
Figure 1.
Summary/Conclusions: Preliminary analysis of real-world data from PRE-
AMBLE suggests that the number of lines of therapy discontinued due to pro-
gression, lines of therapy overall, and disease stage are key risk factors asso-
ciated with the rate of progression/death in patients with MM, demonstrating
an unmet need.
Funding: Bristol-Myers Squibb. Medical writing assistance provided by A Bex-
field, Caudex, funded by Bristol-Myers Squibb.
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ROBUSTNESS OF THE PROGNOSTIC VALUE OF THE SKY92 MARKER
VERSUS FISH MARKERS ACROSS NINE MULTIPLE MYELOMA
COHORTS
M Van Vliet1,*, R Kuiper1, J Ubels1, L Bosman1, B Dumee1, E van Beers1,
L de Best1, A Waage2, S Zweegman3, G Morgan4, J Levy5, D Auclair5, R Fonseca6,
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Background: Multiple Myeloma (MM) is recognized as a heterogeneous group
of patients with varying response and outcome of their disease, associated with
various risk factors including genetic aberrations. With increasing availability of
genetic data, ever more reliable conclusions can be drawn about the relevance
of individual and combined biomarkers. Here we compare multiple stratifications
of MM to evaluate their value in relation to overall survival (OS). All available
biomarkers were used and included interphase FISH (iFISH), virtual FISH
(vFISH), SKY92, ISS and some combinations thereof. The other combination is
SKY92+ISS recently identified to be superior to all other combinations of one or
two biomarkers for identification of both high risk and low risk patients.
Aims: To demonstrate and compare the robustness of the prognostic value of
the SKY92, ISS, SKY92+ISS and various FISH marker risk classification meth-
ods across a wide variety of clinical datasets including NDMM and RRMM,
young/elderly patients and a wide diversity of treatments.
Methods: Nine GEP datasets publicly available or obtained by analysis of the CE
IVD MMprofiler assay were used (Table 1, rows) and evaluated for 17 biomarkers
(Table 1, columns). In each analysis the Cox proportional hazard ratio (HR) and its
p-value are calculated. Interphase FISH (iFISH) data was not available for all
datasets, therefore, the so-called Virtual FISH markers (as classified by GEP sig-
natures with high accuracy) were determined using the MMprofiler assay algorithms.
Note that there is no virtual FISH signature for del(17p). We combined the subtypes
[t(14;16)+t(14;20)] since they are rare but both predictors of poor outcome.
Results: All available data was used to compare prognostic HR and p-values
for overall survival in nine MM cohorts, see Table 1. Note that HOVON-
65/GMMG-HD4 was the training set for SKY92. iFISH data was only available
for a limited set of studies. Therefore, additionally, vFISH results are shown
(HR in white). For some of the datasets, the microarray platform was not HG-
U133Plus2 - for which the MMprofiler vFISH software was developed - such
that no vFISH call was available. There was also missing ISS data for 4 study
cohorts. SKY92 could be determined in all datasets and was always prognostic
(Table 1, white across the column). ISS and the combination of ISS+SKY92
could be determined in 5 datasets and were significant in all 5 of the studies.
The FISH markers did not show robust prognostic values across the evaluated
datasets. Only gain(1q) showed prognostic value in 4 out of 6 datasets. Hazard
ratios are given in Table 1 and cell-shading is white where p-values were sig-
nificant (<0.05).
Table 1. Prognostic value (hazard ratios for OS) of ISS and genetic bio-
markers in nine clinical datasets including NDMM and RRMM. White=sig-
nificant (p<0.05); grey=n.s.; dark grey=NA / not available. 1) HOVON-65/
GMMG-HD4 |n=329|, 2) HOVON-87/NMSG-18 |n=143|, 3) MRC-IX |n=246|,
4) MMGI |n=91|, 5) TT3 |n=139|, 6) TT6 |n=55|, 7) Czech E-MTAB-1038
|n=66|, 8) TT2 |n=351|, 9) APEX |n=264|. FISH column HR with underscores
are based on vFISH, others on iFISH. Inf=infinitely large.
Summary/Conclusions: SKY92, and its combination with ISS, have demon-
strated to be robust prognostic markers in MM while the evaluated FISH mark-
ers do not show robustness for prognostic purposes.
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DARATUMUMAB MONOTHERAPY COMPARED WITH REAL-WORLD
HISTORICAL CONTROL DATA IN HEAVILY PRETREATED PATIENTS WITH
HIGHLY REFRACTORY MULTIPLE MYELOMA: AN ADJUSTED TREATMENT
COMPARISON
J Diels1,*, A Lam2, T Ito3, M Mehra2, I Khan4
1Janssen Health Economics & Market Access EMEA Statistics & Modeling,
Beerse, Belgium, 2Janssen Global Services, LLC, Raritan, NJ, United States,
3Janssen Health Economics & Market Access EMEA, High Wycombe, United
Kingdom, 4Janssen Research & Development, LLC, Raritan, NJ, United States
Background: Daratumumab (DARA) received FDA approval in November
2015 based on data from single-arm phase 2 studies, following fast track/break-
through therapy designation based on preliminary clinical evidence showing
substantial improvements over available therapy for the treatment of heavily
pretreated/refractory patients with multiple myeloma (MM). Recent analyses of
pooled DARA studies and real-world US data revealed median overall survival
(OS) of 19.9 (95% confidence interval [CI], 15.1-not evaluable) months and 7.9
(95% CI, 6.9-8.9) months in heavily pretreated and refractory patients with MM,
respectively (Usmani S, et al. Blood. 2015;126(23): Abstract 4498 and Usmani
S, et al. Blood. 2015;126(23): Abstract 29). In the absence of randomized head-
to-head trials, evidence on the relative treatment efficacy of DARA versus physi-
cian’s choice (PC) based on an adjusted comparison of data from a single arm
trial versus a historical control group of comparable patients can inform the
decisions of both clinicians and payers.
Aims: To estimate the comparative efficacy of DARA, as measured by overall
survival, versus real-world historical control (PC) based on a comparison of
data from DARA monotherapy clinical studies versus real-world US data, adjust-
ed for confounding factors between patient cohorts.
Methods: Patient-level data were pooled from DARA monotherapy clinical stud-
ies (patients treated with DARA 16 mg/kg in the SIRIUS and GEN501 studies)
and from two independent US databases (IMS-LifeLink and OPTUM), which
reflect treatments utilized in a real-world cohort of patients with MM who received
at least 3 prior therapy lines or were double refractory to a proteasome inhibitor
and immunomodulatory drug. Using a multivariate proportional hazards regres-
sion model, the relative treatment effect of DARA compared with PC was esti-
mated, adjusting for imbalances in patient characteristics between patient
cohorts; co-variates included gender, age, albumin, hemoglobin, number of prior
therapies, prior pomalidomide/carfilzomib-exposure, and refractory status.
Results: Baseline characteristics that differed between patients treated with
DARA (N=148) and the real-world US historical control (N=658) included medi-
an age (64 vs 69 y), median lines of prior therapy (5 vs 4), prior treatment with
pomalidomide (55% vs 15%) and carfilzomib (41% vs 28%), and triple/quadru-
ple refractory status (64% vs 14%). The adjusted OS-hazard ratio (HR) for
DARA versus PC was 0.32 (95% CI, 0.22-0.46) compared with 0.44 (95% CI,
0.33-0.58) for unadjusted HR. The impact of adjustment was mainly driven by
differences in refractory status and prior exposure to pomalidomide/carfilzomib.
Summary/Conclusions: This adjusted treatment comparison suggests that
DARA demonstrates improved OS compared with real-world historical control
data in heavily pretreated and refractory MM patients. Such comparisons
allow evaluation of novel agents in the absence of head-to-head comparison
studies.
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IMPACT OF FAMILY HISTORY ON RISK OF PROGRESSION OF MGUS TO
MULTIPLE MYELOMA: A POPULATION-BASED STUDY
K Aradóttir1,*, SH Lund1, O Landgren2, M Björkholm3, I Turesson4, SY Kristinsson1,3
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Background: Multiple myeloma (MM) is characterized by a neoplastic prolif-
eration of plasma cells in the bone marrow and overproduction of monoclonal
immunoglobulins in serum or urine. MM is always preceded by a premalignant
condition called monoclonal gammopathy of undetermined significance
(MGUS). Individuals with MGUS have a 1-1.5% annual risk of developing MM
or a related disease. Furthermore, familial aggregation of MM and MGUS has
been described, and first-degree relatives of MGUS and MM patients have a
2-3 fold increased risk of a lymphoproliferative disorder (LP). We have previ-
ously shown that survival among MM patients with a family history of a LP have
a significantly superior survival compared to sporadic MM. However, the effect
of family history of LP on risk of progression among MGUS is unknown.
Aims: The aim of our study was to compare the risk of progression of MGUS
to MM or other LPs in MGUS individuals with a family history of LPs compared
to sporadic MGUS.
Methods: Individuals with MGUS and their first-degree relatives were identified
using nationwide Swedish Registries. Information on malignancies in relatives
of MGUS patients was obtained by record-linkages to the Swedish Cancer
Registry. A positive family history of LP was defined as MGUS patients having
at least one first-degree relative diagnosed with MM, chronic lymphocytic
leukemia, non-Hodgkin’s lymphoma, Waldenström’s macroglobulinemia, or
Hodgkin’s lymphoma. Cox proportional hazard model was used to obtain hazard
ratios (HR) and 95% confidence intervals (95% CIs). In statistical analysis all
data were adjusted for age, sex, and year at diagnosis.
Results: A total of 24,126 individuals diagnosed with MGUS in 1958-2013 were
included in the study of whom 12,504 were male. Median age at diagnosis was
69.7 and 64.6 years in the sporadic and familial groups, respectively. In a total
of 1666 MGUS individuals, the disorder progressed to MM. When compared to
patients with sporadic MGUS, patients with MGUS and family history of any LP
had similar risk of progression to MM (HR 1.17, 95% CI 0.90-1.53, p=0.23).
The same was true when compared only to individuals with family history of
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MM (HR 0.79, 95% CI 0.52-1.20, p=0.26). Subgroup analyses, stratified by
gender and different age groups gave similar results (data not shown).
Summary/Conclusions: In this large population-based study we have shown
that family history of LPs is not a risk factor for progression among MGUS indi-
viduals. Our findings are of importance for counseling MGUS individuals with
family history and provide information regarding the biology of hereditary LPs. 
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THE SWEDISH MULTIPLE MYELOMA REGISTER: MEDIAN 5-YEAR
SURVIVAL OF 7.3 YEARS IN PATIENTS 65 YEARS AND YOUNGER,
POPULATION-BASED DATA ON 3,876 MULTIPLE MYELOMA PATIENTS
DIAGNOSED 2008-2013
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Background: The Swedish Multiple Myeloma Register (SMMR) is a prospec-
tive observational register designed to document real-world management and
outcomes in newly diagnosed multiple myeloma (MM), and was designed to
improve the quality of the management of MM patients in Sweden
Aims: With high representation and good data quality we can present survival
data on a whole MM population.
Methods: SMMR, initiated in 2008, comprises data on all patients diagnosed
with MM, plasmocytoma, and plasma cell leukemia treated in Sweden. Report
sheet are sent to all clinicians diagnosing MM. Another request is sent to the
clinician one year after diagnosis, requesting information on initial treatment
and complications. Through linkage with the Register of Total Population, we
collected information on vital status until August 6, 2015. This report contains
data on patients reported to SMMR between 2008 and 2013 and follow-up
data from the first year on patients with symptomatic MM 2008-2012, with a
follow-up till August 6, 2015, with focus on survival at 1, 3 and 5 years. Analyses
of incidence, characteristics at baseline, proportion of patients given intensive
treatment, obtaining very good partial remission rate (VGPR) and overall sur-
vival (OS) were estimated. Survival data was analysed with respect to age and
ISS stage at diagnosis.
Figure 1.
Results: The SMMR has a current coverage of 98% compared to the Swedish
Cancer Register on patients 2008-2013, to which reporting is obliged by law.
Clinical data at baseline was available for 3876 patients and one year follow-
up data was available on 2284 symptomatic MM patients (92% of all sympto-
matic MM cases initially reported to the register), from 70 different centers in
Sweden. The median time of follow-up was 4.6 years. The age adjusted inci-
dence was 6.2 MM cases per 100 000 inhabitants and year. The median age
was 71 years, 70 years for men, and 73 years for women. Two third of patients
were 65 years or older. Of the reported patients, 29% were in ISS stage I, 42%
in stage II, and 29% in stage III. Overall, 80% of patients 65 years or younger
received ASCT and 4% of patients above 65 years. In patients 66-70 years,
ASCT was performed in 19%. In the year 2012, 67% of patients received one
of the new drugs (thalidomide, bortezomib, or lenalidomide) as induction, (87%
of patients<66 and 60% >65), an improvement compared to earlier years. The
response grade >VGPR increased from 36% to 46% in the study period. The
1-, 3- and 5-year relative survival was 92%, 79%, and 66% for patients 65
years and younger and 79%, 56%, and 39% for the patients >65 years, respec-
tively. The median relative survival was 7.3 and 3.7 years for patients<66 years
and >65 years, respectively. Early death (<1year after diagnosis) was observed
in 19% of patients. The relative median survival according to ISS stage was
3.2 years and 6.0 years for stages III and II, while not reached for stage I.
Patients with no reported stage had the same survival as stage III patients.
Summary/Conclusions: The SMMR is an instrument for increased quality in
the management of MM in Sweden. This report shows encouraging survival
data on the MM population of Sweden. There was a significant difference in
survival for younger and older patients that cannot be explained by age alone.
The 19% early death rate (<1 year survival) can be compared to 48% in the
period 1964 - 1968 (Swedish Cancer register data) and illustrates the enormous
development in the care of MM patients in Sweden during the last 50 years.
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CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND
DEXAMETHASONE: SUBGROUP ANALYSIS OF THE PHASE 3 ENDEAVOR
STUDY TO EVALUATE THE IMPACT OF PRIOR TREATMENT ON
PATIENTS WITH RELAPSED MULTIPLE MYELOMA
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Background: In a randomized phase 3 study (ENDEAVOR; NCT01568866),
carfilzomib and dexamethasone (Cd) significantly improved median progres-
sion-free survival (PFS) versus bortezomib (BTZ) and dexamethasone (Bd)
(18.7 vs 9.4 months; hazard ratio [HR] 0.53; 95% confidence interval [CI]: 0.44,
0.65; p<0.0001) in 929 patients with relapsed multiple myeloma (RMM).
Aims: This subgroup analysis evaluated treatment with Cd versus Bd in
patients after first relapse versus ≥2 prior lines of therapy as well as the effect
of previous exposure to BTZ or lenalidomide (LEN).
Methods: Adult patients with RMM who had received 1-3 prior lines of therapy
were randomized 1:1 to Cd or Bd. Patients in the Cd arm received carfilzomib
(30-min intravenous [IV] infusion) on days 1, 2, 8, 9, 15, and 16 (20mg/m2 on
days 1 and 2 of cycle 1; 56mg/m2 thereafter) and dexamethasone 20mg on
days 1, 2, 8, 9, 15, 16, 22, and 23 of a 28-day cycle. Patients in the Bd arm
received BTZ 1.3mg/m2 (IV or subcutaneous) on days 1, 4, 8, and 11 and dex-
amethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-day cycle. Treat-
ment was continued until disease progression or unacceptable toxicity. Primary
end point was PFS, secondary end points included overall survival, overall
response rate (ORR; ≥partial response), duration of response (DOR), rate of
grade ≥2 peripheral neuropathy (PN) and safety.
Results: Efficacy outcomes by prior lines of therapy are shown in the Table.
Median PFS for Cd vs Bd was 15.6 months vs 8.1 months, respectively (HR:
0.56; 95% CI: 0.44, 0.73) for patients with prior BTZ exposure and NE vs 11.2
months, respectively (HR: 0.48; 95% CI: 0.36, 0.66) for patients without prior
BTZ exposure. Median PFS for Cd vs Bd was 12.9 months vs 7.3 months,
respectively (HR: 0.69; 95% CI: 0.52, 0.92) for patients with prior LEN exposure
and 22.2 months vs 10.2 months, respectively (HR: 0.43; 95% CI: 0.32, 0.56)
for patients without prior LEN exposure. ORRs for Cd vs Bd were 71.2% vs
60.3% (OR: 1.63; 95% CI: 1.12, 2.36) in patients with prior BTZ exposure, 83.6%
vs 65.3% (OR: 2.72; 95% CI: 1.72, 4.31) in patients without prior BTZ exposure,
70.1% vs 59.3% (OR: 1.60; 95% CI: 1.03, 2.49) in patients with prior LEN expo-
sure and 81.2% vs 64.6% (OR: 2.37; 95% CI: 1.62, 3.47) in patients without
prior LEN exposure. Grade ≥3 adverse events (AEs) were reported in 69.8%
(Cd) and 63.9% (Bd) of patients with 1 prior line and 76.6% (Cd) and 69.9%
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(Bd) of patients with ≥2 prior lines. Grade ≥3 hypertension, dyspnea, and cardiac
failure were more common with Cd vs Bd. The rate of grade ≥2 PN was lower
with Cd vs Bd in patients with 1 prior line (6.5% vs 30.0%; OR: 0.16; 95% CI:
0.09, 0.29) and ≥2 prior lines (5.6% vs 34.1%; OR: 0.12; 95% CI: 0.06, 0.22).
Table 1. Efficacy outcomes and AEs of interest by prior lines of therapy.
Summary/Conclusions: A clinically meaningful improvement in PFS was seen
for patients with RMM who were treated with Cd compared with Bd, regardless
of the number of prior lines of treatment. The improvement was greatest for
those who had received 1 prior line, where median PFS was over 1 year longer
in patients treated with Cd vs Bd. PFS benefit with Cd vs Bd was also main-
tained regardless of prior exposure to BTZ and LEN. A higher ORR was also
observed with Cd vs Bd across all subgroups. Cd had an acceptable benefit-
risk profile in this study.
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CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND
DEXAMETHASONE: SUBGROUP ANALYSIS OF PATIENTS WITH
RELAPSED MULTIPLE MYELOMA BY BASELINE CYTOGENETIC RISK
STATUS (PHASE 3 ENDEAVOR STUDY)
H Goldschmidt1,*, WJ Chng2, MA Dimopoulos3, P Moreau4, D Joshua5,
A Palumbo6, T Facon7, H Ludwig8, L Pour9, R Niesvizky10, A Oriol11, L Rosiñol12,
A Suvorov13, G Gaidano14, T Pika15, K Weisel16, V Goranova-Marinova17,
HH Gillenwater18, N Mohamed18, S Feng18, R Hájek19
1Heidelberg Medical University, Heidelberg, Germany, 2National University
Cancer Institute, National University Health System, Singapore and Cancer
Science Institute of Singapore, National University of Singapore, Singapore,
Singapore, 3School of Medicine, National and Kapodistrian University of Athens,
Athens, Greece, 4University of Nantes, Nantes, France, 5Royal Prince Alfred
Hospital, Camperdown, Australia, 6University of Torino, Torino, Italy, 7CHRU
Lille Hôpital Claude Huriez, Lille, France, 8Wilhelminen Cancer Research Insti-
tute, Wilhelminenspital, Vienna, Austria, 9University Hospital Brno, Brno, Czech
Republic, 10Weill Cornell Medical College, New York Presbyterian Hospital,
New York, NY, United States, 11Institut Català d’Oncologia, Institut Josep Car-
reras, Hospital Germans Trias i Pujol, Barcelona Spain, 12Hospital Clínic de
Barcelona, Barcelona, Spain, 13Hematological Department, First Republican
Clinical Hospital of Udmurtia, Izhevsk, Russian Federation, 14Division of Hema-
tology, Department of Translational Medicine, Amedeo Avogadro University of
Eastern Piedmont, Novara, Italy, 15Department of Hematooncology, University
Hospital Olomouc, Olomouc, Czech Republic, 16Universitatsklinikum Tubingen,
Tubingen, Germany, 17Hematology Clinic University Multiprofile Hospital for
Active Treatment, Plovdiv, Bulgaria, 18Amgen Inc., Thousand Oaks, CA, United
States, 19University Hospital Ostrava and Faculty of Medicine, University of
Ostrava, Ostrava, Czech Republic
Background: In a previous study, single-agent carfilzomib demonstrated activity
in patients with relapsed and refractory multiple myeloma with high-risk cytoge-
netic abnormalities. In the phase 3 study (NCT01568866; N=929 patients) carfil-
zomib plus dexamethasone (Cd) significantly improved progression-free survival
(PFS) by 2-fold compared with bortezomib/dexamethasone (Bd) in patients with
relapsed multiple myeloma (RMM) (18.7 months versus 9.4 months; hazard
ratio [HR]: 0.53; 95% confidence interval [CI]: 0.44–0.65; P<.0001).
Aims: A pre-planned subgroup analysis of efficacy and safety outcomes in patients
treated with Cd vs Bd according to patients’ baseline cytogenetic risk status.
Methods: Adults with RMM who had received 1–3 prior lines of therapy received
either carfilzomib (30-minute intravenous [IV] infusion on days 1, 2, 8, 9, 15, and
16 [20mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 thereafter]) and dexametha-
sone (20mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of a 28-day cycle) (Cd) or
bortezomib (1.3mg/m2 IV bolus or subcutaneous injection on days 1, 4, 8, and
11) and dexamethasone (20mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-day
cycle) (Bd). Treatment continued until disease progression, withdrawal of consent
or unacceptable toxicity. Primary end point was PFS, secondary end points includ-
ed overall survival, overall response rate (ORR), duration of response (DOR),
rate of grade ≥2 peripheral neuropathy (PN) and safety. The high-risk group was
defined (using fluorescence in situ hybridization analysis of baseline bone marrow
samples) as those patients with the genetic subtypes t(4;14) or t(14;16) in ≥10%
of screened plasma cells or deletion 17p in ≥20% of screened plasma cells; the
standard-risk group consisted of patients without these genetic subtypes.
Results: Of the 929 patients, 464 were randomized to receive Cd and 465 to
receive Bd. Baseline cytogenetic risk status was balanced between the treatment
arms (high-risk: Cd, 20.9%; Bd, 24.3%; standard-risk: Cd, 61.2%; Bd, 62.6%;
unknown: Cd, 17.9%; Bd, 13.1%). Efficacy and safety end points by baseline
cytogenetic risk status are presented in the Table. In the high-risk group, median
PFS was 8.8 months (95% CI: 6.9, 11.3) for Cd vs 6.0 months (95% CI: 4.9, 8.1)
for Bd (HR: 0.646; 95% CI: 0.453, 0.921). In the standard-risk group, median
PFS was not estimable (NE) for Cd (95% CI: 18.7, NE) vs 10.2 months (95%
CI: 9.3, 12.2) for Bd (HR: 0.439; 95% CI: 0.333, 0.578). ORRs (≥partial response)
in the high-risk group were 72.2% (Cd) vs 58.4% (Bd) and 79.2% (Cd) vs 66.0%
(Bd) in the standard-risk group. Median DOR in the high-risk group was 10.2
months for Cd vs 8.3 months for Bd. Median DOR in the standard-risk group
was NE for Cd vs 11.7 months for Bd. Grade ≥3 adverse events (AEs) were
reported at higher rates with Cd vs Bd in both the high- and standard-risk groups
(70.1% vs 63.1% and 73.9% vs 68.3%). Grade ≥2 PN occurred less frequently
with Cd vs Bd regardless of cytogenetic risk status (high-risk group: 3.1% vs
35.1%; odds ratio: 0.059; 95% CI: 0.018, 0.198 and standard-risk group: 6.4%
vs 33.4%; odds ratio: 0.135; 95% CI: 0.079, 0.231).
Table 1. Efficacy outcomes and AEs of interest by baseline cytogenetic
risk status.
Summary/Conclusions: Patients treated with Cd had a clinically meaningful
improvement in PFS compared with Bd regardless of baseline cytogenetic risk
status. Higher response rates, greater depth of response and longer DOR were
also reported with Cd vs Bd. Cd had a favorable benefit–risk profile in patients
with high-risk relapsed MM.
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INCREASED LEVELS OF SOLUBLE SYNDECAN-1 AND LDH ARE MAJOR
PROGNOSTIC FACTORS FOR SUBSEQUENT OVERALL SURVIVAL AND
PROGRESSION FREE SURVIVAL AFTER A RELAPSE IN MULTIPLE
MYELOMA
X Papanikolaou1,*, D Maltezas2, E Nikolaou2, T Tzenou2, P Pappaioannou2,
S Kotsanti2, M Dimou2, T Iliakis2, V2, P2, MC Kyrtsonis2
1Athens Medical School Laikon University Hospital, Marousi, Athens, 2Athens
Medical School Laikon University Hospital, Athens, Greece
Background: Despite the recent advances in the therapy of Multiple Myeloma
(MM), a relapse is almost a universal phenomenon in the clinical course of the
disease. Nevertheless only few are known about the prognostic factors that
characterize the relapses in MM, since robust and easily accessible prognostic
factors as the levels of soluble Syndecan-1 (sS-1) or the ratio of involved to
uninvolved free light chains in the serum (FLCR) have been verified only in
newly diagnosed cases of MM. 
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Aims: A series of 245 MM patients with at least one relapse in their disease
course, was studied to identify the prognostic factors that govern the prognosis
of relapse in MM.
Methods: sS-1 levels in the serum were measured through the commercially
available Diaclone™ ELISA kits. Survival statistical analysis was performed
using the SPSS v22 statistical software. The running log rank method was
used for the establishment of the optimal threshold of numerical variables. Clin-
ical and laboratory values used were the ones closest to an established relapse
and prior to the salvage treatment. 
Results: From 01/01/2000 till 20/06/2014, 245 patients with symptomatic MM
and at least one relapse were recorded for a total of 803 relapses.56 patients
had 1 relapse, 51 patients 2 relapses, 48 patients 3 relapses and 90 patients
more than 3. The clinical and laboratory characteristics of the relapses are pre-
sented in Table 1. The median Overall Survival (OS) and median Progression
Free Survival (PFS) after a relapse were 1.7 and 0.9 years (yr) respectively.
For the first relapse OS and PFS were 3.3 and 1.3 years, for the second relapse
OS and PFS were 2.1 and 1 yr, for the third relapse OS and PFS were 1.2 and
0.8 yr, while for the fourth and above OS and PFS were 0.8 and 0.4 yr respec-
tively. Statistically significant variables for the prediction of subsequent OS
after a relapse in univariate analysis were: ISS stage III (HR:1.26, P<0.001),
male sex (HR:1.39, P<0.001), sS-1>245 ng/mL (HR:2.56, P<0.001), LDH>480
IU/L (HR:1.99, P<0.001), number of prior relapses (HR:1.02, P=0.002) and
response to treatment (HR:1.16, P<0.001). For the prognostication of subse-
quent PFS, the following factors were significant in univariate analysis: age≥65
years (HR:1.07, P=0.02), sS-1>245 ng/mL (HR:2.29, P=0.001), LDH>480 IU/L
(HR:1.53, P=0.003), number of prior relapses (HR:1.14, P<0.001) and response
to treatment (HR:1.12, P<0.001). Multivariate analysis revealed sS-1>245
ng/mL and LDH>480 IU/L as the only statistically significant factors for both
OS and PFS. sS-1>245 ng/mL and LDH>480 IU/L retained their statistical sig-
nificance both for univariate and multivariate analysis even when the subgroup
of relapses treated with novel agents was independently studied.
Table 1. Characteristics of MM relapses.
Summary/Conclusions: In conclusion both OS and PFS are gradually declin-
ing after each relapse. While both the number of prior relapses and the
response to salvage treatment are important prognostic factors, subsequent
OSand PFS are mainly dictated by the levels of sS-1 and LDH that characterize
the MM relapse.
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11C- METHIONINE PET SCAN FOR THE DETECTION OF MULTIPLE
MYELOMA LESIONS
R Figueroa1,*, M Marcos1, B García-García2, N Martínez1, S Villar1, S Franco1,
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Background: Multiple Myeloma (MM) is a plasma cell neoplasia that repre-
sents the 10-15% of hematological malignancies. The myeloma diagnostic cri-
teria have recently changed based on the availability of more sensitive tools
for early detection of the disease. This particularly apply to imaging techniques
such as CT, MRI and PET. 11C-methionine is a radiolabeled amino acid that
has proven to have higher avidity for protein synthesis. Some recently published
works show that 11C-MET PET/TAC is useful for detecting bone and
extramedullary lesions in MM and might be a promising tool in the diagnosis
and follow up of this disease.
Aims: The purpose of this study is first to evaluate the performance of 11C-
MET PET/CT in MM as a diagnostic method compared to 18FDG-PET/CT, and
second to analyze the correlation between the metabolic activity and biological
parameters of the disease.
Methods: We have reviewed retrospectively the results of 14 patients (50%
women, ranged 31-79 years) with MM (12 cases), Smoldering Multiple Myelo-
ma (one case) and solitary plasmacytoma (one case), who simultaneously
underwent 11C-MET and 18FDG- PET/CT at our institution. We have analyzed
the number and the uptake value (SUVmax) of the lesions observed with both
techniques and we have correlated these findings with the biological parame-
ters of the disease (M component, plasma cell percentage in bone marrow,
free light chains, immunoglobulins, calcium, renal function). The concordance
and correlation between both techniques were analyzed using Cohen’s kappa
coefficient and Pearson coefficient (SPPS version 19).
Results: A total of 54 lesions were studied (mean 3.8 lesions/patient). The
number of lesions observed with 11C-MET was higher than with 18FDG in 57%
of the patients. Only in two cases 18FDG -PET/CT revealed lesions that were
not seen with 11C-MET, but interestingly in one of them a biopsy confirmed the
non-malignant nature of the lesion. In most cases the SUVmax was higher in
11C-MET for the same lesion compared to 18FDG. Cohen’s kappa coefficient
between both tests was calculated with a result of 0.29 that means a fair agree-
ment between 18FDG and 11C-MET. This coefficient also reflects a 35% of
false negative lesions seen in 18FDG-PET. The following biological parameters
were correlated with a significant increase in the uptake value in 11C-MET
PET/CT: M-component (r=0.28; p=0.02), serum IgG (r=0.58; p=0.002), involved
free light chain (r=0.28; p=0.04) and percentage of plasma cells in the bone
marrow (r=0.32; p=0.03). These correlations were not significant with the
18FDG PET/CT.
Figure 1.
Summary/Conclusions: In our experience, PET with 11C- MET could be a
highly sensitive tool to evaluate MM lesions. Our data, despite the small number
of patients, suggest that it may be superior to conventional 18FDG-PET. Fur-
thermore, there seems to be a significant correlation between some biological
parameters, such as FLC, MC or immunoglobulins levels and the avidity of
uptake. Larger series are needed to confirm the present findings.
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ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES
SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS
WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
(ACE-MM-200 STUDY)
R Niesvizky1,*, P Richardson2, N Gabrail3, S Madan4, A Yee5, K Shain6, J Hoffman7,
J Pagel8, W Bensinger8, A Nooka9, A Agarwal10, J Matous11, MS Raab12,
E Terpos13, K Bhol14, D Tamang14, SS Jones14, J van Duzer14, C Wheeler14,
NS Trede14, N Raje5
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Boston, 3Gabrail Cancer Center, Canton, 4Cancer Therapy & Research Center,
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Background: Histone deacetylase (HDAC) enzymes are attractive therapeutic
targets, but non-selective HDAC inhibitors have toxicities limiting exposure in
patients (pts), particularly in combination with other agents. Ricolinostat (ACY-
1215), is a first-in-class liquid orally available HDAC inhibitor 11-fold more
selective for HDAC6, that synergizes in vitro and in vivo in models of multiple
myeloma (MM) with bortezomib (Santo, Blood, 2012) and with carfilzomib
(Mishima, Br J Haematol, 2015) and with lenalidomide (Len) and pomalidomide
(Pom) (Quayle Blood 2013;122:1952). Ricolinostat, an oral liquid, has an excel-
lent safety profile. (Raje, Haematologica, 2014, Suppl 1). We now identify ACY-
241 as a structurally related, selective inhibitor of HDAC6 in tablet form.
Aims: Determine the safety, tolerability and preliminary efficacy of ACY-241
monotherapy and combination with pom and dexamethasone (dex).
Methods: Based on clinical experience with ricolinostat and non-clinical phar-
macokinetics of ACY-241, we designed a first-in-human phase 1a/1b clinical
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trial of a single-cycle of ACY-241 monotherapy followed by ACY-241 in combi-
nation with Pom and dexamethasone (Dex) in MM pts. A monotherapy/combi-
nation trial (mono/combo) design was chosen to grant pts access to combo
therapy with an active regimen while exploring the safety, pharmacokinetics
(PK) and pharmacodynamics (PD) of ACY-241 monotherapy. Pts with relapsed
or relapsed-and-refractory MM (RRMM) previously treated with ≥2 cycles of
Len and a proteasome inhibitor were eligible. Cohorts of 3 pts had ACY-241
PO QD as monotherapy (180, 360 and 480 mg) on days 1-21 of a 28 day cycle.
If no mono DLT was noted, pts continued to cycle 2 of combo therapy with
ACY-241/Pom/Dex. Safety review committee meetings for mono and combo
therapy were separate. PK of ACY-241, Pom and Dex were analyzed. PD
assessment were acetylated tubulin (HDAC6) and histones (HDAC 1, 2 and 3)
in peripheral blood mononuclear cells.
Results: Since June 2015, 13 safety-evaluable pts have enrolled. Median age
was 62 (46-82) years and median number of prior regimens 2 (1-7). All pts had
RRMM. 62% were refractory to len and 46% to both Btz and Len. Fifty percent
of pts had high risk cytogenetics. No dose relationship of the number or severity
of AEs in either monotherapy or combination therapy were noted. Common tox-
icities in the safety population included grade 1/2 fatigue (38%), cough, back pain
and dizziness (23% each), diarrhea, constipation and nausea (20% each). Grade
3/4 toxicities included neutropenia (4 pts, 31%), thrombocytopenia (23%) and
anemia (8%). No MTD was identified up to the highest dose of ACY-241 at 480
mg QD monotherapy and 180 and 360 mg po QD in combo with Pom/Dex. 360
mg QD was recommended for further clinical exploration of ACY-241 based on
safety and PD data. PK results show dose-linear increase in exposure with no
accumulation, drug-drug interaction with Pom and Dex, or exposure plateau (pre-
viously observed with ricolinostat.) Selective increase in acetylated tubulin was
seen at 180 mg with increasing levels of acetylated tubulin and histones at higher
doses. Confirmed efficacy data (minimum follow-up 3 months) for combo treat-
ment in this refractory pt population (8 efficacy evaluable pts) shows 4 PR, 2 MR
and 2 PD. Three pts had only one efficacy cycle reported and 2 are early.
Summary/Conclusions: ACY-241 is well-tolerated in combination with
Pom/Dex with at least dose proportional PK. Early response data to combo
treatment parallel those observed with ricolinostat/Pom/Dex and compare favor-
ably to historic controls of Pom/Dex. Cohort expansion at biologically relevant
combination doses is ongoing. Updated data will be presented.
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TREATMENT OF PRE-MYELOMA STATES: A CLINICAL DECISION ANALYSIS
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Background: Recent studies suggest that treatment of pts with pre-myeloma
disease may result in reduced progression to myeloma and improvement in
overall survival. However, there is a lack of data to determine which patients
would benefit and what type of treatments are optimal. A decision analysis to
synthesize available data and quantify the benefits and risks of different treat-
ments in different at-risk populations can help clarify both individual and policy
decision-making.
Aims: To quantify the benefit and risks of different treatments in different at-
risk populations. To develop a decision framework that informs both individual
and policy decision-making for treatment of pre-myeloma states.
Methods: Monte Carlo simulations using a Markov Model were used to simulate
the life course of patients diagnosed with pre-myeloma states in the modern
era, either treated pre-emptively or monitored per standard of care. The primary
outcome was number needed to treat (NNT) to save one life from myeloma,
along with life expectancy (LE) and number needed to harm (NNH) given treat-
ment risks. Pre-myeloma risk states modeled included standard risk MGUS
(21% 20-yr progression), high risk MGUS (58% 20-yr progression), and smol-
dering myeloma (78% 20-yr risk of progression). Three interventions were mod-
eled: (1) “high-intensity” treatment (e.g. lenalidomide+dexamethasone) with a
conservatively modeled 50% reduction in risk of progression but also an
increased risk of developing a secondary hematologic malignancy; (2) “low-
intensity” treatment with a 10% reduction in risk of progression; and (3) obser-
vation until progression. Rates of progression, increased risk of hematologic
malignancy, and death rates from myeloma and secondary malignancies were
estimated by literature review. The life course of 500,000 patients for every
combination of pre-myeloma state, treatment, and ages ranging from 35 to 75
was simulated. The model was validated against existing cohort data. Proba-
bilistic sensitivity analyses were conducted to generate 95% “confidence inter-
vals” [95% CI] given uncertainty in model parameters.
Results: NNT and NNH varied substantially by age, pre-myeloma state, and
type of treatment (Figure). For 65 year old patients with high risk MGUS, the
high and low-intensity treatments yielded NNTs of 8.3 [6.8-9.8] and 47.6 [33.6-
90.9] respectively, an increase in LE of +0.9 [0.3-1.5] and +0.2 [+0.1-0.4] yrs
respectively, and an NNH of 29.4 [95% CI 18.2-47.1] for the high-intensity treat-
ment. For 75 yr old patients with MGUS, the high-intensity regimen yielded a
lower NNH (27.8 [17.6-58.7]) than NNT (38.5 [27.2-58.1]), suggesting that more
patients would be harmed by secondary malignancies than be benefited with
treatment, with a non-statistically significant decrease in LE of -0.1 [-0.3-0.1].
In the same cohort, the low-intensity treatment had an NNT of 200 [105.6-
887.5] and no benefit in LE (mean=0 [0-0.1]). In general, younger patients with
higher-risk disease benefitted more from treatment. In 35 yr old patients with
smoldering myeloma, the high and low intensity treatments had NNT of 5.3
[4.8-6.5] and 41.7 [30.3-121.9] respectively, with estimated LE increase of +6.5
[5.5-7.7] and +1.0 [0.4-1.3] yrs, respectively, and a NNH for the high-intensity
regimen of 71.4 [37.7-154.2].
Figure 1.
Summary/Conclusions: The benefit/risk ratio of treatment for pre-myeloma
patients varies considerably depending on age, risk of myeloma progression,
and intensity/risk of treatment. For younger higher-risk pre-myeloma patients,
the benefit/risk ratio of high-intensity pre-myeloma intervention is increased,
whereas for older patients with lower-risk disease a lower-intensity or no treat-
ment is preferred. Though cost and quality of life under these treatments also
need to be considered, our results suggest there are substantial subgroups of
patients with pre-myeloma disease who would benefit from treatment. As we
develop improved therapies and risk-stratification, using such a quantitative
framework will help inform decision-making.
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PHASE I/IIA CLINICAL STUDY OF AUTOLOGOUS DENDRITIC CELL THERAPY
IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
SH Jung1, HJ Lee2, MC Vo2, YK Lee3, SS Lee1, DH Yang1, HJ Kim1, JJ Lee1,3,*
1Department of Hematology-Oncology, 2Research Center for Cancer
Immunotherapy, Chonnam National University Hwasun Hospital, 3Research
Institute, Vaxcell-Bio Terapeutics, Hwasun-Eup, Korea, Republic Of
Background: Cellular immunotherapy using dendritic cells is emerging as a
useful immunotherapeutic modality to treat multiple myeloma (MM). We have
developed potent immunotherapeutic agent (VAX-DC/MM) generated by den-
dritic cells loaded with the ultraviolet B-irradiated autologous myeloma cells. 
Aims: In this study, we evaluated the safety and efficacy of VAX-DC/MM in
patients with relapsed or refractory MM. 
Methods: This trial enrolled relapsed or refractory MM patients who had
received thalidomide- and bortezomib-containing regimen. Patients received
the intradermal VAX-DC/MM injection every week for four weeks. Before the
first injection of VAX-DC/MM, low-dose cyclophosphamide (375 mg/m2, i. v)
was administered to stimulate immune response at D-3. In a phase I trial, each
three patients were treated with 5 x 106, and 10 x 106 cell, respectively. After
higher dose was established as the tolerable dose, an additional 6 patients
were enrolled at 10 x 106 cell doses. 
Results: Median time to VAX-DC/MM therapy from diagnosis was 56.6 months
(28.5-130.5). Patients had received a median of five prior treatments, and 75%
had received autologous stem cell transplantation. VAX-DC/MM therapy was
well tolerated, and most frequent adverse event was grade 1-2 myalgia (33.3%).
In 8 of 9 patients who received 10  106 cell, immunologic response (88.9%)
was observed by interferon-gamma ELISPOT assay or mixed lymphocyte reac-
tion assay for T-cell proliferation. Clinical benefit rate was 66.7% including 1
minor response (11.1%) and 5 stable disease (55.6%), and 3 patients (33.3%)
showed a progression disease. The median progression free survival was 3.1
months (95% CI, 2.8-3.5 months), and all patients are alive.
Summary/Conclusions: In conclusion, VAX-DC/MM therapy was well-toler-
ated, and has activity in heavily pretreated MM. Further studies are needed to
increase the efficacy of VAX-DC/MM in patients with MM.
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ECONOMIC EVALUATION OF CARFILZOMIB+LENALIDOMIDE+DEXAMETHASONE
(KRD) VS LENALIDOMIDE+DEXAMETHASONE (RD) IN RELAPSED OR
REFRACTORY MULTIPLE MYELOMA (R/RMM)
R Fonseca1, S Panjabi2,*, M Campioni3, A Giannopoulou3, A Benedict4,
I Houisse4, S Aggarwal5, A Jakubowiak6
1Department of Medicine, Mayo Clinic in Arizona, Arizona, 2Global Health Eco-
nomics, Amgen Inc, South San Francisco, United States, 3Global Health Eco-
nomics, Amgen, Zug, Switzerland, 4Health Economics, Evidera, Budapest,
Hungary, 5Clinical Development, Amgen, Thousand Oaks, 6Myeloma Program,
University of Chicago, Chicago, United States
Background: In ASPIRE, KRd achieved superior progression free survival
(PFS) (HR=0.69; p=0.0001) and improved quality of life (QoL) (p<0.001) over
Rd in patients (pts) with R/RMM.
Aims: We assessed the cost-effectiveness (CE) of KRd vs Rd from a US payer
perspective with data from ASPIRE and long-term overall survival (OS) data
from the Surveillance, Epidemiology, and End Results Program (SEER).
Methods: A partitioned-survival model with progression-free (PF), post-pro-
gression (PP) and death states was built with a 30 year horizon. Treatment
(Tx) effect for PFS and OS was estimated with parametric regression models
and applied over the time horizon. Since 60% of pre-specified OS events were
observed, post-trial OS transition probabilities were estimated by matching
SEER data to ASPIRE pts. Grade ≥3 adverse events (AEs) with >2% incidence
in any ASPIRE arm were included. Utilities were derived from literature and
adjusted for the relative improvement in QoL increase observed when pts were
PF in ASPIRE. Costs related to drug (WAC prices) as well as wastage (30%
for carfilzomib), administration, monitoring, AE management, and subsequent
Tx were considered. Tx duration was derived fitting ASPIRE data and carfil-
zomib was dosed up to 18 cycles. The base case assessed the CE of adding
carfilzomib to Rd, and considered only additional costs of carfilzomib, i.e.
neglecting Rd drug costs in both arms. A scenario including Rd costs in both
arms was conducted. A 3% discount rate was applied to costs and outcomes.
Results: KRd was more effective compared to Rd, providing 1.134 PF life
year, 1.927 life year, and 1.616 quality-adjusted life year (QALY) gains over
the modelled horizon. KRd incurred $123,524 in total additional costs. Incre-
mental CE ratio (ICER) was $76,416/QALY. With the inclusion of Rd costs,
KRd incurred $179,863 additional costs with an ICER of $111,270/QALY. 
Summary/Conclusions: The model predicts that KRd delivers nearly 2.86 addi-
tional undiscounted life year’s over the standard of care (Rd), and is cost-effective
vs Rd at a willingness-to-pay threshold of $120,000/QALY. Therefore, carfilzomib
when added to Rd delivers considerable incremental value to patients and payers.
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Background: The selective proteasome inhibitor carfilzomib is approved in
the United States (US) as a single agent for the treatment of relapsed and
refractory multiple myeloma (MM) and in combination with dexamethasone for
relapsed MM. It is also approved in the US and Europe in combination with
lenalidomide and dexamethasone for the treatment of patients with relapsed
MM (RMM). In the phase 3 study (ENDEAVOR; NCT01568866) carfilzomib
and dexamethasone (Cd) doubled progression-free survival (PFS) compared
with bortezomib and dexamethasone (Bd) in patients with RMM (median 18.7
vs 9.4 months; hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.44,
0.65; 1-sided p<0.0001).
Aims: A pre-planned subgroup analysis of the ENDEAVOR study according to
patients’ age (<65, 65–74, and ≥75 years of age).
Methods: Adults with RMM (1–3 prior regimens) were randomized to either
the Cd arm (carfilzomib 30-min intravenous [IV] infusion on days [D] 1, 2, 8, 9,
15, and 16 [20mg/m2 on D1, 2 in cycle 1; 56mg/m2 thereafter]) and dexam-
ethasone (20mg on D1, 2, 8, 9, 15, 16, 22 and 23 of 28-day cycles) or the Bd
arm (bortezomib 1.3mg/m2 IV or subcutaneous on D1, 4, 8, and 11) and dex-
amethasone (20mg on D1, 2, 4, 5, 8, 9, 11, and 12 of 21-day cycles). Treatment
continued until disease progression, withdrawal of consent or unacceptable
toxicity. Primary end point was PFS and secondary end points included overall
survival, overall response rate (ORR), duration of response (DOR), safety, and
rate of peripheral neuropathy (PN). 
Results: Of the 929 patients enrolled, in the<65 years subgroup: 223 patients
received Cd and 210 received Bd; in the 65–74 years subgroup: Cd, n=164;
Bd, n=189; and the ≥75 years subgroup: Cd, n=77; Bd, n=66. Patient and dis-
ease characteristics were balanced across treatment arms within each age
subgroup. For all age subgroups, median PFS was improved with Cd vs Bd
(<65 years: not estimable vs 9.5 months [HR, 0.58; 95% CI, 0.44, 0.77]; 65–
74 years: 15.6 months vs 9.5 months [HR, 0.53; 95% CI, 0.38, 0.73]; ≥75 years:
18.7 months vs 8.9 months [HR, 0.38; 95% CI, 0.23, 0.65]) (Table). ORRs in
each age group were also consistently higher in the Cd arm versus the Bd arm
(<65 years: 74% vs 61% [odds ratio, 1.82; 95% CI, 1.21, 2.74]; 65–74 years:
77% vs 66% [odds ratio, 1.80; 95% CI, 1.12, 2.89]; ≥75 years: 84% vs 59%
[odds ratio, 3.75; 95% CI, 1.71, 8.24]). Grade ≥3 hypertension, dyspnea, car-
diac failure, renal failure were more common with Cd vs Bd. However, rates of
grade ≥2 PN were lower in the Cd arm compared with the Bd arm (<65 years:
6% vs 27% [odds ratio, 0.17; 95% CI, 0.09, 0.32]; 65–74 years: 8% vs 34%
[odds ratio, 0.17; 95% CI, 0.09, 0.32]; ≥75 years: 3% vs 43% [odds ratio, 0.04;
95% CI, 0.01, 0.16]). Deaths within 30 days post-study drug due to adverse
events occurred at a similar frequency in the Cd and Bd arms (<65 years: 3%
vs 3%; 65–74 years: 5% vs 3%; ≥75 years: 4% vs 5%).
Table 1. Efficacy outcomes and grade ≥3 adverse events of interest.
Summary/Conclusions: Cd significantly improved PFS and ORR compared
with Bd across all age subgroups. A trend toward a greater improvement was
observed in the eldest-age subgroup (≥75 years) versus the two younger-age
subgroups (<65 and 65-74 years). In the eldest-age subgroup treatment with
Cd was associated with an increased incidence of select grade ≥3 adverse
events of interest, including cardiac failure and hypertension, compared with
treatment with Cd in the younger-age subgroups. Hypertension is a common
and manageable complication in elderly patients and should be monitored. Cd
has a favorable benefit-risk profile in patients with RMM, irrespective of age.
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Background: There are few randomized trials and no well-established treat-
ment standards for Waldenström’s Macroglobulinemia (WM). Data on treatment
choices and their outcome in patients (pts) outside clinical trials are lacking.
Aims: The goal of this observational chart review was to generate real-world
data on diagnosis, treatment patterns, and outcomes for WM over a decade in
a large effort involving several European countries. 
Methods: Physicians completed retrospective electronic records for pts who
fit the following criteria: confirmed WM, symptomatic disease at treatment ini-
tiation, frontline treatment initiated between Jan 2000-Dec 2010, treatment with
at least one salvage regimen (excluding maintenance therapy), and availability
of clinical/biologic evaluation at diagnosis or initial therapy. Study endpoints
included initial/subsequent lines of treatment, progression-free survival (PFS),
and overall survival (OS). The number of pt records per country was prespec-
ified to balance distribution between countries.
Results: Electronic records were reviewed for 368 pts from France (n=85),
United Kingdom (n=62), Germany (n=51), Spain (n=45), Italy (n=40), Greece
(n=25), Netherlands (n=21), Poland (n=14), Czech Republic (n=13), and Austria
(n=12). Data were summarized across 2nd/3rd-lines for 368/155 pts. Median
age at initiation of frontline treatment was 63 yr (range, 29-89); 61% were male.
Reasons for initiating treatment were cytopenias (77%; anemia [75%]), consti-
tutional symptoms (56%), IgM-related symptoms (55%), and organomegaly
(26%). Choice of therapy varied with line of treatment and age; monotherapy
fell from 35% in frontline to 21%/22% in 2nd/3rd-lines (Table 1) and age ≥70
was associated with greater use of monotherapy (40%) vs combination therapy
(29%) in the frontline. Combination therapy with rituximab increased from 36%
in frontline to 63%/56% in 2nd/3rd-lines. Across all lines, rituximab and
cyclophosphamide were the most common agents, excluding steroids, used
as monotherapy or in any combination. Median PFS decreased with successive
lines of treatment from 31 mo for frontline to 24/16 mo for 2nd/3rd-lines. Median
PFS varied by country and choice of agents (Table 1), but was similar for pts<50
and ≥50 y. Improved median PFS was observed for pts who received rituximab
in 2nd-line vs pts who did not (26 vs 19 mo, P=0.014). Treatment outcomes
were similar in 3rd-line with regards to rituximab use (15 vs 16 mo, P=0.69).
The use of rituximab in the frontline did not affect median PFS of subsequent
lines of therapy (2nd-line: 24 vs 23 mo, P=0.87; 3rd-line: 13 vs 16 mo, P=0.12).
Median OS for the overall population was not reached, but was significantly
lower in pts ≥75 yr (70 mo; P<0.0001) or in pts with high-risk IPSSWM risk
score (91 mo; P=0.0014). The current data does not indicate a difference in
OS with frontline rituximab use. Other malignancies were reported in 14% after
receipt of at least one line of treatment for WM.
Table 1. Use of monotherapy or combination regimens and PFS in 2nd-
and 3rd-Line settings overall and by country.
Summary/Conclusions: For WM pts treated in Europe, the most common
reasons for initiating therapy are anemia and constitutional symptoms. Ritux-
imab was the most commonly used agent across all lines of treatment and use
of rituximab was associated with improvement in median PFS in the 2nd-line.
Outside clinical trials, monotherapy is widely used even at first relapse with
notable differences between countries. This large observational dataset will be
an important tool to promote understanding of treatment practices and survival
of WM pts outside of a clinical trial setting.
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Background: The TOURMALINE-MM1 study (NCT01564537) demonstrated
improved progression-free survival (PFS) with the all-oral combination of IRd
vs placebo-Rd (median 20.6 vs 14.7 months; HR 0.74) in patients (pts) with
relapsed/refractory multiple myeloma (RRMM)(Moreau et al, ASH 2015). Based
on this study ixazomib was approved by the US FDA in combination with Rd
for the treatment of pts with MM who have received at least one prior therapy.
Aims: To analyze the efficacy and safety of IRd vs placebo-Rd according to prior
proteasome inhibitor (PI) and prior thalidomide (thal)/lenalidomide (R) exposure.
Methods: Pts with RRMM were randomized 1:1 to receive IRd or placebo-Rd
(ixazomib 4 mg or matching placebo on days 1, 8, and 15, plus lenalidomide
25 mg on days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in
28-day cycles) until disease progression or unacceptable toxicity. Pts were
stratified by number of prior therapies (1 vs 2 or 3), PI-exposed vs PI-naïve
status, and International Staging System (ISS) stage I or II vs III. Pts who had
received prior therapy with PI- and thal/R-based regimens, and pts who were
refractory to thal, were eligible for inclusion. However, pts who were refractory
to PI- or R-based prior therapy were not included.
Results: Of 722 pts, 69% had prior PI therapy (<1% prior carfilzomib) and 55%
had prior thal/R therapy, including 45% prior thal (12% thal-refractory) and 12%
prior R. Prior therapies were balanced between arms. At the primary analysis
(median follow-up ~15 months), consistent PFS benefit was seen with IRd
regardless of prior PI or thal/R exposure (Table). Overall response rate (ORR)
with IRd vs placebo-Rd appeared generally similar across subgroups (PI-naïve:
81% vs 74%; PI-exposed: 77% vs 70%; thal/R-naïve: 80% vs 77%; R-naïve:
78% vs 73%) but slightly lower in thal-refractory pts (70% vs 57%), while ORR
in the placebo-Rd arm appeared somewhat lower in thal/R-exposed (77% vs
67%) and R-exposed pts (77% vs 59%). Complete response plus very good
partial response (CR+VGPR) rates with IRd vs placebo-Rd appeared generally
similar in PI-naïve (54% vs 37%), PI-exposed (46% vs 40%), thal/R-naïve (51%
vs 44%), thal/R-exposed (45% vs 35%), R-naïve (48% vs 39%), and R-exposed
(45% vs 36%) pts, but lower in thal-refractory (30% vs 27%) pts. At a 23-month
analysis, IRd safety profile was generally consistent regardless of prior PI or
thal/R exposure. Rates of grade ≥3 AEs with IRd vs placebo-Rd were 76% vs
66% in PI-naïve, 73% vs 70% in PI-exposed, 75% vs 71% in thal/R-naïve, and
73% vs 67% in thal/R-exposed pts. Rates of individual AEs (all-grade and grade
≥3) with IRd vs placebo-Rd were similar and consistent with those reported for
the overall patient population regardless of prior PI or thal/R exposure, including
common AEs such as GI and hematologic toxicities, rash, and neuropathy, with
the exception of neutropenia in the PI-naïve population; overall rates were 29%
vs 20%, including 21% vs 15% grade ≥3, whereas IRd and placebo-Rd rates
were similar in the overall population and other subgroups. Rates of serious
AEs with IRd vs placebo-Rd were 47% vs 40% in PI-naïve, 46% vs 53% in PI-
exposed, 48% vs 51% in thal/R-naïve, and 45% vs 48% in thal/R-exposed pts.
Table 1.
Summary/Conclusions: The benefit of IRd vs placebo-Rd appeared consistent
across subgroups defined by prior PI and thal/R exposure; IRd safety profile
was also broadly consistent across subgroups.
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Background: Multiple myeloma (MM) is a disease of the elderly, many of
whom often present with comorbidities including RD and CVD (Gupta 2015;
Dimopoulus 2015). While the presence of RD and/or CVD may influence
RRMM treatment choices, there is limited real-world data on prescribing pat-
terns and outcomes in these patient populations (Castelli 2014; Larocca 2015).
Aims: To describe the prevalence of RD and CVD over time, and the variation
in prescribing patterns and clinical outcomes (progression-free survival (PFS)
and overall survival (OS)) by comorbidity profile in RRMM pts initiating second
line therapy (2LT).
Methods: This was a retrospective cohort study using a large national EMR
database in the U.S. Newly diagnosed adult MM patients initiating first line ther-
apy (1LT) between 1/2008 and 12/2014 were followed until death/loss to follow
up or the end of study period (6/30/2015). 2LT was identified by: 1) retreatment
after a treatment gap of >3 months after 1LT discontinuation, or 2) a switch to
another drug combination after starting 1LT. Comorbid RD was based on pres-
ence of a diagnosis (dx) code or a lab value (creatinine clearance<40ml/min or
serum creatinine >2 mg/dL) in the 12 months prior to start of 1LT through the
start of 2LT; and comorbid CVD was based on dx codes in the same timeframe.
Time to new treatment (TTNT) or death was used as a surrogate for PFS.
Kaplan-Meier analyses were performed for TTNT/OS from start of 2LT.
Table 1.
Results: Among 628 RRMM pts (mean age 69 years), 27.4% had comorbid
RD, 7.6% had comorbid CVD, and 12.6% had both RD and CVD prior to 1LT;
this increased to 31.4%, 8.8%, and 27.7%, respectively, prior to 2LT. The dis-
tribution of treatments across 1LT and 2LT is shown in Table 1. In 1LT, pts
with RD±CVD were most likely to receive proteasome inhibitor (PI)-based
therapies; in contrast, pts with CVD only were most likely to receive
immunomodulatory drug (IMID)-based therapies. In 2LT, the use of IMID-
based therapies was most common, except among pts with CVD only where
a similar proportion used IMID-based or PI-based therapies (approx. one-
third). Additionally, intensive regimens (PI+IMID) were more common for all
pts regardless of comorbidity in 1LT compared to 2LT. Median TTNT from 2LT
initiation was 14.3 months (95% CI: 9.2, 19.1) for pts with CVD only, 13.7
months (95% CI: 11.4, 17.8) for pts with RD only, 12.3 months (95% CI: 8.4,
16.6) for pts with RD and CVD, and 20.1 months (95% CI: 16.6, 24.4) for pts
without CVD or RD. OS at 1 yr and 2 yrs from 2LT initiation were 77.8% and
64.1% for those with CVD only, 77.4% and 58.5% for those with RD only,
72.7% and 51.6% for those with CVD and RD, and 88.2% and 78.4% for pts
without CVD or RD (log-rank test, P<0.05).
Summary/Conclusions: Among pts receiving 2LT for RRMM, prevalence of
RD and/or CVD increased from 48% to 68% during the MM clinical course.
The type of therapy varied by presence of comorbidity for 1LT but to a lesser
extent for 2LT. Pts with RD and/or CVD had a shorter TTNT and a lower 1- and
2-yr OS probability relative to those without these comorbidities.
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Background: In a recent genome-wide association study (GWAS), the FOPNL
(fibroblast growth factor receptor 1 oncogen partner N terminal like gene) single
nucleotide polymorphism rs72773978 was identified as a novel adverse prog-
nostic factor in multiple myeloma (MM).
Aims: The aim of our study was to investigate the associations of FOPNL poly-
morphism with clinical characteristics (sex, age, ISS, cytogenetic abnormalities)
as well as treatment outcome (progression free survival, [PFS] and overall sur-
vival, [OS]) in a cohort of Hungarian MM patients.
Methods: Data of 373 MM patients (188 male/185 female; mean age:
60.5±11.2 year) diagnosed from 2005 to 2013 were retrospectively analysed.
As a first line treatment, older regimens (containing no proteasome inhibitor)
were administered in 132 cases, while PI based therapy was applied in 241
cases. The minimal follow up was 24 month. LightCycler melting analysis was
applied to identify rs72773978 polymorphism.
Results: In the whole cohort applying a dominant model, the distribution of
rs72773978 polymorphism was as follows: AA:328/373 (87.9%) vs AT&TT:
45/373, (12.1%). We found no significant difference in sex, age, ISS stage or
citogenetics stratified subgroups. In our cohort FOPNL polymorphism showed
difference in the prognostic effect depending on the treatment applied. In line
with the previous GWAS study, carriership of the minor allele was significantly
associated with adverse PFS among patients treated with non-PI based therapy
(p=0.042). PFS at 24 months was 43.5±4.5% for AA patients (n=124) compared
to 12.5±11.7% for AT&TT patients (n=8). Suprisingly in the PI treatment group,
PFS at 24 months was 51.7±3.5% for AA (n=204) compared to 62.2±8% for
AT&TT (n=37) patients (p=0.082). As significant interaction between FOPNL
and PI treatment was observed (p=0.003), we performed multivariate analyses
(Cox regression considering considering sex, age and ISS as covariates) in
both treatment groups separately. The difference did not remain significant in
either groups (non PI group: p=0.22; HR: 1.78, 95% CI: 0.7-4.5, PI group:
p=0.094; HR: 0.7, 95% CI: 0.47-1.06). Similar comparisons for OS revealed a
similar effect of FOPNL variant in both treatment groups. In the non-PI treated
group adverse prognosis was observed in minor allele carriers: OS at 72
months for AA patients was 49±4.6% compared to AT&TT with 18.8±15.8%
(p=0.022). In the PI-based group, OS at 72 months for AA patients was
40.9±4.5% compared to AT&TT 67.3±8.5% (p=0.048). The test for interaction
between FOPNL and treatment was significant (p<0.001). Separate multivariate
analyses revealed the independent adverse effect of rs72773978 on survival
in the non PI group (p=0.029; HR: 2.9, 95% CI: 1.1-7.6); but not in PI treatment
group: p=0.155; HR: 0.63, 95% CI: 0.34-1.19). 
Summary/Conclusions: In the present study, we confirmed the adverse prog-
nostic effect of FOPNL rs72773978 polymorphism in case of non-PI based
treatment regimens. On contrary this adverse effect was overcome by the appli-
cation of newer, proteasome inhibitor containing treatment protocols.
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Background: The Dutch national clinical guideline recommends bortezomib-
based induction chemotherapy (inductionCT) followed by high dose melfalan
(HDM) and autologous stem cell transplantation (ASCT) for patients with symp-
tomatic multiple myeloma (symMM) aged ≤65 years. In addition, ASCT should
also be considered for patients with symMM aged 66-70 years.
Aims: To evaluate how these recommendations were applied in daily practice
in the Netherlands for patients with symMM aged ≤70 years and, secondly,
what percentage of patients aged 66-70 years was offered ASCT as their first
line treatment.
Methods: From the nationwide population-based Netherlands Cancer Registry,
we identified 476 patients aged ≤70 years diagnosed with symMM in 2014 (60%
male). Of these patients, 318 (67%) were ≤65 years and 158 (33%) were 66-70
years. InductionCT was defined as bortezomib-based chemotherapy regimens
(i.e. BD, PAD, VCD or VTD) with or without (+/-) subsequent HDM and ASCT.
Overall response rate (ORR) was defined as achieving complete or partial
response i.e. CR, VGPR and PR as best achieved response outcome. Data
were analyzed for the total cohort, as well as stratified by age at diagnosis.
Results: Overall, of patients ≤65 years, 283 (89%) were treated with induc-
tionCT, of which VCD was most frequently used (N=231/283;82%), followed
by PAD (N=30/283;11%) and BD (N=22/283;8%). The remaining patients
received other types of chemotherapeutic regimens (2%) or no chemotherapy
at all (9%). Of patients who received inductionCT, 217 of 283 (77%) received
the planned HDM+ASCT. Of patients aged 66-70 years, 61 (39%) received
inductionCT consisting of either VCD (N=38/61;62%), BD (N=19/61;31%) or
PAD (N=4/61;7%). The remaining patients were mostly treated with VMP
(N=77/158;49%), while 8% (N=13/158) did not receive any treatment. In con-
trast to patients aged ≤65 years, only 29 of 61 (48%) patients underwent ASCT
after inductionCT. The ORRs were 86% (242/283) and 72% (44/61) for patients
≤65 and 66-70 years who received inductionCT +/- ASCT, respectively. The
ORR for patients aged 66-70 years who received VMP was 34% (26/77), which
is markedly lower than previously reported in the VISTA trial (ORR, 71%). The
ORR for patients who received inductionCT, but did not proceed to ASCT was
lower as compared to patients who did proceed to ASCT (51% vs 96%) irre-
spective of age group. Moreover, the ORR of patients aged 66-70 years who
received inductionCT (+/- ASCT) was higher than the ORR of patients in the
same age group who received VMP (72% vs 34%).
Summary/Conclusions: Our results show that most patients aged ≤65 years
start with inductionCT and 77% of these are able to proceed to HDM+ASCT. In
addition, among patients aged 66-70 years, 39% start with inductionCT of whom
only 48% received subsequent ASCT. Although based on modest patient num-
bers, the ORR of inductionCT +/- ASCT in patients between 66-70 years was
lower as compared to the ORR in the younger patient group, while higher than
the ORR in the VMP group. This population-based analysis demonstrates that
inductionCT is frequently offered to older patients with similar efficacy as in
younger patients. However, pre-selection strategies for intensive treatment are
insufficient since only half of the older patients subsequently receive their
planned ASCT.
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Background: Survival rates for patients (pts) with MM have improved with the
advent of new therapies, however data on real-world survival outcomes are limited.
Aims: Retrospective analysis using the Registry of Monoclonal Gammopathies
database of the Czech Myeloma Group.
Methods: Pts diagnosed with symptomatic MM (May 2007–June 2014), were
followed from diagnosis until death, loss to follow-up or June 2015. The primary
analysis was to estimate overall survival (OS) from diagnosis; secondary analy-
ses included treatment-line-specific OS and progression-free survival (PFS),
treatment patterns and response. Exploratory analyses included OS and PFS
from treatment initiation by International Staging System (ISS) stage, Interna-
tional Myeloma Working Group (IMWG) risk and therapy type (lenalidomide
plus dexamethasone [Ld] or bortezomib [bor]-based regimens).
Results: 2513 pts were included. Median age at diagnosis was 67.0 years.
Similar proportions of pts had ISS stage I, II or III disease. Median OS (months,
95% confidence interval [CI]) from diagnosis was 50.3 (46.1–54.5) and
decreased from 47.5 (43.1–52.0) at 1st line to 13.2 (11.3–15.2) at 3rd (Figure).
Median PFS (months, 95% CI) decreased from 16.3 (15.4–17.2) at 1st line to
6.0 (5.4–6.6) at 3rd. Main treatments at 1st line (n=2446) were bor- (46%) or
thalidomide-based (40%). At subsequent lines, pts frequently received bor - or
lenalidomide-based regimens (2nd line [n=1118], 49% and 31%; 3rd line
[n=547], 26% and 47%, respectively). Overall response rates decreased across
lines: 58% at 1st line, decreasing to 44% and 28% at 2nd and 3rd lines. Differ-
ences in median OS and PFS by treatment line were observed according to
ISS stage and IMWG risk (Table). An analysis of pts (excluding those in clinical
trials) receiving Ld 2nd to 4th line, showed median OS decreased at each sub-
sequent line (2nd line 26.2 [21.7-30.8] and 3rd line 12.6 [11.4-13.7]), compara-
ble to median OS in all patients. Median PFS was 7.5 (6.3-8.8); values at 2nd
and 3rd lines were 8.7 (7.3-10.1) and 6.6 (5.3-8.0). Similar trends were seen in
pts (excluding those in clinical trials) receiving bor in 2nd to 4th lines. At 2nd
and 3rd lines, median OS values were 27.3 (22.7-31.8) and 16.2 (12.1-20.3);
median PFS values were 11.3 (9.9-12.6) and 5.7 (4.7-6.8).
Table 1.
Figure 1.
Summary/Conclusions: Real-world outcomes in pts with symptomatic MM
are considerably lower than those reported in clinical trials. OS and PFS
decreased significantly with each successive treatment line. Despite availability
of novel agents, MM remains a disease with high unmet need.
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FC-GAMMA RECEPTOR POLYMORPHISMS AND PROGRESSION-FREE
SURVIVAL: ANALYSIS OF THREE CLINICAL TRIALS OF ELOTUZUMAB
IN MULTIPLE MYELOMA
V Poulart*, YM Jou, T Delmonte, M Robbins
Bristol-Myers Squibb, Princeton, United States
Background: Elotuzumab is a humanized IgG1 immunostimulatory monoclonal
antibody that targets SLAMF7, a glycoprotein highly expressed by myeloma
and natural killer (NK) cells. Elotuzumab works via a dual mechanism of action,
both by directly activating NK cells and by facilitating antibody-dependent cell-
mediated cytotoxicity (ADCC) to cause targeted myeloma cell death. Fcγ recep-
tors, including CD16a (FcγRIIIa) and CD32a (FcγRIIa), bind the Fc portion of
IgG1 antibodies to facilitate ADCC.1 Multiple alleles exist for CD16a and CD32a
haematologica | 2016; 101(s1) | 529
Copenhagen, Denmark, June 9 – 12, 2016
that confer affinity for Fc binding; therefore, differences in Fcγ receptor geno-
types could affect responses to elotuzumab.1 The high-affinity allele for CD16a
is determined by a valine (V) residue at amino acid position 158, while a pheny-
lalanine (F) residue determines the low-affinity variant. For CD32a, the high-
affinity allele is a histidine (H) residue at position 131; arginine (R) determines
the low-affinity variant.
Aims: To assess whether CD16a and CD32a polymorphisms affect progres-
sion-free survival (PFS) in patients receiving elotuzumab as monotherapy or
as part of a combination therapy.
Methods: In ELOQUENT-2 (NCT01239797), patients with relapsed/refractory
multiple myeloma (RRMM) and 1–3 prior therapies were randomized to elo-
tuzumab (10 mg/kg IV) in combination with lenalidomide (Len) and dexam-
ethasone (dex; ELd) or Len/dex alone (Ld). In Study 009 (NCT01478048),
patients with RRMM and 1–3 prior therapies were randomized to elotuzumab
(10 mg/kg IV) in combination with bortezomib (Btz) and dex (EBd) or Btz/dex
alone (Bd). In Study 011 (NCT01441973), patients with high-risk (Mayo Clinic
criteria) smouldering MM were treated with elotuzumab (10 mg/kg IV twice
monthly or 20 mg/kg IV once monthly). Patients from ELOQUENT-2 and Study
009 were categorized by CD16a (VV vs FF) and CD32a (HH vs RR) genotype.
Patients from Study 011 were categorized by the presence of ≥1 vs 0 high-
affinity CD16a (VV/VF vs FF) or CD32a (HH/HR vs RR) alleles. PFS by geno-
type was assessed in the elotuzumab and control groups of ELOQUENT-2
and Study 009, and for all patients in Study 011 (combined-dose cohort). 
Results: Genotyping was performed in 339/646 randomized patients in ELO-
QUENT-2, in all 152 patients in Study 009, and in 28/31 patients in Study 011.
In ELOQUENT-2, neither CD16a genotype (VV vs FF) nor CD32a genotype
(HH vs RR) was associated with a difference in PFS distribution in the ELd or
Ld group (Table). In Study 009, CD16a VV vs FF status was associated with
longer median PFS in the EBd arm, but not in the control arm. Given the avail-
able data for each estimate (n=15–19), CD32a genotype did not appear to be
associated with a meaningful difference in median PFS in either the EBd or Bd
group. In Study 011, median PFS was >20 months or non-estimable for all
CD16a and CD32a genotypes. PFS was numerically higher for patients with
≥1 vs 0 CD16a V alleles; however, interpretation is limited by the small numbers
of patients with each genotype.
Table 1. Median PFS (ITT definition) in ELOQUENT-2, study 009, and study
011, by FcyR genotype and treatment group.
Summary/Conclusions: The effect of Fcγ receptor polymorphisms on PFS
may depend on elotuzumab treatment combinations, as CD16a genotype cor-
related with PFS in patients treated with EBd but not ELd. ELd benefits all
patients, irrespective of genotype, as there is no evidence that high-affinity Fcγ
alleles are associated with a differential benefit.
Reference
1. Weng W et al. J Clin Oncol 2003;21:3940-7.
Funding: Bristol-Myers Squibb. Medical writing assistance: M Thomas, Caudex,
funded by Bristol-Myers Squibb.
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HIGH EXPRESSION OF AF1Q IS AN ADVERSE PROGNOSTIC FACTOR
AND A PREDICTION MARKER OF EXTRAMEDULLARY DISEASE IN MULTIPLE
MYELOMA
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Background: Multiple myeloma is an intractable hematological malignancy
with various clinical manifestations, especially extramedullary disease (EMD).
The prognosis of patients with EMD is extremely poor due to limited treatment
options and aggressive nature of EMD, however the mechanism of the pro-
gression of EMD is not well known. AF1q is an oncogene which expressed in
leukemia cells, located in 1q21. The gene is well known as one of the fusion
partners of MLL, and as a poor prognostic factor in acute myeloid leukemia
and myelodysplastic syndrome. Recently, we reported that high expression of
AF1q results in an autonomous Wnt activity that promotes distant metastasis
of breast cancer.
Aims: We hypothesized that high expression of AF1q is a poor prognostic
factor of multiple myeloma and associated with EMD. To evaluate our hypoth-
esis, we analyzed the expression of AF1q in patients with multiple myeloma
and investigated the impact on the prognosis and the progression of EMD.
Methods: Newly diagnosed multiple myeloma patients in National Center for
Global Health and Medicine hospital from January 2001 to March 2013 were
studied. Patients were treated with vincristine-adriamycin-dexamethason or
bortezomib-dexamethason induction therapy followed by autologous stem cell
transplantation using high dose melphalan. The expression of AF1q was eval-
uated using the immunostaining of bone marrow clot samples at the diagnosis
of multiple myeloma. The expression of AF1q was graded from “-“ to “+++”.
EMD was diagnosed by pathological examination and/or CT/MRI/PET. The
clinical response, progression free survival (PFS), and overall survival (OS)
were analyzed using Kaplan Meier method with Log-rank test. Correlation
between EMD and AF1q expression was tested by Chi-square test. 
Results: Clinical data and bone marrow clot samples of 117 patients were
analyzed. Mean age was 54.9 years old, and 51.9% was male. The grades of
AF1q expression were 7 of “-”, 33 of “+”, 35 of “++”, and 42 of “+++”. We defined
the cases with “-” and “+” as low expression, “++” and “+++” as high expression.
Very good partial response or better was obtained after completion of autolo-
gous stem cell transplantation in 42.5% of patients with low AF1q expression
and 37.7% of high expression. There was no statistically significant difference. 
Survival analysis using Log Rank method showed that high expression of AF1q
was associated with significantly shorter progression free survival (3 year PFS
was 56.2% in low AF1q expression vs 30.5% in high AF1q expression,
p=0.009), but not overall survival (3 year OS was 89.6% in low AF1q expression
vs 73.3% in high AF1q expression, ns.). EMD was found in 25.0% of patients
with low AF1q expression and 44.7% of high expression. Chi-square test
showed that the incidence of EMD was significantly higher in patients with high
AF1q expression than low expression (p=0.045)
Figure 1.
Summary/Conclusions: To our knowledge, this is the first study that demon-
strates a molecular marker associated with myeloma with EMD. We found that the
high expression of AF1q was an adverse prognostic factor in multiple myeloma.
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PHASE 1/2 TRIAL OF LENALIDOMIDE IN COMBINATION WITH
CYCLOPHOSPHAMIDE AND PREDNISONE (REP) IN PATIENTS WITH
LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (REPEAT-STUDY)
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Background: The outcome of lenalidomide- and bortezomib-refractory multiple
myeloma (MM) patients is very poor, with a median event-free survival of 5
months and median overall survival (OS) of 9 months. Therefore new treatment
modalities are urgently needed. In this respect, several new drugs have recently
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been approved for the treatment of double refractory MM (such as pomalido-
mide, carfilzomib, and daratumumab). However, next to the development of
new drugs, also the strategy of combining drugs with synergistic activity may
result in significant clinical benefit for patients with advanced myeloma.
Lenalidomide has well-described immunomodulatory effects, even in the setting
of lenalidomide-refractory disease. Similarly, administration of continuous low-
dose cyclophosphamide (metronomically dosed) has direct anti-tumor activity,
as well as several well-characterized immunomodulatory effects. We have pre-
viously shown in a retrospective study that lenalidomide combined with contin-
uous low-dose oral cyclophosphamide (endoxan) and prednisone (REP) had
remarkable activity in heavily pretreated, lenalidomide-refractory MM patients.
Aims: To further evaluate this combination, we initiated a prospective phase
I/II study to determine the optimal dosing schedule of lenalidomide, low-dose
oral cyclophosphamide and prednisone, and to assess its efficacy and safety
in lenalidomide-refractory MM patients.
Methods: 82 lenalidomide-refractory MM patients were included in this trial;
21 were included in the phase 1 dose-finding part with a classic 3+3 dose-
escalation design (5 dose-levels) and 61 patients were included in the phase
II part of this trial in which all patients were treated at the maximum tolerated
dose (MTD). 
Results: The median age of the 82 patients in this phase I/II trial was 66 years
(range 41-82); 71% were male. The median duration from diagnosis was 48
months (range 5-169), median number of prior therapies was 3 (range 1-6),
and 50 patients (61%) had previously received autologous SCT. All patients
were lenalidomide-refractory, 71 (87%) had prior bortezomib treatment, and 54
(66%) had both lenalidomide- and bortezomib-refractory MM. 41% of the
patients had high-risk cytogenetic abnormalities as determined by FISH. The
MTD was defined as 25 mg lenalidomide (days 1-21/28 days), combined with
continuous oral cyclophosphamide (50 mg/day) and prednisone (20 mg/day).
Sixty-seven patients were treated at the MTD (6 in dose-level 4 of phase I and
61 in phase II part of the study). Forty-four of these patients (67%) achieved a
partial response or better, including 12 patients (18.2%) with a very good partial
response and 3 (4.5%) with a complete remission. Eleven patients (16%)
achieved a minimal response, translating to an overall 83% clinical benefit rate.
After a median follow-up of 24.5 months median PFS and OS were 12.1 and
29.0 months respectively. Similar results were achieved in the subset of patients
with lenalidomide- and bortezomib-refractory disease as well as in patients with
high-risk cytogenetic abnormalities. At the MTD, neutropenia (22%) and throm-
bocytopenia (22%) were the most common grade ≥3 hematological adverse
events. Infections (21%) were the most common grade ≥3 non-hematological
adverse events.
Summary/Conclusions: REP is a well-tolerated regimen and induces a high
response rate with prolonged PFS and OS in lenalidomide-refractory MM
patients. REP should be considered a valuable salvage option for lenalido-
mide-refractory MM patients.
This trial was registered at www.clinicaltrials.gov as #NCT01352338.
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Background: Patients with relapsed and refractory multiple myeloma (RRMM)
who are heavily pretreated often have advanced disease and comorbidities,
increasing their susceptibility to adverse events (AEs). The management of
AEs is important to ensure that patients remain on the therapy for as long as
needed to receive a clinical benefit.
Aims: To further characterize the safety profile of pomalidomide (POM)+low-
dose dexamethasone (LoDEX) and management of AEs using pooled safety
data from 3 clinical trials of POM+LoDEX (Richardson et al, Blood, 2014; San
Miguel et al, Lancet Oncol, 2013; Dimopoulos et al, ASH 2015).
Methods: The 3 trials enrolled patients who provided informed consent and
had ≥2 prior therapies, including lenalidomide and bortezomib, and had pro-
gressed on or within 60 days of their last therapy. Patients received POM 4
mg/day on days 1-21 of each 28-day cycle and LoDEX 40 mg (20 mg for those
>75 years of age) weekly until disease progression or unacceptable toxicity.
Thromboprophylaxis was required. Grouped AE terms were used for analysis.
Results: A total of 1088 patients from the 3 trials were included in the safety
population; median age was 66 years (range, 34-88 years). Most patients were
male (57%), had an Eastern Cooperative Oncology Group performance status
of ≤1 (88%), were refractory to both lenalidomide and bortezomib (77%), and
had prior stem cell transplant (68%). The most common grade 3/4 AEs were
neutropenia (56%), infections (34%), anemia (32%), and thrombocytopenia
(26%). The median time to onset was 20 days (range, 1-591 days) in the 693
patients with neutropenia, 15 days (range, 1-498 days) in the 393 patients with
thrombocytopenia, and 41.5 days (range, 1-493 days) in the 748 patients with
infections. AEs were managed by dose modifications and/or supportive care,
including anti-infectives (88%), red blood cell transfusion (45%), granulocyte
colony-stimulating factor (17%), and platelet transfusion (14%). The rate of
grade 3/4 venous thromboembolic events was low (2%). Peripheral neuropathy
(PN) of any grade occurred in 17% of patients; 1% experienced grade 3/4 PN.
The median average POM dose was 4 mg (range, 1.6-4.2 mg). AEs leading to
POM dose interruptions occurred in 66% of patients. AEs leading to dose reduc-
tions occurred in 24% of patients; the most common were neutropenia (8%),
thrombocytopenia (5%), and infections (4%). AEs leading to discontinuation of
POM were infrequent (7%).
Summary/Conclusions: In this large pooled safety analysis, POM+LoDEX
showed an acceptable safety profile in patients with RRMM. AEs were man-
ageable, and discontinuations due to AEs were uncommon.
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RATIONALE AND PHASE 2 STUDY OUTLINE
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Background: Despite advances in the treatment of multiple myeloma (MM),
there is no cure. Patients eventually relapse, requiring multiple lines of treat-
ment. Upregulation of both the vascular endothelial growth factor (VEGF) and
hepatocyte growth factor (HGF) pathways has been implicated in loss of
response to therapy. VEGF and HGF are increasingly overexpressed with MM
progression and have been linked to poor prognosis: they are known to be able
to stimulate neovascularization, bone destruction, and myeloma proliferation,
migration, and adhesion in the bone marrow. Preclinical studies have shown
that refractory, high HGF-expressing MM cell lines can be re-sensitized to treat-
ment by inhibiting HGF/cMET signaling. MP0250 is a bispecific VEGF / HGF
blocking multi-DARPin which is currently in a phase 1 study in solid tumors.
Aims: We are presenting the preclinical rationale for using MP0250 in combi-
nation with bortezomib (BTZ) in a planned phase 2 study in MM patients.
Methods: MP0250 and BTZ, alone and in combination, were tested in an ortho-
topic murine xenograft model in which human MM cells were implanted in murine
tibial bone marrow. Tumor growth and muscle invasion was monitored by caliper
measurements and CT scans, and bone destruction was analyzed by X-ray and
microCT. Ex vivo analysis included the determination of M protein levels.
Results: MP0250 significantly inhibited bone lysis (total and cortical bone vol-
umes) and tumor invasion in a dose-dependent manner. In both the MP0250
and MP0250+BTZ groups, tumor infiltration into the tibial muscle was signifi-
cantly reduced while BTZ alone had no effect. M protein was reduced and inhi-
bition of bone lysis was increased when the combination of BTZ and MP0250
was compared to BTZ alone. The results show that blockade of HGF and VEGF
by MP0250 on its own has a beneficial effect and that enhanced effects can be
achieved in combination with BTZ.
Summary/Conclusions: MP0250, a multi-DARPin specifically blocking HGF
and VEGF, improves the efficacy of BTZ in a preclinical MM model. Consequent
to this and a favorable phase 1 study, MP0250 will be evaluated in a phase 2
study in MM in combination with BTZ+DEX.
*DARPins are small repeat proteins, designed to bind targets with high speci-
ficity and potency, and which can be combined in a modular fashion.
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CAN CAPILLARY ZONE ELECTROPHORESIS MONITOR DARWINIAN
EVOLUTION OF MULTIPLE MYELOMA CLONES? 
PP Kotoucek1,*, D Midda2, R Wenban3, S Peggler3, A Reche3, P Manghat3,
R Lock4
1Haematology, 2Pharmacy, 3Pathology, Darent Valley Hospital, Kent, UK, Dart-
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Background: At the time of diagnosis of multiple myeloma (MM) and similar
disorders there are multiple clones in bone marrow or in extramedullary sites.
Usually only a dominant clone is diagnosed and monitored in daily clinical prac-
tice before, during or after chemotherapy. Non dominant clones are not meas-
ured routinely nor their evolution under pressure of chemotherapy.We present
identification and monitoring of multiple clones of multiple myeloma and similar
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disorders by capillary zone electrophoresis (CZE) in routine clinical settings
and evolution of these clones during a 5 year follow up and during third line
chemotherapy by lenalidomide
Aims: Multiple myeloma is heterogenous disease with multiple clones. There
is no techique available in routine clinical practice to monitor dominant and
non-dominant clones in the same time. Chemotherapy bears a risk of supress-
ing less aggressive dominant clone and enhancing evolution process of very
aggressive and chemotherapy resistant clones. Our aim was to monitor all
clones simultaneously during natural course of disease and during chemother-
apy to understand evolution process in routine practice. 
Methods: 1/CZE results captured from 1.1.2009 till 31.12.2009 in a single hospital
pathology centre with a 5 year follow up correlated with clinical outcomes of
patients. 2/Results of patients with mutliple myeloma on third line chemotherapy
with lenalidomide in single centre from 1.1.2010 till 31.12.2015 monitored by CZE.
Results: 1/ All consecutive patients with any paraprotein visible in CZE within
year 2009 in our centre: N=314. Break down these patients to a number of all
patients with only one paraprotein on CZE is n= 277, a number of patients with
two or three paraproteins is n= 37.Evolution of clones within one year (2009):
from one paraprotein to two visible in CZE was in n=8 patients. One patient
has experienced evolution from one clone to thee clones within one year. 5
year follow up data of all patients with more than 1 paraprotein are available
only in 11 patients from original 37 patients.Their diagnoses were: MGUS n=2
with further increasing number of clones from 2 to 3 within 5 years; CLL n= 2,
one patient with increasing number of paraproteins from 2 to 3, Waldenstroam
Macroglobulinaemia n= 3, one patient with increasing number of paraproteins
from 2 to 3. 2/ Patients on third line chemotherapy n=56 based on lenalidomide
were monitored by CZE. Evolution of multiple clones is demonstrated by CZE 
Summary/Conclusions: CZE is a very sensitive and unique method capable
capturing even non-dominant minor clones and monitoring them during obser-
vation or chemotherapy and to assess response to chemotherapy in a deeper
level in routine practice. CZE can describe selection of clones during
chemotherapy. A high sensitivity of CZE can reveal paraprotein in patients with
lymphopoliferative disorders. For better understanding of CZE in monitoring of
non-dominant clones further correlation with flowcytometry and even with cyto-
genetic and genomic assays are needed.
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Background: The introduction of novel agents, proteasome inhibitors (PIs)
and immunomodulatory drugs (IMIDs), has led to an improvement in prognosis
in multiple myeloma (MM). However, over the course of the disease, less
durable remissions with each successive therapy have been noted in MM. In
a retrospective single-institution, chart review study, patients experienced short-
er overall survival (OS) as they progressed through each line of therapy, first-
line (1LT) and second-line (2LT), OS of 28.4 and 17.1 months, respectively
(Kumar 2004). Other evidence from a multi-center observational analysis of
383 MM patients (treated between 2007 and 2010) reported a median pro-
gression free (PFS) and OS from start of salvage therapy after first relapse of
13 and 35 months, respectively (Durie 2012); however, the clinical course of
RRMM in the era of novel agents among pts treated in the real-world remains
to be elucidated.
Aims: This study aims to describe the PFS and OS of RRMM patients receiving
two or more lines of therapy in the era of novel agents in a large national data-
base in the U.S.
Methods: In this retrospective cohort study using an electronic medical records
(EMR) database from 38 states in the U.S, newly diagnosed, adult MM patients
initiating 1LT between 1/2008 and 12/2014 were followed to identify 2LT accord-
ingly: 1) retreatment after a treatment gap of >3 months of a prior LT, or 2) a
switch to another drug combination after 1LT initiation. Subsequent lines of
therapy, 3LT and 4LT, began with a switch in regimen compared to the previous
line. Pts with salvage stem cell transplants (SCT) were excluded. Time to new
treatment or death (TTNT) was used as a surrogate for PFS. Kaplan-Meier
analyses were performed for OS/TTNT from start of each line of therapy. Obser-
vations were censored at time of loss to follow up or end of study period
(6/30/2015).
Results: Among 628 patients initiating both 1LT and 2LT, mean age was 69.2
years (SD: 10.3) at start of 2LT; 51% were male; 9.6% had known high cyto-
genetic risk MM (del[17p] and/or t[4:14] and/or t[14:16]); 19.6% had a frontline
SCT; 46.7% had a Charlson Comorbidity Index (CCI) score ≥2. PI-based reg-
imens predominated in 1LT (44.2%), 3LT (43.1%) and in 4LT (41.2%) (Table
1). The most common regimen in 2LT was IMID-based (44.2%). PI+IMID-based
combination therapy increased from 17.7% in 1LT to 40.2% in 4LT. As patients
progressed through lines of therapy, median TTNT decreased from 15.1 months
(95% CI: 13.4, 17.3) in 2LT to 7.8 months (95% CI: 6.1, 9.7) in 3LT and 6.9
months (95% CI: 5.1, 11.8) in 4LT. Median OS decreased from 41.0 months
(95% CI: 32.1, 59.5) in 2LT to 30.3 months (95% CI: 20.1, 46.0) in 3LT and
24.8 months (95% CI: 12.8, 43.0) in 4LT.
Table 1. Treatment patterns by line of therapy among MM patients initiat-
ing 1st and 2nd line therapy.
Summary/Conclusions: Median OS and time to progression from 2LT was
longer than previously reported (Durie 2012; Kumar 2004). However, succes-
sive treatment regimens yielded progressively shorter TTNT and OS durations.
These data may support treatment decision making by informing the trade-offs
between prognosis, treatment effectiveness and toxicity.
Reference
1. Durie ASCO 2012; abs 8095 Kumar, et al. Mayo Clin Proc. 2004; 79(7):867-874.
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PRACTICE PATTERNS AND OUTCOMES IN ELDERLY U.S. PATIENTS
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
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Background: Multiple myeloma (MM) is a disease of the elderly; median age
at diagnosis is 70 yrs (Larocca 2015). The advent of novel therapies has
improved survival (OS) among newly diagnosed MM (NDMM) patients (pts)
(Kumar 2014). But, the link between therapeutic regimens and OS benefit in
elderly pts is not clearly established (Kumar 2014; Verlest 2012). Real-world
information regarding prescribing patterns and clinical outcomes in elderly pts
with RRMM is limited.
Aims: To describe the prescribing patterns and clinical outcomes, and to evaluate
the impact of age on progression-free survival (PFS) and OS in elderly RRMM
pts initiating second line therapy (2LT) in a large, national database in the U.S.
Methods: In this retrospective cohort study of an electronic medical records
(EMR) database, NDMM adult pts initiating first-line therapy (1LT) between
1/2008 and 12/2014 were included and 2LT was identified accordingly: 1) retreat-
ment after a treatment gap of >3 months of 1LT, or 2) a switch to another drug
combination after starting 1LT. Third-line therapy (3LT) began with a switch in
regimen post 2LT. Pts with salvage stem cell transplants (SCT) were excluded.
Time to new line of therapy (TTNT) or death was used as a surrogate for PFS.
Cox proportional hazard models for TTNT and OS were conducted from start of
2LT. Pts were censored at loss to follow up or the end of study period (6/30/2015).
Results: Among 628 pts with 1LT and 2LT, 37.1% were ≥75 yrs of age (yo) at
start of 2LT, 51% male; 2% of those ≥75 yr vs 30% of those <75 yr underwent
frontline SCT. Pts ≥75 yo had a higher comorbidity burden (mean Charlson
Comorbidity score [CCI]: 2.1 vs 1.6), and a higher proportion had cardiovascular
disease (CVD [38.6% vs 27.3%]) than those <75 yo at start of SLT. Median fol-
low-up from start of 2LT was 13.0 mos (IQR: 5.2, 23.3).Younger pts were 2-
fold more likely to receive more intensive therapy with a proteasome
inhibitor+immunomodulatory drug (PI+IMID)-based combination both in 1LT
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(21.8% vs 10.8%) and in 2LT (11.1% vs 5.2%) compared to ≥75 yo (Table). In
1LT, older age was associated with an increased use of IMID-based therapies
(42.1% vs 28.9% among ≥75 vs<75 yo). In 2LT, older age was associated with
a higher frequency of PI-based therapies, 39.5% vs 29.6% in the younger
cohort. OS probabilities at 1 yr and 2 yrs were 84.6% and 68.0% for those<75
yrs and 72.3% and 57.4% for those ≥75 yrs. Adjusting for observed confounders
(gender, race, cytogenetic risk, CCI, CVD, yr of diagnosis, 1LT and 2LT regimen
type), older age was associated with a significantly higher mortality risk after
initiation of 2LT (HR: 1.57 [95% CI: 1.2, 2.1], P<0.01, for age ≥75 vs<75 yrs)
(Figure). Median TTNT was 16.6 mos (95%CI: 13.5, 19.1) for pts<75 yrs and
13.8 mos (95% CI: 11.7, 17.8) for pts ≥75 yo. Age was not significantly associ-
ated with TTNT in 2LT in multivariate analyses.
Table 1. Drug therapy by age among MM patients (n=628).
Figure 1. Adjusted overall survival by age from 2LT initiation.
Summary/Conclusions: In 1LT and 2LT in MM, older age appeared to impact
treatment choice with less intensive therapy. The majority of patients received
≥1 novel agent irrespective of age; however, elderly pts were more likely to ini-
tiate IMID-based therapy in 1LT and PI-based therapy in 2LT compared to
younger pts. Older age was associated with significantly worse OS outcomes
after start of 2LT in the real-world.
References
1. Larocca et al. Blood. 2015;126:2179-85;
2. Verlest et al. Haematologica.2012; 97:242;
3. Kumar et al. Leukemia. 2014;28:5:1122-1128.
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COMPARISON OF FOUR NEUROPATHY ASSESSMENT SCALES IN
EVALUATION OF TREATMENT EMERGENT NEUROPATHY IN NEWLY
DIAGNOSED PATIENTS OF MULTIPLE MYELOMA TREATED WITH
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Background: Treatment emergent peripheral neuropathy (TEPN) is a distress-
ing and potentially dose limiting side-effect of bortezomib containing regimen
for multiple myeloma (MM). The reporting of extent and severity of TEPN is
variable due to use of different neuropathy scales. Presently, most investigators
use National Cancer Institute Common Toxicity Criteria for Adverse Events
(NCI CTCAE) for reporting of TEPN.
Aims: We aimed to compare the utility of different neuropathy scoring scales
for detection of TEPN and to evaluate the incidence, severity and electrophys-
iological characteristics of TEPN after bortezomib based regimen in newly diag-
nosed patients of MM.
Methods: We prospectively evaluated the incidence of TEPN in treatment naïve
patients of MM receiving cyclophosphamide, bortezomib and dexamethasone
(CyBorD) on days 1, 8, 15 and 22 of each 28-day cycle, by clinical evaluation,
nerve conduction study (NCS) and four different neuropathy scores- NCI CTC
v4.0, Total neuropathy score reduced (TNSr) and clinical (TNSc) and Numerical
Response Scale (NRS) for neuropathic pain. TNSr includes results of nerve
conduction study in addition to the clinical parameters used in TNSc. Post-treat-
ment increment by one grade for NCI-CTC, by score of ≥2 for TNSr and TNSc,
and by score of ≥1 for NRS defined TEPN. Informed consent was obtained from
each patient and the study was approved by institutional review board.
Results: A total of twenty six patients received CyBorD regimen. Twenty patients
completed follow-up. After a median of 7 (range: 3.5-11) months, the rates of
occurrence of TEPN differed when the four scales were used; viz. NCI CTC=45%
(n=9), TNSr=55% (n=11), TNSc=40% (n=8) and NRS=40% (n=8). All four scales
showed worsening following treatment with CyBorD, especially with regard to
sensory symptoms (p<0.01 for all scales). TNSr could pick up higher number of
cases with TEPN in comparison to any other score, most notably in comparison
to NCI CTCAE. Among 12 patients who did not have TEPN by NCI CTC scale,
41.7% (n=5), 16.7% (n=2) and 8.3% (n=1) patients satisfied the criteria for TEPN
by TNSr, TNSc and, NRS, respectively. When compared against TNSr, sensitivity
for detecting TEPN by NCI CTCAE, TNSc and NRS were 77.8%, 88.9%, and
77.8%, respectively. NCI CTCAE and TNSc, both showed specificity of 63.3%
for detection of TEPN. Specificity with NRS was found to be 54.5%. The higher
detection rate of neuropathy by TNSr is probably due to wider range of scores
given for graded sensorymotor impairment and incorporation of electrophysio-
logical parameters which increases its sensitivity. On NCS, three patients
(42.9%) had sensorimotor and four (57.1%) patients had motor nerve conduction
abnormalities. Five patients (71.4%) had axonal neuropathy while 2 (28.6%)
patients had evidence of demyelination on NCS.
Table 1.
Summary/Conclusions: We suggest that, NCI-CTCAE may be suboptimal in
comparison to TNSr in assessment of TEPN in patients with MM on bortezomib
based therapy. It is desirable to use better scoring systems like TNSr as they
may be more sensitive and they improve our understanding of bortezomib
induced neuropathy. NRS is a simple screening tool that can be used in routine
clinical practice for detecting bortezomib induced neuropathy. Further studies
with large sample size including intraepidermal nerve fiber density testing on
skin biopsy are required to better define TEPN in patients receiving bortezomib.
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SERUM B-CELL MATURATION ANTIGEN IS A BIOMARKER FOR PATIENTS
WITH B-CELL DISORDERS
J Berenson1,*, K Udd1, TM Spektor2, J Wang1, E Sanchez1, G Tang1, C Wang1,
M Li1, H Chen1, PJ Maglione3, C Cunningham-Rundles3
1Institute for Myeloma & Bone Cancer Research, 2Oncotherapeutics Inc.,
WEST HOLLYWOOD, 3Mt. Sinai School of Medicine, New York City, United
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Background: Serum B-cell maturation antigen (sBCMA) is a tumor necrosis
factor receptor family member that is expressed on normal and malignant B-
cells including plasma cells.
Aims: We determined sBCMA levels in large cohorts of patients (pts) with mul-
tiple myeloma (MM), chronic lymphocytic leukemia (CLL) and Waldenström’s
macroglobulinemia (WM) and immune deficiency (ID) including common vari-
able immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Methods: Serum was obtained on healthy individuals and pts with B-cell dis-
orders following informed consent. Enzyme-linked immunosorbent assay
(ELISA) was used to determine sBCMA levels (R&D Systems, Minneapolis,
MN). Kaplan-Meier survival analysis and log-rank comparison tests were used
to determine the association between sBCMA levels and time to first treatment
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(TTFT), overall survival (OS) and progression-free survival (PFS). Similarly,
sBCMA levels were correlated with bone marrow (BM) and PET scan findings
for non-secretory disease (NSD) MM pts. Proportional Hazard Regression
Analysis and a multivariate analysis were utilized to determine the predictive
ability of sBCMA on OS and other prognostic factors including: age, serum
creatinine, serum hemoglobin, and ISS staging. One-way univariate analysis
of variance was performed to study the relationship of sBCMA with bone dis-
ease status, based on presence of osteopenia, osteolytic lesions and fractures
as well as the clinical status. All of the statistical analysis was performed using
JMP Pro for Windows by SAS and P values<0.05 are reported as statistically
significant.
Results: Compared to healthy donors (n=43), pts with untreated active MM
(n=44) showed increased levels of sBCMA (P<0.0001). sBCMA levels corre-
lated with changes in BM plasma cell involvement (Pearson r=0.609; p<0.0001)
and current clinical status (n=164, P-values: 0.0045 CR vs PR;<0.0001 CR vs
NR) for MM pts. Those with other untreated B-cell malignancies showed
increased levels (CLL: n=94, WM: n=29, both P<0.0001). sBCMA correlated
with changes in M-protein levels for MM and WM pts and changes in clinical
status among both MM and CLL pts. Furthermore, sBCMA also correlated with
PET scan and BM findings among MM pts with NSD. Kaplan-Meier analysis
demonstrated that sBCMA levels predict PFS (P=0.0004) and OS (P=0.0043)
among pts with MM (n=242). sBCMA levels correlated with depth of response
(P-values: 0.05 CR vs PR, 0.03 CR vs SD, and 0.004 CR vs PD). Among CLL
pts (n=171), sBCMA levels predicted TTFT (P<0.0001) and OS (P=0.02), and
correlated with WBC count, serum ß2-microglobulin level, IgVH mutational sta-
tus, ZAP-70 scores, and chromosome 13 deletion. Additionally, sBCMA did not
correlate with renal function or presence of the bone disease or other prognostic
factors and maintained independent significance when tested in cohorts of MM
(n=188, Pairwise R=0.18) or CLL (n=155, Pairwise R=0.001) pts. Compared
to healthy donors (n=104), pts with an ID showed lower levels of sBCMA (CVID:
n=46; XLA: n=8; both P<0.0001). Among pts with CVID, sBCMA correlated
with complications from the disease (P=0.01).
Summary/Conclusions: We have identified sBCMA as a novel independent
diagnostic and prognostic biomarker that can monitor and predict outcomes for
pts with MM, CLL and WM which show elevated levels whereas those with ID
including CVID and XLA show decreased levels. Levels of this marker among
pts with B-cell malignancies also correlate with clinical status, predict TTFT,
PFS and OS, and provide MM pts with NSD a way to follow their disease course.
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IMPACT OF IMMUNOPARESIS AND ALTERED SERUM FREE LIGHT CHAIN
RATIO ON THE PROGRESSION OF MONOCLONAL GAMMOPATHY OF
UNDETERMINED SIGNIFICANCE (MGUS) IN A DISTRICT GENERAL
HOSPITAL IN UNITED KINGDOM
B Badugama*
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Background: Monoclonal gammopathy of undetermined significance (MGUS)
occurs in 3% of people >50 y and up to 10% in those >70 years.The risk of
progression is heterogenous.The numbers are expanding and the existing risk
stratification models needs to be dynamically improved to ensure the clinical
monitoring to be more cost effective.The impact of altered serum free light
chain ratio (ASFLCR) and immunoparesis (IP) as tools on MGUS progression
been analyzed in the current study, in addition to the already known prognostic
factors: type of M protein and the amount of monoclonal component. 
Aims: In general, we aimed to identify the impact of immunoparesis and
skewed SFLCR as prognostic factors for progression of MGUS to multiple
myeloma in a district general hospital in UK.The specific objectives were to
determine the socio-demographic characteristics of study population;to identify
proportion of de novo myeloma at presentation and MGUS progressing to
myeloma; to determine the impact of immunoparesis at presentation on pro-
gression of MGUS;to identify any association between abnormal SFLCR and
progression of MGUS.;to find any association between the type of light chains
with the risk of progression.
Methods: A Retrospective cohort. All patients with MGUS and Myeloma from
2000 to 2013 included in the study population. Baseline immunoglobulin, para-
protein and light chain levels are the main parameters. Data sources are med-
ical records of hematology out patients’ clinic department & electronic hema-
tology data base. All patients with monoclonal proteins referred to Department
of Hematology recruited. Other disorders contributing to immunodeficiency:
hypogammaglobulinaemia, lymph proliferative disorders, autoimmune disor-
ders, stage 4 CKD, nephrotic syndrome, and generalized hypoproteinaemic
conditions, Patients on disease modifying drugs and immunosuppressive med-
ications systemic steroids, chemoimmunotherapy within previous 1 year of
diagnosis, Patients having paraproteins together with polyclonal increase in
immunoglobulines on presentation were excluded from the study.
Results: Here, we have assessed the incidence of immunoparesis (IP) and
abnormal serum free light chain ratio (ASFLCR) in a cohort of 653 patients
with MGUS.They were 323 (49.2%) males and 333 (50.8%) females, with their
ages ranging from 34 to 94y, having the median age of 71y. The median time
from the diagnosis to the time of observation was 35 months. The paraproteins:
IgG in 57.8%, IgM in 23.3% and IgA in 17.3%. About 1.2% of were light chain
(LC) MGUS.Approximately, 10% of the myelomas were LC secreting. Kappa
LC identified in 60% and Lambda in 37.6%.SFLCA was not available for the
hospital before 2005. Even later, subjected to selection bias, as it is not an in
house facility.Out of, 437 patients who had the assay 255 were having ASFLCR.
Immunoparesis is seen in 254 (38.7%) and 402 (61.3%) have normal
immunoglobulin levels. There is a significantly positive correlation with the inci-
dence densities of myeloma in the group with >/=2 immunoparesis. The relative
risk is 4.662 (95% CI 1.847-11.772) and the (p 0.001). We have identified pos-
itive correlation of relative risk of MGUS progression to Myeloma in the pres-
ence of abnormal SFLCR.(Rate ratio 2.531).
Summary/Conclusions: It is apparent that immunoparesis and altered SFLC
ratio play a pivotal role in accelerating the MGUS progression to myeloma.
Our current study shows that there a statistically significant evidences that
immunoparesis and serum free light chain ratio correlates positively with MGUS
progression.
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Background: Survival rates have improved for patients with multiple myeloma
(MM), yet relapse remains common. Data on real-world outcomes in these
patients in Europe is limited.
Aims: To provide insights into the survival of patients with symptomatic MM in
the Netherlands through a retrospective analysis of data from the PHAROS
registry, a Dutch population-based database. 
Methods: The PHAROS registry included patients with MM diagnosed between
2004 and 2012 (aged ≥18 years). The study population consisted of 1522
patients starting first-, second- or third-line therapy in 2008 or later (not all
patients in the analysis on second- and third-line therapy were included in the
analysis of previous lines). The primary endpoint was overall survival (OS);
secondary endpoints included progression-free survival (PFS) and healthcare
resource utilisation (HRU).
Figure 1. Kaplan-Meier curves of OS from first-, second-, third- and fourth-
line therapy.
Results: Median patient age was 70, 71, 71 and 72 at the initiation of first-,
second-, third- and fourth-line therapies, respectively. Median follow-up for the
primary endpoint (OS from first-line therapy) was 62.4 months (95% confidence
interval [CI]: 60.6, 64.3). First-line thalidomide-based regimens were prescribed
to 66% of patients (n=608) and bortezomib-based regimens to 15% (n=139).
In the second-line setting (n=583), the majority of patients received bortezomib-
(41%, n=239) or lenalidomide- (27%, n=159) based regimens. Median OS
(95% confidence interval [CI]) in first- (n=917), second- (n=583) and third-line
(n=283) were 37.5 (34.8-41.8), 19.7 (17.2-22.9) and 13.9 (10.5-16.6) months,
respectively. Median PFS (95% CI) were 18.0 (16.3-18.9), 8.9 (7.9-9.7) and
6.4 (5.5-7.2) months, respectively. Large differences were seen between sub-
groups in all treatment-lines, e.g. median OS from first-line therapy was 31.9
(29.1-35.4) and 64.6 (53.2-not reached) months for patients >65 years old and
patients ≤65 years old, respectively, and was 32.2 (29.2-35.5) for patients with-
out prior stem cell transplantation (SCT) (median OS not reached for patients
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with prior SCT). Similarly, median PFS from first-line therapy was 16.2 (14.5-
17.9) and 22.6 (19.8-26.5) months for patients >65 years old and patients ≤65
years old, respectively and 15.2 (13.6-17.0) and 32.0 (26.2-36.5) months for
patients without or with prior SCT, respectively. Mean (standard deviation [SD])
number of inpatient days per month (excluding intensive care unit) were 1.7
(3.4), 1.4 (3.2) and 2.3 (4.6) in first, second and third-line, respectively.
Summary/Conclusions: In patients receiving first-line therapy for MM between
2008 and 2012 in The Netherlands, median OS was approximately three years.
A difference in OS was observed for SCT versus non-SCT patients and
resource use (inpatient stays) increased with later lines. Large differences in
OS were also observed depending on a patient’s age.
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COMPARISON BETWEEN 8-COLOR MULTIPARAMETER FLOW CYTOMETRY
AND NEXT-GENERATION SEQUENCING TO DETECT MINIMAL RESIDUAL
DISEASE IN MULTIPLE MYELOMA PATIENTS WHO UNDERWENT AUTO-SCT
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Background: Autologous stem cell transplantation (ASCT) in conjunction with
novel therapeutic drugs can dramatically improve response rates and the prog-
nosis of patients with multiple myeloma (MM). However, most patients with MM
are considered to be incurable, and relapse owing to minimal residual disease
(MRD) is the main cause of death among these patients. Therefore, new tech-
nologies to assess deeper responses are required. Next-generation sequencing
(NGS) and multiparameter flow cytometry (MFC) methods have been used to
assess MRD. However, the lack of standardization of conventional MFC
approaches has had a negative impact on its reproducibility. Recently, a next-
generation MFC method (EuroFlow) has been developed by the EuroFlow Con-
sortium and the International Myeloma Foundation (IMF) for a highly sensitive
and standardized detection of MRD in MM.
Aims: To compare the prognostic value of MRD detection in autografts in MM
between NGS and EuroFlow.
Methods: A total of 22 newly diagnosed MM patients who underwent ASCT
were included in this study. Median age 60 (range 41-65); males 14, females
8; ISS 1 (n=4), 2 (n=12), 3 (n=6). 6 patients showed high-risk chromosomal
abnormalities (t(4;14) (n=6), del17p (n=1)). The induction regimen was borte-
zomib-based chemotherapy. All patients received melphalan 200 mg/sqm con-
ditioning regimen before ASCT. 18 of 22 (82%) patients received maintenance
therapy using lenalidomide or thalidomide. The best response post-ASCT was
as follows: 10sCR, 1CR, 9VGPR, 2PR. 22 autografts, one from each MM
patient, were analyzed using EuroFlow and NGS methods. The EuroFlow
method was based on a standardized lyse-wash-and-stain sample preparation
protocol, the measurement of high numbers of cells (≥5x106 cells/tube) and an
optimized 8-color, 2-tubes, antibody panel, for accurate identification of plasma
cells (PCs) and discrimination between phenotypically aberrant (aPC) and nor-
mal PC (nPC): tube 1: CD138BV421 /CD27BV510 /CD38FITC /CD56PE /CD45Per-
CP-Cy5.5 /CD19PE-Cy7 /CD117APC /CD81 APC-C750 ; and tube 2: CD138BV421
/CD27BV510 /CD38FITC /CD56PE /CD45PerCP-Cy5.5 /CD19PE-Cy7 /cytoplasmic
(Cy) Immunoglobulin (Ig) κAPC /CyIgλAPC-C750. NGS-based MRD assessment
was performed using the immunosequencing platform (Adaptive Biotechnolo-
gies, South San Francisco, CA) (Martinez-Lopez et al Blood 2014).
Figure 1.
Results: We identified abnormal plasma cells (aPC) in autografts based on
multivariate analysis of individual cells from each patient (e.g. CD56+, CD19-,
CyIgκ+, CD117+). For the MM MRD in autografts, the events from tube 1 and
tube 2 were combined and a median of 5.6×106 (range: 1.3×106-11.7×106)
events was acquired. 12 of 22 (55%) cases were MRD positive by 8-color MFC
while 18 of 22 (82%) cases were MRD positive by NGS. The correlation of
MRD level between 8-color MFC and NGS was relatively high (Fig. A). There
was no significant difference in PFS between MRD negative cases by EuroFlow
(MRDMFC (-)) and MRDMFC (+) cases (Fig. B) (P=0.508). However, MRD neg-
ative cases by NGS (MRDNGS (-)) tended to show better PFS than MRDNGS
(+) (P=0.114) (Fig. C). There was no significant difference in overall survival
between the MRD positive and negative groups.
Summary/Conclusions: In this comparison study of MRD assessment in auto-
grafts using Euroflow and NGS approaches, the NGS platform showed higher
sensitivity and prognostic value than EuroFlow.
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RENAL AND HEMATOLOGIC OUTCOMES OF BORTEZOMIB-BASED
TREATMENT IN PATIENTS WITH LIGHT CHAIN DEPOSITION DISEASE
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Background: Light chain deposition disease (LCDD) is characterized by amor-
phous deposits of monotypic immunoglobulin light chains in the kidneys leading
inevitably to end-stage renal disease (ESRD) if untreated. LCDD is one of the
recently defined monoglonal gammopathies of renal significance (MGRS) and
less often is associated with an underlying symptomatic myeloma. However,
no optimal treatment or response criteria for the evaluation of treatment out-
comes have been established although bortezomib-based regimens have been
recommended based on small patient series.
Aims: to evaluate the outcomes of LCDD after bortezomib-based treatment,
the prognostic effect of clinicopathological characteristics and the impact of
hematologic response to renal survival.
Methods: 18 consecutive patients with renal biopsy-proven LCDD who
received primary therapy with bortezomib were included in the analysis. 
Results: by IF all biopsies had linear staining exclusively for κ or λ chains along
the TBM and/or GBM; other findings included interstitial fibrosis (78%), mesan-
gial expansion/proliferation (72%), tubular atrophy (67%) and nodular mesangial
sclerosis (56%). Median age was 65.5 (range: 46-85) years and 10(55%)
patients were >65 years; 89% presented with hypertension, median 24h pro-
teinuria was 3.3 gr (range 0.4-10.2), 13/18 patients had eGFR<60 ml/min and
9/18 (50%) had eGFR<30ml/min. Fourteen patients (78%) had measurable
FLCs (dFLC≥50mg/l and abnormal ratio). Median bone marrow infiltration was
15% but no patient had symptomatic MM by the CRAB criteria. Bortezomib
with dexamethasone (VD) was given in 12/18(67%) and VD plus cyclophos-
phamide (VCD) in 6/18 (33%) patients for a median of 4 cycles; 10/18(56%)
received bortezomib SC. Among evaluable patients 11/14(79%) had a hema-
tologic response (PR, VGPR or CR), including 5(36%) with CR, 1(7%) with
VGPR and 5(36%) with PR. At the time of diagnosis or during follow-up, 6/18
(33%) patients progressed to ESRD. Three of the 9 patients improved their
eGFR from<15 to 15-29ml/min and 3 patients from 15-29 to 30-59ml/min while
9/18 patients achieved a 50% reduction of proteinuria. Improvement in eGFR
was observed only in patients (6 /14) who achieved a hematologic CR or VGPR,
and no patient who achieved a VGPR or CR developed ESRD. In contrast, 5/8
patients who achieved a PR or less progressed to ESRD (P=0.031). Improve-
ment of proteinuria was observed in all patients who achieved a CR and in 2/9
patients who achieved a hematologic PR. In univariate analysis baseline
eGFR<30ml/min was associated with increased risk for ESRD (OR=8.75,
p=0.086); no pathology feature was associated with renal response or risk of
ESRD. Median follow-up is 39 months and 13/18 patients remain alive; only 3
(17%) had a hematologic relapse/progression. Two patients died on dialysis
and median survival from initiation of dialysis was 5 (range:1-13) months. Three
patients received ASCT as consolidation after bortezomib induction. Borte-
zomib-related peripheral neuropathy occurred in 67% (grade 2 in 7 and grade
3 in 2 patients); in 9/18 patients a dose reduction of bortezomib was required
but no patient discontinued bortezomib due to neuropathy. Neuropathy grade
≥2 occurred in 7/8(87.5%) vs 2/10(20%) patients who received IV vs SC borte-
zomib (P=0.041).
Summary/Conclusions: bortezomib-based treatment is active and safe for
patients with LCDD but at least a hematologic VGPR is required in order to
improve renal prognosis. Prospective studies are needed to determine the opti-
mal management for LCDD and identify further predictors for renal prognosis.
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Background: The survival duration of patients with multiple myeloma is
inversely proportional to their age (Pulte et al, Oncologist, 2011). Pomalidomide
(POM), a distinct immunomodulatory agent with tumoricidal and immunoregu-
latory effects, plus low-dose dexamethasone (LoDEX) is approved in the United
States and European Union for the treatment of patients with relapsed and
refractory multiple myeloma (RRMM) who have had ≥2 prior therapies, includ-
ing lenalidomide and a proteasome inhibitor (bortezomib in the European
Union). Approval was based on 2 phase 3 studies (Richardson, Blood, 2014;
San Miguel, Lancet Oncol, 2013), and the regimen has been further evaluated
in a large confirmatory study (Dimopoulos ASH 2015).
Aims: To conduct a pooled analysis of the impact of age on outcomes in
patients treated with POM+LoDEX in 3 large trials.
Methods: Patients who provided informed consent, had ≥2 prior therapies,
including lenalidomide and bortezomib, and progressed on or within 60 days
of their last therapy were enrolled in the 3 trials. Patients received POM 4
mg/day on days 1-21 of each 28-day cycle and LoDEX 40 mg (20 mg for those
>75 years of age) weekly until disease progression or unacceptable toxicity.
Thromboprophylaxis was required. Outcomes analysis was conducted based
on patient age subgroup (≤65, >65, ≤75, and >75 years).
Results: In total, 1097 patients were assigned to receive POM+LoDEX in the
3 trials and were included in the intent-to-treat population. Baseline demo-
graphic and disease characteristics were similar regardless of age (Table).
Overall response rate (range, 32%-34%) and median progression-free survival
(range, 4.2-4.6 months) were also similar across the age groups. Median overall
survival was slightly longer in the ≤65 vs >65 subgroups (13.4 vs 11.9 months)
but was similar in the ≤75 and >75 subgroups (12.3 months). The median dura-
tion of response was slightly longer in the >65 and >75 subgroups (7.7 and 9.0
months, respectively) compared with the ≤65 and ≤75 subgroups (7.0 and 7.1
months, respectively). In the 1088 patients who received at least 1 dose of
POM+LoDEX (safety population), the median relative dose intensity was 0.9,
and the median treatment duration was 4.8 months in each age subgroup.
Grade 3/4 treatment-emergent adverse events (TEAEs), including neutropenia
(range, 47%-50%), anemia (range, 29%-32%), thrombocytopenia (range, 17%-
25%), and infections (range, 32%-35%) were similar across the age groups.
Additionally, similar rates of TEAEs leading to dose reduction (range, 23%-
26%) and interruption (range, 64%-69%) were observed in the four subgroups.
POM discontinuation due to TEAEs was infrequent (range, 5%-8%).
Table 1.
Summary/Conclusions: POM+LoDEX demonstrated efficacy in patients with
RRMM, with similar progression-free survival and response rates regardless
of age; safety and efficacy in patients >75 years was comparable to that in
patients<75 years. Similarly, the exposure and safety profile were similar across
the age groups. These results support POM 4 mg as an effective starting dose
and use of POM+LoDEX, regardless of age, in patients with RRMM.
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Background: Multiple myeloma (MM) is a hematologic malignancy, its inci-
dence increasing with age. MM patients (pts) present with heterogeneous
health status, whereby defined tests help to objectively define biological fitness,
rather than considering pts’ chronological age. This is specifically relevant,
since treatment options are numerous today. For the discrimination of current
therapies, a variety of MM- and patient-related risk factors, such as comorbidi-
ties (CM) and frailty can be considered. Therefore, the careful assessment of
individual conditions before treatment and with subsequent, defined follow-up
seems relevant. Therapy-related complications and early mortality may sub-
stantially increase in pts with CM, but may also change during treatment.
Aims: Our aim is to establish a prospective comorbidity and functional geriatric
assesment (CF-GA) for MM pts and to show whether the GA shows substantial
changes from baseline (T0) to follow-up (T1 and subsequently T2) and which
tests are most indicative. This has - to the best of our knowledge - never been
assessed in MM.
Methods: This prospective intervention trial performed a simple, defined GA in
consecutive MM pts prior to initiation of antimyeloma treatment and during sub-
sequent follow-up (6-12 [T1] and 24 months [T2]). The GA included the Karnof-
sky Performance Status (KPS), pain scale, rating of fitness, IADL, ADL, malnu-
trition, geriatric depression scale (GDS), mini-mental status (MMS) and estab-
lished comorbidity (CM) scores: Charlson Comorbidity Index (CCI), Hematopoi-
etic Cell Transplantation-Comorbidity Index (HCT-CI), Myeloma Comorbidity
Index (initial-MCI [I-MCI] and revised-MCI [R-MCI]; http://www.myelomacomor-
bidityindex.org) and Kaplan Feinstein (KF). The trial was approved by the ethics
committees of the Freiburg University. All patients provided written informed
consent and all procedures were conducted in accordance with the Declaration
of Helsinki, the International Conference on Harmonization, and Guidelines for
Good Clinical Practice.
Results: Currently a total of 97 consecutive pts have been included in this GA,
all receiving both T0- and T1-assessment (median 12 months after treatment
initiation). The median pt age was 60.3 years (27-83). Between T0 and T1, 54
pts had received stem cell transplants (n=49: ASCT, n=1: allo-SCT, n=4 auto-
allo-SCT); and the other half of pts novel agent-containing, standard
chemotherapy and/or regular surveillance. Significant changes between T0-
to T1-assessments were observed for various GA tests as summarized in Table
1. Of note, all mean test and score results improved, most notably the I-MCI,
R-MCI-, IMWG- and CCI-scores, whereas the Kaplan Feinstein and HCT-CI
remained almost those of baseline levels. Moreover, the KPS, ADL, IADL, fit-
ness as rated both by physicians and patients as well as MMS improved. Of
interest, the fitness rating by physicians seemed to improve more substantially
than that given by pts, demonstrating again that a brief GA assessment with
simple tests is more objective than clinical judgement alone. Pain, depression
and malnutrition also improved, albeit to lesser and non-significant extends.
Table 1. Ga via CM tests and scores: changes from baseline (T0) to fol-
low-up (T1) (n=97 MM pts).
Summary/Conclusions: Our CF-GA contains simple, reliable tests, which
consistently and objectively test MM pts’ fitness before and after treatment.
Our results impressively demonstrate that MM pts’ general and specific fitness
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- as measured via defined GA tests - may improve during follow-up. This was
induced by the implemented antimyeloma treatment, best supportive care
measures and lower disease-specific symptoms after therapy. We continue
this GA in an even larger prospective multicenter cohort to determine each
test’s predictive power for survival and treatment toxicity.
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Background: Improvement of overall survival in multiple myeloma (MM) after
2000 has been reported and it has been associated with introduction of new
therapeutics (Kumar, Blood 2008,111,2516-20 & Kumar, Leukemia
2014,28,1122-28). The Danish National Multiple Myeloma Registry (DMMR)
was established in 2005 and has registered all patients with newly diagnosed
multiple myeloma in Denmark since 1 January 2005. The Danish Myeloma
Study Group (DMSG) published in 2009 the first National evidence-based
guideline for treatment of MM in Denmark. The guideline recommended borte-
zomib based induction treatment for younger MM patients prior to HDT and for
elderly patients with aggressive disease presentation and adverse cytogenetics.
Moreover, lenalidomide was included in the algorithm for treatment of
relapsed/progressive disease.
Aims: We aimed to analyse population-based overall survival in Danish MM
patients in relation to shift in National treatment guidelines in 2009.
Methods: At 30 June 2015, the database had registered a total of 2907 patients, 991
patients<65 years and 1916 patients >65 years, with newly diagnosed treatment-
demanding MM. Age-adjusted survival analyses were done per 1 September 2015.
Results: Comparing OS for patients diagnosed in the two time periods 2005-
2008 and 2009-2015, we found a highly significant improved age-corrected OS
in patients >65 years, increasing from median 24.7 months (2005-08) to median
32.9 months (2009-15) (p=0.003). For patients<65 years at diagnosis the overall
survival also improved from median 67 months (2005-2008) to above 74 months
(median OS not yet reached) (2009-2015) (p=0.02). In patients >80 years at
diagnosis the survival is poor and has not improved significantly between the 2
time periods (median 11.4 vs 14.9 months), and the early mortality rate in these
very elderly is high (about 30% die within 6 months). The prognosis has partic-
ularly improved for MM patients that present with renal insufficiency. The data-
base documents a shift in chosen therapies according to the National guidelines.
Only, novel agents seem to have been less chosen for the most elderly patients.
Summary/Conclusions: Our “real life data” documents improved survival of
MM patients in Denmark after 2008 and demonstrates a significant impact of
National DMSG guidelines on treatment of multiple myeloma.
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Background: The recent International Myeloma Working Group (IMWG) con-
sensus statement recommends whole-body magnetic resonance imaging (MRI)
for patients with suspected smoldering multiple myeloma (SMM) and solitary
plasmacytoma (Dimopoulos et al. 2015). Whole-body diffusion-weighted MRI
(WB-DWI) is a promising technique with higher sensitivity for bone lesions and
lower cost. However, little is known about its sensitivity compared to 18F-fluo-
rodeoxyglucose positron emission tomography (FDG PET-CT).
Aims: The aim of this study is to compare the sensitivity of myeloma-related
bone disease by WB-DWI and FDG PET-CT, and to compare the apparent dif-
fusion coefficients (ADC) of myelomatous lesions with normal healthy controls.
Methods: We identified patients with monoclonal plasma cell disorders that
underwent WB-DWI between July 2015 and February 2016 at Kameda Medical
Center, Kamogawa-shi, Japan. We compared disease burden by matched simul-
taneous assessments of WB-DWI and FDG PET-CT using a previously described
scoring system based on the number and pattern (focal/diffuse) of disease in
each body region (C-spine, T-spine, L-spine, pelvis, ribs/other, long bones).
Whole-body score was calculated as the sum of each body lesion (Sharon et al.
2014). Scans performed in patients in different clinical status were excluded. We
also analyzed ADC values of WB-DWI in comparison to eight healthy volunteers.
Minimal ADC values were measured in each body region (C-spine, T-spine, L-
spine, pelvis, ribs/other) and whole-body ADC value was defined as the mean
ADC value of each body region. Inversion grayscale maximum intensity projection
images of whole-body diffusion-weighted and ACD maps with b value=900s/mm2
were assessed in this study. All statistical analyses were performed with EZR,
which is a graphical user interface for R ver. 3.2.1.
Results: We identified 64 patients that underwent WB-DWI during the study
period. Fifty patients underwent FDG PET-CT in the same disease status. Medi-
an age of the patients was 71 years (range: 53-89) and 23 (44.8%) were male.
Three patients had monoclonal gammopathy of undetermined significance
(MGUS), five patients had SMM, and 42 patients had symptomatic MM, including
five with plasmacytoma. Diffuse lesions were found in 15 (30%) patients by WB-
DWI, while FDG PET-CT detected two (4%) diffuse lesions. The detection ratio
of focal lesions was the same for both procedures. The whole-body score was
significantly higher in WB-DWI than FDG PET-CT (WB-DWI: mean 5.61±8.56
vs FDG PET-CT: mean 1.08, P<0.001). In each body region, scores for WB-
DWI were significantly higher than those for FDG PET-CT. ADC values were
analyzed in 64 patients that underwent diffusion-weighted WB-MRI and com-
pared with eight healthy volunteers. Median age and number of male patients
was 71 years (range 47-89) and 25 (39.6%), respectively. Four patients were
diagnosed as MGUS, eight patients had SMM, and 51 patients had MM, includ-
ing five with plasmacytoma. The median ADC value of the whole body was sig-
nificantly lower in patients with monoclonal plasma cell disorders than in the
healthy volunteers (680mm2/s x10-6 vs 765.5 mm2/s x10-6, P=0.02). In each
body region except C-spine and ribs/other, the ADC value was significantly lower
in patients with monoclonal plasma cell disorders than in the healthy volunteers.
Table 1.
Summary/Conclusions: In patients with monoclonal plasma cell disorders,
WB-DWI is more sensitive than FDG PET-CT for detection of bone lesions.
Assessment of ADC value is an effective method for detecting bone lesions of
monoclonal plasma cell disorders.
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Background: Estimation of plasma cell (PC) infiltrates in bone marrow (BM)
is integral to the diagnosis and monitoring of patients with multiple myeloma
(MM). Traditionally, quantification of BM PCs has been performed by differential
counting of May-Giemsa-stained aspirate smears. Although previous studies
consistently showed a higher % of PCs in BM biopsy sections compared to BM
aspirate smears, BM biopsy with CD138 immunostaining has not been widely
adopted in clinical practice.
Aims: This study was performed to clarify the importance of CD138 immnos-
tainig for quantification of BM PC by comparing the different methods [BM aspi-
rate clot, BM aspirate smear, and multicolor flow cytometry (FCM)] in patients
with MM and monoclonal gammmopathy of undetermined significance (MGUS).
In addition, to clarify the clinical relevance of quantifying BM PCs by CD138
immunostaining, 116 patients with monoclonal gammopathy who did not fulfill
the criteria of smoldering MM (sMM) based on aspirate smears were reexamined
for its diagnosis by BM clots stained with anti-CD138 monoclonal antibody.
Methods: A total of 150 samples of BM biopsy and smears from 100 patients
with MGUS and MM, at diagnosis or following therapy were selected. Percent-
ages of PC of aspirated marrow was quantified by May–Giemsa staining, mul-
ticolor flowcytometry (MFC), and CD138 immunostianing of BM clot section
and biopsy section. PC identification by FCM required at least two markers,
i.e., CD38 and either CD45 or CD138. The percentages of PC were calculated
relative to the total nucleated cell population. We also investigated the clinical
relevance of CD138 immunostaining in the differentiation of MGUS and MM.
BM slide sets from 116 untreated patients with M-protein level <3000mg/dL in
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serum or 500mg/day in urine and without organ damage were re-assessed
with based on the % of BM PCs by CD138 immunostaining.
Results: Median % of PC measured by BM biopsy, BM clot, BM smear, and
FCM were 13.3%, 12.8%, 3.7%, and 2.4%, respectively. There were significant
correlations between BM biopsy and the three other measurement methods,
and BM clot showed the strongest correlation with BM biopsy (r=0.94). In cor-
relation analysis, BM biopsy and BM clot showed significant and very strong
correlations in both NCC ≥40×103/μL and NCC<40×103/μL (r=0.95 and r=0.91,
respectively). Bland-Altman plots showed that BM biopsy agreed well with BM
clot but not with BM smear or FCM. There was a significant fixed bias between
BM biopsy vs BM smear and BM FCM with mean difference of 15.0% and
16.4%, respectively, indicating that both of these measurements significantly
underestimated PCs compared to BM biopsy. However, no significant fixed bias
between BM biopsy and BM clot was observed (mean difference: 1.1%). Pro-
portional bias by regressing the differences in values on means of values with
linear regression analysis showed significant proportional bias between BM
biopsy and BM smear and FCM, but not between BM biopsy and BM clot. As
CD138 immunostaining consistently yielded a higher percentage of BM PCs
than aspirate smear, it is possible that a considerable portion of patients diag-
nosed as MGUS by aspirate smear alone could be reclassified as sMM by
CD138 immunostaining of BM clot or biopsy. We retrospectively reanalyzed the
116 consecutive patients with monoclonal gammopathy and <3000 mg/dL or
500 mg/dL M-protein in serum or urine at our hospital. Among the 116 patients
that met the above criteria, 13 patients (11%) were classified as sMM as PCs
exceeded 10% on aspirate smears. Among the remaining 103 patients, 59
patients (51%) showed >10% PCs by CD138 immunostaining and was reclas-
sified as sMM and the remaining 44 patients (38%) were still classified as MGUS.
Figure 1.
Summary/Conclusions: Our data showed that considerable portion of sMM
patients could be misclassified as MGUS by bone marrow smear alone and
highlight the necessity of CD138 immunostaining of BM biopsy/clot specimens
for correct diagnosis.
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Background: Outcomes for multiple myeloma (MM) have improved with the
introduction of novel therapies, and ongoing trials suggest positive outlooks
for those with relapsed/refractory MM (rrMM). However, head-to-head clinical
trials across treatment options are limited, and as such the evidence on relative
effectiveness to inform best practice is lacking. A recent systematic review1
attempted to address this via a mixed treatment comparison using data from
randomised control trials (RCTs) published before 2015. A network meta-analy-
sis (NMA) was developed to estimate relative treatment effectiveness in this
review, and two evidence networks were compiled, but no comparisons could
be drawn across networks.
Aims: This systematic review is an update to a previously published study and
aims to estimate the relative effectiveness of treatments for rrMM using the
most up to date information available. 
Methods: The literature search for the previous analysis was conducted in
August and repeated again in December 2014. The search was then repeated
January 2016 to identify further RCTs which might have been published in the
interim. Data was extracted from all RCTs that reported median duration of
progression-free survival (PFS), overall survival (OS) or time to progression
(TTP) as a primary or secondary treatment outcome. A Bayesian NMA using
non-informative prior distributions and assuming fixed effects was fitted due to
scarcity of data in the networks. The number of prior treatment lines among
patients recruited into trials in rrMM varied (1-5) and trials conducted in heavily
pre-treated and refractory patient populations (a median of 3 or more prior
lines of therapy) were excluded from the presented analysis in an attempt to
reduce some heterogeneity.
Results: 14 RCTs were included in the initial analysis1. These 14 trials
assessed 16 different treatment regimens. From the updated review, 5 new
RCTs which presented PFS or TTP data for 5 additional treatment regimens
were identified to be included into the existing NMA. The combined trials form
two separate evidence networks; all pairwise comparisons in each network
were estimated in the analysis (figure 1). No relative effects between the two
networks could be estimated. In the larger evidence network, novel agents
combined with len+dex had superior outcomes with carf+len+dex being the
most effective treatment, followed by ixa+len+dex, and then elo+len+dex. In
the other, smaller evidence network, bort+dex+pan was the most effective
treatment, followed by bort+dex+cyc.
Table 1.
Summary/Conclusions: The availability of treatments for rrMM is rapidly
increasing. Within a year of conducting an initial systematic review the PFS and
TTP outcomes of five additional RCTs of treatments for rrMM were released.
Results of the larger network suggest that novel agents combined with len+dex
have superior outcomes compared to other treatment options in the network.
Less inferences can be drawn from the smaller network; of the newly included
RCTs bort+dex+cyc ranked second in the network, whilst new treatment regi-
mens elo+bor+dex and carf+dex ranked lower, and demonstrated no significant
superiority relative to all other treatments in the network. The networks are not
connected and as such it is impossible to make comparisons between the two
regarding overall effectiveness of treatments. More RCTs comparing existing
treatment regimens would greatly supplement these comparisons and allow for
greater certainty. Nonetheless, the presented analysis is a significant step in
evidence-based assessment for treatment in rrMM which indicates that novel
agents combined with len+dex substantially improve treatment outcomes.
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Background: Extended duration of therapy (DOT) is associated with better
clinical outcomes in clinical trials in patients (pts) with multiple myeloma (MM)
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(Palumbo 2015; Mateos 2015). Many of the factors that influence DOT are
more prevalent outside of clinical trials, including older age, and concomitant
comorbidities. Real-world data related to DOT among RRMM pts are limited.
Aims: This study aims to 1) describe DOT of second line (2LT) and third line
(3LT) therapy in RRMM, and 2) evaluate the associations between 2LT DOT
and age; comorbidities; and regimen type.
Methods: In this retrospective cohort study, newly diagnosed adult MM pts initiating
first-line therapy (1LT) between 1/2008 and 12/2014 were followed in a large U.S.
national electronic medical records (EMR) database to identify 2LT accordingly: 1)
retreatment after a treatment gap of >3 months of 1LT, or 2) a switch to another
drug combination after starting 1LT. 3LT began with a switch to another regimen
after 2LT. Pts with salvage stem cell transplants were excluded. Kaplan-Meier analy-
ses were performed to calculate DOT from start of both 2LT and 3LT. Observations
were censored at time of loss to follow up/end of study period (6/30/2015). A two-
tailed log-rank test was used to test for statistical significance between groups.
Results: Among 628 pts, 37.1% were ≥75 years of age; 51.0% were male;
66.4% had ≥1 of the following comorbidities of interest at initiation of 2LT: dia-
betes, renal insufficiency, thromboembolic disease, cardiovascular disease,
peripheral neuropathy. In 2LT, pts were most commonly treated with lenalidomide
(L)-based regimens (36.2%) without bortezomib (B), followed by B-based ther-
apies (33.0%, with/without L). Carfilzomib (C)-based treatments were least com-
mon (8.3%, with/without L). The remaining regimens (Other) comprised of MM-
therapies without L, B, or C (22.6%). Overall, the median DOT in 2LT and 3LT
was 6.9 months (mos) (95% CI: 5.9, 7.7) and 5.5 mos (95% CI: 4.0, 6.2), respec-
tively. DOT in 2LT was similar for those <75 vs ≥75 years, median: 6.3 mos
(95% CI: 5.2, 7.6) and 7.4 mos (95% CI: 5.9, 9.2), P>0.05, respectively (Table).
Pts with baseline comorbidities of interest were significantly more likely to have
a shorter DOT in 2LT, median: 6.2 mos (95% CI: 5.0, 7.4) compared to pts with-
out, median: 9.2 mos (95% CI: 7.0, 11.9), P=0.02. In 2LT, the drug composition
of the regimen was significantly associated with DOT (P<0.0001). L-based ther-
apies had the longest DOT (median: 10.1 mos; 95% CI: 7.9, 11.9) compared to
B-based (median: 6.6 mos; 95% CI: 5.1, 8.0), C-based (median: 4.6 mos; 95%
CI: 3.0, 7.5) and Other regimens (median: 4.8 mos; 95% CI: 3.9, 6.2) (Figure).
Table 1. DOT of 2LT by age and comorbidity.
Figure 1. Treatment duration by regimen type in 2LT.
Summary/Conclusions: DOT wanes with subsequent lines of therapy. Base-
line comorbidities and regimen type in 2LT are significantly associated with
DOT. The longest median DOT was observed with L-based therapies and the
shortest DOT with C-based therapies. Tailored therapy choices that account
for pts’ baseline comorbidities may mitigate the observed variation in DOT.
References
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THE SERUM HEAVY/LIGHT CHAIN IMMUNOASSAY SERVES AS AN
ADDITIONAL VALUABLE TOOL FOR SENSITIVE PARAPROTEIN ASSESSMENT,
RISK STRATIFICATION AND DISEASE MONITORING IN PATIENTS WITH
MONOCLONAL GAMMOPATHY
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Background: A novel polyclonal immunoassay specific for the different light
chain types of intact immunoglobulins (Ig) enables measurement of changes
in the production of clone specific Ig and of the non-involved polyclonal Ig of
the same isotype. This serum heavy/light chain immunoassay (HLC) was devel-
oped to recognize and separately quantify light chain types of each intact Ig
class. Prior studies have demonstrated that immunofixation (IFE) and HLC-
assay are complementary methods, and that HLC-values and -ratios serve as
additional parameters for evaluation of response and early relapse recognition
in patients with monoclonal gammopathies.
Aims: We aimed to a) investigate the HLC-assay compared to standard Multiple
Myeloma (MM)-diagnostics in consecutive MM, smoldering MM (SMM) and Mon-
oclonal gammopathy of undetermined significance (MGUS) patients, b) assess
HLC results in MM vs MGUS and SMM patients, c) define a possible HLC cut-
off for high-risk SMM patients and d) decipher the role of the HLC-assay for
response, stage groups, progression free (PFS) and overall survival (OS) in MM.
Methods: We investigated the HLC [Hevylite™]-assay and compared its results
to standard diagnostics, such as the capillary zone electrophoresis (CZE) and
serum free light chain (SFLC)-assay: SFLC and HLC (IgGκ/IgGλ, IgAκ/IgAλ,
IgMκ/IgMλ) measurements were performed using polyclonal antisera FreeliteTM
and Hevylite™ assays. Standard diagnostics for MGUS, MM and Walden-
ström’s Macroglobulinemia (WM) patients also included IFE and bone marrow
aspiration/biopsies as well as stage (Durie and Salmon and International Stag-
ing System [ISS]) and EBMT response assessment.
Results: We assessed 146 consecutive patients with abnormal M-spike via
CZE: 57 had IgGκ-MM, 24 IgGλ-MM, 8 IgAκ-MM, 7 IgAλ-MM, 5 SMM, 5 light-
chain-only MM, 28 MGUS and 12 had IgM WM. HLC-values and -ratios signif-
icantly correlated with the respective Ig values, isotype-matched SFLCs, M-
gradient, ISS and remission status. Of note, with measurement of HLCs, up to
33% more pathological serum values were detected than via SFLC-assay
alone. Moreover, due to pathological HLC-values, 57% of patients with MGUS
were reclassified as SMM or MM, suggesting that the assay may assist in
recognition of true MGUS, SMM vs symptomatic MM patients. Furthermore,
patients with WM-M-spikes - the latter often difficult to quantify - revealed a
clearly abnormal median IgMκ/λ ratio of 231 (normal range: 1.0-2.4). PFS in
patients with extreme (<0.5/>50) HLC-values vs those without (0.5-50) was
significantly impaired.
Summary/Conclusions: The HLC-assay is of particular value to monitor slow
or indolent disease progression. Moreover, in WM, it can be a helpful additional
technique to quantify the amount of monoclonal Ig clone and to more reliably
decipher MGUS from SMM/MM patients.
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ASSESSMENT OF FRAILTY IN A MULTIPLE MYELOMA (MM) SERIES
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Background: An increasing number of articles overflow literature concerning
the importance of frailty assessment in elderly MM patients in treatment decisions
making. Nevertheless, little is known about frailty assessment influence/impor-
tance in younger MM patients.
Aims: To assess frailty and investigate its impact in MM patients of any age.
Methods: We studied 409 MM patients, diagnosed and followed –up in our
department. Median age was 69 years (31-90) while 55% were males. Twen-
ty-eight percent, 25% and 47% were Durie-Salmon staged 1, 2 and 3 respec-
tively, while 32%, 26% and 42% were ISS staged I, II and III respectively. Twen-
ty-seven percent were asymptomatic (Smoldering MM). MM type was IgG in
66%, IgA in 22% and light-chain in 11% of the population, while 4 patients (1%)
were biclonal. Frailty score was estimated following the Geriatric Assessment
formula that involves Renal score, Katz andAkpom’s basic activities of daily
living (BADL) scale, Lawton and Brody’s instrumental scale (IADL), and the
Charlson Comorbidity Index (CCI). Statistical analysis was performed conven-
tionally with SPSS v22.0 software. 
Results: Of the 409 patients 24% were fit (frailty score 0), 39% were unfit
(frailty score 1) and the rest were frail (14%, 19%, 3% ans 1% with frailty scores
2, 3,4,5 respectively). Frailty score was correlated to OS in the whole cohort
(p<0,0001), being more significant in the symptomatic (p<0, 0001) than in the
asymptomatic group (p=0,01). In the symptomatic patients, all the parameters
examined were significantly correlated to OS [IADL (p<0,0001), BADL
(p<0,0001), Renal score (p<0,0001), Performance status (PS) (p<0,0001), ISS
(p=0,01), abnormal Ca (p=0,006) and abnormal LDH (p=0,007)]. In the Multiple
regression analysis, only ISS (p=0,009), PS (p<0,0001) and level of fitness
(p=0,018) preserved their prognostic value. However, in the patient group >70
years, parameters proven statistically important were GFR (p<0,0001) and CCI
(p=0,04), while, in the age group >75 years, only CCI was correlated to OS
(p=0,002). Finally frailty parameters proved to be more powerful in younger
patients (<65 years), for whom GFR (p<0,0001), CCI (p=0,001), IADL (p=0,009)
and level of fitness (p=0,002) were correlated to OS.
Summary/Conclusions: Intriguingly, frailty score better predicted OS in young
MM patients than in elderly ones.
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DEXAMETHASONE AFTER LENALIDOMIDE FAILURE: INTERIM RESULTS
OF THE POSEIDON STUDY
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Background: The management of patients with primary refractory or relapsed
and refractory multiple myeloma (RRMM) who failed lenalidomide and borte-
zomib treatment poses a clinical challenge. Prognosis for these patients is poor.
The pivotal MM-003 trial demonstrated a benefit of the oral regimen pomalido-
mide (POM) in combination with low dose dexamethasone (LoDEX) for RRMM
patients who had failed lenalidomide and bortezomib treatment. With a median
follow-up of 10 months, POM+LoDEX showed an overall response rate (ORR;
≥partial response [PR]) of 31% vs 10% (p<0.001), a significantly longer pro-
gression-free survival (PFS) and a significant improvement in overall survival
(OS) compared to high-dose DEX. Efficacy of POM+LoDEX was consistent
across various age groups and tolerability was unaffected by age.
Aims: POSEIDON is a non-interventional, prospective, multicenter study
designed to further evaluate effectiveness (ORR, PFS, OS) and safety of
POM+LoDEX in routine clinical practice. It is carried out in 55 private practices
and outpatient clinics in Germany.
Methods: Transplant-ineligible patients with RRMM who have received at least
two prior lines of therapy including both lenalidomide and bortezomib, and who
have demonstrated disease progression or were refractory to their last line of
treatment could be enrolled. Patients received POM+LoDEX according to
SmPC and were treated until disease progression or the development of unac-
ceptable toxicity. At enrollment, patients were prospectively assigned to two
subgroups with regard to lenalidomide in the preceding treatment line (sub-
group A) or no lenalidomide in the preceding treatment line (subgroup B). The
interim analysis was based on the modified intention-to-treat population includ-
ing all patients who received at least one dose of POM.
Results: At data cut-off for this interim analysis (December 1st, 2015), 138
patients have been enrolled; 126 patients were evaluable with a median fol-
low-up of 6.9 months. 66 and 60 patients were assigned to subgroup A and
subgroup B, respectively. Median age was 74 years (range 46-87) with 49%
and 43% of patients >75 years of age in subgroups A and B, respectively. 59%
were male. The median time from diagnosis was 4.8 years (range 0.4-18.2).
Median number of prior treatment lines was n=3 (range 2-9), with n=2 in sub-
group A (range 2-9), and n=4 in subgroup B, respectively (range 2-9). For the
99 patients (55 patients in subgroup A, 44 patients in subgroup B) who received
POM+LoDEX and had at least one response evaluation documented at data
cut-off, the ORR was 26% in subgroup A and 52% in subgroup B, respectively.
Additionally, 13% (subgroup A) and 9% (subgroup B) of these patients achieved
a minor response. The most common ≥grade 3 adverse events were leukope-
nia (10%) and anemia (7%), respiratory tract infections (10%) and vascular
disorders (3%).
Summary/Conclusions: The results of this interim analysis confirm the ben-
eficial effectiveness and safety of POM+LoDEX in heavily pretreated RRMM
patients in a real-life setting. Even lenalidomide and bortezomib refractory
patients with lenalidomide in the preceding treatment line and heavily pretreated
patients >75 years of age do benefit from POM+LoDEX treatment. The interim
data of the non-interventional POSEIDON study are encouraging and highlight
the potential clinical value of POM+LoDEX in these poor prognosis patients.
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(RRMM): CHINA CONTINUATION OF TOURMALINE-MM1
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Background: The global, randomized, double-blind, placebo-controlled, phase
3 TOURMALINE-MM1 study (NCT01564537) demonstrated 35% improvement
in PFS (HR 0.74, p=0.012) with IRd vs placebo-Rd in pts with RRMM (Moreau
et al, ASH 2015). 
Aims: This continuation study assessed the efficacy and safety of IRd vs place-
bo-Rd in pts with RRMM in China as a separate regional expansion of the
global study.
Methods: Eligibility criteria and study design were per the global study, except
high-risk cytogenetic and patient-reported outcome endpoints were not assessed.
The primary endpoint was PFS, assessed by the same independent review com-
mittee (IRC) used in the global study. Pts were analyzed separately from the
global study. Sample size was not based on a formal statistical hypothesis.
Results: 115 pts were randomized and treated (57 IRd, 58 placebo-Rd). Com-
pared to the global study, pts had more advanced disease (63% ISS stage II/III
vs 46% in the global study), were more heavily pretreated (60% vs 41% had 2
or 3 prior therapies), had more frequently received prior thalidomide (84% vs
45%), and more frequently had refractory MM (43% vs 11%). At data cut-off
(12 July 2015; median follow-up 8.0 vs 7.8 mos for IRd vs placebo-Rd), PFS
was significantly improved with IRd vs placebo-Rd: median PFS 6.7 vs 4.0
mos; HR 0.598; 95% CI 0.367–0.972; p=0.035. This benefit was seen across
most prespecified subgroups including those with ISS stage I/II at screening,
pts who had received 2–3 prior therapies, or prior proteasome inhibitor/IMiD
compound therapy. A prespecified sensitivity analysis of PFS according to the
EMA censoring rules was consistent with the primary analysis: median PFS
5.8 mos vs 4.0 mos; HR 0.543; 95% CI, 0.340–0.869; p=0.009. TTP was also
significantly improved with IRd vs placebo-Rd: median TTP 7.3 vs 4.1 mos;
HR=0.583; p=0.032. OS data were not yet mature; 6 (11%) IRd and 16 (28%)
placebo-Rd pts have died. The study remains blinded and is ongoing with a
final analysis for mature OS data planned. Overall response rate was 56% vs
31% (odds ratio=2.84, p=0.007); the ≥VGPR rate was 25% vs 12%. Among
responders, the median duration of response was 7.4 mos with IRd vs 5.6 mos
with placebo-Rd. Pts had received a median of 7 and 5 cycles of IRd and place-
bo-Rd, and 59% and 41% of pts remained on treatment. The median relative
dose intensities of all drugs were high (>95%), similar between arms, and con-
sistent with the global study. The overall safety profile was similar in both treat-
ment groups: 56% vs 62% had grade ≥3 AEs, 23% vs 26% had SAEs, 5% vs
12% discontinued treatment due to AEs, and 4% vs 5% died on treatment.
Common grade ≥3 AEs with IRd vs placebo-Rd included thrombocytopenia
(23% vs 13%), neutropenia (23% vs 19%), anemia (12% vs 26%), and pneu-
monia (16% vs 10%). Rash was seen in 18% vs 19% of pts (no grade ≥3
events); 7% of pts in each group had peripheral neuropathy (no grade ≥3
events). There was no evidence of cardiac or renal toxicity with the addition of
ixazomib, and no new primary malignancies. Based on an observed higher
incidence of herpes zoster reactivation in the IRd treatment group (18%) vs
placebo-Rd (0%), the IDMC recommended an antiviral prophylaxis requirement
for the entire study population still on treatment; the China continuation protocol
was amended accordingly.
Summary/Conclusions: In Chinese pts with RRMM, IRd was associated with
a significant improvement in PFS, with limited additional toxicity, demonstrating
the consistent relative benefit of IRd vs placebo-Rd in this distinct Chinese
population and the global study.
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PROSPECTIVE EVALUATION OF PROGNOSTIC AND PATHOPHYSIOLOGIC
IMPLICATIONS OF BLOOD PRESSURE MONITORING AND BARORECEPTOR
REFLEX SENSITIVITY (BRS) IN PATIENTS WITH AL AMYLOIDOSIS
E Kastritis1,*, M Roussou1, M Gavriatopoulou1, D Fotiou1, D Ziogas1,
M Gavriatopoulou1, K Stamatelopoulos1, C Pamboucas1, E Papadopoulou1,
F Michas1, A Lykka1, E Terpos1, S Giannouli2, MA Dimopoulos1, E Manios1
1Department of Clinical Therapeutics, 2National and Kapodistrian University
of Athens School of Medicine, Athens, Greece
Background: cardiac dysfunction is the major determinant of prognosis in
patients with AL amyloidosis. Elevated levels of cardiac biomarkers (troponin
and of NTproBNP) identify patients at high risk (stage 3 per Mayo stage) but
low blood pressure (BP) is independently associated with poor prognosis espe-
cially in patients with Mayo stage-3 disease (Wechalekar et al Blood 2013).
Cardiac output and autonomic nervous system (ANS) are major regulators of
BP and both are affected in AL amyloidosis. 
Aims: to prospectively evaluate the prognostic role of BP by using standard
and 24 hour BP measurements and evaluate the importance of the deregulation
of ANS in AL amyloidosis by assessing Baroreceptor reflex sensitivity (BRS).
Methods: Newly diagnosed patients, with biopsy confirmed AL amyloidosis,
were prospectively evaluated. All patients underwent standard office BP office
BP measurements (three BP measurements taken at a 1-min intervals, at sitting
position, averaged to obtain a single systolic and diastolic office BP value),
24h ambulatory BP monitoring and a simultaneously electrocardiographic and
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non-invasive BP monitoring (Finometer), under standardized conditions for 15
min. Ambulatory BP monitoring was performed on a usual working day. BP
recordings were obtained automatically at 15-min intervals throughout the 24h
period. BRS was expressed as the alpha-index (a-index), which was estimated
by means of power spectral analysis. 
Results: we evaluated 68 consecutive patients (median age 65, range 40-84
years, 50% males). Heart was involved in 65%, kidneys in 70% and nervous
system in 23%, while 10% were Mayo stage-1, 60% stage-2 and 30% stage-3
and 14% had NTproBNP≥8500 ng/L. Median eGFR was 63 ml/min/1.73 m2.
Primary treatment was bortezomib-based (VD, VCD or BMDex) in 80% and
MDex in 20%. Median office systolic BP (SBP) was 118 mmHg and median
diastolic BP (DBP) was 72 mmHg. SBP was lower in stage 2 vs stage 1 and
stage 3 vs either stage 2 or stage 1 patients (p=0.026) but there was no differ-
ence in the DBP between groups. The median of mean 24h ambulatory SBP
was 112.5 mmHg and for DBP was 69.5 mmHg. Advanced Mayo stage was
associated with lower mean 24h SBP (p=0.048). None of the patients with
Mayo stage 1, 13% of those with stage-2 and 33% of those with stage-3 had
office SBP<100 mmHg. For 24h mean SBP, none with stage 1, 23% with stage
2 and 42% with stage 3 had mean ambulatory SBP<100 mmHg. Lower levels
of SBP were associated with inferior survival: either office SBP<100 mmHg (6
months vs not reached) (p<0.001) or mean 24h SBP<90 mmHg (2 months vs
not reached) (p<0.001) were associated with poor survival and early death.
Further analysis of 24h ambulatory BP recordings indicated higher BP fluctua-
tions among patients with less severe or no heart involvement, while more
often patients with Mayo stage 3 had higher nighttime vs daytime SBP values
than stage 2 or stage 1 patients. Median a-index was 2.85 (range 0.4-5.85) but
it was lower in patients with advanced cardiac involvement and was also lower
in patients who had nerve involvement (median 1.6 vs 3.3, p=0.016), reflecting
both cardiac and nerve involvement by AL amyloidosis. In addition, low a-index
was associated with early death. 
Summary/Conclusions: Low BP, either measured in a sitting position as in
standard office visits or by means of 24h ambulatory measurement, is associ-
ated with poor prognosis in patients with AL amyloidosis. Impaired BRS is asso-
ciated with advanced cardiac and nerve involvement and risk of early death.
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PREVALENCE AND PROGNOSTIC IMPACT OF OLIGOCLONAL BANDS IN
PATIENTS WITH AL AMYLOIDOSIS
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Background: The emergence of oligoclonal bands (OB) in patients with mul-
tiple myeloma (MM) achieving a complete response (CR) is a well-recognized
event after autologous stem-cell transplantation (ASCT) and the use of novel
agents. The presence of OB is considered a benign phenomenon, associated
with favorable outcome due to a deeper humoral immune reconstitution. How-
ever, the frequency of clinical impact and outcomes of the emergence OB in
patients with AL amyloidosis have never been described.
Aims: The objective of this study is to determine the prevalence, natural history
and prognostic impact of OB in patients with AL amyloidosis who achieved at
least a partial response (PR) either after upfront ASCT or after conventional
treatment in patients ineligible for transplant at Hospital Clínic of Barcelona.
Methods: We reviewed the clinical records of patients with AL amyloidosis
from January 1996 to September 2015. Fifty-six patients (27F/29M; median
age at diagnosis 59 years; range 39 to 82) with PR or better after different
induction regimens and/or ASCT were found. Initial baseline demographics,
clinical and laboratory data, treatment and follow-up were collected. Median
follow-up was 3.6 years. An OB was defined by the presence of a serum and/or
urine immunofixation monoclonal spike different either in heavy and/or light
chain component from the original amyloid protein. 
Results: Fifty-three percent (30) of the patients were transplant ineligible while
46.4% (26) that had received an ASCT. The distribution of the immunoglobulin
isotypes at diagnosis was as follows: light chains only (53.6%), IgG (35.7%),
IgA (5.4%), IgM (3.6%), and one patient biclonal (1.8%). The light chain type
was lambda in 43 patients (76.8%). Response achieved was: CR in 50% of
patients, very good partial response (VGPR) 48.2% and PR in one patient.
Three-year survival rate was 84%. We observed OB in 59% of the patients.
The median number of bands per patient was 2 (range 1 to 5). The most fre-
quents isotypes were IgG-kappa (31%) and IgG-lambda (22%). The oligoclonal
phenomenon was more prevalent in patients in CR compared to the other
degrees of response (82.1% vs. 35.7%; p=0.0001). There were no statistical
differences between the emergence of OB and type of treatment received (50%
chemotherapy alone vs. 69.2% ASCT; p=0.145) or isotype of involved light
chains (46.2% for kappa vs. 62.8% for lambda; p=0.29). However, the presence
of OB was more frequent in the group of patients who received induction
chemotherapy (mainly bortezomib-based; 75%) before ASCT as compared to
those who received upfront ASCT (91.7% vs. 50%; p=0.02). Duration of oligo-
clonality for more than one year was more prevalent in patients who underwent
ASCT than in those ineligible for transplant (42.3% vs. 16.7%; p=0.034).
Regarding its prognostic value, the presence of oligoclonality lasting for more
than one year resulted in a significantly longer overall survival (OS) as com-
pared to patients without OB or with only a transient phenomena (p=0.012),
(Figure 1).
Figure 1. Overall survival according to the presence of oligoclonality last-
ing for more than one year compared with those without oligoclonal
bands (OB) or with only a transient phenomena.
Summary/Conclusions: This is the first report describing the prevalence of
OB in patients with AL amyloidosis after first-line therapy, which is even higher
than that observed in patients with MM. The oligoclonal humoral phenomenon
was more prevalent in patients who achieved CR as well as in those who
received induction therapy prior to ASCT. Patients with oligoclonal humoral
response lasting for more than one year had a significantly longer OS than
those with shorter duration, likely reflecting a more robust humoral immune
response.
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INDUCTION IN MULTIPLE MYELOMA
CC Chua1,*, HY Lim1, KL Chai2, J Ong3, S Sim3, M Dickinson3, P Campbell4,
J Hempton4, H King5, C Dowsing5, K Bergin6, S Muir7, S Gibbs7, A Grigg1
1Clinical Haematology, Austin Health, 2Clinical Haematology, St Vincent’s
Health Australia, Melbourne, 3Clinical Haematology, Peter MacCallum Cancer
Centre, East Melbourne, 4Clinical Haematology, Barwon Health - University
Hospital Geelong, Geelong, 5Clinical Haematology, Royal Melbourne Hospital,
6Clinical Haematology, Alfred Health, 7Clinical Haematology, Eastern Health,
Melbourne, Australia
Background: Bortezomib, cyclophosphamide and dexamethasone (VCD)
combination is often used as induction therapy in transplant eligible patients
with multiple myeloma (MM). However, the optimal PBSC mobilization strategy
in this context is not established. 
Aims: To review the efficacy of G-CSF alone (G-alone) versus G-CSF and
cyclophosphamide (G-cyclo) PBSC mobilization strategies in MM patients who
had only received VCD induction prior to autograft.
Methods: Retrospective review of PBSC mobilization strategies in patients
from six apheresis centres from November 2012 to March 2015 after receiving
VCD induction. Extended data were collected from a single centre to January
2016. Prior radiotherapy was not an exclusion criterion. Successful mobilization
was defined as achieving physician-determined target PBSC yield, which in
some older patients was ≥2x106/kg but in most patients was ≥4x106/kg to allow
for two autografts (≥90% of both groups). Plerixafor was used in some centres
as a rescue strategy if PB CD34 ≤10x106/L on the day of planned collection or
PBSC yield was <1x106/kg after first apheresis. Univariate analysis was per-
formed using chi-squared test for categorical data and Mann-Whitney-U test
for continuous variables.
Results: Table 1 summarizes the results of 192 patients. Baseline character-
istics and cumulative exposure to bortezomib and cyclophosphamide were sim-
ilar in both groups. G-alone strategy consisted of G-CSF at 10μg/kg/day (n=120)
or 20μg/kg /day (n=16), administered for a median of 5 days. G-cyclo comprised
of intravenous cyclophosphamide (1g/m2 (n=1), 1.5g/m2 (n=14), 2g/m2 (n=25),
3g/m2 (n=4), 4g/m2 (n=12)) with either G-CSF 5-10μg/kg/day for a median of
4 days (n=35) or single-dose 6mg pegfilgrastim (n=21). Overall, the rates of
successful mobilization and the proportion of patients achieving a total PBSC
yield of ≥4x106/kg were comparable between G-alone and G-cyclo with no sig-
nificant difference in the median number of aphereses to reach this target. How-
ever the G-cyclo group had a significantly higher median PBSC yield per
apheresis and a higher proportion of patients attaining a PBSC yield of
≥4x106/kg with ≤2 apheresis without rescue plerixafor. Ten (18%) G-cyclo
patients had unplanned hospitalization, of which 8 had febrile neutropenia. In
the G-alone group, age ≤60 and G-CSF doses of 20μg/d were significantly
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associated with a higher median PBSC yield. In the G-cyclo group, higher
cyclophosphamide doses for mobilization (3-4g/m2 vs 1-2g/m2) resulted in a
significantly higher PBSC yield. Cumulative bortezomib doses, pre-mobilization
platelet count and prior radiotherapy did not significantly impact on PBSC yield
in either group.
Table 1. PBSC mobilization outcomes with G-alone vs G-cyclo.
Summary/Conclusions: Despite a significantly higher PBSC yield with G-
cyclo mobilization, the G-alone strategy is a reasonable first approach to mobi-
lizing stem cells in the majority of patients receiving VCD induction.
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ROLE OF PET/CT IN PROGNOSTICATING POST-TRANSPLANT OUTCOMES
BASED ON A NEW SCORING SYSTEM: RESULTS OF PIPET-M TRIAL
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V subhash1, P Malhotra1
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Background: Multiple myeloma (MM) is a heterogeneous disorder with varied
responses to transplantation. 18F-FDG-PET/CT has a role in prognosticating
post-transplant outcomes, but the PET positivity has been reported in non-
homogenous fashion leading to difficulty in interpretation and inter-trial com-
parisons. We defined a new staging system for PET/CT reporting in MM and
validated it for predicting post-transplant outcomes, first in the world literature.
Aims: Aim: To assess the role of 18 FDG-PET/CT scan in prognostication of
MM autologous stem cell transplantation (ASCT) candidates.
Objectives: To correlate pre-transplant FDG-PET/CT avidity with (a) Post
transplant outcomes (b) Biochemical Markers (c) MRD as assessed by the
flow cytometry (FCM).
Methods: It is a prospective systematic protocol based single centre observa-
tional study. As part of CTRI registered PIPET-M Trial, all autologous transplant
MM patients underwent 18F-FDG-PET/CT during pre-transplant workup. The
conditioning and treatment protocols were not modified based on PET/CT find-
ings. PET positivity was defined as per a newly defined PIPET-M staging in
lines with modified Deauville’s staging based on target lesion SUVmax (Fig
1A). This staging was further classified into two models for defining PET pos-
itivity based on background physiological FDG uptake as an internal control
(In model 1 - mediastinal SUVmax and in model 2 - Liver SUVmax was taken
as physiological SUVmax) (Fig 1B, C). Progression was defined using revised
IMWG criteria. Using SPSS ver.16.0, OS/PFS was assessed by Kaplan-Meier/
Cox-regression survival analysis.
Results: A total of 43 patients underwent pre-transplant PET/CT evaluation.
The staging was validated in this cohort. Further using model-1, PET negative
patients had better PFS (88.2 vs 69.2%, p-0.65) and better OS (94.1 vs 65.4%,
p-0.01). The hazard of all-cause mortality was 22.445 times higher for PET
positive individuals (p-0.02). Using model-2, only statistically significant result
was delayed neutrophil engraftment in PET-positive patients (11.69 vs 10.5d,
p-0.02). There was good agreement between two models, but model-1 had
significantly higher sensitivity and slightly lower specificity as compared to mod-
el-2 for predicting survival. Inter-observer variability was 0.02 for PIPET staging.
Also, there was good agreement between the PIPET model -1 and MRD by
FCM with Cohen’s Kappa - 0.599,(p<0.0005). Levels of β2M and LDH were
higher in the patients with PET positivity defined based on PIPET model 1,
(Abnormal β2M-χ2 (1, 42)-0.842, p-0.017, Abnormal LDH - χ2 (1, 42)-0.762,
p-0.037). There was no correlation of PET positivity with pre-transplant
SPEP/UPEP/SIFE/SFLCA total of 43 patients underwent pre-transplant
PET/CT evaluation. The staging was validated in this cohort. Further using
model-1, PET negative patients had better PFS (88.2 vs 69.2%, p-0.65) and
better OS (94.1 vs 65.4%, p-0.01). The hazard of all-cause mortality was 22.445
times higher for PET positive individuals (p-0.02). Using model-2, only statis-
tically significant result was delayed neutrophil engraftment in PET-positive
patients (11.69 vs 10.5d, p-0.02). There was good agreement between two
models, but model-1 had significantly higher sensitivity and slightly lower speci-
ficity as compared to model-2 for predicting survival. Inter-observer variability
was 0.02 for PIPET staging. Also, there was good agreement between the
PIPET model -1 and MRD by FCM with Cohen’s Kappa - 0.599, (p<0.0005).
Levels of β2M and LDH were higher in the patients with PET positivity defined
based on PIPET model 1, (p-0.017 and 0.037 respectively). There was no cor-
relation of PET positivity with pre-transplant SPEP/UPEP/SIFE/SFLC.
Table 1.
Summary/Conclusions: Utilizing PET stages based on this newly proposed
staging model is clinically relevant to predict post-transplant OS.
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THE EFFECT OF LEVEL OF RESPONSE TO TREATMENT ON ASSOCIATED
COSTS AND HEALTHCARE RESOURCE UTILIZATION: A RETROSPECTIVE
CHART REVIEW STUDY IN PATIENTS WITH SYMPTOMATIC MULTIPLE
MYELOMA
H Leleu1,*, K Yong2, S Gonzalez-McQuire3, A Flinois4, P Schoen3, M Campioni3,
F Saverio Mennini5, L DeCosta6, L Fink4, C Gazzola4
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Background: An increase in incidence rates, treatment lines and use of novel
agents, with improved efficacy, has impacted costs associated with treating
multiple myeloma (MM). Real-world data are needed to accurately assess
resource use and costs.
Aims: To evaluate how response to treatment affects associated costs and
healthcare resource utilization (HRU) in the UK, Italy and France.
Methods: Physicians (n=189) retrospectively completed case report forms for
patients (pts) with symptomatic MM who, in the 3 months before study start,
had experienced disease progression after receiving specific treatment regi-
mens (those most commonly prescribed) or received best supportive care
(BSC) and died. Pt characteristics, treatment outcomes, costs and HRU were
documented from beginning of last completed treatment line onwards. Pts had
received: 2nd-line bortezomib (bor) or lenalidomide (len); 3rd-line bor, len,
pomalidomide (pom) or bendamustine (ben); 4th-line bor, len, pom or ben; any
regimen at 5th line or above; or BSC only. Costs of medication and resources
were estimated based on standardized schedules and national databases.
Results: Data were collected for 1156 pts on active treatment and 126 pts
receiving BSC. In all countries, mean monthly costs were lower in pts achieving
deeper responses. In the UK, mean monthly costs from start of treatment line
until progression were significantly lower (p≤0.05) for pts achieving a very good
partial response or complete response (≥VGPR) than for pts achieving a partial
response (PR) and for pts with stable or progressive disease (SD+PD) (Table
1). These costs were also numerically lower in Italy. In France, costs for pts
with ≥VGPR were lower than for pts with PR and significantly lower (p≤0.05)
than for pts with SD+PD (Table 1). Medications accounted for 92% of mean
monthly costs in the UK, 88% in Italy and 83% in France. In all countries, when
excluding cost of medication on a monthly basis, achievement of ≥VGPR was
still associated with lower costs. In terms of healthcare resource use, the pro-
portion of pts hospitalized increased with lesser response to treatment: in the
UK, 11%, 16% and 28% of pts with ≥VGPR, PR and SD+PD, respectively,
were hospitalized, and similar trends were observed in Italy (13%, 26% and
28%) and France (16%, 24% and 27%). In terms of overall costs for each coun-
try, the achievement of ≥VGPR was associated with higher mean total costs
than the achievement of ≤PR. Total costs were significantly higher for ≥VGPR
compared with costs for all pts combined (UK €71 414 vs €57 717; Italy €51
359 vs €34 496; France €45 831 vs €37 009; all p≤0.05). When medication
cost was excluded, there was still a trend for pts with ≥VGPR to incur higher
costs. These findings are linked to duration of treatment (DoT) and length of
treatment-free interval (TFI). Mean DoT for pts with ≥VGPR was 10 months in
the UK and 12 months in Italy and France. In all countries this was significantly
longer than for pts with PR and twice as long as that for pts with SD+PD. Sim-
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ilarly, in all countries, TFI until progression for pts with ≥VGPR was significantly
longer than for pts with other response levels.
Table 1.
Summary/Conclusions: Most of the cost of managing pts with relapsed MM
is medication-related. Although overall costs are higher due to longer treatment
duration, mean monthly costs for pts achieving a deeper response to treatment
were lower compared with those pts who had a lesser response. These findings
may be explained by hospitalization rates, as pts who exhibited deeper and
better responses to treatment were hospitalized less frequently than those with
a lesser response.
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SEVERE DECREASE OF BONE MATERIAL STRENGTH IN MONOCLONAL
GAMMOPATHY OF UNDETERMINED SIGNIFICANCE PATIENTS DETECTED
BY OSTEOPROBE® MICROINDENTATION METHOD
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Background: Monoclonal gammopathy of undetermined significance (MGUS)
affects over 3% of adults over 50 years old. Previous studies show that MGUS
patients experience a significant bone fracture risk increase and that MGUS
prevalence is higher in osteoporotic patients (1). The microindentation for in
vivo measurement of bone tissue method (2,3) has shown to detect decrease
in Bone Material Strength (BMS) even at early stages. These findings correlate
with bone fragility and risk of fracture independently of bone mineral density
(BMD) (4) measured by bone densitometry (DXA). 
Aims: To analyze the BMS by Osteoprobe® microindentation method and the
BMD by densitometry in MGUS patients and compare with an age control
matched group.
Methods: We have included 22 patients diagnosed with MGUS. An informed
consent was obtained and a general laboratory workup was undertaken. BMD
measurement at the lumbar spine and hip using DXA (Hologic QDR 4500 SR™,
Hologic, Bedford, MA) was performed. BMS determination by inserting a probe
assembly through the skin covering the anterior midtibia and applying 20 inden-
tations with an Osteoprobe® (Active Life Scientific Sta Barbara CA) device (3)
was done. The results were compared with controls adjusted by sex and age.
Results: MGUS patients present low values of BMS (68.3±5) compared with
control group values (83±4, p<0.001). No significant difference was observed
in BMD between controls and patients (0.977 vs 0.929 p :0,288 at lumbar spine;
0.783 vs 0.730 p: 0,179 at femoral neck; 0.902 vs 0.898 p: 0,157at total femur).
Summary/Conclusions: These results suggest that microindentation method
directly measures bone mechanical properties at the tissue level and can detect
significant decrease of BMS in MGUS patients, which correlates with a greater
risk of fracture. This could be useful to identify MGUS patients that would benefit
from early antiresorptive treatment despite a normal DXA.
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Background: The introduction of novel agents into the treatment paradigm of
MM has improved outcomes; however, MM remains incurable with patients
requiring subsequent lines of therapy post-relapse. Patients with relapsed MM
who are refractory to bortezomib and refractory to or ineligible for lenalidomide
have a median overall and event-free survival of 9 and 5 months, respectively
(Kumar 2012). There is a scarcity of data regarding real-world treatment pat-
terns and clinical outcomes in previous lenalidomide-exposed patients with
relapsed / refractory MM (RRMM).
Aims: This study aims to describe the patient characteristics and treatment
patterns among MM patients treated in the real-world who relapsed or were
refractory to lenalidomide in first-line treatment (1LT) within the U.S.
Methods: This was a retrospective cohort study using a large national EMR
database. Newly diagnosed MM patients initiating a lenalidomide-based 1LT
between 1/2008 and 12/2014 were followed 1 year prior to and up to 7 years
after diagnosis. Maintenance therapy, if given, was included within 1LT. Patients
were required to be ≥18 years of age with evidence of starting second-line ther-
apy (2LT), which was identified accordingly: 1) retreatment after a treatment
gap of >3 months of 1LT, or 2) a switch to another drug combination after
starting 1LT. All patients were followed until death/loss to follow up or the end
of study period (6/30/2015). Based on the International Myeloma Workshop
Consensus Panel 1 and using initiation of 2LT as a surrogate marker for non-
response or progressive disease, lenalidomide-refractory patients, for the pur-
pose of this study, were defined as those who initiated 2LT within 60 days of
1LT discontinuation (Rajkumar 2011). Relapsed patients were those with a >60
day gap between end of 1LT and 2LT initiation.
Results: There were 279 RRMM patients who received lenalidomide in 1LT
(n=89 (31.9%) refractory; n=190 (68.1%) relapsed); overall, mean age was
69.9 years (standard deviation (SD): 9.9) and 49.5% were male. More patients
in the refractory population had known high cytogenetic risk disease (presence
of any: del[17p], t[4:14], t[14:16]) than in the relapsed population (16.9% vs
3.2%), and refractory patients were more likely to have renal impairment (52.8%
vs 37.9%), anemia (65.2% vs 45.3%), hypercalcemia (15.7% vs 3.7%) and
bone disease (30.3% vs 23.7%) at initiation of 2LT than relapsed patients.
Refractory patients were more likely than relapsed patients to receive only PI-
based therapy (57.3% vs 19.5%) and less likely to receive only immunomodu-
latory drug (immunomod)-based therapy (16.9% vs 62.6%) in 2LT (P<0.001
for both; chi-square test). In addition, use of ≥3 drug-therapy in 2LT was higher
in the refractory population than in the relapsed population (40.5% vs 8.4%)
(P<0.001; chi-square test).
Table 1. 2LT by Lenalidomide refractory vs relapsed status.
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Summary/Conclusions: RRMM patients refractory to lenalidomide in 1LT pre-
sented with a higher disease-related symptom burden at start of 2LT, were
treated more aggressively in 2LT, and were more likely to switch to PI-based
therapy than those defined as relapsed. One limitation to this real-world study
is that patients may have stopped 1LT due to factors other than nonresponse
or progressive disease.
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MULTIPLE MYELOMA ON IMMUNOMODULATORY THERAPY BY THE
CALIBRATED AUTOMATED THROMBOGRAM
V Shmeleva1,*, S Voloshin2, S Karpich1, L Papayan1, O Smirnova1
1Laboratory of blood coagulation, 2Haematology department, Russian
Research Institute of Haematology And Transfusion, St-Petersburg, Russian
Federation
Background: Patients with multiple myeloma (MM) have an increased risk of
venous thromboembolism (VTE), particularly when immunomodulatory therapy
is used. It is of great importance to choose proper thrombosis prophylaxis in
these patients. Resistance to activated protein C (APCR) is proposed to be one
of the pathogenic mechanism underlying thrombotic complications in MM
patients. The Calibrated Automated Thrombography (CAT) determines the
action of both procoagulant and anticoagulant factors and is now considered to
reflect patient’s phenotype better than traditional coagulation tests. When throm-
bomodulin (TM) is used CAT becomes sensitive to all disorders of the protein
C (PC) system. Clinical utility of CAT in MM patients needs further elucidation.
Aims: Aim of our study was to evaluate the prevalence of APCR and determine
prothrombotic phenotype in MM patients by an integrated approach with CAT
made in parallel with and without TM. 
Methods: The study involved 63 patients (M/F 23/40, mean age 62,0±14,0 yr)
with MM and 30 age and sex matched controls. Patients and controls gave
informed consent. We divided patients in 3 groups: 30 patients with IgA asso-
ciated MM, 20 patients with IgG associated MM and 13 patients with MM asso-
ciated with IgG on lenalidomide treatment with prophylaxis of VTE by aspirin.
CAT was done according to Hemker et al. at 5 pM TF and 4 μM phospholipids
in platelet poor plasma (PPP) with PPP plasma+/-TM reagent. The procedure
was carried out on an automated fluorometer (Fluoroscan Ascent, Thermolab
system, Finland). Thrombin generation curves were calculated using the
Thrombinoscope software (Thrombinoscope BV, The Netherlands). Lupus anti-
coagulants (LA), activities of FVIII, protein C and S and antithrombin were also
measured. STATISTICA 6.1 was used. 
Results: Importantly endogenous thrombin potential (ETP) and peak thrombin
(PT) in MM patients on lenalidomide were within the normal range. Increased
ETP were defined as values above 95th percentile measured in controls (i.e.
>2114 nMmin in the absence of TM and >1433 nMmin in the presence of TM).
Normal ranges of ETP and PT inhibition calculated in controls were 22-62% and
15-51% respectively, means values of ETP and PT inhibition were 45% and 33%
respectively. Abnormalities of inhibition were more pronounced in IgA associated
MM compared to IgG group without lenalidomide (41% vs 64% for ETP and 25%
vs 53% for PT). The most significant changes in the protein C system activities
were found in IgG group on lenalidomide (mean inhibition of ETP 36% and 24%
of PT). Values below 22% for ETP inhibition and/or 15% for PT inhibition (i.e.
APRC) were found in 3 (23%) of patients on lenalidomide. Though ETP and PT
inhibition showed significant correlation with PC activity (R=0,51 and R=0,63
respectively), all these patients had protein C and S activities as well as FVIII
activity within the normal range and no one demonstrated LA.
Summary/Conclusions: An integrated approach defining an individual’s phe-
notype could help in identifying patients with higher risk for thrombotic event.
We suggest APCR detected by CAT to be important marker of thrombotic risk
in MM patients. Whether these patients would benefit from more active primary
thromboprophylaxis need further elucidation.
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Background: Immune dysfunction is an important feature of Multiple Myeloma
(MM) and has been associated with reduced survival. Studies have shown that
T-regulatory cells (Tregs) implicated in immune surveillance are expanded in
tumors, including MM. Data regarding alterations of Tregs during therapy with
novel agents (NA) i.e. bortezomib and lenalidomide, are limited.
Aims: Our aim was to explore possible alterations of Tregs and lymphocyte
subpopulations (T4, T8, B, NK, NK-like), as well as changes in the levels of
cytokines related to Tregs function and MM biology (IL-6, IL-2, IL-17, TGF-β)
during treatment with NA and to seek for correlations with disease character-
istics and response parameters.
Methods: We evaluated 29 patients with symptomatic MM at diagnosis or
relapse (M/F: 15/14, median age: 61 years, range: 39-77) and 20 healthy vol-
unteers (HV). Eleven patients received bortezomib-dexamethasone (BD)
(group A) and 18 patients received lenalidomide-dexamethasone (Rd) (group
B). The median number of previous treatment lines was 2(0-3). The detection
of Tregs and lymphocyte subpopulations was performed in peripheral blood
samples using flow cytometry analysis. The cytokines were measured in serum
samples using the enzyme-linked immunosorbent assay ELISA. The statistical
analysis was performed with the appropriate methods; p<0.05 was considered
statistically significant.
Results: In group A, no significant alterations of Tregs%, lymphocyte subpop-
ulations or cytokines were observed during treatment. In group B, there was a
significant reduction of Tregs% (p<0.001) and this was more profound in those
who achieved ≥vgPR (p=0.04). No alterations regarding T subpopulations or
cytokines were observed during treatment with NA in either group of patients.
Patients had significantly higher median Tregs% compared to HV (p<0.001).
There were no significant correlations between disease characteristics and
Tregs in either group of patients. In the cox regression analysis, Tregs% did
not correlate with progression-free survival (PFS).
Summary/Conclusions: Herein, we have demonstrated that Tregs% were sig-
nificantly reduced after treatment with Rd especially in patients with ≥vgPR,
suggesting a possible relation of immune surveillance with quality of response.
However, PFS was not affected in the current study. Bortezomib-based treat-
ment had no impact on Tregs number or function. Patients with myeloma had
higher Tregs% compared to HV, confirming the implication of immune impair-
ment in the biology of this disease. No relation between Tregs and disease char-
acteristics was observed in this study nor between Tregs and relative cytokines,
indicating that immune mechanisms underlying MM remain unexplored.
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Background: Multiple myeloma (MM) is a complex disease with several levels
of heterogeneity. The impact of the clinical presentation of MM is probably
underestimated in daily clinical practice. The relationship between the initial
clinical presentation in MM and the outcome in terms of overall survival (OS)
has been recently highlighted (Greenberg et al, 2014). In this study, patients
were divided into four groups: renal failure, anemia, lytic bone disease and a
mixed group. They showed that patients with isolated RF as myeloma-defining
event (MDE) had the worst OS, whereas patients with bone disease had the
best outcome. However, there are many other well-established MDE that can
be further analyzed in this regard. On the other hand, little is known about the
impact of MDE on early mortality.
Aims: The aim of this study is to assess the impact of the key MDE on the out-
come of MM patients, in terms of early mortality and OS.
Methods: All newly diagnosed MM patients recorded in our population-based
registry for which the MDE is known were analyzed. Patients were divided into
nine groups according with the key MDE: bone pain, pathological fracture, ane-
mia, constitutional syndrome (weight loss, decreased appetite, malaise), infec-
tion, other, tumor, renal failure and mixed group (a combination of pain, renal
failure, anemia and other). Median OS was estimated in months by the Kaplan-
Meier method. Log-rank test was used to compare OS curves. Early mortality
was analyzed at two, six, and twelve months. 
Results: The MDE was available in 398 patients. Bone disease is the most fre-
quent MDE (49% isolated bone pain, 8% pathological fracture), followed by
anemia (9.5%). A constitutional syndrome was present in 7.5%, the same per-
centage as the mixed group. Isolated renal failure was detected in 6.3%, infec-
tion in 5.3%, other in 4.5% and a tumor in 2.3%. Median OS for the whole cohort
was 32.7 months (IC 95%, 25-40.4). There were statistically significant differ-
ences in OS between subgroups (p=0.004). The subgroup with the best OS
was anemia (77.6 months) and the worst was constitutional syndrome (8.9
months). The mixed group and the renal failure group had 20.4 and 21.8 months,
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respectively. In patients with bone disease, OS of those with isolated bone pain
reach 40.4, but falls to 18 months for those with pathological fracture. Early mor-
tality at two months was observed in 53 patients (13.5%), whereas 87 patients
(22.7%), and 116 (31.9%) had mortality at six and twelve months, respectively.
In relation to the group constitutional syndrome, 24.1, 40.7, and 60% died at 2,
6, and 12 months. For those with pathological fracture, the percentages were
12.9, 25.8 and 45.2%, respectively. The mixed group had 13.3, 28.6 and 44.4%.
Patients with renal failure had 21.7, 34.8 and 36.4% mortality, respectively.
Summary/Conclusions: The importance of clinical evaluation at diagnosis in
MM should be emphasized. Patients presenting with isolated anemia as the
MDE have the best survival, whereas those with constitutional syndrome have
the worst prognosis. Patients having constitutional syndrome, pathological frac-
ture, renal failure or those in the mixed group as the key MDE have a poor out-
come in terms of early mortality and OS. The potential association between
the MDE and other prognostic factors should be analyzed in depth.
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REVLIMID, BENDAMUSTINE AND PREDNISOLONE (RBP) IN RELAPSED/
REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE II
CLINICAL TRIAL; OSHO-#077
J Beck1,*, S Heyn1, D Gläser2, A Schwarzer3, LO Mügge4, J Uhlig5, B Kragl6,
M Mohren7, FA Hoffmann8, T Lange9, T Schliwa1, T Zehrfeld10, K Ute11,
C Winkelmann12, T Edelmann13, M Andrea1, M Jentzsch1, S Schwind1, C Becker8,
D Niederwieser1, W Poenisch1
1Hematology, University Hospital Leipzig, Leipzig, 2Hematology, Südstadt Hos-
pital Rostock, Rostock, 3Hematology, Hematology Practice Park-Krankenhaus
Leipzig, Leipzig-Probstheida, 4Hematology, University Hospital Jena, Jena,
5Hematology, Private Practice, Naunhof, 6Hematology, University Hospital Ros-
tock, Rostock, 7Hematology, Hospital Stendal, Stendal, 8Hematology, Private
Practice, Leipzig, 9Hematology, Hospital Weissenfels, Weissenfels, 10Hema-
tology, Hospital Torgau, Torgau, 11Hematology, Heinrich Braun Hospital Zwick-
au, Zwickau, 12Hematology, Hospital Wittenberg, Wittenberg, 13Hematology,
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Background: While the role of lenalidomide monotherapy in the treatment of
relapsed/refractory patients with multiple myeloma (MM) is well established,
combination therapies with lenalidomide are still under investigation in many
phase 2/3 studies.
Aims: In the current study, a combination therapy of lenalinomide (Revlimid®),
bendamustine and prednisolone (RBP) was tested in patients with relapsed or
refractory MM. 
Methods: In the previously completed phase 1 study RPB with a dose of 25
mg lenalidomide d 1-21 and 75 mg/m² bendamustine d 1-2 was well tolerated
in patients with relapsed/refractory MM (Pönisch et al. 2013). The treatment
was repeated every 28 days for a maximum of eight cycles. Thereafter, patients
received a maintenance therapy with 10 mg lenalidomide over 10 cycles.
Results: 25 patients (19 patients of the phase 2 study and additional 6 patients
from the highest dose level of the phase 1 study) were included in this analysis.
Twenty two patients (88%) responded after at least two cycles of RBP with 1
sCR, 5 nCR, 8 VGPR and 8 PR. Due to increased haematological toxicity a
dose reduction was required in subsequent therapy cycles in the most of all
patients. 19 patients discontinued the treatment prematurely due to a stem cell
transplantation (n=7), hematological toxicity (n=7), non hematological toxicity
(n=3) or progress (n=2). The median progression-free and overall survival was
22 and 38 months, respectively.
Summary/Conclusions: RBP is a highly effective therapy for patients with
relapsed or refractory MM. However, dose reduction is necessary in many
patients because an increased haematological toxicity rate.
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BETTER OUTCOME IN AL AMYLOIDOSIS (ALA) TREATED WITH MULTIPLE
MYELOMA-ORIENTED REGIMENS COMPARED WITH CYCLOPHOSPHAMIDE/
BORTEZOMIB/DEXAMETHASONE (CYBORD) IN A SINGLE CENTER
EXPERIENCE
A Belotti*, R Ribolla, C Crippa, V Orlando, M D’Adda, A Re, E Morello, C Cattaneo,
G Rossi
Division of Hematology, Spedali Civili, Brescia, Italy, BRESCIA, Italy
Background: Treatment of AL amyloidosis (ALA) is based on anti-myeloma
therapy but there is no standard. Treatment-related toxicity is deemed to be
higher in pts with ALA compared with patients with multiple myeloma (MM).
Recently, the combination of cyclophosphamide-bortezomib-dexamethasone
(CyBorD) showed high rates of haematologic response, although the outcome
of high risk patients remained poor.
Aims: We compared the outcome of patients treated at our center with CyBorD
with patients receiving more intensive therapy, including MM-type chemother-
apy regimens followed or not by high doses of melphalan (HD-Mel) and autol-
ogous stem cell transplantation (ASCT) or upfront HD-Mel with ASCT.
Methods: Of 50 ALA patients (median age 62 years) referred to our center, 48
of whom newly diagnosed between 2007 and 2015, 25 patients received
CyBorD, and 5 of them (20%) subsequently underwent ASCT. By intention to
treat, 18 patients (control group) received more intensive treatment (upfront
ASCT: 6 (33%); conventional myeloma induction therapy (VAD, VTD, VMP):
12 (67%), followed by ASCT in 5 of them, 42%). Seven patients receiving less
intensive therapy were excluded from analysis. Risk groups were identified as
follows: cTnI >0.1ng/ml and/or ECOG PS ≥3: high risk; age ≤65 years with nor-
mal cTnI levels, ECOG PS<3 and eGFR >50ml/min: low risk. Intermediate risk
patients were defined if not meeting criteria for high or low risk. MM diagnosis
was made according to IMWG criteria. Haematological and organ response,
overall survival (OS) and event free survival (EFS: time to 2nd line therapy or
death) were analyzed.
Results: The proportion of high risk patients was 32% in the CyBorD and 28%
in the control group. Median age was 62 and 61 years in the CyBorD group
and in the control group, respectively. Concomitant MM was present in 52%
CyBorD and in 94% control patients. Treatment results of CyBorD patients
were in line with those recently reported (Palladini et al, Blood 2015). Compared
to the control group, no difference was observed in terms of haematologic
response. Overall response rate (ORR) and complete remission (CR) were
72% and 20% in the CyBorD group and 89% and 39% in the control group,
respectively. However, organ response rate was significantly lower in the
CyBorD group (32% vs 75%, p 0.01). Toxicity was manageable in both groups.
After a median follow up of 33 months no significant difference was seen
between CyBorD and control group in terms of EFS (48% vs 61% at 2 years,
respectively; HR 1.5, 95% CI 0.66-3.41), whereas OS was significantly inferior
in the CyBorD group (47.6% vs 80% at 4 years, p 0.027, HR 3.45, 95% CI
1.15-10.36, see Figure 1). Excluding high risk patients in both groups, OS
resulted similar, although a trend toward better long term survival was seen in
the control group.
Figure 1. Overall Survival according to treatment: CyBorD vs MM-type
chemotherapy (control group).
Summary/Conclusions: despite the high haematologic response rates,
CyBorD regimen seems not to overcome the long term poor prognosis associ-
ated with organ damage in ALA. of high risk patients. Selected patients, even
in the high-risk group may have a survival advantage with MM conventional
treatment, including ASCT whenever possible.
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PROGNOSTIC SIGNIFICANCE OF THE REVISED INTERNATIONAL STAGING
SYSTEM IN MULTIPLE MYELOMA
A Sretenovic1,*, J Bila2, J Jelicic1, M Dencic Fekete1, V Djurasinovic1,
M Smiljanic1, V Vukovic1, D Antic2, B Andjelic2, M Todorovic2, B Mihaljevic2
1Clinical Center of Serbia, 2Clinical Center of Serbia, Medical Faculty of Bel-
grade, Clinic of Hematology, Belgrade, Serbia
Background: New prognostic markers are currently in the focus of investigation
in order to personalize treatment approach in multiple myeloma (MM).
Aims: The aim of this study was to analyze the prognostic significance of the
newest Revised International Staging System (R-ISS) in MM patients ineligible
for autologous stem cell transplantation (ASCT). 
Methods: A total of 92 newly diagnosed MM patients (median age 67 years,
range 35-80 years; 44 male/48 female) were analyzed in the study, with follow-
ing distribution: IgG myeloma had 55 patients (59.8%), IgA 18 (19.6%), light
chains 16 (17.4%), and IgD 2 patients (2.2%). According to the clinical stage
(CS, Durie&Salmon), advanced III CS was found in 68 patients (73.9%), II in
18 (19.6%), and symptomatic I CS in 6 (6.5%) patients. The ISS score 1 had
24 (26.1%) patients, 28 (30.4%) ISS 2, and 40 patients (43.5%) had ISS 3.
Elevated LDH level was present in 18/92 patients (19.6%). High risk chromo-
somal abnormalities (CA, iFISH): t(4; 14), del(17p), or t(14;16) were detected
in 14 patients (15.2%). Renal impairment existed in 16 patients (17.4%). New
R-ISS scoring system based on LDH level, ISS and CA defines three risk cat-
egories with the following distribution: RSS I 21 patients (22.8%), II 63 (68.5%),
and III 8 patients (8.7%). Renal impairment existed in 16 patients (17.4%).
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Thalidomide based combinations were applied in 77 patients (83.7%) while 15
patients (16.3%) were treated with bortezomib based combinations. The
patients were ASCT ineligible due to the age, high comorbidity index, progres-
sive disease or personal attitude. 
Results: Overall treatment response (CR/VGPR/PR/MR, IMWG criteria) was
achieved in 77 patients (83.7%). In the group treated with thalidomide based
combinations, 65 patients (84.5%) achieved favourable treatment response,
in comparison to the 12/15 patients treated with bortezomib based combina-
tions. According to the R-ISS score, overall treatment response was achieved
in 20/21 patients (95.2%) with R-ISS I; in 54/63 (85.7%) with R-ISS II; and in
3/8 (37.5%) with R-ISS III. There wasn’t observed correlation between R-ISS
and therapy response neither in the thalidomide treated group (p=0.47) nor in
the bortezomib treated group (p=0.149). The median follow up of analyzed
group was 27 months (range 4-42 months). The components of R-ISS score
as: ISS, elevated LDH and the presence of high risk CA, was found to be the
factors of prognostic significance on PFS (Log Rank=4.19, p=0.041; Log
Rank=12.23, p=0.001; Log Rank=4.94, p=0.026, respectively) and OS (Log
Rank=4.34, p=0.04; Log Rank=13.34, p=0.001; Log Rank=5.08, p=0.024,
respectively). In analyzed group, age didn’t have impact on the PFS or OS
(p˃0.05). The R-ISS was highly statistically relevant regarding PFS (Log
Rank=10.79, p=0.005) and OS (Log Rank=14.41, p= 0.001). Similarly, in the
group treated with thalidomide based combinations, the R-ISS retained prog-
nostic significance on OS (Log Rank=17.54, p=0.0001) and PFS (Log
Rank=12.56, p=0.002). Cox regression analysis confirmed that R-ISS was the
most important prognostic parameter that influenced PFS in thalidomide treated
patients (HR, 5.1; 95% CI, 2.02-12.85; p=0.001). 
Summary/Conclusions: Incorporating the findings of molecular genetics along
with parameters of disease activity, the R-ISS score represents currently most
sensitive prognostic tool in multiple myeloma with consequent implications to
personalized treatment approach.
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SHORT SYSTEMIC TREATMENT CONCURRENT WITH INTENSITY-MODULATED
RADIOTHERAPY BY TOMOTHERAPY (IMRT) SHOWS IMPROVEMENT OF
PROGRESSION-FREE SURVIVAL IN SOLITARY PLASMACYTOMA OF THE
BONE (SPB)
E Le Ray1,*, L Belin2, C Plancher2, D Bouscary1, Y Kirova3
1Hematologie Clinique, Hopital Cochin, 2Biostatistics, 3Radiotherapy, Institut
Curie, Paris, France
Background: SPB is a rare plasma cell dyscrasia characterized by a single
bone tumor without evidence of multiple myeloma. Standard treatment is cur-
rently local 40Gy radiotherapy. Local control is achieved in more than 90% of
patients. However, approximately half of the patients develop further disease
progression, be it a new plasmacytoma or multiple myeloma.
Aims: To determine the impact and tolerance of short-term treatment with
Immunomodulatory Drugs (ImIDs) or proteasome inhibitors (PI) in association
with 40 Gy IMRT on the progression-free survival of SPB patients.
Methods: We retrospectively reviewed the medical and dosimetric records of
all patients treated for solitary plasmacytoma of the bone at a single institution
between 2004 and 2013. All patients had histologically proven plasmacytoma
of the bone, without bone marrow involvement. Initial evaluation included clin-
ical examination, biological tests and radiological exams. The absence of addi-
tional lesions was assessed by standard radiographies associated with a more
sensitive technique such as total body MRI, CT-scan and/or PET-CT. Radio-
therapy modalities were reviewed. Additional treatment was assessed. Toxicity
was evaluated weekly during radiotherapy, then at 6 weeks, 4 months and 1
year using CTCAEv3.0. Local control of the lesion was defined as negativation
of PET-CT. Progression was defined as the incidence of a new plasmacytoma
or a multiple myeloma. Statistical analysis: Progression-Free Survival (PFS)
was defined as the period from the beginning of radiotherapy to the first doc-
umentation of progression or death. Patients alive without progression were
censored at the date of last known contact. PFS was estimated using the
Kaplan Meier method and compared with the log-rank test.
Results: 28 patients were analyzed. Median age was 53.5y. Median follow-up
was 52.2 months (7-99). 15 patients received the standard treatment, a local
40Gy radiotherapy (group 1); 13 patients (46%) received treatment with IMiDs
or PIs, in addition to the 40 Gy local radiotherapy delivered by IMRT (group 2).
In group 2, 9 patients (69%) received 4 cycles of lenalidomide+dexamethasone,
of whom 2 also received bortezomib (15%); 3 received bortezomib+dex for 4
cycles (23%); and 1 received thalidomide for 12 months (7.5%) There was no
significant difference between subgroups by conventional prognostic factors
such as age, localization, M-Spike and ECOG. Toxicity was mostly hematological
and manageable with standard approaches. 1 patient developed profound
venous thrombosis on lenalidomide treatment in spite of aspirin prophylaxis. All
patients achieved local control. Overall survival was more than 95% at 4 years.
1 patient died of disease progression (MM) in group 1. In group 1, 5 patients
(33%) developed SPB and 5 patients developed multiple myeloma (33%) during
follow-up, versus 1 SPB (7.5%) and 1 MM (7.5%) in group 2. PFS rates at 48
months were 50.3% CI95% [29.8 ;84.6] in group 1 and 80.0% CI95% [58.7 ;100]
in group 2. PFS was significantly different between groups (p=0.032).
Summary/Conclusions: An additional treatment with IMiDs or PI to 40 Gy
IMRT is well tolerated and allows prolonged progression-free survival for soli-
tary plasmacytoma of the bone patients. These results need to be confirmed
in a larger, standardized clinical trial.
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POLYCLONAL SERUM IGM AS A PROGNOSTIC MARKER IN NEWLY
DIAGNOSED MULTIPLE MYELOMA
M Napolitano1,*, C Montante1, G Saccullo2, S Mancuso3, MR Lanza Cariccio3,
A malato4, F Fabbiano4, A lucchesi5, F pagan6, C Conticello7, D Mannina8,
F Di Raimondo9, S Siragusa3
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e Sperimentazioni Cliniche, Istituto Scientifico Romagnolo per lo Studio e la
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Background: Normal serum IgM plasma levels have been reported as an
independent marker of good prognosis in patients with multiple myeloma (MM)
but their role has been poorly investigated
Aims: We aimed to evaluate the role of polyclonal serum IgM levels as a sur-
rogate marker of normal residual bone marrow function in newly diagnosed
patients with multiple myeloma (NDMM).
Methods: Data were collected from the enrolling Hematology Centers. Patients
with NDMM were evaluated for polyclonal IgM levels and their correlation with
clinical and laboratory parameters of MM, at diagnosis and up to one year after
standard treatment. Baseline data were retrospectively analyzed between Jan-
uary 2012 and June 2015; analyzed parameters were taken at the following
time-points: diagnosis, after standard treatment and 1 year after diagnosis.
The one-year evaluation was performed at least 3 months after the last autol-
ogous stem cell transplant (ASCT) and at least 2 months after the end of a
first-line treatment in patients not eligible for ASCT. A dedicated database was
created. Statistical analysis was performed with Medcalc 12.5.00. Wilcoxon
test for paired samples was applied when indicated Patients were divided into
two groups based on the serum IgM levels at diagnosis (IgM<0.3 g/L and IgM
≥0.3 g/L,respectively).
Table 1.
Results: At diagnosis, we evaluated 170 NDMM (not IgM myeloma) patients
and divided them into two groups based on polyclonal serum IgM levels (Table).
M protein type frequency was similar between both groups. We found that
patients with polyclonal serum IgM level higher than 0,3g/L had higher hemo-
globin levels (median 12,0 vs 9,90g/dL; p<0,0001) and platelet count (252x109L-1
vs 193x109L-1; p=0,0001), lower β2-microglobulin (3,6 vs 5,3mg/L; p=0,0012),
lower creatinine levels (0,90mg/dl vs 1,09mg/dl; p=0,0209), higher creatinine
clearance (ClCr, 84mL/min vs 69,90ml/min; p=0,0906), lower frequency of ISS
stage III (42% vs 51%; p=0,0024). No significant statistical correlation was found
between IgM plasma levels and LDH, serum calcium and albumin. At regression
analysis, a strong correlation between polyclonal serum IgM level and serum
beta-2 microglobulin (negative; p=0,034) and hemoglobin (positive; p<0,001)
was observed.At the first revaluation, data on 98 patients were available. When
comparing serum IgM polyclonal levels between diagnosis and first re-evalua-
tion, IgM at diagnosis resulted lower (0,16g/L vs 0,29g/L; p=0,0023).Overall
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survival was similar between both groups (82,8 vs 82 months; p=0,9118) and it
was unrelated to the type of treatment administered.
Summary/Conclusions: In newly diagnosed MM, normal IgM levels can be
evaluated as a surrogate marker of good bone marrow residual function in
NDMM. After treatment, IgM do not statistically correlate with any of the clinical
and laboratory prognostic markers examined.
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NEW IMWG COMPARED TO CRAB CRITERIA TO PROPERLY DEFINE
START-TIME THERAPY IN MULTIPLE MYELOMA: A RETROSPECTIVE
SINGLE-CENTER ANALYSIS OF 180 PATIENTS
L Torti1,*, S Pulini1, AM Morelli1, F Bacci2, A Spadano1, P Di Bartolomeo1
1Department of Hematology, Transfusion Medicine and Biotechnology, “Spirito
Santo” Civic Hospital, Clinical Hematology, Pescara, 2Department of Hematol-
ogy and Oncological Sciences, S. Orsola-Malpighi Hospital, Section of
Hematopathology, Bologna, Italy
Background: The diagnosis of Multiple Myeloma (MM) traditionally requires
the evidence of signs of end-organ damage like hypercalcemia, renal failure,
anemia and osteolytic bone lesions,usually referred by the acronym “CRAB”.
The International Myeloma Working Group (IMWG) recently updated the criteria
for the diagnosis of MM,including biomarkers that are considered myeloma
defining events (MDEs).They are: clonal bone marrow plasma cells
>60%,serum free light chain (FLC) ratio >100 and the presence of more than
one focal lesion on magnetic resonance imaging (MRI).
Aims: In this paper we’d like to share our experience regarding the recent
IMWG criteria in a group of 180 newly diagnosed MM patients, to discuss
strengths as well as caveats and uncertainties. Ninety were young and treated
with transplant procedure and ninety were old (more than 65-year-old)and were
treated with different regimens,including new drugs.
Methods: We performed a retrospective analysis of these MM cases with MDEs
diagnosed from 1999 to 2014 in our Department, comparing traditional CRAB
versus recent IMWG criteria. We retrospectively looked for the new defining char-
acteristics published by Rajkumar (Lancet Oncol 2014) during the disease course
before both the development of CRAB events and beginning of treatment.
Figure 1.
Results: We found the occurrence of IMWG new criteria before clear manifes-
tation of the CRAB markers in thirty-eight patients (21% of total). In particular
the majority of this group has shown a FLC ratio>100 (14% of total),5% pre-
sented injuries detected by MRI and only 2% had a bone marrow plasma cells
involvement >60%. Most of them (92%) were followed by development of CRAB
features after a medium time of seven months (range 3-15) and progressed to
active MM requiring therapy in less than one year. In the category of patients
carrying the new criteria 71% were old (median age 70 years, range 53-89),
29% were young. Of them 56% had IgG MM, 26% IgA MM, 18% micromolecular
MM; prevalent light chain was kappa (65%). The majority of these cases (76%)
had a previous history of MGUS and smouldering MM. Only two patients among
180 started therapy not according to classic criteria, but on new IMWG bio-
markers, associated with deterioration of clinical condition and increase in mon-
oclonal component. However three young patients presented new IMWG
events associated with a stable monoclonal protein, good clinical status. Clinical
judgement was most important in this setting, as we decided not to start therapy
and to maintain close follow-up. In our view it is likely that earlier treatment of
these patients would not be beneficial,but might instead result in greater toxicity.
On the other hand patients without IMWG 2014 preceding CRAB criteria,often
identify a high-risk subgroup with a severe and faster biological behavior. The
largest part of them indeed (57%) presented markers of aggressive biological
profile like IgD paraprotein, extramedullary involvement or unfavorable cytoge-
netic abnormalities such as deletion of chromosome 17. Probably a well defined
temporal difference between development of new IMWG and the old CRAB
characteristics could be present only for intermediate-risk MM patients with a
slower kinetics of disease. In most high-risk patients probably new IMWG and
CRAB markers present all together simultaneously.
Summary/Conclusions: Our single-center study confirms the pivotal role of
new IMWG criteria to optimize management of patients with smouldering MM
and to antedate start-time of effective treatment before end-organ damage,
expecially for elderly patients.In our experience the most powerful biomarker
of progression is FLC ratio>100. Neverthless particular caution should be used
in youth patients to avoid too much toxicity of a earlier intervention,that can
also lead to selection of fitter clone and accelerated progression.Finally these
new biomarkers should be critically validated prospectively in future clinical
trials to allow an early treatment in patients without CRAB features with high-
risk markers.
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SPECIAL IMMUNE SIGNATURE OF MM PATIENTS IN LONG TERM
COMPLETE RESPONSE (LTCR) WITH NEGATIVE MINIMAL RESIDUAL
DISEASE (MRD) AFTER AUTOLOGOUS TRANSPLANT (ASCT): A SINGLE
CENTRE EXPERIENCE
A Arteche1, C Muñoz Calleja2, B Aguado Bueno3,*, A Kreutzman3, G Miriam4,
Á Arriero4, I Vicuña Andrés4, A Alegre Amor4
1Imnunology, 2Inmunology, 3H. La Princesa, Madrid, Spain, 4Hematology, H.
La Princesa, Madrid, Spain
Background: The immune profile in MM patients in long term complete remis-
sion (LTCR) could be relevant in MM control and minimal residual disease
(MRD) monitoring.
Aims: To evaluate this hypothesis, we have analyzed the immune profile and
the MRD status of a group of LTCR-MM patients after autologous transplant
(ASCT) and we have compared the results with a healthy control group.
Methods: 13 MM patients, median 60 y (46-71) in LTCR for >7 years, median
9 y (7-19) after ASCT were included. Only 2 patients had received thalidomide
as induction. The rest only chemotherapy schemes. No other patient had
received new drugs neither maintenance. 7 patients received conditioning with
HD Melphalan and 6 with Busulphan+Melphalan. Only 2 patient showed high
hisk iFISH, one with del(17p) and other with t(4;14). Control arm included 15
age-matched healthy blood donors (HD). Peripheral blood was immunopheno-
typed by multiparametric flow cytometry with 8 colours and CD4+ and CD8+ T-
cells, B lymphocytes and NK cells were quantified. Serum immunoglobulins,
free light chains and heavy/light chains (HLC) were quantified. MRD was eval-
uate with bone marrow multiparametric cytometry study (8 colours). Response
was evaluated by IMWG Criteria.
Results: The percentage of CD4+ T-cells in the LTCR group was significantly
lower than in HD (p=0.0002), whereas no differences were observed in the
proportion of total CD8+ T-cells (p=0.3046). Conversely, the relative values of
NK-cells (CD3-CD56+CD16+) were increased in the LTCR group (p=0,0514).
The percentage of total B-cells (CD19+CD20+) in the patients was within normal
range and no significant differences were found when compared to HD.
Remarkably, the normalization of HLC measurements confirmed a complete
reconstitution of the immune paresis in these patients, and a negative MRD by
multiparametric flow cytometry ratified its usefulness at demonstrating a sus-
tained complete response.
Summary/Conclusions: LTCR-MM MRD neg patients could express a partic-
ular immune signature which could reflect a “high quality” immune reconstitution
in terms of anti-tumor immunological surveillance and the recovery of the
humoral immunity. More studies are needed to confirm these results, with
patients treated with new drugs combinations including immunomodulatory ones.
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DURATION OF SECOND LINE TREATMENT AND SURVIVAL IN MULTIPLE
MYELOMA
H Parameswaran1,*, LM Tran2, C Yong3, S Noga4, E Farrelly5, A Raju5, B Seal3,
R Labotka6, M Blazer7, M Jhaveri3, D Romanus3
1Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 2Uni-
versity of California, Berkeley, CA, 3Global Outcomes Research, 4US medical
Affairs, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, Cambridge, MA, 5Real-World Evidence,
Xcenda, Palm Harbor, 6Oncology Clinical Research, Millennium Pharmaceuti-
cals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Lim-
ited, Cambridge, MA, 7Global Health Economics and Outcomes Research,
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Background: Evidence from post-hoc analyses of clinical trials supports the
paradigm of extended treatment leading to an overall survival (OS) benefit in
relapsed/refractory multiple myeloma (RRMM).
Aims: This observational study evaluated whether longer 2nd line treatment
(SLT) duration is associated with improved OS among patients with RRMM.
Methods: In this retrospective cohort study of a US national EMR database,
newly diagnosed adults with MM initiating 1st line therapy (FLT) and SLT
between 1/2008 and 12/2014 were followed through earliest of either 1 year or
death/loss to follow up/end of study period (12/31/2014) after start of SLT. FLT
began with the first claim for MM-directed therapy following diagnosis (dx). SLT
was identified by: 1) retreatment with follow-up regimen with gap of >3 months
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after end of FLT, or 2) switch to another drug combination after FLT. A logistic
marginal structural model was used to estimate the causal effect of SLT duration
on 1-year OS probability, adjusting for time-dependent confounders and base-
line covariates. Immortal time bias was addressed by estimating the effect of
SLT duration on outcome within each monthly interval from start of SLT.
Results: Among 340 patients, mean age was 70 years (standard deviation
(SD), 10); 51% were male; 9% had known high risk MM; 46% received
immunomodulatory (IMID-), 35% received proteasome inhibitor (PI-), and 6%
received PI+IMID-based SLT. Median duration of SLT was 6.87 months (95%
CI: 6.17, 8.40). The odds of 1-year OS were 1.17 times higher for each addi-
tional month of SLT (OR: 1.17 [95% CI: 1.10, 1.25] P<0.001), controlling for
age, gender, cytogenetic risk, comorbidities, race, ethnicity, region, insurance
type, treatment-free interval prior to SLT, FLT/SLT regimen type, year of diag-
nosis (dx), time since initial dx, time-dependent treatment- and MM-related
symptoms, and post SLT regimens (Table 1).
Table 1. Adjusted predicted 1-year OS probability based on DOT in SLT.
Summary/Conclusions: Longer duration of SLT was significantly associated
with longer OS. Despite substantial heterogeneity in patient/disease charac-
teristics and treatment patterns, the clinical benefit of continued longer term
therapy at relapse appears to be generalizable to patients receiving care in
the real-world setting.
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AGE-RELATED HEALTHCARE DISPARITIES IN MULTIPLE MYELOMA
M Puyade1,2,*, G Defossez2, F Guilhot1, X Leleu1, P Ingrand1,2
1INSERM CIC 1402, CHU, 2Registre des Cancers Poitou-Charentes, Faculté
de Médecine et Pharmacie, Poitiers, France
Background: Age is a well-known factor in solid tumor linked to a lower adher-
ence to guidelines. Scarce data exist for hematologic malignancies like Multiple
Myeloma (MM), a disease that affects primarily elderly patients.
Aims: The aim of the study was to investigate the relationships between age,
adherence to guidelines in MM and overall survival.
Figure 1.
Methods: The Poitou-Charentes cancer registry has exhaustively registered
the incident cases of MM from 2008 to 2010. Provided care (diagnosis, staging,
prognosis and first-line treatment) was compared to international guidelines.
Results: Three hundred and sixty seven patients aged 36 to 93y were included.
Compliance to diagnostic procedure was 98%, staging 62%, prognosis 30%
and first-line treatment 89%. Cytogenetic analysis was compliant in 37%
(74%<66y, 31% between 66-74y and 13% for the oldest, P<0.001). Age was
the strongest factor associated to compliant provision of care (OR 14.4 [6.1-
33.8] for<66y, and 2.3 [0.9-6.1] for 66-74y; P<0.0001). The second independent
factor was the diagnosis of multiple myeloma (OR 3.5 [1.6-7.3]; P =0.0009).
Adherence to guidelines increased overall survival after adjustment on age
HR: 1.8 [1.2-2.7], P=0.008.
Summary/Conclusions: Age is linked with inadequate provision of care in
MM, particularly prognosis and first-line treatment. Compliance to guidelines
improves OS. Future guidelines should stress that age and frailty should be
taken into account at Myeloma care, eventually with specific guidelines for this
population.
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THE FIRST TRIAL: ANALYSIS OF THE ASIAN SUBGROUP OF
TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE
MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE AND
LOW-DOSE DEXAMETHASONE
J Lu1,*, JH Lee2, SY Huang3, L Qiu4, JJ Lee5, T Liu6, SS Yoon7, K Kim8,
ZX Shen9, HS Eom10, WM Chen11, CK Min12, HJ Kim13, JO Lee14, JY Kwak15,
W Yiu16, G Chen16, A Ervin-Haynes16, C Hulin17, T Facon18
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Chengdu, China, 7Seoul National University Hospital, 8Sungkyunkwan Univer-
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Shanghai Jiaotong University, Shanghai, China, 10National Cancer Center,
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Background: The incidence of multiple myeloma (MM) in Asian countries is
increasing; therefore, effective treatment options for these patient (pt) populations
are needed (Kim et al, Am J Hematol, 2014). The pivotal phase 3 FIRST trial
investigated continuous treatment with lenalidomide plus low-dose dexametha-
sone until disease progression (Rd continuous) in pts with newly diagnosed MM
(NDMM) who were ineligible for autologous stem cell transplant (ASCT) from 18
countries, including China, South Korea, and Taiwan. Treatment with Rd contin-
uous in the FIRST trial improved progression-free survival (PFS; hazard ratio
[HR]=0.72; P<.001) and overall survival (OS; HR=0.78; P =.02) compared with
melphalan-prednisone-thalidomide (MPT) (Benboubker et al, N Engl J Med, 2014).
Aims: To examine the efficacy and safety of Rd continuous in the Asian pop-
ulation of the FIRST trial.
Methods: Pts with NDMM aged ≥65 years or ineligible for transplant were ran-
domized to 3 treatment arms: Rd continuous, Rd for 18 cycles (Rd18; 72
weeks), or MPT for 12 cycles (72 weeks). The primary endpoint was PFS in
pts treated with Rd continuous vs those treated with MPT (primary compara-
tors). Data cutoff was May 24, 2013; response and progression were assessed
by an independent response adjudication committee. Data cutoff for OS was
extended to March 3, 2014. All pts provided informed written consent.
Figure 1.
Results: In the 114 pts enrolled in Asia, median age (68 yrs [range, 43-86 yrs])
was similar across the Rd continuous (n=36), Rd18 (n=38), and MPT (n=40)
arms but lower than that of the overall study population (73 yrs [range, 40-92
yrs]). Pts in Asia also had a higher rate of Eastern Cooperative Oncology Group
performance status ≥2 (28% vs 22% overall), a higher rate of International
Staging System stage III disease (45% vs 41% overall), and double the rate of
severe renal insufficiency (creatinine clearance<30 mL/min; 18% vs 9% over-
all), the latter of which was more frequent in the MPT (23%) and Rd18 (24%)
arms vs the Rd continuous arm (8%). Median treatment duration was 18.4 mos
(range, 0.5-35.9 mos) for Rd continuous, 11.0 mos (range, 0.6-19.6 mos) for
Rd18, and 11.1 mos (range, 0.3-19.1 mos) for MPT. Treatment with Rd contin-
uous vs MPT resulted in a 39% reduction in the risk of progression or death
(Figure A). Rates of 2-year PFS were nearly doubled with Rd continuous (48%)
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vs MPT (25%). Rd continuous also resulted in a 48% reduced risk of death vs
MPT. Overall response rate was greater in the Rd continuous arm (78%) vs the
Rd18 (66%) and MPT (58%) arms (Figure B). Median duration of response
was not reached for Rd continuous and was 17.2 and 13.8 mos for Rd18 and
MPT, respectively. The most frequent grade 3/4 adverse events with Rd con-
tinuous, Rd18, and MPT were neutropenia (25%, 34%, 44%), anemia (19%,
5%, 15%), pneumonia (6%, 24%, 15%), and thrombocytopenia (14%, 5%, 5%).
Deep vein thrombosis was reported in 1 pt in the MPT arm, and pulmonary
embolism was reported in 1 pt in each treatment arm. There were no reports
of second primary malignancies in the Asian population.
Summary/Conclusions: Rd continuous treatment resulted in numerically larger
PFS and OS benefits and higher response rates compared with MPT in the Asian
subgroup of the FIRST trial, although pt numbers were small. Results were con-
sistent with those in the overall population, with no unexpected safety signals, a
low rate of thromboembolic events, and no second primary malignancies as of
data cutoff. These findings support Rd continuous as a standard treatment for
pts with NDMM who are ineligible for ASCT, including Asian populations.
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DIAGNOSTICS AND PROGNOSTIC STRATIFICATION OF PATIENTS WITH
WALDENSTRÖM’S MACROGLOBULINEMIA-SINGLE CENTRE EXPERIENCE
L Krupkova*, T Pika, M Divoka, M Orviska, J Minarik, T Papajik
Department of Hemato-oncology, University Hospital and Faculty of Medicine
and Dentistry, Palacky University, Olomouc, Czech Republic
Background: Waldenström’s macroglobulinemia (WM) is a rare B-cell neoplasm
defined as lymphoplasmacytic lymphoma with bone marrow infiltration and mon-
oclonal IgM in the serum. More than 90% of WM patients carry a point mutation
L265P in the MYD88 gene and concurrently, almost one third of MYD88L265P-
positive patients harbor frameshift (WHIM-FS) or non-sense (WHIM-NS) muta-
tion in gene CXCR4. The mutations in CXCR4 result in premature stop codons
and in shortening of CXCR4 protein product. Incomplete C-terminal domain of
CXCR4 chemokine receptor is known to hyperactivate CXCR4-mediated sig-
nalization. The presence and type of mutation in genes MYD88 and CXCR4
appears to be significant in diagnostics and prognostic stratification of WM
patients and it also influences the clinical manifestation of the disease.
Aims: To analyze mutational status of MYD88 and CXCR4 genes in patients with
WM, to compare our results with laboratory parameters and to evaluate the prognostic
stratification of the patients according to MYD88 and CXCR4 mutational status.
Methods: Analyzed DNA was isolated from mononuclear fraction of bone mar-
row cells at the time of diagnosis. Mutational status of analyzed genes was
determined using allele-specific PCR (in the case of MYD88) and using direct
Sanger sequencing (in the case of CXCR4). All found mutations were confirmed
by specific cleavage with restriction endonucleases at defined conditions.
Results: We analyzed a group of patients with WM (n=16). We identified 15
MYD88L265P-positive patients (93.8%), and 4 of them (25%) were also CXCR4
mutants (1 patient harbored WHIM-FS mutation and 3 harbored WHIM-NS
mutation). CXCR4 mutations were associated with more aggressive disease
(higher IPSS score, pancytopenia, higher levels of paraprotein and free light
chains in serum, higher bone marrow infiltration; Table 1), and CXCR4WHIM-WT
patients were often asymptomatic. CXCR4 mutations were also associated
with worse treatment response (2 CXCR4WHIM-MUT patients were resistant and
2 patients had a partial response to first-line therapy).
Table 1. The medians of laboratory parameters of the WM patients with
and without CXCR4 mutation.
Summary/Conclusions: The mutational analysis of MYD88 and CXCR4 genes
is essential for the diagnostics and prognostic stratification of patients with WM
and it allows a deeper understanding of the molecular pathogenesis of the dis-
ease. In accordance with published data, we confirmed that CXCR4 mutations
are associated with more aggressive disease presentation and thus affect treat-
ment outcome.
This work was supported by grant IGA-LF-2016-001.
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DESCRIPTION OF PATIENT CHARACTERISTICS, TREATMENT PATTERNS
AND RESOURCE USE FOR PATIENTS WITH MULTIPLE MYELOMA TREATED
IN THREE LOCAL HEALTH UNITS (LHUS) IN ITALY
S Panjabi1,*, D Lambrelli2, S Gonzalez-McQuire3, L Degli Esposti4, S Buda4,
S Saragoni4, V Blini4, E Merinopoulou2, S Ramagopalan2
1Amgen Inc., Thousand Oaks, CA, United States, 2Evidera, London, United
Kingdom, 3Amgen (Europe) GmbH, Zug, Switzerland, 4CliCon S.r.L., Ravenna,
Italy
Background: Recent data on resource utilization and treatment patterns in
multiple myeloma (MM) in Italy are limited.
Aims: The objective of this study was to examine the resource utilization and
treatment patterns of newly-diagnosed patients with MM in Italy.
Methods: Retrospective claims data from the administrative databases of three
LHUs in Lazio, Sicily, and Lombardy in Italy were used. Patients with a hospi-
talization discharge diagnosis of MM between 1 January 2008 and 1 September
2013 were included. To identify newly-diagnosed cases, patients with a prior
MM diagnosis or a prior prescription for bortezomib (Bor), thalidomide (Thal),
melphalan (Mel), lenalidomide (Len) or cyclophosphamide (Cyc) 12 months
prior to entry into the study cohort were excluded. Index date was defined as
the earliest of: date of first MM diagnosis or first prescription of Bor, Thal, Mel,
Len, Cyc, prednisone or dexamethasone in patients with a diagnosis of MM
within six months following prescription date; or the visit date to an oncologist
or hematologist in patients with a diagnosis of MM within six months following
the visit date. The baseline period was defined as 12 months prior to index
date and the follow-up period ranged from the index date (inclusive) until date
of last data collection or patient’s death. Data on patients’ demographics and
clinical characteristics were collected at baseline. Healthcare resource use and
treatment patterns were explored during the entire study period. The identifica-
tion of treatment lines was based on assumptions given the sequencing of
treatments based on key literature and treatment guidelines in Italy.
Results: Overall, 938 patients with MM entered the study cohort; average fol-
low-up was 1.7 years. A total of 157 patients underwent a stem-cell transplan-
tation (SCT) during the study period. The mean age at diagnosis was 69.7 years
(standard deviation [SD]: 12.3). A slight majority of patients were female (52%).
The most common comorbidities at baseline were renal disease (5.9%), other
malignancies (5.8%) and congestive heart failure (4.4%). Among 814 patients
with at least three months of follow-up, 76.4% of patients received at least one
treatment line and 40.8% and 18.3% received at least two and three lines,
respectively. Mel (27.7%) and Bor (21.5%) were the most frequently administered
first- and second-line treatments, while Len showed an increased uptake in third
line and beyond. Bor was the most commonly used first-line treatment in SCT
patients (31.3%), while Mel was the most commonly used first-line treatment for
non-SCT patients (36.5%). During the entire follow-up period, 80% of patients
had at least one hospitalization for MM, 74% of patients had at least one labo-
ratory test and 63% at least one diagnostic test, with the most common proce-
dure being biopsy of bone marrow (53%). The mean annual cost of hospitaliza-
tions and medications per patient was €13,558 (SD: 17,559) and €2,401 (5,532),
respectively. The average annual cost of medication per patient increased from
€2,590 (5,566) for patients in first-line to €3,253 (8,767) and €4,330 (11,439) for
patients in second- and third-line, respectively.
Summary/Conclusions: MM poses a significant economic burden on the nation-
al health system in Italy with hospitalizations being the main cost driver. Treatment
patterns data indicate an unmet need for more effective therapies in Italy.
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OUTCOMES FOR ASIAN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
TREATED WITH CARFILZOMIB AND DEXAMETHASONE VSBORTEZOMIB
AND DEXAMETHASONE: A SUBGROUP ANALYSIS OF THE PHASE 3
ENDEAVOR STUDY (NCT01568866)
JH Lee1,*, SY Huang2, JH Liu3, TY Chen4, P Lawasut5, S Iida6, S Feng7,
S Aggarwal7, WJ Chng8, D Joshua9
1Gachon University Gil Medical Center, Korea, Namdong-Gu, Korea, Republic
Of, 2National Taiwan University Hospital, 3Taipei Veterans General Hospital,
Taipei, 4National Cheng Kung University Hospital, Tainan, Taiwan, ROC, 5King
Chulalongkorn Memorial Hospital, Bangkok, Thailand, 6Nagoya City University
Hospital, Nagoya, Japan, 7Amgen Inc., Thousand Oaks, United States, 8Nation-
al University Cancer Institute, National University Health System, Singapore
and Cancer Science Institute of Singapore, National University of Singapore,
Singapore, Singapore, 9Royal Prince Alfred Hospital, Camperdown, Australia
Background: Carfilzomib is a selective proteasome inhibitor that is approved
as a single agent and in combination with dexamethasone or lenalidomide/dex-
amethasone for relapsed or refractory multiple myeloma (RRMM). The
ENDEAVOR study (NCT01568866) demonstrated statistically and clinically sig-
nificant improvements in progression-free survival (PFS) for carfilzomib and
dexamethasone therapy (Kd) compared with bortezomib and dexamethasone
therapy (Vd; median 18.7 vs 9.4 months [mo]; hazard ratio [HR], 0.53; 95%
confidence interval [CI]:0.44-0.65; 1-sided P<0.001) (Dimopoulos et al, Lancet
Oncol 2016).
Aims: This preplanned subgroup analysis evaluated the efficacy and safety
outcomes in Asian patients (pts) with relapsed MM from the ENDEAVOR study.
Methods: Adult Asian pts with RRMM (1-3 prior regimens) were included. Patients
in the Kd arm received carfilzomib at 20/56 mg/m2 IV of a 28-D cycle. The Vd arm
received bortezomib 1.3 mg/m2 IV or SC of a 21-D cycle. Cycles were repeated
until disease progression or unacceptable toxicity. The primary end point was PFS;
secondary end points included overall survival (immature at the time), overall
response rate (ORR), incidence of grade ≥2 peripheral neuropathy, and safety.
Results: Of 929 pts randomized, 109 (11.7%) were of Asian ethnicity
(Kd=54,Vd=55) from the JAPAC countries and received study treatment. The
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majority were from Japan (n=44; 40.4%) followed by Taiwan (n=24; 22.0%),
Singapore (n=20; 18.3%), Republic of Korea (n=16; 14.7%), and Thailand (n=5;
4.6%). Median PFS follow-up was 8.4 mo (Kd) and 7.6 mo (Vd). Median PFS
was 14.9 mo (Kd; 95% CI:13.1–17.7) vs 8.8 mo (Vd; 95% CI:6.6–NE [not
estimable]) (HR=0.57, [95% CI:0.29–1.14]; Figure 1A), representing a greater
than 6 mo improvement. The ORR was 79.6% (Kd; 95% CI:66.5–89.4) vs
70.9% (Vd; 95% CI:57.1–82.4) (odds ratio=1.604 [95% CI:0.664–3.872]). The
proportion of pts who achieved a best overall response (OR) of ≥complete
response (CR) was higher in the Kd arm (9.3%) vs the Vd arm (1.8%). Also,
the rate of ≥very good partial response (VGPR) in the Kd arm (63.0%) was
more than twice of that in the Vd arm (23.6%). Grade ≥2 peripheral neuropathy
occurred in 0% of pts in the Kd arm and 29% in the Vd arm. Rates of serious
treatment-emergent adverse events (TEAE), significant AEs of interest, and
AEs leading to treatment reduction or discontinuation (Kd or Vd) are shown in
Figure 1B. Similar pt incidence rates of AEs, ≥Grade 3 AEs, and ≥Grade 3
treatment-related AEs were observed between the Kd and Vd arms except for
higher cardiovascular events and hypertension being observed in Kd arm.
Figure 1.
Table 1.
Summary/Conclusions: In general, the efficacy and safety results from the
Asian population analyses paralleled and are consistent with the results from
the overall population of the ENDEAVOR study although the small sample size
limits definitive conclusions regarding rates of AEs. For pts of Asian ethnicity,
Kd therapy lead to clinically meaningful improvements in PFS, ORR, and
CR/VGPR compared with the Vd arm.
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Background: The genomic characteristics of the malignant clone are an impor-
tant aspect of multiple myeloma pathogenesis. It is well known that the disease
is associated with certain cytogenetic abnormalities, some of which confer poor
prognosis. The detection of these abnormalities with fluorescence in situ
hybridization (FISH) can identify a group of patients with high risk who should
be treated differently compared to those with standard risk. 
Aims: Identification of genetic markers as independent prognostic factors for
survival in multiple myeloma patients and assessment of their significance in
the era of novel agents. 
Methods: 92 newly-diagnosed multiple myeloma patients with performed FISH
and/or conventional cytogenetics were evaluated. FISH analysis was performed
in 76 patients, using specific probes for the most frequent high-risk genetic
markers, including t(4;14), del17p, del13, amp1q and del1p. Prognostic factors
for progression-free survival (PFS) and overall survival (OS) were identified by
means of the Cox proportional hazard model for covariate analysis. As possible
prognostic factors the following parameters were included in the regression
model: age, β2-microglobulin levels, hemoglobin levels, platelet counts, crea-
tinine, calcium, percentage of bone-marrow infiltration, extramedullary disease,
plasmablast morphology and presence or absence of the above mentioned
genomic aberrations. Median survival times were calculated and compared
according to the presence or absence of a particular high-risk aberration and
the type of induction therapy (bortezomib-based or conventional). Kaplan-Meier
curves were plotted and compared using the log-rank test. Statistical analyses
were performed with the program SPSS v21. 
Results: The prevalence of high-risk genomic aberrations in our patient cohort
was as follows: del13 in 39 (42.4%) patients; amp1q - in 22 (23.9%); del1p
and del17p each in 15 (16.3%), and t(4;14) in 8 (8.7%) patients. In our analyses
only high β2-microglobulin levels (р=0,035) and del1p (р=0,000) were inde-
pendent prognostic factors for PFS, while high β2-microglobulin (р=0.002),
thrombocytopenia (р=0.037) and del17p (р=0.006) were independent predic-
tors of poor OS. Among the high-risk genetic abnormalities del1p and del17p
had the greatest negative influence on patients‘ outcome, regardless of the
induction therapy performed (conventional or bortezomib-based). Patients with
del1p and 17p had a significantly shorter median survival, compared with
patients without these aberrations, even after induction with a novel agent: 16
months vs 79 months for del1p (p=0.014) and 12 months vs 79 months for
del17p (p=0.001). 
Summary/Conclusions: Del17p is a well-known adverse prognostic factor in
multiple myeloma which is included in the risk stratification models. Presence
of this aberration predicts short survival and such patients are candidates for
clinical trials. Only few data however are present on the prognostic significance
of del1p in the era of novel agents. According to our results patients with del1p
should be considered high-risk, similarly to patients with del17p, and may be
candidates for more aggressive induction therapy. 
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PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF 
POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY
MULTIPLE MYELOMA IN TREATMENT WITH BVD (BENDAMUSTINE
BORTEZOMIB-DEXAMETHASONE)
C Cerchione*, D Nappi, D Salvatore, I Migliaccio, F Pane, L Catalano
Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy
Background: Patients receiving cancer chemotherapy are at increased risk
of neutropenia, leading to increased risk of infections and delay in subsequent
chemotherapy treatments. Recombinant granulocyte colony stimulating factors
(G-CSFs) have been developed to stimulate proliferation and differentiation of
neutrophils in patients receiving chemotherapy. Pegfilgrastim is a pegylated
long-acting recombinant form of G-CSF that extends the half-life and allows
for once-per-cycle dosing, requiring less frequent dosing than nonpegylated
G-CSF. Multiple Myeloma (MM) in advanced phases of disease may be man-
aged by regimens combining agents not frequently employed in early phases
of treatment (e.g. Anthracyclines, Alkylating agents, etc), but myelotoxicity is
the main expected side effect. In this context, G-CSFs are often necessary to
counteract the risks of febrile neutropenia: their use is bound to frequent eval-
uation of neutrophil counts that may not be easy for patients in home-care.
Avoiding severe neutropenia by prophylactic pegfilgrastim seems particularly
useful in these cases.
Aims: The objective of this study was to compare the efficacy and safety of
pegfilgrastim in patients affected by Multiple Myeloma in advanced phase of
disease. treated with BVD (Bendamustine, Bortezomib, Dexamethasone), in
order to determine whether a single subcutaneous injection of pegfilgrastim is
as effective as daily injections of standard filgrastim, in terms of haematological
toxicity, febrile neutropenic episodes, antibiotic usage and hospedalization
duration.
Methods: 47 patients (25 male and 22 female) with a median age of 58.4
years (range 36-82) affected by multiple myeloma, all relapsed and refractory
to a median of 6 lines of therapy (range 2-11), all previously exposed to Borte-
zomib, Lenalidomide, Melphalan and all relapsed after at least one autologous
bone marrow transplantation, had been enrolled.
Results: Since first course, received in our out-patient department, patients
performed blood counts twice weekly and received, from day +8 to day +19
(considering “day+1” the day in which the chemotherapy protocol starts), pro-
phylactic oral chinolonic antibiotics and anti-fungal drugs. During neutropenia
after first cycle of chemotherapy, Filgrastim (5μgr/kg/day for 3 days) was given
if neutrophils count was <1500x10^9cells/L. Median number of filgrastim admin-
istrations was 4.1 (r. 3-6); nadir neutropenia was registered after a median of
11.6 days (r. 8-14); median of nadir neutrophil count was 1.22x10^9cells/L
(range 0.4-1.5x10^9cells/L), with maximum duration of 13 days. From the sec-
ond course of chemotherapy, all patients switched to prophylactic therapy with
pegfilgrastim (6 mg), injected subcutaneously with a single administration on
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day +3 independently from the neutrophil count at that time. Primary endpoint
of this study was the duration of neutropenia (neutrophil count <1.5x10^9
cells/L), comparing pegfilgrastim and filgrastim. During pegfilgrastim, neutrope-
nia was never longer than 8 days, with a consequent reduction of neutropenia-
related infections. Median nadir neutrophil count, evaluated for every patients
for at least three courses of therapy (r. 3-6) registered at day +11, was 1.484
(range 1.04-2.33x10^9cells/L); only six patients (12.7%) needed, one week
after pegfilgrastim administration, a supplement of 3 administrations of filgras-
tim. During pegfilgrastim prophylaxis, neutropenia was shorter than during Fil-
grastim treatment. Besides the mono-administration, pegfilgrastim was well tol-
erated in all patients: main side effects in our patients were mild fever and bone
pain, (9/47 patients,19.1%).
Summary/Conclusions: In conclusions, in patients affected by MM exposed
to myelosuppressive agents in advanced phases of myeloma disease, pegfil-
grastim seems to reduce the incidence of neutropenia and may increase the
possibility to maintain the scheduled time of treatment.
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PREDICTIVE VALUE OF AUTOANTIBODIES AGAINST M2-MUSCARINIC
ACETYLCHOLINE RECEPTOR FOR THE ONSET OF CARDIAC AMYLOIDOSIS
IN MULTIPLE MYELOMA 
L Li*
Background: Multiple myeloma (MM) is a clonal late B-cell disorder in which
malignant plasma cells (PCs) expand and accumulate in the bone marrow,
leading to anemia, lytic or osteopenic bone disease and renal failure. Nowadays
MM has accounted for the second most common hematological malignancy
after non-Hodgkin lymphoma with its incidence of 1% in neoplastic diseases
and 13% in hematological malignance1,2. According to the data3, approximately
10% of multiple myeloma tends to be complicated by cardiac amyloidosis, main-
ly AL amyloidosis, in which the amyloidosis protein is consisted of monoclonal
immunoglobulin light chains produced excessively by plasma cell malignancy.
Moreover, up to 50% of patients with AL amyloidosis would progressively devel-
op restrictive heart failure4. Unfortunately the prognosis is still poor. M2 mus-
carinic receptor is attached to the family of cardiac G-protein-coupled receptors.
Previously the auto-antibodies against the second extracellular loop of M2-
muscarinic acetylcholine receptor (anti-M2-R) have been verified to involve in
the development of various heart diseases characterized by heart failure, such
as idiopathic dilated cardiomyopathy, Chagas’s heart disease and peripartum
cardiomyopathy5-7. Furthermore, the level of anti-M2-R is positively associated
with the increased risk of onset of peripartum cardiomyopathy7. Consequently,
our study aims to explore whether the level of anti-M2-R would rise in MM
patients with or without cardiac amyloidosis and whether anti-M2-R would
increase the risk of cardiac amyloidosis in MM patients.
Aims: 1. Anti-M2-R might participate in the phathophysiologic mechanism of
cardiac impairment complicated by MM;
2. Anti-M2-R can be an earlier predictor to estimate the risk of cardiac amyloi-
dosis in MM patients than NT-proBNP.
Methods: Totally 78 subjects were recruited, including23 MM with cardiac amy-
loidosis, 25 MM without amyloidosis (MM) and 30 normal control (NC). The
frequency and titer of anti-M2-R were compared in the three groups. All MM
were under detection of serum anti-M2-R by ELISA before chemotherapy. The
risk of cardiac amyloidosis was estimated using the univariate and multivariate
logistic regression. 
Results: The positive rates of anti-M2-R in the three groups are 69.6% (16/23)
in MM with cardiac amyloidosis, 40.0% (10/25) in MM and 10.0% (3/30) in NC
respectively (p=0.040,69.6% vs 40% and p=0.003, 40.0% vs.10%).Moreover,
multivariate logistic regression indicates that the presence of anti-M2-R is asso-
ciated with an increased risk of complicated cardiac amyloidosis in MM patients
(OR, 5.5; 95% CI, 1.4-21.4; p=0.013).
Summary/Conclusions: This study demonstrates that the elevated level of
anti-M2-R is an earlier independent predictor for the risk of cardiac amyloidosis
in MM patients.
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Background: Myeloproliferative neoplasms (MPN) are classified based on the
presence of the BCR-ABL1, JAK2 and CALRETICULIN mutations. These are
considered to be mutually exclusive, however rare cases with concomitant occur-
rence of these driver mutations have been reported, representing an ideal model
to chronicle the molecular alterations and to investigate the clonal architecture in
these cases. We report a comprehensive clinical and genetic analysis of sequen-
tial samples obtained from 7 patients with concurrent BCR-ABL1 and JAK2 V617F
or CALR mutations diagnosed at our centers between 1998 and 2015.
Aims: To perform a detailed clinical, morphological and quantitative genetic
analysis of sequential samples obtained from 7 patients with MPN with con-
comitant BCR-ABL1 and JAK2 V617F (n=5) or CALR mutations (n=2) to gain
further insight into clonal architecture and pathogenesis of these rare double-
mutated cases.
Methods: DNAs and RNAs extracted from peripheral blood or bone marrow
samples were used to perform quantitative analysis of the BCR-ABL1 fusion
transcript and JAK2 V617F/CALR mutations as part of the routine molecular
diagnostic workup. The mutation status of 13 genes (JAK2, CALR, MPL,
ASXL1, EZH2, SRSF2, IDH1, IDH2, LNK, CBL, TET2, DNMT3A, TP53) fre-
quently mutated in MPNs was analyzed using next generation sequencing
(NGS). The NGS analysis for performed using the AmpliSeq technology with
an IonTorrent instrument at an average depth of 1000x on 15 sequential sam-
ples from 7 patients.
Results: The quantitative analyses of the BCR-ABL1 fusion transcript and
JAK2 V617F or CALR mutations suggested that these driver mutations occurred
in different clones in 5 out the 7 cases analyzed. The next generation sequenc-
ing analysis of the 13 target genes identified additional mutations in 5 of the 7
cases with concurrent driver mutations (summarized in the heat map in Figure
1). The most frequently mutated gene was TET2 with mutations identified in 3
cases (2 cases with BCR-ABL1 and JAK2 mutation and one case with BCR-
ABL1 and CALR mutation). Both EZH2 and DNMT3A mutations were detected
2 cases. ASXL1 and IDH1 were found to carry mutations in single cases with
BCR-ABL1 and JAK2 mutation. The 5 patients harboring additional mutations
carried 1-3 mutation per sample with one of the cases presenting with 3 addi-
tional mutations affecting the TET2, EZH2 and ASXL1 genes.
Table 1.
Summary/Conclusions: Our analysis of the 7 patients with concurrent MPN
driver mutations suggested that the BCR-ABL1 and JAK2 or CALR mutations
occur in different clones in majority of cases with frequent acquisition of addi-
tional phenotype modifying genes including TET2, EZH2, ASXL1 and DNMT3A.
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ABNORMAL EXPRESSION OF LCN2 (NEUTROPHIL GELATINASE
ASSOCIATED LIPOCALIN) IN MYELOPROLIFERATIVE NEOPLASMS
T Fanelli1,2,*, P Guglielmelli1, F Gesullo1, G Corbizi Fattori1,2, G Rotunno1,
A Pancrazzi1, AM Vannucchi1
1Department of Experimental and Clinical Medicine,University of Florence,
CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms,
AOU Careggi, Florence, 2University of Siena, Siena, Italy
Background: Myeloproliferative neoplasms (MPNs), including polycythemia
vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF),
are clonal hematopoietic stem cells’ disorders. Clonal proliferation in MF is
accompanied by a secondary inflammatory reaction characterized by bone
marrow (BM) stromal changes and abnormal cytokine expression. We recently
reported LCN2/NGAL upregulated mRNA expression in CD34+ cells of MF
patients (Norfo et al. Blood 2014;124:e21-e32); increased BM expression of
LCN2 might facilitate clonal predominance and contribute to a dysfunctional
BM microenvironment (Lu M at al. Blood.2015;126:972-982). 
Aims: We aimed to investigate the clinical significance of LCN2 levels and its
correlation with clinical and molecular aspects in patients with MPNs.
Methods: One hundred well characterized MPN patients (20 PV, 20 ET, 30
PMF, 30 PPV-MF and PET-MF) were included in this study, and 20 health sub-
jects. LCN2 mRNA expression was performed in granulocytes by RTQ-PCR.
Measurements of NGAL plasma protein (PP) were performed by ELISA (Bio-
porto Diagnostics). Mutational status of JAK2, MPL, EZH2, ASXL1, IDH1/2,
CBL, TP53, TET2, DNMT3A, SRSF2 was evaluated as previously reported.
Statistical analyses were conducted with SPSS and Origin software.
Results: Significantly higher levels of LCN2 mRNA and PP were found in PMF
pts (mRNA: median RQ 9.70; PP: median 6.03ng/ml) in comparison with controls
(mRNA:median RQ 1.09, P=.02; PP: median 1.19ng/ml; P=.005). mRNA LCN2
expression in PMF was also significantly higher compared with PV and ET
(median RQ 1.89; P=.01 and median RQ 3.55; P=.02, respectively). Higher lev-
els of PP were also observed in PPV-MF (median 4.82ng/ml) compared to con-
trols (P=.003). LCN2 PP levels comparison among MPN sub-types is reported
in Figure1. In particular LCN2 PP levels in PET-MF (median 2.86 ng/ml) were
two-fold greater than in ET (median 1.395 ng/ml; P=.01), suggesting a link
between increased LCN2 levels and progression to MF. mRNA expression
inversely correlated with hemoglobin levels (P=.03, r=-0.29). LCN2 mRNA levels
were positively correlated with IPSS scores (P=.01), and were higher in ASXL1+
pts (n=23) compared with WT (3.2 vs 10.4, P=.02). CALR+ pts showed lower
levels compared with JAK2+ or Triple Negative (2.60 vs 4.85 vs 8.71 ng/ml
respectively, P=.04), while PP levels were significantly higher in SRSF2+ pts
(n=4) compared to WT (17.35 vs 4.04, P=.02). PP levels were linearly correlated
with CD34+ count (P=.01, r=0.28). In 17 of 33 MF pts, reduction of PP LCN2
levels was observed after treatment with ruxolitinib; of these 6 (54.5%) achieved
a spleen volume reduction and in 7 (63.6%) constitutional symptoms resolved.
Figure 1.
Summary/Conclusions: Lipocalin might represent a novel diagnostic and/or
prognostic marker and could also provide a new therapeutic target in MPNs,
particularly myelofibrosis. Further studies are required to fully clarify the clinical
significance of Lipocalin overexpression in myelofibrosis.
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Background: Somatic mutations in exon 9 of the calreticulin gene (CALR) are
found in the majority of the JAK2V617F negative Philadelphia-negative myelo-
proliferative neoplasms (MPNs) essential thrombocythemia (ET) and primary
myelofibrosis (PMF). A hallmark of the mutated CALR protein is its preferential
expression in megakaryocytes, and so far, mutations in CALR have only been
found in cells of myeloid lineage. However, mutations in the CALR gene are
considered an early event and thus expected to be present in cells of the lym-
phoid compartment as well. The mutant allele burden has been suggested to
have an impact on the disease phenotype, but patients with high mutant allele
burden appear to be rare and it is unknown if homozygous sub-clones is com-
mon in patients. 
Aims: Here we wish to determine if the CALR mutations are present in B- and
T- lymphocytes and investigate if homozygous clones are present in the patients.
Methods: In this study, we separated the myeloid and lymphoid cell fractions
from 11 CALR mutated patients (4 ET, 1 pre-fibrotic primary myelofibrosis (pre-
PMF), 5 PMF, and 1 post-ET MF) using fluorescent activated cell sorting
(FACS). The mutations included the type 1 and type 2 subtypes, and two dif-
ferent 34 base-pair deletions. The allele burden was quantified for type 1 and
2 mutations using allele specific qPCR and the 34 base-pair deletions quantified
by fragment analysis. Granulocytic and erythroid cell colonies from 15 patients
(4 ET, 3 pre-PMF, 7 PMF, and 1 post-ET MF) were cultured in the presence of
erythropoietin and after expansion individual colonies was isolated and ana-
lyzed for the CALR mutant allele burden.
Results: The mutant allele burden was determined in whole-blood (median:
41%, range: 3-47%), granulocytes (CD16+ median: 51%, range: 4.8-63%),
and monocytes (CD14+; median: 47%, range: 5.6-61%). In 3 of 11 patients
(27%), the type 1 mutation was found in T-lymphocytes (CD3+; median: 6.4%,
range: 5-7.8%), and in 2 of 11 patients (11%) in B-lymphocytes (CD19+; medi-
an: 25%, range: 18-31%). One patient had the type 1 mutation in both cell
types. The type 2 mutation was found in T-lymphocytes of a single patient
(16%). Isolated granulocytes and erythroid cells from cultured cell colonies
revealed the CALR positive clones from all patients to be heterozygous for the
mutations.
Summary/Conclusions: The presence of the CALR mutations in both myeloid
and lymphoid lineages indicates the CALR mutation to be an early event in a
multipotent hematopoietic stem cell expanding as a heterozygous mutated
clone of the myeloid lineage to become dominant in the majority of CALR
mutated MPN patients.
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FAILURE OF MEGAKARYOCYTE APOPTOSIS IN MYELOPROLIFERATIVE
NEOPLASMS
J Malherbe1,*, K Fuller1,2, CC So3, B Guo1, R Howman2, W Erber1,2
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Background: Megakaryocytic hyperplasia and morphological atypia are char-
acteristic features of the myeloproliferative neoplasms (MPN) and its entities:
polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofi-
brosis (MF). Data from murine and ex vivo models suggest that multiple molec-
ular abnormalities (e.g. JAK2V617F, CALR mutations) underpin megakaryocyte
expansion in the MPN. Limited studies also show that megakaryocytes utilize
apoptotic caspases to shed platelets and in the MPN, they may have apoptotic
disturbances. Despite these claims, there is little data demonstrating the precise
apoptotic defects and pathways affected in megakaryocytes of human MPN. 
Aims: We investigated the apoptotic pathobiology of megakaryocytes in human
MPN. We determined whether these disturbances targeted the intrinsic and/or
extrinsic apoptotic pathways and examined their differential associations
between MPN disease entities and the JAK2V617F and CALR driver mutations.
Methods: Bone marrow trephines of MPN (PV=20, ET=72, MF=53) and con-
trols (n=15) were studied. These included JAK2V617F, CALR-mutated (CALR-
Mut) and double negative (JAK2V617F-/CALRWT) cases. Sections were stained
with antibodies to pro-apoptotic (BNIP-3, caspase-8, caspase-9, Diablo, p53)
and anti-apoptotic (Bcl-XL, survivin) effectors involved in the intrinsic and extrin-
sic apoptotic pathways using an immuno-alkaline phosphatase and Fast Red
chromogen detection system. Megakaryocyte positivity was assessed by light
microscopy and the percent positive determined per case. Mean differences
(MD) in megakaryocyte positivity between MPN entities and JAK2V617F/CALR
mutation states were statistically evaluated. Megakaryocyte positivity was also
correlated with platelet count. 
Results: Megakaryocytes in MPN showed significantly greater positivity for
anti-apoptotic Bcl-XL and survivin, and pro-apoptotic Diablo, caspase-8 and
p53 than controls. However, MPN had significantly fewer pro-death BNIP-3
positive megakaryocytes (MD=42.8%, p<0.0001). Caspase-9 was only mar-
ginally increased in MPN (MD=4.3%, p=0.02). The apoptotic dysregulation was
most marked in MF. Significantly fewer BNIP-3 positive megakaryocytes were
seen in MF than ET (MD=14.7%, p=0.008). MF also had fewer caspase-9 pos-
itive megakaryocytes compared with both PV (MD=33.8%, p=0.003) and ET
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(MD=19.8%, p=0.02). However, p53 was increased ~2.7-fold in MF versus PV
(p=0.007). CALRMut megakaryocytes typically had pyknotic chromatin and low-
er pro-apoptotic BNIP-3 levels relative to JAK2V617F (MD=24.2%, p=0.0008).
Platelet counts correlated positively with caspase-9 megakaryocyte positivity
in MPN (r=0.28, p=0.002), and strengthened among MF (r=0.34, p=0.03) and
CALRMut cases (r=0.50, p=0.03).
Summary/Conclusions: Megakaryocytic hyperplasia in the MPN is assisted
by disruptions of the intrinsic apoptotic pathway. Our data shows overexpression
of anti-apoptotic Bcl-XL and survivin to be the key apoptotic inhibitors mediating
megakaryocyte survival. In MF, apoptotic failure is exacerbated by reductions
in pro-death BNIP-3 and caspase-9; this may relate to the marked formation of
cohesive megakaryocyte sheets and abnormal nuclear morphology common
in MF. CALR mutations also showed greater reductions in pro-apoptotic BNIP-
3 compared with JAK2V617F. Finally, the upregulation of caspase-9 seen in
megakaryocytes of CALR-mutated cases may account for the thrombocytosis
associated with this molecular subgroup.
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INCREASED PLASMA NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE
(NAMPT) IS ASSOCIATED WITH A HYPERPROLIFERATIVE PHENOTYPE
AND RESTRAINS DISEASE PROGRESSION IN MPN-ASSOCIATED
MYELOFIBROSIS
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Background: Myeloproliferative neoplasm (MPN)-associated myelofibrosis is
a clonal, neoplastic disorder of the hematopoietic stem cells, in which inflam-
mation and immune dysregulation play an important role. Somatic mutations
of JAK2 (JAK2V617F), CALR or MPL genes ar pathogenetically linked to the
disorder. JAK-STAT pathway activation is the main mechanism of myeloprolif-
eration; however, available evidence indicates that inflammatory/immune mech-
anisms play an important role in the phenotype of MPN-associated myelofibro-
sis by increased production of inflammatory cytokines and reduced number of
regulatory T-cells. Nicotinamide phosphoribosyltransferase (NAMPT), intracel-
lularly, is an enzyme that converts nicotinamide into nicotinamide mononu-
cleotide, precursor of nicotinamide adenine dinucleotide (NAD+), which is
essential for cellular metabolism, energy production, DNA repair, and survival.
NAMPT exists also as an extracellular protein defined in literature as Pre-B
cell colony-enhancing factor (PBEF) or as an adipokine called visfatin. Different
type of cells are able to release this protein, but its role as a cytokine is still
unknown. Emerging data implicate eNAMPT in the pathogenesis of a number
of different human diseases that share an inflammatory basis, such as rheuma-
toid arthritis, type 2 diabetes, acute life-threatening processes such as acute
lung injury, sepsis, and tumorigenesis. In the tumour microenvironment, e-
NAMPT induces monocyte polarization to M2 macrophages secreting tumor-
promoting cytokines and inhibiting T-cell responses rendering this pleiotropic
molecule a novel player in tumor/host cross-talk. The function of NAMPT in
MPN-associated myelofibrosis biology is completely unknown
Aims: Here we examined plasma levels of eNAMPT in patients with MPN-
associated myelofibrosis and their effects on disease phenotype and outcomes.
We also studied the concordance of eNAMPT levels with the marker of general
inflammation high-sensitivity C-reactive protein (hs-CRP).
Methods: A total of 333 MPN-associated myelofibrosis patients (187 males
and 146 females) and 31 age- and gender-matched normal-weight controls
were enrolled in the study. The control group was selected among the general
population excluding individuals with a body mass index greater than 25. At
study entrance, all participants gave their informed consent, and study protocol
was approved by the Ethics Committee of our Hospital before implementation.
Since there is no accepted definition of disease severity, we evaluated a “sever-
ity score” by indexing leukocytosis, thrombocytosis, and splenomegaly (myelo-
proliferation index), and anemia, leukopenia, and thrombocytopenia (myelode-
pletion index) Levels of eNAMPT and hs-CRP were simultaneously assayed in
209 MPN-associated myelofibrosis patients. Twenty-four polycythemia vera or
essential thrombocythemia patients were used as controls. eNAMPT levels
were measured using a commercial immunoassay kit (BioPlex, BioRad Her-
cules, CA, USA) according to manufacturer instructions. All samples were
assayed in duplicate. 
Results: In the 333 MPN-associated myelofibrosis patients enrolled in the
study main body, risk stratification according to the IPSS/DIPSS prognostic
scoring system showed a predominance of low and intermediate I risk classes
(74% of the patients). The severity score of the disease based on spleen size
and hematological parameters measured at the time of eNAMPT analysis
ranged from 0 to 6 with a median value of 3. The “myeloproliferation index”
(range 0 to 4) had a median value of 3 and was equal to or lower than 1 in 39
patients (46.4%), while the “myelodepletion index” (range 0 to 4) had a median
value of 2 and was equal to or lower than 1 in 34 patients (40.5%). eNAMPT
was over expressed in MPN-associated myelofibrosis (n=333, median 1,487
ng/L, range 81-96,031) compared to healthy subjects (n=31, median 268 ng/L,
range 81-4,981; P=0.001). There was no difference in the median eNAMPT
level between patients with PMF and post-PV or post-ET myelofibrosis. eNAM-
PT expression was correlated with higher white blood cell count
(R=0.13;P=0.029), higher hemoglobin (R=0.20;P<0.001) and higher platelet
count (R=0.25;P=<0.001), suggesting that eNAMPT is an indispensable per-
missive agent for myeloproliferation of MPN-associated myelofibrosis. In 209
patients with MPN-associated myelofibrosis we simultaneously assayed eNAM-
PT and hs-CRP. Patients with MPN-associated myelofibrosis had higher levels
of hs-CRP than healthy controls (median, 0.15 ng/µl, range, 0.02 to 11.4). How-
ever, the individual values of eNAMPT were not correlated with those of hs-
CRP level, suggesting that eNAMPT in MPN-associated myelofibrosis does
not behave as a canonical inflammatory cytokine. In addition, higher levels of
eNAMPT predicted longer time to blast transformation, and protected against
progression towards thrombocytopenia and large splenomegaly.
Summary/Conclusions: In conclusion, in MPN-associated myelofibrosis high
levels of eNAMPT mark the myeloproliferative potential and, at variance with a
high number of cancers, are protective against disease progression.
E1336
DOES THE MUTATIONAL STATUS AFFECT THE BONE MARROW
MORPHOLOGICAL DATA IN PATIENTS WITH CLASSICAL PHILADELPHIA
NEGATIVE MYELOPROLIFERATIVE NEOPLASMS?
L Medina-Vega, L Hernández-Nieto, H Álvarez-Argüelles, B Soria,
L Gutiérrez-Murillo, T Martín-Santos, A Martín-Martín, C De Bonis, S Martín-Batista,
S Lakhwani, G González-Brito, MT Hernández-García, E Salido, JM Raya*
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Background: It is known that there may be a correlation between a genetic or
molecular alteration and the presence of characteristic histomorphological
changes in the bone marrow (for example, 5q- syndrome). In recent years,
molecular alterations described in chronic Philadelphia-negative myeloprolif-
erative neoplasms, mainly JAK2 V617F, calreticulin (CALR) and MPL, have
gained great diagnostic and prognostic interest.
Aims: Our objective was to analyze the possible influence of the mutational
status of these diseases on the histomorphological appearance of the bone
marrow.
Methods: We have retrospectively studied 140 patients atended at our center
between 1998 and 2013, with a diagnosis of Philadelphia-negative myelopro-
liferative neoplasm. The series included 44 patients with polycythemia vera
(PV, male 61%, mean age 61, range 28-82), 78 with essential thrombo-
cythemia (ET, female 62%, mean age 54, range 16-81) and 18 with primary
myelofibrosis (PMF, male 61%, mean age 63, range 46-95). We determined
the presence or not of the mutations for JAK2, CALR and MPL by standard
methods. All patients had performed a bone marrow trephine biopsy at diag-
nosis, and samples were examined by two hematologists and a pathologist
with proven experience on these entities. A total of 18 histopathological char-
acteristics were analyzed: overall and differential (erythroid, myeloid and
megakaryocytic) cellularity, megakaryocytes features (size, disposition in
dense or loose clusters, nuclei morphology, presence of “naked” nuclei, intrasi-
nusoidal and paratrabecular location), anormal location of immature precur-
sors, emperipolesis, presence of lymph nodes, microvasculature density, vas-
cular ectasia, iron stain, osteoclerosis, collagen fibers, CD34+ precursors, and
intrasinusoidal hematopoiesis. Arrangement was considered when the degree
of consensus included at least two observers. Statistical analysis was per-
formed using the SPSS 17.0 version.
Results: The frequency and distribution of mutations were as follows: 1) PV:
JAK2 V617F mutation in 88.4% of cases and JAK2 exon 12 mutation in 4.7%;
2) ET: JAK2 V617F mutation in 43.4% of analyzed patients, CALR mutation in
26.4% and none was carrier of MPL mutation; 3) PMF: JAK2 V617F mutation
in 37.5%, CALR mutation in 31.2% and none with MPL mutation. No morpho-
logical differences were found in the bone marrow of patients diagnosed with
PV or ET according to their mutational status (carriers or not of mutations in
JAK2 in PV cases, and carriers or not of JAK2 or CALR mutation in patients
with ET). However, some significant changes were observed in patients with
PMF. In the latter group of patients, the JAK2 V617F mutation is associated
with a significantly increased overall marrow cellularity when compared with
CALR mutation (predominantly normocellular) (p=0.025). Meanwhile, carriers
of CALR mutation, compared to those with JAK2, show significant changes in
nuclear lobulation of megakaryocytes (mostly hyperlobulated versus normo-
or hypolobulated in JAK2 mutated) (p=0.019). The emperipolesis phenomenon
was significantly more frequent in PMF patients carrying the JAK2 V617F muta-
tion when compared with JAK2 non-mutated (p=0.024), and a substantially
higher frequency of “naked” nuclei of megakaryocytes was observed in PMF
CALR mutated cases in comparison with CALR non-mutated (p=0.035).
Summary/Conclusions: In our experience, the mutational status appears to
influence the histopathological changes observed in the bone marrow of
patients with primary myelofibrosis, but not in polycythemia vera or essential
thrombocythemia. Further studies including a larger volume of patients are nec-
essary to confirm these findings.
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Background: The BCR-ABL-negative myeloproliferative neoplasms (MPN)
are a group of heterogeneous hematological diseases with constitutive JAK-
STAT pathway activation. However, despite the recent advances in unravelling
disease etiology (JAK2 activating mutations), there is still no curative treatment
outside bone marrow transplantation. Epigenetic alterations, like histone acety-
lation, play pivotal roles in the pathogenesis of several hematological malig-
nancies, including MPN. Preliminary data showed that histone deacetylase
inhibitors (HDACis) promoted in cell death and growth arrest of myeloid neo-
plastic cells in vitro. Importantly, HDACis have proven efficacy in clinical prac-
tice, producing remissions and increasing the overall survival in hematological
malignancies. HDAC inhibition has also produced results in MPN patients, an
effect severely limited by toxicity. 
Aims: In order to explore the mechanism of action of HDACis in MPN, we ana-
lyzed the impact of HDACi in the cellular biology of MPN cell lines and primary
bone marrow cells. 
Methods: Primary MPN cells were obtained from bone marrow samples at
diagnosis following informed consent. SET2, HEL and UKE-1 MPN cell lines
were used. Both primary cells and cell lines were incubated with the different
pharmacological reagents and at different time points, the cells were stained
for Apoptosis and Reactive Oxygen Species (ROS) for detection by Flow
Cytometry.
Results: Vorinostat decreased cellular viability in primary MPN cells, particularly
affecting the monocytic lineage, and this was associated with a concomitant
decrease in ROS levels. In MPN cell lines we showed that a wide range of HDACi
(Vorinostat, Trichostatin A, Butyric Acid and Depsipeptide) produced these effects.
Interestingly, HDACi-induced apoptosis was dependent on decreased ROS levels
suggesting that both events are connected and necessary for MPN cell death
induced by HDACi to occur. By combining both HDACi and ROS reducing drugs
(ROS production inhibitors; ROS scavengers and AntiOxidants) we were able to
increase MPN cell death in a synergistic manner.
Summary/Conclusions: These results point to a promising synergistic effect
of HDACi with ROS depleting drugs in the context of MPN, which must be con-
firmed in vivo and in the clinical setting. These combinations could improve
efficacy a tolerability of these agents in MPN, opening the door to a new ther-
apeutic alternative.
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REDUCED FREQUENCY OF CIRCULATING CD4+CD25+CD127LOWFOXP3+
REGULATORY T CELLS IN PRIMARY MYELOFIBROSIS
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Background: A systemic dysregulation of immune system, represented by
increased plasma levels of several inflammatory cytokines, and clinical and
laboratory findings of autoimmunity, has been documented in primary myelofi-
brosis (PMF). Regulatory T cells (Tregs), currently identified as CD4+T cells
with high expression of CD25 (interleukin-2 receptor), low expression of CD127
(IL-7 receptor), and high expression of FOXP3, are known to play a crucial
role in the maintenance of T cell homeostasis and immunologic tolerance.
Moreover, Treg cell defects have been associated with different autoimmune
diseases, and a Treg cell deficit due to a mutation in the FoxP3 gene has been
shown to cause aggressive autoimmunity and early death. Although a clinical
study has indicated decreased number of Treg cells in the active status of PMF,
conflicting results have been reported up to now.
Aims: In this study we investigated the frequency of Tregs, identified as
CD4+CD25+CD127lowFoxP3+ cells, to clarify whether or not Treg cell number
is reduced in PMF, and to investigate the associations between Tregs frequency
and disease phenotype
Methods: Tregs frequency was assessed by flow cytometry in 202 patients
with PMF, all out of therapy at time of sampling, and in 24 healthy subjects
(HS), comparable for sex and age. Spleen-derived Tregs were evaluated in 17
different patients undergoing splenectomy for symptomatic splenomegaly and
in 8 HS splenectomized for abdominal trauma. At study entrance, all partici-
pants gave their informed consent, and study protocol was approved by the
Ethics Committee of our Hospital before implementation. A single cell suspen-
sion was obtained from splenic samples by means of mechanical dissociation
followed by density gradient centrifugation. The frequency of
CD4+CD25+CD127lowFoxP3+ cells was calculated as a percentage of positive
cells in the total CD4 gate. For the Treg suppression assay circulating
CD4+CD25+ T cells were immunoselected and cultured in triplicate with soluble
anti-CD3/anti-CD28 and autologous irradiated cells. At day 4, 3H thymidine
(2Ci/well) was added to cultures for 16 hours and proliferation measured by
the amount of incorporated 3H.
Results: Compared with HS who had a median Treg frequency of 1.99%
(range, 0.48% to 6.51%), patients with PMF had a median frequency of Tregs
of 0.80% (range 0% to 10.2%; P<0.001). A similar trend was observed in the
spleen were HS had a median Treg frequency of 1.20% (range 0.36% to 3.97%)
and patients with PMF a median of 0.35% (range 0.04% to 1.26%; P<0.001).
This result secures that the reduced frequency of circulating Tregs was not
due to cell recruitment to sites of active malignancy, like spleen. To support
that blood and spleen Tregs were independently regulated among total
CD3+CD4+ cells, we measured the percentages of CD3+CD4+ in blood and
in total spleen lymphocytes. They resulted non different from healthy individuals
(data not reported). The percentage of suppression of Tregs on the proliferation
of effector T-cells was comparable in patients with PMF (38.7%) and HS
(36.5%) indicating that Tregs isolated from patients were functionally active. In
patients bearing JAK2V617F mutation (N=126) we observed a higher frequency
of circulating Tregs than those non mutated (N= 74; median, 1.00 vs 0.70; P=
0.002), and patients with high JAK2V617F allele burden (≥50%) had higher
frequency of circulating Tregs than those with low allele burden (P= 0.07). In
CALR mutants, the reduction of circulating Tregs was statistically associated
with older age, longer disease duration, and higher IPSS/DIPSS prognostic
score, and a strict direct correlation between Treg frequency and haemoglobin
was documented. 
Summary/Conclusions: Our findings showed that a large fraction of PMF
patients had reduced frequency of Tregs, a non clonal component of bone
marrow and spleen microenvironment. Blood Treg cell defect was particularly
evident in patients lacking JAK2V617F mutation: in CALR mutated patients
the defective Treg percentage was associated with an advanced and prognos-
tically unfavourable disease, and strongly correlated with severity of anemia.
These results open new research perspectives and support new therapeutic
strategies aimed at increasing the number of Tregs in PMF.
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Background: Splenomegaly (SM) is frequently observed in Myeloproliferative
Neoplasms (MPNs). Many MPN symptoms have been attributed to
splenomegaly but studies exploring these associations are lacking.
Aims: We sought to evaluate how the presence of severe splenomegaly
(>10cm below costal margin [BCM]) impacts patient symptomatology and
relates to other clinical features.
Methods: Data was collected among an international cohort of MPN patients
including polycythemia vera (PV), essential thrombocythemia (ET) and myelofi-
brosis (MF) without splenectomy as reported previously (Emanuel et al., JCO
2013). Subjects completed BFI and MPN-SAF instruments. Items were scored
on a 0 (absent) to 10 (worst imaginable) scale. For individuals completing at
least 6 of the 10 MPN-SAF TSS items, the survey was scored by multiplying
the average score across items by 10 to achieve a 0 to 100 scaled score.
Demographics, clinical features and symptom scores were compared between
splenomegaly subgroups using ANOVA F-tests or chi-squared tests.
Splenomegaly was assessed by clinicians based on physical examination and
reported as an estimated value BCM. Patients were categorized into ‘No-SM’
(non-palpable), ‘Mild-SM’ (1-10cm) and ‘Severe-SM’ (>10cm).
Results: Demographics: A total of 2043 patients were included in the analysis
(No-SM, n=1462; Mild-SM, n=404; Severe-SM, n=177) with a mean spleen size
of 2.6 cm BCM (range 10.1-31.0 cm). Patients were of expected age (59.7 years)
and similar gender distribution (54.6% female). MPN subtypes included ET
(41.9%), PV (35.2%) and MF (22.9%). The most prevalent prognostic risk group
for each subtype was as follows: ET, intermediate (46.1%); MF, Int.-1 (54.9%);
PV, High (49.2%). Compared to a history of prior thrombosis (20.3%), anemia
(8.7%), leukopenia (9.9%), thrombocytopenia (11.0%), red blood cell transfu-
sions (5.8%) and prior hemorrhage (5.0%) were relatively uncommon. Clinical
Correlations: When compared to No-SM populations, patients with Severe-SM
were most likely to be >60 years (54.5% vs 45.5%, p=0.015) and have MF
(62.7% vs 10.8%, [p<0.001]). Severe-SM patients were also most likely to suffer
from anemia (29.3% vs 4.0%), leukopenia (16.4% vs 7.5%) and thrombocy-
topenia (34.2% vs 7.1%, all p<0.001), along with prior hemorrhages (8% vs
4.2%, p=0.029) and have the highest transfusion requirements (15.3% vs 2.8%,
p<0.001). In contrast, No-SM patients were most likely to have a history of prior
thrombosis (20.1% vs 14.3%, p=0.046). SM did not correlate with gender or
individual prognostic risk categories. Symptoms: Severe-SM was associated
with the highest Total Symptom Scores (TSS, 28.5 vs 16.3 in No-SM, p<0.001)
and individual symptom scores for all items assessed, with the exception of
fever and bone pain (both p>0.05; Figure 1). Highest scores were noted for
fatigue (4.9 vs 4.1, p=0.006), early satiety (3.6 vs 2.3, p<0.001), inactivity (3.4
vs 2.2, p<0.001), and impact on overall quality of life (3.8 vs 2.7, p<0.001).
Abdominal discomfort (2.9 vs 1.7, p<0.001) and weight loss (1.9 vs 1.1, p<0.001)
scores were of relatively low severity in comparison to other complaints.
Figure 1.
Summary/Conclusions: Spleen size directly correlates with symptoms unre-
lated to the abdominal cavity and overall MPN disease burden. The lack of
association between spleen size and prognostic risk scores suggests low risk
patients may still suffer from significant, undermanaged symptomatology.
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Background: About 85% of patients (pts) with Essential Thrombocythemia
(ET) harbors one of three driver mutations: JAK2, calreticulin (CALR) and MPL;
the remaining are defined “triple-negative”. Recent studies have analyzed the
clinical and hematological features of ET or primary myelofibrosis (MF) accord-
ing to mutational genotype. However the clinical impact of these mutations
seems to differ between cases of ET and MF. In particular controversial data
were reported regarding the risk of MF progression in triple-negative and CALR
mutated ET.
Aims: We retrospectively analyzed a cohort of 350 ET pts, diagnosed between
1990 and 2015 according to WHO classification, and we compared the clinical
phenotypes and outcome of CALR mutant cases with the group of JAK2V617F
positive and triple-negative pts.
Methods: Hematological parameters, cardiovascular factors, IPSET score,
microvascular symptoms and thrombotic complications were reported for each
cohorts of ET pts, as well as cytoreductive treatment. During follow-up, pro-
gression to MF and leukemic evolution were also recorded. Mann-Whitney test
was used for numerical comparisons while Chi-square test was used for nom-
inal ones. Overall survival (OS) and myelofibrosis-free-survival (MFS) and
Leukemia-free-survival (LFS) were estimated by Kaplan–Meier analysis and
compared with the Log-rank test.
Figure 1.
Results: Among 350 ET pts, CALR mutations were detected in 69 (19.7%),
JAK2V617F mutations in 216 (61,7%) and MPL mutations in 13 (3.7%). 52
(15%) pts were triple-negative. The median follow-up was 77,5 months, with a
longer time of observation for CALR mutants (median 125 months). JAK2-
mutated ET had a higher risk of thrombosis at onset, which was about three
times higher than CALR mutated pts or triple-negative ET (20,4% vs 7,2% vs
17,3% respectively, p=0,05). No difference between JAK2, CALR mutated and
triple-negative ET was identified in terms of incidence of recurrent thrombosis
during follow-up. Compared to those with JAK2 mutation, CALR-mutated ET
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pts were characterized by younger age (p=0,012), lower leukocyte count
(p<0,0001) and hematocrit (p<0,002) and higher platelet count (p<0,0001) and
presented a lower IPSET score (p<0,0001). Triple-negative pts showed a low
IPSET score, similar to CALR-mutated pts; they had a lower incidence of
microvascular symptoms (13.5%) in respect to JAK2 (39,8%) and CALR-mutat-
ed (34,8%) pts (p<0,0006 and p=0,014, respectively), with a low intensity of
cytoreductive treatment. Interestingly, CALR-mutated ET presented an
increased risk of progression to MF (24,6%) in comparison with JAK2V617F
positive (5,6%) and triple-negative (7,7%) ET (p<0,0001). CALR type 1 deletion
seemed to be strongly associated with MF evolution (15/17 pts). Median MFS
seemed shorter in JAK2 positive pts (79,77 months) compared to CALR-mutat-
ed (106,44 months) and triple-negative ET pts (96,04 months). As shown in
Figure 1, we finally documented a better OS in CALR pts than in JAK2 positive
group (median OS 317 vs 251 months respectively; p=0,007). No difference in
LFS according to different genotypes was demonstrated.
Summary/Conclusions: This study in a large cohort of ET supports and
extends the growing body of evidence showing that different mutational geno-
types in ET present significant differences with regards to clinical and hemato-
logic presentation as well as risk of MF progression. Even though OS was
higher, CALR mutation-positive patients appear to have a higher risk of evolu-
tion to MF compared to the JAK2 V617F-positive and triple-negative pts.
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Background: The gold standard for the diagnosis of prefibrotic primary myelofi-
brosis (prePMF) remains the histomorphologic assessment of bone marrow
(BM) biopsy samples. Clinically, especially early cases are difficult to distinguish
from other myeloproliferative neoplasm (MPN), in particular essential throm-
bocythemia (ET). Most prominently, thrombocyte counts are not different in
those two entities. However, several clinical features are frequently encountered
in prePMF, that are not routinely found in ET. The revised 2015 WHO diagnostic
criteria recognize four of these features as minor criteria for prePMF, at least
one of which must be present to establish the diagnosis: anemia, leukocyte
counts ≥11 G/L, elevated lactate dehydrogenase levels (LDH) as well as pal-
pable splenomegaly. 
Aims: The aim was to evaluate the new WHO minor criteria for prefibrotic pri-
mary myelofibrosis on a cohort of histomorphologically characterized patients.
Methods: From a multicenter database, 161 cases of prePMF in which the
diagnosis had been established through BM biopsy, were selected. The pres-
ence of the minor criteria was then assessed at diagnosis. The results were
compared to 186 patients diagnosed with ET from the same database. A fiber
grade of 1 was present In 54 of prePMF patients, while no ET patients showed
increased fibrosis in the BM.
Results: One or more minor criteria could be found in 90.7% (146/161) patients
with prePMF, while this was true for only 52.7% (98/186) of ET cases. In both
entities elevated LDH levels were the most prevalent feature (77.0% vs 29.0%,
p<0.001), followed by high white blood cell counts. There were no significant
differences between patients with fiber grade 0 or 1, except in splenomegaly
(37.4% vs 42.9%, p=0.030). The number of minor criteria increased with age.
While prePMF patients with one criterion were aged 60 years, patients that
displayed all four symptoms were aged 74 years. Accordingly, overall survival
was shorter in patients with a higher disease burden.
Table 1.
Summary/Conclusions: The revised minor criteria for prePMF could be well
reproduced in this population. In combination with the histomorphologic assess-
ment, they are suitable to correctly establish the diagnosis of prePMF. However,
there is a small subgroup of prePMF patients that show no minor criteria at
time of diagnosis. These patients should be monitored closely and their diag-
nosis should be re-evaluated if they should present with one of the features.
The proportion of ET patients that also display one or more minor clinical symp-
toms underlines the central role of histomorphologic differentiation of MPN
patients.
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Background: The 2008 WHO diagnostic criteria of Essential Thrombocythemia
(ET) require the integration of clinical, molecular and histological parameters.
Megakaryocytes (Mk) are the mainstay of bone marrow (BM) histological
assessment, as they are present at increased numbers and display peculiar
cytological features. While the morphology of ET-associated Mk has been wide-
ly studied, their objective quantification may prove challenging (e.g. biased
count due to variable BM cellularity in patients of different age).
Aims: This study aimed to: (i) identify a quantitative parameter to define the
number of Mk, irrespective of BM cellularity; (ii) define a Mk threshold to objec-
tively discriminate between ET from non-neoplastic BM samples.
Methods: The present study considered BM biopsies from: (i) 89 patients with
WHO-defined ET; (ii) 6 patients with secondary/reactive thrombocytosis (ST);
and (iii) 22 controls with normal platelet counts and no evidence of BM disease.
For the aims of this study, each biopsy was assessed for the following histolog-
ical parameters: (i) BM cellularity; (ii) total number of Mk; (iii) BM biopsy area
(as measured by digital imaging techniques). These parameters were used to
calculate Mk density (ratio between total number of Mk and BM biopsy area)
and its cellularity-normalized value (here referred to as “megakaryocytic index”),
calculated as: Total number of Mk/(BM biopsy area) x (BM cellularity). Statistical
analysis was performed using one-way ANOVA and ROC curve analysis.
Results: Differences in BM cellularity among ET and control cases were not
statistically significant. ET patients had higher values of Mk density and Mk
index compared to both ST and normal controls (Table 1) (p<0.01). At ROC
curve analysis, Mk density had limited efficacy in distinguishing ET from non-
neoplastic BM samples (threshold value: 10.5/mm2; sensitivity: 89.9%; speci-
ficity: 90.9%). Better results were obtained with the Mk index (threshold value:
25.5/mm2; sensitivity: 94.4%; specificity: 95.5%).
Table 1. Histological parameters (mean±SD) of ET, ST and control marrow
biopsy samples.
Summary/Conclusions: BM cellularity can greatly vary among patients, main-
ly as a result of the age-related decrease of hematopoietic elements. This may
impair the evaluation of the Mk number (a key feature for the diagnosis of ET
and other myeloproliferative neoplasms). Our model allows the quantification
of Mk, irrespective of BM cellularity. In particular, a megakaryocytic index
≥25.5/mm2 can sensitively and specifically discriminate between ET and non-
neoplastic controls. Poorer results have been obtained by Mk density. In con-
clusion, the megakaryocytic index may represent a valuable tool for the histo-
logical diagnosis of ET.
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Background: JAK2V617F-mutated essential thrombocythemia (ET) and poly-
cythemia vera (PV) represent a biological spectrum of the same JAK2V617F
disease modulated by several acquired and constitutional factors. In this sense,
the phenotypic transformation of ET to PV occurs in 3-10% of patients. There
is scarce information comparing the clinical and molecular profile of this group
of patients, at baseline and at the time of transformation.
Aims: To characterize the clinical and molecular profile of a group of 10 ET
patients who evolved to post-ET PV, before and after transformation.
Methods: From a whole cohort of 262 ET patients, 10 cases that evolved to
post-ET PV (3.8%) were included in the study. In all patients, PV diagnosis
was established according to the demonstration of an increased red cell mass
(>125%). JAK2V617F was analyzed by quantitative allele specific PCR in gran-
ulocytes at ET and post-ET PV diagnosis. To determine acquisition of 9p loss
of heterozygosity (LOH), breakpoints for chromosome 9p were mapped using
fluorescence microsatellite PCR. Targeted next generation sequencing (NGS)
was used to detect additional non-driver somatic mutations. Clonality based
on X-chromosome inactivation pattern by HUMARA and JAK2 46/1 haplotype
were also analyzed. The study was approved by the local Ethics Committee
and informed consent was obtained according to the Declaration of Helsinki.
Results: All 10 patients (male/female: 2/8) initially diagnosed with ET according
to WHO criteria fulfilled the criteria for PV after a median of 75 months (range:
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13-305). One patient started cytoreductive treatment prior to the transformation.
The main clinical and hematological data at the time of ET and post-ET PV are
summarized in Table 1. JAK2V617F evolutionary pattern was available in 8
patients. In all instances, a progressive increase in the JAK2V617F allele bur-
den was documented. Mitotic recombination of 9p was observed in 4/10 patients
(40%) and 3 of them corresponded to the patients with higher JAK2V617F
increase. Mutations in ASXL1 (n=1), DNMT3A (n=1) and TP53 (n=1) were
detected at the time of transformation. Clonal hematopoiesis could not be
demonstrated in any case. The JAK2 46/1 haplotype was present in 7 out of 8
available patients (87.5%), 4 in heterozygosis and 3 in homozygosis.
Table 1. Main clinical and hematological features at the ET and Post-ET
PV diagnosis.
*Median (range). # Available in 8 patients. M: male. F: female. ET: Essential thrombocythemia.
Post-ET PV: polycythemia vera post essential thrombocythemia.
Summary/Conclusions: An increase in JAK2V617F allele burden is observed
in all ET patients transforming to PV and may be accompanied by other mech-
anisms such as acquisition of 9p LOH or additional somatic mutations.
Funding. This study was supported by grants from the Ministry of Education
and Science of Spain and Instituto de Salud Carlos III FEDER (FIS
PI10/018087, PI13/00557, PI13/00393, RD12/0036/0010) and SGR 2014-567.
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Background: The Evaluation of Xagrid Efficacy and Long-term Safety (EXELS)
study (NCT00567502) is the largest prospective observational cohort of high-
risk patients with essential thrombocythemia (ET) reported to date. Although
anagrelide (ANA) is typically well tolerated, as patients with ET often have car-
diac risk factors, it is important to analyze ANA’s cardiac safety in these patients.
Aims: The primary objective of EXELS was safety and pregnancy outcomes
of ANA compared with other cytoreductive therapies (CRT). Here we assess
palpitations and arrhythmia events as reported in EXELS.
Methods: High-risk patients (≥1 of age >60 years, previous thrombotic event,
platelet count >1000x109/L) with ET were enrolled across 13 countries in Europe
from 2005-2009. Patients were required to be receiving CRT. Data, including
events predefined in the protocol (PDEs), were collected every 6 months for 5
years for all patients.
Results: 3649 patients were categorized according to treatment at registration
as follows: ANA (n=804), ANA+other CRT (n=141), other CRT (n=2666). Over
80% of patients received either hydroxycarbamide (HC) or ANA, and 69.8% of
patients received anti-aggregatory therapy. At registration, median age was lower
in the ANA (55.5 years) and ANA+other CRT (59.0 years) groups vs the other
CRT group (70.0 years). Due to the non-interventional nature of the study, patients
were able to switch treatments and did not necessarily remain in the same group
over the entire observation period. As such, the analysis of palpitations and
arrhythmia events were performed according to the treatment group patients
were on for at least one day during the study. Higher rates of palpitations were
observed in patients receiving ANA alone (1.69%, n=19) vs other CRT alone
(0.21%, n=6; Table). Similar differences were observed for tachycardia# events;
2.04% of patients (n=23) receiving ANA experienced tachycardia compared to
0.24% (n=7) of those receiving other CRT. There did not appear to be a clear dif-
ference in rates of supraventricular arrhythmia* events observed between patients
receiving ANA (1.06%, n=12) or other CRT (1.34%, n=39). This was also observed
with ventricular arrhythmias** with no apparent difference between the ANA only
group (0.09%, n=1) vs other CRT (0.10%, n=3). Very low rates of other arrhyth-
mias*** were observed across all groups. Similar rates of palpitations, tachycardia
and arrhythmias (supraventricular, ventricular and other) were seen in patients
receiving ANA+other CRT compared with ANA alone.
Table 1.
#Tachycardia comprises tachycardia, tachycardia paroxysmal and tachyarrhythmia (not other-
wise defined).
*Supraventricular arrhythmia comprises atrial fibrillation/atrial flutter, arrhythmia supraven-
tricular, supraventricular extrasystoles, supraventricular tachycardia and sinus tachycardia.
**Ventricular arrhythmia comprises ventricular fibrillation/ventricular tachycardia/ventricular
extrasystoles.
***Other arrhythmia comprises arrhythmia (not otherwise defined), bradycardia, extrasystoles,
sinus bradycardia.
Summary/Conclusions: Of the most commonly reported cardiac PDEs, pal-
pitations and tachycardia were more frequently observed with ANA vs other
CRT. Arrhythmia events (supraventricular, ventricular and other) were observed
at similar rates in the ANA and other CRT groups. Palpitations, tachycardia and
arrhythmia events were reported at a similar rate in the ANA+other CRT group
compared with the ANA group. While there may be an increase in specific car-
diac events with ANA, these are mostly mild and reversible with appropriate
treatment.
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Background: Symptom burden in myelofibrosis (MF) is severe and a risk factor
for mortality (Blood 2010;115(9):1703-8). In trials comparing JAK2 treatment
to best available therapy, patients receiving JAK2 therapy had significant alle-
viation in disease related symptom burden and decreased spleen size (N Engl
J Med 2012;366:787-798).
Aims: To date no studies have evaluated which cutoffs are most associated
with Dynamic International Prognostic Scoring System (DIPSS) risk score and
thus may identify patients for further symptom-directed treatment.
Methods: Patient demographics, symptom burden, DIPSS risk classification,
and spleen size were collected from MF patients at an office visit. Symptoms
were assessed via the MPN-10 total symptom score (TSS, JCO
2012;30(33)4098-103). The TSS was calculated as the summated 10-item
score, reported in a range of 0-100 for patients completing at least 6/10 symp-
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tom items. Associations of symptoms (worst single symptom score and TSS
utilizing various cutoffs) with DIPSS risk and spleen size (categorized as >10cm
and separately as >15cm) were investigated using ANOVA F-tests and ordinal
logistic regression. Lowest Akaike Information Criteria (AIC) was used to select
an optimal model among all a priori models.
Results: Demographics and symptom burden: 851 MF patients with known
DIPSS risk score or spleen size were selected, of which 695 were JAK2
inhibitor-naïve (420 with DIPSS risk, 425 with known spleen size). Among par-
ticipants, 58% had a TSS >20. The worst single symptom (or multiple worst if
tied) was most often fatigue (50%) followed by night sweats (19%) and satiety
(19%). The worst single symptom score was >5 for 57% patients, and 50%
had both a TSS >20 and worst single symptom score >5. Associations of symp-
toms with DIPSS risk and spleen size: Similar to prior published data, increased
TSS was significantly associated with higher DIPSS risk score (p<0.001) with
mean TSS of 15.8, 24.5, 30.1, and 37.7 for low, int-1, int-2, and high risk groups,
respectively. Increased TSS was also significantly associated with spleen size
(>10cm: mean TSS 25.2 vs 30.0, p=0.02; >15cm: 25.5 vs 32.9, p=0.004).
Increased worst single symptom severity was associated with higher DIPSS
risk score (mean worst single symptom score 5.0 vs 6.3 vs 7.0 vs 7.5, p<0.001)
as well as the largest spleen size (>10cm: 6.3 vs 6.8, p=0.11; >15cm: 6.3 vs
7.3, p=0.02). Ordinal logistic regression modeling of DIPSS risk: When com-
paring models, worst single symptom score >5 had the lowest AIC (Table 1),
suggesting this as an optimal model predicting increased risk. In this model,
worst single symptom score >5 was associated with 14.1%, 49.3%, 32.3%,
and 4.3% probabilities of being low, int-1, int-2, and high risk, compared to
20.8%, 52.8%, 23.7%, and 2.7% for single score ≤5. The next best model was
based on a TSS score >20 alone (AIC 936.657). Among combined TSS and
single item models, a combined TSS >20 and single item >5 had the relative
lowest AIC (938.51).
Table 1. Ordinal logistic regression models of DIPSS risk score (N=420)
by symptoms in JAK2-naïve myelofibrosis patients.
Summary/Conclusions: Alleviation of MPN symptoms, now measurable
through standardized instruments such as the TSS, are an integral part of
assessing therapeutic impact in both clinical practice and trials. In our modeling,
a cutoff criteria of the worst single symptom being >5/10 is optimal for predicting
increased DIPSS risk score suggesting that this criterion may differentiate
between which patients will most benefit from symptom-based treatment. We
propose that JAK2 inhibitor treatment be strongly considered in any JAK2-
inhibitor naïve MF patient with an individual symptom score >5.
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OSTEOPROTEGERIN (OPG) AND INTERLEUKIN-8 (IL-8) IMMUNOSTAINING
IN BONE MARROW (BM) BIOPSIES OF PATIENTS WITH PH-NEGATIVE
MYELOPROLIFERATIVE DISORDERS (MPD) AT DIAGNOSIS: CLINICAL
CORRELATIONS
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Background: Both IL-8 and OPG have been implicated in the pathogenesis
and clinical manifestations of myelofibrosis (MF), the most severe Ph(-) MPD.
IL-8 and its receptors were reported to promote altered megakaryocyte (MGK)
growth (Emadi et al), a typical MF finding, while OPG was found upregulated
in endothelial cells (Bock et al).
Aims: To evaluate the expression and intensity of IL-8 and OPG immunostain-
ing in BM biopsy of MPD patients at diagnosis and to study any eventual cor-
relations between them and clinical characteristics or outcome.
Methods: 78 patients were studied, diagnosed with MPN from 1984 to 2012
with a median follow up period of 55 months. Median age was 65 years, 49
were males. 22% were diagnosed with polycythemia vera (PV), 42% with essen-
tial thrombocytosis (ET) and 36% with MF. Of those, 58% had splenomegaly,
8% had bone pain, 81% presented with fatigue, 9% had sweating, 11.5% expe-
rienced a thrombotic event, 5% lost weight and 77% were JAK2 positive. Kary-
otype was abnormal in 32% while 7% presented unfavourable karyotype find-
ings. Immunostaining for IL-8 and OPG was performed on paraffin-embedded
4μm sections of formalin fixed BM biopsies, carried out at the time of diagnosis,
using the two-step peroxidase conjugated polymer technique. Grade of positivity
and intensity of IL-8 and OPG expression was scored according to a 0 to 3
scale. Statistical analysis was performed conventionally, using the SPSS version
22.0 package, and p values<0.05 were considered significant.
Results: There was no significant difference observed concerning the grade
of expression of both stainings among the different MPN-groups. High intensity
of IL-8 expression in MGK correlated, in the whole cohort, with a high neutrophil
count (p=0.029), low lymphocyte count (p=0.026), and increased haemoglobin
(p=0.02). OPG was also expressed in cells of myeloid lineage (MLC) and its
high intensity in MLC was observed in patients with high platelet counts
(p=0.015). High intensity of OPG expression in MGK correlated with high neu-
trophil counts (p=0.045), high hemoglobin (p=0.045), high platelet counts
(p=0.02), and a favourable karyotype (p=0.006). Most importantly, OPG low
intensity in MGK correlated with poor survival (p=0.012). There was no corre-
lation found between OPG and bone pain.
Figure 1.
Summary/Conclusions: Our most important finding is that high intensity of
OPG expression in MGK correlated with increased survival and a favourable
karyotype in patients with MPDs (PV, ET and MF). To the best of our knowledge,
this finding has not been reported yet. It should indeed be further validated.
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MYELOPROLIFERATIVE NEOPLASMS AND THROMBOSIS: A DANISH
COHORT STUDY
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Background: Arterial (AT) as well as venous thromboembolism (VTE) are
causes of morbidity and mortality in patients with myeloproliferative neoplasms
(MPN). Despite cytoreductive therapy and antiplatelet drugs MPN patients
seem more prone to develop both AT and VTE than the background population.
The influence of known cardiovascular risk factors on the risk of thrombosis in
MPN patients is debated.
Aims: To investigate the absolute and relative risks of AT and VTE in MPN
patients compared to matched controls in a prospective population based
cohort study, adjusting for cardiovascular risk factors. 
Methods: The Diet, Cancer and Health (DCH) Study is a Danish prospective
population based cohort study enrolling 57.053 subjects between 1993-1997.
Follow-up for this study was until 2008. Subjects were excluded if they had
pre-baseline history of AT, VTE or cancer. Diagnosis of MPN was identified by
linking to the Danish National Patient Registry, which provides information on
date of diagnosis coded in the ICD-8 or ICD-10 system. All identified cases of
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VTE and AT, which in this study was either myocardial infarction (MI) or stroke,
have been objectively confirmed by trained personnel looking through medical
records or discharge letters, biochemical investigations and diagnostic images.
Information on cardiovascular risk factors was obtained by self-administered
questionnaires at baseline. Biometric measures were obtained by trained tech-
nicians at enrolment. For each MPN patients five participants matched on age
and sex were identified in the DCH cohort. We used Cox regression models to
estimate the relative risk of AT and VTE in MPN patients.
Results: During follow-up 72 women and 71 men were diagnosed with MPN,
mean age was 56.8 years. Among MPN exposed subjects 10 MI’s, 6 cases of
stroke and 3 VTE events were observed after MPN diagnosis, corresponding
to incidence rates of 15.4 events per 1000 person years (10-3 p-y), 9.3*10-3 p-
y and 4.4*10-3 p-y. In the Cox regression analysis MPN was associated with a
significantly higher risk of MI, Hazard Ratio (HR) 5.7, 95% confidence interval
(95%CI) 2.4-13.7. The HR for stroke among MPN exposed was 2.2, 95%CI
0.8-5.7. The observed VTE events resulted in a HR of 5.6, 95%CI 1.1-27.8 in
the regression analysis. Our study was underpowered regarding the adjusted
regression analysis.
Table 1. Absolute and relative risks of thrombosis.
Summary/Conclusions: In our prospective cohort study a 6-fold increased
risk of MI was observed among MPN patients. The risk of stroke was increased
by 2-fold, however not statistically significant. The risk of VTE was increased
by 6-fold in MPN patients, however the number of events in this study was too
few for adjusted analysis.
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PROCOAGULANT MICROPARTICLE IS A NEW SURROGATE BIOMARKER
FOR THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE
NEOPLASMS
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Background: Previous studies have identified several clinical and genetic
markers for thrombosis in myeloproliferative neoplasm (MPN) patients, such
as age >60 years, thrombosis history, cardiovascular risk factors, and the pres-
ence of JAK2 mutation. Microparticles (MPs) are circulating small vesicles
released from the membranes of activated or apoptotic cells, which contribute
to thrombosis with their procoagulant activities. However, to date, there have
been a very few reports evaluating the relationship between the levels of MPs
and procoagulable state in MPN patients.
Aims: In this study, we characterized MPs in MPN patients and assess their
relationship with the thrombotic events in MPN patients in comparison with pre-
viously reported risk factors in the practical setting.
Methods: We analyzed 52 patients with MPNs: 17 with PV, 31 with ET, 1 with
Primary myelofibrosis (PMF), and 3 with secondary MF, according to the revised
WHO criteria and 12 healthy controls. The patient group consisted of 35 men
and 17 women with a median age of 68 years ranging from 30 to 87 (at analy-
ses). Thrombotic events were observed in 16 cases (30.8%). To assess the
levels of MPs, we extracted platelet free plasma (PFP), in which MPs were
enriched from sodium citrate-anticoagulated blood by centrifugations. Quan-
tiﬁcation and phenotypic characterization of MPs were performed by Flow
cytometry. This study was approved by the ethics committee at Kindai Univer-
sity, and patients provided written informed consent.
Results: There was no difference in the total amount of MPs between MPN
patients and controls (MPNs vs controls: median 2240 vs 3110/μL PFP;
p=0.058), whereas MPN patients had more AnnexinV+ or tissue factor (TF)+pro-
coagulant MPs (PCMPs) than controls (median±SD 15.1±6.2% vs 11.5±7.4%,
p<0.05; 2.5±1.6% vs 0.89±0.52%, p<0.05, respectively). The majority of PCMPs
derived from platelets and endothelial cells in MPN patients, which was con-
firmed by positivity for CD41a and CD146, respectively. The levels of AnnexinV+
and TF+ MPs tended to decrease in response to cytoreductive treatment in
MPN patients but with no significant difference (n=35: p=0.143, p=0.084,
respectively). Also, there was no statistically significant association between
PCMP levels and common hematopoietic parameters (e.g. Hb, WBC, and PLT
counts), suggesting that PCMPs were elevated independently of excessive
hematopoiesis in MPN patients. In addition, none of age, cardiovascular risk
factors, and JAK2 mutation showed a statistically significant relationship with
thrombosis history in untreated MPN patients (n=17) by univariate analysis. In
this setting, only high levels of TF+ MPs showed a strong association with
thrombosis history (p<0.01). The ROC analysis revealed that the best cut-off
value of TF+ MPs in accordance with thrombosis history was >52.0/μL PFP
with 100% sensitivity and 75.0% specificity (AUC: 0.88, 95% CI: 0.71-1.0;
p=0.102). These data indicate that elevated levels of TF+ MPs will be a new
surrogate biomarker to predict thrombotic events in MPN patients.
Summary/Conclusions: The current study shows the presence of elevated
PCMPs in the peripheral circulation of MPN patients, which was supposed to
contribute to the thrombotic events in these patients. Moreover, measuring
PCMPs, especially TF+ MP levels, seems to be a promising strategy to predict
thrombosis in MPN patients. Further studies to analyze their pathologic roles
in thrombosis may provide us with a new approach to prevent thrombotic events
in MPN patients.
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Background: Systemic mastocytosis (SM) comprises a group of rare myeloid
neoplasms characterized by accumulation of mast cells (MC) in various tissues,
predominantly skin, bone marrow (BM), and visceral organs. Depending on the
affected organ(s), SM-related organ damage, and involvement of other
hematopoietic lineages, SM can be divided into indolent SM (ISM) and advanced
SM (advSM). The KIT D816V mutation is a primary driver of disease manifes-
tations while the presence and number of additional mutations, e.g. in SRSF2,
ASXL, or RUNX1 (S/A/R gene panel), have a strong adverse impact on disease
phenotype and prognosis. However, only little is yet known about the prognostic
impact of aberrant clinical, laboratory or hematological parameters.
Aims: We sought to evaluate the influence of organomegaly, as measured by
magnetic resonance imaging (MRI)-based volumetry of liver and spleen as well
as other known clinical and hematological characteristics, on disease evolution
and overall survival (OS) in SM.
Methods: We retrospectively analyzed 108 patients (median age 64 years,
range 27-82; male 57%) with ISM (n=41) or advSM (n=67) (aggressive SM/mast
cell leukemia [ASM/MCL], n=12 or SM/ASM/MCL with associated hematologic
non-mast cell lineage disease [AHNMD], n=55). Median observation time from
the date of MRI was 26 months (range 1-79); 33/108 (31%) patients have died
in the observation period. The 2-year OS probability of all patients was 77%,
with a median OS of 5.4 years. 
Results: The median volumes of liver and spleen were 2035 mL (range 1034-
4265) and 540 mL (range 92-3193), respectively. Overall, MRI-documented
hepatomegaly (>2400 mL) was observed in 31/108 (29%) patients, and
splenomegaly in 67/108 (62%) patients (ISM 12%, advSM 88%). Splenomegaly
was mild (≥450 mL) in 43/67 (64%) patients and marked (≥1200 mL) in 24/67
(36%) patients. High disease burden, presence of an AHNMD and organ dam-
age (C-findings) were strongly associated with mildly or markedly increased
spleen volume (P<0.05). In multivariate analysis, however, only an increased
spleen volume ≥450 mL (hazard ratio [HR], 9.4; 95% confidence interval [CI],
[2.2-39.9]; P=0.0002) and an elevated alkaline phosphatase (AP; HR 8.4 [3.2-
22.1]; P<0.0001) remained independent predictive adverse prognostic markers
for OS. The 2-year OS was 100%, 76%, and 56%, respectively (P<0.001), for
patients with 0 (low-risk, n=37), 1 (intermediate-risk, n=32) or 2 (high-risk, n=39)
parameters. If available (n=74), the relative frequency of mutations in the S/A/R
gene panel was significantly different in the various risk groups (low: 0/15, inter-
mediate: 12/24 [50%], high: 28/35 [80%], P<0.01).
Summary/Conclusions: Splenomegaly and elevated AP provide relevant
prognostic information in SM patients that is independent of other clinical, lab-
oratory or hematological parameters. In addition to the recently identified
adverse prognostic impact of mutations in the S/A/R gene panel, this data will
have major implications for the implementation and validation of novel prog-
nostic scoring systems on the basis of larger patient cohorts, such as the
dataset of the ECNM registry, with the long-term objective to develop an IPSS
for patients with SM. 
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Background: Deferasirox (DFX) is an oral iron chelator widely employed in
the treatment of iron overload during thalassemic syndromes and myelodys-
plastic syndromes.
Aims: At present, very few data are available on the treatment with DFX in
patients with Ph- Myeloproliferative Neoplasms(MPN) and transfusional
requirement.
Methods: To address this issue, we report here on 37 patients (M 29; F 8) with
MPN and iron overload secondary to transfusional requirement enrolled in the
database of our regional cooperative group who received a treatment with DFX.
Of them, 33 had a primary Myelofibrosis, 3 a post Essential Thrombocythemia
myelofibrotic phase and 1 a post Polycythemia Vera myelofibrotic phase.
Results: According to IPSS classification, 7 patients (18.9%) resulted low/inter-
mediate-1 risk, 13 (35.1%) intermediate-2 risk and 17 (46.0%) high-risk. The
main features of the patients at diagnosis and at baseline of DFX treatment
are reported in the Table 1.Treatment with DFX was started after a median
interval from diagnosis of 12.3 months [interquartile range (IR) 7.6-37.6] and
from start of transfusion dependence of 11.0 months (IR 6.0-17.4), with a medi-
an of 27 packed red cells units received (IR 17-39). The starting DFX dose
was 20 mg/Kg in 21 patients (56.7%), 15 mg/Kg in 11 patients (29.7%) and 10
mg/Kg in 5 patient (13.5%). All patients were evaluable for toxicity: extra-hema-
tological toxicity of all WHO grades was reported in 20/37 patients (54.1%)
and consisted of gastro-intestinal symptoms in 7 patients, transient renal impair-
ment in 10 patients and skin reactions in 3 patients: however, only 3 patients
(8.1%) needed a permanent discontinuation for toxicity. As to chelation efficacy,
after a median treatment period of 15.4 months (IR 8.1-22.3), 4 patients
achieved ferritin levels<500 ng/ml, 9 patients ferritin levels<1,000 ng/ml and 3
patients presented a reduction >50% of basal ferritin but with levels >1,000
ng/ml, with a global response rate of 16 out 37 patients (43.2%): among the
remaining 21 patients, 2 discontinued for early toxicity, 18 did not have any fer-
ritin reduction and 1 had an early unrelated death (<6 months of treatment). As
to hematological improvement, 7/37 patients (18.9%) showed an unexpected
and persistent rise of Hb levels >1.5 g/dl, with disappearance of transfusional
requirement in 5 cases. The median overall survival of the whole cohort from
DFX initiation was 20.7 months (95% CI 16.1-25.1): the median overall survival
from DFX initiation in patients with chelation response was 46.9 months (95%
CI 23.6-70.1) compared to 15.8 months (95% CI 2.9-28.7) in patients without
chelation efficacy (p=0.007).
Table 1.
Summary/Conclusions: Treatment with DFX is feasible and effective in MPN
with iron overload. Moreover, also in this setting an hematological improvement
can occur in a sizeable rate of patients.
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Background: Calreticulin (CALR) mutations occur in 15-24% of patients with
essential thrombocythemia. The 52-bp deletion (mutation type 1) and the 5-bp
insertion (mutation type 2) are the most frequent alterations, being 45-53%
and 32-39% of all mutations; the remaining types are described in very few
patients each. CARL-mutated ET has a higher platelet count, a lower leukocyte
count, a lower haemoglobin level, and a lower thrombotic risk in respect to the
JAK2 V617F-ET. However, the differences between types 1 and 2 have been
rarely investigated (Tefferi A et al, Am J Hematol 2014; 89: E121). 
Aims: To assess in a retrospective multicenter cohort of CALR-mutated ET patients
the clinical and laboratory features of type 1, type 2, and types non-1/non-2.
Methods: We analysed a retrospective cohort of 172 patients with CALR-
mutated ET diagnosed according to the updated WHO 2014 criteria. CALR
mutation was type 1 in 91 patients (52.9%) (M/F 46/45, median age at diagnosis
59 yrs, range 18-84), type 2 in 55 patients (32.0%) (M/F 17/38, median age at
diagnosis 43 yrs, range 17-85), and type non-1/non-2 in 26 patients (15.1%)
(M/F 11/15, median age at diagnosis 46 yrs, range 20-83). Laboratory and clin-
ical features were compared among the groups. The relative risk of thrombosis
between groups was estimated by a Cox proportional hazards model. 
Results: The total observation time was 1586 pt-years (median 7.5, range 0.1-
34 years). As previously reported, male sex and younger age were more pres-
ent in type 1 mutation than in type 2 (p=0.02 and p=0.002, respectively). On
the other hand, no significant difference in sex and age distribution was found
between patients with type non-1/non-2 mutation and those with type 1 and
type 2. Patients with type 1, type 2, and type non-1/non-2 mutations did not
significantly differ in the rate of splenomegaly (10.9% vs.14.5% vs 0%), Hb
gr/dL (median 13.4, range 9.4-16.5 vs median 13.6, range 11-16 vs median
13.6, range 10.9-13.4), Hct (median 0.40, range 0.28-0.49 vs median 0.41,
range 0.33-0.43 vs median 0.40, range 0.32-0.48), leukocyte count x109/L
(median 8.43, range 4.63-17.15 vs median 8.05, range 3.56-13.40 vs median
7.82, range 4.55-15.30), and platelet count x109/L (median 787, range 454-
2000 vs median 920, range 465-1743 vs median 887, range 453-2042). As for
clinical phenotype, patients with type 1, type 2, and type non-1/non-2 mutations
did not significantly differ in the rate of microvascular disturbances (17.5% vs
16.3% vs 15.3%), need of cytoreduction (71.4% vs 72.7% vs 73.0%), major
bleeding (19.7% vs 27.2% vs 23.0%), transformation to myelofibrosis (9.8%
vs 12.7% vs 11.5%), occurrence of solid neoplasia (14.2% vs 9.0% vs 7.6%).
No patient evolved to acute leukemia. Thrombosis occurred in type 1 in 26.3%
of cases (arterial thrombosis in 14 cases, venous in 8, both sites in 2), in type
2 in 21.8% of cases (arterial thrombosis in 6 cases, venous in 6), and in type
non-1/non-2 in 7.6% of cases (arterial thrombosis in 2 cases). In patients with
type 1 the risk of thrombosis was increased over time with a borderline statis-
tical significance in comparison with type 2 (hazard ratio, HR, 1.77, 95%CI
0.91-3.64) and type non-1/non-2 (HR 3.31, 95%CI 0.91-6.29).
Summary/Conclusions: Male sex and younger age are confirmed to be more
present in type 1 than in type 2. In this cohort of ET patients the type of CALR
mutation did not influence significantly other laboratory and clinical features.
However, a trend towards a higher thrombotic risk was displayed in type 1,
deserving further studies.
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Background: In addition to the JAK2 46/1 haplotype, a recent study reported
that germline variations at JAK2 rs12339666, TERT rs2736100, HBS1L-MYB
rs9376092 and MECOM rs2201862 are associated with myeloproliferative neo-
plasms (MPNs) in European populations.
Aims: In this study, we sought to evaluate the association of these five germline
variations (JAK2 46/1 haplotype is tagged by rs12343867) with MPNs in Tai-
wanese population.
Methods: A total of 178 MPN patients (111 ET, 53 PV and 14 PMF) seen at Mack-
ay Memorial Hospital were enrolled into this study. Genetic testing in MPN patients
has been approved by the institutional review board. All patients were screened
for JAK2V617F, CALR and MPL mutations. All the above 5 germline variations
were genotyped by high-resolution melting analysis and/or Sanger sequencing.
Data of healthy controls were obtained from 118 local controls, published papers,
and Taiwan Biobank database (https://taiwanview.twbiobank.org.tw). Chi-
square or Fisher’s exact test were used to analyze difference between patients
and healthy controls, and to calculate odds ratios and 95% confidence intervals.
Population attributable risks (PAR) were calculated as previously described.
The SPSS software (version 22.0) was used for statistical analysis, and a two-
side p value<0.05 was defined as significant.
Results: The JAK2 46/1 haplotype, JAK2 rs12339666 and TERT rs2736100
were significantly associated with MPN cases (p value, 7.5x10-8, 3.2x10-8 and
3.0x10-6, respectively), and JAK2V617F-positive cases (n=121) (p=7.0x10-10,
2.7x10-9 and 5.9x10-7, respectively). For the whole cohort, the PAR for JAK2
46/1 haplotype, JAK2 rs12339666 and TERT rs2736100 were 43.6, 42.1 and
28.5, respectively. In JAK2V617F-negative cases (n=55), only the JAK2 46/1
haplotype remained statistically significant (p=0.044). When stratified by dis-
ease subtypes, the JAK2 46/1 haplotype, JAK2 rs12339666 and TERT
rs2736100 were significantly associated with both polycythemia vera
(p=7.9x10-10, 6.8x10-10 and 6.1x10-4, respectively) and essential thrombo-
cythemia (p=1.5x10-4, 1.8x10-3 and 4.9x10-4, respectively). The JAK2 46/1
haplotype, JAK2 rs12339666 and MECOM rs2201862 were significantly asso-
ciated with primary myelofibrosis (p=0.021, 0.01 and 0.007, respectively).
Summary/Conclusions: In this cohort, germline variations at JAK2 (both the
46/1 haplotype and rs12339666) and TERT rs2736100 were significantly asso-
ciated with MPNs in Taiwanese population.
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MORPHOLOGIC DYSPLASIA IS ASSOCIATED WITH A MORE AGGRESSIVE
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Background: Primary myelofibrosis (PMF), post-essential thrombocytemia-
MF (PET-MF) and post-polycythemia vera-MF (PPV-MF) are Philadelphia-chro-
mosome negative myeloproliferative neoplasms (MPNs). These diseases are
frequently associated with driver mutations within the JAK-STAT signaling cas-
cade. However, additional mutations may be acquired during disease progres-
sion. MDS/MPNs are distinct myeloid diseases with similar genetic and mor-
phologic characteristics of myelodysplasia and MPNs. To better understand
the significance of these mutations, we correlated DNA mutation profiles with
bone marrow (BM) dysplasia and clinical outcomes.
Aims: Evaluate the impact of non-driver mutations and BM dysplasia on clinical
outcomes in patients with PET-MF, PPV-MF, and PMF.
Methods: We identified 19 patients diagnosed with PMF and 18 patients with
PET- or PPV-MF, reviewed their BM biopsies and aspirates, and performed
NGS with a 37 gene myeloid panel. At least 2 hematopathologists, blinded to
original diagnosis and genetic results, classified the BM biopsies according to
WHO guidelines and morphologic dysplasia. A committee of hematologists and
hematopathologists reviewed all data and rendered a consensus diagnosis.
Statistical comparisons between groups relied on the two-sided student’s t-
test; the log-rank test was utilized for survival assessments. This study was
approved by our IRB
Results: The mean age at diagnosis was 57.1 years and NGS occurred at a
median of 2.2 months from diagnosis; the mean length of follow-up is 8.2 years.
Fourteen patients (39%) had an abnormal karyotype. JAK2 mutation V617F
was identified in 25 (68%) patients, CALR or MPL mutations were present in 8
(22%), and 4 had no identifiable driver mutation. Patients had a mean of 2
mutations; TET2, EZH2, IDH1, IDH2, DNMT3A, and ASXL1 represent the most
common mutations. For analysis, patients were divided according to the dynam-
ic international prognostic scoring system plus risk: high (7), int-2 (17), and
low/int-1 risk (13) disease. Those with high-risk disease were significantly more
likely to have BM dysplasia relative to those with low/int-1 disease (77% vs
33%, P:<0.05) and twice as likely to be re-categorized as MDS/MPN overlap
syndrome (67% vs 35% and 23%) during consensus review. These patients
had a trend toward a higher mutational burden (3* vs 2.2 and 1.7* mutations,
*P: 0.09), and were twice as likely to have an unfavorable karyotype (*67% vs
41% and *8%, *P:<0.05). Clinically, these patients experienced a more aggres-
sive disease phenotype with a shortened overall survival (OS) compared to
patients with non-dysplastic MF. Five patients in this analysis had TET2 muta-
tions. TET2 mutated patients were more likely to have BM dysplasia compared
to wild type (WT) (80% vs 50%). These patients were younger at diagnosis
(mean: 49.3 vs 60.4 years, P:<0.05), had a higher number of non-driver muta-
tions (3.8 vs 1.2, P: 0.001), were more likely to have an unfavorable karyotype
(80% vs 42%) and circulating blasts (40% vs 14%). Six year OS was signifi-
cantly shorter in the TET2 mutated group vs WT (P:<0.05).
Figure 1.
Summary/Conclusions: Distinguishing between ‘MF with dysplasia’ and
MDS/MPN is a diagnostic challenge because the significance and natural his-
tory of MPN dysplasia is poorly understood. Our data demonstrate that this
dysplasia is associated with established clinical and genetic markers of aggres-
sive disease, including mutations of TET2. Taken together, this suggests that
MPN with dysplasia represents a MPN with aggressive disease biology and
shortened survival.
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MUTATIONS: AN EXPERIENCE OF A SINGLE CENTER IN CHINA
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Background: Primary myelofibrosis (PMF) is a Philadelphia-chromosome-neg-
ative myeloproliferative neoplasm (MPN) in which JAK2V617F, CALR and
MPLW515 mutations are the most frequent driver mutations. PMF appears to
have different clinical features in different population. For example, Chinese
patients have different clinical and laboratory features compared with PMF in
patients of predominately European descent. These differences may affect
prognostic scoring systems which might require revision based on the popula-
tion being evaluated.
Aims: In current study, we focus on the contribution of driver mutations (JAK2,
MPL and CALR) to survival and propose a clinical-molecular prognostic model
based on the data from a single center in China.
Methods: 402 consecutive subjects with PMF had a bone marrow sample col-
lected at diagnosis or referral, February 1990 to February, 2015 at the Institute
of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sci-
ences were enrolled. Follow-up data were available for 361 subjects. Median
follow-up of survivors was 36 months (range, 1-385) months. Patients were
divided randomly into a study group (n=279) and a test group (n=123). The
impact of JAK2, MPL or CALR mutations on prognosis was analyzed by uni-
variate- and multivariate survival analyses.
Results: JAK2V617F mutations were detected in 189 subjects (47%),
MPLW515 mutations in 13 (3.2%) and CALR mutations in 81 (20.1%). 119 sub-
jects (29.6%) had no detectable mutation in JAK2, MPL or CALR. There were
30 (37%) type-1 and 48 (59.3%) type-2 CALR mutations. In the study group,
patients with CALR type-2 mutations or no detectable mutation had briefer sur-
vival compared to those with JAK2, MPL or CALR type-1 or other less common
CALR mutations (HR 2.99, 95% CI 1.935-4.619, P<0.001). Therefore, patients
were categorized into the high-risk with CALR type-2 mutations or no detectable
driver mutation and the low-risk without aforementioned mutations status. A
multivariate analysis of prognostic factors in the study group identified the fol-
lowing independent factors (P<0.05): Dynamic International Prognostic Scoring
System (DIPSS) risk group, palpable spleen and the status of JAK2, MPL or
CALR mutations. We assigned each factor a weight: (1) 3 for DIPSS high-risk;
(2) 2 for DIPSS intermediate-2 risk; (3) 1 for DIPSS intermediate-1 risk; (4) 0.5
for no splenomegaly, (5) 1 for CALR type-2 mutation or non-mutated JAK2,
MPL and CALR. Subjects were categorized into 4 risk cohorts: (1) low (score
0-1; 39.5% of patients); (2) intermediate-1 (score 1.5-2; 34% of patients); inter-
mediate-2 (score 2.5-3; 19% of patients); and high (score ≥3.5; 7.5% of patients;
Fig. 2A).The revised clinical-molecular prognostic model divided patients into
4 prognostic groups with significantly different outcomes (Figure 1) and had a
significantly higher predictive power for survival than the DIPSS. The model
was validated in the test group.
Figure 1.
Summary/Conclusions: This study indicates that the prognostic system includ-
ing driver mutations (JAK2, MPL and CALR) status could more accurately eval-
uate survival for patients with PMF.
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Background: Patients with Philadelphia (Ph) -negative chronic myeloprolifer-
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ative neoplasms (MPNs) can experience visual symptoms which are caused
by microcirculatory disturbances, but the risk of other ophthalmic manifestations
such as age-related macular degeneration (AMD) is unknown. AMD causes
progressive loss of the central vision and it is the most common cause of blind-
ness in elderly in western countries. Chronic inflammation is involved in the
development and progression of both AMD and MPNs, and similar inflammatory
pathways are dysregulated. Our previous findings suggest that patients with
Ph-negative MPNs have increased prevalence of AMD at time of diagnosis.
The potential link between the diseases is possibly explained by the degree of
systemic inflammation in patients with MPNs, which may predispose some
individuals to develop AMD.
Aims: To determine the risk of AMD in patients with essential thrombocythemia
(ET), polycythemia vera (PV), myelofibrosis (MF) and unclassifiable MPN
(MPN-U) compared to the general population.
Methods: We undertook an observational matched cohort study and included
patients diagnosed with Ph-negative MPNs in Denmark between 1994 and
2013. We included nationwide cohorts of patients with ET, PV, MF and MPN-
U by using population-based registries. To compare the risk of AMD, we iden-
tified 10 individually sex-and-age matched comparisons from the general pop-
ulation for each patient. We excluded patients and comparisons who had a
prior AMD diagnosis or a follow-up time of less than 30 days after the MPN
was diagnosed. Everyone was followed until death, December 31, 2013, or
until they were diagnosed with any AMD diagnosis at a hospital. Cox propor-
tional hazards models were used to estimate the hazard ratio (HR) of AMD in
patients with Ph-negative MPNs (ET, PV, MF, MPN-U) as well as separately
for each MPN subgroup. We adjusted for smoking (proxy measure used by
including smoking related diagnoses from the Danish National Patient Registry)
as smoking is a risk factor for developing AMD. Additionally, we also adjusted
for risk-time (1994-2001, 2002-2006, 2007-2013), since new AMD treatments
were introduced in Danish hospitals in 2002 and 2007. This could imply that
individuals were more likely to be diagnosed with AMD at hospitals after these
treatments had been introduced.
Results: We included 7 958 patients with Ph-negative MPNs and 77 445 sex-
and-age matched comparisons in the study, after 365 patients and 2 619 com-
parisons had been excluded. Of the excluded individuals, 222 patients (1 907
comparisons) had a prior AMD diagnosis and 143 patients (712 comparisons)
had a follow-up time of less than 30 days. In total, we included: ET=2 628;
PV=3 063; MF=547 and MPN-U=1 720 patients. Significant more patients with
ET, PV and MPN-U had smoking-related diagnoses compared to comparisons
(p<0.05), but no difference was seen for patients with MF. Smoking was asso-
ciated with an increased risk of AMD in both patients and comparisons. We
found an increased risk of AMD in patients with Ph-negative MPNs (ET, PV,
MF, MPN-U), adjusted hazard ratio (HR) [95% confidence interval] =1.28 [1.10-
1.48]. Subset analyses of the HR in each MPN subgroup revealed an increased
risk of AMD in each group, but the risk was only significantly increased in
patients with PV. The smoking and risk-time adjusted HR (95% CI) was 1.15
[0.88-1.49] for ET; 1.42 [1.15-1.76] for PV; 1.54 [0.67-3.53] for MF and 1.33
[0.93-1.88] for MPN-U.
Summary/Conclusions: Our study indicates that patients with Ph-negative
MPNs have increased risk of AMD compared to the general population. We
speculate that the increased risk is caused by chronic inflammation, but further
studies are needed to investigate the potential causal relationship.
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Background: Primary myelofibrosis (PMF) and essential thrombocythemia
(ET) share the same mutations in JAK2 and CALR but differ in their clinical
features and outcomes. 
Aims: Here, we assessed the impact of JAK2 and CALR mutations on the
clinical features at diagnosis and on the outcome of patients with PMF or ET
treated with standard of care including the JAK2 inhibitor ruxolitinib.
Methods: We studied the clinical and genetic features of 212 patients (median
age at diagnosis, 60 years [y]; range, 22-93 y) with PMF (n=93), ET (n=84) or
PMF/ET (n=35). Diagnosis was made applying the WHO 2008 criteria, with no
clear assignment to PMF or ET possible for patients with PMF/ET. CALR muta-
tions were primarily assessed in patients without JAK2 V617F. Median follow-
up time was 5.9 y. Associations were assessed using the Mann-Whitney U-
Test for continuous and Fisher’s exact test for categorical variables. Overall
survival (OS) and leukemia-free-survival (LFS) were estimated using the
Kaplan-Meier-method and compared using the log-rank-test.
Results: In the entire cohort of 212 patients, 58.6% carried a JAK2 V617F
and, of the JAK2 V617F negative patients tested for CALR mutations, 38.3%
had a CALR type 1/type 1-like and 25.5% a type 2/type 2-like mutation. Patients
with CALR mutations were of younger age at diagnosis (p=0.003) and of pre-
dominantly male gender in comparison to JAK2 V617F positive patients (58.8%
vs 48.8%). Patients with CALR mutations tended to present more often with
splenomegaly at diagnosis than patients with JAK2 V617F (p=0.19). Consid-
ering ET patients only, patients with JAK2 V617F presented with higher white
blood counts compared to those with CALR mutation (p=0.0006). Among the
PMF patients, those with CALR mutations had higher platelet counts at diag-
nosis than those with JAK2 V617F (p=0.043). Of the 212 patients, 77.4%
received treatment specific for PMF or ET (excluding aspirin); 58% had hydrox-
yurea, 12.8% received an allogeneic blood stem cell transplantation. Regarding
the outcomes, patients with JAK2 V617F had slightly higher rates of throm-
boembolic events compared to those with CALR mutations (35.8% vs 23.5%,
p=0.21). There were significant differences in OS and LFS in the PMF cohort
with patients with CALR mutations having better OS (p=0.047; 10y rates 88.9%
vs 65.1%) and LFS (p=0.049) than patients with JAK2 V617F; the difference
in the OS remained significant among patients aged >60y (p=0.02). Among
the ET patients, we did not observe differences in OS or LFS according to the
JAK2 V617F or CALR mutation status. Importantly, PMF patients with CALR
mutations had a similar risk profile in terms of OS as ET patients (p=0.71),
implicating that CALR mutations attenuate the generally accepted adverse
prognosis associated with the diagnosis of PMF as opposed to that of ET.
Among the 24 PMF patients treated with ruxolitinib, there were no significant
differences in the reduction of spleen size, changes in blood counts or OS
between patients with JAK2 V617F or CALR mutations, suggesting that
response to ruxolitinib is independent of the JAK2 and CALR mutation status.
Summary/Conclusions: JAK2 V617F and CALR mutations are associated
with distinct clinical features in ET and PMF. Patients with PMF and CALR
mutation have an OS better than that of PMF patients with JAK2 V617F and
similar to that of patients with ET. The treatment response to ruxolitinib is similar
among PMF patients with JAK2 V617F or CALR mutations, which refers to the
role of JAK-STAT signaling in both mutation types.
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Background: The JAK2V617F mutation is found in about 50 to 60% of cases
of essential thrombocythemia (ET) while 5% to 10% of JAK2V16F negative ET
patients carry MPL mutations at codon 515. Recently, mutations at exon 9 of
CALR, were identified in 50% to 70% of ET patients with nonmutated JAK2
and MPL (double-negative).
Aims: To analyze the prevalence of JAK2V617, CALR and MPL mutations in
a population of patients with WHO-defined ET and their association with clinical
and laboratory features.
Methods: We retrospectively analyzed a cohort of ET patients in a single cen-
ter, between 2010 and 2014. The JAK2V616F mutation was detected by allele-
specific polymerase chain reaction (PCR) testing. For the detection of MPL
exon 10 and CALR exon 9 mutations, we applied PCR amplification and Sanger
sequencing.
Results: Of the 172 patients studied, 111 (64.5%) carried JAK2V617F mutation
(JAK2+), 35 (20.3%) CALR mutation (CALR+), 6 (3.5%) MPLW515K/L mutation
(MPL+) and 20 (11.6%) patients had nonmutated JAK2, MPL and CALR (triple-
negative). These mutations were mutually exclusive and therefore, CALR-pos-
itive cases represented 63.5% of double-negative ET cases. Within the 35
CALR+ patients, 21 (60%) carried the type 1 mutation, 10 (28.6%) the type 2
mutation and 4 (11.4%) carried other less frequent indels. Compared to JAK2+
patients, CALR+ patients had a younger age at diagnosis (<60 years) (57.1%
vs 31.5%; p=0.006) and a higher platelet count (≥900x10^9/L) (51.4% vs
26.1%; p=0.005). On the other hand, the JAK2+ patients presented a higher
hemoglobin level (≥15g/dL) compared to CALR+ patients (45.9% vs 20%; p=
0.006). No differences were found between type 1 and type 2 CALR+ sub-
groups. The distribution according to thrombotic risk classification was statis-
tically different (p=0.003) among the two groups: the percentage of low/inter-
mediate risk patients was 48.6% (n=17/35) in the CALR+ group vs 22.5%
(n=25/111) in the JAK2+ group. The distribution of International Prognostic
Score for Essential Thrombocythemia (IPSET) categories was also statistically
different (p=0.002) among the three groups analyzed: the percentage of high
risk patients was 38.7% (n=43/111) in the JAK2+ group, 20% (n=7/35) in the
CALR+ group and 10% (n=2/20) in the triple-negative group. The IPSET-throm-
bosis model also stratified patients with significant difference (p<0.001) among
the three groups: the percentage of high risk patients was 82.9% (n=92/111)
in the JAK2+ group, 17.1% (n=6/35) in the CALR+ group and 5% (n=1/20) in
the triple-negative group. When comparing the two groups, CALR+ patients
belonged more frequently to the low-risk group than those with JAK2+ (48.5%
vs 5.4%; p<0.001). The incidence of thrombotic events was 25% (n=43/172)
and most occurred prior to the diagnosis of ET (74.4%; n=32/43). The group
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of triple-negative patients had the lower incidence of thrombotic events (5%)
vs the CALR+ group (17.1%) and vs the JAK2+ group with the highest incidence
of thrombotic events (32.4%) (p=0.015). Transformation to post-ET myelofibro-
sis occurred in 7 patients (3 CALR+, 2 triple-negative, 1 MPL+ and 1 JAK2+;
p=0.093). The median overall survival (OS) was not reached in any group and
no differences were identified in OS by univariate analysis according to muta-
tional status (CALR+ vs JAK2+ vs MPL+ vs triple-negative; p=0.3).
Summary/Conclusions: Our study confirms that CALR-mutated ET is pheno-
typically and biological distinct from JAK2-mutated ET with regard to clinical
presentation and thrombotic risk.
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WITH DIFFERENT COAGULATION FACTOR POLYMORPHISMS
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Background: The group of myeloproliferative neoplasms (MPNs) are known
for their different phenotypes but similar vascular events complications. Blood
cells, interaction between them, and the activation of coagulation factors play
a role in the pathogenesis of thrombosis in MPNs. Platelet-specific polymor-
phisms, FVII as well as β-fibrinogen single nucleotide polymorphisms (SNP’s)
have been never analyzed together in patients with MPNs.
Aims: To evaluate the effects of coagulation factor VII, β-fibrinogen and TT
genotype of GP c.807C>T single nucleotide polymorphisms, and the risk of
thrombosis in patients with PV, ET, and PMF at the Department of Oncology
and Hematology of the Institute of Oncology, the Lithuanian University of Health
Sciences.
Methods: We included 108 patients in this survey. Findings of clinical and
hematological analyses were collected. Genotyping was done using PCR and
PCR-RFLP analysis
Results: TT genotype of GP c.807C>T polymorphism was more frequently found
in the group of MPN patients with arterial thrombosis compared to the MPN
patients who were thrombosis-free (26.5% vs 11.5%, p=0.049). CT genotype of
β-fibrinogen c.-148C>T polymorphism occurred significantly more frequently in
MPN patients with arterial and total thrombosis compared to the wild type or
homozygous genotype (respectively, 57.7% vs 40.0 vs 12.5%; p=0.027), (64.7%
vs 44.4% vs 25% p=0.032). The carrier state for 323P10 variant of FVII SNP
(summation of P10/10 and P0/10) was significantly more frequent in MPN patients
with total thrombosis compared to the wild-type genotype carriers (71.4% vs
43.4%, p=0.049). The coexistence of both genotypes - heterozygous β-fibrinogen
c.-148C>T and FVII -323P0/10 SNP - statistically significantly increased the odds
of arterial thrombosis in MNP patients (21.1% vs 3.7%, p=0.008).
Summary/Conclusions: We found that 323P10 variant of FVII, TT genotype
of GP c.807C>T and CT genotype of β-fibrinogen c.-148C>T SNP polymor-
phism may be associated with risk of thrombosis in patients with MPNs.
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A PHASE 1 OPEN LABEL STUDY TO DETERMINE THE PHARMACOKINETICS
OF PACRITINIB IN PATIENTS WITH MILD TO SEVERE RENAL IMPAIRMENT
AND END STAGE RENAL DISEASE (ESRD) COMPARED WITH HEALTHY
SUBJECTS
S Al-Fayoumi*, S Amberg, H Zhou, L Millard, JW Singer, M Campbell
CTI BioPharma Corp., Seattle, United States
Background: Treatment and management of patients with hematologic malig-
nancies and co-morbid renal impairment (RI) is challenging as the kidneys are
a major route of excretion for many therapeutic agents. The conduct of a RI
study is an important regulatory requirement to support appropriate dosage rec-
ommendation in patients with RI. Patients with myelofibrosis (MF) and moderate
to severe RI treated with the JAK1/JAK2 inhibitor ruxolitinib require dosage
reductions. Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3,
IRAK1, and CSF1R being evaluated for patients with primary or secondary MF.
Aims: Evaluate the pharmacokinetics (PK) and safety of pacritinib and its major
metabolite in patients with RI (mild, moderate, severe, and ESRD requiring
hemodialysis) compared with healthy age-, sex-, and weight-matched control
participants.
Methods: Study participants (N=39) who provided written informed consent
included healthy volunteers and subjects with RI (mild, moderate, severe based
on estimated glomerular filtration rate and ESRD on hemodialysis). All partici-
pants except those with ESRD received a single dose of pacritinib 400 mg,
with PK and urine assessments conducted for up to 168 h post-dose. Subjects
with ESRD received 1 dose of pacritinib 400 mg in each of 2 periods (dialysis
and inter-dialysis) separated by a 14-day washout. Pacritinib was administered
immediately before and after hemodialysis in the dialysis and inter-dialysis peri-
ods, respectively, followed by PK assessments for 72 h post-dose.
Results: Time to maximum plasma concentration (tmax) was reached at 8, 6,
and 5.5 h post-dose in patients with mild, moderate, and severe RI, respectively;
tmax was 7 h in patients with ESRD. In healthy controls, tmax was 8 h post-
dose. Pacritinib plasma concentrations demonstrated comparable elimination
phases across RI groups. Excretion of pacritinib in urine was minimal (1.0-
1.4% of dose over 72 h interval) and RI did not decrease urinary excretion. PK
analysis revealed slightly higher maximum plasma concentration (Cmax) and
total exposure (area under the plasma concentration-time curve [AUC]) in
patients with RI vs healthy controls, which are unlikely to be of clinical relevance
(Table). Cmax and AUC were similar for patients with ESRD during dialysis and
inter-dialysis periods. Apparent total clearance (CL/F) was comparable across
RI groups. All adverse events (AEs) were grade 1-2; diarrhea was the most
frequent AE.
Table 1.
Summary/Conclusions: PK parameters and renal excretion of pacritinib were
not significantly affected by RI. Administration of 400 mg single doses of pacri-
tinib to patients with RI was well tolerated. Dosage adjustment for pacritinib is
not warranted in patients with RI.
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rence, Italy, 3Johannes Wesling Academic Medical Center, University of Han-
nover Teaching Hospital, Minden, Germany, 4St. István and St. László Hospital,
Semmelweis University, Budapest, Hungary, 5Royal Brisbane Hospital, Herston,
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Background: Polycythemia vera (PV) is characterized by excessive prolifera-
tion of erythroid, myeloid, and megakaryocytic components in the bone resulting
in an increased risk of thromboembolic events, cardiovascular complications,
and disease progression. Both hydroxyurea (HU) and interferon-alpha (IFN)
are used as first-line treatment for high-risk pts with PV but pts may become
resistant/intolerant (Barbui. JCO 2011; 29(6):761-770). The recent phase 3
RESPONSE study showed that ruxolitinib (RUX) was superior to best available
therapy (BAT) following HU resistance/intolerance; however, little information
has been presented on the sub-group of pts treated with IFN in BAT arm. 
Aims: This subgroup analysis of RESPONSE study evaluates the safety and
efficacy of pts treated with IFN in the randomized BAT arm before and after
crossover to RUX.
Methods: RESPONSE, an open-label, phase 3 study enrolled pts with PV,
who were resistant to or intolerant of HU per modified European LeukemiaNet
criteria, had splenomegaly and required phlebotomy (PBT) to control hematocrit
(HCT). Pts were randomized 1:1 to RUX (110 pts) 10 mg bid or BAT (112 pts),
of which 13 pts received at least one dose of IFN during the randomized treat-
ment phase. Pts were evaluated for HCT control (<45%) without PBT; spleen
response (≥35% reduction in spleen volume from baseline by magnetic reso-
nance imaging); and complete hematologic response [CHR: HCT<45%, white
blood cell (WBC) ≤10×109/L, platelet (PLT) count ≤400x109/L]. JAK2V617F
allele burden, adverse events (AEs) and hematologic abnormalities were
assessed for randomized and crossover treatment. 
Results: Baseline demographics were comparable among RUX (N=110) and
IFN-treated pts of the BAT arm (N=13). Three pts (23%) received IFN at some
time prior to inclusion in the RESPONSE trial. On trial, 9 pts were treated with
PEG-IFN and 4 pts were treated with non-PEG-IFN at varying doses. All IFN
pts discontinued and crossed over to RUX due to lack of efficacy (11 pts crossed
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over prior to wk 48 and 2 pts after wk 48). No pt treated with IFN achieved
spleen response and only 23% of pts achieved HCT control without PBT from
wk 8 to 32 (40% and 60% while on RUX therapy, respectively). Thirty-eight
percent, 31%, and 31% of pts required no PBT, 1 PBT, and ≥2 PBT, respectively,
from wk 8 to 32 of randomized treatment and only 15% of pts achieved CHR
at wk 32. Following crossover to RUX, 62% of pts achieved spleen response
and PBT requirements decreased (64% of pts did not require any PBT and no
pt required ≥2 PBT from wk 32 to 80 after switching to RUX). A majority of pts
randomized to IFN had modest reductions in WBC, PLTs, and JAK2V617F
allele burden over the course of treatment (figure), with most pts showing
further reduction after crossover to RUX. The rates and incidence of hemato-
logic abnormalities (WBC, PLT, and neutrophils) reduced after crossover to
RUX with the exception of hemoglobin (prior to crossover: grade 1 [N=2] and
grade 2 [N=1]; after crossover: grade 1 [N=5] and grade 2 [N=2]). Similarly,
rates and incidence of nonhematologic AEs (systemic, metabolic, gout, pruritus,
and fatigue) reduced after crossover to RUX with the exception of infections
(primarily grade 1 or 2). Four pts discontinued crossover treatment due to AE
(N=3) or pt decision (N=1). One death due to CNS hemorrhage occurred after
crossover to RUX (not related to study drug).
Figure 1. Spaghetti plot of hematocrit (A), WBC (B), platelet counts (C)
and JAK2V617F allele burden (D) over time in interferon patients.
Summary/Conclusions: In the HU-resistant/intolerant PV population of the
RESPONSE study, no pt treated with IFN achieved spleen response and a
limited number of pts achieved HCT control. However, following crossover to
RUX, pts showed improvement in hematologic and spleen response with an
overall reduction in PBT procedures and a majority of pts being able to achieve
spleen response.
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FOR FDA QUALIFICATION: COMPREHENSIVE LITERATURE SEARCH
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Background: Myelofibrosis (MF) is recognized for its debilitating constitutional
symptoms, splenomegaly, profound cytopenias and inflammatory state. Current
MPN PROs (MF-SAF, MPN-SAF and MPN-10) have proven sensitive for symp-
tom detection. Formal FDA qualification requires that these tools integrate a
comprehensive literature search of previously reported symptoms as well as
complete physician cognitive debriefing. 
Aims: In this investigation, we aimed to complete these required steps to ascer-
tain the most prevalent and pertinent MPN symptoms for PRO inclusion.
Methods: Literature Search: An initial review of the published literature was
performed using OVID Medline®. The Medical Subject Headings (MeSH) terms
included ‘primary myelofibrosis’ or ‘MF’, ‘Myeloid metaplasia’ and ‘agnogenic
myeloid metaplasia’ which were meshed with ‘symptom’ or ‘signs and symp-
toms’ and limited from 1980 to 2011. Articles that were not original research or
in the English language were excluded. Articles were then individually reviewed
for content with further exclusion of case reports where search terms occurred
concurrently with other medical conditions, articles presenting in-vitro data and
articles with a primary focus on pharmacotherapy that utilized the MPN-SAF,
MPN-SAF TSS or MF-SAF. Articles were then evaluated for all symptoms and
recorded by the number of publications they were reported in. Cognitive
Debriefing: International MPN specialists were contacted via email to complete
the Physician Cognitive Debriefing Evaluation via a REDCAP® survey. Implied
consent was provided through survey completion and demographic data was
recorded. Responders were asked a series of questions on each symptom
acquired through the literature search, along with three free-standing questions
on MF PRO development. Thirteen responders were also contacted to com-
plete an in-person interview and respond to eight questions on MF-PRO devel-
opment. Descriptive statistics were used for data analysis.
Results: The OVID Medline search yielded 166 articles for MF which were
then individually reviewed. A total of 30 symptoms were extracted from the lit-
erature and recorded for incorporation into the REDCAP survey. The survey
was distributed to 48 MPN specialists and 17 (35.4%) agreed to participate.
Most responders were Caucasian (94.1%) and male (76.5%) with >5 years
experience (94.1%) as physicians. Providers saw between 1-5 (58.8%), 6-10
(23.5%) or >10 (11.8) MF patients per week and most held primary practices
in Europe (70.6%). Survey responses to symptom questions are provided in
Figure 1. During in-person interviews, some providers felt that a different list of
symptoms should be provided to patients with: early vs late MF (61.5%), pri-
mary vs secondary MF (7.7%) and clinical trial settings vs office environments
(23.1%). Most providers felt that ‘inactivity’ (100%), ‘fever’ (92.3%) and ‘weight
loss’ (92.3%) were signs as opposed to symptoms of the disease, though
should still be included in the PRO (92.3% for each). Most providers believed
that the ideal survey length should be between 10-20 questions. Two providers
believed that ‘health economics’ and ‘activities of daily living’ should be inte-
grated into a final PRO.
Figure 1.
Summary/Conclusions: Results of the literature search and Physician Cog-
nitive Debriefing support that the MPN-SAF currently addresses the most fre-
quent and symptomatic MF symptoms, with the exception of four items (dysp-
nea, easy bruising, arthralgias, nausea). Addition Patient Cognitive Debriefing
is required to ensure that the final PRO is comprehensive of the most important
symptoms to patients.
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Background: Polycythemia vera (PV) and essential thrombocythemia (ET)
are two chronic hematological malignancies with no curative project. Interna-
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tional consensus recommends combining long-term low dose antiplatelet drug
and a cytoreductive therapy to reduce hyperviscosity (thrombosis) and pheno-
typic evolutions (myelofibrosis and acute leukemia). There is actually no study
in the literature which evaluates the level of adherence in this population.
Aims: The aim of our study was to evaluate patient adherence rate to physicians
prescriptions, explore the reasons and identify the occurrence of side effects.
Methods: A total of 134 patients treated for PV or ET with a median follow-up
of 6.8 years were asked for about their adherence using a one-shot question-
naire designed by investigators. Data on complications (thrombosis and indus-
trial) were collected from diagnosis to the time of consultation. All the patients
signed inform consent before completing the form.
Results: Twenty-eight percent (37 patients) of the patients reported non-adher-
ence to their cytoreductive drug. Patients who forgot their anti-platelet or anti-
coagulant drugs (22 patients=X%) are mostly those who belong to the first non-
adherent group (15/22; p<0.0001). In total, 44 patients (32.8%) were declared
as non-adherent. A typical profile of these patients could be described: patient
who lives alone (p=0.007), rather young (p=0.06) and male (p=0.09). The main
cause of non-compliance was oblivion (23/37, 69.7%). Polymedicated patients
were significantly more adherent (p=0.001). Thrombotic history were recorded
in 21.7% of patients (21/97) members against 24.3% of non-adherent patients
(9/37) (p=0.74). On the other hand, myelofibrotic evolutions were more seen in
adherent group (14.4% vs 5.4%, p=0.233). Side effects related to anti-prolifer-
ative treatments were reported by 101 patients (75.4%), and were most fre-
quently cutaneous (53/101, 52.5%) or mucosal toxicity (16/101, 15.8%) likely
due to the high prevalence of hydroxycarbamide (94/134, 70%).
Summary/Conclusions: For patients treated for PV or ET, non-adherence to
anti-proliferative treatment and anti-agregant therapy seems to be frequent.
We did not found any correlation with history of thrombosis and myelofibrotic
evolution. The patients will be followed for five years to assume the occurrence
of new events instead to correlate them with adherence in a prospective way.
An analysis of data on a total population of 286 patients will be presented at
the conference.
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MYELOFIBROSIS (MF): A REAL LIFE EXPERIENCE ON 31 UNSELECTED
PATIENTS
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Background: Anemia in MF is common but few therapeutic options are avail-
able. ESA are safe and widely used but the experience in MF is limited and
only a few reports are available.
Aims: We evaluated the safety and efficacy of ESA in MF in a real life context.
Methods: We retrospectively analyzed all the MF patients treated with ESA in
our institutions. ESA was started in transfusion-dependent patients or if hemo-
globin (Hb) was <10g/dL. According to IWG-MRT and ELN 2013 revised
response criteria, anemia response (AR) was defined as a 2 g/dL increase in
Hb level for transfusion-independent patients or becoming transfusion-indepen-
dent for transfusion-dependent patients. The possibility of pretreatment variables
to predict a AR to ESA was analyzed using Chi-squared test and Student’s t-
test. The duration of response was estimated using the Kaplan-Meier method.
Results: Thirty-one MF patients were treated for anemia with ESA (median
age at diagnosis 68 years, range 38-85). MF was primary in 42% of the patients
while 26% and 32% of the cases were secondary to polycythemia vera or
essential thrombocythemia, respectively. JAK2 mutation was detected in 62%
of the patients. Seven patients were transfusion-dependent while in the other
group median Hb value was 9.1 g/dL (range 7.9-9.9) at the beginning of ESA
treatment. Median time from MF diagnosis to ESA start was 3 months (range
0-89). Fourteen patients received epoetin-alpha (originator product) while 11
cases were treated with epoetin-zeta and 5 with other biosimilar ESA. Median
ESA starting dose was 40000 U/weekly (range 8000-40000). One patient
received low-dose darbopetin-alpha. Median follow up of living patients after
ESA start was 27 months (range 3-80). Globally the AR rate was 52%. Most
response occurred in the first 3 months, with a median time to AR of 2 months
(range 1-7). Nine patients not responsive to standard-dose ESA increased dose
to 80000 U/weekly and 2 of them responded. Two of the 5 patients treated with
low-dose ESA (i.e.<20000 U/weekly) responded. Median duration of response
was 29 months and the probability of maintaining AR at 12 months was 75%.
The elapsed time from MF diagnosis to ESA treatment start was predictive of
response to ESA: AR rate among patients who started ESA within 3 months
from MF diagnosis was 87% vs 14% in the others, p<0.01. Transfusion-depen-
dent patients showed a trend towards a reduced probability of AR (29% vs
67%, p=0.08). No other predictive factors of response could be found. Among
patients with an available baseline serum erythropoietin level (13/31), only 3
showed a value above 125U/L and 1 of them achieved AR after ESA dose
increase. Considering the most frequently used types of ESA in our patients,
both originator epoetin-alpha and epoetin-zeta obtained favorable results (43%
vs 70%, p>0.1).The treatment was well tolerated and no significant adverse
events related to ESA were reported. In 5 patients an increase in splenomegaly
was recorded during ESA therapy.
Summary/Conclusions: Our report confirms the safety and efficacy of ESA
for anemia in MF with a fair response duration and it suggests that an early ini-
tiation of ESA treatment could yield better results. Besides, we confirm the neg-
ative predictive value of transfusion dependence. Epoetin-zeta achieved result
at least equal to originator epoetin-alpha, an observation that need to be con-
firmed but could be important when treatment costs are taken into account.
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A RETROSPECTIVE COHORT STUDY REPORTING ON THE DISEASE
CHARACTERISTICS AND OUTCOMES OF PATIENTS DIAGNOSED UNDER
THE AGE OF 50 YEARS WITH PRIMARY OR SECONDARY MYELOFIBROSIS
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Haematology, Guy’s and St Thomas’ Foundation Trust, London, United Kingdom
Background: Myelofibrosis (MF), a rare clonal haematopoietic disorder is com-
monly diagnosed in the 6th or 7th decade of life. The clinical and molecular
profile of younger patients remains poorly defined.
Aims: In this retrospective study we evaluated patients who were ≤50 years of
age at diagnosis with WHO-defined primary MF (PMF), post-essential throm-
bocythaemia MF (PET-MF) or post-polycythaemia vera MF (PPV-MF) managed
at our centre.
Methods: Forty three patients with a median age of 43 years (range 19-50
years) at diagnosis were included; 24/43 (55.8%) were male. Median follow-up
was 44 months (range 0-208 months). Twenty (47%) had a diagnosis of PMF,
14/43 (33%) PET-MF and 9/43 (21%) PPV-MF.
Results: Concerning mutations 22/43 (51%) had JAK2V617F, 18/43 (42%)
CALR, 0/43 (0%) MPL mutations and 3/43 (7%) were ‘triple negative’ (TN). The
IPSS and DIPSS scores were low risk in 26/39 (67%) and 26/39 (67%), inter-
mediate-1 in 8/39 (21%) and 11/39 (28%), intermediate-2 in 3/39 (8%) and 2/39
(5%) and high risk in 2/39 (5%) and 7/39 (18%), respectively. Univariate analysis
did not demonstrate any significant impact of mutational status upon haemo-
globin, leukocytes, platelet count, circulating blasts, red blood cell transfusion
need, splenomegaly or constitutional symptoms at diagnosis. Additionally, we
did not observe any influence of driver mutation on age at diagnosis, gender,
IPSS or DIPSS scores. Comparing JAK2V617F and CALR mutated subjects,
there was a significant increase in the presence of palpable splenomegaly in
the JAK2V617F mutated patients (p<0.05). TN patients were more like to have
a platelet count<100x109/L (p=0.073), adverse karyotype (p=0.06), a high
DIPSS-plus score (p=0.076), and the only transformation to acute myeloid
leukaemia (AML) occurred in a TN patient. Two thrombotic events occurred: a
deep vein thrombosis in a JAK2V617F mutated patient, and a myocardial infarc-
tion in CALR mutated patient, giving an overall calculated incidence rate of 1%
patient-year. No major bleeding events were identified. Only one patient pro-
gressed to AML with an overall calculated incidence rate of 0.5% patient-year.
No deaths were recorded during the follow-up period.
Summary/Conclusions: The distribution of driver mutations in our cohort of
patients with MF diagnosed age less than 50 years differs from that of the
overall MF patient population; we report that 51% of patients had JAK2V617F
mutation vs 58-64.7% for the broader patient population, 42% CALR mutated
vs 22.7-25%, 0% MPL mutated vs 4-8.3% (1,2). The frequency of TN patients
mirrors that of the wider MF population, 7% in our cohort vs 8.6-8.7% in the lit-
erature (1,2). Although we were not able to demonstrate any significant impact
of driver mutation status on age, gender or laboratory parameters, we recorded
a higher incidence of splenomegaly in JAK2V617F mutated patients compared
to CALR mutated patients, (P=0.047). We found that TN status appeared to be
associated with higher risk profile and transformation to AML.
Our findings suggest that younger MF subjects may have a higher frequency
of CALR mutations and a more indolent disease course i.e. low IPSS and
DIPPS score, lower incidences of thromboembolic events and with less evi-
dence of negative prognostic variables and disease progression compared to
the general MF population.
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Background: The diagnosis of polycythemia vera (PV) is based on clinical
and biological criteria defined by the World Health Organization (WHO 2008).
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The proposed revised version (WHO 2016) has lowered the threshold hemo-
globin (Hb) level for the diagnosis of PV from 18.5 g/dl in men and 16.5 g/dl in
women to an hemoglobin level of 16.5 g/dl in men and 16 g/dl for women. The
importance to lower hemoglobin threshold in the evaluation of patients with
absolute erythrocytosis has not been validated yet.
Aims: To evaluate the importance of the new hemoglobin threshold we retro-
spectively assessed the frequency of polycythemia vera versus secondary ery-
throcytosis in patients with absolute erythrocytosis categorized according to
hemoglobin value at diagnosis.
Methods: We included in the current study all patients recorded in our database
with a diagnosis of polycythemia vera or secondary erythrocytosis who showed
isolated absolute erythrocytosis at diagnosis according to the new proposed
WHO criteria (Hb >16.5g/dl in men and >16g/dl in women, leukocyte count
<10x109/L, platelet count <450x109/L). We stratified these patients according
to their hemoglobin level at diagnosis (<17g/dl, 17-19g/dl, 19-21g/dl, 21-23g/dl,
>/=23g/dl) and calculated the percentage of PV cases in each subgroup. Only
patients assessed for both V617F and exon 12 JAK2 mutations were included
in the study.
Results: Patients who satisfied the above criteria were 236 patients, including
82 PV and 154 secondary erythrocytosis. Diagnosis of PV was made according
to WHO 2008 criteria (Hb >16,5g/dl (female) or 18,5g/dl (male) or >15g/dl
(female) or 17g/dl with a sustained increase of >2g/dl from baseline, JAK2
V617F or exon 12 mutation, low erythropoietin level and/or panmyelosis at
bone marrow analysis). As shown in table 1, around one third of patients strat-
ified in the subgroup with the lowest hemoglobin (Hb below 17 g/dl) had a final
diagnosis of PV, thus reinforcing the importance to perform JAK2 analysis also
in patients with moderate erythrocytosis. This was particularly important in
female patients. Namely, when we repeated the same stratification taking into
account sex distribution, we observed that half (52.6%) of female patients with
Hb level <17g/dl received a final diagnosis of PV. According to our data set,
instead, no male patient with Hb lower than 17 g/dl was diagnosed with poly-
cythemia vera. Patients who satisfied the above criteria were 236 patients,
including 82 PV and 154 secondary erythrocytosis. Diagnosis of PV was made
according to WHO 2008 criteria (Hb >16,5g/dl (female) or 18,5g/dl (male) or
>15g/dl (female) or 17g/dl with a sustained increase of >2g/dl from baseline,
JAK2 V617F or exon 12 mutation, low erythropoietin level and/or panmyelosis
at bone marrow analysis). As shown in table 1, around one third of patients
stratified in the subgroup with the lowest hemoglobin (Hb below 17g/dl) had a
final diagnosis of PV, thus reinforcing the importance to perform JAK2 analysis
also in patients with moderate erythrocytosis. This was particularly important
in female patients. Namely, when we repeated the same stratification taking
into account sex distribution, we observed that half (52.6%) of female patients
with Hb level <17g/dl received a final diagnosis of PV. According to our data
set, instead, no male patient with Hb lower than 17g/dl was diagnosed with
polycythemia vera.
Table 1.
Summary/Conclusions: In patients with isolate erythrocytosis it is important
to perform screening for JAK2 mutations also when hemoglobin level is slightly
increased (>16,5 in men and >16 in women) as a significative proportion of
patients with polycythemia vera show at diagnosis only mild erythrocytosis.
This result reinforces the importance to lower the hemoglobin threshold
required for PV diagnosis as proposed by the new WHO criteria, especially as




PROGNOSIS FACTORS CONDITIONING THE RISK OF MIELOFIBROTIC
TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA: SIGNIFICANCE
OF ALLELIC BURDEN AND THE NUMBER OF LEUCOCYTES AT DIAGNOSIS
IN YOUNG PATIENTS
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Background: Even though there are predictive prognostic scores of thrombotic
risk in patients with Essential Thrombocythemia (ET), there is no agreement
established on the factors influencing the evolution of myelofibrosis in these
patients, this is a factor that adversely affects their life expectancy, which is ini-
tially similar to that of the healthy population of the same age. 
Aims: To analyse in a group of patients with ET the impact of parameters such
as age, platelet count at diagnosis, number of leucocytes, time until cytore-
ductive therapy was needed, time under observation, presence of JAK2 V617F
mutation and allelic burden on the risk of myelofibrotic transformation.
Methods: We analysed a total of 100 patients diagnosed in our centre between
1996 and 2013 based on bone marrow study. All patients received anti- platelet
agregation and began cytoreductive therapy with hydroxyurea and / or ana-
grelide according to IPSET criteria. JAK2 V617F mutation was detected by
allele - specific real- time quantitative in peripheral blood samples. Homozygous
patients for the mutation occurred when the load allelic was >50%, being the
rest considered heterozygous. Statistical analysis was performed using SPSS
version 15.0 software, considering a statistical significant difference if p<0.05.
Results: Average age of the study population was 63 years. 73% of patients
had JAK2 V617F mutation, being homozygous for the same 7% of patients.
11% of patients progressed to myelofibrosis, with a median follow-up of 5 years
from diagnosis to transformation. The transformed and untransformed groups
were similar in platelet count at diagnosis, time under observation, time to need
for cytoreductive treatment and presence of the mutation JAK2 V617F, although
there is a tendency to older (74 vs 63) and more number of leukocytes
(15,1x10e9 /L vs 9,6x10e9 /L) in the transformed versus non-transformed
group. Patients with JAK2 V617F mutation and allelic burden above 40% had
a higher risk of myelofibrotic transformation in the multivariate analysis, with
an accumulated incidence at 5 years of 57.1% (Figure 1), p=0.04.
Figure 1. Probability of evolution to positive JAK2 myelofibrosis.
Summary/Conclusions: Patients with ET and JAK2 V617F mutation have an
increased risk of myelofibrotic transformation when allelic burden is above
40%, which is why specific therapeutic strategies will be needed aimed at
reducing allelic burden to maintain an adequate life expectancy in young
patients with this condition. Leucocytes cell count at diagnosis would be a vari-
ant to be considered in the prognostic stratification, although specific studies
are required to examine this in more detail.
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ACTIVATED STAT5 DRIVES PERIPHERAL T CELL LYMPHOMAS
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Background: STAT5 transcription factors are essential regulators of differen-
tiation, survival and proliferation during hematopoiesis. Hyperactive STAT5 sig-
naling requires enhanced tyrosine phosphorylation (pYSTAT5), which is fre-
quently found in hematopoietic cancers and is associated with negative prog-
nosis. Importantly, recurrent gain-of-function STAT5 variants have been report-
ed in Peripheral T Cell Lymphoma (PTCL) patients, who suffer from aggressive
diseases with no targeted therapy options.
Aims: We aim to analyze STAT5-dosage dependent effects on hematopoiesis.
Here, we investigated whether constitutive activation of STAT5 suffices to drive
PTCL and whether inhibition of the JAK/STAT pathway offers a novel thera-
peutic opportunity in this disease.
Methods: We used cS5F, a hyperactive point mutant of STAT5A (S710F), to
generate mouse models expressing the transgene under the vav-promoter at
low (vcS5lo) or high (vcS5hi) levels from hematopoietic stem cells (HSC) on.
The phenotypes were characterized by regular blood sampling, flow cytometric
analysis of hematopoietic cells and HE, anti-CD3e and -Ki67 stainings on organ
sections. RNA-seq and gene-set enrichment analysis was done to confirm the
PTCL-like disease of vcS5hi mice. We quantified STAT5 expression levels in
PTCL patient tissues by immunohistochemistry and qPCR. Effects on viability
and pYSTAT5 levels of murine and human PTCL cell lines after JAK-STAT5
signalling inhibitor treatment were determined.
Results: High pYSTAT5 levels in vcS5hi mice led to an aggressive expansion
of CD8+ T cells being lethal between 25 and 45 weeks of age. In contrast, vcS5lo
mice developed only a mild expansion of CD8+ T cells with no effect on life
expectancy. The vcS5hi PTCL-like disease was associated with lymphadenopa-
thy, splenomegaly and T cell infiltrations into various organs. The CD8+ T cells
were transplantable and expressed T cell activation markers. Furthermore, the
number of active cycling HSCs increased. The expression profile determined
by RNA-seq correlated closely with human PTCL forms. STAT5 expression and
activation levels were found to be elevated in PTCL patients. Treatment with
Ruxolitinib, Tofacitinib and a novel STAT5 SH2-domain inhibitor decreased
murine and human PTCL cell line viability in response to pYSTAT5 decline.
Summary/Conclusions: Our results obtained from mouse models and patients
support the concept that enhanced STAT5 signaling drives PTCL and that
STAT5 represents a target in these life-threatening malignancies.
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MECHANISM, CONSEQUENCES AND THERAPEUTIC TARGETING OF
ABNORMAL IL-15 SIGNALING IN CUTANEOUS T-CELL LYMPHOMA
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Background: Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin’s
lymphoma of skin-homing T-cells. It represents about 70-80% of all cutaneous
lymphoma with unknown pathogenic mechanisms and no cures. There is good
evidence to support a divisive role of interleukin-15 (IL-15) in controlling onco-
genic processes in CTCL, since it serves to increase T-cell survival, proliferation,
migration and invasion in CTCL cell lines. 
Aims: While the malignant CD4+ T-cells from CTCL patients appear to produce
and be activated by IL-15, the role of this cytokine in the pathogenesis of CTCL
remains unresolved. With the intent of gaining insight into mechanisms of IL-
15 overexpression and its role in CTCL pathogenesis, we first confirmed the
relevance of IL-15 by showing stage-dependent overexpression in lesional skin
and peripheral blood CD4+ T-cells from CTCL patients. We elucidated at least
one mechanism by which IL-15 can be overexpressed in vivo, and then inves-
tigated the biological and clinical aspects of a spontaneous epidermotropic
CTCL that develops in mice that constitutively overexpressing IL-15. 
Methods: We explored shared molecular aberrations between the CTCL in IL-15
transgenic mice and human CTCL, which could be replicated in normal human T-
cells exposed to IL-15. We also interrogated the IL-15 animal model with the pur-
pose of identifying mechanisms and pathways amenable to selective pharmaco-
logical targeting for preclinical validation using isotype specific HDAC inhibitor.
Results: Here we report that CTCL patients show increased IL-15 in a clinical
stage-dependent manner. Mechanistically, we show that Zeb1 is a transcrip-
tional repressor of IL-15 in T-cells and that hypermethylation of the Zeb1 binding
region within the IL-15 promoter, as seen in CTCL patients, prevents Zeb1
binding and causes increased transcription of IL-15. Using a transgenic mouse
model of IL-15, we provide evidence that overexpression of IL-15 induces a
spontaneous CTCL that mimics the human neoplasm. Excessive autocrine pro-
duction of IL-15 in T-cells inhibits an HDAC1-mediated negative autoregulatory
loop, resulting in the upregulation of HDAC1 and HDAC6, and transcriptional
induction of the onco-miR-21. Interruption of IL-15 downstream signaling with
isotype-specific HDAC inhibitors halts (HDAC1) or significantly delays (HDAC6)
the progression of CTCL in vivo and provides pre-clinical evidence supporting
a hierarchical model of oncogenic signaling in CTCL. 
Summary/Conclusions: In summary, we provide in vivo evidence that IL-15
likely can have a causal role in the pathogenesis of at least some cases of
CTCL, in part via the epigenetic inhibition of the transcriptional repressor, Zeb1,
that in turn leads to overexpression of IL-15 and activation of specific HDACs.
IL-15 transgenic CTCL mice provide a novel model for studying the develop-
ment of CTCL and evaluating potential therapies. Selective inhibition of
HDAC1/2 produces a comparable halt in the progression of experimental CTCL
as that seen with the pan-HDAC inhibitors, and thus may provide an equally
potent yet less toxic alternative in the clinic. Our findings not only demonstrate
a critical role for IL-15-mediated inflammation in cutaneous T-cell lymphoma-
genesis, but also uncover a new oncogenic regulatory loop in CTCL involving
IL-15, HDAC1, HDAC6 and miR-21 that show differential sensitivity to isotype-
specific HDAC inhibitors.
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Background: Waldenström’s Macroglobulinemia (WM) represents a B-cell lym-
phoproliferative disorder, classified as a lymphoplasmacytic lymphoma, accord-
ing to the WHO classification. Previous studies have identified familial aggre-
gation of WM cases, and the clustering of B-cell lymphoproliferative disorders
among first degree relatives of patients with WM, including chronic lymphocytic
leukemia, non-Hodgkin lymphoma, multiple myeloma, IgM-MGUS and IgG/IgA-
MGUS, thus suggesting a possible contribution of inherited susceptibility to
familial WM. Nevertheless, whether relatively common germline variants may
contribute specifically to familial WM cases, remains unexplored.
Aims: To identify the potential contribution for inherited susceptibility to familial
WM. To define the functional relevance of the most recurrent observed variant.
Methods: Whole exome sequencing was performed on germline DNA obtained
from four members of a single family with documented coinheritance of WM
(three affected; 1 unaffected) and applied bioinformatic tools to identify candidate
germline variants likely to have a biological role in WM. Additional 246 inde-
pendent, unrelated WM cases (50 probands from familial cases; 196 from non-
familial cases) were screened for the identified variants. The DNA was size-
selected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent).
Samples were multiplexed and sequenced on Illumina HiSeq flow cells with the
goal of an average depth of coverage of 100x. Allele frequencies (AF) in 1000G,
as well as PolyPhen-2 prediction, were used to quantify the deleteriousness of
SNVs. Variants with AF >0.05 in 1000G were filtered out, and the remaining
SNVs were defined as potential familial WM-associated variants. Gene prioriti-
zation was obtained by using GRAIL and global coexpression network COX-
PRESdb. Functional validation was performed by engineering WM cells for the
most recurrent variant, by using site-directed mutagenesis and LentiORF.
Results: LAPTM5(c403t) and HCLS1(g496a) represented the most recurrent
variants, present in 3/3 affected members of the index family. Each of these
variants was present in 8% of the unrelated familial cases, in 0.5% of the non-
familial cases and in <0.05 of a control population. To interrogate a possible
involvement of LAPTM5 and HCLS1 in WM biology, we used the HEFalMp
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database to construct a combined LAPTM5/HCLS1 module and interrogated
whether this module is disrupted in WM patients compared to healthy donors
(HDs), using an independent gene expression profile dataset (GSE6691). We
demonstrated a statistically significant high gene-to-gene connectivity in HDs,
while the sub-network was disrupted in WM. Importantly, the change in mean
connectivity was significantly different in the WM- versus the HD-modules
(P<0.0001). Together, these findings suggest a conserved high interactivity
between LAPTM5 and HCLS1 in normal B cells, while WM cells present a dis-
rupted pattern of connectivity, which likely impacts disease biology. Previous
studies have reported on LAPTM5 over-expression in patients with B-cell lym-
phomas. LAPTM5c403t was the most significantly predicted variant to be func-
tionally related to the WM mRNA signature, and therefore dissected its func-
tional relevance, by using site-directed mutagenesis in WM cells. LAPTM5c403t
mutated cells presented with enhanced cell growth, NF-kBp65 activation and
phospho- NF-kBp65 nuclear translocation, compared to the non-mutated cells,
thus suggesting the role of the LAPTM5(c403t) variant in enhancing WM cell
proliferation through modulation of NF-kB activation.
Summary/Conclusions: LAPTM5(c403t) and HCLS1(g496a) may represent
predisposition alleles in patients with familial WM. Future studies will be needed
to clarify the penetrance of specific alleles as well as possible combinatorial effects.
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Background: Obinutuzumab (GA101) is a novel glycoengineered type II anti-
CD20 monoclonal antibody that induces a high level of non-apoptotic direct
cell death and, due to increased affinity for FcγRIII on effector cells, results in
enhanced antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis
(ADCP). Venetoclax (ABT-199/GDC-0199) is a novel, orally bioavailable, selec-
tive BCL-2 inhibitor that induces intrinsic apoptosis in preclinical models of
hematological malignancies (NHL, AML, MM) and primary CLL patient samples. 
Aims: Based on their complementary mechanisms of action involving increased
apoptosis (venetoclax) or direct cell death (obinutuzumab) we aimed to determine
if the combination of both agents has the potential for greater efficacy in treating
B lymphoid malignancies such as NHL and CLL when compared to monotherapy
and co-treatment with other anti-CD20 antibodies such as rituximab.
Methods: In vitro studies primarily utilized fluorescence activated cell sorting
(FACS) to measure direct cell death induction/apoptosis on NHL cell lines
(WSU-DLCL2, SU-DHL4 and Z138) and primary CLL patient samples (n=27)
as well as the impact of BCL-2 inhibition on ADCC induction. ADCC assays
utilized peripheral blood mononuclear cells (PBMCs) isolated from healthy
donors as effector (E) cells and SU-DHL4 as target (T) cells and measured by
Lactate dehydrogenase (LDH) release using the LDH Cytotoxicity Detection
Kit (Roche Applied Science). in vivo efficacy of venetoclax monotherapy or in
combination with anti-CD20 antibodies was evaluated in WSU-DLCL2, SU-
DHL4 and Z138 sub-cutaneous xenograft models. Venetoclax (100 mg/kg)
was administered daily by oral gavage for 21 days and anti-CD20 antibodies
(1 mg/kg) were delivered intrapertioneally once during the treatment period. 
Results: Venetoclax enhanced induction of cell death when combined with
obinutuzumab or rituximab in SU-DHL4, WSU-DLCL2 and Z138 cell lines.
However, a greater degree of cell death was observed when venetoclax was
combined with obinutuzumab versus rituxumab at lower drug concentrations.
Importantly, venetoclax did not antagonize natural killer (NK)-cell mediated
ADCC or B cell depletion induced by obinutuzumab or rituximab treatment.
Treatment of SU-DHL4, WSU-DLCL2 and Z138 xenografts with venetoclax
plus obinutuzumab resulted in complete regressions, increased overall
response rates or greater tumor growth inhibition in vivo. Moreover, monother-
apy with venetoclax following combination treatment with obinutuzumab result-
ed in sustained in vivo efficacy and increased duration of response in SU-DHL4
and WSU-DLCL2 xenograft models suggesting a potential benefit of utilizing
venetoclax as maintenance therapy. In primary CLL samples (from untreated
or relapsed patients), venetoclax plus anti-CD20 antibody drug combination
treatment significantly increased B cell depletion (based on direct cell
death/ADCC) after 7 days in culture ex vivo. Under these conditions, venetoclax
in combination with obinutuzumab was more effective than the combination
with rituximab or venetoclax alone. Moreover, co-culture with nurse-like cells
that increases B-cell survival did not protect primary CLL cells from venetoclax
demonstrating that drug efficacy is maintained in a protective tumor microen-
vironment such as lymph node. 
Summary/Conclusions: Collectively, our data demonstrate that combination
of obinutuzumab with venetoclax results in greater cell death and robust anti-
tumor efficacy in xenograft models representing NHL sub-types and primary
CLL patient samples that is superior when compared to co-treatment with rit-
uximab. The preclinical data presented supports clinical investigation of obin-
utuzumab and venetoclax combination therapy, which is currently in phase Ib
clinical trials for relapsed/refractory CLL (clinical trial.gov identifier
NCT01685892), and warrants further investigation in other B-cell malignancies
such as NHL.
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Background: CD47 binds to signal-regulatory protein α (SIRPα) on the surface
of macrophages and delivers a “do not eat” signal that suppresses phagocy-
tosis. There is strong evidence that many hematological and solid tumors
upregulate cell surface expression of CD47 as a means to exploit the CD47-
SIRPα pathway and escape macrophage-mediated immune surveillance.
Blockade of CD47 using TTI-621, a soluble SIRPα-Fc fusion protein (SIRPαFc),
is a promising therapeutic strategy to neutralize the suppressive effects of
CD47 and promote the eradication of tumor cells by host macrophages. 
Aims: Here we have examined the effect of TTI-621 on human hematological
tumor cells in vitro and in vivo.
Methods: Human macrophages were derived from peripheral monocytes of
healthy donors. For the in vitro phagocytosis assay, tumor cells were co-cul-
tured with macrophages for two hours in the presence of TTI-621 or control Fc
protein. Phagocytosis was assessed by confocal microscopy or flow cytometry.
Acute myeloid leukemia (AML) xenografts were performed in NOD.SCID mice.
Cells from AML patients were transplanted intra-femorally, and following a three
week engraftment period, mice were dosed with 5 mg/kg mouse SIRPαFc or
3.3 mg/kg control Fc protein three times/week for four weeks. AML engraftment
was determined by%CD45+CD33+ human cells. Lymphoma xenografts were
performed in SHrN mice. Namalwa cells were injected subcutaneously into
each flank. Toledo cells were injected in 50% Matrigel. Three days (Nawalma)
or 10 days (Toledo) after tumor cell implantation, animals received 10 mg/kg
mouse SIRPαFc or 6.75 mg/kg control Fc protein, daily five times/week, for
three weeks. Tumor volumes were monitored until they reached the maximum
volume of 1500mm3.
Results: We first assessed the ability of TTI-621 to trigger macrophage-medi-
ated phagocytosis of cancer cells. In cultures left untreated or treated with a
control Fc fragment, macrophages exhibited a low level of phagocytosis, con-
sistent with CD47-mediated suppression. Blockade of CD47 by TTI-621 led to
a dramatic increase in the phagocytosis of human tumor cell lines of both
myeloid and lymphoid origin, including non-Hodgkin lymphoma lines. Further-
more, TTI-621 enhanced macrophage-mediated phagocytosis of primary tumor
samples from patients with AML, myelodysplastic syndrome, multiple myeloma
and B- and T-cell acute lymphoblastic leukemia. In total, 77% (23/30) of cell
lines and 97% (32/33) of primary patient samples were readily phagocytosed
following treatment with TTI-621. We next evaluated the in vivo efficacy of a
mouse surrogate of TTI-621 in an AML xenograft model. Treatment of mice with
mouse SIRPαFc for four weeks significantly reduced the tumor burden in the
injected femur of 7/10 patient samples compared to a control Fc protein, while
dramatically reducing the tumor burden in non-injected bone marrow in all 10
AML patient samples. Finally, we assessed the in vivo activity of mouse SIRPαFc
in xenograft models of Burkitt lymphoma (Namalwa) and diffuse large B cell
lymphoma (Toledo). Treatment with SIRPαFc ablated the growth of Namalwa
and Toledo tumors and was superior to rituximab therapy in both models.
Summary/Conclusions: Collectively, these data indicate that TTI-621 is active
across a broad range of human hematological tumors. A Phase I clinical trial
of TTI-621 in patients with advanced hematological malignancies is currently
underway (ClinicalTrials.gov #NCT02663518).
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Background: ALK+ anaplastic large cell lymphoma (ALK+ ALCL) is charac-
terized by chromosomal translocations of ALK gene locus, the most frequent
being the t(2;5)(p23;q35) resulting in aberrrant expression and activation of the
NPM-ALK oncoprotein. The NPM-ALK activates multiple oncogenic pathways
including the mTOR-Raptor (mTORC1) pathway, however, the potential role of
mTOR-Rictor (mTORC2) complex in ALCL pathogenesis is yet unknown. 
Aims: To investigate the potential role of Sin1, a critical component of the mTORC2
complex required for its integrity and activation, in ALK+ ALCL pathogenesis.
Methods: Expression, phosphorylation, and localization of Sin1 protein were
assessed by Western blot after subcellular fractionation, immunofluorescence
and confocal microscopy in 3 ALK+ and 2 ALK- ALCL cell lines. Physical inter-
action between various proteins was assessed by co-immunoprecipitation
assays. Real-time RT PCR was used to assess Sin1 gene products at the RNA
level. Transfection experiments were performed in BaF3 cells and in ALK+ and
ALK- ALCL cells using NPM-ALK and Sin1 expressing plasmids and Sin1-
shRNA constructs (gene silencing). Standard cell viability, proliferation and
colony formation assays as well as flow cytometry were utilized to assess cell
growth and survival following forced expression or gene silencing of Sin1 gene,
as well as after treatment with ALK and STAT3 inhibitors. In a cohort of 32 pre-
viously untreated patients with ALK+ ALCL, Sin1 protein expression was
assessed by immunohistochemistry performed on a tissue microarray. 
Results: Sin1.1 and Sin1.5 were the main isoforms detected in immunoblots
and they were differentially expressed among ALK+ and ALK- ALCL cell lines.
Sin1 protein was co-localized with activated (Ser473-phosphorylated) AKT
kinase in ALCL cells. Treatment of ALK+ ALCL cells with Crizotinib led to
reduced expression and de-phosphorylation of Sin1 protein. Forced expression
of Sin1.1 and Sin1.5 isoforms resulted in increased cell proliferation in ALK+
ALCL cells with downregulation of the CDK inhibitor p21. Inversely, knocking
down Sin1 gene by two specific Sin1-shRNA constructs resulted in dramatic
decrease of cell viability and colony formation (by 80%) of ALK+ ALCL cells,
which was associated with AKT de-activation and downregulation of the anti-
apoptotic BCL-XL and MCL-1 proteins. Using our in vitro system and ex vivo
(xenografts) mouse model, Sin1 gene expression was, at least in part, regulated
by STAT3 transcription factor. In the cohort of ALK+ ALCL patients, Sin1 protein
was expressed in all 32 tumors studied with cytoplasmic and nuclear pattern.
Summary/Conclusions: Taken together, these novel findings suggest that
mTORC2 complex, through Sin1-dependent activation of AKT and possibly
other AKT-independent functions, may contribute to cell cycle and apoptosis
deregulation and oncogenesis in ALCL. Thus, modulation of mTORC2 activity
might represent a novel target for investigational therapy in patients with ALCL.
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Background: Diffuse large B cell lymphoma (DLBCL) comprises a large group
of disease entities with high molecular heterogeneity and variable treatment
responsiveness. Results from gene expression profiling (GEP) studies high-
lighted the role of cell of origin, namely activated B cell-like cells (ABC) and
germinal center B cells (GCB), and stromal gene signatures for predicting clin-
ical outcome and stratifying patient risk. However, translation of GEP informa-
tion in easily applicable prognostic biomarkers remains a challenge. 
Aims: We applied an innovative GEP-based computational method, namely
CIBERSORT, to determine the cellular composition of DLBCL microenvironment
and investigate associations between abundance of certain tumor-infiltrating
non-malignant cell types and molecular/clinical traits of the disease. 
Methods: We generated a gene signature matrix including a total number of
1028 genes that distinguish 17 different immune and non-immune cell types,
the latter including adipocytes, endothelial cells (EC), pericytes and myofibrob-
lasts (MF). This matrix was used to perform CIBERSORT analysis (on-line
access to the webserver http://cibersort.stanford.edu/) of GEP data from 3 pub-
licly datasets (GSE10846, GSE19246 and GSE34171) of overall 604 DLBCL
cases. The relative percentage of each tumor-infiltrating cell fraction was esti-
mated and a global heatmap of tumor microenvironment composition was gen-
erated. Results were also stratified according to either cell of origin or clinical
outcome data and significant differences in each subgroup calculated by a two-
sided Mann-Whitney test.
Results: By applying CIBERSORT, we found that, among immune cells, mem-
ory B cells, plasma cells, NK cells, dendritic cells, CD4 T cells and macrophages
mainly infiltrate DLBCL tissues. In particular, plasma cells, NK and dendritic
cells showed significant higher proportion in ABC than GCB tumors, whereas
CD4 T-cells and dendritic cells were prevalent in patients with better outcome.
Notably, among stromal cells, MF was the most represented population and
exhibited a significant predominance in patients with more favorable outcome
and a strong positive correlation with overall survival (Figure 1). Consistently,
the fraction of MF was significantly larger in GCB tumors compared with ABC
subtypes. These latter resulted more enriched in EC.
Figure 1.
Summary/Conclusions: By estimating relative fractions of DLBCL-infiltrating
cells using CIBERSORT, we studied unknown aspects of tumor microenviron-
ment with potential prognostic implications. Our data suggest that the composi-
tion of DLBCL with diverse molecular and clinical features also differ in term of
immune and, particularly, stromal cell infiltration. These findings are in line with
previous reports highlighting the prognostic value of specific stromal gene sig-
natures and support further studies aimed at uncover novel prognostic/predictive
biomarkers correlated with non-malignant tumor-associated cell subsets.
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Background: Anaplastic large cell lymphoma (ALCL) is an aggressive type of
T-cell non-Hodgkin lymphoma with high frequency in childhood. The current
WHO classification recognizes two distinct types of ALCL based on the expres-
sion of the anaplastic lymphoma kinase (ALK), the ALK+ and the ALK- ALCL.
The ALK+ ALCL is characterized by chromosomal translocations involving the
alk gene locus, the most frequent being the t(2;5) leading to aberrant expression
and activation of NPM.ALK oncoprotein. The latter is known to activate multiple
oncogenic pathways including the Ras/ERK, JAK/STAT3, PI3K/AKT/MTOR,
JNK/Jun, Sonic Hedgehog and others, resulting in cell cycle and apoptosis
deregulation. However, the potential role of bi-directional crosstalk between
the microenvironment (TME) and ALCL cells is not yet known. Exosomes are
endosome-derived vesicles that contain DNA, RNA, proteins, lipids and other
factors that have been reported to play significant role in intercellular signaling.
Their role in the ALCL-TME interactions has not been investigated to date.
Aims: To characterize the ALCL-derived exosomes and investigate their pos-
sible functional interactions with microenvironment using an in vitro system as
well as an ex vivo mouse model of ALK+ and ALK- ALCL.
Methods: Exosomes derived from ALK+ and ALK- ALCL cell lines were isolated
using well established ultracentrifugation protocols. The exosomes were sub-
sequently characterized by nanoparticle tracking analysis (NanoSight) and
transmission electron microscopy for their size and shape. The molecular com-
position of exosomes at the RNA and protein level was assessed by real time
RT-PCR and Western blotting, respectively. Stromal cells including bone mar-
row-derived fibroblasts and mesenchymal stem cells were co-cultured with
ALK+ and ALK- ALCL cells or they were educated with exosomes and the bio-
logic effects were investigated. Uptake levels of exosomes by recipient lym-
phoma or stromal cells were assessed by DIR labeling and flow cytometry.
Expression of proteins associated with the Cancer-Associated Fibroblasts
(CAF) was evaluated by immunofluorescence and confocal microscopy. The
biologic effects of co-cultured lymphoma and stromal cells after ALK (Crizotinib)
and STAT3 (Stattic, XIII) inhibition were analyzed with standard cell viability
and proliferation assays and flow cytometry in our in vitro ALCL system. In addi-
tion, an ex vivo mouse model for ALK+ and ALK- ALCL (xenografts) was used
in this study.
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Results: We characterized for first time the ALK+ and ALK- ALCL-derived exo-
somes. Transmission electron microscopy and nanoparticle tracking analysis
showed significant differences in exosome size among various ALCL cell lines.
Western blot analysis performed on both, whole cellular and exosomal lysates,
confirmed the expression of various exosomal markers including Rab5, Alix,
and CD82. Lack of AIF in the exosomal lysates served as a quality control.
More importantly, Western blot analysis revealed the presence of critical com-
ponents of the ALK signaling in NPM-ALK positive ALCL-derived exosomes
including pALK, pSTAT3, AP-1 transcription factors, pAKT and mTOR pathway
kinases. ALCL-derived exosomes were uptaken by ALK+ and ALK- ALCL cells
at a high level ranging from 30% to 80% at 6 hours, and similarly, they were
uptaken by bone marrow-derived fibroblasts and mesenchymal stem cells at
a high level as well. Co-culture of the ALCL cells with stromal cells resulted in
activation of stromal fibroblasts that acquired a CAF phenotype (aSMA+) as
shown by immunofluorescence and confocal microscopy. Furthermore, co-cul-
turing of ALK+ ALCL and stromal cells altered response (sensitivity) of ALK+
ALCL cells to Crizotinib treatment at a moderate level.
Summary/Conclusions: This is the first study to characterize the ALK+ and
ALK- ALCL-derived exosomes and demonstrate potential exosome-associated
interactions between the ALCL and stromal cells. Ongoing functional studies
will enrich our understanding for the involvement of the microenvironment in
the mechanisms of resistance to targeted therapy that would lead to more effi-
cient therapeutic approaches for the ALCL patients.
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A 6-GENE EXPRESSION SIGNATURE IN MANTLE CELL LYMPHOMA:
RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)-MCL-0208
TRIAL
R Bomben1,*, S Ferrero2, M Dal-Bo1, T D’Agaro1, A Re3, A Evangelista4,
AM Carella5, A Zamò6, U Vitolo7, P Omedè2, C Rusconi8, L Arcaini9,10, L Rigacci11,
S Luminari12, A Piccin13, S Cortelazzo14, M Ladetto15, V Gattei1
1Clinical and Experimental Onco-Ematology Unit, Centro di Riferimento Onco-
logico, Aviano, Aviano, 2Department of Molecular Biotechnologies and health
sciences, Hematology Division, University of Torino, Torino, 3Hematology,
Spedali Civili, Brescia, 4Unit of Cancer Epidemiology, Azienda Ospedaliera
Universitaria Città della Salute e della Scienza, Torino, 5Division of Hematology
1, IRCCS A.O.U. San Martino IST, Genova, Genova, 6Department of Pathology,
University of Verona, Verona, 7Città della Salute e della Scienza Hospital and
University, SC Hematology, Torino, 8Division of Hematology, Niguarda Ca’
Granda Hospital, Milano, 9Department of Hematology Oncology, Fondazione
IRCCS Policlinico San Matteo, 10Department of Molecular Medicine, University
of Pavia, Pavia, 11Hematology, Universita’ degli Studi di Firenze, Firenze,
12Department of Diagnostic, Clinical and Public Health Medicine, University of
Modena and Reggio Emilia, Modena, 13Department of Haematology and Bone
Marrow Transplantation, Regional Hospital, S. Maurizio, Bolzano/Bozen,
14Hematology, Unità di Oncologia Medica ed Ematologia, Istituto Clinico
Humanitas-Gavazzeni, Bergamo, 15Division of Hematology, Az Ospedaliera
SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Background: The aggressive clinical behavior of mantle cell lymphoma (MCL)
is mainly attributed to the t(11;14)(q13;q32) traslocation and cyclin D1 (CCND1)
overexpression. Nevertheless, a certain degree of clinical/biological hetero-
geneity has been reported.
Aims: To identify MCL subsets with peculiar clinical/biological features in the
context of a cohort of homogeneously treated MCL patients.
Methods: The study used gene expression profiling (GEP) and quantitative
real-time PCR (qRT-PCR) validations in peripheral blood (PB, n=46) and for-
malin fixed paraffin embedded (FFPE, n=42) samples from 82 MCL cases
enrolled in the Fondazione Italiana Linfomi (FIL)-MCL-0208 randomized clinical
trial (high-dose therapy followed by autologous transplantation).
Results: i) Unsupervised and supervised analyses. GEP from 27 PB samples
were analyzed by principal component analysis (PCA) and divided in two sub-
groups named PCA1 (14 cases) and PCA2 (13 cases). Supervised analysis,
according to PCA classification, identified a gene expression signature of 902
probes (700 up-regulated). Gene Set Enrichment Analysis (GSEA) demon-
strated a significant enrichment of five B Cell Receptor (BCR)-related gene
sets, these genes being constitutively over-expressed in PCA2 samples. ii)
Identification of a “PCA2-type” gene signature. By merging the lists of differen-
tially expressed genes and the BCR signaling related genes according to
GSEA, a group of 14 genes, all overexpressed in PCA2 cases, was obtained.
Among these genes, 6 genes, AKT3, BCL2, BTK, CD79B, PIK3CD, and SYK,
were selected for further validations. iii) Generation of a 6-gene prediction mod-
el. These 6 genes were analyzed by qRT-PCR and utilized to generate a pre-
diction model by using 17 cases as training cohort and 10 cases as validation
cohort (all from PB samples). By this approach, 10/10 cases of the validation
cohort were correctly assigned according to the PCA2/PCA1 classification.
qRT-PCR was then utilized to classify 19 additional cases (10 PCA2 cases)
not employed in GEP. Overall, in the 46 cases, 23 cases were classified as
PCA2 by the GEP/qRT-PCR approach. iv) Clinical/biological correlations. No
association was found between the 6-gene signature and IGHV status (33/41
unmutated IGHV cases) and the overexpression of SOX11 (15/27 cases over
the median value). Moreover, no association was found with the presence of
the main recurrent mutations of the ATM, BIRC3, CCND1, KMTD2, NOTCH1,
TP53, TRAF2, WHSC1 genes. Finally, an “ad-interim” analysis of progression
free survivals (PFS) suggested a shorter PFS (2-years PFS 76% vs 44%,
p=0.04) for PCA2 cases. v) Application of the 6-gene signature to FFPE sam-
ples. By testing the 6-gene signature, by qRT-PCR in FFPE samples, 22 and
20 cases were classified PCA1 or PCA2, respectively. Again, in this independ-
ent series, PCA2 group demonstrated a trend for shorter PFS (2-years PFS
95% vs 80%, p=0.15). Merging together cases analyzed using PB and FFPE
material, PCA2 patients had a shorter PFS (2-years PFS 85% vs 61%, p=0.02).
vi) 6-gene signature and sensitivity to the BCR inhibitor ibrutinib. We investi-
gated the proliferation rate of the MCL cell lines Rec-1, Jeko-1, Mino, JVM-2,
JVM-13, and Z-138 in presence or in absence of ibrutinib 10 nM for 7 days. By
qRT-PCR sensitive cell lines showed higher expression levels of the selected
six genes than the resistant counterpart, and were classified as PCA2.
Summary/Conclusions: A novel 6-gene expression signature related to the
BCR pathway has been found to characterize MCL cells with peculiar
clinical/biological features and sensitivity to BCR inhibitors.
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BONE MARROW MESENCHYMAL STEM/STROMAL CELLS FROM
SPLENIC MARGINAL ZONE LYMPHOMA PATIENTS SHOW DISTINCT
INTRINSIC CHARACTERISTICS AND EFFECTS ON B-LYMPHOCYTE
CHEMOTAXIS AND APOPTOSIS
A Kalyva1, C Pontikoglou2,*, C Kalpadakis2, E Stagakis2, L Kalaitzaki1,
G Pangalis3, HA Papadaki2
1Hemopoiesis Research Laboratory, 2Department of Hematology, University
of Crete School of Medicine, Heraklion, Crete, 3Department of Hematology,
Iatriko Athinon Psychiko Branch, Athens, Greece
Background: Splenic marginal zone lymphoma (SMZL) originates from the
neoplastic transformation of mature B-lymphocytes. In most cases, B-lympho-
cytes infiltrate bone marrow (BM), suggesting a potential involvement of BM
microenvironment in disease pathology.
Aims: To examine BM-derived mesenchymal stem/stromal cells (MSCs), since
they comprise key components of the BM hematopoietic stroma, in order to
investigate if they exhibit altered intrinsic properties in vitro or if they stimulate
altered B- and T-cell immunomodulatory properties in SMZL patients compared
to healthy controls.
Methods: BM MSCs were isolated and expanded in vitro from 12 SMZL
patients and 11 healthy controls. MSCs were cultured for a total of 5 passages
(P) and were phenotypically characterized by flow cytometry (FC). The colony
forming unit-fibroblast (CFU-F) assay was used to estimate MSC frequency
within the BM mononuclear cell (BMMC) fraction in P0 and their clonogenic
capacity in P2. MSCs differentiation to adipocytes and osteoblasts was
assessed by cytochemical stains. Their proliferative potential was evaluated
by Methyl Triazolyl Tetrazolium assay. To assess the effect of SMZL MSCs on
lymphocyte proliferation, B- and T-cells were immunomagnetically isolated (Mil-
tenyi Biotec) from peripheral blood (PB) of normal individuals, labeled with car-
boxyfluorescein succinimidyl ester (Gibco) and subsequently cultured in the
absence or presence of confluent layers of SMZL or normal MSCs, in the pres-
ence of activating factors. B cell apoptosis was evaluated via FC using 7-AAD
staining, after co-culturing with SMZL or normal MSCs. Finally, B-cell chemo-
taxis was evaluated by monitoring the migration of isolated B-cells through a
5µm pore membrane in a transwell plate towards the confluent layers of either
SMZL or normal MSCs.
Results: In vitro expanded MSCs from both groups were adherent cells with
a spindle-shape morphology, which expressed CD29, CD73, CD90 and CD105
and were negative for the CD14, CD34 and CD45 cell surface markers. SMZL
and Normal MSCs were similar in their differentiation to adipocytes and osteo-
cytes as evidenced by Oil Red O and Alizarin Red staining, respectively. The
frequency of MSCs within the BMMC compartment was significantly lower in
patients as compared to healthy individuals (2.51 vs 7.95 colonies per 105
ΒΜΜCs respectively; p=0.04) apparently due to the predominance of the lym-
phoma cells within patient BMMCs. SMZL MSCs in comparison to Normal
MSCs at P2, displayed defective clonogenic potential (3.36 vs 6.23 colonies
respectively, p=0.03) and reduced proliferative potential (p<0.03). In co-culture
experiments, SMZL and Normal MSCs showed no difference in their effect on
normal B-cell or T-cell proliferation. However, SMZL MSCs produced a statis-
tically significant advantage on B-cell survival as measured in B-cell apoptosis
experiments. More specifically, 50±1.46% of B cells cultured in medium alone
were apoptotic, while only 23±2.63% and 17±0.77% of B cells co-cultured with
either Normal MSCs or SMZL MSCs were apoptotic (p=0.009 when comparing
SMZL vs Normal MSCs). Finally the transwell migration assays showed that
SMZL MSCs displayed a stronger chemotactic activity on isolated normal B-
cells, in comparison to Normal MSCs, with the percentages of migrated B-cells
being 34% and 22% respectively, (p=0.009).
570 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Summary/Conclusions: Our data suggest that SMZL MSCs are intrinsically
defective in terms of proliferative and clonogenic potential and moreover they
exert distint anti-apoptotic and chemotactic effects on healthy-donor derived B
cells. The impact of SMZL MSCs on the properties of patient derived peripheral
B cells is currently under investigation.
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INTERRUPTION OF CCL20-CCR6 INTERACTION INHIBITS METASTASIS
OF ADVANCED CUTANEOUS T-CELL LYMPHOMA
H Tagawa1,*, S Ikeda1, A Kitadate1, N Takahashi1, M Sugaya2
1Hematology, Akita University, Akita, 2Dermatology, University of Tokyo,
Bunkyo-Ku, Japan
Background: The expression of interleukin-22 (IL-22), chemokine receptor
CCR6, and its ligand CCL20 is upregulated in advanced Cutaneous T-cell lym-
phoma (CTCL) (Miyagaki et al., Clin Cancer Res 2011). We have also shown
that a non-coding RNA, microRNA-150 (miR-150), is silenced in advanced
CTCL, and that the miR-150 downregulates CCR6 directly and CCL20 indi-
rectly. Based on these data, we hypothesized that continuous CCR6 and CCL20
upregulation might lead to continuous CCL20-CCR6 interaction in CTCL cells
and in turn, lead to metastasis to distal organs in a nutrition-dependent manner.
We further found that IL22RA1, one of the IL-22 receptor subunits, was aber-
rantly overexpressed in CTCL, and that its knockdown decreased CCL20 pro-
duction. These results suggested that the IL-22 produced by the CTCL cells
might activate the IL-22 receptor in these cells, leading to the activation of
downstream targets and subsequently increasing the transcription of CCL20
(Ito et al., Blood 2014). However, we could not determine the downstream cas-
cade of IL-22 that mediates CCL20 transcription activation.
Aims: Aim of this study is to determine whether 1) CCR6-CCL20 interaction is
actually functional in advanced CTCL cells representing metastatic capability,
and 2) which transcriptional factor(s) might activate CCL20 activation.
Methods: Immunohistochemistry of p-STAT3 and CCR6 were performed for
five patients with Mycosis Fungoides patients of early and advanced phase of
the same individual. CTCL cell lines such as My-La, HH MJ and HUT78 were
used for in vitro experiment. Transient knockdown of IL22RA1, CCR6, and
CCL20 was conducted for detecting functional analysis of CTCL cells. To deter-
mine whether the transient knockdown of STAT3, CCL20, or CCR6 or treatment
with neutralizing CCL20 antibody could reduce the migration ability of CTCL
cells, we conducted an in vitro migration assay. To examine the in vivo effect
of neutralizing CCL20 antibody, we used NOD/Shi-scid IL-2γnul mice inoculated
with CTCL cells (namely CTCL mice). Written informed consent was obtained
from all patients prior to collection of specimens, in keeping with all institutional
policies and according to the Declaration of Helsinki. Samples were collected
under a protocol approved by the Institutional Review Boards of Akita University
and University of Tokyo.
Results: We demonstrated increased STAT3 expression during the progression
of primary CTCL. STAT3 was spontaneously activated and mediated the tran-
scription of CCL20 in CTCL cell lines. However STAT3 was not spontaneously
activated in mantle cell lymphoma cell lines because these cell lines required
upstream stimulation of IL-22 for activation of CCL20. In vitro migration assay
demonstrated that all treatments reduced the nutrition-dependent migration
activity of CTCL cells. Notably, treatment with neutralizing CCL20 antibody
reduced the migration ability of the cells without decreasing the expression of
CCL20 and CCR6. This demonstrates that the CCL20-CCR6 interaction is actu-
ally functional in metastatic CTCL cells. in vivo administration of neutralizing
CCL20 antibody significantly prolonged the survival of the CTCL mice.
Figure 1.
Summary/Conclusions: These findings suggested that automatic activation
of the STAT3/CCL20/CCR6 cascade was actually involved in advanced CTCL
lymphomagenesis. On the other hand, activation of STAT3 might require
upstream stimulation of IL-22 in early CTCL (see image Figure). Thus, disruption
of CCL20-CCR6 interaction could be a key therapeutic strategy against
advanced CTCL.
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TUMOR GENE EXPRESSION PROFILES ASSOCIATED WITH SINGLE-AGENT
COPANLISIB ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH
INDOLENT AND AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
L Liu1,*, K Koechert2, J Cheng1, J Garcia-Vargas1, BH Childs1, M Dreyling3, C Peña1
1Bayer HealthCare Pharmaceuticals, Whippany, United States, 2Bayer AG,
Berlin, 3Klinikum der Universität München LMU, Munich, Germany
Background: Copanlisib, a novel pan-class I PI3K inhibitor with predominant
activity against α and δ isoforms, has shown promising single agent anti-tumor
activity in a phase 2 study (NCT01660451, part A) in heavily pretreated patients
with indolent and aggressive lymphoma.
Aims: Tumor gene expression profiling was used as a discovery tool to identify
genes or pathways associated with copanlisib treatment outcomes and provide
potential predictive markers and rationale for novel combinations.
Methods: Single gene multivariate approach and gene set enrichment analysis
(GSEA) using RNA expression array data from archival tumors from patients
enrolled in the phase 2 trial were performed to identify genes and pathways
associated with copanlisib efficacy. A weighted gene expression score (WGS)
reflecting overall expression level for each pathway was generated from logistic
regression and Cox proportional hazards models to assess association with
response status and progression-free survival (PFS), respectively.
Results: A total of 24 patients including both indolent and aggressive lymphoma
were available for analysis. Patients had either complete response (n=3), partial
response (n=5), stable disease (n=11), or progressive disease (n=5) as best
clinical response; follicular lymphoma (FL, n=10), marginal zone lymphoma
(n=2), mantle cell lymphoma (n=2), diffuse large B-cell lymphoma (DLBCL,
n=5), transformed indolent lymphoma (n=2) or chronic lymphocytic leukemia
(n=3). The GSEA gene sets ranked highest for correlation with response were
those reflecting upregulated B-cell receptor (BCR) signaling and a PI3K signa-
ture (including both α and δ isoforms), with normalized enrichment scores of
1.92 and 1.62 and false discovery rates of 0.014 and 0.087, respectively.
Response rates were increased in patients with high BCR and PI3K WGS com-
pared to low (nominal p=0.06 and 0.07, AUC=0.81 and 0.75, respectively). PFS
was longer in copanlisib-treated patients with high (above the median) BCR
WGS (377 vs 62 days, HR=0.035, nominal p<0.0001) and in patients with high
PI3K WGS (288 vs 104 days, HR=0.24, nominal p=0.02) compared to those
with low. In contrast, upregulation of NFҡB, IL6/JAK/STAT3, stromal and inflam-
matory process gene sets and the individual genes NOP10, MT2A, and CSTB
were potentially associated with lower likelihood of response to copanlisib.
Summary/Conclusions: Durable response to single-agent copanlisib is asso-
ciated with tumors with PI3K pathway activation and/or strong BCR signaling.
A strong NFҡB expression profile is associated with lower likelihood of response
to single-agent copanlisib. The higher response rate in FL as compared to DLB-
CL is consistent with a predominant BCR/PI3K expression profile in FL, with
low NFҡB activation. These results suggest that FL even in advanced stage
and prior extensive treatment can respond to single-agent copanlisib. Efficacy
in DLBCL may require combination therapy, adding agents that target NFҡB
pathway to copanlisib.
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PROGNOSTIC IMPACT, PHENOTYPIC AND MOLECULAR CHARACTERIZATION
OF CONCORDANT AND DISCORDANT BONE MARROW INVOLVEMENT
IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
S Alonso1,*, M Alcoceba1, M García-Alvarez1, JC Caballero1, J Davila1, O Blanco2,
MD Caballero1, M González1, N Gutiérrez1, A Martín1
1Hematologia, 2Pathology, Hospital Universitario de Salamanca, Salamanca,
Spain
Background: In the rituximab era, the biology and prognostic influence of bone
marrow (BM) infiltration in patients with diffuse large B-cell lymphoma (DLBCL)
has been hardly studied. 
Aims: In this retrospective study, we aimed to investigate: i) the prognostic
influence of concordant (DLBCL histology) and discordant (low-grade lym-
phoma) BM infiltration in patients with DLBCL; ii) the correlation of cell of origin
(COO) of the DLBCL and the type of BM infiltration; iii) the clonal relationship
between BM and lymph node (LN) tumor cells in the discordant cases; and iiii)
the incidence of TP53, CMYC, BCL2, BCL6 genetic alterations in the cases
with BM infiltration.
Methods: All patients with histological diagnosis of DLBCL in our center from
January 1, 1999 were included. Survival analysis was performed only in the
patients treated with rituximab (R) plus curative chemotherapy. All BM samples
were reviewed and classified as concordant or discordant infiltration according
to histological criteria. COO was assessed by Hans method. Phenotypic
description of discordant marrows was performed by flow cytometry (FCM).
Clonal relationship between BM and lymph node (LN) was performed by VDJ
sequencing according to BIOMED-2 protocol. TP53, CMYC, BCL2, BCL6 were
analyzed using fluorescence in situ hybridation (FISH).
Results: From 232 patients included in the study, 36 (15%) had concordant
histological BM infiltration and 22 (9%) discordant. Phenotypic characterization
of the discordant cases, including those detected only by FCM, was heteroge-
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neous, representing different types of indolent B-cell lymphomas:CLL (7), FL
(8), MZL (4) LPL (2), DLBCL (23), Composite (2), Not specified (8). Clonality
studies from the 15 evaluable discordant cases, confirmed the same clone in
both BM and lymphadenopathy in 12 patients (80%); we observed that the
most frequent VH segment was VH4.34, only seen in patients with non-germi-
nal center (non-GCB) COO phenotype. FISH analysis revealed a high rate of
genetic aberrations, particularly in the concordant group of patients, as shown
in table 2. BCL2 translocations stood out in the GC phenotype group, while
CMYC gains concentrated among those with discordant BM infiltration. TP53
deletions, were mostly seen in the concordant non-GC group of patients. Sur-
vival analysis were conducted in the 189 patients treated with R plus curative
chemotherapy. With a median follow up of 58 months, 5-year PFS was signif-
icantly worse in patients with concordant BM infiltration (30,4%) compared with
those with discordant (64.8%, p=0.004) or without infiltration (67.8%, p=0.001).
This negative influence of concordant BM involvement on PFS was independ-
ent of IPI in the multivariate analysis (HR=2.25, 95% CI 1.2 to 4.3, p=0.01). IPI
was the only variable with independent influence on OS. By combining COO
and type of BM infiltration, we observed that patients with discordant BM and
non-GC COO were a group not previously described with decreased PFS
(41.9% at 5 years) as compared with the non-infiltrated GCB group (78.3%,
p=0.007) and the non-infiltrated non-GCB group (73%, p=0.05) (Figure 1).
Figure 1.
Summary/Conclusions: Our results confirm the adverse prognosis of con-
cordant BM infiltration but reveal that the type of BM infiltration could be more
informative when combined with DLBCL COO and FISH analysis, allowing bet-
ter prognostic stratification of patients. Among discordant cases we find a high
rate of clonal relationship between the two different histologies, which suggest
that most cases are histologic transformations from a low-grade lymphoma.
Larger prospective studies are needed to confirm these results.
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MULTIPLE NF-KB INDUCERS PROMOTE C-MYC-DEPENDENT B-CELL
LYMPHOMAGENESIS
N Arnaud1,*, A David1, M Fradet1, H Lascaux1, U Zimber-Strobl2, C Ouk-Martin1,
N Gachard1, J Feuillard1, N Faumont1
1UMR 7276, Limoges, France, 2Department of Gene Vectors, Research Center
for Environmental Health GmbH, Munich, Germany
Background: Not only Burkitt lymphoma (BL) with the translocation of MYC,
but also diffuse large B-cell lymphoma (DLBCL) by other mechanisms (muta-
tion, amplification, promoter dysregulation…) are associated with dysregulation
of c-Myc, the master transcription factor for proliferation. DLBCL’s are classified
in two subgroups: “Germinal center B-cell” (GCB) without and “activated B-
cell” (ABC) with constitutive NF-kappa B activation. This constitutive activation
of NF-kappa B can be the result of genetic alterations (MYD88, A20, TRAF2,
and TRAF5) or the activation of B-cell receptor or CD40. These features raise
the question of the synergy between NF-kappa B and c-Myc in ABC DLBCL.
By inducing c-Myc and NF-kappa B, via in particular, the viral oncogene LMP1
(Latent Membrane Protein 1), Epstein-Barr virus (EBV) immortalized B cells
are another example of the coexistence of these two transcription factors in
continuous proliferating B-cells. Although BL are described without NF-kappa
B activation, frequent association with EBV raises the question of the role of
NF-kappa B activation during the early phase of the oncogenic process.
Aims: To study the synergy between NF-kappa B and c-Myc using the effect of
several NF-kappa B drivers in the context of a continuous activation of c-Myc.
Methods: In vitro, study of an EBV and c-Myc double inducible human B-cell
model and Burkitt lymphoma cell lines. Ex vivo and in vivo, study of TLR9 activation
of B cells from the λ-c-Myc transgenic mouse model. In vivo, study of double
transgenic mouse model with constitutive activation of CD40 and c-Myc (mouse
CD40 / Myc). Techniques used are those for studying functional proliferation,
apoptosis, B-cel-differentiation, expression of protein and regulation of genes.
Results: Our results show that induction of NF-kappa B in the context of over-
expression of c-Myc, i) by EBV latency III program, provides a selective advan-
tage to those cells (gene expression in favor of a high metabolism, intense pro-
liferation and protection against apoptosis), ii) by TLR9 (in vivo and in vitro mod-
el) increases the survival and proliferation of B lymphocytes of λ-c-Myc mice
(increase of activated B cells, splenomegaly, increased B cells proliferation),
and iii) by CD40 in the double transgenic CD40/Myc mice have a very aggressive
B lymphomagenesis with in vivo increased proliferation and tumorigenesis.
Summary/Conclusions: We concluded that, whatever the tested model, NF-
kappa B and c-Myc are functionally synergistic for transformation B cells.
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PROGRAMMED CELL DEATH 1 EXPRESSION IS ASSOCIATED WITH
INFERIOR SURVIVAL IN PATIENTS WITH PRIMARY CENTRAL NERVOUS
SYSTEM LYMPHOMA
SY Hyun1,*, H Cho2, SJ Kim2, YR Kim3, JY Lee2, H Park2, JE Jang2, Y Kim2,
JW Cheong2, YH Min2, JS Kim2
1Wonju Christian Hospital, Wonju, 2Severance Hospital, 3Gangnam Severance
Hospital, Seoul, Korea, Republic Of
Background: Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2
have been shown to mediate immune evasion in various cancers, but their
prognostic roles have not been studied in patients with primary central nervous
system lymphoma (PCNSL).
Aims: To evaluate the prognostic role of immunohistochemical PD-1, PD-L1,
and PD-L2 expression in immunocompetent patients with PCNSL.
Methods: We performed a retrospective, immunohistochemical study on 76
PCNSL patients at initial diagnosis initially treated homogenously with high-
dose methotrexate (HD-MTX)-based chemotherapy, and evaluated the prog-
nostic roles of high PD-1, PD-L1, and PD-L2 expression. The cut-off values for
high PD-1 (≥70 cells/high power field [HPF]), PD-L1 (≥100 cells/HPF), and PD-
L2 (≥100 cells/HPF) were determined by the area under the receiver operating
characteristic curve.
Results: The median follow-up duration for surviving patients was 31.9 (range,
2.4–128.5) months. Sixteen (21.1%) patients received consolidative upfront
ASCT after a median of 4 cycles (range 2–4) of HD-MTX-based chemotherapy.
Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1%
patients, respectively. High PD-1 (HR: 4.95, 95% CI: 1.54–15.86, P=0.007)
and MSKCC prognostic scoring (HR: 2.56, 95% CI: 1.17-5.64, P=0.019) were
independently associated with inferior overall survival on multivariate analysis.
High PD-1 also remained an independent prognostic factor for inferior progres-
sion-free survival (HR 2.73, 95% CI: 1.12-6.69, P=0.028), as did MSKCC prog-
nostic scoring (HR: 1.56, 95% CI: 1.09-2.45, P=0.041) on multivariate analysis.
However, there were no differences in survival according to the expression
levels of PD-L1/PD-L2. Patients with high expression of PD-1 showed signifi-
cantly shorter survival compared to those with low expression of PD-1 (P=0.008
for OS, and P=0.037 for PFS) (Figure A, B). In a subgroup analysis of 60
patients who did not receive upfront ASCT, high PD-1 expression tended to
associate with inferior OS (P=0.145) and PFS (P=0.197) (Figure C, D). How-
ever, among 16 patients who received upfront ASCT, high PD-1 expression
was significantly associated with inferior OS (P<0.001) and PFS (P=0.008)
(Figure E, F).
Figure 1.
Summary/Conclusions: We found that high PD-1 expression was associated
with inferior survival in patients with PCNSL. PD-1 may be considered a bio-
marker and potential therapeutic target in PCNSL.
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ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION
WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN’S LYMPHOMA
A Romano1,*, NL Parrinello1, D Tibullo1, C Vetro1, C Giallongo1, P La Cava1,
A Chiarenza1, G Motta1, V Simeon2, L Caruso3, S Cosentino4, M Ippolito4,
U Consoli5, P Musto2, F Di Raimondo1
1Division of Hematology, University of Catania, Catania, 2Laboratory of Pre-
clinical and Translational Research, CROB Referral Cancer Center of Basilicata,
Rionero in Vulture, 3Division of Hematology, Ospedale Ferrarotto, 4Nuclear
Medicine Center, Azienda Ospedaliera Cannizzaro, 5Division of Hematology,
ARNAS Garibaldi, Catania, Italy
Background: The role of microenvironment in the pathogenesis of classic
Hodgkin`s Lymphoma (HL) is well recognized. Our previous work showed that
myeloid-derived suppressor cells have prognostic meaning, but their detection
in peripheral blood is controversial due to lack of specific surface markers that
could help to distinguish from mature polymorphonuclear neutrophils (PMN). 
Aims: Evaluate if mature PMN in HL are different from healthy and in particular
if they are immunosuppressive
Methods: Using oligonucleotide microarrays, we first evaluated the gene
expression profile (GEP) of PMN at the steady state in 5 HL and 5 healthy sub-
jects matched for sex and age, identifying arginase (Arg-1) among the first 10
genes differentially expressed in HL versus healthy PMN. Secondly, we inves-
tigated if HL-PMN could suppress T-cell activation. Thirdly, since we found that
N-HL immunosuppression was due to the increased amount of Arginase-1, we
prospectively measured Arginase (s-Arg-1) in sera collected from 118 HL
patients, distinguished in a training set (N=40) and a validation set (N=78), and
35 healthy participants. 
Results: Arg-1 was increased in HL-PMN (at both m-RNA and protein level),
with an increased activity up to 15 times compared to healthy subjects matched
for age and sex. In lymphocytes isolated from healthy subjects and PHA-acti-
vated, T-cell proliferation and expression of activation markers were down-reg-
ulated by co-culture of with HL-N at ratio 1:2, 1:4, and 1:8. s-Arg-1 was
increased in HL patients compared to healthy subjects, and reduced after ther-
apy. At diagnosis, s-Arg-1 was higher in patients with advanced stage (p=0.045),
carrying B-symptoms (p=0.0048) and with a positive PET-2 scan after two
cycles of chemotherapy (p=0.012). In the validation set, baseline levels of s-
Arg-1 >200 ng/mL resulted in 92% sensitivity and 56% specificity to identify
patients with positive PET-2 scan. Patients carrying s-Arg-1 more than 200
ng/mL had a shorter progression free survival. In multivariate analysis, PET-2
and s-Arg-1 at diagnosis were the only significant prognostic variables (respec-
tively p=0.0004 and p=0.012). With these two prognostic variables, we were
able to define three distinct groups based on PET-2 status after two cycles of
chemotherapy and s-Arg-1 level at diagnosis. Patients with low s-Arg-1 and
negative PET-2 scan (score 0, N=63) had 89.5% PFS at 36 months versus
67.6% of patients with at least one unfavourable prognostic factors (score 1,
N=46) versus 37% of those patients with high s-Arg-1 and positive PET-2 (score
2, N=9, p=0.0004). 
Summary/Conclusions: In HL, neutrophils are dysfunctional and immunosup-
pressive. They also produce Arg-1 that can be easily measured and represents
a promising prognostic tool, to validate in larger prospective series.
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A NOVEL DIGITAL PCR ASSAY FOR MYD88 L265P MUTATION DETECTION
IN WALDENSTRÖM MACROGLOBULINEMIA: MINIMAL RESIDUAL
DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING
FREE DNA 
D Drandi1,*, E Genuardi1, I Dogliotti1, I Sciascia1, F Guerrini2, B Mantoan1,
M Gilestro3, V Muccio1, P Ghione1, P Omedè3, S Galimberti2, L Orsucci4,
F Cavallo1, M Boccadoro1,3, M Ladetto5, S Ferrero1
1Molecular Biotechnology and Health sciences, University of Torino, Torino,
2Clinical and Experimental Medicine, University of Pisa, Pisa, 3Hematology,
4Hematology 2, Città della Salute e della Scienza, Torino, 5Hematology, AON
SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Background: MYD88L265P mutation is the earmark of Waldenström
Macroglobulinemia (WM) and might represent an ideal marker for minimal resid-
ual disease (MRD) monitoring. However, current diagnostic tools, as allele-
specific quantitative PCR (ASqPCR), are not sensitive enough for MRD moni-
toring on peripheral blood (PB), harboring low concentrations of circulating
tumor cells. Besides, cell-free DNA (cfDNA) analysis has been shown to be
highly promising for mutational studies. However, more sensitive approaches
are needed and droplet digital PCR (ddPCR) might thus represent a powerful
tool in this setting.
Aims: Here we describe the applications of a new, highly sensitive, ddPCR
assay for MYD88L265P detection to assess: 1) its feasibility for MYD88L265P
mutation screening and MRD monitoring in bone marrow (BM) and PB; 2) its
potential application for mutational studies on cfDNA isolated from plasma.
Methods: BM, PB and plasma samples from a local series of WM and IgG-lym-
phoplasmacytic lymphomas (LPL) and IgM-MGUS patients (pts) were collected
at baseline and during follow-up. 20 healthy subjects were used as negative con-
trols. Genomic DNA (gDNA) and plasma derived cfDNA were extracted, according
to the blood or body fluid protocols, by Maxwell RSC automatic system
(Promega). MYD88L265P was assessed on gDNA (100ng) and cfDNA (5μl) by a
custom ddPCR assay on a QX100 System (Bio-Rad). For comparison ASqPCR
was assessed on gDNA (100ng), as described [Xu L, 2013]. MYD88L265P cut-off
was settled based on the healthy samples background level. IGH-based MRD
analysis was performed as described [Ladetto M, 2000; Drandi D, 2015].
Results: Once optimized, MYD88L265P ddPCR assay sensitivity was compared
to ASqPCR on a ten-fold serial dilution standard curves. Whereas ASqPCR
confirmed the reported sensitivity of 1.00E−03, ddPCR reached a sensitivity of
5.00E−05. Overall, 137 samples from 77 pts (68 WM, 6 LPL, 3 IgM-MGUS), 86
baseline (64 BM, 22 PB) and 51 follow-up (23 BM and 28 PB), were analyzed.
Median values at baseline were: age 67 years (range: 38-88), IgM 2.2 g/l (0.3-
10.8), IgG for LPL 1.9 g/l (0.8-3.4), B2M 2.6 mg/l (0.14-7.9), infiltration at BM
biopsy 45% (0-90%), BM infiltration by flow cytometry 10% (range: 0-87%). 12
pts had splenomegaly and 15 adenopathies. 63/64 (98.4%) diagnostic BM sam-
ples and 19/22 (86.4%) diagnostic PB samples scored positive for MYD88L265P
(BM median 4.5%, range: 0.02-72.6%: PB median 0.15%, range: 0.01-27.8%)
(all 3 negative PB had a positive BM match). To investigate the concordance
between methods, 100 samples (60 BM, 40 PB) were tested by both ASqPCR
and ddPCR. Overall a good concordance was observed (p=0.0005) with the
majority of discordances found in the follow-up samples (13/60 ddPCR posi-
tive-ASqPCR negative, 11/60 ddPCR negative-ASqPCR positive). However,
ddPCR was able to detect a higher number of mutated cases in diagnostic
samples (38 vs 36). Moreover, to investigate whether MYD88L265P ddPCR
could be used for MRD monitoring we compared it to the gold standard IGH-
based MRD assay. Preliminary results on baseline and follow-up samples (18
BM, 5 PB) from 5 pts, selected from 33/57 (57.9%) displaying an IGH rearrange-
ment, showed highly superimposable results between methods. Finally, pivotal
results on cfDNA from 33 pts showed 1 log higher median levels of MYD88L265P
mutation in cfDNA from plasma (0.7%, range 0-25,7%) compared to PB
(0.037%, range: 0.01-20.0%).
Summary/Conclusions: MYD88L265P ddPCR is a feasible and highly sensitive
assay for mutational screening and MRD monitoring in WM, particularly in sam-
ples harboring low concentrations of circulating tumor cells (e.g. PB after
immunochemotherapy). Moreover, cfDNA from plasma samples represents a
promising tissue source and might be an attractive, less invasive, alternative
to PB or BM for MYD88L265P detection. Methodological validation against IGH-
based MRD detection and flow cytometry, as well as correlations with clinical
data, are currently ongoing.
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THE ROLE OF PREGNANCY IN PROMOTING NON-HODGKIN LYMPHOMA
GROWTH AND AGGRESSIVENESS
T Katz1,*, A Abd El Wahed2, N Bettman1, M Hayun1, I Avivi3, NA Horowitz1
1Rambam Health Care Campus, 2Faculty of Medicine, Technion, Israel Institute
of Technology, Haifa, 3Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background: Lymphoma is the most common hematological cancer reported
during pregnancy. Recent data suggest that unlike lymphoma occurring outside
of pregnancy, pregnancy-associated non-Hodgkin lymphoma is characterized
by an excessive involvement of reproductive organs, advanced disease stage
at diagnosis and an aggressive course, potentially leading to a high death rate
of mothers. However, the mechanisms facilitating this clinical phenomenon are
not fully defined. 
Aims: The current study aimed to explore the hypothesis that pregnancy-
induced hormonal milieu could be an important mediator in the interaction
between lymphoma cells and their associated microenvironment, which may
potentially contribute to the growth and progress of lymphoma developing dur-
ing pregnancy. 
Methods: BALB/c pregnant and non-pregnant mice were subcutaneously (s.c.)
inoculated with murine B cell lymphoma cells (A20). Primary tumor growth was
measured biweekly in both groups. Several human lymphoma cell lines
(Ramos, Raji and Bl2) and the human lymph node (LN) stromal cell line (HK)
were assessed using flow cytometry, Western blot and qPCR analysis, for the
expression of estrogen and progesterone receptors (ER α&β and PR, respec-
tively). The direct effect of estradiol (E2) or progesterone on lymphoma cell
proliferation was analyzed by trypan blue exclusion. The effect of E2 on the
expression of growth factors VEGF-C and VEGF-D and their receptor VEGFR3
in lymphoma and stromal cells was analyzed by qPCR. Similarly, the expression
of metalloproteinases MMP-2 and MMP-9 was evaluated.
Results: Pregnant mice showed a significantly accelerated tumor growth, as
demonstrated by its increased volume and weight, following lymphoma cell
inoculation compared to non-pregnant mice (Fig. 1). All the three lymphoma
cell lines, as well as LN stromal cells were found to express ER α&β, but not
PR. The Ramos lymphoma cell line treated with E2 demonstrated an increased
proliferation rate. This effect was found to be mediated by ERα. In contrast,
progesterone appeared to have no effect on lymphoma cell proliferation or via-
bility. Furthermore, E2 induced the expression of VEGF-C and VEGF-D mRNA
in lymphoma and LN stromal cells. Notably, the expression of their receptor
VEGFR-3 was elevated in lymphoma cells. Likewise, E2 treatment resulted in
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increased expression of MMP-2 and MMP-9 mRNA in lymphoma and LN stro-
mal cells, respectively.
Figure 1.
Summary/Conclusions: The results of the current study have demonstrated
for the first time that pregnancy significantly enhances lymphoma growth in vivo.
This finding could be partially explained by a direct impact of pregnancy-induced
estrogen on lymphoma cell proliferation through its effect on the expression of
growth factors and metalloproteinases on lymphoma and LN stromal cells.
These potential mechanisms need to be be further explored and validated.
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ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WITH THE VARI-
ANT EEF1G-, RNF213- AND ATIC-ALK FUSIONS IS FEATURED BY COPY
NUMBER GAIN OF THE REARRANGED ALK GENE
I Wlodarska1,*, JA van der Krogt1, J Finalet Ferreiro1, K Jacobs2, E Geerdens2,
A Uyttebroeck3, P Vandenberghe1, T Tousseyn4, J Cools2
1Center for Human Genetics, KU Leuven, 2Center for the Biology of Disease,
VIB, 3Department of Pediatrics, UZ, Leuven, 4Department of Pathology, UZ
Leuven, Leuven, Belgium
Background: Molecular pathogenesis of ALK-positive Anaplastic Large Cell
Lymphoma (ALK+ ALCL) is not completely understood. Approximately 80% of
ALK+ ALCL cases harbor the t(2;5)(p23;q35)-associated NPM1-ALK rearrange-
ment, while variant 2p23/ALK translocations involving at least nine partner
genes have been identified in the remaining cases. The 5’ALK partners play a
key role in the constitutive activation of the chimeric protein by mediating its
oligomerization and its subcellular localization. In addition, they impact a range
of biological activities of ALK chimeras, including proliferation, transformation
and metastatic capacities. Comparative analysis of biological properties of ALK
oncoproteins, however, is hampered by the relative low frequency of different
variant ALK fusions.
Aims: The aim of the present study was to identify novel ALK-related fusions in
ALK+ ALCL and to gain more insight into the molecular pathogenesis of this tumor.
Methods: Six cases of ALK+ ALCL with a cytoplasmic expression of ALK
recently diagnosed in our institution were selected. The ALK fusions were char-
acterized using 5’RACE PCR, low coverage full genome sequencing (LCFGS),
FISH, array CGH and QRT-PCR. Functional studies were performed on the
IL3-dependent Ba/F3 cell line transformation model. 
Results: The ALK partner genes identified in the present cases included
EEF1G (Eukaryotic translation elongation factor 1 gamma), a novel ALK partner
located at 11q12.3 (one case), and the already known genes, RNF213/ALO17
(17q25) (one case) and ATIC (2q35) (four cases). Notably, all six cases dis-
played a similar LSI ALK break-apart FISH pattern showing copy number gain
of the rearranged ALK gene. The LSI 3’ALK/red signal was duplicated on
der(11)t(2;11)(p23;q12.3) in the case with EEF1G-ALK and amplified in cases
with the RNF213-ALK (5-7 extra red signals) and ATIC-ALK (2-4 extra red sig-
nals) rearrangements. FISH pattern in the ATIC-ALK cases suggests the pres-
ence of underlying inv(2)(p23q35) associated with one or two copies of the
derivative i(2)(q10) carrying two additional ATIC-ALK loci each, as previously
reported (PMID: 10706887). FISH findings were confirmed by array CGH in
two available cases. These data provide a strong evidence that ALCL driven
by at least three variant ALK fusions (EEF1G-, RFN213- and ATIC-ALK), but
not by the classic NPM1-ALK, requires an increased gene dosage of the
rearranged ALK. To assess whether this need is caused by the weaker pro-
moter of EEF1G, RFN213 and ATIC, compared to the NPM1 promoter, we
determined at first the relative mRNA expression level of the four ALK partner
genes. The study revealed a significantly lower expression of EEF1G, RNF213
and ATIC in nonmalignant lymph nodes when compared to NPM1. In the next
step, we compared oncogenic potential of all four fusions in the murine
hematopoietic IL-3 dependent Ba/F3 cell line. We found that EEF1G-ALK,
RNF213-ALK and ATIC-ALK are less potent to transform BaF3 cells than
NPM1-ALK, which showed the highest oncogenic potential.
Summary/Conclusions: ALK+ ALCL driven by three variant ALK fusions,
EEF1G-ALK (novel), RNF213-ALK and ATIC-ALK, are characterized by copy
number gain of the rearranged ALK. These lymphomas, but not the NPM1-
ALK-positive ALCL, likely require an increased gene dosage of the rearranged
ALK to compensate the relatively low and insufficient expression of the chimeric
gene driven by the partner genes. Occurrence of the ATIC-ALK rearrangement
in four out of six cases analyzed confirms that ATIC-ALK is the most prevalent
variant fusion in ALK+ ALCL.
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THE IMMUNE SURVEILLANCE CONSTRAINTS B CELL LYMPHOMAS
WITH CONTINUOUS CD40 SIGNALING TO AN INDOLENT PHENOTYPE
C Vincent-Fabert1,*, N Arnaud1, U Zimber-Strobl2, J Feuillard1, N Faumont1
1Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL) UMR
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Background: LMP1/CD40 transgenic mice, with specific expression of the
chimeric protein composed of the transmembrane domain of LMP1, the main
Epstein Barr Virus oncoprotein, and intracellular signaling domain of CD40 in
B cells, develop indolent lymphomas after one year in 60% cases. LMP1/CD40
expressing B cells are characterized by constitutive activation of the MAPK
JNK and ERK as well as the non-canonical NF-kappa B signaling pathway
(Hömig-Hölzel et al., 2008). Since (i) NF-kappa B can induce a strong immune
surveillance of the tumor when activated by LMP1, such as in transgenic LMP1
mice (Zhang et al., 2012) or in EBV immortalized human B cells (Le Clorennec
et al., 2006, 2008) and (ii) not all LMP1/CD40 transgenic mice will develop a
tumor, we supposed that the LMP1/CD40 activation signal could also favor
some immuno-surveillance of B cells.
Aims: We asked the question of the control by the immune system on B-cell
lymphoproliferation related to the constitutive activation of CD40 since the acti-
vation signal is very similar to that of the EBV protein LMP1. 
Methods: In order to test the effect of immunosuppression on the kinetics of
tumor emergence, we injected every day for 3 months the immunosuppressive
Cyclosporin A molecule (CsA) at a dose of 10 mg/kg to 8 months-old wild type
(WT) or LMP1/CD40 mice.
Results: While cyclosporin A was toxic in vitro on B cells, in vivo lymphoma-
genesis B was accelerated with a greater splenomegaly and increased number
of tumor cells in the blood in LMP1/CD40 mice treated with CsA in comparison
to untreated mice. Morphologically, tumor B cells of mice treated with CsA were
larger with a more immunoblastic phenotype, both on blood smears and spleen
tissue sections. Proliferation was increased both ex vivo and in vivo (Ki67 and
BrdU labeling). Similarly, the number of cells with an activated phenotype was
increased in CsA treated LMP1/CD40 mice. Finally, we noted that the injection
of CsA increases the expression of PDL -1/B7 -H1 and decreases the expres-
sion of CD95.
Summary/Conclusions: Despite direct toxic effect on B-cells in vitro, immuno-
suppressive treatment with CsA accelerates CD40 signal dependent B-cell
lymphomagenesis in vivo by inducing the transformation of an indolent tumor
into a tumor morphologically and phenotypically resembling to a Richter syn-
drome. This suggests that B-cell lymphomagenesis related to constitutive CD40
signaling is under partial control of the immune microenvironment, which may
influence tumor morphology. This may give some clues explaining why indolent
B-cells lymphomas may transform in aggressive form.
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EXPLOITING OXIDATIVE PHOSPHORYLATION TO IMPROVE ANTIBODY
THERAPY OF LYMPHOMA
E Vilventhraraja*, J Gribben, A Ivanov
Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom
Background: Diffuse Large B Cell Lymphoma (DLBCL) is the most prevalent
non-Hodgkin’s lymphoma (NHL) in adults. Since the addition of the Type I anti-
CD20 antibody Rituximab to chemotherapy, overall survival of patients has
improved dramatically compared to the pre-Rituximab era. However DLBCL
has the worst survival rates out of all NHLs with an average 5-year survival of
55%. Unfortunately 40% of all DLBCL patients relapse within 2 years, and
those that relapse or have refractory disease tend not to respond well to anti-
body-based salvage therapies. This has prompted many to try and enhance
the efficacy of anti-CD20 antibodies in order to improve first-line treatment of
DLBCL, resulting in the evolution of Type II humanised anti-CD20 antibodies.
Metabolism has been reported to be involved in Type II anti-CD20 antibody-
mediated cell death, however the mechanism and extent of metabolic involve-
ment remains unknown.
Aims: The aim of this investigation is to see whether oxidative phosphoryla-
tion can be exploited to improve the efficacy of Type II anti-CD20 therapy of
DLBCL.
Methods: Here, we established a panel of DLBCL cells that consisted of two
groups of cell lines; one group harbouring a gene expression profile (GEP)
with an enrichment of genes associated with an oxidative phosphorylation
(OxPhos) phenotype, and the other group without this gene signature. We
used the XF Seahorse Mito Stress Test to reveal bioenergetic profiles of the
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cell lines before and after treatment with a panel of anti-CD20 antibodies that
included Type I and Type II anti-CD20 antibodies. This assay utilises the differ-
ential activity of four mitochondrial inhibitors to calculate basal respiration, ATP
production, and maximal and spare respiratory capacity of the cell. Using the
same method we then assessed whether chemically manipulating oxidative
phosphorylation added to the effect on the bioenergetic profile observed fol-
lowing treatment with anti-CD20 antibodies. Finally, we performed clonogenic
survival assays to assess whether cytotoxicity of anti-CD20 antibodies was
enhanced by simultaneous treatment with Metformin, a well-established
inhibitor of oxidative phosphorylation.
Results: We have observed that treatment with anti-CD20 antibodies has a
significant effect on the bioenergetic profile of all DLBCL cells in our panel.
Each of the antibodies in our panel had a differential ability to increase or
decrease bioenergetic activity, in a cell-line specific manner. Further, we have
shown that treatment with Metformin causes a significant reduction in the
amount of energy produced by oxidative phosphorylation in both groups of cells
in our panel. Finally, when analysing the clonogenic survival of cell lines we
have found that the cytotoxicity of Type II anti-CD20 antibodies, was enhanced
by simultaneously treating cell lines with an oxidative phosphorylation inhibitors.
Summary/Conclusions: With regard to clonogenicity of DLBCL cells, our data
suggests that compounds that inhibit oxidative phosphorylation enhance the
cytotoxicity of Type II CD20 antibodies. We believe that understanding the
mechanism of loss of clonogenic survival will allow us to establish effective
treatment combinations to significantly improve the efficacy of anti-CD20 anti-
body therapy in DLBCL.
E1390
CORRELATION OF PRE-TREATMENT SERUM CYTOKINE ABNORMALITIES
AND BLOOD MARKERS OF IMMUNOSUPPRESSION IN PATIENTS WITH
LYMPHOMA
M Binder1,*, MM O’Byrne2, MJ Maurer2, SM Ansell3, AL Feldman4, JR Cerhan2,
AJ Novak3, LF Porrata3, BK Link5, TE Witzig3
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Background: Multiple studies have demonstrated that higher ratios of pre-treat-
ment absolute lymphocyte counts (ALC) and absolute monocyte counts (AMC)
are associated with improved outcomes in non-Hodgkin (NHL) and Hodgkin lym-
phoma (HL). Conversely, elevated serum cytokines at diagnosis are associated
with inferior outcomes. Lymphocytes and monocytes have been implicated in
immune surveillance, suppression of host anti-tumor immunity, and alterations of
the tumor microenvironment supporting growth and survival of lymphoma cells.
The relationship between pre-treatment serum cytokines and ALC and AMC
remains unknown. We hypothesized that patients with elevated serum cytokines
would be more likely to have suppressed ALC/AMC ratios.
Aims: To evaluate the relationship between pre-treatment serum cytokines and
ALC/AMC ratios in patients with newly diagnosed diffuse large B-cell lymphoma
(DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), T-cell lym-
phoma (TCL), and HL.
Methods: We studied pre-treatment samples from 725 patients with lymphoma
(DLBCL=202, FL=216, MCL=88, TCL=69, HL=150) who enrolled in the Uni-
versity of Iowa / Mayo Clinic Lymphoma SPORE between 2002 and 2011 and
were part of previous studies on cytokine secretion in lymphoma. Three-hun-
dred seventy-six of these patients also had ALC/AMC ratios available, obtained
from pre-treatment complete blood counts. Serum cytokine concentrations in
patients and controls were measured using a standard ELISA (Invitrogen,
Camarillo, CA) and analyzed using the Luminex-200 system. Data were
acquired using STarStation software (Applied Cytometry, Dinnington, UK).
Twelve cytokines passed quality control and were determined to have adequate
measurements within the dynamic ranges of the assays: IL-1Ra, IL-2R, IL-8,
IL-12p40p70 (IL-12), EGF, HGF, FGF-β, EOTAXIN, MIP-1β, MCP-1, IP-10, and
MIG. The cytokines used for analysis were median-normalized to correct for
plate effects. To assess the relationship between pre-treatment serum cytokines
and ALC/AMC ratios, Spearman’s rank correlation coefficients were calculated.
P-values below 0.001 were considered statistically significant.
Table 1. Correlations between blood cytokines and ALC/AMC ratios by
disease.
Values denote Spearman’s rank correlation coefficients (* for p<0.001)
Results: The median age at enrollment was 60 years (18 - 93), 407 patients
(56%) were male. Ann Arbor stages were I-II (35%), III-IV (64%), or unknown
(1%). Nineteen percent were experiencing B symptoms and 30% had bone
marrow involvement. International prognostic index scores were 0-1 (49%), 2
(28%), 3 (16%), or 4-5 (6%). Table 1 shows the statistically significant correla-
tions by lymphoma type.
Summary/Conclusions: Patients with NHL or HL with high pre-treatment
serum cytokines tended to have lower ALC and higher AMC. Similar results
were observed in all subsets except MCL. These data support the notion that
high levels of serum cytokines are immunosuppressive and add to our under-
standing why the ALC/AMC ratio is of prognostic significance in lymphoma. It
also provides further rationale to target immunosuppressive monocytes and
the tumor microenvironment for therapeutic benefit.
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KPT-8602, A SECOND GENERATION CLINICAL STAGE SELECTIVE
INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND SHOWS ENHANCED
ANTI-TUMOR ACTIVITY WHEN COMBINED WITH VENETOCLAX OR
BENDAMUSTINE IN DLBCL
E Baloglu*, H Chang, W Senapedis, T Kashyap, S Elloul, S Shacham, S Friedlander
Karyopharm Therapeutics, Newton, MA, United States
Background: Selinexor, the first-in-class oral selective inhibitor of nuclear
export (SINE) compound, is currently in Phase 1/2 clinical trials for the treatment
of solid and hematological malignancies, including relapsed/refractory diffuse
large B-cell lymphoma (DLBCL; NCT02227251). XPO1, the target of selinexor,
has been shown to export >200 cargo proteins from the nucleus including major
tumor suppressors (TSPs). SINE compounds prevent the nuclear export of
many of TSPs facilitating suppressor reactivation. KPT-8602 is a second gen-
eration clinical stage oral SINE compound currently undergoing a Phase 1/2
open label study in patients with relapsed/refractory multiple myeloma
(NCT02649790).
Aims: In preclinical studies KPT-8602 demonstrated improved tolerability over
selinexor, possibly due to its reduced brain penetration. The goal of this study
was to test whether single agent or combination of KPT-8602, with either vene-
toclax (selective BCL2 inhibitor) or bendamustine (DNA damaging agent) can
further enhance the anti-tumor effect of KPT-8602 in DLBCL.
Methods: The effects of KPT-8602, bendamustine and venetoclax as single
agents and KPT-8602 in combination with either bendamustine or venetoclax
on cell viability were tested on a panel of DLBCL cell lines (i.e. RL, DB, SUDHL4,
SUDHL10, Pfeiffer, U937, and Farage including the double hit lymphomas Tole-
do, DoHH2, and SUDHL6) using MTT assays. Total RNA and whole protein cell
lysates from DLBCL cells were extracted and analyzed by qPCR and
immunoblots. DoHH2 sub-cutaneous xenograft in mice were treated with KPT-
8602, venetoclax or bendamustine alone or in combinations of KPT-8602-ben-
damustine or -venetoclax. Percent tumor growth inhibition (%TGI) and overall
survival were determined for each treatment condition. Tumors were collected
and analyzed using standard immunohistochemistry (IHC) methods.
Results: Combinations of KPT-8602 with bendamustine or venetoclax were
highly effective both in vitro and in vivo. Using an MTT assay, we showed KPT-
8602 was potent against a panel of DLBCL cells (median IC50: ~100 nM) and
was synergistic/additive when combined with bendamustine or venetoclax. In
the KPT-8602-bendamustine combination DoHH2 xenograft, treatment with
each drug showed a%TGI of 52% (KPT-8602) and 76% (bendamustine) while
the combination%TGI was 107%. Western and IHC analyses showed that KPT-
8602 reduced the expression of key DNA Damage Response (DDR) proteins
preventing treated cells from repairing the damage induced by bendamustine.
In the KPT-8602-venetoclax in vivo study, the individual drugs had similar%TGI
(52%; KPT-8602 and 56%; venetoclax). However, when the two drugs were
combined, the treatment showed an additive effect (98%). Although, the anti-
BCL2 proteins, Bax and Bim, were upregulated in KPT-8602 treated xenograft
tumors, these pro-apoptotic pathway proteins were elevated to a greater extent
in the combination-treated tumors suggesting the two drugs induced non-redun-
dant mechanism of apoptosis activation.
Summary/Conclusions: KPT-8602 shows single agent activity as well as
enhanced antitumor activity in combination with bendamustine or venetoclax
through modulation of the DDR and BCL2 pathways in models of DLBCL
(including double hits). These data provide rational support for the study of sin-
gle agent KPT-8602 and in combinations with bendamustine or venetoclax in
future DLBCL clinical trials.
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ANALYSIS OF DIFFERENT BIOLOGICAL FACTORS IN PATIENTS AFFECTED
BY PERIPHERAL T-CELL LYMPHOMAS NOT OTHERWISE SPECIFIED:
GATA-3 EXPRESSION IS ASSOCIATED TO REFRACTORY DISEASE AND
POOR OUTCOME
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Background: Peripheral T-cell lymphomas (PTCL) have an aggressive clinical
course with a poor 5-year overall survival with conventional therapy. Autologous
stem cell transplantation (autoSCT) and allogeneic stem cell transplantation
(alloSCT) can improve long-term disease control in first and second remission,
respectively. Prognostic factors are not able to discriminate patients with
chemorefractory disease. Preliminary evidence from gene expression profiling
(GEP) and immunoistochemical studies have suggested that the majority of
PTCL-not otherwise specified (PTCL-NOS) can be subdivided in two different
groups based on GATA3 and Tbet (transcription regulators of T-helper 2 and T-
helper 1 lymphocytes) expression with a poorer prognosis in the former group.
Aims: Because GEP studies are not feasible in routine clinical practice, we
investigated whether expression changes of those proteins could be evaluated
by immunohistochemistry (ICH) and used to predict prognosis
Methods: We collected paraffin tissues from 47 consecutive patients (pts) with
a diagnosis of PTCL-NOS treated at different Italian Institutions, and 38 were
available for analysis. Histology was centrally reviewed. Sections were analyzed
for Ki-67, GATA3, T-bet expression by IHC. Results were expressed as mean
percentages of positive tumor cells. Cases were regarded as immunoreactive
for GATA-3 and T-bet if at least 27% and 25% of neoplastic cells exhibited positive
staining, respectively. In case of GATA-3, we performed a quantitative analysis
[from score 0 (<1%) to score 4 (>80%)] combined with staining intensity [score
1 (weak) to score 3 (strong)] and we defined high score for a summary value of
6-7. Median age was 57 years (range,18-79 years); 13 (38%) pts were charac-
terized by IPI>2; 29 pts (76%) were candidated to transplantation whereas 9
(24%) were not due to age >65 years (n=8) or limited stage/IPI (n=1). All the pts
received an anthracycline-based induction chemotherapy followed by autoSCT
in 9 patients (7 in first remission); 16 pts (42%) underwent alloSCT in first remis-
sion (n=3) or at relapse (n=13). The median follow-up of alive pts was 33 months.
Results: The mean value of Ki67 expression was 60% (range, 10%>95%).
Only 5 of 38 (13%) pts were immuno-reactive for T-bet whereas 17 of 38 (45%)
were positive for GATA-3. Only two (5%) pts were characterized by double
expression of GATA-3 and T-bet. 5 pts (31%) had a high GATA3 score that
was associated with a median PFS of only 6 months. We did not observe dif-
ferences baseline clinical characteristics between pts with positive (n=17) and
negative (n=21) immunostaining for GATA-3. Pts immunoreactive for GATA3
were characterized by poor response to anthracycline therapy: 10 of 17 PD
(58%) as compared to 4 of 21 (19%) in the negative cohort (p=0.01). Cases
with positive GATA3 expression were significantly associated with a reduced
5-year PFS as compared to those with no expression [PFS: 6%
(95%CI:0%>22%) versus 39% (95%CI:18%>59%), (p=0,03); OS: 38%
(95%CI:13%>63%) versus 58% (95%CI:30%>78%),(p=ns), respectively]. By
multivariable analysis, GATA-3 and Ki67 retained prognostic value on PFS
whereas both GATA-3 and IPI influenced significantly the OS.
Summary/Conclusions: Our analysis identifies GATA3 ICH expression as a
strong prognostic and predictive biomarker among PTCL-NOS. Pts with positive
GATA3 expression values were characterized by chemorefractory disease and
poorer outcome even with transplantation strategies. Validation of this biomark-
er in a larger series of patients is ongoing.
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IN MANTLE CELL LYMPHOMA, BCR SIGNALING AND WNT PATHWAY
INDUCE Β-CATENIN STABILIZATION AND CELLULAR RE-LOCALIZATION
BY DIFFERENT MECHANISMS
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F Baran-Marszak1
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Background: Mantle cell lymphoma (MCL) cells survival relies on the B-cell
receptor (BCR) signaling pathway that also facilitates the interactions with the
microenvironment. In more than 50% of MCL cases, the Wnt/β-catenin pathway
is activated and contributes to cyclin D1 and c-myc expression. As both path-
ways are important for cell survival as well as tumor cell adhesion, we hypoth-
esized that a cross talk between BCR signaling and β-catenin could affect the
cell homeostasis and could be targeted by specific inhibitors.
Aims: The aim of the project is to identify the role of β-catenin in MCL and how
it is activated. In parallel, the inhibition of a cross talk between the BCR signaling
and the Wnt pathway by ibrutinib is analysed.
Methods: Peripheral blood B cells from MCL patients (n=8) were pretreated
with Wnt/ β-catenin inhibitors: XAV-939 (25 μM), promoting degradation of β-
catenin through the Axin dependent destruction complex or PKF118-310 (500
nM) blocking the interaction of β-catenin with the transcription factor TCF4.
Cells were pre-treated with quercetine (20µM) a PI3K inhibitor, or Ibrutinib
(5µM) a BTK inhibitor. BCR signaling pathway was then stimulated with soluble
anti-IgM (10 mg/ml). As a control, Wnt/β-catenin pathway was activated by the
conditioned media from human bone marrow stromal cells secreting large
amount of Wnts. Apoptosis, β-catenin -dependent genes expression and β-
catenin subcellular localization were analyzed by flow cytometry, RT-qPCR
and cell fractionation respectively. 
Results: β-catenin expression is detected in all leukemic MCL samples in vari-
able amount. The inhibition of β-catenin/TCF transcriptional complex by
PKF118-330 induces tumor cells apoptosis, suggesting an important contribu-
tion of β-catenin to MCL cell survival. In parallel, β-catenin level increases rap-
idly in response to BCR stimulation and this stabilization is inhibited by a pre-
treatment with Ibrutinib showing the existence of a cross talk between these
two survival pathways. Wnt stimulation stabilizes β-catenin and its translocation
into the nucleus leads to an increase of the target genes i.e. axin2, cyclin D1
and LEF1. After BCR stimulation, even though β-catenin rapidly translocates
into the nucleus it does not induce the same transcriptional response, sug-
gesting a different role of β-catenin when activated by BCR or Wnt. Moreover,
stabilization of β-catenin degradation complex by a pretreatment with XAV939
does not induce its degradation after BCR stimulation suggesting that BCR
signaling interferes with the β-catenin degradation process. Thus, the impact
on β-catenin by BCR signaling is likely independent from Wnt.
Summary/Conclusions: The BCR signaling pathway leads to β-catenin sta-
bilization and nuclear translocation. However, this nuclear translocation trans-
lates into a different transcriptional response than the one induced by Wnt.
Most likely, β-catenin associates with different nuclear partners driving the
expression or repression of BCR specific genes. Since β-catenin can stabilize
cell adhesion structures, β-catenin likely represents another player through
which the BCR signaling impacts on the interaction of MCL cells with the
microenvironment. Importantly, this cross talk can be efficiently interrupted by
Ibrutinib, currently used in mantle cell lymphoma treatment.
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METHOTREXATE ELIMINATION AND TOXICITY: THE ROLE OF MTHFR
677C>T POLYMORPHISM IN PRIMARY CNS LYMPHOMA PATIENTS
TREATED WITH HIGH DOSE METHOTREXATE MONOTHERAPY
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Background: Methylenetetrahydrofolate reductase (MTHFR) plays a key role
in metabolism and homeostasis of intracellular folate, and substitution of C >T
is reported to be associated with decreased MTHFR enzyme activity, contribut-
ing to low folate level. The genetic association of MTHFR 677C>T in methotrex-
ate (MTX) toxicity was evaluated in a number of studies, however the results
were conflicting. The substantial heterogeneity within the study population
could compromise the effect of MTHFR 677C>T polymorphism on MTX toxicity,
and conflicting published results may have attributed to this.
Aims: The aim of this study was to evaluate the role of MTHFR 677C>T poly-
morphism in MTX toxicity within a homogenous study population by limiting
cancer type to primary central nervous system lymphoma (PCNSL) and
chemotherapy protocol to the first four cycles of high dose methotrexate
monotherapy and fixed leucovorin rescue regimen (HD-MTX & HD-ARA regi-
men).
Methods: Data of patients diagnosed with PCNSL treated with HD-MTX & HD-
ARA regimen were retrieved. The effect of MTHFR 677C>T polymorphism on
the incidence of MTX toxicity was evaluated using a generalized estimating
equation analysis.
Results: A total of 111 patients (402 cycles) was included in the analysis. The
hematologic toxicity and nephrotoxicity were most frequently presented in
patient with heterozygous variant genotype, with an incidence of 57 (29.1%)
and 7 (3.6%). The incidence rate of hepatotoxicity and oral mucositis requiring
treatment was highest in patient with wild genotype (hepatotoxicity: 7.3%, oral
mucositis: 4.1%). None of the patients with homozygous variant genotype expe-
rienced the oral mucositis. Twenty eight point six percent of nephrotoxicity
occurred in cycles with delayed elimination, and delayed elimination was most
frequently seen in patients with homozygous variant genotype (3.6%). The risk
for developing clinically meaningful hematologic toxicity was higher in patients
with heterozygous variant genotype than wild genotype (odds ratio; OR: 2.60,
95% confidence interval; CI: 1.32-5.09, P-value=0.0055). No valid difference
was observed between patients with homozygous variant and wild genotype
in terms of hematologic toxicity. Other explanatory variables shown to increase
the risk of hematologic toxicity were the presence of delayed elimination (OR:
10.06, 95% CI:2.87-35.31, P-value=0.0003), high serum lactate dehydroge-
nase level exceeding the upper range of normal at the time of diagnosis (OR:
2.04, 95% CI:1.09-3.81, P-value=0.0257) and concomitant administration of
penicillin antibiotics with MTX (OR: 2.88, 95% CI:1.17-7.07, P-value=0.0213).
No correlation between age, sex, Eastern Cooperative Oncology Group per-
formance status, concomitant administration of proton pump inhibitor and
hematologic toxicity was demonstrated. For hepatotoxicity, MTHFR 677C>T
polymorphism was the only explanatory variable included in the model. The
MTHFR 677C>T polymorphism was not shown to be correlated with risk of
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hepatotoxicity (heterozygous variant genotype; OR: 0.75, 95% CI: 0.29-1.96,
P-value=0.5575, homozygous variant genotype; OR: 0.80, 95% CI: 0.24-2.69,
P-value=0.7176).
Summary/Conclusions: The MTHFR 677C>T polymorphism is shown to be
a valid marker in predicting MTX associated hematologic toxicity. Clinically sig-
nificant nephrotoxicity might occur in patients without delayed elimination, sug-
gesting that factors other than serum MTX level could play a role. MTX induced
hepatotoxicity and oral mucositis occur independently of the serum MTX level.
E1395
IMPACT OF TREATMENT ON RNA EXPRESSION OF IMMUNE PROFILE IN
PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA
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Background: Although immunosuppression has long been recognized in clas-
sical Hodgkin lymphoma (cHL), the underlying basis for the lack of an effective
immune response against tumor remains unclear. Recently, our group showed
increased frequencies of pro and anti-inflammatory cytokines, such as inter-
leukins (IL)-6, IL-10, TNF-alpha and sCD25, in cHL patients and the impact of
treatment on these cytokines. These cytokines participate in the Hodgkin and
Reed-Sternberg (HRS) cells survival and immunological escape.
Aims: In this study we aimed to evaluate the immune gene expression profile
in cHL patients at diagnosis and the impact of treatment on this profile.
Methods: Twenty consecutively diagnosed cHL patients, with whole blood RNA
extracted at diagnosis and after treatment, were recruited for this study and
prospectively evaluated. The general expression of 96 messengers RNAs pres-
ent in the peripheral blood and involved in immune response was performed
by a customized quantitative real-time PCR array (TaqMan® Low Density
Array). We also included 7 healthy controls. The data was normalized with B2M
mRNAs levels and relative gene expression was calculated by the 2^DDCt
method, considering Wilcoxon test and Benjamini-Hochberg adjustment to cor-
rect p-values.
Results: At diagnosis we observed that blood of cHL patients presents higher
expression of IL-10 (2.4 fold, p=0.013) and decreased expression of CCL2 (-5
fold, p=0.028), CD40 (-2 fold, p=0.013) and HLA-DRA (-2 fold, p=0.028) com-
pared with healthy controls. On the other hand, after treatment, the mRNAs
levels returned to normal and no immune-related gene studied was found in
different amounts when compared to control subjects. Considering patients
after treatment, an important reduced expression of BCL2 (1.5 fold, p= 0.043),
CCL2 (3,7 fold, p= 0.003); CCL22 (1.9 fold, p=0.025); CCL5 (1.7 fold, p=0.025),
CD40 (2.2 fold, p=0.007), CD80 (2 fold, p=0.015), CSF2(2,5 fold, p=0.007),
HLA-DRA (1.7 fold, p=0.025), IL-2RA (1.7 fold, p=0.025), IL-4 (2.5 fold,
p=0.007), IL-6 (3.7 fold, p=0.007), LTA(1.7 fold, p=0.038), RORC (1.6 fold,
p=0.025) in comparison with cHL patients before treatment. Epidemiologic and
clinical correlation are currently being done.
Table 1.
Summary/Conclusions: In this study, we showed that, at diagnosis, cHL
patients presented with more inflammatory gene expression and, after treat-
ment, a more effector immunological profile is found. Interestingly, posttreatment
immunological profile is similar to healthy controls. Understanding cHL associ-
ated immunosuppression and the immune reconstitution after treatment maybe
the key to develop new prognostic factors and treatment strategies.
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MIR-181C REGULATES BRK1, PART OF THE WAVE COMPLEX, AND IS
INVOLVED IN T CELL FUNCTION
SP Lim*, G Mufti, J Gaken
King’s College London, London, United Kingdom
Background: miRNAs are short endogenous non-coding RNAs of 18-25
nucleotides in length which play an important role as negative regulators of
gene expression either through mRNA degradation or translational repression.
miRNAs have been shown to be involved in many cell functions such as angio-
genesis, cell adhesion, cell differentiation, cell proliferation and cell survival.
Thus, their aberrant expression implicated in various types of cancer including
haematological malignancies. In this project, we studied miR-181 family which
has been reported to play a crucial role in haematopoiesis, including megakary-
ocytic, erythroid and myeloid differentiation as well as B and T cell development
and differentiation. Most of the available methodologies for miRNA target iden-
tification are based on computational algorithms. Therefore, there is a relatively
high incidence of false positive target identification. To enable the identification
of biologically relevant miRNA targets, a novel functional assay was developed
in our lab, which is based on positive/negative selection (Gaken et al, 2012).
By using this assay, we identified two functional targets of miR-181c which are
BRK1 and DHTKD1. Due to the well-known role of WAVE protein (BRK1 is a
component of the WAVE complex) in actin polymerisation in T cells, and the
published studies on the function of BRK1 in cell migration in neuroblastoma,
squamous cell lung carcinoma, renal carcinoma and osteosarcoma, we focused
on studying the biological roles of BRK1 in T cells. As a model system, we used
Jurkat T cells and investigated the role of BRK1 in actin polymerisation. 
Aims: The aims of this project are to identify the potential targets of miR-181
family by using a dual selection functional assay and to study the roles of BRK1
(identified target of miR-181c) in actin polymerisation and T cell functions, in
association with WAVE2 complex.
Methods: Using a functional assay, we identified BRK1 and DHTKD1 as novel
targets of miR-181c/d and validated these targets by quantitative RT-PCR and
western blot analysis of cells transfected with miR-181c/d as well as miR-181c
and d inhibitors. We focused on ascertaining the roles of BRK1 in T cell func-
tions. We demonstrated a targeted reduction of BRK1 in Jurkat T cells through
shRNA (lentiviral strategy) or siRNA knockdown. The effects of BRK1 knock-
down on actin polymerisation and Jurkat T cells functions including changes in
total cellular F-actin content, T cell proliferation, T cell activation, lamellipodia
formation and T cell spreading as well as cell migration were assessed. 
Results: By using the novel functional assay, two targets of miR-181c/d have
been identified which are BRK1 and DHTKD1. Both of the genes were validated
as targets for miR-181c at protein level. To study the roles of BRK1 in Jurkat T
cell functions, we first showed that knockdown of BRK1 in Jurkat T cells reduced
the expression of other proteins (WAVE2, Abi1, Sra1 and Hem1) that are part
of the WAVE2 complex and this indicated that any effects on T cell functions
due to BRK1 knockdown is indeed a result of dissociation of WAVE2 complex.
Stable knockdown of BRK1 in Jurkat T cells showed changes in total cellular
F-actin content prior and after T cell activation by F-actin staining using Rho-
damine phalloidin. Next, we showed that stable BRK1 knockdown decreased
cell proliferation by trypan blue staining. Also, BRK1 knockdown showed
reduced CD69 expression, indicating defects in T cell activation. Besides that,
we also demonstrated that knockdown of BRK1 caused defects in lamellipodia
formation and cell spreading upon Jurkat T cell activation. Knockdown of BRK1
also resulted in defects in cell migration in Jurkat T cells.
Figure 1.
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Summary/Conclusions: This study showed that miR-181c regulates BRK1
by translational repression and BRK1 plays a crucial role in Jurkat T cell func-
tions including cell proliferation, T cell activation, cell spreading and cell migra-
tion mediated via actin polymerisation.
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BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS
TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE
II CLINICAL TRIAL (ROMULUS)
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Background: Polatuzumab vedotin (PoV) is an antibody drug conjugate (ADC)
comprised of a monoclonal antibody targeting the B-cell marker, CD79b, linked
to the microtubule-disrupting agent, monomethyl auristatin E (MMAE). PoV
has shown clinical activity in patients with relapsed/refractory (R/R) non-
Hodgkin lymphoma. Target expression, CD79b, and expression of anti-apop-
totic factors, such as BCL-2, have the potential to mediate sensitivity and/or
resistance to ADCs. Moreover, diffuse large B-cell lymphoma (DLBCL) is a
heterogeneous disease in which distinct subtypes defined by gene expression
profiles and, in some cases, prevalence of genetic variants, have been defined.
Aims: Perform a retrospective biomarker analysis on tumor samples at base-
line (archival biopsies) from patients in the phase II trial (ROMULUS) who
received PoV with rituximab, to correlate the activity of PoV with biomarkers in
R/R DLBCL and follicular lymphoma (FL).
Methods: We evaluated target expression (CD79b) and potential for PoV
resistance driven by BCL-2 expression by immunohistochemistry (IHC) and
quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 34
DLBCL and 19 FL patients with sufficient tissue for analysis. In DLBCL, cell of
origin (COO) was evaluated by signature gene expression and a linear predictor
score method described previously.1 Additionally, mutations (i.e., CD79b,
CARD11, MYD88 and EZH2) enriched in COO DLBCL subtypes, and that may
confer resistance to anti-lymphoma therapies, were evaluated using a multi-
plexed gene panel by next-generation sequencing.
Results: CD79b expression was comparable in DLBCL and FL by qRT-PCR
and IHC. Consistent with the role of CD79b as a B-cell lineage marker, expres-
sion was seen in all samples. There was a range of CD79b expression, but
~90% of patients had expression at higher levels (IHC2/3+). Response to PoV
was independent of CD79b expression, as responses were seen in patients
with both high and lower levels. For BCL-2, there was no significant difference
in expression across indications by qRT-PCR. However, while high BCL-2
expression (IHC 2/3+) was observed in ~90% of FL patients, expression was
more distributed across levels in DLBCL. Importantly, there was no relationship
between BCL-2 expression and response to PoV by IHC or qRT-PCR. PoV
showed activity in both GCB and the more aggressive ABC DLBCL subtypes.
Moreover, we observed mutations associated with COO, including EZH2 (n=2)
in GCB patients and dual CD79b/MYD88 (n=2) in ABC patients. Tumor shrink-
age and clinical response to PoV were observed in these patients. Similarly,
mutations, such as MYD88 (n=2), associated with resistance to ABC targeting
agents were also observed but clinical response was variable.
Summary/Conclusions: These analyses demonstrate broad activity of PoV
in R/R DLBCL and FL. CD79b was expressed across B-cell malignancies;
while a majority of samples expressed high levels of CD79b, even minimal
expression was sufficient for PoV activity. Though anti-apoptotic regulators,
like BCL-2, have potential to drive resistance to microtubule-disrupting agents,
this was not observed with PoV. While the DLBCL treatment landscape is evolv-
ing to account for biologic subtypes, PoV showed activity independent of sub-
type, in contrast to other targeted therapies. Overall, the robust and expansive
activity observed with PoV may position it as an effective component of therapy
across DLBCL subtypes and FL. Studies of PoV combined with other anti-lym-
phoma agents in multiple indications, including in newly diagnosed DLBCL
patients, are ongoing.
Reference
1. Pfeifer, et al. Leukemia. 2015;29:1578-86.
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ROLE OF BORTEZOMIB IN COMBINATION WITH AEROBIC OXIDATION
INHIBITOR ON BURKITT LYMPHOMA CELLS
T Wang*, X Shao, J Cai, B Xu, J Zhong, F Chen
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University, Shanghai, China
Background: Caner and non-malignant cells vary vitally with respect to their
metabolic pathway. Consuming elevated levels of glucose from a frequently nutri-
ent-poor environment in order to satiate anabolic respiratory reactions, is a suf-
ficiently prevalent phenomenon of cancer cell metabolic adaptions, which has
been conceptualized as the “Warburg effect”. However, the molecular mechanism
underlying this metabolic reprogramming is obscure. Recent investigations pro-
pose that the oncogene-directed metabolic reprogramming, rather than the per-
manent malfunction of mitochondrial oxidative phosphorylation (OXPHOS), may
have profound effects on aerobic glycolysis. The biochemical aspects of the War-
burg effect outline a strong explanation for the cause of cancer cell proliferation.
However, the more reliant of malignant cells manifest on glycolysis, the more
vulnerable to drugs targeting this pathway they will be. Prognosis of Burkitt lym-
phoma, the most aggressive B-cell lymphoma, is poor even in the Rituximab
era. Therefore, targeting the aberrant metabolic pathway rather than illimitably
increase the dose of chemotherapy prompts a highly desirable strategy for treat-
ing this aggressive lymphoma. Bortezomib is the first proteasome inhibitor
approved for treating multiple myeloma and mantel cell lymphoma. In addition to
the well-known mechanism on proteasome inhibition, bortezomib is supposed
to have effects on the phosphoinositide 3-kinase/protein kinase B/mammalian
target of rapamycin (PI3K/Akt/mTOR) pathway, which is deemed crucial to under-
pin the glycolysis of malignant cells. Given the central role of glycolysis in cancer
metabolism, we sought to explore the effect of bortezomib on tumor cell metab-
olism in Burkitt lymphoma. Considering the fact that even counteracting glycol-
ysis, cancer cells shows low-glucose resistance, which may associate with an
increased compensatory upregulation of mitochondrial OXPHOS, the present
study was undertaken to investigate the potential of using Bortezomib in combi-
nation with OXPHOS inhibitor as a novel therapy for Burkitt lymphoma.
Aims: To investigate the effect of bortezomib (BTZ) in combination with aerobic
oxidation inhibitor oligomycin (OM) on proliferation and apoptosis of Burkitt
lymphoma cell line Raji, and to explore its possible molecular mechanism.
Methods: Raji cells were treated with different concentrations of BTZ (0, 5, 10,
15, 20, 25 and 30 nmol/L) alone or in combination with OM (0.05 µg/mL). Cell
proliferation was detected by CCK-8 method. The mRNA and protein expression
levels of oncogene C-myc, hypoxia inducible factor-1α (HIF-1α) and its target
genes vascular endothelial growth factor (VEGF) and glucose transporter 1
(GLUT1), as well as key enzymes and proteins related to glycolysis pathway
including hexokinase II (HKII), lactic dehydrogenase (LDHA) and succinate dehy-
drogenase (SDHA) were detected by real-time fluorescent quantitative PCR and
Western blotting, respectively. Glucose consumption and lactic acid generation
were examined by Glucose (hexokinase, HK) Assay Kit and Lactate Assay Kit,
respectively. Apoptosis and cell cycle distribution were analyzed by FCM.
Results: The result of CCK-8 method showed that treatment with different con-
centrations of BTZ could inhibit the proliferation of Raji cells in a dose-dependent
manner (all P<0.01), the inhibition effect was significantly enhanced at lower
initial concentrations of BTZ (5, 10, 15 and 20 nmol/L) in combination with OM
(all P<0.01). The expression levels of C-myc, HIF-1α, VEGF, GLUT1, HKII,
LDHA and SDHA mRNAs and proteins were suppressed by BTZ, and the
expression levels were further down-regulated due to treatment with BTZ in
combination with OM (all P<0.05). The inhibition of glucose consumption and
lactic acid generation induced by BTZ in combination with OM was significantly
enhanced as compared with those induced by BTZ alone (both P<0.05). The
result of FCM showed that BTZ could induce apoptosis of Raji cells in a dose-
dependent manner, and the cell cycle was arrested in G2/M phase under a rel-
atively high concentration of BTZ (25 nmol/L). Furthermore, when BTZ was
used in combination with aerobic oxidation inhibitor OM, significant synergistic
effect was observed; besides, the cell cycle was arrested at G0/G1phase
instead.
Figure 1.
Summary/Conclusions: BTZ can hinder the glycolysis pathway in Burkitt lym-
phoma cell line Raji, which can also be enhanced by the involvement of aerobic
oxidation inhibitor OM, acting as a synergistic inhibition. The mechanism of
this synergy may be interpreted as inhibiting the dual metabolic pathway, name-
ly glycolysis and aerobic oxidation. This inhibition of dual metabolic pathway
may imply a novel approach to the treatment of Burkitt lymphoma.
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IN CLASSICAL HODGKIN LYMPHOMA PATIENTS
S De Matteis1,*, S Carloni1, F Limarzi2, R Napolitano1, C Agostinelli2
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tal, Bologna, Italy
Background: Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine
kinase involved in glycogen metabolism, in cell cycle progression, differentiation
and embryogenesis. One of the major biological functions of GSK-3β is to inhibit
β-catenin by sequestration and promotion of its proteasomal degradation in
the Wnt canonical pathway. Aberrant GSK-3β has been implicated in the patho-
genesis of many disorders such as diabetes, Alzheimer’s and Parkinson’s dis-
ease and cancer. The biological role of GSK-3β in classical Hodgkin lymphoma
(cHL) has not yet been clarified.
Aims: The aim of this study is to clarify the biological relevance of GSK-3β in
the regulation of the β-catenin in cHL.
Methods: Three tissue microarrays (TMA) for immunohistochemical studies
were obtained from formalin-fixed paraffin-embedded samples collected at diag-
nosis from 100 cHL patients. TMA sections were investigated by antibodies
reactive with pY216 and pS9 GSK-3β and β-catenin. Three samples of hyper-
plastic lymph nodes were added to investigate the expression of the same
markers in the reactive lymphoid tissue. Immunohistochemical preparations
were visualized and images were captured using Olympus Dot-slide microscope
digital system equipped with the VS110 image analysis software.
Results: Our results showed that the pY216 GSK3β, which is the stimulatory
form of the kinase, was observed in 100% of cHL cases with a range of positivity
in the neoplastic population from 8% to 100% and a mean expression of 56%.
In 78/100 cases, we noticed that the kinase was predominantly relocated in
the nucleus of the Hodgkin and Reed-Sternberg cells (Figure A), in which it is
expected to be highly active. Conversely, the germinal centres of the reactive
follicles showed a weak cytoplasmic positivity of the stimulatory pGSK-3β.
Moreover, 20 samples were assessed positive for the inhibitory form pS9 GSK-
3β with a range of positivity from 1% to 58% and a mean expression of 8%. β-
catenin was detected only in 12% of the cases with a nuclear localization (Figure
B). Interestingly, a statistically significant association between the presence of
β-catenin in the nucleus and the inhibitory pGSK-3β expression was observed
(P=0.013).
Figure 1.
Summary/Conclusions: Our results reported the constitutive activation of the
stimulatory pGSK-3β that plays a previously unrecognized important role in the
negative regulation of β-catenin transcription activity in cHL cells, by affecting
its binding to the promoters of a subset of related-target genes. GSK-3β is an
intriguing protein that seems to be involved in the pathogenesis of cHL, but
many questions remain unanswered and the role of GSK-3β and its potential
application in this disease become an interesting aspect to clarify. These data
suggest GSK-3β as a promising novel target for therapeutic intervention in cHL.
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AUTOLOGOUS STEM CELL TRANSPLANTATION MODULATES T-CELL
RECEPTOR PROFILES IN HIV-INFECTED AND -UNINFECTED PATIENTS
WITH NON-HODGKIN LYMPHOMA
D Bertoli1,*, M Chiarini1, F Serana1, C Ghidini1, A Sottini1, V Giustini1,
M Vaglio Tessitore1, A Roccaro1, C Cattaneo2, C Lamorgese2, A Re2, G Rossi2,
L Imberti1
1Centro di Ricerca Emato-oncologica AIL (CREA), 2Hematology, ASST Spedali
Civili, Brescia, Italy
Background: Treatment of HIV+ lymphoma patients has been greatly improved
by the combination of highly active antiretroviral therapy with high-dose
chemotherapy and autologous stem cell transplantation (ASCT). It has been
demonstrated that the T-cell recovery after ASCT does not differ between HIV+
and HIV- patients with non-Hodgkin lymphoma (NHL), because the two groups
present with a similar thymic output, as measured by means of T-cell receptor
excision circles (TRECs) quantification. Nevertheless, whether T-cell repertoire
(TCR) modifications may occur at the same extent in the two group of patients
receiving ASCT has not been described yet.
Aims: To better elucidate the extent of T-cell recovery and its effects on the
TCR repertoire in HIV+ and HIV- patients with NHL who underwent ASCT.
Methods: Eleven ASCT-treated HIV+ and nine HIV- NHL patients were followed
for 2 years (T0: pre-ASCT; T6, T12 and T24: 6, 12 and 24 months from ASCT,
respectively). The number of TRECs was measured by quantitative real-time
PCR. Recent T emigrants (RTE), the cells that were recently produced in the
thymus, were identified as CD4+CD45RA+CCR7+ lymphocytes expressing the
CD31 molecule. The analysis of TCR beta variable (TCRBV) families was per-
formed by complementarity determining region 3 (CDR3) spectratyping. The
deviation of CDR3 size distributions from a theoretical Gaussian curve in each
TCRBV family was analysed both qualitatively and quantitatively using the gen-
eralized Hamming distance method. Results were compared to that of age
matched healthy controls (HC).
Results: Starting at T6, both HIV+ and HIV- patients presented with a gradual
but significant increase in naïve CD4 lymphocytes (difference between means:
T12 − T6=27 cells/ml, p=0.011), RTE (T12 − T6=23 cells/ml, p=0.003) and
TRECs+ cells (T12 − T0=1355 TRECs/ml, p<0.001) that reached the top at
T24. TCR repertoire analysis showed that, compared to HC, the mean propor-
tion of TCRBV families with shifted, restricted and mono/oligoclonal profiles of
TCRBV families was significantly higher in samples obtained pre-ASCT (HIV+
− HC=32.3%, p<0.001; HIV- − HC=39.8%, p<0.001) and post-ASCT (HIV+ −
HC=29.8%, p=0.002; HIV- − HC=24.2%, p=0.012) in both groups of patients.
Quantitative analysis showed that the mean perturbation of CDR3 distributions
was higher compared to HC in infected and uninfected patients both pre-ASCT
(HIV+ − HC=10.5%, p<0.001; HIV- − HC=12.8%, p=0.001) and post-ASCT
(HIV+ − HC=13.1%, p<0.001; HIV- − HC=12.6%, p<0.001). However, in both
HIV+ and HIV- patients, the pattern of TCR repertoire distortions changed 24
months after ASCT, as supported by modifications in the number of perturbed
TCRBV and within the CDR3 distribution profiles, leading to either enlargement
or restriction of the TCR heterogeneity.
Summary/Conclusions: Using different approaches, we confirmed that new
CD4+ cell production is similarly increased in HIV+ and HIV- patients with NHL
that received ASCT. The production of new lymphocytes was not sufficient to
induce a general enlargement of the TCR repertoire but, nevertheless, led to
relevant modifications of TCRBV family profiles, not related to HIV infection.
Because TCR repertoire is usually extremely stable in HC, these modifications
cannot be merely due to a physiologic repertoire “drift” over time, but are likely
due to a repertoire re-assortment occurring after ASCT. Modulation of TCR
repertoire may have important implications for immune system-mediated anti-
infective and anti-tumor activities.
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DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) STUDY REVEALS
BIOLOGICAL HETEROGENEITY BETWEEN ETHNICALLY DIVERSE
COUNTRIES; VALIDATION OF 6-GENE PROGNOSTIC SCORE IN AN
INTERNATIONAL COHORT
N Tekin1,2,*, N Omidvar3, T Morris4, B Timar5, E Gagyi5, P Conget6, F Bruna6,
R Basak7, O Naik7, C Udomsakdi Auewarakul8, N Sritana9, D Levy10, SP Bydlowski10,
J Pereira11, MP Dimamay12, F Natividad12, JK Chung13, N Belder2, I Kuzu14,
D Paez15, M Dondi15, R Carr16, H Ozdag2, RA Padua17
1Department of Viral Transformation, Heinrich-Pette Institute Leibniz Institute
for Experimental Virology, Hamburg, Germany, 2Biotechnology Institute, Ankara
University, Ankara, Turkey, 3Haematology Department, University of Cardiff
School of Medicine, Cardiff, 4MRC Clinical Trials Unit, University College Lon-
don, London, United Kingdom, 51st Department of Pathology and Experimental
Cancer Research, Semmelweis University, Budapest, Hungary, 6Centro de
Medicina Regenerativa, Facultad de Medicina Clinica Alemana, Universidad
del Desarrollo, Santiago, Chile, 7Translational Research Laboratory, Depart-
ment of Molecular Pathology, ACTREC-Tata Memorial Centre, Mumbai, India,
8Chulabhorn Cancer Centre and Faculty of Medicine, Siriraj Hospital, Mahidol
University, 9Cancer Molecular Diagnostics Unit, Chulabhorn Hospital, Bangkok,
Thailand, 10Laboratory of Genetics and Molecular Hematology, 11Department
of Hematology, University of São Paulo Medical School, São Paulo, Brazil,
12Research and Biotechnology Division, St. Luke’s Medical Center, Quezon,
Philippines, 13Seoul National University Hospital, Seoul, Korea, Republic Of,
14Department of Pathology, Ankara University School of Medicine, Ankara,
Turkey, 15Department of Nuclear Sciences and Application, Division of Human
Health, International Atomic Energy Agency, Vienna, Austria, 16Department of
Haematology, Guy’s & St Thomas’ Hospital, King’s College, London, United
Kingdom, 17Institut Universitairé d’Hématologie, Inserm Unit 1131, Université
Paris VII, Hôpital Saint-Louis, Paris, France
Background: Biological variation may arise from ethnic diversity or environ-
ment which may influence disease or host response. The International Atomic
Energy Agency sponsored a prospective cohort study of diffuse large B-cell
lymphoma (DLBCL) in countries from 5 United Nations-defined geographical
regions to test this hypothesis. 
Aims: The molecular analysis of DLBCL was conducted aiming to use the pre-
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viously reported 6-gene score (LMO2, BCL6, FN1, CCND2, SCYA3 and BCL2)
(Lossos N Engl J Med 2004; 350: 1828–37) as a predictor of prognosis in DLB-
CL and validation of the utility of this scoring system in an international cohort.
Methods: Consented patients with DLBCL (n=162) in Hungary (n=28), Chile
(n=27), India (n=27), Thailand (n=27), Brazil (n=18), Turkey (n=15), Philippines
(n=13) and S Korea (n=7) were treated with R-CHOP between 2008 and 2013.
RNA from formalin fixed paraffin embedded (FFPE) diagnostic tissue was
shipped to a central laboratory. Expression of the 6 genes were assayed, using
either high volume or low volume (Brazil) cDNA, by Taqman QPCR and relative
quantification assigned based on expression ratio to normalised copy number.
In a multivariate analysis, as described in the following equation: mortality-pre-
dictor score=(-0.0273xLMO2)+(-0.2103xBCL6)+(-0.1878xFN1)+(0.0346xCC-
ND2)+(0.1888xSCYA3)+(0.5527xBCL2), variation in gene expression by coun-
try was investigated using analysis of variance, while variation in event-free
(EFS) and overall survival (OS) for the whole cohort was investigated using
Cox proportional-hazards regression models. 
Results: There was significant inter-country variation for all 6 genes individually
(p<0.0001), and when combined in the 6-gene model (p<0.0001). The variation
in 2y EFS between countries ranged from 56% (Turkey) to 85% (Chile) With
the analysis of the cohort as a whole the 6-gene score returned a hazard ratio
of 0.35 (95% CI 0.17–0.74) for OS, demonstrating the score can stratify relative
survival risk. To further develop the prognostic value, patient mortality-predictor
scores were ranked into 2 groups with lower or higher risk of death. In a uni-
variate Kaplan–Meier model of these 2 groups [low (n=81), and high (n=81)],
defined by the prediction model based on the weighted expression of the 6
genes (Malumbres Blood 2008; 111:5509-5514), there was no significant dif-
ference in EFS between low and high risk groups (p=0.18); however, a signif-
icant difference in OS between low and high risk (p<0.01) was observed (Figure
1A). When patients with a high international prognostic indicator (IPI) (3-5),
n=51, and low IPI (0-2), n=111 were analysed separately, the 6-gene score did
not add prognostic value to the low IPI cases (p=0.08), but did add additional
predictive value for OS, though not EFS, in high IPI cases (Figure 1B, p<0.05).
There was no significant difference between patients treated with CHOP (n=28)
or R-CHOP (n=132) for EFS or OS. Conclusion: The analysis of this cohort
showed that the 6-gene model added prognostic information for overall survival
in high IPI cases, thereby validating its utility for predicting outcome in an inter-
national setting.
Figure 1. Kaplan-Meier curves showing 6-gene predictor score correlating
with overall survival (OS) and adding a prognostic value to a high Inter-
national Prognostic Index (IPI).
Summary/Conclusions: The analysis of this cohort showed that the 6-gene
model added prognostic information for overall survival in high IPI cases, there-
by validating its utility for predicting outcome in an international setting.
Non-malignant hematopoietic disorders
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EVALUATION OF IRON OVERLOAD IN THE HEART AND LIVER TISSUE
BY MAGNETIC RESONANCE IMAGING AND ITS RELATION TO SERUM
FERRITIN AND HEPCIDIN CONCENTRATIONS IN PATIENTS WITH
THALASSEMIA SYNDROMES
V Karakus1,*, A Uğur Kurtoğlu2, DE Soysal3, E Kurtoğlu4
1Department of Hematology, Muğla Sitki Kocman University Research and
Training Hospital, Muğla, 2Department of Biochemistry, Antalya Research and
Training Hospital, Antalya, 3Department of Internal Medicine, Katip Celebi Uni-
versity, Ataturk Research and Training Hospital, izmir, 4Department of Hema-
tology, Antalya Research and Training Hospital, Antalya, Turkey
Background: Thalassemias are inherited disorders characterized by the pres-
ence of hypochromic microcytic anemia due to the reduced or absent production
of one or more globin chains in hemoglobin. Individuals with thalassemia are
classified according to genotype and the severity of anemia as thalassemia
major, intermedia, or minor. Life expectancy is dependent on lifelong blood
transfusions and iron-binding therapies. Iron overload (IOL) and associated tis-
sue damage are the most important factors that determine mortality and mor-
bidity.
Aims: We aimed to evaluate iron accumulation in the heart and liver by MRI
in thalassemia major, thalassemia intermedia, and S-ß thalassemia patients
and to examine its association with ferritin and hepcidin levels.
Methods: Serum ferritin and hepcidin levels were recorded. Iron overload (IOL)
in the liver and heart parenchyma was determined based on the standardized
R2 and T2* values calculated on MRI. The results were evaluated considering
the tissue iron overload, serum ferritin and hepcidin levels. 
Results: Comparing the 109 patients with the 30 healthy controls showed the
mean age: 24.4±11 vs 31.2±5 years, and, median levels of serum ferritin and
hepcidin: 1693 vs 40 ng/mL and 1.94 vs 0.355 ng/mL; (p=0.0001), respectively.
In order of the disease diagnosis, the median cardiac T2* and hepatic R2
values were: 25.3 msec, 31.4 msec, 28.2 msec, and, 4.49 msec, 8.14 msec,
and 10.35 msec on MRI, respectively. Comparing age, serum ferritin and hep-
cidin levels in the patients with or without iron overload, only ferritin was signif-
icantly higher (p=0.004) in the patients with IOL by means of cardiac tissue,
and, age and ferritin were significantly higher (p=0.036 and p<0.001) in the
patients with IOL by means of liver tissue. Positive correlations between serum
ferritin levels and the severity of IOL were found (p=0.002 and p<0.001). 
Summary/Conclusions: In the present study, enhanced intestinal iron absorp-
tion in the intervals between successive transfusions characterized by
decreased serum hepcidin levels were considered to result in iron accumulation
in our patients.
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HYPERFERRITINEMIA AND SERUM INFLAMMATORY CYTOKINES IN
ADULTS WITH GAUCHER DISEASE TYPE 1
F Lorenz1, E Pawlowicz2, C Kämpe Björkvall3, A Bulanda Brustad2, M Machaczka2,*
1Department of Radiation Sciences, Section of Hematology, Umea University,
Umea, 2Hematology Center Karolinska, Karolinska University Hospital Hud-
dinge, Stockholm, 3Department of Medicine, Sunderby Regional Hospital of
Norrbotten County, Lulea, Sweden
Background: Gaucher disease type 1 (GD1, OMIM #230800) is a rare multi-
system lysosomal storage disorder (autosomal recessive). The storage of glu-
cosylceramide in macrophages produces an inflammatory response with iron
recycling dysregulation and a release of cytokines. Patients with GD1 suffer
from an increased susceptibility to malignancies (e.g., multiple myeloma), and
while the underlying mechanisms are not known, it is postulated to be associ-
ated with macrophage dysfunction and immune dysregulation.
Aims: This study was undertaken to evaluate ferritinemia, iron metabolism
profiles and inflammatory cytokine concentrations in Swedish patients with
GD1.
Methods: The study included 16 adults with GD1 aged 20–86 years. All but
one patient (94%) carried at least one allele with c.1226A>G (N370S) mutation
in the GBA1 gene. Zimran’s severity score index (SSI) was calculated for all
patients at the time of their inclusion in the study. The following laboratory vari-
ables were collected from fresh blood for analysis: iron profile (s-ferritin, p-iron,
p-TSAT); HFE gene mutations; s-hepcidin; LFTs; CRP; serum IL-1β, IL-6, IL-
8, IL-10, TNF-α; serum sIL-2Rα. Assessment of the aforementioned variables
was performed at baseline (the first blood sampling at Karolinska) and at fol-
low-up (every 6–12 months).
Results: Hyperferritinemia >500 µg/L was present in all but 3 patients (81%).
Values of P-transferrin, P-Fe, and P-TSAT were within normal limits for all but
one patient. There was no correlation between hyperferritinemia and patient’s
sex, spleen status, and clinical status as defined by the Zimran’s SSI. HFE
gene mutations were analyzed in 11 patients: 4 pts were heterozygous for
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His63Asp mutation, one pt was heterozygous for both His63Asp and Cys282Tyr
mutations, and 6 patients had no mutation in the HFE gene. No obvious corre-
lation between ferritinemia and HFE genotype was detected in the studied
group. Serum hepcidin concentrations were analyzed in 10 patients; 7 pts had
normal hepcidin results; one pt with a normal ferritinemia (75 µg/L) had a low
hepcidin concentration at 4 µg/L and 2 pts with a hyperferritinemia of 1910 and
833 µg/L had elevated hepcidin at 50 and 55 µg/L, respectively. Cytokine and
inflammatory marker analysis The serum concentrations of IL-1β, IL-8, IL-10
were normal in all studied GD1 patients. The mean and median serum con-
centrations of TNF-α, IL-6, sIL-2Rα, and CRP were within normal limits in all
studied patients. However, in 5 of 11 patients (45%) TNF-α was moderately
increased. Additionally, 2 patients with the highest TNF-α concentrations (28.4,
and 30.4 ng/L) showed mildly elevated IL-6 concentrations (5.9 and 10.7 ng/L,
respectively). In the first aforementioned patient, CRP was increased to 12
mg/L but was normal in the second patient. Of note, the first patient was diag-
nosed with concomitant chronic lung infection (Mycobacterium avium and
Aspergillus fumigatus). Serum levels of IL-6 were within normal limits in the
remaining 14 patients (87%). Serum sIL-2Rα concentrations were within normal
range in 62% of patients (10/16). Longitudinal assessment of hyperferritinemia
and inflammatory cytokines in treated patients with GD1 Eight patients with at
least 36 months’ follow-up data were eligible for a longitudinal assessment of
ferritinemia, TNF-α, IL-6, IL-8, and sIL-2Rα. Four patients were untreated when
their baseline sampling was performed and began GD1 therapy. All remained
on unchanged therapy throughout follow-up. Longitudinal assessments of the
studied variables for the treated patients are presented in the figure.
Figure 1.
Summary/Conclusions: The study revealed that hyperferritinemia is common
in Swedish GD1 patients. Unlike hemophagocytic lymphohistiocytosis, hyper-
ferritinemia in GD1 is not associated with high serum levels of sIL-2Rα. In
some, but not all patients TNF-α and IL-6 levels could be mildly elevated. GD1
therapy has a potential to improve ferritinemia and cytokine levels.
E1404
PEG-HBCO MEDIATED CARBON MONOXIDE AND OXYGEN TRANSFER
TO HYPOXIC RED BLOOD CELLS PREVENT, SLOW, AND/OR REVERSE
SICKLING IN VITRO
R Jubin*, P Buontempo, R Yglesias, C Buontempo, A Abuchowski
Prolong Pharmaceuticals, South Plainfield, United States
Background: In Sickle Cell disease (SCD), a mutation promotes HbS poly-
merization causing abnormal cell morphology that results in occlusion of small
blood vessels and increased circulatory inflammation. PEGylated-carboxyhe-
moglobin (PEG-HbCO; SANGUINATE) is a novel therapeutic agent designed
to release carbon monoxide (CO) and then transfer oxygen (O2) to hypoxic tis-
sue and cells. PEG-HbCO was shown to mediate transfer of either a CO or O2
and restore normal morphology to hypoxic, sickled RBCs in vitro. Studies are
now focused on the potential therapeutic implications of delaying sickling, which
should maintain normal blood flow through hypoxic microvasculature. 
Aims: Current in vitro studies examined the effects of time and dose of PEG-
HbCO to not only reverse, but also prevent or delay sickling by transferring CO
and expedite atmospheric O2 transfer to the sickled RBCs. 
Methods: Reversal of sickling were conducted by deoxygenating RBCs from
healthy and SCD volunteers followed by treatment with either PEG-HbCO, fully
oxygenated PEG-Hb (PEG-HbO2) or PEG-BSA. For prevention of sickling stud-
ies, fully oxygenated RBC suspensions were treated with increasing amounts of
PEG-HbCO and then subjected to hypoxia for 3 hours. Time-dose effects were
quantified by area under the curve (AUC) analysis. O2 transfer studies were con-
ducted by treating hypoxic, sickled RBCs to increasing concentrations of PEG-
HbCO and raising the pO2 from 3.8mm to 40mm. In all studies, the fractions of
CO-Hb, O2-Hb and reduced Hb were determined by co-oximetry and sickled
RBCs were quantified by imaging flow cytometry of fixed RBC specimens.
Results: PEG-HbCO -mediated delivery of either CO or O2 unsickles SCD
RBCs. The sickle reversion time-course studies showed differential kinetics
between the CO and O2 capacity to cause unsickling. AUC analysis at 20 min-
utes demonstrated that both CO and O2 reversed sickling by 41% and 42%,
respectively. PEG-HbO2 was able to exert substantial unsickling by 5 minutes,
where PEG-HbCO showed a delayed, more pronounced effect, peaking approx-
imately 20 to 40 minutes post-treatment. When fully oxygenated SCD RBCs
were pretreated with PEG-HbCO prior to oxygenation, sickling was inhibited
with an IC50 of 2.5±0.6 mg per mL in deoxygenated saline. In addition, treatment
concentrations below IC50 values had increased time-dose AUC values indi-
cating that sickling was delayed. Oxygen transfer facilitation studies indicated
that PEG-HbCO increased the rate of unsickling as measured by AUC by 50%
and 15% at 4 and 2 mg per mL, respectively. These levels are within the expect-
ed therapeutic dosage of PEG-HbCO.
Summary/Conclusions: RBCs from patients with SCD undergo morphological
changes. It is only when the fraction of oxygenated HbS reaches a sufficient
level that reversion to normal morphology occurs which promotes vascular per-
fusion. These experiments showed a concentration and time-dependent effect
of PEG-HbCO ability to deliver both O2 and CO to sickled RBC. Additionally
since ASH 2016, PEG-HbCO was shown to improve rheology and down-regu-
late inflammation in a hemorrhagic shock model; these pathologies also exist
in SCD. These data suggest that PEG-HbCO is a promising gas transfer agent
that has the potential to improve sickle cell morphology by reversing sickling;
the underlying pathology of sickle cell disease co-morbidities as well as
decrease hypoxia-induced inflammation. SCD patients with hyperhemolysis
and acute chest syndrome have been treated with PEG-HbCO under eINDs.
Phase 2 trials with PEG-HbCO are underway in SCD vaso-occlusive crisis.
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HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: RETROSPECTIVE ANALYSIS
FOR PROGNOSTIC FACTORS
B Dholaria*, W Hammond, A Shreders, T sher
Hematology- Oncology, Mayo Clinic, Jacksonville, United States
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life- threatening
systemic inflammatory condition. Due to rarity of the cases, it presents difficul-
ties in diagnosis and management. Survival remains poor despite aggressive
chemotherapy. Patients with fever of unknown origin, lymphadenopathy, dete-
riorating performance status, encephalopathy and elevated systemic inflam-
matory parameters frequently show no clear cut diagnostic criteria specific for
HLH. Among adults, late onset of inherited HLH is possible, but acquired HLH
triggered by infection, malignancy or autoimmune disease is more frequent
than in pediatrics.
Aims: Patient outcomes varied markedly despite standardize therapy. Reliable
prognostic disease markers may help to tailor intensity of therapy and predict
long term outcomes. We attempt to look for variables associated with difference
in mortality within 30 days of diagnosis.
Methods: We performed a retrospective search on mayo clinic patient database
for the patients with the diagnosis of HLH from 2005 to 2015. HLH-04 criteria
were used to select the study population.1 Patients were divided in two groups
based on survival after the diagnosis. We analyzed different clinical and labo-
ratory parameters to detect significant difference between patients expired with-
in 30 days of diagnosis or survived longer than 30 days. Chi-square analysis
was performed between two groups of patients: 1- Time to death from diagno-
sis<30 days. 2- Time to death from diagnosis >30 days. We assessed difference
in various clinical and laboratory parameters.
Table 1.
Results: Demographics: 40 patients were included in the analysis who met
HLH- 04 criteria. Mean age was 49 years, 40% (16/40) were female and 60%
(24/40) were male. Underlying HLH etiology was malignancy 37% (15/40),
infection 20% (8/40), rheumatological 17% (7/40), idiopathic 20% (8/40). Two
patients were peripartum and one with Kikuchi syndrome. Fever was present
in 90% (36/40) and splenomegaly was found in 75% (30/40) of the patients.
Labs: Average ferritin at diagnosis 19546 mcg/L, ferritin peak 36284 mcg/L,
ALP 226U/L, AST 274U/L, T. bilirubin 6.3mg/dL, LDH 937 U/L, triglyceride 269
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mg/dL, albumin 2.4g/dL and EBV DNA PCR were positive in 32% (13/40) of
the patients. Treatment: Median time from onset of symptoms to start the treat-
ment was 8.1 weeks. Steroids were used in 92% (37/40), etoposide was used
in 55% (22/40), and HLH 04 protocol (Etoposide/dexamethasone/cyclosporine)
was used in 40% (16/40) of the patients. IVIG was used in 13% with underlying
rheumatological process. Mean follow up was 57 weeks (0.1 to 336 weeks) for
the whole group. Total 40% (16/40) died within 30 days of diagnosis.
Outcomes: Risk of 30- days mortality was significantly higher in the patients
with ferritin >5000 mcg/L at the time of diagnosis and age >55 years. Out of
total 40 patients, 54% (12/22) died in ferritin >5000mcg/L group and 22% (4/18)
died in ferritin<5000 mcg/L group within 30 days. (p- 0.03) Death rate within 30
days was 65% (11/17) with age >55 years and 22% (5/23) with age<55 years
at the time of diagnosis of HLH. (p-0.05). We did not find any significant differ-
ence in the following factors: 30 day mortality was 31% (4/13) in EBV positive
group and 44% (12/27) in EBV negative group (P-0.40); 50% (8/16) in malig-
nant group and 33% (8/24) in non- malignant. (P-0.29). No difference between
the groups in terms of gender, etoposide use, and time to start treatment was
found in 30 days mortality. Table 1 summarizes the findings.
Summary/Conclusions: Elevated ferritin at the time of diagnosis and older
age are associated with significant risk of 30 day mortality from HLH. In com-
bination with other prognostic factors age and ferritin can be used to risk strat-
ification at the time of diagnosis. These factors can be incorporated in future
clinical trials to choose different treatment pathways.
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CLINICAL RELEVANCE OF LOW PERCENTAGE OF GLYCOSYLATED
FERRITIN IN MANAGEMENT OF ACQUIRED HEMOPHAGOCYTIC
LYMPHOHISTIOCYTOSIS: A SINGLE CENTER EXPERIENCE
M Nabergoj1,*, M Marinova2, L Astolfi3, G Binotto1, M Zaninotto2, M Plebani2,
F Vianello1, G Semenzato1
1Hematology and Clinical Immunology, 2Department of Laboratory Medicine,
3Department of Neuroscience, Padova University School of Medicine, Padova, Italy
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-
threatening condition characterized by excessive chaotic and uncontrolled
inflammation leading to multiorgan failure and death. HLH can be either primary
(familial), when caused by a genetic mutations affecting cytotoxic function, or
secondary (acquired), when due to infectious, malignant, rheumatologic or
metabolic conditions. Although diagnostic scores have been proposed such
as HLH-04 criteria, which were validated only in pediatric patients, and the
HScore, HLH diagnosis is still challenging owe to lack of solid criteria allowing
differential diagnosis with other multisystem illnesses characterized by fever,
hepatic failure, and neurologic symptoms. Recently, a percentage of glycosy-
lated ferritin (GF)<20% has been proposed as highly specific of HLH and useful
in the differential diagnosis from other hyperinflammatory syndromes, such
severe sepsis and flare of a secondary underlying disease.
Aims: To validate the usefulness of glycosylated ferritin levels in identification
of patients with HLH and to evaluate its potential role in predicting treatment
outcome.
Methods: Over a 2-year period, nineteen adult (>18 years) patients with a clin-
ical and laboratory pattern consistent with HLH were included in the study.
HLH-04 criteria and HScore were applied for HLH diagnosis. The percentage
of glycosylated ferritin was measured by an in-house assay (Marinova et al, in
press). Specificity and sensitivity for each approach was then calculated.
Results: Ten out of 19 (53%) subjects had clinical and laboratory findings con-
sistent with HLH. In all cases an underlying disorder was identified: infection
(n=1), autoimmune disease (n=1), malignancy (n=1), Hodgkin or non Hodgkin
lymphoma (n=1 and n=6, respectively). All but one patient (90%) fulfilled the
HLH-04 criteria, whereas a high probability HScore (>90%) was present in 7
out of 10 subjects (70%). Nine out of 19 patients (47%) in whom HLH was
ruled out, underlying disorders were autoimmune disease (n=1), infection (n=1),
AML (n=1), non-Hodgkin lymphoma (n=5). Among these 9 patients, 2 (22%)
met at least five HLH-04 criteria and no one had a HScore probability >90%.
Ferritin levels failed to differentiate patients with HLH (11565±95161 vs
4669±3541 μg/L, HLH vs non-HLH, p=0,18). When GF was measured in our
cohort, a percentage of GF level<20% was observed in 9/10 patients with HLH,
whereas all unaffected patients had GF level >20%. We found a negative linear
correlation between HScore and GF percentage (p<0,05, r=-0,54) and between
HLH-04 criteria and GF percentage (p<0,05, r=-0,47). All three methods were
able to significantly discriminate affected patients from unaffected (all p<0,05),
but GF level<20% showed higher sensitivity against HScore (90% vs 70%)
and better specificity against HLH-04 (100% vs 78%). Moreover, GF shows
higher negative predictive value compared to the other diagnostic methods
(GF: 90%). Five patients had GF levels measured over the course of the dis-
ease. Although the very limited number of patients does not allow to draw any
conclusion, two patients who did not show recovery of GF levels >20% within
one week after treatment initiation died within one month, while 3 patients who
experienced a rise in GF >20% showed a resolution of HLH-related clinical
picture and longer survival (median 6 months). 
Summary/Conclusions: In our study a fraction of glycosylated ferritin<20%
showed high concordance between HLH-04 criteria and HScore and it seemed
of help in identifying patients affected by HLH when scores are contradictory
as well as in excluding false positive cases. Monitoring GF levels over the
course of HLH may also allow to predict response to therapy.
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PROSPECTIVE STUDY OF SPLENECTOMY IN AUTO-IMMUNE CYTOPENIA
OF CHILDREN
N Aladjidi1,*, Y Bertrand2, H Fernandes1, B Nelken3, M Pasquet4, N Cheikh5,
S Bayart6, C Armari-Alla7, H Chambost8, Y Perel1, T Leblanc9, G Leverger10
1pediatric oncohematology unit/CEREVANCE/CIC1401, Inserm CICP, Univer-
sity Hospital of Bordeaux, Bordeaux, 2Pediatrics, Institut d’Hématologie et d’On-
cologie Pédiatrique, Lyon, 3Pediatric Hematology Unit, University Hospital of
Lille, Lille, 4Pediatric Hematology Unit, University Hospital of Toulouse,
Toulouse, 5Pediatric Hematology Oncology Unit, University Hospital of
Besançon, Besançon, 6Pediatric Immuno-Hematology Oncology Unit, Univer-
sity Hospital of Rennes, Rennes, 7Pediatrics Unit, University Hospital of Greno-
ble, Grenoble, 8Pediatric Hematology Unit, University hospital of Marseille -
Timone Enfants, Marseille, 9Hemato-Immunology Unit, Robert Debré Hospital,
APHP, 10Pediatric Hematology Unit, Armand Trousseau Hospital, APHP, Paris,
France
Background: Chronic immune thrombocytopenic purpura (cITP), autoimmune
hemolytic anemia (AIHA) and Evans syndrome (ES) are rare autoimmune dis-
eases in children, characterized in 20-70% of cases by recurrent outbreaks
and treatment dependence. In AIHA and ES, the effectiveness of splenectomy
has never been clearly established, as it was in ITP. Since 2004, the
OBS’CEREVANCE cohort has been recording all the cases of auto-immune
cytopenias in children treated in the 30 French pediatric hematology units.
Aims: This prospective observational national study reports the practice, effi-
cacy and safety of splenectomy performed for all the patients of this cohort.
Methods: On 1st January 2016, patients recorded in this cohort who underwent
splenectomy in second-line after immunoglobulin and/or steroid failure, before
the age of 18, were analyzed in 3 homogeneous groups according to the target:
isolated cITP, isolated AIHA, and ES.
Results: Among the 1094 children included in the cohort, diagnosed between
1986 and 2014 (556 isolated cITP, 356 isolated AIHA and 172 ES), 181 under-
went a splenectomy. 86 of those splenectomies were performed in third or
more line in heterogeneous patients. 95 splenectomies were carried out on
second-line, 80 for isolated cITP, 8 for isolated AIHA and 7 for ES. Laparoscopy
was realized in 79% of cases. The median age at splenectomy was respectively
11.5, 5.9 and 8.4 years. The median delay from diagnosis to splenectomy was
respectively 2.3, 0.7 and 1.8 years. The complete response achievement rate
was similar in the 3 groups. With a median follow-up of 5 years post splenec-
tomy, there was no need for further immunosuppressive treatment for 64/80
cITP (80%), 4/8 AIHA (50%) and 1/7 SE (15%). Of these 69 patients, 84%
were still in continuous complete remission at the last follow-up (54 cITP, 4
AIHA, 0 ES). Comparative relapse-free survival curves are presented. Three
of the four deaths are possibly related to the weight of the treatments. Infections
and thrombosis were more frequent in AIHA and ES than in cITP.
Summary/Conclusions: This prospective national study provides the first evi-
dence-based comparative data on children with early splenectomy for those
rare diseases. The benefit-risk ratio of splenectomy seems lower in AIHA and
SE than in cITP. Some underlying immune deficiencies as autoimmune lym-
phoproliferative syndrome are formal contraindications. Prospective pediatric
studies will refine alternative immunomodulatory strategies aiming to delay
splenectomy as late as possible in children with AIHA or ES.
E1408
A RETROSPECTIVE REVIEW OF BACTEREMIA AND OSTEOMYELITIS IN
SICKLE CELL PATIENTS PRESENTING WITH FEVER IN LEBANON
S Khalife1,*, R Ahmad1, R Haidar2, N Khoury3, G Dbaibo1, MR Abboud1
1Pediatrics and Adolescent Medicine, 2Surgery, 3Diagnostic Radiology, Amer-
ican University of Beirut Medical Center, Beirut, Lebanon
Background: Patients with sickle cell disease have higher risk of infections
with encapsulated bacteria due to immature immune response and functional
asplenia manifested by impaired complement activity. This has led historically
to serious bacterial infections which include bacteremia with Streptococcal
pneumonia and osteomyelitis mainly caused by Salmonella species.
Aims: In this study we aim to review the bacteremia rates in sickle cell patients in
the era of vaccination against Streptococcus pneumonia and osteomyelitis rates
with the causative organisms. The purpose is to prove an emergence of gram neg-
ative organisms, other than Salmonella, as the cause of osteomyelitis; and the
vast decrease in Streptococcal pneumonia bacteremia rates after vaccination.
Methods: We conducted a retrospective chart review of 158 sickle cell patients
registered at our database. Every patient presenting to ER with fever had his
chart reviewed for blood cultures, pus cultures and MRI results for osteomyelitis
over a period of 13 years. 16s ribosomal DNA was also performed to detect
organisms not recovered by regular cultures.
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Results: Sickle cell patients reviewed included 117 patients with SS type (74%),
36 patients with SB thalassemia type (23%), 2 patients with SC type (1%), 2
patients with SD type (1%), 1 patients with SO Arab type (1%). Patient ages
ranged between 3 years and 40 years, with mean of 16 and median of 15. In
the time period of the study, 105 patients (66%) presented to ER with fever
leading to 581 febrile episodes. 341 episodes were in males (59%) and 240 in
females (41%); 384 patients had SS type (66%), 171 had SB thalassemia type
(29%), 26 had SD(5%). A total of 912 blood cultures were obtained. None of
those grew Streptococcus pneumonia (0%), 14 cultures grew Staphlococci
coagulase negative (1.5%), 1 culture grew Salmonella paratyphi B, and 3 cul-
tures grew Salmonella group C (in same patient). There was a total of 9
episodes of osteomyelitis documented by imaging among patients who pre-
sented with fever (1.5%). 4 of the patients were females (44%), 5 were males
(56%), 7 patients had sickle type SS (78%) and 2 had SB thalassemia type
(22%). Ages ranged from 6 years to 28 years, with mean of 14 years. 4 patients
(44%) had positive cultures and 5 patients (56%) had negative cultures. Cul-
tures (puss/tissue) obtained included 1 with Enterobacter cloacae, 1 with Bac-
teroides, 1 with Pseudomonas aeruginosa (by 16s rDNA) and the fourth was a
blood culture growing Salmonella group C. 16s rDNA was performed on tissue
samples of 4 patients with osteomyelitis. Two of those patients had negative
16s rDNA and cultures. The remaining patients had Bacteroides detected by
both modalities in one patient, and Pseudomonas aeruginosa detected only by
16s rDNA, not by culture, in the other. Osteomyelitis occurred in the spine in 3
patients (33%), in lower extremities in 3 patients (33%) and in upper extremity
in 3 patients(33%). All our patients received pneumococcal vaccination, 104
patients (63%) were on hydroxyurea, and 86 patients (47%) were on oral peni-
cillin prophylaxis.
Summary/Conclusions: Immunization against Streptococcus pneumonia has
virtually eliminated pneumococcal bacteremia as was evident in our patient
population. However, there was emergence of gram negative organisms, other
than Salmonella as the cause of osteomyelitis. This has important implications
for the empiric antibiotic coverage in sickle cell patients with osteomyelitis.
Molecular testing by 16s rDNA is to be considered to detect causative organ-
isms of osteomyelitis on tissue/ pus cultures when cultures fail to grow any.
E1409
FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN OMAN: AN
UPDATE ON UNIQUE CLINICAL AND MOLECULAR FEATURES
M Elshinawy1,*, A Al Rawas2, Y Wali2
1Pediatric Hematology, SQUH & Faculty of Medicine, Alexandria University,
Muscat & Alexandria, 2Pediatric Hematology, Sultan Qaboos University Hospi-
tal, Muscat, Oman
Background: Familial hemophagocytic lymphohistiocytosis (FHLH) is a rare
life-threatening autosomal recessive disorder. Due to high rate of consan-
guineous marriage in Oman, the incidence of HLH is relatively higher in this
part of the world. Clinically, HLH is characterized by unexplained high-grade
fever and splenomegaly associated with bi/pancytopenia, hyperferrtinemia,
hypofibrinogenemia and hypertriglyceridemia.
Aims: To review the clinical features, laboratory findings, molecular character-
istics, course and outcome of all cases of FHLH in Oman.
Methods: A retrospective/prospective data analysis of all patients diagnosed
with FHLH in Oman during the period from January 1997 to February 2016
was done. Flowcytometry has been used as a fast method to detect perforin
expression at diagnosis. Direct DNA sequencing was done to specify mutations
in patients and their families. Our results have been initially confirmed and val-
idated by Karolinska Institute, Sweden.
Results: Forty-eight patients (26 males & 22 females) with FHLH were identi-
fied. Their median age was 88 days with a range of (3 days– 13 months). Thir-
ty-seven patients (77%) had positive consanguinity, while 25 (52%) had positive
family history. Forty-one patients (85.4%) presented with fever and 44 (91.6%)
had splenomegaly. Twenty-seven cases (56.25%) had evidence of central nerv-
ous system involvement detected either at diagnosis or during the course of
therapy. Atypical rare clinical presentations included capillary leak syndrome in
5 cases (10.5%), severe hypertrophic obstructive cardiomyopathy in 2 siblings
after receiving high dose dexamethasone, and bilateral renal infiltration as a
unique clinical feature in a 2 month-old male infant (Figure 1). Of note, renal
involvement in this patient was completely reversed after 4 weeks of chemother-
apy. Bicytopenia was found in 39 (81.3%) infants, hypertriglyceridemia in 28
(58.3%) and hypofibrinogenemia in 45 (93.8%). All patients had serum fer-
ritin>500 ng/ml. At molecular level, the most commonly detected genetic abnor-
mality was perforin gene mutation (FHLH2), identified in 14 out of 17 studied
families (82.4%). Syntaxin 11 mutation (FHL4) was detected in only one patient,
while MUNC 13-4 mutation was not found. Two families did not show any muta-
tions. The high incidence of perforin gene mutations may denote a common
genetic pool of FHLH cases in Oman. Twenty-three (47.9%) cases passed
away. Fifteen infants were referred late after being treated with antibiotics in
peripheral hospitals as presumed cases of sepsis. Our standard of care is HLH-
2004 protocol, followed by hematopoietic stem cell transplant (HSCT). Twen-
ty-one patients were successfully transplanted in our center. It is noteworthy
that three of them have received haploidentical HSCT.
Figure 1.
Summary/Conclusions: We report an updated registry of FHLH cases in
Oman, including typical and atypical unique clinical presentations, characteristic
molecular features, course of the disease and treatment outcome. Taken into
consideration the relatively higher incidence of FHLH in this part of the world,
we recommend premarital screening, implementation of pre-implantation genetic
diagnosis (PGD) for high risk families and raising the awareness of health care
professionals in order to suspect and refer new cases as early as possible.
E1410
CLINICAL PRESENTATION AND OUTCOME OF BENIGN HISTIOCYTIC
DISORDERS IN CHILDREN
AA Tantawy1,*, IA Ragab1, NH Elsherif1, SM Elsayed2, HG Ali1, SM Makkeya1,
HI Elsantiel1
1Pediatric Hematology&oncology, 2medical genetics, children hospital, Ain
Shams University, Cairo, Egypt
Background: Langerhans cell histiocytosis (LCH)& Hemophagocytic lympho-
histiocytosis (HLH) are the most common benign histiocytic disorders. The clin-
ical picture of LCH varies from single-system to multisystem disease which
carries a potentially poor prognosis. HLH is referred to as either a“primary”
form which is hereditary, or a “secondary” form associated with an underlying
illness. The disease is invariably fatal if untreated.
Aims: Our goal was to evaluate the different clinical presentations of histiocytic
disorders, mainly LCH and HLH. and to determine their outcome and survival
in relation to the predisposing factors and the current treatment protocols
Methods: Demographic, clinical, laboratory and radiographic data of patients
diagnosed with LCH and HLH over a period of 10 years was retrosecpectively
collected. Protocol of treatment was evaluated including the 1 and 3 year event
free and overall survival rates
Results: This study included 19 LCH patients (median age 2.3 years) with a
males to female ratio of 1:1.7. All LCH patients had multisystem affection, 16
(84.2%) had risk organs involvement. Seven patients(36.8%) had Bone marrow
infiltration; 13 (68.4%) patients had hepatosplenomegaly and 14 (73.7%) had lung
infiltrations in their CT. In our study 19(94.7%) of LCH patients received LCH III
protocol, while only one (5.3%) patient received LCHII protocol of treatment. Six
(31.6%) had received salvage line, half of them (3 patients) needed only one treat-
ment protocol, 1patient needed 3 salvage and the last 2 patients received 2 salvage
treatment. Six patients died, the median duration from diagnosis till death duration
was 1.9 year. Their 1,3 years overall survival was 78.9% and 46.1%. Twenty six
patients with HLH were registered; their median age was 3.4 yrs with a male to
female ratio of 2:1. Ten patients had HLH secondary to another disease (2 patients
(7.7%) had ALL, 2 (7.7%) had Chediak Hegashi, 3(11.5%) had LCH, one had
Wolman, one with myelodyplasia and one with ALPS). Sixteen (61.5%) patients
did not have an underlying disease, 4 of them(15.4%) had MUNC13-4 gene muta-
tion, 1(3.8%) had RAB27A gene mutation and 1(3.8%) patient had LYST gene
mutation, and 2 patients had no common HlH mutations. Thrombosis was reported
in 2(7.7%) of the patients and (19.3%) of them presented initially with skin lesions,
moreover five (19.3%) patients had CNS manifestations but only 2 of them had
positive findings in their MRI and CT brain. Most of the patients were treated
according to HLH 2004 protocol, while only 2 received HLH 94 protocol. twelve
patients (46.2%) had reactivations, 6 needed only one reinduction, 4 had 2 rein-
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ductions and 2 had 3 reinductions. We report the death of 18 patients, with a
median duration since the diagnosis till death of 3.36months.
Summary/Conclusions: All our LCH patients had multisystem (MS) risk organ
affection, hence the high reactivation and the low overall survival rate. The
increased awareness of the HLH criteria for diagnosis, allowed early and accu-
rate detection of cases, yet the death rate is still high.
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PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CLINICAL FEATURES
AND OUTCOME IN 124 PATIENTS EVALUATED IN A SINGLE CENTER
M Zanichelli1,*, D moromizato2, G fonseca2, L suganuma2, S gualandro3
1Bone marrow transplantation, Itaci - HC FMUSP, 2Hematology, Hematology -
HCFMUSP, 3Hematology, Hematology-FMUSP, São Paulo, Brazil
Background: The Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare
acquired disorder of hematopoietic stem cells characterized by intravascular
hemolytic anemia, thrombotic phenomena and marrow failure. It is caused by a
somatic mutation in the phosphatidylinositol glycan class A (PIG-A) X-linked
gene, responsible for a deficiency in GPI-anchored proteins (GPI-AP). The lack
of the GPI-AP complement regulatory proteins (CD55 and CD59) leads to the
main manifestations of the disease. The Paroxysmal Nocturnal Hemoglobinuria
(PNH) is a rare acquired disorder of hematopoietic stem cells characterized by
intravascular hemolytic anemia, thrombotic phenomena and marrow failure. It
is caused by a somatic mutation in the phosphatidylinositol glycan class A (PIG-
A) X-linked gene, responsible for a deficiency in GPI-anchored proteins (GPI-
AP). The lack of the GPI-AP complement regulatory proteins (CD55 and CD59)
leads to the main manifestations of the disease. The Paroxysmal Nocturnal
Hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells
characterized by intravascular hemolytic anemia, thrombotic phenomena and
marrow failure. It is caused by a somatic mutation in the phosphatidylinositol
glycan class A (PIG-A) X-linked gene, responsible for a deficiency in GPI-
anchored proteins (GPI-AP). The lack of the GPI-AP complement regulatory
proteins (CD55 and CD59) leads to the main manifestations of the disease. The
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disorder of
hematopoietic stem cells characterized by intravascular hemolytic anemia,
thrombotic phenomena and marrow failure. It is caused by a somatic mutation
in the phosphatidylinositol glycan class A (PIG-A) X-linked gene, responsible
for a deficiency in GPI-anchored proteins (GPI-AP). The lack of the GPI-AP
complement regulatory proteins (CD55 and CD59) leads to the main manifes-
tations of the disease. The Paroxysmal Nocturnal Hemoglobinuria (PNH) is a
rare acquired disorder of hematopoietic stem cells characterized by intravascular
hemolytic anemia, thrombotic phenomena and marrow failure. It is caused by a
somatic mutation in the phosphatidylinositol glycan class A (PIG-A) X-linked
gene, responsible for a deficiency in GPI-anchored proteins (GPI-AP). The lack
of the GPI-AP complement regulatory proteins (CD55 and CD59) leads to the
main manifestations of the disease. The Paroxysmal Nocturnal Hemoglobinuria
(PNH) is a rare acquired disorder of hematopoietic stem cells characterized by
intravascular hemolytic anemia, thrombotic phenomena and marrow failure. It
is caused by a somatic mutation in the phosphatidylinositol glycan class A (PIG-
A) X-linked gene, responsible for a deficiency in GPI-anchored proteins (GPI-
AP). The lack of the GPI-AP complement regulatory proteins (CD55 and CD59)
leads to the main manifestations of the disease. The Paroxysmal Nocturnal
Hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells
characterized by intravascular hemolytic anemia, thrombotic phenomena and
marrow failure. It is caused by a somatic mutation in the phosphatidylinositol
glycan class A (PIG-A) X-linked gene, responsible for a deficiency in GPI-
anchored proteins (GPI-AP). The lack of the GPI-AP complement regulatory
proteins (CD55 and CD59) leads to the main manifestations of the disease.
Aims: The objective of this study was to describe the clinical features at diag-
nosis and outcome of PNH patients followed-up at a single institution.
Methods: Demographic, clinical, haematological and biochemical data were
collected from patients followed-up at the our centre. The diagnosis of PNH
was established using flow cytometry.
Results: 880 patients were tested for PNH. A hundred forty patients had PNH
clone. Of these, 124 had complete records and were included in this study (61
male and 63 female). The median age at diagnosis was 29.5 years (range 10-
72). Ninety one patients (74%) had a previous diagnosis of Aplastic Anemia, 5
patients had MDS (4%) and 28 (22.5%) patients had classical PNH. The most
common symptom at diagnosis was fatigue present in 109 patients (88%).
63/124 (51%) had bleeding and / or hemorrhagic suffusion, 18 (14%) jaundice,
23 (18%) hemoglobinuria, 13 (10%) abdominal pain, 11 (9%) thrombosis, 4
(3%) renal failure and 34 (27%) fever / infection. Median hemoglobin at diag-
nosis was 7.9 (2.6 to 14.0), median neutrophils / mm3 was 1.050 (100-8400)
and median platelet 21,500 / mm3 (1000-494000). 55/124 (44%) had LDH>1.5
times or more the upper limit of normal. Fifty one (41%) patients had PNH
clone>50% in granulocytes. During evolution 31/124 (25%) patients had throm-
bosis, 33/124 (27%) had hemoglobinuria and 15/124 (12%) had renal failure.
Patients with classical PNH received supportive treatment with red blood cell
transfusions, folic acid, prophylactic anticoagulant (14 patients with PNH
clone>50%) and long-term anticoagulation (31 patients with thrombosis). Two
patients have been treated with eculizumab. 23/80 (28.6%) patients with
AA/PNH have undergone bone marrow transplantation and the others (n=57)
were immunosuppressed with cyclosporine and antithymocitic globulin. 15/57
patients after immunosuppressive treatment, developed in a median period of
3.4 years (2-11 years), large clones (>50%) behaving like classical PNH. In
this period 8 patients with classical PNH died. The causes of death were throm-
bosis in 4 patients and infection in the others.
Summary/Conclusions: This study has a limitation because it was retrospec-
tive. Despite of that our results are similar to those found in the literature except
in the occurrence of abdominal pain (less than expected). Eculizumab is not
available for all patients in our centre. Because of that we have prophylactically
anticoagulated patients with PNH clone above 50% and no contraindications
for the procedure.
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EPSTEIN-BARR VIRUS-ASSOCIATED T-LYMPHOPROLIFERATIVE DISORDERS
IN ADULTS: A CASE SERIES OF 13 PATIENTS IN A SINGLE INSTITUTION
AND REVIEW OF LITERATURE
P Shi*, S qian, Y xie
Department of hematology, Hangzhou first people’s hospital, Hangzhou, China
Background: Epstein-Barr virus (EBV) usually infected B lymphocytes, some-
times also infected T- or natural killer (NK)-cells. EBV-associated T/NK cell
lymphoproliferative disease (EBV-T/NK-LPD) represents a continuous spec-
trum of diseases, ranging from benign hyperplasia of reactivity to clonal and
malignant lymphoproliferations. Epstein-Barr virus-associated T/NK-cell lym-
phoproliferative disorder in children and young adults is a systemic disease,
and features with EBV infection of T or NK cells cloned proliferation.
Aims: To understand the clinical features of EBV-associated T/NK cell lym-
phoproliferative disease and its poor prognosis, recognize the importance of
early diagnosis and timely treatment.
Methods: Retrospective analysis of 13 patients with clinical features, EB virus
spectrum, treatment and prognosis
Results: we report 13 adult cases of systemic Epstein-Barr virus-positive T-
cell lymphoproliferative disorder including 9 males and 4 females with a median
age of 41 years old (range,24-75). the most common clinical symoptoms were
fever 92.3% (12/13), splenomegaly 100% (13/13), hepatomegaly 30.8% (4/13),
lymph node enlargement 38.5% (5 /13), blood cells decrease 92.3% (12/13),
abnormal liver function 76.9% (10/13), elevated lactate dehydrogenase 76.9%
(10/13), coagulant function abnormality 61.5% (8/13). All patients had signifi-
cantly increased serum EBV-DNA levels (3.41×104-6.61×106 copy/ml). EBER
were positive by Fluorescence in situ hybridization (FISH) (5 cases lymph node
and 8 cases bone marrow). T lymphocytes were involved in this group, 7 cases
were diagnosed as chronic active EB virus infection (CAEBV), and 6 cases
were diagnosed as EBV-associated hemophagocytic lymphohistiocytosis
(HLH).One paient with CAEBV had no fever and blood cells decreases, keeping
stable disease with prednisone treatment; and another one patient with CAEBV
progress for aggressive NK cell leukemia after 4 months diagnosis, with
EPOCH regimen combined L-asparaginase chemotherapy. The remaining 11
patients were treated with immunochemotherapy containing etoposide, but the
effect is not good. In a median follow-up time of 18 months, one patient was
free of disease, one was alive with disease, and eleven died of disease in 5
months, respectively.
Summary/Conclusions: Adult systemic EBV + T/NK-LPDs was relatively rare
disease and the prognosis is poor. Our report adds to the understanding of
these rare disease with early diagnosis and intervention.
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MICROVASCULAR NETWORK IN BONE MARROWS OF TREATMENT-NAÏVE
PATIENTS WITH TYPE 1 GAUCHER DISEASE: SKEWED ANGIOGENIC
SIGNALS IN AN INFLAMMATORY MILIEU
M Klimkowska*, M Machaczka1, I Vedin2, J Palmblad3
1Hematology Center, Karolinska University Hospital, 2Department of Medicine
and Hematology, Karolinska Institute, 3Department of Medicine and Hematol-
ogy, Karolinska Insitute, Stockholm, Sweden
Background: Gaucher disease (GD) is characterized by accumulation of glu-
cocerebroside-storing macrophages, called Gaucher cells (GC) in various
organs, including bone marrow (BM). Since macrophages play a major role in
chronic inflammation, it can be assumed that macrophage proliferation in GD
can elicit or modify local inflammation-associated phenomena, including angio-
genesis.
Aims: The study was aim to evaluate microvascular network in BM samples
from untreated patients with GD type 1, and compare them to samples from
healthy adults.
Methods: Bone marrow core biopsies from 11 treatment-naïve patients with
GD type 1 (3 women, 8 men, median age 68.5 years), followed at the Hema-
tology Center, Karolinska University Hospital, were analyzed retrospectively.
Biopsies from 36 subjects (18 women, 18 men, median age 63.6 yrs) with no
hematological diseases, were used as controls. In the immunohistochemically
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and immunofluorescent stained samples, the following parameters were ana-
lyzed: cellularity, vessel morphology, microvascular density (MVD), vessel wall
pericyte coverage and expression of proangiogenic growth factors (VEGF,
ANGPT1 and 2). In GD biopsies, analyzes were performed separately in areas
with greater and lower percentage of infiltrating GC (≥50% and <50% in a high
power field).
Results: In GD patients, hematopoietic tissue was hypercellular for age, and
MVD was 2.6-fold higher than in controls (p<0.001). In GC rich areas, MVD
was 1.4-fold higher (p=0.026) and vessel architecture was abnormal as com-
pared to GC poor areas. Moreover, 30±17% of GD BM vessels were pericyte-
coated, significantly fewer than in controls (48±16%; p<0.001). Expression of
ANGPT1 and 2 was significantly higher in BM vessel walls in GD samples than
in controls (7.2 and 13.2 fold higher, respectively), whereas VEGF expression
was 20-fold lower in GD (p<0.05 for all parameters). MVD values correlated
with BM cellularity, particularly in GC rich areas. Gaucher cells stain moderately
for ANGPT1 and 2, and variably for VEGF.
Figure 1.
Summary/Conclusions: Bone marrow in patients with GD type 1 demon-
strates abnormal angiogenesis, with defective pericyte coating, and skewed




POINT OF CARE PLATELET REACTIVITY TESTING AND DOSE-TITRATION
IN A DOUBLE-BLIND STUDY OF PRASUGREL IN CHILDREN WITH SICKLE
CELL ANAEMIA
JA Jakubowski1,*, CC Hoppe2, C Zhou1, BE Smith1, PB Brown1, LE Heath1,
B Inusa3, DC Rees4, MM Heeney5, J Kanter6
1Eli Lilly and Company, Indianapolis, 2Children’s Hospital Oakland Research
Institute, Oakland, United States, 3Paediatric Haematology, Evelina Children
Hospital, 4Paediatric Hematology, King’s College Hospital, London, United King-
dom, 5Dana-Farber / Boston Children’s Cancer and Blood Disorders Center,
Boston, 6Sickle Cell Research, Medical University of South Carolina, South
Carolina, United States
Background: Platelet activation and aggregation induced by release of ADP
from haemolysed sickle erythrocytes may contribute to vaso-occlusion and
ischaemic pain, a hallmark of sickle cell anaemia (SCA). Anti-platelet agents
such as prasugrel (Pras) that target the P2Y12 ADP receptor may thus provide
benefit. However, the potential increase in haemorrhagic stroke risk with high
levels of platelet inhibition in SCA makes dose titration imperative. Previous
studies suggested that a PRU (P2Y12 reaction unit, a measure of ADP-induced
platelet aggregation) range of 231-136 would be appropriate to determine the
risk / benefit ratio of prasugrel in SCA, and could be achieved by individual
dose adjustment based on platelet testing - a challenge in a double blind study.
Aims: Attenuation of platelet reactivity to a pre-defined target range in patients
with SCA, by dose titration using point-of-care platelet testing. 
Methods: The DOVE study was a Phase 3 double-blind, placebo (Pbo) con-
trolled study of Pras in pediatric patients with SCA. Treatment assignment was
balanced according to hydroxyurea (HU) use, age group and country. Baseline
PRU values were determined by VerifyNow® P2Y12 (VN-P2Y12), a point-of-
care platelet aggregation test which reports both PRU and% platelet inhibition
(% inhibition) values. Over the subsequent 6 weeks patients returned for repeat
VN-P2Y12 assessment and, if necessary doses were adjusted to titrate patients
into a PRU range of 231-136, with a lower PRU value indicating greater platelet
inhibition. The final dose was fixed for the remainder of the study, adjusted only
if deemed necessary by changes in body weight. The majority of patients
returned after 9 months for a final VN-P2Y12 measurement. All VN-P2Y12 data
were encrypted and entered into an interactive voice response system which
instructed the investigator to maintain or adjust the current dose for patients in
both the Pras and Pbo (mock titration) arms, thus maintaining the blinding of
the study.
Table 1.
Results: 170 patients were assigned to the treatment arm and received Pras;
of these, 160 were titrated to a final dose. Baseline (predose) PRU values were
similar for both Pras and Pbo groups (Table). After titration to the final Pras
dose, PRU values dropped to 203 (from 276 at baseline) and remained low
through 9 months. In contrast and as expected, PRU values in the Pbo group
did not change after mock titration or at 9 months. Baseline VNP2Y12-report-
ed% inhibition levels were low in both Pras (2.8%) and Pbo (2%) groups.
Mean% inhibition in the Pras group increased to approximately 22% after titra-
tion to the final dose and was maintained at this approximate level (19.4%)
through 9 months of treatment. In the Pbo group, there was no change from
baseline in% inhibition at either timepoint.
Summary/Conclusions: Although primary efficacy endpoints were not met in
the DOVE study, the results of platelet function studies indicate that in the
majority of patients, Pras at the final dose administered effectively reduced
ADP-mediated platelet reactivity with a corresponding increase in platelet inhi-
bition. This was achieved using encrypted point-of-care testing. Additionally,
results demonstrated that safety was not compromised on the treatment arm,
raising the question as to whether higher levels of platelet inhibition might pro-
vide a more optimal benefit/risk ratio.
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E1413
THE STUDY OF GENETIC MUTATIONS THAT INFLUENCES
THROMBOPOIESIS IN PATIENTS WITH NEOPLASMS: THE ROLES OF
ANKRD26, RUNX-1 AND ETV6
S Ferrari*, F Vianello, AM Lombardi, I Cortella, I Barzon, F Fabris
Department of Medicine, University of Padua, Padua, Italy
Background: The phenotype of inherited thrombocytopenia is characterized
by different sizes of platelets, different degrees of thrombocytopenia, the pres-
ence or absence of platelet function defects, and an association with syndromes
involving other cell lines or other organ functions. In particular, some forms of
inherited thrombocytopenia secondary to 5’ UTR of ANKRD26, RUNX-1, and
ETV6 mutations are associated with neoplasms of haematological or non-
haematological type.
Aims: Study of genetic mutations in ANKRD26, RUNX-1 and ETV6 that influ-
ences thrombopoiesis in patients with myelodysplasia (MDS).
Methods: We study the presence of mutations in the 5’UTR of the ANKRD26,
RUNX-1, and ETV6 gene in the following cohorts of patients: a) 27 patients
affected by sporadic and familial thrombocytopenia and normal platelet vol-
umes, b) 12 patients with myelodysplasia and normal platelet count, c) 9
patients with myelodysplasia with prevalent thrombocytopenia.
Results: In the cohort of the studied patients we found mutations in the 5’UTR
of the ANKRD26, RUNX-1 and ETV6 genes only in 6 patients with thrombocy-
topenia and MDS of the group c. The mutations found are 5. One deletion in
exon 1 of the ANKRD26 gene (c.60_62del AGA), three mutations in the RUNX-
1 gene: a missense mutation with a modification in the amino acid polarity in
exon 4 (c.76C>G), a deletion (c.934del A) and an insertion (c.1214_1215insTG),
respectively, in exon 8 and 9. Finally, a deletion in intron 1 of the ETV6 gene
(c.28+192delC). All the mutations found were not present in public databases.
Summary/Conclusions: The preliminary data demonstrated that mutations
in the ANKRD26, RUNX-1 and ETV6 genes were present in patients with MDS
and prevalent thrombocytopenia. Even if the involvement of these genes in
megacaryopoiesis is well known, the exact mechanism responsible for throm-
bocytopenia is not yet clear. As the pathology is extremely rare, it is difficult to
find data for genotype-phenotype analyses. However we hypothesized that
these mutations are responsible for the low platelet counts in patients with
myelodysplasia. Greater knowledge about the pathogenesis of these forms of
thrombocytopenia will facilitate finding new therapies for them. This will have
important clinical implications since platelet transfusion is the only therapeutic
option for these patients. Defining the molecular mechanism of thrombocy-
topenia in these patients could constitute the first step on the path leading to
new therapeutic possibilities with TPO mimetics as has been demonstrated in
hereditary form of thrombocytopenia.
E1414
DECREASED PLATELET FUNCTION IN ACUTE MYELOID LEUKAEMIA
AND MYELODYSPLASIA DETECTED BY A NEW TEST OF PLATELET
AGGREGATION OF VIABLE CELLS USING FLOW CYTOMETRY
PJ Vinholt1,*, H Frederiksen2, C Nielsen3
1Department of Clinical Biochemistry and Pharmacology, 2Department of
Haematology, 3Department of Clinical Immunology, Odense University Hospital,
Odense, Denmark
Background: It is unknown why only some thrombocytopenic patients bleed
despite equally low platelet counts. Platelet function is likely to be of importance,
but is difficult to access as results from existing platelet aggregation methods
have major methodological limitations at low platelet count.
Aims: The aim was to establish a method for measuring platelet aggregation
of viable platelets in thrombocytopenic patients. Secondly, we investigated
platelet function in thrombocytopenic patients with acute myeloid leukaemia
(AML) or myelodysplasia (MDS).
Methods: Washed platelets were split in two and differently labelled with fluores-
cent dye (Calcein AM and Calcein Violet) and added to AB-positive donor plasma
in a 1.5 mL tube. Agonist was added (collagen-related peptide, adenosine diphos-
phate (ADP) or thrombin-receptor activator peptide-6 (TRAP)), samples were
shaken for 5 min and subsequently analyzed using flow cytometry. Double-colored
events in stimulated samples were defined as platelet aggregates. Effect of addi-
tion of platelet inhibitors (abciximab, ticagrelor or vorapaxar) was determined.
Using flow cytometry, platelet activation after addition of agonist to whole blood
was evaluated by fl ow cytometry using antibodies to detect alpha-granule release
(P-selectin(CD62p)), dense-granule release (CD63) and activated fibrinogen
receptor (PAC1 binding), respectively. Surface receptor levels were quantified
using antibodies against GPIIb/IIIa (CD41/CD61), GPIb(CD42b)/GPIX(CD42a)),
and CD49b. Participants were ≥18 years, healthy individuals or patients with AML
or MDS. Participants who received platelet inhibitors within two weeks, platelet
transfusions, or major surgery within one week were excluded. Informed consent
was obtained. Comparisons were made with Wilcoxon ranksum test.
Results: Presence of aggregates in unstimulated samples was low (≤4%). The
intra-assay coefficient of variation was 1-3%. Increasing inhibition of platelet
aggregation at increasing dose of platelet inhibitors was observed. Enrolled
were ten patients (n=8 AML/n=2 MDS) and nine healthy controls with platelet
count ranging 6-47 x 109/L versus 145-337 x 109/L, respectively. The inter-
individual variation among healthy persons were low (Figure 1). Collagen-relat-
ed peptide and TRAP-induced aggregation were lower for patients compared
with controls, while no difference in ADP-induced aggregation was found. Three
patients reported bleeding episodes within the past one month and comprised
three out of four persons with platelet aggregation below 34% for any agonist.
No difference was observed in platelet count in patients with versus without
bleeding episodes: 23 x109/L (12-24 x109/L) versus 25 x109/L (6-47 x109/L),
p=0.51. Platelet activation was lower for patients versus controls for all agonists.
There was a strong correlation between results from the platelet activation
method and platelet aggregation method e.g. for PAC1-binding versus colla-
gen-related peptide induced aggregation, r=0.96, p<0.001. No difference in
expression of platelet surface receptor levels was found.
Figure 1.
Summary/Conclusions: Based on the presented method for testing platelet
aggregation of viable cells, our study shows that low platelet aggregation by
the method identifies thrombocytopenic patients with bleeding problems among
AML/MDS patients with thrombocytopenia. This platelet aggregation method
may be useful for providing indications for prophylactic platelet transfusions or
for evaluating indication of platelet inhibitor therapy in thrombocytopenic indi-
viduals. Further, it may facilitate the important distinction between inherited
thrombocytopenia from immune thrombocytopenia.
E1415
SEASONAL VARIATIONS OF PRIMARY IMMUNE THROMBOCYTOPENIA
INCIDENCE IN ADULTS
G Moulis1,2,3,*, S Guénin4, N Limal4, M Michel4, P Bierling5, B Godeau4,
M Mahévas4
1Internal Medicine, Toulouse University Hospital, 2UMR 1027, INSERM, 3CIC
1436, Toulouse University Hospital, Toulouse, 4Internal Medicine, 5EFS, CHU
Henri Mondor, Créteil, France
Background: Seasonal variations of primary immune thrombocytopenia (ITP)
incidence have been suggested in cohorts of childhood ITP. The existence of
such variations is not well known in adult ITP. 
Aims: The aims of this study were to assess the variations of primary ITP inci-
dence in a clinical cohort of adult patients and to detect differences in seasonal
patterns about the outcome of patients, differentiating ITPs lasting less than 3
months (defined by complete remission before 3 months: stable normal platelet
count without any bleeding, without any exposure to treatment active on ITP)
and ITPs lasting more than 3 months (i.e. persistent and chronic ITPs).
Methods: We conducted a retrospective study in the patient database of the
French National Referral Center for Adult Autoimmune Cytopenias in Créteil,
France. ITP was defined in accordance with international guidelines. We
restricted the population to adult patients (aged ≥15 years) with primary ITP
whose onset occurred between 1990 and 2014. ITP onset was defined by the
date of first abnormal platelet count (<100 x 109/L) in patients with previous
normal platelet count. Demographics data (age and gender), platelet count at
ITP onset, bleeding score excluding the age at ITP onset, first line treatment
and ITP activity at 3 months were also extracted from the database. We, then,
calculated the proportion of patients with ITP symptoms onset by calendar
month, with their 95% confidence intervals.
Results: Out of 663 primary ITP patients included in the study, 127 (19.1%)
were excluded due to missing record of calendar month of first abnormal
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platelet count. Median age was 40.9 years (range: 15.0-94.2), and 358 (66.8%)
were females. Median platelet count at ITP onset was 14.0x109/L and 131
(26.2%) patients had bleeding signs. Median Khellaf’s bleeding score excluding
the age was 3 (range: 0-36). Out of these 536 patients, 321 (59.9%) became
persistent or chronic (lasted more than 3 months) and 184 (34.3%) lasted less
than 3 months (31 patients with missing value for this data). In regards to first-
line treatment, 452 (84.3%) were treated by corticosteroids and 193 (36.0%)
were exposed to with IVIg. Overall, there was a significantly higher proportion
of patients with ITP onset in January/February than in August (nadir). Variations
were marked in ITPs lasting less than 3 months. In this population, two smaller
peaks of incidence were also observed: in June and in October. By contrast,
there was no significant difference of ITP incidence by calendar month in ITPs
that became persistent or chronic.
Summary/Conclusions: This study tends to confirm seasonal variations of
ITP incidence with peak in winter and nadir in August in adults, as suggested
by a previous population-based study in France. This pattern corresponds to
influenza outbreak in France. The two smaller peaks (in June and in October)
observed in ITP lasting less than 3 months are superimposable to enterovirus
outbreaks in France. Both influenza and enterovirus have been associated with
ITP occurrence in children. Moreover, vaccine against influenza tended to be
protective against ITP onset in adults in a recent case-control study in France.
In conclusion, this study suggests that ITP lasting less than 3 months in adults
may be timely linked with major viral outbreaks in France, unlike persistent and
chronic ITP. Further prospective epidemiological and microbiological studies
are needed to confirm this observation.
E1416
SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF
SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE
THROMBOCYTOPENIA (ITP)
M Tarantino1,*, J Bussel2, V Blanchette3, J Despotovic4, C Bennett5, A Raj6,
B Williams7, D Beam8, J Morales9, M Rose10, X Wang11, M Eisen11
1The Bleeding and Clotting Disorders Institute, Peoria, 2Department of Pedi-
atrics, Division of Hematology, Weill Medical College of Cornell University, New
York, United States, 3Hospital for Sick Children, Toronto, Canada, 4Texas Chil-
dren’s Hematology Center, Houston, 5Emory University, Atlanta, 6Pediatric
Blood and Cancer Disorders Clinic, Louisville, United States, 7Lady Cilento
Children’s Hospital, South Brisbane, Australia, 8Cook Childrens Medical Center,
Forth Worth, 9Louisiana State University Health Sciences Center, New Orleans,
10Nationwide Children’s Hospital and The Ohio State University College of
Medicine, Columbus, 11Amgen Inc., Thousand Oaks, United States
Background: Pediatric patients with chronic immune thrombocytopenia (ITP)
that completed the romiplostim phase 1/2 or phase 3 study could enroll in this
open-label long-term extension study.
Aims: To examine the long-term effects of romiplostim in children with chronic ITP.
Methods: All patients received subcutaneous romiplostim once weekly. The ini-
tial dose was the final dose from the parent study or 1 µg/kg (for patients previ-
ously receiving placebo or that had not received romiplostim for >24 weeks),
adjusted weekly from 1-10 µg/kg to target platelet counts of 50-200×109/L.
Results: A total of 66 patients (parent study: phase 1/2, n=12; phase 3, n=54)
entered the extension study; 1 patient withdrew consent before treatment. At
baseline, median (min-max) age was 11 (3–18) years; 56% were female; 61%
were white, 14% African American, and 14% Hispanic/Latino; 9.1% had prior
splenectomy. Median (min-max) treatment duration was 57.9 (1–269) weeks.
Median (range) average weekly romiplostim dose was 5.5 (0.1–10.0) µg/kg.
Thirteen patients discontinued treatment: consent withdrawn (n=6), noncom-
pliance (n=2), administrative decision (n=2), nonresponse (n=2), and per pro-
tocol (n=1). For 15 patients (23%), the first study week was the first week they
were receiving romiplostim (ie, they received placebo in the parent study). Fifty-
six (86%) patients (or caregivers) self-administered romiplostim. Twenty-one
(32%) patients received rescue medications on 63 occasions (for low platelet
counts [n=35], bleeding/bruising [17], pre- or post-procedure [9], and other [2]);
treatments included IVIg (n=10), prednisone (9), aminocaproic acid (3), tranex-
amic acid (2), methylprednisolone (2), and platelet transfusion (1). Patients
required rescue treatment during the first 3 months (27/63 instances), >3–6
months (9), >6–9 months (6), >9–12 months (7), and after 1 year (14) in the
extension study. Five patients who previously received placebo received rescue
medication in this extension, mostly during the first 3 months (10/14 instances).
Three patients achieved remission (platelet counts ≥50×109/L for 24 weeks
with no ITP treatments): 1) A 9-year-old boy with ITP for 8 years; after 4 years
of romiplostim, he entered remission for the last 2 years as of this datacut; 2)
An 11-year-old boy with ITP for 6 years; after 3 years of romiplostim, he entered
remission for the last year; and 3) A 17-year-old girl with ITP for 8 years; after
6 years of romiplostim, she entered remission for the last 44 weeks of the study.
Thirty-nine serious AEs occurred in 14 patients, including pyrexia (n=3), epis-
taxis (n=2), and thrombocytopenia (n=2); 3 were deemed treatment-related
(anemia, epistaxis, and thrombocytopenia), and none led to discontinuation of
romiplostim. Five patients had life-threatening AEs, including thrombocytopenia
(n=2) and infection, decreased platelet counts, and subcutaneous abscess
(n=1 each); none were fatal or deemed treatment-related. Bleeding AEs
occurred in 47 patients; 3 were deemed treatment-related by the investigator
(gingival bleeding, petechiae, and epistaxis). No thrombotic events were report-
ed. There were no peripheral blood abnormalities suggestive of malignancy to
warrant a bone marrow examination in any patient. Anti-romiplostim neutralizing
antibodies were found in one patient at end of study after 50 weeks. This patient
received rescue medications for much of the study.
Figure 1.
Summary/Conclusions: In this ongoing open-label extension study of children
with chronic ITP, romiplostim for ≤5.2 years maintained platelet counts with a
safety profile similar to that seen in past studies.
E1417
SAFETY AND EFFICACY/EFFECTIVENESS OF SECOND-LINE TREATMENTS
IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC
REVIEW OF THE LITERATURE
K Cetin1, F Callaghan2, J Fryzek3, L Bylsma3, C Bezold3, B Mehta4,*
1Center for Observational Research, Amgen Inc, Cambridge, 2Center for Obser-
vational Research, Amgen Inc, San Francisco, 3EpidStat Institute, Ann Arbor,
4Development, Amgen Inc, Thousand Oaks, United States
Background: Immune thrombocytopenia (ITP) is a rare disorder characterized
by low platelet counts and an increased tendency to bleed. Typical first-line
therapies include corticosteroids, intravenous immunoglobulin, and anti-D.
Patients who fail initial treatment or relapse may require second-line treatment,
yet definitive guidelines in this setting are lacking, presumably because of a
paucity of relevant rigorous clinical research.
Aims: To systematically review studies evaluating the safety and efficacy/effec-
tiveness of therapies used to treat ITP in the 2nd-line setting (splenectomy,
azathioprine, cyclophosphamide, cyclosporine A, danazol, dapsone, eltrom-
bopag, mycophenolate mofetil, rituximab, romiplostim, and vinca alkaloids),
with a focus on randomized controlled trials (RCTs).
Methods: Using comprehensive search strings, Cochrane Central Register of
Controlled Trials, the Cochrane Database of Systematic Reviews, PubMed,
EMBASE, and clinicaltrials.gov were searched with no time or geographic con-
straints. Studies in which these agents were used as first-line therapy; with<20
patients; in populations of children, pregnant women, or patients with secondary
thrombocytopenia; or not published in English were excluded. Studies were
reviewed for several safety and efficacy endpoints. Twelve prospective, ran-
domized, placebo- or standard-of-care (SOC)-controlled studies were further
evaluated given their comparable study designs and levels of evidence provid-
ed. Outcomes common to multiple studies (bleeding, overall and complete
platelet response, and use of rescue therapies) were summarized and indirectly
compared using forest plots of calculated risk or response ratios for each out-
come from each study.
Results: Final abstraction was performed on 165 articles meeting inclusion cri-
teria. The majority of studies were observational in nature and none represented
interventional studies providing head-to-head comparisons of the second-line
therapies. Twelve prospective, randomized, placebo- or SOC-controlled studies
evaluated the efficacy and safety of either one of two thrombopoietin-receptor
(TPO-R) agonists (romiplostim [n=5] and eltrombopag [n=5]) or rituximab (n=2).
Although aspects of study design, outcome definitions, and specific subject inclu-
sion/exclusion criteria varied across the studies, patients receiving romiplostim,
eltrombopag, or rituximab tended to demonstrate a reduced risk of bleeding and
use of rescue therapy and an increased likelihood of platelet response compared
with patients receiving either placebo or SOC almost without exception. These
risk/response differences tended to be greatest in trials involving a TPO-R ago-
nist (e.g., the range of response ratios for overall platelet response was 1.81-
34.28 for romiplostim versus placebo/SOC; 1.40-14.00 for eltrombopag versus
placebo; and 0.86-1.09 for rituximab versus placebo).
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Summary/Conclusions: Data from rigorous RCTs are still currently limited for
most second-line ITP treatment options. Twelve prospective, randomized place-
bo- or SOC-controlled studies were identified but covered only three (eltrombopag,
rituximab, and romiplostim) of the several second-line medical treatment options
available. These studies provide high-quality evidence regarding the efficacy and
safety of these three therapies and, in the absence of head-to-head data, offer
insights regarding how they compare to one another in terms of clinical outcomes.
E1418
THYROID DYSFUNCTION AND ITS RESPONSES TO TREATMENT ARE
ASSOCIATED WITH THROMBOCYTOPENIA IN CHRONIC HEPATITIS
B-INFECTED SUBJECTS WITH COMPENSATORY CIRRHOSIS
J Xue, JM Zhang, XL Zhu, LP Xu, Q Jiang, J Lu, H Jiang, HX Fu, KY Liu,
XJ Huang, XH Zhang*
Peking University Institute of Hematology, Peking University People’s Hospital,
Beijing, China
Background: Many reports have demonstrated a significant relationship
between thrombocytopenia and thyroid dysfunction and its treatment. However,
the pathogenetic link between these conditions has not been clarified. Autoim-
mune theory has been well-supported hypothesis. Our previous studies have
demonstrated that chronic hepatitis B (CHB) withcompensatory cirrhosis
accompanied by thrombocytopenia is an important research subject. Addition-
ally, we have observed many casesof hypothyroidism in CHBpatients with
thrombocytopenia in our clinicalstudies. However, no information is available
regarding the association between thyroiddysfunction and thrombocytopenia
in CHBpatients with compensatory cirrhosis. 
Aims: We investigated whether thrombocytopenia in patients diagnosed with
CHB withcompensatory cirrhosis is related to thyroid dysfunction, and further
explored the treatment and the platelet response to treatment. 
Methods: Thrombocytopenia was defined as a platelet count of <100×109/L.
We divided all patients into two groups based onplatelet counts of <50×109/L
and >50×109/L. The prevalence of thyroid dysfunction, including normal thyroid
function, overt or subclinical hyperthyroidism, and overt or subclinical hypothy-
roidismwas determined in each group. Thyroid function and liver function were
detected periodically. During treatment, platelet counts were assessed weekly
during the first month and then every 4 weeks for one year. Treatment of thyroid
dysfunction and treatment responses were also recorded. 
Results: A total of 261 patients were enrolled in this observational study. Among
the 30(11.49%) patients with abnormal serum TSH levels, there were 6 (2.29%)
with hyperthyroidism, and 24 (9.20%)with hypothyroidism, and 60% were
female. Patients with a platelet count <50×109/L had a higher incidence of
hypothyroidism, which developed in 11% of patients in group A (platelet count
<50×109/L) compared with 8.07% in group B (platelet count >50×109/L)
(P<0.05). Serum TSH was significantly higher but serum FT3,FT4,TT3, and
TT4 were significantly lower in group A (P<0.05). We identified risk factors
associated with platelet count before therapy. Logistic regression analysis
showed that serum TSH, FT3, FT4,TT3 and TT4 levels were positively asso-
ciated with the platelet count. We calculated the difference in platelet count
from baseline for each time pointduring treatment. A greater change was
exploredin group A than group B (P<0.05). In each group, the change in platelet
count was higher in patients who received treatment for their thyroid condition
(P<0.05).We further assessed factors influencing patients who had a platelet
response compared with those who had no reponse. Highly significant variables
associated with a platelet response, even in the multivariate analysis, included
serum TSH, FT3, FT4, TT3 and TT4 levels.
Summary/Conclusions: This is the first studyto demonstratethat thyroid dys-
function, especially hypothyroidism, is common in patients with CHB accom-
panied by thrombocytopenia.Females are more likely to develop thyroid dys-
function. Thyroid function is associated with platelet counts. Additionally, a
more dramaticplateletcountresponse was observed with administration of thy-
roid hormone therapy in patients with hypothyroidism, even in the multivariate
analysis.It may provide a novel approach for thetreatment of thrombocytopenia
in CHB patients with compensatory cirrhosis. 
E1419
RITUXIMAB THERAPY AS PROPHYLAXIS AGAINST THROMBOTIC
THROMBOCYTOPENIC PURPURA: COMPARISON OF STANDARD AND
REDUCED DOSE REGIMENS
JP Westwood1,*, D Ellis1, S Mc Guckin1, K Langley2, V McDonald3, M Thomas1,
M Scully1
1Department of Haematology, University College Hospital, 2Haemostasis
Research Unit, University College London, 3Centre for Haemostasis and
Thrombosis, St Thomas’ Hospital, London, United Kingdom
Background: Acute antibody-mediated thrombotic thrombocytopenic purpura
(TTP) is a thrombotic microangiopathy with high morbidity and mortality. Rit-
uximab is highly effective when given as prophylaxis in patients at high risk of
acute TTP relapse, but the ideal dosing regimen is unknown.
Aims: A retrospective cohort study across two centres was performed to com-
pare outcomes between TTP patients given rituximab prophylaxis at standard
dose (375mg/m2) vs reduced dose (200mg), weekly for 4 weeks.
Methods: Patients had all previously had at least one acute TTP episode, and
were deemed at high risk of TTP relapse based on ADAMTS13 activity dropping
to ≤15%, having previously been documented in the normal range. Outcome
measures included normalisation of ADAMTS13, subsequent relapse rate.
Comparison was made of time to re-treatment for patients given standard dose
vs reduced dose rituximab.
Results: Rituximab was given in 51 patient episodes, to 32 patients (24F, 8M);
in 19 episodes (14 patients) this was re-treatment where patients had received
rituximab prophylaxis on at least one prior occasion. In 47/51 (92%) episodes,
patients had a median pre-prophylaxis reduction in ADAMTS13 level of ≤15%.
Patients received standard dose rituximab in 24 episodes and reduced dose
in 27 episodes. Normalisation of ADAMTS13 occurred in 48/51 (94%) patients.
Over a median follow up of 14.5 months (range 9-133 months), there were
only 2 subacute relapses, both occurring in the reduced dose group. Of the 29
patients requiring re-treatment, 12/29 (41.4%) had received standard dose,
and 17/29 (58.6%) reduced dose, at a median 22.5 months (range 10-112
months) in the standard dose group, and 12 months (range 9-33 months) in
the reduced dose group, p=0.1351.
Summary/Conclusions: Rituximab therapy is effective as prophylaxis nor-
malising ADAMTS13 and preventing acute TTP relapses in patients with
immune TTP. Standard dose rituximab prophylaxis may be associated with
longer treatment free survival than reduced dose. 
E1420
MODELING AND SIMULATION (M&S) SUPPORT ELTROMBOPAG (EPAG)
DOSAGE ESCALATION BASED ON PLATELET COUNT FOR PEDIATRIC
PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA
(CITP)
J Grainger1,*, N Sirachainan2, MB Wire3, V Aslanis4, W Sallas5, J Zhang6,
J Bussel7
1Royal Manchester Children’s Hospital, Manchester, United Kingdom,
2Ramathibodi Hospital, Bangkok, Thailand, 3Chimerix, Durham, United States,
4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corpo-
ration, East Hanover, 6PAREXEL International, Research Triangle Park, 7Weill
Cornell Medicine, New York, United States
Background: EPAG is approved for use in patients with persistent or cITP,
chronic hepatitis C, and severe aplastic anemia. M&S supported EPAG dosing
in adult populations (Gibiansky E et al. J Clin Pharmacol 2011; Hayes S et al. J
Clin Pharmacol 2011; Wu K et al. J Clin Ther 2015; Zhang J et al. Pharm Res
2015).
Aims: To support initial EPAG doses and dose titration based on platelet count
response in pediatric patients with cITP.
Methods: Plasma EPAG concentration and platelet count (PLTC) data collected
in pediatric cITP patients in the PETIT & PETIT2 studies (Bussel JB et al. Lancet
Haematol 2015; Grainger JD et al. Lancet 2015) were analyzed by nonlinear
mixed-effects modeling. Patients received EPAG for ≥24 weeks. Doses were
increased at 2-week intervals for PLTC<50 Gi/L, decreased for >200 Gi/L, and
interrupted for >400 Gi/L. Serial pharmacokinetic (PK) samples were collected
at Week 6 in PETIT. A single PK sample and PLTC were collected at all visits in
both studies. A population PK (PPK) model was developed with PETIT data. Fol-
lowing successful external validation with data from PETIT2, data from both stud-
ies were combined to obtain final model parameter estimates. PLTC data were
fitted alone using individual post-hoc PK parameter estimates. Simulations of
PLTC for various starting doses and dose titration schedules were completed.
Results: The analyses included 168 patients (mean age 9.5 [1–17] years;
weight 42.1 [11–135] kg; baseline PLTC 14 [1–38] Gi/L; 51% female; 20% East
Asian; 6% splenectomized); 98% received prior ITP medication. Concurrent
ITP medications were used at 17% of the PLTC assessments. PK was
described by a 2-compartment model. Inter-individual variation (IIV) was includ-
ed on apparent clearance (CL/F), intercompartmental exchange/clearance rate
(Q/F), distribution volume of central compartment (Vc/F), and inter-occasion
variability (IOV) on CL/F. Typical values were CL/F=0.612 L/h, Vc/F=2.74 L,
Q/F=0.716 L, distribution volume of peripheral compartment (Vp/F)=21.5 L,
and Ka=0.189/h. The final PPK/pharmacodynamics (PD) model was a 7-com-
partment life-span model, including 3 PK and 4 PD compartments. Zero-order
production rate of platelet precursors (KIN) was fixed to the value from adult
healthy volunteers (KIN=1.43 Gi/L/h). The increase in KIN due to EPAG was
linearly related to plasma EPAG concentrations by the parameter SLOP (ie,
linear coefficient of drug effect on KIN). SLOP, first-order maturation rate of
platelet precursors (KOUT), and proportion of patients identified as responders
(P1) were estimated; IIV was included on SLOP and KOUT. Typical PD param-
eter values were P1=0.96, SLOP=0.651 mL/µg in responders, and
KOUT=0.0126/h, and increased with age. The average platelet half-life was 7
h. A majority of patients, as also seen in PETIT/PETIT2, required dose esca-
lation to achieve target platelet response.
Summary/Conclusions: M&S supports eltrombopag starting doses and dose
adjustments based on platelet counts in children with cITP. A majority of children
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require dose escalation from eltrombopag starting doses to achieve platelet
thresholds ≥50 Gi/L. Higher starting doses may need to be considered when
clinically indicated such as in cases of severe bleeding or pending surgery.
Studies NCT00908037/NCT01520909 were sponsored by GlaxoSmithKline;
EPAG became an asset of Novartis AG as of March 2, 2015.
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EXPRESSION OF GLUCOCORTICOID RECEPTOR ISOFORMS (A, Β, Γ,
AND P) IN ADULT EGYPTIAN PRIMARY IMMUNE THROMBOCYTOPENIA
PATIENTS
M Eldefrawy1,*, N A. M. Hamed1, D Elneely2, O Gallab1, B Jepngetich3
1Hematology, 2Clinical Pathology, Faculty of Medicine Alexandria, Alexandria,
Egypt, 3Hematology, Moi Teaching and Referral Hospital, Moi, Kenya
Background: Glucocorticoid (GC) resistance has been demonstrated in nearly
30% of primary immune thrombocytopenia (ITP) patients even managed with
high dosages GC. The biological effects of GC are mainly mediated through
activation of glucocorticoid receptors (GR). An insight into the molecular mech-
anisms underlying GC resistance is important to avoid GC treatment in patients
contraindicated from steroid use.
Aims: We aimed at determining glucocorticoid receptor (GR) isoforms expres-
sion in adult ITP and its relation to glucocorticoid resistance.
Methods: Thirty three ITP patients from the Hematology unit, Alexandria Main
University Hospital were the subject of the study. They were subdivided into
two groups (sensitive and resistant) according to their response to 4 weeks
GC treatment. 15 healthy volunteers of matched age were also included. Glu-
cocorticoid Receptor α, β, γ and p gene expression were measured in cases
and controls by real time Polymerase Chain Reaction. (QIAamp® RNA blood
mini kit (cat no. 52304). Informed written consent was obtained from allpatients
and the study was approved by theMedical Ethical Committee.
Results: The mean age value of glucocorticoids sensitive (GCS), glucocorticoid
resistant (GCR) and control group was 33.4±11.6, 38.1±12.3 and 31.7±5.8
years respectively (F=1.496, p=0.235). Half of our female patients (n=14) were
GC resistant while all the males (n=5) were GC sensitive. Statistically significant
difference between GR alpha mRNA isoform and GRa/ GRβ ratio was detected
between GC resistant and GC responsive group while GRp, GRγ and GRβ
were insignificantly differed between groups. GRα is expressed in most human
tissues and cell line. It functions as ligand-dependent transcription factors.
There is a wide variability in median value of GRα between our GCS and GCR
patients. The ratio of GRα/GRβ expression is critical to the glucocorticoid
responsiveness of various cells. Higher ratios correlate with glucocorticoid sen-
sitivity, while lower ratios correlate with glucocorticoid resistance. There was
non-statistically significant correlation between GR α and age (r=-0.302, p=
0.087). GRα had a strong inverse correlation with GRβ and a significant direct
correlation with GRγ and p. Fig. 1 shows ROC curve of different GR isoforms
in predicting GC resistance in ITP. GRα/β ratio had the highest sensitivity
(81.8%) and is the most accurate predictor of GC resistance (79.2%). GRγ had
the highest specificity (86.7%). GRβ had the lowest sensitivity (9.1%) and the
lowest specificity (26.7%).
Figure 1.
Summary/Conclusions: In this study, we noted a statistical significant differ-
ence between GR alpha mRNA isoform and GRa/ GRβ ratio within ITP patients.
GRa and GRa/ GRβ were higher among GC sensitive compared to GC resistant
groups. GRα/β ratio had the highest sensitivity (81.8%) and is the most accurate
predictor of GC resistance (79.2%). We concluded that the study of GRa and
GRa/ GRβ ratio is recommended early in ITP assessment to avoid unnecessary
glucocorticoids side effects during treatment.
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ABNORMALITY OF CD8+ CD28- SUPPRESSOR T CELLS IN PRIMARY
IMMUNE THROMBOCYTOPENIA
H Li*, D Zhang, R Yang
Institute of Haematology and Blood Disease Hospital, Chinese Academy of
Medical Sciences & Peking Union Medical College, Tianjin, China
Background: Primary immune thrombocytopenia (ITP) is an acquired disorder
characterized by autoantibody-mediated platelet destruction and insufficient
platelet production. Multiple factors have been implicated in ITP pathogenesis,
including loss of immune tolerance. CD8+CD28- suppressor cells (Ts), which
have been identified in recent years, play important roles in maintenance of
peripheral immune tolerance. Thus Ts cells are involved in immune escape of
tumor and pathogenesis of several autoimmune diseases. Ma et. al. found
steroid treatment selectively increased Ts proportion in both the passive and
active mice models of ITP, suggesting Ts may be involved in ITP. However,
until now, the role of Ts cells in ITP etiology was not clear yet.
Aims: To evaluate whether the number and the regulatory functions of Ts were
abnormal in ITP patients, and found the reasons for these defects.
Methods: A total of 90 active ITP patients, 21 ITP patients in remission and 93
age- and sex-matched healthy donors (HCs) were enrolled in this study. And (1)
the proportion of CD8+CD28- Ts cell was detected by flow cytometric analysis
(FACS). (2) The CD8+CD28-Ts, CD8+CD28+/CD4+ effector cells and CD4-
CD8- cells (as antigen presenting cells, APCs) were sorted by MACS, and then
mixed lymphocyte reaction and BrdU method were used for evaluating the
inhibitory rate of Ts cells. Here, Transwell (TW) experiments were also performed
to identify soluble cytokines or direct cell-contact was involved in immune regu-
lation of Ts cells. (3) The sorted Ts and APC were co-cultured with PHA and IL-
2, then after 48 hours, CD80, CD86, ILT3 and ILT4 expressions on CD14+ mono-
cyte were analyzed by FACS. And the proliferation of APC were detected by
BrdU corporation after 72 hours. (4) Peripheral blood mononuclear cells were
activated by PHA and IL-2 for 24 hous, following ICOS, PD-1 expression on Ts
cells surface and IL-10 expression in Ts cells (were reactivated by PMA, BFA
and Ionomycin for final 4 hours) were examined by FACS.
Results: (1) The percent of Ts cells in peripheral blood from active ITP patients
were lower than those of HCs, although Ts proportion seems elevated in patients
with remission, there was no difference between ITP patients in remission and
active ITP patients or HCs. (2) Ts cells both from HCs and ITP patients inhibited
CD8+CD28+/CD4+ effector cells proliferation in quantity dependent manner.
The inhibition effect of Ts on CD4+ effector cells at ratio 1:2 and inhibition effect
of Ts on CD8+CD28+ effector cells at ratio 1:4 were significantly lower in ITP
patients than that in the HCs. (3) Ts cells from HCs and ITP patients suppressed
effector cells proliferation both in the presence and absence of a TW; In addition,
the suppressive degree of Ts cell from HCs is greater in the absence of TW,
while no difference was found between presence and absence of TW groups in
ITP patients. Thus, the results suggested that both the soluble mediators and
direct cell-contact were involved in suppressive function of Ts cells, and the cell-
contact regulated ability of Ts cells form ITP patients may be have defect. (4)
The ICOS expressions on Ts cell surface with or without activation were both
decreased in ITP patients than that in HCs. However, the PD-1 and IL-10 expres-
sions of Ts cells were not different between ITP patients and HCs. (5) Ts cell
inhibited proliferation of APCs both in HCs and ITPs. However, inhibition rate
will decreased in ITPs than that of HCs. Moreover, Ts from HCs could down-
regulated CD80, up-regulated of ILT3 and ILT4 expressions on CD14+ mono-
cytes, but these abilities were disappeared in Ts cells from ITP patients.
Summary/Conclusions: The down-regulation of number and inhibitory func-
tion of Ts cells in active patients indicated that Ts defect was involved in patho-
genesis of ITP. In addition, decreased ICOS expression on Ts cell surface and
loss the ability of regulating co-stimulator expression on APCs were partly illus-
trated the reasons for defect s of Ts.
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FIRST OBSERVATION OF TUBB1 GENE MUTATIONS IN TURKISH
PATIENTS WITH MACROTHROMBOCYTOPENIA
D Özkan1,*, AA Waheed2, A Kandilci2, N Akar3
1Okan University, Vocational School of Health Service, Istanbul, 2Gebze Tech-
nical University, Moleculer Biology and Genetic Department, Kocaeli, 3Tobb-
etu Hospital, Pediatrics Department, Ankara, Turkey
Background: Frequency of the rare bleeding disorders (RBDs) in the general
population ranges from 1:500.000 to 1:2 millions. In countries with a high rate
of consanguineous marriages RBDs occur more frequently, representing a sig-
nificant clinical and social problem. Macrothrombocytopenia (giant platelet syn-
drome) is an autosomal dominant disorder and previous studies have demon-
strated that Myosin Heavy Chain 9 (MYH9) mutations lead to this disorder. The
pathogenesis of almost the half of diseases related to MYH9 gene is unknown.
So its diagnosis is not possible. The membrane skeleton and the link between
actin filaments of skeleton and microtubules contain the normal platelet mor-
phology. The defects occurred on these systems results with macrothrombo-
cytopenia. The relation between macrothrombocytopenia and the defect
occurred on microtubules that consisted by alpha and beta tubulin heterodimers
can be explained by the defect occurred on Tubulin Beta 1 (TUBB1) gene.
According to HGMD (Human Gene Mutation Database) data; 52 mutations are
defined in MYH9 gene between 2004-2014. 17 of these mutations are defined
in patients with giant thrombocyte syndrome(macrothrombocytopenia). Only 2
haematologica | 2016; 101(s1) | 589
Copenhagen, Denmark, June 9 – 12, 2016
mutations are defined related to TUBB1 gene, so the researches done on rela-
tion between TUBB1 and macrothrombocytopenia is limited. The guiding indi-
cators on the treatment of this disease can be achieved in case of defining the
effects of TUBB1 mutations on megakaryocytes-microtubule organization, pro-
platelet formation and platelet morphology
Aims: In this study, we aimed to analyze TUBB1 gene at Turkish population
with clinically diagnosed macrothrombocytopenia.
Methods: A written informed consent for genetic analysis was obtained from
the patients. The patient blood was collected from various hematology clinics
in Turkey. In this study, TUBB1 gene mutation analysis was performed by using
the blood of patients diagnosed with macrothrombocytopenia following the
DNA isolation. Then samples were sequenced using a DNA sequencer (Beck-
man Coulter, USA). Sequencing are evaluated using with FinchTV program.
Results: TUBB1 gene analysis of Turkish patients with macrothrombocytope-
nia revealed a novel heterozygous Cytosine to Timin nucleotide change at 821
at exon4 (p.T274M/ Threonin to Methionine), at a child and his father in the
same family, 99 nucleotide ahead which is at nucleotid 920, there is a novel
heterozygous Guanine to Adenin nucleotide change, this situation caused to
change of Arginine aminoacid to Histidine aminoacid at 307 position (p.R307H)
in protein. These changes are conserved at evolutionary process, so we can
say that these transitions are novel mutations. We also identified a double base
pair substitution at nucleotide positions 130-131 at exon 2,this transition
encodes the Q43P (p.Gly43Pro, p.Gly43His) mutant form of the protein.
(nucleotide and aminoacid numbering as per m RNA GenBank entry
NM_758664).
Summary/Conclusions: In this study, we identified the first TUBB1 mutation;
combined 821C>T and 920 G>A mutations in a family and these mutations are
not defined previously in Human Gene Mutation Database (HGMD). And Q43P
single nucleotide polymorphism is defined firstly at Turkish population, so they
are very important findings in terms of explaining the relationship of
macrothrombocytopenia and TUBB1 gene.
Funding: This research is financially supported by Starting R&D Projects Fund-
ing Program (3001) of The Scientific and Technological Research Council of
Turkey (TUBITAK)
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PLATELET INCREASING STRATEGIES IN PATIENTS WITH IMMUNE
THROMBOCYTOPENIA REQUIRING LONG-TERM ANTITHROMBOTIC
PROPHYLAXIS
V De Stefano*, A Ciminello, T Za, S Betti, F Bartolomei, E Rossi
Institute of Hematology, Catholic University, Rome, Italy
Background: As in the general population, patients with immune thrombocy-
topenic purpura (ITP) can develop pathologies requiring long-term treatment with
anticoagulant or antiplatelet agents. Challenging situations in this setting are
antithrombotic prophylaxis in patients with atrial fibrillation (AF), artery stenosis,
previous cardiac or vascular surgery, percutaneous transluminal coronary angio-
plasty (PTCA) with or without stenting, arterial or venous thrombosis. Concomitant
use of platelet increasing treatment is mandatory for acceptable safety.
Aims: To summarize a monocenter experience in the management of ITP
patients requiring long-term antithrombotic treatment and concomitant platelet
increasing treatment.
Methods: We analysed the medical records of 108 ITP patients referred to
our Center since 2000 to 2015; we identified 18 patients with risk situations
making necessary platelet increasing treatments (M/F 11/7, median age at the
treatment 52 yrs, range 47-90). Antithrombotic treatments were categorized
as vitamin K-antagonists (VKA), direct oral anticoagulants (DOACs), low molec-
ular weight heparin (LMWH), antiplatelet agents (aspirin, clopidogrel,
indobufene). Platelet increasing treatments were categorized as prednisone
(PDN), high-dose dexamethasone (DEX), high-dose immunoglobulins (HD-
IG), thrombopoietin receptor agonists (TPO-RA: eltrombopag ETP, romiplostim
RPL). A platelet count >100 x109/L or >30 x109/L in at least 4 consecutive
weeks defined complete response (CR) or partial response (PR). Antithrombotic
treatments were started at a platelet count higher than 50 x109/L. 
Results: All patients had previously received at least one line of treatment
(one line=4, two lines=7, three lines=4, >three lines=3); five patients had had
splenectomy. Four patients had AF and received AVK (n=2), DOACs (n=1),
LMWH (n=1); two had carotid stenosis and received aspirin; one underwent
aortic valve replacement and received after surgery AVK and then aspirin; one
underwent angioplasty of popliteal aspirin plus clopidogrel; one patient had
coronary bypass and received indobufene; three patients had coronary stenting
and received AVK (n=1) and aspirin plus clopidogrel (n=2); four patients had
deep venous thrombosis of the legs and received LMWH for 6 to12 months;
two patients had caval vein and portal vein thrombosis, respectively, and
received VKA; one patient had retinal vein thrombosis and received LMWH.
The median platelet count before the platelet increasing treatment was 46
x109/L (range 13-67). Twelve patients received TPO-RA (ETP=10; RPL=2), 3
patients received PDN, 2 patients received DEX, and one received HD-IG and
PDN. Nine patients receiving TPO-RA achieved CR, and three PR (62, 91,
and 99 x109/L); on the other hand four patients receiving steroids achieved
CR, and one PR (88 x109/L). The remaining patient with caval vein thrombosis
had no response after HD-IG and PDN and a caval filter was placed. All the
other patients received antithrombotic treatment at therapeutic doses. No
thrombotic or bleeding event was recorded after starting antithrombotic treat-
ment together with a platelet increasing treatment. 
Summary/Conclusions: Antithrombotic treatments can be given safely in
patients with ITP after having obtained an increased platelet count. TPO-RA and
steroids are both effective as platelet increasing strategies, but possible long-
term side effects due to prolonged steroid treatment should induce caution.
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THE ROLE OF ROMIPLOSTIM IN CHEMOTHERAPY-INDUCED THROM-
BOCYTOPENIA TREATMENT
L Entrena Ureña*, D Fernandez Jimenez, Z Mesa Morales, F Hernandez Mohe-
do, M Jurado Chacon
Haematology, Virgen de la Nieves Hospital, Granada, Spain
Background: The thrombocytopenia due to chemotherapy and/or marrow infil-
tration is a common complication in cancer patients. When it is moderate or
severe, it can cause difficulties in the clinical management and the continuity of
full-dose treatment. Romiplostim stimulates the thrombopoietin receptor inducing
proliferation and differentiation of megakaryiocites, so administered at the right
time, it could lead to a faster recovery or maintenance of platelet counts, avoiding
delays and dose adjustments which may cause poor response to chemotherapy.
Aims: To evaluate safety and efficacy from Romiplostim in post-chemotherapy
thrombocytopenia.
Methods: 15 patients with malignancies, 11 non-hematologic (2 breast cancer,
2 colon cancer, 2 carcinoid tumors, 1 glioblastoma multiforme, 1 neuroen-
docrine tumor, 1 endometrial cancer, 1 germ cell tumor and 1 small cell lung
cancer) and 4 lymphomas (2 follicular lymphomas, 1 diffuse large B-cell lym-
phoma and 1 Hodgkin lymphoma) were treated with Romiplostim. The median
age was 54 years (29-84) and the median baseline platelet counts was 69 x
109 L (8-90). All were receiving chemotherapy, 3 in first-line and the rest in sec-
ond-line or later and 53% had marrow invasion. 14 patients develop cytopenia,
requiring red cells transfusion (60%), platelet transfusion (47%) and the use of
granulocyte-colony stimulating factor (G-CSF) (66%). The median starting dose
of Romiplostim was 1 mcg/kg (1-3) and the median maintenance dose was 3
mcg/kg (1-4), for a median time of 50 days (7-322).
Results: 2 patients achieved no response, one of them requiring continued
platelet transfusion support to carry on with chemotherapy. 87% of patients
achieved response, in 11 cases with platelet counts of >100 x 109L. This
allowed the use of full-dose chemotherapy and according to the initial scheme,
except for dose adjustment in 2 cases due to platelet counts of<50 x 109L.
Romiplostim treatment was well tolerated, with no treatment-related toxicities
observed. No haemorrhagic events were reported over this period.
Table 1.
Summary/Conclusions: Thrombopoietin and its receptor are new therapeutic
targets in the development of drugs for diseases associated with thrombocy-
topenia. Apart from his habitual use, Romiplostim achieved an increase in
platelet counts in cancer patients, even after several treatment lines, making
possible the use of full-dose chemotherapy and without delays, which could
result in a therapeutic benefit. Despite the good results achieved, it would be
necessary a larger number of patients to prove the thrombopoietin receptors
agonists as equivalents to G-CSF and erythropoietin in post-chemotherapy
cytopenias.
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PRIMARY IMMUNE THROMBOCYTOPENIA TREATED WITH ROMIPLOSTIM
IN ROUTINE CLINICAL PRACTICE: A RETROSPECTIVE STUDY FROM
THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA REGISTRY
IU Doobaree1, R Nandigam1, L Mensah2, A Seesaghur2,*, H Patel3, S Wetten2,
D Provan1
1Barts and The London School of Medicine and Dentistry, 2Amgen Limited,
London, 3Amgen Limited, Cambridge, United Kingdom
Background: Immune Thrombocytopenia (ITP) is a rare disorder characterized
by low platelet counts, leading to an increased tendency to bleed. Adult chronic
ITP patients (pts) in Europe who are refractory to other treatments (e.g. corti-
costeroids, immunoglobulins) are eligible for treatment with romiplostim, a
thrombopoietin-mimetic peptibody. Since ITP treatment-related decisions are
principally dependent on clinical expertise or pt preference, observational stud-
ies can provide a better understanding of ITP treatment in routine practice.
590 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Aims: To describe the demographic and clinical characteristics of patients with
ITP receiving romiplostim in the UK, and to provide details on platelet counts, and
the use and pattern of administration of romiplostim in routine clinical practice.
Methods: The United Kingdom Immune Thrombocytopenia (UKITP) Registry ret-
rospectively and prospectively collects demographic and ITP-related clinical data
on primary ITP pts enrolled by consent through a network of 68 centres throughout
the UK. All adults (≥18yrs) within the UKITP registry who received at least one
dose of romiplostim in routine clinical practice from October 2009 until 31st January
2015 were included in the analysis. Data described included demographic and
clinical characteristics and ITP medications in patients since ITP diagnosis until
end of follow-up and platelet counts before and after romiplostim initiation.
Results: At the time of data extraction from the registry (31st January 2015), a
total of 1440 ITP pts were registered and 118 patients were treated with romi-
plostim. The median age at ITP diagnosis of the romiplostim cohort was 59
years (IQR: 36, 73). Members of the cohort had been diagnosed since 1980,
with 50% diagnosed between 2010-14. The median time from ITP diagnosis to
romiplostim initiation for those diagnosed between 2010-14 was 0.9 years (IQR:
0.3, 1.9). Almost three-quarters (73%) of patients initiated romiplostim ≥1 year
from ITP diagnosis, and 12% of patients initiated romiplostim within 3 months
of ITP diagnosis. There were some differences in baseline demographics
between splenectomised and non-splenectomised patients (Table). Most
patients (77%) had received at least three different ITP medications before
romiplostim. The most common prior ITP treatments were corticosteroids (90%),
intravenous immunoglobulin (IVIg) (77%), and rituximab (57%). The median
maximum weekly dose of romiplostim was 3.1 mcg/kg (IQR: 2.0, 6.0). 82% of
patients had 2 or fewer ITP medications after romiplostim initiation. The median
platelet count within 2 weeks before romiplostim initiation was 17 x 109/L (IQR:
8, 41), which rose to 81 x 109/L (IQR: 31,155) within 1 month of romiplostim
treatment and remained >50 x 109/L thereafter.
Table 1. Demographic and clinical characteristics of the romiplostim
cohort overall, and by splenectomy status at romiplostim initiation.
Summary/Conclusions: Limitations include potential selection bias into the
registry and the small sample size and heterogeneous nature of the selected
cohort. This retrospective analysis of secondary and tertiary care data from the
UKITP registry provides a valuable insight in the real-world ITP pt population
prescribed with romiplostim in the UK.
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VARIATIONS IN CYTOKINE GENE POLYMORPHISM AMONG EGYPTIAN
CHILDREN WITH PRIMARY IMMUNE THROMBOCYTOPENIA
G Mokhtar1, N El-beblawy1, A Adly1, N Elbarbary1,*, T Kamal2, E Hasan1
1Hematology and Oncology Unit, Department of Pediatrics,Ain shams Univer-
sity, 2Human Genetics Unit, Department of Pediatrics,Ain shams University,
Cairo, Egypt
Background: Childhood immune thrombocytopenia (ITP) is a common pedi-
atric hematologic disorder with an association between the cytokine gene poly-
morphisms affecting the cytokine production and autoimmune diseases at the
stage of formation of disease and in the course of disease and their responses
to treatment.
Aims: To evaluate the possible role of cytokine genes as well as of their poly-
morphisms in Childhood ITP, we analyzed the allelic and genotypic frequencies
of different cytokine gene polymorphisms known to be related to autoimmunity
and inflammation (IL-6−174, IL-10−1082, IL-17F, TNF- α−308, 1RaVNTR) in
Egyptian patients with ITP and healthy control subjects. In addition we assessed
the potential role of these polymorphisms in relation to phases of ITP, disease
progression and response to different treatment modalities.
Methods: A total of 50 (22 males, 28 females) pediatric patients with primary
ITP (20 newly diagnosed, 30 chronic) and 50 healthy controls age and sex
matched were investigated via polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) analysis for cytokine gene polymorphism.
Information on demographic characteristics, duration of disease, bleeding
symptoms, life threatening bleeding, severity of bleeding, disease phases, type
and response to different types of treatment were assessed. 
Results: Compared to controls, all patients showed a higher frequency of IL-
6−174 CC (P= 0.0001, OR=7.048, 95% CI=2.18-22.7), higher GA genotype of
TNF-α(−308) (P= 0.001, OR=6.469, 95% CI=2.0-20.9), higher CC genotype of
IL-17F (P= 0.0001,OR=55.545, 95% CI=14.4-213.2), higher GG of IL-10−1082
(P= 0.029, OR=3.6, 95% CI=1.08-12.18) and A1A2 genotype of IL- 1RaVNTR
(P=0.039, OR=2.374, 95% CI=1.03-5.4). The frequency of IL-6 (-174) C allele
(66% vs 49%, P=0.015), A allele of TNF-α−308 (24% vs 6%, P=0.001), A2 allele
of IL-1RaVNTR (30% vs 14%, P=0.007), IL-17F C allele (89% vs.53%,
P=0.0001) were significantly higher in all patients with ITP compared to controls.
However, there was no significant difference revealed in allele distribution of IL-
10(-1082) (p=0.67). IL-10 GA and IL-1Ra A1A1genotypes were higher among
chronic patients (P=0.042, P=0.001 respectively) compared to newly diagnosed.
There were no significant differences between different cytokine genotypes and
the various clinical features including gender, age,disease duration, bleeding
score, wet purpura, life threatening bleeding among newly diagnosed ITP
patients (P>0.05). On the other hand, among chronic patients with ITP, 30%
presented with mucosal bleeding (wet purpura) with highest prevalence among
CC genotype (50%) followed by GC genotype (15.4%)and lastly GG genotype
(0%) of IL-6 (P=0.048). Of note, the age of diagnosis of chronic patients was
significantly higher than the newly diagnosed patients with ITP (2.84 versus 5.75
years(P=0.011). Best platelet response to steroid treatment was found among
GC genotype of IL-6 (-174) and GG genotype of IL-10(-1082) in all patients with
ITP with P value of (P=0.001 and P=0.002 respectively).
Summary/Conclusions: This suggests that previously mentioned cytokine
gene polymorphisms possibly contribute to the susceptibility of acquisition of
childhood ITP. Furthermore, GA genotype of IL-10 and A1A1 genotype of IL-
1Ra polymorphisms are associated with increased risk of chronic ITP. IL-6 (-
174) and IL-10 (-1082) genes might play a role in the effectiveness of steroid
therapy among patients with ITP. However, the role of other genetic and envi-
ronmental factors cannot be entirely ruled out.
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LOW-DOSE RITUXIMAB AS PRE-EMPTIVE THERAPY IN MULTI-RELAPSING
AND PRIMARY REFRACTORY PATIENTS WITH ACQUIRED IDIOPATHIC
THROMBOTIC THROMBOCYTOPENIC PURPURA: A MONOCENTRIC RET-
ROSPECTIVE STUDY
L Fianchi1,*, M Criscuolo1, S Lancellotti2, MT Voso3, A Giordano1, N Piccirillo1,
R De Cristofaro2, L Laurenti1, G Zini1, S Sica1, G Leone1, V De Stefano1,
L Pagano1
1Hematology, 2Hemostasis Research Center, Fondazione Policlinico Universi-
tario A.Gemelli/Catholic University, 3Biomedicine and Prevention, Tor Vergata
University, Rome, Italy
Background: Acquired idiopathic thrombotic thrombocytopenic purpura (TTP)
is a life-threatening microangiopathic disorder for which therapeutic plasma
exchange (TPE) and steroids represent the primary standard of care. However,
a significant proportion of patients still experiences refractory disease, with
exacerbations shortly after a perceived remission, or relapse.
Aims: The aim of this retrospective study was to evaluate the long-term efficacy
of rituximab in preventing early death in refractory/exacerbated TTP and avoid
relapse in “relapsing” patients.
Methods: We collected retrospectively clinical data on all patients with acquired
TTP, admitted to our Hematology Department between January 2005 and
December 2015. Forty-eight patients [37 female and 11 male; median age:
42.5 years (range 17-80)] were registered and treated for TTP in this period.
Results: Thirty-six patients were included at their first episode of TTP, while 12
patients had a history of multiple relapses [median 2 (range 2-4)], in the previous
10 years (1995-2004). Nine of 48 patients (19%) were diagnosed with TTP dur-
ing pregnancy. Median platelet and hemoglobin values at diagnosis were
13x109/l (range 5-49) and 7,9 g/dl (4,2-10.1),respectively. ADAMTS-13 con-
centration was measured at diagnosis or at relapse in all patients and was<10%
in all cases [median 0% (range 0-6)]. Anti-ADAMTS13 autoantibodies were
present in all 23 patients tested. All 48 patients received TPE associated to
1mg/kg methyl-prednisolone as frontline therapy. After a median of 10 TPE
(range 8-18), 32 patients (67%) (20/36 naïve, 12/12 at relapse) achieved dis-
ease remission [normal platelet counts, increase of ADAMTS-13 activity [medi-
an 78% (range 50-215)] and disappearance of inhibitors), while 16 (33%) result-
ed refractory or experienced exacerbation. Rituximab (RTX), at the dose of
375 mg/m2 weekly for 4 weeks, was then added to TPE in 27 patients (56%),
including 15/36 patients at their first TTP episode, who resulted refractory to
TPE or showed exacerbation, and in the 12 relapsing patients, to prevent sub-
sequent relapse. One patient with TTP exacerbation died early, prior to RTX
start. Complete response to RTX was documented in 12 of 15 refractory
patients, and in all 12 relapsing patients. Three patients died early, before the
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second RTX dose, resulting into 8% overall 30-day mortality rate (4 patients).
Mainteinance treatment with low dose RTX (100 mg every three months for 2
years) was then administered to 23 patients (12 relapsing and 11 refractory),
while 1 patient refractory to TPE refused maintenance. At a median follow up
of 34 months (range 1-87) from the first dose of maintenance none of the
patients relapsed, and we did not observe any infectious complications. This
resulted into a significant reduction in the incidence of relapses after RTX treat-
ment (HR 4.26, 95% CI 1.511-12.05, p 0.0089). ADAMTS-13 activity was stable
at >50% and inhibitors were not detected during follow-up visits, performed
every three months in all 23 patients. 
Summary/Conclusions: Our results suggest that pre-emptive treatment with
low dose rituximab, is safe and effective to maintain remission also in patients
with primary refractory TTP or with a history of multiple relapse.
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THE INTERLEUKIN-17F (7488T/C) GENE POLYMORPHISM AND THE RISK
OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA IN EGYPTIAN
PATIENTS
S Yousry1,*, G H.Shaheen1, N Diaa1, H N.Ellithy2
1Clinical Pathology, 2Internal Medicine, Cairo University, Giza, Egypt
Background: Chronic primary immune thrombocytopenia (ITP) is an acquired
autoimmune disease characterized by both reduced platelet counts and sup-
pression of megakaryocyte and platelet development.IL-17F is a novel inflam-
matory cytokine and plays an important role in some autoimmune diseases by
inducing the expression of multiple chemokines, cytokines, and adhesion mol-
ecules. IL-17F (7488T/C) polymorphism influence IL-17 expression and activity.
Thus, considering the abnormal percentage of T helper 17 cells and the report-
ed high levels of circulating IL-17F in patients with primary immune thrombo-
cytopenia suggests a possible role of IL-17F (7488T/C) polymorphism in devel-
opment of chronic ITP.
Aims: We investigated the role of IL17F polymorphism (7488T ⁄ C) on the sus-
ceptibility and clinical features of chronic ITP in Egyptian patients and if it may
be linked to response to treatment with glucocorticoides.
Methods: A cohort of 107 patients with chronic ITP and 100 healthy control
were enrolled in this case control study.Genotyping of IL17F (7488T/C) gene
polymorphism was determined by the polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) technique
Results: Chronic ITP patients had a significantly higher frequency of the IL-
17F 7488-TT genotype compared to controls (84.1% vs 70.0%; Odd ratio=
2.269; P-Value=0.015).Furthermore the IL17F 7488 TT genotype was signifi-
cantly associated with poor response to corticosteroid therapy; 11.1% were
steroid responsive vs 88.9% were not responsive (P value= 0.001)
Summary/Conclusions: These findings suggest that the IL-17F 7488 T allele
is significantly associated with the development of chronic ITP, suggesting a
role for IL-17F polymorphism in the pathogenesis of chronic ITP.
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ELTROMBOPAG SAFETY AND EFFICACY IN OLDER THAN 65 YEARS
OLD PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS IN CLINICAL
PRACTICE
TJ González-López1,*, MT Alvarez-Román2, JA Hernández-Rivas3, G Pérez-Rus4,
C Pascual4, S Bernat5, F Fernández-Fuentes6, B Sánchez-González7,
MM Andrade8, I Jarque9, PE Olivera10, V Martínez-Robles11, M Gómez-Nuñez12,
A Fernández-Rodriguez13, M Cortés14, MA Fuertes-Palacio15, R Fisac16,
MJ Peñarrubia17, C Aguilar18, A Bárez19, E De Cabo20, C Fernández-Miñano21,
JR González-Porras22, LJ García-Frade23
1Department of Hematology, Hospital Universitario de Burgos, Burgos, 2Depart-
ment of Hematology, Hospital Universitario La Paz, 3Department of Hematology,
Hospital Infanta Leonor, 4Department of Hematology, Hospital General Univer-
sitario Gregorio Marañón, Madrid, 5Department of Hematology, Hospital La
Plana, Castellón, 6Department of Hematology, Hospital Universitario Insular de
Gran Canaria, Las Palmas de Gran Canaria, 7Department of Hematology, Hos-
pital del Mar, Barcelona, 8Department of Hematology, Hospital Universitario
Miguel Servet, Zaragoza, 9Department of Hematology, Hospital La Fe, Valencia,
10Department of Hematology, Hospital Valle de Hebron, Barcelona, 11Depart-
ment of Hematology, Hospital de León, León, 12Department of Hematology,
Hospital Parc Taulí, Sabadell (Barcelona), 13Department of Hematology, Hospital
Universitario Central de Asturias, Oviedo (Asturias), 14Department of Hematol-
ogy, Fundació Hospital Asil de Granollers, Granollers (Barcelona), 15Department
of Hematology, Hospital Clínico Lozano Blesa, Zaragoza, 16Department of
Hematology, Hospital de Segovia, Segovia, 17Department of Hematology, Hos-
pital Clínico de Valladolid, Valladolid, 18Department of Hematology, Hospital de
Soria, Soria, 19Department of Hematology, Hospital de Avila, Avila, 20Depart-
ment of Hematology, Hospital del Bierzo, Ponferrada (León), 21Department of
Hematology, Hospital Vega Baja, Orihuela (Alicante), 22Department of Hema-
tology, Hospital Clínico Universitario de Salamanca, Salamanca, 23Department
of Hematology, Hospital Rio Hortega, Valladolid, Spain
Background: Eltrombopag is a a thrombopoietin receptor agonist (TPO-RA)
approved for chronic primary immune thrombocytopenia (ITP) patients. How-
ever, ITP clinical practice in more than 65 years old patients could not reflect
efficacy and safety of clinical trials results.
Aims: To evaluate the safety and efficacy results of eltrombopag in older than
65 years old patients in a real world setting
Methods: 81 equal or more than 65 years old primary ITP patients from 23
Spanish centers who had been treated with eltrombopag and included in the
Spanish Eltrombopag ITP Registry were retrospectively evaluated.
Results: -The median age of the whole cohort was 75 (IQR, 69-79) years. Our
case series included 16 newly-diagnosed, 16 persistent and 49 chronic primary
ITP patients [78 (IQR, 73-81), 78 (IQR, 74-85) and 73 (IQR, 68-76) median
years, respectively]. There were 51 women and 30 men. 23% of patients had
a Charlson Comorbidity Index score of 2 or more at diagnosis. The median
time from ITP diagnosis to eltrombopag initiation was 36 (IQR, 4-47) months
[1(IQR,0-1.25), 4(IQR,6-8) and 57(IQR, 22-73) months, for each of the groups].
The median number of therapies before starting eltrombopag was 2 (IQR, 1-
3), including rituximab (18%), romiplostim (17%) and splenectomy (10%). At
the time of treatment start, 22 of 81 patients (27%) patients were receiving
concomitant medication for primary ITP, mainly including corticosteroids (20%)
or immunoglobulins (11%). 24 of 81 (30%) patients had bleeding symptoma-
tology during the month preceding the starting eltrombopag. At eltrombopag
initiation the median platelet count was 27 x 109/L (IQR, 7-26 x 109/L). 68 of
81 (84%) patients had a response (R) to eltrombopag treatment whilst 62
patients (76%) achieved a complete response (CR; platelet count >100 x
109/L). [R and CR rates were 94% and 87% in newly-diagnosed ITP; 75% and
68% in persistent ITP; 84% and 75% in chronic ITP]. Women reached 86%
and 78% of R/CR while 80% and 73% of men. Responses were 91% in patients
who received concomitant ITP medication at baseline and 64% in patients with-
out other added treatments. The proportion of patients achieving a platelet
response was quite similar regardless bleeding at starting eltrombopag (79%
and 86% for patients with and without bleeding, respectively). Of the 82
patients, 20 (24.4%) experienced one or more adverse events during treatment
with eltrombopag. Adverse events were mainly grade 1–2 in severity. The com-
monest adverse effects reported during eltrombopag treatment were diarrhea
and headache. Eight percent of patients (7 of 82) had hepatobiliary laboratory
abnormalities (HBLAs). On the other hand, we observed seven deaths: three
of them were caused by ITP severity (cerebral bleedings), two were due to
progression of COPD (chronic obstructive pulmonary disease), one was a
gram-negative sepsis and one patient suffered an arrhythmia related sudden
death. A subanalysis of primary ITP patients with more than 80 years (6 male
and 14 female), revealed as high efficacy rates as younger patients (85% of
CR with 75% of responses). This kind of patients are expected to be a very
frail patients. Nevertheless, only 7 (35%) patients of this population reported
adverse events.
Summary/Conclusions: Our case series describe the great efficacy and safety
results observed with the use of eltrombopag in our more than 65 years old
ITP patients. However more studies are needed to confirm the possible use-
fulness of TPO-RAs in this variety of primary ITP cases.
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WERE THE MEASUREMENTS STANDARDIZED SUFFICIENTLY IN PUBLISHED
PAPERS ABOUT MEAN PLATELET VOLUME?
C Beyan1,*, E Beyan2
1Department of Hematology, Gulhane Military Medical Academy, 2Department
of Internal Medicine, Kecioren Training and Research Hospital, Ankara, Turkey
Background: Recently, mean platelet volume (MPV) aroused interest of the
researchers and several studies about MPV changes in various pathological
conditions were published.
Aims: The aim of this study was to evaluate the data accuracy of MPV meas-
urements in these studies.
Methods: The study was performed using the data of 181 studies contain
healthy control subjects within 1181 paper about mean platelet volume indexed
by PubMed database since 2012.
Results: 81 studies (%44.7) were performed retrospectively. Healthy control
groups included 80.52±70.51 subjects (mean±standard deviation). The distri-
butions of gender in 16 (8.8%) and age in 12 studies (6.6%), and platelet counts
in 28 studies (15.5%) were not reported. The gender and age groups were not
differing significantly by the means of platelet counts (r= -0.40; p >0.05). EDTA,
low (1:9) and high concentrate (1:4) citrate were used as an anticoagulant in
112, 7 and 2 studies, respectively and type of anticoagulant was not noted in
60 studies (33.1%). There was no study to compare the different anticoagu-
lants. The instruments of Beckman Coulter, Sysmex, Abbott Cell-Dyn, Siemens
ADVIA, Mindray BC-6800, HORIBA ABX Micros 60 and Diatron Abacus Junior
B were used for the measurements of MPV in 53, 46, 32, 9, 2, 2, and 1 studies,
respectively and the used technology in automated blood cell counting was
not specified in 36 studies (19.9%). The MPV values measured with Sysmex
was higher significantly than the MPV values measured with Beckman Coulter,
Abbott Cell-Dyn and Siemens ADVIA. The MPV measurements varied up to
17.8% by the instruments. The measurement times between 15 minutes-2
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hours was significantly different from the measurement times<15 minutes and
>2 hours. The MPV measurement times from venipuncture were not indicated
in 86 studies (47.5%). The MPV measurements by the MPV measurement
times and plus the used instruments varied up to 17.8% and 27.7%, respec-
tively. Both the MPV measurement times and used instruments were not stated
in 29 studies (16.0%). Only 47 prospective studies (26.0%) enlightened about
type of anticoagulant, used instruments for MPV measurement, MPV meas-
urement time, platelet counts and MPV values.
Summary/Conclusions: As a result, the measurements were not standardized
sufficiently in published papers about MPV. It may be explained the differences
between the results of studies made same pathological conditions.
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COMPARISON OF MEAN PLATELET MASS AND MEAN PLATELET
COMPONENT IN IMMUNE THROMBOCYTOPENIA, HYPOPROLIFERATIVE
THROMBOCYTOPENIAS, AND HEALTHY INDIVIDUALS
H Melinscak1,*, T Mirzoyev1, YT Hong2, M Varma1
1Hematology-Oncology, 2Pathology, Mount Sinai St. Luke’s-Roosevelt, New
York, United States
Background: Immune thrombocytopenia (ITP) remains a diagnosis of exclu-
sion. The Siemens ADVIA 120 has the capacity to calculate the mean platelet
(PLT) component (MPC), a measure of PLT density, and the mean platelet mass
(MPM), neither of which are currently employed in clinical decision making.
Aims: To determine if the MPC and MPM are significantly higher in ITP (reflect-
ing increased PLT granules) than in hypoproliferative thrombocytopenia (HT)
and in the healthy population. 
Methods: Institutional review board approval was obtained. A prospective study
was initiated in September 2013. This trial is registered at ClinicalTrials.gov.
Patients at Mount Sinai Roosevelt Hospital with ITP, as defined by the ASH
2011 practice guidelines, and HT’s (delineated in Results section) were includ-
ed. A reference population was established. Patients with human immunodefi-
ciency virus, hepatitis C, cirrhosis, pregnancy, and disseminated intravascular
coagulation were excluded. Enrollment of 20 patients in each arm and 10
healthy individuals in the control arm was planned. Lavender tri-potassium
EDTA tubes were filled and analyzed on the Siemens ADVIA 120 within a period
not exceeding 2 hours from their collection. MPC and MPM values were com-
pared for all 3 groups using one-way analysis of variance. The student’s t-test
was used to compare these parameters in the patient groups.
Results: Twenty patients with ITP, 20 patients with HT (4 aplastic anemia, 8
chemotherapy-induced thrombocytopenia, 3 myelodysplasia, 1 acute myeloge-
nous leukemia, 1 hairy cell leukemia, 1 multiple myeloma, and 2 drug-induced
thrombocytopenia (valproic acid, imatinib)), and 10 controls were enrolled. Base-
line characteristics of the patient groups were similar. Median age, M:F ratio,
and mean PLT count were 54 years, 0.67:1, and 62,500/µL (ITP) and 60.5 years,
1:1, and 53,900/µL (HT), p>0.05. MPC (g/dL, mean +/- SD) for each group was
26.7 +/- 1.89 (ITP), 24.2 +/- 1.89 (HT), and 28.09 +/- 0.74 (controls), p<0.01.
MPM (pg, mean +/- SD) for each group was 2.43 +/- 0.451 (ITP), 1.95 +/- 0.210
(HT), and 1.91 +/- 0.10 (controls), p<0.01. Comparison of these parameters for
the 2 patient groups showed statistical significance (p<0.01).
Summary/Conclusions: MPM is significantly higher in ITP than in HT and in
controls, likely reflecting increased granular content. While MPC is significantly
higher in ITP than in HT, it is highest in controls, etiology unclear. Future studies
should further evaluate these parameters for distinguishing ITP from other
thrombocytopenias.
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ELTROMBOPAG LOW DOSES AS PROPHILAXIS OF CHEMOTHERAPY
INDUCED THROMBOCYTOPENIA (CIT) IN CANCER PATIENTS TREATED
WITH PLATINUM BASED CHEMOTHERAPY
F Iuliano1,*, S Blotta2, E Iuliano3, MA Santoro1, P Alessia1, M Luci1, A Pomillo1
1Internal Medicine, UO di Onco-Ematologia PO “N.Giannettasio”, Rossano,
2ASST Bergamo Est, UOC Oncologia, Seriate (BG), 3Magna Graecia Univer-
sity, UO di Oncologia, Catanzaro, Italy
Background: Chemotherapy-induced thrombocytopenia (CIT) can cause delay
or reduction in subsequent courses of chemotherapy. As reported in literature,
thrombocytopenia occurred in 82% of those receiving only carboplatin, and in
58%, 64%, and 59% of those receiving combination therapies with carboplatin,
gemcitabine or paclitaxel, respectively. Eltrombopag is an oral, non-peptide
thrombopoietin receptor agonist that has been shown efficacy and safety in
chronic immune thrombocytopenia (ITP) patients not responding to previous
therapy by raising the platelets count in both continued long-term administration
and in a repeated short-term administration. Eltrombopag bound the throm-
bopoietin receptor in the transmembrane region, an area different from where
thrombopoietin or romiplostim bound, and activated the thrombopoietin receptor
in a different fashion. Here, we report on a series of 18 patients at high risk of
CIT because of platinum chemotherapy schedules who received low doses
eltrombopag as prophilaxis 
Aims: To prevent CIT in patients who cannot be supported by platelet transfusions
and for whom the maintenance of dose intensity is crucial for remission or survival.
Methods: A total of 18 consecutive adult patients, female (60%), median age
47 years (range 28 - 65) were enrolled in the study.The reason of chemotherapy
has been ovary cancer in 4 patients, colon cancer in 6 patients, relapsed DLBC
lymhoma in 4 patients, TNBC in 2 patients, pancreatic cancer in 2 pts. All
patients received eltrombopag 25 mg by mouth twice a weekly as soon as the
platelet count falls below 80000 mmc, and continued on treatment until com-
pletion of cycles of chemotherapy.
Results: The mean platelet count nadir was 60000 mmc; the number of days
with platelet count<80000/µL was 4 days; The maximum value reached was
270,000 mmc. No treatment-related toxicity was observe. The principal end-
points of the study: avoid nadir platelet counts<50,000/µL,platelet
transfusions,bleeding events, chemotherapy dose reductions chemotherapy
delays. were achieved in all patients.
Summary/Conclusions: In our opinion low dose eltrombopag prophilaxis can
be an effective and safe strategy for preventing the CIT.
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THERAPEUTIC APPROACH TOWARDS SYMPTOMATIC THROMBOCYTOPENIA
IN DENGUE HEMORRHAGIC FEVER
T Jameel1,*, I saleem2
1Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia,
2Iffefaq Hospital, Lahore, Pakistan
Background: Introduction: Immune-mediated destruction of platelets is
thought to be the mechanism of thrombocytopenia seen after the viremic phase
of dengue hemorrhagic fever (DHF). Immuno-suppressants such as steroids,
immune globulin and Anti D immunoglobulin are effective in the treatment of
this type of immune thrombocytopenic purpura.
Aims: To evaluate the efficacy of oral Prednisolone in the rate of resolution of
thrombocytopenia and monitoring of complications in patients recovering from
Dengue hemorrhagic fever.
Methods: A controlled study was carried out on diagnosed cases Dengue hem-
orrhagic patients presenting with sever thrombocytopenia and symptoms like
confluent ecchymosis, epistaxis and purpuric rashes. This study was conducted
in Ittefaq hospital (trust) in collaboration with KAU Jeddah, during the period of
October to December 2013. Treatment group received steroids in two forms
i.e. 1st line therapy prednisolone orally or as 2nd line therapy of initial I/V high
dose (prednisolone) in pulse doses i.e. 40 mg bid for four days and later oral
prednisolone as in 1st line therapy with omeprazole 20 mg bid in addition to
standard treatment. Control group received standard supportive care only.
Results: A total of 341 suspected patients were admitted in hospital. Serological
diagnosis was confirmed in 166 patients. CBC revealed platelet count ≤100x109/l
in 106 patients. A group of symptomatic febrile patients have platelet
count<20x109/l was selected for therapeutic intervention. 1st line therapy (oral
prednisolone was stated in 43 patients. In Fourteen patients 2nd line therapy
(high dose dexamethasone pulse) therapy was instituted. Seven of them attained
complete response whereas two patients achieved partial response. Four patients
were shifted to Anti D therapy. Three deaths occurred during our study. Rest of
all the patients improved and were discharged in due course of time.
Summary/Conclusions: This small scale preliminary study shows promising
results in reducing the morbidity of patients in a relatively serious stage but
large scale double blinded randomized controlled studies are needed before
making recommendations on use of steroids in symptomatic thrombocytopenic
patients with dengue hemorrhagic fever.
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WISCOTT ALDRICH SYNDROME IN A GIRL! WHAT IS THE MYSTERY?
A Akdemir1,2, M Witzel3, T Patiroglu4, Ma Ozdemir4, M Karakukcu4, C Klein5,
E Unal4,*
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Turkey, 2Division of Hematology-Oncology, Department of Pediatrics, Dr von
Hauner Children’s Hospital, Ludwig Maximilians University, 3Department of
Pediatrics, Division of Pediatric Hematology Oncology, Dr. von Hauner Chil-
dren’s Hospital, Munich, Germany, 4Department of Pediatrics, Division of Pedi-
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Background: Wiscott-Aldrich Syndrome (WAS) is an X-linked recessive inher-
ited immunodeficiency; which is presented with micro-trombocytopenia,
eczema, recurrent infections, and increased incidence of autoimmune diseases,
and malignencies. WAS gene is located on the short arm of X chromosome,
and encodes WAS protein (WASP). WASP is expressed in hematopoietic stem
cell-lineages and responsible for cytoskeleton reorganization affecting the func-
tions of T, B, NK- cell, granulocytes, dendritic cells and platelets. Mutation in
the WAS gene ends up with X-linked thrombocytopenia (XLT) or classical WAS.
The prevalence of WAS is, 1 in 100 thousand live births.
Aims: In this presentation we would like to share our experience about a girl
diagnosed with WAS.
Methods: A 7 year old female patient was followed with trombocytopenia since
she was born. She had been hospitalized for recurrent infections, gastrointesti-
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nal bleedings, and CMV pneumonia. Bilateral ventilation tube regarding to per-
sistent otitis media was also performed. Serum immunoglobulin levels were
checked, Ig A and Ig E levels were increased, Ig M level was decreased and
Ig G level was normal. Western blot studies confirmed the reduced WAS protein
expression in peripheral mononuclear blood cells. The complete WAS gene
was sequenced, one heterozygous mutation in Exon 7, leading to a premature
stop codon p.G219*, c.655G>T was found. 
Results: WAS is an X-linked recessive disorder, which is seen in male patients
due to the transition. But, in case of X gene inactivation, it can also be presented
in female patients.
Summary/Conclusions: The clinicians must be vigilant about the possibility
of X linked diseases such as WAS in females.
Quality of life, palliative care, ethics and health
economics
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EFFECT OF EXERCISE AND COUNSELING INTEGRATED IN THE CLINI-
CAL MANAGEMENT OF ACUTE LEUKEMIA ON PHYSICAL FUNCTION
AND QUALITY OF LIFE DURING CONSOLIDATION CHEMOTHERAPY: A
MULTICENTER RANDOMIZED TRIAL
M Jarden1,*, T Møller2, L Kjeldsen2, H Birgens3, K Birgens4, L Adamsen2
1UniversityHospitals Center for Health Research, 2Copenhagen University
Hospital, Copenhagen University, 3Department of Hematology, Herlev Hospital
- Copenhagen Universiy, 4Institute of Public Health, Department of Biostatistics,
University of Copenhagen, Copenhagen, Denmark
Background: Exercise and counseling interventions, widely used as rehabili-
tation strategies in cancer patients to remedy disease and treatment-related
sequelae is novel in patients with acute leukemia due to the life threatening
nature of the disease, the intensive treatment and safety monitoring require-
ments.
Aims: We assessed whether an exercise and counseling intervention could
prevent and modulate physical and functional debilitation and improve health-
related quality of life (HRQoL) in a two-center, randomized controlled trial of
patients with acute leukemia during outpatient consolidation chemotherapy.
Methods: Patients were randomized to usual care or a twelve-week supervised
exercise and counseling intervention. The primary outcome was 6 minute walk
distance (6MWD), and secondary outcomes included submaximal VO2 max,
sit-to-stand test, biceps arm curl, and patient-reported HRQoL questionnaires.
70 patients were randomly assigned to the intervention (n=32) or control group
(n=34), and 62 completed study requirements (88.6%).
Results: Changes in the primary outcome 6MWD differed significantly across
randomization groups (85.5 m [51.2-119.8], p<0.0001) and physical capacity
and functional outcomes were substantial (effect sizes 1 or above). Self-rated
leisure-time physical activity levels, health-related quality of life (FACT-An) and
levels of depression and anxiety differed significantly between groups, in favor
of the intervention group. Eight patients experienced non-serious adverse
events.
Summary/Conclusions: Exercise and counseling in patients with acute
leukemia undergoing outpatient consolidation chemotherapy improved physical
and functional capacity, physical activity levels, HRQoL and psychological well-
being. The role of exercise and counseling integrated in the clinical setting has
the potential of optimizing the management of acute leukemia and may facilitate
resumption of everyday activities.
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COST-EFFECTIVENESS ANALYSIS OF A DIRECTLY SELECTED
CMV-SPECIFIC T CELL THERAPY FOR MANAGEMENT OF CMV DISEASE
IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION: A UK
ANALYSIS
M Nuijten1,*, C Kielar2, K Peggs3
1Health Economics, A2M, Amsterdam, Netherlands, 2Cell Medica Ltd, 3Stem
Cell Transplantation and Immunotherapy, University College Hospital, London,
United Kingdom
Background: Hematopoietic stem cell transplantation (HSCT) is a curative
treatment option for a variety of malignant and non-malignant hematological
diseases. However, cytomegalovirus (CMV) infection, an acknowledged com-
plication after HSCT, is associated with significant morbidity, decreased patient
survival, and considerable cost to health-care systems. Two randomized clinical
studies, CMV~ACE/ASPECT and CMV~IMPACT (NCT01220895 and
NCT01077908), assessed the efficacy and safety of a CMV-specific T cell ther-
apy for prevention or treatment of CMV reactivation post allogeneic HSCT.
Aims: We assessed the cost-effectiveness of a CMV-specific T cell therapy for
the management of CMV disease in patients after allogeneic HSCT in the UK.
Methods: A Markov model, reflecting current clinical guidelines, was developed
to estimate cost-effectiveness of a CMV-specific T cell therapy for the man-
agement of CMV infections and CMV disease in patients after allogeneic HSCT
in the UK from the perspective of the NHS in 2015. Here we report the results
of this economic analysis in the CMV disease setting. Data sources, in the
model, included the two randomized clinical trials for the CMV-specific T cell
therapy, published literature, national costs, tariff lists, and a Delphi panel of 7
English hematologists. The model simulated clinical and economic outcomes
associated with the a CMV-specific T cell therapy and standard treatment. The
main comparators in the analysis depended on the positioning of the CMV-
specific T cell therapy and were foscarnet in 2-line and cidofovir in 3-line. Clin-
ical probabilities included response probabilities, mortality and recurrence.
Inpatient costs included daily hospital stay, laboratory analyses, microbiological
culture, specialists’ visits, therapy acquisition and administration costs. Utilities
were included for the Quality Adjusted Life Years (QALY).
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Results: The use of the CMV-specific T cell therapy as 2-line CMV disease
treatment increases costs from £27,882 to £30,656, which results in additional
costs of £2,774, but leads to a gain in QALYs of 0.215 from 3.179 to 3.394.
Consequently, the incremental cost-effectiveness ratio (ICER) is £12,902/QALY.
The probabilistic sensitivity analysis (PSA) shows a probability of 79% that the
ICER remains below £30,000/QALY. The use of the CMV-specific T cell therapy
as 3-line CMV treatment increases total costs from £27,882 to £28,648 leading
to additional costs of £766, but to a gain in QALYs of 0.031 from 3.179 to 3.210.
Consequently, the resulting ICER is £24,710/QALY. The PSA shows the prob-
ability is 53% that the ICER remains below £30,000/QALY. The impact of risk
adjustment for the clinical benefits of the CMV-specific T cell therapy versus
standard therapy on the ICER was explored. The health economic outcomes
were sensitive to a risk adjustment for mortality, but not for response and recur-
rence in the 2-line setting. In the 3-line setting, the ICER was sensitive to risk
adjustment for mortality and response, but not to recurrence. The analyses
also show that the health economic outcomes were quite robust for both 2-line
and 3-line positioning of the CMV-specific T cell therapy for other variables.
The favourable cost-effectiveness of the CMV-specific T cell therapy results
mainly from the prevention of treatment failure and as a consequence the avoid-
ance of mortality and the cost of salvage therapy.
Summary/Conclusions: CMV-specific T cell therapy is a cost-effective treat-
ment for patients with CMV disease after allogeneic HSCT in 2-line and 3-line
therapeutic treatment in the UK setting.
E1438
CLINICAL CHARACTERISTICS, TREATMENT PATTERNS AND HEALTH
CARE RESOURCE UTILIZATION AMONG ITALIAN PATIENTS WITH
RELAPSED REFRACTORY MULTIPLE MYELOMA: RESULTS FROM A
PROSPECTIVE OBSERVATIONAL STUDY
A Palumbo1, A Zagorska2,*, S Popov3, T Zyczynski2, C Davis2, P Di Rienzo2
1University of Torino, Torino, Italy, 2BMS, Princeton, United States, 3Parexel
International, Moscow, Russian Federation
Background: Knowledge of clinical practice and healthcare resource utilization
(HCRU) in relapsed refractory multiple myeloma (RRMM) can inform and
improve national treatment strategies.
Aims: To describe clinical and treatment characteristics, HCRU and associated
costs in patients (pts) with RRMM in Italy compared to a general European cohort.
Methods: PREAMBLE (NCT01838512) is a prospective, multi-region (US, Cana-
da, EU: Italy, France, UK, Germany), observational study with up to 3 years of
follow up per pt. Eligible pts have ≥1 prior therapy for MM with disease progression
from the most recent therapy, and have initiated index therapy with immunomod-
ulatory drugs (IMiDs) and/or proteasome inhibitors (PIs) within 90 days prior to
or 30 days after study consent. Demographics, treatment and HCRU data were
collected, including hospitalizations, visits to healthcare professionals due to MM,
diagnostic tests, MM treatments and concomitant medications. Costs were cal-
culated by assigning standardized specific costs from Italy and other EU countries.
Descriptive statistics from an interim analysis are reported.
Results: At the cutoff date (December 7th 2015), 764 of 815 enrolled pts had
received treatment (509 in Europe, including 197 in Italy), with a median fol-
low-up of 15.1 (Q1–Q3: 8–24) months. Pts were mostly male with mean age
68 years, both in Italy and the EU. At study entry the majority of pts were
relapsed (Italy 76%; EU 80%) or refractory (Italy 23%; EU 20%). In Italy most
pts were ISS stage I (44%) or II (33%); EU pts were equally spread across
severity stages. In both cohorts 44% of pts had prior transplantation. 72% of
pts in Italy had comorbidities, commonly one (25%) or two (21%). Cardiovas-
cular (40%) and metabolic (16%) disorders were most frequent. 39% of pts
receiving PIs and 19% of pts receiving IMiDs had no comorbidities. In Italy for
index therapy, 101 pts received IMiDs, 92 PIs and 4 IMiDs+PIs. The most com-
mon scheme amongst IMiDs was lenalidomide and amongst PIs bortezomib,
both in combination with dexamethasone. Duration of index therapy varied
between treatment types: median 8.8 (Q1–Q3: 3.9–14.2) months for IMiDs; 4.6
(2.8–6.2) for PIs; 4.4 (2.2–7.5) months for IMiD+PIs, with a similar pattern
observed in the EU cohort. 52% of pts in Italy had received 1 prior line of ther-
apy; most commonly bortezomib-based schemes. Average HCRU for RR MM
patients during the first year of follow-up was lower in Italy compared to Euro-
pean cohort (Italy: mean 1.1 visit/year [max 27]; EU: 13.8 visits/year [max 112]).
In both cohorts the number of visits decreased in subsequent years. In Italy
HCRU differed by treatment: mean number of visits/year for pts treated with
IMiD: 0.76, PI: 1.2, IMiD+PI: 7; the majority being hospital outpatient visits
(68%) and all-cause hospitalization (17.5%). In the EU cohort, after outpatient
visits (63%), most common were clinic/physician office visits (18%). The main
reason for hospitalization was management of MM (Italy 78%; EU 67%). Cost
distribution was heterogeneous among pts in both cohorts (median overall
costs during index treatment: 116,000 (Q1–Q3: 78–152) euros in Italy; 88,000
(44–149) euros in the EU). Main cost drivers were MM treatments, concomitant
medications (in Italy only for PI-treated pts) and hospitalizations.
Summary/Conclusions: Preliminary data from the PREAMBLE prospective
observational study show variation in the management of RRMM pts in Italy
having lower HCRU compared with the EU cohort. Routine management and
disease progression continues to drive HCRU in MM.
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EVALUATION OF PSYCHOMETRIC PROPERTIES OF EUROPEAN ORGAN-
ISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE
QUESTIONNAIRE CORE 15 PALLIATIVE (EORTC QLQ-C15-PAL) IN MUL-
TIPLE MYELOMA PATIENTS
XH Hu1,*, AM Rodriguez2, B Katic2, L Purnomo1, CJ Gibson1
1Celgene Corporation, Summit, NJ, 2PatientsLikeMe, Boston, MA, United States
Background: The EORTC QLQ-C15-PAL was developed by shortening the
QLQ-C30 from 30 to 15 items for easier administration to patients receiving
palliative care. Its performance in measuring health-related quality of life
(HRQoL) in relation to its parent version in patients with multiple myeloma (MM)
has not been previously evaluated.
Aims: To assess the psychometric properties of the EORTC QLQ-C15-PAL in
relation to the QLQ-C30 in patients with MM at different disease stages.
Methods: US patients with self-reported MM were recruited through an online
patient-powered network, PatientsLikeMe. Upon completion of informed con-
sent, study participants were asked to provide a brief MM treatment history
and complete the EORTC QLC-C30. Domain scores for QLQ-C30 and QLQ-
C15-PAL were calculated. Item-scale correlations, and floor and ceiling effects
for all items on the QLQ-C30 were stratified by disease progression and pallia-
tive care status separately. To measure equivalent-form reliability, regression
analysis was used to determine the proportion of variance (R-squared) using
QLQ-C30 as the response variable and QLQ-C15-PAL as the explanatory vari-
able for those domains shortened in the QLQ-C15-PAL. Intraclass correlation
coefficients (ICCs) were calculated between the subscales shortened in QLQ-
C15-PAL. The internal consistency of domains with 2 or more items was
assessed using Cronbach α coefficients.
Results: A total of 199 patients completed the online survey, and 10 patients
were excluded from the analysis because they had not received any MM treat-
ment. Of the remaining 189 patients, the median age was 61 years (range, 37-
82 years) and 57.6% were women. 51 patients (27.0%) received palliative care
currently or previously and 65 patients (34.4%) switched treatment regimens
at least once due to disease progression. With few exceptions, item-scale cor-
relation, and floor and ceiling effects were in similar ranges for all items regard-
less of disease progression status or palliative care status. R-squared values
ranged from 0.72 to 0.92 and ICCs varied from 0.87 to 0.96. Cronbach α coef-
ficients for Physical Functioning, Emotional Functioning, and Fatigue were 0.64,
0.76, and 0.76, respectively.
Summary/Conclusions: The EORTC QLQ-C15-PAL appears to be a reason-
able substitute to measure HRQoL in patients with MM at different disease
stages.
E1440
CRYOPRESERVATION OF MATURE OOCYTES TO PRESERVE FERTILITY
IS FEASIBLE WITHOUT TREATMENT DELAY IN YOUNG ADULT
LYMPHOMA PATIENTS
S Viviani1,*, E Somigliana2, G Mangili3, M Soldarini1, A Paffoni2, E Papaleo3, L
Devizzi1, A Dodero1, L Farina1, F Filippi2, C Sigismondi3, F Raspagliesi4,
P Corradini1
1Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto
Nazionale dei Tumori, 2Obstetrics and Gynecology; Infertility Unit, Fondazione
Ca’ Granda Ospedale Maggiore Policlinico, 3Obstetrics and Gynecology, San
Raffaele Hospital, 4Gynecologic Oncology Surgery, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy
Background: Advances in the treatment of lymphomas have led to a substan-
tial decline in the mortality rate and a remarkable improvement in the long-term
outcomes, that has raised patients’ expectations of a better quality of life, among
which fertility preservation represents an imminent wish. However the majority
of treatment protocols consist of combination chemotherapy (CT) which may
lead to infertility due to severe injury to ovarian reserve, when alkylating agents
–containing regimens, CT combined with radiotherapy (RT) on the pelvis, high-
dose CT and autologous hematopoietic stem cell reinfusion and/or allogeneic
bone marrow transplantation have to be given in the course of the disease.
Attempts to prevent ovarian damage during CT±RT include a) the concomitant
administration of Gonadotropin Releasing Hormone (GnRH) agonists, but
results of randomized trials have led to controversial results, b) ovarian tissue
cryopreservation, which requires two subsequent laparoscopic sessions, carries
the possibility of malignant cells reimplantation and has produced only a limited
number of published live births c) mature oocyte cryopreservation, d) embryo
cryopreservation, which is not admitted by italian rules and requires the avail-
ability of a male partner.
Aims: To evaluate in a prospective observational study the acceptability and
feasibility of the procedure of ovarian hyper-stimulation and mature oocyte
retrieval and cryopreservation, in female patients with newly diagnosed Hodgkin
(HL) and non Hodgkin lymphoma (NHL).
Methods: Female patients aged ≥18 years and ≤38 years with histologically
proven untreated HL or NHL at any stage, diagnosed at Istituto Nazionale
Tumori of Milan, without contraindications to ovarian stimulation, i.e. sympto-
matic rapid progressive disease, and/or superior vena cava syndrome, active
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viral infectious disease and ovarian failure, were eligible for the study. After
having addressed expected gonadal toxicity of CT±RT during their first haema-
tological evaluation, they were referred to gynecological counseling. Ovarian
reserve was assessed by antral follicle count regardless of the menstrual cycle.
If the woman consented, she underwent ovarian hyper-stimulation according
to a random start protocol. Briefly, gonadotropins were started the same day
regardless of the menstrual cycle and the cycle was monitored through serial
ultrasounds to tailor the initiation of GnRH antagonists and to identify the most
proper time for ovulation trigger
Results: From July 2013 to December 2015 20 patients were enrolled into the
study, median age was 27 years (range, 19-35), 16 patients were diagnosed
with HL, 4 with NHL (2 DLBCL, 1 PMBCL, 1 follicular). Median time from first
hematological visit and gynecological counselling was 2 days (range, 0-10),
median time from diagnostic biopsy and gynecological counselling was 14 days
(range, 0-29). 11 out of 20 (55%) patients were considered eligible and/or
accepted to undergo ovarian stimulation; 6 patients refused due to personal
reasons, 1 due to gynecological reasons (ovarian cysts), 1 due to symptomatic
progressive disease after the first gynecological visit and in 1 DLBCL NHL
patient stimulation was suspended due to initial superior vena cava syndrome.
Median time from first gynecological visit and oocyte retrieval was 13 days
(range, 12-16); median number of retrieved oocytes was 16 (range, 11-32) and
median number of cryopreserved oocytes was 14 (range, 9-23). Median time
from oocyte retrieval and CT start was 4 days (2-14). 
Summary/Conclusions: Preliminary results of this study document that ovar-
ian hyper-stimulation and oocyte retrieval using a random start protocol is
feasibile in young females diagnosed with HL or NHL without a significant
delay in CT start. The number of mature oocyte cryopreserved is adequate
and comparable to non-cancer patients. Oocyte cryopreservation should be
systematically considered in lymphoma patients of childbearing age before
starting gonadoxic therapy and should be preferably performed during staging
procedures.
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PSYCHOMETRIC VALIDATION OF THE SF-36V2® HEALTH SURVEY IN AN
AL AMYLOIDOSIS POPULATION
MK White1, M Bayliss1, KL McCausland1, S Guthrie2,*
1Optum, Lincoln, RI, 2Prothena Biosciences Inc, South San Francisco, CA,
United States
Background: Light chain (AL) amyloidosis, a rare protein misfolding disease,
leads to deficits in health-related quality of life (HRQoL). Patients with AL amy-
loidosis present with a wide variety of non-specific symptoms, organ involve-
ment, and functional impairment. The SF-36v2® Health Survey (SF-36v2), a
general HRQoL survey, has been used to quantify the impact of AL amyloidosis
on HRQoL, though to-date there is no evidence of its psychometric validity for
use with AL amyloidosis patients.
Aims: To document the psychometric properties of the SF-36v2 among AL
amyloidosis patients, including tests of data quality, scaling success, reliability,
and validity.
Methods: Adults (≥18 years old) with self-reported AL amyloidosis completed
baseline (n=341) and one-month follow-up (n=252) surveys online to assess
HRQoL, clinical and socio-demographic characteristics. Data quality evaluation
(DQE) checks included item and scale distributions and a response consistency
index (RCI). The online system did not allow out of range values or missing
data. Scaling success was evaluated against assumptions of summated rating
scales. Internal consistency reliability used Cronbach’s α. Test-retest reliability
used intra-class correlations (ICC) between baseline and one-month follow-up
scores among a stable disease subgroup (n=180). Scale convergent and dis-
criminant validity was tested and used correlations between scores from the
SF-36v2, the Kansas City Cardiomyopathy Questionnaire (KCCQ-12), Patient
Global Assessment of Functioning (GAF), and other surveys. Known-groups
validity tests used ANOVA of scores across patient groups varying in disease
severity (self-reported hematologic response status, and Patient Global Impres-
sion-Severity (PGI-S)).
Results: DQE showed excellent response distribution and RCI (94.1%). Scale
reliability (Cronbach’s α ≥ 0.780 across all 8 domains) and test-retest reliability
(ICC ≥ 0.731) were acceptable. Tests of summated rating scale assumptions
were satisfactory. Scale convergent and discriminant validity showed strong
correlations with conceptually related measures. Tests for known-groups validity
showed that the mean scores for respondents with self-reported complete
hematologic response or remission were significantly greater than scores for
respondents with no response to treatment (p<0.05 for all scores). Similarly,
mean scores were also significantly associated with responses to the PGI-S
(p<0.0001 for all scores).
Summary/Conclusions: This study provided robust evidence of the psycho-
metric properties of the SF-36v2 in a diverse sample of patients with AL amy-
loidosis. Planned future analyses will assess responsiveness and confirm psy-
chometric properties of the SF-36v2 in clinic-based samples of AL amyloidosis
patients.
Study supported by: Prothena Biosciences Inc
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MONOCENTRIC ASSESSMENT OF THE PROFESSIONAL PRACTICES IN
THE MANAGEMENT OF PAIN DURING BONE MARROW ASPIRATION
G Poenou1,2,*, S Zia Chahabi1,2, N Gendron1,2,3, N Rivet1,2, T Belleville-Rolland1,2,3,
M Ciaudo1,2, V Siguret2,3,4, P Gaussem1,2,3, L Darnige1,2
1Hématologie, AP-HP, European Hospital Georges Pompidou, 2Université Paris
Descartes, Sorbonne Paris Cité, 3Inserm UMR-S1140, Paris, France, 4Héma-
tologie, AP-HP, Lariboisère, Paris, France
Background: Bone marrow aspiration performed for the diagnosis of hema-
tologic malignancies is known for being painful. However, pain management is
a current concern in the follow-up of patients with chronic diseases.
Aims: Within this overall dynamic of improvement of the analgesic gesture
support, an evaluation of the professional practices was initiated by the Hema-
tology Department of the European Georges Pompidou Hospital (Paris,
France). The aim of this study was to evaluate the factors involved in the feeling
of pain during bone marrow aspiration.
Methods: This monocentric cohort study included 480 patients from 2010 to
2015. They underwent bone marrow aspiration and filled out a standardized
questionnaire-based survey including: demographic characteristics (patient’s
sex and age, medical department), clinical data (bone hardness, puncture site,
diagnosis assumptions and final diagnosis), analgesia methods (lidocaine
patch, infiltration with lidocaine, inhalation sedation and premedication) and
processing (patient anxiety; intensity of pain evaluated after bone marrow aspi-
ration quoted by the patient and the operator, using a visual analog scale (VAS)
from 0 to 10; awareness of the gesture by the patient).
Results: Among the 480 patients, 58% were men. Patients’ average age was
68.7 years. Most patients were from Nephrology (16%), Hematology (16%)
and Internal medicine (30%) departments. The main indication of bone marrow
aspiration was the diagnosis assessment of monoclonal gammapathies (30%).
The most used puncture site was sternal site (88%) and in most cases the
bone hardness was described as medium (64%). Bone marrow examination
allowed us excluding a central origin for the hematologic anomaly in 43%
patients. The foremost analgesia method was the use of lidocaine patch (80%)
with an average exposure of 68 minutes. Half of patients declared not to be
anxious before bone marrow aspiration. Pain was generally rated between 3
and 4 on a scale of 10 (43%), and lower than they had expected (58%). Overall,
97% of bone marrow aspirations were performed under analgesia.(Table
1.Pain’s management). Analgesic treatment was found significantly effective
compared with no analgesia? (p<0.001). Patients experienced less pain when
they considered that they were well-informed (p<0.001).Women were signifi-
cantly more sensitive than men (p<0.05). In our study, sternal site was more
painful than superior iliac bone site (p<0.001). There were no relationships
between pain intensity and patients’ age, medical department, bone hardness,
diagnosis assumptions, final diagnosis, a particular analgesia method and
patient anxiety (p>0.05).
Table 1.
Summary/Conclusions: The perception of and reaction to pain are influenced
by the psychological state of the patient. This is an undisputed fact that medical
staff should provide information on the steps taken in daily practice and our
study on bone marrow aspiration is consistent with this behavior. The preven-
tion and management of pain require an integrated approach between its sen-
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sori-discriminative component and its psychological dimension. In our study,
we show the benefit of analgesia together with intelligible information in the
management of pain during bone aspiration.
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BURDEN OF ILLNESS ASSOCIATED WITH MULTIPLE MYELOMA
M Singh1,*, G Kay1, J O’Rourke1, J Eaton1, D Berg2, T Skacel2, M Jhaveri2,
B Seal2, HM Lin2
1ICON Health Economics, ICON, Abingdon, United Kingdom, 2Millennium Phar-
maceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, Cambridge, United States
Background: Multiple myeloma (MM) is a cancer of plasma cells originating
in bone marrow and affecting multiple organs. It accounts for 0.8% of all new
cancers and is the 2nd most common haematological cancer in the US. It is an
incurable disease with an average survival of 4-5 years. Median age at diag-
nosis is approximately 70 years. MM poses humanistic and economic burden
by affecting the health related quality of life (HRQoL) of the patients and/or car-
ers and by impacting healthcare budgets, respectively.
Aims: To review the humanistic and economic burden of MM.
Methods: Two targeted literature reviews were performed; one each for human-
istic and economic burden. MEDLINE®, Embase and PubMed (for e-publica-
tions ahead of print) were searched to identify relevant publications from 2005
to date. EconLit and NHS Economic Evaluations Database (EED) were
searched to identify articles specific to the economic burden. Search terms
included disease, QoL and economic terms.
Results: A total of 1029 abstracts for the humanistic burden review and 629
abstracts for economic burden review were identified and screened. Twenty
articles were included in the humanistic burden and 18 in the economic burden
review. MM is associated with substantial burden of illness. Patients experience
a high symptom burden that adversely affects their HRQoL. Bone pain and
fatigue are the most common symptoms of the disease. Patients exhibit
impaired physical, role, cognitive, emotional and social functioning. Coping with
the disease and managing its consequences including loss of independence
and being vigilant to prevent incidences of fracture emerge as the predominant
factors of the disease. The causes of disease burden are similar in newly diag-
nosed and/or RRMM patients, with both populations experiencing significant
symptom burden which adversely affects their HRQoL. However, the burden in
RRMM patients worsens with disease progression such as increased bone
pain, fractures and fatigue. Additionally, there is considerable burden on care-
givers who report restricted social, leisure, professional/work activities. MM
also imposes significant economic burden. The total cost varies depending on
whether the disease presents as asymptomatic or symptomatic and by line of
treatment. Non-drug costs, which include hospitalisation, autologous stem cell
transplant (ASCT), adverse events and ambulatory costs account for approxi-
mately 54% of the total cost. Patients treated with novel agents or ASCT and
patients who experience skeletal-related events incurred the highest spend for
hospitalisation. Some adverse events associated with novel agent treatment
required hospitalisation; anaemia and neuropathy were most common. These
were associated with a mean length of stay of 9 to 14 days in R/R patients
depending on the novel agent received. Costs of productivity loss due to MM
were evaluated in one study. Patients who undergo ASCT incurred the highest
costs of productivity loss based on working days and hours lost by the patients
and caregivers, respectively. Improved outcomes associated with ASCT were
not assessed in this study.
Summary/Conclusions: MM poses significant humanistic and economic bur-
den; which increases with disease progression and subsequent lines of therapy.
HRQoL in these patients diminishes with symptom severity and disease progres-
sion. The total cost of illness is driven by treatment line and choice. These findings
warrant the need for more effective therapy with better safety profile delaying
disease progression, reducing symptoms and improving patient’s outcome.
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WHAT IS THE EFFECT OF VENOUS THROMBOEMBOLISM AND
POST-THROMBOTIC SYNDROME ON HEALTH-RELATED QUALITY OF
LIFE? A SYSTEMATIC REVIEW AND META-ANALYSIS
B Lubberts1,*, NR Paulino Pereira1, C Kabrhel2, D Kuter3, C DiGiovanni1
1Orthopaedic Surgery, 2Emergency Medicine, 3Clinical Hematology, Massa-
chusetts General Hospital, Boston, United States
Background: There is limited insight for patients, their families, and their
providers into the mid and long-term effects of pulmonary embolism (PE), deep
vein thrombosis (DVT), and post thrombotic syndrome (PTS) on health related
quality of life (HRQOL). 
Aims: We conducted a systematic review and meta-analysis of the literature
to (1) assess the HRQOL for patients with a minimum follow-up of one year
after an episode of PE or DVT, and (2) to assess the HRQOL for patients with
DVT who develop PTS.
Methods: PubMed, EMBASE, and the Cochrane Library were search from
inception to October 12th, 2015. All studies measuring HRQOL at least one
year after an episode of PE or DVT, with or without development of PTS, were
selected. Data were extracted by two of the authors and pooled using random-
effects meta-analysis. Heterogeneity was assessed with I2 and Tau2 tests. SF-
12, SF-36, and VEINES-QOL were evaluated with pooled standardized mean
difference (SMD) and 95% confidence intervals (CI).
Results: Fourteen studies were included for meta-analyses. In patients with
PE physical health was impaired (SMD:-0.30, 95% CI: -0.46 to -0.15, Tau2: 0.0,
I2:0%, 2 studies) and mental health was similar to population norms (SMD:
0.14, 95% CI: -0.01 to 0.30, Tau2: 0.0, I2: 0%, 2 studies). In patients with DVT
physical health (SMD:-0.22, 95% CI: -0.53 to 0.10, Tau2: 0.21, I2: 94%, 9 stud-
ies), mental health (SMD: 0.03, 95% CI: -0.12 to 0.19, Tau2: 0.03, I2: 73%, 9
studies), and disease specific quality of life (SMD: 0.04, 95% CI: -0.10 to 0.18,
I2: 2.5%, Tau2: 0.0, 8 studies) were similar to population norms. Patients who
develop PTS reported worse physical health (SMD:-0.89, 95% CI: -1.21 to -
0.57, Tau2: 0.14, I2: 82%, 7 studies), mental health (SMD:-0.27, 95% CI: -0.43
to -0.11, Tau2: 0.01, I2: 31%, 7 studies), and disease specific quality of life
(SMD:-0.97, 95% CI: -1.35 to -0.59, Tau2: 0.30, I2: 84%, 10 studies) than pop-
ulation norms.
Table 1.
Summary/Conclusions: Patients who had a PE event report worse physical
health. Quality of life after a DVT event is comparable to population norms,
although those who develop a PTS have worse overall quality of life. These
data can be used to inform patients in the rehabilitation process.
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TREATMENT HISTORY, TOLERABILITY AND IMPACT ON HEALTH-RELATED
QUALITY OF LIFE IN AL AMYLOIDOSIS
M Bayliss1, MK White1, KL McCausland1, S Guthrie2,*
1Optum, Lincoln, RI, 2Prothena Biosciences Inc, South San Francisco, CA,
United States
Background: Light-chain (AL) amyloidosis is a rare disease characterized by
misfolded amyloid protein deposits in tissues and vital organs. There are cur-
rently no FDA- or EMA-approved medications indicated for AL amyloidosis;
however, chemotherapy, stem cell transplants (SCT), and immunomodulary
drugs can reduce the production of amyloid-forming light chains. All existing
regimens have tolerability problems due to treatment-related symptoms (TRSs).
The SF-36v2® Health Survey (SF-36v2) is a widely-used general health-related
quality of life (HRQoL) survey that can be used to describe and quantify the
impact of many diseases and treatments.
Aims: To describe the history of treatments, past and current TRSs, and impact
on HRQoL among a diverse sample of individuals with AL amyloidosis.
Methods: We report baseline data from an online non-interventional study was
initiated in 2015 among patients with self-reported AL amyloidosis (n=341).
Patients reported their current and prior treatment for AL amyloidosis. Aspects
of TRSs were captured based on the following: 1) lifetime history of TRSs
(dichotomous variable); 2) consequence of TRSs (discontinuation of a treatment;
reduction of a treatment; or maintenance of treatment despite TRSs); and 3)
ability to tolerate the current AL amyloidosis treatment (based on a 4 point scale
from “extremely poorly” to “very well”, higher scores indicate better tolerability).
The prevalence of each treatment type and TRSs were estimated. The patients’
ability to tolerate the current treatment was evaluated in relation to specific med-
ications and HRQoL (as measured by the SF-36v2® Health Survey Physical
[PCS] and Mental [MCS] Component Summary scores) using chi square tests
for categorical variables and t-tests and ANOVA for continuous measures.
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Results: The most commonly reported treatments were dexamethasone (81%
reported ever being treated, 52% reported as the current treatment), bortezomib
(72% ever, 36% current), SCT (53% ever, 24% current), melphalan (47% ever,
15% current), cyclophosphamide (46% ever, 20% current), and lenalidomide
(28% ever, 15% current). Many patients reported combination treatments, includ-
ing cyclophosphamide+bortezomib+dexamethasome (CyBorD, 17% current).
Half of the patients (51%) had received three or more different treatments. Nearly
three-quarters (71%, n=226) reported ever having problems tolerating AL amy-
loidosis treatment, of which nearly half (47%, n=107) had discontinued at least
one treatment. Nearly half (46%) of those currently being treated reported some
tolerability issue (less than very good tolerability). Tolerability varied across the
common treatments from a low of 3.22 (SD=0.90) for cyclophosphamide to a
high of 3.61 (SD=0.52) for SCT. Problems with tolerating current medications
corresponded with decrements in HRQoL (both MCS and PCS, p<0.001).
Summary/Conclusions: Lifetime history of TRSs was high. Discontinuation
of life-saving AL amyloidosis treatments was fairly common, though most
patients were able to tolerate their current regimen. The high prevalence of
treatment discontinuation and history of multiple AL amyloidosis treatments
suggests that physicians and patients try a variety of treatments to balance
tolerability and efficacy. TRSs are associated with decrements in HRQoL, over
and above the burden of AL amyloidosis. These findings highlight the impor-
tance of assessing HRQoL during treatment for AL amyloidosis to better under-
stand tolerability, and the need for more treatment options for AL amyloidosis,
particularly those with favorable tolerability.
Study supported by: Prothena Biosciences Inc.
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ICU AND LONG-TERM MORTALITY ANALISIS OF HEMATOLOGOGICAL
MALIGNANCIES ADMITTED IN ICU. A UNICENTRIC SEVEN YEARS
REVIEW IN A SPANISH HOSPITAL
A Jiménez-Ubieto1,*, R Garcia-Gigorro2, P Martinez- Sánchez1, A Rodriguez1,
L Montejano1, C Grande1
1Hematología, Hospital 12 de Octubre, 2Intensive care, Hospital 12 de ocutbre,
Madrid, Spain
Background: Improvements in survival in patients with haematological malig-
nancies (HM) admitted to the intensive care unit (ICU) has largely been reported
in uncontrolled cohorts. Newly diagnosed patients should be admitted, since
their prognosis is still to be defined. Nevertheless the admission of the remain-
ing patients remains a matter of substantial controversy.
Aims: To analyse the survival of HM patients admitted to ICU over a 7-year
period (from 2008 to 2014) in a single high complexity Spanish hospital
Methods: We conducted a detailed retrospective study of sequential adult ICU
admissions with HM in a single centre, considering numerous variables with
regard to their influence on ICU and mortality. Overall survival (OS) was defined
as the time from ICU admission to death from any cause, and surviving patients
were censored at last follow-up. OS were calculated using the Kaplan–Meier
method estimates and the differences assessed by the log-rank test. All P-
value less than 0.05 were considered significant.
Figure 1.
Results: Overall, 67 HM patients were included, 62% were male, with a median
age of 59 years (IQR: 19–82). The median APACHE II was 22 (IQR: 12-49).
The hematologic diagnosis was as follow: 25 lymphomas (37%), 9 Multiple
Myeloma (MM) (13%), 6 chronic lymphocytic leukaemia (CLL) (9%) and 28
acute leukaemia or myeloproliferative or myelodisplasic syndromes in acute
phase (41%). Disease status at the moment of UCI admission was: 19 (28%)
in complete response (CR), 24 (36%) with a newly diagnosis disease and 24
(36%) whit active disease (of those, 18 patients were refractory to disease
specific treatment and 6 patients were chemosensitive). 67% of patients were
on active oncologic treatment at the moment of UCI admission. Principal ICU
diagnosis was sepsis (68%). Median number of organ failures was 2 (IQR: 0-
4); 71% presented a respiratory and 70% a hemodynamic failure.70% accurate
vasoactive drugs, 64% invasive mechanical ventilation and 34% dialysis. More
than one third of patients (36%) presented neutropenia at the moment of UCI
admission. Median ICU length of stay was 7 days (IQR: 1-48) and median hos-
pital length of stay was 38 days (IQR: 8-109). ICU mortality was 46% (25% of
the deaths occurred the first day of ICU admission, and 75% within the first
week). The rates for ICU, 1-month, 6-month and 12 month mortality were 48%,
55% and 66%, respectively. With a median follow-up from the day of UCI admis-
sion of 18.5 months (IQR: 8-66), estimated OS at 1, 6 and 12 months were
51%, 44% and 41%, respectively (fig. 1a).Hematologic diagnosis (fig. 1b) status
of the disease at the moment of ICU admission (fig. 1c) and the number of
organ failure (≤2: 67% vs ≥3: 28%, P=.009) were the most powerful predictor
variables associated with an increased OS.
Summary/Conclusions: OS of our HM patients is not worse than that recently
reported from other specialist units.The decision for or against ICU admission
of patients with HM should become dependent of the underlying malignant dis-
ease and especially with the status of the disease at the moment of admission.
Almost 50% of survivors are still alive one year after ICU admission, suggesting
that an important subgroup of HM patients benefit from ICU admission. In addi-
tion, only 25% of patients died beyond the 1st week of admission, not consum-
ing resources without benefit. A multidisciplinary approach between intensivists
and hematologists is essential in these patients.
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THE IMPACT OF HAEMATOLOGICAL MALIGNANCY ON PATIENTS’
HEALTH-RELATED QUALITY OF LIFE AND SYMPTOMS: A QUALITATIVE
STUDY
S Salek1,*, P Goswami1, A Fielding2, J Kell3, R Else4, E Oliva5, T Ionova6
1School of Life and Medical Sciences, University of Hertfordshire, Hatfield,
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versity Health Board, Cardiff, 4Patient Research Partner, Milton Keynes, United
Kingdom, 5Haematology Unit, Azienda Ospedaliera, Reggio Calabria, Italy,
6National Medical Surgical Centre and Multinational Centre for Quality of Life
Research, St Petersburg, Russian Federation
Background: The impact of haematological malignancies (HM) in patients’
lives is not well understood. For some there is a possibility of cure, for others
treatment aims at prolonging survival or containing symptoms and complica-
tions. We present interim results of a cross-sectional qualitative study in patients
with HM.
Aims: The aim of this study was to investigate the impact of a wide range of
haematological malignancies and their treatments on patients’ health-related
quality of life (HRQoL) and Symptoms.
Methods: Multicentre Ethics approval was obtained from the NRES South
West Bristols, UK. Adult patients with HM as per 2008 WHO classification,
capable of reading English and able to give the written informed consent were
recruited from inpatient/outpatient clinics of two secondary care hospitals in
England and Wales. This qualitative study employed semi-structured face-to-
face interviews with open-ended questions related to HRQoL and symptoms.
All the interviews were audio recorded and transcribed verbatim and content
analysis was carried out using the NVivo 11 qualitative analysis software.
Figure 1. Prevalence of quality of life issues (n=55).
Results: Fifty-five patients (male=27; mean age=60 years; SD=15.2; median
age 63 years; and age range =21-83 years) with mean duration of the HM of
3.8 years (SD=4.7; median=2.1 years; and range= 19 days-23 years) were
recruited into the study. Diagnoses were Acute Myeloid Leukaemia (11), Acute
Lymphoid Leukaemia (3), Chronic Myeloid Leukaemia (6), Chronic Lymphoid
Leukaemia (4), Aggressive Non-Hodgkin’s Lymphoma (3), Indolent Non-
Hodgkin’s Lymphoma (7), Hodgkin’s Lymphoma (3), Multiple Myeloma (12),
Myeloproliferative Neoplasm (3) and Myelodysplastic Syndrome (3). There
were overall 44 categories of issues identified which were important from the
patient perspective. These issues were then divided into two broad categories:
QoL and symptoms. The QoL issues which had the highest impact on patients’
lives (Figure1) were: ‘social life and participatory function; going on holidays
and travelling; physical functioning or independency; sleeping patterns; eating
and drinking habits; work life; and sexual life’ from high to low prevalence,
respectively. Forty-four percent of the patients experienced impairment in dif-
ferent aspects of their work life with the prevalence of sixty-two percent (4 job
role function; 2 made redundant; 3 relationship with co-workers; and 24 overall
work life). Most of the patients who suffered from financial difficulties because
of their HM were from 35-65 age group. With respect to disease related symp-
toms, 62 issues were identified, the most prevalent being ‘tiredness (35%),
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feeling unwell (24%), breathlessness (23%), lack of energy (16%), back pain
(15%) and weight loss (13%)”, from high to low prevalence respectively. Out of
78 treatment related symptoms identified, the most prevalent symptoms were
‘tiredness (36%), feeling sick (17%), breathlessness (14%), loss of appetite
(9%), neutropenia related symptoms such as infections & slowed healing (8%),
nausea (8%) and lack of energy (8%)’, from high to low prevalence, respec-
tively.
Summary/Conclusions: The findings of this study clearly indicate that haema-
tological patients’ lives are greatly affected by their disease and treatment. This
highlights the need for development of a new measure of HRQoL and symp-
toms, specific for the assessment of patients with HM to evaluate individual
intervention strategies in daily clinical practice. This could lead to greater patient
engagement in the process of clinical decision-making.
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USE OF PRE-RECORDED AUDIO-VISUAL INFORMATION FOR PATIENTS
DIAGNOSED WITH SIX COMMON MALIGNANT HAEMATOLOGICAL
DISORDERS WITH AN AIM TO IMPROVE PATIENT EXPERIENCE AND
FACILITATE BREAKING BAD NEWS
H Ahmad*, B Van Staden
Haematology, Burton Hospitals NHS Foundation Trust, Burton on Trent, United
Kingdom
Background: The diagnosis of a haematological malignancy can be over-
whelming for patients. Shock and fright are common initial patient responses
to bad news and may prevent patients from fully understanding important infor-
mation given to them during the consultation. Use of printed information can
be helpful but often these may be too detailed for patients to extract the key
information from these in a timely manner. The plan for treatment requires
shared decision making with the patient which in turn depends on patient under-
standing the key facts about the diagnosis and the treatment approaches.
Although this key information is provided during consultation, the patient may
have difficulty remembering these facts due to reasons noted above. This hurdle
can potentially be overcome with the use of pre-recorded audio-visual patient
information materials which can help patients to recall and also share key infor-
mation with their loved ones. We report here on our innovative project to pro-
duce pre-recorded audio-visual information for patients about six common
haematological malignancies.
Aims: We applied for and secured a grant from a charity for a two year project
to develop and produce professionally recorded short films for patient informa-
tion about six common haematological malignancies. The conditions chosen
were: Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, High
grade Lymphoma, Low grade Lymphoma, Myeloma and Hodgkin’s disease.
Methods: We started by consulting and seeking guidance from numerous
patients with these conditions. We also spoke and took advice from experienced
health professionals working with haemato-oncology patients. Based on the
wisdom gathered we compiled the key evidence based facts about each of
these diseases and their management. Details on specific treatment regimen
were not included and the importance of building a partnership with the treating
team was emphasized as the source of specific detail about planned therapy.
These key evidence based facts were then converted into lay language which
became the written scripts for each short film. A 10-15 minute short film was
recorded for each of six diseases with the help of a professional team special-
ising in creating educational films. A clip about the role of specialist nurses was
also recorded. We also included additional voice recordings of real patients
talking about their experience with the same diagnosis / disease.
Results: The result of this two year project was a professionally produced DVD
for each of the six diseases. The patient information films have been recorded
in English language with possibility of translation /transliteration as sub-titles.
As a proof of concepts each DVD short film has been translated to Polish lan-
guage subtitles using this method. The copies of the DVDs can be produced at
fairly low cost to be given out to patients. However, keeping with current trends,
most patients are able to use web based information technology quite easily.
In view of this we have expanded the project by developing a dedicated website
(www.patientmedianetwork.com) to make these audio-visual materials available
online to make it easy to access them without the need for DVD players etc.
Also by making it freely available on the web, it shall serve patients beyond our
geographic boundaries as anyone can access this patient information resource
online now.
Summary/Conclusions: Pre-recorded, purposeful and specific audio-visual
information can not only provide key facts about the diagnosis and its manage-
ment but can also be used to create hope. It can be a resource to improve recall
of important information as the patient and family can listen to it again and again
after the initial visit to the clinic. And better understanding of their disease helps
with patient participation in shared decision making which enhances their sub-
sequent adaptation to the illness and its experience. Most importantly aim of
this work is to reduces human suffering associated with diagnosis of these
haematological malignancies and help optimize patient adjustment to the journey
ahead. Our work also illustrates the importance of informatics and technology
to improve patient-centeredness and we are keen to share our innovative work
and ideas with the wider professional community.
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SEXUAL DYSFUNCTION AMONG FEMALE LYMPHOMA PATIENTS IN
MALAYSIA
DLC Ng1,*, GG Gan2, L Yeh Chwan2
1Medicine, University Malaysia Sarawak, Samarahan, 2Medicine, University
Malaya, Kuala Lumpur, Malaysia
Background: Sexual dysfunction is a recognized long-term consequence
among cancer patients who had received cytotoxic chemotherapy. Previous
studies on female dysfunction were mainly on patients with breast cancer or
gynecological malignancies. This is the first study of sexual dysfunction among
lymphoma patients in this region.
Aims: To study the prevalence of sexual dysfunction among lymphoma patients
and its association factors.
Methods: This is a cross sectional survey which was conducted among female
lymphoma patients who attend haematology clinic at University Malaya Medical
Centre, Kuala Lumpur, Malaysia. Patients age 18 years and above were recruit-
ed and patients with previous gynecological surgery, other previous malignancy
and those who are newly diagnosed were excluded. Demographic data and
medical history were obtained from patients and medical notes. Patients were
interviewed using the validated Female Sexual Function Index (FSFI), Euro-
pean Organization for Research and Treatment of Cancer (EORTC QLQ C30)
and Hospital Anxiety and Depression Scale (HADS). Presence of anxiety and/
or depression symptoms were identified with cut off score of 8/21 for each sub-
set. Data were analyzed using SPSS version 21.0. Total sum of FSFI scores
were dichotomized into 2 categories; presence and absence of sexual dys-
function based on cut off value of 26.55. Associations between the demographic
/ clinical factors, HADS groups, and quality of life scores with sexual dysfunction
were tested using Pearson Chi-Square or Fischer Exact Test where applicable. 
Results: A total of 107 women aged 51.71±17.48 years (18-89) participated, of
which 72% (n=77) were not sexually active for more than 4 weeks. The main
reasons for non-sexually active were 1) no partner, 63.6% (n=49), followed by
2) problems suffered by partners, 24.7% (n=19) and 3) physical problem suffered
by patients, 18.2% (n=14). Among those with partners, 70% (n=21) had sexual
dysfunction despite being sexually active. Mean score of FSFI for patients with
partner was 16.27 (± 10.28). All of these patients had lack of sexual desire. The
sexual dysfunction was not significantly associated with demographic charac-
teristics (age group, ethnicity, religion, education levels) or clinical characteristics
(presence of comorbidity, remission status, treatment received, progress of treat-
ment). However it was associated with menopausal state X2(1)=7.366, p=0.007.
Presence of anxiety (22.4%) and depression (8.2%) symptoms was not signifi-
cantly associated with sexual dysfunction. There was no significant association
between sexual dysfunction and quality of life.
Table 1.
Summary/Conclusions: The prevalence of sexual dysfunction among lym-
phoma patients were higher than in general populations and unreported by
most of our patients. Further study on association of sexual dysfunction and
quality of life is needed. Partners’ problem should not be neglected in assess-
ment of female patients with sexual dysfunction.
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FATIGUE, QUALITY OF LIFE AND PHYSICAL FITNESS IN PATIENTS WITH
MYELOMA
O McCourt1,*, M Heinrich2, A Fisher2, B Paton3, R Beeken2, A Hackshaw4,
A Rismani5, S D’Sa5, K Yong6
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Institute, University College London, 5Department of Haematology, University
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Background: Myeloma is a haematological malignancy characterised by peri-
ods of active, symptomatic disease that require intensive treatment, followed
by periods of stable disease of ‘plateau phase’. Complications include anaemia,
hypercalcaemia, infections, renal failure, neuropathy and bone destruction
which can lead to significant physical disability and impaired quality of life
(QOL). Additionally, cancer-related fatigue is a common, chronic and often-
debilitating side-effect of treatment. Combined, these factors could potentially
lead to very low levels of physical fitness, further accelerating the decline in
QOL of patients with myeloma. There are, however, limited data on objectively
measured fitness in patients with myeloma, and it is unclear to what extent fit-
ness is related to fatigue and QOL. 
Aims: To evaluate levels of physical fitness, cancer-related fatigue and QOL
in a myeloma survivorship population, and examine how these variables are
related to one another. 
Methods: Patients with myeloma were recruited to a survivorship lifestyle
cohort study from hospital outpatient clinics. Participants were included if they
had stable disease for at least 6 weeks, off treatment or on maintenance treat-
ment, with ECOG 0-2, and were clinically able to carry out exercise testing.
Fatigue was measured using the fatigue sub-scale of the Functional Assess-
ment of Chronic Illness Therapy Fatigue Score (FACIT-F). A high score on the
FACIT-F represents less fatigue, ranging from 0-52. QOL was assessed using
the emotional well-being and functional well-being sub-scales of the Functional
Assessment of Cancer Therapy (FACT-G) score. Higher scores in the FACT-
G indicate better QOL, ranging between 0-52. VO2peak was measured during
cardiopulmonary exercise testing (CPET) with a cycle ergometer.
Results: 51 patients in plateau phase were included in these analyses. Median
age was 64 years (range 42-78), and 59% were male. 5 patients were older than
70. Median time from last treatment was 19 months (range3-139). Mean fatigue
(FACIT-F) score was 40.94 (median 45, range 8-52), and 20 patients had a score
below the mean reference range of 40.1.Mean quality of life (FACT-G) score was
40.58 (median 42, range 19.4-52), and 21 patients had a score below the mean
reference value of 38.4. Mean VO2peak was 17.59ml/kg/min (SD ±4.94, range
10-28ml/kg/min). FACIT-F scores and VO2peak were positively correlated r=0.30
p<0.04. FACT-G scores and VO2peak were positive correlated r=0.31 p<0.03.
FACIT-F and FACT-G scores were positively correlated r= 0.60 p<0.001.
Summary/Conclusions: Patients with higher levels of cardiopulmonary fitness
scored higher on FACIT-F fatigue and FACT-G QOL measures. This indicates
that patients with higher levels of fitness were less fatigued and had higher
levels of emotional and functional well-being. A significant proportion of patients
had scores below normative means for both fatigue and QOL. This analysis of
baseline data in a post treatment myeloma survivorship group provides support
for further investigation into the use of PA interventions delivered during and
post cancer treatment to improve physical fitness and reduce fatigue so as to
enhance QOL in this population.
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PALLIATIVE CHEMOTHERAPY PEPC (PREDNISOLONE, ETOPOSIDE,
PROCARBAZINE AND CYCLOPHOSPHAMIDE) IS EFFECTIVE AND
TOLERABLE IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMAS
I Kryachok*, I Titorenko, T Kadnikova, K Filonenko, T Skrypets, Y Kushchevyy,
I Pastushenko, O Aleksik, K Ulianchenko, O Novosad 1, A Martynchyk,
I Stepanishyna, A Novdah
Oncohematology, National Cancer Institute, Kiev, Ukraine
Background: Nowadays there are no universally accepted protocols and spe-
cific criteria for carrying out palliative chemotherapy in patients with lymphopro-
liferative diseases. The main problem of palliative chemotherapy is to choose
an optimal treatment strategy for conducting effective therapy with minimization
of adverse events. Therefore, there are a lot of needs to organize studies to
improve palliative chemotherapy protocols in patients with lymphomas.
Aims: In the department of oncohematology the present trial was aimed to
study the efficacy and toxicity of PEPC chemotherapy in research period from
August 2011 to November 2015. 
Methods: A total of 70 patients were included in study who received PEPC
chemotherapy with palliation aim. Indications for palliative treatment were:
relapsed or refractory Hodgkin or Non-Hodgkin lymphomas after 2nd and 3rd
line treatment without efficacy and contraindications of further treatment, with
the aim of nonradical treatment. Patients received therapy every day till leuko-
cytes level <3x10 9/L: prednisone 20mg, cyclophosphamide 50mg, etoposide
50 mg, procarbazine 50 mg. When leukocytes level decreased below (<3 x 10
9/L) therapy was stopped and then renewed when leukocytes were recovered
>3x10 9/L in every day regimen or every other day or fractional regimen (5 times
a week, then 2 day break). The daily dose was always the same, perhaps it
was only a change in the number of days in a week in which to take the drugs.
Another goal was to investigate subjective improvement in general condition.
Results: A total of 70 patients were enrolled. Median age of patients was
46,85±4,3 years (from 19 to 74 years old), 38 man, 32 woman. There were
included 25 patients with Hodgkin’s lymphoma and 45-Non-Hodgkin lymphoma
(large B-cell lymphoma-35 pts, MZL-35, CLL/SLL-2, T-lymphoblastic-3, periph-
eral T-cell lymphoma-1, anaplastic-1). Relapsed lymphoma was diagnosed in
37 patients. The number of relapses ranged from 1 to 5 (median 1,69±0.90).
Refractory lymphoma was observed in 43 patients. As a second and third line
treatment patients received DHAP, GVP, GEMOX, ICE, MINE chemotherapy.
Prior to palliative course they received an average of 2.03+0.62 - treatment
lines (from 1 to 5 salvage-regimens). Response rate to therapy was assessed
in 46 patients. OR was achieved in 36,95% (n=17), CR - 6,52% (n=3), PR -
30,43% (n=14), SD - 39,13% (n=18). All patients had subjective improvement
in general condition. PD on therapy with no apparent positive response was
observed in 23.91% patients (n=11). Duration on PEPC therapy ranged from
1 to 15 months, average duration of therapy was 5,15±2,01 months (from 3 to
20 months). Nonhematologic toxicities (II / III grade CTC NCI v.4.02) are seen
in 19 patients (27,14%). Infectious complications were observed in 3 patients
(8,1%), febrile neutropenia (grade III-IV) - 27 (29,7%) and grade I-II - 12
(17,14%). Grade III anemia occurred in 5 patients (7,14%), grade II anemia-in
23 (32,85%). Thrombocytopenia (grade III) registered in 3 patients (4,28%)
without hemorrhagic syndrome.Currently, 22 (31.4%) patients continue treat-
ment. Because of disease progression 48 patients died. 
Summary/Conclusions: PEPC chemotherapy is an effective treatment for
extremely unfavorable group of patients with relapsed/refractory non-Hodgkin’s
lymphoma and Hodgkin’s lymphoma and has an acceptable toxicity profile.
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OUT-OF-POCKET ECONOMIC BURDEN AMONG COMMERCIALLY
INSURED PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IN
THE U.S.
B Seal1,*, S Schwartz2, M Jhaveri1, M Lingohr-Smith3, J Lin3, D Romanus1
1Millennium Pharmaceuticals, Inc., Cambridge, 2Wharton School of the Uni-
versity of Pennsylvania, Philadelphia, 3Novosys Health, Green Brook, United
States
Background: Patient (pt) outcomes have markedly improved with the intro-
duction of novel agents for multiple myeloma (MM), but the economic burden
of MM management in the U.S. is high. The increasing burden of out-of-pocket
(OOP) costs on cancer pts is of concern especially with a shift in insurance
coverage towards more cost-sharing. Annual OOP expenditures have been
estimated as $5,054 for lung cancer (2015 US $, Romanus 2008) and $5,472
for solid tumors (Zafar 2013). Data on OOP costs in MM in the era of novel
treatments are limited.
Aims: This retrospective cohort study estimated overall healthcare costs (OHC)
of MM management and OOP burden among commercially insured U.S. pts
newly diagnosed with MM (NDMM) in the U.S.
Methods: Pts<65 years of age with NDMM were identified, based on ICD-9-
CM codes, in the MarketScan claims database from 1/1/2008 to 9/30/2013.
Pts initiating MM treatments were followed from the date of initial MM treatment
(index date). All pts had continuous medical and prescription (Rx) commercial
insurance coverage 12 months (mos) before (baseline period) and at least 12
mos after (follow-up) the index date. Pts with claims for transplants or Medicare
insurance were excluded. Pt socio-demographic characteristics were evaluated
during the 12-mo baseline period. Cumulative OHC (sum of payments to the
provider paid by the insurance, the patient and other payers) and OOP pay-
ments (sum of copayments, co-insurance and deductibles paid by pts) were
determined at 1-, 2-, and 3-years post-index date among pts who had contin-
uous commercial insurance coverage through each corresponding year.
Results: Among 628 commercially insured pts with NDMM, mean age was
56.2 years (SD:6.3); 54.6% were male, 32.8%, 33.4% and 33.8% had a Charl-
son Comorbidity Index (CCI) score of 0, 1-2, 3+, respectively; 57.2% were
enrolled in a preferred provider organization (PPO) plan, 17.7% in a healthcare
managed organization (HMO) plan; 38.2% resided in the South, 24.8% in the
West, 22.5% in the North Central, and 13.9% in the Northeast regions of the
U.S. Mean total healthcare payments per patient in year 1 were $202,593, with
$76,595 for outpt medical services, excluding drug and drug administration,
$42,681 for inpt services, $35,491 for outpt MM drug and drug administration
services, $40,414 for MM drug prescriptions, and $930 for the emergency room
(Table). Over time the relative proportions of OHC by service type were con-
sistent. Over the 3 year study period, OOP payments ranged from 2.2% to
2.7% of the total healthcare payments (Table). Total cumulative OOP costs
increased from $4,363 in year 1 to $9,909 over the first 3 years after the index
date. MM drug related OOP (those administered in outpatient clinics or filled
as an Rx) ranged from 1.6% in year 1 and 2 to 1.7% in year 3 of total MM drug
treatment expenditures. The main contributor to OOP costs was related to out-
patient medical services, $2,200, $3,704 and $5,099 through years 1, 2 and 3,
respectively.
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Table 1.
Summary/Conclusions: In this study based claims data from 2009 to 2013,
the main cost driver of OHC and OOP among U.S. NDMM pts receiving treat-
ment was accounted for by non-MM drug therapy related services. Mean MM
drug therapy and drug administration related OOP costs were less than $100
per month. These results are based on commercial claims and do not reflect
reimbursements from copayment assistance programs.
References
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HOW PATIENTS PERCEIVE A SWITCH FROM IMATINIB TO NILOTINIB:
RESULTS OF A PATIENT-CENTERED ANALYSIS
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Background: Despite impactful result achieved with imatinib, about 40% of
patients experience treatment failure and more than 15% the persistence of
long-term side effects that impaired quality of life.
Aims: To investigate how a change in TKI therapy has an impact on familiar,
social and working setting of CML patients’ daily life.
Methods: A structured questionnaire was administered to patients switched to
nilotinib second-line after imatinib resistance or intolerance for not less than 6
months and not more than 36 months, regardless type of response. Twenty-
five Italian centers participated collecting 142 patients.
Results: There were 61% males and 39% females, median age was 57 years
(range 29-91). 65% with superior scholar degree. Median time from diagnosis
for the overall cohort was 8 years, with 9% diagnosed less than 4 years, 66%
from >4 to<10 years and 25% for ≥10 years. Sixty-one% of patients changed
because of loss of efficacy with imatinib, whereas 39% for persistence of
intolerance. Median time in imatinib treatment was 5 years, whereas median
time with nilotinib after switch was 2 years. Overall, the level of satisfaction
was requested to nilotinib and imatinib, respectively, and 93% of nilotinib-
treated patients reported high level as compared to 52% of imatinib-treated
patients. Dissecting this data, nilotinib-treated population reported in particular
high satisfaction for achieved response (64%), for the level of daily quality of
life (33%) and for tolerability (32%). Comparing imatinib and nilotinib, the
majority of patients reported an impact of therapy on daily activities: 64%
with imatinib reported low productivity at work (as compared to 33% with nilo-
tinib) with 57% of them required absences from work (as compared to 35%
with nilotinib). Analysing psychological perceptions, 64% of patients treated
with imatinib reported the sensation of no longer feel themselves (as com-
pared to 33% with nilotinib), and 36% to feel uncomfortable with their families
(as compared to 18% with nilotinib). Overall, after switch, more patients
referred a strong improvement of approach in daily living towards disease
and therapy. More common emotions requested to patients to represent actu-
al therapy with nilotinib were “trust” (65% vs 24% with imatinib), “joy” (52%
vs 4% with imatinib) and “serenity” (29% vs 10% with imatinib); indeed,
referred to previous therapy with imatinib, the more common emotions report-
ed were “worry” (52% vs 22% with nilotinib), sadness” (30% vs 6% with nilo-
tinib). “fear” (27% vs 15% with nilotinib), “frustration” (22% vs 4% with nilo-
tinib). After switching to nilotinib, it has been asked perceptions about a pos-
sible discontinuation: 50% of patients would discontinue due to trust in per-
sonal physician, 26% to no longer feel sick and only 18% of patients would
not stop for fear to losing all benefits achieved.
Summary/Conclusions: The results of this patient-centered analysis indicating
high level of satisfaction in CML patients who switch to nilotinib after previous
imatinib therapy, with improvements toward social, working and familiar daily life.
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PSYCHOMETRIC PROPERTIES OF THE GREEK TRANQOL QUESTION-
NAIRE FOR MEASURING QUALITY OF LIFE IN GREEK ADULT PATIENTS
WITH THALASSEMIA MAJOR
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Background: Greece is a country with a large population of thalassemia
patients. To date, there only a few studies measuring quality of life in Greek
thalassemia major patients, with the available data mainly derived from generic
QoL questionnaires. TranQoL is a novel disease-specific QoL instrument that
has been specifically developed to assess QoL in thalassemia major patients.
Aims: This study aimed to evaluate the construct validity, reliability and respon-
siveness of the Greek translated version of the TranQoL questionnaire. 
Methods:
The novel Greek TranQoL and the valid generic Greek SF-36v2 questionnaires
were administered in 94 consecutive thalassemia major patients that were fol-
lowed up at the Adult Thalassemia Unit of “Hippokration” general hospital of
Thessaloniki, Greece, one of the largest thalassemia centres in Greece. Both
questionnaires were completed anonymously during two subsequent transfu-
sion visits, 2-3 weeks apart. A week after the transfusion visit the participants
were asked to complete the TranQol at home, a third time, and describe any
change in their quality of life using a 7-point Likert-type scale. Construct validity
was assessed using Pearson’s correlation between the TranQoL scores and
the SF-36v2 scores at the first visit. In addition, the t-test or analyses of variance
were used to compare TranQoL scores between patient groups that have known
differences in quality of life. Assessment of reliability involved the determination
of internal consistency by calculating the Cronbach’s α-coefficient. Accordingly,
the intra - class correlation coefficient (ICC) between the TranQol scores of the
baseline visit and the subsequent visit was calculated in order to assess test-
retest reliability. In order evaluate responsiveness, we used the paired t-test
method to compare TranQoL scores between the transfusion visit and the home
visit, in the group of patients who reported to be at least “a little better” after
their last blood transfusion.
Results: There was a moderately strong correlation between the TranQoL
summary and both the SF-36 Physical and Mental Component Summaries
(r=0.43, p<0.001 and r=0.520, p<0.001 respectively). There was also a mod-
erately strong correlation between the Physical Health scale of TranQoL and
the relevant SF 36 scales, including Physical Functioning (r=0.4, p<0.001), role
- physical (r=0.6, p<0.001) and bodily pain (r=0.5, p<0.001). In terms of relia-
bility, TranQoL exhibited good internal consistency, with a Cronbach alpha coef-
ficient reported of 0.89. Test-retest reliability was excellent (intra-class correla-
tion coefficient, 0.9). Regarding know groups validity, patients with hypothy-
roidism had significantly lower TranQoL summary scores compared to patients
without hypothyroidism (65%, range: 57-83 vs 75%, range: 42-98, p<0.05).
There was also a significant difference in the score of the domain “school and
career functioning” for oral (81±17%) vs subcutaneous iron chelation (70±29%).
In terms of responsiveness, in the patients subgroup that rated their QoL as
better in the Likert-type scale, there was a 4.2 point (SD 5.0) improvement in
TranQol scores, from their transfusion visit (73.9%) to one week later at the
home visit (78.1%), (p<0.005). 
haematologica | 2016; 101(s1) | 601
Copenhagen, Denmark, June 9 – 12, 2016
Summary/Conclusions: In conclusion, the psychometric properties of the
Greek version of TranQoL confirmed that it is valid, reliable and responsive to
change. The TranQoL can be incorporated into future studies of thalassemia
major in Greek patients.
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BIG DATA ANALYTICS & PATHOLOGY SERVICES IN NHS: ACHIEVING
STEP CHANGES IN CAPACITY
M Laffan1, S Douglas2, R Littlewood2,*
1Haematology, imperial college london, 2Applied, Applied Strategic, London,
United Kingdom
Background: A major hospital Trust in London provides healthcare for a large
population across Medicine, Surgery, Obstetrics and other specialties. Three
laboratories are on sites using automated, high capacity analysers to provide
pathology services much of which requires rapid turnaround. The major chal-
lenge for laboratories in this situation is centred on the high throughput tests
comprising full blood count, assessment of renal/ liver function, and coagulation.
To date these services have not been subjected to detailed analysis of demand,
efficiency of use of analyser capacity and efficiency of physician requesting.
Aims: First to determine the factors limiting the turnaround times for routine
testing throughout periods of varying demand and those factors limiting the
optimum use of existing analyser resources. Second, to identify requesting
practices that are inefficient or which drive the changes in demand.
Methods: A database consisting 20M data points from 1M pathology test
requests, recorded over 1 year was provided including details of requester and
site of request with way points defining the passage of the sample from request
time through to test reporting. This allowed a map of volume and activity over
time and test turnaround times identifying bottlenecks and changes in efficiency.
Parameters showing healthcare professional ordering of tests, location of
patient and laboratory site were also provided and analysed.
Results: Initial descriptive analysis showed 1 particular laboratory had difficulties
achieving its potential capacity utilization rate and target turnaround times. Bot-
tlenecks were clearly identified at sample entry into the laboratory and at vali-
dation of results. These resulted in build-up of samples and delays in reporting
that were staggered in time: thus although the peak in TAT occurs at 4pm the
extra capacity was required prior to this, revealing a negative, delayed impact
of test arrival on test turnaround time. This has obvious implications for laboratory
management. The fastest 10% of FBC tests were reported in 0.2hr and 80% in
1.5 hrs but the slowest 10% varied from 2-120 hours. Of 200,000 tests
processed per year at one lab, 47% were ordered by clinical division Medicine,
34% Surgery & Cancer / Clinical Haematology, 15% Women and Children. Med-
icine was the leading requester at all 3 sites. Of 2,000 physicians, 87% order
fewer than 500 tests per year. Some intensive requesting practices are probably
masked by the use of common requesting codes. 61% of patients have only 1
to 2 tests per year, the proportion of patients having 100 tests per year being
less than 1%. However at one site >1% of patients had >50 tests per year, iden-
tifying an intensively monitored population. Measurement of true machine capac-
ity highlighted a large gap between current performance and maximum potential
indicating that better sample profiling and management could produce savings.
The maximum capacity for FBC was 420 tests per hour but the average per-
formance was 60/hr and the peak rate of reporting only 95/hr.
Summary/Conclusions: Big data analytics and process mapping identified 2
rate-limiting steps to performance inherent in current test system: test received
at lab and validation of results. Close analysis of such a large dataset indicates
how we can optimise the laboratory processes and improve utilisation of current
installed capacity in NHS pathology services.
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THE EFFECTIVENESS OF CLINICAL TRIAGE: CLOSING THE AUDIT LOOP
L Vanhinsbergh*, F Chowdhury
Haematology, NHS, London, United Kingdom
Background: In 2014-2015 there were 85 million outpatient clinic attendances
in NHS hospitals across the UK with a cost to secondary care exceeding £15
billion. 25.9 million (30 percent) of these were first appointments. In 2014 we
audited a 6 month period of haematology outpatient clinic referrals and estab-
lished the effectiveness of clinical triage in filtering inappropriate referrals. We
established that 74% of all new patient referrals were from primary care in
2014. Of the rejected referrals 96% were from primary care. 
Aims: In 2015, we implemented audit guided interventions, consisting of struc-
tured consultant led primary care teaching sessions across the North West
London region. These sessions were specifically designed to educate and
guide primary care physicians regarding haematological symptoms and blood
parameters requiring secondary care input. The intervention was made with
the aim of both capturing potential haematological malignancies at an early
stage and also reducing inappropriate referrals. The proposed secondary out-
come of this intervention was cost efficiency saving and improvement in region-
al haematology care.
Methods: Data was collected retrospectively from a local clinic referral database
containing information on all new patient referrals including demographics, refer-
ral reason and triage outcome. We compared data from a four month period
(June to September) in 2014 with the same four month period a year later in
2015.
Results: Our data shows a 31 percent increase in monthly referrals in 2015.
The mean monthly referral number increased from 169 in 2014 to 244 in 2015.
Despite this we saw a reduction in the percentage of inappropriate referrals to
the service. In 2014 a monthly mean of 22 percent of referrals were rejected
with feedback provided to the referring clinician. In 2015 the rejected referral
rate was reduced by 6 percent to a monthly mean of just 16 percent for the
same time of year period. 37% of referrals were for clotting/ thrombosis, 23%
potential haematological malignancy including 2 week waits and the remaining
40% general haematology.
Summary/Conclusions: Our data support the ongoing use of consultant led
clinical triage and primary care education in order to reduce the significant cost
burden of new patient clinics whilst remaining safe for patient care.
E1457
USE OF COMBINED ORAL ADMINISTRATION OF ANALGESIA AND
ANXIOLYSIS FOR PAIN ASSOCIATED WITH BONE MARROW ASPIRATION
AND BIOPSY
A Gravetti, C Cerchione*, A Casoria, N Pugliese, L Marano, F De Gregorio,
M Di Perna, M Picardi, V Martinelli, F Pane
Hematology, Ematologia e Trapianto/AU Federico II, Napoli, Italy
Background: Bone marrow aspiration and biopsy (BMB) is central to the diag-
nosis and management of many haematological disorders and is a safe pro-
cedure associated with low morbidity and mortality. For adults, the infiltration
of local anesthesia at the biopsy site has been used as the principal form of
analgesia for BMBA. Unfortunately pain relief is often incomplete especially
during aspiration of the bone marrow. In addition, pain is likely to contribute to
the anxiety the patient may already be experiencing.
Aims: In this study we assessed an oral administration of analgesia (fentanil-
ACTIQ) and anxiolysis (midazolam). 107 consecutive ambulatory adult patients
referred for bone marrow examination were enrolled. Informed consent for the
procedure was obtained from all patients.
Methods: All patients received local anaesthesia (LA) with 10 mL of injected
2% lignocaine, but 52 patients received LA alone (group A) and 55 patients LA
plus 5 mg midazolam (oral administration) and 200 mcg of Fentanyl trans-
mucoso (group B), 30 min before the procedure. The pain level was assessed
with the Numeric Rating Scale which distinguishes ten levels of pain, from 0 to
10 in five times of procedure (baseline, start LA T1, aspiration T2a, biopsy T2b,
five minutes after the end of the procedure T3). At the end, all were given a
questionnaire about efficacy, satisfaction, comfort with three levels (1/low-
2/medium-3/high).
Results: This medium values were found: at time T1 the medium level of pain
was 0.87 for the group A vs 0.88 of group B, at time T2a 3,63 group A vs 3,54
group B, at time T2b 4,63 group A vs 4 group B (p<0,05), time T3 0,41 group
A vs 0,16 group B (p<0.05). In addition 21 Patients, who have already under-
gone the procedure without sedoanalgesia, saw to prefer the new medication. 
Summary/Conclusions: Our preliminary results seem interesting because
underline the different subjective perception of pain in the two groups and espe-
cially show a main level of satisfaction and comfortable in our patients under-
gone medication with sedoanalgesia and a lower level of anxiety in view of a
possible repeat of examination.
E1458
THE IMPACT OF AL AMYLOIDOSIS ON ABSENTEEISM, REDUCED
PRODUCTIVITY, AND JOB LOSS
S Guthrie1,*, MK White2, KL Mccausland2, M Bayliss2
1Prothena Biosciences Inc, South San Francisco, CA, 2Optum, Lincoln, RI,
United States
Background: Debilitating chronic conditions and their treatments often nega-
tively impact patient’s ability to work, resulting in absenteeism, reduced pro-
ductivity, and job loss. Light-chain (AL) amyloidosis is a rare disease in which
misfolded light chains are deposited in tissues, which may lead to organ failure,
disability, and death. Current treatments are known to affect patients’ function-
ing and well-being, but there is little evidence to date on the impact of AL amy-
loidosis on patients’ ability to work.
Aims: To describe the impact of AL amyloidosis on patients’ work using data
from qualitative and quantitative research.
Methods: Data for these analyses were collected from two phases of a broad
research program on the experience of patients with AL amyloidosis. First,
qualitative in-depth individual telephone interviews were conducted with 10
patients. Results are presented from coded interview transcripts that were ana-
lyzed using a grounded theory approach to identify themes. Second, a quan-
titative online survey including a battery of patient-reported outcome measures
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was conducted in a separate sample of patients (n=341). The data presented
are based on the Work Productivity and Activity Impairment (WPAI) question-
naire for the subset of employed patients, including a single-item measure of
the number of hours absent from work due to AL amyloidosis and a multi-item
scale assessing overall lost productivity. Wilcoxon-Mann-Whitney tests were
used to compare mean WPAI scores by time since diagnosis (<12 months ago
vs ≥12 months ago) among those with cardiac involvement.
Results: In qualitative interviews, 7 of 10 patients reported that AL amyloidosis
impacted their ability to work, manifesting as loss of focus or productivity, absen-
teeism including extended leaves of absence, and job loss. Patients reported
underperforming at work and attributed this to symptoms, treatment side effects,
and time required for doctor visits. Most felt their employers were supportive of
their health needs; however, in some cases, job loss led to financial difficulties
for families and frustration at subsequent changes in household roles. In the
quantitative study, 115 patients (38.3%) were currently employed. Of these,
the mean age was 56.1, 56% were female, and 10% were non-Caucasian. On
average, employed patients reported being absent from work 5 hours per week
and a 27.6% reduction in overall work productivity due to AL amyloidosis.
Patients with cardiac involvement reported significantly higher absenteeism
compared to those without cardiac involvement (mean hours absent per week:
15 vs 2.5 hours, respectively, p<0.02). Within the subgroup with cardiac involve-
ment, overall lost work productivity for those diagnosed within the past year
was twice that of patients with cardiac involvement who were diagnosed more
than a year ago (54.4% vs 25.4%, respectively, p<0.04).
Summary/Conclusions: These results indicate that AL amyloidosis has a sig-
nificant impact on patients’ work, causing absenteeism, impaired productivity,
and job loss. These results highlight additional costs of AL amyloidosis that are
not related to medications or procedures, but are borne by patients, their
employers, and their families. Advancements in treatment options for patients
with AL amyloidosis and increased attention to patients’ functioning and well-
being could potentially minimize these hidden costs.
Study supported by: Prothena Biosciences Inc.
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HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE
MYELOMA IN RELATION TO LINE OF TREATMENT AND RESPONSE
XH Hu1,*, K Bozena2, M Lowe2, L Purnomo1, C Gibson1, AM Rodriguez2
1Celgene Corporation, Summit, NJ, 2PatientsLikeMe, Boston, MA, United
States
Background: Health-related quality of life (HRQoL) in patients with multiple
myeloma (MM) has mostly been evaluated in controlled trials composed of
largely homogeneous patient populations. There is a paucity of literature exam-
ining HRQoL in patients with MM at different treatment stages in a real-world
setting.
Aims: To document and compare self-reported HRQoL outcomes in patients
with MM across different lines of treatment and response status.
Methods: US patients with self-reported MM were recruited through an online
patient-powered network, PatientsLikeMe. Upon completion of informed con-
sent, study participants were asked to provide their MM treatment history and
complete the European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30). HRQoL scores were com-
pared using the Kruskal-Wallis test across the following subgroups: patients
who had received stem cell transplant (SCT); patients who had not switched
their drug regimens as a result of disease progression; patients who had 1-3
drug regimen switches because of disease progression; and patients who had
≥4 switches because of disease progression. HRQoL domain scores were also
compared across subgroups based on response status reported to patients at
their last provider visit (complete response, partial response/under control/sta-
ble, relapse/recurred or not responsive/progressive disease) irrespective of
treatment lines.
Results: A total of 199 patients completed the online survey. Of these, 10
patients were excluded from this analysis because they had not received any
MM treatment. Of the remaining 189 patients, the median age was 61 years
(range, 37-82 years) and 57.6% were women. 58 patients reported receiving
SCT, 66 patients reported not switching treatment regimens because of disease
progression, 43 patients reported 1-3 switches because of disease progression,
and 22 reported ≥4 switches because of disease progression. Global HRQoL
domain scores varied from 58.3 to 68.7 (P =.279) as measured by the EORTC
QLQ-C30. Comparable HRQoL in other domains were also reported across
different treatment lines. Patients reporting their most recent response status
as “complete response” had the highest Global HRQoL score (71.7) relative to
patients reporting their most recent status as “partial response/under control or
stable” (63.0) or “relapsed/recurred or not responsive/progressive disease”
(55.6; P =.012). Similarly, statistically significant higher HRQoL scores were
reported in the Physical Functioning, Social Functioning, and Pain domains in
patients who experienced complete responses.
Summary/Conclusions: Domains of Global HRQoL, Physical Functioning,
Social Functioning, and Pain in patients with MM treated in usual care settings
were associated with their response status.
E1460
POMALIDOMIDE OR CARFILZOMIB USE IN PATIENTS WITH RELAPSED
MULTIPLE MYELOMA: REAL-WORLD TREATMENT PATTERNS, TIME TO
NEXT TREATMENT, AND ECONOMIC OUTCOMES
K Parikh1,*, L Purnomo1, S Abouzaid1, CC Chen2, C McGuiness2, M Hussein1,
R Wade2
1Celgene Corporation, Summit, NJ, 2IMS Real-World Evidence Solutions and
Health Economics & Outcomes Research, Plymouth Meeting, PA, United States
Background: Pomalidomide (POM) is an immunomodulatory agent first
approved in the United States in February 2013 in combination with dexam-
ethasone (DEX). Carfilzomib (CAR) is a proteasome inhibitor first approved in
the United States in July 2012. Both POM and CAR were approved for patients
with relapsed multiple myeloma (MM). Real-world data on the use of these
agents in the United States are limited.
Aims: The aim of this study was to fill in gaps in real-world data on treatment
patterns and outcomes with POM or CAR in patients with relapsed MM. 
Methods: Patients with ≥2 MM diagnoses (ICD-9 203.0x) and a POM or CAR
claim (index date) from 2/1/2013 to 2/28/2015, assumed to be relapse therapy,
were identified in the PharMetrics PlusTM US claims database. Treatment reg-
imens were defined as all MM therapies observed within 60 days of index.
Patients with both POM and CAR within 60 days of index were excluded. Time
to next treatment (TTNT), a proxy for disease progression, was defined as the
addition of a new agent >60 days from index or treatment restart following a
>90-day gap in therapy. Plan-paid median monthly apportioned costs were
reported for total follow-up time, and Wilcoxon rank-sum tests were used to
compare the cohorts.
Results: A total of 454 patients indexed to POM (n=264) or CAR (n=190) were
identified. The mean age was 61.6 years (SD=9.3 years), 60.1% were men,
and these characteristics were similar between groups. Pre-index stem cell
transplant occurred at any time in 34.5% of POM patients and 26.3% of CAR
patients (P =.064). POM+DEX (47.0%) and POM alone (33.0%) were the most
common indexed POM treatments; and CAR alone (45.3%) and CAR+DEX
(14.7%) were common indexed CAR treatments. The most frequently observed
next-line treatment for POM-indexed patients was addition of or switch to
CAR±DEX (29.0%), and for CAR-indexed patients it was switch to POM+DEX
(9.3%), and CAR alone (6.7%) or CAR+DEX+cyclophosphamide (6.7%). For
patients followed-up to disease progression (POM, n=100; CAR, n=75) the
mean TTNT was longer for POM-indexed patients compared with CAR-indexed
patients (6.9 vs 5.3 months; P =.0164). With a mean follow-up time of 8.9
months across both groups, 22.0% were still on index treatment, 17.0% were
on subsequent treatment (POM, 17.8%; CAR, 15.8%), 9.7% were not on treat-
ment, 25.3% had died (POM, 25.0%; CAR, 25.8%), and 26.0% had lost eligibility
prior to classification. Median monthly costs were lower for POM vs CAR
patients ($18,298 vs $24,734; P =.001).
Summary/Conclusions: This retrospective study of POM or CAR treatment
in patients with relapsed MM found a significantly longer TTNT with POM-based
regimens vs CAR-based regimens. POM-based regimens were observed to
have lower monthly costs through the end of follow-up compared with CAR-
based regimens.
LB2265
INFLUENCE OF EXTENDED CARE ON LIVING QUALITY OF PATIENTS
AFTER ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION
X Du1, C Zhang, AH Sun1, X Zhang2,*, PY Kong1, L Gao1
1Department of Hematology, Xinqiao Hospital, Third Military Medical University,
2Department of Hematology, Xinqiao Hospital,Third Military Medical University,
Chongqing, China
Background: Patient satisfaction with health care has become a widely recog-
nised patient reported outcome of the quality and clinical effectiveness of health
services. Assessment of patient satisfaction is essential to ensure that care
and services meet the needs of patients because the expectation of quality
care can vary between patients and practitioners.
Aims: To evaluate the influence of extended care on living quality of patients
after allogeneic hematopoietic stem transplantation.
Methods: A total of 80 patients after allogeneic hematopoietic stem transplan-
tation were enrolled in this study. They were randomly divided into intervention
group and control group according to hospital number ending(odd and even
numbers).The intervention group cases were given the extended care after dis-
charging from hospital, but no intervention for the control group,and the quality
of life was evaluated by using cancer patients quality of life measure scale
developed by European Organization for research and treatment of
cancer(EORTC) in the two groups at 1 month and 3 months after discharged.
Results: At 1 month after discharge,the cognitive function score and emotion
function score in intervention group were better than that of control group; at 3
months after discharge,the scores of physical function,role function,cognitive
function,social function,general health status and fatigued,insomnia symptoms
in intervention group were better than that of control group. 
Summary/Conclusion: Extended care for patients after allogeneic hematopoi-
etic stem transplantation can effectively improve the quality of life of them.
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SAFETY IN PROCEDURE OF EVALUATION FOR PRESCRIPTION OF
ENDURANCE EXERCISES IN PATIENTS WITH SICKLE CELL DISEASE: A
PILOT STUDY
LA Messonnier1,2, B Gellen3,4, S Peyrot4, R Lacroix1, T Rupp1,5, F Galactéros 5,6,7,
P Bartolucci5,6,7,*, L Féasson5,8,9
1Laboratoire Interuniversitaire de Biologie de la Motricité, Université Savoie
Mont Blanc, Chambéry, 2Laboratoire d’Excellence GR-Ex, PRES Sorbonne
Paris Cité, Paris, 3Faculté de Médecine et de Pharmacie, Université de Poitiers,
Poitiers, 4Service de Cardiologie, APHP - GHU Henri Mondor-Albert Chenevier,
Créteil, 5Laboratoire d’Excellence GR-Ex, PRES Sorbonne Paris Cité, Paris,
6IMRB équipe 2, Université Paris-Est Créteil, 7Centre de Référence des Syn-
dromes Drépanocytaires Majeurs, GHU Henri Mondor-Albert Chenevier,
Créteil, 8Unité de Myologie, Centre Référent Maladies Neuromusculaires Rares
Rhône-Alpes, CHU de Saint-Etienne, 9Laboratoire Interuniversitaire de Biologie
de la Motricité, Université de Lyon, Saint-Etienne, France
Background: Physical activity is considered as potentially harmful in patients
with sickle cell disease (SCD) and is therefore usually discouraged. Literature
reports that during exercise, SCD patients may display gas exchange abnor-
malities, dyspnea, elevated pulmonary artery systolic pressure, left ventricular
diastolic dysfunction, arterial hypoxemia. Vigorous exercise can also induce
acidosis, hemorheological alterations, endothelial dysfunction and oxidative
stress, which may trigger vaso-occlusive crisis in those patients. However,
moderate and regular physical activity seems to be not only safe but also poten-
tially beneficial for SCD patients (Barbeau et al. 2001, Faës et al. 2014, Martin
et al. 2015).
Aims: The aim of the present study was i) to propose a submaximal incremen-
tal exercise test sufficiently intense to evaluate the physical ability of the patients
but not intense enough to induce severe adverse events, and ii) to test the
safety of moderate-intensity endurance exercise sessions individualized on
basis of data obtained in i).
Methods: Twenty adult patients with homozygous SCD (12 men and 8 women,
aged 21-53 years, 78.2±2.0% and 9.8±1.9% of HbS and HbF, respectively)
participated in this study approved by the ethics committee (ClinicalTrials.gov
NCT02571088). All patients underwent a submaximal incremental exercise
(SIE). SIE started at 20 W and 30 W for women and men, respectively. After 2
minutes at this load, and every 2 minutes thereafter, workload increased by 10
W and 15 W for women and men, respectively. During exercise, twelve-lead
EKG, heart rate (HR), pulmonary ventilation (VE), oxygen uptake (VO2), systolic
(SBP) and diastolic (DBP) blood pressure, peripheral capillary oxygen satura-
tion (SpO2), blood lactate concentrations ([Lac-]) and rate of perceived exertion
(RPE) were measured. Exercise was stopped (exercise completion) when a
[Lac-] of 4 mmol.L-1 was reached in order to limit acidosis. The first lactate
threshold (LT1) was determined as the first inflection point of the [Lac-] vs work
rate curve. Besides, eight men and seven women of the group took part in
three constant-load submaximal endurance exercise sessions. Each session
lasted 40 min and consisted in a 5-min warm-up, 30 min of cycling at the work-
load corresponding to LT1, and 5 min of active recovery. HR, SpO2 and [Lac-]
were checked regularly and values at the end of exercise were recorded. Work
rate was adjusted between sessions to target a [Lac-] of ~2.5 mmol.L-1, which
is usually used for endurance exercise in healthy sedentary and trained sub-
jects. Descriptive statistics are expressed as mean±standard error (SE).
Table 1.
Results: Results are presented in table 1. Although submaximal, the incre-
mental exercise was physiologically stressful since exercise completion inter-
vened at ~85% of maximal theoretical heart rate (HRmax-theor). SIE allowed
estimation of LT1 and related parameters (e.g., workload) for prescription of
endurance exercise in SCD patients. HR, SpO2, [Lac-] and RPE observed dur-
ing the constant load exercises were close to the expected values based on
SIE. None of the studied patients experienced severe adverse events during
or after SIE and endurance exercises.
Summary/Conclusions: We concluded that this procedure of SIE allowed
evaluation of physical ability of SCD patients without inducing severe adverse
events. Besides, SIE provided useful data (i.e., LT1 and related parameters)
allowing prescription of apparently safe endurance exercises in patients with
SCD. Armed of this experience, an individualized endurance training program
might be proposed to patients with SCD.
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ANXA2 GENE POLYMORPHISM (RS7170178) IS ASSOCIATED WITH
OSTEONCROSIS DEVELOPMENT IN SICKLE CELL ANEMIA
DA Pereira-Martins1,*, JL Coelho-Silva1, A Ferreira da Cunha2, J Cabral-Peres3,
F Ferreira Costa4, A da Silva Araújo3, AR Lucena-Araujo1, MA Bezerra1
1Departament of genetics, Federal University of Pernambuco, Recife, 2Depart-
ment of Genetics and Evolution, Federal University of São Carlos, São Carlos,
3Hematology Hospital, Hematology and Hemotherapy Foundation of Pernam-
buco, Recife, 4Haematology and Hemotherapy Centre, University of Campinas,
Campinas, Brazil
Background: The occurrence of vaso-occlusive crisis (VOC) and chronic
hemolysis are clinical complications frequently observed in patients with sickle
cell anemia (SCA). Nevertheless, these complications may vary in intensity
and frequency within of the disease and several studies support the idea of a
genetic component involved in the clinical modulation of these complications.
With this in mind, two previously published genetic variants in ANXA2 gene
(ANXA2*5681 G>A and IVS-14-1046 C>T) were associated with the develop-
ment of specific clinical complications in SCA. Initially described as an important
modulator of the bone mineralization and co-activator of the fibrinolysis process,
the imbalance of the ANXA2 expression may constitute a promising molecular
marker for clinical heterogeneity in SCA.
Aims: Here, we evaluated the clinical impact of ANXA2*5681 G>A and IVS-
14-1046 C>T polymorphisms in patients with SCA, diagnosed and followed by
a single reference center from northeast Brazil.
Methods: Seven hundred fourteen SS-genotyped patients were enrolled. The
median age was 25 years (range: 3-61 years), with 347 males (49%). One
hundred ninety four (27%) were younger than 18 years. The main clinical com-
plications described in patients with SCA (osteonecrosis, stroke, acute chest
syndrome, priapism, leg ulcer) were obtained from medical records. The last
update occurred in January 2016. The ANXA2*5681 G>A (rs7170178) and
IVS-14-1046 C>T (rs7163836) polymorphisms were detected by real-time PCR.
For test if both selected polymorphisms could influence the ANXA2 gene
expression, 70 patients with SCA were selected at random and the total RNA
was isolated from peripheral blood. The ANXA2 transcript levels
(Hs_00743063_s1) were analyzed by real-time quantitative PCR quantified
using the GAPDH as endogenous control.
Results: Overall, 144 patients (20%) developed leg ulcer, followed by priapism
(97 patients, 14%), osteonecrosis (84 patients, 12%), acute chest syndrome
(82 patients, 11%), and stroke (70 patients, 10%). One hundred and thirty-four
patients (19%) had none of the main clinical complications aforementioned.
According to ANXA2*5681 genotype, 105/714 patients (15%) carried the GG
genotype, while 285/714 (40%), and 314/714 (45%) presented the GA and AA
genotypes, respectively. ANXA2*5681 polymorphism was associated a higher
frequency of osteonecrosis (P<0.0001). In fact, univariate analysis demon-
strated that AA-genotyped patients had a 3-fold higher risk to develop
osteonecrosis (OR: 3.3, 95%CI: 1.9-5.9; P<0.0001). These data were consis-
tent with multivariate analysis (OR: 3.08, 95%CI: 1.6-5.8; P=0.001), considering
fetal hemoglobin levels, number of VOC/year, sex, and age as confounders. In
addition, the cumulative probability of osteonecrosis was significantly higher in
AA-genotyped patients (88%) compared to non AA-genotyped patients
(GG+GA patients, 43%; P=0.001). The AA genotype retained its prognostic
value in multivariate proportional hazards regression analysis (HR: 2.4, 95%CI:
1.4-3.8; P<0.001). Finally, AA-genotyped patients with osteonecrosis had a
lower ANXA2 transcript levels compared to GG- and GA-genotyped patients
(P<0.05). We could find no impact for the IVS-14-1046 polymorphism with
none of the variable analyzed.
Summary/Conclusions: ANXA2*5681 polymorphism in homozygosis may be
an independently predictor of osteonecrosis and may impact the ANXA2 tran-
script levels, with possible decrease of the encoded protein, in SCA.
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ATP11C IS DOWNREGULATED IN LEUKOCYTES AND RETICULOCYTES
IN SICKLE CELL ANEMIA
D Martins1,*, J Coelho-Silva1, A da Silva Araújo2, J Cabral-Peres2,
A Ferreira da Cunha3, MA Bezerra1, AR Lucena-Araujo1
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and Hemotherapy Foundation of Pernambuco, Hematology Hospital, Recife,
3Department of genetics and evolution, Federal University of São Carlos, São
Carlos, Brazil
Background: In general, the phosphatidylserine (PS) exposure represents the
major cause of blood cells adhesion to the vascular endothelium, and may con-
tribute for vaso-occlusive crisis and extravascular hemolysis in beta-hemoglo-
binopathies, including sickle cell anemia (SCA). Such process may be poten-
tiated by the SS-hemoglobin polymerization and significantly worsened in the
absence of physiologic mechanism involved in PS internalization. In this con-
text, members of the P4-type ATPase family constitute an important class of
enzymes responsible for phospholipids translocation in plasma membrane, and
several evidence suggests that the low expression of the ATP11C gene (a spe-
cific member of the P4-type ATPase family) is associated with higher rate of
PS exposure in peripheral blood cells. Corroborating these data, the evaluation
of erythropoiesis in ATP11C-deficient mice showed an abnormal shape of ery-
throcytes, lower rate of PS translocation, and shortened life span of mature
erythrocytes, with consequent anemia. Therefore, it is conceivable that lower
ATP11C transcripts levels may act as an important genetic modifier, increasing
the PS exposure and, consequently, enhancing the adhesion of leukocytes,
platelets, erythrocytes and vascular endothelial cells in SCA.
Aims: Here, we evaluated the gene expression profile of the ATP11C in gran-
ulocytes, mononuclear cells and reticulocytes from patients with SCA, beta-
thalassemia and healthy donors. We also correlated these findings with the
main chronic clinical complications in SCA.
Methods: Sixty-four patients with SCA (median age: 31 years, range, 15-61
years), with 35 male (55%), and fully characterized for βS-globin gene haplotype
(bantu/bantu), and co-inheritance alpha-thalassemia (absence of -3.7kb dele-
tion) were included. Total RNA from granulocytes, mononuclear cells, and retic-
ulocytes was isolated. In addition, 14 patients with beta-thalassemia and 16
healthy donors (hemoglobin profile AA) were enrolled. ATP11C transcripts levels
(Hs_00937051_m1) were analyzed by real-time quantitative PCR using the
median value of GAPDH and 18S as endogenous control.
Results: First, we analyzed the ATP11C transcript levels in granulocytes,
mononuclear cells and reticulocytes from patients with SCA. Reticulocytes pre-
sented lower levels of ATP11C transcripts (P<0.05). We next showed that the
SCA reticulocytes had a lower ATP11C transcripts levels compared to beta-
thalassemia and healthy donors reticulocytes (P<0.05). Of interest, ATP11C
transcript levels were lower in both leukocytes (granulocytes and mononuclear)
and reticulocytes from patients with SCA compared to healthy donors
(P=0.023). According to the chronic clinical complications frequently reported
in patients with SCA, 13 patients (20%) had leg ulcer solely, followed by cere-
brovascular disease (7 patients; 11%). Twenty-one patients (33%) had more
than one clinical complication (including osteonecrosis along with acute chest
syndrome, and priapism), and 23 patients (36%) had no documented clinical
complication. Patients who presented more than one clinical complication exhib-
ited lower ATP11C transcripts levels (P<0.05).
Summary/Conclusions: Although limited number of patients and no validation
data in an independent cohort constitute the main limitations of our study, our
results showed that ATP11C transcript levels is decreased in SS-genotyped
cells, in particular reticulocytes, and such decrease may be associated with
higher rate of clinical complications in SCA.
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A 6 NUCLEOTIDE IN FRAME DUPLICATION IN PIEZO1 GENE IN TWO
FAMILIES WITH DEHYDRATED HEREDITARY STOMATOCYTOSIS
I Andolfo1,*, R Russo1, F Manna1, G De Rosa1, A Gambale1, L De Franceschi2,
A Iolascon1
1Dept. of Molecular Medicine and Medical Biotechnologies, University Federico
II of Naples, Ceinge, biotecnologie avanzate, Naples, 2Department of Medicine,
University of Verona, Piazzale Lo Scuro 10, Verona, Italy, Verona, Italy
Background: Dehydrated hereditary stomatocytosis (DHSt), also known as
hereditary xerocytosis, is an autosomal dominant congenital hemolytic anemia
associated with a monovalent cation leak. DHSt consists of an usually com-
pensated hemolysis, associated with moderate splenomegaly. Blood smears
show variable numbers of stomatocytes, elevated reticulocyte count and a
slightly increased red cell mean corpuscular volume (MCV). DHSt red blood
cells (RBCs) exhibit decreased intraerythrocytic K+ content and increased
intraerythrocytic Na+ content. The causative gene of this condition was recently
identified in the FAM38A gene encoding the mechanosensitive cation channel,
PIEZO1 (Andolfo I., et al, 2013; Zarychanski R., et al, 2012). Several functional
characterizations of identified PIEZO1 mutations in DHSt families have uni-
formly demonstrated gain-of-function properties consistent with the increased
net ion fluxes leading to DHSt (Andolfo I., et al, 2013; Albuisson J, et al, 2013;
Bae C., et al, 2013). Recently, a new causative gene of DHSt was identified in
the KCNN4 gene encoding the Gardos channel (Andolfo I., et al, 2015; Raphael
R-M, et al, 2015; Glogowska E., et al, 2015). The Gardos channel/KCNN4 is a
widely expressed Ca2+-dependent K+ channel that mediates the major K+
conductance of erythrocytes (Begenisich T, et al, 2004).
Aims: In this study we performed osmotic gradient ektacytometry and DNA
sequence analysis of PIEZO1/KCNN4 genes in seven patients with clinical
suspicion of DHSt from two unrelated families (family 1 and family 2) to assess
the clinical diagnosis.
Methods: Deformability of the RBCs of the patients and relative control subjects
were evaluated by osmotic gradient ektacytometry using the Laser-assisted
Optical Rotational Cell Analyzer (LORCA). Genomic mutational screening was
performed by direct sequencing analysis, as previously described (Andolfo I.,
et al, 2013).
Results: Ektacytometric analyses showed a leftward shift of the bell-shaped
curve for all the patients in respect to the healthy controls indicating dehydration
of the RBCs. Subsequently, DNA analysis of the patients revealed no mutations
in KCNN4 gene and the mutation c.7473_7478dupGGAGCT, p.Glu2492_Leu
2493dup in PIEZO1 gene that cosegregated with the disease phenotypes in both
the families. Both Glu2492 and Leu2493 residues are highly conserved in PIEZO1
(http://genome.ucsc.edu/). Interestingly, the duplication is localized in the C-ter-
minal domain of the protein that was recently identified as the pore of the
mechanosensitive cation channel. Moreover, the proband of the family 1 showed
another de novo PIEZO1 mutation c.5591G>A, p.Arg1864His in cis with the dupli-
cation p.Glu2492_Leu2493dup. Of note, the proband presents a more severe
clinical phenotype when compared to that observed in his affected father.
Summary/Conclusions: Molecular characterization of seven DHSt patients
from two unrelated families revealed a novel in frame duplication and a novel
missense mutation in PIEZO1 gene. We are currently performing a functional
study to evaluate the causative role of both novel mutations here described.
Particularly, we are characterizing the possible modifier role of the de novo
mutation, p.Arg1864His, in cis with the inherited duplication on the occurrence
of severe phenotype observed in the proband of family 1.
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NON DELETIONAL ALPHA THALASSAEMIA AND STRUCTURAL
HAEMOGLOBINOPATHIES OF ALFA CHAIN MOLECULAR CHARACTERIZATION
IN SPAIN IN A COHORT OF 1623 PATIENTS
F De La Fuente Gonzalo*, JM Nieto, M Guijorro Gonzalez-Conde, RB Martinez Martinez,
FA Gonzalez Fernandez, A Villegas Martinez, P Ropero Gradilla
Hematology, Hospital Clínico San Carlos, Madrid, Spain
Background: Thalassaemias are a heterogeneous group of inherited anaemias
that are characterized by the reduction or total absence of the synthesis of one
or more globin chains. Structural haemoglobinopathies are inherited disorders
in which the sequence of one of the globin chains, which form the haemoglobin,
is altered.
Aims: To analyze the distribution of demographic variables of patients with α-
thalassaemia and structural haemoglobinopathies in our region and to describe
the molecular heterogeneity of both diseases and to examine the incidence of
non-deletional α-thalassaemia within all cases of α-thalassaemia.
Methods: Studied Subjects: From January 2009 to December 2014, 1,623
individuals were studied from different Spanish regions (both native and immi-
grant populations). It was an study comprising 1,470 patients with hypochromic
and microcytic anaemia, 176 subjects with a peak of abnormal haemoglobin
and 23 patients who were studied for both diagnosis. Diagnostic techniques:
α-thalassaemia required a conventional haemocytometer study, the reticulocyte
count, the determination of Hb A2 and Hb F by ion exchange HPLC and quan-
tification of the Hb H inclusion bodies. The diagnosis of structural haemoglo-
binopathies required capillary electrophoresis of haemoglobins and reversed
phase or globin chain HPLC. Molecular biology techniques: automatic extraction
of the DNA, discarding the most frequent large deletions and point mutations
using the α-globin StripAssay®, discarding other large deletions by MLPA, and
Sanger sequencing for other point mutations.
Table 1.
Results: The demographics results are summarised in table 1 (Table 1: Demo-
graphics data including age, ethnicity and Autonomous community of residence
of the patients). Gender balance was found in this study. Clinical diagnosis: 1
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hydrops fetalis, 18 Hb H disease, 1,200 thalassaemias traits and 160 thalas-
saemia silent carriers were recorded within the α-thalassaemia clinical diag-
nostics. Regarding structural haemoglobinopathies, there were only 2 cases
of haemoglobinopathies with low oxygen affinity and 1 case of haemoglobin
M, which represented the only symptomatic patients. Genetic diagnosis: 1,298
carriers of the α-thalassaemia deletion were identified (905 heterozygous, 366
homozygous and 27 double heterozygous). A total of 188 patients with non-
deletional α-thalassaemia were found (185 heterozygous and 3 homozygous).
A total of 176 patients had structural haemoglobinopathies of the α chain (173
heterozygous and 3 homozygous). Finally, it is important to note that this study
described 9 and 5 new alterations responsible for non-deletional α-thalas-
saemia and structural haemoglobinopathies of the α chain, respectively.
Summary/Conclusions: 1)Most individuals were diagnosed with α-thalas-
saemia at an early age, particularly in severe cases. Further, the disease
occurred predominantly in Caucasians and, to a lesser extent, in Asians. 2)Non-
deletional α-thalassaemia represented 12% of all α-thalassaemias in our
region, representing a higher value than described to date. 3)The most common
deletion in our region was the 3.7Kb deletion that is common in Mediterranean
populations, followed by Asian -SEA and -FIL. The alterations responsible for
non-deletional α-thalassaemia are most represented by the Hph and Hb
Groene Hart and, in the case of structural haemoglobinopathies, Hb Le
Lamentin and Hb J-Paris. However, there is a high heterogeneity in the popu-
lation analysed with the discovery of 36 and 35 different alterations responsible
for non-deletional α-thalassaemia and structural haemoglobinopathies of the
α chain, respectively.
E1466
OXIDATIVE STRESS IN COMPLEMENT-MEDIATED HEMOLYSIS: THE
AMELIORATING EFFECT OF FERMENTED PAPAYA PREPARATION
E Fibach1,*, E Rechmilewitz2
1Hematology, Hadassah University Hospital, Jerusalem, 2Hematology, The E.
Wolfson Medical Center, Holon, Israel
Background: The complement (C’) and the redox systems play important roles
in the physiological functioning of the body, such as the defense system, but
they are also involved in various pathological conditions, including hemolytic
anemia. Antioxidants ameliorate oxidative stress by preventing generation of
free radicals, by scavenging and preventing their accumulation and by correct-
ing their cellular damage.
Aims: Using experimental model systems, we studied the interaction between
the C’ and the redox systems in C’-mediated hemolysis in Paroxysmal Noctur-
nal Hemoglobinuria (PNH) and in Auto-Immune Hemolytic Anemia (AIHA), and
the ameliorating effect of fermented papaya preparation (FPP), an antioxidant-
containing product of yeast fermentation of Carica papaya Linn.
Methods: PNH-like cells were generated by treating normal human red blood
cells (RBC) with the sulphydryl compound 2-aminoethyl isothiouronium bro-
mide. AIHA was simulated by treating group-A RBC with anti-blood group A
antibodies. Both treated RBC were incubated with fresh (C’-containing) autol-
ogous or O-type serum. Reactive oxygen species (ROS), as a parameter of
oxidative stress, and the surface C’-protecting CD55 and CD59 antigens were
measured by flow cytometry.
Results: The sulphydryl-treated RBC demonstrated a PNH-like phenotype
manifested by reduced surface expression of CD55 and CD59. In both systems,
treated RBC underwent hemolysis about 40 min following interaction with acti-
vated C’. Hemolysis was preceded by an abrupt increase in ROS generation.
Inactivation of the C’, either by heat (56oC for 30 min) or by the addition of an
anti-C’ antibody, effectively reduced the ROS generation and hemolysis, indi-
cating both are mediated by active C’. Addition of FPP (20 mg/ml) during the
exposure to activated C’ significantly reduced ROS generation and hemolysis.
Summary/Conclusions: The present results suggest that oxidative stress, in
conjunction with activated C’, may be involved the underlying symptoms of PNH
and AIHA such as intra- and extra-vascular hemolysis. Currently, a humanized
monoclonal antibody that specifically targets the C’ protein C5 is the main treat-
ment modality for PNH and some other hemolytic anemias. The present results
raise the possibility that treatment with antioxidants might be considered as a
potential therapeutic modality for C’-mediated hemolytic anemias. Since FPP is
well tolerated and relatively inexpensive compared to the humanized anti-C’
monoclonal antibodies, its use may be considered as an alternative or an adju-
vant therapeutic modality in PNH and other C’-mediated hemolytic anemias.
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INEFFECTIVE ERYTHROPOESIS DUE TO AN ALPHA SPECTRIN GENE
DEFECT 
B Clark1,2,*, F Smith2, D Brawand2, P Rushton2, M Oakley2, D Rees1,3
1Dept Molecular Haematology, Kings College London, 2Molecular Pathology,
Viapath LLP at Kings College Hospital, 3Dept Haematological Medicine, Kings
College Hospital, London, United Kingdom
Background: Inherited red cell membrane disorders result from genetic
changes within membrane and cytoskeletal proteins. When altered these pro-
teins affect the deformability of the red cell and the stability of the membrane,
which affects red cell function and results in a reduced red cell life span. Hered-
itary spherocytosis and elliptocytosis are relatively common with 1 in 2000
North Europeans being affected. Specific alpha spectrin gene variants, such
as the low expression allele (LELY) have carrier frequencies of 20%, contribut-
ing to the high frequency that hereditary elliptocytosis is seen. The severity of
the haemolytic anaemia is variable with some individuals unaware they are
affected while others are lethal requiring in-utero transfusion for survival. We
have identified two cases of particular interest. Both have a have a thalas-
saemia like syndrome with marked ineffective erythropoiesis due to mutations
in the SPTA1 gene, coding for alpha spectrin. Case 1 presented with neonatal
anaemia and liver failure, and is transfusion dependent. Case two presented
with fetal anaemia and was treated with intrauterine transfusions; neonatally
case two presented with hepatitis, anaemia and relative reticulocytopenia, and
is also transfusion dependent.
Aims: To identify pathogenic variants in red cell membrane genes which
account for ineffective erythropoiesis observed in the two patients. 
Methods: Case 1 used whole exome sequencing of a nuclear family to identify
the causative mutation while targeted sequencing using a focused red cell
gene panel identified the pathogenic variant in the second case. Bespoke bioin-
formatics was used to analyse the data and call the variants.
Results: Case 1: Identified to be homozygous for the c. 7132C>T; p.Gln2378
* pathogenic variant in SPTA1 gene. Both parents were carriers and unaffected
which is consistent with a recessive inheritance model. Case2. Identified to be
homozygous for the c.2659C>T; p.Arg887* pathogenic variant in the SPTA1
gene. The individual was also homozygous for the SPTA1 c.[5572C>G; 6531-
12C>T]; p.Leu1858Val low expression allele (Alpha Spectrin LELY). The par-
ents were carriers of the pathogenic variant and also homozygous for the low
expression allele. They did not have a clinically significant condition. 
Summary/Conclusions: In both cases the affected individual was homozygous
for a truncating mutation within SPTA1. The individual in case 1 was also homozy-
gous for alpha spectin LELY and this may have contributed to the more severe
phenotype, requiring intrauterine transfusion. We suggest, due to this novel muta-
tion the red cells are too fragile to be released from the marrow, resulting in the
phenotype of ineffective erythropoiesis (low reticulocytes) rather than haemolytic
anemia, which is typically associated with alpha spectrin mutations.
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IRON DEFICIENCY PREVALENCE AND RISK FACTORS IN CHILDREN
YOUNGER THAN 6 YEARS-OLD IN FRANCE: A POPULATION-BASED
STUDY
AS Sacri1, S Hercberg2, A Bocquet3,4, I Vinatier5, C Levy6,7, B Blondel1,
C Vincelet8, P Hebel9, M de Montalembert1,10,*, L Gouya11, M Chalumeau1,10
1INSERM UMR 1153 Obstetrical, Perinatal and Pediatric Epidemiology
Research Team (EPOPé) Center for Epidemiology and Statistics Sorbonne
Paris Cité (CRESS) DHU Risks in Pregnancy Paris Descartes University,
2INSERM UMR 1153 Nutritional Epidemiolgy Research Team (EREN) Center
for Epidemiology and Statistics Sorbonne Paris Cité (CRESS) DHU Risks in
Pregnancy Paris Descartes University, 3Comité de Nutrition de la Société
Française de Pédiatrie, 4Association Française de Pédiatrie Ambulatoire
(AFPA), Paris, 5Laboratoires CERBA, Saint-Ouen l’Aumone, 6Association Clin-
ique et Thérapeutique Infantile du Val-de-Marne (ACTIV), Saint-Maur des fos-
sés, 7Université Paris Est, IMRB- GRC GEMINI, Créteil, 8Observatoire Région-
al de la Santé (ORS) Ile-de-France, 9Centre de Recherche pour l’Etude et
l’Observation des Conditions de vie (CREDOC), 10Service de Pédiatrie
générale, Hôpital Necker-Enfants malades, AP-HP, Université Paris Descartes,
Paris, 11Centre Français des Porphyries, Hôpital Louis Mourier, Assistance
Publique Hôpitaux de Paris, INSERM U1149, CNRS ERL 8252, Centre de
Recherche sur L’inflammation, Laboratoire d’excellence, GR-Ex, Université
Paris Diderot, Sorbonne Paris Cité, Colombes, France
Background: Iron deficiency (ID) is considered as the most frequent micronu-
trient deficiency in the world including in well-resourced countries. Iron deple-
tion, the first stage of ID, corresponds to a reduction of body iron stores and is
usually diagnosed by serum ferritin (SF) measurement. ID in early years is
associated with impaired neurodevelopment both at the short and long terms.
Several strategies have been proposed to prevent and/or to screen ID in chil-
dren. The effectiveness of these strategies can be evaluated by the prevalence
of ID. Estimated prevalences of ID in Europe are highly variable, probably
because population-based studies are lacking.
Aims: Our objectives were to estimate ID prevalence and to assess ID risk
factors among French children younger than 6 years-old in a population-based
study.
Methods: We conducted a secondary analysis on the biobank constituted dur-
ing the national survey “SaturnInf”, carried out by the InVS-French Institute for
Public Health Surveillance [Etchevers, 2014]. The Saturninf study recruited
3831 French children younger than 6 years-old between 2008 and 2009 accord-
ing to a two stages probability sample design. For the present ancillary study,
we measured SF (electro-chemiluminescence immunoassay) and CRP
(immunoturbidimetric assay) on the sera kept frozen at -80°C for children with
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the following criteria: parents’ written consent, sera aliquot in sufficient quantity,
lack of inflammatory syndrome (CRP<10 mg/l), and available socio-demograph-
ic data. ID was defined by a SF level<10 or<12 µg/l. Uni- and multivariate analy-
ses were performed to identify ID risk factors and correlations with SF.
Results: The 657 included children (17% of the children included in the Sat-
urninf study) had an average age of 3.1 years (SD 1.6), 58% were boys, 12%
had a mother born outside France, and 22% a family with a healthcare coverage
type linked to poverty (“CMU”). SF median was 45 µg/l (IQR: 29-75). ID preva-
lence was 3% (95%CI: 2-5) and 4% (95%CI: 3-6) for a SF threshold of 10 and
12 µg/l, respectively. At a 10 µg/l threshold, ID prevalence was higher (p<0.05)
when the mother was born outside France (8%) and when the healthcare
expenses were covered by CMU (7%). Significantly (p<0.05) lower SF levels
were observed among males (median 42 µg/l vs 52), when the mother was
born outside France (34 vs 46), was unemployed (38 vs 46) or had a low edu-
cational level (38 vs 47), when the father had a low educational level (38 vs 48)
and when the healthcare expenses of the family were covered by CMU (39 vs
47), but not (p>0.4) among youngest children (47 before 2 years-old, 41
between 2 and 3, 46 after 3 years-old) nor when the father was unemployed
(39 vs 47). After adjustment, a lower SF level was significantly (p<0.01) asso-
ciated with a male gender and a lower mother’s educational level.
Summary/Conclusions: In this first population-based study in France, ID
prevalence was much lower (3 to 4% depending on SF threshold) than preva-
lences retrieved in other French and European studies performed in precarious
populations but close to the lower values observed in other population-based
studies in Europe. Male gender and low mother’s educational level were inde-
pendent risk factors for ID, as in other studies. Further studies are needed to
explore the relation between this low ID prevalence and the national French
preventive strategy of ID in children that is mainly based on the recommendation
of a universal use of fortified cow’s milk formula between 1 and 3 years of age.
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IGG MEDIATED OPSONIZATION MECHANISM ACCORDING TO THE
UNDERLYING PROTEIN DEFICIENCY IN HEREDITARY SPHEROCYTOSIS:
TESTING A HYPOTHESIS
S Rocha1,*, E Cleto2, J Barbot2, F Ferreira3, A Quintanilha4, L Belo1, M Lima5,
E Bronze-da-Rocha1, A Santos-Silva1
1UCIBIO, REQUIMTE, Laboratório de Bioquímica, Departamento de Ciências
Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal,
2Sector de Hematologia Pediátrica, Centro Hospitalar do Porto - Hospital Santo
António, 3Serviço de Hematologia Clínica, Hospital São João, 4Instituto de
Ciências Biomédicas Abel Salazar, Universidade do Porto, 5Sector de Hema-
tologia, Centro Hospitalar do Porto - Hospital Santo António, Porto, Portugal
Background: Hereditary Spherocytosis (HS) is the most common non-immune
congenital hemolytic anemia in individuals of northern European ancestry, rang-
ing from an asymptomatic condition to a severe life-threatening anemia which
results from an erythrocyte membrane protein defect. Splenectomy corrects
anemia, though the intrinsic erythrocyte membrane defect persists. Reliene et
al. (1) proposed that the type of protein deficiency underlying HS determines
erythrocyte in vivo survival since, after splenectomy, the opsonization mecha-
nism mediated by IgG (which involves the binding of natural occurring antibod-
ies to erythrocyte membrane band 3) is distinct for spectrin/ankyrin- and band
3-deficient HS. 
Aims: Our study aimed to evaluate the levels of membrane bound IgG and
band 3 aggregates, according to the protein deficiency underlying HS, in order
to ascertain how our HS population fitted this hypothesis. 
Methods: We studied 35 healthy individuals and 125 HS patients [(82
unsplenectomized (unspl) and 43 splenectomized (spl)] previously studied for
membrane protein deficiency identification (2). Membrane bound IgG and the
high molecular weight aggregates (HMWAg) of band 3 (as percentage of total
band 3) were determined by western-blot. 
Results: We analyzed our data according to spectrin, ankyrin- and band 3-
deficient HS (Figure 1).
Figure 1.
Summary/Conclusions: For spl band 3-deficient HS, our results were in agree-
ment with the work from Reliene et al. (1), since IgG levels were increased, as
well as the amount of band 3 aggregates (to which IgG binds), in comparison
with either the control or ankyrin deficiency groups, confirming that in these indi-
viduals membrane loss through vesiculation does not include band 3 loss, leav-
ing these cells susceptible to IgG mediated opsonization. Since they found that
the amount of IgG was not increased in relation to controls, these same authors
(1) proposed that for spl spectrin- and ankyrin-deficient HS, the vesiculation of
the membrane leads to the loss of band 3 clusters and, consequently, less
opsonization occurred, thus explaining the higher deformability of these patients’
cells. Our results were slightly different because we analyzed spectrin- and
ankyrin-deficient HS separately. For spl ankyrin-deficient HS, our findings cor-
roborate those from Reliene et al. (1), as we found lower membrane bound IgG
and HMWAg than in band 3 deficiency, and no difference to the control group,
meaning that band 3 was lost through vesiculation (hypothesis that is strength-
ened by HMWAg in unspl ankyrin-deficient being lower than in band 3-deficient
HS). However, for spectrin-deficient HS, our results were comparable to those
found for band 3 deficiency. This might imply that in spectrin-deficient HS the
membrane structural modifications are such that membrane loss does not
include band 3, leaving these patients’ cells prone to increased IgG linkage. As
cell deformability has not been evaluated, we cannot say if the mechanism of
opsonization in spl spectrin-deficient HS is comparable to band 3-deficient or to
ankyrin-deficient HS, which is an issue that requires further studies.
Acknowledgments: This study was sponsored by a PhD grant (SFRH/BPD/
80023/2011) attributed to S. Rocha by FCT and FSE and with financial support
from FCT/MEC through national funds and co-financed by FEDER, under the
Partnership Agreement PT2020 in association with the reference UCIBIO
(UID/MULTI/04378/2013-POCI/01/0145/FERDER/007728).
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GROWTH DIFFERENTIATION FACTOR-15 IS ELEVATED IN PATIENTS WITH
COMPOUND HETEROZYGOUS SICKLE CELL AND BETA-THALASSEMIA
AND CORRELATES WITH HEMOLYSIS, ENDOTHELIAL DYSFUNCTION AND
ANGIOGENESIS
E Voskaridou1,*, K Larrisi2, E Terpos3, A Margeli2, D Christoulas4, M Dimopoulou1,
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Athens, School of Medicine, 4Hematology Department, 251 General AirForce
Hospital, 5Laboratory of Hematology and Blood Bank Unit, “Aretaieio” Hospital,
National and Kapodistrian University of Athens, School of Medicine, Athens,
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Background: The clinical manifestations of Sickle Cell Disease (SCD) include
episodes of vascular occlusion, chronic hemolytic anemia and frequent infec-
tions. SCD is also characterized by the presence of a chronic inflammatory
state manifested by leukocytosis and monocytosis and increased circulating
levels of pro-inflammatory cyto- and chemokines. Growth Differentiation Fac-
tor-15 (GDF-15), also known as macrophage inhibitory cytokine 1 (MIC-1) and
non-steroidal anti-inflammatory drug-activated gene (NAG-1) is a member of
the transforming growth factor- superfamily. Expression of the GDF-15 gene
in cardiomyocytes, vascular smooth muscle cells, and endothelial cells is
strongly upregulated in response to oxidative stress, inflammation and tissue
injury. Increased GDF-15 concentrations have been associated with an adverse
prognosis in patients with acute coronary syndromes and chronic heart failure.
Aims: The aim of this study was to evaluate the GDF-15 levels in patients with
compound heterozygous SCD and beta-thalassemia (HbS/βthal) and to explore
possible associations with disease features, such as hemolysis, inflammation,
endothelial dysfunction and angiogenesis.
Methods: Seventy-five adult Caucasian patients with HbS/bthal were included
in the study, while 20 healthy individuals served as controls. Patients with
HbS/βthal divided in two groups: group A included 36 patients under hydroxy-
carbamide (HC+) treatment and group B included 39 patients without hydrox-
ycarbamide (HC-) treatment. Along with hematology and blood chemistry
parameters determination, measurements of circulating levels of GDF-15, hs-
CRP, vWF-antigen, hs-TnT and Placental Growth Factor (PlGF) were measured
in patients with HbS/βthal and controls using immunoenzymatic techniques.
Results: The main results of the study showed that: GDF-15 were elevated in
patients with HbS/βthal compared to controls (1,980.7±159.8 vs 665.4±50.9
pg/mL, p<0.0001). Regarding hydroxycarbamide treatment, GDF-15 levels
were elevated in (HC+) patients compared to (HC-) patients (2,478±222.6 vs
1,520±204.7 pg/mL, p=0.002), or 30/36 vs 21/39 patients with elevated GDF-
15 levels (c2=0.002). GDF-15 levels correlated significantly with markers of
erythropoiesis, such as Hb, HbF, ferritin and reticulocytes (r=-0.424, p<0.01;
r=0.562, p<0.001; r=0.423, p<0.001 and r=0.510, p<0.001, respectively), with
markers of hemolysis, such as LDH and uric acid (r=0.412, p<0.001 and
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r=0.321, p=0.005, respectively), and with markers of endothelial dysfunction
and angiogenesis such as vWF-antigen and PlGF (r=0.238, p<0.05 and
r=0.461, p<0.001, respectively). Surprisingly, no correlation was found between
GDF-15 and hs-CRP levels (p>0.65).
Summary/Conclusions: These findings suggest a multifactorial role of GDF-
15 in patients with HbS/βthal as it correlates with hemolysis, endothelial dys-
function and angiogenesis. The higher GDF-15 levels measured in patients
treated with hydroxycarbamide may reflect a possible drug reaction. More stud-
ies are needed to clarify the exact role of GDF-15 in HbS/βthal.
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MOLECULAR CHARACTERISATION OF 85 INDIVIDUALS WITH PYRUVATE
KINASE DEFICIENCY
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logical Medicine, King’s College Hospital, 4Molecular Haematology, Division
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Background: Pyruvate kinase (PK) deficiency is the most common glycolytic
cause of non-spherocytic haemolytic anaemia. It is inherited as an autosomal
recessive condition with 50 individuals per million being affected in the Cau-
casian population. The PKLR gene codes for Pyruvate Kinase, a red cell spe-
cific isoenzyme that converts phosphoenolpyruvate to pyruvate which releases
ATP. ATP is essential for red cell function and without it the half-life of the red
cell is reduced, being cleared by the spleen and liver. There are 200 known
mutations which can cause PK deficiency, which is diagnosed using an enzyme
assay. KLF1 is a transcription factor known to bind to the promoter of the PKLR
gene and drives expression. Variants in the KLF1 gene have previously been
shown to produce a PK deficient phenotype.
Aims: We screened for genetic variants in individuals with PK enzyme activi-
ty<11 IU/g Hb to determine if a genetic cause could be identified in every case.
Methods: Individuals with reduced PK enzyme activity underwent PKLR gene
sequencing. Cases without an affected genotype were screened for indels in
the PKLR gene followed by sequencing of the KLF1 gene.
Results: Of the 85 cases, 21 were identified with genotypes consistent with PK
deficiency with 27 cases left having identified only a single pathogenic variant.
35 Cases were left without a pathogenic variant (although 38% of samples were
heterozygous for the c.-248delT polymorphism), all falling within the range of 8-
11 IU/g Hb. This is consistent with other labs that use lower normal range. The
sequencing analysis identified ten variants not previously described (c.319 A>G,
c.508-57 G>A, c.508-2 A>G, c.602 G>T, c.627 G>C, c.822 C>G, c.959 T>C,
c.965+2 T>C, c.1063 A>G, c.1299 C>A) of which seven are likely to be highly
pathogenic. One individual had a deletion encompassing exon 11 in combination
with a missense variant. One unknown variant (c.881 C>A) was identified in the
KLF1 gene and in silico tools predicted this to be damaging. There were no
PKLR variants found in this patient, yet they had a PK activity of 3.5 IU/g Hb.
Summary/Conclusions: Genetic investigations into the PKLR gene is not
diagnostically informative in individuals with a PK enzyme activity of >8 IU/g
Hb. Of the 39 individuals with an enzyme activity of<8 IU/g Hb, 46% had two
affected alleles, 44% had one affected allele, and in 10% of the cases no path-
ogenic variants were identified. The enzyme activity range of the 10% group
(n=3) was 7-7.9 IU/g Hb excluding the individual with a variant in KLF1. This
indicates that the more severe the PK enzyme deficiency the more likely the
assay is to identify a genetic cause. In those cases with a genetic cause most
are non-synonymous base changes probably resulting in protein instability.
Two splice site variants were identified affecting the core consensus motif and
also a single case with a deletion, all predicted to be severe alleles. It is
unknown if the KLF1 gene variant is influencing PKLR gene expression, and
further work is necessary to understand this.
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STRUCTURAL HAEMOGLOBINOPATHY CARRIERS CAN BE IDENTIFIED
BY LABORATORY PARAMETERS PROVIDED BY ADVIA 2120 ANALYSER
D Velasco-Rodríguez1,*, JM Alonso-Domínguez2, FA González-Fernández3,
A Muriel4, L Abalo5, M Sopeña5, J Villarrubia1, M Tenorio1, P Ropero-Gradilla3,
F de la Fuente-Gonzalo3, J Martínez-Nieto3, A Jiménez-Martín1, G Moreno1,
FJ López-Jiménez1, F Cava5
1Hematology, Hospital Ramón y Cajal, 2Hematology, Fundación Jiménez Díaz,
3Hematology, Hospital Clínico San Carlos, 4Statistics, Hospital Ramón y Cajal,
5Hematology, Laboratorio Central de la Comunidad de Madrid BR Salud,
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Background: Hemoglobinopathies have spread owing to human migrations,
and the number of people needing diagnosis and management of these con-
ditions is increasing. More than 1500 variant Hb have been described to date.
In more than 95% of variant Hb, the structural alteration is a point mutation
that produces a single amino acid substitution in a globin chain. Carriers are
asymptomatic, and clinicians need to accurately identify them and provide ade-
quate genetic counselling to them in order to prevent the occurrence of homozy-
gous or compound heterozygous offspring.
Aims: The aim of our study was to identify red blood cell (RBC) laboratory
parameters that discriminate between structural hemoglobinopathy carriers
and healthy subjects
Methods: Samples of 500 variant Hb carriers (355 HbAS, 104 HbAC, 19 HbAD,
7 HbAE, 7 HbAO-Arab, 4 alpha-chain variants and 4 Hb Lepore) and 251 nor-
mal controls were run on an Advia 2120 analyser (Siemens Medical Solutions
Diagnostics, Tarrytown, New York, USA). Hb variants were detected by HPLC
in the HA-8160 analyzer (Menarini Diagnostics, Florence, Italy) and further
characterised according to their alkaline and acid electrophoretic pattern using
cellulose acetate electrophoresis. Classic hematological parameters and RBC
populations of the complete blood count (CBC) were assessed in all subjects.
A multivariable binary logistic regression model was created to predict the prob-
ability of a subject carrying any structural hemoglobinopathy.
Results: Variant Hb carriers presented significantly higher RBC count
(4.96×1012/L vs 4.84×1012/L, p=0.031), lower MCV (85.39 fL vs 92.81 fL,
p<0.001), lower MCH (28.97 pg vs 30.18 pg, p<0.001), higher MCHC (34.29
g/dL vs 32.71 g/dL, p<0.001), higher RDW (14.10% vs 12.94%, p<0.001), low-
er%MACRO (0.67% vs 1.63%, p<0.001), higher%MICRO (2.31% vs 0.42%,
p<0.001), higher%HYPER (1.99% vs 0.45%, p<0.001), lower%HYPO (1.51%
vs 2.47%, p<0.001) and higher M/H (9.31% vs 0.67%, p<0.001). A clinical pre-
diction rule was developed by assigning one point to each of the most efficient
variables: mean corpuscular volume (MCV)<88.4 fL, RBC distribution width
>13.4%, percentage of microcytic RBCs (%MICRO) >0.7% and the ratio of
microcytic RBCs to hypochromic RBCs >0.8. A score of 0, 1, 2, 3 or 4, resulted
in a probability of 9.6%, 36.3%, 66.7%, 85.2% or 98.3%, respectively.
Summary/Conclusions: Although molecular analysis (gold standard) or anoth-
er laboratory technique such as electrophoresis and/or HPLC is mandatory for
the diagnosis of structural hemoglobinopathies, a CBC is a quick, cheap and
handy test that provides useful information for a presumptive diagnosis of these
entities. RBCs of variant Hb carriers are smaller, denser and show a higher
degree of anisocytosis in comparison to RBcs of normal controls. Structural
hemoglobinopathy investigation should be performed if a score of 3 or 4 is
seen in subjects belonging to ethnic groups with a high prevalence of variant
Hb. Our model is not structured as a complex mathematical formula, and in
our opinion, this facilitates its clinical use. Although differences in haematolog-
ical parameters have been reported by many authors, none evaluated the value
of the CBC as a screening tool to identify variant Hb carriers.
E1473
HEMOGLOBINOPATHIES WITH LEVELS HBA2 DECREASED. DELTA
GENE MUTATIONS FOUND IN A SPANISH CENTER
P Ropero*, FA González, JM Nieto, F de la Fuente-Gonzalo, M Guijorro,
A Villegas, R Martínez
Hematology, Hospital Clínico San Carlos, Madrid, Spain
Background: HbA2 reaches its final value (2.5% -3.5%) in the first year of life.
Due to this low expression and the lack of significant pathology, HbA2 is not
considered relevant, but mutations in the δ gene can cause δ-thalassemia and
Hb variants of δ chain are interesting because they interfere in HbA2 quantifi-
cation. HbA2 consists of chains of α globin and δ; therefore, alterations in any
of these genes may influence HbA2 levels.
Aims: We present structural hemoglobinopathies and thalassemias that pres-
ent with decreased levels of HbA2, as well as the first compilation of mutations
in the gene δ globin, found in Spain.
Methods: The 208 patients that were analyzed presented HbA2 values below
2.5% and microcytic and hypochromic or normocytic and normochromic without
iron deficiency anemia. HbA2 and HbF levels, as well as the different hemo-
globins, were measured and analyzed by ion-exchange HPLC (VARIANTTM
II). Hemoglobins were studied by capillary zone electrophoresis (CE) (Sebia)
and globin chains by reverse-phase HPLC. Genetic analysis of the α and δ
genes was carried out by automatic sequencing and, in the case of α genes,
by multiplex PCR.
Results: In α-thalassemia (n=94), HbA2 levels ranged from 1.39 to 2.43%; in
δ-thalassemia (n=5), HbA2 levels researched in δ+-thalassemia 1.77% and for
δ0-thalassemiain 1.70%; in δβ-thalassemia (n=13), homozygosity resulted in
undetectable HbA2 levels. Structural hemoglobinopathies (n=96), all heterozy-
gous, in the α chain (n=84) and δ chain (n=12) had HbA2 rates of 1.76% and
1.75%, respectively. 
Summary/Conclusions: 208 samples, with HbA2<2.5%, showed α gene or δ
globin anomalies of quantitative (thalassemia) or qualitative (structural hemo-
globinopathies). In the α-thalassemia, the greatest loss of genes corresponds
to the lowest levels of HbA2, since α genes are preferably combined to form
the β HbA. The heterozygous δ +-thalassemia had higher levels than δ0-tha-
lassemia. It should be suspected of a δ-thalassemia when, in normal and with-
out iron deficiency, HbA2 levels are lower than the 2%., in these cases the
direct sequencing of the gene δ, it will reveal a point mutation in homozygous
or heterozygous state. In the δβ-thalassemia, homozygosity no levels of HbA2.
The decrease in levels of HbA2 in α chain hemoglobinopathies is owing to a
new α globin chain (αX) because its variant corresponding HbA2 (α2Xδ2) is
formed. The greater decrease corresponds to homozygosity, because there is
less αA globin chain synthesis, regardless of the mutated gene (α1 or α2). In
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this work we have identified five variants of δ chain because they are relatively
common and generally easy to detect not only because halved the HbA2 value,
but because they often show a second fraction of HbA2 almost the same
expression, whether prior or after normal HbA2. The variant HbA2-Madrid was
first described in the literature. HbA2 is an essential parameter in the differential
diagnosis of thalassemia. Using the HPLC and EC provide not only the quan-
tification of HbA2 but also information other hemoglobins, so the same analysis
helps identify hemoglobin variants of either strand and detect thalassemias not
otherwise It has been possible diagnosis, avoiding that risk couples may be
advised incorrectly.
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ACTIVIN B PRODUCED BY SINUSOIDAL ENDOTHELIAL/KUPFFER CELLS
IN RESPONSE TO INFLAMMATORY STIMULI INDUCES HEPCIDIN
EXPRESSION THROUGH UNCANONICAL SIGNALING IN HEPATOCYTES
Y Kanamori1,*, M Sugiyama2, O Hashimoto3, M Murakami4, T Matsui1, M Funaba1
1Division of Applied Biosciences, Graduate School of Agriculture, Kyoto Uni-
versity, Kyoto, 2Laboratory of Veterinary Anatomy, 3Laboratory of Experimental
Animal Science, Kitasato University School of Veterinary Medicine, Towada,
4Laboratory of Molecular Biology, Azabu University School of Veterinary Med-
icine, Sagamihara, Japan
Background: Hepcidin, a liver-derived peptide hormone, is involved in the
pathogenesis of anemia under inflammation. Activins and BMPs bind to corre-
sponding type I and type II receptors and phosphorylate Smad2/3 and
Smad1/5/8, respectively, as canonical signaling pathway. BMPs are well known
to up-regulate hepcidin expression through the canonical signaling pathway
when hepatocytes accumulate excess iron. On the other hand, activin B is sug-
gested as a key molecule responsible for the up-regulation of hepcidin in inflam-
mation based on the following two evidences: (1) the elevation of activin B
mRNA level in the livers of LPS-injected mice, and (2) the stimulation of hepcidin
expression by activin B in hepatocytes. Furthermore, activin B has been shown
to activate uncanonical Smad1/5/8 signaling as well as canonical Smad2/3 sig-
naling in hepatocytes. 
Aims: We examine the following three points in the present study: (1) which
cell-types in the liver are responsible for the up-regulation of activin B by inflam-
matory stimuli, (2) which receptor combination is responsible for the induction
of Smad1/5/8 phosphorylation and hepcidin expression by activin B, and (3)
whether activin B induces uncanonical Smad1/5/8 signaling in extrahepatic cells.
Methods: A male Sprague-Dawley rat was intraperitoneally injected with LPS
(5 mg/kg). After 2.5 h of injection, hepatocytes and non-parenchymal cells were
collected from the liver by collagenase-perfusion. Sinusoidal endothelial and
Kupffer cell-rich fraction was isolated from non-parenchymal cells by a two-
step density gradient centrifugation. The expression of activin B was measured
by RT-qPCR. Rat primary hepatocytes, HepG2 human hepatoma cells, C2C12
myoblasts, 3T3-L1 pre-adipocytes, and RAW264.7 murine macrophage-like
cells were stimulated with 2 nM of activin B. Phosphorylation of Smad1/5/8 and
mRNA level of hepcidin or Id1 were examined. HepG2 cells were transfected
with siRNAs of type I or type II receptors and luciferase reporter of murine hep-
cidin promoter. After transfection, cells were treated with activin B. Transcrip-
tional activity of hepcidin was assayed.
Results: Significant expression of activin B was detected in sinusoidal endothe-
lial and Kupffer cell-enriched fraction isolated from the liver of a rat injected
with LPS, while expression of activin B in hepatocyte-enriched fraction was
almost negligible, suggesting that sinusoidal endothelial cells or Kupffer cells
are the major sources of hepatic activin B under inflammation. Knockdown of
the BMP type I receptor, ALK2 or ALK3, indicated that ALK2, but not ALK3, is
involved in the responsiveness of the hepcidin promoter to activin B through
the activation of Smad1/5/8 signaling in HepG2 cells. Knockdown of the type II
receptor ActRIIA inhibited activin B-mediated Smad1/5/8 phosphorylation and
hepcidin transcription. These results suggest that upon the binding of activin
B, the receptor complex, ALK2 and ActRIIA, stimulates Smad1/5/8 signaling,
followed by induction of hepcidin. Unexpectedly, the induction of Smad1/5/8
phosphorylation and hepcidin expression by activin B was resistant to LDN-
193189, an inhibitor of ALK2 and ALK3, whereas those actions of BMP2 was
sensitive to the inhibitor. These results implicate that unknown mechanisms
distinct from BMP signaling are involved in the modulation of Smad1/5/8 sig-
naling by activin B. We also showed that activin B increased phosphorylation
of Smad1/5/8 and mRNA level of Id1, a representative BMP response gene, in
C2C12 cells, 3T3-L1 cells and RAW264.7 cells, implicating that activin B-
induced uncanonical Smad1/5/8 signaling is independent of cell-type. 
Summary/Conclusion: Upon inflammatory stimuli, sinusoidal endothelial cells
and/or Kupffer cells up-regulate activin B expression in the liver, followed by
induction of Smad1/5/8 phosphorylation and hepcidin expression in hepatocytes
via the receptor complex of ALK2 and ActRIIA. In addition, activin B-induced
Smad1/5/8 signaling is not limited to hepatocytes. The present study provide
novel insights into the molecular mechanisms underlying induction of hepcidin
by inflammation and the possible roles of activin B-mediated Smad1/5/8 sig-
naling in several tissues.
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TREATMENT WITH CYCLOSPORIN IN AUTO-IMMUNE CYTOPENIAS IN
CHILDREN: THE EXPERIENCE FROM THE FRENCH COHORT OBS’
CEREVANCE
M Penel Page1, Y Bertrand2, D Kherfellah3, H Fernandes3, Y Perel3,
G Leverger4, G Michel5, N Sirvent6, T Leblanc7, N Aladjidi3,*
1Pediatrics, Institut d’Hematologie et d’Oncologie Pédiatrique, 2Pediatrics, Insti-
tut d’Hématologie et d’Oncologie Pédiatrique, Lyon, 3Pediatrics, Universitary
Hospital, Bordeaux, 4Pediatrics, Trousseau Hospital, Paris, 5Pediatrics, Timone
Hospital, Marseille, 6Pediatrics, Universitary Hospital, Montpellier, 7Pediatrics,
Robert Debré Hospital, Paris, France
Background: Auto-immune cytopenias are rare in children, and there is no rec-
ommendation about treatments in case of resistance or dependence to steroids.
Aims: Since 2004, the cohort OBS’CEREVANCE has been recording the cases
of auto-immune cytopenias in children treated in the 30 French pediatric hema-
tology units. This study reports the treatment with cyclosporin for all the patients
of the cohort treated with cyclosporin for auto-immune hemolytic anemia (AIHA),
Immune throbopenic Purpura (ITP) and Evans Syndrome (ES).
Methods: We analyzed the data of 15 AIHA, 7 ITP and 12 ES. Median age
was 4.5 years for AIHA and ES, 7.2 for ITP. Ten patients had underlying immun-
odeficiency and 5 had auto-immune disease.
Results: The best response was a complete remission (CR) for 7 AIHA, 1 ITP
and 6 ES, maintained in median 8.6 months for AIHA and 25.5 months for ES.
The treatment allowed steroids decrease in 9 cases of AIHA and 9 ES. Three
patients treated for AIHA maintained CR after discontinuation of treatment,
whereas all the patients with ES relapsed during or after treatment. Toxicity
was acceptable. Median residual level was 96.5 mg/L (31-369) for patients
achieving CR or PR and 117 mg/L (23-956) for patients with no response.
Table 1.
Summary/Conclusions: Given our results, we propose to use cyclosporin for
AIHA (excluding in context of immunodeficiency) and ES, after failure of corti-
costeroids, or in case of dependence to steroids. We propose to base the pre-
scription on aplastic anemia treatment recommendations with a blood level
residual target between 50 and 100 mg/L: treatment at least three months
before concluding to failure, treatment at least a year at full dose in case of
response, very slow decrease over several months, return to previous dose in
case of relapse during the decrease, or to full doses in case of relapse at treat-
ment discontinuation, monitoring of residuel level, in case of success (CR), tox-
icity or failure.
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INTERNATIONAL SENTINEL SITE SURVEILLANCE OF PATIENTS WITH
TRANSFUSIONAL HEMOSIDEROSIS TREATED WITH DEFERASIROX IN
ACTUAL PRACTICE SETTING
A El-Beshlawy1,*, B Inusa2, D Beneitez3, B Xicoy4, M Soledad Duran Nieto5, A
Vorog6, A Azmon7, G Gilotti6, M Elalfy8
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Thomas’ Hospital NHS Trust, London, United Kingdom, 3Hospital Universitari
Vall d’Hebron Hematology Department, 4ICO-Badalona-Hospital Germans Trias
i Pujol, Josep Carreras Leukemia Research Institute, Barcelona, 5Hospital
Materno Infantil de Jaen, Departamento de Hematologíca, Jaen, Spain, 6Novar-
tis Pharmaceuticals Corporation, East Hanover, New Jersey, United States,
7Novartis Pharma AG, Basel, Switzerland, 8Ain Shams University, Cairo, Egypt
Background: Long-term iron chelation therapy (ICT) is required in regularly
transfused patients (pts) to reduce the chronic iron overload (IOL) which is a
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major complication causing morbidity and mortality. The oral iron chelator
deferasirox (DFX) is indicated for the treatment of chronic IOL due to blood
transfusions in adult and pediatric pts aged ≥2 years (yrs). Multiple clinical
studies have established the efficacy and safety of DFX in transfusion-depen-
dent pts with IOL. The present study reports the results of a postmarketing
active surveillance program for DFX.
Aims: To evaluate the long-term safety and clinical management of DFX in adult and
pediatric pts aged ≥2 yrs with chronic transfusional IOL in the actual practice setting.
Methods: Pts aged ≥2 yrs treated with DFX for transfusional hemosiderosis
according to the local prescription information were enrolled in this non-inter-
ventional study. Data were collected for 3 yrs from initiation of treatment with
DFX, and retrospective data were collected in pts who had treatment with DFX
for up to 1 yr prior enrollment. The primary endpoints were as follows: (a) the
proportion of pts with at least 1 notable increase in serum creatinine (SrCr),
defined as >33% above baseline (BL) and the age adjusted upper limit of nor-
mal (ULN) in at least 2 consecutive measurements (≥7 days apart), and (b)
notable increase in alanine aminotransferase (ALT), defined as >5×ULN in at
least 2 consecutive measurements (≥7 days apart).
Results: Of the 120 pts enrolled, majority were diagnosed with β thalassemia
(n=49), sickle cell disease (SCD, n=31), and myelodysplastic syndrome (MDS,
n=21) (Table 1). The mean age (±SD) was 7.5±4.2 yrs in pts with<18 yrs (n=69)
and 57.9±22.1 yrs in pts with ≥18 yrs (n=51) of age. Median duration of DFX
exposure was 29.9 months and average actual dose was 23.2±8.2 mg/kg/d. 
Overall, 42.5% (<18 yrs, n=45; ≥18 yrs, n=6) of pts completed the study. The
most common reasons for study discontinuation (>10%) were subjects who no
longer required study drug (19.2%), adverse events (AEs, 12.5%), and consent
withdrawal (10.8%). Dose reductions and interruptions occurred in 39.3% and
23.9% of pts, respectively. Of the 46 pts who had dose reductions, 5 pts report-
ed increase in SrCr (n=3) and ALT (n=2). Of the 28 pts who had dose interrup-
tions, 3 pts reported increase in SrCr (n=2) and ALT (n=1). Notable increase in
SrCr was observed in 12% (14 of 117; 95% CI, 7.1-19.2) of pts with MDS (n=3),
SCD (n=7) and other anemias (n=4). Notable increase in ALT was observed in
1 pt (0.9%; 95% CI, 0.0-5.2) with β thalassemia (BL ALT missing). Overall,
34.2% (40 of 117) of pts had AEs suspected to be related to DFX, including
AEs (>5%) such as diarrhea (9.4%), increase in SrCr (7.7%), and vomiting
(6.0%). A total of 4.3% (5 of 117) of pts had serious AEs (SAEs), suspected to
be related to DFX, and SAE >1% was gastrointestinal hemorrhage (1.7%).
The AEs leading to the discontinuation of DFX occurred in 18.8% of pts (MDS,
n=11; β-thalassemia, n=2; SCD, n=2; other anemias, n=7) regardless of the
relationship with DFX, including AEs (>2%) such as increase in SrCr (3.4%)
and diarrhea (2.6%). None of the pts discontinued DFX due to the increase in
ALT. Eight (6.8%; MDS, n=4, other anemias, n=4) on-treatment deaths were
reported, all in pts ≥18 yrs of age, majorly due to gastrointestinal disorders
(n=2) and neoplasms (n=2). Of these 8 deaths, 7 were not suspected to be
related to DFX (data unknown, n=1).
Table 1.
Summary/Conclusions: The results demonstrated a safety profile for DFX
which is consistent with previously published data. The data demonstrates that
changes in SrCr can be managed with dose adjustments or interruptions and
occasionally led to permanent discontinuation. DFX has been associated with
rare hepatic toxicity. Only 1 pt had a notable increase in ALT. The overall inci-
dence of AEs that lead to DFX discontinuation was higher in pts with MDS dur-
ing the study.
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EVALUATION OF THE FOOD INTAKE, NUTRITIONAL STATUS AND NUTRITIONAL
DEFICIENCY IN CHILDREN WITH SICKLE CELL DISEASE: PRELIMINARY
RESULTS OF A CROSS - SECTIONAL STUDY
F Menzato1,*, F Piras2, A Battistin2, G Verlato2, M Montanaro1, S Zaccaria1,
C Marin1, G Basso1, R Colombatti1, L Sainati1
1Clinic of Pediatric Hematology-Oncology, 2Dietetics and Clinical Nutrition, Uni-
versità degli Studi di Padova, Padova, Italy
Background: Children with Sickle Cell Disease (SCD) have poor growth com-
pared to their peers; they also present a higher percentage of cognitive impair-
ment compared to age matched controls. Clinical practice shows that the pres-
ence of nutritional deficiencies with important clinical implications (anemia,
abnormal bone metabolism..) is frequent in these patients and that it can have
an adverse impact on disease severity. Currently there are no European studies
that correlate specific nutritional deficiency to the nutritional intake; demonstrat-
ing the correlation between reduced or inappropriate dietary intake and selective
nutritional deficiencies could lead to targeted nutritional interventions aimed at
improving the nutritional status and the altered hematological parameters.
Aims: 1) To identify any nutritional deficiencies in patients with SCD and correct
them promptly. 2) To identify, if possible, the correlations between nutritional
status, dietary intakes and deficiency states, and between states of deficiency
and clinical expression of the disease, including patient’s performance
assessed through ad hoc questionnaires.
Methods: Children with SCD of the clinic of Pediatric Hematology-Oncology
in Padua were included in this prospective study. An ad hoc questionnaire (on
food frequency, quantity and eating habits) was administered; the data were
processed with GEDIP 4 software to derive the minimum, average amounts,
maximum and standard deviations of various nutrients and to compare them
with the recommended requirements in the Recommended intake levels
(RDAs, 2014 edition). Nutritional status was assessed by weight, height, Body
Mass Index and arm circumference that were used for drawing the percentiles
using CDC growth curves. The following hematochemical parameters were
evaluated at Time 0: Complete Blood Count, PTH, Vitamins A, D, E, ferritin,
serum iron, zinc, copper, calcium, phosphate, folic acid, methylmalonic acid,
homocysteine, blood gas analysis. These parameters will be re-assessed at
Time 1 (6 months) and 2 (12 months) to evaluate the effectiveness of any addi-
tional therapy.
Results: 72 consecutive pediatric patients with SCD were included in our study
(SS 62/72, 8/72 SC, 2/72 Sß), 31 F and 41 M, mean age 9.6 years (range: 8
months-23 years), from 1st March 2015 to 31st August 2015. The main nutri-
tional deficiencies were: folic acid (9/72); Vitamin D (62/72) correlated with
increased PTH (27/72); Vitamin A (43/72); Vitamin E (0/72); serum iron (23/72);
zinc (18/72). In some cases high levels of methylmalonic acid (10/72) and
homocysteine  (4/71) have been reported, showing lack of Vitamin B12. The
following supplementations were given: folic acid (55/72), vitamin D (57/72),
iron (15/72), zinc (1/72); in the remaining cases with slight deficits were provided
appropriate dietary advices. At the moment 37/72 patients underwent the nutri-
tional assessment questionnaire, which shows a nutritional intake of 69% of
energy intake established by the RDAs, and values between 25° and 50°P for
weight, height, BMI and arm circumference for age. Their protein intake is on
average 150% from the RDAs, while recording contributions of about 50% for
calcium, iron and folic acid and 8% for Vitamin D. Even if most of the patients
are African first generation immigrants with a specific but balanced dietary
habits; a significant part of them belongs to low-income families and feeds with
“junk food”, which could be the cause of their nutritional deficits.
Summary/Conclusions: Preliminary data of our study does not show an ade-
quate intake of macro and micro nutrients for SCD children; calcium, iron, folic
acid and especially Vitamin D are the most deficient nutrients and determine
suboptimal growth state. The continuation of the study, with a larger number of
subjects, will help us to highlight the possible correlation of nutritional status
with the progress and severity of the disease.
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CLINICAL SAFETY AND EFFICACY OF FERRIC CARBOXYMALTOSE IN
THE TREATMENT OF IRON DEFICIENCY: META-ANALYSIS EVALUATING
INDIVIDUAL PATIENT DATA OF 18 RANDOMIZED TRIALS
Y Beguin1,*, A de Francisco2, H Brunner-La Rocca3, B Roubert4, L Southall4
1Department of Hematology, University Hospital of Liège, Liège, Belgium, 2Dial-
ysis Unit and Nephrology Section, Hospital Universitario Valdecilla, Santander,
Spain, 3Department of Cardiology, Maastricht University, Maastricht, Nether-
lands, 4Vifor Pharma Ltd., Glattbrugg, Switzerland
Background: Iron deficiency and iron deficiency anemia are highly prevalent
in both industrialized and developing countries. Patients and special popula-
tions with a wide variety of underlying conditions are affected and may experi-
ence debilitating symptoms. Intravenous iron therapy is indicated when oral
iron supplementation is not tolerated or iron absorption is ineffective. Ferric
carboxymaltose (FCM) is an intravenous iron formulation for administration of
single doses up to 1000 mg iron during a short administration time (≥15 min-
utes).
Aims: The aim of this analysis was to describe the safety and efficacy of FCM
across studies with different patient populations.
Methods: Individual patient data collected at European trial sites of 18 ran-
domized controlled clinical trials performed by Vifor Pharma were analyzed.
Study populations included patients with chronic kidney disease, inflammatory
bowel disease, chronic heart failure, cancer, and women of childbearing age.
FCM treated patients were compared to a pooled comparator group, including
other intravenous iron formulations, oral iron, placebo or standard medical
care. All treatment emergent adverse events (TEAEs) and related TEAEs were
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investigated, with focus on special adverse events of interest, including changes
in serum phosphorus levels. Furthermore, therapeutic efficacy parameters
(hemoglobin, ferritin and transferrin saturation) were analyzed over time.
Changes from baseline in laboratory parameters are statistically presented as
least-squares means (LS means) and standard errors (SE).
Results: Data from 3,331 patients with iron deficiency were analyzed. Of these,
1,969 patients had received FCM. The mean cumulative dose of FCM over the
first 6 weeks was 1,124±417 mg iron, with single doses of 1,000 mg iron in
36% of the patients. Overall, the most frequent related TEAEs in the FCM group
were serum ferritin increased (1.4%), headache (1.4%), and nausea (1.0%). In
the pooled comparator group, the most frequent related TEAEs were constipa-
tion (2.5%), diarrhea (1.8%) and nausea (1.0%). Among patients with available
serum phosphorus values over time (FCM n=1,370; comparator n=1,194),
27.4% of subjects in the FCM group and 2.0% in the comparator group had a
value below 2.0 mg/dL at any time during the first 8 weeks of follow-up. Signs
and symptoms that could possibly be related to transient decrease in phosphate
level (using the broad SMQ-definition) were reported in 9.6% of FCM-treated
subjects and in 11.3% in the comparator group. In the FCM group, hemoglobin
steadily increased from the first post-treatment assessment at week 1 or 2
(n=1,404; mean changes from baseline: 0.411 [0.098] g/dL) to week 4 (n=1,619;
1.176 [0.168] g/dL) and week 8 (n=1,398; 1.466 [0.190] g/dL). Ferritin and
transferrin saturation were significantly increased in the FCM group compared
with comparator pool, at all time points (p<.0001; week 1 or 2, 4, 8), and
remained stable throughout the 8-week period (mean change from baseline at
week 8: +227.7 [53.7] vs 105.7 [53.8] ng/mL and +13.4 [1.2] vs 8.5 [1.2]%,
respectively; p<.0001), reflecting repletion of iron stores.
Table 1.
Summary/Conclusions: This large-scale analysis is based on individual
patient data and includes a broad variety of different patient populations. The
results confirm that FCM is effective and has a similar tolerability to the pooled
comparator. FCM causes a transient decrease in phosphate levels but this
does not appear to increase the reported frequency of associated signs and
symptoms. 
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CHANGES IN GAMMA GLOBIN MRNA LEVELS DO NOT CORRELATE
WITH TOTAL HEMOGLOBIN OR FETAL HEMOGLOBIN LEVELS IN BETA
THALASSEMIA INTERMEDIA PATIENTS ON HYDROXYUREA
GK Viswanathan1,*, A Aggarwal1, P Sharma1, S Chhabra1, J Kaur Hira1,
A Trehan2, P Malhotra3, R Das1
1Hematology, 2Pediatrics, 3Internal Medicine, Postgraduate Institute of Medical
Education and Research, Chandigarh, India
Background: Hydroxyurea is a hemoglobin-F inducing drug used to increase
hemoglobin levels in sickle cell disease and β-thalassemia intermedia. The
response to hydroxyurea is variable among individuals and its mechanism of
action is less well understood. This prospective study on β-thalassemia intermedia
patients aimed at analysing the effects of hydroxyurea on γ-globin mRNA levels
and correlate its dynamics with changes in total hemoglobin and fetal hemoglobin
levels to better understand its mechanism of action. The underlying β thalassemia
mutations, α thalassemia deletions and Xmn-1Gγ (C-T) polymorphism were char-
acterised and correlated with changes in γ-globin mRNA levels.
Aims: To study the changes in γ-globin mRNA levels in β-thalassemia inter-
media patients on hydroxyurea compared to baseline levels and correlate them
with changes in total hemoglobin and fetal hemoglobin levels.
Methods: Eleven newly diagnosed individuals with β-thalassemia intermedia
were included in the study. Changes in γ-globin mRNA levels were compared
at baseline and after 6 months of hydroxyurea therapy. These were correlated
with changes in hemoglobin, hemoglobin-F, hemoglobin-A2 levels and red cell
parameters. The quantitation of γ-globin mRNA levels was done by real time
PCR (Roche Lightcycler 480®). ARMS-PCR was used to study the β tha-
lassemia mutations and GAP-PCR was employed to study the α globin gene
deletions. Xmn-1Gγ (C-T) polymorphism was studied by PCR-RFLP.
Results: The study group included nine pediatric cases and two adult patients
with age at enrolment ranging from 2 to 30 years. The male to female ratio was
1.2: 1. Four mild, five moderate and two severe β-thalassemia intermedia cases
were enrolled. Milder β-thalassemia mutations were responsible in majority of
cases for the thalassemia intermedia phenotype. The most frequent β-tha-
lassemia mutation in our study group was -88 (C-T) followed by Cap+1 (A-C).
All the eleven patients were negative for the 8 α-globin gene deletions tested
by GAP-PCR. Seven patients were Xmn-1Gγ (-/-), two patients Xmn-1-Gγ (+/+)
and two were of Xmn-1Gγ (+/-) genotype. Seven patients (63.6%) were good
responders, two (18.2%) were partial and two (18.2%) were non-responders to
hydroxyurea therapy. The mean increase in Hb post-HU therapy was 1 g/dl.
The mean HbF increased by 1.5 g/dl in the post-HU group. Six (54.5%) patients
had increased relative expression of γ-globin mRNA after HU therapy, 4 (36.4%)
patients had decreased relative expression and one patient (9%) did not show
any change measured by qRT-PCR. Four patients who had a decrease in rel-
ative expression of γ-globin mRNA after hydroxyurea therapy did not show a
drop in Hb; rather all had a rise in Hb ranging from 0.8 to 2.6 g/dl. The relative
expression of γ-globin mRNA levels did not correlate with rise in hemoglobin.
Xmn-1Gγ (C-T) polymorphism was associated with high fetal hemoglobin levels
at baseline and also post hydroxyurea. Hydroxyurea showed good response in
majority of the patients. These results indicate that the actions of hydroxyurea
might extend beyond γ-globin gene regulation. The mean hemoglobin A2 levels
were decreased post hydroxyurea compared to baseline. This indicates hydrox-
yurea might affect regulation of other globin genes apart from the γ-globin gene.
In addition there was improvement in red cell parameters (red cell indices,
nucleated red cell count and reticulocyte count), bilirubin and lactate dehydro-
genase levels indicating that hydroxyurea has a role in improving red cell rhe-
ology and survival.
Figure 1.
Summary/Conclusions: In our study, the changes in relative expression of γ-
globin mRNA levels (both increased and decreased levels) as measured by
qRT-PCR did not directly correlate with changes in either of total hemoglobin
or fetal hemoglobin levels. The increase in hemoglobin levels even in patients
with decreased relative expression of γ-globin mRNA levels suggests that alter-
nate mechanisms of action of hydroxyurea exist to increase the fetal hemoglo-
bin and total hemoglobin in β-thalassemia intermedia patients. Xmn-1Gγ (C-T)
polymorphism is associated with better response to hydroxyurea.
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FERROPORTIN DISEASE: A CASE SERIES AT THE REGIONAL REFERRAL
CENTER FOR IRON DISORDERS IN VERONA
C Piubelli1, P Bozzini2, A Castagna1, G Marchi2, M Rizzi2, F Busti1, R Pozzi-
Mucelli3, L Xumerle4, M Delledonne4, O Olivieri1, D Girelli1,2,*
1Department of Medicine, University of Verona, 2Veneto Region Referral Center
for Iron Disorders, Azienda Ospedaliera Universitaria Integrata, 3Department
of Diagnostics and Public Health, Section of Radiology, 4Department of Biotech-
nology, University of Verona, Verona, Italy
Background: Ferroportin Disease (FD), due to mutations in the SLC40A1 gene
encoding for the hepcidin receptor and cell membrane iron exporter ferroportin,
is deemed as the most frequent form of “atypical” or “non-HFE” Hereditary
Hemochromatosis (HH) (Wallace DF, Genet Med 2015). To date, knowledge
on FD is mainly based on individual case reports, with heterogeneous clinical
and biochemical features.
Aims: The aim of the work is to describe our experience as Regional Referral Cen-
ter for Iron Disorders, after the recent implementation of a next generation sequenc-
ing (NGS)-based 2nd level genetic test for the molecular diagnosis of non-HFE HH.
Methods: We used our recently validated molecular test (Badar S, Am J Hematol
2016) combining capture and enrichment of the five HH genes (HFE, HFE2,
TFR2, SLC40A1/ferroportin, and HAMP/hepcidin) through HaloPlexTM Technol-
ogy and NGS using the IlluminaHiSeq 1000 platform (Illumina, San Diego CA).
Results: New cases of FD have been detected, so that we are now following
9 FD patients from 7 families. The 3bp-deletion p.Val162del, the most frequent
FD-associated variant reported in literature was found in 3 families. We recently
detected a new variant (p.Leu233Gln) in a patient showing mixed
biochemical/pathological features between Type 4A/4B HH, i.e. marked hyper-
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ferritinemia (6,923 ng/ml), elevated transferrin saturation (85% at diagnosis),
iron deposition in both liver and spleen at MRI, and iron overload in both Kupffer
cells and hepatocytes at liver biopsy. Noteworthy, the mutation affected the
same residue involving a different mutation (p.Leu233Pro) previously described
in a patient with a quite similar phenotype (Girelli D, J Hepatol 2008). All 4
patients with p.Val162del (all females, age range 30-69) had marked hyperfer-
ritinemia (range 1,101-3,020 ug/L) and normal transferrin saturation. Despite
in some cases hyperferritinemia dated back several years without treatment
before the correct diagnosis, all patients were clinically asymptomatic, with no
overt biochemical signs of liver disease. Hepcidin levels in FD patients were
high-normal at diagnosis, but tended to decrease with iron depletion through
phlebotomies.
Summary/Conclusions: Our single center experience confirm FD disease as
the most frequent atypical HH, and call for multicentre registries to better define
the clinical features of this heterogeneous condition.
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LONG-TERM SAFETY AND EFFICACY OF DEFERASIROX IN PEDIATRIC
PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS: RESULTS FROM
A 5-YEAR OBSERVATIONAL STUDY (ENTRUST)
E Vichinsky1,*, A El Beshlawy2, A Alzoebie3, A Kamdem4, S Koussa5,
T Chotsampancharoen6, A Bruederle7, G Gilotti8, J Han8, M Elalfy9
1Children’s Hospital & Research Center, Oakland, United States, 2Cairo Uni-
versity, Cairo, Egypt, 3Sheikh Khalifa Medical City, Abu Dhabi, United Arab
Emirates, 4Centre Hospitalier Intercommunal, Créteil, France, 5Chronic Care
Center, Hazmieh, Lebanon, 6Songklanagarind Hospital, Songkhla, Thailand,
7Novartis Pharma AG, Basel, Switzerland, 8Novartis Pharmaceuticals, East
Hanover, United States, 9Ain Shams University, Cairo, Egypt
Background: Young patients with red blood cell disorders, such as β thalassemia
major (βTM), sickle-cell disease (SCD) and Diamond–Blackfan anemia (DBA),
receive regular transfusions from an early age and consequently accumulate
iron. Complications of iron overload include organ damage and delayed
growth/development, therefore optimal management of iron is required.
Deferasirox, a once-daily oral iron chelator, has demonstrated safety and efficacy
in adult and pediatric patients with transfusional hemosiderosis. As requirements
for therapy may be lifelong, continual assessment of long-term outcomes is valu-
able, as conducted in the 5-year multinational, observational ENTRUST study.
Aims: Evaluate the long-term safety and efficacy of deferasirox in younger
transfusion-dependent children with chronic iron overload in clinical practice.
Methods: Patients aged 2–<6 years at enrolment were prescribed deferasirox
according to local labels, with dose adjusted based on serum ferritin, thera-
peutic goals, tolerability and changes in patient weight. Parents/guardians pro-
vided written, informed consent. The primary objective was to evaluate safety,
specifically renal and hepatic function, assessed by ≥2 consecutive post-base-
line measurements ≥7 days apart of serum creatinine (SCr) >age-adjusted
upper limit of normal (ULN) and >33% from baseline and alanine aminotrans-
ferase (ALT) >5xULN. Secondary objectives included analysis of serum ferritin,
investigator-reported adverse events (AEs) and growth.
Table 1.
Results: In total, 267 patients (mean age 3.2 years: 61.4%<4 years, 38.6% ≥4
years) with βTM (n=176, 65.9%), SCD (n=52, 19.5%), DBA (n=12, 4.5%) and
other anemias (n=27, 10.1%) were enrolled and received ≥1 deferasirox dose.
122 (45.7%) patients discontinued, most commonly (>5% of patients) due to
‘Other’ reasons (n=55; 20.6%), loss to follow-up (n=19, 7.1%) and AEs (n=18,
6.7%; most commonly increased ALT and increased AST, n=7 each). Mean±SD
deferasirox exposure and dose were 44.1±21.2 (range 1.2–65.6) months and
25.8±6.5 mg/kg/day, respectively. Most patients (n=172; 64.4%) received an
average blood intake >7 mL/kg/month. Median serum ferritin decreased from
1702 (range 334–9577) ng/mL at baseline (n=243) to 1127 (range 38–6428)
ng/mL at 5 years (n=84). Eight (3.1%) patients had two consecutive SCr
increases >age-adjusted ULN and >33% from baseline; two received
deferasirox dose adjustments to resolve the observed SCr increase. Overall,
11 (4.2%) patients had two consecutive ALT increases >5 or >10xULN, three
of whom received deferasirox dose interruptions. There were no unexpected
adverse events (AEs) or laboratory abnormalities. The most frequently
observed AEs with suspected relationship to study drug (Table) were increased
ALT (21.1%), increased AST (11.9%), vomiting (5.4%) and rash (5.0%). A
steady increase in weight was observed.
Summary/Conclusions: This long-term, observational study of deferasirox in
pediatric patients supports previous trials indicating favorable safety and efficacy.
Over half the patients completed the 5-year study, with limited discontinuations
due to AEs. Few patients experienced notable increases in renal or hepatic
assessments and continued deferasirox therapy at the same or reduced dose.
In this pre-pubertal study population, growth was normal. Thus, with regular mon-
itoring and dose adjustments, effective long-term chelation therapy with
deferasirox is manageable in the majority of pediatric patients in clinical practice.
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CONCURRENT TREATMENT OF APLASTIC ANEMIA (AA) WITH
IMMUNOSUPPRESSIVE THERAPY AND PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (PNH) WITH ECULIZUMAB
M Griffin*, P Hillmen, T Munir, S Richards, L Arnold, K Riley, C Pelton, A Hill
Hematology, Leeds teaching hospitals, Leeds, United Kingdom
Background: At least 50% of aplastic anaemia (AA) patients have a PNH
clone. Many have a small proportion of PNH cells requiring monitoring alone
whereas others may present with both significant aplasia as well as PNH. Con-
current treatment for AA and PNH may therefore be required.
Aims: This retrospective analysis assess’s the outcome of patients with con-
current PNH and aplastic anaemia who require complement blockade with
eculizumab alongside immunosuppressive therapy (IST) for AA
Methods: The PNH National Service database (Leeds) was reviewed retro-
spectively. Patients who commenced eculizumab within a year of their aplastic
anaemia treatment, or those treated for aplasia who were already established
on eculizumab were selected.
Results: Fourteen patients were treated with eculizumab and immunosuppres-
sive therapy concurrently. Median age was 38.5 years (range 7-76). AA treat-
ment varied as per national guidelines dependant on the patient’s age, patient
choice and co-morbidities. Seven out of fourteen received ATG and ciclosporin
(median follow-up 20 months post ATG), six received ciclosporin monotherapy
(median follow-up from commencement of ciclosporin 97 months). 6 of the 7
patients receiving ATG+Ciclosporin responded, two achieved complete
response (CR) and four a partial response (PR), one of whom required
tacrolimus and subsequently achieved a CR with androgen therapy and one
who achieved PR with oxymetholone. One did not respond and achieved a CR
with a bone marrow transplant (BMT). Median granulocyte count reduced from
88% to 50% post ATG treatment however there was no change in the monocyte
PNH clone. Of the six patients treated with ciclosporin monotherapy, one had a
CR with concurrent androgen therapy, two had a PR, one had a CR then
relapsed and is now in PR on recommencement of ciclosporin, two had no
response. There was no change in the granulocyte PNH clone following
ciclosporin treatment. One patient proceeded to first line bone marrow trans-
plantation (mean follow-up from presentation 7 months). Both BMT recipients
stopped eculizumab post transplant due to resolution of PNH. Two patients died,
one from infection following a PR with ATG and ciclosporin, and one from
unknown causes who had not responded to treatment. One patient had spon-
taneous remission of their PNH and stopped eculizumab; the remaining nine
patients continue on eculizumab. Fourteen age matched controls not on
eculizumab received similar therapies, nine of whom received ATG and
ciclosporin (median follow-up from ATG commencement 37 months). Four had
a CR, one had a CR then relapsed with no response to re-introduction of
ciclosporin, one had a PR and two had no response, one of whom had a BMT
with CR and one achieved CR with oxymetholone. One ATG patient is awaiting
response (four months post ATG). Five patients were treated with ciclosporin
monotherapy (median follow-up from ciclosporin commencement 115 months).
Two had a CR, one had a PR then relapsed, one had no response and achieved
a PR with oxymetholone and one is awaiting response (three months post
ciclosporin commencement).
Summary/Conclusions: Concurrent treatment of AA with IST and PNH with
eculizumab has not previously been reported. The response rates for IST in
patients on eculizumab compared with age matched controls were similar, with
similar numbers of patients achieving CR or PR with IST. Eculizumab therapy
does not appear to affect response to IST for aplastic anaemia patients.
This strategy may be required especially with improved life expectancy for
PNH patients receiving complement inhibition therapy. The patients in this
study were treated in accordance with current aplastic anaemia guidelines and
the presence PNH should not influence this.
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4 YEAR COST-ANALYSIS OF AUTOMATED RED CELL EXCHANGE
TRANSFUSION FOR MANAGEMENT OF RECURRENT PAINFUL CRISES
IN ADULT PATIENTS WITH SICKLE CELL DISEASE
DA Tsitsikas 1,*, A Ekong 1, L Berg 1, B Sirigireddy 1, N Lewis 1, RJ Amos 1
1Haematology, Homerton University Hospital NHS Foundation Trust, London,
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Background: Automated red cell exchange transfusion (ARCET) is a promising
modality in treating chronic complications in sickle cell disease (SCD). However,
concerns around the cost of the procedure may limit its adoption in some insti-
tutions.
Aims: To assess the cost implications / financial gains of regular ARCET for
SCD patients who have been on the programme for 4 years for recurrent pain
in our institution.
Methods: We adopted ARCET in our institution in June 2011 and 8 patients
have been on the programme for 4 consecutive years for management of recur-
rent painful crises. Data were collected retrospectively and the hospital atten-
dance of these patients one year prior to the intervention (as a comparator)
and every year after starting ARCET were analysed. Prices for different aspects
of the service were provided by the divisional operational manager of the depart-
ment and the haematology laboratory manager and were as follows: Haema-
tology day unit unplanned attendance: £1022, emergency department (ED)
attendance: £235, in-patient stay up to 8 days: £1540 and in-patient stays in
excess of 8 days: £1540+£294 / every day in excess of 8. The total cost of
blood over these 4 years was £309,200, the cost of using the day unit for the
procedures £218,400 and the cost of the consumables used £36,839 giving a
total cost of £564,439 for the 4 years. Cost of hospital attendance without the
intervention was projected over 4 years based on the hospital attendance the
year prior to commencing the intervention.
Results: 1) Total day unit unplanned attendance (without admission): 222 days
one year prior to intervention, projected 888 over 4 years with projected cost
£907,536. Attendance after intervention was 103, 142, 78 and 37 days 1, 2, 3
and 4 years post intervention respectively with a total of 360 days in 4 years and
an actual cost of £367,920 and a 4 yr projected cost reduction of £539,616. 2)
Total ED attendance (without admission): 173 days one year prior to intervention,
projected 692 over 4 years with projected cost £162,620. Attendance after inter-
vention was 130, 86, 72 and 53 days 1, 2, 3 and 4 years post intervention respec-
tively with a total of 341 days in 4 years and an actual cost of £80,135 and a 4
yr projected cost reduction of £82,485. 3) Total in-patient episodes up to 8 days:
42 one year prior to intervention, projected 168 over 4 years with projected cost
£258,720. Episodes after intervention were 48, 31, 37 and 32 1, 2, 3 and 4 years
post intervention respectively with a total of 148 episodes in 4 years and an
actual cost of £227,920 and a 4 yr projected cost reduction of £30,800. 4) Total
in-patient episodes in excess of 8 days: 26 one year prior to intervention, pro-
jected 104 over 4 years with projected cost £160,160. Episodes after intervention
were 11, 13, 10 and 11 1, 2, 3 and 4 years post intervention respectively with a
total of 45 episodes in 4 years and an actual cost of £69,300 and a 4 yr projected
cost reduction of £90,860. 5) In-patients days in excess of 8: 485 days one year
prior to intervention, projected 1940 over 4 years with projected cost £570,360.
In-patient days in excess of 8 after intervention were 73, 138, 57 and 86 days
1, 2, 3 and 4 years post intervention respectively with a total of 354 days in 4
years and an actual cost of £104,076 and a 4 yr projected cost reduction of
£466,284. Overall, cost was £564,439 with projected savings of 1,210,045 and
a 4y projected cost benefit of £645,606.
Summary/Conclusions: ARCET appears cost-effective for management of
recurrent pain in SCD in the medium-long term.
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PREDICTIVE ROLE OF MYOCARDIAL FIBROSIS IN THALASSEMIA
INTERMEDIA PATIENTS
A Meloni1,*, M Cinquetti2, N Giunta3, P Giuliano3, V Positano1, A Carrà4,
N Dello Iacono5, A Massa6, G Sinagra2, A Pepe1
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Diparti-
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Trieste, 3Unità Operativa Complessa di Radiologia, ARNAS Civico “Benfratel-
li-Di Cristina”, Palermo, 4Unità Operativa di Pediatria, Ospedale “G. Da Salice-
to”, Piacenza, 5Centro Microcitemia-Day Hospital Thalassemia Poliambulatorio
“Giovanni Paolo II”, Ospedale Casa Sollievo della Sofferenza IRCCS, San Gio-
vanni Rotondo (FG), 6Servizio trasfusionale, Ospedale “Giovanni Paolo II”,
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Background: Myocardial fibrosis detected by late gadolinium enhancement
(LGE) cardiac magnetic resonance (CMR) is currently used to predict adverse
cardiovascular events in different cardiomyopathies. However, its clinical impli-
cations in thalassemia intermedia (TI) have not been studied.
Aims: The aim of this study was to assess the distribution and the predictive
value of myocardial fibrosis for future events in TI.
Methods: We considered 218 white TI patients (37.82±11.00 years, 113
females) consecutively enrolled in the Myocardial Iron Overload in Thalassemia
(MIOT) network and free of cardiac complications concomitant to CMR. LGE
images were acquired to detect myocardial fibrosis and the extent of LGE areas
was quantified using a semiautomatic, previously validated software.
Results: Myocardial fibrosis was detected in 46 patients (21.1%). LGE followed
a subendocardial ischemic pattern typical of coronary artery disease in two
patients. One patient showed both an ischemic and non ischemic pattern. Thir-
ty-two patients had a single focus while 14 had at least two foci. The mean
number of LGE segments per patient was 2.70±1.52. LGE involved the septal
region in 76.1% of patients. The extent of LGE areas was 2.09±1.77% of the
total left myocardial mass. Twenthy-two (47.8%) patients showed fibrosis in
the infero- or anteroseptal junction, 18 (39.1%) had a non ischemic no-junctional
pattern (intra or subepicardial) and 6 (13.0) had both a junctional and no-junc-
tional pattern. Mean follow-up was 56.76±23.17 months. We recorded 13 car-
diac complications: 1 heart failure, 7 arrhythmias and 5 pulmonary hypertension
(PH). Myocardial fibrosis was a significant prognosticator for arrhythmias, PH
and cardiac complications globally considered (see Table). Number of segments
with LGE and extent of myocardial fibrosis were comparable in patients who
developed cardiac complications versus the patients who did not.
Table 1.
Summary/Conclusions: In TI patients, myocardial fibrosis is a predictor of
adverse outcome.
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ORAL HIGH DOSE LIPOSOMIAL IRON VS INTRAVENOUS IRON IN
SIDEROPENIC ANEMIA PATIENTS INTOLERANT/REFRACTORY TO IRON
SULPHATE. MULTICENTRIC RANDOMIZED STUDY
G Giordano1,*, A parente2, R gigli3, M magri1, G berardi4, B carabellese5,
F d’amico2, L luciano2, R fratangelo2, G niro3, A licianci6, L di marzio6
1medicine, Regional Hospital “A. Cardarelli”, 2molise university, 3laboratory
medicine, Regional Hospital “A. Cardarelli”, 4general medicine, asrem molise,
5nuclear medicine, 6hospital management, Regional Hospital “A. Cardarelli”,
Campobasso, Italy
Background: In iron deficiency anemia support with intravenous iron allows a
faster anaemia correction and a faster ferritin increase than iron sulfate. Fre-
quently iron sulfate and intravenous iron generate adverse events as hypoten-
sion, urticarioyd reactions, shock, epygastralgia, constipation or diarrhea. High
doses of oral iron frequently are poorly tolerated because of adverse events.
Aims: Aim of this study is to verify if high doses of oral liposomial iron are safe,
cost-effective and well tolerated as standard doses of intravenous ferrigluconate
in patients with iron deficiency anemia intolerant/refractory to iron sulphate.
Methods: We considered two group of patients(RANDOMIZED 1:1) with iron
deficiency anemia without other relevant comorbidities. In group A M/F was
2/3, 15 patients had haemorragic gastritis, 8 hemorragic enteric bleeding
angiodysplasia, 22 hypermenorrhaea, median level of hemoglobin (Hb) was
8.5 g/dl(R 6.5-10), median ferritin level was 5 ng/ml (R 3-21), with a normal
level of CRP or ESR, and received liposomial iron 30 mg 4 tablet/day. In group
B M/F was 2/3, 18 patients had haemorragic gastritis, 6 hemorragic enteric
bleeding angiodysplasia, 21 hypermenorrhaea, median level of Hb was 8.2
g/dl(R 7.5-9.5), median ferritin level was 7 ng/ml (R 2-19), with a normal level
of CRP or ESR, and received iv sodium ferrigluconate 62.5 mg iv in NS 100 ml
in 3 h/day. The median treatment costs in each group were calculated consid-
ering the monthly global treatment cost for each patients in the treatment period.
This provided an estimate of the costs, independent of the precise cost of the
drug, but tied to the final outcome (efficacy) of the therapeutic strategy used
during the observation period.
Results: In group A,1g Hb increase was observed after a median of 9 days
(R 7-15), a target Hb level of 12g/dl was achieved in a median time of 4 weeks
(R 2-5) with a median cost of € 120/months (R 95-180), 12(26%) patients
showed adverse events (7 epigastralgia, 5 diarrhoea). In group B,1 g Hb
increase was observed after a median of 7 days (R 6-11), a target Hb level of
12g/dl was achieved in a median time of 3 weeks (R 1.5-4) with a median cost
of €300/months (R 250-380), 10(22%) patients showed adverse events (2
hypotension, 2urticaria and headhace).
Summary/Conclusions: Oral high dose liposomial iron support is safe, fast,
well tolerated and cost-effective as intravenous iron in sideropenic anemia.
This study needs confirmation on a larger cohort of patients.
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DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS: METHOD VALIDATION
AND FIRST DIAGNOSTIC EXPERIENCE OF TWO CENTERS
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Background: Osmotic gradient ektacytometry (Osmoscan) is part of the lab-
oratory diagnosis process of hereditary spherocytosis (HS) and other red blood
cell membrane disorders. A new generation ektacytometer, the LoRRca Max-
Sis, has recently become commercially available. We here present for the first
time the experience of two independent institutions with this analyzer in HS
diagnostic settings.
Aims: The objectives were (a) to validate the LoRRca MaxSis analytically inde-
pendently in two centers, (b) to estimate the diagnostic accuracy of the various
parameters available from the Osmoscan curve and their clinical application
for HS diagnosis, (c) to establish a standardization of result reporting and cut-
off values of Osmoscan parameters for HS diagnosis, and (d) to introduce the
next generation osmotic gradient ektacytometry in the diagnostic work-flow of
RBC membrane disorders.
Methods: Inter- and intra-assay variability and sample stability for different
storage (4°C and 20°C) and anticoagulant conditions (K2-EDTA, Li-Heparin
and acid-citrate-dextrose) were studied. In addition, we performed Osmoscan
on samples from patients with HS (N=40), probable HS (N=21), auto-immune
hemolytic anemia, AIHA (7), and patients with other pathologies (N=37). Daily
control samples (n=54 in Erasme Hospital and n=80 in University Medical Cen-
ter Utrecht) were run in parallel with patient samples. Laser-assisted measure-
ments of RBC deformability under changing osmotic gradient and constant
sheer stress were expressed and recorded as elongation index (EI). An
Osmoscan curve was created with the following parameters: EI min (minimal
elongation index), O min (the osmolality at EI min), EI max (the maximal elon-
gation index), O max (the osmolality at EI max), O hyper (the osmolality in the
hypertonic region at 50% of the EI max), EI hyper (the EI at O hyper), and area
under the curve (AUC). Patient results for the various Osmoscan parameters
were expressed as percent of change (increase or decrease) compared to the
mean of controls.
Results: Analytical performance of the LoRRca MaxSis ektacytometer showed
an inter-assay variability between 0.2% and 3%. Samples were stable for 48-
72 hours depending on temperature storage and anticoagulant used. No dif-
ference was observed for any of the Osmoscan parameters between the “HS”
group, “probable HS” and “AIHA” group. However, a significant difference was
observed between the “HS” group and the “other pathologies” group for O min,
EI max, EI hyper, and the AUC. The following diagnostic cut-offs were estab-
lished for HS: an increase of more than 21.5% for the osmolality point at the
minimal elongation index (O min), a decrease of more than 8.5% for the max-
imal elongation index (EI max), and a decreased area under the curve (AUC)
of more than 18.5% compared to the mean of controls.
Summary/Conclusions: The next generation ektacytometer is an efficient tool
for the laboratory diagnosis of HS. Samples are stable, thereby enabling long-
distance shipping to specialized laboratories. Additionally, the proposed stan-
dardized reporting of results allows inter-laboratory exchange and comparison.
Different parameters of the Osmoscan curve were found useful for HS diagno-
sis but particularly the AUC, the O min and the EI max parameters. Finally, we
considered the introduction of the next generation ektacytometry Osmoscan
in the diagnostic work-flow of RBC membrane disorders at two levels: (1) as a
potent screening method in a general laboratory, and (2) as an effective inter-
mediate step between the screening laboratory methods and the confirmatory
protein deficiency tests or DNA-based methods in a reference laboratory.
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NEURO-PSYCHIATRIC INVOLVEMENT IN PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (PNH)
W Barcellini1,*, E Scola2, S Lanfranconi3, M Grottaroli4, F Binda1, B Fattizzo1,
P Bianchi1, C Boschetti1, M Buoli4, CA Altamura4, N Bresolin5, F Triulzi2,
A Cortelezzi6
1Oncohematology Unit, 2Neuroradiology Unit, 3Neurology Unit, IRCCS Foun-
dation Ca’ Granda Ospedale Maggiore Policlinico, 4Department of Psychiatry,
University of Milan, IRCCS Foundation Ca’ Granda Ospedale Maggiore Poli-
clinico, 5Neurology Unit; Dino Ferrari Centre, Neuroscience Section, IRCCS
Foundation Ca’ Granda Ospedale Maggiore Policlinico, 6Oncohematology Unit,
IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico and University
of Milan, Milan, Italy
Background: PNH is a rare disorder due to a deficiency in GPI–anchored pro-
teins, characterized by haemolytic anaemia, marrow failure and thrombosis.
Thrombotic events in PNH generally occur in unusual sites, such as hepatic,
portal, mesenteric, splenic, and renal veins. Case reports of cerebral venous
sinus thrombosis and arterial ischemic strokes are described in PNH. However,
no systematic studies have been reported in asymptomatic patients
Aims: to investigate neuro-psychiatric involvement and neuroradiological find-
ings in PNH patients
Methods: 17 PNH patients underwent non-enhanced cerebral magnetic res-
onance imaging (MRI), and intracranial arterial and venous angio-MRI. The
following variables were evaluated: chronic ischemic small vessel disease,
quantified according to ARWMC scale (Wahlund LO, Stroke 2001); focal alter-
ations consistent with silent ischemic strokes; active or previous bleeding or
micro-haemorrhages; atrophy. Moreover, abnormalities of the circle of Willis
and its branches, and of cerebral venous sinus were evaluated. Psychiatric
evaluation included the Brief Psychiatric Rating Scale, the Structured Clinical
Interview 1 for DSM IV Axis Disorders (SCID-1), the Short Form (36) Health
Survey, and the Trail making test
Results: Clinical and haematological parameters of patients are shown in
table; 15/17 patients were classic haemolytic (60% transfusion dependent),
and 2 PNH in the context of aplastic anemia (both transfusion-dependent until
treatment with ATG-Cya). Abdominal pain was present in 41% (N. 1, 2, 4, 10,
11, 14, 15), and abdominal thrombosis in 18% (N. 2, 7, 10). Eculizumab was
administered in 53% of cases for transfusion dependence, abdominal pain
and/or thrombosis. On MRI, 10 subjects showed white matter (WM) abnormal-
ities related to chronic ischemic small vessel disease. In particular, 5 subjects
displayed periventricular WM vascular degeneration, and 6 deep WM focal
chronic ischemic lesions. In one subject (N.10) a focal abnormality >5 mm was
detected. The evaluation of WM and basal ganglia lesions (ARWMC scale)
gave a score of 2 in 2 subjects (N.7, 17), a score of 4 in 3 subjects (N. 2, 10,
11), and a score of 5 in 1 subject (N. 9). No subject displayed active or previous
bleeding. Two patients (80 and 81 yrs) showed atrophy of the cerebral hemi-
spheres. Regarding vascular abnormalities, one subject (N.1) had hypoplastic
left transverse sinus with irregularities in the sinus wall, suspected for prior
partial venous thrombosis. Intracranial artery stenosis or aneurysm, and Moya–
Moya like alterations were not observed. Finally, cerebral MRI was unremark-
able in 7/17 subjects. Neurological clinical examination was normal in all
patients. Psychiatric evaluation did not reveal any psychotic behaviour (except
a doubt case in which emerged ideas of delusional thoughts), and test scores
for visual attention and task switching resulted appropriate to age. SCID-1
highlighted the presence of a case of generalized anxiety disorder and the sus-
pect of a case of bipolar disorder type 2. The SF36 results evidenced a better
health perception than the norm, and even a perception of increased quality of
life.
Table 1.
Summary/Conclusions: Although largely related to age, unexpected chronic
ischemic white matter involvement was present in PNH, and particularly impor-
tant in two subjects with severe haemolytic disease (N. 9 and 10), of whom
one not in eculizumab. White matter lesion burden in asymptomatic patients
may help the decision to start therapy, which is not always easy on the
clinical/haematological basis.
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SLEEP OBSTRUCTIVE APNEA SYNDROME (SOAS) IS NOT ASSOCIATED
WITH MARKED ERYTHROCYTOSIS. A STUDY ON 337 PATIENTS
P Morel1,*, S Lecerf2, O Florea2, H Vandeputte2, A Duhamel3, JP Marolleau1,
L Garcon1
1CHU d’Amiens, Amiens, 2Centre Hospitalier de Lens, Lens, 3CHRU de Lille,
Lille, France
Background: Normal values of hemoglobin concentration (Hb) and hematocrit
(Ht) depend on gender only.
Aims: To check the role of age and frequent disorders that may influence ery-
thropoiesis (renal function, iron metabolism and oxygenation abnormality).
Methods: This prospective study enrolled 337 patients (pts) aged 16 to 88
years (median 61, M/F=1.51) referred to the sleep unit of Hospital of Lens. All
patients had arterial blood gas, blood cell count and routine chemistry. Apnea
hypopnea index (AHI) was available in 250 pts.
Results: Severe SOAS (AHI>30/hour) was found in 121 pts (48% of evaluated
pts). Median HB and HT was 13.3 g/dL (range from 8.5 to 17.2 g/dL) and 40.7%
(range 18,1 to 51,4%) respectively. Only 5 pts presented with increased HB
(>17.5 g/dL in male, >15.5 g/dL in female) and HT (>50% in male and >47% in
female). Conversely, anemia (HB<13.5 g/dL in male,<12.5 g/dL in female or
HT<40% in male,<37% in female) was present in 118 pts (35%): Renal failure
(MDRD creatinine clearance<60 ml/min), iron deficiency (ferritin<30 µg/L) or
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features of anemia of chronic disease (CRP>10 mg/L or ferritin >400 µg/L)
were observed in 84 (25%), 58 (17%) and 72 (21%) pts respectively. Finally,
173 pts presented none of these disorders (no cause of anemia) and 219 pts
presented without anemia according to HB and HT criteria (non-anemic pts).
Female pts had lower HB and HT than male pts (median 12.6 g/dL and 38.5%
vs 13.9 g/dL and 42.4%,respectively, p<0.0001). HB and HT were mainly influ-
enced by age and also MDRD creatinine clearance (that takes age and gender
into account) (table 1). The relationships between age and HB and HT were
confirmed in linear models (R2=0.133 and 0.118, respectively, p<0.0001) and
these inverse relationships were validated in an independent seris of 3892
patients referred in the medicine units of the Centre Hospitalier Universitaire of
Amiens. Testing the lack of fit showed that the linear model was inadequate in
the subgroup of male pts, and smoothing spline analysis showed an increase
in the inverse relationship between HB and age in elderly male pts older than
60 years. AHI was the only respiratory parameter that influenced only HB
(r=0.13085, p=0.047). There was no significant correlation between AHI and
age, no significant difference in the distribution of AHI in male and female. Nev-
ertheless, significant correlations were observed between AHI and HB and HT
when the analyses were performed in the non anemic pts (r=0.20676, p=0.0067
and r=0.18340, p=0.0163 respectively) and in pts without cause of anemia
(r=0.20092, p=0.0224 and r=0.16335 p=0.0644 respectively).
Table 1.
Summary/Conclusions: This prospective study showed an inverse relation-
ship between age and HB and HT. We confirmed the rarity of marked erythro-
cytosis in pts with SOAS and the weak correlation between AHI and HB and
HT. Our data suggested that SOAS pts also frequently present with character-
istics that may play a part in reducing HB and HT. Thus, checking the presence
or the absence of associated comorbidity should be considered in SOAS pts
with erythrocytosis.
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“SEPARATING THE WHEAT FROM THE CHAFF” CONGENITAL HEMOLYTIC
ANEMIA STUDY WITH A TARGETED NEXT GENERATION SEQUENCING
PANEL
C Bento, T Magalhães Maia*, AC Oliveira, L Relvas, H Almeida, J Pereira,
E Cunha, L Manco, L Ribeiro
Clinical Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal
Background: Diagnosing a Coombs negative hemolytic anemia (HA) can be
a true challenge, specially in the absence of family history or when the periph-
eral blood smear is not very informative. A few years ago, we had to sequence
gene by gene by Sanger methodology, which was time costly. Nowadays, with
Next Generation Sequencing (NGS) panels it is much faster, nevertheless we
may be drowned in a large number of putative pathological mutations. The con-
cept of one mutation (or two for the autossomal recessive disorders) one dis-
ease, have changed and now we have to deal with pathological variations or
not, or modulating factors. As a reference laboratory dedicated to the study of
benign red blood cell disorders (RBC) we have many of HAs with an identified
molecular lesion, but also several cases, that even though thoroughly screened
for hemoglobinopathies, enzymes and membrane defects remained without
identification of the pathological mutations. This has implications at prognostic
and therapeutic level, and makes the correct genetic counseling impossible.
Aims: Identify the molecular causes in a group of 14 patients with congenital
HA, after screening for the most common hemoglobinopathies, enzymopathies
and membranopathies.
Methods: Informed consent was signed for all the individuals in the study. We
have used a targeted NGS panel encompassing the exonic regions of 24 genes
(del Orbe et al, 2015) and sequenced 14 samples from patients with a congen-
ital HA. In all the samples the common screening tests for RBC disorders were
preformed, like high performance liquid chromatography (HPLC) for Hb variants,
enzymatic quantification and membrane disorders screening tests as cryohe-
molysis test and eosin-5’-maleimide. The variants found were classified using
in sillico analysis and the presence of pathological and likely pathogenic variants
were confirmed by Sanger sequencing and, when available, familial studies
were performed.
Results: All the samples showed a great number of variants, the majority were
benign or likely benign (a media of 320/sample) or of unknown significance or
likely pathogenic (media of 25/sample). Only 8 samples showed pathologic
variants that can justify the clinical presentation. Most of them are associated
with membrane disorders (Table). In 5 of the samples no pathological mutations
were found, in one sample (sample 11) we found a NT5C3A missense mutation
but in the heterozygous state (Sanger sequencing of all gene also didn’t reveal
any other mutation). Three samples are compound heterozygous for mutations
in the SPTA1 gene, three have a combination of mutations in different genes
affecting membrane structure, one is a compound heterozygous for two mis-
sense CDAN1 mutations not described before. Sample 5 is form a sickle cell
disease patient with an uncommon presentation in the newborn period, a
PIEZO1 mutation inherited from the mother and a EPB41 mutation inherited
from the father are likely to be the causes of the aggravated phenotype.
Table 1. Results of the NGS sequencing-pathological variants.
Summary/Conclusions: After in sillico analysis of the variants found by NGS
(almost 350 per sample) and confirmation by Sanger sequencing of the patho-
logical variants, we have identified a molecular cause for the HA in 8 of the 14
samples studied. This study confirms that target NGS is the most complete
and cheaper method for sequencing the genes associated with AH but, for the
cases that remain without mutations, whole exome sequencing or whole
genome sequencing need to be done, in order to identify new genes that can
later be added to the AH panel.
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SERUM HEPCIDIN-25 IN COMPARISON WITH BIOCHEMICAL MARKERS
AND HAEMATOLOGICAL INDICES FOR THE DIFFERENTIATION OF
ANAEMIA STATES AND CORRELATION WITH RESPONSE TO ORAL IRON
A Cowley1,*, A Cooper2, S Lewis3, W Thomas1
1Haematology, 2Biochemistry, 3Gastroenterology, Plymouth Hospitals NHS
Trust, Plymouth, United Kingdom
Background: Hepcidin is a key regulator of iron metabolism and may be a
useful analyte in the differentiation of iron states in anaemia. Hepcidin is down
regulated in the presence of iron deficiency to promote iron absorption and is
up regulated when iron stores are in excess or in the setting of inflammation
via IL-6. In combination with hypochromia indices and other markers of iron
deficiency such as reticulocyte haemoglobin (Ret-He), a raised hepcidin level
may provide evidence of both reduced iron absorption and iron restricted ery-
thropoiesis. Conversely, a low or normal hepcidin level may be suggestive of
true iron deficiency. In recent years immunoassays have become more readily
available, allowing hepcidin to complement existing routine biochemical indices
to differentiate anaemia states.
Aims: The primary aim of this study was to assess whether there was a corre-
lation between hepcidin and markers of iron status in patients referred via the
iron deficiency clinic at Plymouth Hospitals NHS Trust. The second objective was
to investigate the association of baseline hepcidin-25 with response to oral iron.
Methods: Patients referred to the iron deficiency anaemia clinic by their GP
were prospectively recruited. A clinical history, examination, blood tests includ-
ing haematological indices and biochemical markers, appropriate investigations
and oral iron supplementation were prescribed where appropriate. To determine
the response to oral iron, the full blood count was repeated at 1 and 3 months.
For the measurement of hepcidin-25, serum was frozen at -70C and then deter-
mined by batch analysis using a commercial ELISA kit (DRG Instruments, Mar-
burg, Germany). Patients were classified as having iron deficiency anaemia
(IDA), anaemia of chronic disease (ACD) or the combined state of iron restricted
erythropoiesis (IRE) with ACD (ACD/IRE) using clinical findings and standard
biochemical markers and haematological indices.
Results: The Hepcidin-25 immunoassay performed well, with a low within- and
between- assay coefficient of variation. The table shows the numbers and char-
acteristics of the patients allocated to the 3 types of anaemia. Numbers given
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as median and interquartile range. Hepcidin concentrations correlated signifi-
cantly with ferritin concentrations. Serum hepcidin was less than 1 ng/mL in 80
of 85 patients with IDA. This is consistent with previous data. There were no
linear associations seen between hepcidin and other indices of anaemia (Total
Hb, MCV, MCH, Ret-He, Transferrin, Transferrin saturation, Iron and CRP). 96
patients had a trial of oral iron, with 65 responding (increase of >10g/l by 12
weeks) and 31 failing to achieve an adequate rise in haemoglobin. There was
no correlation between response to oral iron and hepcidin.
Table 1.
Summary/Conclusions: A positive correlation exists between Hepcidin-25
and serum ferritin. The majority of patients in this study had iron deficiency
anaemia and correspondingly low hepcidin concentrations. A low hepcidin did
not correlate with subsequent response to oral iron therapy. Further investiga-
tion, however, of hepcidin in anaemic patients with normal to high ferritin levels
is warranted to further evaluate the role of this hormone in the management of
these patients.
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EFFECT OF ZINC SUPPLEMENTATION ON GLUCOSE METABOLISM,
OXIDATIVE STRESS AND IRON TRAFFICKING PROTEINS IN TRANSFUSION
DEPENDENT PATIENTS WITH THALASSEMIA
P Walter1,2,*, C Curtis1, M Hodge1, M Razavi3, M Minkley1, A Lal2, A Higa2,
D Killilea2, T Pearson3, E Fung2
1Biology, University of Victoria, Victoria, Canada, 2Hematology, UCSF Benioff
Children’s Hospital, Oakland, United States, 3Biochemistry, University of Vic-
toria, Victoria, Canada
Background: Thalassemia (Thal) is a genetic anemia of incomplete erythro-
poiesis causing iron overload and roughly 25% of patients to be marginally
zinc (Zn) deficient. Nearly 30% of adult subjects with Thal will develop diabetes,
thought to be related to transfusional iron overload, but the diabetogenic effects
of altered Zn status are not well known. It is hypothesized that a functional Zn
deficiency in Thal may affect insulin secretion, glucose homeostasis and/or
oxidative stress. Oxidative stress can be manifested by labile plasma iron (LPI),
a component of non-transferrin bound iron that is often found in Thal suffering
from iron overload. LPI is both redox-active and chelatable, and is the likely
culprit of distributing iron to peripheral tissues inducing tissue iron overload.
LPI can catalyze lipid peroxidation and release malondialdehyde (MDA) and
4-hydroxynonenal (4-HNE) from cells, which are lipid peroxide damage-asso-
ciated molecular patterns that indicate tissue damage and induce inflammation.
To monitor the proteins that may traffic this free iron we used an advanced pro-
teomics technique, measuring soluble transferrin receptor (sTfR), transferrin,
haptoglobin, hemopexin and inflammatory proteins C-reactive protein (CRP)
and Immunoglobulin G (TgG).
Aims: The purpose of this pilot project is to determine Zn supplementation
effects on 1) circulating levels of oxidative stress and iron trafficking proteins
and 2) glucose homeostasis and insulin secretion in Thal.
Methods: 39 subjects with informed consent were enrolled (9 Thal with dia-
betes (DM), 20 Thal without DM, 10 controls). Thal on intervention (60%
Female, 28.4±11.0y) had a 2 hr OGTT at 3 time points (0, 3 and 6 mos) and
took 25 mg Zn/d between 3 and 6 mos. 30% of Thal and 44% of DM had low
serum Zn at baseline. LPI was measured using fluorogenic dihydrorhodamine
123 (measures reactive radicals) with desferrioxamine as a chelator. Both MDA
and MDA+4-HNE was measured using N-methyl-2-phenylindole. Iron trafficking
proteins were measured by MRM mass spectrometry.
Results: C-peptide levels were significantly reduced in DM compared to controls
(p=0.002) as were lipase levels compared to controls (33 vs 21 IU/L, p=0.04).
Serum Zn was related to beta cell function by the Homeostatic Model Assess-
ment (HOMA) (r=0.45, p=0.049) and in subjects with low serum Zn supplemen-
tation improved insulin response to the glucose challenge (p=0.04). LPI, MDA,
and 4-HNE were significantly elevated in Thal vs Control (4.95μM±3.12 vs -
1.81±2.45 p=0.0004; 4.8 vs 3.0 µM, p=0.005; 9.37±2.94 vs 13.9±5.84 µM,
p=0.024). MDA patients with low iron levels at baseline were found to have an
increase in MDA over time vs those with high iron (p=0.005). LPI, MDA, and 4-
HNE comparisons between all three time points of Zn therapy in Thal patients–
with results of both Control and DM patients–did not show significant differences.
However, significant differences were noted in Thal patients vs Controls for the
following iron trafficking related proteins: sTfR, transferrin, haptoglobin, hemo-
pexin and TgG (p<0.05).
Summary/Conclusions: These preliminary data suggest that in patients with
Thal, Zn status is related to insulin resistance and beta cell function, possibly
related to circulating LPI, oxidative stress and some iron trafficking proteins
such as sTfR or hemopexin. More results are needed to explore how non-inva-
sive therapy may improve glucose tolerance in Thal patients.
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AN SPECKLE TRACKING IMAGING REVEAL MYOCARDIAL IRON OVERLOAD
IN THALASSEMIA MAJOR? A COMBINED ECHOCARDIOGRAPHY AND
CARDIAC MAGNETIC RESONANCE STUDY
A Meloni1,*, F Pizzino2, A Terrizzi2, M Allò3, S Macchi4, G Giuffrida5, C Paci6,
V Positano1, M Missere7, P Keilberg1, G Di Bella2, C Zito2, A Pepe1
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Azienda
Ospedaliera Universitaria “Policlinico G. Martino”, Messina, 3Servizio
Microcitemia, Presidio Ospedaliero ASL 5, Crotone, 4Servizio Trasfusionale,
Ospedale “Santa Maria delle Croci”, Ravenna, 5Divisione Clinicizzata di Ema-
tologia, Ospedale “Ferrarotto”, Catania, 6Centro Trasfusionale, Ospedale “S
Maria alla Gruccia”, Montevarchi (AR), 7Dipartimento di Immagini, Fondazione
di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy
Background: Cardiac complications related to myocardial iron overload (MIO)
remain the main cause of morbidity and mortality in thalassemia major (TM).
Cardiac magnetic resonance (CMR) is a unique non-invasive technique to
quantify MIO and the multislice T2* technique allows the identification of differ-
ent patterns of MIO. Unfortunately, the availability for CMR scans in validated
centers is still limited in many countries. On the other hand, echocardiography
is a widely diffused, non-expensive and feasible technique, with elevated accu-
racy in the evaluation of cardiac function and morphology. Nevertheless, stan-
dard echocardiographic examination fails in detecting MIO until a substantial
reduction of the left ventricular ejection fraction (LVEF) occurs. The evaluation
of myocardial deformation by two-dimensional speckle tracking imaging
(2DSTI) demonstrated a great accuracy in detecting subtle myocardial dys-
function in many different pathologic conditions.
Aims: We aimed to investigate the role of 2DSTI in the detection of MIO in
patients affected by TM, comparing the data of myocardial deformation with
T2* values derived by CMR.
Methods: We recruited 31 TM patients [15 males (48,4%); mean age:
37.87±9.64 years] consecutively enrolled in the Myocardial Iron Overload in Tha-
lassemia (MIOT) Network. All patients underwent to CMR and to echocardiog-
raphy in the same day. CMR was performed with a 1.5-T scanner and segmental
and global T2* values were measured with a previously validated software (HIP-
PO MIOT®). Values of GLS were derived from the three apical views, while radial
and circumferential strain were obtained from the three parasternal short axis
views. All the echocardiographic examinations were performed with a commercial
ultrasound system (Mylab-alpha, Esaote) equipped with a 1-4 Mhz phased array
probe.
Results: Mean global heart T2* was 35.91±12.69 ms (range:5.63-47.13 ms).
Six patients (19.4%) showed pathologic T2* values (<20 ms) indicative of MIO.
GLS showed a significant correlation with T2* values (R=-0.401; P=0.025),
moreover, the percentage of patients with altered GLS (lower or equal -19)
was significantly higher in the group with a significant MIO than in the group
with no significant MIO (global heart T2* ≥20 ms) (83% vs 28%, P<0.05). Logis-
tic regression demonstrated that patients with impaired GLS had a significant
higher risk of showing pathological T2* values (Odds-ratio-OR=12.86,
95%CI=1.27-130.54; P=0.031). No relation was observed between GLS, age
and sex, and between T2* values, LVEF, radial strain and circumferential strain.
Summary/Conclusions: Left ventricular GLS can be useful in detecting subtle
myocardial dysfunction due to MIO in TM patients, demonstrating a significant
correlation with MIO detected by CMR.
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THE IMPACT OF CARDIAC AND HEPATIC MRI ASSESSMENT ON THE
CLINICAL MANAGEMENT OF AUSTRALIAN PATIENTS WITH TRANSFUSION
DEPENDENT ANEMIAS OR NON-TRANSFUSION-DEPENDENT
THALASSEMIA IN THE TIMES STUDY
PJ Ho1,*, D Hiwase2, R Ramakrishna3, N Viiala4, D Ross5, E Zor6, O Gervasio7,
DK Bowden8
1Royal Prince Alfred Hospital, Sydney Medical School, Sydney, 2Royal Adelaide
Hospital, Adelaide, 3Southern Sydney Haematology, 4Liverpool Hospital, Syd-
ney, 5Flinders Medical Centre, Adelaide, 6Novartis Pharmaceuticals Australia
Pty Limited, North Ryde, 7Novartis Pharmaceuticals, Sydney, 8Monash Medical
Centre, Melbourne, Australia
Background: Iron overload can lead to impaired organ function and is asso-
ciated with significant morbidity and mortality, the risks of which can be reduced
by effective long-term iron chelation therapy (ICT) and control of iron loading.
Magnetic resonance imaging (MRI) allows accurate, reproducible assessment
of iron load and its use may affect clinical management decisions, leading to
improved patient care. The epidemiological TIMES study used MRI to assess
prevalence and severity of cardiac and hepatic siderosis in a large population
of Australian patients with transfusion-dependent anemia or non-transfusion-
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dependent thalassemia (NTDT). In this analysis of the TIMES study, we report
the impact of MRI results on investigator treatment decisions.
Aims: To determine the prevalence of iron overload by MRI and its impact on
the clinical management of iron overload in a population of patients with trans-
fusion-dependent anemia or NTDT.
Methods: Patients with thalassemia major (TM), NTDT (β thalassemia inter-
media, β thalassemia/Hb E, Hb H disease), myelodysplastic syndromes (MDS)
or other chronic anemias were enrolled. Patients with NTDT had serum ferritin
(SF) >300 ng/mL; others had a lifetime history of ≥20 units red blood cell (RBC)
transfusions and SF >500 ng/mL. Past medical history was collected (including
red blood cell (RBC) transfusion, ICT and hematologic data). Prospective MRI
(FerriScan) was used to determine R2 liver iron concentration (LIC) and
myocardial T2* (mT2*). Treatment decisions were assessed and recorded using
an investigator questionnaire after evaluation of patient MRI results.
Results: Of the 243 enrolled patients, 10 and 48% had cardiac and hepatic
siderosis, respectively. In all disease groups, mean LIC was above the target
range (3-7mg Fe/g dw), while mean mT2* was normal (≥20ms). 65.8% of
patients received ICT for ≥1 month before or during the study. During the 12-
month period prior to the study, 55.9% received deferasirox, 11.9% received
deferoxamine and 2.5% received deferiprone. All patients with TM had received
ICT; among patients with MDS, NTDT or other anemia types, some patients
were chelation naïve (CN)/minimally chelated (MC, chelation<1 month in life-
time; Table). MRI assessment led to a change in management in 105 (45.9) of
all evaluable patients (n=229) and in ~60% of CN/MC patients with MDS (17/27
[63.0%]) and other anemias (22/37 [59.5%]; Table). Across all diseases, the
predominant changes were increasing chelator dose (43/75 [57.3%]) and start-
ing chelation (27/75 [36.0%]; Table). In patients who had received ICT for >1
month, the most frequent change was increasing chelator dose (TM, 20/23
[87.0%]; MDS, 11/16 [68.8%]; NTDT, 4/7 [57.1%]; other anemias, 5/6 [83.3%]).
In CN/MC patients, starting ICT was the predominant change (MDS, 10/13
[76.9%]; NTDT, 2/2 [100.0%]; other anemias, 8/8 [100.0%]). Cardiac MRI
assessment (mT2*) was the key driver for ICT decisions in patients with TM
(63.8%; ranked as the most important factor in the treatment decision); however,
LIC was the key determinant in patients with MDS (42.0), NTDT (44.4%) and
other anemias (56.3%).
Table 1.
Summary/Conclusions: These data provide real-life insight into the impact of
MRI on treatment decisions in a large population of patients with heterogeneous
causes of chronic anemia receiving RBC transfusions. A change in ICT manage-
ment due to MRI analysis occurred in nearly half of all patients. This emphasizes
the importance of accurate monitoring of iron load in patients with transfusion-
dependent anemias or NTDT to allow for informed clinical decision making.
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HOME-BASED CONTINUOUS 24-HOUR DEFEROXAMINE VIA A
PERIPHERALLY INSERTED CENTRAL CATHETER IN SEVERE AND
REFRACTORY IRON OVERLOAD: A CONVINIENT AND EFFECTIVE
APPROACH IN THALASSEMIA MAJOR PATIENTS
K Belhoul, H Dewedar*, F Alkhaja, A Farag, N Susan
Thalassemia centre, Dubai Health Authority, Dubai, United Arab Emirates
Background: Severe iron overload leads to significant morbidity and mortality
in β-thalassemia major (TM) patients. Intensive chelation is required in these
patients to reduce iron to lower risk thresholds and avoid the development or
worsening of end-organ dysfunction. Continuous intravenous deferoxamine
(DFO) infusion in the inpatient setting remains the only management option in
patients who fail to respond to high chelator doses, combination therapy, or
those with symptomatic dysfunction requiring rescue therapy. The approach,
however, may be associated with inconvenience and time lost in prolonged
hospital admissions.
Aims: To evaluate the efficacy and safety of home-based continuous 24-hour
DFO infusion via a peripherally inserted central catheter (PICC) in TM patients
with severe and refractory iron overload.
Methods: This was a retrospective cohort study of TM patients attending our
center between October 2013 and August 2015 who had received home-based
continuous 24-hour DFO infusion via PICC. To receive such therapy, patients
had to have no contraindication to PICC line insertion of DFO. They also had
to have severe iron overload with evidence of no response to mono or combined
therapy with subcutaneous DFO, defeiprone, or deferasirox. Severe iron over-
load was defined as a liver iron concentration (LIC) >15 mg/g, cardiac T2*<8
msec, or cardiac T2* 8-15 msec with any of the following: a left-ventricular ejec-
tion fraction (LVEF)<45% per echocardiogarphy, cardiac arrhythmia, compen-
sated or decompensated clinical heart failure, or two or more endocrinopathies.
The dose of DFO was 40 mg/kg titrated based on the index (<0.025) by Porter
el al, administered with or without concomitant oral chelation. 
Results: A total of 41 patients received home-based continuous 24-hour DFO
infusion via PICC during the observation period (mean age 28.4±5.6 years,
51% male). Among these, 9 (22.0%) discontinued therapy, 7 (17.1%) only
had<6 months follow up, while 25 (61.0%) patients had >6 months follow up
and were included in efficacy analysis. Seventeen (42%) received concomitant
deferasirox and 21 (51%) received deferiprone. Reported adverse events in
the 41 patients included: local reaction (n=17), renal tubular acidosis (n=6),
arthritis (n=4), line thrombosis (n=4), line displacement (n=4), local infection
(n=4), systemic infection (n=2), retinopathy (n-1). None of the patients required
hospitalization, developed new endocrine complications or progressed to
advanced cardiac disease and no treatment related mortality was observed.
In the efficacy cohort (n=25, mean age 28.2±5.0 years, 36% male), patients
had receive treatment for an average of 431±137 days. There was a significant
and remarkable decrease in mean serum ferritin level (10848±5872 to
4095±4116 ng/mL, p=0.0001) and LIC (37.5±9.9 to 12.6±11.0, p=0.001) and a
significant increase in cardiac T2* (8.1±3.5 msec to 12.4±6.3 msec, p=0.002).
Heart failure was reversed in 2 out of 3 patients and LVEF improved from a
mean of 40% to 60%. Eight out of 9 insulin-dependent diabetic patients had
insulin dose reduction (mean reduction 34.3±0.2 Units), while one patient shifted
to an oral hypoglycemic. All of the eight patients on oral hypoglycemic agents
prior to treatment manged to stop it successfully.
Summary/Conclusions: Home-based continuous 24-hour DFO infusion via
PICC is an effective treatment option in TM patients with severe iron overload
that could not be controlled otherwise by other chelation regimens. The conven-
ience of home-based therapy further promotes the role of this therapy in such
high risk patients, although data from prospective clinical trials remain of merit.
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A STUDY OF BONE AND JOINT INVOLVEMENT IN THALASSEMIA MAJOR
A Nayyar1, S Kakkar2,*, P Sobti3, H Selhi4
1Pediatrics, Dayanand Medical College & Hospital, 2Pediatrics, Dayanand Med-
ical College &Hospital, 3Pediatric Hemato-oncology, Christian Medical College
& Hospital, 4Orthopaedics, Dayanand Medical College & Hospital, Ludhiana,
India
Background: Thalassemia major is an inherited hemoglobinopathy causing
imbalance in globin chain synthesis, ineffective erythropoiesis and increased
peripheral haemolysis. Thalassemia patients have a variety of bone and joint
disorders like bone pain, deformity, growth failure, rickets, scoliosis, spinal
deformity, nerve compression, pathological fractures, osteopenia and osteo-
porosis. There is a paucity of data about the extent of bone and joint disorders
in thalassemia in developing countries.
Aims: 1. To determine bone and joint involvement in thalassemia major. 2. To
evaluate serum biochemical parameters of bone formation and resorption and
their relation with bone and joint formation. 3. To evaluate DEXA scan scores of
Thalassemia patients and find a correlation, if any, with daily physical activity.
Methods: The study was carried out on 40 thalassemia patients between 5-18
years of age under regular follow up at our centre. All patients were interviewed
as per a well-structured proforma for symptoms relating to bone and joint dis-
ease as described by the patient/parents in past one year and physical activity
by QAPACE questionnaire. Venous blood samples were drawn under aseptic
conditions and used for estimation of biochemical parameters (calcium, phos-
phorus, alkaline phosphatase, vitamin D, parathyroid hormone, thyroid hormone
and serum ferritin). Enrolled subjects were scanned for bone mineral density
(BMD) at femur neck, trochanter and Ward’s angle using dual energy X ray
absorptiometry.
Results: A total of 40 patients were enrolled in the study (M:F=80:20). Half the
patients (n=20) had symptoms pertaining to bone and joint disease. The most
common symptom was leg pain (42.50%), followed by backache (22.50%),
generalized weakness (20%) and joint pains (20%). Asymptomatic patients had
greater mean serum vitamin D as compared to the symptomatic patients (22.2
vs 15.08 ng/ml)(p= 0.225). Five patients were detected to have osteopenia, all
above 10 years of age. The mean BMD in symptomatic patients at femur neck,
trochanter and ward’s angle was 0.781, 0.639 and 0.735 g/cm2 respectively as
compared to 0.754, 0.635 and 0.722 g/cm2 in asymptomatic patients. The dif-
ference was not statistically significant. Patients with low BMD had lower mean
pretransfusion Hb (<9 g/dl) (p= 0.01).Eighty percent of osteopenic patients had
sedentary lifestyle as compared to 44% of patients with normal BMD. Bone
mineral density did not have any correlation with vitamin D levels, serum ferritin
and type of chelation therapy.
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Summary/Conclusions: Pre transfusion hemoglobin of more than 9 g/dL has
a protective role in maintaining good bone health and bone mineral density
and helps to prevent osteopenia. Engaging thalassemia patients in physical
activity has a positive effect on bone mineral density. Low vitamin D levels con-
tribute to symptoms of bone and joint involvement in thalassemia and the same
needs to be determined and supplemented.
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EVALUATION OF WHILE MATTER INTEGRITY BY DIFFUSION TENSOR
MRI AND NEUROCOGNITIVE FUNCTIONS IN NON-STROKE CHILDREN
WITH SICKLE CELL DISEASE
M El-Tawil1, I Ragab1,*, K Ahmed2, E Abdel-Kader1, S Abdel-Sattar2,
M Abdel-Maguid3
1Pediatrics, 2Radiodiagnosis, 3neuropsychiatry, Ain Shams University, Cairo,
Egypt
Background: Cerebral vasoocclusion may result in overt or silent infarctions,
whether in absence of infarction, it may induce subtle ischemic changes need
to be determined. Conventional brain MRI cannot precisely delineate
microstructural changes and the white matter tracts of the brain. Diffusion-ten-
sor imaging (DTI) can detect and quantify microstructural brain changes.
Aims: We aimed to evaluate the ability of multiple diffusion measures to detect
subtle changes in the white matter integrity in patients with SCD compared
with age and sex matched healthy control subjects; and to correlate the MRI
findings with neurocognitive functions.
Methods: We performed a cross-sectional case control study including twenty
one patients with SS and Sβ0 with age between 5-15 years. All patients were
free from any neurological symptoms with no history of stroke. They were sub-
jected to history taking and revision of hospital records for details of diagnosis
including age, hemoglobin electrophoresis, transfusion, hydroxyurea, hospital
admission and SCD complications. Diffusion tensor MRI (DTI) were done for
all patients and ten age matched healthy control subject. Fractional anisotropy
(FA) and apparent diffusion coefficients (ADCs) were calculated in regions of
interest selected in various brain areas (superior and inferior frontal, parietal,
occipital, and temporal white matter areas), centrum semiovale, basal ganglia
(lentiform nucleus), pons, cerebellar white matter areas. Transcranial doppler
was done for the patients with assessment of flow velocities in different brain
regions. Cognitive assessment was done using the following tests, Wechsler
intelligence scale for children for measuring IQ, the Benton visual retention
test for visual memory and Wisconsin card sorting test is used as a measure
of ‘executive’ or higher-order cognitive functions.
Results: Patients group included 7females (33.3%) and 14 males (66.7%), with
mean age of 11.2±3.2 years, weight for age SDS was (-0.029±1.6), height for
age SDS (-0.243±1.4) and median age at diagnosis was 18 months. As regards
admission etiologies over the last year, 19 patients had vaso-occlusive crises
(90.5%), 3 patients had acute chest syndrome(14.3%). Twelve patients were
receiving frequent transfusions (57.1%). Patients with SCD had mean full scale
IQ, verbal and performance IQ below 90 and there is no significant difference
between patients and control group in full scale IQ (P= 0.892), verbal IQ (P=
0.759) and performance IQ (P =1). Concerning executive functions tested by
WCST there was no significant difference in all parameters of the tests between
patients and control group except for (non preservative errors) (P= 0.045).
Regarding MRI DTI there was no significant difference between patients and
control group in both FA and ADC in superior and inferior frontal, temporal, pari-
etal, occipital, basal ganglia and cerebellum.No significant difference in FA and
ADC results in patients with CBF velocity less and above 70cm/sec. There was
positive correlation between difference in errors in BVRT and ADC of right frontal
lobe (r=0.458) and parietal lobe (r=0.455). While there was negative correlation
between ADC of right temporal lobe and FSIQ (r=-0.452), VIQ (r=- 0.518) and
positive correlation between FSIQ and FA of left temporal lobe (r=0.475).
Summary/Conclusions: In absence of clinical evidence of cerebral infarction,
white matter integrity by MRI DTI and neurocognitive functions in children and
adolescents with SCD were preserved compared with healthy control group.
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PROHEPCIDIN CONCENTRATIONS IN GAUCHER DISEASE AND FABRY
DISEASE: INVESTIGATING THE ROLE OF HEPCIDIN IN ABNORMAL IRON
HOMEOSTASIS AND ANAEMIA
A Creamer*, A Li, D Hughes
Haematology Department, Royal Free Hospital, London, United Kingdom
Background: Hepcidin is a 25-amino acid peptide first identified in 2001. It is
recognised to have a key role in the regulation of iron stores, acting on duodenal
enterocytes, macrophages and hepatocytes. Hepcidin levels have been found
to respond to inflammatory cytokines (IL-6), iron status, erythropoetic activity
and oxygen tension. Its precursor, prohepcidin, is synthesised by the liver and
can be measured by a commercially available ELISA. Gaucher disease (GD)
and Anderson-Fabry disease (AFD) are lysosomal storage disorders, a het-
erogenous group of diseases resulting from an inherited defect in a specific
lysosomal enzyme or associated proteins. Haematological abnormalities includ-
ing anaemia and disordered iron homestasis are recognised in GD. AFD is
more commonly associated with organ dysfunction, but anaemia has also been
described.
Aims: The Lysosomal Storage Disorders Unit at the Royal Free Hospital, Lon-
don, has a unique cohort of patients with GD and AFD. By measuring serum
prohepcidin levels, along with haematological indices and levels of circulating
inflammatory cytokines, we sought to investigate the role of hepcidin/prohepcidin
in GD and AFD. We looked specifically at whether it may have a role in the
pathophysiology of the disordered iron profile and anaemia associated with GD.
Methods: Consecutive samples from patients with GD (n=33) or AFD (n=41)
and normal control subjects (n=10) were obtained. All patients gave informed
consent. Commercial ELISA kits were used to measure soluble transferrin
receptor (Biovendor Medicine Inc) and IL-6 (BD Biosciences). A commercial
ELISA for prohepcidin (DRG International Inc) was used.
Results: A total of 33 patients with GD were included, with 27 receiving enzyme
replacement therapy (ERT). A total of N= 41 patients with AFD were included,
of which 26 were receiving ERT. All groups had mean haemoglobin (Hb) within
normal reference ranges. Mean soluble transferrin receptor (sTfR) levels were
below lab reference ranges (1.8-4.6mg/L) for both ERT and non-ERT receiving
patients in GD and AFD groups (GD on ERT mean 1.51mg/L, no ERT
1.47mg.L, AFD on ERT mean 1.04 mg/L, no ERT 0.93mg/L). GD patients had
mean ferritin levels elevated above the upper limit of normal reference range
(Non-ERT group mean=453 µg/L, ERT group mean 398 µg/L). For AFD
patients, mean ferritin was within in the normal range for both ERT (88 µg/L)
and non-ERT (54 µg/L) receiving groups. In all groups, there was a wide range
of serum prohepcidin levels (figure 1). Mean prohepcidin was lower in both
AFD and GD groups vs controls, but this did not reach statistical significance
in any group. There was no correlation between prohepcidin and Hb, serum
IL-6 or serum sTfR in any group.
Figure 1.
Summary/Conclusions: Our study confirms previous results that GD is asso-
ciated with a hyperferritinaemic state which is not found in AFD. As sTfR levels
in GD and AFD patients were low, this appears to be secondary to inflammation
rather than iron status. As in previous studies, we found IL-6 levels to be higher
in GD patients then controls. Anaemia was not prevalent in any patient groups,
although this may be masked by treatment and appropriate transfusion in a
carefully monitored patient group. There was no significant difference between
prohepcidin levels in AFD or GD patients and controls, and no correlation
between Hb, IL-6, or iron status with prohepcidin in any group. The extent to
which prohepcidin reflects hepcidin itself is controversial, but there is a growing
body of evidence that prohepcidin levels are affected by inflammatory condi-
tions, iron deficiency anaemia and changes in EPO levels, amongst other
things. Further studies, with a higher number of patients, and using an ELISA
targeted against hepcidin itself are required to further explore what role it may
play in AFD/GD patients.
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L-ARGININE SUPPLEMENTATION DECREASES HEMOLYSIS AND
PULMONARY ARTERIAL HYPERTENSION IN SICKLE CELL DISEASE
PATIENTS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED
TRIAL
JR Friedrisch1,*, CM Bittar2, CM Bittar1, MCG Meirelles1, LE Daudt1, AA Paz1,
LM Fogliatto1, BK Friedrisch3, SSM Barreto4, LMDR Silla1
1Service of Hematology and Bone Marrow Transplantation, Hospital de Clínicas
de Porto Alegre, 2 Service of Hematology and Bone Marrow Transplantation,
Hospital de Clínicas de Porto Alegre, HCPA, Porto Alegre, 3UNISC, Santa Cruz
Do Sul, 4Division of Pulmonary Medicine, HCPA, Porto Alegre, Brazil
Background: Low nitric oxide (NO) bioavailability contributes to vasculopathy
in sickle cell disease (SCD), and is associated with increased morbimortality.
Since the obligate substrate for NO production is arginine and enhanced NO
bioavailability markedly decreased hemolysis and oxidative stress in SCD, we
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hypothesized that oral L-arginine (LA) supplementation could be beneficial for
SCD outcomes and a reduction the in degree of hemolysis.
Aims: We assessed the impact of 6 months of LA supplementation on SCD
clinical outcomes: leg ulcers, priapism, pulmonary arterial hypertension (PAH),
and vaso-occlusive pain episodes, and the degree of hemolysis rate.
Methods: Sixty-eight patients with SCD were randomized for this double-blind-
ed placebo-controlled trial. Patients received LA (0.1g/kg/day) or placebo for 6
months.
Results: The LA group presented more pronounced decrease in lactate dehy-
drogenase (DHL) (1065±495 U/L to 784±267 U/L vs. 952±383 U/L to 907±395
U/L; p=0.03) and a tendency of PAH reduction. Ten patients of the study group
had PAH (6 in the LA group and 4 in the placebo group). The tricuspid regurgi-
tant jet velocity (TRV) in the 6 patients receiving LA decreased from 2.83±0.36
m/s to 2.46±0.36 m/s, while the TRV in the 4 patients receiving placebo
increased from 2.75±0.35 m/s to 2.80±0.18 m/s (p=0.13), representing a ten-
dency of PAH reduction in the LA group. Non drug-related severe adverse
events were perceived.
Summary/Conclusion: In conclusion, supplementation of LA was associated
with a significant reduction in hemolytic activity with and a tendency towards
reduced PAH. Weighing outlays and benefits, these preliminary results provide
a strong rationale for therapeutic use of LA in SCD disease and other chronic
hemolytic diseases, although an extended multi-center trial with larger number
of SCD individuals is warranted to confirm these findings.
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HOW SHOULD WE SELECT THE MOST VULNERABLE THALASSEMIC
PATIENTS FOR IRON OVERLOAD EVALUATION BY MRI IN A RESOURCE
LIMITED COUNTRY?
S Ekwattanakit1,*, P Saiviroonporn2, K Sanpakit3, N Siritanaratkul1, J Buaboonnam3,
A Khuhapinant1, B Rerkudom 2, S Erberich4, J Wood5, R Krittayaphong6,
V Viprakasit3
1Division of Hematology, Department of Medicine, 2Department of Radiology,
3Division of Hematology/Oncology, Department of Pediatrics, Faculty of Med-
icine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 4Department of
Radiology , 5Division of Pediatric Cardiology, Department of Pediatrics, Chil-
drens Hospital of Los Angeles, Keck School of Medicine, University of Southern
California,, Los Angeles, CA, United States, 6Division of Cardiology, Department
of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Background: Serum ferritin (SF) can be used for determination of iron overload
(IO), however, it does not perfectly correlate with tissue iron status in transfu-
sion-dependent thalassemia (TDT) and even worst in non-transfusion-depen-
dent thalassemia (NTDT). The magnetic resonance imaging (MRI) for cardiac
T2* and liver iron concentration (LIC) is now considered as a gold standard for
IO evaluation in thalassemia worldwide. Nevertheless, this tool was not widely
available and expensive in Thailand. 
Aims: To evaluate the SF cut-off level for diagnosis of severe IO in real-life sit-
uation and determine the utility of SF in predicting IO in thalassemic patients
and select the most vulnerable patients for further MRI evaluation. 
Methods: In this retrospective cross-sectional study, total 1,034 standard MRI
(LIC and cardiac T2*) evaluations performed at Siriraj hospital during 2009-
2014 and paired clinical data including SF were collected. Regardless of globin
genotypes, all 350 thalassemia patients were divided into NTDT (N=108, 162
LIC and 89 cardiac T2* results) and TDT (N=242, 696 LIC and 692 cardiac T2*
results). Different SF cut-off values were tested at 100 or 250 ug/l intervals and
receiver operating characteristic (ROC) analysis was performed. 
Results: Using SF >800 ug/l to predict LIC ≥5 mgFe/g dw, 86.4% of NTDT
would be correctly started on iron chelation. However, 42% of patients (42/100)
with LIC ≥5 mgFe/g dw had SF between 301-800 ug/l and 62.7% (42/67) of
those with SF 301-800 ug/l had LIC ≥5 mgFe/g dw. Using threshold of SF
>300ug/l, we could detect IO in 92% (92/100) of those with LIC ≥5 mgFe/g dw.
When α-NTDT patients were excluded, ROC analysis found that SF >400 ug/l
correctly predict LIC ≥5 mgFe/g dw in 90% of β-NTDT with lower risk of delayed
treatment than using SF threshold >800 ug/l (40.6% vs. 61.9%, according to
NPV). Of 89 cardiac T2* results in NTDT (SF range of 24-11,668), none had
T2* <20ms. For TDT, ROC analysis suggested SF >3,500 ug/l was the best
predictive threshold for T2* <20ms (AUC=0.785), while SF >2,500 ug/l was an
appropriate cut-off level for LIC ≥15mgFe/g dw (AUC=0.861).
Summary/Conclusion: In a resource limited setting for MRI, SF could be used
as a predictive marker for selecting severe IO in both TDT and NTDT. In NTDT,
MRI for cardiac T2* could be omitted and, once for diagnosis, MRI for LIC
should be done in those with SF >300 ug/l. For TDT, the SF cut off of >2,500
and >3,500 ug/l are useful to predict patients with severe LIC and cardiac
siderosis, respectively.
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ASSESSING NPM1 MUTATIONS TYPE A AS MINIMAL RESIDUAL DISEASE
MARKER BY DIGITAL DROPLET PCR BEFORE STEM CELL TRANSPLANTATION
IS A STRONG PROGNOSTIC FACTOR IN PATIENTS WITH AML
M Bill*, L Kloss, M Jentzsch, J Grimm, K Schubert, J Schulz, M Knyrim, M Cross,
V Vucinic, G Behre, W Poenisch, GN Franke, D Niederwieser, S Schwind
Hematology and Oncology, University of Leipzig, Leipzig, Germany
Background: Acute myeloid leukemia (AML) patients (pts) who relapse after
hematopoietic stem cell transplantation (HCT) have a dismal prognosis. Iden-
tifying AML pts with high risk of hematological relapse after HCT is crucial for
treatment guidance. Mutations in the NPM1 gene (NPM1mut) occur early in
leukemogenesis & are relatively stable during disease course, representing
suitable Minimal residual disease (MRD) markers. Recently, MRD assessment,
based e.g. on the quantitative detection of NPM1mut, has been shown to be of
clinical relevance. However, data in pts receiving HCT is limited.
Aims: We tested the feasibility of NPM1mut type A (NPM1mutA) - representing
up to 80% of all NPM1mut-as pre-HCT MRD marker using digital droplet PCR
(ddPCR) for sensitive & specific absolute quantification without the use of stan-
dard curves.
Methods: We identified 46 AML pts with available bone marrow (BM) pre-HCT
(within 30 days before HCT) & NPM1mutA who were in complete remission with
(CR; n=42; 91.3%) or without complete hematological recovery (CRi; n=4; 8.7%).
Median age was 64.5 (range 33.1-74.1) years (y). Pts received HCT after mye-
loablative (Cyclophosphamide 2x60mg/kg+12Gy total body irradiation [TBI],
n=11) or non-myeloablative (Fludarabine 3x30mg/m²+2Gy TBI, n=35) condition-
ing at our institution between 2000 & 2015. Median follow-up was 2.1y.
NPM1mutA & CEBPA mutation status were assessed by Sanger sequencing &
presence of an internal tandem duplication in FLT3 by fragment analysis in diag-
nostic BM. NPM1mutA copy numbers were assessed by ddPCR in pre-HCT
BM. Results were normalized to ABL1 copy numbers. Samples were measured
in triplicates & those with mutation burden ≤0.01% or<3 positive droplets were
defined as negative according to the manufacturer’s recommendations.
Results: At diagnosis 40 pts (87.0%) had a normal karyotype. According to
European LeukemiaNet (ELN) classification 26 (56.5%) had favorable, 14
(30.4%) intermediate-I, 5 (10.9%) intermediate-II & 1 (2.2%) adverse genetic
risk. 18 pts harbored a FLT3-ITD & 4 were CEBPA mut. We found 13 (28.3%)
of the 46 pts to be MRD+ pre-HCT (NPM1mutA/ABL1 range 0.014% - 612.88%).
Except for a trend for lower peripheral blast count at diagnosis (dx) in the MRD+
group (P=.07) no differences were detected between MRD+ & MRD- pts in other
clinical or molecular characteristics (i.e. agedx, sex, ELN group distribution, Hbdx,
Plateletsdx, white blood countdx, BM blastsdx, CR1 vs CR2 vs CRi, CEBPAmut,
FLT3-ITD). The number of chemotherapy cycles pre-HCT was not different
between the MRD+ & MRD- group. Eleven pts relapsed of which 9 (81.8%)
were MRD+ pre-HCT. Four patients did not experience relapse but were MRD+,
2 of them died within 100 days after HCT due to treatment-related complications.
With respect to the remission status, only 2 (50%) of the 4 pts transplanted in
CRi suffered relapse & both were MRD+. MRD+ pre-HCT was associated with
a significantly higher cumulative incidence of relapse (P<0.001, Figure 1A) &
shorter overall survival (OS, P=0.004, Figure 1B).
Figure 1.
Summary/Conclusions: Our study demonstrated that the novel ddPCR is a
feasible method to determine NPM1mutA MRD burden by absolute quantifica-
tion. Pre-HCT MRD+ identified pts with a significantly higher relapse rate &
subsequently shorter OS independently of the clinical, cytogenetical & molec-
ular context. MRD monitoring by NPM1mut detection before HCT should be
incorporated in clinical trials to validate these data & guide therapeutic decisions
for AML pts.
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HLA-DRB1*04 CONFERS BETTER OVERALL SURVIVAL TO MALE
PATIENTS WITH LYMPHOID MALIGNANCIES FOLLOWING ALLOGENEIC
HAEMATOPOIETIC STEM CELL TRANSPLANTATION
K Balassa1,*, H Andrikovics1, P Remenyi2, A Batai2, A Bors1, KP Kiss1, A Szilvasi3,
K Rajczy4, D Inotai3, E Torbagyi2, L Lengyel2, A Barta2, L Gopcsa2, A Tordai5,
T Masszi6
1Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion
Service, 2Department of Haematology and Stem Cell Transplantation, St. Istvan
and St. Laszlo Hospital, 3Transplantation Immunogenetics Laboratory, 4Hun-
garian Stem Cell Donor Registry, Hungarian National Blood Transfusion Serv-
ice, 5Department of Pathophysiology, 63rd Department of Internal Medicine,
Semmelweis University, Budapest, Hungary
Background: Several studies reported associations of individual human leuko-
cyte antigen (HLA) genes and outcome of allogeneic haematopoietic stem cell
transplantation (allo-HSCT). Similarly, HLA genes were found to predispose to
certain lymphoid malignancies. HLA-DRB1*04 is among the documented
genetic risk factors for lymphoid malignancies, and in some studies the risk
was identified to be male-restricted.
Aims: In this study we looked into the effect of HLA-A, -B and -DRB1 allele
groups on overall survival (OS) following allo-HSCT in patients with lymphoid
malignancies.
Methods: Data of 186 consecutive adult patients, who underwent first allo-
HSCT for a lymphoid malignancy at our single centre in Hungary between 2007
and 2013, were retrospectively analysed. The median follow-up time for sur-
viving patients was 44 months. In the cohort five patients (3%) received a graft,
mismatched for HLA-A, and none for HLA-B or HLA-DRB1 at the antigen level.
There were slightly more patients undergoing transplantation from a sibling
donor (106/186, 57%).
Results: Examining the role of HLA status on survival, analyses showed that
carriers and non-carriers displayed no survival difference for any of the HLA-A
or -B allele groups. However, OS of HLA-DRB1*04 carriers was significantly
better compared with non-carriers (24-month OS 66±8% [n= 36] vs 50±4%
[n=150], p=0.01). As baseline transplantation characteristics were uneven in
the two groups, we conducted multivariate analyses, which showed that the
association remained independent (p=0.05, odds ratio [OR] 0.55, 95% confi-
dence interval [CI]: 0.3-1). In view of previous reports of sex-specific features of
HLA-DRB1*04, we performed separate analyses for male (n=114) and female
(n=72) patients. Interestingly, the survival benefit was confined to males
(p=0.01), whereas in female individuals no difference was detected (p=0.41).
The baseline transplantation characteristics were comparable in female and
male patients. Furthermore, we found that the donor gender also affected the
outcome. The survival of male patients varied significantly according to recipi-
ent/donor gender pairs and HLA-DRB1*04 carriership (p=0.04). Surprisingly, in
male recipients the best survival was achieved in HLA-DRB1*04 carriers who
received a graft from a female donor, followed by those HLA-DRB1*04 carriers
for whom the donor was male. HLA-DRB1*04 negative patients displayed worse
survival compared with carriers, and among them the survival was worse for
those whose donor was female. No clear explanation was found to explain the
survival benefit, although there was a tendency for less CMV reactivation/dis-
ease among HLA-DRB1*04 carriers (3/36, 8% vs 31/150, 21%, p=0.097).
Summary/Conclusions: In summary, we observed in a cohort of 186 patients
with lymphoid malignancies that HLA-DRB1*04 male carriers had significantly
better overall survival following allo-HSCT compared to non-carriers. Our find-
ings support that HLA-DRB1*04 carriership might result in male-specific con-
sequences in the lymphoid malignancy patient group. Our results suggest that
the prognosis of patients with sex-specific disease risks might be modified by
transplantation from the opposite sex. Our findings should be confirmed in larg-
er patient populations, and similar data could affect donor selection preferences
for HLA-DRB1*04 carrier patients in the future.
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IMPACT OF T CELL DOSE ON OUTCOMES OF NON-MYELOABLATIVE
ALLOGENEIC TRANSPLANTS IN MULTIPLE MYELOMA
A Nair1,*, T Das1, T Walker1, A Kalff1,2, K Bergin1,2, J Hocking1,2, S Avery1,
D Curtis1,2, S Patil 1, D Klarica1, J Muirhead1, J Reynolds2, A Spencer1,2
1Haematology, Alfred Health, Melbourne, 2Monash University, Melbourne, Aus-
tralia
Background: Donor T cells are responsible for graft versus host disease
(GVHD) following allogeneic stem cell transplantation (alloSCT). Studies have
shown a reduced incidence of GVHD but increased relapse risk with T cell
depleted transplants. T cell replete stem cells are generally used for non-mye-
loablative (NMA) alloSCT to prevent graft failure and to avail the benefit of a
potential graft versus tumor effect which is considered the major tool for disease
control in this type of transplant. T cell doses in individual T cell replete trans-
plants vary and to the best of our knowledge no previous studies have looked
at the impact of T cell dose on the outcome of NMA alloSCT. We routinely per-
form tandem autologous (ASCT)-NMA alloSCT for high risk as well as relapsed
multiple myeloma (MM) patients at our centre. High risk MM patients are
defined by the presence of at least 2 out of 5 risk features including International
Staging System score 3, adverse cytogenetics [t(4;14),17p- on FISH and/or
complex karyotype], elevated lactate dehydrogenase, plasma cell leukemia
(all at diagnosis) and induction failure (<PR) with bortezomib or IMID-based
induction therapy. These patients receive ‘upfront’ tandem ASCT-NMA SCT
and the patients relapsing following conventional treatment receive ‘deferred’
tandem ASCT-NMA SCT. All patients receive high dose Melphalan conditioned
ASCT and within 2-3 months, receive an outpatient-based Fludarabine
(48mg/m2 X 3days) and TBI (2Gy X1day) conditioned NMA SCT from matched
sibling or unrelated donors. We use Cyclosporine and Mycophenolate mofetil
as GVHD prophylaxis.
Aims: To find out whether the outcomes after NMA SCT for MM were influenced
by the T cell dose received.
Methods: After obtaining informed consent, we undertook a retrospective
analysis of patients who underwent tandem ASCT-NMA SCT from May 2008
to June 2015 for MM. Primary end points were progression free survival (PFS)
and overall survival (OS). Secondary end points were cumulative incidences
of acute GVHD, chronic GVHD and relapse, treatment related mortality and
achievement of donor chimerism.
Results: Out of 59, 19 patients had received T cell dose of ≥3x108/kg. This
high dose cohort (Hi-T) was compared to 40 patients who got <3x108/kg T
cells (Lo-T). Median age was 59yrs (range 22-66yrs) for Hi-T and 54yrs (range
38-67yrs) for Lo-T (p=0.43). 52.5% of patients received upfront transplants in
Hi-T against 42% in Lo-T (p=0.23). 68% of patients had unrelated donors in
Hi-T versus 57.5% in Lo-T (p=0.22). After a median follow up of 45.7 months,
PFS and OS were significantly inferior in Hi-T group (median PFS 366 days vs
1067 days, p=0.05, median OS 752 days vs not reached, p=0.002). Cumulative
incidences of grade 2-4 acute GVHD and extensive chronic GVHD were higher
in Hi-T (47% vs 17.5%; p=0.03 and 80% vs 50%; p=0.04 respectively). There
were 5 treatment related deaths (26.3%) in Hi-T (all due to GVHD) against 2
(5%) in Lo-T (both due to infections); (p=0.009). Cumulative incidence of
relapse was not different between the arms (48% vs 49% respectively at 4yrs.).
Achievement of donor CD3 chimerism at different time points (days 30, 60, 90
and 180) was not different between the arms. All patients who were alive at 1yr
achieved full donor chimerism. On multivariate analysis, Hi-T was independ-
ently associated with inferior OS.
Figure 1.
Summary/Conclusions: To conclude, in NMA alloSCT for MM, the T cell dose
infused has a significant influence on outcomes. Limiting the T cell dose to
<3x108/kg can improve the OS and reduce TRM and GVHD. Larger ran-
domised trials are required to confirm this observation.
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LOW DOSE TOTAL MARROW/TOTAL LYMPHOID IRRADIATION (TMI/TLI)
INSTEAD OF TOTAL BODY IRRADIATION (TBI) INDUCE FULL DONOR
CHIMERISM BEFORE T-REPLETE HAPLOIDENTICAL TRANSPLANTATION
B Sarina1,*, A Rimondo1, P Mancosu2, L Morabito1, S Bramanti1, R Crocchiolo1,
P Navarria3, J Mariotti1, L Castagna1
1Hematology Unit, Humanitas Cancer Center, 2Physics Service of Radiation
Oncology Department, 3Radiotherapy and Radiosurgery Department, Istituto
Clinico Humanitas, Rozzano, Italy
Background: T cell replete haploidentical stem cell transplantation (haploSCT)
with post-transplantation cyclophosphamide (Cy) (PT-Cy) has been increas-
ingly applied in high-risk hematologic patients. In the original, nonmyeloablative
conditioning regimen (NMAC) included low dose total body irradiation (TBI).
Aims: The aims of the study were to evaluate the engraftment, chimerism,
and tolerance of NMAC regimen with low dose total marrow and lymphoid irra-
diation (TMI/TLI) instead of TBI, in patients with advanced disease.
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Methods: Between April 2009 and August 2015, 98 patients received a hap-
loSCT at our institution. NMAC was used in 60 patients. For 20 patients (33%),
TMI/TLI (2 Gy) was used instead of TBI. 12 of 20 (60%) had bone and/or bone
marrow involvement. The median age was 49 years (range 20-68). NMAC con-
sisted of fludarabine (30mg/m2/day) on day -6 to -2, Cy (14.5mg/kg/day) on
days -6 and -5, TMI/TLI (200 cGy in a single fraction) on day -1, followed by
bone marrow or peripheral blood stem cell graft. Graft versus host disease/host
versus graft prophylaxis consisted of Cy (50mg/kg/day) on days +3 and +4,
and from day +5 mycophenolate mofetil until day +35 days, and tacrolimus or
cyclosporine A.
Results: Patient characteristics are shown in Table 1. The median follow-up
time was 15 months (range 6-48). Immediate tolerance was good and no
patients developed nausea or vomiting nor parotid hyperplasia. The median
time to ANC >500/µL, and platelet recovery >20,000/µL was 22 days (range
16-28) and 27 days (range 12-41), respectively. At day +30, full donor chimerism
was obtained in all evaluable patients (19/20). The cumulative incidence of
acute grade ≥2 was 20% (95% CI: 6.0-39.9). No severe/moderate cGVHD was
observed. The 1-yr cumulative incidence of relapse, overall survival and non-
relapse mortality were 23% (95% CI: 6.1-45.8), 60% (95% CI: 38.4-81.6) and
30% (95% CI: 11.8-50.8), respectively. Causes of death were: disease pro-
gression (n=2), septic shock (n=2), fungal pneumonia (n=2), renal failure (n=1)
and JCV encephalopathy (n=1). Engraftment, chimerism, aGVHD incidence
were not different to patients receiving conventional TBI.
Table 1. Patient characteristics.
Summary/Conclusions: This retrospective analysis suggests that TMI/TLI
could substitute conventional low dose TBI, with a sufficient degree of immuno-
suppression of recipient, allowing engraftment and full donor chimerism. More-
over, the 100 days TRM, the relapse incidence, aGVHD and cGVHD were com-
parable to that observed in the TBI group.
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POSITIVITY OF WHOLE BODY POSITRON EMISSION TOMOGRAPHY
(PET) BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION HAS
NEGATIVE PROGNOSTIC IMPACT BUT IT DIFFERS ACCORDING TO
LYMPHOMA SUBTYPE AND LINE OF ASCT
D Pohlreich1,*, B Vackova1, M Trnkova1, R Pytlik1, M Trneny2
1BMT unit, 2Dept of hematooncology, General Teaching Hospital Charles Uni-
versity, Prague, Czech Republic
Background: Pre-transplant PET is considered as an important prognostic
variable. Positive PET is usually linked with worse prognosis. There is however
limited information if there are any differences in PET impact according to line
in which is ASCT performed as well as different lymphoma subtypes.
Aims: To analyze the impact of the pre-transplant PET on post-transplant out-
come of patients with lymphoma according to lymphoma subtypes and the line
of treatment.
Methods: Retrospective analyzes of patients who underwent ASCT between
2010 and 2014. Only pts. with pre-transplant PET were eligible for the analysis.
PET had to be performed after the last cycle of chemotherapy before ASCT in
interval less than 60 days. Patients who were PET negative and received one
more cycle of chemotherapy due to logistic reasons were eligible. Visual PET
evaluation was used in comparison to mediastinum and liver accumullation. All
pts. signed the informed consent and agreed with data analysis.
Results: There were 350 pts. transplanted for lymphoma between 2005 and
2014. Pre-transplant PET was performed in 253 pts. Patients who were PET
positive (PET+), but received additional chemotherapy before ASCT without
PET reevaluation (n=20) were excluded from the study. In two patients PET
findings were inconclusive and were excluded as well. Altogether 231 patients
were evaluated, age at ASCT 53y (21-71), male/female 134/97, DLBCL 108/43%
(68 in 1. line, 40 at relapse) FL 33/14% (2 in 1. line, 31 at relapse), MCL 43/19%
(41 in 1. line, 2 at relapse), HL 21/9% (1 primary progressive in 1. line, 20 at
relapse) and others 26/11% (13 in 1. line, 13 at relapse). Altogether 79 (34.2%)
patients were PET positive (PET+) and 152 were PET negative (PET-). PET+
pts. had significantly higher death or relaps risk (HR 1.75, p 0.04). There was
however only borderline impact of PET in 1st line ASCT (p 0.06) and significant
in at relapse ASCT (p 0.002). It was mainly due to DLBCL, where was found
significant risk for PET+ in the whole group (HR 2.35, p 0.02). No difference
was observed in the 1st line ASCT (p ns) with PET negative predictive value
(NPV)=0.91 and PET positive predictive value (PPV)=0.13. Patients with DLBCL
and ASCT at relapse had significantly worse outcome (HR 2.42, p 0.037) with
NPV 0.63 and PPV 0.47. The majority of MCL pts (41) underwent 1st line ASCT.
There was significanty worse outcome for PET+(HR 157.3, p<0,0001) with NPV
0.88 and PPV 0.43. There was limited number of FL (31) and HL (20) patients
resp. transplanted for relapse and there was found only trend for worse outcome
of PET+ pts for HL (HR 3.7, p 0.11, NPV 0.76, PPV 0.42) and no difference in
FL subgroup (HR 0.64, p 0.49, NPV 0.75, PPV 0.14).
Summary/Conclusions: We have confirmed prognostic value of pretransplant
PET. We have however found that there are differences in lymphoma subtypes
(1st line ASCT for DLBCL vs MCL), and differences according to the line of
ASCT (1st line ASCT vs at relapse ASCT DLBCL) with differences in NPV (high
in 1s line ASCT DLBCL and MCL vs low at relapse ASCT for all subtypes) and
PPV (low in 1st line ASCT for DLBCL). Lymphoma subtype as well as line of
treatment should be considered in the PET finding interpretation before possible
treatment change based on pretransplant PET.
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WHAT IS THE OUTCOME OF PATIENTS WITH ACUTE LEUKEMIA WHO
SURVIVE SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE?
O Ringdén1, M Labopin2, A Maihol2, D Beelen3, Y Fløisand4, A Ghavamzadeh5,
J Finke6, G Ehninger7, L Volin8, A Ganser9, S Giebel10, A Nagler11,*
1BMT Unit, Stockolm, Sweden, 2Hôpital Saint Antoine, Paris, France, 3BMT
Unit, Essen, Germany, 4BMT Unit, Oslo, Norway, 5BMT Unit, Teheran, Iran,
6BMT Unit, Freiburg, 7BMT Unit, Dresden, Germany, 8BMT Unit, Helsinki, Fin-
land, 9BMT Unit, Hannover, Germany, 10BMT Unit, Gliwice, Poland, 11BMT
Unit, Tel Hashomer, Israel
Background: Acute graft-versus-host disease (GVHD) is a major complication
of allogeneic hematopoietic stem cell transplantation (HSCT). With new prom-
ising therapies, survival may improve in patients with severe acute GVHD. 
Aims: We wanted to analyze the long-term outcome among patients who sur-
vive severe acute GVHD.
Methods: This is a landmark analysis of 23,567 patients with acute leukemia
who survived >6 months after HSCT during 2002-2014. Patients with severe
acute GVHD (n=1,738) were compared to controls. 
Results: Patients with severe acute GVHD had a higher non-relapse mortality
(NRM) and chronic GVHD compared to controls (p<10-5). Extensive chronic
GVHD was 26.9% before 6 months and 27.2% after 6 months in the severe
acute GVHD group (p<10-5). The probability of relapse was significantly lower
in the severe acute GVHD group, and leukemia-free survival (LFS) and survival
was significantly lower than for the controls (p<10-5). Five-year LFS in patients
who survived severe acute GVHD was 49% as opposed to 61% in controls
with no or mild, and 59% in patients with moderate GVHD.
Summary/Conclusions: HSCT patients who survive severe acute GVHD have
a high risk of extensive chronic GVHD, a higher NRM, a lower relapse proba-
bility and lower LFS, compared to other HSCT patients.
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SCLERO-CORNEAL LENSES SAFE AND EFFICIENT FOR THE TREATMENT
OF KERATOCONJUNCTIVITIS SICCA IN PATIENTS WITH REFRACTORY
OCULAR GVHD: A STUDY ON BEHALF OF THE SFGM-TC
L Magro1,*, A delcampe2, M robin3, S n’gyen4, A huynh5, MT rubio6, F suarez7,
S vigouroux8, I yakoub-agha9
1CHRU Lille (France), Hôpital Claude Huriez, Lille Cedex, 2hôpital Charles
Nicolle, CHU Rouen, Rouen, 3hôpital saint louis, assistance puplique hîpitaux
de paris, 4hôpital la pitié salpétrière, assistance puplique hôpitaux de paris,
paris, 5hematologie, oncopole, toulouse, 6hôpital saint antoine, 7hôpital Necker,
assistance puplique hôpitaux de paris, paris, 8hematologie, CHU Bordeaux,
bordeaux, 9hôpital claude Huriez, CHRU Lille, Lille Cedex, France
Background: Keratoconjunctivitis sicca syndrome (KCS) due to chronic GvHD
(cGvHD) is responsible for major alteration in quality of life of patients under-
going allogeneic stem cell transplantation (allo-CST). The conjunctival fibrosis
secondary to inflammation is often slow and subtle and is responsible for
impaired corneal and conjunctival epithelial surfaces potentiated by tear quan-
titative and qualitative deficiency. Treatment of KCS remains disappointing;
variable success in the correction of the conjunctival dryness has been obtained
with variety of topical treatments with or without systemic immunosuppressive
agents. These treatments, though, do not seem to have any effect on sicca
symptoms and patients’ quality of life. Sclero-corneal lenses bring a valid ther-
apeutic option by creating a pre-corneal reservoir of tears allowing permanent
lubrication of the epithelium, the protection of the corneal surface against the
eyelid and ciliary mechanical friction and against environmental stresses and
the creation of a uniform refractive surface to be taken into optimum optical
load and stable visual acuity.
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Aims: Scleral lenses bring a valid therapeutic option by creating a pre-corneal
reservoir of tears allowing permanent lubrication of the epithelium, the protec-
tion of the corneal surface against the eyelid and ciliary mechanical friction
and against environmental stresses and the creation of a uniform refractive
surface to be taken into optimum optical load and stable visual acuity. In this
multicenter retrospective study we wanted to assess the incidence of scleral
lenses on sixty one patients concerning by refractory ocular GVHD.
Methods: We describe the safety and efficacy of Sclero-corneal lenses in a
retrospective analysis of 62 patients with KCS due to cGvHD following allo-
CST. All patients had superficial punctate keratitis refractory to standard treat-
ments. Evaluation of patients was carried out by two ophthalmologists. cGVHD
was recorded according standard criteria. Ocular surface disease index (OSDI)
and Oxford score were used to evaluate ocular symptoms. The scale of
“Monoyer” was used and converted into visual acuity “LOG MAR” for compar-
ative purposes of the study.
Results: All patients but two agreed to hold the lenses. The 62 patients were
equipped with sclero-corneal lenses. With a median follow-up of 22 months
(IQR 8-43) from the treatment with lenses, all patients have experienced an
improvement in their quality of life with a clear improvement of dry-eye symp-
toms. This quality of life is also improved by decreasing the frequency of eye-
drop instillation and the attenuation of the discomfort and post-instillation visual
fluctuation. At two months, all patients but one experienced improvement in
OSDI score with a median of 92 points (range, 40-100) before lenses to a
median of 25 points (range, 3-90). We also observed improvement or stability
of visual acuity with median gain of -0.2 (range, -1 to +0.1) LOG MAR acuity
and improvement or stability of the Oxford score score with a median of 3
points (range, 0-5) before lenses to a median of 1 points (range, 0-4) after
lenses. with a median gain of 2 points in almost all patients. 
Summary/Conclusions: Treatment of KCS with sclero-corneal lenses is prom-
ising. Whenever possible, this approach should be considered in patients expe-
riencing KCS due to cGVHD.
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UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION
FOLLOWING BUSULFAN BASED REDUCED INTENSITY CONDITIONING
AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR ADVANCED
HODGKIN´S LYMPHOMA
MJ Pascual, M Ortiz, J Díez*, S Lorente, I Sánchez, I Vidales, A Contento, MA
Cuesta, L Baeza, G Navarro, M Espeso, AI Heiniger
Department of Hematology, Regional Hospital, Málaga, Spain
Background: Hodgkin´s Lymphoma (HL) is a potentially “curable malignant
disease” with chemotherapy, radiotherapy or, eventually, high-dose chemother-
apy followed by autologous stem cell transplantation (SCT). For patients relaps-
ing after auto-SCT or those with advance refractory lymphoma, allogeneic SCT
is a valid option. In this setting, our institution has opted for haploidentical
donors as source of stem cells for allo-SCT in advanced HL patients.
Aims: Patients with advanced HL who received haploidentical SCT (haplo-
SCT) were retrospectively analyzed in terms of overall survival (OS), progres-
sion-free survival (PFS) and graft versus host disease (GVHD).
Methods: From May 2012 to September 2015 eighteen haplo-SCT were per-
formed at our hospital on patients with HL who had relapsed after auto-SCT or
had needed more than three lines of chemotherapy to reach any kind of
response. The conditioning regimen consisted of cyclophosphamide (Cy) 14.5
mg/Kg on days -6 and -5, fludarabine 30 mg/m2 on days -6 to -2 and busulfan
(Bu) on days -3 and -2. GVHD prophylaxis consisted of Cy 50 mg/Kg on days
+3 and +4, followed by tacrolimus plus mycophenolate mofetil from day +5.
Results: The median age of the cohort was 31 years (19-58). The HCT-CI >2,
EBMT score >3 and high DR index were 28%, 67% and 11%, respectively.
Thirty-nine percent of all patients were not in complete remission and eleven
percent were in progression at the time of transplantation. The median number
of treatment lines before SCT was five (4-11) and brentuximab-vedotin was
employed as bridge to the allo-SCT in 44% of cases. Thirty-nine of the patients
had received a previous autograft and one patient both, auto-SCT and allo-
SCT. Median time to haplo-SCT from diagnosis was 42 months. The stem cell
sources were bone marrow (22%) and peripheral blood (78%). All the patients
engrafted and full donor chimerism was reached in 100% of the entire cohort
at day +30. The median times to neutrophil (>0.5 x 10e9/L) and platelet recov-
ery (>20 x10e 9/L) were 18 (13-30) and 26 (10-44) days from SCT.
Extramedullary toxicity grade 3-4 occurred in 2 cases. One of them developed
severe hepatic veno-occlusive disease which was resolved with defibrotide.
Seventeen patients were evaluable for acute and chronic GVHD. The 100-day
cumulative incidence (CI) of grade II-IV acute GVHD was 35% (7% grade III-
IV) with a median time of 33 days (23-80). The cumulative 3-year incidence of
moderate chronic GVHD was 13%. With a median follow-up of 14 months
(range 2-44), the CI of non-relapse mortality (NRM) and of relapse were 5%
(1/18) and 42% (6/18), respectively. The actuarial OS and PFS at 45 months
was 77% and 57%, respectively. Fifteen patients are alive, 12 disease free.
The causes of death were relapse (n=2) and BK virus encephalitis (n=1).
Relapses are being treated with brentuximab-vedotin followed by donor lym-
phocyte infusions (DLI), with no cases of GVHD.
Summary/Conclusions: Haplo-SCT with Bu based RIC and high-dose post-
transplantation Cy offers high rates of remission in advanced HL, with low inci-
dence of GVHD and NRM. In our experience, retreatment with brentuximab-
vedotin combined with DLI is well tolerated and a good option to manage
relapses after haplo-SCT.
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UNRELATED TRANSPLANT FOR SEVERE APLASTIC ANEMIA (SAA):
LONG TERM RESULTS AND RISK FACTOR ANALYSIS FOR OVERALL
SURVIVAL
V Funke*, C Bernardi, M Oliveira, M Bitencourt, C Bonfim, S Nabhan,
C Bonamin, D Setubal, L Ribeiro, G Loth, S Michelle, R Pasquini
Hematology, Federal University of Parana, Curitiba, Brazil
Background: For patients with SAA, Transplantation from an unrelated donor
(UD) is usually considered after failure of at least one course of immunessu-
pression. This strategy is based on a relatively high risk of complications for
UD transplant recipients, such as graft rejection, graft-versus-host disease
(GvHD) and infections. However, the outcome of unrelated donor transplants
has significantly improved in recent years, due to better donor selection, con-
ditioning regimen otimization and better supportive care.
Aims: The authors aim to describe results from 51 patients with SAA who have
received unrelated allogeneic transplants in a single reference institution from
1997 to 2014 and identify risk factors for survival.
Methods: Data of 51 patients were retrieved from the center databasis. Fisher
exact test was used for categoric variables and Kaplan Meier for survival esti-
mates. P level of significance was<0,05. Primary endpoint was overall survival.
Secondary endpoints were engraftment, acute and chronic gvhd and identifi-
cation of risk factors for survival.
Results: There were 30 females and 21 males. Median age was 15 years old
(0-47). Median total number of cells infused was 3,4 x 108/kg.61% of the
patients have received more than 50 transfusions previously. Conditioning reg-
imen were: CY 120+TBI 1320 +/- ATG in 16 (31%) patients, Bu 12 mg/kg+ Cy
120+ ATG in 18 (35%), and Fludarabine+Cy+ATG in 8 (16%), Fludarabine,
Cy+TBI 200 in 9 (18%) patients. Stem cell source was marrow in 84%, cord
blood in 13% and peripheral blood in 3% of patients. Transplants were full
matched in 32 (62%) patients, had one mismatch (out of 12) in 12 (24%) and
2 mismatches in 7 (14%) patients. Engraftment was complete as evaluated by
donor chimerism at day 30 and 100 post transplant in 36 patients (71%), partial
in 4 (8%) and graft failure was observed in 9 (18%) patients. Acute GVHD
grade II-IV was seen in 9 patients (18%) and NIH moderate to severe chronic
GVHD was seen in 8 (16%) patients. Median overall survival was 328 days (4-
4287) and estimated 5 years overall survival was 55%. Risk factors for survival
identified were: HLA mismatch and stem cell sources other than marrow.
Summary/Conclusions: Unrelated transplants are a feasible salvage therapy
for patients with SAA refractory to immunessupression, being HLA compatibility
and marrow stem cell source factors with a positive impact on survival.
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DIFFERENT CLUSTERS OF IMMUNOLOGIC VARIABLES ARE ASSOCIAT-
ED WITH CHRONIC GVHD AND RELAPSE IN A DYNAMICAL MODEL
C Skert1,*, S Perucca1,2, L Imberti2, M Chiarini2, V Giustini2, C Ghidini2,
M Malagola1, F Cattina1, V Cancelli1, B Rambaldi1, S Bernardi1,2, N Polverelli1,
D Russo1
1Usd Tmo Adulti, 2CREA Diagnostics Department, Brescia, Italy
Background: The long-term efficacy of allogeneic haematopoietic stem cell
transplantation (SCT) relies primarily on the Graft-versus-tumor (GVT) effect,
which partially overlaps with Graft versus Host disease (GvHD), the most com-
mon cause of morbidity and mortality in HSCT. Immune parameters that uni-
vocally associate with GVHD or GVT have not been identified yet.
Aims: In this study, lymphocyte subsets together with TCR-repertoire analysis,
and index of thymic and bone marrow output were evaluated at different time
points, in order to identify possible predictors of chronic GVHD and ineffective
GVT.
Methods: Prospective evaluations of lymphocyte subsets, thymic and bone
marrow output were performed in 40 patients before SCT, at 30, 90, 180 days
and 1 year after SCT. CD4+/CD8+ naïve, central memory, effector memory,
terminally differentiated effector memory (TEMRA) cells, subsets of regulatory
T-lymphocytes, immature B cells, naïve, switched and unswitched memory B
cells, memory double negative (IgD-CD27-) B cells were analysed by flow
cytometry. Analysis of thymic and bone marrow output was performed by detec-
tion of T cell receptor excision circles (TRECs) and kappa-deleting recombina-
tion circles (KRECs). TRECs and KRECs were simultaneously quantified by a
duplex quantitative Real-Time PCR. Heteroduplex assay was used to perform
TCR-repertoire analysis. A 2-step multivariate analysis was performed using
principal component analysis (PCA) and Cox regression analysis, to solve the
problem of the high number of variables (immunological, patients- and trans-
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plant related) in comparison with the relatively limited and heterogeneous pool
of patients.
Results: Chronic GVHD was observed in 9 patients (median time: 7 months,
range 4-10). In 2-step multivariate analysis, lower values of regulatory effector
memory lymphocytes at day +30 and lower percentage of CD8+TEMRA cells
at +90, together with lower values of immature B cells and KRECs at +180
were inversely correlated with chronic GVHD (HR 0,4; p=0,002). The relapse
rate (30%; median time: 9 months, range 3-48) was used as clinical index of
ineffective GVT. The following clusters (C) of immunological parameters were
associated with relapse: C1(pre-transplant lower values of CD4+central mem-
ory, all regulatory, and regulatory central memory cells; HR 4,0 p=0,02); C2(pre-
transplant higher percentage of mature B cells, lower values of switched mem-
ory B cells and KRECs at day+90; HR 0,1 p=0,008).
Summary/Conclusions: Different clusters of immunological parameters at dif-
ferent time points were evidenced as predictors of cGVHD and ineffective GVT,
allowing a clear-cut distinction between these immunological reactions.
Changes in pre- and post-transplant B-lymphopoietic microenvironment and
imbalances in the subsets of B-cells may influence GVHD and GVT. The atyp-
ical association of regulatory T-cells with GVHD may be explained by the relative
efficiency of different subsets of regulatory T-cells (naïve>memory), as shown
in some experimental models. The correlation of CD8+TEMRA at +90 with
chronic GVHD may early indicate a persistently activated and dysregulated
immune system. The validation of these clusters of immunological parameters
as specific early predictors of GVHD or GVT, even before SCT, could potentially
allow the development of pre-emptive and targeted therapies.
E1507
THE JAK2 46/1 HAPLOTYPE IS ASSOCIATED WITH ACUTE
GRAFT-VERSUS-HOST DISEASE IN ACUTE MYELOID LEUKEMIA
PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
N Meggyesi1,*, K Balassa1, T Krahling1, P Remenyi2, A Batai2, A Bors1,
KP Kiss1, E Torbagyi2, L Gopcsa2, L Lengyel2, A Barta2, G Varga3, A Tordai4,
H Andrikovics1, T Masszi2
1Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion
Service, 2Department of Haematology and Stem Cell Transplantation, St. Istvan
and St. Laszlo Hospital, 33rd Department of Internal Medicine, 4Department of
Pathophysiology, Semmelweis University, Budapest, Hungary
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
has proven to be the most effective treatment option for certain hematological
malignancies, however the favorable outcome of the procedure could be jeop-
ardized by graft-versus-host disease (GvHD). Cytokines play a well established
role in the mechanism of acute GvHD (aGvHD) and many of the involved
cytokines relay their signal through the Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway.
Aims: In the present work, we investigated whether recipient and donor JAK2
46/1 haplotype could affect allo-HSCT outcomes, such as aGvHD, relapse rate
and mortality in AML patients.
Methods: We examined the association of recipient and donor JAK2 46/1 hap-
lotypes and allo-HSCT outcome in a cohort of 124 adult patients diagnosed
with AML, who received first allo-HSCT in complete remission (CR) between
January 2007 and December 2013 at our single center. For identification of
JAK2 rs12343867 from genomic DNA LightCycler melting curve analysis (Light-
Cycler 480II, Roche Diagnostics) was performed.
Results: Presence of JAK2 46/1 haplotype was associated with higher fre-
quency of aGvHD grades II-IV (carrier vs non-carrier recipients 42% vs.19%
p=0.008 and carrier vs non-carrier donors 40% vs 21%, p=0.038). We confirmed
significantly higher risk if both, recipient and donor were 46/1 haplotype carriers
compared to those where recipient and donor were non-carriers (OR=5.242,
95% CI=1.784-15.404, p=0.003). Relapse free survival (RFS) did not differ
between 46/1 haplotype carrier and non-carrier recipients (2-year RFS
69.1±6.1% vs 54.2±6.9%, respectively, p=0.25), but we found significant alter-
ations in the cause of death between the subgroups. In the 46/1 haplotype
group the major causes of death were transplantation related complications,
including aGvHD (18/21, 86%), while 3 deaths (14%) were attributed to relapse.
In the non-46/1 haplotype subgroup 48% died of relapsing leukemia, while non-
relapse mortality accounted for 52% (p=0.024). If donors were 46/1 carriers,
patients more often died of transplantation related complications (81% vs 50%,
p=0.049). The relapse rate was comparable in patients transplanted from a
carrier or a non-carrier donor. Survival analysis according to the donor haplotype
showed a favorable RFS in the non-46/1 haplotype group (2-year RFS 71±6 vs
53±7%, p=0.033). The difference in 2-year RFS rates remained significant in
the four recipient-donor groups [64±8% (non-carrier recipient, non-carrier
donor), 82±8% (carrier recipient, non-carrier donor), 36±11% (non-carrier recip-
ient, carrier donor) and 61±8% (carrier recipient, carrier donor); p=0.038).
Summary/Conclusions: Although the exact pathomechanism is yet to be
explored, our findings suggest that recipient and donor JAK2 46/1 haplotypes
might be involved in the regulation of aGvHD.
E1508
IN THE ERA OF TKIS, WHICH PH+ ACUTE LYMPHOBLASTIC LEUKEMIA
PATIENTS ARE SUITABLE FOR AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION?
X Liu*, E Jiang, Y Huang, D Yang, Y He, J Wei, L Qiu, S Feng, M Han
Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical
Sciences & Peking Union Medical College, Tianjin, China
Background: Outcome of Philadelphia-positive acute lymphoblastic leukemia
(Ph+ ALL) improved significantly with the introduction of tyrosine kinase
inhibitors(TKIs).The role of autologous stem cell transplantation(auto-SCT) in
this setting has gradually received increasing attention.
Aims: The aim of our study was to determine which Ph+ ALL patients are suit-
able for auto-SCT in the era of TKIs.
Methods: Fifty-nine Ph+ ALL patients received SCT and TKIs therapy were
enrolled in this study,the auto-SCT group has 23 patients and the matched sib-
ing donor(MSD-SCT) group has 36 patients.We analysized retrospectively the
data according SCT type and the statue of molecular response.
Results: The 3-year overall survival(OS) rates of patients in the auto-HSCT
group and MSD-SCT group were 67.1±10.3%, and 67.0±8.3% (P=0.701); the
3-year leukemia-free survival (LFS) rates were 53.9±10.9% and 61.3±10.5%
(P=0.918); the incidence of replase(IR) were 46.3±11% and 25.5±7.9%
(P=0.31); the transplantation-related mortality(TRM) were 0 and 14.7±6.1%
(P=0.058). Twenty-seven patients reached molecular remission within 3 months
after induction therapy and could stably maintain this response before trans-
plantation(CMR3). The patients received the second generation TKIs(nilotinib
or dasatinib) seemed to have a higher possibility to reach CCR3 than those
received imatinib(70% vs 40.8% P=0.18). For these patients who reached
CCR3, The 3-year OS of patients in the auto-HSCT group and MSD-SCT group
were 90.9±8.7% and 78.7±11% (P=0.503); the 3-year LFS were 80.8±12.2%
and 75.0±10.8% (P=0.661); the IR were 19.2±12.2% and 19.6±10.2%
(P=0.909); the TRM were 0 and 6.2±6.1% (P=0.407).
Figure 1.
Summary/Conclusions: Those patients who reached CMR3 were suitable for
auto-SCT.The second generation TKIs could help more patiens benefit from
auto-SCT.
E1509
COULD GRAFT VERSUS TUMOR EFFECT IMPROVE OUTCOMES IN
MYELOID MALIGNANCIES WITH ACTIVE DISEASE UNDERGOING
REDUCE INTENSITY ALLOGENEIC TRANSPLANT?
O Lopez Godino*, E Pérez López, S Alonso, M Cabrero, JM Bastida Bermejo,
O Ferré, F López Cadenas, L Vázquez, MD Caballero, L López Corral
Hematology department, Hospital Universitario de Salamanca, Salamanca,
Spain
Background: Allo-transplant (allo-HSCT) has become a significant treatment for
refractory and relapsed haematological malignances; however, relapse remains
a mayor cause of treatment failure. Reduce intensity conditioning (RIC) regimens
have shown to be safe and effective in older patients or with comorbidities, but
patients with chemorefractory disease still have high relapse rates and poor out-
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comes. Although graft versus tumor effect (GVT) has been demonstrated in some
malignancies, the benefit for relapsed acute myeloid leukaemia (AML) and
myelodisplastic syndrome (MDS) is often limited because of its rapid growth.
Aims: Analysis of patients with myeloid malignancies (including AML, MDS
and secondary myelofibrosis) receiving RIC allo-HSCT with or without complete
response (CR) in terms of transplant related mortality (TRM), event free survival
(EFS) and overall survival (OS) in order to investigate the GVT in both groups. 
Methods: We analysed 169 patients who underwent to allo-HSCT in our centre
between 1995-2015. Characteristics of both groups are described on table 1.
Although cytogenetic abnormalities are not available at this moment, the data
is been recording and this variable will be included in the final analysis.
Results: In the overall series and with a median follow-up of 36 months for
patients alive, the estimated OS and EFS at one year, two years and five years
was 71%, 64% and 58% and 61%, 51% and 45% respectively. The mainly
cause of death was relapse in 32 patients (19%) and 25 (15%) due to TRM. In
the Kaplan-Meier analysis the variables associated with OS (p<0,05) were:
CR status, III-IV acute graft versus host disease (GVHD), development of
cGVHD, fungal infection, thrombotic microangiopathy and veno-occlussive dis-
ease while just the development of cGVHD (p=0,001) with differences between
grades: limited (p=0,046, HR 0,37, 0,14-0,98) and extensive (p=0,00, HR 0,24,
0,11- 0,52) and development of thrombotic microangiopathy (p=0,004, HR 4,6,
1,6-12,8), but not CR status at the moment of allo-HSCT (p=0,49), maintained
significance in multivariate analysis. Regarding the outcomes on the basis of
disease status at transplant, there were differences between CR and not CR
patients in terms of OS (p=0,02, not achieved vs 32 months) and EFS (p=0,012;
71 vs 9 months) but there where no differences in PFS (p=0,6); attending the
TRM (p=0,05, estimated 8% vs 22% at 1 year), there were differences manly
due to the GVHD related mortality (p=0,05; 2% vs 17% at 1 year). Exploring
the GVT in both groups separately: in the group of patients with CR, there were
differences between patients without cGVHD compared with patients with lim-
ited or extensive cGVHD (p=0,00) with median OS not achieved in all groups;
but in those patients without CR, just extensive cGVHD seems to be effective
(p=0,00) with a median OS not achieved vs 10 and 28 months in those patients
without and with limited cGVHD respectively.
Table 1.
Summary/Conclusions: In our series, the PFS of patients without CR at the
moment of transplant was similar to those with CR, but the first group had
worse OS, EFS and higher TRM due to a larger rate of severe acute GVHD
with a high proportion of induced GVHD because the early withdrawal of the
immunosuppressive treatment. On the other hand, patients without CR and
development of extensive cGVHD had long term survival rates, similar to those
patients with CR, reflecting the GVT. Efforts should be focus on avoid severe
aGVHD maintaining the GVT in order to improve the TRM rates with new
immunosuppressive strategies and improve the management of minimal resid-
ual disease.
E1510
PROTECTIVE EFFECT ON CHRONIC GRAFT-VERSUS-HOST DISEASE
OCCURRENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS WITH EPSTEIN BARR VIRUS VIREMIA
TREATED BY RITUXIMAB
S Xue*, S Ji, X Bao, T Tao, X Ma, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Chronic graft-versus-host disease (cGVHD) is an important
cause of late morbidity, mortality and impaired quality of life in patients after
allogeneic hematopoietic stem cell transplantation (allo-HSCT). It has been
demonstrated that B cells are involved in cGVHD pathogenesis, which is evi-
denced by the presence of antibodies reactive to the host tissue in allo-HSCT
patients with active cGVHD. It has also been proven that Rituximab could have
a distinctly therapeutic effect on cGVHD in allo-HSCT patients. And now the
prophylactic effect of Rituximab on cGVHD is being focused on. However, until
now, no related studies have been conducted in Chinese patients.
Aims: To assess the prophylactic effect of Rituximab on cGVHD, a group of
Chinese allo-HSCT patients receiving Rituximab to eliminate EBV viremia with-
in 100 days following transplant is retrospectively evaluated.
Methods: Between January 2012 and August 2014, a total of 102 allo-HSCT
patients from the First Affiliated Hospital of Soochow University, who underwent
a myeloablative conditioning regimen and suffered EBV viremia within post-
transplantation 100 days with a median time of 54 days (range 14-99), were
included in this study. Among them, 50 (49%) patients (Rituximab group)
received Rituximab treatment by 375mg/m2 weekly to deal with EBV viremia,
while other 52 cases (control group) were treated by other anti-EBV agents. A
competing risk model was adopted to compare the cumulative incidence of
cGVHD, relapse rate and transplantation related mortality (TRM) between Rit-
uximab group and control group. Death and relapse were treated as competing
events in the analysis of cGVHD. Overall survival (OS) and progression-free
survival (PFS) were estimated by the Kaplan-Meier method.
Results: All patients either in Rituximab group or in control group achieved
viral load negativity except 3 patients who died before achieving viral negativity.
In the Rituximab group, the median start time of Rituximab administration is
post-transplantation 64 days (range 23-101) and the median count number of
Rituximab administrations was 1 (range 1-4). The overall cumulative incidence
of cGVHD in the cohort at 6-, 12-, 24-month were 23.5%, 42.2% and 46.1%,
respectively. Retrospectively, the cumulative incidence of cGVHD in Rituximab
group was lower at each time point (14.0% vs 32.7%, 34.0% vs 50%, 36.1%
vs 54.1% at 6-, 12-, 24-month, respectively, P=0.059) when compared with
controls. Moreover, there was no significant difference regarding cumulative
relapse rate (P=0.48) and TRM (P=0.39) between two groups. Multivariable
analyses corrected by other factors showed that Rituximab was one of the
independent factors for the reduction of cumulative incidence of cGVHD (Haz-
ard ratio (HR)=0.37, 95%CI=0.178-0.767, P=0.0075). Additionally, survival
analyses showed that there was no significant difference between two groups
regarding overall survival (OS) (P=0.667) or progression free survival (PFS)
(P=0.571).
Summary/Conclusions: Rituximab administrated in post-transplantation early
phase could reduce the cumulative incidence of cGVHD and play a protective
role in cGVHD occurrence among allo-HSCT patients but without increasing
relapse rate and TRM.
E1511
CHANGES OF PLASMA COMPLEMENT C3B, C5B AND VWF, ADAMTS13
IN PATIENTS WITH THROMBOTIC MICROANGIOPATHY AFTER
HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Y Han*, J Qi, J Wang, J Chen, J Su, Z Ma, Y Tang, X Wu, H Qiu, Z Wang,
C Ruan, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Transplant-associated microangiopathy (TMA) is an uncommon
but devastating complication in patients undergoing hematopoietic stem-cell
transplantation (HSCT). It may be confused with severe graft-versus-host dis-
ease (GVHD), infection, and other transplant related thrombotic diseases. Lim-
ited studies have shown the changes in plasma VWF/ADAMTS13 or comple-
ment activation markers in patients after HSCT. However, the role of
VWF/ADAMTS13 and complement activation in patients with TMA and GVHD
is not fully understood. 
Aims: Current study is to investigate the alterations of plasma levels of C3b,
C5b and VWF/ADAMTS13 in patients with TMA and to explore their roles in
the pathogenesis and early diagnosis of transplant-associated TMA.
Methods: From 2011 to 2014, 14 patients with TMA were enrolled into the
study in a single medical center. 71 other patients following HSCT were recruit-
ed as control subjects including 11 cases of hepatic vein occlusion disease
(VOD), 20 cases of severe infections, 20 cases of severe II-IV° GVHD and 20
cases without complications. Blood sample was collected before transplantation
and at the onset of transplantation related complication. Fluorescence reso-
nance energy transfer substrate (FRETS)-VWF73 assay detected plasma
ADAMTS13 activity. Collagen-binding assay and latex immunoassay deter-
mined VWF activity and VWF antigen, respectively. Plasma VWF multimer was
determined by agarose gel electrophoresis and Western blot. Plasma levels of
complement C3b and C5b were measured with ELISA. 
Results: Compared with the levels before transplantation, plasma ADAMTS13
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activity and VWF antigen or activity in the patients with TMA did not differ from
those who developed TMA, with infection or GVHD or without any complication
(p>0.05). However, plasma ADAMTS13 activity decreased and the ratio of VWF
antigen/activity increased significantly in patients with VOD (p<0.05). Plasma
VWF multimer distribution was similar in patients with infection, GVHD or with-
out complication, but ultralarge multimers of VWF was present in patients with
TMA and VOD. Plasma levels of complement C3b was increased in patients
after HSCT (198.46 ng/ml ±14.78 ng/ml) compared with healthy subjects (85.02
ng/ml±8.50ng/ml) (p<0.05), but exhibited no difference in the other groups.
Plasma C3b increased significantly in patients with TMA and GVHD (p<0.05).
The plasma levels of C3b were higher in the TMA group (480.70
ng/ml±66.76ng/ml) than the GVHD group (298.50 ng/ml ±32.06 ng/) (p<0.05).
Also, plasma levels of C5b in patients with TMA were significantly increased
(1059.49 ng/ml ±85.57 ng/ml) as compared with those before transplantation
(653.19ng/ml ±44.91ng/ml) and other groups (p<0.05). 
Summary/Conclusions: We conclude that plasma ADAMTS 13 activity and
the ratio of VWF antigen/activity remained stable in the patients with trans-
plant-associated TMA, but the levels of complement C3b and C5b, particularly
the C5b, increased significantly, suggesting the critical role of complement path-
way in the pathogenesis of TMA. C5b may be a specific biomarker for early
diagnosis of TMA but C3b is a marker for both TMA and GVHD.
E1512
DONOR KIR HAPLOTYPE B EXACERBATES ACUTE GVHD IN
HLA-MISMATCHED HEMATOPOIETIC CELL TRANSPLANTATION: A
SINGLE-CENTER RETROSPECTIVE ANALYSIS
R Hosokai1,*, M Masuko2, Y Shibazaki2, A Saitoh1, T Furukawa2, C Imai1
1Department of Pediatrics, Niigata University Graduate School of Medical and
Dental Sciences, 2Division of Stem Cell Transplantation, Niigata University
Medical and Dental Hospital, Niigata-shi, Japan
Background: Following allogeneic hematopoietic stem cell transplantation
(allo-HSCT), natural killer (NK) cells play a role in immune responses such as
graft versus tumor (GVT) and graft versus host disease (GVHD). Killer-cell
immunoglobulin-like receptors (KIR) regulate the function of NK cells by inter-
acting with MHC class I molecules. KIR haplotype A contains only one stimu-
latory KIR (2DS4), whereas haplotype B contains 2 to 5 stimulatory KIR genes.
Previous studies have demonstrated the effect of donor KIR haplotypes on
allo-HSCT outcomes. Some investigators showed that donor KIR haplotype B
augmented GVT and suppressed GVHD, consequently improving survival.
However, the association between donor KIR haplotypes and clinical outcomes
after allo-HSCT remains controversial.
Aims: To investigate the impact of donor KIR haplotypes on clinical outcomes
in a Japanese cohort from a single center.
Methods: We retrospectively analyzed the clinical outcomes of patients with
hematological malignancies who underwent allo-HSCTs at Niigata University.
From 1989 to 2011, 304 HSCTs were performed. DNA samples were available
for 152 donor KIR haplotypes. Of these 152, HSCTs from HLA-haploidentical
family donors, umbilical cord blood, and unrelated donors with administration
of anti-thymocyte globulin (ATG), as well as HSCTs for non-malignant hemato-
logic disorders, were excluded. The remaining 106 cases, including 44 AML,
28 ALL, 14 CML, 11 NHL, and 9 MDS, were enrolled. HLA-matched sibling
donors and 10/10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele-matched
unrelated donors were defined as the HLA full-match group. Donors with at
least one HLA allele mismatch were defined as the HLA mismatch group. KIR
genotyping was performed with a PCR-rSSO kit.
Results: There were 61 donors with KIR haplotype A (57.5%) and 45 with KIR
haplotype B (42.5%). The distribution of KIR haplotypes in this cohort was sim-
ilar to that previously reported in the Japanese population. A comparison of the
two groups of donors with KIR haplotypes A and B revealed no significant dif-
ferences in the overall survival, cumulative incidence of relapse, and non-
relapse mortality, possibly due to the small sample size and the dominance of
non-AML malignancies. The cumulative incidence of grade II-IV acute (a)GVHD
was not significantly different (16.4% vs 33.3%; P=0.051). However, grade III-
IV aGVHD was significantly more frequent in patients receiving grafts from KIR
haplotype B donors (4.9% vs 20.0%; P=0.02). The cumulative incidence of
severe aGVHD was evaluated according to the degree of HLA matching. In the
HLA full-match group, there was no significant difference between KIR haplo-
type A and B in the cumulative incidence of grade III-IV aGVHD (5.7% vs 8.7%;
P=0.68). In contrast, in the HLA mismatch group, the cumulative incidence of
grade III-IV aGVHD was significantly higher in patients receiving grafts from
KIR haplotype B donors (5.3% vs 37.5%; P=0.02). In multivariate analysis,
donor KIR haplotype B was the only significant risk factor for grade III-IV aGVHD
(hazard ratio 3.92; CI, 1.04-14.75; P=0.04).
Summary/Conclusions: These findings demonstrated that donor KIR haplo-
type B was an independent risk factor for severe aGVHD in HLA-mismatched
HSCTs using conditioning regimens without ATG. This observation suggests
that genetic determinants of the functional properties of donor NK cells can
affect the severity of aGVHD, which is thought to be solely induced by donor
T-cells. Furthermore, it indicates that under strong T-cell alloreactivity, NK cells
may have a role in worsening aGVHD.
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A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VSBUCYVP16
CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH HODGKIN’S LYMPHOMA
S Singer1,*, YA Efebera2, Q Zhao2, D Abounader3, P Elder2, CC Hofmeister2,
DM Benson2, S Penza2, L Andritsos2, R Klisovic2, S Vasu2, W Blum2,
S Jaglowski2, BM William2, B Bolwell3, B Pohlman3, M Kalaycio3, D Jagadeesh3,
B Hill3, R Sobecks3, N Majhail3, SM Devine2, R Dean3
1Internal Medicine, 2Division of Hematology, The Ohio State University Wexner
Medical Center, Columbus, 3Division of Hematology, The Cleveland Clinic
Foundation, Cleveland, United States
Background: High dose chemotherapy followed by autologous hematopoietic
stem cell transplantation (AHSCT) is an optional treatment for patients with
relapsed Hodgkin’s Lymphoma (HL). A number of conditioning regimens are
routinely used. However, the optimal conditioning regimen in terms of antitumor
effect and toxicities remains unknown. We compare the outcomes of Carmus-
tine, Etoposide, Cytarabine, Melphalan (BEAM) used at the Ohio State Univer-
sity to that of Busulfan, Cyclophosphamide, Etoposide (BUCYVP16) used at
the Cleveland Clinic Foundation.
Aims: To compare the efficacy and toxicity of BEAM and BUCYVP16 condi-
tioning regimens in patients with relapsed HL undergoing AHSCT.
Methods: We retrospectively analyzed patients treated with BEAM (n=128) or
BUCYVP16 (n=105) followed by AHSCT between 2006 and 2014. Kaplan-
Meier estimates were used to analyze progression free survival (PFS) and
overall survival (OS). Cumulative incidence of relapse (CIR) was measured
from transplant date until relapse, treating deaths as competing risks using
Pepe and Mori test.
Results: Patient characteristics were similar for age (median 34 (19-73) vs 38
(19-69), p=0.51), disease stage (p=0.17), prior radiation exposure (p=0.21),
comorbidity index (p=0.58), and response status at transplant (89.1% CR/PR
vs 90.3%) for BEAM vs BUCYVP16 respectively. Differences were number of
prior treatments (median 3 (1-10) vs 2 (1-5), p<0.01), and median CD34 dose
infused (4.45 x10^6 vs 7.25, p<0.01) for BEAM vs BUCYVP16. Median follow-
up from diagnosis and transplant was 7.0 years and 4.2 years respectively for
BEAM and 6.5 years and 3.8 years for BUCYVP16. Median day to neutrophil
engraftment was 10 (8-13) vs 10 (9-12) (p<0.01) and median time to platelet
engraftment was 18 (13-70) vs 16 (7-49) (p<0.01) for BEAM vs BUCYVP16.
Patients receiving BEAM had a lower CIR at 1, 3, and 5 years compared to
BUCYVP16 (p<0.001). PFS at 1, 3 and 5 years from HSCT was 80%, 70% and
66% for BEAM vs 65%, 45% and 33% for BUCYVP16 respectively (P<0.001).
OS from HSCT at 1, 3, and 5 years was also longer in the BEAM cohort: 94%,
88%, and 79% compared to 88%, 72%, and 54% in the BUCVY16 cohort
(p<0.001, Figure 1). Grade 3/4 mucositis was higher for patients receiving
BUCYVP16 (p=0.01). There were no differences in hemorrhagic cystitis, veno-
occlusive disease or second primary malignancy.
Figure 1.
Summary/Conclusions: This large retrospective study supports the use of
BEAM as a conditioning regimen for AHSCT for relapsed HL. Both PFS and
OS were longer for the BEAM cohort with a lower CIR.
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A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS
BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN’S
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Background: High dose chemotherapy followed by autologous hematopoietic
stem cell transplantation (AHSCT) has become the standard of care for patients
with relapsed chemo-sensitive Non-Hodgkin’s Lymphoma (NHL). Various con-
ditioning regimens have been developed to improve outcome, but no regimen
has proven superior. We compare the outcomes of Carmustine, Etoposide,
Cytarabine, Melphalan (BEAM) used at the Ohio State University to that of
Busulfan, Cyclophosphamide, Etoposide (BUCYVP16) used at the Cleveland
Clinic Foundation.
Aims: To compare the efficacy and toxicity of BEAM and BUCYVP16 condi-
tioning regimens in patients with relapsed NHL undergoing AHSCT.
Methods: We retrospectively analyzed patients treated with BEAM (n=269) or
BUCYVP16 (n=409) followed by AHSCT between 2006 and 2014. Kaplan-
Meier estimates were used to analyze progression free survival (PFS) and
overall survival (OS). Cumulative incidence of relapse (CIR) was measured
from transplant date until relapse, treating deaths as competing risks using
Pepe and Mori test.
Results: Patient characteristics were similar for age (median 60 (20-77) vs 58
(27-78)), disease stage at diagnosis (p=0.29), prior radiation exposure (p=0.68),
and response status at transplant (94.7% CR/PR vs 93.2%) for BEAM vs
BUCYVP16 respectively. Differences were number of prior treatments (median
2 (1-8) vs 2 (1-13), p<0.01), comorbidity index (74.0% 0-3 vs 80.9%, p=0.03),
and median CD34 dose infused (4.3 vs 6.02, p<0.01) for BEAM vs BUCYVP16.
Median follow-up from diagnosis and transplant was 6.6 years and 4.0 years
respectively for BEAM and 7.0 years and 4.3 years for BUCYVP16. Median
day to neutrophil engraftment was 10 (8-19) vs 10 (9-15) (p<0.01) and median
time to platelet engraftment was 18 (11-69) vs 16 (3-129) (p<0.01) for BEAM
vs BUCYVP16. There were no statistical differences in CIR, PFS or OS. At 1,
3 and 5 years from AHSCT, PFS was 75%, 59%, and 46% vs 72%, 54%, and
44% (p=0.52); OS 88%, 75%, and 66% vs 83%, 69% and 59% (p=0.11) in the
BEAM vs BUCYVP16 groups respectively (Figure 1). Veno-occlusive disease
(VOD) was higher in the BEAM group (7 pts (2.6%) compared to none in
BYCYVP16 (p<0.01)) but grade 3 or 4 mucositis was lower in BEAM (24.2%)
compared to 56.1% in BUCYVP16 (p<0.01). There were no differences in hem-
orrhagic cystitis or second primary malignancy.
Figure 1.
Summary/Conclusions: This large retrospective study showed no statistical
difference in PFS, OS, or CIR between BEAM and BUCVP16 conditioning reg-
imens for AHSCT in relapsed NHL. Veno-occlusive disease occurred more fre-
quently in the BEAM group, while grade 3 or 4 mucositis occurred more fre-
quently in the BUCYVP16 group.
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MINIMAL RESIDUAL DISEASE ANALYSIS USING DEEP SEQUENCING OF
NPM1 AT THE TIME OF STEM CELL TRANSPLANTATION CAN PREDICT
RELAPSE IN ACUTE MYELOID LEUKEMIA
SJ Alm1,*, M Nicklasson2, E Malmberg1, L Palmqvist1,3, M Brune2, L Fogelstrand1,3
1Department of Clinical Chemistry and Transfusion Medicine, Institute of Bio-
medicine, Sahlgrenska Academy at University of Gothenburg, 2Section of
Hematology, Department of Internal Medicine, 3Department of Clinical Chem-
istry, Sahlgrenska University Hospital, Gothenburg, Sweden
Background: Assessment of minimal residual disease (MRD) in acute myeloid
leukemia (AML) has become increasingly more important for risk stratification,
early detection of relapse and monitoring after stem cell transplantation (SCT).
In AML with mutation in NPM1, RT-qPCR (reverse transcription-quantitative
polymerase chain reaction) after first-line treatment has been shown to have
high predictive value. However, there are numerous recurrent mutations in the
NPM1 gene and therefore specific MRD analyses of each individual mutation
would require an overwhelming number of specific RT-qPCR assays. Using
targeted deep sequencing, the same assay can be applied for all described
NPM1 mutations, and serve as a cost-effective alternative for MRD analysis
also in cases with rare NPM1 mutations.
Aims: The aim of this study was (i) to investigate whether deep sequencing
may provide predictive information in the SCT setting, and (ii) to analyze poten-
tial relationship between deep sequencing and chimerism analyses post SCT.
Methods: A total of 37 bone marrow samples from 19 patients with AML with
mutated NPM1 were analyzed using targeted deep sequencing before (within
one month) and three months after SCT. Sequencing was performed in multi-
plex on the Illumina MiSeq platform, using Truseq-library preparation, with cov-
erages ranging between x6-18x105, a threshold of significance of 0.006% and
a between run-CV of 2.1%. Calling of mutated and wild-type NPM1 sequences
was performed using an in house-script. Based on the linearity and sensitivity
of the assay, NPM1 MRD positivity was defined as variant allele frequency
(VAF) ≥0.025% and NPM1 MRD negativity as VAF<0.025%. Chimerism analy-
sis with STR-PCR (short tandem repeat-polymerase chain reaction) was per-
formed on bone marrow samples taken three months after SCT. Follow-up sta-
tus of patients was collected from the local stem cell transplantation registry.
The study was approved by the local ethics committee.
Results: Nine out of the 37 bone marrow samples displayed NPM1 MRD pos-
itivity. Four of these were detected pre-SCT, and five post-SCT. In samples
with NPM1 MRD positivity, the NPM1 mutation load ranged from 0.033-1.1%
in VAF. Of the 5 patients with NPM1 positivity post-SCT, only one had mixed
chimerism, defined as >1% recipient donor T cells or CD34+ cells. There was
no correlation between results from chimerism analysis and NPM1 mutation
load detected with deep sequencing. In patients with NPM1 MRD positivity
either pre- or post-SCT, the relapse-free and overall survival were significantly
shorter compared with patients with NPM1 MRD negativity at both time points
(p=0.002 for both). In fact, all patients relapsing (n=5) showed NPM1 MRD
positivity in at least one of the samples.
Summary/Conclusions: In summary, MRD monitoring using targeted deep
sequencing of NPM1 is a highly sensitive technique, and in this study NPM1
MRD positivity both pre- and post-SCT was highly predictive of relapse in AML
after SCT. Chimerism analysis using STR-PCR appeared in this study to be
less predictive of imminent relapse, at the time points analyzed. We conclude
that detection of residual leukemic cells with deep sequencing is of value for
clinical monitoring before and after SCT, allowing for early relapse-preventing
intervention.
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Background: Diagnosing, scoring and treating chronic graft-versus-host disease
(cGVHD) is challenging because of polymorphic manifestations and lack of bio-
markers for the diagnosis and assessment of disease activity. Several guidelines
have been published, however the clinical practice remains demanding.
Aims: With this study we investigated the ‘real life’ management of cGVHD in
32 Italian Center members of GITMO (Gruppo Italiano Trapianto Midollo Osseo).
Methods: A detailed survey with 41 multiple-choice questions about the use of
guidelines, and the first and further lines of treatment and management of
cGVHD has been proposed to all adult and pediatric GITMO Centers (N=60)
Results: Thirty-two Centers replied, and according to the survey’s results, 29
Centers referred to published guidelines for cGVHD management (mainly those
proposed by National Institute of Health, NIH), however only 13 find them fully
adequate. As shown in Figure 1, the main reasons for complain were related
to second line treatment. According to NIH definition, most of the Centers
(N=25) started treatment when severe cGVHD occurred, whereas 4 Centers
also considered bad prognostic features regardless the grading. All Centers
agreed on the use of prednisone as first line treatment, which was started at
the dose of 1 mg/kg in 26/33 Centers. Prednisone alone was used in 4 Centers,
while in the others it was associated to extracorporeal photo-apheresis (ECP,
N=25), calcineurine inhibitors (CNI, N=17) and mycophenolate mofetil (MMF,
N=11). A great inter-center variety has been reported regarding the duration of
treatment, as well as the indication to and the choice of steroid-sparing agents.
All but 6 Centers referred to NIH criteria to define response. Objective meas-
urements (i.e. pulmonary function and lab tests), patient reports and ability to
treatment discontinuation were scored as of great importance for response
judgment, whereas physician opinion was scored as medium. In case of com-
plete response, 30/32 Centers tapered steroid slowly, but there was no unifor-
mity on the definition of slow taper (9/32 agreed on 10% reduction/week). Treat-
ment failure, steroid refractoriness, intolerance or dependency were the main
reasons for second line therapy. Sixteen Centers stated to have a policy for the
choice of second line treatment, and the choice was customized according to
organ involvement and patients condition in 24/32 Centers. Seven Centers
declared a policy for third line of treatment. Overall, CNI, ECP and MMF were
the most used treatments for refractory cGVHD: CNI regardless the involved
organ, ECP and sirolimus for skin, lung, and gastrointestinal (GI) involvement,
imatinib for skin and lung, infliximab and MMF for liver and GI, and rituximab
for skin. ECP was available in 25/32 Centers. Finally, all responding Centers
reported a strong need and willing to participate in prospective multicenter trials
for both first and second line treatment of cGVHD; only 2 of them had a protocol
open for refractory GVHD.
Figure 1. Are you satisfied from the current guidelines?
Summary/Conclusions: Despite the presence of guidelines, this survey
showed a great disparity in the management of cGVHD, especially for refractory
disease. The survey further emphasized the great interest and need for
prospective trials investigating this setting.
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Background: Hematopoietic stem cell transplantation (HSCT) is being increas-
ingly used as curative therapy for severe disorders of the hematopoietic system
such as thalassemia. The use of therapeutic phlebotomy post-HSCT is often
difficult to perform in younger or anemic children. Deferiprone is shown to be
related with bone marrow suppression and compliance to deferoxamine is low.
Studies that evaluate the safety of deferasirox (DFX) in this setting, are limited.
Aims: The aim of this study is to evaluate safety and efficacy of DFX in Tha-
lassemia Major patients in a Post Transplant setting.
Methods: This was a prospective, phase 2, multicenter, single-arm study to
evaluate efficacy and safety of DFX in beta-thalassemia major (TM) patients
who have undergone HSCT. The primary objective was to evaluate if DFX could
provide safe chelation in patients with transfusional iron overload within a time
period of 6 months to 2 years after HSCT. Transfusion independent patients
aged ≥2 to<18 years old who had undergone HSCT with a washout period of
at least 3 months after immunosuppressive therapies and had iron overload at
screening defined by serum ferritin (SF) of >1000 μg/L or cardiac MRI T2*<20
ms or liver iron concentration (LIC, by MRI R2) of ≥5 mg/g were included in the
study. Patients received DFX at an initial dose of 10 mg/kg/day with up titration
every 3 months by 5 mg/kg/day per investigator judgment to the intended 20
mg/kg/day dose. Therapy continued for 52 weeks or until SF reached below
500 μg/L.
Results: Data from 27 patients enrolled (median (range) age 9.07 years (3-
16), 70,4% males) were included in this analysis. One patient discontinued on
week 14 due to withdrawal of consent. 20 patients were able to achieve the
intended dose of 20 mg/kg/day. Safety From a total of 140 Adverse Events
(AEs), 10 (7.1%) AEs in 4 patients were suspected to be related to study drug.
The majority of AEs were of Grade I (n=81, 57.9%) or II (n=48, 34.3%). A total
number of 6 (4.7%) SAE’s were reported. 8 (5.7%) AEs resulted in study drug
interruption or dose adjustment, 1 of which was suspected to be related to the
study drug (ALT increase). On 51 (36.4%)AE’s, no action was taken. Median
ALT level decreased from 27 IU/L (range: 10-119) at baseline to 17 IU/L (range:
9-205) at week 52. Median AST level decreased from 35,5 IU/L (range: 17-
66.5) to 26 IU/L (range:18-78) at week 52 (Figure 1). The median SCr was sim-
ilar at baseline (0.4 mg/dL range: 0.2-0.7) and week 52 (0.4 mg/dL range: 0.2-
1) Median cystatin C was similar at baseline (0.7 mg/mL range: 0.5-1) and
week 52 (0.7 mg/mL range: 0.5-1) (Figure 2). No dose adjustments were
required due to nephrotoxicity. Increased proteinuria was described in 9 (33.3%)
patients, irrespective of dose at 52 weeks. No patient with proteinuria required
dose adjustments. Efficacy SF significantly and consistently decreased through
52 weeks from a median of 1718 μg/L (range: 873.7-2919) to 845.3 μg/L (range:
146.2-2740), p<0.001. At week 52, 9 (33.3%) patients reached SF<500 μg/L,
p<0.001. LIC also significantly decreased from a median of 8.60 mg/g (range:
2.8-43) to 4.1 mg/g (range 0.9-12.5), p<0.001. Cardiac T2* increased from a
median of 25.95 ms (range: 4.5-51) to 28 ms (18.5-44), p=0.520.
Figure 1.
Summary/Conclusions: Our findings suggest that DFX dose escalation up to
15-20 mg/kg/day is safe for TM patients following successful HSCT regarding
nephrotoxicity and hepatotoxicity. 15-20 mg/kg/day deferasirox was also effi-
cacious and this was evident through significant reductions of systemic and
hepatic iron overload.
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Background: Some “classical” patient-, donor- and transplant characteristics,
such as age, gender disparity, donor type, HLA-match, and source of stem
cells, have been reported as predictors for acute and chronic GVHD. However,
no studies analysed these “classical” variables together with parameters of
metabolic and endocrine functions that may potentially influence the immune
system.
Aims: Patient-and transplant variables together with index of liver and thyroid
function, and some parameters of protein and lipid metabolism were retrospec-
tively evaluated at different time points after transplantation, in order to identify
possible predictors of acute and chronic GVHD and to calculate a risk score.
Methods: Clinical and transplant characteristics, number and type of infections
before and after SCT were analysed in 200 patients. The following variables
were also analysed pre-SCT, at day +7,+14,+21,+28, at+3 and +6 months:
LDH, parameters of liver function; parameters of protein and lipid metabolism;
thyroid function tests; autoimmune parameters; body mass index. A 2-step
multivariate analysis was performed using principal component analysis and
Cox regression analysis. Based on the regression coefficient of Cox analysis
for each significant predictor, a scoring system for acute and chronic GVHD
was calculated.
Results: In multivariate analysis, diagnosis of Myelodisplastic Syndrome or
Chronic Myeloid Leukemia (p=0.0004), conditioning regimen including Total
Body Irradiation (p=0.0003), and pre transplantation urea >34 mg/dl with +21
day urea >54 mg/dl (p=0.0008) were predictors for acute GVHD. Score values
for each factor are 2, 1, 1, respectively and the system had a score range
between 0 and 4. The probabilities of acute GVHD according to the sum scores
ranged from 8% (score 0) to 98% (score 4). Female donor (p=0.0008), pre-
SCT TSH values ≥2 mU/L with +28 day urea ≥39 mg/dl (p=0.02), +6 month
total protein<5,5 g/dl with gamma-GT ≥347 U/L (p=0.0001) resulted predictors
for moderate/severe chronic GVHD. Risk of chronic GVHD at +6,5 month
ranged from 3% (score 0) to 97% (score 4).
Summary/Conclusions: Our study evidenced that factors other than those
“classical” may be associated to GVHD. The scoring system included routine-
parameters, which are easily available in clinical practice. Urea levels depend
on the balance between protein intake, endogenous catabolism and urinary
excretion. The inflammatory microenvironment of GVHD promotes muscle
catabolism and hence, increased urea levels. Increased urea levels could be
indirect index of increased uremic toxins as well, which may stimulate the pro-
duction of pro-inflammatory cytokines and the activation of leukocytes.
Increased urea levels and uremic toxins could also derive from a dysregulated
metabolism of the gut microbiome that may influence immune system. Our
findings suggest the usefulness to study in deep the complex network between
metabolic/endocrine functions and immune system for a holistic approach of
the transplant management.
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Background: Hepatic veno-occlusive disease (VOD) is a common and serious
complication of hemotopoietic stem cell transplantation (HSCT) in children.
Aims: We aimed to assess prospectively the use of prophylactic defibrotide in
pediatric patients undergoing HSCT.
Methods: In this study, 76 patients who underwent HSCT were given defi-
brotide prophylaxis as 25 mg/kg per day in four divided intravenous infusions
over 2h, starting on the same day as the pretransplantation conditioning regi-
men. The mean duration of use of defibrotide is 20 days as a prophylaxis.
Results: In this study, 76 patients were recruited, 53 male patients and 23
female patients, with the average of 9.3 years, range 1-20; 4% infants, 55%
children and 41% adolescent. There were 33 patients with thalassemia major,
30 patients with leukemia, 7 patients with aplastic anemia, one patient with Dia-
mond Blackfan anemia, two patients with congenitale dyserythropoetic anemia,
one patient with osteopetrosis, one patient with famial hemophagocytic lym-
phohistiocytosis, and one patient with Kostman syndrome. All transplants were
allogeneic. No serious side effects were seen. In eight patients developed clinical
VOD (Seattle criteria). In these patients, defibrotide dose was increased to a
treatment dose of 40-60 mg/kg per day. One infant patient with Kostman syn-
drome and one patient with aplastic anemia died due to hepatic and pulmonary
veno-occlusive disease. After 24 months of follow up, 6 patients who developed
VOD are being well and no patient have transplant related complications.
Summary/Conclusions: Hepatic veno-occlusive disease, which is caused by
hepatocyte and sinusoidal vessel endothelium damage, can ocur early after
HSCT, and in its severe form, may lead tol iver faillure, hepatorenal syndrom,
portal hypertension, and eventually death from multiorgan faillure. In this
prospective study, we demonstrated that the use of defibrotide is safe and
effective in preventing and treating VOD in pediatric patients at high risk.
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Background: The superiority and safety of strengthening conditioning regimen
for single-unit umbilical cord blood transplantation (sUCBT) in hematological
malignancies remain controversial.
Aims: To define whether intensified myeloablative regimen is superior to con-
ventional myeloablative regimen for single-unit umbilical cord blood transplan-
tation (sUCBT) in hematological malignancies.
Methods: We retrospectively analyzed the clinical data of 251 hematological
malignancies undergoing sUCBT from Apr 2000 to Dec 2014 at Anhui provincial
hospital hematology department. In these patients, 216 received the intensified
myeloablative conditioning regimen (IMCR), and 35 received the myeloablative
conditioning regimen (MCR). We evaluated the effect of IMCR without ATG on
patient outcomes. Among the IMCR group, 106 patient received TBI/Ara-C/CY
regimen, 41 received Ara-C/Bu/CY regimen, 69 received Flu/Bu/CY regimen,
and all received a combination of CsA and MMF for the prophylaxis of GVHD.
For the MCR group, 35 patients received Bu/CY regimen using CsA/MMF±ATG
or MTX for the prophylaxis of GVHD.
Results: The cumulative incidence of myeloid and platelet engraftment of the
IMCR group was significantly higher than that in the MCR group (96.98% vs
82.81%, 85.89% vs 51.79%, P=0.000, 0.003, respectively). Corresponding
incidences of transplantation-related mortality (TRM) by 180 days in the IMCR
group and the MCR group were 19.50% vs 41.67% (P=0.0028), respectively.
The incidence of CMV infection and pre-engraftment syndrome were signifi-
cantly higher in the IMCR group compared with that in the MCR group (68.8%
vs 40%, 82.9% vs.48.6%, P=0.001, 0.000, respectively). There were no differ-
ences in the incidence of grade II to IV aGVHD, grade III to IV aGVHD and 2-
year cumulative incidence of relapse. Up to Oct. 2015,with a median follow-up
of 30 months, the estimated 3-year overall survival and disease-free survival
in the IMCR group were both significantly higher than that of the MCR group
(62.4% vs 35.5%, 60.1% vs 35.5%, P=0.000,0.004, respectively). For 49
patients not in remission at transplantation in the IMCR group, the cumulative
incidence of 2-year relapse was 21.92% (95%CI, 21.15-22.69%), which was
comparable with patients in remission (P=0.115). The estimated 3-year overall
survival and disease-free survival of advanced patients undergoing IMCR were
54.8% and 52.1%, respectively. For six patients older than 40 years, the inci-
dences of myeloid, platelet engraftment and 180d TRM were not significantly
different from patients between 20 and 40 year old and those younger than 20
year100% vs.96.36% vs.96.73%, 66.67% vs.91.32% vs.84.75%, 16.67%
vs.19.87% vs.18.48%, P=0.418, 0.405, 0.975, respectively).
Summary/Conclusions: This study is the first to show the superiority of inten-
sified myeloablative regimen to conventional myeloablative regimen. A large-
scale prospective study was needed to investigate its application.
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Background: Graft-versus-host disease (GvHD) and GvHD-associated mor-
bidity and mortality are major obstacles to the success of transplantation from
unrelated and haploidentical donors. Negative depletion of α/β(+) T cells and
CD19+ B lymphocytes is a technology of graft manipulation with a potential to
improve GvHD control and immune reconstitution. 
Aims: The aim was to study retrospectively the outcomes of TCR-alpha/beta
depleted transplants in a group of pediatric acute myeloid leukemia patients
with the emphasis on two consequtive GVHD prophylaxis regimens.
Methods: A total of 59 pediatric patients with acute myeloblastic leukemia (17
female, 42 male, median age 9,1 years, range 0,6-22) underwent allogeneic
HSCT between May 2012 and June 2015. Twenty two patients received hap-
loidentical graft, 37 - a graft from matched unrelated donor. Disease status at
transplant was CR1 in 40 pts., CR≥2 in 10 pts., active disease(AD) in 9 pts.
Transplantation in CR1 was performed according to risk stratification scheme
in the current institutional AML protocol. For all patients it was first HSCT.
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TCRαβ+/CD19+ depletion of HSCT with CliniMACS technology was imple-
mented in all cases. All patients received Treosulfan/Melphalan/Fludarabine
as conditioning regimen. Two regimens of GvHD prophylaxis were used: regi-
men 1 (n=31): ATG (horse, ATGAM) 50 mg/kg and post-transplant Tacro/MTX
(n=28), or no post-transplant prophylaxis (n=3); regimen 2 (n=28): ATG (rabbit,
thymoglobuline) 5 mg/kg, rituximab 200mg/m2 and post-transplant bortezomib
(n= 27) or Tacro/MTX (n=1). The median dose of CD34+ cells in transplant was
7,9 x106/kg (range 1-21), TCRα/β - 15x103/kg (range 0,6-210).
Results: Primary engraftment of WBC and platelets was achieved in 58 (98,3%)
patients at a median of 14 days, 1 pt. with AD had primary graft failure with no
evidence of leukemia and was retransplanted from MUD. No case of graft rejec-
tion was registered. Early mortality was low with a +100-day pTRM - 3,4% (95%
CI: 0,1-13.2), 3-year pTRM-10,8% (95%CI: 5-23). The 2 early deaths included
viral infections (ADV), four late: bacterial sepsis in 1 pt. and viral infection(ADV
and CMV) in 3 pts, all with extensive chronic GvHD. Cumulative incidence (CI)
of acute GvHD grade ≥II was 20,3% (95% CI: 12-34), grade III–IV 8,5% (95%CI:
4-20) and chronic GvHD-28% (95% CI: 18-45). No correlation between graft
composition and aGvHD was noted. CI of acute GvHD was significantly lower
in a group with regimen 2: 7,4% (95% CI: 2-28) vs 31,3% (95% CI: 19-52) in
group with regimen 1, p=0,028. Regimen 2 was also effective in prevention of
chronic GvHD: CI at 1 year after HSCT was 14% vs 36%, p=0,085 Median time
of follow-up for survivors is 1,9 years (range 7 months-3,5 years). CI of relapse
at 3 year is 27,6% (95%CI: 18-43). Three year pEFS is 62% (95%CI: 49-75), 3-
year pOS - 64% (95%CI: 50-78). There was no significant difference in survival
and relapse rate according leukemia subtype, remission status and donor type.
Summary/Conclusions: We confirm that the depletion of TCR-alpha/beta and
CD19 lymphocytes from the graft ensures high engraftment rate and acceptable
transplant-related mortality in pediatric AML patients. All major outcomes were
equivalent between transplantation from unrelated and haploidentical donor.
GvHD prophylaxis including Thymoglobulin/Rituximab/Bortezomib improves
GvHD control in recipients of TCRα/β- depleted grafts in comparison to
ATGAM/Tacro/MTX apparently without loss of anti-leukemic activity.
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Background: Acquired severe aplastic anemia (SAA) is a life-threatening dis-
ease and allo-geneic hematopoietic stem cell cell transplantation (HSCT) is a
curative treatment. Recent researches indicate that haploidentical HSCT (hap-
lo-HSCT) is an effective therapeutic option for SAA.
Aims: To evaluate the efficiacy and safety of haploidentical hematopoietic stem
cell transplantation (haplo-HSCT) in patients with acquired severe aplastic ane-
mia (SAA), who lacked suitable related or unrelated HLA-matched donors
Methods: 39 SAA patients underwent haplo-HSCT from Jul 2012 to Jun 2015
at our center. There were 23 males and 16 females at a median follow-up of 11
(range, from 0 to 36) months. The median time from diagnosis to transplantation
was 1 (range, from 0.5 to 52) months. The median ages of SAA patients and
related haploidentical donor were 23 years (range, 9 to 51years) and 45 (range,
from 21 to 61) years, respectively. All patients were given BuCy plus ATG con-
ditioning regimen. GVHD prophylaxis regimen consisted of cyclosporine A
(CsA), mycophenolate motetil (MMF), and short-term methotrexate.
Results: Stem cells were collected from bone marrow in 23.08% (n=9) of
patients, peripheral blood in 2.56% (n=1), bone marrow plus peripheral blood
in 74.36% (n=29) patients. 36 patients received haplo-HSCT combined with
the third part of cord blood transfusion 92.31%. The median stem cell dose
transplanted was 9.76 (range, from 4.02 to 20.10)×108/kg for mononuclear
cells, while 3.4 (range, from 1.05 to 8.60)×108/kg for CD34 cells. 36 patients
achieved neutrophil engraftment at a median of 12 (range, from 9 to 28), and
29 patients achieved platelet engraftment at a median of 29 (range, from 10 to
26) days. Cumulative incidence of III°~IV° acute graft versus host disease
(aGVHD) was 8.9±4.9%. 6 patients died of transplant-related mortality (TRM),
including 4 from severe infection, 1 from TMA and 1 from encephalorrhagia.
The 2-year overal survival rate of all patients was 83.2%±6.4%.
Summary/Conclusions: Haplo-HSCT is likely to be an option for SAA patients
without suitable related or unrelated HLA-matched donors, in consideration of
the acceptable TRM and severe GVHD incidences.
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EBV AND CMV INFECTION IN RECIPIENTS OF HAPLOIDENTICAL
ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING TWO DIFFERENT
DOSES OF ANTITHYMOCYTEGLOBULIN AS CONDITIONING REGIMEN
R Lin1, Y Wang2, T Yang3, Y Xu4, F Huang1, Z Fan1, S Zhang2, Y Ji2, N Xu1,
Y Gao1, J Sun1, X Huang2, Q Liu1,*
1Department of Hematology, Nanfang Hospital, Southern Medical University,
Guangzhou, 2Peking University Institute of Hematology, Beijing, 3Department
of Hematology, Fujian Medical University Union Hospital, Fuzhou, 4Department
of Hematology, Xiangya Hospital, Central South University, Changsha, China
Background: Antithymocyteglobulin (ATG) has been widely used to prevent
acute graft-versus-host disease (aGVHD) in recipients receiving haploidentical
hematopoietic stem cell transplantation (HSCT). Notwithstanding, immunosup-
pressive effect of ATG increases the risk for infections, especially viral infection.
Therefore, the optimal dose of ATG which elicits adequate immune suppression
and limits the development of viral infection/reactivation is needed to be studied. 
Aims: To evaluate the effect of different doses of ATG on post-transplant viral
infection, this multicenter prospective study was conducted to compare EBV
and CMV infection in haploidentical HSCT recipients receiving 7.5 mg/kg or 10
mg/kg of ATG. Besides, the incidence of aGVHD was compared between the
two arms.
Methods: Between January 2013 and August 2015, 217 consecutive patients
with hematological malignancies undergoing haploidentical HSCT were enrolled
in 4 hospitals. One hundred and ten patients were randomized to receive a
total dosage of 7.5 mg/kg of ATG and 107 were randomized to receive 10 mg/kg
of ATG. 
Results: The 1-year cumulative incidence of EBV infection were 30.7±6.0% in
7.5 mg/kg of ATG arm and 43.1±6.0% in 10 mg/kg arm (P=0.107). CMV infec-
tion were comparable in the two arms (7.5 mg/kg arm: 79.6±3.9% vs 10 mg/kg
arm: 84.1±3.6%, P=0.188). Acute GVHD grade II to IV within 100 days occurred
in 35.9±5.2% of the patients with 7.5 mg/kg ATG and 19.2±4.8% of those with
10 mg/kg ATG (P=0.004). The incidence of aGVHD grade III to IV within day
100 were 14.1±3.9% in 7.5 mg/kg arm and 7.3±3.3% in 10 mg/kg arm
(P=0.072). No difference in the 1-year cumulative overall survival was found
(75.8±6.8% in 7.5 mg/kg arm vs 73.7±4.6% in 10 mg/kg arm, P=0.192). 
Summary/Conclusions: Compared with 10 mg/kg of ATG, the application of
7.5 mg/kg might reduce the viral infection after haploidentical HSCT and not
increase the risk for severe aGVHD.
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AUTOLOGOUS STEM CELL TRANSPLANT WITH NON CRYOPRESERVED
HEMATOPOIETIC STEM CELL IN ALGERIAN PATIENTS WITH MULTIPLE
MYELOMA
A Bekadja*, S talhi, K amani, M brahimi, S osmani, N yafour, A krim, R bouhass
Hematology and cell therapy, EHU1st November, Oran, Algeria
Background: For younger patients under 65 years of age, induction followed
by high-dose chemotherapy with autologous stem cell transplantation (ASCT)
is the standard treatment in multiple myeloma (MM). There is limited experience
with non-cryopreserved autologous hematopoietic stem cell transplantation. 
Aims: We evaluated the efficacy and safety of non-cryopreserved storage of
ASCT in patients undergoing ASCT for MM.
Methods: From May 2009 to December 2013, 134 patients with MM were treat-
ed in our center in Oran. The median age at ASCT was 55 years (range; 27-
67). There were 80 males and 54 females. The median harvested CD34+ cell
count was 3,5x106/kg (range; 1, 22 to 13, 24). Autologous stem cell was mobi-
lized using G-CSF alone (10 µg/kg/day for 5 days). Leukapheresis to harvest
stem cells were performed on day -2 and -1. The grafts were kept in a conven-
tional blood bank refrigerator at +4°C until reinfusion on day 0. The conditioning
regimen consisted of melphalan 200 mg/m2.
Results: All patients had engraftment on the median of day 10 (range; 7 to 17)
and platelet transfusion independence on the median of day 13 (range; 9 to 24).
There was no graft failure. Mucositis grade 3/4 was seen in 68% patients. Trans-
plant related mortality at 100 days was 2.9%. The overall response to transplant
was 92%. In the 130 evaluable patients, the median post-transplant overall sur-
vival had not been reached. The estimated overall survival at 75 months was
63% with 95% confidence interval and the median post-transplant disease free
Survival was 35 months (0.05%). 93 (72%) patients are alive and 75 (81%) with-
out disease activity after a median follow-up of 35 months (range; 3 to 75).
Summary/Conclusions: We conclude that high dose chemotherapy and autol-
ogous transplant with non cryopreserved ASCT is a simple, effective and safe
method for MM with equivalent results, and that cryopreservation is not neces-
sary in the treatment of MM under our work conditions in developing countries.
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SECONDARY ANTIFUNGAL PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT: THE NIGUARDA HOSPITAL EXPERIENCE
S Ferrari*, M Zancanella, E Zucchetti, G Grillo, R Cairoli, A Nosari
Niguarda, Milan, Italy
Background: As allogeneic hematopoietic SCT (HSCT) is the only curative
treatment for the majority of acute leukemia patients (pts), clinicians encounter
the therapeutic dilemma of balancing cytotoxic therapy and HSCT with the risk
of invasive mold infections (IMIs) relapse-related morbidity and death. Use of
effective, less toxic antifungals and routine early chest CT implementation,
leading to prompt intensive antifungal therapy, improved responses and sur-
vival. These developments have increased the interest regarding the efficacy
of secondary antifungal prophylaxis (SAP), but data are limited.
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Aims: The aim of the study was to evaluate the IMI relapse rate and associated
mortality rate after allogeneic HSCT in a cohort of pts with hematological malig-
nancies. We assessed the HSCT outcome of pts with a history of IFI and the
efficacy of SAP.
Methods: We retrospectively collected data of pts with IFI treated at Niguarda
bone marrow transplant center between 2004 and 2016. Among the 322 HSCT
recipients we identiﬁed 36 pts, median age 49 yrs (range 16-67), with a history
of IFI. The underlying malignancies were AML (26), ALL (8), myelodysplastic
syndrome (2). Hematologic disease status at transplant was CR (26), PR (6)
and refractory disease (4). Conditioning regimens were myeloablative in 22
pts and reduced-intensity conditioning in 14.
Results: The IFI diagnosis according to the EORTC/MSG criteria was proven,
probable and possible in 6 (2 A.fumigatus, 1 A.terreus, 1 Absidia Corymbifera
and 2 Mucor), 5 and 25 pts, respectively. Sites of involvement included lung
(31), sinuses (3), central nervous system (1) and breastbone (1). The median
duration of antifungal treatment before SCT was 110 days (10-360) and the IFI
status at transplantation was CR, PR (defined as presence of residual pul-
monary localizations at CT scan but no symptoms) and active in 18, 16 and 2
pts, respectively. During the peritransplant period 31 pts received SAP with
liposomal amphotericin (Amb), 1 pt received both Amb and Posaconazole, 2
pts Voriconazole, 2 pts Caspofungin. After engraftment 12 pts (1 active IFI, 5
PR and 6 CR) continued antifungal therapy: 6 received Voriconazole, 1
Posaconazole, 5 Amb for a median period of a month; 3 of Amb pts continued
prophylaxis with Posaconazole (2) and Voriconazole (1) up to ciclosporine sus-
pension. By day +100, IFI progression occurred in only 1 pt with active hema-
tologic disease and proven aspergillosis who rapidly died. No fungal recurrence
was present in the other pts, also in presence of CMV reactivation (15 pts). We
observed 16 cases of aGVHD (12 with possible, 1 with probable and 3 with
proven IFI) and 18 cases of cGVHD, treated with steroid therapy (median dura-
tion 17 months, 1-80). Among GVHD pts only one had a possible IFI reactiva-
tion (20 months from HSCT) in absence of SAP. With a median follow-up of 37
months (1–118) 20 pts died due to leukemia relapse (10), bacterial infections
(6), GVHD/transplant toxicities (3), IFI (1).
Summary/Conclusions: In our experience (1 IFI-related death and 1 possible
late IFI reactivation) with a correct SAP, prior IFI may no longer be considered
a contraindication for allo-SCT. However, new data are needed to guide the
use of SAP and to improve the cost-effectiveness of treatment. Determination
of appropriate time to discontinue SAP is one of the many areas where more
data are needed. Prolonged fungal pre-transplant therapy, aiming to achieve
a clinically undetectable state of infection, followed by SAP during transplant
may allow the SCT with reduced fungal reactivation.
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EFFECT OF DONOR KIR GENOTYPE ON THE OUTCOME OF PEDIATRIC
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
HH Koo1,*, SH Lee1, JW Lee1, KH Yoo1, KW Sung1, ES Kang2, SJ Kim3,
K Kim3, JH Jang3, CW Jung3
1Department of Pediatrics, 2Department of Laboratory Medicine and Genetics,
3Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea, Republic Of
Background: Natural Killer (NK) cells have recently attracted for the potential
role in graft-versus-tumor effect and NK cell alloreactivity was investigated in
several studies.
Aims: The impact of donor killer immunoglobulin-like receptor (KIR) phenotype
and genotype on the outcome following allogeneic hematopoietic stem cell
transplantation (HSCT) in children was evaluated.
Methods: We prospectively evaluated the gene content and expression of the
KIR in children undergoing allogeneic HSCT for malignant diseases. The
incompatibility between donor KIR and recipient KIR ligand (receptor-ligand
(R-L) mismatch) was defined if the donor has an inhibitory receptor for which
the cognate ligand is absent in the recipient. Donors were assigned to A or B
KIR haplotype donor according to their gene content. A haplotype donor was
defined as the individual having only genes of the group A KIR haplotypes. All
other individuals having one or more B haplotype specific genes were defined
as B haplotype donor.
Results: All 42 patients received allogeneic HSCT from sibling (n=11), unre-
lated donor (n=20), or haploidentical donor (n=11) between January 2011 and
December 2013. Seventeen transplants were performed in patients with acute
myeloid leukemia, 15 in patients with acute lymphoblastic leukemia, 8 in
patients with neuroblastoma, and 2 in patients with other solid tumors. Five
donor-recipient pairs had KIR R-L match and remaining 37 donor-recipient
pairs had KIR R-L mismatch. The 2-year relapse-free survival (RFS) was 100%
in recipients with R-L match and 69.3±8.9% in recipients with R-L mismatch,
respectively (P=0.18). However, recipients who received HSCT from B haplo-
type donor had better RFS than those who received HSCT from A haplotype
donor (93.3±6.4% vs 58.0±12.0%, P=0.03). Furthermore, there was no relapse
in four recipients who received HSCT from donors having 2 or more B gene-
content motifs. Survival benefit of B haplotype donors was found in both HLA-
matched and mismatched transplants. Donor KIR genotype and R-L mismatch
did not have any significant effect on rates of grade III-IV acute graft-versus-
host disease (GVHD) or chronic GVHD. In multivariate analysis, A haplotype
was the only independent factor predicting increased risk of relapse (RR 16.5,
95% CI 1.3-217.4, P=0.03).
Summary/Conclusions: This analysis has identified decreased relapse and
improved RFS in patients who received allogeneic HSCT from donors having
B haplotype. KIR genotyping should be considered for successful selection of
a NK cell alloreactive donor.
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DEVELOPMENT AND CLINICAL EVALUATION OF DIGITAL PCR ASSAYS
FOR SENSITIVE CHIMERISM ANALYSIS BASED ON DELETION/INSERTION
POLYMORPHISMS
T Stahl1, C Rothe2, MU Böhme2, S Mersmann3,*, N Kröger1, B Fehse1
1Department of Stem Cell Transplantation, University Medical Centre Ham-
burg-Eppendorf, Hamburg, 2R&D, 3Product Management, Biotype Diagnostic
GmbH, Dresden, Germany
Background: Examination of chimerism has become a crucial means to mon-
itor engraftment and, in the absence of specific disease markers, detect recur-
rence of leukemic cells after allogeneic stem cell transplantation. Various tech-
niques have been established for chimerism analysis; the most often used
STR amplification has high power of discrimination, but its detection limit is
restrained to 1%>5%. Consequently, more sensitive approaches are required
to ensure earlier detection of engraftment failure or relapses.
Aims: We have previously shown that digital PCR assays detecting
deletion/insertion polymorphisms (DIPs) combine excellent sensitivity (routinely
≤0.1%) with accurate quantification over a large dynamic measurement range.
Moreover, built on the dPCR principle, there is no need for standard curves
and replicate measurements. Here we aimed at introducing a whole panel of
digital-PCR based assays for routine chimerism measurement.
Methods: We selected a set of 53 DIPs and tested their suitability for duplex
analysis in combination with a reference gene and a Y-chromosome specific
locus. We identified 29 DIPs with high power of discrimination and good per-
formance in duplex PCR.
Results: Assays were optimized and technically validated; applicability for
diagnostics was confirmed on clinical samples in direct comparison with STR
and qPCR. Finally, we established a screening plate for initial genotyping with
DIP-specific digital duplex assays for convenient application of the system in
every-day diagnostics.
Summary/Conclusions: In conclusion, we have developed and validated
assays for regular chimerism determination including a screening plate for
initial DIP assessment. The new tool ensures precise, robust and fast analysis
of hematopoietic chimerism with a regular sensitivity of ≤0.1% (for ≥20 ng of
genomic DNA). We propose that the new method will be highly useful for clinical
routine diagnostics.
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IRON-CHELATING THERAPY IMPROVES OUTCOME OF ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MDS
C Gu, C Li*, X Chen, H Liu, J Ma, T Wang, Q Zou, J Chen, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Iron overload (IO) is general among patients with myelodysplas-
tic syndrome (MDS). IO increased the non-relapse mortality after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Therefore, the application
of iron chelating therapy in allo-HSCT attracts the extensive attention recently.
r severe HC following HSCT.
Aims: To investigate the effect of iron chelating therapy on hematopoietic
reconstitution and related complications of allogeneic hematopoietic stem cell
transplantation (allo-HSCT) in patients with myelodysplastic syndrome (MDS). 
Methods: Various clinical parameters were analyzed retrospectivly in 57 MDS
patients with iron overload (IO)who received allogeneic transplantation. Accord-
ing to the level of serum ferritin (SF) before transplantation, we divided the
patients into two groups: the effective treatment group (19 cases,
SF<1000ng/ml) and iron overload group (38 cases, SF≥1000ng/ml). 
Results: (1) 30/57 cases were received iron chelating treatment, 19/30 (63%)
cases obtained obvious curative effect, the SF level before transplantation
was<1000ng/ml, the median was 561(223-846) ng/ml. The effort of other 11/30
(37%) cases was not obvious, with the SF level before transplantation was
≥1000ng/ml,the median was 1262(1100-2352) ng/ml. 27/57 patients didn’t
received iron chelating therapy before transplantation, the SF level before trans-
plantation was≥1000ng/ml,the median was 1540(1320-3112) ng/ml. (2) The rate
of fully-engraftment in the effective treatment group and iron overload group
was 19/19 (100%) and 34/38 (89%). And the latter group had 4/38 (11%) cases
failed the hematopoietic reconstitution.The medium time of myeloid and platelet
reconstitution of the 19 cases of effective treatment group was (12±2) and (16±6)
days respectively, while those of 34 cases of iron overload group was (13±3)
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and (18±6) days. The hematopoietic reconstruction was shorten in the former
group, however the difference between the two groups had no statistical signif-
icance (P=0.441, P=0.579). (3) The infection rate of the effective treatment group
and iron overload group was 7/19 (37%) patients and 28/34 (82%) patients
respectively. The risk of infection of the effective treatment group was decreased
significantly (P=0.002). (4) The incidence of aGVHD of the effective treatment
group was 5/19 (26%) patients, all of which were I-II degree. The incidence of
aGVHD of iron load group was 22/34 (65%) cases, with 16 cases of I-II degree,
6 cases of III-IV degree. The risk of aGVHD in the effective treatment group was
significantly decreased (P=0.01). (5) The median disease-free survival (DFS) in
effective treatment group was 28.9 (0.3-89.5) and 21.2 (0.1-81.0) months in iron
load group during a median follow-up period of 22.0 (0.1-89.0) months.The DFS
of effective treatment group was prolonged (P=0.053).
Summary/Conclusions: Effective iron chelating therapy before transplantation
was helpful to hematopoietic reconstitution, and significantly reduced the inci-
dence and degree of infection and aGVHD, decreased transplantation related
mortality(TRM) and prolonged DFS, thereby improved the success rate of trans-
plantation in MDS.
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IMPACT OF CYCLOSPORINE-A CONCENTRATION IN T CELL-REPLETE
HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION
X Yang*, A Sun, S Yang, X Hu, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Previous studies on HLA-identical allo-HSCT (allogeneic
hematopoietic stem cell transplantation) have shown that level of blood CSA
concentration during early stage after HSCT were significantly associated with
risk of severe aGVHD (acute graft versus host disease). However, there
remains a lack of data on T cell-replete haploidentical HSCT in which using
ATG combined with CSA, MTX, MMF to prevent GVHD. Objective: This study
was to investigate whether CSA (cyclosporine-A) levels impact on clinical out-
comes of patients in the T cell-replete haploidentical allo-HSCT setting.
Aims: This study was to investigate whether CSA (cyclosporine-A) levels impact
on clinical outcomes of patients in the T cell-replete haploidentical allo-sct (allo-
geneic stem cell transplantation) setting.
Methods: we retrospectively analyzed 140 consecutive patients who conducted
T cell-replete haploidentical allo-sct in our institution to assess effect of CSA
concentration in early stage on clinical outcomes including hematopoietic recov-
ery, aGVHD (acute graft versus host disease), infection, DFS (disease free sur-
vival), and OS (overall survival). 
Results: The median concentrations of CSA in the blood in the 1st, 2nd, 3rd
and 4th week after allo-sct were 218ng/ml (rang:54-1377ng/ml), 235ng/ml
(rang:27-1500ng/ml), 263ng/ml (rang:20-1500ng/ml), and 270ng/ml (rang:4-
1500ng/ml); 46%, 40%, 27% and 18% of the patients had CsA blood levels
below 200 ng/mL during these weeks. 39 patients developed grade 2–4 aGVHD
for a cumulative incidence of 27.8% at a median of 32 days.CSA levels during
1st, 2nd, and 4th week didn’t affect patients’ hematopoietic recovery, aGVHD,
infection, DFS, and OS significantly (p>0.05). However, patients having CSA
concentration below 200ng/ml in the 3rd week had a higher cumulative incidence
of grade 2-4 aGVHD (p=0.02). In a multivariate logistic regression analysis, low
CSA concentration (below 200ng/ml) in the 3rd week remained the independent
risk factor of grade 2-4 aGVHD (p=0.02). CSA level in the 3rd week was not
associated with patients’ engraftment, infection, DFS, and OS (p>0.05).
Summary/Conclusions: The analysis presented here emphasize that ade-
quate management of CSA levels in the early stage, especially during the
periengrafment period, can improve clinical outcomes in the T cell-replete hap-
loidentical allo-sct setting.
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HYPERBARIC OXYGEN THERAPY IS CLINICALLY EFFECTIVE FOR
REFRACTORY VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Y Suzuki1,*, T Oyake1, M Asahi1, N Sugawara1, Y Okano1, Y Fujishima1,
Y Aoki1, S Kowata1, S Ito2, Y Ishida1
1Hematology and Oncology, Internal Medicine, 2Medical Oncology, Iwate Med-
ical University School of Medicine, Morioka, Japan
Background: Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoi-
etic stem cell transplantation (HSCT) has been frequently associated with viral
infection of adenovirus (ADV), BK virus (BKV), JC virus (JCV) or another virus-
es. Antiviral drugs are of limited efficacy, and the optimal treatment for HC has
not yet been established. Hyperbaric oxygen (HBO) may benefit these patients,
but efficacy and safety of HBO for HC has not been evaluated sufficiently. 
Aims: To clarify the efficacy and safety of HBO therapy for viral HC, we retro-
spectively evaluated clinical data during the therapy.
Methods: In 199 cases of allogeneic HSCT from September 1994 to November
2015, we experienced 8 cases of refractory viral HC by ADV or JCV. We eval-
uated the effectiveness of HBO therapy in 8 patients with refractory HC after
allogeneic HSCT at our institution. 
Results: All 8 patients had macroscopic hematuria associated ADV or BKV
infections. Patients received 100% oxygen in a hyperbaric chamber at 2.1
atmospheres for 90-120 min per day, 5 days per week, with 13 median treat-
ments (range, 10-16). The 5 of 8 patients (62.5%) showed complete resolution
of hematuria in 7 days. The pain during urination disappeared in all 8 patients
(100%) in 5 days. Urinary DNA titers of ADV or BKV declined after HBO.
Patients who started on HBO earlier after diagnosis of HC responded sooner
and better than those who did on HBO later. Interestingly, 3 of 8 patients (37.5%)
showed dramatic recovery from refractory acute graft versus host disease
(GVHD) symptom accompanied by thrombotic microangiopathy (TMA), after
HBO therapy for refractory virus-associated HC. 
Summary/Conclusions: HBO therpy was generally well tolerated, and proved
to be a reliable option for refractory viral HC cases to manage their condition.
E1531
THE INFLUENCE OF NK CELL ALLOREACTIVITY ON OUTCOME AFTER
T-CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LEUKEMIA
V Zakharova1, Z Shekhovtsova2, E Raykina1, O Shragina1, L Shelikhova2,
D Balashov2, Y Skvortsova2, A Maschan3, M Maschan2,*
1Laboratory of molecular biology, 2HSCT, 3Dmitry Rogachev Federal Research
Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russian
Federation
Background: HSCT from human leukocyte antigen (HLA) haplotype-mis-
matched family members is the only curative option for patients with high-risk
acute leukemia who do not have a matched donor. Natural killer (NK) cells are
the first lymphoid cell population to reconstitute after allogeneic HSCT. It is
believed that NK alloreactivity is regulated by quantitative differences in acti-
vating and inhibitory signals (mediated by activating and inhibitory killer cell
immunoglobulin-like-receptors (KIRs), which recognize HLA class-I alleles (KIR
ligands)). A number of studies demonstrated beneficial effects of donor activat-
ing KIRs and KIR-ligand mismatches on transplant outcome.
Aims: In the present study we tested if donor KIR haplotype, particular KIR
genes and KIR-ligand mismatch have an effect on relapse incidence and event-
free survival (EFS) in pediatric patients with acute lymphoblastic leukemia (ALL)
and acute myeloid leukemia (AML). 
Methods: Fifty eight patients between 1/2012 and 6/2015 in complete remission
with ALL(n=26) and AML(n=32) were included in this study. Patients received T-
cell-depleted haploidentical transplants after myeloablative conditioning regimen
and post-transplant tacrolimus (n=24) or bortezomib (n=34) as GVHD prophy-
laxis. In all cases GCSF-mobilized PBSC were depleted of TCR-alpha/beta and
CD19+ cells with CliniMACS Plus. All samples were typed for HLA-A,-B,-C,-
DRB1,-DQB1 by sequence-based typing. KIR genotype was performed by
sequence-specific primers. “Receptor-ligand” model (at least one inhibitory KIR
gene expressed in the donor in the abscence of the appropriate HLA-molecules
in the recipient’s ligand repertoire) was used to predict NK alloreactivity. The
role of donor B vs A KIR haplotype and the number of total, inhibitory or activating
KIR in the donor was evaluated. The effect of each individual KIR gene was
analyzed. Cumulative incidence estimates were used for relapse and nonrelapse
mortality, because they are competing risk. The Gray test compared univariate
competing risk outcome. The Kaplan-Meier method evaluated EFS.
Results: All patients had primary engraftment (median 14 days for neutrophils
and 15 days for platelets). The median number of total KIR genes in donor was
10(range, 7-15), activating 3(1-6), inhibitory 7(5-9). No significant effect of KIR
genotype was found in patients treated with tacrolimus and in the whole cohort
of patients. Incidence of relapse decreased for patients treated with bortezomib
by: donor’s B/x haplotype compared to A/A, 12±6.5 vs 22.2±13.6, p=0.05; higher
total number of KIR genes (total KIR, 0 vs 29.4 ±10.9, p=0.005; activating KIR,
0 vs 29.4 ±10.9, p=0.004; inhibitory KIR, 8.7±5.9 vs 27.3 ±13.2, p=0.014; Influ-
ence of particular KIR genes on the incidence of relapse was detected:
KIR2DS2(10±6.7 vs 21.4±10.7, p=0.05); KIR2DS3(0 vs 22.7±8.8, p=0.028);
KIR2DL2(10±6.7 vs 21.4±10.7, p=0.05); KIR2DL5B(0 vs 21.7±8.5, p=0.035).
No significant influence was observed for other KIR genes. Based on clinical
studies “receptor-ligand” model was analyzed in patients with AML. There was
no correlation between KIR-ligand mismatch and relapse risk and EFS (p=0.97
and p=0.50 respectively).
Summary/Conclusions: There is increasing evidence that impact of donor
NK alloreactivity and KIR genotype is dependent on the transplant protocol.
Our results suggest that the use of bortezomib instead of prolonged tacrolimus
may contribute to the beneficial effects of donor NK cells.
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ETANERCEPT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE: A SINGLE CENTER EXPERIENCE
N de Jong1,*, L Saes1, C Klerk2, M van der Klift3, J Cornelissen1, A Broers1
1Hematology, Erasmus Medical Center, Rotterdam, 2Hematology, VU University
Medical Center, Amsterdam, 3Hematology, Amphia Hospital, Breda, Nether-
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Background: Acute graft-versus-host disease (aGVHD) is a major cause of
morbidity and mortality after allogeneic stem cell transplantation (alloSCT).
High dose systemic glucocorticosteroids (steroids) are currently recommended
as first-line treatment for grade II-IV aGVHD resulting in overall complete
responses (CR) in 40 to 50 percent of patients. Currently, there is no standard
second-line treatment for steroid-refractory aGVHD (SR-aGVHD). Etanercept
is a recombinant human tumor necrosis receptor fusion protein which inhibits
the biological activity of tumor necrosis factor alpha (TNFα) involved in the
pathophysiology of aGVHD. Studies that have investigated the use of anti-
TNFα as primary as well as secondary treatment in aGVHD have shown prom-
ising results.1,2
Aims: Here we report the results of a retrospective analysis of patients with
SR-aGVHD treated with etanercept in our center. 
Methods: We studied the outcome of sixteen patients following alloSCT with
SR-aGVHD, who gave consent for second-line treatment with the TNFα
inhibitor etanercept (Enbrel, Pfizer) between January 2009 and April 2013.
Etanercept was added to the initiated first-line treatment with high dose steroids
combined with cyclosporine A (CsA) or mycophenolate mofetil (MMF) and
administered subcutaneously twice weekly at a dose of 25 mg for a maximum
of eight weeks. 
Results: aGVHD developed at a median of 61 days post-transplantation. In
all cases it concerned grade 3 aGVHD of the gut. Second-line treatment with
etanercept was started at a median of 13 days after the initiation of first-line
treatment. First-line treatment consisted of 2 mg/kg steroids combined either
with CsA in fourteen patients or MMF in two patients and was continued during
treatment with etanercept until a sustained response was achieved. The overall
response rate was 50%, including a complete response (CR) in three patients
(18.8%) and a partial response (PR) in five patients (31,3%). Responses were
reached after a median duration of treatment of 9 days (range 5-40 days).
Despite a promising initial response rate, five out of eight responding patients
lost their response. One CR patient developed progressive GVHD after treat-
ment with etanercept had to be discontinued because of the development of
post-transplant EBV-related lymphoproliferative disorder. In addition, four PR
patients lost their response during treatment with etanercept. Clinically signif-
icant infectious complications occurred in thirteen patients, including bacterial
septicemia, viral infections and invasive pulmonary aspergillosis. Eventually,
all sixteen patients died at a median of 57 days (range 1 –267 days) after ini-
tiation of etanercept. Death was caused by progressive GVHD in seven cases
(43.8%), opportunistic infections in six cases (37.5%), cardiac death in two
cases (12.5%) and relapse of the original malignancy in one case (6%). 
Summary/Conclusions: Second-line treatment of SR-aGVHD of the gut with
the TNFα inhibitor etanercept did not meet the promising results reported by
Busca et al.2 While etanercept showed a promising initial response rate of 50%
in our patients, survival was very poor, which was mainly due to opportunistic
infections in the context of ongoing or progressive GVHD, even in patients,
who initially responded.
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HEMOCOAGULASE FOR THE TREATMENT OF SEVERE HEMORRHAGIC
CYSTITIS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
M Xue*, F Chen, D Wu, S Xue
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Hemorrhagic cystitis (HC) is a common and potentially severe
complication after allogeneic hematopoietic stem cell transplantation (HSCT).
Despite many therapies have been tested in the treatment of severe HC, no
definitive treatment has been established. Hemocoagulase is an established
hemostatic agent, but its efficacy for HC has not been evaluated.
Aims: The aim of this study is to investigate the clinical efficacy of hemocoag-
ulase for severe HC following HSCT.
Methods: We treated Twenty patients with severe HC (macroscopic hematuria
with clots and macroscopic hematuria with renal or bladder dysfunction, with
symptoms of cystitis) following HSCT with hemocoagulase. All the patients
were initially treated with hyperhydration, forced diuresis and red cell and
platelet transfusion support. For the patients with cytomegalovirus (CMV) repli-
cation in plasma determined by polymerase chain reaction, ganciclovir or fos-
carnet sodium was given. When patients developed macroscopic hematuria
with clots, hemocoagulase was given, 1U iv twice per day for 5 days as a
course. If the macroscopic hematuria disappeared at the sixth day after stop-
ping the drug, hemocoagulase was no longer given. If not, the next course
was given. During the treatment, the blood clotting factors was monitored for
2 to 3 times weekly. If the fibrinogen was decreased, the plasma or fibrinogen
was transfused to correct the blood coagulation abnormality. The urine speci-
ments reserved before and after hemocoagulase respectively were examined
by naked eye and microscope to evaluate the efficacy.
Results: Patients included 12 males and 8 females with a median age of 27
years (range, 13-57years). The median time to onset of severe HC was 28
days after HSCT (range, 14 to 70 days). The HC was cured (disappearance of
macroscopic hematuria without relapse) in 18 patients(2 cases were cured
after 1 courses, 9 cases were cured after 2 courses, 2 cases were cured after
3 courses, 2 cases were cured after 4 courses, 2 cases were cured after 5
courses, 1 cases were cured after 9 courses), improved (amelioration of macro-
scopic hematuria) in 1 patients after 3 courses and uncontrolled (persistence
of macroscopic hematuria with red cell transfusion requirements) in 1 patients
who died of pulmonary infection and pneumorrhagia. For the patients with
response, macroscopic hematuria disappeared at a median time of 28 days
after the treatments (range, 4-127 days). Among 20 patients, 7 cases had no
decrease of fibrinogen (2 cases were cured after 1 courses, 5 cases were
cured after 2 courses), the other 13 cases had obvious decrease of fibrinogen,
while after the infusion of plasma or fibrinogen, the fibrinogen recoveried. There
was no patient required interruption of treatment.
Summary/Conclusions: Hemocoagulase seems to be a safe and effective
drug for severe HC following HSCT.
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HCT.CI PREDICTS MORBI-MORTALITY IN AUTOLOGOUS STEM CELL
TRANSPLANTATION
M Berro1,*, LA Bet1, JI Trucco1, MM Rivas1, P Longo1, MI Paganini1, L Ballestracci1,
MC Foncuberta2, A Vitriu2, GD Kusminsky1
1Hematology, Hospital Universitario Austral, Pilar, 2Hematology, Alexandre
Fleming, CABA, Argentina
Background: Hematopoietic Stem Cell Transplant Comorbidity Index (HCT.CI)
score, described by Sorror, is a useful tool to assess the risk for Non Relapse
Mortality (NRM) after Allogeneic HSCT. The impact of this score in Autologous
HSCT is still to be confirmed.
Aims: To determine the impact of HCT.Ci score in the morbidity and mortality
after autologous HSCT, assessing the 100 day morbidity defined as orothraque-
al intubation (OTI), dialysis or vasopressors need, early mortality (before day
100) and long term NRM. 
Methods: We retrospectively reviewed 473 medical records of patients that
received an autologous HSCT in our centres between October 2002 and Sep-
tember 2015. Median age was 49 years (range 1-74 years), 58% were male,
prevalent diseases were Multiple Myeloma (37%), Non Hodgkin Lymphoma
(26%) and Hodgkin Lymphoma (20%), 29% were in complete remission, 42%
received one chemotherapy scheme before transplant, 46% two schemes and
12% three or more (heavily pre-treated). Regarding comorbidities, 42% had
low risk (LR) HCT.CI (score 0), 47% intermediate risk (IR) (1-2) and 12% high
risk (HR) (≥3). For univariate analysis we use Chi2 for dichotomic variables,
Kaplan-Meier for Overall Survival (OS) and cumulative incidence for NRM; for
multivariate analysis we used logistic regression for dichotomic and Cox regres-
sion for time dependant variables.
Figure 1.
Results: Median follow up was 1.3 years. Early mortality (day 100) was 4.4%,
9% required OTI, 8.5% vassopresors and 2.2% dialysis, 1-3 years NRM and OS
were 7-9% and 85-79% respectively. High risk HCT.Ci patients had a significant
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increase in 100 day mortality compared to low and intermediate risk (11% vs
4.1% vs 2.6% respectively, p=0.02), OTI (18% vs 8% vs 7%, p=0.02), dialysis
(9% vs.2% vs 0.5%, p=0.001) and NRM (1-3 years HR vs LR/IR 15-15% vs 5-
7%, p=0.02) (figure 1). After multivariate analysis these outcomes remain signif-
icant (comparing HR vs LR/IR): early mortality (OR 3.4, 95% CI 1.1-10.4), OTI
(OR 2.9, 95% CI 1.3-6.7), dialysis (OR 8.8, 95% CI 2.4-32.6) and NRM (OR 2.6,
95% CI 1.05-6.6). Other than comorbidities, Multiple Myeloma patients had a
significant reduction in NRM (OR 0.25, 95% CI 0.1-0.8) and OTI (OR 0.28, 95%
CI 0.1-0.83); patients older than 60 years had a significant increase in NRM (OR
4.6, 95% CI 2.1-10.5) and heavily pre-treated patients had a significant increase
in NRM (OR 3.3, 95% CI 1.4-7.9) and OTI (OR 2.4, 95% CI 1.1-5.6).
Summary/Conclusions: We observed that HCT.CI had a significant impact
on Autologous HSCT treatment related mortality basically due to early toxicity
express as 100 day mortality and the three main morbidity outcomes. This
observation should be confirmed in larger series.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR INTRAVASCULAR
LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY OF THE OF THE
EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION
LYMPHOMA WORKING PARTY
J Meissner1,*, H Finel2, A Boumendil2, S Dietrich1,2, E Kanfer2,3, G Laboure2,4,
M Abecasis2,5, J Cornelissen2,6, J Delage2,7, J Finke2,8, U Hess2,9,
H Ludwig2,10, M Mohty2,11, T Pabst2,12, P Pioltelli2,13, S Robinson2,14, P Samaras2,15,
P Dreger1,2
1University Hospital, Heidelberg, Germany, 2Lymphoma Working Party, Euro-
pean Society for Blood and Marrow Transplantation, Paris, France, 3Hammer-
smith Hospital, London, United Kingdom, 4University Hospital, Bordeaux,
France, 5Inst. Potugues Oncologia, Lisboa, Portugal, 6Erasmus MC-Daniel den
Hoed Cancer Centre, Rotterdam, Netherlands, 7CHU Lapeyronie, Montpellier,
France, 8University Hospital, Freiburg, Germany, 9Kantonsspital, St. Gallen,
Switzerland, 10Wilhelminenspital, Vienna, Austria, 11Hopital Saint Antoine,
Paris, France, 12University Hospital, Bern, Switzerland, 13Ospedale San Ger-
ardo, Monza, Italy, 14Bristol Oncology Centre, Bristol, United Kingdom, 15Uni-
versity Hospital, Zürich, Switzerland
Background: Intravascular large B-cell lymphoma (IVLBCL) represents a rare
lymphoma subtype characterized by the selective growth of malignant cells
within the lumina of small vessels. The combination of rituximab and cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely used as
first-line therapy but with about half of the patients being progressive within 2
years, outcome is inferior to non-intravascular diffuse large B-cell lymphoma.
Aims: Since the value and timing of autologous stem cell transplantation
(autoSCT) in the treatment of IVLBCL is undefined, the objective of this study
was to analyze for the first time the efficacy of autoSCT for IVLBCL in a larger
cohort of Western patients.
Methods: This is a registry-based retrospective multicentre study including
patients aged 18 years or above with histologically verified IVLBCL who under-
went autoSCT between 1 January 2002 and 31 December 2013 and were reg-
istered with the European Society for Blood and Marrow Transplantation
(EBMT) database. Of 97 patients identified in the EBMT registry, a full data set
could be obtained for 19 patients. After exclusion of patients with a histopathol-
ogy report not confirmative for the diagnosis of IVLBCL, the final study cohort
consisted of 11 patients.
Results: The median age of the 11 patients was 55 (range 34-68) years. All
had stage IV disease with CNS involvement in 5 patients. First-line treatment
was mainly based on R-CHOP or a CHOP-like regimen. The median time from
diagnosis to transplant was 6 months. Six patients were autografted in first
remission while 5 patients received more than one line of treatment prior to
autoSCT. Disease status at autoSCT was complete remission in 8 patients and
partial remission in 3 patients. After a median follow-up of surviving patients of
51 months (range 12-95), 8 patients were alive and free of progression. One
patient (transplanted in first remission) died treatment-related whereas 2
patients relapsed 15 and 27 months post autoSCT, both with more than one
previous treatment line. No relapse occurred in patients autografted in first
remission. 4-year progression-free survival of all 11 patients was 71%.
Summary/Conclusions: The outcome of this to date largest patient cohort
compares favorable to the outcome after standard R-CHOP and is in line with
the outcome of autoSCT in small Asian case series. Furthermore our data sug-
gest that the outcome of autoSCT performed in first remission may be superior
to that of autoSCT performed after multiple lines of therapy. Consolidative
autoSCT performed in first remission after R-CHOP-like therapy results in favor-
able long-term outcome for patients with IVLBCL and thus appears to be a
valuable treatment option for fit patients up to an age of 65-70 years.
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RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
FOR CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WHO FAILED
TYROSINE KINASE INHIBITORS
V Funke*, AC Brandao, R Savian, J Oliveira, D Setubal, L Medeiros, C Bonamin,
N Farah, AL Mion, R Pasquini
Hematology, Federal University of Parana, Curitiba, Brazil
Background: Chronic Myelogenous Leukemia (CML) is a myeloproliferative
neoplasm. The hallmark is the presence of a reciprocal t(9;22)(q34;q11.2)-
Philadelphia chromosome (Ph), resulting in which produces a BCR-ABL fusion
gene and therefore a BCR-ABL protein with constitutive tyrosine kinase activity.
Tyrosine kinase inhibitors (TKI) are the first line of treatment. However, some
patients are resistant. Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT) is indicated for patients with Chronic Myelogenous Leukemia (CML)
who develop resistance to tyrosine kinase inhibitors (TKI). 
Aims: The main aim is analyzing outcomes of HSCT in 49 patients with CML
resistant to TKI and identifying risk factors for overall survival (OS) and disease
free survival (DFS) in those patients. 
Methods: We analyzed the outcomes of 49 patients resistant to TKIs trans-
planted at the BMT Center of Federal University of Paraná, from January 2001
to August 2015. The study is retrospective, observational and analytical, held
from data record in either STMO database or medical chart. Informed consent
was waived. Kaplan-Meyer method was used to build survival curves and Log-
rank test to compare them. The established level of significance was p<0.05.
The following risk factors were analyzed: donor and recipient sex, age at HSCT,
pre-HSCT imatinib, second generation inhibitors or interferon, conditioning reg-
imen, immunoprophylaxis, donor type, stem cell source, HLA compatibility,
engraftment, acute graft versus host disease (aGVHD), chronic graft versus
host disease (cGVHD), disease phase and previous response to TKI (hemato-
logic and cytogenetic). Multivariate analysis was performed using Cox Regres-
sion model to identify risk factors for overall survival and disease-free survival. 
Results: Chronic graft versus host disease (GVHD) (n=16) was associated to
a higher OS (p=0,04) whereas acute GVHD (n=13) was associated to a lower
OS. Regarding to DFS, a myeloablative (MA) conditioning regimen (n=45) lead
to higher survival probability (p=0.00182). BCR-ABL mutation analysis was per-
formed before HSCT in 55% of the patients (n=27) and found in 33% (n=9).
The presence of mutations was a significant risk factor for OS (p=0.00366).
The median OS was 373 days (33-3677) and the median DFS was 273 days
(0-3677). Five years probability of survival was 41% for entire group.
Summary/Conclusions: HSCT is an important alternative for patients with TKI
resistance. Chronic GVHD was associated with a 3,6 lower probability of death,
while occurence of acute GVHD had a negative impact, increasing probability of
death in 3 times. Worse outcome was showed for patients with pre-transplant
mutations. Myeloablative conditioning was significantly associated with better DFS.
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EQUIVALENT OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION
IN ACUTE MYELOID LEUKEMIA PATIENTS WHO HAD T (8;21) WITH AND
WITHOUT ADDITIONAL ABERATIONS
H Chen*, KY Liu, LP Xu, Q Jiang, YH Chen, HH Zhu, YY Lai, YR Liu, XJ Huang
Peking University, People’s Hospital, Peking University Institute of Hematology,
Beijing, China
Background: Although acute myeloid leukemia (AML) patients who had t(8;21)
had favorable outcome after high-dose therapy with autologous stem cell trans-
plantation(ASCT). It was still a heterogeneous disease. Limited data was report-
ed about outcome in AML patients who had t(8;21) with additional cytogenetic
abnormalities after ASCT.
Aims: In the current cohort study we investigated long-term survival of AML
patients who had t(8;21) with and without additional aberations after ASCT.
Methods: Patients with de novel AML who had t(8;21) with or without additional
cytogenetic abnormalities, younger than 60 years were eligible. G banding and
FISH analysis were performed to test cytogenetic aberations. Peripheral blood
stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD
level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at
least 2-coursrs of consolidation therapy including high-dose Ara-C. MRD was
monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T, The
conditioning regimen was busulphan/cytoxan.
Results: between March 2008 and March 2014, 27 eligible patients were
enrolled. All enrolled patients were Chinese. Median age was 30 years (range,
13- 56 years). Fourteen patients were male and 13 were female. Eleven patients
had additional aberrations, including –y (n=6), -x (n=2), del (8q) (n=1), del(9q)
(n=1), del(9q) and –x (n=1). Patients’ characteristics between the two groups
were comparable. At the median follow-up 46 months (range,6.5 to 92 months)
after consolidation therapy, the 5-year leukemia-free survival (LFS) and overall
survival (OS) for the total patients were 88.9%±6.0% and 90.3% ±6.8% after
consolidation therapy. For the patients with and without additional aberations,
LFS were 87.5% and. 90.9%, p=0.832. OS were 90.8% and 90.9%, p=0.752,
respectively. Two relapse patients after ASCT received haploidentical related
transplantation and were still alive in CR after following-up 74 and 64 months.
Summary/Conclusions: AML patients who had t (8;21) with and without addi-
tional aberations had equivalent long-term survival after ASCT in Chinese, if
patient achieved CR1 with MRD level less than 0.1% before transplant. Allo-
geneic HSCT including haploidentical related transplant is a salvage therapy
for relapse patients after ASCT.
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ANTIBACTERIAL PROPHYLAXIS REDUCES THE RISK OF BACTEREMIA
IN PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA UNDERGO-
ING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION
I Vaxman*, U Rosovski, M Moshe, L shargian, O Pasvolsky, D yahav, J Bashara,
M Lahav, R Gurion, H Magen, L Vidal, G Itzhaki, A Peck, M Navon Sela,
P Raanani, M Yeshurun
Beilinson, Petah Tikva, Israel
Background: Bacterial infections are a major cause of morbidity and mortality
in patients undergoing autologous stem cell transplantation (ASCT). However,
whether these patients benefit from antibacterial prophylaxis is unclear. The
few studies which addressed this issue are limited by small sample size or the
use of multiple anti-microbial agents. Current guidelines recommend consid-
ering the use of antibacterial prophylaxis in patients with anticipated neutrope-
nia of 7 days or more. At our center, patients undergoing ASCT were given
ciprofloxacin for antibacterial prophylaxis until 2012. This change in policy pro-
vides a unique opportunity to study the potential benefit of antibacterial pro-
phylaxis in ASCT.
Aims: To explore the efficacy and adverse effects of ciprofloxacin prophylaxis
in patients undergoing ASCT.
Methods: This is a single center retrospective study. Data were collected from
the medical records of all patients with a diagnosis of non-Hodgkin’s lymphoma,
Hodgkin’s disease or multiple myeloma (MM) who underwent ASCT at Rabin
Medical Center between 03/2007 and 12/2015. Until 10/2012 all patients were
given oral ciprofloxacin 500 mg BID starting concomitantly with the conditioning
regimen (BEAM for lymphoma and melphalan for multiple myeloma) until the
first febrile episode or until engraftment. After 10/2012, our treatment policy has
changed and we stopped using antibacterial prophylaxis in the ASCT setting.
Results: Between 03/2007 and 12/2015 303 patients received 327 high dose
chemotherapy followed by ASCT. The median age at time of transplant was 55
years (range: 16 to 72) and 186 patients (57%) were males. The diagnosis
was MM in 174 patients (46%), NHL in 110 patients (34%) and HD in 43 patients
(13%). 154 consecutive patients were given ciprofloxacin prophylaxis and 171
patients were not given ciprofloxacin prophylaxis before and after 10/2012,
respectively. Overall, 10% (n=32) of the patients had a bacteremia, 16% (n=27)
in the group of patients who did not receive prophylaxis, compared to only 3%
(n=5) in the group of patients who received prophylaxis (P<.0001). The rates
of febrile neutropenia were 84% (N=129) in patients who received prophylaxis
compared to 91% (155) in patients who did not receive antibacterial prophylaxis
(P=0.06). The number needed to treat (NNT) in order to prevent one episode
of bacteremia is 4.9. The frequency of all other infections, the duration of hos-
pitalization, and the rates of all cause and infection-related mortality were not
significantly different between groups. Of note, ciprofloxacin prophylaxis was
not associated with an increased in bacterial resistance. Patients with lym-
phoma were younger (median 53 years, range: 19-72) than patients with MM
(median 58, range: 33-68) but similar in all other demographic characteristics.
The median duration of aplasia was 6 days (range: 4 to 13) in patients with
MM after high-dose melphalan and 8 days (range 5 to 14) in patients with lym-
phoma after BEAM (p<0.0001). However, both groups seemed to equally ben-
efit from antibacterial prophylaxis. In a multivariable analysis ciprofolxacin pro-
phylaxis significantly decreased the odds of bacteremia (Odds Ratio: 0.19
(Confidence interval: 0.07 to 0.52)). Age, diagnosis, and the duration of aplasia
were not associated with the risk of bacteremia
Summary/Conclusions: Ciprofloxacin prophylaxis markedly reduced the risk
of bacteremia and neutropenic fever in lymphoma and MM patients undergoing
ASCT without increasing the incidence of resistant bacterial strains in patients
receiving ciprofloxacin prophylaxis. The NNT in order to prevent one episode
of bacteremia is 4.9, suggesting that antibacterial prophylaxis should be con-
sidered in ASCT.
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EFFECTIVE USE OF ORAL RIBAVIRIN FOR RESPIRATORY SYNCYTIAL
VIRAL INFECTIONS IN ADULT ALLOGENEIC HAEMATOPOIETIC STEM
CELL TRANSPLANT RECIPIENTS
C M Gorcea1,*, E Tholouli1, A Turner2, E Davies3, E Battersby3, M Saif1, F Dignan1
1Department of Haematology, 2Department of Virology, 3Pharmacy Depart-
ment, Manchester Royal Infirmary, Manchester, United Kingdom
Background: Respiratory syncytial virus (RSV) is a common cause of respi-
ratory viral infections and is associated with increased morbidity and mortality
in patients undergoing haematopoietic stem cell transplantation (HSCT). Little
is known about the best management strategy in this high risk group and there
is very little data on oral ribavirin treatment. 
Aims: The outcome of adult allogeneic HSCT recipients with RSV infection
treated with oral ribavirin was analysed at a single UK centre.
Methods: We performed a retrospective analysis of 23 consecutive RSV cases
treated with oral Ribavirin between December 2010 and February 2015. Patient
characteristics: male 12, median age 52 years (range 20 to 69). Underlying
diagnoses: acute leukaemia 11, myelodysplasia 4, aplastic anaemia 3, multiple
myeloma 3, chronic leukaemia 2. Allogeneic HSCT characteristics: 16 reduced
intensity conditioning (RIC) and 7 myeloablative conditioning. RSV diagnosis
was established by polymerase chain reaction (PCR) assay. At diagnosis, 7
patients presented with lower respiratory tract infection (LRTI) as defined by
new infiltrate on chest X-ray (CXR), signs on auscultation or hypoxia, whereas
16 experienced upper RTI. All patients with a positive RSV PCR result received
treatment. We initiated oral Ribavirin at a dose of 15mg/kg divided into 3 daily
doses with no subsequent dose escalation. The median treatment duration
was 10 days (range 5 to 47). Additional therapies were administered concomi-
tantly: 3 patients received immunoglobulin replacement, 17 received antimi-
crobials and 3 patients also received antifungal treatment for suspected super-
imposed bacterial or fungal infection. Patients were retrospectively scored
using the immunodeficiency scoring index for RSV (ISI-RSV) which takes into
consideration neutropenia (<0.5x109/L), lymphopenia (<0.2x109/L), age (≥40
years), myeloablative conditioning regimen, graft versus host disease (GVHD
acute/chronic), corticosteroid treatment and pre-engraftment period (or within
30 days of HSCT) to determine the risk of progression to LRTI. In our cohort,
14 patients were low risk with an ISI of 0-2 (2 patients ISI 0, 6 patients ISI 1, 6
patients ISI 2) and 9 patients were moderate risk with an ISI of 3-4 (8 patients
ISI 3, 1 patient ISI 4) and therefore oral treatment was felt to have been appro-
priate, on retrospective analysis. 
Results: The treatment was well tolerated with minor side effects in 2 patients.
In total, 19 patients completed exclusively oral ribavirin treatment, whereas 4
were escalated to aerosolised ribavirin due to worsening symptoms. Only 7
patients required admission for intravenous antibiotics and/or aerosolised rib-
avirin. The median admission period was 7 days (range 1 to 16). None of the
patients required intensive care admission. After a median follow-up of 17
months (range 4 to 48), 17 patients are alive and 6 died. One patient died of
RSV pneumonitis complicated with bacterial and suspected fungal infection
on the background of relapsed disease and 5 died of unrelated causes.
Summary/Conclusions: RSV in post allogeneic HSCT patients remains a
challenge due to the high frequency of infection and increased morbidity and
mortality associated with RSV LRTI. Prompt initiation of treatment is essential
and may avoid unnecessary hospital admission. Our experience supports the
use of oral ribavirin in selected adult HSCT recipients, after a careful risk
assessment has been performed. Prospective studies and larger numbers of
patients are needed to determine the optimal therapy for this patient group.
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EFFICACY AND SAFETY OF BIOSIMILAR FILGRASTIM (ZARZIO®) AFTER
AUTOLOGOUS STEM CELL TRANSPLANT: UPDATE OF A COMPARATIVE
STUDY WITH LENOGRASTIM AND PEG-FILGRASTIM
F Marchesi1,*, M Vacca2, S Gumenyuk1, A Pandolfi2, D Renzi1, F Palombi1,
F Pisani1, A Romano1, A Spadea1, F Ipsevich2, M De Rienzo3, E Papa1,
M Canfora4, ML Foddai3, L Pierelli2, A Mengarelli1
1Hematology and Stem Cell Transplant, Regina Elena National Cancer Insti-
tute, 2Leukapheresis and Cellular Therapy Unit, S. Camillo-Forlanini Hospital,
3Immuno-Transfusional Medicine Unit, 4Scientific Direction, Regina Elena
National Cancer Institute, Rome, Italy
Background: Biosimilar Granulocyte Colony-Stimulating Factor (G-CSF) has
been approved on the basis of comparable quality, safety and efficacy as the
originator product. So far, biosimilar Filgrastim Zarzio® has been approved also
for autologous peripheral stem cell mobilization and for prophylaxis of sever
neutropenia duration following conditioning chemotherapy and stem cell infu-
sion. However, there is still general skepticism about safety and efficacy of
Zarzio® in these setting of patients, considering the lack of prospective studies
with a long follow-up.
Aims: The aim of the study was to evaluate the efficacy and the safety of
Zarzio® when used as hematologic recovery after autologous stem cell trans-
plant (ASCT).
Methods: From March 2013 to November 2015, 114 consecutive adult patients
with hematologic malignancies (Plasma cell disorders n=68; Non Hodgkin and
Hodgkin’s lymphomas n=42; others n=4) underwent ASCT in our Institution.
Zarzio® was given at the dosage of 5 mcg/Kg beginning to day 3 from infusion
of stem cells and continued until neutrophilis recovery. Hematologic recovery
after ASCT was defined as an absolute neutrophilis count upper than 0.5x109/L
and a platelets count upper than 20 x 109/L in three consecutive checks. This
cohort of patients was compared with two historical cohorts of patients in our
Institution: a) 99 consecutive adult patients treated with Lenograstim
(Myelostim®) at dosage of 5 mcg/Kg daily given from day 3 after infusion from
January 2009 to February 2013; b) 60 consecutive adult patients treated with
peg-filgrastim (Neulasta®) at dosage of 6 mg single dose at day 3 after infusion
from March 2006 to December 2008.
Results: The three patient cohorts were similar for all baseline features ana-
lyzed, without any significant differences in terms of sex, median age, diagnosis,
median chemotherapy lines prior ASCT, disease status at ASCT, conditioning
regimen and median infused CD34+ cells. We analyzed the time of hematologic
recovery after stem cell infusion, the occurrence of fever of unknown origin
(FUO) in neutropenia, documented infectious episodes and needing of intra-
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venous antibiotics, number of red blood and platelet transfusions, the days of
hospitalization and the transplant-related mortality (TRM). The results of the
study show a significantly shorter time to neutrophilis and platelet recovery
(P=0.001 and P=0.007, respectively) in the cohort of patients treated with Neu-
lasta®, whereas no difference was observed among the other two groups. As
for the other analyzed parameters, we didn’t observe any significant difference
among the three patient cohorts for all the other analyzed parameters. In par-
ticular, we did observe a similar incidence of FUO episodes (P=0.102), micro-
biologically documented infections (P=0.424) and needing of intravenous antibi-
otics (P=0.612). Moreover, we didn’t find any significant differences as for trans-
fusional needing (P=0.099), median hospitalization time (0.102) and TRM
(P=0.709). No difference in terms of drug-related adverse events was observed
in the three patient cohorts with no reported serious adverse events. Similar
results were obtained performing two separate sub-analysis only for lymphoma
or myeloma patients.
Summary/Conclusions: Despite the limitations due to the non-randomized
nature of the study, from our data biosimilar Filgrastim (Zarzio®) seems to be
substantially equivalent in terms of efficacy and safety to Lenograstim
(Myelostim®) and Peg-Filgrastim (Neulasta®), when used for hematological
recovery after ASCT in adult patients with hematologic malignancies.
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EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF
ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPEC-
TIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS
M Malagola1,*, V Cancelli2, C Skert1, P Ferremi Lealia3, E Ferrari3, A Tiburzi3,
ML Sala3, I Donini4, P Chiusolo5, A Muffetti6, M Battista7, N Polverelli1, A Turra1,
F Cattina1, B Rambaldi1, F Schieppati1, A Bosi4, S Sica8, P Corradini6, F Patri-
arca7, M Marini3, D Russo1
1Chair of Hematology, Bone Marrow Transplant Unit, University of Brescia, AO
Civili Brescia, Brescia, Italy, 2Experimental and Clinical Sciences, Chair of
Hematology, Bone Marrow Transplant Unit, University of Brescia, AO Civili
Brescia, 3Immunohematology and Transfusion Medicine Unit, AO Cvili, Brescia,
4Bone Marrow Transplant Unit SODc Ematologia, AOU Careggi, Firenze, 5UO
Ematologia, Policlinico Universitario A Gemelli, Università Cattolica del Sacro
Cuore, Roma, 6SC Ematologia, Istituto Nazionale Tumori, Milano, 7Clinica Ema-
tologica, AOU Santa Maria della Misericordia, Udine, 8UO Ematologia, Poli-
clinico Universitario A Gemelli, Università Cattolica del Sacro Cuore, Brescia,
Italy
Background: Extracorporeal photopheresis (ECP) is considered a valid sec-
ond-line treatment of both acute and chronic GVHD, which represent the most
frequent causes of morbidity and mortality after allo-SCT in hematological malig-
nancies.
Aims: According to an observational multicentric study, we report here a retro-
spective analysis on the use and results of ECP in 94 patients with acute and
chronic GVHD, recruited in 6 italian Centres.
Methods: 94 patients with aGVHD grado ≥ 2 (n=45) and cGVHD (n=49) were
submitted to ECP after first-line steroid-based therapy. ECP treatment consisted
on conventional bi-weekly procedure for 4 weeks. Then, most of the patients
were treated with bi-weekly procedures every 2 weeks for 4 other weeks.
Response to steroid was assessed after 7 days for aGVHD and 15 days for
cGVHD.
Results: aGHVD: 45 patients with aGVHD were treated with ECP. In 22 (49%)
ECP was used as salvage treatment, being these patients non responsive to
steroid (NR). 19/22 (86%) achieved a CR after ECP, whose median duration
was 77 days (range 20-1112). The median duration of steroid therapy was 101
days (range 24-772), with a median of 22 days (range 7-80) on full steroid
dose. The median duration of steroid on tapering was 82 days (range 0-756).
8/22 (36%) patients developed a cGVHD (extensive in 6 cases and limited in
2 cases). After a median follow up of 419 days (range 61-2149), 11/22 (50%)
patients are alive. In 23/45 cases (51%) ECP was used earlier, being these
patients partially responsive to steroid. Among these patients, 22 (96%)
achieved the CR after ECP. In this setting of patients, the median duration of
steroid was 88 days (range 32-719), with a median of 18 days (range 4-69) on
full dose steroid therapy. The median duration of steroid on tapering was 68
days (range 0-700). The median duration of ECP treatment was 194 days
(range 22-933). 7/23 (30%) patients developed a cGHVD (extensive in 6 cases
and limited in 1 case). With a median follow up of 741 days (range 81-1819),
17/22 (77%) patients are alive. Among the 45 patients with aGVHD, the pro-
jected 2 years OS was 50% for the patients with steroid-refractory aGVHD ver-
sus 80% for the patients with steroid partially responsive aGVHD (p=0,07), and
the cumulative incidence of cGVHD at 1 year was 48% vs 23%, respectively
(p=0,32). cGVHD: 49 patients with cGVHD were treated wiht ECP. 12/49 (24%)
and 37/49 (76%) had limited and extensive cGVHD, respectively. The median
time of cGVHD onset was 193 days (range 43-3756), the median time from
steroid to ECP was 26 days (range 0-1347) and the median duration of ECP
was 276 days (range 19-2861). The median duration of steroid therapy in this
group was 276 days (range 19-2861). 22/49 patients (45%) and 17/49 patients
(35%) achieved a CR and PR, respectively. After a median follow up of 811
days (range 152-4676), 44/49 patients (90%) are alive, 28 of whom (64%) on
immunosuppressive therapy.
Summary/Conclusions: ECP confirmed to be an effective treatment in aGVHD
steroid-resistant patients as it can induce a CR in more than 80% of the cases,
with 50% of these patients becoming long-term survivors. In aGVHD steroid
partially-responsive patients it can probably allow a faster steroid tapering, with
more than 70% of patients becoming long term survivors. In cGVHD steroid-
resistant patients, ECP are associated with an overall response rate of 80%,
with 90% of patients who become long-term survivors.
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IMPACT OF PLERIXAFOR ON HOSPITAL EFFICIENCY: A SINGLE CENTER
EXPERIENCE
N Azar*, M Ouzegdouh, S Choquet, V Leblond
Hematology department, Hôpital Pitié-Salpêtrière, Paris, France
Background: Plerixafor in combination with granulocyte colony-stimulating
factor (G-CSF) has shown to increase mobilization of peripheral blood stem
cells (PBSC) as compared to G-CSF alone in patients undergoing autologous
stem cell transplantation (ASCT). However, up to 25% of patients treated with
G-CSF alone still fail mobilization. Adding plerixafor to the regimen of poor
mobilizers allows to rescue these patients from mobilization failure and to
reduce the number of apheresis sessions. Furthermore, it was hypothesized
that the use of plerixafor would lead to a better prediction of the number of
apheresis time-slots needed and a reduction of time-slots lost. This in turn
would free hospital resources which could be dedicated to other procedures.
Aims: The goal of this retrospective study was to capture the impact of plerix-
afor on mobilization outcome and on the efficiency of the apheresis department.
Efficiency was described in terms of time-slots lost and the number of extra-
corporeal photopheresis (ECP) sessions carried out. ECP, whose benefit is
generally recognized in patients with cutaneous T-cell lymphoma and graft ver-
sus host disease, is a procedure which carries some similarities with standard
apheresis techniques and may therefore be carried out by the same staff pro-
vided some additional training. The demand for this procedure has steadily
increased over the last years, but could not be matched by available health
care resources. 
Methods: Hospital records of patients treated before (2005-2008) and after
(2009-2014) introduction of plerixafor were collected and analyzed retrospectively.
Main outcomes were mobilization failure rate and number of time-slots lost due
to insufficient mobilization, ie low CD34 count. Secondary endpoints included the
number of apheresis sessions per patient, mean CD34+ cells collected, the num-
ber of ASCT and ECP sessions carried out, and costs per ASCT patient.
Results: Following plerixafor introduction, the mobilization failure rate dropped
from 12% to 4% and the mean number of time-slots lost per patient dropped
from 1.39 to 0.89. Additional drug costs due to plerixafor were partially balanced
by a reduction in apheresis sessions, resulting in an additional cost of 700 €
per ASCT candidate. More importantly, with the use of plerixafor, the availability
of time-slots turned from erratic to predictable such that freed capacity could
be dedicated to other apheresis procedures, and the number of ECP sessions
increased from 0 in 2005 to 685 sessions in 2014 (see Figure).
Figure 1.
Summary/Conclusions: Plerixafor not only improved mobilization outcomes
for patients undergoing ASCT, but also reduced uncertainty around scheduling
of apheresis sessions, leading to a decrease in time-slots lost. Freed resources
were used to manage patients requiring ECP therapy, showing that the intro-
duction of plerixafor had much wider implications beyond that of improvement
in PBSC mobilization. Even though this result is not generalizable, in a climate
of stretched resources it is important to consider the opportunity and redistrib-
ution investment possible with freed capacities.
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A TREOSULFAN-BASED TOXICITY-REDUCED CONDITIONING REGIMEN
IS SAFE AND FEASIBLE FOR CHILDREN WITH NON-MALIGNANT
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Background: Hematopoietic stem cell transplantation (HSCT) as a treatment of
non-malignant diseases has improved over the last decades. Less toxic chemother-
apy during conditioning aims at reducing transplant related mortality with the risk
of an increased rejection rate. Non-malignant disorders are chemo-naïve and carry
an increased risk of transplant rejection compared to malignant diseases.
Aims: Aim of the present study was to evaluate safety and feasibility of a tre-
osulfan-based toxicity-reduced conditioning regimen in pediatric patients under-
going HSCT.
Methods: This retrospective study analyzed the safety and feasibility of a tre-
osulfan-based conditioning between 2009 and 2013 in 31 pediatric HSCT recip-
ients (17 males, 14 females) with a median age of 7.8 years (range 0.1-18.2
years), undergoing allogeneic HSCT for non-malignant diseases, thalassemia
(n=11), leukodystrophies (n=6), severe combined immunodeficiency (n=4),
sickle cell disease (n=3), familial hemophagocytic lymphohystiocytosis (n=3)
and others (n=4). The chemotherapy during the conditioning regimen consisted
of fludarabine 150 mg/m2 in 5 single doses (5 x 30 mg/m2) between day -7
and day -3. Treosulfan was given in a dosage of 42 g/m2 in 3 single doses (3
x 14 g/m2) between day -6 and day -4. On day -2, thiotepa was applied in a
dosage of 10 mg/kg bodyweight per day, twice a day (2 x 5 mg/kg BW).
Between day -6 and day -3, patients received treatment with 4.5 mg /kg BW
anti-thymocyte globulin (ATG) in 4 dosages (1 x 0.5 mg/kg BW as test dosage;
1 x 1.0 mg/kg BW; 2 x 1.5 mg/kg BW). Patients received transplants from a
matched sibling donor (MSD, n=15), a matched unrelated donor (MUD, n=12),
a mismatched unrelated donor (MMUD, n=1), a matched family donor (MFD,
n=2), or a mismatched family donor (MMFD, n=1). The median observation
period was 2.0 years (range 34 days - 5.6 years) and included the time of
measurement directly before the start of conditioning until December 2014.
Results: Primary engraftment occurred in 97% of the patients, with a median
time of 15 days after transplantation to reach >1000 leukocytes per µl peripheral
blood and a median time of 21 days to reach platelet counts, which did not
require transfusions anymore. After re-transplantation, final engraftment
occurred in 67% of the patients. Graft-versus-Host Disease (GvHD) grade II
and III-IV occurred in 6% and 9% of the patients, and chronic GvHD occurred
in 0% of the patients. Rate of other grade IV side effects was low, except for
grade IV stomatitis that occurred in 42% of the cases. Transplant related mor-
tality (TRM) was observed in 7% of the patients after one year. HSCT recipients
with hemoglobinopathies were accompanied by a rejection rate of 31% com-
pared to 0% rejection rate among all other patients. Mixed chimerism occurred
in 71% of the cases. Mixed chimerism >50% occurred in 42% of the cases and
mixed chimerism >80% occurred in 23% of the cases.
Summary/Conclusions: In conclusion, a treosulfan-based conditioning regi-
men resulted in excellent engraftment rates with low toxicity in children with
non-malignant diseases. However, in children with hemoglobinopathies, the
rejection rate was not acceptable occurring in around one third of the cases.
Future prospective controlled studies will have to clarify the long-term outcome.
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POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST
DISEASE PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMATOLOGIC
MALIGNANCIES TRANSPLANTED FROM HAPLOIDENTICAL AND
MATCHED UNRELATED DONORS
A Abrosimov1,*, L Shelikhova1, Z Shekhovtsova1, D Balashov1, Y Skvortsova1,
E Kurnikova2, M Ilushina1, I Shipitsina1, D Shasheleva1, R Khismatullina1,
E Gutovskaya1, S Blagov1, N Myakova3, D Litvinov4, D Baidildina5, G Novichkova6,
M Maschan1, A Maschan6
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Background: Standard GvHD prophylaxis regimens impair the graft-versus-
tumor (GVT) effect, delay immune reconstitution and are associated with high
rate of infections. High-dose post-transplantation cyclophosphamide (PTCy)
targets alloreactive donor T cells proliferating early after BMT, promotes regu-
latory T cell and permits rapid immune reconstitution.
Aims: In this pilot trial we evaluate the safety and effects of PTCy in unmanip-
ulated haploidentical and matched unrelated transplantation (MUD) in pediatric
patients with hematologic malignancies.
Methods: Twenty eight pediatric patients with high risk hematologic malignan-
cies underwent unmanipulated allogeneic bone marrow (BM) (n=26) or periph-
eral blood stem cell (PBSC)(n=2) transplantation followed by PTCy between
April 2014 and September 2015 with a median follow-up of 9 months (1,5-19).
Nineteen patients were transplanted from haploidentical donors and 9 from
MUD. The median age was 10,4 years (range 1,9-18); 14 patients with ALL, 4
AML, 8 JMML and 2 with HD; 16 patients were in remission (CR) (14-ALL, 1-
AML, 1-HD), 12 had active disease (AD) (8-JMML, 3-AML, 1-HD). In 11 pts
this was a second allograft. Twenty-six pts received myeloablative Treosulfan/
Melphalan/Fludarabine and 2 pts - reduced-intensity Fludarabine/TAO 2Gy/
Thiotepa as conditioning regimen. GvHD prophylaxis consisted of PTCy on
day +3, +4 and tacrolimus from day +5 in all pts., 12 (43%) pts. also received
ATG (rabbit, thymoglobuline) at 5 mg/kg/course.
Results: Primary engraftment was achieved in 27(96,4%) of 28 pts., the medi-
an time to neutrophil and platelet recovery was 20 days (14-45) and 21 days
(10-97). Twenty seven (96,4%) patients were in full donor chimerism on day
+30. Early mortality was 14,9% (95% CI: 6-36), causes of death included viral
infections (n=3); GvHD and viral infection (n=1). Cumulative incidence (CI) of
acute GvHD grade ≥II was 50% (95%CI:34-74), grade III–IV - 34% (95%CI:19-
62) and chronic GvHD-19% (95%CI:8-45). No correlation between the use of
ATG and acute/chronic GvHD was noted. CI of relapse was 15,4% (95% CI:
6-38) and was significantly lower in CR vs AD group: 0% vs 36% (95% CI: 17-
77), p=0,015. One year event-free survival (EFS) was 69,7% (95%CI: 52-87)
and overall survival (OS) - 76% (95%CI: 59-93). One year pOS was significantly
lower in the ATG group 58% (95%CI: 30-86) vs non-ATG group 93% (95%CI:
79-100), p=0,039. One year pEFS was 87% for patients in remission and 48%
for patients with active disease (p=0,028). There was no significant difference
in survival and relapse rate according to donor type.
Summary/Conclusions: Our study demonstrates the high rate of engraftment
with acceptable transplant-related mortality in pediatric patients with hematological
malignancies after unmanipulated HSCT with posttransplant cyclophosphamide.
The data need to be confirmed in a larger trial with long-term follow-up.
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ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION FOR NON-HODGKIN’S
LYMPHOMAS A RETROSPECTIVE ANALYSIS OF 77 CASES
AM Picleanu1,*, S Novelli2, A Esquirol2, AC Caballero2, I Garcia2, R Martino2,
S Saavedra2, J Briones2, J Sierra2
1Hematologia, Filantropia Hospital, Craiova, Romania, 2Hematologia, Hospital
Sant Pau, Barcelona, Spain
Background: Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group
of malignancies characterized by uncontrolled proliferation of clonal lympho-
cytes, which have varied aggressiveness. Allogeneic stem-cell transplantation
(allo-SCT) is a therapeutic option for advanced and otherwise incurable NHL.
The major drawbacks associated with this therapy are graft-versus-host dis-
ease (GVHD) and infections. On the positive side, it is becoming clear that in
the allo-SCT setting there is a graft-versus-lymphoma effect. Selection of the
appropriate patients and donors, as well as the transplantation timing still is a
matter of debate.
Aims: To investigate the factors that influenced the outcome after allo-SCT for
NHL over a 20 years period in a Spanish University hospital
Methods: Retrospective analysis of patients with NHL who received an allo-
SCT between January 1995 and December 2014. Statistical analyses were
performed using the IBM SPSS Statistics version 21. Survival curves were
estimated by the Kaplan-Meier method and compared using the log-rank test.
Variables were selected based on previous studies: age (≤60 vs >60 years),
gender (male vs female), previous ASCT, disease status pre allo-SCT, number
of chemotherapy lines before allo-SCT, intensity of conditioning regimen (abla-
tive vs reduced intensity), HLA compatibility (no mismatch vs mismatch), related
donor vs unrelated donor. Cox regression method was used to develop a prog-
nostic model of OS.
Table 1.
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Results: The characteristics of the series are summarized in Table 1. Indolent
NHL (iNHL) accounted for 43% of patients (n=33) and aggressive NHL 57%
(n= 44). Within aggressive NHL, 16% were of T-cell origin.The median time fol-
low-up after alloSCT was 23 months (range 0-232). The OS at median time
was 53.5% and the PFS was 53.8% (only 9 progressed). The main cause of
death (n= 48) were GVHD 37.5% (n=18), infections 22.9% (n=11), secondary
malignancies 8.3% (n=4) and veno-oclussive disease 4.2% (n=2). Age and
response pre allo-SCT had statistically significant impact on OS in multivariate
analysis (p<0.01) The OS for patients ≤60 years old vs.>60 years old were
58.% and 24%, respectively.The OS for patients in CR pre allo-SCT was 60%
and for patients in PR was 55%. All patients with progressive disease were
death at median time of follow-up.
Summary/Conclusions: Allo-SCT is a feasible option for high risk of relapse
lymphoma patients. Old patients and those with non-responsive disease before
allo-SCT should be considered for alternative therapies. The results are remark-
able in younger patients with sensitive NHL.
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BEING OVERWEIGHT/OBESE PRIOR TO ALLOJENEIK HEMATOPOIETIC
STEM CELL TRANSPLANTATION (ALLO-HSCT) IS RELATED TO BETTER
OVERALL SURVIVAL (OS) AND DECREASED NON-RELASE MORTALITY
E Atilla*, P Ataca Atilla, S Civriz Bozdag, M Kurt Yuksel, P Topcuoglu, H Akan,
M Beksac, O Arslan, O Ilhan, M Ozcan, S Kocak Toprak, G Gurman
Ankara University School of Medicine Department of Hematology, Ankara,
Turkey
Background: Obesity is an increasingly important health problem in developed
countries and a cause of variability in treatment outcomes. The effect of being ower-
weight or obese had been studied in various populations in patients undergoing
Allo-HSCT. Sorror et. al reported obesity as a factor in hemetopoietic cell trans-
plant-specific comorbidity index and increased risk of non-relapse mortality (NRM).
Aims: In this study, we evaluated the impact of obesity on acute graft vs host
disease (aGVHD) risk, overall survival (OS), relapse rate (RR), relapse free
survival (RFS) and NRM in patients undergoing Allo-HSCT.
Methods: Retrospectively, 245 patients who underwent allo-HSCT between
2000 and 2015 at Ankara University School of Medicine was included in our
study. Patients were classified into four groups based on pretransplant BMI
values according to World Health Organization as follows: underweight
(BMI<18.5 kg/m2, n=17), normal (18.5 ≤BMI<25 mg/kg/m2, n=116), overweight
(25 ≤BMI<30 mg/kg/m2, n=78) and obese (BMI ≥30 mg/kg/m2, n=34). Patients
received weight adjusted chemotherapy doses. Characteristics of patients were
compared using the Chi-squared test for categorical variables. The probilibity
of OS was calculated by the Kaplan-Meier method.
Figure 1.
Table 1.
Results: The patient characteristics are given in the table. Mean age of the
group was 36.8 (range, 16-71). Overweight and obese patients received more
bone marrow as a stem cell source (P=0.033). Bone marrow failure syndromes
were more common diagnosis in normal and underweight recipients (p=0.0001).
Myeloablative conditioning were prefered in overweight and obese group
(p=0.002). Five year OS in underweight, normal, overweight and obese groups
were as follows: 51%, 60%, 74% and 83% (P=0.005). Relaps rate was higher
in underweight and normal compared to overweight and obese but not statis-
tically different (23% vs 19%, P=0.53). 2-year RFS in underweight, normal,
overweight and obese groups were as follows: 33%, 29%, 41%, 50%, P=0.069).
The incidence of aGVHD detected higher in obese and overweight group how-
ever not statistically significant (44% vs 40%, p=0.6). NRM was lower in over-
weight and obese group (12% vs 31%, P=0.001).
Summary/Conclusions: Interestingly, we have demostrated that being over-
weight/obese improved OS and decreased NRM in our cohort. Relapse rate
was higher in underweight and normal weight group however not statistically
significant.
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EXPRESSION OF CD143 ON CD34-POSITIVE CELLS IN PERIPHERAL
BLOOD AND APHERESIS PRODUCTS IN PATIENTS WITH HEMATOLOGICAL
MALIGNANCIES AT THE MOBILIZATION OF PERIPHERAL BLOOD
PROGENITOR CELLS (PBPCS)
M Kanaeva*, I Galtseva, Y Davydova, N Kapranov, T Gaponova, L Mendeleeva,
E Parovichnikova, V Savchenko
National Research Center for Hematology, Moscow, Russian Federation
Background: Angiotensin converting enzyme (CD143) is a part of the renin-
angiotensin system catalyzing the cleavage of angiotensin I to angiotensin II.
CD143 is expressed in blood-forming tissues of the human embryo: para-aortic
splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver and bone marrow.
Transplantation into NOD/SCID mice and cultivation have shown that
CD34+/CD143+ cell progenitors, but not CD34+/CD143-, sustain multilineage
hematopoietic cell engraftment and have long-term culture-initiating cell potential.
Aims: To estimate of CD143 expression on CD34+ cells in peripheral blood
and apheresis products in patients with hematological malignancies before and
after the mobilization of PBPCs.
Methods: The study included 31 patients: 16 women and 15 men aged 22-68
years old (median 52). 29 patients were diagnosed with multiple myeloma and
2 - Hodgkin’s lymphoma. Analysis of CD34+ cells was performed by flow cytom-
etry (FACSCantoII, Becton Dickinson) using monoclonal antibodies: CD34 PE,
CD45 FITC, and CD143 APC (Becton Dickinson). The percentage of CD34+
among CD45+ cells and the percentage of CD34+/CD143+ in CD34+ popula-
tion were calculated in peripheral blood of patients before mobilization and in
peripheral blood and apheresis products on the day of leukapheresis. The mobi-
lization was performed with cytotoxic chemotherapy (cyclophosphamide - 4
g/m2 - 24 patients, patient - 2 DHAP)+5 mg/kg G-CSF (CC+G-CSF) in 26 cases
and with G-CSF (10 mg/kg) only - in 5 cases. The control group included periph-
eral blood samples from 10 healthy donors without mobilization.
Results: The percentage of CD34+ cells in peripheral blood before mobilization
from all patients was 0.03±0.01% compared to healthy control group with
0.024±0.004% (p=0.62). The percentage of CD34+/CD143+ was 12.33±1.55%
(3.42±1.43% in healthy donors, p=0.004). After the mobilization percentage of
CD34+ cells in peripheral blood was 0.08±0.05% when mobilization was per-
formed with G-CSF, and in case of using CC+G-CSF the percentage of CD34+
was 0.83±0.18% (p=0.09). The percentage of CD34+/CD143+ cells with G-
CSF mobilization was 28.32±4.06%, compared to 46.07±2.96% (p=0.01) in
patients with CC+G-CSF mobilization. The apheresis products contained
0.36±0.11% of CD34+ cells after mobilization with G-CSF, and 1.55±0.25% of
CD34+ cells after mobilization with CC+G-CSF (p=0.048). The percentage of
CD34+/CD143+ cells in apheresis products was 29.16±5.99% when mobiliza-
tion was carried out with G-CSF and 47.96±2.77% (p=0.01) in patients with
CC+G-CSF mobilization.
Summary/Conclusions: Thus, increase of CD34+/CD143+ cell number in
peripheral blood and apheresis products after mobilization has been shown.
Increase of CD34+/CD143+ cells in patients after mobilization of PBPCs with
chemotherapy and G-CSF was significantly greater in contrast to the mobiliza-
tion with G-CSF alone. Patients with hematological malignancies before mobi-
lization had higher percentage of CD34+/CD143+ cells in peripheral blood then
healthy donors that may be due to previous chemotherapy.
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A COMPARISON OF ORIGINATOR G-CSFS VERSUS BIOSIMILAR G-CSFS
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Background: Autografting is widely used for the treatment of hematological
malignancies, especially for lymphoproliferative diseases. In recent years,
biosimilar G-CSFs (BioG-CSFs) have gradually been introduced into clinical
practice to mobilize peripheral blood hematopoietic stem cells (CD34+ cells)
and reduce the duration of neutropenia. 
Aims: This study was designed to assess, in the setting of “real life” clinical
practice, the role of BioG-CSFs and to compare them with a historical patient
cohort treated with “originator” G-CSFs after autografting. The study was
prompted by the growing propensity for the use of biosimilar growth factors to
reduce overall costs and by the imminent implementation of other novel biosim-
ilar molecules.
Methods: The study period was 2006-2015 during which standard policies for
autografting did not change. Primary endpoints were post transplant engraft-
ment kinetics, transfusion requirements and duration of hospitalization. Sec-
ondary objective was one-year overall survival. Day of neutrophil engraftment
was defined as the first of 3 consecutive days of absolute neutrophil count
≥500/ul whereas day of platelet engraftment was defined as the first of 7 con-
secutive days of platelets ≥20.000/ul unsupported by transfusion.
Results: 276 patients were studied for a total of 354 transplants. Underlying
diseases included multiple myeloma (n=204), non-Hodgkin lymphoma (n=56),
Hodgkin lymphoma (n=9), chronic lymphocytic leukemia (n=2), acute myeloid
leukemia (n=4) and histiocytic sarcoma (n=1). Seventy-eight multiple myeloma
patients received double autologous transplant. Conditionings were as follows:
melphalan 200 mg/m2 for myeloma; busulfan/cyclophosphamide for acute
myeloid leukemia; BEAM or FEAM-like for lymphoproliferative disorders. Over-
all,148 and 206 patients received originator G-CSFs and BioG-CSFs respec-
tively. Infused CD34+ cells were 4.99 (IQR 3.77-5.05) x106/kg/body weight and
4.17 (IQR 3.66-5.00) x106/kg/body weight in the originator G-CSFs and BioG-
CSFs cohorts. Cumulative incidences of neutrophil recovery at day +15 and
+25 were 95.3% (95% CI 91.7% - 98.8%) and 99.3% (95% CI 97.6% - 100%)
and 96.1% (95% CI 93.4% - 98.8%) and 98.5% (95% CI 96.8% - 100%) in the
originator G-CSFs and BioG-CSFs groups respectively (p=0.980). These data
were confirmed by Propensity Score adjustment, HR 1.03 (95% CI 0.87-1.2),
p= 0.763. Cumulative incidence of platelet recovery at day +30 was 98.6%
(95% CI 96.5% - 100%) and 96.1% (95% CI 93.4% - 98.8%) in the originator
G-CSFs and BioG-CSFs cohorts (p<0.001). Of note, no differences between
cohorts were found in a) median duration of neutropenia (median: 7 and 6
days, p=0.180) b) platelet (median 1 pool/patient in both, p=0.441) and red
blood cell (median: 0/patient in both, p=0.703) transfusion requirements, hos-
pital stay (median: 20 days in both, p=0.270). Interestingly, engraftment kinetics
after the second transplant were faster for both neutrophil and platelet recov-
eries (HR 1.34 (95% CI 1.1-1.62), p=0.003 and HR 1.30 (95% CI 1.01-1.67),
p=0.038, respectively, by multivariate models). No severe adverse reactions
attributable to growth factors were documented. Finally, one-year overall sur-
vival was comparable between cohorts (p=0.901).
Figure 1.
Summary/Conclusions: In this sizable study, BioG-CSFs were as effective
as originator G-CSFs. Moreover, their extensive use led to a significant cost
containment.
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FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
AGGRESSIVE B AND T CELL LYMPHOMA
TD Tan1,*, MC Wu1, LW Chiou1, PY Chen1, JS Wu2
1Hematology and Medical Oncology, 2Radiation Oncology, Koo Foundation
Sun Yat-Sen Cancer Center, Taipei City, Taiwan, ROC
Background: Either autologous or allogeneic haematopoietic stem cell trans-
plantation is the salvage and even curative treatment for relapsed lymphoma.
For high risk aggressive B cell or T cell lymphoma, frontline auto-transplantation
can also improve survival.
Aims: We investigated the outcome between frontline versus salvage auto-
transplantation for aggressive lymphoma including B cell, T cell, and Hodgkin
lymphomas.
Methods: For high risk aggressive B cell lymphoma (stage III and IV or IPI
score above 3) and aggressive T cell lymphoma except ALK+ ALCL, we retro-
spectively compared the outcome of frontline autologous transplantation and
non-transplant or salvage transplant patients.
Results: Between 2001 and 2015, we have 95 patients undergoing autologous
(N=67) and allogeneic (N=28) haematopoietic stem cell transplantation. The
5-year overall survival was 70.4% and 59.1%, respectively. For high risk
aggressive B cell lymphoma undergoing frontline autotransplant, the overall
survival was 81.8%. During the same period, 5-year overall survival of stage
III and IV diffuse large B cell lymphoma patients treated at our institute were
58% and 45%, respectively. For aggressive T cell lymphoma, 66.7% versus
0% of 5-year overall survival for frontline versus salvage autotransplant.
Summary/Conclusions: Frontline autotransplant should be considered in
selected high risk aggressive B cell lymphoma patients and is very important
for aggressive T cell lymphoma patients.
LB2269
PHASE 2A STUDY OF ALXN1007, A NOVEL C5A INHIBITOR, IN SUBJECTS
WITH NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE
(GVHD) INVOLVING THE LOWER GASTROINTESTINAL TRACT
AM Alousi1,*, B Yao2, B Overman1, V Ratanatharathorn3, S Gill4, G Socié5,
Y Dai2, S Chasan-Taber6, K Anderson2, A Mujeebuddin2, R Champlin1,
E Shpall1, S Holtan7
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Alexion
Pharmaceuticals, Inc., New Haven, CT, 3Karmanos Cancer Center, Detroit,
MI, 4University of Pennsylvania, Philadelphia, PA, United States, 5Service d’Hé-
matologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France, 6The Dartmouth
Institute for Health Policy & Clinical Practice, Hanover, NH, 7University of Min-
nesota, Minneapolis, MN, United States
Background: Murine models implicate complement in multiple steps of the
acute GVHD cascade. Transplantation of donor T cells deficient in C3a and
C5a as well as pharmacologic exposure to C5a receptor blockade have all
been shown to reduce GVHD lethality in mice. In humans, complement activa-
tion has been correlated with gastrointestinal (GI) GVHD. 
Aims: For this reason, we performed a multicenter Phase 2a trial
(NCT02245412) of ALXN1007, a recombinant humanized monoclonal C5a
antibody, in patients with newly diagnosed acute GVHD of the lower GI tract.
Methods: Between 14 Nov 2014 and 13 Nov 2015, a total of 15 patients with
biopsy-confirmed acute GVHD of the lower GI tract consented, enrolled, and
received weekly intravenous administration of 10 mg/kg ALXN1007, in combi-
nation with methylprednisolone at an initial dose of 2 mg/kg, through day 56.
The primary objective was to assess the day 28 overall acute GVHD response
rate along with safety and pharmacokinetics/pharmacodynamics (PK/PD).
Results: Median age was 60 years (range, 25-69); 60% were male, and acute
myeloid leukemia was the most common diagnosis (33%). At enrollment, lower
GI stages 1, 2, and 3 were present in 7, 2, and 6 patients, respectively. Day 28
overall acute GVHD response rate was 77% (2 patients were nonevaluable
due to leukemia relapse at day 18 or early withdrawal). Complete GI GVHD
response rates at days 28 and 56 were 69% and 77%, respectively. Day 56
overall acute GVHD response rate, day 180 nonrelapse mortality, and overall
survival were 77%, 12.5%, and 69.2%, respectively. PK/PD analyses suggest
that the dose may have been suboptimal with 10/13 patients achieving <90%
inhibition of C5a. Day 28 response rate was higher in those achieving 90%
inhibition (3/3) versus in those with less C5a inhibition (6/10). The drug was
well tolerated with just 1 grade 2 infusion-related reaction and no grade 3 or
higher adverse events attributable to the study drug.
Summary/Conclusions: The efficacy and safety data suggest that ALXN1007
is a promising therapy for patients with acute GVHD involving the lower GI
tract. The level of C5a inhibition might be an important biologic parameter to
predict clinical response. PK/PD analyses suggested higher doses and fre-
quency may be needed to optimize C5a inhibition and maximize clinical
response. For this reason, the trial has been amended to test 20 mg/kg weekly
and twice-weekly dosing.
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RABBIT ANTITHYMOCYTE GLOBULIN VERSUS ALEMTUZUMAB IN
ALLOGENEIC STEM CELL TRANSPLANTATIONA META-ANALYSIS
X Zhang, C Zhang*, HJ Yan, L Gao
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Department of Haematology, Xinqiao Hospital, The Third Military Medical Uni-
versity, Chongqing, China
Background: Rabbit antithymocyte globulin (ATG) and alemtuzumab have
been used for graft-versus-host disease(GVHD) prophylaxis in allogeneic
haematopoietic stem cell transplantation, but which is more efficient remain
unclear.
Aims: This study is to analysize the role of rabbit antithymocyte globulin versus
alemtuzumab in allogeneic stem cell transplantation.
Methods: we perform a meta-analysis of all studies comparing rabbit antithy-
mocyte globulin (ATG) and alemtuzumab for graft-versus-host disease(GVHD)
prophylaxis in allogeneic haematopoietic stem cell transplantation to evaluate
their benefits and drawbacks. There are 7 studies (one prospective and six ret-
rospective)for comparing ATG vs alemtuzumab in GVHD prophylaxis with 622
patients.
Results: Our results showed that the incidence of grade II-IV acute GVHD(RR
1.51, 95% CI 0.97-2.34, P=0.07), incidence of grade III-IV acute GVHD (RR
1.48, 95% CI 0.63-3.47, P=0.37) had a statistically non-significant reduction in
alemtuzumab group, however , alemtuzumab significantly impaired OS (HR
0.61 (95% CI 0.41-0.90, P=0.01) compared with ATG. The incidence of overall
chronic GVHD(RR 0.97, 95% CI 0.67-1.40, P=0.87) and the incidence of
relapse(RR 1.03, 95% CI 0.72-1.47, P=0.88) were similar in the two groups.
Summary/Conclusions: We propose that using alemtuzumab for GVHD pro-
phylaxis is beneficial for allogeneic stem cell transplantation due to the efficacy
in grade III/IV acute GVHD, but OS is impaired compared with ATG group.
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A PRELIMINARY DISCUSSION ON THE RELATIONSHIP BETWEEN
SERUM BIOMARKERS AND AGVHD IN PATIENTS WITH ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
L Tan, HJ Yan, L Gao, Y Liu, C Zhang, L Gao, X Zhang*
Department of Hematology, Xinqiao Hospital the Third Military Medical Univer-
sity, Chongqing, China
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
is an effective means for the treatment of a variety of hematologic malignancies.
Acute graft versus host disease (aGVHD) is a common complication after allo-
HSCT. And it seriously affects the quality of life and survival rate of patients and
is also the main cause of non relapse mortality in allo-HSCT patients. The diag-
nosis of aGVHD mainly depends on the clinical manifestations and pathological
examination of the damaged target organs. But its clinical symptoms are change-
able and lack of specificity, the pathological examination often in clinical diag-
nosis and treatment because of various reasons can not be carried out.
Aims: To explore the relationship between serum biomarkers and aGVHD in
allo-HSCT patients at different time points, and to provide theoretical basis for
early intervention and prognosis evaluation of aGVHD. 
Methods: Collection the serum samples of patients with allo-HSCT in Novem-
ber 2014 to November 2015 in the Department of Hematology, Xinqiao Hospital,
Third Military Medical University . 10 patients with aGVHD were selected as
the case group, and 10 patients without aGVHD were randomly selected as
the control group. Protein chip technology was used to detect the content of IL-
1β, IL-7, IL-8, ST2, vWF in plasma of the two groups patients in 7 days before
transplantion and 7 days, 14 days, 28 days, 56 days, 100 days after transplan-
tation.
Results: Compared aGVHD group and non-aGVHD group, 7 days and 56 days
after transplantion, the level of ST2 in serum were significantly increased
(P<0.05); 28 days, 56 days and 100 days after transplantion, the level of IL-7 in
plasma were significantly increased (P<0.05); 56 days after transplantion, the
level of IL-1β in plasma were significantly increased (P<0.05); Serum IL-8 and
vWF were not significantly different between two groups in every time points.
Summary/Conclusions: The content of IL-1β, IL-7, ST2 in serum of patients
with aGVHD after transplantation is higher than that of patients who were not
aGVHD, and they can be used as the auxiliary diagnosis index of aGVHD and
is helpful to early diagnosis and intervention of aGVHD. Monitoring of serum
biomarkers for aGVHD immune targeted therapy provides a new direction.
Thrombosis and vascular biology
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TLR2-PI3K/AKT SIGNALING PATHWAY INVOLVED IN PLATELET ACTIVATION
INDUCED BY GROUP B STREPTOCOCCI
L Ma1,*, X Liu2, G Zhang2
1Medicine, 2Hematology, Sun Yat-sen Memorial Hospital, Guangzhou, China
Background: Platelets not only play an inportmant role in the initiation of hemo-
stasis and thrombosis,but also participate in immune and inflammatory
response. Most studies focus on the platelet-bacteria interaction and demon-
strate that bacteria are capable of bind to,aggreating and activating platelets.
Human platelets are reported to express several groups of TLRs, which parti-
ciated in the inflammation process. and monitoring host infection.Recent data
from our laboratory demostrated that Group B streptococci(GBS) could induce
platelet aggregation and up-regulate the expression of CD62P and further study
shows that platelet TLR2 might involve in the activation.GBS,or streptococcus
agalactiae,is one of the most common cause of life-threatening sepsis,pneu-
monia and meningitis in neonates,pregnant women,the elderly and immuno-
compromised adults.Therefore,illuminating the mechanisms of GBS-induced
platelet activation is important for providing the basis for platelets in defense
against infection and immunity.Since increasing reports have shown that the
PI3-K/Akt signaling pathway regulates platelet activation and hemostasis,it is
possible to research the TLR2 related signaling pathway. 
Aims: Exploring whether TLR2-PI3K/Akt signaling pathway involved in the
platelet activation induced by GBS.
Methods: 1. Platelets were from healthy volunteers (all genders, 25-52 years
old) who had not taken any anti-platelet drugs (like aspirins, clopidogrel and
abciximab) during the previous 30 days. GBS 639 were isolated from sepsis
patients. 2. Platelet aggregation, the expression of platelet CD62P and PAC-1
were used as the indicator of platelet activation. GBS-induced platelet aggre-
gation was assayed by light transmission; platelet TLR2, CD62P and PAC-1
expression were determined by flow cytometry; AKT and AKT phosphorylation
expression were determined by RT-PCR or western blot assay. In some exper-
iments, platelets were pre-incubated with PI3-K specific inhibitors LY294002
or anti-TLR2 monoclonal antibody.. 3. Statistical analysis: Data are reported
as the mean±SD. Treatment groups were compared with the appropriate control
(s), and statistical signiﬁcance was examined using the two-tailed t-test. Differ-
ences were considered signiﬁcant when P=0.05. All values were analyzed using
SPSS version 17.0 software.
Results: 1. Platelet activation and TLR2 protein expression: Platelet aggrega-
tion, surface expression of TLR2, CD62P and PAC-1 induced by GBS were
increased significantly on the platelets upon activation with GBS 639. However
incubated with anti-TLR2 monoclonal antibody, they all decreased. 2. PI3-K/Akt
signaling pathway: Real-time PCR showed that the PI3-K and Akt mRNA
expression levels were increased significantly in the platelets stimulated with
GBS 639. Western blot results showed that of Akt phosphorylation triggered by
GBS was occurred as early as 15 min and increased gradually to reach a peak
at 2 h post-infection and no significant changes were observed in total Akt pro-
tein expression during the infection. However, the expression of p-Akt, platelet
aggregation and surface expression of CD62P and PAC-1 induced by GBS
were significantly inhibited in the presence of a PI3-K inhibitor LY294002. 3.
The relationship between TLR2 and PI3-K/Akt signaling pathway in platelet
activation: Platelet p-Akt expression levels induced by GBS were significantly
decreased after the activity of platelet TLR2 was blocked by anti-TLR2 mono-
clonal antibody, and no significant changes in total Akt protein expression.
Summary/Conclusions: GBS induced platelet activation through the TLR2-
PI3-K/Akt signaling pathway in human platelets.
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FUNCTIONAL ANALYSIS OF VON WILLEBRAND FACTOR IN MOUSE
MODEL OF ACUTE ISCHEMIA-REPERFUSION KIDNEY INJURY
S Ono1, H Matsui1, M Noda1, K Nishio2, M Sugimoto1,*
1Regulatory Medicine for Thrombosis, 2General Medicine, Nara Medical Uni-
versity, Kashihara, Japan
Background: Acute kidney injury (AKI), an abrupt loss of renal function, is
often seen in clinical settings and may become fatal. The adhesive protein von
Willebrand factor (VWF) plays a pivotal role in platelet thrombus formation
under high shear stress conditions and is recently understood as a key protein
in a cross-talk between inflammation and thrombosis. 
Aims: We therefore assumed that VWF may be involved in the pathophysiology of
AKI, the major cause of which could be an insufficient renal circulation and/or inflam-
matory cell infiltration in the kidney. To test this hypothesis, we studied the relevant
role of VWF in AKI in mouse model of acute ischemia-reperfusion (I/R) kidney injury.
Methods: Mice (male, 8-12 weeks of age), whose right kidney were surgically
removed 1 week prior to the kidney I/R experiment, were anesthetized with
inhaled isoflurane and then placed in an abdominal position on a heating pad.
Surgical incision was given on the left side of back and the left kidney was
brought out and kept outside during the operation. Both renal artery and vein
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were clamped at the renal hilus by a clamping clip for 30 min ischemia. Then
a clip was taken off to provoke the reperfusion of renal blood flow, which was
monitored by Laser Doppler flowmetry. The kidney was then put back in a body
and skin incision was closed. The renal blood flow was measured again 30 h
after reperfusion and mice were then sacrificed for blood collection.
Results: We compared 15 wild-type (WT) and 16 VWF-gene deleted (knock-
out; KO) mice (from The Jackson Laboratory, Bar Harbor, ME). Excess blood
loss was not observed in all mice (WT or KO) during whole surgical process.
Although no difference was seen immediately after reperfusion, significantly
(p<0.05) higher renal blood flow at 30 h after reperfusion was confirmed in
VWF-KO mice, as compared to WT (KO; 24.0±2.3 vs WT; 15.1±1.46
ml/min/100g of kidney weight, and the reperfusion/base flow ratio: KO; 1.0±0.07
vs WT; 0.6 ±0.07). Consistent with the renal blood flow data, the serum crea-
tinine value at 30 h after reperfusion were significantly (p<0.05) lower in VWF-
KO mice than WT (KO; 2.77±0.11 vs WT; 3.15±0.11 mg/dl).
Summary/Conclusions: Our results suggest that VWF does play a role in the
pathogenesis of AKI, in which VWF-dependent thrombotic or inflammatory
responses may trigger thrombotic ischemia or endothelial damages of vascular
bed in the kidney. Thus, proper functional regulation of VWF would be beneficial
for better microcirculation and vessel functions in the kidney, suggesting a
novel therapeutic potential against AKI.
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INCREASED PLATELET LEUKOCYTE INTERACTIONS IN TYPE 2 DIABET-
IC INDIVIDUALS COMPARED TO HEALTHY CONTROLS
Z Mkandla1,*, T Matsha1, G Davison1, B Nkambule2
1Department of Biomedical Sciences, Cape Peninsula University of Technology,
Cape Town, 2School of Laboratory Medicine & Medical Sciences (SLMMS),
University of Kwazulu-Natal, Durban, South Africa
Background: Type 2 diabetes mellitus (T2DM) is considered as a form of low
grade inflammatory response. Activated platelets are involved in inflammatory
processes and bind to inflammatory cells monocytes and neutrophils to form
platelet leukocyte aggregates (PLAs). Platelet bound neutrophils and mono-
cytes become activated (expressing CD69) and undergo a phenotypic change
into pro-coagulant phenotypes expressing tissue factor (CD142).
Aims: 1) To investigate the baseline levels of platelet activation in pre-diabetes
and diabetes and compare this to normal controls. 2) To investigate the per-
centage of monocytes and neutrophils forming aggregates with platelets (PMA’s
and PNA’s) in pre-diabetes and diabetes and comparing this to normal individ-
uals. 3) To investigate the up regulation of pro-thrombotic and activation anti-
gens on the surface of monocytes and neutrophils (Tissue Factor and CD69)
in pre-diabetic and diabetic individuals.
Methods: Peripheral blood was collected into 4.5ml sodium citrate tubes con-
taining 3.2% sodium citrate, samples were analysed within 1 hour of collection on
the Navios 8 colour flow cytometer (Beckman Coulter, Miami, Florida). To ensure
reporting on standardized results, flow check pro fluorescent labelled beads (Beck-
man Coulter, Miami, Florida) were used to standardise the optical path and laminar
flow of the instrument. Blood was also collected into serum separator tubes (SST),
heparin and EDTA for both biochemical and haematology testing. 50µl of citrated
blood was incubated with 5µl of an antibody cocktail containing the antibodies
CD42b-FITC, CD142-PE, CD69-PC5, CD16-PC7 and CD14-APC.After 10 minute
incubation in the dark at room temperature each sample was lysed with 500µl
Versalyse lysing solution for 15 minutes. 500µl of PBS was added to the sample
and it was immediately analysed on the flow cytometer.
Results: Our results showed increased levels of platelet leukocyte aggre-
gates%PLA in pre-diabetes and diabetes therefore indicating increased inter-
actions between platelets and leukocytes in the peripheral blood of pre-DM
and DM individuals. The diabetic group showed increased baseline levels of
circulating platelets monocyte aggregates (%PMAs) median 49.04[36.78-62]
compared to the control group 7.2[5.4-9], p<0.0001. Baseline platelet neutrophil
aggregates (%PNAs) were significantly increased in the DM group [median
13.56(10.17-16.95)] compared to the control group [median 6.01(4.51-7.51)]
p<0.0001. We also showed increased levels of tissue factor expression, a main
part of the coagulation cascade, on the monocytes and neutrophils possibly is
causing the hyper-coaguable state seen in diabetic individuals causing CVDs.
Tissue factor (TF) expression on both monocytes for the diabetic group were
significantly higher than the control group and correlated with increased levels
of%PMAs (r=0.6744, p<0.0001).
Summary/Conclusions: In this study we showed increased PLAs in diabetic
individuals than normal controls which may be responsible for the cardiovas-
cular complications in diabetic patients. The increased tissue factor expression
on monocytes and neutrophils in diabetic individuals may also contribute to
the pro-coagulant state.
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ANTICOAGULATION THERAPY AND A CAREFUL INTERDISCIPLINARY
MANAGEMENT OF SPLANCHNIC VEIN THROMBOSIS: A SAFE AND
EFFECTIVE APPROACH
S Rupoli1,*, M Gironella1, L Canafoglia1, G Micucci1, I Federici1, G Svegliati Baroni2,
A Fiorentini3, A Riva4, AR Scortechini1, L Da Lio5, E Honorati1, P Leoni1
1Department of Clinical and Molecular Sciences, Clinic of Hematology, 2Depart-
ment of Gastroenterology, 3Departmemnt of Gastroenterology and Transplan-
tation, Clinic of tropical, parassitology and chronic hepatitis Infectious Diseases,
4Department of Gastroenterology and Transplantation, Clinic of Emerging Infec-
tious Diseases, 5Clinical Pathology, Polytechnic University of Marche Region,
Ancona, Italy
Background: Splanchnic vein thrombosis (SVT) are unusual thrombosis that
may be associated with underlying disorders either local or systemic. The opti-
mal initial treatment of SVT is uncertain and limited data regarding safety and
efficacy of anticoagulation are available at present.
Aims: In this report, we present our recent experience with SVT and discuss
our treatment algorithm.
Methods: We retrospectively reviewed the records of 38 patients diagnosed
as SVT that attended our anticoagulation clinic until June 2015. All clinical, lab-
oratory, therapeutic and outcome data were collected for each patient. In
patients who were not actively bleeding, anticoagulation treatment was started
as soon as possible according to the platelet count. For a platelet count
>50.000/mcl, we administered initial full dose low-molecular-weight heparin
(LMWH) and antivitamin-K (AVK; target INR range 2-3 or 1.8-2.5 in the pres-
ence of additional risk factors for bleeding), half or prophylactic dose of LMWH
for a platelet count between 30.000/mcl and 50.000/mcl and no treatment below
30.000/mcl. Moreover an appropriate prophylaxis with beta-blockers or with
endoscopic therapies was extensively employed in in our cohort of cirrhotic
SVT. The quality of oral anticoagulation was assessed by the time in therapeutic
range (TTR). The response to initial anticoagulant therapy was evaluated as
vessel recanalization and computed according to the Kaplan-Meier method.
Major bleeding (ISTH definition) and vascular events (arterial and venous
thrombosis) were also assessed.
Results: Thirty eight patients were included (median age 51 years; 71.1%
males); portal vein thrombosis was the most common site of thrombosis
(52.6%), followed by multiple venous segments involvement (34.2%). Hepatic
cirrhosis was the common cause (44.7%) while myeloproliferative neoplasms
were identified in four patients (10.5%). Thirteen patients (34.2%) were diag-
nosed incidentally. Thirty five patients (92.1%) were treated with anticoagulation
(47.4% with AVK; median TTR 57%). Twenty three patients remained on anti-
coagulant treatment during the whole study period. During a median treatment
duration of 27 months, the incidence rate of vascular events was 2.1 per 100
patient-years (1.6 and 0.8 per 100 patient-years among patients treated with
LMWH alone or AVK respectively). Major bleeding occurred in one patient treat-
ed with AVK, corresponding to an incidence rate of 0.8 per 100 patient-years.
Twenty six patients (68.4%) obtained vessel recanalization or thrombosis res-
olution. The probability of recanalization of the occluded vessels was 50% at
30 months. The median follow-up was 30.9 months (2-213); four patients
(26.7%) died for causes not related to anticoagulation (cirrhosis, cancer).
Summary/Conclusions: The use of our treatment algorithm and a careful
interdisciplinary management of SVT, appears to be safe and effective even
for patients with major risk factors for bleeding (e.g. liver cirrhosis).
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FIBRINOGEN GENETIC VARIABILITY AND COAGULATION PROCESS
MEDIATE ATHEROSCLEROSIS MANIFESTATIONS AND AFFECT THE
EXTENT OF THE DISEASE
Z Pallantza*, N Papageorgiou, M Kozanitou, K Tsiligianni, M Pitsinou, M Malliotakis,
E Andronopoulou, O Zoupouli, A Vlachopoulou, C Stefanadis, D Tousoulis
Athens Ippokratio Hospital, Athens, Greece
Background:
Aims: Evidence suggests that altered coagulation and fibrinogen genetic vari-
ability may contribute to atherogenesis. Therefore, we examined the combined
effects of the rs1800790, rs2070011 fibrinogen polymorphisms on coagulation
and endothelial function as well as the effect of coagulation on atherosclerotic
manifestations.
Methods: In the present study we enrolled 422 patients with stable angina
(SA) and 277 controls. The rs1800790 (G455A) and the rs2070011 (G58A)
polymorphisms were detected by appropriate genotyping. Fibrinogen and D-
Dimer levels, as well as factors (f) V, X activity were measured by standard
coagulometry techniques. Flow-mediated dilation (FMD) was assessed by
brachial ultrasound.
Results: We have shown that the 455AA homozygosity was associated with
increased fibrinogen levels in both groups (p=0.035 controls and p<0.001 SA).
In addition, homozygotes for the 58A allele had lower fibrinogen levels in con-
trols (p=0.038). Both the 58AA (p=0.027) and 455AA homozygotes (p=0.022)
had higher levels of D-Dimer in the SA group. The 455AA homozygotes had
also increased fV activity in the SA group (p=0.048). No effects were observed
on fX activity and FMD. Further analysis revealed that fibrinogen levels were
strongly associated with SA (1.005 [1.003-1.007], p<0.001) as well as the pres-
ence of myocardial infarction (MI) (1.003 [1.001-1.005], p=0.001). Similarly, D-
Dimer levels were also strong predictors of CAD (1.001 [1.001-1.002], p<0.001),
but not of MI (1.000 [1.001-1.001], p=0.083). Surprisingly, when fV and fX activ-
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ities were examined for possible associations with clinical presentations, we
found that fV activity was associated with increased number of diseased vessels
(1.016 [1.001-1.030], p=0.037), while fX activity was strongly related to MI
(0.985 [0.973-0.997], p=0.013).
Summary/Conclusions: Our results demonstrate that the rs1800790 variant
increases significantly fibrinogen, D-Dimers levels and fV activity, contributing
to atherogenesis. Moreover, fibrinogen and D-Dimers levels are strong predic-
tors of SA and MI. Interestingly, in our study we have shown for the first time
that fV and fX are associated with the number of diseased vessels and the risk
of MI respectively.
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INTERVENTION TO OPTIMIZE VENOUS THROMBOEMBOLISM PREVENTION
IN A COMMUNITY TEACHING HOSPITAL
U Goldberg*, V Patel, N Pasco, D Biobaku, M Kalavar
Kingsbrook Jewish Medical Center, Brooklyn, United States
Background: According to the U.S. Surgeon General, venous thromboem-
bolism (VTE) affects 350,000 to 600,000 Americans each year and is implicated
in over 100,000 deaths (The Surgeon General’s Call to Action to Prevent Deep
Vein Thrombosis and Pulmonary Embolism. Rockville, MD: Office of the Sur-
geon General, US; 2008.). Noting that only half of eligible patients in our inpa-
tient medical service were receiving VTE prophylaxis (VTEP), our hospital insti-
tuted an intervention to improve performance on this critical measure.
Aims: To evaluate the efficacy of an electronic medical record (EMR)-based
intervention to optimize VTEP among patients admitted to our institution.
Methods: In February of 2011, our hospital’s information technology depart-
ment instituted an automated prompt in the EMR system designed to increase
the number of VTEP-eligible patients receiving VTEP. The prompt guides res-
ident physicians in the process of admitting patients to a “hard stop” screen
entreating them to identify VTE risk factors in the patient and to choose from a
list of evidence-based VTEP therapies (including but not limited to heparin,
sequential compression devices, and an option to not order VTEP if contraindi-
cated). Concurrently, an educational presentation was offered to residents
explaining the intervention and re-educating them on evidence-based VTEP
guidelines. The computerized prompt remains in use today.
Results: Data covering 964 patients admitted in the month prior to the imple-
mentation of the VTEP prompt and 673 patients from after implementation were
collected and analyzed. Prior to the implementation of the VTEP prompt, 49.0%
of 964 patients were found to have received VTEP therapy. Following prompt
implementation, that number rose 16.9% to 65.9% of patients. Data is contin-
ually collected and assessed semiannually.
Summary/Conclusions: As advances in medical technology continue to
improve patient care, optimization of medication utilization becomes increas-
ingly important. With underuse of critical medications raising the risk of iatro-
genic illness, it remains the responsibility of the patient care team to engage in
best practices to minimize these risks. Our intervention has demonstrated that
VTEP utilization may be optimized by the use of a low-cost, easily imple-
mentable, and easily replicable intervention that effectively leverages the EMR
system.
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ERYTROCYTE-RELATED PHENOTYPES AND GENETIC SUSCEPTIBILITY
TO THROMBOSIS
N Vilalta1, AF Remacha2,*, MP Sardà2, JA Millón1, N Pujol-Moix3, A Ziyatdinov3,
J Fontcuberta1, J Nomdedéu2, JM Soria3, JC Souto1
1Hemostasis and thrombosis, 2Hematology Department, 3Unit of Genomics of
Complex diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background: Venous thromboembolism (VTE) is a common disease that
involves the interaction of genetic and environmental risk factors. Previous
studies have estimated a heritability of approximately 60% for the risk of VTE.
Using variance analysis, intermediate phenotypes related to thrombosis have
identified genetic risk factors. Erythrocyte-related phenotypes are considered
good risk factors.
Aims: To investigate the relationship of erythrocyte-related phenotypes with
the risk of VTE.
Methods: Our study used the Genetic Analysis of Idiopathic Thrombophilia 2
(GAIT 2 Project) sample, which consisted of extended pedigrees (935 individu-
als). The sample had 120 subjects with thromboembolism (86 with VTE, 47 with
arterial thrombosis and 13 with both). The following possible risk factors were
evaluated: Red blood cell and indices, reticulocytes, serum iron, total iron binding
capacity, serum ferritin, serum transferrin receptor (STFR), haptoglobin, serum
vitamin B12 (B12), serum folate and red blood cell folate. Using the variance
component method, heritability (h2), the household effect and all of the pheno-
typic, genetic and environmental correlations with VTE were estimated.
Results: The h2 of VTE was 0.67. Most erythrocyte parameters showed sig-
nificantly high h2. In addition, VTE was correlated with: hematocrit (0.52,
p=0.01), red blood cell distribution width (RDW) (0.28, p=0.05), immature retic-
ulocyte fraction (IRF) (0.45, p=0.008), transferrin saturation index (-0.7, p=0.05),
STFR (0.4, p=0.006), and B12 (0.34, p=0.03).
Summary/Conclusions: We demonstrated a genetic relationship between
erythrocyte phenotypes and VTE, and we identified 6 intermediate phenotypes
as risk factors. We suggest that these risk factors will be useful in the search
for thrombosis-related genes.
This work was supported by the following Spanish grants: FIS PI11/0184, FIS
PI12/00612, Red Investigación Cardiovascular RD12/0042/0032, and for the
following grants from the Generalitat de Catalunya: AGAUR 2009 SGR/1147
and AGAUR 2009 SGR/1240. Juan Millon was supported by Institut de Recerca
contra la leucèmia Josep Carreras (IJC).
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INTENSIVE HEMATOLOGY SCREENING FOR MYELOPROLIFERATIVE
NEOPLASM AND EARLY RADIOLOGICAL INTERVENTION IS ASSOCIATED
WITH EXCELLENT OUTCOMES IN BUDD CHIARI SYNDROME
A Mo1,*, A Testro2, J French2, M Robertson2, P Angus2, A Grigg3
1Haematology, Monash Hospital, Clayton, 2Liver Transplant Unit, 3Haematol-
ogy, Austin Health, Heidelberg, Australia
Background: Budd Chiari Syndrome (BCS) is a rare and life-threatening dis-
order, resulting from thrombosis of the hepatic veins. Aetiologies include pro-
thrombotic states such as Myeloproliferative Neoplasm (MPN). Current treat-
ment strategies involve a step-wise approach of anticoagulation followed suc-
cessively by radiological and surgical interventions, and ultimately liver trans-
plantation.
Aims: We aimed to retrospectively describe our institution’s experience with
the management of patients with BCS, including the diagnosis (by bone marrow
biopsy and molecular testing for JAK2 and calreticulin mutations) and man-
agement of concomitant MPN.
Methods: In this retrospective study, approved by the hospital’s Research
Ethics committee, all cases of primary BCS, including new and recurrent pre-
sentations, presenting between January 2000 and August 2012 were identified
from the hospital’s computerised database.
Results: 27 patients with primary BCS presented during the study period.
Twenty-four patients (89%) had identifiable risk factors, with the commonest
being MPN, detected in 17/24 (71%) of the tested patients. This included 4
patients who initially presented with normal peripheral blood counts. The MPN
diagnosis was made on the basis of JAK2V617F positivity (n=13), either alone
(n= 8) or with a confirmatory bone marrow biopsy (n=5); or on marrow biopsy
alone (n=4). The calreticulin mutation was detected in 2/9 tested patients (one
patient with JAK2 negative MPN and one with ET with unknown JAK2 status).
Subtypes of MPN included: Polycythaemia Vera (n=8), Essential Thrombocy-
tosis(n=6), MPN unclassified (n=2) and Chronic Myeloid Leukaemia (n=1). An
additional thrombophilic state was present in six of the MPN patients: the oral
contraceptive pill (n=4), factor V Leiden heterozygosity (n=1), anticardiolipin
antibody and recent in-vitro fertilisation (IVF) treatment (n=1). Of the six patients
with a known diagnosis of MPN prior to BCS, three were on treatment with
hydroxyurea, aspirin or venesection but none were anticoagulated prior to BCS
diagnosis. Of the 11 patients with newly diagnosed MPN, additional treatment
included hydroxyurea alone (n=3), venesection alone (n= 2), hydroxyurea and
venesection (n=2), hydroxyurea and splenectomy (n= 1) and interferon (n= 1).
Three patients with MPN were not given additional cytoreductive treatment:
two in the context of normal peripheral blood counts, and one diagnosed just
prior to death. All patients in the study were anticoagulated with warfarin or
Low Molecular Weight Heparin, and 2 of the MPN patients also had aspirin. 25
of the 27 (92.6%) patients also had upfront radiological interventions, consisting
of TIPS (transjugular intrahepatic portosystemic shunt) in 18 (67%) patients
and/or angioplasty/stenting in 11 (40%). No patient developed TIPS failure. At
a median follow up of 59 months (range 2 to 248 months), the overall survival
was 96% at one year and 81% at five years, much greater than predicted by
the patients’ median Rotterdam score of 1.16 (range 0.07-2.11). No patients
required liver transplantation.
Summary/Conclusions: There is a high incidence of MPN in patients with pri-
mary BCS, predominantly JAK2V617F positive, including patients with normal
peripheral blood counts at the time of diagnosis. All BCS patients should there-
fore have JAK2 testing and, if negative, calreticulin mutation testing. A bone
marrow biopsy should be considered if these are negative, in the context of
unexplained polycythaemia or thrombocytosis. Furthermore, we advocate early
radiological hepatic decompression as an alternative to the step-wise approach,
as we have demonstrated excellent medium term outcomes with no TIPS failure
and no patients requiring transplantation.
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FIBRIN SHEATHS ON CENTRAL VEIN CATHETERS AS A RISK FACTOR
FOR DEEP VEIN THROMBOSIS IN CHILDREN WITH ACUTE
LYMPHOBLASTIC LEUKEMIA
D Fedorova*, P Zharkov, A Sugak
Federal Research Clinical Centre Of Pediatric Hematology, Oncology And
Immunology N.A. D.Rogachev, Moscow, Russian Federation
Background: Indwelling of central vein catheter (CVC) is well known as a risk
factor for deep vein thrombosis (DVT) especially in patients with malignancies.
The term «CVC-related thrombosis» is attributed to mural thrombosis that
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involves CVC, adheres to vessel wall and partially or totally occludes the vessel
lumen. However, presence of CVC in a central vein may result in emerging not
only «true» mural thrombosis but so-called fibrin sheaths (FS) that envelope
CVC but do not involve venous wall. Despite high FS incidence data on its
clinical importance is scarce. 
Aims: To investigate the role of FS in DVT development; to reveal the efficacy
of anticoagulant therapy in patients with DVT with previous FS.
Methods: We analyzed data on 182 CVC inserted in 113 patients with acute
lymphoblastic leukemia (ALL) aged from 1 to 19 years. Data were collected
retrospectively from electronic hospital charts. The diagnosis of DVT and FS
was made by means of echocardiography (ECHO) and Doppler ultrasound
scanning (DUS) of extracranial brachiocephalic veins. DUS has been per-
formed at different time after CVC implantation depending on clinical indications
and physician’s opinion. A «p» value<0,05 was considered statistically signifi-
cant. Data were analyzed using the IBM SPSS for Windows Software. Univari-
ant logistic regression analysis was performed for estimation of FS significance
for DVT development. Between group comparisons were performed by chi-
square or Fisher’s exact test depending on sample value.
Results: FS were detected on 63 (35%) CVC. Incidence of FS was 2,71 events
per 1000 catheter days. Catheter-related DVT was revealed in 51 (28%) cases.
In 24 of them FS preceded DVT emerging. Presence of FS was significantly
associated with subsequent DVT (odds ratio (OR) 2,75, 95% confidential inter-
val (CI) 1,32-5,74, р=0,003). After detecting of FS, anticoagulant prophylaxis
was started in 31 cases. In this group DVT subsequently developed in associ-
ation with 15 (48%) CVC. In group that did not receive anticoagulants DVT
developed in 9 (32%) cases. In both groups there was one occlusive DVT. Dif-
ference in DVT incidence between groups with and without anticoagulant pro-
phylaxis after FS detecting was statistically insignificant (р=0,908). FS resolu-
tion occurred independently of anticoagulants usage (р=0,598).
Figure 1.
Summary/Conclusions: According to our data, FS was detected on 35% of
CVC. Presence of FS was associated with subsequent CVC-related DVT
emerging. Efficiency of anticoagulants for FS resolving is doubtful. The question
whether anticoagulant prophylaxis of DVT should be started after FS detecting
remains unclear. Large prospective studies are required to resolve this issue.
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FIBRINOGEN GENETIC VARIABILITY ACCELERATES ATHEROGENESIS
BY ALTERING THE INFLAMMATORY PROCESS AND COAGULATION IN
PATIENTS WITH DIABETES MELLITUS TYPE 2 AND HYPERTENSION
Z Pallantza*, N Papageorgiou, M Kozanitou, D Goubini, P Parigori, L Plavouk-
ou, G Mallios, B Palioura, M Karagrigoriou, C Stefanadis, D Tousoulis
Athens Ippokratio Hospital, Athens, Greece
Background:
Aims: Hypertension (HTN) and diabetes mellitus (DM) are significant risk fac-
tors for atherosclerosis and characterised by altered coagulation and inflam-
matory process. In the present study we aimed to investigate the role of fib-
rinogen genetic variants (rs180070 and rs2070011) on coagulation and inflam-
mation in patients with combined DM and HTN
Methods: 744 subjects (HTN and DM) were enrolled in our study. Fibrinogen
polymorphisms were determined by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP) technique. Fibrinogen, interleukin-6
(IL-6), high sensitivity C-reactive protein (hsCRP) CD40L, D-dimers and factors
V, X activity were measured with appropriate laboratory methods.
Results: In HTN patients, hsCRP levels were higher in the group of patients
with higher fibrinogen levels compared to patients with lower and intermediate
fibrinogen levels [0.28 (0.12–0.42) vs 0.17 (0.04–0.38) vs 0.18 (0.09–0.39),
p=0.032)]. In addition, we found a significant effect of the rs180070 poly-
mophism on IL-6 levels among HTN and DM. In HTN, IL-6 levels were higher
in AA homozygotes of the rs180070 compared to all other genotypes (AG or
GG) (4.96±0.69 vs 3.7±0.2, p=0.046). Similarly, DM patients homozygotes for
the A allele (rs180070) had higher IL-6 levels (6.72±0.99 vs 4.01±0.35,
p=0.016). In multivariable analysis, the only independent predictor of IL-6 levels
in DM was the AA genotype [β(SE): 0.216 (1.76), P=0.047]. In hypertensives,
AA (rs180070) homozygosity was the only adjusted independent predictor of
IL-6 levels [β(SE): 0.151 (0.642), P=0.032]. Subgroup analysis of HTN and
DM patients did not reveal any differences of CD40L levels in the presence of
AA genotype (rs180070) (p=0.919 for DM and p=0.144 for HTN). We did not
observe any significant change in IL-6 or CD40L levels with the presence of
the AA genotype of the rs2070011 among the studied subgroups. Finally, we
found that the AA homozygosity (rs180070) was associated with increases D-
dimer levels in both DM and HTN (DM: 741.6±109,4 vs 487.3±35.6, p=0.028,
HTN 623.3±79.6 vs 388.6±23.5,p=0.048).
Summary/Conclusions: The AA homozygosity (rs180070) was associated
with higher IL-6 levels and CD40L concentrations. We also showe for the first
time, to our knowledge, that the AA homozygosity (rs180070) is associated
with increased D-dimer levels. Our results of this study showed that higher lev-
els of fibrinogen were associated with elevated D-dimer levels. Homozygotic
status for the rs180070 polymorphism was also related to higher D-dimer levels
both in HTN and DM patients.
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VENOUS THROMBOSIS IN PUERPERIUM IS ALSO DOMINANTLY LOCALIZED
IN LEFT LEG, BUT TENDS TO BE MORE MASSIVE THAN THROMBOSIS
DURING GESTATION
J N Bodrozic1,*, P Miljic1,2, D Lekovic1,2, D Sefer1, D Vasic3, M Gojnic Dugalic2,4
1Clinic of Hematology, Clinical Center of Serbia, 2Medical Faculty, University
of Belgrade, 3Clinic for Vascular and Endovascular Surgery, 4Clinic for Gyne-
cology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia
Background: During pregnancy and puerperium different factors play role in
pathogenesis of venous thrombosis, and they may influence on localization
and extent of thrombosis. Compression of iliac veins by gravid uterus is respon-
sible for dominance of thrombosis in left leg during gestation. On the other
hand, after delivery and during puerperium blood hypercoagulability plays a
key role in pathogenesis of thrombosis, but little is known about anatomic dis-
tribution and extent of venous thrombosis in legs during puerperium. 
Aims: To investigate the anatomic distribution and extent of deep vein throm-
bosis of the lower extremity during pregnancy and puerperium.
Methods: Retrospective analysis of 174 consecutive women with pregnancy
related venous thrombosis of lower extremities that were referred to our insti-
tution from January 2004 to December 2015 has been performed. The locali-
sation of thrombosis was classified as a thrombosis of left or right leg, proximal,
distal or massive (proximal+distal). Thrombosis of superficial veins was exclud-
ed. All thrombotic episodes were confirmed with duplex ultrasonography.
Descriptive statistics and chi square test were used for statistical analysis.
Results: Out of 174 women with pregnancy related thrombosis, 26 (15,5%)
developed thrombosis during the first trimester, 23 (13,3%) during second, 37
(21,2%) during third and 87 (50%) during puerperium. Thrombosis of the left
leg developed 127 (73%) women, and of the right leg 40 (23%). Bilateral throm-
bosis occurred in 7 (4%) of women. Prevalence of left leg thrombosis was 66%,
78%, 83%, 69% during first, second, third trimester and puerperium, respec-
tively. Prevalence of right leg thrombosis was 33%, 13%, 13%, 26%. Left leg
thrombosis was more frequent throughout gestation but also during puerperium
than thrombosis in right leg (p<0,05). In our group of patients, 68 (39%) devel-
oped massive thrombosis, 81 (47%) proximal and 25 (14%) distal thrombosis.
Prevalence of massive thrombosis during first, second, third trimester and puer-
perium was 41%, 30%, 13%, 52% respectively, of isolated proximal veins was
48%, 57%, 84%, 27%, and of distal veins 11%, 13%, 3%, 21%. The difference
between different periods of pregnancy and puerperium regarding distribution
and extent of thrombosis was statistical significant (p<0,05). Before the delivery
most common localization of thrombosis was in proximal veins, while massive
thrombosis occurred most frequently in puerperium. 
Summary/Conclusions: We observed that deep vein thrombosis of the left leg
occurred more frequently than thrombosis of the right leg not only during gestation
but also during puerperium. This indicates that significant proportion of throm-
boses in pueperium might have initiated in last period of gestation and become
clinically overt only after delivery. More massive thrombosis observed in puer-
perium points to importance of blood hypercoagulability on extent of thrombosis.
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A NOVEL ADAMTS13 MUTATION IN A PEDIATRIC PATIENT WITH
CONGENITAL AND ACQUIRED ADAMTS13 DEFICIENCY
K Yalçın1,*, A Cairo2, E Güler1, I Mancini3, F Peyvandi2,3, A Küpesiz1
1Pediatric Hematology Oncology, Akdeniz University School of Medicine,
Antalya, Turkey, 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and Fondazione
Luigi Villa, 3Department of Pathophysiology and Transplantation, Università
degli Studi di Milano, Milan, Italy
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Background: Thrombotic thrombocytopenic purpura (TTP) is a rare and life-
threatening disorder caused by the deficiency of von Willebrand factor (VWF)
cleaving protease, ADAMTS13. Severe ADAMTS13 deficiency (activity lev-
els<10% of normal) can be due either to anti-ADAMTS13 autoantibodies
(acquired TTP) or to ADAMTS13 gene mutations (congenital TTP).
Aims: In this report, we describe the novel mutation and clinical history of a
pediatric patient with both congenital and acquired ADAMTS13 deficiency.
Methods: A 8 years old girl presented with easy bruising and thrombocytopenia.
She was diagnosed with immune thrombocytopenic purpura (ITP) when she
was 8 months old and followed with mild thrombocytopenia. Family history was
unremarkable. At admission, blood work-up exhibited anemia, thrombocytope-
nia, fragmented erythrocytes, and schistocytes. Elevated serum LDH was
detected. Renal function tests were impaired. TTP was diagnosed and started
double volume plasma exchange (PEX) immediately. She was unresponsive
to plasma exchange therapy. We used high dose methylprednisolone, acetyl-
cysteine, cyclosporin, rituximab, vincristine and cyclophosphamide therapies
unfortunately, there was no response. In spite of splenectomy, clinical status
was deteriorated. We continued PEX beside all these therapies. During the
treatment she had serious complications related to TTP as partial retina detach-
ment, convulsion, renal failure and myocardial hypertrophy. During the treat-
ment she had to be transfused with 118 units erythrocyte and despite of all
efforts she died at the nineth month of TTP attack.
Results: The patient had undetectable ADAMTS13 activity (measured by
FRETS-VWF73 assay) and antigen (measured by Technozym ADAMTS13 Anti-
gen assay) and a high titer of anti-ADAMTS13 IgG. ADAMTS13 activity of the
patient’s mother was 60%. According to these results congenital and acquired
ADAMTS13 deficiency seemed to be together in one patient. The genetic analy-
sis identified the presence of a nonsense mutation in homozygous state on the
ADAMTS13 gene, a C to T substitution at nucleotide589 in the exon 6
(c.589C>T) leading to the substitution of the Glutamine 197 with a premature
stop codon (p.Gln197X) in the metalloprotease domain in homozygous state.
The mutation was also confirmed in heterozygous state in the patient’s mother
(her father died in an accident years ago).
Summary/Conclusions: This patient is unique with complex phenotype (con-
genital and acquired ADAMTS13 deficiency together) and novel mutation in
ADAMTS13 gene. Similar complex phenotype is reported before and in that
case ticlodipine is the trigger factor for acquired TTP. We could not detect any
trigger factor for acquired TTP as drugs or infections. We also measure a high
titer of anti-ADAMTS13 IgG at admission before the first plasma exchange. 
The novel mutation has not been previously reported in the literature and there
aren’t any data from in vitro expression studies. However, due to its location
within the metalloprotease domain, it is most probably responsible for the defi-
ciency of protein product and its activity. This phenotipic complexity and muta-
tion could be a novel type of TTP with severe clinical status and unresponsive
to treatment.
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PEDIATRIC VENOUS THROMBOEMBOLISM: A SINGLE CENTRE EXPERIENCE
N N Ozdemir*, G Dikme, H Kızılocak, B Koç, T Celkan
Pediatric Hematology Oncology, Istanbul University, Cerrahpasa Medical Fac-
ulty, Istanbul, Turkey
Background: Pediatric venous thromboembolism (VTE) and associated com-
plications are rare but increasing. We reviewed our experience of pediatric VTE
in 20 years.
Aims: To identify predictors of pediatric VTE, efficacy of treatment and preva-
lence of complications.
Methods: A retrospective chart review of patients aged 1 to 18 years with VTE
was done.Data were collected on demographics, risk factors, thrombophilia
work-up, treatment, and relapse. Neonatal and catheter related thrombosis
cases were excluded.
Results: Sixty-five pediatric patients (M/F: 1.5) were recruited. Median age at
diagnosis was 8.7 years (range: 1 month -17 years). Thrombotic locations were
cerebral veins (n=34), lower extremities (n=12), upper extremities (n=7), DVT &
pulmonary embolism (n=1), splenic and/or portal veins (n=7), renal vein (n=2),
mesenteric veins (n=1), and purpura fulminans (n=1). In 35 patients (53%), a
probable acquired risk factor was identified; the most common risks were
leukemia, mastoiditis, vasculitis, congenital heart defect and infections. Throm-
bophilia work-up showed FV Leiden mutation (n=12), low protein C (n=12), high
FVIII levels (n=10), low anti-thrombin-3 (n=4), high homocytein level (n=3), pro-
thrombin 20210a mutation (n=3) in 33 patients (50%). Fifty-four patients received
anti-coagulant therapy; the majority (n=49) received low molecular weight
heparin (LMWH) and acetylsalicylic acid (n=4). Three received warfarin, one
was on dabigatran study and one received rivoraxabin. Low molecular weight
was given as single dose at a dose of 100 u/kg to all patients. Five had recurrent
thrombosis under treatment, one was on dabigatran and the rest were on LMWH.
One patient with vasculitis had post-thrombotic syndrome.
Summary/Conclusions: The etiology of pediatric venous thromboembolic dis-
ease (VTE) is multifactorial, and in most children, 1 or more clinical and inherited
risk factors are present. In our experience low dose LMWH may be used with
success in pediatric VTE.
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ANTITHROMBOTIC EFFECTS OF ARGININ-CONTAINING GLYPROLINE
M Grigorjeva*, T Obergan, L Lyapina
Биология, Ломоносова, Москва, Russian Federation
Background: It has been shown that glyproline peptides have the anticoagu-
lant, fibrinolytic and antiplatelet action in the organism. The decrease of platelet
aggregation can be enhanced by adding to the molecule of glyprolines arginine,
which causes the release of NO in the bloodstream. 
Aims: The aim of this study was to determine the antithrombotic effects of argi-
nine-containing glyproline Pro-Gly-Pro-Arg (PGPR) in rats with experimental
venous thrombosis.
Methods: The peptide PGPR was administered to experimental rats intranasal-
ly for 4 days in a daily dose of 1 mg/kg. Control animals similarly received
saline. Then venous thrombosis (Wessler model) was simulated in rats. The
degree of clot formation was assessed by weight of thrombus (mg). The state
of the hemostasis system was estimated used standard methods: determination
of anticoagulant activity (APTT), fibrinolytic activity on fibrin plates, ADP-
induced aggregation of platelets. 
Results: It is established that preliminary injection of PGPR lead to decrease
of thrombus formation in experimental rats on 60%. Thrombus formation in
control rats-100%. Moreover in the blood plasma of experimental animals anti-
coagulant and fibrinolytic activity were increased by 21% and 30% respectively.
Platelet aggregation was decreased at 25% compared with the control. 
Summary/Conclusions: Thus arginine-containing glyproline Pro-Gly-Pro-Arg
showed anticoagulant, fibrinolytic and antiplatelet properties. Therefore this
drug had significant antithrombotic effects, and prevented the thrombus forma-
tion in the organism.
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IMPACT ON MOTHER AND NEWBORN OF ANTITHROMBIN III DEFICIENCY
DURING PREGNANCY
D Fernandez-Jimenez1,*, L Entrena-Ureña1, I García-Cabrera2, MJ Gutierrez-Pimentel1,
M Jurado-Chacon1
1Complejo Hospitalario Universitario de Granada, Granada, 2Hospital de Santa
Ana, Motril, Spain
Background: During pregnancy, the risk of suffering thromboembolic disease
increases fivefold. The most significant risk factors are a prior history of throm-
bosis followed by the presence of thrombophilia, with ATIII deficiency associated
to a greater risk of thrombosis and complications during pregnancy (including
miscarriage, intrauterine growth restriction, fetal death, placental abruption, pre-
eclampsia and HELLP syndrome). The ideal treatment for such women remains
undefined, given that limited clinical data is available and most cases are report-
ed on an individual basis or on a small scale. It is widely accepted that most of
these patients should receive thromboembolic prophylaxis, although the dosage,
duration and type of anticoagulant remains a contentious issue.
Aims: Evaluate the impact of antithrombin deficiency and the different treat-
ments in pregnant women.
Methods: Retrospective 30-year study of pregnant women with ATIII deficiency.
We analysed a total of 57 pregnancies in 21 women diagnosed with ATIII defi-
ciency (10 due to family history, 2 due to a child having shown the deficiency
and the remainder due to personal history). The average age was 29 (19-41).
4 pregnant women displayed cardiovascular risk factors (1 high blood pressure,
1 smoker, 1 dyslipidemia and the other a smoker plus sufferer of dyslipidemia)
and 8 had additional thrombophilia (6 with heterozygous Factor V Leiden, one
protein S deficiency and one combined homozygous factor XII deficiency and
heterozygous Factor V Leiden).
Results: Of the 57 pregnant women, 2 of whom were carrying twins, 38 received
no treatment as the antithrombin III deficiency was diagnosed at a later date.
From this group, 22 resulted in live births, 12 miscarried, 6 suffered an intra-
uterine stillbirth and 2 experienced intrauterine growth retardation. In terms of
maternal complications that went untreated, 2 women developed pre-eclampsia
and there were 5 thrombotic events (2 pulmonary thromboembolisms, one of
which with sinus-related thrombosis and 4 deep vein thromboses). As part of 6
pregnancies, patients received Acenocumarol due to a history of thromboses. 19
pregnant women received treatment: 15 low molecular weight heparin (LMWH)
in therapeutic doses subject to Anti Xa control (6 received Acenocumarol previ-
ously due to a history of thromboses), 1 LMWH in intermediate doses and 3 in
prophylactic doses. At the same time, ATIII 50UI/kg/72 hours was administered
to 4 patients and 2 took Acenocumarol from week 12. During the peripartum peri-
od, two received LMWH, another ATIII and 13 ATIII linked to LMWH in prophylactic
doses. Post-partum, 9 patients received Acenocumarol (6 having received bridg-
ing treatment via ATIII and LMWH and 3 just via LMWH) and 10 LMWH (5 of
which with ATIII). From amongst the 19 pregnancies as part of which treatment
was administered, 17 resulted in live births. Complications recorded included one
pre-eclampsia, one miscarriage and one maternal death due to severe sinus
thrombosis, all three of which occurred in patients receiving a prophylactic dose
of Heparin. The only adverse effect of the treatment involved bleeding from a
caesarean wound in one of the patients receiving ATIII and LMWH. 10 received
an epidural with no adverse effects.
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Table 1.
Summary/Conclusions: In our experience, the rate of maternal-fetal compli-
cations in patients with an ATIII deficiency is clearly higher than amongst the
general population; furthermore, there is a higher number of adverse effects in
the group receiving no treatment. Although in the series of cases in hand, ther-
apy using LMWH and/or ATIII has been demonstrated as an effective and safe
strategy, these patients must be subject to strict monitoring, as complications
can occur throughout the pregnancy and post-partum period, particularly in
the case of inadequate thromboprophylaxis. Further research is needed to
establish and standardise action protocols.
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REVIEW OF PATIENTS WITH CEREBRAL SINUS THROMBOSIS OVER A
7 YEAR PERIOD: SINGLE CENTRE EXPERIENCE FROM A UNIVERSITY
HOSPITAL IN THE UNITED KINGDOM
I Kaddam1,*, A Barua1, P Gupta2, D Chandra1
1Staffordshire Thrombosis and Anticoagulation Centre, 2Department of Neurol-
ogy, University hospital of north Staffordshire, Stoke-on-Trent, United Kingdom
Background: Cerebral sinus venous thrombosis (CVST) is a rare form of
venous thromboembolism, usually affecting younger individuals. It has a wide
range of clinical presentation and sometimes difficult to diagnose.
Aims: We present a retrospective review of 83 patients who were diagnosed
and treated for CVST over a 7 year period at a University hospital in the United
Kingdom
Methods: Electronic clinical records of all patients who were diagnosed and
treated for CVST between 1st January 2008 and 31st December 2014 were
reviewed. 
Results: Eighty three patients (45 females, 38 males) with median age 35
years (range between 2 months - 80 years) were diagnosed and treated for
CVST during this period. Headache was the most common presentation report-
ed by 70% patients, followed by seizures (19%), motor deficit & aphasia (18%),
altered sensorium (13%), confusion (7%), photophobia(6%), and cranial nerve
palsy(5%). Twenty five (30%) of patients had intracranial bleed at the time of
presentation. Diagnosis of CVST was confirmed by contrast head CT (14%),
CT venogram (54%), contrast brain MR (16%) and MR venogram (20%). Twen-
ty patients (24%) developed CVST during pregnancy, puerpurium or due to
oral contraceptive use. Cancer (glioblastoma 1, meningioma 4, acute leukaemia
3, other cancers 8), neurosurgery (n=11), head injury (n=6) and ENT infections
(n=9) were provoking factors in (50%) of the patients. No provocation could be
identified in 16 patients (19%). The commonest affected site involved was the
transverse sinus (62%) followed by sigmoid sinus (51%) and superior saggital
sinus (44%). In over half of the patients (n=47) more than one sinus was
involved with thrombosis. Patients were treated with anticoagulation (83%),
hemi-craniotomy (4%), endovascular surgery (3%). No anticoagulation was
given in 14 (16%) patients. After a follow-up of 24-84months, 54% of patients
had a complete recovery. Residual neurologic impairment was seen in 25
patients (intracranial HT, persistent headaches, secondary epilepsy). Thirteen
patients died (median age =57, range14-71 years). Cause of death was unre-
lated to CVST in 10 patients (progressive cancer 9; cerebral abscess 1). Ade-
quate follow up clinical information was not available for 5 patients 
Summary/Conclusions: CVST is a rare site thrombosis usually affects
younger individuals and has a varied clinical presentation. Clinician should
have a low index of suspicion to ensure prompt diagnosis and effective treat-
ment. With modern management majority of patients can expect a complete
recovery with no residual sequelae.
Transfusion medicine
E1566
WHAT DO FINAL YEAR MEDICAL STUDENTS KNOW ABOUT TRANSFUSION
MEDICINE?
S Lovato1,2,*, R Patel2, J Stanger2, A Southgate3, A Sharif1,3
1Undergraduate education, Imperial College, 2Haematology, 3Undergraduate
education, LNWH NHS Trust - Northwick Park and St Mark’s Hospitals, London,
United Kingdom
Background: Blood component transfusion is a common procedure performed
among different specialities. Every year transfusion errors are reported as cause
of mortality and major morbidities. To improve the safety of the procedure the
staff involved have to be adequately trained. Including transfusion training in
medical school can improve patient safety. In UK most medical schools under-
graduate curriculum includes transfusion related topics, but there are no national
survey to assess the quality of teaching or the knowledge of the students.
Aims: To investigate the knowledge of final year medical students on transfu-
sion medicine topics and evaluate if interprofessional teaching delivered with
the collaboration of a transfusion practitioner and the pathology laboratory can
improve their knowledge.
Methods: Topics relevant to transfusion safety were extrapolated analysing
SHOT reports. Nineteen final year medical students were offered a two hours
teaching involving case based discussion, visit to the transfusion laboratory
and application of the knowledge acquired through simulation. The teaching
session was delivered by the local haematology teaching fellow with the help
of a transfusion practitioner and the collaboration of the transfusion laboratory. 
Students’ knowledge was tested before and after the teaching session with an
open answer test.
Results: There was a significant improvement between the average score in
the pre-teaching and post-teaching test (36% vs 73%). Topics where the dif-
ference in the percentage of students who were able to answer correctly was
more evident where: patient monitoring (0% vs 94%), indication for irradiated
products (0% vs 78%), blood component prescriptions (5% vs 100%), acute
transfusion reactions (16% vs 94%). Improvement of knowledge was observed
also for: delayed transfusion reactions (0% vs 44%), understanding of FFP
compatibility (0% vs 44%) and understanding of group and save test (0% vs
44%), interestingly in the group that had practical teaching in the transfusion
laboratory on this topic the rate of correct answer was 100%.
Summary/Conclusions: Transfusion medicine topics are covered during med-
ical school, however when tested, this group of final year medical students
were unable to answer correctly to question about essential practical aspects
of the transfusion process. Improving education in transfusion medicine for
medical students will help them in their future role as doctors and can improve
patient safety. A short teaching session in collaboration with transfusion prac-
titioner and transfusion laboratory was an effective way to improve students
short term knowledge. Further studies are required to find the best way to
improve short term and long term knowledge on transfusion medicine.
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BLOOD TRANSFUSION IN CARDIAC SURGERY IS ASSOCIATED WITH
WORSE PROGNOSIS
JM García-Gala1,*, A Gonzalez-Pérez2, E Martinez-Revuelta1, J Zanabili Al-Sibai3,
M Argüello-Junquera3, T Arias-Fernández3, F García Menendez-Tevar3
1Transfusion Service, 2Cardiac Intensive Care Unit, 3Hematology Department,
Hospital Universitario Central de Asturias, Oviedo, Spain
Background: Transfusion has been associated with a worse prognosis in
patients undergoing cardiac surgery so restrictive attitude to transfuse had
been proposed.
Aims: In order to assess the impact of transfusion in patients undergoing car-
diac surgery we reviewed patients admitted to cardiac ICU.
Methods: Data concerning age, sex, reason for ICU admission, type of surgery,
transfusion, preoperative haemoglobin, length of stay in the ICU, ICU survival,
EUROSCORE prior to surgery and extracorporeal time from patients admitted
in cardiac ICU of our hospital between January 2004 and June 2014 were col-
lected. Univariate analysis with different variables and then a logistic regression
model was
Results: We analysed data from 4,315 patients (63% male / 37% female)
admitted to the unit during this period. Median age of 67.88 years (0-91 years).
93% were postoperative cardiac surgery. The most common reasons for sur-
gery were valvular surgery (34.5%) coronary surgery (28%), coronary and
valve surgery (18%). 3282 of patients (76.1%) were transfused. Patients under-
going valvular surgery were most frequently transfused than those who under-
went coronary surgery (77% versus 66%). Transfused patients had lower
haemoglobin at the time of surgery than those who were transfused (12.7±1.7
versus 14, 51±1.33, p<0.001). Of the total patients analysed, 23.7% had Hb<12
g / dl at the time of surgery. Of these, 97% were transfused compared to 69%
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who had Hb>12 g / dl (p<0.001). Patients with Hb level>12 g / dl had a survival
of 95% versus 88% in the group with Hb<12 g / dl (p<0.001). 97% of non-trans-
fused patients survive versus 88% of transfused patients (p<0.001) with a rel-
ative risk of survival of 3.87 (95% CI 2.67-5,99) within the group without trans-
fusion. For most common types of surgery:
Table 1.
Patients who were transfused had a shorter average length of stay in the ICU
than those who were not (8.46±3.95 days versus 15±3.4, p<0.001)
In the logistic regression analysis, the only variable that showed significant for
survival was transfusion.
Summary/Conclusions: Transfusion is associated with a negative effect on
the survival of patients undergoing cardiac surgery, 24% of patients undergoing
cardiac surgery have anaemia at surgery. Patients with a better hemoglobin
prior to surgery have a lower risk of being transfused so it must be necessary
to establish measures to improve the haemoglobin prior to cardiac surgery in
order to improve outcome of this patients.
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TRANSFUSION PRACTICES USED IN TERMINAL STAGE -CANCER-PATIENTS
A Argyrou1*, A Livada2, G Fakinos2, A Charalambous1, E Grouzi2, A Gafou1
Blood Bank, General and Oncology Hospital “Agioi Anargyroi”, 2Blood Bank,
Oncology Hospital “Agios Savvas”, ATHENS, Greece
Background: Despite the increased attention to quality palliative care, dying
of oncology patients often take place in the ward or intensive care unit rather
than hospice and with an intensive level of medical care.
Aims: To investigate the transfusion practises for the terminally ill cancer
patients as part of their medical care during the last seven days of life.
Methods: We conducted a retrospective review of the causes of consecutive
deaths oncology patients who succumbed in two Oncology Hospitals between
April 2015 and June 2015. Patients were categorized as: solid tumor-patients,
haematological malignancy-patients and no cancer-patients. We recorded the
pretransfusion tests performed for these patients (ABO grouping, detection and
identification tests for unexpected alloantibodies, crossmatching), as well as
the transfusion episodes per patient and the number of transfused units per
transfusion episode, during the last seven days of life. X2-test and one-way
ANOVA tests were used for the statistical analysis. The number of transfused
platelets corresponds to equivalent number of platelets random-donor.
Results: 211 patients [116 males (55%) and 93 females (45%)] of mean age 67
years old (range 18-92) had died during the study period. Of them, 163 (77.25%)
were solid tumor-patients, 11 (5.22%) were haematological malignancy-patients
and 37 (17.53%) were no cancer-patients. The number of pretransfusion tests
performed and blood product units transfused, are shown in the Table.
Table 1.
Summary/Conclusions: 1. Blood transfusion practices remained intensive in
terminal stage-cancer-patients and does not seem to be different compared to
non-cancer patients. 2. Patients with haematological malignancies had even
more intensive transfusion practises especially regarding the platelet- transfu-
sion- episodes. 3. Cooperation with local hospital Transfusion Medicine Com-
mittee and the Ethics Committee, and proper allocation of medical resources
could result in providing the optimal end-of-life care for cancer patients. The
blood is a valuable but limited source. The health services have the duty to
achieve both the maximum “beneficity” by transfusing blood products to the
terminally ill patients, and “justice” by not depriving other patients of necessary
transfusions.
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THE SHP-2/ERK2-MEDIATED SIGNALING REGULATES BRANCHED I
FORMATION BY CONTROLLING THE C/EBPΑ BINDING TO IGNTC
PROMOTER REGION IN THE ERYTHROID-DIFFERENTIATION
YC Twu1,*, YH Lee1,2, FL Chang1, H Ho1
1Department of Biotechnology and Laboratory Science in Medicine, Natinal
Yang-Ming University, Taipei, 2Department of Medical Research, Mackay
Memorial Hospital, New Taipei, Taiwan, ROC
Background: The straight and branched repeats of poly-LacNAc chains char-
acterize the histo-blood group i and I antigens, respectively. In the human
hematopoietic cell model, the transcription factor CCAAT/enhancer binding pro-
tein a (C/EBPa) regulates branched I antigen formation through IGnTC expres-
sion in both erythroid- and granulocytic-differentiation. However, the detail
mechanisms for the regulation on the I synthesis along these different lineages
remain unclear.
Aims: To investigate the regulatory mechanisms for branched I antigen forma-
tion during the erythroid- and granulocytic-differentiation.
Methods: The sodium butyrate (SB)- and retinoic acid (RA)-induced differentiated
K-562 cells were served as the erythroid- and granulocytic-differentiation model,
respectively. The wild type and mutant form of ERK2 and SHP-2-overexpressing
K-562 cells were used to study the involvement of MAP kinase-mediated path-
ways and upstream signaling molecule in the I antigen formation. CHIP analysis
was used to compare the binding affinity of C/EBPa to IGnTC promoter.
Results: The ERK2-mediated signaling specifically regulated the synthesis of
I antigens during the erythroid-differentiation, but not for granulocytic-differen-
tiation. SHP-2 acted as upstream regulator of ERK2 to control the phosphory-
lation status of Ser21 on C/EBPa, which affect the binding affinity to IGnTC
regulatory region, and to govern the I antigen formation.
Summary/Conclusions: In this K-562 cell model when induced by SB, the
SHP-2-ERK2 signaling is specific for the branched poly-LacNAc formation dur-
ing erythroid-differentiation.
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PEGYLATED CARBOXYHEMOGLOBIN BOVINE EXHIBITS SUPERIOR
RESUSCITATIVE CAPACITY IN RODENT MODEL OF SEVERE HEMORRHAGE
R Jubin1,*, A Abuchowski1, P Buontempo1, C Buontempo1, B Song2, W Nugent2
1Prolong Pharmaceuticals, South Plainfield, 2Song Technologies, Baltimore,
United States
Background: PEGylated Carboxyhemoglobin bovine (PEG-HbCO) is a novel
biological therapy designed to release carbon monoxide and then transfer oxy-
gen to hypoxic tissue. Prior in vitro cell culture and in vivo animal models includ-
ing stroke and myocardial infarction have demonstrated the PEG-HbCO exhibits
both anti-inflammatory and anti-hypoxia activities. Severe hemorrhage results
in rapid hypotension and tissue hypoxia. Fluid restoration and pressors are
standard of care that positively impact blood pressure and circulatory volume,
but unfortunately they have minimal impact towards resolution of tissue hypoxia
and systemic inflammation resulting from hemorrhagic shock.
Aims: A rat model of severe hemorrhage was developed to evaluate the effects
of PEG-HbCO on cardiovascular and respiratory macro function in comparison to
the colloid volume expander, Hetastarch. Additionally, microscopic measurements
of microcirculation and tissue oxygenation were compared between the two resus-
citative agents as well as circulating markers of inflammation and hypoxia.
Methods: Male Sprague-Dawley rats underwent a controlled 45% blood volume
hemorrhage at 3.5 ml x min-1 x kg-1 through a cannulated carotid artery and
were maintained in a hypovolemic, hemorrhagic shock phase for 30 minutes.
Resuscitation fluids were infused at a rate of 3.5 ml x min-1 x kg-1 to a volume
equal to 20% of the total estimated blood volume through a cannulated jugular
vein. Systemic measurements were recorded via a cannulated femoral artery
that was connected to a pressure transducer while microcirculatory parameters
were collected through phosphorescence quenching and intravital microscopic
examination of the exteriorized spinotrapezius muscle. 
Results: Compared to baseline, the 45% hemorrhage produced a significant
reduction in heart rate, blood pressure, arterial diameter and interstitial fluid
oxygen partial pressure (ISF PO2). Resuscitation with either PEG-HbCO or
Hetastarch improved animal heart rate and mean arterial pressure systemic
parameters towards pre-conditional baseline levels, but only PEG-HbCO -treat-
ed animals showed an improvement in ISF PO2. The impact of improved sys-
temic variables was evident in mortality with untreated animals (sham) expiring
an hour after hemorrhage, while Hetastarch resuscitated animals expired after
4 hours. PEG-HbCO animals survived for the entire 8 hour observation period.
In addition to extended survival times, PEG-HbCO animals showed steady sys-
temic and microcirculatory parameters. Hetastarch resuscitated animals, how-
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ever, developed rigor mortis in their limbs at approximately 3 hours post-hem-
orrhage, which was concurrent with a rapid decline in systemic variables. Addi-
tionally, only PEG-HbCO yielded reduction in hypoxia and inflammatory gene
expression levels as compared to Hetastarch and sham control animals. 
Summary/Conclusions: Systemic hypoxia is a major factor in trauma-related
mortality and early intervention can improve survival rates. This study showed
that PEG-HbCO has a unique capacity to restore macro and microcirculatory
functions in addition to reducing inflammation and tissue hypoxia. Moreover,
reestablishing blood pressure is acutely important for post-hemorrhage survival





FIVE YEARS OF HEMOVIGILANCE REPORTS OF COMPLICATIONS OF
THE BLOOD DONATION REPORTED AT A TERTIARY CARE CENTRE IN
KARACHI
B Nepal*
Blood Bank, Dr. Ishrat ul Ebad Khan Institute of Blood Diseases, Karachi, Pak-
istan
Background: There is a minor chance of risk among blood donors. Even
though blood donors are usually screened for the presence of risk factors,
sometimes blood donations can put a person at panic.
Aims: The safety of the blood supply depends on the actions to protect both;
blood transfusion recipient and the blood donor. Hemovigilance practice of
learning of complications of blood donation and protecting them from such
complications is the best way to minimize the risk to blood donor.
Methods: Comprehensive blood donor hemovigilance program was studied
at Dr. Ishrat ul Ebad Khan Institute of blood diseases, Karachi from 2010 to
2015. Outlines of reported and communicated complications were collected
after whole blood donation. Analysis was done by general logistic regression.
Results: Complications after 30,000 Whole blood donation procedures calcu-
lated 1620 total. (54 per 1,000 donations). The majority of the complications
were faint and pre-faint reaction with light headedness (58.6%), Sore arm
(24%), Bruises and hematoma (14.4%). Minor complications were
Agitation/sweating (2%) and arterial puncture (1%). Markers of the complica-
tions were age, sex, race, weight, blood pressure and donation status. All asso-
ciated independently after whole blood donation. Age and first-time status were
associated with a significantly higher risk of complications with 18-22 years
old at higher risk compared to 23 to 50 years old. First-time donor were at
higher risk compared to repeat donor.
Summary/Conclusions: The results of this study are helpful in identifying and
understanding the promoter to complication of blood donation. Donor age and
status were strong predictors of complications. The remedies and specific areas
of care should be provided.
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A NEW METHOD FOR ACTIVATING PLATELETS IN PLATELET-RICH
PLASMA TO USE IN REGENERATIVE MEDICINE: A CYCLE OF FREEZING
AND THAWING
RA Çetinkaya1, I Eker2, S Yılmaz3, A Ünlü4, A Pekel5, R Ilıkçı Sağkan5,
Z Ertaş6, O Gürsel2,*, HU Muşabak5, E Yazıcı3, S Yılmaz3, C Açıkel7, IY Avcı8,
F Avcu6
1Infectious Diseases, Gulhane Military Medical Faculty, Haydarpaşa Hospital,
İstanbul, 2Pediatric Hematology, 3Blood Bank, 4Surgery, 5Allergy and Immunol-
ogy, 6Hematology, 7Biostatics, 8Infectious Diseases, Gülhane Military Medical
Faculty, Ankara, Turkey
Background: Platelet-rich plasma (PRP) is a platelet-derived product, which
exhibits regenerative properties and have been widely used in regenerative
medicine. Platelet-rich plasma can be used with or without previous platelet
activation, for what purpose is to be used. There are different ways of activating
platelets. Activating platelets by freezing cycles is a new, not widely known and
applied method. 
Aims: The objective of the study was to assess whether and to which amount
a cycle of freezing/thawing may affect the amount of growth factors in autolo-
gous platelet-rich plasma.
Methods: Fifteen ml of whole blood was obtained by venipuncture and col-
lected in two citrated tubes from 20 healthy, male volunteer donors to obtain
PRP. After preparation of PRP with standard methods, they were divided into
two groups. First group was activated by adding 10% calcium gluconate to
finalize PRP with volume ratio of 1:10. Second group was cryopreserved at -
80°C for 24 hours. Of the obtained PRP, insulin-like growth factor-1 (IGF-1)
platelet-derived growth factor (PDGF-BB), basic fibroblast growth factor (bFGF)
concentrations were measures using the ELISA kit following the manufacturer’s
instructions.
Results: The mean platelet count of the donors and the autologous PRPs
were 238,5±44,7 x 103 / µl and 544,7±161,5 x 103 / µl, respectively. Overall,
there was an increase in the concentration of the insulin-like growth factor-1
(IGF-1) platelet-derived growth factor (PDGF-BB) and basic fibroblast growth
factor (bFGF) after a cycle of freezing and thawing. But only the increase in
PDGF levels were significant (218,90±30 and 78,95±49,42 respectively; p:
0,0001). There was not a statistically significant difference between the GF
levels of freeze thawed and calcium activated PRPs. A cycle of freezing/thawing
was the only independent factor associated with growth factor yield in multi-
variate model. In summary overall, there was an increase in the concentration
of the three GFs, but only PDGF was significant. There was not a significant
difference between the GF levels of post-freezed and calcium activated PRP.
A cycle of freezing/thawing was the only independent factor associated with
growth factor yield in the multivariate model.
Summary/Conclusions: With its features of being simple, inexpensive and
easy for standardization; a cycle of freezing/thawing may be the method of
choice in the future for PRP activation procedure, especially for obtaining PRPs
rich in PDGF, without inducing fibrin matrix.
This study is done with the support of the Turkish Society of Hematology, with
the approval number of 2014-8.
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PERFORMING ELUTION TEST WITH MONOSPECIFIC ANTIHUMAN GLOBULIN
UNMASKS MULTIPLE IMMUNOGLOBULIN COATING; IMPLICATIONS ON
IMPROVING MULTIPLE IMMUNOGLOBULIN DETECTION SENSITIVITY IN
AIHA SCREENING
Z Bezirgiannidou1,2,*, E Kontekaki1, S Papamichos2, A Christoforidou2, S Zisa-
ki1, K Chouchos3, I Kotsianidis2, D Margaritis2, E Mantadakis4
1Blood Transfusion Center, University Hospital of Alexandroupolis, 2Department
of Haematology, Democritus University of Thrace Medical School, 3Biomedical
Engineering Department, University Hospital of Alexandroupolis, 4Department
of Paediatrics, Democritus University of Thrace Medical School, Alexandroupo-
lis, Greece
Background: Autoimmune Haemolytic Anemia (AIHA) basic screening
includes: (i) Direct Antiglobulin Test (DAT) using monospecific antihuman glob-
ulin (MAHG), namely anti-IgG, anti-IgA, anti-IgM, anti-C3c and anti-C3d, to
detect the autoantibody immunoglobulin (Ig) class(es) or complement frag-
ments on erythrocyte membrane; (ii) Indirect Antiglobulin Test (IAT) using poly-
specific antihuman globulin (PAHG), comprised of anti-IgG and anti-C3d, to
identify autoantibody(ies) in serum or red blood cells (RBCs) elution. Current
elution techniques are valuable for allowing the identification of antibody speci-
ficity and the elimination of false positive DAT cases. The use of only anti-IgG
in IAT implies that: (a) Non-IgG classes causing AIHA will be missed in elution
test, rendering false negative results, (b) Elution test in AIHA caused by multiple
Ig classes would allow non-IgG classes to be missed, generating misleading
results.
Aims: To highlight that in DAT (+) RBCs coated with multiple Igs, DAT is not
sufficient to unmask all the putative Ig classes and to suggest a method that
potently unmasks multiple Ig coating. 
Methods: Acid elution (DiaCidel/BIO-RAD) was performed on 59 patients’ DAT
(+) RBCs. The eluates were screened by IAT against a commercially available
panel of RBCs (ID-DiaPanel) using PAHG Liss/Coombs gel cards (Biorad,
Switzerland). An additional method using MAHG gel cards (DC-Screening
I/BIO-RAD) in elution IAT was also applied. Seven patients were excluded from
the study since their DAT positivity was due to alloantibodies following recent
transfusion or non-specific reactions. Of the remaining 52 patients, only 21
(40.38%) fulfilled the diagnostic criteria for autoimmune haemolysis; 17 pre-
sented with AIHA and 4 with Evans syndrome. DAT positivity without haemol-
ysis was observed in 31 (59.61%) patients, representing a random finding dur-
ing pretransfusion testing.
Results: Initial screening of blood samples by DAT identified 49 warm and 2
cold autoantibodies, as well as one mixed type autoantibody. When AIHA was
caused by multiple Ig classes, the use of MAHG in elution IAT allowed the
identification of Ig classes that were not detected by the standard DAT. In detail,
six DAT (+) and IgM (-) cases by DAT were identified as IgM (+) by elution IAT;
three IgG (-) DAT (+) cases were found to be IgG (+) by elution IAT; and five
DAT (+) IgA (-) cases by DAT were identified as IgA (+) by elution IAT. Overall,
in 14 out of 52 cases (26.92%), the DAT missed to identify multiple Igs coating.
Even though elution IAT with PAHG would identify the three IgG (-) DAT (+)
cases, still 11 cases with multiple Igs (21.15%) would have been missed, a
statistically significant difference (p=0.012). It is notable that 11 of the 14 missed
cases (78.57%) presented with severe autoimmune haemolysis.
Summary/Conclusions: In cases of AIHA caused by multiple Ig classes, we
assume that monospecific antiserums in DAT bind mainly with the dominant Ig
class due to the high concentration of bound antibodies on the RBC membrane
(like the prozone phenomenon). This constraint is bypassed when Igs are dis-
carded from the RBC membrane in elution, since they are available to react
with PAHG by IAT. However, the latter applies only for IgGs, since non-IgGs
are not detectable by PAHG. In conclusion, we report an efficient method for
unmasking non-IgGs participating in multiple Ig coating, i.e., the use of MAHG
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in IAT elution. This method may have clinical implications, because AIHA is fre-
quently severe when multiple Ig coating occurs.
E1575
BIOTINYLATION OF ERYTHROCYTES FOR CLINICAL RESEARCH
D De Back1,*, R Vlaar2, B Beuger3, B Daal4, J Lagerberg4, D de Korte4,
M van Kraaij5, R Bruggen3
1BCR, 2BTT, 3Blood Cell Research, 4PPO, 5UTG, Sanquin, Amsterdam,
Netherlands
Background: Within Sanquin there are currently several clinical transfusion
protocols in development or already realized, where the objective is to assess
the efficacy and safety of erythrocyte transfusions in certain categories of
patients (MDS patients, IC patients). This question arises from the fact that up
to 25% of the donor erythrocytes are cleared within 24 hours after a transfusion,
a phenomenon that is becoming more and more linked to side effects of trans-
fusion in the receiver. The mechanisms that ensure that erythrocytes are cleared
are to a large extent still unclear. Identification of the routes that lead to the
clearance of erythrocytes are especially important for the transfusion practice.
Aims: The goal is therefore to develop a standardized labelled blood product
(GMP) that can be used for clinical research and evaluation of new blood products.
Methods: The yield after transfusion is difficult to measure. Although autologous
red blood cells (RBCs) have a different genetic make-up than the transfused
products, it is difficult to distinguish donor from recipient RBCs. Previously,
donor erythrocytes were labelled with Chromium-51, a radioactive label a pro-
cedure that is not allowed in the Netherlands. Another option is to discriminate
on the basis of differences in minor blood group antigens. This, however, is
laborious and not always possible. A third possibility is to label erythrocytes
with biotin, also known as vitamin B8. The advantage of labelling with biotin is
that different concentrations of biotin labelling can be used, allowing the detec-
tion of several RBC transfusions in 1 patient.
Results: Former studies have shown that labelling with biotin is safe, also upon
multiple exposures. We found that labelling with biotin does not affect the life
span or function of the RBCs, and remains stable over time, also when the ery-
throcyte concentrate (EC) needs to be irradiated to prevent Graft vs Host dis-
ease. Furthermore, labeling with different densities of biotin gives reliable iden-
tification of different populations of donor RBCs. However, about 12,5% of
healthy volunteers may develop antibodies against biotin, without clinical con-
sequences, and resolve spontaneously within a year time. Lastly, biotin can be
stored in different concentrations, in bags that are compatible with blood bags,
without loss of quality, and with preservation of properties.
Summary/Conclusions: Having arrived at the end of the validation study, it
shows that EC that are labeled with biotin, can be produced in a standardized
manner under GMP conditions, and can be used for clinical research and eval-
uation of new blood products.
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KNOWLEDGE, ATTITUDE AND PRACTICE ABOUT THE VOLUNTARY
BLOOD DONATION AMONG THE YOUNG STUDENT POPULATION OF
KARACHI
B Nepal*
Blood Bank, Dr. Ishrat ul Ebad Khan Institute of Blood Diseases, Karachi, Pakistan
Background: Safe blood is a crucial and irreplaceable component in the med-
ical management of many diseases. The Voluntary non-remunerated blood
donation is the ideal sources of quality blood, which forms less than 15% of the
demand of the blood in Pakistan. Motivation among the youth, particularly stu-
dents, is essential to make voluntary blood movement more successful.
Aims: To assess the knowledge, attitude and practice regarding the voluntary
blood donation among the young student population of Karachi so that an effec-
tive approach can be made regarding motivation enrollment of voluntary non
remunerated blood donors in future in Pakistan
Methods: A cross sectional prospective study was conducted among 600 stu-
dents from different universities and colleges of Karachi. A well-structured and
pre-tested questionnaire, in English, was used to access the knowledge, atti-
tudes and practices about voluntary blood donation. A scoring mechanism was
used to understand overall knowledge level. The participants were given a brief-
ing about the objectives of the study and confidentiality about the personal data.
Obtained data was analyzed by using statistical package of social sciences
(SPSS) version 17.0 in computer. Statistical significance level was set at p=0.05.
Results: The sample population consisted of 54% male and 46% female stu-
dents in the age group of 18-28 years. Only 65% of the students have heard
about voluntary blood donation and 28% of the students have given blood once
in their lifetime and among them 19% are blood donors at the moment. 42% of
the participants believed that there is a specific reason why they don’t donate
blood and 59% believed that there is a risk involved for the donors, when donat-
ing blood. 80% students wanted to promote voluntary blood donation. Fear and
lack of awareness on blood donation are the reasons for not donating blood.
Students gather information about voluntary blood donation from several
sources mostly schools, colleges, family and friends.
Summary/Conclusions: This study showed that myths and misconceptions
are leading the youngsters not to donate blood. Study also showed how increas-
ing awareness and marketing through different ways can boost the culture of
voluntary blood donation in society. Student population can be motivated to
participate in different ways. There is a dire need to mobilize the electronic
media for educating our youth about voluntary blood donation due to its access
to masses.
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CURRENT STATUS OF INCIDENTS CAUSED BY HEMOSIDEROSIS IN
PATIENTS WITH HEMATOLOGIC DISEASES: RESULTS FROM SPANISH
HAEMOVIGILANCE SYSTEM
P Romero García, E Morente Constantin, MDP Garrido Collado, MA García
Ruiz*, M Jurado Chacón
Servicio de Hematología y Hemoterapia, Complejo Hospitalario Universitario
de Granada, Granada, Spain
Background: The Blood Safety System (Haemovigilance - HV) enables to col-
lect and analyze incidents related to donation, preparation of blood components
and transfusion. The purpose is to know the complications and adverse reac-
tions occurred during the transfusion process, to establish effective control
measures that can prevent these events. HV should cover the entire transfusion
chain. Among transfusion-related complications, the Hemosiderosis is an inci-
dent characterized by a very low level of reporting. We have analyzed Hemo-
siderosis at national state and inside our CCAA (Andalusia). Post-transfusion
hemosiderosis is a frequent complication of hematologic diseases, as well as
part of their treatment. It is defined as the accumulation of iron in organs and
tissues in patients who are receiving regular transfusions of packed red blood
cells. Malignant hematological diseases will require regularly transfusions, iron
overload, therefore, will be a common side effect in these patients. It is directly
related to the number of transfusions received. After transfusing 10 bags, iron
is deposited in tissues, after 20, the risk of developing a secondary hemochro-
matosis increases.
Aims: We intend to investigate the percentage of hemosiderosis reports to the
Spanish Haemovigilance system. In the European Union, there are various HV
systems, to note: French Haemovigilance system: Is governmental, with a com-
plex structure, notification of all adverse effects and mandatory reporting. Eng-
lish Haemovigilance system (SHOT): notification of serious adverse effects and
voluntary reporting. Spanish system (HV): a simpler structure model, voluntary
reporting of adverse events and reactions. Notifications are virtually nonexistent
except in the French system. Although reporting of post-transfusion hemo-
siderosis is mandatory in the French haemovigilance network since 1994, exist-
ing data is limited.
Methods: We reviewed the transfusion incidents caused by iron overload which
have been reported to the Spanish HV system and the Andalusia HV system
of, comparing them with the ones notified by our hospital from 2013 to 2015
and their underlying hematologic diseases. Cases in Spanish HV system: 2007:
3. 2008: 15. 2009: 10. 2010: 10. 2011: 16. 2012: 10. 2013: 88. Andalusia: 2007-
2012: 0. 2013: 71. (Figure 1).
Results: In 2013 we identified 57 cases, 32 men and 25 women, from 20 to
87 years old, average of 56, who have been transfused with packed red blood
cells. The results vary from 10 CH to 73 CH transfused (average of 25 CH per
patient). Postransfusional ferritin levels were over 1000 mg/l (average of 2869
mg/l). In 2014 we have notified 76 cases, 50 men and 26 women, from 24 to
83 years old) (average of 56). The number of CH transfused varied from 10 to
130 (average of 31 CH). The number of post-transfusion ferritin ranged
between 1,041 and 15,190 mg/l. In 2015, 42 cases have been reported: 18
women and 24 men, between the ages of 17 and 81, with an average of 51
years old. The number of CH transfused ranged from 10 to 107 (average of
33.3 CH). Post-transfusion ferritin ranged between 1.274 and 8.858.4 mg/l.
Firstly, the largest number of hyperferritinemia cases was found in patients
with acute myeloid leukemia. Secondly, in patients with monoclonal gam-
mopathies found. And thirdly, in patients with non-Hodgkin lymphoma. Other
diagnoses were myelodysplastic syndrome, chronic lymphocytic leukemia etc.
(Figure 2).
Figure 1.
Summary/Conclusions: The most frequent cause of hemosiderosis secondary
to transfusion in our hospital has been acute leukemia, with a predominance
of acute myeloid leukemia over acute lymphoblastic leukemia. It is very impor-
tant to properly track ferritin levels in patients undergoing multiple transfusions
in order to establish chelation therapy when necessary and to prevent the
organic damage of secondary hemochromatosis. In the results published by
the Andalusian HV system in 2013, we can highlight the increase of notifications
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of post-transfusion hemosiderosis to the Hemovigilance system, as well as the
increasing number of near-miss reported in 2013. This is valued as an improve-
ment in the notification of such events. Communication of Hemosiderosis cases
to the Hemovigilance System helps to create protocols for polytransfused
patients because of hematologic diseases. Hemovigilance in Spain is, today,
a fully integrated tool within the activities carried out by Transfusion Hospital
Centers and Services. Among the remaining challenges we highlight: Getting
a more uniform level of notification and to Advance in the optimal use of blood
and blood components: safe, effective and efficient.
E1578
USE OF OCTAPLASLG IN THE TREATMENT OF THROMBOTIC
MICROANGIOPATHIES (TMA)
S McGuckin*, C Vendramin, F Alwan, JP Westwood, M Thomas, M Scully
Department of Haematology, University College London Hospital, London, Unit-
ed Kingdom
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare and acute
disorder and plasma exchange (PEX) remains the life-saving therapeutic pro-
cedure in patients with TTP and other thrombotic microangiopathic anemias
(TMA). OctaplasLG (Octapharma), a virally inactivated prion reducing plasma,
has replaced the Solvent-Detergent Fresh-Frozen Plasma (Octaplas®;
Octapharma) to improve the safety of plasma.
Aims: Aim of this study was to assess safety of OctaplasLG administration for
patients undergoing PEX.
Methods: We performed a prospective study of 90 patients, treated with PEX
for TMAs from a single institution over a 36 month period, January 1st 2013-
December 31st 2015. We recorded: virology on admission and in remission for
all patients, allergic reactions to plasma, citrate toxicities associated with PEX,
venous thrombotic events (VTE) rates and incidence of central venous access
(CVA) line sepsis (which can result in exacerbation of TTP).
Results: Over the 36-month period, a total of 981 PEX procedures were per-
formed (median 9, range 0-37). 62 patient episodes were TTP: 45 females
(median age: 47 years; range: 15-89) and 17 males (median age: 49 years;
range: 21-79); 51 patient episodes were De Novo presentations (43 idiopathic,
5 HIV, 1 Congenital and 2 Pancreatitis) and 11 were relapsed presentations.
17 patient episodes were HUS / aHUS, of which 12 females and 5 males. 11
patient episodes were ‘Other TMAs’ (8 females and 3 males). Citrate toxicity
was 5.3% of PEX, (facial and limb tingling). Plasma reactions were 1.7% of
PEX (hives and facial swelling) relieved by anti-histamines. No episodes of
anaphylaxis and no TRALI were reported. Two cases of line associated sepsis
were recorded and 11 cases of VTE were diagnosed (5 PE; day of PE (range):
5-35; platelets count (range): 35-228; 6 DVT; day of DVT (range): 6-43;
platelets count (range): 86-264). Virology was checked for all patients. On
admission for Hepatitis B they were subdivided into different groups: 57
patients had no evidence of infection or immunisation, 12 patients had evi-
dence of previous immunisation and 9 patients had previous evidence of Hep-
atitis B infection. No viral transfer was documented following treatment. HCV
Ab on admission: 89 negative, 1 positive. There was no antibody transfer post
treatment. Pre PEX HIV: 5 positive, 85 negative. No seroconversion was
detected post treatment.
Summary/Conclusions: Citrate toxicities are reduced in severity, likely due
to shortened PEX with the Optya. Reactions with Octaplas remain minimal,
with no severe anaphylaxis noted. VTE events, despite prophylactic LMWH
starting when platelets are >50x109/L, occurred in 12% of cases, with 50%
completed PEX when VTE was recorded. Adherence to our CVA line policy
has resulted in a further reduction to our line related infections. In plasma high
volume users, virology is important on admission to establish viral profile of
the patients and in the follow-up for checking eventual infectious transmission.
To date no viral transfer or antibody transfer or seroconversions were reported
post treatment, likely due to safety of OctaplasLG. 
E1579
DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA ASSOCIATED WITH
ROMIPLOSTIN
HJ Campo Palacio*, A Salamanca Cuenca, C Blazquez Goñi, MA Correa Alonso
Haematology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain
Background: Drug-induced immune hemolytic anemia (DIIHA) is a rare con-
dition with an estimated incidence of about one per million patients per year.
The exposure to a specific drug induces a sudden drop in circulating red blood
cells (RBCs). Many drugs have been implicated in causing red cell (RCBs)
destruction, with the most common being second and third generation
cephalosporins. The initial serologic presentation is not fully appreciated, caus-
ing the disorder to be underdiagnosed. Romiplostim is a thrombopoietin recep-
tor agonist approved for adult patients with chronic immune thrombocytopenic
(ITP) who have been refractory to other treatments. It has also been used in
some hyporegenerative thrombocytopenia cases. Here we report the case of
a patient who gradually developed DIIHA with Romiplostim-related antibodies
Methods: CASE REPORT: A 67-year-old female was diagnosed with acute
myeloid leukemia in February 2014. She received induction chemotherapy
(QT) with Idarubicin and Cytarabine (3+7) achieving complete remission (CR)
without hematological recovery. Persistent pancytopenia did not allow con-
solidation QT. In June 2014, she initiated erythropoietin (EPO) and Romi-
plostim treatment. EPO was suspended two months later and Romiplostin
dose, which had come to 4 µg/kg/week was reduced to 0.5 µg/kg/week, keep-
ing platelets count >100 X 103/µL. Subsequent bone marrow aspirations con-
firmed maintained complete remission. In October 2015, hemoglobin (Hb)
concentration was 12.8 gr/dL (normal range 13.5-16.5 gr/dL) and platelets
count 133 x 103/µL (normal range 130-400 x 103/µL). Four weeks later the
patient referred asthenia. Laboratory tests showed Hb 9.7gr/dl. We ruled
leukemia relapse and discontinued romiplostim. Ten days after last dose of
romiplostim, laboratory analysis was notable for the following: Hb 10.2 gr/dl,
reticulocytes 9.3%, LDH 513 mg/dl, bilirrubin 0.63 mg/dl and haptoglobin 117
mg/dl. Peripheral blood smear showed anisocytosis, polychromasia and sphe-
rocytes. Based on her clinical history and laboratory evaluation there was a
high suspicion of a potential inmune hemolytic process. Serologic findings
showed a strong positive DAT with polyspecific antiglobulin sera (3+) and
monospecific anti-C3d sera (2+), being negative with monospecific anti-IgG
sera. Eluate with group O RBCs was nonreactive and IAT (indirect antiglobu-
ling test) was negative. Cold agglutinin anti-I was detected in patient´s plasma,
titer 32 and thermal activity<20ºC. Patient´s plasma was strong reactive (2+)
with romiplostin-treated RBCs (ID-Card LISS/Coombs, BIORAD). Eluate react-
ed weakly with romiplostim treated RBCs but did not react with the untreated
RBCs. Both of them, plasma and eluate, were non reactive with saline-sus-
pended untreated RBCs. After discontinuating the drug, Hb concentration and
reticulocyte count were normalized. At the present time, her Hb concentration
is 13.5gr/dl and DAT is negative.
Summary/Conclusions: This case highlights the importance for clinicians to
maintain high index of suspicion for DIIHA in patients with unexplained hemol-
ysis. It is also important to provide of specialized serological testing to clarify
the suspected diagnosis. Romiplostim should be considered as a possible risk
factor in development of immune hemolytic anemia. To our knowledge, this is
the second report that implicates Romiplostim as a drug inducing DIIHA, being
the other one in a patient with ITP.
E1580
ANALYSIS OF DATA CONCERNING PLATELET TRANSFUSIONS DURING
A TWO-MONTH PERIOD IN A TERTIARY CARE HOSPITAL
V Voulgaridou*, F Girtovitis, E Ntinopoulou, V Bakaloudi, A Konstantinidou,
M Pape, M Chatzikyrkou, O Perperidou, E Hassapopoulou-Matamis
Blood Center, AHEPA University General Hospital, Thessaloniki, Greece
Background: Blood Centers should constantly evaluate their policy, get
informed about the impact it has in clinical practice and eventually reinforce or
modify some attitudes. Platelet transfusions are a subject of controversy con-
cerning the importance of ABO matching, of providing single donor platelets
rather than random donor etc.
Aims: The purpose of our study was to analyze data on all platelet transfusions
performed in our Institution, in order to draw information about the age of the
patients, the type, the blood group and the age of the platelet units issued. 
We ultimately wanted to examine to what degree the current practice conformed
to the principles of our Blood Center, concerning ABO and Rhesus blood group
matching, administration of plateletpheresis units (SDPs) rather than random
donor platelets (RDPs), issue of units as fresh as possible, avoiding outdating.
Methods: Having defined as one «transfusion event» the administration of
one or more platelet units in a 24-hour period for each patient, we registered
all platelet transfusion events in our Tertiary Care Hospital in the two month
period May-June 2015. For each patient transfused, we registered the age (in
order to separate to two categories: adults and pediatric) as well as the type
(SDP or RDP) and the «age» of the units. Differences in the ABO and Rh group
between the patients and the platelet units they received, were registered and
analyzed.
Results: In the two-month period 258 platelet transfusions were performed,
198 in 38 adults (27 men and 11 women, aged 63±17 years) and 60 transfu-
sions in 10 children (5 boys and 5 girls) aged 6,9±2,4 years. In total, 1482
platelet units were administered, of which 1438 RDPs and 44 SDPs. The adults
were given SDPs in 9.09% of the transfusion events (18/198). In the remaining
transfusion events 1285 platelet units from random donors were administered,
in average 7.5±1.98 units per adult patient. The children were given SDPs in
43.33% of the transfusion events (26/60) and RDPs in the remaining transfusion
events, with an average of 4.5±1.4 units per child. All SDPs were of ABO and
Rh group identical to the patients’, while 31,7% of RDPs were of different ABO
group. The following table shows how fresh the platelet units were. In the same
2-month period, disposal of 137 out of 1619 platelet units produced, was reg-
istered: 136 (8.4%) RDPs and 1SDP (0.061%). 79/137 RDPs and 1 SDP were
destroyed due to expiration, 14/137 due to positive serologic and/or molecular
testing, 11/137 due to confidential unit exclusion (CUE) and 32/137 RDPs due
to other reasons.
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Table 1.
Summary/Conclusions: The strategy of the Blood Center to provide platelet
units of identical ABO blood group to the patient’s, was accomplished 100% in
the case of SDPs, but only in 68.2% of the transfusion events during which
RDPs were administered. The already satisfactory percentage of «fresh» units
(more than 2/3 of units administered, were less than 3 days old) can probably
be further improved. It is advisable to investigate whether it would be helpful to
increase the proportion of SDPs for adults, at least to the same extent as for
pediatric patients. With better planning and better collaboration with the other
Blood Centers, the number of units outdated could be minimized.
E1581
ASSESSING THE OUTCOMES OF PATIENTS FOLLOWING GRANULO-
CYTE TRANSFUSION
D Rodger1, O Varsou2, R Soutar2,*
1University of Glasgow, 2SNBTS, Glasgow, United Kingdom
Background: The use of granulocytes in transfusion medicine is not a new
concept. Despite continual advances in the process and over half a century of
recorded use in clinical practice, the efficacy of these blood products continues
to be the subject of much debate. Authors worldwide have reported differing
results regarding the outcomes of patients following such transfusions and our
understanding of the clinical course of patients receiving transfusions today is
largely at the same level as the original pioneers in this field.
Aims: The aim of this project was to assess the use of granulocyte transfusions
in the West of Scotland in recent years and evaluate the outcomes of the
patients who received these transfusions.
Methods: A retrospective single-arm case series study was carried out with
the data being collected for the time period between January 2012 and October
2015.
Results: In total, 20 patients (10 [50%] women and 10 [50%] men) were includ-
ed. Granulocyte transfusions were discontinued in 8 patients (40%), as there
was clinical improvement. This included the patients requiring granulocytes for:
severe neutropenia with a non-healing dental extraction (deceased due to end
stage AML); severe neutropenia with an infected haematoma (deceased with
cause unknown); neutropenic sepsis (alive); pancytopenia (alive); pneumonia
(alive); peri-anal abscess (alive); necrotising fasciitis (alive); and lung fungal
infection (alive). Eight patients (40%) also deteriorated and for this reason the
granulocyte transfusions were stopped. This included the patients that required
granulocytes for the following reasons: two patients with neutropenic pyrexia
(both deceased with the cause of death being respiratory failure for one patient
and a chest infection refractory to treatment for the other patient); severe neu-
tropenia with pericarditis and a fungal infection (deceased due to neutropenic
sepsis); neutropenic sepsis (deceased due to neutropenic sepsis); neutropenic
sepsis with lung abscess (deceased from chest infection that was refractory to
treatment); pancytopenia (deceased due to haemodynamic instability); nasal
sinus fungal infection (deceased from neutropenic sepsis); and Klebsiellaoxy-
toca sepsis (deceased due to respiratory failure). Interestingly, from the patients
that deteriorated the following pathogens were noted in microbiological testing:
Amoeba (querying Acanthamoeba), throat and sputum Candida, heavy yeast
growth, Klebsiellaoxytoca, and Pseudomonas aeruginosa along with Staphy-
lococcus hominis in the blood. When comparing the above two groups (i.e. 8
patients showing clinical improvement versus 8 patients deteriorating), the
median age was 40 years (IQR=47.5; minimum age=2; maximum age=64; 6
women [75%]; 2 men [25%]) for the patients that improved and 60 years
(IQR=39.25; minimum age=0.92; maximum age=66; 2 women [25%]; 6 men
[75%]) for the patients that deteriorated.
Summary/Conclusions: The data confirms the variable outcomes in patients
receiving granulocyte transfusions. However those patients who showed clinical
improvement were noted to be younger than those who deteriorated while there
was also a discrepancy between the sexes with women typically having better
outcomes than men. Atypical organisms were also associated with poorer out-
comes suggesting a multifactorial cause for a less successful outcome.
Although this is a non-randomised study the patient outcomes are encouraging
considering their clinical severity. We therefore continue to use granulocyte
transfusions derived from Buffy coats in these situations.
E1582
THE USE OF ERYTROCYTE-APHERESIS FOR THE TREATMENT OF
HEREDITARY HEMOCHROMATOSIS: OUR EXPERIENCE
A Bruzzese1,*, A Bruzzese2, R Forgione3, P Orlando3, V Bruzzese3
1Dipartimento di Biotecnolgie ed Ematologia, Università “La Sapienza”, Roma,
2UOC Nefrologia e Dialisi, Policlinico Universitario, Messina, 3U.O. Emodialisi,
ASP 5 RC, Taurianova, Italy
Background: The erytrocyte- apheresis has proved advantageous for the treat-
ment of patients with hereditary hemochromatosis (HH) and iron overload,
rather than the traditional “bloodletting”, allowing a less frequent treatment and
more personalized. It would lead to a greater decrease in serum ferritin for
single treatment procedure, without a major reduction in Hepcidin. This may
be clinically relevant, being able to prevent an increase in intestinal iron uptake
and a vicious circle resulting in the need for frequent treatments. The accessi-
bility to the method, however, is hindered by the lack of access to the extracor-
poreal circulation, required to achieve it.
Aims: To facilitate access of the erytrocyte- apheresis to a population of sub-
jects suffering from hemocromatosis, we made available the expertise in the
field of extracorporeal circulation, the staff of a hemodialysis center. After an
activity of about 10 years, we have conducted a retrospective observational
study, comparing with some parameters, subjects undergoing erytrocyte-
apheresis with a control group that continued to be subjected to bloodletting.
Methods: Over a period of 10 years, we treated, 37 patients with hematological
diagnosis of hereditary hemochromatosis with erytrocyte- apheresis. We have
selected among the patients with the same diagnosis that continued to be sub-
jected to bloodletting, a “control” group of 38 patients with similar nosographic
characteristics. The retrospective assessment has been focused on the follow-
ing parameters: hematocrit, levels of blood ferritin, number of treatment proce-
dures, length of intervals between a treatment and another. We also evaluated
the costs of treatment.
Results: The mean number of treatment / year procedures was significantly
lower for patients treated with erytrocyte- apheresis compared to those treated
with bloodletting. The average time interval between two consecutive treatments
is a result of 2.3 times longer for the erytrocyte- apheresis compared to blood-
letting. The interval between two consecutive procedures of erytrocyte- aphere-
sis has shown a tendency to a progressive increase in the longer time interval
of time between a drain and the other. The average annual cost of treatment
with erytrocyte- apheresis was about twice compared to those of bloodletting. 
Summary/Conclusions: The erytrocyte- apheresis reduced, in our experience,
significantly the number of treatment procedures rather than the bloodletting.
We believe that, where there is easily available the acces to the extracorporeal
circulation for cell separation, the erytrocyte- apheresis procedure could
become the treatment of choice for patients suffering from hemochromatosis.
E1583
THE OUTCOME OF PREOPERATIVE TRANSFUSION GUIDELINE ON SICK-
LE CELL DISEASE PATIENTS AT KING FAHD HOSPITAL-JEDDAH (KSA)
DS Felemban1,*, A Qadi2, R Chatterjee3, R Bajoria4
1Blood bank and transfusion medicine, 2Medical Department, King Fahd Hos-
pital Jeddah, MOH, Jeddah 21472, Saudi Arabia, 3MSc in Haemoglobinopathy,
4Director of MSc in haemoglobinopaty, institute for women’s haelth, London
WC1E 6HX, United Kingdom
Background: We have developed a local hospital preoperative transfusion
guidelines for sickle cell disease (SCD) patients to reduce the perioperative
and the postoperative complications. 
Aims: This study was conducted to evaluate the outcome of practice on SCD
patients undergoing surgeries in our institution.
Methods: A retrospective review of 75 SCD patients undergoing surgery at
King Fahd Hospital, Jeddah, Saudi Arabia was conducted between April 2005
and May 2010. The medical records were reviewed to define the perioperative
risks and the postoperative complications in relation to the type of transfusion
modality selected. 
Results: The medical record of 75 SCD patients who undergoing surgeries
were reviewed. Preoperatively, 25.3% had complete exchange transfusion
(CETX), 17.3% had partial exchange transfusion (PETX), 26.7% had simple
top up transfusion (STX) and 30.7% had no transfusion (NTX). The postoper-
ative complications were 20% vaso-occlusive crises (VOC), 2.7% acute chest
syndrome (ACS), and 16% had fever. There was 33.3% patients with prolonged
duration of the hospital stay. There was no significant difference in the outcome
of postoperative fever, VOC, ACS, and the length of hospital stay between all
types of transfusion modalities. However, The correlation was highly significant
between the pre-operative haemoglobin (Hb) level and postoperative fever
(P=.001) and VOC (P =.002). Interestingly, SCD patients who received hydrox-
yurea were observed to have less postoperative complication like fever (P=.015)
and vaso-occlusive crises (P=.011), while those who received prophylactic
heparin in the postoperative period were found to have a reduced length of
hospital stay (P=.005) and vaso-occlusive crises (P=.001).
Summary/Conclusions: The guidelines for preoperative transfusion in SCD
patients was effective in reducing the postoperative morbidity and mortality.
However, this guidelines establish the surgical situations where preoperative
transfusion is needed and the optimum regimen for different surgical types.
E1584
FREQUENCY OF REACTIVE BLOOD DONORS IN A TERTIARY CARE
HOSPITAL, KARACHI, PAKISTAN
B Nepal*
Blood Bank, Dr. Ishrat ul Ebad Khan Institute of Blood Diseases, Karachi, Pakistan
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Background: Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV),
and hepatitis B virus (HBV) are blood-borne viruses and share transmission
routes among at-risk populations, specifically injection drug use and remote
blood transfusions before modern donor screening for these pathogens, making
co-infection common. Morbidity and mortality from infection with HCV in HIV-
infected patients are increasing and have become a major challenge in the
management of such patients. In recent years, number of patients infected
with HBV or HCV or HIV or co-infected with either of the two viruses, has
increased tremendously in Karachi population. IDUs (intravenous drug users),
MSM (Men who have Sex with Men) and individuals having unsafe sex are
among the people who are identified as groups at higher risk of contracting
these infections than others. But these studies does not give an exact picture
of prevalence and frequency of these infection in Karachi’s population as focus
of most of these studies were individuals already involved in behaviors (intra-
venous drug use and unsafe sex) regarded as high risk behaviors.
Aims: To find the frequency of different types of reactive healthy blood donors
at a tertiary care hospital, Karachi, Pakistan.
Methods: The retrospective observational study carried out on both male and
female healthy blood donors. Data from complete blood screening from January
2013 to December 2014 were collected and frequency of various types of reac-
tive blood donors was sorted out to get an actual picture. All the blood products
were screened for HBV and HIV Using enzyme linkedimmunosorbent assay
(Elisa plate washer version 3 and Elisa plate reader stat fax 3200). HCV screen-
ing was performed on Architect 2000 SR Chemiluminescent micro plate
immune assay (CMIA). Malarial parasite tested by making thick and thin smear
seen under microscope. Syphilis was tested by ICT method.
Results: A total number of 6996 healthy donors were received and about 624
were found to have blood screening positive in various combination. The high-
est numbers of isolates was HbsAg reactive 214, HCV 213, VDRL 170, HIV 26
and 1 case of malarial parasite. More prevalent in male population. In this study
there were seven donors found with HCV –VDRL co infection and five co infect-
ed with HCV and HbsAg two donors with HIV and HbsAg infected and two
donors were HbsAg and VDRL reactive.
Summary/Conclusions: This study supports that HBV, HIV and syphilis preva-
lence is high and HIV prevalence is low in healthy blood donors.
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MASSIVE TRANSFUSION IN SON ESPASES UNIVERSITY HOSPITAL
FROM 2010 TO 2015: A SINGLE CENTRE EXPERIENCE
S Ruiz*, A Perez, L Garcia, A Gutierrez, A Sampol
Hematology, Hospital Universitario Son Espases, Palma de Mallorca, Spain
Background: The definition of massive transfusion (MT) is the need of at least
10 packed red blood cells units (PRBCs) in 24 hours in response to a situation
of uncontrolled bleeding. However there is still no consensus for the clinical
management of these situations. 
Aims: The aim of this study was to analyze the events of MT in our center and
variables associated to mortality within 24 hours and 30 days after MT.
Methods: The records of the Transfusion Service of the Son Espases Univer-
sity Hospital were retrospectively reviewed for cases of patients who required
at least 10 PRBCs units within 24 hours during the period of 2010-2015. Their
demographic and clinical-biological data were collected.
Results: A total of 93 episodes of MT were identified between 2010 and 2015.
The median age of patients was 56 years (15-88) with 69 (74%) males and 24
(26%) females. Descriptive consumption data were: total units transfused in
our MT cases were 1444 PRBCs, 537 plasma units and 233 pooled platelets.
Median transfusion counts were 13 (10-36) PRBCs, 6 (0-14) plasma units and
2 (0-9) pooled platelets. Median ratio PRBCs/plasma and ratio PRBCs/platelets
were 2.7 (1.1-14) and 6 (1.3-23), respectively. We analyze the influence of var-
ious variables related to survival at 24 hours and 30 days of the MT. Mortality
at 24 hours and 30 days of MT were respectively 28% and 38%, with no differ-
ences according to sex (p=NS) or age (p=NS). However these mortalities were
significantly higher in politrauma patiens (46% and 43%) compared to aortic
pathology (30% and 37%) and other causes (23% and 20%) (p=0.046 and
p=0.007), for mortality at 24 hours and 30 days respectively. Variables signifi-
cantly influencing mortality at 24 hours and 30 days were the number of PRBCs
(p=0.008 and p=0.015) and the ratio of PRBCs/plasma transfused (p=0.003
and p=0.049), respectively. Median number of transfused PRBCs was respec-
tively 13 (10-30) and 16 (10-36) for patients surviving and non-surviving after
24 hours and 30 days. Median PRBCs/plasma ratio was respectively 2.5 (1.1-
14) and 3.9 (1.5-9) for patients surviving and non-surviving after 24 hours and
respectively 2.55 (1.2-14) and 3.3 (1.1-13) for patients surviving and non-sur-
viving after 30 days.
Summary/Conclusions: The MT is accompanied by high mortality rates and
involves a high consumption of blood components. In our series, we found an
increased mortality in the first 24 hours and in the first 30 days, in patients
receiving higher number of PRBCs and with higher PRBCs/plasma ratios. It
would be necessary to establish protocols for massive transfusion in each cen-
ter to unify treatment criteria and optimize the ratio PRBCs/plasma.
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CLINICAL EFFECTS OF CHRONIC RED BLOOD CELL EXCHANGE AND
DIFFERENT TYPES OF RED CELL CONCENTRATES IN PATIENTS WITH
SICKLE CELL DISEASE
S Cabibbo*, C Fidone, V Spadola, G Garozzo, A Antolino, O Manenti, M Poidomani
Immunohematology and Transfusion Medicine Service, ASP 7, Ragusa, Italy
Background: For patients with severe SCD not eligible for hydroxyurea, two
major therapeutic options are currently available: blood transfusion, and bone
marrow transplantation. Either urgent or chronic red blood cell transfusion ther-
apy, is widely used in the management of SCD but determines a progressive
increase of ferritin level and is also limited by the development of antibodies to
red cell antigens. The introduction of chronic red blood cell exchange and
prestorage filtration to remove leucocytes and the use of techniques for multi-
component donation could be a good solutions. 
Aims: Thus, the aims of our studies were to evaluate the clinical effects of the
different blood components in terms of annual transfusion needs and the inter-
vals between transfusion, moreover we evaluated the efficacy of chronic red
blood cell exchange (manual or automatic with cell separator) in preventing
SCD complications and limiting iron overload.
Methods: In our center we follow 78 patients affected by Sickle Cell Disease.
We selected 36 patients occasionally treated with urgent red blood cell
exchange because they had less than 2 complications/Year, and 42 patients
regularly treated with chronic red blood cell exchange because they had more
than 2 complications /Year with Hospital Admission. Moreover among these
we selected 10 patients for fulfilling the criteria of continuous treatment at the
Centre for at least 48 months with no interruptions, even sporadic and absolute
transfusion dependency. All 10 patients were evaluated for a period of 4 years,
during which two different systems of producing RCC were used. In the second
two the patients were transfused with RCC obtained from filtering whole blood
prestorage or with RCC from apheresis filtered prestorage. These products
differed from those used in the preceding two years, during which the leucode-
pletion was obtained by bed-side filtration
Results: For all the patients we performed 782 automatic red blood cell
exchanges and 4421 units of RCC were transfused. The exchange procedures
were extremely well-tolerated by the patients and adverse effects were limited
to symptoms of hypocalcaemia during automatic red blood cell exchange with
cell separator. After every red blood cell exchange we obtained HbS level<30%.
The10 patients selected received respectively a mean of 6.9 and 6.1 units of
RBCs exchanged per automatic procedure, in the first two years and in the
second two years. Alloantibody developed in 14 patients but only 2 clinically
significant and about the observed frequency of transfusion reactions it was
very low. All patients treated with chronic red blood cell exchange had an
improvement of the quality of life with a reduced number of complications/year
(<2/year) and good compliance and moreover patients had limited iron overload
making chelating therapy easier.
Summary/Conclusions: In conclusion this study was focused on the most
suitable characteristics of blood components for use in sickle cell disease
patients and the choice of systematically adopting prestorage filtration of whole
blood, enabled us to have RCC with a higher Hb concentration than standard.
Moreover chronic manual or automatic red blood cell exchange as an alterna-
tive approach to simple long-term RBC transfusions give many advantages by
being more rapid and tolerable as well as clinically safe and effective and min-
imize the development of iron overload especially when procedure was carried
out with an automatic apparatus. To note that the clinical advantages for
patients derived from good selection of the donor and good practices in the
production of the blood components.
E1587
FREQUENCY OF RED CELL ANTIGENS AND ANTIBODIES IN THE
POPULATION OF NORTH-EASTERN REGIONS OF RUSSIAN FEDERA-
TION
E Butina*, G Zaitseva, T Koryakovtseva, A Karavaeva
Immunogematology, Federal State Institute of Science “Kirov research Institute
of Hematology and Blood Transfusion of the Federal Medical and Biological
Agency of Russia”, Kirov, Russian Federation
Background: Providing immunological compatibility of donor and recipient
can prevent the development alloimmunization, the occurrence of hemolytic
transfusion reactions and increase the effectiveness of transfusion therapy.
The frequency of red blood cell (RBC) antigens and alloantibodies is different
in populations from different races and geographic areas.
Aims: To study the frequency of Rhesus phenotypes and RBC alloantibodies
in donors and recipients of blood components residing in north-eastern regions
of the Russian Federation.
Methods: Data from 8087 donors and 2648 patients with hematological dis-
eases were analysed in 2009-2015. Research blood samples was carried out
by erythrocyte-magnetized technology (Diagast, France) and gel agglutination
assay (BioRad, USA).
Results: Established following frequency of Rhesus phenotypes: СсDее -
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30.35%, ССDee-19.39%, СсDЕе-15.88%, ссddee-15.34%, ccDEe-13.00%,
ccDEE-3.24%, ccDee-1.72%, Ccddee - 0.90%, ccddEe-0.07%, CCddee-
0.05%, CcDEE-0.05%, CCDEe-0.02%, CCDEE-0%, CCddEE-0%. The inci-
dence of RBC antibodies in blood donors is very low (0.49%) compared with
the incidence in patients with hematological diseases, who received transfusion
therapy (1.93%) (p<0.01). The most common specificities of antibodies in
donors were anti-D (0.22%), in recipients - anti-E (0.3%), anti-K (0.26%), anti-
D (0.23%). Differences in the frequency of anti-E and anti-K antibody in donors
and recipients are significant (p<0.01) (table).
Table 1. Frequency and specificity of RBC alloantibodies in blood donor
and patients with hematological diseases
* - The differences between the groups of donor and patients were significant (p <0.01).
Summary/Conclusions: In the population of north-eastern regions of Russian
Federation the most frequent phenotypes СсDee, ССDee, ссddee, СсDEe and
anti-D, -E, -K alloantibodies. Analysis of immunohematological parameters of
donors and recipients allows targeted collection, banking and storage of blood
components.
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SEROLOGICAL AND MOLECULAR CHARACTERIZAZATION OF RHD
VARIANTS
B Foglieni1,*, L Raffaele1, I Guarnori1, M Spreafico1, F Rossi2, P Lanzini3,
L La Rosa4, D Prati5
1Dept. of Transfusion Medicine and Hematology, ASST Lecco - A. Manzoni
Hospital, Lecco, 2SIMTI, ASST Monza, Monza, 3SIMT, ASST Valtellina e Alto
Lario, Sondrio, 4SIMT, ASST Vimercate, Vimercate, 5ASST Lecco - A. Manzoni
Hospital, Lecco, Italy
Background: RhD is the most important, immunogenic and polymorphic Rh
antigen, which plays a key role in transfusion medicine. Anti-D antibodies remain
the leading cause of the hemolytic disease of the newborn, and antigen D com-
patible units are chosen when transfusions are needed. Screening tests are
based on panels of monoclonal antibodies developed to identify the majority of
D variants, but Rh D typing is a constant challenge in donor routine testing,
since in presence of RHD blood group polymorphisms of RH partial D or weak
D phenotypes may vary according to reagent and method used. In January
2015, the Lombardy transfusion system has been deeply reorganized, and
screening tests performed by 27 transfusion centers have been centralized into
8 centers. In our department, we are now testing for ABD about 85,000 units
per year.
Aims: The aim of the study was to describe the findings of ABD typing per-
formed with a different system based on agglutination on solid phase technol-
ogy, different from the ones previously used, based on gel-card technology.
Methods: From March 2015 to March 2016, AB0/Rh typing of blood donations
were performed by solid phase technology with a completely automated system
(Capture-R Ready-Screen, Immucor). Results were compared with data
obtained by gel-card. Samples with negative or weak anti-D reactivity were
screened for the presence of RhD variants with different anti-D sera and
advanced serological kits such as ID-Partial RhD Typing (Biorad), and, further-
more, they were analyzed for DAT testing. Discrepant or inconclusive samples
were selected for further investigation with molecular techniques, based on
allele specific PCR for the detection of 14 RhD weak and 48 RhD partial variants
(Inno-Train, Essemedical).
Results: A total of 82,000 blood donations, collected from 38,515 donors, were
analyzed for AB0 and RhD blood groups. In 130 donors (0.3%) a weak or dis-
crepant RhD typing with different anti-sera were obtained. All of them were
analyzed for the presence of RhD variants by molecular approach, which iden-
tified: 117 weak D alleles (91 type 1, 7 type 2, 6 type 3, 1 type 4, 1 type 5, 10
type 11, 2 compound heterozygote type 1+4 and type 2+4) and 12 partial D
alleles (9 DFR, 1 DNB, 2 DV). In 2 subjects none of the RhD variants analyzed
were found. All RhD variants were identified by both gel-card and solid phase
technologies, except the weak D type 11 (885G>T) variant carried by 10 sub-
jects, which showed a completely negative results with all monoclonal gel-card
antisera used, and only the D weak cells analysis on Immucor microplates
revealed a weak reactivity. This RHD variant is commonly classified among the
Del phenotype, since it can be only identified by adsorption and elution tech-
niques. The RhD typing of blood component of these 10 blood donors were
changed from Rh negative to Rh positive. Moreover, all the RhD variants iden-
tified showed a strong correlation between serological reactivity obtained with
different anti-sera and molecular results. All RHD variants were identified in
subjects with Cc or Ee phenotype, and a linkage disequilibrium between RHD
variants and RHCE phenotypes were observed.
Summary/Conclusions: Solid phase methods were highly sensitive in detect-
ing very weak RhD expression variants, such as DEL, which is important for
the prevention of anti-D post-transfusion or newborn immunizations. Molecular
methods help in the differentiation and definition of partial D and weak D types,
providing additional information for transfusion procedures.
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HBV VACCINATION PROGRAM IN ITALIAN BLOOD DONORS: EFFECTIVENESS
AND POTENTIAL THREAT OF VACCINATION FAILURES TO THE SAFETY
OF BLOOD SUPPLY
M Spreafico*, F Fumagalli Maldini, L Raffaele, B Foglieni, A Berzuini, I Guarnori,
D Prati
Department of Transfusion Medicine and Hematology, Azienda Socio-Sanitaria
Territoriale (ASST) di Lecco, Lecco, Italy
Background: In Italy, vaccination against HBV in newborns, extended to 12-
year-old children, was mandated in 1991. Recombinant HBsAg of A2 genotype,
aimed to protect across all genotypes, is used. However, occasional reports of
infection with non-A2 HBV genotype in vaccinated blood donors presenting
with occult HBV infection (OBI: HBsAg negative, HBV DNA positive) raised
concerns about the broad genotype efficacy of vaccines as well as to the safety
of blood supply. OBI is a potential risk factor for post-transfusion hepatitis, hepa-
tocellular carcinoma, cirrhosis and HBV reactivation.
Aims: The aim of the study was to investigate the efficacy of HBV vaccination
in Italy, where HBV D genotype is prevalent.
Methods: In March 2015 we started 12 month project among Italian blood
donors vaccinated at 12 years of age (group A) or in infancy (group B). Donors
were enrolled and tested for HBsAg, anti-HBc, anti-HBe, anti-HBs titre and
HBV DNA. Dilution and avidity tests were performed on anti-HBc positive sam-
ples to confirm true positive results. The persistence of anti-HBs according to
the time elapsed from vaccination was also evaluated.
Results: Out of 1055 enrolled blood donors, 295 were vaccinated in infancy
(28%) and 760 (72%) at 12 years. No anti-HBc positive result was found in
group B, whereas 5 donors (0,7%) in group A were anti-HBc positive, HBsAg
and HBV DNA negative (p=0.3). Avidity testing confirmed the anti-HBc positivity
in 3/5 donors (anti-HBc specificity: 99.72%), all with high avidity. None of them
have detectable circulating HBV DNA. One of them, vaccinated at 13 years of
age, was also anti-HBe positive. Anti-HBs titres were<10 IU/mL in 381 (36%)
subjects, corresponding to 64% of donors vaccinated in infancy (n=189) and
25% of vaccinated at 12 years of age (n=192). Age at vaccination was an inde-
pendent predictor of low anti-HBs titer (R2: 0.048; 95% CI: 11.14-19.24) by
logistic regression analysis.
Summary/Conclusions: In Italy, HBV vaccination program in newborns seems
to be effective to ensure protection against HBV infection. The prevalence of
anti-HBc positivity among donors vaccinated at 12 years of age was low, but
further studies are needed to clarify whether vaccinated anti-HBc positive
donors are threat for transfusion safety. Vaccination in adolescence results in
more prolonged immunogenicity than vaccination in infancy, reflecting a more
developed immune system.
LB2274
RED CELL AND HAEMOGLOBIN ABNORMALITIES ARE POTENTIAL
BARRIERS TO BLOOD DONATION IN PERSONS OF SUB-SAHARAN
ETHNICITY
A Berzuini*, B Foglieni, M Spreafico, D Prati
Hematology and Transfusion Medicine Department, Ospedale Manzoni, Lecco,
Italy
Background: A substantial increase of persons affected by Sickle Cell Disease
(SCD) is expected in European countries, due to migratory flows from Sub-
Saharan (SSA) and other endemic areas. Blood transfusion is the essential
treatment for people affected by SCD but, due to an intrinsic susceptibility, at
least 1/3 of them develop red blood cell (RBC) alloimmunization, which is also
favoured by the peculiar antigen patterns found in SSA. For these reasons
SCD patients should receive fully matched blood starting from early childhood,
and the only way to reach this objective is to include in the donor pool persons
of the same ethnicity, who are also at risk of having congenital red cell and
haemoglobin (Hb) defects. The conditions are potentially harmful for blood
recipient due to increased risk of hemolysis and/or veno-occlusive crises after
transfusion.
Aims: The aim of this study was to assess the prevalence of RBC and Hb
defects in an apparently healthy population of first generation foreign citizens
native of SSA areas.
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Methods: In March 2014 we started a 24-months program for the recruitment
of foreign citizens to become blood donors in the area of Lecco, Italy. Of 450
potentially eligible persons, 175 (65 f, 110 m), gave their informed consent to
undergo clinical and behavioural pre donation assessments according to the
European regulation, as well as to the glucose-6-phosphate dehydrogenase
(G6PDH) concentration and Hb electrophoresis.
Results: G6PDH concentration could be determined in 169 persons, allowing
us to identify 55 (33%) with reduced enzyme concentration, including 25 (15%)
with severe deficiency (i.e. <5 u/gHb). Despite the X-linked transmission, 8%
of females had severe deficiency. Hb electrophoresis could be assessed in
173 persons. The overall prevalence of Hb variants was 32%: 28 subjects
(21% f, 12% m), were carriers of HbS; 19 (11%) had beta thalassemia trait,
and 8 (5%) were HbC carriers. Coexpression of G6PDH deficiency and HbS
was found in 5% of subjects.
Summary/Conclusions: Despite the clinicians expectations of an increased
availability of donors from SSA to provide a better matched blood supply for
SSD patients, a substantial proportion of candidate donors will be carrier of
RBC and/or Hb abnormalities, representing a major contraindication to blood
components preparation.
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INHIBITORY EFFECTS OF QUERCETIN ON ANGIOGENESIS IN T-ALL
CELL LINES AND ZEBRAFISH IN VIVO
LJ Shen*, FY Chen, HY Liu, JH Zhong, H Zhong,xLi
Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai, China
Background: Microvessel dendity was significantly increased in organs from
patients with T cell acute lymphocyte Leukemia (T-ALL). Notch1 activating
mutations was identified in more than 60% of T-ALL case, and has been demon-
strated as one of the most important pathways in angiogenesis. Quercetin, a
kind of polyphenolic bioflavonoid, has showed strong anti-tumor effects and
antiangiogenesis on various cancers.
Aims: we constructed Notch1 overexpression transgenic zebrafish, then, treat-
ed zebrafish embryos and T-ALL cell lines (A3 and Molt-4) with quercetin to
explore its role in anti-angiogenesis of T-ALL.
Methods: Quercetin (>95% pure) was dissolved in <0.1% dimethylsulfoxide.
Using T lymphocytes specific promoter Rag2, we introduced human intracellular
domain Notch1 (ICN1) gene into Tg(fli1:EGFP) zebrafish, tagged with RFP gene.
In previously work, we vertified that these fish are closely resemble the main
aspects of human ALL. Zebraﬁsh embryos were collected and treated with various
concentrations of quercetin (0, 80, 160, 240µM) dissolved in 4mL egg water and
incubated in six-well plates (20 embryos per well) at 28.5°C from 14 hours post
fertilization (hpf) to 86 hpf. Morphological changes and vessel density were
observed and imaged with ﬂuorescence microscope. The subintestinal vessels
(SIVs) and intersegmental artery (ISV) of the zebraﬁsh were chosen for the meas-
urement of the length by image analyse software Image-Pro Plus 6.0. Cell line
growth inhibition assay was performed at different concentrations of quercetin
(0, 15, 30, 60, 90, and 120μM) with Cell Counting Kit-8. A3 and Molt-4 cells apop-
tosis was measured with AnnexinV-FITC/PI Apoptosis Detection Kit after treated
with 30μM or 60μM of quercetin at 24, 48 and 72h. Quantitative real-time PCR
and western blot analyses were used to detect the changes of angiogenic factors
after dosing. All statistical analyses were carried out in Graphpad Prism 5.
Results: It showed that quercetin can significantly block the SIVs and ISV for-
mation in Notch1 transgenic zebrafish model. Two of the T-ALL cell lines (A3
and Molt-4) have high expression of Notch1. The IC50 at 48h for quercetin in
A3 and Molt-4 were (35.17±1.46)μM and (33.24±2.35)μM, respectively. Their
proliferation was significantly inhibited by quercetin in a dose- and time-depen-
dent manner. Furthermore, the mRNA and protein levels of VEGF, DLL4,
Notch1 and Hes1 were gradual inhibited with the concentration and exposure
time increasing. After treatment with various concentrations (30µM and 60µM)
of quercetin for 48h, the maximal apoptosis rates were (70.24±3.58)% in A3
cells, (61.05±2.37)% in Molt-4 cells, respectively. In contrast, less than 5% of
untreated cells underwent apoptosis under the same conditions (Figure 1).
Figure 1.
Summary/Conclusions: These finding suggested that quercetin could inhibit
angiogenesis by targeting VEGF regulated DLL4/Notch signaling pathway and
supposed to be a potential drug candidate for T-ALL therapy.
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THE TERAPEUTIC POTENTIAL OF EMBRIONARY SIGNALING PATHWAYS
INHIBITION IN ACUTE LYMPHOBLASTIC LEUKEMIA
A Pires1,2, J Jorge1,2, R Alves1,2,3, AC Gonçalves1,2,3, AB Sarmento-
Ribeiro1,2,3,4,*
1Laboratory of Oncobiology and Hematology, Faculty of Medicine, 2Center of
Investigation in Environment, Genetic and Oncobiology (CIMAGO), Faculty of
Medicine, 3Center of Neurosciences and Cell Biology/Biomedical Institute of
Investigation of Light and Image (CNC.IBILI), University of Coimbra, 4Hema-
tology Department, Centro Hospitalar e Universitário de Coimbra (CHUC),
Coimbra, Portugal
Background: Embrionary signaling pathways, such as Wingless (WNT),
Hedgehog (Hh), and Notch pathways, are essential for differentiation and self-
regulation of stem cells, and their deregulation have been associated with sev-
eral hematological neoplasias. Acute lymphoblastic leukemia (ALL) is charac-
terized by the abnormal proliferation and accumulation of immature lymphoid
cells within the bone marrow and lymphoid tissues, which can arise from the
aberrant activation of embryonic signaling pathways. Therefore, these pathways
may constitute new therapeutic targets for ALL treatment.
Aims: Evaluate the therapeutic potential of IWR-1, GDC-0449, and Gamma
Secretase XXI inhibitor (GSXXI), inhibitors of WNT, Hh and Notch signaling
pathways, respectively, in ALL in vitro models.
Methods: For this purpose, we used two ALL cell lines, CEM as a T cell ALL
model, and KOPN-8 as a B cell ALL model. Both cell lines were cultured in
absence and presence of different concentrations of IWR-1, GDC-0449 and
GSXXI. Trypan blue assay was used to evaluate the effect of these inhibitors
on cell viability and density. Cell death was determined by optical microscopy
(May-Grunwald Giemsa staining) and by flow cytometry (FC) using the Annexin
V and Propidium Iodide double staining. FC was also used to measure levels
of apoptosis modulators, BAX and BCL-2, cell cycle (PI/RNase assay) and
mitochondrial membrane potential (through the fluorescent probe JC1).
Results: Our results showed that IWR-1 reduces only the viability and prolif-
eration of KOPN-8 cells in a time and dose dependent manner (being the max-
imal inhibitory concentration, IC50, approximately 50 μM at 48 hours of expo-
sure), having no effect in CEM cells. On the other hand, GDC-0449 and GSXXI
reduces cell viability and proliferation in a time, dose and cell line dependent
manner, being the KOPN-8 cells the most sensitive. We found that the IC50 at
48 hours to GDC-0449 was 75 μM and 150 μM and to GSXXI was 25 μM and
30 μM, for KOPN-8 and CEM cells, respectively. All inhibitors induced cell death
by apoptosis, confirmed by the BAX/BCL-2 ratio, morphological analysis, and
mitochondrial membrane depolarization. The analysis of cell cycle progression
revealed that all inhibitors induce cell cycle arrest in G0/G1 phase in both cell
lines, except in CEM when incubated with IWR-1
Summary/Conclusions: In conclusion, our results suggest that IWR-1, GDC-
0449 and GSXXI could be a potential new targeted therapy in acute lymphoblas-
tic leukemia; however, the therapeutic efficacy is cell type-dependent.
This work was supported by CIMAGO, GAI, FMUC, and Banco Santander
Totta; Ana Pires by LPCC/Pfizer 2015, Joana Jorge by LPCC-NRC/CIMAGO,
and Raquel Alves by FCT (SFRH/BD/51994/2012) grants.
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TRANSPLACENTAL CARCINOGEN EXPOSURE INCREASES THE LEVELS
OF DNA DAMAGEA IN HUMAN UMBILICAL CORD BLOOD AND MOUSE
C57BL/6 BONE MARROW CELLS
N Zareian1,*, A Kaidi2, N Brown3, T Phillips1, C Badie3, P Case1
1School of Clinical Sciences, 2School of Cellular & Molecular Medicine, Uni-
versity of Bristol, Bristol, 3Radiation Effects Department, Centre for Radiation,
Chemical and Environmental Hazards, Public Health England, Didcot, United
Kingdom
Background: Acute leukaemia is the principal subtype of paediatric cancer
and, despite success in treatment, its aetiology remains unclear. Maternal expo-
sure to radiation and benzene metabolites during foetal development has been
implicated in its aetiology as the first hit in the context of a minimal two-hit
model of the natural history of the disease. Although there might not be an
exclusive cause, an abnormal immune response to childhood infections has
been proposed as the plausible aetiology. We have previously shown that a
human placental barrier responds to different types of toxic challenge and oxida-
tive stress by secreting molecules that cause DNA damage and chromosome
aberrations in different cell types distal to the barrier including human fibroblast
and human embryonic stem cells.
Aims: We aimed to investigate: a. the aetiology of childhood leukaemia by
focusing on the role of the placenta in foetal leukaemogenesis; b. the effect of
nanoparticles (NP) as drug delivery molecules on preventing DNA lesions dur-
ing pregnancy.
Methods: In vitro. Human umbilical cord blood (UCB) cells were exposed indi-
rectly to 30 µM hydroquinone (HQ) and benzoquinone (BQ) across bilayered
cell barriers of human trophoblast choriocarcinoma-derived cell line BeWo
grown on transwell inserts (pore size, 0.4 mm). Media with no HQ and BQ was
the control. Ex vivo. To investigate the effect of radiation-induced bystander
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mechanism and pharmacological treatment on preventing DNA damages,
female C57Bl/6J mice at day 12 gestation were exposed to a whole body expo-
sure non-irradiated, 100 mGy or 1 Gy X-irradiation (AGO, United Kingdom,
dose rate 0.5 Gy/min (250 kVp and 13 mA)); the placentae were removed 4
hrs post-irradiation and cultured with 3 conditions: with no drug additive, with
MitoQ bound to NP (MQNP) and with blank NP (BNP) as the control for MQNP.
Total bone marrow (BM) from age-matched female C57Bl/6J was exposed to
conditioned media. DNA damage was measured using quantitative immuno-
cytochemistry for a panel of DNA damage markers including γH2AX and 53BP1
(DNA double-strand break (DSB)) and FANCD2 (interstrand crosslinks (ICL)).
The experiments were carried out in triplicate.
Results: Exposure of UCB to HQ and BQ across BeWo barrier increased level
of DNA damage. UCB cells showed significantly more damage after 24 hrs expo-
sure (γH2AX (p=0.002), 53BP1 (p=0.001) and FANCD2 (p=0.04), Figure 1).
Exposure of murine BM cells to conditioned media with no drug additive increased
DNA DSB and ICL. BM γH2AX-positive cells showed increased DNA DSB at 1
Gy (p=0.006) but the difference was not statistically significant at 100 mGy
(p=0.07). BM 53BP1-positive and BM FANCD2-positive cells showed significantly
more DNA damage compared to their control counterparts at both 100 mGy and
1 Gy doses (p=0.01 and p=0.001, p=0.02 and p=0.0001, respectively). MQNP
prevented DNA damaging secretions in BM treated cells however this effect was
more pronounced in BM 53BP1-positive and BM FANCD2-positive cells at both
100 mGy and 1 Gy doses (γH2AX (p=0.1 and p=0.06), 53BP1 (p=0.002 and
p=0.02) and FANCD2 (p=0.02 and p=0.1), respectively).
Figure 1.
Summary/Conclusions: Our data show that transplacental exposure of
human UCB and murine BM cells to carcinogens BQ/HQ and irradiation
increases levels of DNA damage presumably leading to increased genome
instability. Furthermore, a marked increased phosphorylation of histone H2AX,
53BP1 and FANCD2 in BM cells indicates the effect of a radiation-induced
bystander mechanism. DNA damaging secretion conferred by irradiation expo-
sure in the ex vivo model could be prevented by applying nanotechnology-
based drug delivery molecules to the placental conditioned medium and further
investigations are ongoing. These findings suggest the importance of placenta
as a barrier in DNA damage signal propagation during embryo development
and provide new insights into the link between placental signaling and foetal
leukaemogenesis. Whether these events lead to the accumulation of further
genetic aberrations in the context of a minimal two-hit model for leukaemia ini-
tiation remains to be further elucidated.
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CROSSTALK OF NOTCH1 AND NOTCH2 SIGNALING IN T-ALL CELL LINES
Y Okuhashi1,2,*, S Tohda2, S Hosogaya1
1Medical technology, Tokyo University of Technology, Ota, 2Laboratory Medi-
cine, Tokyo Medical and Dental University, Bunkyo, Japan
Background: Notch signaling is crucial for the growth of leukemia cells. We
reported the effects of γ-secretase inhibitors (GSIs), which block Notch activa-
tion, on the growth of leukemia cells. GSIs suppressed the growth through
induction of apoptosis in most of cell lines. Conversely, the growth of some cell
lines were promoted by GSI treatment. For example, we previously reported
GSI-XXI treatment suppressed the growth of KOPT-K1 cells while it promoted
that of Jurkat cells, both of which are T-lymphoblastic leukemia (T-ALL) cells
with constitutive Notch activation. However, the mechanisms of this phenom-
enon have not been fully clarified.
Aims: In this study, we investigated the mechanisms focusing on the crosstalk
between NOTCH1 and NOTCH2 signaling in Jurkat cells.
Methods: Two T-ALL cell lines (KOPT-K1 and Jurkat) were used. The cells
were transfected with siRNAs targeting NOTCH1 (siN1), NOTCH2 (siN2) or
control siRNA by using the pipette tip chamber-based electroporation system.
The effects of siN1 and siN2 on the expression levels of mRNA and protein of
NOTCH-related molecules were examined by quantitative RT-PCR and
immunoblotting, respectively. The effects of siN1 and siN2 on short-term growth
were examined using a colorimetric WST-8 assay. To examine the effects of
siRNA on morphological differentiation and apoptosis, cytospin preparations
were prepared from harvested cells stained with Wright stain.
Results: Transfection with siN1 and siN2 selectively suppressed the expression
of NOTCH1 and NOTCH2 mRNA and protein, respectively. NOTCH1 knock-
down as well as NOTCH2 knockdown suppressed the growth and induced
apoptosis of KOPT-K1 while they promoted the growth of Jurkat. In Jurkat,
NOTCH1 knockdown increased the level of NOTCH2 protein. On the other
hand, NOTCH2 knockdown increased the level of NOTCH1, cleaved NOTCH1
fragment (active form of NOTCH1), HES1 and MYC protein in Jurkat. In KOPT-
K1, the expression of these protein was not significantly affected by siN1 and
siN2. The knockdown NOTCH1 and NOTCH2 did not affect the expression of
mTOR, Hedgehog and Wnt signal-related proteins in both cell lines.
Summary/Conclusions: Using siRNA-mediated knockdown experiments, we
found that not only NOTCH1 knockdown but also NOTCH2 knockdown affected
the growth of these NOTCH1-mutated, NOTCH2-unmutated T-ALL cell lines.
The growth suppression by NOTCH2 knockdown did not involve the suppres-
sion of MYC expression, which was suppressed by NOTCH1 knockdown. We
also found the crosstalk between NOTCH1 and NOTCH2 in Jurkat, which sug-
gests that Jurkat might have reciprocally compensating system between two
NOTCH. It might cause the resistance to GSIs. To our knowledge, this is the
first report to show the interaction between NOTCH1 and NOTCH2 expression
in T-ALL cell lines.
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ACTIVATION OF IRS1/ BETA-CATENIN AXIS IN ACUTE LYMPHOBLASTIC
LEUKEMIA
JC Fernandes*, APN Rodrigues Alves, JA Machado-Neto, R Scopim-Ribeiro,
B Alves Fenerich, F Borges da Silva, B Pinto Simões, E Magalhães Rego,
F Traina
University of São Paulo - USP, Ribeirão Preto, Brazil
Background: Acute lymphoblastic leukemia (ALL) is an aggressive cancer of
immature progenitors that shows aberrant activation of signaling pathways.
Insulin-like growth factor 1 (IGF1) and its receptor regulate normal cell growth
and contribute to transformation and growth of malignant cells. In solid tumors,
IGF1 has the ability to activate a cascade of downstream phosphorylation
events including translocation of beta-catenin to the nuclei, and activation of
the target gene MYC. In fibroblasts, IGF1 was found to induce nuclear IRS1
translocation, IRS1/beta-catenin association and MYC transcription. When
highly expressed, MYC may acts as oncogene, contributing to the development
of cancers, including hematopoietic neoplasm.
Aims: We herein aimed to investigate the IRS1/beta-catenin axis in ALL cells.
Methods: Bone marrow or peripheral blood samples were obtained from 58
patients with ALL and 13 healthy donors. T-ALL cell lines, Jurkat and MOLT-4,
and B-ALL cell lines, Namalwa and Raji, were obtained from ATCC. Gene
expression was measured by quantitative real-time PCR; relative expression
was calculated using the expression of beta-actin as an endogenous control.
The Mann-Whitney test was used to compare the median of gene expression
among normal donors and patients with ALL. Protein expression, associations
and cellular localization were evaluated by immunoprecipitation, immunoblot-
ting and western blotting analysis, subcellular fractionation and confocal
microscopy. To evaluate the effects of IGF1 upon IRS1 and beta-catenin cellular
localization, cells were submitted to starvation in serum-free medium for 24
hours, followed by IGF1 stimulation (20 ng/mL) and/or IGF1R pharmacological
inhibition (OSI-906; 20 µM), for 24 hours.
Results: IRS1, beta-catenin, and MYC relative gene expression were signifi-
cantly higher in ALL patients compared to normal donors (IRS1, ALL: medi-
an=1.10 [minimum=0.01 - maximum=9.96] vs normal donors: 0.34 [0.19 - 1.49],
p=0.01); (beta-catenin, ALL: 1.12 [0.23 - 5.18] vs normal donors: 0.56 [0.01 -
1.57], p=0.002); (MYC, ALL: 1.78 [0.06 - 28.37] vs normal donors: 0.33 [0:13 -
1.13], p=0.0003). A positive correlation between beta-catenin and MYC mRNA
expression (p=0.002, r=0.39) and between IRS1 and MYC expression (p=0.02,
r=0.29) was found. In ALL cell lines (Jurkat, MOLT-4, Namalwa and Raji) high
expression of IGF1R, IRS1, beta-catenin and MYC protein were observed.
IRS1 and beta-catenin was found to be located in the nuclei and the cytoplasm
of ALL cell lines by subcellular fractionation and western blotting analysis. The
confocal microscopic analysis reveals elevated co-localization of IRS1/beta-
catenin in both nuclei and cytoplasm of ALL cell lines (r≥0.69). In Jurkat cells,
the constitutive protein interaction IRS1 and beta-catenin were observed; IGF1
stimulation increased nuclear translocation of IRS1 and beta-catenin. The
IGF1R inhibitor OSI-906 decreased IGF1R tyrosine phosphorylation,
decreased nuclear beta-catenin translocation and MYC protein expression in
Jurkat cells.
Summary/Conclusions: IRS1, beta-catenin and MYC mRNA expression were
elevated in ALL patients compared to normal controls. The IRS1/beta-catenin
protein association observed in ALL cell lines, together with the data that IGF1
modulates IRS1 and beta-catenin nuclear translocation and MYC expression
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indicate that the IRS1/beta-catenin axis is activated in ALL cells, which may
represent an important signaling pathway involved in the pathophysiology of
the disease.
PB1593
WHOLE EXOME SEQUENCING OF RELAPSED PEDIATRIC T-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
K Karrman1,*, A Biloglav1, K Paulsson1, B Johansson1, A Castor2
1Division of Clinical Genetics, Department of Laboratory Medicine, 2Department
of Pediatrics, Skåne University Hospital, Lund University, Lund, Sweden
Background: Acute lymphoblastic leukemia (ALL) is the most common malig-
nancy of childhood responsible for a quarter of all pediatric cancers. T-cell ALL
(T-ALL) makes up 10-15% of childhood ALL. Close to 80% of children diag-
nosed with T-ALL survive the disease if treated according to standard protocols.
However, one in five T-ALL patients relapse and for this group the outcome is
very dismal, less than half of the patients are cured.
Aims: We undertook exome sequencing of matched diagnostic, remission and
two relapse (relapse 1 and 2) DNA samples from a pediatric T-ALL patient.
Methods: Agilent SureSelect exome capture was used and each capture library
was sequenced on the HiSeq2000 platform. >98% of the targets were
sequenced with at least 20x coverage.
Results: In total, 66 somatic single nucleotide variants (SNVs) were detected
in the three samples. Almost half of the SNVs detected at diagnosis were also
seen at relapse 1 and/or 2 (7/15, 47%). This result hence indicates that the
relapse evolves from a clone present at diagnosis. STAT5B mutations, including
N642H, were recently implicated as a putative drivers of T-ALL. We identified
the N642H mutations in a homozygous state in both diagnostic and relapse
samples, further validating the role of STAT5B in T-cell leukemogenesis. Two
separate NOTCH1 mutations were seen in minor subclones at diagnosis. Inter-
estingly, these mutations were not seen in the relapse samples, however
relapse 2 acquired a FBXW7 mutation which could render the leukemic cells
renewed aberrant NOTCH1 activity. The vast majority of identified SNVs (51/66,
77%) were selectively seen in the relapsed samples. Notably, some relapse-
specific mutations were detected in genes responsible for drug resistance;
ABCA2 and NT5C2.
Summary/Conclusions: To elucidate genes involved in relapsed T-ALL could
hopefully result in new targeted treatments.
PB1594
INCOMPLETE IGH GENE REARRANGEMENTS (DH-JH) AS A MINIMAL
RESIDUAL DISEASE TARGET IN ADULT ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS
L Sedlackova1,*, M Ondrackova1, L Zejskova1, R Plachy1, A Zavrelova2,
J Horacek2, V Petecukova3, M Karas4
1Laboratory for Molecular Diagnostics, synlab czech s.r.o., Prague, 24th Depart-
ment of Internal Medicine – Hematology, Charles University Hospital and Fac-
ulty of Medicine, Hradec Kralove, 3Internal Clinic of Hematology, University
Hospital Kralovske Vinohrady, Prague, 4Department of Hemato-Oncology, Uni-
versity Hospital in Plzen, Pilsen, Czech Republic
Background: Monitoring of minimal residual disease (MRD) is an important prog-
nostic tool in acute lymphoblastic leukemia (ALL) patients. Currently, one of the
most widely used techniques to detect and quantify MRD is allele-specific real-
time polymerase chain reaction (qPCR) based on clonal rearrangement of
immunoglobulin heavy chain (IGH) or T-cell receptor genes. These molecular
targets can be detected in approximately 90% of adult B-cell precursor ALL at ini-
tial diagnosis. In patients, where it is not possible to detect a clonal complete IGH
rearrangement, additional MRD targets, such as immunoglobulin light chain (IGL)
or incomplete IGH (DH-JH) rearrangements, could be also used. The first step
in the recombination process of the IGH locus is a rearrangement of DH and JH
segments which represents one of the earliest events in B-cell development.
Incomplete DH-JH joints were observed in 20 – 25% of B-cell precursor ALLs.
Therefore, in adult ALL patients without clonal complete IGH rearrangement,
incomplete DH-JH rearrangements could be potentially used as MRD target.
Aims: The goal of our work was the application of clonal incomplete DH-JH
rearrangements as MRD targets in routine laboratory practice.
Methods: Since 2010, we have performed clonal complete IGH rearrangement
analysis in 45 patients with ALL suspicion in effort to obtain suitable MRD target.
In 18 patients, where it was not possible to detect clonal complete IGH marker,
screening by the multiplex PCR using BIOMED-2 primer sets for the detection
of clonal DH-JH rearrangement was made as the next step. After sequencing
of the clonal DH-JH rearrangement, allele-specific oligonucleotides were
designed for each MRD target on the basis of the sequence data of the junc-
tional regions. Tests for MRD were conducted by qPCR using TaqMan technol-
ogy (Rotor-Gene Q, Qiagen).
Results: Clonal incomplete DH-JH rearrangements were detected and
sequenced in 11 out of 18 ALL patients at initial diagnosis. Two out of 11 patients
had another available molecular target for MRD monitoring (BCR/ABL,
MLL/ENL) and for additional 3 patients MRD analysis was not requested. The
qPCR assays were developed for 6 patients who were subsequently monitored
for MRD. From February 2011 to January 2016 we examined 59 samples from
bone marrow (n=57) or peripheral blood (n=2). The assay detection sensitivity
achieved the threshold of 10-4 to 10-5 (1 leukemic cell in 10 000 cells to 1
leukemic cell in 100 000 cells). The MRD levels of residual leukemic cells cor-
related with clinical outcome. The clonal DH-JH markers found in these patients
and used for the MRD analysis were the only option for residual leukemic cells
monitoring with sensitivity of at least four orders of magnitude.
Summary/Conclusions: Clonal incomplete DH-JH gene rearrangement tar-
gets are applicable for routine MRD testing of ALL patients as a reliable sensitive
method for MRD assessment and should be considered as a complementary
target for PCR-based clonality assessment and MRD monitoring.
PB1595
WHOLE EXOME SEQUENCING (WES) IN PHILADELPHIA NEGATIVE
(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) EXTRAMEDULLARY
RELAPSES IDENTIFIED COMMON JAK2 MUTATIONS
A Ferrari1,*, C Papayannidis1, V Robustelli1, A Ghelli Luserna di Rorà1,
M Manfrini1, A Padella1, E Imbrogno1, C Venturi1, G Marconi1, C Sartor1,
MC Abbenante1, V Guadagnuolo1, MC Fontana1, A Gazzola2, A Laginestra2,
C Mannu2, N Testoni1, J Shira3, G Martinelli1
1University of Bologna, Institute of Hematology “L. e A. Seràgnoli”, 2University
of Bologna, Department of Experimental Hematopathology and Hematology
Sections, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital,
Bologna, Italy, 3FASTERIS, Genève, Switzerland
Background: Acute lymphoblastic leukemia (ALL) is a complex disease with
multiple factors related both to the disease itself and host biology that signifi-
cantly affect outcome. Appropriate risk stratification and a better understanding
of the genomic landscape underlying this disease have led to improvement in
overall survival in children. Even with these advances, outcome remains unsat-
isfactory in adults, mainly in the Philadelphia chromosome negative subgroup.
Here we report a 22-year-old man with pre-B ALL who was negative for the
recurrent known molecular rearrangements (E2A-PBX, TEL, AML1- MLL-AF4).
The patient (pt) received different therapeutic regimens and allogenic stem cell
transplantation but he did not achieve a remission. Fourteen months after diag-
nosis (dx), leukemia extramedullary relapsed at the breast and later at lymph
node in the groin (CD34+, TdT+,PAX5+, CD19+, CD22+, CD3-).
Aims: to dissect the genetic landscape in order to predict treatment failure and
identify targets amenable to inhibition by targeted therapies we compared the
genomic profile of 3 different tissues.
Methods: Whole exome sequencing (WES) was performed on dx bone marrow
(BM), breast (BR) and lymph node (LN) samples at the time of relapse using
the Illumina Hiseq2000 platform. Matched samples of primary tumour and
germline DNA from buccal swab were also analyzed. The post-transplantation
BR and LN samples were further matched with donor peripheral blood DNA.
MuTect and Varscan tools to call mutations (Single Nucleotide Variants=SNVs
and/or INDELs) were used. 3 sample SNP array analysis were also performed.
Results: WES analysis from 3 samples identified 522 point mutations and 35
indels that occur in 474 genes (Table 1). The number of total mutations at the
time of relapse is higher both in BR and LN samples compare to dx BM. The
majority of mutations occurred on genes localized on chr1 (74); the mean num-
ber of mutations/chr is 24 (2-74). BR and LN sample have 57 mutations in com-
mon (5 in BM and BR, 2 in BM and LN). Mutect identified 26 mutations in both
relapsed samples. They include a mutation in FAAH gene, which is also found
fused with NSUN4 at the dx (RNASeq). This analysis revealed some other
fused genes that were detected mutated with WES. Nine genes are confirmed
to be mutated in all 3 samples: 7 nonsynonymous SNVs (ACHE, COL4A2,
LOC554223, NPHS1, SLC36A1, TMEM89 and JAK2), 1 stopgain mutation
(NTNG2) and 1 indel (HELZ2). Excluding JAK2, no direct relations between
these genes and leukemia were reported so far. The JAK2 mutation S1032Y
were detected in all 3 samples, instead the R683G one in the BM and BR. CD8
is and presents 2 mutations in both BM and BR. SNP array analysis also reveals
that this gene was deleted in heterozygosity in the BM and LN. One copy of
EBF1, INPP4B, ZCCHC7 genes are deleted in all 3 samples (SNP array). EBF1
is described to be associated to ALL. So far, we confirmed ZCCHC7 is fused
with PAX5 in BM and BR, as previously described (Roberts KG, 2012).
Table 1.
Summary/Conclusions: The Ph- ALL extramedullary relapses show higher
genetic instability, with similar low frequency mutation profile. WES suggest
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that JAK2 alterations are driver mutations. This finding could be helpful for a
targeted therapy. Supported by: ELN, AIL, AIRC, PRIN, progetto Regione-Uni-
versità 2010-12 (L. Bolondi), FP7 NGS-PTL project.
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NOTCH1 INHIBITION REGULATES EVOLUTIONARY CONSERVED MIRNAS
IN T-CELL LYMPHOBLASTIC LEUKEMIA
V Saccomani1,*, E Piovan1,2, A Grassi2, J Yu 3, F Bordin1, S Minuzzo1,
P Zanovello1, V Tosello2
1Università degli Studi di Padova, 2Istituto Oncologico Veneto IOV-IRCCS,
Padova, Italy, 3Herbert Irving Comprehensive Cancer Center,Columbia Uni-
versity, New York, NY 10032, United States
Background: Activating mutations in the NOTCH1 ligand-activated transcription
factor oncogene are found in over 60% of human T-cell lymphoblastic leukemia
(T-ALL), where they result in high levels of NOTCH1 signaling. Among multiple
functions of oncogenic NOTCH1, there are evidences of the role of non-coding
RNAs in NOTCH-induced leukemia. MicroRNAs (miRNAs) are short, single-
stranded RNA molecules of approximately 22 nucleotides in length that regulate
gene expression by directing their target mRNAs for degradation or translational
repression. Dual translocations, that simultaneously affect the 17-92 cluster and
NOTCH1, highlight the oncogenic importance of this interaction in T-ALL. More-
over, miR-19 was found to play a crucial role in promoting leukemogenesis in
NOTCH1-induced T-ALL. In addition, miR-451 and miR-223 have been described
to play an important role downstream NOTCH1 in T-ALL cells both in mouse and
human models. Beside these relevant discoveries, data regarding the miRNAs
that are significantly regulated following NOTCH1 inhibition are still ill-defined.
Aims: In this study we analyzed NOTH1-regulated miRNAs following NOTCH1
inhibition in T-ALL cells in view of future therapies that may combine NOTCH1
inhibition with microRNA based therapy. Specifically we pursued the following
aims: - To generate microarray profiles of NOTCH1-regulated microRNAs from
T-ALL cells using a mouse model of NOTCH1-induced leukaemia; - To combine
analysis of NOTCH1-regulated microRNAs and gene expression profiling fol-
lowing in vivo inhibition of NOTCH1 signalling pathway; -To identify and validate
evolutionary conserved differentially regulated miRNAs.
Methods: We thus used a mouse model of NOTCH1-induced leukemia, that
carries a NOTCH1 mutation recurrently found in human T-ALL patients
(L1601P/DPEST). NOTCH1 inhibition was performed in vivo using a gamma
secretase inhibitor (DBZ) and the treatment schedule was sufficient to deter-
mine a significant reduction of cleaved-NOTCH1. miRNAs profiling was per-
formed using a mouse array (8X60K release 19.0; Agilent) that detected 1,247
mouse miRNAs. In parallel, gene expression analysis was performed using
SurePrint G3 Mouse Gene Expression v2 array (Agilent) for the identification
of about 27000 genes and 4578 lncRNAs.
Results: MYC and NOTCH signature resulted strongly down-regulated follow-
ing NOTCH1 inhibition by Gene Set Enriched Analysis (GSEA) demonstrating
the efficacy of our experimental model. From the miRNAs prolife, we obtained
27 up-regulated and 22 down-regulated miRNAs following NOTCH1 inhibition.
Notably, among the NOTCH1 down-regulated miRNAs, we found the miR-17-
92 cluster, previously reported highly expressed in T-ALL samples. Their reg-
ulation was also confirmed in another mouse model of NOTCH1-induced T-
ALL and in human T-leukemia cells. Notably, we identified miR-34a-5p, miR-
22a-3p, miR-199a-5p and miR-29a-3p significantly up-regulated following
NOTCH1-inhibition suggesting a putative role as tumor suppressors in
NOTCH1-driven leukemia. In particular, miR-22a-3p resulted significantly up-
regulated following NOTCH1 inhibition both in mouse and human T-ALL cells.
Summary/Conclusions: In conclusion, the cluster 17-92 resulted to have a
prominent role amongst the down-regulated miRNAs both in mouse and human
T-ALL cells. Importantly, we identified novel up-regulated miRNAs downstream
NOTCH1 inhibition. In particular, miRNAs 22a-3p resulted significantly up-reg-
ulated in human T-ALLs upon GSIs treatment. Further bioinformatics and func-
tional analysis will be performed to elucidate the role of these novel miRNAs
in NOTCH1-induced leukemia.
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ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF TWO CASES WITH
THE RARE E1A3 BCR/ABL FUSION PROTEIN
F Sartori*, B Lopez Andrade, MA Duran Pastor, JC Amat Medina, JJ Martinez
Serra
Hematology, Hospital Son Espases, Palma de Mallorca, Spain
Background: The Philadelphia chromosome is the result of a reciprocal
translocation between chromosome 22 and chromosome 9 that juxtaposes the
breakpoint cluster region (BCR) to the Abelson tyrosine kinase protein. Several
variants exist depending of the breakpoint in the BCR gene, being the more
known ones p210, p230 and p190 bcr-abl which is the most frequently asso-
ciated with ALL. Other rare variants exists (e1a3, b2a3, e6a2) the e1a3 is cre-
ated by the fusion of BCR exon 1 to ABL exon 3. The molecular prognostic of
these rare variant forms is still unclear.
Aims: We report two cases of adult B-ALL Ph+bearing the rare BCR/ABL fusion
protein e1a3. It is important that our lab is able to detect these variants of
unclear prognosis.
Methods: The first patient is a 43 years old man who presented this blood
test: leukocytes 136,00x10 3/uL, Hemoglobin 11,70gr/dL, platelets 39,70x10
3/uL. In the peripheral blood smear 93% of small-medium sized lymphoblasts.
The bone marrow aspirate confirmed the infiltration of 90% lymphoblasts; the
immunophenotype was: CD19+CD10+CD34+TdT+DR+CD79 alfa+CD20-
Cytoplasm IgM negative CD33+. The cytogenetic analysis of the BMA revealed
the karyotype: 46,XY,del(9)(p22)t(9;22)(q34;q11),del(20)(q13) which confirm
the diagnosis of B-ALL Ph+.Patient underwent induction chemotherapy plus
imatinib reaching a morphological CR with persistence of Ph+. Currently is
candidate to an allogenic SCT as consolidation. The second patient is a 65
year old man whose blood test revealed: leukocytes 223,00 10 3/uL, hemoglo-
bin 11,60 gr/dL and platelets 118 10 3/uL. In the peripheral blood smear: 80%
lymphoblasts confirmed by the immunophenotype CD19+CD34+
DR+CD10+CD22+low intensity CD20- TdT+Cytoplasmatic IgM negative
CD33+. The BMA confirmed an infiltration of 25% lymphoblasts. The cytoge-
netic analysis showed the karyotype: 46,XY,t(9;22)(q34;q11). He started induc-
tion therapy plus imatib; because of refractory disease is currently ongoing
reinduction. He’s not candidate to SCT because of his un-fit status.
In both cases the molecular analysis detected the presence of the BCR-ABL
e1a3 variant. Our lab procedure isolates patient RNA from peripheral blood
and is subjected to a two round multiplex RT-PCR reaction. In order to avoid
RNA quality and/or handling errors, we included an internal positive control in
which a 690-bp segment of the ubiquitously expressed transcription factor E2A
mRNA was amplified. The primers and PCR conditions used in the first and
second round of the nested PCR reaction are described by Pallisgaard et al.
We identified an atypical amplification band of approximately 100 bp. In order
to confirm the presence of a BCR-ABL transcript this band was extracted from
the agarose gel, purified and then analyzed by DNA sequencing. cDNA
sequence confirmed the presence of the e1a3 BCR-ABL transcripts.
Results: Reviewing the literature we found 20 cases bearing the e1a3 fusion
proteins already described: 14 patients with B-ALL, 5 with CML and 1 patient
first diagnosed with CML who experienced a B-ALL type blast crisis. Among
the B-ALL patients, 8 are reported dead. It should be studied if this variant cor-
relates to a worse prognosis, which is currently unknown (Figure 1).
Figure 1.
Summary/Conclusions: We add to the literature two new cases of patients with
B-ALL bearing the rare BCR/ABL fusion protein underlining the importance of
detecting it; this variant could be missed in the laboratory testing giving a false
negative; its role is unclear but seems to have a worse prognosis. More studies
have to be done in order to understand the prognosis of this rare variant.
PB1598
ABERRANT DNA METHYLATION-INDUCED GENE INACTIVATION IS
ASSOCIATED WITH THE T-CELL LEUKEMIAS DIAGNOSIS AND/OR
THERAPY
EJ Kim*, M Lee, YR Jung
Kirams, Seoul, Korea, Republic Of
Background: Aberrant hypermethylation of tumor suppressor genes is known
to play an important role in the development of many tumors, and aberrant
DNA hypermethylation was recently identified in hematologic malignancies,
where it is thought to hold relevance in leukemogenesis.
Aims: These observations led us to focus on our comprehensive study to
examine the prevalence of aberrant promoter methylation in a selected panel
of genes that could be potentially involved in T-cell leukemia. In addition to
identifying new biomarkers, exploration of methylation patterns could be used
to guide T-cell leukemia therapies.
Methods: Here, we used pyrosequencing (a sensitive, easy and effective real-
time sequencing-by-synthesis technique) to assess changes in the methylation
levels of individual genes between normal peripheral blood (in which they are
not normally methylated) and two T-cell keukemia cell lines (in which they are
hypermethylated).
Results: We report that there are differences in the DNA methylation patterns
seen in normal peripheral blood and two T-cell leukemia cell lines. We identify
nine genes (CLEC4E, CR1, DBC1, EPO, HAL-DOA, IGF2, IL12B, ITGA1, and
LMX1B) that are significantly hypermethylated in T-cell leukemias cell lines,
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and suggest that aberrant hypermethylation of these normally unmethylated
genes may induce their transcriptional and expressional silencing. Furthermore,
we observed that the expression levels of DNMT1 and DNMT3a were signifi-
cantly decreased by 5-aza-2’-deoxycytidine (5-Aza-dC), which is a demethyla-
tion agent known to deplete DNA methyltransferases (DNMTs) in leukemia can-
cer cells and restore the expression levels of their target genes in Jurkat cells.
Summary/Conclusions: Together, our results show that aberrant hyperme-
thylation is an important molecular mechanism in the progression of T-cell
leukemias, and thus could prove useful as a prognostic and/or diagnostic mark-
er. Moreover, 5-Aza-dC might be a promising candidate for the treatment of T-
cell leukemia.
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EVALUATION OF WNT AND HEDGEHOG SIGNALING PATHWAYS IN
PEDIATRIC B ACUTE LYMPHOBLASTIC LEUKEMIA - A PRELIMINARY
STUDY
M Coucelo1,2,*, A Pires2,3, AC Gonçalves2,3,4, AT Simões1, J Azevedo1,
MJ Brito5, S Silva5, ML Ribeiro1, AB Sarmento-Ribeiro1,2,3,4
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2Laboratory of Oncobiology and Hematology, 3Center of Investigation in Envi-
ronment, Genetic and Oncobiology (CIMAGO), FMUC, 4Center of Neuro-
sciences and Cell Biology/Biomedical Institute of Investigation of Light and
Image (CNC.IBILI), Faculty of Medicine, University of Coimbra (FMUC), 5Pedi-
atric Oncology Unit, Hospital Pediatrico, Centro Hospitalar Universitário de
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Background: Deregulation of signaling pathways such as Wingless (Wnt) and
Hedghehog (Hh) that participate in normal hematopoietic stem-cell self-renewal,
differentiation and proliferation have been implied in the leukemogenic process.
Aims: Our goal was to establish the activation patterns of Wnt and Hh signaling
pathways in pediatric B-ALL patients in order to identify novel prognostic mark-
ers and new targets for therapeutic strategies.
Methods: We studied 9 bone marrow samples from pediatric patients with B-
ALL, 8 at diagnosis and 1 at relapse (average age 10,2y, 4F:5M). Seven B-ALL
had no recurrent genetic alterations (group 1, n=6), including the relapsed
patient (group 2, n=1), and 2 B-ALL had a t(4;11) (MLL-AF4) (group 3, n=2).
Three bone marrow samples without neoplastic disease were used as controls
(average age 9y, 3F). All samples were submitted to a gene expression array
that included 84 genes for each signaling pathway, Wnt (RT2 Profiler PCR
Array, Qiagen) and Hh (Hedgehog Signaling Pathway, Biorad). Results were
analyzed by RT2 Profiler PCR Array Data Analysis v3.5 (Qiagen) and consid-
ered statistically significant when p ≤0,05.
Results: In B-ALL patients Wnt signaling pathway genes were tendentiously
downregulated. Group 1, comparing with control group, showed downregulation
of WNT (WNT1/2B/5B/6/7A/7B/10A/10B/16) (p≤0,05) and FZD (FZD4/5/7/9)
(p≤0,05) family genes, Wnt negative regulators (DKK3,KREMEN1,SFRP4)
(p≤0,05) and cell cycle target genes (CCND1,RHOU)(p≤0,05). Group 3, when
compared with group 1 revealed upregulation of WNT (WNT1,WNT10B)
(p≤0,05), FZD (FZD3,FZD5,FZD9) (p≤0,05), negatives regulators (WIF1, KRE-
MEN1) (p≤0,05)and target genes WISP1 and FOSL1 (p≤0,05). B-ALL patients
at relapse, when compared with the other groups, showed a tendency for Wnt
upregulation, including LEF-1.
Hh signaling pathway results were more heterogeneous. Group 1, comparing
to controls, presented a downregulation of some ligands (SHH) and receptors
genes (PTCHD1,BOC,LRP2) (p<0,05) and upregulation of others
(CDON,PTCHD2,RAB23) (p<0,05), with downregulation of some important Hh
regulators and target genes (GLI2,ZIC2,FGF9,OTX2,GREM1,SFRP1, VEG-
FA)(p<0,05) and upregulation of others (CSNK1E, BCL2,p<0,05). Both, group
3 and the B-ALL patient at relapse, showed a tendency for downregulation of
Hh ligands, target genes and transcription factors, when compared to group 1.
Summary/Conclusions: Our results, although very preliminary, suggest that
B-ALL pediatric patients with no recurrent genetic alterations tend to present
downregulation of Wnt signaling pathway genes and abnormal expression of
Hh signaling pathway. Present results suggest that these pathways may provide
novel prognostic markers and therapeutic targets, and are currently being val-
idated in a larger patient cohort.
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SERUM PROFILE OF CYTOKINES, CYTOKINE RECEPTORS AND
ADHESION MOLECULES IN PATIENTS WITH NEWLY DIAGNOSED ACUTE
LYMPHOBLASTIC LEUKEMIA AND IN HEALTHY SUBJECTS
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Background: Cytokines and adhesion molecules have been studied as mark-
ers of immune system activation in various diseases including hematological
malignancies. The knowledge gained from multiple cytokine and adhesion mol-
ecule analysis could allow better diagnosis and disease management.
Aims: The aim of our study was to evaluate serum profile of cytokines, cytokine
receptors and adhesion molecules in patients with newly diagnosed acute lym-
phoblastic leukemia (ALL) and in healthy subjects. Correlations between ana-
lytes were evaluated separately in both groups.
Methods: Serum samples of 30 newly diagnosed ALL patients (median age 46,
range 22–75 years, 20 males) and 15 healthy subjects (median age 41, range
25–58 years, 11 males) were analyzed. We evaluated serum levels of 31 analytes,
specifically 21 cytokines, 4 soluble cytokine receptors, 5 soluble adhesion mole-
cules and Matrix Metalloproteinase-9. From cytokines, we measured Interleukins
(IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-
23), Epidermal Growth Factor (EGF), Granulocyte Macrophage Colony Stimu-
lating Factor (GM-CSF), Interferon-γ (IFN-γ), Macrophage Inflammatory Protein-
1α (MIP-1α), Monocyte Chemotactic Protein-1 (MCP-1), Tumour Necrosis Fac-
tor-α (TNF-α), Vascular Endothelial Growth Factor (VEGF) and soluble receptors
for IL-2 (sIL-2Rα), IL-6 (sIL-6R), TNF-α type I and II (sTNFR-1,2). From soluble
adhesion molecules, we measured E-Selectin (E-SEL), L-Selectin (L-SEL), P-
Selectin (P-SEL), Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell
Adhesion Molecule-1 (VCAM-1). All analytes were measured by biochip array
technology on Evidence Investigator analyzer (Randox). Statistical evaluation
was done by a professional statistician using software R 3.2.3 (R Core Team
2015). Probability values (p) <0.05 were considered statistically significant.
Results: Comparing cytokine and adhesion molecule levels in newly diagnosed
ALL and healthy subjects, we found significant increase in ALL in serum levels
of IL-6, IL-8, IL-15, MIP-1α, MCP-1, sIL-2Rα, sIL-6R, sTNFR-1, sTNFR-2, L-
SEL, ICAM-1 and VCAM-1 (p<0.01). Furthermore, we found in ALL significant
decrease in serum levels of IL-3, IL-4 and GM-CSF (p<0.01). Serum levels of
other evaluated analytes were without significant differences. In the group of
ALL patients, we found statistically significant correlations between sTNFR-1
and sTNFR-2 (r=0.805; p<0.0001), IL-1α and IL-4 (r=0.700; p=0.008), sTNFR-
2 and MIP-1α (r=0.657; p=0.037), sTNFR-2 and VCAM-1 (r=0.652; p=0.044). In
the control group of healthy subjects, we found statistically significant correlations
between EGF and IL-7 (r=0.876; p=0.009), EGF and IL-8 (r=0.856; p=0.022).
Other correlations between analytes did not reach statistical significance.
Summary/Conclusions: Our results show that serum levels of some cytokines,
cytokine receptors and adhesion molecules are significantly altered in patients
with newly diagnosed ALL, reflecting activity of the disease. We found statistically
significant correlations between some analytes within ALL and control group. Fur-
ther studies are needed to establish if the alterations observed in the levels of
these molecules could be used as a clinically relevant biomarker for ALL.
The work was supported by a long-term organisation development plan 1011
(FMHS).
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WILM’S TUMOUR GENE (WT1) EXPRESSION IN PEDIATRIC PATIENTS
WITH ACUTE LYMPHOBLASTIC LEUKEMIA
N Mikhael*
Clinical pathology department, Alexandria Faculty of Medicine, Egypt, Alexan-
dria, Egypt
Background: The Wilms Tumor gene (WT1) encodes a transcription factor
involved in kidney development and malignancy. WT1 expression in a subpop-
ulation of early CD34+cells has suggested its involvement in hematopoiesis.
Wilms’ tumor gene 1 (WT1) is overexpressed in the majority of adult acute
leukemias and has been identified as an independent adverse prognostic factor.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer rep-
resenting 23% of pediatric cancers. Previous reports show controversial results
regarding utility of WT1 expression as a prognostic and MRD marker in child-
hood ALL.
Aims: The aim of this work was to study the impact of WT-1 gene expression
at diagnosis in a group of Egyptian children with ALL relating it to prognosis,
also determine the efficacy of using this marker in minimal residual disease
monitoring as compared to standard immunophenotyping methods.
Methods: This study was conducted on 70 children with newly diagnosed as
ALL, assessment of WT-1 gene was done by real time PCR in BM samples at
diagnosis and at day 28 of treatment.
Results: Positive WT-1 gene expression was positive in 48 cases (68.6%) and
negative expression in 22 cases (31.4%). There was statistically significant dif-
ference between positive and negative WT-1 gene expression groups regarding
immunophenotyping, where all cases that showed aberrant expression of CD13
and CD33 were positive for WT1(p=0.028). There was significant correlation
between WT1 expression at diagnosis and response to induction chemother-
apy, 12/48 cases positive for WT-1 gene expression, showed MRD at d 28
while in negative WT1 group none were positive for MRD (p=0.029). There
was a correlation between WT1 level expression at day 28 and MRD as detect-
ed by immunophenotyping. (p=0.021).
Summary/Conclusions: WT-1 gene expression is important prognostic factor
related to response to therapy as defined by d28 MRD. WT1 level can be used
as MRD marker by itself for follow up and comparable to standard immunophe-
notypic methods.
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PROGNOSTIC IMPACT OF ABERRANT SURFACE MARKERS EXPRESSION
IN T- ACUTE LYMPHOBLASTIC LEUKEMIA
S Adnan Awad1,*, L Fathalla1, I Eldesouky2, N Elsharkawy1
1Clinical Pathology Departement, 2Clinical Oncology Department, National
Cancer Institute - Cairo University, Cairo, Egypt
Background: Immunophenotyping is very important in diagnosis, and risk
stratification of T-ALL with MRD proven to be the strongest prognostic indicator.
Few small-scale studies have reported aberrant CD markers (CD10-CD34-
CD13/CD33) in T-ALL with much conflict about its prognostic impact.
Aims: To study aberrant expression of CD10, CD34 and myeloid associated
antigens (CD13/CD33) in T-ALL patients and to investigate its correlation with
clinical and biologic features, treatment response (MRD) and overall survival.
Methods: This study included 62 newly diagnosed T-ALL patients from the
National Cancer Institute (NCI) in Egypt during the time period from September
2012 to December 2014. All patients had undergone full history, thorough clin-
ical examination, complete blood count (CBC), and BM aspiration. Immunophe-
notypic markers and minimal residual disease (MRD) at fixed time points in
BM aspirate samples were studied by four-color flowcytometry EPICS XL (Coul-
ter Corporation, Hialeah, FL, USA).
Results: Patients were classified into three phenotypes based on their
immunophenotyping characteristics (CD3 cytoplasmic/surface, CD1a,
CD4/CD8 expression): early T (16/62, 25.8%), T-intermediate (39/62, 63%),
and T- late (7/62, 11.2%). Comparisons of different phenotypes regarding clin-
ical factors (Age, Sex, initial mediastinal mass), hematological (Hemoglobin,
leucocytes counts (TLC), Platelet counts, initial BM blast%), aberrant CD mark-
ers (CD10, CD34, CD13/CD33), MRD (Day 15, 33 and 56) and overall survival
revealed significant variations regarding: TLC where the highest was T-late
phenotype (P=0.014), MRD D33 (P=0.039) and MRD D56 (P=0.007) where T-
late phenotype shows a better outcome. CD10 was expressed on 17/62
(27.4%), CD13 and/or CD33 on 10/62 (16.1%), CD34 on 15/62 (24.2%) of cas-
es and co-expression of CD10 and CD34 on 5/62 (8%). Significant associations
were found aberrant markers and different phenotypic groups where
CD10+CD34+phenotype and CD13/CD33 occur almost exclusively in early-T
groups (P=0.007 and 0.002 respectively). CD10 shows borderline significant
better MRD outcome at D33 (P=0.057) and also slightly better overall survival.
CD34 shows significantly worse MRD D33 (P=0.045) but no correlation with
OS. Though all five patients with CD10+CD34+phenotype shows MRD<0.01
by D33 and then after, no significant correlation was found with MRD nor OS;
which maybe be explained by small patient number. CD13/CD33 expression
shows significant correlation with worse MRD D33 (P=0.017) with worse -but
not significant- OS (Table 1).
Table 1. Clinical, biological and prognostic criteria of T-ALL phenotypes.
Summary/Conclusions: Immunophenotypic groups and aberrant expression
(CD10, CD34, CD10+CD34 and CD13/CD33) have an important prognostic
value in T-ALL, which is evident by their effect on MRD D33, D56 and OS.
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BOTANICAL ALKYL HYDROQUINONE HQ17(3) INDUCES ENDOPLASMIC-
RETICULUM STRESS AND AUTOPHAGY BEFORE THE ONSET OF
CYTOTOXICITY ON THE T(9;22) PHILADELPHIA CHROMOSOME
POSITIVE SUP-B15 ALL CELLS
CW Chen1, YJ Chang1, LI Lin1, DT Lin2, CY Hu1,*
1Department of Clinical Laboratory Sciences and Medical Biotechnology,
2Department of Pediatrics, National Taiwan University Hospital, College of
Medicine, National Taiwan University, Taipei, Taiwan, ROC
Background: Acute lymphoblastic leukemia with Philadelphia chromosome
(Ph+-ALL)(t(9;22)BCR-ABL) is a very high risk (VHR) hematological neoplasm.
Constitutively active BCR-ABL oncoprotein together with multiple genetic
lesions contribute to a very aggressive clinical cause that tyrosine kinase
inhibitors (TKIs) combined with multi-agent chemotherapy fail to convey long-
term disease control. Searching for agents selective to leukemias and investi-
gating the molecule mechanisms involved in the inhibitory effects on leukemic
cells will help to develop new anti-leukemic therapeutics for the Ph+-ALL.
HQ17(3) [10’(Z),13’(E),15’(E)-heptadecatrienyl-hydroquinone], a natural prod-
uct isolated from the sap of Rhus succedanea, exhibited very effective cytotoxic
effect on the TKI-refractory Ph+-ALL SUP-B15 (IC50:1.9 µM) and other ALL
cell lines, but spared normal peripheral blood mononuclear cells. Combination
of HQ17(3) and Imatinib has synergistic cytotoxic effect on SUP-B15 cells.
Aims: To investigate the characters of, and the molecular pathways involved
in the HQ17(3)-induced cytotoxic effects in Ph+-ALL SUP-B15 cells.
Methods: HQ17(3)-treated and control SUP-B15 cells were stained and analyzed
by flow cytometry: membrane lipid disturbance was analyzed by Annexin V/PI
stain, DNA fragmentation was defined as sub-G1 fraction of cellular DNA content
after the PI staining, mitochondrial membrane potential (MMP) loss were stained
by DiOC6(3). Pan-caspase inhibitor (zVAD-fmk), receptor interacting protein 1
(RIP1) inhibitor (necrostatin-1, Nec-1), iron-chelator (deferroxamine, DFO), 3-
methyladenine (3MA) or chloroquine (CQ) (autophagy inhibitors), and lysosomal
protease inhibitors were used in combination with HQ17(3) in some experiments.
Acridine orange stain and confocal microscopy are used to visualize the changes
of lysosomes in the presence of HQ17(3). Autophagic flow in response to HQ17(3)
was revealed by accumulation of LC3B-II visualized by western blot analysis and
aggregation of ectopically expressed GFP-LC3 indicator.
Results: Introduction of HQ17(3) induced extensive cell death within 24 hours
characterized by losing plasma membrane integrity (PI+) concomitant with PS
exposure (Annexin V+), which was not prevented by zVAD-fmk and/or Nec-1.
Cell death displayed MMP loss and profound nuclear DNA fragmentation that
could be attenuated by ROS scavengers. Acidic vesicles were significantly
increased 4 hours after treatment of HQ17(3) then diminished when cell death
was evident. Lysosomotropic DFO abolished the HQ17(3)-induced acidic vesi-
cles and subsequent cell death. Application of AEBSF (serine protease inh.)
and/or pepstatin/CA074-Me (cathepsin D/B inh.) did not rescue cells from
death. Autophagy markers were enhanced in HQ17(3)-treated cells. Autophagy
inhibitors (3MA and CQ) showed a modest protective effect. Further, HQ17(3)
treatment gave rise to early and sustained AKT and mTOR activation and
induced ER stress as shown unfolded protein response markers eIF2a phos-
phorylation and upregulated ER chaperon Grp78.
Summary/Conclusions: Naturally-derived HQ17(3) displayed significant cyto-
toxicity on Ph+-ALL SUP-B15 cells. HQ17(3) leads to ER stress and induces
iron-dependent autophagy followed by necrotic-like, caspase-independent cell
demise that is different from RIP1-mediated necroptosis or lysosomal protease-
mediated cell death. These results suggest that agents selectively induce or
sustain ROS in leukemic cells may induce ER stress and autophagy-associated
cell death, and would potentially augment the treatment for VHR-ALL with
t(9;22) translocation.
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COMPARATIVE ANALYSIS OF CLONAL IG AND TCR GENE REARRANGE-
MENTS IN ADULT PH-NEGATIVE ALL AT THE DIAGNOSIS AND AT THE
RELAPSE
S Smirnova1, J Sidorova1, B Biderman1, K Sychevskaya2, E Parovichnikova3,
N Ryzhikova1, A Sudarikov1,*
1Department of Molecular Hematology, National Research Center for Hema-
tology, 2The faculty of fundamental medicine, Moscow State University,
3Department of Hematological Oncology and BMT, National Research Center
for Hematology, Moscow, Russian Federation
Background: Clonal rearrangements of immunoglobulin (IG) and T-cell recep-
tor (TCR) genes are the targets for minimal residual disease (MRD) assess-
ment. The level of the MRD is an independent prognostic factor and its moni-
toring is important to identify patients with high risk of relapse. One of the pitfalls
of MRD detection by means of IG and TCR gene rearrangements in ALL is
clonal evolution possibly caused by V(D)J recombinase activity. Several studies
have showed that the pattern of IG and TCR gene rearrangements in ALL
patients may change during the course of disease. In relapse some gene
rearrangements may be lost while new gene rearrangements may occur.
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Change of clonal rearrangements, during tumor progression may lead to the
loss of a target for MRD studies and false-negative results.
Aims: Studying the phenomenon of clonal heterogeneity in adult patients with
ALL at the diagnosis and relapse of disease.
Methods: We have determined T- and B-cell clonality in six adults with Ph-
negative ALL at the time of diagnosis and at the relapse. B-cell clonality was
assessed by immunoglobulin heavy chain gene rearrangements IGH (VH –
JH) and light kappa chain gene rearrangements IGK (Vk – Jk/Vk – KDE/Intron
RSS – KDE). T-cell clonality was assessed by T-cell receptor gamma chain
TCRG (VG – JG), beta chain TCRB (VB – JB /DB – JB) and delta chain TCRD
(VD – JD/DD2 – JD/ VD – DD3/ DD2 – DD3) gene rearrangements. Multiplex
BIOMED-2 primer system for PCR and Gene-Scan analysis have been used.
Results: In two patients with B-cell ALL one of clonal rearrangement presented
at the diagnosis was lost at the relapse of disease while new rearrangements
emerged. In one patient with a diagnosis of early T-ALL clonal rearrangements
of the genes TCRD, TCRB and TCRG, identified at the diagnosis were exactly
the same in relapse. In one patient all the rearrangements identified at the diag-
nosis were preserved at the relapse and several new rearrangements appeared.
In one case five rearrangements disappeared at the relapse of disease out of
seven identified at the diagnosis (Figure 1). In one patient only one clonal
rearrangement was revealed at the diagnosis of B-cell ALL and at the relapse of
the disease this rearrangement was preserved, but there were a few new. To
analyze initial ALL samples for possible presence of minor clones that lately we
have found in relapse we used appropriate family-specific primers to V and J-
region instead of multiplex primer mixtures. Despite increased to 10-2-10-3sensi-
tivity no detectable cell populations of these subclones were found.
Figure 1.
Summary/Conclusions: Mismatch in clonal rearrangements at the diagnosis
and at the relapse of disease was identified in five of six (83%) patients, indi-
cating clonal instability during the course of treatment. Clonal evolution and
diversity of clonal IG and TCR gene rearrangements could be one of the fea-
tures of tumor progression. Also it could be speculated that many clonal IG and
TCR gene rearrangements may present at different amounts at the diagnosis,
however less abundant clones could be “invisible” due to the limitation of meas-
uring sensitivity. Later major clones may disappear under the influence of
chemotherapy while others could gain proliferation capacity. Study of the clonal
evolution and heterogeneity in ALL and their impact on treatment efficacy should
help to develop new prognostic factors and therapeutic strategies.
Email address: dusha@blood.ru
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POTENTIAL GOOD TARGET FOR IMMUNOTHERAPY – PRAME ANTIGEN
HAS SELF-ACTIVATING ABILITY
V Misyurin1,2,*, A Misyurin1,2, A Misyurina2,3, Y Finashutina1,2, N Lyzhko1,2,
O Solopova1, L Kesaeva1,2, N Kasatkina1, E Misyurina4, E Pushkova2, A Uvarova1,
A Inshakov1, O Burova1, M Baryshnikovа1
1FSBI « N.N. Blokhin Russian Cancer Research Center», 2«GeneTechnology»
LLC, 3National Research Center for Hematology, Ministry of Health of Russia,
4City Clinical Hospital No52, Moscow, Russian Federation
Background: According to literature, PRAME (preferentially expressed antigen
in melanoma) protein may be exposed on extracellular membrane. Interestingly,
that PRAME is structural homolog of TLR2 protein. TLR2 activates NF-kB sig-
naling pathway and NF-κB activates an expression of TLR2. As a result, TLR2-
mediated activation of expression TLR2 is possible event. If PRAME is similar
to TLR2, it’s possible to suggest PRAME-mediated activation of its own expres-
sion. PRAME protein is expressed in a wide range of cancers. In addition, this
protein is non-active in cells of somatic tissues and is highly immunogenic. If
PRAME is expressed in a tumor cell, it’s possible to increase an expression
level of PRAME; this can lead to higher immunogenicity of tumor cells. This
method could be a powerful in context of specific anti-PRAME immunotherapy.
Aims: To show that intracellular PRAME protein expression level is increased
in case of binding anti-PRAME antibody with cell membrane.
Methods: We created a mouse monoclonal antibody 5D3F2, specifically rec-
ognizing PRAME antigen. Tree cell lines were used for incubation with anti-
PRAME antibody: acute monocytic leukemia cell line THP-1, acute myeloid
leukemia cell line NOMO-1 and disseminated melanoma cell line mel IBR.
Expression level of PRAME gene was evaluated by RQ-PCR. Cell lines THP-
1 and NOMO-1 were incubated in RPMI 1640 with addition of anti-PRAME
antibody. Antibody concentration was 10 ug/ml, and amount of cells counted
10000/ml. Samples of cells was analyzed after 1, 2 and 4 hours and after 1, 2
and 3 days of incubation. Number of PRAME-expressing cells was determined
by flow cytometry using a FITC-labeled antibodies 5D3F2. All experiments were
repeated 3 times.
Results: PRAME gene expression level was 1,67% in THP-1; 0,46% in NOMO-
1 and 963% in mel IBR relative of ABL expression level before experiment.
According to flow cytometry data, number of PRAME-expressing cells THP-1
and NOMO-1 before experiment was 11,4% and 3,6%, respectively. Intensity
of PRAME-expressing cells in THP-1 fluorescence after incubation with anti-
body 5D3F2 was 101,21% (after 1 hour), 75,79% (2 hour), 88,45% (4 hour),
421,28% (1 day), 433,33% (2 day) and 820,37% (3 day). Fluorescence intensity
of PRAME-expressing cells in NOMO-1 after incubation with antibody 5D3F2
was 93,88% (1 hour), 87,07% (2 hour), 74,67% (4 hour), 175,45% (1 day),
562,67% (2 day) and 146,33% (3 day).
Summary/Conclusions: PRAME protein is expressed on THP-1 and NOMO-
1 cell surface. Antibody 5D3F2 binds with cell membrane and it could explain
decrease of fluorescence intensity in first hours. FITC-labeled 5D3F2 show this
reduction because many PRAME epitopes are closed by non-labeled 5D3F2.
But after 1 and more days number of PRAME epitopes on cell surfase grows,
and flow cytometry reaction displays it. This finding suggests that it is possible
to develop an anti-PRAME monoclonal antibody for therapy PRAME-positive
disease. Moreover, PRAME expression level may be increased during therapy
with these antibodies. It can be useful, because PRAME-expressing cell
becomes more immunogenic after binding with a potential therapeutic anti-
PRAME antibody. We did not investigate the role of NF-kB, but it will be our
next challenge.
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ABERRANT IMMUNOPHENOTYPES IN B-ACUTE LYMPHOBLASTIC
LEUKEMIA
F Ceran, M Falay, Y Kalpakci, S Dagdas, G Ozet, DN Avci*
Hematology, Ankara Numune Education and Research Hospital, Ankara, Turkey
Background: Recently immunophenotyping has a critical role for diagnosis
and classification of leukemia and lymphoma. Immunophenotyping is used
increasingly for identification of some subtypes, treatment follow-up of minimal
residual disease (MRD) and even for prognostic purposes. Also, myeloid and
T cell aberrant antigen expressions help to distinguish B acute lymphoblastic
leukemia (B-ALL) from hematogones.
Aims: The aim of this study was to evaluate myeloid and T cell aberrant expres-
sions in B-ALL patients who had been referred to our flow cytometry center.
Methods: We retrospectively analyzed the flow cytometry data of newly diag-
nosed 417 B-ALL samples which were collected in our laboratory between the
years 2002-2016. We used a large panel of monoclonal antibodies against lym-
phoid, myeloid and precursors antigens.
Results: Aberrant antigens were detected in 143/417 (34.29%) of B-ALL
patients. Expression of myeloid antigens was a common aberrancy in B-ALL.
The leukemic lymphoblasts exhibited aberrant expression of 4 myeloid antigens
and 5 T-cell antigens. The most frequently expressed antigen was CD33
(74/143), followed by CD13 (57/143), MPO (2/143), and CD11b (1/143). Dual
expression of CD13 and CD33 was seen in 24 patients. Expression of T-cell
aberrant antigens was observed in only 8 patients. CD2 was positive in 3
patients, CD5 was positive in 2 patients, and CD3, CD7, CD56 were positive
separately in 3 patients.
Summary/Conclusions: Aberrant antigen expression is important in MRD fol-
low-up, also it is reported to be associated with prognosis and cytogenetic
abnormalities. In literature, adult B-ALL cases expressing CD13 and CD33
have been reported to be related to BCR-ABL positivity. MPO aberrant antigen
expressions are very rare and BCR-ABL has been reported mostly negative in
MPO positive patients. We have detected MPO aberrant antigen expression in
2 patients, none of them has BCR-ABL positivity. Expression of T-cell antigens
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has rarely been reported in B-ALL, and the significance of this aberrant antigen
expression is unclear. Several studies showed that T-cell aberrant expression
leads higher relapse risk and it is associated with adverse cytogenetic abnor-
malities.
PB1607
THE EXPRESSION LEVEL OF HLS5 IS CORRELATED WITH THE
CLINICAL OUTCOMES OF ACUTE LYMPHOID LEUKEMIA (ALL) PATIENTS
J Huang1,*, J CHEN2, J JIN3
1Hematology, the Fourth Affiliated Hospital, College of Medicine,Zhejiang Uni-
versity, Yiwu, 2Institute of Hematology, Zhejiang University, 3Department of
Hematology, the Fourth Affiliated Hospital, College of Medicine,Zhejiang Uni-
versity 2Department of Hematology, the First Affiliated Hospital, College of
Medicine and3 Institute of Hematology, Zhejiang University, Hangzhou, China
Background: HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil) fam-
ily, a family of tumor suppressive genes including Pm, Tif1-α,Herf and Rfp, it
has been reported to regulate erythroid differentiation, to be activated during
the conversion of J2E erythroleukemic cells to monocytoid cells, and assumed
to be a tumor supressor. However, the role of HLS5 in acute lymphoblastic
leukemia has never been explored.
Aims: To identify the expression of HLS5 and the relationship to the clinical
outcom to ALL.
Methods: Bone marrow of 63 de novo ALL patients were collected, the
mononucleated cells separated, RNA extracted and the HLS5 expression level
detected using real-time quantitative PCR. SPSS 16.0 used for data analysis.
Results: The high HLS5 expression level (the higher 25% of all the patients)
is correlated with longer overall survival and event free survival (both p˂0.05),
but the correlations between HLS5 expression level and blast count, WBC, Hb
level, platelet count, IK6 status and Ph chromosome status are not significant.
Summary/Conclusions: The expression level of HLS5 in de novo ALL patients
may associate with the clinical outcome, but the exact mechanism needs further
investigation.
Acute lymphoblastic leukemia - Clinical
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COMPARISON OF THE PROGNOSTIC SIGNIFICANCE OF MINIMAL
RESIDUAL DISEASE AND THE CONVENTIONAL PROGNOSTIC FACTORS
IN THE TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA
PATIENTS
S Lozenov1,*, B Spassov1, Y Petrov1, V Stoeva1, T Yankova1, K Ignatova1,
Y Zhechev1, M Staneva1, T Mihailova1, D Peichev1, S Simeonov1, D Nihtyanova1,
M Guenova2, G Balatzenko3, M Donchev1, G Arnaudov1, G Mihaylov1
1Clinical hematology department, 2Hematopathology department, 3Molecular
biology and cytogenetics laboratory, Nshathd, Sofia, Bulgaria
Background: During the past couple of decades the response rates, the
leukemia free survival and the 5 year overall survival (OS) in adult patients with
acute lymphoblastic leukaemia (ALL) have improved significantly. There is an
ongoing trend to improve further OS through better risk assessment. The risk
stratification in different treatment protocols is usually based on groups of con-
ventional prognostic risk factors, such as – white blood cells count (WBC) at
diagnosis, immunophenotype, cytogenetic and molecular abnormalities, achieve-
ment of CR and time to achievement of CR, age with some variations among the
different study groups. To improve the results of risk stratification through the
conventional risk factors, the evaluation of the level of minimal residual disease
(MRD) and its use for treatment decision making have been introduced. Several
studies have already established the contributory role of MRD levels for the pre-
diction of relapse and continuous complete remission (CCR) in the ALL patients.
Despite the growing involvement of MRD evaluation in the risk stratification of
adult ALL patients, there is a continuing need to better address the specific role
MRD examination should play among other ALL prognostic factors and to better
establish the best time point for ALL MRD evaluation.
Aims: With the present retrospective assessment we aimed to compare the
impact of minimal residual disease and a group of conventional prognostic fac-
tors on the overall survival of adult ALL patients.
Methods: We analyzed retrospectively 81 patients with adult ALL, that were
treated in the National Specialized Hospital for Active Treatment of Hematology
Diseases (NSHATHD) between 1.1.2009 and 1.1.2016, of them 53 were CR
achievers. The minimal residual disease (MRD) levels of the patients were
measured through 8-color flow cytometry and through semiquantitative RT-
PCR, following the BIOMED 1 program protocol for the patients with a MLL-
AF4 and BCR-ABL fusion transcripts chromosome. MRD negativity or molec-
ular complete remission (molCR) was defined as a level of less than 10-4 ALL
cells or lack of expression of fusion transcripts.
Results: MRD negativity had a statistically significant impact on OS 70.3% vs
10.7% for the MRD negativity non-achievers. The conventional risk factors did
not seem to convey greater prognostic significance with differences between
conventional risk groups in terms of OS not reaching statistical signifcance
and the multivariate analysis demonstrating significance only of MRD status,
WBC and PSECOG with hazard ratios of 5.241, 3.070, 2.061, respectively.
Allogeneic hematopoietic stem cells transplantation significantly improved OS
in the patients who did not achieve MRD negativity with 3-year overall survival
of 38.9% vs 11.7%.
Summary/Conclusions: The impact of molCR status on survival will probably
lead to new risk stratification strategies based to a greater extent or even exclu-
sively on the MRD status. The optimal time for MRD risk stratification remains
to be established.
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PROGNOSTIC IMPACT OF CD20 EXPRESSION IN ADULTS WITH
PHILADELPHIA CHROMOSOME NEGATIVE PRECURSOR B-CELL ACUTE
LYMPHOBLASTIC LEUKEMIA
I Djunic1,2,*, M Virijevic2, N Kraguljac-Kurtovic2, V Knezevic2, T Dragovic-
Ivancevic2, A Novkovic1,3, M Mitrovic1,2, N Colovic1,2, A Vidovic1,2, N Suvajdzic-
Vukovic1,2, D Tomin1,2
1Medical Faculty of Belgrade University, 2Clinic for hematology, Clinical Center
of Serbia, 3Clinical Hospital Center “Zemun”, Belgrade, Serbia
Background: Prognostic influence of immunophenotypic markers in acute
lymphoblastic leukemia (ALL) is well recognized. The prognostic significance
of CD20 expression in precursor B-cell acute lymphoblastic leukemia (ALL)
has been investigated first in childhood and than in adult with conflicting results.
Aims: The aim of this study was to determine the prognostic impact of CD20
expression on outcome in adult patients with Philadelphia chromosome nega-
tive (Ph-) precursor B-cell ALL. The second goal was to estimate, in comparison
to the results, is there a need to incorporate monoclonal anti CD20 antibody
(Rituximab) in routine treatment of these patients, where it is not available, to
improve their outcome.
Methods: This single center study involved 122 patients with de novo Ph- pre-
cursor B-cell ALL diagnosed in period 2003 – 2015, with follow-up period of 72
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months. For CD20 antigen expression, detected by flow-cytometry, the cut-off
value ≥20% was taken as positive (CD20+). As risk factors for rate of complete
remission (CR) and overall survival (OS) in months in this cohort of patients
the following were evaluated: age, leukocytosis (<30x109/L vs ≥30x109/L) and
CD20 expression. In period of 2003 – 2006, the patients were treated with reg-
imen LALA 94, while in period 2007-2015 they were treated with protocol Hyper-
CVAD. The applying of monoclonal anti CD20 antibody (Rituximab) with
chemotherapy was no available.
Results: The mean age of the patients was 42 years (range 19-77). The
CD20+was recorded in 41 (33.6%) of patients. The estimated risk factors had
no influence to achievement of CR. However, the univariate analysis showed
that age ≥55 years (p=0.035) and CD20+(p=0.042) had significant impact on
poor OS. Multivariate analysis indicated CD20+as the most important risk factor
for poor OS: p=0.001, HR=3.853(95% CI=1.755-8.461.
Summary/Conclusions: This study showed the negative impact of CD20
expression in Ph- precursor ALL on outcome of these patients. Also, we point
out the importance of incorporation monoclonal anti CD20 antibody (Rituximab)
in combine with chemotherapy in routine treatment of these patients to improve
its outcome.
PB1610
CLINICOPATHOLOGIC CHARACTERISTICS ASSOCIATED WITH NATURAL
KILLER CELL ACTIVITY BY MEASUREMENT OF INTERFERON-GAMMA
IN HEMATOLOGIC MALIGNANCIES
S Park1, YC Mun2, CM Seong2, HJ Huh3, J Huh1,*
1Laboratory Medicine, 2Internal Medicine, Ewha Womans University College
of Medicine, Seoul, 3Laboratory Medicine, Dongguk University, Ilsan Medical
Center, Ilsan, Korea, Republic Of
Background: Natural killer (NK) cells play a key role in innate immune responses
and an important component of anti-cancer defenses. Evaluation of NK cell activity
could be invaluable to estimate the status and the outcome of cancers. Defects in
NK cell cytotoxicity have been reported in hematologic malignancies. Conventional
methods such as 51Cr release assay and CD107a degranulation assay may be
useful to determine NK cell activity, but they require complex experimental setups
and are not appropriate for routine laboratory test. Recently, a commercialized kit
for measurement of NK cell activity was developed, which measure released inter-
feron-gamma secreted by ex vivo stimulated NK cells in whole blood.
Aims: The purpose of this study was to investigate clinicopathologic charac-
teristics associated with NK cell activity by measurement of interferon-gamma.
Methods: The study group included 134 patients (61 at diagnosis and 73 at
follow up) diagnosed as having hematologic malignancies between Mar 2015
and Jan 2016. The NK cell activity was measured by commercialized kit (NK
Vue assay, ATgen, Sungnam, Korea), which is a quantitative sandwich ELISA
to measure released interferon-gamma secreted by NK cells in whole blood
collected in PROMOCA tube (an engineered recombinant cytokine that specif-
ically activates NK cells). NK cell activity was expressed as ratio which patient’s
result was divided by upper normal level. NK cell activity was analyzed using
294 specimens obtained from patients at diagnosis or follow up.
Results: The median ratio value of NK cell activity was 1.27 (range: 0.03-8.0).
Comparing with NK cell activity of 61 patients at diagnosis (12 AML, 5 ALL, 3
CML, 2 MDS/MPN, 11 MM, 25 lymphoma, 3 solid cancer), ALL patients had
significantly decreased NK cell activity (median: 0.16, range: 0.16-0.26) than
lymphoma patients (median: 1.05, range: 0.03-2.35, P=0.0196). No significant
differences were found among other hematologic malignancies at diagnosis.
Among the total patients including at diagnosis and follow up, NK cell activity
was positively correlated with percentage of lymphocytes (r=0.346, P<0.0001),
whereas NK cell activity showed weak negative associations with total WBC
counts (r=-0.126, P=0.0324), neutrophil counts (r=-0.155, P=0.0083) and NLR
(neutrophil/lymphocyte ratio) (r=-0.227, P<0.0001). Of particular, NK cell activity
had positive correlations with percentage of lymphocytes in patients with AML
(r=0.693, P=0.0125), lymphoma (r=0.502, P<0.0001) and multiple myeloma
(r=0.427, P=0.0011). The regression analysis between NK cell activity and lym-
phocyte subsets identified by flow cytometry (CD56+NK cell, CD3+T-cell,
CD4+T-cell and CD19+B-cell) did not show significant associations except for
CD8+T cell counts (r=0.159, P=0.0083). The CRP didn’t show a significant
association with NK cell activity(r=0.126, P=0.6076).
Summary/Conclusions: This study showed that the NK cell activity was sig-
nificantly decreased in ALL patients, comparing with that of lymphoma patients
and NK cell activity was not correlated with NK cell counts identified by flow
cytometry. NK cell assay by measurement of interferon-gamma secreted by ex
vivo stimulated NK cells in whole blood, could be useful to evaluate and monitor
the NK cell activity in hematologic malignancies.
PB1611
MINIMAL RESIDUAL DISEASE: COMPARISON BETWEEN TWO METHODS
IN A CLINICAL DIAGNOSTIC LABORATORY.
A Lemes*, L Torres, D Fiallo, DLI Silvia, C Bilbao, GC Maria Teresa, T Molero
Hematología, Hospital Universitario de Gran Canaria Doctor Negrín, Lasd Pal-
mas de Gran Canaria, Spain
Background: Flow cytometry and molecular techniques are the most important
methods for monitoring minimal residual disease (MRD) in leukemia.
Evaluation of specific molecular markers represents the most sensitive and
specific analysis in MRD leukemia, however the existence a small number of
markers which in few cases are valid to follow the course of the disease is a
limiting factor. Because of this, there is the necessity to identify new widely rep-
resented markers in AML and that could predict relapse
On the other hand, immunophenotype associated to leukemia (LAIP) have
been proved to be very useful in the detection of MRD and it can be used up
to 85% of patients.
Aims: The aim of this study was to compare the concordance of MRD meas-
ured by flow cytometry with standardized molecular techniques including NPM1,
Inv16 and AML1-ETO. Furthermore, we also analyzed the behavior of WT1 at
this respect in order to determine whether overexpression of WT1 could be a
new MRD marker.
Methods: A total of 35 samples of bone marrow from patients with AML in dif-
ferent stages of the disease were assessed. We analyzed NPM1, Inv16 and
AML1-ETO by using the gold standard quantitative PCR techniques and these
results were compared first with the results obtained by flow cytometry, and
then with WT1 levels measured through non standardized quantitative PCR.
In order to analyze antigen expression by flow cytometry, we used a combina-
tion of eight monoclonal antibodies, according to the panels and procedures
suggested by EuroFlow Group. We analyzed about 1,000,000 events to asses
MRD with a sensitivity of 10-4, so MRD was registered as positive when we
detected at least 100 events with LAIP, (MRD=0.01%).
Results: Our results revealed:- High concordance between MRD by Flow
Cytometry and standardized molecular techniques, with a sensitivity of 88%
and a specificity of 72% (Table 1). However, when we compared standardized
vs non standardized techniques, WT1 showed a sensitivity of 100% and speci-
ficity of 47% (Table 2).
Table 1.
Table 2.
Summary/Conclusions: 1. Flow cytometry is a useful tool for detecting MRD
in AML. However, it is important to establish cutoffs to predict relapse in the dif-
ferent stages of the disease.2. The results regarding WT1 may reflect the lack
of standardization in the quantification of the marker, although it shows high
specificity for the presence of disease.
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SEASONAL CLUSTERING OF ADULT ACUTE LEUKEMIAS IN A SUB-
TROPICAL AREA OF BRAZIL
I Lorand-Metze1,2,*, RA Pereira3, KB Pagnano2, K Metze3
1Internal Medicine, 2Hematology/Hemotherapy Center, 3Pathology, University
of Campinas, Campinas, Brazil
Background: Seasonal peaks in the diagnosis of acute leukemias have been
reported in different countries all over the world. These peaks may be caused
by temporal changes in environmental factors (pollutant agents, allergens,
pathogens) or by the known seasonal changes in the human immune system.
Particularly, childhood acute lymphoblastic leukemia (ALL) has been studied,
but results are inconsistent. Winter peaks have been found in Sweden, Finland,
Iran, and South Africa, but a summer peak has been described in England.
Brazil is a large country with latitudes ranging from the equator to sub-tropical
areas. The Tropic of Capricorn passes near the city of São Paulo. So, the state
of São Paulo has a hot and rainy summer, and a dry winter with days of low
temperatures in the night.
Aims: We examined the seasonal trends in adult acute leukemia in our region
analyzing the relation between the number of newly diagnosed cases of ALL
and AML per month and maximum and minimum temperatures, as well as plu-
vimetric data during the last 25 years.
Methods: We examined the monthly number of newly diagnosed cases of AML
and ALL (age <18 years) and its relation to monthly maximal, minimal and medi-
an temperatures as well as the amount of rainfall.
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Results: During this period, 1303 AMLs and 236 ALLs entered the study. Con-
cerning ALL, there was a significant positive correlation between the absolute
minimum monthly temperature, the pluviometric index of the month of diagno-
sis, as well as these features in the 3 previous months. In a multiple regression
analysis, only the pluvimetric index of the month before diagnosis entered into
the final model (r=0.177; p=0.001). Concerning AML, there was a significant
positive correlation (r=0.12; p=0.01) only with the absolute maximum temper-
ature of the month of diagnosis. None of the other variables examined were
found to be significant.
Summary/Conclusions: We observed a seasonal variation in the diagnosis
of adult ALL related to temperature and especially to rainfall in the months pre-
ceding the diagnosis. This may be associated with a higher incidence of envi-
ronmental allergens or infections in the more humid months of the year, leading
to the outbreak of the disease, as has also been postulated for childhood and
adult ALL in other countries. Concerning AML, a clear relation was found only
with actual high temperature peaks. Perhaps, the temperature stress could
provoke decompensation of an already existing bone marrow failure making
the patients seek for medical assistance. This does not exclude that other envi-
ronmental factors related to the pathogenesis of AML may act with different
intensities in different climatic conditions.
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PROGNOSIS OF CHILDREN WITH ACUTE HYPERLEUKOCYTIC
LYMPHOBLASTIC LEUKEMIA TREATED WITH MODIFIED ST JUDE TOTAL
XV PROTOCOL
M Cetin*, S Aytac, C Dogancay Karahan, B Kuskonmaz, S Unal, F Gumruk,
M Tuncer
1Pediatric Hematology, Hacettepe University, Ankara, Turkey
Background: Acute leukemias with high white blood count (greater than or
equal to 100,000/mm3) have a poor prognosis with an increased risk of early
morbidity and mortality.
Aims: In this study we aim to analyse outcome of all complications due to
hyperleucocytosis including tumor lysis syndrome, hyperuricemia, renal failure,
disseminated intravascular coagulation and treatment modalities of these com-
plications during remission induction beside long term outcome.
Methods: Between January 2008 to December 2015, 206 children with ALL
were diagnosed at Hacettepe University Faculty of Medicine, Ihsan Dogramaci
Children’s Hospital. However 33 were excluded from the study (infant leukemia
(n=11), relapse ALL referred to our center and/or initialy treatment was given
by another center (n=6), secondary ALL(n=1), mature B cell ALL(n=7), early
death (n=7), lost to follow up(n=1)). 173 remained in the study and 20 out of
173 were diagnosed as hyperleukocytic high risk acute ALL.
Results: There were 8 female,12 male with a median age of 5 years old (between
1 to16,7 years). Mean initial WBC conunt is 206x103/µl (119-462x10-3/µl). 9 were
T cell immunophenotype however 8 were Calla+B cell and 3 were Calla-B cell
phenotype. Initial CNS involvement was 33% among these hyperleukocytic ALL
patients. Translocation (9;22) was found to be positive in 2 and they received
allogeneic hematopoeitic stem cell transplantation. MRD status by flowcytometer
was done on the 15th day of remission induction and all except one was found
to be under <0.1%. Relapse was observed 3 out of 20 (15%) in this group(com-
bined relapse BM+CNS(n=1), isolated CNS(n=1), isolated bone marrow (n=1)).
However all patients including 3 HSCT patients and relapse patients were in
complete remission and alive.
Summary/Conclusions: In our study hyperleukocytic high risk All patients did
show slightly improved survival when compared with the literature.
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THE POTENTIAL EFFECT OF CATHEPSIN B ON THE CLINICAL COURSE
OF CHILDHOOD ALL
B Zalewska-Szewczyk1,*, P Gorniak2, W Justyna1, S Janczar1, K Wyka1,
W Mlynarski1
1Department of Pediatrics, Oncology, Hematology and Diabetology, Medical
University of Lodz, Lodz, 2Department of Hematological Diagnostics, Institute
of Hematology and Transfusiology, Warsaw, Poland
Background: Cathepsins belong to the ubiquitous family of lysosomal cysteine  
proteases responsible for the conversion and degradation of intracellular pro-
teins. In many types of cancer increased overexpression of cathepsin B (CTSB)
was observed, in some solid tumors, overexpression of cathepsin B and L is
considered a negative prognostic factor. Published pilot data showing a rela-
tionship between an increased expression of cathepsin B and L (CTSB, CTSL)
and a worse outcome in acute myeloblastic leukemia.
Aims: The aim of this study was to evaluate the potential significance of CTSB
expression in childhood ALL.
Methods: CTSB expression was evaluated in bone marrow cells collected at
the time of diagnosis in 32 children aged 1.4 to 17.9 years, mean 7.16, 17 boys
with newly diagnosed acute lymphoblastic leukemia who were treated at a single
center according the protocol ALL IC 2002. In the bone marrow samples taken
at the diagnosis RNA was isolated, in a further step of reverse transcription reac-
tions were carried out using a commercially available kit (Applied Biosystems,
USA). Determination of the expression was performed by real-time PCR.
Results: For the further analysis the expression above the upper quartile was
defined as high. It was observed that the children with high CTSB expression
were diagnosed at a younger age (median 6.51 vs 2.41 years, p=0.047). There
was no correlation between the level of expression of CTSB in leukemia cells
and WBC at baseline (p=0.31). The CTSB expression level in leukemia cells
had no effect on the activity of L-asparaginase after the first dose (median of
89.42 IU/L vs 93 IU/L, p=0.226), early response (status bone marrow 15th day
of induction, p=0.256), the response to steroid therapy (p=0.53) and the status
of the CNS (p=0.37).
Summary/Conclusions: In summary, this pilot study may suggest the potential
importance of CTSB in acute lymphoblastic leukemia in children. Further analy-
sis in a larger study group is needed.
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HEPATIC VENOOCCLUSIVE DISEASE DURING TREATMENT OF ACUTE
LYMPHOBLASTIC LEUKEMIA MANAGED WITH DEFIBROTIDE
H Kızılocak, N Ozdemir*, G Dikme, T Celkan
Pediatric Hematology Oncology, Istanbul University, Cerrahpasa Medical Faculty,
Istanbul, Turkey
Background: Hepatic venoocclusive disease (VOD) which is the non-throm-
botic obliteration of small intrahepatic veins, presents with the clinical triad of
jaundice, hepatomegaly, and/or upper right quadrant pain and ascites. Definitive
diagnostic tests are not available.
Aims: VOD is a common complication of cytoreductive therapy used for
hematopoietic stem cell transplantation (HSCT). However, it may develop dur-
ing conventional-dose treatment of acute lymphoblastic leukemia (ALL), and
even more rarely, during induction treatment.
Methods: We describe four patients in whom VOD developed during induction
treatment for ALL.
Results: All of the four cases, three male and one female, were diagnosed
with B-cell ALL. One of them developed VOD at the end of his first protocol
phase-1 (P1F1), day 31 of his treatment and presented with hepatomegaly,
direct hyperbilirubinemia and increased liver transaminases. The patient’s ultra-
sonography of the liver with doppler studies showed minimal ascites and rever-
sal of flow in the portal veins which suggests the presence of VOD. Other three
cases developed VOD at second cytarabin (ARA-C) block of the protocol 2
phase 2 (P2F2) and presented with abdominal distension, weight gain,
hepatomegaly, ascites, direct hyperbilirubinemia, severe thrombocytopenia,
anemia, increase of liver transaminases and abnormalities of coagulation. Defi-
brotide was started at a dose 25 mg/kg/day and VOD recovered both with clin-
ical and laboratory findings at all patients.
Summary/Conclusions: Hepatic venoocclusive disease not only develops
after HSCT, but also may develop during treatment for ALL. All patients with
elevated liver enzymes, ascites, hepatomegaly, hyperbilirubinemia and severe
thrombocytopenia must be evaluated for VOD.
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STUDY OF BONE DENSITY AND OSTEOCALCIN LEVEL IN CHILDREN
WITH ACUTE LYMPHOBLASTIC LEUKEMIA
A Elsharkawy1,*, M Salama1, K Moghazy2, A Elhadidy3, M Youssef1
1pediatrics, 2Radiology, 3Clinical Pathology, Alexandria university, Alexandria,
Egypt
Background: Leukemias are the most common malignant neoplasms in child-
hood, with acute lymphoblastic leukemia (ALL) accounting for 75% of all child-
hood leukemias and 30% of all childhood cancers. An increasing number of
children survive ALL, approaching approximately 80% over the last 2 decades,
as a result of improved and more intense chemotherapy. Musculoskeletal
abnormalities are well recognized in children with ALL at diagnosis, during
treatment, and persist as long-term sequelae after treatment. Osteotoxic
chemotherapy, steroid exposure, poor nutrition, low vitamin D, and poor muscle
mass contribute to the development or worsening of bone pathology during
therapy that may result in osteoporosis, fracture, and osteonecrosis. Risk-
directed therapy has substantially improved treatment outcomes for pediatric
ALL, with 5-year survival rates approximating 80% . Given success of this mag-
nitude, it is important to address the management and prevention of bone tox-
icity. The current study evaluated the bone density and alterations in biochem-
ical mineral status in children with ALL at time of diagnosis, during chemother-
apy and after finishing chemotherapy.
Aims: To study Bone density and serum osteocalcin level in children with acute
lymphoblastic leukemia.
Methods: Serum osteocalcin and DXA scan were evaluated in 45 children
with ALL,15 at diagnosis and before starting chemotherapy, 15 during
chemotherapy and 15 after completing their treatment regimen.
Results: From the total 45 patients, 23 (51.1%) had low osteocalcin level and
662 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
36 (80%) had low bone mineral density (48% had osteopenia and 32% had
osteoporosis).
Summary/Conclusions: Musculoskeletal abnormalities are present in children
with ALL at diagnosis, during treatment, and persist as long-term sequelae after
treatment.
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EARLY IDENTIFICATION OF CALM-AF10 MUTATION BY MOLECULAR
PROFILING HELPS TO RISK STRATIFY HIGH RISK T-ALL FOR EARLY
VUD ALLOGENEIC BONE MARROW TRANSPLANT
A Dicu1, J Russell2, D Shor1, T Klemencickozul3, S Wedderburn4, W Knibbs1,
B Manasse5, D Bloxham6, J Morgan1, H Warner-Charlick7, A Hodson8,
M Prahladan9,*
1Haemato Oncology, 2Haemato-Oncology, Ipswich Hospital, Ipswich, 3Haemato
Oncology, Ipswich Hospital, Cambridge, 4Haemato Oncology, Ipswich Hospital
NHS trust, Ipswich, 5Haemato Oncology Diagnostic centre, Addenbrookes Hos-
pital, 6Haemato oncology diagnostic centre, Addenbrookes Hospital, Cambridge
University Hospital NHS Foundation trust, 7Haemato Oncology, Ipswich Hos-
pital/ Adddenbrookes Hospital, Cambridge UNiversity Hospital NHS Foudation
Trust., 8Haemato Oncology, Ipswich Hospital/ Addenbrookes Hospital, Cam-
bridge University Teaching Hospitals NHS Foundation Trust., 9Haemato Oncol-
ogy, Ipswich Hospital/Addenbrookes Hospital, Cambridge University Teaching
Hospital NHS Foundation Trust, Cambridge, United Kingdom
Background: The t(10;11)(p12;q23) and t(10;11)(p12;q14) translocations,
which encode the clathrin-assembly protein-like lymphoid myeloid leukemia
gene (PICALM)- MLLT10 (formerly CALM-AF10), are recurrent chromosomal
rearrangements found in some patients with T-cell acute lymphoblastic leukemia
(T-ALL), and are associated with poor outcomes to standard chemotherapy.
PICALM-MLLT10-positive cases often have positive expression of CD13, CD33
or CD34, but negative expression of the T-lineage markers CD5, TdT, cCD3
and CD7.
Aims: Mutational analysis on RT-PCR in conjunction with flow cytometry, fluo-
rescent in situ hybridization (FISH) and metaphase karyotyping, increases the
sensitivity for detecting primary and secondary cytogenetic abnormalities in
patients with high-risk T-ALL.
Methods: We report a 34-year-old lady with T-ALL who presented with a medi-
astinal mass. Blast cells in the bone marrow aspirate demonstrated strong
expression of CD7, CD13, CD56, HLA-DR, cytoplasmic CD3, and equivocal
expression of CD99. No other T-cell-associated antigens were detectable (includ-
ing CD1a, CD2, surface CD3, CD4, CD5, CD8, CD16, CD57, CD34 and TdT).
The T-Lymphoblastic Leukaemia FISH panel was negative. Chromosomal analy-
sis showed 46,XX,t(10;11)(p13;q14)[5]/46,XX, with balanced reciprocal translo-
cation between the short arm of chromosome 10 and the long arm of chromo-
some 11. Genome molecular profiling showed recurrent translocation PICALM-
MLLT10 [CALM-AF10];t(10;11)(p13;q14) with no disruption of the MLL (11q23)
locus, confirming the negative MLL FISH result. The patient achieved complete
remission following phase-two induction on the UKALL14 protocol and elected
to have a volunteer unrelated donor (VUD) myeloablative allogeneic bone mar-
row transplant. She remains in complete remission 14 months post-transplant.
Results: The positive outcome for our patient, following allogeneic transplant,
reflects similar reports from the UKALLXII/ECOG2993 trial for patients with the
MLLT10 [CALM-AF10];t(10;11)(p13;q14) mutation. The use of mutational analy-
sis on RT-PCR early in the diagnostic process, in this case, allowed prompt
detection of a high-risk cytogenetic abnormality and more accurate risk strati-
fication that guided the decision to proceed to allogeneic transplant.
Summary/Conclusions: Early identification of high risk cytogenetic abnormality
incorporating mutational analysis using RT -PCR along with immunophenotype,
FISH and karyotype help to risk stratify patients for allogeneic bone marrow trans-
plant resulting in successful outcome in patients with in high risk T-ALL.
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THE INCIDENCE OF ACUTE LEUKEMIA IN SOME REGIONS OF THE
RUSSIAN FEDERATION
A Zalina1,*, S Kulikov1, M Rusinov1, E Zotina2, L Gavrilova3, A Pristupa4,
N Vopilina5, E Borisenkova6, E Parovichnikova1
1National Research Center for Hematology, Moscow, 2Kirov Clinic Hospital,
Kirov, 3Mordovia Republic Hospital, Saransk, 4Ryazan Regional Clinical Hos-
pital, Ryazan, 5Tambov Regional Clinical Hospital, Tambov, 6Kaluga Regional
Clinical Hospital, Kaluga, Russian Federation
Background: The incidence of acute leukemia (AL) in US and European coun-
tries is about 5 per 100000 according data from cancer registries. Russian Fed-
eral Сancer Register (RFCR) reported AL incidence rate across the country as
about 3 per 100000.
Aims: To evaluate the age-gender specific incidence, profile and other epi-
demiologic characteristics AL in Russia regions.
Methods: Russian Hematology Society in 2013 initiated the AL population
based registry study in which participated 5 regions of Russia Federation. The
primary goal was to pre-registry patients for clinical studies, and secondary -
to evaluate the epidemiology of AL. 5 regions were included into analysis of
epidemiology statistics. The criteria were the fullness and reliability of AL cases
registration. Also, only regions with one big hematological center accumulating
all AL cases were chosen. All new cases were recorded on-line into special
Web based data capture system.
Results: The registry was started at 1st April of 2013 and is ongoing. 216 new
ALL cases from Kirov, Ryazan, Kaluga, Tambov regions and Mordovia republic
(4,7 M of population) were included into analysis. The distribution by AL sub-
types was following: AML - 131 (60,6%), ALL - 40 (18,5%), APL - 8(3,7%), other
- 37 (17,1%). Median age was for AML - 59 (17-85), ALL - 38 (16-80), APL 55
(38-79) years. Gender female/male proportions 121\95.
The incidence rate estimates by region are listed in Table1.
Table.1 Incidence of adult AL in 5 Russian regions.
Region                 Adult                        Registered            Duration             Incidence
                    population (106)                cases
                  All       M        F            All       M        F              (y)            All       M        F
Kirov           1.15    0.52    0.63          47       22       25           2.14          1.90    1.98    1.84
Mordovia    0.72    0.33    0.40          52       29       23           2.06          3.49    4.31    2.81
Ryazan       1.01    0.45    0.56          45       17       28           1.90          2.34    1.98    2.63
Kaluga        0.88    0.39    0.48          33       15       18           2.03          1.84    1.86    1.83
Tambov       0.95    0.43    0.52          39       12       27           1.98          2.06    1.41    2.60
The frequencies of AL cases in age strata are distributed as following: 5 (2,3%)
- in 15-19 age group; 39 (18%) - in 20-39 age group; 78 (36,1%) - in 40-59 age
group; 89 (41,2%) - in 60-79 age group; 5 (2,3%) - in 80-99 age group.
Summary/Conclusions: AL patients registered in the Russian Federation are
younger then AL patients of European registries (AML -58years vs 71years;
ALL - 38 years vs 54years, respectively). The significant percentage of uniden-
tified variants AL (17.1%) is a significant problem. We should emphasize that
the recorded incidence of AL in our study is quite low. It’s close of morbidity
estimations of RFCR, but notably lower than European and American registers.
This discrepancy can be explained by significantly reduced registration activity
and primary diagnostics of AL in the older age groups.
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PRIMING REGIMENTS BASED ON IDARUBICIN, OR ACLACINOMYCIN OR
PIRARUBICIN COMBINING WITH CYTARABINE AND G-CSF FOR
REINDUCTION OF REFRACTORY/RELAPSED ALL
J Zhu1, Y Miao2, Y Zhang3, Y Zhu4, H Zhu4, Z Wu1, G He4,*, J Li4
1Department of Hematology, the People’s Hospital of Taizhou, Yangzhou and
Nantong University, Taizhou, 2Department of Hematology, The First People´s
Hospital of Yancheng, Yancheng, 3Department of Hematology, The Second
People´s Hospital of Huaian, Huaian, 4Department of Hematology, JiangSu
Province Hospital,The First Affilated Hospital of NanJing Medical University,
Nanjing, China
Background: Acute lymphoblastic leukemia (ALL) is one of the most common
leukemias with complete remission(CR) rate between 70% and 90%. While the
refractory/relapsed ALL is more difficult to treat with poor prognosis. CAG regiment
was used for for 6 refractory/relapsed T-cell ALL patients and received high CR
rate. So how about CAG regiment for B-cell ALL? What is the situation after the
expansion of the cases ? Whether the response rate, adverse reactions would
be improved if we use other anthracyclines, such as idarubicin and pirarubicin
instead of aclacinomycin for the refractory/relapsed ALL? In our study, the IAG,
CAG or PAG regiments were used for refractory/relapsed acute lymphoblasti-
cleukemia respectively The response rate and adverse reactions were elevated.
Aims: To compare the therapeutic effects and adverse reactions of the
chemotherapies which were based on idarubicin, aclacinomycin or pirarubicin
combining cytarabine and granulocyte-colony stimulating factor as IAG, CAG,
and PAG regimens respectively, for refractory/relapsed acute lymphoblastic
leukemia.
Methods: The priming reinduction regiment was used to 43 cases with refrac-
tory/relapsed acute lymphoblastic leukemia (ALL). IAG, CAG and PAG regi-
ments were non-randomly used to 13, 18 and 12 cases respectively. The clinical
effects and adverse reactions of three regiments were evaluated..The factors
which might affect the clinical effects were evaluated according to different
ages, immunophenotypings and white cell counts.
Results: he overall response rate (ORR) of the priming regiments was 62.8%,
with 46.5%(20) of complete remission (CR), 9.6% (7) of partial remissions (PR)
and 37.2% (16)of non-remission (NR). 7 (53.8%) CR and 2 (15.4%) PR were
observed in the IGA group with the ORR at 69.2%. In the CAG group, there
were 8 CR cases (44.4%) and 3 PR cases (16.6%) with the ORR at 61%. While
in the PAG group 5 CR cases (41.7%) and 2 PR cases (16.6%) with the ORR
at 58.3% were observed. There was no statistical difference of ORRs among
the three groups (P=0.837); no statistical difference of the ORRs between the
patients over and under 60 years old.(60.0% vs 54.3%; P=0.272); no statistical
difference was showed of the ORRs between the T-cell ALL and B-cell ALL
patients (68.4% vs 54.1%; P=0.542) and between hyperleukocytic group and
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non- hyperleukocytic group (50% vs 64.9%; P=0.808). Major adverse reactions,
including bone marrow suppression, infection, gastrointestinal reaction and
liver function impairment were tolerable after anti-infection, blood cell increasing
and transfusion therapy. 6 patients survived and 12 died in the CAG group, 5
cases survived and 8 died in the IAG group, and in the TAG group, the numbers
were 7 and 5. No statistical difference of survival time was found when com-
pared in pairs or simultaneously for the three groups.
Summary/Conclusions: Preliminary results show that the priming chemother-
apy regimens based on small doses of different kinds of anthracyclines were
effective on refractory/relapsed ALL patients with good tolerance, minor non-
hematological toxicity and side-effects.
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TEL-AML1 POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA-
SINGLE CENTRE EXPERIENCE
M Kourti1,*, V Sgouropoulou1, A Athanassiadou2, E Papakonstantinou2,
A Taparkou3, D Koliouskas1
1Pediatric Oncology Department, Hippokration General Hospital, 2Hematology
Department, Papanikolaou General Hospital, 3First Pediatric Department, Aris-
totle University of Thessaloniki, Thessaloniki, Greece
Background: The reciprocal translocation t(12;21)(p13;q22) is the most fre-
quent chromosomal rearrangement in childhood B-cell precursor acute lym-
phoblastic leukaemia (ALL), which results in a chimeric transcription factor
TEL-AML1 (ETV6-RUNX1) and is associated with favorable prognosis.
Aims: We performed a retrospective analysis of B-cell ALL patients who were
treated in the last five years in our department in order to investigate the inci-
dence, the clinical characteristics and cytogenetic features of TEL-AML1 pos-
itive patients.
Methods: Pretreatment bone marrow (BM) samples were successfully ana-
lyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) for the
molecular detection of the TEL/AML1 fusion gene. BM samples were also cul-
tured and analyzed by standard cytogenetic methods. The immunophenotype
was determined using a panel of monoclonal antibodies (MoAbs) with flow
cytometry.
Results: A total of 51 patients with ALL displayed G-banded karyotypes and
were informative for molecular analysis and were included for analysis. All
patients were treated according to ALLIC-BFM 2009 protocol. On the basis of
EGIL classification, the immunophenotype analysis permitted the characteri-
zation of 32 cases (62.7%) as pre-B ALL, 10 (19.6%) as common ALL and 9
(17.7%) as pro-B ALL. The TEL-AML1 fusion gene was identified in 11 patients
of which 7 (63.6%) had pre-B, 3 (27.3%) pro-B ALL and 1 (90.1%) common
ALL. The incidence of TEL-AML1 fusion gene was 21.6% (11/51 patients). The
TEL-AML1 positive patients were studied with regard to their gender and it
revealed that 7 were females and 4 males with median age of 4.16 (range:3.41-
13.16 years). The median leucocyte count was 8.3x109/L (range 2.6-67x109/L)
According to the presenting features, 91% of the TEL/AML1-positive cases
were enrolled in the IR group and 9% in the SR. Moreover, all TEL/AML1-pos-
itive cases lacked evidence for BCR/ABL and MLL/AF4 fusion mRNAs. No
structural chromosomal changes were noted in TEL-AML1 positive children.
Hyperdiploidy of 47-48 chromosomes was encountered in 18.18% (2/11) of
the children with TEL-AML1 rearrangement; however, none of TEL-AML1 pos-
itive patients had hyperdiploidy of more than 50 chromosomes. All cases were
prednisone good responders and they were all very early good responders
(minimal residual disease <10-3 at day 15. All patients are in continuous com-
plete remission with event-free and overall survival of 100%.
Summary/Conclusions: Conclusions: The TEL-AML1 fusion gene is a com-
mon genetic anomaly in childhood ALL patients and our results are consistent
with literature. Further investigation with a larger sample size and for a longer
time is warranted.
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MATRIX METALLOPROTEINASES 2 & 9 AND TISSUE INHIBITOR OF
MATRIX METALLOPROTEINASE 1 AS MAJOR PLAYERS IN CLINICAL
COURSE OF EGYPTIAN PEDIATERIC ACUTE LYMPHOBLASTIC
LEUKEMIA PATIENTS
E Kandel1, M Saleh1,*, M Khalil1, E Ebeid2, N Alieldin3
1Clinical Pathology, 2Pediatric oncology, 3Biostatistics and Cancer Epidemiol-
ogy, National Cancer Institute of Egypt, Cairo, Egypt
Background: Acute lymphoblastic leukemia (ALL) is the most frequent acute
leukemia affecting pediatric patients. Gelatinase B/matrix metalloproteinase -
9 (MMP9) as well as MMP-2 (gelatinase-A) and their inhibtor Tissue inhibitor
of matrix metalloproteinases (TIMP)-1 play a crucial role modulating the biology
of the cancer stem cell niche.
Aims: Study the impact of expression of MMP2, MMP9 and TIMP1, as well
as, MMP2/TIMP1 and MMP9/TIMP1 ratios on different facets of disease pro-
gression in pediatric ALL in terms of laboratory and clinical parameters having
prognostic significance, disease-free and overall survival .
Methods: Bone marrow samples were drawn from 53 Egyptian pediatric ALL
patients presented to Pediatric Oncology Department, National Cancer Insti-
tute, Cairo University. An informed consent in accordance with the Declaration
of Helsinki was obtained. Intracytoplasmic MMP-9 FITC, MMP-2 PE and
TIMP-1 FITC was done. MoAbs were supplied from R&D system(614 McKin-
ley Place NE, Minneapolis, MN 55413) analysis was done within 24 hours of
sampling. Sample analysis was done by multicolor flow cytometry (Coulter
Epics XL, Hialeah, USA). Gating strategy was applied using dim CD45/side
scatter. Data analysis was done on Winlist 6 (Verity Software House, Top-
sham, ME).
Results: The study included 53 pediatric ALL patients, 34 males and 19
females, age ranged from 1-18 year with a median of 6 years. A significantly
higher total leukocyte count (TLC) among TIMP-1 positive ALL cases and a
borderline significantly higher TLC among MMP9 positive ones (P=0.03 and
0.06, respectively) were found. As regards clinical parameters, hepatomegaly
was higher among MMP-9 positive cases (P=0.03). Regarding the relation of
MMP2 and MMP9 in to their inhibitor; MMP2/TIMP1 ratio was significantly cor-
related to MMP9/TIMP1 ratio (p<0.001).
ROC curve using MMP2/TIMP2 ratio as greater than or equal to 0.02 will detect
MRD D42 response (negative or <0.01) with a sensitivity of 73.7%, specificity
of 72.7%, positive predictive value 82.4% and negative predictive value of
61.5%. A low MMP2/TIMP1 ratio correlated significantly with presence of
splenomegaly (p<0.02). Patients with MMP2/TIMP1 ratio <2.0% had shorter
overall survival with mean 48±3.4 months as compared to those with ratios
≥2.0% (p=0.04).
Summary/Conclusions: MMP2, MMP9, TIMP1expression as well as,
MMP2/TIMP1 and MMP9/TIMP1 ratios had influential implication on disease
progression and clinical course on pediatric acute lymphoblastic leukemia.
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OUTCOME OF ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC
LEUKEMIA IN THE IMATINIB ERA IN THE SOUTH OF TUNISIA
I Frikha1,*, M Medhaffer1, S Hadiji1, O Kassar1, S Mnif2, H Bellaaj1, M Ghorbel1,
F Kallel1, N Ben Abdeljalil3, H Sennana4, M Elloumi1
1Hematology, Hedi Chaker Hospital, Sfax, Tunisia, Sfax, 2Pasteur Institute,
3CNGMO, Tunis, 4cytogenetic laboratory, Sousse, Tunisia
Background: The Philadelphia chromosome (Ph), t(9;22), is seen in about 20
to 30% of adults diagnosed with acute lymphoblastic leukemia (ALL). It has
been associated with poorer prognosis. Tyrosine kinase inhibitors (TKIs) tar-
geting the BCR-ABL oncogenic protein from this translocation have been incor-
porated into treatment regimens used to treat patients with Ph-positive ALL. In
this study we analyzed the clinical, biological features and therapeutic results
of patients with Ph ALL treated with chemotheray and Imatinib.
Aims: Determinate the outcome of Philadelphia acute lymphoblastic leukemia
in the era of Imatinib in the South of Tunisia
Methods: From January 2007 to March 2015, 10 patients aged 21 to 55 years
diagnosis with de novo Philadelphia chromosome–positive acute lymphoblastic
leukemia, in the department of clinical hematology of Hedi Chaker Hospital,
and treated according to the GRAAPH protocol. Cytogenetic analysis and Bcr-
Abl transcript was performed for all patients. Imatinib was associated with
chemotherapy since 2007 at a dose of 600-800 mg/day. Hematopoietic stem
cells transplantation (SCT) was indicated in patients aged under 45 years in
complete remission and have a sibling related donor.
Results: Ten patients with de novo Ph ALL were treated with the GRAAPH
protocol. The median age at the diagnosis was 44 years (21 to 55 years), 6
patients were aged under 45 years. Sex ratio (M/F) was 0,43. The median
WBC was 28G/L (3,4 to 104 G/L). Nine patients had a transcript Bcr-Abl positive
and one patient had only the t (9,22) without transcript Bcr-Abl. Eight patients
(80%) achieved complete remission (CR). Among the 4 patients in CR and
with indication to allogeneic SCT, only 3 patients were allograft. Among them,
2 patients are alive in good molecular response after a follow up of 4 and 2
years and the other patient died in post allogeneic transplant with acute graft
versus host disease (GVHD). The 5 patients who were not allograft, 2 are alive
in good molecular response after a follow up of 4 and 6 years and the other 3
patients died with disease progression .
Summary/Conclusions: In the pre-imatinib era, treatment outcomes of adult
patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic
leukemia (ALL) were dismal. However, imatinib, in combination with conven-
tional chemotherapy, has dramatically changed outcomes, producing approx-
imately 95% complete remission, 80% in our study and 50% overall survival
with or without allogeneic SCT.
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NK-CELL LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA: CLINICAL AND
LABORATORY FEATURES, AND PROGNOSIS
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Background: NK-cell lymphoblastic leukemia/lymphoma (NK-LL) is a rare type
of acute leukemias. According to the WHO Classification of Tumors of
Haematopoietic and Lymphoid Tissues NK-LL is reviewed in chapter “Acute
leukaemias of ambiguous lineage”.
Aims: To determine clinical and laboratory features and prognosis of NK-LL.
Methods: From 2000 to 2014 only in 1 of 161 (0.6%) patients treated in the
department of Hematology of N.N. Blokhin Russian Cancer Research Center
was diagnosed NK-LL. Over the same period a diagnosis of NK-LL has been
set additionally 3 patients in the Laboratory of Immunology Hematopoietic of
N.N. Blokhin Russian Cancer Research Center more. The disease was diag-
nosed in accordance to the 2008 WHO classification. The differential diagnosis
was carried out with other CD56-positive tumors – AML-M0, blastic plasmacy-
toid dendritic cell neoplasm, T-ALL, and neoplasms of mature NK cells. In the
group NK-LL were 4 patients: 3 men and 1 woman. The median age was 52.5
years (ranged from 29 to 82 years).
Results: All patients stated the total bone marrow blast metaplasia (>70%),
common extramedullary lesion: generalized lymphadenopathy,
hepatosplenomegaly, lesions of skin, tonsils, mediastinal, central nervous sys-
tem (CNS) by type neuroleukemia. Blasts cytochemical reaction on myeloper-
oxidase, lipids and nonspecific esterase were negative. In all cases the blast
cells were strong positive to CD56 (69.8-99.1%) and the T-associated antigen
CD7 (66.2 - 92%), and negative to myeloid, T- and B-lymphoid antigens. PCR
identified the lack of gene rearrangement chain T-cell receptor in one patient.
Cytogenetic study was not performed. Induction therapy of patients with NK-
LL carried out mainly by the program of treatment of acute lymphoblastic
leukemia (ALL). CR was achieved in 2 patients, however, proved to be of short-
term (1 and 7 months.). The longest remission duration (20 mo.) was obtained
using a combined regimen RACOP for the treatment of relapse. Overall survival
in the group did not exceed 3 years (1-29 mo.).
Summary/Conclusions: The analysis indicates the low efficiency of current reg-
imens NK-LL. Success in treatment of patients depends on prompt and accurate
diagnosis, as well as the development of new therapeutic approaches.
Acute myeloid leukemia - Biology
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TECHNICAL VALIDATION OF A NEXT-GENERATION SEQUENCING PANEL
FOR ACUTE MYELOID LEUKEMIA DIAGNOSIS
M Llop1,*, CM Alonso*2, M Ibañez1, J Cervera1,3, E Such1,3, L Pedrola1,
I Martin1, E Onecha4, R Ayala4, MA Sanz1,3, E Barragan1,5
1Instituto de Investigación Sanitaria La Fe, 2Hematology Department, Hospital
Arnau de Vilanova, 3Hematology Department, Hospital Universitari i Politècnic
La Fe, Valencia, 4Hematology Department, Hospital 12 de Octubre, Madrid,
5Clinical Pathology Service, Hospital Universitari i Politècnic La Fe, Valencia,
Spain
Background: Recurrently mutated genes have been described for acute
myeloid leukemia (AML). However, only a few (NPM1, CEBPA, FLT3) have
prognostic and clinical implications and are systematically analysed, usually
by individual assays. The development of high throughput techniques as next-
generation sequencing (NGS) allows a parallel detection of these markers and
enables the inclusion of novel molecular targets.
Aims: Our aim is to validate the clinical applicability to routine laboratories of
a hotspot NGS panel that includes recurrently validated mutated genes and
other potentially actionable targets.
Methods: We included 130 de novo AML samples previously characterized for
FLT3-D835, NPM1-T288, DNMT3A-R882, and CEBPA mutations by conven-
tional molecular biology techniques (CMBT). We tested the Ion Ampliseq AML
community panel (Life Technologies) (IAACP) which requires 40 ng of DNA per
sample and includes hotspots of ASXL1, BRAF, CBL, FLT3, IDH1, IDH2, JAK
2, KIT, KRAS, NRAS, PTPN11, RUNX1 and WT1; and the entire coding
sequence of CEBPA, DNMT3A, GATA2, TET2 and TP53. The design does not
include the FLT3-ITD region. Libraries were sequenced in the Ion PGM (n=12)
and the Ion Proton platforms (n=118). For comparison, 3 patients were
sequenced in both platforms. To determine if the hotspot approach is adequate,
a subset of 25 patients was also analyzed with a custom panel (Sure Design
Tool (Agilent)) that included the complete coding sequence of the genes includ-
ed in the IAACP except from CBL and GATA2. Libraries were prepared with
250 ng of DNA per sample and sequenced in an Illumina platform.
Results: The IAACP sequenced in the Proton platform yielded a mean depth of
5916 reads, mean uniformity was 92.19% and mean on-target reads 89.05%.
Two amplicons (RUNX1_239.66909 and ASXL1_235.1.76662) showed a strong
strand bias (x5) towards the forward strand systematically. The PGM platform
yielded a mean depth of 2500 reads, mean uniformity of 91.86% and mean on-
target reads of 93.39%. GATA2_47.1.16110 and DNMT3A_23.66955 amplicons
showed a strong bias towards the forward strand (100X) and the reverse strand
(42X), respectively. For both platforms we observed intra-run differences regard-
ing read depth and strand bias, however, none of the 239 amplicons showed a
mean depth lower that 250X (Figure 1). Patients sequenced in both platforms
yielded the same mutations. IAACP found 100% of the previously known muta-
tions by CMBT plus 11 extra mutations that were negative by CMBT. These muta-
tions were reconfirmed by Sanger sequencing. Among the 25 patients analysed
with the custom panel, 53 variants were found. Fifty (95%) were also detected
with the IAACP. The remaining 3 variants (5%) were located outside the hotspot
regions in genes with poor clinical significance. Additionally, the IAACP detected
13 variants in the overlapping regions not found by the custom panel.
Figure 1.
Summary/Conclusions: In conclusion, the IAACP is reliable and reproducible
for routine diagnosis. It allows detection of known important mutations with
increased sensibility compared with CMBT, and also detection of complemen-
tary mutations with potential clinical implications. The main limitation of its
design is the absence of amplicons covering FLT3-ITD region. The hotspot
approach yields a higher mean read depth than the whole coding sequence
analysis without significant losses and it requires less input DNA. Moreover,
analysis of strand bias and low coverage regions is mandatory to assess
sequencing quality and to perform extra assays if necessary.
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MUTATIONAL ANALYSIS OF ACUTE MYELOID LEUKEMIA WITH A
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cia, 4Hematology Department, Hospital 12 de Octubre, Madrid, 5Clinical Pathol-
ogy Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background: In the last years numerous recurrently mutated genes have been
described for acute myeloid leukemia (AML). Although only CEBPA, NPM1
and FLT3-ITD have been incorporated to risk stratification algorithms, other
genes like RUNX1, ASXL1, DNMT3A or TP53 are currently being evaluated
and could be soon incorporated. Furthermore, FLT3, IDH1/2 or KRAS are being
tested as potential therapeutic targets. Next generation sequencing (NGS)
assays allows a parallel detection of these genes.
Aims: The aim of this study is to characterize the mutational status of a series
of “de novo” AML patients using a NGS panel that includes the hotspots of
most recurrently mutated genes and other potentially actionable targets.
Methods: We studied 130 AML patients diagnosed from June 1999 to June
2014 in a single centre. Inclusion criteria were age <65 years, diagnosed
with non-promyelocytic AML, treated according PETHEMA AML clinical pro-
tocols and with available DNA sample at diagnosis. Ion Ampliseq AML com-
munity (IAAC) panel was employed for mutation detection. This panel
includes hotspots of ASXL1 (exon 12), BRAF (V600E), CBL (exons 8-9),
FLT3 (codons 676, 830-850), IDH1 (exon 4), IDH2 (exon 4), JAK 2 (exon
14), KIT (exons 8, 10, 11 and 17), KRAS (exons 2-4), NRAS (exons 2-4),
PTPN11 (exons 3,7,8,13), RUNX1 (exons 3-8) and WT1 (exons 7 and 9),
and the entire coding sequence of CEBPA, DNMT3A, GATA, TET2 and TP53.
Libraries were amplified with Ion Torrent Ampliseq 2.0 beta and sequenced
in the Ion PGM or Proton platforms. Variant annotation was carried out with
the Ion Reporter Software (Life Technologies). Polymorphisms, synonymous,
low depth read mutations (<100X) and low read% variants (<5%) were filtered
out. Moreover, regions with intrinsic strand bias or low coverage were curated
with the Integrative Genomics Viewer (IGV). FLT3-ITD mutations, which are
not included in the panel design, were detected by capillary electrophoresis
(Thiede 2002 Blood).
Results: Regarding cytogenetics, 9 patients showed favourable risk, 82 with
intermediate risk (70 normal karyotype) and 23 unfavourable risk. For the
remaining 6 patients cytogenetics could not be assessed. The IAAC panel
found 322 variants in 125 patients. In brief, 59 NPM1 mutations, 49 in DNMT3A
(30/49 mutations (61,22%) were the R882 mutation), 36 in TET2, 31 in CEBPA
(13 patients showed biallelic mutations), 21 in RUNX1, 18 in NRAS, 16 in IDH2,
15 in FLT3, 15 in TP53, 11 in GATA2, 11 in PTPN11, 11 in ASXL1, 8 in WT1, 7
in IDH1, 7 in KRAS, 4 in KIT, 2 in CBL and 1 mutation in BRAF (Figure 1).
Moreover, 31 FLT3-ITD mutations were detected by conventional techniques.
The average of mutations per patient was 2.71 (range 0-8). Only 5 (3.8%)
remained wild type. NPM1, DNMT3A and FLT3 (including FLT3-ITD) mutations
were significantly enriched in the intermediate risk group (p<0.001 p=0.002,
p=0.004, respectively), while TP53 mutations aggregated in the unfavourable
karyotype group (p<0.001). NPM1 mutations significantly concurred with
DNMT3A and FLT3 mutations (p<0.0001, p<0.0001, respectively), and these
three genes are mutually exclusive with TP53 (p<0.001; p=0.005, p=0.011)
and RUNX1 (p=0.001, p=0.018, p=0.047) mutations. NPM1 and FLT3 were
also mutually exclusive with GATA2 (p=0.010 and p=0.016). NPM1 and CEBPA
were mutually exclusive (p=0.036), as well as FLT3 with NRAS (p=0.014), and
ASXL1 with NRAS (p=0.038). NPM1 and PTPN11 mutations showed concur-
rence (p=0.012) (Figure 2).
Summary/Conclusions: IAAC panel detects mutations with validated prog-
nostic relevance (NPM1 and CEBPA) and other mutations with probable diag-
nostic or prognostic value and/or potential therapeutic targets are also studied
and identified in one assay. The parallel study of numerous mutations allows
the identification of recurrence and exclusivity patterns.
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MYELOID-SPECIFIC EXPRESSION OF SOX4 INDUCES EXPANDED
MYELOPOIESIS WITH RETARDED CELL DIFFERENTIATION - A NOVEL
ZEBRAFISH LEUKEMIA MODEL
LI Lin1, JW Lu1,*, MS Hsieh1, HA Hou2, CY Chen2, HF Tien2
1Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan Uni-
versity, 2Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan,
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Background: SOX4 belongs to a family of Sox (SRY-related HMG-box) tran-
scription factors, including Sox4, Sox11, and Sox12. Abnormal expression of
SOX4 is related to malignant transformation and cancer metastasis. Overex-
pression of SOX4 is associated with clonal dominance of hematopoietic stem
cells, repopulation advantage of various stem/progenitor cells, block in differ-
entiation of myeloid progenitor cells, and induction of myeloid leukemia. Recent-
ly, the expression of SOX4, as a direct target of C/EBPα, is reported to inversely
correlate with C/EBPα activity. Downregulation of SOX4 attenuates self-renewal
capability of leukemic cells and restored their normal differentiation process.
SOX4 overexpression resulting from C/EBPα inactivation contributes to the
development of leukemia with a distinct leukemia-initiating cell (LIC) phenotype.
In addition, several fusion proteins resulting from chromosomal aberration,
such as MOZ-TIF2, AML1-ETO, UNP98-HOXA9, were closely linked to SOX4
upregulation, further suggesting the significance of SOX4 in leukemogenesis.
Zebrafish is a popular animal model in biomedical researches. Here, we add
to its strength for leukemia research by providing a novel transgenic SOX4
zebrafish model.
Aims: To establish SOX4 transgenic zebrafish research model.
Methods: By using Multisite Gateway system®and Tol2 transposon technology,
we established a construct including spi1 promoter, human SOX4 gene and
EGFP. This construct was then injected into zebrafish embryos. After a series
of fluorescent selection, stable transgenic SOX4 zebrafish - Tg(CG-spi1-SOX4-
EGFP)were generated. The expression of hematopoiesis-related transcription
factors were evaluated by quantitative real-time polymerase chain reaction
(qRT-PCR) or whole-mount in situ hybridization (WISH) technique. The histo-
logical pictures of kidney marrow (KM) were examined by light microscope
Results: We found that SOX4 could be detected at 20 hpf (0.2~1.7x103
copies), and then increased gradually during development. At 5 dpf, level of
SOX4 was up to 2~10x103 copies. However, there were no significant differ-
ences in the expression of hematopoiesis-related transcription factors, such
as csf1r, cebpa, l-plastin, mpeg1, mpo, runx1 and c-myb in spite of the
expression of SOX4. These results indicated that the SOX4 transgenic
zebrafish had normal hematopoiesis in the larval stage. However, in com-
parison with age-matched AB-wild type fish, the KM of 5-month old transgenic
zebrafish Tg(CG-spi1-SOX4-EGFP) had a greater number of myeloid pro-
genitors (9.24±2.75% vs 5.27±0.74%; p<0.05); those of 9-month old had a
greater number of myeloid progenitors (18.00±8.78% vs 5.73±0.64, p<0.01),
less number of mature erythroid cells (19.55±5.98% vs 27.93±6.03%, p<0.05)
and greater M:E ratio (10.39±7.81 vs 3.72:1±0.53, p<0.05); those of 12-month
old had significant difference in all blood components (17.61±8.07% vs
7.00±1.10% in myeloid progenitors; 62.06±7.82% vs 42.07±3.18% in
myelomonocyte/neutrophil; 4.11±0.72% vs 16.20±1.12% in lymphocytes;
5.44±1.45% vs 10.06±2.55% in immature erythroid cells;10.78±3.40% vs
4.61±0.64% in mature erythroid cells and M:E ratio of15.77±5.34 vs
4.61±0.64, p<0.05 for all above).
Summary/Conclusions: These results indicate that SOX4 transgenic
zebrafish develops a gradual expansion of myeloid cells, which fail to differen-




A COMBINED APPROACH TO DETECT RARE FUSION EVENTS IN ACUTE
MYELOID LEUKEMIA
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V Guadagnuolo1, C Papayannidis1, V Robustelli1, E Imbrogno1, N Testoni1,
M Cavo1, M Delledonne3, I Iacobucci1, CT Storlazzi4, E Ficarra2, G Martinel-
li1
1Seragnoli Institute, Department of Experimental, Diagnostic and Specialty
Medicine, University of Bologna, Bologna, 2Dept. of Control and Computer
Engineering DAUIN, Politecnico di Torino, Torino, 3Personal Genomics, Per-
sonal Genomics, Verona, 4Department of Biology, University of Bari, Bari, Italy
Background: A complex network of events characterizes Acute Myeloid
Leukemia (AML), including point mutations, epigenetic modification, copy-num-
ber alterations, gene-expression alterations and fusion events. A recent study
revealed that 45% of AML patients carry one fusion gene and 50% of detected
fusions were novel and not recurrent events (TCGA, N Engl J Med; 2013).
However, the leukemogenic potential of these fusions and their prognostic role
are still unknown.
Aims: The aim of the study was to identify rare gene fusions having a causative
role in leukemogenesis and which may be a target for personalized therapy in
AML cases with rare chromosomal translocations.
Methods: RNAseq was performed on 4 AML patients (#59810, #20, #84 and
#21, Hiseq1000 Illumina) and deFuse and Chimerascan was used to detect
fusions. Putative chimeras were prioritized according to cytogenetic analysis.
In addition, we exploited Pegasus and Oncofuse to select biologically relevant
fusions cryptic at cytogenetic analysis. Selected fusions were validated with
Sanger sequencing.
Results: The reliability of our bioinformatic analysis was confirmed thanks to
the detection of the CBFβ-MYH11 transcript in the sample #84 associated to
the inv(16). We detected two in-frame fusion genes in sample #20: CPD-PXT1
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which appeared as the reciprocal fusion product of t(6;17) translocation, and
SAV1-GYPB, which remained cryptic at cytogenetic analysis. The first chimera
involved a metallocarboxypeptidase and a partner whose biological function is
unknown. The second chimera involved the oncogene SAV1, a central player
of the Hippo pathway, which controls the proliferation and promotes the apop-
tosis. The fusion event causes the loss of the protein-protein interaction domain
of SAV1, which is fundamental for its stability. Sample #21 carried an in-frame
fusion transcript involving the genes OAZ1 and MAFK. The first gene is involved
in the polyamine synthesis, while the latter one is a transcriptional regulator.
The putative fusion protein was formed by the cis-acting elements sensitive to
polyamine levels of OAZ1 and the bZIP domain of MAFK. We detected two
fusion transcripts in sample #59810: ZEB2-BCL11B, associated with translo-
cation t(2;14), and CNOT2-WT1, associated with t(11;12). In particular, three
different isoforms of the in-frame chimera ZEB2-BCL11B were expressed: the
full length (Isoform 1), the Isoform 2 with one exon of BCL11B spliced and the
Isoform 3 with 2 exons of BCL11B spliced. Gene expression profiling showed
an upregulation of ZEB2 and BCL11B transcripts in the patient’s blasts, com-
pared to 53 AML samples with no chromosomal aberrations in the 14q32 region.
On the contrary, CNOT2-WT1 was an out-of-frame gene fusion and the recip-
rocal of the fusion revealed the intron retention of CNOT2.
Summary/Conclusions: Our data suggest that fusion events are frequent in
AML and different approaches, including G-banding, molecular biology, bioin-
formatics and statistics, need to be integrated in order to better understand
AML pathogenesis. The lack of recurrence in the landscape of AML gene
fusions confers heterogeneity to the pathogenesis of the disease and we are
further investigating the pathogenetic potential of the identified translocations,
in order to identify common patterns of oncogenic events, which may be exploit-
ed to stratify patients and tailor personalized therapies.
Acknowledgements: ELN, AIL, AIRC, progetto Regione-Università 2010-12 (L.
Bolondi), Fondazione del Monte di Bologna e Ravenna, FP7 NGS-PTL project.
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Background: One of the potential mechanism responsible for evading cytotoxic
T lymphocytes by tumor cells might be the programmed death-1 receptor (PD-
1) signaling pathway. PD-1 and its ligand PD-L1 play a key role in tumor immune
escape and the formation of tumor microenvironment, promoting tumor devel-
opment. Recent findings showed elevated expression of PD-1 and PD-L1 on
CD34+cells in acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) patients suggesting that deregulation of PD-1/PD-L1 axis may contribute
the MDS pathogenesis. Moreover, in patients treated with epigenetic therapy
PD-L1 and PD-1 expression was upregulated indicating that induction of PD-1
and PD-1 ligands may be involved in hypomethylating agents (HMAs) resist-
ance. PDCD1 polymorphisms are associated with susceptibility to several types
of cancer.
Aims: We aim to characterize the PDCD1 expression and six PDCD1 polymor-
phisms in AML, MDS and s-AML patients samples as well as determine whether
expression of PD-1 in those patients is driven by the genetic background.
Methods: PDCD1 mRNA expression was assessed in bone marrow mononu-
clear cells (BMMC) of 62 MDS, 54 AML and 8 s-AML patients samples using
qRT-PCR method. Six SNP for PD-1 that demonstrate relevant associations
with a higher risk of developing autoimmune diseases were assessed in AML,
MDS and s-AML patients as well as 100 healthy volunteers (HVs): PD-1.1
(rs36084323), PD-1.3 (rs11568821), PD-1.5 (rs2227981), PD-1.6 (rs10204525),
PD -1.7 (rs41386349), PD-1.9 (rs2227982). Moreover, immunohistochemical
(IHC) stainings of 12 AML and 8 MDS bone marrow smears for PD-1 protein
were performed.
Results: We observed significant decreased PDCD1 expression in AML group
compared to HVs and MDS, (median: 0.0001 vs 0.0003, p<0.001 and 0.0001
vs 0.0003, p<0.001) but no differences in MDS and s-AML groups compared
to HVs. IHC stainings showed PD-1 expression on blast cells in 6/12 AML and
6/8 MDS cases ranging from 1-92%. AML patients were stratified into three
genetic groups according to prognosis: favorable risk, intermediate I risk and
intermediate II/adverse risk and PDCD1 expression was compared between
these groups. No significant differences were found between these groups.
MDS patients were divided according to IPSS scoring systems into two groups:
first with IPSS ranging from 0.0 to 0.5 and second with IPSS from 1 to 3. No
significant difference were observed between these groups in case of PDCD1
expression (median: 0.0004 vs 0.0002, p=0.11). We observed significant dif-
ferences in PDCD1 expression level regarding to PD-1.1.5 polymorphism.
Moreover, analysis of a PD-1.1.3 polymorphism in HVs and MDS groups
revealed that genotype GG was associated with nearly fivefold lower risk of
disease (OR=4.93, p=0.009). We observed significant differences in OS in AML
patients in case of presence of certain genotypes of PD-1.1.6. Genotype AA
was significant associated with higher risk of shorter OS compared to the rest
of the genotypes (58 vs 333 days, HR=35; p=0.0188).
Summary/Conclusions: We found significant differences in PDCD1 expres-
sion in AML and MDS patients that might indicate deregulation of a signal trans-
duction through the PD-1/PD-L1 axis. By IHC stainings we were able to deter-
mine PD-1 expression on blast cells in 6/12 AML and 6/8 MDS bone marrow
smears. Moreover, SNP analysis in AML patients revealed potential prognostic
impact of PD-1.1.6 polymorphism.
This work was supported by National Centre for Science Grant HARMONIA
(UMO-2013/10/M/NZ5/00313).
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MOLECULAR CYTOGENETIC ANALYSIS OF COMPLEX KARYOTYPES IN
PATIENTS WITH MDS AND AML
L Grebenyuk*, T Obukhova, G Alimova, L Shishigina, V Troitskaya,
E Parovichnikova, V Savchenko
1National Research Center for Hematology, Moscow, Russian Federation
Background: Cytogenetic findings at diagnosis are among the most important
independent prognostic factors in patients with MDS and AML. Complex kary-
otype involving three or more chromosome abnormalities is associated with
poor prognosis and disease progression. Precise identification of chromosome
abnormalities in complex karyotype by conventional cytogenetic analysis (CCA)
is limited due to low resolution of this method. Molecular cytogenetic techniques
such as fluorescence in situ hybridization on interphase cells nuclei (FISH),
multicolor fluorescence in situ hybridization on chromosomes (mFISH) and
multicolor banding (mBAND) have significantly higher sensitivity and allow to
identify complex chromosome abnormalities, marker chromosomes, submicro-
scopic deletions and specify chromosomes breakpoints.
Aims: The aim of our study is to characterize complex karyotypes in patients
with MDS and AML using combination of molecular cytogenetic techniques.
Methods: Over a 2-year period CCA of bone marrow samples was performed in
234 patients with MDS and 83 patients with AML at diagnosis. Complex karyotypes
were revealed in 20 patients (9 males and 11 females, median age 55 years), 11
patients with MDS (4.7%) and 9 patients with AML (10.8%). mFISH (24XCyte,
MetaSystems) was performed in all 20 patients. Based on the results of CCA and
mFISH we analyzed abnormal chromosomes using FISH with locus-specific and
centromere DNA probes (LSI EGR1/D5S23, D5S721 Dual Color Probe Set in 12
cases, TP53/CEP 17 FISH Probe Kit in 10 cases, D7S522/CEP 7 FISH Probe Kit
in 9 cases, CEP 8 SpectrumOrange DNA Probe Kit, ATM/CEP 11 FISH Probe Kit,
LSI MLL Dual Color, Break Apart Rearrangement, D20S108 FISH Probe Kit, 1p36
Microdeletion Region Probe – LSI p58 (1p36)/TelVysion 1p/LSI 1q25 in each case
one, ABBOTT), as well as mBAND probe (XCyte mBAND 5, XCyte mBAND 7,
XCyte mBAND 15, XCyte mBAND 17, MetaSystems).
Results: CCA revealed an average of 4 karyotype abnormalities (from 3 to 14).
Structural chromosome rearrangements were found in 20 cases: random translo-
cations in 5 cases (25%), all of them were defined as simple reciprocal transloca-
tions, additional material of unknown origin in 12 cases (60%), marker chromo-
somes in 11 cases (55%). Non-random structural rearrangements were found in
3 patients: t(6;9) – 1, del5q31 -1 and del7q31 - 1 case. Most frequent numerical
abnormalities were typical for MDS and AML trisomy 8 – 5 cases (25%), monosomy
5 - 8 (40%), 7 - 7 (35%) and 17 - 3 cases (15%). Molecular cytogenetic analysis
revealed additional chromosome aberrations and/or additional chromosome break-
points in 17 of 20 cases (85%). Translocations were found in 18 cases (90%): 9
(50%) – simple reciprocal translocations, 4 (22%) – complex translocations involv-
ing 3 chromosomes, 3 (16,5%) - complex translocations involving more than 3
chromosomes. In karyotype of 17 patients (85%) we found abnormalities of chro-
mosomes 5 (60%), 7 (50%), 11 (20%) and 17 (45%). Except one case, chromo-
some breakpoints were identified in typical regions of known or potential genes:
5q31, 7q31, 11q23 and 17p13. Deletions 5q and 7q were confirmed in both cases.
Monosomy 7 was confirmed in two of seven cases only. In all other cases with
monosomy 5, 7, and 17 on the results of conventional analysis mFISH revealed
fragments of these chromosomes involved in translocations. Based on the results
of FISH all of these translocations, except one case, were combined by deletion
of loci 5q31, 7q31 and 17p13. All marker chromosomes and chromosomes with
additional material of unknown origin were recognized as complex translocations
or derivative chromosomes with breakpoints in both arms.
Summary/Conclusions: In our study applying of molecular cytogenetic meth-
ods allowed to identify all numerical and structural abnormalities, unrecognized
at CCA, clarify chromosome breakpoints and determine markers chromosomes
origin. True monosomy 7 was confirmed in 10% only, and for chromosomes 5
and 17 true monosomy is not found. Combination of conventional and molecular
cytogenetic techniques (FISH, mFISH and mBAND) is necessary for precise
characteristic of complex karyotypes in MDS and AML and determination of
exact breakpoints loci of potential oncogenes and tumor suppressor genes.
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GENOMIC CHARACTERIZATION OF PATIENTS WITH LOW-RISK ACUTE
MYELOID LEUKEMIA (AML)
MI Prieto-Conde1,*, C Jiménez1, M Alcoceba1, M García-Álvarez1,
ME Sarasquete1, A Balanzategui1, M Hernández-Ruano1, E Sebastián1,
R Corral1, L Marín1, F Ramos2, A Godoy3, A Bárez4, NC Gutiérrez5, R García-
Sanz5, M González-Díaz5, MC Chillón5
1Hematology Department, University Hospital of Salamanca-IBSAL, Salaman-
ca, 2Hematology Department, Hospital de León-Ibiomed, León, 3Hematology
Department, Hospital Miguel Servet, Zaragoza, 4Hematology Department, Hos-
pital Nuestra Señora de Sonsoles, Ávila, 5Hematology Department, University
Hospital of Salamanca, Salamanca, Spain
Background: Not all acute myeloid leukemia (AML) patients classified at diag-
nosis as cytogenetic and/or molecular favorable risk display a good outcome.
In fact, up to 40% of patients with core binding factor (CBF) AML will relapse
and not all may be cured. In the same way, a half of NPM1 mutated patients
have a relapse during the first 3 years after diagnosis and only biallelic disrup-
tion of CEBPA (biCEBPA) is required for a favorable outcome that not avoid a
relapse rate of 44%. However, mutations responsible for poor outcome in these
previously low-risk classified subsets have not been clearly defined.
Aims: 1) To determine the mutational profile of favorable risk AML: CBF-AML,
NPM1-mutated AML lacking FLT3-ITD and biCEBPA AML. 2) To identify muta-
tions at diagnosis responsible for poor outcome by comparing patients who
experiment relapse vs patients who do not relapse.
Table 1.
Figure 1.
Methods: A cohort of 46 patients with favorable-risk AML (median age 55 years)
(PETHEMA AML-99-2010) (Table 1). FLT3-ITD mutations were analyzed by flu-
orescent PCR and capillary electrophoresis. None of the patients harbored FLT3-
ITD. A total of 54 genes were targeted by 568 amplicons that ranged from 225
to 275 bp. The combined coverage was 141 kb in sequence length. Amplicon
libraries were prepared by TruSight Myeloid sequencing panel (Illumina, CA) and
paired-end sequencing runs were performed on a MiSeq (Illumina) genome
sequencer. Minimum depth for reliable analysis was fixed in 100x. Sequences
obtained were analyzed with the Variant Studio v2.1 software (Illumina).
Results: We found 144 mutations in 44 of 46 patients of the global series (3.3
(0-8 mutations/patient) with a mean read depth of 8230x. Only 2 patients
remained wild-type for all analyzed genes. Figure 1 displays the mutational
distribution of the patients who suffered relapse and patients who do not relapse
in the three groups studied. The CBF group (n=18) showed a high frequency
of KIT mutations (33%) that were not present in the other low-risk groups. Sev-
en patients harbored NRAS/KRAS mutations (39%), showing a great involve-
ment of RAS pathway in this subset. Other relevant genes affected were ASXL1
and CUX1 (28% and 17%, respectively). The NPM1 mutated group (n=26)
presented a high incidence of DNMT3A, IDH1 and IDH2 mutations, as
described previously (35%, 38% and 15%, respectively). Moreover, a 23% of
these patients carried mutations in the phosphatase PTPN11 and a 15% in the
cohesin complex gene STAG2. The two biCEBPA mutated patients showed
altered variants in the transcriptional regulator GATA2. Regarding the prog-
nostic value of these alterations, we found that patients with a better course of
the disease had a lower frequency of mutations in NRAS/KRAS genes. There-
fore, we analyzed the prognostic value of these variants in the CBF group and
it was correlated with a trend to a shorter relapse free survival (3 years, 86%
vs 42% p=0.125). With respect to KIT mutations we did not find significant dif-
ferences in their clinical adverse impact since 5 of the 6 mutated patients were
in first complete remission probably because they underwent stem cell trans-
plantation. Concerning the NPM1 group, mutations were similar in patients
with a good outcome and patients who relapse.
Summary/Conclusions: This technology is able to find altered variants with
high accuracy in AML patients. Although based on small numbers of patients,
we observed a clear alteration of the RAS pathway in CBF patients, which sug-
gests the need of further studies about new alternatives to standard chemother-
apy in NRAS/KRAS mutated patients.
PB1632
CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBI-
NATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE
MYELOID LEUKEMIA
A Beghini1,*, F Lazzaroni1, L Del Giacco2, O Soderberg3, D Biasci4, M Turrini5,
L Prosperi2, R Brusamolino6, U Landegren3, R Cairoli7
1Dept. of Health Science, 2Department of Biosciences, University of Milan,
Milan, Italy, 3Department of Immunology, Genetics and Pathology, Uppsala
Universitet, Uppsala, Sweden, 4Cambridge Institute for Medical Research, Uni-
versity of Cambridge, Cambridge, United Kingdom, 5Department of Internal
Medicine, Valduce Hospital, Como, 6Department of Pathology, 7Department
of Oncology, Hematology Unit, Niguarda Hospital, Milan, Italy
Background: The WNT/β-catenin pathway play a critical function in the regu-
lation of cell proliferation, differentiation, and apoptosis, playing a major role in
fueling stem cell activity and sustaining tissue regeneration in a dose dependent
manner in several adult stem cell niches including bone marrow. Previous
results obtained by our research team provided direct evidences that WNT/β-
catenin signaling is diffusely activated in the AC133+acute myeloid leukemia
(AML) cells. The mRNA in situ detection analysis revealed that WNT10B results
to be expressed in leukemic blasts as well as in stromal-like cells, suggesting
an autocrine/paracrine mechanism of Wnt signaling induction in the leukemic
bone marrow microenvironment. Conversely, the activation of Wnt signaling,
marked by expression of the dephosphorylated β-catenins, is restricted only to
a smaller subpopulation of AC133bright cells.
Aims: In the present study, focusing our attention on the major locus associated
in hematopoiesis to the regenerative function, we provide evidences for a recur-
rent rearrangement involving the WNT10B locus within intron 1 (IVS1). More-
over, we demonstrated the consequent expression of a non-physiological tran-
script variant, WNT10BIVS1, retaining 77 nucleotide of IVS1 and lacking exon1,
and we analyzed the significance in AML.
Methods: In order to provide accurate quantification of mRNA levels of
WNT10B and the related WNT10BIVS1 transcript variant and analyze the clin-
ical relevance of their expression, we carried out the gene expression analysis
by Droplet DigitalTM PCR on mononucleated cells derived from n=125 AML
patients [de novo, N=118 (intermediate-adverse risk N=70; favorable risk
N=48); therapy-related, N=7, informed consent was obtained]. Analyzing
patients according to the three main scoring systems, formerly the Medical
Research Council (MRC), European LeukemiaNet (ELN), and National Com-
prehensive Cancer Network (NCCN), we were able to distinguish groups of
patients at different outcomes with a statistically significant wise.
Results: We observed that canonical WNT10B mRNA was highly expressed
in all de novo AML patients here examined, while WNT10BIVS1 mRNA transcript
levels resulted undetectable in patients classified with favorable-risk (p <0.001).
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Furthermore, we demonstrated absence of both WNT10B and WNT10BIVS1
expression in therapy-related patients (p <0.005). Moreover, we have also eval-
uated the effects of transient wnt10b overexpression on early hematopoiesis
in the zebrafish model and therefore, to this aim wnt10b synthetic mRNA was
microinjected in the zebrafish zygote to mimic, in vivo, the Wnt signaling over-
expression we had previously observed in AC133bright AML cells. Interestingly,
an increase of erythromyeloid progenitors, and a simultaneous reduction in the
number of circulating neutrophils is detected.
Summary/Conclusions: The results presented here provide compelling evi-
dence that regeneration-associated Wnt signaling exceeds the homeostatic range
in the majority of human AML cases. Taking these issues into consideration, we
revealed that it is possible to recognize three distinct WNT10B/ WNT10BIVS1
patterns, suggesting a potential role of WNT10BIVS1 transcript as a marker for
the intermediate-adverse risk AML patients. These findings, if confirmed in a
larger population of patients, may help to refine diagnostic or prognostic criteria
for previously described neoplasms, and to introduce newly recognized disease
entities possibly characterized by distinct causative pathogenic mechanisms.
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ANALYSIS OF CLONAL IMMUNOGLOBULIN AND T-CELL RECEPTOR
GENE REARRANGEMENTS IN ACUTE MYELOID LEUKEMIA
Y Huang1,*, Z Xie1, A Jacobsen1, D Duong1, J Panganiban1, W Huang1,
B Patay1, D Hubbard2, T Le2, G Pawlowsky3, NC Adams3, J Thornes1,
JE Miller1,2,3, T Stenzel1
1Invivoscribe, 2LabPMM LLC, San Diego, United States, 3LabPMM GmbH,
Martinsried, Germany
Background: Acute myeloid leukemia (AML), the most common form of
leukemia, carries a high mortality rate and economic burden. In 2015, approx-
imately 39,130 individuals were diagnosed in the United States and Europe
with roughly half that number dying from the disease (1,2). With the advent of
more sensitive molecular assays, the complex architecture and functional het-
erogeneity of AML has become appreciated though not yet fully elucidated.
Fundamentally, understanding the hematopoietic stem cell (HSC) self-renewal
and differentiation model will aid in this goal. Initial hierarchical hematopoietic
models focused on the lymphoid and myeloid lineage groupings to be segre-
gated. Recently studies suggest that lineage commitment of hematopoietic pro-
genitors may be both multidirectional and reversible with changes in lineage
caused by both intrinsic and environmental factors (3). Though AML is classified
as a myeloid neoplasm, we were interested in determining the prevalence of
clonal rearrangements within the immunoglobulin heavy (IGH) and light chain
(IGK), T-cell receptor gamma (TRG) loci in AML patient samples.
Aims: Assess the frequency of IGH, IGK, and TRG rearrangements in AML
patient samples.
Methods: DNA was extracted by QIAcube from a random sampling of 200 AML
anonymized patient residual peripheral blood (PB) or bone marrow (BM) speci-
mens. DNA was quantified by NanoDrop and normalized. Each DNA sample was
tested for 6 different PCR master mixes: IdentiClone IGH Tubes A, B, C, which
target the framework (FR) 1, 2, and 3 regions, respectively; IGK Tube A, IGK
Tube B, and TRG 2.0. Amplicon products were analyzed using the ABI 3500 XL
instrument. Based on the florescent signals, clonal (positive) or polyclonal (neg-
ative) were assessed per instructions of use accompanying the IdentiClone assay.
Results: The IdentiClone IGH assay identified 23 (12%), 14 (7%) and 16 (8%)
clonal positive samples for FR 1, 2 and 3, respectively. Combining all three
IGH tubes increased the clonal detection rate to 28 (14%) with 172 (86%) sam-
ples determined to be negative. The IdentiClone IGK assays identified 39 (20%)
and 29 (15%) clonal positive samples for Tube A and Tube B, respectively.
Combining the two IGK tubes increased clonal detection to 56 (28%), with 143
(72%) determined to be negative. Combining all 5 IGH+IGK tubes, 65 (33%)
clonal positive samples and 135 (68%) clonal negative samples were identified.
The TRG 2.0 assay detected 85 (43%) clonal positive samples and 114 (57%)
clonal negative samples. Overall, using 6 tubes of PCR MM across IGH, IGK
and TRG assays, 113 (57%) samples were identified as clonal positive and 87
(44%) samples were identified as clonal negative.
Summary/Conclusions: Over 50% of AML samples demonstrated at least
one clonal IG or TCR gene rearrangement. Although clonal rearrangements
occur in individuals over 60 years of age, clonal rearrangement assays com-
bined with outcome data for AML patients may provide clinical utility and further
elucidate functional heterogeneity.
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GPC4, THE GENE OF SIMPSON-GOLABI-BEHMEL SYNDROME, IS
AMPLIFIED ON EXON 9 AND REVEAL A POSSIBLE PATHOGENETIC ROLE
FOR APL PROGRESSION OR RELAPSE.
S Lo Monaco*, MC Fontana, M Manfrini, C Papayannidis, G Marconi, S Paolini,
V Guadagnolo, A Padella, G Simonetti, A Ghelli Luserna Di Rorà, S Parisi,
C Sartor, MC Abbenante, M Cavo, G Martinelli
Istituto Seragnoli, Bologna, Italy
Background: Cytogenetical and molecular analysis of acute promyelocytic
leukemia (APL) have improved the knowledge about the genomic mechanism
at the origin of this pathology identifying t(15;17) and the fusion gene PML-
RARa. New targeted therapies were introduced in treatment of APL, as all-
trans retinoic acid (ATRA) and arsenic trioxide. Even though these therapies,
a 10% of patients (pts) still relapse. Single Nucleotide Polymorphism (SNP)
microarray can detect cytogenetic lesions mostly involving structural alterations
with losses or gains of chromosomic material. These abnormalities could be
predictive of response and can help define therapeutic strategies. SNP microar-
ray can also detect copy-neutral loss of heterozygosity (CN-LOH) or Uniparental
Disomy (UPD), relevant to induce oncogene duplication, tumor suppressor inhi-
bition and epigenetic reprogramming.
Aims: To improve conventional cytogenetic analysis and identify new genomic
abnormalities that underlie the pathogenesis of APL, we perform SNP array-
based genotyping.
Methods: We performed SNP 6.0 and Cytoscan HD Array (Affymetrix) in 23 APL
(21 de novo and 2 relapsed) and then analyzed by Nexus Copy Number (BioDis-
covery, v.7.5) and R-Bioconductor. This method reveal Copy Number Alteration
(CNA) and CN-LOH that standard cytogenetic analysis could not detect. Briefly,
CNA were filtered for variants already annotated in Database of Genomic Variants
(DGV). Furthermore, CNA less than 1 kb were removed. Significant (p<0.05)
genes in which CNA events occur were summarized per patients. Moreover,
commons CNV regions among patients were detected.All the pts in our cohort
were treated at the hematological Institute of Bologna. Each patient was affected
by newly diagnosed or relapsed APL, in accordance with WHO 2008 classifica-
tion. All of them were treated with ATRA-IDA schedule of therapy.
Results: By Nexus Copy Number, we found that the relapsed pts presented
more CNA than the newly diagnosis, in particular 3 out of 23 pts (a newly diag-
nosis and 2 relapses), showed interesting alteration on GPC4 (exon 9) and in
the q26.2region of GPC3. We found that this group of 3 pts presented a minimal
common region of amplification of GPC4 (chr X: 132,432,100-132,435,915)
with a significant p value (p<0.05).Moreover, GPC3 q26.2 region presented
significant abnormalities with more copy number gain and copy number loss,
which may play a role in the pathogenesis of APL. Also UPD were found for
both GPC4 (5/23 pts) and GPC3 (6/23 pts) genes, with a p value of 0.0264 for
GPC4 and 0.009 for GPC3.
Summary/Conclusions: GPC4 and GPC3 are coding genes for glypicans,
heparan sulfate proteoglycans which have a role in the control of cell growth
and cell division. Alteration of these genes are described as first events in the
pathogenesis of Simpson-Golabi-Behmel syndrome, characterized by abnormal
cellular proliferation and augmented cancer risk. Our suggestion is that these
two genes may play a role in the improvement of pathogenesis and resistance
of APL pts. Further studies will be necessary to confirm and validate these data
in order to understand the role of these genes in APL.
Aknowledgement: ELN, AIL, AIRC, PRIN, progetto Regione-Università 2010-
12(L. Bolondi), FP7 NGS-PTL project
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PROGNOSTIC IMPACT OF COMPLEX KARYOTYPE ON OUTCOME OF
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA WITH CHROMOSOME 5 AND/OR 7 ABNORMALITIES
TL Gindina*, N Mamayev, S Bondarenko, A Alyanskiy, O Slesarchuk, A Borovkova,
S Razumova, E Nikolaeva, Y Gudozhnikova, L Zubarovskaya, B Afanasyev
R.M. Gorbacheva Memorial Research Institute of Pediatric Oncology, Hema-
tology and Transplantation, 1st Pavlov State Medical University of Saint Peters-
burg, Saint-Petersburg, Russian Federation
Background: Chromosome 5 and 7 abnormalities often occur in acute myeloid
leukemia (AML) both as a single chromosomal aberration and a part of the
complex karyotype (CK), and constitute a high-risk group. Breems et al., 2008
have identified a monosomal karyotype (MK), defined by the presence of at
least 1 autosomal monosomy and 1 structural chromosomal abnormality or at
least 2 autosomal monosomies, which associated with dismal outcome in AML
patients. However, whether or not the prognostic impact of MK and CK remains
relevant for patients who have undergone allogeneic hematopoietic stem cell
transplantation (allo-HSCT) is still unclear.
Aims: To evaluate the prognostic impact of chromosome 5 and 7 abnormalities
both as a single chromosome aberration and a part of the complex or mono-
somal karyotype on outcome of allogeneic hematopoietic stem cell transplan-
tation in AML patients.
Methods: In this study, outcomes in 44 AML patients with 5q-, 7q-/monosomy
7, who were transplanted in our University between 2008 and 2015, were ana-
lyzed. All patients and transplant characteristics are listed in Table 1.
Results: CK and MK were identified in 19 (43%) and 8 (18%) cases, respec-
tively. The median follow-up was 525 (46-2186) days. Overall survival (OS)
was 39% (95% CI 22-55) and event free survival (EFS) was 20% (95% CI 8-
35) at 3 years estimated with Kaplan-Meier method. In univariate analysis,
prognostic factors associated with increased OS and EFS were age (>18 vs
<18 years; p=0.01, p=0.05, respectively), the disease status at transplant (com-
plete remission vs active diease; p=0.10, p=0.01, respectively), complex kary-
otype (CK- vs CK+; p=0.05, p=0.002, respectively), and stem cells source (bone
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marrow vs other source; p=0.03 for OS only); monosomal karyotype (MK- vs
MK+; p=0.009 for EFS only). Other factors including variant of AML, patient
sex, donor type, conditioning regimen, number of transplanted CD34+cells,
and type of chromosome abnormality were not associated with survival. In mul-
tivariate analysis, age (HR-3.67; P=0.01), the disease status at allo-HSCT (HR-
2.64; P=0.03), the stem cell source (HR-3.04; P=0.02), and complex karyotype
(HR-2.48; P=0.03) remained statistically significant for OS. Moreover, age (HR-
2.63; P=0.01), the disease status at transplant (HR-2.63; P=0.01) and complex
karyotype (HR-3.29; P=0.002) were independent predictors of EFS (Figure 1).
Table 1.
Number of patients                                                                                     44 (100%)
AML
De novo AML                                                                                               27 (61%)
Secondary AML                                                                                           17 (39%)
Patient sex, n (%)
Male                                                                                                           22 (50%)
Female                                                                                                       22 (50%)
Age at HSCT, median, (range) years                                                           31.2 (1.2-67)
Age group
≤18 yo                                                                                                       15 (34%)
≥18 yo                                                                                                       29 (66%)
Cytogenetics, n (%)
5q                                                                                                              15 (34%)
-7/7q-                                                                                                        24 (55%)
5q- together with -7/7q-                                                                               5 (11%)
Complex karyotype -                                                                                    25 (57%)
Complex karyotype+                                                                                    19 (43%)
Monosomal karyotype –                                                                               36 (82%)
Monosomal karyotype+                                                                                 8 (18%)
Clinical stage at HSCT, n (%)
CR1≥                                                                                                          13 (30%)
CR2                                                                                                             7 (16%)
Active disease                                                                                             24 (54%)
HSC source, n (%)
Bone marrow                                                                                               24 (55%)
Peripheral blood                                                                                          15 (34%)
Both                                                                                                            5 (11%)
Conditioning regimen, n (%)
MA                                                                                                             10 (23%)
Non-MA                                                                                                      34 (77%)
Donor type, n (%)
HLA-id sibling                                                                                              13 (30%)
Matched unrelated                                                                                      20 (45%)
Haploidentical                                                                                             11 (25%)
Number of transplanted CD34+ cells, mediana (range) x106/kg                 6.3 (1.6-17.9)
Figure 1.
Summary/Conclusions: The results indicate, that chromosome 5 and 7 abnor-
malities as a part of the complex karyotype but not monosomal karyotype is




MUTATIONAL PROFILE BY NEXT-GENERATION SEQUENCING IN ACUTE
MYELOID LEUKEMIA (AML): A SINGLE CENTER EXPERIENCE
G Piras*, R Asproni, M Monne, AD Palmas, A Uras, N Marziliano, G Latte
Laboratorio Specialistico di Ematologia, Hematology, San Francesco Hospital,
ASLNuoro, Nuoro, Italy
Background: AML is a clonal disorder of hematopoietic stem and progenitor
cells caused by acquired and occasionally inherited genetic alterations. Cyto-
genetic aberrations together with gene mutations are powerful prognostic mark-
ers and the mutational profile can be incorporated in the decision making
processes to treatment.
Aims: A real-life cohort of AML patients from Sardinia (Italy) was analyzed to
evaluate the usefulness of a next-generation sequencing (NGS) gene panel
for the detection of mutations associated with AML in a context of routine diag-
nostic molecular workup.
Methods: Thirty AML patients, 15 males and 15 females with median age of
60 years (range 18-88 years) were enrolled for the study. DNAs were screened
with IonAmpliseq AML panel (ThermoFisher) on IonPGM platform. The panel
includes hotspots mutations of the genes: ASXL1 (exon 12), BRAF
(V600E),CBL(exons 8-9), FLT3(codons 676,830-850), IDH1(exon 4),
IDH2(exon 4), JAK2 (exon 14), KIT (exons 8, 10, 11 and 17), KRAS (exons 2-
4), NRAS (exons 2-4), PTPN11 (exons 3,7,8,13), RUNX1 (exons3-8), WT1
(exons 7,9), and the entire coding sequence of CEBPA, DNMT3A, GATA, TET2
and TP53 genes.The panel design does not include the FLT3-ITD gene region.
Genomic libraries were prepared using Ion AmpliSeq™2.0 (ThermoFisher)
chemistry and library clonal amplification was performed by emulsion PCR
using Ion PGM™Template HiQ OT2 Reagents. Combination of 5 libraries on
an Ion 318™Chip resulted in >2500X average coverage depth with >97% of
the target bases covered at 500X. Genomic variants were filtered and analysed
through AmpliseqAML single 5.0 workflow.
Results: The mean count of sequencing reads obtained per sample was 0.73
million and the mean sequencing depth was over 2500X with 91% uniformity.
Seventy-five mutations in 19 genes were detected in 31 samples with an aver-
age of 2.3 mutations per sample. TP53 mutations were found in 4 patients of
whom one with unfavorable cytogenetics.The AML panel detected 15 mutations
(20%) in NPM1, 6 (8%) TET2, 10 (13%) DNMT3A, 6 (8%) CEBPA, 5 (7%)TP53,
3 (4%) RUNX1,4 (5%) FLT3, 4 (5%) IDH2, 2 (3%) ASXL1, 5 (7%) GATA2, 6
(8%) PTPN11 and 3 (4%) KIT genes. Only one patient remained wild-type for
these genes. Based on mechanism of action, genes involved in signal trans-
duction and DNA methylation were the most frequently mutated, accounting
for the 39% and 32% of detected mutations, respectively. The AML gene panel
identified 100% of previously identified mutations by conventional molecular
biology techniques in FLT3(TKD), NPM1, IDH1-2 and CEBPA genes. Muta-
tional profiles obtained by NGS allowed to refine cytogenetic classification in
the normal karyotype subgroup shifting a large proportion of patients (24 out
of 30) from the intermediate to poor risk category. In one patient we were able
to assess clonal dominance over the course of the disease treatment. A female
50 y.o. diagnosed with AML-M2 presented at diagnosis IDH2 p.R172K mutation,
DNMT3A p.F640fs*11 and CEBPA p.P196_P197insHP at frequencies of 42%,
49% and 20%, respectively. Monitoring of mutation levels in two consecutive
bone marrow samples during treatment according to AML1310 protocol,
demonstrated treatment associated clonal responses. IDH2 mutation had a
frequency of 7.3% after 4 weeks of therapy and resulted absent after 8 weeks
(not detected over 6500 reads), while DNMT3A and CEBPA mutations were
present at the levels of 30% and 47%, respectively. Longitudinal monitoring of
three mutations indicated the presence of independent clones behaving dis-
cordantly during therapy.
Summary/Conclusions: A targeted multi gene panel analysis can provide in
a short turnaround time a pretreatment mutational profile as well as the MRD
status helping decision of intensity and type of induction therapy and modulation
of post remission strategies.
PB1638
MRD MONITORING AND DETECTION OF MOLECULAR RELAPSE IN
PEDIATRIC AML USING STANDARDIZED QPCR ASSAYS
MK Holz1,*, C Walter1, M Hansen2, C von Neuhoff1, H Hasle2, D Reinhardt1,
N von Neuhoff1
1Pediatric Hematology and Oncology, University Children’s Hospital Essen,
Essen, Germany, 2Department of Clinical Medicine - Paediatrics, Aarhus Uni-
versity, Aarhus, Denmark
Background: Acute myeloid leukemia (AML) is one of the most life threatening
malignancies in children and adolescents. In current multi-center treatment
protocols, the remission status of a patient is still determined morphologically
and/or by flow cytometric as the percentage of AML blasts in the bone marrow.
Although introduced in ALL for more than 10 years, no AML study group so far
has been able to systematically perform real-time quantitative polymerase
chain reaction (qPCR) as one of the most senstive methods to detect the pres-
ence of leukemic cells down to levels of 1:106.
Aims: The aim of the present study was to develop the methodology for mon-
itoring the residual levels of AML blasts over time for patients with defined
genetic aberrations enrolled in the AML-BFM 2012 clinical trial or in the study
registry. These aberrations included t(8;21), t(9;11), inv(16) and NPM1 Mutation
A. All patients were treated according to the AML-BFM study protocols.
Methods: We performed qPCR on mRNA isolated from bone marrow biopsies
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and peripheral blood samples of pediatric AML patients. Bone marrow specimen
were collected at initial diagnosis and after therapy blocks as indicated in the
protocol. If possible, peripheral blood was collected every 4 weeks during main-
tenance therapy. We collaborated with a diagnostic laboratory in Denmark to
develop and optimize standard operation procedures (SOPs) and to further
standardize the MRD-monitoring methodology. Mutation-specific TaqMan
probes were used and validation was performed by exchanging and analysing
samples and data in parallel in both laboratories using the ∆∆Ct method. ABL
proto-oncogene 1(ABL) and beta-2-microglobulin (B2M) were selected as ref-
erence genes for amplification.
Results: Out of 159 patients with newly diagnosed pediatric AML from 06/2014
to 02/2016, 44 patients had genetic aberrations that could be detected and
monitored using qPCR with specific primers. This included 12 patients with
t(8;21), 16 patients with t(9;11), 12 patients with inv(16) and 4 patients with
NPM1 mutation A. For 36 patients, we were able to analyze samples from at
least 3 time points. We were able to reach sensitivity levels from 10-3 to 10-6
depending on both the quality of the bone marrow specimen as well as the
specific assay.
Summary/Conclusions: We demonstrated here that qPCR for four defined
genetic aberrations during and after therapy is a useful tool to prospectively
monitor the AML blast levels. Due to the high sensitivity of this methodology it
is possible to detect a molecular relapse at an earlier time point compared to
standard morphological or flow cytometric analysis. We also showed that the
successful standardization of the qPCR allowed to directly compare the MRD
results from different laboratories.
PB1639
AMPLICON BASED PANEL TARGETED RESEQUENCING WITH THE
TRUSIGHT MYELOID PANEL IN 100 PEDIATRIC AML PATIENTS
C Walter*, D Reinhardt, N von Neuhoff
Pediatric Hematology and Oncology, University Children’s Hospital Essen,
Essen, Germany
Background: Acute myeloid leukemia (AML) is one of the most threatening
malignancies in children and adolescents. The accumulation of mutations in
leukemia stem cells (LSC) is believed to lead to the development of leukemia.
Cyto- and molecular genetics already identified several aberrations which are
relevant in leukemogenesis, prognosis and therapy. Nevertheless, the molecular
landscape and clonal evolution of AML and its clinical relevance, especially for
pediatric patients, is not yet well described. Next Generation Sequencing as an
emerging sequencing technology provides the possibility to generate sequence
data of high quality and detect genetic aberrations in a minimum of time.
Aims: The aim of this study was to apply amplicon based panel targeted rese-
quencing by using the TruSight Myeloid Panel (Illumina) on a MiSeq Dx System
(Illumina) to analyse 100 children with suspicion of AML at the time of initial
diagnosis to detect the genetic variants.
Methods: All the patients analysed in this study were screened in order confirm
or exclude the diagnosis of AML. With the confirmation of AML, the patients
were treated according to the AML-BFM therapy protocols. Next Generation
sequencing (NGS) with the TruSight Myeloid panel on a MiseqDX was per-
formed. The sequencing panel is designed to identify somatic mutations asso-
ciated to myeloid malignancies in 54 genes. Validation was initially performed
using data for 10 patients obtained from Sanger-Sequencing from 7 diagnos-
tically relevant mutations and compared to the data obtained from NGS. The
genes actually relevant for prognosis and treatment stratification are CEBPA,
FLT3, GATA1, KIT, NRAS, NPM1 and WT1.
Results: Every variant detected with Sanger Sequencing could be recovered
in the NGS data. In 4 patients we could even detect additional mutations. Vari-
ants were detected and analysed using two different analysis software (Variant
studio vs Sophia DDM) and the results were compared. Almost all variants
were detectable in both software, although great insertions and deletions are
detectable only by Sophia DDM. We could detect CEBPA mutations in 16
patients, FLT3 ITD in 10 patients, FLT3 TKD mutations in 2 patients, GATA1
mutations in 6 patients, KIT mutations in 25 patients, NPM1 mutations in 7
patients, NRAS mutations in 14 patients and WT1 mutations in 24 patients. In
26 patients, we could not detect any mutation in these 7 genes. 23 patients
had two different mutations at the same time and even three mutations could
be detected in 4 patients. The analysis of variants detected in the 47 other
genes covered in the panel is still ongoing.
Summary/Conclusions: Amplicon based panel targeted resequencing with the
TruSight Myeloid panel provides the possibility to detect mutations in 54 genes
associated to myeloid malignancies within 3 days after the sample arrived at our
lab. The aim now is to adapt the report of the clinical findings to the detected vari-
ants, especially for variants in genes that were not yet diagnostically relevant.
The confirmation of pathogenicity of variants in a broad range of genes could
promote the possibilities of personalized targeted therapy.
PB1640
EMBRYONIC STEM CELLS ANTIGEN (ESCA) EXPRESSION IN ACUTE
MYELOID LEUKEMIA CELLS
T Picot1,*, C Aanei2, A Fayard3, E Tavernier-Tardy3, P Flandrin-Gresta2,
S Tondeur2, M Gouttenoire3, E Wattel4, D Guyotat3, L Campos-Catafal2
1Laboratoire d’Hématologie, CHU de Saint Etienne, 2Laboratoire d’Hématolo-
gie, CHU de Saint-Etienne, 3Département d’Hématologie, Institut de Cancérolo-
gie Lucien Neuwirth, Saint-Priest-en-Jarez, 4Laboratoire de Biologie de Mod-
élisation de la Cellule, Lyon Sud, Lyon, France
Background: Acute Myeloid Leukemia (AML) is characterized by the expansion
and resistance to apoptosis of poorly differentiated myeloid cells. This disease
occurs when genetic and epigenetic processes transform an immature
hematopoietic stem or progenitor cell, which reacquire self-renewing properties,
and retain an undifferentiated state. Long term propagation of the disease is
mainly due to a subset of proliferative, undifferentiated population, termed
leukemic stem cells (LSC), which give rise to the leukemic clone. The frequency
of LSC in the bulk of leukemic cells is highly variable. Several studies have
suggested that LSC belongs to the CD34+CD38- compartment and represent
the malignant counterpart of normal hematopoietic stem cells (HSC). LSC can
be identified by aberrant expression or down regulation of differentiation mark-
ers expressed by normal HSC. Self-renewal and lack of differentiation are also
features of stem cells and has been associated with the expression of genes
including those known as “Yamanaka’s factors”. The products of these genes
are surface receptors (SSEA1 and SSEA3) and transcription factors (OCT¾,
SOX2, and NANOG). There are some data concerning the abnormal expression
of these proteins in solid tumors, but very few data are available in AML.
Aims: The aim of our study was to evaluate the expression of 5 ESCA (SSEA1,
SSEA3, NANOG, OCT¾ and SOX2) in leukemic cell lines, and in hematopoietic
stem cell (HSC) subsets (CD34+CD38- and CD34+CD38+) from normal bone
marrows (NBM) and in 106 samples from AML patients.
Methods: The expression of 5 ESCA was assessed by Multicolor Flow Cytom-
etry and was confirmed by Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR).
Results: We observed a high expression of ESCA in AML cell lines (Mean Flu-
orescence Intensity Ratio MFIR>10, Cycle threshold Ct<40). Their expression
was evaluated in CD34+, as well as in the remaining CD45+low “blasts” after
basophils and dendritic cells removal. We observed an up-regulation of the tran-
scription factors OCT¾ and SOX2 with 2-fold higher expression (p<0.05) in AML
cells as compared to normal cells. These results were associated with the up-
regulation of SSEA3. Conversely, SSEA1 protein was down-regulated in LSC
(1.7-fold higher expression in normal cells compared to leukemic cells, p<0.05).
The expression of OCT¾, SOX2 and SSEA3 was higher in CD34+CD38- than in
CD34+CD38+subsets in HSC as well as in leukemic cells. The level of SSEA1
and NANOG were higher in more differentiated (CD34+CD38+) cells. Significant
correlations were observed with recurrent molecular abnormalities. The expres-
sion of OCT¾ and SOX2 was lower in promyelocytic leukemia (APL) (p<0.005).
SOX2 was also lower in AML with RUNX1-RUNX1T1 rearrangements (but not in
AML with CBFβ-MYH11). Instead SSEA1 levels were higher in AML with CBF
rearrangements (p<0.001), but not in APL. There was no correlation with other
biological characteristics (WBC, other genetics subtypes). We also evaluated the
prognostic value of ESCA expression in the 69 patients who received an intensive
treatment. The rate of complete remission was not influenced by the level of
expression of ESCA. There was a trend (p=0.06) for better overall and leukemia-
free survival for patients with high OCT¾ and SOX2 levels, that was unexpected
because of the inverse correlation with favourable genetic subtypes.
Summary/Conclusions: In conclusion, these results prompt us to evaluate
the potential role of ESCA in leukemogenesis and to test the relevance of these
markers for better LSC identification. Prognostic value should be assessed in
larger series by multivariate analysis.
PB1641
ASSOCIATION BETWEEN POLYMORPHISM OF FOLATE AND METHIONINE
METABOLISM GENES AND ABERRANT DNA METHYLATION IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
Z Sidorova1,*, S Kapustin1, I Kostroma2, S Gritsaev2, A Chechetkin3
1Laboratory of biochemistry, 2Hematological Clinic, 3FSBI “Russian Research
Institute of Hematology and Transfusiology of FMBA”, Saint-Petersburg, Russ-
ian Federation
Background: Aberrant DNA methylation of tumor-supressor genes may be
involved in the development of acute myeloid leukemia (AML) and myelodys-
plastic syndrome (MDS). Polymorphism of folate and methionine metabolism
(FMM) related genes can influence the methylation processes and, therefore,
operated on both AML and MDS development.
Aims: The aim of this study was to assess the association between polymor-
phism of FMM related genes and aberrant methylation of promoter regions of
several tumor supressor genes in AML and MDS patients.
Methods: Fifty-seven patients with AML (20 men and 37 women, mean age 51.0
yrs) and 51 patients with MDS (24 men and 27 women, mean age 62.4 yrs) were
genotyped for the MTHFR C677T, MTHFR A1298C, MTR A2756G, MTRR A66G
and MTHFD G1958A polymorphisms by PCR-RFLP technique. The differences
in allele and genotype frequencies were assessed by Fisher’s exact test with
computation of odds ratios (OR), their 95% confidence intervals (CI) and p-values.
Methylation-specific PCR was used to study the methylation status of promoter
regions of SOX7, p15INK4b, SFRP1, SFRP4 and SFRP5 genes.
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Results: Thirty patients AML (10 men and 20 women) and 21 patients MDS (9
men and 12 women) had aberrant methylation of 0-2 genes (0-2 MG group AML
and MDS respectively). Twenty seven patients AML (10 men and 17 women)
and 30 patients MDS (15 men and 15 women) had aberrant methylation of 3-5
genes (3-5 MG group AML and MDS respectively). In MDS group, hypermethy-
lation of all 5 genes was found in 5 men and was not found in female patients
(20.8% vs 0.0%, respectively, OR=15.5, 95%CI: 0.8-297.0, p=0.02). At the same
time, aberrant methylation of all 5 genes was found in 8 AML patients (4 men
and 4 women, 20.0% vs 10.8%, respectively, OR=1.9, 95%CI: 0.4-8.2, p=0.45).
The presence of the MTHFR 1298C allele was increased in male patients AML
from the group 0-2 MG when compared to male MDS patients in the 0-2 MG
group (73% vs 43%, respectively, OR=3.7, 95%CI: 1.1-11.9, p=0.042). The pres-
ence of the MTHFR 677T allele was increased in female AML patients from the
group 3-5 MG when compared to female AML patients in the 0-2 MG group
(76.5% vs 35.0%, respectively, OR=6.0, 95%CI: 1.4-25.7, p=0.02), but was not
different between women from 3-5 MG and 0-2 MG groups MDS patients (46.7%
vs 33.4%, respectively, OR=1.8, 95%CI: 0.4-8.4, p=0.7). It is interesting, that
positivity for the MTHFR 677T allele was significantly increased in male MDS
patients from the group 0-2 MG when compared to male 3-5 MG group (100.0%
vs 46.7%, respectively, OR=21.5, 95%CI: 1.2-437, p=0.01). In male patients with
MDS, the MTHFD 1958 AA genotype was more frequently seen in the group 3-
5 MG than in the group 0-2 MG (33.0% vs 0.0%, respectively, OR=9.9, 95%CI:
0.5-205.0, p=0.12). This genotype was also overrepresented in the group 3-5
MG of women with AML when compared to group 0-2 MG of female AML patients
(29.4% vs 5.0%, respectively, OR=7.9, 95%CI: 0.8-76.3, p=0.08).
Summary/Conclusions: We conclude that polymorphism of the FMM genes
could have an important role in mechanism of epigenetic disturbances at AML
and MDS, associated with aberrant methylation of CpG islands of tumor-
supressor genes.
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LOCALIZATION OF FLT3-ITD IS ASSOCIATED WITH RESPONSE TO
INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA
U Schnetzke*, M Fischer, B Spies-Weisshart, M Fleischmann, I Hilgendorf,
A Hochhaus, S Scholl
Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkolo-
gie, Universitätsklinikum Jena, Jena, Germany
Background: FLT3-ITDs (internal tandem duplications) represent the most fre-
quent molecular aberrations in acute myeloid leukemia (AML) that are both vir-
tually patient-specific and associated with a higher probability of relapse. Several
studies addressed the question whether the diversity of FLT3-ITD affects the
clinical outcome of AML patients. We present patient-specific sequence analysis
of FLT3-ITD-positive AML patients and its correlation with clinical data.
Aims: FLT3-ITD sequence analysis focused on ITD localization and the presence
of distinct amino acid motives. We sought to establish a relationship between the
localization of the internal tandem duplication in FLT3 and response to therapy.
Methods: 43 patients (26 female, median age 57 years, 84% with de novo
AML) diagnosed and treated in a single center were retrospectively analysed.All
patients received intensive induction chemotherapy according to one of the
following protocols of the Ostdeutsche Studiengruppe für Hämatologie und
Onkologie (OSHO): AML96 or AML2002 protocol containing idarubicine for
patients up to 60 years old and AML97 or AML2004 protocol containing mitox-
antrone for elderly patients.
Results: FLT3-ITD localization more downstream can be correlated with impaired
leukemia-free survival (LFS) while the level of significance is not reached in our
small cohort of AML patients. In contrast, all investigated amino acid motifs (e.g.
YVDFREY) had no impact on the clinical outcome. Importantly, the probability to
achieve a complete remission (CR) after AML induction chemotherapy is affected
by the localization of the internal tandem duplication. In detail, CR rate is signif-
icantly higher in those patients who present with FLT3-ITD localized towards the
N-terminus (86.4% vs 57.1%, p=0.045, Chi squared test).
Summary/Conclusions: We hypothesize that FLT3-ITDs that are located clos-
er to the C-terminus of FLT3 are associated with an unfavorable prognosis due
to a lower CR rate following induction chemotherapy of AML.
PB1643
MITOCHONDRIAL SPECIFIC ROS HYPEROXIDATION VIA PEROXIREDOXIN
III HAS IMPORTANT ROLES ON ARSENIC TRIOXIDE INDUCED APOPTOSIS
IN ACUTE PROMYELOCYTIC LEUKEMIA
CM Seong1,*, YC Mun1, JY Ahn1, ES Yoo2, KE Lee1, E Nam1, SN Lee1,
HA Woo3, SG Rhee4
1Department of Internal Medicine, 2Pediatrics, Ewha Womans University
School of Medicine, 3Graduate School of Pharmaceutical Sciences, Ewha
Womans University, 4Yonsei Biomedical Research Institute, Yonsei University
College of Medicine, Seoul, Korea, Republic Of
Background: Despite that the Arsenic trioxide (ATO) is an effective therapeutic
drug for acute promyelocytic leukemia (APL), some APL cells are resistant to
ATO treatment. Previous studies reported that the apoptotic processes by ATO
treatment was due to the accumulation of ROS in the cells and its balance of
redox enzymes. However, not only the mechanisms of apoptosis via reactive
oxygen species (ROS) and peroxiredoxin (PRX) but its resistance during ATO
treatment remain elusive.
Aims: Aims of current study are to elucidate that the upregulation of ROS pro-
duction and the changes of redox enzyme may be major players of anti-leukemia
effect in APL-derived NB4 cells during ATO treatment and to find ways to poten-
tiate of the anti-leukemic effects by maniplating ROS and its redox enzymes.
Methods: NB4, one of the human acute promyelocytic leukemia cell lines, was
treated with 2 μM arsenic trioxide to induce apoptosis for 16-48 hours in RPMI-
1640 medium supplemented with 10% FBS in CO2 humidified atmosphere at
37°C. Apoptosis was measured by staining with 7-amino-actinomycin D (7-
AAD) with flow cytometry. 2, 7-dichlrodihydro-fluorescein-diacetate (H2DCF-
DA) and MitoSOX Red were used to detect cellular and mitochondrial levels of
ROS. SO2 form for PRX I, PRX II, and PRX III were detected by western blot
assay. Steady state level of sulfiredoxin (SRX) and caspase 3, 9 were also
studied by western blot analysis. To evaluate of the effect of SRX depletion,
NB4 cells were transfected with small interfering RNA (siRNA).
Results: Intracellular ROS of NB4 cells was increased significantly after 16 hour
of ATO treatment but decreased after 24 hour of ATO treatment. Mitochondrial
ROS of NB4 cells was increased significantly after 39 hour of ATO treatment.
Apoptosis of NB4 cell after ATO treatment was increased as time elapsed (24%
on 16hr, 26% on 24hr, 48% on 39hr, and 60% on 48hr). Increased cysteine
sulfinic acid (Cys–SO2H) of PRX III, oxidized form, was observed as a hyperox-
idation reaction in NB4 cells after ATO treatment in concordance with mitochon-
drial ROS increment of NB4 cells. Increased expressions of cleaved caspase-9
and cleaved caspase-3 were also observed during NB4 cell apoptosis by ATO
treatment. Meanwhile, SRX expression was increased in NB4 cells after ATO
treatment which was rather unexpected observation. Down regulation of SRX
by siRNA promoted ROS generation and apoptosis in ATO-treated NB4 cells.
Summary/Conclusions: These findings suggest that ATO-induced anti-
leukemic activity can be down regulated by an enhancing oxidized PRX III
reduction after ATO-induced SRX activation and that down regulation of SRX
can enhance the apoptosis in ATO-treated NB4 cells. This result might provide
the insights for finding novel ways in the development of strategies, which may
potentiate ATO-induced apoptosis in APL cells.
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HIGH EXPRESSION OF TIM-3 ON BLAST CELLS IS ASSOCIATED WITH
GOOD PROGNOSTIC FACTORS IN DE NOVO NON-M3 AML
X Wu*, L Xu, J Xu, M Zhu, C Fu, Y Han,xTang, H Qiu, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: T-cell immunoglobulin and mucin domain-containing molecule3
(Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion.
Tim-3 has also been identified in various solid tumors. However, the role of
Tim-3 expression on blast cells in acute leukemia is not well understood.
Aims: In this study, we aimed to explore the role of Tim-3 in patients with de
novo acute leukemia and the correlation between Tim-3 and clinicopathological
prognosis.
Methods: The study cohort consisted of 121 patients including 76 cases with
de novo non-M3 AML and 45 cases with ALL. These patients’ bone marrow
samples were collected and then bone Marrow mononuclear cells (BMCs)
were isolated for flow cytometry to detect Tim-3 expression on blast cells.
E_LINK3”>clinicopathological prognosis.
Results: According to FAB type, 76 AML patients were diagnosed as M0(n=2),
M1(n=16), M2(n=20),M4(n=20),M5(n=16) and M6(n=2), respectively. And ALL
group were comprised of 38 cases with B-cell ALL and 7 cases with T-cell ALL.
The results came out that Tim-3 expression on blasts in de novo AML patients
significantly increased compared with that of ALL patients (P=0.00). Moreover,
the frequency of Tim-3 high expression was higher in M4 patient than that in
other AML patients according to FAB type (P=0.00). Tim-3 high expression
was also closely associated with inv(16) (P=0.01) and C/EBPA mutation
(P=0.03). The mutations of the following six genes, i.e., FLT3-ITD, NPM1, C-
KIT, IDH1/IDH2, DNMT3A, had little to do with the expression of Tim-3. Addi-
tionally, it is more likely to find higher level of Tim-3 in low-risk group than in
intermediate- and high-risk groups (P=0.04). The expression of Tim-3 was pos-
itively correlated with CD13 (r=0.33,P=0.02), CD34 (r=0.51, P=0.00), CD7
(r=0.40, P=0.00) in AML patients. As for the ALL patients, Tim-3 expression
significantly increased in the T-ALL group than in the B-ALL group (P=0.00).
The expression of Tim-3 in ALL patients was positively correlated with
CD34(r=0.32, P=0.00), CD7(r=0.56, P=0.01) and negatively with CD10(r=-
0.35,P=0.02), CD19(r=-0.24,P=0.00), CD20(r=-0.31,P=0.01). Tim-3 expression
was not significantly associated with potential prognostic factors, including age
or cytogenetic risk in ALL patients. AML patients with high Tim-3 expression
achieved significantly high CR rate (P=0.01) and then their Tim-3 expression
significantly decreased after CR (P=0.00), but such trend did not occur in ALL
patients.
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Summary/Conclusions: These findings suggest that high Tim-3 expression on
blast cells is associated with good prognosis and detection of Tim-3 expression
may be helpful to predict clinicopathological prognosis in non-M3 AML patients.
PB1645
MEIS1 IS ESSENTIAL FOR THE MAINTENANCE OF HUMAN ACUTE
MYELOID LEUKEMIA BLASTS INDEPENDENT OF MLL REARRANGEMENTS
J Liu*, YZ Qin, S Yang, Y Wang, YJ Chang, T Zhao, Q Jiang, XJ Huang
Peking University People’s Hospital, Beijing, China
Background: Acute myeloid leukemia (AML) is one of the common hematopoi-
etic malignancies with high mortality. Although the outcome of patients with
AML has improved by optimized chemotherapy regimens and bone marrow
transplantation, leukemia relapse remains one of the most challenging problems
during clinical treatment. Sustained existence of AML blasts is a fundamental
determinant for the leukemia development and resistance to therapy. Recent
evidences suggest that Meis1 is tightly associated with the self-renewal capacity
of normal hematopoietic stem cells. Meis1 was also found to be essential for
the development of mixed lineage leukemia (MLL)-rearranged leukemia.
Whether Meis1 functions independently of MLL abnormality in the context of
leukemia is of major interest.
Aims: To elucidate whether Meis1 functions independently of MLL abnormality
in the maintenance of leukemia blasts.
Methods: We performed siRNA-mediated gene silencing experiments in the
cultured human AML cells without MLL rearrangements. Next, we detected the
expression levels of Meis1 in the bone marrows from 95 patients with newly
diagnosed AML excluding promyelocytic leukemia and 30 healthy donors. All
patients did not express a set of recognized AML-associated fusion genes. The
association between the Meis1 levels and the response to chemotherapy was
further explored.
Results: Deficiency of Meis1 expression impaired the maintenance and survival
of cultured human AML blasts, which is independent of MLL abnormality. In the
patients with newly diagnosed AML and without MLL rearrangements, high lev-
els of Meis1 expression were found in 64 of 95 (67.4%) AML patients whereas
31 of 95 (32.6%) patients showed the dramatically low levels, compared with
the median level of Meis1 expression in healthy donors. We further demon-
strated that high levels of Meis1 expression were associated with the poor
response to conventional chemotherapy, compared with the group with low
Meis1 levels (p=0.028).
Summary/Conclusions: We identified a distinct expression pattern of Meis1
levels in patients with newly diagnosed AML and highlighted a role of Meis1 in
regulating maintenance and survival of human AML cells without MLL abnormality.
These results implicate Meis1 functions as an important regulator and could be
an independent prognostic factor during the progression of human AML.
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ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE AMELIORATES
CYTARABINE-INDUCED OVEREXPRESSION OF NUCLEOPHOSMIN AND
DRUG-INDUCED-CHEMORESISTANCE IN HL-60 AML CELLS
D Kim1,*, YH Kwon2, BH Choi1, DH Lee1, JH Kang1, HG Yi3, CS Park1
1Department of Pharmacology, Inha University School of Medicine, 2Inha
Research Institute for Medical Sciences, 3Deparment of Internal Medicine, Inha
University School of Medicine, Incheon, Korea, Republic Of
Background: Nucleophosmin (NPM or B23) is a ribosomal protein located
mainly in nucleolus, and multifunctional enzyme in cancer cell growth and pro-
tein synthesis. Particularly, it has been suggested that NPM plays a role in the
positive regulation of cell proliferation, thus observed the over-expression levels
in pathological higher grades of tumor and actively proliferating cells than nor-
mal cells. On the other hand, AMP-activated protein kinase (AMPK) is a critical
energy sensor to regulate homeostasis and plays a potential role for anti-cell
proliferating activity.
Aims: We investigated the effects of AMPK activation on the cell death (apop-
tosis) and NPM expression in AML (acute myeloid leukemia) cells (HL-60) treat-
ed with low or high dose of an antileukemic drug cytarabine to understand the
mechanisms responsible for AML cells chemoresistance.
Methods: Cell viability was assessed using MTS assay. Apoptosis and cell
cycle progression were evaluated by flow cytometry assay. Protein and mRNA
expressions were detected with real time-PCR and Western blot assay.
Results: Interestingly, we found that the level of NPM expression was increased
significantly in cytarabine-treated cells without dose-dependency of cell death,
indicating the drug-induced cell resistance. In the same point, cytarabine also
inhibited the phosphor-activity (Thr172) and expression level of AMPK, which
has mTOR-p70S6K pathway-repressor activity. As expected, single cytarabine
treatment increased the ratio of p-mTOR/mTOR and p-p70S6K/p70S6K. Co-
treatment of AMPK activator (phenformin or AICAR) in cytarabine-treated HL-
60 AML cells inhibited significantly the induction of NPM expression level with
the decrease of phosphor-activities of mTOR and its substrate p70S6K, resulted
in the accelerated cell apoptosis.
Summary/Conclusions: Our results suggest that AMPK activation might be
used to sensitize AML cells to cytarabine with the control of NPM expression
levels, thus the lower therapeutic dose and the less adverse effects.(Corre-
spondence to HG Yi and CS Park; Medical Research Center no. 2014009392)
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SERUM LEVELS OF CYTOKINES AND SOLUBLE ADHESION
MOLECULES IN ACTIVE ACUTE MYELOID LEUKEMIA AND COMPLETE
REMISSION: EVIDENCE OF ENDOTHELIAL CELL ACTIVATION
T Kupsa1,2, J Vanek3, P Zak2, L Jebavy1,2, JM Horacek1,2,*
1Department of Military Internal Medicine and Military Hygiene, Faculty of Mil-
itary Health Sciences, 24th Department of Internal Medicine - Hematology, Uni-
versity Hospital and Charles University, Faculty of Medicine, 3Department of
Informatics and Quantitative Methods, University of Hradec Kralove, Faculty of
Informatics and Management, Hradec Kralove, Czech Republic
Background: Acue myeloid leukemia cell are highly resistant to therapy. The
presumed molecular basis of this resistance is the effect Tumor Necrosis Factor-
α (TNF-α) and other cytokines on endothelial adhesion molecule expression.
Aims: The aim of this study was to test the hypothesis that cytokines and sol-
uble adhesion molecules are involved in endothelial cell activation in acute
myeloid leukemia (AML).
Methods: A total of 84 AML patients were studied. Two subgroups comprising
84 samples collected in active disease and 45 samples collected at AML complete
remission (CR) were evaluated. Samples obtained after allogeneic stem cell
transplantation were not included. We evaluated serum levels of the following 29
analytes: interleukins (IL-1α,IL-1β,IL-2,IL-3,IL-4,IL-5,IL-6,IL-7,IL-8,IL-10,IL-12,IL-
13,IL-15), Epidermal Growth Factor (EGF), GM-CSF, IFN-γ, Macrophage Inflam-
matory Protein-1α (MIP-1α), Monocyte Chemotactic Protein-1 (MCP-1), TNF-α,
Vascular Endothelial Growth Factor (VEGF), E-selectin (E-SEL), P-selectin (P-
SEL), Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Mol-
ecule-1 (VCAM-1), Matrix Metalloproteinase-9, soluble IL-2 receptor-α (sIL-2Rα)
and soluble receptors for IL-6 (sIL-6R) and TNF-α type I and II (TNFR-1,2). All
biomarkers were measured by biochip array technology on Evidence Investigator
analyzer (Randox). Probability values (P)<0.05 were considered significant.
Results: In active disease, the levels of VCAM-1 correlated with ICAM-1
(P˂0.0001), E-SEL (P=0.0011), leukocyte count (P=0.0006), TNF-α (P˂0.0001),
TNFR-2 (P˂0.0001), TNFR-1 (P=0.0047), LDH (P˂0.0001), IL-2Rα (P=0.0224)
and IL-6R (P=0.0240). The ICAM-1 levels correlated with E-SEL (P=0.0285),
TNFR-1 (P=0.0007), LDH (P=0.0344) and IL-6 (P=0.0646). E-SEL correlated
with P-SEL (P˂0.0001), leukocyte count (P˂0.0001), LDH (P˂0.0001), TNFR-1
(P=0.0152), TNFR-2 (P=0.0202). CRP levels correlated with IL-6 (P˂0.0001),
ICAM-1 (P=0.0122) and negatively with albumin levels (P=0.0175). The platelet
count correlated with IL-7 (P˂0.0001), EGF (P˂0.0001) and VEGF. There was
no correlation of age or haemaglobin levels with any evaluated analyte. In CR
the levels of IL-7 (P˂0.0001), EGF (P˂0.0001) and VEGF (P˂0.0001) were higher,
which was related to normalized platelet count. The levels of IL-6 were lower in
CR with no significant correlation with CRP levels. The levels of VCAM-1, ICAM-
1, E-SEL and P-SEL were decreased compared to active disease, which was
not significant after Bonferroni correction of P. The P-SEL correlated with platelet
count (P˂0.0001) and IL-8 (P˂0.0001), which was not observed in active disease.
VCAM-1 correlated with ICAM-1 (P=0.0027), but not with E-SEL or P-SEL. The
E-SEL did not correlate with P-SEL.
Summary/Conclusions: Our findings are in agreement with the results of stud-
ies showing that cytokine and chemokine expression are largely independent
of variables, such as age, gender and haemoglobin levels. In active disease
the adhesion molecule levels are influenced as a whole and correlate with
leukocyte count, LDH and levels of TNF-α, TNFR-1 and TNFR-2. Understanding
the relationship of evaluated analytes in active AML and CR is more important
than simple comparison of their levels. Endothelial cells can release both E-
SEL and P-SEL. This happens in active disease, where the correlation of E-
SEL and leukocyte count is significant. In CR there was no significant correlation
of E-SEL with P-SEL or leukocyte count. Platelets release only P-SEL and are
the major source of P-SEL in CR. We interprete these data as direct evidence
of endothelial cell activation in active AML.
The work was supported by a long-term organisation development plan 1011
(FMHS).
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ARE TP53BETA AND TP53GAMMA EXPRESSION LEVELS CORRELATED
TO NPM1/FLT3 MUTATIONAL STATUS?
K Matiakowska*, A Bartoszewska-Kubiak, E Bielinska, M Morgut-Klimkowska,
O Haus
Department of Clinical Genetics, Collegium Medicum in Bydgoszcz, Nicolaus
Copernicus University in Torun, Bydgoszcz, Poland
Background: TP53 encodes a tumor suppressor protein which consists of
transactivation, DNA-binding and oligomerization domains. Due to alternative
splicing it may exist in 13 different isoforms. Alternative splicing of intron 9
leads to production of 2 different proteins, p53β and p53γ, without oligomer-
ization domain (stop codon is localized in exon 9b). These isoforms can be
present in acute myeloid leukemia (AML) cells. p53β binds to BAX promoter
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and can induce apoptosis independent from p53 wt. It also regulates p53
activity. In AML high expression of p53β and p53γ proteins may play role in
response to treatment by enhancing cells sensitivity to chemotherapy. It has
been showed that patients have longer survival after treatment. NPM1
(nucleophosmin gene) mutations are frequent alterations in normal kary-
otype AML (NK AML). Until now 56 different mutations of exon 12 of NPM1
have been described, mostly insertions. The NPM protein plays an important
role in cell cycle and apoptosis control. It cooperates with several proteins,
including p53 and ARF. While patients with NPM1 mutations are stratified to
favorable risk group, internal tandem duplications (ITD) in the fms-like tyro-
sine kinase-3 gene (FLT3) (i.e. FLT3ITD) are poor prognosis factors.
Aims: The aim of the study was to assess mutational status of NPM1/FLT3
in association with TP53beta and TP53gamma expression levels.
Methods: 56 NK AML patients with NPM1 and/or FLT3ITD mutations were
included in the study. Analysis of TP53β and TP53γ expression levels was
possible only in 36 patients. Relative expression results were analyzed with
ΔΔCt method, with ABL as a control gene and K562 cell line as a
calibrator.
Results: In all 36 cases, TP53β and TP53γ transcripts were detected. 17
patients were NPM1+/FLT3-, 14 were NPM1+/FLT3+and 5 were NPM1-
/FLT3+. Assessed median expression level of TP53β was much higher (ΔΔCt
43,87) than TP53γ (ΔΔCt 10,52; p=0,000027). Furthermore, according to
statistical analysis, expression level of TP53γ was significantly associated
with NPM1/FLT3 mutations (p=0,008). We also classified patients according
to median expression value of TP53 to two groups: with overexpression or
with small expression. Median WBC count in patients with overexpression of
both isoforms was higher (75,4 G/L) than in group where expression of both
isoforms was below median value (30G/L). Expression level of TP53γ was
also correlated to WBC (p=0,05) and patients’ age (p=0,015).
Summary/Conclusions: Obtained results may indicate a clinical importance
of analysis TP53 isoforms expression together with clinical data of patients.
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IMPACT OF ADDITIONAL CYTOGENETIC ABERRATIONS ON OUTCOME
OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH RUNX1-RUNX1T1 ACUTE MYELOID LEUKEMIA
TL Gindina*, N Mamayev, S Bondarenko, A Alyanskiy, A Borovkova, S Razumova,
O Slesarchuk, E Nikolaeva, L Zubarovskaya, B Afanasyev
R.M. Gorbacheva Memorial Research Institute of Pediatric Oncology, Hema-
tology and Transplantation, 1st Pavlov State Medical University of Saint Peters-
burg, Saint-Petersburg, Russian Federation
Background: RUNX1-RUNX1T1-positive acute myeloid leukemia (AML) is
considered as a favorable group. Allo-HSCT has been generally used for
relapsed patients (pts), although prognostic factors are still unclear and prog-
nostic significance of additional cytogenetic aberrations (ACA) in transplanted
pts is contradictory.
Table 1.
Number of patients                                                                                  25 (100%)
Patient sex, n (%)
Male                                                                                                           15 (60%)
Female                                                                                                       10 (40%)
Age at HSCT, median, (range) years                                                         20.2 (2-58)
Age group
≤18 yo                                                                                                       12 (48%)
≥18 yo                                                                                                       13 (52%)
Cytogenetics, n (%)
t(8;21) without additional cytogenetic aberration                                           12 (48%)
t(8;21) with additional cytogenetic aberration                                               13 (52%)
Complex karyotype -                                                                                    16 (64%)
Complex karyotype+                                                                                     9 (36%)
Time from diagnosis to HSCT, n (%)
<360 days                                                                                                  14 (56%)
>360 days                                                                                                  11 (44%)
Clinical stage at HSCT, n (%)
CR                                                                                                              13 (52%)
Active disease                                                                                             12 (48%)
HSC source, n (%)
Bone marrow                                                                                               13 (52%)
Peripheral blood                                                                                          11 (44%)
Both                                                                                                             1 (4%)
Conditioning regimen, n (%)
MA                                                                                                             12 (48%)
Non-MA                                                                                                      13 (52%)
Donor type, n (%)
HLA-id sibling                                                                                               7 (28%)
Matched unrelated                                                                                      12 (48%)
Haploidentical                                                                                              6 (24%)
Aims: To evaluate impact of additional cytogenetic aberrations on outcome of
allogeneic hematopoietic stem cell transplantation in patients with RUNX1-
RUNX1T1 acute myeloid leukemia
Methods: In this study, outcomes in 25 RUNX1-RUNX1T1-positive AML
patients (pts), who were transplanted in a single institution between 2008 and
2015, were analyzed. All patients and transplant characteristics are listed in
Table 1.
Results: The median follow-up was 566 (8 – 2127) days. Overall survival
(OS) was 33% (95% CI 14-53) and relapse free survival (RFS) was 26%
(95% CI 9-45) at 4 years estimated with Kaplan-Meier method. In univariate
analysis, prognostic factors associated with increased OS and RFS were
age (>18 vs <18 years; p=0.03, p=0.0006, respectively), donor type (match
related vs match unrelated vs haploidentical; p=0.0003, p=0.02, respectively),
disease status at transplant (complete remission vs active disease; p=0.0002,
p=0.005, respectively), the interval from diagnosis to transplant (<360 vs
>360 days; p=0.008, p=0.9, respectively), ACA (ACA- vs ACA+; p=0.02,
p=0.009, respectively) (Figure 1), complex karyotype (CK- vs CK+; p=0.004,
p=0.0003, respectively). In multivariate analysis, the ACA (HR-13.5; P=0.04),
the donor type (HR-6.86; P=0.01), the interval from diagnosis to HSCT (HR-
6.80; P=0.02) remained statistically significant for OS. Moreover, age (HR-
0.11; P=0.004) and the donor type (HR-4.16; P=0.04) were independent pre-
dictors of RFS.
Figure 1.
Summary/Conclusions: The study demonstrates that the ACAs are inde-
pendent prognostic factor for RUNX1-RUNX1T1-AML in transplanted pts.
Since chemotherapy and cytotoxic conditioning regimen may be responsible
for production of new ACAs, these regimens should be change by substitution
of more toxic alkylating agents to less toxic.
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ABERRANT METHYLATION OF PROMOTER REGIONS OF SOX7,
P15INK4B AND WNT PATHWAY ANTAGONIST GENES IN PATIENTS WITH
ACUTE MYELOID LEUKEMIA
I Kostroma1,*, Z Sidorova2, S Gritsaev1, S Tiranova3, I Martinkevitch4,
N Semenova5, Z Chubukina6, S Kapustin2, A Chechetkin1
1hematological clinic, 2biochemistry laboratory, 3clinical laboratory, 4cytogenetic
laboratory, 5histologic laboratory, 6immunologic laboratory, Russian Institute
of Hematology and Blood Transfusion, St.Petersburg, Russian Federation
Background: Aberrant methylation of CpG islands of tumor-supressor genes
may be involved in the development of acute myeloid leukemia (AML) and be
associated with the natural history of the disease.
Aims: To reveal the features of aberrant methylation of promoter regions of
SOX7, p15INK4b and Wnt pathway antagonist genes in AML patients.
Methods: The data of 57 AML patients with median age of 51.0 years were
analyzed. Next AML variants were diagnosed: 2 patients with M0, 7 M1, 23
M2, 4 M4, 8 M5, 3 M6 and 10 with myelodysplasia. Cytogenetic data were
available in 56 patients. Normal karyotype was identified in 31 (54.4%) patients.
Other 25 patients had different chromosomal aberrations including complex
karyotype in 8 patients. Methylation-specific PCR was used to study the methy-
lation status of promoter regions of SOX7, p15INK4b and Wnt pathway antag-
onist genes.
Results: The frequency of aberrant methylation was next: SFRP1 68.4%,
p15INK4b 63.2%, SOX7 47.4%, SFRP4 42.1%, SFRP5 35.1%. Absence of
aberrant methylation was found in 5 (8.8%) patients. The most frequent finding
was methylation of 2 and 3 genes simultaneously: 29.8% and 21.1% accord-
ingly. Half of the patients with aberrant methylation status of all 5 studied genes
had AML with dysplasia. The most part of patients with complex karyotype
(62.5%) had aberrant methylation of 3-5 genes. The difference in the number
of patients with complex or normal karyotype who had aberrant methylation of
all 5 studied genes was significant: 50.0% vs 9.7% OR=9.3 95% CI 1.5-58.0;
p=0.022. The patients with normal karyotype and without FLT3 and NPM1
mutations were separated according to the number of genes with aberrant
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methylation: 0-2 vs 3-5. There was no significant difference in overall and
relapse free survival between these groups.
Summary/Conclusions: Aberrant methylation of SOX7, p15INK4b and Wnt
pathway antagonist genes is recurrent biologic phenomenon in AML patients.
More often this finding occurs in AML patients with myelodysplasia and complex
karyotype.
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INCIDENCE AND MAIN CHARACTERISTICS OF T(12;22)(P13;Q12)/
MN1-ETV6-POSITIVE ADULT BULGARIAN ACUTE MYELOID LEUKEMIA
PATIENTS: A SINGLE INSTITUTION EXPERIENCE
G Balatzenko1,*, S Angelova1, Y Georgieva2, B Spassov3, K Ignatova3,
G Mihailov3, S Toshkov1, M Guenova 2
1Laboratory of Cytogenetics & Molecular Biology, 2Laboratory of Hematopathol-
ogy & Immunology, 3Department of Clinical Hematology, National Hospital for
Active Treatment of Hematological Diseases, Sofia, Bulgaria
Background: Background: Translocation t(12;22)(p13;q12) is a recurrent, but
rare genetic abnormality in acute myeloid leukemia (AML). To our knowledge,
only 14 cases of t(12;22)-positive AML have been published so far. This translo-
cation results in the MN1-ETV6 fusion gene formation, however, in only 5 of
the reported t(12;22)-positive AMLs, the presence of MN1-ETV6 fusion gene
was confirmed molecularly [1;2;3]. Due to the rareness of the disease data
about the clinical and laboratory features of t(12;22)-positive AML patients are
still limited.
Aims: To determine the incidence and the main characteristics of t(12;22)-pos-
itive AML.
Methods: Bone marrow aspirates of 645 adult AML patient were tested in the
Laboratory of Cytogenetics and Molecular Biology of the National Specialized
Hospital for Active Treatment of Hematological Diseases – Sofia during a 10-
years period. Successful karyotypes were obtained in 555 patients (86%). In
all cases with t(12;22), the presence of MN1-ETV6 rearrangement was addi-
tionally tested by fluorescence in situ hybridization (FISH) and reverse tran-
scription polymerase chain reaction (RT-PCR). The AML diagnosis and sub-
classification were performed according to the World Health Organization Clas-
sification criteria (2008).
Results: Overall, t(12;22) was detected by conventional cytogenetics in three
patients (0.54%). In all of them the translocation was identified as a sole chro-
mosome abnormality and the MN1-ETV6 fusion was confirmed by FISH and
RT-PCR. None of the patients was positive for BCR-ABL1, CBFb-MYH11,
AML1-ETO, FLT3-ITD, JAK2 V617F, and NPM1 mutations. Two of the patients
were male and one was female, aged 60, 65 and 71 years, respectively. White
blood cell counts varied from 4.6x109/L to 77.5x109/L, platelet counts from
14x109/L to 104x109/L, and hemoglobin from 81 g/L to 125 g/L. Morphology
was myelomonocytic in all patients, associated with granulocytic dysplasia in
one of the cases and presented as a hypoplastic leukemia in another. Bone
marrow blasts accounted for 58%>88%. Flow cytometry revealed CD34 positive
expression and aberrant myelomonocytic phenotypes in all three patients, with
CD56 positive and CD4 positive immune labeling in 2 patients each. Aberrant
expression of other lymphoid-associated antigens (CD7/CD19) was also detect-
ed in one case. No splenomegaly was found in all of the patients, while mild
liver enlargement was observed in one of them. Two of patients received con-
ventional cytarabine/antracycline-based induction therapy. Unfortunately, early
death occurred in both cases. The third patient refused chemotherapy and was
lost of follow up.
Summary/Conclusions: Our study confirmed the low incidence of
t(12;22)/MN1-ETV6-positive AML. Though heterogeneous in terms of clinical
and laboratory presentation, the reported patients were characterized by
absence of additional chromosomal aberrations, aberrant myelomonocytic phe-
notype and a high induction-induced death rate.
Acknowledgements: This study was partially supported by the National Science
Fund, Ministry of Education, Youth and Science.
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INCREASED RISK OF TUBERCULOSIS IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA IN AN ENDEMIC AREA: A NATIONWIDE POPULATION-BASED
STUDY
CJ Liu1,*, YM Zheng2, P Hsu2, YC Liu1, JP Gau1, LT Hsiao1, YB Yu1,
CH Tzeng1, PM Chen1, TJ Chiou3, JH Liu1
1Division of Hematology and Oncology, 2Department of Medicine, 3Division of
Transfusion Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
Background: To date, few studies have investigated the association between
tuberculosis (TB) and acute myeloid leukemia (AML).
Aims: We therefore aim to assess the impact and the risk factors of TB in
patients with AML for a better risk stratification strategy.
Methods: We conducted a nationwide population-based study using data
retrieved from Taiwan’s National Health Insurance Research Database to deter-
mine the incidence of TB and to analyze the risk factors for TB in patients with
newly diagnosed AML. From 2000 to 2011, we identified 6,771 AML patients
and the same number of subjects without AML matched for sex, age, and
comorbidities. Cox proportional hazards models were applied for further analy-
sis. AML-related therapies were assessed as time-dependent covariates to
avoid immortal time bias.
Results: Compared with the matched cohort, AML patients exhibited a higher
risk for TB (adjusted hazard ratio [HR] 4.31, 95% confidence interval [CI] 3.27–
5.67, p <0.001), with an increased risk for both pulmonary (adjusted HR 4.22,
95% CI 3.13–5.69, p <0·001) and extrapulmonary (adjusted HR 4.86, 95% CI
2.40–9.84, p <0.001) TB. Adjusted HRs of TB occurrence for follow-up periods
of <1, 1–2, 2–5, and ≥5 years were 9.61 (95% CI 5.69–16.25), 5.40 (95% CI
2.88–10.13), 1.89 (95% CI 0.94–3.79), and 1.81 (95% CI 0.71–4.63), respec-
tively. Multivariate analysis showed that being male (adjusted HR 1.47, 95% CI
1.06–2.04, p=0.020) and having liver cirrhosis (adjusted HR 2.08, 95% CI 1.17–
3.70, p=0.012) were identified as independent risk factors for developing TB in
AML patients. However, treatment with idarubicin, daunorubicin, high-dose
cytarabine, or hematopoietic stem cell transplantation did not increase the risk
of TB development. AML patients who developed TB had a higher mortality
rate than those who did not (adjusted HR 1.63, 95% CI 1.33–1.99, p <0.001)
(Figure 1).
Figure 1.
Summary/Conclusions: Patients with AML had a higher risk of TB, especially
within two years of diagnosis. Being male and having liver cirrhosis were inde-
pendent risk factors for TB in AML patients. Physicians should be aware of the
TB situation among their respective populations, particularly those in endemic
areas.
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DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA
(APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED
TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
A Jillella1,*, M Mody2, G Harpaul2, M Arellano1, H Khoury1, Z Al-Kadhimi1,
M McLemore1, E Winton1, M Gaddh1, L Heffner1, L Bernal-Mizrachi1,
J Galipeau1, A Langston1, K Sitchenko1, V Jonnalagadda1, K Bradley3, V Kota1
1Department of Hematology and Oncology, Winship Cancer Institute of Emory
University, 2Department of Medicine, 3Department of Pathology, Emory Uni-
versity School of Medicine, Atlanta, United States
Background: APL is a highly curable malignancy with reported survival above
90% in many large co-operative group studies. Treatment of low and interme-
diate risk patients showed an expected survival of 99% with retinoic acid
(ATRA)/Arsenic (ATO) combination versus 91% with ATRA/chemotherapy at 2
haematologica | 2016; 101(s1) | 675
Copenhagen, Denmark, June 9 – 12, 2016
years. These spectacular results are not evident in the general population. US
SEER data showed that 1 and 5 year relative survival in APL patients is 71%
and 65%. Studies from Swedish Cancer Registry and Brazil showed that early
deaths (ED) can be approximately 30%. This is in contrast to observation in
clinical trials where the early mortality is approximately 5%. Common causes
of death are hemorrhagic complications (HC), differentiation syndrome (DS),
infection and multi-organ failure (MOF). It is now agreed that the most common
cause of treatment failure in APL is ED; and decreasing ED will improve pop-
ulation wide survival in this most curable leukemia. We report our institutional
experience that showed a decrease in ED by using a streamlined set of guide-
lines and expert advice as needed.
Aims: To identify the impact of streamlined guidelines
Methods: We reviewed charts of patients with newly diagnosed APL and treat-
ed at our institution between January 2007 and August 2013 (earlier group).
We compared these outcomes with those diagnosed from September 2013 to
January 2016 (newer group) when we put in place a set of streamlined guide-
lines to improve ED. In addition to the guidelines, three faculty members with
an interest in APL provided input as needed in the management of all newly
diagnosed patients.
Results: From 01/2007 to 01/2016, 108 patients were treated; 75 patients
managed prior to and 33 after establishment of guidelines. One Jehovah’s Wit-
tness patient was excluded from the newer group for refusing transfusions and
subsequently died. Median age was similar at 45 years in both groups (range
19-86 and 21-81 respectively). Patients above 60 years were approximately
30% (23/75 and 10/32) and platelet count (29 and 30) were similar in both
groups. In the earlier group, median white cell count (WBC) (4.2 and 2.2) and
proportion of high risk (WBC >10,000/ml) patients (36% vs 21%) were higher.
In the earlier group, induction regimen consisted of ATRA in combination with
anthracycline (50, 66%), arsenic (12, 16%), other chemotherapy (8, 10%) or
single agent ATRA in (5, 6%) patients. In contrast in the newer group, ATRA
with ATO was the preferred induction regimen in 24 (75%) and anthracycline
based treatment was used in 6 (18%) patients. 2 patients received ATRA alone.
Overall the ED rate was higher in the earlier group with 19 patients (25%) dying
in the first month. The causes of death were DIC (9), DS (7) and infection/MOF
(3). 5 patients presented with large intracranial bleeds and were extremely ill.
Excluding the patients that were referred late, the mortality was 18%; similar
to some single institution studies but more than what is seen in clinical trials.
After the institution of our algorithm, mortality was reduced to 9.4% (3/32 ED).
Cause of ED was DS (2) and DIC (1). The incidence of severe DS (18% vs
6%) and sepsis (28% vs 16%) were lower in the newer group. The improved
outcomes (25% vs 9.3%) is probably multifactorial due to lower number of high
risk patients, more frequent arsenic based induction, use of streamlined guide-
lines and advice by dedicated APL experts.
Summary/Conclusions: Our experience shows that a streamlined treatment
algorithm along with input from experts will result in better outcomes in this
most curable hematological malignancy even at academic centers. We believe
our experience warrants large scale implementation of our model and is
presently approved as an ECOG/ACRIN trial.
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CLINICAL SIGNIFICANCE OF IMMUNOPHENOTYPIC CHANGES AT THE
FIRST RELAPSE IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS
H Shimizu1,*, T Ishizaki1, T Mitsui1, N Hatsumi2, S Takada2, T Saitoh1,
A Yokohama1, T Sakura2, H Handa1
1Department of Hematology, Gunma University, 2Leukemia Research Center,
Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan
Background: Immunophenotypic changes (IPC) between diagnosis and the
first relapse are found in up to 90% of relapsed acute myeloid leukemia (AML)
cases, and are considered as a result of major clone shift and/or clonal evolution
of AML cells, just like additional cytogenetic abnormality (ACA) which we report-
ed that was the strongest negative prognostic factor in relapsed AML patients.
Aims: Because the clinical significance of IPC has not been elucidated in adult
AML patients, we conducted a large-scale retrospective study to address this
unsolved issue.
Methods: Of the 375 adult patients diagnosed with non-APL AML between
1990 and 2010, 108 relapsed patients whose immunophenotypic data both at
diagnosis and at the first relapse were available were included in this study. All
these patients underwent intensive chemotherapy. AML cells were sorted with
usual CD45/SSC gating, and CD7, CD19, CD13, CD33, CD34, HLA-DR, and
CD56 were analyzed. IPC was diagnosed when more than 50% increase or
decrease of at least one antigen-positive from diagnosis to the first relapse
was observed. Overall survival (OS) was defined as the interval from the date
of the first relapse to the date of death. Fisher’s exact test was used to compare
binary variables. OS was estimated with the Kaplan-Meier method and com-
pared using the log-rank test. Multiple logistic regression analysis and the Cox
proportional hazard model were used for multivariate analysis of predisposing
factors and prognostic factors, respectively. Values of p <0.05 were considered
to indicate statistical significance.
Results: Of the 108 patients included in this study, 65 patients were male, and
43 were female. The median age was 56 years (range, 18–78 years). According
to the definition described above, 46 patients (43%) experienced IPC at the
first relapse. With univariate analysis, t(8;21) was extracted as a statistically
significant predisposing factor for IPC at the first relapse (69%). Multivariate
analysis revealed t(8;21) and M4/5 as independent predisposing factors.
Excluding one patient that directly proceeded to allo-SCT without re-induction
chemotherapy, the 107 patients with IPC showed a similar second remission
rate when comparing with those without IPC (42.1% vs 44.0%, respectively;
p=0.848). Additionally, among all 108 patients, there was no significant differ-
ence in the 2-year OS rates after the first relapse between patients with and
without IPC (34.4% vs 29.3%, respectively; p=0.212). Multivariate analysis
extracted ACA, high-risk karyotype, fewer than 12 months duration of the first
remission, and no allogeneic stem cell transplantation (allo-SCT) after the first
relapse, but not IPC. Of the 46 patients with IPC (median age: 55, range; 18–
78 years), 18 underwent allo-SCT after the first relapse. The 2-year OS rates
after the first relapse were significantly different between patients undergoing
allo-SCT after the first relapse and those treated only with chemotherapy
(62.7% vs 17.9%; p <0.001). With multivariate analysis, undergoing allo-SCT
after the first relapse was identified as an independent prognostic factor, in
addition to ACA and duration of the first remission.
Summary/Conclusions: These findings suggested that IPC had no prognostic
impact in relapsed AML patients, unlike acquisition of ACA. As t(8;21) was
extracted as an independent predisposing factor for IPC as well as ACA, sus-
ceptibility for clonal evolution might be high in t(8;21) AML patients. Clarification
of the biological background of IPC may contribute to the development of novel
therapeutic strategies and improved treatment outcomes in adult AML patients.
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HIGH FREQUENCY OF OCCULT CENTRAL NERVOUS SYSTEM
INVOLVEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL
NEOPLASM AT DIAGNOSIS: ROLE FOR INTRATHECAL PROPHYLAXIS?
L Martin-Martin1,*, J Almeida1, H Pomares2, E González-Barca2, P Bravo3,
T Giménez4, C Heras5, JA Queizán6, E Pérez-Ceballos7, V Martínez8, N Alonso9,
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Tarragona, 5Infanta Leonor Hospital, Madrid, 6Hospital of Segovia, Segovia,
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Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare
aggressive myeloid neoplasm which shows a high rate of central nervous system
(CNS) recurrence (≈30%) and a short overall survival (OS), usually <1 year.
Despite this, screening for CNS involvement is not routinely performed at diagnosis
and intrathecal (IT) prophylaxis is not regularly administered in BPDCN patients.
Aims: To analyse the incidence of CNS involvement in BPDCN patients at
diagnosis and to evaluate the potential benefit of intrathecal prophylaxis
administration.
Methods: Forty-one stabilized cerebrospinal fluid (CSF) samples from 13 con-
secutive BPDCN patients were evaluated for the presence of CNS involvement
by next generation flow cytometry immunophenotypic studies. Cases were
evaluated at diagnosis (n=10) or at relapse (n=3) and subsequently, after IT
therapy. The 10 patients studied at diagnosis received high-risk acute lym-
phoblastic leukaemia (ALL)-type treatment, including one dose of triple intrathe-
cal therapy (TIT), as CNS prophylaxis at each treatment phase. For CSF-pos-
itive cases, additional IT treatment was given until two consecutive CSF-neg-
ative samples were obtained. In order to validate the impact of CNS involve-
ment and CNS-directed therapy on patient outcome, an independent validation
cohort of 23 BPDCN was retrospectively analysed. Informed consent was
obtained from all patients.
Figure 1. Prognostic impact on OS of intrathecal prophylaxis/therapy
administration at diagnosis in BPDCN patients.
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Results: Despite none of the patients presented with neurological symptoms
at disease staging, occult CNS involvement was detected in 6/10 cases eval-
uated at diagnosis and 3/3 studied at relapse/progression. Detection of tumour
cells in CSF at diagnosis was associated with a ≥20% bone marrow infiltration
by tumour cells. BPDCN patients evaluated at diagnosis received IT treatment
-either CNS prophylaxis (n=4) or active therapy (n=6)- and all but one remain
alive (median follow-up of 20 months). In contrast, all three patients assessed
at relapse/progression died (Figure 1). Follow-up CSF samples obtained after
TIT showed absence of tumour cells in 6/6 CSF+cases studied at diagnosis,
either after one -5/6 cases- or 4 doses of therapy (6/6 cases). The potential
benefit of IT treatment administered early at diagnosis on OS and CNS recur-
rence-free survival (RFS) of BPDCN was further confirmed in a retrospective
cohort of another 23 BPDCN patients. Univariate analysis of prognostic factors
performed in the whole patient cohort (n=36) showed a favourable impact on
CNS-RFS and/or OS for children, patients receiving ALL-type therapy, allo-
geneic hematopoietic stem cell transplant and IT prophylaxis/treatment at diag-
nosis, the later variable emerging as the only independent (favourable) prog-
nostic factor for CNS-RFS (p=.02, hazard ratio [HR]=11.2, 95% confidence
interval [CI]: 1.4 – 88.8) and OS (p=.001, HR=7.6, 95% CI: 2.2 – 25.9).
Summary/Conclusions: Our findings show that BPDCN patients studied at diag-
nosis frequently display occult CNS involvement; moreover, these data also indi-
cate that treatment of occult CNS disease might lead to an improved outcome
for BPDCN. These results suggest that the CNS could be a persistent blast-cell
sanctuary in BPDCN patients with leukemic presentation, due to the limited power
of cytostatic drugs to cross the blood-brain barrier into the CSF and brain
parenchyma. This reservoir of leukemic cells may also contribute to the high rate
of bone marrow/systemic disease recurrence observed in these patients.
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APPLICABILITY OF THE PATIENT’S “FITNESS” CRITERIA IN ELDERLY
AML IN CLINICAL PRACTICE
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N Suvajdzic-Vukovic1,2, D Tomin1,2
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Background: The prognosis for acute myeloid leukemia (AML) patients older
than 65 years of age is poor. Besides age, comorbidities, a proper assessment
of patient’s fitness represents a important step in the therapeutic decision-mak-
ing process in elderly AML patients. Recent study proposed a set of objective
criteria to define pts fit or unfit to conventional intensive chemotherapy (i-CT),
non-intensive chemotherapy (ni-CT) or best supportive care (BSC)(Ferrara et
al., Leukemia, 2013).
Aims: The aim of this study was to investigate: a) applicability of “fitness” cri-
teria; b) the concordance between “fitness” categorization of pts and the type
of treatment they actually received; c) the outcome of pts according to “fitness”,
to the prognostic stratification of European Leukemianet (ELN) and to the treat-
ment received.
Methods: This single-center study involved 201 adult patients with nonpromye-
locytic de novo AML aged ≥65 years (median age 70 years, range 65-83 years)
diagnosed between January 2009 and December 2015. Pts were categorized
according to “fitness” criteria, retrospectively: as fit to i-CT (FIT), unfit to i-CT
(UNFIT), or unfit even to ni-CT (FRAIL). According to ELN recommendation, pts
were at low-risk (6 pts: 3.2%), intermediate-I (91 pts: 48.4%), intermediate-II (39
pts: 20.7%), or high risk (52 pts: 27.7%). The patients were treated with i-CT 89
(44.5%), 66 pts (33%) ni-CT, such as low-dose cytarabine and 45 pts (22.5%)
BSC, including cytoreductive therapies (hydroxyurea) and/or transfusion.
Results: Among 201 pts, 98 (49%) were FIT, 79 (39.5%) were UNFIT, and 23
(11.5%) were FRAIL. Their median age was 67, 73 and 72 years. Median overall
survival (OS) of FIT, UNFIT and FRAIL pts was 4, 3 and 1 months, (FIT vs oth-
ers: p<0.0001, UNFIT vs FRAIL: p=0.012). Overall concordance between “fit-
ness criteria” and the treatment actually received by pts were 77% in FIT, 84%
in UNFIT and 96% in FRAIL pts. Median OS of pts receiving i-CT, ni-CT or BSC
was 6, 3 and 3 months in FIT (p=0.001); 2,3,4 months in UNFIT (p<0.047).
Median OS in FRAIL pts receiving ni-CT or BSC was 1 vs 2 months, (p<0.107).
CR rate was 50% in LR, 40% in Int-I, 25.6% in Int-II, 25.5% in HR, (p=0.039).
OS rate was 5 in LR/Int-I vs 3 months in Int-II/HR pts (p<0.0001). Comprising
ELN prognostic stratification with fitness, the use of i-CT obtained a significantly
better median OS of 12 months in FIT pts at ELN LR/Int-I compared to 4 months
in pts at Int-II/HR (p=0,008).
Summary/Conclusions: This study has shown that a fitness was significantly
related to patient’s outcome. Applying the fitness criteria could be useful in clin-
ical practice for therapeutic decision-making in elderly AML patients.
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CHARACTERIZATION AND PROGNOSTIC IMPACT OF FLT3-ITD
MUTATIONS IN INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA
M Amorim*, E Aguiar, P Gomes, M Lopes, M Soares, J Bastos, R Damas,
M Gomes, C Marini, F Trigo, J Guimarães
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Background: The adverse impact of internal tandem duplications (ITDs) of
the FMS-like tyrosine kinase 3 gene (FLT3) in acute myeloid leukemia (AML)
has been related to specific ITD characteristics such as the FLT3-ITD/wt allelic
ratio (AR), length of mutation and insertion site.
Aims: To evaluate FLT3-ITD mutations, as well as NPM1 mutations, and the
prognostic impact of the FLT3-ITD AR, size, number and the insertion site of
ITDS in AML patients with intermediate-risk karyotype.
Methods: This single-centre study included 148 AML patients with intermedi-
ate-risk karyotype according to the European LeukemiaNet criteria. Screening
of FLT3-ITD and NPM1 mutations was performed in diagnostic bone marrow
samples by PCR with labeled primers and GeneScan-based fragment-length
analysis. In FLT3-ITD patients, size and number of ITDs were collected and
FLT3-ITD AR was calculated. The ITD insertion site was determined by direct
sequencing of PCR products in a subgroup of patients. For survival analysis,
median (Md) value was used to dichotomize continuous variables.
Results: FLT3-ITD mutations were found in 29% (43/148) of patients. The
majority of patients (36/43) had a single ITD, four patients – two ITDs and one
patient - three ITDs. Median ITD size was 42 bp (range, 18 to 108 bp). The
FLT3-ITD AR varied from 0.02 to 13.48, with a median of 0.57. DNA sequence
analysis of 26 single FLT3-ITDs patients revealed that the insertion site was
localized in juxtamembrane domain (JMD, amino acids 572-609) in 77%
patients and in tyrosine kinase I domain (TKD1, amino acids 610-615) in 23%
of patients. A trend for worst overall survival (OS) was noted for patients with
insertion site in TKD1 (P=.09). FLT3-ITD was significantly longer in cases with
an insertion site in TKD1 compared with ITD insertion in JMD (69 vs 36 bp,
P=.008). Concerning pretreatment patients characteristics, white blood counts
(P<.001), serum lactate dehydrogenase (P=.002), and bone marrow blasts
(P=.03) differed significantly with increasing AR. Regarding clinical outcome,
only patients candidates to intensive chemotherapy were included (N=128).
FLT3-ITD patients with high mutant level (AR>0.57) had significantly worst OS,
median of 7.6 months, than low mutant level and wt patients (25.6 vs 23.2
months, P=.003). A trend for worst Disease Free Survival (DFS) was noted for
patients with AR>0.57 (Md=5.7 months) compared with low ratio (Md=15.6
months) and wt patients (Md=23 months), P=.05. When the analysis was
restricted to NPM1mut AML patients (60/146), FLT3-ITD patients with high AR
had significantly worst OS (Md=7.6 months) than low mutant level (Md=34.7
months); OS for wt patients was not reached (P<.001). FLT3-ITD patients with
high AR had a DFS significantly lower (5.8 months) than low AR (15.6 months)
and wt type patients (37.9 months), P=.01. No significant difference was
observed between low ratio and wt patients for DFS (P=.09), whereas for OS
was (P=.02). No significant difference was observed in DFS and OS regarding
insertion site, size and number of ITDs.
Summary/Conclusions: We confirmed that FLT3-ITD allelic ratio was the only
ITD characteristic with significant prognostic marker for OS and DFS within our
cohort of FLT3-ITD intermediate-risk AML patients. Nevertheless we were able
to identify a trend for worst OS in patients with ITD insertion site in TKD1. More-
over, we were able to show that, among patients with concomitant NPM1 muta-
tion, DFS was not significantly different between ITD low burden and wt patients.
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LEUKEMIA BY SERIAL MEASUREMENT OF WT1 GENE EXPRESSION
LEVELS
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O Slesarchuk, T Gindina, L Zubarovskaya, B Afanasyev
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Background: The major problem in the treatment of acute myeloid leukemia
(AML) with allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
the relapse of the underlying disease, poorly responsive to chemotherapy. For
its early detection, molecular monitoring methods were introduced, of which
serial measurement of Wilms Tumor-1 (WT1) gene expression levels is con-
sidered to be the most efficient (Candoni et al., 2011; Zhao et al., 2011; Mamaev
et al., 2015).
Aims: We aimed to estimate the molecular monitoring potential for early detec-
tion of relapse and the quality of its treatment in AML patients after allo-HSCT.
Methods: A serial measurement of WT1 gene expression levels by quantitative
real-time polymerase chain reaction (PCR) was conducted in 65 AML patients
in the post-transplant period. The threshold for identification of WT1 gene over-
expression was above 250x104 copies of the ABL gene. The clinical and labo-
ratory characteristics of AML patients after allo-HSCT are presented in Table 1.
Results: The maximum initial level of WT1 gene expression ranged from 259
to 56884 copies/104 copies of ABL gene (9869 copies on average). Its expres-
sion hardly depended on the cytological type of AML or the cytogenetic type of
the cells. According to the obtained data on WT gene expression, two groups
of patients were formed. The first group consisted of 28 patients with stable
normal WT1 gene expression during the post-transplantation period; the second
group consisted of 37 patients with impaired WT1 gene expression. In the peri-
od after transplantation WT1 gene expression levels were consistent with or
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surpassing those of specific markers of minimal residual disease in parallel
analysis. Our data showed that in one-third of the patients WT1 overexpression
preceded the increase in blast cells in the bone marrow, thus predicting a
relapse. For post-transplantation relapse therapy hypomethylating agents in
combination with or without donor lymphocyte infusion were applied in 31
patients. The therapy results were not encouraging. In 22 patients mortality
was due to the relapse of the underlying disease. Complete remission was
only achieved in 6 patients with AML. Three of them later died from GVHD,
acute heart failure and sepsis on D+101, D+541 and D+350 after allo-HSCT
respectively.
Table 1.
Number of patients                                                                      65
AML
AML de novo                                             51 (0-4, 1-6, 2-12, 3-1, 4-20, 5-6, 6-1, 7-1)
Secondary AML                                                                            14
Patient sex, n
Male                                                                                            36
Female                                                                                        29
Age at HSCT (mediana)                                                           26 (4-56)
Cytogenetics, n
Favorable                                                                                      0
Intermediate                                                                                50
Infavorable                                                                                   15
Molecular markers, n
Yes                                                                                              16
No                                                                                               49
HSC source, n
Bone marrow                                                                                34
Peripheral blood                                                                           31
Conditioning regimen, n
MA                                                                                              44
Non-MA                                                                                       21
Donor type, n
HLA-id sibling                                                                               12
Matched unrelated                                                                       41
Haploidentical                                                                              12
Number of transplanted CD34+cells (mediana)                4,78*106 (2,2-11,9)
Summary/Conclusions: Molecular monitoring of acute myeloid leukemia after
allo-HSCT using serial measurement of WT1 gene expression levels allows to
reveal cytological relapses at an earlier stage and may soon be used to assess
the treatment of prognostically adverse post-transplant relapses of AML.
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Background: Priming regimen(e.g., CAG) combined with Decitabine is
increasingly being used to treat acute myeloid leukemia, especially in elderly
patients. However, the particular mode of administration and dosage of
Decitabine has not been unified.
Aims: This pilot study was designed to evaluate the efficacy and safety of adjust-
ed CAG (aCAG) regimen combined with Decitabine treatment for elderly patients
with newly diagnosed or refractory/relapsed acute myeloid leukemia (AML).
Methods: All patients (age≥60 years, PS≤2) in this study were treated with
aCAG-D regimen: Cytarabine (10mg/m2/12h, days 1-8), Aclarubicin (5-
7mg/m2/day, days 1-8), Granulocyte colony-stimulating factor (300μg/day, days
0-8 or stopped when WBC count >20×109/L) and Decitabine(25mg/m2/day,
days 5-8) for two cycles.
Results: The median age of the twelve patients (seven men and five women)
able to be evaluated, which contained nine de novo patients and three
refractory/relapsed patients, was 67 years (range of 60-75 years). A total of nine
patients (75.0%) achieved complete remission (CR) after the aCAG-D treatment,
including eight of whom achieved CR after only one treatment cycle. In nine
newly diagnosed patients eight cases achieved CR (88.9%) and another got par-
tial remission (PR). Meanwhile, three other refractory/relapsed patients achieved
CR/ partial remission (PR)/no response (NR) respectively. The overall response
rate (ORR) and CR after two treatment cycles were 91.6% and 75.0%, respec-
tively. In patients with CR, the median time was 24.2 days (range of 16-43 days)
for granulocyte recovery and 17.9 days (range of 11-37 days) for platelet recovery.
After a median follow-up of 11 months (range of 4.5-22 months), one patient died
due to secondary infections; one patient showed a relapse; five patients died
due to progression of the disease; five patients maintained CR. The median over-
all survival (OS) of 13 months(range of 4.5-22 months) for those who achieved
CR was significantly longer than that of patients who did not achieved CR(5
months). The main adverse events were grade IV bone marrow suppres-
sion(12/12 patients) and grade I-IV secondary infection(11/12 patients). There
was no treatment-related mortality during remission induction (Figure 1).
Figure 1.
Summary/Conclusions: The regimen combined aCAG and Decitabine, which
designed to use CAG scheme for priming firstly, then add Decitabine to target
tumor cells in the S-phase of the cell cycle, demonstrates good efficacy for
elderly AML patients, especially in de novo patients. Meanwhile, this regimen
didn’t give rise to serious myelo-suppression and secondary infection. In gen-
eral, aCAG-D regimen was well tolerated by the elderly patients with de novo
or relapsed/refractory AML and showed promising clinical efficacy.
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HOME CARE ADMINISTRATION OF SUBCUTANEOUS AZACITIDINE (AZA)
AND DOMICILIARY MANAGEMENT OF FRAIL PATIENTS AFFECTED BY
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A FEASIBILITY STUDY
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Background: Home delivery of parenteral antineoplastic agents may allow an
appropriate treatment for frail or disable patients (pts) with acute myeloid
leukemia (AML)/myelodysplastic syndrome (MDS), whose management would
be otherwise hampered by clinical barriers or conditioned by hospitalization
requirements.
Aims: To describe the feasibility of a home care (HC) program that provides a
managing package capable of supporting pts with their parenteral AZA therapy
at home.
Methods: A retrospective analysis of the clinical features, use of resources,
follow-up and HC satisfaction rating of frail homebound pts affected by AML or
intermediate-high risk MDS with a clinical frailty scale score >4, who received
at home subcutaneous AZA (75 mg/sqm/7 days).
Results: Overall, 106 pts with AML/MDS received AZA therapy; in 13 out of 31
pts (4%) with AML and in 7 out of 75 pts (9%) with MDS, the drug was adminis-
tered at home. Reasons for the HC solution were: i) disability in 15 pts (11 AML/4
MDS), ii) early discharge from the ward in 5 (2 AML/3 MDS). The pts’ median
age was 76 yrs (range 59-83), Karnofsky PS 50% (range 40-60%), Activity Dayly
Living score 4 (range 1-6), Charlson co-morbidity index 2 (range 1-3). The mean
No. of AZA courses in AML and MDS patients was 3 (1-6) and 2 (1-4), respec-
tively. At home, 409 units of packed red cells were transfused, with a mean No.
of 20 units transfused/per patient (range 0-94). During AZA therapy, 13 pts had
infections with a mean No. of infections/patient of 1.9 (range 0-7). In 37 out of 38
cases (97%), infections were managed at home with i.v. antibiotic administration.
Overall, hospitalization occurred in 8 out of 20 pts (40%). AZA therapy at home
was started as a first course in 6 pts, whereas it was continued in 14 pts following
courses already delivered at hospital, with a mean No. of 2.8 courses (range 1-
4) and 2.1 (range 1-6), administered respectively. In 83% of cases, pts rated HC
as more than good. Eighteen pts discontinued HC AZA: 15 due to disease pro-
gression and 3 because of an infection-related hospitalization. The median length
of HC after AZA interruption was 111 days (1-343). Two pts are still on treatment
with AZA, 18 pts have died: 11 at home or at a hospice, 7 while hospitalized. The
pts median survival time from the start of AZA was 143.2 days (range 5-284) for
AML pts and 229.7 days (range 49-411) for MDS pts.
Summary/Conclusions: Home administration of AZA proved feasible through
the availability of a domiciliary service that guaranteed a high number of trans-
fusions, blood sampling and i.v. antimicrobial therapy, combined with an
approach of palliative care. Pts with poor prognosis AML/MDS had the oppor-
tunity of undergoing a specific epigenetic treatment at home, while living a con-
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siderable time interval outside the hospital with a high satisfaction level for HC.
Inappropriate hospitalizations were reduced, with an overall median time at
home of nearly 5 months for AML and 7.6 months for MDS pts. Death during
the hospice care occurred in 61% of cases.
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ELANE MUTATION C233TER PREDISPOSES PATIENTS WITH SEVERE
CONGENITAL NEUTROPENIA TO ACUTE MYELOID LEUKEMIA
D Dale1,*, AA Bolyard1, M Kelley1, V Makaryan1, L Boxer2, MA Bonilla3,
M Cavieres4, P Tan5, F Firkin6
1Medicine, UNIVERSITY OF WASHINGTON, Seattle, WA, 2Pediatric Hema-
tology/Oncology, University of Michigan, Ann Arbor, MI, 3Pediatric Hematol-
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Background: Mutations in ELANE are the most frequent cause for cyclic and
congenital neutropenia. In a genotype-phenotype study, we previously reported
that mutations G214R which replaces glycine (nonpolar, neutral) with the much
larger arginine (polar, strongly basic) amino acid, and C151Y which disrupts
the second disulfide bond of the protein are associated with severe outcomes.
(Makaryan et al., Curr Opin Hematol 2015;22:3-11) Termination mutations were
associated with leukemic transformation, but the number of these patients was
relatively small.
Aims: To investigate the natural history and long-term consequences of muta-
tions in ELANE.
Methods: The Severe Chronic Neutropenia International Registry (SCNIR) has
enrolled 3 patients with the termination mutation C223ter. All three have devel-
oped acute myeloid leukemia.
Results: Patient #1 is a 38 year old female residing in Michigan USA. She was
diagnosed with SCN in 1989 at age 11. She started G-CSF in 1989, 11.5
mcg/kg/day. Because of a poor response, G-CSF was gradually increased to
24 mcg/kg/day. After 15 years, she was switched to peg G-CSF, 3 mg every 10
days for the next 11 years. In February 2015 at age 37, she had blasts in the
blood and marrow revealing 65.8% blasts. Ten months ago, she underwent
HSCT, GvHD has resolved, platelets are holding at 59K without transfusions
and she receives darbepoetin alfa to maintain hemoglobin. Patient #2 is a 25
year old female residing in Western Australia. She was diagnosed with SCN in
1991 at age 4.5 months. She was started at age 5 months on G-CSF at 5
mcg/kg/day and the dose increased to 20 mcg/kg/day because of a poor
response. After 12 years, she was switched to peg G-CSF 6 mg q 14 days
after 12 years because of her poor neutrophil response. She received Neulasta
6 mg every 14 days for 11 years. She became pregnant in May 2015 having
had 3 previous pregnancies (2 terminations and one live birth). In the second
month of her fourth pregnancy, she appeared to be losing her response to peg
G-CSF. About two months later, she was found to have hypertrophied gums
with infiltration of immature myeloid cells, consistent with the abnormal cells
also found in her bone marrow. She was maintained on G-CSF, prednisone,
and blood products because without the growth factor she was severely ill.
With this approach, she delivered a healthy male infant at 30 weeks via C-sec-
tion. She had a HSCT five weeks after delivery and is now 2 months post-
transplant, in serious condition with the donor marrow beginning to respond.
Patient # 3 was a 6 year old female who resided in Chile. She was diagnosed
with SCN in 1997 at 10 months and started G-CSF at 15 mcg/kg/day. There
was a poor response requiring an increase of G-CSF to 37.5 mcg/kg/day. After
3 years on G-CSF, she developed AML presenting with increased blasts, ane-
mia and thrombocytopenia. She received chemotherapy; HSCT was not avail-
able. She died from complications of AML in 2002. Mutations in G214R, C152Y
and C223ter have no obvious common features in terms of effects on the active
site, glycosylation sites, or disulfide bonds of the enzyme. These mutations
and others associated with evolution to AML are often relatively resistant to
treatment with G-CSF, but the biological basis for resistance to G-CSF as well
as the risk of evolution to AML is not known.
Summary/Conclusions: Understanding the biological basis for the diversity
of genotype-phenotype relationships for mutations in ELANE, particularly how
some mutations predispose to a high risk of AML, is critical for improving the
diagnosis and treatment of this form of hereditary neutropenia.
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ACUTE MYELOID LEUKEMIA IN THE ELDERLY TREATED AGGRESSIVELY
IN A NON-TRANSPLANT CENTER: A SINGLE CENTER OF EXPERIENCE
D Mota,*, J Carda, P César, M Pereira, E Cortesão, A Crisóstomo, L Ribeiro
Clinical Haematology, Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal
Background: Most cases of Acute Myeloid Leukemia (AML) occur in older
patients in whom, considering biological variation associated with chemoresis-
tance and comordibities, defines a challenging population. While overall survival
(OS) in patients with AML decreases with age, most studies performed in elderly
patients showed Complete Remission (CR) rates between 50 and 60% if they
are treated aggressively.
Aims: This study aims to characterize an elderly population with a diagnosis
of AML (considering age subgroups, cytogenetic risk groups, type of intended
treatment and use of consolidation) and to analyze the impact of different treat-
ment approaches on complete response (CR) and their overall survival (OS).
Methods: We analysed 157 patients aged over 60 years with the diagnosis of
AML (excluding acute promyelocytic leukemia, according the 2008 World Health
Organization classification) treated agressively. Retrospective analysis of clinical
and laboratory data, between 1st January 2005 and 31st December 2015.
Results: Of all patients, 55% were male. The median age at diagnosis was 67
years and 68% of patients were over 65. In this population 49% (N=77) of AML
were secondary to another haematological disorder (40%, N=63), or as conse-
quence of prior chemotherapy for another malignancy (9%, N=14). According to
the French-British-American classification, the most frequent subtypes were M4
(23%), followed by the M2 and M1 subtypes (22% each) and M5 (19%). We
obtained conventional karyotype cytogenetic results in 64% of our patients, of
whom 4% were of low risk, 45% of intermediate risk and 15% of high risk. We
choose an aggressive treatment strategy in these 157 patients, pre-selected
according to age, performance-status and comorbidities, attaining a CR rate of
52%. The main induction regimens were MIC/MICE (N=113), ICE/3+7 (N=30),
ARA-C (N=12). OS was respectively 43%, 49% and 8% at 10 months, with sig-
nificant difference between MIC/MICE and ICE/3+7 when compared with ARA-
C regimen (p<0.05). During hematological recovery, 62% presented febrile neu-
tropenia, 10% presented mucositis (grade ≥3) and 8% presented palmar-plantar
rash with cytarabine. The median days to hematological recovery was 28. The
use of consolidation therapy after CR in this age group didn’t improve overall
survival (62 vs 53% at 12 months, p=N.S.). OS was 15% at 12 months and 10%
at 24 months with a statistically significant difference in survival between the 60-
65, and over 65 age groups at 12 months (20% vs 12%; p<0.05). Progression
of the haematological malignancy was the primary cause of death in 43% of
patients and infection in 22%; 6% died from bleeding complications.
Summary/Conclusions: Although we concluded that a significant proportion
of patients treated aggressively obtain CR, in our series the use of consolidation
didn’t improve OS. However aggressive treatment strategies may induce sev-
eral complications so treatment decisions should be individualized to each
patient, according to risk factors, such as age and cytogenetics, performance
status and co-morbidities. The recommendation is to whenever possible enroll
the patient in a clinical trial.
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ACUTE PROMYELOCYTIC LEUKEMIA: A CONTEMPORARY SINGLE-
INSTITUTION EXPERIENCE
M Hessenauer1,*, N Farhadfar2, N Gangat2
1Internal Medicine, 2Hematology, Mayo Clinic, Rochester, United States
Background: Acute promyelocytic leukemia (APL) is a rare hematologic malig-
nancy, with an incidence of 600-800 cases per year in the United States. At our
institution, fewer than 10 patients with a new diagnosis of acute promyelocytic
leukemia are treated each year.
Aims: We aim to describe our experience with patients treated for acute
promyelocytic leukemia at our institution over the last 15 years.
Methods: After Mayo Clinic institutional review board approval, we searched
our institutional electronic database for those 18 years and older with a new
diagnosis of acute promyelocytic leukemia between January 1, 2000 and
December 31, 2015. We meticulously gathered all patient information through
electronic chart review.
Results: Out of a total of 89 patients reviewed, 59 patients had complete data
available. The median age at diagnosis was 61 years (range: 18-80 years). 34
patients were male, and 25 were female. 9 patients (15.3%) presented with
high-risk disease, 27 (45.8%) had intermediate-risk disease, and 23 (39.0%)
had low-risk disease. 5 patients (8.5%) had received chemotherapy for prior
malignancies. 50 patients (84.7%) received ATRA with anthracycline-based
chemotherapy, and 9 received ATRA and arsenic induction. 58 of 59 (98.3%)
patients achieved complete remission after induction chemotherapy. One
patient died during induction due to diffuse alveolar hemorrhage. After a median
follow-up of 51 months (range: 1-180 months), 53 of 59 (89.8%) patients remain
alive. 2 patients died of causes related to APL, 1 of a non-APL-related cause,
and 3 died of unknown causes. Among 9 patients treated with ATRA and arsenic
induction, all achieved complete remission and were alive at the time of last
follow-up. 28 patients (47.5%) presented with disseminated intravascular coag-
ulation (DIC) at diagnosis. Out of 28 patients with DIC, 9 (32.1%) experienced
hemorrhage, and 19 (67.9%) experienced thrombotic events. 23 of 59 patients
(40.0%) developed differentiation syndrome; 3 of 9 patients (33.3%) treated
with arsenic and 20 of 50 patients (40.0%) treated with chemotherapy. 6 of the
9 patients (66.7%) treated with ATRA-arsenic had grade 3 or 4 neutropenia for
15 days or more during induction therapy. 46 of 50 patients (92.0%) treated
with ATRA-chemotherapy had grade 3 or 4 neutropenia during induction. Infec-
tion was documented during induction therapy in 5 of 9 patients (55.6%) treated
with arsenic and 26 of 50 patients (52.0%) receiving chemotherapy. 4 of the 6
patients (66.7%) who developed hepatic toxicity were receiving arsenic. Overall,
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7 of 59 patients (11.9%) have relapsed, and 10 of 59 patients (16.9%) devel-
oped a secondary malignancy in our cohort.
Summary/Conclusions: Herein, we summarize our single-institution experi-
ence with acute promyelocytic leukemia treated over the last fifteen years. A
comparison of the adverse events and efficacy of ATRA and chemotherapy
versus ATRA and arsenic needs further exploration.
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SUCCESSFUL BL-8040 TREATMENT FOR RELAPSED AML PATIENTS
SINGLE CENTER EXPERIENCE
J Rowe*, Y Pereg
Hematology, Rambam Medical Center, Jerusalem, Israel
Background: BL-8040 is a high-affinity antagonist of CXCR4, a chemokine
receptor that is directly involved in tumor progression, angiogenesis, metasta-
sis, and cell survival. BL-8040 binds to CXCR4 on leukemic cells, inhibiting its
function, thus releasing them from the protective microenvironment of the bone
marrow (BM) resulting in amplification of their sensitivity to chemotherapy. BL-
8040 also has a direct anti-tumor effect by selectively inducing apoptosis of
malignant cells.
Aims: To assess the effectiveness of BL-8040 in combination with cytarabine
(Ara-C) in three patients with relapsed AML who were treated under compas-
sionate protocol.
Methods: Treatment of relapsed AML patients with SC BL-8040 1.25mg/kg on
days 1-7 together with Ara-C 1.5 gr/m2 from day 3-7.
Results: Case 1: A 75 year old male with relapsed AML, 7 years after initial
diagnosis. At the time of diagnosis he had normal karyotype and treated suc-
cessfully with 7+3 followed by consolidation with Ara-C. At time of relapse he
presented with dysplastic changes and additional chromosome 13 karyotype.
At relapse the patient was treated with Ara-C and BL-8040. On day 35 his BM
was in complete remission (CR) with less than 5% blasts. Maintenance therapy
with azacitidine began three months later. Nine months post induction the
patient is still in CR. Case 2: A 23 year old male with a history of Hodgkin lym-
phoma at age 17. At the age of 20 he was diagnosed with AML with the t(8;21)
chromosomal abnormality. He was treated with 7+3 followed by consolidation
with Ara-C. A year later he relapsed and received an allogeneic transplant (allo-
HSCT). Two years post-transplant the patient relapsed with intra and
extramedullary disease represented by a large chest wall mass. He was treated
with BL-8040 and Ara-C as a salvage treatment. There was some resolution
of the extramedullary mass on the first 2 days of monotherapy treatment with
BL-8040 (before the onset of Ara-C). The patient experienced severe injection
site pain and generalized muscle pain which required narcotics for analgesia.
The patient entered CR on day 34 and underwent a second allo-HSCT. Almost
a year and half post BL-8040 salvage treatment the patient is still in CR. Case
3: A 66 years old female with relapsed AML, 14 months after first diagnosis. At
the time of diagnosis she presented with a complex karyotype. She received
induction treatment followed by allo-HSCT but relapsed 3 months later. She
was then treated with Ara-C and donor lymphocyte infusion (DLI) reaching CR;
7 months later she relapsed again. A second salvage treatment with BL-8040
and Ara-C was provided. During treatment she suffered from severe muscle
pain (chest and legs). The patient didn’t reach response showing 52%
myeloblasts on day 24 BM examination. Two days later the patient died. The
direct cause of her death is likely to be disease related.
Summary/Conclusions: Three patients were treated with BL-8040 and Ara-
C as salvage therapy for relapsed AML. The safety profile was similar and the
adverse events were well managed. These were characterized by injection
site reactions and severe muscle pain. BL-8040 in combination with Ara-C can
be administered safely to relapsed, heavily pretreated, AML patients. BL-8040
in combination with Ara-C has been shown to be an effective regimen for bone
marrow as well as extramedullary AML. BL-8040 in combination with Ara-C
should be considered as a bridging therapy for allo-HSCT.
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IMPACT OF GRANULOCYTE COLONY STIMULATING FACTOR FOR
OUTCOMES OF NON-M3 AML PATIENTS TREATED WITH ANTHRACY-
CLINE-BASED INDUCTION (7+3 REGIMEN) CHEMOTHERAPIES
KW Kang1,*, DS Kim1, SR Lee1, HJ Sung 1, SJ Kim2, CW Choi1, BS Kim1,
Y Park1
1Department of Internal Medicine, Korea University School of Medicine,
2Department of Internal Medicine, Sungkyunkwan University School of Medi-
cine, Seoul, Korea, Republic Of
Background: Currently most guidelines recommend primary granulocyte colony-
stimulating factor (G-CSF) prophylaxis in patients with solid cancer who have an
approximately 20% or higher risk for febrile neutropenia. However, these recom-
mendations are not as clear for patients with acute myelogenous leukemia (AML).
Aims: To identify the role of G-CSF in induction treatment in patients with newly
diagnosed AML, we analyzed the efficacies of administration based on clinical
situations such as the development of neutropenia or fever, and investigated
the impact of G-CSF exposure on the anti-leukemic efficacies of induction
chemotherapy.
Methods: A total of 285 patients enrolled in the Korea University AML registry
from September 2001 to March 2015 were analyzed and classified based on
G-CSF administration: (1) no G-CSF exposure during induction (no G-CSF
group), (2) administration initiated immediately after the development of neu-
tropenia (absolute neutrophil counts, <1000/μL) but before the development
of febrile neutropenia (preemptive group), and (3) administration initiated after
the development of febrile neutropenia (therapeutic group).
Results: G-CSF administration resulted in faster ANC recovery compared to
that in the no G-CSF group (p <0.001), but did not significantly affect the dura-
tion of neutropenia or chemotherapy-induced febrile neutropenia (CIFN) in both
the preemptive and therapeutic group. In treatment-related mortality (TRM)
multivariate analysis, the therapeutic group had higher TRM than the preemp-
tive group (OR 5.921, 95% confidence interval 1.316–26.634, p=0.020), with
no significant difference between the preemptive and no G-CSF groups (OR
2.454, 95% CI 0.482-12.495, p=0.280). Only quinolone prophylaxis was shown
to be effective in reducing the incidence of CIFN (p=0.001). There were no sig-
nificant differences in remission rate, cumulative incidence of relapse, overall
survival, and relapse-free survival among the groups (Table 1).
Table 1. Univariate and multivariate analysis for risk factors associated
with treatment-related mortality.
Summary/Conclusions: G-CSF administration during induction chemotherapy
in non-M3 AML patients can accelerate neutrophil recovery without affecting
treatment outcomes. It is best administered at least before the development of
febrile neutropenia in order to prevent TRM. Quinolone prophylaxis might be
effective in reducing CIFN.
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ADULT BIPHENOTYPIC ACUTE LEUKEMIA: THE EGYPTIAN NATIONAL
CANCER INSTITUTE EXPERIENCE
A Darwish1,*, M Samra1, N Alsharkawy2, O Gaber1
1Medical Oncology, 2Clinical Pathology, National Cancer Institute, Cairo, Egypt
Background: Biphenotypic acute leukemia is a rare form of leukemia. Knowl-
edge concerning the clinical and biological presentation, as well as the outcome
of treatment, in adult is limited
Aims: Our objective was to analyze the biological features and outcome of
patients diagnosed with BAL in our institute.
Methods: This is a retrospective analysis of the clinical, biological, and
immunophenotypic features of 30 biphenotypic acute leukemias (BALs), fulfill-
ing modified EGIL’s score, and treated in the medical oncology department at
the National Cancer Institute (NCI-Cairo) between 2005& 2010. Myeloid and
T-lineage features were demonstrated by cytoplasmic myeloperoxidase and
CD3; B-lineage features were demonstrated by CD19, CD22 and CD10.
Figure 1.
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Results: There were 18 men and 12 women; all were adult with a male to female
ratio 3:2. The median age of the patients at diagnosis was 40 years (range, 19-
62).The median white blood cell (WBC) count, hemoglobin concentration and
platelet count were 31x103/dl (range, 2-275), 7g/dl (range, 4.1-11) and 53x103/dl
(range, 14-539), respectively. Morphological assessment showed myeloid features
in 14, and undifferentiated in sixteen patients. According to the EGIL classification,
there were 20 cases of myeloid+B-lymphoid leukemia (66.7%), 5 cases of
myeloid+T-lymphoid (16.7%), and 5 cases of trilineage myeloid+B+T-lymphoid
leukemia (16.7%). The most common phenotypic feature was the expression of
CD45 antigen which was positive in 27 (93.1%) patients. Cytogenetic results were
available for only 4 patients. Eight patients received ALL-tailored therapy, 14
received AML-tailored therapy while 8 were either unfit for chemotherapy or died
before induction treatment. Patients that received ALL-tailored chemotherapy had
a better CR achievement rate (87.5%) over the patients that received AML-tailored
chemotherapy (35.7%). The 6, 12 & 24 months overall survival (OS) were 33.3%,
30.0% & 26.6% respectively. Although patients with trilineage phenotype had better
OS at 6, 12 & 24 months this was not of statistical significance (Figure 1).
Summary/Conclusions: Biphenotypic acute leukemia is a poor-risk disease.
Despite the progress in the treatment of acute leukemia there are no uniform
criteria about whether to treat BAL patients as ALL or AML. Further prospective
collaborative studies are needed to investigate proper treatment protocols for
this entity.
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SALVAGE REGIMENT WITH FLAT FOR REFRACTORY AND RELAPSED
AML: EXPERIENCE A SINGLE CENTRE
A Salamanca*, D Madrigal, R Saldaña, E Martin, S Garzon
Haematology, Hospital Jerez de la Frontera. Área Sanitaria Norte de Cádiz.,
Cadiz, Spain
Background: Outcomes in patients with acute myeloid leukemia (AML) who
are primary refractory or early relapsed are dismal, and there is not one stan-
dard therapy for all patients. Allogeneic hematopoietic stem cells transplantation
(HSCT) is the treatment with the highest probability of cure when is possible to
reduce the leukemia burden with salvage chemotherapy regimen prior to trans-
plantation.
Aims: In this study, we report our experience of salvage chemotherapy regimen
with fludarabine 30 mg/m2, cytarabine 2 g/m2 and topotecan 1.5 mg/m2 on
days 1 to 4 (FLAT), for refractory or relapsed AML treated in our institution.
Methods: Analytical, observational and retrospective study. We included all
patients treated with FLAT from 2008 to 2016 in our center. We studied disease
status prior to salvage therapy (refractoriness to one or two previous regimens
Vs early or late relapse), cytogenetic risk profile (favorable, intermediate or
adverse), response (complete response [CR], partial response [PR] or refractory
disease [RD]) and survival (overall survival [OS]).
Results: Twenty-four patients were treated with FLAT in the last eight years in
our center. Median age at time of treatment was 55 years old (range 39-69).
AML was the underlying condition in all individuals. Cytogenetic risk profile at
diagnosis (ELN) was favorable in 2 patients, intermediate in 10 and adverse in
9 of them. It was not determinate in 3 patients. Ten patients received FLAT sal-
vage course for primary refractory AML, 1 for secondary refractory AML, 11 for
relapsed AML after chemotherapy and 2 for relapsed AML after stem cell trans-
plant (allo-SCT). Median OS was 16 months (range 1-86), with median follow
up of 41 months. OS in primary refractory AML was 20 months (1-84) and 14
months (3-86) in relapsed AML. RC rate after FLAT was 45.8% (11 patients),
higher in refractory disease (7 out of 11). Treatment related mortality was 16%.
After reaching CR or PR, 7 patients underwent allogeneic transplantation. In
this group, OS was 23 months (2-84). Four patients did not undergo transplan-
tation despite reaching CR because of infection complications or early relapse
while unrelated donor search was activated. Four patients underwent a sequen-
tial approach with a third salvage chemotherapy and allo-SCT despite refrac-
toriness to FLAT; two of them could reach CR with this approach.
Summary/Conclusions: FLAT is an efficient salvage regimen for refractory
and relapse AML. An acceptable CR rate allowed patients to continue with allo-
geneic-SCT and a longer overall survival. This combination has an acceptable
safety profile, even for the patients who were treated after transplant.
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KINETICS OF WT1 OVER-EXPRESSION IN ACUTE MYELOID LEUKEMIA
PATIENTS WHO RECEIVED STANDARD CHEMOTHERAPY OR
UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION
N Eisa1,2,*, S Shamaa1,2, M Khalaf3, E Azmy1,2, A Agm4, M Samra5, Z Emarah2,6
1Clinical Hematology Department, Oncology Center, Mansoura University, 2Inter-
nal Medicine, Faculty of Medicine, Mansoura University, Mansoura, 3Clinical
Hematology Department, 4Clinical Pathology Department, Hematology and
Oncology Hospital, Maadi Armed Forces Medical Compound, 5Medical Oncology
Department, National Cancer Institute, Cairo University, Cairo, 6Medical Oncology
Department, Oncology Center, Mansoura University, Mansoura, Egypt
Background: Wilms’ tumor 1 (WT1) gene expression is well-known pan
leukemia marker which overexpressed in more than 90% of newly diagnosed
acute myeloid leukemia patients. However, the clinical utility of WT1 monitoring
has been somewhat controversial.
Aims: The aim of this study is to compare WT1 transcript level kinetic changes
in patients with AML either received standard chemotherapy (Arm A) or under-
went allogeneic stem cell transplantation (Arm B).
Methods: Peripheral blood samples collected from 26 patients diagnosed with
AML at initial diagnosis. Further samples collected from 9 patient who received
standard chemotherapy (Arm A) at post-induction and post-intensification time
points. Further samples collected from 8 patients who underwent allogeneic stem
cell transplantation (Arm B) before conditioning, at day 30 and at day 100. The
remaining 9 patients were not included in the analysis due to either early death
or a negative WT1 at diagnosis. Quantitative RT-PCR detection of WT1 gene
transcript level using Ipsogen WT1 profile Quant was performed on peripheral
blood samples in both arms at the different time points mentioned before.
Results: We observed significant difference in the median values of WT1 tran-
script level at the 3 time points for patients with Arm A (P value 0.011) while for
allogeneic arm B the median values were nearly the same at the 3 time points
(P value 0.687). We found that WT1 level post-induction correlates with mor-
phologic response (P value: 0.04). The median values for WT1 level were more
for relapsed rather than non-relapsed cases in both arms at the 3 time points,
but this difference was statistically insignificant except at D100 in arm B (P-
value 0.046) and about to be significant at post-intensification (P value was
0.064) in arm A (Figure 1).
Figure 1. WT1 kinetics. A: WT1 kinetics for arm A. B: WT1 kinetics for arm
B. C: WT1 transcript level between relapsed and non-relapsed case in
arm A. D: WT1 transcript level between relapsed and non-relapsed case
in arm B.
Summary/Conclusions: We identified a positive correlation between WT1
transcript level and morphological response. Therefore, elevation or rising WT1
transcript levels after intensifications or beyond day 100 post-transplant may
be a marker of impending relapse that if validated in larger studies, may warrant
either close observation or pre-emptive intervention. Although our results are
poorly reaching the level of significance, probably due to the small sample size,
WT1 transcript level showed dynamic changes with treatment and may be a
marker for relapse. We recommend further studies with larger number of
patients in different centers to confirm these results.
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STANDARD INDUCTION CHEMOTHERAPY IN CHILDREN WITH MLL-AF9
ACUTE MYELOID LEUKEMIA AND SEVERE DISSEMINATED INTRAVAS-
CULAR COAGULATION IS ASSOCIATED WITH HIGH MORTALITY
A Colita1,2,*, M Asan3, A Gheorghe3, C Zaharia3, L Radu2, M Safta2, M Dragomir3,
C Jardan2, A Colita2
1Pediatric Hematology & BMT, Fundeni Clinical Institue, 2Carol Davila University
of Medicine, 3Fundeni Clinical Institue, Bucharest, Romania
Background: MLL-AF9 AML is a rare subgroup of unfavorable prognostic
leukemia secondary to t(9;11)(p22;q23) with particular clinical aspects, mainly
severe coagulopathy.
Aims: To analyze the clinical, hematological and coagulation parameters at
diagnosis and correlation with the outcome after chemotherapy initiation in chil-
dren with MLL-AF9 leukemia treated according to a BFM 2004 AML protocol in
a single center.
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Methods: Six consecutive patients with MLL-AF9 AML were identified by flu-
orescence in situ hybridization and Nested PCR in our center in the last 10
years. The diagnostic was completed by bone marrow morphology and
immunophenotyping, standard kariotype and coagulation tests (AP, aPTT, INR,
D-Dimers, PDF, Fbg, PC, PS, AT III). Patients were treated according to the
BFM 2004 AML protocol. All patients received fresh frozen plasma. Informed
consent has been obtained from parents.
Results: Between 2006-2015 we treated 74 patients with AML, 6 (8,1%) being
diagnosed with MLL-AF9 AML, fusion type 6A in all cases. The kariotype has
been performed in all patients, but we obtained interpretable result only in 2
patients, all of them without abnormal cytogenetics. The patient characteristics
are shown in Table 1. All patients had laboratory signs of variable degrees of
DIC at diagnosis documented by prolonged coagulation times, presence of fib-
rin degradation products (FDP) and elevated D-Dimer levels. Three patients
developed during the first 2 days after chemotherapy initiation a respiratory
distress syndrome and seizures associated with cerebral hemorrhage with fatal
outcome in the next 2-5 days. The initial hemostasis/coagulation analysis in
these patients showed platelet counts 30x109/L, 70x109/L, respectively
165x109/L, but with high D-Dimer levels 1670, 2430, respectively >60.000 µg/L
(upper detection limit for our laboratory). The other 3 patients completed the
induction chemotherapy without special complications. The BM aspirate and
MLL-AF9 monitoring confirmed the complete remission (CR). The
hemostasis/coagulation analysis in these patients showed similar platelet
counts (60 x109/L, 54 x109/L, 30 x109/L), but associated with lower levels of
D-Dimers (1070, 960, 1020µg/L).
Table 1.
Patient characteristics                                                                 No. 6 cases
Sex ratio M/F                                                                                   5/1
Age median                                                                                  2y 6 mo
FAB type                                                                                M1:1/M5:3/M7:2
Hg median                                                                                    7.6 g/dl
PLT median                                                                                  62x109/L
WBC median                                                                             19.13x109/L
Blasts median                                                                           13.88x109/L
Hepatomegaly                                                                                  4/6
Splenomegaly                                                                                  3/6
Summary/Conclusions: MLL-AF9 is a poor prognostic AML subtype, associ-
ated with a higher mortality at induction treatment. Half of the patients in our
cohort had a severe DIC associated at onset, with high D-Dimers levels (more
than twice upper normal limit) that worsened after chemotherapy initiation lead-
ing to respiratory failure and cerebral hemorrhage in absence of severe throm-
bocytopenia. For our cohort the presence of significant coagulopathy at onset
is associated with poor prognosis, suggesting a clinical evolution of this syn-
drome that is similar with AML M3 outcome in the absence of all-trans retinoic
acid associated chemotherapy.
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CD34 POSITIVE CELL COUNT DETECTED BY MULTI-COLOR FLOW
CYTOMETRY (MFC) AFTER FIRST INDUCTION THERAPY IN ACUTE
MYELOID LEUKEMIA (AML) EFFECTS ON SURVIVAL AND RELAPSE
E Atilla*, P Ataca Atilla, S Civriz Bozdag, M Kurt Yuksel, P Topcuoglu, O Arslan,
M Beksac, M Ozcan, O Ilhan, H Akan, K Dalva, G Gurman, S Kocak Toprak
Ankara University School of Medicine Department of Hematology, Ankara,
Turkey
Background: Minimal residual disease (MRD) is defined as detection of low
levels of leukemic cells and had been shown to correlate with an increased
risk of relapse and shortened survival in Acute Lymphoblastic Leukemia. How-
ever there is a controversy in definition of MRD in AML.
Aims: Our aim is to evaluate the effects of CD34 positive cell count of >1.0%
after first induction therapy on survival and relapse in AML in our cohort.
Methods: CD34 positive cell count of >1.0% was measured in newly diagnosed
148 AML (excluding acute promyelocytic leukemia) patients by multi-color flow-
cytometry (MFC) based detection after first induction regimen in between 2007
and 2015. Chi-square test and kaplan-meier curves were used for statistical
analysis. P<0.05 was considered statistically significant.
Results: The median age was 47 (range, 21-82). 78 (52%) of patients were
male. AML risk stratification at diagnosis were as follows; low risk (21%), stan-
dart risk (38%), high risk (22%). For the induction regimen, 11 geriatric patients
received azacytidine and 137 patients got standart 3+7 (ARA-C/daunorubicin).
23.5% of patients (35/148) were not in remission and received reinduction ther-
apy. CD34 positive cell count>1.0% was detected in 49.7% patients (74/148)
after induction. High dose ARA-C consolidation treatments (mean 2 cycles,
range 1-6) were administered and 87 patients (58%) underwent allogeneic-
stem cell transplantation due to their risk status. The relapse rate of patients
with CD34 positive cell count >1.0% was significantly higher than CD34 positive
cell count lower than 1.0% (58% vs 32%, P=0.01). RFS rate at 12 months was
higher in CD34 positive cell count lower than 1.0% (72% vs 41%, P=0.1). 2
year OS significantly improved in patients with in CD34 positive cell count lower
than 1.0% (83% vs 66%, P=0.049) (Figure 1).
Figure 1.
Summary/Conclusions: CD34 positive cell count >1.0% detected by MFC
after first induction is related to higher risk of relapse and decreaced OS.
Despite techniques for detection of MRD in AML evolve rapidly, MFC remains
a useful tool.
PB1671
ACUTE MYELOID LEUKEMIA WITH MYELODISPLASIA-RELATED
CHANGES: A REVIEW OF 58 CASES AT A SINGLE CENTRE
S Martin-Batista*, B Soria, BJ González-González, T Martín-Santos, A Martín-
Martín, C De Bonis, S Afonso, B Esquivel, L Gutiérrez-Murillo, MJ Rodríguez-
Salazar, S Iraheta, S Lakhwani, P Machado, MT Hernández-García, JM Raya
Hospital Universitario de Canarias, La Laguna, Spain
Background: The WHO-defined category (2008) of acute myeloid leukemia
with myelodysplasia-related changes (AML-MRC) includes cases with 20% or
more blasts in the peripheral blood or BM and (1) dysplastic morphology in
50% or more of the cells in two or more myeloid lineages and/or (2) a preceding
MDS or MDS/MPN phase and/or (3) specific myelodysplasia-related genetic
abnormalities. In consecuense, this is a heterogeneous disorder defined by
morphologic, genetic, or clinical features.
Aims: Our objective was to analyze the main characteristics of patients with a
diagnosis of AML-MRC who were treated and followed in our institution.
Methods: We have retrospectively studied all the cases of AML-MRC that
were seen at our hospital in the last fiveteen years. Main recorded data included
age, sex, a previous diagnosis of myelodysplastic síndrome (MDS), peripheral
blood cell counts, serum lactate-dehydrogenase level, bone marrow aspirate
features, cytogenetics, immunophenotype by flow cytometry, therapeutic
approach, response to treatment, overall survival and mortality. Statistical
analysis was performed using the SPSS 17.0 version.
Results: From 2001 to 2015, 58 patients were diagnosed with AML-MRC at
our hospital. Mean age at diagnosis was 72 years (median 75, range 23-90)
and 60,3% were men. A previous diagnosis of MDS was noted in 43 patients
(74%), with the following distribution: refractory cytopenia with multilineage
dysplasia, 22 cases (38%); RAEB-1 or 2, 17 (29%); refractory anemia, 3 (5%);
and refractory anemia with ring sideroblasts, 1 (1,7%). According to WHO cri-
teria, cytogenetic abnormalities sufficient to diagnose AML-MRC were found
in 7/31 patients with a conclusive caryotypic result (22,6%). A diagnosis of
AML-MRC based only in morphological findings was performed in 9 patients
(15,5%).
With respect to the findings on blood at diagnosis, leukopenia was present in
53% and leukocytosis in 28%; anemia in 93% (macrocytic 30%) and throm-
bopenia in 84%. Pancytopenia was found in 47% of cases and a high level of
serum lactate-dehydrogenase in 42%. The more frequent phenotypic markers
of blast cells, analysed by flow cytometry, were HLA-DR (80% of cases), CD34
(74%), CD33 (72%), CD13 (68%), CD117 (68%), CD38 (62%) and MPO (48%).
Some aberrant expressions were found, being CD7 positivity the most frequent
(34% of cases); positivities for CD56 (10%) and CD4 (3%) were also observed.
The “3+7” induction regimen was applied in 24% of patients, while 5-azacytidine
was the drug of choice in 21%. Paliative or supportive treatment was used in
the majority of cases (55%). Nine of 14 patients (64%) obtained complete
remission after “3+7” scheme (four still alive), and only one (8%) among those
treated with 5-azacytidine. At the moment of closing this study, 52 patients had
died (89,7%), with a mean overall survival of 14 months (range 0-60), and 6
were still alive after a mean follow-up of 53 months (range 16-168). Mean age
of survivors at diagnosis was 57.5 years, compared with 74 years of that who
have died. Among the recorded data, those associated with a better outcome
were younger age (p=0.028), positivity for CD56 (p=0.005) and intensive treat-
ment (p=0.026).
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Summary/Conclusions: In our experience, AML-MRC occurs mainly in elderly
patients and is associated with a poor prognosis. The age at diagnosis (and
therefore, the probability of receiving intensive chemotherapy) seems to be a
strong determinant of prognosis; also, CD56-positive cases exhibited a lower
mortality rate than those negative. Further studies are needed to confirm these
findings and new therapeutic strategies should be investigated to improve out-
come in this group of patients.
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THE ROLE OF DAILY ECG-MONITORING IN THE MYOCARDIAL INJURY
DIAGNOSIS ON THE BACKGROUND OF ANTHRACYCLINE LOW
CUMULATIVE DOSES IN PATIENTS WITH ACUTE LEUKEMIA IN
COMBINATION WITH ISCHEMIC HEART DISEASE
T Lymanets*, I Skrypnyk, G Maslova
Chair of Internal Medicine #1, Ukrainian Medical Stomatological Academy,
Poltava, Ukraine
Background: Anthracycline-induced cardiotoxicity is a complicated problem of
treating patients with acute leukemia (AL), which can lead to the acute cardiac
events development. Ischemic heart disease (IHD) is one of the cardiotoxicity
risk factors, which requires monitoring of changes in myocardial bioelectric activity
on the background of anthracycline low cumulative doses (CDs) in these patients.
Aims: To assess the nature of electrocardiogram (ECG) changes on the back-
ground of anthracycline low CDs in patients with AL taking into account con-
comitant ischemic heart disease.
Methods: The study involved 93 patients with newly diagnosed AL (acute lym-
phoblastic leukemia – 21 pts, acute myeloid leukemia – 72 pts), mean age 16-
72 years, 48 (51.8%) men, 45 (48.2%) women, ECOG I-II. Their polychemother-
apy (PCT) programs included anthracyclines. According to the presence of
concomitant IHD patients were divided into two groups: I (n=57) – AL patients
without concomitant IHD; II (n=36) – AL patients with concomitant IHD. The
standard 12-lead ECG and daily ECG-monitoring were performed for patients
of both groups in achieving the CD from 100 to 200 mg/m2 for doxorubicin,
which amounted 179.5±24.11 mg/m2 and 172.1±23.15 mg/m2 in patients of
groups I and II respectively.
Results: The sinus tachycardia, repolarization processes violations and QRS
complex voltage reduction were registered in 16 (28%) pts of group I according
to the standard 12-lead ECG. In 29 (80.5%) pts of group II on the sinus tachy-
cardia background the following changes were revealed: right bundle branch
block – in 2 (5.6%) pts, left anterior fascicular block – in 2 (5.6%) pts, first-
degree atrioventricular block – in 2 (5.6%) pts, supraventricular extrasystoles
– in 4 (11.1%) pts, lower voltage and repolarization processes reduction – in 8
(22.2%) pts. The ST segment depression was registered in 13 (36.1%) pts, the
Q-T interval prolongation – in 6 (16.6%) pts, T wave changes – in 6 (16.7%) pts
of group II. According to the daily ECG-monitoring in 28 (49%) pts of group I
with minimal physical activity on the tachycardia background the episodes of
solitary supraventricular extrasystoles were detected. In all 36 (100%) patients
of group II the periods of tachycardia were recorded, that were accompanied
by the increasing number of single supraventricular extrasystoles, episodes of
paired and group supraventricular extrasystoles – in 24 (66.6%) pts, single
episodes of ventricular extrasystoles – in 19 (52%) pts and increased number
of clinically significant ST segment depression periods – in 29 (80.5%) and Q-
T prolongation – in 14 (38.8%) patients.
Summary/Conclusions: Low CDs up to 100-200 mg/m2 for doxorubicin in AL
patients without ischemic heart disease are accompanied by the cardiotoxic
effects development in the form of arrhythmias: sinus tachycardia, supraven-
tricular extrasystoles. In case of concomitant ischemic heart disease presence
the complex of myocardial bioelectric activity disorders develops, such as
arrhythmias, conduction abnormalities and silent myocardial ischemia. With
the purpose of early anthracycline-induced cardiotoxicity diagnosis in patients
with AL receiving PCT it is necessary to conduct daily ECG-monitoring, which
has greater sensitivity compared with standard 12-lead ECG.
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MOLECULAR DIAGNOSTIC ON BONE MARROW BIOPSY SPECIMEN: AN
INNOVATIVE CLINICAL TOOL WITH MAJOR IMPACT ON CLINICAL
DECISIONS.
M Gavillet*, S Mathieu, O Spertini
Hematology, CHUV, Lausanne, Switzerland
Background: Genetics is currently central to diagnosis, prognosis and measure
of response to therapy (minimal residual disease, MRD) for patients with acute
leukemia, myeloid or lymphoid. These tests are usually conducted on bone
marrow aspirate by various techniques (karyotype, fluorescence in situ
hybridization, reverse transcription polymerase chain reaction, or DNA sequenc-
ing). In case of a dry tap these most valuable information are often lost.
Aims: Since January 2014, we implemented a method for DNA and RNA
extraction from bone marrow biopsy specimen in case of a dry tap at diagnosis
or during follow up. Here we present the method, results and relevance of the
analysis conducted so far.
Methods: Bone marrow biopsy is immediately sunken in either RNAlater (QIA-
GEN, as for other products listed below) for transcript expression analysis such
as acute myeloid leukemia (AML) recurrent genetic anomaly or MRD determi-
nation. In case DNA-based analysis is warranted, such as analysis of BCR
rearrangements and NOTCH mutations, the biopsy specimen is put into phos-
phate buffer saline (PBS). Biopsy material is then manually crushed and solved
in Qiazol for RNA and PBS for DNA. Manual extraction according to the
phenol/chloroform is performed prior to RNA purification, quantification and
reverse transcription according to manufacturer’s instruction. DNA purification
and quantification is performed similarly. Analyses are performed according to
established standards for bone marrow aspirates.
Results: We retrospectively identified 32 analysis from 20 patients with either
acute lymphoid leukemia (ALL, n=6), acute myeloid leukemia (AML, n=12) or
high risk myelodysplastic syndromes (MDS, n=2). Dry tap occurred either at
diagnosis (n=11) or during follow up (n=21), regardless of diagnosis (lymphoid
or myeloid neoplasia), blast count (median 5%, range: 1-95%) or marrow fibro-
sis (median 2, range 0-4). In seven samples, this technique allowed to identify
a mutation in NMP1, with impact on diagnosis and prognosis, which is not
amendable to other techniques (karyotype or FISH). Seventeen more samples
allowed to quantify minimal residual disease (levels of WT1 or BCR-ABL tran-
scripts), which is either not possible or less refined by alternative cytogenetic
methods. Seven patients had more than one sample, which allowed correlation
with and refinement of response assessment by histology. On 11 occasions
(37.5%) the result of molecular analysis had a major impact on therapy (mostly
distinction of Philadelphia positive vs negative ALL n=5, targeted therapy for
FLT3-ITD transcript n=1, identification of relapse/refractory disease n=2, deci-
sion between autologous vs allogeneic transplantation for consolidation n=2).
Summary/Conclusions: The method presented here is a readily accessible
variant of the commonly used molecular diagnostic techniques. Its use can
confirm, expand and usually refine the analysis available on the bone marrow
biopsy specimen, and in one third of the cases, have a significant impact on
therapy options.
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ACUTE MYELOID LEUKEMIA IN OLDER PATIENTS: COMPARISON OF
THE EFFECTIVENESS OF THERAPY AND SURVIVAL ANALYSIS.
A SINGLE CENTER EXPERIENCE
A Klak-Skubis1, K Kapelko-Slowik1,*, J Dybko1, D Urbaniak-Kujda1, M Biernat2,
S Stapor1, K Kuliczkowski1
1Hematology, Blood Neoplasms and Bone Marrow Transplantation, 2MIcrobi-
ology, Wroclaw Medical University, Wroclaw, Poland
Background: Acute myeloid leukemia (AML) is disease of older adults with
median age over 65 years. The effect of age and severe comorbidities are
associated with high incidence of early death, low rate of complete remission
(CR) and poor survival. Treatment options for elderly patients include: intensive
chemotherapy, less-intensive regimens, best supportive care as well as enroll-
ment in clinical trials. Therapeutic decisions in older AML patients are highly
challenging and need to be individualized since the outcome in this group
remains still unsatisfactory.
Aims: The aim of the study was to compare results of different treatment strate-
gies in elderly patients with AML and to analyze overall survival in examined
patients.
Methods: Patients. We describe a single center experience of 101 patients
(41 females and 60 males) with diagnosis of AML, hospitalized in the Depart-
ment and Clinic of Hematology, Blood Neoplasms, and Bone Marrow Trans-
plantation, Wroclaw Medical University between 2007 and 2014. Median age
was 70,6 years (range, 60-90 years). In 85 patients AML was diagnosed de
novo, whereas 16 patients had secondary AML. Adverse, intermediate and
favorable karyotype was found in 14, 82 and 5 patients, respectively. All patients
were enrolled into therapeutic procedures according to the age, karyotype, per-
formance status and comorbidity index. Fifty-five patients were treated with
intensive chemotherapy regimen based on daunorubicin and cytarabine (DA,
“3+5-7”), 22 patients obtained azacitidine (AZA), 14 patients were treated with
low-dose cytarabine (LDAC), and only 10 patients received best supportive
care (BSC). We estimated percent of CR, early mortality rate, leukemia free
survival (LFS) and overall survival (OS).
Results: CR was achieved in 24 patients (44%) who received DA, and in 10
patients (28%) with less-intensive therapy. LFS was comparable in both these
groups (5 vs 4 months), but superior in patients who received DA. Eight-week
early mortality rate was up to 15% after intensive induction therapy and 10%
after AZA and LDAC regimens. Nevertheless, median OS in patients treated
with DA was marginally superior (5 month) than in patients who received low
intensive treatment (4 month) and significantly longer than in patients with BSC
(1 month).
Summary/Conclusions: The DA regimen remains still a best standard therapy
in older AML patients with good performance status and low comorbidity index.
Low-intensive treatment strategies (azacitidine, low-dose cytarabine) seem to
be good therapeutic options for older patients with severe comorbidities.
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ARSENIC TRIOXIDE AS THE FIRST LINE THERAPY FOR PATIENTS WITH
SECONDARY MITOXANTRONE-RELATED ACUTE PROMYELOCYTIC
LEUKEMIA ON THE BACKGROUND OF MULTIPLE SCLEROSIS
T Lobanova1,*, V Troizkaya1, A Sokolov1, S Kravchenko1, L Plastilina1,
O Gavrilina1, A Sidorova1, G Galstyan2, E Parovichnikova1
1Hematological Oncology and BMT, 2Intensive care unit, National Research
Center for Hematology, Moscow, Russian Federation
Background: Mitoxantrone (MT) is a topoisomerase II inhibitor which impairs
DNA repair mechanisms. It is well known to induce acute leukemia with
absence of myelodysplastic phase. MT therapy is often associated with translo-
cation t(15;17), which defines the development of acute promyelocytic leukemia
(APL). MT remains an effective drug for treatment of remitting progressive
phase of multiple sclerosis (MS). The APL risk in patients with MS depends on
MT dose (≤60mg/m2, ≥60mg/m2). Long MS anamnesis, severity of somatic
status and evolvement of therapy-related acute leukemia (TRAL) in such
patients requires new approaches to treatment.
Aims: To describe the optimal treatment protocols for MS patients with APL,
taking into account the patients somatic status.
Methods: From January 2014 to February 2016 in the Department of Hema-
tological Oncology and BMT 15 pts with APL were treated, and 2 of them (39
and 58 y.o.) were with long anamnesis (over 15 years) of MS (remitting pro-
gressive phase, cerebral-spinal form). First patient (pt) due to fast progression
of MS got MT therapy several times a year, in total≥60mg/m2, second pt
received MT with 60mg in total. Both pts developed APL after 2 years of MT
injections. Severity of somatic status was determined by hemorrhagic syndrome
(skin and mucosa), coagulation disturbances, granulocytopenia and lower para-
paresis with pelvic organs dysfunction due to MS. Pts had intermediate risk
APL, cytogenetic analysis showed translocation t(15;17), molecular – bcr1 tran-
script in both cases.
Results: For the first patient we started all trans-retinoic acid (ATRA) therapy
with arsenic trioxide (ATO). Good tolerance to treatment was stated. After 1
month of treatment APL molecular remission was established. The neutropenia
period lasted 6 days; catheter-associated sepsis, vaginal and urinary infections,
QTc lengthening to 0,48ms were diagnosed. The course of treatment was com-
pleted according to ATRA and ATO protocol (E. Estey, 2006). APL remission
retains for 16 months. Neurologic symptoms of MS stay stable since the start
of APL therapy. The second pt was started with chemotherapy protocol (AIDA),
on day 14 he developed septic shock, severe pneumocystis pneumonia with
acute respiratory failure. In 2 days he was transferred to the intensive care unit
for prolonged invasive mechanical ventilation. Due to long lasting cytopenia
(30 days), severe infectious complications, the polyneuropathy deteriorated
and tetraplegia developed after status stabilization. ATO therapy with further
combination ATRA+ATO was started. Morphological complete remission (CR)
and cytogenetic CR were achieved after chemotherapy, molecular CR – after
28 days of ATO. 5 courses of ATO and ATRA+ATO treatment completed. No
severe complications were noted and the duration of CR is 8 months. Upper
limbs function has recovered, lower limbs – only partially.
Summary/Conclusions: Our experience shows high toxicity of chemotherapy
protocol in APL patients with MS. Such protocols cause severe infectious com-
plications due to long period of immunosuppression and may worsen the neu-
rologic status. ATO and ATRA combination as the first line therapy of therapy-
related APL in such pts allows to achieve molecular remission with lower toxic
effects and without deterioration of MS course.
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THE ACUTE CLINICAL AND LABORATORY CONSEQUENCES OF ORAL
MUCOSITIS DEVELOPED AFTER REMISSION INDUCTION CHEMOTHER-
APY IN ACUTE LEUKEMIA PATIENTS
A Yigit1, N Guler2,*, P Buyukkaya2, M Turgut2, D Ozatli2
1Internal Medicine, 2Hematology, Ondokuz Mayis University, School of Medi-
cine, Samsun, Turkey
Background: Chemotherapeutic (CT) agents frequently cause oral mucositis
(OM) as a side effect during the treatment of acute leukemia. Patients with OM
are generally more predisposed to intraoral infections. OM also affects the
nutrition, swallowing, and quality of life.
Aims: To analyze the consequences of post chemotherapy developed OM in
acute leukemia patients.
Methods: Seventy-two adult patients with newly-diagnosed Acute Myeloblastic
leukemia (n=59), Acute Lymphoblastic Leukemia (n=13) were included. CTs
were 7+3 ARA-C+idarubicin (n=43), Azacitidine (n=13), idarubicin+ATRA (n=2),
low dose ARA-C (n=1), Hyper-CVAD (n=8), CALGB (n=5). Patients divided
into two groups as post-chemotherapy OM or not. Evaluation was performed
by same physician daily according to WHO (World Health Organization) OM
classification. Stage 1: Oral soreness, erythema; stage 2: Oral erythema, ulcers,
solid diet tolerated; stage 3: Oral ulcers, liquid diet only; stage 4: Oral alimen-
tation impossible.
Results: OM occurred in 27 (37%) of 72 patients. Appearance time of the OM
after the initiation day of the CT was 6.3±3.4 days and OM were continued for
9.7±5.8 days. There were no significant differences in sociodemographic data,
type of leukemia, CT protocol, and smoking status between the two groups.
Mostly OM were stage 2 (40.7%, n=11). Others were stage 1 (14%, n=4), stage
3 (29.6%, n=8), stage 4 (14.8%, n=4). Microorganisms in the oral mucositis
swab cultures were detected in 12 out of 27 patients with OM. They were
Pseudomonas aeruginosa (n=4 patient, 14.8%), Streptococcus viridans in (n=2;
7.4%), Enteroccus faecium in (n=2), Candia albicans (n=1; 3.7%), Acinetobac-
ter baumannii (n=1), Morganella morganii (n=1), Enterobacter cloacae (n=1).
Microorganisms in blood cultures of patients with OM were detected in 7
(25.9%) out of 27 patients. This ratio was low as 11% (5 out of 45) in patients
without OM. There wasn’t any relationship between microorganism in swab
culture and blood culture as same in patients. Microorganism in blood cultures
of patients with OM were: Staphylococcus hominis (n=2 patients, 7.4%), ESBL
Negative E.coli (n=2; 7.4%), Acinetobacter baumannii (n=1; 3.7%), Staphylo-
coccus Epidermidis (n=1), Coagulase negative staphylococcus (n=1). Microor-
ganisms in blood cultures of patients without OM were such as: Staphylococcus
Epidermidis (n=2; 4.4%), ESBL Negative E.coli (n=1; 2.2%), Staphylococcus
capitis (n=1), Staphylococcus hominis (n=1). The mean duration of neutropenia
in OM group was 32 days compared to 22 days in the without OM group
(p=0.02). The pre-treatment level of serum albumin was lower, and the levels
of CRP and LDH during mucositis were higher in the patients with OM (p<0.001,
p<0.001and p=0.002, respectively). Mortality was higher in the group with OM,
9 (6 patients with stage 3 or 4 OM; 3 patients with stage 1) in 27 vs 6 in 45
patients (p=0.04). Six of 12 patients who developed severe mucositis (stages
3 and 4) died. The fever appeared on day 7.1±0.87 of the CT in the patients
with OM, whereas fever was observed on day 4.1±0.67 in the patients without
OM (p=0.002).
Summary/Conclusions: The development of OM may have a role about
prognostic value in the patients receiving CT because of the extended dura-
tion of neutropenia, higher levels of LDH and CRP, and a higher rate of mor-
tality in patients with OM. Furthermore, we would like to highlight that the
patients with low levels of albumin prior to chemotherapy should be more
closely followed for OM.
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ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS. ANALYSIS OF 102
CASES
H Ionita1,*, I Ionita1, M Cheveresan1, C Ionita2, D Calamar1, D Oros1, M Ionita3
1Hematology, 2Surgery, 3Internal Medicine, University of Medicine and Farmacy
Victor Babes Timisoara, Timisoara, Romania
Background: Acute myeloid leukemia (AML) is more frequent in elderly
patients and the prognosis is very poor. There is no established standard treat-
ment, since the survival of patients treated with intensive chemotherapy is 15%
at 3 years. Most patients are not candidates for intensive treatment due to age,
comorbidity or other biological characteristics. The management of old patients
with AML remains controversial, specially in those cases affecting very old
patients (aged ≥70).
Aims: It is presented the experience of our centre (single centre experience)
with a group of patients from the period 1995-2014.
Methods: We conducted a retrospective analysis of 102 consecutive patients
65years of age or older, diagnosed for AML between January 1995 and Decem-
ber 2014, in Department of Hematology, County Hospital, Timisoara, Romania.
Without selection (33.1%) had evolved from prior myelodysplastic syndrome.
Patients were divided into 3 groups according to the treatment: no treatment
(supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m2/12h
s. c. days 1-21) and high intensity treatment (Idarubicin 10 mg/m2 days 1 and
3; Ara-C 100 mg/m2/12h days 1-3; Etoposide 100 mg/m2 days 1-3).
Results: Total number of subjects was 57 men and 45 women. Median patient
age was 73 years (range, 65-87 years); mean Karnofsky index was 70; 72
patients received treatment and 30 of them did not; M3 subtype was excluded,
overall survival was 6,2 months, significant differences were observed in the
mean overall survival between the treated and no-treated groups (12,5 vs 2,5
months respectively; p=0,015). The patients treated with supportive therapy had
a median length of hospital stay of 16 days, while the patients treated with
chemotherapy had a median length of hospital stay of 75 days. In the low intensity
group (45 patients) an overall response of 30% was observed; in the high intensity
one (27 patients), overall response was 50% no statistical differences were
observed between both groups considering all subgroups of response (p=0,14).
Summary/Conclusions: Overall survival in the treated group is higher than in
the non-treated one, differences reached statistical significance. Comparing
both arms of treatment no statistical differences were observed in the quality
of response, though a higher proportion of complete responses were observed
in the high intensity group. An adequate selection of patients for chemotherapy
treatment leads to a low mortality rate. Further research is needed to establish
optimal management and improve outcomes of elderly patients with AML.
684 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
Aggressive Non-Hodgkin lymphoma - Clinical
PB1678
HIGH DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLAN-
TATION RESULTS IN EXCELLENT LONG TERM SURVIVAL IN PRIMARY
MEDIASTINAL B CELL LYMPHOMA
T Struessmann*, K Fritsch, A Zober, A Baumgarten, J Duyster, J Finke, R Marks
Hematology, Oncology, and Stem-Cell Transplantation, Medical Center - Uni-
versity of Freiburg, Freiburg, Germany
Background: Primary mediastinal B cell lymphoma (PMBL) is a rare subtype
of diffuse large B cell lymphoma and has some clinical and pathologic features
of classical nodular sclerosing Hodgkin lymphoma. Patients are predominantly
young women and often present with a locally invasive anterior mediastinal
mass. The optimal treatment of PMBL is unknown and differs in clinical practice.
Standard immunochemotherapy alone is inadequate and has resulted in routine
consolidation with mediastinal radiation. There is only a paucity of prospective
data and best results were achieved with rituximab based regimens combined
with radiotherapy or dose intensified therapy (DA-EPOCH-R) without radiation.
Here we present a single center 10 year retrospective survey indicating that
high dose therapy with autologous stem cell support (HDT/ASCT) results in
excellent long term outcome.
Aims: Aim of this study is to investigate the infrequent population of PMBL
patients, as a single center survey, regarding treatment strategies and long-
term outcome.
Methods: All patients with PMBL who presented at Freiburg University Medical
Center since 2005 were evaluated according to their baseline characteristics,
treatment modality and treatment outcome. From 2005 on patients were treated
with upfront HDT/ASCT after R-CHOP induction and R-VCPE (rituximab, epiru-
bicin, etoposide, cisplatin, cyclophosphamide) intensification. Conditioning reg-
imen was BEAM (group A). From 2011 onwards patients were treated with an
early intensified protocol: Dense R-MTX/CHOP-14 (6 cycles CHOP-14, dose
dense rituximab on days 0, 1, 4, 8, 15, 22, 29, 47, 61 and 75. High-dose MTX
was administered on days 30 and 76 right before standard CHOP). Patients
who did not achieve a complete metabolic response were intensified as
described above (group B). Radiotherapy consolidation was not routinely per-
formed in both treatment groups.
Results: 25 patients were identified. Median age was 32 y (range 19-57y),
with predominantly females (64%). Disease stage was mostly III/IV (76%). All
patients presented with bulky disease and elevated LDH. 36% had an ECOG-
Score of ≥2. 72% of patients presented with more than one extranodal site
involvement. 88% presented with high-intermediate or high risk aaIPI. Nine
patients were intended to receive upfront HDT/ASCT (group A). Of these
patients one was primary refractory to R-CHOP-21 and died early in the course
of disease. Three patients received consolidating radiotherapy. 2-year PFS and
OS were 88.9%, respectively. 14 patients were treated with upfront dense R-
MTX/CHOP-14 (group B). Six patients achieved only partial remission and
received HDT/ASCT as consolidation. Five patients received additional medi-
astinal radiotherapy. 2-year PFS and OS were 85.7% and 100%. In addition to
both groups, two patients were treated with six cycles of R-CHOP-21+2xR
(group C). With a median follow-up of 35.9 months estimated 3-year progres-
sion-free and overall survival for all patients were 83.2% and 83.6%, respec-
tively. Despite a complete metabolic response after R-MTX/CHOP-14 induction
two relapses were observed in this group. One relapse was observed after six
cycles R-CHOP-21 and mediastinal radiation. Patients who underwent upfront
HDT/ASCT or received HDT/ASCT consolidation in addition to dense R-
MTX/CHOP-14 induction had an excellent long-term outcome with a 3-year
PFS and OS of 100%, respectively. According HDT/ASCT or no-HDT/ASCT
survival curves do significantly differ (Figure 1). There was no transplant related
mortality. No second malignancies were observed yet.
Figure 1. Kaplan-Meier curve for A) progression-free survival and B) over-
all survival stratified by high dose treatment (HDT/ASCT) or no high dose
treatment (no-HDT/ASCT) for all PMBL patients.
Summary/Conclusions: Our results support that dose intensification is nec-
essary in PMBL patients. Regarding the role of HDT/ASCT our data suggest
that an approach using upfront HDT/ASCT (group A) or as intensification for
patients failing complete metabolic response after induction (group B) is safe
and results in excellent long term survival.
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THE REVISED INTERNATIONAL PROGNOSTIC INDEX IS MORE USEFUL
IN COMBINATION WITH SERUM INTERLEUKIN-2 RECEPTOR LEVEL FOR
DETERMINING THE PROGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA
S Kuwahara1,*, H Kaneko1,2, T Fujino1, M Ohshiro1, Y Tsutsumi1,3, T Iwai1,
H Uchiyama1, J Kuroda4, M Taniwaki4
1Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital,
2Department of Hematology, Aiseikai Yamashina Hospital, 3Department of
Hematology, Japanese Red Cross Kyoto Daini Hospital, 4Department of Hema-
tology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background: The current standard of care for diffuse large B-cell lymphoma
(DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP). The International Prognostic Index (IPI) was developed
to predict the outcome prior to the availability of rituximab. The addition of rit-
uximab to CHOP dramatically improved clinical outcomes in patients with DLB-
CL. Therefore, some major modifications to the IPI have been reevaluated in
the rituximab era. The revised IPI (R-IPI), a clinical tool used to predict patient
outcome, has been implemented and validated; however, it has not been estab-
lished for general practical use. Serum soluble interleukin-2 receptor (IL-2R)
level has been identified as a marker of poor outcome in patients with DLBCL.
Aims: In this study, we analyzed to determine whether incorporation of serum
IL-2R level into the factors of R-IPI allow for wider differentiation of outcomes.
Methods: The clinical records of 227 consecutive patients in our center with
DLBCL diagnosed between 2003 and 2013 who received rituximab were retro-
spectively analyzed. Data for IPI factors (age >60 years, stage III/IV disease, ele-
vated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group
performance status ≥2, and >1 extranodal site of disease) and serum IL-2R level
upon diagnosis were collected retrospectively. The normal upper limit of serum
IL-2R level was set at 519 U/mL using an enzyme immunoassay system. The R-
IPI segregated patients into 3 outcome groups. A combination of R-IPI and serum
IL-2R level identified 6 groups. The survival period was calculated from treatment
initiation and estimated using Kaplan-Meier method. Death from any cause or
relapse was defined as an event. Survival was compared between risk groups
using the log-rank test. This study was conducted in accordance with the Decla-
ration of Helsinki and its amendments. The protocol was approved by the Ethics
Committee of the Japanese Red Cross Kyoto Daiichi Hospital.
Results: A total of 227 patients with DLBCL were enrolled, and 54 patients
had normal serum IL-2R levels, on the basis of which, 12 were categorized as
a very good prognostic group, 39 a good prognostic group, and 3 a poor prog-
nostic group according to the R-IPI; similarly 173 patients had elevated serum
IL-2R levels, on the basis of which, 4 were categorized as a very good prog-
nostic group, 81 a good prognostic group, and 88 a poor prognostic group.
With a median observation period of 39 months (range, 1 - 205), the 3-year
overall survival (OS) was 72.9% for all patients. and 100%, 94.4%, and 100%
for 3 prognostic groups of patients with normal serum IL-2R levels, according
to the R-IPI. Similarly, the 3-year OS for patients with elevated serum IL-2R
level was 100%, 81.7%, and 68.7%, respectively (p=.002). Moreover, 12
patients with a very good prognostic group per the R-IPI showed favorable
prognoses regardless of serum IL-2R level (100% 3-year OS). However, serum
IL-2R level significantly differed between with good and poor prognostic groups.
According to the serum IL-2R level, 3-year OS was 94.4%, and 81.7%, respec-
tively, for patients with the good prognostic group (p=.02) and 100% and 60.5%,
respectively, for those with the poor prognostic group (p=.02).
Summary/Conclusions: A new scoring system is needed for better risk strat-
ification and establishing the appropriate therapeutic strategy in the rituximab
era. R-IPI is a useful prognostic marker, particularly in patients with elevated
serum IL-2R levels. The combination of serum IL-2R level with R-IPI might pro-
vide a more precise risk stratification and serve as a useful prognostic predictor
in DLBCL patients to identify candidates for experimental therapy other than
R-CHOP.
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SALVAGE TREATMENT WITH R-IEV (RITUXIMAB, IFOSFAMIDE, EPIRU-
BICIN, ETOPOSIDE) AND AUTOLOGOUS STEM CELL TRANSPLANT FOR
RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
S Gumenyuk1,*, F Marchesi1, P Anticoli Borza2, D Renzi1, F Palombi1, F Pisani1,
A Romano1, A Spadea1, M Canfora3, E Papa1, A Mengarelli1
1Hematology and Stem Cell Transplant, Regina Elena National Cancer Institute,
2Hematology, San Giovanni-Addolorata Hospital, 3Scientific Direction, Regina
Elena National Cancer Institute, Roma, Italy
Background: The better salvage treatment before Autologous Stem Cell Trans-
plant (ASCT) for relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL)
hasn’t been still definitively established. The phase III CORAL study, comparing
R-ICE (Rituximab, Ifosfamide, Carboplatin, Etoposide) versus R-DHAP (Ritux-
imab, Dexametasone, Cisplatin, Cytarabine) in relapsed DLBCL patients didn’t
demonstrate a significant difference in terms of response rate and Progres-
sion-Free Survival (PFS) between the two groups. Therefore, the ESMO (Euro-
pean Society of Medical Oncology) guidelines recommend the use of R-ICE or
R-DHAP or R-GDP (Rituximab, Gemcitabine, Dexamethasone, Cisplatin) as
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salvage regimen for relapsed/refractory DLBCL, considering the similar efficacy
of all these treatment schemes.
Aims: The aim of the study was to evaluate the efficacy and safety of salvage
treatment with R-IEV (Riruximab, Ifosfamide, Epirubicin, Etoposide and Dex-
amethasone) followed by ASCT in relapsed/refractory DLBCL patients.
Methods: From July 2007 to December 2015, 42 consecutive adult patients
with relapsed (n=17) or refractory (n=25) DLBCL patients underwent a salvage
treatment with three courses of R-IEV (Rituximab 375 mg/m2 on day 0, Ifos-
famide 2500 mg/m2, Etoposide 150 mg/m2, Dexamethasone 20 mg, on days
1-3, Epirubicin 100 mg/m2 on day 1) every 21 days in two different Hematology
Institutions of Rome (Regina Elena National Cancer Institute, n=20; San Gio-
vanni Addolorata Hospital, n=22). For all patients we planned a Peripheral
Blood hematopoietic Stem Cell (PBSC) harvest after the second or the third
course of chemotherapy, if the bone marrow wasn’t or was involved at salvage
treatment start, respectively, using Filgrastim or Lenograstim 5 mcg/Kg. All
patients underwent a febrile neutropenia prophylaxis with Filgrastim (n=14),
Lenograstim (n=18) or Pegfilgrastim (n=10) in all courses of treatment. All
patients underwent a baseline evaluation of Performance Status (PS) and
comorbidities, and left ventricular ejection assessment.
Results: The median age of patients at the start of salvage treatment was of
48 years (range: 23-62). At diagnosis, 38 patients (90%) were in advanced (III-
IV) Ann-Arbor stage and 18 (43%) presented intermediate-high IPI score. More-
over, 35 patients (83%) had a 0-1 ECOG PS and 15 (36%) had not any relevant
comorbidities. As first line treatment, 29 patients (69%) were treated with R-
CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Pred-
nisone), whereas the remaining 13 with other chemotherapeutic regimens. At
the time of salvage treatment start, 25 patients (59%) were defined as refrac-
tory, 7 (17%) were relapsed within 12 months from the end of previous treat-
ment line and 10 (24%) were relapsed after more than 12 months. After the
end of R-IEV, a Complete Remission (CR) was obtained in 30 patients (71%),
9 patients were in Partial Response (PR, 21%), whereas the remaining 3
patients (8%) were defined as refractory to salvage treatment. PBSC collection
was successfully performed in 40 patients, whereas in the remaining two wasn’t
carry out for early progression (n=1) or harvest failure (n=1). Actually, 37
patients underwent ASCT after BEAM (Carmustine, Etoposide, Cytarabine,
Melphalan) conditioning chemotherapy. Out of 40 patients in which a PBSC
collection was successfully performed, three patients didn’t undergo ASCT for
progression of disease (n=1), clinical choice (n=1) and patient refusal (n=1). A
grade 3-4 neutropenia and a febrile neutropenia occurred in 78% and 31% of
patients, respectively. However, we didn’t observe any cases of toxic death or
cardiac relevant complication. After a median follow-up of 36 months (range:
3-116), the 2-year-PFS and OS (2y-PFS and 2y-OS) from the start of salvage
treatment were of 73.8% and 83.3%, respectively.
Summary/Conclusions: From our experience, R-IEV salvage regimen with
consequent ASCT was highly effective in relapsed/refractory DLBCL patients,
permitting to obtain an impressive 2y-PFS, with a good safety profile. Further
prospective randomized studies comparing R-IEV with other standard salvage
regimens should be useful to establish the better therapeutic approach for
these patients.
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A COMPARISON STUDY BETWEEN ALLOGENEIC AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANT FOR HIGH-RISK PERIPH-
ERAL T-CELL LYMPHOMAS (PTCL)
H Huang*, Q Wang, Z Jin, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Peripheral T-cell lymphomas (PTCLs) are heterogeneous malig-
nancies sharing common elements of chemotherapy resistance and poor out-
come with standard treatments. Attempts to improve outcomes have included
autologous or allogeneic hematopoietic cell transplantation (autoHCT or allo-
HCT). both modalities lead to durable remissions in recurrent disease settings
and might be important in consolidating first remission. However, key questions
remain, including relative efficacy of autologous versus allogeneic approaches,
and HCT timing (first-line consolidation v relapse).
Aims: Herein, we analyzed outcomes of 60 cases recieved autoHCT or allo-
HCT in our center.
Methods: From July 2007 to July 2014, Outcomes of 60 patients undergoing
autologous HCT (autoHCT) or allogeneic HCT (alloHCT) were analyzed retro-
spectively. Primary outcomes were nonrelapse mortality (NRM), relapse/pro-
gression, progression-free survival (PFS), and overall survival (OS).
Results: All 60 patients were at high risk group (carried with IPI≥3), with a median
age of 31 (13-55) years old. Of the 60 cases, 22 were PTCL-not otherwise spec-
ified (PTCL-NOS), 22 with ALK negative anaplastic large cell lymphoma (ALK-
negative ALCL) and 16 with angioimmunoblastic T-cell lymphoma (AITL). Before
receiving transplantation, 40/60 patients were in complete remission (CR) and
20/60 patients were not remission (NR). Twenty-one (21/60) received allo-HSCT
and thirty-nine patients (39/60) received auto-HSCT. In the 20 NR patients before
transplant, 11 patients received allo-HCT and 9 patients received auto-HCT. After
a median follow-up of 39 (range 1-96) months, the K-M analysis showed that the
5-year PFS for auto-HSCT and allo-HSCT were 61% and 60% (P=0.724). 1-
year NRM was higher (22.5% vs 7.8%) for alloHCT. The 5-year OS for auto-HCT
and allo-HCT were 62% and 61% (P=0.724). There were no statistically signifi-
cant differences between the auto-HSCT and allo-HSCT. However, autoHCT
recipients were more likely in complete remission (CR; 76.9% vs 47.6%; P <0.01)
and with chemotherapy-sensitive disease.
Table 1. Baseline characteristics of the patients.
Summary/Conclusions: Both autoHCT and alloHCT approaches can benefit
patients with PTCL. We did not find a difference in PFS and OS between auto-
HCT and alloHCT, although NRM increased significantly in alloHCT. However,
our results suggest that outcomes of alloHCT are better for refractory and
relapsed patients with PTCL. nd overall survival (OS).
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PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RITUXIMAB PLUS
CHOP (R-CHOP)
SI Go1, MJ Park2, HG Kim1, MH Kang1, GW Lee1,*
1Internal Medicine, 2Radiology, Gyeongsang National University School of
Medicine, Jinju, Korea, Republic Of
Background: Sarcopenia, defined as the loss of skeletal muscle mass and
strength, is one of the criteria for cancer cachexia. A computed tomography
(CT) scan has been accepted as one of the most preferred tools toassess sar-
copenia. Measuring the extent of sarcopenia by CT in patients with malignancy
has severaladvantages, including accurate quantification of muscle mass, pre-
cise differentiation between fat andmuscle, and wide availability as a routine
diagnostic tool in cancer. Sarcopenia evaluated by CT isknown to be related
to an increased risk of chemotherapy toxicity, poorer functional status,
andreduced survival in malignancy.
Aims: In this study, we investigated the prognostic impact of sarcopenia in all
age groups of patients with DLBCL using an extended cohort. Additionally, a
new prognostic model, including sarcopenia and other significant prognostic
factors, was constructed using a nomogram.
Methods: In total, 187 consecutive DLBCL patients treated with induction R-
CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone) immunochemotherapy were reviewed.Sarcopenia was defined as
the lowest sex-specific quartile of the skeletal muscle index, calculated bydi-
viding the pectoralis muscle area by the height. Clinical outcomes were com-
pared between thesarcopenic and non-sarcopenic groups. A nomogram was
constructed from the Cox regression model for overall survival (OS).
Results: Treatment-related mortality (21.7% vs 5.0%, p=0.002) and early dis-
continuation of treatment(32.6% vs 14.9%, p=0.008) were more common in
the sarcopenic group than in the non-sarcopenic group. The 5-year progres-
sion-free survival (PFS) rates were 35.3% in the sarcopenic group and 65.8%
in the non-sarcopenic group (p <0.001). The 5-year OS rates were 37.3% in
the sarcopenic group and 68.1% in the non-sarcopenic group (p <0.001). Sar-
copenia and the five variables of the International Prognostic Index (IPI) were
independent prognostic factors in a multivariate analysis for PFS and OS, and
were used to construct the nomogram. The calibration plot showed good agree-
ment between the nomogram predictions and actual observations. The c index
of the nomogram (0.80) was higher than those of other prognostic indices (IPI,
0.77, p=0.009; revised-IPI, 0.74, p <0.001; National Comprehensive Cancer
Network-IPI, 0.77, p=0.062).
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Summary/Conclusions: This study demonstrates the role of sarcopenia as a
poor prognostic marker in DLBCL patients. We suggest that dose adjustment
and intensive supportive care should be considered in DLBCL patients with
sarcopenia receiving induction R-CHOP immunochemotherapy. Further
prospective studiesare warranted to confirm the prognostic role of sarcopenia
and to externally validate the nomogramincluding sarcopenia in DLBCL.
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GOOD RESULTS WITH R-CHOP-14 THERAPY IN PRIMARY MEDIASTINAL
LARGE B-CELL LYMPHOMAS. THE CHEMOKINE TARC IS AN EXCELLENT
MARKER OF TUMOR ACTIVITY AND IN TREATMENT EFFECTIVITY IN
MEDIASTINAL LYMPHOMAS.
T Schneider1,*, B Deák1, Z Molnár1, E Szaleczky1, E Várady1, F Varga1, E Tóth2,
J Strausz2, K Kajáry3, É Jederán4, O Csuka5, I Gaudi6, A Rosta1
1Center for Lymphomas, 2Surgical and Molecular Tumour Pathology Centre,
National Institute of Oncology, 3Pozitron-Diagnosztika Health Centre, 4Depart-
ment of Radiological Diagnostics, 5Department of Pathogenetics, 6Department
of Epidemiology, National Institute of Oncology, Budapest, Hungary
Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare
disease that belongs to the group of aggressive, diffuse large B-cell lymphomas
and is associated with a characteristic clinical feature. Data from evidence-
based treatments are not available. Retrospective studies suggest that the so
called third generation treatments are more effective than the previous standard
treatment with 21-day cycles R-CHOP. Nowadays, dose-dense DA-EPOCH-R
treatment is well tolerated by young patients and appears to be even more
effective.
Aims: Our research shows that dose-dense R-CHOP-14 treatment is as effec-
tive as the more aggressive DA-EPOCH-R. There is no earlier data for the role
of TARC (thymus activation-regulated chemokine) in PMBCL as a disease activ-
ity marker. The change of TARC level during the treatment was monitored.
Methods: Between July 2005 and June 2015, 56 newly diagnosed, untreated
PMBCL patients were subject to treatment with R-CHOP-14. The average age
of the 33 (59%) female and 23 (41%) male patients was 32 years (range: 21-
53 years). Using the R-IPI, 9 patients were the very good, 46 patients were the
good and one patient was in the worse prognostic group. The combination of
CHOP-14 and rituximab administered in 14-day cycles was used as treatment;
the treatment regimen also included preventive administration of filgastrim. The
average number of cycles of the chemotherapeutic treatments was 6.6 (range:
4-8). After the final R-CHOP-14 treatment high energy photon radiation was
used to the residual mediastinal abnormalities in 46 cases as consolidation
treatment. Before diagnosis could be performed two patients received life-sav-
ing irradiation. Since May 2013 we have investigated the role of TARC to follow
the disease activity in 13 cases.
Results: The planed treatment was completed in 55 (98.2%) patients and in
54 (96.4%) patients we achieved complete remission verified by PET/CT. One
patient, who did not get complete remission, was cured with high-dose
chemotherapy and autologous stem cell transplantation. One patient died after
the fourth cycle R-CHOP-14, due restrictive pulmonary disease and ARDS.
The average duration of the follow-up period was 57 months (range: 10-126
months), during which time only one relapse was shown. The relapse free sur-
vival is 98.1%. One patient did not wish to receive further oncological treatment,
she was only one who died due lymphoma. The lymphoma specific mortality is
98.2%. Two young female patients (with hereditary mental retardation) died in
lung tuberculosis 9 and 13 month after the end of the treatment. The overall
survival rate is 92.9%; the event free survival is 91.1%. Before the treatment
all but one out of 13 cases extremely high TARC level was found. The TARC
levels were dropped quickly in the normal range due the treatment effect.
Summary/Conclusions: In the treatment of PMBCL the R-CHOP-14 was
found highly effective, short-term and well tolerable. Further investigation and
research is needed to find out if radiation therapy is necessary. The TARC
proved to be a very good marker in PMBCL which signs the activity of disease
and the effectivity of treatment well and early.
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PROGNOSTIC VALUE OF PRETREATMENT ADVANCED LUNG CANCER
INFLAMMATION INDEX (ALI) IN DIFFUSE LARGE B-CELL LYMPHOMA
PATIENTS TREATED WITH R-CHOP CHEMOTHERAPY
YH Park1,2,*, JH Lim2, HG Yi2, MH Lee2, CS Kim2
1Department of Hematology and Oncology, Hanil General Hospital, Seoul,
2Department of Hematology and Oncology, Inha University Hospital, University
of Inha College of Medicine, Incheon, Korea, Republic Of
Background: It has become evident that cancer-related inflammation plays
an important role in the development and progression of various types of cancer
and adversely influences response to anti-cancer therapy. Advanced lung can-
cer inflammation index (ALI), a novel inflammation-based prognostic system,
has been demonstrated to be a prognostic factor of survival in some solid can-
cers. However, the prognostic usefulness of ALI has not been investigated in
lymphoma.
Aims: The authors investigated the ability of ALI to predict response to
chemotherapy and survival in patients with diffuse large B-cell lymphoma
(DLBCL).
Methods: The records of 212 patients with newly diagnosed DLBCL treated
by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone) chemotherapy were reviewed. ALI values were calculated by dividing
the product of body mass index and blood albumin level by peripheral blood
neutrophil/lymphocyte ratio. Patients were allocated to a low pretreatment ALI
group (n=82, 38.7%) or a high pretreatment ALI group (n=130, 61.3%) using
on optimal ALI discriminatory cutoff value for survival of 15.5 as determined by
receiver operating curve analysis.
Results: The proportion of older patients (aged >60 years) was significantly
higher in the low ALI group than in the high ALI group (63.4% vs 36.2%,
p<0.001). More patients had advanced disease (Ann Arbor stage III/IV) in low
ALI group at initial diagnosis (72% vs 54.6%, p=0.014). Poor Eastern Cooper-
ative Oncology Group performance status (ECOG PS, p=0.001), presence of
B symptoms (p=0.002), and high-risk of International Prognostic Index (IPI,
p=0.029) were observed more frequently in the low ALI group. Complete remis-
sion rates in the low and high ALI groups after completing R-CHOP chemother-
apy (after 6 to 8 cycles) were 54.9% (45/82) and 75.4% (98/130), respectively
(p=0.008). During a median follow-up of 54 months (range, 6-92 months),
patients in the low ALI group had shorter 5-year PFS (58.1% vs 77.3%, p=0.006)
and OS (64.2% vs 80.2%, p=0.008) than patients in the high ALI group. Multi-
variate analysis showed advanced disease (hazard ratio [HR] 2.425, 95% con-
fidence interval [CI] 1.514-3.128, p=0.013), bulky disease (diameter ≥10 cm,
HR 1.568, 95% CI 0.678-4.287, p=0.043) and low pretreatment ALI (HR 1.927,
95% CI 0.893-3.598, p=0.021) were significantly associated with poorer PFS.
Regarding OS, age >60 (HR 2.298, 95% CI 1.628-6.118, p=0.015), ECOG PS
≥2 (HR 1.814, 95% CI 0.874-6.521, p=0.024), high-risk IPI (HR 2.872, 95% CI
1.658-5.723, p<0.001), advanced disease (HR 2.431, 95% CI 1.422-6.249,
p=0.002) and low pretreatment ALI (HR 2.645, 95% CI 1.542-5.974, p=0.001)
were all found to be independently associated with shorter OS. Interestingly, a
low ALI before R-CHOP chemotherapy reverted to a high ALI during treatment
in 58 patients (27.4%) and median OS of these patients (not reached) was bet-
ter than that of patients whose ALI remained low (n=24, 25 months; p<0.001).
Conversely, patients with a persistent low ALI during treatment showed worse
survival.
Summary/Conclusions: This study shows a significant association exists
between pretreatment ALI and response to R-CHOP chemotherapy and progno-
sis in DLBCL. Changes in ALI during the course of chemotherapy might also pro-
vide additional information about survival, particularly for patients with a low pre-
treatment ALI. Our findings suggest ALI is an inexpensive, potential prognostic
marker in patients with DLBCL that can be readily used in routine practice.
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FACTORS RELATED TO NON-HODGKIN’S LYMPHOMA LONG-TIME TO
TREATMENT INITIATION AND IMPACT ON SURVIVAL IN A POPULATION
BASED STUDY IN FRANCE: IS THERE A ROLE OF SOCIOECONOMIC STATUS?
S Le Guyader-Peyrou1,2,*, S Orazio1,2, O Dejardin3, M Maynadie4,xTroussard5,
A Monnereau2,6
1Registre des Hémopathies malignes de la Gironde, Réseau Repih, Institut
Bergonie, 2INSERM U1219 Epidemiology of Cancer and Environmental Expo-
sure, Isped, Bordeaux, 3U1086 INSERM_UCBN, Cancers et Preventions,
Caen, 4Registre des Hémopathies malignes de Cote d’Or, EA 4184, Université
de Bourgogne, Réseau REPIH, Dijon, 5Registre des hémopathies malignes
de Basse Normandie, Réseau REPIH, Caen, 6Registre des Hemopathies
malignes de la Gironde, Institut Bergonie, Bordeaux, France
Background: Diffuse large B cell lymphoma (DLBCL) is one of the most frequent
non-Hodgkin’s lymphoma histological subtype for which care management is
well codified and remaining still an aggressive disease potentially curable with a
combination of anthracycline-based chemotherapy. In this context, time to treat-
ment initiation (TTI) could be having an impact on the patient’s survival.
Aims: The aim of this study was to identify the socioeconomic and medical factors
predicting a long TTI and determine the impact of a long delay on overall (OS)
and relative (RS) survival (excess mortality due to lymphoma) for DLBCL patients.
Methods: We performed a population-based “high-resolution” study including
all patients diagnosed with DLBCL in three registry-areas in France (Gironde,
Côte d’Or and Basse-Normandie) between 2002-2008. Medical and socioeco-
nomic factors (GP’s density, rural area, distance to the nearest reference centre,
index deprivation) were collected. TTI was the delay in days between diagnosis
and treatment initiation. A long TTI was considered for 75thpercentile and very
long TTI for the 90th percentile. Three multivariate analysis logistic regressions
were performed for the first aim using median, 75th and 90th percentiles TTI as
dependant variables. For each patient, the follow-up period continued from the
date of diagnosis to the death or until June, 30, 2013. For survival outcome we
fitted a multivariate cox model for OS and an Esteve model for RS (3 and 5
years). Net survival (NS) using Pohar Perme unbiaised method was also cal-
culated for 1, 3 and 5 years.
Results: We included 1084 DLBCL patients (median age 71(9-99) years) and
sex ratio H/F 1.12.The median TTI was 27 days, interquartile (15-42); The long
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TTI was 42 days and a very long TTI was considered >63 days. Each depen-
dant variable has been analysed in details. Among these variables in multi-
variate logistic regression, adjusted on age and sex, we first confirmed that
elevated serum lactate dehydrogenase and disseminated stage of disease
were independently associated with a TTI>63 days (OR: 0.37 IC 95%: 0.22-
0.63 and OR: 0.59 IC 95%: 0.37-0.93, respectively). The registry areas and
outpatient diagnosis were both independently associated with a long TTI (OR:
1.89 IC 95%: 1.38-2.60 for patients of north of France; OR: 1.55 IC 95%: 1.01-
2.39 for outpatients). In contrast, the socioeconomic status (European Depri-
vation Index) was not associated with the delay of treatment initiation. Median
of follow up was 5 years. For the respective long TTI groups, 5 years OS esti-
mates were 55% and 60.5%; 5 years NS estimates were 62.3% and 67.7%.
We found no association between a TTI>63 days and overall survival or relative
survival.
Summary/Conclusions: This study shows that medical factors such as LDH
and stage of disease influence a longer delay of treatment. To be diagnosed in
the same place of care management that treated seems to be also a factor of
earlier treatment. Socioeconomic status is not associated with TTI whatever
the delay. Finally, our results emphasize disparities according to France area.





R-CHOP-21 PLUS LOW DOSE ETOPOSIDE VERSUS DA-EPOCH-R IN
PATIENTS WITH AIDS-RELATED GCB DIFFUSE LARGE CELL B CELL
LYMPHOMA; SINGLE CENTRE EXPERIENCE
I Kozlov1,*, V Kozlov2, N Strembitska2, O Ryzhak2, L Batyuk2, M Chupryna2,
V Leonov2, H Chikalova2
1Internal Medicine #1 with additional course of cardiovascular diseases, Odessa
National Medical University, 2Odessa Regional Clinical Hospital, Odessa, Ukraine
Background: Treatment of AIDS-related diffuse large cell B cell lymphoma (DLB-
CL) with low CD4 count (<100 mm3) remains a great challenge for hematologists.
Balancing between competing needs of lymphoma treatment and HIV manage-
ment is crucial for achieving long term survival. Previous studies have shown
strong advantage of DA-EPOCH-R versus R-CHOP in AIDS-related lymphomas.
However hematological toxicity profile of this regimen is quite considerable espe-
cially in patients with AIDS with decreased bone marrow reserves. Combination
of standard R-CHOP with low dose etoposide (R-CHOEP) could be effective
alternative option in AIDS-related GCB-type DLBCL management.
Aims: The aim of our study was to evaluate if R-CHOEP benefit of R-DA-EPOCH
in patients with AIDS-related GCB DLBCL considering hematological toxicity.
Methods: Thirty one patients (pts) with AIDS-related GCB DLBCL have been
enrolled in study. All pts had low CD4 count with mean amount 78 cells/mm3
and did not receive HAART before the enrolment. They have been divided into
two arms. First arm (n=14) received standard R-CHOP with 50 mg/m2 etopo-
side infusion on days 1-3. Second arm received DA-EPOCH-R as it has been
described in previous studies. FDG-PET scans have been done before and
after the treatment.
Results: Complete response (CR) has been achieved in 93% in DA-EPOCH-R
arm and in 85% in R-CHOEP arm. Hematological toxicities have been observed
in both arms in all cycles of treatment. However in DA-EPOCH-R arm neutropenia
mean period was 16 days when in R-CHOEP arm 11 days; thrombocytopenia
period was 11 and 3 days respectively. Septic complications in DA-EPOCH-R
arm have been observed in 53% when in R-CHOEP arm in 31%.
Summary/Conclusions: Patients treated with R-CHOEP had shorter periods
of neutropenia and thrombocytopenia in comparison with DA-EPOCH-R group,
where periods of neutropenia and thrombocytopenia were longer and resulted
in higher rate of infectious complications. Considering comparable CR rate in
both groups R-CHOP plus low dose etoposide could be effective option with
lower hematological toxicity profile in AIDS-related DLBCL with CD4 count less
than 100 cells/mm3.
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THE PROGNOSTIC IMPACT OF SERUM ALBUMIN IN DOUBLE HIT/DOUBLE
EXPRESSING AGGRESSIVE B CELL LYMPHOMAS: A PILOT STUDY
EVALUATING SAAB SCORING SYSTEM
C Talati1,*, J Sandoval-Sus1, S Dalia2, B Shah3, C Bello3, P Chervenick3,
E Ayala3, F Locke3, M Kharfan-Dabaja4, E Sotomayor5, L Sokol3, J Chavez3
1Moffitt Cancer Center, University of South Florida/Moffitt Cancer Center, Tam-
pa, 2Mercy Clinic, Mercy Clinic, Joplin, 3Malignant Hematology, 4Bone Marrow
Transplantation, Moffitt Cancer Center, Tampa, 5Malignant Hematology, George
Washington University, Washington, DC, United States
Background: Double hit lymphomas (DHL) [rearrangements of MYC and
BCL2/BCL6, and double expressing lymphomas (DEL) [expression of MYC
and BCL6/BCL2 by immunohistochemistry] represent a subset of diffuse large
B-cell lymphoma (DLBCL) with poor overall survival (OS). Several prognostic
scores have been tested to clinically stratify these patients with the double hit
score (DHS) being the most recently developed model (Petrich 2014).
Aims: We explored the use of serum albumin (SA) as prognostic factor in DHL
as previously shown in DLBCL (Dalia 2013).
Methods: We included 100 patients from Moffitt Cancer Center database from
January 2008 to December 2015 with DHL and performed a retrospective chart
review. Recorded clinical data included SA, hemoglobin, age, International
Prognostic Index (IPI), DHS, and lymphopenia. Pairwise Cox Comparison was
used to develop a weighted scoring system. Kaplan-Meier method with Cox
proportional hazard model was used to determine OS.
Results: The median age was 63 (18-87), stage III/IV in 73.1%, bulky disease
(>10cm) in 47.4%, B symptoms in 41.67%, CNS involvement in 14.1%, extra-
nodal (EN) involvement in 34.7% of the patients. Patients with DHL and DEL
were 60.2% and 39.8%, respectively. The median OS for the cohort was 15
months. Multivariate analysis identified Age >60 (1 point), SA <3.7 (4 points),
bulky disease (2 points) and Stage III/IV (1 point) as prognostically significant.
LDH and EN dropped from the model. SAAB scoring consisted of 3 groups:
Very good (0-2), Good (3-5), Poor (6-8). The 3-years OS was compared among
scoring systems (Table 1).
Table 1.
Score (N=100)                                                    3 Year-OS                         P-value
SAAB                                                                                                           0.005
Very good (SAAB=0-2)                                               45%                                  
Good (SAAB 3-5)                                                      30%                                  
Poor (SAAB=6-8)                                                       NA*                                   
R-IPI                                                                                                            0.437
Very Good (R-IPI=0)                                                 100%                                 
Good (R-IPI=1-2)                                                      30%                                  
Poor (R-IPI=3-5)                                                        32%                                  
Double Hit Score (DHS)                                                                                 0.281
Low (DHS=0)                                                            26%                                  
Intermediate (DHS=1)                                               29%                                  
High (DHS=2 or more)                                               27%                                  
*Highest survival was 18 months.
Summary/Conclusions: Compared to the R-IPI and DHS, the new SAAB
score better discriminated prognostic groups in DHL/DEL. Confirmation in a
larger and multicenter study is needed to validate these findings. SA might rep-
resent a surrogate of comorbid status and worse biology in patients with
DHL/DEL.
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CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH
PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA TREATED WITH
INTENSE SHORT-PULSE CHEMOTHERAPY, R-CHOP OR R-DA-EPOCH
A RETROSPECTIVE OBSERVATIONAL STUDY
K Mors1,*, S Döring2, S Fuhrmann1, C Gerecke1, H Stein3, I Anagnostopoulos4,
WD Ludwig1, A Pezzutto5, R Ratei6
1Hematology, Oncology, Helios Klinikum Berlin Buch, 2Hematology, Oncology,
Charite, University Medicine Berlin, 3Pathology, Pathodiagnostik Berlin,
4Pathology, Charite, University Medicine Berlin, 5Hematology, Oncology, Char-
ité University Medicine Berlin, Berlin, 6Hematology, Oncology, Carl-Thiem-
Klinikum Cottbus, Cottbus, Germany
Background: Primary mediastinal large B-cell lymphoma (PMBL) is a locally
highly aggressive tumour and accounts for approximately 2.4% of adult non-
Hodgkin’s lymphoma (NHL). Overall survival rates (OS) between 46 – 79%
have been reported but optimal treatment regimens remain to be defined.
Aims: Retrospective, longitudinal assessment of clinical risk factors and out-
come of three different treatment regimens for patients with primary mediastinal
large B-cell lymphoma.
Methods: We performed a longterm longitudinal retrospective study to analyze
the clinical characteristics and the treatment outcome of 63 adult patients with
primary mediastinal large B-cell lymphoma in two large hematology depart-
ments in Berlin. The study was approved by the Charité Ethic Committee.
Between 1996 and 2016 patients were registered at the time of treatment start
and data on demographics, clinical features and laboratory parameters were
recorded during treatment and follow up. The prognostic impact of IPI-value,
pleural or pericardial effusion, LDH, gender and presence of bulky disease was
analyzed with univariate analysis with respect to overall survival (OS) and
event-free survival (EFS). Survival analyses were performed with the Kaplan-
Meyer method and the log-rank test for comparison using SPSSÒ.
Results: Between 1996 and 2016 37 female patients with a median age of 31
years and 26 male patients with a median age of 36 years were registered. Ini-
tial presentation in Ann Arbor stage I: 22%, stage II: 41%, stage III: 9% and
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stage IV: 28%. B-symptoms: 42%. Bulky disease with a tumor >10cm was pres-
ent in 36.2% of all patients. Extranodal manifestations were detected in 30%
and either pleural or pericardial effusions was present in 56% of all patients. 16
pts. (26%) were treated according to an intensive short-pulse B-NHL type
chemotherapy protocol without Rituximab (B-NHL) and 22 patients (36%) with
Rituximab (R-B-NHL), respectively. R-CHOP and R-DA-EPOCH was adminis-
tered in 12 pts. (20%) and 6 pts. (10%), respectively. 4 pts. received either
CHOP without Rituximab or R-ACVBP. Almost all patients received adjuvant
involved field radiotherapy after completion of chemotherapy, usually with a
total dose of 36 Gy. The probability of event-free survival (pEFS) and OS at 5
years for all patients was 73.5±6.7% and 81.3±6.0%, respectively. For 16 pts.
treated with a short-pulse B-NHL type protocol without Rituximab 5-year EFS
and OS was 64.3±12.8% and 78.7±11.0%, respectively. With the addition of
Rituximab the 5-year EFS and OS (22 pts.) increased with this therapy to
79.4±10.7% and 91.7±8.0%, respectively. Treatment with R-CHOP for 12 pts.
led to a 5year EFS and OS of 77.1±14.4% and 75.0±15.3%, respectively. 5-
year survival analysis for the 6 pts. treated with R-DA-EPOCH was not calcu-
lated due to short follow up (Figure1). Except for IPI-value there was no signif-
icant prognostic impact of pleural or pericardial effusion, LDH, gender or pres-
ence of bulky disease.
Figure 1.
Summary/Conclusions: The addition of Rituximab to the intensive short-pulse
B-NHL type chemotherapy protocol led to an improved 5 year EFS and OS. Treat-
ment with R-CHOP seems to be slightly inferior with respect to clinical outcome.
We did not find a higher predilection of young female patients and there was no
significant prognostic impact of bulky disease, pleural or pericardial effusion, ele-
vated LDH or gender. The best treatment regimen for this rare entity of B-cell
lymphoma remains be determined in a randomized multicenter trial.
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POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY
FEATURES OF TYPE II ENTEROPATHY ASSOCIATED T CELL LYMPHOMA
T Chan1,*, E Lee2, PL Khong2, YL Kwong1, E Tse1
1Medicine, Queen Mary Hospital, Hong Kong, 2Diagnostic radiology, The Uni-
versity of Hong Kong, Hong Kong, Hong Kong
Background: Type II enteropathy associated T cell lymphoma (EATL) is a rare
malignancy in the West and the only form of EATL in the East. 18F-fluo-
rodeoxyglucose (FDG) positron emission tomography computed tomography
(PET/CT) findings have not been described for type II EATL.
Aims: Type II EATL is increasingly recognized as a separate entity from type I
EATL, we report herein the PET/CT findings of in a large cohort of patients, so
that more can be known for this new disease entity.
Methods: Consecutive patients with type II EATL diagnosed between January
2008 and July 2015 were studied. The diagnosis was based on typical
histopathological and immunophenotypical features. Standard clinical and bio-
chemical evaluations for staging and response assessment were undertaken.
Treatment protocols evolved over this period and were heterogeneous.
Results: Six men and four women with type II EATL investigated by PET/CT
at diagnosis and relapse were retrospectively analysed. On presentation, the
primary involved sites were the small bowel (N=8), stomach (N=1) and large
bowel (N=1). The uninvolved small bowel did not show undue FDG-avidity to
suggest enteropathy. Distant lymph nodes and organs were involved in four
cases (40%). The primary lesions were hypermetabolic except in one case,
where the colonic lesion was eumetabolic. At relapse, the stomach and large
bowel might be involved even if the primary tumours arose from the small
bowel, and multiple extra-intestinal metastases occurred. Interestingly, the lung
and the brain were frequently involved (40% and 20% respectively).
Summary/Conclusions: These findings showed that in contrast to classical
EATL, where the small bowel is the exclusive primary site (owing to its origin
from coeliac disease associated enteropathy) and distant metastases even
during relapse are exceptional, type II EATL could on presentation and during
relapse involve any part of the gut, and metastasize to multiple extra-intestinal
sites. These observations support the proposition of classifying this lymphoma
as a distinct clinicopathological entity (monomorphic epitheliotropic intestinal
T-cell lymphoma) to differentiate it from classical EATL.
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THE INFLUENCE OF GENETIC POLYMORPHISMS BCL-2 AND C-MYC IN
PATIENTS WITH DLBCL TREATED WITH RCHOP TO ACHIEVE COMPLETE
REMISSION
S Sretenovic1,*, S Mitrovic2, B Mihaljevic3, S Đukic1
1Clinic of Haematology, 2Center of pathology, Clinical Centre Kragujevac,
Kragujevac, 3Clinic of Haematology, Clinical Centre Srbia, Belgrade, Serbia
Background: Non -Hodgkin’s diffuse large B- cell lymphoma (DLBCL) repre-
sents a heterogeneous group of aggressive lymphomas, which are character-
ized by the presence of large, transformed B cells. DLBCL with both transloca-
tions C-MYC and BCL-2 provides double-hit lymphoma and is characterized
by poor response to standard therapy with an aggressive clinical course.
Aims: What is the influence of BCL-2 and C-MYC in DLBCL treated with
RCHOP to achive complete remission.
Methods: We analyzed the population of 62 patients primary DLBCL, treated
with immunochemotherapy R-CHOP/21 day. Testing BCL-2 and C-MYC was
conducted with classical FISH analysis. Complete remission (CR) was defined
as the absence of disease after the therapy. We tested the sensitivity and speci-
ficity, and statistical analysis was performed in Windows SSPS (22.00), a sta-
tistical significance defined as p <0,05.
Results: The study group consisted of 32 men and 30 women, mean age was
59.76+/- 14,38. The patients were in CS III and IV in 81.9%. After applying the
first therapeutic line RCHOP, 30 patients or 48.7% achieved a complete remis-
sion. The frequency of FISH/BCL2+in the group with complete remission was
40% and in the group without a complete remission of 46.2%. Achieving com-
plete remission was not statistically significantly different between subjects
FISH/ BCL-2 positive and negative (χ 2 test, p=0,585). Frequency FISH/C-
MYC in the group with complete remission was 36.7%, while in the group with-
out CR it was 43.8%. Achieving complete remission was not significantly differ-
ent between patients FISH/ C-MYC positive and negative (χ 2 test, p=0,570).
The frequency of both positive FISH/ BCL-2 and C-MYC, with the presence of
at least one positive polymorphism and negative both, it is not statistically sig-
nificantly different in comparison to achieving a complete remission (χ 2 test,
p=0,600). Respondents with BCL-2 and C-MYC negative were slightly over-
represented in the group with the complete remission of 43,3%, compared to
the patients without complete remission of 31,3%. A bit higher frequency BCL-
2 positive patients 31,3% was observed in group without achieving the complete
remission, but in patients with complete remission of 20%. The sensitivity
observed in the presence of both polymorphisms as well as the sensitivity of
FISH positive BCL-2 or C-MYC findings was the same, about 45%. Specificity
was the same in the presence BCL-2 or C-MYC gene polymorphism at about
60%, while it was the lowest in the presence both genetic polymorphism
Summary/Conclusions: In our study, the sensitivity observed in the presence
of both or single mutation was the same, about 45%. Specificity in all observed
parameters was relatively small, which means that the absence of the observed
risk factors does not mean the emergence of the complete remission. The exis-
tence C-MYC and BCL-2 is not a good predictor of achieving complete remis-
sion in the era of rituximab.
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ANAPLASTIC LARGE CELL LYMPHOMA IN ADULTS: RESULTS AND NEW
APPROACH OF TREATMENT
L Gorenkova*, S Kravchenko
National Research Centre of hematology, Moscow, Russian Federation
Background: Anaplastic Large Cell Lymphoma (ALCL) represents supgroupe
of peripheral T-cell lymphoma and constitutes 10-12% of this groupe. According
to WHO classification 2008 ALCL is subdivided by two types depending on
presence of ALK gene rearrangement: ALK-positive (ALCL ALK+) and ALK-
negative (ALCL ALK-). ALCL ALK+has a favorable prognosis with CHOP in
patients without adverse prognostic factors and event free survival (EFS) reach-
es 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall
survival (OS) and EFS doesn’t reach more than 50%. Autologous stem cell
transplantation (auto-SCT) in first complete remission takes an advantage.
Aims: to estimate an efficacy of intensive chemotherapy in treatment of ALCL
ALK+and ALCL ALK-
Methods: The study included 64 patients with ALCL (38 ALCL ALK+26
ALCL ALK-)
Results: 36 patients with ALCL ALK+were treated according NHL BFM-90: OS
and relapse-free survival were 90% and 83%, respectively, median survival was
67 months. In 16 patients with ALCL ALK- was used NHL-BFM-90 protocol –
common response (CO) was achieved in 8 from 16 patients (50%), however 6
patients had disease progression and 3 had a relapse. Thus, OS and EFS were
37,5% and 31% respectively. 8 patients were treated by TL-REZ-09 protocol.
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Complete/partial remission were acieved in 4 patients, 3 had disease progres-
sion. The highest efficacy was observed in 5 patients underwent auto-SCT in
first complete remission: 4 from 5 patients alive in remission and one in relapse.
Summary/Conclusions: Patients with ALCL ALK+have favorable prognosis
and high treatment results on NHL BFM-90 protocol. Selection of induction
chemotherapy regimen before auto-SCT in patients with ALCL ALK- continue
to be unsolved question. In patients who didn’t achieve a common response
like second line therapy could be DexaBEAM protocol with subsequent auto-
SCT.
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DOSE ADJUSTED REPOCH IN UNTREATED DE NOVO DIFFUSE LARGE
B CELL LYMPHOMA - A SINGLE CENTRE SINGAPORE EXPERIENCE
ACY Tso*, VS Sampath, KH Ong
Haematology, Tan Tock Seng Hospital, Singapore, Singapore
Background: The current standard of care for untreated Diffuse Large B Cell
Lymphoma (DLBCL) remains as Rituximab plus CHOP chemotherapy
(RCHOP). Some studies suggested that certain subtypes of DLBCL respond
better to dose adjusted REPOCH. However, data comparing the efficacy of
RCHOP with REPOCH is scarce.
Aims: To compare the outcome of untreated de novo DLBCL of dose adjusted
REPOCH chemotherapy with historical controls.
Methods: This is a retrospective analysis of all patients between age 18 – 70 with
any stage of treatment naïve de novo DLBCL; who received RCHOP chemother-
apy between 2009 to 2013, and REPOCH chemotherapy between 2013 to 2016.
DLBCLs that were transformed from low grade lymphomas were excluded.
Demography, histology, stage, immunohistochemistry biomarkers for cell of origin
(GCB versus ABC using Hans algorithm), cytogenetics, details of chemotherapy,
responses and duration of follow-up were included for analysis. 2 years overall
survival (OS) and progression free survival (PFS) were calculated.
Results: 46 evaluable patients were followed up between 2009 and 2016
with 20 in the RCHOP cohort and 26 in the REPOCH cohort. The character-
istics between the RCHOP and REPOCH groups were comparable: average
age were 54 and 53.9 years respectively, 15 of 20 (75%) and 18 of 26 (69%)
patients had stage 3 or 4 disease respectively. 50% and 20% of the RCHOP
group; and 73% and 23% of the REPOCH group have the ABC and GCB sub-
types of DLBCL respectively. The median follow-up period for the RCHOP
and REPOCH groups were 40.5 (range 8 -70) and 16 (range 3 - 35) months.
Kaplain Meier survival curves showed that the OS and PFS of REPOCH were
greater than that of RCHOP, although they were not statistically significant
(OS Log-rank test: z=0.71, p=0.48; PFS Log-rank test: z=1.52, p=0.13). The
2 years OS of the RCHOP and REPOCH groups were 89% and 100% respec-
tively; and the 2 years PFS of the RCHOP and REPOCH groups were 75%
and 95% respectively (Figure 1).
Figure 1.
Summary/Conclusions: In the literature, the GCB subtype is generally more
than twice as common as the ABC subtype and confers a better overall out-
come. In our institution, the ABC subtype was around 3 times more prevalent
than the GCB subtype, suggesting the biology of the disease may differ with
ethnicity and imply a more aggressive phenotype. Although our data suggests
REPOCH to be superior to RCHOP in treatment naïve de novo DLBCL patients,
a longer follow-up period may be required to observe a statistical difference in
the OS and PFS. Further prospective randomized comparison between these
two regimens in the Asian population is warranted.
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BASELINE RENAL FUNCTION AS A PROGNOSTIC INDICATOR IN
PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH
R-CHOP IMMUNOCHEMOTHERAPY
J Hong1,*, S Lee1, J Park1, JY Ahn2, JY Jung1, JH Lee1
1Department of Internal Medicine, 2Department of Laboratory Medicine,
Gachon University College of Medicine, Incheon, Korea, Republic Of
Background: Recently the prognostic value of baseline renal impairment (RI)
has been evaluated in patients with newly diagnosed cancers: baseline RI
assessed by blood urea nitrogen showed significant relationship to overall sur-
vival (OS) of patients with advanced non-small cell lung cancer (Zhang et al.,
Int J Cancer 2015;136:382) or to early mortality among patients with resectable
pancreatic adenocarcinoma (Sohal, et al., Cancer 2015;121:1779).
Aims: In this study, we evaluated the prognostic value of baseline RI in patients
with diffuse large B-cell lymphoma (DLBCL) uniformly treated with conventional
three-weekly rituximab plus cyclophosphamide, adriamycin, vincristine, and
prednisolone (R-CHOP21) immunochemotherapy in single institution.
Methods: Patients with newly diagnosed de novo DLBCL treated with ≥1 cycle
of R-CHOP21 were included. Glomerular filtration rate (GFR) was calculated
using serum ceratinine level from pre-treatment serum chemistry data and other
clinical information. RI was defined as a GFR of <60 mL/min/1.73 m2according
to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Results: 185 patients treated from Mar. 2006 to Jan. 2015 were included and
analyzed. For the median follow up period of 44.1 months (95% CI, 37.5 -
50.7), 53 patients (28.6%) underwent any event and 44 (23.8%) died. 3-year
Event-free (EFS) and OS were 71.1% and 76.5%, respectively. Both standard
and the NCCN-IPI showed good prognostication. However, NCCN-IPI more
efficiently separated patients of low-intermediate vs high-intermediate risk com-
pared to standard IPI, and the patients of high risk group according to NCCN-
IPI showed poorer OS compared to those according to standard IPI. 19 patients
had RI according to CKD-EPI formula: 5 patients had pre-existing CKD, 2 had
post-renal acute kidney injury (AKI) caused by DLBCL, and another 2 had
hypercalcemia and/or hyperuricemia, suggesting AKI due to the electrolyte
imbalance due to lymphoma. We could not define the reason of RI of the other
10 patients: they were aged ≥70 years (range 71 – 89) except 2 patients with
49 and 69 years, respectively. Patients with RI showed inferior OS compared
to those without RI (3-yr OS 26.7% vs 81.8%, p <0.001). There was no differ-
ence of OS between patients with a GFR of ≥90 vs ≥60 - 89 mL/min/1.73 m2
(3-yr OS 82.4% vs 76.7%, p=0.436), suggesting that only RI defined by GFR
below 60 mL/min/1.73 m2 is a meaningful prognostic indicator of OS. In multi-
variate analysis, RI was an IPI-independent prognostic biomarker (Table 1).
Among patients with high or high-intermediate risk according to standard IPI,
patients with neither anemia of Hb <10 g/dL nor RI had superior OS vs patients
who had one of them or vs those with both of them. These findings were main-
tained when the analysis was restricted to patients with high risk according to
standard IPI. Use of NCCN-IPI instead of standard IPI showed same result.
Table 1. Univariate and multivariate analysis for event-free and overall
survival.
Summary/Conclusions: Patients with baseline RI had inferior OS compared
to those without RI. Because RI was an independent prognostic factor for OS
in multivariate analysis whereas age >60 years (or ≥70 or even ≥75 years
instead) was not, RI might have a role of the biological age-indicator of patients
with DLBCL and therefore affect to OS. In combination with Hb <10 g/dL, RI
enhanced prognostication in patients classified as higher risk group according
to either standard or NCCN-IPI.
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INCIDENCE AND PROGNOSIS OF EPSTEIN-BARR VIRUS-POSITIVE
DIFFUSE LARGE B-CELL LYMPHOMA IN VERY ELDERLY PATIENTS
(AGED OVER 80 YEARS)
T Tomikawa1,*, M Tokuhira1, R Watanabe1, T Tabayashi1, Y Tanaka1,
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Y Takahashi1, Y Kimura1, M Sagawa1, T Anan-Nemoto1, M Higashi2,
JI Tamaru2, M Kizaki1
1Department of Hematology, 2Department of Pathology, Saitama Medical Cen-
ter, Saitama Medical University, Kawagoe, Japan
Background: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma
(DLBCL) of the elderly is a newly-described lymphoproliferative disorder (LPD)
as a provisional entity in the 2008 WHO classification. The definition is a clonal
B-cell proliferation associated with EBV, age at diagnosis over 50 years, and
no secondary immune deficiencies. The prognosis is reportedly significantly
inferior compared with EBV-negative DLBCL.
Aims: The aim of this study was to clarify the incidence of EBV infection and
its related clinical features in very elderly patients with DLBCL.
Methods: We retrospectively analyzed 190 DLBCL patients diagnosed in our
institute from January 2008 to December 2013. Diagnoses were immunohisto-
chemically confirmed and the in situ hybridization detection technique for EBV-
encoded small RNAs (EBER) was performed in all cases. EBV results were
compared with clinical and immunochemical data according to age.
Results: The median age was 70.0 (22.7-97.1) years, and the median follow-
up duration was 33.6 (0.2-96.5) months. The average EBER positivity was
4.6% in all patients. The mean EBV positivity of tumor samples in age groups
were: 20-49 years (n=25), 0%; 50-59 years (n=32), 3.6%; 60-69 years, (n=38),
3.8%; 70-79 years (n=61), 8.9%; and over 80 years (n=34), 3.4% (1/34). The
5-year overall survival (OS) of all 190 patients was 58.2%, and that of EBV-
positive patients (n=8) was 62.5%; the difference was not significant.
Summary/Conclusions: The reported incidence of EBV-positive DLBCL among
patients of Asian and Latin American origin ranges from 9 to 15%, and the inci-
dence of EBV-associated LPD increases with advancing age (Castillo JJ, et al.
Oncologist 2011; 16: 87-96). Only 4.6% of the current DLBCL patients were
EBER-positive; the reported peak (8.9%) was in the 70-79 years group, whereas
the peak in that group in our cohort was only 3.4%. The immunophenotypic
analysis results were similar in each age group, suggesting the patient population
of this study was not deviated. In contrast to previous reports, the prognosis for
EBV-positive and -negative DLBCL was similar. In conclusion, the characteristics
of the EBV-positive DLBCL of the elderly identified in this study differ in several
ways from that previously reported, and may be a new subtype of B-cell lym-
phoma; further studies to examine this possibility are warranted.
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OLDER PATIENTS WITH DLCLB-SHOULD ALL BE TREATED WITH INTENT
TO CURE?
M Purić*, B Živković, D Ristić, N Milanović
Department of medical oncology; Chemotherapy of haematological malignancy
and bone sarcomas, Institute for Oncology and Radiology of Serbia, Belgrade,
Serbia
Background: The incidence of diffuse large B cell lymphoma (DLCLB) increas-
es in the elderly. Older age is associated with the presence of concomitant dis-
ease making the therapy difficult. Concidering the results of earlier studies, age
itself should not be a justification for a paliative care decisions or reduced inten-
sity chemotherapy. However, elderly patrients as more fragile, do not always
receive the right treatment. So, the best method for identifying non-fit patients
is not known.
Aims: To evaluate if Age Adjusted Carlson score (AACS) at diagnosis can pre-
dict clinical outcome in older patients with DLCLB receiving the first– line
chemotherapy.
Methods: Patients at the Institution for Oncology and radiology of Serbia
between 2005 and 2015 who were diagnosed and received first-line chemother-
apy for DLCLB, older than 65 years were enrolled. Clinical and treatment data
were recorded including AACS at the diagnosis. Survival time was estimated
using the Kaplan- Meier (KM) method, and Cox proportional hazard model was
used to evaluate the risk factors significance for survival. A p-value <0.05 was
considered significant.
Results: 87 patients were included in the study. 23 (26.44%) patients were
older than 75 years, 52 (59.77%) were female, 38 (43.67%) were Ann Arbor
stage 1 and 2, 28 (32.18%) were International prognostic index (IPI) score 0-
1; and 38 (43.68%) were intermediate high or high risk. 44 (50.57%) patients
were AACS≤5 and 43 (49.43%) patients were AACS≥6. Extronadal involvement
was present in 65 (74.71%) patients at diagnosis. 60 (68.97%) patients were
treated with Rituximab. 38 (43.68%) patients received CHOP, 27 (31.03%)
mCHOP, 12 (13.79%) CVP and 10 (11.49%) CEOP regimen, with or without
Rituximab. Statistically significant difference for overal responce rate (ORR)
was registered between CHOP and CVP arm (p=0.004), as for mCHOP and
CVP arm (p=0.001). CEOP was not inferior to CHOP (p=0.37) and
mCHOP(p=0.47) in term of ORR. Complete responce rate (CRR) was signifi-
cantly better in CHOP (73.68%), m CHOP (74.07%) and CEOP (80%) groups,
than in CVP group (25%). ORR and CRR were better when Rituximab was
used (ORR and CRR were 100% and 79.31%/78.26% for RCHOP/RmCHOP,
but 88.89%/50% and 55.56%/50% for CHOP/mCHOP). There was no differ-
ence in toxicity among chemotherapy regimens. After a median follow-up of 43
months (range, 1-128), median overal survival (OS) times were 91 months (54-
not reached) for CHOP, 8.5 months (2- not reached) for CVP. Median OS was
not reached for mCHOP and CEOP arm. The CVP regimen was associated
with a significantly worse OS and PFS than was the CHOP regimen (p=0.0002)
or mCHOP regimen (p=0.0006). CHOP was uncommon in AACS≥6 group
(p=0.003). There was no difference between AACS≤5 and AACS ≥6 groups in
the frequency of other chemotherapy regimens. ORR was significantly better
in AACS≤5 (p=0.005). Median OS were not reached for AACS≤5 and 43 months
(20- not reached) for AACS≥6. Patients with AACS≥6 had significantly shorter
PFS (p=0.006) and OS (p=0.001) than patients with AACS≤5.
Summary/Conclusions: AACS≤5 was associated with a significant reduction
in the risk of death among older patients with DLCLB treated with different
chemotherapy regimens. This study suggests that AACS may predict responce
to chemotherapy and survival in older patients with newly diagnosed DLCLB.
As predictive biomarker and clinical prognostic indicator for OS and PFS, AACS
may be useful in defining the group of older DLCLB patients that would have
more benefit from best supportive care instead of chemotherapy.
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THE PROGNOSTIC NUTRITIONAL INDEX AS A PREDICTOR OF
PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
V Periša1,*, L Zibar2, A Knezović3, I Periša4, J Sinčić-Petričević1, I Aurer5
1Hematology, 2Nephrology, University Hospital Centre Osijek, Osijek, 3Com-
munity Health Centre Đakovo, Community Health Centre Đakovo, Đakovo,
4Community Health Centre Vinkovci, Community Health Centre Đakovo,
Vinkovci, 5Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
Background: The prognostic nutritional index (PNI), an indicator of nutritional
status and systemic inflammation, is associated with short- and long-term out-
comes of various malignancies. The prognostic value of the PNI in diffuse large
B cell lymphoma (DLBCL) remains unknown.
Aims: The aim of present study is to determine the prognostic value of baseline
PNI in DLBCL patients.
Methods: We retrospectively analyzed data from 76 DLBCL patients treated
with R-CHOP or R-CHOP-like regimens. We evaluated the significance of PNI
as a predictor of response to treatment, overall survival (OS) and event-free
survival (EFS).
Results: Lower PNI levels were found in patients with advanced Ann Arbor
clinical stage (47.56±6.97 vs 53.28±5.43, P<0.001) and in those with poor
response to therapy (41.63±6.1 vs 51.08±6.11, P<0.001). Patients with
PNI≤44.55 (cut-off was calculated by receiver operating chararacteristics) had
significantly worse 5-year OS (35% vs 88.8%, P<0.001, log rank test) and 5-
year EFS (28% vs 81.3%, P<0.001, log rank test). Cox regression analysis
showed that PNI≤44.55 was an independent prognostic factor for OS (HR
4.729, 95% CI 1.327-16.854) and EFS (HR 3.024, 95% CI 1.037-18.819).
Summary/Conclusions: PNI is an important prognostic factor in DLBCL, in
addition to and independent of the International Prognostic Index. PNI may
emerge as a simple, fast, easy to use and inexpensive new prognostic marker
for DLBCL patients in routine clinical practice.
PB1698
ROLE OF PET/MRI IN HEMATOLOGIC MALIGNANCIES: PRELIMINARY
OBSERVATIONS
GD Mendez de Paz1,*, A Serrano Maestro1, ML Bengochea Casado1, L Garcia
Canamaque2, V Perez Duenas3, J Perez de Oteyza1
1Department of Hematology, 2Department of Nuclear Medicine, 3Department
of Radiology, Hospital HM Norte Sanchinarro, Madrid, Spain
Background: Hybrid imaging using simultaneous PET/MRI could be a valuable
diagnostic modality for the staging and follow-up of patients with hematologic
malignancies. Since the availability of this technique is currently restricted to a
small number of centers, data available in this setting is still limited.
Aims: Our objective is to analyze the results and potential advantages of
PET/MRI in hematologic malignancies.
Methods: A total of 30 PET/MRI studies were performed at our institution using
a Biograph mMR device. Informed consent, which included use of clinical data,
was obtained before every procedure. PET/MRI was performed 45 minutes
after injection of 18F-FDG. Images were obtained from orbital region to proximal
third femur. Magnetic Resonance was obtained by HASTE sequencing.
Results: A total of 21 patients were studied. Median age was 62 years (range
35-89).Patients’ diagnoses were: Diffuse Large B Cell Lymphoma (8 patients);
Follicular Lymphoma (3); Multiple Myeloma (2); Primary Central Nervous Sys-
tem Lymphoma (2); Hodgkin Lymphoma (3); Plasmacytoma (1) and other Low
grade Lymphomas (2). In 7 patients (23%) PET/MRI was used for initial staging,
and in 11 patients (37%) it was used for follow-up, comparing previous results
with other staging techniques (CT scan/PET-CT). In 3 patients (12%) the
PET/MRI was used to study possible relapse of the disease. In 9 patients (30%)
a second PET/MRI was performed for either follow-up (6 patients, 20%), or to
evaluate potential relapse (3 patients,10%). Of all procedures performed,
PET/MRI was useful for establishing initial stage (6 patients, 20%); confirm
response to therapy (14 patients. 46%); and prove disease relapse (3 patients
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10%). Finally, in 7 patients (23%) in whom conventional imaging had shown
residual disease, PET/MRI was able to demonstrate complete remission.
Summary/Conclusions: Taken together, our results suggest that PET/MRI is
a promising technique which may improve diagnostic accuracy, with a reduction
of radiation dose in patients with hematologic malignancies. Further studies
are needed in order to validate this technique for clinical use.
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DOSING OF CHEMOTHERAPY IN OBESE ADULT PATIENTS WITH
HAEMATOLOGICAL MALIGNANCIES: A SURVEY OF PRACTICE IN THE
UK
A Preston1,*, N Duncan2, S Robinson1, J Braybrooke1
1Bristol Haematology & Oncology Centre, University Hospitals Bristol NHS
Foundation Trust, Bristol, 2Pharmacy Department, University Hospitals Birm-
ingham NHS Foundation Trust, Birmingham, United Kingdom
Background: With obesity levels increasing to epidemic proportions, treating
obese patients optimally with chemotherapy is a significant issue. There is
accumulating evidence of increased cancer risk in obese patients and obesity
related co-morbidities can compromise relative total dose intensity, resulting in
poorer overall survival in some tumour types.
In 2010 the American Society of Clinical Oncology (ASCO) convened an expert
panel to review the literature on chemotherapy dosing in obesity. The panel
concluded that up to 40% of obese patients received “capped” doses because
of clinicians’ concerns regarding toxicity. They concluded that there was no
evidence of increased toxicity in such patients and released a Clinical Practice
Guideline recommending that obese patients should be dosed on their actual
(full) body weight.
Aims: To investigate UK clinical practice in this area and establish whether it
has changed as a result of the ASCO Clinical Practice Guideline.
Methods: A questionnaire was completed by 81 specialist cancer services
pharmacists from the British Oncology Pharmacy Association. The question-
naire assessed: 1) criteria used for defining obesity, 2) if dose adjusting for
obesity was undertaken at individual hospitals and if so what methodology it
was based on, 3) if practice had been influenced by the ASCO guideline and
4) what formulae/ methods were being used to assess body surface area
(BSA), ideal body weight (IBW) and glomerular filtration rate (GFR).
Bone marrow transplant conditioning and treatment of leukaemia were exclud-
ed to reflect ASCO’s guideline; treatment of Non-Hodgkins and Hodgkins Lym-
phoma were included.
Results: Of the 73 pharmacists who fully responded, just less than half (47%)
stated that their hospitals follow ASCO’s recommendations and dose on actual
body weight. The most common reasons for non-adherence included the lack
of robust evidence and a need for clinical teams to discuss the guidelines and
reach a consensus of how to adapt locally. Of the 53% who confirmed that
they reduce doses in obese patients, 30% dose reduced in all obese patients
and 70% in selected patients where ‘capping’ decisions were based on treat-
ment goal (100%) and the pharmacokinetics of the individual drugs (38%).
There was no uniformity in formulae used for BSA, IBW or GFR calculations.
Methodology varied for defining obesity, adjusting the dose, assessing GFR
and some centres used IBW in GFR formulae, some actual body weight. This
lack of uniformity is not unique to the UK and is likely to be a widespread issue.
Summary/Conclusions: Further research is needed to clarify chemotherapy
dosing in obese patients to aid clinicians and pharmacists in these decisions.
Pharmacokinetic and pharmacogenetic studies would provide a more person-
alised approach to treatment, and can be undertaken in the context of large
prospective trials. Until evidence is available for specific cancers, a unified
approach to dosing in obesity based on current guidance should be encouraged.
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RITUXIMAB DURING INDUCTION THERAPY MIGHT NOT IMPROVE
OVERALL SURVIVAL OF VERY ELDERLY JAPANESE PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA
Y Miyata1,*, T Yano2, Y Abe3, S Okamura4, M Otsuka5, M Hidaka6, K Sunami7,
N Inoue8, M Sawamura9, T Ito10, S Yoshida11, T Shimomura12, K Kitano13,
H Iida1, T Naoe1, H Nagai1
1Hematology, Nagoya Medical Center, Nagoya, 2Hematology, Tokyo Medical
Center, Tokyo, 3Hematology, Kyushu Cancer Center, 4Hematology, Kyushu
Medical Center, Fukuoka, 5Hematology, Kagoshima Medical Center, Kagoshi-
ma, 6Hematology, Kumamoto Medical Center, Kumamoto, 7Hematology,
Okayama Medical Center, Okayama, 8Hematology, Osaka Medical Center,
Osaka, 9Hematology, Nishigunma National Hospital, Shibukawa, 10Hematol-
ogy, Kure Medical Center, Kure, 11Hematology, Nagasaki Medical Center, Omu-
ra, 12Hematology, Hiroshima-nishi Medical Center, Otake, 13Hematology, Mat-
sumoto Medical Center, Matsumoto, Japan
Background: As aging of population is advancing, the number of the elderly
patients with diffuse large B-cell lymphoma (DLBCL), most common type of
lymphoma, is increasing. In addition to difficulty to treat patients age 80 and
over due to comorbidities and poor organ functions, the optimal treatment of
these patients with DLBCL remains unclear since there was no well-controlled,
randomized trial to confirm clinical benefits of rituximab during induction therapy
for these patients, unlike younger patients.
Aims: In this study, we assessed clinical contribution of rituximab during induc-
tion therapy on survival of Japanese patients with DLBCL age 80 and over,
especially in actual practical setting.
Methods: Previously, we reported that rituximab-containing remission induction
therapy improved the outcome of Japanese patients with mature B-cell lym-
phoma newly diagnosed at 20 National Hospital Organization hospitals from
January 2000 to December 2004. A retrospective study was conducted using
this database, although it lacks detailed information on treatment, e.g. combi-
nations of drugs, dose intensities of each drug, and the number of treatment
cycles.
Results: From database, we identified 100 patients age 80 and over (12.5%)
from 798 DLBCL patients. Only 15 patients (15.0%) didn’t receive an anthra-
cycline-containing regimen, and were excluded from further analyses. This
ratio was statistically higher, compared to younger patients (p<0.0001). Among
85 patients who received anthracycline-containing regimens, 45 deaths were
observed during follow-up period, and 8 deaths (17.8%) were due to other than
lymphoma. This was not significant, compared to younger patients (p=0.859).
Based on administration of rituximab in remission induction therapy, 85 patients
were divided into two groups since patients didn’t receive rituximab during
induction until its approval for DLBCL in September 2003 in Japan. Sixty-two
patients (72.9%) were treated without rituximab (R- group) and 23 patients
(27.1%) with rituximab (R+group). Median follow-up periods were 38.7 months
and 21.8 months, respectively. No significant difference of patient characteris-
tics, age, sex, disease stage, extranodal involvement, B symptom, PS, LDH,
IPI and AA-IPI, were observed between two groups. Better response was
observed in R+group than R- group (CRR 56.5% vs 43.5%, ORR 82.6% vs
66.1%), but these differences were not significant (p=0.3337 and p=0.183
respectively). Estimated 2-year progression-free survival of R+group was sig-
nificantly higher than R- group (50.4% vs 25.6% p=0.030), but 2-year overall
survival was similar (45.3% vs 42.3% p=0.344). The same trends were seen
when deaths of other than lymphoma were censored (p=0.260). R- group was
further divided into 2 groups, patients who never received rituximab throughout
their lifetimes (R-R- group n=48) and those who received rituximab during sal-
vage therapies (R-R+group n=14). Median survivals of these groups were sim-
ilar (19.2 months vs 21.8 months p=0.900), and there was no significant differ-
ence from R+group (p=0.351 and p=0.486 respectively).
Summary/Conclusions: Rituximab during induction therapy didn’t improve
overall survival of Japanese patients with DLBCL age 80 and over, unlike
younger patients. However, later administration of rituximab during salvage
therapies could improve prognosis. Large-scale studies are further needed to
confirm these results.
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PROGNOSTIC ROLE OF NTPROBNP LEVELS AT DIAGNOSIS IN ELDERLY
PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
V Bozzoli1,*, MC Tisi2, E Maiolo2, E Alma2, AM Leone3, D Francesco2, S Hohaus2
1Hematology, Ospedale Vito Fazzi, Lecce, 2Hematology, 3Cardiology, Catholic
University S. Cuore, Rome, Italy
Background: Immunochemotherapy using the R-CHOP regimen (Rituximab,
Cyclophosphamide, Doxorubcin, Vincristine and Prednisolone) represents the
standard treatment of elderly patients (pts) with Diffuse Large B Cell Lymphoma
(DLBCL), but treatment can be complicated by cardiac side effects often attrib-
uted to the cytotoxic drug doxorubicin. NTproBNP levels in plasma are typically
increased in patients with left ventricular dysfunction and have been proposed
as a marker for cardiac injury during cytotoxic treatment.
Aims: The aim of this study was to investigate the prognostic role of NTproBNP
at diagnosis in elderly DLBCL pts.
Methods: We conducted a retrospective analysis, including 130 elderly (≥65
years) pts, median age 74 years (range 65-91), diagnosed with DLBCL from
2009 to 2014 in our institution for whom NTproBNP levels at diagnosis were
available. The impact of NTproBNP levels on response and survival was eval-
uated in 126 patients who either received anthracycline-containing
immunchemotherapy (92 pts) or immunochemotherapy without anthracyclines
(34 pts). Anthracycline consisted in standard doxorubicin in 52 pts and liposo-
mal doxorubicin in 40 pts.
Results: At diagnosis, 82/130 pts (63%) showed elevated NTproBNP levels.
NTproBNP levels correlated positively with age (p=0.0001), and creatinine val-
ues (p=0.001) and negatively with levels of albumin (p=0.0001), and hemoglo-
bin (p=0.0001). Poor performance status (ECOG ≥2) was associated with high-
er levels of NTproBNP (p=0.0004). Pts with a previous history of hypertension
and ischemic heart disease had increased NTproBNP levels (p=0.006, and
p=0.02, respectively). There was no correlation between NTproBNP and left
ventricular ejection fraction at diagnosis (Spearman’s rank coefficient p=0.7,
ps=-0.05). In a multivariate analysis, albumin levels <4 g/dl retained the signif-
icant association with elevated NTproBNP levels (p=0.004). Patients with nor-
mal NTproBNP levels at diagnosis had a higher probability of complete
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responses (91 vs 70%, p=0.02). Higher NTproBNP levels were associated with
inferior event-free and overall survival both in univariate (p<0.001) and multi-
variate analysis including IPI and anthracycline-containing chemotherapy as
significant parameters (Table 1).
Table 1. Multivariate Cox regression analysis for event-free survival.
Summary/Conclusions: NTproBNP levels at DLBCL diagnosis are frequently
elevated in elderly patients with DLBCL, predict poor outcome and are associ-
ated with a number of patient characteristics reflecting “host-related factors”,
such as age, history of cardiac injury, performance status and laboratory abnor-
malities as low hemoglobin and albumin values. Studies on mechanisms that
lead to increased NTproBNP levels in addition to wall stress on myocardiocytes
are warranted.
PB1702
AGGRESSIVE LYMPHOMA: DEMOGRAPHICS, DIAGNOSTIC PATTERNS
AND OUTCOMES IN GROOTE SCHUUR HOSPITAL IN CAPE TOWN,
SOUTH AFRICA
C Levetan1,*, E Verburgh2, N Novitzky2, C du Toit2, Z Mohamed3
1MEDICINE, 2Haematology, 3Oncology, University of Cape Town, Cape Town,
South Africa
Background: The high rate of HIV in South Africa led to an increasing incidence
of aggressive non Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), but
also of infection with Mycobacterium tuberculosis (TB) which may mimic lym-
phoma. We have observed in Cape Town that lymphoma patients present with
advanced disease and that their route to diagnosis is often markedly delayed.
Aims: This study describes the demographic distribution of aggressive lym-
phomas in our Cape Town institution as well as examine survival outcomes as
impacted by documented time delays along the diagnostic pathway.
Methods: We studied 163 patients diagnosed and treated for aggressive lym-
phoma by Radiation Oncology and Haematology at Groote Schuur Hospital
Cape Town in 2013/14. We collected diagnostic and outcome data from hos-
pital records and patient interviews. We constructed a pathway to diagnosis
as previously described by Howell DA et al., in BMC Hematology 2013 Oct
31;13(1):9. Delays along the diagnostic pathway were divided into three time
frames. 1. Patient delay (time from first symptoms until first contact with a
medical practitioner) 2. Diagnostic delay (time from first medical contact to
diagnostic biopsy). 3. Treatment delay (time from biopsy to referral to our unit
and initiation of therapy).
Results: NHL was diagnosed in 122 (74.8%) and HL in 41 (25.2%). In the NHL
cohort 29 patients (23.8%) were HIV positive and in HL 18 patients (43.9%),
p=0.014. There was no significant association between HIV status and stage
at presentation and HIV positive patients did not have a significantly poorer
overall survival (OS) (59.6% vs 69%, p=0.251). There was, however, a signifi-
cant association of HIV with progressive disease in the alive group at time of
data analysis (8 patients (28.6%) vs HIV negative 10 patients (12.5%), p=0.05).
HL had better OS compared to NHL (35 (85.4%) vs 73 (59.8%), p=0.003). The
HL cohort was more likely to present with high-risk disease (80.5%), lym-
phadenopathy (82.9% vs 56.6% p=0.001) and B-symptoms (73.2% vs 54.1%
p=0.032). Despite presenting at this advanced stage, they waited significantly
longer for referral from first doctor’s visit to diagnostic biopsy (125 days versus
43 days p=0.01) and from first symptoms to treatment (271 versus 97 days
p=0.004). Investigations for the diagnosis of TB as well as empiric TB treatment
had a major impact on this delay. Empiric TB treatment was given to 26% of
the HL cohort prior to diagnosis of lymphoma, compared to 4.9% in the NHL
cohort (p=0.00). Fine needle aspiration (FNA) was carried out in 63 (61%) prior
to excisional biopsy and in 17 (27%) FNAs were repeated. Only 10 of 88 FNA
studies (11%) suggested lymphoma. Time delay between FNA and diagnostic
biopsy median 22 days (IQR 9.8-64). Longer delay from first doctors visit to
referral for diagnostic biopsy was associated with an increased mortality (alive:
median 40 days (IQR 23-69), dead: median 64 days (IQR 27-154), p=0.04).
This is also true for time from first doctor’s visit to treatment (alive: median 59
days (IQR 29-122), dead: median 97 (51-205), p=0.03) and for time from first
symptoms until treatment (alive: median 103 days (61-178), dead: median 131
(IQR 73-299), p=0.04).
Summary/Conclusions: In aggressive lymphoma diagnosis the period between
first patient contact with a health professional and the diagnostic biopsy is crucial.
FNA examination is often the first step in the diagnostic pathway of lym-
phadenopathy in South Africa due to the high rate of TB and poor access to
diagnostic biopsy. This led to an inappropriately long 3-week median delay from
first FNA to diagnostic biopsy. These three key areas - use of FNA, poor access
to excisional biopsy and treatment with empiric TB therapy – significantly delayed
diagnosis resulting in severe consequences with increased patient mortality.
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TRANSGASTRIC ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE
ASPIRATION BIOPSY FOR LYMPHOMA DIAGNOSIS OF ISOLATED
SPLENIC LESIONS
A Cuccaro1,*, F Attili2, F D’Alò1, A Larghi2, MC Tisi1, S Bellesi1, S Sica1,
LM Larocca3, S Hohaus1
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Background: Isolated splenic lesions are relatively infrequent, but represent
a diagnostic challenge, as tissue sampling for histologic analysis may be diffi-
cult, in particular if the size of the lesion is small. Percutaneous image-guided
splenic biopsies are rarely performed due to the perceived high risk of hemor-
rhage that could lead to urgent splenectomy, and diagnostic splenectomy is
often preferred as primary diagnostic procedure. Endoscopic ultrasonography
(EUS)-guided fine needle aspiration (EUS-FNA) biopsy allows sampling of tis-
sue which is adjacent to the stomach wall. EUS provides a good imaging of the
spleen through the gastric wall. There have been only few cases of successful
histopathologic diagnoses by EUS-guided splenic biopsies reported in the lit-
erature. We report our experience with trans-gastric EUS-FNA in the investiga-
tion of patients with isolated splenic lesions suspicious for lymphoma.
Aims: We retrospectively assessed the diagnostic performance and safety of
EUS-FNA to elucidate the tissue diagnosis of splenic abnormalities suspicious
for lymphoma.
Methods: Between 2009 and 2016, we evaluated nine patients with splenic
lesions detected by CT, Positron Emission Tomography (PET) and US in our
Institution. We used a linear echo-endoscope and 19/20 gauge needles for
transgastric EUS-FNA biopsy. Patients were admitted to the hospital to guar-
antee an overnight monitoring after the procedure. Platelet counts were in the
normal range and INR was <1.5.
Results: The age of the patients was 40–83 year (average 58.6 year); five
patients were male and four female. All patients presented focal splenic lesions
that varied in size from 17 to 100 mm (average 41 mm). Bone marrow biopsy
was negative for lymphoma localization, and lymph node involvement was
absent or minimal. There was no evidence of bleeding or other complications
related to the procedure after splenic EUS-FNA biopsy. In seven patients tissue
sampling was sufficient for a pathological diagnosis (78% sensitivity). Diag-
noses were Hodgkin Lymphoma in two patients, and Diffuse Large B-cell Lym-
phoma (DLBCL) in five patients. Only two patients required further diagnostic
procedures, including laparoscopic spleen biopsy in one patient and splenec-
tomy in one patient. In both cases final diagnosis was DLBCL.
Summary/Conclusions: Transgastric EUS-FNA biopsy of splenic lesions is a
safe diagnostic procedure with high sensitivity for the diagnosis of lymphoma,
reducing the need for splenectomy.
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THE LYMPHOCYTE COUNT AND THE MONOCYTE COUNT AND THE
LYMPHOCYTE TO MONOCYTE RATIO AT DIAGNOSIS WERE A PROG-
NOSTIC PARAMETERS IN DIFFUSE LARGE B-CELL LYMPHOMA:
RESULTS FROM A LARGE MULTICENTER STUDY
A Bekadja1,*, H Touhami2, Z Zouaoui3, N Mesli4, N Mehalhal5, A Bachiri6,
M Talbi7
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Background: There is increasing evidence that tumor microenvironment and
host immunity play an important role in lymphoma progression. The absolute
lymphocyte count (ALC) and the absolute monocyte count (AMC), calculated
from the complete blood count, were considered a surrogate for host immunity.
Aims: The aim of this collaborative multicenter study was to verify the prog-
nostic significance of ALC, AMC and ALC/AMC ratio in a large cohort of newly
diagnosed patients with DLBCL and we also examined whether ALC and AMC
could be utilized as a simple Independent prognostic factors for survival.
Methods: It is a retrospective and multicenter study carried-out by seven hema-
tology departments in the western of Algeria. 467 patients with DLBCL had been
diagnosed during an eight years period (2007-2014). All patients, older than 16
years, were included in the study. The median age at the diagnosis was 54 years
(16 to 89). There were 265 males and 202 females. The localized stage (I-II)
was 43% and the advanced stage (III-IV) was 57%. The performans status
(PS≥2) was 41%. LDH increased level in 47%. The number of extra-nodal
involved sites was as follows: 0=26%, 1=43%, 2=19%, ≥3=12%. The IPI score
were as follow: low risk=41%, intermediate low risk=23%, intermediate high
risk=24% and high risk=12%. The IPI-R score were as follow: very good=11%,
good=52%, bad=37%. The overall survival (OS) and progression free survival
(PFS) were calculated according to Kaplan and Meier method and the survival
curves were compared using the Log Rank test. The multi-factorial survival
analysis was performed by the use Cox regression test. The end point date was
the December the 31st 2015. The median of follow up was 24 months (6-109).
Results: The mono-factorial analysis of OS (comparison of the survival curves)
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showed: Age (≥60 vs <60) (p=0.5); sex (M vs F) (p=0.04); Performans Status
(0-1 vs ≥2) (p=0.06); the Ann Arbor (localized vs advanced stage (p=0.008).
Bulky vs no Bulky (p=0.32); B symptoms (A vs B) (p=0.05); LDH (Normal vs
Increased) (p=0.4); IPI score (p=0.046); IPI-R score (p=0.16- p=0.002 and
p=0.001); ALC (>1000µl vs <1000µl) (p=0.082); AMC (>630/µl vs <630/µl)
(p=0.001). ALC/AMC ratio (≥2.11 vs <2.11) (p=0.001). The mono factorial analy-
sis of PFS showed: Sexe (p=0,247); PS>=2 (p=0,325); the Ann Arbor localized
vs advanced stage (p=0,089); IPI score (p=0,709); IPI-R score (p=0,581);
LDH>Normal vs Increased (p=0,465); AMC >630 (p=0,778); ALC>1000
(p=0,155) and the ALC/AMC ratio ≥2.11 vs <2.11(p=0, 03). The multi-factorial
analysis of the overall survival showed that the most discriminative prognostic
factors were: Age>60 years old (HR=1.77, p=0.002); Female sex (HR=0.58,
CI 95% 0.41-0.82, p=0.002); PS<2(HR=0.58, CI 95% 0.41-0.81, p=0.002),
ALC>1000 (HR=1.28 IC 95% 0.68-2.42, p=0.043), AMC>630 (HR=0.72 IC 95%
0.45-1.15, p=0.018), ALC/AMC ratio>11 (HR=1.54 IC 95% 0.72-3.02, p=0.02).
Summary/Conclusions: This study shows that a simple parameters like
absolute lymphocyte count (>1000/mm3) and monocyte count (>630/mm3)
and the lymphocyte to monocyte ratio at the diagnosis can easily be used rou-
tinely in the evaluation of newly diagnosed diffuse large B-cell lymphoma to
identify high –risk patients with a worse survival in the rituximab era.
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THE ABSOLUTE MONOCYTE AND PLATELET COUNTS IN PRIMARY
GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS TREATED
WITH RITUXIMAB AND CHOP
B Spassov*, D Vassileva, S Nikolov, P Ganeva, G Mihaylov, G Balatzenko,
M Guenova
NSBALHZ, Sofia, Bulgaria
Background: Primary gastric lymphoma (PGL) accounts for 3% of gastric
malignancies and 10% of lymphomas. The most common histological subtype
of PGL is the primary gastric diffuse large B cell lymphoma (PGDLBCL). The
standard of care of PGDLBCL patients (pts) is the combination rituximab-CHOP
immunochemotherapy (R-CHOP). Recently serum albumin (SA), β2-microglob-
ulin (B2M), hemoglobin level (Hb), absolute neutrophil (ANC), lymphocyte
(ALC), monocyte (AMC) and platelet counts (PC) etc have been introduced
into the clinical practice for better pts’ stratification. However the data regarding
the prognostic significance of these markers are limited.
Aims: Therefore, we decided to access the possible prognostic impact of SA,
B2M, Hb, ANC, ALC, AMC and PC in R-CHOP treated PGDLBCL pts.
Methods: We retrospectively reviewed the clinical outcome of 42 R-CHOP
treated PGDLBCL pts with median age 56.7 years and 54.76% male. The lab-
oratory levels of SA, Hb, ANC, ALC, AMC and PC were recorded. Serum B2M
levels were measured radioimmunologically. The best cut off values of SA,
B2M, ANC, ALC, AMC and PC to predict overall survival (OS) by Kaplan-Meier
method were calculated by a receiver operating characteristic (ROC) curve
analysis. Univariate and multivariate analyses were performed by the log rank
and Cox proportional-hazards methods, respectively.
Results: The estimated 5-year OS of the whole group was 80.9%. The median
values of SA, B2M, Hb, ANC, ALC, AMC and PC were 39.1 g/L, 2.95 mg/L,
121 g/L, 4.69 G/L, 1.79 G/L, 0.51 G/L and 324 G/L, respectively. By applying
the best cut off values of SA, B2M, Hb, ANC, ALC, AMC and PC that were 33.9
g/L, 2.6 mg/L, 105 g/L, 6.12 G/L, 1.77 G/L, 0.518 G/L and 335 G/L, respectively,
it was observed that only Hb, ANC, AMC and PC correlated with OS. The inde-
pendent prognostic significance, however, was confirmed in multivariate analy-
sis only for AMC and PC (hazard ratios 15.482 and 13.525; p=0.012 and
p=0.017, respectively). The dichotomized AMC and PC generatedthe AMC/PC
prognostic index (PI) and stratified patients into3 risk groups: very good (AMC
<0.518 G/L and PC <335 G/L),good (AMC <0.518 G/L or PC <335 G/L) and
poor-risk (AMC ≥0.518 G/L and PC ≥335 G/L) populations. For both the very
good and good-risk groups median OS has not been reachedwith estimated
5-year OS of 100% and 86.4%, respectively whereas the median OS for poor-
risk pts was 4 months with an estimated 5-year OS of 28.6% (p<0.001).
Summary/Conclusions: AMC and PC are independent prognostic markers
to predict survival in PGDLBCL patients. AMC/PC PI could provide additional
prognostic information for better stratification of these pts.
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TWENTY YEARS’ EXPERIENCE OF TREATMENT OF ADOLESCENTS AND
YOUNG ADULTS WITH NON-HODGKIN LYMPHOMA – A SINGLE CENTER
EXPERIENCE
R Ratzon1,2,*, S Tzadok2, P Raanani1, R Gurion1,2
1Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin
Medical Center, Petah Tikva, 2Sackler School of Medicine, Tel Aviv University,
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Background: Adolescents and young adults (AYAs) with non-Hodgkin lym-
phomas (NHL) comprise a unique group of patients, under-represented in clin-
ical trials. Furthermore, the prognosis of these patients is inferior to that of
younger patients with hematological malignancies. Therefore, many questions
regarding the biology and treatment strategies of this group remain unan-
swered.
Aims: We aimed to determine the characteristics of AYA NHL patients in the
last 20 years in a single tertiary center. Also, we intended to identify risk factors
for poor prognosis in this population.
Methods: We reviewed retrospectively the database of our NHL patients at
the Rabin Medical Center between the years 1995-2014 and identified patients
who met the following criteria: age 18-40 years old, a confirmed histological
diagnosis of NHL and treatment in our institution, with at least one year follow-
up. In order to define prognostic factors we used the Mann-Whitney U test to
compare between the group of patients with poor outcome and those with
better outcome. 3-year event free (EFS) and overall survival (OS) were calcu-
lated according to the Kaplan-Meier analysis.
Results: A total of 85 patients with confirmed diagnosis of NHL were included
in this study. Median age was 32 (range, 18-40) years with 42% male. 74 patients
(87%) were diagnosed with aggressive lymphoma and 11 (13%) with indolent
lymphoma. The histologic subtypes included diffuse large B-cell lymphoma -
50%, primary mediastinal B-cell lymphoma - 28%, Burkitt lymphoma - 9%, fol-
licular lymphoma - 12%, marginal zone lymphoma - 1%. Due to the small num-
ber of patients with indolent lymphoma, this group of patients was not analyzed.
B symptoms were present in 32 patients (43%) and 48 had bulky disease (68%).
More than half of the patients had advanced stage disease. The IPI score was
low (0-1) in 40 patients (56%), low-intermediate (2) in 12 patients (17%) and
intermediate-high (3) in 19 patients (27%). Half of the patients were treated with
CHOP like regimen (CHOP, R-CHOP, CHOEP), 30% were treated with
MACOP\VACOP-B with or without rituximab and 16% received intensive regi-
mens (hyper-CVAD & GMALL). Most patients (74%) received rituximab as part
of their treatment regimen. 92% of the patients achieved complete remission
(CR), 19% of them relapsed. 14 patients (19%) underwent stem cell transplan-
tation: 12 autologous and 2 allogeneic. Overall, 7 patients died during follow -
up, 6 of them with DLBCL and 1 with PMBCL. All died due to progressive dis-
ease. 3-year EFS and 3-year OS for the whole group was 74% and 90%, respec-
tively, for patients with DLBCL-67% and 86%, respectively and for patients with
PMBCL- 90% and 96%, respectively (Figure 1). The results of Mann-Whitney
U test revealed that the group of patients with worse outcome had higher IPI
(p=0.03), higher aaIPI (p=0.03) and lower use of rituximab in the treatment reg-
imen compared to those with better outcome (p=0.05).
Figure 1.
Summary/Conclusions: In our cohort of AYA patients with NHL, DLBCL was
the most frequent subtype of lymphoma followed by PMBCL. This is in accor-
dance with previous reports. The 3 year EFS and OS of AYA patients with DLB-
CL in our cohort were lower or similar to other studies of AYA patients while
results for patients with PMBCL were superior to those in the literature. The
aaIPI/IPI score was validated in our cohort as a reliable prognostic index. As
in adults, the inclusion of rituximab in a combined regimen was associated with
better outcomes than chemotherapy alone.
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PRETREATMENT CRP LEVEL IN DLBCL PATIENTS: AN IMPORTANT
PREDICTOR OF TREATMENT RESPONSE IN RESOURCE CONSTRAINT
SETTINGS
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Background: The currently available prognostic model for Diffuse Large B Cell
Lymphoma (DLBCL) is not sufficient to predict the outcome of this heterogenous
group of DLBCL. There is a need to find better prognostic markers for optimal
risk stratification of DLBCL patients.
Aims: This study aimed to evaluate the prognostic significance of proinflammatory
markers in pretreatment peripheral blood sample of patients of DLBCL.
Methods: We measured levels of CRP and Th1 and Th2 cytokines (IL2, IL4,
IL6, IL10, IFN gamma and TNF alpha) in the pretreatment serum of 46 newly
diagnosed DLBCL patients and in 10 healthy controls. CRP was measured by
nephelometry and cytokines were measured using flowcytometric bead array
assay. We compared the levels of these proinflammatory markers between
cases and control groups. We evaluated the correlation of levels of these proin-
flammatory markers with disease characteristics like B symptoms, Ann Arbor
stage, IPI and with treatment response.
Results: The median age of cases was 55 years (range 13-80 years) while
that of controls was 46 years. Among DLBCL patients 72% were males and
28% were females. According to the IPI scoring the low, intermediate and high
risk groups comprised of 28%, 28%, and 44% patients respectively. Of the 41
patients who received treatment, 58% achieved CR, 12% achieved PR and
24% had progressive disease respectively after frontline treatment with
chemotherapy. In this study we found that the levels of CRP, IL4, IL6, IL10 and
IFN gamma were significantly elevated in DLBCL patients as compared to the
control group as shown in Table 1. The pretreatment serum level of CRP in
DLBCL patients was significantly elevated in those with B symptoms and high
risk IPI group as compared to those without B symptoms and low risk IPI respec-
tively. It was also noted that IL2 showed a significant inverse correlation with
stage and IPI of DLBCL patients. The median serum value of CRP was 30.5mg/l
and 81mg/l in patients who achieved complete remission (CR) and those who
did not achieve CR respectively after the frontline chemotherapy (p value -
0.007). The median serum level of IL6 was 31.5pg/ml and 14pg/ml respectively
in those who achieved overall response (OR) and those who did not achieve.
Thus OR was significantly lower in those patients with elevated IL6 (p value -
0.05).
Table 1. Comparison of cytokine levels between cases and controls.
Summary/Conclusions: Pro inflammatory markers can be used to predict
treatment outcome in DLBCL patients. Our work concludes that there is alter-
ation in cytokine profile of patients with DLBCL with inclination towards height-
ened Th2 response. CRP has shown a significant correlation with adverse dis-
ease characteristics and treatment response. It can emerge as a readily avail-
able and cost effective prognostic marker to predict treatment response in DLB-
CL patients especially in resource constraint settings.
PB1708
PROGNOSTIC IMPACT OF MYC/BCL-2 PROTEIN OVEREXPRESSION IN
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA:
A SINGLE-INSTITUTION EXPERIENCE
L García-Sanchis1,*, F ANTONIO2, T Anabel3, P Jose Luis3, S Carlos3, TM Jose3
1Hemathology, Hospital General Castellón, Castellón, 2Pathology, 3Hemathol-
ogy, Hospital Clinico de Valencia, Valencia, Spain
Background: Protein overexpression and rearrangements of myc and bcl-2
genes have been related with an adverse prognosis in diffuse large B-cell lym-
phoma (DLBCL) patients in the rituximab era. But data are not always consistent
and sometimes contradictory.
Aims: To analyze the incidence of MYC and BCL2 protein overexpression in
DLBCL as well as to evaluate the prognostic impact in terms of time to pro-
gression (TTP) and overall survival (OS).
Methods: We carried out a single institution study with tissue biopsies obtained
from patients diagnosed of DLBCL in the period 1994-2011. Tissue fixation and
processing were performed using standard methods. Tissue microarrays
(TMAs) that contained two representative 2-mm cores from each tumor were
prepared. Immunohistochemical stainnings were performed using fully auto-
mated protocols. We used the following antibodies: MYC (clone Y69;Roche),
BCL2 (clone 124; DAKO). The cut-off level for BCL2 and MYC expression was
50% and 10% respectively. MYC and BCL2 expression were evaluated by an
pathologist expert as well as an hematologist. At the same time, MYC and
BCL2 expression was evaluated using computerized image analysis with Image
Pro Plus 6.0. A mean number of 1000 cells were analyzed per case. TTP and
OS curves were built by the Kaplan_Meier method and compared by the log-
rank test. Impact of TTP and OS was studied by the Cox regression test.
Results: 140 DLBCL patients were included, median age was 70 (23-76),
male/female ratio 73/67, Ann Arbor stage III or IV: 73 (52%), high LDH 72 (51%),
high β2-microglobulin 62 (44%) low risk IPI 53 pt, int-low 26pt (19%), int-high
31pt (23%), high 28pt (20%) IPI ≥3: 59pt (42.1%). 45 patient were treated with
CHOP-like regimens and 95 with rituximab-CHOP schedules. Median follow-
up (alive pts) was 49 months(12,135).
Results: We observed MYC overexpression (≥10%) in 101pt (72%), BCL2
overexpression (≥50%) in 71pt (50%) and both in 56pt (40%). We did not
observe any correlationship between MYC, BCL2 or both overexpression and
clinical-biologic baseline characteristics. Patients with MYC and BCL2 overex-
pression had a lower complete response rate than the rest: 62% versus 76%
(p=0.09). Patients with both markers had a worse 5 year TTP: 67% versus 83%
(p0.09) and also a worse 5 year OS: 60% versus 79% (p0.05),. When we
restricted the analysis to the rituximab-treated patients, patients with both mark-
ers had a worse 5-y TTP and OS than the rest (57% vs 73%, p=0.05) and (58%
vs 85%, p=0.002). In the multivariate analysis including the IPI variable and
myc/bcl-2, myc/bcl-2 overexpression showed an independent prognostic value
on OS, HR 3,876(1.58, 9.51), p=0.003.
Summary/Conclusions: In our experience the protein overexpression of MYC
and BCL-2 had a negative impact on the outcome, specially in the rituximab
era with a lower CCR and a significant worse TTP and OS. Further studies on
these area are required.
PB1709
DOUBLE - HIT NON- HODGKIN’S LARGE B-CELLS LYMPHOMAS IS MORE
FREQUENT THAN WE THINK, BUT IPI SCORE IS NOT THE PREDICTOR
GOOD ENOUGH TO RECOGNIZE THIS TYPE OF LYMPHOMA
S Sretenovic1,*, S Mitrovic2, B Mihaljevic3, D Jovanovic1
1Clinic of Haematology, 2Center of pathology, Clinical Centre Kragujevac,
Kragujevac, 3Clinic of Haematology, Clinical Centre Serbia, Belgrade, Serbia
Background: Diffuse large B-cell lymphoma (DLBCL) exhibits various mor-
phologies, immunophenotypes, genetic aberrations, and clinical courses. These
features vary across geographic regions, suggesting geographic heterogeneity
as a characteristic of this type of lymphoma. DLBCL constitutes 31–34% of all
non-Hodgkin’s lymphomas in western countries, but in poor countries up to
50%. DLBCL is classified as the lymphoma with different entity in the recently
published classification of the World Health Organization (WHO classification).
Double-hit lymphomas (DHLs), as currently defined by the World Health Organ-
ization classification, are those lymphomas expressing the co-occurrence of
MYC and BCL2 or BCL6 rearrangement as detected by fluorescence in situ
hybridization (FISH) or standard cytogenetics.
Aims: Is the IPI score good predictor for recognize Double Hit in DLBC lym-
phomas.
Methods: We studied 62 patients with de novo DLBCL over the last six years
and investigated the prognostic relevance of BCL-2 and C-MYC rearrange-
ments positivity found by FISH. The prognostic significance of BCL-2 and C-
MYC expression was evaluated within the context of DLBCL different subtypes
and IPI score, but all treated with R-CHOP/ 21 day. Statistical analysis was
performed by SPSS for Windows (22.0) and significance of p<0,05.
Results: We studied 62 patients with DLBCL, male 32 and female 30, mean
age was 59,76+14,38 year. 58% of patients had high and intermediate high IPI
score, whilst 42% of patients had low IPI score. With CS IV and III was 82%
and only 18% had CS I and II. Patients with BCL-2 and C- MYC positivity found
by FISH (13/62) – double hit, had a bad outcome and median OS was only 14
months. ECOG performance status 0 and 1 had 71% patients. No statistically
significant differences in the frequency of BCL-2+between the group with low
vs high IPI risk, (χ2-test, p=0,492). There was no statistically significant differ-
ence in the incidence of C-MYC+between the group of high and low IPI risk,
(χ2-test, p=0,426). Intergroup analysis of the group of high vs low risk IPI, both
positive, both negative or at least one negative gene polymorphism did not
show statistically significant difference,(χ2-test, p=0,884).
Summary/Conclusions: Although currently available techniques such as
haematologica | 2016; 101(s1) | 695
Copenhagen, Denmark, June 9 – 12, 2016
immunohistochemistry may still be used, whole genomic analytic techniques
like FISH will likely play a major role in the evaluation of patients in the future
to determine optimal personalized treatment, but FISH is exspensive and IPI
score is not good enough to recognize double-hit.
PB1710
EFFICACY OF GEMCITABINE AS SALVAGE THERAPY FOR RELAPSED/
REFRACTORY AGGRESSIVE NON HODGKIN LYMPHOMA PATIENTS
M Zlotnick1, A Avigdor2, E Ribakovsky2, A Nagler2, M Kedmi2,*
1Department of Medicine E, 2Division of Hematology and Bone Marrow Trans-
plantation, Chaim Sheba Medical Center, Ramat Gan, Israel
Background: High-dose therapy with stem-cell support (ASCT) is the standard
treatment for relapsed non-hodgkin lymphoma (NHL), but is not feasible for
elderly or frail patients. Gemcitabine-based salvage regimens were previously
shown to be an effective treatment option with response rates as high as 80%
accompanied by a relatively benign toxicity profile. Our local policy is to use
these regimens either for frail patients that are not eligible for ASCT, or for
relapse post ASCT.
Aims: Since we had the clinical impression that our success rates are lower
than the reported, we decided to retrospectively analyze the outcome of NHL
patients that were treated with gemcitabine-based regimens in our institute.
Methods: Based on local pharmacy query we annotated 35 patients that were
treated with gemcitabine-based regimens between 1/2007-1/2015 for
relapsed/refractory aggressive NHL. Clinical features and outcomes were eval-
uated using thorough medical record review. Statistical analysis was done
using Chi square test and Kaplan-Meier method.
Results: The study cohort included 23 males and 12 females. Median age was
67.2 (28-83). Median follow-up from gemcitabine initiation was 8.7 months (0.4-
48.7). The most frequently used protocol was gemcitabine-oxaliplatinum (77%,
n=27). Eighty percent of patients (n=28) received full dose while 20% (n=7)
received reduced dose regimens. Twenty-seven patients had B cell and 8 had T
cell lymphoma. All patients received a median of 2 prior regimens (1-5), of which
at least 1 was anthracycline-based therapy. Seventeen patients (49%) had
relapsed while 18 (51%) had refractory disease. Overall response rate (ORR)
was 37%, with 29% (n=10) CR, 8% (n=3) PR, and 63% (n=22) PD or SD. Of the
13 responders, 8 patients (61%) experienced relapse or progression during follow
up. Median PFS was 61 days (range 12-1318), median OS was 23.7 months
(0.4-48.7). Sixteen patients (45%) deceased during follow up. Grade 3-4 hema-
tological-toxicity was reported in 17 patients (49%). Hospitalization due to treat-
ment induced toxicity occurred in 12 patients (34%). Eight due to infections, 2
due to bleeding, 1 due to trauma and 1 due to abdominal pain. Several factors
were tested as predictors of PFS: number of previous treatement regimens, dose
intensity (full vs reduced), cell of origin, length of prior remission and relapsed vs
refractory disease. The only predictor for better PFS was relapsed vs refractory
disease (median 151 vs 41 days p=0.017) (Figure 1).
Figure 1.
Summary/Conclusions: compared to previous published data in relapsed/
refractory aggressive NHL, we observed less favorable outcome along with worse
toxicity. Although ORR was 37%, the median PFS after gemcitabine-based reg-
imens was dismal (61 days). The only predictor for better PFS was relapsed as
oposed to refractoy disease. Notabely, the 4 long term survivors were all treated
in first (n=3) or second relapse (n=1) and received full dose regimen. Our single
institution results are inferior than the published literature. The admnistration of
gemcitabine based therapy as salvage regimen for patients with relasped /refrac-
tory NHL was with limited success. Innovative therapies are urgently in need for
this devastating patient population as well as randomized studies.
PB1711
EFFICACY OF ESHAP REGIMEN IN THE ABSENCE OF AUTOLOGOUS
STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY T-CELL
LYMPHOMA
L Norasetthada*, A Tantiworawit, T Rattanathammethee, S Hantrakool,
C ChaiAdisaksopha, E Rattarittamrong
Division of Hematology, Department of Internal Medicine, Faculty of Medicine,
Chiang Mai University, Chiang Mai, Thailand
Background: After relapse, prognosis of patients with peripheral T-cell lym-
phoma (PTCLs) was poor. Currently, there was no standard salvage regimen
for PTCLs. ESHAP regimen, consisting of etoposide, methylprednisolone, high-
dose Ara-C, and cisplatin, is one of the well accepted regimens for relapsed or
refractory (R/R) lymphoma. However, the efficacy of ESHAP have been exam-
ined in the cohorts of various subtypes of R/R NHL, not specifically described
the outcome in those with PTCLs.
Aims: The purpose of this study was to determine the efficacy and safety of
ESHAP as first salvage regimen, not followed by stem cell transplantation
(SCT), in R/R PTCLs.
Methods: According to institute’s treatment plan, ESHAP was recommended
as first salvage regimen for R/R PTCLs. We retrospectively evaluated the effi-
ciency and safety of ESHAP in patients with PTCLs who progressed after one
prior therapy and did not undergo salvage SCT. Disease status at first
relapse/progression was categorized as early relapse (relapsed within 12
months after the completion of frontline therapy), late relapse (relapsed after
12 months of frontline treatment) and refractory disease (achieving less than
partial response after frontline chemotherapy).
Results: From 2004 to 2014, 33 patients with R/R PTCLs received ESHAP as
first salvage regimen at Chiang Mai University hospital. Overall response rate
was 46% with complete responses (CR) of 39%. Median duration of response
was 18 months with the longest duration of 131 months. Patients with PTCL-
NOS, the most common subtype treated in this cohort (n=18), had ORR of
50% (CR/CRu 44%). None of the patients with HSTL and EATL type II respond-
ed to ESHAP. Reponses were independently influenced by disease status at
first relapse/progression (Odd ratio; OR 2.7, 95%CI: 1.46-5.15) and secondary
IPI (OR 2.12, 95%CI: 1.06-4.29). Median second progression-free (PFS) and
overall survival (OS) were 8.0 and 11.0 months, respectively. Patients having
late relapsed disease after frontline treatment had more favorable OS than
those having early relapsed or refractory disease with a median OS of 21, 17
and 3 months, respectively (P=.001). The corresponding figures for median
second PFS were 16, 8 and 2 months, respectively (P=.001). Patients achieving
CR after ESHAP had significantly better median OS (39, 7 and 5 months,
P<.0001) and second PFS (33, 2 and 2 months, P<.0001) than those achieving
PR or having progressive disease. By multivariate analysis, the only factor
affected OS was the response to ESHAP (HR 4.7, 95%CI 2.2-10.0, P<.0001)
while second PFS was affected by the response to ESHAP (HR 5.9, 95%CI
2.4-14.6, P<.0001) and disease status at relapse/progression (HR 3.4,
95%CI1.2-9.7, P-value=.025). Grade 3-4 neutropenia (45.5%) and thrombo-
cytopenia (33.4%) were common but manageable. Grade I-II transient rising
of serum creatinine was observed in 36.4% of patients.
Summary/Conclusions: ESHAP has acceptable efficacy and toxicity for R/R
PTCLs. It offers a long-term survival in patients with chemosensitive relapse
who are not suitable for SCT.
PB1712
PRALATREXATE IN COMBINATION WITH BORTEZOMIB FOR RELAPSED
OR REFRACTORY PERIPHERAL T CELL LYMPHOMA IN ELDERLY
PATIENTS: A PILOT TRIAL
SS Lee*, SH Jung, JS Ahn, YK Kim, JJ Lee, HJ Kim, DH Yang
Department of Hematology and Oncology, Chonnam National University Hwa-
sun Hospital, Hwasun, Korea, Republic Of
Background: Peripheral T cell lymphoma (PTCL) is a heterogeneous group
of aggressive lymphoma with poor prognosis and there is no efficacious stan-
dard regimen for the relapsed or refractory disease. Particularly, elderly patients
generally have impaired bone marrow function, altered drug metabolism,
comorbidities, and poor functional status. Therefore, the treatment of elderly
patients with relapsed or refractory PTCL remains a challenge for clinicians.
Aims: A recent report demonstrated that the combination of pralatrexate and
bortezomib enhanced efficacy compared with that of either agent alone in vitro
and in vivo models of T cell malignancy. Hence, we performed a pilot study
that evaluated the response rate, duration of response and safety profile of
this combination regimen in elderly patients with relapsed or refractory PTCL.
Methods: Five elderly patients (age ≥65 years) with relapsed or refractory
PTCLs, who progressed following one or more prior chemotherapy, were inves-
tigated. The histological subtypes were consisted of 2 PTCL-NOS, 2 AITL, and
1 NK/T cell. Two patients were previously treated with methotrexate-containing
chemotherapy. Pralatrexate (15 mg/m2) and bortezomib (1.3mg/m2) were
administered intravenously on day 1, 8 and 15 and repeated every 28 days for
4 cycles. Concomitant medications were included that vitamin B12 (1 mg) was
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injected within 14 days before pralatrexate infusion and oral 45mg of leucovorin
was taken during entire days of chemotherapy. The interim and final response
were assessed according to the revised International Workshop Criteria (IWC).
Results: All 5 patients are men with median age of 71 years (range: 67 – 74).
The number of prior systemic therapies ranges 1 to 5. Of 5 patients, two achieved
partial response (PR) after 2 cycles and one achieved complete response (CR)
after 4 cycles which have lasted 8 months until now. Another patient with interim
PR progressed after 3 cycles. Two responders had no history of prior methotrex-
ate-containing treatment and histologically all PTCL-NOS. Three other patients
progressed after one or 2 cycles. The most common adverse events were mucosi-
tis and anorexia. Four patients complained of mucositis, but only 1 week delay
of treatment was required for grade 3 mucositis in one patient. Generally most
patients tolerated combination therapy. All patients were treated with planned
pralatrexate without dose reduction or discontinuation due to toxicity. Only one
dose of bortezomib was omitted due to peripheral neuropathy among all patients
and one episode of herpes zoster occurred. None of the patients postponed treat-
ment due to hematologic adverse events.
Summary/Conclusions: Combination therapy with pralatrexate and borte-
zomib could be used effectively and safely as a salvage therapy for relapsed
or refractory PTCL in elderly patients. Larger studies are needed for evaluating
benefit of combination therapy over single pralatrexate therapy.
PB1713
TREATMENT OUTCOME OF DIFFUSE LARGE B CELL LYMPHOMA IN
RITUXIMAB ERA AND THE PROGNOSTIC VALUE OF R-IPI SCORE AT A
CANCER CENTER IN TAIWAN: SINGLE INSTITUTION EXPERIENCE
MT Sung*, WH Wu, LW Chiou, AC Feng, MC Wu, PY Chen, WH Liu, HH Cheng,
TD Tan
Multidisciplinary Teams of Lymphoma & Leukemia, Koo Foundation Sun Yat-
Sen Cancer Center, Taipei City, Taiwan, ROC
Background: The treatment outcome of diffuse large B cell lymphoma showed
major improvement in rituximab era. The predictor of outcome is still under
investigation.
Aims: To review and analyze the treatment experience of newly diagnosed dif-
fuse large B cell lymphoma in rituximab era in our institution.
Methods: We retrospectively reviewed medical records from Jan 2005 to Dec
2014 from our institution. We figured out patients with newly diagnosed diffuse
large B cell lymphoma. Clinical characteristics, treatment response, treatment
modality, and survival were analyzed.
Figure 1. 2005-2014 overall survival of DLBCL by R_IPI.
Results: From Jan 2005 to Dec 2014, there were 292 newly diagnosed diffuse
large B cell lymphoma in our institution. Median age was 57 years old. 50.7% of
patients had advanced stage (stage III&IV), and 7.9% had poor performance sta-
tus(ECOG2-4). According to revised International Prognostic Index score(R-IPI
score), 21.6% had very good prognosis (score 0), 47.2% had good prognosis
(score 1 or 2), and 31.2% had poor prognosis(score 3,4 or 5). According to primary
site,62.3% had lymphadenopathy, 8.2% had mediastinum disease, 16.1% had
gastrointestinal disease. Ki67 was available in 59.9% of patients. According to
cell origin, germinal center B-cell-like(GCB) was 11.7% and non-GCB was
9.9%.78.4% of patients did not perform the test. HBsAg was positive in 25.3% of
patients. 81.3% of patients were treated with RCHOP-like regimen. Complete
remission(CR) was achieved in 79.4% of patients. 3-year event free survival(EFS)
and overall survival(OS) were 70% and 75.3%, respectively. 5-year event free
survival(EFS) and overall survival(OS) were 64.9% and 70%, respectively. The
5-year OS was 92.7%,77.5%,66%,47.3% in stageI/II/III/IV, respectively(p<0.001).
The 5-year OS was 91.8%, 78.9%,42.8% in R-IPI very good group, good group
and poor group, respectively(p<0.001). CR, treated with R-CHOP-like regimen,
R-IPI score predicted the outcome of the patient. Primary site, Ki67, GCB were
not associated with outcome in our cohort. Though Taiwan is in HBV endemic
area, HsAg was not associated with outcome in our cohort (Figure 1).
Summary/Conclusions: Diffuse large B cell lymphoma has good prognosis
for majority of patients in rituximab era. R-IPI score has significant prognostic
value in Asian population. However, for patients with higher stage and higher
IPI score, further investigation to improve outcome is still required.
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TREATMENT PECULIARITIES OF NON-HODGKIN’S LYMPHOMAS IN
CHILDREN WITH NIJMEGEN BREAKAGE SYNDROME
K Olena1,*, TV Irina2, S Olga3, L Volodimir3
1hematology, Western Ukrainian Specialized Children’s Medical Centre, Insti-
tute of Blood Pathology and Transfusion Medicine, 2hematology, Western
Ukrainian Specialized Children’s Medical Centre, 3Institute of Blood Pathology
and Transfusion Medicine, Lviv, Ukraine
Background: Nijmegen breakage syndrome (NBS) is rare autosomal recessive
disorder, typically characterized by increased chromosome fragility phenome-
non, immune deficiency, hypersensitivity to radiation and high predisposition
to malignancy.
Aims: To investigate the effectiveness of cytostatic treatment of non-Hodgkin
lymphomas (NHL) in children with NBS.
Methods: 1992 through 2014 one hundred children in the Hematology Depart-
ment of Lviv Children hospital were first diagnosed with, 9 (9%) out them with
NBS. The median age of this children group was 8 years and 8 months (from
4 years 4 months to 14 years 11 months old). Male to female ratio was 3:2. The
diagnosis of NBS was based on specific phenotype features, results of clinical,
genetic (657del5 NBN gene mutation) and laboratory investigations. The diag-
nosis of NHL was based on clinical symptoms, morphological and immunolog-
ical analysis of tumor substrate. Patients received treatment according to BFM-
group protocols (NHL-BFM-90/95, NHL-DGLLU-2000).
Results: The NHL types were established as follows: lymphoblastic lymphoma
(LBL) in 3 patients, diffuse large B-cell lymphoma (DLBCL) in 6 patients. In most
cases the primary manifestations were nodal: peripheral lymph nodes - in 9
patients, mediastinal – in 7, abdominal lymph nodes - in 3, and spleen – in 7 chil-
dren. Involved extranodal sites included liver (6 patients), lung and pleura (5), skull
bones (2), kidney (1), CNS (1). Atypical cells (L1/L2 and L3-type lymphoblasts
according to FAB-classification) in the bone marrow were found in 2 patients with
LBL, 1 – with DLBCL. Cytostatic treatment was initiated in 8 patients. One patient
was in the terminal state and died before the specific treatment. Three patients
died upon the completion of first chemotherapy cycles, due to serious infectious
complications (pneumonia, pneumothorax, enteropathy, necrotic stomatitis, palatal
fistula). In a 4 year old boy with DLBCL, after 2 cycles, the tumor didn’t go into
regression. The salvage therapy (ICE+rituximab) was not effective; the child died
of lymphoma progression. In 4 patients the cytostatic treatment was successful.
Three children with LBL received a full course of protocol treatment without reduc-
ing the doses of cytostatic and are in remission at present (duration of remission
in months – 215, 39, 30). In one girl with DLBCL the treatment was discontinued
after the 5th cycle (AA N2) of NHL-DGLLU-2000 protocol, because of coccyx area
soft tissue necrosis, thus the last BB cycle was not conducted. After 11 years of
remission in this patient a secondary tumor (meningioma) was diagnosed, her
treatment with the CyberKnife radiosurgery was effective.
Summary/Conclusions: The complexity of the clinical course of NHL in NBS
patients was preconditioned by the presence of concomitant infections on the
background of combined immunodeficiency, which caused death of 4 patients
at the beginning of the treatment. One patient died from lymphoma progression.
Specific NHL treatment in NBS patients is possible and effective, given the
individual correction of doses and schedules of applied cytostatic agents, and
if adequate supportive therapy is provided concomitantly. Nonetheless, after
successful NHL treatment in children with NBS, the risks of secondary tumor




VARIATION IN R-CHOP REGIMENS FOR PATIENTS WITH STAGE II-IV
DIFFUSE LARGE B-CELL LYMPHOMA IN THE NETHERLANDS
M Brink1,*, DE Issa2, AG Dinmohamed1,3,4, ME Chamuleau5, O Visser1
1Department of Research, Netherlands Comprehensive Cancer Organisation,
Utrecht, 2Department of Hematology, Jeroen Bosch Hospital, ‘s Hertogenbosch,
3Department of Hematology, Erasmus MC Cancer Institute, 4Department of
Public Health, Erasmus University Medical Center, Rotterdam, 5Department of
Hematology, VU Medical Center, Amsterdam, Netherlands
Background: The 2014 Dutch national clinical practice guideline for diffuse
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large B-cell lymphoma (DLBCL) recommends 8x R-CHOP21 or 6x R-CHOP14
followed by 2 additional cycles of rituximab (2R) as first line therapy for stage
II-IV DLBCL patients with an age-adjusted International Prognostic Index
(aaIPI) of 1-3. However, international guidelines tend to promote 6x R-CHOP21
as the preferred first line treatment.
Aims: The aim of this population-based study was to evaluate which treatment
regimens were applied in the Netherlands.
Methods: We selected 840 patients diagnosed in 2014 with stage II-IV DLBCL
and aaIPI 1-3 (median [range] age 69 years [18-99]; 55% male) from the nation-
wide population-based Netherlands Cancer Registry. All patients were treated
outside clinical trials. In this study, first line treatment was defined as 6x or 8x
R-CHOP14/21, and, in case of 6x R-CHOP14/21, with or without 2R. Overall
response rate (ORR) was defined as achieving complete or partial response,
i.e. CR(u) or PR. Data were analyzed for the total cohort, as well as stratified
by age and treatment regimen.
Results: Treatment with R-CHOP14/21 was initiated in 651 (78%) patients,
while 103 (12%) patients received other (chemo)therapeutic regimens. The
remaining 86 (10%) patients received no therapy. Of those who received R-
CHOP14/21, 508 (78%) completed 6x or 8x, 122 (19%) received less than 6x,
and 21 (3%) received 7x. Of the patients who completed treatment (6x+/- 2R or
8x), 6x R-CHOP21, 6x R-CHOP21+2R and 8x R-CHOP21 regimens were pro-
vided in 21%, 20% and 45% of patients, while 6x R-CHOP14, 6x R-CHOP14+2R
and 8x R-CHOP14 in 3%, 3% and 8% of patients, respectively. Of note, 8x R-
CHOP14/21 was most commonly applied (53%; N=269). Patients aged <65
years (N=233) more often received 8x (82%), whereas patients aged ≥65 years
more often received 6x (72%). As for patients aged 65-74 years (N=160), 39
(24%) patients received 6x R-CHOP21, 49 (31%) 6x R-CHOP21+2R and 55
(34%) 8x R-CHOP21. Only 17 (11%) patients received 6x R-CHOP14+/- 2R or
8x R-CHOP14. For patients aged ≥75 years (N=115), all but one received R-
CHOP21 regimens, of which 43% received 6x, 39% 6x with 2R and 17% 8x.
The ORR was 88% (448/508) for patients who completed treatment. Further,
the ORR was 87% for 8x R-CHOP21, 83% for 6x R-CHOP21 and 94% for 6x
R-CHOP14+2R and this was irrespective of age group.
Summary/Conclusions: Our results show that treatment with R-CHOP was
initiated in 78% of patients with stage II-IV DLBCL and an aaIPI of 1-3. Three-
weekly regimens were applied to 85% of patients who completed treatment.
Although based on modest patient numbers, the ORR for 6x R-CHOP21, which
is the internationally preferred R-CHOP regimen, was 83%. That value com-
pares somewhat lower to the ORRs in the 8x R-CHOP21 and 6x R-
CHOP14+2R groups, i.e. 87% and 94%, respectively. Collectively, these pop-
ulation-based analyses demonstrate that there is variation in the provision of
R-CHOP regimens in daily practice, which could be related to the ongoing
debate among clinicians in the Netherlands whether 6x or 8x R-CHOP21 should
be the standard of care as first line therapy for stage II-IV DLBCL patients with
an aaIPI of 1-3.
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DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS FOR PRIMARY
MEDIASTINAL LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY
ON 86 PREVIOUSLY UNTREATED PATIENTS
I Ilyasova*, M Kichigina, E Medvedovskaya, O Trofimova, E Osmanov,
G Tumyan, N Falaleeva, P Zeynalova
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
Background: Primary mediastinal large B-cell lymphoma (PMBCL) arising
from thymic medulla B cell, occurring more often in young females and char-
acterized by a locally invasive anterior mediastinal bulky mass that often causes
cough, dyspnea and a superior vena cava syndrome. Previous retrospective
studies have suggested that it may respond better to more intensive chemother-
apy regimens than to standard CHOP. The prognostic role of PET/CT scan
and the feasibility of consolidation with radiotherapy (RT) on residual mediasti-
nal mass still remain unclear.
Aims: To assess the impact of different immunochemotherapy regimens on
survival outcomes in newly diagnosed patients with PMBCL.
Methods: We identified 86 pts with PMBCL treated in N.N. Blokhin Russian
Cancer Research Center during last 10 years (2004-2014). The median age
was 29 years (15-63), 56% were female, 62% had I/IIE stages, LDH elevated
in 81% pts. Patients received three different regimens chemotherapy (CT):
MACOP-B+R- 52 pts (group 1), R-CHOP -18 pts (group 2), R-EPOCH - 16 pts
(group 3). After completion of CT, PET/CT scan was performed on 56 of 86 pts
and in 20 of 56 (36%) it was abnormal. Radiation therapy to the mediastinum
received 69 pts (80%).
Results: With a median follow 34 months, progression-free survival (PFS) was
80%, overall survival (OS) - 86%. There is no significant differences in PFS
and OS depending on the CT regimens (p=0.1). It should be noted that none
of the 16 patients treated on EPOCH-R, had relapse or disease progression.
4-year PFS was 91% in patients who were PET negative before RT regardless
of the CH regimens,
Summary/Conclusions: Immunochemotherapy combined with local irradiation
remains the standard treatment for PMBCL. Perhaps, more number of patients
will be able to demonstrate significant benefit one chemotherapy regimens
over the other and define the role of consolidation RT in patients with PET-
negative mediastinal mass after standard chemoimmunotherapy.
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TREATMENT OF HIGH RISK AGGRESSIVE B CELL LYMPHOMAS WITH
DA EPOCH R– A RETROSPECTIVE ANALYSIS
M Panny1, K Troppan2, P Neumeister2, T Nösslinger1, K Holzer1, H Greinix2,
F Keil1,*
1Department of Hematology and Oncology, Hanusch Hospital, Vienna, 2Depart-
ment of Hematology, Medical University of Graz, Graz, Austria
Background: Promising results in patients suffering from high risk DLBCL,
Burkitt`s lymphoma (BL), gray-zone lymphoma (GZL) and primary mediastinal
B cell lymphoma (PMBCL) treated with DA-EPOCH R have been reported.
Aims: To evaluate retrospective toxicity and efficacy in DA EPOCH R treated
patients.
Methods: In our centres high risk DLBCL - defined as double-hit/double hit
score 2 or high/ high-intermediate risk NCCN IPI - BL, MGZL and PMCL are
treated with DA EPOCH R. Retrospective analysis of toxicity and efficacy in
DA EPOCH R treated patients.
Results: So far 39 previously untreated patients with a median age of 54a
(28a – 76a) have been treated with a total of 190 cycles of DA EPOCH R: 16
DLBCL, 9 GZL, 8 PMBCL, 6 BL. 37 Patients have finished treatment, 2 are
stilll on treatment. Targeted ANC <500/l occurred in 46%, thrombocytopenia
<25.000/l in 20% and anemia <8g/dl in 12,5% of all cycles. Dose escalation
was possible in 27 (73%) patients – but only in 5 (38%) of 13 patients >65a.
15 (63%) of 24 patients aged <65a received at least dose level 3 (144%
increased dose of Etoposide, Doxorubicin, Cyclophosphamide). Due to periph-
eral sensory neuropathy, Vincristine had to be dose reduced in 52% of all
cycles. Other CTCAE grade III/IV non-hematopoietic toxicities were infrequent
and manageable. After a median follow up of 10 month (range: 1-25) overall
survival (OS) rate is 74%. 2 patients in PR were (1 PMBCL, 1 GZL) bridged to
allogenic stem cell transplantation, 1 patient in CR had to be switched to a less
toxic regimen due to repeated febrile neutropenia after 3 cycles of. In 18 high
risk DLBCL patients (8 DHS2/DHL, 8 high/high intermediate NCCN IPI) OS is
80% after a median follow up of 12 month. From 8 (4GZL, 2 DLBCL, 1 BL, 1
PMBCL) relapsed/ refractory patients 7 died. Causes of death were: 2 infectious
complications (1 DLBCL HIV associated, 1 GZL) and 5 progressive disease
Summary/Conclusions: Although still preliminary data DA EPOCH R seems to
be a feasible treatment with acceptable toxicity and a promising response rate.
Dose escalation is age dependent. Especially in patients with high risk DLBCL
DA EPOCH R is an alternative to insufficient induction therapy with R CHOP.
PB1719
SINGLE-HIT LYMPHOMA PATIENTS HAD MORE PRONOUNCED BENEFIT
FROM DOSE-INTENSIFIED CHEMOTHERAPY THAN DOUBLE-HIT
LYMPHOMA PATIENTS. SINGLE-CENTER EXPERIENCE.
A Misyurina1,2,*, E Baryakh3, S Kravchenko1, A Kovrigina1, T Obukhova1,
V Misyurin4, J Mangasarova1, L Plastinina1, E Nesterova1, A Magomedova1,
E Penskaya1, A Vorobiev1
1National Research Center for Hematology, 2”GeneTechnology” LLC, 3City
Clinical Hospital № 52, 4N.N. Blokhin Russian Cancer Research Center,
Moscow, Russian Federation
Background: B-cell lymphomas with c-MYC rearrangement are characterized
by aggressive clinical behavior and poor prognosis when R-CHOP-21 is used.
An efficacy of intensified chemotherapeutic regimens continues to be debatable.
Aims: To represent treatment results of MYC+agressive B-cell lymphomas
with dose-intensified chemotherapy.
Methods: Since 2007 till 2015 years in National Research Center for Hama-
tology 23 cases of c-MYC rearranged non-Burkitt B-cell lymphomas (5 DLBCL
and 18 BCLU intermediate between DLBCL and BL) were diagnosed. Ratio
between men and women was 9:14. Median age was 51 years old (30-70).
ECOG ≥2 was in 18 (78%) cases; 19 (83%) of pts had III-IV stage according
Ann-Arbor classification; 17 (74%) had more than one extranodal site: 7 (30%)
- bone marrow involvement, 2 (9%) - CNS; 18 (78%) pts had IPI 3-5. In 15
cases c-MYC translocation partner was locus of IGH gene, in 4 cases – locus
of IGL or IGK gene, in 4 cases – undefined. In 8 cases with available karyotype
were revealed complex abnormalities. MYC+/BCL2+double-hit lymphoma
(DHL) was in 6 cases, MYC+/BCL6+DHL was in 3 pts, others 14 pts had sin-
gle-hit lymphoma (SHL). In all cases dose-intensified treatment strategy was
initially chosen: in 4 cases - R-DA-EPOCH and in 19 cases – protocol BL-M-
04 consisted of A-C-A-C 4-6 courses (Course A: dexa 10 mg/m2 1-5 days; Mtx
1500 mg/m2 1st day12-hours infusion; ifosfamide 800 mg/m2 1-5 days; vin-
cristine 1 mg/m2 1st day; doxorubicine 50 mg/m23rd day; AraC 150 mg/m2 4-5
days bid; etoposide 100 mg/m2 4-5 days, iv. Course C: dexa 10 mg/m2, 1-5
days; Mtx 1500 mg/m21st day12-hours infusion; vinblastine 5 mg/m2 1st day;
AraC 2000 mg/m22-3 days bid; etoposide 150 mg/m23-5 days, iv. AraC 30 mg,
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Mtx 15 mg, dexa 4 mg 1st day of each course, intrathecally). Rituximab was
indicated in 12/19 cases. AutoSCT was performed in 5 cases. Kaplan-Meier
method and log-rank test were used to estimate treatment results (SAS 9.3).
Results: 9/23 (39%) pts had a complete remission, 6/23 (26%) pts had a partial
remission, 7/23 (30%) pts had disease progression (in one case after autoSCT),
one pt (4%) died from infectious. In one case (4%) of DLBCL early relapse had
occurred. 2-year overall survival (OS) and event-free survival (EFS) were 51%
(median - 9,0 months (0,6-89,1)) and 40% (median 7,3 months (0,1-89,1)),
respectively. DHL pts had worse treatment results compared with SHL pts: 2-
year OS was 30% (median – 8,2 months (0,6-54,1)) vs 64% (18,6 months (1,1-
89,1)) in DHL vs SHL groups, respectively (p=0,06) (Figure 1). 2-year EFS was
13% (median – 3,5 months (0,3-21,4)) vs 56% (median 17,4 months (0,1-89,1))
in DHL vs SHL groups, respectively (p=0,03) (Figure 1).
Figure 1.
Summary/Conclusions: Single-hit lymphoma patients have more pronounced
benefit from dose intensification compared with miserly results in double-hit
lymphoma patients.
PB1720
DICEP IS AN EFFECTIVE CHEMOTHERAPEUTIC REGIMEN FOR PATIENTS
WITH RELAPSED OR REFRACTORY LYMPHOMAS WHO FAILED PRIOR
SALVAGE CHEMOTHERAPIES
A Al Garni*, P Kaloyannidis, N Al Mulhem, M Ali, A Al Bahrani, A Al Sagheir,
K Al Anazi, H Al Hashmi
Adult Hematology and SCT, King Fahad Specialist Hospital, Dammam, Saudi
Arabia
Background: The outcome of patients (pts) with relapsed or refractory Hodgkin’s
(HL) and Non Hodgkin lymphomas (NHL) post failure of response to 1st salvage
treatment tends to be very poor even after autologous stem cell transplantation
(ASCT). Though several 2nd line salvage regimens have been used, the optimal
treatment still remains an issue of clinical investigation and there is an unmet
need for salvage chemotherapies, sufficiently strong to reduce the tumor burden
with acceptable toxicities to allow safe yet successful ASCT.
Aims: We herein evaluated the DICEP regimen [Dose Intesified
Cyclophoshamide (1,750 gr/m2), Etoposide (350 mg/m2) and Cisplatin (35
mg/m2), days 1-3] in terms of safety and efficacy regarding disease response
and stem cell mobilization and collection.
Methods: We retrospectively analyzed the data of 21 (10 HL, 11 NHL) pts with
a median age of 26 (16-60) yrs who had refractory or relapsed disease after
ABVD or R-CHOP regimens (6-8 cycles) and received as 1st line salvage
chemotherapy at least 2 cycles of ESHAP (13 pts), ICE (3 pts), ESHAP+ICE
(2 pts) and other regimens (3 pts). Two out of 21 achieved complete remission
(CR) post 1st salvage, 17 partial remission (>50% response, PR) while 2 had
stable or progressive disease. A single cycle of DICEP was administered either
as mobilization chemotherapy (in 2 pts with CR), or as 2nd salvage treatment
for patients with PR, stable or progressive disease.
Results: DICEP was well tolerated and no lethal or major organ toxicities were
observed. Nevertheless, all patients experienced hematological toxicity (gr 3-
4 WHO) and 18/21 developed febrlile neutropenia (3/18 experienced sep-
ticemia), however that completely resolved with the appropriate antibiotic ther-
apy not requiring admission to intensive care unit. The hospitalization period
was 20 (11-25) days. All patients were successfully mobilized and a medium of
7,9 (2,8 -33,5)x106/kg CD34+cells were collected after a median of 1 (1-3) days
of apheresis procedure. Post DICEP administration, a further overall disease
improvement of 42% was observed (6 additional CRs and 2 PRs), whilst in 1
pt the disease proved to be refractory. Finally 20/21 pts underwent ASCT. The
3,5yrs overall survival (OS) and progression free survival (PFS) from DICEP
administration were 50% for the whole cohort of patients. Specifically, for HD
pts the 2 yrs OS and PFS were estimated to be 75% and 65% respectively,
while for NHL the 3,5 yrs OS and PFS were 45% and 50% respectively.
Summary/Conclusions: Taking into account the limitations of the retrospective
nature of the present study, it seems that DICEP regimen is a sufficient salvage
treatment demonstrating acceptable toxicity without negatively affecting the
collection process. The promising overall response rates post DICEP in com-
bination with the encouraging OS and PFS rates achieved post ASCT in that
heavily pretreated group of patients, strongly support the rationale to use DICEP
regimen not only as a “bridge” to a successful ASCT but also as 1st line salvage
regimen in selected pts.
PB1721
THE COMPARISON OF THE PROGNOSIS SCORING SYSTEMS BETWEEN
EVENT-FREE SURVIVAL AT FIRST 24 MONTHS AND OVERALL SURVIVAL
IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
M Maden1,*, M Demir1, A Gokyer2, V Bas2, K Sacar Kubuc2
1Trakya University, Hematology Department, 2Trakya University, Internal Med-
icine Department, Edirne, Turkey
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
subtype of non-Hodgkin lymphoma (NHL). R-CHOP (Rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisone) is curative in the majority of DLB-
CL patients. However, about one-third of patients will have refractory disease
or relapse following the therapy. Therefore, risk stratification at diagnosis for
patients with DLBCL is of great clinical interest. Recently, it is shown that event-
free survival (EFS) at first 24 months from the time of diagnosis in patients who
received rituximab-based chemotherapy onwards the similar survival rates with
healthy patients in their own age group and gender. Recently, the scoring sys-
tem for prognosis called IPI24 is effective to predict the first 24-month EFS
(EFS24) in DLBCL patients.
Aims: In this study, we aimed to compare the risk stratification anticipated by
IPI24, IPI and NCCN-IPI for patients treated with RCHOP in the first EFS24 and
overall survival in Trakya University Medical Faculty Hematology department
and identify the prognosis scoring system which makes best risk stratification.
Table 1.
Methods: Clinical and laboratory data of 284 patients who have been diagnosed
with NHL in our center since 2004 were retrospectively analyzed. The patients
who were under the age of 50 and over the age of 85 and also receiving
chemotherapy except for R-CHOP, apart from DLBCL were subtracted from the
study and 103 patients (57 M, 46 F) were enrolled in the study. Clinical and lab-
oratory data of the patients were obtained by scanning files. According to IPI
and NCCN-IPI, patients were analyzed depending on 4 risk groups (low, low-
intermediate, high-intermediate, high) which are created on using age, LDH,
ECOG score, extranodal organ involvement and Ann Arbor stage. But the risk
of events on the first 24 months calculated by IPI24 were calculated with the QX
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calculator using age, sex, absolute lymphocyte count, bulky lymph node masses
(>10cm), LDH, ECOG score and Ann Arbor stage. Data were analyzed with
SPSS statistical software. Whether the prognostic scores were independent
indicators or not in terms of survival and event-free survival was examined using
Cox regression analysis. P<0.05 was considered significantly.
Results: The mean age of 103 patients in our study was 60±9 years and in%48
of them had extranodal disease,%64 of the patients had advanced dis-
ease,%24 of the patients had solid disease. In%37 of the patients ECOG score
was ≥2.%38 of the cases were dead. NCCN-IPI was the most successful prog-
nostic model to predict EFS24 in the patients (p<0.001). While IPI24 was sta-
tistically significant to predict EFS24 (p=0.03), IPI was not sufficient (p=0.13)
(Table 1A). While the best prognostic model was NCCN-IPI to predict the overall
survival in 24 months (p<0.001), IPI and IPI24 were insufficient (with order
p=0.08, p=0.7) (Table 1B). To predict the overall EFS and overall survival in
the patients, the best prognostic model was NCCN-IPI (p<0.001), but IPI and
IPI24 were insufficient (p>0.05) (with order Table 1C-D).
Summary/Conclusions: In DLBCL patients before treatment, while NCCN-
IPI was superior to IPI 24 as a prognostic scoring system to predict EFS24, IPI
was insufficient. Similarly to predict overall survival, NCCN-IPI was the best
prognostic model. Due to the mean age of our patients was high and the num-
ber of the patients was not enough IPI24 could be insufficient when compared
to NCCN-IPI to predict EFS24 and overall survival. It would be useful to do
more studies to show the effectiveness of IPI24 for determining the risk factors
before the treatment on DLBCL patients.
PB1722
EFFICACY OF SPLENECTOMY IN DIFFUSE LARGE CELL LYMPHOMA
Y Yevstakhevych1,*, J Vygovska2, I Yevstakhevych1, M Semerak1, V Loginskiy3
1Surgery and Transfusion Medicine, 2Heamatology, 3SI “Institute of Blood
Pathology and Transfusion Medicine NAMS of Ukraine”, L’viv, Ukraine
Background: Diffuse large cell lymphomas (DLCL) are often associated with
splenomegaly. Large-size spleen causes both abdominal discomfort, cytopenia,
regional portal hypertension and a decreased efficacy of chemotherapy. This
is why splenectomy is indicated in such cases.
Aims: To retrospectively analyze the efficacy of splenectomy in patients with dif-
fuse large B-cell lymphoma (DLBCL) and diffuse large Т-cell lymphoma (DLТCL).
Methods: 43 patients with DLBCL and two patients with DLТCL underwent
splenectomy.
Results: Splenectomy was performed in 25 male and 18 female patients aged
25-76 years with DLBCL. Indications for splenectomy included splenomegaly
(in all patients), hyperslenism (anemia, leukopenia, thrombocytopenia) – in 25
patients (58.1%), regional portal hypertension – in 20 (46.5%) patients; inefficacy
of chemotherapy – in 18 (41.9%) patients, and concomitant autoimmune
hemolytic anemia (warm type) – in two patients. Splenectomy proved effective
in 40 (93%) patients with DLBCL: abdominal syndrome, anemia and leukopenia
were reverted, hemolysis in AIHA relieved, and the platelet count was normalized
in patients with concomitant thrombocytopenia. The following complications
were observed postoperatively: bilateral pneumonia (1 patient), chronic adrenal
insufficiency (3 patients), acute thrombophlebitis of superficial veins of the right
leg (1 patient), acute pancreatitis (4 patients), and thrombosis of residual limb
of the splenic vein (3 patients). One patient died immediately following splenec-
tomy. This lethal outcome was caused by acute cardiovascular insufficiency,
which developed within 4 days after operation. Splenectomy did not prove effec-
tive in patients with DLBCL. The surgery did not result in normalization of con-
comitant cytopenia in one female patient who died within 1 month after splenec-
tomy due to both progression of illness and chronic adrenal insufficiency. Another
female patient achieved a short-term recovery following surgery (hemoglobin
level as well as leukocyte and platelet count normalized) but she developed a
cytopenia after 30 days and passed away due to a rapid deterioration of illness
and multi-organ insufficiency. As shown by a retrospective analysis of long-term
results of splenectomy in patients with DLBCL, the overall survival post splenec-
tomy reached 63.9 months, and the mean treatment-free survival reached 36.8
months. 11 patients did not require administration of chemotherapy following
splenectomy at all. 17 patients with DLBCL (39.5%) developed a relapse of ill-
ness at different timepoints after surgery. Splenectomy was performed in two
patients with DLТCL. In both cases, surgical treatment proved ineffective, and
the patients died within 1 month following intervention due to a relapse of cytope-
nia, rapid deterioration of illness and multi-organ insufficiency.
Summary/Conclusions: Splenectomy remains to be an effective treatment
option in non-Hodgkin lymphomas. In DLBCL, the surgery helps relieve both
abdominal discomfort and hypersplenism; symptoms of regional portal hyper-
tension alleviate; there is less or no need in administration of chemotherapy;
and there is no more hemolysis in concomitant AIHA. In DLТCL, splenectomy
is ineffective and should be thus avoided.
PB1723
DONOR-TRANSMITTED TRIPLE-HIT LYMPHOMA IN A RENAL ALLOGRAFT
RECIPIENT
L Biavati1,*, E Orciuolo2, S Galimberti3, MI Ferreri4, F Basolo5, G Buda6,
F Caracciolo2, E Ciabatti3, S Grassi3, U Boggi7, M Petrini3
1Scuola Superiore Sant’Anna, 2Hematology Unit, Azienda Ospedaliero-Uni-
versitaria Pisana, 3Clinical & Experimental Medicine, University of Pisa, 4Lab-
oratory of Cytogenetics, Azienda Ospedaliero-Universitaria Pisana, 5Unit of
Pathological Anatomy, University of Pisa, 6Hematology Unit, Azienda
Ospedaliero-Universitaria Pisana, 7General & Transplant Surgery, University
of Pisa, Pisa, Italy
Background: Donor cancer transmission is a rare long-term complication of
kidney transplantation that carries an estimated risk of approximately 0.05%.
Diagnosis and management of these malignancies are difficult because of their
rarity and the need for an individualized approach to treatment. CM is a 30-
years-old man with a medical history significant for chronic kidney disease who
underwent kidney transplantation in May 2015 with his mother as the donor. In
July 2015, the donor presented with an abdominal mass diagnosed as a triple-
hit lymphoma (THL), a subset of highly aggressive B-cell lymphomas charac-
terized by the overexpression of MYC, BCL2 and BCL6. Initial staging with
PET/CT and bone marrow biopsy showed widespread disease with no marrow
involvement, while circulating tumor DNA (ctDNA) assay confirmed a clonal B-
cell proliferation. Analysis of ctDNA was performed on recipient’s plasma, but
ctDNA levels were undetectable. In September 2015, CM developed a perigraft
mass that was identified as a THL as well. The peculiar clinical presentation
and the histochemical similarities of the two THLs raised the suspicion that the
same lymphoma had been transmitted from the donor to the recipient during
the transplant procedure.
Aims: This case describes donor transmission of THL with kidney transplan-
tation and points out difficulties in diagnosis and management.
Methods: Lymphoma biopsy specimens from both donor and recipient were
obtained and prepared for histological and immunohistochemical (IHC) studies
and stained for the identification of Ki67, CD20, BCL6, BCL2, MYC, CD10,
MUM1/IRF4, CD5, cyclin D1, CD3, EBV-LMP1 and TdT. DNA was extracted
from the biopsies of both donor and recipient THL with standard methods. Sam-
ples were assessed for nine microsatellite loci and a segment of the X-Y homol-
ogous gene amelogenin by PCR with use of a kit for chimerism determination.
Fluorescent in-situ hybridization (FISH) studies were performed on specimen
sections using probes for sex determination. B-cell clonality analyses targeting
the IGH gene for rearrangements were conducted on ctDNA obtained from
plasma of both donor and recipient and from the recipient’s bone marrow.
Results: Histology and IHC showed identical findings in both donor and recip-
ient. In particular, MYC, BCL2 and BCL6 were positive and the proliferative
index was more than 90%. FISH recognized an XX pattern in both samples.
Microchimerism analysis pointed out that the donor and the recipient biopsies
had identical profiles considering discriminant alleles and amelogenin (see
Figure 1). Moreover, the recipient sample profile was significantly different
from his basal allelic profile obtained from peripheral lymphocytes at the time
of the diagnosis. B-cell clonality in the donor sample was detected at the time
of the diagnosis, however ctDNA levels assessed on recipient’s sample were
undetectable. The same clonal band was persistently detected by ctDNA
analysis of the recipient plasma and bone marrow only after September 2015.
Figure 1.
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Summary/Conclusions: We describe the transmission of a highly aggressive
B-cell non-Hodgkin lymphoma by kidney transplantation. The THL was trans-
planted along with the renal graft, while immunosuppressive therapy and
immunological impairment enabled its growth and expansion. The patient went
on to complete the full course of 2 cycles of R CODOXM/IVAC and associated
withdrawal of immunosuppression achieving a complete remission and pre-
serving graft function. The donor underwent the same intensive regimen and
achieved a complete response as well.
PB1724
TREATMENT OF C-MYC/BCL2 DOUBLE EXPRESSER DLBCL WITH
R-CHOP CHEMOIMMUNOTHERAPY: AN AUSTRALIAN SINGLE CENTRE
EXPERIENCE
TF Ng1,2,*, A Whiteside3, H Rose1, D Kipp1, B Tawfik3, P Campbell1,4
1Clinical Haematology, University Hospital Geelong, Geelong, 2Haematology,
Fiona Stanley Hospital, Perth, 3Anatomical Pathology, St John of God Pathol-
ogy, 4School of Medicine, Deakin University, Geelong, Australia
Background: Co-expression of c-myc and BCL2 in Diffuse Large B-cell Lym-
phoma (DLBCL), (increasingly known as ‘double expresser’ DLBCL), is asso-
ciated with inferior outcome with standard-of-care R-CHOP
immunochemotherapy.
Aims: To retrospectively identify patients with ‘double expresser’ immunophe-
notype within our patient cohort of DLBCL, and to analyze their outcomes fol-
lowing treatment.
Methods: Chart review of patients with DLBCL treated with RCHOP chemoim-
munotherapy between 2007 and 2014 at our institution. We retrospectively per-
formed immunohistochemical staining for c-myc and BCL2 on pre-treatment
tumor tissue blocks to identify patients with ‘double expresser’ immunopheno-
type. Other prognostic factors including the revised international prognostic
index (R-IPI) score, initial bulky disease (>7.5cm) and cell of origin were also
recorded and analyzed. Progression-free survival (PFS) were analyzed using
Kaplan–Meier curves and statistically tested with the Gehan-Breslow-Wilcoxon
test. 2-tailed chi-square test was used to compare incidence of various prog-
nostic factors in subgroup analysis.
Results: 89 patients were included in the study. Patients with high risk R-IPI
score, bulky disease, and elevated serum lactate dehydrogenase level (LDH)
showed reduced progression-free survival (p=0.03, p=0.04, p=0.002 respec-
tively). In particular, LDH above 2 times of upper limit of normal (ULN) was
associated with a 56% reduction in PFS. There was no significant difference in
PFS between ‘germinal center’ and ‘non-germinal center’ cell of origin subtypes
of DLBCL. 34 patients were found to have ‘double expresser’ immunopheno-
type. They showed a higher rate of disease progression (32% vs 16%, p=0.03),
than the remaining DLBCL patients, with progression occurring predominantly
within 24 months of treatment. The ‘double expresser’ subgroup also had a
higher incidence of bulky disease (50% vs 13%, p=0.01), and LDH above
2xULN (35% vs 11%, p=0.005), at presentation. All patients with normal LDH
levels and non-bulky disease (n=7) remained in remission at a median follow-
up of 32 months (Figure 1).
Figure 1.
Summary/Conclusions: We present a small single center series of ‘double
expresser’ DLBCL. Patients with the double expresser phenotype had a higher
incidence of bulky disease and markedly elevated LDH level, which was asso-
ciated with higher risk of disease progression. Knowing this, it may be reason-
able to adopt a more intensive treatment approach for these patients. Interest-
ingly, having a normal LDH level at diagnosis and absence of bulky disease
(known good prognostic factors) retained their protective influence even in
patients with ‘double expresser’ phenotype.
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METRONOMIC CHEMOTHERAPY IMPROVES SURVIVAL IN RESPONDING
PATIENTS WITH RECURRENT/REFRACTORY LYMPHOMA
B Sanchez-Gonzalez1,*, MP Ferraro1, F Garcia-Pallarols1, D Lopez-Aventin2,
E Gimeno1, E Torres1, L Martinez-Serra1, A Senin1, F Gallardo2, A Salar1
1Hematology, 2Dermatology, Hospital del Mar, Barcelona, Spain
Background: Metronomic chemotherapy (MC) consists of continuous admin-
istration of oral chemotherapy at low, potentially less toxic doses without pro-
longed drug-free breaks. MC might be a useful for many patients with recurrent
or refractory lymphomas that are unable to tolerate intensive therapies.
Aims: The aim of this study was to retrospectively analyze the efficacy and
toxicity of MC in recurrent or refractory lymphomas in our Institution.
Methods: Retrospective analysis of patients with lymphoma treated with MC
from 2009 to2014 in our Institution. The metronomic scheme consisted of oral
50 mg of prednisone, 50 mg of cyclophosphamide, 50 mg of etoposide, and/or
50 mg of procarbazine evenly distributed throughout the day. Clinical response,
duration of response, progression-free survival (PFS) and overall survival (OS)
was evaluated. Clinical response was defined as improvement of the symptoms
of lymphoma and/or shrinkage of tumours (lymph nodes or affected organs) by
physical examination and/or imaging.
Results: Patient demographics and characteristics: 28 lymphoma patients con-
secutively treated with MC were included. 10 patients had diffuse large B-cell
lymphoma (DLBCL), 6 cutaneous T-cell lymphoma (CTCL), 5 peripheral T-cell
lymphoma (T-NHL), 4 Hodgkin lymphoma (HL), 1 mantle cell lymphoma, 2
other types of non-Hodgkin lymphoma. Median number of prior regimens was
3 (range 1-8). 26 patients (93%) had refractory disease to prior treatment.
Efficacy: Clinical response was observed in 23 patients (82%) with a median
duration of response 6 months (95% CI, 0-11 months). No differences were
found in clinical response rate, duration of response, PFS and OS among the
aggressive or indolent lymphomas. With a median follow-up of 14 months,
median OS was 6 months. Of note, responders to MC showed a significantly
increased OS (median OS of 11 months in responders vs 1 months in non-
responders (p<0.001) (Figure 1). Remarkably, PFS was also significantly higher
in responders, 42% of cases were progression-free at 6 months in responders
vs 0% in non-responders (p<0.001). Twenty patients died: progressive disease
(n=15), infection (n=4) and non-related (n=1). Toxicity: Seventeen patients
(61%) had adverse events grade 3/4, mainly hematologic. A total of 6 patients
had infections grade ≥3: urinary tract infection (n=2), pneumonia (n=2), mul-
tiresistant Pseudomonas aeruginosa bacteremia+Cytomegalovirus infection
(n=1) and Escherichia coli sepsis (n=1). The main cause of treatment discon-
tinuation was progressive disease. Only one gastrointestinal adverse event
grade 4 led to MC discontinuation (3.6%). Dose modifications of MC drugs was
performed in 15 patients (54%) and 12 patients required use of granulocyte
colony stimulating factor (G-CSF). 54% of patients received cotrimoxazole as
primary or secondary prophylaxis.
Figure 1.
Summary/Conclusions: Our study supports the anti-tumor activity of MC in
patients with advanced lymphoma chemo-resistant and relapsed to multiple
therapies with no other therapeutic alternatives. Clinical responses were
observed in all lymphoma subgroups and the toxicity profile was acceptable,
even in heavily pretreated patients. Even most of our cases had been consid-
ered refractory to prior treatment, responding patients to MC had an improved
PFS and even OS.
PB1726
RELATIVE TOTAL DOSE INTENSITY OF TREATMENT WITH R-CHOP IN
OBESE VERSUSNON OBESE LYMPHOMA PATIENTS DOSED ON ACTUAL
BODY WEIGHT: A SINGLE CENTRE EXPERIENCE
A Preston1,*, S Robinson1, P Mehta1, N Duncan2
1Bristol Haematology & Oncology Centre, University Hospitals Bristol NHS
Foundation Trust, Bristol, 2Pharmacy Department, University Hospitals Birm-
ingham, Birmingham, United Kingdom
Background: The number of obese patients in the UK is growing to epidemic
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proportions and due to an aging population the incidence of cancer is also
increasing. To ensure good patient outcomes it is imperative that we optimally
treat obese patients, particularly in the curative setting for diseases such as
diffuse large B-cell lymphoma (DLBCL). In 2012 the American Society of Clin-
ical Oncology (ASCO) released a Clinical Practice Guideline recommending
that obese patients should be dosed on their full body weight. It is recognised
however that clinicians in the UK continue to dose adjust (or ‘cap’ doses) in
fear of excess toxicity.
Aims: This study aims to assess whether dosing on actual body weight in
obese patients with R-CHOP chemotherapy for DLBCL affects relative total
dose intensity of treatment (RTDI).
Methods: A retrospective analysis was performed of 77 consecutive patients
who had received treatment with R-CHOP chemotherapy for DLBCL from 2006
to 2010. After exclusions for insufficient individual patient data or modifications
to the regime e.g. addition of etoposide (R-CHOEP), the remaining number of
patients for analysis was 66 (obese patients dosed on full body weight; n=18
and non-obese; n=48). Baseline characteristics were recorded. Weight and
height measurements within 1 month of treatment initiation were used to calcu-
late body surface area (BSA) and body mass index (BMI). Patients were defined
as obese if BMI ≥30kg/m2 as per WHO classification. IBW was calculated for
obese patients using the BJ Devine formula. RTDI was calculated using previ-
ously published methods. It is the ratio of Actual Total Dose Intensity (ATDI) and
Planned Total Dose Intensity (PTDI) expressed as a percentage i.e. RTDI
(%)=ATDI/ PTDIx100. PTDI is the planned dose intensity over the entire treat-
ment duration, averaged across the chemotherapy agents used. For permanent
treatment discontinuation for a reason other than disease progression, relapse
or death, the remaining cycles are calculated with planned length and zero dose.
In cases of disease progression, relapse or death PTDI is calculated based on
number of cycles completed. ATDI is the actual average dose intensity over the
real treatment duration i.e. actual total dose (mg)/duration of therapy (weeks).
RTDI therefore takes into account the effects of treatment delays as well as
dose reductions, and premature cessation of therapy due to reasons other than
disease progression or death. It is a surrogate marker of survival and multiple
studies have demonstrated that achieving an average RTDI >90% is associated
with improved long term outcomes. The chi squared test for trend was used to
test for a trend in the number of patients being dose reduced at baseline between
the two groups. Univariate analysis was performed for age, gender, performance
status (PS), baseline characteristics including renal function, hepatic function,
full blood count, line of treatment, and GCSF usage using chi-squared tests, t-
tests and Mann-Whitney tests. Multivariable linear regression was performed
to adjust for confounding factors.
Results: Before adjusting for confounding factors, there was a non-significant
difference in average RTDI for R-CHOP between obese and non-obese
patients of 7.22%. After adjusting for age, gender, performance status, and
whether patients were dose modified in the 1st cycle, a multivariable linear
regression showed a reduction in this difference to 5.67% . There was no evi-
dence to suggest a difference in RTDI between the two groups (Table 1).
Table 1.
                                            Obese N=18        Control (non-obese) N=48        P-value
Average RTDI Mean (sd%)        94.05 (7.13)                 86.83 (16.05)             0.071 (t-test)
Summary/Conclusions: These findings, although of limited value due to small
patient numbers, would reassure clinicians and pharmacists that full weight
based dosing in obese patients should not lead to excess toxicity. In conjunction
with the broader published literature and ASCO’s Clinical Practice Guideline
they support dosing on actual body weight for R-CHOP for obese patients with
DLBCL.
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OUTCOME OF OLDER PATIENTS WITH B-LARGE CELL LYMPHOMA
(B-LCL) – AN OBSERVATIONAL STUDY OF KROHEM, THE CROATIAN
COOPERATIVE GROUP FOR HEMATOLOGICAL DISEASES
Z Mitrovic1,*, D Dujmovic2, V Pejsa1, A Duletic-Nacinovic3, S Ostojic-Kolonic4,
I Radman2, S Basic-Kinda2, P Gacina5, R Ajdukovic-Stojsavljevic1,
L Skare-Librenjak6, V Perisa7, I Aurer2, D Nemet2
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Background: Approximately half of the patients with diffuse large B-cell lym-
phoma (DLBCL) are older than 60 years and their outcome is inferior in com-
parison to younger patients.
Aims: We aimed to assess the impact of age, risk factors and the type of treat-
ment on event-free survival (EFS) and overall survival (OS).
Methods: In this retrospective study, 304 patients with DLBCL older than 60
years or equal were included. A total of 218 patients were included in an obser-
vational study of patients treated with rituximab conducted at 15 general and
university hospitals in 2007 and 2008. Additional patients were recruited from
two clinical centers.
Figure 1.
Results: The median age was 73 years (range 60-90), 144 were men and 160
women. 205 patients were treated with R-CHOP, 27 with R-CVP, 24 with R-
CNOP (mitoxantrone instead of doxorubicin), 20 with R-DA-EPOCH, 9 with R-
CEOP (etoposide instead of doxorubicin), and 19 patients received other regi-
mens or no chemotherapy. After a median follow up of 52 months for survivors,
the estimated 5-year EFS and 5-year OS were 43% and 47%, respectively. Half
of the patients are alive at the time of last follow up. Lymphoma, infections, and
cardiac events were the leading causes of death. A total of 52% patients died
during first-line treatment, 24% died in remission, and 24% died in relapse.
There were 16 secondary malignancies reported. The aaIPI significantly corre-
lated with EFS (p=0.002) and OS (p=0.001). Gender, bulky disease (>5cm),
and extranodal involvement were not associated with survival, whereas B symp-
toms were significantly predictive of EFS (p=0.002) and OS (p<0.001). Age had
a negative impact on survival: patients between 60 and 65 years fared well (5-
year OS 65%), patients from 66 to 75 years of age worse (5-year OS 46%), and
those older than 75 years the worst (5-year OS 38%); p=0.004 (Figure 1A).
Treatment choice also influenced EFS and OS: R-CVP and R-CNOP had worst
outcomes worst, whereas those of R-CEOP and R-DA-EPOCH were at least
comparable to R-CHOP; p=0.025 for EFS, p=0.009 for OS (Figure 1B).
Summary/Conclusions: R-CHOP remains the standard of care in elderly
patients with B-LCL. The aaIPI and presence of B symptoms influence prog-
nosis. Survival decreases with age; cut-offs at 65 and 75 years are discrimina-
tive. R-CNOP has only modest efficacy, similar to R-CVP. Etoposide may serve
as an alternative to anthracyclines for patients with cardiac comorbidities, and
R-DA-EPOCH may represent a good option for high-risk patients.
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TREATMENT TOXICITIES AND OUTCOME OF AN INTENSIVE
IMMUNOCHEMOTHERAPY REGIMEN (FAB LMB96) FOR ADULT AGGRESSIVE
B CELL NON-HODGKIN LYMPHOMAS (BNHL) AT RISK FOR OR WITH
CENTRAL NERVOUS SYSTEM INFILTRATION
J Desterro*, M Koehler, J Lobato, R Coutinho, F Pierdomenico, S Carvalho,
MJ Frade, A Nunes, M Gomes da Silva
Serviço de Hematologia, Instituto Português de Oncologia Francisco Gentil
Lisboa, Lisboa, Portugal
Background: The treatment of diffuse large B cell lymphomas (DLBCL) at risk
for CNS infiltration is not well established but may benefit of regimens including
systemic drugs crossing the blood-brain barrier. Furthermore, different studies
have showed that patients with lymphomas with features intermediate between
DLBCL and Burkitt (Int-BNHL) and MYC-rearranged lymphomas have inferior
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outcomes when treated with R-CHOP compared to more intensive regimens.
Treatment toxicity is a major concern in this setting where a superior efficacy
has yet to be prospectively established.
Aims: We retrospectively reviewed the clinical and genetic characteristics,
treatment toxicities and outcomes of DLBCL patients at risk for CNS infiltration
and Int-BNHL selected for aggressive treatment at our institution between 2009
and 2013.
Methods: Selection was based on age, performance status, ≥2 extranodal
sites (ENS) plus elevated LDH, CNS infiltration at diagnosis or MYC-rearrange-
ment. Fab LMB96 regimen includes alkylator/anthracycline/high-dose
methotrexate-based induction and high-dose cytarabine/etoposide or cytara-
bine/methotrexate-based consolidation, followed by maintenance; intrathecal
chemotherapy is administered at induction and consolidation. Toxicities were
graded according to CTCAE. Response was defined by conventional criteria
and overall survival (OS) determined from diagnosis until death or last follow
up. Treatment toxicities and outcomes of stage IV, intermediate-high and high-
risk IPI DLBCL patients receiving R-CHOP during the same period were
reviewed for reference.
Results: 15 patients with DLBCL (9) or Int-BNHL (6), median age 48 (23-65)
yo, 6 men, with stage IV disease were treated with the LMB96 protocol to which
Rituximab was added at the beginning of the induction and consolidation cycles.
10/11 evaluable patients had MYC rearrangements detected by FISH (MYC+).
CNS involvement at presentation occurred in 3 patients and bone marrow infil-
tration in 6. 93% of the patients had ECOG performance status 0-1 and 12 had
IPI 3-5; the other 3 patients had either CNS infiltration or MYC+. 74% and 43%
of 94 treatment cycles were complicated by grade 3-4 hematological and infec-
tious toxicities, respectively. These toxicities occurred mostly during induction
and consolidation. All patients were admitted for induction/consolidation cycles
and required transfusion support, myeloid growth factors and IV antibiotics.
Serious neurological (1%) and gastrointestinal (13%) toxicities were also
observed. Dose reductions/premature interruptions occurred in 6 patients Com-
plete response occurred in 13/14 (93%) evaluable patients. With a median fol-
low-up of 37.8 months, 3 patients (20%) died, 2 of toxicity (13%) and 1 with
progressive lymphoma; median OS was 36 months. In 40 patients with stage
IV DLBCL patients aged ≤65 yo diagnosed in the same period and treated with
R-CHOP (75% IPI 3-5, 90% high LDH, 65% ≥2 ENS), CR rate was 67.5%.
18/40 (45%) patients died, 14 of NHL and 2 (5%) of toxicity; median OS was
27 months.
Summary/Conclusions: In this retrospectively analyzed, single-center study
we show that an intensive immunochemotherapy regimen is feasible and highly
effective in selected patients with high-risk BNHL. R-CHOP, although widely
applicable, demonstrated poor disease control in the reference sample. Large
prospective studies are vital to assess the impact of intensive regimens in the
outcome of unselected patients with aggressive lymphomas.
PB1729
MANAGEMENT OF PRIMARY HEPATIC NON-HODGKIN’S LYMPHOMA
(PHL)
C Cerchione1,*, A De Renzo2, M Masarone3, C Cimmino1, R Della Pepa1,
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5Medicina Interna, Seconda Università di Napoli, 6Anatomia Patologica, Uni-
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Background: Primary Hepatic (PHL) is a rare form of NHL, characterized by
the exclusive involvement of the liver at the moment of the diagnosis, whereas
other localizations, such as lymph nodes, spleen, bone marrow and peripheral
blood, or other tissues are free of disease at least for 6 months after diagnosis.
Even if its occurrence is rare, PHL should enter in the differential diagnosis of
every space-occupying liver lesion, in particular if they are present in concomi-
tance with normal levels of AFP and/or CEA and in absence of liver cirrhosis.
Aims: Only small series of PHL have been investigated in literature, neverthe-
less a non-fortuitous association with Hepatitis C Virus (HCV) infection has
been reported among these series. The prognosis is believed to be dismal,
with early recurrence and short survival.
Methods: Patients diagnosed with PHL at our institution between 1990 and
2014, among a population of 600 NHL, were retrospectively analyzed. 11 PHL
were defined, 10 patients had a B-cell lymphoma, DLBCL in 6. The prevalence
of HCV infection was 72%. Combination CHT was the mainstay of treatment
for PHL. 10 patients were treated with CHT (10/11 : 90%). In 7 patients, the
multi-drug regimen we used consisted of the CHOP or a CHOP-like scheme;
in 2 of them (diagnosed after 2002) rituximab was added, at standard schedule.
In the indolent types a fludarabine-based scheme was used. One patient with
a single-focal lesion underwent to surgical treatment, with a CR. 11/11 patients
achieved complete remission of the disease after the frontline therapy (six CHT
courses/surgical treatment) (CR : 100%). Only one patient, 47 years old, Diffuse
Large B-Cell Lymphoma, relapsed 144 months after CR: she underwent to
retreatment with Rituximab+CHOP with the result of SD, so she underwent to
third line treatment with R-Bendamustine, but, due to cardiotoxicity, she had to
stop treatment and in the same month died for heart failure.
Results: At time, 10/11 (90%) of patients are alive with a median overall survival
(OS) was 123 months (r. 40-228) and median disease- free survival (DFS) was
120 months (range 36-223), no statistically significant differences were found
between PHL and other types of NHL in terms of OS and DFS. HCV infection
did not appear to influence the results of therapy.
Summary/Conclusions: Our study confirms the rarity of PHL, shows a high
prevalence of HCV infection, and demonstrates that the outcome of patients
with PHL may be favorable.
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LEUKEMIZATION OF FOLLICULAR LYMPHOMA: DIAGNOSTIC
FEATURES AND CLINICAL COURSE OF A RARE FORM OF THE DISEASE
E Nesterova1,*, AM Kovrigina1, EA Baryakh2, AE Misyurina1, YK Mangasarova1,
LV Plastinina1, TN Obuhova1, EG Gemdzhian1, IA Vorobyev3, AI Vorobyev1,
SK Kravchenko1
1Moscow, National Research Center for Hematology, 2Moscow, City Clinical
Hospital №52, 3Moscow, Moscow State University named after Lomonosov,
Moscow, Russian Federation
Background: Follicular lymphoma is а frequent lymphoid neoplasm, account-
ing for 22 percent of all non-Hodgkin’s lymphoma in Russia. At diagnosis, some
patients with FL manifest a detectable leukemic phase – leukemization (FL-
LP), but this feature has been seldom described and has poorly prognosis.
Aims: to characterize a group of patients with FL with leukemization and eval-
uate the efficacy of therapy (R-CHOP /R-FMC/high dose therapy (HDT)).
Methods: Among 250 patients diagnosed with FL in National Research Center
for Hematology, 18 (7, 2%) had characteristic FL-LP (by cytological blood
smears and flow cytometry analysis). 8/18 patients had extranodal foci: lung,
stomach, spleen, lumbar muscles, upper jaw, vertebrae. 17/18 patients had
bone marrow involvement. Morphologically in biopsies of tumors in the majority
of patients had a indolent FL (10/18 pts were diagnosed with I-II cytological
grade of FL, nodular tumor growth and nodular-diffuse tumor growth in 14/18
pts). As first line therapy we used standard therapy (R-CHOP or R-FMC) or
HDT with autoSCT.
Results: Median follow-up was 66 months (range 12–217). The 5-year overall
survival (OS) and progression-free survival (PFS) were: 70% (standard error
10) and 35% (15), respectively (Figure 1A-B), Median OS was not reached,
median RFS was 3 years.
Figure 1.
Summary/Conclusions: FL with leukemization characterized by a low overall
and disease-free survival. The most effective treatment regimens of this group
are: R-CHOP with autoSCT or R-FMC. These courses allow a greater degree
to achieve complete eradication of the tumor clone in the bone marrow. Given
the recurrent course of the FL, the most expedient to conduct autoSCT in first-
line therapy.
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DIFFUSE LARGE B-CELL LYMPHOMA IN HIGH RISK AAIPI 2-3 YOUNG
PATIENTS: CLINICAL PRESENTATION AND SURVIVAL AFTER FIRST LINE
STANDARD R-CHOP THERAPY
MQ Salas Gay1,*, E Domingo-Domenech1, S Mercadal1, V Paredes1, A Oliveira1,
C Aguilera1, F Climent2, M Encuentra3, A Fernandez de Sevilla1, A Sureda1,
E González Barca1
1Hematology, Hospital Duran i Reynalds, 2Patologist, Hospital Universitario de
Bellvitge, 3UIC, Hospital Duran i Reynalds, Barcelona, Spain
Background: The outcome of diffuse large B-cell lymphoma (DLBCL) has sub-
stantially improved with the addition of Rituximab (R) to chemotherapy regimens
although there is not a randomized trial comparing R-chemotherapy versus
chemotherapy alone in high risk young patients.
Aims: We aim to present a retrospective study of the clinical, immunohisto-
chemical features (IHC), and survival of patients≤60 years with aaIPI 2-3 treated
with 6 cycles of standard R-CHOP in a single center.
Methods: Three hundred sixty seven patients were diagnosed of DLBCL from
January of 2004 to June of 2015 in our centre, 119 (32.4%) were ≤60 years
and 63 (52.9%) of them had aaIPI 2-3. Cases were classified as germinal center
(GB) or activated B-cell (ABC) subtype according with the IHC Hans’s algorithm.
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Clinical and biological features, progression free survival (PFS) and overall
survival (OS) were analyzed. Survival curves were estimated using the Kaplan-
Meier method and compared using the log-rank test.
Results: Sixty three young patients with aaIPI 2-3 DLBCL were included. Median
age was 50 years (range 21-60), 29 (46%) were male. Clinical characteristics at
presentation were: ECOG ≥2 in 45 (67.2%), Ann Arbor stage III-IV 53 (84.1%), B
symptoms 27 (42.9%), Bulky >5cm mass 19 (30.2%), extra nodal disease 43
(68.3%), CNS involvement 3 (4.8%), high LDH 37/53 (69.8%), high B2M 12/25
(48%), aaIPI2 48 (71.6%) and aaIPI3 15 (23.8%).Thirty-six cases had data to be
classified by IHC: 22 (61.1%) CGB and 14(38.9%) ABC. Sixty-two (98.4%) patients
started treatment: 58 (92%) with 6 cycles of R-CHOP and 4 (8%) of R-CHOP-like
(2 R-CNOP, 1 R-Bortezomib-CAP and 1 GA101-CHOP). Nine (14.2%) patients
did not complete treatment, 5 due to adverse events (2 not recorded, 2 severe
infections, 1 cardiac event) and 4 due to progression. Intrathecal prophylaxis was
administered in 10 (16.1%) cases and as therapy in the 3 patients with CNS
involvement. Response was evaluated with PET/CT in 41 (71.8%) patients. Inten-
tion to treat response rate was: CR 46 (73%), PR 4 (6.3%), refractory disease 9
(14.3%), not evaluable 4 (6.3%). With a median follow-up of 44 months PFS was
69% and OS was 70%. PFS was 75.2%in patients with aaIPI 2 and 46.7% in
patients with aaIPI3 (p=0.02). OS was 77.4% and 38.7% respectively (p=0.01).
Sixteen patients relapsed or progressed[AS1], 4 were lost of control and 12[AS2]
were treated with a second line regimen in our center (9 R-ESHAP, 1 MTX-ARAC,
1 Burkitt regimen and 1 DHAP). Only 3 patients achieved enough response (2
CR and 1 PR) to[AS3] undergo an autologous stem cell transplant. After second
line therapy, median PFS was 2 months and median OS was 4 months.
Summary/Conclusions: Six cycles of R-CHOP is an effective first line regimen
for young patients with aaIPI2, but alternative therapies are needed for patients
with aaIPI3. Moreover, only a small percentage of patients who fail first line
therapy are rescued. Clinical trials with new drugs are needed especially for
the very high risk population.
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ANALYSIS OF RISK FACTORS FOR CENTRAL NERVOUS SYSTEM
RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: THE EXPERIENCE
OF A TERTIARY HOSPITAL
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Background: Central nervous system (CNS) relapse is an uncommon (5%)
unfavorable complication of diffuse large B-cell lymphoma (DLBCL). Independ-
ent predictors at diagnosis have been described to establish higher-risk groups
that benefit from CNS prophylaxis: IPI ≥3, elevated serum LDH levels, B symp-
toms, bulky mass, CD5+, MYC rearrangement, >1 extranodal involvement,
ECOG >1 and absence of Rituximab in systemic treatment. Many studies have
demonstrated that the frequency of CNS relapse varies from 10% to 50%,
depending on risk factors.
Aims: Analyze triple intrathecal therapy to prevent CNS relapse in DLBCL with
high risk factors.
Methods: We analyzed retrospectively, from 2009 to 2015, 75 patients with
newly diagnosed DLBCL. The decision to administer them all triple intrathecal
therapy (TIT) (metotrexate, cytarabine, hydrocortisone) was based on the CNS
relapsing risk factors in DLBCL described above. Systemic therapy was CHOP-
like. Qualitative variables are described in percentages and quantitative vari-
ables are described with means and standard deviations. We use Chi square
test to compare different categorical variables with CNS relapse. The overall
survival is tested with Kaplan-Meier tables.
Results: Of 75 patients, 41 were male. Median age at diagnosis was 62 years.
6 (8%) patients experienced CNS relapse. The mean Overall Survival (OS)
was 62 months CI 95% (55-69). OS at 6 months was 90.4%, at 2 years 80.5%
and at 5 years 72%.Table 1 shows comparison between parameters described
and CNS relapse.
Table 1.
Risk factors at diagnosis                           Frequency (n)      CNS relapse (%)      P value
B symptoms (Yes/No)                                       37/38                  10.8/5.3             0.430
Bulky mass (Yes/No)                                         19/56                  10.5/7.1             0.640
Ann-Arbor Stage (I-II/III-IV)                                11/64                   9.1/7.8              0.999
Serum LDH levels (elevated/non-elevated)          46/29                   8.7/6.9              0.999
Extranodal sites (0-1/>1)                                  42/33                  4.8/12.1             0.395
IPI (0-2/3-5)                                                    30/35                   6.7/8.9              0.999
CNS involvement at diagnosis (Yes/No)               2/73                    50/6.8               0.155
Rituximab (Yes/No)                                            73/2                     8.2/0                0.999
CD5 (Positive/Negative)                                      4/53                     0/9.4                0.556
MYC rearrangement (Negative/Not realized)         6/69                   16.7/7.2             0.405
Summary/Conclusions: Spanish GELTAMO group has recently published
the Guideline for diagnosis, prevention and therapeutic management of CNS
involvement in DLBCL. In our experience, TIT was effective to prevent CNS
relapse (8% compare to 10-50% described in literature in high risk patients).
However, patients with very high risk factors could benefit from combination
therapy recommended by GELTAMO based on inmunochemotherapy+TIT+
High Dose Metotrexate.
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ANALYSIS OF THE TOXICITY AND EFFICACY OF LIPOSOMAL CYTARA-
BINE IN THE PROPHYLAXIS AND TREATMENT OF CNS LYMPHOMATOSIS:
THE BALEARIC LYMPHOMA GROUP EXPERIENCE
M Garcia-Recio1,*, A Cladera2, L Bento1, J Dominguez2, S Ruiz de Gracia1,
F Sartori1, R Del Campo2, L García1, C Ballester1, J Bargay2, A Sampol1,
A Gutierrez1
1Hematology, Univerity Hospital Son Espases, 2Hematology, Hospital Son
Llatzer, Palma, Spain
Background: CNS lymphomatosis is a generally fatal complication of aggres-
sive NHL. Without specific CNS prophylaxis the risk of CNS relapse is higher
(20-30%) in patients with very aggressive NHL such as burkitt or lymphoblastic
lymphoma/leukemia. DLBCL has a lower risk (around 5%) but several factors
have been identified that increase the incidence of CNS relapse to levels similar
to very aggressive NHL. All above mentioned patients are candidates for CNS
prophylaxis. However there is no consensus about which is the best way of
administering CNS prophylaxis. Best results seem to be associated to the use
of intravenous (iv) high-dose methotrexate (HDMTX) but with significant toxicity.
Other options are intrathecal (IT) administration of MTX, cytarabine or liposomal
cytarabine (ITLC). However no randomized trial has been performed to test
which is the best option in terms of tolerance and efficacy.
Aims: We aim to analyse the experience of the centres of the Balearic Lym-
phoma Group about the tolerance, toxicity and efficacy of ITLC in the prophy-
laxis and therapy of CNS lymphomatosis.
Methods: We retrospectively reviewed all cases treated with ITLC in Son
Espases and Son Llatzer Hospitals. Standard diagnostic, response assessment
and follow-up data was obtained from medical records. All cerebrospinal fluid
(CSF) samples were evaluated through 8-colours flow cytometry. Survival
analysis was done using Kaplan-Meier curves and the Log-rank test.
Results: From 2005 to 2015, 58 patients received ITLC. They received a total
of 180 ITLC injections. Toxicity was as follows: 33% headache, 20% neurolog-
ical deficits, 11% nausea, 9% dizziness, 4% vomiting, 4% fever, 2% transient
blindness and 2% photophobia. In the prophylactic cohort (n=26) with a median
follow-up of 55 months (17-81) only 3 CNS relapses (11%) were observed in
a testicular DLBCL, Burkitt and plasmablastic lymphoma. This represents a
cumulative incidence of CNS relapse of 8%, 14% and 20%, respectively for
DLBCL, Burkit/lymphoblastic and plasmablastic lymphoma. In the treatment
cohort (n=32), complete clearance of CSF was obtained in 77% of cases (86%,
62% and 100% of respectively DLBCL, Burkit/lymphoblastic lymphoma and
Primary CNS lymphoma). Median OS was 6 months (0-16). Causes of death
were lymphoma progression in 19 patients (79%), treatment toxicity in 2 and
other non-related in 3 (12%) (Table 1).
Table 1.
Characteristics                                Global                Prophylaxis              Treatment
                                                 group(n=58)          cohort (n=26)         cohort(n=32)
Median age (range)                        53 (10-85)             47 (12-85)             55 (10-81)
Gender:
·Male                                            44 (76%)                19 (73%)                25 (78%)
· Female                                         14 (24%)                 7 (27%)                  7 (22%)
Diagnostic:                                                                                                      
DLBCL                                          31 (53%)                17 (65%)                14 (44%)
Lymphoblastic or Burkitt                16 (27%)                 7 (27%)                  9 (28%)
Primary CNS Lymphoma                 6 (10%)                   1 (4%)                   5 (16%)
Mantle Cell Lymphoma                    3 (5%)                    1 (4%)                    2 (6%)
Peripheral T-cell lymphoma              1 (2%)                    0 (0%)                    1 (3%)
Follicular Lymphoma                       1 (2%)                    0 (0%)                    1 (3%)
First line treatment:                                                                                          
· Intensive treatment ALL-like           14 (24%)                 7 (27%)                  7 (22%)
·Intensive treatment for CNS           11 (19%)                  1 (4%)                  10 (31%)
·Conventional CHOP-like                 23 (40%)                17 (65%)                 6 (19%)
Other                                              10 (17%)                  1 (4%)                   9 (28%)
Summary/Conclusions: The toxicity profile was good especially when con-
comitant IT and oral dexamethasone was administered. In the prophylactic
cohort the incidence of CNS relapse was low in the DLBCL group similar to
previously reported for iv HDMTX and much better than IT MTX. ITLC may be
a good alternative for CNS prophylaxis but randomized clinical trials are need-
ed. Patients in treatment cohort had a high rate of clearance of CSF but survival
is still poor in CNS lymphomatosis.
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HODGKIN LYMPHOMA IN MANSOURA REGION (EGYPT), ANRS 12263
STUDY
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soura University, Mansoura, Egypt, 4Department of Pathology, Paris 5
Descartes University, Paris, France, 5Department of Pathology, 6Faculty of
Medicine, Mansoura University, Mansoura, Egypt, 7Department of Adult Hema-
tology, Paris 5 Descartes University, 8Department of Internal Medicine and Clin-
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Background: The prevalence of Hepatitis C virus in Egypt is 14.7%, which is
considered the highest in the world. Genotype 4 represents about 93.1% of
cases which is considered among the highest prevalence areas of genotype 4
all over the world. Non-Hodgkin lymphoma is the 5th most common cancer in
both male and female in Egypt. The association of HCV infection and develop-
ment of B-cell lymphoproliferative especially the causative relationship not yet
clear in Egypt.
Aims: the aim of this primary pilot study is to evaluate the incidence and clinical
characteristics of HCV associated lymphoma in Egypt.
Methods: Between January 2012 and January 2013, we enrolled 110 adult
patients with newly diagnosed B cell NHL. HCV infection was defined by the
detection of anti-HCV antibodies by enzyme-linked immunosorbent assays with
or without viraemia at initial diagnosis. Patients with Hepatitis B virus co-infec-
tion could be included but not those with HIV co-infection. Anti HCV positive
samples, underwent HCV-RNA testing at disease diagnosis beside a rheuma-
toid factor screen.
Results: The incidence of B cell non-Hodgkin lymphoma associated with HCV
infection was 60.9% (67/110 patients) which is considered the highest reported
value in the literature. The incidence of cases presented with viraemia was
80% (32/40 patients). As regard histology, the majority of HCV associated lym-
phoma were DLBCLs (71.6%), SLL/CLL (13.4%), marginal zone (7.5%) and
follicular (7.5%).
Summary/Conclusions: B cell lymphomas are highly associated with HCV
infection (In Egypt incidence=60.9% vs 2.5% in France). The difference in geno-
type distribution may be responsible for different incidence and behavior of
HCV associated lymphoma. Further studies is needed to have a molecular sig-
nature for this unique environmental and genetic background.
PB1735
PRIMARY BONE LYMPHOMA (PBL) - “REAL WORLD” EXPERIENCE OF A
SINGLE CANCER HOSPITAL. CLINICAL CHARACTERISTICS,
PROGNOSTIC FACTORS AND MANAGEMENT OF TWELVE PATIENTS.
D Stoumbos1,*, I Patsias1, G Papageorgiou1, E Fergadis1, C Gkekas1,
EE Christaki1, E Asmanis1, P Lampropoulou1, A Tsakiridou1, P Repousis1,
A Megalakaki1, I Skouras2, A Petridis3, M Kotsopoulou1
1Hematology, 2Radiology, 3Radiation Oncology, Metaxa Cancer Hospital, Peira-
ias, Greece
Background: PBL was first described as a distinct clinopathological entity on
‘reticulum cell sarcoma of bone’ in 1939 by Parker and Jackson. It is a very
rare condition which constitutes less than 1% of all malignant lymphomas, less
than 2% of all bone tumors and less than 5% of extra-nodal lymphomas. A
number of studies have been reported, but most with a limited number of
patients. Being an uncommon entity, there is a lack of experience in paramaters
such as clinical characteristics and optimal management.
Aims: To determine patient characteristics, prognostic and treatment factors
that could affect outcome measured by overall survival (OS) and complete
remission (CR).
Methods: Herein, we retrospectively review 12 patients diagnosed with PBL
and treated at our institution from 2001 to present.
Results: The demographic and clinical characteristics of the 12 patients at
the time of diagnosis are summarized in Table 1. The median age of the
patients was 49 years old (range, 31-81 years). Eight (70%) patients were
female and 4 (30%) male. The histological type of all 12 patients (100%) was
Diffuse Large B-Cell Lymphoma. Ten patients (83%) were presented with Ann
Arbor Stage I or II disease. Two patients (17%) had high stage disease. The
median follow-up after achieving CR (without relapse) to date was approxi-
mately 80 months (range, 0-170 months). Our analysis demonstrated that age
less than 47 years normal LDH level, Ann Arbor Stage I or II and female gender
were found to be favorable prognostic factors for achieving CR and OS.
Notably, the pelvis was the most frequently primary involved site of the bone
(5; 41.5%). All twelve patients underwent chemotherapy with most of them
(10; 83%) receiving six to eight cycles of the RCHOP regimen. The majority
(11; 92%) of them received radiotherapy. After front line chemotherapy followed
by radiotherapy most patients (9; 75%) achieved CR. Among the remaining
three patients, the one died before completing first line chemotherapy due to
an infection while in chemotherapy-induced neutropenia. The other patient is
undergoing autologous stem-cell transplantation due to refractory PBL. The
third one achieved CR after he underwent autologous stem-cell transplantation
due to refractory PBL. Both patients that had refractory disease were male
and initially diagnosed with high stage PBL. The median OS was 89,5 months
(range, 6-178 months).
Table 1. Patient demographic and clinical characteristics.
                                                                                         Median     Range
Age                                                                                       49 years                  31 - 81
Gender M/F                                                                                   4 (30%)/8 (70%)
Serum LDH                                                                           250 IU/L                137 - 857
Clinical Stage I & II                                                                              10 (83%)
Pelvis as primary involved site of the bone                                            5 (41,5%)
Initial CTx: RCHOP                                                                                10 (83%)
Response to initial treatment CTx+RT: CR                                                9 (75%)
ASCT                                                                                                    2 (17%)
Follow up after CR (without relapse)                                      80 months                 0 - 170
OS                                                                                     89.5 months               6 - 178
Summary/Conclusions: Although the total number of patients was relatively
small, the data from our study supports that most PBL patients have had early
stage disease (IE-IIE) on diagnosis which also was the most important favorable
prognostic factor. Overall, patients with primary lymphoma of the bone with
DLBCL have an excellent prognosis and only a limited number of patients
underwent autologous stem-cell transplantation in order to achieve CR.
PB1736
PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: EXPERIENCE AT
A SINGLE CENTER IN JORDAN
M Ayesh (Haj Yousef)1,*, Z Audat2, K Alwaneh1, Y Khader3
1Medicine, 2orthopedic, 3Public health, Jordan University of Science and Tech-
nology, Irbid, Jordan
Background: Diffuse large B cell lymphoma (DLBCL) is the most common
type of non-Hodgkin’s lymphoma, although there may be geographical and eth-
nic differences with respect to DLBL; these differences are associated with par-
ticular clinicopathologic features and outcomes. Primary bone diffuse large B
cell lymphoma (PBDLBL) comprises 4–5% of all extranodal non-Hodgkin lym-
phoma (ENHL) cases and less than 1% of all malignant lymphomas. PBDLBL
is so rare that many of its characteristics remain unknown, with no data at all
available from Jordan.
Aims: To examine the epidemiology and clinical features of PBDLBL in Jordanian
patients as a model for other Middle East countries in which such data are scarce.
Methods: Between September 2002 and December 2015, 112 patients aged
16 years and above were diagnosed with DLBL and treated at King Abdullah
University Hospital.Patients with ENHL were included in the study only if they
had a tissue diagnosis of DLBL at the site of involvement. According to the site
of ENHL involvement at the time presentation Clinical stage was defined accord-
ing to the Ann Arbor classification. Disease involving the lymph nodes, spleen,
and Waldeyer’s ring were defined as “nodal”.
Results: This retrospective study included 114 patients with DLBCL (54 females
and 60 males; age range, 16 to 94 years; mean (SD), 51.0 (18.7) years). Of
these, 66 (57.9%) presented with heterogeneous extranodal organ involvement.
Of all extranodal sites, bone was involved in nine (14%) cases. Of these cases,
33% were female and 67% were male. The mean age of patients with extra
nodal involvement was 46.7 (20.6) years. There was no significant difference
between those with nodal and those with extranodal lymphomas in terms of
gender (p=0.656) or age (p=0.158). The spine was the most common site of
extranodal involvement with DLBL in six patients, the pelvis in one patient, the
clavicle in one patient, and the scapulae in one patient. Back pain was the most
common presenting symptom (six (67%) patients). A pathological fracture was
noted in one patient (11%), a shoulder mass in one patient, and lower limb
paralysis in one patient. No B symptoms were present in any patient. Serum
lactic dehydrogenase (LDH) levels were elevated in only one patient.
Summary/Conclusions: PBDLBL was the second most common extranodal
manifestation of DLBL (14%), with the spine being the most frequent site.the
most common extranodal site was the gastrointestinal tract (18%). Back pain
was the main presenting symptom, with an absence of B symptoms. LDL levels
were normal in most patients. The present study highlights geographic and eth-
nic variations in the primary disease site in patients with DLBL.
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THE INFLUENCE OF CARDIOVASCULAR COMORBIDITIES ON THE
THERAPEUTIC RESPONSE AND PROGNOSIS OF PATIENTS DIAGNOSED
WITH AGGRESSIVE NON HODGKIN LYMPHOMA
P Monica1,*, SR Cristina1, PO Ovidiu1, B Ema-Cristina1, O Dacian1, J Cristian2,
I Ioana1, I Maria1, I Hortensia1
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1Hematology, Municipality Emergency Hospital of Timisoara, 2Onco-hematol-
ogy and Bone Marrow Transplantation, Emergency Children’s Hospital LOUIS
TURCANU, III. Clinic of Pediatrics, Timisoara, Romania
Background: The NHLs are a heterogeneous group of lymphoproliferative
malignancies with different patterns of behavior and responses to treatment.
The aggressive type of NHL has a shorter natural history, but a significant num-
ber of these patients can be cured with intensive chemotherapy regimens.
Aims: The aim of this study was to determine to what extent cardiovascular
comorbidities influence choice of therapy, treatment response and survival of
patients diagnosed with NHL.
Methods: We have retrospectively analyzed clinical data of 47 aggresive NHL
patients who were consecutively diagnosed at the Hematology Department of
the Municipality Hospital of Timisoara,between 2009 and 2015. Disease stage
and treatment were established after collecting clinical,laboratory, and patho-
logical data. Survival analysis was estimated by means of the Kaplan-Meier
curves and comparison of survival between subgroups was performed using
the log-rank test. IBM SPSS Statistics 23 was the software that was used.
Results: There were 20 patients males and 27 females, averaging the age of
53.82 years, a median age at diagnosis of 56 years and a standard deviation
of 15.49. The estimated overall survival at 5 years for the whole group of
patients is 45% while the free survival disease at 5 years is 38%. In the case
of patients diagnosed with high blood pressure (HBP), the overall survival is
45% at 5 years compared to the 43% for the patients who did not show HBP
while the free survival disease for the patients diagnosed with HBP at 5 years
is 45% compared to those who did not indicate the presence of HBP (37%). As
for the coronary artery disease (CID), there were found differences both for
the overall survival at 5 years (59% versus 41%) and for the free survival dis-
ease at 5 years (58% versus 32%). Also, for the patients diagnosed with heart
failure the overall survival at 30 months proved to be 0% compared to the over-
all survival for those who did not show this pathology (65%), and this is the
same for the free survival disease found at these patients (p=0.025).
Summary/Conclusions: All the patients were subjected to polychemotherapy
of R-CHOP or R-CNOP type. Referring to the associated cardiovascular com-
momorbidty neither the high blood pressure nor the coronary artery disease
prove to be factors of negative prognosis, neither did they influence the survival
and nor required the diminution of the chemotherapy dosages. Only the heart
failure influenced the survival.
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LATE MYELOTOXICITY OF INTENSIVE MODIFIED PROGRAM NHL-BFM-90
IN ADULT POOR-PROGNOSIS PATIENTS WITH DIFFUSE LARGE B-CELL
LYMPHOMA
E Dorokhina*, A Magomedova, V Dvirnyk, I Galtseva , S Glinkina, S Kulikov,
T Obuchova , S Kravchenko
National Reserch Center of Hematology, Ministry of Health of Russia, Moscow.,
Moscow, Russian Federation
Background:
High dose chemotherapy showed to be more effective compared with standart
dose therapy in DLBCL patients with poor prognosis, but late myelotoxicity
wasn’t estimated enough.
Aims: To evaluate late myelotoxicity of intensive modified program NHL-BFM-
90 (mNHL-BFM-90) in adult poor-prognosis patients with diffuse large B-cell
lymphoma (DLBCL).
Methods: Results of complex clinical, laboratory and instrumental examination,
including cytological, histological and standard cytogenetic bone marrow study
of 40 patients with DLBCL which received mNHL-BFM-90 protocol in the Hema-
tology Research Center in the period since 2002 till 2009 years were analyzed.
Group consisted of 20 men, 20 women, median age – 57 (31-76) years at the
time of survey. Comparison group included 19 patients (8 men and 11 women),
median age – 70 (39-80) years at the time of survey, who received CHOP /R-
CHOP-21 therapy. Median follow-up after completion of treatment - 6 years.
Results of study of bone marrow were analyzed before chemotherapy and
after 5-10 years after treatment. Cellularity of bone marrow, the amount of ery-
throid, granulocytic and megakaryocytic germs, signs of dysplasia, and dys-
plastic changes of stroma were determined by histologically and cytologically.
Also performs standard cytogenetic bone marrow examination to identify kary-
ological violations. As late myelotoxicity were considered signs of toxic damage
of bone marrow, which appeared first time in late period after chemotherapy .
Cases with initially presented and preserved after chemotherapy myelotoxicity
signs, as well as presence and absence of baseline after chemotherapy –
weren’t taken into account.
Results: Cytopenia (with no signs of myelodysplasia and substitutive transfu-
sions of blood components need) were detected in 52% of patients with high-
dose group, 46% of cases are accounted for thrombocytopenia. Reduced cel-
lularity of bone marrow in 15 (38%) patients, p=0.02, reducing of erythroid and
megakaryocytic germs in 13 (33%), p=0.01, and 19 (48%), p=0.009, respec-
tively, stroma changes in 17 (43%) patients, p=0.02, were revealed like signs
of late myelotoxicity in patients after high-dose chemotherapy for mNHL-BFM-
90 program. Standard cytogenetic study of bone marrow was performed for
first six patients, all had a normal karyotype, without any karyological abnor-
malities, therefore further study wasn’t performed.
Summary/Conclusions: Long-term myelotoxicity of high-dose program
mNHL-BFM-90 exceeds significantly toxicity of standard therapy CHOP/R-
CHOP-21. However, myelodysplastic syndromes or cytopenia requiring trans-
fusions of blood components wasn’t observed.
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ANALYSIS OF CLINICAL PARAMETERS, ABSOLUTE LYMPHOCYTE AND
ABSOLUTE MONOCYTE COUNT IN PATIENTS WITH DIFFUSE LARGE B
CELL LYMPHOMA
J Jelicic1,*, M Torodovic Balint1, D Antic1, B Andjelic1, O Markovic2, I Petkovic3,
A Sretenovic1, J Bila1, V Vukovic1, V Djurasinovic1, M Smiljanic1, I Pejicic3,
B Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, 2Clin-
ical Hospital Center “Bezanijska Kosa”, Belgrade, 3Clinic of Oncology, Univer-
sity Clinical Centre Nis, Nis, Serbia
Background: The results of gene expression profiling (GEP) analysis of diffuse
large B cell lymphoma (DLBCL) confirmed existence of two subtypes of DLBCL
with different outcome. In order to reproduce GEP findings several studies
have investigated the potential role of absolute lymphocyte count (ALC),
absolute monocyte count (AMC) and ALC/AMC as surrogate markers. Howev-
er, the contradictory data were reported.
Aims: The aim of this study was to evaluate prognostic significance of clinical
parameters, laboratory parameters: ALC, AMC and ALC/AMC on the overall
survival (OS) and event free survival (EFS).
Methods: A total of 583 patients (295 females/288 males) with the median age
of 60 years (range 18-89) were included in the study. According to the Ann
Arbor classification, stage I, II, III and IV had 74 patients (12.7%), 212 (36.4%),
110 (18.9%) and 187 (32.1%), respectively. Bulky disease was present in 190
patients (32.6%) and B symptoms in 370 patients (63.5%). Bone marrow
involvement was present in 77 patients (13.2%). Low Revised International
Prognostic Index (R-IPI) was presented in 97 patients (16.6%), intermediate in
307 (52.7%) and high in 174 (29.8%). Median ALC at diagnosis was 1.35x109/l
(range 0.07-17.8x109/l), AMC 0.60x109/l (range 0.06-8.58x109/l) and ALC/AMC
2.5 (range 0.07-37.0x109/l). Cut off values for LAC, AMC and ALC/AMC were
used as previously published and included 1.1x109/l, 0.62x109/l and 2.6x109/l
for ALC, AMC and ALC/AMC, respectively. Regarding cell of origin according
to Hans algorithm, 45.3% of patients had GC (germinal center) type, while
64.7% had non-GC type. All patients were initially treated with rituximab plus
CHOP or CHOP like protocols.
Results: Complete remission (CR) was achieved in 425 patients (72.9%), par-
tial remission (PR) in 79 (13.6%), stable disease (SD) in 19 (3.3%) and pro-
gressive disease in 60 (10.3%). Disease relapse was confirmed in 88 patients
(15.1%). The patients with B symptoms of disease had inferior OS (Log
Rank=11.27, p=0.001) and EFS (Log Rank=12.62, p=0.001) compared to those
without B symptoms. Furthermore, presence of bulky disease influenced OD
(Log Rank=10.58, p=0.001) and EFS (Log Rank=11.35, p=0.001). The prog-
nostic value of R-IPI was highly statistically significantfor both OS (Log
Rank=62.3, p<0.0001) and EFS (Log Rank=56.83, p<0.0001). The patients
with GC type had better OS (Log Rank=7.44, p=0.006) and EFS (Log
Rank=6.34, p=0.012) compared to non-GC type. However, there was no influ-
ence of ALC, AMC and ALC/AMC neither on OS nor EFS. Multivariate analysis
among significant parameters (presence of B symptoms, bulky disease, R-IPI
and cell of origin GC vs non-GC type), has pointed out the major impact of R-
IPI on OS (HR 1.75, p<0.0001) and (HR 1.44, p=0.0001) along with the pres-
ence of B symptoms (OS, HR 1.51, p=0.01; EFS, HR 1.58, p<0.008).
Summary/Conclusions: ALC, AMC and ALC/AMC failed to prove influence
on survival of DLBCL patients indicating the need for new potential surrogate
markers of GEP results. Moreover, R-IPI as clinical prognostic score may help
to differentiate risk groups within DLBCL patients.
PB1740
OUTCOME AND PROGNOSTIC FACTORS IN DIFFUSE LARGE B-CELL
LYMPHOMA: AN INSTITUTIONAL EXPERIENCE OF A TERTIARY CARE
CENTRE FROM INDIA
R Mahajan1,*, BS Yadav1, S Kumar1, A Gupta1, S Ghoshal1, SC Sharma2,
R kapoor1, N Kumar1
1Radiotherapy and Oncology, Post Graduate Institute of Medical Education
and Research, Chandigarh, 2Radiotherapy And Oncology, Mmu, Mullana,
Ambala, India
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common
non-Hodgkin’s lymphoma(NHL), accounting for approximately 30% of all new
diagnoses. We conducted the retrospective study in our institution to analyze
the main clinical features at diagnosis, response to therapy and the outcome
of patients diagnosed with DLBCL.
Aims: To analyze the prognostic factors, response to therapy and the outcome
of patients with DLBCL.
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Methods: This study enrolled 74 patients with histologically confirmed diagnosis
of DLBCL treated from January 2003 to December 2014. Complete clinical patient
and disease related details were recorded. All patients were treated with
chemotherapy with or without radiotherapy. Clinical features, treatment response
and impact of different prognostic factors on clinical outcome were analyzed.
Bulky disease was defined as any mass greater than 10cm in diameter.
Table 1.
Results: Median age of presentation was 50 years (range 18-85 years).
55(74.3%) of the patients were ≤60 years age and 19(25.7%) were >60 years
age. Out of 74 patients, 53 were males and 21 were females. Ann Arbor clinical
stage at diagnosis was 36(48.6%) stage I, 20(27%) stage II, 13 (17.6%) stage
III, and 5(6.8%) stage IV respectively. Bulky disease was present in 6 patients
(8.1%). Nodal disease was present in 40(54.1%) patients and 34(45.9%) had
extranodal disease presentation. Supradiaphragmatic disease was seen in
44(59.5%) and 15(20.3%) had infradiaphragmatic as well as disease on both
sides of the diaphragm. Most of the patients (93.2%) received either CHOP or
R-CHOP chemotherapy. 43(58.1%) patients received consolidative radiother-
apy. The median follow-up period was 22 months (range, 2 to 147 months).
Complete response was seen in 51(68.9%) patients. With addition of radiation
9.4% improvement in local control was seen. Relapses was seen in 10(13.5%)
patients, out of which 5(6.8%) had nodal and 5(6.8%) had visceral relapse. At
22 months, disease free survival (DFS) and overall survival (OS) was 66% and
81.5% respectively. Stage, International prognostic index (IPI), supradiaphrag-
matic disease, number of sites, extranodal diasease and number of nodal sites
involvement were important prognostic factors having significant impact on
response, DFS and OS (Table 1).
Summary/Conclusions: This study represents the largest Indian experience
to treat DLBCL. Stage, IPI, supradiaphragmatic disease, number of sites, extra-
nodal disease and number of nodal sites were the important prognostic factors
for response, DFS and OS.
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STUDY OF DISPARITIES BETWEEN SERUM LDH AND SOLUBLE
INTERLEUKIN-2 RECEPTOR (SIL-2R) IN DIFFUSE LARGE B-CELL
LYMPHOMA (DLBCL) PATIENTS
T Okatani1,*, H Asaoku2, K Toishigawa1, T Ochi1, R Imanaka1, K Kyo1, M Itagaki1,
K Shinya1, Y Katayama1, K Iwato3, K Taiichi1
1Division of Hematology, 2Division of Laboratory, 3Division of Transfusion,
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima
city, Japan
Background: Serum LDH or serum interleukin-2 receptor (sIL-2R) are two of
the most important tumour markers of malignant lymphoma, and of diffuse large
B-cell lymphoma (DLBCL), which is the most common histological types of
non-Hodgkin lymphoma. We usually find elevated values of both in DLBCL
patients; however, sometimes there are cases where, unexpectedly, only one
value does not exhibit an abnormal level, while the other does.
Aims: To analyse the clinical characteristics of cases where serum LDH and
sIL-2R are not correlated.
Methods: We retrospectively analysed 556 patients that visited our hospital
from March 1994 to June 2012 and who were diagnosed for the first time as
having DLBCL. We drew a distribution chart of the ratio of serum LDH and nor-
mal level (LDH/N) and serum sIL-2R. (Figure 1.) The median LDH/N was 1.04
(0.38-20.59), and sIL-2R was 1,420 (119-40,000). Then, we decided two
groups; group I was LDH/N >2, sIL-2R <2,000U/ml, and group II was LDH/N
<1, sIL-2R >3,000U/ml.
Results: The median age of the DLBCL patients was 67 years (19-97). Thirteen
patients were in group I (six female and seven male), and a total of 13 patients
were diagnosed as being at an advanced clinical stage of disease. There were
five patients aged over 60 (38%), but there were nine cases (69%) in which
Performance Status (PS) was over 2. Twelve patients (92%) belonged to the
higher-risk group, in which International Prognostic Index (IPI) was over 3. As
for incidence, there were four (31%), primary mediastinal cases, seven (54%)
extra-nodal onset cases, and bulky mass was observed in nine (69%). We
were able to review six cases for pathological diagnosis; three were of the GCB
type and three were the non-GCB type. On the other hand, 15 patients were in
group II (seven female and eight male), 10 cases (67%) were over 60 years of
age, but there were only four (27%) cases in which PS was over 2, and finally
there were three (20%) in the higher-risk group. Ten cases (67%) had retroperi-
toneal mass and seven (47%) showed bone marrow involvement. Pathological
diagnosis could be reviewed again in six cases; two were the GCB type and
four were non-GCB type.
Figure 1.
Summary/Conclusions: DLBCL is a heterogenous disease. By analysing cas-
es of disparity biomarkers between LDH and sIL-2R, we showed the possibility
of identifying subgroups.
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DIFFUSE LARGE B-CELL LYMPHOMA IN THE ELDERLY: REAL-WORLD
OUTCOMES OF IMMUNOCHEMOTHERAPY IN ASIAN POPULATION
JO Lee*, JM Byun, SM Bang, JS Lee
Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of
Background: The International Prognostic Index (IPI) has been the primary
scoring system for predicting the survival in diffuse large B-cell lymphoma (DLB-
CL). However, the validity of IPI in the era of immunochemotherapy is somewhat
uncertain, and the age cut-off for defining “elderly” patients remains especially
controversial. Moreover, elderly DLBCL patients frequently do not receive ade-
quate treatment, compromising the chance of complete remission.
Aims: We sought to evaluate real-life outcomes of immunochemotherapy in
elderly DLBCL patients from a homogenous Asian population.
Methods: This was a single-center, retrospective study of 192 DLBCL patients
over 60 years of age treated with first line rituximab – cyclophosphamide, dox-
orubicin, vincristine, and prednisone between May 2004 and July 2014. Treat-
ment schedule, adverse events and survival outcomes were analyzed overall
and by four age groups (over 60 to 64, 65 to 69, 70 to 74, 75 and above).
Results: Patients of 75 years of age and older were associated with significantly
lower complete remission (CR) rate (86.5% vs 81.4% vs 82.0% vs 51%;
P<0.001) and higher treatment related mortality (TRM) (5.4% vs 9.3% vs 13.1%
vs 33.3%; P=0.001). Advanced age was also related to dose reductions (24.3%
vs 39.5% vs 73.8% vs 100%; P<0.001) and less likelihood of completing
planned chemotherapy cycle (73% vs 79.1% vs 78.7% vs 51%, P=0.005). Sig-
nificantly poorer progression free survival (PFS) (3-year PFS rate, 45.9% vs
44.2% vs 44.3% vs 11.8%; P=0.043) and overall survival (OS) (3-year OS rate,
64.9% vs 58.1 vs 55.7% vs 23.5%; P<0.001) were observed for patients aged
≥75 years old. Multivariate regression analyses identified age ≥75 and initial
ECOG performance status as potential risk factors associated with OS.
Summary/Conclusions: In conclusion, elderly patients <75 years old or those
with better performance status were tolerable to standard immunochemother-
apy, with acceptable survival profiles. In Asian elderly DLBCL population, 75
years seems to be judicious cut-off age for predicting the treatment outcomes.
Treating patients aged ≥75 years requires more innovative therapy options and
not just dose reductions.
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EXPERIENCE WITH R-MINICHOP IN CLINICAL PRACTICE IN THE OLDEST
PATIENTS WITH AGGRESSIVE NON HODGKIN’S LYMPHOMA
C De Ramon Ortiz*, M Monsalve, B Diaz Jordan, A Muñoz Gama, P Gomez
Prieto, A Lopez de la Guia, P Baltasar, V Jimenez Yuste, M Canales
Hematologia y Hemoterapia, HOSPITAL UNIVERSITARIO LA PAZ, Madrid,
Spain
Background: About 40% of aggressive Non Hodgkin’s Lymphoma (NHL) are
diagnosed in patients older than 70 years. However, the experience in the
treatment of this group of patients is very limited. The encouraging results of
the GELA group (Peyrade et al., Lancet Oncol 2011) with the R-miniCHOP
regimen in patients older than 80 years suggest that a substantial proportion
of them can be cured, and therefore it is recommended as the standard therapy
in this population.
Aims: The aim of this study is to analyse our experience in using this regimen
in elderly patients with aggressive lymphoma.
Methods: We retrospectively analysed patients consecutively diagnosed with
aggressive NHL, older tan 70 years, treated with R-miniCHOP regimen (ritux-
imab 375 mg/m2, cyclophosphamide 400 mg/m2, doxorubicin 25 mg/m2, vin-
cristine 1 mg, prednisone 60 mg/day) in our center, from August 2010 to
December 2015.
Table 1. Patient’s characteristics
Characteristics                                                              n=30
Age, median                                                              81 yo (73-85)
Women                                                                              18
Comorbidities
- Cardiovascular                                                                 15
- HBV                                                                                 4
- HCV                                                                                 3
- Previous neoplasia                                                            5
Histology
- Diffuse large B-cell lymphoma                                          25
- Mantle Cell                                                                       2
- Burkitt                                                                              3
Stage III-IV                                                                         21
IPI
- Low                                                                                  3
- Intermediate/low                                                              4
- Intermediate/high                                                             5
- High                                                                                18
Figure 1.
Results: Thirty patients who received at least 1 course of treatment were
included in our analysis. Clinical characteristics are summarized in Table 1. It
is remarkable the poor prognosis of our patients, with median age of 81 years,
the associated comorbidities and the high IPI. The median of treatment cycles
received was 6 (1-8), 50% of cases received 6 cycles. Nine patients received
prephase (Vincristine 1 mg and/or prednisone). Four patients received radio-
therapy. Most frequent toxicity was hematological (grade 2 anemia and grade
3 afebrile neutropenia), ocurring mostly during the first cycle. Only one death
occurred due to treatment toxicity (grade 4 neutropenia and sepsis). In seven
patients, at least one cycle was postponed because of toxicity. The overall
response rate was 63,3%, with 63,1% of patients achieving a complete
response. During treatment, 11 patients experienced progression, 10 died and
one reached partial response after salvage therapy with R-GEMOX (5 cycles).
One death occurred because of other causes (arterial hemorrhage secondary
to traumatism). During follow-up, three patients relapsed, with a median dura-
tion of response of 29.3 months. With a median follow-up of 17.15 months,
median survival has not yet been reached (Figure 1).
Summary/Conclusions: R-miniCHOP represents an effective and safe regi-
men in this group of patients, confirming the previous experience of the GELA
group. Toxicity observed in the first cycle shows the need of administering
prephase in all patients.
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PROGNOSTIC FACTORS AND TREATMENT OUTCOME OF PEDIATRIC
ANAPLASTIC LARGE CELL LYMPHOMA TREATED AT THE CHILDREN
CANCER HOSPITAL EGYPT
H Abdelrahman Sayed1,*, S El Semary2, I Atteya3, M Sedky1, S Talaat1,
O Hassanain4
1Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, 2Pedi-
atric Oncology, Bany Sweif University, Bany Sweif, 3Pediatric Oncology, Nation-
al Cancer Institute, 4Research, Children Cancer Hospital, Cairo, Egypt
Background: Anaplastic large cell lymphoma (ALCL) belongs to the group of
high-grade non-Hodgkin’s lymphomas (NHLs) and typically presents as an
aggressive systemic disease, with or without extranodal involvement. ALCL
cells are characterized by the expression of the CD30/Ki-1 and more often by
a T-cell phenotype. Frequently; ALCL is associated with the t(2;5)(p23;q35)
chromosomal translocation, which gives rise to the fusion gene NPM–ALK.
Recent data suggest that t(2;5) positive ALCL respond better to therapy and
have a higher survival rate than translocation negative ALCL, thus implying
that NPM–ALK expression may have a significant prognostic impact
Aims: The aim of the current study is to report the clinico-epinediologic data,
prognostic factors and treatment outcome of pediatric ALCL treated at the Chil-
dren Cancer Hospital Egypt during 8 years period.
Methods: A retrospective study including all patients diagnosed and treated as
ALCL from july 2007 till July 2014 at CCHE. The diagnosis of ALCL was based
on established morphologic and immunohistochemical criteria. ALK1 antibody
directed to the NPM/ALK protein was used to detect the t(2;5) translocation.
Results: Forty-three patients were enrolled in our study, forming 5.4% of all
NHL patients treated at CCHE within this period. They were 26 males (60.5%),
and 17 (39.5%) females. Mean age was 11.5 years, median 11.7, range (3.7
to 17.2 years).The most common tumor primary site was generalized lym-
phadenopathy (62%). ALK status was available in 65% of the cohort (28
patients), of which 75% (21 patients) was positive and 25% negative. Bone
marrow was free in all patients, while 5 patients (11.6%) had CNS involvement.
Stage II and III were 37.2% each (16 patients), while stage IV was 14% (6
patients). Evaluation of tumor response post induction showed 25 (58%) of
patients in complete remission (CR), 15 (34.9%) had partial remission (PR), 2
(4.7%) were progressive (PD), and 1 (2.4%) stationary disease (SD), while at
the end of treatment 83.7% were in CR, 11.6% PD and 4.7% relapsed. At the
end of the study period, 81.4% (36 patients) were alive, and (8 patients) 18.6%
died. The mean FU period was 50months (range 12-96). The 4 years OS and
EFS is 80.9% and 71.1% respectively.
Summary/Conclusions: Results of treatment of ALCL in our center are com-
parable to most of the reported studies. Salvage for relapsing and progressing
patients is difficult, and the outcome is extremely poor, hence the need to iden-
tify biologic or clinical prognostic factors including minimal residual tumor to
better evaluate chemotherapy response.
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CLINICAL OUTCOME AND PROGNOSIS IN 49 PATIENTS WITH MANTLE
CELL LYMPHOMA TREATED WITH ROUTINE CLINICAL PRACTICE
G Tumyan*, P Zeynalova, N Falaleeva, I Ilyasova, V Larionova, E Osmanov
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
Background: Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin’s
lymphoma (NHL) that has commonly an aggressive clinical course and a poor
prognosis. Current frontline intensive therapies have improved the outcome for
patients (pts). Although these regimens have high response rates, most pts even-
tually have a relapse. There is not always possible to find a relationship between
the intensity of treatment and survival outcomes of pts with MCL.
Aims: To assess the impact of treatment intensity on survival outcomes in
newly diagnosed patients with MCL.
Methods: We conducted a retrospective analysis for pts with MCL diagnosed
between 2004 and 2014 through our institutional databases. Frontline treatment
modalities were categorized into 2 groups: high intensity (R-HyperCVAD or
equivalent and/or stem cell transplant) and moderate intensity therapy (R-
CHOP, R-B or equivalent). Median progression free survival (PFS) and overall
survival (OS) for each treatment group were estimated using the Kaplan-Meier
(KM) method and compared using the log rank test. Cox regression was used
to identify univariate predictors of survival.
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Results: A total of 49 pts MCL were identified. Median age was 58 yrs (31-78),
69% were male, 94% had advance stages and 59% bone marrow involvement;
MIPI low (54%), int. (26%), high (20%). High and moderate intensity treatment
accounted for 19 (39%) and 30 (61%) of pts. 53% pts in moderate group fol-
lowed by R maintenance. Intensively treated patients were more likely to be
young and have B symptoms (58% vs 20% respectively). With a median fol-
low-up of 48 months, median PFS was 42 mos and OS not yet reached. Despite
median duration of response with high and moderate intensity treatment was
57 mos vs 30 mos, there was no statistically significant difference in PFS
(p=0,46) and OS (p=0,16) by treatment strategy. This lack of survival difference
was true for all pairwise log-rank comparisons between treatment groups. No
significant correlation with OS was observed with age (p=0,56), MIPI risk
(p=0,13), or treatment intensity (p=0.30).
Summary/Conclusions: In our retrospective analysis, we were not able to
validate the hypothesis, that frontline intensive treatment may improve OS in
MCL. These data highlight the lack of a “standard of care” in MCL, and provide
further rationale for the use of novel agents in newly diagnosed MCL.
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PREVALENCE OF LYMPHOPROLIFERATIVE DISEASES IN PATIENTS
WITH AUTOIMMUNE DISORDERS
V Djurasinovic1,*, P Djuradjevic2,3, D Antic1,4, B Andjelic1,4, A Sretenovic1,
V Vukovic1, J Bila1,4, J jeličić1, M Todorovic-Balint1,4, B Mihaljevic1,4
1Institute of hematology, Belgrade, 2Medicall faculty, University of Kraguje-
vacdic, 3Clinical center Kragujevac, Kragujevac, 4Medical faculty University of
Belgrade, Belgrade, Serbia
Background: Lymphoproliferative disorders can be found in patients with pre-
viously diagnosed autoimmune disorder.
Aims: We have evaluated type of lymphproliferative disease in population of
pts with autoimmune disorders and differences between genders.
Methods: Data from national registry for lymphoproliferative diseases were
analysed. From 1992-2015. there was 45pts, male 9(20%) and female 36(80%),
median age 57(33-76)years.
Results: 42(93%) of pts previously had autoimmune disesase with average
7,63(0,7-27) years. There were: systemic lupus erythematosus (SLE)
22/36(61%), reumathoid arthritis (RA) 8/36 (22%) and systemic sclerosis (SS)
6/36(17%) in women and SS 5/9 (56%), SLE 2/9(22%), RA 1/9(11%), polim-
iozitis 1/9(11%) in men.40(89%)pts had non Hodgkin lymphoma (NHL), multiple
myeloma (MM) 3(7%) and Hodgkin lymphoma 2(4%). In NHL group 20 were
DLBCL, indolent 18- NHL foll. and 2 very agressive.
Summary/Conclusions: The most frequent autoimmune disorder was SLE in
women and SS in men.NHL DLBCL was the most common lymphorpoliferative
disease. Pts with these condiotions had higher stage of disease at the diagnosis
and there was no difference in survival between male and female pts.
Bleeding disorders (congenital and acquired)
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SUCCESSFUL SEQUENTIAL THERAPY USING RFVII WITH A NOVEL
AGENT (PLASMA-DERIVED FACTOR FVIIA AND FACTOR FX MIXTURE)
TO CONTROL PERIOPERATIVE BLEEDING IN A PATIENT WITH SEVERE
HEMOPHILIA A AND INHIBITORS
K Isobe1,*, K Koh1, T Uehara1, M Yanagi1, Y Ikeda1, C Oyama1, K Sasaki1,
K Watanabe1, M Mori1, Y Arakawa1, H Taketani2, R Hanada1
1Department of Hematology/Oncology, Saitama Children’s Medical Center,
Saitama, 2Department of Joint Surgery, Research Hospital of the Institute of
Medical Science, The University of Tokyo, Tokyo, Japan
Background: The bypass therapy is usually performed to control bleeding in
patients with hemophilia and inhibitors; however, approximately 10% cases are
resistant to that using a single agent in the perioperative period. The plasma-
derived factor FVIIa and factor FX mixture (pd FVIIa/FX), containing human
serum-derived FVII and FX in a 1: 10 ratio, was recently developed in Japan
as a novel bypassing agent. The bypass effect induced by FVII is enhanced
under a high concentration of FX. We hypothesized that pd FVIIa/FX would
induce a stronger bypass effect than conventional sequential therapy using
aPCC and rFVII. Here we report our experience of sequential therapy using pd
FVIIa/FX and rFVII as a bypass therapy during the perioperative period in a
patient with severe hemophilia A and inhibitors.
Aims: To determin optimal dose of of rFVII and pd FVIIa/FX based on a pre-
operative PK study.
Methods: A pharmacokinetics (PK) study used by pd FVIIa/FX was performed
a week before surgery. FX and FVII level was measured 15 minutes, 6 hours
and 24 hours after pd FVIIa/FX (120 mcg/kg) was administered. FX level was
measured at Kaketsuken Co. (Japan) by activated partial thromboplastin time
assays under a high concentration of FVII. The Based on the PK study, FVII
and FX activity levels were simulated to determine the optimal dose and interval
of rFVII when rFVII and pd FVIIa/FX were administered. Thromboelastography
(ROTEMR) was used to rapidly allow to monitor the coagulation intra-opera-
tively. Case: A 10-year-old male was diagnosed with severe hemophilia A at 8
months old. At 13 months old, inhibitor to factor FVIII (maximum 1625 BU/ml,
the most recent: 19.2 BU/ml) was detected. He received immune tolerance
induction therapy using rFVIII or VWF/FVIII for 2 years but with no response.
At 4 years, he was started on prophylactic aPCC as a bypass therapy. At 10
years, he experienced frequent spontaneous intra-articular hemorrhage, par-
ticularly in the left knee and right ankle. Therefore, he was transferred to our
institution to receive arthroscopic synovectomy of these joint. When the surgery
started, the following sequential therapy was also initiated in accordance with
the simulation: pd FVIIa/FX (120 mcg/kg) was administered three times every
36 h and rFVII (60mcg/kg) every 2 h. The interval of rFVII administration was
gradually extended. Six days after surgery, the sequential therapy was switched
to prophylactic aPCC administration.
Results: 1) Coagulation: The measured activity levels of rFVII and FX were
almost the same as the simulation data. The INTEMRassay, in the ROTEMR,
used to monitor the intrinsic pathway showed that coagulation was recovered
by sequential therapy. 2) Safety: In accordance with the product document, pd
FVIIa/FX (120 mcg/kg) every 36 h was administered and no thrombotic events
were detected. 3) Efficacy: Little bleeding was observed during surgery, and
no sign of intra-articular hemorrhage was observed on physical examination
after surgery. 4) Cost: This regimen contributed to a 45% cost reduction com-
pared with that with single agent bypass therapy using rFVII.
Summary/Conclusions: Sequential pd FVIIa/FX and rFVII as a bypass therapy
during the perioperative period is feasible and effective for patients with severe
hemophilia A and inhibitors. It is necessary to determine the optimal dose of
rFVII based on a preoperative PK study.
PB1748
CONTINUOUS INFUSION FOR LIFE THREATENING HEMORRHAGE OF
HEMOPHILIA PATIENT
K Lee1,*, J Kim1, J Seo1, S Hyun2
1Pediatrics, Kyungpook National University School of Medicine, Daegu, 2Inter-
nal Medicine, Yonsei University Wonju College of Medicine, Wounju, Korea,
Republic Of
Background: Continuous infusion (CI) compare to bolus infusion has a merit
of factor concentrate saving as much as 30% with same hemostatic effect. All
biologic products will drcrease its activity even in vitro.
Aims: According to the instruction of inside package the factor concentrate
recommend to administer within 3 hours of reconstitution at room temperature.
Universally 24 hours’ volume of CI were reconstituted at one time in almost all
hospital. We applied this CI for life-threatening hemorrhage with a different
method since 1996.
Methods: Thirty five of life threatening hemorrhage or major surgery from 28
patients were enrolled in this study for 15 years. All patients received FVIII con-
haematologica | 2016; 101(s1) | 709
Copenhagen, Denmark, June 9 – 12, 2016
centrates with initial loading dose of FVIII 50U/kg and then the continuous infu-
sion, 3 U/kg/hr for 3 days, and then gradually decreased the amount for 2
weeks. We empirically prepared the material of CI with every 2-4 hours recon-
stitution to keep a desired in vivo factor level. To verify of this we checked in
vitro factor activity of 3 drugs as time goes on recently.
Results: Thirty five events were intracranial hemorrhage in 17, general surgery
in 9 and orthopedic surgery in 9. Age distribution was 0-32 yr (mean; 24.8 yr).
Severity was severe (16), moderate (7) and mild (5). We confirmed in vivo
factor activity within permissible level in all patients. All recovered from hemor-
rhage or surgery and are healthy, but one had limping gate and one had mild
neurologic sequelae for more than 10 years. The mean in vitro factor activity
at 2, 4, 6, 8 and 24hours of reconstitution were gradually decreased to 97.7%,
95.3%, 92.9%, 90.6 and 73.0% respectively in all 3 drugs.
Summary/Conclusions: All biologic products decrease their activity as time
goes on even in vitro. Empirically, we reconstitute the concentrate every 2-4
hours for CI since 1996. And we confirmed the in vitro activity will decrease as
time goes on. In continuous infusion we have to reconstitute the concentrate
every 2-4 hours to make a desired in vivo factor level.
PB1749
THE GENETIC ANALYSIS OF TWO PATIENTS WITH CONGENITAL
COAGULATION FACTOR XI DEFICIENCY
R Zhou*, N Zhou, J Ouyan
Haematology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Medical School, Nanjing, China
Background: Factor-XI deficiency (FXID) is a rare inherited autosomal reces-
sive disord.
Aims: To analyze genetic mutation and explore its molecular pathogenesis for
two patients with congenital coagulation factor XI deficiency
Methods: Two patients were found to have prolonged activated partial thrombin
time (aPTT), then their activity of coagulant factors were tested and aPTT mixing
test with incubation were performed. Low activity of the FXI  (FXI: C) was found
in both. Two patients’ blood was collected, and their DNA was extracted. Poly-
merase Chain Reaction (PCR) was used to amplify all exons and exon-intron
boundaries, and then the products of PCR were sequenced directjy. The mutation
was determined through alignment of the normal FXI genomic DNA sequence
by software chromas. The segment with mutation was sequenced backward.
Results: aPTT and FXI:C was 109.6s and 0.4% for patient 1 and 50.1s and
6.7% for patient 2,respectively.The results of aPTT mixing correction test and
activities of other coagulant factors were all in normal range for both patients.
The results of sequencing showed that a de novel homogenous nucleotide
18A deletion (18delA) mutation in exon2 was detected in patient1, leading
frame shift mutation (Val-13TrpfsX15), and that combined heterogenous muta-
tion, a nucleotide 738G>A transition in exon7 and a nucleotide 1021G>A tran-
sition in exon9, resulting a Trp228stop substitution and a Glu323Lys substitu-
tion,respectively, were detected in patient 2.
Summary/Conclusions: These mutations might be the molecular pathogen-
esis for two patients with congenital coagulation factor XI deficiency, respec-
tively.
PB1750
A NOVEL FIBRINOGEN VARIANT: DYSFIBRINOGENEMIA ASSOCIATED
WITH ΓASP185ASN SUBSTITUTION
R Zhou*, N Zhou, J Ouyan
Haematology, The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Medical School, Nanjing, China
Background: Congenital dysfibrinogenemia is a qualitative congenital fibrinogen
disorder characterized by normal antigen levels of a dysfunctional fibrinogen.
Aims: A patient with abnormal coagulation test was diagnosed as congenital
dysfibrinogenemia. In this study, the causative mutations responsible for dys-
fibrinogenemia were detected in proband and her child.
Methods: The proband from Nanjing, China was presented with low fibrinogen
and prolonged thrombin time (TT) during prenatal routine medical examination
but with asymptoms. Her son also had low fibrinogen and prolonged TT. After
extraction, genomic DNA was amplified by polymerase chain reaction. DNA
sequencing was performed on the purified PCR products.
Results: Two heterozygous missence mutations including AαArg16His and
γAsp185Asn were discovered in the proband. Her son only harbored the former
mutation. AαArg16His had been reported by other teams and γAsp185Asn
was identified firstly in our study as a novel variant. Endonuclease restriction
digestion was performed to exclude polymorphism. The homologous
sequences alignment was compared among different species to identify this
new mutation site was a kind of conservative one.
Summary/Conclusions: The heterozygous AαArg16His and γAsp185Asn
mutations identified in the study probably underlies the dysfibrinogenemia in
this pedigree. The novel fibrinogen variant (γAsp185Asn) was named as fib-
rinogen Nanjing.
PB1751
INHIBITOR TO FIBRINOGEN WITHOUT PROPHYLACTIC THERAPY IN A
PATIENT WITH CONGENITAL AFIBRINOGENEMIA. A CASE REPORT
T Patiroglu*, E Yilmaz, E Unal, M Karakukcu, MA Ozdemir
Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey
Background: Afibrinogenemia is a rare condition and has an estimated
prevalance of 1:1000000. The more common manifestations of afibrinogenemia
are umblical stump bleeding, and bleeding from mucosal surfaces, particularly
menorrhagia, epistaxis, gastrointestinal bleeding and intracranial hemorrhage.
Aims: We report a case with congenital afibrinogenemia which had pulmonary
and intracranial hemorrhage. Although the patient had not prophylactic therapy
with fibrinogen concentrate nor cryoprespitate before admission to the hospital,
laboratory investigation revealed mixed test positivity
Methods: A case of an 18 years-old girl with congenital afibrinogenemia admit-
ted to our department because of dyspnea and tachipnea. Her chest X-ray and
CT showed pulmonary hemorrhage. Therefore, she was administered with fib-
rinogen conscentrate in doses of 50 mg per kg and prednisolon in doses 1 mg
per kg. Furthermore, she underwent a generalized convulsion on second day
and neuroimaging tests revealed intracranial hemorrhage. Although she was
treated with fibrinogen concentrate and cryoprespitate every day her laboratory
investigation revealed prolonged PT, aPTT and TT tests and fibrinogen level
in plasma lower than 0.5g /L. Hence, we performed mixed test and the result
was positive. On follow up, she was given IVIG in doses of 2 g per kg once and
plasma exchange was planned every day. Furthermore, she was treated with
fibrinogen concentrate and cryoprespitate every day to raise fibrinogen level
in plasma to 1 g/L. Unfortunately, she died at intensive care unite because of
intracranial hemorrhage 17 days after admission to the hospital.
Results: Replacement therapy is generally effective in treating of bleeding
episodes in congenital afibrinogenemia. Options for replacement include plas-
ma-derived fibrinogen concentrate, cryoprespitate, and fresh frozen plasma;
Antifibrinolytic agents may be used especially for dental procedures. Prophy-
lactic therapy have been employed after life-threatening bleedings such as
intrcranial hemorrhage. Acquired inhibitors have been rarely reported after
replacement and prophylactic therapy.
Summary/Conclusions: We surprisingly revealed inhibitor to fibrinogen (mixed
test positivity) although the patient did not have prophylactic therapy with fibrino-
gen concentrate nor cryoprespitate before admission to the hospital.
PB1752
ROLE OF HIGH DOSE ASCORBIC ACID IN TREATMENT OF METHAMO-
GLOBINEMIA
K Sahu*, D Dhibar , P Deo, S Jain , S Varma , S Kumari 
Internal Medicine, PGIMER, Chandigarh, India
Background: Methaemoglobin (MetHb) is an oxidized form of haemoglobin.
MetHb has high affinity for oxygen, resulting decrease delivery of oxygen to
the tissue. It can be congenital but in clinical practice drugs induced acquired
form is more common. Methylene blue is used as first line therapy but the role
of vitamin C in the treatment of methaemoglobinemia is yet to be established.
Here we are presenting our experience with high dose of vitamin C used suc-
cessfully to treated methamoglobinemia.
Aims: To study the role of high dose of ascorbic acid for treatment of methamo-
globinemia.
Methods: This study was conducted over the span of 3 months (Nov 2015-
Jan 2016). All patients visiting emergency services with suspected methamo-
globinemia were included. In total we found three cases of the proven
methamoglobinemia. Patients were given the best supportive therapy including
haemodialysis, PRBCs, oxygen supplementation etc. All three patients were
given high dose of ascorbic acid (2000mg/day).
Results: Table 1 mentions in detail the demographic details of patients included
in the study. Two out of three patients had history of accidental consumption
of inciting agent, while the third was prescribed dapsone for immune thrombo-
cytopenia. Case 2 developed massive intravascular haemolysis leading to
acute kidney injury requiring haemodialysis (5 sessions). All our patients were
normal G6PD activity. Due to unavailability of methylene blue, it was decided
to give high dose of ascorbic acid as an anti-oxidant (2000mg/day for 5 days
followed by gradual tapering) to all these patients. All patients responded dra-
matically to this medication and had reduction of Meth-Hb levels.
Table 1. Treatment of cases of methamoglobinemia with 2000mg/day of
Ascorbic acid
Age/Sex        Precipitating factor         Baseline Meth-Hb    Baseline disease     Outcome
45/M      Dapsone (300mg/day) for ITP             25         Immune thrombocytopenia  Alive
15/M        Naphthalene ball poisoning            25.5%                      None                  Alive
25/M           Paint thinner poisoning                 46.4                       None                  Alive
Summary/Conclusions: Higher doses of ascorbic acid (2000mg/day) has
proven to be beneficial in cases of methamoglobinemia.
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PROPHYLAXIS FOR HEMOPHILIA PATIENT IN KOREA
K Lee1, S Hyun2,*, J Seo1, J Kim1
1Pediatrics, Kyungpook National University School of Medicine, Daegu, 2Inter-
nal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea,
Republic Of
Background: Prophylaxis compare to on-demand treatment for severe hemo-
philia patients has a great profit for not only life quality but also life itself.
Aims: We have started prophylaxis for 5 intracranial hemorrhage patients after
recovery since 1996. Fifteen years later, prophylaxis for hemophilia A and B
patients only under 15 y/o have been approved by National Health Insurance
Review and Assessment from January, 2011.
Methods: Intracranial hemorrhage was observed in 16 episodes from 9 patients
between 1996 and 2002 at our hospital. All patients received FVIII concentrates
with initial loading dose of FVIII 50 U/kg and then the continuous infusion, 3
U/kg/hr for 3 days, and then gradually decreased the volume for 7-10 days.
We persuaded the patient/parent for life long prophylaxis to prevent further life-
threatening hemorrhage. Five among 8 patients followed the prophylaxis (30
U/kg, 3 days/week).
Results: Age distribution was 2 mo-26 yr (mean; 8.8 yr). Severity was severe
(4), moderate (4) and mild (1). Trauma history was in only 1 case. Initial symp-
tom was vomiting (8), headache (4), seizure (3), and irritability (1). Time interval
between first symptom and arrival at ER were 15 min to 10 days (mean;
1.7days). Intracranial bleeding site was variety. Inhibitor was in 1 case and 2
cases were transient type. Previous life threatening hemorrhage history was
observed in 5 cases (ICH in 4 and GI bleeding in 1). Family history was
observed in 7 cases. Eight patients received FVIII concentrates with initial load-
ing dose of FVIII 50 U/kg and then the continuous infusion, 3 U/kg/hr for 3 days,
and then gradually decrease the volume for 7-10 days. Inhibitor patient was
treated with by-passing agent. Craniotomy was done in 4 cases and no oper-
ation was in 4 cases. All recovered except one (who died within 30 minutes
after arrival, bleeding site was cerebellar vermis & 3rd ventricle) and are alive
without any neurologic sequelae except one with mild limping gate for more
than 10 years.
Summary/Conclusions: Prophylaxis for severe hemophilia has to expand to
all age, to moderate hemophilia with previous life threatening bleeding history
and to inhibitor patients in Korea.
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VON WILLEBRAND DISEASE AND ACQUIRED VON WILLEBRAND
SYNDROME – A DIAGNOSTIC ALGORITHM
MM Campos1,*, V Pishchanskyy1, F Carriço2, MJ Marques1, ME Ribeiro1,
T Araújo1
1Department of Immunohemotherapy (Head: D. Espírito Santo), Hospital Curry
Cabral - Centro Hospitalar Lisboa Central, EPE, 2Laboratory of Hematology,
Hospital Santa Maria - Centro Hospitalar Lisboa Norte, EPE, Lisboa, Portugal
Background: Von Willebrand disease (VWD) is a common inherited bleeding
disorder (prevalence of 1:10000) but acquired von Willebrand syndrome
(AVWS) is a very rare bleeding state associated with lymphoproliferative, myelo-
proliferative, cardiovascular and autoimmune conditions, hypothyroidism, ure-
mia, liver cirrhosis, pancreatitis and the use of ciprofloxacin, griseofulvin, val-
proic acid and tetracycline. More than 60% of the few reported cases of AVWS
correspond to lymphoma, multiple myeloma, monoclonal gammopathy of unde-
termined significance, essential thrombocythemia, polycythemia vera, chronic
myeloid leukemia and primary myelofibrosis.
Aims: To establish a diagnostic algorithm for VWD and AWVS, differential diag-
nosis must be done including other coagulopathies. Factor VIII:C (FVIII:C) and
von Willebrand factor (VWF) are endothelium injury markers and their levels
may increase in inflammatory diseases. Individuals with blood group O exhibit
lower levels of VWF but there is a general raise of VWF with ageing.
Methods: The prothrombin time (PT) and the activated partial thromboplastin
time (APTT) are not reliable tests in screening for diagnosis of VWD. Optional
tests as thrombin time or fibrinogen are not relevant. So, a basic approach with
PT, APTT, and an evaluation of platelet count, morphology and function, must
be followed by WVF-specific tests, like a profile with VWF antigen (VWF:Ag),
functional VWF (VWF:f) that corresponds to VWF activity (VWF:Act) or VWF
ristocetin cofactor (VWF:RCo) and FVIII:C. For inhibitor screening the VWF:f
is carried out with several dilutions of patient plasma with factor diluent (the
parallelism loss suggests an inhibitor, which can be present in AWVS). Another
procedure is the plasma mixing test with patient plasma and normal plasma.
Low-dose ristocetin-induced platelet aggregation (RIPA), multimer analysis by
agarose gel electrophoresis, molecular genetics, VWF binding to collagen
(VWF:CB) and VWF propeptide (VWFpp) by enzyme-linked immunosorbent
assay (ELISA) are other resources for specialized laboratories.
Results: The diagnostic algorithm (Figure 1) summarizes our methodology.
The Table 1 shows our laboratory results of different types of VWD, AVWS and
low VWF.
Table - Laboratory results of different types of VWD, AVWS and low VWF
(levels in%)
                              Case 1      Case 2     Case 3    Case 4    Case 5    Case 6     Case 7
VWF:Ag                       35.0          34.0        30.2        9.0        49.1      53.4        13.4
VWF:RCo                     33.0           8.0     <7.0 (4.8)      -          45.4      39.1        8.2
VWF:Act                      36.0   <19.0 (10.0)     -     <19.0 (1.0) 40.9         -     <19.0 (3.2)
FVIII:C                         64.0          53.0        37.7        4.0        54.8      53.5        18.1
VWF:CB                       27.2           8.1            -           8.1           -            -             -
RIPA                              -                            -         Absent        -            -             -
Multimers                 Normal     HIMWM       -      All absent      -            -             -
Genetics (mutations)      -               -        R1374H       -             -            -             -
VWF:f parallelism           -               -             -             -             -             -        Inhibitor
Defects                      Type 1      Type 2A   Type 2M   Type 3   Low VWF Low VWF    AWVS
Gender (M/F)                 F               F             M            F             F            M             F
Age (years)                   42            33          34          34          35         18           74
Figure 1.
Summary/Conclusions: 1) We propose an algorithm for the diagnostic
approach of mucocutaneous bleeding with high clinical suspicion of VWD,
platelet type pseudo-VWD (PT-VWD) and AVWS. 2) The main goal is to create
a multistep screening based in threshold values. 3) The differentiation between
type 2B VWD and PT-VWD is essential to avoid misdiagnoses and provide
adequate therapy. 4) The clarification between type 1 VWD and low level of
VWF:Ag and/or VWF:RCo (30-50%) is controversial: asymptomatic individuals
don’t need an extensive testing, only those with a past severe hemorrhages (a
good predictor of recurrence) or presenting relatives with similar levels require
an advanced assessment. 5) If VWFpp is available it may be helpful in the
identification of type 1C VWD.
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DIAGNOSTIC CHALLENGES IN ACQUIRED VON WILLEBRAND DISEASE:
A COMPLEX CASE OF PROSTATE CARCINOMA
PE Claus1,*, E Moreau1, D Deeren2
1Clinical Biology, 2Hematology, AZ Delta, Roeselare, Belgium
Background: Acquired von Willebrand disease (AVWD) is a rare bleeding dis-
order associated with a variety of underlying diseases and with clinical mani-
festations similar to congenital von Willebrand disease.
Aims: We present a case of prostate carcinoma in which AVWD was diag-
nosed.
Methods: The patient was an 80-year-old man who suffered from ulcerative
colitis. He was diagnosed with a Gleason 7 prostate adenocarcinoma for which
he received radiotherapy in combination with hormonal therapy. Due to melena
he underwent a coloscopy during which biopsies were taken. The procedure
was complicated by diffuse bleeding and a cardiac infarction. Urgent coronary
artery bypass surgery (CABG) was performed but was also complicated by
postoperative bleeding. Laboratory studies showed a normal platelet count, a
prolongation of the activated partial thromboplastin time (aPTT) and low factor
VIII levels. His von Willebrand factor (VWF) antigen level and ristocetin cofactor
activity were low.
Results: The diagnosis of AVWD in this patient challenged us to look for the
different pathogenic mechanisms of the disease. Several disorders have been
described to be associated with AVWD, the commonest being hematoprolifer-
ative, cardiovascular and autoimmune disorders. Neoplasms are rarely docu-
mented and their pathogenic mechanisms are not well known. The underlying
mechanisms differ among these disorders and may even overlap. These
include, among other things, mechanical destruction of VWF under high shear
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stress and development of autoantibodies. Selective and/or non-selective
absorption of VWF on or inside malignant cells is believed to be the main mech-
anism in hematoproliferative and non-hematologic malignancies.
Summary/Conclusions: In this report we give a concise overview of the mech-
anisms of the diseases that we encountered in this complex case.
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TAR SYNDROME - DIAGNOSTIC AND TREATMENT. CASE REPORT
V Grajqevci-Uka*, R Maxhuni, B Abrashi, F Selimi
Hemato-oncology, UCCK, Pediatric Clinic, Prishtina, Kosovo
Background: Thrombocytopenia absent radius syndrome (TAR) is a rare
genetic disorder that is apparent at birth. TAR syndrome is inherited as an
autosomal recessive trait. This disorder is characterized by low levels of
platelets in blood (thrombocytopenia) resulting in potentially severe bleeding
episodes primarily during infancy.
Aims: Presentation of the case with (TAR) syndrome which was admitted to
Hematology Oncology Unit at Pediatric Clinic with petechia and hematomas
skin.changes,
Methods: : A 2.5 month old male child, was admitted in our unit with petechial
and hematoma’s skin changes and epistaxis. Diagnosis of the patient was
made with help of the clinical examinations, laboratory findings, radiological
images and genetic reaserch.
Results: At the radiological imaging examination of the upper limbs, radius
was absent in both shoulders.. Complete blood count: hemoglobin, 11 g/dL;
mean corpuscular volume, 95 fl; mean corpuscular hemoglobin, 34 pg; reticu-
locytic count, platelet count, 20,000/uL; prothrombin time, 12.8 seconds; partial
thromboplastin time, 28.0 seconds. Liver function tests had the following results:
bilirubin (total), 6.20mg/dL; (direct), 0.25 mg/dL; glutamic pyruvic transaminase,
35 U/L; and glutamic oxaloacetic transaminase, 34 U/L. Electrolytes and kidney
function were: Na, 146 mmol/L; K, 3.8 mmol/L; serum creatinine, 0.9 mg/dL.
TORCH screens were normal Radiography of the forearm showed bilateral
absence of radii. Abdominal and cranial ultrasonography were normal. The
genetic analysis was positive.
Summary/Conclusions: TAR syndrome is a rare genetic disorder character-
ized by low platelet level and radial aplasia. The tranfusions with platelet con-
centrate is needed when patient is presented with low platelets count.
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PROPHYLAXIS IN RARE FACTOR DEFICIENCIES OF CHILDREN
Z Salcioglu1,*, H Sen1, G Aydogan1, F Akıcı1, Z Baslar2
1Pediatric Hematology-Oncology, Kanuni Sultan Suleyman Education and
Research Hospital, 2 Hematology, Cerrahpasa Medical School, Istanbul, Turkey
Background: Rare factor deficiencies (RFD) cover the deficiencies of fibrino-
gen, Factor II, Factor V, Factor V+VIII, Factor VII, Factor X, Factor XI, Factor
XIII, and vitamin K associated factors. Many national and international study
groups conducted studies regarding the diagnosis and treatment of rare factor
deficiencies in 2000s. The existence a mortality and morbidity risk associated
with severe bleedings has brought the search for prophylaxes related to these
disorders into the agenda. In addition, the good results obtained with primary
and secondary prophylaxes in haemophilia cases have attracted the attention
to the possibility that the same consideration could also be applied to rare
factor deficiencies. Prophylaxis is recommended in these patients if such
severe bleedings as central nervous system bleedings, gastrointestinal bleed-
ings, and articular hemorrhages recur.
Aims: Our prophylaxis application related to 13 congenital rare factor deficiency
cases being followed at our clinic comprising of five patients with Factor VII
deficiency, four patients with Factorxdeficiency, three patients with afibrinogen-
emia, and one patient with FV deficiency, were evaluated in our article.
Methods: Information concerning our patients was compiled from patient files
and the data contained in the electronic information processing environment
created after 2005.
Results: Presenting ages of our patients ranged between one week and 7
years of age. Seven of them were boys and 6 were girls. Prophylaxis was
applied due to intracranial bleeding to three of our Factor VII deficiency patients,
for gastrointestinal system bleeding to one of them, and for the development
of chronic hemarthrosis and hemarthrosis that requires the application of
radioisotope synovectomy to one patient. 20 mcg/kg active recombinant FVII
was used once a week in the prophylaxis of our FVII deficiency cases. Transi-
tion to two doses a week was required for one patient. Prophylaxis is being
applied with 20 IU/kg prothrombin complex concentrate two days a week to
our patients with Factorxdeficiency for central nervous system bleedings and
with 50 mg/kg fibrinogen every two weeks to our patients with afibrinogenemia
for recurring intramuscular bleedings causing severe pain and difficulty of walk-
ing. Our patient with FV deficiency to whom prophylaxis is applied due to
intracranial bleeding, on the other hand, receives 20 ml/kg fresh frozen plasma
once a week. The prophylaxis periods of our patients range between 2 months
and 9 years.
Summary/Conclusions: The observation as well as clinical and laboratory
findings of our patients together with the details related to their prophylaxis
processes were presented in our proceedings accompanied with the relevant
literature.
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TWO IMPORTANT FACTORS WHICH AFFECT HEMOSTASIS IN
HEMOPHILIA PAITENT WITH SURGERY
K Lee1, J Kim1, J Seo1, S Hyun2,*
1Pediatrics, Kyungpook National University School of Medicine, Daegu, 2Inter-
nal Medicine, Yonsei University Wonju College of Medicine, Wounju, Korea,
Republic Of
Background: The severity and hemostasis in hemophilia is based on one’s
factor level. In surgery of hemophilia patient appropriate hemostasis is very
important for prognosis. Individual pharmacokinetic is quite different especially
in recovery rate (RR).
Aims: We evaluate the prognosis of surgical cases according to different recov-
ery rate recently. And we infused the concentrate in bolus followed by contin-
uous infusion method during and after surgery. Also we checked in vitro factor
activity as time goes on.
Methods: Twenty seven major surgeries were done in 20 patients (severe;
12, moderate; 4 and mild; 4). The mean age was 32 yr. The patient was divided
into 3 groups. Group A (A) composed of 12 patients whose RR was above 0.8
with no further correction. Group B (B) composed of 10 patients whose RR are
below 0.8 with further correction to make 1.0 before surgery. Group C (C) com-
posed 5 patients whose RR was below 0.8 without further correction because
of emergency operation. In continuous infusion we reconstitute the concentrate
every 2-4 hours volume because in vitro factor activity will decrease as time
goes on.
Results: The hospitalization periods of A, B and C were 14.5+/-12.1, 13.9+/-
4.0, and 45.8+/-15.7 respectively (p=0,015 and 0.006 in A & C and B & C). The
consumption of factor A concentrate of A, B and C were 481+/-195 U/kg,
1,311+/-283 U/kg and 3,502+/-1,529 respectively (p<0,001 in A & B and
p=0.006 in B & C). Complications such as hematoma, sepsis CNS infection
and hydrocephalus were observed in C. The mean in vitro factor activity at 2,
4, 6, 8 and 24 hours of reconstitution were gradually decreased to 97.7%,
95.3%, 92.9%, 90.6 and 73.0% respectively in all 3 drugs. Best activity at 24
hours was observed in light shield sample.
Summary/Conclusions: Although the recovery rate will be changed in different
condition and time preliminary check is important for the emergency. In contin-
uous infusion we recommend to reconstitute the concentrate every 2-4 hours
to make a desired in vivo factor level.
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INTERLEUKIN-27 RS153109 POLYMORPHISM AND THE RISK FOR
ACQUIRED APLASTIC ANEMIA IN A CHINESE POPULATION
M Ge*, W Yu, Y Zheng
State Key Laboratory of Experimental Hematology, Institute of Hematology &
Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union
Medical College, Tianjin, China
Background: Acquired AA, characterized by pancytopenia in peripheral blood
(PB) and bone marrow (BM) hypoplasia, is a BM failure syndrome attacked by
autologous T cells on BM hematopoietic progenitors. Interleukin-27 (IL-27), as
a novel heterodimeric cytokine of the IL-12 family, has been shown to play a
vital role in the pathogenesis of aplastic anemia (AA) .The present studies
demonstrated that IL-27 enhanced the production of TNF-α and IFN-γ in both
CD4+and CD8+T lymphocytes from AA patients, and the elevated IL-27 and IL-
27-induced TNF-α and IFN-γ overproduction might be involved in the patho-
genesis of AA. Among the IL-27 polymorphisms identified, the SNP of IL-27
rs153109 polymorphism has been reported to be associated with the risk of
asthma, chronic obstructive pulmonary disease and inflammatory bowel dis-
eases. To our knowledge, little is known about the role of the SNP of IL-27 in
individual susceptibility to AA. To address this question, we have detected the
IL-27 rs153109 polymorphism with an aim of identifying site(s) of variation,
which may be helpful for better understanding the genetic influences of this
gene. We herein performed a case-control study to investigate whether the IL-
27 rs153109 polymorphism is associated with AA in Chinese people.
Aims: The aim of the present study was to investigate the association of single
nucleotide polymorphisms (SNP) of IL-27 gene with the risk for aplastic anemia
(AA).
Methods: Patients Studied - The subjects comprised 205 AA patients (109 male
and 96 female) with age range of (14–76 years) referred to our hospital, and 196
healthy controls from the employees of our hospital. The characteristics of the
subjects are shown in Table 1A. Extraction of Genomic DNA - Genomic DNA
was extracted using DNA Purification Kit (promega Cat. #A1125 Beijing, China)
according to the manufacturer’s protocols. IL-27 rs153109 Genotyping by Poly-
merase Chain Reaction-restriction Fragment Length Polymorphism (PCR-RFLP)
- The genotyping of the TRAF1/C5 rs10818488 was performed by PCR-RFLP.
The upstream primer 5΄- ACCAAGAAACCCCATCCTCT -3΄ and the downstream
primer 5΄- TCAGTCAGTGACCAGGATCG -3΄ were used to generate a region of
224 bp of IL-27 gene. Genotyping for IL-27 rs153109 SNP was performed by
restriction analysis using the PaeR7I restriction enzyme (New England Biolabs),
which digests specifically DNA amplified from the G (but not the A) allele into
179-bp and 45-bp fragments. Both undigested and digested PCR products were
visualized in 2% agarose gel stained with ethidium bromide. Genotypes were
scored blindly, and analyses of all ambiguous samples were repeated. Statistical
Analysis - SPSS16.0 (SPSS Inc., Chicago, IL) was used for statistics analysis. A
p value <0.05 was considered to be statistically significant.
Table 1.
Results: In our study, the IL-27 rs153109 polymorphism genotypes between
AA patients and healthy controls were first determined and compared. The fre-
quencies of AA, AG and GG genotypes, and A and G alleles were 39.5%,
48.3%, 12.2%, 63.7% and 36.3%, respectively, in AA patients. There was no
significant differences in terms of genotype and alleles distributions between
AA patients and healthy controls (P=0.653 and 0.908, respectively).(Table 1B).
Furthermore, AA patients were further subdivided into three groups according
to the disease serevity: vSAA, SAA, and NSAA. The distribution of this poly-
morphism genotype was compared between each of these three groups and
the controls, respectively. No statistical differences were identified (Table 1C).
We also investigated whether the IL-27 rs153109 polymorphism could influence
response to treatment. Nine of 205 (4.4%) patients were lost to follow-up.
Responders included complete and partial responders. No significant correla-
tions between the genotype and allele frequencies and response of treatment
in this cohort of AA patients were observed (Table 1D).
Summary/Conclusions: In conclusion, IL-27 rs153109 polymorphism may not
play an important role as a genetic risk factor in the pathophysiology of AA in a
Chinese population. More studies with larger sample are warranted to further
confirm the role of IL-27 rs153109 polymorphism in determining the risk of AA.
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THE DYSFUNCTION OF PLATELETS IN PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA
R Fu*, Y Meng, H Liu, Y Wang, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Thrombosis is a dangerous complication of paroxysmal nocturnal
hemoglobinuria (PNH), with a high mortality rate. However, the mechanism
underlying the development of thrombosis in PNH remains unclear.
Aims: To explore the function of platelets in PNH.
Methods: Serum concentrations of the terminal complement complex (sC5b-
9) were determined by ELISA and the levels of C5b-9, CD61 and CD62p on
platelet membranes by flow cytometry. Clinical parameters were assessed,
including D-dimer and platelet aggregation induced by adenosine diphosphate
(ADP) and arachidonic acid (ARA).
Results: Serum sC5b-9 concentrations were significantly lower in the
PNH/PNH-AA than in the control group (p<0.01). C5b-9 deposition was signif-
icantly higher on CD59- platelets than on CD59+platelets in PNH/PNH-AA
patients and healthy controls (p<0.01 each). D-dimer concentration was signif-
icantly higher in PNH/PNH-AA patients, especially those with lactate dehydro-
genase concentrations >1000 U/L, than in controls (p<0.05). CD61 (p<0.05)
expression was lower on CD59+platelets in PNH than controls and CD59−
platelets in PNH. CD62p(p<0.01) expressions were lower on CD59− and
CD59+platelets (p<0.01) in PNH than controls. Platelet aggregation stimulated
by the agonists ADP and ARA was lower in the PNH/PNH-AA than in the control
group (p<0.05). Interestingly, CD61 expression on CD59+platelets was higher
in PNH patients than in patients with higher type II PNH clones.
Figure 1.
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Summary/Conclusions: Platelet function of platelets, especially of
CD59+platelets, was inversely inhibited in PNH/PNH-AA even in the presence
of continuous hypercoagulation.
PB1761
IDENTIFICATION OF HAEMOSTASIS SYSTEM PATIENTS, SUFFERING
FROM APLASTIC ANEMIA
V Kobilyanskaya1,*, S Bessmeltsev1, E Shilova2, T Morozova1
1Hematology department, 2Russian research Institute of Hematology and
Transfusiology of the FMBA of Russia, St-Petersburg, Russian Federation
Background: Since the first description by Paul Arliam acquired aplastic ane-
mia (AA) over 100 years ago, but today this disease remains in the spotlight
hematologists and physicians in adjacent fields. AA - a serious disease of the
blood system, resulting from damage to the stem cells (precursors of all blood
cells), resulting in a profound inhibition of normal hematopoiesis with the devel-
opment of pancytopenia. One of the main clinical manifestations is hemorrhagic
syndrome caused by thrombocytopenia and impaired activity of plasma coag-
ulation factors: reduction factors of the prothrombin complex, decreased fib-
rinogen, lack of blood clot retraction. However, some patients with AA, there is
a tendency to hypercoagulability, which is not as widely described in the sci-
entific literature as hemorrhagic manifestations.
Aims: The search for diagnostic markers hypercoagulation status in patients
with AA.
Methods: The research material was venous blood 25 patients (17 men and 8
women, mean age 38±0,5), with a diagnosis of «aplastic anemia». Patients
received standard immunosuppressive therapy without platelet transfusions.
Platelet count ranged from 8 to 30x10 9/l. Plasma level of hemostasis was eval-
uated in the following coagulation tests: activated partial thromboplastin time
(APTT), prothrombin time Quick (PT), thrombin time (TT), the concentration of
fibrinogen (Fg), the activity of the factor VIII, activity of antithrombin (AT). The
control group consisted of 40 clinically healthy men and women of similar age.
Results: Compared to the normal performance of screening tests (APTT, PТ,
TТ, FG) in 18 (72%) of 25 patients reported a significant increase in the activity
of factor VIII, which is usually regarded as an indicator hypercoagulation state
of hemostasis (189,8%±96,5% against normal value 119,0%±30.5%, p <0,001).
In 8 (44%) of 18 patients with elevated factor VIII revealed reduced levels of
antithrombin, which amounted to 68% (fluctuations from 74% to 62%). How-
ever, clinical manifestations hypercoagulation syndrome (thrombosis and
thromboembolism) single patient not were observed.
Summary/Conclusions: Thus, in patients with AA showed increased activity
of factor VIII and decreased levels of anti-thrombin. Whether these indicators
markers hypercoagulation state, or is it a manifestation of compensatory func-
tions, which prevent severe hemorrhagic complications in this category of
patients. Research in this direction continues. Our further studies aimed at
clarifying roles in the body of the identified changes
Bone marrow failure syndromes incl. PNH - Clinical
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ACQUIRED HLA-B*40:02 MUTATION LEADING TO FRAME SHIFT IN 
DIOPATHIC APLASTIC ANEMIA
J Huh1,*, YC Mun2, HJ Huh3
1Laboratory Medicine, 2Internal Medicine, Ewha Womans University College
of Medicine, Seoul, 3Laboratory Medicine, Dongguk University, Ilsan Medical
Center, Ilsan, Korea, Republic Of
Background: Idiopathic aplastic anemia(AA) has been reported to be associ-
ated with autoimmunity to hematopoietic stem/progenitor cells (HSPCs). Spe-
cific human leukocyte antigen (HLA) alleles are the target antigens of autore-
active cytotoxic T cells (CTL). One study reported that Japanese patients with
idiopathic AA typically inherited only those four HLA alleles such as HLA-
A*02:01, HLA-A*02:06, HLA-A*31:01 and HLA-B*40:02. (Katagiri et al., 2011).
AA acquired copy number neutral loss of heterozygosity of the 6p arms (6p
CN-LOH), leading to loss of one HLA haplotype. Moreover, the missing haplo-
type was concentrated in the same particular alleles : HLA-A*02:01, HLA-
A*02:06, HLA-A*31:01 and HLA-B*40:02. Therefore, 6p CN-LOH may arise
from selective pressure to escape from autoreactive CTL through loss of HLA
alleles. In the other hand, nonsense mutation in HLA-B*40:02 (CAG to TAG)
at codon 54 in exon 2 of HLA-B*40:02 with no involvement of 6p CN-LOH in a
case with AA was first reported by Osumi T et al., (Br J Haematol
2013:162:706).
Aims: In this study, we report a patient with idiopathic AA who acquired a muta-
tion in HLA-B*40:02 allele (4 nucleotide deletion, leading frame shift). Our case
is the second report of HLA-B*40:02 mutation, to our best knowledge.
Methods: HLA high resolution typing was performed by sequence based typing
(Biowithus HLA PCR-SBT, Korea).
Results: A 54-year-old man was diagnosed with severe acquired AA with normal
karyotype. Although he received immunosuppressive therapy (cyclosporine and
anti-thymocyte globulin) for 8 months, he didn’t achieve remission and regular
blood transfusions and G-CSF had been required. Therefore, stem cell trans-
plantation was scheduled. His HLA results identified by high resolution sequenc-
ing based typing in a peripheral blood sample was HLA-A*26:01, HLA-A*33:03,
HLA-C*03:04, HLA-C*07:01, HLA-DRB1:07:01, HLA-DRB1:15:01, HLA-
DQB1:02:02, HLA-DQB1:06:02. However, HLA-B could not be easily typed
by sequencing based typing. To resolve the problem, we performed the low
resolution HLA typing using SSP(sequence-specific primer) method and the
result showed HLA-B*40 and HLA-B*44. Furthermore, HLA-B type of one
sibling having HLA-A, HLA-C and HLA-DRB1 matching was HLA-B*40, HLA-
B*44. We reanalyzed HLA-B high resolution typing using DNA from patient’s
buccal epithelial cells, patient’s peripheral blood and the sibling’s peripheral
blood. The HLA-B typing of patient’s buccal epithelial cells and the sibling’s
blood showed the same results : HLA-B*40:02, HLA-B*44:03. By a closer
examination of sequence electropherogram of patient’s peripheral blood, we
identified that that 4 nucleotides (ACAC deletion) were deleted between
codon 187 and 188 in exon 4 of HLA-B*40:02, leading to a frame shift. The
mosaicism of wild type and mutant HLA-B*40:02 alleles was restricted to
patient’s blood cells, not buccal epithelial cells.
Summary/Conclusions: Acquisition of mutation could not be an accidental
event, but is caused by immunological escape and selection, because HLA-
B*40:02 is a possible target antigen of T cells in idiopathic AA. Activated
CTLs might kill HSPCs that expressed HLA-B:40:02, whereas HSPCs carry-
ing the mutation might survive with a growth advantage over other HSPCs
expressing HLA-B:40:02. Our case suggests that mutation (ACAC deletion)
of HLA-B:40:02 could be a possible mechanism to restore hematopoiesis via
immune escape with no involvement of 6pLOH.
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HEMATOPOIESIS FEATURES OF APLASTIC ANEMIA PATIENTS WITH
PNH CLONES
E Shilova1, V Balashova2, N Semenova2,*, V Rugal2
1Department of Hematology, 2Laboratory of leukosis studies, Russian
research institute hematology and transfusiology, Saint-Petersburg, Russian
Federation
Background: One of the reasons for the development of aplastic anemia
(AA) is considered immunopositive inhibition of hematopoiesis – cytotoxicity
of antigen-specific T lymphocytes and over-production of inflammatory
cytokines type I. In addition, AA may be associated with defective hematopoi-
etic stem cells (HSC) and a violation of the regulatory effect of stromal
microenvironment. It is known that colony-forming units (CFU) HSC of AA
patients drastically reduced and may be absent at all. At the same time in AA
patients often recorded the emergence of PNH clones. However, the func-
tional potential of HSCs of the indicated category of patients is characterized
by little
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Aims: Study of CFU HSC bone marrow of AA patients depending on the
presence of PNH clones.
Methods: The research is based on the bone marrow aspirates of 55 AA
patients with no PNH clone and 25 patients with PNH clones. CFU HSC was
studied using the method of culturing cells in complete nutrient medium
Metho-Cult HYY35 on the basis of methyl cellulose. This environment con-
tains all the necessary growth factors and is able to support the growth of
erythroid, granulocyte-monocyte and multilinear colonies. The cultivation was
carried out in CO2-incubator at t – 37° C for 14 days in Petri dishes with a
diameter of 40 mm.
Results: Revealed a sharp decline CFU HSC of AA patients with primarily
established diagnosis prior to treatment. The total number of colonies in patients
without PNH clones amounted to 57,0 (0-252) 1х105 of myelokaryocytes. At
the same time, the number of colonies in PNH patients amounted to 130,0 (8-
293) for the same volume of myelokaryocytes. The results suggest that CFU
bone marrow HSC in AA patients with PNH clones is significantly higher than
in patients without PNH clones. On this basis we can conclude about the relative
safety of the proliferative potential of HSC in AA patients with PNH clones.
Summary/Conclusions: Analysis of CFU HSC confirms a defect in the devel-
opment of progenitor hematopoietic cells in AA. However, in patients with AA
with PNH clones the level of violations of the proliferative activity of HSC is
expressed to a lesser extent. It is known that the effectiveness of therapy
significantly higher in AA patients with PNH clones. Given our data on the
functional status of HSC, it is possible to conclude that higher efficiency of
treatment of AA patients with PNH clones may be associated with relative
preservation of proliferative potential of HSC in this category of patients.
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COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
A Sempere*, S Bonanad, A Moret, L Cordon, S Romero, A Regadera, I Jarque
Hematology and Hemotherapy Unit, Hospital Universitari i Politècnic La Fe,
Valencia, Spain
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare life-
threatening acquired clonal hematopoietic stem cell disorder characterized
by chronic complement activation associated with intravascular hemolysis,
thrombosis, and bone marrow failure. Before the availability of anti-comple-
ment therapy with eculizumab, treatment remained largely supportive, since
the only curative procedure available is allogeneic hematopoietic stem cell
transplantation (HSCT), which is associated with substantial morbidity and
mortality.
Aims: This study was planned to report on the management and clinical
course in a series of PNH patients in a tertiary reference centre reflecting
trends in diagnosis and management through the last four decades.
Methods: This descriptive, observational, single centre study evaluated
patients diagnosed with PNH between January 1979 and January 2016. An
electronic case report form was completed for each patient using clinical data
collected from digital or paper medical records. Patients were divided into
three groups according to the Parker classification: classic, associated with
another bone marrow failure syndrome (BMFS) or subclinical.
Results: A total of 37 patients (mean age 37.2 years±20.6, 20 male (54%)]
were included. A large number of diagnoses were made after 2008 (16
patients, 43%), related to improvements in flow cytometry (FC) analysis. The
median follow-up time was 6.9 years [IQR: 3.4-15.2]. Nine patients (24%)
were diagnosed with classic PNH, 26 (70%) with BMFS; and 2 (5%) with sub-
clinical PNH. Median values for laboratory parameters at diagnosis were:
serum lactate dehydrogenase (LDH) 489 UI/L [IQR: 404-1123]; hemoglobin
9.8 g/dL [IQR: 9.1-10.9]; haptoglobin 10 mg/dL [IQR: 7.8-57]; and serum cre-
atinine 0.8 mg/dL [IQR: 0.6-1.1]. At diagnosis 68% of patients presented with
pancytopenia. All 20 patients with FC data had GPI-deficient granulocytes
(median 5.5% [IQR: 1-31]), as well as GPI-deficient monocytes (median 3%
[IQR: 0.5-39.5]). Seven patients had type III erythrocytes (median 2.7% [IQR:
0.4-12]). As expected, FC analysis showed that the GPI-deficient cell clone
size was higher in classic PNH than BMFS. A total of 15 patients (41%)
required transfusion support. The most frequent therapy was immunosup-
pression (70%). Twelve (32%) patients, 3 of whom had classic PNH, under-
went allogeneic hematopoietic stem cell transplantation (HSCT) at a mean
age of 30 years (range 23–37 years). The stem cell source was peripheral
blood in eight patients (67%), bone marrow in three (25%) and umbilical cord
blood in one. Only two patients received eculizumab (5%). Two patients with
classic PNH had a history of severe thrombotic complications (Budd-Chiari
syndrome, pulmonary thromboembolism). At last follow-up, eight (22%)
patients had died (3 with classic PNH, 5 with BMFS). The leading causes of
death were hemorrhage and HSCT-related complications.
Summary/Conclusions: PNH is a rare disease with a highly variable clinical
outcome. Improvements in FC techniques have contributed substantially to
detect new cases in recent years. Long-term follow-up studies like ours facil-
itate a better understanding of the natural history of PNH and contribute to
improve the management of our PNH patients.
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CLINICAL CHARACTERISTICS OF CHINESE PAROXYSMAL NOCTUR-
NAL HEMOGLOBINURIA DIAGNOSED BY FLAER
J Li 1, S Wang2, H Hua1, W Shen 2, Y Wu 2, J Li 2, G He2,*
1Department of Hematology, The Third Affiliated Hospital of Nantong Univer-
sity, Wuxi, 2Department of Hematology, JiangSu Province Hospital,The First
Affilated Hospital of NanJing Medical University, Nanjing, China
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone
marrow failure disorder caused by the absence of glycosylphosphatidylinositol
(GPI) on the membranes of blood cells. It was claimed that FLAER gave a
more accurate assessment of the GPI anchor deficit in PNH .It can detect as
few as 1% PNH monocytes and neutrophils in aplastic anemia, that were oth-
erwise undetectable using CD55 and CD59 on RBC’s. Therefore, the clinical
characteristics of PNH patients diagnosised by FLAER method might be dif-
ferent from previous CD55/CD59 and Ham test used before in China.
Aims: To find the clinical characteristics of Chinese paroxysmal nocturnal
hemoglobinuria diagnosed by FLAER.
Methods: The clinical data of 98 cases diagnosed by FLAER methods from
September 2011 to March 2014 were analyzed retrospectively, including
demography, clinical features, laboratory examination results and complica-
tions.
Results: 48 were male and 50 were female, median age 30.5 years (1~74
years), the median follow-up time were 24 months (12 ~30 months). 11
patients with PNH less than 18 years of age belong to adolescents, 6 patients
of them were male, median age was 13 years (1~16 years). There were 43
cases of classic PNH (43.9%), 45 of PNH combined with other specific bone
marrow disorders (45.9%), 10 cases of subclinical PNH (10.2%).
The clinical features (Table 1) showed many patients with bone marrow fail-
ures. Fatigue (71.4%), hemoglobinuria (41.8%), headache/dizziness (38.8%),
bleeding (22.4%), and dyspnea (19.4%) were commonly encountered symp-
toms. Thrombosis in 9 cases (9.18%), 3 cases of deep vein thrombosis, 1
case of pulmonary thromboembolism, 2 cases of mesenteric venous throm-
bosis, and 2 cases of hepatic portal thrombosis happened in group of classic
PNH. Only one case of hepatic portal thrombosis was found in PNH with
aplastic anemia. 17 cases cooccurrented with renal impairment respectively,
there were 14 patients (14.5%), 16 patients (16.3%) and 1 patient (1%) at
stage of CKD1, CKD2, and CKD3 respectively. Only 2 cases of PNH were
suffered with pulmonary hypertension. The estimated OS at 3 years after
diagnosis as 82.0%, 11 patients who died during follow-up period. Compari-
son of OS among the three subcategories was no statistical
significance(P=0.978). Univariate analysis revealed that thrombocytopenia
(P=0.048),abdominal pain(P<0.001), thrombotic events (P<0.001),and recur-
rent infections(P<.001) were of risk factors affecting survival. Multivariate
analysis further confirmed that thrombotic events and recurrent infections
remained to be statistically significant risk factors affecting survival (Table 2).
Table 1. Clinical features of patients with PNH.
Characteristic                      Classic PNH     PNH SBMD    Subclinical PNH       Total
Hemoglobinuria                      30(69.8%)      11(24.4%)            0 (0%)          41 (41.8%)
Abdominal pain                       4 (9.3%)         2 (4.4%)             0 (0%)            6 (6.1%)
Dysphagia                               4 (9.3%)           0 (0%)               0 (0%)            4 (4.1%)
Headache/ dizziness              13(30.2%)      25(55.6%)            0 (0%)          38 (38.8%)
Pectoralgia                                0(0%)            1(2.2%)              0(0%)            1 (1.0%)
Back pain                                3(7.0%)            0(0%)               0 (0%)            3 (3.1%)
Dyspnoea                               9(20.9%)       10(22.2%)            0(0%)          19 (19.4%)
Bleeding                                 2 (4.7%)        19(42.2%)         1 (10.0%)        22(22.4%)
Fatigue                                  30 (69.8%)     34 (75.6%)         6 (60.0%)       70 (71.4%)
Infections                                 0 (0%)            9(20%)              1(10%)         10 (10.2%)
PNH with another specified bone marrow disorder PNH SBMD
Summary/Conclusions: Bone marrow failure is frequently found in the Chi-
nese Patients with PNH. Renal, liver impairment and thrombosis in rare sites
was relatively common. But pulmonary arterial hypertension happened sel-
dom. Thrombotic events and recurrent infections influenced survival of
patients with PNH.
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PREVALENCE AND PATTERNS OF TREATMENT OF APLASTIC ANEMIA
IN KOREA
H Kim1,*, JC Jo1, Y Choi1, SK Park2, MH Chang3
1Division Of Hematology and Cellular Therapy, 2Department of Pediatrics,
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3Division of Oncology-Hematology, National Health Insurance Service Ilsan
Hospital, Ilsan, Korea, Republic Of
Background:
Aplastic anemia (AA) is a relatively rare bone marrow failure syndrome and
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has the wide variety of cytopenia spectrum from transfusion-independent
mild cytopenia to severe pancytopenia that needs for allogeneic hematopoi-
etic cell transplantation (HCT). However, the exact incidence of AA in whole-
nation-wide survey and the whole picture of treatment pattern is extremely
rare.
Aims: We aimed to figure out the real incidence and treatment pattern of AA
in Korea as a nation-wide database analysis. Also we wanted to know
whether incidence and treatment had regional variation.
Methods: We collected AA patients from Korea National Health Insurance
Service (KNHIS) database. The minimal requirements for the diagnosis of
AA were registation to a rare/difficult to treat disease as AA and performance
of bone marrow biopsy at the time of registration. Newly diagnosed patients
were defined as a new entry to registration as AA. Treatment were collected
from the each drug prescription. Region was categorized into 4 areas accord-
ing to city size; capital city, metropolitan city, samll city and rural area.
Results: Data between year 2008 and 2012 were collected from KNHIS data-
base. The annual prevalance of AA was 8.6, 15.3, 20.5, 22.9 and 23.6 (aver-
age 17.5) patients per million (PPM) in years 2008, 2009, 2010, 2011, 2012,
respectively. Prevalence of male (average 17.5 PPM) and female (average
18.9 PPM) were similar. Prevalence increased as the age increased: average
12.9 PPM in younger than 10y old; average 25.5 PPM in older than 80y old.
Reginal differences were found: average 17.3 PPM in capital city, 17.7 PPM
in metropolitan cities, 12.9 PPM in small cities and 24.2 PPM in rural areas.
The crude incidence rates (CIRs) were similar in recent 5 years: 6.8 PPM in
2008, 8.9 PPM in 2009, 9.5 PPM in 2010, 9.4 PPM in 2011 and 8.4 PPM in
2012. There were age differences in CIRs. CIR in elderly population was
more than 2 times higher when comparing with younger population: average
5.4 PPM in population younger than 10y; average 13.2 PPM in elderly pop-
ulation older than 80y. Average CIRs in reginal categories were 8.6 PPM in
capital city, 8.3 PPM in metropolitan cities, 6.1 PPM in small cities and 10.8
PPM in rural areas. Treatments of newly diagnosed AA patients were follows:
transfusion in 74.1%, cyclosporin in 34%, thymoglobulin in 26.4%, G-CSF in
44.6% and HCT in 12.5% . Thymoglobulin and HCT were received 34.5%
and 21.5% of newly diagnosed AA youger than 40y, but the rates were droped
to 16.8% and 4.5%, respectively in older than 40y patients.
Summary/Conclusions: Korea has high CIR of AA than wetern countries.
CIR increases as age increases. Rural areas has higher CIR than small cities.
The treatment pattern was different between younger age group and older
age group as expected.
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APLASTIC ANEMIA IN CENTER TUNISIA
A Bechir1,*, R Haifa1,2, B Emna1, BS Nesrine1, BY Yosra1, K Abderrahmen1
1Hematology, Farhat Hached Hospital, Sousse, 2Hematology, Farhat Hached
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Background: Aplastic anaemia is a rare but very serious blood disease, com-
bining a central pancytopenia and bone marrow hypocellularity. Its etiology
remains mostly unknown. Treatment is either allogeneic hematopoietic stem
cell or on immunosuppressive therapy.
Aims: 1- To analyze the epidemiological, clinical and laboratory patients. 2-.
Evaluate the terms and therapeutic results. 3- To study the different responses
and survival depending on the treatment administered.
Methods: This is a retrospective study conducted over 14 years (January 2000
- December 2013) which included 95 patients with acquired aplastic anemia,
diagnosed and treated at the hematology department of the University Hospital
Farhat Hached hospital Sousse.
Results: The median age of patients was 32 years. The sex ratio was 1.26. At
diagnosis, all patients were symptomatic. An anemic syndrome associated with
hemorrhagic syndrome was the main factor of discovery (44.2%). At the initial
blood count, pancytopenia was observed in 92.6% of patients. The myelogram
showed a poor marrow in 85.2% of patients. A bone marrow biopsy, bone mar-
row was wealth 0-1 95.8% of patients. Myelosuppression was, moderate in 33
patients (34.7%), severe in 26 patients (27.4%) and severe in 36 patients
(37.9%) by the score of Camitta. Fourteen patients underwent a bone marrow
allograft. One patient received the anti-lymphocyte serum in combination with
ciclosporin. Immunosuppressive treatment with cyclosporin alone was under-
taken in 51 of our patients. Forty-two patients received androgen therapy, pre-
scribed alone or in combination with ciclosporin or corticosteroids. At the end
of our study: 35 patients (36.8%) were in CR, 6 patients (6.3%) in PR, 14
patients (14.7%) and RM 39 patients (41.1%) in Failure . One patient was lost
to follow just after diagnosis. The factors that significantly influenced the
response were the severity of myelosuppression, sex, hemoglobin, the rate of
white blood cell, the neutrophil rate and allograft. The overall survival rate at 2
years was 47.3% at 5 years and 44.9%. The allograft is the most significant
prognostic factor for survival.
Summary/Conclusions: Despite progress regarding treatment protocols,
changes in the Aplastic anaemia is often fatal. The overall mortality rate in our
series is due to the problem of access to specific therapies, namely the allo-
geneic hematopoietic stem cell and lymphocyte serum.
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MONITORING OF SMALL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
CLONE IN PATIENTS AFFECTED BY SEVERE APLASTIC ANEMIA OR
APLASTIC ANEMIA
R Milani1,*, MT Lupo-Stanghellini2, F Giglio2, B Migliavacca1, G Torriani1,
L Santoleri3, F Ciceri4
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Background: Flow cytometry is the gold standard method for screening of
paroxysmal nocturnal hemoglobinuria (PNH). The most reliable marker to
detect and monitor small granulocyte or monocyte PNH clones is FLAER (flu-
orescent aerolysin), especially in conditions such as myelodysplastic syn-
dromes or bone marrow failure, when traditional GPI-linked surface marker
expression can be significantly altered. More than 50% of aplastic anemia
patients have a PNH clone detectable by highly sensitive assays, although the
underlying mechanism is yet to be unveiled.
Aims: Monitoring of small PNH clone in patients followed at our Institute for
severe aplastic anemia or aplastic anemia.
Methods: Between May, 2011 and Feb, 2016, sixteen patients with severe
aplastic anemia (sAA)/ aplastic anemia (AA) provided 52 blood samples for
PNH flow cytometry at different time points in the course of their evaluation
and treatment. We performed serial quantification of the PNH clone size by
multiparameter flow cytometry using a Navios cytometer (Beckman Coulter)
and Navios software. The immunophenotype evaluation is performed on EDTA
whole blood samples. Granulocytes, monocytes and red blood cells (RBCs)
were gated using forward and side scatter as well as lineage-specific markers.
The GPI-linked markers FLAER and CD59 were comparatively evaluated. Neu-
trophils and monocytes were screened with FLAER/CD24/CD14/CD33/CD45
combination. The sensitivity of detection allowing identification of PNH clone
sizes as small as 0.01% for RBCs and 0.03% for granulocytes.
Results: Eight of 16 sAA/AA patients were detected to have PNH clone posi-
tivity. All of them were treated with standard immunosuppressive therapy such
as antithymocyte globulin and cyclosporine (ATG/CsA) or CsA alone and two
non responder patients received allogeneic stem cell transplantation (alloSCT)
after myeloablative conditioning. Granulocyte PNH clone was <1% in 4 patients,
1-5% in 3 patients and >30% in one patient. Lactate dehydrogenase (LDH)
values were normal in all patients except the one with PNH clone >30%, who
had clinical evidence of hemolysis. Haptoglobin level was normal in 5 patients.
Two patients with PNH clone 1-5% had very low concentration of haptoglobin,
without altered LDH values. These were patients who did not respond to
ATG/CsA and received alloSCT. Direct Antiglobulin Test (DAT) were negative
in all patients. PNH clone sizes were stable during immunosuppressive therapy
courses with a median follow up of 42 months (3-60), while PNH clone became
undetectable after alloSCT and haptoglobin levels returned to normal values
(respectively 6 month and 36 month follow up).
Summary/Conclusions: Whether the presence of a small PNH clone in the
setting of hypocellular marrow failure has clinical significance or predicts
response to treatment and outcomes is still controversial, an accurate moni-
toring of PNH clone with high sensitive assays and hemolysis parameters might
be useful to clarify the pathophysiology of these complex and rare diseases.
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RARE RECURRENT CHROMOSOMAL ABNORMALITIES IN CLL DETECTED
BY CONVENTIONAL CYTOGENETICS AFTER STIMULATION WITH
CPG-ODN & IL-2 AND FISH
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Background: Characteristic chromosomal abberations (i.e. 11q, 13q, 17p,
and+12) play crucial role in chronic lymphocytic leukaemia (CLL) as important
idenpendent prognostic factors. Combination of FISH and conventional chro-
mosome banding (CBA) after stimulation with CpG oligonucleotides (CpG-
ODN) and interleukin-2 (IL-2) allowed to capture increased number of chromo-
somal anormalities. We focused on rare recurrent chromosomal aberrations
(RCA) that can provide new prognostic information in CLL.
Aims: Metaphase cytogenetic and molecular-cytogenetic analyses were per-
formed in 766 CLL-patients from 2008 to 2015 (293 female, 473 male, median
age at the time of analysis: 67 years) to evaluate the incidence of RCA.
Methods: CBA was performed on peripheral blood or bone marrow samples
cultured in medium with stimulants. FISH was performed on unstimulated cells
for detection of trisomy 12, del(11q), del(13q), del(17p). RCA were confirmed
by interphase FISH (I-FISH), multicolor FISH or multicolor banding.
Results: A total of 714/766 (93,2%) cases were succesfully stimulated for
metaphase analysis. Chromosomal aberrations were detected in 600/714
(84,0%) of patients by combining both methods. RCA were detected in 144
cases (144/714, 20,2%) and they were as follows: 3,5% rearrangement of IGH
(translocations partners 2, 4, 8, 9, 11, 12, 13, 16 and 19), 3,4% gain of 2p,
3,4% del(6q), 2,5% del(14q), 1,7% gain of 8q (MYC gene), 1,3% del(8p),
1,3%+18, 1,1%+19, 0,6% del(5q), 0,6% t(18;22), 0,4% gain of 12q, 0,4%+21
and 0,1% t(2;18).
Summary/Conclusions: Cytogenetic results are highly relevant in defining the
prognosis of CLL patients. I-FISH as gold standard for detection of important
chromosomal aberrations and CBA after stimulation with cocktail of CpG-ODN
and IL-2 are efficient tools (methods) in routine diagnostic (analysis) of chromo-
somal aberrations. The importance of RCA in CLL will be discussed in the poster.
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OXIDATIVE STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA
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Background: Oxidative stress (OS) is an imbalance between production of
free radicals and reactive metabolites, so-called oxidants or reactive oxygen
species (ROS), and their elimination by protective mechanisms, referred to as
antioxidants. Extensive evidence has shown that disturbances of oxidative
metabolism are a common feature of transformed tumor cells. However, the
effect of OS levels in chronic lymphocytic leukemia (CLL) is largely unknown.
Aims: To investigate the oxidative stress status in CLL and analyze the rela-
tionship with the disease status and prognostic factors evaluated at diagnosis.
Methods: We analyzed peripheral blood samples from 76 patients with untreat-
ed CLL evaluated at diagnosis (48 male and 28 female; mean age 67 years;
range 36-90 years; 57 patients with A Binet stage, 15 patients with B stage,
and 4 patients with C stage) and 20 healthy individuals as matched control
group. Serum total antioxidant capacity was determined by performing the d-
ROMs test, whose chemical principle is based on the ability of a biological sam-
ple to oxidize N,N-diethylparaphenilenediamine (normal range 250-300 U
CARR, where 1 U CARR is equivalent to 0.8 mg/L H2O2), while serum OS
was assessed by means of BAP test, which measures the ability of a serum
sample to reduce iron from the ferric to the ferrous ionic form (optimal value
>2.200 micromol/L reduced iron).
Results: A significant oxidative damage was showed in CLL patients (d-ROMs
test: 407 U CARR±194; range 194 - 794; BAP-test: 2.033 micromol/L±310.6;
range 1.024 – 3.300) with respect to normal controls (d-ROMs test: 259.6 U
CARR±87.5; range 158 - 425; BAP-test: 2.505 micromol/L±306; range 1.876-
3.045) (p 0.0014 and 0.0001, respectively). However, no correlations were
found with absolute lymphocytosis, haemoglobin and platelet levels, Binet dis-
ease stage and cytogenetics abnormalities (evaluated only in 52 patients)
detected by FISH (normal vs del17p vs del11q vs trisomy12 vs del13q14).
Unmutated IgVH CLL patients displayed significantly higher d-ROMs test values
than mutated IgVH patients (p 0.0057). On the contrary, no differences were
found in BAP test according to mutational IgVH status. At a mean follow-up of
50 months (range 6-211 months), 16 patients progressed needing treatment.
d-ROMS test was found significantly higher at diagnosis in this cohort of patients
with respect to non progressed patients (501 U CARR±135 vs 385±149; p
0.006). No differences were also found with respect to BAP test. Finally, no
correlations were found between time to treatment and both d-ROMS and BAP
test levels.
Summary/Conclusions: CLL patients show oxidative stress features
(increased oxidative damage, evaluated by d-ROMs test, and reduced antiox-
idant capacity, measured by means of BAP test) which are usually irrespective
of clinical and biological characteristics detected at diagnosis, reflecting con-
stitutive CLL findings, rather than disease burden and activity. In particular, dif-
ferently from a previous observation (Collado R et al., 2014), no correlations
were found in our cohort of patients between increased oxidative damage and
unfavourable cytogenetics subgroups. Our data support the investigational use
of antioxidants in the clinical setting.
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THE ROLE OF CD38, CD23, CD200 AND CD43 EXPRESSION IN
DISCRIMINATION OF CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE
CELL LYMPHOMA
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Background: Chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma
(MCL) share many features and their differential diagnosis may be challenging,
especially when a leukemic picture alone is present. Monoclonal antibody pan-
els are often useful, with CD23 being the most reliable. In the CD5+/CD10-
subgroup cases with CD23+cells are usually classified as CLL, whereas CD23
– cells are diagnosed as MCL. However, the immunphenotypic profile of MCL
cells is a quite heterogeneous, and cases of CLL and MCL can frequently over-
lap to a significant degree. MCL diagnosis should be confirmed by immunohis-
tochemical cyclin D1 detection, sometimes with equivocal or even negative
results. Other cytofluorimetric, cytogenetics or molecular techniques are reliable
but not widely available.
Aims: B-CLL leukemic cells express CD23, CD22, CD38, CD79b, CD200 and
CD43 antigens may improve the distinction between CLL and MCL cases. Both
CD200 and CD43 are used in clinical cytometry laboratories for a long time
now,but need for harmonization
Methods: We investigated by 5 color multiparametric flow cytometry 357
patients (241 males and 116 females; median age of 68±10,6 years) diagnosed
with B-cell LPD were studied. According to the WHO criteria (R), patients were
grouped as follows: 308 cases CLL,31 cases MCL, 18 cases HCL . Median PB
lymphocyte counts at diagnosis were of 19.8 × 109 lymphocytes/l (range: 0.8–
274 × 109 lymphocytes/l). Diagnosis of all MCL was confirmed by immunohis-
tochemisrty detection of cyclin D1 or detection of t (11:14) by FISH. The mon-
oclonal antibodies (MoAbs) used for flow cytometry labeling were obtained
from the Beckman Coulter Company (BC, Florida, USA). CD45, CD79b, CD3,
CD5 FITC, CD10 PE, CD11c, CD19, CD20, CD22, CD23, CD25, CD38, CD103,
FMC7, CD43 (clone DFT1), Kappa, Lambda, CD200 (clone OX2, Becton/Dick-
inson Biosciences-BD, USA) MoAbs were used for this purpose
Results: We found in one CLL case CD200 negative, and one case CD43 neg-
ative. However we have not observed any CD23 negative in all CLL cases. We
observed 10 MCL cases CD23+, 3 cases CD200 positive and 2 cases CD43
positive. CD200 appeared a valuable marker in the differential diagnosis of
CLL and MCL (p<0.001). As for CD43 expression in CLL, it was positive in 297
(96.4%) cases but negative in only 11 (3.6%) cases while it was negative in 20
(64.5%) and positive in 11 (38.5%) cases. CD43 was significantly different
between CLL and MCL. In the MCL group, the proportion of the CD43 cases
was significantly higher (p<0.001), CD38,CD22,CD79b are not significantly.
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Summary/Conclusions: We concluded that although CD 23, CD22, CD79b,
CD38 is not a useful marker in discrimination of CLL and MCL, CD43 and CD200
used together in routine panels could be of diagnostic utility in excluding MCL
diagnosis. However, as with other markers, the use of these markers may also
be flawed by heterogeneous distribution and variable expression. Therefore,
standardized sampling and staining for flow cytometry and specific techniques
should be primarily defined, and then followed by the evaluation of these markers
and harmonization studies in larger and more diverse patient populations.
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LYMPHOCYTIC LEUKEMIA- CORRELATION WITH CLINICAL AND
LABORATORY PARAMETARS
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Background: CD38 receptor and interleukin 6 (IL-6) level increases prolifera-
tion and survival of chronic lymphocytic leukemia (CLL) cells and increased
CD38 expression as well as IL-6 level are a negative prognostic marker CLL
patients. CD38 and IL-6 have a genetic polymorphism characterized by a C>G
variation.
Aims: This study was designed to examine the influence of CD38 (184C/G;
rs6449182) and IL-6 (-174 G/C; rs1800795) gene polymorphism on laboratory
and clinical parameters in chronic lymphocytic leukemia (CLL) patients.
Methods: Genotyping polymorphism is performed using restriction fragment
length polymorphism-polymerase chain reaction for CD38 (184C/G) and IL-6
(-174 G/C) in 44 CLL patients and 5 healthy subjects. We separated CLL
patients in three groups: 1) the G allele for IL-6 and C allele for CD38; 2) the
C allele for IL-6 and CD38; 3) the full fragment for either IL-6 or CD38. The
plasma level of VEGF was measured using immunoassay. Kaplan-Meier
method was used for estimating survival rates.
Results: A higher prevalence of the C allele was found both in CD38 (184C/G,
84%) and IL-6 (-174 G/C, 66%) gene polymorphism of CLL patients. Further-
more, we found a lower level of CD38-positive cells in group 1 of CLL patients.
The group 3 has significantly higher level of thrombocytes and lactate dehy-
drogenase (425 U/l, p<0.05) than group 2. The group 1 has increased beta 2
microglobulin in comparison of group 3. According to previous reports for a
strong correlation between CD38 and VEGF expression, we found increased
levels of plasma VEGF (med 50, range 16 - 438 ng/mL) in CLL patients vs
control subjects and in group 1 of CLL vs other two groups (med 79 vs 50 and
53 ng/mL in groups 2 and 3, respectively). According to the pattern of bone
marrow infiltration, the diffuse type was the most present in group 1 (33%),
while the nodular/interstitial was dominant in group 3 (91.7%). Furthermore,
patients in the group 3 demonstrated the most favorable clinical stage according
to Binet (A - 91.7%) and Rai (0 – 75%). Regarding CD38 expression, there
was no significant difference between groups, although patients with C allele
exhibited reduced CD38 expression (12% vs 25%). Mean overall survival was
97, 101 and 82 months in group 1, 2 and 3, respectively without statistical sig-
nificance. Median survival in group 1 and 3 was 65 and 79 months, respectively,
while in group 2 was not reached . No statistical significant difference in survival
among three groups was noted (p=0.90).
Summary/Conclusions: Presented results revealed that CLL patients with
the full fragment for either IL-6 or CD38 genes tend to have more favorable
clinical and laboratory parameters at diagnosis, but do not exhibit survival
advantage.
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THE EXPRESSION OF TOLL-LIKE RECEPTORS IN PATIENTS WITH
B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.
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Background: B-cell chronic lymphocytic leukemia (B-CLL) presents with pro-
gressive accumulation of monoclonal B-cells in the peripheral blood, bone mar-
row and lymphoid organs. B-CLL is characterized by heterogenous clinical out-
come. Some patients have an indolent disease and the others have an aggres-
sive clinical course of B-CLL. Toll-like receptors (TLRs) play an important role
in B-cell activation and maturation and may be involved in the pathogenesis of
B-cell lymphomas. TLRs are essential receptors of the innate immune system
and key regulators of the acquired immune system. TLRs are mainly expressed
in human immune related cells such as monocytes, neutrophils, macrophages,
dendritic cells, T cells, B cells and NK cells. The expression of TLRs and their
association with other prognostic factors in B-CLL patients remains unclear.
Aims: The aim of our study was to evaluate the expression of TLR2, TLR4
and TLR9 and their significance as biological markers in patients with B-cell
chronic lymphocytic leukemia.
Methods: 60 patients with newly diagnosed B-CLL were evaluated (29 females
and 31 males). The median age of patients was 68 years (range: 52-88 years).
The diagnosis was performed according to the IWCLL/NCI criteria for CLL. 40
patients (67%) had early-stage CLL (Rai stage 0-II) and 20 patients (33%) had
advanced-stage CLL (Rai stage III and IV). All patients were either untreated.
The healthy control group included 14 age-matched individuals (7 females and
7 males). Using quantitative reverse transcriptase PCR, the mRNA expression
of genes TLR2, TLR4 and TLR9 was measured. The relative quantitation was
indicated by cycle threshold (Ct) values. The Ct value of the target genes was
normalized (ΔCt) to the Ct value of the GUS gene of the samples. The results
were statistically analysed using ‘STATISTICA 8,0’. Statistical analysis was
performed by means of Mann-Whitney’s U-test and p<0,05 indicated a signif-
icant difference. Overall survival (OS) was determined using Kaplan-Meier
method. The long-rank test was used to compare the curves.
Results: In comparison to control group TLR2 and TLR4 mRNA expression
was higher in B-CLL patients than in healthy individuals (ΔCt TLR2 6.46±9.58
vs 0.98±0.43 and ΔCt TLR4 11.91±70.22 vs 2.21±0.32)(p<0.05). TLR9 mRNA
expression was higher in control group than in patients with B-CLL (ΔCt TLR9
23.65±16.29 vs 3.35±1.93) (p<0.05). We found that patients with higher mRNA
expression of TLR9 had significantly longer OS than patients with lower mRNA
expression of TLR9 (p<0.05).TLR2 mRNA expression was higher in patients
with advanced-stage CLL (Rai stages III and IV) than in patients with early-
stage disease (Rai stages 0-II) (ΔCt TLR2 19.10±17.76 vs 7.94±6.25) (p<0.05).
Moreover we observed that expression of TLR2 in patients with anemia was
significant higher than in patients without anemia (ΔCt TLR2 17.18±14.29 vs
7.10±5.98) (p<0.05) (Figure 1).
Figure 1.
Summary/Conclusions: In conclusion, our results suggest that TLRs could
become new potential biological markers for the clinical outcome in patients
with B-cell chronic lymphocytic leukemia. However, this observation should be
validated by a larger study.
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AGING AND PD-1 & PD-L1 GENE EXPRESSION: MARKERS OF
IMMUNOSENESCENCE?
L Dang1, K Willard Gallo2, S Garaud2, H Duvillier3, JN Lodewyckx4, C Solinas2,
P Da Silvia2, C Gu 2, C Sibille5, D Bron3,*
1Dpt of Hematology and Molecular Immunology Unit, 2Molecular Immunology
Unit, 3Dpt of Hematology, Institut Jules Bordet (ULB), 4Molecular Immunology
Unit, Institut Jules Bordet, 5Anatomo-pathology Dpt, Institut Jules Bordet (ULB),
Brussels, Belgium
Background: Aging is characterized by a progressive decline in immune sur-
veillance that favors infection and cancer development. Cancer cells can
escape immune surveillance by upregulating inhibitory immune checkpoint
such as PD-1 and PD-L1. High surface expression of PD-1 was reported in
association with T-cell exhaustion. The PD-1/PD-L1 axis inhibits the immune
response leading to anergy of lymphocytes.
Aims: In this study, we examined the expression of PD-1 and PD-L1 genes in
lymphocytes subsets according to age.
Methods: Lymphocyte subsets (CD3+CD4+; CD3+CD8+, CD19+) were iso-
lated using the MACS isolation system from PBMC of healthy donors (HD) and
Chronic Lymphocytic Leukemia (CLL) patients. PD-1, PD-L1, IL4 and IFNɣ
were quantified by qRT-PCR for each purified lymphocyte subset.
Results: PD-1, PD-L1, IL4 and IFNɣ gene expression was studied using qRT-
PCR to evaluate 28 HDs [14 HDs under 50y (median-: 38) and 14 HDs above
50y (median: 62)] compared with 23 untreated CLL patients (median age: 69).
The purity of each lymphocyte subset was 95%>99%. PD-1 was significantly
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up-regulated in most lymphocyte subsets in the older group: CD4+, CD8+T cells
and CD19+B cells (p=0.015; 0.02 and 0.01, respectively). Compared with a sim-
ilar age group of HDs, PD-1 expression was strongly upregulated in CD4+,
CD8+and CD19+subsets of CLL patients (p=0.001; 0.002 and <0.001). High
PD-L1 expression was correlated with age in the normal B lymphocytes
(p=0.046). The leukemic B cells also expressed higher levels of PD-L1 than cir-
culating normal B cells as compared with the older group of healthy donors
(p=0.001). In order to further investigate the PD-1/PD-L1 axis contribution to T
cell dysfunction, we have checked for the expression of IL4 and IFNɣ genes in
CD4+and CD8+lymphocytes subsets, respectively. A significant down-regulation
of IL4 and IFNɣ (p=0.008 and 0.001) in CLL patients was also demonstrated.
Summary/Conclusions: 1) PD-1 and PD-L1 gene expression is correlated
with aging 2) Upregulation PD-L1 is even more pronounced in leukemic B cells,
suggesting a potential benefit of anti PD-1/PD-L1 drugs in CLL patients 3) In
CLL patients, upregulation of PD1 and lower expression of IL4 and IFNɣ gene
are observed in CD4+and CD8+T cells.
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NEXT GENERATION SEQUENCING (NGS) ION TORRENT AMPLISEQ-TM
TECHNOLOGY FOR THE IDENTIFICATION OF TP53 MUTATIONS
SCREENING OF 39 CASES OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
L De Stefano1,*, S Bossio1, M Gentile2, E Vigna2, A Palummo1, N Caruso2,
G Iaquinta1, F Storino1, A Neri3, G Cutrona4, F Fais5, P Tassone6, M Ferrarini7,
F Morabito8, AG Recchia1
1Unità di Ricerca Biotecnologica and Hematology Unit, Department of Onco-
hematology, Azienda Sanitaria Provinciale, Aprigliano (CS) and A.O. of Cosen-
za, Cosenza, Italy, Aprigliano (CS), 2Hematology Unit, Department of Onco-
hematology, A.O. of Cosenza, Cosenza, Italy, Cosenza, 3Centro di Ricerca per
lo Studio delle Leucemie, Fondazione IRCCS, Università di Milano, Milano,
4IRCSS, AOU S. Martino-IST, 5IRCSS, AOU S. Martino-IST, Genova, 6Univer-
sity of Magna Graecia and Cancer Center, Catanzaro, 7IRCSS Scientific Divi-
sion, AOU S. Martino-IST, Genova, 8Unità di Ricerca Biotecnologica and Hema-
tology Unit, Department of Onco-hematology, Azienda Sanitaria Provinciale,
Aprigliano (CS) and A.O. of Cosenza, Cosenza, Italy, Cosenza, Italy
Background: NGS technology allows to study the molecular genetics of CLL
through the comprehensive detection of genetic lesions.
Aims: We describe the application of a NGS panel based on Ion AmpliSeqTM
technology to analyze the full coding region of TP53 (ex 2–11) in a single
workflow.
Methods: Purified B-cells, from 39 therapy-free CLL patients (pts) visiting our
outpatient clinic. Library preparation and sequencing were performed on the
Ion TorrentTM-PGM platform (Thermofisher) according to the manufacturer’s
protocols. For each run, 10 pooled samples were loaded on a 316chip and
sequenced (flow rate 500x). Data processing, filtering and base calling were
performed using the Ion Torrent server v4.4.2. Based on Variant Caller Param-
eters we accepted all variants with an allele frequency (VAF)>5% with high
quality, rejected variants had VAF<3% and low quality. Genomic sequences
were compared to the IARC TP53 database and confirmed using Sanger
sequencing.
Results: ION-PGM sequencing data showed a high coverage in 90% of
sequenced amplicons with average coverage uniformity of 89%, average mean
depth of 13130 (range 8812–17960), and 97% of mapped reads on target. We
identified 84 variants in 39 pts (including synonymous [N=2/2 pts] and non-
synonymous [NS] mutations [n=44/26 pts]) in TP53 regions. A total of 84 vari-
ants were identified in 30/39pts (77%). Overall, of the 39 pts analyzed, 9 pts
were TP53WT, while 30/39 76.9% presented variants along the entire TP53
sequence. 3/39 presented only intronic mutations and were considered
TP53WT; 1/39 pts with a 3’UTR mutation with VAF=4.5%. In the remaining 26
pts NGS identified 46 exonic mutations (range, 1-5 variants/patient): 6/26 with
clonal mutations only, defined as VAF>10%, (23.1%); 16/26 (61.5%) clonal and
subclonal; and in 4/26 (15.4%) only subclonal variations were identified. Exon
mutation hotspots were located in ex-7 (domain IV), ex-11 (C-terminal) and the
3’UTR, with 13, 11, and 10 variants, respectively. Overall, a notable% of muta-
tions were identified having a VAF between 3–5%(60/84 variants, 71.4%) and
between 5–10% (6/84, 5.9%), which may be considered subclonal variants
defined as below the detection limit of Sanger sequencing. Of the 46 exon vari-
ants (26 pts) identified, 44 were NS mutations with the following effects at the
protein level: 28 deleterious, 3 frameshift, 12 neutral, 1 stop/loss and 2 unclas-
sified mutations and were indicated as alterations likely producing nonfunctional
protein according to in silico analysis. The mutations in the 3’UTR (10) and
5’UTR (1) could potentially affect regulation of TP53 gene expression by target
miRNA and/or transcription factors. Correlation with FISH analysis showed that
of the 4 pts with del17p, 3 pts presented a clonal TP53 mutation (with VAF
range 22.5–94.7%) in the remaining allele, while the 4th presented a subclonal
mutation with a VAF of 3.1%, of note this was the only del17p patient alive in
this cohort.
Summary/Conclusions: The ION PGM-TP53 panel offers an easy to use plat-
form for the evaluation of small clonal TP53 mutations. A total of 67/84mutations
were detected as small TP53-mutant subclones having a VAF<10%, that would
likely be considered WT by Sanger sequencing, demonstrating the high sensi-
tivity of the technique. The presence of subclonal mutations could anticipate
the development of a chemo-refractory phenotype among CLL pts requiring
treatment. We are currently evaluating TP53 clonal alterations identified by
NGS screening in these CLL pts prospectively. Special thanks to Celegene and
AIRC-CARICALRegional Grant 16695.
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GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE
TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
C Tomuleasa*
Research Center for Functional Genomics, Iuliu Hatieganu University of Med-
icine and Pharmacy, Cluj Napoca, Romania
Background: Chronic lymphocytic leukemia (CLL) is a monoclonal disorder
that is characterized by a continuous accumulation of malignant lymphocytes.
Despite progress in targeted therapy options for CLL, relapse or progression
to a Richter syndrome still appears. Thus, a more focused and targeted thera-
peutic option is required. This can be achieved by increasing the concentration
of a cytostatic drug in the tumor while reducing its’ systemic toxicity.
Aims: In the continuous effort toward the development of more efficient thera-
peutic approaches for the treatment of CLL, in the current study we report the
conjugation of rituximab antibody drug onto spherical gold nanoparticles. Their
effective trans-membrane delivery inside CLL cells and their validation as real-
potential therapeutics with increased efficacy, in comparison with drug alone.
Methods: The internalization of Rituximab-nanocarriers was proved by the
strongly scattered light from gold nanoparticles and was correlated with the
results obtained by trans mission electron microscopy and dark-field microscopy.
The therapeutic effect of the newly designed drugs was investigated by several
methods including cell counting assay as well as the MTT assay.
Results: The therapeutic effect of the newly-designed drugs was investigated
by several methods including cell counting assay as well as the MTT assay
and was found to be superior when compared with the drug alone, data con-
firmed by state-of-the-art analyses of internalization, cell biology (flow cytometry,
apoptosis and autophagy assay), genomics (RT-PCR for MS4A1) and pro-
teomics (confocal microscopy and western blotting for CD20).
Summary/Conclusions: The efficient formation of drug-nanocarriers was
proved by spectroscopic characterization of the particles. The internalization
of rituximab-nanocarriers was proved as a result of the strongly scattered light
from gold nanoparticles and was correlated with the results obtained by TEM
and dark field microscopy.
PB1777
THE ROLE OF TUMOR NECROSIS FACTOR (TNF) AND IT’S SOLUBLE
RECEPTORS, STNFRI AND STNFRII, IN MYELOSUPRESSION DEVELOPING
IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
V Barilka1,*, V Matlan *2, S Prymak3, O Vygovska4, O Shalay5, V Loginsky6
1Immunocytology and genetics of blood neoplasms, SI Institute of Blood Pathol-
ogy and Transfusion Medicine of the NAMS of Ukraine, 2* Lviv National Medical
University named Danylo Halytsky, Lviv, Ukraine, 3SI Institute of Blood Pathology
and Transfusion Medicine of the NAMS of Ukraine, Lviv, Ukraine, 4department of
hematology, SI Institute of Blood Pathology and Transfusion Medicine of the
NAMS of Ukraine, 5immunocytology and genetics of blood neoplasms, 6immuno-
cytology and genetics of neoplasms of blood, SI “Institute of Blood Pathology
and Transfusion Medicine of the NAMS of Ukraine”, Lviv, Ukraine, Lviv, Ukraine
Background: Myelosupression with severe anemia or thrombocytopenia refers
to the adverse factors in clinical course of B-CLL. The production of TNF, a
pleiotropic cytokine, and it’s soluble receprors (sTNFRs), sTNFRI and sTNFRII,
in B-CLL patients (pts) in blood are broken, but the final role of these proteins
in development of myelosupression in B-CLL pts is studied poorly.
Aims: To determine the role of TNF, sTNFRs in myelosupression developing
in B-CLL pts.
Methods: Determination of TNF, sTNFRs was performed using blood plasma
of 74 pts with B-CLL at different stages of the disease before treatment. Deter-
mining the concentration of TNF was carried out by biological methods, using
mouse fibroblasts cell culture line L929. The level of sTNFRI and sTNFRII was
performed by immunological methods using the kits of BioSource Europe S.A.,
Belgium. These parameters were analyzed in relation with complete blod counts
of the pts with B-CLL. The control group consisted of 15 healthy donors. Prob-
ability statistics was evalueted using Student’s t-test. The reletionship between
the concentration of TNF, sTNFRs and hemograms of pts at different stages
(A,B,C by Binet) of B-CLL was established by correlation coefficient (r), which
was calculated by Excel program.
Results: The significantly higher levels of TNF (0,938±0,124 ng/ml), sTNFRI
(2,740±0,277 ng/ml) and sTNFRII (32,180±4,350 ng/ml) were established in
plasma of B-CLL pts at all stages of the disease compared with healthy donors
(0,089±0,017 ng/ml; 1,210±0,014 and 4,170±0,231 ng/ml, accordingly). On the
other hand, appreciably lower levels (p<0,001) of TNF (0,482±0,184 ng/ml)
and sTNFRII (17,080±1,294 ng/ml) were determined in plasma of B-CLL pts at
early stages in comparision with more advanced stages, B-C (1,011±0,260 and
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33,300±5,690 ng/ml, accordingly). An increased reticulocytosis (>10 0/00), as
a sign of hemolytic syndrome, was accompanied by significantly higher levels
of TNF in plasma comparing to pts with a normal number of reticulocytes
(1,266±0,114 vs 0,752±0,188ng/ml). The concentrations of TNF and sTNFRII
correlated negatively with hemoglobin level (r=-0,37) but positively with
absolute lymphocytic count (r=0,42) at early stages of the disease. In addition,
any changes in concentrations of these proteins were not detected in plasma
of B-CLL pts with thrombocytopenia.
Summary/Conclusions: These studies suggest that increasing of the con-
centration of TNF and sTNFRs in B-CLL, possibly as a result of their production
by leukemic cells, may adversely affect hematopoiesis, promote hemolysis and
development of anemia of different origin in B-CLL pts. In advanced stages of
B-CLL an augmented secretion both of TNF and sTNFRII comparing with early
stages may contribute to the leukemic progression. Determination of TNF and
sTNFRs in blood of B-CLL pts may be used to predict the development of ane-
mia as well as to initiate treatment, especially at early stages of this disease.
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IS CD200 EXPRESSION A SIGNIFICANT MARKER FOR DIFFERENTIATION
OF B- LYMPHOPROLIFERATIVE DISEASES? IN A SINGLE TUBE ANALYSIS
P Aytan*, I Kozanoglu, N Buyukkurt, M Yeral, M Kasar, S Solmaz, C Boga,
H Ozdogu
Hematology, Baskent University Adana Medical and Research Hospital Bone
Marrow and Transplantation Centre, ADANA, Turkey
Background: B cells have specific antigen patterns and flow cytometric tech-
niques have been used for discrimination of chronic lymphoproliferative disor-
ders (CLDs). Despite CD23 is considered a reliable marker, because of its
positivity in chronic lymphocytic leukemia (CLL) and negativity in mantle cell
lymphoma (MCL), there are some cases where CD23 does not discriminate.
CD 200 is a trans-membrane glycoprotein belonging to the immunoglobulin
super-family mostly expressed by B cells.
Aims: Our aim was to evaluate CD200 expression in the diagnosis and clas-
sifications of B-cell CLDs in a single tube by using flow cytometric techniques.
Methods: This is a retrospective study utilizing data on consecutive patients with
B CLDs in a single center. The study was performed on erythrocyte-lysed whole
peripheral blood samples, after staining with directly conjugated monoclonal anti-
bodies. A single tube was designed to include CD45, CD19, CD5, CD23, CD22,
CD10, CD20 and CD200. Samples were analyzed using 8-color MFC (FACS
Canto II; BD, Bioscience), and FACS DIVA was used for data analysis. An antigen
was considered positive when at least 20% of the cells expressed that antigen.
Results: A total of 59 B-CLD patients - 42 male (71.2%) and 17 female (28.8%)
- were evaluated between January 2014 and January 2016. All patients
expressed CD19 and while CD20 was found to be positive in all but one CLL
case. 36 patients were diagnosed as CLL and 4 patients diagnosed as atypical
CLL (aCLL). A total of 19 patients were diagnosed as lymphoma; 3 of them were
mantle cell lymphoma (MCL), 2 of them were marginal zone lymphoma (MCL),
2 of them were follicular lymphoma (FL), 2 of them were diffuse large B cell lym-
phoma (DLBCL) and 2 of them were small lymphocytic lymphoma (SLL). Also 8
patients were unclassified and they were defined as other B lymphoproliferative
diseases. While CD200 was positive in all CLL and aCLL patients, it was negative
in MCL, MZL, DLBCL patients. CD200 was also positive in unclassified form of
B lymphoproliferative diseases in 5 patients. The sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) of CD200 for diag-
nosis of B-CLL are 100%, 52.2%, 76.6% and 100% respectively. These values
were 100%, 47.8%, 75% and 100% respectively for CD5. CD 23 was positive in
32 of 36 B-CLL patients (88.9%), and weak positive in the remaining 4 B-CLL
patients (11.1%). CD 23 was also found to be positive in 1 (4.3%), weak positive
in 4 (17.4%) and negative in 18 (78.3%) patients without B-CLL.
Summary/Conclusions: Multiple reports have showed that CD 200 expression
is moderate –high in CLL. However, it is dim to negative in mantle cell lym-
phoma and proposed as another marker to distinguish between CLL and MCL.
CLL/ SLL demonstrates low intensity staining for surface immunoglobulin, low
expression of CD 22, CD 79B, strong expression of CD 5 and CD 23 but
leukemic phase of MCL can be misdiagnosed as CLL. Since MCL is a more
aggressive disease and generally treated differently than B-CLL, it is important
to differentiate them. In our study, it is showed CD200 expression has a great
impact on accurate B-CLDs at diagnosis and it could be added to the routine
panels and might be able to show in a single tube by using 8 colour flow cytome-
ter . Also there is high expression of CD200 in B-CLL and it could be a good
option for targeted immune therapy in the near future.
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STRUCTURAL AND FUNCTIONAL ALTERATIONS OF THE COMPLEMENT
SYSTEM IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
R Michelis1,*, C Suriu1,2, L Akria1,2, M Barhoum1,2, A Braester1,2
1Haematology, Galilee Medical Center, Nahariya, 2Faculty of Medicine in
Galilee, Safed, Israel
Background: Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia in the western world, accounting for 30% of all leukemias. The ther-
apeutic approach in CLL includes chemotherapeutic regimens of purine ana-
logues and therapeutic monoclonal antibodies. The immunotherapeutic
approach triggers immune responses against the leukemic B-cells that syner-
gize with cytotoxic chemotherapeutic agents. The therapeutic monoclonal anti-
bodies mediate anti-tumor effects through complement-mediated cytotoxicity
(CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and phagocy-
tosis. The efficacy of the CDC thus depends on the expression level of the tar-
geted antigen on B-cells, the integrity of apoptotic cascades within tumor cells,
the functional capacity of effector cells, and the availability and activity of the
complement system.
Aims: To study structural and functional characteristics of key complement
components in untreated CLL patients, in order to develop a marker which will
assist in identifying patients who are likely to be less responsive to future
immunotherapy treatment.
Methods: Blood samples were collected from 13 untreated CLL patients and
8 healthy controls (HC). Clinical biochemical and haematological parameters,
as well as CLL staging were recorded. Three key complement components,
C3, C4 and C5 were studied by Western blot analysis. The activity of the com-
plement system before and after activation with Zymosan or aggregated IgG
was followed by the levels of C5b-9, the terminal product of complement acti-
vation, using ELISA. The link between levels of complement activity and com-
plement isoforms, as revealed by Western analysis, was studied.
Results: The Western analysis results indicate differences in the pattern of
C5 and C4 in CLL patients compared to HC subjects. Specifically, the C5 com-
plex, which exists as a single band in HC, appeared in CLL patients as a clear
double-band. This alteration was observed in >50% of the patients. Western
analysis did not indicate clear differences in C3 pattern in the patients. Activity
analysis revealed higher basal levels of C5b-9 in the CLL patients (compared
with HC), that were particularly high in the patients presenting altered pattern
of C5. Maximal activation, achieved by Zymosan or aggregated IgG, appeared
to be inversely correlated with basal activation levels.
Summary/Conclusions: These preliminary data demonstrate a possible link
between the activation potential of the complement system in CLL patients and
alterations in the complex structure of C5. The exact mechanism by which
“modified” C5 distracts the complement activity needs further clarification. Yet,
the appearance of “modified” C5 in CLL patients with disturbed complement
activity bears the potential to develop a marker which will assist in identifying
patients who are likely to be less responsive to future immunotherapy treatment
due to compromised CDC. Development of such a marker may assist clinicians
in refining and personalizing the immunotherapeutic approach, improving CDC
and consequently the therapy results.
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BACH2 & PRDM1: PREDICTIVE MARKERS OF IMMUNOSENESCENCE IN
AGING?
L Dang1, K Willard Gallo2, S Garaud 2, H Duvillier3, JN Lodewyckx 2,
C Solinas2, P Da Sivia2, C Gu 2, C Sibille 4, D Bron3,*
1Hematology and Molecular Immunology Unit, 2Molecular Immunology Unit,
3Dpt of Hematology, 4Anatomo-Pathology Unit, Institut Jules Bordet (ULB),
Brussels, Belgium
Background: Aging is characterized by a progressive decline in immune sur-
veillance that favours cancer development. This is illustrated by the high median
age of most malignant hemopathies. There is currently a lack of information
related to genetic or epigenetic modifications of tumor suppressor genes
(TSGs) in ageing immune cells. Our previous studies investigated the 6q dele-
tion in T-cell lymphoproliferative diseases and we reported that BACH2 gene
is a candidate TSGs.
Aims: In this study, we examined whether BACH2 and PRDM1 could be predic-
tive markers of immunosenescence in lymphocytes subsets according to age.
Methods: Lymphocytes subsets were analysed using multi-colour flow cytom-
etry to assess expression of CD45, CD3, CD4, CD8, CD45RA, CD25, CD197,
CD19, CD27, CD5, CD56 and CD16. Lymphocyte subsets were isolated using
the MACS isolation system for subsequent molecular investigations. BACH2
and PRDM1 were quantified by qRT-PCR and western blotting for each purified
lymphocytes subset.
Results: Peripheral blood samples were obtained from 35 healthy donors
(HDs) of different ages (20y to 90y), including 18 HDs under 50y (median: 36)
and 17 HDs above 50y (median: 61). Absolute lymphocyte counts did not vary
between these two groups but alterations in lymphocyte subsets distribution
were detected. The number of naïve T cells and CD8+cytotoxic T cells was
significantly reduced in the older group (p=0.01 and 0.002). Our data confirmed
that the CD4:CD8 ratio and effector T cells numbers are significantly increased
(p<0.0001 and 0.01) with age. BACH2 and PRDM1 gene expression was stud-
ied by using qRT-PCR to evaluate 28 HDs [14 HDs under 50y (median: 38)
and 14 HDs above 50y (median: 62)] compared with 23 untreated Chronic
Lymphocytic Leukemia (CLL) patients (median age: 69). The purity of each
lymphocytes subset was 95%>99%. BACH2 was significantly down-regulated
in most lymphocytes subsets in the older group: CD4+, CD4+naïve, CD8+T
cells and CD19+B cells (p=0.001; 0.005; 0.004 and 0.03, respectively). Com-
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pared with a similar age group of HDs, BACH2 expression was even more
severely reduced in CD19+, CD4+, CD8+subsets of CLL patients (p=0.004;
0.001 and <0.001). In contrast, PRDM1 was significantly up-regulated in the
CD4+and CD8+T cells (p=0.003; 0.001) of CLL patients but not in leukemic B
cells. There was inverse correlation between BACH2 and PRDM1 (Pearson
r=0.82; p<0.0001) in T cells of CLL patients. In addition, by using western blot
BACH2 and BLIMP1 protein expression in CD4+, CD8+and CD19+lymphocytes
correlated significantly with their transcripts expression levels. These observa-
tions uncover the roles of BACH2 and PRDM1 in the survival of immune cells
in HD and CLL patients.
Summary/Conclusions: Our investigations suggest that BACH2 and PRDM1
expression is correlated with immunosenescence. Moreover, in CLL patients,
this down regulation of BACH2 is even more pronounced. Further investigation
should be conducted to better understand the role of unbalanced expression
of BACH2 and PRDM1 genes in lymphocytes functions and survival.
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ALTERED SETMAR EXPRESSION ASSOCIATES WITH CLINICAL
CHARACTERISTICSIN CHRONIC LYMPHOCYTIC LEUKEMIA
F Piazera1,*, R Lucena-Araujo2, F Morato de Oliveira2, E Magalhaes Rego2,
F Saldanha-Araujo2, F Pittela Silva1
1Laboratory of Molecular Patology of Cancer, University of Brasilia, Brasilia,
2Department of Internal Medicine, University of São Paulo, Ribeirão Preto,
Brazil
Background: The Chronic lymphocytic leukemia (CLL) is the most common
chronic lymphoid malignancy in the western population. To date, several studies
have been developed to elucidate the genetic factors involved in the biology
and progression of CLL. Epigenetic changes have been shown to be increas-
ingly important in the genesis of various tumors and especially in chronic lym-
phoid neoplasms.Histone methylation is one of the leading and most studied
epigenetic events. The gene SETMAR(or METNASE) was associated with car-
cinogenesis of acute myeloid leukemia by losing disjuntion checkpoint in cells
treated with inhibitors of protein topo II alpha such as etoposide, doxorubicin
and mitoxantrone. However, the role of SETMAR in CLL leukemogenesis
remains unknown.
Aims: Determine relative expression of the gene in SETMAR CLL samples.
Methods: In this study, we evaluated the relative expression of SETMAR[FP1]
between a group of 59 CLL patients and 10 samples from peripheral blood of
healthy blood donors by real-time qPCR.Quantification of SETMAR was per-
formed by Real Time PCR (qPCR) and normalized to endogenous ACTIN
expression. Results were analyzed by the comparative 2 -ΔΔCt method. The
amount of target gene, normalized to the endogenous control gene and relative
to a reference sample, was converted into relative quantification. Based on the
distribution of SETMAR expression in CLL samples, we adopted the median
value as the cutoff to dichotomize CLL patients in “low expression group (LEG)”
and “high expression group (HEG)”. The expression of SETMAR was thencor-
related with clinical relevant prognostic factors such ascytogenetic, immunophe-
notypic and hematologic features in this disease.
Results: We found that SETMAR was significantly overexpressed in patients
with CLL compared to controls (p <0.0014). After the dichotomy, the LEG
showed high leukocyte count (p <0.0050), low platelet count (p <0.0489) and
predominance of cytogenetic abnormalities (p <0.030). The clinical staging of
BINET and expression of ZAP-70 did not show statistical significance between
the LEG and the HEG. Our results shows that SETMAR expression is altered
in CLL patients when compared to healthy controls, and revealed that a lower
expression of SETMAR in patients is clinically associated with chromosomal
instability and progression of the tumor mass though increased leukocytosis.
Summary/Conclusions: These findings are immediate in CLL samples, and fur-
ther studies are necessary for evaluation as a prognostic factor in this disease.
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P-GLYCOPROTEIN TRANSPORT ACTIVITY UNDER REDOX BALANCE
CHANGES IN LYMPHOCYTES OF PATIENTS WITH B-CHRONIC
LYMPHOCYTIC LEUKEMIA
Y Harmaza1,*, A Tamashevski1, N Goncharova2, E Slobozhanina1, A Svirnovski2
1Laboratory of Medical Biophysics, Institute of Biophysics and Cell Engineering
of National Academy of Sciences of Belarus, 2Laboratory of the cellular drug
resistance mechanisms, Republican Scientific and Practical Center for Trans-
fusiology and Medical Biotechnologies, Minsk, Belarus
Background: The experimental data about the close relationship between
tumor progression and cellular redox balance are published lately. It is shown
that the redox balance alterations play a key role in the cell response to the
anticancer agents influence, and it is an important regulator of the protein-
transporters associated with the phenomenon of multidrug resistance (MDR)
expression. However, the impact of the redox imbalance in human tumor cells
on the functional activity of MDR proteins has not been studied yet. Such inves-
tigations necessary for explanation of the conventional chemotherapy possible
failure and their protocols modification, taking into account the features of MDR
transporters functioning under the cellular redox balance changing.
Aims: To study the influence of chemotherapeutic agents on the redox status
of lymphocytes of patients with B-chronic lymphocytic leukemia (CLL) and to
assess the P-glycoprotein (P-gp) transport activity in these cells.
Methods: Lymphocytes were separated from the CLL patients peripheral blood
by density gradient centrifugation on histopaque. Monoclonal antibody UIC2-
PE (Immunotech) was used to evaluate P-gp expression and functional activity,
anti-CD5-FITC (Immunotech) and anti-CD19-PC5 (Beckman Coulter) were
used to determinate CD19+CD5+B-CLL cells. Reactive oxygen species (ROS)
level and low-molecular antioxidants content were assessed using СМ-H2DCF-
DA (Molecular Probes) and Antioxidant assay kit (Sigma), respectevly. Cells
viability was assessed using Calcein-AM test and propidium iodide (Sigma).
All investigations were carried out on the FACScan and FACScanto II (BD).
Results: The effect of drugs applied in the treatment of CLL (purine nucleosides
- fludarabine and cladribine analogs: fludarabel (Flu), 17,5 μM and leucladine
(Leu), 7,0μM (Belmeddrugs, Belarus); anthracyclines – doxorubicin (Dox), 1,72
μM (Sigma); vinca-alkaloids – vincristine (Vincr), 47,2 nM (Lens-Farm, Russia))
on the functional activity of membrane transporter P-gp associated with MDR in
lymphocytes of patients with B-CLL is studied. Also the ROS level and low-mol-
ecular antioxidants content are evaluated in leukemic cells during the chemother-
apeutic drugs metabolism. A degree of low-molecular antioxidants involvement
in maintaining of the redox balance in lymphocytes of patients with B-CLL under
exposure to drugs was determined. It is found that change of the ROS level in
the leukemic B-lymphocytes comparative to values in intact cells, as well as its
further recovery leads to increase of P-gp transport activity. The viability of
leukemic B-cells under exposure to the antitumor drugs decreases and depends
on the redox balance changes but to a lesser degree than in donor’s B-cells, as
had been established previously. Nevertheless, the statistically significant rela-
tionship between the functional activity of the membrane protein P-gp and viability
of lymphocytes of patients with B-CLL wasn’t detected.
Summary/Conclusions: The received results has allowed to characterize the
functioning of the main MDR transporter under redox balance changing caused
by the metabolism of the investigated anticancer drugs.
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IDENTIFICATION AND ROLE OF HUMAN REGULATORY B LYMPHOCYTES
IN CHRONIC LYMPHOCYTIC LEUKEMIA
A Mohr*, A Bordron, JO Pers, C Jamin
Laboratoire d’Immunothérapies et Pathologies Lymphocytaires B EA2216,
INSERM ESPRI, ERI29, BREST, Brest, France
Background: Chronic lymphocytic leukemia (CLL) is the most common
leukemia in Europe. There is no curative treatment. CLL is characterized by
expansion of CD19+CD5+B cells in blood, lymph nodes and bones marrow. In
this pathology, immune responses are disrupted, at least due to dysfunctions
of T cells, contributing to the immunodeficiency and the disease progression.
Generally speaking, B lymphocytes play an intricate role in the immune system
and are able to slowdown the anti-tumor responses favoring tumor escape.
They are called regulatory B cells.
Aims: The main focus of this project is to evaluate the regulatory function of
CLL B cells, aiming to estimate their influence on the lack of anti-tumor respons-
es mediated by T cells.
Methods: In vitro models of co-cultures between T and B cells are used to
appraise the regulatory capacity of CLL B cells on T cell proliferation evaluated
by flow cytometry. Regulatory activity of CLL B cells, stimulated or not with CpG-
ODN, is estimated as their ability to inhibit the T cell proliferation. Concurrently,
phenotypic characteristics of regulatory B cells and T cells are evaluated.
Results: Two groups of patients have been identified following CpG-ODN stim-
ulation. The first group presents defective regulatory B cell functions compared
with control B cells. In the second group, no inhibitory activity is detected, lead-
ing even to T cell proliferation in some cases. Compared with unstimulated
cells, stimulation with CpG-ODN do not induce any regulation, suggesting
insensitivity of the second group. Surprisingly, the level of TLR9 expression is
similar in both groups. Furthermore, no correlation is found between functional
and phenotypic signature of T and B cells. However longitudinal study suggests
a switch of group with a strong clinical course.
Summary/Conclusions: These results suggest functional TLR9 pathway but
alteration of the regulatory-induced function of CLL B cells in the first group, while
the TLR9 pathway seems to be totally defective in the second group of patients,
explaining the lack of regulation. To go further, it will be of interest to identify the
molecular mechanisms damaging the TLR9 pathway. These results would con-
tribute to clarify the lack of anti-tumor immune response found in the CLL patients.
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PRAME PROTEIN IS LOCATED IN EXTRACELLULAR SIDE OF
MEMBRANE AND MIGHT BE A GOOD TARGET FOR ANTIBODY THERAPY
OF HEMATOLOGICAL MALIGNANCIES
N Lyzhko1,2,*, Y Finashutina1, V Misyurin1,2, O Solopova1, A Misyurin1,2,
L Kesaeva1,2, N Kasatkina1, E Misyurina3, O Burova1, M Baryshnikova1
1FSBI “N.N. Blokhin Russian Cancer Research Center”, 2«GeneTechnology»
LLC, 3City Clinical Hospital No52, Moscow, Russian Federation
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Background: PRAME protein is not expressed in normal cells, but is active in
large number of tumor cells. Thus PRAME protein might be a promising target
for cancer immunotherapy. It is known that PRAME located in nucleus and
cytoplasm of tumor cells. Tajeddine et al., (2005) and Wadelin et al., (2010)
reported that this protein was located in nucleus and cytoplasm of tumor cells.
On the other hand, Proto-Siqueira et al., (2006) and Quintarelli et al., (2008)
found this protein on cell membrane.
Aims: To prove that PRAME protein is located on tumor cell surface and can
bind with a specific monoclonal antibody.
Methods: We used 11 samples of B-CLL patients blood and cell lines К562,
THP-1 and NOMO-1. 5 samples of healthy blood donors were used as negative
controls. PRAME expression level was determined by RQ-PCR in blood of 8 B-
CLL patients and in cell lines. PRAME epitops in surface of cell from patients
and cell lines was determined by flow cytometry and immunocytochemistry exper-
iments. Cell lines were incubated with anty-PRAME monoclonal antibodies
(mAbs) 5D3F2 and 6H8F12, together and separately, at concentrations 111 and
112 ug/ml, 11 and 12 ug/ml, respectively. Cell count was carried out after incu-
bation with mAbs. The number of dead cells was evaluated during MTT assay.
Results: PRAME expression level in K562 THP-1 and NOMO-1 cells lines
was 104%, 1,6% and 0,5%, respectively. 6 patients were PRAME-negative
and 2/8 had PRAME expression median lewel 4,43%. According to flow cyto-
metric data K562, THP-1 and NOMO-1 cell lines had PRAME-positive cells
14%, 3% and 0,9%, respectively. One patient had 0% PRAME-positive cells
(flow cytometric data) and none mRNA of PRAME gene expression (RQ-PCR
data), one another patient had 100% PRAME-positive cells whith mRNA
expression level 8,84%). Immunocytochemistry data showed, that protein
PRAME was located in cell’s surface of 11,5% cells in blood of 2/4 patients
with B-CLL (we hadn’t RQ-PCR data in this cases). К562 and THP-1 cells
decreased growth rate by 15-20% and about 15-20% of died cells was
observed after incubation with mAbs 5D3F2 and 6H8F12, together and sepa-
rately, at concentrations 11 and 12 ug/ml, respectively. К562 and THP-1 cells
decreased growth rate by 50% and about 4% of cells died after incubation with
mAbs 5D3F2 and 6H8F12, together and separately, at concentrations 111 and
112 ug/ml, respectively. NOMO-1 cells decreased growth rate by 30% and
around 10% of cells died after incubation with mAbs 5D3F2 and 6H8F12 togeth-
er at concentrations 11 and 12 ug/ml. NOMO-1 cells decreased growth rate by
30% during incubation with mAb 6H8F12 at concentration 112 ug/ml, but this
cells didn’t die. NOMO-1 cell did not demonstrate slowing of cell growth or
dying after incubation with mAb 5D3F2 at concentration 111 ug/ml.
Summary/Conclusions: We confirmed evidence that PRAME protein is locat-
ed on surface of cancer cells. The protein is expressed only in cases when
mRNA of PRAME is expressed. Cytostatic and cytotoxic effect of mAbs 5D3F2
and 6H8F12 were detected. This mAbs are effective against cell lines К562,
THP-1 and NOMO-1. Interestingly, at a lower concentration mAbs have a more
pronounced effect. In cases with higher expression level of PRAME gene in
cells, we obserwed a greater number of cells with PRAME epitopes on cell
surface and more powerful MAbs-depended cytostatic and cytotoxic effect.
Our data suggest that PRAME might be a promising target for immunotherapy
of PRAME-positive patients with B-CLL.
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CD49D AND CD26 ARE INDEPENDENT PROGNOSTIC MARKERS FOR
DISEASE PROGRESSION IN PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA
L Ibrahim*
Clinical Pathology And Haematology, Mansoura Faculty of Medicine- Egypt,
Abu Dhabi, United Arab Emirates
Background: CLL is characterized by extremely variable clinical course. Sev-
eral prognostic factors can predict disease progression and therapeutic out-
comes in those patients.
Aims: The aim was to evaluate the use of CD49d and CD26 as independent
prognostic markers in CLL patients. The present study measured surface
expression of CD49d and CD26 by three-color flow cytometry in a series of
103 untreated CLL patients.
Methods: The present study measured surface expression of CD49d and
CD26 by three-color flow cytometry in a series of 103 untreated CLL patients.
We evaluated the prognostic role of CD49d and CD26 to predict the risk of
lymphocyte doubling, disease progression and overall survival.
Results: We evaluated the prognostic role of CD49d and CD26 to predict the
risk of lymphocyte doubling, disease progression and overall survival.We con-
firmed that CD49d and CD26 were significant predictors of lymphocyte dou-
bling(P b 0.001 for both markers) and disease progression (P b 0.001 for both
markers) but insignificant for overall survival(P=0.303 and 0.519 respectively.
Multivariate analysis between clinical parameters and flow cytometry markers
revealed that CD49d and CD26 are independent prognostic markers for lym-
phocyte doubling (HR=1.487 P=007 and HR=2.248, P=0.014 respectively) and
progression to a more advanced stage (HR=3.191, P=0.049 and HR=7.887,
P=0.003) (Figure 1).
Summary/Conclusions: Also, concordant expression of both markers was
found to improve their predictive power. Many studies reported that CD49d
and CD26 combined analysis was found to improve their power to predict the
risk of lymphocyte doubling and disease progression. CD49d and CD26 have
independent prognostic value and we suggest its use as a part of routine panel
for prognostic stratification of CLL.
Figure 1.
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IMPORTANCE OF CD38 MARKER IN PROGNOSIS OF B CELL CHRONIC
LYMPHOCYTIC LEUKEMIA (B-CLL) IN THE NEW ERA
D Dukovski,*, S Trajkova, I Panovska, L Cevreska
Hematology, Clinic for Hematology - Skopje, Skopje, Macedonia
Background: Several published studies suggested that transmembrane gly-
coprotein- CD38 on the surface of leukemic cells. CD38 is accepted as a
dependable marker of unfavorable prognosis and as an indicator of activation
and proliferation of CLL cells.
Aims: The aims of the present study were to establish the predictive value of
the CD38 expression and to examine the corelation between CD38 positivity
and other established prognostic markers in our CLL patients in the new era.
Methods: Peripheral blood samples from 180 consecutive treatment naïve
CLL patients were analyzed by flow cytometry for CD38 expression on
CD5/CD19 leukemic cells. Various patients established prognostic character-
istics and molecular markers were studied in correlation to time to treatment
(TTT). The Kaplan-Meier method was used to construct survival curves, and
the log-rank statistic was used to compare these curves.
Results: CD38 was expressed in 63% of the patients. Patients with high CD38
expression (30% or more) with high value of B2M and advance disease accord-
ing to Binet had significantly shorter survival times (p=0 .00001) and
(p=0.00033) respectively.
Multivariate analyses showed that CD38 expression is an important prognostic
factor for shorter TTT associated high B2M level (P .000002), age(P.00000),
gender(P.00000), lower hemoglobin level (P.00008),hepatomegaly (P.00086)
Summary/Conclusions: CD38 expression identified a group of patients with
aggressive disease that was considered by traditional staging to be early-stage
disease (Rai stages 0-II or Binet A). Patients with CD38 samples have signifi-
cantly aggressive disease regardless of their clinical stage. But today in era of
molecular and genetics markers when CD38 is loosing it prognostic value in
CLL patients prognosis, we propose serial analyses of the percentage of
CD38+cells to be done, resembling indicators of leukemiccell proliferation and
may signal clone evolution to a more aggressive state.
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IMPACT OF IGVH MUTATIONAL STATUS IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA WITH ISOLATED GOOD AND INTERMEDIATE
RISK GENETIC ABERRATIONS
J Sandoval-Sus1, LM Juárez Salcedo2,*, C Talati1, S Dalia3, BD Shah1, C Bello1,
J Lancet1, KL Sweet1, R Komrokji1, EM Sotomayor4, F Locke1, MA Kharfan-
Dabaja1, L Sokol1, JC Chavez1, J Pinilla-Ibarz1
1Department of malignant hematology, Moffitt Cancer Center, Tampa, United
States, 2Haematology Department, Principe de Asturias University Hospital,
Alcalá de Henares, Spain, 3Hematology/Oncology, Mercy Clinic, Joplin, 4Hema-
tology/Oncology, George Washington University, Washington D.C., United
States
Background: Genetic abnormalities in chronic lymphocytic leukemia (CLL)
have prognostic impact. The presence of trisomy 12 (T12) and normal karyotype
(NK), and 13q deletion (del13q) are associated with an intermediate and good
risk profile in CLL, respectively (Dohner et al. NEJM, 2000). The unmutated
status of the immunoglobulin variable heavy chain gene (IgVH) correlates with
survival in sole del13q CLL (Gladstone et al., Leukemia 2011). The prognostic
relevance of IgVH mutational status in isolated intermediate risk genetic variants
(T12 and NK) has not been described. We investigated the impact of the IgVH
mutational status in CLL patients with isolated del13q, T12 or NK in a large sin-
gle institution cohort.
Aims: To assess the prognostic impact of the IGVH mutational status in CLL
patients with isolated del13q, T12 and NK.
Methods: From January 2000 to January 2013 we identified 1267 CLL patients
using the Moffitt Cancer Center and Total Cancer Care databases. Descriptive
data was reported in patients with both unmutated (<2% from the germline
sequence) and mutated IgVH (>2% from the germline sequence). Time to first
treatment (TFT) and overall survival (OS) were estimated using the Kaplan-
Meier method and the log-rank test. A significant difference was considered at
p≤0.05. All analyses were done using SPSS version 19.0.
Results: We identified 145 CLL patients (median age: 59 years) with isolated
del13q (mutated IgHV=96, 66.2%; unmutated IgVH=49, 33.8%), 49 patients
(median age: 64 years) with isolated T12 (mutated IgVH=17, 34.7%; unmutated
IgVH=32, 65.3%), and 79 patients (median age: 57 years) with NK (mutated
IgVH=41, 51.9%; unmutated IgVH=38, 48.1%), respectively. Unmutated IgVH
was associated with shorter TFT in patients with sole del13q (unmutated 2.1
years vs mutated 6.0 years, p <0.001) and isolated NK (unmutated 1.9 years
vs mutated 3.3 year, p=0.05). IgVH mutational status had no impact in the TFT
of patients with sole T12. Patients with isolated del13q and mutated IgVH had
a longer median OS compared to unmutated patients (not reached vs 10.5
years, p=0.03). Nonetheless, the IgVH mutational status did not significantly
impact the OS of sole T12 patients (p=0.29) and NK (p=0.14) (Figure 1).
Figure 1. Overal survival per IGVH mutational status.
Summary/Conclusions: Our results confirm the negative impact of the unmu-
tated IgVH status in CLL patients with isolated del13q. The mutational IgVH
status did not impact the OS of T12 and NK CLL patients.
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REDISTRIBUTION PATTERN AND ASSESSMENT OF EARLY RESPONSE
TO IBRUTINIB IN CLL BY TOTAL TUMOR MASS SCORE (TTM) - KROHEM
CLL2 STUDY
O Jaksic1,*, S Basic Kinda2, I Aurer2, D Carzavec3, I Mandac Rogulj4, V Haris1,
J Sincic Petricevic5, G Rincic3, V Pejsa1, S Ostojic Kolonic4, B Jaksic4,
D Nemet2
1University Hospital Dubrava, 2University Hospital Centre Zagreb, 3University
Hospital Centre Sisters of Mercy, 4University Hospital Merkur, Zagreb, 5Uni-
versity Hospital Centre Osijek, Osijek, Croatia
Background: Ibrutinib is Bruton’s tyrosine kinase inhibitor with significant efficacy
in CLL. Ibrutinib monotherapy usually leads to redistribution of tumor mass from
lymphoid organs to peripheral blood before eventual response in all compart-
ments. This leads to certain problems in response assessment by iwCLL criteria
requiring several modifications. Total Tumor Mass score (TTM) (Jaksic, BJH
1980) is a simple quantitative clinical parameter for evaluation of tumor mass in
all relevant lymphoid compartments in CLL (PB+BM, LN and spleen) that was
successfully used in CLL trials by several international cooperative groups
(EORTC, IGCI) in alkylator and purine analog era. It is helpful in routine clinical
practice for monitoring of total tumor load, progression and/or response to treat-
ment. Due to its characteristics TTM may overcome problems caused by signif-
icant redistribution during TKI treatment (Jaksic, BJH 2014).
Aims: To evaluate usefulness of TTM in evaluation of response and redistribution
during ibrutinib treatment in CLL patients in a real life setting.
Methods: This is an observational study from Croatian cooperative group for
hematological malignancies (KROHEM) were data from patients included in ibru-
tinib NPP (420 mg daily) were collected on national level. Thirty patients with
relapsed/refractory B-CLL were included, 24 males and 6 females, median age
65.5 years (50-83) and median 2 prior lines of therapy (1-6). There were 4 pts
with del 17p and 6 with del 11q (out of 24 with data). Baseline routine evaluation
was done before ibrutinib treatment. Clinical and laboratory assessments of tumor
mass were collected at start and on months 1, 3, 6, 9 and 12. Bone marrow
assessment, US and MSCT scans were performed when clinically indicated.
Response was assessed by modified iwCLL criteria (Hallek, Blood 2008, 2012,
2013) and by TTM criteria (Jaksic, BJH 2014). TTM scoring system: TM1=√Lym-
phocytes (×109/l), TM2=largest palpable lymph node (cm), TM3=spleen below
left costal margin (cm). TTM=TM1+TM2+TM3, TTM-D=TM1/TTM (percentage of
tumor mass in leukemic compartment). ∆TTM – response/progression, ∆TTM-D
- redistribution
Results: At 6th month 81% of patients responded with tumor mass (TTM) reduc-
tion >25%; 67% of patients responded with tumor mass reduction >50% and
43% of patients responded with tumor mass reduction >75%. Modified iwCLL
response correlated well with TTM response criteria on months 3, 6 and 9 (Spear-
man correlation 0.538, p<0.001; 0.762, p<0.001; 0.739, p<0,009 respectively),
but not in month 1 (Spearman correlation 0.175, p=0.356). At month 6, there
were 13/21 patients in PR and PR+PR-Ly 19/21 (iwCLL) compared to 14/21
(TTM reduced >50%) and 17/21 (TTM reduced >25%) respectively. Lymphocy-
tosis changed from baseline=1.0 to months 1, 3, 6 and 9 (median 2.60; 1.95;
0.67 and 0.51 respectively) taking into account all cases. However, while this
describes a typical increase, actually no increase of lymphocytosis at month 1
was observed in 30% of patients. Neither multiple stepwise regression found any
statistically significant correlation with baseline predictors, nor were patients with
increase of lymphocytosis at month 1 significantly different from typical responders
in distribution of baseline predictors according to Mann Whitney U test. Tumor
distribution (TTM-D, median) rose from 0.47 (baseline) to 0.84 in month 1, and
to 1.0 from months 3 on. Multiple stepwise regression with response at month 6
as dependent variable and 10 predictor variables at baseline: age, disease dura-
tion, previous lines of therapy, lymphocytosis, lymph node size, spleen size, TTM,
TTM-D, hemoglobin and platelets identified in the model only TTM at baseline as
significant negative predictor of response (p=0.001) (Figure 1).
Figure 1. TTM response at 6 months.
Summary/Conclusions: TTM is a simple and useful parameter successfully
applied in ibrutinib treated patients in routine clinical practice for response
assessment and follow-up. It is highly correlated with modified iwCLL criteria
after 3rd month. It is more robust then iwCLL criteria because it incorporates
and quantify tumor redistribution and therefore can be applied regardless of
therapy used without specific modifications.
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A NEW PROGNOSTIC SCORING SYSTEM FOR TTFT FOR PATIENTS WITH
CLL IN CHINA
H Li*, W Xiong, Z Li, L Qiu
State Key Laboratory of Experimental Hematology, Institute of Hematology and
Blood Disease Hospital,Chinese Academy of Medical Sciences and Peking
Union Medical College, Tianjin, China
Background: The established clinical staging systems (Rai/Binet) can not
accurately discriminate among prognostic groups, especially for patients in
early stages. Several prognostic factors have been identified to predict the out-
come of patients with chronic lymphocytic leukemia (CLL), but only a few stud-
ies analyzed more markers together.
Aims: In this study, we identified the biologic prognostic markers and combined
them in a new prognostic scoring system, the CLL prognostic index (CLL-PI)
for predicting time to first treatment (TTFT) in patients with CLL in China.
Methods: Taking advantage of a population of 402 untreated Chinese patients
with CLL at early and advanced stage of disease, we identified the strongest
prognostic markers of TTFT and, subsequently, in a cohort of 173 patients we
integrated data of traditional staging system, cytogenetic lesions and
immunoglobulin heavy chain variable region (IGHV) mutational status in CLL-
PI. The median follow-up time was 45 months (ms). Methods of multivariable
statistics were applied, and the end point was TTFT.
Results: Based on multivariate Cox regression analysis, three independent
factors for TTFT were identified: clinical stage (Rai risk group), del17p and
IGHV mutation status. Applying weighted grading of these three independent
factors based on regression parameters, a CLL-PI was constructed, which
could categorize four different risk groups [low (score 1), intermediate (score
2), high (score 3) and extremely high risk (score 4-6)] with significantly different
TTFT (median TTFT of NR, 65.0 ms, 24.0 ms and 12.5 ms, respectively,
p<0.001). Further, this index provided accurate estimation regarding overall
survival (OS) (median OS of NR, 210.0 ms, 97.0 ms and 43.0 ms, respectively,
p<0.001] (Tables 1 and 2, Figure 1).
Table 1. Scores assignment to three independent factors of PI
Rai risk group                  Scores          IGHV status            Scores          17p-         Scores
Low (Rai 0)                           1                 M-IGHV                    0            Negative          0
Intermediate (Rai I-II)            2                  U-IGHV                    1            Positive           2
High (Rai III-IV)                     3                                                                                
Abbreviation: IGHV, mutated immunoglobulin heavy chain variable region; M, mutated; U, unmu-
tated.
Table 2. Survival data in each subgroup according to the scoring system
Groups (PI scores)               N     Median TTFT (months)       95% CI (months)      p-value
Low risk (=1)                        21                   NR                               NE-NE                0.000
Intermediate risk (=2)           56                 65.0                           40.9-89.1                 
High risk (=3)                       67                 24.0                            6.2-41.8                  
Extremely high risk (4-6)        27                 12.5                            7.6-17.4                  
Abbreviation: CI, confidence interval; TTFT, time to first therapy; NR, not reached; NE, not eval-
uated.
Figure 1.
Summary/Conclusions: This study developed a weighted, integrated CLL-PI
which combines the most important genetic prognostic markers (IGHV mutation
status, 17p deletion) with traditional clinical stage. This newly modified PI could
be used to discriminate among groups and may help predict the TTFT and
prognosis of patients with CLL.
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AN ASSESSMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL) WHO ARE ELIGIBLE FOR FIRST-LINE THERAPY BUT
UNSUITABLE FOR FULL-DOSE FLUDARABINE
D Jeyakumaran1,*, S Cote1, A Kempel-Waibel2
1HEOR, Janssen EU HEMAR, High Wycombe, United Kingdom, 2HEOR, Phar-
mametrics GmbH, Freiburg, Germany
Background: Chronic Lymphocytic Leukemia (CLL) is a rare disease which
has been granted orphan designation by the EMA. Treatment of CLL is only
initiated in patients with symptomatic, active disease and treatment options
are dependent on patient characteristics. The European Society for Medical
Oncology (ESMO) identifies three subgroups of symptomatic CLL patients who
are eligible for front-line treatment; physically fit patients, elderly patients or
those with major comorbidities, and patients with del17p/TP53 mutation. Older
patients and those with severe comorbidities are less able to tolerate the full-
dose fludarabine treatments prescribed to physically fit patients. Fludarabine-
based therapies are also considered unsuitable for patients with the
del17p/TP53 mutation. These patient subgroups may thus benefit from the
introduction of newer, less aggressive therapies.
Aims: The aim of this analysis is to estimate the number of CLL patients who
require treatment initiation but who are unsuitable for treatment with full-dose
fludarabine, namely those who are elderly (≥70 years), or those who are
younger but have comorbidities (aged between 65 and 69 with comorbidities).
It also identifies the number of patients with the del17p/TP53 mutation. To our
knowledge this is the first study to stratify the total symptomatic, treatment
naïve CLL patient population by these patient characteristics which influence
treatment decisions.
Methods: A targeted literature review was conducted in Medline and Embase,
as well as in cancer-related statistical sources in nine European countries (Bel-
gium, France, Germany, Italy, Spain, UK, Netherlands, Poland and Sweden),
applying all relevant keywords related to the disease and to the parameters to
be assessed (incidence, prevalence, mortality, survival, asymptomatic, symp-
tomatic, age, fitness, comorbidities). Based on relevant articles extracted and
reviewed, the annual number of patients unsuitable for full-dose fludarabine is
estimated.
Results: Patients eligible for first-line therapy comprise all newly diagnosed
symptomatic CLL patients as well as patients who have transitioned from an
asymptomatic disease state to an active disease state. The crude incidence
rate of CLL was found to range from 3.88 per 100,000 in Germany to 6.9 per
100,000 in the UK. Of these newly diagnosed patients, between 51.9% and
75.6% are asymptomatic. Approximately 5.0% to 7.8% of previously diagnosed
patients transition from an asymptomatic state to a symptomatic state every
year. Assuming a mean CLL incidence rate of 4.94 per 100,000 and a mean
yearly transition rate of 6.4%, the total estimated number of patients eligible
for front-line treatment in 2015, across the nine European countries considered,
was 12,370. Of these symptomatic patients, 986 (8.0%) had the del17p/TP53
mutation. Among symptomatic patients without the del17p/TP53 mutation,
56.5% were aged ≥70, and 6.7% were aged between 65 and 69 with major
comorbidities. Thus in 2015, across the nine European countries considered,
there were an estimated 7,191 symptomatic CLL patients aged ≥70 or aged
between 65 and 69 with major comorbidities, who were eligible for first-line
treatment but not suitable for full-dose fludarabine.
Summary/Conclusions: This study provides an in-depth overview of the treat-
ment-naïve CLL patient population across nine European countries and pro-
vides an estimate of the number of patients unsuitable for full-dose fludarabine
and fludarabine-based therapies, and who could potentially benefit from newer,
more tolerable therapies.
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INSULIN-LIKE GROWTH FACTOR SYSTEM AS A PROGNOSTIC
BIOMARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA: A CROSS-S
ECTIONAL STUDY
M Dalamaga1, GS Christodoulatos2, M Triantafilli3, K Karmaniolas4,
G Sotiropoulos5, A Lekka3,*
1Biological Chemistry, University of Athens, School of Medicine, 2Laboratory
of Hematology, KAT Hospital, 3Laboratory of Hematology, 4Internal Medicine,
5NIMTS General Hospital, Athens, Greece
Background: B-cell chronic lymphocytic leukemia (B-CLL) is characterized
by the accumulation of long-survived B lymphocytes arrested in G0/1 phase
by impaired apoptosis. Growth factors may contribute to paracrine or autocrine
loops affecting CLL cell survival via the induction of apoptosis-related genes.
Insulin-like growth factor I (IGF-I), which is mainly produced by hepatocytes,
constitutes an important anti-apoptotic factor for several malignant cells. Fur-
thermore, IGF-I and its main binding protein IGFBP3 are related to the devel-
opment and pathogenesis of insulin resistance, diabetes as well as in obesity-
associated malignancies.
Aims: The goal of the present study was to evaluate circulating levels of IGF-I
and IGFBP3 in patients suffering from B-CLL and control participants. We also
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explored the ratio of IGF-I/IGFBP3, which gives a mechanistic insight into IGF-I
bioavailability, as well as IGF-I and IGFBP3 as prognostic parameters of B-CLL.
Methods: Blood samples were collected from ninety five cases with incident
B-CLL and an equal number of hospital controls, admitted for non-neoplastic
and non-infectious conditions, matched on gender, age and year/month of diag-
nosis (±1 month) between 2001 and 2007. Informed consent was obtained
from all study participants. Serum IGF-I and IGFBP3 were determined using
commercially available ELISA assays (DIAsource ImmunoAssays S.A, Lou-
vain-la-Neuve, Belgium). Moreover, serum lactate dehydrogenase (LDH), β2-
microglobulin (BMG), lymphocyte morphology and the surface expression of
CD38 in >30% of B-CLL lymphocytes were assessed. Statistical analysis of
the data was performed using univariate and multivariate analyses with IBM-
SPSS® version 23 for Windows.
Results: Overall, B-CLL patients had a significantly elevated body mass index
(BMI) as compared to control participants (27.8 vs 26.7 kg/m2; p<0.01). In uni-
variate analysis, circulating levels of IGF-I were similar in cases compared to
controls (126.75±21.41 versus 125.10±25.50 ng/mL, respectively, p=0.63).
However, serum IGFBP3 was significantly lower in cases than controls
(3.16±0.96 versus 4.22±1.03 μg/mL, respectively, p<0.001) while the IGF-I/IGF-
BP3 ratio was significantly elevated in cases compared to controls (0.049±0.07
versus 0.030±0.05, respectively, p=0.01). Lower serum IGFBP3 levels were
associated with B-CLL risk in multivariable analyses adjusting for age, gender,
date of diagnosis, family history of lymphohemopoietic cancer, BMI, serum IGF-
I and insulin (<0.001). In B-CLL patients, serum IGF-I was significantly and
positively associated with Binet stage, IGFBP3, LDH and BMG (p<0.001), and
negatively associated with age (p<0.001).
Summary/Conclusions: The observed results highlight the potential involve-
ment of IGF-I bioavailability in the B-CLL pathogenetic process. Circulating
IGF-I might be a potential biomarker for B-CLL prognosis. Further prospective
and longitudinal studies are needed in order to confirm these observations as
well as to elucidate the contribution of the IGF-I system in B-CLL progression.
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SECONDARY MALIGNANCIES IN CHRONIC LYMPHOCYTIC LEUKEMIA:
A SINGLE CENTRE RETROSPECTIVE ANALYSIS
G Reda1,*, B Fattizzo1, R Cassin1, N Orofino1, E Flospergher1, D Consonni2,
W Barcellini3, A Cortelezzi1
1Oncohematology Division, 2Epidemiology Division, IRCCS Ca’ Granda
Ospedale Maggiore Policlinico and University of Milan, Milan, 3Oncohematology
Division, IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of
Milan, Milano, Italy
Background: Chronic lymphocytic leukemia (CLL) is characterized by pro-
gressive immunodeficiency with high prevalence of infections, autoimmune
phenomena and secondary malignancies. The immune deregulation may be
due to the disease itself or it may be a consequence of the treatment per-
formed.
Aims: To evaluate the occurrence of second cancers in CLL patients and their
relationship with clinical and laboratory features as well as with therapy lines.
Methods: Clinical history of 514 CLL patients diagnosed and followed from
1983 until 2014 at our Institution were retrospectively evaluated and the diag-
nosis of a second cancer was collected. History of neoplasia preceding CLL
diagnosis was also registered. Student t test for continuous variables, chi-
square test for categorical ones and Log rank test for survival analysis were
performed.
Results: Clinical, hematological and biological characteristics are listed in Table
1. Secondary cancers were categorized according originating organ/tissue;
skin cancers were divided into melanoma and non-melanoma. During the follow
up 88 patients (17%) developed secondary cancers, with a mean time from
diagnosis to secondary neoplasia of 9 years. Considering tumor histology, we
observed 9 blood, 9 lung, 5 breast, 19 uro-genital tract (5 kidney, 10 prostate,
4 bladder, 2 uterus, and 2 ovarian), 15 gastro-enteric tract (12 colon, 2 gastric
and 1 tongue), 4 pancreas, 3 melanoma and 15 skin cancers other than
melanoma. No significant differences were observed according to age, gender,
Rai/Binet stage and hematologic parameters in patients with or without sec-
ondary tumors (Table 1). Considering CLL prognostic features, the development
of second cancers was associated with higher age (p<0.001) at diagnosis,
increased beta2microglobuline levels (p=0.03) and un-mutated VHIG status
(p<0.005; Figure 1). At variance, no association was found with 13q, 11q or
17p deletion, chromosome 12 trisomy, nor with ZAP-70 and CD-38 positivity
(Table1). Past history was positive for malignancies in 70 patients (13%): 2
blood, 3 airways (2 lower and 1 upper), 3 breast, 6 uro-genital tract (3 bladder,
3 prostate, 2 uterus and 1 ovarian), 3 gastro-enteric tract, 3 skin cancers other
than melanoma, and 3 melanoma. On the whole, 46/88 (52.3%) and 219/426
(51.4%) patients with or without secondary cancers, underwent at least one
therapy line. More specifically, 86 patients were treated with fludarabine con-
taining regimens, of whom 11 developed a secondary cancer; 180 with chlo-
rambucil, of whom 34 developed a secondary tumor and 65 with alemtuzumab,
of whom 10 were later diagnosed with a second cancer. During the follow up,
121 patients died, of whom 8 directly from secondary malignancies, 41 from
CLL progression, 2 from thrombotic events, and 11 from infections.
Table 1.
Figure 1.
Summary/Conclusions: Secondary malignancies are not infrequent in patients
with CLL and patients with un-mutated VHIG status are at higher risk of devel-
oping a second cancer. As secondary neoplasia are not clearly related to bio-
logic markers or to the treatment performed, a careful clinical follow up, encom-
passing sex and age adjusted tumors screening is advised.
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COMPLEX ACTIVATION OF ANGIOGENIC SIGNALING IN CHRONIC
LYMPHOCYTIC LEUKEMIA: EVIDENCE FROM CIRCULATING ANGIOGENIC
CYTOKINES
L Smolej1,*, C Andrys2, P Vodarek1, M Motyckova1, M Simkovic1, D Belada1,
P Zak1
14th Department of Internal Medicine - Hematology, 2Institute of Clinical
Immunology and Allergology, University Hospital and Charles University Faculty
of Medicine, Hradec Kralove, Czech Republic
Background: Angiogenesis is an important and well-known player in the biol-
ogy of chronic lymphocytic leukemia. Elevated plasma/serum concentrations
of various angiogenic cytokines have been reported in CLL; however, their
exact prognostic role, association with modern prognostic factors and impact
on clinical course (especially overall survival) is largely unknown.
Aims: To evaluate prognostic significance of vascular endothelial growth factor
(VEGF), fibroblast growth factor-2 (FGF-2), soluble endoglin (sCD105),
angiopoietin-2 (Ang-2), transforming growth factor-1 (TGF-β1) and inhibitors
endostatin and thrombospondin-1 (TSP-1) in patients with untreated CLL fol-
lowed at a single tertiary center.
Methods: Plasma levels of VEGF, FGF-2, sCD105, Ang-2, TGF-β1, endostatin
and TSP-1 were quantified using enzyme-linked immunosorbent assay (ELISA
Quantikine kits, RD Systems) in 206 patients with CLL (median age, 64 year;
males, 69%; Rai modified risk: low/intermediate/high in 38/46/16%; unmutated
IGVH genes, 58%; del 11q/del 17p by FISH, 19 and 4%) and 80 healthy controls.
Plasma concentrations ≥median of the CLL cohort were considered elevated.
Results: VEGF, FGF-2, sCD105 and Ang-2 were significatly elevated in com-
parison to the control group; differences in TGF-β1, endostatin and TSP-1 were
on the border of statistical significance (Table 1). There was a positive associ-
ation of high Ang-2 with unmutated IGHV genes (p=0.027); patients with high
sCD105 and lowTGF-β1 had more advanced Rai stages (p=0.0004 and
p=0.052). High levels of Ang-2, endostatin, sCD105 and low TGF-β1 correlated
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with shorter time to first-line therapy (p=0.0001, p=0.0001, p=0.0021 and
p=0.027); in addition, patients with high Ang-2 and endostatin had significantly
shorter overall survival (p=0.0006 and p=0.015).
Table 1.
Summary/Conclusions: Our results indicate that a complex network of angio-
genic signaling is active in CLL and has an impact on clinical course; Ang-2
and endostatin appear to possess the best prognostic value and deserve further
evaluation.
Supported by DRO (Univ Hospital Hradec Králové, 00179906).
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FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB,
DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK
CLL (ORIGINAL PROTOCOL)
AR Pettitt1,*, F Polydoros2, J Dodd2, M Oates1, K Lin3, N Kalakonda1,
H McCarthy4, A Bloor5, A Schuh6, A Duncombe7, C Dearden8, C Fegan9,
B Kennedy10, C Yap11, SE Coupland1, P Hillmen12
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tion Trust, Manchester, 6Department of Oncology, Churchill Hospital, Oxford,
7Southampton General Hospital, Southampton, 8Haemato-Oncology Trials
Unit, Royal Marsden NHS Foundation Trust, Sutton, 9University Hospital of
Wales, Cardiff, 10Leicester Royal Infirmary, Leicester, 11Cancer Research UK
Clinical Trials Unit, University of Birmingham, Birmingham, 12Faculty of Medi-
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Background: 17p- chronic lymphocytic leukaemia (CLL) is notorious for its resist-
ance to chemotherapy. The Phase II NCRI CLL206 trial showed that alemtuzum-
ab plus high-dose methylprednisolone was safe and effective in this setting,
although the median progression-free survival (PFS) was only 11.8 months (J
Clin Oncol 2012;30:1647-55).
Aims: In an attempt to improve on these results, the NCRI CLL210 trial was
developed to examine the safety and efficacy of alemtuzumab, dexamethasone
and lenalidomide which has activity in 17p- CLL.
Methods: Patients with previously untreated 17p- CLL or CLL progressing within
12 months of FCR received dexamethasone (40 mg po day 1-4 of weeks
1,3,5,7,9,11,13,15), lenalidomide (5 mg od weeks 3-4 and 10 mg od weeks 5-
24) and alemtuzumab (30 mg sc days 1,3,5 of weeks 7-22). Patients who
achieved a complete response (CR) or partial response (PR) were allowed to
proceed to allogeneic stem-cell transplantation if considered appropriate, or were
randomised to lenalidomide maintenance (10 mg od until disease progression)
versus no further treatment. Supportive medication consisted of allopurinol, G-
CSF, co-trimoxazole, aciclovir, itraconazole, lansoprazole, alendronic acid,
aspirin, plus immunoglobulin replacement therapy where appropriate. Written
informed consent was obtained from all patients prior to entering the study. The
primary endpoints were post-induction CR/CRi rate and progression-free rate
after 2 years of maintenance therapy. Response data were assessed by an inde-
pendent endpoint review committee using the 2008 NCI/IWCLL criteria.
Results: Sixteen patients out of the planned 85 were recruited from 7 UK sites
during the first 7 months of recruitment before accrual was halted in September
2012 due to withdrawal of marketing authorisation for alemtuzumab. The protocol
was subsequently amended to replace alemtuzumab with ofatumumab. This
report describes the outcome of the initial cohort of alemtuzumab-treated patients
(8 untreated and 8 FCR failures; 17p- in 13). Ten patients (62%) completed induc-
tion, whereas 6 (38%) stopped induction prematurely due to toxicity (3), disease
progression (1), change in diagnosis (1) or death (1). Three patients (19%) pro-
ceeded to allogeneic stem-cell transplantation, 5 (31%) were randomised to
lenalidomide maintenance (3) or no further treatment (2) and 2 (12%) withdrew
from the randomised part of the trial despite completing induction successfully.
The post-induction OR and CR/CRi rate among evaluable patients (11) was 91%
and 18% respectively. The progression-free rate after 2 years of maintenance
phase among evaluable patients (4) was 50% in both treatment arms. With a
maximum follow-up period of 46 months, the median PFS for all 15 eligible
patients was 29.3 months. The median OS was not reached since there were
only 4 deaths. Grade ≥3 toxicity occurred in 93% of patients and the treatment-
related mortality was 6%.
Summary/Conclusions:Although the small sample size prevents definitive con-
clusions from being drawn, the results of this prematurely terminated study sug-
gest that alemtuzumab, dexamethasone and lenalidomide is feasible to deliver
in most patients with high-risk CLL and has an acceptable safety profile. The
regimen also appears to be effective, with a high overall response rate and a
median PFS somewhat longer than the 11.8 months that was observed with
alemtuzumab plus methylprednisolone. We conclude that the efficacy of gluco-
corticoid/alemtuzumab in this setting may be enhanced by the addition of lenalido-
mide without incurring significant additional toxicity.
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SERUM RESISTIN IN RELATION TO B-CELL CHRONIC LYMPHOCYTIC
LEUKEMIA RISK AND ITS CORRELATIONS WITH PROGNOSTIC
BIOMARKERS
M Dalamaga1, GS Christodoulatos2, M Triantafilli3, K Karmaniolas4,
G Sotiropoulos3, A Lekka3,*
1Biological Chemistry, University of Athens, School of Medicine, 2Laboratory of
Hematology, KAT Hospital, 3Laboratory of Hematology, 4Internal Medicine,
NIMTS Hospital, Athens, Greece
Background: Excess weight and insulin resistance are now considered risk fac-
tors for many types of malignancies, including leukemia and lymphoma. Potential
mechanisms that may link obesity and insulin resistance to B-cell chronic lym-
phocytic leukemia (B-CLL) include also the abnormal secretion of adipocytokines.
Resistin, an adipocytokine belonging to the family of resistin-like molecules, was
originally discovered as a molecule enhancing insulin resistance or impaired
hepatic sensitivity to insulin and provoking hyperglycemia without affecting periph-
eral insulin sensitivity. However, data in humans are controversial.
Aims: In this cross-sectional study, we attempted to investigate the contribution
of resistinemia to B-CLL risk taking into account potential important confounders
including the family history of lymphohematopoietic cancer (LHC), body mass
index (BMI), serum insulin and other adipocytokines. We also attempted to ascer-
tain whether a relationship between serum resistin and prognostic markers exists
amongst patients with B-CLL diagnosis.
Methods: Blood samples were collected from 95 cases with incident B-CLL and
95 hospital controls, admitted for non-neoplastic and non-infectious conditions,
matched on gender, age and year/month of diagnosis (±1 month) between 2001
and 2007. Informed consent was obtained from all study participants. Serum
resistin was determined using a commercially available ELISA assay (Phoenix,
CA, USA). Furthermore, serum lactate dehydrogenase (LDH), β2-microglobulin
(BMG), lymphocyte morphology and the surface expression of CD38 in >30% of
B-CLL lymphocytes were assessed. The statistical analysis of the data was per-
formed using IBM-SPSS® version 23 for Windows.
Results: Patients with B-CLL had on average a higher BMI as compared to con-
trol participants (27.8 vs 26.7 kg/m2; p<0.01). Significantly, more patients than
controls presented a positive family history of LHC (13 vs 3 controls; p<0.01). In
univariate analysis, circulating levels of resistin were statistically significantly ele-
vated in cases as compared with controls (10.43±5.42 versus 8.12±4.88 ng/mL
respectively, p=0.002). However, although serum higher resistin was associated
with B-CLL risk in unadjusted analyses, in multivariable analyses controlling for
age, gender, date of diagnosis, family history of LHC, BMI, serum insulin, leptin
and adiponectin levels, serum resistin presented a borderline statistical signifi-
cance with B-CLL occurrence (OR: 1.08, 95% CI: 0.99-1.16, p=0.06). Amid
patients, serum resistin was not associated with Binet stage (p=0.85) and
absolute lymphocyte count (p=0.55). Nevertheless, circulating resistin presented
a borderline negative correlation with BMG (p=0.07) and CD38 (p=0.07).
Summary/Conclusions: Circulating resistin was found to be elevated among
cases as compared to controls in univariate analysis. It has been recently shown
that hyperesistinemia is linked to the risk for many malignancies. These results
need to be confirmed in larger study populations using a prospective study
design; but if reproduced in adjusted analyses they may suggest that resistin
may be upregulated and/or upregulate the synthesis of other inflammatory factors
etiologically linked to B-CLL etiopathogenetic process.
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CALRETICULIN GENE MUTATION IN HAIRY CELL LEUKEMIA AND
RELATIONSHIP WITH PROGNOSIS
S Subari1,2,*, A Kizikli1, S Kul3, S Oztuzcu4, G Nacarkahya4, I Sari5, M Turker1,
M Pehlivan2, V Okan2, M Yilmaz2
1Internal Medicine, 2Hematology, 3Biostatistics, 4Medical Biology, 5Pathology,
Gaziantep University, Gaziantep, Turkey
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Background: Hairy cell leukemia (HCL) is a malignant hematologic neoplasm
characterized by peripheral blood and bone marrow hairy cells. Etiology of dis-
ease is not clear. Calreticulin (CRT) is a protein located on endoplasmic retic-
ulum which plays role on protein folding, calcium homeostasis, regulation and
loading antigenic peptides into major histocompatibility class-I in the cells. As
of today, CRT gene mutations were determined in JAK2 and MPL negative
myeloproliferative neoplasms. However, the effect of this gene mutation on
hairy cell leukemia which is a lymphoproliferative disease is unknown.
Aims: To study the presence of CRT mutations in hairy cell leukemia and
effects.
Methods: A retrospective single institution study chart review of cases with
HCL at Gaziantep University between 2005- 2015 was performed. Patients
with precise hairy cell leukemia were included. Bone marrow tissue biopsy
samples were used. Following the isolation of genetic material and gene
sequence analysis by PCR, mutations were investigated for CRT. Complete
blood count, peripheral blood smear, bone marrow aspiration and biopsy, flow
cytometry were used to diagnose HCL patients. Laboratory counts were deter-
mined as anemia <12g/dL, thrombocytopenia <100x109/L, neutropenia <1
x109/L and monocytopenia <0.2 x109/L. We used French Society of Hematology
remission criteria for treated hairy cell leukemia. Appropriate ethics approval
approval was obtained in accordance with the Helsinki declaration. Comparison
between group medians was done using Mann Whitney U, while survival esti-
mates were calculated using Kaplan-Meier curves SPSS V22.
Results: Out of 33 HCL samples, 21 (63.6%) CRT exon-9 sequencing analyses
could be performed and CRT gene mutation was not detected in any. In the
clinical analysis of these patients median age was 54 years, with 26 (78.8%)
patients were males. Labs at diagnose included median white blood cell was
2.7 x109, Hemoglobin 9.5 g/dL, platelet 58 x109, monocytes 0.28x109, lympho-
cyte 1.3 x109, neutrophil 1 x109. Laboratory count were found anemia in 22
(%73.3), trombocytopenia in 21 (70%), neutropenia in 14 (48.3%) and mono-
cytopenia in 12 (41.4%) of patients. Out of 33 patients, 27 (90%) had
splenomegaly documented at the time of diagnosis. When evaluated pretreat-
ment splenic size by ultrasound, median spleen size was 20.3 centimeter (medi-
an%25-75, 16.5-24). Cladribine was used in the treatment of 23 (69.7%)
patients. Among these patients’ complete response was 13 (56,5%), partial
response was 3 (13%) and overall response was 69.5%. Splenomegaly was
significantly high in patients without monocytopenia (p=0.05). There were sur-
vival differences between treated (n=23) and untreated (n=10) patient groups
(85.6±3 and 17.7±7.8 median months, respectively p=0.001). The patients who
treated had significantly longer overall survival compared to those untreated.
Furthermore, pretreatment median hemoglobin level was higher in remission
group compared to no remission group as 10.1 g/dL vs 8.5 g/dL respectively
and there was a statistically significant difference between them (p=0.047).
Summary/Conclusions: This is the first study carried out regarding CRT gene
mutation in HCL in the literature. We consider that CRT gene mutations are not
effective on disease pathogenesis. As a result, spleen size was larger in patients
with who had no monocytopenia and initial hemoglobin levels were higher in
remission group. This result may be an important finding in terms of timing of
treatment in patients with HCL. In this respect, it may be appropriate approach
to start to the treatment before anemia develops. Additional larger studies are
needed to confirm our results.
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FACTORS ASSOCIATED WITH TREATMENT CHOICE AND RESPONSE IN
RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
PATIENTS RE-TREATED WITH RITUXIMAB: THE OBSERVATIONAL
PERLE STUDY
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Background: The treatment of patients with relapsed and refractory chronic
lymphocytic leukemia (r/rCLL) previously treated with rituximab-based regimen
(R) and re-treated with rituximab is relatively complex.
Aims: Exploratory analyses were conducted to identify factors leading to the
choice of a specific combined chemoimmunotherapy: R-Bendamustine (RB),
R-purine analogs (RP), R-alkylating agents (RA) or others regimens (Oth) and
factors associated with the quality of response.
Methods: PERLE is a prospective non-interventional cohort study (main results
presented at EHA 2014 - P876) conducted in r/rCLL patients. Two sets of
exploratory analyses using data-mining methods were performed on baseline
characteristics: decision trees to find patterns of factors defining subgroups of
patients and random forests to provide a robust predictor model with a ranking
between all available information. To confirm these outputs, standard logistic
models, univariate and multivariate were implemented. Among baseline char-
acteristics (clinical, demographics, disease and patients’ management)
analysed with data mining, some were identified as candidate factors. The most
impacting factors associated either with choice of chemotherapy or with
response were confirmed by multivariate analyses.
Results: Overall, 310 patients were included. Their median age was 72 years
[35 - 93] and 68% were men. The majority (187, 60%) was in first relapse. Ritux-
imab was administered during first (69%), second (94%), or both (16%) previous
treatment lines. More than half of the patients received RB, 16% received RP
and 18% received RA (including 40% with chlorambucil). RB was favored in
patients with a previous purine based-treatment (OR=2.36 [1.4; 3.9]) which is
the opposite of RP (OR=0.39 [0.2; 0.8]). RA was preferentially prescribed in
elderly patients (≥70 y.o., OR=4.29 [2.0; 8.9]). Overall response rate (ORR) at
the end of induction was 84%. A significantly better response was observed with
the use of 500mg/m2 rituximab dose versus 375mg/m2 (84.5% versus 53.4%),
when neutrophils count was ≥1.109/L versus <1.109/L, (76.3% versus 47.4%)
and when response duration was ≥12 months versus <12 months (80.1% versus
62.5%). The number of previous rituximab-based treatment lines also impacts
the quality of the response: ORR 76.2% with 1 treatment line versus ORR 45.0%
with 2 previous treatment lines. Imbalance between responders and non-respon-
ders according to 17p deletion was also observed (patients with deletions: 49%
responders; without deletion: 80%). Furthermore, ORR differences were observed
between treatment groups: 85% with RB, 89% with RP, and 78% with RA. In this
observational study, adverse events (all grades) were hematological (26.9%,
including neutropenia (11.9%)) and infectious (14.4%). Grade ≥3AEs occurred in
28.4% of patients and were mainly hematological (19.7%); 22 patients (6.9%)
died during induction treatment (15 deaths related to progression; 7 for AEs).
Summary/Conclusions: In real-life setting, treatment choice for r/r CLL is mul-
tifactorial. Overall, whatever the patient’s profile and the treatment strategy, the
dose of rituximab (500mg/m²), as well as a single previous rituximab-based
treatment line, are associated with a significantly better quality of response.
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PLATELET DYSFUNCTION CAUSED BY IBRUTINIB TREATMENT IN
PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. MONOCENTRIC
EXPERIENCE: CLINICAL AND LABORATORY CHARACTERIZATION
I Innocenti1,*, MA Alberelli2, F Autore1, S Sica1, E De Candia2, L Laurenti1
1Department of Hematology, 2Department of Oncology and Hematology, Insti-
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Background: Ibrutinib (IBR) is a potent and irreversible inhibitor of Bruton’s
tyrosine kinase (Btk), approved for treatment naïve of chronic lymphocytic
leukemia (CLL) with del 17p or TP 53 mutation or for patients (pts) with
relapsed/refractory (R/R) disease. IBR treatment is associated with bleeding
events, mostly mild to moderate (I-II grade of severity), rarely severe (III-IV
grade of severity). The mechanism causing these bleeding events remains
unknown. A defect of platelet function has been hypothesized and inhibition of
signaling by glycoprotein VI (GP-VI) has been previously described. IBR asso-
ciated bleedings and platelet dysfunction may be relevant in CLL pts who are
elderly and with comorbidities.
Aims: To investigate and characterize the effect of IBR on platelet function in
vitro and in vivo in pts with CLL.
Methods: Nine pts with CLL were treated with oral IBR at dose of 420 mg/day;
7 received IBR in monotherapy for relapsed/refractory CLL and 2 in association
with monoclonal antibody anti-CD20 for treatment-naïve CLL. Median age was
68 years (57-75); 5 pts had unmutated IgVH and 2 had 17p deletion on FISH.
The median number of prior therapies in R/R CLL pts was 3 (range 2-7). After
a median follow up of 14 months (range 6-20) all pts achieved a partial
response. Thereafter 2 pts discontinued IBR therapy: 1 for Richter’s transfor-
mation, 1 underwent allogeneic HSCT. All pts before and after initiation of treat-
ment with IBR were studied with light transmission aggregometry (LTA) using
platelet-rich-plasma and the following agonists : ADP 2-4 uM, PAR1-AP 25 uM,
Collagen 10 ug /mL, arachidonic acid 1 mM, ristocetin 0.6-1.2 mg/mL; meas-
urement of von Willebrand factor(vWF) antigen and ristocetin cofactor activities
by chemiluminescent immunoassay.
Results: We recorded only grade I or II bleeding events (bruising, petechiae,
conjunctival hemorrhage, rectal bleeding) in 7 pts at a median time of 3 months
after IBR treatment (range 1-9); no patient needed treatment interruption or dose
reduction. Eight pts displayed abnormalities of the aggregation induced by 10
ug/ml collagen after initiation of IBR treatment. At these collagen concentration,
only significant prolongation of the lag phase was measured (74.6+/- 23.7 sec
vs basal 40.4+/- 17.2 sec), whereas the maximal aggregation was not impaired
(67.9+/- 21.4% vs basal 85.5+/-5.8%). Interestingly, in 5 pts a significant improve-
ment of the aggregation by 2 uM ADP (91.2+/- 5.1% vs basal 39.3+/- 24.6%)
and 4 uM ADP (91.6+/- 2.9% vs basal 65.4+/- 19.4%) during IBR treatment was
reported. On the contrary the aggregation by PAR1-AP, ristocetin and arachi-
donic acid was not affected under IBR. Finally, in 3/3 pts the vWF antigen and
ristocetin cofactor activity were higher at the onset of the disease (169+/- 38%)
and returned to normal values under IBR treatment (111.4+/- 47%).
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Summary/Conclusions: Our study showed that collagen induced platelet
aggregation resulted impaired while ADP induced aggregation improved upon
IBR treatment. Finally the levels of vWF were significantly higher in CLL pts
before treatment and normalized during IBR. In conclusion, IBR treatment in
CLL pts causes a mild bleeding phenotype most probably due to platelet dys-
function. The bleeding risk was unrelated to platelets count. The assessment
of platelet aggregation in IBR treated CLL pts could help to predict and monitor
bleeding risk, and to guide pts through invasive procedures.
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Background: Several studies in chronic lymphocytic leukemia (CLL) have
determined the achievement of minimal residual disease (MRD) negativity as
an independent favorable prognostic factor, leading to prolonged disease-free
and overall survival, regardless of the treatment protocol or the presence of
other pre-existing prognostic indicators. Novel therapies that incorporate purine
analogs, monoclonal antibodies and new agents targeting the B-cell receptor
signalling pathway recently improved response rates in relapsed/refractory
CLL. The number of patients achieved MRD negative remission increased.
Aims: To estimate of response rate and MRD after ibrutinib therapy in the
treatment patients with relapsed/refractory CLL.
Methods: 47 pts were included in the analysis. Stratification of patients into
prognostic groups based on identified chromosomal abnormalities by standard
GTG-method and interphase FISH analyses with use of DNA probes: LSI RB1
(13q14), LSI ATM (11q22), CEP12, LSI TP53 (17p13.1) (Abbott). Group 1
(n=26): 1st line rituximab-based chemotherapy (RB-12, FCR-14); Group 2
(n=17): 2nd and subsequent lines of rituximab-based chemotherapy (RB-12,
FCR-4, R-CHOP-1) and Group 3 (n=9): ibrutinib-based therapy (420 mg daily
oral Ibrutinib±Rituximab). Median age in Group 1 was 57 years (35-67), in Group
2-62 years (49-83), in Group 3-65 years (51-82). Patients received, regardless
of the programs of therapy. We have used NCI-IWCLL revised guidelines for
treatment initiation and assessment of response. MRD was detected by multi-
color flow cytometry of bone marrow in patients achieved a complete or partial
remission: Group 1-26 pts, Group 2-7 pts, Group 3-4 pts.
Results: Patients with unfavorable chromosomal abnormalities were detected
in each group: Group 1-4 pts (del(11q)-3, complex karyotype-1); Group 2-2 pts
(combination del(11q) with del(13q)); Group 3-1 pts (del(17p)). Overall response
rate (ORR) in Group 1 was 100%: complete remission (CR)-10 pts (unfavorable
prognosis (UP)-2), partial remission (PR)-16 pts. Group 2: ORR 82% (CR-1
pts, PR-13 pts (UP-2)); stable disease (SD)-1 pts, progression disease-2 pts.
Group 3: ORR 89% (CR-3 pts, PR-5 pts (UP-1); SD-1 pts). MRD-negative
remission was achieved in 46% pts in Group 1 (12/26: CR-6 pts (UP-1), PR-6
pts (UP-2)), in Group 2-14% (1/7, CR), in Group 3-25% (1/4, CR).
Summary/Conclusions: Evaluation of response and MRD after ibrutinib-
containing programs therapy in the treatment patients with relapsed/refractory
chronic lymphocytic leukemia require further research. The influence of
genetic abnormalities on the treatment efficacy and MRD status has yet to
be defined.
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USE OF IBRUTINIB IN PATIENTS WITH B CELL LYMPHOID MALIGNANCIES:
ADVERSE EVENTS AND MANAGEMENT IN COMMUNITY SETTING
W Alexander, R Ramakrishna*, P Reddy
Southern Haematology and Cancer Research Institute, Wollongong, Australia
Background: Bruton’s tyrosine kinase (BTK) is expressed in B-cell malignan-
cies, playing an important role in B-cell receptor (BCR) signaling and offering
a promising new strategy for the development of targeted drugs. Malignant B
cells in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)
rely on BCR signaling pathways for cell survival, proliferation, adhesion, and
migration. Ibrutinib is a BTK inhibitor which has been found to be an effective
therapy option in patients with relapsed/refractory mantle cell lymphoma,
relapsed/refractory chronic lymphocytic leukemia/small cell lymphoma (SLL)
or newly diagnosed patients with CLL and a chromosome 17 deletion (del
17p)1. Most responses tend to be partial, but nearly two thirds of MCL and CLL
patients treated have had a durable response, despite many being refractory,
having high risk cytogenetic abnormality and/or heavily pre-treated2. The med-
ication is tolerable with <10% of trial patients discontinuing use due to side
effects3. Published trial data highlight side effects including nausea, diarrhoea,
fatigue, bleeding, decrease in blood cell counts, renal impairment2. Our analysis
of data on side effects from this drug in our cohort differs from those side effects
highlighted in drug trials.
Aims: To better understand the side effect profile of ibrutinib and management
of these patients in real life.
Methods: A cohort of 36 patients all refractory to at least two lines of therapy
or with del 17p were entered into this study; with a mix of 25 patients with CLL,
7 with SLL, 4 with MCL. All were treated with ibrutinib at either 560mg/day
(MCL) or 420mg/day (all others) until disease progression or death with a medi-
an treatment time of 9 months.
Response and adverse event data has been recorded for these patients and
subsequently analysed.
Results: In our cohort the most common side effects were dermatologic com-
plications, affecting nearly one third of patients to some degree. As well, one
sixth of patients in our cohort experienced symptomatic gastro-oesophageal
reflux requiring treatment with proton pump inhibitors. We had one patient who
experienced transaminitis related to ibrutinib requiring cessation of therapy.
No patient in our cohort experienced cytopenias or renal impairment or signif-
icant diarrhoea or nausea related to therapy. Bruising and platelet dysfunction
was noted in 20% of patients, especially if already on antiplatelet therapy (APA)
or anticoagulants (OAC). None of these patients required cessation of either
therapies, but dose or frequency reduction of APA or OAC.
Most of the patients in our cohort have achieved at least very good partial
response, with only six patients with progressive disease (all with CLL or SLL).
Summary/Conclusions: Our real life experience of using ibrutinib in patients
with refractory CLL or MCL has shown very good response with most patients
tolerating the therapy very well. In our cohort the side effects were different
from those recorded in clinical trials. Cutaneous reactions and acne like lesions
as well as staphylococcal infections appear to be more common than appreci-
ated and GIT side effects were less common in our experience. We have found
topical treatment of acne lesions with antibiotics to be mostly effective and oral
or intravenous antibiotics required for extreme cases. Ibrutinib therapy is a well
tolerated and effective therapy option for patients with high-risk CLL or MCL.
Therapy can be managed in the community without requiring hospitalisation.
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APPLYING PROBED CAPILLARY ISOELECTRIC FOCUSING (PROBED
CIEF) FOR RESPONSE MONITORING OF SIGNAL INHIBITOR THERAPY
DIRECTED AGAINST BRUTONS TYROSINE KINASE (BTK) IN CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL)
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1Institute of Cancer Studies, University of Manchester, Manchester, 2Haema-
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Background: Signals mediated through the B cell receptor (BCR) of chronic
lymphocytic leukemia (CLL) are central to disease pathobiology. Bruton’s Tyro-
sine Kinase (BTK) is a key regulator of BCR signalling. Small molecule
inhibitors of BTK (BTKi) have therefore emerged as effective therapeutic
agents. BTKi treatment is particularly successful in CLL; however responses
may not be complete or durable. It is therefore important that we have tools to
monitor disease response and direct therapy. Probed capillary isoelectric
focussing (probed cIEF) uses fine capillaries that contain an ampholyte pH-
gradient to separate protein within cell-lysates according to their charge. Many
post-translational modifications induce significant changes to charge, and mod-
ified proteins are readily separated. Antibodies that recognise specific signal-
molecules are then used to probe the samples and to generate profiles that
demonstrate the presence and relative abundance of different charge-forms of
the target molecule. These charge-forms reflect structural alteration, lipid mod-
ification or different phosphorylation states, modifications that reflect differential
activation of the signalling molecule. The technique offers the capability to
detect and evaluate the full range of changes to BTK, and therefore can be
used to support clinical monitoring of drug effectiveness.
Aims: To evaluate the use of probed cIEF in signal response monitoring for
patients treated with BTK inhibitors.
Methods: CLL cells were cultured in-vitro in the presence or absence of BCR
activation (anti-IgM cross-linkage) with and without BTKi (ibrutinib). Cells
lysates were separated according to charge using an ampholyte pH-gradient
(nested 5-8). To assess BTK response, separated protein was probed with
total BTK antibody to generate profiles of the presence and relative abundance
(area under curve for peak volumes (Compass software)) of different charge-
forms of the molecule. Ex-vivo cells of CLL pre and post in-vivo BTK signal
inhibitor therapy were analysed to compare with in-vitro profiles.
Results: Phosphoprotein traces were reliably obtained yielding reproducible
dose-response profiles. A significant complexity of charge-forms was identified
for BTK, with a range of peaks differing substantially between resting and acti-
vated cell states. Ibrutinib greatly changed the profile of BTK, both through
new peak formation and peak shifts that were not attributable to recognised
effects of the drug against standard regulatory motifs. The peak changes we
observe are therefore complex, they combine the expected prevention of BTK
activation, but also new and unexpected changes not simply a return to the
“resting state profile” of the molecule. We suggest these form a molecular sig-
nature representing a biomarker of drug response. Studies of inhibitor action
in clinically treated and clinically responsive CLL cells mirrored that of our profile
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of BTKi treated cells in-vitro indicating our profile to represent biochemical mod-
ification of BTK signalling after clinically relevant therapy.
Summary/Conclusions: Probed cIEF offers the capability to monitor complex
signal-interactions, and to identify important signalling changes in a simple,
objective and reproducible manner. Future work will aim to precisely identify
the biochemical changes that underlie the specific peaks of the BTK profile
that may represent clinically useful biomarkers of treatment response.
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IS C-REACTIVE PROTEIN A RELIABLE SURROGATE MARKER FOR
INFECTION TO HELP FACILITATE DISCHARGE IN PATIENTS ON IBRUTINIB?
(A SINGLE CENTRE EXPERIENCE
D Sparksman*, KZ Maw, S Sadullah, C Gomez, M Mangi
Haematology, James Paget University Hospital, Gorleston, United Kingdom
Background: C-Reactive Protein (CRP) is an acute phase protein made by
the Liver in response to interleukin-6 (IL-6). It is produced from cells including
macrophages, T and B Cells in response to inflammation. It is a poor marker
of sepsis at day zero, rising at 4-6 hours and peaking at 36 hours. Ibrutinib is
a covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an essential part of
the B-cell receptor signalling pathway. It mediates both the microenvironment
system and promotes survival and proliferation of B-cells. Anecdotally, since
Ibrutinib’s introduction as a treatment for Chronic lymphocytic Leukaemia (CLL),
Mantle Cell Lymphoma (MCL) and Waldenstrom’s Macroglobulinaemia (WM)
we have noticed some patients admitted with confirmed infections whose CRP
response was lower than expected.
Aims: To analyse the correlation between CRP and confirmed infections in all
patients on Ibrutinib at a small single centre in the UK.
Methods: We retrospectively reviewed the notes of all 46 patients who had
been started on Ibrutinib since its approval, and collected data including sequen-
tial CRP’s (significant if >60 mg/L) for all episodes requiring admission with
confirmed infection, defined as a positive culture result (blood, sputum, skin
swab, mid stream urine), or imaging changes consistent with an infection (as
reported by Radiology).
Results: Of the 46 patients (29 CLL, 17 MCL) to have received treatment, only
16 (10 CLL, 6 MCL) were admitted to hospital with infection. 5 of these 16
patients had multiple admissions resulting in 25 admission episodes. Of these
25 episodes only 15 met the criteria for confirmed infection. On analysis of the
data, the mean length of stay was 10.1 days with a mean admission CRP of 73
mg/L which rose to 85 mg/L at 48 hours. The majority of the episodes (10/15,
67%) appear to have had an appropriate CRP response in the first 48 hours.
Of interest one of these 10 was diagnosed with Listeria monocytogenes on
multiple blood cultures, the admission CRP (58 mg/L) did not rise significantly
at 24 hours (68 mg/L) and fell thereafter. The patient never mounted an appro-
priate response for the clinical picture and by the time she died at day 15 her
CRP was 3 mg/L. Of the 5 remaining episodes who’s CRP remained low in the
first 48 hours (mean CRP 25 mg/L) 4 had imaging and symptoms consistent
with a chest infection and 1 was blood culture positive for Pseudomonas aerug-
inosa sepsis (mean length of admission in this group 10.2 days). The data
shows 33% of admission episodes with confirmed infection did not have a sig-
nificant rise in CRP in the first 48 hours.
Summary/Conclusions: In clinical trials Ibrutinib has shown excellent results
and the number of patients taking it stand to rise considerably over the coming
years. Our single centre study is relatively small and did not obtain enough data
to say whether CRP is a reliable surrogate marker for infection in this group.
However the 5 cases with low CRP and to a certain extent the 6th (Listeria mono-
cytogenes case) mentioned above raise the possibility that Ibrutinib could have
an effect on CRP that has yet to be identified. The proposed possible mechanism
would be IL-6 reduction. For this reason we have changed departmental policy,
stopping Ibrutinib on admission, relying on clinical picture in the first 48 hours
before re-checking CRP to assess response to treatment and therefore likelihood
for discharge. Possible areas for further investigation include a multicentre study
looking for correlation, comparing alternative inflammatory markers and evaluating
IL-6 release in patients with infections on Ibrutinib.
Chronic myeloid leukemia - Biology
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DYNAMICS OF BCR-ABL1 MULTIPLE MUTATION DETECTED BY
SUBCLONING AND SEQUENCING IN TYROSINE KINASE INHIBITOR
RESISTANT CML
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HJ Hwang1, KM Kee1, EJ Jang1, DW Kim1,2
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Background: BCR-ABL1 kinase domain (KD) point mutation causes resist-
ance to tyrosine kinase inhibitors (TKI) in CML patients through impaired
binding of TKI to the target site. One of the characteristics of patients with
BCR-ABL1 kinase domain point mutations is the fact that some patients have
multiple mutations. However there have not been many studies showing that
data about clinical relevance or dynamics of multiple mutation during CML
treatment.
Aims: The aim of this study to was to evaluate dynamics and characteristics
of multiple mutations in the serial samples from the patients carrying multiple
mutations using subcloning and sequencing.
Methods: Since 2002, 735 CML patients were screened for mutation analysis
due to sign of resistance to TKI including imatinib, nilotinib, dasatinib, bosutinib,
radotinib or ponatinib at Seoul St Mary’s Hospital using direct sequencing and
ASO-PCR. Among them, 42 patients showed multiple mutations. We analyzed
serial samples from the 42 patients using subcloning and sequencing to inves-
tigate whether the multiple mutations are on same clone (defined as compound
mutation), separated clones (defined as polyclonal mutation) and characterize
its clinical relevance and dynamics.
Results: Details on response and survival outcome of 42 patients with mul-
tiple mutations is shown in Table 1. In order to investigate whether the multiple
mutations are on same clone or on separated clone, we cloned serial samples
from the 42 patients. Cloning of cDNA region corresponding to BCR-ABL1
KD into plasmid was performed and followed by transformation into competent
cells, colony formation, plasmid preparation of 20 colonies from each sample,
and then direct sequencing. Distribution of disease phase at first multiple
mutation detection, advanced phase or blast phase was 48% and chronic
phase was 52%. With a median follow-up of 35.6 months (range, 4.8-224),
20 different mutations were detected by direct sequencing in 42 patients. 36
patients harbored 2 mutations and 6 patients harbored 3 mutations. Among
42 patients with Multiple mutation, 19 (45%) and 23 (55%) patients had com-
pound mutation and polyclonal mutation, respectively. of 19 patients with
compound mutation, 18 patients (95%) were dead. 26 of 42 patients (62%)
developed multiple mutations including T315I. Among them, 16 patients (62%)
also had P-loop mutation.
Table 1.
Summary/Conclusions: Analysis of serial samples from a same patient pro-
vided evidence of dynamic change of portion of compound mutation. In most
case, portion of the containing compound mutation was increased as treat-
ment went on, indicating the clone harboring compound mutation can take
survival advantage over TKI treatment in comparison of the clone containing
individual type of mutation. In addition, some patients showed change in indi-
vidual mutation type comprising multiple mutations as treatment went on.
Patients with compound mutation showed poor outcomes compared with
polyclonal mutation in our cohort, further investigation on a large patient
cohort will be needed. Updated data about dynamics and characteristic of
multiple mutations with longer follow-up duration will be presented in the
meeting.
*Even though E255k detected by direct sequencing, it was not detected by
subcloning and sequencing.
haematologica | 2016; 101(s1) | 729
Copenhagen, Denmark, June 9 – 12, 2016
PB1804
PPARΓ IS A NOVEL THERAPEUTIC TARGETS IN PH-POSITIVE LEUKEMIA
CELLS
S Okabe*, T Tauchi, Y Tanaka, J Sakuta, K Ohyashiki
Department of Hematology, Tokyo Medical University, Shinjuku-Ku, Japan
Background: ABL tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib
and dasatinib have demonstrated the potency against Philadelphia chromosome
(Ph)-positive leukemia patients. However, resistance to ABL TKI can develop in
chronic myeloid leukemia (CML) patients due to BCR-ABL point mutations and
leukemia stem cells, because ABL TKIs cannot eradicate leukemia stem cells.
Therefore, new approach against BCR-ABL mutant cells and LSCs may improve
the outcome of Ph-positive leukemia patients. Peroxisome proliferator-activated
receptors (PPARs) compose a superfamily of nuclear hormone receptors and
regulate the transcription of target genes. Three subtypes of PPARs (α, γ and
δ/β) have been identified. PPARγ is expressed not only adipose tissue but also
cancer cells. The PPARγ agonist, pioglitazone was used for the treatment of
diabetes patients. Recently, it has been reported that PPARγ agonist eradicate
leukemia stem cells of CML patients (Prost S et al. Nature. 2015;525:380-3).
Aims: We hypothesized that targeting PPARγ, in combination with ABL TKI,
would result in enhanced therapeutic activity in Ph-positive leukemia cells
including T315I mutation and primary samples.
Methods: In this study, we investigated the effect of PPARγ agonist, pioglita-
zone on Ph-positive leukemia cell lines (K562, NCO2, Ba/F3 BCR-ABL, Ba/F3
T315I) and primary samples.
Results: 72 h treatment of pioglitazone did not exhibit cell growth inhibition
against K562 cells.
We found that mRNA of PPAR subunit, PPARα and PPARγ was increased after
pioglitazone treatment. We examined the intracellular signaling after treatment
of pioglitazone. We found phosphorylation of BCR-ABL and Crk-L was not
reduced after pioglitazone treatment. In contrast, phospohorylation of AMP-acti-
vated protein kinase (AMPK) was increased and S6 ribosomal protein was
reduced. We investigated the pioglitazone activity against T315I positive cells.
Pioglitazone did not induce cell growth inhibition of Ba/F3 T315I cells. However,
combined treatment of Ba/F3 T315I cells with ponatinib and high concentration
of pioglitazone caused more cytotoxicity than each drug alone. Phosphorylation
of BCR-ABL and Crk-L was not reduced. However, phosphorylation of S6 ribo-
somal protein was reduced and AMPK phosphorylation and cleaved poly (ADP-
ribose) polymerase (PARP) was increased after ponatinib and pioglitazone treat-
ment. We also found that the treatment of ponatinib and pioglitazone exhibits
cell growth inhibition against Ph-positive primary samples with T315I mutation.
Phosphorylation of S6 ribosomal protein was reduced and AMPK phosphoryla-
tion and cleaved poly (ADP-ribose) polymerase (PARP) was increased after
ponatinib and pioglitazone treatment. We next investigated the anti-angiogenic
effects of PPARγ agonist on human umbilical vein endothelial cells (HUVEC).
Pioglitazone inhibited tube formation of HUVEC (size, length and junction) in
matrigel assay. Pioglitazone also inhibited chemotaxis of HUVEC.
Summary/Conclusions: Our study indicated that administration of the PPARγ
agonist, pioglitazone enhances the effects of ABL TKI and is effective in sup-
pression of angiogenesis, suggests that PPARγ agonist may possess promising
clinical relevance as a candidate for treatment of Ph-positive leukemia patients.
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PLASMA PROTEOMICS IN CHRONIC MYELOID LEUKEMIA PATIENTS
BEFORE AND AFTER INITIATION OF TYROSINE KINASE INHIBITOR
THERAPY REVEALS INDUCED TH1 IMMUNITY AND LOSS OF
ANGIOGENIC STIMULI
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B Simonsson1, S Mustjoki6, U Olsson-Strömberg1, A Loskog2
1Department of medical sciences, 2Department of immunology, genetics and
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Background: Chronic myeloid leukemia (CML) treated with tyrosine kinase
inhibitors (TKIs) in most cases have an excellent long-term prognosis. However,
there are still problematic issues in a smaller proportion of CML patients related
to TKI resistance and long-term treatment side effects and costs. Much is still
unknown about why patients respond differently to TKI treatment and why
some patients are even able to stop TKI treatment without disease relapse
while others relapse quickly despite seemingly good, durable treatment
responses. Proteomics is an area of growing interest and the simultaneous
measurement of many proteins is now possible using multiplex assays. Multi-
plexing is used for several purposes, such as surveys of changes in protein
abundance, biomarker validation and clinical diagnostics and to our knowledge,
the usefulness of plasma proteomics has not been evaluated in CML patients.
Aims: In this pilot study we investigated a total of 124 proteins in plasma from
CML patients with the purpose of identifying proteins that are differently
expressed at diagnosis and after TKI treatment initiation, either as a result of
the decreased disease burden or as an effect of the TKI treatment itself.
Methods: Samples were taken from 14 CML patients at diagnosis and after
three months of TKI treatment (imatinib or dasatinib). Samples were analyzed
by three different multiplex platforms: Human proinflammatory 9-plex Ultra-
Sensitive kit by MesoScale Discovery, Multi-analyte profiling (MAP) technology
by Myriad RBM and Proseek Oncology 1 by Olink. Results were correlated to
disease activity (Sokal score, presence of Ph+stem and progenitor cells at
diagnosis) and treatment response.
Results: Many protein markers were significantly altered after three months of
TKI treatment. Some proteins were analyzed on more than one platform and
results for markers present in low concentration in plasma were sometimes
contradicting between platforms, which may reflect the specificity and sensitivity
variation of the platforms used. It is also highlighting possible difficulties ana-
lyzing multiple markers of different concentration ranges in a single sample at
one dilution. The protein patterns demonstrated a decrease of pro-tumorigenic
analytes (VEGF, TGFβ, IL10, CD31, MICA) while some analytes known to be
of importance to T-helper 1 (Th1) immune responses and anti-cancer immunity
were increased after TKI initiation (IL12, CXCL9/MIG, IFNγ) (Figure 1), likely
reflecting a restoration of normal immune functions after treatment initiation.
Interestingly, the level of TGFβ, which has been connected to the maintenance
of leukemic stem cells, was correlated to the leukemic stem cell burden
(Ph+CD34+CD38- cells) at baseline. We also found reduced angiogenic stimuli
which could reflect normalization of bone marrow angiogenesis after treatment
initiation since increased bone marrow vascularity and elevated angiogenic
factors have been described in untreated CML patients. Further, some single
plasma proteins were identified that can be of potential interest to study further
for biologic, prognostic or therapeutic significance such as E-selectin, uPAR,
growth hormone and carbonic anhydrase IX.
Figure 1.
Summary/Conclusions: Plasma proteomics seems feasible and useful in
CML patients, both for studying patterns of protein expression and for identifying
single proteins differentially expressed before and after treatment. Hence, plas-
ma proteomics can be used to gain better understanding of drug mechanisms
and treatment responses in CML. Some of the significantly altered proteins
indicate novel disease or treatment mechanisms and further studies may give
novel insights in CML and TKI therapy.
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LEUKEMIC STEM CELLS DEFINED BY DIPEPTIDIL-PEPTIDASE IV (CD26)
EXPRESSION IN CD34+CD38- STEM CELLS AND TYROSINE KINASE
INHIBITOR THERAPY IN CHRONIC MYELOID LEUKEMIA
P Rodrigues Santos1,2,*, J Almeida2, P Couceiro2, V Alves1, L Ruzickova3,
P Freitas-Tavares3, M Santos-Rosa1
1Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra,
2Lab Imunologia e Oncologia, Centro de Neurociências e Biologia Celular, Uni-
versidade de Coimbra, 3Serv Hematologia, Centro Hospitalar e Universitário
de Coimbra, Coimbra, Portugal
Background: Recently, dipeptidil-peptidase IV (DPP IV; CD26) has been
described as a specific marker of leukemic stem cells (LSC) within the
CD34+CD38-Lin- compartment present in chronic myeloid leukemia (CML)
patients. These cells seem to be difficult to eradicate by tyrosine kinase inhibitors
(TKI), although the efficacy of different generations of TKI remains unknown. In
addition, the negative influence of these LSC on optimal therapy responses
(time to achieve major molecular response) is under investigation in CML.
Aims: In this study, we aimed at the evaluation of the presence of LSC in
chronic phase CML patients to establish the additional parameters to better
define the efficacy of different therapeutic strategies.
Methods: Peripheral blood samples from chronic phase CML patients (n=45)
under Interferon-alpha 2b (IFN-α 2b), imatinib, dasatinb, nilotinib, bosutinib
and ponatinib therapy were analyzed by multi-parametric flow cytometry for
the characterization of LSC. Buffy coats (n=3) from healthy blood donors were
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used as control. Cytokines and chemokines were evaluated in a 34-plex panel
by xMAP technology (Luminex®).
Results: Circulating CD34 positive cells were increased in chronic phase CML
patients when compared to controls (0.15±0.05% vs 0.06±0.05%). CD26 was
found expressed in CML CD34+CD38-Lin- stem cells (12.07±4.14%) and absent
in controls. CD26 expression was higher in LSC compared to progenitor cells
(MFI 704.6±200.8 vs 270.4±34.8). We also found SDF-1 significantly overex-
pressed in CML patients undergoing TKI treatment when compared to IFN-α
2b. An impairment of LSC to respond to SDF-1, associated with less migration
to stem cells niche, has been observed, although they express high levels of
CXCR4. All of our chronic phase CML patients with detectable LSC in peripheral
blood samples needed to change therapy and/or increase TKI dose and the
majority of these patients present high or intermediate clinical prognostic risk
score (Sokal) on initial evaluation.
Summary/Conclusions: Detection of LSC defined by CD26 in CD34+CD38-
Lin- stem cells might be an important tool to improve CML treatment strategy
in the near future.
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MODULATION OF LEUKOTRIENE SIGNALING INHIBITING CELL GROWTH
IN CHRONIC MYELOID LEUKEMIA
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Background: The introduction of tyrosine kinase inhibitors (TKI) has dramati-
cally improved the outcome in chronic myeloid leukemia (CML). However, for
most patients cure remains unlikely due to residual, detectable leukemic stem
cells. This may be due to aberrant regulation of BCR-ABL-independent signaling
pathways. One such suggested pathway leads to the formation of leukotrienes
(LT), inflammatory mediators indicated to play a role also in the tumorigenicity
of several malignancies (e.g. in the colon, prostate, breast, lung). We have pre-
viously shown that CML patient-derived myeloid cells have an elevated capacity
to synthesize LT, paired by an increased expression of the enzyme LTC4 syn-
thase (LTC4S). Recently an up-regulation of the arachidonate 5-lipoxygenase
(5-LO) gene was observed in BCR-ABL-positive CML mice, together with an
improved animal survival when this enzyme was pharmacologically inhibited.
Aims: To examine the effect of leukotriene-signaling-modulating compounds
on the growth of human CML cells.
Methods: Human CML cells were grown in 3-day in vitro cultures (MTT), with
and without addition of different specific blockers of LT-signaling and tyrosine
kinase inhibitors (TKI). Protein expression was determined by Western blot.
Results: The cysteinyl-LT1-receptor (CysLT1rec) antagonist montelukast sig-
nificantly reduced the growth of K562, KCL22 and KU812 CML cells in culture
in a dose-dependent manner (IC50 1.1-1.7 μM, i.e. clinically achievable con-
centrations). Montelukast also inhibited the growth of the CysLT1rec-expressing
colon cancer cell line HCT116, but not of normal fibroblasts. As expected, sev-
eral TKIs, including imatinib, also clearly suppressed the growth of the CML
cells. When combining montelukast with imatinib an additive inhibition occurred.
Similarly, inhibition of CML cell growth was also evident after addition of the 5-
LO-inhibitor BWA4C, the 5-LO-activating protein (FLAP) inhibitor licofelone and
the LTB4(BLT)1-receptor antagonist LY293111. All three CML cell lines where
shown to express 5-lipoxygenase, LTA4hydrolase and LTC4S, key enzymes in
the formation of bioactive leukotrienes.
Summary/Conclusions: Our data indicate that blocking of LT-signaling selec-
tively suppresses expansion of human CML cells and may thus provide an
additional therapeutic possibility targeting residual disease in this leukemia.
Some of the tested pharmaceuticals are already in clinical practice for non-
hematological disorders, facilitating the initiation of prospective CML intervention
trials.
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ISODERIVATIVE PHILADELPHIA CHROMOSOME IN PATIENTS WITH
CHRONIC MYELOID LEUKEMIA
A Lukianova1,*, K Kotlyarchuk1, O Zotova1, I Vanko1, A Pastwinska2, J Rygier3,
B Pienkowska-Grela3
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Center and Institute of Oncology, Warsaw, Poland
Background: The key point in pathogenesis of chronic myeloid leukemia (CML)
is occurrence of Philadelphia chromosome as a result of reciprocal translocation
of chromosomes 9 and 22 leading to formation of the BCR-ABL fusion gene.
Increasing number of copies of this oncogene may be one of the reasons for
disease progression and lack of response to treatment with tyrosine kinase
inhibitors. Usually, this process develops due to occurrence of additional copies
of the Ph-chromosome without alteration of its structure. This report however
describes 5 cases of changed morphology of derivative chromosome 22 (par-
ticularly isochromosome 22), leading to increased number of BCR-ABL gene
copies. Despite the fact that occurrence of an isochromosome can be quite
frequent in various malignancies reports concerning isoderivative chromosome
22 are quite rare.
Aims: The aim of this study was an attempt to establish the mechanisms lead-
ing to modifications of derivative 22 structure; and to investigate the number of
BCR-ABL gene copies and its localization.
Methods: Methods of conventional cytogenetics (karyotyping of bone marrow
cells) and FISH using BCR-ABL DC DF probe (Vysis) were applied.
Results: Cytogenetic aberrations involving increased numbers of copies of Ph-
chromosome and BCR-ABL gene were detected in 30 patients overall. Occur-
rence of 1 or more additional Ph-chromosomes without structural changes was
found in 25 of the cases. Structural modifications of derivative chromosome 22
were revealed in 5 patients. Evidences of isoderivative chromosome 22 were
found in 4 of them in amount of 1-2 copies per metaphase plate, whereas in 1
case dicentric isoderivative chromosome 22 was detected in amount of 1-5
copies per metaphase plate (Figure 1). Presence of two copies of BCR-ABL on
both arms of isoderivative 22 in all cases was confirmed by FISH on metaphase
plates. It was hence proved that the detected isoderivative 22 in these 4 patients
was composed of the long arms of Ph-chromosome with fragments of chromo-
some 22 and 9 linked by centromere of chromosome 22. Presence of two copies
of BCR-ABL was also confirmed by FISH for the patient with dicentric isoderiv-
ative chromosome 22. However, in this case the isoderivative comprised two
cetromeres of chromosome 22 and the long arms were connected by telomeric
areas of the translocated fragments of chromosome 9. Total number of BCR-
ABL copies in cells with isoderivative was 2-10. The described abnormalities
were detected in 4 patients treated with imatinib. Therapy was subsequently
changed to nilotinib in 3 of them and to dasatinib in 1 patient. After switching to
nilotinib cytogenetic response was not achieved in 2 patients who subsequently
died of disease progression. In case of dasatinib the patient also failed to reach
cytogenetic response. Only in one patient after 2 years of nilotinib complete
cytogenetic response (CCyR) was obtained. In remaining 5th patient who failed
after 1 year of imatinib without any clonal evolution treatment was changed to
nilotinib. After 6 months of this treatment CCyR was achieved, however after 12
months occurrence of isoderivative 22 was for the first time detected in 50% of
the cells. The patient currently continues being followed.
Figure 1.
Summary/Conclusions: The paper describes 5 cases of rare structural mod-
ifications of derivative chromosome 22, leading to increased numbers of copies
of BCR-ABL gene. In majority of these cases patients were resistant to treat-
ment with tyrosine kinase inhibitors. Detected aberrations most probably rep-
resent one of the mechanisms of the secondary resistance and disease pro-
gression in CML.
PB1809
MOLECULAR AND FUNCTIONAL INTEGRITY OF CRYOPRESERVED
CHRONIC MYELOID LEUKAEMIA CD34-POSITIVE HAEMATOPOIETIC
STEM CELLS
C Hodkinson1,*, D Sewell1, J Downes1, K Jestice2, J Baxter1
1Cambridge Blood and Stem Cell Biobank, Dept. of Haematology, University
of Cambridge, 2Stem Cell Laboratory, Clinical Haematology, Cambridge Uni-
versity Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Background: Biopreservation is a billion dollar industry, despite this, access
to large numbers of high quality biospecimens remains a challenge for many
researchers. Chronic myeloid leukaemia (CML) is a rare condition of approx-
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imately 1 new case per 100,000 in the UK per year. CML is a clonal disorder
originating from a CD34-positive haematopoietic stem cell. Studies of molec-
ular targets and functional processes in tumour-initiating stem cells have
greatly enhanced the understanding of oncogenesis and disease progression,
but the impact of freezing, thawing and long-term storage on tumour-initiating
cells is under reported. Knowledge of these bioprocesses is critical to the
development of high-quality biobank collections.
Aims: To investigate the effect of cryopreservation on CML CD34-positive
cells and the utility of such material for downstream molecular and functional
analyses.
Methods: Mononuclear cells (MNCs) and CD34-positive cells were isolated
from excess cryopreserved autologous peripheral blood stem cell (PBSC)
harvests, collected between 1990 and 2006, fresh whole blood from untreated
CML patients, and healthy NHS blood donors. Cells were cryopreserved by
controlled-rate freezing, stored in gas-phase liquid nitrogen and underwent
three cycles of freeze-thaw (FT). Molecular and functional assays were per-
formed at each cycle. RNA integrity number (RIN), as a measure of total RNA
quality, were assessed on an Agilent Bioanalyzer, and semi-quantitative PCR,
using GUSB as a reference gene, was performed to evaluate BCR-ABL gene
expression. CD34-positive cell frequency was determined by two-colour flow
cytometry using CD34 PE-Cy5.5 and the vital dye Calcein. Analysis of CD34-
positive cell clonogenic potential was conducted using a colony-forming unit
(CFU) assay, whereby cells were incubated in complete CFU media, supple-
mented with 3U/ml erythropoietin, for 16 days.
Results: Mean RIN values for normal and CML cell subsets were ≥7. RIN
values for normal MNCs and CD34-positive cells were significantly higher
(p<.01) compared to CML cellular subsets; there was no significant effect of
repeat FT on total RNA derived from either normal or diseased cell subsets.
GUSB and BCR-ABL expression were significantly higher (p<.05) in freshly
isolated CML cell subsets compared to FT cycles 2 and 3, but not cycle 1. A
downward trend in the ratio of BCR-ABL:GUSB expression was observed
with repeat FT cycles but this did not reach statistical significance. The fre-
quency of live CD34-positive cells remained stable with successive FT cycles.
No difference in CFU potential was observed for CD34-positive cells in
healthy donors between fresh and FT cycle 1, but significantly fewer (p<.05)
colonies were observed for successive FT cycles. Cryopreservation of CML
CD34-positive cells resulted in a significant reduction (p<0.5) in CFU potential
compared to fresh material.
Summary/Conclusions: Long-term storage and cryopreservation has min-
imal impact on the quality of genetic material for use in downstream molecular
analysis. However, gene expression data indicates a potential global down-
regulation of gene regulation post freeze-thaw and functional studies suggest
that while CD34-positive cells are sufficiently robust to withstand cryopreser-
vation they experience a loss in proliferative potential, to which CML derived
cells are more sensitive. This implies that there are different handling and
storage requirements for cell subsets derived from healthy and diseased indi-
viduals, highlighting the need to standardise biospecimen preparation and
storage for meaningful analyses where access to fresh material is limited.
PB1810
COMBINED ANTICANCER ACTIVITY AND SIRNA DELIVERY BY DENGUE
VIRUS CAPSID PROTEIN PEPTIDES PEPR AND PEPM AGAINST CHRONIC
MYELOID LEUKEMIA
I Figueiredo1,*, JM Freire1, BG de la Torre2, AS Veiga1, D Andreu2, FJ Enguita1,
MA Castanho1
1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lis-
boa, Lisboa, Portugal, 2Department of Experimental and Health Sciences,
Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona,
Spain
Background: Cancer remains a major cause of morbidity and mortality world-
wide. Although progress has been made regarding chemotherapeutic agents,
new therapies that combine increased selectivity and efficacy with low resist-
ance are still needed. In the search for new anticancer agents, therapies
based on biologically active peptides, in particular, antimicrobial peptides
(AMPs), have attracted attention for their decreased resistance development
and low cytotoxicity. AMPs, which have been essentially studied and devel-
oped as potential alternatives for fighting infectious diseases, have been test-
ed as anticancer peptides (ACPs) in cancer therapy either alone or in com-
bination with other conventional drugs. Moreover, the usage of cell-penetrat-
ing peptides (CPP) to deliver anticancer drugs, such as siRNA targeting
molecular causes of cancer are currently being developed.
Aims: Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder
caused by a single genetic mutation, a reciprocal translocation that originates
the BCR-ABL gene with constitutive tyrosine kinase activity. Because there
is a specific gene associated to this pathology it is an optimum therapeutic
target for RNA silencing therapy (siRNA). Thus we developed a siRNA-based
therapeutic approach in which the siRNA is delivered by Dengue Virus Capsid
Protein-derived peptides, pepM and pepR. These peptides were used with
the intention of having have dual role, to deliver siRNA into cells and act as
Anticancer molecules by targeting intracellular cancer signaling events.
Methods: Dengue virus-peptides ability to transfect the positive BCR-
ABL+Cell Line (BV-173) was evaluated by confocal microscopy following GFP
fluorescence emission after plasmid expression. Anti-BCR-ABL siRNA design
was performed using a siRNA design web-tool and the BCR-ABL downreg-
ulation kinetics (48h to 168h) after transfection by Dengue virus-peptides
was evaluated by RT-PCR. The Anticancer action of either pepR or pepM
was assessed by genome-wide analysis microarray and further validated by
testing BV 173 cell cycle and cell proliferation analysis by RT-PCR.
Results: siRNA design for BCR-ABL retrieved 148 potential siRNA
sequences, which were reduced to 5 BCR-ABL siRNA for in vitro analysis
after thorough screening. Positive efficacy of siRNA targeting BCR-ABL was
tested using a commercial transfection agent. Significant BCR-ABL gene
knockdown were observed for siRNA #3 when delivered by pepM with max-
imum decrease at 120h. Both pepM and pepR showed downregulation effects
on proliferative CML cancer-related signaling pathways having direct impact
on BV 173 cell cycle and proliferation at the G2/M phase.
Summary/Conclusions: With this work we showed the potential therapeutic
technology of combining a drug delivery system (CPP) with anticancer prop-
erties to deliver functional siRNA into CML cell model. Acting together, these
conjugates significantly decreased BCR-ABL gene expression levels, and
perturbed leukemogenic cells homeostasis, revealing a potential scaffold to
develop an alternative CML therapy. The development of a selective ACP is
still a current challenge. It is not straightforward the prediction and design
peptides with antitumor activity and we believe that these results will enrich
ACP-structure based prediction.
PB1811
ASSOCIATION OF 3’BCR GENE DELETION WITH LACK OF MOLECULAR
RESPONSE IN CML PATIENTS WITH PH-VARIANTS TREATED WITH
TYROSINE KINASE INHIBITORS
S Angelova1, B Spassov1,*, G Tsvetkova2, G Balatzenko1, V Hrischev1,
K Batschvarov3, E Hadjiev2, G Mihaylov4
1National Specialized Hospital for Active Treatment of Hematological Diseases,
2Department of Internal diseases, UMHAT “Alexandrovska”- Clinic of hematol-
ogy, 3Specialized Children’s Oncohaematology Hospital, 4National Specialized
Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria
Background: Chronic myeloid leukemia (CML) is a disease of the clonal
hematopoietic stem cells caused by a balanced translocation t(9,22)(q34;q11)
forming derivate 22 or Philadelphia chromosome (Ph), and molecularly
BCR/ABL gene fusion. The standard for treatment of CML patients (pts) is
therapy with tyrosine-kinase inhibitors (TKIs). About 8-10% of Ph+CML pts
have more composite rearrangements involving additional chromosomes
(Ph-variants) or cryptic translocations. Ph-variants are accompanied more
frequently by microdeletions in the regions of chromosome breakpoints than
by standard t(9,22)(q34;q11). Although the proportion of CML pts with Ph-
variants resistant to TKI therapy is the same as in the group with standard
translocation, the specific mechanisms involving Ph-variants in TKI resistance
are still unclear.
Aims: Evaluating the molecular-cytogenetic impact to resistance of TKIs
treated CML pts with Ph-variants.
Methods: We have analyzed 13 CML cases, 12 of which were with Ph-vari-
ants and 1 of the patients was with cryptic translocation detected via G-band-
ing cytogenetic analysis (CyG) and metaphase fluorescence in situ hybridiza-
tion (met-FISH). The pts are aged 16 to 78 years and were treated with TKIs
and followed for at least 18 months in hematology clinics in Sofia, Bulgaria.
No less than 20 metaphases with CyG and no less than 10 with met-FISH
were examined in each patient. Hematologic, cytogenetic and molecular
responses were evaluated regularly.
Results: Our data showed that the following breakpoints were included in
three- or four-way translocations: 1q42, 2q37, 3p25, 4p14, 4q33, 6q21, 7q34,
8q24, 11q11, 17q21, 19p13 (in 2 cases), 22q13 and Хq26. At diagnosis, two of
the 13 pts had additional aberrations in the karyotype besides Ph-variants. The
met-FISH technique allowed us to detect that the rearrangements in 10 of the
cases are more complex than registered by CyG: additional chromosomes or
additional regions in the visibly rearranged chromosomes were involved in 2
of the cases; loss of the 5’ portion of ABL gene (5’ ABL) was observed in 3 of
the cases, deletions in 3’BCR and 3’ABL genes were detected in 4 and 1 cases,
respectively. Complete cytogenetic (CCgR) and major molecular response
(MMR) were achieved in 61.5% (8/13) of the pts. The 3’BCR gene deletions
were observed in 80% (4/5) of the pts without MMR. Two out of 5 resistant pts
have the same t(9;19;22)(q34;p13;q11), but only one of them has a 3’BCR
deletion with no achievement of CCgR and MMR. The the latter patient (without
the 3’BCR deletion) has achieved CCgR and suboptimal molecular response
on the 18 month after the start of the therapy.
Summary/Conclusions: We suggest that the lost of material in the chromo-
some 22 region including 3’BCR gene in CML pts with Ph-variants may be
associated with TKIs resistance. Further research is necessary to confirm
these results.
732 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
PB1812
PROTEOMIC PROFILE CORRELATES TO MOLECULAR RESPONSE IN
PATIENTS WITH CHRONIC MYELOID LEUKEMIA
N Sgherza1,*, VM Garrisi2, A Iacobazzi3, G De Tullio3, E Savino2, I Abbate2,
N Cascavilla1, A Guarini3
1Hematology Unit-IRCCS “Casa Sollievo della Sofferenza”, San Giovanni
Rotondo, 2Clinical & Experimental Pathology Laboratory-National Cancer
Research Centre “Istituto Tumori Giovanni Paolo II”, 3Hematology Unit-National
Cancer Research Centre “Istituto Tumori Giovanni Paolo II”, Bari, Italy
Background: Recent advances in the proteomic field have allowed us to better
understand the biology of several cancer types and/or discover new candidate
biomarkers. Very few data are available about the serum protein expression of
patients with Chronic Myeloid Leukemia (CML).
Aims: The aim of our pilot study was to evaluate a correlation between depth
of molecular response (MR) and proteomic profile of CML patients, and if pos-
sible to find novel potential biomarkers complementary to currently existing
proven tools to monitor therapy response.
Methods: Thirty sera from peripheral blood (PB) were sampled from 8 patients
in MR1 response, 6 in MR2, 11 in MR3, and 5 in MR4. For 11 patients serum
from bone marrow (BM) was also available. In particular 3 were sampled from
patients in MR1, 3 in MR2, 4 in MR3, 1 in MR4. The one patient at diagnosis
was included in MR1 group. Samples were divided into 2 groups according to
the achievement of MR3: Group A, which comprised 14 samples from patients
with a MR lower than MR3, and Group B, including 16 samples from patients
who experienced a MR greater than or equal to MR3.The association of pro-
teomic profile with MR was investigated using the SELDI ToF Mass Spectrom-
etry platform. Each specimen was analyzed in duplicate. Expression Differences
Mapping analysis was applied in order to generate a cluster peaks list, which
describes how a singular peak is expressed in the specimen spectrum. Finally,
with the aim to give a preliminary identity to the most differentially expressed
peaks, an in silico identification was attempted using the Mascot database
search available at www.matrixscience.com.
Results: Comparing PB sera from group A and group B, only a peak at 5075
Da had a p-value=0.05. Comparing sera from patients with different MR (MR1
vs MR2 vs MR3 vs MR4), statistical analysis found two features at 11092 Da
and once again that at 5075 Da as differentially expressed and statistically sig-
nificant (P-value=0.0034 and 0.0084 respectively) between MR1 and MR4. In
particular the peptide at 11092 Da was overexpressed in MR4 patients. Also
the peak at 5075 Da was highlighted as statistically significant, but its signifi-
cance was less important than that of 11092 Da due to a slightly worse sensi-
tivity (80%). Sera from PB were compared with those extracted from BM. Inter-
estingly, no difference was highlighted. Regarding the two peaks (5075 Da and
11072 Da) we hypothesized that they were closely related, probably as a frag-
mentation product. With the aim to quickly give a preliminary identity to the
peptide, we attempted an “in silico” mass peptide finger print using the open-
source tool available at www.matrixscience.com. The bioinformatic tool identi-
fied the peptide with a high probability score, as a truncated part of a larger
nuclear protein ZMIZ2. It would interact with the Wnt/β-catenin pathway partic-
ipating in its activation. As suggested by data from literature, we can try to
hypothesize that, unlike non responders, in the serum of responsive patients a
part of ZMIZ2 is present, as a consequence of the degradation of the entire
protein; this finding results in an under-regulation of the Wnt/β-catenin pathway
with consequently a better response.
Summary/Conclusions: These preliminary data suggest that the peptide at
11092 Da is very closely related to a good response. Our efforts are now ori-
ented to definitively confirming the identity of the peptide and to clarify its role.
PB1813
EVALUATION OF BECLIN-1 PROTEIN EXPRESSION IN CHRONIC
MYELOID LEUKEMIA PATIENTS ON IMATINIB THERAPY
Z Emarah1,2,*, L Mahmoud3, A Mansour3, M Elzaafarany1,2, R Elsaied3,
A EL-Sebaie3
1Medical Oncology, Oncology Center, Mansoura University, 2Internal Medicine,
3Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Man-
soura University, Mansoura, Egypt
Background: Imatinib is a tyrosine kinase inhibitors that used for the treatment
of chronic myeloid leukemia (CML). Recent studies showed imatinib-induced
cell death in many types of cancers. Autophagy is the physiological process in
which cellular components are broken down by the lysosomal activation. Beclin-
1 is a protein that encoded by the BECLN1 gene which sits at the core of
autophagy regulation.
Aims: the aim of this study is to evaluate the role of Beclin-1 in regulation of
BCR-ABL1 fusion gene in patients with chronic myeloid leukemia.
Methods: Peripheral blood samples collected from 30 patients (16 males and
14 females) diagnosed with CML at Oncology Center Mansoura University.
Ages ranged from 18 to 50 (44.7±10.2) years. Diagnosis was based on typical
finding in the peripheral blood smear and bone marrow aspiration then con-
firmed by detection of Philadelphia chromosome by cytogenetics or BCR/ABL1
fusion gene using Quantitative RT-PCR. Further samples collected form 30
apparently healthy individuals (16 males and 14 females) subjected as matched
controls. Beclin-1 protein was measured by ELISA technique in serum of con-
trols and patients before starting treatment (Time point A) and after 6 months
of Imatinib therapy (Time point B).
Results: there was a significant increase in mean Beclin-1 protein level in CML
patients either at initial diagnosis (32.6 ng/dl, p ≤0.001) or after 6 month of ima-
tinib therapy (44.3, p ≤0.001) compared to matched control (9.5 ng/dl). Although
its mean level increased after 6 month of imatinib therapy, this increase was
not statistically significant. There was a strong negative correlation between
mean Beclin-1 protein and hemoglobin level (r=-0.56, p=0.001), white blood
cells count (r=-0.62, p=0.008), BCR/ABL1 fusion gene level (r=-0.43, p=0.03).
Summary/Conclusions: there was a statistically significant negative correla-
tion between Beclin-1 protein expression and BCR/ABL1 fusion gene level.
Beclin-1 protein expression may be used as a dynamic biomarker to predict
response to imatinib therapy. However, larger studies are needed to validate
these results.
PB1814
REVERSINE TRIGGERS MITOTIC CATASTROPHE AND APOPTOSIS IN
BCR-ABL POSITIVE CELLS
APNR Alves*, JA Machado-Neto, PS Scheucher, HH Paiva, EM Rego, F Traina
Internal Medicine, University of Sao Paulo at Ribeirao Preto Medical School,
Ribeirao Preto, Brazil
Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative
neoplasm of the hematopoietic stem cell characterized by the presence of the
oncoprotein BCR-ABL1, which have a constitutive tyrosine kinase activity. The
tyrosine kinase inhibitors for BCR-ABL1 (e.g. imatinib, dasatinib and nilotinib)
can lead towards the elimination of the BCR-ABL1 clone and increase survival
of CML patients. However, acquisition of resistance to tyrosine kinase inhibitors
has emerged as a challenge for CML patients and the identification of novel tar-
gets is necessary. BCR-ABL1 activation induces aurora kinase A (AURKA) and
aurora kinase B (AURKB) expression, which are serine-threonine kinases that
play an important function in chromosome alignment, segregation and cytoki-
nesis during mitosis. Aurora kinase inhibition has proven to be an attractive anti-
cancer approach. In the present study, we explored the cellular effects of rever-
sine, an AURKA and AURKB inhibitor, in the BCR-ABL1positive K562 cell line.
Aims: Based on the evidence of participation of aurora kinases in the BCR-
ABL1 signaling pathway and CML malignant phenotype, we explored the cel-
lular effects of reversine in BCR-ABL1 positive cells.
Methods: K562 cell line was treated or not with the AURKA and AURKB phar-
macological inhibitor, reversine, at 1, 10, 20 and 50µM for 24, 48 and 72 hours.
After drug exposure, cells were evaluated for cell viability (MTT assay) and
apoptosis (Annexin V/PI and cleavage caspase 3). For DNA content distribution
analysis (Cycletest™ Plus DNA Reagent Kit) and Confocal immunofluores-
cence microscopy, K562 cells were treated or not with reversine at 1 and 10µM
for 48 hours. Comparisons between the control and treated groups were per-
formed by the ANOVA test and Bonferroni post-test. A p value <0.05 was con-
sidered statistically significant. At least three independent experiments for each
method were tested.
Results: In K562 cells, reversine treatment significantly reduced cell viability in
a dose- and time-dependent manner (all p<0.05). Using a nonlinear regression
analysis, IC50 citotoxicity for K562 was 44.6 µM for 24 hours, 12.9 µM for 48
hours and 9.4 µM for 72 hours. We evaluate the DNA content distribution of K562
cells, since aurora kinases are known to be an important protein family for cell
cycle progression and success of mitosis. We observed an increased percentage
of K562 cells with tetraploidization (4N) or endopolyploidization (>4N) upon rever-
sine treatment. These findings were confirmed by confocal microscopy analysis,
which reveals large cells with several nucleus. Taken together, these data indicate
that reversine is a potent inductor of mitotic catastrophe. Reversine significantly
induced apoptosis in dose- and time-dependent manner (all p<0.05). In order to
confirm our results regarding reversine-induced apoptosis, we also evaluated
the caspase 3 cleavage in K562 cells and increased levels of cleaved-caspase
3 were observed in a dose-dependent manner.
Summary/Conclusions: Our preclinical study establishes that reversine pres-
ents an effective antileukemia activity against K562 cells and provide new
insights on anti-cancer opportunities for CML.
PB1815
COMPARISON BETWEEN AUTOMATED AND MANUAL INTERPHASE
FLUORESCENT IN SITU HYBRIDIZATION (FISH) ANALYSIS OF T(9;22)
(Q43;Q11.2)
H Chaker*, J Lavoie
Cytogenetics Laboratory, Children’s Hospital, Montreal, Canada
Background: Metafer 4 or Metacyte is an automatic interphase FISH scoring
system offered by MetaSystems. The scanning system contains a motorized
microscope and a computer that achieves microscope control and real time
image analysis.
Aims: Around the world, many laboratories have adopted Automated FISH
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scoring for interphase FISH analysis, however few have reported their experi-
ence. In our laboratory, we have validated automated FISH analysis for a num-
ber of probes, including BCR/ABL ES Dual Color Translocation (Abbott). Detec-
tion of t(9;22)(q34;q22) generating the BCR-ABL gene fusion by FISH is a tool
available for clinical diagnosis and treatment monitoring of Chronic Myeloid
Leukemia (CML).
Methods: Six different pools of leukemic blood cell suspensions were used as
negative controls and 55 CML patient samples were analyzed by automatic
FISH and manual analysis.
Results: A Cut off value of 0.8µm was set as maximum distance between sig-
nals for fusion count and 1.2µm as minimum spot distance for red and green
spot count. Compared to manual read, the scored nuclei are categorized in a
higher number of signal patterns with automated FISH analysis. In addition,
the number of nuclei per category is different between the two methods. How-
ever, there was a strong correlation between automated and manual interpre-
tation results. Only one case out of the 55 cases analyzed was discordant
(1.8%), with results above normal reference range by Automated analysis, but
within the normal range by Manual analysis.
Summary/Conclusions: Our scoring and interpretation criteria, as well as the
advantages of the automated approach will be discussed.
Chronic myeloid leukemia - Clinical
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HALVING TIME AND LOG REDUCTION ARE GOOD PREDICTORS OF
OPTIMAL MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
PATIENTS WITH SUB-OPTIMAL RESPONSE AT 3 MONTHS
MJ Mendes*, M Coucelo, AT Simões, A Pereira, JC Almeida, M Duarte, LF Araújo,
ML Ribeiro
Hematology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Background: In Chronic Myeloid Leukemia (CML) the 3-month molecular eval-
uation defines suboptimal responders with BCR-ABL1>10%. This group shows
worse prognosis and is thought to benefit from treatment change to 2nd-line
TKIs in an early onset. Nonetheless, some patients respond favorably long-
term without treatment change. The decline rate of the BCR-ABL1, measured
at 3M of treatment, may distinguish patients with suboptimal response that will
achieve good responses from those who will need therapy switch.
Aims: In a group of CML patients, analyze clinical and laboratorial differences
between patients with optimal/sub-optimal response, after 3M of Imatinib. To
determine the predictive value of halving time and log reduction for optimal
molecular response at 6 and 12M in patients with suboptimal response.
Methods: Single center retrospective analysis of 24 CP-CML patients treated
with Imatinib 1st-line. Halving time at 3M of treatment calculated according to
the formula proposed by Branford et al., (2014), c=-ln(2)/k, c is the halving
time, k (k=[ln(b)-ln(a)]/d) the reduction in BCR-ABL1 transcript between initial
(a) and 3M quantification (b), divided by the number of days (d) between the
two evaluations. Log reduction (log(a/b)) calculated at 3M of treatment, a is
the 3M QPCR value and b the baseline value. Descriptive statistic analysis
performed using the SPSS (v.21). The predictive value was calculated through
the area under the curve (AUC), using MedCal statistical program. The optimal
cut-offs were calculated using the Younden (J) Index.
Results: Between January 2006 and August 2014, 24 patients were diagnosed
with CP-CML and started on Imatinib 400mg id; 16 male (66,7%) and 8 female
(33,3%), median age=57,71 years(±15,75). Clinical-laboratory findings at diag-
nosis: mean Hb=12,42g/dL (±1,81;), Plts=452,92x103/uL (±299,51), median
Leuc=75,1x103/uL (141), mean peripheral basophil percentage=2,43%(±1,8)
and peripheral blasts=2,3% (±2,07); mean LDH=1302,79U/L (±852,41); mean
palpable spleen size=13cm (±5,97). Sokal and EUTOS scores were obtained
for 21/24 patients (Sokal score: 3 (14,3%) low-risk; 9 (42,9%) intermediate-
risk; 9 (42,9%) high-risk. EUTOS score: 19 (90,5%) low-risk; 2 (9,5%) high-
risk). The mean time between initial and 3M QPCR evaluation was 93,25 days
(±18,43). At 3M, 14 patients (48,3%) had optimal and 10 (41,7%) suboptimal
response. Transcript level at baseline was significantly higher in the suboptimal
group (127,3±70,62 vs 73,53±25,5;p=0,04). In the suboptimal group, the halv-
ing time was highly predictive of optimal molecular response at 6M
(AUC=0,93;p<0,0001), as well as response failure (AUC=0,83;p=0,02). The
log reduction was highly predictive of optimal molecular response at 6M
(AUC=0,96; p<0,0001), at 12M (AUC=0,83;p=0,03) and for response failure at
12M (AUC=0,85;p=0,01). The most predictive cut-off values (J) for halving time
and log reduction were obtained for the 6M optimal response (J=0,87). A halving
time of 22,59 days and a -1,1 log reduction were predictors of optimal molecular
response at 6M.
Summary/Conclusions: In this group, patients with suboptimal response at
3M had a significantly higher BCR-ABL1 transcript at baseline. A halving time
of 22,59 days and a -1,1 log reduction predicted optimal molecular response
at 6M. In an early time-point of molecular evaluation, the use of parameters
evaluating kinetics of the transcript decline will contribute to discriminate
patients outcome and guide treatment options.
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EVALUATION OF CLINICAL EFFICACY AND SAFETY OF GENERIC
IMATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
I Cojbasic1,*, L Macukanovic-Golubovic1,2, M Vucic1,2, N Govedarovic1,2
1Clinic of Hematology and Clinical Immunology, Clinical Center Nis, Serbia,
2Medical Faculty, University of Nis, Nis, Serbia
Background: Application of generic imatinib (GI) should allow to lower price
of cancer drug making it available to a larger number of patients, that way
improving health care of the population. Serbia was one of the first countries
in Europe to adopt generic imatinib which has been used since 2012. There-
after, all patients with CML have been switched from the original imatinib (OI)
to GI, while newly diagnosed CML patients have been frontline treated with GI.
Aims: The aim of this study was to evaluate the clinical efficacy and safety of
GI in the treatment of patients with CML both as frontline therapy and continued
therapy after switching from the OI.
Methods: Our study included 70 adult patients with chronic phase CML that
were treated with OI and/or GI in the period from August 2006 until February
2016. Patients were divided into two study groups: the first one had 34 patients
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switched from the OI to GI, second had 36 newly diagnosed patients who were
treated with GI as frontline therapy. All patients underwent hematological, cyto-
genetic and molecular monitoring and had been treated in accordance with the
applicable national guidelines and ELN recommendations.
Results: The median follow-up was 74.7 months (range 46-115) for the patients
who started treatment with OI and 20.3 months (range 6-43) for those receiving
frontline GI. In the both analysed groups a slight predominance of female sub-
jects was found. In the first group, at the time of the switch from OI to GI, all
patients achieved complete cytogenetic response (CCgR) while major molec-
ular response (MMoR) achieved 25/34 (73.5%) of analysed patients. During
41 months of follow-up, 6 patients lost CCgR, but after switching to the 2nd line
therapy nilotinib, all have achieved secondary CCgR. The overall rate of MMoR
for the group of patients that switched from OI to GI was 22/28 (78.6%). Among
newly diagnosed patients receiving frontline GI, the overall rate of CCgR was
29/36 (80.6%), while overall rate of MMoR was 17/36 (47.2%). During the study
follow-up, 10 patients were switched to 2nd line therapy nilotinib due to cytoge-
netic refractoriness or relapse and 7 of them achieved secondary CCgR. When
the two study groups were compared regarding the most common non-hema-
tologic adverse events (AEs) of any grade, in the group that started with OI
therapy, there were peripheral edema (n=8), skin reactions (n=4) and myalgia
(n=3), while in group with frontline GI there were nausea (n=10), peripheral
edema (n=6) and fatigue (n=4). In both groups most common hematological
AEs were neutropenia (n=5 vs n=4) and thrombocytopenia (n=2 vs n=3). There
were no dose reductions due to toxicities in both groups.
Summary/Conclusions: The results of our study have shown that generic
imatinib is not inferior in efficacy and safety compared to the original imatinib.
Despite these encouraging results, the need remains for the large prospective
randomized studies that would allow for the definitive confirmation of the generic
imatinib efficiency in the treatment of patients with CP-CML.
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PREDICTIVE FACTORS OF STABLE DEEP MOLECULAR RESPONSE IN
CHRONIC PHASE CML PATIENTS TREATED WITH DASATINIB OR
NILOTINIB AFTER IMATINIB FAILURE
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Background: Front-line treatment of newly diagnosed Chronic Myeloid
Leukemia (CML) patients with 2nd generation tyrosine kinase inhibitors (2G-
TKIs) dasatinib (DAS) or nilotinib (NIL) resulted in higher rates of deep molec-
ular response (MR) as compared to imatinib. Very little is known about rates
and stability of deep MR when 2G-TKIs are used after imatinib failure.
Aims: To assess the probability and predictors of stable deep MR in ≥2nd line
of treatment.
Methods: We restrospectively analyzed 127 chronic phase CML patients treat-
ed with imatinib 400 mg daily as first-line therapy and then switched to 2G-
TKIs for resistance or intolerance. Patients progressing to advanced phases
before switch were excluded. Deep molecular response (MR4) was defined as
BCL-ABRISratio ≤0.01% or undetectable disease with ≥10,000 ABL copies.
Patients with MR4 lasting ≥2 years, ongoing at the last contact, and with at
least a Q-PCR test every 6 months were defined as stable MR4. Patients with
any sample >0.01% BCR-ABLIS after the achievement of MR4 were defined as
unstable MR4. Age, sex, Sokal and EUTOS risk score, type of BCR-ABL tran-
script, duration of imatinib, reason for switch to 2G-TKIs and early molecular
response to 2G-TKIs have been examined for the association with stable MR4.
Frequencies were compared by Fisher’s exact test. Univariate and multivariate
regression analysis were performed using the competing risk model of Fine
and Gray.
Results: Median age at diagnosis was 55 years (range 20-88) and median
duration of imatinib treatment was 19 months (range 1-115). Patients resistant
(n=89; 70%) or intolerant (n=38; 30%) to imatinib were switched to DAS (n=82;
64.5%) or NIL (n=45; 35.5%). Thirty-six patients were resistant or intolerant to
their first 2G-TKI and were switched to 3rd-line NIL (n=20), DAS (n=12), bosu-
tinib (n=2), or ponatinib (n=2). At a median follow-up of 52 months after switch
to 2G-TKI (range 6-126), best deep MR to 2G-TKI was: no MR4 in 57 patients
(45%), unstable MR4 in 28 patients (22%; 24 with 2nd line and 4 with 3rd line
treatment), and stable MR4 in 42 patients (33%; 37 with 2nd line and 5 with 3rd
line treatment). Five-year cumulative incidence of stable MR4 was 28.7%
(95%CI: 18.9-37.3%). Age, sex, risk scores at diagnosis, type of BCR-ABL tran-
script, duration of imatinib and type of 2G-TKI were similar between patients
with or without stable MR4 (Table 1). Predictors of stable MR4 were reason for
switch to 2G-TKI (intolerance vs resistance HR 0.41, 95%CI: 0.22-0.79;
p=0.007) and 3-month BCR-ABL level after 2G-TKI start (≤10%IS vs >10%IS
HR 0.08, 95%CI: 0.01-0.59; p=0.01). Three stable MR4 patients attempted dis-
continuation and are presently in treatment-free remission phase at 2, 22 and
27 months after 2G-TKI stop, respectively.
Table 1. Characteristics of patients and frequency or MR4 (unstable or
stable).
Summary/Conclusions: In this retrospective, real-life experience, long-term
use of 2G-TKIs in ≥2nd line of treatment after imatinib failure resulted in more
than half of patients achieving the “safe haven” of deep MR, with around 60%
of them in stable MR4, a prerequisite for discontinuing treatment.
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MTOR INHIBITION IN CML: A NEW THERAPEUTIC OPTION
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Background: BCR-ABL1 fusion gene, which encodes an oncoprotein with a
deregulated tyrosine kinase activity, is the hallmark of chronic myeloid leukemia
(CML) – a myeloproliferative disorder. Despite the high rate of response to
treatment with Imatinib and other tyrosine kinase inhibitors (TKI), the number
of patients with suboptimal response or resistance to TKI has been increased.
The BCR-ABL oncoprotein activates multiples signaling pathways responsible
for tumor cells characteristic, namely the high cellular proliferation rate and
resistance to apoptosis. One of these pathways is the PI3K/AKT/mTOR path-
way, which is correlated with the increase in cell survival and resistance to
apoptosis. Leukemic stem cells use these pathways as a mechanism of defense
against treatment and as tumor maintenance.
Aims: The aim of this study was to evaluate the therapeutic potential of the
mTOR inhibitor, Everolimus, in CML cell lines sensitive and resistant to TKI
and in primary cultures of CML patients.
Methods: For this purpose, we used a CML cell line sensitive to Imatinib, the
K562 cells, and established two sub-cell lines resistant to Imatinib, the K562-
RC and K562-RD cells. Cell lines were treated in the absence and presence of
different concentrations of Everolimus and the effect in cell viability was ana-
lyzed by the resazurin assay. Cell death was determined by flow cytometry
(FC) using the Annexin V/Propidium Iodide staining. The cell cycle analysis
was accessed using Propidium Iodide incorporation by FC. Ex-vivo studies
were performed in peripheral blood samples of 56 patients under TKI treatment.
In our cohort, 52 (93%) patients presented molecular response and 4 (7%)
cytogenetic response. Moreover, 39 (74%) patients were treated with Imatinib,
and 14 (26%) with 2nd or 3rd generation TKI. Patients’ samples were culture
with increasing concentrations of Everolimus during 48h. Cytotoxic effect was
evaluated by FC in different cell populations using Annexin V staining.
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Results: Our results show that Everolimus induced a reduction in cell lines
viability, with an IC50 of 20µM for sensitive cells and 25µM for Imatinib resistant
cell lines. The cell death was induced by apoptosis and this drug has also an
antiproliferative effect through an arrest in cell cycle progression in G0/G1.
In ex-vivo studies, Everolimus reduced cell viability by increasing apoptosis of
hematopoietic stem cells (CD34+cells) without cytotoxicity to lymphocytes. In
the the dose of 25 µM this mTOR inhibitor induced in CD34 cells an increase
of 19% of these cells positive to annexin V compared with control, and only
8% of lymphocytes are in apoptosis. Comparing the response to TKI treatment
with sensibility to Everolimus, we observed a tendency to higher efficacy in
patients with cytogenetic response (CR) comparing with patients under molec-
ular response (MR) (24,5% vs 18,7% of CD34 cells positive to annexin V).
When compared patients under Imatinib treatment versus patients treated with
2nd or 3rd generation TKI, we observed a better response to Everolimus in the
second group, also associated with lower toxicity to lymphocytes.
Summary/Conclusions: Our results reveal the efficacy of Everolimus in induc-
ing cell death in CML cells, without cytotoxicity to normal cells, suggesting that
Everolimus could be an alternative targeted therapeutic approach in CML
patients. However, it is important to increase the number of patients in the
study to confirm our results.
This work was support by CIMAGO (Project 18/12) and R.A. was supported by
FCT with a PhD grant (SFRH/BD/51994/2012).
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(2G-TKI) ON FIRST LINE TREATMENT IN 73 PATIENTS WITH CML-CP
OUTSIDE OF CLINICAL TRIALS. ANDALUSIAN CML REGISTRY (RALMC)
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Background: Even though they were approved last June 2011 to be used on
first line, it is not a common procedure to begin treatment of CML-CP with 2G-
TKI, despite it has been demonstrated its efficacy and safety against imatinib
on ENESTnd and Dasision clinical trials.
Aims: To describe the RALMC experience in terms of efficacy and safety of
2G-TKI on first line of treatment in CML-CP in real life evidence.
Methods: Descriptive analysis of 73 RALMC patients, treated from the outset
in 18 hospitals of Andalusia (Spain) with nilotinib and dasatinib from June 2011
out of clinical trials. Results of BCR ABL are expressed in IS by means of
GenXpert system. Responses are cataloged according to the 2013 ELN group
guidelines. Toxicity of each treatment, overall survival (OS), failure free survival
(FFS), event free survival (EFS) and progression free survival (PFS) were eval-
uated. Event was defined as death from any cause, progression to accelerated
phase (AP) or blast crisis (BC), loss of CCgR or MMR and change of treatment
for any reason.
Results: Median of 49 years of age (18-78) and median of follow-up of 38 months
(3-56). 59% male, 41% female. 54% low, 26% intermediate, 20% high Sokal
index. 79% low, 21% high Eutos score (n 63). Treatment of first line: nilotinib 46
(63%), dasatinib 27 (37%). Probability of achieving CCgR at 6 months was 100%
(54 of 54 evaluated patients). Probability of achieving MMR at 12 months was
85,7% (54 of 63 evaluated patients) and MMR at 18 months 93,4% (57 of 61
evaluated patients). Depth of the responses are detailed in the Table 1. No sta-
tistically significant differences are found between both treatments as they
achieve MMR in months 12 and 18. In our patients treated with 2G-TKI in first
line, probability to obtain BCR ABL ≤10% in month 3 (65 evaluated patients) was
100% and ≤1% of 77% (50 of 65 evaluated patients). In both branches of treat-
ment, 77% of patients obtained rates of BCR ABL ≤1% (30 patients of 39 evalu-
ated with nilotinib and 20 of 26 with dasatinib). Overall median value of BCR-
ABL at 3 months was 0.16% (0.22% nilotinib, 0.15% dasatinib). Probability to
achieve MMR in month 12 if BCR ABL in month 3 was <1.5% is of 94% as
opposed to BCR ABL ≥1.5% which is 55% (p-value 0.001). Only one death is
reported on the dasatinib branch (death related with CML). EFS with nilotinib
was 85.5%, and 74.4% with dasatinib. FFS with nilotinib was 89.9% and 86.1%
with dasatinib; there is no statistically significant differences between both treat-
ments in terms of EFS and FFS (p-value 0.28 and 0.73 respectively). No patient
of the series progresses to AP or BC. 12 treatment changes are carried out; 5
due to toxicity (7%): 2 with nilotinib (1 neutropenia, 1 dermatological toxicity) and
3 with dasatinib (1 pleural effusion, 1 thrombocytopenia, 1 ocular thrombosis). 7
treatment changes due to lack of efficacy (9.5%): 4 failures due to CCgR loss, 2
dasatinib and 2 nilotinib (mutational study was positive with nilotinib: 1 E308V
and 1 T315l mutation), 2 fails due to MMR loss (1 dasatinib, 1 nilotinib) and 1
change from nilotinib to dasatinib in month 9 due to warning.
Table 1.
Summary/Conclusions: The use of nilotinib and dasatinib as first-line treat-
ment is consolidated as an excellent therapeutic alternative to CML-CP. Show-
ing with our series the efficacy and safety of 2G-TKI, with high rates of cyto-
genetic and molecular responses, deep and early, and low rates of toxicity
carrying over treatment changes. The cutoff point of BCR ABL in month 3 of
1.5% could determines the optimal response in month 12 as soon as they
achieve MMR.
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Background: Radotinib is a selective second generation BCR-ABL1 tyrosine
kinase inhibitor approved for the treatment of chronic myeloid leukemia (CML).
In the previous dose-safety relationship analyses (Leuk Lymphoma. DOI
10.3109/10428194.2015.1113278), a positive association was found between
the radotinib dose adjusted for the patient’s body weight (Dose/BW) and the
risk of dose-limiting toxicity (DLT). Hence, a weight-based dosing method was
suggested to improve the safety outcomes of radotinib.
Aims: To explore an optimal radotinib dosing regimen for the treatment of
chronic phase (CP) CML based on the dose-efficacy as well as dose-safety
relationship analyses of Phase 3 study data
Methods: The Phase 3 data were derived from a total of 160 newly diagnosed
patients with CP CML treated with radotinib 300 mg BID or 400 mg BID (fixed
dose regardless of BW). A logistic regression analysis was conducted to assess
the impact of Dose/BW of radotinib on the achievement of major molecular
response (MMR) (dose-efficacy relationship) or occurrence of DLT (dose-safety
relationship) within 48 weeks of treatment. Subsequently, an optimal Dose/BW
cut-off was selected based on chi-square tests and Kaplan-Meier analyses
with log-rank test.
Results: Efficacy. A statistically significant inverse relationship was found
between Dose/BW and the probability of achieving MMR when gender was
controlled for (p=0.033). A significantly higher rate of MMR was achieved in
patients who received <6.5 mg/kg than ≥6.5 mg/kg (56% vs 34%; chi-square
test, p=0.045). Safety. A statistically significant positive relationship was found
between Dose/BW and the probability of DLT occurrence (p=0.003). Among
various Dose/BW cut-offs, the greatest difference in the rate of DLT occurrence
was observed between patients who received <6.5 mg/kg and ≥6.5 mg/kg
(57% vs 91%; chi-square test, p <0.001) with the median time to first DLT being
194 days and 83 days, respectively (log-rank test, p <0.001). Therefore,
Dose/BW of 6.5 mg/kg BID appears to be a threshold dose of radotinib below
which the efficacy is improved as well as the risk of toxicity is reduced.
Summary/Conclusions: The results indicate the need for dose adjustment of
radotinib according to the patients’ individual BW. Based on the proposed cut-
off of Dose/BW 6.5 mg/kg BID, the radotinib doses for patients weighing ≤60
kg and >60 kg are suggested to be 300 mg BID and 400 mg BID, respectively.
A randomized well-controlled clinical trial would be needed to confirm the effi-
cacy and safety of this weight-based dosing strategy.
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Background: Ponatinib is a tyrosine kinase inhibitor (TKI) indicated for adult
patients with refractory chronic- (CP), accelerated- (AP), or blast-phase (BP)
chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ALL), or those with the T315I mutation. Fifty-four
patients from 17 Belgian centres entered the ponatinib Named Patient Pro-
gramme (NPP) from August 2012 through September 2015.
Aims: To provide evidence of the efficacy and safety of ponatinib in real-world
Belgian patients.
Methods: Limited patient data were collected prospectively for patients enrolled
in the NPP, based on a questionnaire approved by the Ethics Committee of the
Cliniques Universitaires Saint-Luc. Demographic data are presented for all
patients, and efficacy and safety data for patients recruited from August 2012
through June 2015 with at least 3 months of follow-up. All patients provided
informed consent.
Results: Patients with CP-CML (N=35), AP/BP CML (N=5) or Ph+ALL (N=14)
had a median age of 62 years; 89% were in ≥3rd-line of TKI therapy. Mutation
analysis revealed baseline mutations in 43% of CP-CML and 83% of Ph+ALL
patients; 42% and 40% of mutations were T315I. Of CP-CML patients 63%
received a starting dose of 45mg/day, 29% 30mg/day and 8% 15mg/day. Dose
reductions occurred in 42% of CP-CML patients: 29% due to adverse events and
13% to prevent cardiovascular complications after achieving response. For
Ph+ALL patients, starting doses were 45 mg/day (69%), 30 mg/day (23%), and
15 mg/day (8%). Among 27 CP-CML patients with outcome data, 10 patients
stopped ponatinib within 3 months due to: disease progression (n=2), thrombo-
cytopenia (n=2), gastrointestinal complaints (n=2), cutaneous lesions, uncon-
trolled hypertension, ischemic CVA and planned allotransplant (n=1 each). Best
responses in CP-CML patients treated beyond 3 months were: major molecular
response (MMR; n=10), complete cytogenetic response (CCyR; n=3), partial
cytogenetic response (PCyR; n=2), and complete hematologic response (CHR;
n=2). Four of 17 CP-CML patients discontinued due to disease progression (n=2)
and vascular occlusive events (toe necrosis after 19 months [n=1]; cardiac death
after 14 months [n=1]). Thirteen CP-CML patients remain on treatment (median:
17 months; Figure 1). Among 10 evaluable Ph+ALL patients, 4 achieved MMR,
3 of whom remain in remission after 15, 24 and 33 months.
Figure 1. Treatment duration for 17 patients with CP-CML that continued
ponatinib treatment beyond 3 months.
Summary/Conclusions: Despite limited data, ponatinib appears efficacious
in the Belgian NPP; results appear comparable to the PACE clinical trial, which
included resistant or intolerant CML and Ph+ALL patients.
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Background: Recent studies have demonstrated that measurements of BCR-
ABL1 transcript levels at 3 months were able to identify high-risk patients treated
with imatinib (IM). However, the value of early molecular response (EMR) has
not been fully defined. Until now, whether no achievement of BCR-ABL1 tran-
scripts ≤10% after 3 months of treatment is sufficient to define failure necessi-
tating a change of treatment remains obscure.
Aims: The aim of this study was to identify predictive factors for an achievement
of 12-month major molecular response (MMR) in the patients who failed 3-
month EMR, as additional information to guide clinical decisions on selecting
high-risk patients.
Methods: Among 413 newly diagnosed CP CML patients who received IM with
no prior treatment and had available molecular data at 3 months, 120 (29.1%)
patients failed to achieve 3-month EMR. Finally, to identify predictive factors
for an achievement of 12-month MMR, 94 patients with available decision for
12-month MMR were included in this study. All qRT-PCR were tested with at
least 4.5-log sensitivity in a single laboratory (Leukemia Research Institute,
The Catholic University of Korea, Seoul, Korea).
Results: Ninety-four newly diagnosed CP CML patients (including 69 men and
25 women) were analyzed. With a median age of 36 years (range, 14-73 years),
the distribution of low, intermediate, and high Sokal risk scores were 30%, 42%
and 25%, respectively, with 4% unknown risk. 16 (17%) patients of the patients
who did not achieve a 3-month EMR had MMR at 12 months, while 78 (83%)
patients failed to achieve MMR at 12 months. Univariate analyses revealed
that female sex, transcript type of b3a2, >0.65 of log reduction of BCR-ABL1
from individual baselines to 3 months, and smaller spleen size were potential
predictive factors for an achievement of 12-month MMR. After adjusting for fac-
tors affecting achievement of 12-month MMR on univariate analyses, multivari-
ate analyses showed that transcript type of b3a2, compared to b2a2 (RR of
0.09, P=0.022) and >0.65 of log reduction of BCR-ABL1 from individual base-
lines to 3 months (RR of 5.75, P=0.031) were independent factors for the
achievement of 12-month MMR. The patients with larger spleen size showed
a trend for no 12-month MMR (RR of 0.82, P=0.057).
Summary/Conclusions: This study analyzed various predictive factors for an
achievement of 12-month MMR in the patients group who failed 3-month EMR.
It provides additional information on selecting high-risk patients necessitating
a change of treatment. Base on our findings, the patients with transcript type
of b2a2, larger spleen size, and ≤0.65 of log reduction of BCR-ABL1 from indi-
vidual baselines to 3 months need a clinical decision of changing therapy
according to the results of qRT-PCR at 3 months. Further clinical investigations
in a larger patient population with longer follow-up are needed.
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REAL-WORLD TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN
PATIENTS WHO FAILED ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS)
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Background: In the era of tyrosine kinase inhibitors (TKIs) most (chronic
phase) CP-CML patients can expect to achieve excellent response with 1st-
line (1L) therapy. However, in those who relapse, as many as one-third will not
achieve a major molecular response in 2nd line (2L), and over time, up to one-
half relapse. Lipton et al. (Leuk Res, 2015) reported that for CP-CML patients
receiving a 3rd line (3L) TKI, sequential treatment with a 2nd-generation (2G)
TKI after a prior 2G TKI failure is effective in only 22-26% of patients. Under-
standing real-world patterns of care and outcomes in this poor prognosis subset
of CML patients is critical to developing new treatment strategies.
Aims: To document treatment patterns and measure real-world duration of
treatment (DOT) across therapy lines in CML patients who were treated with
≥2 prior TKI lines.
Methods: In a retrospective study, the Navigating Cancer® electronic medical
record (EMR) database was used to examine treatment patterns and estimate
the benefit of TKI therapy in real-world practice. This database is comprised of
community oncologists across the US. Patients with an ICD-9 code for diagno-
sis of CML, between August 2001-August 2015, who were treated with ≥2 prior
lines of TKIs from pharmacy records were included. Patients included were
≥18 years of age at index date (initiation of 3L treatment), with no prior history
of concomitant treatment for secondary cancers. Disease phase was reported
in clinical progress notes. Line of therapy (LOT) was assigned for each specific
regimen. Treatment discontinuation was defined as a gap in therapy of >90
days. As a surrogate for treatment benefit, DOT was calculated from prescription
dates and days of therapy dispensed.
Results: One-hundred and fifty two CML patients met all inclusion criteria: 51%
were female, and 67% Caucasian (16% unknown), with a mean age at index
date of 58.7 years (23-88 years). Disease phase was available for 85 patients,
among whom 64 were in CP-CML at most recent follow-up. For all 152 patients,
the median DOT was 2.98 months in 1L, 1.01 months in 2L, and 5.45 months
in 3L. For the 64 CP-CML, 3L DOT was 7.89 months. The most common treat-
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ment sequence for the first 3 lines was imatinib/dasatinib/nilotinib (observed in
20% of patients). 61% of 3L therapy received 2G agents (24% dasatinib, 28%
nilotinib, 9% bosutinib), 30% received imatinib, and 9% received ponatinib.
Among 3L patients, 35% discontinued treatment and 38% progressed to 4-6
total lines. Most common 4L treatment was dasatinib (33%) followed by imatinib
(24%), ponatinib (16%) and nilotinib and bosutinib (both 14%). 52% of all 4L
TKI use was in patients who had received the same drug in an earlier LOT.
Summary/Conclusions: Our analysis affirms the limited effectiveness of cur-
rent therapies in patients who relapse after 2LTKI for CP-CML. Use of 2G TKI
and imatinib in 3L remains common among community oncologists. Our analy-
sis identifies a subset of CML patients who not only fail quickly after TKI initia-
tion, but subsequent 2G TKI treatment has short DOT. A variety of treatment
sequences were observed across patients in ≥3L, and early switching of ther-
apy appears common, suggesting an absent standard of care. In addition, the
observed 52% repeat use of TKI in 4L suggests significant unmet need. More
research into understanding the optimal treatment of these poor prognosis
patients is needed to address the unmet clinical need.
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Background: The STIM trial, stood in innovative point of view, indicate that
imatinib may be successfully stopped in patients with deep molecular respons-
es. Subsequently, the feasibility of various TKIs discontinuation trials have been
investigated. The most important factor in TKIs discontinuation trials is the
molecular response of BCR-ABL. The molecular response affected by many
factors, such as Sokal score, percentage of basophil, additional chromosome
anomaly and so on. Another important factor for the success of TKIs stop study
is adverse events of TKIs itself. Several patients are not able to continue the
TKIs by the adverse events.
Aims: Stepwise dose escalation method of NIL improved the proportion of
patients who had treatment free Remission or not. A prospective, multicenter,
single-arm phase 2 trial was conducted.
Methods: The Stepwise Dose Escalation Method for Nilotinib Stop trial in Patients
with Chronic Myeloid Leukemia (Step Stop trial) was a prospective, multicenter,
single-arm phase 2 trial. Adult CML-CP patients with newly diagnosed or expe-
rienced TKIs (imatinib, dasatinib or nilotinib) was enrolled. The first half of this
study was “stepwised induction (achieve CMR) and consolidation (for 2 years)
phase”, stepwise dose escalation of NIL was conducted to avoid discontinuation
of NIL by the adverse events. And the second half was “stop and monitoring
phase”.Eligible patients were administered nilotinib with stepwise dose escalation
method, i.e. 150 mg per day for 2 weeks, 300mg per day for 2 weeks, 450mg
per day for 2 weeks, and a final dose, 600 mg per day was continued. After
achieve MR4.5, patients was received nilotinib consolidation therapy for 2 years.
The primary end point was the proportion of patients who had treatment free
remission at 12 months from the final day of the administration. The trough levels
of NIL were examined and relapse was defined as a loss of MMR.
Results: Between November 2013 and August 2015, 26 patients was enrolled.
22 patients were previous treated and 4 patients were newly diagnosed. 16
patients were male and 10 patients were female. A median age was 55.2 years
old (range 30-79). 21 patients were PS0, and 5 patients were PS 1. No patients
were dropped out of stepwise Dose Escalation phase and consolidation phase.
A total of 21 pts were found adverse events (81%), and 14 pts were found cutis
such as itching and rash (54%). No severe adverse event was found and tol-
erability for NIL administration was 100%.No significant changes were found
in the peripheral Lymphocytes count (CD3+, CD19+, and CD16+56+), but NK
activities were significantly increased between before and after treatment by
NIL (n=25, Before:6.184(%), After 9.48(%),. %: +53%, p-value 0.004).
Summary/Conclusions: The sustainable rate of the chemotherapy by NIL for
CML-CP was 100% by the stepwise dose escalation method. These method
may improve CML treatment. NK activities might be induced by NIL. Primary
endpoint of this study,the proportion of patients who had treatment free remis-
sion at 12 months, would be presentated at EHA after day.
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IMMUNOMODULATORY EFFECT OF DASATINIB THERAPY IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
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Background: Dasatinib is a second generation tyrosine kinase inhibitor (TKI),
widely used in patients (pts) with chronic myeloid leukemia (CML), especially
in failure after imatinib. The quite often side effect of dastinib is lymphocytosis
and pleural effusion (PE). These phenomenons are probably connected with
immunological mechanisms.
Aims: The aim of our study was analysis of the influence of three presently
used TKIs: imatinib, nilotinib and dasatinib on different populations of lympho-
cytes: B cells (Bc), T helper (Th), T suppressor (Ts), T regulatory (Treg), NK
cells (NKc) and NKT cells (NKTc).
Methods: A total 37 pts with CML from Department of Haematology and Bone
Marrow Transplantation in Lublin were recruited to this study. There were 17
pts on imatinib therapy (imatinib group; IG), 10 pts on nilotinib therapy (nilotinib
group; NG) and 10 pts on dasatinib therapy (dasatinib group; DG). As control
group there were 23 healthy volunteers. Material for the analysis was vein
blood collected from CML pts after minimum 3 months of TKIs therapy. Blood
samples were used for the evaluation of lymphocyte count and its immunophe-
notype to distinguish such subpopulataions as: Bc, Th, Ts, Treg, NKc and NKTc.
Results: Patients treated with dasatinib had significantly higher median number
of lymphocytes in blood (3.59 G/L) compared with pts treated with nilotinib
(2.31 G/L; p<0.01) and imatinib (1.93 G/L; p<0.001). The median
CD19+expression (Bc) in comparison with control group was significantly lower
in DG than in IG and NG (p=0.00039). There was no significant difference in
Th, Ts and NKTc antigens expression. The analysis showed that in DG there
was significantly higher expression of NKc antigens (CD3-CD16+CD56+) com-
pared with control group than in IG and NG (p<0.05). The expression of Treg
antigens (Foxp3+CD4+CD25high) was significantly lower in DG compared with
control group than in IG and NG (p<0.001).
Summary/Conclusions: The results of our study showed immunomodulatory
effect of dasatinib therapy in pts with CML manifested by increase of lympho-
cyte count and NK cells and decrease of Treg and B cells. This action of dasa-
tinib is associated with such immunological phenomenon as PE and may be
considered as additional factor influencing on better clinical response.
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Background: 2013 ELN recommendations defined endpoints in the treatment
of chronic myeloid leukemia patients, introducing the concept of early molecular
and warning response, but did not provide precise indications on timing of pos-
sible early switch to overcome negative prognosis.
Aims: Aim of our study is to evaluate how Italian physicians are adherent to
ELN recommendations and how the different use of available TKIs would have
changed therapeutic strategies.
Methods: We collected 218 patients treated consecutively, outside clinical tri-
als, in 13 different Italian centers.
Results: There were 124 males and 94 females, median age 58 years (range
18-90), 20 patients with a previous neoplasia. Ten patients had at baseline
ACA (6 major routes). According to Sokal risk, 50% of patients were low, 35%
were intermediate and 16% were high risk. According to Eutos risk, 87% were
low and 13% were high risk. As frontline treatment 55 patients received dasa-
tinib (52 patients started with 100 mg, 3 at reduced dose), 82 patients received
nilotinib 300 mg BID and 81 patients started imatinib (67 patients at 400 mg,
14 at <400 mg). Median age and comorbidities at baseline strongly influenced
choice of TKI at baseline. At 3 months, in the dasatinib-treated cohort, 81% of
patients were classified as optimal responders and 7% were warning but none
of them changed therapy, due to concomitant comorbidities or toxicity experi-
enced that allowed modification of dose. At 6 months, 84% of patients were in
the optimal response category, 6% in the warning response (none of them
changed) and 4% in failure category (1 patient increased the dose to 140
mg/day). At 12 months, 72% were in the optimal category, 25% in the warning
category (none of them changed due to BCR-ABL/ABL ratio slightly above
0.1%) and 6% were in failure category (1 patient switched to nilotinib). At 3
months, in the nilotinib-treated cohort, 90% of patients were classified as opti-
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mal responders and 4.8% as failure (1 patient switched to dasatinib). At 6
months, 87% of patients were optimal, 6% warning (none of them changed)
and 3% were failure (only 1 patient switched to dasatinib). At 12 months, 80%
were in the optimal category, 16% in the warning category (none of them
changed due to a ratio BCR-ABL/ABL slightly above 0.1%) and 9% in the failure
category (1 patient switched to dasatinib and 1 patient switched to ponatinib).
In the imatinib-treated cohort, at 3 months, 74% of patients were classified as
optimal responders, 16% patients were warning (5 switched to second-gener-
ation TKIs), 3.7% were failure (2 switched to other TKIs). At 6 months, 72% of
patients were in the optimal category, 27% were in the warning category (1
patient only changed therapy) and 3% were failure (only 1 patient switched to
dasatinib). At 12 months, 52% were in the optimal category, 32% were warning
category (none of them changed due to comorbidities) and 15% were in failure
category (3 patients switched to nilotinib or dasatinib, 1 patient to high dose
imatinib). Cytogenetic analysis at 6 and 12 months was not performed in 40%
of patients already in MR3.
Summary/Conclusions: The results of this retrospective analysis indicated
that with frontline second-generation TKIs, warning and failure category were
reduced at 3 and 6 months and that with this approach, Italian physicians were
less likely to perform an early switch.
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COMBINATION OF HEMOGLOBIN LEVEL AT PRESENTATION WITH
MOLECULAR RESPONSE AT 3 MONTHS BETTER PREDICTS SURVIVALS
AND DEEP MOLECULAR RESPONSE TO IMATINIB IN CHRONIC-PHASE
CHRONIC MYELOID LEUKEMIA PATIENTS
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Background: Anemia at presentation is not uncommon in newly diagnosed
chronic-phase chronic myeloid leukemia(CP-CML). However, hemoglobin level
at diagnosis of CP-CML is not included in the formulas for calculating three
scoring systems, namely Sokal, Hasford and EUTOS scores, for predicting sur-
vival outcomes. To our best knowledge, studies on the prognostic values of
hemogobin levels at diagnosis of CP-CML were scarce, especially in associa-
tion with survial outcomes and treatment responses.
Aims: We retrospetively collected data from consecutively newly diagnosed
CP-CML patients treated with Imatinib to explore the value of hemoglobin level
at presentaiton in predicting survival outcomes and treamtment responses as
compared with current scoring systems.
Methods: A cohort of 154 newly diagnosed CML-CP patients treated with front-
line Imatinib was surveyed retrospectively from January 2001 to April 2014.
The cut-off value of baseline hemoglobin (Hb) level at diagnosis was defined
as 10.0 g/dl arbitrarily. The influence of severe anemia (Hb<10.0 g/dl) and three
CML scoring systems (Sokal, Hasford, and EUTOS) at diagnosis on treatment
response landmarks, progression-free survival (PFS), event-free survival (EFS)
and overall survival (OS), were examined by univariate and multivariate analy-
ses. The discriminatory abilities of three prognostic models and baseline char-
acteristics were examined by using the Cox proportional hazards model, and
the consequences of the Cox model were expressed with the Akaike information
criterion (AIC), which revealed how the EFS, PFS and OS were affected. The
model with lower AIC is more explanatory and informative.
Results: Severe anemia with Hb<10.0 g/dl was identified in 43 (27.9%) of 154
newly diagnosed CP-CML patients treated with Imatinib. Patients with Hb<10.0
g/dl was associated with splenomegaly (76.7% vs 52.3%, p=0.006), high EUTOS
risk (37.2% vs 16.2%, p=0.005), high Sokal score (48.8% vs 22.5%, p=0.001),
high Hasford score (27.9% vs 7.2%, p=0.001), additional chromosomal abnor-
malities (25.6% vs 12.6%, p=0.049) but not associated with gender. Hb<10.0
g/dl was associated with higher white blood cell count (median=177.4 vs 88.6,
p<0.001), blast percentage in peripheral blood (PB)(median=2.0% vs 1.0%,
p=0.002), and eosinophil percentage in PB (3.0% vs 2.0%, p=0.038), but not
assciated with MCV, basophil percentage in PB or platelet counts. Patients with
Hb<10.0 g/dl had less favorable treatment responses including BCR-ABL≦10%
at 3 months (51.2% vs 68.5% in Hb≧10.0 g/dl, p=0.045), complete cytogenetic
response at 6 months (19.0% vs 50.5% in Hb≧10.0 g/dl, p<0.001), and major
molecular response at 12 months (22.5% vs 45.2%in Hb≧10.0 g/dl, p=0.009).
Furthermore, Hb at 10.0 g/dl could significantly distinguish EFS, PFS and OS
with lower AIC value as compared with EUTOS, Hasford and Sokal scores.
Moreover, combination of BCR-ABL≦10% at 3 months with Hb≧10.0 g/dl at
presentation, it could predict the patients with better EFS, PFS, and OS and
deeper molercular responses (MR4.5) (Figure 1).
Summary/Conclusions: Severe anemia (Hb<10.0 g/dl) at presentation was
associated with less favorable treatment responses, poor EFS, PFS and OS in
newly diagnosed CP-CML patients treated with frontline Imatinib. Combination
of Hb≧ 10.0 g/dl at presentation with early molecular resposne (BCR-
ABL≦10%) a 3 months, it could better predict survival outcomes and cumulative
incidence of deep molecular response (MR4.5) as compared with current three
scoring systems. Our study highlights the need for revisiting traditional CML
scoring systems in the TKI era and suggests that CP-CML patients with Hb
level≧ 10.0 g/dl at presentation and with early molecular response at 3 months
might respond to Imatinib well thereafter.
Figure 1.
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Background: Elderly patients are a substantial proportion of chronic myeloid
leukemia (CML) patients (22% in a population-based registry study performed
in Europe) (Hoffman V et al., Leukemia 2015;29:1336-43) but are under-rep-
resented and selected in academic and commercial studies. Their treatment
and their outcome are poorly known.
Aims: To investigate the treatment, response and outcome in an unselected
cohort of elderly patients with newly diagnosed chronic phase (CP) CML.
Methods: In a cohort of 337 newly diagnosed, adult, CP, Ph+,BCR-ABL1+,
CML patients who were registered according to the population-based criteria
in two Italian Regions (Emilia-Romagna and Sicily) between 2008 and 2012,
we identified 85 patients (25%) who were ≥70 years old. Five of them were
treated only with hydroxyurea (HU); 17 of them were treated in first-line with
nilotinib. We report here on the 63 patients who were treated in first-line with
imatinib, 400 mg once daily.
Results: Males were 54%. Median age at diagnosis was 77 years (range 70-
95). Median follow-up was 48 months (range 30-65), so that median patients
age at data analysis was 81 years. Sokal risk distribution was 3% low, 56%
intermediate, and 41% high. 41 patients (65%) received only imatinib. 14
patients (22%) were switched to a 2nd generation TKI for failure. 8 patients
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were switched to a 2nd generaion TKI (n=5) or to HU (n=3) for toxicity.
Responses and outcomes are shown in the Table 1. Molecular responses (early
molecular response, major molecular response, and deeper molecular
response) were in the range reported for younger patients in prospective stud-
ies of treatment. Overall survival was poorer, because 19% of patients died in
MMR or in CP without any evidence of progression, due to age-related com-
plications, mainly cardiovascular and cerebrovascular.
Table 1.
Summary/Conclusions: These data reinforce the concept that in CML age is
not a barrier to the success of a targeted therapy.
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CHRONIC MYELOID LEUKEMIA
E Tothova1,*, A Kafkova2, L Stejskal3, R Hajek4
1Dpt of Clinical and Medical Biophysics, University UPJS, Kosice, Slovakia,
2Dpt. Oncohematology, HEMKO l.t.d, Kosice, Slovakia, 3Hematooncology, Uni-
versity of Ostrava, 4Hematooncology, Universtity of Ostrava, Ostrava, Czech
Republic
Background: Protein tyrosine kinase inhibitors (TKI) are currently an important
drug class in the treatment of leukemia. They represent targeted cancer therapy
and have become the treatment of choice in chronic myeloid leukemia (CML).
Many studies clearly have demonstrated that they were able to induce thyroid
abnormalities including hypothyroidism and less often hyperthyroidism.
Increased awareness and monitoring of thyroid function tests are important in
patients maintained on TKIs. Thyroid dysfunction is a well-known adverse effect
of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib.
Aims: The aim of this study was to investigate the effect of second-generation
TKIs on thyroid function in chronic myeloid leukemia (CML) patients treated in
2 centres.
Methods: We retrospectively assessed the effect of the first-generation TKI
imatinib and the second-generation TKI nilotinib and dasatinib on thyroid func-
tion tests in 73 Philadelphia chromosome-positive (Ph-positive) chronic myeloid
leukemia patients.
Results: Overall, 11 of 73 (15%) had one or more thyroid function test abnor-
malities during follow-up. Hypothyroidism or hyperthyroidism were found in 6
of 73 (8,2%) and 3 of 73 (4.1%) cases after a median of 6 and 22 weeks,
respectively. In most patients thyroid dysfunction was transient without clinical
symptoms. Therapy of hypo-/hyperthyroidism was required in three patients.
Thyroid dysfunction never resulted in the discontinuation of TKI therapy. Under
treatment with imatinib, nilotinib, and dasatinib, thyroid abnormalities were
detected in 25%, 35%, and 40%, respectively. Three of 45 patients treated
with nilotinib had evidence for an autoimmune thyroiditis (antibody positive in
2 of 3 patients) with an episode of hyperthyroidism preceding hypothyroidism.
Summary/Conclusions: Thyroid dysfunction is a common adverse event with
second-generation TKI therapy in patients with Ph-positive chronic myeloid
leukemia. Although the mechanism is still unclear, the higher frequency of thy-
roid abnormalities, including autoimmune thyroiditis, warrants regular and long-
term monitoring of thyroid function in these patients.
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Background: Since the introduction of TKI treatment in CML in the beginning
of this century, the expected survival of CML patients has increased substan-
tially and is now close to the survival of the background population. Thus, the
prevalence of CML has increased dramatically, and the number of patients in
therapy, needing molecular monitoring increases accordingly. Whereas a large
number of studies analyze the outcome of CML in cohorts, no population-based
studies to our knowledge have focused on the distribution among the various
TKIs and the molecular response.
Aims: The aim of this multicenter study was to measure the cross sectional
molecular BCR-ABL1 response in CML patients in a demographic area and to
analyze the molecular response across the different treatments available along
with the distribution of treatment duration.
Methods: All hematological centers in Denmark and Iceland were invited to par-
ticipate. One blood sample was taken in two Paxgene tubes per CML patient
after informed consent as part of a routine visit and shipped to central BCR-ABL1
analysis in the EUTOS MR4.5 certified laboratory in Vejle along with information
on date of birth, gender, current treatment, dose, start date and line of treatment.
Results: Eight out of ten hematological centers I Denmark participated in the
study as well as the Icelandic center. Five of the centers included more than
95% of their CML patients and in total 360 samples were included. One blood
sample was lost during preparation, and of the remaining 359 samples 354
samples fulfilled the EUTOS quality criteria for Molecular Response (MR) scor-
ing (>24,000 GUSB copies per qPCR well). In the MR scoring system the
patients were found to be 6.5% >MR2.0, 7.3% in MR2.0, 19% in MR3.0
(=MMR), 17% in MR4.0 (of which 55/59 were BCR-ABL1 positive) and 50% in
MR4.5 (of which 26/176 were BCR-ABL1 positive). Thus 150 pt (42%) were
BCR-ABL1 negative and in MR4.5, indicating that the potential for TKI inter-
ruption was high in this population, predominantly treated with imatinib. The
average and median age of the patient group at sampling time was 58.7 years
and 61.0 years, respectively with a gender distribution of 57% males and 42%
females. Of the 360 patients, 214 pt (59%) were in 1st line treatment, average
duration 10.4 years (197/Imatinib, 4/Dasatinib, 12/Nilotinib and 1/NA); 97 pt
(27%) were in 2nd line treatment, average duration 3.3 years (16/Imatinib,
47/Dasatinib, 28/Nilotinib, 5/TKI and/or interferon combinations and 1/Pause
(BCR-ABL1 negative); 33 pt (9%) were in 3rd line treatment, average duration
2.6 years (3/Imatinib, 8/Dasatinib, 18/Nilotinib, 3/Bosutinib and 1/Pause (BCR-
ABL1 negative); 10 pt (3%) were >3rd line treatment, average duration 1.1 year
(1/Imatinib, 5/Dasatinib, 3/Bosutinib, 1/Ponatinib); 3 pt were transplanted; 1
BCR-ABL1 positive pt had been in treatment free remission for 12 years; and
2 pt lacked information on treatment line.
Summary/Conclusions: This study describes in the Danish and Icelandic
CML patient population the present distribution of treatment, treatment line and
duration combined with molecular response.
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SAFETY AND EFFICACY OF PONATINIB IN REAL WORLD CLINICAL
PRACTICE. RESULTS FROM THE SPANISH COMPASSIONATE USE
PROGRAM. A GELMC STUDY
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de Jaen, Jaen, 8Servicio de Hematología, Hospital Universitario Virgen Macare-
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tología, Hospital Meixoeiro, Vigo, Vigo, 13Servicio de Hematología, Hospital
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SAS de Jérez de la Frontera, Cádiz, 18Servicio de Hematologia, Servicio de
Hematología, Hospital Regional Universitario Carlos Haya, Málaga, 19Servicio
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Background: In clinical trials, ponatinib has demonstrated excellent efficacy
in heavily pretreated chronic myeloid leukemia (CML) patients. However, a
high rate of vascular complications has been reported with the standard dose
of 45 mg per day, and seems to be associated with previous cardiovascular
(CV) risks. Hence, close safety monitoring and tapering of the dose have been
recommended, although there are limited data supporting their benefit. Since
patients included in clinical trials are a selected population, there is a need of
real world data to properly assess the results of ponatinib treatment.
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Aims: The purpose of this study is to provide safety and efficacy information
from patients treated with ponatinib in real world clinical practice.
Methods: We have retrospectively collected data from 23 patients treated with
ponatinib after resistance to previous treatment with tyrosine kinase inhibitors
(TKIs). Molecular biology tests were done according to ELN guidelines and
BCR-ABL/ABL is expressed as% IS. Clinical and comorbidities information
(including CV risk factors were collected before and during ponatinib treatment.
Results: Median age at diagnosis was 56 years (34-83). Most (70%) had CV
risk factors and 20% had suffered a previous CV event. The percentage of low,
intermediate and high-risk Sokal groups were 25%, 45% and 15%, respectively.
Median time of TKIs exposure before ponatinib was 43 months. One patient was
treated in accelerated phase (AP), while the rest were in first or second chronic
phase (CP). Thirty seven (%) of the patients had previously received 2 TKIs (ima-
tinib, dasatinib, nilotinib, or bosutinib), and N (62%) had received ≥3 . At ponatinib
start, 69% of patients had not achieved complete cytogenetic response (CCyR)
while the rest were in CCyR (including 17% with major molecular response
(MMR)). Sixty percent of the patients had one or more BCR-ABL1 kinase domain
mutations at the time of ponatinib start (45% had T315I mutation). Median fol-
low-up was 29 months (3-53). Initial daily dose was 45, 30, and 15 mg in 85%,
5%, and 10% of patients, respectively. The initial dose was reduced in half of the
patients, either due to side effects or to minimize the CV toxicity. In the last control,
ponatinib daily dose was 45 mg, 30 mg and 15 mg in 65%, 10%, and 25% of the
patients, respectively. Probabilities to obtain or maintain previous CCyR or MMR
were 65% and 25%, respectively. Fifty eight percent of patients without CCyR at
baseline achieved CCyR (17% achieving MMR), while 60% of patients with CCyR
at baseline improved their molecular response. No differences in the response
rates were observed depending on the mutational status or the initial ponatinib
dose. By 43 months, event free survival, and progression free survival were 50%
and 80%, respectively. At time of analysis, 40% of the patients had discontinued
ponatinib due to toxicity (25%), lack of efficacy (25%), hematopoietic stem cell
transplantation (37%) or death (13%). Most common non-hematological toxicities
were liver toxicity (20%), lipase increase (10%), and hypertension 15%. No CV
events were reported during treatment.
Summary/Conclusions: Ponatinib was shown to rescue a significant propor-
tion of patients failing prior TKI treatment. It is worth noting that, with of a median
follow-up of more than 2 years, no CV events appeared, suggesting that early
dose modification could be protective against the occurrence of vascular com-
plications.
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Background: The search of surrogate prognostic markers for early detection
of high risk disease progression still is actual problem in chronic myeloid
leukemia (CML) management. The existing prognostic scales consider char-
acteristics only at moment of diagnosis, whereas individual BCR-ABL level
trend remains out of its vision.
Aims: The aim of this study was to evaluate the relationship between individual
characteristics of early response to treatment and BCR-ABLIS level at 12 months.
Table 1. The frequency of the optimal response (MMR) achievement at 12
months of TKI therapy in the relationship with type of first line therapy.
Methods: Fifty-four patients with chronic phase CML were included in the study.
Forty-one patients started treatment with the first generation of tyrosine kinase
inhibitors (TKI1) - Imatinib 400 mg QD. Twelve patients were treated with the
second generation of tyrosine kinase inhibitors (TKI2) as first-line: Nilotinib 300
mg BID and 1 patient with Dasatinib 100 mg QD. Fourteen patients initially
treated with TKI1 were subsequently switched to TKI2 (Table 1). We have con-
ducted multivariate analysis of relationship between BCR-ABLIS levels at 12
months and early molecular response (EMR, BCR-ABLIS level ≤10% at 3
months) achievement, individual rates of BCR-ABL decline, type of first line
therapy, fact of switching therapy from TKI1 to TKI2.
Results: The parameters that have statistical significance influence on BCR-ABLIS
level at 12 months of therapy were as follows: individual rate of BCR-ABL decline
from 3 months to baseline (<0,1/>0,1) – p=0.044, type of first-line therapy
(TKI1/TKI2) – p=0.0002, switching of therapy from TKI1 to TKI2 (yes/no) –
p<0.0001. Achievement of EMR did not reach statistical significance – p=0,51. In
addition, we have revealed the fact, that timely switch to TKI2 for resistant CML
patients led to the rates of MMR achievement at 1 year of therapy similar to the
MMR rate in the remaining TKI1 treated patients, eliminating resistance to TKI1.
Summary/Conclusions: Individual characteristics of the early response to
treatment, for example individual rate of BCR-ABL decline, might be used as
predictors of achievement optimal treatment result in CML treatment. The ade-
quate treatment switching from first to second generations can restore treatment
efficacy in resistant patients.
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PATIENTS IN ESTONIAN POPULATION
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Background: Tyrosin kinase inhibiitor (TKI) imatinib is the gold standard 1st
line therapy of chronic phase chronic myeloid leukemia (CP-CML). Imatinib
was implemented in Estonia for the 1st line therapy of CML in July 1, 2006.
However in 2012 generic version of imatinib was approved in European Union
and since January 1, 2014 only generic imatinib has been available in Estonia.
Aims: The aim of the study was to evaluate the clinical efficacy of generic ima-
tinib in the treatment of CP-CML in Estonia and to compare results with historical
group of patients treated brand name imatinib.
Methods: 25 patients in CP-CML have been diagnosed during 2014-2015 and
have started 1st line treatment with generic imatinib. Optimal response was
assessed at 3, 6 and 12 months after the start of treatment according to Euro-
pean LeukemiaNet 2013 guidelines: BCR/ABL ≤10%, <1% and ≤0,1% at 3, 6,
12 months respectively. For comparison historical group of 72 patients in CP-
CML who received brand name imatinib for 1st line treatment during 2006-2013
were used. In this group pre-treatment with hydroxyurea for maximum 3 months
but not interferon-alfa was allowed, OR was assessed at 6, 12 and 18 months
after the start of imatinib and defined according to European LeukemiaNet 2010
recommendations.
Results: OR with generic imatinib was achieved in 16/21 (76.2%) evaluable
patients at 3 months, 11/14 (78.6%) patients at 6 months and 7/11 (63.6%) at
12 months. At 18 months there were only 3 evaluable patients who all obtained
OR. None of the patients not having OR at 3 months and continuing with ima-
tinib, obtained OR later. One patient without OR at 3 and 6 months, progressed
to lymphoid blastic crisis in 9 months after diagnosis. Two patients had failure
to generic imatinib - one patient having BCR/ABL level at 6 months over 10%
and one patient over 1% at 12 months; both patients were switched to the 2nd
generation TKIs. Three patients having OR at 3 and 6 months lost it by 12th
month, but 2 of them had treatment interruption periods due to poor tolerability.
No new safety signal emerged. The most common adverse effects to generic
imatinib occurring more than 10% of patients were nausea/vomiting,
diarrhea/constipation, muscle pain in legs, periorbital oedema and allergic skin
reactions. Due to adverse events 6 patients were switched to different generic
imatinib and one patient not tolerating two different generic imatinibs was
switched to the 2nd generation TKI. In the historical group OR was achieved in
33/45 (73%) evaluable patients at 6 months and 33/50 (66%) patients at 12
months. At 18 months OR was obtained in 22/51 (43%) evaluable patients.
None of 11 patients not in OR at 6m obtained OR at 12m or 18 months.
Summary/Conclusions: Generic imatinib appears to have the same efficacy
as brand name imatinib. Despite differences in group size and OR definition by
European LeukemiaNet 2010 vs 2013 recommendations the treatment results
with generic and brand name imatinib were quite comparable with 78.6-66% of
OR rate at 6 months and 63.6-66% at 12 months. To improve treatment results,
for patients not achieving early OR at 3 months or 6 months should be offered
treatment with 2nd generation TKI.
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Background: Studies on CML in last decade have correlated early molecular
response (EMR) both at 3/ 6 months and velocity of BCR-ABL reduction with
MMR at 18 months. But, this requires molecular monitoring at 3 monthly interval
to the least till the achievement of MMR as per NCCN/ELN guidelines. For
studying velocity of fall, the molecular monitoring is required at further greater
frequency. In resource constraint settings, it is very difficult to monitor patient
with qPCR for BCR-ABL transcripts at regular interval owing to the poor edu-
cational status, financial constraints, logistic issues (non-availability of testing
facilities at all places) and lack of standardization at various labs. Considering
these limitations, it is very essential to identify surrogate markers which are
universally available for predicting MMR at 18 months.
Aims: To study the role of CHR as a surrogate for MMR at 12 and 18 months
in resource constraint settings in patients unable to afford frequent molecular
monitoring.
Methods: Study Design: It’s a prospective single center observational study
from northern India. This is part of PRICE study (PGIMER Real world Indian
CML Experience) registered vide UTN U1111-1177-8918 and under registration
in CTRI. Patients: As part of this study a total of 230 CML patients were
screened prospectively attending Adult Hematology Clinic of the host institution.
All patients (age>12 years) who were fulfilling the diagnostic criteria of CML-
CP before initiation of imatinib therapy were included in the study. Exclusion
criteria were either (a) patients in accelerated phase and blast crisis or (b)
patients in whom Imatinib was discontinued due to hypersensitivity/ intolerant.
Protocol: As part of this study protocol, all newly diagnosed cases of CML-CP
were managed with TKI therapy with regular molecular monitoring (3, 6, 12, 18
and 24 months). Patients were initially evaluated with complete hemogram,
bone marrow analysis and diagnosis was then confirmed with qualitative molec-
ular test to detect the presence of BCR-ABL translocation. Sokal, Hasford and
EUTOS scores were calculated at baseline. Imatinib, was started and Clinical
examination and hemogram was done at weekly intervals to assess for com-
plete hematological remission. Molecular responses at 3, 6 months for EMR
and 12, 18 months for MMR was monitored in all these patients.
Results: 85.1% patients achieved CHR within 12 weeks with median time to
achieve CHR being 40 days. Median time to achieve CHR was longer in female
patients (42 days) as compared to male patients(36 days), difference was not
statistically significant (p=0.636). Patients who achieved MMR at 12 months
had a mean CHR duration of 42 days (SD-437.79, n=73) and the patients who
didn’t achieve MMR at 12 months the mean duration of CHR was 62.81 days
(SD-55.8, n=69). The difference was statistically significant (p=0.01). We also
compared the duration of CHR with MMR at 18 months. The patients who
achieved MMR at 18 months had a mean CHR duration of 35.45 days (SD-
25.41 n=56) and among the patients who didn’t achieve MMR at 18 months
the mean duration of CHR was 56.71 days (SD-59.6, n=28). The difference
was again significant with p value of 0.024 (Table 1).
Table 1.
Categories of MR                     Groups                n         Days to achieve CHR        P value
EMR at 3 months                BCR/ABL <10%        159                  46.79                    
<0.001
                                         BCR/ABL >10%         32                   81.34
OMR at 6 months                BCR/ABL <1%         113                  46.11                      0.02
                                          BCR/ABL >1%          77                   64.16
MMR at 12 months            BCR/ABL <0.1%        69                   39.16                     0.001
                                        BCR/ABL >0.1%        69                   62.81
MMR at 18 months            BCR/ABL <0.1%        56                   35.45                     0.024
                                        BCR/ABL >0.1%        28                   56.71
Summary/Conclusions: CHR is a good marker to predict the disease
response in patients with CML on therapy.
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Background: Presence of fusion gene BCR-ABL1 is indicative of chronic myel-
ogenous leukemia. Quantitative assay of BCR-ABL1 transcript in patient blood
can measure response to therapy. Harmonization of BCR-ABL1 transcript
assay results among laboratories is needed in order to standardize clinical
reporting. In 2009 the World Health Organization (WHO) developed a panel of
four BCR-ABL1 primary standards to calibrate secondary standards and to
establish an international scale (IS) for reporting assay results as a ratio of
fusion transcript to control gene transcript (%IS). Reliable secondary standards
are essential for monitoring performance of BCR-ABL1 quantitative assays.
Aims: This study creates a panel of BCR-ABL1 secondary standards, based
on the WHO primary standards, for use with Xpert BCR-ABL Monitor assay
(Cepheid).
Methods: Maine Molecular Quality Controls, Inc. (MMQCI) manufactured a
panel of four secondary standards consisting of BCR-ABL1 b3a2 fusion tran-
script and ABL1 control gene transcript in a proprietary stabilizing matrix. Tran-
script ratios were calibrated to yield the same%IS results as the four WHO pri-
mary standards: approximately 0.01%IS, 0.1%IS, 1%IS, and 10%IS. Three
lots of MMQCI panels were tested on one lot of Xpert BCR-ABL Monitor con-
temporaneous with testing WHO primary standards.
Results: Three unique lots of MMQCI secondary standards panels yielded
quantitative results in good agreement with one another and with the WHO
primary standards panel at each of the four%IS levels. MMQCI secondary stan-
dards panels demonstrated linearity across the range of%IS levels, comparable
to linearity of WHO primary standards.
Summary/Conclusions: MMQCI’s BCR-ABL1 secondary standards panel
shows potential for verifying performance of Xpert BCR-ABL Monitor, thereby
contributing to harmonization of minimal residual disease (MRD) measure-
ments to the International Scale. This approach to creating standards second-
ary to WHO primary standards serves as a model for creation of secondary
standards for Xpert BCR-ABL Ultra (Cepheid).
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Background: Clinical outcomes and survival of chronic myeloid leukemia
(CML) patients treated with ABL tyrosine kinase inhibitors (TKIs) have signifi-
cantly improved. To achieve a good prognosis, including cessation of TKI treat-
ment, a rapid and deep response to TKIs is important. Elderly patients usually
cannot receive the standard dose (100mg QD) of dasatinib because of its
adverse effects (AE). Nevertheless, several elderly patients achieve a deep
response to very low doses of ABL TKIs.
Aims: We retrospectively analyzed the efficiency of low dose dasatinib in eld-
erly patients with CML.
Methods: We retrospectively evaluated imatinib-resistant and -intolerant CML-
CP patients aged 65 or over who had been administrated less than 100mg QD
dasatinib between 2010 and 2015 at Saga University Hospital. We estimated
therapeutic efficiencies based on bcr-abl mRNA levels measured by RQ-PCR
compensated according to international scale (IS) and/or TMA (transcription
mediated amplification) method for peripheral blood. In the TMA method, unde-
tectable is considered to be the same as a 4-log reduction (MR4) of RQ-PCR
on the IS. In addition to efficacy, adverse effects at lower doses of dasatinib
were also investigated.
Results: Twenty-one elderly CML-CP patients were investigated. Sixteen
patients (76.2%) were newly diagnosed. The median age at diagnosis was 72
years old (range, 65–83). Thirty-three per cent were male, and the median fol-
low up time was 20.5 months (range, 4–56). The mean dose of dasatinib was
24.6 mg. The numbers of patients receiving a mean dasatinib dose of 50mg or
less and 20mg or less were 19 (90.4%) and 15 (71.4%), respectively. Twenty
patients (95.2%) and 16 patients (76.2%) achieved a major molecular response
(MMR) and a MR4, respectively. In addition, 10 patients (47.6%) achieved a
MR4.5. The median durations of dasatinib treatment to achieve a MMR and an
MR4 were 6 months (range; 2–11) and 12 months (range; 3–50), respectively.
All cases achieved a complete cytogenetic response (CCyR) within 12 months.
In the case of the 15 patients receiving a mean dose of 20 mg or less, 14
patients (93.3%) achieved a MMR and 11 patients (73.3%) achieved a MR4.
The median durations of MMR and MR4 were 6 months (range, 3–10) and 9.5
months (range, 3–38), respectively. Additionally, 13 patients treated with a dose
of 20mg or less as first line therapy. MMR and MR4 were achieved in 84.6%
and 69.2%, respectively. 53.8% achieved a MR4.5. The median durations of
MMR and MR4 were 6 months (range, 3–11) and 10 months (range; 4–38),
respectively, in this cohort. The main AE was plural effusion (6 patients; 28.5%).
Surprisingly, HBV reactivation occurred in 2 patients treated with 20 mg QD.
Except for 1 patient who changed to another TKI because of gastrointestinal
bleeding, most AEs became tolerable after dose reduction. Seven patients
administered 50 mg or less had increased large granular lymphocyte counts.
Summary/Conclusions: Treatment with dasatinib at lower than standard dos-
es was well tolerated and resulted in an adequate molecular response in elderly
CML patients without causing severe AEs. Thus, prospective studies should
be performed to determine the effects of administering lower doses of dasatinib
to elderly CML-CP patients.
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Background: Ponatinib is an oral tyrosine kinase inhibitor (TKI) that has been
designed to be effective also in patients who harbor the TKI-refractory threonine
to isoleucine mutation at position 315 (T315I). In December 2014 the drug was
granted an accelerated approval by the FDA, based on the promising results
from the phase II PACE trial. Nevertheless, the wide use of the drug has been
limited due to safety matters, in particular arterial thrombotic complications,
reported in up to 17% of patients. Currently, there is little real-life information
regarding the use of ponatinib outside of clinical trials.
Aims: 1) To characterize patients with chronic myeloid leukemia (CML) who
received ponatinib. 2) To determine safety profile of ponatinib outside clinical
trials. 3) To assess the efficacy of ponatinib outside clinical trials.
Methods: Between 4.2011 and 7.2015 (51 months) 24 patients in 7 medicals
with CML received ponatinib. We reviewed the medical records of these patients
and asked their physicians to rank the quality of life of their patients on a 1 to
5 scale.
Results: The median age was 44 years (rang: 23 to 79) and most were in
accelerated (21%, N=5) or blast crisis (41%, N=10) phases at time ponatinib
was initiated. Prior to ponatinib, the patients were treated for a median of 55
months (range: 1 to 215) with 1 to 3 different TKIs (median: 3). Thirteen received
at least one course of chemotherapy or interferon-α, and two underwent allo-
geneic bone marrow transplantation. Mutations at the bcr-abl DNA binding
domain were detected in 11 patients (69%) and T315I mutation in 8 of those.
Based on the medical history, 48% were at-risk for vascular complications either
because of prior cerebrovascular event or myocardial infarction (18%) or
because of vascular risk factors (30%). Baseline ECG and cardiac ECHO stud-
ies were available in 11 patients and none had significant structural or functional
pathology. Patients were followed between1 to 34 months at time of analysis
(median: 6 months) and during this time 4 patients died and 14 were still receiv-
ing ponatinib. Patients discontinued the treatment either because of major car-
diovascular events (N=3), severe pancytopenia (N=1), planned bone-marrow
transplantation (N=1) or because they were lost to follow-up (N=1). Seventeen
patients were available for response assessment at time of analysis and the
overall response rate was 77% (N=13). Five of six patients at chronic phase
achieved either complete or major molecular response. Eight patients at accel-
erated phase or at blast crisis (8/11, 72%) achieved either hematological (5/11,
45%) or molecular response (3/11, 27%). Two of those, with hematological
response, underwent allogeneic bone marrow transplantation. The median sub-
jective scoring of ponatinib contribution to the quality of life of patients was 2.4
(range 1 to 5). Physicians that gave low scoring mentioned Severe weakness,
myalgia and cytopenias were mentioned as a major concern.
Summary/Conclusions: In real- life setting ponatinib is generally used as a
last resort. In our cohort, it was almost exclusively given to patients who expe-
rienced failure to previous TKIs. Only one third of patients tolerated the recom-
mended dose of 45mg. Yet, response rate was still relatively high, suggesting
that a daily dose of 30mg might be appropriate. With only 6 months of follow-
up we documented 3 cardiovascular events (12%) that prompted discontinua-
tion of the drug. The high response rate and overall contribution to quality of
life in patients, who already experienced failure of other TKIs, support the use
of ponatinib in this setting.
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Background: Bleeding is observed time to time in chronic myeloid leukemia
(CML) patients using tyrosine kinase inhibitors (TKI). It has been suggested
that tyrosine kinase inhibitors can disrupt platelet functions and cause beeding
without thrombocytopenia in CML patients.
Aims: In this study, we aimed to evaluate platelet functions of CML patients
using tyrosine kinase inhibitors and examine in conjunction with beeding symp-
toms to find out whether there is a correlation between them.
Methods: In this study, bleeding surveys were performed for 68 CML patients
in cronic phase receiving imatinib (n=47), dasatinib (n=15) and nilotinib (n=6).
Hematology analyzer LH780 (Beckman Coulter) was used for measurement of
complete blood counts. BCS XP coagulation analyzer (Siemens) was used for
measurement of PT, aPTT, TT, fibrinogen and factor assays. In our coagulation
laboratory, platelet rich plasma pool was prepared and light transmittance agre-
gometry (Chrono-Log) was used for the evaluation of platelet functions. Platelet
agregation was induced in in vitro conditions by different agonists (ADP, epi-
nephrine, collagen, ristocetin) and the agregation percentage/time graph was
analyzed to evaluate platelet functions.
Results: The median age was found as 47 years (range, 18-78 years) in CML
patients. Complete blood counts and coagulation test results were in normal
range; white blood cell count 6.72,5 ×103/µL, hemoglobin 13.0±1,7 g/dL,
platelets 234.7±74,5 ×103/µL, PT 12,8±1,4 sn, INR 1,0±0,1, aPTT 27.6±2,8
sec, TT 16.5±2,0 sec, fibrinojen 325.7 mg/dL and Factor VIII levels were
120,8±11,2%. When the bleeding survey results were analysed, the patients
who have bleeding score below 3 were accepted as minor bleeding. When the
relation between bleeding scores and TKI treatment were evaluated; we
observed that 25,6% of the patients who use imatinib and 20% of the patients
who use dasatinib have minor bleeding symptoms. In Nilotinib treatment group,
no bleeding symptom was observed. In total, 22% of CML patients under TKI
treatment have bleeding symptoms; 17,6% with bleeding score 1 and 4,4%
with bleeding score 2. In platelet function tests, when aggregation was induced
by ADP, epinephrine, collagen and ristosetin, secretion type defect was
observed in 26% of the patients. No correlation was observed between platelet
function defects and minor bleeding symptoms in these patients.
Summary/Conclusions: As a result, platelet agregation disorders can be
observed in CML patients treated with tyrosine kinase inhibitors. However,
platelet dysfunction is not associated with bleeding disorder. Furthermore, the
effect mechanism of tyrosine kinase inhibitors on platelet homeostasis warrants
further investigation.
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ELEVEN-YEAR RESULTS OF THE THERAPY OF CML TYROSINE KINASE
INHIBITOR IN A LARGE INDUSTRIAL CENTER OF SIBERIA
A Lyamkina1,*, T Pospelova1
1Therapy, hematology and transfusiology, Novosibirsk State Medical University,
Novosibirsk, Russian Federation
Background: Modern method of therapy inhibitors tyrosine kinase (ITK) of
chronic myeloid leukemia (CML) allows patients have long-term remission and
life expectancy comparable to the general population. The effectiveness of
treatment depends on the sensitivity of the malignant clone to a medicine, and
from of patient compliance of treatment.
Aims: To evaluate eleven-year results of therapy of chronic myelogenous
leukemia treatment with tyrosine kinase inhibitors.
Methods: For the period of January 2004 and up until now the 103 CML patients
have been observed at the municipal hematology center of Novosibirsk – capital
of Siberia: 39 men (37.9%) and 64 women (62.1%), with age ranging from 16 to
78 years, and the mean value being 43.4±14.15 years, 71.8% patients was includ-
ed in the analysis (74 patients): 71 people in the chronic phase, 3 - in the accel-
eration phase. All patients in the chronic phase started taking the TKI in the first
6 months after diagnosis of CML. Patients in accelerated phase and blast crisis
were diagnosed before 2003, these patients were significantly pre-treated with
various cytotoxic medications and interferons. All patients are receiving treatment
by various tyrosine kinase inhibitors (imatinib at a dose of 400-800 mg per day,
nilotinib at 800 mg per day, dasatinib 80-100 mg per day). In Russia, imatinib
therapy became available only in 2004, as part of the charity program GIPAP (on
treatment 10% of patients). All the patients treatment became available in 2005.
Today in Russia are using generic medications Philachromin® and Genfatinib®,
instead of using original medication Glivec®, their effectiveness requires further
observation. New patients - 10 people (9.7%), they are treated by the TKI less
than 6 months and have not got the analysis. Also excluded from the analysis of
19 people (18.4%) with low compliance to therapy, they have not received an
adequate response to treatment. 22 patients have died: 9 patients in chronic
phase, for reasons not related to hematological malignancies, 13 patients with
low compliance due to the progression of CML.
Results: Administration of a TKI as a first and second line was followed by a
complete clinical and hematological response in 98.5% patients, complete cyto-
genetic response (CCyR) – in 83,1%, major molecular response (MMO) – in
63,1%. In 3 patients AP - clinical and hematological response. Survival was
analyzed in patients administered TKI, as compared to patients not adminis-
tered TKI (data based on the retrospective review of medical records of CML
patients observed at Novosibirsk municipal hematology center for the period of
1999 – 2004). A statistical method of calculating the cumulative fraction of sur-
vivals (Kaplan-Meier) was used to evaluate survival, with p<0,05 established
as the reliability criterion. No medial survival was established in the group
administered TKI, the 11-year survival - 84.8%, the estimated 15-year survival
was 71,2%. Overall event-free survival rate was 57.8%, in the chronic phase -
69.7%. In the group treated with other cytotoxic agents median survival was
4.1 years, the estimated 15-year survival rate - 3%, p <0,000001.
Summary/Conclusions: TKI (оriginal medicine and branded generics) are
considered an effective and safe method of treatment for CML in CP, if the
patient in compliance with all recommendations of the doctor, associated with
a high MMO rate in the chronic phase, which leads to a significant increase in
the overall and event-free survival.
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CML AS PART OF DUAL MALIGNANCIES: POSSIBLE MECHANISMS AND
REVIEW OF LITERATURE
K Sahu*, U Yanamandra, A Khadwal, G Prakash, P Malhotra, S Varma, N Varma
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Internal Medicine, PGIMER, Chandigarh, India
Background: Since the time Imatinib Mesylate has been recommended as
standard of care for chronic myeloid leukaemia, the overall survival of CML
patients is almost equivalent to general population. Improved survival in CML
patients have provided an opportunity to study disease behaviour and its asso-
ciations in long term basis.
Aims: To study the incidence of secondary malignancies in CML and their out-
come.
Methods: We reviewed the medical records of all the CML patients treated
with Imatinib at PGIMER, Chandigarh, India from 2001-2014.
Results: During a 15 year period (Jan 2001 to Dec 2014), a total of 2183
patients of CML were registered with the adult haematology clinic of PGIMER,
Chandigarh of which 1677 patients were included where complete patient details
were available. A total of 15 patients were found to have co-existent second
malignancy with CML. Four patients had CML as the secondary malignancy.
Among 15 patients, three patients had synchronous and 12 had metachronous
malignancy. The median age of the patients was 50y (25-66) at the time of diag-
nosis in this series. Of the 15 patients five were male and rest 10 were female.
None of our patients were on 2nd line TKI (Nilotinib and Dasatinib). Two of these
15 patients were in accelerated phase and none in blast phase at the time of
diagnosis. History of smoking was present in only one patient who developed
bladder cancer and one patient was consumed alcohol in non cirrhogenic doses.
None of our patients had history of any carcinogenic exposure. Median duration
of imatinib therapy in patients with secondary malignancy is 45.5 months (5 to
130 months). Median duration of follow up was in patients with dual malignan-
cies. Two patients with dual malignancies succumbed to their illness because
of blast crisis and one among them was lost to follow up for last 1.5year. None
of the patients of CML succumbed to the co-existing malignancy. In patients
with CML presenting as primary malignancy (patient no 1-8) the median interval
until development of secondary malignancy was 62.3 months (ranged from 8 to
240 months). Whereas, in patients with CML presenting as secondary malig-
nancy the median interval of development of CML was 118.5 months (range 60
to 144 months). None of our patients of co-existent malignancy with CML under-
went bone marrow transplantation. Cumulative incidence of second cancer (all
categories) in our CML patient cohort is 0.0089. Accordingly, within the limitations
of the number of patients which are enrolled in this retrospective analysis, the
total number of cases of cancer could be in accordance with the incidence of
cancer in the Indian population.
Summary/Conclusions: None of our patients of co-existent malignancy with
CML underwent bone marrow transplantation. Cumulative incidence of second
cancer (all categories) in our CML patient cohort is 0.0089. Accordingly, within
the limitations of the number of patients which are enrolled in this retrospective
analysis, the total number of cases of cancer could be in accordance with the
incidence of cancer in the Indian population.
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THE RESULTS OF TYROSINE-KINASE INHIBITORS TREATMENT IN
CHRONIC MYELOID LEUKEMIA PATIENTS ACCORDING TO 2013
EUROPEAN LEUKEMIANET RESPONSE CRITERIA: RUSSIAN SINGLE-
CENTER STUDY
O Shukhov1,*, A Turkina1, E Chelysheva1, G Gusarova1, I Nemchenko1,
A Bykova1, A Abdullaev2
1Scientific and Advisory Department of Chemotherapy of Myeloproliferative
Neoplasms, 2Laboratory of molecular hematology, Federal State Budgetary
Institution Hematology Research Center of Health Ministry of Russian Feder-
ation, Mosсow, Russian Federation
Background: The 2013 European LeukemiaNet (ELN) response criteria define
when to change therapy in the case of treatment failure, when the treatment
with tyrosine-kinase inhibitors (TKIs) of CML patients should be continued (opti-
mal response) and when a careful monitoring is required (warning). To date,
no data presented that show the results of the treatment approach according
to ELN2013 response criteria.
Aims: The aim of the study was to evaluate the results of TKIs treatment in
CML patients according to ELN2013 recommendations.
Methods: The prospective study included 71 adult patients with newly diag-
nosed CML in chronic phase. Baseline demographics characteristics: median
age: 44 years (interquartile range (IQR) 31-57 years); male sex: 51% (n=36);
Sokal score: high 23%, intermediate 27%, low 50%. Baseline treatment: ima-
tinib (IM) 400 mg (n=63), nilotinib (NIL) 600 mg (n=7), dasatinib (DAS) 100 mg
(n=1). The switching to another TKI or increasing doses was performed at
3,6,12 months or late in case of failure according to ELN2013 recommenda-
tions. Therapy was also changed in cases with no early molecular response
(EMR) (BCR-ABL ≤10% at 3 months). Overall survival (OS), cumulative inci-
dence of complete cytogenetic response (CCyR), major molecular response
(MMR) and deep molecular response (MR4 or deeper) were evaluated (Inten-
tion-to-treat analysis).
Results: The failure was recorded in 14 (20%) cases (at 3 months n=6, at 6
months n=3, at 12 months n=2, after 12 months n=2, 1 patient died before 3
month assessment due to progression). Imatinib was a baseline treatment in
all failures. Therapeutic options for failures: increasing dose of IM (600 mg)
n=2, switching to DAS n=5, switching to NIL n=4, 2 patients are currently being
examined before switching. In 6 cases switching or IM dose escalation was
performed because of no EMR (out of failure) (NIL n=3, DAS n=1, IM600 mg
n=2), other reasons (toxicity, late warning): n=4 (NIL n=2, DAS n=2). Median
time to switching after failure detection was 67 days (IQR 36-103 days). Median
follow-up: 19 months (IQR 12-31 months). Still alive: n=69; on IM treatment:
n=44 (64%), on 2nd TKI: n=25 (36%). The 3-yars OS was 96%. Cumulative
incidence of CCyR, MMR and MR4 was 98%, 86% and 73% respectively. Inde-
pendent of switching, cumulative incidence of MR4 was higher in group with
EMR than no EMR: 73% and 22%, respectively (p=0,03) (3 months landmark)
(Figure 1).
Figure 1.
Summary/Conclusions: The principle of early therapy modification in patients
with no optimal response according to ELN2013 response criteria allows to
reach CCyR (the main surrogate endpoint for survival) in almost all cases.
Early molecular response is a predictor of achieving deeper molecular response
not depending on early switching approach.
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OUT OF THE BAG – FUNCTIONAL CHARACTERIZATION OF EX VIVO
EXPANDED MSC
S M Lopes*, A Pinho, F Amado, S Ferreira, F Bordalo, S Roncon
Cellular Therapy, IPO PORTO, Porto, Portugal
Background: Bone marrow (BM) derived mononuclear cells (MNC) are the
starting point of numerous protocols, such as ex vivo expansion of HPC, neuro
and mesenchymal stem cells (MSC). We have previously established that the
BM collection bag and filter system (which are usually discarded) are an alter-
native source of MNC, yielding viable and sterile cells equivalent to 50ml of fil-
tered BM, and should not be considered clinical waste. The viability and func-
tionality of the recovered MNC were evaluated by trypan blue exclusion and in
vitro differentiation into MSC, respectively.
Aims: In order to further validate the applicability of these cells, MSC obtained
were tested for morphology, immunophenotype, ability to hamper alloreactivity
and to differentiate into adipocytes. tyle=’mso-ansi-language:EN-GB’>We have
previously established that the BM collection bag and filter system (which are
usually discarded) are an alternative source of MNC, yielding viable and sterile
cells equivalent to 50ml of filtered BM, and should not be considered clinical
waste. The viability and functionality of the recovered MNC were evaluated by
trypan blue exclusion and in vitro differentiation into MSC, respectively.
Methods: The collection bag and filter system were back-washed and rinsed
with RPMI under aseptic conditions and MNC isolated by density gradient cen-
trifugation. To obtain long term MSC cultures, MNC were cultured in DMEM
media supplemented with foetal bovine serum, at 37ºC and 5% CO2. Cultures
were replated when confluence was reached. MSC morphology was confirmed
with a reverse microscope, and immunophenotype by flow cytometry. To assess
adipogenic differentiation capacity, MSC were cultured in the presence of dex-
amethasone and diclofenac, with adipocytes generation tested by Oil Red stain-
ing of lipid deposits. To evaluate their imunossupressive role a one way MLR
was performed. Briefly, irradiated MNC (stimulator) and CFSE-dyed MNC
(responder) were co-cultured in the presence or absence (control) of MSC.
After 7 days of incubation, proliferation of responder cells was measured by
flow cytometry.
Results: In all cases, filter recovered MNC viability was superior to 90%, and
long term MSC cultures were established, as shown by morphology and
immunophenotype (CD105+, CD44+, CD90+, CD73+, CD45-, CD14-, and
CD34-). To further characterize our MSC lineage differentiation, a hallmark of
MSC, was shown by Oil Red staining of MSC-derived adipocytes. Another char-
acteristic of MSC, down regulation of alloreactivity, was demonstrated in vitro,
with a consistent 20% reduction of proliferating cells. -family:Calibri;mso-bidi-
font-family:”Times New Roman”; mso-ansi-language:EN-GB;mso-fareast-lan-
guage:EN-US;mso-bidi-language:AR-SA’>MSC morphology was confirmed
with a reverse microscope, and immunophenotype by flow cytometry. To assess
adipogenic differentiation capacity, MSC were cultured in the presence of dex-
amethasone and diclofenac, with adipocytes generation tested by Oil Red stain-
ing of lipid deposits. To evaluate their imunossupressive role a one way MLR
was performed. Briefly, irradiated MNC (stimulator) and CFSE-dyed MNC
(responder) were co-cultured in the presence or absence (control) of MSC.
After 7 days of incubation, proliferation of responder cells was measured by
flow cytometry.
Summary/Conclusions: With this study we demonstrated that, from the usu-
ally discarted BM collection bag and filter system, long term MSC cultures can
be established. These cells can be expanded ex vivo, maintaining an appropri-
ate phenotype and functional capabilities, being suitable for both investigation
and clinical settings.
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FUNCTIONAL CAPACITY OF TUMOR LYSATE-PULSED MONOCYTE-
DERIVED DENDRITIC CELLS INDUCING IN VITRO IMMUNE RESPONSES
C Pinho1,*, S Lopes1, F Amado1, A Verdelho2, J Abreu de Sousa3, S Roncon1
1Cellular Therapy, 2Neurosurgery, 3Oncology Surgery, IPO PORTO, Porto, Por-
tugal
Background: Dendritic cells (DC) have been shown to be a promising adjuvant
to initiate antitumor immune responses. Over the last years, several methods
have been developed to isolate DC from cancer patients, ex vivo expand and
pulse them, aiming to generate highly immunogenic clinical grade infusion prod-
ucts.
Aims: In order to validate our previously established in vitro methodology for
DC generation, the present study aims to assess the functional capacity of the
DC final product inducing immune responses. usion products.
Methods: As part of an authorized pre-clinical study with solid tumors, four
experiments were performed using tumor lysates (2 glioblastomas, 1 sarcoma
and 1 breast cancer) for DC stimulation. DC were differentiated from monocytes
obtained from peripheral blood (PB) and subsequently matured and pulsed
with previously prepared tumor lysate, during 8 days of culture in cytokines-
supplemented medium. Loaded mature DC (mDC) were evaluated for cell
counting, viability, morphology and immunophenotype. DC functionality was
evaluated via one-way MLR using peripheral blood mononuclear cells (PBMC)
which were isolated from PB by density gradient centrifugation and pre-labeled
with the ‘green’ fluorescent dye CFSE. The CFSE+PBMC (responder cells)
were co-cultured with mDC (stimulating cells) in a 96-well plate. PBMC without
DC stimulation was used as negative control. In both MLR and negative control,
the same tumor lysate used in DC stimulation was added or not. After 7 days
of incubation at 37°C, 5% CO2, proliferation of responder cells was measured
by flow cytometry.
Results: The single-cell suspension obtained at the end of culture showed:
numerous cells presenting extended and multiple dendrites; up-regulation of
the characteristic maturation markers CD83/CD86; and down-regulation of
CD14, marker of the precursor cells. Taken together these results prove the
achievement of the DC maturation state. These final loaded mDC were
assessed for the antigen presentation skills by their in vitro allostimulatory
capacity of PBMC. The average percentage of proliferating PBMC obtained
when co-cultured with mDC was greater than that verified without DC stimula-
tion (47.7±3.0% vs 19.3±8.4% and 47.0±5.0% vs 8.8±3.5%, with and without
tumor lysate, respectively). Despite the small sample size, DC stimulation con-
sistently induced more than double the PBMC proliferation.
Summary/Conclusions: This study demonstrated the functionality of the mDC
final product to induce in vitro immune responses. With our mDC manufacturing
protocol validated, we are motivated to obtain the legal authorization for the
implementation of this Advanced-Therapy Medicinal Product in clinical grade.
It may be beneficial for the patients to have cell collection, production and
administration available in the same hospital setting.
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CELLULAR IMMUNOTHERAPY: A STORY OF HOPE
A Van De Velde1,2,*, H Daenens3
1Haematology, University Hospital Antwerp, Edegem, 2BIOMAB, University of
Antwerp, 3DigitalStories, Antwerp, Belgium
Background: Narrative medicine is a medical approach that recognises the
value of people’s narratives in clinical practice, research and education. Nar-
rative medicine aims not only to validate the experience of the patient, but also
to encourage creativity and self-reflection in the health care provider and
researcher.
Aims: Rupert Suply, a young adult diagnosed with Ewing Sarcoma, was includ-
ed in a study with dendritic cell vaccination to prolong his second remission
period. This new therapy slowed down the aggressive tumor growth. Because
he is convinced that cellular immunotherapy gave him many extra quality years
and he believes in its future possibilities he knows that his story of HOPE is his
way of contributing to clinical practice and research.
Figure 1.
Methods: In a documentary short film, directed by Hedwige Daenens, we use
narrative medicine to describe our progress of adoptive cellular therapy in dis-
eases where relapse remains a major problem and has an important impact on
survival. Rupert tells us his moving story and guides the audience through the
different steps in making a cancer vaccine. We filmed at the Center for Cell
Therapy and Regenerative Medicine CCRG of the University Hospital Antwerp.
This project was made possible by a collaboration with Biological and Medical
Art in Belgium BIOMAB, based at the University of Antwerp, and the country’s
leading organisation to promote interdisciplinary research between scientists
and those with an interest in the synergy between Art, Science and Technology.
Results: Leukapheresis, DC generation, antigen loading of DCs by electropora-
tion of WT1-encoding mRNA, cryopreservation of WT1 mRNA-electroporated
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DCs, timing of first vaccination, thawing of the DC vaccine, immunisation sched-
ule, route of administration and vaccine dose are described by using documentary
methods in a hospital and research setting. Each procedure is explained in detail
by a qualified member of staff understandable for a general audience. This movie
shows a series of various interactive scenes at different departments, mostly
restricted areas, during Rupert’s path creating his personal cancer vaccine.
Summary/Conclusions: Narrative medicine is a valuable tool to describe cell
collection, processing and therapy. It promotes understanding between
researcher, clinician, nurse and patient, encourages additional therapeutic
options and generates new hypotheses. The documentary A STORY OF HOPE
was presented for the first time at this year’s EBMT meeting (Figure 1).
Hematopoiesis, stem cells and microenvironment
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MAGIC-TT-MEDIATED CELLS TARGET TRANSPLANTATION INTO BONE
MARROW WHICH INCLUDES THE STUDY OF CELL DISTRIBUTION IN
VIVO AND THE EFFECTS OF HEMATOPOIETIC RECONSTRUCTION
H Huang1,*, Q Jiang1, Y Zhou1, Q Zhang1,xSun2, M Zhang2, J Sun1, Q Mai2,
Z Zheng2, Y Lu2, L Liu2, J Majaw2, N Gan3, S Jiang2
1Nanfang Hospital, 2Southern Medical University, Guangzhou, 3Ningbo Uni-
versity, Ningbo, China
Background: Target cell transplantation to bone marrow (BM) is possible by Mag-
netism-induced cell target transplantation (MagiC-TT) (EHA2015posterP701).
Aims: RFP-MSC were used to observe the cell’s distribution and the following
effect, additionally CD45+GFP cells were used to evaluate the promotion of
hematopoietic reconstitution of MagiC-TT.
Methods: 1) Target transplantation of MSC: Fe3O4@PDA@Au nanoparticles
(NPs) were synthesized and introduced into Luciferase gene modified RFP-MSC
(Luc-RFP-MSCs). Magnetized and wt Luc-RFP-MSCs were compared on the
biological feature and their ability of migration ex vivo. Then magnetized RFP-
MSCs were micro-injected into the femur cavity of the mice with the help of X-
ray (Figure 1a), under magnet in M group or without in W group. Biolumines-
cence, FACS, PCR and histopathological analysis were ued after transplantation.
20 eGFP transgenic mice and another 20 C57 mice were used. 2) CD45+cells
transplantation: 34 C57 mice were randomly divided into 2 groups evenly. 7.5Gy
myeloablative irradiation were given 1d before, then CD45+cells were isolated
by MACS from eGFP transgenic mice and freshly micro-injected into right femur,
1×106 cells/20uL per mouse, with or without magnet for 24hrs (M or W group).
At 0h, 24h, 72h after injection, every 3 mice in both groups were sacrificed at
each time point for detection, then remaining 8 mice in both groups were com-
pared with the general conditions, hematopoietic recovery, GFP+cells in different
organs etc.
Results: 1) Target transplantation of MSCs: NPs exist within or on the surface
of magnetized RFP-MSCs (Figure 1b), no obvious change was found. The mag-
netized RFP-MSCs were capable of target migration under magnetism ex vivo.
Bioluminescence assay showed that the magnetized Luc-RFP-MSCs appeared
in the lung of W group 5 min after cell injection, while fixed in the femur of M
group mice. However, on withdrawal of magnet 1h after cell injection, strong
fluorescence was observed in the lung of M group gradually (Figure 1c). By
pathological examinations, FACS and PCR, large number of RFP-MSCs were
observed to reside within the BM in M group while few in W group, thereby
demonstrating the specific BM target transplantation of magnetized RFP-MSCs.
Those RFP-MSCs were found to survive more than 3m in different organs. 2)
CD45+cells transplantation: The mice that survived were 7/8 vs 1/8 in M or W
group respectively (Figure 1d). The GFP% in femurs of both groups (Table 1)
also proved the specific BM target transplantation in M group. Platelet recovery
in M group is faster than that in W group (12.33d±2.42d vs 16.38d±2.39d,
P=0.009); and the lowest value of decreased hemoglobin in M group was higher
than that of W group (43.75±13.02 vs 13.75±5.18, P<0.001).
Figure 1.
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Table 1. Comparison of the percentage of RFP-MSCs in M group and W
group by flow cytometry.
Summary/Conclusions: Fe3O4@PDA@Au NPs rendered MSCs their capa-
bility of target transplantation by MagiC-TT technique. MagiC-TT also helps in
the recovery of PLT after transplantation after CD45+hematopoietic cell trans-
plantation .
PB1847
IMPLICATION OF THE PERCENTAGE OF MACROPHAGES WITH
HAEMOPHAGOCYTOSIS IN THE DIAGNOSIS AND PROGNOSIS OF
PATIENTS WITH HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
T Knight Asorey1,*, C Prats Martín1, RM Morales Camacho1, F Márquez-
Malaver1, O Pérez López1, E Arbelo1, MT Vargas1, T Caballero Velázquez1,
MA Herrera1, J Borrero2, R Bernal1, JA Pérez Simón1
1Haematology and haemotherapy Service, Hospital Universitario Virgen del
Rocio- Virgen del Macarena, 2Department of Pathology, Hospital Universitario
Virgen del Rocio, Sevilla, Spain
Background: Haemophagocytic lymphohistiocytosis (HLH) is a serious con-
dition whose diagnosis is based on clinical,analytical and histopathological cri-
teria established by “The International Histiocyte Society”(IHS) in 2004.
Haemophagocytosis is one of the diagnostic criteria. However,haemophago-
cytosis can also be observed in other disorders in absence of HLH.
Aims: To review a series of patients with HLH and determine the percentage
of macrophages and macrophages with haemophagocytosis observed in bone
marrow aspirate (BMA). To compare the haemophagocytosis in this group with
that observed in patients without HLH. To evaluate the possible impact of both
parameters in diagnosis and survival of HLH patients.
Methods: A retrospective study of 31 patients diagnosed with HLH between
2008-2015.Cytomorphological review was carried out by 2 experienced cyto-
haematologists. The percentage of macrophages was established from a min-
imum sample of 500 nucleated cells and the percentage of haemophagocytosis
from number of macrophages (minimum 30 macrophages).Clinical and analyt-
ical data were gathered concerning diagnosis, treatment and follow-up. A control
group consisting of patients with haemophagocytosis without HLH criteria was
formed. SPSS v19.0 was used for the statistical analysis. Survival analyses
were performed using Kaplan-Meier method.
Results: 31 patients were included:median age 41 (range 6 months-80
years),17 male and 14 female. Underlying diseases were:lymphomas 11/31
(36%); infections 10/31 (32%): 3 EBV, 3 leishmanosis, 2 CMV and 2 leish-
manosis associated to EBV; autoimmune diseases 5/31 (16%); other causes
(solid neoplasm and surgery) 2/31 (6%); idiopathic 3/31 (10%). At diagnosis
30/31 (97%) had fever and 27/31 (87%) had splenomegaly. One cytopenia
was observed in 5/31 (16%), bicytopenia 12/31 (39%) and pancytopenia 14/31
(45%). Biochemical parameters:hyperferritinemia in 20/31 (64%),hypertriglyc-
eridemia in 13/31 (42%),high levels of LDH 17/31 (55%), and hypofybrino-
genemia in 9/31 (29%).From the total, 12 patients (39%) were treated accord-
ing to IHS protocol; 10 (32%) with chemotherapy aimed at lymphoma; 3 (10%)
steroides; 5 (16%) with antibiotics and 1 was not treated. At median of follow
up of 8.2 months,overall survival was 50%. 15 of 31 patients died, 10 of them
(32%) within the first 90 days. 40 patients with haemophagocytosis not attrib-
uted to HLH were used as control group. Underlying diseases were:lym-
phomas 11/40 (27.5%);cytopenias 8/40 (20%);leukaemias 4/40 (10%);plasma
cell neoplasms 3/40 (7.5%);bone marrow failure 3/40 (7.5%);myelodysplastic
or myeloproliferative syndromes 3/40 (7.5%);infections 2/40 (5%);other causes
6/40 (15%).The average of macrophages in patients with HLH was 1.5%
(range 0.5-90%) compared to 1% (0.2- 35%) in the control group (p=0.25).
The average percentage of macrophages with haemophagocytosis in patients
with HLH was 25% (range 0.5-75%) compared to 3.5% (0.5- 60%) in control
group (p<0.001). In the group of patients with HLH, those who had a percent-
age of macrophages >1.5% had a median survival of 99 days compared to
243 days for those with lower percentage (p=0.76). Patients with percentage
of macrophages with haemophagocytosis >25% had a survival rate of 107
days compared to 190 days for those who had a percentage lower than 25%
(p=0.45).
Summary/Conclusions: The percentage of macrophages observed in BMA
in patients fulfilling criteria of HLH is similar to that of patients without HLH.
However, there are significant differences in the percentage of macrophages
with features of haemophagocytosis. This information could be useful in the
differential diagnosis. Among patients with HLH, a trend towards a lower
median survival was observed in those with the highest percentage of
macrophages as well as in those with a higher percentage of haemophago-
cytosis.
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BIOSIMILARS OF FILGRASTIM – ZARZIO® - ASSOCIATED TO PLERIXAFOR
ARE EFFECTIVE FOR MOBILIZATION IN LYMPHOMA PATIENTS DEFINED
AS HARD TO MOBILIZE
A Tempescul1,*, V Rebiere1, M Zdrenghea2, C Tripogney3, JC Ianotto1
1Clinical Hematology, Teaching Hospital Brest, Brest, France, 2Clinical Hema-
tology, UMF Cluj, Cluj-Napoca, Romania, 3EFS site de Brest, EFS Bretagne,
Brest, France
Background: he biosimilars of G-CSF are the object of debates on their effi-
ciency and their harmlessness princeps medicine. Their use and efficiency for
mobilization of the peripheral stem cells (CSP) were less studied. Even less
informations are available on the association of biosimilars and Plerixafor in
view of the peripheral stem cells harvest in patients defined as hard to mobilize. 
Aims: We present our experience on the association of Zarzio ®-Plerixafor for
mobilization of lymphoma patients, define as hard to mobilize, with the aim of
obtaining of a sufficient graft for an autologous stem cell transplantation.
Methods: Between January, 2012 and December, 2014, we identified 18
patients, 9 mens and 9 women with an average age of 53 years (22-69 years)
which benefited from a harvest of the peripheral stem cells at University hospital
Brest, France. The patients underwent stimulation by Zarzio ® 30MUI two injec-
tions a day, during 5 days (D-4 has D0) and Plerixafor 0.24mg/kg starting at
day 0 J0. The stimulation was pursued until the obtaining of a sufficient graft
(defined as more than 2.5 millions CD34+/ kg) or for a maximum of 3 consec-
utive days. We collected for the patients the number of aphaeresis per patient
and the number of the CD34+cells harvested by aphaeresis and by patient.
Results: All in all we have made 39 aphaeresis in 18 patients that underwent a
double stimulation. The average number of aphaeresis per patient was of 2.16
sessions (1-3/patient). Two patients benefited from a single session of aphaeresis,
eleven patients benefited from two sessions of aphaeresis and five patients of
three sessions of aphaeresis. For twelve of eighteen patients (66.7%) we
achieved the target of a sufficient graft according to the local consensus (2.5x106
CD34+/ kg). For 14 of 18 patients (77.8%) there was a sufficient according to the
recommendations EBMT (2x106 CD34+cells/kg) on the minimum necessity has
the autograft.The average number of CD34+taken by aphaeresis was 1.58x106
cells/kg (0.22-6.31x106 CD34+cells/kg). The total average number of the
CD34+cells harvested per patient was 3.41x106/kg (1.5-6.77x106 CD34+cells/kg).
Summary/Conclusions: We analyzed in a cohort of 18 lymphoma patients
defined as hard to mobilize the results of the peripheral stem cell harvest
obtained after stimulation by plerixafor associate to a biosimilar of filgrastim -
Zarzio ®. We obtained a sufficient graft in 77% according to international rec-
ommendation with a limited number of aphaeresis procedure – 2.1 aphaeresis
per patient. The results obtained by associating Zarzio® and Plerixafor for
peripheral stem cell harvest in lymphoma patients defined as hard to mobilize
are comparable with those obtained with products princeps and publish in the
literature.
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THE ROLE OF ENDOTHELIAL CELL-EXPRESSED ΑLPHA HEMOGLOBIN
AND ITS MOLECULAR CHAPERONE AHSP IN BLOOD PRESSURE
REGULATION
C Lechauve1,*, L Biwer2, A Freiwan1, S Frase3, H Tillman4, B Isakson5, M Weiss1
1Hematology, St. Jude Children’s Research Hospital, Memphis, 2University of
Virginia, Charlootesville, 3Cellular Imaging, 4Veterinary Pathology, St. Jude
Children’s Research Hospital, Memphis, 5Molecular Physiology and Biophysics,
University of Virginia, Charlootesville, United States
Background: Because hypertention is the leading indicator of cardiovascular
disease, understanding the blood pressure regulation and regional blood flow
to specific vascular beds is of great medical importance. We have recently
hypothesized a new mechanism for blood pressure regulation mediated specif-
ically by the alpha subunit of hemoglobin (αHb) [1].
Aims: The α subunit (but not the β subunit of Hb) is expressed in endothelial
cells (ECs) within the myoendothelial junction (MEJ), a structure in resistance
arteries where ECs and smooth muscle cells (SMCs) cross-communicate to reg-
ulate vascular tone. In the MEJ, αHb is proposed to degrade NO via the dioxy-
genase reaction and thereby increase vascular tone. Moreover, aHb forms a
complex with endothelial nitric oxide synthase (eNOS, the major local source of
NO production) and cytochrome B5 reductase (CYB5R3) an enzyme that reduces
ferric αHb to favor dioxygenase activity [1-3]. Alpha hemoglobin stabilizing protein
(AHSP) is a molecular chaperone that binds free αHb, stabilizes its structure and
also regulates its redox state, at least in the context of red blood cells [4,5]. Free
αHb is extremely unstable and would not be expected to exist without a binding
partner in cells. Moreover, we showed previously that AHSP converts bound fer-
rous αHb into a stable hexacoordinate ferric form that lacks ability to degrade NO
[6,7]. Based on this data, we hypothesized that AHSP both stabilizes αHb and
regulates its redox state and dioxygenase activity in vascular ECs.
Methods: We investigated this hypothesis by using vascular cell co-culture
model composed of human coronary ECs and SMCs, and Ahsp-/- and alpha
thalassemic mice strains.
Results: Our studies demonstrate that αHb interaction with AHSP and eNOS
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is mutually exclusive and αHb protein expression is disrupted in Ahsp-/- and
alpha thalassemic ECs, resulting in reduced arterial tone, lowered blood pres-
sure and abnormal arterial structure.
Summary/Conclusions: Through these mechanisms, AHSP-bound αHb may
regulate blood vessel tone dynamically according to ambient conditions and
CYB5R3 availability.
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THE “NORMOBARIC OXYGEN PARADOX”: INFLUENCE OF NEW
MODELS ON THE EVOLUTION OF ERYTHROPOIETIN, RETICULOCYTE
COUNT AND HEMOGLOBIN CONCENTRATION IN PATIENTS UNDERGO-
ING BREAST RECONSTRUCTION SURGERY
R Calabrese1,*, M Khalife1, J Valsamis2, C Balestra3, F Urbain4, M Sosnowski1
1Anesthesiology, Institut Jules Bordet, 2Clinical Biology, CHU-Brugmann,
3Divert Alert Network (DAN), Europe Research Division, 4Plastic and Recon-
structive Surgery, Institut Jules Bordet, Brussels, Belgium
Background: The “Normobaric Oxygen Paradox” (NOP) is a physiologic mech-
anism that induces an increase of endogenous erythropoietin (EPO) production
by creating a state of relative hypoxia in subjects previously exposed to a period
of normobaric hyperoxia, followed by a rapid return to normoxia. To date, the
oxygen exposure duration and the inspired oxygen fraction required to observe
a significant increase in hemoglobin or EPO production are not clearly defined.
Aims: This study sought to observe the effect of two models of relative hypoxia
compared to a control group on EPO, reticulocytes and hemoglobin stimulation
through the NOP theory in patients undergoing breast reconstruction surgery.
Figure 1.
Methods: After local ethic committee approval and obtaining written informed
consent, thirty patients undergoing deep inferior epigastric perforator (DIEP)
flap breast reconstruction were prospectively randomized into 3 groups. Nine
patients were excluded from analysis for lack of results and/or patient with-
drawal. The first group (G1; n=7) was exposed to 5 L O2/m for 60 minutes per
day through a nasal cannula from day one to day nine postoperatively. The
second group (G2; n=6) was similarly exposed to O2, but on alternate days,
while the third group (G3; n=8) served as control. All groups recived FiO2=50%
during surgery. Serum EPO was measured on day 0 and postoperatively on
days 2, 3, 4 and 9. Serum hemoglobin level and reticulocyte count were meas-
ured on day 0 and postoperatively on days 7 and 9. Taking the initial value as
100%, percentage changes in EPO and reticulocytes were calculated, thereby
allowing an appreciation of the magnitude on change rather than the absolute
values. We used a two-way analysis of variance (ANOVA) for repeated meas-
ures to test the variation between groups and over time.
Results: We noticed a pic% EPO elevation at days 3 and 4 with no significant
difference between the groups (Figure 1A). At day 9,% EPO in G1, G2 and G3
was 649,1±295,6; 478,5±305,1 and 406,1±124,6 mIU/mL respectively (p>0,05)
(Figure 1B). However, the% EPO at day 9 in G1 tended to be more elevated
compared to G2 and G3. At day 9, reticulocyte count was more elevated in G1
compared to G2 and G3 (Figure 1C). Hemoglobin level in G1, G2 and G3 was
10,04±0,77; 10,73±1,14 and 10,64±0,96 g/dL respectively (Figure 1D).
Summary/Conclusions: Relative hypoxia seems to be a stimulus for EPO
production in all our groups. However, further studies are needed in non-sur-
gical patients with larger sample size and longer follow-up to determine its real
impact on hemoglobin.
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THE RELATIONSHIP BETWEEN BONE MARROW STROMAL
FIBROBLASTS, MYELOGRAM PERFORMANCE AND EFFICIENCY OF
CHEMOTHERAPY IN CHILDREN WITH ACUTE LEUKEMIA
K Bruslova1,*, N Tsvietkova1, L Panchenko2, L Lyashenko3, T Pushkareva1,
S Yatsemyrskyy1, O Kuznetsova1
1Radiation Hematology for Children, SI “National Research Center for Radiation
Medicine of NAMS of Ukraine, 2SI”Institute of Traumatology and Orthopedics
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NAMS of Ukraine, Kiev, Ukraine
Background: Tumor microenvironment plays an important role in cancer ini-
tiation and progression. The cancer associated fibroblasts impact on resistance
development to chemotherapeutic agents in the treatment of acute leukemia
(AL) discussed.
Aims: The aim of the study was to determine the relation between colony-
forming efficiency of bone marrow stromal fibroblasts, myelogram parameters
and effectiveness of chemotherapy (CT) in children with lympho- and myelo-
variants of acute leukemia (ALL, AML).
Methods: The study involved 38 children: ALL - 24, AML - 14. Age of children
ranged from 6 to 18 years. Treatment was performed by standard protocols.
Investigation of patients executed in complete remission phase after full
chemotherapy course of primary diagnosis leukemia. Retrospective surveil-
lance was conducted for 15 years. The effectiveness of chemotherapy evalu-
ated by presence/absence of AL relapse. Among patients with ALL the relapse
stated in 8 persons, among AML - in 7 children. Efficiency of bone marrow stro-
mal fibroblast colony-forming units (E -CFUf) in vitro, myelogram performance
were studied. Spearman correlation coefficient, U- test were used.
Results: E-CFUf not depend on the variant of acute leukemia (Uemp.=61.5).
In patients with AL we found the inverse correlation between the E-CFUf index
and the percentage of erythroblasts (Rs=- 0,52) and monocytes (Rs=- 0,45) in
the bone marrow. The direct connection between the number of monocytes
and erythroblasts in myelogram defined (Rs=+0,59), probably because of their
joint operation in the development of erythroid elements of hematopoiesis. The
inverse correlation(Rs=-0,44) between the percentage of monocytes in patients
myelogram and AL relapse occurence was found.
Summary/Conclusions: The inverse correlation between stromal fibroblasts
and erythroblasts as monocytes in the bone marrow of AL children indicates
the regulatory role of stromal microenvironment elements in the functioning of
hematopoiesis in the development of malignancy. Discovered correlation
between relapse development and the number of monocytes in the AL patients
bone marrow after end of protocol treatment opens up further possibilities to
determine the mechanisms of chemoresistance formation at AL and review the
ways to prognose the effectiveness of treatment of such patients.
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APHERESIS COLLECTION OF MOBILIZED HEMATOPOIETIC STEM
CELLS FROM PERIPHERAL BLOOD IN HEALTY DONORS – 15 YEARS
OF EXPERIENCE
R M Grubovic1,*, L Cevreska2, B Georgievski2, S Genadieva-Stavric2,
A Stojanovic2, S Useini3, A Pivkova2, Z Stojanoski2, E Petkovic3, L Cadievski2,
M Grubovic3
1Head of Stem Cell Collection, Institute for Transfusion Medicine of RM, Medical
Faculty - Skopje, 2University Hematology Hospital, 3Institute for Transfusion
Medicine of RM, Medical Faculty - Skopje, Skopje, Macedonia
Background: Mobilized hematopoietic peripheral blood stem cell (PBSC) has
been widely used for allogeneic transplantation in different hematologic malig-
nancies. Optimal donor and recipient outcomes require maximized stem cell
collection efficiency.
Aims: The aim of our study is to present our experience of 15 years in collecting
of PBSC in healthy donors.
Methods: This is a retrospective study performed in the Institute for Transfusion
Medicine of Republic of Macedonia and University Hematology Hospital for
period from January 2001 till December 2015. All donors were HLA typed and
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matched; they were fully informed on the donation procedure and signed an
informed consent for donation. Minimum dose required to ensure successful
and sustained engraftment was 2x106/kg CD34+cells and 2x10^8/kg mono-
nucleated cells (MNC). PBSC harvesting was performed with continuous flow
cell separator Baxter C53000 and COBE Spectra using conventional-volume
apheresis processing the 2 – 2.5 total blood volumes per apheresis. A femoral
catheter was used for harvesting and Acid Citrate Dextrose formula A is used
for anticoagulation. Recombinant human granulocyte colony-stimulating factor
(G-CSF) is used to mobilize PBPC for collection. Harvesting of PBSC is usually
performed after 4 to 5 days of G-CSF subcutaneous administration at a dose
of 10 μg/kg body weight.
Results: All the donors were siblings of the patients treated at the University
Hematology Hospital. There were 126 apheresis procedures performed in 74
healthy sibling donors. There were 48 males and 26 females, aged 19-55. The
single procedure usually took 3-4 hours and the volume of collected stem cells
was 50-220 ml. The needed number of MNC and CD34+cells was successfully
collected by 1.7 apheresis (range 1-2). There were 9 ABO incompatible donors.
Procedures for mobilization and collection of PBPC from healthy donors are
generally well tolerated. The only adverse effects of the apheresis procedure
were bone pain as reaction of G-CSF and numbness of the extremities as reac-
tion of ACD-A (hypocalcemia), which occur rarely and were very mild. The col-
lected PBSC were used in allogeneic stem cell transplantation in patients with:
acute myeloid leukemia – 61.3%, acute lymphoblastic leukemia – 17.7%, chron-
ic myeloid leukemia – 9%, myeloproliferative disorders – 4.1%, severe aplastic
anemia – 2.7%, non-Hodgkin lymphoma – 2.7%, chronic lymphoblastic
leukemia - 1.3%, Hodgkin disease – 1.3% and multiple myeloma – 1.3%.
Summary/Conclusions: The apheresis collection of PBSC in healthy donors
is an effective and safe procedure. We are developing a National Stem Cell
Donors Registry as a part of Bone Marrow Donors Worldwide. In that way we
hope we will help widen the world network of stem cell donors and enlarge the
possibility for each patient to find the right match.
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PERFORMANCE EVALUATION OF Q-FLAG OF HEMATOLOGY ANALYZER,
SYSMEX XN-20
HR Kim*, OJ Kweon
Chung-Ang University College of Medicine, Seoul, Korea, Republic Of
Background: The Sysmex XN modular analyzer (Sysmex, Kobe, Japan), which
were introduced in 2011, applied several new analysis channels compared to
previous analyzer, XE series. White cell precursor channel (WPC), one of the
new channels, adopted fluorescence flow cytometry technology and developed
especially for detecting myeloblasts or lymphoblasts more accurately than any
other channels applied in previous modules.
Aims: Our study aim to investigate the flagging performance of Sysmex XN-
20 modular analyzer focusing on the Q values.
Methods: We investigated the performance of Q values flagging according to
interinstrumental agreement, intrainstrumental precision, and diagnostic accu-
racy. Tested suspect flags are “blasts/abnormal lymphocytes”, “atypical lym-
phocytes” from white cell differential channel, and “blasts” from white cell pre-
cursor channel.
Results: In interinstrumental agreement evaluation, two XN modules showed
significant Q value correlation for each suspect flags although Pearson’s cor-
relation coefficient for “blasts/abnormal lymphocytes” and “blasts” flags were
too low; they were 0.28 and 0.29. However, from Pearson’s chi-square tests,
there were significant difference in flagging performance between two analyzers
for all of each flags (P<0.01 for all of tested flags). Absolute agreement rates
were ranged from 65.0% to 83.5%, and kappa values were ranged from 0.305
to 0.501. In intrainstrumental precision evaluation, for the specimens with Q
value of 50-150, standard deviations were ranged from 4.8 to 23.9 for
“blasts/abnormal lymphocytes” flag, from 18.7 to 59.1 for “blasts” flag, and from
11.0 to 23.0 for “atypical lymphocytes” flag during 10 replicates. For diagnostic
accuracy, in the default Q value cutoff setting (Q value of 100), sensitivities and
specificities for “blasts/abnormal lymphocytes” flag were 90.1% and 73.8%, the
values for “blasts” flag were 92.1% and 86.3%, and the values for “atypical
lymphocytes” flag were 70.0% and 89.9%, respectively.
Summary/Conclusions: We recommend to adjust the Q value threshold set-
ting for “blast/abnormal lymphocyte”, “blast” and “atypical lymphocytes” because
of their inadequate diagnostic accuracy of default threshold setting. However,
their poor intrainstrumental precision and interinstrumental agreement weaken
the reliability of Q value flags.
Hodgkin lymphoma - Clinical
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SURVIVORSHIP PROGRAM: SECOND MALIGNANCIES IN LYMPHOMA
SURVIVORS
MP Simula1,*, AM Mamusa1, S Usai1, E Montaldo2, E Angelucci1
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Background: Improvements in the treatment of both Hodgkin’s (HL) and non
Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long
term survivors. However this patient’s population is at high risk of developing
late therapy related complications that can negatively affect long term survival
and quality of life.
Aims: In our institution the HL and aggressive NHL long term survivors are fol-
lowed up in a dedicated clinic since September 2014. Here we report prelimi-
nary data on second malignancies.
Methods: We have collected retrospective data on second tumours in 469 con-
secutive lymphoma survivors.
Results: We have analyzed data regarding 469 patients coming in our clinic
from 15 September 2014 to 18 February 2016, 247 have been successfully
treated for HL and 222 for nHL. Two hundred thirty three were females, 236
males; median of age at lymphoma diagnosis was 29 years for HL (range 13-
84) and 48 years for nHL (range 12-83). Median age at last observation in the
follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range
24-88).The median of duration of follow up was 18 years for HL (range 5-40)
and 13 years for nHL (range 5-37).Sixty two patients (13%) experienced a sec-
ond cancer, 4 of them had 2 neoplasms, so we documented 66 second tumours
(Table 1). They were: 23 skin (35%) and 43 non cutaneous cancers (65%). The
non skin neoplasms were: 10 breast, 9 gastroenteric, 8 thyroid, 6 prostatic, 1
lung, 4 bladder, 1 renal, 1 tongue, 1 testis 1 gynecological metastatic, and 1
cutaneous appendages malignant cancers (Table 2). Four of these tumours (2
colon, 1 thyroid and the metastatic gynecological one) have been diagnosed
with our program of early diagnosis of second cancers and thyroid dysfunctions.
The median of time between diagnosis of lymphoma and diagnosis of second
malignancy was 18 years (range 1-41). Regarding the previous therapies: medi-
astinal radiotherapy has been administered to 7 out of 10 of the females with
breast cancer (70%), mantel or neck radiotherapy to 6 out of 8 (75%) with thy-
roid cancer; no one of the intestinal and prostatic cancers have received abdom-
inal radiotherapy; one out of 4 of the patients with urinary cancer (25%) had
abdominal radiotherapy and MOPP/ABVD regimen; the one with lung cancer
had MOPP chemotherapy and mantle radiotherapy. Chemotherapy has been
administered for the treatment of lymphoma to 6 with breast (60%), to 7 with
thyroid (88%), to all with gastroenteric (100%), and to 4 with bladder cancers
(67%). Median of age of breast cancer in our setting was 50 years (range 38-
70), of thyroid cancer was 40.5 years (range 24-55), and of gastroenteric cancer
was 66 years (range 42-83). Moreover we have documented relapse of their
original lymphoma in 3 patients (2 HL and 1 nHL) respectively at 9, 22 and 28
years after initial diagnosis.
Table 1. Features of patients with second neoplasms.
Table 2. Type of second malignancies in our lymphoma survivor patients.
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Summary/Conclusions: In our Department we described a significant number
of cases of second neoplasms in the lymphoma survivors population: 4 of these
(9% of non cutaneous cancers) were detected by tests done for early diagnosis
of late complications. These results outlne the importance of a risk adapted
plan for early diagnosis of cancers in this setting of patients that would be
encouraged by both hematologist and general practitioners.
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GEMCITABIN, VINORELBINE AND PREDNISOLONE (GVP)±RITUXIMAB
COMBINATION IN RELAPSED/REFRACTORY LYMPHOMA CASES:
RETROSPECTIVE ANALYSIS
S Paydaş1,*, E Bagir2, M Ergin2
1Medical oncology, 2pathology, Çukurova University, Adana, Turkey
Background: Lymphomas are heterogenous group of disorders and relapse
is not infrequent after standard chemotherapy regimens. Salvage regimens
are used to determine the chemosensitivity before stem cell transplantation.
GVP combination is one of the salvage regimens used as in cases with
relapsed /refractory Hodgkin Lymphoma (HL) or non- Hodgkin Lymphoma
(NHL).
Aims: The aim of this study is to evaluate the results of Gemcitabin, vinorelbine
and prednisolone GVP plus minus Rituximab regimen in cases with lymphoma
treated by GVP.
Methods: Thirty seven cases with lymphoma were included in this analysis.
Age range was between 18-77, male female ratio was 20/17. Twenty one of
the cases had HL and 16 had NHL. Among NHL, 8 had diffuse large B cell lym-
phoma (DLBCL), 3 had peripheral T cell lymphoma (PTCL), 3 had indolent
NHL (iNHL), 2 had transformed NHL and one had anaplastic large cell lym-
phoma. All the cases had been treated by standard first line chemotherapy
regimens. Results were analyzed retrospectively.
Results: The most commonly used 1st line salvage regimen was DHAP±Rit-
uximab. GVP±Rituximab was used as 1st line, 2nd line and after than 4th line
setting in 7, 28 and 2 cases, respectively. Response to 1st line GVP±Rituximab:
complete response (CR) was detected in 1 case, partial response (PR) in four
cases, minimal response (MR) in one case and progressive disease (PD) in
one case. Response to 2nd line GVP±Rituximab: CR, PR and PD were detect-
ed in 5, 9 and 14 cases, respectively. Responses according to lymphoma sub-
types: 1st line GVP setting CR, PR and PD were detected in 1, 1, 1 cases with
HL and PR and MR in 3 and 1 cases with NHL. In 2nd line GVP setting CR,
PR and PD were detected in 5, 6 and 7 cases with HL and 1, 2 and 8 cases
with NHL, respectively.
Summary/Conclusions: GVP as salvage regimen in second line setting,
although the number of the cases treated in 1st line setting is limited, is a rea-
sonable choice with 50% overall response rate in cases with HL but not in NHL.
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LYMPHADENOPATHY WITH ELEVATED IGG4 PLASMA CELLS IN
CHILDHOOD: A POSSIBLE ASSOCIATION WITH MALIGNANCIES OR
IMMUNE MEDIATED DISEASES
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bino, Azienda Ospedaliera-Università di Padova, Padova, 3Dipartimento di
Patologia, Ospedale San Bortolo, Vicenza, Vicenza, 4Dipartimento di Patologia,
Università degli Studi di Padova, 5Unità di Chirurgia Pediatrica, Dipartimento
della Salute della Donna e del Bambino, Azienda Ospedaliera di Padova,
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Background: IgG4 related disease (RD) is a fibroinflammatory condition, iden-
tified in 2003, that can involve every organ and apparatus. The diagnostic cri-
teria for IgG4 (RD) are based on three characteristics of the disease: organ
enlargement or nodular lesions in different organs, increase of serum IgG4
and infiltration of IgG4 plasma cells. The most frequent disease manifestations
are autoimmune pancreatitis, sialadenitis, dacryoadenitis and retro-peritoneal
fibrosis; IgG4 related lymphadenopathy is rare. Differential diagnosis of IgG4
RD are malignancies and autoinflammatory diseases. It is usually diagnosed
in middle and senile aged men; only few pediatric cases in literature are
described, and the organs involved are orbits, lungs, mediastinum and
abdomen. Lymphadenopathy of IgG4 (RD) is often the first manifestation of
the disease, that could progress and involve any organ; a disease localized
only in lymph nodes is rare and poorely characterized. No pediatric cases of
IgG4 related lymphadenopathy or association with malignancies or other
immune-mediated disorder are described in literature.
Aims: To describe for the first time two pediatric cases of lymph node histological pat-
tern of IgG4 (RD) with association with lymphoma and immune-mediated disease.
Methods: Data of the two pediatric patients were retrospectively reviewed.
The specimens for the histological analysis were centrally reviewed.
Results: Data of two patients with a histological pattern of IgG4 lymphadenopathy
were analyzed. Both of them had a history of persistent lymphoadenopathy.
Patient #1, a 11 years old male, with normal serum IgG4 concentration, had a
first cervical lymph node biopsy with the evidence of progressive transformation
of germinal centers and a high number of IgG4 plasma cells; two months later,
for increasing of lymph nodes dimension, he had a second biopsy and the diag-
nosis of nodular lymphocyte predominant Hodgkin Lymphoma (HL) was made.
He was treated with three cycles of prednison, vinblastine and cyclophosphamide,
obtaining a complete remission (follow-up: 18 months). Patient #2, a 18 years
old male, with a personal history of asthma and atopic dermatitis, had a persistent
neck lymphadenopathy after 8 years from an infectious mononucleosis. He had
high serum IgG4 concentration. Histology showed follicular hyperplasia and
increased IgG4 plasma cells in germinal centers. Following analysis evidenced
elevated (10%) double negative TCR alpha-beta positive T cells, suggesting the
diagnosis of Autoimmune Lymphoproliferative Syndrome (ALPS). Fas-mediated
apoptosis assay is currently ongoing.
Summary/Conclusions: We described for the first time 2 pediatric cases with
with histological lymph node characteristics usually found in IgG4 (RD); in par-
ticular in one patient this finding was associated with a nodular lymphocyte
predominant HL, in another patient with clinical and hematological features
suggestive of ALPS. The significance of this histological finding in adult patients
with isolated lymphadenopathy is still unclear and rare correlations with lym-
phomas and with autoimmune diseases are reported. Our data suggest that
also in childhood this pattern is not specific for IgG4 RD but may be present in
different malignant and non malignant disorders. A careful throughout exami-
nation and follow-up should be carried out in patients affected by IgG4 RD or
with lymph node biopsy showing the IgG4 features, to monitor the possible
development of lymphoma and other immune mediated diseases.
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LATE RELAPSE OF HODGKIN LYMPHOMA – IS IT DIFFERENT IN
CLINICAL CHARACTERISTICS AND OUTCOME?
O Markovic1,*, B Andjelic2, O Tarabar3, M Todorović2, B Filipović1, J Bila2,
D Antić2, D Marisavljevic1, B Mihaljević2
1Hematology, Clinical Hospital Center “Bezanijska kosa” Medical Faculty Bel-
grade, 2Hematology, Clinic of Hematology, KCS, 3Hematology, Military Medical
Academy, Beograd, Serbia
Background: Relapse of Hodgkin lymphoma usually occur in 20-30% patients.
The disease relapse usually occur within the first 5 years after the diagnosis,
with the trend of the diminishing after three years ans subsequently, only minor-
ity relapses after 5 years.
Aims: The aim of this study was to evaluate the clinical characteristics, prog-
nostic factors, therapy and outcomes of patients with late relapse (>5 years).
Methods: We retrospectively analyzed clinical presentation, the prognostic
significance of clinical parameters, therapy and outcome in the group of patients
with very late relapse of Hodgkin lymphoma and compare them with patients
who relapse earlier.
Results: In group of 102 patients with relapsed Hodgkin disease 16(15.68%)
patients had very late relapse of disease. Median time to very late relapse was
86 months (range 61 to 199 months). Most of these patients (11, 68.5%) were
in advanced clinical stage (III, IV). 11(68.75%) patients with very late relapse
were treated with high dose chemotherapy and autologous bone marrow trans-
plantation. Second complete response was achieved in 13(81.25%) patients.
At a median of 4,5 years after therapy for very late relapse, 13(81.25%) patients
are still alive and free of disease and 3 patients died: 2 patients from Hodgkin
lymphoma, and one patient from brain tumor. There was not noticed significant
difference between initial clinical parameters between of patients with very late
relapse and patients who relapse earlier. Median survival of patients with very
late relapse of disease was significantly longer (p=0.001). However, survival
calculated from the moment оf relapse of disease was not significantly different
between these two group of patients (p=0.83).
Summary/Conclusions: The late relapse is relatively rare event in our group
of patients with Hodgkin lymphoma. Patients with very late relapse have longer
OS, than the patients who relapse earlier, but survival calculated from relapse
was not significantly different. Remains an open question is it necessary to
apply high dose therapy and autologous transplantation in all patients with very
late relapse of disease. Further clinical trials are needed to characterize best
therapy option in patients with very late relapse tailored to disease risk and
comorbidities.
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LYMPHOMA SURVIVORSHIP AND CARDIOVASCULAR DISEASES
SURVEILLANCE
MP Simula1,*, AM Mamusa1, S Usai1, G Locci2, E Angelucci1
1Struttura Complessa di Ematologia e Centro Trapianti. Ospedale Oncologico
di Riferimento Regionale. Cagliari, Italia, 2Struttura Complessa di Cardiologia,
AOB Cagliari, Cagliari, Italy
Background: Improvements in the treatment of Lymphomas have resulted in
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an increasing number of long term survivors. This patient’s population is at risk
of developing late therapy related complications that can negatively affect their
survival and quality of life.
Aims: In our institution since September 2014 the Hodgkin’s (HL) and aggres-
sive non Hodgkin’s Lymphomas (nHL) long term survivors are followed up in a
dedicated clinic aimed to detect long term clinical problems that can affect peo-
ple undergone previous radiation therapy and/or chemotherapy.
Methods: We had planned electrocardiographic and echocardiografic evalua-
tion in patients without known cardiological problems.
Results: We have analyzed data regarding consecutive 469 patients coming
in our clinic from 15 September 2014 to 18 February 2016, 247 have been
treated for HL and 222 for nHL. Two hundred thirty three were females, 236
males; median of age at diagnosis was 29 years for HL (13-84), 48 years for
nHL (12-83); median of age at last observation in the follow up clinic was 50
years for HL (range 21-89) and 62 years for nHL (range 24-88). The median of
duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL
(range 5-37). Thirty seven of our patients had cardiovascular disorders before
the diagnosis of lymphoma. The cardiac function has been studied in three
hundred sixty one of our patients. Two hundred twenty five out of 361 (62%)
developed cardiac abnormalities of different type and severity in the period fol-
lowing treatment for their lymphoma (Table 1 and Table 2). They were 124
females (55%) and 101 males; 126 had previous HL (56%) and 99 nHL.The
median age at cardiovascular disease detection was 54 years (range 20-83).
The median time between diagnosis of lymphoma and diagnosis of cardiovas-
cular diseases was 14 years (range 0-43).The most common cardiac distur-
bances described were valvulopathies of different type and grade (95), arterial
hypertension (76) and ischemic cardiopathy (32); some patients had more than
one alteration. Moreover 77 out patients showed a diastolic relaxation abnor-
mality without ventricular dysfunction which whose the only alteration detected
in 33 cases.
In 114 patient abnormalities were first detected during screening in asympto-
matic condition: in fact we had planned electrocardiographic and echocardio-
grafic evaluation in 206 patients without known cardiological problems. One
hundred fourteen out of 206 screened (55%) showed previous unknown cardiac
disturbance. Regarding the previous therapies: mediastinal radiotherapy had
been administered in 64 of patients with valvulopathies (and in all with only cal-
cification) (67%), in 13 with ischemic cardiopathies (41%) and in 33 with diastolic
relaxation abnormality (43%); chemotherapy antracycline-based had been
receveid by 77 with valvulopathies (81%), by 19 with ischemic cardiopathies
(60%) and by 73 with diastolic relaxation abnormality (95%).
Table 1. Feature of survivors patients.
Table 2. Type of cardiovascular disorders in the lymphoma survivors (225
patients).
Summary/Conclusions: Our analysis confirms that a high percentage of
patient survived to lymphomas can develop cardiovascular diseases and outline
the importance of cardiac surveillance.Their monitoring would be promote
because can detect asymptomatic structural and functional anomalies as dias-
tolic relaxation abnormality considered an early sign of cardiomyopathies.
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OSTEONECROSIS DETECTED BY WHOLE BODY MAGNETIC
RESONANCE IN PATIENTS WITH HODGKIN LYMPHOMA TREATED BY
BEACOPP
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Background: The treatment of Hodgkin Lymphoma (HL) has led to the pro-
gressive achievement of high survival rates over the last years . ABVD regimen
has been considered for a long time the standard treatment for advanced-stage
HL patients, due to well documented efficacy and a favourable toxicity profile.
Several studies demonstrated the increase of progression-free survival rates
by using BEACOPP regimen compared to ABVD, especially in advanced-stage
disease, at the cost of increased toxicity. Osteonecrosis (ON) is a complication
of chemotherapy that may compromise the patient’s quality of life and it is often
identified in advanced stages when the only available treatment is joint replace-
ment. The use of corticosteroids is one of the most common risk factors, respon-
sible for 10-30% of cases of ON.
Aims: The purpose of this retrospective study was to assess the frequency of
ON with the Whole Body MRI (WB-MRI) scans performed on patients with HL
treated by different chemotherapy regimens, including protocols with high doses
of corticosteroids.
Methods: We evaluated the WB-MRI scans performed on 42 patients with HL
treated by three chemotherapy regimens (6 ABVD, 2 ABVD+4 escalated BEA-
COPP, 2 ABVD+4 escalated BEACOPP+4 standard BEACOPP), excluding
those patients with main risk factors for ON. All the patients underwent WB-
MRI without contrast agent administration and FDG-PET/CT before treatment,
after two cycles of ABVD, after four cycles of escalated BEACOPP and a month
after the end of chemotherapy.
Results: Six out of 7 patients (85.7%) who received 2 ABVD followed by 4
cycles of escalated BEACOPP+4 standard BEACOPP and 1 out of 5 patients
(20%) who received 2ABVD followed by 4 BEACOPP escalated presented ON,
with a statistically significant difference of frequency between the two groups
of patients (p<0.05); whereas no injury has been reported in patients treated
by only ABVD. The ON lesions identified in those patients treated with eight
BEACOPP were all absent on the WB-MRI scans performed after four escalated
BEACOPP, so they developed ON during the last four cycles of chemotherapy.
Among a total of 48 ON lesions observed, 23 (48%) were detected in the knee;
multifocal ON were detected in six out of seven patients (86%).
Summary/Conclusions: The development of ON seems to be strictly related
to the chemotherapy protocol adopted and the number of cycles received,
strengthening the hypothesis of a correlation between the dose of corticos-
teroids included in the BEACOPP scheme and this complication. WB-MRI can
be considered as a helpful tool that allows, not only for staging and follow
patients with lymphoma, but also to detect ON in patients treated with corticos-
teroids, avoiding radiation exposure or contrast administration.
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MORPHOLOGIC PATTERN AND PROGNOSTIC SIGNIFICANCE OF CD30
DISTRIBUTION WITHIN NEOPLASTIC CELLS IN HODGKIN LYMPHOMA
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Background:
Hodgkin’s lymphoma (HL) is a highly curable disease and 5-year survival is
improving, being currently 86%. Cure rates of more than 90% for early HL and
more than 70% for those with advanced HL are expected. CD30 protein is
expressed on Hodgkin and Reed-Sternberg (HRS) cells in nearly all cases of
classical Hodgkin lymphoma (HL). CD30 is present on a cell membrane and
on the Golgi complex of the endomembrane cell system. Given the growing
clinical application of CD30 targeting we were interested to see if there is vari-
ability in distribution of CD30 protein between the cell surface and the cytoplasm
and the impact on outcome.
Aims: Given the growing clinical application of CD30 targeting we were inter-
ested to see if there is variability in distribution of CD30 protein between the
cell surface and the cytoplasm and the impact on outcome.
Methods: To further assess the presenting features and the prognostic signif-
icance of CD30 expression in HL we performed a retrospective single institution
study of 179 cases with a median follow-up of 5 years. The median ages were
40 years (range, 14–83 years) for men and 34 years (range, 16–77 years) for
women; Histological subtypes of HL were nodular sclerosis in 155 (87%), mixed
cellularity in 19 (11%), lymphocyte rich in 5 (3%) of cases. Stages III-IV were
present in 116 pts (65%), bulky disease in 68 pts (38%), extranodal disease in
21 (12%) and 73 (41%) had a score >2 (intermediate-high-risk). Combined
radio-chemotherapy was administered in 116 pts (65%) and chemotherapy
alone in 63 (35%).The CD30 protein was evaluated in formalin-fixed paraf-
finembedded (FFPE) tissue sections by immunohistochemistry (IHC) with mon-
oclonal mouse antihuman antibody CD30 (clone Ber-H2) (Dako). Morphological
pattern (localization of CD30) of CD30 expression was evaluated in each case
under a microscope examination.
Results: FFPE tissue specimens from 179 HL patients were examined.
Immunophenotype was typical of classical HL, and HRS cells were positive for
CD30 in all cases. Immunostaining for CD30 was present only on the Golgi
body in 147 (82%) of cases, and it was demonstrated on the Golgi body and
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on the cell membrane in 32 (18%) of cases. The 32 patients with golgi and sur-
face CD30 expression had poor prognosis compared with the patients with
CD30 surface alone (5 year progression-free survival [PFS], 20% versus 86%;
p<0.001).
Summary/Conclusions: In our series of 179 patients with classical HL, pre-
dominant pattern of CD30 expression was cytoplasmic (Golgi body), and only
18% of cases demonstrated cell surface and cytoplasmic expression, with the
evidence of poor prognosis.
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EFFICACY AND SAFETY OF APREPITANT FOR PREVENTION OF
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN PEDIATRIC
PATIENTS
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Background: Chemotherapy-induced nausea and vomiting (CINV) are com-
mon side effects for cancer patients with a considerable impact on quality of
life. Traditional regimens to prevent CINV commonly contain a combination of
corticosteroid plus ondansetron, a 5-hydroxytryptamine receptor antagonist.
Nevertheless, CINV persist in 20-30% of patients and in 40% remains even
after of chemotherapy (delayed nausea and vomiting). The NK-1 receptor
inhibitor aprepitant, in addition to usual anti-emetic therapy, seems to improve
both acute and delayed nausea and vomiting in adults. Preliminary studies
have shown good efficacy and tolerability also in adolescents; however, trials
of using aprepitant in pediatric hemato-oncologic disease are limited.
Aims: Here, we report our experience about the safety and the efficacy of
aprepitant in children and adolescents with Hodgkin Lymphoma (HL), treated
with highly emetogenic chemotherapy.
Methods: Pediatric patients aged >10 years and with diagnosis of HL received
aprepitant as part of triple antiemetic prophylaxis during a cycle of chemother-
apy. Aprepitant was administered orally at a dose of 125 mg on Day 1 and 80
mg on Days 2 and 3; at the same time, patients received ondansetron at a
dosage of 4 mg/mq and dexamethasone (0.5-2 mg/kg). The efficacy of the
drug was evaluated through a questionnaire given to the patient in the next
cycle, after obtaining informed consent. Toxicity was evaluated according to
CTCAE criteria (v 4.02: Sept. 15, 2009).
Results: Ten patients were enrolled between January 2015 and January 2016;
nine received a first line chemotherapies (COPP/ABV, ABVD), while only one
of them underwent a fourth-line therapy (Bendamustine); mean age was 13.6
(range 11-16 yrs) and mean number of cycle administered was 3.8 (range 1-
6). Five of ten patients reported nausea with a variable intensity from 2 to 6,
measured with a scale from 1 to 10; only two patients reported vomiting (2 and
4 episodes). All patients experienced a grade III-IV neutropenia and a a slight
increase in transaminases, effects likely related to chemotherapy; no other
side effects were registered.
Summary/Conclusions: In our experience, aprepitant, in combination with
ondansetron and dexamethasone, significantly decreased the incidence of
CINV in children receiving highly emetogenic chemotherapy. We obtained a
complete response rate of 50% with a good toxicity profile. This results make
us continue to use aprepitant in our patients, since the reduction of nausea
and vomiting sensation represents a considerable advantage on quality of life
and therapeutic efficacy.
Indolent Non-Hodgkin lymphoma – Clinical
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TCL1A EXPRESSION IN SPLENIC MARGINAL ZONE LYMPHOMAS (SMZL)
AND CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN
(CBL-MZ): CORELLATION WITH IMMUNOPHENOTYPE, MYD88L265P
EXPRESSION AND CLINICAL DATA
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A Dimitrakopoulou5, E Koulieris1, P Konstantinou6, M Moschogiannis1,
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Background: SMZL and CBL-MZ display significant similarities. TCL1A
expression may be a valuable tool for the diagnosis of SMZL. TCL1A has been
recently shown to be highly expressed in Waldenstrom macroglobulinemia,
although data is limited.
Aims: The aim of the present study was to evaluate TCL1A expression in a
series of bone marrow samples involved by SMZL and CBL-MZ and correlate
the findings with other immunophenotypical, morphological, and clinical data,
as well as with the presence of MYD88 L265P mutation.
Methods: 45 patients were retrospectively analyzed: 20 with SMZL and 25
with CBL-MZ. Immunohistochemical staining was performed using the following
antibodies: CD5, CD20, Ki67, cyclin D1, TCL1, T-bet, DBA44, CD23, CD27,
IRTA1. MYD88 L265P mutation was detected by allele specific PCR.
Results: The main clinical characteristics as well as immunohistochemical and
molecular findings are summarized in the Table 1.TCL1A staining was negative
in 17/20 cases of SMZL (85%) and 22/25 (88%) cases of CBL-MZ.DNA-44
was positive in 17/24 (71%) of cases in both groups. None case expressed
IRTA1. T-bet was positive in 55% and 36% of SMZL and CBL-MZ cases,
respectively. No correlation was found between TCL1A and DBA44 expression.
Regarding SMZL cases, all TCL1A-positive cases were also positive for CD27.
8/25 (28%)CBL-MZ cases were positive for the presence of MYDL265P muta-
tion. In SMZL cases only 1/11 patient was positive for the presence of MYD88.
No correlation was found between TCL1A expression and the presence of
MYD88 mutation. None of the mutated cases were TCL1A positive. Among
TCL1A-positive SMZL cases, 1/3 presented disease progression with histologic
transformation to double-hit lymphoma. All TCL1A-negative SMZL cases were
treated with rituximab-monotherapy and are alive without disease.2/3 TCL1A-
positive CBL-MZ cases progressed and required therapy due to the presence
of cytopenias and one of them died of the disease. None of the TCL1A-negative
CBL-MZ cases presented disease progression.
Table 1. Characteristics of SMZL and CBL-MZ cases.
Summary/Conclusions: Both SMZL and CBL-MZ display similar pattern of
TCL1A, DBA44, IRTA1 and T-bet expression. TCL1A is rarely expressed in
SMZL and CBL-MZ cases. No correlation was found between TCL1A and
DBA44 expression. No correlation was found between TCL1A and MYDL265P
mutate. CD27 and TCL1A were not mutually exclusive. TCL1A expression may
be associated with worse outcome, although the number of TCL1A positive
cases are small in order to reach safe conclusions.
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DESCRIPTION OF LATE ONSET NEUTROPENIA IN PATIENTS TREATED
WITH BENDAMUSTINE PLUS RITUXIMAB
B Verriere1,*, L Gastaud2, F Peyrade2, A Thyss2, D Re2
1Pharmacy, Antibes General Hospital, Antibes, 2Oncology, Anticancer Center
Antoine Lacassagne, Nice, France
Background: Bendamustine (B) is an alkylating drug indicated for the treatment
of patients with chronic lymphoid leukemia (CLL) who are not eligible to Flu-
darabine. In addition, Rummel et al. (Lancet 2013) described B associated with
Rituximab (R) as a therapeutic alternative to R-CHOP in follicular and other
indolent lymphomas. Although hematoxicity of B is largely described in the lit-
erature, both late onset neutropenia and lymphopenia occurring after the last
cycle of immunochemotherapy are not described.
Aims: We report a cohort of patients treated with B+R showing late onset neu-
tropenia after the end of lymphoma treatment.
Methods: This is an observational retrospective study (Anticancer Center
Antoine-Lacassagne, Nice and General Hospital, Antibes, France) including
patients treated from January 2009 to June 2015. The study included patients
with CLL and indolent NHL (follicular, mantle cell and marginal zone) having
received at least one cycle of the association of R (375mg/m²) and B (70 or
90mg/m²x 2 D) as part of their first or second line treatment. Assessment of
hematotoxicity was performed according to CTCAE v4.0. We excluded patients
with neutropenia preexisting to immunochemotherapy or relapsing within 3
months after the end of induction treatment.
Results: 287 patients received one to six cycles of B+R. We noted a total of
83 episodes of late onset of neutropenia (51 grade I/II, 32 grade III/IV) in 36
patients (follow-up 12 months). The characteristics of those 36 patients are the
following: sex ratio (M/F) 0.61; median age 73 years (48 to 93); 94% PS 0/1;
36% CLL, 42% follicular lymphomas (FL), 14% mantle cells lymphomas (MCL)
and 8% other indolent lymphomas (including marginal lymphoma). Dose inten-
sity is 100% for B and R with an average of 5 cycles (92% of patients received
more than 4 cycles of R+B). Among 15 patients with FL, 13 received a mainte-
nance treatment after B+R, with R monotherapy (mean number of cycles: 5.9)
that was interrupted in 8 for at least grade II neutropenia. Grade III/IV neu-
tropenia occurred in 9 patients (including 2 patients with FL treated with R main-
tenance). There was no event of febrile neutropenia within the study period.
Four patients had ongoing grade I/II neutropenia one year after the last cycle
of immunochemotherapy. Bone marrow smears weren’t performed systemati-
cally in our patients (n=13).
Summary/Conclusions: In our retrospective study we describe late onset neu-
tropenia in lymphoma patients treated with R+B. The incidence reported is
12,5% (11% for grade ≥3). Although we did not observe febrile neutropenia in
those patients, late onset neutropenia directly impacts on the strategy of lym-
phoma treatment especially in FL patients receiving R maintenance. We cannot
determine separately the impact of R or B for late onset neutropenia but it is
hypothesized that the association of R+B increases late onset neutropenia
when compared to each treatment alone. Exploratory sub-group analysis is
under way. Considering those results, we suggest a close hematologic follow-
up of patients treated with R+B immunochemotherapy in order to identify and
treat late onset neutropenia.
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IS THERE A REAL INCRESED PREVALENCE OF HEPATITIS B REACTIVA-
TION IN PATIENTS WITH CD20+INDOLENT NON HODGKIN LYMPHOMA
DURING MAINTENANCE WITH RITUXIMAB?
O Vitagliano1,*, F Trastulli1, L Simeone1, V Russo1, L Marano1, M Raimondo1,
C Cimmino1, R Della Pepa1, G Giagnuolo1, S Luponio1, G Beneduce1,
C Cerchione1, M Masarone2, M Persico2, A De Renzo1, F Pane1
1Division of Hematology, University Federico II, Naples, 2Internal Medicine and
Hepatology Unit, University of Salerno, Salerno, Italy
Background: Hepatitis B reactivation is a potentially serious complication of
anti CD20 antibody (Rituximab) based chemotherapy regimens although spo-
radic HBV reactivation cases are reported in patients on maintenance with sin-
gle therapy Rituximab.
Aims: The aim of this study is to assess the prevalence of HBV reactivation
among patients HBsAg-/HBcAb+undergoing maintenance chemotherapy with
Rituximab.
Methods: We have analyzed 148 patients treated for non Hodgkin’s lymphoma
according to standard maintenance therapy with Rituximab (375 mg/mq every
2 months for 2 years) from January 2007 to February 2016. Patients received
different chemotherapy regimens during induction: 15.5% (23/148) with
RCHOP, 27% (40/148) with R-FN, 22% (23/148) R-Bendamustine, 4% (6/148)
with R-Fludarabine, 4% (6/148) with R-Leukeran, 19% (28/148)with R-CEOP,
2% (3/148) with R-CVP, 0.6% (1/148) with R-FC, 0.6% (1/148) with R-C, 1.2%
(2/148) with R-FN and Bendamustine and 3% (5/148) with Rituximab monother-
apy. We performed blood tests for HBV (HBsAg, HBsAb, HBeAg, HBeAb,
HBcAb) and liver function tests in all patients at diagnosis and before each
administration of maintence with Rituximab. Patients HBsAg-/HBcAb+with
increased level of transaminases perfmormed HBV-DNA test. Six patients with
HBsAg+received prophylactic therapy with antiviral drugs during induction and
maintenance therapy.
Results: 69.6% of the patients (103/148) completed therapy with Rituximab
and 30.4% of the patients (45/148) are still in maintenance therapy : 32% of
the all patients (47/148) were HBcAb+positive. Only 4.2% (2/47) of these
patients occurred HBV reactivation.
Summary/Conclusions: In clinical practice patients HBsAg-/HBcAB+treated with
Rituximab in single therapy are normally considered for prophylaxis with lamivu-
dine. In our experience HBsAg-/HBcAB+patients don’t received therapy with antivi-
ral drugs during maintenance therapy with Rituximab. Only two of our patients
experienced HBV reactivation during maintence therapy. In terms of cost benefit
analysis there is an advantage in the monitoring approach that was used in our
patients in respect to universal prophylaxis, with a savings of about € 3.400,00 for
each patient and a total cost of 159.000€ for all our patients. This study is the first
study which analyzes HBV reactivation among HBcAb positive patients which
underwent to maintenance therapy with Rituximab for indolent NHL.
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THE ABSOLUTE LYMPHOCYTE COUNT AS INDEPENDENT PARAMETER
MAY PREDICT PROGNOSIS OF FOLLICULAR LYMPHOMA PATIENTS
J Jelicic1,*, M Todorovic1, B Andjelic1, D Antic1, O Markovic2, I Petkovic3,
A Sretenovic1, J Bila1, V Vukovic1, V Djurasinovic1, M Smiljanic1, I Pejicic3,
B Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, 2Clinical
Hospital Center “Bezanijska Kosa”, Belgrade, 3Clinic of Oncology, University
Clinical Centre Nis, Nis, Serbia
Background: The role of absolute lymphocyte count (ALC), absolute monocyte
count (AMC) and lymphocyte to monocyte ratio (LMR) in follicular lymphoma
(FL) as potential surrogate markers of gene expression profiling analysis has
been investigated with consequently reported contradictory data.
Aims: The aim of this study was to evaluate the role of clinical and laboratory
parameters, including ALC, AMC and LMR, on the overall survival (OS) and
event free survival (EFS).
Methods: A total of 185 patients (106 females/79 males) with median age of
55 years (range 30-88 years) were analyzed. Majority of patients (87.6%) were
in advanced Ann Arbor clinical stage (III-V), while 8.1% had leukemic phase of
the disease. Bone marrow infiltration had 61.1% patients and histopathological
grade 3 of disease had 25.4% of them. Low FLIPI (Follicular Lymphoma Inter-
national Prognostic Index) had 22.2% of patients, intermediate 28.1% and high
44.3%. Pre-therapy median ALC was 1.83x109/L (range 0.10-123.9x109/l),
AMC 0.52x109/l (range 0.06-12.39x109/l) and LMR 4.0 (range 0.04-97.0x109/l).
Cut off values were set on 1.1x109/l, 0.63x109/l and 4.7x109/l for ALC, AMC
and LMR, respectively, according to the previously published data. All patients
were treated with immunochemotherapy.
Results: Complete remission (CR) was achieved in 64.9% of patients, partial
remission (PR) in 27.0% and 8.1% of patients had primary resistant disease.
The disease relapse was verified in 39.5%. The following variables didn’t influ-
ence neither OS nor EFS: gender, Ann Arbor disease stage, presence of B
symptoms, bulky disease, and leukemic phase of disease. However, the FLIPI
had significant impact on the OS (Log Rank=11.75, p=0.003) and EFS (Log
Rank=9.14, p=0.01). Furthermore, the patients with lymphoma grade 1-3 had
superior OS (Log Rank=10.70, p=0.001) and EFS (Log Rank=6.89, p=0.009)
compared to the patients with grade 3. The patients with ALC≥1.1x109/l had
better OS (Log Rank=4.135, p=0.042) and EFS (Log Rank=3.9, p=0.049) com-
pared to those with lower ALC values. However, AMC and LMR were not in
correlation with the outcome. Multivariate Cox regression analysis among FLIPI,
lymphoma grade and ALC, has sorted over lymphoma grade as the most impor-
tant parameter that influenced OS (HR=6.57, 95% CI 1.49-6.58, p=0.003) and
EFS (HR=2.56, 95% CI 1.24-5.32, p=0.011) along with the FLIPI (OS, HR=1.50,
95% CI 1.09-2.05, p=0.012; EFS, HR=1.4, 95% CI 1.03-1.92, p=0.03).
Summary/Conclusions: In FL patients ALC, as individual parameter, markedly
influenced survival. Moreover, in the rituximab era FLIPI still retains prognostic
significance along with the histological grade of FL illustrating biologically dif-
ferent course of disease.
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PEGFILGRASTIM IN PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA
DURING RITUXIMAB-BENDAMUSTINE TREATMENT IN INDOLENT NON
HODGKIN LYMPHOMA : A REAL-LIFE EXPERIENCE
C Cerchione,*, A De Renzo, C Cimmino, M Raimondo, M Di Perna, M Picardi,
F Pane
Hematology, Ematologia e Trapianto/AU Federico II, Napoli, Italy
Background: Febrile neutropenia (FN) is a serious side effect of chemotherapy,
and even when it does not result in significant morbidity, mortality and costs, it
normally leads to a delay in chemotherapy treatments.
Aims: Pegfilgrastim is a pegylated long-acting recombinant form of G-CSF
which extends the half-life, requiring less frequent dosing. The objective was
to evaluate the efficacy and safety of pegfilgrastim in newly diagnosed patients
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with indolent NHL, in treatment with R-Bendamustine (RB), in order to deter-
mine whether a single injection of pegfilgrastim is as effective as daily injections
of filgrastim, in terms of toxicity, febrile neutropenic episodes, antibiotic usage,
and hospitalization duration.
Methods: 59 patients (31 M/28 F), median age 48.7 years (range 33-87), since
first course of treatment performed blood counts twice weekly and received,
d8-d19, prophylactic oral quinolones and anti-fungal drugs. During neutropenia,
filgrastim (5 µg/kg/d for at least 3 days) was given “on demand” if neutrophils
count was <1000x109 cells/L. Median number of filgrastim administrations was
3.4 (r.3-5); nadir neutropenia was registered after a median of 9.1 d. (r.8-15);
median of nadir neutrophil count was 1.27x109 cells/L (range 0.3-1.7x109
cells/L), with maximum duration of 11 days. From the second course, all
patients switched to pegfilgrastim (6 mg) prophylaxis, injected subcutaneously
with a single administration on day+4.
Results: During pegfilgrastim, neutropenia was never longer than 7 days, with
a consequent reduction of risk of infections. Median nadir neutrophil count,
evaluated for at least 3 courses of therapy (r.3-6) registered at d+11, was 1.626
(range 0.88-2.11x109 cells/L); only 9 patients (15.2%) needed, after pegfilgras-
tim, a supplement of 3 administrations of filgrastim. During pegfilgrastim, neu-
tropenia, when present, was shorter than during filgrastim treatment (median
of 3.3 d, range 3-8). Pegfilgrastim was well tolerated: main side effects were
mild fever and bone pain (8/59 : 13.5%). Moreover, no hospitalization was
needed during pegfilgrastim, while two hospitalization for pneumonia were
needed during filgrastim. During observation, no patient died during filgrastim
or pegfilgrastim.
Summary/Conclusions: In patients affected by newly diagnosed patients
indolent NHL, in treatment with RB, pegfilgrastim seems to reduce the incidence
of neutropenia, is better tolerated and may increase the possibility to maintain
the schedule of treatment.
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RISK OF HISTOLOGIC TRANSFORMATION (HT) IN SPLENIC MARGINAL
ZONE LYMPHOMA (SMZL) PATIENTS TREATED WITH RITUXIMAB
C Kalpadakis1,*, G Pangalis2, S Sachanas2, T Vassilakopoulos3, D Rondogianni4,
A Dimitrakopoulou5, E Koulieris2, M Moschogiannis2,xYiakoumis2, M Psyllaki1,
P Tsirkinidis2, H Papadaki1, P Panayiotidis6, M Angelopoulou3
1Haematology, University of Crete, Heraklion, 2Haematology, Athens Medical
Center-Psychikon branch, 3Haematology, University of Athens, 4Anatomic
Pathology, Evangelismos Hospital, 5Immunology Laboratory, Laikon General
Hospital, 61st Department of Propedeutics, University of Athens, Athens,
Greece
Background: SMZL is an indolent lymphoma with long survival. The risk of
HT is not well defined, ranging between <5% to >20% in various reports. Rit-
uximab has shown significant activity in the treatment of SMZL. In the rituximab
era there is no study assessing the incidence of HT in SMZL patients.
Aims: To analyze the incidence and risk factors for HT in a large series of
SMZL patients homogeneously treated with rituximab.
Methods: The studied cohort included 89 SMZL patients diagnosed and treated
between 2003 and 2015 exclusively with rituximab monotherapy as first line
treatment. 41% were males with a median age of 65 years (range, 41-95). 6/89
(7%) presented with B-symptoms and 43% with elevated LDH. According to
IPI, 31% were classified as intermediate high and high risk. No patient was
HCV(+). The response rate to rituximab was 95%. HT was confirmed by
detailed immunomorphologic study and defined by a biopsy-proven transfor-
mation of previous SMZL into an aggressive entity. Overall survival (OS) and
progression free survival (PFS) were estimated by the Kaplan-Meier method.
Results: 7-year PFS and OS of the whole population were 69% and 87%,
respectively. After a median follow-up of ….years, HT was observed in 4(4%)
patients. HT occurred at a median interval of 40 months (range: 32-114) after
diagnosis. The main features at diagnosis of the patients who experienced HT
are summarized in the Table 1. Transformation into diffuse large B cell lymphoma
(DLBCL) was documented in all patients. In one of them a “double hit lymphoma”
was reported due to the presence of the rearrangement of c-MYC, and BCL2.
In one case a coexisting low-grade component was present in the context of
the same specimen.Risk of HT was ?% at 5 and 10 years after diagnosis. At the
time of HT 2 patients had high LDH and one B-symptoms. No patient had
splenomegaly, while BM was infiltrated by HT in one patient (Table 1). The site
of transformation was the lymph nodes in all cases, and additionally BM in one
case (the one with the double hit lymphoma). Immunohistochemistry showed
positivity of CD30 in 3/4 cases. Treatment at the time of HT included RCHOP in
3 and R-Bendamustine in one case. Two patients achieved CR, one PR, while
the fourth did not respond and is alive with progressive disease. At a median
follow-up of 10 months (range, 5-13) after HT, 3 patients are alive, 2 in CR, 1 in
PR and one with PD.
Summary/Conclusions: To our knowledge, this is one of the largest series of
consecutive SMZL patients treated homogeneously with rituximab monother-
apy, evaluating the incidence and risk factors for HT. HT occurred in 4% of the
cases as a relatively early event during disease course. Post-transformation
survival cannot be safely assessed due to short follow up after HT.
Table 1. Main features at diagnosis and at the time of HT in the four
patients who were transformed in DLBCL.
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OUTCOMES OF INDOLENT LYMPHOMAS (INHL) IN THE ELDERLY - AN
OBSERVATIONAL STUDY OF KROHEM, THE CROATIAN COOPERATIVE
GROUP FOR HEMATOLOGICAL DISEASES
D Dujmovic1,*, S Bašić Kinda1, B Dreta1, A Duletić-Nančinović2, I Radman1,
D Radić-Krišto3, G Rinčić4, V Pejša5, J Sinčić-Petričević6, J Jakelić-Piteša7,
H Holik8, I Aurer1, D Nemet1
1Department of Hematology, UHC Zagreb, Zagreb, 2Department of Hematol-
ogy, UHC Rijeka, Rijeka, 3Department of Hematology, CH Merkur, Zagreb,
4Department of Hematology, UHC Sestre Milosrdnice, Rijeka, 5Department of
Hematology, CH Dubrava, Zagreb, 6Department of Internal medicine, UHC
Osijek, Osijek, 7Department of Internal Medicine, UHC Split, Split, 8Department
of Internal medicine, CH Slavonski Brod, Slavonski Brod, Croatia
Background: New treatment approaches have improved outcomes in patients
with indolent NHL. However, only limited data exist on outcomes of elderly
patients.
Aims: We performed this observational study to analyse disease characteris-
tics, treatment patterns, outcomes and prognosis of elderly patients with indo-
lent B-NHL.
Methods: Data were generated from a country-wide observational study of
patients treated with rituximab in 2007 and 2008 and from the KroHem Lym-
phoma registry. Only those receiving front-line treatment were included; watch-
and-wait patients were excluded.
Results: We identified 172 patients older than 60 years. Median age was 72,
the oldest treated patient was 95 years old; 58% were women. 82 patients had
follicular lymphoma (FL), 59 marginal zone lymphomas (MZL), 16 small lym-
phocytic lymphoma (SLL) and 15 lymphoplasmacytic lymphoma (LPL). Median
follow-up of the whole cohort was 44 months. Most patients received R-CHOP
(45%) or R-CVP (39%). Selected patients with stage 1 disease were treated
with radiotherapy only and those with splenic lymphomas with surgery. Only
22 received rituximab maintenance. 5-year overall survival (OS) was 61% and
progression-free survival (PFS) 46%. Extranodal MZL had best OS and PFS
(72% and 66% at 5y respectively). FL had better OS but not PFS (64% and
42% at 5y respectively) than non-FL iNHL. Nodal MZL, SLL and LPL had similar
outcomes (OS at 5y 53%, 48% and 47%; PFS at 5y 44%, 38% and 33%,
respectively). Best outcomes were seen in the group of patients amenable to
local therapy: surgery or irradiation. R-CHOP did not improve OS in comparison
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to R-CVP but there was a trend to better PFS, especially in patients with FL
(p=0.07). When compared to younger patients registered in the observational
study, patients older than 60 had somewhat inferior OS and PFS, but the dif-
ference in outcomes between those younger and older than 75 was striking
(p<0.0001) (Figure 1). All types of deaths were more frequent in the very elderly,
but deaths during treatment especially so; 22% of deaths in the group between
60 and 75 occurred during front-line treatment in comparison to 37% in those
above 75. In contrast, 58% of deaths in those between 60 and 75 occurred
after relapse in comparison to only 37% in the older group.
Figure 1.
Summary/Conclusions: It seems that the prognostic influence of iNHL types
has remained unchanged from the pre-rituximab era with extranodal MZL hav-
ing the best prognosis, followed by FL. Patients with stage one disease have
an excellent outcome. The impact of anthracyclines seems limited. Currently
used regimens are too toxic or not effective enough in patients older than 75.
In this group of patients new treatment approaches are needed that would
reduce mortality during front-line treatment without compromising efficacy.
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RESPONSE ASSESSMENT USING IWG2007 AND DEAUVILLE CRITERIA
IN B-CELL NON-HODGKIN LYMPHOMA PATIENTS TREATED WITH 90Y-IT
M Andrade-Campos1,*, P Lievano2, T Baringo2, P Giraldo1
1Translational Research Unit, IIS-Aragon. CIBERER., 2Nuclear Medicine,
Miguel Servet University Hospital, Zaragoza, Spain
Background: 90Y-Ibritumomab-tiuxetan (90Y-IT) has become an efficient alter-
native therapy in non-Hodgkin Lymphoma (NHL). The staging and response
assessment have changed and PET/CT scan with Deauville/Lugano criteria
have become the recommended tool.
Aims: To analyse our updated information of patients treated with 90YIbritu-
momab/tiuxetan in our institution comparing the IWG2007 Chenson and
Lugano/Deauville criteria to analyse treatment outcome.
Methods: 120 NHL patients were included in a clinical protocol conducted by
a multidisciplinary team and treated in the same centre. For this sub study 54
patients have been included, all of them followed by more than 12 months and
the response assessed with PET/CT scan after 12 weeks out therapy using
the same machine, the images were available for re-assessment retrospectively
according Deauville/Lugano criteria. Endpoints: objective response rate (ORR),
time to relapse (PFS) overall survival (OS).
Results: Until August 2015, 56 patients had receive therapy with 90Y-IT and
completed at least 1 year of follow-up were considered to analysis; M/F 29/27
mean age 59.7 years (31-86); ECOG 0-1 94.4%. According WHO classification:
follicular-NHL 44 (78.6%), mantle cell-NHL 2 (3.6%), DLCB-NHL 7 (12.5%) and
MALT-NHL 3 (5.4%). Score risk distribution: low 19 (33.9%), intermediate 24
(42.9%) and advanced 13 (23.2%). 54.5% of patients were stage IV. The major-
ity of patients received ≤2 (90.7%) previous therapy schedules and >2 (9.3%).
The mean follow-up time: 53.1 months (95% CI: 12; 145). 31 (57.4%) patients
received 90Y-IT as consolidation of first line therapy and 23 relapsed/refractory
(42.6%). According IWG2007 criteria: ORR was 98.2% CR: 50 (92.6%); PR 3
(5.4%) and 1 failure (1.9%) in relapsed/refractory disease. According Lugano
following the recommendation of Deauville criteria about the presence of resid-
ual mass and the scale of 5 points, the response were: CR (1-2 scores or 3
scores with a reduction respect the baseline and no presence of residual dis-
ease) 46 (85.2%), presence of residual disease (scores 4-5 or mass with score
3 without a reduction respect baseline): 8 (14.8%). During follow-up 13 patients
(24.1%) had relapsed, 10 were categorized as CR by IWG2007, 9 CR by
Lugano and 7 CR by Deauville with a higher negative predictive value. The
mean PFS: 109.6 months (95% CI: 94.8; 124.4) median NR. However for
patients classified as CR by Deauville, the mean PFS was 117.1 month (102.2-
132.0), median NR, and 40.7 (16.4-65.2), median 16 (6.2-25.7) months for the
rest, (Figure 1). During follow up eight patients have dead, 5 of them after 55
or more months after 90Y-IT therapy. Dead were related to disease in 7 patients.
Figure 1. PFS according deauville classification after 90Y-IT therapy.
Summary/Conclusions: In our series of NHL patients treated with 90Y Ibritu-
momab tiuxetan, the re-assessment of response by PET/CT scan according
Deauville criteria at the end of therapy shows more restrictive for CR when
scale 3 combining with residual mass is considering as residual disease,
improving the accuracy of CR in 7.4% and prolonged PFS in 7.5 months,
respect IWG2007.
PB1870
SHOULD STAGE I AND II FOLLICULAR LYMPHOMA BE TREATED EVEN
IN THE RITUXIMAB ERA?
DS Toral Ibarra*, AM Gonzalez Salinas, MM Ibarra Molares, A Bobes Fernandez,
WM Torres Jimenez, FA Gonzalez Fernandez, M Polo Zarzuela, R Martinez
Martinez 
Hemathology and Hemotherapy, Hospital Clínico San Carlos, Madrid, Spain
Background: The optimal management of stage I and II follicular lymphoma
(FL), according to consensus guidelines, is not well defined, there are hetero-
geneous criteria to choose the option of treatment and the decision used to be
based on uncontrolled experiences. Diverse treatment approaches are used
because the most of guidelines recommended a broad spectrum of alternatives
that includes from observation to radiotherapy or chemotherapy, without clear
indications to choose one. It is still widely accepted to observe advanced stage
FL in case of asymptomatic and stable disease, nevertheless, this watch-and-
wait policy is not too well established in early stages. The clinical outcome of
patients with follicular lymphoma has been improved since the introduction of
rituximab, nevertheless the guidelines still recommend the radiotherapy as a
first option.
Figure 1.
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Aims: This study was launched to evaluate the time to relapse with the three
more common approaches in the Rituximab era.
Methods: All patients with histologically confirmed diagnosis of follicular lym-
phomas grade I-II were selected from our data base starting from January
2000 to June 2015.
Results: From January 2000 to June 2015, 179 patients were diagnosed of
follicular lymphoma in our Institution. 35 patients were staged as I and II, 5
patients were excluded from the analysis because of not rigorous staging as
defined by bone marrow biopsy and an imaging study either with computed
tomography [CT] scan of the whole body or a positron emission tomography
[PET]/CT scan, and 3 patients were excluded because of bulky stage II. The
median age at diagnosis was 58 years (range 29-78). PET/CT was done in
52% patients. Treatments given to staged patients were rituximab/chemother-
apy (R-chemo; 37%) that includes regimes such as R-CHOP (cyclophos-
phamide [C], doxorubicin, vincristine [V] and prednisone [P]) R-CVP, R-FC (flu-
darabine [F], cyclophosphamide), chemotherapy without immunotherapy
(3.7%), RT (25.9%), observation (29.6%), and other (3.7%). With a median
follow-up of 70 months for PFS, there were 3 progression events (11,11% of
patients). PFS was statistically significant improved with observation compared
with patients treated either receiving R-QT or RT (p=0.042). There were nos-
tatistical differences in PFS according to FLIPI 1 or 2 score, histological grade
or BCL-6 expression in univariate analysis. There were not differences in overall
survival (Figure 1).
Summary/Conclusions: This retrospective monocentric study suggest that
observation could be a valid approach for patients of FL stage I and not bulky
II, not only for stage III or IV. PFS did not improve with treatment, even with rit-
uximab-containing chemotherapy regimens. It is necessary prospective and
randomized studies in these cases to get stronger conclusions.
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18FDG-PET ROLE OF IN THE EVALUATION OF BONE MARROW
INFILTRATION IN PATIENTS WITH NHL
F Trastulli1,*, L Marano1, A De Renzo1, S Pellegrino2, T Mannarino2, N Frega2,
L Simeone1, O Vitagliano1, V Russo1, M Raimondo1, I Peluso1, M Notarangelo1,
L Catalano1, CG Mainolfi2, F Pane1
1Division of Hematology, 2Department of Radiology, University Federico II,
Naples, Italy
Background: 18FDG PET/CT is now the standard procedure to evaluate indo-
lent and non indolent non-Hodgkin lymphoma (NHL). It plays an important role
in staging, restaging, prognosis and planning treatment. On the other hand
bone marrow infiltration affects stage, prognosis and therapeutic approach
Aims: To compare three basal 18FDG PET/CT parameters to detect bone mar-
row infiltration in patients with newly diagnosed non Hodgkin lymphoma (NHL).
Methods: 25 patients with newly diagnosed NHL from February 2012 to Feb-
ruary 2016 were retrospectively analyzed. All patients received diagnosis both
18FDG PET/CT contrast enhanced scan and bone marrow biopsy in the poste-
rior iliac crest. There were three evaluation parameters of 18FDG PET/CT to
detect bone marrow infiltration: visual analysis, maximal standardized uptake
values (SUVmax) in bone marrow of iliac crest (>2.5) and ratio of maximal stan-
dardized uptake values of iliac crest bone marrow to liver intensity (Deauville
score positive when ratio >1). All results were compared with the bone marrow
biopsy. Twelve patients (48%) had an aggressive NHL (9 DLBCL, 1 Burkitt
Lymphoma, 1 T cell lymphoma, 1 mantle cell lymphoma,); 13 (52%) had indo-
lent NHL (7 follicular lymphoma, 2 marginal zone lymphoma, 4 small lympho-
cytic lymphoma)
Results: We divided patients in two different groups: indolent and aggressive
NHL. For each group we analyzed the accuracy, sensitivity and specificity of
the three parameters (visual analysis, SUVmax and Deauville score). Aggres-
sive NHL: Accuracy, sensitivity and specificity accord to visual analysis were
60%, 75% and 25%, respectively. Accuracy, sensitivity and specificity accord
to SUVmax were 50%, 71% and 20%, respectively. Accuracy, sensitivity and
specificity according to Deauville score were75%, 89% and 33%, respectively
Indolent NHL. Accuracy, sensitivity and specificity accord to visual analysis
were 53%, 14% and 100%, respectively. Accuracy, sensitivity and specificity
accord to SUV max were 46%, 43% and 50%, respectively. Accuracy, sensitivity
and specificity according to Deauville score were77%, 57% and 100%, respec-
tively. Taking into consideration the aggressive NHL group the three parameters
compared to standard bone marrow biopsy point to high sensitivity and low
specificity. In indolent group the three parameters point to low sensitivity and
high specificity. In particular, in this later group, the presence of 4 CLL patients
(31%) commonly not FDG avid could have reduced the sensitivity of the imag-
ing procedure compared to bone marrow. According to preliminary observation
Deauville score seems to be more accurate in evaluation of bone marrow infil-
tration both in indolent and in aggressive NHL patients.
Summary/Conclusions: Although obtained in a small group of patients, our
results show a significant correlation between bone marrow infiltration verified
by biopsy procedures and peculiar aspects of bone marrow FDG uptake, in
particular when they are analyzed by the Deauville score.
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SUCCESSFUL SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS
RITUXIMAB AT THE ULSTER HOSPITAL, BELFAST, NORTHERN IRELAND
R Dillon1,*, Y Ong1, M Bowers1, J Hamilton1, P Carlin2, M El-Agnaf1
1Haematology Dept, 2Research Dept, Ulster Hospital, Belfast, United Kingdom
Background: Chemo-Immunotherapy is currently widely used in treating lym-
phoproliferative disease. There is ever increasing indications for the monoclonal
antibody, rituximab, with varied chemotherapy regimens. In our chemotherapy
day unit there has been a significant increase in patients requiring chemo-
immunotherapy. This increase has led to increasing waiting times for patients
to start their chemotherapy. In 2005, a group at the Ulster Hospital completed
a project examining the use of rapid intravenous (IV) rituximab infusion over
90 minutes as opposed to standard 4 ½ hours administration at this time, for
continuing therapy as long as the first infusion had been tolerated without any
reaction (El-Agnaf, et al., 2007). With the availability of subcutaneous (SC) rit-
uximab, the group decided to switch to this product for patients with DLBCL
and Follicular Lymphoma being treated with a combination of rituximab and
chemotherapy.
Aims: - Investigate the safety profile of SC Rituximab in treatment of
DLBCL/Follicular lymphoma. - Impact of SC Rituximab on the resource utilisa-
tion within our department.  - Convenience of adminstration of SC Rituximab
for both patients and nursing staff.
Methods: We examined the notes of all patients who received subcutaneous
Rituximab either in combination with CHOP, CVP or alone as maintenance
treatment. The first dose of rituximab was given IV as per the product mono-
graph. The second and subsequent doses for eligible patients were given over
5-6 minutes SC at a fixed dose of 1400 mg. All eligible patients received stan-
dard oral premedication of prednisolone, chlorphenamine and paracetamol.
Patients were monitored closely and any adverse events recorded using
National Cancer Institute (NCI) common terminology criteria for adverse events.
Vital signs (Blood Pressure (BP), temperature, pulse, digital O2 saturation and
respiratory rate) were checked before the first Rituximab infusion and 15 min-
utes after the infusion commenced. If normal at these time points, they were
then checked 30 minutes later and at infusion end. For SC rituximab, vital signs
were measured prior to first injection, and one hour post administration. If the
patient had no adverse reaction to the first SC injection, subsequent SC therapy
was given with vital signs monitored prior to injection only. A sample of patients
were contacted by telephone and asked about their treatment preference. The
nursing staff were also asked about their preference.
Results: There were no reported adverse reactions to the first infusion in all
patients. SC rituximab was well tolerated apart from mild local skin reactions.
None of these reactions requires specific therapy and did not preclude further
SC treatments. The service change from IV to SC was smooth with no issues
noted by staff involved. In total 29 patients (7DLBCL and 22 Follicular lym-
phoma) received 135 vials of 1400mg SC rituximab from 1st January 2015 until
31st December 2015. If all 29 patients had rapid IV infusion over 90mins, they
would have taken 202hours 30mins (if each infusion went smoothly). Our SC
rituximab patient sample took 37hours 30mins to infuse (allowing 10mins for
injecting the SC rituximab and 1hour observation post 1st SC rituximab). This
equated to a minimum saving of 165 nursing hours. Our pharmacy takes
31mins to manufacture IV rituximab as opposed to 7mins for SC rituximab. In
2015 we saved our pharmacy a minimum of 55hours. Patients uniformly pre-
ferred SC Rituximab over IV, as did the nursing staff.
Summary/Conclusions: A number of studies (Salar, et al., 2014) (Davies, et
al., 2014) showed that there was non inferiority of SC rituximab (1400 mg)
compared with IV rituximab (375 mg/m2) for treatment outcomes and that the
only safety considerations relates to a higher incidence of administration related
reactions. Overall response rate and complete response rate indicate that
switching to SC rituximab has no effect on anti-lymphoma activity, but decreas-
es overall administration time to 5-6 minutes without significantly affecting
patient safety, and is acceptable to patients. Switching from IV to SC Rituximab
has had a significant impact on the time spent for the patient in the unit, the
time pharmacy saved in Rituximab preparation and storage of the product and
the time saved by nursing staff administering the drug.
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THERAPY AND LONG-TERM RESULTS OF HEPATITIS C-ASSOCIATED
INDOLENT NON-HODGKIN LYMPHOMA
S Lepkov1,*, I Subortseva2, G Tumyn3, O Kolomiytsev3, P Zeynalova3,
A Kovrigina2, N Kokosadze3, O Ettinger1, J Riabuhina3, I Iliasova3, I Komarov3
1Therapy, Russian National Research Medical University Named by N.I
Pirogov, 2Hematology, Hematology Research Center, 3Oncology, Cancer
Research Center by N.N. Blochina, Moscow, Russian Federation
Background: The incidence of chronic hepatitis C (HCV) in patients with indo-
lent B-cell non-Hodgkin’s lymphoma (IL) is approximately 15%. In those cases
where the tumor cell NHL patients were in the presence of hepatitis C virus
protein by immunohistochemistry (IHC), we define diagnosis of hepatitis C
associated indolent lymphoma (IL+C).
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Aims: Since 2004 to 2014 81 patients were observed with IL+C. The median
age 50 years, the disease is equally common in men and women. Almost all
patients (97%) were determined III-IV st of the disease. In 25% of patients were
primary extranodal variants IL+C . Most often determined by the follicular lym-
phoma, 74%, 32% - cell lymphoma marginal zone. HCV RNA was determined in
82% of patients in the blood, the median viral load was 2.3x105 copies/mL.
Increased ALT and LDH was diagnosed in 71% and 82%, respectively.
Methods: As a first-line therapy of 52 patients was only antiviral treatment by
interferon and ribaverin . If tumor remission was achieved, the antiviral therapy
lasted for 2 years. 29 patients as a first line therapy was immunochemotherapy
(R-CHOP, R-CVP).
Results: Complete and partial remission of antiviral therapy were obtained in
88% of patients, on immunochemotherapy - in 64% of patients. Median pro-
gression-free survival in patients with IL+C treated with antiviral treatment was
42 months, during immunochemotherapy - 19 months (p=0.00001). Five-year
overall survival was 67% and 32%, respectively (p=0.0003). After immunohi-
moterapy in 19 patients was the relapse of the disease . All this patients was
treated by antiviral therapy as second-line therapy . Complete and partial remis-
sion was achieved in 92% of patients. Median progression-free survival in these
patients was 31 months.
Summary/Conclusions: Antiviral therapy in first-line and relapse of disease bet-
ter then immunochemotherapy in the overall effectiveness, of the disease-free
survival and overall survival in patients of NHL associated with hepatitis C. Antiviral
therapy is a priority for patients with hepatitis C-associated lymphoma.
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DURABLE RESPONSES WITH IDELALISIB MONOTHERAPY IN PATIENTS
WITH RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
(SLL)
AJ Davies1,*, AK Gopal2, IW Flinn3, P Ghia4, A Goy5, E Abella-Dominicis6,
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Nashville, TN, United States, 4Universita’ Vita-Salute San Raffaele and IRCCS
Instituto Scientifico San Raffaele, Milan, Italy, 5John Theurer Cancer
Center/Hackensack University Medical Center, Hackensack, NJ, 6Gilead Sci-
ences, Inc., Foster City, CA, United States, 7Hospices Civils de Lyon, University
Claude Bernard, Pierre Benite, France, 8Department of Medicine, Washington
University School of Medicine, St Louis, MO, United States
Background: SLL, an indolent non-Hodgkin lymphoma (iNHL), is often diag-
nosed at an advanced stage, and patients (pts) with relapsed or refractory
(R/R) disease have a poor prognosis.Idelalisib (IDELA), is a selective, oral
PI3Kδ inhibitor which as monotherapy (IDELA-mono) showed considerable
anti-tumor activity in pts with R/R iNHL in phase 1 (Study 02; NCT00710528)
and phase 2 studies (Study 09; NCT01282424; Gopal et al. NEJM.
2014;370:1008-18).
Aims: The objective of this post hoc analysis was to describe the efficacy
and safety of IDELA-mono specifically in pts with R/R SLL enrolled in Study
02 or Study 09.
Methods: Eligible pts with previously-treated SLL were those with R/R dis-
ease (disease status defined by response to last prior regimen) treated with
IDELA-mono across 7 dose cohorts (minimum dose 50 mg BID; maximum
dose 350 mg BID) in Study 02, and those with double-refractory disease (to
both rituximab and an alkylating agent) treated with IDELA-mono (150 mg
BID) in Study 09. In both studies, IDELA was continued until progressive dis-
ease (PD) or unacceptable toxicity. Radiographic and pertinent clinical data
were reviewed by an independent review committee (IRC) to determine
response based on standard criteria for lymphomas (Cheson et al. J Clin
Oncol. 2007;25:579-86).
Results: A total of 39 pts with R/R SLL participated in the 2 trials, 11 in Study
02, (5 on IDELA doses ˂100 mg BID; 6 on IDELA doses ˃100 mg BID), and
28 in Study 09 (IDELA 150 mg BID).  The median age of pts was 69 and 65
yrs [range 34-87], and 73% and 75% were male, in Studies 02 and 09, respec-
tively. In both studies, 82% of pts had Ann Arbor Stage IV disease at baseline
and had received a median of 4 prior regimens [range 1-9]. In Study 02, 9 of
the 11 pts (82%) had refractory disease; all 11 pts had received prior regimens
containing fludarabine. In Study 09, 27/28 pts (96%) were refractory to both
rituximab and an alkylating agent (1/28 pts had received insufficient cycles
of bendamustine). Common prior therapies included: rituximab (n=28),
cyclophosphamide (n=25), bendamustine (n=21), vincristine (n=19), and flu-
darabine (n=18).  The overall response rate (ORR) was 6/11(55%) in Study
02, with all 6 responders achieving a partial response (PR) and 3/11 pts (27%)
having stable disease (SD). In Study 09, the ORR was 17/28 (61%), with a
complete response (CR) reported in 1/28 pts (4%), a PR in 16/28 pts (57%)
and SD in 10/28 pts (36%); 1 pt (3.6%) was not evaluable. Among responders,
median time to response was 0.9 mo and 1.9 mo, respectively; median dura-
tion of response (DOR) was 2.3 mo and 12.5 mo. Median progression-free
survival (PFS) was 3.7 mo (Study 02) and 11.4 mo (Study 09). Median (KM-
estimated OS was not reached for Study 02; OS was 88.9% at 12 mo, 88.9%
at 24 mo and 59.3% at 36 mo. Median KM-estimated OS was 22.5 mo in
Study 09; OS was 89.1% at 6 mo, 74.3% at 9 mo and 70.4% at 48 mo. In
Study 02, grade ≥3 AEs and laboratory abnormalities occurring in ≥20% of
pts included pneumonia (n=5), febrile neutropenia (n=3), and neutropenia
(n=4). In Study 09, these AEs and laboratory abnormalities included pneu-
monia (n=7) and neutropenia (n=8).
Summary/Conclusions: IDELA-monotherapy provides clinical evidence of
efficacy in pts with R/R SLL, with a safety profile similar to that described in
other larger clinical trials.
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INITIAL TREATMENT RESPONSE PREDICTS THE OUTCOME OF ELDERLY
FOLLICULAR LYMPHOMA PATIENTS TREATED WITH IMMUNOCHEMO-
THERAPY
B Andjelic1,2,*, J Jelicic1, M Todorovic1,2, J Bila1,2, D Antic1,2, V Djurasinovic1,
A Sretenovic1, V Vukovic1, M Smiljanic1, B Mihaljevic1,2
1Clinic for Hematology, Clinical Center of Serbia, 2Faculty of Medicine, Univer-
sity of Belgrade, Belgrade, Serbia
Background: Advanced age is considered as an unfavorable prognostic fac-
tor for follicular lymphoma (FL). The optimal treatment approach for elderly
FL patients is still not clearly defined.
Aims: The aim of this study was to compare the outcome of FL patients
between by age (50-60 years and more than 60 years) two adjacent patients
groups treated with immunochemotherapy. The second aim was to identify
high risk patients for poor outcome.
Methods: A retrospective study was performed on 101 FL patients older than
50 years who had to be treated, including the patients who were previously
on watch and wait. Forty-eight patients were older than 60 years. All the
patients were treated with immunochemotherapy R-CHOP or R-CVP in the
period 2002-2014. Totally 10 patients received R-CVP, of whom 5 were older
than 60 years. The examined parameters in statistical analysis were gender,
FLIPI score, the presence of B symptoms, bulky disease, bone marrow
involvement, ECOG PS, FL grade and response (complete remission or not)
on initial treatment.
Results: The median age of the patients was 58 (range 51-82). Complete
remission (CR) was achieved in 65 (65.3%) patients. None of the examined
parameters was more often present on diagnosis in elderly patients compared
to patients 50-60 years old. Patients older than 60 yrs had significantly shorter
overall survival (OS) compared to patients 50-60 years old (log rank=4.855,
p<0.05), while there was no difference in event free survival (log rank=0.015,
p>0.05). Elderly patients with ECOG PS >1, as well as the patients who didn’t
achieve CR had significantly worse OS (log rank=4.892, p<0.05; log
rank=33.980, p<0.01; respectively), while none of the examined parameters
had an influence on EFS. In patients 50-60 years old, the patients who didn’t
achieve CR had significantly worse EFS (log rank 13.977, p<0.01), while none
of the examined parameters had an influence on OS. The multivariate Cox
regression analysis identified treatment response as an independent prog-
nostic factor for OS in elderly patients and for EFS in patients 50-60 years old.
Summary/Conclusions: The patients older than 60 years with FL had worse
outcome when compared to 50-60 years old patients. According to our results,
achieving CR on initial treatment should be one of the goals in treating elderly
FL patients.
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DURABLE RESPONSES WITH IDELALISIB MONOTHERAPY IN PATIENTS
(PTS) WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA
(MZL)
E Gyan1,*, P Martin2, A Armas3, AK Gopal4, ND Wagner-Johnston5,
E Abella-Dominicis6, W Ye6, B Philip6, B Sorenson6, J Walewski7, S de Vos8
1Service d’Hématologie et thérapie cellulaire, Centre Hospitalier Universitaire,
TOURS CEDEX 1, France, 2Division of Hematology/Oncology, Weill Cornell
Medical College, New York, NY, 3Calaway Young Cancer Center, Glenwood
Springs, CO, 4Medical Oncology Division, University of Washington School of
Medicine, Seattle, WA, 5Dept. of Medicine, Washington University School of
Medicine, St. Louis, MO, 6Gilead Sciences, Inc., Foster City, CA, United States,
7Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Warsaw, Poland, 8Division of Hematology/Oncology, David Geffen School of
Medicine at UCLA, Los Angeles, CA, United States
Background: MZL is a group of indolent non-Hodgkin lymphomas (iNHL) aris-
ing from marginal zone B cells in lymph nodes and/or extranodal tissues, is
classified per the World Health Organization as splenic MZL (SMZL), nodal
MZL (NMZL) and extranodal marginal zone B-cell lymphoma (mucosa-associ-
ated lymphoid tissue; MALT). Given the rarity of MZL, few randomized trials
have directly compared treatment options. Thus, there is a lack of consensus
about best practices. Idelalisib (IDELA) showed considerable anti-tumor activity
in pts with relapsed/refractory (R/R) iNHL in a phase 1 (P1) dose-escalation
study (NCT00710528; Flinn, 2014) and in pts with refractory iNHL in a phase
2 (P2) study (NCT01282424; Gopal, 2014).
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Aims: The objective of this post hoc analysis was to describe the safety and
efficacy of IDELA in a subset of pts with MZL.
Methods: The P1 and P2 studies were single-arm monotherapy trials that
assessed safety and efficacy of idelalisib in R/R hematologic malignancies
(P1) or iNHL (P2). Eligible pts with MALT, NMZL or SMZL were those with R/R
disease (disease status defined by response to last prior regimen) in the P1
study and those with double-refractory disease (to both rituximab and an alky-
lating agent) in the P2 study. IDELA was given as monotherapy (P1: minimum
dose 50 mg BID, maximum dose 350 mg BID; P2: 150 mg BID) until progres-
sive disease (PD), death or unacceptable toxicity. Radiographic and pertinent
clinical data were reviewed by an independent review committee (IRC) to deter-
mine the response based on standard criteria for lymphomas (Cheson et al. J
Clin Oncol. 2007;25;579-586).
Results: In all, 21 pts with MZL were enrolled, 6 in the P1 and 15 in the P2
study: 12 with MALT, 7 with NMZL and 2 with SMZL. Median age was 74 and
72 yrs [range 50-91], and 50% and 80% were male, in the P1 and P2 studies,
respectively. Pts had received a median of 4.5 prior regimens in the P1 study
[range 1-10] and a median of 2 prior regimens in the P2 study [range 2-9]. The
median (range) IDELA exposure was 5 mo (0.4-16.4) and 6.4 mo (1.8-21.6) in
the P1 and P2 studies, respectively. In the P1 study, Gr≥3 adverse events
(AEs) occurring in ≥20% of pts included diarrhea (3/6), and chills, fatigue,
pyrexia, urinary tract infection and dizziness (each 2/6); key Gr ≥3 laboratory
abnormalities occurring in ≥20% of pts included thrombocytopenia (4/6), and
anemia, neutropenia, and ALT and AST increases (each 2/6). In the P2 study,
Gr≥3 diarrhea and Gr≥3 neutropenia laboratory abnormalities each occurred
in 3/15 pts. Of the 21 pts, 9 (43%) achieved a response. Outcomes by MZL
subtype are shown in the Table 1. Median times to first response were 1 mo
and 3.5 mo in the P1 and P2 studies, respectively. In the P1 study, the median
duration of response (DOR) was 8.2 mo, and in the P2 study 18.4 mo. In the
P1 study, with median follow-up time of 5 mo, median progression free survival
(PFS) was 7.4 mo; in the P2 study, with median follow-up time of 20 mo, median
PFS was 6.6 mo. Overall Survival (OS) was 100% at 1 yr in the P1 study, and
in the P2 study was 86% at 6 mo, 79% at 9 mo, and 72% at 1 yr.
Table 1.
Best Overall Response, n                    CR                  PR                  SD                  PD
MALT                                                    1                     4                     6                     1
NMZL                                                   0                     2                     4                     1
SMZL                                                    0                     2                     0                     0
Summary/Conclusions: Although the sample size was small, IDELA showed
promising activity in pts with R/R MZL. IDELA was well tolerated with no appar-
ent disease-specific safety signals.
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THE STRUCTURE AND EFFICACY OF B-CELL LYMPHOMA’S REAL LIFE
TREATMENT ACCORDING DATA OF THE REGIONAL SEGMENT OF THE
RUSSIAN FEDERATION’S FEDERAL REGISTER
S Volkova*
Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russian Fed-
eration
Background: The Russian federal program of “7 nosology” since 2008 has
given the chance of stable treatment CD20+B cell lymphoma patients with rit-
uximab, B cell chronic lymphoid leukemia patients with rituximab and fludarabin
and multiple myeloma (MM) patients with bortezomib in combination with con-
ventional chemotherapy. The obtaining medications provide patient’s inclusion
in the federal register and exception from the register in case of death and
other actions.
Aims: To analyze the federal register’s regional segment of the of patients with
B-cell mature lymphomas, residents of the Nizhny Novgorod Region of RF
(Population of the Nizhny Novgorod Region in 2008 of-3359,8 thousand and
in 2015 – 3164,2 thousand people) for receiving demographic data and efficacy
of real life treatment with using rituximab without or with fludarabin and con-
ventional chemotherapy on the basis of overall survival (OS) by Kaplana-Mey-
er’s method.
Methods: Materials and methods: from Jan 2008 to Dec 2015 2094 patients are
allocated, the analysis has included 2051(98%) with diagnoses: C82 Follicular
lymphoma – 103 (5%), C83.0 – Lymphoma from small lymphocytes, Nodal mar-
ginal zone lymphoma, Lymphoplasmacytic lymphoma (excepting Waldenstrom
macroglobulinemia) – 183 (9%), C83.1 – Mantle cell lymphoma -46 (2%), C83.3
– Diffuse large B-cell lymphoma (all variants) – 532 (26%), C91.1 – Chronic lym-
phocytic leukemia – 578 (28%), C90 – multiple myeloma - 609 (30%). Date of
death is determined in 713 (35%) cases, other censored for date of the last data
in the register. The OS of patients is defined from the date of inclusion in the pro-
gram of 7 nosology. In the groups the OS is defined depending on a sex, age
group with the step in 10 years, of a year of inclusion in the program of 7 nosology.
To analyze the Excel and Statistica 9 software are used.
Results: The probability of OS from the moment of inclusion in the register
within 12 months for patients with C82 was 87%, C83.0 - 84%, C83.1 - 67%,
C83.3 - 77%, C91.1 - 86%. The probability of OS for patients with C82 till 96
months is 72%, C 83.0 till 93 months – 29%, C 83.1 till 34 months – 59%, C
83.3 till 96 months - 61%, C 91.1 till 96 months - 45%, (Chi-square=23,2,
p=0,0001). In groups except C91.1 women prevailed, distinctions of OS accord-
ing sex aren’t received. Only in the group C 91.1 men (315) prevailed (women
154), the median of OS for women isn’t reached, for men – 62 months (р
<0,003). Depending on age with a step in 10 years in all groups distinctions in
OS aren’t received. The maximum number of patients with the diagnosis C82,
C83.1, C83.3, C91.1 were in age 60-69 years, with the diagnosis C83.0 – in
age 50-59 years. Only patients with the diagnosis C83.3 are registered in all
age groups. During 2009-2015 the number of the patients included in the reg-
ister in a year with diagnoses of C82 has made from 7 to 24, on average 13;
C83.3 – from 32 to 96, on average 68, C91.1 – from 30 to 83, on average 63;
C83.0 – from 16 to 27, on average 21, C 83.1 from 1 to 15, on average 9. In
each group of distinctions of survival depending on a year of inclusion in the
program of 7 nosology it isn’t received (Figure 1).
Figure 1. Overall surviving patients with mature B-cell lymphomas
(Kaplan-Meier).
Summary/Conclusions: The rituximab for all CD20+lymphomas and fludara-
bin+rituximab for BCLL improve the outcome patients in real life clinical practice.
The register interacted to the mechanism of the provision of medication is the
effective resource allowing to have demographic data and data on efficacy
treatment in real life medical practice.
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DETECTION OF MYD88 (L265P) SOMATIC MUTATION IN SPLENIC
MARGINAL ZONE LYMPHOMA (SMZL)
C Kalpadakis1,*, G Pangalis2, M Angelopoulou3, M Roumelioti4, S Sachanas2,
F Kontopidou5, A Dimitrakopoulou6, E Koulieris2, M Moschogiannis2,
MC Kyrtsonis4, T Tzenou4, S Kokoris7,xYiakoumis2, P Tsirkinidis2,
C Pontikoglou1, H Papadaki1, P Panayiotidis4, T Vassilakopoulos3
1Haematology, University of Crete, Heraklion, 2Haematology, Athens Medical
Center-Psychikon branch, 3Haematology, 41st Department of Propedeutics,
52nd Department of Internal Medicine, University of Athens, 6Immunology Lab-
oratory, Laikon General Hospital, 7Haematology Laboratory, Attikon University
Hospital, Athens, Greece
Background: MYD88 L265P is a somatic mutation that has been identiﬁed in
about 90% of Waldenstrom macroglobulinemia (WM)/ lymphoplasmacytic lym-
phomas (LPLs). Several reports demonstrated the presence of the mutation in
other lymphomas mainly DLBCL of activated type and SMZL. In SMZL, the
frequency of MYD-88 mutation ranges between 0-21% in various studies.
Aims: The aim of the present study was to determine the presence of L265P
MYD-88 mutation in a well characterized series of SMZL cases along with an
extended analysis of the clinical, morphologic, immunophenotypic and histo-
logic features.
Methods: We retrospectively evaluated 37 SMZL cases. The identification of
MYD 88 L265P mutation was performed in blood or BM mononuclear cells
with allele specific PCR. The sensitivity of the method was 10-3.
Results: The main clinical and laboratory characteristics are shown in the
Table 1. 11/37 (30%) were males with a median age of 62 years. All cases pre-
sented with splenomegaly and one with B-symptoms. Lymphadenopathy was
evident in 7 cases (19%). Bone marrow (BM) was infiltrated in all cases, with
a mixed (nodular and intrasinusoidal) pattern of infiltration in most cases. Para-
proteinemia was present in 9/29 (31%), 6 of the IgG and 3 of the IgM type.None
of the studied cases had positive serology for the hepatitis C virus. Anemia
and thrombocytopenia were found in 28% and 8%, respectively. MYD-88 L265P
mutation was detected in one case (1/37, 3%). This was a case of a 62-year
old man with IgMκ paraproteinemia of low level (550mg/dl), lymphocytosis
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(8000/μL), no anemia, mild to moderate splenomegaly (max 15.6 cm), small
hilar lymphadenopathy and 60% BM infiltration with a nodular and intrasinu-
soidal pattern. At the time of CR documentation, disease was not detectable
including the disappearance of the IgMκ monoclonal fraction in the blood,
except the presence of the MYD-88 mutation in the BM mononuclear cells
which in the same specimen was IgVH negative. The other two patients with
an IgM monoclonal band were negative for the MYD-88 mutation, as were
those with IgG monoclonal gammopathy.
Table 1. Characteristics of the SMZL cases studied for the presence of
MYD-88 L265P mutation.
Summary/Conclusions: Based on our findings, MYD88 L265P mutation is
very rare in SMZL. In our series of 37 SMZL cases, MYD88 L265P mutation
was detected in only one case (3%), which a monoclonal IgMκ was present.
Our findings support the view that the presence of an IgM monoclonal gam-
mopathy in the serum, with a lymphocytic – lymphoplasmacytic infiltration of
the BM by no means document the diagnosis of WM/LPL.
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SIGNIFICANT ROLE OF FLOW CYTOMETRY IN THE DIAGNOSIS AND
FOLLOW UP OF GASTRIC LNH
S Luponio1,*, A De Renzo1, M Romano2, A Miranda2, D Sgambato2, M Raia3,
G Scalia3, R Della Pepa1, M Raimondo1, L Marano1, F Pane1, L Del Vecchio3
1Hematology, university Federico II, 2Clinical and Experimental Internal Medicin,
AOU SUN, 3Biotecnologie Avanzate, CEINGE, Naples, Italy
Background: The diagnosis of lymphoma is mainly based on morphology, but
the diagnostic accuracy is greatly increased by the use of ancillary techniques
like immunophenotyping, cytogenetic and molecular tests. This multiparametric
approach is recommended by WHO classification.
Aims: To evaluate the role of flow cytometry in the study of gastric biopsies
with suspect of NHL. We have assessed the validity of integration of histological
and cytometric assays to optimize diagnosis of lymphoproliferative diseases
and to lower the number of inconclusive cases at histological exam. The aim
of flow cytometry was to define lineage and clonality of lymphoid proliferation,
thus giving a support to final diagnostic assessment.
Methods: 33 patients with primary gastric lymphoma underwent, from January
2007 to December 2015, to double gastric biopsy at diagnosis or during follow
up. Diagnosis was MALT in 19/33 (58%), DLBCL in 9/33 (27%) and other his-
tological type in 5/33 (15%). Every patient underwent complete staging and
the stage was I/E in 18/33 and II/E in 15/33. Therapy was antibiotic eradication
of HP in 8/33 pz and chemo-immunotherapy in accordance with guidelines.
Samples for histology were fixed with formalin and stained with HE, then tested
by antibodies for CD3, CD5, CD10, CD20, CD21, CD23, CD30, CD38, CD43,
CD45RO, CD79a, CiclinaD1, BCL-2, BCL-6, Ki67, EMA, k e l. Samples for flow
cytometry were put in saline, sent to laboratory within thirty minutes and
processed with standard methods. A cytometric pattern was defined as patho-
logical if there was an evident atypical assembly of B or T lymphoid antigens
along with clonal restriction for Ig light chains or TCRVb repertoire.
Results: We have carried out 44 biopsies in a population of 33 patients and
we obtained a final diagnosis in all cases. Diagnosis was: NHL in 11/42 (9
MALT,1 follicular lymphoma,1 DLBCL), plasmacytoma in 1/42, and benign con-
ditions in the remaining 32/44. There was strict concordance between the two
methods, but in one case flow cytometry was negative and histology was pos-
itive for lymphoma, in other one positivity of flow cytometry led to histological
revision and, finally, to full concordance.
Summary/Conclusions: This study demonstrated that flow cytometry is an
easy and reliable diagnostic tool for gastric lymphoma: assumed that its goal
is to assess lineage and clonality, it is fast, sensitive and specific. It is synergistic
to histology, especially in difficult cases like biopsy performed during a revalu-
ation after chemotherapy or antibiotic therapy, or reactive conditions where
lymphoid infiltrates can mimic lymphoma. Histological diagnosis certainly
remains the gold standard for lymphoma diagnosis but flow cytometric typing
can usefully support histology to reach a correct diagnosis in 100% of cases.
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RESULTS OF LAPAROSCOPIC SPLENECTOMY IN SPLENOMEGALY
O Soboleva*, K Ntanisian, S Karagyulyan
Hematologic surgery, Hematology Research Center for Hematology, Ministry
of Health of the Russian Federation, Moscow, Russian Federation
Background: Surgical approach to splenectomy depends on clinician’s expe-
rience and laparoscopic technique. However, splenectomy in patients with
splenomegaly remains a challenge. Due to the lack of randomized controlled
studies the main sources of data to evaluate surgical approach to splenomegaly
are case-control series.
Aims: Our goal was to determine criteria for laparoscopic approach to
splenomegaly
Methods: Since 1999 1027 patients underwent laparoscopic splenectomy
(LS) at our department. Spleen size was considered to determine surgical
approach in connection with other factors such as abdominal cavity volume.
Splenomegaly was detected in 506 cases of 1027 LS performed. In this
group the mean spleen size was 21.25 sm (range 14-34 sm), mean spleen
weight was 1016 g (range 300-2650 g). The mean age was 37 years (range
14-72 years). Indications were same as for the open procedure. Mean oper-
ative time was 137 min versus 115 min in open procedure. Mean blood loss
was 54 ml versus 664 ml in open procedure. Conversion rate was 19.7%
(100 cases). Spleen hilum infiltration and perisplenitis were the factors most
commonly leading to conversion. There were no severe complications and
no deaths.
Results: Splenomegaly is not considered a crucial factor to determine surgical
approach. We’ve separately analyzed 250 LS performed before 2003. Conver-
sion rate in this group was 22%, and it was as high as 31% in cases of
splenomegaly. Since 2003 gaining experience resulted in conversion rate
decrease to 18.7% in patients with splenomegaly. The conversion rate
decreased with the increasing surgical experience. Apparently excessive spleen
size is relevant if analyzed in proportion to limited working space in abdominal
cavity. Conversion rate in lymphoproliferative disorders was 28% and for benign
disorders – 13%. LS has proved to have advantages over open procedure such
as minimal tissue injury, improving exposure to the superior pole and splenic
pedicle and minimization of pancreatic injury. Even if excessive spleen size
leads to conversion, laparoscopic approach facilitates dissection as the first
operative step.
Summary/Conclusions: LS is being increasingly used in patients with
splenomegaly. Spleen size is not the most important factor to determine
approach to splenectomy. There is a decrease in conversion rate with the
increasing surgical experience. Laparoscopic approach to splenomegaly is
preferable considering sufficient knowledge and skill of the operating surgeon.
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BRAF GENE MUTATIONS AND PROGNOSTIC SIGNIFICANCE OF
CLINICAL FINDINGS IN CASTLEMAN DISEASE
M Türker1,*, S Subari1, M Keklik2, MS Dal3, N Sahin4, M Comert5, G Alanoglu6,
E Kara7, S Kocarslan8, E Gundogan9, H Buyukbayram10, O Ayyildiz3, A Unal2,
S Oztuzcu11, N Akpolat4, G Saydam5, S Bircan6, C Demir7, I Sari12, M Yilmaz9
1Internal Medicine, Gaziantep University School of Medicine, Gaziantep,
2Hematology, Erciyes University School of Medicine, Kayseri, 3Hematology,
Dicle University School of Medicine, Diyarbakir, 4Hematology, Inonu University
School of Medicine, Malatya, 5Hematology, Ege University School of Medicine,
Izmir, 6Hematology, Suleyman Demirel University School of Medicine, Isparta,
7Hematology, Van Yuzuncu Yıl University School of Medicine, Van, 8Pathology,
Harran University School of Medicine, Sanliurfa, 9Hematology, Gaziantep Uni-
versity School of Medicine, Gaziantep, 10Pathology, Dicle University School of
Medicine, Diyarbakir, 11Medical Genetics, 12Pathology, Gaziantep University
School of Medicine, Gaziantep, Turkey
Background: Castleman’s Disease is a quite rare lymphoproliferative disorder.
The association with IL-6 secretion, HIV/HHV-8 is well described, but the patho-
genesis is not fully understood. BRAF is a serine/threonine kinase that has an
important role in the mitogen activated protein kinase (MAPK) pathway. Dys-
regulation of this pathway and gene mutations lead to development of malig-
nancy. BRAF mutations are present in malignant melanoma, colorectal cancer,
ovarian carcinoma, papillary thyroid carcinoma and hairy cell leukemia.
Aims: We aimed to determine the presence of BRAF gene mutation in Castle-
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man’s Disease and to assess clinical data of disease and the relationship with
prognosis.
Methods: This retrospective study included 34 patients who were diagnosed as
Castleman’s Disease between 2007-2014 from 8 different medical centers in
Turkey. Clinical and laboratory findings of the patients have been evaluated from
medical records. All tissue samples were characterized for the presence of the
BRAF mutation by pyrosequencing. Statistical analysis was performed to deter-
mine any associations among histological variants,clinical type and clinical fea-
tures of the patients including age, gender, survival, and laboratory findings.
Results: There were 17 men and 17 women. Hyaline vascular variant was the
most common subtype (75.6%). The study included 21 (61.8%) cases with uni-
centric Castleman’s Disease (UCD) and 13 (38.2%) cases with multicentric
Castleman’s Disease (MCD). Hyaline vascular variant was more common in
the UCD group (p<0.05). Cases were divided in 3 sites according to involve-
ment; thoracic, abdominal and cervical. The majority of patients (61.7%) had
cervical involvement. 10 of patients (29.4%) had more than one region involve-
ment. The plasma cell variant was significantly higher in men (p=0.006). The
mean age was significantly higher in the plasma cell group and MCD (p<0.05).
CRP levels were found significantly higher in plasma cell variant compared to
hyaline vascular variant (p<0.05). The BRAF gene mutation was not detected
in all tissue samples. Hepatomegaly and/or splenomegaly were presented sig-
nificantly common in patients with multiple site involvement (p<0.05).
Splenomegaly was presented significantly common in MCD (p=0.001). 3-year
overall survival was significantly higher in patients treated with only radiotherapy
or chemotherapy in addition to radiotherapy when compared to only chemother-
apy (p=0.001). Mean survival was significantly higher in patients with hyaline
vascular variant and UCD (p <0.05).
Summary/Conclusions: This study is the most comprehensive study in our
country about Castleman’s Disease and we obtained important information
about clinical, histopathological and prognostic features of the disease. We
suggest combined therapy with radiotherapy is superior to chemotherapy alone,
but as we know the efficiency of radiotherapy in the treatment of unicentric
Castleman’s Disease and we may have got this outcome due to some of the
unicentric patients in our study were treated by radiotherapy alone.
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OCULAR ADNEXAL LYMPHOMAS: A CASE SERIES
S Dhawan1,*, MA Khan1, N Barrett1, R Kapoor1, M Mulhern2, S Kumar1,
E Elhassadi1, F Jackson1, S Kennedy3, B Hennessy1
1Haematology Department, University Hospital Waterford, 2Ophthalmology
Department, Whitfield Clinic, Waterford, 3Pathology Department, Royal Victoria
Eye and Ear Hospital, Dublin, Ireland
Background: Ocular lymphomas comprise only 1% of all non-Hodgkin lym-
phomas (NHL)1. However, it is a common extranodal site (5-15% of the extra-
nodal cases)2. Lymphoma arises from the localized lymphoid tissue affecting
the orbit, the eyelids, the conjunctiva and the lacrimal gland. The high curative
potential of the local disease makes prompt diagnosis clinically important.
Aims: Case series involving 16 patients with ocular adnexal lymphoma and
study of their treatment outcomes.
Methods: Retrospective review of 16 patients’ records from Royal Victoria Eye
and Ear Hospital Dublin and University Hospital Waterford with a diagnosis of
ocular adnexal lymphomas (OAL).
Results: In our case series, we found that follicular lymphomas were the most
common subtype (50%), followed by extranodal marginal zone B-cell lymphoma
or mucosa-associated lymphoid tissue (MALT) lymphoma (37.5%) and diffuse
large B-cell lymphoma (12.5%). Majority of the patients were between the ages
of 70-80 years. Male to female ratio was 1:1.3. Nine patients (56.2%) had primary
OAL, 6(37.5%) had concurrent systemic involvement and one (6.25%) presented
with ocular relapse of systemic disease. The most common presenting complaint
was swelling of the eye or visible lump (62.5%) and the most common site was
the orbit (37.5%) followed by conjunctiva (25%) and eyelid (25%).
Summary/Conclusions: Ocular site of the tumor does not influence the natural
history of NHL. Localized disease was controlled in all cases. 10 patients
(62.5%) had localized disease; radiotherapy remained the standard of treat-
ment. Patients with localized disease who were treated with 4 cycles of mon-
oclonal antiCD20 antibody (Rituximab) alone responded well to the treatment
and sustained remission. Treatment with Rituximab alone averts potential tox-
icity of radiotherapy (e.g. cataract formation). Systemic disease accounted for
37.5% of the cases and were treated with systemic chemotherapy.
References
1. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat
Oncol Biol Phys. 1984; 10:333-340.
2. Lambo MJ, Brady LW, Shields CL. Lymphoid tumors of the orbit. In: Alberti
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RISK FACTORS AND MICROBIOLOGICAL FEATURES OF BLOODSTREAM
NONTYPHOIDAL SALMONELLA INFECTION IN ADULT PATIENTS RECEIVING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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Background: In patients receiving allogeniec hematopoietic stem cell trans-
plantation (allo-HSCT), it is not uncommon to encounter post-transplant infec-
tion and/or acute or chronic graft-versus-host disease (aGVHD or cGVHD)
which commonly involve gastrointestinal tract and liver. Thus, post allo-HSCT
patients might be vulnerable to foodborne pathogens, such as nontyphoidal
salmonella (NTS) infection. To the best of our knowledge, very few reports dis-
cuss this issue of post allo-HSCT bloodstream NTS infection. We retrospec-
tively analyzed the clinical risk factors and microbiological features of blood-
stream NTS infection among adult allo-HSCT recipients during a 12-year period
in our institution.
Aims: To determine the survival outcomes, the risk factors and microbiological
features of bloodstream nontyphoiidal salmonella infection in adult allo-HSCT
recipients.
Methods: We retrospectively reviewed adult (age ≥18 years) allo-HSCT recip-
ients between 2003 and 2014 with regular follow-up till October 2015. Pre-
transplant and transplant-related clinical data were collected. Myeloablative
conditioning included busulfan (4mg/kg/day for 4 days) and cyclophosphamide
(60mg/kg/day for 2 days), or total body irradiation (TBI) of 12 Gy combined
with cyclophosphamide (60 mg/kg/day for 2 days). Fludarabine-based condi-
tioning were administered to elderly patients or with comorbidities. Standard
protocol with cyclosporin (i.v 3.0 mg/kg/day in 2 split doses with dose being
adjusted to maintain trough plasma level at 100-250 ug/L) and short-term low
dose methotrexate were adopted for GVHD prophylaxis. Recipients of unre-
lated donor transplants also recieved anti-thymocyte globulin (2mg/kg/day for
3 days). The overall survival (OS) in patients with or without bloodstream NTS
infection was analyzed by Kaplan-Meier method. A log-rank test was used to
compare survival curves for statistical significance. Odds ratios (ORs) and the
95% confidence interval (CI) were calculated using logistic regression models.
We used multivariate logistic regression models to calculate odds ratios while
adjusting for possible independent confounding factors. All risk factors with
p<0.1 in the univariate model further entered into the multivariate analysis. All
statistical testing was performed using 2-tailed tests; p<0.05 was considered
statistically significant.
Figure 1.
Results: Total nine patients (2.13%) of 423 patients recieving allo-HSCT expe-
rienced post-tansplant bloodstream NTS infection in a median onset of 315
days after HSCT. As for the nine with NTS infection, fever was a majorly pre-
senitng symptom. Metastatic infection of knee joint occurred in 2 patients. One
suffered from concurrent bloodstream NTS infection and spetic arthritis and
the other one had subsequent septic arthritis after 42 days of bloodstream NTS
infection. Salmonella group D was cultured in eight out of nine patients (89%).
Of note, among the 9 bloodstream NTS infection, 7 patients had cGVHD, 5 of
whom suffered from extensive cGVHD. Fortunately, all patients recovered with
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antibiotic therapy, which comprised of a at least third-generation cephalosporin
or a quinolone or both. In addition, in patients with or without bloodstream NTS
infection, there was no statistical difference of post-transplant survival (p=0.322;
Figure 1). After multivariate analysis, there were statistical significances in
patients receiving non-myeloablative conditioning (OR: 4.604; 95% CI: 1.098-
19.308; p=0.037) and post-transplant extensive cGVHD (OR: 8.054; 95% CI:
2.048-31.674; p=0.003).
Summary/Conclusions: In a cohort of 423 adult patients recieving allogeneic
hematopoietic SCT, 9 patients (2.13%) developed post-transplant NTS infection,
including two patients had subsequent or combined metastatic infection. Mul-
tivariate analysis revealed that extensive chronic graft-versus-host disease
(GVHD) (OR 8.054, p=0.003) and non-myeloablative transplant conditioning
(OR 4.604, p=0.037) were significant risk factors for NTS infection. Our study
determined the risk factors and microbiological features for this infection.
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THE REAL WORLD USE OF BISPHOSPHONATES IN MULTIPLE MYELOMA
AT UNIVERSITY COLLEGE HOSPITAL (UCH), LONDON: A COMPARISON
WITH LATEST GUIDANCE
O Cohen*, N Rabin, S D’Sa, R Popat, A Rismani, K Yong
Haematology, University College London Hospital, London, United Kingdom
Background: The use of intravenous bisphosphonates in patients diagnosed
with myeloma is regarded as standard of care, irrespective of the presence of
bone lesions. The only exceptions may be patients in advanced renal failure,
or those with osteonecrosis of the jaw (ONJ). Zoledronic acid is the bisphos-
phonate of choice given evidence of an anti-myeloma effect, including survival.
Optimal duration of bisphosphonate usage is less clear but the recommendation
from the International Myeloma Working Group (IMWG) is to continue for a
minimum of 1-2 years after which discontinuation can be considered if complete
response (CR) or very good partial response (VGPR) is achieved. This guid-
ance is recommended but not always followed. We review clinical practice sur-
rounding bisphosphonate usage at a tertiary centre.
Aims: To describe the real world use of bisphosphonates in patients attending
a specialist myeloma clinic and how it compares with published guidance.
Methods: A sample of 60 patients with symptomatic myeloma was taken
sequentially from clinic lists in December 2015. Data was collected for these
patients from clinical case record (CDR) and electronic prescribing system
(Chemocare) in regards to current disease status, chemotherapy, bisphospho-
nate use and complications and renal function. A literature search was per-
formed using Pubmed in order to collate the latest guidance.
Results: 60 patients with myeloma attending the myeloma clinic were identified.
Of these, 55% were male. 10% patients were <50 years old, 72% patients were
aged 50-70 and 18% were >70 years old. 27% were diagnosed with myeloma
within the last 2 years. Disease isotypes were: 52% IgG, 12% IgA, 17% kappa
light chain, 13% lambda light chain and 6% other disease type. 52% were on
active treatment; 17% on Bortezomib regimens, 25% on Lenalidomide, 8% on
Pomalidomide and 2% on other regimens. 58% of patients had abnormal renal
function (GFR<90ml/min). 57/60 were commenced on a bisphosphonate at
diagnosis, which was Zoledronic acid in 77% of all cases but just 46% in patients
with eGFR <60ml/min. In all other cases, it was Pamidronate. All patients had
renal function monitored via a blood test prior to each bisphosphonate infusion
but urine albumin was not measured. DEXA scans were not routinely done to
assess bone density. 88% of patients diagnosed within 2 years were still on 4-
weekly bisphosphonates. After 2 years, 12% had the bisphosphonate stopped
whilst 48% had the frequency reduced to 2-3 monthly. The remaining 40%
remained on monthly treatment. Of the 40% on monthly bisphosphonate treat-
ment more than 2 years from diagnosis, most (88%) were being actively treated
for their myeloma. Of the 31 patients on active treatment, 71% were still on 4
weekly bisphosphonates. Of patients with an eGFR of <60ml/minute, 64% had
their bisphosphonate dose reduced. One patient had a reduction in treatment
frequency as a consequence of ONJ. A further 4 patients had dental intervention
documented during bisphosphonate treatment, one of whom had their bispho-
sphonate treatment held for 2 months as a result.
Summary/Conclusions: Compliance with IMWG guidance on initiation of bis-
phosphonates occurred in 95% of cases. Zoledronic acid is used less frequently
in patients with abnormal renal function. Whilst frequency of bisphosphonate
use often reduces after 2 years (61%), there is marked variability in the time
point and disease status at which this occurs. Further work is required to clarify
optimal duration of bisphosphonate use and scheduling, and the adjustments
for osteonecrosis and dental intervention.
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ANTIFUNGAL PROPHYLAXIS WITH MICAFUNGIN IN PATIENTS UNDERGOING
AUTOLOGOUS AND ALLOGENIC STEM CELL TRANSPLANTATION. A
SINGLE CENTRE EXPERIENCE
A Alba Sosa*, P González Sierra, A Cruz Díaz, E López Fernández,
L Moratalla López, Z Mesa Morales, A Romero Aguilar, M Jurado Chacón
Hematology, Complejo Hospitalario Universitario de Granada, Granada, Spain
Background: Micafungin is an echinocandin antifungal approved for prophy-
laxis in patients undergoing allogenic hematopoietic stem cell transplantation.
It has a broad spectrum against yeasts and filamentous fungi. In our institution,
we employ Posaconazole as antifungal primary prophilaxis for allogenic trans-
plantation and Fluconazole for autologous procedures but there are different
situations that require us to change the protocol such as tolerance or toxicity
to azoles or interactions with other drugs such as rapamycin.
Aims: Analyze the efficacy and safety of the use of Micafungin for antifungal
prophylaxis in patients undergoing autologous and allogenic hematopoietic
stem cell transplantation. 
Methods: Between January 2013 and December 2015, 77 patients have
received Micafungin at doses 50 mg daily. 51 (66.2%) of them were male. The
mean age at transplantation was 43.7 years-old (20-61). Diagnoses were 23
acute leukemias (29.8%) twenty-two (28.5%) Non-Hodgkin Lymphoma, twelve
(15.5%) Hodgkin Disease, six (7.7%) myelodisplastic síndrome, five (6.4%%)
Multiple Myeloma, five (6.4%) philadelphia-negative chronic myeloproliferative
neoplasms, three (3.8%) aplastic anemia and one case of Chronic Myeloid
Leukemia. Most of the stem cell transplantation were allogenic (85%). Only
seven (8.8%) and five (6.5%) were autologous and haploidentical procedures
respectively. Major of Conditioning regimen was myeloablative (71.3%), 17.5%
undergoing reduced intensity conditioning regimen and only 11.3% no myelobla-
tive regimen. 46.3% of the patients presented absolut neutrophils count (ANC)
less than 1000/mm3. The average duration of treatment with micafungin was
20.7 days (5-150) and the median duration was 14 days. The reason to start
micafungin treatment was primary prophylaxis in ten cases (10%), bad gas-
trointestinal tolerance to azoles in fifty-four cases (70.1%), farmacological inter-
actions with azoles in seven patients (9%) and toxicity to azoles in only five
patients (6.4%). 
Results: Reason to finish prophilaxys with micafungin was the improve of the
gastrointestinal syntoms and, consequently, the end of prophilaxys period in
fifty-two cases (67.5%). Six patients (7.8%) presented breakthrough fungal infec-
tion. Other causes were positive antigen galactomannan (2 patient), persistent
fever (5 patient), exitus not attributable to IFI (5 patient), toxicity to micafungin
(2 patients) and unknown cause in four patients. Six patients (7.8%) presented
breakthrough fungal infection (all probably invasive fungal infection according
to the EORTC criteria). Isolated fungi were Geosmithia argillaceae, Aspergillus
Fumigatus, Aspergillus Flavus and Aspergillus spp. Mortality due to Fungal infec-
tion was 3.8% (three patients). With regards to tolerance, there were no reports
about any infusional reaction. Only 2 patient referred micafungin liver toxicity
grade II without any problem when the micafungin was suspended.
Summary/Conclusions: 1. Micafungin at doses of 50 mg/24 hours, is an effec-
tive and safe option for yeast prophylaxis in patients undergoing autologous
and allogenic stem cell transplantation. 2. In our series, although they have
identified six breakthrough infections (7.8%), it must be noted that these were
patients with active refractory GVHD to several lines of immunosuppressive
therapy, including, of course, high-dose steroids. Maybe, we have to use pro-
phylaxis protocol based on liposomal anfotericin, with a better anti-mold spec-
trum, in this group of high risk patients. 3. The safety of the treatment was
excellent, without tolerance problems. The kidney and liver function was not
altered by treatment with micafungin.
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THE POSITIVE IMPACT OF ANTIMICROBIAL STEWARDSHIP IN THE
BIGGEST PEDIATRIC HAEMATOLOGY ONCOLOGY CENTRE, RUSSIA
V Pirumova, G Solopova*
Infection Prevention and Control, Dmitry Rogachev Research Center for Pedi-
atric Hematology, Oncology and Immunology, Moscow, Russian Federation
Background: Multidrug resistant organisms (MDRO) are the emerging problem
across the world, and one of the most effective and mandatory steps in solving
it is optimization of antibiotics use. Here we present the first results of the fight
against MDRO at the Dmitry Rogachev Center for Pediatric Hematology, Oncol-
ogy and Immunology, Moscow, Russia (Center).
Aims: The Infection Prevention and Control Department (IPCD) has made a
number of steps to rationalize the use of anti-infectives.
Methods: On January 1st, 2014, the algorithm for empirical anti-infective ther-
apy in febrile neutropenia was implemented. It included recommendations for
first line (empiric) antibacterial therapy (in accordance with the patient’s risk
group), spectrum of recommended evaluation tests and rules for treatment
modification. For example, fluoroquinolones and ceftazidime were excluded
from empiric therapy and reserved for the targeted one only. The same recom-
mendations were made regarding tigecycline and ertapenem. Another step was
the implementation of guidelines for perioperative antibiotic therapy, with
cephalosporins I-II regarded as the drugs of choice in most of cases. Along
with those measures, precise control of antibiotics and antifungals discontinu-
ation was established. For the evaluation of the effectiveness of the results we
have calculated the use of the most common classes of antibiotics and antifun-
gals (per 100 bed-days) before the intervention and a year after it. Microorgan-
isms’-wise drug resistance index (DRI) was also calculated.
Results: Having compared the respective rates before and after the interven-
tion, we detected the overall decrease of use in vancomycin (64%), piperacillin/
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tazobactam (15%), aminoglycosides (15%) and fluoroquinolones (7%) in all
the Center’s departments. Calculated separately, the rates were significantly
higher for the intensive care unit, where interaction compliance with the IPCD
was the highest: reduction of aminoglycosides use -58%, fluoroquinolones
-66%, cephalosporins III-IV-8%, vancomycin-82,5%, piperacillin/tazobactam
-52%, carbapenems-20%, linezolid-47%. The use of colistin remained on the
same level, while the use of tigecycline raised 35%. As for antifungals, the
analysis showed a 75% reduction of use in amphotericin B and an 18% reduc-
tion in case of voriconazole. Posaconazole raised 25%. Although echinocandins
were used as the drugs of choice in empiric antifungal therapy in febrile neu-
tropenia algorithm (in accordance with the ECIL recommendations), their use
remained on the same level. During the surveillance period DRI levels for
P.aeruginosa and E. coli dropped down (graph 1). In terms of money, the reduc-
tion of anti-infectives use have saved the Center around €500,000 in 12 months.
It is important to mention that the rates of infections-related mortality has not
increased since the intervention (26 in 2013 compared to 16 in 2014).
Figure 1.
Summary/Conclusions: The reduction of antibiotics and antifungals use and
as a result - the decrease of microbial resistance and money savings in hema-
tology/oncology hospital is an achievable goal. Every hospital should make
the effort to initiate and sustain an effective Antimicrobial Stewardship Pro-
gram.
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INVESTIGATION OF RELATIONSHIP BETWEEN NEUTROPENIA AND
SERUM CHITOTRIOSIDASE AND NEUTROPHIL GELATINASE RELATED
LIPOCALIN ENZYME ACTIVITY IN CHILDREN UNDERGOING
CHEMOTHERAPY
O Gursel1,*, I Eker1, O Babacan1, S Kılıc2, E Kurekci1
1Department of Pediatric Hematology, 2Department of Pediatrics, Gulhane Mil-
itary Medical Academy and Medical Faculty, Ankara, Turkey
Background: Human chitotriosidase (ChT) is a member of the chitinase family
and it is synthesized and secreted by activated macrophages and neutrophilic
granulocyte progenitors. Neutrophil gelatinase related lipocalin (NGAL) is sit-
uated in secondary granules of granulocytes and is specific to neutrophils.
Aims: The aim of this study was to investigate the relationship between neu-
tropenia and serum ChT and NGAL levels in patients with hematologic malig-
nancy and hospitalized because of febrile neutropenia.
Methods: This study included 27 children between 1-15 years old, who have
hematologic malignancies and whose chemotherapies were still ongoing and
were known not having a disease that leads to macrophage activation. Com-
plete blood count (CBC),serum levels of c-reactive protein (CRP), lactate dehy-
drogenase (LDH), ChT and NGAL were determined before the initiation of
chemotherapy while the patients were not neutropenic. The same tests were
studied also in the severe neutropenic period and after the recovery of neu-
tropenia. Serum ChT and NGAL levels of the patients during these periods
were compared. Whether there is a correlation between the number of neu-
trophils and these enzyme levels were also investigated.
Results: Total granulocyte count (TGC), CRP, LDH, NGAL and ChT levels
were statistically significant different between the periods of severe neutrope-
nia, improving neutropenia and recovered neutropenia (p:0,0001). There was
a statistically significant positive correlation between ChT and TGC levels dur-
ing the period of severe neutropenia (p:0.034, Pearson’s r: 0,418). There was
not a statistically significant relationship between NGAL and TGC levels during
the period of severe neutropenia. 
Summary/Conclusions: The results of our study exhibiting a statistically sig-
nificant difference, between serum ChT and NGAL levels, during the periods
of severe neutropenia, improving neutropenia and recovered neutropenia, sup-
ports the data suggesting that these enzymes are secreted by neutrophils.
Especially, statistically significant positive correlation between ChT and TGC
levels suggests that levels of this enzyme can be used as a marker to determine
the period of recovery from neutropenia. Further studies are needed to inves-
tigate the relationship between febrile neutropenia prognosis and NGAL and
Cht levels.
PB1888
EPIDEMIOLOGY OF FEBRILE EVENTS (FE) IN NEUTROPENIC PATIENTS
(PTS) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED BY
«ALL-2009» PROTOCOL
V Okhmat*, G Klyasova, V Troitskaya, E Gribanova, S Kravchenko, E Parovichnikova
National Research Center for Hematology, Moscow, Russian Federation
Background: Hematological patients with acute leukemia undergoing intensive
myelosupressive treatment are at high risk for severe, life-threatening infections.
Aims: To evaluate the epidemiology of FE in neutropenic pts with ALL on dif-
ferent chemotherapy phases (CP).
Methods: Single-center, prospective observational study in adults with newly
diagnosed ALL treated by «ALL-2009» protocol (NCT01193933) was performed
from Jan 2013 till Jan 2016. Pts were followed up for 180 days. 
Results: Total of 44 pts were enrolled (22 - male, 22 - female; median age 26
(17-61). On admission hyperleukocytosis was in 25% (11/44) of pts, ECOG
score ≥3 had 61% (27/44). These pts had 271 CP (induction I-43, induction II-
42, consolidation I-42, consolidation II - 41, consolidation III-40, consolidation
IV - 33, consolidation V - 30). Neutropenia was in 33% of CP, median duration
9 (2 - 45) days, more frequent and prolonged in induction then in consolidation
(58% vs 22%, p<0.0001; 19 vs 6 days, p<0.000001). FE occurred in 18%
(48/271) of CP, more often in,induction than in consolidation (36% vs 9%,
p<0.0001). FE (48) reasons were: fever of unknown origin (FUO) in 29% (14),
clinically documented infection (CDI) in 48% (pneumonia - 17, cellulitis - 6)
and bloodstream infection (BSI) in 23% (11). Among BSI pathogens Gram-
negative bacteria were in 77% (E. coli-3, Salmonella spp.-3, K. pneumonia-2,
E. asburae-1, C. youngae - 1), Gram-positive bacteria were in 23% (B. cereus-
1, S. aureus-2). BSI was polymicrobial in 18% (2/11). Rate of invasive mycoses
(IM) was 14% (6/44): 2 - invasive aspergillosis, probable (IA), 1 - mixed IA,
probable plus mucormycosis, 3 - hepatosplenic candidiasis. All IM occurred in
induction. Nobody had IM in consolidation (p=0.0002). Overall 180 days mor-
tality was 5% (2/44), 1 patient died in induction (1-IA plus mucormycosis) and
1 in follow-up period (BSI due to Salmonella spp.).
Summary/Conclusions: Our study showed moderate rate of infections (18%)
in ALL pts treated by «ALL-2009» protocol. FE were more frequent in,induction
than in consolidation (36% vs 9%). Most pts (71%) had CMI and BSI. IM
occurred only in induction. Overall 180 days mortality was relatively low (5%).
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THE CLINICAL SIGNIFICANCE OF PROCALCITONIN MONITORING IN
INFECTED PATIENTS WITH HEMATOPATHY
J Zheng, A Sun*, T Zhang, W Chang, S Chen, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Due to the application of the drugs such as high doses of
chemotherapy, immune inhibitors and hormone, hematopathy patients are
becoming more likely to get granulocyte lack and the resistence to infection.
For those patients with the application of the peripheral venipuncture in gran-
ulocyte lack period, infection incidence can be as high as 53% ~ 80%. Accord-
ingly, infection is one of the most common life-threatening complications, and
therefore the early diagnosis and treatment of infection is very important to
better prognosis. But now there is no sufficient sensitive markers to reflect the
level of inflection in hematopathy patients. Traditional markers such as the
number of white blood cells, C - reactive protein have no obvious specificity in
the diagnosis of hematologic malignancies with infection. Positive bacteriology
of blood culture is the only gold standard in the diagnosis of patients with blood-
stream infections.However, it can’t meet the requirements for early and rapid
diagnosis, because the blood culture positive rate is only 10% ~ 20%, and
pathogen isolation and culture time is long; Calcitonin original protein (PCT) is
the precursor of calcitonin,which has been proven to be high in a variety of dis-
ease infection since it was found in 1993. Furthermore, it is a sensitive and
specific indicator in early granulocyte lack with severe bacterial infections.
Aims: To evaluate the clinical value of procalcitonin (PCT) measurement and
its dynamic monitoring in hematopathy patients undergoing chemotherapy or
transplant-related infections.
Methods: The clinical data were collected and analyzed retrospectivey in 497
hematopathy patients with serum PCT above 0.5μg/L. The procalcitonin were
compared between the patients with septic shock and those without. The pro-
calcitonin were also compared between the patients with positive blood culture
and those with negative blood culture. Further, theprocalcitonin were compared
between the patients with gram-positive bloodstream infection and those with
gram-negative bloodstream infection. Receiver operating characteristic (ROC)
curve was used to evaluate the diagnostic value of procalcitonin in predicting
sepsis. PCT values were collected at the onset of fever and 3, 7, 14, 21, 28
days after antimicrobial therapy. The dynamic change of PCT after operation
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was compared between the patients whose infection was successfully con-
trolled and those without adequate control.
Results: There were totally 497 hematopathy patients with serum PCT value
>0.5μg/L, 421 (84.7%,421/497) cases among whom were diagnosed with infec-
tion based on clinical symptoms and microbiological assays. Out of these 421
patients, we found that 296 (70.3%, 296/421) cases’ PCT values increased
(>0.50μg/L) within 24 hours after having a fever. The median (range) procalci-
tonin level [6.29 (0.505-100) μg/L]was significantly higher in 59 (14.0%, 59/421)
patients with septic shock than in those (86.0%, 362/421) without [1.16 (0.502-
100) μg/L,Z=-7.726,P<0.01].408 patients received blood culture examination.
The median (range) procalcitoninlevel [2.47 (0.508-100) μg/L]was significantly
higher than in 167 patients with positive blood culture than in 240 patients with
negative blood culture [1.15 (0.501-100) μg/L, Z=-5.762, P<0.01]. Additionally
the median (range) procalcitoninlevel [4.315 (0.508-100) μg/L] was significantly,
higher in 108(64.7%, 108/167) patients with gram-negative sepsis than in 37
(22.2%, 37/167) patients with Gram-positive sepsis [1.39 (0.521-55.44) μg/L,
Z=-2.024, P<0.01]. The area under the curve (AUC) for PCT was 0.670, where-
as a cut-off value of 2.05μg/L, provided the best sensitivity and specificity with
a value of 54.3, and 70%, respectively. The dynamic changes of 289 monitoring
PCT patients reflected the infection course. No significant difference was found
between the patients with deteriorate and persistent infection and those whose
infection was successfully eradicated properly within 72 hours (P>0.05). How-
ever,the PCT after 72 hours were significantly different among the three group
(All P<0.01).
Summary/Conclusions: Procalcitonin monitoring could be used as a rapid
and supplementary diagnostic marker of infection,especially in blood culture-
negative infected patients.Additionally,its dynamic change could also reflect
the infection course,which provides a better guide for the use of antibiotics.
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PREVALENCE OF CYTOPENIAS IN PATIENTS LIVING WITH THE HUMAN
IMMUNODEFICIENCY VIRUS. AN OBSERVATIONAL COHORT STUDY
DL Teofilo1,*, A Enrico1, F Otermin2, M Szelagowski1, MV Prates1, H Dick1,
S Yantorno1, JJ Napal3, S Ramirez Borga2, J Milone1
1Hematologia, 2Infectologia, 3Medicina interna, Hospital Italiano La Plata, La
Plata, Argentina
Background: HIV-induced immunosuppression was an important reason for
the increased morbidity and mortality. Disorders in haematopoiesis are encoun-
tered far less frequently in the current era of highly active antiretroviral therapy
(HAART). The expected survival of people living with HIV who are diagnosed
early in the course of infection and who have access to modern antivirals now
almost equals that of the general population. Ineffective haematopoiesis from
direct suppression of bone marrow progenitor cells by HIV infection or indirectly
through excessive secretion of inflammatory cytokines induced by HIV, can blunt
haematopoiesis. So too can nutritional deficiencies, infiltrative bone marrow dis-
ease of infectious or neoplastic origin, and adverse drug effects. Cytopenias
play a significant role in the morbidity associated with HIV. Although cytopenias
may be poorly documented, they can also impact negatively on quality of life.
Aims: To analyze the prevalence of cytopenias in patients with HIV infection
and evaluate the impact of HAART in our patients.
Methods: This is a retrospective study of 108 patients older than 16 years,
HIV infected, diagnosed between 2002-2014. Their medical histories were ana-
lyzed. Data was collected from laboratory at the moment of diagnosis, one year
later and two years of follow-up. 98 patients were included in this analysis. We
did not include patients with pediatric HIV infection or a history of vertical trans-
mission and patients with loss of follow-up (follow-up less than 2 years).
Table 1.
Results: The selected 98 patients showed a median age of 37.7 years (r16-
65), 74% were male. At the time of diagnosis, 44% had anemia, 40% thrombo-
cytopenia and 5% leukopenia (table 1). Only 8% of the patients had neutrope-
nia. At the beginning, anemia was present in 48% of female and 36% of male
patients. At the time of diagnosis, 31.6% (n31) were diagnosed with AIDS
(according to WHO criteria). Out of these 31 patients, 61% had anemia basal
vs 28% in those without AIDS at the start (p:0.001). At 12 months, only 29% of
the patients showed anemia, with improvement in both male and female
patients compared to the time of diagnosis as well as in the group of patients
with initial AIDS. The presence of thrombocytopenia was observed in 5% of
the patients. At 24 months of follow-up, 21% had anemia, and only 7% of those
who initially had a diagnosis of AIDS. The thrombocytopenia appeared in 7%.
None of the patients presented leukopenia at 12 or 24 months. As regards
HAART, out of the 98 patients, 64.2% (n:63) received treatment since the diag-
nosis. Within this group, the emergence of anemia at 1 and at 2 years was
22% and 15% respectively, compared to 24% and 16% in patients who received
no treatment at the beginning. Twenty-three of the patients who received zidovu-
dine (AZT) developed anemia after one year of treatment. Those who did not
receive AZT, the 27% presented anemia at 12 months. None of the patients
who received AZT treatment showed leukopenia at one year of follow-up.
Summary/Conclusions: In our experience, the most frequent hematological
alteration was anemia, mainly at the time of diagnosis and in patients with AIDS.
The haemoglobin level evolved favorably in all patients, regardless of the pres-
ence or absence of antiretroviral therapy at the beginning. The thrombocytopenia
was more frequent at the time of diagnosis, but it decreased with time. The less
frequent cytopenia was the leukopenia, showing no association with HAART.
HIV associated cytopenias are very frequent and its appearance occurs mainly
at the time of the diagnosis. When faced with this type of cytopenias, it is manda-
tory to have this infectious disease in mind within the diagnosis algorithm.
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IMMUNOGLOBULIN SUPPLEMENTATION IN ACUTE LYMPHOBLASTIC
LEUKEMIA TREATMENT IN A SINGLE PEDIATRIC INSTITUTION:
COMPARISON BETWEEN TWO CONSECUTIVE AIEOP CLINICAL TRIALS
F Petruzziello, G Giagnuolo, A De Matteo, R Parasole*, G Sepe, E Ruberto,
G Menna, S Buffardi, V Poggi
Pediatric Hemato-Oncology, Santobono-Pausilipon Hospital, Naples, Italy
Background: The intensification of chemotherapy in childhood acute lym-
phoblastic leukemia (ALL) has dramatically improved the 5-years overall sur-
vival but, at the same time, has increased the site effects therapy related. The
most common complication remains the immunosuppression that causes
increased risk of infections. The recent introduction of a pegylated formulation
of L-Asparaginase (Peg-L-Asp), with more prolonged half-life and immunosup-
pressive effect than native E. Coli L-Asp, could result in a greater injury on ALL
patients’ humoral immunity. 
Aims: We compared the rate of supportive Immunoglobulin (Ig) infusion during
two consecutive therapeutic protocol of the Italian Association of Hematology
and Pediatric Oncology (AIEOP) in a single pediatric center. The first trial, ALL
2009, contained Peg-L-Asp and the second, ALL 2006, native L-Asp; the
remaining chemotherapy was similar.
Methods: Seventy-three patients, stratified in high-risk (HR; n=19), medium-
risk (MR; n=32) and standard risk (SR; n=22), enrolled in ALL 2009 protocol,
were compared with 68 patients (15 HR, 30 MR and 23 SR), of ALL 2006 trial.
Patients submitted to a bone marrow transplantation or early relapsed were
excluded by the analysis. Number of Immunoglobulin infusions, type and number
of L-Asp administrations, risk stratification, IgG levels at diagnosis and episode
of infections were collected by clinical records of both protocols. Possible cor-
relations between Ig supplementation rate and the other parameters were ana-
lyzed using t-Student test and linear regression. Immunoglobulins were supple-
mented for Ig levels beyond 5.0 g/L at the standard dose of 0.5 g/kg.
Results: In ALL 2009 protocol, mean of Ig infusions were 6.2±2.9 SD (range
1-12) in HR, 2.8±2.0 SD in MR (range 0-8), and 2.2±2.1 SD in SR (range 0-4),
while in ALL 2006, mean of Ig administrations were 2.9±1.7 in HR (range 0-6),
1.2±1.3 in MR (range 0-6) and 1.5±1.6 in SR (range 0-7), respectively. A higher
rate of Ig infusions was observed in ALL2009 trial but this cumulative rate is
not statistically significant. However, the difference between HR and MR risk
stratification for the average of Ig infusions was significant (p <0.05) comparing
ALL2009 and ALL 2006 trials. No correlation was found between Ig supple-
mentations and risk of infections, number of L-Asp administrations, and IgG
level at diagnosis.
Summary/Conclusions: In our experience, an higher Ig supplementation was
observed in the very intensive protocol (HR and MR), mostly in ALL2009 trial.
Further studies, with more extensive series of patients, need to understand the
reason to the increased demand of immunoglobulin support in HR and MR
patients treated with Peg-L-Asp.
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CANDIDAEMIA SPECTRUM: RESULTS OF A THREE-YEAR ANALYSIS AT
THE PEDIATRIC HAEMATOLOGY ONCOLOGY CENTRE, RUSSIA
V Pirumova*, G Solopova
Infection prevention and control, Dmitry Rogachev Research Center for Pedi-
atric Hematology, Oncology and Immunology, Moscow, Russian Federation
Background: Invasive infections due to Candida spp. are among the leading
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causes of morbidity and mortality of immunocompromised pediatric patients.
Candidemia levels are still high, despite the ongoing improvements in diag-
nostics, prophylaxis and treatment possibilities. It not only affects the outcomes
of cancer treatment, but also shifts the treatment costs. As for now, there are
no data available on the epidemiology of invasive candida infections for pedi-
atric hematology/oncology in Russia.
Aims: The study’s aim was to determine the rate and spectrum of candidemia
in Russia’s largest pediatric hematology/oncology center.
Methods: We present a retrospective analysis of candidemias occurred at the
Dmitry Rogachev Center for Pediatric Hematology, Oncology and Immunology,
Moscow, Russia. All blood cultures positive for Candida spp. taken from 22
March 2013 to 22 November 2015 have been identified, and all first patient-
episode pairs have been included. Spectrum of species, patient’s characteris-
tics, treatment strategies and outcomes have been analyzed.
Results: During surveillance period 34 episodes in 32 patients occurred. 36
Candida spp. were identified. 2 patients had 2 separate candidemia episodes,
and in 2 cases more than one Candida spp. was cultured. Age distribution was
0-21 years (58% 0-3 years, 16% 5-10 y., 26% 11-21 y.). The majority of patients
had some sort of hematological malignancy (39%), 29% had primary immun-
odeficiency, 26% had solid tumors and 3% had severe congenital neutropenia.
6 patients among all those with candidemia were after hematopoietic stem
cells transplantation (18.7%). C. parapsilosis was responsible for the majority
of episodes (53%) (graph 1). In 11 of 18 isolates the ecchinocandines suscep-
tibility testing was performed: 10 (90.9%) were susceptible, 1 had intermediate
susceptibility. As the first line therapy, 19 patients (59%) received echinocan-
dins, 6 - amphotericin B, 3 - voriconazole, and 3 - fluconazole. In all cases
antifungals were given within 24 hours from the time of execution of the blood
cultures. One patient did not receive any therapy (although the central line was
removed immediately). Central line was removed in 29 (88%) cases. Speaking
of the outcomes, 72% patients were alive at the end of the episode. Mortality
attributed to Candidemia was 12.5% (4 cases), with the time median of 21 day
(3-37 days).
Figure 1.
Summary/Conclusions: Invasive candidiasis is a common complication in
pediatric hematology/oncology patients. In our hospital in 2013-2015 can-
didemia accounted 8.6% of all bloodstream infections. C. parapsilosis was
responsible for the majority of the cases, while mixed infections were rare. The
attributive mortality was as high as 12.5%.
PB1893
RISK FACTORS FOR INFECTION AND HIGH MORTALITY RATE AMONG
PATIENTS WITH KPC PRODUCING KLEBSIELLA PNEUMONIAE 
BACTERAEMIAS IN A HAEMATOLOGY UNIT
A Galanopoulos1,*, P Bakarakos1, D Tsokanas1, G Drakos1, M Orfanidou2,
G Ganteris2, H Vagiakou2, P Giakkoupi3, A Vatopoulos4, H Malamou-Lada2,
N Anagnostopoulos1
1Hematology Department, 2Medical Microbiology, GNA “G.Gennimatas”,
3Microbiology, 4Microbiology, National School of Public Health, Athens, Greece
Background: Emergence of carbapenem resistant enterobacteriae, especially
Klebsiella spp, causing nosocomial infections is growing worldwide and has
become a great challenge especially for clinicians and the Public Health Sys-
tem. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneu-
moniae (KPC-Kp) infections in Haematology Unit patients are associated with
increased mortality.
Aims: This study was carried out to determine risk factors for KPC-Kp infections
and predictors of mortality in Haematology Unit patients with KPC-Kp bacter-
aemias.
Methods: In this retrospective study of a 3-year period, all patients with hos-
pital-acquired KPC-Kp isolation were included and were compared with other
non bacteraemic patients. K. pneumoniae were identified by Vitek 2 technology,
antibiotic susceptibility was determined by agar disk diffusion method and min-
imum inhibitory concentrations were determined by Etest. The presence of the
blaKPC gene was confirmed by PCR. Molecular typing was performed by
pulsed field gel electrophoresis (PFGE) of Xbal-restricted genomic DNA.
Results: Eighteen episodes of infections were identified and KPC-Kp strains
were isolated from 16 patients. Acute myeloid leukaemia was the underlying
disease in 10 patients, non-Hodgkin lymphoma in two and acute lymphoblastic
leukaemia, chronic lymphoblastic leukaemia, aplastic anaemia and multiple
myeloma, one each. Seven of them were males and nine were females and
their median age was 70 years (range: 25-83). The medical records of patients
were retrospectively collected for demographic, clinical, and microbiological
data. Clinical infections versus hospitalization and the outcome of infected
patients were defined. The median duration between admission and the isola-
tion of KPC-Kp strains was 24 days. Twelve patients were neutropenic during
the bacteraemias. Colonization or bacteraemia from multiple pathogens, includ-
ing multidrug resistant P. aeruginosa, K. pneumoniae (ESBL), vancomycin
resistant Enterococcus and various fungi were concurrently identified in 12
patients with bacteraemia from K. pneumoniae. All patients had either multiple
or prolonged hospitalizations and all of them had received antibiotics for pro-
phylaxis or treatment prior to the isolation of the pathogen. Infection due to
KPC- Kp was the leading cause to death in 11/16 patients (68,8%). One patient
died of brain hemorrhage (not attributed to his infection), three died of infections
caused by other bacteria, after having survived the KPC infection, and three
remained alive. Risk factors for KPC-Kp bacteraemia were the number of intra-
venous catheters or ports, prior prolonged administration of high spectrum of
cephalosporins and prolonged hospitalization. In multivariate analysis the age,
performance status, prolonged severe neutropenia, resistance to gentamicin
and septic shock were independent predictors of mortality.
Summary/Conclusions: We found many risk factors involved in KPC-Kp infec-
tions among Haematology Unit patients. The high mortality rate in these
patients reinforces the urgent implementation of appropriate infection control
measures to prevent the spread of carbapenemases producing Enterobacte-
riaceae.
PB1894
PLASMA POSACONAZOLE CONCENTRATION DURING CONCOMITANT
TREATMENT WITH PROTON PUMP INHIBITHOR OMEPRAZOLE IN
ADOLESCENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
M Ribersani1,*, K Paciaroni1, C Alfieri1, G De Angelis1, C Gallucci1, J Gaziev1,
A Isgrò1, M Marziali1, P Sodani1, L Dori2, S Fallani3, A Novelli3, C Girmenia4,
G Lucarelli1
1Istituto Mediterraneo di Ematologia-Policlinico Tor Vergata, 2U.O.C. Malattie
Infettive, Policlinico Tor Vergata, Rome, 3Dipartimento di Scienze della Salute,
Sezione di Farmacologia Clinica e Oncologia, University of Florence, Florence,
4Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina
Rigenerativa, La Sapienza University, Rome, Italy
Background: Posaconazole (PCZ) is a broad-spectrum triazole approved for
primary antifungal prophylaxis in patients (pts) with acute myeloid leukaemia
or myelodisplastic syndrome during chemotherapy, in pts who develop a graft
versus host disease (GVHD) after allogeneic stem cell transplant (allo-SCT)
and for salvage therapy of pts with invasive fungal diseases (IFD). Concomitant
use of PCZ suspension (PCZ-susp) and proton pump inhibitors (PPIs) has
been associated with a significant reduction in the bioavailability of the antifun-
gal drug, however, whether and in what extent this reduction affects the prob-
ability in reaching the target levels should be defined. Furthermore, few data
are available in the paediatric population.
Aims: Omeprazole is a PPI often prescribed to allo-SCT recipients who receive
steroids for prophylaxis or treatment of GVHD, therefore concomitant PPI and
PCZ-susp are commonly administered. In this study the impact of omeprazole
on plasma PCZ concentration (PPC) in 4 adolescents who received PCZ-susp
after allo-SCT was evaluated.
Methods: This study represents a sub-analysis of a large, prospective, multi-
center trial which included adult and paediatric allo-SCT pts. The trial was
approved by Ethic Committee, written informed consent was obtained from
each parent prior to any study-related activity. They were 3 males and 1 female
(aged 11-13-16 and 17 years) and they were affected by sickle cells disease
and β-thalassemia (2 pts each) and underwent allo-SCT from related donors.
Two pts received PCZ-susp for second line therapy of proven Aspergillus Ter-
reus infection and possible IFD respectively, and other 2 pts received PCZ-
susp for primary prophylaxis during GVHD. PCZ-susp was administered at
standard dose (600 mg/die or 12 mg/Kg regard to the weight). Plasma samples
were stored at -80°C. The PPC was measured by high-pressure liquid chro-
matography at a reference pharmacology laboratory in Florence. All pts
received concomitant treatment with omeprazole during the entire PCZ-susp
therapy. At steady state (after 5 days of treatment) 0.7 mcg/ml was considered
the therapeutic cut-off value.
Results: Overall, 2, 2, 3 and 6 samples were obtained, respectively. In two pts
PPC was always above the cut-off value (mean 2.34 and 1.19 mcg/ml respec-
tively), while in two pts the first PPC was inadequate (0,27 and 0,49 mcg/ml
respectively) but reached higher values at a second evaluation (0,50 and 2,05
mcg/ml respectively), without changing the dosage of the drug. The patient with
persistent sub-therapeutic PPC suffered of gastro-intestinal GVHD with diarrhoea.
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Summary/Conclusions: PPC monitoring is considered a standard good prac-
tice in pts treated with PCZ-susp. However, considering that a timely PPC mon-
itoring is difficult to perform in several centers, clinical conditions which may
impact on the bioavailability of the drug can be considered for the safe use of
PCZ-susp without PPC monitoring. This small experience in adolescent SCT
pts doesn’t seem to show a significant impact of omeprazole in the bioavailability
of PCZ-susp. In the only patient with inadequate PPC, diarrhoea, and not con-
comitant PPI, presumably was the cause of reduced absorption. While diar-
rhoea has been associated to impaired intestinal absorption in several experi-
ences, concomitant use of PPI doesn’t seem to significantly impact on PPC
and doesn’t seem to be considered an absolute indication to PPC monitoring.
PB1895
A NOVEL MARKER FOR DIFFERENTIAL DIAGNOSIS BETWEEN HEPATITIS
B AND HEPATITIS C USING ROUTINE COMPLETE BLOOD COUNT AND
CELL POPULATION DATA
J Kahng1,*, K Han2
1Department of Laboratory Medicine, College of Medicine, The Catholic Uni-
versity of Korea, Bucheon, 2Department of Laboratory Medicine, College of
Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of
Background: Final diagnosis of hepatitis B or hepatitis C requires various
immunologic and molecular diagnostic tests, and accordingly takes a significant
amount of time prior to initiation of treatment. There is a high incidence of hep-
atitis in Korea, incurring high medical costs for hepatitis B (HBV) and hepatitis
C (HCV). Reports have recently come that propose screening markers using
CBC with cell population data (CPD) for infectious diseases such as sepsis
and tuberculosis. If such screening markers for hepatitis are developed, it will
contribute to the reduction of time prior to treatment and medical costs. 
Aims: The study aims to find any possible screening marker or a combination
of parameters detecting HCV from HBV among hepatitis patients using CBC
with CPD.
Methods: We analyzed 3787 CBC data from 3721 individuals including patients
with hepatitis (325 HBV and 84 HCV), anemia, malignancy, infection other than
hepatitis, and health check-up at Seoul St. Mary’s Hospital, Korea, between
December 2012 and July 2014. We used an automatic hematology analyzer
(DxH 800, Beckman Coulter Inc., Miami, FL, USA) to obtain data including
CBC-diff and CPD from using direct current impedance to measure cell volume
(V) for accurate size of all cell types, ratio frequency opacity to characterize
conductivity (C) for internal composition of each cell, and a laser beam to meas-
ure light scatter (S) for cytoplasmic granularity and nuclear structure. Each
CPD parameter value for WBC, neutrophils, lymphocytes, eosinophils, mono-
cytes, NN RBCs (non-nucleated RBCs) is first stored in Excel, and the values
are divided by the mean value from the normal health check-up individuals.
HBV and HCV cases are colored red and blue, respectively, and sorted in
ascending order in Excel. After sorting, we identify grouping of HBV or HCV
cases for each parameter. If grouping is found, the parameter is taken as a
marker; otherwise, e.g., even distribution, the parameter is of no value as a
marker. The cutoff value for each candidate marker is set when the combination
of them yields over 75% both of sensitivity and specificity.
Results: A combination marker composed of four parameters with cutoff values
for detecting HCV in the mixture of HBV and HCV is as follows: SD C NNRBC
>0.93; MN NNRBC C/AL2 >0.55; MN AL2 EO (Eosinophils) >0.97; SD V Ly >1.
The new combination marker detected 142 cases which consist of 64 from 84
HCV cases (76.2%) and 78 from 325 HBV cases (24.0%).
Summary/Conclusions: A new set of CPD marker is proposed with 76.2%
sensitivity and 76.0% specificity to differentiate hepatitis C from hepatitis B
within less than 1 hour by simple CBC test, reducing time and costs as a screen-
ing measure.
PB1896
PREVENTION AND TREATMENT OF INVASIVE FUNGAL INFECTIONS IN
PATIENTS WITH HEMATOLOGICAL MALIGNANCIES - RESULTS FROM A
SINGLE HEMATOLOGICAL CENTRE
JL Iványi1,*, M Plander1, T Szendrei1, C Tóth2
1Department of Hematology, 2Department of Pathology, University Teaching
Hospital Markusovszky, Szombathely, Hungary
Background: Invasive fungal diseases could influence morbidity and early
treatment-related mortality in patients of malignant hematological disorders
treated with aggressive chemotherapy,especially in acute leukemias or after
hematopoietic stem cell transplantation.
Aims: In an observational survey during 2010-2015 we investigated in our
hematological department occurence of invasive systemic fungal infections
(aspergillosis, systemic candidiasis, other species), methods of antifungal pri-
mary and secondary preventions and therapy of patients with acute myeloge-
nous and lymphoblastic leukemias, lymphomas and transplant recipients
according tot the criteria of EORTC/MSG, as well.
Methods: During suspect mycotic infection identification of pathogenic fungi
specimens taken from blood and/or stool, bronchoalveolar lavage and histological
analysis by autopsy, moreover chest/abdominal CT were performed (proven,
probable and possible infections). Within period of survey 61 patients (pts) with
acute myelogenous leukemia (AML), 32 ones with acute lymphoblastic leukemia
(ALL) treated with aggressive cytostatic regimens, in small number other patients
of hematological malignancies with systemic fungal infections were also analysed.
During prolonged neutropenia patiens were getting antimycotic prevention (in
myelogenous leukemia rather posaconazol, in lymphoblastic leukemia mainly
fluconazol) in probable or proven mycotic infections such as in Candida infections
first line liposomal AmphotercinB, echinocandins, or other second-line drugs
(caspofungin), in suspect or manifest Aspergillus infection mostly voriconasol
was given (empiric, pre-emptive or targeted treatment strategy).
Results: Systemic Candida infection proven by autopsy in four pts with AML
(4/61), in three with ALL(3/32), Mucormyces in one with AML were diagnosed
post mortem, probable candidiasis in five others (myeloma, lymphomas, chronic
lymphocytic leukemia). Mold infection (Aspergillosis) proven by autopsy in 14/61
pts with AML, in 2 pts with ALL,and in two posttransplanted one, they survived
after voriconazol therapy. In invasive Candida sepsis from 10 pts five expired,
5 recovered,out of 25 pts with Aspergillosis 13 ones (chiefly pts with AML) died
despite antimycotic treatment, mortality in both fungal infections was equal (50-
50%). In remaining pts getting antimycotic prophylaxis during neutropenic
episodes invasive fungal infections did not occured.
Summary/Conclusions: Incidence of Candida infections was higher in ALL,
whilst of Aspergillosis in AML, however mortality rate was high and same in
both groups.but recently due to the early introduction of pre-emptive antifungal
therapy fatal outcome could be diminished. Antifungal prophylaxis in prolonged
neutropenia reduced frequency and severity of systemic fungal manifestation
resulted in better survival data in our leukemic patients.
PB1897
EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS OF BLOODSTREAM
INFECTIONS IN HEMATOLOGICAL CANCER PATIENTS
V Chebotkevich*, E Kiseleva, N Stizhak, E Kaytandzhan, V Burylev, A Garifullin,
S Bessmeltsev
Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Bloodstream infections (BSI) are life-threatening illness for
immunocompromised patients with hematological malignancies.
Aims: To compare epidemiology, causative pathogens and outcome of hospi-
tal-acquired BSI.
Methods: During the period 2007-2014 239 blood samples obtained from
patients (pts) with hematological malignancies wеre studied. All blood cultures
were incubated in the continuous monitoring system for 7 days before discard.
The real-time PCR was used for indication DNA of human herpesviruses: Her-
pesvirus 6 (HHV-6), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV). All
patients, who showed fever or signs/symptoms of infection underwent at least
two sets of blood culture. In this study 65 pts (with 79 episodes of BSI) who ful-
filled criteria of systemic inflammatory response syndrome with positive periph-
eral blood cultures were investigated. All pts received empirical anti-infectious
therapy with subsequent correction based on the bacteriological, virological
and mycological analyses results.
Results: A total Gram-positive (G+) accounted for 62.7% of BSI, Gram-negative
(G-) for 33.3% and mixed (G+ and G-) for 4,0%. Among G+ BSI Coagulase
Negative Staphylococci and Staphylococcus aureus were the most frequent
pathogens (92.0%), among G- BSI Escherichia coli (42.9%) was predominant.
Fungi (Candida spp (5), Rhodotorula spp. (1), Aspergillus fumigatus (3)), includ-
ing mixed infections, were responsible in 11.4% of BSI. It is shown that the inci-
dences of BSI were significantly more frequent at the background of detectable
CMV and EBV specific DNA in blood (38.1% and 51.1% respectively vs 4.8 and
24.9% in pts without BSI, p<0.05) With regard to the outcome 30 days mortality
was 15/79 (19.0%) (7/47 (14.9%) in G+ vs 6/25 (24.0%) in G- BSI).
Summary/Conclusions: The empirical anti-infectious therapy showed high
efficacy. Further epidemiological surveillance is warranted in order emerging
resistant strains and related mortality. Reactivation of CMV and EBV is signif-
icantly associated with higher incidence of bacterial BSI.
PB1898
SIMULTANEOUSLY MONITORING OF SERUM AND URINE
CYTOMEGALOVIRUS DNA IN PATIENTS UNDERWENT HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Y Lu*,xZhang, S Liao, F Li, Y Chen
The third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Background: Hemorrhagic cystitis (HC) is one of the most common complica-
tions after hematopoietic stem cell transplantation (HSCT). Early diagnosis of
HC is very important to improve the disease prognosis.
Aims: The aim of this work is to explore the significance of simultaneously
monitoring serum and urine cytomegalovirus(CMV) DNA on diagnosing HC
after HSCT.
Methods: 57 patients were included in this study and median age was 32 years
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(range 10-54). 40 patients were diagnosed of acute leukemias, 6 were lym-
phoma, 5 were severe aplastic anemia, 4 were chronic myelocytic leukemias,
1 was myelodysplatic syndrome and 1 was multiple myeloma. Among the 57
patients, 30 patients received graft from HLA-identical relative donors, 10
patients received graft from HLA- identical unrelated donors, 10 underwent
auto-HSCT and 7 underwent unrelated cord blood transplantation. Serum CMV
DNA was tested weekly by real-time PCR from one week before conditioning
to 100 days after HSCT. For patients with CMV viremia or lower urinary tract
symptoms, urine CMV DNA was also tested. 
Results: Within 100 days after transplant, 23/57 (40.35%) patients developed
CMV viremia. Among the 23 patientsa, 8 developed CMV uremia. Only 2
(5.88%) patients presented CMV uremia in the 34 patients with normal serum
CMV DNA. All of the 10 patients with CMV uremia had complaints of lower uri-
nary tract symptoms and were found abnormal urine routine result and CMV
related HC was considered. 10 patients received anti-virus treatment and all
of them obtained complete remission.
Summary/Conclusions: The incidence of CMV infection is still high during
HSCT. For patients with CMV viremia, urine CMV-DNA surveillance is neces-
sary in order to diagnose HC early and improve the disease prognosis.
PB1899
MORTALITY PREDICTORS IN PATIENTS WITH BLOOD MALIGNANCIES
IN INTENSIVE CARE UNIT AFTER CHEMOTHERAPY
B Bakirov*, A Baybulatova
The Clinic of Bashkir state medical university, N.Mostovaya str. 8-38, Ufa, Russ-
ian Federation
Background: The leading role in the treatment of malignant blood diseases
belongs to high-dose chemotherapy. However, despite the high rates of suc-
cessful treatment of hemoblastosis, the complications such as suppression of
the immune system, septic neutropenia, DIC, multiple organ failure threaten
the patient’s life. The patients are transferred to the intensive care unit (ICU)
for the treatment of such complications. The practical application of new treat-
ment regimens and medications can successfully treat and stabilize patients
in critical conditions. Despite this, currently there are groups of patients (espe-
cially those who have the extended lung ventilation and multiple organ failure)
with poor prognosis of therapy outcome.
Aims: The identification of adverse outcome predictors allows to determine in
time the treatment approach, which significantly reduces the risk of developing
complications, the cost of treatment, significantly improving survival.
Methods:There was made a retrospective analysis of 138 adult patients in
State Financed State Institution “Republican Clinical Hospital named after GG
Kuvatova of Ufa” with malignant blood diseases, who received different
chemotherapy protocols. However the complications developed, which required
treatment of these patients in the intensive care unit. Critical analysis was made
using the scales SOFA, LODS, ODIN, SAPS II, APACHE II, ICNARC model.
Predisposing causes of hospital mortality for all patients were calculated
according to the method of Knaus et al. Statistical analysis was made using
Statistica package, 9.2. (StataCorp. LP, College Station, TX). The average age
of patients - 28.7 years, AML (acute myeloid leukemia) - 88 patients (63.8%),
ALL (acute lymphocytic leukemia) - 34 patients (24.6%) and 16 patients (11.6%)
with other blood system diseases.
Results: The average time of a patient’s staying in the unit before being trans-
ferred to the intensive care unit: 7 days. At average, duration of stay in the ICU
was 15.5 days. According to the results of staying in ICU the patients were
divided into two groups. The first group included patients with fatal case - 47
patients. In this group 6 patients got artificial pulmonary ventilation (12.8%), 11
patients had neutropenia (23.4%), 14 patients had inotropic support (29.8%),
8 patients had a fungal infection (17.0%), 13 patients had a confirmed sepsis
(27.7%) and 35 patients had trombocytes less 50x109/ l (74.5%). 35 patients
had more than 2 of target affected organs (25.4%). The second group included
patients who were transferred from ICU with physical condition improvement -
91 patients, 17 patients have neutropenia (18.7%), 4 patients have fungal infec-
tion (4.4%), 26 patients have thrombocytes less 50х109/L (28.6%), and 18
patients have sepsis (19.8%). 31 patients have more than 2 of target affected
organs (22.5%). According to the analysis of the first and second groups, the
average score on APACHE II - 32 and 12, respectively, on-scale SAPS II - 76
and 34, SOFA - 20 and 5, LODS -4.05 and 6.4, ODIN -1.1 and 1.49.
Summary/Conclusions: The mortality predictors of patients in intensive care
unit after chemotherapy are multiple organ failure (loss of 2 or more organ sys-
tems), as well as prolonged mechanical ventilation. Many other proposed cri-
teria (eg, age, neutropenia, and data of physiological disturbance rating scales)
should not be considered as an absolute outcome predictors of ongoing inten-
sive care.
PB1900
INVASIVE FUNGAL INFECTIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC
LEUKEMIA: SINGLE CENTER EXPERIENCE IN TURKEY
T Patiroglu*, E Yilmaz, A Ozcan, E Unal, M Karakukcu, MA Ozdemir
Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey
Background: Invasive fungal infections (IFI) are a major cause of morbidity
and mortality in patients with hematological malignancies. The risk of IFI
increase in prolonged febrile neutropenia and stem cell transplantation.
Aims: We aim to present the data of patients with acute lymphoblastic leukemia
(ALL), who developed IFI between the years of 2010 and 2015 at the pediatric
hematology department of Erciyes University’s Medical Faculty.
Methods: We assessed 166 patients with ALL, aged between 2 and 18 years
(mean age of 5 years) in this retrospective study. There were 73 female and
93 male patients. They were grouped as IFI and oral candidiasis. Serum galac-
tomannan, computerized tomography scanning and cultures of tissue, blood
or fluids were used to make a definitive diagnosis of IFI.
Results: Among 166 patients with ALL, 21 (12.6%) developed IFI. Furthermore,
110 patients (66.2%) had oral candidiasis. Ten patients (47.6%) with IFI had
relapsed/ refractory ALL and three of them underwent haploidentical stem cell
transplantation. Five patients (23.8%) also had high-risk ALL. We found Can-
dida spp in 7 patients (33.3%) with IFI, 10 Aspergillus spp (47.6%), 1
Zygomycetes (4.76%), 1 G. capitatum (4.76%), 1 A. strictum (4.76%) respec-
tively. One patient (4.76%) had candidiasis and aspergillosis. All patients
received fluconazole as proflactic antifungal therapy during chemotherapy.
Effective antifungal drugs were started after diagnosis of IFI. Nine patients
received granulocyte suspensions in addition to antifungal therapy. Eleven
patients (52.8%) died because of IFI despite all the therapy efforts.
Summary/Conclusions: Since invasive fungal infections (IFI) are a major cause
of morbidity and mortality in patients with ALL, further studies are needed to
investigate new diagnostic and therapeutic strategies to identify and prevent IFI.
PB1901
EPIDEMIOLOGY AND PROGNOSIS OF PATIENTS WITH HEMATOLOGIC
MALIGNANCIES ADMITTED TO INTENSIVE CARE
R haifa*, A Bechir, B emna, B rania, BY yosra, K abderrahim
Hematology, farhat hached hospital, sousse, Tunisia
Background: The hospitalisation in intensive care unit of a patient with malig-
nant haematology constitutes a difficult problem for haematology and intensive
care teams.
Aims: -carry out an assessment of activity of the medical intensive care unit
of Farhat HACHED hospital in Sousse. -studying demographic and haemato-
logical characteristics of these patients and their specific care in the ICU, mostly
in terms of organ failure -study the short-term survival of the population -Finally,
this study will attempt to identify prognostic factors for ICU mortality.
Methods: Single retrospective study, in the medical intensive care unit of Farhat
Hached hospital Sousse on 20 years (1994-2014).this study included 105
patients with haematological malignancies.
Results: During the study period, 6000 patients were hospitalized in the inten-
sive care unit of which 105 (1.75%) had hematologic malignancies. the median
age of the study population was 49 years (15-86 years). the sex ratio was 1.56.
the 2 most frequent haematological diseases were non-Hodgkin lymphoma
and acute myeloid leukaemia. 33,3% of patients were in the diagnosis stage;
51.4% were in relapse or progression stage and 18.1% were in complete remis-
sion. the median scores of APACHE and SAPSII scores were respectively 48
and 32. The reason for admission of patients was acute respiratory failure in
nearly half the cases. The cause of acute respiratory failure was pneumonia in
54% and an acute oedema of the lungs in 35% of cases. 45% of patients were
intubated and ventilated; the median duration of invasive mechanical ventilation
was 2 days. 27 patients had received non-invasive ventilation therapy (25.5%)
at admission. forty two (40%) patients needed treatment with catecholamine’s.
the median length of ICU stay was 4 days and the mortality rate in ICU was
therefore 73.3%. Independent predictors factors of mortality in intensive care
were severity at admission (score SAPSII) (p=10-3), the use of invasive
mechanical ventilation (p=0.015), and the use of catecholamine’s (p=0.038).
Summary/Conclusions: The short-term prognosis, according to this study, is
exclusively predicted severity at admission, the use of invasive mechanical
ventilation, and the use of catecholamines. According to recent data, discussion
between haematologist and intensive care, the very early admitted patients
and non invasive ventilation seem to improve survival.
PB1902
USEFUL CLINICAL FEATURES AND HEMATOLOGICAL PARAMETER FOR
THE DIAGNOSIS OF DENGUE INFECTION IN ACUTE FEBRILE ILLNESS
PATIENTS
A Tantiworawit*, J Chaloemwong, T Rattanathammethee, S Hantrakool,
C Chai-Adisaksopha, E Rattarittamrong, L Norasetthada
Internal medicine, division of Hematology, Chiang Mai university, Maung Chiang
Mai, Thailand
Background: Dengue infected patients are presented with acute febrile illness
without localizing signs and symptoms. Clinical presentations may mimic other
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infections. The serology (Dengue nonstructural protein 1 (NS1) antigen or
Dengue IgM antibody) for definite diagnosis is costly and inaccessible in many
hospitals. There was no study to identify these daily changes to distinguish
dengue infection from the other causes in acute febrile illness patients.
Aims: The aim of the study was to identify the clinical features and hematologic
parameters from complete blood count (CBC) to distinguish dengue infection
from the other causes in acute febrile illness patients.
Methods: This was a retrospective study. All patients who presented with acute
fever between September 2013 and July 2015 were included. The diagnosis
with dengue infection must be confirmed by serology (Dengue NS1 antigen or
IgM antibody). The control group included rickettsia, leptospirosis, malaria, and
primary bacteremia patients who also presented with acute febrile illness with-
out localizing signs. The sample size by calculation was 300 and divided in to
2 groups. Clinical data and CBC results from diagnosis until recovery were
reviewed and compared between two groups.
Results: One hundred fifty-four dengue patients and 146 control patients were
included. Headache, nausea, loss of appetite and bleeding diathesis were sig-
nificantly presented in dengue patients compared to control group 47.4 vs 34.2,
33.8 vs 15.1, 34.4 vs 15.8, 5.8 vs 0% respectively (p=0.05). There were several
hematologic parameters from CBC which were diverse in dengue patients com-
pared to control group. Moreover, this study also identified the day of fever
which these parameters were statistically significant. The dengue group had
higher hemoglobin and hematocrit from day 3 to day 10 (highest on day 7; 14.3
vs 12.9 g/dl, 43.3 vs 39.2%, p <0.001), lower white blood cell (WBC) count
from day 1 to day 10 (lowest on day 4; 3,333 vs 8,561 per cu.mm., p <0.001)
and lower platelet count from day 3 to day 10 (lowest on day 6; 68,910 vs
196,137 per cu.mm., p <0.001). For the differential count of WBC, dengue
infection showed higher monocytes on day 1-4 (highest on day 2; 11.7 vs 5.4%,
p <0.001), higher atypical lymphocytes on day 5-9 (highest on day 7; 13 vs
0.4%, p <0.001) and higher eosinophils on day 9-10 (highest on day 9; 2.2 vs
0.7%, p 0.001). Furthermore, the neutrophil to lymphocyte ratio of dengue group
was >1 on the first 5 days then reversed on day 6 to Day 9 (0.69, 0.89, 0.83,
and 0.80 respectively) but in non-dengue group, the ratio was always >1.
Summary/Conclusions: We identified important clinical features and useful
CBC parameters to differentiate dengue patients from other causes of acute
febrile illness patients. This could be done in local hospital to give diagnosis,
tailor to further investigation and early treatment.
Myelodysplastic syndromes - Biology
PB1903
DIFFERENT WHO SUBTYPES OF CHROMOSOMALLY NORMAL MDS
SHARE COMMON AMPLIFIED AREAS ON ACGH/SNPA
P Bernasconi*, I Dambruoso, M Boni, PM Cavigliano, B Rocca, R Zappatore,
I Giardini, C Calvello, M Caresana, A Orlando
SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Background: Various studies have reported that aCGH and SNPa can reveal
hidden prognostically relevant karyotype alterations in chromosomally normal
MDS patients as compared to conventional cytogenetics: aCGH offers a supe-
rior resolution of unbalanced chromosomal defects and SNPa identifies areas
of copy neutral loss of heterozygosity (LOH).
Aims: Thus, the principal aims of the present study were to test the power of
aCGH/SNPa in chromosomally normal MDS patients, to establish whether the
extension and the number of cryptic gains/losses and LOH areas correlated
with the WHO MDS subtype and to check whether patients with the same WHO
subtype shared common abnormal areas. 
Methods: aCGH/SNPa were carried out on the DNA of mononuclear cells from
fifteen patients examined between January 2013 and December 2015. There
were four females and eleven males, whose median age was 66 years (range
24-78). According to WHO classification, 9 patients were diagnose as RA, one
as RA with ringed sideroblasts, one as refractory cytopenia with multilineage
dysplasia (RCMD), one as RAEB-1 and 3 as RAEB-2. According to R-IPSS, 11
patients were considered low-risk, 2 intermediate-1 risk and 2 intermediate-2
risk. Median follow-up was eight months (range 1-23). At the time of the analy-
ses one patient who progressed to AML and was submitted to two allogeneic
HSCT (allo-HSCT) has relapsed and died; the RAEB-1 patient progressed to
RAEB-2 and is alive nine months after an allo-HSCT. Molecular karyotyping
was performed using the SurePrint G3 Human Cancer CGH+SNP Microarray
Kit 4X180 (Agilent Technologies, Santa Clara, CA, USA) according to the man-
ufacturer’s enzimatic labeling protocol. The array was scanned through the Agi-
lent scanner G26000DA and analysed with CytoGenomics software (v3.0.6).
FISH was carried out to confirm aCGH/SNPa results; commercial probes were
obtained from Abbot Molecular Inc. (Chicago, Il, USA) and Kreatech (Amster-
dam, NL) and applied according to manufacturer’s guidelines. 
Results: aCGH/SNPa revealed an abnormal pattern in all MDS patients. In
the three RAEB-2 patients aCGH showed the highest number of cryptic chro-
mosomal lesions and many areas of LOH. Unexpectedly, two RAEB-2 patients
presented a monosomy 7 together with additional defects including a p53 loss
and a 5q deletion. The clinical value of these aCGH/SNPa results was strength-
ened by the fact that one patient progressed to AML that never achieved com-
plete remission despite two allo-HSCT, whereas the other two patients experi-
enced a quick AML progression. In the other twelve patients aCGH/SNPa
detected small chromosomal lesions which size varied between 5kb and 1.8Mb
and LOH areas of much longer size (range 1Mb-5.7Mb). Interestingly, by com-
paring the various chromosomal lesions, it was observed that different patients
with different WHO MDS subtypes shared common amplified areas that includ-
ed the NOTCH1 gene in five patients and the FGFR3 gene in three.
Summary/Conclusions: i) aCGH/SNPa can truly reveal cryptic chromosomal
lesions in chromosomally normal MDS patients, a finding that determines a
change in patients’ R-IPSS score; ii) advanced MDS presented the highest num-
ber of lesions which size was longer than that of lesions present in early MDS;
iii) patients with different WHO MDS subtypes shared common amplified areas
that contained cell cycle genes with a potential role in MDS pathogenesis.
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THE ASXL1 GENE ALTERATIONS IN BONE MARROW CELLS OF
PATIENTS WITH DELETION 20Q AND MYELOID DISORDERS
J Brezinova1,*, I Sarova1, H Lhotska2, S Ransdorfova1, S Izakova2, K Svobodova2,
L Podskalska2, J Markova1, Z Zemanova2, J Cermak1, A Jonasova3, K Michalova2
1Institute of Hematology and Blood Transfusion, 2Center of Oncocytogenetics,
31st Medical Department, General University Hospital, Prague, Czech Republic
Background: In recent years, identification of gene mutations together with
chromosomal aberrations allows the better characterization and treatment strat-
ification of patients with myeloid disorders. Deletion of 20q - del(20q) - is a
recurrent abnormality observed in myelodysplastic syndromes (MDSs), myelo-
proliferative neoplasms (MPNs), or acute myeloid leukemia (AML). As a sole
aberration this finding gives a good prognosis. In our previous study we proved
a fusion of the ASXL1 and TSHZ2 genes resulting in an isodicentric chromo-
some of a deleted 20q in a patient with MDS. The ASXL1 gene maps to chro-
mosome region 20q11.21 and in contrast with del(20q) recurrent mutations in
this gene are generally associated with poor prognosis.
Aims: The aim of this study was to determine the frequency of ASXL1 gene
alterations in bone marrow cells of patients with del(20q) and/or with ider(20q)
as a sole aberration and to characterize the breakpoints with molecular cyto-
genetic techniques.
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Methods: Fluorescence in situ hybridizations (FISH) with locus specific probes
for 20q11 and 20q12 regions (Abbott, Kreatech) confirmed the cytogenetically
observed deletions of 20q in a cohort of 21 patients (15 male, 6 female, median
age 69 years) with myeloid disorders (MDS 14x, MPN 3x, myelofibrosis 2x,
thrombocytopenia 2x). In nineteen patients deletion of 20q was a sole aberra-
tion, in two patients an isodicentric chromosome of deleted 20q was detected
by FISH with a subtelomeric probe 20p/20q (Abbott). Metaphase FISH mapping
with a set of four bacterial artificial chromosome (BAC) probes (BlueGnome)
localized in 20q11.21 and 20q13.2 was used to determine the breakpoints.
Array comparative genomic hybridization (aCGH, CytoChip Cancer 4x180K
v2.0, BlueGnome/Illumina) was performed on DNA samples of bone marrow
cells of 11 patients with suspected ASXL1 gene deletion to find out the gene
copy number variation.
Results: A weak signal of RP11-358N2 BAC probe (30.93-31.12 Mb from
telomere on the short arm, 20q11.21) was observed in six patients (29%), sug-
gesting the proximal breakpoint of the deletion in the ASXL1 gene (30.95-31.03
Mb, 20q11.21). However, the distal breakpoint in the TSHZ2 gene (51.80-52.11
Mb; 20q13.2) was found in one patient only. In seven patients (33%) the signal
of RP11-358N2 BAC probe was not present on the derivative chromosome
confirming the ASXL1 gene deletion. In the remaining eight patients the prox-
imal breakpoint of the deletion was determined distally to the ASXL1 gene. In
the group of six patients with proximal breakpoint in ASXL1 gene aCGH deter-
mined the breakpoint: in one patient in exon 1, in one patient in exon 4, in three
patients behind the exon 4, in one patient in exon 5-8 and in one patient in
exon 12. Five patients died in a group of thirteen patients with ASXL1 gene
alteration.
Summary/Conclusions: Deletion 20q is assumed to play a key role in patho-
genesis of myeloid malignancies. FISH with BAC probes used is a reliable fast
technique that can point out patients with ASXL1 alterations and therefore
potentially worse prognosis than expected. In our cohort, the ASXL1 gene was
altered in thirteen out of twenty-one patients (62%). We suppose that the deter-
mination of the ASXL1 gene alterations in del(20q) cases may have the prog-
nostic impact, but the relations with clinical data should be studied in a larger
cohort of patients.
Supported by MHCR project for conceptual development of research organi-
zation 00023736, RVO-VFN64165 and GACR P302/12/G157.
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ASSOCIATION BETWEEN POLYMORPHISM OF FOLATE AND METHIONINE
METABOLISM RELATED GENES AND ABERRANT DNA METHYLATION
IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
Z Sidorova1,*, S Kapustin1, I Kostroma2, S Gritsaev2
1Laboratory of biochemestry, 2Hematological Clinic, FSBI “Russian Research
Institute of Hematology and Transfusiology of FMBA”, Saint-Petersburg, Russ-
ian Federation
Background: Abnormal DNA methylation is often seen in patients with
myelodysplastic syndrome (MDS). Polymorphism of folate and methionine
metabolism (FMM) related genes can influence the methylation process and,
therefore, modify the risk of MDS development.
Aims: The aim of this study was to assess the association between polymor-
phism of FMM related genes and aberrant methylation of promoter regions of
several tumor supressor genes in MDS patients.
Methods: Fifty-one patients with MDS (24 men and 27 women, mean age
62.4 yrs) were genotyped for the MTHFR C677T, MTHFR A1298C, MTR
A2756G, MTRR A66G and MTHFD G1958A polymorphisms by PCR-RFLP
technique. The differences in allele and genotype frequencies were assessed
by Fisher’s exact test with computation of odds ratios (OR), their 95% confi-
dence intervals (CI) and p-values. Methylation-specific PCR was used to study
the methylation status of promoter regions of SOX7, p15INK4b, SFRP1, SFRP4
and SFRP5 genes.
Results: Twenty-one patients (9 men and 12 women) had aberrant methylation
of 0-2 genes (0-2 MG) and 30 patients (15 men and 15 women) had aberrant
methylation of 3-5 genes (3-5 MG). The MTRR 66 GG genotype was more fre-
quently seen in the group 0-2 MG than in the group 3-5 MG (47.6% vs 13.3%,
respectively, OR=5.9, 95%CI: 1.5-22.9, p=0.011). The MTHFR 1298 CC variant
was present in 6 patients from the 3-5 MG and in 1 patient from the group 0-2
MG and (20.8% vs 4.8%, respectively, OR=5.0, 95%CI: 0.6-45.1, p=0.2). The
presence of the MTHFR 677T allele was increased in male patients from the
group 0-2 MG when compared to male patients in the 3-5 MG group (100% vs
46.7%, respectively, OR=21.5, 95%CI: 1.2-437, p=0.01), and female patients
from the 0-2 MG group (100% vs 33.4%, respectively, OR=35.9, 95%CI: 1.7-
770, p=0.005). At the same time, positivity for the MTHFR 677T allele was not
different between women from 0-2 MG and 3-5 MG groups (33.4% vs 46.7%,
respectively, OR=1.8, 95%CI: 0.4-8.4, p=0.7). The simultaneous presence of
the MTHFR 677T allele and MTRR 66GG genotype was more often detected
in the 0-2 MG group than in the 3-5 MG group (33.3% vs 10.0%, OR=4.5,
95%CI: 1.0-20.1, p=0.07).
Summary/Conclusions: We conclude that polymorphism of the FMM related
genes could have an important role in mechanism of epigenetic disturbances in
MDS associated with aberrant methylation of CpG islands of tumor-supressor genes.
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DEPLETION OF PROINFLAMMATORY MONOCYTES AND INCREASED
LEVELS OF CD56 EXPRESSION ON CLASSICAL MONOCYTES IN THE
PERIPHERAL FROM PATIENTS WITH LOWER RISK MYELODYSPLASTIC
SYNDROMES
A Aires1, C Moreira2, R Cabral2,*, M Gonçalves2, AS Jorge2, V Mesquita2,
ML Queirós2, A Mota2, C Gonçalves2, L Pinho2, L Xavier2, J Coutinho2,
I Freitas3, C Lau2, MDA Teixeira2, M Lima4
1Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
(ICBAS/UP), 2Hematology, 3Laboratory Hematology, Hospital de Santo António
(HSA), Centro Hospitalar do Porto (CHP), 4Hematology, Hospital de Santo
António (HSA), Centro Hospitalar do Porto (CHP); Multidisciplinary Unit for
Biomedical Sciences (UMIB/ICBAS/UP), Porto, Portugal
Background: Myelodysplastic syndromes (MDS) are hematologic neoplasms
characterized by morphologic dysplasia and peripheral blood (PB) cytopenias.
Flow cytometry (FC) studies have revealed that bone marrow monocytes (Mon)
from MDS patients have abnormal maturation patterns and aberrant antigen
expression. However, the immunophenotypic alterations in PB monocytes (PB-
Mon) have been much less explored.
Aims: To evaluate the levels of CD11b, CD11c, CD13, CD14, CD15, CD16,
CD64 and HLA-DR expression in PB-Mon from patients with lower risk MDS
(LR-MDS), as compared to normal individuals (NI). To quantify the proinflam-
matory (CD14+loCD16+) and classical (CD14+hiCD16-) PB-Mon subsets, and
to search for abnormal CD56 expression on PB-Mon from LR-MDS patients.
Methods: Fourteen patients with LR-MDS (8 males, median age 76 years),
and an equal number of NI (blood donors, 8 males, median age 55 years) were
studied. Patients who were being treated with myeloid growth factors were
excluded, as did patients with active infections and other concomitant neo-
plasms. The median time from the diagnosis was 7.6 years, ranging from 0.5
to 12.6 years. Seven patients had refractory anemia with ringed sideroblasts
(RARS), 4 patients had refractory cytopenias with unilineage dysplasia (RCUD),
and 3 patients had refractory cytopenias with multilineage dysplasia (RCMD).
Eight patients had low IPSS risk and 6 patients had intermediate 1 IPSS risk.
The median PB-Mon count was of 426/mm3 (17 to 1132), in LR-MDS
(>1000/mm3 in 1 case) and 482/mm3 (294 to 937), in NI (no cases with
>1000/mm3). PB samples were collected into EDTA-K3 containing tubes. Cell
immunophenotyping was performed by 8-color FC using fluorochrome conju-
gated monoclonal antibodies with different specificities (T1: CD15-FITC, CD13-
PE, CD34-PerCPCy5.5, CD10-PC7, CD11b-APC, CD14-APC-H7, CD16-V450,
CD45-KO; T2: HLA-DR-FITC, CD64-PE, CD34-PerCPCy5.5, CD56-PC7,
CD11c-APC, CD14-APC-H7, CD16-V450, CD45-KO), and a whole blood stain-
lyse-and-then wash method (FACSLysing, Becton Dickinson–BD). A normal
PB sample was run in parallel with each patient. Sample acquisition was per-
formed in a FACSCanto II flow cytometer (BD), calibrated according to the
Euroflow SOP. Data analysis was done with Infinicyt (Cytognos). Results are
expressed as median, minimum and maximum values of the median fluores-
cence intensity observed for each marker. P values <0.05 were considered
statistically significant (Mann-Whitney U test).
Results: PB-Mon from patients with LR-MDS had FSC and SSC similar to the
PB-Mon from NI (p>0.05). In the same way, the overall levels of CD13, CD14,
CD15, CD45 and CD64 expression on PB-Mon from patients with LR-MDS did
not differ significantly from those observed in NI (p>0.05). In contrast, PB-Mon
from LR-MDS patients had significantly higher levels of CD56 (p=0.006), and
lower levels of CD11c (p=0.004), CD16 (p=0.005) and HLA-DR (p=0.042), and
showed a tendency for a lower CD11b expression (p=0.089), as compared to
NI. Additionally, PB-Mon from LR-MDS patients had a marked decrease in the
fraction of CD14+loCD16+ subset (3.1% ranging from 0.1 to 8.1% and 11.5%
ranging from 4.1 to 27.7%, respectively; p<0.001). Moreover, CD14+hiCD16-
PB-Mon from LR-MDS patients had a significantly higher% of CD56+ cells, as
compared to NI (14.8% ranging from 0.1 to 98.7% and 7.1% ranging from 0.1
to 14.9%, respectively; p=0.026).
Summary/Conclusions: PB-Mon from patients with LR-MDS have abnormal
levels of CD11b, CD11c, CD16 and CD56 expression and a high classical/proin-
flammatory Mon subset ratio.
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PRIMARY RESISTANCE TO AZACYTIDINE IN MDS: PRELIMINARY DATA
ON THE POTENTIAL ROLE OF HIF-1A EXPRESSION
V Bakou1, A Spathis2, F Kontsioti1, D Vasilatou1, C Economopoulou1, A Bouhla1,
K Gontopoulos1, C Roubakis1, G Stavroulaki1, I Glezou1, S Papageorgiou1,
E Bazani1, P Karakitsos2, E Kontandreopoulou3, N Viniou3, A Galanopoulos4,
K Zafeiropoulou5, A Symeonidis5, G Dimitriadis1, V Pappa1,*
1Second Department of Internal Medicine and Research Institute, 2Department
of Cytopathology, Attikon University General Hospital, 3Department of Hema-
tology, Laiko General Hospital of Athens, 4Department of Clinical Hematology,
General Hospital of Athens ‘G. Gennimatas’, Athens, 5Hematology Unit, Gen-
eral University Hospital of Patras, Patras, Greece
Background: The hypomethylating agent azacytidine is the standard of care
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for patients with high-risk myelodysplastic syndromes (MDS) (IPSS intermedi-
ate-2 or high) and patients with AML with 20-30% bone marrow blasts. Never-
theless, approximately 40% of patients fail to respond, whereas even respon-
ders will inevitably relapse. Currently, the exact mechanisms of azacytidine fail-
ure are largely unknown and there is no approach to circumvent azacytidine
resistance. Hematopoietic and leukemia stem cells (HSCs and LSCs, respec-
tively) reside in a particularly hypoxic niche and several reports have demon-
strated the significance of hypoxia in the regulation of both physiological and
malignant hematopoiesis. In addition, Hif-1α regulates the expression of human
equilibrative nucleoside transporters (ENTs) and ribonucleotide reductase (RR),
both of which are involved in the transport and intracellular metabolism of
hypomethylating agents.
Aims: The scope of this study is to investigate the potential role of Hif-1α in
azacytidine resistance in MDS patients.
Methods: Bone marrow samples from 26 de novo MDS patients and 2 CMML
patients (21 males and 7 females) with a median age of 75 (60-89) and 10
healthy donors were collected. MDS patients were classified according to WHO
as RCMD (1/28), RAEB I (6/28) and RAEB II (19/28) and received treatment
with azacytidine at the dose of 75mg/m2 x7 days SC. Before treatment, bone
marrow mononuclear cells were isolated using the Ficol-paque method, fol-
lowed by RNA extraction using TRIzol reagent and cDNA preparation using
Superscript II reverse transcriptase. Hif-1α expression was estimated by real
time PCR TaqMan gene expression assay, using the appropriate primers and
probes. Relative gene expression was calculated by comparative threshold
cycle (ΔΔCt) method. β-actin was used as a housekeeping gene.
Results: Out of the 28 patients used in our study, 17 responded to azacyti-
dine-treatment (including CR, PR and HI) while 11 failed to respond. We found
by real time PCR that the ΔΔCt ratio of Hif-1α/β-Actin expression for control
samples was 0,72±0,13, for MDS patients who responded to azacytidine- treat-
ment was 1,564±0,439, while for non-responders 0,839±0,17.
Summary/Conclusions: Our data suggest that increased pretreatment expres-
sion of Hif-1α might be associated with better response to azacytidine, indicating
a potential role of hypoxia signaling in azacytidine resistance. These encour-
aging initial results need to be further confirmed in a larger number of patients.
The identification of hypoxia related mechanisms in azacytidine resistance will
provide novel insights regarding the links of hypoxia signaling with the epige-
netic derangement in the pathobiology of MDS and can serve as a platform for
the therapeutic targeting of the Hif-1α pathway.
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PU.1 EXPRESSION CORRELATES WITH PATIENT DISEASE STATUS IN
THE MYELODYSPLASTIC SYNDROMES, A NEW PROGNOSTIC MARKER?
R Simpson1, A Goddard1, J Lally1, C Graham2, CR Rinaldi1,*
1School of Life Science, University of Lincoln, Lincoln, 2School of Healthcare
Science, Manchester Metropolitan University, Manchester, United Kingdom
Background: Myelodysplastic syndromes (MDS) are a group of clonal
hematopoietic stem cell disorders characterised by ineffective haematopoiesis
and dysplasia, manifesting as variable degrees and combinations of peripheral
blood cytopenia. The result is often transfusion-dependent anaemia, increased
risk of infection, bleeding complications, and an increased potential of progres-
sion to acute myelogenous leukaemia (AML). In recent years treatment with 5-
azacytidine (AZA) has seen an increase in patient survival for intermediate and
high-risk group MDS patients, although the precise mechanism of action is not
yet fully understood. Previous studies have demonstrated down regulation of
the PU.1 transcription factor in high-risk MDS patients, which can be reversed
by administration of AZA. However, it is not currently known if PU.1 levels cor-
relate with MDS disease severity and/or prognosis.
Aims: Assess if PU.1 expression levels in MDS patients correlate with disease
prognosis as determined by risk group stratification using the Revised Interna-
tional Prognostic Scoring System (IPSS-R). In addition, we will use commercially
available cell lines (SKM-1, MOLM-13, K562, HL60) to explore the potential of
AZA in correcting down-regulated PU.1 expression that is seen in high-risk MDS.
Figure 1.
Methods: BM specimens were collected from 10 patients diagnosed with MDS
who were stratified according to IPSS-R guidelines (5-low, 3-int, 2-high risk)
and from 13 haematological normal controls. Samples were enriched for the
mononuclear fraction by Ficoll separation. Total RNA was extracted and
analysed by Real Time PCR for PU.1 expression relative to the housekeeping
gene GAPDH using the 2-ΔΔCT method. In vitro models of MDS, SKM-1 and
MOLM-13 were treated with 1 μM AZA for 24, 48, or 72hr followed by analysis
of PU.1 expression analysis by RT-qPCR.
Results: Analysis of patient samples revealed that PU.1 expression is signifi-
cantly lower in high-risk patients compared controls. In addition, preliminary
data suggests that PU.1 expression also correlates with disease severity and
could provide insight as a prognostic marker. PU.1 expression was significantly
increased upon treatment with 1 μM AZA in commercially available cell lines.
Summary/Conclusions: PU.1 is found to be down regulated in high-risk MDS
and it appears that expression correlates well with the IPSS-R classification of
prognosis group. As such, PU.1 provides a potential biomarker for MDS diag-
nosis and progression. In addition, PU.1 expression in MDS in vitro models is
increased by treatment with AZA providing a potential mechanism for AZA func-
tion in vivo.
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MLPA® (MULTIPLEX LIGATION-DEPENDENTPROBEAMPLIFICATION) IS
A FEASIBLE, COST-EFFECTIVE, TECHNIQUE FOR GENETIC CLASSIFICATION
OF MYELODYSPLASTIC SYNDROME
E Anguita Mandly1, DS Toral Ibarra1,*, WM Torres Jiménez1, R Oancea Ionescu2,
A Chaparro1, A Campaña1, C Cotarelo2, R Martínez Martínez1
1Hemathology and Hemotherapy, 2Cytogenetics, Hospital Clínico San Carlos,
Madrid, Spain
Background: Since their inclusion in IPSS-R in 2012, cytogenetic alterations
play a decisive role in the prognosis of patients with myelodysplastic syndrome
(MDS). These alterations may be identified through several methods; cytoge-
netic study, including karyotype and FISH, is the most widely used and proved.
However, new molecular techniques for the detection of these alterations have
appeared which may be equally effective and far less expensive.
Aims: This study evaluates the MLPA cost-effectiveness in detecting cytoge-
netic alterations comparing it directly to FISH as gold standard test and kary-
otype.
Methods: We prospectively collected 131 bone morrow mononuclear cells
samples from 118 MDS patients from September 2011 to June 2015. DNA was
isolated by salting out and Multiplex Ligation-dependent Probe Amplification
(MLPA), MRC Holland, following manufacturer recommendations. We did cyto-
genetic studies (karyotype and FISH) by conventional techniques. Human mate-
rial and clinical information was obtained with informed consent and approval
of institutional ethics committee.
Results: We obtained MLPA data from 131 bone marrow samples from 118
patients with morphological diagnosis of MDS, examined in our Institution. Kary-
otype was performed in 104 samples, the technique failed in six and 21 were
not sent. FISH was only performed in cases with with abnormal or dubious
karyotype; MLPA was performed in 125 samples, in 6 cases we did not receive
sample. Alterations were detected in 39.4%, 71.4% and 52% by kariotype,
FISH and MLPA, respectively. Specificity of MLPA could be assessed by com-
paring it with karyotype. Instead we could analyze the sensitivity of MLPA com-
paring with the most sensitive standard technique, FISH. Forty results were
included for sensibility analysis, 31 studies corresponded to new diagnosis and
9 to follow-up samples. Comparing MLPA with karyotype, MLPA showed a high
specificity 95% (p<0.05) (S: 71% E 95%). We could compare fISH and MLPA
in 40 cases (Figure 1), MLPA analysis showed sensitivity of 75% and specificity
of 85.7% (p<0.05). The results were correlated in 74.2%. We observed a
increase of sensitivity (85% and 82% (p<0.05) in the subgroup of new diagnosis.
Moreover, MLPA detected several alterations which had gone unobserved by
FISH, such as: –Y, SMAD4+ y 8pq+. MLPA also proved less expensive in both
reagents and staff time.
Figure 1.
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Summary/Conclusions: Our data indicate that MLPA is a useful tool, as valid
as FISH and with a better cost-effectiveness. Although it has sensitivity limita-
tions (in cases of follow-up), it can be used as first-line screening and also as
a complementary test for the cytogenetic study. Furthermore, MLPA allows the
simultaneous assessment of many loci and the detail study of the most impor-
tant ones, adding more information to the analysis of copy number variations,
which are the most frequent and relevant abnormalities in MDS.
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CHARACTERIZATION OF THE ERYTHROPOIETIC RESPONSE OF THE
DYSPLASTIC MARROW
M Pereira1,*, M Santos1, R Tenreiro1, E Cortesão1, M Fortuna2, AB Sarmento-Ribeiro1,
L Ribeiro1, A Paiva2
1Clinical Hematology Department, 2Flow Cytometry Operational Unit, Coimbra
University Hospital Centre, Coimbra, Portugal
Background: Myelodysplastic syndromes (MDS) are characterized by periph-
eral citopenias within the context of a dysplastic, and frequently hypercellular
bone marrow. Anemia is one of the most frequent findings, with 20 to 40% of
patients responding to exogenous erythropoietin (Epo), with or without the
addition of G-CSF, despite normal to elevated levels of serum endogenous
Epo, reflecting the complexity of erythropoietic control in these syndromes.
Nevertheless, a different likelihood of response to exogenous Epo has been
identified between patients with Normal (<=20 IU/L), Mildly Elevated (20-100
IU/L), Moderately Elevated (100-500 IU/L) and Markedly Elevated (>500 IU/L)
endogenous Epo levels.
Aims: To further characterize the early erythropoietic response in MDS and its
relation to serum Epo levels, and thereby analyze the medullary response to
anemia, focusing on the percentage of erythroblasts in maturation stages I to
IV, the expression of surface transferrin receptor (TfR, CD71) and the levels of
hemoglobin (Hb) and ferritin.
Methods: We prospectively analyzed 57 newly-diagnosed MDS patients,
focusing on MDS subtype; bone marrow morphology; and endogenous Epo
levels, serum ferritin levels and Hb concentration at diagnosis. Flow cytometry
was performed on all patients (CD45, CD34, CD117, HLA-DR, CD71, CD36,
CD35, CD44 and CD105) and on 16 normal controls (samples collected during
orthopedic surgery).
Results: Patients (63.2% female) had a mean age of 71.2±11.3 years (range:
22-89) and controls (68.8% female) had a mean age of 63±15; 70.2% of
patients had RCMD, 8.8% had RCUD, 8.8% had RCRS, 7.0% had RAEB-1,
3.5% had RAEB-2 and 1.8% had 5q- syndrome; 35% of patients had Normal
Epo, 53% had Mild elevations, 8% had Moderate and 4% had Marked eleva-
tions. There was no association between the percentage of erythroblasts (by
flow or morphology) and the MDS subtype (p=NS), degree of dysplasia (p=NS),
Epo levels (p=NS), ferritin levels (p=NS) or Hb levels (p=NS), nor between
Epo levels and the MDS subtype (p=NS), although, as expected, there was an
inverse correlation between Hb and Epo levels (r= -0.35, p=0.0014). There
were no differences in the percentages of erythroblasts in stages I to IV
between the normal marrow and MDS patients with Normal-to-Mildly elevated
Epo levels (p=NS); however, there was a significant threefold increase in Stage
I (2.2±1.0% vs 0.7±0.1%, p<0.001) and Stage II (4.8±2.9% vs 1.8±0.2%,
p=0.02) erythroblasts in patients with Epo levels over 100 IU/L compared to
patients with Epo<100 IU/L. There was a decrease in the expression of TfR in
patients with MDS with Epo<100 IU/L compared to Epo>100 IU/L, for Stages
I (p<0.001), II (p=0.019) and III (p<0.001), but not IV (p=NS), with patients with
Epo>100 IU/L reaching a similar expression of transferrin receptor as normal
marrows, across all stages (p=NS for I to IV).
Summary/Conclusions: There was an expected inverse correlation between
Hb and Epo levels that, however, was not reflected in the percentage of ery-
throblasts in the bone marrow. The distribution of erythroblasts by maturation
stage was identical in normal marrows and patients with MDS with normal to
mildly elevated (<100 IU/L) Epo, as observed in the clinical model of response
to exogenous Epo. The percentage of early stage erythroblasts increased in
patients with Epo levels >100 IU/L, likely reflecting an increase in the commit-
ment of CD34+ cells to the erythroid lineage. The expression of surface trans-
ferrin receptor decreased in all stages with Epo<100 IU/L compared to the nor-
mal marrow, with levels over 100 IU/L being necessary to obtain similar levels
of expression of TfR to the normal marrow, possibly explaining the clinical mod-
el of increased likelihood of response to exogenous Epo in patients with levels
<100 IU/L, and the fact that the expression of surface transferrin receptor is
Epo-dependent both through transcriptional and post-transcriptional mecha-
nisms.
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USEFULNESS OF MUTATIONAL ANALYSIS FOR DIAGNOSIS OF
IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND
MYELODYSPLASTIC SYNDROME
DS Lee1,*, B Hwang2, K Im1, SN Park3, D Bang4, SY kim1, JA Kim1
1Dept of Laboratory Medicine, Seoul National University College of Medicine,
2Department of Chemistry, Yonsei University College of Natural Science,
33Cancer Research Institute, Seoul National University College of Medicine,
4Department of Chemistry, Yonsei University College of Natural Science, Seoul,
Korea, Republic Of
Background: Myelodysplastic syndrome (MDS) is a heterogeneous group of
myeloid neoplasms characterized by cytopenias that are associated with
impaired hematopoietic differentiation, and have a risk of progression to acute
myeloid leukemia (AML).
Aims: Aim of this study is to identify the frequency of clonality revealed by next
generation targeted sequencing in patients with idiopathic cytopenia of
unknown significance.
Methods: A total of 36 patients with idiopathic cytopenia of undetermined sig-
nificance (ICUS), were enrolled in this study. Targeted sequencing of 87 select-
ed genes was performed.
Results: The putative mutations were analyzed compared to a normal refer-
ence control population. 25. /36 (69.4%) ICUS patients harbored at least one
mutation.
Figure 1.
Summary/Conclusions: The molecular profiling of target genes can improve
diagnostic accuracy for ICUS and MDS and can assist better subclassification
of prognostic groups of MDS patients.
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THE USAGE OF NEUT-X AND NEUT-Y PARAMETRES IN A ROUTINE
HEMATOLOGY LABORATORY AS DIAGNOSTIC MARKERS OF
MYELODYSPLASTIC SYNDROMES (MDS)
P Tsiatsiou*, A Tsocha, F Netsika, K Kouirouxis, D Lazaridou, L Skoura,
A Nikolaidou
Clinical Microbiology, AHEPA University Hospital, THESSALONIKI, Greece
Background: NEUT-X and NEUT-Y are structural parameters provided by a
hematological analyzer, SYSMEX XE-5000. Notably, NEUT-X evaluates the
neutrophil granularity and NEUT-Y the nuclear maturity, which are the average
value side scatter diffraction and fluorence, respectively.
Aims: The aim of this study is to investigate the values of NEUT-X and NEUT-
Y as diagnostic markers in a routine hematology laboratory in patients with
Myelodysplastic Syndromes (MDS)
Methods: The investigation was conducted in ΑΗEPA University hospital. A
total of 134 whole-blood samples were collected in tubes with K3-EDTA and
were analysed in approximately 3 h of collection, from outpatients and inpa-
tients from different hospital units. 67 of them were from patients with MDS
defined from clinical and laboratory findings. Also, 67 randomly selected sam-
ples from patients without MDS were included in this study, as a control group.
These patients didn’t have, perforce, normal values for the complete blood
count (CBC). Some of them had anemia due to various causes. Patients with
MDS revealed in their majority microscopically hypogranulation or agranulation
(N=45) and patients in the other group showed in their blood films neutrophils
with normal granulation. The two groups were similar in regard to sex (67 males
- 67 females) and age (52 - 90 years avg=78 years). The values of the NEUT-
X and NEUT-Y parameters were measured by SYSMEX XE-5000. Mean value
comparison independent samples tests was used in order to examine the sta-
tistical significance between patients with MDS and control group. The signifi-
cance level was defined as p <0.05 All statistical analysis was performed using
SPSS 22 and Mc Excel 2010.
Results: The values of NEUT-X and NEUT-Y (mean+/-SD) for the control group
were (137,49+/-3.17) and (41,02+/-2,70) respectively. The MDS group revealed
lower mean values for NEUT-X and NEUT-Y (131,44+/-9,01) and (38,40+/-8,21).
The values of NEYT-X and NEYT-Y of MDS were statistically significant lower
than the NEYT-X and NEYT-Y values of control (p-values were less than 0,05).
Summary/Conclusions: There is a proportion between low NEUT-X and
NEUT-Y values and neutrophil dysplasia. These structural parameters can
contribute as auxiliary indicators to the differential diagnosis MDS from other
770 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
diseases especially in elderly people with anemia. Also, they can be used as
an important part of the daily routine complete blood count.
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LOW LEVELS OF CD10, CD11B, CD13, AND CD16 EXPRESSION IN THE
PERIPHERAL BLOOD NEUTROPHILS FROM PATIENTS WITH LOWER
RISK MYELODYSPLASTIC SYNDROMES
C Moreira1, A Aires2, R Cabral1,*, M Gonçalves1, AS Jorge1, V Mesquita1,
L Oliveira1, M Santos1, A Mota1, C Gonçalves1, L Pinho1, L Xavier1, J Coutinho1,
I Freitas3, C Lau1, MDA Teixeira1, M Lima4
1Hematology, Hospital de Santo António (HSA), Centro Hospitalar do Porto
(CHP), 2Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
(ICBAS/UP), 3Laboratory Hematology, Hospital de Santo António (HSA), Centro
Hospitalar do Porto (CHP), 4Hematology, Hospital de Santo António (HSA),
Centro Hospitalar do Porto (CHP); Multidisciplinary Unit for Biomedical Sci-
ences (UMIB/ICBAS/UP), Porto, Portugal
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group
of hematologic neoplasms characterized by morphologic dysplasia, aberrant
hematopoiesis and peripheral blood (PB) cytopenias, and an increased prob-
ability of transformation to acute leukemia. Diagnosis of MDS relies on well-
defined cytological and cytogenetic criteria but is challenging in a significant
number of patients. The detection of abnormal maturation patterns and aberrant
antigen expression in the bone marrow (BM) cells has been extensively studied
by flow cytometry (FC) and is now considered a promising tool to improve MDS
diagnostics. However, the value of immunophenotyping the PB cells from
patients with MDS has been largely ignored. Having regard to accessibility of
PB samples, it would be useful to establish FC criteria for the diagnosis of MDS
in the PB. 
Aims: To evaluate the levels of CD10, CD11b, CD13, CD15, CD16 and CD45
expression in PB neutrophils (PB-Neut) from patients with lower risk MDS (LR-
MDS), as compared to normal individuals (NI).
Methods: Fourteen patients with previously diagnosed LR-MDS (8 males,
median age 76 years), and an equal number of NI (blood donors, 8 males,
median age 55 years) were studied. Patients who were being treated with
myeloid growth factors were excluded, as did patients with active infections
and other concomitant neoplasms. The median time from the diagnosis was
7.6 years, ranging from 0.5 to 12.6 years. Seven patients had refractory anemia
with ringed sideroblasts (RARS), 4 patients had refractory cytopenias with uni-
lineage dysplasia (RCUD), and 3 patients had refractory cytopenias with mul-
tilineage dysplasia (RCMD). Eight patients had low IPSS risk and 6 patients
had intermediate 1 IPSS risk. The median PB-Neut count was of 2590/mm3
(365 to 6945), in LR-MDS (<1500/mm3 in 4 cases) and 4181/mm3 (3083 to
8633), in NI (no cases with <1500/mm3). PB samples were collected into EDTA-
K3 containing tubes. Cell immunophenotyping was performed by 8-color FC
using fluorochrome conjugated monoclonal antibodies with different specificities
(CD15-FITC, CD13-PE, CD34-PerCPCy5.5, CD10-PC7, CD11b-APC, CD14-
APC-H7, CD16-V450, CD45-KO), and a whole blood stain-lyse-and-then wash
method (FACSLysing, Becton Dickinson–BD). A normal PB sample was run in
parallel with each patient PB sample. Sample acquisition was performed in a
FACSCanto II flow cytometer (BD), calibrated according to the Euroflow SOP.
Data analysis was done with Infinicyt (Cytognos). Results are expressed as
median, minimum and maximum values of the median fluorescence intensity
observed for each marker. P values <0.05 were considered statistically signif-
icant (Mann-Whitney U test).
Results: PB-Neut from patients with LR-MDS had significantly lower FSC
(p=0.008) and SSC (p<0.001), as compared to those of NI. In addition, the lev-
els of CD10 and CD11b (p<0.001 in both cases), CD16 (p=0.002) and CD13
(p=0.022) expression in PB-Neut from patients with LR-MDS were significantly
decreased in patients with LR-MDS, as compared with NI. No significant differ-
ences were observed for CD15 and CD45 expression (p>0.05). 
Summary/Conclusions: PB-Neut immunophenotyping may provide useful
information for the diagnosis of MDS, as a complement to cytomorphology.
Each center should establish its own normal reference values, on the basis of
monoclonal antibodies (clones, fluorochromes) and experimental conditions
used. In addition, should be given special attention to the conditions of calibra-
tion and stability of the cytometer.
Myelodysplastic syndromes – Clinical
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MULTIDISCIPLINARY EVALUATION AT BASELINE AND DURING TREATMENT
IMPROVES THE RATE OF COMPLIANCE AND EFFICACY OF
DEFERASIROX IN ELDERLY MYELODYSPLASTIC PATIENTS
L Del Corso1,*, E Parodi2, N Bardi1, A Bellodi1, G Berisso3, M Brunofranco4,
T Calzamiglia5, C Di Grazia6, R Filiberti7, R Ghio1, S Galimberti8, E Molinari1,
R Russo2, M Rousseau8, M Scudelletti9, R Tassara10, MT Van Lint6, E Arboscello1
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Sanremo Hospital, Sanremo, 6Hematology and Bone Marrow Transplantion,
7Epidemiology, Biostatistics and Clinical Trials and b Department of Laboratory
Medicine, irccs-auo san martino-ist, Genova, 8Hematology and Bone Marrow
Transplantion, Irccs AOU Pisana, Pisa, 9Internal Medicine, Sestri Levante Hos-
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Background: Myelodysplastic syndromes (MDS) are one of the most common
hematologic malignancies, the median age at diagnosis is 75 years in most of
the series; therefore it can be considered a disease of the elderly patients (pts).
Red blood cell transfusion (RBCT) is the main stone of supportive care and a
cardinal option to keep patients alive while waiting for effects of specific thera-
peutic strategies. Transfusion dependency and the consequence iron overload
(IOL) has been identified as an independent factor associated with decreased
survival. The most important guidelines recommend to start iron chelation ther-
apy (ICT) in all MDS pts with low- and INT1 risk disease with life expectancy
>1 year, who have elevated serum ferritin (SF) up to 1000 mcg/L or evidence
of iron overload and/or received at least 20 RBCT.
Aims: The aim of the study was to assess the effectiveness of (ICT) in relation
of dosing and right management of adverse events (AE) particularly the renal
injury. We also evaluate hematological response.
Methods: The safety and the efficacy of DFX were examined in a retrospective
multicenter observational study of transfusion MDS patients with International
Prognostic Score System (IPSS) low- or INT-1 risk. We included all pts treated
with DFX up to 12 months, divided into two groups: the first one (group A) not
under multidisciplinary assessment and the second group (group B) with pts
under multidisciplinary control by hematologist, Internist, Nephrologist and
Immune-hematologist. All pts received DFX at starting dose of 10 mg/kg/day
increased up to 30mg/kg/day according to transfusion regimen, SF, IOL, and
tolerance.
Results: We evaluated 44 MDS pts (13 female, 31 male); 26 belonging to the
first group and 18 to the second group. The mean age was respectively
74.3±9.0 and 77.9±5.5. The ECOG 0-1 was 84.6% and 83.3%, respectively.
The median of RBCT prior starting DFX was 20 (range 3-60) in the first group
and 13 (4-150) in second group. The median serum ferritin level at baseline
was 1125.5 ng/mL (388-2099) and 1317.0 ng/mL (160-3018), respectively.
Serum ferritin level decreased at least of 20% as follows: in 29% of pts of first
group and in 31% of second group at 3 months, in 17% and 36%, respectively,
at 6 months. At 12 months percentages were 22% and 58%, respectively
(p=0.06). The drug related AE was evaluated by the Common Terminology Cri-
teria for Adverse Events (CTCAE version 4.02). The SAE occurred in 11% at 3
months, 29% at 6 months and 16% at 12 months. The most Common AE were
diarrhea and serum creatinine increase. The rate of drop out after renal AE
was respectively 0% and 10%. The positive hematological response in overall
pts was observed in 16% at 6 months and 20% at 6 months.
Summary/Conclusions: Un appropriate multidisciplinary assessment of the
pre-existing or concomitant comorbidities, the evaluation of the home therapy
and of the possible interaction with DFX, a vigilance in co-administration with
nephrotoxic drugs may represent strategies to improve the safety and the
adherence to ICT and thus the effectiveness. Early starting therapy with DFX
at lower doses, maintaining the same dose for the first months avoiding rapid
iron depletion, regular clinical and laboratory monitoring appears essential to
identify early treatable renal and potentially renal injury avoiding serious adverse
effects without necessarily interrupting DFX therapy.
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PEPTIDE VACCINATION AGAINST CANCER TESTIS ANTIGENS IN
COMBINATION WITH AZACITIDINE FOR PATIENTS WITH MYELODYSPLASTIC
SYNDROME AND ACUTE MYELOID LEUKEMIA: AN ONGOING PHASE I
STUDY
S Holmberg1,*, A Ortved Gang1, IM Svane2, I Høgh Dufva1, S Reker Hadrup3
1Dept. of Hematology, 2Center for Cancer Immune Therapy, Herlev Hospital,
Herlev, 3Section for Vaccinology and Immunology, Technical University of Den-
mark, Copenhagen, Denmark
Background: Myelodysplastic Syndrome (MDS) is a clonal disorder and char-
acterized by increasing bone marrow failure due to accumulation of genetic
and epigenetic changes in hematopoietic stem cells. Patients with high-risk
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disease have a poor prognosis and a high risk of progression to Acute Myeloid
Leukemia (AML). The dysplastic cells harbor chromosomal breakage, point
mutations and promoter hyper-methylation of tumor suppressor genes. For
most patients, who are not eligible for bone marrow transplantation, hypomethy-
lating agents, such as azacitidine (AZA), are currently the only treatment option.
The demand for more effective therapies in this patient group is huge. Though
the mechanism of AZA is not fully elucidated re-expression of tumor suppressor
genes can serve as a mechanism for growth arrest. In addition, there is accu-
mulating evidence for an up-regulation of cancer testis antigens (CTA), which
could lead to increased immune recognition of tumor cells and immune-medi-
ated tumor cell killing. CTA’s are known to be immunogenic and are only
expressed at immunoprivileged sites and on malignant cells, making them
attractive as targets for therapeutic cancer vaccination.
Aims: We have set up a phase I trial where we combine the treatment of
hypomethylating agents with a peptide vaccine, to boost an immune response
against four selected tumor associated antigens which are known to be regu-
lated by methylation, in patients with high-risk MDS and AML.
Methods: For this vaccine specifically three CTA’s were chosen where abun-
dant re-expression has been shown following AZA treatment, including NY-
ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein
has proven to be an important antigen in hematological malignancies and is
likewise upregulated in response to AZA treatment. The peptides are between
25-29 mer and include a broad selection of HLA class I and II epitopes. Each
vaccine contains ~50 µg of each peptide and is mixed as a suspension with
Montanide ISA-51. The use of synthetic long peptides has shown superior
effect in contrast to minimal peptide sequences. They contain several CD4 and
CD8 T- cell epitopes for a broad range of HLA types, and thus allowing inclusion
of participants without prior selection based on HLA expression. Inclusion com-
mence after six courses of AZA and following a treatment evaluation. If there
is continued indication of AZA treatment, a set of three vaccinations is given
together with the following three courses of AZA. An additional vaccination is
then given every six months for two years or until there is unfavorable disease
progression. 
Results: At the time of writing we are planning for the inclusion of our first
patient which is expected to take place in late March 2016. Preliminary results
from the first vaccinations will be available to show at the conference. 
Summary/Conclusions: 15 patients from the department of Hematology at
Herlev Hospital, Copenhagen, Denmark, will be included starting March 2016.
The primary endpoint is to elucidate whether the combination of AZA and pep-
tide vaccination is a safe and tolerable treatment, but specific immune respons-
es and clinical efficacy will also be evaluated.
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PROGNOSTIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA
FROM SOUTH AMERICA
J Gonzalez1,2,*, J Arbelbide3, Y Bestach4, MM Rivas5, AL Basquiera6, R Crisp7,
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Background: Chronic myelomonocytic leukemia (CMML) is a clonal hemato-
logicdisorder sharing features of myelodysplastic syndromes (MDS)and chronic
myeloproliferative (MP) disorders.The International ScoringPrognostic System
(IPSS) for MDS and its recent revision (IPSS-R)excluded CMML-MP cases.
Thus, the CPSS (CMML Prognostic Scoring System) was designed specifically
for patients with CMML in 2013. Also, the German Group proposed to divide
CMML-1 into: CMML-0 and CMML-1 according to the limit of <5% bone marrow
blasts in 2014.However, both proposalshave not been widely reproduced.
Aims: To evaluate different prognostic factors for survival and evolution to
AML, to validate the CPSS and to test the new proposed cut-point for BM blast
in South American population with CMML de novo.
Methods: This is a multicenter analysis of 234 patients with de novo CMML
from Argentina (152) and Brazil (82) diagnosed between March 1985 to Decem-
ber 2015. Clinical and hematologic data of patients was retrospectively col-
lected and diagnosis of de novo CMML wasperformed according to WHO 2008
criteria.
Results: The CMML population showed a median age of 71 (range 15-95)
years being 83% older than 60 years old, with a sex ratio M/F: 2.1. With a
median overall survival of 31 months, 56 (24%) evolved to AML and 122 (52%)
died. Table 1 shows the distribution of patients according to CMML-MD and
CMML-MP subtypes; to WHO classification and to German proposal, kary-
otypes according to CPSS. Also, the different variants for the CPSS were cal-
culated, including transfusion requirement, hemoglobin level limit of 10g/dL
and the adjusted by gender. As it is shown, most of the prognostic parameters
and all CPSS proposals were useful to predict outcome in our population
(Kaplan Meier and log-rank, p<0.05). Since transfusion data was not available
for most patients, only models including both hemoglobin cut-points were ana-
lyzed in multivariate analysis (Cox Regression, Backward-Stepwise method).
The CPSS (hemoglobin threshold of 10 g/dL) sustained its independence both
for survival [p<0.001, exp(B) 1.912] and evolution to AML [p<0.001, exp(B)
2.352]. Also LDH level and the German Proposal, not included in the original
CPSS system, were analyzed in a multivariate model. This last cut-off for BM
blast showed an additive value to predict survival and evolution to LMA
[p=0.053 and p=0.003, exp(B) 1.335 and 2.057] when compared with the
CPSS-Hb variant [p<0.001 and p=0.052, exp(B) 1.654 and 1.537]. Our results
showed that the new proposed classification for CMML dividing them into
CMML-0, -1 and -2 may add prognostic value to the CPSS.
Table 1.
Summary/Conclusions: Our results showed that the new proposed classifi-
cation for CMML dividing them into CMML-0, -1 and -2 may add prognostic
value to the CPSS.
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SERUM ERYTHROPOIETIN (SEPO) TESTING, LEVELS, AND SUBSEQUENT
TREATMENT PATTERNS FOR TRANSFUSION-DEPENDENT PATIENTS
WITH MYELODYSPLASTIC SYNDROMES (MDS)
A Gerds1,*, G Binder2, A Fliss2, M McGuire2, S Hawthorne3, K King-Concialdi3,
M DiBonaventura3
1Cleveland Clinic, Cleveland, OH, 2Celgene Corporation, Summit, NJ, 3Kantar
Health, New York, NY, United States
Background: The European Society for Medical Oncology and the National
Comprehensive Cancer Network have developed guidelines for the treatment
of MDS, describing sEPO level as a useful measure at initial evaluation and
for supporting decisions about whether to treat with erythropoietin-stimulating
agents (ESAs). A high pre-treatment sEPO level is associated with a lack of
response to ESAs, and therefore patients with high sEPO levels should be
considered for other therapies. 
Aims: To evaluate rates of sEPO testing and sEPO levels, and the subsequent
use of ESAs among patients who became transfusion-dependent (TD) at or
after MDS diagnosis.
Methods: A retrospective chart review of patients with MDS was conducted in
the US. 26 oncologists and hematologists provided data from sequential patient
charts. Patient inclusion criteria were: age ≥18 years, diagnosis of International
Prognostic Scoring System Low/Intermediate-risk MDS within the last 1–5
years, and TD onset ≥12 months previously. Patients who had high-risk disease
prior to TD onset, had a concurrent malignancy, or were in an MDS clinical trial
were excluded. Demographics, disease history, treatment history, and lab val-
ues were collected and reported descriptively. Results were compared using
chi-square tests.
Results: Information was collected on 133 TD MDS patients. 57.9% were male
and median age was 67 years (range 37–89), with a median of 25 months
since diagnosis (range 12–58). 66 (49.6%) patients had an sEPO test at diag-
nosis; of these, 39.4% had levels ≥200 mU/mL, including 13.6% ≥500 mU/mL.
For patients without sEPO testing, reasons included practice dynamics (28.4%),
testing not considered worthwhile (28.4%), and no intent for ESA use (17.9%).
Excluding this latter group, 21.8% of untested patients were treated with ESA
vs 36.4% of those tested (P=0.08).
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Summary/Conclusions: Of US patients with TD MDS, only half had undergone
sEPO testing at diagnosis. Many had sEPO ≥200mU/mL, including a proportion
with ≥500 mU/mL; alternative treatments to ESAs should be considered for
these patients. Nevertheless, ESA use occurred in nearly a fifth of patients not
tested at diagnosis, suggesting that expanded sEPO testing may identify addi-
tional patients not appropriate for ESAs.
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IS A 1ST LINE ERYTHROPOIETIN APPROACH IN MYELODYSPLASTIC
PATIENTS WITH DEL 5Q- USEFUL?
P Volpicelli*, M Mancini, A Ferretti, I Carmosino, ML De Luca, F Vozella,
S Trasarti, E Sangiorgi, C Lisi1, M Breccia, R Latagliata, G Alimena
Cellular Biotechnologies and Hematology, Policlinico Umberto I, Rome, Italy
Background: Efficacy and safety of Erythropoietin (EPO) in patients with
myelodysplastic syndromes (MDS) have been demonstrated by various studies,
with response rates ≥60%. On the other hand, MDS patients with 5q deletion
(del5q) and transfusion requirement can achieve high response rates with
Lenalidomide, but this drug has shown severe hematologic and extra-hemato-
logic toxicities.
Aims: Thus, it could be advisable to evaluate the efficacy of EPO treatment as
1st therapeutic choice in this subset of patients.
Methods: To address this issue, 65 consecutive patients with MDS and del5q-
[M/F 18/47, median age at onset 72.9 yrs, interquartile range (IR) 65.2-81.1]
who received EPO treatment at our Institution from 6/2000 to 7/2015 were ret-
rospectively evaluated.
Results: According to WHO 2008, 30 patients (46.2%) were classified as del5q-
syndrome, 1 (1.5%) as refractory anemia, 20 (30.8%) as refractory citopenia
with multilineage dysplasia, 9 (13.8%) as refractory anemia with excess of
blasts-1 and 3 (4.6%) as refractory anemia with excess of blasts-2: according
to IPSS risk assessment, 30 patients (46.2%) were low-risk, 23 (35.4%) inter-
mediate-1, 9 (13.8%) intermediate-2 and 3 (4.6%) high-risk. As to karyotype,
42 patients (64.6%) had an isolate del5q-, while in the remaining 23 patients
(35.4%) there were other co-existing cytogenetic abnormalities. Median age at
EPO start was 73.3 yrs (IR 65.9 - 81.7), with a median interval from diagnosis
of 6.2 months (IR 1.5-14.3). Median Hb level at baseline was 9.0 g/dl (IR 8.2-
9.5) and 25 patients (38.5%) were transfusion dependent. Median EPO level
at baseline was 120 mU/ml (IR 68.8-270). Thirty-one patients (47.7%) received
standard dose EPO (30,000 - 40,000 UI weekly) and 34 (52.3%) high-dose
(60,000 - 80,000 UI weekly). On the whole, 22/65 patients (33.8%) [5/25 (20%)
with transfusional requirement and 17/40 (42.5%) without transfusional require-
ment at baseline] achieved an erythroid response according to IWG 2006 cri-
teria, after a median EPO treatment period of 1.9 months (IR 1.0-2.7): among
these 22 responding patients, 14 (63.6%) lost the response after a median
response period of 14.6 months (IR 7.6-29.6), while 8 patients (36.4%) are still
in response continuing EPO treatment. In the remaining 43 non responding
patients, EPO treatment was discontinued after a median period of 4.0 months
(IR 2.0-5.9) due to resistance. The median overall survival of the entire cohort
from EPO initiation was 47.5 months (95% CI 33.7-61.2), without differences
between responding and non responding patients (p=0.1).
Summary/Conclusions: This retrospective evaluation showed a substantial
reduced efficacy of EPO treatment in patients with del5q- compared to other
MDS low-risk subgroups, thus supporting the choice of lenalidomide as 1st line
approach in such subset of MDS, particularly in patients with del5q- and trans-
fusional requirement.
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PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) SCREENING IN
PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN CLINICAL
PRACTICE: FREQUENCY AND INDICATIONS
S Wong1,*, B Dalal2, H Leitch3
1Medicine, Royal College of Surgeons, Dublin, Ireland, 2Division of Laboratory
Hematology, Vancouver General Hospital, 3Hematology, St. Paul’s Hospital
and the University of British Columbia, Vancouver, Canada
Background: MDS is a group of bone marrow disorders characterized by inef-
fective hematopoiesis leading to peripheral blood cytopenias. Most MDS
patients (pts) develop significant anemia and red blood cell (RBC) transfusion
dependence (TD). In PNH, mutations in the phosphatidyl inositol glycan (PIGA)
gene lead to lack of the glycosylphosphatidyl inositol (GPI) anchor on the cell
surface allowing complement-mediated lysis to occur. The PNH phenotype
includes direct antiglobulin test (DAT) negative hemolysis and cytopenias
including TD anemia, hemoglobinuria (resulting in iron deficiency in some pts),
and thrombosis. PNH clones are detected in up to 50% of MDS pts, might con-
found the reason for RBC TD and PNH+ MDS pts may have better response
to immunosuppressive therapy (IST). Eculizumab is the first specific treatment
for PNH approved in Canada (2009). It reduces hemolysis and RBC transfusion
requirements, prevents thrombosis, improves renal function, quality of life and
overall survival (OS).We wanted to determine whether PNH as a contributor to
anemia is considered in MDS pts.
Aims: We wanted to determine whether PNH as a contributor to anemia is
considered in MDS pts.
Methods: All pts with MDS seen at St. Paul’s Hospital were reviewed. Only pts
with a bone marrow biopsy confirmed MDS diagnosis (dx) since 2009 were
included. Data extracted were baseline clinical and laboratory features, clinical
course, treatment and outcome. Indicators of hemolysis including increased
levels of lactate dehydrogenase (LDH), bilirubin (BILI) andreticulocyte count
(RETICS), decreased haptogobin (HAPTO), and results of DAT testing were
recorded. High resolution PNH testing was done by flow cytometry for expres-
sion of FLAER, CD24, CD14, and CD59 on neutrophils, monocytes and RBC.
Results: Of 395 MDS pts, 152 were diagnosed in 2009 or later. Median age at
MDS dx was 73.5 (range 38-91) years and 66% were male. MDS dx was: RA,
n=7; RARS, n=17; RCMD±RS, n=40; RAEB, n=23; hypoplastic, n=4; other,
n=61. IPSS scores were: low, n=53; int-1, n=59; int-2, n=32; and high, n=8.
MDS treatment was supportive care only in 53 pts. The erythropoietin (EPO)
level was >500mIU/mL in 4 pts. LDH, BILI and RETICS were measured (and
elevated) in 96 (23), 109 (10) and 142 (14) pts, respectively and HAPTO was
decreased in 2 of 7 measured. DAT was negative in 9 of 13 pts and serum fer-
ritin level <100ng/mL in 14 of 116. No pts had hemoglobinuria or thrombosis.
The hemoglobin was <100G/L in 86 at MDS dx. 79 (52%) pts were RBC TD,
with a median transfusion requirement of 4 (1-8) units/8 weeks. PNH testing
was positive in 1 of 11 pts tested. Reasons for PNH testing were: anemia, n=3
(with abdominal symptoms and pre-MDS dx, n=1 each); new MDS dx,
n=2;hypoplastic MDS, n=2; decreased HAPTO; increased RBC transfusion
requirements; and iron deficiency, n=1 each; see Figure and Table. Of patients
with an RBC transfusion requirement >4 units/8 weeks none underwent PNH
testing. At a median follow up of 21.1 (0.7-69.9) months for all patients, 113
were alive and the median OS was not reached.
Figure 1.
Summary/Conclusions: PNH was tested for infrequently in MDS patients in
clinical practice. Only 11 (7%) of MDS pts since 2009 had PNH testing done
despite potential indicators of hemolysis in 27%. Clinical rather than laboratory
indicators prompted PNH testing in 6 of 11 pts. Although the clinical significance
of PNH clones in MDS is not yet fully defined, complement mediated hemolysis
could exacerbate anemia. As there is now an effective treatment available, and
PNH+ MDS pts may respond to IST, screening for PNH in MDS should be con-
sidered.
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COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK
MYELODYSPLASTIC SYNDROMES
DM Dunia*, G Nuria, D Miguel, A Jaime, G Helga, S Dolores, M Dolores,
P Blanca, F Cristina, V Alejandro, H Sonia
Hematologia, Hospital universitario de Guadalajara, Guadalajara, Spain
Background: 5-azacitidine (AZA) significantly prolonged overall survival in
higher-risk patients with myelodysplastic syndromes (MDS) in international
phase III trial (AZA-001). However, data about efficacy of AZA in lower risk
MDS are less consistent and only few studies have addressed this topic.
Aims: Evaluate efficacy and security of AZA in low/int-1 risk MDS patients.
Methods: we evaluate the efficacy and safety in low and intermediate-1 risk
MDS patients.
Results: In our institution, a total of 59 MDS patients were treated with AZA
between 2006 to September 2015. We evaluated 40 patients diagnosed accord-
ing to WHO criteria as low/intermediate-1 International Prognostic Scoring Sys-
tem (IPSS) risk MDS. At baseline, median age was 75 year old (range 46-90),
male/female ratio 26/14. Median time from diagnosis to Aza treatment was 19,8
months (range 1-185). 80,9% patients were transfusion-dependent, 85,7% had
received a prior treatment (rhu-EPO+G-CSF 44,4%, only rhu-EPO 55,5%).
Low/Int-1 risk patients received AZA dose of 75mg/sqm/d subcutaneously dur-
ing days 1-7 in a 28-day cycle. The median number of monthly cycles was 11
(range 1-50), and 58% completed at least 6 treatment cycles, respectively.86%
patients had a overall response (53% transfusional independence, 23% PR,
10% CR). OS was 44 months. Overall adverse events documented in these
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patients were neutropenia (33%), anaemia (22%) and thrombocytopenia (17%).
Non-hematological adverse events: injection site reaction 39%, 50% constipa-
tion, 22% diarrhea and 10% fever. Response duration ranged from 4 to 43
months (median 12 months). 25% patients lost response. There were no sig-
nificant differences in response rate according to age, previous treatment,
transfusion requirements, basal EPO and Hb pre-AZA. 8 patients (13%) were
transformed to AML after median 23 months (7-36), Time since AZA treatment
14 months (1-24m).
Summary/Conclusions: 1.- 86% patients achieved a overall response. 2.-
Time to response is early (3 months), although some patients response later
(5 cycles or more). 3.- Efficacy and safety of AZA treatment is a valid alternative
in low/int-1 risk MDS patients.
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A REAPPRAISAL OF THE AZA TREATMENT OUTCOME: ASSESSING THE
VALUE OF DISEASE STABILISATION AND EFFECT OF TREATMENT
SCHEDULE MODIFICATION
EM Casartelli1,*, L Borin1, C Gambacorti Passerini1, L Antolini2, P Pioltelli1,
EM Elli1, M Fedele1, M Fumagalli1, M Parma1
1Ematologia, Ospedale San Gerardo Monza, 2University of Milano Bicocca,
Monza, Italy
Background: 5-Azacytidine is a chemical analog of cytidine used in the treat-
ment of myelodysplastic syndrome. We considered two unanswered questions
in the treatment of myelodisplastic syndrome: the significance of stable disease
and the impact of dose reduction or treatment delay on the outcome of patients.
Aims: In this study we considered a population of patients affected by
myelodysplastic syndrome with IPPS intermediate 2 or high risk treated with
5-Azacytidine. We analysed the prognostic impact of stable disease and treat-
ment schedule modification. 
Methods: We retrospectively analysed 57 patients treated with 5-Azacytidine
from 2008 to 2015 at San Gerardo Hospital, Hematological Unit (Monza, Italy).
We defined the response to treatment according to International Working Group
2006. All patients continued the treatment until loss of response, even if they
obtained stable disease. The median number of cycles of drug was 7, from a
minimum of 1 to a maximum of 27.
Results: The median time between the start of treatment and the loss of
response is 24 months. In the subgroup of patients who did not receive bone
marrow transplantation the median time is 20 months. The median survival
after loss of response is 4,8 months. We established 3 classes: 20 patients
obtained a response to treatment, defined as complete response, partial
response, marrow CR, cytogenetical response, hematologic improvement; 15
patients obtained stable disease; 22 patients failed the treatment. The median
survival from the diagnosis in responding patients, patients with stable disease,
or treatment failure is respectively 27 months, 30 months and 10 months. Sim-
ilarly the median survival from start of treatment of these 3 classes is respec-
tively 23 months, 27 months and 3,7 months. Fourteen out of 57 patients
required, during the treatment, a dose reduction of 5-Azacytidine or treatment
delay because of toxicity. Considering the treatment efficacy we deduced that
53% of patients who did not need a treatment schedule modification obtained
a response or stable disease (23 of 43). Indeed 85% of patients who required
a dose reduction or a treatment delay obtained a response or stable disease
(12 of 14). This difference, despite the few cases, appears statistically signifi-
cant with p value 0,02. In the subgroup of patients who required a dose reduc-
tion the median survival from diagnosis is 31 months versus 25 months in
patients who do not have dose reduction. Similarly the median survival from
start of treatment is respectively 23 months and 16,7 months. The median sur-
vival of all patients who required a treatment schedule modification, as dose
reduction or treatment delay, is 31 months from the diagnosis and 23 months
from the start of treatment, versus 21 months and 16 months in patients who
respected the schedule.
Summary/Conclusions: This study shows that in patients affected by
myelodysplastic syndrome with IPSS intermediate 2 or high risk treated with
5-Azacytidine, the stable disease should be considered response to treatment.
The only patients who have low median survival are treatment failures, in fact
outcome is similar in responders and in patients with stable disease. Further-
more dose reduction or treatment delay does not seem to adversely affect the
therapy efficacy and survival, but they reduce the treatment toxicity.
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DIAGNOSTIC VALUE OF PERIODIC ACID-SCHIFF POSITIVITY OF BONE
MARROW ERYTHROBLASTS IN MYELODYSPLASTIC SYNDROMES
R Invernizzi*, E Travaglino, F Quaglia, R Bastia, I Ambaglio, C Milanesi,
E Boveri, MG Della Porta, L Malcovati, M Cazzola
IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
Background: The revised 2008 WHO classification confirmed minimal mor-
phological criteria of myelodysplastic syndrome (MDS) diagnosis: at least 10%
of bone marrow (BM) cells of at least one hematopoietic cell lineage must show
unequivocal dysplasia to be considered as dysplastic. Morphological abnor-
malities of erythroid cells include cytoplasmic Periodic acid-Schiff (PAS) posi-
tivity, but the PAS positivity diagnostic power is not yet fully clear. Neither was
this morphological aspect taken into account by the “Rete Ematologica Lom-
barda (REL)” clinical network that proposed a structured and reproducible
approach for the precise recognition of BM dysplasia (Della Porta et al.
Leukemia 2015; 29:66-75).
Aims: Since dysplastic alterations of BM precursors and of peripheral blood
cells are still fundamental for diagnostic classifications, the aims of our study
were to evaluate the diagnostic value of erythroblast PAS positivity in MDS
and to investigate a possible correlation between PAS positivity levels and
other morphological and clinical features.
Methods: We retrospectively examined the results of the cytochemical PAS
staining for glycogen in BM smears from 120 MDS patients, 105 patients with
non-clonal cytopenia and 49 healthy subjects. By counting 100 nucleated cells
for the erythroid lineage and classifying them for their degree of PAS reactivity,
we developed a PAS score for MDS identification on the basis of a ROC curve
analysis. 
Results: PAS positive erythroblasts were observed in 74 (62%) MDS patients,
43 (41%) patients with non-clonal cytopenia and 12 (24%) healthy subjects
(p<0.0001). In MDS, both positivity rates (mean 3.9%, range 0-31%) and scores
(mean 5.8, range 0-49) were significantly higher than those in normal and
pathologic controls (p=0.0001 and p<0.0001, respectively). Positive erythrob-
lasts showed diffuse or granular cytoplasmic reactivity. In MDS, no significant
relationship was detected between erythroblast PAS positivity rate or score
and dyserythropoiesis grading, multilineage dysplasia or excess blasts, where-
as there was a significant inverse correlation between PAS score values and
percentages of BM erythroblasts (p=0.041) and between PAS score values
and percentages of ring sideroblasts (p=0.012). Anemic patients showed higher
score values than non-anemic subjects (p=0.016). PAS positivity was unrelated
to karyotype abnormalities. A ROC curve analysis allowed us to identify a PAS
score value >0 (AUC=0.642, p=0.0001) and a PAS positive erythroblast per-
centage >0 (AUC=0.629, p=0.0002) as optimal cut-off to discriminate MDS
patients from controls with sensitivity and specificity ranging from 62% to 66%.
Positive and negative predictive values of PAS positivity were 74% and 58%,
respectively. Considering the most discriminant morphological features for
dyserythropoiesis, the weight of both PAS positivity rate and score in the recog-
nition of BM dysplasia was lower than that of ring sideroblasts and megaloblas-
tosis, but higher than that of defective hemoglobinisation, nuclear lobulation,
multinuclearity, cytoplasmic fraying, pyknosis, and internuclear bridges. 
Summary/Conclusions: The evaluation of BM erythroblast PAS positivity may
be useful in the work-up of patients with suspected MDS, especially if there is
only unilineage dysplasia without excess blasts or ring sideroblasts. This
parameter should be included in the diagnostic morphological panel to be used
for a correct application of the WHO classification.
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NFE2L2,KEAP1AND NQO1GENE EXPRESSION IN MYELODYSPLASTIC
SYNDROME AND MONOCLONAL GAMMOPATHIES-CLINICAL IMPLICATIONS
J Jorge1,2, AC Gonçalves1,2,3, E Cortesão1,2,4, C Geraldes1,2,4, B Gomes1,
A Pires1,2, S Fernandes1, R Alves1,2,3, L Ribeiro4, AB Sarmento-Ribeiro1,2,3,4,*
1Laboratory of Oncobiology and Hematology (LOH),University Clinic of Hema-
tology and Applied Molecular Biology, Faculty of Medicine, 2Center of Investi-
gation on Environment Genetics and Oncobiology, Faculty of Medicine, 3Center
for Neuroscience and Cell Biology (CNC.IBILI), University of Coimbra, 4Clinical
Hematology Service, Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal
Background: Oxidative stress (OS) deregulation has been associated with
almost all neoplastic diseases, including leukemia, where it contributes to dis-
ease development and progression. NRF2 (Nuclear factor erythroid-2-related
factor 2) is a transcription factor codified by NFE2L2 gene (Nuclear factor ery-
throid2-like 2) that activate many antioxidant and detoxification genes, like the
NQO1 (NAD(P)H:quinone oxidoreductase 1) gene, through its binding to antiox-
idant response element (ARE) and regulate ARE-mediated gene expression
and induction. Moreover, NRF2 is strongly regulated by KEAP1 (Kelch-like
ECH-associated protein 1). NRF2-KEAP1 system seems to have an extremely
important role in OS regulation, contributing for disease development and/or
influence therapy response.
Aims: Our aim was to evaluate the expression levels of NFE2L2, KEAP1 and
NQO1 genes in Myelodysplastic Syndrome (MDS) and Monoclonal Gam-
mopathies (MG) patients, and its correlation with clinical and laboratorial data,
in order to identify potential biomarkers of diagnosis and/or prognosis.
Methods: We evaluated 135 samples, 53 MDS (26 refractory cytopenia with
multilineage dysplasia; 8 chronic myelomonocytic leukemia; 7 refractory cytope-
nia with unilineage dysplasia; 5 refractory anemia with excess blasts-1; 4 refrac-
tory anemia with ringed sideroblasts; 2 refractory anemia with excess blasts-
2; 1 5q-), 40 MG (15 monoclonal gammopathies of undetermined significance;
25 multiple myeloma) and 42 controls (Ctl). Samples were collected after
informed consent obtained in accordance with the Helsinki Declaration. Real-
time PCR was used to evaluate the gene expression level of NFE2L2, KEAP1,
774 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
NQO1 andGUS (control gene). Results were considered statistically significant
when p<0,05.
Results: Our results showed that patient’s group presents higher KEAP1
expression levels comparing to controls (Patients: 0,175; CTL: 0,097; p=0,04),
while NFE2L2did not presented differences between any groups. When we
analyzed by pathology, it was observed that KEAP1 gene expression levels
was higher in GM patients compared with controls (GM:0,2059; CTL: 0,09717;
p=0,009). No association was observed between MDS and CTL; however
RCDM patients have lower levels of NFE2L2 (RCMD: 1,754; CTL: 5,033;
p<0,05) and higher levels of KEAP1 (RCMD: 0,185; CTL: 0,097; p=0,005). Fur-
thermore, our preliminary results for NQO1 gene expression showed that MDS
patients present lower levels than controls (MDS: 0,1884; CTL: 01969;
p=0,0058). No associations were found between clinical and laboratory data
(erythropoietin and ferritin levels) and the analyzed genes. Through ROC analy-
sis we observed that NFE2L2 (cut off <2,044; sensitivity: 75%; specificity:
83,3%) and KEAP1 levels (cut off >0,1627; sensitivity: 54,17%; specificity:
86,67%) might be diagnostic biomarkers for RCMD patients, as well as, NQO1
levels for MDS patients (cut off >0,00654; sensitivity: 74,29%; specificity:
78,26%). Also, KEAP1 levels might be biomarkers for MM patients (cut off
>0,1645; sensitivity: 52,38%; specificity: 86,67%). Survival analysis showed
that RCMD patients with NFE2L2 expression levels over 2,044 and KEAP1
levels under 0,1645 present a tendency for lower survival. The same is
observed in MM patients with KEAP1 levels under 0,1645.
Summary/Conclusions: Our results suggest that the expression pattern of
NFE2L2, KEAP1 and NQO1 genes might be associated with the development of
hematological malignancies, and may have a great potential as diagnostic and
prognostic biomarkers for Myelodysplastic Syndrome and Multiple Myeloma.
This study is supported by Center of Investigation in Environment Genetics
and Oncobiology (CIMAGO), Jorge J. by LPCC-NRC/CIMAGO 2015 Grant,
Pires A. by LPCC-Pfizer 2015 Grant andAlves R. is supported by Portuguese
Foundation to Science (FCT) grant (SFRH/BD/51994/2012).
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BIOSIMILAR ERYTHROPOIETIN ALFA FOR THE THERAPY OF ANEMIA IN
“LOWER RISK” MYELODYSPLASTIC SYNDROMES. INTERIM RESULTS
FROM A PROSPECTIVE OBSERVATIONAL STUDY OF THE “RETE
EMATOLOGICA LOMBARDA” (EPOREL)
AM Pelizzari1,*, E Borlenghi1, J Mariotti2, M Riva3, A Molteni4,
D Lambertenghi5,6, A Passi1, V Orlando1, C Lamorgese1, E Morra3
1Hematology, Asst Spedali Civili Brescia, Brescia, 2Hematology and Transfusion
Unit, Asst Treviglio-Caravaggio, Bergamo, 3Hematology, O.Niguarda Ca’ Gran-
da, 4Hematology, Ospedale Niguarda Ca’ Granda, 5Medicine III, Asst SS Paolo
e Carlo, 6University of Milan, Milan, Italy
Background: Biosimilar EPO use for the treatment of anemia of MDS is based
on therapeutic equivalence extrapolated from originator drug employed in other
clinical settings; specific prospective evaluation of their activity in MDS are
scarce. From November 2014 “lower risk” pts with newly-diagnosed MDS
referred to the haematologic centres of REL and symptomatic anaemia partic-
ipate to an observational multicenter prospective study on efficacy and safety
of biosimilar EPO (EPOREL1 protocol).
Aims: 1) Primary endpoint: to prospectively assess the response rate of “lower
risk” MDS anaemic pts treated with biosimilar EPO alfa; 2) Secondary endpoint:
to validate the prognostic power of Scandinavian Myelodysplasia Group score
(SMG) (Hellstrom-Lindberg E et al, Br J Haematol 1997; 99:344) in this setting.
Methods: The study was in accordance with the ethical standards of the Com-
mittee of Human Experimentation of the coordinating center. MDS were diag-
nosed according to WHO 2008 criteria and classified according to IPSS and
IPSS-R. EPO alfa was administered subcutaneously at the starting dose of
40.000 U/w. EPO was doubled in not responsive pts after 2 ms, reduced at
mainteinance dose if hgb ≥12 g/dl and stopped in case of refractoriness,
relapse, AML evolution, death or major toxicity. Responses were defined by
IWG criteria 2006.
Table 1.
Results: Data were collected from the charts of 26 consecutive pts treated
with biosimilar EPO alfa; 21 were evaluable (five too early). Median age was
79 yrs (71-90); F/M 0,3. Their diagnostic and prognostic characteristics are
described in Table 1. Twelve (57%) pts were transfusion dependent with median
transfusion need of 2 units/ms (1-3). Median haemoglobin was 8,7 (7,5-9,8)
and median endogeneous serum EPO, evaluable in 19 pts (90%), was 50 U/L
(11-1410). Fifteen pts (71%) responded after a median time of 1 mo (1-10; D.S.
4,1, C.I.95%), 5/12 (42%) transfusion dependent pts reached transfusion inde-
pendency. EPO dose was incremented to 80.000U/w in 13 pts (62%) after a
median of 2 ms (1-8). After a median f.up of 6 ms (2-15), all responsive pts
maintained the response and are still on treatment. Ten of 11 (91%) pts with
SMG score good and 1/6 (17%) pts with SMG score intermediate achieved an
erythroid response (p=0.005). No adverse events were reported up to now.
AML evolution was documented in three non responsive cases after a median
follow-up of 3 ms (2-6): two pts were off therapy; one case IPSS int1, IPSS-R
int, normal karyotype, evolved during treatment. Two pts died: one off-therapy
after AML transformation for septic shock, one responsive with previous car-
diopathy for congestive hearth failure.
Summary/Conclusions: To our knowledge this is the first prospective study
on MDS pts treatment with biosimilar EPO alfa (HX575). The response rate
and safety profile of biosimilar EPO alfa is comparable with published data on
originator EPO, even in this older MDS cohort. The study confirms the prog-
nostic power of SMG score in this setting. Further evaluation after prolonged
follow-up on larger series of pts is warranted.
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PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES AND
THEIR INFLUENCE ON OVERALL SURVIVAL
T Sotirova1,*, O Karanfilski1, B Georgievski1, A Stojanovic1, S Stankovic1,
S Genadieva-Stavric1, M Pavkovic1, A Eftimov2, A Dimovski2
1Hematology, University Clinic of Hematology, 2Center for Biomolecular Phar-
maceutical Analyses, Faculty of Pharmacy, Skopje, Macedonia
Background: Prognostic factors have been evaluated so far in different com-
binations in order to detect those that would influence overall survival (OS) in
patients with MDS and would be incorporated in future revisions of prognostic
scoring systems.
Aims: 1.Analysis of chromosomal abnormalities with ‘Multiplex ligation-depen-
dent probe amplification’ (MLPA), 2.Evaluation of the prognostic significance
of age, sex, bone marrow (BM) blast percentage, cytopenias, MCV, transfusion
dependency, serum ferritin, LDH, serum albumin, comorbidities and chromo-
somal abnormalities and 3.Their implication on OS and transformation in acute
myeloid leukemia (AML).
Methods: 215 adult patients with ‘de novo’ and t-MDS were included in the
study, diagnosed at the University Clinic of Hematology in Skopje, from January
2011 till April 2015, with follow-up period of 52 months. Patients were divided
into two groups: 70 patients as an investigational group (IG) and 145 patients
as a control group (CG). Detection of the chromosomal abnormalities was per-
formed with the method MLPA. Informed consent was obtained.
Results: Patients were classified according to the FAB and WHO classifica-
tions. Risk stratification was made in accordance with IPSS and R-IPSS. OS
and transformation in AML were followed. We evaluated the association among
17 factors and OS in the IG. The univariate analysis revealed only 4 from 17
factors associated with OS: platelet number, blast percentage in the BM, IPSS
and R-IPSS. Multivariate analysis revealed that predictors of the event were
platelets <100x109/L, IPSS - low risk and R-IPSS-intermediate risk. We also
evaluated the association among 14 factors and OS in the CG. The univariate
analysis revealed only 5 from 14 factors associated with OS. The OS was asso-
ciated only with age, platelet number, blast percentage in the BM, WHO sub-
types and comorbidities. Multivariate analysis revealed that predictors of the
event were age <50 years and platelets <100x109/L. Transformation in AML
was detected in 26 (12.1%) patients.
Summary/Conclusions: MLPA proved to be a reliable method for detection of
chromosomal abnormalities in MDS. Platelets <100x109/L, IPSS - low risk and
R-IPSS-intermediate risk in the IG and age <50 years and platelets <100x109/L
in the CG influenced OS in our cohort. Only age was not incorporated in the
IPSS and R-IPSS. Probably, it should be taken in consideration in further refine-
ment of the prognostic scoring systems.
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CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MYELODYSPLASTIC
SYNDROMES (MDS) IN ADULTS ACCORDING TO THE DATA OF MUNICIPAL
HEMATOLOGY DEPARTMENTS IN MOSCOW, RUSSIA
S Semochkin1,2,*, T Tolstykh2, G Dudina3, O Fink4, E Misyurina2
1Oncology, Hematology and Radiotherapy, Pirogov Russian National Research
Medical University, 2Hematology, City Clinical Hospital #52, 3Hematology,
Moscow Clinical Research Center, 4Bone marrow transplantation, Russian Chil-
dren’s Clinical Hospital, Moscow, Russian Federation
Background: The myelodysplastic syndromes (MDS) are a distinct group of
clonal disorders of hematopoietic stem or progenitor cells characterized by inef-
fective hematopoiesis, peripheral cytopenias, abnormal dysplastic cell mor-
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phology, and potential for clonal evolution to secondary acute myeloid leukemia
(AML). AML is eventually diagnosed in up to 30-40% of MDS cases. Popula-
tion-based registry data in the USA and Europe indicate an incidence of MDS
in western countries of around 3-5 cases per 100.000 person-years with male
predominance. The epidemiology of MDS has been carefully investigated in
western countries while exact data on the epidemiology of MDS in Russia are
absent.
Aims: To study the registered incidence of MDS in adults in the city of Moscow,
to evaluate methods of diagnosis confirmation and choice of therapy in the
system of Health Care.
Methods: The observational study included adult patients with newly diag-
nosed MDS in 2010, who were residents of Moscow. Evaluation of overall sur-
vival (OS) conducted as of September 2014.
Results: A total of 201 (male-110, female-118) adult patients were reported to
the system of Moscow Health Care with newly diagnosed MDS in 2010. Median
age at diagnosis was 71.5 years (range, 23.9-93.7). The incidence rate of MDS
was 2.0 cases per 100.000 persons per year in the general adult population.
Incidence accurately increased with age (Fig. 1). The maximum incidence 18.1
cases per 100.000 men was registered in the age over ≥85 years and 9.8
cases per 100.000 women in age 75-79 years. Most frequent morphological
types of MDS distributed as follows: refractory anemia (RA)-33.8%, refractory
anemia with ring sideroblasts (RARS)-8.4%, refractory cytopenia with multilin-
eage dysplasia (RCMD)-12.0%, refractory anemia with excess blasts-1 (RAEB-
1)-12.9% и RAEB-2-21.9%. Cytogenetic variants of MDS assessed only in 36
(17.9%) patients. All patients divided into 5 groups depending on the type of
first-line therapy: 69 patients treated with epoetin alfa or beta (rHuEpo) as
monotherapy; 20-low-dose ara-C (LDAC); 12-hypomethylating agents (azaci-
tidine, decitabine); 60-symptomatic (red cell transfusion for low-risk MDS) and
38 - palliative care (elderly and weakened high-risk patients). Two patients with
5q- syndrome treated with lenalidomide. With a median follow-up for survivors
46 months 4-year overall survival (OS) for all patients was 34.8±13.4% (median
24.3 months). Early mortality over the first 60 days was 5.0%. rHuEpo used
primarily in low-risk patients: 4-year OS 60.7±5.9%. Hypomethylation agents
and LDAC applied in advanced MDS morphological variants: 4-year OS
25.0±12.5% (median 21.1 months) and 15.0±8.0% (15.3 months) respectively.
Depending on the morphological variant of the 4-year OS was the following:
5q- syndrome-57.1±18.7% (median › 46 months); RA-50.8±6.1% (35.7); RARS-
35.3±11.6% (32.8); RAEB-1 - 32.8±9.4% (24.7) and RAEB-2-5.7±3.7% (15.3).
Figure 1.
Summary/Conclusions: The incidence of MDS in Moscow, Russia is 1.5-2
times lower than in Europe and the United States. Current diagnostic standards
under the mandatory health insurance does not include genetic and molecular
studies. Implementation a cytogenetic study and FISH in MDS typical chromo-
somal abnormalities in all patients with unexplained cytopenias will improve
the diagnostic level.
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HIPERFERRITINEMIA IN MYELODISPLASTIC SYNDROME (MSD)
PATIENTS CORELATION WITH EVOLUTION AND SURVIVAL
M Ionita1, I Ionita2, D Calamar2, C Ionita3, D Oros2, O Potre Oncu2, H Ionita2,*
1Internal Medicine, 2Hematology, 3Surgery, University of Medicine and Farmacy
Victor Babes Timisoara, Timisoara, Romania
Background: Most myelodysplastic (MDS) patients have anemia and many
of them require red blood cells (RBC) transfusions leading to iron overload.
Hematological improvement during iron chelation therapy was first pointed out
more than twenty years ago. This phenomenon seems to be more frequent
after introduction of Deferasirox. The most simple test assessing iron overload
is serum ferritin concentration.
Aims: Assessment of hyperferritinemia incidence in MDS patients at the
moment of MDS diagnosis, and correlation between ferritin level and evolution
an survival in patients diagnosed with MDS.
Methods: The retrospective data collection from a single center experience
(Department of Hematology County Hospital, Timisoara, Romania) between
January 2005 and December 2014 included 121 patients (73men and 48
women) with MDS. All the patients had complete blood count and serum ferritin
level, and complete follow-up data.
Results: Ferritin level above1000 ng/mL was found in 45 patients (31%) (Group
1) and ferritin level ≤1000ng/mL in 76 patients (69%) (Group 2). Most patients
with significant hiperferritinemia, were RBC transfusion dependent (78% of
patients). Among patients with ferritin level ≤1000 ng/mL, 48% were RBC trans-
fusion dependent. Serum hemoglobin concentration was lower in Group 1
patients in comparison with Group 2 patients (6.2 g/dL vs 9,3 g/dL, p<0,001).
The most frequent MDS subtype in Group 1, were patients with refractory ane-
mia (RA) (32%), compared with patients with ferritin ≤1000 ng/mL - 15%
(p<0,04). According to IPSS score, there were no differences between studied
groups. Median follow up was 15 months. There was an improved overall sur-
vival (OS) in RBC transfusion independent patients compared to RBC transfu-
sion dependent patients, but mean OS was not significantly statistically different
in studied groups. No correlation was found between ferritin level and time to
acute myeloid leukemia (AML) transformation.
Summary/Conclusions: Hiperferritinemia >1000 ng/mL does not influence
survival and time to AML transformation in MDS patients. The most frequent
MDS subtype in patients with ferritin level >1000 ng/mL was MDS RA. Among
patients with ferritin level >1000 ng/mL 76% were RBC dependent.
PB1928
EFFICACY AND SAFETY OF XIAOAIPING TABLETS IN THE TREATMENT
OF ELDERLY PATIENTS WITH INTERMEDIATE-RISK/HIGH-RISK
MYELODYSPLASTIC SYNDROME: A PILOT TRIAL
X Sun1,*,xDai1, Z Xu1, D li2,xZhu1, L li1
1Hematology, Jiangsu province hospital of TCM, 2Hematology, Nanjign Benq
Hospital, Nanjing, China
Background: Myelodysplastic syndromes (MDS) represent a group of biolog-
ically and clinically heterogeneous clonal hematopoietic neoplasms with very
poor treatment efficacy and clinical outcomes and patients have been recom-
mended enrolled in clinical trials. Traditional Chinese medicine has also made
some progress in the treatment of MDS in resent years. Xiaoaiping tablet, an
herbal medicine widely used as an anticancer wonder drug, is the extract of
Marsdenia tenacissima (Tong-guan-teng in Chinese folk medicine),which is
officially recorded in the Chinese Pharmacopoeia Marsdenia tenacissima.
Since 1990s,Xiaoaiping preparations including tablet,injection and syrup which
are all extractions of the plants, demonstrate anti-tumor effect on gastric, hepat-
ic carcinoma and leukemia.
Aims: To observe the efficacy and safety of Xiaoaiping tablets in the treatment
of elderly patients(over 60 years-old) with intermediate-risk/high-risk myelodys-
plastic syndrome.
Methods: Twenty-four patients were enrolled in the study. They received
Xiaoaiping tablets (2.4-3.0g,oral,3 times daily) combined with supportive care
therapy. The primary endpoint of efficacy was measured by the number of days
between blood transfusions as well as haematolgical indicies. The changes in
ECOG performance status were observed as well as adverse events.
Results: Twenty-one patients of the twenty-four completed therapy. Two
patients (9.5%) had a complete remission (CR) 3 patients (14.3%) had a partial
response (PR), the overall response rate was 23.8%. Eleven patients had
haematological improvement (HI), with the HI rate being 52.4%. Haematologic
indices of hemoglobin, total neutrophil count and platelet post Xiaoaiping-treat-
ment were significantly higher than those before treatment (P<0.05).After treat-
ment, the average interval of transfusion of red blood cells (RBC) and platelets
was extended (P<0.05). The ECOG scores post-treatment was lower than
those before treatment (P<0.05). Toxicities were limited. There were no grade
3 or 4 adverse events.
Summary/Conclusions: Xiaoaiping tablet was an efficacious intervention as
measured by hematological indices, the number and frequency transfusions
and patients performance status. It was an effective and safe agent in the treat-
ment of elderly patients with intermediate-risk/high-risk MDS, and the tablets
might be a promising therapy for this group of patients.
PB1929
MYELOTOXICITY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF
NEUROENDOCRINE TUMORS: A DECADE OF EXPERIENCE
M Kesavan*, JH Turner
School of Medicine and Pharmacology, University of Western Australia, Perth,
Australia
Background: Myelodysplastic syndrome (MDS) and acute leukemia (AL) have
been associated with peptide receptor radionuclide therapy (PRRT) in heavily
pre-treated patients with a prior history of exposure to alkylating agents. Com-
menced 15 years ago PRRT is now becoming established as first and second
line therapy for gastrointestinal and pancreatic neuroendocrine tumors (GEP-
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NETS). Current therapies gain only marginal, albeit statistically significant,
increase in progression free survival (PFS) without meaningful objective
responses and are accompanied by significant toxicity. With the incidence of
GEPNETS rising in the Western world, myelotoxicity is now the most significant
potential adverse event following PRRT.
Aims: This review of the literature, and our own decade of experience with
lutetium-177-octreotate-capecitabine +/- temozolamide PRRT-chemotherapy
of GEPNETS analyses the risk of both short and long-term hematotoxicity.
Methods: All of the literature on myelotoxicity in associated with PRRT of NETS
reported in papers published over the past 15 years has been reviewed and
compared with our own experience of lutetium-177 PRRT combined with octreo-
tate-capecitabine-temozolomide radiosensitising chemotherapy. Relevant pri-
mary research concerning myelotoxicity and PRRT was identified using medical
databases. Key articles published from 2000 onwards were obtained primarily
from PubMed, Ovid and Cochrane databases. Specific focus was given to arti-
cles published in Cancer Biotherapy and Radiopharmaceuticals, European
Journal of Nuclear Medicine and Molecular imaging, Neuroendocrinology, Jour-
nal of Clinical Oncology and Endocrine Related Cancer.
Results: Sixteen key articles involving primary research were identified; 12
articles relating to PRRT as monotherapy and 4 articles relating to PRRT in
combination with chemotherapy and/or novel agents. A total of 2225 patients
were treated (2104 treated with PRRT monotherapy and 121 with PRRT com-
bination) all of whom had been exposed to prior therapies, including somato-
statin analogs, alkylating agents, radiotherapy, prior PRRT and surgery with
the majority having had exposure to greater than two prior lines of treatment.
The average age of patients in these studies ranged from 53 to 64 years with
median duration of follow up ranging from 6 to 62 months. Short-term myelo-
toxicity was observed in 221 patients (10%), occuring in 213 of 2104 patients
treated with PRRT monotherapy and 8 of 121 patients treated with PRRT com-
bination. Acute toxicity manifested as modest self-limited grade 3/4 toxicity
(CTCAE or WHO) most often affecting platelets then WBC and lastly hemoglo-
bin, and was commonly observed during the first cycle of treatment, with the
lowest nadir predictive of time taken for recovery. Toxicity manifesting early
was easily managed with dose modification or therapy cessation, and was
ameliorated by appropriate patient selection based on age, prior therapies,
comorbidities and adequate baseline myeloid function. Long-term toxicity in
the form of MDS and AL was a rare stochastic event occurring in only 32 (1.4%)
of all the patients treated with PRRT (24 cases of MDS, 6 cases of MDS with
subsequent transformation to AL and 2 cases of AL alone). Where bone marrow
biopsy was performed the majority of cases of MDS displayed complex cyto-
genetic abnormalities, consistent with secondary MDS following exposure to
chemotherapy with alkylating agents or irradiation. The development of MDS
was a risk factor for AL. No significant difference in relative risk of MDS/AL was
noted between patients salvaged with PRRT monotherapy or PRRT combina-
tion (1.4% and 1.6% respectively). Factors associated with development of sig-
nificant short and long-term myelotoxicity included age >70 years, impaired
renal function, baseline cytopenias, prior number of therapies, prior chemother-
apy (especially alkylating agents) and prior radiation therapy. The latter two
factors were associated with a significant of development of MDS and AL.
Summary/Conclusions: Early therapy with PRRT-containing regimens
improves outcomes, minimizes myelotoxicity and renders the risk of MDS and
AL negligible.
PB1930
ASSESSMENT OF B AND T LYMPHOCYTES FUNCTION IN PATIENTS
WITHMYELODYSPLASTIC SYNDROMES
M M Moussa*, W Elsalakawy
Internal Medicine, Hematology and BMT unit, Ain Shams University, Cairo,
Egypt
Background: An activated immune system has been observed in patients with
myelodysplastic syndrome but its exact contribution to disease development
and control is not fully clarified. The successful use of immunosuppressive ther-
apies, the potentially curative role of allogeneic stem cell transplant, and the
more recent data showing improved peripheral cytopenias and elimination of
certain common cytogenetic abnormalities with immunomodulatory agents;
highlight the role immune dysregulation in the development of MDS.
Aims: The aim of this study is to assess B and T cell function in patients with
MDS and correlate them to the risk status of MDS.
Methods: The study included 30 adult Egyptian patients diagnosed with MDS
based on blood picture, bone marrow examination and cytogenetic studies.
Patients were classified according to IPSS risk scoring system. Immune system
assessment was done by performing: antinuclear antibodies, coombs’ test,
serum protein electrophoresis and CD4/CD8 ratio in peripheral blood.
Results: We’ve found an association between inverted CD4/CD8 ratio and
higher risk strata, presence of neutropenia and transfusion dependence.
Regarding Humoral immune system involvement, positive coombs test was
related significantly to younger age, higher bone marrow blasts count. Poly-
clonal gammopathy-as well-was found to be associated with higher bone mar-
row blasts count and presence of cytogenetic abnormalities.
Summary/Conclusions: Immune dysregulation-in the form of inverted
CD4/CD8 ratio, positive ANA, positive coombs’ test and polyclonal gammopa-
thy-is well documented in myelodysplastic syndrome, and it is probably related
to younger age, higher IPPS risk, higher bone marrow blasts count and the
presence of cytogenetic abnormalities.
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DOMICILIARY AZACITIDINE: A NEW EXPERIENCE IN OUR CENTER
I Herráez Balanzat1,*, MA Duran Pastor1, E Delgado Mejía2, MDC Ballester Ruiz1,
A Pérez Montaña1, A Novo García1, C Martorell Puigserver3, E Torres del Pliego2,
A Sampol Mayol1
1Hematology, 2Internal Medicine, 3Pharmacy, Hospital Son Espases, Palma
de Mallorca, Spain
Background: Azacitidine is an antineoplastic agent used in adults with no indi-
cation of bone marrow transplantation and with a diagnosis of intermediated-2
or high risk myelodisplastic syndrome (MDS), high risk chronic myelomonocytic
leukemia (CMML) or myeloid acute leukemia (AML).
Aims: Show the experience of using domiciliary Azacitidine and to evaluate its
effectiveness in a third level hospital. Evaluate the patient’s satisfaction. Esti-
mate the efficiency of the treatment.
Methods: Retrospective observational study including patients who have
received treatment with domiciliary Azacitidine from June 2015 to January 2016.
The following variables were chosen: gender, age, base pathology, treatment
cycles, secondary effects, readmissions, Exitus and satisfaction. Domiciliary
hospitalization unit (DH), trains patients and their families and monitors vital
signs during the treatment. We have revised the official cost for one-day stay
in an adult day hospital (ADH) versus domiciliary administration according to
the July 2014 issue of “BOIB”. Telephone surveys were conducted (table 1),
asking patients and their families (with a score from 0 to 10), to evaluate the
quality of the service.
Results: We have nine patients, six male and three female, between the ages
54-84. The treatment cycles at home vary between 1 and 8. We had no read-
missions during the treatment. Three adverse effects appeared: itching, cuta-
neous reaction and asthenia. Of the nine patients, two died due to disease pro-
gression. We compared the costs for one treatment cycle: at the ADH the cost
was 3,850 Euros (550 Euros a day for seven days) with the costs of the same
treatment at home, which was 2,037 Euros (291 Euros a day for 7 days). If we
calculate all the 34 cycles received, the costs would be 130,900 Euros for
receiving the drug at the hospital, versus 69,258 Euros at home. In 7 months
that we conducted the domiciliary program, the hospital saved 61,642 Euros.
The telephone survey showed that 100% of the questions were answered with
the maximum score.
Table 1.
Summary/Conclusions: There were no readmissions during the treatment
and the secondary effects were minor, so we conclude that home administration
is safe. All patients had a high level of satisfaction and experienced an improve-
ment in their quality of life. The treatment with Azacitidine in DH has the same
effectiveness and more efficiency than in ADH.
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A RETROSPECTIVE REVIEW OF AZACITIDINE THERAPY IN AN IRISH
UNIVERSITY HOSPITAL SETTING
J M Nolan1,*, M Leahy1, D O’Keeffe1, J Nally2, H O’Leary1
1Haematology, 2Pharmacy, University Hospital Limerick, Limerick, Ireland
Background: Azacitidine (AZA) is a a hypomethylating agent and nucleoside
analogue of cytidine. Hypomethylating agents have revolutionised the therapy
of intermediate-2 and high-risk myelodysplastic syndrome (MDS), chronic
myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) in
patients fit for neither intensive therapy nor haematopoietic stem cell transplan-
tation (HSCT). 
Aims: This retrospective review aimed to examine the usage of AZA com-
menced for any indication during a three year period in a university teaching
hospital in Ireland. Data collected pertained to patient and disease character-
istics, safety, efficacy, overall and progression free survival and the effect of
therapy on transfusion dependence.
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Methods: A retrospective analysis of patients receiving AZA at University Hos-
pital Limerick in a three year period from October 2012 until October 2015 was
conducted. Data was collected from patients’ paper and electronic records and
the electronic laboratory system. Included patients received at least one cycle
of AZA. The World Health Organization Classification was used to classify dis-
ease status. Overall (OS) and progression-free survival (PFS) were calculated
from the date of commencement of AZA therapy and were calculated using
Kaplan-Meier estimates. 
Results: Twenty-eight (28) patients commenced AZA between October 2012
and October 2015. 64% of patients were male and the cohort had a median
age of 70 years (range 42-80 years). These patients comprised 3 patients with
IPSS intermediate risk (level 2) MDS, 5 patients with IPSS high-risk MDS, 6
patients with CMML, 2 patients with MDS/MPN overlap, 1 patient with hypoplas-
tic MDS, 1 patient with refractory anaemia with ring sideroblasts (RARS-MDS)
and 10 patients with AML. Of the 10 patients with AML, 4 patients had 20-30%
bone marrow myeloblasts confirmed morphologically and by flow cytometry
and 6 patients had >30% blasts. 26 patients (93%) were transplant-ineligible
due to age or comorbidity and 2 had received previous reduced intensity
haemopoietic stem cell transplantation. An additional 2 patients had received
prior intensive induction chemotherapy for AML. 55% of patients responded to
therapy including achievement of stable disease. 66% of patients required red
cell support initially, of whom 37% achieved red cell independence. CTCAE
grade 3 or 4 toxicities were mostly haematological, with 66% of patients expe-
riencing same. 52% of patients required at least one admission during AZA
therapy, predominantly for severe infections (88%). Median OS and PFS were
as follows: AML 9.4 months and 8.7 months, high-risk MDS 3 months and 2.6
months and CMML 8 months and 4.5 months.
Summary/Conclusions: AZA improved OS for patients with AML who were
ineligible for intensive therapy or HSCT in our institution. AZA was well tolerated
in general and brought about transfusion independence in 37% of transfusion-
dependent patients. The most significant toxicities were haematological and
relating to severe infection, often requiring hospital admission. Hypomethylating
agents continue to provide an excellent therapeutic option for these difficult-to-
treat patients.
Myeloma and other monoclonal
gammopathies - Biology
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CLINICAL CHARACTERISTICS, OUTCOME AND PROGNOSTIC FACTORS
OF SURVIVAL OF MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST
VERY GOOD PARTIAL RESPONSE AFTER FIRST LINE TREATMENT IN
THE ERA OF NOVEL AGENTS
E Giannopoulou1,*, E Terpos2, P Konstantinidou1, A Gerofotis1, E Verrou1,
S Papadaki1, V Palaska1, N Karampatzakis1, D Stamati1, K Keramidioti1,
A Ananiadis1, K Kokoviadou3, D Markala3, D Mallouri3, E Kastritis2, I Batsis3,
I Sakellari3, E Katodritou1,3
1Hematology, Theagenion Cancer Center, Thessaloniki, 2Greek Myeloma
Study Group, Athens, 3Greek Myeloma Study Group, Thessaloniki, Greece
Background: Depth of response defined by conventional methods i.e. the
achievement of at least very good partial response (≥vgPR) or complete
response is correlated with OS in both eligible and non eligible for transplan-
tation Multiple Myeloma (MM) patients. However, there are limited data regard-
ing the prognostic factors for OS in patients who manage to achieve ≥vgPR. 
Aims: Our aim was to study the clinical characteristics and outcome of MM
patients who achieve ≥vgPR after first line treatment and seek for prognostic
factors for OS.
Methods: We reviewed the records of 464 consecutive symptomatic MM
patients diagnosed and treated in a single center between 2000-2015 (median
age: 68 years, range: 29-90 years; M/F: 247/217; IgG: 261, IgA: 118, light
chain: 65, non-secretory: 15, IgD: 4, IgM:1; ISS1: 142, ISS2: 146, ISS3: 176). 
Results: Two hundred and sixty-eight patients (58%) achieved ≥vgPR after
first line treatment (group A) and 196 (42%) had <vgPR (group B). With regard
to clinical characteristics, patients in group A were younger, they had lower β2-
microglobulin levels and higher levels of serum calcium (p<0.05 for all param-
eters). Molecular cytogenetics revealed that high-risk features i.e. del17p and/or
t(4;14) and/or t(14;16) were present in 33% of patients. Revised International
Staging System (R-ISS) was evaluated in 404/464 patients (87%). The number
of patients with high risk features or the distribution of R-ISS did not differ
between the two groups. Overall, the number of patients treated with novel
agents (NA) in first line did not differ between groups; however, in group A, the
number of patients who received thalidomide-based regimens was marginally
higher (p=0.01). High dose therapy and autologous transplantation (ASCT)
was offered in 20% of patients in group A vs 7% in group B (p<0.001). The
median progression-free survival (PFS) of patients in group A vs group B was
26 months (95% CI: 23-29) vs 11 (95% CI: 8-13) (p<0.001). The median PFS2
did not differ between groups. After a median follow up of 8 years (95% CI: 80-
114), 69/268 patients of group A are alive (26%) vs 61/196 patients of group B
(31%). The median OS for patients in group A vs those in group B was 44
months (95% CI: 39-48) vs 27 months (95% CI: 18-36) (p<0.001). With regard
to group A, in the univariate analysis, age, creatinine, LDH, ISS, R-ISS, the
presence or not of high-risk molecular cytogenetics, the type of 2nd line treat-
ment and ASCT predicted for overall survival (OS). In the multivariate analysis,
the presence of high risk molecular cytogenetics was the only independent
negative predictor for OS (p=0.01, HzR: 0.57 95% CI: 0.37-0.8). Median OS
for patients with high risk cytogenetics vs standard risk patients, was 68 months
(95% CI: 45-91) vs 46 months (95% CI: 40-52) (p=0.01); 5-year OS was 60%
in group A vs 37% in group B. In addition, the presence of high risk molecular
cytogenetics strongly predicted for PFS (HzR: 0.57 95% CI: 0.4-0.8, p=0.01). 
Summary/Conclusions: Despite the established prognostic significance of the
achievement of ≥ vgPR, OS within this group is not uniform. High-risk molecular
cytogenetics independently predict for PFS and OS suggesting that high-risk
patients display gene instability, which compromises sustained response and
eventually patients’ survival. Despite depth of response, close monitoring, includ-
ing minimal residual disease is warranted in patients with high-risk molecular




IDENTIFICATION OF PROGNOSTIC RELEVANT GENETIC ABNORMALITIES
IN MULTIPLE MYELOMA USING MICROARRAY-BASED GENOMIC
PROFILING IN ROUTINE DIAGNOSTICS
PJ Poddighe1,*, D Olde Weghuis2, H Wessels1, S Wezenberg2, M van der Mespel1,
S Bhola1, S Zweegman3, M Stevens-Kroef2
1Dept of Clinical Genetics, VU University Medical Center, Amsterdam, 2Dept
of Human Genetics, Radboud University Medical Center, Nijmegen, 3Dept of
Haematology, VU University Medical Center, Amsterdam, Netherlands
Background: Multiple myeloma (MM) is a neoplasm that exhibits a broad
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heterogeneity in both biological behavior and clinical presentation. Specific
copy number abnormalities (CNAs) such as hyperdiploidy, 1p loss, 1q gain,
13q loss and 17p (TP53) loss, and IGH translocations, such as
t(4;14)(p16;q32) and t(14;16)(q32;q23), play key roles in the pathogenesis of
MM and, in addition, provide important information on its prognosis and treat-
ment response. In routine diagnostics such prognostic relevant chromosomal
abnormalities are detected by interphase fluorescence in situ hybridization
(iFISH) on enriched plasma cells. However, iFISH analysis of multiple loci is
laborious and provides only genetic information of the probe targets. Microar-
ray-based whole genome profiling, on the other hand, will provide genome-
wide genetic information, allowing the detection of small (cryptic) copy number
alterations (CNAs) and copy neutral loss of heterozygosity (CNLOH), that are
nor identified by targeted iFISH.
Aims: In this study we wanted to validate the detection of prognostic relevant
copy number aberrations in MM by micro-array based genomic profiling.
Methods: We subjected 37 MM samples to iFISH with the diagnostic probe for
the detection of prognostic relevant CNA, i.e. D5S23/D5S721/CEP9/CEP15
for ploidy assessment, LSI 13 (13q14) for the identification of loss of 13q, LSI
TP53 (17p13.1) for the identification of loss of 17p, and CDKN2C/CKS1B for
the identification of loss of 1p32 and gain of 1q21. Next, we performed microar-
ray-based genomic profiling using the high density SNP-based CytoScan HD
array platform.
Results: All prognostic relevant CNAs as detected by iFISH were also observed
by microarray-based whole genome profiling. Micro-array was able to detect
small clones with CNA, present in only 15% of the cells, which was lower than
the EMN-proposed detection limit of 20% for CNA. In addition, in four cases
micro-array revealed a copy neutral loss of heterozygosity (CNLOH), and in
four other cases a 1p21 or 1p16 loss, which was outside the 1p32 iFISH target
region.
Summary/Conclusions: In routine diagnostics the micro-array approach is a
good and fast alternative for iFISH for the detection of prognostic relevant CNAs
in multiple myeloma.
PB1936
CYR61/CCN1 STIMULATED THE PROLIFERATION AND DIFFERENTIATION
OF OSTEOBLASTS IN MYELOMA BONE DISEASE IN VITRO
R Fu*, H Liu, F Peng, Z Liu, G Wang, L Li, J Song, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Myeloma bone disease (MBD) is a most common complication
of multiple myeloma, which can cause high mortality. Cysteine-rich 61 (Cyr61
or CCN1), one secreted protein in bone marrow(BM) microenvironment, has
diverse effects on many cellular activities like growth and differentiation. How-
ever, the effect of CCN1 on osteoblasts (OBs) in MBD is unclear.
Aims: To explore the effect of CCN1 on osteroblasts in MBD.
Methods: The levels of CCN1 in MBD patients were detected by ELISA and
RT-PCR. The OBs from MBD patients were cultured with CCN1 in vitro, and
proliferation and differentiation of OBs were observed. The transcription factors,
runt-related transcription factor 2 (Runx2), β-Catenin and bone morphogenetic
protein-2 (BMP2), were investigated by RT-PCR.
Results: The results showed that CCN1 level elevated in BM supernatant and
CYR61 overexpressed in OBs in newly diagnosed MBD patients. After 30ng/L
CCN1 stimulation for 24 hours in vitro, the OBs quantity increased to
(3.39±1.21) × 105/mL, significantly higher than the blank (P=0.046). Meanwhile,
the amount of mineralized nodules (14.33± 5.72/HPF) was also significantly
increased than the blank group (9.11±0.97/HPF) (P=0.048). Futhermore, Runx2
and β-Catenin upregulated in OBs after CCN1 stimulation.
Figure 1.
Summary/Conclusions: In conclusion, CCN1 can stimulate the proliferation
and differentiation of OBs via Wnt pathway in MBD.
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STABLE IN VITRO BORTEZOMIB RESISTANCE OF MYELOMA CELLS IS
CHARACTERIZED BY CHROMOSOME 1Q21 COPY NUMBER GAIN
X Papanikolaou1,*, R Edmonson2, E Tian2, S Johnson2, J Sawyer2, V McLeod2,
R Tytarenko2, B Barlogie3, J Epstein2, C Heuck2
1Athens Medical School, Marousi, Athens, Greece, 2University of Arkansas for
Medical Sciences, Myeloma Institute, Little Rock, 3Mount Sinai Medical School,
New York, United States
Background: Bortezomib (Bz), the first agent of a new class of drugs in Multiple
Myeloma (MM) -proteasome inhibitors (PI)-, has shown remarkable activity in
MM and forms an important part of modern MM treatment. Nevertheless in the
clinical setting refractoriness to the agent eventually develops in most cases
with detrimental effects in their subsequent survival. Numerous publications
have addressed this issue through in vitro developed models of acquired Bz
resistance (BzR), however the results were quite different in each one and no
common factor between them could be identified.
Aims: In order to address these issues a native effort was made for the devel-
opment of an in vitro model of BzR that would resemble the clinical reality in
the most accurate way. 
Methods: Two MM cell lines were used, one resembling a multisensitive (JJN3)
and the other a multiresistant (U266) drug behavior, that were both sensitive to
Bz.Instead of a continuous increasing exposure to the agent, an intermittent
one was chosen to resemble in a more accurate way the clinical pattern of
drug exposure and subsequently the mechanisms of BzR. 
Results: As a result of this method a 20 fold increase in the 48h Bortezomib
IC50 was noted for both cell lines. The Bz resistant cell lines proved to be stable
in the phenotype of resistance. The increase in the IC50 was able to be verified
a year after the cell lines were cultured in normal medium. Bz resistant cell
lines were cross-resistant with other PI, even with the PI Carfilzomib which
belongs to a different drug category. A stable ratio of 3 fold increase in carfil-
zomib IC50 for every 10 fold increase in Bz IC50 was found in various different
levels of BzR. Both basal activity and IC50 for the Bz specific β5-subunit of the
proteasome was not statistical different in both Bz resistant and naive cell lines
implying that the proteasome was not directly implemented in BzR and no pump
flow mechanism was implicated. Interestingly enough the two MM cell lines
through the various stages of their acquired BzR followed different phenotypical
pathways. JJN3 through their evolution of their BzR and in accordance with
various publications developed a more immature phenotype with loss of per-
centage and intensity of CD138 by flow cytometry, decreasing levels of the
plasma cell differentiation factor XBP-1 and decreased immunoglobulin pro-
duction both in terms of cell line specific immunoglobulin gene probe expression
and cytoplasmic immunoglobulin content. On the contrary U266 retained per-
centage and intensity of CD138, while exhibiting increasing levels of XBP-1
and increased immunoglobulin production both in terms of cell line specific
immunoglobulin gene probe expression and cytoplasmic immunoglobulin con-
tent. Driven from the stable nature of BzR of the cell lines, we applied
metaphase cytogenetics, spectral karyotyping (SKY) and Fluoresence in situ
Hybridization (FISH) to detect any structural genetic abnormalities. Both
metaphase cytogenetics and SKY did not reveal any differences, while FISH
was able to detect an increase in chromosome 1q21 copy number evident in
both Bz resistant cell lines all in the form of jumping translocations.
Summary/Conclusions: In conclusion this work provides the in vitro verification
of the linkage of 1q21 amplification and BzR. The fact that 1q21 amplification
has been found to correlate with prognosis and a relapsed/refractory phenotype
not only in MM but also in a multitude of solid tumors implies that at least part
of BzR is linked with universal drug resistance mechanisms in cancer.
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ROLE OF EPO IN THE ANGIOGENIC ACTIVITY OF BONE MARROW
ENDOTHELIAL CELLS OF MGUS AND MULTIPLE MYELOMA PATIENTS
D Ribatti*, B Nico
Department of Basic Sciences, Neurosciences and Sensory Organs, University
of Bari Medical School, BARI, Italy
Background: Increasing evidences suggest several biological roles for ery-
thropoietin and its receptor (Epo and EpoR), unrelated to erythropoiesis, includ-
ing angiogenesis.
Aims: Here, we detected the expression of EpoR in bone marrow-derived
endothelial cells from monoclonal gammopathy of undetermined significance
(MGUS) and multiple myeloma (MM) patients (MGECs and MMECs, respec-
tively) and assessed whether Epo plays a role in MGECs- and MMECs-medi-
ated angiogenesis.
Methods: This study was designed to determine the effects of Epo on ECs
from monoclonal gammopathy of undetermined significance [MGUS, (MGECs)]
and MMECs in in vitro and in vivo experimental assays.
Results: We show that EpoR is expressed by both MGECs and MMECs even
though at a higher level in the first ones. Both EC types respond to rHuEpo in
terms of cell proliferation, whereas other responses, including activation of
JAK2/STAT5 and PI3K/Akt pathways, cell migration and capillarogenesis are
enhanced by Epo in MGECs, but not in MMECs. In addition, the conditioned
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media of both Epo-treated cells induce a strong angiogenic response in vivo
in the chorioallantoic membrane assay, comparable to that of vascular endothe-
lial growth factor (VEGF).
Summary/Conclusions: Overall, these data highlight the effect of Epo on
MGECs- and MMECs-mediated angiogenesis: MGECs are more responsive
to Epo treatment than MMECs, probably because over-angiogenic phenotype
of MMECs is already activated by their autocrine/paracrine loops occurring in
the “angiogenic switch” from MGUS.
Acknowledgments. This work was supported by European Union Seventh Frame-
work Programme (FP7/2007-2013) under grant agreement n.278570 to DR.
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POLYMORPHISM OF IL-10 RECEPTOR Β AFFECTS THE PROGNOSIS OF
MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE AND/OR
BORTEZOMIB
T Kasamatsu1,*, T Saitoh1, R Ino1, Y Kitamura1, K Honma1, N Gotoh1, H Handa2,
M Matsumoto3, M Sawamura3, A Yokohama4, N Tsukamoto5, H Murakami1
1Graduate School of Health Sciences, 2Department of Medicine and Clinical
Science, Gunma University, Maebashi, Gunma, 3Nishigunma National Hospital,
Shibukawa, Gunma, 4Blood Transfusion Service, 5Oncology Center, Gunma
University Hospital, Maebashi, Gunma, Japan
Background: Interleukin-10 (IL-10) and IL-10 receptor (IL-10R) single
nucleotide polymorphisms (SNPs) have been implicated in the pathogenesis
of many cancers, including hematologic malignancy. However, no previous
studies have examined the possible association between IL-10/IL-10R SNPs
and MM, especially prognosis in MM patients. 
Aims: We investigated the influence of IL-10 -592C/A, IL-10RA I224V and IL-
10RB K47E on the risk to develop multiple myeloma (MM) and clinical features
of MM.
Methods: We extracted the genomic DNA from 128 MM patients and 202
healthy controls, and determined IL-10 promoter-592C/A (rs1800872), IL-10RA
(rs2228055) and IL-10RB K47E (rs2834167) genotypes by using the PCR-
restriction fragment length polymorphism method. Overall survival (OS) was
defined as the interval from the date of diagnosis to the date of death or last
clinical appointment.
Results: No statistically significant differences were observed in the genotype
and allele frequencies of IL-10 -592C/A, IL-10RA I224V and IL-10RB K47E
between MM patients and healthy control. IL-10RA II genotype was significantly
associated with lower hemoglobin level than IV and VV genotypes (mean±stan-
dard deviation, 9.21±2.46 vs 10.3±2.33 g/dl, P=0.021). IL-10 -592 AA genotype
was significantly associated with better OS than CA and CC genotypes (median
OS, 74.5 vs 46.3 months, P=0.047). We observed significant differences in
survival between patients treated with thalidomide and/or bortezomib and with
conventional treatment (median OS, 74.5 vs 38.2 months, P=0.021). Therefore,
we also examined the effect of IL-10 and IL-10R polymorphisms on clinical
variables and OS in patients treated with thalidomide and/or bortezomib. IL-
10-592 AA genotype was significantly associated with low albumin level than
CA and CC genotypes (mean±standard deviation, 9.21±2.46 vs 10.3±2 .33
g/dl, P=0.021). In addition, IL-10RB EE genotype was significantly associated
with poor survival than KK and KE genotypes (median OS, 46.3 vs 78.8 months,
P=0.015) (Figure 1).
Figure 1. OS of patients treated with thalidomide and/or bortezomib
according to the IL-10RB K74E genotype.
Summary/Conclusions: Our findings indicate that IL-10 and IL-10R gene
polymorphisms may not contribute to susceptibility to MM, but they may be
associated with the severity and prognosis of MM. Especially, IL-10RB K47E
polymorphism influence the poor prognosis of patients treated with thalidomide
and/or bortezomib.
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DIETARY HABITS ACROSS THE LIFESPAN AND RISK OF MONOCLONAL
GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION
BASED SCREENING STUDY
M Thordardottir1,*, E Lindqvist2, S Lund1, R Costello3, J Torfadottir4, D Burton3,
L Steingrimsdottir4, N Korde5, S Mailankody5, G Eiriksdottir6, L Launer7,
T Harris7, O Landgren5, V Gudnason6, S Kristinsson1,2
1Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 2Department of
Medicine, Division of Hematology, Karolinska University Hospital and Karolin-
ska Institutet, Stockholm, Sweden, 3Multiple Myeloma Section, National Cancer
Institute, National Institute of Health, Bethesda, United States, 4Unit for Nutrition
Research, University of Iceland, Reykjavik, Iceland, 5Myeloma Service, Division
of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York,
United States, 6Icelandic Heart Association, Kopavogur, Iceland, 7National
Institute on Aging, National Institute of Health, Bethesda, United States
Background: All multiple myeloma (MM) cases are preceded by the prema-
lignant state, monoclonal gammopathy of undetermined significance (MGUS).
The etiology of MGUS and MM is to a large extent unknown. However,
researchers have found an elevated risk of MM to be associated with low occu-
pation-based socioeconomic status, income, education, and high body mass
index (BMI), indicating that lifestyle related factors, such as diet, may be impor-
tant risk factors. Few studies on the effect of diet on MM have been conducted
and the results have been inconclusive. No studies have been conducted on
the effect of diet on MGUS.
Aims: The aim of this study was to explore the effect of high vs low intake of
fish, salted/smoked fish, fish oil, meat, salted/smoked meat, milk and milk prod-
ucts, fruits, vegetables, potatoes, rye bread, whole wheat bread, and
oatmeal/muesli on MGUS and progression to MM.
Methods: This study was based on participants from the Age, Gene/Environ-
ment Susceptibility-Reykjavik Study (AGES-RS; N=5,764; mean age=77 years
[range=66-98]; 58% females), which is a continuation of the population-based
Reykjavik Study (N=30,795). AGES-RS was initiated in 2002 and ended in 2006.
Participants in the AGES-RS provided retrospective information on dietary habits
in adolescence (14-19 years), midlife (40-50 years), as well as at study baseline
using a short food frequency questionnaire. Serum protein electrophoresis and
free light chain analyses was performed on all subjects to identify MGUS and
light chain-MGUS (LC-MGUS). They were followed prospectively until 2014 and
information on MM diagnosis was collected through the Icelandic Cancer Reg-
istry. Logistic regression and Cox regression models were used to analyze risk
of MGUS and MM, adjustments were made for age and sex.
Results: A total of 300 MGUS (5.2%) and 52 LC-MGUS (0.9%) cases were
identified. We found that high consumption of fruits in adolescence and high
consumption of whole wheat bread in midlife were inversely associated with
MGUS (odds ratio (OR)=0.63, 95% confidence interval (CI) 0.52-0.97 and
OR=0.76, 95% CI 0.59-1.00, respectively), and that high consumption of meat
and rye bread in midlife were inversely associated with LC-MGUS (OR=0.44,
95% CI 0.23-0.84 and OR=0.32, 95% CI 0.14-0.78, respectively). Other food
items did not have an effect on MGUS or LC-MGUS risk (Table 1). Additionally,
in an analysis were MGUS and LC-MGUS were combined (cMGUS) we found
that high consumption of rye bread and potatoes in both adolescence and
midlife were inversely associated with cMGUS (OR=0.70, 95% CI 0.55-0.95
and OR=0.63, 95% CI 0.45-0.96, respectively) when compared to individuals
with low intake at both time points. A total of 18 individuals were diagnosed
with MM during a mean follow-up of 8.2 years. We found an inverse association
between high fruit intake in late life and progression to MM (hazard ratio
(HR)=0.30, 95% CI 0.11-0.82). Other food items did not have an effect on pro-
gression (Table 1).
Table 1.
Summary/Conclusions: Our findings suggest that certain dietary factors dur-
ing adolescence and/or midlife might reduce risk of MGUS and LC-MGUS.
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Results regarding LC-MGUS should be interpreted with caution due to low sta-
tistical power. The findings also suggest that high late life intake of fruits might
reduce the risk of progression to MM. The exact biological mechanism for these
associations is not clear and more studies are needed to clarify the underlying
mechanism for this finding.
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HEAVY-LIGHT CHAIN IMMUNOASSAYS FOR DIAGNOSIS AND MONITORING
IGA MULTIPLE MYELOMA: SAVING PITFALLS ON PROTEIN
QUANTIFICATION
M Andrade-Campos1,*, N Espinosa-Lara2, E Colorado-Ledesma2, J Grasa2,
P Giraldo3
1Translational Research Unit, IIS-Aragon. CIBERER., 2Hematology and Hemo-
therapy, Miguel Servet University Hospital, 3Translational Research Unit, IIS-
Aragon. CIBERER. FEHHA, Zaragoza, Spain
Background: Diagnosis and follow-up of Multiple Myeloma (MM) include the
assessment of the involved protein named monoclonal component (MC) by
serum protein electrophoresis (SPEP) with M-spike densitometry as the gold
standard. MC quantification is usually not problematic for patients with IgG MM
due to protein characteristics (molar weight, protein charge and migration);
however, for IgA MM there are often some difficulties to impossibility their quan-
tification. About 25% of monoclonal gammopathies are IgA subtype; due to the
co-migration in alpha or beta area and the presence of IgA dimers, the diagnosis
and follow-up is difficult based in the quantification of M-spike using conven-
tional SPEP. The separate determination of intact immunoproteins of mono-
clonal and polyclonal isotype (heavy/light IgAk/IgAL, HLC) allows quantifying
the monoclonal IgA and also assesses immunoparesis status.
Aims: To evaluate the correlation between M-spike concentration by SPE and
the quantification by HLC and ratio, and their usefulness as biomarker for early
biological relapse detection in IgA MM.
Methods: Every patient with an IgA monoclonal gammopathy, diagnosed of
secretory MM according to the criteria for MM diagnosis by the IMWG, and
treated in our hospital, was taken in account. The diagnosis and follow-up of
monoclonal gammopathies were performed in our Hematology-immunoproteins
lab. A chart review was performed collecting: demographic data, clinical stage
at diagnosis and protein data: (SPEP, UPE of 24h), quantification of total
immunoproteins, inmunofixation (IFX), quantification of FLC, HLC and their
ratios (FreeliteTM, HevyliteTM, The Binding Site, Birmingham, UK). Time of
study: May 2008-Agosto 2015. 
Results: Forty-seven patients were included. Females/males: 23/24; mean
age: 67.43 (32-88 years); IgAk: 26 (55.3%); IgAL: 21 (44.7%); 34% of patients
had free light chains detectable in urine. A total of 182 protein assessments
were registered, 51 present a value of M-spike below 10 g/L, in 62 (34.0%)
there were no M-spike by SPEP, but in 39 an abnormal HLCr demonstrated
monoclonality confirmed by IFX in 30 samples. The isotype analysis at diagno-
sis for IgAk patients reveals: mean M-spike concentration 9.61 g/L (0-37.2),
HLC-IgAk 24.71 g/L (0.02-63.94), HLC-IgAk minus HLC-IgAL: 24.52 g/L (0-
63.94); for IgAL patients shows: mean M-spike concentration 11.4 g/L (0-25.6),
HLC-IgAL concentration 17.61 g/L (0.6-41.1), and HLC-IgAL minus HLC-IgAk
16.95 g/L (0.06-41.08). Immunoparesis at diagnosis (abnormal HLC ratio) was
present in all patients. In 144 samples with positive MC by SPEP, the mean
concentration of M-spike for IgAk samples was 18.43 g/L (1-64.22), HLC-IgAk
22.54 g/L (0.2-109.20), and HLC-IgAk minus HLC-IgAL: 22.51 g/L (0-109.19);
and for IgAL samples: 16.2 g/L (1-49.50), HLC-IgAL 20.87 g/L (0.56-55.65),
and HLC-IgAL minus HLC-IgAk 20.35 g/L (0.10-55.27). The correlation between
both techniques for patients with measurable M-spike for SPEP was excellent,
remarking the sensitivity of the HLC (p=0.003 for IgA-k and p<0.001 for IgA-L);
the HLCr is a good biomarker for monitoring response. 
Summary/Conclusions: In this study, 34.0% of SPEP studies in IgA MM do
not identify MC, nevertheless more than 50% of them showed monoclonality
quantify by HLC-IgA, improving the quantification in cases with low concentra-
tions. The incorporation of this tool for diagnosis and monitoring in IgA MM
patients improve the accuracy of follow up. An updated analysis including the
value of HLCr in relapse detection will be included in case of acceptance.
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IL-1R AND IL-1RA IN THE DEVELOPMENT OF MULTIPLE MYELOMA
A Pavlova1,*, I Pavlova1, L Bubnova1, S Bessmeltsev2
1Immunohaematology laboratory, 2Deputy Director for Research, Russian Insti-
tute of Haematology and Transfusion, Saint-Petersburg, Russian Federation
Background: Various cytokines are involved in the pathogenesis of Multiple
myeloma (MM). They play a significant role in the development of tumor clone.
It is known that single nucleotide polymorphisms (SNP) in the gene regulatory
regions can influence on cytokines production which can effect on the devel-
opment of the disease.
Aims: The aim of this study was to identify SNP genes of IL-1R (pst11970C/T)
and IL-1RA (mspa111100T/C) associated with the development of MM among
the residents of the North-West region of Russia as well as determining the
severity of bone tissue damage.
Methods: We analyzed 50 MM patients which were divided into two groups
depending on the detected changes in the bones (median age: 69.7±8.6): 1st
group (22 patients) - with severe osteolytic bone lesions (III stage of the Durie-
Salmon staging system); 2nd group (28 patients)-with manifestations of osteo-
porosis and isolated pockets of lysis (II stage of of the Durie-Salmon staging
system). The diagnosis of symptomatic MM was verified based on the criteria
of the International Working Group on myeloma. The most frequent type of
myeloma that was observed in patients was G type (80%). The frequencies of
myeloma A, as well as disease of light chains were about 20%. The control
group consisted of 50 healthy unrelated Caucasoid blood donors (median age:
51.2±6.9). All analyzed people were from St.-Petersburg, Russia. Genomic
DNA was extracted from the peripheral blood and gene genotyping was per-
formed by use of PCR-SSP (Cytokine genotyping Kit, Invitrogen). Allele fre-
quencies and expected Hardy Weinberg equilibrium (HWE) for each SNP were
determined. P values less than 0.05 were considered statistically significant.
Results: Based on the SNP analyses we found that in general cohort of patients
with MM some genotype frequencies differed from the control group. For
instance, genotypes of IL-1RTT and IL-1RATT were varied in control group and
group of patients 0.33 vs 0.16 and 0.28 vs 0.46 respectively (р≥0.05). However,
genotype IL-1RTT in MM patients with severe bone lesions (1st gr.) occurs
more often than in group of patients with symptoms of osteoporosis (2nd gr.):
0.33 vs 0.06 respectively (p≤0.05). Although, genotype IL-1RCT in the 2nd gr.
was registered frequently compare to 1st gr. and control group- 0.50 vs 0.33
and 0.33 respectively (р≥0.05). However, IL-1RATT genotype frequency was
less common in healthy people (0.28) compare to patients with MM (0.45 in 1st
gr., 0.47 in 2nd gr.; p≤0.05). Finally, IL-1RACT was higher in control group (0.50)
compare to patients with severe osteolytic bone lesions (0.33) and patients
with symptoms of osteoporosis (0.40), р≥0.05.
Summary/Conclusions: Thus, our results allow to describe some genotypes
as markers associated with the development of MM (IL-1RATT). In addition, it
can be assumed that the genotype IL-1RTT associated with the development
of severe osteolytic bone lesions in multiple myeloma in turn genotype IL-1RCT
as an immunogenetic marker of a lighter form of bone disease manifested with
osteoporosis and isolated pockets of lysis.
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ZOLEDRONIC ACID INHIBITS CELL GROWTH OF MULTIPLE MYELOMA
CELLS AND SHOWS SYNERGISTIC ANTIMYELOMA EFFECTS WITH
BORTEZOMIB VIA DOWNREGULATION OF PIM-2 THROUGH NF-KB PATH-
WAY
R Fu*, Z Liu, H Liu, F Peng, L Li, K Ding, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Recent studies showed that the third-generation biphosphonate
Zoledronic acid (ZOL) can exhibit direct antitumour activity. However, its pos-
sible machnism remains unknown.
Aims: To explore the mechanism of Zol’s antitumor activity.
Methods: In this study, RPMI-8226 cell line were treated with ZOL alone at
various concentrations and combined with Bortezomib in vitro, then Cell prolif-
eration, cell apoptosis, downsteam signaling pathway were detected by qRT-
PCR and Western blot.
Figure 1.
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Results: We found that ZOL alone strongly inhibited proliferation of myeloma
cells in vitro and induced their apoptosis. The same results were obtained in
ZOL combined with Bortezomib after 24h. Futhermore, we found that Ras,
pAKT and NF-kB were suppressed by ZOL alone and combined with Borte-
zomib at 24h. We demonstrated NF-Kb/pim-2 pathway which were also inhib-
ited at 24h. However, it did not show the same results at 48h. additionally,NF-
kB plays a pivotal role in regulating of pim-2 which proved by the result of
downregulation of pim-2 was appered when the NF-kB inhibitor(Ro 106-9920)
was used in RPMI-8226 cell line.
Summary/Conclusions: In conclusion, ZOL and the combination of ZOL with
Bortezomib inhibited proliferation of myeloma cell via inhibiting NF-Kb/pim-2
pathway. Ras and pAkt were also inhibited. Combination of Zol with Bortezomib
within 24 hours maybe more benefitial to alleviate tumour load in MM patients.
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VALIDATION OF REVISED INTERNATIONAL STAGING SYSTEM (R-ISS)
IN THE ERA OF NOVEL AGENTS: REAL-WORLD DATA ON 481 MYELOMA
PATIENTS FROM A GREEK MYELOMA CENTER
E Giannopoulou1,*, E Terpos2, P Konstantinidou1, E Verrou1, S Papadaki1,
V Palaska1, A Gerofotis1, N karampatzakis1, K Kokoviadou3, D Markala3,
E Gagkos3, I Batsis3, IS3, A Anagnostopoulos3, E Katodritou1,3
1Hematology, Theagenion Cancer Center, Thessaloniki, 2Greek Myeloma
Study Group, Athens, 3Greek Myeloma Study Group, Thessaloniki, Greece
Background: Risk stratification has a crucial role in the management of Multiple
Myeloma (MM). International staging system (ISS) has been a powerful tool for
risk stratification and prognosis in MM for many years. Recently, a revised ISS
(R-ISS) has been validated in a large study that included patients enrolled in
international randomized studies. This staging system combined ISS with two
additional prognostic factors of overall survival (OS), that is abnormal lactate
dehydrogenase (LDH) and high risk molecular cytogenetics i.e. del17p and/or
t(4;14) and/or t(14;16). According to the aforementioned study, R-ISS represents
a single powerful prognostic system that stratifies MM patients more effectively
than conventional ISS with respect to the relative risk of their survival. Data
regarding the prognostic value of R-ISS outside clinical trials, are limited.
Aims: Herein, we have presented real-world data regarding the prognostic value
of R-ISS, in a large number of MM patients from a single Greek Myeloma Center.
Methods: We have reviewed the records of 481 consecutive symptomatic MM
patients diagnosed and treated in our center between 2000-2015 (median age:
68 years, range: 29-90 years; M/F: 258/:223; IgG: 271, IgA: 124 Light chain:
66, non-secretory: 15, IgD: 4, IgM:1 ISS1: 153, ISS2: 148, ISS3: 180). 
Results: R-ISS was available in 411 patients (M/F: 221/190; median age: 68
years, range: 29-90 years; IgG: 237, IgA: 103 Light chain: 53, non-secretory:
13, IgD: 4, IgM: 1; ISS1: 101, ISS2: 144 and ISS3: 165). Fifty-seven (13.8%)
patients had R-ISS1, 286 patients had R-ISS2 (69.5%) and 68 patients had R-
ISS3 (16%). High-risk molecular cytogenetics were present in 27% of patients
while high LDH was present in 27% of patients. Overall, 280/481 patients (58%)
were treated with novel agents (NA) combinations in first line (IMiD-based:
168, Vel-based: 110, conventional therapy: 194, missing data: 9). Second line
therapy was administered in 230/481 patients; 78% was treated with NA
(Lenalidomide-dexamethasone: 67, Vel-based: 44, Thal-based: 70, chemother-
apy: 49). Autologous transplantation was offered in 68/190 (36%) eligible
patients. After 1st line therapy, the objective response rate was 82%, while at
least very good partial response (≥vgPR) was achieved by 58% of patients.
After a median follow up of 8 years (95% CI: 80-114), 135/481 (28%) patients
are alive. In the univariate analysis, age, creatinine, ISS, R-ISS, molecular
cytogenetics, type of 1st and 2nd line treatment, achievement of ≥vgPR and
autologous transplantation (ASCT) predicted for overall survival (OS). In the
multivariate analysis, R-ISS and ≥vgPR were independent predictors for sur-
vival (p<0.001, HzR:0.4, 95% CI: 0.2-0.6 and p=0.03, HzR: 0.6, 95% CI: 0.4-
0.9, respectively). Median OS for patients with R-ISS1, R-ISS2 and R-ISS3,
was 92 months (95% CI: 55-129), 36 months (95% CI: 32-40) and 20 months
(95% CI: 13-27), respectively (p<0.001). A subgroup analysis confirmed the
prognostic role of R-ISS irrespective of age (<65 or ≥65), period of diagnosis
(<2006 or ≥2006), type of treatment (bortezomib-based, IMiD-based or
chemotherapy) and administration or not of ASCT. 
Summary/Conclusions: Our results confirm that R-ISS is the most powerful
prognostic factor for OS in an unselected MM population. Its predictive value
is maintained across different groups of patients providing a simple and avail-
able tool for risk stratification of MM patients, which is essential for therapeutic
decisions. 
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THE EFFECT OF HYPOXIA ON NOTCH PATHWAY IN MULTIPLE MYELOMA
NICHE
S Garavelli1,*, M Colombo1, N Platonova2, MT Palano1, F Baccianti1, A Neri2,
C Raffaella1
1Department of Health Sciences, 2Department of Oncology and Hemato-oncol-
ogy, University of Milano, Milano, Italy
Background: Multiple myeloma (MM) is an incurable hematological tumor rep-
resenting 13% of all hematological malignancies and tumor cells accumulate
in the bone marrow (BM) of patients. Several evidences demonstrate that Notch
signaling mediates critical events in MM progression. The Notch pathway is
highly conserved and consists of 4 receptors and two different ligand families
(Delta and Serrate). Recently Notch receptors and ligands have been shown
to be upregulated during MM progression and their signaling positively regu-
lates cell proliferation, drug resistance and BM infiltration. Hypoxia is defined
as a low oxygen condition and can induce angiogenesis; HIF-1α is the key
mediator of hypoxic response and a transcription factor that can switch on dif-
ferent types of genes, which, in turn, regulate angiogenesis (VEGF) and pro-
liferation of various stem cell populations. Recent reports indicate that HIF-1α
may positively regulate Notch signaling and enhance the expression of Notch
downstream genes. In MM, hypoxia can sustain stem cell-like population in
MM and HIF-1α derived from bone marrow endothelial cells can have a role in
promoting drug resistance in patients with MM.
Aims: The aim of this work is to evaluate if and how hypoxia can affect the
activation of Notch signaling in MM microenvironment and the underlying mech-
anism.
Methods: OPM2, U266, H929 and RPMI8226 cell lines were cultured in com-
plete RPMI-1640 medium. To induce an hypoxic-like condition, cells were treat-
ed with Cobalt Chloride (CoCl2) 100 μM for 24 h. To analyze the modulation of
the expression of HIF-1α, the MM cells were treated with CoCl2 100 μM for 2h,
6h, 12h and 24h. We evaluated the effect of hypoxia on cells proliferation,
apoptosis and cell cycle; Western Blot and qPCR were used to analyze how
hypoxia can affect the activation of the Notch pathway. Cell proliferation:
absolute cell counts were determined using the volumetric count tool of the
BD FACSVerse™ System (BD Biosciences, USA). Apoptosis: MM cell lines
were treated with CoCl2 100 μM for 24h and stained with Annexin V-FITC and
Propidium Iodide, then processed using the BD FACSVerse™ System (BD
Biosciences). Western Blot: 100 μg of proteins were loaded on a 8% polyacril-
amide gel and transfer onto a nitrocellulose membrane. The membrane was
incubated with the following antibodies: Actin (Santa Cruz Biotechnology), HIF-
1α (Santa Cruz Biotechnology) and Notch2-cleaved (Abcam). Quantitative
PCR reactions were carried out on a 7500 Fast Real-time PCR system (Applied
Biosystems) using the MaximaTM SYBR Green/ROX qPCR Master Mix (Ther-
moScientific).
Results: The MM cell lines OPM2, U266, H929 were treated with CoCl2 100
μM for 24 to mimic hypoxic condition and we evaluated the effect on cell pro-
liferation and apoptosis: hypoxia inhibits proliferation in all MM cell lines used
(H929, U266 and OPM2) and induces apoptosis only in H929 cell lines. To
analyze the molecular effects of hypoxia, we treated MM cell lines with CoCl2
100 μM for 2h, 6h, 12h and 24h and performed a Western Blot. HIF-1α is highly
expressed in treated cells if compared to normal controls; the hypoxic condition
induced the expression of pro-angiogenic factors i.e. VEGF and SDF-1α. Inter-
estingly these have been reported to be controlled by Notch. Consistently,
hypoxia induced the activation of Notch2 receptor.
Summary/Conclusions: Our results, although still preliminary, indicate that
hypoxia can affect MM cell lines survival and proliferation and finally and that
it is able to induce the activation of the oncogenic Notch pathway.
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A NOVEL TOOL TO MONITOR ANGIOGENESIS IN BONE MARROW
SMEARS: DETECTION AND QUANTIFICATION OF ENDOTHELIAL
PROGENITOR CELLS BY MULTIPLE-LABELING IMMUNOFLUORESCENCE
ANALYSIS
MM Tenreiro1,*, R Malhó2, M Silveira3, ML Correia4, MA Brito1
1Department of Biochemistry and Human Biology, Faculty of Pharmacy, Uni-
versidade de Lisboa, 2BioISI, Instituto de Biossistemas e Ciências Integrativas,
Faculty of Sciences, Universidade de Lisboa, 3Instituto Português de Oncologia
Dr. Francisco Gentil, 4Faculty of Pharmacy, Universidade de Lisboa, Lisbon,
Portugal
Background: Angiogenesis is a crucial event in cancer, as it is present in
tumor growth, invasion and metastasis. It is considered to have a key role in
several haematological malignancies that affect the bone marrow, such as mul-
tiple myeloma. Tumor neovascularization and angiogenesis involve the recruit-
ment of endothelial progenitor cells (EPCs), which are bone-marrow derived
circulating progenitors with the potential to differentiate into cells of the endothe-
lial lineage. Two types of EPCs have been described: early EPCs, which can
also be called angiogenic cells, and mature EPCs or endothelial outgrowth
cells. These two types of cells differ in markers expression, morphology, pro-
liferative potential and in vitro function, like vascular tube formation. Identifica-
tion of EPCs is still a challenging task, since these cells display no specific
cell-surface antigen. Even so, it is widely accepted that early EPCs are positive
for the following markers: cluster of differentiation (CD)133, which is expressed
by haematopoietic and progenitor cells;,CD34, characteristic of hematopoietic
stem cells and activated endothelium of small vessels;,and vascular endothelial
growth factor receptor (VEGFR)-2, present in endothelial lineage. Regarding
mature EPCs, they are considered CD133-/CD34+/VEGFR-2+.
Aims: To overcome the difficulty in the assessment of EPCs, usually by flow
782 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
cytometry and cell culture, we decided to develop a new triple-labelling immuno-
fluorescence analysis protocol to assess EPCs in bone marrow smears as a
tool to monitor the angiogenesis process and disease progression in patholo-
gies like multiple myeloma.
Methods: Bone marrow smears archived at the Hematology Service of Instituto
Português de Oncologia Dr. Francisco Gentil, Lisbon, from multiple myeloma
patients were used. Smears were fixed and permeabilized with a 75%
methanol/25% acetone/0.01% Triton X-100 solution and blocked with 10% goat
serum/1% bovine serum albumin in PBS or 10% rabbit serum serum/1% bovine
serum albumin in PBS, according to the host species of the secondary anti-
bodies. Triple labelling was performed using antibodies against CD133, CD34
and VEGFR-2, followed by species-specific secondary antibodies, and nuclei
labelling with DAPI. Smears were analysed under a confocal laser microscope
and/or a widefield epifluorescence microscope with appropriate excitation and
emission filters.
Results: With this protocol, it was possible to identify cells that were triple
(CD133+, CD34+ and VEGFR-2+) and double labelled (CD133-, CD34+ and
VEGFR-2+), which correspond to early EPCs and mature EPCs, respectively.
Furthermore, quantification of the total number of labelled nuclei allowed the
establishment of the percentage of early EPCs and mature EPCs relatively to
the cellular population of the bone marrow smear. Moreover, analysis of sam-
ples of the same patient collected at different time points allowed the establish-
ment of differences in EPCs subsets along the course of the disease.
Summary/Conclusions: Our protocol is an easy and accessible method to
monitor angiogenesis based on analysis of EPCs, which can be implemented
in any laboratory equipped with a suitable microscope. This protocol may be
used to study multiple myeloma, as well as other pathologies involving
enhanced angiogenesis in the bone marrow, therefore constituting a novel tool
for early detection of angiogenesis and efficient monitoring of neovascularization
along disease progression and treatment.
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THE EFFECT OF MIR-146A OVEREXPRESSION ON THE PROLIFERATION
AND APOPTOSIS OF MULTIPLE MYELOMA CELL LINE
S Kazemzadeh1,*, S Kaviani1, J Sabour Takanlu1, T Akbari Saeed2
1Department of Laboratory Hematology & Blood Banking, Tarbiat Modares Uni-
versity, Tehran, 2Department of Laboratory Hematology & Blood Banking, Ker-
man University of Medical Sciences, Kerman, Iran
Background: After lymphoma, multiple myeloma (MM) is the second most
common hematological malignancy worldwide contributing 1% of all cancers
and nearly 2% of cancer mortalities. Deregulation of microRNAs has been impli-
cated in the pathogenesis of multiple myeloma. miR-146a is one of the most
important microRNAs in tumor initiation and progression which has a dual effect
and act as a tumor promoter or a tumor suppressor. 
Aims: The present study aimed to evaluate the functional effect of miR-146a
in multiple myeloma cells.
Methods: The expression of miR-146a was examined in myeloma cell line, L363
by qRT-PCR. The effect of overexpression of miR-146a on proliferation and apop-
tosis of myeloma cells was further evaluated by lentiviral-based delivery method.
Results: According to our results, the expression of miR-146a significantly
increased in cells transducted with transfer vector compered to non-transducted
cells (P-value=0.001). Transfection of miR-146a resulted in significant decrease
in tumor cell proliferation (P-value=0.001) and significant increase in apoptosis
of multiple myeloma cells (P-value=0.004). 
Summary/Conclusions: According to previous studies, miR-146a has a dual
effect in cancers. Our result suggested that miR-146a acts as a tumor sup-
pressor in MM. It seems that miR-146a regulates an miR-146-NF-κB negative
feedback regulation loop in myeloma cells by inhibiting the expression of IRAK1
and TRAF6 and consequently prevents tumor cell proliferation and enhanced
apoptosis.
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MAST CELLS INDUCE MYELOMA PLASMA CELLS’ PROLIFERATION
G Tsirakis1,*, M Devetzoglou2, A Kolovou1, K Pappa3, E Stavroulaki4,
R Vyzoukaki5, M Alexandrakis2
1Hematology, General Hospital of Chania “St George”, Chania, 2Hematology,
University Hospital of Heraklion, 3Internal Medicine, 4Hematology, Venizelion
Hospital of Heraklion, 5Microbiology, University Hospital of Heraklion, Heraklion,
Greece
Background: Mast cells (MCs) are inflammatory cells that participate actively
in multiple myeloma (MM) progression. They mainly enhance angiogenesis
through production of various pro-angiogenic molecules, whereas they may
also participate per se in the vascular plexus.
Aims: The aim of the study is to explore whether MCs participate in other
aspects of MM progression, such as proliferation of plasma cells.
Methods: We studied 57 newly diagnosed patients with active MM, 26 of them
in at least partial remission after receiving bortezomib-containing regimens,
and 20 age and sex-matched healthy controls. We studied in bone marrow
MCs density (MCD) and plasma cells’ proliferation rate (using immunohisto-
chemical expression of tryptase and PCNA, respectively) and in sera levels of
angiopoietin-2 (Ang-2) end endoglin (sCD105) (using ELISA).
Results: All variables were higher in active MM patients compared to both
healthy subjects and responders to conventional treatment (p<0.001 in all cas-
es). Moreover, in active MM patients, MCD correlated positively with PCNA
expression (r=0.490), Ang-2 (r=0.554) and sCD105 (r=0.566) levels (p<0.001
for all cases).
Summary/Conclusions: MCs enhance angiogenesis and probably through
this procedure they also induce proliferation of plasma cells. Although the cor-
relation seems to be rather indirect, MCs are major participants in MM pro-
gression and therefore could be considered possible targets for therapeutic
interventions.
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EARLY DETECTION OF PLASMA CELL DYSCRASIA IN SERUM PROTEIN
ELECTROPHORESIS
M Rebordao*, S Francisco, M Silva, L Costa
Laboratório Patologia Clinica, Hospital Forças Armadas, Lisboa, Portugal
Background: Monoclonal gammopathies are characterized by an excessive
production of a single, or rarely more, types of immunoglobulins. They arise
from the proliferation of one specific B cells malignant clone (plasma cell dyscra-
sia), which in turn generates an homogeneous population of monoclonal
immunoglobulins. Early detection of these clones can be made by serum protein
electrophoresis, which shows a different plot curve or a small narrow peak. 
Aims: To early identify plasma cell dyscrasias by small changes in the elec-
trophoretic curve profile, enabling a sooner diagnosis, effective follow-up and
treatment.
Methods: A retrospective analysis was made. A total of 7265 electrophoretic
curves from 4987 patients (no replicates) were analyzed - 3568 men and 1419
women with average ages of 51.0 and 57.8 years respectively. Patients with
an electrophoretic changed pattern were divided into 2 groups. Group-I: alter-
ations of the curve pattern between beta and gamma regions, including distor-
tions and small peaks; Group-II: evident monoclonal peak. Electrophoresis was
performed in agar gel and the chains were identified by immunofixation. Blood
cells counts were studied in both groups. Statistical analysis was performed by
SPSS and the critical level of significance was set at p≤0.05.
Results: Monoclonal gammopathy was identified in 3.5% of the patients (n=176).
The average age of this group was 70.0 years old and they were mostly male. To
characterize these monoclonal gammopathies by immunofixation, a second har-
vest was performed in 34 of these patients-54.8% was associated with heavy
chain IgG (n=17), 22.6% associated with IgA (n=7) and 19.4% with IgM (n=6) -
kappa light chains 58% and lambda light chains 42%. 1 patient had biclonal gam-
mopathy IgG and IgM (lambda light chain) and 3 patients did not have any band
alteration. In Group-I (18 patients -58.1%) the average age was 69.6 years. The
mean quantification of beta region was 15.4g/L (reference range 7-13 g/L). The
mean quantification of gamma region was 13.3 g/L (reference range 6-16 g/L).
The mean quantification of distortions and small peaks from this group by den-
sitometry was 4.7g/L. This population had an average of 4.4x1012/L red blood
cells and 13.6 g/L of hemoglobin. Monoclonal gammopathy of undetermined sig-
nificance (MGUS) was the most common diagnosis (6 patients- 33.3%). This
population of patients contrasts and differs significantly from Group-II (13 patients
- 41.9%). Group II average age was 74 years old. Electrophoretic curve displayed
a well-defined monoclonal peak of 14.7g/L (p <0.001), with an average of
3.83x1012/L red blood cells (p=0.048) and 11.2g/L of hemoglobin (p=0.010). Mul-
tiple myeloma (4 patients-33.3%) and Waldenström macroglobulinemia (2
patients-15.4%) were the most common diagnosis.
Summary/Conclusions: The characterization of monoclonal gammopathies
by immunofixation allowed an early detection of situations that can lead to a
plama cell dyscrasia. Initially, the protein levels in electrophoresis can be normal
or slightly higher so, to detect these diseases in a timely effective manner is
extremely important to analyse the electrophoretic curve pattern.
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SERUM LEVELS OF E-SELECTIN AND VCAM-1 IN ACTIVE MYELOMA
S Kyriakaki1, A Kolovou2, G Tsirakis2,*, R Vyzoukaki3, A Papadopoulou3,
A Antonakis4, M Alexandrakis1
1Hematology, University Hospital of Heraklion, Heraklion, 2Hematology, General
Hospital of Chania “St George”, Chania, 3Microbiology, University Hospital of
Heraklion, 4School of Medicine, University of Crete, Heraklion, Greece
Background: Adhesion of myeloma plasma cells in bone marrow is an impor-
tant hallmark for their homing. Various adhesion molecules participate in this
process, such as E-selectin and VCAM-1. These molecules seem to participate
in both cancer and inflammation.
Aims: The study, for the first time, of serum levels of E-selectin and VCAM-1
in active myeloma patients and correlation with bone marrow mast cell’s density
(MCD), serum levels of soluble endoglin (sCD105) (marker of endothelial acti-
vation) and disease progression.
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Methods: We studied 54 newly diagnosed active myeloma patients and 20
healthy controls. We estimated bone marrow MCD using the immunohisto-
chemical expression of tryptase and measured serum levels of E-selectin,
VCAM-1 and sCD105 with ELISA.
Results: All parameters were higher in active myeloma patients compared to
controls (p<0.001 for all cases) and were also increasing in parallel with ISS
stages (p<0.001 for all cases). Significant positive correlations between MCD
and levels of E-selectin (r=0.448), VCAM-1 (r=0.597) and sCD105 (r=0.667)
(p<0.001 for all cases) were noted.
Summary/Conclusions: We found increased serum levels of the adhesion
molecules, correlating with MCD, sCD105 and mainly with disease progression.
These increased levels may represent increased bone marrow expression,
which in turn may be the result of both enhanced angiogenesis and inflamma-
tion. By these means, E-selectin and VCAM-1 may be regarded as markers of
disease activity.
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RISK FACTORS ASSOCIATED WITH EARLY MORTALITY IN PATIENTS
WITH MULTIPLE MYELOMA IN THE NOVEL-AGENTS ERA
SH Jung1,*, SS Lee1, HK Kim2, K Kim2, SJ Kim2, JW Cheong3, SJ Kim3,
JS Kim3, JS Ahn1, DH Yang1, HJ Kim1, JJ Lee1
1Department of Hematology-Oncology, Chonnam National University Hwasun
Hospital, Hwasun-Eup, 2Devision of Hematology-Oncology, Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School of Med-
icine, 3Devision of Hematology, Department of Internal Medicine, Yonsei Uni-
versity College of Medicine, Severance Hospital, Seoul, Korea, Republic Of
Background: Although the introduction of novel agents improved the survival
outcomes in patients with multiple myeloma (MM), some patients died within
less than one year (early mortality, EM) following the diagnosis.
Aims: In this study, we evaluated the EM rate, and investigated the risk factors
associated with EM in MM patients.
Methods: Retrospective data from 542 patients who were initially treated with
a novel agent-containing regimen were analyzed. 
Results: The median overall survival (OS) for the entire cohort was 56.5
months. The median OS in the 2010-2014 group was longer than in the 2002-
2009 group (59.2 months vs 49.1 months, P=0.054). The rate of EM was
13.8%, and the most common cause of EM was infection and comorbidity. In
multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥4),
low body mass index (BMI <20 kg/m2), thrombocytopenia, and renal failure
were significantly associated with EM. The presence of none, 1, or ≥2 factors
was associated with a 4.1%, 14.3%, or 27.4% risk of EM (P <0.001), respec-
tively. The median OS times was significantly different depending on the pres-
ence of factors associated with EM (P <0.001).
Summary/Conclusions: In conclusion, the ACCI (≥4), low BMI, thrombocy-
topenia and renal failure were strong predictors for EM in the novel agent era.
These data may help manage MM patients and improve survival.
Myeloma and other monoclonal
gammopathies - Clinical
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EXPECTANCY OF LIFE AND INCIDENCE RATE OF NEWLY DIAGNOSED
MULTIPLE MYELOMA (NDMM) PATIENTS. 15 YEARS RETROSPECTIVE
ANALYSIS
B Ballina, S Cerdá, V Martínez-Robles, JA Rodriguez-Garcia, F Escalante*
Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: In the last decade we have assisted to an amazing improvement
in the management and expectancy of life of Multiple Myeloma (MM) patients. 
Past decade also shows us a new demographic data in our society: the incre-
ment of expectancy of life and an excellent performance status.  New expensive
but very effective antimyeloma (antiMM) agents are in the center of attention
of Hematologic and Public Healthcare Systems.
Aims: We have analysed our data base and calculate incidence by sex, age
and three 5-years periods of time at diagnosis and obtain tendencies to get
ready for next decade of ageing people with best antimyeloma agents.
Methods: We retrospectively analysed the incidence of patients with new diag-
nostic of Multiple Myeloma (NDMM) from 1998 to 2012. Then we divide the
cohort in several groups: sex and age at diagnosis (3 groups) and three 5-year
period of time (1998-2002, 2003-07 and 2008-12). Characteristics of patients:
n= 273. Male/female: 170/103.  Median age at diagnosis: 74 years (Range:
39-100). We don’t see differences in median age between that three 5-years
periods.  We have calculated the incidence per 100000 inhab/year using census
data of our Local Registry of Tumours of our Public Health Area. (Table 1)
Results: There were a constant increase of Annual Average Incidence of more
than 10% in the 3 periods: 4.57 vs 5,12 (+12%) vs 6,15 (+34,6%). This incre-
ment was due to older patients more than younger one. This young group
accounts for a constantly near one quarter of all NDMM. There were a constant
incidence of about 16-18 per 100000/year NDMM in population over 65 y. We
don’t observe large differences between groups over and under 75 years.
Summary/Conclusions: We have observed a more than expected incidence
of NDMM in our Public Health Area.  Demographics of other Public Health
Areas Average Annual Incidence were quite different to ours, because of ageing
of population in our Area. A preliminary analysis of incidence of period of 2013-
14 are similar to last 2008-2012 period.
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IMPACT OF TIME SPENT WAITING FOR AUTOLOGOUS TRANSPLANTATION
ON THE OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA
F Ripamonti1,*, M Da Vià2, F Cocito2, S Mangiacavalli1, P Bernasconi1,
AA Colombo1, D Caldera1, CS Cartia2, M Ubezio1, I Casetti2, C Klersy3,
M Cazzola2, A Corso2, EP Alessandrino1
1Hematology- Bone Marrow Transplantation, 2Hematology, 3Servizio di Bio-
metria e Statistica, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Background: Autologous stem cell transplantation (Tx) is still the standard of
care for symptomatic myeloma patients (pts) eligible for high-dose procedure.
Whether time lasting between stem cell collection and Tx (Wait-Tx) has an
impact on Tx outcome itself is matter of debate.
Aims: The aim of this study is to evaluate whether Wait-Tx impacts on the out-
come of transplanted myeloma pts.
Methods: We reviewed data of 233 myeloma pts treated with HD Melphalan
between January 2000 and December 2013; 20 pts with primary refractory dis-
ease and 26 pts treated with a double transplant program were excluded. One
hundred eighty seven (187) pts entered the analysis: Male/Female
99(53%)/88(47%), median age 55 years (28-69), Myeloma Type IgG/IgA/light
chain/non secretory 111(59%)/38(20%)/33(18%)/5(3%), Durie&Salmon stage
II/III 26(14%)/161(86%). Induction therapy consisted of 4 VAD cycles in 83 pts
(44%) treated from 2000 to 2005 or 4 Bortezomib-based cycles in 104 pts
(56%) treated from 2006 to 2013. Stem cell collection was primed with a single
course of DCEP or HD-EDX followed by G-CSF at 10 mcg/kg until completing
stem cell collection (PBSC). Tx conditioning regimen consisted of single HD-
Melphalan infusion 200 mg/m2 in 137 pts (73%); HD Melphalan was given at
the reduced dose of 160 mg/m2 in 50 pts (27%) due to comorbidity. Response
was defined according to International Myeloma Working Group criteria.
Results: Median time between stem cell collection and transplantation (Wait-
Tx) was 4 months (range 0.9-13.8 months). After a median follow up after Tx
of 49 months (range 24-75 months), 140 patients (74%) relapsed or pro-
gressed, median progression free survival (PFS) after Tx was 23 months (range
12-54 months), with a median OS after Tx of 70 months (range 34 months -not
reached). PFS was not different between tertiles of Wait-Tx (T1= 0.9-3.2
months, T2= 3.3- 4.6 months, T3=4.7-13.8 months; logrank test p=0.45, cfr
Figure 1). When multivariate analysis was performed including Wait-Tx, age at
Tx, disease status at Tx (≥VGPR vs PR vs <PR), type of induction (bortezomib
based vs VAD) as covariates, disease status at transplant ≥PR (HR 2.88, CI
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1.65-5.03, p<0.05) and bortezomib based induction (HR 0.63, CI 0.42-0.94,
p=0.024) significantly correlated with longer PFS, while Wait-Tx was not asso-
ciated with an increased risk of progression (HR 0.98, 95%CI 0.86-1.12,
p=0.76). Similar results were found as far as OS was concerned (Wait-Tx HR
1.12, 95% CI 0.94-1.32, p=0.180; bortezomib based induction vs VAD, HR 0.7,
95% CI 0.4-1.2, p=0.223; ≥PR, HR 2.04, 95% CI 1.05-3.9, p=0.034).
Figure 1.
Summary/Conclusions: Time frame between PBSC collection and stem cell
infusion had no significant impact on the outcome of transplanted myeloma
patients. Response to induction treatment and bortezomib based induction
therapy are both predictive of better outcome ensuring a longer PFS after trans-
plantation.
PB1954
SINGLE CENTRE OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION
FOR MULTIPLE MYELOMA
T Rider*, R Benjamin, M Streetly, A Pagliuca, S Schey, M Kazmi, K Smith,
J Jegard, S Omar, L Floro, J O’Sullivan
Haematology, Kings College Hospital, London, United Kingdom
Background: The introduction of novel drugs and autologous stem-cell trans-
plantation (SCT) have improved outcomes in multiple myeloma (MM) but most
patients relapse and remain uncured. Allogeneic SCT is a potentially curative
therapy but high transplant-related mortality (TRM) limits use of this strategy.
Reduced-intensity transplants have reduced TRM but consequently higher
relapse rates occur.
Aims: Our primary aim was to evaluate progression free survival (PFS) and
overall survival (OS) in patients with MM who underwent allogeneic SCT at our
centre. We also examined the effect of several factors on PFS and OS; pre-
allogenic SCT disease status, prior autologous SCT and number of lines of
treatment, in addition to conditioning regimen, age, and 6 month chimerism
levels.
Methods: A retrospective analysis of medical records for all consecutive MM
patients that underwent allogeneic transplantation at our centre between May
1999 and December 2015. 
Results: 29 MM patients underwent allogeneic SCT at a median age of 51
with the median year of transplant being 2005. Prior to allogeneic SCT a median
of 3.6 treatment lines (range 2-9) were administered, including an autologous
SCT which 79.3% of the cohort received. The subtype of MM was; IgG 48.3%,
IgA 20.7%, plasma cell leukaemia 17.2%, kappa light chain myeloma 10.4%
and lambda light chain disease 3.4%. Prior to allogeneic SCT 41.2% were in
complete remission, 14.8% in very good partial remission (VGPR), 29.2% in
partial remission and 14.8% had stable disease. A sibling was the stem cell
donor in 57.1% of cases, the remainder had matched unrelated donors. 51.7%
of patients received fludarabine, melphalan and alemtuzumab conditioning,
13.8% received fludarabine, busulfan and alemtuzumab, other regimens used
included those utilising anti-thymocyte globulin ATG or total body irradiation.
PFS and OS were 35 and 56 months respectively. The 10 year PFS was 23%
and OS was 49%. 14 deaths occurred during a median follow-up of 58.1
months. Age, pre-allogeneic SCT disease status, 6 month chimerisms and type
of conditioning regimen had no significant effect on PFS or OS. Those with
fewer than 4 lines of treatment prior to allogeneic SCT had longer OS (P=0.4)
and PFS (P=0.015). IMiD therapy was given to 51.7% of patients pre-allogeneic
SCT and 27.6% received velcade. Those that received 1 autologous SCT
(n=16) had longer OS (P=0.026) compared to those that received 2 (n=7) or
no autologous SCT (n=6), but PFS was not affected. Neutrophil engraftment
occurred after a median of 13 days. Graft versus host disease in the first 100
days occurred in 4 patients and in 5 patients after 100 days. 4 patients had
pre-planned maintenance therapy post allogeneic SCT. Donor lymphocyte infu-
sion was given to 9 patients post allogeneic SCT at a median of 9 months post
allogenic SCT, a median of 3 infusions were administered. 2 patients subse-
quently received an autologous SCT post allogeneic SCT at a median of 36.5
months. A median of 1 line of treatment (range 0-5) were given to the 13 patients
who relapsed following allogeneic SCT. 
Summary/Conclusions: Our data indicates that performing an allogeneic SCT
after less than 4 lines of treatment and after 1 autologous SCT yields better
outcomes. Low disease burden as demonstrated by achieving at least a VGPR
is also optimal, although not significant in our data. The role of immunomodu-
lation including maintenance therapy post allogeneic SCT needs to be fully
examined in prospective clinical trials to optimise the chance of allogeneic SCT
being curative.
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OUTPATIENT STEM CELL MOBILIZATION WITH INTERMEDIATE-DOSE
CYCLOPHOSPHAMIDE IS A SAFE AND EFFECTIVE PROCEDURE
A Pompa*, F Guidotti, G Mometto, M Goldaniga, F Rossi, R Marcolin, L Baldini,
A Cortelezzi
UOC Oncoematologia, Fondazione IRCCS Ca’Granda - Ospedale Maggiore
Policlinico, Milano, Italy
Background: Autologous stem cell transplantation (ASCT), even in the era of
new drugs, is the treatment of choice in younger and fit Multiple Myeloma (MM)
patients. Cyclophosphamide (CY) at different doses has been shown to be an
effective regimen for collecting peripheral blood stem cells (PBSC) in MM. Clin-
ical trials have demonstrated that intermediate dose CY (3 and 4 g/m2, ID-CY)
combined with G-CSF, is an efficient mobilizing regimen with less toxicity com-
pared with high dose CY (7 g/m2, HD-CY) in term of neutrophil recovery, throm-
bocytopenia, need of transfusions and IV antibiotics. (Goldschmidt, BMT 1996;
Fitoussi, BMT 2001). The method used for PBSC mobilization has not been
shown to affect overall transplantation outcomes (Kumar, Blood 2009). Mobi-
lization therapy is usually administered in an inpatient regimen, for the concern
of toxicity.
Aims: Our purpose is to evaluate the safety of mobilization therapy adminis-
tered in an outpatient regimen, with the prospect to lower costs and minimize
patient inconvenience, maintaining an optimal yield.
Methods: One hundred patients with newly diagnosed MM underwent outpa-
tient stem cell mobilization with CY 3 g/m2 (80%) or 4 g/m2 (20%) + G-CSF
after induction therapy with VEL-based (81%) or VAD (19%) regimens. G-CSF
10 mcg/Kg was started by day +5 and continued until completion of apheresis.
No antibiotics prophylaxis was routinely used. Day 0 was defined as the CY
infusion day. CY was administered in 2-4 consecutive 1h infusions (depending
on total dose). Hyper-hydration (3.5/4 l), antiemetics and the uroprotectant
Uromitexan were began IV 1 hour before CY infusion. Subsequently, Uromi-
texan was continued at home orally in the next 12h. Furthermore, the patient
was advised to drink 2.5/3 l of water in the next 24h. Blood count was monitored
at day + 4 and daily from day +7. CD34+ cells were counted on peripheral
blood by day 7; apheresis was started at leukocyte rise and with a value of at
least 20 CD34+/μl. Number of apheresis depended on the number of CD34+
cells collected to obtain al least 4x106 CD34+/Kg. Stem cells were then manip-
ulated and cryopreserved with standard techniques.
Results: Results are actually available for 88 of these patients. Median age at
mobilization therapy was 57y (range 34-68). Response prior of mobilization
was CR/sCR in 18%, VGPR in 52%, PR in 27%, and PD in 3%. Chemotherapy
was very well tolerated. Most frequently observed adverse events (AEs) were
nausea and vomiting of grade 1-2. Two patients experienced cystitis (one grade
1, one grade 2), 2 patients fever and infections. Only one patient required hos-
pitalization for AEs for fever without microbiological findings, rapidly regressed
with IV antibiotics. There were no other significant AEs related to chemotherapy.
All patients proceeded to stem cell harvest and reached CD34+ target, but 7
patients required administration of Plerixafor on demand. After mobilization, 85
patients proceeded to ASCT.
Summary/Conclusions: In conclusion, outpatient mobilization with ID-CY
appears to be an efficient and safe procedure, with minimal and manageable
side effects and low rate of hospitalization. Outpatient mobilization could ame-
liorate the quality of life of patients and reduce costs, avoiding or minimizing
the hospitalization rate, without compromising the safety profile and the success
of PBSC collect.
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CLINICAL CHARACTERISTICS OF PATIENTS WITH MULTIPLE MYELOMA
PRELIMINARY RESULTS OF A PROSPECTIVE MULTICENTER REGISTRY
OF THE COMUNIDAD VALENCIANA (SPAIN)
MJ Cejalvo1, M Panero2, P Ribas2, I Jarque3, A López4, P Pérez5, A Avaria6,
I Castillo7, M Guinot8, S Beltrán9, A Gascón10, A Montava11, A Teruel12,
M Arnao13, P Lorente14, MÁ Ruíz15, F Ibáñez16, B Villarrubia17, JL Sánchez18,
R Ferrer19, P Fernández20, M Blanes21, A Mauricio22, V Conesa23, J de la
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Background: Multiple myeloma (MM) is the second most common malignant
B-cell disorder. It accounts for 1% of all malignant diseases and for slightly
more than 10% of all hematological malignancies. Based on international data,
the incidence of MM in Spain has been estimated to be 0.056/1000 of popula-
tion. However, most of this information is collected from secondary sources as
press releases, industry, associations, analyst reports and others but real life
epidemiological data based on national or local registries is lacking.
Aims: In order to have a better knowledge of the clinical characteristics at
diagnosis of MM patients and to know the real incidence and prevalence of
patients with newly diagnosed MM in our environment, the Grupo de Estudios
de Mieloma (GREMI) developed in 2013 a prospective, multicenter registry
including every patient undergoing a first diagnosis of MM in every public or
private sanitary center of the Comunidad Valenciana, Spain.
Methods: The CV involves three regions in Spain (Alicante, Castellón, and
Valencia) with a global population of 5,034,665 habitants. A total of 2,578,719
people live in Valencia, 1,868,438 in Alicante and 587,508 in Castellón. Diag-
nosis of MM is done according to the International Myeloma Working Group cri-
teria. Primary data collection for the registry is done in every center by the local
investigators. Immediately after a new diagnosis of MM is performed, the patient
is registered on-line by means of an electronic database. Clinical and epidemi-
ological data at presentation, the type of therapy administered, and survival sta-
tus are included. We present the preliminary epidemiological, clinical, and lab-
oratory results of the patients included in the registry in the period 2013-2014.
Results: From January 2013 to December 2014, a total of 332 patients have
been registered in 23 centers. The overall incidence of patients with newly
diagnosed MM (NDMM) in the Comunidad Valenciana in the study period was
0.066/1000 of population (0.046 in Alicante, 0.082 in Castellón, and 0.077 in
Valencia). Three hundred and twenty-seven (98.5%) patients were of Cau-
casian descent. Median (range) age of the series was 70.76 (43.07-92.15)
years and 95 (28.61%) of the patients were younger than 65 years. One hun-
dred and seventy-seven (53.3%) patients were male. Overall, IgG myeloma
was the most commonly observed type of myeloma (174 patients, 52.4%).
Eighty-eight (26.5%), 52 (15.7%), and 82 (24.7%) patients presented with an
International Staging System of I, II, and III, respectively. Clinical and laboratory
data at time of diagnosis are shown in the Table 1.
Table 1.
Summary/Conclusions: This is the first epidemiological registry for NDMM
patients available in Spain. Our preliminary results indicate that the incidence
of MM in the Comunidad Valenciana is similar to that generally reported. Cyto-
genetic data were routinely collected in the great majority of patients 248
(74.7%). Survival data during the study period will be presented.
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PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM)
PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT
LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN
IMMUNOMODULATORY AGENT
PG Richardson1,*, V Hungria2, SS Yoon3, M Beksac4, MA Dimopoulos5,
A Elghandour6, WW Jedrzejczak7, WW Jedrzejczak8, TN Nakorn9,
N Siritanaratkul10, R Schlossman11, J Hou12, P Moreau13, S Lonial14, JH Lee15,
H Einsele16, F Binlich17, M Sopala18, A Roy19, A Panneerselvam20, J San Miguel21
1Dana Farber Cancer Institute, Boston, United States, 2Irmandade da Santa
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Turkey, 5National and Kapodistrian University of Athens, Athens, Greece,
6Alexandria University, Alexandria, Egypt, 7Medical University of Warsaw, War-
saw, Poland, 8Division of Stem Cell Transplantation and Immunotherapy, 2nd
Department of Medicine, University Hospital Schleswig-Holstein and University
of Kiel, Kiel, Germany, 9King Chulalongkorn Memorial Hospital and Chula-
longkorn University, 10Siriraj Hospital, Bangkok, Thailand, 11Dana-Farber Can-
cer Institute, Boston, United States, 12Chang Zheng Hospital, Shanghai, China,
13University Hospital of Nantes, Nantes, France, 14Winship Cancer Institute,
Emory University, Atlanta, United States, 15Department of Internal Medicine,
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Of, 16Medizinische Klinik und Poliklinik II, University of Würzburg, Würzburg,
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Background: Panobinostat (PAN), in combination with bortezomib (BTZ) and
dexamethasone (DEX), is approved in the EU for the treatment of adult patients
with relapsed and/or refractory multiple myeloma (MM) who have received ≥2
prior regimens, including BTZ and an immunomodulatory drug, based on sig-
nificant clinical benefit of PAN+BTZ+DEX PANORAMA-1.
Aims: This analysis focuses on the impact of PAN+BTZ+DEX on patient expe-
rience, including measures of symptoms, function, and health-related quality of
life (HRQoL), measured by FACT/GOG-Ntx, QLQ-MY20, and EORTC-QLQ-30.
Methods: In PANORAMA-1, patients who had received between 1 and 3 pre-
vious treatment regimens were randomized 1:1 to receive up to 12 cycles of
PAN or placebo (PBO), in combination with BTZ+DEX. PRO measures were
administered at screening, cycle 1 day 1, and every 6 weeks thereafter until
end of treatment. We present here the results at the end of 24 weeks, after
completion of the first 8 cycles of the study treatment (treatment phase 1).
Results: In the approved EU population, PRO baseline data were available
for 71 and 69 PAN+BTZ+DEX and PBO+BTZ+DEX treated patients, respec-
tively, for the EORTC QLQ-C30, Global Health Status/QoL scale and for 70
patients in each treatment arm for the QLQMY20, Disease Symptoms (DS)
subscale and the FACT/GOG-Ntx Neurotoxicity subscale. At Week 24, FACT-
GOG-Ntx scores were similar across treatment arms, suggesting no difference
in neurotoxicity symptoms (31.75 vs 33.57 for PAN+BTZ+DEX vs
PBO+BTZ+DEX treated patients, respectively). In both treatment arms, symp-
toms scores were generally low on the scale of 0-100, with lower scores in the
QLQ-MY20 DS subscale observed following treatment initiation and no differ-
ence between arms observed at Week 24 (23.84 vs 16.55 for PAN+BTZ+DEX
vs PBO+BTZ+DEX treated patients, respectively). EORTC QLQ-C30 Global
Health Status/QoL scores were generally stable after treatment initiation, and
comparable in the 2 arms at Week 24 (53.82 vs 58.05 for PAN+BTZ+DEX vs
PBO+BTZ+DEX treated patients, respectively).
Summary/Conclusions: These findings support the addition of panobinostat
to the well-established BTZ+DEX regimen as an efficacious treatment option
with limited symptomatology and impact on patients’ HRQoL. With the increas-
ing importance of patient-relevant humanistic benefits in determining the overall
value of oncology products findings such as these are important for treatment
decision making.
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RETROSPECTIVE COHORT ANALYSIS EXAMINING THE EFFICACY AND
SAFETY OF (V)DTPACE IN NEWLY DIAGNOSED AND RELAPSED/
REFRACTORY MYELOMA PATIENTS-THE UK EXPERIENCE
P Sriskandarajah1,2,*, H Jolly2, P Idaikkadar2, C Pawlyn2,3, K Mohammed2,
C Dearden2, M Potter2, F Davies4, G Morgan4, K Boyd2, M Kaiser2,3
1Division of Cancer Therapeutics, Institute of Cancer Research, 2Haematology,
Royal Marsden Hospital, 3Division of Molecular Pathology, Institute of Cancer
Research, Sutton, United Kingdom, 4Myeloma Institute, University of Arkansas
for Medical Sciences, Little Rock, United States
Background: Multiple myeloma remains incurable in spite of advances in treat-
ment. In the UK, the combination of dexamethasone, thalidomide, cisplatin,
doxorubicin, cyclophosphamide and etoposide (DTPACE) continues to play a
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role in patients with relapsed/refractory multiple myeloma (RRMM), either as a
bridge to stem cell transplant, or for rapid tumor debulking. Recently, bortezomib
has also been included (VDTPACE) - this combination was introduced by the
Arkansas group in the Total Therapy 3 (TT3) study, where MM patients received
this as induction prior to tandem autologous stem cell transplant (ASCT), result-
ing in enhanced response rates and prolonged survival. However, due to the
intensity of both VDTPACE and DTPACE, these regimes have not been adopted
by many centers and results outside the Arkansas group have therefore been
rarely reported. At the Royal Marsden Hospital (RMH) we have used
(V)DTPACE in selected cases where standard therapies are deemed inade-
quate, including newly diagnosed patients with specific high risk features, sal-
vage treatment for those who were primary refractory and in patients with RR
disease.
Aims: To assess response rates, impact on stem cell harvest and tolerability
in myeloma patients treated with (V)DTPACE at RMH.
Methods: We retrospectively reviewed the medical notes for all myeloma
patients treated with (V)DTPACE at RMH between 2010 and 2015. Our primary
objective was ORR defined as PR or better. Secondary objectives included
number of stem cells harvested (if applicable) and toxicities (as per CTCAE
v4.0 criteria). Patient demographics including age, gender and prior treatment
exposure were also analyzed.
Results: Between 2010 and 2015, 53 patients received DTPACE and 26
received VDTPACE. The median age was 55 years with a male predominance
(61%). 7/79 (9%) patients received treatment upfront due to high-risk disease
features, including 2 patients with plasma cell leukemia and 2 with extensive
extramedullary disease at presentation. 8/79 (10%) were primary refractory
(<PR) to first-line therapy while the rest (64/79, 81%) had RRMM receiving
median 2 (range 2-8) prior lines of therapy including thalidomide (72%), borte-
zomib (75%), lenalidomide (46%) and autologous stem cell transplant (47%).
All patients had EDTA clearance scan as well as cardiac assessment prior to
treatment. 15/79 (19%) received 1 cycle (V)DTPACE, 58/79 (73%) received 2
and 6/79 (8%) received 3. 49/79 (62%) proceeded to transplant of which only
4 failed to mobilize stem cells. Mean stem cell harvest was 2.64x106/kg. The
ORR (≥PR) observed following DTPACE was 100% (20% CR) in newly diag-
nosed, 100% in primary salvage and 51% (13% CR) in RR patients. Following
VDTPACE, ORR was 100%, 71% and 82% (6% CR) respectively. Commonly
reported toxicities included Grade 3≥ neutropenia (94%) and Grade 3≥ throm-
bocytopenia (48%). No thrombo-embolic events or grade 3≥ neuropathy were
reported. At analysis, 39/79 (49%) patients were alive. There were no treat-
ment-related deaths. Survival data is currently analysed and will be presented
at meeting.
Summary/Conclusions: Our results demonstrate the efficacy of VDTPACE in
newly diagnosed and relapsed/refractory patients, in spite of prior exposure to
thalidomide or bortezomib. Importantly this regimen can safely be used to sal-
vage patients with an insufficient response to conventional first-line therapy.
VDTPACE had no impact on stem cell mobilization, and was well tolerated with
no treatment-related deaths reported.
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THE ROLE OF COMORBIDITY ON EARLY MORTALITY IN MULTIPLE
MYELOMA. A SINGLE INSTITUTION POPULATION-BASED STUDY
EMPHASIZING THE NEED FOR STANDARDIZATION
R Ríos-Tamayo1,*, JJ Lahuerta2, J Sáinz1, MJ Sánchez3, DYL Chang3,
JJ Jiménez-Moleón4, JM Puerta1, T Rodríguez5, JL García de Veas5, P Garrido1,
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sity of Granada, 5Immunology, University Hospital Virgen de las Nieves, Grana-
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Background: Multiple myeloma (MM) is a very heterogeneous and complex
disease with variable survival. The variability in the outcome cannot be fully
explained by the current systems of stratification. Early mortality (EM) remains
a serious obstacle to further improve the recent trend towards increased survival
demonstrated in recent years (Ríos-Tamayo et al, 2015). However, the definition
of EM is not standardized, precluding a proper comparison between studies.
Furthermore, no study has systematically focused on the impact of comorbidity
on EM in MM to date.
Aims: The aim of this study is to assess the impact comorbidity on the outcome
of MM patients, in terms of EM, in a large cohort of real-life patients. On the other
hand, all relevant studies on this topic to date have been critically analyzed.
Methods: All newly diagnosed symptomatic MM patients recorded in our pop-
ulation-based registry from January 1985 to December 2015 were analyzed.
The study was divided into six periods of five years. Twenty baseline comor-
bidities were studied, along with common prognostic factors. EM was measured
at three key cutoff points: two (EM2), six (EM6) and twelve (EM12) months.
Univariate and multivariate binary logistic regression models were used to test
independent variables as risk factors for EM.
Results: Six hundred and thirty-one MM patients were recruited in our MM
clinical registry during the period of study. A complete assessment of comor-
bidity was available in 426 patients (68.6%) at the moment of diagnosis. Exclud-
ing patients not fit for MM-directed therapy, the percentage for EM2, EM6 and
EM 12 was 10.6%, 20% and 28.6%, respectively. For the whole cohort, only
age and serum creatinine were independent risk factors for EM in all the cutoff
points analyzed. The presence of respiratory disease and light chain MM (bor-
derline) were associated with EM2, whereas the ISS III and liver disease were
predictors for EM6, and finally, the lactate dehydrogenase level, the hepatitis
virus C infection and the presence of respiratory disease were significantly
associated to EM12. Table I highlights recent studies on this topic. The differ-
ences in the type of study as well as in the cutoff point used preclude appropriate
comparisons.
Table 1. Results of recent studies on NDMM early mortality.
Abbreviations: NDMM= Newly diagnosed multiple myeloma, EM2=Early Mortality at two months,
EM6=Early Mortality at six months, EM12=Early Mortality at twelve months, a,% EM according
to estimated glomerular filtration rate (<30, 30-59 or >30 ml/min), b% EM within 24 months.
Summary/Conclusions: The role of comorbidities in EM of MM patients
remains to be determined. However, our study confirms the crucial role of renal
failure and provides some evidence about the time-dependent impact of specific
comorbidities in detailed cutoff points for EM. We suggest that all three cutoff
points should be analyzed in the future, in order to allow comparisons between
studies.
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CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE
PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
M Ri1,*, K Suzuki2, T Chou3, I Sugiura4, N Takezako5, K Sunami6, T Ishida7,
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Background: Carfilzomib (CFZ) is an epoxyketone proteasome inhibitor that
binds selectively and irreversibly to the constitutive proteasome and immuno-
proteasome. The combination of CFZ with lenalidomide (Len) and dexametha-
sone (Dex) (CRd) has shown efficacy in a phase 3 study (ASPIRE) in relapsed
multiple myeloma (Stewart et al, 2014).
Aims: This phase 1 study was designed to evaluate the safety, tolerability, effi-
cacy and pharmacokinetics of CRd regimens in Japanese patients with relapsed
or refractory multiple myeloma (RRMM). This was a company sponsored trial
(Ono Pharmaceutical Co., Ltd.).
Methods: Adults with RRMM who had received at least 1 prior treatment were
eligible. CFZ was administered as a 10-minute infusion on days 1, 2, 8, 9, 15,
and 16 of 28-day treatment cycles (20 mg per square meter on days 1 and 2
of cycle 1 and 27 mg per square meter thereafter) during cycles 1 through 12
and on days 1, 2, 15, and 16 during cycles 13 through 18. Len (25 mg) was giv-
en on days 1 through 21 during cycles 1 through 18. Dex (40 mg) was admin-
istered on days 1, 8, 15, and 22 during cycles 1 through 18. The efficacy end-
point included the rate of overall response (ORR). Treatment responses and
disease progression were assessed by investigators based on the central lab-
oratory results with the IMWG Uniform Response Criteria. All patients provided
written informed consent.
Results: Twenty six Japanese RRMM patients were enrolled. The median num-
ber of previous regimens was 4 (range, 1-10). The median number of cycles
dosed was 4 (range, 1-8 cycles). The proportion of patients with previous ther-
apies of bortezomib and lenalidomide was 88.5% and 61.5%, respectively. A
total of 53.8% of patients had high risk abnormal cytogenetics [t (4; 14), t (14;
16), del (17p) or hypodiploid]. In this study, CRd regimen used in ASPIRE study
was well tolerated in Japanese population. The ORR was 88.5% (90%CI, 72.8
to 96.8). Subgroup analysis demonstrated that the ORR was not affected by
previous therapies and abnormal cytogenetics. The median PFS and OS were
not estimated because of the short follow-up period. The most common AEs
included lymphocyte count decreased (53.8%), platelet count decreased
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(53.8%), hyperglycemia (38.5%), hypophosphatemia (38.5%), constipation
(30.8%), white blood cell count decreased (30.8%), and rash (30.8%). The
most common Grade 3 or higher AE were lymphocyte count decreased
(42.3%), platelet count decreased (23.1%), hypophosphatemia (19.2%), ane-
mia (11.5%), neutrophil count decreased (11.5%), white blood cell count
decreased (11.5%) and hyperglycemia (11.5%). Peripheral Neuropathy was
observed in 15.4% but no Grade ≥3 or peripheral neuropathy with pain was
reported. None of the patients experienced interstitial lung disease. The plasma
CFZ concentration showed a rapid decrease after intravenous administration
with T1/2 of 0.580–0.740h. The exposure of CFZ increased in a dose-depen-
dent manner with the AUCinf of 326-445 ng*h/mL, Cmax of 1540-2030 ng/mL.
Table 1.
Summary/Conclusions: This is the first study that CRd regimen was evaluated
in heavily pre-treated MM patients (median 4 prior regimens). CRd regimen
was well tolerated and showed a compelling efficacy in Japanese RRMM
patients. A comparison of this study with CRd arm in ASPIRE phase 3 study
showed that the results of the ORR were similar (88.5% and 87.1%), despite
the more heavily pretreated patient population in this study (median 4 vs 2
prior regimens). The safety and efficacy of the CRd regimen in Japanese




PROGNOSTIC SIGNIFICANCE OF EXTRAMEDULLARY DISEASE DETECTED
BY PET/CT ON OUTCOMES OF AUTOLOGOUS TRANSPLANT IN MULTIPLE
MYELOMA PATIENTS
U Yanamandra1,*, M BR2, A Reddy2, K Agarwal2, K Kant Sahu1, N Varma1,
V subhash1, P Malhotra1
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Background: Multiple myeloma is a heterogenous disorder with varied
responses to transplantation. In the past investigators have reported numerous
staging systems, risk stratification models based on laboratory/clinical param-
eters and genetic information to predict these heterogenous responses. But
the disease mostly negative by biochemical tests before transplantation making
it a poor choice to predict responses. 18F-FDG-PET/CT has numerous advan-
tages in terms of ability to assess extra medullary disease in addition to the
extent of active disease. The relevance of extramedullary disease in predicting
response is scarce and evolving. 
Aims: To study the role of pre-transplant EMD in the prognostication of multiple
myeloma patients post autologous transplant.
Methods: All autologous transplant patients underwent 18F-FDG-PET/CT as
part of the pre-transplant workup. The conditioning and treatment protocols
were not modified based on PET/CT findings. Extramedullary disease (EMD)
on PET/CT was defined as FDG uptake more than Liver SUVmax at any
extramedullary site (including soft tissues or lymphoreticular structures includ-
ing spleen) of at least 5mm in size. We aimed at identifying the prognostic
value of the pre-transplant type of lesions on PET/CT in predicting biochemical/
clinical progression-free survival (PFS) and overall survival (OS). We also cor-
related the EMD status with pre-transplant biochemical markers (SPEP, UPEP,
SIFE, SFLC, β2M and LDH). The revised IMWG criteria were used for defining
progression.
Results: A total of 43 patients underwent pre-transplant PET/CT evaluation of
which seven patients had EMD. On Cox proportional regression hazard model
EMD had a hazard for post-transplant all-cause mortality of 5.46 times in
patients than the medullary disease (p-0.045) (Fig 1A). The 6-year median OS
in patients with medullary and extramedullary PET lesions were 80.6%, and
57.1% respectively as shown Fig. 1B. Kaplan-Meier analysis showed poorer
OS in patients with EMD χ2 (1-0.496, p-0.481). There was no significant differ-
ence in clinical or biochemical EFS among patients with EMD. The median
PFS (Clinical) in patients with medullary and extramedullary PET lesions were
77.8%, and 71.4% respectively (p-0.997). The median PFS (Biochemical) in
patients with medullary and extramedullary PET lesions were 55.6%, and
57.1% respectively (p-0.352). Engraftment was delayed in patients with EMD
(Neutrophil-11.57 vs 10.83 days, platelet engraftment - 13.0 vs 12.63 days)
though the results were not significant (p-0.274, 0.85). Pre-transplant β2M and
LDH were significantly higher in patients with EMD (p-0.036). A chi-square test
was performed and no relationship was found between the PET positivity and
pre-transplant UPEP, SPEP and SIFE with χ2 (1, 42)-0.737, p-0.391, χ2 (1,
43)-0.632, p-0.580 and χ2 (1, 42)-0.305, p-0.580 respectively.
Figure 1.
Summary/Conclusions: EMD detected on 18F-FDG-PET/CT has a higher
hazard for mortality and significantly correlated with pre-transplant higher β2M
and LDH levels. The Smaller sample size was a major limitation of the study
and was responsible for certain differences in measured variables not being
statistically significant. To conclude, detection of EMD by pre-transplant 18F-
FDG-PET/CT has a significant prognostic role in multiple myeloma patients
undergoing autologous peripheral blood stem cell transplant.
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ASSOSIATION BETWEEN ENDOTHELIAL AND PLATELET DERIVED
MICROPARTICLES AND VENOUS THROMBOSIS IN NEWLY DIAGNOSED
PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON HODGKIN
LYMPHOMA (NHL) - PRELIMINARY REPORT
L Usnarska-Zubkiewicz1,*, M Podolak-Dawidziak1, U Zalewska-Dorobisz2,
M Olszewska-Szopa1, I Prajs1, J Dębski1, K Kuliczkowski1
1Department of Haematology, Blood Neoplasms and Bone Marrow Transplan-
tation, 2Dept of General and Pediatric Radiology, Wroclaw Medical University,
Wrocław, Poland
Background: Multiple myeloma and non-Hodgkin lymphoma and its treatment
are frequently complicated by development of venous thromboembolism (VTE).
The incidence of thrombotic complications dramatically raise after highly pro-
thrombotic therapeutic regimens e.g. with thalidomide and lenalidomide in MM.
Aims: The aim of this study was to examine whether procoagulant micropar-
ticles (MPs) derived from endothelial cells (EMPs) and platelets (PMPs) con-
stitute an enhanced risk for venous thrombosis.
Methods: We studied 22 patients (pts) without history of VTE, 10/12 F/M, aged
24-84 years. There were 13 pts of MM (9 cases of IgG, 2 of IgA, 1 IgM and 1
non secretory MM) and 9 pts with nHL (5 cases of DLBCL, 2 anaplastic T cell
lymphoma and 2 FL).All patients underwent routine coagulation tests. Flow-
cytometry was used for quantification of endothelial cell (CD133+) microparti-
cles (EMPs) and platelet (CD61+) microparticles (PMPs). In all pts ultrasound
examination of venous system of the lower extremities was performed. Both
deep and superficial veins of both limbs were evaluated. Conventional and
Doppler imagination, as well as elastography and options to detect microcal-
cifications (micropure) were used.
Results: The ultrasound examination revealed the presence of vein thrombosis
in 11 pts (group I, n=11). Five out of 11 pts with bilateral lesions in VSM (vena
saphena magna, great saphenous vein) and lower leg veins or bilateral in VSM
only comprised subgroup Ia. Six pts with unilateral blood clots in VSM formed
group Ib. Thrombosis was observed in 7 pts with MM and 4 with nHL, and
bilateral thrombotic lesions were demonstrated in 2 MM and 3 nHL pts. The
remaining 11 pts showed no thrombosis (group II). The mean percentage of
EMPs (CD133+) was 1,04±1,03, and it did not significantly differ between
thrombotic (group I) and non-thrombotic patients (group II) 1,22±1,24 vs
0,85±0,77, p=0,406), but there was a trend for increased EMPs in the subgroup
Ia (1,37±1,17). The percentage of PMPs (CD61+) was 13,14±4,68 and similar
in all studied groups: group I 12,82±3,28 vs group II 13,45±5,92 (p=0,759),
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including subgroup Ia (11,80±2,32). Mean plasma fibrinogen (FBG) concentra-
tion was 3,65±1,85 g/L and did not significantly differ in MM and nHL patients
with and without thrombosis (4,06±1,90 vs 3,24±0,1,80 g/L, p=0,309). But FBG
level in subgroup Ia was found to be significantly higher than that in the remain-
ing patients (5,07±2,45 vs 3,23±1,48, p=0,047). Mean D-dimer level was
2,59±4,70mg/L, and there was not significantly different in patients with and
without thrombosis (4,01±6,40 vs 1,16±0,97 mg/L, p=0,159), however D-dimer
was elevated in subgroup Ia in comparison with that in group II (2,52±1,29 vs
1,16±0,97 mg/L, p=0,034).
Summary/Conclusions: Venous thrombosis was confirmed in 11 of 22 patients
with newly diagnosed patients with MM and n-HL. In patients with many throm-
botic lesions there was a trend for elevated activity of endothelial cells (EMPs),
but not platelets (PMPs).
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GALECTIN-3 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN
PATIENTS WITH MULTIPLE MYELOMA
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Background: Galectins are a family of lectin molecules that have emerged as
key players in inflammation and tumor progression by displaying intracellular
and extracellular activities. Increased expression of galectin-3 (Gal-3) has been
associated with chronic myeloid leukemia, multiple myeloma, and chronic lym-
phocytic leukemia. Although modern treatment options for multiple myeloma
produce high response rates, the interrelation between elevated Gal-3 and sur-
vival rate is not fully understood. Moreover, elevated Gal-3 associates with
increased cardiovascular risk. In this context there is possibility to use statins
in multiple myeloma patients to prevent unfavorable outcomes under control of
Gal-3 level.
Aims: The aim of the study was to investigate an interrelationship between
pre-treatment Gal-3 level and one-year survival rate in subjects with multiple
myeloma.
Methods: One hundred twelve subjects with multiple myeloma who reached
at least partial remission were enrolled in the study. All subjects gave their writ-
ten informed consent to participation in the study. Patients were divided into 2
groups based on whether or not statins were included in their treatment: a statin
group (n=51) and a no statin group (n=61). Among patients in the statin group,
31 patients received 20- mg/day atorvastatin and 20 patients received 40-
mg/day atorvastatin. None of the patients had received any lipid-modulating
medications, including statins or fibrates, before enrollment. Observation period
was up to 1 year. Blood samples for biomarkers measurements were collected.
ELISA method for measurements of circulating level of Gal-3, and NT-pro-brain
natriuretic peptide (NT-pro-BNP) were used. Concentrations of Gal-3 and NT-
pro-BNP for cumulative survival rate were tested.
Results: Within 1 year progressions were reported in 23 patients (8 statin users
(15.7%) and 15 never statin users (24.6%) (P<0.05)). 92 cardiovascular events
were reported in 36 patients, (12 statin users (23.5%) and in 24 never statin
users (39.3%) (P<0.01)). Lipid lowering effect in statin users was associates
with declined serum Gal-3 level, whereas in not statin users similar response
was not appeared. No any changes in hemodynamics and other biomarkers
between both cohorts were found. Univariate logistic regression had exhibited
that Gal-3 (odds ratio [OR]=1.13; 95% CI=1.07–1.25; P=0.003), NT-proBNP
(OR=1.05; 95% CI=1.03–1.08; P=0.001), and statin therapy (OR=1.06; 95%
CI=1.01– 1.10; P=0.001) predicted one-year cumulative cardiovascular events.
Gal-3 (odds ratio [OR]=1.09; 95% CI=1.05–1.19; P=0.02), and statin therapy
(OR=1.05; 95% CI=1.01– 1.9; P=0.04) predicted one-year progression free
survival. After adjustment on statin therapy, Gal-3 remained independent pre-
dictor one-year cumulative cardiovascular events (OR=1.07; 95% CI=1.05–
1.10; p=0.001). When initial serum Gal-3 level has incorporated into prediction
model, statin therapy was found as predictor for improving survival in patients
with elevated serum Gal-3 level (>14 ng/ml).
Summary/Conclusions: Elevated pre-treatment galectin-3 level was found a
powerful predictor of positive effects of statins in patients with multiple myeloma.
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CLINICAL SIGNIFICANCE OF OSTEOBLAST PRECURSORS AND OSTEOCLAST
PRECURSORS IN EARLIER DIAGNOSIS AND MONITORING OF MYELOMA
BONE DISEASE
R Fu*, H Liu, F Peng, L Li, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Multiple myeloma (MM) is a kind of plasma malignant tumor.
Myeloma bone disease (MBD) is a most common complication of MM, with up
to 80% of them developing osteolytic lesions.The primary diagnostic procedure
for the detection of bone involvement in MM is conventional radiography. Limited
sensitivity was an important disadvantage of conventional X-ray in MBD.
Aims: To find more sensitive markers to diagnose bone disease earlier and
evaluate the effect of therapy.
Methods: we detected circulating osteoclast precursors (OCPs) and osteoblast
precursors (OBPs) by flow cytometry, comparing with special biochemical mark-
ers, such as tartrate-resistant acid phosphatase isoform 5b (TRACP-5b), car-
boxy-terminal cross-linking telopeptide of type I collagen (CTX), osteocalcin
(OCN) and procollagen I amino-terminal propeptide (PINP).
Results: The results showed that circulating OBPs in the newly diagnosed MM
patients significantly decreased compared with the normal controls (7.14% vs
12.82%, P=0.045). While circulating OCPs in the newly diagnosed patients and
remission patients were significantly increased than the normal controls (2.46%
vs 0.17%, P=0.000; 1.87% vs 0.17%, P=0.000, respectively). According to X-
ray, newly diagnosed patients were divided into stage A and B (without and
with osteolytic lesions). Compared with the normal controls, circulating OBPs
in stage A and B reduced (12.82% vs 7.47%, P=0.041; 12.82% vs 7.14%,
P=0.010, respectively), while circulating OCPs elevated (0.17% vs 2.71%,
P=0.001; 0.17% vs 2.37%, P=0.010, respectively). The levels of TRACP-5b
and CTX in the newly diagnosed patients were higher than the normal controls
(P=0.014, P=0.037) and remission patients (P=0.025, P=0.003), and they were
significantly higher in stage B than the normal controls (P=0.015, P=0.002).
However, PINP and OCN levels had no significantly changes in different stages.
Figure 1.
Summary/Conclusions: In conclusion, abnormal circulating OBPs and OCPs
were found earlier before X-ray in MM and still existed in remission patients,
indicating that they maybe novel predictive markers for early diagnosing and
monitoring bone disease.
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BORTEZOMIB IN COMBINATION WITH HIGH DOSE MELPHALAN AS
CONDITIONING REGIMEN IS SAFE AND IMPROVES THE RESPONSE
RATES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
B Dalla Palma1,*, L Prezioso1, F Accardi1, I Manfra1, F Aversa1,2, N Giuliani1,2
1Hematology and BMT Unit, Azienda ospedaliero-universitaria, 2Clinical and
Experimental Medicine, University of Parma, PARMA, Italy
Background: High dose therapy followed by autologous stem cell transplan-
tation (ASCT) is the standard of care as first-line treatment in eligible patients
with newly diagnosed Multiple Myeloma (MM). High-dose Melphalan (HDM) is
the standard conditioning regimen before ASCT. Recent evidence suggests
that the depth of response after the induction therapy influences the progression
free survival (PFS) and, in most studies, the overall survival (OS). To improve
the depth of response after ASCT in transplant–eligible MM patients the intro-
duction of Bortezomib (BOR) to high-dose Melphalan (HDM) in conditioning
regimen has shown to be effective without increased hematological toxicity. 
Aims: Aim of the study is to evaluate safety and response rates in patients
treated with BOR+HDM as conditioning regimen before ASCT.
Methods: In this study we retrospectively analyzed, in a single center, 27
patients treated with BOR-HDM as conditioning regimen as compared to a his-
torical cohort of 21 patients treated with HDM alone in order to evaluate the
safety and the response rate of the combination treatment. All patients in both
groups were treated with novel agents as part of induction therapy. The condi-
tioning regimen consisted in HDM (100-200 mg/m2, depending on age and
comorbidity) administered on day -2, and only for patients in the BOR-HDM
group, a single-dose Bortezomib at the dosage of 1.3 mg/m2 on day -1. Stem
cells were reinfused on day 0. 
Results: Any significant difference was not observed between the two cohorts
of MM patients analyzed regarding the median age at diagnosis (61 vs 59
years) and the dose of Melphalan. Distribution of ISS stage was similar in the
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two groups, as well as that of high-risk cytogenetic or ultra high-risk features
(ISS III plus high-risk cytogenetic). Moreover the response rates after the induc-
tion therapy was not statistically different in the two groups of patients analyzed.
Any significant difference on hematopoietic recovery rates was not observed
in BOR+HDM as compared to HDM alone, with a mean time to neutrophil
recovery of 12 days (range 9-18) and to platelet recovery of 13 days (range
10-28) in both groups. BOR+HDM conditioning was well tolerated, with no
increase of neuropathy occurrence. We then analyzed the response rate after
ASCT, showing that the overall response rate was significantly higher in BOR-
HDM group as compared to HDM (P=0.028) with a higher number of complete
response (CR) (54% vs 17%). The number of stringent CR was also signifi-
cantly higher in BOR-HDM as compared to HDM alone (3 vs 0).
Summary/Conclusions: In conclusion, this retrospective analysis suggests
that BOR-HDM is safe as conditioning regimen with a higher response rate
after ABMT in comparison to the standard HDM regimen, giving the rational
design for randomized studies needed to assess whether this conditioning reg-
imen is superior to HDM alone.
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OSTEONECROSIS OF THE JAW IN PATIENTS WITH MULTIPLE MYELOMA
IN THE ERA OF MORE POTENT BISPHOSPHANATES
M Pavkovic1,*, G Petrusevska2, R Jovanovic2, L Cadievski1, O Karanfilski1,
S Genadieva-Stavric1, L Cevreska1, S Trpkovska-Terzieva1, T Sotirova1, A Sto-
janovic1
1Univeristy Clinic for Hematology, 2Institute for Pathology, Medical Faculty,
Skopje, Macedonia
Background: Long term use of bisphosphonates has been associated with
increased incidence of osteonecrosis of the jaw (ONJ). ONJ is commonly pre-
cipitated by a tooth extraction or other stomatological procedure in patients
treated with long term, potent, high dose intravenous bisphosphonates for the
management of myeloma, breast or prostate cancer. ONJ is most commonly
reported in patients with MM, but it can occur in all cancer patients treated with
bisphosphonates for bone metastatic disease.
Aims: The aim of this study was to evaluate the incidence of ONJ in patients
with myeloma treated with bisphosphonates during the last 11 years in our
institution.
Methods: We have analyzed 422 patients diagnosed with multiple myeloma
in our institution in the period of 2002-2013. Median age at diagnosis was 63
years (range: 36-91), median duration of myeloma was 3.9 years (3 months-
14 years). Most common isotype of myeloma was IgG Isotype (62%) and
almost 80% of patients had bone lesion at the time of diagnosis. Most common
chemotherapy protocol was thalidomide based protocol with more than half of
patients treated with thalidomide. Only 351/422 patients (83.2%) were treated
with bisphosphonates. 
Results: Incidence of ONJ in patients treated with bisphosphonates was 9/351
(2.6%). Median duration of bisphosphonates treatment was 28.5±19.4 months
(range: 3-98 months). Most commonly used bisphosponate was i.v.
pamidronate 175/351(49.8%), while 218/351 (62.1%) were treated with two or
more types of bisphosphonates. Zolendronate was used in 79 patients (22.5%).
83 patients (23.6%) received oral forms of bisphosphonates; 56.2% patients
were treated with i.v. forms of pamidronate, ibondronate, clodronate or zolen-
dronate, and 85 patients (24.2%) received combination of oral and i.v. forms
of bisphosphonates. Mean duration of bisphosphonates therapy was 33.8±21.7
months. When we compare the incidence of ONJ in the period before and after
2009 (year when we started to use zolendronic acid in the treatment of MM),
we could notice a rise in the number of cases with ONJ. In the period 2002-
2009 we have registered only 2/190 (1%) cases with ONJ comparing to
7/161(4,3%) patients with ONJ in the period 2009-2013. Despite the evident
rise in the number of cases of ONJ in the era of more potent bisphsphonates,
these difference was not significant (p=0.058).
Summary/Conclusions: The incidence of ONJ in our institution is similar to
already referred incidence in other studies and it has become more common
complication of bisphosphonate treatment since we have started to use more
potent intravenous forms of bisphosphonates. High cumulative doses of bis-
phosphonates, type of used bisphosphonate, poor oral health, and dental
extractions may be significant risk factors for ONJ development. Preventive
measures like stomatological examination before bisphosphonates treatment
and regular stomatological check-ups during bisphosphonates treatment must
be considered.
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A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION
WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH
RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
S Hagiwara1,*, S Okamoto2, K Matsue3, S Iida4, K Sunami5, T Komeno6,
K Suzuki7, K Ando8, M Taniwaki9, K Tobinai10, T Chou11, H Kaneko12, H Iwasaki13,
C Uemura14, H Tamakoshi14, MH Zaki15, T Doerr15, Y Kuroda16, T Ichinohe16
1National Center for Global Health and Medicine Hospital, 2Keio University
Hospital, Tokyo, 3Kameda General Hospital, Chiba, 4Nagoya City University
Hospital, Aichi, 5Okayama Medical Center, Okayama, 6Mito Medical Center,
Ibaraki, 7Japanese Red Cross Medical Center, Tokyo, 8Tokai University Hos-
pital, Kanagawa, 9University Hospital Kyoto Prefectural University of Medicine,
Kyoto, 10National Cancer Center Hospital, Tokyo, 11Niigata Cancer Center
Hospital, Niigata, 12Osaka Red Cross Hospital, Osaka, 13Kyushu University
Hospital, Fukuoka, 14Celgene KK, Tokyo, Japan, 15Celgene Corporation, Sum-
mit, NJ, United States, 16Hiroshima University Hospital, Hiroshima, Japan
Background: Pomalidomide in combination with low-dose dexamethasone
(POM + LoDEX) has shown efficacy in patients with relapsed and refractory
multiple myeloma (RRMM). In this patient population, POM + LoDEX prolonged
progression-free survival (PFS) compared with POM alone (Richardson et al,
Blood, 2014) and provided a PFS and overall survival (OS) benefit compared
with high-dose DEX alone (San Miguel et al, Lancet Oncol, 2013), while demon-
strating an acceptable safety profile. To evaluate the safety and efficacy of
POM + LoDEX in Asian patients with RRMM, an additional study enrolling only
Japanese patients was conducted.
Aims: This multicenter, single-arm, open-label phase 2 trial (MM-011) aimed
to evaluate the efficacy and safety of POM + LoDEX in Japanese patients with
RRMM.
Methods: Patients with progressive disease on or within 60 days of their last
prior therapy and who had received ≥2 prior therapies, including ≥2 cycles of
lenalidomide and of bortezomib (either separately or in combination) were
included. Patients received oral POM 4 mg per day on days 1-21 and oral
LoDEX 40 mg per day (20 mg if aged >75 years) on days 1, 8, 15, and 22, and
the course was repeated every 28 days until disease progression, unacceptable
toxicity, or withdrawal. The primary endpoint was overall response rate (ORR;
≥partial response) of POM + LoDEX according to the International Myeloma
Working Group criteria. All pts provided written informed consent.
Results: Thirty-six patients were enrolled between December 2013 and July
2014 at 13 sites in Japan. The median age of patients was 64.5 years (range,
43-78 years); 11% were aged >75 years. Patients received a median of 6.5
prior anti-myeloma regimens (range, 2-15) and had a high tumor burden (81%
had Durie-Salmon stage II or III disease). Thirty-five patients (97%) were refrac-
tory to lenalidomide, and 21 patients (58%) were refractory to both lenalidomide
and bortezomib. At the data cutoff (February 3, 2015), 16 patients (44%)
remained on treatment, and study drugs were discontinued in 20 patients due
to disease progression (n=14 [39%]), adverse event (AE; n=2 [6%]), death
(n=1 [3%]), and other reasons (n=3 [8%]). The ORR was 42% (n=15 [95% CI,
26% - 58%]), including complete response in 3% (n=1) and partial response in
39% (n=14) of patients. Median PFS was 10.1 months (median follow-up, 7.7
months), and at a data cutoff of September 25, 2015, 1-year OS was 58.5%
(median follow-up, 11.3 months). In the 15 responders, median time to
response was 1.9 months (range, 0.9-5.5 months), and median duration of
response was not reached. The most common grade 3/4 hematologic AEs
were neutropenia (n=23 [64%]), anemia (n=15 [42%]), and thrombocytopenia
(n=11 [31%]). Pneumonia (n=3 [8%]) and decreased appetite (n=3 [8%]) were
the most common grade 3/4 non-hematologic AEs. Peripheral neuropathy (all
grades) occurred in 8% (n=3) of patients. No deep vein thrombosis or pul-
monary embolism was reported. Overall, AEs were similar to those seen in
other POM studies, and no new significant AEs were reported in patients in
this study. Nine patients died on study (or within 28 days of the last dose of
study drug), 8 due to multiple myeloma and 1 due to AE (pneumonia and aggra-
vated asthma, suspected to be related to study drug).
Summary/Conclusions: POM + LoDEX is an effective treatment in heavily
pretreated Japanese patients with RRMM, with an acceptable safety profile
that is comparable to those seen on POM studies in RRMM in other regions.
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IMPACT OF ERYTHROPOIESIS STIMULATING AGENTS ON OVERALL
SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA
S Ortiz Zuluaga1,*, K Javier1, C Villegas1, MT Orero1, M Roig1, I Luna1,
M López1, R Collado2, D Ivars2, PL Pérez1
1Hematology, 2Hospital General Universitario de Valencia, Valencia, Spain
Background: Treatment with erythropoiesis stimulating agents (ESA) in onco-
logic patients remains controversial. Since 2007, the FDA has included the
addition of a black box label warning and the implementation of a risk man-
agement program for ESA prescription. Regarding treatment with ESA in
patients with multiple myeloma (MM), there are only three studies with discor-
dant results.
Aims: The purpose of our study is to explore the impact of ESA on overall sur-
vival in a cohort of MM patients treated in our center.
Methods: Between 2002 and 2015, 212 patients were diagnosed of MM in
our center. We excluded 55 patients: 23 patients with diagnosis of smoldering
myeloma and 32 patients candidates for palliative care because of age and
comorbidities. We collected demographic information, clinical and laboratory
data, staging according International Score System (ISS), regimens of treat-
ment, overall survival (OS) as well as information on erythropoietin use for all
patients.
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Results: One hundred and fifty five patients were included: 63 received recom-
binant human erythropoietin (rhEPO) at least 1 month. The median total dose
was 440000 international units (IU) (range 40000-10920000). Patient’s char-
acteristics according EPO therapy are presented in table. Patients treated with
rhEPO showed more advanced stages, higher creatinine levels and required
hemodialysis more frequently. Nevertheless autologous stem cell transplanta-
tion was performed more frequently in non-EPO patients. There was no differ-
ence in first line therapy between rhEPO and non-EPO patients. The median
OS in all patients was 31 months (CI95% 22.67-39.33) and we did not observe
differences between EPO and non-EPO groups (35 vs. 31 months, Log Rank
p=0.96). However, when looking at the influence of total EPO doses on out-
come, we observed differences in OS between patients who received doses of
EPO >400000 IU, vs. patients with lower doses or untreated (50 vs. 23 months,
Log Rank p=0.047). Multivariate analysis (Cox Regression) showed, age, albu-
min, Beta 2 microglobulin and rhEPO doses as independent prognostic factors
for OS.
Table 1.
*UMW: U-Mann-Whitney, **Fisher test, ***Chi-square test
Summary/Conclusions: The use of rhEPO does not have a negative effect in
MM patients. Our study suggests that treatment with high doses of rhEPO could
have a positive impact to improved OS. However, prospective randomized stud-
ies to confirm these data are required.
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FDG-PET/CT IN MULTIPLE MYELOMA A CORRELATION OF SUV AND ISS
SCORE
B Østergaard1,*, AL Nielsen2, O Gerke2, JR Mortensen1, JT Asmussen3,
TEJ Ormstrup4, P Holdgaard5, T Plesner6, A Alavi7, PF Høilund-Carlsen2,
N Abildgaard1
1Hematology, 2Nuclear Medicine, 3Radiology, Odense University Hospital,
Odense C, 4Nuclear Medicine, 5Radiology, 6Hematology, Vejle Hospital, Vejle,
Denmark, 7Nuclear Medicine, University of Pennsylvania, Pennsylvania, United
States
Background: FDG-PET/CT is a promising methodology for staging, prognos-
tication and response evaluation in multiple myeloma (MM). High intensity of
FDG uptake measured as SUV (standard uptake value) at diagnosis is asso-
ciated to more aggressive disease and reduced overall survival1,2 However, it
is unknown if the informative value is independent of other prognostic markers.
1) Bartel, T. B., et al. Blood 114.10 (2009): 2068-76. 2) Zamagni, E., et al. Blood
118.23 (2011): 5989-95.
Aims: We aimed to investigate the association of the intensity of FDG uptake
in the most intense focal lesions and established prognostic markers in MM,
including ISS and revised ISS (R-ISS).
Methods: As a part of a prospective study3 with evaluation of new imaging
technologies in MM we explored the first 35 included patients with treatment
demanding MM. Patients were enrolled at diagnosis and studied with standard-
ized baseline 18F-FDG-PET/CT prior to any given anti-myeloma treatment.
Patients that had received steroids or bisphosphonates were excluded. Two
experienced specialists, a nuclear medicine specialist (ANL) and a radiologist
(JTA) evaluated the PET/CT. The lesion with the highest FDG uptake was
described by a semi quantitative software ROVER for the values of lesion vol-
ume, SUVmax, SUVpeak, SUVmean and SUVmeancorr (SUVmean corrected
for partial volume effects). Finally SUVmax was standardized to liver according
to the Deauville criteria. Quantitative values were tested for correlation to prog-
nostic indices ISS and revised ISS (R-ISS) using Kruskall Wallis test and Fis-
chers exact test. STATA14 was used for analyses. 3) ClinicalTrials.cov. ID:
NCT02187731
Results: One patient had incomplete ISS data. Thus 34 patients were included
in the analysis. 19, 11 and 4 patients were stratified into ISS group I, II and III,
respectively. 9, 24 and 1 patient were stratified into the revised ISS group R-
ISS1, R-ISS2 and R-ISS3, respectively. SUVmax values were between
3.6Mbq/ml and 27.8Mbq/ml and lesion volumes between 0.9ml and 216ml. 6
patients had Deauville score 3, and 12 Deauville score 4, and 6 patients had
Deauville score 5. FDG uptake (SUVmax) standardized to liver showed corre-
lation to ISS (p=0.03) but not the R-ISS (p=0.85). Absolute SUVmax, SUVpeak,
SUVmean, SUVmeancorr were not correlated to neither ISS nor R-ISS (p val-
ues (0.3-0.8).
Summary/Conclusions: 34 newly diagnosed MM patients were tested for
association between FDG uptake values and the prognostic indices ISS and
R-ISS. Only a marginal significant association between FDG uptake standard-
ized to liver according to the Deauville criteria and ISS was observed. The use
of FDG uptake values standardized to liver compensate for the general meta-
bolic activity in the body and may therefore be more informative than absolute
SUV values. Our cohort does not show a strong association between FDG
SUV values and ISS or R-ISS, which may indicate that FDG PET offers prog-
nostic information independent of R-ISS. At the meeting we will present an
extended cohort. The association between FDG uptake values and prognostic
factors in MM warrants further studies.
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INFECTIONS IN MULTIPLE MYELOMA: AN UNDERSTIMATE RISK FACTOR
OF COMORBIDITY
G Barila*, N Compagno, A Liço, T Berno, F Cinetto, C Agostini, G Semenzato,
R Zambello
Dept of Medicine, Hematology and Clinical Immunology section, Padua Uni-
versity School of Medicine, Padua, Italy
Background: Multiple myeloma (MM) represents the second most common
haematological malignancy characterized by the proliferation of monoclonal
plasma cells in the bone marrow. The natural history of the disease may be
complicated by the occurrence of infections that can be related to the develop-
ment of neutropenia (mostly therapy related) and/or hypogammaglobulinemia.
Immunoglobulin (Ig) classes defect represents a major characteristic of this
disease both in the indolent phase (smouldering MM, sMM), where immuno-
paresis constitute a risk factor for progression to active Myeloma according to
the Spanish Group risk model, and in symptomatic Myeloma. Furthermore, this
deficit can be worsen by concomitant chemotherapy.
Aims: The aim of this study was to analyse the frequency, the type and the
major risks factors of severe infections in our cohort of patients affected by MM.
Methods: A cohort of 291 patients affected by MM (93 smouldering MM, 198
symptomatic MM) followed from 1996 to 2015 was retrospectively studied for
the presence of severe infections (infections requiring hospitalization) during
the natural history of the disease. Infections were distinguished in neutropenia
related infections and not neutropenia related infections according to Absolute
Neutrophil Count (ANC <1,000/μl or ANC>1,000/μl respectively). Durie-Salmon
(DS) and ISS staging system were used for MM patients staging.
Results: Seventy-three out of 291 patients developed severe infections during
the natural history of the disease (98 total events). The majority of these infec-
tions occurred in symptomatic MM patients (70 out of 73 patients with 93 out
of 98 infections); as a consequence, infections were significantly associated to
symptomatic MM (p<0.001, χ2=34.76). Among symptomatic patients, 40
patients (45 infections) developed infectious events at the time of the diagnosis
and/or during induction therapy, while the other 30 patients (48 infectious
events) received at least one prior therapy before the event. Interestingly, 26
events (28%) occurred in neutropenic patients while remnant 67 (72%) in not
neutropenic patients. Furthermore, almost all neutropenia related infections
were also therapy related (25/26, 96%), while almost 30% of neutropenia unre-
lated infections (20 out of 67) occurred in patients out of therapy. In particular,
infections represented Myeloma defining event in 11 patients (12% of total
infections, 16% of neutropenia unrelated infections). Thirty-nine of remnant 47
infectious events (83%) occurred in patients treated with novel agents with pre-
dominance of proteasome inhibitors based therapy with respect to IMIDs based
therapy (26 vs 11), with 2 events occurring during combination therapy. DS
stage III and ISS III were significant associated to severe infections (DS p<0,05,
χ2=5,5; ISS p<0,05, χ2=6,33); furthermore, DS stage III and ISS stage III were
statistically related to neutropenia unrelated infections (p<0,05, χ2=6,3), while
there was no significant relationship to neutropenia related infections.
Summary/Conclusions: Severe infections represent a significant comorbidity
in MM, in particular in symptomatic MM, while sMM patients are generally
saved. Most of these type of infections involve not neutropenic patients char-
acterized by high risk disease and developed during induction therapy. These
results allow to stratify and to identify those patients who may eventually benefit
from immunoglobulin supplementation.
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PREVALENCE OF OCULAR DISORDERS IN MULTIPLE MYELOMA
M Pennisi1,*, L Berchicci2, E Miserocchi2, V Cacioppo3, A David3, A Scialdone3,
L Crucitti1, I Lo Russo4, G Modorati2, V Montefusco4, P Corradini1,4
1Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano,
2Dipartimento di Oculistica, Istituto Scientifico San Raffaele, Università Vita e
Salute, 3Dipartimento di oftalmologia, Fatebenefratelli e oftalmico, 4Ematologia,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Background: Overall survival of multiple myeloma (MM) patients has increased
significantly due to the availability of new drugs. However, since MM is an incur-
able disease, patients are exposed to repeated lines of therapy with different
agents. It is therefore increasingly important to monitor the long-term side-effects
of treatments. In the present study we focused on ocular disorders.
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Aims: Assessing the prevalence of ocular disorders in patients treated or in
follow-up for MM.
Methods: 87 symptomatic MM patients were enrolled in a prospective protocol
which consisted in a complete ophtalmologic evaluation. Best corrected visual
acuity (BCVA) was assessed; lens opacities were classified according to the
LOCS III score; intraocular pressure was measured and was considered patho-
logical if >21 mmHg; Schirmer test was pathological if <15 mm. Binary logistic
regression analysis (univariate and multivariate) were conducted to relate ocu-
lar disorders to age, comorbidities (diabetes, hypertension, smoking, autoim-
munity) and MM variables (time from diagnosis to last treatment and to ocular
evaluation, cumulative dose of dexamethasone, exposure to lenalidomide,
thalidomide, bortezomib and melphalan, previous autologous or allogeneic
transplantation and graft-versus-host-disease).
Results: Median age was 63 years. Median number of previous lines of treate-
ment was 2 (range 1-10). Median time from diagnosis to ophtalmologic evalu-
ation was 37 months (range 2-160). Median cumulative dose of dexametha-
sone was 1600 mg (range 80-8480). Inadequate visual acuity was found in
35/71 pts (49%); severe visual loss (<20/40) was found in 13/71 pts (15%), 10
of which had pre-existing ocular history of lazy eye, myopia, pseudophakia,
vitrectomy, retinitis pigmentosa and trauma. No relation was found with cumu-
lative steroid dose, duration or type of treatment. Instead, age and history of
hypertension resulted to be independent risk factors for visual impairment, also
in multivariate analysis (age OR: 4.6 p=0.004; hypertension OR: 2.8 p=0.05).
Retinal disorders (11%) were related to age and hypertension in multivariate
analysis. Fifty percent of patients (44/87) had lens opacities of any grade:
cataract was observed in 6/87 pts (7%), and in all cases was posterior sub-
capsular cataract LOCS III >/= 2; moderate lens opacities were observed in
32% pts (28/87), while 23% showed nuclear or concomitant nuclear/cortical
opacities (LOCS III=2-3) and 9% posterior subcapsular opacities (LOCS III=1).
Lens opacities related with age >63 years (OR: 4.0 p=0.009) and time from
diagnosis >37 months (OR: 2.6 p=0.05) in multivariate analysis. No association
was found with cumulative steroid dose or other drugs exposure. Only 1 patient
showed elevated intraocular pressure. Inadequate tears production was
observed in 52% pts (45/87), but no statistically association with treatments or
comorbidities was observed.
Summary/Conclusions: Our study shows a high prevalence of visual impair-
ment and early lens opacities in MM patients. We observed a higher prevalence
of posterior subcapsular cataract compared to other cataract subtypes, unlike
in the healthy population, probably due to the chronic systemic steroids expo-
sure. A high prevalence of inadequate tear production was observed, as well.
Interestingly, no significant increase in intraocular pressure was noticed, pos-
sibly because of chronic but pulse administration of steroids. Patients with
hypertension show an increased risk of retinal disorders. We recommend an
adequate ophthalmologist follow-up in treated MM patients.
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BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGE-
MENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-
LIFE EXPERIENCE
C Cerchione1,*, L Catalano1, AE Pareto1, S Basile1, L Marano1, I Peluso1,
L Simeone1, O Vitagliano1, S Palmieri2, F Ferrara2, F Pane1
1Hematology, Ematologia e trapianto/au federico ii, 2Hematology, AORN A.Car-
darelli, Napoli, Italy
Background: Bendamustine is a bifunctional alkylating agent, with low toxicity,
proved to be effective in relapsed, refractory and in new diagnosed Multiple
Myeloma (MM).
Aims: It has been evaluated efficacy and tolerance of Bendamustine, in com-
bination with bortezomib-dexamethasone (BVD) in patients with relapsed and
refractory MM (rrMM), whose prognosis is particularly severe. A regional retro-
spective real-life analysis of patients with rrMM who had been treated with
BVD as salvage therapy has been performed.
Methods: 47 patients (25 M/22 F), with rrMM, median age at diagnosis 58.4
years (r. 36-82), median age at start of treatment 61.3 years (r.37-83) treated
with several lines of treatments (median 6, r. 2-11), every refractory to all the
drugs previously received (also Bortezomib), received BVD (Bendamustine 90
mg/sqm days 1,2; Bortezomib 1.3 mg/sqm days 1,4,8,11, Dexamethasone 20
mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progres-
sion. ISS was equally distributed, and cytogenetic was evaluable in 9 patients,
and in particular one del13q and one t(11;14). All the patients had previously
been treated with schedule containing bortezomib and IMIDs, 90% of them
with melphalan, 77% with cyclophosphamide, 34% with antracyclines and 30%
had also received radiotherapy. 58% of them had undergone at least to a single
auSCT. All patients were relapsed and refractory to last therapies received
before BVD.
Results: Bendamustine was well tolerated, with grade 3 transfusion-dependent
anemia in 29% of patients, and 41% grade 3 neutropenia (no ospedalization
was required, no septic shocks were observed). No severe extrahematologic
toxicity was observed, only grade 1 gastrointestinal side effect (nausea), treated
by common antiemetic drugs. According to IMWG, after a median follow-up of
9 months (r.2-36), ORR was 57% (27/47: 2 CR, 3 VGPR, 14 PR, 8 MR) with 8
PD and 12 patients in SD, which can be considered as an impressive result in
this subset of rrMM patients. In particular, for 6 patients, BVD was, after having
achieved a PR, a bridge to second auSCT, and for one patient a bridge to
auSCT. Median time to response was 1.3 months (r.1-3), median OS from diag-
nosis was 61.4 months (range 6-151), median OS from start of Bendamustine
was 9.3 months (range 2-36).
Summary/Conclusions: BVD has shown significant efficacy in a particular
severe setting of patients, relapsed and refractory to all avaiable therapeutic
resources, and in particular cases it could be considered as a bridge to a sec-
ond autologous or allogenic BMT.
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SECOND MALIGNANCIES AND MULTIPLE MYELOMA. A SINGLE-INSTITU-
TION EXPERIENCE IN SPAIN
S Cerdá*, B Ballina, V Martínez-Robles, N De Las Heras, Ja Rodriguez-Garcia,
F Escalante
Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: Outcome of patients with Multiple Myeloma (MM) has improved
significantly in the past decade. Therefore, the risk of developing second malig-
nancies (SM) has become a relevant aspect to explore. Although the associa-
tion of several treatments employed in this disease, such as alkylators, lenalido-
mide or radiotherapy and second malignancies is well known in the literature,
subsequent neoplasms may also reflect the effect of other etiologic factors,
host characteristics or environmental exposures. In previously reported series,
MM patients with SM have consistently showed poorer prognosis.
Aims: Retrospective analysis of a cohort with a consistentof more than 15
years follow-up period.
Methods: We retrospectively analysed the incidence of SM in 296 consecutive
patients with MM diagnosis in our institution between 1998 and 2014, focusing
on epidemiological aspects as well as on survival analysis. Characteristics of
patients: n=296. Gender: male/female: 172/124. Median age at MM diagnosis:
72 years (39-100).
Results: 44 different cancers in 43 patients (15%) were observed. They were
mostly male (69.8%) vs female (30.2%) The median age at diagnosis was 73
years (46-94). Different neoplasms were separated in those appearing before
or synchronously (n=27; 61%) vs after the MM diagnosis (n=17; 39%) with a
mean developing time to the second malignancy of 67 (0-273) and 42 months
(2-161) respectively. The majority presented solid tumors (n=39; 88.6%) in con-
trast to hematologic neoplasms (n=5; 11.4%). The largest group showed
prostate (n=9), gynecologic (n=7), colorectal (n=6) and genitourinary (n=6) as
more frequent types of cancer. Myelodysplastic Syndrome (MDS) represented
80% of patients with hematologic processes and typically appeared after the
MM diagnosis. No acute leukemia was found in our series. The cumulative
incidence of second cancers was 2.6% at 2 years, 10.4% at 5 years and 18.6%
at 10 years. No differences were found in overall survival between MM patients
with or without an associated second malignancy (p=0.23).
Summary/Conclusions: SM are a growing problem in cancer patients due to
their larger survival.  From our data, previous and solid neoplasms are most
frequent than subsequent and hematologic neoplasms in MM patients. Further
studies are necessary to assess the risk and etiology of SM in MM, although
they seem not to represent a poorer outcome in terms of survival.
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A PHASE 2 TRIAL OF SMALL-DOSE BORTEZOMIB, LENALIDOMIDE, AND
DEXAMETHASONE (SVRD) AS CONSOLIDATION/MAINTENANCE
THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
T Sato1, H Kuroda2, Y Nagamachi3, S Iyama1, A Fujimi4, Y Kamihara1, Y Konu-
ma5, M Yoshida1, S Ibata1, A Tatekoshi1, A Hashimoto1, H Horiguchi1, K Ono1,
K Murase1, K Takada1, K Miyanishi1, M Kobune1, Y Hirayama6, J Kato1,*
1Department of Clinical Oncology and Hematology, Sapporo Medical University,
School of Medicine, Sapporo, 2Gastroenterology and Hematology/Clinical
Oncology, Steel Memorial Muroran Hospital, Muroran, 3Department of Hema-
tology, Kiyota Hospital, Sapporo, 4Department of Hematology and Oncology,
Oji General Hospital, Tomakomai, 5Department of Hematology and Oncology,
Asahikawa Red Cross Hospital, Asahikawa, 6Division of Internal Medicine,
Higashi Sapporo Hospital, Sapporo, Japan
Background: Consolidation (two to four cycles of combination therapies) and
maintenance (continuous therapy, usually with single agents, until the time of
disease progression) are commonly used in clinical practice after induction
therapy for patients with multiple myeloma (MM). There have been many trials
to support the use of consolidation/maintenance to maintain the response
achieved after autologous hematopoietic stem cell transplantation or conven-
tional treatments and to improve patient survival with single agent or combina-
tion therapy. However, no definitive information is available regarding which
drug or which combination of drugs is the most favorable for consolidation/main-
tenance. The combination therapy with bortezomib, lenalidomide and dexam-
ethasone (VRD) is a powerful regimen for relapsed/refractory as well as newly
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diagnosed MM as an induction therapy. However, severe adverse events (AEs)
may become a problem when VRD is introduced without dose-reduction as a
consolidation/maintenance therapy.
Aims: The aim of this multicenter, open-label, single-arm, phase 2 study was to
determine the efficacy and safety of reduced-dose VRD regimen (small VRD:
sVRD) in Japanese patients with MM in the consolidation/maintenance setting.
Methods: Eligible patients were age ≥20 and ≤80 years, with measurable symp-
tomatic MM. Patients must have received at least 1 prior regimen and achieved
at least a partial response (PR) by the International Myeloma Working Group
(IMWG) Uniform Response Criteria. Patients received subcutaneous borte-
zomib (1.3 mg/m2 on days 1 and 15), oral lenalidomide (10 mg on days 1-21)
and oral dexamethasone (40 mg on days 1, 8, 15 and 22). The course was
repeated every 4 weeks for 6 cycles. Patients with at least a PR at the end of
cycle 6 could continue sVRD treatment. Patients discontinued therapy if they
experienced progressive disease (PD) or unacceptable toxicity, if no more addi-
tional benefits could be expected, or if the patient/investigator decided to dis-
continue therapy for any reason.
Results: Sixteen patients were enrolled. All patients could complete 6 courses
of sVRD treatment. The median duration of sVRD treatment was 8.0 courses
(range, 6-28 courses), with 56.3% (n=9) and 25.0% (n=4) undergoing >6 and
>12 cycles, respectively. The reasons for treatment discontinuation were com-
pletion of 6 courses (n=7, 43.8%), disease progression (n=3, 18.8%), secondary
primary malignancies (SPM) of acute lymphoblastic leukemia (ALL) (n=1,
6.3%), AE of grade 2 pneumonia (n=1, 6.3%), or other (patient refusal or physi-
cian preference) (n=4, 25.0%). The overall response rate and the complete
response (CR) rate were 100% and 43.8%, respectively. In particular, one
patient with CR and two patients with very good PR (VGPR) at enrollment
achieved stringent CR (sCR) during 6 courses of sVRD. In 9 patients with PR
at enrollment, 1 achieved VGPR, but 8 remained in PR. Nevertheless, 2 out of
8 patients with PR after 6 courses of sVRD finally achieved VGPR or sCR after
a total of 18 or 24 courses of sVRD, respectively. With a median follow-up time
of 29.4 months, the median progression-free survival (PFS) and overall survival
(OS) were not reached, while the PFS and OS rates at 2.5 years were 66.6%
and 77.3%, respectively. Three patients died and their cause of death was dis-
ease progression in all cases. It is noteworthy that the three patients who dis-
continued sVRD treatment due to PD were the same three patients who died
in spite of various post-study therapies. Univariate analysis demonstrated that
disease progression as a reason for discontinuation of sVRD had a negative
impact on OS. One dose modification of dexamethasone from 40 mg/day to 20
mg/day was required because of grade 2 hypertension after the 3rd course of
sVRD. One patient had discontinued all study drugs because of grade 2 pneu-
monia after 6 courses of sVRD. There were no grade 3 or 4 hematologic or
nonhematologic AEs. After enrollment, 2 new hematologic malignancies, i.e.,
ALL in one patient and myelodysplastic syndrome (MDS) in another patient,
were diagnosed.
Figure 1.
Summary/Conclusions: Our sVRD regimen as a consolidation/maintenance
therapy was well-tolerable and highly effective in patients with MM who
achieved at least PR after any induction therapy. We conclude that the dosage
of bortezomib and lenalidomide in our sVRD regimen may be able to reduce
AEs and have preserved efficacy simultaneously in the consolidation/mainte-
nance setting.
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BONE MARROW RETICULIN FIBROSIS AS A PROGNOSTIC MARKER IN
NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN THE
ERA OF NOVEL AGENTS
C Suriu1,2,*, M Livne2, V Sonkin1, L Akria1,2, M Barhoum1, A Braester1,2
1Galilee Medical Center, Naharia, 2Faculty of Medicine in Galilee, Bar-Ilan Uni-
versity, Safed, Israel
Background: Different prognostic strategies are used in order to stratify newly
diagnosed multiple myeloma (MM) patients at the time of diagnosis. The survival
of MM patients has improved significantly in the last decade, attributed espe-
cially to the use of novel therapeutic agents (immunomodulatory drugs and
proteosome inhibitors). Bone marrow (BM) biopsies from patients with MM at
diagnosis may show different degrees of reticulin fibrosis, but its clinical signif-
icance is unclear.
Aims: To evaluate the prognostic impact of the BM reticulin fibrosis in our cohort
of patients, treated in the era of novel agents.
Methods: We retrospectively reviewed the medical records of 51 patients treat-
ed between 2006 and 2014 at Galilee Medical Center, Nahariya, Israel. BM
biopsies were graded for reticulin fibrosis (grades 0-3) based on the the Euro-
pean consensus report. Overall survival (OS) was measured from the time of
diagnosis to the date of death or last follow-up. Progression free survial (PFS)
was measured from the time of diagnosis to the date of progression or death.
Univariate and multivariate survival analysis was performed using Cox Regres-
sion Model and Kaplan-Meier method with Log Rank (Mantel-Cox) test.
Results: 51 newly diagnosed MM patients were evaluated. The median age
was 69 years (range: 47-88 years); 29 (56.9%) patients were male. The para-
protein type was: 28 (55%) IgG, 12 (23.5%) Light Chain and 9 (17.6%) IgA; 12
(24.5%) patients were ISS I, 12 (24.5%) were ISS II, 25 (51%) were ISS III. 31
(64.6%) patients were treated with chemotherapy, 12 (25%) were treated with
chemotherapy followed by ASCT and 5 (10.4%) patients had conservative ther-
apy. 41 patients (80.4%) were treated with novel agents at diagnosis. The medi-
an follow-up for the entire cohort after the diagnosis was 30.3 months (range
0.2-112.7 months). At the time of writing, 30 (58.8%) patients were living. For
the statistic analysis we separated the patients into two groups: low grade fibro-
sis (grade 0-1) versus high grade fibrosis (grade 2-3). BM fibrosis characteristics
did not differ significantly among patients with respect to age, sex, paraprotein
type and albumin level. Patients with higher grade of fibrosis were more likely
to have lower hemoglobin level (p=0.009), higher creatinine (p=0.007) and cal-
cium level (p=0.008) with ISS III (p=0.002). Univariate analysis of overall sur-
vival (OS) showed that only age <65 (p=0.001), and treatment with novel agents
(p=0.004) were significantly associated with better survival. Lower degree of
fibrosis showed a tendency, not statistically significant for better survival: 72
mo vs 40 mo (p=0.14). On univariate analysis of PFS only lower grade of fibrosis
was significantly associated with better survival (p=0.024) and a tendency for
longer PFS with lower grade of fibrosis was seen in multivariate analysis of
PFS (p=0.064). In subgroup analysis for patients treated with novel agents
lower degree of fibrosis was still statistically significant for PFS (p=0.02).
Summary/Conclusions: In our cohort of patients, the degree of fibrosis was
statistically significant for survival of MM patients, especially for PFS. This sur-
vival benefit is seen also in patients treated with novel agents. These results
confirm that examination of the grade of fibrosis of the bone marrow at time of
diagnosis of MM patients can provide better prognostic significance. These
results should be validated in other cohorts.
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LEPTOMENINGEAL MYELOMATOSIS-A RARE COMPLICATION IN
MULTIPLE MYELOMA
M Bommer1,*, J Krönke2, M Kull2, D Bunjes2, P Schwarzwälder2, V Teleanu2,
C Langer2
1Hematology, Oncology and Infectious diseases, Alb-Fils Kliniken Göppingen,
Göppingen, 2Hematology, Oncology, Rheumatology and Infectious diseases,
University of Ulm, Ulm, Germany
Background: Involvement of the central nervous (CNS) system in patients with
Multiple Myeloma (MM) is a rare event, occuring mostly during late stage of dis-
ease. However, there are reports about an increasing incidence of extramedullary
myeloma manifestations since the introduction of so called novel agents.
Aims: We therefore tried to optimize the diagnostic workup in patients with
suspected neoplastic meningitis of Multiple Myeloma - so called leptomenigeal
myelomatosis (LMM)-by incorporating different techniques.
Methods: Between 04/2005 and 10/2013 we identified 15 cases with CNS-
MM. The involvement was confirmed by magnetic resonance imaging (MRI),
cerebrospinal fluid cytology as well as by flow cytometry. Additionally, cIg-FISH
and DNA probes mapping to chromosome bands 1q21.2, 9q34, 13q14, 14q32,
17p13, and 22q11 were applied to 4 of the 15 cases. In one case, high-resolu-
tion genome-wide screening for genetic alterations using SNP-array analysis
(Affymetrix Microarray Human Genome SNP 6.0) was performed on the CNS
involvement as well as on the corresponding bone marrow (BM) aspirate.
Results: The median time from initial diagnosis until the occurrence of LMM
was 463 days. Only two patients presented with CNS manifestation within 180
days after initial diagnosis. Seven patients were diagnosed at late stage of dis-
ease e.g. after high dose melphalan treatment. At diagnosis of LMM, the median
age was 59 years. The median cell count in the cerebrospinal fluid was 21/µl
(Range 1/µl -1333/µl). All CSF samples showed malignant pleocytosis, con-
firmed by flow cytometry in 12/15 patients. CIg-FISH presented cytogenetically
defined high risk features in all samples tested: 3 of 4 patients showed a translo-
cation t(4;14), one patient had a 17p13 deletion. Using high-resolution genome-
wide screening assays revealed different subclones at the two clinical sites
(CSF, BM). Treatment for LMM consisted of intrathecal chemotherapy (9 of 15
cases) and radiation therapy (7 of 15 cases). Despite treatment, the outcome
of patients with confirmed LMM was dismal with a median overall survival after
diagnosis of LMM of 69 days. Only one patient survived longer than 2 years
after diagnosis of CNS involvement.
Summary/Conclusions: By combining several technical procedures (MRI,
cytology, flow cytometry, cIg-FISH and SNP-array analysis) it is possible to
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identify the vast majority of patients with LMM. However, management of affect-
ed patients remains challenging and the survival is generally short after diag-
nosis of LMM.
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A PHARMACOKINETICS CLINICAL STUDY OF BORTEZOMIB SUBCUTA-
NEOUS INJECTION VERSUS INTRAVENOUS INJECTION COMBINED
WITH CHEMOTHERAPY IN CHINESE PATIENTS WITH NEWLY DIAG-
NOSED MULTIPLE MYELOMA-INTERIM RESULTS
C Fu1,*, D Wu1,xZhu1, S Jin1, L Yan1, S Yan1, P Wang1, Y Ge2, M Chang2
1Hematology, 2First Affiliated Hospital of Soochow University, Suzhou, China
Background: Bortezomib was licensed for administration as a bolus i.v. injec-
tion. This route of administration has demonstrated efficacy and safety in pre-
viously untreated patients with multiple myeloma (MM). However, the i.v. route
can be a potential barrier to treatment for patients with poor venous access
and limits prescribing flexibility. Subcutaneous (SC) administration of borte-
zomib showed the advantage in safety and comparable efficacy compared with
IV administration. 
Aims: However, there is no PK data of bortezomib SC administration for Chi-
nese patients. Our trial was to investigate the pharmacokinetics of the two
routes of administration in Chinese population. Demographic and baseline
characteristic, pharmacokinetics and safety data till the first VD treatment com-
pletion were reported here. (ClinicalTrial.gov Identifier: NCT01812096)
Methods: This was a randomized, single-center, open-label study. The study
included the following 4 sections: screening, VD regimen therapy (blood sam-
ples collection for PK analysis), extended treatment period (PAD regimen
and/or subsequent ASCT) and follow-up period. 20 patients were determined
to be randomly assigned in a 1:1 ratio to receive bortezomib subcutaneous or
intravenous administration combined with chemotherapy. SC or IV bortezomib
was administered at 1.3mg/m2, d1, 4, 8, 11, combined with dexamethasone
(10 mg, bid, i.v., d1~2, 4~5, 8~9, 11~12) in the 1st cycle, every 21days, following
2-4th cycles of PAD regimen, bortezomib was SC or IV administered at
1.3mg/m2 on d1, 4, 8, 11; Doxorubicin 40 mg/m2, i.v.d1; Dexamethasone (Dex)
10 mg, bid, i.v., d1~2, 4~5, 8~9, 11~12;.every 28 days. Patients who were eli-
gible for transplant underwent ASCT after the 4th cycle. Patients who were not
eligible for transplant continued the 5-6th cycle treatment of PAD regimen. The
blood samples for pharmacokinetics analysis were collected at the 15 time
points d1, 11-14 of the first VD treatment. Patients had maximum 6 months fol-
low-up after completing or terminating the treatment.
Results: From September 2014 to June 2015, 21 patients (10 patients in SC
group and 11 in IV group) were enrolled in our study. 18 patients (10 in SC
group and 8 in IV group) enrolled in the pharmacokinetic analysis. Median age
in SC group was 56.8 yrs and 57.5 yrs in IV group. 81.82% patients had IgG
isotype in the IV group and 40.00% patients had IgA isotype in the SC group.
A Higher proportion patient had light chain isotype (20.00%) in the SC group.
The median accumulative dose of bortezomib in VD treatment was much the
same in each group. Mean maximum plasma concentration (Cmax) was
46.56ng/ml in SC group and 182.45ng/ml in IV group. Median time to Cmax
(Tmax) was longer in SC group (0.25 h) than in IV group (0.03h). Mean borte-
zomib systemic exposure (AUClast) was similar between SC injection and IV
administration (234.83vs266.75). Inter-patient variability in Cmax (percent coef-
ficient of variations) was 24.76 in SC group and 30.79 in IV group. Treatment
related TEAEs were reported in 7 of 10 patients (70%) in SC group and 9 of
11(81.82%) in IV group. Treatment related Grade≥3 TEAEs were reported in 2
of 10 patients (20%) in SC group and 3 of 11 patients (27.27%) in IV group.
TEAE leading to drug discontinuation was only reported in 1 of 11 patients
(9.09%) in IV group. No Serious TEAE was reported in either group. The inci-
dence of neutropenia was higher in IV group.
Summary/Conclusions: In conclusion, our interim data suggest that SC
administration is a promising alternative to IV administration. The efficacy and
safety information will be further presented in the final results.
Acknowledgments: This study was funded by Xi’an Janssen Pharmaceutical
Co, Ltd.
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CHEMOTHERAPY ADHERENCE IS FAVORABLE PROGNOSTIC FACTOR
FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA WHO TREATED
WITH FRONTLINE BORTEZOMIB CONTAINING REGIMEN
JH Moon1,*, JY Kim1, YJ Lee1, SK Sohn1, HS Lee2, YS Kim2, WS Lee3
1Hematology/Oncology, Kyungpook National University Hospital, Deagu,
2Hematology/Oncology, Kosin University Gospel Hospital, 3Hematology/Oncol-
ogy, Inje University Pusan Baik Hospital, Pusan, Korea, Republic Of
Background: Elderly patients with multiple myeloma (MM) are vulnerable to
adverse events and the patients’ treatment goal may be different from young
patients. For elderly patients with MM, the toxicity of bortezomib (BTZ)-based
regimen causes frequent dose reduction and interruption of BTZ which could
result in poor outcomes.
Aims: This study evaluated the adherence to chemotherapy and treatment
outcomes for elderly patients who treated with frontline BTZ containing regimen
and non-BTZ containing regimens.
Methods: This study retrospectively analyzed the outcomes of 146 elderly
patients (≥65 years) with MM diagnosed from 2007 Mar to 2015 Mar. To eval-
uate the regimen adherence, the patients who treated with more than 4 cycles
were regarded as favorable adherence group and the others as unfavorable
adherence group. The effects of toxicity on the adherence to frontline regimen
and long term outcomes were also evaluated in the current study.
Results: Among 146 patients, frontline therapy was VMP in 77 patients
(52.7%), MP in 50 (34.2%) and CTD in 19 (13.0%). Median age at diagnosis
was 70 years (range 65-90 years) and 85 patients (58.2%) were over 70 years
old. ECOG performance status showed 2-4 in 49 patients (33.6%). ISS risk
groups were stage I in 14 patients (9.6%), II in 64 (43.8%), and III in 68 (46.6%).
Median cycles of frontline regimens were 5 cycles (range 1-9 cycles) with VMP
and 6 cycles (range 1-77 cycles) with non-BTZ containing regimens (p=0.032).
Maximal treatment response was ≥VGPR in 40 patients (51.9%) and 13
(18.8%) in VMP regimen and non-BTZ regimens, respectively (p<0.001). Reg-
imen adherence was favorable in 49 patients (63.6%) and 52 (75.4%) in front-
line VMP regimen and non-BTZ regimens, respectively (p=0.126). Major cause
of non-adherence was side effects in VMP, while poor response and regimen
change were major causes of non-adherence in non-BTZ regimens. Despite
poor response to frontline chemotherapy in non-BTZ regimens, 3-year overall
survival (OS) rate was not significantly different compared to frontline VMP
regimen: 65.3±8.2% and 47.9±7.8% in VMP and non-BTZ regimens (p=0.159)
because all the patients who showed poor response to frontline therapy
received second-line BTZ containing regimens. However, among the patients
with frontline VMP regimen, those with good adherence to chemotherapy result-
ed in better 3-year OS rate than those with poor adherence: 72.4±9.7% and
52.6±13.2% (p=0.002). In the multivariate analysis, ECOG performance status
2-4 (HR 3.409, 95% CI 1.133-10.261, p=0.029) and non-adherence to
chemotherapy (HR 4.896, 95% CI 1.617-14.829, p=0.005) were poor prognos-
tic factors for OS.
Summary/Conclusions: Frontline BTZ-containing regimen showed higher
response rate than non-BTZ regimens and good adherence was associated
with favorable long-term outcomes. However, regimen adherence was com-
promized for high incidence of adverse effects with BTZ-contaiing regimen.
Therefore, understanding the risk of toxicities and adequate management of
side effects needed to have favorable outcomes for the patients with BTZ con-
taining regimen.
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PROGNOSTIC SIGNIFICANCE OF EXPRESSION OF MULTIDRUG RESIST-
ANCE GENES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE
MYELOMA TREATED WITH BORTEZOMIB-CONTEINING THERAPHY
Y Chernykh*, A Golenkov, L Vysotskaya, K Belousov
Clinical haematology, Moscow Regional Research and Clinical Institute,
Moscow, Russian Federation
Background: Most drugs used to treat multiple myeloma, are substrates for
protein multi-drug resistance. Their effectiveness is reduced in cells with
increased expression of genes encoding these proteins. The proteasome
inhibitor bortezomib is not a substrate for protein P-gp, encoded by MDR 1
gene.
Aims: The aim of our study was to examine the prognostic significance of the
alternative (non-P-gp dependent) mechanisms of multidrug resistance (MDR)
in the bone marrow aspirate in patients with newly diagnosed multiple myeloma
(MM).
Methods: The study included 15 patients (6 men and 9 women) with estab-
lished diagnosis of multiple myeloma stage III by DurieSalmon system. The
age of patients ranged from 50 to 78 years. The mRNA expression of MDR
genes, 1 MRP, BCRP, LRP was determined by semi-quantitative RT-PCR in
mononuclear fraction of the bone marrow aspirate. Numeric value correspon-
ding to the amount of mRNA expression of each studied gene, represented as
the ratio of the numerical values of the mRNA expression of each gene to a
numeric value of mRNA expression of the gene GAPDH. All patients subse-
quently received treatment with bortezomib-containing chemotherapy schemes
in the amount of 6 courses.
Results: Although the patients had not received cytostatic therapy, detected
mRNA expression of all studied genes MDR. The average number of MDR gene
transcripts was 1.7±0,24, MRP 1 1±0,14, BCPR 1,04±0,22, LRP 1,47±0,17
points. Because previous studies have shown that the proteasome inhibitor
bortezomib is a basic drug for the treatment of MM is not a substrate of P-gp,
the analysis of survival in subgroups of patients with the number of LRP gene
transcripts above and below the mean. Overall survival of patients with increased
expression of the gene was significantly worse than that of whom with reduced
expression of LRP (17,1±3,65 vs 53, 9±10 months, P˂0.005).
Summary/Conclusions: Increased expression of LRP gene exert a poor sur-
vival of patients with multiple myeloma for cytostatic treatment, the bortezomib
containing chemotherapy programs.
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THE STRATUS TRIAL (MM-010): ANALYSIS OF THE ITALIAN SUBGROUP
OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
TREATED WITH POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE
M Cavo1,*, P Corradini2, F Di Raimondo3, A Vacca4, M Petrini5, AM Cafro6,
T Caravita di Toritto7, M Offidani8, G Semenzato9, R Zambello10, A Lazzaro11,
F Patriarca12, MT Petrucci13, F Rodeghiero14, M Simcock15, A Slaughter15,
J Herring16, T Peluso15, A Palumbo17
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Bologna, 2IRCCS Istituto Nazionale Tumori University of Milan, Milan, 3Depart-
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Chiara Hospital University of Pisa, Pisa, 6Niguarda Ca’ Granda Hospital, Milan,
7Division of Hematology, S.Eugenio Hospital, Rome, 8Clinica di Ematologia,
AOU Ospedali Riuniti di Ancona, Ancona, 9Venetian Institute of Molecular Med-
icine, 10Department of Medicine, University of Padua, Padua, 11Hematology
Unit and Bone Marrow Transplant Centre, Hospital of Piacenza, Piacenza,
12Hematology DISM, University of Udine, Udine, 13Hematology Department,
Department of Cellular Biotechnologies and Hematology, Sapienza University,
Rome, 14San Bortolo Hospital, Vincenza, Italy, 15Celgene International Sàrl,
Boudry, Switzerland, 16Celgene Corporation, Summit, NJ, United States, 17Uni-
versity of Torino, Torino, Italy
Background: There are few treatment (Tx) options and overall survival (OS)
is short for patient (pts) with relapsed/refractory multiple myeloma (RRMM)
who have failed or progressed on Tx with agents such as lenalidomide (LEN)
and bortezomib (BORT) (Kumar et al, Leukemia, 2012). Pomalidomide (POM),
a distinct immunomodulatory agent with tumoricidal and immunoregulatory
effects, plus low-dose dexamethasone (LoDEX) is approved in the United
States and European Union (EU) for the Tx of pts with RRMM who have had
≥2 prior Tx, including LEN and a proteasome inhibitor (BORT in the EU). Tx
with POM + LoDEX has shown statistically greater survival benefits than Tx
with high-dose DEX (San Miguel et al, Lancet Oncol, 2013) or POM alone
(Richardson et al, Blood, 2014). POM + LoDEX has also demonstrated high
overall response rates (ORRs) in pts with RRMM in the STRATUS trial (MM-
010), a single-arm, open-label phase 3b study being conducted in 19 countries
across Europe, with Italian pts constituting the largest national subset
(Dimopoulos et al, EHA 2015).
Aims: To examine the efficacy and safety of POM + LoDEX in the Italian pop-
ulation of the STRATUS trial.
Methods: Pts with RRMM (progressive disease [PD] on or within 60 days of
last prior Tx) who had experienced Tx failure with BORT and LEN, had received
adequate prior alkylator therapy, and provided informed consent were eligible.
Pts received POM 4 mg on days 1-21 of a 28-day cycle in combination with
DEX 40 mg (20 mg for pts aged >75 yrs) on days 1, 8, 15, and 22. Thrombo-
prophylaxis was required for all pts. Pts were treated until PD or unacceptable
toxicity. Primary endpoint was safety.
Results: In the 219 pts enrolled in Italy, median age was 67 yrs (range, 42-84
yrs), 55% were male, and 37% of pts were International Staging System stage
III. The median time since diagnosis was 5.5 yrs. Patients were heavily pre-
treated, with a median of 4 prior anti-myeloma regimens (range, 2-11), and
most pts were refractory to LEN (95%), BORT (82%), or both LEN and BORT
(78%). As of May 4, 2015, 2 pts (1%) were not treated, 54 pts (25%) were still
on Tx, and 163 pts (74%) had discontinued. The most common reasons for
discontinuation were disease progression (50%), death (10%), and adverse
events (AEs; 5%). After a median follow-up of 11.3 mos, in the intention-to-
treat population, the ORR was 37.9% (range, 31.4% - 44.7%), the median dura-
tion of response was 6.8 mos (95% CI, 4.9-10.8 mos), median progression-
free survival (PFS) was 5.2 mos (95% CI, 4.4-6.4 mos), and median OS was
12.0 mos (95% CI, 10.6-15.2 mos). The most frequent grade 3/4 treatment-
emergent AEs were neutropenia (56.7%), anemia (25.8%), thrombocytopenia
(23.5%), and pneumonia (12.4%). Grade 3/4 venous thromboembolism (deep
vein thrombosis and pulmonary embolism) and peripheral neuropathy was infre-
quent (2.3% and 0%, respectively). AEs led to dose reductions or interruptions
of POM in 23.0% and 71.0% of pts, respectively, and the median relative dose
intensity for POM was 0.90.
Summary/Conclusions: POM + LoDEX was active in this study subgroup,
which was representative of the heavily pretreated MM-010 population. Efficacy
outcomes, including PFS and OS, were consistent with those seen in previous
trials. POM + LoDEX treatment was well tolerated, and no new safety signals
were observed. AEs were appropriately managed, and discontinuations due to
AEs were infrequent. This study confirms that POM + LoDEX is effective in
patients with advanced RRMM, including those who have experienced failure
of prior Tx with BORT and/or LEN.
PB1982
RISK OF HYPERTENSION (HTN) AND MALIGNANT HYPERTENSION
(MHTN) IN PATIENTS TREATED FOR MULTIPLE MYELOMA (MM)
K Mezzi1, A Chari2,*, S Aggarwal1, S Zhu1, W Werther1, D Felici3, A Lyon4
1Amgen Inc., South San Francisco, 2Mount Sinai Hospital Ruttenberg Treat-
ment Center, New York, 3Onyx Pharmaceuticals, Inc., an Amgen subsidiary,
South San Francisco, United States, 4NIHR Cardiovascular Biomedical
Research Unit, Royal Brompton Hospital and Imperial College London, London,
United Kingdom
Background: HTN is commonly reported in patients (Pts) with MM and may
be associated with older age, disease-related complications, or sequelae of
MM treatments.
Aims: To evaluate incidence rates (IR) of HTN and mHTN in treated MM Pts
in the United States and the risk of mHTN development in MM Pts with pre-
existing HTN.
Methods: Newly-treated adult MM Pts were identified from Truven MarketScan
claims database from 1/1/05 to 3/31/14 using ICD-9 codes to identify disease
state, HTN, mHTN, and comorbidities. Inclusion criteria were new diagnosis of
MM with start of MM treatment, ≥12 months continuous enrollment (CE) prior
to diagnosis, prescription drug coverage, and ≥30 days of CE following initial
diagnosis. Non-MM Pts were matched on age (within+/-5 yrs), gender, and dis-
tribution of index dates to MM Pts. Risk of HTN and mHTN based on existing
HTN and other cardiovascular (CV) comorbidities were evaluated over time.
Results: Study included 7895 MM Pts (38% with HTN history) and 23685 non-
MM patients (24% HTN history). The IR of HTN in MM and non-MM Pts was
260 and 178 per 1000 person-years (PYRs), respectively. The IR of mHTN in
Pts with and without HTN history were 10.25 and 3.29 per 1000 PYRs, respec-
tively for MM patients; 4.25 and 1.88 per 1000 PYRs, respectively for non-MM
Pts. Risk of HTN (HR: 1.30; 95% CI: 1.22, 1.37) increased 30% in MM vs non-
MM Pts. MM Pts with (HR: 1.90; 95% CI: 1.26, 2.87) or without (HR: 1.54; 95%
CI: 1.04, 2.28) HTN history had a higher risk of mHTN events during the obser-
vation period vs non-MM Pts. In MM Pts with HTN history, the risk of mHTN
was significantly increased with the following comorbid conditions: cardiomy-
opathy (HR: 2.79; 95% CI: 1.20, 6.48), renal failure (HR: 2.13; 95% CI: 1.36,
3.34), and diabetes mellitus (HR: 1.59; 95% CI: 1.05, 2.39).
Summary/Conclusions: This study confirms that incidence of HTN and mHTN
is higher in newly-treated MM Pts vs non-MM Pts. Existing HTN is a risk factor
for MM Pts developing mHTN. Management of CV risk factors and comorbidities
in MM Pts is important based on the increased risk of HTN and mHTN among
these Pts.
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DIARRHEA INCIDENCE IN MULTIPLE MYELOMA PATIENTS TREATED
WITH LENALIDOMIDE AND POMALIDOMIDE
M Capecchi*, P Corradini, V Montefusco
Ematologia Trapianto di Midollo Osseo, Istituto Nazionale dei Tumori, Milano,
Italy
Background: Daily clinical practice in hematology is increasingly relying on
novel biological drugs, with new toxicity profiles that hematologists should learn
to manage. Immunomodulatory drugs (IMiDs) have a pivotal role in the treat-
ment of multiple myeloma (MM), and are typically administered as a continuous
treatment. Thalidomide is a well know constipation-inducing agent. On the con-
trary, physicians are aware that lenalidomide (Len) may induce gastrointestinal
(GI) disorders, in particular diarrhea, but little is known of this side effect. More-
over, no specific data on GI side effects are reported on the third-generation
IMiD Pomalidomide (Poma).
Aims: Description of incidence and management of diarrhea in a retrospective
cohort of Len- or Poma-treated MM patients.
Methods: One hundred and twenty-six consecutive Len-treated, and 59 Poma-
treated MM patients were retrospectively analyzed in terms of diarrhea occur-
rence. In this analysis we included Len patients consecutively treated from
June 2005 to December 2015, and Poma patients consecutively treated from
August 2010 to September 2015. A descriptive analysis of diarrhea incidence,
onset time, and response to treatments was performed.
Results: The median age of the 126 Len-treated patients was 65 years (range
35-87); 57 (45%) received one or two autologous stem cell transplants, and 12
(10%) patients received an allogeneic stem cell transplant before Len start; 55
(44%) patients received Len as a first line therapy, 32 (25%) patients as a second
line therapy, and 39 (31%) as third or subsequent line of therapy. Thirty (24%)
patients had diarrhea during Len treatment. Among these patients, 27 (90%)
had grade 1 diarrhea, 3 (10%) patients had grade 2 diarrhea, and no patients
had grade 3 or more diarrhea. Seventeen (53%) patients had abdominal cramps
and 2 (6%) patients had rectal tenesmus. Diarrhea occurred at a median of 10
cycles. Almost all patients (29, 97%) had a correlation of diarrhoeic episodes
with assumption of food, and most patients (24, 80%) reported persistent diar-
rhea during the rest period. Since some patients reported a worsening of diarrhea
associated to fat consumption, 14 patients were advised to avoid diary products,
and in 9 of them (64%) a benefit was observed. Loperamide was used in all
cases, and 19 (63%) patients had a reduction of symptoms. Eleven (37%)
patients had a poor control with loperamide and were treated with cholestyra-
mine, which was effective in all cases. Nine (30%) patients had Len dose reduc-
tion, and 5 had a reduction of the diarrhea. In 19 cases Len was stopped, result-
ing in the rapid resolution of diarrhea in all cases. The same analysis conducted
in 57 Poma-treated patients did not show any GI symptoms.
Summary/Conclusions: Adverse GI events are common in new targeted
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drugs, and a better understanding of the underlying physiopathological mech-
anism is the basis for a correct management. In particular, IMiDs have a gas-
trointestinal toxicity profile with peculiar characteristics for the different gener-
ations. The first-generation IMiD Thalidomide is well known to be associated
with constipation, sometimes very severe. The second-generation IMiD Len
has an opposed GI toxicity profile, characterized by diarrhea. In our study diar-
rhea is mainly mild, but still quite disturbing. However, it seems that a combi-
nation of dietary counselling, along with loperamide and cholestyramine treat-
ment may control this symptom. On the other side, we confirm that Poma does-
n’t have relevant GI side effects.
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TRABECULAR BONE SCORE (TBS) AND DEVELOPMENT OF FRACTURE
IN MULTIPLE MYELOMA
EM Lee1,*, YS Kim1,2, HS Lee1, LC Park1, DJ Kim1, JH Choi1
1Internal medicine, 2Kosin Gaspel University of Hospital, Busan, Korea, Repub-
lic Of
Background: Osteolytic bone lesions are common complications in patients
with multiple myeloma, and have impact on the quality of life because of the
risk of fractures. Trabecular bone score (TBS) is a novel texture index derived
from dual energy X-ray absorptiometry (DXA) of lumbar spine images, providing
information of bone microarchitecture independent of bone mineral density.
Aims: The aim of this study was to test if TBS may be useful to predict bone
fractures in patients with multiple myeloma.
Methods: TBS was calculated retrospectively from existing DXA images of the
lumbar spine, in 20 patients with newly diagnosed multiple myeloma. We ana-
lyzed the development of fractures in these patients.
Results: The median age of the patients was 66 years (range, 49-77), and 15
patients (75%) were female. Fifteen patients had osteopenia (5 patients, 25%)
or osteoporosis (10 patients, 50%) by using DXA. Osteolytic bone lesions were
observed in 18 patients (90%) at the time of diagnosis. The median duration
of follow-up was 31.9 months (95% CI, 20.1-43.7 months), 6 events (long-bone
fractures in 5 events, vertebral fracture in 1) of fracture were occurred in 5
patients (25%). The mean TBS of lumbar spine (L1-4) in patients who experi-
enced development of fractures (1.162±0.032 [95% CI, 1.122-1.201]) was lower
than patients who did not (1.255±0.154 [95% CI, 1.170-1.3]), however, there
was no statistical significance (p=0.061). Among TBS of individual lumbar
spines, L2 showed significantly lower score in patient who experienced devel-
opment of fractures (1.135±0.085 [95% CI, 1.030-1.241] vs 1.243±0.169 [95%
CI, 1.149-1.336], p=0.032).
Summary/Conclusions: TBS of lumbar spine in patients with multiple myelo-
ma could be helpful to predict development of fractures, however, further inves-
tigations are needed.
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BORTEZOMIB MAINTENANCE TREATMENT IN PATIENTS WITH
MULTIPLE MYELOMA-A SINGLE CENTER EXPERIENCE
I Micheva*, S Dimitrova, R Rachev, H Varbanov, M Mehmed, V Gerov,
A Antonov, L Gercheva
Haematology, University Hospital, Varna, Bulgaria
Background: The long-term maintenance therapy in multiple myeloma (MM)
after definitive therapy may prolong remission and delay relapse. Bortezomib
has been used as post-autologous stem-cell transplantation (ASCT) consoli-
dation therapy. Other trials have investigated Bortezomib maintenance for
ASCT patients, and for those who are ASCT ineligible.
Aims: To define the role of Bortezomib maintenance therapy (MT) in patients
with MM after achieving complete response (CR) or very good partial response
(VGPR).
Methods: 37 patients with newly diagnosed symptomatic MM with CR or VGPR
after Bortezomib based induction regiments were included in the analysis. 23
patients received MT with Bortezomib 1.3 mg/m2 once every 2 weeks. 14
patients remained on follow up until progression. 
Results: 19 of the patients were men and 18 women with median of age 64,2
years. 11 cases were with IgA myeloma, 20 with IgG, and 6 with light chain
myeloma. According to ISS 10 patients were in stage I, 7 in stage II, and 20 in
stage III. CR was achieved in 13 (56,5%) of the patients in MT group and in 6
(42,8%) in the group on follow up. Total of 14 patients underwent ASCT - 10
(43,4%) from the patients on MT and 4 (28,5%) on follow up. After a median
follow up of 31.8 months (range, 10-65 months) none of the patients on Borte-
zomibe MT progressed. In contrast, in the patients group on follow up, 12 from
14 patients progressed within median time of 24,17 months (range, 7-60
months). No correlation was found between the progression and myeloma
type, ISS stage, type of response and ASCT.
Summary/Conclusions: Our results reveal undoubtedly the impotence of
Bortesomib maintenance in patients achieved CR or VGPR.
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RELAPSED AND REFRACTORY MULTIPLE MYELOMA, EVOLUTION AND
COMPLICATIONS SINGLE CENTER EXPERIENCE
I Ionita1, L Cheveresan1, M Iordache1, D Calamar1, C Ionita2, D Oros1,
M Ionita3, H Ionita1,*
1Hematology, 2Surgery, 3Internal Medicine, University of Medicine and Farmacy
Victor Babes Timisoara, Timisoara, Romania
Background: Multiple myeloma (MM) is a malignant plasma cell disorder. It is
the second most frequent haematological malignancy and characterized by
malignant plasma infiltration or the bone marrow and is associated with an
increased level of monoclonal protein in the blood and/or urine. The treatment
of MM has undergone significant developments in recent years, and the new
agents with potent anti tumor activity has considerably improved the survival
of MM patients.
Aims: Retrospective evaluation of the therapeutic results, the evolution and
complications of therapy with bortezomib, doxorubicin and dexamethasone
(PAD) in the treatment of relapsed/refractory myeloma patients.
Methods: 62 patients were treated for median of four 28-day PAD cycles (1-
8). Bortezomib was given at 1.3 mg/m2 (days 1, 4, 8,11), doxorubicin at 9
mg/m2 (days 1-4) and dexamethasone 20 mg p.o. (days 1-4, 8-11).
Results: 62 patients were evaluable for efficacy, 59% had refractory disease
and 41% were relapsed. The median age was 65 years (37-80), 59% were
male, 41% female. Serum protein electrophoresis revealed a localized band in
74% of patients, and immunoelectrophoresis or immunofixation showed a mon-
oclonal protein in 85%. A monoclonal light-chain was found in the urine in 63%.
Non-secretory myeloma was recognized in 3% of patients, whereas light-chain
myeloma was present in 16%. Serum albumin less than 3mg/dl was found in
58% of patients. Conventional radiographs showed an abnormality in 81%.
Median time from diagnosis was 16 months (2-115) and median number of prior
therapy lines was 2 (1-5).Overall response rate of 58% was observed, 28% of
patients achieved a complete response (CR), 22% a very good partial response
(VGPR), 30% a partial response (PR). Stable disease (SD) was observed in
20%. The median progression free survival (PFS) was 15,2 months. The most
common grade 3-4 toxic effects were neutropenia 14%, thrombocytopenia 12%,
anemia 12%, infections 16%, peripheral neuropathy 10% and gastrointestinal
disturbances 5%. One toxic death (1.1%) due to sepsis was noted.
Summary/Conclusions: The combination of bortezomib, doxorubicin and dex-
amethasone (PAD) is well tolerated and induced clinically signifiant responses
and prolonged remission duration in patients with relapsed and refractory MM.
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BENDAMUSTINE, LENALIDOMIDE AND DEXAMETHASONE (BLD)
COMBINATION THERAPY IN RELAPSED AND REFRACTORY MULTIPLE
MYELOMA: A SINGLE CENTER EXPERIENCE
L Ciuffreda*, D Diomede, RM Miccolis, G De Santis, C Buquicchio, TM Santeramo,
G Tarantini
Haematology, Ospedale di Miccoli, Barletta, Italy
Background: Lenalidomide is an analogue of thalidomide with immunomod-
ulatory properties and is effective and safe in the treatment of Multiple Myeloma.
Lenalidomide (Len) plus Dexamethasone (Dex) is approved for the treatment
of Relapsed/Refractory MM patients following at least 1 prior therapy. Ben-
damustine (Ben), a bifuncyional agent, shares properties of alkilanting agents
and purine analogs. We report data on efficacy and safety of BLD in patients
(pts) with relapsed/refractory MM.
Aims: Our aim was to evaluate effectiveness and feasibility of BLD regimen in
pts with relapsed or refractory MM
Methods: From September 2014 through October 2015 9 pts with relapsed or
refractory MM with 1-3 prior lines of therapy were treated with BLD regimen.
The series included 9 pts, six females and three males; 5 pts with relapsed
MM and 4 with refractory MM. Median age was 70 (range 55-73). All patients
had symptomatic MM and had previously been treated with bortezomib-based
regimen. Five patients received BLD as second line therapy, four as third
line.Ben was administered intravenously at a dose of 75 mg/mq on day one
and two of each cycle. Pts received lenalidomide 10 mg orally on days 1- 21
and oral dexamethasone 40 mg/day (days 1, 8, 15 and 22). Cycles were repeat-
ed every 28 days for a total of 4 courses. Maintenance therapy included
lenalidomide 25 mg/day on days 1-21 and dexamethasone 20 mg/die (days 1,
8, 15 and 22) until progression. Pts received concomitant anti-thrombotic
(aspirin 100 mg/day) and anti-viral prophylaxis and additional supportive treat-
ment with granulocyte colony stimulating factor (G-CSF) in case of grade 3 or
grade 4 neutropenia occurring during cycles.Safety assessment (clinical
exhamination, hematological evaluation) was performed weekly during cycle
1 and monthly thereafter. Response assessment was performed after four
cycles. Response assessment was based on the International Uniform
Response Criteria.
Results: As Grade 3-4 hematological toxicity we observed: neutropenia (55%),
thrombocytopenia (44%) and anemia (33%). Grade 3-4 non hematologic
adverse events were: infection (22%), hyperglycemia (33%), fatigue (44%) and
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diarrhea (11%). No thromboembolic events were reported. We did not observe
peripheral neuropathies. One patient discontinued therapy because of pro-
longed neutropenia and thrombocytopenia. 8 patients were evaluated for
response after four courses; 7 pts (87,5%) achieved al least a partial response
(PR), including 3 (37,5%) very good partial response (VGPR) and 1 (12,5%)
complete response (CR). 3 pts (after achieving VGPR) successfully harvested
peripheral blood stem cells (PBSC). 
Summary/Conclusions: In conclusion in our study BLD combination was well
tolerated with a mild toxicity profile and has shown effectiveness in patients
with relapsed or refractory MM. It could represent a reasonable option for
relapsed-refractory MM pts, including transplant-eligible patients.
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OUTCOME OF PATIENTS WITH NONSECRETORY AND SECRETORY
MULTIPLE MYELOMA AFTER FIRST LINE TREATMENT CONSOLIDATED
WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
THE SINGLE CENTRE EXPERIENCE
J Romejko-Jarosinska*, A Druzd-Sitek, A Borawska, M Kotarska, J Tajer,
E Wojciechowska-Lampka, J Walewski
Department of Lymphoid Malignancy, Maria Sklodowska-Curie Memorial Can-
cer Centre & Institute of Oncology, Warsaw, Poland
Background: Nonsecretory multiple myeloma (NSM) is an uncommon type of
multiple myeloma. It is defined as the presence of monoclonal plasma cells in
bone marrow biopsy or in other organs and the absence of monoclonal protein
in immunofixation in serum and urine. There are limited data about outcome
after first line treatment with consolidation high dose chemotherapy following
autologous hematopoietic stem cell transplantation (ASCT).
Aims: We retrospectively evaluated outcomes and predictive factors for overall
survival (OS) and progression free survival (PFS) in all myeloma patients, in non-
secretory myeloma (NSM) and in secretory myeloma (SM) groups, who received
high dose chemotherapy and ASCT between 1998-2015 after first line treatment.
Methods: We identified 114 myeloma patients: 23 (20%) with non-secretory
myeloma and 91 (80%) with secretory myeloma. Median time from first treat-
ment to ASCT was 8 months (range 4–28 months). All patients achieved
response to first line treatment: complete remission or partial response.
Results: The median OS and median PFS were 41 (range 2- 205) months and
25 (range: 2- 205) months, respectively. Five year OS and 5-year PFS were
70% [95%CI (59%, 79%)] and 42% [95%CI(31%, 53%)], respectively. For NSM
and SM groups 5-year OS were 54%[95%CI (31%,77%) and
74%[95%CI(64%,75%)] respectively, (p=0.14) and 5-year PFS were
45%[95%CI(24%,66%)] and 41%[95%CI (29%,53%), respectively. (p=0.79).
Age, sex, disease stage, disease status before ASCT, induction chemotherapy,
radiotherapy had no influence on OS and PFS for all, NSM and SM groups in
univariant analysis. The presence of monoclonal IgG protein in SM patients
was associated with better OS compared to OS in NSM group (p=0.04) and
the presence of monoclonal protein with kappa light chain in SM patients related
to longer PFS compared to PFS in NSM group (p=0.05) in univariant analysis.
Summary/Conclusions: There were no significant differences in OS and PFS
for non secretory and secretory myeloma patients after first line treatment con-
solidated by high dose chemotherapy and ASCT. However, patients with mon-
oclonal IgG protein had significantly better OS than patients with NSM.
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PLASMABLASTIC LYMPHOMA (PBL) AND EXTRAMEDULLARY
PLASMABLASTIC TRANSFORMATION OF PLASMA CELL MYELOMA
(PCM): DIAGNOSTIC MORHOLOGICAL, IMMUNOHISTOCHEMICAL AND
CLINICAL CHARACTERISTICS
CM Vadikolia1,*, C Papadopoulou1, G Mpokolas1, G Pahiadakis2, N Protogeros1,
E Papagrigoriou1, S Milias3, C Georgopoulos1
1Haematology Department, 2Gastroenterology Department, 3Histopathology
Department, 424 Army General Hospital, Thessaloniki, Greece
Background: PBL is an aggressive growth of neoplastic cells that resemble B
immunoblasts in morphology and are immunophenotypically indistinguishable
from plasma cells and lack B cell markers. Even though it was first described
in the setting of immune suppression and in fact underlying HIV infection and/or
EBER positivity in the neoplastic cells are frequent, it is now increasingly iden-
tified in immunocompetent patients with extreme heterogeneity in terms of
nodal and extra nodal involvement. However, extramedullary lesions with plas-
mablastic morphology are not uncommon in patients with PCM, where they
usually develop in the course of a refractory disease. The differential diagnosis
may be challenging in initial presentation and the complexity is further magnified
as both entities have features that overlap with several other lymphomas with
plasmablastic morphology.
Aims: To evaluate and compare morphological, immunohistochemical, molec-
ular and clinical characteristics of patients with PBL and plasmablastic trans-
formation of PCM.
Methods: We present patients with documented PBL, with liver and bone
involvement, plasmablastic transformation of PCM with multiple sites of involve-
ment in the oral cavity and the gastrointestinal tract and plasmablastic trans-
formation of orbital soft tissue plasmacytomas.
Results: Histopathological examination showed large confluent plasmablasts
with abundant cytoplasm and central oval vesicular nuclei with coarse chromatin
pattern and prominent nucleoli. They mostly appear as large centroblasts and/or
immunoblasts and cannot be readily classified as a B cell or a plasma cell neo-
plasm or have a more apparent plasma cell differentiation with a paranuclear
hof, eccentric large nuclei and basophilic cytoplasm. Background necrosis,
karyorrhexis and increased mitotic figures are prominent. Immunohistochem-
istry is similar with plasma cell neoplasms, positive for CD79a, MUM-1, CD38
and CD138 and the majority negative for CD45 and negative for CD20, PAX-5
and bcl-6. Perhaps the only difference detected in our cohort of patients was
the expression of CD56 and CD10 which were negative in PBL. MYC is
expressed in about 50% of cases. All patients have very elevated levels of LDH
and poor risk cytogenetics. The clinical course is aggressive and response to
treatment is poor, with evolution to plasma cell leukaemia in the non PBL
patients and overall survival of no more than 6 months from the diagnosis of
PBL or the plasmablastic transformation.
Summary/Conclusions: When an underlying plasma cell dyscrasia is not yet
known, the distinction of a high grade aggressive lymphoma with plasmablastic
features may be arbitrary, particularly if there are coexistent marrow involve-
ment, presence of paraproteinaemia, bone lesions and a certain degree of
plasmacytic differentiation. It is not clear in the literature whether those are
entirely different entities or share a common pathogenetic mechanism. Systemic
investigation towards the identification of novel markers and the refinement of
our current combination of diagnostic tools may enable a more accurate dis-
tinction and definition. 
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RETROSPECTIVE COMPARISON OF SAFETY AND EFFICACY OF BUCY
AND HDM AS REGIMEN BEFORE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
S Jin*, Y Xu, J Zhou, C Fu, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Melphalan-based regimen is the standard regimen before autol-
ogous stem cell transplantation (ASCT) in the patients with multiple myeloma,
but now melphalan is not on the China’s market. There were positive data
reported in other researches in terms of safety, response rate and long-term
survival on busulfan combined with other alkylating agents as regimen before
ASCT in MM patients. 
Aims: This study retrospectively compare the data in our single center on MM
patients with busulfan (BU) and cyclophosphamide(CY) as regimen before
ASCT form December to June 2013 to December 2014 with the high-dose mel-
phalan (HDM) regimen. long-term survival on busulfan combined with other
alkylating agents as regimen before ASCT in MM patients.
Methods: 20 cases with BUCY and 17 cases with HDM regimen before ASCT
in MM patients were compared in terms of incidence of adverse reaction, the
rate of hematopoietic reconstitution, therapeutic effect evaluation and survival.
Results: There is no significant differences between age, gender, duration from
diagnosis to transplantation, the type of disease and ISS stage, the number of
cycles of induction chemotherapy and disease status before transplantation in
the two groups. A 10-day of median myeloid hematopoietic recovery time was
observed in both groups, and the median megakaryocyte hematopoiesis recon-
struction time was 10-day and 11-day (P >0.05), respectively, in BUCY and
HDM group. The incidence of liver function injury above grade 2 in BUCY group
was higher than that in HDM group (30% vs 0, P <0.05), but there were no
hepatic veno occlusive disease (VOD) occurs in both groups. And there was
no significant difference in other all regimen toxicity, especially above grade 2
toxicity, and treatment related mortality (TRM) within 100-day of two groups
were 0. The partial response(PR) rate after transplantation in BUCY group was
significantly decreased (6/20 vs 0/20, p<0.05), while the patients in the HDM
group were not observed this phenomenon. The median PFS of HDM group
was 17 months, and the median PFS of BUCY group and median OS of both
groups had not been reached yet.
Figure 1.
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Summary/Conclusions: BUCY regimen did not show weakness in safety and
survival compared with HDM regimen, which prompt the possibility of BUCY
regimen replacing the HDM regimen as the standard regimen in China.
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CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD)
AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS
J Vasquez1,*, R Ruiz1, K Aliaga1, F Valencia1, D Enriquez1, V Palacios2,
S Quintana1, L Casanova3
1Medical Oncology, Instituto Nacional de enfermedades neoplásicas, 2Medical
Oncology, Hospital Cayetano Heredia, 3Medical Oncology, Instituto Oncologico
Miraflores, Lima, Peru
Background: Major progress has occurred in multiple myeloma (MM) treat-
ment in recent years. However, due to limited healthcare resources, newer
agents are not readily available. In this setting traditional therapy such as oral
cyclophosphamide, thalidomide and dexamethasone (CTD) represents an
alternative for treatment in newly diagnosed MM.
Aims: To assess the clinical efficacy and toxicity of cyclophosphamide, thalido-
mide and dexamethasone.
Methods: Retrospective study with the regimen CTD (cyclophosphamide
400mg/m2 for 5 days, thalidomide 100mg/d increasing to 200 mg/day if toler-
ated, and dexamethasone 40mg weekly; in 28-day cycles), in patients with
newly diagnosed MM treated at Instituto Nacional de Enfermedades Neopla-
sicas in Lima, Perú, between January 2008 and July 2013. Survival outcomes
were estimated by Kaplan-Meier method.
Results: Fifty-nine patients were found to meet the selection criteria. Mean
age was 56 years (27-68). Fifty-nine percent (n=35) were male. Salmon Durie
stage III disease was present in 88.1%. The median number of treatment cycles
delivered was 11 (range 4-12). After a median of 31 months follow-up (range
5-81), the overall response rate was 69.5%, with a 39% stringent complete
response (SCR), complete response (CR) and very good partial response
(VGPR), one patient (1.7%), three patients (5.1%), and nineteen patients
(32.2%) respectevely. Median progression free survival (PFS) was 35 months.
Five-year overall survival (OS) was 58.5%. The most common adverse events
include neutropenia of all grades (44.1%), febrile neutropenia (grade III/IV
18.6/11.9%), severe infection (8.4%), deep venous thrombosis (6.8%). Out of
37 patients eligible for HSCT, 8 (21.6%) proceeded with it after this treatment
regimen and 9 patients (24.3%) out of 37 are in maintenance. Treatment-related
deaths occurred in 4 patients (6.7%) whose ages were 62, 64, 74, and 76
years-old.
Summary/Conclusions: CTD achieves durable responses with tolerable tox-
icity. This regimen represents a feasible and effective approach for MM patients
in low income healthcare settings with tolerable side effects profile.
PB1992
PROGNOSTIC FACTORS IN PATIENTS WITH BENCE JONES MULTIPLE
MYELOMA
JL Garcia De Veas Silva1, R Rios Tamayo2,*, C Bermudo Guitarte3, JC Rojas Noboa4,
R Duro Millán4, T De Haro Muñoz1
1Clinic Laboratories, 2Hematology, Complejo Hospitalario Universitario de
Granada, Granada, 3Clinical Biochemistry, 4Hematology, Hospital Universitario
Virgen Macarena, Sevilla, Spain
Background: Bence Jones Multiple Myeloma or Light Chain Multiple Myeloma
(LCMM) is characterized by the production of only lights chains. It can be found
approximately in 15% of MM patients and it is considered to have a worse
prognosis than Intact Immunoglobulin Multiple Myeloma.
Aims: The aim of this study is to evaluate the prognostic value of serum free
light chains (sFLC) at presentation in newly diagnosed LCMM patients.
Methods: 43 patients with LCMM were included in this study during a period
of five years. sFLC levels were measured by nephelometry (Freelite, The Bind-
ing Site, Birmingham, UK) and sFLC ratio was calculated as K/L. Clinical and
laboratory variables including sFLC, albumin, beta-2-microglobulin (B2M), cre-
atinine, hemoglobin, calcium, LDH, M-protein size, plasma cell infiltration, pres-
ence of plasmacytoma and presence of lytic bone lesions) were recorded and
evaluated for their impact on the patient’s outcome. Statistical analysis was
performed using SPSS 23. Overall survival (OS) was analysed by Kaplan-
Meier method and curves compared by Log-Rank test.
Results: The median age of the patients included in the study was 69 years
(range 59-75) and 51% were female. The median follow-up was 32 months
(range 17-45 months) and during the period of study there were fourteen dis-
ease-related deaths. According to ISS; 28% patients had stage 1, 41% had
stage 2 and 30% had stage 3. At diagnosis, the proportion of patients with
renal impairment (creatinine>2 mg/dL), anemia (Hb<10 g/dL), hypercalcemia
(Ca>11 mg/dL) and presence of bone lesions were 28%, 35%, 12% and 70%,
respectively. The median percentage of BM plasma cells was 18% and 19% of
patients had plasmacytoma at diagnosis. Altered sFLC ratio at diagnosis
defined by K/L ratio <0.26 or >1.65 was observed in all the patients. Median
sFLC levels in patients with kappa light chain restriction (n=20) was 413 mg/L
(range 128-1612 mg/L) and in those with lambda light chain restriction (n=23)
was 985 mg/L (range 270-2858 mg/L). The median sFLC ratio for kappa secre-
tors and lambda secretors were 43 and 0.01, respectively. The cohort of
patients was separated in two groups based on sFLC ratio cut-off of <0.01 or
>43. The 5-years OS was significantly inferior in patients with high sFLC ratios
(<0.01 or >43, 12% 5y-OS), compared with those with low sFLC ratios (between
0.01 and 43, 74% 5y-OS) with median survivals of 45 months and NR, respec-
tively (p=0.017, HR=3.70, CI95% 1.15-11.87). Involved sFLC (iFLC) levels
above the median values (kappa≥413 mg/L and lambda≥985 mg/L for kappa
and lambda secretors, respectively) predicted a worse prognosis. The 5-years
OS was 70% in patients with iFLC levels below the median and 0% in those
with iFLC levels above the median, with median survivals of NR and 45 months,
respectively (p=0.009, HR=4.33, CI95% 1.31-14.28). Other variables signifi-
cantly associated with adverse outcome were B2M>3.5 mg/L (p=0.006) and
albumin<3.5 g/dL (p=0.023). There was no significant correlation with the others
variables.
Summary/Conclusions: sFLC ratio and involved FLC levels above median
values at diagnosis are important risks factors of worse prognosis in patients
with Bence Jones Multiple Myeloma.
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COMORBIDITY AS A FACTOR OF PROGNOSIS IN MULTIPLE MYELOMA
N Skvortsova*, T Pospelova, I Nechunaeva, I Kovynev
State Medical University, City hematological center, Novosibirsk, Russia,
Novosibirsk, Russian Federation
Background: Despite the modern possibilities of therapy, multiple myeloma
(MM) is an incurable disease with a wide variety of outcomes, depending on
the presence of risk factors. MM Classification based on the criteria of
Durie/Salmon and the ISS, include, primarily, the risk factors associated with
the disease itself. However, factors associated with the patient, such as co-
morbidities and organ dysfunction which further affect the outcome of the tumor,
is still not fully integrated into the predictive model.
Aims: To analyze the effect of prognostic factors: age, sex, medical condition
and comorbidities, as well as indices of comorbidity and Sharlson Freiburger,
overall survival (OS) in patients with MM.
Methods: 206 patients with MM (91 men and 115 women) analyzed. Patients
ranged in age from 36 to 81 years (median 68 years). The statistical analysis
was used software package SPSS 23. Effect of studied factors on the long-
term prognosis was estimated by odds ratios (confidence interval 0.95). In
developing the model predicting the likelihood of an unfavorable outcome were
used methods of correlation, factor and regression analysis.
Results: during the factor analysis, all investigated prognostic factors, such
as somatic status, GFR <30 mL/min/1.73 m2, the presence of any tumor or
metastasis of solid tumors, and had a significant effect on the agents. The
prevalence of comorbidity in patients with MM at diagnosis was - 80%. The
most common diseases have been associated disease of the gastrointestinal
tract (88.4%), cardiovascular (78.6%), urinary (44.5%) and endocrine systems
(26.8%). In assessing the prognostic impact on overall survival and an index
of comorbidity Sharlson Freiburger index shows that both indices significantly
affect the survival of patients with MM, depending on the increase in their score
on the scales (P <0.001). Median survival in the evaluation of Freiburger index
was 55.0, 29.5 and 19.5 months for 0, 1 and 2-3 scores, respectively. Sharlson
comorbidity index also indicated a significant difference in the survival rate of
patients corresponding to 0, 1-2, and ≥3 points.
Summary/Conclusions: so comorbidity patients affects the survival and effec-
tiveness of treatment in patients with MM, reducing these figures.
PB1994
PLASMA CELL LEUKEMIA: A 10-YEAR SINGLE CENTER EXPERIENCE
AL Pinto*, A Roque, MJ Mendes, G Ferreira, JC Almeida, LF Araújo, M Duarte,
E Cortesão, M Gomes, C Geraldes, AI Crisóstomo, L Ribeiro
Clinical Hematology Department, Coimbra University Hospital Center, Coimbra,
Portugal
Background: Plasma cell leukemia (PCL) is a rare disorder representing less
than 5% of malignant plasma cell diseases and defined by the presence of
clonal plasma cells in the peripheral blood with an absolute count of >2x109/L
and/or >20% of the white blood cells. It presents either as primary disease
(pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma,
and usually has an aggressive course and poor outcome.
Aims: To evaluate clinical features, prognostic factors and treatment outcome
in patients with PCL.
Methods: A single center retrospective case-series study was performed. Data
from patients diagnosed with PCL between January 2006 and December 2015
were collected and analysed.
Results: We identified 15 patients with PCL (5 male/10 female, median age
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68 years, range 44-78) of whom 11 had pPCL and 4 sPCL. In sPCL the median
time to leukemic progression was 22.3 months, with a median of 3 previous
therapeutic lines. The subtype of monoclonal component found at diagnosis
was IgG (n=7), IgA (n=2), IgE (n=1), light chain only (n=3) and non-secretory
(n=2). Median plasma cell count in peripheral blood was 4.05x109/L (range
0.3-60.5) with a median proportion of plasma cells of 32% (range 11-85).
At baseline, most of the patients had poor performance status with ECOG³2
(n=9), advanced stage disease classified at stage III according to International
Staging System (n=11) and Durie-Salmon Staging System (n=10), and at least
one end-organ damage (n=14). Extramedullary disease was present in 5 cases.
Elevated lactate dehydrogenase was observed in 11 patients (median 338U/L,
range 118-2610, N<248U/L) and β2-microglobulin in 12 (median 17.7mg/L,
range 1.0-62.1). In 8 patients cytogenetic studies were carried out by conven-
tional cytogenetic analysis and by FISH. Seven of them presented high risk
cytogenetic alterations. Four patients received anthracycline-based regimens
as first-line treatment, 2 single alkylating agents and 6 bortezomib or lenalido-
mide as additional or unique treatments. In 3 patients, with very aggressive
disease and poor performance status, early death occurred, allowing only pal-
liative treatment with steroids. Two patients underwent autologous hematopoi-
etic stem cell transplantation after first line treatment. Eight patients achieved
complete or partial response. The median overall survival (OS) was 4.5 months
and OS at 2 years was 12.5%. Significantly longer OS was observed in patients
responding to first-line treatment versus those who did not respond (median
9.6 vs 0.9 months, p=0.002); in patients who received bortezomib during the
course of the disease (median 23.8 vs 0.9 months, p=0.022), and in patients
with good performance status (ECOG <2) at the time of diagnosis (9.6 vs 4.1
months, p=0.024).
Summary/Conclusions: PCL is a rare disease with a poor prognosis, aggres-
sive clinicobiological features and a low response rate to conventional treat-
ment. Although our conclusions are limited by the small sample size, our study
shows that good performance status and response to first-line treatment present
a positive impact on survival. The use of bortezomib also appears to improve
outcomes by lengthening OS.
PB1995
A SINGLE CENTRE EXPERIENCE OF DPACE-BASED THERAPY WITH
LENALIDOMIDE OR THALIDOMIDE +/- BORTEZOMIB PRIOR TO
AUTOLOGOUS TRANSPLANT IN MYELOMA
T Parker*, K De Abrew, R Lown, M Jenner
Haematology, University Hospital Southampton NHS Foundation Trust,
Southampton, United Kingdom
Background: DPACE (infusional Cisplatin, Doxorubicin, Cyclophosphamide,
Etoposide and oral Dexamethasone) with Thalidomide and Bortezomib is used
within the Arkansas Total Therapy Regimen for myeloma. We have used
DPACE-based therapy for high-risk and poorly responsive myeloma prior to
autologous transplant (ASCT).
Aims: To establish the toxicity and efficacy of DPACE based chemotherapy
with a combination of thalidomide or lenalidomide and/or bortezomib as a stand
alone therapy or prior to consolidation with autologous stem cell transplant in
high risk or poorly responsive myeloma.
Methods: We conducted a retrospective review of 22 patients treated at a sin-
gle centre with DPACE-based therapy between 2010-2015 incuding two who
received DPACE-based therapy as two separate treatment lines. Overall sur-
vival and time to next treatment from commencement of DPACE-based therapy
were estimated using a Kaplan-Meier method and the impact of categorical
variables assessed using a log rank analysis. Median follow-up was 2.1 years.
Results: PS was 0 (72.7%) or 1 (27.3%). ISS at commencement of DPACE
was I (27.3%), II (22.7%) and III (36.4%). 15 of 22 patients had FISH performed
prior to DPACE of which 40% had 2 or more adverse abnormalities (gain 1q,
loss 1p, loss 17p, t(4;14), t(14;16), t(14;20)). Patients received DPACE with an
Immunomodulatory agent (Lenalidomide 62.5% or Thalidomide 37.5%) and
66% received Bortezomib. DPACE-based therapy was used as primary therapy
in 4/24 (16.6%) for and as salvage for suboptimal response in 20/24 (83.3%).
Two cycles were given in 22/24 (92%). Patients received a median of 2 units
of red cells per cycle (range 0-8 in cycle 1, 0-12 in cycle 2). Median platelets
transfusions equalled 1.5 (0-6) in cycle 1 and 3.5 (0-9) in cycle 2. All patients
experienced grade 4 neutropenia with median duration of 6 days in cycle 1 and
5 days in cycle 2. Grade 3-4 sepsis occurred in 9/24 (37.5%) in cycle 1 and
7/22 (31.8%) in cycle 2. All planned patients harvested successfully. From start
of DPACE-based therapy, median OS was 23.3 months. Median TTNT was
12.6 months. Treatment-related mortality was 1/24 (4.1%) due to sepsis. Fol-
lowing DPACE-based therapy, 12/24 (50.0%) achieved CR or VGPR. 15/24
(62.5%) were consolidated with transplant (one allogeneic). Consolidation with
ASCT demonstrated a clearly superior OS (77.1% vs 0% at 2 years, p<0.001)
and improved TTNT (median 33.1 vs 4.3 months, p=0.007). Lenalidomide did
not impact on toxicity or response rates. There were no reported second primary
malignancies in any patients.
Summary/Conclusions: DPACE-based therapy is an effective induction or
salvage therapy prior to ASCT in high risk or poorly responsive myeloma. Tox-
icity is manageable and stem cell harvest is achievable. Time to next treatment
and overall survival is significantly longer in those consolidated with stem cell
transplant indicating that there is limited value in using PACE-based chemother-
apy without stem cell transplant. Initial data does not indicate a difference
between Lenalidomide or Thalidomide in toxicity, response rates or survival
although longer follow-up is warranted to investigate this further.
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FLOW CYTOMETRY BASED MRD ANALYSIS VERSUS IMMUNOFIXATION
ELECTROPHORESIS FOR RESPONSE ASSESSMENT OF MYELOMA
PATIENTS ON TREATMENT
MUS Sachdeva1,*, P Sharma1, P Bose1, N Varma1, P Malhotra2
1Hematology, 2Internal Medicine, Postgraduate Institute of Medical Education
and Research, Chandigarh, India
Background: Minimal residual disease (MRD) analysis by multiparametric flow
cytometry (MFC) is a sensitive method to evaluate treatment efficacy in patients
of plasma cell myeloma (PCM), and also as a tool for predicting patient out-
comes and guiding therapeutic decisions. In the present study, we compared
MRD levels in patients of plasma cell myeloma after chemotherapy or autolo-
gous stem cell transplant (ASCT), assessed by MFC, with immunofixation elec-
trophoresis (IFE) and also the serum M-band status.
Aims: To evaluate the utility of MFC (six colour - three tubes) assay for detection
of residual disease in patients of PCM and compare it with results of serum
protein electrophoresis (SPEP) for M-band and immunofixation electrophoresis
(IFE) done at same time.
Methods: Twenty six PCM patients (16 males & 10 females) were included in
the study with mean age of 55.5 (range 37-80) years. Nine patients were post-
ASCT (day +100), and 17 patients were on chemotherapy (majority treated
with combination of cyclophosphamide, bortezomib and dexamethasone) and
had completed induction at time of MRD analysis. MRD was analyzed using a
dual laser BD FACS Canto II. Pre-titrated cocktail of CD38, CD138, CD19,
CD45, cytoplasmic Kappa and lambda light chain, CD56, CD81, CD27, CD28
and CD200 were used in 6-color combination of three tubes for MRD analysis.
IFE and M-band detection were also performed and compared.
Results: Ten out of 26 patients had detectable residual disease by MFC and/or
IFE. MRD by MFC was detectable in 8 patients with mean of 1.79% (0.004-
6.44%), all eight belonging to post-induction chemotherapy group. Only 4 of
these 8 patients (50%) revealed both IFE positivity and detectable M-band.
Two out of these 10 patients were MRD negative, however revealed IFE posi-
tivity as well as detectable M-band in one, and the other patient was only IFE
positive (Table 1). Remaining 16 patients did not show evidence of residual
disease by any of the three methods. Statistical analysis between MRD-positive
(8/26) and MRD-negative (18/26) groups revealed no significant difference
between age and sex distribution, mean values of hemoglobin, leukocyte count,
platelet count, serum creatinine, serum calcium and serum albumin and the
mean percentage of plasma cells on bone marrow aspirate smears (Mann-
Whitney U test).
Table 1. Comparison of results of the 10 patients showing persistent resid-
ual disease by SPEP/ IFE/ MFC, along with plasma cell percentages on
bone marrow aspirate smears.
Summary/Conclusions: MRD detection by multiparametric flow cytometry is
a sensitive technique and should be routinely performed in addition to
immunofixation electrophoresis and serum protein electrophoresis for more
accurate assessment of treatment-response, better prognostication and further
management of plasma cell myeIoma patients.
PB1997
DIAGNOSIS, PROGNOSIS AND RISK ASSESSMENT OF MULTIPLE
MYELOMA: IDENTIFYING GAPS AND ADDRESSING EDUCATION NEEDS
FOR HEMATOLOGISTS AND ONCOLOGISTS
E Van Laar1,*, S Fagerlie1, O Landgren2
1Medscape, 2Department of Medicine, Memorial Sloan Kettering Cancer Cen-
ter, New York, United States
Background: The diagnostic and prognostic criteria for multiple myeloma (MM)
have rapidly evolved as the therapeutic landscaped has advanced. Further-
more, in 2014, the MM diagnostic criteria were revised to incorporate biochem-
ical parameters in addition to traditional symptomatic criteria. These emerging
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changes require that the clinician interpret and integrate this new information
into clinical practice.
Aims: A 2-part study was conducted with the first part focused on identifying
clinical gaps in prognosis and diagnosis of patients with MM and the second
part focused on determining the effect of educational intervention designed to
address the identified clinical gaps.
Methods: Education interventions for hematologists/oncologists were devel-
oped and posted online (http://www.medscape.org/sites/advances/multiple-
myeloma). Two of the interventions used a 25-question self-assessment
focused on identifying clinical practice gaps in MM while the third comprised a
20-minute video of a two MM expert discussion designed to narrow the knowl-
edge and competence gaps of hematologists and oncologists. Learning in the
video-based intervention was assessed by comparing each learner’s responses
to pre-education questions with responses to the same questions posed after
education. The McNemar’s chi-square test was used to assess whether the
mean pre-assessment score was different from the mean post-assessment
score. Activities were posted online July 2015 and data were collected through
September 2015.
Results: Responses of 434 hematologist/oncologists who completed all
assessment questions in at least one intervention during the study period were
analyzed. At baseline, identified clinical gaps included: the inability to recognize
clinical features of high-risk disease (82% incorrect), inability to identify tools
for assessing prognosis (73% incorrect), inability to distinguish unfavorable
(44- 56% incorrect) or favorable (47% incorrect) cytogenetics, inability to assign
the International staging system (ISS) score (26% incorrect), inability to detect
clinical relapse (49% incorrect), and inability to interpret the IMWG diagnosis
criteria (40-79% incorrect). For the second phase of the study, the education
intervention focused on IMWG guidelines in newly diagnosed MM and utilized
a study group of matched hematologist/oncologist learners (N=58). After par-
ticipation in educational intervention, 84-95% of hematologist/oncologists
selected the correct answer regarding diagnostic criteria (Table 1).
Table 1. Post-education Outcomes.
Summary/Conclusions: Despite the publication and dissemination of recent
guideline updates, clinician show gaps in knowledge of clinical diagnostic and
prognostic criteria for MM. This study identified specific education needs of
physicians treating patients with MM regarding diagnostic, prognostic and risk
stratification and demonstrated increased knowledge after participation in a
targeted online intervention. Learners showed a mean improvement of 49%
(range: 38-55%) in knowledge of IMWG diagnostic criteria in post assessments.
Future education is warranted on practical application of diagnosis criteria, lab-
oratory thresholds, prognostic, and monitoring tools, and proper risk assess-
ment in order to enhance prompt diagnosis and effective disease manage-
ment.
PB1998
IDENTIFICATION OF MULTIPLE MYELOMA IN PATIENTS ATTENDING
EMERGENCY SERVICES WITH SEVERE BONE PAIN
JL Garcia De Veas Silva1, R Rios Tamayo2,*, C Bermudo Guitarte3,
R Duro Millán4, M Jurado Chacon2, T De Haro Muñoz1
1Clinic Laboratories, 2Hematology, Complejo Hospitalario Universitario de
Granada, Granada, 3Clinical Biochemistry, 4Hematology, Hospital Universitario
Virgen Macarena, Sevilla, Spain
Background: Bone metastases are due to a variety of primary tumors that
include Multiple Myeloma (MM) and solid tumors (lung, breast, prostate). Its
effects result in pain refractory to conventional analgesic treatments and oste-
olysis leading to pathological bone lesions. Sometimes, patients with age>50
years, intense and repetitive bone pain are treated with analgesics without
assessing the possibility of a MM at Emergency Services (ES). Typically, after
several visits to the ES because of progressive increase of pain and evidence
of bone damage the patient is admitted to study a possible MM. Early study of
the pathological bone lesions is crucial for a correct diagnosis and to increase
the survival time of patients. The protocol “SPE+FLC” that uses serum free light
chains determination (FLC) and serum protein electrophoresis (SPE) enables
sensitive quantification of a possible monoclonal component in the study of MM.
Aims: The aim of our work is to study the diagnostic utility of the protocol
“SPE+FLC”.
Methods: During a period of 12 months, we studied 44 patients with age>50
years old, intense bone pain and recurrent visits to Emergency Service where
imaging methods (X-Rays, CT scan and MRI) showed osteolytic lesions, ver-
tebrae collapse and pathological fractures that may be associated a MM or
metastasis from a primary tumor of unknown origin (TU). The protocol
(SPE+FLC) was applied to every patient to study a possible MM and the deter-
mination of tumor markers to discard a TU with bone metastasis. 
Results: The diagnosis was: MM in 16 patients (36%), TU with bone metastasis
in 14 patients (32%) and 14 patients without tumoral pathology (32%). In MM
patients, the median age was 68 years (range 58-75) and the median time
from symptoms to diagnosis was 5 months (range 2-7) with a median number
of visits to Emergency Service of 3. The diagnosis was intact immunoglobulin
MM in 13 patients and Bence-Jones MM in 3 patients. According to ISS system
for MM; there were 2 patients in stage 1 (12%), 4 patients in stage 2 (25%)
and 10 patients in stage 3 (63%). During the study there were 3 MM related
deaths. The protocol “SPE+FLC” had a sensitivity of 100%, specificity of 97%,
PPV of 94% and PNV of 100%.
Summary/Conclusions: In patients with age>50 years, intense bone pain
with pathological bone lesions, the application of the protocol “SPE+FLC” allow
us to detect a possible MM in order to apply an early treatment and increase
the survival time of the patient.
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LIGHT-CHAIN ESCAPE IN MULTIPLE MYELOMA: A NEW PATTERN OF
DISEASE RELAPSE CHANGING BIOLOGY. A SINGLE-CENTER EXPERIENCE
OF THREE CASES
L Torti1,*, S Pulini1, AM Morelli1, F Bacci2, A Spadano1, P Di Bartolomeo1
1Department of Hematology, Transfusion Medicine and Biotechnology, “Spirito
Santo” Civic Hospital, Clinical Hematology, Pescara, 2Department of Hematol-
ogy and Oncological Sciences, S. Orsola-Malpighi Hospital, Section of
Hematopathology, Bologna, Italy
Background: Multiple Myeloma (MM) is characterized by the production of a
monoclonal protein which can be an intact immunoglobulin, free light chain
(FLC), both or, in rare cases, neither. The introduction of novel drugs has
changed the natural history of the disease, leading to new manifestations of
relapse. Light chain escape (LCE) defines a kind of relapse in which the FLC
increase is not accompanied by a concomitant raise of the original monoclonal
component (MC). 
Aims: Disease biology and progression in MM is now thought to be the result
of Darwininan-like evolution process: multiple pathological clones are present
at MM diagnosis, possibly producing different monoclonal proteins. The cases
presented here indicate that disease progression and relapse may be associ-
ated with selective outgrowth of a specific FLC producing clone. 
Methods: Here we report three cases diagnosed with aggressive LCE between
2001 and 2015 at a single institution. We even include an interesting case of
IgG lambda monoclonal MM who relapsed after double autologous stem cell
transplantation (ASCT)changing face presenting like FLC MM lambda with a
new rare IgD lambda monoclonal pattern.
Figure 1. A) Histopathological examination of inguinal lymph node
revealed plasmocytoma with immunostaining positive for chain lambda
(40x). B-C-D) Bone marrow biopsy demonstrated plasmocytoma (Giemsa
40x), with Ki67 expression in bone marrow plasma cells >20% and
immunostaining positive for lambda chain (20x). Case 1.
Results: Patient 1. A 63-year old woman was diagnosed with IgG-lambda
(stage IA, ISS2) with trisomy of chromosome 5 and 9. Before the “new drug
era”the patient received 3 cycles of chemotherapy according to VAD regimen,
followed by tandem ASCT; she achieved a VGPR. After 9 years the patient
developed an enlargement of right inguinal lymph node and then painless sub-
cutaneous mass above left shoulder. Biopsy of the 2 nodular lesions confirmed
extramedullary plasmocytomas (Fig1A). The patient did not show classic mon-
oclonal protein but a new little MC IgDlambda protein with an abnormal secre-
tion of serum FLC lambda. Bone marrow plasma cells were dysmorphic (Fig
1B), with high proliferation index measured by immunohistochemical staining
Ki67>20% (Fig1 C) and positive for lambda chain assessement (Fig 1D). Serum
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LDH levels at recurrence resulted high. Patient 2. A 64-year old man suffering
from IgG-kappaMM stage IIIA, ISS2 underwent double ASCT and then was
enrolled in PANORAMA study because of relapsing disease. He then started
salvage therapy with lenalidomide and dexamethasone, but after 23 cycles he
showed progressive disease with the features of LCE kappa. He presented a
complex karyotype with trisomy of chromosome 9, 15 and gene rearrangement
of 14q32, increase of LDH and plasmoblastic medullary cytomorphology. Patient
3. A 51-year old woman presented IgG-lambda MM stage IIIA ISS3 with
extramedullary involvement (L5-S1) and deletion in 17p chromosome. She was
treated according to VTD therapy followed by double ASCT and dexametha-
sone maintenance. She remained in remission of disease for 60 months until
an increased amount of serum FLC lambda appeared and rapidly increased,
with multiple vertebral bodies collapses and bone marrow infiltration of 40%
atypical plasma cells showing various prognostically unfavorable genetic signs
(1q amplification, 17p deletion, 13 deletion, 14q32 rearrangement).
Summary/Conclusions: These cases represent a documented series of a
rare but clinically important mode of relapse. They suggest the potential selec-
tive pressure exerted by novel agents and highlight the importance of FLC
monitoring in MM patients undergoing ASCT and/or treatment with biological
and new drugs. LCE underlines the intraclonal heterogeneity of MM; it was
recently associated with shortened overall survival. Hematologists should keep
in mind this possibility of evolving biology of disease in the “high dose and
novel agent era”.
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DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN
MULTIPLE MYELOMA
C Cerchione*, D Nappi, I Migliaccio, D Salvatore, F Pane, L Catalano
Hematology, Ematologia e Trapianto/AU Federico II, Napoli, Italy
Background: Bortezomib-based therapies are suggested as standards of care
in management of patients with newly diagnosed and relapsed multiple myelo-
ma. The recommended dose and schedule of Bortezomib is 1.3 mg/mq admin-
istred on days 1, 4, 8, and 11 of 21-day cycles, a regimen active and well tol-
erated. Subcutaneous administration of bortezomib could be a good option for
patients, particularly those with poor venous access. It’s known that home intra-
venous administration of bortezomib is feasible to adequately informed patients,
because we have recently demonstrated that a solution of bortezomib powder
in normal saline stored at 4°C remains stable for nearly one month.
Aims: Since 2009, in our unit all patients requiring bortezomib for the treatment
of multiple myeloma perform intravenous injection of the drug at home, after
having been supplied with the exact dose in saline solution, in ready-to-use
plastic syringes, appropriately prepared under hood in sterile conditions. This
procedure reduces the time spent by patients in hospital, improving conven-
ience for patients and physicians. However, in some patients venous access
may be difficult or sometimes unfeasible. As the drug is not histotoxic, subcu-
taneous administration is feasible, and this possibility is particularly attractive
in domestic settings.
Methods: Safety and efficacy of subcutaneous injections of bortezomib at the
same dose as i.v. administrations (1mg/sm, days 1, 4, 8, 11), but dissolved in
smaller saline volume (max. 1ml), in association with oral dexamethasone
20mg/dd. 1-2,4-5, 8-9, 11-12, was verified in 108 patients affected by multiple
myeloma, with poor venous access. In particular, the efficacy, evaluated as
reduction of the monoclonal component during the i.v. period vs the s.c. period
was performed in a subgroup of 12 patients.
Results: Results indicated an equivalence between the two administration
modalities, according to other larger controlled studies. Based on these reports,
108 patients, requiring Bortezomib as part of anti Myeloma regimens, have
been systematically treated by subcutaneous injections, performed at home.
No significant side effects have been reported so far and quality of life is par-
ticularly improved. In particular, in 37 of them we have evaluated an equivalence
between the subcutaneous and intravenous administration, according to other
controlled studies.
Summary/Conclusions: The possibility to perform an antineoplastic regimen
at home is particularly well accepted by all patients affected by multiple myelo-
ma, with an achievement of a very good quality of life.
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AL AMYLOIDOSIS: REAL WORLD EVIDENCE FROM ARGENTINA
N Schutz, E Nucifora*, D Fantl1, J Arbelbide, A Aguirre, V Otero, P Sorroche, B
Cesar, G Gustavo, H Garcia Rivello, B Boietti, S Maria, L Posadas Martinez
Medicina Interna, Hematología, Hospital Italiano de Buenos Aires, CABA,
Argentina
Background: AL amyloidosis is a challenge in clinical practice due to the dif-
ficulties in diagnosis and treatment. We present our experience from the RIA
Amyloidosis Registry managing this patients.
Aims: To evaluate the characteristics and outcomes of patients with Amyloido-
sis in Argentina.
Methods: Ambispective cohort observational study of patients with AL Amyloi-
dosis included in the Amyloidosis RIA Registry from January 2006 till July 2015.
Review of electronic medical records by the amyloidosis team. Data were
analysed with SPSS program using conventional descriptive statistics and
Kaplan Meier survival curves.
Results: The RIA Registry includes 140 patients: 6% (9) AA amyloidosis, 7%
(10) FAP amyloidosis; 8%(11) senil amyloidosis; 24% (36) localized amyloido-
sis; 18% (27) unidentified and 34% (47) AL amyloidosis. Multiple myeloma
patients with amyloidosis were excluded from the Registry. We included in this
study the 47 patients with confirmed AL amyloidosis. 64% (31) were males with
a median age of 58 years (35-81). The main reasons for consultation were
heart failure (81%); proteinuria (62%); nephrotic syndrome (30%); renal failure
(26); peripheral neuropathy; autonomic disfunction and gastrointestinal com-
plaints (10%). In the laboratory workup only 56% of patients had a measurable
M protein spike. Nevertheless, all patients had detectable clonal free light chains
by inmunofixation or serum free light chain assays. The most frecuente light
chain involved was lambda. Data regarding proBNP or BNP were available in
34 patients and only 4 patients had normal results. Due to delay in the diagnosis
9 patients died before starting proper treatment. Other 6 patients were treated
in other hospitals (no data available). From the 32 patients treated in our hos-
pital: 5 patients received upfront cardiac transplantation followed by CYBORD;
20 patients received low dose CYBORD; 4 patients received IMIDs and 3
patients conventional chemotherapy (prior to 2008). Autologous bone marrow
transplantation was performed in 10 patients. The response rate was: complete
response in 18 patients; partial reponse in 7 patients; progressive disease 1
patient; not evaluable 6 patients. There were 7 deaths; 3 in complete reponse
and 2 in partial response. The main causes of death were cardiac failure (5)
and sepsis (2).The median overall survival of patients treated in our hospital
was 86 months (IC95 27-144).
Summary/Conclusions: AL Amyloidosis is underdiagnosed in Argentina. The
consequent delay in diagnosis and start of treatment has a huge impact in the
quality of life and survival of this patients. Low dose CYBORD is a good treat-
ment option with and adecuate response rate and safety profile considering
the difficulties associated with amyloid organ damage. M spike and free light
chains response do not always correlates with organ response which usually
occurs much later. Therefore it is important to consider heart transplantation in
young patients with severe amyloid myocardiopathy as it remains the main
cause of death in this patients.
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RETROSPECTIVE STUDY OF THE EFFICACY, ECONOMY AND SAFETY
OF TREATMENT WITH SUBCUTANEOUS INJECTION OF BORTEZOMIB
IN DE NOVO PATIENTS WITH MULTIPLE MYELOMA
S Yan, P Wang, Y Xu, H Zheng, L Ma, S Jin, C Fu*, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Multiple myeloma(MM) is a clonal plasma cell malignancy. NCCN
guidelines recommended bortezomib-based therapies as the first front-line
treatment in patients with newly diagnosed and relapsed multiple myeloma.
Oakervee H E, et al proved that PAD combination (bortezomib/doxorubicin/dex-
amethasone) can improve survival for previously untreated MM patients.Periph-
eral neuropathy(PN) is a well-known and unavoidable side effect of bortezomib,
which is limited to the usage for some patients. The multi-centers clinical
research,suggested that subcutaneous administration of bortezomib was non-
inferior to the standard intravenous route of delivery but could reduce side-
effects of bortezomib, particularly in peripheral neuropathy. But China is lack of
data about the usage of bortezomib.
Aims: To explore the efficacy and safety of subcutaneous injection of borte-
zomib in the treatment of de novo MM patients.
Methods: A total of 57 MM patients treated with bortezomib, adriamycin and
dexamethasone form June 2008 to January 2015 were analyzed. Among them
28 received conventional PADiv with the intravenous bolus of bortezomib and
another 29 received PADih with the subcutaneous injection of bortezomib. The
efficacy and safety of two groups were evaluated.
Results: The overall response rate was 94.6% of all patients after four courses
of PAD induction.67.9%, 32.1% in PADiv group and 60.7%,30.4% in PADih
group achieved response>=VGPR and sCR/CR. The median follow-up of PADiv
group was 40(1.5-73) months and PADih was 20(1.5-30) months. There was
no difference of TTP and DFS between Two groups. But PADih group showed
a more favorable OS (p=0.004)even though with a shorter period of follow-up.
The statistical results showed that the most common hematologic toxicities of
grade 3/4 in the PAD group were granulopenia(67.9%), leukopenia(67.9%),
thrombocytopenia (67.9%) and anemia (35.7%), and non-hematologic toxicities
of grade 3/4 mainly included infection (39.3%), constipation (25%), diarrhea
(21.4%), peripheral neuropathy(21.4%), fever (21.4%), VZV infection (17.9%)
and anorexia (17.6%). Accordingly, the hematologic toxicities of grade 3/4 in
the PADih group were granulopenia(55.2%), thrombocytopenia (51.7%),
leukopenia(41.4%), anemia(41.4%) and non-hematological toxicities were
mainly constipation(34.5%), nausea(27.6%), anorexia(17.2%), diarrhea (17.2%)
and vomiting(10.3%). A total of 27 patients(47.4%) treated with Velcade suffered
from peripheral neuropathy. Incidence of PN of two groups even grade 3/4
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showed no statistic difference. 39.3% PADiv patients were infected during the
treatment and 3 died from severe pneumonia. The incidence of infection in
PADiv and PADih group shows great difference(P=0.000). Among other grade
3/4 adverse reactions, only data of leukopenia(P=0.045) and VZV infection
(P=0.023) show differences. Remarkably, six patients (21.4%) receiving PADiv
due to severe PN reduced dose of Velcade or Suspended treatment. Patients
treated with PADih did not appear serious infection. Average length of hospital
stay per circle of PADih and PADiv group is 24, 15 days, respectively (P=0.000).
Comparison of supportive therapies including G-CSF, platelets transfusion,
resuscitation, prevention of infection, nutrition and bortezomib reduction or sus-
pension through chi-square analysis showed that proportion of platelet trans-
fusion and prevention of infection was statistically significant (P=0.094;
P=0.091) when alpha=0.1. Ratio of resuscitation, anti-infection drugs, suspen-
sion or reduction of bortezomib in PADiv group is higher(P=0.009; P=0.002;
P=0.011). 
Summary/Conclusions: The PADih regimen by changing bortezomib from
intravenous bolus to subcutaneous injection significantly reduced adverse
events, improved the safety of clinical application of bortezomib without affect-
ing curative effect, and had greatly improved the overall survival due to lower
incidence of infection in the PADih patients. In addition, subcutaneous borte-
zomib could obviously reduce the length of stay in hospital per circle and inci-
dence of infection and decrease the cost of treatment. 
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THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH BORTEZOMIB
TREATMENT IN MULTIPLE MYELOMA
A Pedraza1,*, A Gonzalez1, C Vicente Ayuso1, M Garcia Roa1, L Sanchez2,
W Torres1, S Toral1, A Velazco1, A Bobes1, R BM Martinez2, M Mateo2
1Hematologia y Hemoterapia, 2Hospital Clinico San Carlos, Madrid, Spain
Background: Thrombotic microangiopathy (TMA) is a very diverse medical
condition defined by the presence of microangiopathic hemolytic anemia
(MAHA), thrombocytopenia and microvascular thrombosis, being characteristic
of the MAHA schistocytes in peripheral blood. From an etiopatogenics point of
view, it can be classified as primary, when there is clear evidence of a disorder
caused by TMA, as the TTP and HUS, and secondary, when the TMA is a
symptom of underlying conditions such as tumor processes, pregnancy, HIV
infection, bone marrow transplant and exposure to certain drugs. Today, drug
induced TMA is clearly recognized and it has been reported that at least 22
drugs involved in this process, including various chemotherapeutic agents
(cyclosporine, mitomycin C, gemcitabine, bevacizumab, ect) and other sub-
stances such as vaccines, herbal products and homeopathic drugs.
Aims: We show the sixth case reported to date of bortezomib-induced throm-
botic microangiopathy in MM.
Methods: 52 year-old woman diagnosed with multiple myeloma stage IIIA IgG
Lambda ISS II with anemia and without thrombocytopenia, creatinine 0.84
mg/dL and glomerular filtration rate of 81 mL/min, discreet elevation of LDH
and Beta2 microglobulin, monoclonal component of 2.2 g/dL IgG lambda and
urine 6390 mg/dl, bone lesions in dorsolumbar vertebrae and medullogram
with infiltration for plasmatic cells monoclonales of 25-35%. She starts first-
line treatment with bortezomib, lenalidomide and dexamethasone. The eleventh
day of treatment presents sudden increase of creatinine and a decrease in the
filtration rate, oliguria, and the progressive decrease of platelets. In addition,
hypertransaminasemia with hyperbilirubinemia and increased PCR, gradual
rise in LDH and decreased haptoglobin documented. In the peripheral blood
smear the platelet count was verified and frequent presence of schistocytes
was reported. Within the analytical study, not immune anemia is found with a
negative Coombs test, normal coagulation tests, serology, Shiga toxin in feces
and negative pregnancy test, ADAMTS13 activity of 33% and negative
ADAMS13 antibodies, and complement levels were normal. The treatment was
started with plasmapheresis until all 12 sessions were completed with progres-
sive improvement. After 5 additional cycles of chemotherapy with dexametha-
sone and lenaidomida without bortezomib, and an autologous stem cell trans-
plant, she reached very good partial response.
Results: So far, 5 cases of post TMA bortezomib have been described in the
literature (Table 1). The acute immunological reaction and the drug toxicity are
the two recognized hypothesis that explain the development of thrombotic
microangiopathy secondary to drugs. The variavility in the time of the beginning
of the TMA in five cases, ADAMS13’s different values and the absence of anti-
bodies in one of them, suggests that not only the immune mechanism is
involved in his etiopatogenia. Nevertheless, other drugs such as ticlopidine,
produce MAT by a clearly immune mechanism unleashing a severe decrease
of the activity of ADAMS13 by the production of antibodies anti ADAMS13.
Though, the immunomodulatory capacity of the bortezomib inside the bone
marrow microenvironment was demonstrated, still it is not known if such a con-
dition could have any relation with the development of MAT; of fact, a case of
microangiopathy successfully treated with bortezomib has been reported, argu-
ing the blockage of plasma cells and B-lymphocytes autoreativos. On the other
hand, other medicines like the monoclonal antibodies anti VEGF (ej. beva-
cizumab) that alter directly the angiogenesis have been associated with TMA.
Bortezomib in addition from blocking the action of the proteasome, also sup-
presses the production and secretion of VEGF, which could be related to an
altered angiogenesis and endothelial damage characteristic of TMA. For the
treatment of MAT diverse empirical therapies were used, without restarting the
bortezomib in any of five cases and the clinical being solved in all of them.
Table 1. Case reports of TMA associated with BTZ.
Summary/Conclusions: TMA must be recognized as a potentially serious
secondary side effect to its administration of bortezmib in patients who develop
MAHA, thrombocytopenia and acute renal failure.
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A SINGLE CENTRE REAL LIFE EXPERIENCE ON MULTIPLE MYELOMA
(MM) PATIENTS: SUBCUTANEOUS (SUBQ) VERSUS INTRAVENOUS (IV)
BORTEZOMIB (BOR)
MS Infante*, I Gonzalez, C Muñoz, C Heras, MA Foncillas, K Marín, JA Hernandez
Hospital General Infanta Leonor, madrid, Spain
Background: The outcome of multiple myeloma patients (MM) has significantly
improved over recent years, mainly due to the discovery of novel antimyeloma
agents together with a better knowledge of the biology of the disease [Kumar
et al. 2008]. One of these novel agents is bortezomib, the first in the class pro-
teasome inhibitors introduced in the clinical practice approximately one decade
ago. However, toxicity, especially peripheral neuropathy, as well as the intra-
venous route required for its administration are the two most significant borte-
zomib-related issues. To try to reduce the peripheral neuropathy, new guidelines
for its management and the introduction of weekly schedules of administration
have contributed to significantly decrease its incidence and the subcutaneous
(subQ) administration has been recently introduce to avoid the intravenous
(IV) route. Results obtained in phase I/II and III studies have confirmed that
subcutaneous administration is feasible and represents an additional step
towards the optimization of bortezomib use, resulting in a probably more con-
venient method than the IV route that is at least as effective.
Aims: To evaluate efficacy and tolerability of Bortezomib (IV vs sub Q) in stan-
dard combination myeloma regimens. Moreover, we compared the incidence
of peripheral neuropathy.
Methods: We reviewed data of 50 consecutive MM patients treated at our Hema-
tologic division between October 2008 to November 2015. Standard criteria were
applied to evaluate response rate and neurotoxicity (NCI CTCAE national Cancer
institute common terminology criteria for adverse events version 4.0).
Figure 1.
Results: Our case serie is composed by 50 patients diagnosed with MM and
treated in 1º line with combination regimen including Bortezomib (subQ or IV).
Median age 75 years (range 39-89). 17/50 (34%) were administered VD regi-
men (7 subQ vs 10 IV), 27/50 (54%) patients were administered VMP (15 subQ
vs 12 IV), 2/50 patients (4%) received poliQT VMCP/VBAD (IV Bortezomib)
while 4 patients (8%) received VDT regimen as induction to transplant consol-
idation with subQ Bortezomib. Overall survival (OS) of the serie was 84 months
(47-120 range) (Figure 1) with a free progression survival (FPS) of 23 months
(19-30 range): no difference was found between subQ or IV Bortezomib regi-
men in terms of survival. There were 12 cases (24%) of neurotoxicity in our
serie: 2/12 (16%) patients with VTD (subQ Bor) where the role of the
inmunomoduladory drug in the toxicitiy must be considered; 6/12 (50%) cases
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with IV Bor and 4/12 (33%) cases with subQ Bor: all 5/6 cases of neurotoxicity
in IV Bortezomib were grade III with need of suspension of the drug. In subQ
population there were 1 case with grade I toxicity and 3 cases of grade II neu-
rotoxicity with reduction of the dose.
Summary/Conclusions: In our real life experience OS and FPS in our serie is
notable, with 84 months and 23 months described. In terms of toxicity there were
slightly more cases of neutorotoxicity in IV Bor population with higher grade of
toxicity than the subQ population. In conclusion, the subQ formulation of borte-
zomib represents an additional step towards the optimization of bortezomib use,
resulting in a more convenient route that is at least as effective as the IV route.
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REAL WORLD EXPERIENCE OF BORTEZOMIB RE-TREATMENT FOR
PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE
Y Reyal1,2,*, R Popat3, S Cheesman4, A Rismani3, S D’Sa3, N Rabin3, K Yong1
1Haematology, UCL Cancer Institute, 2Haematology, St George’s University
Hospital, 3Haematology, 4University College London Hospitals NHS Trust, Lon-
don, United Kingdom
Background: In the United Kingdom (UK), bortezomib (Velcade, Janssen)
based triplet regimens are commonly used as first line therapy for both trans-
plant eligible and ineligible patients. The efficacy of re-treatment with bortezomib
monotherapy or bortezomib plus dexamethasone in subsequent lines of therapy
has been previously reported. However there are limited data on re-treatment
at first relapse, particularly with bortezomib-based triplet regimens which are
more commonly used in current practice.
Aims: This study aimed to evaluate the efficacy of bortezomib triplet regimens
at first relapse in patients previously treated with first line bortezomib. The
safety of bortezomib as re-treatment was also assessed. 
Methods: This was a retrospective analysis of MM patients at first relapse
treated with bortezomib, who had also received bortezomib as first line therapy.
Twenty three sequential patients from a single UK center who had achieved at
least a partial response (≥PR) and a treatment free interval (TFI) of a minimum
of 60 days from first line bortezomib treatment (i.e. not refractory) were identi-
fied. Response to treatment and disease progression were defined by the Inter-
national Myeloma Working Group criteria.
Results: A triplet bortezomib combination was used as first line therapy in 78%
of patients (n=18/23) with a median of five cycles given (range 4-8). No patient
received maintenance therapy. The median time to best response (TTBR) was
3.5 months (range 0.7-9.0) and the median duration of response (DOR) was
14.9 months (range 4.7-44.5). The overall response rate (ORR) to bortezomib
at first relapse was 87% (PR 39%, VGPR 35%, CR 13%). The median TTBR
was 4.1 months (range 0.7 -15.0) and median DOR was 11.5 months (range
1.0-18.5). After first line bortezomib, the median time to progression (TTP) was
18.9 months (range 7.3-49.6) whilst it was 14.4 months (range 1.4-16.6) at first
relapse. The median TFI was 20.7 months (range 2.0-62.8) after first line borte-
zomib and 10.4 months (range 1.0-14.0) after bortezomib re-treatment. Ten
patients received ASCT at first line compared to 11 at first relapse. Treatment-
related toxicity was also evaluated. At first line, eleven patients (48%) experi-
enced peripheral neuropathy (PN) (all grade 1). There were three (13%) grade
3-4 non-hematological adverse events (AE), which were all infections. All but
one patient restarted bortezomib at full dose at relapse. Only two patients (11%)
required a subsequent dose reduction (for PN). Eleven patients (61%) experi-
enced PN with first relapse treatment (all grade 1-2). There were two grade 3
AEs (diarrhoea and febrile neutropenia). All patients who relapsed for a second
time were able to proceed to a third line regimen which was most commonly
lenalidomide and dexamethasone.
Summary/Conclusions: This single center study in real life patients demon-
strates that bortezomib combinations used at first line and sequentially at first
relapse represent a valid treatment strategy for selected patients. 
PB2006
FIRST EXPERIENCES WITH GENERIC BORTEZOMIB ADMINISTRATION
ONE CENTRE EXPERIENCE
A Jungova*, S Vokurka, P Jindra
Hemato-oncology department, Charles University Hospital Pilsen, Pilsen,
Czech Republic
Background: Multiple myeloma (MM) is malignant haemato-oncology disease
characterised by clonal proliferation of plasmocytomas. Disease treatment is
started with induction therapy in the symptomatic phase of the disease. Regi-
mens with combination of vincristine, doxorubicin and corticoid were used in
the last century. From 2002 are used in the Czech Republic “new drugs” as
thalidomide and bortezomib (several years later also lenalidomide). As standard
induction regimen is VTD regimen recommended (bortezomib, thalidomide and
dexamethasone). Original drugs with bortezomib (Velcade) are still used, but
generics drugs with equivalent active substance are also on the market now.
These generics should be equivalent with originals. According our first experi-
ences none serious adverse events were presented, other complications were
of similar character as with original bortezomib.
Aims: First experiences in administration of generic bortezomib, adverse
events, patient’s toleration.
Methods: During 11-12/2015 generic bortezomib was administered to 28
patients (altogether 80 applications) at our department
Results: Adverse events after generic bortezomib applications occurred in 28
patients. Anaemia (c.18%) and thrombocytopenia (c. 14%) were between most
often complications. From complication of lower grade occurred tiredness
(17%), infection (3%), neuropathy (8%) and diarrhoea (3%).
Summary/Conclusions: We administered altogether 80 generic bortezomib
applications to 28 patients at Haematology and oncology department in 11-
12/2015. During this time none serious complication occur and most of adverse
effects were of I. and II. grade. These complications were similar to original
bortezomib complications. Other comparison with original product in longer
time is necessary.
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DEVELOPMENT OF RAS-INDUCED ZEBRAFISH LEUKEMIA MODELS
E Alghisi1, M Konantz1, M Mione2, C Lengerke1,3,*
1Department of Biomedicine, University Hospital Basel, Basel, Switzerland,
2Karlsruhe Institute of Technology, Institute of toxicology and genetics, Eggen-
stein- Leopoldshafen, Germany, 3Clinic for Hematology, University Hospital
Basel, Basel, Switzerland
Background: The zebrafish has emerged as a versatile novel experimental
model for studies on developmental hematopoiesis and leukemogenesis. Sev-
eral oncogenes involved in human leukemia have been successfully overex-
pressed in zebrafish embryos. However, despite first encouraging results, these
models often fail to fully recapitulate human myeloid malignancy, perhaps due
to early lethality caused by transgene expression or lack of secondary events
necessary for full malignant transformation.
Aims: Here we present a RAS overexpression zebrafish model that we plan
to use for investigations on molecular mechanisms involved in leukemia initi-
ation and progression and for drug screening that can identify novel anti-
leukemic compounds.
Methods: We take advantage of the Gal4/UAS binary system and of existing
transgenic lines and overexpress human oncogenic HRAS in zebrafish
hematopoietic cells under the control of specific promoters (fli.1, pu.1, runx.1,
mpeg1). The generated HRAS-transgenic fish lines are followed microscopi-
cally until the time-point of death or sexual maturity and hematopoietic cell
development is studied correspondingly at embryonic (fli.1, pu.1), larval (pu.1,
runx1) and adult stages (runx1) also by in situ hybridization/real-time PCR
analysis of hematopoietic gene expression, flow cytometry, immunohistochem-
istry and/or blood smear morphological assessment. 
Results: Different phenotypes were observed depending on the promoter driv-
ing the oncogene expression. HRAS induction via the early hematopoietic pro-
moter fli.1 affects primitive hematopoiesis inducing myelo-erythroid proliferation
and delayed erythrocyte maturation resulting in an expansion of hematopoietic
tissues (Alghisi et al. 2013). Unfortunately, studies at later stages are not pos-
sible in these fish due to their early lethality resulting from vascular defects
and cardiac edema. Alternatively, HRAS expression driven by runx1, pu.1 and
mpeg1 allows survival at these early stages permitting studies on larval and
adult hematopoiesis. Interestingly, at 1 month, runx1-HRAS fish displayed a
cellular expansion of hematopoietic stem/progenitor cells (HSPC) in the kidney
marrow (KM), the zebrafish definitive hematopoietic compartment. Cytospin
preparation and flow cytometric analyses revealed high numbers of undiffer-
entiated stem/progenitor cells in both KM and peripheral blood of HRAS trans-
genic fish, suggesting that HRAS-overexpression in HSPCs expands this com-
partment by inducing its proliferation and perhaps additionally by impairing dif-
ferentiation capacity. Furthermore, mpeg1-HRAS fish showed increased num-
bers of blood progenitors in the KM and abnormal gene expression of progen-
itor markers as demonstrated by qRT-PCR. Analysis of pu.1-HRAS juvenile
fish is under way.
Summary/Conclusions: We are currently further investigating the effects of
runx1-driven HRAS on the hematopoietic compartment and generate tools to
explore potential cooperation of HRAS with other oncogenes during leukemo-
genesis. A screen analyzing compounds successfully suppressing the effects
of HRAS on zebrafish hematopoiesis is underway and the results will be pre-
sented at the meeting.
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MOLECULAR AND CYTOGENETIC PROFILE OF PATIENTS WITH PRI-
MARY MYELOFIBROSIS
L Polushkina1,*, I Martynkevich1, V Shuvaev1, E Petrova1, L Martynenko1,
N Cybakova1, M Ivanova1, E Shabanova1, I Zotova1, T Zamotina1,
A Zhernyakova1, A Savrilova2, D Shikhbabaeva1, M Fominykh1, K Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, 2Republican Clinical Hospital of Tatarstan Republic, Kazan’, Russian
Federation
Background: Primary Myelofibrosis (PMF) is hematopoietic stem cell malig-
nancy characterized by clonal proliferation of myeloid-lineage cells. The molec-
ular basis of this event includes mutations in JAK2, MPL and CALR genes,
called clonal markers (CM), cytogenetic abnormalities and epigenetic disorders.
The variability of the clinical course among patients with PMF due to different
CM and epigenetic status requires close analysis for possible stratification by
risk groups.
Aims: The aim of our study was to estimate overall survival (OS) in PMF
patients depending on the type of CM, cytogenetic and epigenetic features.
Methods: We have examined 89 patients with PMF. Median age was 59 years
(range 19-82). For all patients the detection of V617F mutation of JAK2 was
done. JAK2-negative samples were tested for MPL 515 codon mutations (PCR-
RFLP) and 9th exon mutations of CALR gene by direct sequencing. Seventy-
three patients underwent the analysis of mutations in EZH2 and ASXL1 genes
with high resolution melting method followed by direct sequencing of probably
mutated samples. Karyotype research was done for 39 patients with available
bone marrow samples.
Results: CM were detected in 64 patients: JAK2+ 46.1% (41/89), CALR+
21.3% (19/89), MPL+ 4.5% (4/89) cases. No clonal markers were found in
28.1% (25/89) patients considered triple-negative (TN). Median survival of TN
patients was the shortest and amounted to 4 years (p=0.041), JAK2+ 11.9
years. In CALR+ and MPL+ patients during follow-up of 10 and 4 years, respec-
tively, median survival has not been reached. According to the results of cyto-
genetic analysis patients were divided into 2 groups: the first group included
20 patients with normal karyotype (NK) and 5-with del(13)(q22), del(20)(q12),
add(6)(p25), del(6)(q15) single features; the second group consisted of 13
patients with complex abnormalities and unfavorable aberrations (+8, -7/7q-,
i(17q), inv(3), -5/5q-, 12p-). Median survival in the first group was 7.4 years, in
the second group-4.5 years. It should be noted separately that unfavorable
karyotype frequency was distinct in groups with different CM: CALR+ 0% (0/8),
JAK2+ 35% (6/17), TN 54% (7/13) cases (р=0.053). We have detected 18
mutations of ASXL1 gene in 16 patients (21.9%): fourteen patients had single
mutation and two patients harbored 2 mutations at once. Mutation frequency
was significantly higher in CALR+ patients compared to JAK2+ (37.5% (6/16)
and 6.9% (2/29), р=0.037, resp.) and in TN patients compared to JAK2+ (33.3%
(8/24) and 6.9% (2/29), р=0.044, resp.). Two mutations in EZH2 gene (2.2%)
were observed in TN, ASXL1+ patients. Both cases characterized of high-risk
progression of PMF. The first patient (men, 61-year-old, complex karyotype)
progressed to blast phase rapidly from the diagnosis and died after 8 months.
The second patient (men, 75-year-old, NK) had severe thrombocytopenia and
died from hemorrhagic stroke after 5 months since the diagnosis.
Figure 1.
Summary/Conclusions: Type of CM, cytogenetic aberrations and epigenetic
changes can be correlated with different prognosis of PMF. The absence of
CM and unfavorable karyotype are associated with reduced overall survival.
The impact of epigenetic status on the prognosis in PMF patients requires fur-
ther study.
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ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUST-
NESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY
INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES
M Perricone1,*, F Palandri1, M Angelini2, L Bagli3, E Bellesia4, M Donati5,
D Gemmati6, B Giannini3, P Zucchini7, S Mancini8, P Storti9, S Trubini10,
G De Matteis11, S Di Zacomo12, M Favarato13, MA Fioroni14, M Gusella15,
G Maccari16, F Navaglia17, M Svaldi18, L Toffolatti19, L Orlandi20, V Laloux21,
M Manfrini22, A Cuneo6, P Galieni2, R Marasca7, E Pazzaglia5, A Sensi3,
A Tieghi4, N Giuliani9, P Leoni8, D Vallisa10, M Bonifacio11, P Di Bartolomeo23,
V Fazio14, D Gatti18, F Gherlinzoni19, R Paolini17, M Plebani15, M Tiribelli16,
F Cassavia20, F Orsini20, M Cavo22, E Ottaviani22, G Martinelli22
1Institute of Hematology “L. and A. Seràgnoli”, bologna, 2Laboratorio UOC di
Ematologia Area Vasta N°5 Ospedale Mazzoni, Ascoli Piceno, 3Laboratorio
Unico- AUSL della Romagna UO Genetica Medica, Pievesestina di Cesena,
4Clinical Chemistry and Endocrinology Laboratory, Imaging and Laboratory
Diagnostic Department, Hematology Unit, Oncology and Technology Depart-
ment, Hospital S. Maria Nuova, IRCCS, Reggio Emilia, 5Laboratorio Patologia
Clinica, AO Ospedali Riuniti Marche Nord, Pesaro, 6Department of Medical
Sciences, Ctr. Hemostasis & Thrombosis, Section of Hematology, University-
Hospital of Ferrara, Ferrara, 7Department of Medical and Surgical Sciences,
Division of Hematology, University of Modena and Reggio Emilia, Modena,
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8Lab. Clinica Ematologia, Dipartimento Scienze Cliniche e Molecolari, Univer-
sità Politecnica delle Marche, Ancona, 9Dipartimento di Medicina Clinica e
Sperimentale ed Unità di Ematologia, Azienda Ospedaliero-Universitaria di Par-
ma, Parma, 10Laboratorio di Biologia Molecolare UO Anatomia Patologica e
UO Ematologia e Centro Trapianti, Ospedale “G. da Saliceto”, Piacenza, 11DAI
Patologia e Diagnostica UOC Laboratorio Analisi dU e Dipartimento di Medicina,
Sezione di Ematologia, Azienda Universitaria Integrata di Verona, Verona,
12U.O.C. di Immunoematologia-Medicina Trasfusionale-Lab. Ematologia, ASL
Pescara Ospedale Spirito Santo, Pescara, 13UOS Diagnostica Molecolare,
Dipartimento di Patologia Clinica, ULSS12 Veneziana, Venezia, 14UOC medi-
cina di laboratorio, P.O. San Salvatore, ASL n. 1 Avezzano, Sulmona, L’Aquila,
15Laboratorio di Farmacologia e Biologia Molecolare, Ospedale S. Luca, Azien-
da ULSS18, Rovigo, 16Division of Hematology and Bone Marrow Transplanta-
tion, Azienda Ospedaliero-Universitaria di Udine, Udine, 17UOC Medicina di
Laboratorio, Azienda Ospedaliera-Università di Padova, Padova, 18Haematol-
ogy and BMT, Azienda Sanitaria dell’Alto Adige, Comprensorio di Bolzano,
Bolzano, 19Department of Pathology and Haematology, Treviso General Hos-
pital, Treviso, 20Werfen- Instrumentation Laboratory SpA, Milano, Italy, 21QIA-
GEN GmbH, Hilden, Germany, 22Institute of Hematology ‘L. and A. Seràgnoli’,
Bologna, 23UOC di Immunoematologia-Medicina Trasfusionale-Lab. Ematolo-
gia, ASL Pescara Ospedale Spirito Santo, Pescara, Italy
Background: In chronic myeloproliferative neoplasms (MPNs), the quantifica-
tion of the JAK2V617F allele burden (AB) is crucial for diagnosis and prognosis
assessment, and also for disease monitoring after allogeneic stem-cell trans-
plantation. To-date, a plethora of techniques for JAK2V617F,determination is used
over different molecular laboratories, with substantial differences in specificity
and sensitivity. Given the need to provide reliable and comparable molecular
results, the standardization of molecular techniques is of utmost importance.
Aims: The aims of this multicenter study were: 1) to evaluate the inter- and
intra-laboratory variability in JAK2V617F,quantification in 19 Italian molecular
laboratories; 2) to identify the most robust assay for the standardization of the
molecular test; 3) to allow consistent interpretation of individual patient analysis
results.
Methods: A network of 19 Italian molecular laboratories was established. The
study was coordinated by the Institute of Hematology “L. and A. Seràgnoli”,
Bologna, and was developed in 3 different rounds (Fig. 1). In routine practice,
2 laboratories did not assess JAK2V617F,mutation whereas 7 used a qualitative
approach and 10 performed a quantitative evaluation. Both reagents and DNA
samples were provided by Werfen-IL SpA and QIAGEN. Raw data and runs
validity were checked according to handbook recommendations. Statistical
analysis was carried out by QIAGEN/Bologna University.
Results: In the 1st round, we aimed to investigate the inter-laboratory variability
on different mutation loads. All laboratories using a quantitative approach were
able to determine the expected JAK2V617F,AB. Conversely, laboratories using
a qualitative approach did not detect the positivity of samples with a low AB
(0.15%). To further investigate the inter-laboratory variability on low-positive
samples, we developed a 2nd round, in which 3 additional laboratories were
included. In this 2nd round, each laboratory performed 2 runs with ipsogen
JAK2 MutaQuant kit and 2 runs with their routinely used method. None of the
laboratories using qualitative “in-house” methods were able to detect low-pos-
itive samples, while quantitative results by ipsogen JAK2 MutaQuant kit showed
only a small variability among different laboratories at low AB (0.1 and 1%; CV
=0.42 and 0.24, respectively). The 3rd round was intended to confirm the robust-
ness of the ipsogen JAK2 MutaQuant kit in a larger cohort of laboratories. The
study was therefore extended to 9 additional laboratories. “Home-made” meth-
ods were excluded and all laboratories performed 2 runs with the ipsogen JAK2
MutaQuant kit. Quantitative results were well reproducible across all mutation
loads. Only one laboratory failed to quantify 0.1% sample in one run. Impor-
tantly, all laboratories clearly distinguished between the 0.1 and 1% mutated
samples (0.1 and 1%; CV =0.46 and 0.77, respectively).
Table 1. Design of the study.
Summary/Conclusions: The first result of the study is that a qualitative
approach is not sensitive enough to detect the JAK2V617F mutation at a low
(≤1%) burden. Conversely, the ipsogen JAK2 MutaQuant kit resulted highly
efficient and sensitive in the quantitative detection of all mutation loads. This
study sets the basis for the creation of an Italian network of molecular labora-
tories focused on the diagnosis of MPNs, including not only JAK2V617F, but
also Calreticulin and MPL mutations. The network will aim to identify/standard-
ize the most efficient and cost-effective techniques for the evaluation of these
mutations, so to produce reliable and reproducible molecular data.
PB2010
PHARMACOLOGICAL ACTIVITY PROFILING OF PACRITINIB IN THE
BIOMAP® HUMAN PRIMARY CELL PLATFORM
R Watson1,*, S Al-Fayoumi1, V Sharlene2, A O’Mahony2, E Berg2, J Singer1
1Translational Sciences, CTI BioPharma, Seattle, 2DiscoverX, South San Fran-
cisco, United States
Background: Pacritinib is an orally available kinase inhibitor with specificity
for JAK2, FLT3, IRAK1 and CSF1R. Comprehensive mapping of the pharma-
cological profile of pacritinib should enable a better understanding of the mech-
anistic basis of pharmacological action and support the utility of pacritinib in
physiologically-relevant therapeutic areas. 
Aims: The main goal of this study was to explore the effects of pacritinib on
biomarkers relevant to human disease using BioMAP® Human Primary Cell
Systems. A secondary goal was to compare and contrast the profile of pacritinib
using this platform with that of other clinically available kinase inhibitors, to
gauge the potential for differentiating effects of pacritinib in the clinical setting. 
Methods: Pacritinib was evaluated in the BioMAP® Diversity PLUS panel by
DiscoverX Corporation. Twelve human primary cell based systems were stim-
ulated with one or more well-described biological factors to activate multiple
disease-relevant signaling pathways. Each primed system was then tested with
four concentrations of pacritinib ranging from 26-711 nM, encompassing phys-
iologically and clinically relevant concentrations of the free drug (~200 nM in
plasma). Anti-proliferative activity of pacritinib was determined for several
human primary cell types and 148 biomarkers were measured by high-through-
put immune-based assay. Biomarkers impacted by pacritinib treatment were
evaluated for dose-dependency, and compared to a reference database of
compounds including ruxolitinib (Jakafi), a JAK2 inhibitor approved for use in
myelofibrosis.
Results: Exposure to pacritinib resulted in anti-proliferative activity in human
endothelial cells, T cells, B cells, and coronary artery smooth muscle cells at
711 nM. This effect was most pronounced in B cells, the only cell type in which
proliferation was also impacted at the lower, clinically relevant range. Cytotox-
icity was not observed in any of the cell types. In addition, pacritinib had promi-
nent immunomodulatory activities in the BT system modeling T-cell dependent
B-cell activation. In the BT system, pacritinib resulted in statistically significant,
concentration-dependent decreases in soluble TNFα, IgG, IL-17A, IL-17F, IL-
2 and IL-6. Statistically significant, but less pronounced effects were also
observed on inflammatory, tissue remodeling, and hemostasis-related activities.
A comparison of pacritinib’s profile at 711 nM with that of 1 µM ruxolitinib in the
BT system demonstrated that pacritinib had more inhibitory effects on immune
biomarkers, with fewer effects on biomarkers in other systems modeling differ-
ent tissue biology. 
Summary/Conclusions: BioMAP® analysis indicated that pacritinib impacts
several disease biomarkers in a manner that may translate to differentiated
therapeutic benefit. For instance, pacritinib’s marked inhibition of inflammatory
cytokines IL-17A and IL-17F and TNFα is potentially beneficial in rheumatoid
arthritis, atherosclerosis, and/or psoriasis. The information obtained in the Bio-
MAP® platform provided valuable insights that enabled selection of follow-up
studies to perform in relevant animal disease models. Moreover, pacritinib’s
profile was distinct from that of ruxolitinib, which may underlie some of the com-
parative differences observed in the clinical setting. In order to further charac-
terize pacritinib’s effects on human disease models in comparison to other com-
pounds, an expanded follow-on BioMAP® study is planned.
PB2011
A NOVEL REAL-TIME PCR ASSAY SET FOR DETECTION OF DIVERSE
CALR MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS
R Jäger1,*, JD Milosevic Feenstra1, E Bogner1, B Gisslinger2, M Schalling2,
S Turcan Debono3, H Gisslinger2, R Kralovics1,2
1CeMM - Research Center for Molecular Medicine of the Austrian Academy of
Sciences, 2Department of Internal Medicine I, Medical University of Vienna,
Vienna, Austria, 3HalioDx SAS, Marseille, France
Background: Mutations in the CALR gene have been found in a large propor-
tion of patients suffering from myeloproliferative neoplasms (MPN). While 52bp
deletions (Type 1) and 5bp insertions (Type 2) constitute >80% of CALR muta-
tions, a variety of other insertion-deletion mutations have been reported, all
within a 66bp mutational hotspot in exon 9 of CALR. Reliable and efficient
detection of those somatic driver mutations is crucial for MPN diagnosis and
patient management.
Aims: We previously characterized our MPN patient cohort for insertions and
deletions in the CALR gene using a PCR-based fragment sizing assay in com-
bination with Sanger sequencing. Here we compare the characteristics of this
fragment analysis with a novel real-time PCR (qPCR) based assay set (ipsogen
CALR RGQ PCR Kit, provided pre-launch by QIAGEN, Hilden, Germany).
Methods: Fragment analysis of CALR exon 9 was performed using high-res-
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olution sizing of fluorescent dye labeled PCR products on a 3130xl Genetic
Analyzer (ABI, Foster City, CA). The ipsogen CALR RGQ PCR Kit was applied
according to the manufacturer’s instructions in 7 separate hydrolysis-probe-
based qPCR reactions per sample within the same run. The kit identifies Type
1 and Type 2 mutations using ARMS PCR, in which a primer mismatch prevents
elongation on wild-type (WT) DNA. Minor variants of CALR mutations are
detected through a PCR clamping approach using 3’-phosphate blocked
oligonucleotides complementary to WT sequence. For both fragment analysis
and the ipsogen assay we determined dynamic range and detection limits
through serial dilution of mutant genomic DNA (gDNA) in WT gDNA, generating
CALR mutational burden standards down to 0.01%.
Results: Using the ipsogen CALR RGQ PCR Kit, we re-tested gDNA from 48
MPN patients (10 Type 1, 10 Type 2, 18 minor variants, 10 CALR mutation
negative) previously evaluated by fragment analysis. Concordance between
both assays was 100%. While the ipsogen assay formally requires a per reac-
tion input of 50ng gDNA freshly isolated from peripheral blood, our samples
were from a mixed cohort of various storage time and isolation protocols. More-
over, we applied the ipsogen assay on a large proportion of our samples using
DNA inputs of 25ng and 10ng, respectively. CALR mutational status could be
confirmed for all those cases. We next determined the limit of detection (LoD)
of Type 1 and Type 2 mutations for both the ipsogen assay and fragment analy-
sis. While limit-of-blank-based calculation of LoD revealed 0.39% and 0.08%
for Type 1 and Type 2 ipsogen assays, respectively, fragment analysis could
reliably detect 2.5% but not 1% CALR mutational burdens. Determination of
the dynamic range revealed linearity for the fragment analysis down to the
2.5% detection limit. For the ipsogen assays, linearity on the log-scale could
be observed down to 1% and 0.5% CALR mutant burden for Type 1 and Type
2 assays, respectively. Within these dynamic ranges, standard curves could
be produced with a correlation coefficient of >0.98. 
Summary/Conclusions: While fragment analysis represents a rapid, cost-
effective assay for screening larger cohorts in a multi-well format, the specific
identification of Type 1 and Type 2 mutations requires Sanger sequencing in
addition. The ipsogen CALR RGQ PCR Kit offers, at once, reliable detection
of CALR mutations and specific identification of Type 1 and Type 2 mutations,
requiring minimal processing and equipment (Rotor-Gene Q MDx, QIAGEN).
Moreover, the ipsogen assay showed superior sensitivity over fragment analy-
sis and might therefore be most suitable for tracking the dynamics of the malig-
nant MPN clone.
PB2012
THE S100 PROTEINS AS MEDIATORS OF INFLAMMATION ARE INCREASED
IN MYELOPROLIFERATIVE NEOPLASM AND DOWNREGULATED BY
JAK2 INHIBITION
M Diklić1, M Buač2, O Mitrović2, B Beleslin-Čokić3, T Subotički2, D Dragoslava2,
V Čokić1,*
1Laboratory of experimental hematology, 2Laboratory of neuroendocrinology,
Institute for Medical Research, University of Belgrade, 3Clinic for Endocrinology,
Diabetes and Metabolic Diseases, Genetic laboratory, Clinical Center of Serbia,
Belgrade, Serbia
Background: Chronic inflammation is associated with sustained myeloprolif-
eration, while S100 proteins have been shown to regulate cell proliferation, dif-
ferentiation and inflammation in pathological conditions. S100A8, A9 and A12
produced by cells of myeloid origin were mediators of inflammation, while
S100A4 regulated cell proliferation in neoplasia. S100A4 and A12 are produced
via activation of the JAK-STAT pathway, constitutively activated in myeloprolif-
erative neoplasm (MPN).
Aims: This study analyzed the inflammation linked S100 proteins in MPNs:
polycythemia vera (PV, n=16), essential thrombocythemia (ET, n=16), primary
myelofibrosis (PMF, n=20), according to JAK2V617F and CALR mutation sta-
tus, and healthy controls (n=8), and their regulation in JAK2V617F mutated
human erythroleukemia cell line (HEL) during MPN simulated therapy.
Methods: S100A4, A9 and A12 mRNA levels in granulocytes and HEL cells
are measured by real time PCR, while protein expression of S100A4, A8, A9
and A12 are examined in granulocytes and plasma of MPN using immunoblot-
ting and immunoassay, respectively. In addition, S100A9 is determined by
immunohistochemistry in bone marrow. Also, levels of S100A4, A9 and A12
are measured by real time PCR and immunoblotting in HEL cells incubated 48
hours with hydroxyurea and specific JAK2 inhibitor 1,2,3,4,5,6-hexabromocy-
clohexane (HBC). Mutations of JAK2V617F and CALR exon 9 are analyzed
by DNA sequencing and allelic PCR.
Results: S100A12 mRNA level is significantly increased in JAK2V617F het-
erozygous ET patients, but downregulated in JAK2V617F heterozygous PV
patients and PMF without mutation (p<0.05). However at protein level,
S100A12 is significantly increased only in granulocytes of ET patients without
mutation (p<0.05) and plasma of PV and PMF without JAK2V617F mutation
(70 ng/ml, p<0.01). Besides non significant modification at mRNA levels,
S100A4 and S100A9 protein expression demonstrated a common significant
increase in granulocytes (p<0.01), followed by increased quantity of S100A9-
positive cells in bone marrow and S100A8/A9 proteins in plasma of MPN
patients (51 and 28 ng/ml, p<0.01). Presence of CALR mutation augmented
S100A8/A9 levels in plasma and granulocytes of ET and PMF patients. After
48 hour, hydroxyurea and specific JAK2 inhibitor HBC significantly decreased
S100A4 mRNA levels in HEL cells (p<0.01). Further on, protein expression of
S100A4 and S100A9 are also significantly downregulated by hydroxyurea and
JAK2 inhibitor HBC in HEL cells (p<0.05).
Summary/Conclusions: S100A4, A9 and A12 mRNA and protein levels are
not generally influenced by JAK2V617F mutant allele burden. S100A4 and
anti-inflammatory S100A8/A9 protein levels demonstrated stable elevation in
contrast to sporadic pro-inflammatory S100A12 appearance in MPNs. More-
over, JAK2 inhibition reduced S100A4 and S100A9 levels in HEL cells.
S100A8/A9 could serve as a clinical biomarker and therapeutic target in MPNs,
with existing S100A8/A9 blockers permitted for clinical testing.
PB2013
HIGH SENSITIVITY MLPA ASSAY FOR THE DETECTION OF THE RECURRENT
CALR, JAK2, KIT AND MPL MUTATIONS WITH ≥1% ALLELE BURDEN IN
MYELOPROLIFERATIVE NEOPLASMS
M Steenkamer1,*, A Stuitje1, L Atanesyan1, K Stouten2,3, M van de Werken2,
R Castel2, S Savola1
1Tumour Diagnostics, MRC-Holland, Amsterdam, 2Clinical Chemistry and
Haematology, 3Internal Medicine, Albert Schweitzer Hospital, Dordrecht,
Netherlands
Background: Myeloproliferative neoplasms (MPNs) are chronic hematopoietic
stem cell malignancies, characterized by clonal proliferation of blood cells.
Recurrent mutations in CALR, JAK2, KIT and MPL genes are important molec-
ular markers for classification and prognostication of MPNs. Multiplex Liga-
tion-dependent Probe Amplification (MLPA) is a widely used technique for gene
copy number detection, also allowing simultaneous identification of known point
mutations. However, the sensitivity of standard MLPA is limited to a mutant
allele burden of ≥10%. To overcome this limitation, we have introduced a high
sensitivity MLPA assay enabling detection of an allele burden as low as 1% for
the most frequent mutations in MPN.
Aims: To demonstrate the feasibility of a modified MLPA assay to detect ≥1%
mutant allele burden using artificial positive DNA and cell line samples. Valida-
tion of this assay is done with MPN patient samples.
Methods: Salsa MLPA P520 MPN probemix was designed and optimized to
detect ≥1% mutant allele burden of the eight most frequent mutations in MPNs:
CALR, 52-bp deletion and 5-bp insertion in exon 9 (L367fs*46 and K385fs*47),
JAK2, deletions in exon 12 (N542_E543del and E543-D544del), JAK2, sub-
stitution in exon 14 (V617F), KIT, substitution in exon 17 (D816V) and MPL,
substitutions in exon 10 (W515L and W515K). The performance of the newly
developed MLPA assay was optimized and tested on artificial positive DNA
samples with 1% mutation burden. The performance of the assay was further
validated using commercial reference DNA samples with 1% allelic burden of
JAK2 V617F and KIT D816V mutations, as well as by using dilution series of
a JAK2 V617F positive, UKE-1 cell line, where the allelic burden was confirmed
by the Ipsogen MutaQuant assay. Validation on diagnostic MPN patient sam-
ples (n=167) was performed in a single-blind setting.
Results: Results obtained by high sensitivity MLPA assay were concordant
with an allele-specific PCR results in MPN patient samples. Moreover, 2 novel
cases with 1.4-5% JAK2 V617F burden, which were not detected by allele-
specific PCR, were identified with our novel assay and confirmed by the Ipso-
gen MutaQuant assay. Furthermore, no false positive calls for mutations were
obtained when testing on healthy human DNA samples (n=143).
Summary/Conclusions: Our results demonstrate that the P520 MPN MLPA
assay is a reliable method for simultaneous detection of eight frequent muta-
tions in MPNs, even when the patient DNA sample has a low (1-5%) mutant
allele burden. These results merit further consideration of MLPA as a possible
alternative for mutation testing for newly diagnosed MPN patients.
PB2014
FUNCTIONAL STUDY OF TWO NEW POINT MUTATIONS OF EPOR GENE
IN PRIMARY FAMILIAL CONGENITAL POLYCYTHEMIA
E Peroni1, AM Lombardi1, F Gherlinzoni2, PM Stefani3, I Bertozzi4, ML Randi4,*
1Dept of Medicine - DIMED, University of Padua, Padova, 2Hematology Dept,
Ca’ Foncello Hospital, 3Hematology, Ca,Foncello Hospital, Treviso, 4Depart-
ment of Medicine -DIMED, University of Padua, Padova, Italy
Background: Primary Familial Congenital Polycythemia (PFCP) is extremely
rare. It is caused by mutations in the EPO receptor (EPOR) gene (locus
19p13.3-p13.2) resulting in hypersensitivity to erythropoietin EPO stimulus. In
PFCP, in spite of reduced levels of serum EPO, mutated EPOR is ‘’switched
on’’ to stimulate red blood cell production by erythroid progenitor cells but with-
out ‘’switch off’’ mechanism.
Aims: Evaluate the functional effect of two EPOR gene novel mutations.
Methods: In our huge cohort of patients with erythrocytosis, we found 2 unre-
lated patients carrying novel mutations in EPOR gene. We performed a func-
tional assay to evaluate the activation of EPOR signaling in these mutations:
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first we created mutated plasmids to transfect K562 cell as model. 48h after
electroporation, we performed a stimulating assay with EPO following a time
course at 0’, 5’ 15’ 30’ and 45’. We finally studied the signaling cascade activity
with Western Blot analysis.
Results: Both observed mutations were found in exon 8 of EPOR gene:
c.1013G>A, p.Cys338Tyr and c.1022C>T, p.Thr341Met. The EPOR signaling
cascade resulted more active in mutated cells than in WT cells when stimulated
with EPO. 5’ and 15’ after stimulation, transfected cells with C338Y mutation
showed higher phosphorylation of STAT5 compared to T341M mutation. We
observed also a similar phosphorylation pattern of ERK occurring earlier than
STAT5 (at 0’ and 5’), while no signal of activity was detected in JAK2 and AKT
cascades.
Summary/Conclusions: In this study, we report two new missense mutations
of the EPOR gene, located in exon 8 as all the 22 previous described functional
mutations. Exon 8 encodes the C-terminal negative regulatory domain of the
protein. Both mutations here described impair the C-terminal negative regula-
tory domain of EPOR resulting in a gain-of-function in the EPOR signalling cas-
cades, more relevant for C338Y than T341M mutation. These novel mutations,
causing hyperactivity, increase proliferation and differentiation, and decrease
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CLINICAL-BIOLOGICAL PROFILE AND RESPONSE TO IMATINIB IN
MYELOID AND LYMPHOID NEOPLASM ASSSOCIATED WITH
EOSINOPHILIA AND IDIOPATHIC HYPEREOSINOPHILIC SYMDROME
F Hernández Mohedo1,*, JR Molina Hurtado2, S Durán Nieto3, A Mellado
Gázquez4, I Marchante Cepillo5, A Jiménez Velasco6, A Ruiz Calderón7,
G Garcia Donas8, M Anguita Arance9, JM Puerta Puerta1, C Ruiz Nuño6,
P Lopez Garrido1
1Hematology, Complejo Hospitalario Universitario de Granada, Granada,
2Hematology, Hospital Reina Sofía, Córdoba, 3Hematology, Complejo Hospi-
talario de Jaén, Jaén, 4Hematology, Hospital Torrecárdenas, Almeria, 5Hema-
tology, Hospital Puerta del Mar, Cádiz, 6Hematology, Hospital Universitario de
Málaga, Málaga, 7Hematology, Hospital Riotinto, Riotinto, 8Hematology, Hos-
pital Juan Ramón Jiménez, Huelva, 9Hematology, Hospital San Agustín,
Linares, Spain
Background: Primary eosinophilic diseases are a broad and heterogeneous
subgroup of hematological disorders with a very low incidence (SEER database
age-adjusted incidence rate 0.036 per 100.000). They have been generally
defined as peripheral blood eosinophilia (≥1.5x109/L), tissue infiltration and
end-organ damage. According to the OMS-2008 classification, primary
eosinophilic diseases are subdivide in a mayor category of myeloid and lym-
phoid neoplasms with eosinophilia and abnormalities of PDGFRA/B or
FGFR1(MNP-Eo); chronic eosinophilic leukemia not otherwise specified (CEL-
NOS), idiopathic hypereosinophilic syndrome (HES) and lymphocytic T variant
hypereosinophilia (HES-L).
Aims: The MPN-Eo associated with abnormalities of PDGFRA/B frequently
respond to low doses of Imatinib, while is controversial the role of Imatinib in
idiopathic HES. In this study we show our series of HES, with the aim of describ-
ing the clinical-biological profile and the rate of responses to Imatinib in both
subtypes of HES, with and without PDGFRA/B abnormalities.
Methods: We performed a retrospective and descriptive analysis in GAMFIN
cooperative group (Andaluz philadelphia-negative chronic myeloproliferative
neoplasm group) of diagnosed patients with hypereosinophilic disease (OMS-
2008 and HDWG Workshop 2010 classification) and differential diagnostic algo-
rithm of Tefferi et al. (Mayo Clin. Proc. 2010; 85:158-164). From 2005 to 2015
clinical and biological profile is analyzed with statistical software IBM SPSS.19
Results: We have analyzed a total of 20 cases of MPN-Eo, with an age-adjusted
incidence rate of 0.029/100.000 habitants/year (2014 Andalucía Population Statis-
tic), subdivided according to the OMS-2008 classification of eosinophilic diseases
in:7 cases ofMPNs-Eo associated with abnormalities of PDGFRA(6)/PDGFRB(1),
1 case of CEL-NOS(t(8;13)(p12;q12)+21 and FISH FGFR1 positive), 1 HES-L case
and 11 cases of idiopathic HES. Our series shows a similar distribution by sex
(11M/9F) and a lower age at diagnosis in MPN with PDGFRA/B(41,14 vs 54,6;
p=0.044). The most frequent clinical presentation was: constitutional syndrome
(60%),lung disease (40%), heart disease (35%:71,4% vs18,2%, 0.049; in
PDGFRA/B and HES), skin involvement (35%), bowel damage (25%), rhinitis/asth-
ma (20%), adenopathy (10%) and myalgias(5%); 35% of patients with
splenomegaly(71,4% vs 9,1%, p=0.013; in NMP-PDGFRA/B and Idiopathic HES)
(p=0,013). Bone marrow karyotype was normal in all but 2 patients: 1 PDGFR-B
(5q33) case and another CEL-NOS(8p). 25% cases were initially treated with Ima-
tinib, and another 16 patients (55%) received it in second line. With a median fol-
low-up of 94,33 months in the 6 cases of PDGFRA, 100% reach early hematological
complete response (HCR: 6,20+/-4,60 weeks) and molecular response in 4 evalu-
able cases by FISH(MCR5+/-4,12 moths), 1 case PDGFRB, after 1 moth of follow-
up, reach partial response (PR) and 1 case CEL-NOS(FGFR1+), is treated with
low doses of PEG-IFN, but 6 months later progressed to lymphoblastic lymphoma.
In the 11 cases of idiopathic HES, with a median follow-up of 28+/-29,16 months,
9 cases received Imatinib and six of them reached CHR (66%), while three patients
discontinued the therapy (1: no response, and 2 intolerance). Finally, only three
cases of Idiopathic HES treated with hydroxycarbamide reached CHR.
Summary/Conclusions: The incidence rate of HES, gender and age distribu-
tion, and clinical-biological profile, in our community of Andalucía, are similar
to that previously described in other series. In the majority of patients with MPN-
Eo we must tested a therapy with Imatinib, regardless PDGFRA or PDGFRB
abnormalities, because a significant subgroups of patients respond, while
responses in patients with PDGFRA or PDGFRB abnormalities are more fre-
quents, deepest and fastest. The prognosis and survival depend on the tissue
damage, especially cardiac injury, presents at diagnosis in 71,4% of patients
with PDGFRA/B abnormalities, frequently irreversible. This suggests a clear
recommendation to treat these types of MPN-Eo early, mainly with Imatinib at
diagnosis, in order to avoid cardiac damage
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BASELINE CHARACTERISTICS AND RISK FACTORS FOR LEUKEMIA-FREE
AND OVERALL SURVIVAL IN BULGARIAN PATIENTS WITH PRIMARY
MYELOFIBROSIS-A NATIONAL COHORT STUDY
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versity Hospital Sv.Georgi Plovdiv, Plovdiv, 6Hematology Clinic, Medical Uni-
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Hematology and Oncology, University Hospital Sv.Georgi Plovdiv, Plovdiv,
8Clinic of Hematology and Oncology, Military Medical Academy, Sofia, 9Depart-
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Background: Primary myelofibrosis (MF) is a rare form of BCR-ABL1(-) myelo-
proliferative neoplasm (MPN). Comprehensive research on the characteristic
of this life-threatening condition has not been done in Bulgaria yet. Therefore,
the Working Group of MPN of the Bulgarian Society of Hematology initiated a
nationwide study.
Aims: To determine the prevalence of MF in the country, and to provide data
on the baseline clinical and laboratory parameters and factors for leukemic
transformation and overall survival (OS) of a national cohort of patients (pts)
with the disease.
Methods: Data on 284 MF pts diagnosed and/or treated in 2014-2015 in 10
clinical centers covering the territory of the country with a population of
5242000>25-yrs of age were analysed. Major demographic, clinical and labo-
ratory parameters, risk profiles according to the international prognostic system
(IPSS) and the version for dynamic evaluation of risk (DIPSS and DIPSS-
PLUS), and therapeutic approaches were evaluated at baseline as well as in
regard to leukemia-free (LFS) and OS in 250 pts.
Results: A male/female ratio of 1.6:1 was determined. The mean age at diag-
nosis was 64.24 yrs (range 25-86 yrs). In 250 (88%) pts primary MF was diag-
nosed and in the other 34 (12%) secondary MF developed after another MPN.
The most common symptoms were enlarged spleen (78%), anemia (58%), ≥1
constitutional symptoms (41%), thrombocytopenia (21%) and leukocytosis
(20%). In 252 (91.2%) pts the diagnosis was confirmed with bone marrow his-
tology and the severity of fibrosis was determined with silver stain in 77% of
the cases. Molecular analysis was conducted in 179 (63%) pts and 113 (63.1%)
were positive for JAK2 V617F mutation, including as expected 84% of sec-
ondary vs 60% of primary MF (p=.014). In primary MF, analysis revealed a sig-
nificant association only between JAK2 mutation and platelet counts
<100x109/L (p=.018) and transfusion dependence (p=.043). In 20 (7.4%) pts
blast transformation was registered regardless of the primary or secondary
nature of MF. Univariate analysis of parameters at the time of diagnosis
revealed a significant association between inferior LFS and peripheral blood
blasts >1% (p<.0001), leukocytosis >20x109/L (p<.0001), platelet counts
<100x109/L (p=.001), hypercatabolic symptoms (p=.01), splenomegaly (p=.01),
and treatment history with hydroxyurea (p=.03). Median OS was 6.2 yrs and
as expected, it was significantly shorter in pts with leukaemic transformation
(3.6 yrs vs 7.3 yrs, log rank test p=.002). According to the IPSS, DIPSS and
DIPSS-PLUS pts were categorized predominantly in intermediate-high (IHR)
and high risk (HR) groups: 68%>79%>87%, respectively. A significant associ-
ation was confirmed between the OS and risk profiles (p<.0001). In total, 71%
of pts required treatment (e.g. hydroxyurea, erythropoetin, androgen, interferon,
corticosteroids, ruxolitinib). Splenectomy was performed in 4% of the pts, while
RBC transfusions were indicated in 59%. Interestingly, therapy of any kind was
significantly associated with better survival in all DIPSS-PLUS risk categories
except for HR group who might be the candidates for novel therapies (p=.009
in low risk vs p=.002 in IHR groups vs p=.127 in HR).
Summary/Conclusions: The study provides, for the first time, nationwide data
on the 5.4/100000 prevalence and basic features of Bulgarian pts with MF in regard
to clinical and laboratory presentation as well as to prognostic parameters and OS.
Contributions: LG, MG, GM, GB designed the study and contributed equally to
this work. MG, YT conducted data analysis. DT, DT, GD, GT, LS, MZ, NP, SD,
TD, VG, VS, YP performed research and contributed equally to this work.
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DISEASE CHARACTERIZATION AND TREATMENT PATTERNS OF
PATIENTS WITH MYELOFIBROSIS: ANALYSIS OF US CLAIMS DATABAS-
ES
M Mehra1,*, G Wang2, J He1, J Bussolari2, A Desai1
1Janssen Global Services, LLC, 2Janssen Research & Development, LLC,
Raritan, United States
Background: Myelofibrosis (MF), a rare myeloproliferative neoplasm, is char-
acterized by clonal myeloproliferation, ineffective erythropoiesis, bone marrow
stromal changes, hepatosplenic extramedullary hematopoiesis and aberrant
cytokine expression. Patients (pts) present with splenomegaly, constitutional
symptoms, moderate to severe anemia, thrombocytopenia and leukocytosis.
MF has a profound negative impact on survival and quality of life. Presentation
may be primary (PMF) or MF transformation from essential thrombocythemia
(ET) or polycythemia vera (PV), or may be secondary from diseases such as
myelodysplastic syndrome, leukemia, and lymphoma (Other MF). Management
options include allogeneic stem cell transplantation, hydroxyurea, interferon
alpha, alkylating agents, splenectomy, splenic radiotherapy, and the JAK1/2
inhibitor ruxolitinib.
Aims: Characterize disease and treatment patterns in pts with MF using 2 US
health insurance claims databases.
Methods: The Truven Marketscan (Commercial Claims and Encounters and
Truven Medicare) database was retrospectively analyzed to identify pts with
MF diagnosed between 2006 and 2015 using ICD-9 codes 238.76 and 289.83.
Pts aged ≥18 years with ≥1 month of history prior to diagnosis were included.
Pts were categorized as PMF, post-PV/ET MF, or Other MF based on earliest
MF diagnosis code. Demographic characteristics, constitutional symptoms,
platelet counts, and treatment patterns were summarized. Treatment regimens
were analyzed according to the following hierarchy (highest to lowest; “± O”
referring to combination with any other treatment listed lower in the hierarchy):
ruxolitinib±O, hydroxyurea±O, chemotherapy±O, stem cell transplant±O,
splenectomy±O, radiation±O, best supportive care (BSC)±O, and steroids only.
Sub-analysis of ruxolitinib uptake post launch (in 2011) will be presented.
Results: We identified 6795 pts with MF diagnosis between 2006 and 2015.
Based on the exclusion criteria, 6123 pts were included; 3211 (52.4%) were
male, and median age at diagnosis was 66 years. A total of 1425 (23.3%), 840
(13.7%), and 3858 (63.0%) pts had PMF, post-PV/ET MF, and Other MF,
respectively. Prevalence of splenomegaly at baseline was 11.1% in PMF, 15.5%
in post-PV/ET MF, and 7.8% in Other MF. Platelet counts at baseline (± 90
days of index MF diagnosis) were available for 149 (2.4%) pts; mean and medi-
an platelet levels were 270,323/μL and 218,000/μL, respectively; 16 (10.7%)
pts had platelet counts of <50,000/μL and 116 (77.9%) had platelet counts of
>100,000/μL (Table). Overall 3502/6123 pts (57.2%) received ≥1 regimens for
MF. Mainstays of initial treatment included hydroxyurea±O (964 treated pts;
27.5%), and BSC±O (753; 21.5%). Only 425/3502 treated pts (12.1%) received
ruxolitinib±O as first-line treatment; by category, pts receiving first-line ruxoli-
tinib±O included 194/1390 treated pts (14.0%) with PMF or post-PV/ET MF
and 231/2112 treated pts (10.9%) with Other MF. Hydroxyurea±O was the most
common first-line regimen for pts with PMF or post-PV/ET MF (463/1390;
33.3%); BSC±O (517/2112; 24.5%) and steroids (615/2112; 29.1%) were the
most common first-line regimens for pts with Other MF.
Table 1.
Summary/Conclusions: MF was typically diagnosed in pts aged ≥65 years,
and was associated with splenomegaly or thrombocytopenia at baseline in a
minority of pts. In the present database analysis, ~55-60% pts received treat-
ment. Although ruxolitinib was approved in the US in 2011 for treatment of
high- or intermediate-risk PMF or post-PV/ET MF, there is limited information
in the database on its clinical use as a first-line treatment.
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RISK FACTORS AND OUTCOMES OF ASIAN PATIENTS WITH
MYELOPROLIFERATIVE NEOPLASMS (MPNS) IN LEUKAEMIC
TRANSFORMATION
G Kam*, ZY Myint, LH Lee, C Chuah, GC Wong
Department of Haematology, Singapore General Hospital, Singapore, Singapore
Background: Progression to acute leukaemia is a rare event in the natural his-
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tory of the MPNs, namely essential thrombocythaemia (ET), polycythaemia vera
(PV) and myelofibrosis. Prognosis in MPN patients with leukaemia transforma-
tion (LT) is almost universally fatal and no effective treatment is available.
Aims: As data on Asian patients with MPN in LT is lacking, we evaluated the
risk factors and outcomes of Asian MPN patients with LT in this retrospective
single centre analysis.
Methods: We reviewed the case records of 824 Asian patients with MPNs from
our institution’s IRB approved MPN registry. Patients with LT were compared
with other patients in the registry who did not have LT on follow up.
Results: Among 824 MPN patients, 30 were identified to have LT from 2002 to
2015. The median follow up was 6.2years. Median age of LT was 72years and
occurred at a median of 33.2years after diagnosis. 3.9% (n=22) of ET, 0.5%
(n=1) of PV and 11.5% (n=7) of myelofibrosis patients progressed to acute
leukaemia (p <0.05). Time to LT was longest for ET (11years), followed by
myelofibrosis (3.9years) and PV (1.5years) (p=0.018). There was no impact of
JAK2, Calreticulin and MPL mutations on LT (p=0.55). Patients with LT had
lower Hb at diagnosis (12.7g/dL vs 14.8g/dL, p=0.001). A trend to higher pre-
senting leukocyte count (15.5x 109/L vs 12.6x109/L, p=0.053) and older age of
diagnosis of MPN (59.5years vs 56years, p=0.061) was seen in patients with
LT (p=0.053). On log-rank test, MPN subtype (p<0.05), presenting Hb <10g/dL
(p<0.05), presenting WBC ≥13x109/L (p=0.009), presenting platelet count
≥1000 x109/L (p=0.045) and age at diagnosis of MPN ≥60years (p=0.001) were
factors for shorter time to LT. Use of hydroxyurea (p=0.17) and exposure to
more than one cytoreductive agent (p=0.45) had no impact on LT. Using all co-
variates with a p value ≤0.10, we developed a model using Cox proportional
hazard model to determine the relative effect of these variables on LT. The
model included the above variables and presence of splenomegaly at diagnosis
(p=0.071). A presenting leukocyte count ≥13x109/L (HR 5.73, 95% Confidence
Interval [CI] 1.84-17.88, p=0.03) and presenting Hb <10g/dL (HR 8.05, 95%CI
1.66-38.95, p=0.01) were independent poor prognostic factors for LT. At LT,
43.3% (n=13) had complex/ adverse cytogenetics. 30% (n=9) had clonal pro-
gression compared to karyotype analysis at diagnosis (seven did not have prior
cytogenetics results). Median survival after LT was 2.5months. A diagnosis of
LT after 2009 (when azacytidine became available at our institution) was not
shown to affect survival after LT (p=0.73). Outcomes were not different whether
LT occurred below or above the age of 60years (p=0.73). One patient (3.3%)
was lost to follow up. 63.3% (n=19) received supportive treatment including
palliative chemotherapy. 16.7% (n=5) received azacytidine-based chemother-
apy, while 13.3% (n=4) received an AML-type regimen/ allogeneic stem cell
transplant and one (3.3%) received experimental treatment. Survival for the
different treatment modalities was not statistically significant (p=0.19): palliative
chemotherapy/ supportive care 1.5months, azacytidine-based 3.1months, inten-
sive chemotherapy/ allogeneic stem cell transplant 8.1months.
Summary/Conclusions: As in published literature, outcomes for Asian MPN
patients in blast phase are dismal. In this study, a presenting Hb <10g/dL and
presenting WBC ≥13x109/L were predictors of LT in MPN. Existing treatment
modalities are ineffective in attaining long term remission and have not improved
survival over time.
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SAFETY AND EFFICACY OF RUXOLITINIB IN CLINICAL PRACTICE FOR
PRIMARY AND SECONDARY MYELOFIBROSIS
M Breccia1,*, A Andriani2, M Montanaro3, E Abruzzese4, F Buccisano5,
M Cedrone6, A Centra7, N Villivà2, F Celesti3, MM Trawinska4, A Di Veroli5,
B Anaclerico6, G Colafigli1, A Spadea8, L Petriccione9, G Cimino7, R Latagliata1,
G Alimena1
1Dept Cellular Biotechnologies and Hematology-Sapienza University, 2Nuovo
Regina Margherita Hospital, hematology, Rome, 3Belcolle Hospital, Hematol-
ogy, Viterbo, 4S.Eugenio Hospital, 5Tor Vergata University, 6S. giovanni Hospi-
tal, Hematology, Rome, 7S. Maria Goretti Hospital/, Hematology, Latina, 8IFO,
Hematology, Rome, 9Frosinone Hospital, Hematology, Frosinone, Italy
Background: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and
approved for the treatment of primary and secondary myelofibrosis (MF).
Reduction of spleen volume, improvement of constitutional symptoms and
improved quality of life have been reported as major findings in sponsored ran-
domized clinical trials. 
Aims: Aim of our study is to report safety and efficacy of ruxolitinib in 98 patients
affected by MF treated outside clinical trials.
Methods: Patients were collected and treated consecutively by the Lazio Coop-
erative Group for Ph negative myeloproliferative diseases. 
Results: There were 45 males and 53 females, median age was 61.8 years
(range 35.3-88). Forty-five patients were diagnosed as primary MF and 53 as
evolution from a previous MPN: 31 after Polycythemia Vera, 20 after Essential
Thrombocythemia and 2 were not specified. Median splenomegaly at baseline
was 6 cm. At baseline, IPSS stratification revealed 4 patients with low risk, 27
with intermediate-1 risk, 42 as intermediate-2 and 23 as high risk. Seventy-
seven patients (78.5%) experienced constitutional symptoms at baseline and
out of 80 patients tested, 58 (72%) were JAK2V617F mutated. Overall, 40
patients received hydroxyurea as firstline treatment, 30 patients received other
chemotherapeutic approaches, whereas 28 were treated with ruxolitinib front-
line. Median time from diagnosis to start of ruxolitinib in the whole cohort was
34.6 months. All patients at the time of treatment were intermediate-2/high risk
according to IPSS. Hematological parameters pre-treatment were: median
haemoglobin level 10.4 gr/dl, median WBC count 11x109/l, median platelet
count 239x109/l. Median splenomegaly pre-treatment was 10 cm. As regards
initial daily dose, according to platelet count, 5 patients started with 5 mg BID,
7 patients with 10 mg BID, 26 patients with 15 mg BID and 60 patients with 20
mg BID, with a median initial daily dose of 20 mg BID. Fifty-eight patients (59%)
required a dose modification during the first 3 months, which consisted in a
dose reduction due to haematological toxicity in the majority of cases. After 24
weeks of treatment, 48% of patients experienced a clinical benefit with some
degree of reduction in spleen volume: in particular, according to revised IWG-
MRT criteria, 5 patients (5%) achieved a complete response (CR), 8 patients
(8%) a partial response, 6 (6%) a clinical improvement (CI), 28 (28.5%) a spleen
response, whereas 25 patients did not achieve any response and 24 were not
evaluable. At 48 weeks, 52% of patients obtained a clinical benefit: of them 7
patients (7%) had a CR, 10 (10%) a PR, 6 patients (6%) a CI and 28 patients
(28.5%) a spleen response. Overall, 66% of patients had disappearance of
baseline symptoms burden. After 1 year, of 72 evaluable patients, 52% achieved
and maintained a clinical benefit. Adverse events of special interest at any
grade included anemia (39.7%), thrombocytopenia (25.5%), infections (16.3%,
of which 10 were bronchopneumonia), fluid retention (3%), diarrhea (2%) and
abdominal pain (2%). After a median follow-up of 16 months from start of rux-
olitinib, median daily dose decreased to 10 mg BID and 21 patients (21%) dis-
continued the drug (8 for toxicity, 4 for progression, 4 lack of efficacy, 1 patient
underwent BMT, 1 second neoplasia, 3 deaths). 
Summary/Conclusions: The results of this retrospective multicentric analysis
confirmed the efficacy of ruxolitinib outside clinical trials with more than half of
treated patients achieving and maintaining a clinical benefit and most of them
reporting relief from symptoms. 
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RESULTS IN ELDERLY CHRONIC MYELOMONOCYTIC LEUKEMIA
PATIENTS TREATED WITH 5-AZACYTIDINE
DM Dunia1,*, G Nuria1, D Miguel1, A Jaime1, S Dolores2, M Dolores2, H Sonia2,
P Blanca2
1Hematologia, 2Hospital universitario de Guadalajara, Guadalajara, Spain
Background: Two hypomethylating (HMT) agents,5-azacytidine (AZA)and
decitabine have been approved by the FDA for the treatment of CMML. Initial
data on HMT efficacy came from studies in patients with high-risk myelodys-
plastic syndrome (MDS), including, however, only a few cases of CMML.
Hypomethylating agents are associated with overall response rates of approx-
imately 30% to 40%, with complete remission rates of about 15%.
Aims: Evaluate efficacy and security of AZA in CMML patients.
Methods: we retrospectively collected clinical data of 8 patients (7 males/1
females) with a median age of 80 years (range72-86) diagnosed with CMML
and treated with AZA, in our institution between 2010-2015.
Results: 5 (63%) patients were diagnosed as CMML-1 and 3 (37%) patients as
having CMML-2 subtype. AZA was administered at 75mg/m2 daily for 7 days,
every four weeks. Response was assessed after median number of 6 cycles.
Our patient cohort received a median number of 17 cycles (3-30) of therapy.
Overall survival was 42 months (25-74 months). Progression free survival was
23 months (4-28 months). The median time to first response was 4 months.
Causes of death were: 3 patients (38%) did evolution to AML (median time to
progression 3 months). 3 patients had a sepsis. 1 patient had a lung cancer.
Summary/Conclusions: AZA in elderly CMML patients is efficacy and safety.
The response were quickly and cytopenias were controlled.
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ONLINE STREAMING YOGA IS A FEASIBLE NON-PHARMACOLOGIC
MANAGEMENT STRATEGY IN MYELOPROLIFERATIVE NEOPLASM
PATIENTS
J Huberty1,*, R Eckert1, K Gowin2, A Dueck2, R Mesa2
1School of Nutrition and Health Promotion, Arizona State University, 2Mayo
Clinic, Phoenix, United States
Background: Up to 84% of Myeloproliferative Neoplasm (MPN) patients report
a reduced overall quality of life (QoL). While MPN patients often experience an
array of disease and treatment-related symptoms, fatigue is the most frequently
reported symptom (93%). Yoga may be an effective approach to improving
symptom burden (i.e., fatigue) and QoL in MPN patients based on evidence
suggesting yoga may improve fatigue and QoL in other cancer types. (e.g.,
breast, endometrial). 
Aims: To examine the feasibility (i.e., acceptability, demand, practicality) of a
home-based, online-streamed yoga intervention in MPN patients. A secondary
aim was to examine the effects of yoga on self-reported symptom burden and
QoL outcomes.
Methods: MPN patients were recruited nationally using social media. Partici-
pants were asked to complete 60 minutes of online-streamed yoga per week
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and to complete online self-report surveys administered via Qualtrics (demo-
graphics, symptom burden (MPN-SAF TSS), and QoL (i.e., pain, anxiety,
depression, sleep, sexual function via PROMIS). Surveys were administered
at baseline (wk 1), mid-point (wk 7), and post-intervention (wk 12). Weekly
yoga minutes were self- reported and collected weekly with adherence defined
as achieving ≥60 min/wk.
Results: Patients: Two hundred and forty-four MPN patients completed the
eligibility survey, 134 were eligible, 55 completed the informed consent and 38
participated in the 12-wk study. The most common reasons for ineligibility were
a diagnosed mental illness (n=55) and already regularly performing mindful
activity (n=46). Thirty patients had completed the intervention at the time of
this analysis. Among those (N=30; mean age=55.8±9.2 years; mean
BMI=25.0±4.4 kg/m2;,86.7% female), polycythemia vera was the most preva-
lent diagnosis (43.4%), followed by essential thrombocythemia (36.6%) and
myelofibrosis (20.0%). The majority of participants were diagnosed >3 years
ago (63.3%) and were JAKV617F positive (70%). Baseline measures were as
follows: MPN-SAF TSS mean=34.6±14.0; Fatigue mean=6.6±2.5; Anxiety
mean=51.9±7.0; Depression mean=47.5±7.6; Sleep mean=49.7±6.8. Yoga
Participation & Safety: Just over 43% (13/30) of study participants averaged
≥60 min/wk of yoga. Overall yoga participation averaged 59.3±32.0 min/wk.
Overall, 68% of participants were either satisfied (32%) or very satisfied (36%)
with online yoga and 75% of participants agreed (46%) or strongly agreed
(29%) that they felt safe from injury while practicing. Only one adverse event
was reported (irritated enlarged spleen). Impact of Yoga Intervention: From
baseline to post-intervention, there were significant improvements in self-report-
ed symptom burden (MPN-SAF TSS mean reduction of 4.77±8.29; p=0.004),
fatigue (MPN-SAF TSS mean reduction of 0.83±2.15; p=0.003), anxiety
(PROMIS mean reduction of 5.02±7.97; p=0.002), depression (PROMIS mean
reduction of 2.89±7.73; p=0.049), and sleep (PROMIS mean reduction of
3.76±3.60; p<0.001). When examining the differences between those that aver-
aged <60 min/wk compared to those that averaged ≥60 min/wk, there were no
significant differences in outcomes. 
Summary/Conclusions: A 12-wk, home-based, online-streamed yoga inter-
vention is feasible for MPN patients. Although the sample size of this study
was small, this study suggests that online yoga may be effective for improving
MPN related symptoms and self-reported QoL outcomes (i.e., anxiety, depres-
sion, sleep). Interestingly, outcomes were not significantly different between
those that averaged <60 min/wk of yoga compared to those that averaged ≥60
min/wk of yoga. Future research should explore the minimal dose needed for
improved symptom burden and QoL in MPN patients. Additionally, a random-
ized controlled trial with an active control group will help to determine the effec-
tiveness of yoga for self-reported patient outcomes.
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ASCITES A MANIFESTATION OF AGGRESSIVE SYSTEMIC MASTOCYTOSIS
CAN SUCCESSFULLY BE TREATED WITH MIDOSTAURIN (PKC412)
I Dybedal1,*, S Skipper Madsen2, R Fykse Halstensen3, V Stenberg4, L Farkas5
1Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Medical
Faculty, University of Copenhagen, Copenhagen, Denmark, 3Internal Medicine,
Nordland Hospital, Bodø, 4Internal Medicine, Vestre Viken Hospital, Hønefoss,
5Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background: Systemic mastocytosis (SM) is a myeloproliferative neoplasia
caused by uncontrolled proliferation and accumulation of pathological mast
cells in one or more extracutaneous organs. The 2008 WHO classification
divides SM into several subtypes including aggressive SM (ASM) with at least
one “C finding.” Among the four different “C findings” is palpable hepatomegaly
with impairment of liver function, ascites and/or portal hypertension. Midostaurin
(PKC412) is a new and so far not approved drug shown to have a strong
inhibitory activity on neoplastic human mast cells carrying the D816V KIT muta-
tion and with an acceptable side-effect profile.
Aims: The primary objective was to assess the clinical effect of PCK412 on
ascites in patients with ASM. The secondary objective was to study the effects
of PCK412 on other symptoms and findings in ASM patients.
Methods: All our patients with ASM and ascites were receiving midostaurin on
a “compassionate use program” provided by Novartis. The 4 patients were ≥18
years and had a verified ASM according to the 2008 WHO classification. Liver
biopsies, demonstrating mast cell aggregates, were performed in two of the
patients. Portal hypertension was verified by abdominal ultrasound. All the
patients had ascites and carried the D816V KIT mutation. The effect of PKC412
on ascites was evaluated by means of clinical examination, abdominal com-
puted tomography and/or abdominal ultrasound.
Results: In all of the patients, PKC412 had a significant clinical effect on
ascites. From having a need of pleuracentesis weekly or every second week,
all of they became independent of pleuracentesis. Their quality of life enhanced
dramatically. The patient with the most frequent need of pleuracentesis nearly
died by peritonitis probably associated to all his interventions. The initial dosage
of midostaurin was 100 mg twice daily. Two of the patients, further confirmed
the efficacy of midostaurin by revealing relapse of ascites after having stopped
with midostaurin because of sickness. In both cases the production of ascites
ceased, and the need of pleuracentesis ended by reintroducing PKC412.
Summary/Conclusions: In all these patients with ASM, midostaurin had an
excellent effect on ascites. Although this material is very small, all 4 out of 4
patients with ASM and ascites responded and became independent of para-
centesis. The correlation between relapse of ascites when stopping midostaurin
and disappearing when the medication was reintroduced, strongly supports a
positive effect on ascites, which is a clinical finding that troubles many patients
with ASM. It became nearly fatal for one patient in our material. In order to val-
idate a significant effect of PCK412 on ascites in patients with ASM, studies on
a larger population is needed.
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QUALITY OF LIFE AND SYMPTOM BURDEN IN MYELOFIBROSIS
PATIENTS: A REAL WORLD STUDY
T Ionova1,2,*, L Anchukova3, O Vinogradova4,5, T Gritsenko6, A Evseev7,
L Kozlova8, K Kurbatova1,2, G Kuchma8, E Lomaia9, A Lyamkina10, E Machulaytene11,
A Myasnikov7, T Nikitina1,2, M Pankrashkina4, T Pospelova10, A Rodionova1,
E Usacheva12
1Multinational Center for Quality of Life Research, 2Saint-Petersburg MultiSpe-
ciality Medical Center, Saint-Petersburg, 3Vologda Regional Clinical Hospital,
Vologda, 4Hematological City Center, Botkin City Clinical Hospital, 5Pirogov
Russian National Research Medical University, Moscow, 6Samara State Med-
ical University, Samara, 7Republican Hospital named after V.A. Baranov,
Petrozavodsk, 8Orenburg State Medical University, Orenburg, 9Federal Alma-
zov North-West Medical Research Center, Saint-Petersburg, 10Novosibirsk
State Medical University, Novosibirsk, 11Outpatient diagnostic department,
12R.M. Gorbacheva Memorial Institute of Children Hematology and Transplan-
tation, Pavlov State Medical University, Saint-Petersburg, Russian Federation
Background: Myelofibrosis (MF) is associated with poor prognosis, significant
symptom burden, and worsened quality of life (QoL). Assessment of patient-report-
ed outcomes is an effective way to identify patients’ risks/benefits of MF treatment.
Aims: We aimed to study QoL and symptom burden in MF pts in a real world setting
as well as to make comparisons in the groups depending on treatment modality.
Methods: A total 93 pts with MF were enrolled in the multicenter real world
QoL study-64 (69%) with primary MF, 14 (15%) post-essential thrombocytope-
nia MF, 15 (16%) post-polycythemia Vera MF. Median age-59 years (range
28–90); male/female-37/56. All pts received the best available treatment (BAT,
n=62) or ruxolitinib (n=31) for at least 6 months (median 12 months, range 6–
238). High proportion of pts (79%) had IPSS intermediate or high risk. All pts
completed the SF-36 QoL questionnaire, symptom assessment questionnaire
CSP-MF and Patient Global Impression of Change (PGIC) tool; physicians col-
lected information about disease and treatment from medical records. Integral
QoL Index was calculated on the basis of SF-36 QoL questionnaire. For sta-
tistical analysis ANOVA, multiple regression and χ2 test were applied.
Results: 23 pts (24.7%) from 93 pts were full spleen reduction responders, 31
pts (33.3%)-moderate responders, 39 pts (42%)-non-responders. Number of
full responders was higher in pts receiving ruxolitinib as compared to BAT
(48.4% vs 12.9%, р<0.0001). QoL in all SF-36 scales was significantly worse
in pts with MF comparing to healthy controls; the most pronounced impairment
was observed in role physical functioning (39.8 vs 76.9), physical functioning
(58.1 vs 85.3) and role emotional functioning (52 vs 77.1); Integral QoL Index
in pts was lower than in healthy controls-0.3 vs 0.55 (p<0.0001). More than
one third of pts had significant or severe QoL impairment: Integral QoL Index
was 7 times less as compared to healthy controls. Pts receiving BAT showed
more pronounced QoL impairment as compared to pts receiving ruxolitinib:
they had worse physical functioning (51.3 vs 74.7), role physical and role emo-
tional functioning (32.2 vs 61.3, 43 vs 75.3), general health (40.9 vs 53.6),
vitality (43.9 vs 60.2), social functioning (58.4 vs 81), and mental health (52.1
vs 67), p<0.05; Integral QoL Index was significantly lower-0.24 vs 0.47
(p<0.0001). Positive changes in health condition measured by PGIC were
reported in 67% pts receiving ruxolitinib vs 40% patients receiving BAT
(p=0.01). The majority of pts (74%) exhibited at least one moderate-to-severe
symptom; the most prevalent among symptoms were fatigue, inactivity, pain in
bones/muscles, insomnia, dizziness and feeling of worry. These symptoms
were more pronounced in pts on BAT comparing to pts on ruxolitinib (p<0.05).
Inactivity appeared to have the most significant negative impact on QoL; mul-
tiple linear regression model indicated significant relationship between symptom
severity and Integral QoL Index (R-squared=0.65, р<0.001) with the highest
regression coefficient for inactivity (Beta-coefficient=0.6).
Summary/Conclusions: Patient-reported outcomes such as QoL and symp-
tom burden in MF pts during treatment in a real world setting may be a solid
supplement to clinical outcomes and may contribute to better disease control
and improved quality of care of this difficult patient population. The data of this
real world study demonstrate benefits of ruxolitinib therapy from patient per-
spective and support the results of clinical studies.
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Background: Polycythemia vera (PV) is a myeloid neoplasm characterized by
platelet activation and thrombotic risk. According to PVSG, the antithrombotic
therapy includes low dose ASA. However, there are insensivity ASA PV patients.
It is debated if inherited thrombophilia increases the polycythemic platelet acti-
vation and, hence, the ASA platelet insensivity.
Aims: Therefore, we evaluated βFibrinogen G-455-A gene polymorphism, as
thrombophilic molecular mutation associated with increased platelet aggrega-
tion, platelet count, hematocrit (HCT), β-thromboglobulin (β-TG) and platelet
factor 4 (PF4) as markers of platelet activation, fibrinogen (Fg), Platelet func-
tional activity (PFA) as indicator of ASA platelet sensitivity and clot formation
time (CFT), as indicator of aspirinated platelets contribution to clot firmness.
We studied 40 patients (28 men, 12 women; mean age 64 years, range 35_85
years) with PV according to WHO criteria. Fifty subjects served as controls.
Methods: The mean duration of disease was 9 years. All patients were on phle-
botomy and ASA (100 mg once day). The βFibrinogen G-455-A genotype was
determined using a commercialized polymerase chain reaction kit with sequence-
specific primers. Platelets and HCT were measured by automated analyzer. βTG
and PF4 were determined by ELISA. PFA and CFT were measured by Platelet
Function Analyzer (PFA-100) and by ROTEM delta, respectively.
Results: All patients had heterozygous βFibrinogen G-455-A. The mean
platelet and mean HCT value were 428±180 x109/L and 47±3%. All patients
had normal Fg (244±47mg/dl), high β-TG and PF4 (133±47 IU/ml vs 20±11
IU(ml and 45±21 IU/ml vs 6±2 IU7ml, respectively) (p<.0001 and p<.001,
respectively), prolonged C/EPI closure time (CT, units: s, n.v. 84-160 s) (252±48
s) and normal CFT (CFT, units: s, n.v. 30-110 s) (50±7 s).
Summary/Conclusions: These findings suggest that βFibrinogen G-455-A
gene polymorphism is not associated with ASA platelet insensitivity in patients
with polycythemia vera.
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Background: The JAK2 V617F mutation is found in 50-60% of cases of essen-
tial thrombocythemia while 30% of cases carry calreticulin gene (CALR) and
5% MPL substitution. Recent studies have analyzed the clinical and hemato-
logic features in essential thrombocythemia and have demonstrated the phe-
notypically differences between JAK2 V617F and CALR mutations. 
Aims: We analyzed a Spanish cohort of 101 cases of essential thrombocythemia
with JAK2 V617F or CALR mutations. We studied the hematologic and clinical
features, including the thrombotic and hemorrhagic events and we compared
both groups in order to study different phenotypes in essential thrombocythemia.
Methods: We retrospectively analyzed a cohort of 101 cases of essential
thrombocythemia diagnosed between 1990 and 2015. We examined the fre-
quency of JAK2 V617F and CALR mutations, the clinical (Age, gender, throm-
botic and hemorrhagic events) and hematologic features (platelets, leukocytes
and hemoglobin counts) and the overall survival in these patients. The mutation
load of JAK2 V617F was determinated with real-time quantitative PCR. For the
detection of CALR exon 9 mutations, fragment analysis have been used. Sta-
tistical analyses were performed with SPSS software.
Table 1.
Results: In our study we identified 80% with JAK2 V617F mutation and 20%
with CALR mutation (type 1, 70%; type 2, 25%; and others, 5%). The mean
age of patients with CALR mutation was 52 years (range 28-83) and JAK2
patients was 63 years (range 24-90). The CALR group had more males (60%)
compared to JAK2 group (40%) and were younger at diagnosis (P=0,007). The
CALR group had higher platelet counts (1.006,950±482,2 x109/L versus
707,794±256,3L; p=0,001), lower hemoglobin concentration and lower leuko-
cyte counts, not being statistically significant. Venous and arterial thrombosis
were more frequent in JAK2 patients (30%; p=0,030) who had also more car-
diovascular risk factors. However, thrombosis in these patients was not related
to the platelet counts. Hemorrhages were more frequent in CALR patients (90%;
p=0.012) and strongly associated with higher platelet counts (p=0.001) and
less with low hemoglobin levels (p=0.227). We also observed that the two
groups have similar overall survival.
Summary/Conclusions: In our study, we have observed that patients with
CALR mutation were younger and they had higher platelet counts compared
with JAK2 mutation group. CALR mutation patients showed a higher risk of
developing hemorrhagic events while JAK2 mutation-positive showed a higher
risk of venous thrombosis. Thrombosis events were also related to higher leuko-
cyte counts and the presence of cardiovascular risk factors, which were more
frequent in the JAK2V617F group. However, we did not find differences in over-
all survival between both groups. In conclusion, this study confirms that essen-
tial thrombocythemia with CALR or JAK2 mutations have biological and phe-
notypical differences. Therefore, it might be useful for a better understanding
of the prognosis and treatment in this disease.
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Background: Arterial and venous thrombotic events are observed to be higher
in BCR-ABL negative Myeloproliferative Neoplasms (MPN) than the normal
population. These complications are most important causes of morbidity and
mortality. β2 glycoprotein I antibody (β2-GPI Ab) (anti-apolipoprotein H Antibod-
ies) is an important marker of thrombosis in autoimmune diseases. 
Aims: In our study, we aimed to evaluate the association of thrombosis and
levels of β2-GPI Ab in BCR-ABL negative MPN patients without no genetic pre-
disposition to thrombosis.
Methods: Seventy one patients with BCR-ABL negative MPN and 62 controls
were included. Exclusion criteria were present of cardiovascular risk factors,
malignancy, active infection, renal failure, and being smaller than 18 years old.
Genetic and laboratory testing (such as Factor V Leiden, prothrombin G20210A,
activated protein C resistance and homocysteine) for thrombophilia were done
in all patients and controls in order to evaluate accurately association between
thrombosis and β2-GPI Ab.
Results: Average level of β2-GP Ab was 187 U/ml in all 133 persons (patient
and control groups). Average level of β2-GP Ab was 217 U/mL in 71 patients
with BCR-ABL negative MPN and 160 U/mL in 62 controls. This difference was
statistically significant (p=0.006). Subgroup analysis in patients are seen in
Table 1. There was no difference between patients with or without history of
thrombosis according to the β2-GPI Ab levels (p=0.144).
Table 1. Relationship of β2-GPI Ab Level and History of Thrombosis in
Patient Group.
Summary/Conclusions: Despite the known increased risk of thrombosis and
hemorrhage in MPNs, mechanisms are still not fully clear. To our knowledge,
our study is the first study evaluating the relationship between β2-GPI Ab and
thrombosis in BCR-ABL negative MPNs after genetic risk factors excluded.
While β2-GPI Ab level was significantly higher in patients with MPN than in nor-
mal subjects; no significant difference was determined between patients with
or without thrombosis. Alongside β2-GPI Ab, assessment of antibodies against
domain IV-V of β2-GP may be useful.
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Background: There are controversies regarding on which cell parameter may
be more conveniently used as a surrogate criteria of an increased red cell
mass (RCM), that is, hemoglobin (HB) level and hematocrit (HCT) value.
According to the 2007/2008 WHO classification, HB level should be >18.5 g/dl
in men and >16.5 g/dl in women and/or increased HCT. It has been argued
that application of these criteria may result in an underdiagnosis of PV by
excluding patients with actual RCM mass that is 25% above mean predicted
value, but whose HB and HCT levels are below the WHO guidelines. Therefore,
recently the WHO revised the criteria and in 2015 made a new proposal low-
ering the HB/HCT threshold to 16.5 g/dl/49% in men and 16 g/dl/48% in women.
Aims: We aimed to apply the proposed WHO 2015 criteria in order to determine
whether this contribution in the identification of masked PV would compensate
the work overload in our laboratory and clinical practise.
Methods: We selected samples of patients from routine analytical test that
meet the new proposed WHO criteria from 22/12/2015 to 23/01/2016 and stud-
ied the presence of JAK2V617F mutation as mayor diagnosis criteria for PV.
JAK2V617F mutation was determined qualitatively by amplification refractory
mutation system polymerase chain reaction assay. We collected white blood
count, erytrocytes and platelets levels as well. For statistical analysis has been
used ShapiroWilk test to check the normality of the data of quantitative vari-
ables. The statistical program used was R Core Team (2014).
Results: In our study, there were 48 patients: 47 men and 1 woman. The median
age of the patients was 48,5 years (range: 17-73). The median of HB was 17.7
g/dL (16.5-18.3) and the median HCT was 51.35% (48.1-55.4%). The number
of positive JAK2V617F mutation was cero. The rest of analytical characters
were: Erythrocytes (average 5.44 10e6/uL, 1.36-6.52), leykocytes (average 9.09
10e3/uL, 3.87-19.8) and Platelets (average 259.02 10e3/uL, 134-416).
Summary/Conclusions: Amont the 48 patients, none of them vas positive for
JAKV617F mutation. Admission of new criteria would means a high increase
in the numbre of patients to be evaluated, implying an enhane human and lab-
oratory resource consumption, with a significant economic impact. Based on
our results, we wonder whether these new proposed WHO criteria should be
approved.
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Background: Somatic mutation of the JAK2 V617F is associated with the
pathogenesis of myeloproliferative neoplasms (MPNs) and it is an important
diagnostic marker. However, V617F JAK2 was detected also at 0.2-1% of the
adult population, without the MPN when using highly sensitive allelic load test
(Xu X, et.al., 2007; Nielsen C., et.al., 2014). The V617F JAK2 mutation signif-
icantly increases the risk of both arterial and venous thrombosis, including
cerebral vessels, visceral intestinal veins and especially Budd-Chiari syndrome
(Smalberg JH, et.al., 2012). These causes of hospitalization may be the first
manifestations of MPN.
Aims: Evaluate the frequency of the JAK2 V617F mutation in different cohorts
of hospital patients and blood donors. 
Methods: Allele-specific RT PCR was performed to detect of the JAK2 V617F
allele load in whole blood samples among the following groups: healthy blood
donors, patients who were included in the program of routine inspections,
patients who were are hospitalized in general hospitals, as well as those who
were directed by hematologist with suspected to MPN.
Table 1. JAK2 V617F mutation frequency among cohorts.
Results: The frequency of the JAK2 V617F mutation was maximal when the
patients were directed by a hematologist with MPN suspected (Table 1). Mini-
mum prevalence was observed in healthy blood donors. Among patients from
non-hematological hospital departments 12% cases (3 of 24 patients) with
JAK2-V617F had ischemic stroke. Participation in voluntarily medical exami-
nation reveals patients with mutation but who have no any hematological abnor-
malities in 95% cases were directed by hematologist with suspected to MPN.
Summary/Conclusions: High risk of thrombosis and of the MPN development,
as well as the potential risk of transmission of the transformed cell clone to
recipients of the bone marrow and blood, raises the issue of screening for
JAK2 V617F among some cohorts of patients. An analysis of “benefit - harm”,
taking into account the effectiveness of preventive measures will be the subject
of additional studies.
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(SINGLE CENTER EXPERIENCE)
I Subortseva*, A Melikyan, A Kovrigina, T Kolosheynova, A Abdullaev,
A Sudarikov, S Kulikov
National Haematology Research Center, Moscow, Russian Federation
Background: Polycythemia vera is a heterogeneous group of diseases. In
patients who don’t meet the World Health Organization (WHO) criteria for overt
polycythaemia vera (PV), a diagnosis of latent/masked PV (mPV) can be deter-
mined. MPV is characterized by JAK2V617F positive, morphological features
of bone marrow for PV according to WHO, but hemoglobin <18,5 g/dL in men
and <16,5 g/dL in women.
Aims: The aim of this study was to identify clinical features of mPV as a sep-
arate group of PV.
Methods: The study included 81 patients observed in the outpatient depart-
ment of National Research Center for Hematology from 2014 to 2015, 50
patients with PV and 31 patients with mPV.
Results: Distribution of patients by gender was statistically comparable. Patients
with PV was older compared to mPV: median age was 56 and 44. Between the
groups of patients with mPV and PV obvious difference in red blood cells
(5.37x1012/L (4.1-6.5x1012/L) vs 6.94x1012/L (5.4-8.8x1012/L)); hemoglobin
(14,8 g/dL (10,0-16,7 g/dL) vs 17,8 g/dL (13,6-24,7 g/dL)); hematocrit (45% (30-
52%) vs 53% (42-70%)). Median platelet counts higher in the group of patients
with mPV compared with PV: the median was 644x109/L (179-1978x109/L) vs
636x109/L (137-2437x109/L). Differences of white blood cells was not reveale
in the two groups. All the patients were V617F JAK2 positive. Determination of
allele burden JAK2V617F performed 29 patients with mPV and 37 patients with
PV. JAK2 allele burden was significantly higher in patients with PV compared
to mPV: median 14% (3-57%) and 55.5% (24-86%) respectively. Thrombosis
revealed in 38% (12 patients) with mPV and in 16% (10 cases) in the PV. It was
mainly venous in the case of mPV with a high frequency of splanchnic vein
thrombosis. Arterial thrombosis detected only in 4 cases.
Summary/Conclusions: Masked PV is a separate nosological variant of PV.
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THROMBOCYTHEMIA
A Zherniakova*, I Martynkevich, V Shuvaev, L Polushkina, M Fominykh,
V Udaleva, I Zotova, D Shiсhbabaeva, K Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, Russian Federation
Background: Particular molecular marker detection (JAK2 V617F, MPL,
CALR) or its absence (triple-negative (TN)) in essential thrombocythemia (ET)
can be served as a basis of different biological neoplasm behavior. 
Aims: The aim of this study was to investigate interactions (differences) between
the presence of each molecular marker, clinical features and course of ET.
Methods: One hundred and fifty ET patients, who had been diagnosed at our
institution according to WHO 2008 criteria. The following parameters were
assessed: age, gender, complete blood count, clinical symptoms (weakness,
headache, dizziness, arthralgia, constitutional symptoms, erythromelalgia,
splenomegaly), thrombotic complications and bleeding. Overall survival (OS)
in ET patients with different molecular markers were analyzed by Kaplan-Meyer
method and compared between groups. Log-rank, ANOVA Kruskal-Wallis test
and the Chi-square test with Yate’s contingency correction were used for sta-
tistical analysis.
Results: Median age was 56 years (range 19-82), 110 patients (73%) was
female. Median follow-up was 28 months (range 1-168). The following muta-
tions were detected: JAK2V617F (JAK2+) n=115 (76,7%), MPL+ n=1 (0,7%),
CALR+ n=14 (9,3%) and triple-negative (TN) molecular status was registered
in n=20 (13,3%) patients. Complete blood count mean values (standard devi-
ations) at initial ET diagnosis were: JAK2+: Hb 14.2 (17.6) g/dL, WBC 9.7 (3.7)
x109/L, PLT 831 (273) х109/L. MPL+: Hb 12.3 g/dL, WBC 7.1x109/L, PLT 2079
х109/L. CALR+: Hb 13.8 (16.7) g/dL, WBC 9.3 (3.9) х109/L, PLT 1086 (453)
х109/L. TN: Hb 13.6 (15.6) g/dL, WBC 11.4 (4.7) х109/L, PLT 777 (230) х109/L.
The presence of CALR mutation was associated with significant higher platelets
level (p=0.03). The symptoms frequencies according molecular markers groups
were as followed: JAK2+: weakness-34.8%, headache/dizziness-20.9%,
arthralgia-19.1%, splenomegaly -16.5%, erythromelalgia-8.7%, pruritus-5.2%,
constitutional symptoms-4.4%. MPL+: weakness only (100%). CALR+: weak-
ness-21.4%, headache/dizziness-7.1%, splenomegaly-21.4%, erythromelal-
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gia-14.3%. TN: weakness-25.0%, headache/dizziness-25.0%, arthralgia-
25.0%, splenomegaly-10.0%, erythromelalgia-10.0%, pruritus-5.0%. Thrombo-
sis rates according molecular markers groups were: JAK2+ - 48.6%; CALR+ -
14.2% - and TN-30.0%. Bleeding frequency in CALR+ patients was 21.4% and
for JAK2+ patients 6.9%. Overall survival (OS) was significant higher in CALR+
group compared to others (JAK2+ and TN, р=0.019).
Figure 1.
Summary/Conclusions: The presence of JAK2V617F mutation in ET patients
is associated with higher thrombosis risk, despite the fact of CALR+ patients
had higher platelets level. OS in CALR+ ET patients was significant higher
compared to JAK2+ and TN.
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Background: The Philadelphia-negative myeloproliferative neoplasms (MPN)
are clonal hematopoietic stem cell malignancies characterized by overproduction
of one or more myeloid lineages. The discovery of the JAK2 V617F (JAK2) muta-
tion in 2005 was a crucial step towards unraveling the pathogenesis of the MPN
and finally provided a clonal marker for the diagnosis of Polycythaemia Vera (PV),
Essential Thrombocytosis (ET) and Primary Myelofibrosis (PMF). Previously diag-
nostic guidelines of MPN were fraught with controversy due to the absence of
exactly such a defining feature. The JAK2 mutation makes it possible to definitely
diagnose >95% of PV, and 50-60% of both ET and PMF cases.
Aims: We retrospectively analysed our tertiary care institution patient population
in whom this test was requested since its inception in 2007. JAK2 was request-
ed in two groups: patients presenting with thrombosis and with probable MPN.
We looked at the role of the JAK2 mutation analysis in the diagnostic algorithm
of MPN and in patients presenting with thrombosis.
Methods: We created a database with detailed folder review of 267 patients
who had undergone the JAK2 test between 2007 and 2013 in Groote Schuur
Hospital. The initial presentation of each patient was analysed for two variables,
namely raised cell counts (cytoses) or thrombotic complications, or both. The
diagnostic algorithm for MPN implementing the JAK2 analysis was applied to
each patient. In addition to JAK2, patients with sustained erythrocytosis were
investigated with serum erythropoietin (s-EPO), red cell mass (RCM) and bone
marrow examination (BME). 
Results: Mean age at testing were 51.2 years. Male gender predominated
(n=153; 57.3%). In our population 30% (n=80) of all patients and 64.5% (n=78)
of MPN patients were JAK2 positive; the other 2 JAK2 positive patients had
mixed myelodysplastic-myeloproliferative syndrome. One-hundred-twenty-one
patients were diagnosed with an MPN: ET patients (n=38) tested JAK2 positive
in 34%; PMF (n=27) in 63% and PV (n=56) 86% positive. Of the 103 patients
investigated for a sustained erythrocytosis, only 56 (54%) could be confirmed
as PV. RCM and s-EPO indicated a relative erythrocytosis in 24 patients, the
other 23 patients had erythrocytosis of undetermined origin. Sixty-seven
patients presented with thrombotic complications: 26 with MPN diagnosis (39%)
and 51 (61%) where MPN was ruled out. The diagnosis of MPN was associated
only with those patients who exhibited sustained cytoses while presenting with
thrombosis. MPN patients presenting with thrombosis were 0.7 times as likely
to be JAK2 positive as negative, the difference was not significant.
Summary/Conclusions: The JAK2 mutation analysis was positive in the major-
ity of our MPN population in accordance with published results but in a signifi-
cant minority other methods of diagnosis remain important. The percentage
JAK2 positivity in the PV population was lower than previously reported. Fur-
thermore, almost half of patients investigated for sustained erythrocytosis did
not fulfil criteria for PV. These patients with relative or undetermined erythrocy-
tosis form a significant minority where current diagnostic and pathogenetic
methods are lacking. Our analysis indicates that employing the JAK2 test to
uncover an underlying MPN in patients presenting with thrombosis is unlikely
to yield a positive result in the absence of sustained cytoses. Proven MPN
patients presenting with thrombosis were just as likely to be JAK2 negative as
positive.
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Background: Ruxolitinib, an oral Janus Kinase (JAK)1 and JAK2 inhibitor, was
approved in the European Union in August 2012 for treating disease-related
splenomegaly and constitutional symptoms in adults with primary myelofibrosis
(PMF), post-polycythaemia vera myelofibrosis (PPV-MF), and post-essential
thrombocythaemia myelofibrosis (PET-MF), following the results of two phase
III trials (COMFORT-I and COMFORT-II). The James Paget University Hospital
and Ipswich Hospital have treated 31 MF patients (24 and seven, respectively)
with ruxolitinib since March 2013.
Aims: To assess the efficacy and safety of ruxolitinib in MF in the clinical setting.
Methods: Retrospective analysis of 31 MF patients treated with ruxolitinib from
March 2013 to February 2016 at the James Paget University Hospital and Ipswich
Hospital. Patients with greater than three months’ follow-up were included.
Results: The patient group was 58% male, with a median age of 69 years
(range 58–92). Ruxolitinib was first-line therapy in eight patients (26%) and sec-
ond-line in 23 (74%). The indication for treatment was painful splenomegaly in
17 (55%) patients, constitutional symptoms in 13 (42%) and portal hypertension
in one (3%). Fifteen patients (48%) had PMF, ten (32%) had PPV-MF, five (16%)
had PET-MF and one (3%) had post-myeloproliferative disorder (unclassified)-
MF. Seventeen (55%) patients had an International Prognostic Scoring System
(IPSS) score of three (high risk), 13 (42%) had an IPSS score of two (interme-
diate risk-2), and one (3%) had an IPSS score of one (intermediate risk-1).
Twenty-two patients (71%) were JAK2 V617F positive and one (3%) had a CALR
mutation. The median duration of treatment was 17 months (range 5-35). Twen-
ty-six patients (84%) had a therapeutic response. Of the 17 with painful
splenomegaly, eight (47%) had >50% reduction in spleen length, six (35%) had
<50%, and three (18%) had no change. Nonhaematologic adverse events (AEs)
were uncommon and low grade. Weight gain was the most common, occurring
in 25 (81%) patients. Minor infections, including oral candidiasis, were also com-
mon and easily treated. One patient, however, developed Aspergillus pneumonia
after 17 months and died. The most common haematologic AEs were anaemia
and thrombocytopaenia. All patients developed anaemia; nine (29%) required
transfusions and 12 (39%) required erythropoietin. Nine patients (29%) devel-
oped thrombocytopaenia (grade 3/4 in three patients) which was managed by
dose reduction, or drug interruption, without permanent discontinuation. Four
patients (16%) progressed to acute myeloid leukaemia (AML) after a median of
four months (range 3-15) and died. Another patient died after losing therapeutic
response at 16 months. Our leukaemia-free survival, progression-free survival,
and overall survival rate is 81% vs 80% in COMFORT-II at three years. Currently,
25 patients (81%) remain on treatment.
Summary/Conclusions: In our experience, overall response rate and tolera-
bility to ruxolitinib was similar to the COMFORT-II trial. The most common non-
haematologic AEs were weight gain and minor infections. Furthermore, in many
cases weight gain was a desired outcome attributable to improved constitutional
symptoms, spleen size, and nutritional status. Conversely, haematologic AE
rates may be higher than in the trial setting. Anaemia was observed in all
patients and thrombocytopaenia commonly required dose adjustments. There
was also a higher than expected incidence of transformation to AML. Most AEs,
however, were low grade and readily managed. The majority of patients remain
on active treatment.
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Background: Red cell distribution width (RDW) provides a quantitative meas-
ure of anisocytosis and it is associated with the presence of subclinical systemic
inflammation and a poor outcome in a variety of diseases when elevated. Aniso-
cytosis is a feature of primary myelofibrosis (PMF) but it’s prognostic role in
PMF has not yet been evaluated.
Aims: To determine whether anisocytosis bears prognostic significance in
patients with PMF and its relation to disease features.
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Methods: 33 newly-diagnosed patients with PMF were analyzed in this study.
Baseline RDW values were obtained in addition to other routine blood analyses
(CRP, LDH, complete blood count and iron metabolism parameters) and JAK2
V617F mutational status. Patients were staged according to IPSS prognostic
scoring system, liver and spleen size were assessed by palpation. The Mann
Whitney U test, the Pearson correlation and the Χ2 test/ the Fisher test were
used where appropriate. Survival analyses were performed using methods of
Kaplan and Meier, the log-rank test and the Cox regression analysis. All sta-
tistical tests were two-sided and P values <0.05 were considered significant. 
Results: Median RDW was 19.0% (15.2% - 22.5%). RDW correlated signifi-
cantly with hemoglobin (p=0.005), CRP (p=0.031), spleen size (p=0.036) and
IPSS score (p=0.003). Patients with more pronounced anisocytosis had an
inferior overall survival (OS)-very-high RDW (≥19.0%) vs high RDW (15.1% -
18.9%) subgroup, HR 5.37, p=0.002. RDW remained significantly associated
with OS (p=0.002) in a multivariate model including IPSS score, hemoglobin
level and CRP.
Figure 1.
Summary/Conclusions: PMF pathogenesis surpasses inflammation as only
cause of anisocytosis. A higher degree of anisocytosis is associated with more
advanced disease features and a decreased overall survival. RDW encom-
passes standard prognostic score and may help in the rapid detection of
patients with an unfavorable prognosis.
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RISK FACTORS FOR THROMBOTIC COMPLICATIONS IN PATIENTS WITH
PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
E Simonovic1,*, L Macukanovic-Golubovic2, V Colic1
1Internal Medicine, General Hospital, Leskovac, 2Internal Medicine, Clinic of
Haematology, Nis, Serbia
Background: Myeloproliferative neoplasms (MPN) are a group of clonal
hematopoietic stem cell malignancies, characterized by overgrowth of one or
more blood lines with normal or nearly normal maturing of those cells in the
bone marrow and extramedullary hematopoietic organs. MPN are acquired
prothrombogenic conditions. The mechanism of increased predisposition to
thrombosis in myeloproliferative neoplasms is not clear enough. It is thought
that the mechanisms that lead to thrombosis in MPN are the following:
increased blood cell mass; abnormal platelet function and the phenomenon of
spontaneous aggregation. The following factors have been associated with the
incidence of thrombosis: the increased level of products formed in the activation
of platelets (thromboxane, p-selectin); increased microparticle formation as the
part of a membrane with various cell structures of platelet origin; JAK2V617F
mutation. In MPN patients an increased activity of coagulation system occurs
due to resistance to the anticoagulant function of thrombomodulin.
Aims: The aim of this study is to monitor potential risk factors for the develop-
ment of thrombotic complications in patients with Philadelphia-negative chronic
myeloproliferative neoplasms.
Methods: During the five-year period we monitored the occurrence of throm-
botic complications in 139 patients of both sexes, aged between 30 and 87
years, being diagnosed with Ph-myeloproliferative neoplasm. Patients were
classified into the following groups: 1. Group with the polycythemia vera (PV)
(61); 2. Group with essential thrombocythemia (ET) (28); 3. Group with idio-
pathic myelofibrosis (IMF) (25); 4. Group with unclassified myeloproliferative
neoplasm (MPNs) (25). The following possible risk factors were monitored:
age, leukocyte count, platelet count, the presence of JAK2V617F mutation,
cardiovascular risk factors (smoking, hypertension, diabetes mellitus, dyslipi-
demia). We used methods of clinical, laboratory, ultrasound and CT scans.
Results: The highest percentage of thrombotic complications (arterial and
venous) was found in the group of patients with ET and MPNs (p <0,01), and
then in the group with PV (p <0,05). In all three groups, the incidence of throm-
botic complications in patients older than 60 years was higher (p<0,001). The
leukocyte count ranged from 2,2-17,1x109/L and the platelet count ranged from
10,2 -1856,5x109/L. The highest leukocyte count was recorded in the group of
patients with PV and MPNs (p <0,001) and the lowest in the group of patients
with the IMF (p <0,01). The highest platelet count was found in the group of
patients with ET, and the lowest in the group of patients IMF. Thrombotic com-
plications in those groups were more frequent in percentage with patients with
leukocytosis, but statistical significance was present only in the group with
MPNs. No statistical significance was detected between the platelet count and
thromboembolic complications in either group. Thrombotic complications were
more frequent in JAK2V617F positive patients, but the statistical significance
existed only in the group with PV. Considering cardiovascular risk factors only
hypertension was significantly more common in the group with PV and MPNs.
The largest number of patients with thrombotic complications had two or more
cardiovascular risk factors (p <0,05).
Summary/Conclusions: The patients over 60 years of age, as well as the
presence of two or more cardiovascular risk factors are the most important for
the incidence of thrombosis. Leukocytosis and JAK2V617F may be considered
as potential risk factors for thrombosis in patients with myeloproliferative neo-
plasms, particularly with PV, ET I MPNs. Further follow-up and a larger number
of subjects are needed. The follow-up of patients with unclassified myelopro-
liferative neoplasms has particularly important, which showed a high prevalence
of thrombotic complications, and with the aim of their further differentiation.
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JAK2, MPL, AND CALR MUTATIONS IN CHINESE HAN PATIENTS WITH
ESSENTIAL THROMBOCYTHEMIA
J Xu*
Clinical Hematology, Nanjing Drum Tower Hospital, the Affiliated Hospital of
Nanjing University Medical School, Nanjing, China
Background: Essential thrombocythemia (ET) is a chronic Philadelphia chro-
mosome-negative myeloproliferative neoplasm characterized by the overpro-
duction of circulating platelets in the periphery due to the excessive proliferation
of megakaryocytes in the bone marrow [1]. The recurrent Janus kinase 2 (JAK2)
V617F mutation has been an important molecular marker for myeloproliferative
neoplasms (MPNs) since its discovery in 2005 [2]. However, only 50-60% of
ET cases are associated with the JAK2 V617F mutation. Among the 40% of
patients with ET who lack the JAK2 V617F mutation, 3-5% carry mutations at
codon 515 of the gene encoding the thrombopoietin receptor, a myeloprolifer-
ative leukemia virus oncogene (MPL) [3]. In 2013, somatic mutations in calreti-
culin (CALR) were found in 20 to 25% of patients with ET or primary myelofi-
brosis (PMF) [4,5]. Like JAK2 and MPL mutations, somatic mutations of Cal-
reticulin (CALR) have been identified as a potentially powerful diagnostic tool
for patients with ET [6].
Aims: we studied a population of patients with ET and analyzed the frequency
of JAK2, CALR, or MPL mutations as well as patients’ hematological charac-
teristics.
Methods: The patients and the data were selected retrospectively from the
myeloproliferative neoplasm database established for scientific research at the
Department of Hematology of Drum Tower Hospital. A total of 110 patients with
ET were enrolled (60 females and 50 males with a mean age of 55.7 years,
range 13–88 years); they had been diagnosed at the Department of Hematol-
ogy between 2012 and 2015 according to the WHO Classification of Tumours
of Hematopoietic and Lymphoid Tissues (2008)[7]. The clinical and laboratory
data were reviewed from medical records.
Results: Among the 110 patients tested, JAK2 V617F was the most common
mutation, observed in 62 patients (56.3%), while CALR mutations were detect-
ed in 21 patients (19.1%). One patient (0.9%) carried the MPL W515L mutation.
A mutation in JAK2 exon 12 was not detected in any patient. Two ET patients
had both CALR and JAK2 V617F mutations. The incidence of triple-negative
(negative for JAK2/MPL/CALR) patients was 25.5% (28/110).
Summary/Conclusions: In summary, we have described the mutation profile
of our Chinese cohort of ET patients. CALR mutations are a useful diagnostic
marker for JAK2/MPL-negative ET patients because they are typically mutually
exclusive with a JAK2 mutation and are present in a relatively high frequency.
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WHAT IS THE SECRET OF THE JAK2 MUTATION ALLELE LOAD STABILITY
IN SOME PATIENTS WITH MPN?
T Subbotina1,2,*, I Olkhovskiy1,3, R Shaikhutdinova2, E Dunaeva4, K Mironov4,
A Gorbenko1, M Stolyar1,2, E Vasiyliev1,5, M Mikhalev1,6, G Shipulin4
1Krasnoyarsky branch of Hematology Research Center Russian Ministry of
Health Ministry of Health, 2Siberian Federal University, 3Krasnoyarsk Scientific
Center SB RAS, Krasnoyarsk, 4Federal Budget Institute of Science «Central
research institute for Epidemiology», Moscow, 5Krasnoyarsk regional hospital,
6City Clinical Hospital № 7, Krasnoyarsk, Russian Federation
Background: It is known that the level of JAK2 mutation allele load in patients
with myeloproliferative neoplasms (MPN) in the disease dynamics can be con-
tinuously stable and not be associated with clinical symptoms or effects of hydrox-
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yurea (HU) (Theocharides A et al, Haematologica, 2008; Besses C et al, Br J
Haematol, 2011). Reasons and mechanisms of this kind of «homeostasis» in the
level of circulating mutation JAK2 positive cells in some patients are unclear.
Aims: Evaluate the level of JAK2 mutation allele load in MPN patients in the
disease dynamics and HU effects.
Methods: This study included 14 JAK2 positive (V617F or exon 12 mutations)
MPN patients. The informed consents from these patients were obtained. DNA
was extracted from venous blood leukocytes. Quantification of JAK2 V617F and
JAK2 exon 12 mutations allele load was performed by pyrosequencing method
as described in (Dunaeva E et al Klin Lab Diagn, 2014). JAK2 variance (MUT)
was calculated as a measure of relative changes in allele load between the
baseline and follow-up sample (Theocharides A et al, Haematologica, 2008).
Results: Following variants were identified according to the level of JAK2 muta-
tion allele load in the disease dynamics and HU effects (Table 1): 1) The level
of JAK2 mutation allele load was increased more than twice (№3 and №13).
Until now this patients do not have the significant clinical MPN manifestations
and do not need HU-treatment; 2) The level of JAK2 mutation allele load was
found to remain stable over follow-up time of observation independently of
whether patients were already or not under HU treatment at the time of first
sampling; 3) The level of JAK2 mutation allele load was reduced after HU treat-
ment. We did not find any dependency between the allele load dynamics and
patient’s clinical status, disease phenotype, disease duration and venous blood
cellular account.
Table 1. Characteristics of the patients included in the study.
*The allelic load was determined at the primary address to the doctor with MPN symptoms
Summary/Conclusions: Our data suggest the JAK2 mutation allele load can
remain stable for a long time in some patients. The observed increase of the
mutation allele load in untreated patients probably will be to increase to the
level of its stabilization at full development of the clinical MPN picture. The dif-
ferences of the allele load dynamics between individual patients may be asso-
ciated with the individual features of the intracellular signaling networks and
will be the subject of additional studies.
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PLATELET COUNT AS A RISK FACTOR FOR HEMORRHAGIC COMPLICATIONS
IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE
NEOPLASMS
E Simonovic1,*, L Macukanovic-Golubovic2, V Colic1
1Internal Medicine, General Hospital, Leskovac, 2Internal Medicine, Clinic of
Haematology, Nis, Serbia
Background: Myeloproliferative neoplasms (MPN) are a group of clonal
hematopoietic stem cell malignancies, characterized by overgrowth of one or
more blood lines with normal or nearly normal maturing of those cells in the
bone marrow and extramedullary hematopoietic organs. Hemorrhagic syn-
drome is a complication that occurs in about a quarter of patients with PV and
even 60% of patients with ET. Bleeding can complicate the clinical course of
IMF. It has been manifested in the form of petechiae and ecchymoses, or may
be life-threatening as uncontrolled esophageal bleeding. It occurs due to inef-
fective megakaryocytopoiesis, retention of platelets in the enlarged spleen,
qualitative platelet disorders, acquired deficiency of factors V and vWF, dis-
seminated intravascular coagulation. The increased platelet count affects the
adsorption of the larger von Willebrand multimers onto the platelet membrane,
thus acting to eliminate them from circulation and degradation.
Aims: The aim of this study is to monitor the platelet count as a potential risk
factor for occurrence of hemorrhagic complications in patients with chronic
myeloproliferative neoplasms.
Methods: During the three-year period we monitored the occurrence of hem-
orrhagic complications and platelet count in 120 patients of both sexes aged
between 27 and 86 years, being diagnosed with Ph-myeloproliferative neo-
plasms. Patients were classified into the following groups: 1. Group with the
polycythemia vera (PV) (51); 2. Group with essential thrombocythemia (ET)
(24); 3. Group with idiopathic myelofibrosis (IMF) (20); 4. Group with unclassi-
fied myeloproliferative neoplasm (MPNs) (25). We used methods of clinical,
laboratory, endoscopy, ultrasound and CT scans.
Results: Platelet count ranged from 2,2-2134,5,1x109/L. The highest platelet
count was recorded in the group of patients with ET and MPNs (p<0,001) and
the lowest in the group of patients with the IMF (p<0,01). There was no statistical
significant difference detected between the groups of patients with PV and
MPNs with regard to platelet count. The highest percentage of hemorrhagic
complications was found in the group of patients with ET and IMF (p<0,01) and
then in the group with MPNs. Hemorrhagic complications have been more fre-
quent in patients with platelet count below 10x109/L (p<0,05) and in patients
with platelet counts over 1000x109/L (p<0,01). Life-threatening bleeding com-
plications were the most common in patients with platelet count below 5x109/L
and in patients with platelet count over 1500x109/L. Haemorrhage was the
cause of mortality in 15% of patients with MPN.
Summary/Conclusions: The platelet count can be considered as a significant
parameter for monitoring the risk of hemorrhagic complications in patients with
myeloproliferative neoplasms, particularly with ET and IMF. Further follow-up
and a larger number of subjects are needed. The follow-up of patients with
unclassified myeloproliferative neoplasms has particularly important, which
showed a high prevalence of hemorrhagic complications, and with the aim of
their further differentiation.
haematologica | 2016; 101(s1) | 815
Copenhagen, Denmark, June 9 – 12, 2016
Non-Hodgkin & Hodgkin lymphoma - Biology
PB2040
PROLIFERATING KI67 EXPRESSING B-CELLS ASSOCIATE WITH
CD4+PD1+ T-CELLS IN MARGINAL ZONE LYMPHOMA
K Wickenden1,*, N Nawaz1, E Lakidou1, A Wilson1, K Straatman2, S Wagner1,
M Ahearne1
1Cancer Studies, 2Biochemistry, University of Leicester, Leicester, United King-
dom
Background: Specific microbial antigens have been implicated in the devel-
opment and maintenance of several types of marginal zone lymphoma sug-
gesting that an abnormal immune response is essential for driving B-cell pro-
liferation. Reasoning that T-cell stimulation, especially from CD4+ T-cells, might
make important contributions to promoting B-cell proliferation we carried out a
detailed analysis of infiltrating T-cells in 8 cases of nodal marginal zone lym-
phoma.
Aims: The aim of the study was to undertake the first detailed study of T-cell
subsets in marginal zone lymphoma in order to determine the relationship of
individual subsets to proliferating lymphoma B-cells.
Methods: We carried out multiplex immunohistochemistry and validated the
results to show that, for the combinations of antibodies employed, there was
firstly no reduction in intensity after several rounds of staining and destaining
and secondly that there was no significant carry over from one round to the
next. The stained slides were scanned and, utilising a custom macro written
for ImageJ software, we enumerated CD4+ T-cell subsets (TH1- CD4+TBET+,
Treg - CD4+FoxP3+, follicular helper (Tfh) - CD4+PD1+ and follicular regulatory
(Tfr) - CD4+FoxP3+PD1+). 
Results: In all cases CD4+,T-cells constituted a major portion of infiltrating T-
cells, mean 39.8% (range 13.5 to 70.3%). There were, however, large differ-
ences in the CD4+ T-cell subset composition; Tfh cells varied from 2.5 to 36%
of all CD4+,T-cells,whilst Tregs accounted for 2.7 to 24.7%. We also compared
architecture of T-cell infiltration across cases and found that T-cells were not
homogenously distributed and that CD4+PD1+ cell clusters could show some
association or no association with CD4+FoxP3+ clusters and, in one case,
repulsion from CD4+FoxP3+ clusters. In order to quantitate the associations
we carried out Pearson correlations. For comparison normal tonsil showed a
Pearson correlation of -0.4 i.e. no overalp, between CD4+PD1+ and
CD4+FoxP3+ cells whereas there were varying degrees of association (range
0.3 to 0.8) for the lymphoma samples. By contrast proliferating Ki67+ lymphoma
B-cells associated with CD4+PD1+ cell clusters (Pearson 0.1 to 0.6) whatever
the relation to CD4+PD1+ cells to CD4+FoxP3+ cells. To confirm this result we
used an alternative method to analyse clustering (the Morisita index). This pro-
duced similar results with normal tonsil having a Morisita index of 0.2 for
CD4+PD1+ and CD4+FoxP3+ whereas lymphoma samples showed higher
degrees of association (range 0.3 to 0.9). The Morisita index also confirmed
association between proliferating B-cells and CD4+PD1+ cells; normal tonsil
0.8 and lymphoma (0.4 to 0.8).
Summary/Conclusions: Collectively our data suggests an unsuspected asso-
ciation between CD4+PD1+ T-cells and proliferating lymphoma B-cells in mar-
ginal zone lymphoma.
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CLINICAL IMPLICATIONS OF MYD88 L265P MUTATION IN PATIENTS WITH
DIFFUSE LARGE B-CELL LYMPHOMA
A Sidorova*, E Zvonkov, A Sudarikov, N Severina, N Gabeeva, A Kovrigina,
V Troitskaya, V Savchenko
National Research Center for Hematology of the Ministry of Healthcare of the
Russian Federation, Moscow, Russian Federation
Background: It is now well known fact that recurrent mutation in the MYD88
gene (L265P MYD88) is identified in about 90% of Waldenström macroglobu-
linemia, in approximately one-quarter of patients (pts) with diffuse large B-cell
lymphoma (DLBCL) and in a minority of cases of other lymphoproliferative dis-
orders. Evidence is beginning to accumulate that L265P MYD88 mutation in
pts with DLBCL has strong association with clinical phenotypes and outcomes.
Aims: To evaluate the clinical implications of MYD88 L265P mutation in pts
with DLBCL.
Methods: We analyzed the data of 75 pts (median age 50 years, range 18-77,
33/42 female/male ratio, 39 extranodal and 36 nodal disease) with de novo
DLBCL diagnosed between 1999 to 2015 at National Research Center for
Hematology. Pts were classified as germinal center B-cell-like (GCB) or non-
GCB DLBCL using the Hans algorithm. For molecular analysis DNA was
extracted from 56 cryopreserved and 19 formalin-fixed paraffin-embedded
tumor tissue. The mutational status of a sample was determined by real-time
PCR (RT-PCR).
Results: MYD88 L265P mutation was detected in 14(18,7%) out of 75 pts. Half
of pts with MYD88-positive MYD88 L265P mutation DLBCL are older than 60
years compared with only 24,6% of those pts with MYD88 unmutated DLBCL.
In terms of sex ratio the data show a double preponderance of males at MYD88
L265P positive DLBCL (9:5) as compared with MYD88 wild type DLBCL with
the same number of males and females (33:28). There was equal distribution
of pts across high-intermediate and high risk groups of the international prog-
nostic index both in MYD88 mutated and MYD88 unmutated pts (71,7% vs
63,9%). The majority of pts in both groups had elevated serum lactate dehydro-
genase levels, 12/14 (85,7%) and 47/61 (77%) respectively. Tumors with high
Ki-67>80% expression were found in 13(92,8%) of pts MYD88 mutation versus
43(70,5%) pts with MYD88 wild type DLBCL. All 14(100%) pts with MYD88
L265P DLBCL were non-GCB DLBCL as compared to 42/61(72%) pts with
MYD88 unmutated DLBCL. Eleven (78,6%) out of 14 pts with MYD88 mutation
had extranodal lesions (р<0,05). Five (45,4%) of 11 cases MYD88 L265P extra-
nodal DLBCL were present in immune-privileged site DLBCL (central nervous
system, testis) versus 4(14,2%) out of 28 pts with MYD88 wild type extranodal
DLBCL (р<0,05). The table summarizes baseline characteristics pts.
Table 1.
Summary/Conclusions: It is apparent from the present study that MYD88
L265P mutation was significantly associated with extranodal DLBCL (78,6%)
and prevalent in immune-privileged site DLBCL. Detection of MYD88 L265P
mutation by RT-PCR could improve diagnosis non-GCB DLBCL as a comple-
ment to immunohistochemistry.
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QUINACRINE SYNERGIZES WITH DOXORUBICIN IN INHIBITING THE
SURVIVAL OF DLBCL CELL BY SUPPRESSING NF-KB AND ALTERING
CELL-CYCLE PROGRESSION
Y Shujun*, O Guifang, Z Huilin, S Lixia, Z Ping,xZhijuan
Hematology Department, Ningbo First Hospital, Ningbo, China
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell
non-Hodgkin lymphoma that affects patients of all ages with a wide range of
clinical presentations. Although DLBCL is curable even in advanced stages,
up to one-third of patients will not achieve cure with initial therapy. To test drug
combinations that could improve the efficacy of chemotherapeutics used cur-
rently. We combined doxorubicin (dox) with quinacrine (qc), which inhibits the
FACT complex that is required for NF- κB transcriptional activity.
Figure 1.
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Aims: The aim of this study was to test drug combinations that could improve
the efficacy of chemotherapeutics currently used, such as dox, to Provide new
and better drugs for clinical treatment of DLBCL.
Methods: Cells were maintained in RPMI-1640 medium supplemented with
10% FBS. All cells were kept at 37°C in a humidified atmosphere with 5% CO2.
Cell viability was determined by the MTT assay. The combination index (CI)
was assessed by using Calcusyn software. Cells stained with propidium iodide
(PI), the cell-cycle distribution was assessed by FACScan (BD) Biosciences
analysis. Cells were infected with the NF-κB-luciferase Lentiviral construct and
stably selected with puromycin. The influence of Qc on the activity of NF-κB
was tested using luciferase assay system.
Results: Qc synergizes with dox in inhibiting the proliferation of DLBCL cell
lines; Qc has the ability to suppressing NF-κB-dependent luciferase activity,
which means qc inhibits the activity of NF-κB, as well as alrer the cell cycle of
DLBCL cell lines.
Summary/Conclusions: Qc can inhibit the growth of DLBCL tumor cells,
enhance the curative effect of chemotherapy drugs such as dox, its possible
mechanism is qc could inhibit the NF-kB activity which plays key roles in DLBCL
cell survival and chemotheraputic resistance, as well as alter the cell cycle pro-
gression.
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VALIDATION OF LST EUROFLOW® PROTOCOL BY MULTIPARAMETRIC
FLOW CYTOMETRY IN SCREENING OF LYMPHOPROLIFERATIVE
NEOPLASTIC DISEASE IN CHILE
A Berkovits1,*, M Oyarzo2, M Burotto3, P García-Huidobro1, M Zamora1, D Araos1
1Clinical Laboratory Department, Immunology Section, 2Pathology Department,
3Hemato-oncology Department, Clinica Alemana de Santiago, Santiago, Chile
Background: Immunophenotype analysis by multiparametric flow cytometry
(MFC) is an important tool, together with pathology, cytogenetical and molecular
analysis, for the diagnosis, classification and treatment monitoring of hemato-
logical malignancies. The accurate identification of abnormal lymphocytes by
MFC requires a unique standardized combination of fluorochrome-conjugated
antibodies. The international consortium of standardization, Euroflow®, elabo-
rated a lymphoproliferative disease screening panel (LST) aiming the identifi-
cation of normal or aberrant B, T or NK lymphocytes in different tissues.
Aims: Confirm that the screening of lympholiferative disease using MFC analy-
sis with LST Euroflow® panel, in an accurate method to recognize, quantify
and characterize abnormal lymphocyte populations in lymphoma positive tissue
biopsies in Chilean population.
Methods: Retrospective analysis of tissue and/or bone marrow samples sent
simultaneously to both the pathology laboratory for biopsy (reviewed by only
one expert hematopathology of our institution) and to immunology section of
Clinica Alemana de Santiago for immunophenotyping analysis, since the imple-
mentation of LST Euroflow® protocol for lymphoproliferative disease screening.
All tissues were processed in 8 colors FACSCanto cytometer by BD Bioscience
II. The panels and fluorochromes used in every analysis were: CD4 and CD20
in PacB, CD45 in AmCyan, CD8 and SmIgl in FITC, CD56 and SmIgk in PE,
CD5 in PerCPCy5.5, CD19 and TCRgd in PECy7, SmCD3 in APC and CD38
in APCCy7. 
Results: One hundred and seventy-four samples with suspect of lymphoprolif-
erative disease and concomitant pathology report in our institution were revised
from June 2013 to December 2015. Exclusion criteria included Hodgkin Lym-
phoma and non-hematological neoplastic diagnosis by histology (14 and 11 tis-
sues samples respectively). Fifty tissues were positive for lymphoproliferative
disease by biopsy, including 16 follicular lymphomas, 12 diffuse large B cell lym-
phomas, 7 SLL/CLL, 5 mantle cell lymphomas, 3 lymphoplasmocytic lym-
phomas, 3 marginal zone lymphomas, 2 Hairy cell leukemia, 1 T gamma-delta
lymphoma and 1 multiple myeloma. The screening analysis by MFC using LST
panel showed abnormal and/or clonal population in 100% of positive lympho-
proliferative disease biopsies. In the analysis of the non-neoplastic histological
biopsies (87 samples), MFC detected subclinical clonal or abnormal lymphocytic
population in 10 cases, being both negatives in 77. The sensitivity, specificity,
positive predictive value and negative predictive value of LST for diagnosis of
lymphoproliferative disease was 100%, 89%, 86% and 100% respectively.
Summary/Conclusions: Lymphoproliferative panel LST is an effective screen-
ing tool for lymphoma diagnosis in Chilean population in different tissues includ-
ing bone marrow.
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IMPACT OF THE NAGASAKI ATOMIC BOMB ON THE INCIDENCE RATE
AND OUTCOME OF FOLLICULAR LYMPHOMA
T Jo1,*, M Yamashita1, S Irie2, K Horio1, K Shigematsu3, M Mine4, T Aikawa5
1Hematology, 2Pharmacy, 3Pathology, Japanese Red Cross Nagasaki Genbaku
Hospital, 4Scientific Data Registry, Atomic Bomb Disease Institute, Nagasaki
University, 5Laboratory Medicine, Japanese Red Cross Nagasaki Genbaku
Hospital, Nagasaki, Japan
Background: In Nagasaki and Hiroshima, approximately 75,000 and 120,000
citizens, respectively, died within 3 months of the 1945 atomic bomb explosions.
Furthermore, 80,000 and 140,000 citizens, respectively, survived exposure.
During the following 70 years, high-dose radiation exposure has induced vari-
ous cancers, including leukemia; thyroid, lung, gastric, and colon cancers; and
myelodysplastic syndromes (MDS). Additionally, approximately 10% of cancer-
carrying patients of Nagasaki atomic bomb survivors have multiple primary
cancers in various tissues. This high-dose radiation exposure not only increased
the risk of developing various types of cancer, but also worsened the overall
survival (OS) rate. We recently reported significantly shorter OS among
Nagasaki atomic bomb survivors with MDS versus patients without such radi-
ation exposure (Jo et al., Anticancer Research 2015). 
Aims: We investigated whether high-dose radiation exposure would similarly
affect the incidence rates and outcomes of follicular lymphoma (FL) and diffuse
large B-cell lymphoma (DLBCL).
Methods: The youngest atomic bomb survivors are aged approximately 70
years, presenting a challenge to perform prospective cohort studies. Therefore,
we conducted a retrospective cohort study of the incidence rates and outcomes
of FL and DLBCL in cases diagnosed at our hospital between January 2004
and December 2013. The primary objectives were to compare the incidence
rates of FL and DLBCL in atomic bomb survivors (A-Bomb) and non-A-Bomb
patients, and determine the OS rates.
Results: Table 1 lists the number of patients. Seven and 51 A-Bomb patients
and 49 and 91 non-A-Bomb patients had FL and DLBCL, respectively. The inci-
dence rate of FL versus DLBCL was significantly less among A-Bomb patients
than among non-A-Bomb patients (P=0.0009). There was no significant differ-
ence in OS between A-Bomb and non-A-Bomb patients with DLBCL (P=0.3065,
hazard ration [HR]: 1.311, 95% confidence interval [CI]: 0.7813–2.198). In con-
trast to DLBCL, the OS rate was significantly lower in A-Bomb patients with FL
than in non-A-Bomb patients (P=0.0092, HR: 5.425, 95% CI: 2.151–220.1). In
both FL and DLBCL patients, there were no significant differences of back-
ground factors except for the median age between A-Bomb and non-A-Bomb
patients. The respective median ages of A-Bomb and non-A-Bomb patients
with DLBCL differed significantly at 75 (range, 62–91) and 73 (range, 17–93)
years (P=0.0038). The respective median ages of A-Bomb and non-A-Bomb
patients with FL also differed significantly at 80 (range, 63–90) and 60 (range,
28–80) years (P <0.0001). The age difference had no impact on the OS rate of
DLBCL. Therefore, the shorter OS of A-Bomb patients with FL cannot be
accounted only for the age difference between A-Bomb and non-A-Bomb
patients. Some other unknown factors caused by high-dose radiation exposure
of the Nagasaki Atomic Bomb could be linked to the OS difference.
Table 1.
Summary/Conclusions: Compared with non-A-Bomb patients, A-Bomb
patients had a significantly lower FL incidence rate and significantly shorter
OS. We previously reported significantly reduced OS among MDS patients
exposed to the Nagasaki atomic bomb. These data suggest an influence of
atomic bomb exposure and warrant further study for etiological clarification.
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CD39 EXPRESSION ON CD4 T INFILTRATING LYMHOCYTES IN THE
TUMOR MICROENVIRONMENT OF LYMPHOMAS
R Di Gaetano1,*, V Gasparetto1, B Callegari1, MA De Benedetto1, A Scapinello2,
G Tagariello1
1Haematology, 2Pathology, Hospital, Castelfranco Veneto, Italy
Background: In tumor microenvironment (TME) a variety of mechanisms favor
a tumor-protection, one of them is the accumulation of extracellular adenosine
(ADO) by up-regulating activity of ectoenzime CD39. The generation of ADO
from ATP metabolism is recognized as a mechanism for immunosuppressive
function of regulatoty T cell (Treg), a component of the CD4+ T lymphocytes
expressing variable functional molecules and involved in tumor escape.
Aims: It has been well-documented the increase of Treg in various solid tumor
and the higher CD39 expression in some types of human cancer. We have
evaluated the CD39 and the CD26 (an adenosine deaminase) on CD4+T infil-
trating lymphocytes in lymph node with lymphoma to verify the expression of
two markers and whether they could be an attractive features for analysis of
TME of a non Hodgkin lymphoma (NHL).
Methods: We analyzed by flow cytometry (FC) immunophenotyping non-neo-
plastic (10) and B-NHL (48) lymph node samples. and we measured the CD26
and CD39 on CD4+ T lymphocytes in all tissues. Among B-NHL were 14 diffuse
large B cell lymphoma (DLBCL) and 3 relapsed.
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Results: Compared to non-neoplastic samples, CD4+T cells of NHL showed
statistically significant difference on CD26 (67% vs 39.5%; p <0.001) and on
CD39 (6% vs 34%; p <0.001). In NHL, compared to other entities the value of
CD26 on DLBCL (39.5% vs 34%) and on the relapsed (39.5% vs 29%) was
not significantly different; while CD39 on both groups, DLBCL (34% vs 54%; p
<0.005) and relapsed (34% vs 74%; p <0.001), resulted significantly increased.
Figure 1.
Summary/Conclusions: Although the regulatory activity of immune system
can employ a diversity of molecular mechanisms, the presence of enzymati-
cally-competent CD39 on surface of infiltrating CD4+T suggest that the CD39
pathway can be a distinct mechanism utilized by Treg in TME of lymphomas.
Furthermore, the tendency to the reduction (heightened in the relapsed) of
CD26, connectable to a lower activity of adenosine deaminase, beside the up-
regulated expression of CD39, could underlies an increased accumulation of
extracellular ADO and its important role in Treg-mediated immune response
suppression. Data of DLBCL, resembling the relapsed, tend to differentiate
from other entities for a more suppressive functional profile. Together, these
simple and fast assays obtained by FC support the finding that ATP-ectonu-
cleotidase-adenosine system may have a role in mediating Treg activity also
in lymphomas suggesting that CD39 represents a possible target for cancer
immunotherapy.
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SERUM PROTEOMIC PROFILES OF HODGKIN’S LYMPHOMA PATIENTS
SHOW DIFFERENTIAL EXPRESSION ACCORDING TO EPSTEIN-BARR
VIRUS STATUS
J Musacchio1,*, JS Fischer2, CH Garcia2, PC Carvalho3, A Scheliga4, CG Fer-
reira4, MG Carvalho2
1Hematology Service, Oncologia D’Or, Rio de Janeiro, 2Federal University of
Rio de Janeiro, 3Oswaldo Cruz Institute, 4Brazilian National Cancer Institute,
RJ, Brazil
Background: Despite the advances in understanding of Hodgkin’s lymphoma’s
molecular pathogenesis, its association with EBV remains unclear. In this study,
we assessed serum protein profiles from EBV associated and non-associated
Hodgkin’s lymphoma patients and identified three differentially expressed pro-
teins that are candidate biomarkers.
Aims: The aim of the present study was to identify and analyze differentially
expressed proteins in pooled sera from patients with HL according to EBV status.
Methods: Blood samples were obtained from 16 patients with recently diag-
nosed HL before treatment. Blood samples from 10 healthy volunteers were
also included. The inclusion criteria used for EBV non-associated HL were the
negativity of EBV in buffy coat, plasma, and lymph node. Conversely, patients
with EBV associated HL should have EBV detected in buffy coat or plasma,
and lymph node. MALDI-MS was performed using a 4700 Proteomics Analyz-
er® (Applied Biosystems).
Results: The patients’ median age at diagnosis was 26 years (range 15-56)
and 38% were men. Our analysis revealed about 265 spots with a mean of 86
(35%) identified spots on each gel. Five spots were indicated as having different
normalized volumes when compared to each other (p<0.05) (Figure1). Two
up-regulated proteins were detected in patients with EBV non-associated HL,
and identified as inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) and hap-
toglobin (HP). Only one protein, fibrinogen beta chain, was down-regulated in
the serum from EBV-associated HL patients.
Table 1.
Summary/Conclusions: We identified three serum proteins that may serve
as potential biomarkers in HL, according to EBV status.The biological function
of ITIH4 is still unknown. A possible role is the modulation of cell migration and
proliferation during the development of the acute-phase response. These find-
ings may suggest that EBV presence could inhibit ITIH4 expression. Serum
HP levels in the lymphoma patients have also been described to be significantly
higher than in the control group and have been correlated to response to treat-
ment. These results suggest HP as a new tumor marker for lymphoma. Here
HP is not increased in patients with advanced stage disease, but in absence
of systemic EBV infection, which is in line with prior observations: a recent
study described some phenotypes with a higher HP concentration (HP 1-1 and
HP 2-1) are less prone to positive EBV serology. In spite of FGB has been
described as a serum acute phase reactant protein, their levels were decreased
in patients diagnosed with EBV associated HL. The cytokines IL-4, IL-10 and
IL-13 have a protective effect against vascular injury leading to atherosclerosis,
dose dependently down regulate the biosynthesis of fibrinogen, and some of
these cytokines are known involved in the HL pathophysiology. In conclusion,
the present study represents an initial and necessary step needed to identify
proteins that are differentially expressed between patients with EBV associated
and non-associated HL. We demonstrated that protein profiling of serum sig-
nificantly, accurately and reproducibility distinguished EBV associated and non-
associated HL patients. This is the first report combining analysis of serum
proteomics of HL patients, according to EBV status, and the pooled sera
approach as an appropriate initial approach. Following the identification of
spots, future studies with more samples are still required to validate our results.
Besides such validation could be performed in large scale by other techniques
(e.g., ELISA-based methods).
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EVALUATION OF NEUTROPHIL-LYMPHOCYTE RATIO IN PATIENTS WITH
MYCOSIS FUNGOIDES
R Eren1,*, N Nizam2, MH Doğu1, S Mercan3, AV Turgut Erdemir3, E Suyanı1
1Hematology, 2İnternal Medicine, 3Dermatology, İstanbul Training and
Research Hospital, istanbul, Turkey
Background: Neutrophil lymphocyte ratio (NLR), an indicator of inflammation,
has been lately demonstrated as a prognostic factor in various lymphoprolifer-
ative disorders. However, the effects of NLR has not been investigated in myco-
sis fungoides (MF) patients yet. 
Aims: The aim of this study is to investigate the relationship between the neu-
trophil-lymphocyte ratio (NLR) and treatment demand (systemic PUVA and/or
chemotherapy), time to treatment, progression in stage, time to progression in
stage in MF patients.
Methods: The data of 117 patients, who were followed with the diagnosis of
MF at Department of Dermatology in Istanbul Training and Research Hospital
between April 2006 and January 2016, were reviewed retrospectively. Neu-
trophil-lymphocyte ratio was calculated from complete blood count of patients
at the time of diagnosis. The cut-off score for NLR was determined as 2 accord-
ing to the median NLR level which was 1.96. Statistical evaluation was made
by SPSS 15 package program. x2,Fisher’s exact test was used for evaluating
categorical values and Mann Whitney U test for continuous values in patient
groups.
Results: At the time of diagnosis, the median age of patients was 54 years
(range, 21-90). 62 (53%) of the patients were female and 55 (47%) were male.
60 (51.3%) patients had stage Ia, 18 (15.4%) had stage Ib, 35 (29.9%) had
stage IIa, 1 (0.9%) had stage IIIa and 3 (2.6%) had stage IVa disease. 77 (65.8%)
patients required treatment during follow up. The median time from diagnosis
to treatment was 2 (range, 0-64) months. 63 (53.8%) patients showed progres-
sion in disease stage. The median time from diagnosis to progression in stage
was 23 (1-108) months. There was no significant difference in treatment neces-
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sity, time to treatment, progression in stage, time to progression in stage in
patients with a NLR≥2 and NLR<2 (p=0.331, 0.987, 0.065, 0.119 respectively).
Summary/Conclusions: Although NLR has been demonstrated to have prog-
nostic role in various lymphoporliferative disorders, it seems that there is no
association between the NLR and treatment demand (systemic PUVA and/or
chemotherapy), time to treatment, progression in stage, time to progression in
stage in mycosis fungoides (MF) patients.
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TO DOSE OR NOT TO DOSE: ARE IL-10 AND IL-10:IL-6 RATIO ACCURATE
BIOMARKERS TO DETECT LEPTOMENINGEAL INVOLVEMENT IN SMALL
B-CELL LYMPHOPROLIFERATIONS?
M Costopoulos1,*, R Kim1, S Choquet2, K Maloum1, C Algrin2, C Houillier3,
C Settegrana1, J Villemonteix1, M Brissard1, C Quiney1, F Davi1, V Leblond2,
H Merle-Beral1, M Le Garff-Tavernier1
1Biological Haematology Department, 2Clinical Haematology, 3Neuro-oncology
Department, Pitie-Salpetriere Hospital, Paris, France
Background: Identifying the etiology of neurological symptoms in blood malig-
nancies is still a challenging issue. Lymphomatous meningitis (LM) is mainly
described in aggressive B-cell lymphomas (diffuse large B-cell (DLBCL) and
Burkitt lymphomas). Leptomeningeal involvement in small B-cell lymphoprolif-
erations is a rare, poorly described condition, mentioned only in a few case
reports. The diagnosis is suspected in patients with non-specific central nervous
system (CNS) symptoms and non-specific results on medical imaging. The
diagnosis is confirmed by cytology (detection of tumor cells) in the cerebrospinal
fluid (CSF). However, its sensitivity is low due to the scanty amounts of CSF
and the rapid cell death. During the past decade, new complementary
approaches have been proposed including flow cytometry (FCM) and quantifi-
cations of soluble biomarkers. More recently, interleukin-10 (IL-10) has been
described as a candidate to diagnose primary central nervous system lym-
phoma (PCNSL) and systemic DLBCL with CNS involvement. Dosages can be
processed using multiplex techniques with the possibility to undergo simulta-
neous multiple dosages on small volumes.
Aims: The aim of our study was to evaluate the diagnostic value of interleukin
IL-10 and IL-6 quantifications combined with the IL-10:IL-6 ratio in CSF of
patients suffering from LM secondary to systemic small B-cell lymphoprolifer-
ations.
Methods: We carried out a retrospective monocentric study over 4 years on
23 patients suffering from small B-cell LM: 5 chronic lymphocytic leukemias, 3
mantle-cell lymphomas, 13 Waldenström macroglobulinemias (WM) and 2
unclassified B-cell lymphomas. All patients presented CNS symptoms and doc-
umented LM (revealed either by cytology or FCM) at the diagnostic stage or
before intrathecal chemotherapy. IL-10 and IL-6 quantifications were performed
in CSF using the Cytometric Bead Array® technique (BD BiosciencesTM) on a
FACSCanto II flow cytometer (BD BiosciencesTM), with a limit of detection of
2.5pg/ml.
Results: As there is no well-defined IL-10 cutoff in the literature, we applied
the IL-10:IL-6 ratio with a threshold set at 1 used to diagnose intra-ocular lym-
phoma. More than half of the patients (n=14) had an undetectable level of IL-
10 along with low levels of IL-6, leading to an IL-10:IL-6 ratio <1 or undeter-
minable (group n°1). Patients in group n°2 also had ratios ≤1 but with detectable
levels of IL-10. All patients with ratios≤1 (groups n°1 and 2) presented small B-
cell lymphoproliferations with LM but no evidence of aggressive B-cell lym-
phoma. Patients in group n°3 had ratios >1. Two patients had PCNSL simulta-
neously diagnosed in the CSF and one patient had a WM transformed into
DLBCL during follow-up. These 3 patients presented an increased IL-10 level
(≥10 pg/ml). Thus, IL-10 and IL-10:IL-6 ratios in small B-cell lymphoproliferations
unexpectedly differed from those observed in DLBCL. Our findings demonstrate
the need of IL-10 and IL-6 quantification with the use of IL-10:IL-6 ratio in small
B-cell lymphoproliferations to exclude any other aggressive B-cell malignancy.
Interestingly, in WM patients with L, also called Bing Neel syndrome, IL-6 levels
seemed higher (median: 10 pg/ml) than in other patients.
Summary/Conclusions: In conclusion, we describe for the first time that CSF
IL-10 is not increased in small B-cell lymphoproliferations with LM. However,
we report its usefulness in revealing more aggressive lymphomas in the context
of either a transformation or when associated with another “hidden” lymphoma
such as PCNSL. Supplementary data will be prospectively collected to confirm
our results.
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PROGRESS IN THE DIAGNOSIS OF PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA
A Debliquis1,*, J Voirin2, I Harzallah1, M Maurer3, F Lerintiu4, B Drénou5, G Ahle6
1Laboratoire d’hématologie, Groupe Hospitalier de la région Mulhouse Sud
Alsace, Mulhouse, 2Service de Neurochirurgie, 3Laboratoire d’hématologie,
4Anatomopathologie, Hôpitaux civils de Colmar, Colmar, 5Service et laboratoire
d’hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mul-
house, 6Service de Neurologie, Hôpitaux civils de Colmar, Colmar, France
Background: Central nervous system lymphomas are aggressive tumors requiring
a prompt diagnosis for successful treatment. Stereotactic brain biopsy remains the
standard procedure, but the time needed for histopathology is usually over 2 days.
Aims: During stereotactic brain biopsy, the trocar is rinsed with saline solution
and we evaluated the contribution of cytomorphology and flow cytometry of
this rinse fluid usually removed.
Methods: Eighteen patients with suspected localized brain lymphoma under-
went stereotactic brain biopsy. Brain biopsy tissue sample and/or brain biopsy
rinse fluid were analyzed by cytomorphology combined with flow cytometry.
Eleven patients had both types of sample, four patients had only brain biopsy
tissue sample, and three patients had only brain biopsy rinse fluid. Histopathol-
ogy was used as a reference. 
Results: Histopathology characterized ten diffuse large B-cell lymphomas and
eight other diseases: three glioblastomas, one necrosis, one Erdheim-Chester
disease, one cerebral vasculitis, one stroke and one anaplastic astrocytoma.
Cytomorphology and flow cytometry showed lymphoma cells in nine out of the
ten lymphomas. Three cytomorphology or flow cytometry negative results were
reported for lymphomas in tissue samples due to low cellularity and biopsy
sample conditioning. No lymphomatous cells were found by cytomorphology
or flow cytometry in the eight other diseases. Rinse fluid results were consistent
with histology in all cases studied (sensitivity and specificity, 100%). All lym-
phomas characterized by flow cytometry were: CD5-, CD20+, Ki67 high and
CD10 was expressed in six out of the nine cases as in histopathology. CD44,
CD184, BCL2, and BCL6 showed variable expression. The median time to
result was 4.5 days (range, 2-10) for histopathology, while 5 h (range, 3-20)
were required for both cytomorphology and flow cytometry. 
Summary/Conclusions: Brain biopsy rinse fluid alleviates problems of tissue
sample distribution compared to tissue sample. Its analysis performs diagnosis
of B-cell lymphoma in a few hours and, associated with histopathology, allows a
multidisciplinary diagnosis. This study shows that cytomorphology combined with
flow cytometry on brain biospy rinse fluid is a new, fast, and useful strategy.
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CSF IGH REARRANGEMENT IN HIGH-RISK DLBCL PATIENTS TREATED
WITH INTRATHECAL PROPHYLAXIS
MC Tisi1,*, F D’Alò1, S Bellesi1, E Maiolo1, E Alma1, A Cuccaro1, P Chiusolo1,
MT Voso2, S Hohaus1
1Institute of Hematology, Catholic University Rome, 2Department of Biomedi-
cine and Prevention, Università Tor Vergata, Rome, Italy
Background: Central nervous system (CNS) involvement is one of the most
serious and devastating complications for patients with diffuse large B-cell lym-
phoma (DLBCL). Patients with risk factors for secondary CNS localization as
specific extranodal sites, bone marrow localization and high IPI score, are can-
didates for intrathecal prophylaxis. Cerebrospinal fluid (CSF) is routinely ana-
lyzed by cytology for the presence of lymphoma cells, while the role of the IgH
rearrangement assay on CSF has not been studied in high-risk DLBCL patients
treated with intrathecal prophylaxis.
Aims: To evaluate the incidence of IgH clonal rearrangement at diagnosis in
high-risk DLBCL treated with intrathecal prophylaxis.
Methods: Patient population included 55 patients with aggressive B-cell lym-
phoma without CNS involvement, including 51 pts with DLBCL and 4 patients
with unclassifiable lymphoma with intermediate features between DLBCL and
Burkitt lymphoma. All patients were treated with R-CHOP-like regimens asso-
ciated to intrathecal methotrexate prophylaxis given during the first 4 cycles of
systemic therapy. Twenty-two patients were consolidated with ASCT. CSF sam-
ples at the first lumbar puncture were analyzed for IgH rearrangement. After
CSF centrifugation, DNA was extracted through the EZ1 DNA Tissue Kit (Qia-
gen) using the BioRobot EZ1 (Qiagen). VH FR2-JH and VH FR3-JH rearrange-
ment were amplified in two semi-nested PCRs by using the B-cell lymphoma
kit-FL (Experteam), and analyzed by Gene Scanning on the ABI 3100 Genetic
Analyzer (Applied Biosystem). 
Results: A clonal IgH rearrangement in the liquor was detected in 16 of 55
patients (29%), while it was polyclonal or absent in remaining 39 patients. In
4/55 (7%) patients, the number of cells in the CSF was elevated. In the 4
patients with elevated CSF cells, IgH analysis showed a monoclonal band in 1
patient and a polyclonal rearrangement in 3 patients. The presence of clonal
IgH rearrangement was associated with elevated (>40 mg/dl) protein levels in
the liquor (p=0.001). In particular, only 3/30 (10%) patients with a normal CSF
protein level showed a clonal IgH, while a clonal IgH rearrangement was present
in 13/25 (60%) patients with elevated CSF protein levels. No association was
found between detection of clonal IgH in CSF and patient characteristics, as
age, stage, bone marrow or extranodal involvement, LDH and international
prognostic index IPI. Eight patients with clonal IgH on CSF were serially ana-
lyzed at sequential lumbar punctures: the clonal IgH peak disappeared in 7
patients and persisted only in one patient. Three patients developed CNS
relapse (5.5%), one of 16 patients with clonal IgH on CSF (6%) and 2 of 39
patients with polyclonal IgH on CSF (5%).
Summary/Conclusions: Clonal IgH rearrangements are frequently present in
the CSF of high-risk DLBCL patients and tend to disappear during repeated
CNS-directed prophylaxis. No association between detection of clonal IgH
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rearrangement and risk of CNS relapse was found in patients treated with
intrathecal methotrexate.
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HODGKIN’S LYMPHOMA AND AUTOIMMUNE DISEASES
B Rym*, F Talbi, Se Belakehal, S Chaib, N Demmane Debbih, Fz Ardjoun
Algiers, Algeria, Algiers, Algeria
Background: Hodgkin’s lymphoma (HL) is a tumor disease of the lymphoid
tissue characterized by presence of Reed-Sternberg cells. Autoimmune phe-
nomena are associated with HL. They may precede the clinical presentation
of HL, occur concurrently or later, either spontaneously or following treatment.
The relationship between HL and autoimmune diseases has been reported as
bi-directional, however there is a few data in general population.
Aims: Evaluation of the percentage of autoimmune diseases associated with
HL on a retrospective study of 80 cases.
Methods: A retrospective study in the hematology department, conducted over
a period of 5 years (from 2008 to 2012), which concerned 80 cases of HL.
The diagnosis is histological completed with immunohistochemistry using anti
CD15 and anti CD30 anibody. Patients are classified according to the classifi-
cation of Ann Arbor.We used prognostic classifications: the EORTC for localized
stages and IPS for advanced stages.A clinical assessment is performed and
includes: blood glucose, renal assessment, liver function tests, viral serology,
a respiratory functional exploration, electrocardiogram and echocardiography.
Patients are treated with ABVD chemotherapy associated with mantle radio-
therapy.In front of presence of warning signs (palpitations, dyspnea, asthenia,
bone pain, thrombosis) an immunological assessment is carried out in search
of lupus anticoagulant, anticardiolipin, anti-histone antibodies, anti-nuclear fac-
tor, thyroid function tests (TSH, FT3, FT4, ATG, ATPO), cervical ultrasound.
Biopsies are sometimes carried out in the context and the type of autoimmune
disease and sought by the existence of clinically detectable lesions (biopsy of
the salivary glands, skin...).
Results: Eighty cases were included, 5 (6,2%) of which, had an autoimmune
disease diagnosed previously, simultaneously or after lymphoma. There are 4
women and 1 man. Autoimmune diseases were: lupus erythematosus, thy-
roiditis autoimmune, celiac disease, sarcoidosis. The diagnosis was made after
lymphoma in 4 patients and before in 1 patient,no deaths were registered.
Table 1.
Summary/Conclusions: HL association with an autoimmune disease is esti-
mated at 6.2%. There was an important prevalence of autoimmune diseases
in girls with HL.The contribution of the activity of the autoimmune disease and
immunosuppressive drugs in the development of HL is still not understood. It
might be interesting to try to define a population at risk, by personal or family
history of autoimmunity and regular and rigorous monitoring of patients during
and after treatment with unusual clinical and biological signs.
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EFFECTS OF MICRORNA-21 ON APOPTOSIS BY REGULATING THE
EXPRESSION OF PTEN IN DIFFUSE LARGE B-CELL LYMPHOMA
R Fu*, C Li, H Liu, Y Wang, W Song, Z Shao
Department of Hematology, Tianjin Medical University General Hospital, Tianjin,
China
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malig-
nancy and the most common subtype of non-Hodgkin’s lymphoma in China.
We found that plasma miR-21 level was significantly higher in B-cell lymphoma.
However, the exact contribution of miR-21 in DLBCL remains unknown.
Aims: To determine the function and mechanism of miR-21 in DLBCL.
Methods: miR-21 and phosphatase and tensin homolog (PTEN) expressions
were examined through real-time PCR and immunohistochemical methods.
Moreover, the effects of antisense oligonucleotide (ASO) targeting miR-21
(ASO-21) were observed in DLCBL cell line.
Results: Results showed that miR-21 expressions in cell line and tissues of
patients were significantly higher than those in normal controls, which were
inversely correlated with PTEN expression. MiR-21 expression was significantly
higher in stage III/IV patients than in stage I/II patients. After downregulating
the miR-21 expression, apoptosis of DLBCL cells increased and PTEN protein
was upregulated.
Figure 1.
Summary/Conclusions: These results suggested that miR-21 affects apop-
tosis of lymphoma cells by regulating the expression of PTEN in DLBCL, which
may be associated with increased poor prognosis for DLBCL patients and rep-
resents a useful approach for DLBCL treatment.
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PROSPECTIVE COMPARATIVE STUDY BETWEEN CYTOLOGY COUPLED
TO THE FLOW CYTOMETRY BY FINE NEEDLE ASPIRATION AND
HISTOLOGY IN THE DIAGNOSIS AND CLASSIFICATION OF LARGE B
CELL LYMPHOMA
MR Abbadi1,*, SE Belakehal1, L Sahraoui1, FZ Ardjoun1, A Kacimi2
1Hématology, 2Histopatholology, HCA, algeria, Algeria
Background: Lymphoma B cells can be studied by flow cytometry (FCM) using
fine needle aspiration (FNA) on suspensions of lymph node or extra nodal
samples. The cytological analysis and the use of special immunophenotypic
markers allows orientation of diagnosis.
Aims: Importance of the FCM coupled to morphology in ambulatory diagnosis
of B-cell lymphoma.
Methods: Cases of NHL that were diagnosed primarily by FNA at our institu-
ation between january 2010 and december 2015. 180 samples were studied
(140 lymph nodes and 40 extra nodal samples). 134 samples from the 121
evaluable patients referred for suspicion of lymphoma were studied: these
patients were, a cytological study and a fine needle aspiration coupled with
FCM. 10 antibodies were tested. Large B cell lymphoma was diagnosed in 37
patients (28%) of 33 lymph nodes, 2 pleural fluids and 2 subcutaneous masses.
Histological examination with immunohistochemistry were performed in 31
patients: 23 lymph nodes, 1 bone marrow, 2 tonsillectomies, 2 vaginal, 1 skin,
1 bronchial and 1 nasal mass.
Results: In our study the mean age was 60 years, with a male predominance
(Ratio =1.8). On the cytological analysis: all smears were monomorphic in most
cases, with large cells appearance, regular nucleus and basophile cytoplasm.
On CMF analysis, the diagnosis was de novo in 31 patients and at relapse in
6 patients. lymph node involvement in 33 cases (89%), extra nodel in 4 cases
(11%). The markers (CD20, CD22, CD79b) positive in 100% of cases; CD5
positive in 45% with low expression. CD23 and CD10 were negatives in 90%
of cases. Isotype restriction was lambda in 83%. Histological analysis: 26 cases
Diffuse Large B-cell lymphoma (DLBCL), 3 cases B small-cell NHL, 1 case
reactive hyperplasia (RH) and 1 case adenocarcinoma. Immunohistochemistry:
CD20 was positive in all DLBCL. The correlation between the FCM and histol-
ogy in the diagnosis of de novo large B cells NHL was 84%.
Summary/Conclusions: FCM enhances diagnostic ability of FNA cytology,
playing a crucial role in a rapid and accurate differential diagnosis between
RH, B-NHL and T-NHL. In addition, immunophenotyping of FNA samples con-
tributes to a more precise sub classification of B-NHL when combined with
histopathology.
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THE DURATION OF FIRST COMPLETE REMISSION OF DIFFUSE LARGE
B CELL LYMPHOMA COMPARED TO NONGCB, MUM1/IRF4, AND
EXPRESSION OF BCLXL AND KI67 IN IMMUNOCHEMOTHERAPY ERA
A Sofo Hafizovic1,*, N Obralic2, A Chika3, N Bilalovic3, A Dizdarević-Rekić1, M Vila1
1Clinic of Hematology, 2Oncology Institute, 3Pathology Institute, Clinical Center
University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Background: The cell has developed mechanisms for maintaining haemosta-
sis. Apoptosis with its internal and external signalling pathways is one of those
mechanisms.
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Aims: To determine the impact of immune phenotype and oncogene charac-
teristics on the duration of first complete remission with DLBCL
Methods: Study was retrospective-prospective. 60 patients were analysed with
de novo DLBCL were treated and followed in Clinical Center University of Sara-
jevo. Follow up median was 47 months (3-91). Patients were divided into two
groups: GCB and nonGCB. In the first line of treatment all patients received
immunochemotherapy R-CHOP. Biopsy material was analysed for: CD20, bcl-
6, CD10, MUM1/IRF4, bcl2, bclxl, bax, bad and bid. Statistics: spearman’s
analysis was used where p<0.05 was considered significant.
Results: Significantly positive correlation in the group IPI>2 was found with
respect to bclxl expression p=0.044 and IPI>2 with respect to expression of
Ki67 ≥50% p=0.035. Clinical stage III/IV has a significant negative impact on
the duration of CR1 in the total group, p=0.005 and the group Ki67 ≥50%
p=0.009. Duration of CR1 in the entire group had negative correlation when
compared to MUM/IRF4 with p=0.024 and bclxl with p=0.013. Duration of CR1
is in negative correlation to the group nonGCB p=0.03 and Ki67 ≥50%, p=0.001.
Summary/Conclusions: found a significant negative correlation between the
duration of first complete remission of DLBCL compared to nonGCB expression
MUM1/IRF4, bclxl and Ki67.
Non-malignant hematopoietic disorders
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HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: EXPERIENCE OF AN
HOSPITAL IN NORTHEN SPAIN IN THE LAST 22 YEARS
V Martinez-Robles1,*, S Calleja-Antolin2, B Ballina1, S Cerdá1, S Fernandez-Ferrero1,
F Rondón1, A Ahmadi1, F Escalante1, JA Rodriguez-Garcia1
1Hematology and Hemotherapy, 2Immunology, Complejo Asistencial Universi-
tario de Leon (CAULE), Leon, Spain
Background: Hemophagocytic lymphohistiocytosis (HLH) is a very unusual
and disastrous dysfunction of the immune system leading to an uncontrolled
cytokine storm that has become more recognized over the past decade. HLH
was first described in 1939 by Scott and Robb-Smith. This disease is character-
ized by lengthy and overwhelming activation of antigen-presenting cells
(macrophages, histiocytes) and CD8+ T and NK cells. All this scenario produces
an important hyperinflammatory condition and organ damage including fever,
splenomegaly, cytopenias, coagulophaty and/or hypertrigliceridemia. Histiocyte
Society (HS) criteria have been extensively applied for diagnosing HLH, however
not all of them are usually showed at the initial presentation. HLH could be dis-
played in two different contexts: primary (genetic, usually in children, known as
familial form) and secondary (acquired), caused by malignancy, infections, meta-
bolic conditions or autoimmune disorders. This disorder is a life-threatening dis-
ease which should be suspected and treated as soon as possible.
Aims: Analyzing the casuistry of hemophagocytic syndromes, diagnostic cri-
teria, treatment applied and evolution in our hospital and making a comparison
with the current literature.
Methods: A retrospective analysis was carried out through the medical records
of all patients with suspected diagnosis of HLH between 1994 and 2016 in one
hospital. Age, clinical features, diagnostic criteria proposed by the HS, etiology,
treatment and evolution were analyzed. In our study only 17 out of 49 patients
met the requested criteria.
Results: The number of cases was 17 (M7/F10). The median age at diagnosis
was 67 years, ranged between 4 and 84 years. Clinical development was fast
in almost all patients, except in two of them with long-standing pancytopenia.
The most frequent causes of consultation were fever and general syndrome.
All of them met 5 or more of the criteria necessary for the diagnosis. sIL-2R
level and NK activity were underestimated because they were not tested in
more than half of the cases. All of them were secondary (11 malignancies, 4
infections, 1 autoimmune disease), unable to clarify the cause in 1 of them.
Only 8 patients survived HLH (47%), although 6 died for other complications.
94/04 HLH treatment according to protocol was established in 5 of them. In the
rest of them the triggering cause was treated. The most frequent causes of
death were liver failure, infectious complications and bleeding. Test results
were: hyperferritinemia (100%), hypertriglyceridemia (87.5%), liver enzyme
alteration (52.9%), hypofibrinogenemia (33.3%), esplenomegaly (70.6%),
hemophagocytosis in bone marrow (94.1%), 100% of tested patients presented
high sIL-2R level.
Figure 1.
Summary/Conclusions: Despite being a serious disease and with rapidly tor-
pid course it remains underdiagnosed, obtaining the diagnosis, in most of the
cases after hemophagocytosis phenomena is visualized in bone marrow.
According to the literature, the main reasons for consultation and hospitalization
are similar to those presented in our hospital. The response to treatment is dif-
ficult to compare because most of patients has been treated with different ther-
apeutic regimens. In conclusion, it is always needed considering the possibility
of a HLH diagnosis when we have a patient with fever and pancytopenia not
clearly explained, and the importance of requesting simple test with high prof-
itability such as ferritin and triglycerides in all suggestive picture.
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SPLEEN ENLARGEMENT AS ONLY MANIFESTATION OF NIEMANN PICK
DISEASE TYPE C
L López de Frutos1,2,*, P Alfonso1,2,3, JJ Cebolla1,2, P Irún1,2,3, I Ballesteros4,
T Bernal5, A Bustamante6, M Gaona7, P León8, C Loureiro9, E Ojeda10, F Santos11,
P Giraldo1,2,3
1Spanish Foundation of Gaucher Disease and Other Lisosomal Disorders
(FEETEG), 2Aragon Institute for Health Research (IIS Aragón), 3Centro de
Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER),
Zaragoza, 4Hospital Comarcal de la Axarquía, Vélez, 5Hospital Universitario
Central de Asturias, Oviedo, 6Hospital Universitario Virgen del Rocío, Sevilla,
7Hospital Universitario de Burgos, Burgos, 8Hospital Universitario Dr Peset,
Valencia, 9Hospital do Meixoeiro, Vigo, 10Hospital Puerta de Hierro, 11Hospital
Universitario La Paz, Madrid, Spain
Background: Niemann-Pick disease type C (NPC) is a rare autosomal reces-
sive lysosomal storage disorder (LSD) characterized by multiple lipid storage
triggering intracellular impairment trafficking. NPC shows a wide phenotypic
spectrum (visceral, neurological and psychiatric manifestations), the most of
patients develop symptoms in early childhood; however there are a subtype
mainly identified in adults and characterized by aisle spleen enlargement and
cytopenias raising the differential diagnosis with a hematologic malignancy.
Aims: The main objective of this study is report probands state NPC only-vis-
ceral phenotype and its characterization. Secondary aims are identifying if
plasma lysosomal biomarkers can facilitate the differential diagnosis between
LSD and haematological malignancies and if that only-visceral phenotype pre-
sented genetic differences with neurological phenotypes
Methods: Firstly, plasma lysosomal biomarkers as Chitotriosidase activity
(ChT), CCL18/PARC and 7-Ketocholesterol (7-KC) concentrations were
assessed trough biochemistry approaches ChT activity was evaluated through
an artificial substract, CCL18/PARC concentration using ELISA technique and
7-KC employing liquid chromatography and tandem mass spectrometry. Lastly,
genetic characterization of NPC1 and NPC2 genes were carried out.
Clinical/analytical records were gathered from the information provided by
physicians.
Results: In the last five years, 363 probands were recruited. 51 of them were
identified at least one genetic variation reported as pathogenic or unknown
significance (VUS) in NPC, 10/51 showed only-visceral symptoms related to
NPC. Focused in only visceral cases, they were 35.0 (13.4-41.5) [median
(Interquartil range)] years old and a ratio male/female 6/4. None developed
neurological symptoms during following-up. Splenomegaly was 16.5 (9.2-18)
cm under costal rib in all cases with size information and 1 case presented
neonatal jaundice. Hemoglobin 14.5 (12.7-15.3) g/dL, platelets 121.5 (106-
231.5) x109/L. Increased biomarkers: ChT activity 119.0 (69.0-266.0)
nmol/mL/h, CCL18/PARC and 7-KC concentration were 156.0 (151.0-158.0)
ng/mL and 190.3 (103.7-355.9) ng/mL respectively. Four patients had been
splenectomized. The histological study showed numerous histiocytic cells,
loaded with small vacuoles and lipid appearance (“foamy cells”). These cells
were CD68+ and some of them were stained with hard Giemsa blue and PAS
positive, diastase resistant, while others showed a slight positivity. Molecular
variants identified in NPC1, reported as pathogenic or VUS, were: p.C177T,
p.N222S, p.V664M, p.Q775P, p.N916S, p.P1007A, p.D1097N, p.A1151T,
p.L1241*, p.R1274T and c.1998+8C>G. NPC2 gene does not show any vari-
ations. All genetic variations were found in heterozygosity, 6/10 subjects pre-
sented two variants.
Summary/Conclusions: The biomarkers CCL18/PARC or 7-KC are increased
in all cases that can be analyzed and they constitute good indicators of lyso-
somal storage disease that might facilitate the differential diagnosis with hema-
tologic malignancies. None of the genetic variants found in NPC1 were exclu-
sively for this only-visceral phenotype.
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THROMBOPOIETIN MIMETICS AS “A BRIDGE TO RECOVERY”. SINGLE
CENTER EXPERIENCE IN FOUR PATIENTS WITH CHRONIC PRIMARY
IMMUNE THROMBOCYTOPENIA
P Spina, S Impera, M Floridia, AM Todaro, M Salerno, F Castagna, D Caudullo,
U Consoli*
Hematology, ARNAS Garibaldi, Catania, Italy
Background: The thrombopoietin (TPO) mimetics are approved for the treat-
ment of chronic primary immune thrombocytopenia (ITP) and have the potential
for use in several additional clinical settings. Treatment is usually indicated in
patients with platelet counts <30x109/L and those with counts between 30 and
50x109/L with bleeding or at risk of bleeding (e.g. planned surgery, dental
extraction, parturition, active peptic ulcer). Although most ITP patients require
initial or second line treatment, sometimes platelet levels or hemorrhagic man-
ifestations are not clinically relevant and observation may represent an accept-
able clinical strategy. Unfortunately, clinical management of chronic ITP may
change over time because of the onset of new clinical condition that may require
a temporary higher platelets number for a safe clinical management. Surgery,
cancer chemotherapy, dangerous activities may temporarily change the ther-
apeutic strategy of patients with chronic ITP. In these patients there is a signif-
icant probability of obtaining some improvement or remission but “on demand
treatment” with short courses of therapy (often with corticosteroids, IVIg or
TPO mimetics) although warranted to manage bleeding or high-risk of bleeding,
are poorly investigated and not sufficiently addressed in the current guidelines. 
Aims: In particular some patients with a otherwise “safe” platelet levels may
require a temporary treatment to overcome the onset of new clinical conditions.
Here, we report on four patients with refractory ITP who received TPO-mimetics
as a bridge to recovery from surgical procedures or chemotherapy treatment
for diagnosis of cancer.
Methods: Four patients with isolated ITP were given TPO mimetics to increase
the platelet count prior to initiation their medical o surgical treatment. We
reviewed their baseline clinical characteristics, and clinical course.
Results: We found that a short course of Romiplostim or Eltrombopag may
increase the platelet counts enough to enable surgery or to complete
chemotherapy. All 4 patients achieved sustained remissions requiring no further
treatment. No rebound thrombocytopenia was observed after stopping Romi-
plostim and none of the patients had bleeding or thrombotic complications. 
Summary/Conclusions: Our clinical experience shows that TPO mimetics treat-
ment, in certain patients with milder chronic ITP, may be chosen as intermittent treat-
ment to temporarily raise platelet counts to overcome upcoming surgery, chemother-
apy treatment or other clinical conditions requiring a “safer” platelet level.
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EVALUATION OF INTRACRANIAL CEREBRAL BLOOD FLOW VELOCITIES
IN SPLENECTOMIZED AND NON-SPLENECTOMIZED Β-THALASSEMIA
INTERMEDIA PATIENTS USING TRANSCRANIAL DOPPLER SONOGRAPHY
A Kanavaki1, P Delaporta1, D Kyriakopoulou1, I Papasotiriou2, K Spengos3,
A Kattamis1,*
1First Department of Pediatrics, University of Athens Medical School, 2Depart-
ment of Clinical Biochemistry, ‘Aghia Sophia’ Children’s Hospital, 3First Depart-
ment of Neurology, University of Athens Medical School, Athens, Greece
Background: Beta-thalassemia intermedia (βΤΙ) is a congenital hemolytic ane-
mia with a widely variable clinical phenotype. A high incidence of clinically silent
cerebral ischemic events (SCI) has been reported in splenectomized β-ΤI
patients. These could be due to cerebral large-vessel disease.
Aims: Based on the example of sickle cell disease, we applied transcranial
Doppler sonography (TCD) to evaluate cerebral vessels velocity as a possible
indicator of cerebral vasculopathy in these patients.
Methods: We included in our study 30 patients with βΤΙ, 17 patients with
splenectomy (group A) and 13 non splenectomised ones (group B), aged
between 13 and 63 years-old (median: 34, mean: 40). Non imaging TCD was
performed in all patients and the TAMV values in the anterior (ACA), middle
(MCA), posterior (PCA) cerebral and the basilar (BA) artery were measured.
Nine of the patients have been also examined by brain MRI/MRA (7 patients
from group A and 2 patients from group B).
Results: None of the patients had a TAMV value ≥200cm /sec. In group A the
maximum TAMV of the examined vessels were 104 cm/sec MCA R, 139 cm/sec
MCA L, 89 cm /sec ACA R, 93 cm/ sec ACA L, 59 cm /sec PCA R, 64 cm/sec
PCA L, 75 cm/sec BA. In the same group the mean and median values were
72.4/ 75 cm/sec MCA R, 72/72.5 cm/sec MCA L, 66.3/67 cm /sec ACA R, 59/57
cm/sec ACA L, 43.5/43 cm/ sec PCA R, 43.5/ 41 cm /sec PCA L, 55.5/ 55 cm
/sec BA respectively. In group B the maximum TAMV were 88 cm/sec MCA R,
93 cm/sec MCA L, 98 cm /sec ACA R, 93 cm/ sec ACA L, 55 cm /sec PCA R,
59 cm/sec PCA L, 68 cm/sec BA. In the same group the mean and median val-
ues were 69.6/ 66 cm/sec MCA R, 76.5/78 cm/sec MCA L, 69.7/69 cm /sec
ACA R, 56.7/57 cm/sec ACA L, 38.5/37 cm/ sec PCA R, 43.6/44 cm /sec PCA
L, 47.1/ 46.5 cm /sec BA respectively. We found no statistically significant dif-
ference (p>0.05) in the TAMV values for all examined vessels between the two
groups. No statistically significant difference was found between the two groups
concerning age, gender, hemoglobin and hematocrit levels. There was a sta-
tistically significant difference in PLT blood count that was elevated in splenec-
tomised β-ΤI patients (p<0.01) as it was expected. From the patients who were
also examined by MRI only one had a SCI lesion on MRI, but without any
abnormality on TOF-MR angiography.
Summary/Conclusions: Our results do not show increased TAMV velocities
and do not support the presence of large vessels vasculopathy in splenec-
tomised β-ΤI patients. These findings agree with recent published data accord-
ing to which SCIs in these patients might be due to microangiopathy or venous
thromboembolism.
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FAT EMBOLISM SYNDROME IN 4 PATIENTS WITH NON-HB SS SICKLE
CELL DISEASE
A Collins1,*, T Bull2, R Gahlaut3, M Roberts-Harewood4, A Yardumian4, M Besser2
1Haematology, Addenbrooke’s Hospital (Cambridge University Hospitals Foun-
dation Trust), 2Haematology, 3Histopathology, Addenbrooke’s Hospital (Cam-
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Background: Fat embolism secondary to bone marrow necrosis may occur in
patients with sickle cell disease giving rise to respiratory, neurological and
haematological complications - the so-called fat embolism syndrome (FES).
FES is more common in non-SS genotypes.
Aims: We present 4 recent cases of suspected or confirmed FES in adult
patients with Hb SC seen in our hospitals and review the clinical, radiological
and histological findings of this under-recognised and potentially devastating
complication of ‘milder’ forms of sickle cell disease.
Methods: Case 1. A 53 year old man with Hb SC was admitted with malaise,
fevers and rigors. The following day he dropped his GCS and was transferred
to ITU. MRI brain showed widespread small infarcts. He became pancytopenic.
Bone marrow examination showed widespread necrosis. Follow-up MRI
showed multiple microhaemorrhages. Despite supportive care including top up
transfusions he retained a major neurological deficit. Case 2. A 50 year old
woman with Hb SC was admitted with abdominal and joint pain. That evening,
she deteriorated with hypoxia, pyrexia and tachycardia. CT showed no major
PE. She was given antibiotics and transferred to ITU where exchange transfu-
sion was initiated. A drop in the platelet count was noted. She suffered a cardiac
arrested and died. At post mortem pulmonary fat embolism was found. Case
3. A 56 year old man with Hb SC was admitted with body pain and breathing
difficulties and deteriorated within hours. Chest x-ray showed bilateral haziness.
Despite antibiotics he deteriorated further with a fall in GCS and acute kidney
injury and was transferred to ITU before being exchange transfused. CT showed
cerebral oedema. An MRI performed a few days later showed numerous wide-
spread small haemorrhagic foci. GCS remained low despite removal of seda-
tion. Case 4. A 30 year old man with Hb SC was admitted with leg and arm
pain. Over the following days he complained of back pain of an unusual severity.
On the third day of admission, he suddenly deteriorated with hypoxia and con-
fusion. He developed acute renal failure, deranged liver function tests and
coagulopathy. He had a rapid drop in haemoglobin and platelets. He was admit-
ted to the intensive care where an exchange transfusion was performed. MRI
brain showed numerous microhaemorrhages. An MRI of his lumbosacral region
showed extensive bone marrow change in keeping with the suspected diagno-
sis. He had a stormy few days on ITU but slowly improved and was discharged
from hospital alive but with subtle cognitive issues.
Results: Fat embolism is an under-recognised phenomenon associated with
major morbidity and mortality in sickle cell disease. The presentation may mimic
a thromboembolic complication but is often characterized by a combination of
venous and arterial infarction. It has a characteristic radiological appearance
when involving the brain. Pancytopenia with high numbers of nucleated red
cells is typical. LDH is often very high.
Summary/Conclusions: A high index of suspicion is required to make the
diagnosis of fat embolism syndrome ante-mortem. In case reviews, a survival
advantage has been reported in patients managed with exchange transfusions
although this has not been verified by prospective studies.
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RESULTS OF STANDARD TREATMENT FOR APLASTIC ANEMIA IN CHILDREN
E Butina, E Vaskina*, N Minaeva
Immunogematology, Federal State Institute of Science “Kirov research Institute
of Hematology and Blood Transfusion of the Federal Medical and Biological
Agency of Russia”, Kirov, Russian Federation
Background: Acquired aplastic anemia (AA) is a disorder characterized by
pancytopenia, hypocellular bone marrow and an absence of infiltrative disease
of the bone marrow. The incidence of AA in Russian Federation is 2-6 cases
among 1 million children per year. The hematopoietic stem cell transplantation
(HSCT) is the most effective treatment for AA. Immunosuppressive therapy
(IST) including antilymphocyte globulin, cyclosporine is the standard therapy
for patients who do not have a HLA-matched sibling donor.
Aims: Evaluation of results of treatment of children with acquired aplastic ane-
mia in 2005-2015.
Methods: The study included 23 children with acquired aplastic anemia at the
age from 3 to 18 years (median age - 11 years): 11 boys and 12 girls. Very
severe disease was diagnosed in 12 patients, severe AA - in 8, non-severe AA-
in three patients. The hemorrhagic syndrome with uterine, nasal and intestinal
bleeding was observed in 25% of patients.
Results: Remission was achieved after the first course of IST in 12 patients.
The second course of IST was held in 5 patients with very severe AA, including
as a therapy for relapse in three patients. Early hematologic relapse was diag-
nosed in 2 patients, the later relapse - in 1 patient. HSCT from an related donor
carried two children after the first course of ICT. Unrelated donor HSCT was
performed in two patients after the second course of IST. Five patients at this
time continue to receive cyclosporin therapy, two of these patients are depend-
ent on transfusional support. One child was killed in a month from the beginning
of ICT. Cause of death - sepsis, severe hemorrhagic syndrome. On 01.01.2016,
17 patients (77%) are in complete clinical remission.
Summary/Conclusions: Five year overall survival rate 95,6%. Event-free five
year survival rate 80,3%.
PB2061
THE OUTCOME OF HIGH RISK LANGERHANS CELL HISTIOCYTOSIS
(LCH) IN EGYPTIAN CHILDREN. A SINGLE CENTER EXPERIENCE
MS Sedky1,2,*, A Hamoda1,3, H Taha4, I Zaki5, O Hassanain6, A Elhadad1
1Pediatric hematology Oncology, Children Cancer Hospital, Cairo, 2Pediatrics,
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Cancer Institute, 4Pathology, 5Radiodiagnosis, 6Clinical research, Children Can-
cer Hospital, Cairo, Egypt
Background: High risk multi-system organs (RO+) Langerhans cell histiocy-
tosis (LCH) including hemopoietic cytopenias, liver and spleen disease, have
the highest mortality if failing first line treatment. Methotrexate (MTX) association
with Vinblastine (VBL) and Prednisone (PRED) has been tried upfront and a
second line cladribine (2cda) has been proposed in RO+LCH.
Aims: To present the outcome of RO+ LCH in a pediatric single centre population.
Methods: A total of 50 RO+ LCH patients, M/F 26/24, median age 1.7 years
(0.19-10.1) treated between August 2007 and June 2015 were retrospectively
analyzed. A first line VBL, PRED with MTX without a different second line was
adopted till 2012 where methotrexate was omitted and 2cda was introduced as
a salvage line.
Results: The 5 year overall survival (OS) is 69% and the event free survival
(EFS) is 17%. At week 6 and 12, “better’ response was obtained in 37(74%)
and 33 (66%) patients respectively. Seventeen (34%) and 15 (30%) patients
progressed and reactivated their disease respectively. At last follow up, 34 and
2 patients were in ‘better’ and ‘worse’ status respectively and 14 patients died.
In univariate analysis, the factors that affected OS were hemopoietic cytopenias
with 33%, 76% and 62% in tri, bi and monocytopenia respectively p0.017,
hepatic affection with 25%, 93% and 61% in hepatic dysfunction, hepatomegaly
and both respectively p 0.027, combined RO+ with 47%, 68% and 100%, in tri,
bi and mono organ(s) respectively p 0.045, number of induction: 47% and 76%
in one cycle and 2cycles respectively p0.026, failure of 1st line treatment: 27%,
76% and 50% in progression, reactivation and both respectively p <0.001,Sal-
vage with 2cda 56%, and 45% without p0.001, progression salvage with 2cda
57% and 10% without p0.008. The factors that affected EFS were cytopenias
with 0%, 19%, and 34% in tri, bi and monocytopenia respectively p0.015, bony
CNS risk sites with 9% versus 27% if none p 0.06, MTX 26% with and 13%
without p0.005. The factors that affected reactivation were: male gender p0.014,
season autumn/winter p<0.01, lung cysts p0.043. The factors that affected dis-
ease progression were tricytopenia p <0.01, hepatic dysfunction p<0.01, hepatic
dysfunction and hepatomegaly combination p0.04. 
Summary/Conclusions: The outcome of RO+LCH in pediatric egyptian pop-
ulation remains satisfactory despite a high proportion of reactivation. Disease
progression post induction carries a dismal prognosis without a salvage line.
Hemopoietic tricytopenias and hepatic dysfunction carry the worst prognosis.
Methotrexate as a 1st line and 2cda as salvage line are efficient in improving
the outcome.
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GENDER DISPARITIES IN CARDIO-RESPIRATORY FITNESS AMONG A
COMORBIDITY FREE ANEMIC POPULATION
R Shouval1,2,*, S Katz3, A Nagler1, D Merkel1, I Ben-Zvi2, S Segev4, Y Sidi5,
I Goldenberg6, S Kivity7, E Maor6
1Hematology and Bone Marrow Transplantation, 2Internal Medicine F, 3Sheba
Medical Center, Ramat Gan, Israel, 4Institute for Medical Screening, 5Internal
Medicine C, 6Leviev Heart Center, 7Internal Medicine A, Sheba Medical Center,
Ramat Gan, Israel
Background: Anemia is a common hematologic disorder characterized by
reduced absolute number of circulating red blood cells. It has been established
as a poor prognostic factor in a variety of medical disorders. Nonetheless, the
functional impact of anemia on cardiorespiratory fitness (CRF) in healthy indi-
viduals has mostly been explored in small interventional studies, simulating
acute rather than chronic states.
Aims: Using differing criteria for anemia diagnosis, while analyzing males and
females separately, the primary and secondary objectives were to evaluate the
effect of anemia on CRF and overall survival, respectively, in apparently healthy
adults.
Methods: We retrospectively analyzed 16,332 self-referred subjects undergo-
ing exercise stress testing as part of a routine screening program. Subjects
were non-smoking, free of diabetes, ischemic heart disease, or chronic kidney
disease. Anemia was defined by either the World Health Organization (WHO)
criteria (Hemoglobin (Hb) less than 13 g/dl and 12 g/dl for males and females,
respectively), or Beutler and Waalens’ (BW) criteria (Blood, 2006) (less than
13.7 g/dL and 13.2 g/dL for males younger and older than 60 years, respectively,
and 12.2 for females). Fitness was categorized into age- and sex-specific quin-
tiles according to Bruce protocol treadmill time. Multivariate logistic regression
was used to evaluate the association between anemia and low CRF in the
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baseline visit as well as during multiple visits. A multivariate Cox proportional
hazards regression model was constructed for survival analysis.
Results: The mean age of the cohort was 46±10 years and 70% were men.
Median follow-up was 10 years. Mean Hb levels were 13.09±0.96 and
15.05±0.96 among women and men, respectively (p<0.001), with higher pro-
portion of anemia among women (10.8% versus 1.6% according to WHO criteria,
and 15% versus 6.1% according to BW criteria, respectively; p<0.001 for both).
Baseline visit anemia, according the WHO and BW criteria, was associated with
a risk adjusted increase of 33% (1.06-1.66, 95% confidence interval (CI)) and
24% (1.01-1.52, 95% CI) for low CRF, respectively (p<0.05 for both). However,
no association was observed in males, regardless of anemia threshold. These
findings were corroborated in a repeated measures analysis of 71,200 sequential
visits (Figure 1), where only in females, anemia resulted in a 38% (1.17-1.63,
95% CI) and 22% (1.05-1.40, 95% CI) increase in risk for low CRF (p<0.01 for
both). Lack of regular physical activity, elevated body mass index, total choles-
terol and fasting glucose levels were also independently associated with low
CRF in the multivariate model, regardless of gender. With respect to survival,
only anemia in men, as opposed to women, was associated with an increased
risk for mortality, especially when adopting a more stringent criteria for diagnosis
(hazard ratio of 3.06 (1.65-5.68, 95% CI) and 1.83 (1.06-3.17, 95% CI), using
the WHO criteria and BW criteria respectively, p<0.05 for both).
Figure 1.
Summary/Conclusions: Anemia’s functional and prognostic significance dif-
fers between genders in a cohort of comorbidity free subjects. Anemia, regard-
less of diagnostic criteria, was associated with low fitness only in females, while
increased mortality was solely observed in males. Taken together our findings
indicate differing anemia mechanisms and physiological responses between
genders. Moreover, we suggest a functional and prognostic, rather than an
epidemiologic approach, for setting anemia diagnosis thresholds.
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ASSESSMENT OF A COHORT OF BETA THALASSEMIA PATIENTS: NEW
CHALLENGES
F Benmegherbi1,*, N Benmouafek2, L Cheriflouazani1, A Benomar1, I Boumedjadji1,
L Aissou1, D Abdelmoumen2, Y brahiti2, M Bradai1
1Hematology, CHU Frantz Fanon, Blida, 2Pediatric, Nafissa Hamoud Academic
Hospital, Algiers, Algeria
Background: The combination of transfusion and chelation therapy has dra-
matically extended the life expectancy of Beta-thalassemic patients who can
now survive into their fourth and fifth decades of life. The goal of long-term
transfusional support is to maintain the patient’s hemoglobin level at 9-10 g/dl.
However, complications are still frequent and affect the patients’ quality of life,
particularly in countries with limited resources.
Aims: The main objective of this study is to determine the prevalence of promi-
nent complications in a cohort of Algerian thalassemia patients.
Methods: This study was conducted to assess 81 polytransfused Beta-tha-
lassemic patients, mean age 16 years (6-31), sex ratio: 37M/44G: We assess
blood transfusion regime, pre-transfusion hemoglobin, iron overload, by serum
ferritin level, hepatic iron concentration. Bone mineral density (BMD) measure-
ments at lumbar and femoral regions have been done using dual x-ray absorp-
tiometry. We assess Growth and pubertal maturation (Taner stage), and dosing
gonadic hormone dosage, calcium, vitamin D, Parathyroid, and thyroid hor-
mone.
Results: The pretransfusion hemoglobin level was maintained between 6 and
9 g/dl in 90% of patients. Additionally, 5% had levels less than 6 g/dL, 5% from
9 to 11 g/dL. Fifty-five percent of patients had undergone splenectomy at a
median age of 9 years (range, 1-31 years). Ferritin levels ranged: 147 to 13500
ng/mL (median, 4992 ng/mL). Among 44 patients assessed, 77% had values
of 15 mg/g dry weight or higher, 50% LCI>43 mg/gdw, 20% had moderate LCI
15 to 7 mg/gdw, only 1 patient <7mg/gdw. Hepatic biopsy, performed in 26
patients (assessed for bone morrow transplantation), all had hepatic fibrosis
moderate to severe (Metavir score). BMD performed in 49 patients, prevalence
of lumbar osteoporosis and osteopenia were 38% and 62%. Dosage of vitamin
D performed in 34 patients:5 <10ng/ml, 17 [10-20ng/ml], 8 [20-30ng ml], 4 nor-
mal >30ng/ml. 12 patients receive Biphosphonate treatment. Short stature was
seen in 65% of our patients. Hypogonadism was diagnosed in 22,9% of 74
patients who had reached pubertal age: 50% of hypogonadic females and
males were receiving hormonal substitution. No patient had Hypoparathy-
roidism and primary hypothyroidism. 3 cases of primary amenorrhea, and 2
diabetes aged 17 and 31 years. Despite high ferritine serum no patients had
heart disease requiring medication. The goal of long-term hypertransfusional
support is to maintain the patient’s hemoglobin level at 9-10 g/d. This threefold
is rarely reached in our patients, for mixture of reasons (compliance, limited
blood pack). Iron chelation has been formerly limited, reason of the high preva-
lence of hemochromatosis in the majority of our patients. Intensification of iron
therapy is now assessed to obtain reversal tissues lesions. Well treated 90%
of thalassemics patients reached normal puberty; in contrast, in our group of
patients, only 20% achieved normal pubertal status after 16 years. Poor puber-
tal growth and impaired sexual maturation, and endocrine abnormalities in chil-
dren, adolescents and young adults have been observed because of conven-
tional treatment deficiency, substitutive hormonal therapy is indicated. BMD is
a good index of bone status in patients with Thalassemia and should be done
in these patients annual. 
Summary/Conclusions: High prevalence of complications among our tha-
lassemics signifies the importance of more detailed studies along with thera-
peutic interventions. The survival of patients with thalassemia major improving,
but the prevalence of severe complications is still high.
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MYCOPLASMA PNEUMONIAE AS A CAUSE FOR NEUTROPENIA IN CHILDREN
M Papadopoulou1, P Panagopoulou2,*, V Koulourida3, M Economou4,
E Papadopoulou-Alataki3, E Haidopoulou3, M Eboriadou-Petikopoulou3
1Infectious Diseases Laboratory, Papageorgiou Hospital, 24rth Paediatric
Department, 3Papageorgiou Hospital, 41st Paediatric Department, Medical
School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Background: Extrapulmonary manifestations of Mycoplasma pneumoniae
infection are uncommon and include hematologic, gastrointestinal, muscu-
loskeletal, dermatologic, and neurologic complications. Neutropenia on the
other hand can be caused by a variety of causes including infections. The
microorganisms that are commonly associated with neutropenia are: viruses
(Epstein-Barr virus, Cytomegalovirus, hepatitis viruses, human immunodefi-
ciency virus, parvovirus B19, influenza, measles), bacteria (Salmonella, Bru-
cella, Bordetella pertussis, Rickettsia), mycobacteria and rarely fungi (dissem-
inated histoplasmosis).
Aims: Based on the observation that some of our patients that were evaluated
for neutropenia had serologic evidence of recent Mycoplasma infection we
hypothesised that Mycoplasma pneumoniae might also be a cause of neu-
tropenia in children.
Methods: To this aim we retrospectively studied the medical records of all
patients that had been hospitalized in a tertiary pediatric department during a
17-month period because of a serologically proven Mycoplasma pneumonia
infection (positive IgM antibody titers). The demographic characteristics (age,
gender), the clinical presentation, medications and other laboratory parameters
were also recorded. Neutropenia was defined as an absolute neutrophil count
below the 3rd percentile for age and gender. Every patient was matched for
age and gender with another patient with similar clinical presentation but in
whom antibodies against Mycoplasma pneumoniae were not detected. Student’s
t-test and chi-square test were used for statistical analyses as appropriate.
Results: In total 290 patient were tested for Mycoplasma. Ninety patients (50
females) with positive IgM antibodies againt Mycoplasma pneumoniae were
identified. Amongst them 18 patients (20%) were also found to have neutrope-
nia (four severe, four moderate, and 10 with mild neutropenia). Mean age (±SD)
was 7.11 (±3.67) years. Mean neutrophil count was 1045/mm3. Thirteen
patients (72%) presented with a respiratory tract infection, two were investi-
gated because of fever of unknown origin, one for ITP, one for parotitis and
one for cervical lymphadenopathy. All patients recovered from their neutropenia.
This group was then compared with the patients that had negative antobodies
for Mycoplasma, in which 7 cases of neutropenia were recorded (7.8%). Com-
parison with chi-square test based on a two by two table showed that this dif-
ference is statistically significant (p<0.05).
Summary/Conclusions: Infection with Mycoplasma pneumoniae is usually
associated with hemolytic anemia. There are only a few reports of other hema-
tologic toxicities in humans. In this study we showed that Mycoplasma infection
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might be associated with a form of a transient post-infectious neutropenia in
20% of the study group. Given the fact that evaluation for neutropenia maybe
time consuming and expensive, it is important for practitioners to be aware of
this rare complication of Mycoplasma infection. Moreover, should this observa-
tion be confirmed, the administration of an appropriate antibiotic might be ben-
eficial and shorten the duration of the neutropenia.
PB2065
EVANS SYNDROME: A RETROSPECTIVE STUDY OF 30 CASES
K Zahra*, C Hasnia, HM Hamza, Z Monia, BS Nesrine, A Bechir, BY Yosra,
K Abderrahim
Hematology, Hospital Farhat Hached, SOUSSE, Tunisia
Background: Evans syndrome is a very rare autoimmune disorder in which
an individual’s antibodies attack their own red blood cells and platelets. Both of
these events may occur simultaneously or one may follow on from the other.
Usually idiopathic, it is also associated with lymphoproliferative disorders and
autoimmune diseases.
Aims: Study the epidemiological, clinical, biological, etiological and therapeutic
aspects of Evans syndrome.
Methods: This is a retrospective and analytic study about 30 cases of Evans
syndrome observed in the hematology department of Sousse, over a period of
14 years.
Results: There were 18 men and 12 women (sex ratio=1,5) with a median age
of 40 years. The circumstances of discovery were an anemic syndrome in all
patients, mainly due to paleness and asthenia. Concerning biology, regenerative
anemia was normocytic in 20 cases and macrocytic in 10 cases, thrombocy-
topenia below 100000/mm3 was observed in all patients. There were also bio-
logical signs of hemolysis: hyperbilirubinemia, high LDH rate in all patients.
Direct Coombs test was positive for Ig G + Complement, IgG and complement
in 13, 8 and 9 cases, respectively. Evans syndrome was idiopathic in 20 cases
and secondary to lymphoproliferative disorders in 5 cases, autoimmune disor-
ders in 5 cases. All patients received corticosteroid treatment in addition to folic
acid therapy and etiological treatment in the non idiopathic cases with complete
remission in 10 cases. Immunosuppressive therapy (endoxan) was prescribed
in 10 patients with complete remission in 5 patients. Anti-CD20 monoclonal anti-
body was prescribed in 8 patients with complete remission in 4 cases.
Summary/Conclusions: Glucocorticoids and/or intravenous immunoglobulins
are the mainstay of the treatment in the majority of patients with Evans syn-
drome. When these treatments fail, patients often require cytotoxic drugs or
splenectomy.
PB2066
THE STUDY OF THE SPECTRUM OF THALASSEMIC MUTATIONS AT THE
NORTH-WEST REGION OF RUSSIA
Y Zhilenkova1,*, S Bessmeltsev2, A Kozlov1
1clinical chemistry, The North-West State Medical University n.a.I.I. Mechnikov,
2hematology and transfusiology, the Russian Scientific and Research Institue
for Hematology and Transfusiology, Saint-Petersburg, Russian Federation
Background: Beta-thalassemia - a hereditary disorders of hemoglobin syn-
thesis, which are transmitted in an autosomal recessive inheritance. The main
stage of the prevention of thalassemia is the molecular diagnosis of thalassemic
mutations in the fetus conducted at 1st trimester of pregnancy. The possibility
of this diagnosis is determined by the availability of data on the molecular
defects of beta-globin gene in this region.
Aims: To examine the incidence of mutations of beta-globin gene in the North-
West region for the development of measures for the prevention of beta-tha-
lassemia.
Methods: Molecular diagnostic was performed at 65 patients (men - 31, women
- 34, from 2 to 58 years) with a diagnosis of beta-thalassemia (minor and major),
were examined and treated at The Consultative and Diagnostic Center for Chil-
dren and The Russian Research Institue of Hematology and Transfusiology
(Saint-Petersburg). All patients living in St. Petersburg, but have a different eth-
nic composition: 40% - Azerbaijanis; 33.8% - Russian, who (according to them)
havn’t Caucasian or Mediterranean roots; 11.3% - Bulgarians, Cypriots; 8.7%
- Dagestan; 6.2% - patients of mixed families (one parent - Russian, the other
- from the Caucasus or Mediterranean). Diagnos thalassemia set on the basis
of red blood cells parameters (microcytosis - the MCV <80 fl, hypochromia -
MCH <27 pg, Mentzer index <11.4) and hemoglobin fractions (Hb A2>3% and/or
Hb F>1%). The material for the study served as the venous blood. Red blood
parameters were determined on the hematology analyzer Sysmex XT-4000i
(Sysmex, Japan), fractions of hemoglobin investigated by capillary elec-
trophoresis (MINICAP, Sebia, France). Mutations of the beta-globin gene was
determined by reverse- hybridization of method of biotinylated multiplex-PCR
products (β-GlobinStripAssay, ViennaLabDiagnostics, Austria).
Results: In examined patients 5 homozygous (large form of thalassemia), 2
compound heterozygous and 58 heterozygous (small form) were applied. A total
of 10 thalassemic mutation was found: codon 8 (-AA) - 38%; IVS 1.110 (G>A) -
27%; 5 codon (-CT) - 7%; IVS 1.6 (T>C) and IVS 2.1 (G>A) - 6%; IVS 2.745
(C>G), IVS 1.1 (G>A) iIVS 1.5 (G>C) - 4%; codon 8 \ 9 - 3%; -101 (C>T) - 1%.
Summary/Conclusions: The most frequent mutations of the beta-globin gene
in St. Petersburg were codon 8 (-AA) - 38% and IVS 1.110 (G>A) - 27%.
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THE ETHNIC DIFFERENCE IN RBC-RELATED INDICES BETWEEN KOREAN
AND UAE AND THE MUTATION PROFILE IN THALASSEMIA OF UAE: ONE-YEAR
EXPERIENCE IN UAE AS THE KOREAN PHYSICIANS
HR Lee1,2,*, S Hong1,2, M Han1,2
1Department of Laboratory Medicine, Sheikh Khalifa Specialty Hospital, Ras
Al Khaimah, United Arab Emirates, 2Department of Laboratory Medicine, Seoul
National University Hospital, Seoul, Korea, Republic Of
Background: Sheikh Khalifa Specialty Hospital (SKSH) of the United Arab
Emirates (UAE) has been operating by Seoul National University Hospital of
the Korea since February 2015. The rules of three [3 x red blood cells
(RBC)=Hemoglobin (Hb), 3xHb=hematocrit (Hct)] has been used to evaluate
RBC-related indices of patient samples. We empirically found out that Arab
patients are showing the discrepancy in these ratios due to relatively low mean
corpuscular volume (MCV) in comparison with Korean patients, although they
are in the non-anemic state. Also, regarding the thalassemia, characterized by
the microcytosis, the prevalence of thalassemia in Korea is much lower than
those in UAE. Therefore, the microcytic feature of UAE patients and thalassemia
have been the unique experiences to Korean physicians.
Aims: First, we analyzed the RBC-related indices of different ethnic groups
(Korean vs Arab) and adult patients showing microcytic anemia, such as iron-
deficiency anemia (IDA) and thalassemia. Second, we reported the mutation
profile showing in thalassemia that diagnosed in our hospital during one-year.
Methods: We collected the additional blood sample for the complete blood cell
(CBC) count from the SKSH staff who received a medical check-up and gave
written consent to the study. Among the data obtained, we selected data from
Korean and Arab staff who were in the non-anemic state according to the WHO
criteria (Hb ≥13 g/dL in male and Hb ≥12 g/dL in female). RBC indices, such as
the MCV, mean corpuscular hemoglobin (MCH), and mean corpuscular hemo-
globin concentration (MCHC), were measured. We also retrieved the CBC data
from the IDA patients showing the ferritin level of lower than 10 ng/mL, and
from the patients diagnosed as thalassemia through the Hb electrophoresis or
HBA1/HBA2 and HBB gene analysis.
Results: The data from 48 Korean staff, 53 Arab staff, 69 IDA patients, and 21
thalassemia patients were enrolled. The RBC-related indices are following
according to the groups; MCV, 92.2±3.5 fL (range, 85.3-102.0 fL), 86.9±4.2 fL
(73.7-94.4 fL), 72.0±7.1 fL (58.1-90.0 fL), 70.4±5.5 fL (61.1-82.5 fL), respec-
tively; MCH, 30.8±1.4 pg, 28.2±1.9 pg, 21.3±3.3 pg, 21.6±2.5 pg, respectively;
MCHC, 33.4±1.1 g/dL, 32.5±1.2 g/dL, 29.3±2.4 g/dL, 30.5±1.5 g/dL, respec-
tively. The MCV, MCH, and MCHC of Korean are significantly higher than those
of Arab (P <0.001, P <0.001, P=0.001, respectively). There are no significant
differences in RBC-related indices between IDA and thalassemia patients in
our study. For mutation profile of thalassemia, we analyzed total 22 adult and
children thalassemia patients confirmed by gene analysis. Among 22 patients,
12 were α-thalassemia, seven were β-thalassemia, two were diagnosed with
both α- and β-thalassemia, and one was diagnosed with both α-thalassemia
and sickle cell anemia. The most common α-thalassemia was α+-thalassemia
trait due to 3.7-kb and deletion of HBA1/HBA2 gene (7/14, 50.0%) and the
most common mutation of β-thalassemia was c.92+5G>C mutation of HBB
gene (5/9, 55.6%). Distinctively, the homozygous or heterozygous c.1-
?_429+?del in the HBA2 gene were detected in four α-thalassemia patients,
which has not been reported previously.
Summary/Conclusions: There is the difference in the RBC size between Kore-
an and Arab. We found out the unique deletion mutation of alpha-thalassemia.
This is the report by one-year experience in UAE as Korean physicians. We
expected to report the characteristics of RBC size and thalassemia mutation




THE INCIDENCE OF CD36 DEFICIENT MONOCYTE AND PLATELET AND
ITS CORRELATION WITH DIABETES IN SOUTH KOREA
J Kahng1,*, K Han2
1Department of Laboratory Medicine, College of Medicine, The Catholic Uni-
versity of Korea, Bucheon, 2Department of Laboratory Medicine, College of
Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of
Background: CD36, a synonymous term for platelet glycoprotein IV, GP (gly-
coprotein) IIIb, is an 88-kD glycoprotein that is expressed in such various cells
as platelets, monocytes, macrophages, erythroblasts, capillary endothelial cells,
adipocytes, epithelial cells in the kidney and cardiac myocytes. Hematologically,
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it is used as a representative antigen of platelets and monocytes in flow cyto-
metric differential cell counting. Various reports prove the existence of racial
variations with regard to CD36 deficiency: 0.3% in Caucasians, 3-11% in Japan,
0.5% in Type 1 and 1.3% in Type II for Chinese, and 0.3% of the U.S. population.
And other studies show decreased insulin sensitivity and postprandial hyper-
triglyceridemia as the metabolic manifestations of CD36-deficient subjects. How-
ever, there has been no report on the nature of CD36 deficiency for Koreans.
Aims: The authors aim to find out CD36 deficiency incidence of South Korea
and any potential correlations between diabetes patients by studying blood
samples from diabetes patients, leukopenic samples, and normal samples.
Methods: We collected data from 757 individuals including 521 leukopenic
patients, 105 diabetes patients, and 131 normal subjects at Seoul St. Mary’s
Hospital, Seoul, Korea between August 2013 and March 2014. Routine CBC
with WBC differential count with an automatic blood cell analyzer (DxH800) was
performed in conjunction with analysis by flow cytometry by using Hematoflow
with Cytodiff. The 5-color/6-marker reagents (Cytodiff panel) were CD36-FITC,
CD2-PE, CD294-PE, CD19-ECD, CD16-PC5, and CD45-PC7 antibodies. To
confirm the platelets, CD41a-PE/CD36-FITC dual staining was added. To con-
firm the monocytes, CD11c-PE/CD36-FITC dual staining and peripheral blood
smear slide reviews were used. We strictly adhered to the manufacturer’s man-
ual for analysis: 100 uL of blood samples was mixed with 10 uL of Cytodiff
reagent, and incubated for 20 min at room temperature. Lysing solution (Ver-
salyse solution; Beckman Coulter) was used for 15 min to break down red blood
cells. After washing, a flow cytometer (FC500) was used to collect 10,000 cells.
The analysis software, self-gating and separating populations by automatic logic
pathways, analyzed the Cytodiff results automatically. The gates were adjusted
only in case of large debris contamination or incomplete separation of basophils
and myeloblasts. Samples were all analyzed in duplicate.
Results: Of the 757 cases, 22 cases (2.91%) were either of type I (9 cases,
1.19%), or of type II (13 cases, 1.72%). Of 131 normal subjects, 4 cases
(3.05%) were either of type I (1 case, 0.76%), or of type II (3 cases, 2.29%).
Of 105 diabetes cases, 3 cases (2.86%) were of type II. And finally, of 521
leukopenic cases, 15 cases (2.88%) were either of type I (8 cases, 1.54%), or
of type II (7 cases, 1.34%). Our t-tests showed no significant differences among
the groups, and no correlation was found between diabetes and CD36 inci-
dence, or between leucopenia and CD36 incidences (chi-square test and Fish-
er’s exact test), with the odd ratios of 0.97 and 0.98, respectively. No significant
difference was found between the 22 cases and the remaining 735 cases in
terms of sex, age, previous illness, hemoglobin level, WBC count, monocyte
count, and platelet count.
Summary/Conclusions: The overall incidence of CD36 deficient monocytes
and platelets based on 757 Korean subjects was 2.91%, manifesting no sig-




OSELTAMIVIR IN THE TREATMENT OF PRIMARY IMMUNE
THROMBOCYTOPENIA
HJ Campo Palacio*, RM Campos Alvarez, A Salamanca Cuenca
Haematology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain
Background: Primary immune thrombocytopenia (ITP) is an immune bleeding
disorder with an increased destruction of autologous platelets. Autoantibody
specificity is usually against GPIIb/IIIa in 70-80% of patients or GPIb in 20% of
them. Firts-line treatment includes immunosuppressive and immunomodulatory
agents, that is corticosteroids (CS) or intravenous immunoglobulin (IVIG).
Splenectomy is considered for patients with persistent lack of response. How-
ever, about 20% patients are inexplicably refractory to both therapies. Recent
studies in refractory ITP patients suggest an association between anti-GPIb
autoantibody and a poor response to conventional therapies, as well as platelet
desialylation. This leads to platelet elimination by hepatocyte Ashwell-Morell
receptors, especially in the absence of macrophages. Therefore, it may be a
role for sialidase inhibitors in ITP treatment. Oseltamivir phosphate conven-
tionally serves as anti-influenza agent. It inhibits viral neuraminidase as well
as glycolipids sialylation on human T cells surface. We report a case of an
adult ITP patient who was resistant to multiple therapeutic approaches but was
successfully treated with Oseltamivir phosphate.
Methods: A 64-year-old female was diagnosed with ITP. She was initially treat-
ed with high dose CS and IVIG, with a complete response (CR) that lasted for
15 years. She relapsed with severe thrombocytopenia and minor bleeding. Her
platelet counts remained low despite using CS and IGIV, so she initiated recom-
binant human thrombopoietin (TPO) agonist reaching maximum dose without
response, so we added danazol and rituximab, either with non response. During
this period, she presented with lower gastrointestinal bleeding so she under-
went a splenectomy. She continued with TPO agonist and Danazol to maximum
doses. Three months after splenectomy she reached secure but fluctuating
platelet counts, presenting a massive portal and mesenteric thrombosis. She
started therapeutical LMWH with close monitoring of platelets count, and sus-
pended TPO agonist as well as danazol. Two months later, she lost platelet
response and had to iniciate different immunosuppressive drugs: Vincristine,
Azathioprine, Mycophenolate Mofetil and Cyclosporin, without response.
Patient’s platelet was then assessed by flow cytometry and revealed a loss of
terminal sialic acids in platelets surface as well as neuraminidase activity in
plasma, data compatible with a platelet destruction mechanism independent
of immune receptors that could justify refractoriness to prior treatments. An
alternative therapeutic regimen with Oseltamivir phosphate, as a last resort for
the management of this patient, was initiated. She was informed and consent-
ed. It was given orally 75mg twice daily for 5 days. Then, a new platelet assess-
ment was done, demonstrating normalization of sialic acids expression. But
thrombocytopenia persisted, so Azathioprine was added looking for a synergic
effect. Nowadays, she continues treatment with Azathioprine twice a day and
remains in CR for seven months
Summary/Conclusions: In this case, treatment with oseltamivir could restore
platelet membrane, avoiding its destruction by the hepatic rethiculoendothelial
system and allowing immunosuppressive drugs (Azathioprine) to control the
immune destruction mechanism. At the present time Oseltamivir is not still
approved for ITP. However, this case highlights the need for prospective studies
to verify the effectiveness of this new approach and the possibility of new indi-
cations for this drug.
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MULTIPLE PHENOTYPIC EXPRESSION OF HARRIS PLATELET SYNDROME
A Das1,*, HK Elias2, G Guha3, S Harris4, HV Naina5
1Cardiology, Beth Israel Deaconess Medical Center, Boston, 2Internal Medicine,
Icahn School of Medicine at Mount Sinai St Luke’s- Roosevelt Hospital,
NewYork, United States, 3School of Chemical and Bio Technology, SASTRA
University, Thanjavur, India, 4Division of Gastroenterology, UT southwestern,
5Department of Internal Medicine, Plaza Medical center, Dallas, United States
Background: Harris platelet syndrome (HPS) is an autosomal dominant
macrothrombocytopenia with mild to moderately severe thrombocytopenia and nor-
mal platelet function. HPS has been reported from healthy blood donors of the Indian
subcontinent, particularly from the northeastern part of India including West Bengal.
Aims: A prospective study was done to characterize the different phenotypes
of HPS among blood donors from West Bengal. 
Methods: HPS is defined as healthy blood donors having a mean platelet vol-
ume (MPV) greater than 12 fL (normal <10 fL) with or without concomitant
thrombocytopenia in the absence of any significant past history of bleeding
disorder in either themselves or their first degree relatives. Blood samples were
collected in ethylenediaminetetraacetic acid (EDTA) and analyzed using imped-
ancemethod (Coulter SYSMEX X100, Tokyo, Japan).
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Results: A total of 326 eligible blood donors were included in this study. Two
hundred (61%) of the blood donors fulfilled criteria for a diagnosis of HPS.
Three distinct phenotypes were observed. Fourteen (4%) was noted to have
varying thrombocytopenia with normal MPV; 166 (51%) had anormal platelet
count with giant platelets and 20 (6%) donors had classic HPS characterized
by thrombocytopenia with giant platelets. HPS donors with low platelet count
had a lower median platelet bio-mass compared with their normal counterparts,
(13.62 vs 29.38, p<0.001).In comparing peripheral smears between controls
(i.e normal platelet count and normal MPV) and the variants of HPS, no obvious
difference was noted in the red blood cell morphology.
Table 1.
Summary/Conclusions: A prospective population based study will be ideal to
further explore the clinico-pathological significance of these variants of
HPS.This study shows that HPS may manifest with isolated thrombocytopenia
without giant platelets. It is important to reccognize this variant to avoid unnec-
essary investigations and treatment.
PB2072
FREQUENCY OF PLATELET FUNCTION DISORDERS IN PATIENTS
PRESENTING WITH BLEEDING
A Memon*, S Adil
Department of Pathology & Laboratory Medicine, Aga Khan University Hospital,
karachi, Pakistan
Background: Inherited platelet function disorders may present with bleeding
of variable severity and unknown frequency and may be frequently missed.
They are increasingly recognized as an important cause of bleeding, particularly
in adolescent girls with menorrhagia. The prevalence of congenital platelet dis-
orders in our population has not been established, however, these disorders
are relatively more common in communities where consanguineous marriages
are more frequent like in the Middle East and India, but very limited information
is available in developing countries like Pakistan about their prevalence so we
attempted to assess the frequency of these disorders in our population.
Aims: Considering the higher prevalence of consanguineous marriages in Pak-
istani population, it is assumed that the incidence of platelet disorder must be
higher. Therefore, the purpose of this study is to determine the frequency of
platelet function disorders in patients presenting with bleeding. Previous studies
conducted in Pakistan observed all causes of bleeding disorders like Haemo-
globinopathies, von willebrand disease, Hemophilia & others, but our study
specifically focused on platelet function disorders because these can lead to
severe bleeding and are frequently missed.
Methods: Cross sectional study done between March to October 2014 at sec-
tion of Haematology Aga Khan University Hospital. 5mlof whole blood sample
in sodium citrate tube was collected for detection of platelet functions disorders.
Platelet rich plasma was made by centrifugation and was used for testing.
Platelet function studies were performed by using aggregation platelet aggre-
gometer (Chrono-Log aggregometer model 700). ADP, Collagen, Epinephrine
and Ristocitin were used as agonists.
Results: 32 patients fulfilled inclusion criteria 18 females, 14 males with age
range 3 years to 22 years. Out of these 32 patients 13 patients (40.62%) had
platelet function disorder with female predominance (8 females, 5 males).Age
ranges between 6 years to 22 years. Out of these 13 patients, 7 had Glanz-
mann’s- thrombasthenia, 4 had Bernard-Soulier syndrome & 2 patients were
labeled with Quebec platelet disorder.
Summary/Conclusions: 40% of these 32 patients had platelet function disor-
ders. This is an ongoing study further data will be added on completion of spe-
cific period.
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ELTROMBOPAG USE IN SEVERE ITP AND BEYOND, A SINGLE CENTRE
COHORT
A Taylor*, F Laskou, J Westwood, S McGuckin, M Scully
Haematology, University College London Hospital, London, United Kingdom
Background: Thrombopoietin receptor (TPO) agonists are licensed for immune
thrombocytopenia purpura ITP). Potential for use in other thrombocytopenic
conditions is being explored.
Aims: Our aim was to demonstrate the efficacy of eltrombopag in ITP -whether
for severe disease or bridging therapy for surgery or chemotherapy. We also
examined the use of eltrombopag in malignancy-associated thrombocytopenia,
whether from disease or chemotherapy.
Methods: We retrospectively identified all patients who had received eltrom-
bopag from a single institution. Patients were identified who had received
eltrombopag as part of standard treatment pathways, as well as those for whom
special consideration was sought (ie refractory thrombocytopenia in advanced
malignancy). Eltrombopag was commenced from between March 2012 (as the
first documented prescription time point) to January 2016. For ITP, we included
those deemed to have a ‘severe’ phenotype according to the international con-
sensus guidelines. All patients fulfilled these criteria, warranting second-line
treatment beyond steroids and IVIg. Many had failed multiple previous lines or
had comorbidities limiting options. For non-ITP thrombocytopenic patients, indi-
cation for eltrombopag was examined on a case-by-case basis, according to
benefit versus risk, since prescription was off-label. The primary indication was
to enable chemotherapy, based on oncology requirements for platelet counts
>100x109/L.
Results: Our total cohort of 62 patients (36 males and 26 females) was treated
over 8 years. This included 50 ITP patients requiring treatment for severe/refrac-
tory disease (n= 36), or bridging therapy (n=14). In the refractory group, 25
patients had primary ITP and 11 secondary ITP; including HIV (n=5), viral (n=2)
malignancy (n=1) and other autoimmune aetiologies (n=3). Follow up was 1 to
85 months (median 12.5 months), with median 4 previous lines of therapy.
Median time between ITP diagnosis and eltrombopag commencement was 24
months in the refractory ITP group. The delay was partially due to eltrombopag
availability. In the overall ITP cohort (n=50), complete response (CR) was
achieved in 28 patients (56%), partial response (PR) in 19 (38%) and no
response (NR) in 3 patients (6%). Median time to response was 3 weeks (1 to
44 weeks). At follow up, 17 patients were in CR (34%) and 29 patients in PR
(58%). Eltrombopag dose ranged from 25 to 100mg daily, with a median of
25mg (n=12). The difference in response at follow up was due to dose reduction,
whilst maintaining haemostatic platelet counts. The malignancy-associated
group included 12 patients. Eltrombopag use achieved CR in 6 patients (50%),
PR in 3 (25%) and NR in 3 (25%).
Summary/Conclusions: In conclusion, eltrombopag use in the severe ITP
setting achieved a response in 94% cases. For severe or refractory disease,
dose reduction was possible once response achieved. Although not CR by
strict definition, a safe platelet count could be maintained- typically >50x109/L-
without bleeding sequelae. In the bridging cohort, eltrombopag proved a reliable
means of improving platelet counts for intervention, without the problems asso-
ciated with steroids or IVIg. Beyond ITP, eltrombopag may be of practical benefit
during chemotherapy and other myelosuppressive treatment, to ensure optimal
dosing of these therapies via platelet count support. Although our non-ITP
cohort was small, CR was achieved in half of these patients. Further trials are
needed to demonstrate which patients may benefit from eltrombopag during
treatment for malignancy-associated thrombocytopenia.
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CHANGES IN PLATELET AGGREGATION DURING PREGNANCY AND THE
IMMEDIATE POSTPARTUM PERIOD
B Hussein1,*, A Maarouf1, K Gomez2, J Davies2, D Obeng-Tuudah2, A Riddell2,
R Kadir2
1Haematology, Nanakali Hospital for Blood Diseases and Cancer, Erbil, Iraq,
2Haematology, Haemophilia Center and Thrombosis Unit, Royal Free Campus,
UCL, London, United Kingdom
Background: Platelet dysfunction is implicated in uteroplacental disorders.
During the early stages of gestation platelets have important roles in the process
of placentation. Platelet function contributes to enhanced haemostasis at deliv-
ery. However, there is limited data on the changes of platelet function during
normal pregnancy. Understanding physiological changes of platelet aggregation
during different stages of pregnancy is helpful for better understanding of patho-
physiology of abnormal placentation.
Aims: To assess platelet aggregation during three trimesters of pregnancy and
immediate postnatal period in normal healthy women compared to control non-
pregnant group. 
Methods: Cross-sectional cohort study including a total of 46 women: 10 par-
ticipants for each trimester, 10 postnatal cases and 6 control non-pregnant
women. Case selection was based on specific inclusion criteria. 30mL of venous
blood was obtained from each participant following consent. Light transmission
aggregometry was performed with Dual channel Payton 600B aggregometer
using six platelet aggregating agonist (epinephrine, adenosine triphosphate,
collagen, ristocetin, arachidonic acid and U46619).
Results: The findings included reduced secondary aggregation curve appear-
ance in pregnant and postnatal women when compared to control group, which
was most apparent in the third trimester. Compared to non-pregnant controls,
platelet aggregation induced by ADP and collagen were reduced during third
trimester while epinephrine induced aggregation was reduced during the first
trimester. 
Summary/Conclusions: Reduced platelet reactivity in response to epinephrine
during early pregnancy can be considered as a mechanism to reduce throm-
bosis and allow normal placentation while diminished ADP and collagen induced
aggregation in third trimester could be a compensatory mechanism since preg-
nancy associated with hyper-coagulation particularly in late stages.
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PLATELET DISTRIBUTION WIDTH IS ELEVATED IN IMMUNE
THROMBOCYTOPENIC PURPURA, BUT THE VALUES REPORTED IN
XN-3000 AND ADVIA2120I WERE NOT COMPATIBLE
YK Lee*, M Kim, EJ Lee, E Lee, HJ Kang, HS Kim
Department of Laboratory Medicine, Hallym University College of Medicine &
Hallym University Sacred Heart Hospital, Anyang-si, Korea, Republic Of
Background: Platelet distribution width (PDW) value as well as its unit is
reported through different algorithms in different hematologic analyzers, and
the correlation between PDW values in different hematologic analyzers has
never been explored. Recently, PDW is indicated as a marker estimating the
status of platelet production. 
Aims: As the clinical significance of PDW is increasing, but not yet established,
we analyzed the correlation between PDW values reported in Advia 2120i and
XN-3000. We also compared the PDW values in immune thrombocytopenic
purpura (ITP) and essential thrombocythemia (ET).
Methods: PDW was measured in 153 healthy individuals as a control group
using both instruments. Twenty-three ITPs and 15 ITPs were tested using Advia
2120i and in XN-3000, respectively. ET group consists of 15 in Advia 2120i
and 18 in XN-3000.
Results: In the control group, PDW did not correlated with platelet count, mean
platelet volume (MPV), and age in Advia 2120i. In XN-3000, PDW did not corre-
lated with platelet count or age, either, however, PDW significantly correlated
with MPV (y=2.034x-9.111, r2,= 0.916, p<0.001). PDW values reported in the
two instruments did not correlate with each other (y=0.184x+2.592, r2,=0.474,
p<0.001). The reference value was 40.0% ~ 64.2% in Advia 2120i, and 9.0 fL ~
16.0fL in XN-3000. PDW was elevated in ITP in both instruments compared with
control group (median PDW 63.1% vs 50.5% in Advia 2120i; 14.9 fL vs 11.9fL in
XN-3000) with statistical significance (p<0.001). PDW was elevated in ET in
Advia 2120i (59.1%, p<0.0001), but decreased in XN-3000 (10.0fL, p<0.001).
Summary/Conclusions: We analyzed the correlation of PDW values reported
in Advia 2120i and XN-3000 for the first time, and showed that they are not
compatible. PDW was affected by MPV in XN-3000, probably due to the cal-
culation algorithm. PDW was elevated in ITP, suggesting the high proportion
of large young platelets in this disease. However, the changes in PDW in ET
were opposite in the two instruments, which requires further investigation. 
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INTERLEUKIN 31 AS A MARKER OF ALLERGY IN IMMUNE
THROMBOCYTOPENIA IN CHILDREN
AAG Tantawy1,*, M Reda1, D Abdel Aziz2
1Pediatric Department, 2Clinical Pathology Department, Faculty of Medicine,Ain
Shams University,Cairo,Egypt, Cairo, Egypt
Background: Allergy and autoimmunity are two potential outcomes of dysreg-
ulated immunity both are characterized by inflammatory reaction that leads to
the injury of target tissues. Interleukin-31 (IL31) is a recently discovered
cytokine expressed in many human tissues, predominantly by activated CD4(+)
T cells and has integral role in allergy pathogenesis.
Aims: to evaluate the relation between ITP and allergy in children by ques-
tionnaire for allergic manifestations and measuring serum IL31 and serum IgE..
Methods: 62 ITP patients aged 1-18 years (median 6 years) were included,
36 had chronic ITP and 26 acute ITP, male to female ratio was 4:1, and were
compared to 30 age and sex matched controls.All were subjected to: determi-
nation of allergy score by questionnaire, measuring IgE level (RAST method)
and ELISA serum IL31 level assessment.
Results: Compared to controls, ITP patients had signinificantly higher allergy
score (p<0.001), higher IL31 level (p=0.000), but non significant difference in
serum Ig E levels.There was statistically significant higher IL31 level in allergy
positive score ITP patients compared to allergy negative score patients
(p=0.000), and statistically significant positive correlation between IL31 level
and score of allergy (r=0.646, p=0.000).There was no correlation between
serum IgE level and score of allergy,and no significant difference between
patients and controls regarding serum IgE level. There was no significant dif-
ference between acute and chronic ITP in the score of allergy, IgE level or
IL31levels, and there was no difference in these parameters between steroid
responsive and steroid resistant ITP patients.
Summary/Conclusions: This preliminary study reveals that children with aller-
gic manifestations are at higher risk to develop ITP, but this will not probably
affect the clinical presentation, treatment outcome or prognosis of immune
thrombocytopenia.
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SHORT AND LONG-TERM OUTCOMES OF SPLENECTOMY AND SURGICAL
COMPLICATIONS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC
PURPURA (ITP) IN A SINGLE CENTER IN ALGERIA
H Brahimi1,*, C Guezlane1, Y Bouchakor-Moussa1, R Benhizia2, EM SI Ahmed2,
MT Abad1
1Hematology, EHS ELCC CAC, Faculty of Medecine, University of Blida 1,
2Surgery, CHU Frantz Fanon Faculty of Medecine, University of Blida 1, Blida,
Algeria
Background: Among several treatment of immune thrombocytopenic purpura,
glucocorticoides are the first one resulting in a high rate of response; unfortu-
nately most patients (pts) responding to this treatment fail to maintain durable
response. Splenectomy, the second line treatment produces an important rate
of durable responses, about 60-80%.
Aims: To report and evaluate the short and the long-term outcomes and surgical
complications in adults and children with ITP who underwent splenectomy.
Methods: We rewieved the medical records of 142 pts who underwent splenec-
tomy for ITP from 1987-2014. Response was defined as: complete response
(CR): platelet count>100000/µl ; partial response (PR): platelet count
>50000/µl, no response (NR) or failure: platelet count <50000/µl, relapse: loss
of CR.142 patients were splenectomized: 44 males (31%) and 98 females
(69%),Sex ratio=0,45.Median âge at diagnosis was 26,8 years (2-71); there
were 101 adults and 41childreen .Median âge at splenectomy was 28,8 years
(5-72). At the time of splenectomy, 31 pts were childreen (29%) and 111 were
adults. 71 (50%) were splenectomized because they were corticostreroid
dependency and 50% because they failed to corticosteroids. The median time
from diagnosis to splenectomy was 25,1 months (2-156) The median platelet
count at diagnosis was 27000/µl and the median preoperative platelet count
was 60000/µl. 
Results: Before splenectomy,134 pts(94,3%) received only steroids at initial
treatment. 139 pts were vaccinated (pneumococcal vaccine) before splenec-
tomy and after it. In pts with severe thrombocytopenia intravenous corticos-
teroids were done in 33 cases(23,2%).Laparoscopic splenectomy was per-
formed in 54 pts and open splenectomy in 88 cases.In the post operative peri-
od, we noted wound infection in one case; 3 cases requiring open surgery
because intra abdominal hemorrhage, one death resulting from neurological
disorder related to adrenal insufficiency. Accessory spleen was removed in
one patient. Prophylactic antibiotic therapy was systematic during the 2 first
years. For 136 informative pts: the median follow up after splenectomy was
80,1 months.Good responses (CR+PR) was achieved at month 1 for 127
(89,4%) of pts: CR: 118 (83%),PR: 09 (6,3%) whereas the remaining (09) were
refractory to splenectomy. After 1 year: 125 pts followed: 95 CR, 4 PR, 9 NR.
After 2 years: 114 pts followed: 89 CR, 2 PR, 7 NR. Relapses are encountered
in 24 (16,9%) pts with an median time of 28,6 months. 21 of these pts were
treated, resulting of 12 CR, 03 PR and 06 steroids dependency (one was reop-
erated for an accessory spleen for relapse 4 years after the first splenectomy).
Among the failures, a multiple myeloma apparead 43 months after the ITP ; In
one case, the histological study revealed a non hodgkin lymphoma; the ITP
has preceded an autoimmune disease in 4 cases (an autoimmune hemolytic
anemia after 62 months, 2 cases of systemic lupus erythematous respectively
after 42 and 100 months and 1 case of Biermer’s anemia 128 months after the
ITP) ; 2 cases of family ITP (one pt splenectomized and her daughter followed
for ITP that preceded rheumatoid arthritis,2 sisters splenectomized have died,
one in operative period by fatal h.emorrhage and the second 151 months after
splenectomy after relapse as Evans syndrome.The median total follow up of
the 142 patients was 103 months.
Summary/Conclusions: Our study documents that splenectomy si an effective
treatment for ITP by the frequency of RC, the excellent outcomes of this pro-
cedure for patients with ITP and the mortality rate decreased. However predic-
tive factors of success remain to be clarified.
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THROMBOPOIETIN RECEPTOR AGONIST SWITCH IN ADULT PRIMARY
IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS: A RETROSPECTIVE
COLLABORATIVE SURVEY FROM 4 SPANISH CENTERS
S Lakhwani1,*, M Perera2, F Fernández-Fuerte3, MA Rios de Paz4, M Torres2,
JM Raya1, MT Hernandez1
1Hematology, Hospital Universitario de Canarias, Santa Cruz de Tenerife,
2Hematology, Hospital Universitario de Gran Canaria Dr. Negrín, 3Hematology,
Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria,
4Hematology, Hospital Universitario Nuestra Señora de La Candelaria, Santa
Cruz de Tenerife, Spain
Background: Thrombopoietin receptor agonists (TRA), romiplostim (ROM)
and eltrombopag (ELT), have changed in the last years the treatment of ITP
showing that there is both a increased platelet destruction and a suboptimal
platelet production in ITP. Although both drugs activate the same receptor,
mechanism of action is different and they don’t activate the same intracellular
signalling pathways. That explains why some patients respond to one and not
to the other TRA and also the different side effect profile. There are few data
evaualting the TRA switch in ITP.
Aims: To describe the reasons and the result of TRA switching in adult ITP
patients of the four main centers of our region (Canary Islands) in Spain.
Methods: We retrospectively analized a total of 26 adult patients with ITP who
were switched from ROM to ELT or vice versa. Clinical and biological param-
eters were recorded.
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Results: Our series comprise 10 men and 16 women with a mean age of 55
years (range 16-84) when they received the first TRA. All the patients received
steroids as the first line treatment. Before starting the first TRA, 9 patients
(35%) received Rituximab, 7 patients (27%) received anti-D immunoglobulin,
5 patients (19%) received azatioprine, and only 8 patients (31%) had splenec-
tomy performed. The mean number of previous lines before the first TRA was
2.7 (range 1-4), and 9 patients (35%) received a TRA as second line. ROM
was the first TRA in 17 patients who switched to ELT with a median time of 8,8
months. In 9 patients ELT was the first TRA and median time to switch to ROM
was 3,4 months. The main reasons for switching were lack of efficacy (n=10),
patient’s preference (n=8), side effects (n=5) and platelet-count fluctuation
(n=3). The following table shows what happened in each of these situations.
When switch was due to inefficacy, all the cases who received ROM first
responded to ELT but only 66% of the patients who received ELT first reponded
to ROM. Conspicuously the average of ROM maximum dose was only 4,5
μg/kg/week, very far from the maximum recomended dose (MRD), while the
average of ELT maximum dose was 70 mg/day, very near to the MRD. All the
changes due to patient preference were from ROM to ELT because of the route
of administration. All the patients who switched due to side effects responded
to both TRA. Three patients switched from ROM to ELT because platelet-count
fluctuation with poor outcome: one did not respond and two responded to ELT
but count fluctuation persisted. Six responders patients to the second TRA are
now without treatment: four patients achieved a complete response with the
second TRA and two patients underwent splenectomy after second TRA and
they also achieved a complete response.
Table 1.
Summary/Conclusions: As previously reported, in our series we can observe
that: When the patient respond to the first TRA and the switch is not due to
inefficacy there is a high probability of responding to the second TRA (100% in
our series). When the switch is motivated by lack of efficacy, the patient could
respond to the second TRA specially if the first TRA dose is bellow the MRD.
PB2079
THROMBOPOIETIN-RECEPTOR AGONISTS (TPO-RAS) IN IMMUNE
THROMBOCYTOPENIA (ITP): EXPERIENCE IN OUR CENTER
K Javier González*, S Ortiz Zuluaga, C Villegas DaRos, P Pérez Rodríguez,
MT Orero Castello, M Roig Pellicer, I Luna Del Valle, M López Pavia,
R Collado Nieto, D Ivars i Santacreu, A Cervero Martí
Hematology, Hospital General Universitario de Valencia, Valencia, Spain
Background: Thrombopoietin-receptor agonists (TPO-RAs), Romiplostim
(ROM) and Eltrombopag (ELT) constitute an effective therapeutic option for
patients with immune thrombocytopenia (ITP). However, several questions
remain unclear concerning their use. 
Aims: Our aim is to describe our experience with the use of TPO-RAs in ITP
with particular reference to sequential treatment with both drugs, their use prior
to invasive procedures and the prognostic factors for response.
Methods: We reviewed all patients with ITP who received treatment with TPO-
RAs at standard doses in our department. The following variables were evalu-
ated: age, gender, platelet count, previous treatments (including splenectomy),
time of follow- up from diagnosis and response to TPO-RAs. Response was
defined by the ITP International Working Group response criteria. Comparisons
between categorical variables were made with χ2 or Fisher exact test and Mann-
Whitney U test was used for quantitative variables. Logistic regression was
used to identify factors associated with response. 
Results: Between October 2009 and December 2015, 49 patients were treated
with TPO-RAs, 17 men and 32 women, with a median age of 67 years. 36
patients received treatment with ROM (32 as first line and 4 as second line
TPO-RAs) and 34 with ELT (17 1st line, 17 2nd line), with a median platelet
count of 19.000 (range 2000-78000) before starting treatment. The overall
response with ROM was 83% (30/36) and 74% (25/34) for ELT. 10 patients
were treated with TPO-RAs previous to invasive procedures, 6 with one dose
of ROM and 4 with ELT for a month. 6 patients achieved response, 4 with ROM
and 2 with ELT. 21 patients with ITP were treated with both ROM and ELT
sequentially. Response was observed in 13 of 17 patients switched from ROM
to ELT, including 2 of 3 non-responders to ROM. Three of 4 patients switched
from ELT to ROM responded to treatment. Response rate for patients switched
because of relapse after transient response was observed in 5 of 9 patients; in
contrast, 8 patients switching because of poor tolerance or personal preference
achieved response. There was no statistical difference between responders
and refractory patients in terms of age, gender, platelet count before therapy,
splenectomy or number of previous treatments (table 1). Patients who initially
responded to corticoids had a higher response rate to TPO-RAs. In logistic
regression only initial response to corticoids showed prognostic impact with a
hazard ratio of 10,5 (p=0,005).
Table 1.
Summary/Conclusions: TPO-RAs are an effective salvage therapy for refrac-
tory ITP. Switching from one TPO-RAs to the other is an effective option. TPO-
RAs could be a useful treatment option when aiming a rapid platelet count
increase. Initial response to corticosteroids is the only predictive factor of
response in our study.
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THROMBOCYTOPENIA AND FOLATE DEFICIENCY IN PREGNANT
WOMEN
Y Ouarhlent1,*, N Boudjerra2, H Bounecer3
1Hematology, CHU of Batna, Batna, 2Hematology, CHU of Benimessous,
Algiers, 3Epidemiology, CHU of Batna, Batna, Algeria
Background: Micronutrient deficiency among pregnant women is common,
folate deficiency is seen in the developments ways countries in parturients having
a low socioeconomic level in blood count it may be noted a thrombocytopenia.
Aims: To evaluate the thrombocytopenia observed in parturients deficient in
vitamin B9.
Methods: this is a study of cases of thrombocytopenia observed in a cohort of
375 pregnant women with a B9 deficiency, followed antenatal care in the first
trimester(T1), second (T2) and third (T3).
Results: the average age of pregnant women was 30.11±6.9 years. The aver-
age platelet in our sample is 223 + 89.38 103/ml, the average with extreme
depending on the quarters is as follows: T1= 223 103/ml (34000-512000)/ml,
T2= 226 103,(4500-512000) T3= 221,103/ml (31000-414000). The average
serum folate is 7.36 + 3.19 ng/ml: T1= 7.6 (2.3 to 20.0) ng/ml, T2= 7.07 (2.2 to
14.2) ng/ml and T3=7.3 (2.0 to 18.0) ng/ml. The average red cell folate is 201
+ 61.74 103ng/ml; T1=206,9 (65.0 to 397.0), T2=195,5(65-321) and T3= 202.6
(66-417). The correlation between red cell folate: and platelets is r=0.284 **
p=2,06.10-8 Regression thrombocytopenia was noted during treatment (B9
orally) during the first month in all cases.
Summary/Conclusions: This study shows that it is necessary to know this
association because thrombocytopenia associated with deficiencies of vitamin
B9 in pregnant women are frequent and rapid response to treatment of defi-
ciency of vitamin B9.
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SAFE BUT FLUCTUATING RESPONSE TO TREATMENT WITH TPO MIMETICS
IN PREGNANT PATIENT WITH REFRACTORY ITP
E Omenetto*, A Bertomoro, ML Randi, I Bertozzi, E Duner, V Rancitelli, F Fabris
Department of Medicine - DIMED, University of Padua, Padova, Italy
Background: Maternal platelet count less than 20x10^9/L has been associated
with risk of spontaneous bleeding, postpartum haemorrhage, and placental
abruption. 5% of newborns will be born with platelets less than 20x10^9/L and
less than 1% will have bleeding complications. Primary treatment options for
maternal ITP are similar to those of non pregnant adult patients: corticosteroids
and IV-Ig are the first-line treatments.
Aims: Describe a case of use of TPO-mimetic during pregnancy in refractory ITP.
Methods: We report a case of a 25 years old Moldovan woman with refractory
chronic primary immune thrombocytopenia (ITP), diagnosed on 2002. On 2006
the patient underwent splenectomy with a partial response and low dose of
prednisone (2.5 mg/die) obtaining a stable remission (platelets 150 x10^9/L).
During the follow-up the patient underwent abdominal CT scan, which was neg-
ative for an accessory spleen. In November 2013, the ITP recurred with petechi-
ae and platelets were 6 x10^9/L; platelet associated autoantibodies against
GpIIb/IIIa (HPA 1a/3a) and GpIb (HPA 5b/5a) were positives. Since the patient
was refractory to full doses of prednisone (1 mg/kg) and IV-Ig (1g/kg for 2 days),
she was treated with increasing doses of romiplostim, (NPLATE®) (1 mcg/kg
up to 3,5mcg/kg) once a week for 26 weeks. The response to TPO-mimetic
was fluctuating with both severe thrombocytosis and symptomatic thrombocy-
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topenia needing platelet transfusions. The patient was then treated on April
2014 with Rituximab (375mg/m x 4 doses) with complete response.
Results: The ITP remission continued until April 2015, when at 21st week of
gestation, relapsed (Figure 1). She was treated again with prednisone and two
IV-Ig courses with transitory response. After an unsuccessful course with dex-
amethasone (40mg/kg) we obtained the patient informed consent for the use
of romiplostim (1mcg/kg up to 10 mcg/kg) once a week for 3 weeks before
delivery, without response. The elective caesarean delivery was performed on
26 week of pregnancy with the infusion of platelet concentrates due to a severe
thrombocytopenia (platelets 3x10^9/L. Major bleeding complications did not
occur, and baby’s platelets were normal. After delivery, romiplostin was admin-
istered for other 10 weeks with fluctuating positive response (Figure 1).
Because of the discontinuous response to romiplostim, we shifted to oral
eltrombopag (Revolade® 50 mg/day) waiting for a new course with rituximab.
Due to a severe thrombocytosis (platelet 1985x10^9/L) the TPO mimetic has
been withdrawal after only one week. The response to rituximab was complete
and stable, steroid was gradually tapered until suspension and the ITP remitted
without any therapy so far.
Figure 1.
Summary/Conclusions: There are few case report on ITP treated with romi-
plostim during pregnancy, and no one showing fetal complications. Although
TPO mimetics have not been indicated in pregnant ITP, it may represent an
important alternative treatment choice for refractory cases because its speed
of activity and an high rate of success. In our patient, we obtained a positive
response to romiplostim during the first recurrence of ITP and after delivery
but both responses were discontinuous without finding the lowest effective
dose. Therefore we tried a switch to eltrombopag after delivery, but the
response to the standard initial dose was characterized by an extreme throm-
bocytosis. We can speculate that TPO mimetic are safe during pregnancy in
ITP but they may require more customized dosages mostly after delivery.
Instead, using rituximab we obtained a complete and longstanding response
showing the effectiveness of the combination of drugs that act by different but
complementary mechanisms.
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HIGH-DOSE DEXAMETHASONE IN TREATMENT OF CHILDREN WITH
CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA
M Sarhan*, A Elsharkawy, E Ahmed, B Elshibiny
Pediatrics, Faculty of Medicine - Mansoura University, Mansoura, Egypt
Background: Chronic idiopathic thrombocytopenic purpura (ITP) is a big dilem-
ma in hematology. About one fifth of cases diagnosed as acute ITP takes a
chronic course which known as thrombocytopenia that persists after twelve
months after onset. Cellular immunity plays a central role in thrombocytopenia.
Alterations in T cell subsets and decreased numbers and activity of regulatory
T cells are common. Cytotoxic T cells may also mediate toxicity against platelets
and megakaryocytes. Treatment strategy includes first line therapy as corticos-
teroids, IVIG, anti-Rh (D), and second line therapy as high dose dexamethasone,
anti-CD20 (rituximab), thrombopoietin receptors agonist and splenectomy.
Aims: to evaluate the therapeutic response of a high dose dexamethasone in
a series of Egyptian children with chronic ITP.
Methods: The study included 27 children with chronic ITP comprising 12 males
(44.4%) and 15 females (55.6%). One child was withdrawn from the study due
to acquired diabetes and hypertension with 26 patients completing the treat-
ment course. Dexamethasone should be administrated by intravenous infusion
in a dose of 40 mg/m2/day on two divided doses for four consecutive days and
repeated every 4 weeks for 6 cycles. DXA scan should be done as a baseline
and after finishing therapy to evaluate bone mineral density of the patients.
Repeated CBC, blood pressure, and blood glucose levels were evaluated
through infusion days.
Results: Complete remission (CR) was achieved in 3 patients (11.1%) after
the 1st dose, in 5 patients (18.5%) after the 2nd dose, in 5 patients (18.5%)
after the 3rd dose, in 6 patients (22.2%) after the 4th dose, in 7 patients (26.9%)
after the 5th dose and in 7 patients (26.9%) in the 6th dose. Assessment of the
overall response after 1 months of course completion revealed that CR was
achieved in 7 patients (26.9%) while remission (R) was achieved in 8 patients
(30.8%) and 11 patients (42.3%) had no response. In the current study, on
binary logistic regression, older age was the only significant predictor of treat-
ment response.
Summary/Conclusions: High dose dexamethasone can be proposed as a
first-line treatment for children with chronic ITP with tolerable side effects.
Repeated cycles of therapy seem to be more efficient than only one cycle. Sta-
tistical significance of remission in older children, age can be considered as a
predictor of treatment response. 
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GAUCHER DISEASE WITH IMMUNE THROMBOCYTOPENIA (ITP): A CASE
REPORT AND TREATMENT WITH ELTROMBOPAG
LM Borin*, L Verga, F Farina, A Aroldi, PE Pioltelli
Hematology Division, San Gerardo Hospital, Monza, Italy
Background: Gaucher disease (GD) is a rare multi-systemic metabolic disor-
der due to the accumulation of glucocerebroside in macrophages. The non-
neuronopathic type is characterized by enlargment of liver and/or spleen, skele-
tal abnormalities, pancytopenia. Thrombocytopenia is usually related to hyper-
splenism and infiltration of bone marrow by lipid-laden macrophages namely
Gaucher cells. Enzyme replacement therapy (ERT) restores the hemoglobin
and platelet count in GD patients.
Aims: In GD ERT treated patients, immune thrombocytopenia (ITP) should be
considered if persistent low platelet counts is found. Traditional treatmant reg-
iments with steroid and splenectomy should be used with caution. Splenectomy
may worsen bone lesions and steroids may induce osteopenia and joints avas-
cular necrosis. Thrombopoietin receptor analogues (romiplostim and eltrom-
bopag) are therapeutic option in ITP patients. The use of romiplostim is reported
in 2 cases of GD patients. We report the beneficial use of eltrombopag in one
patient who suffered from GD.
Methods: 18 YO female patient was diagnosed with Gaucher disease at age
14 (N307S/D399U) and she received imiglucerase. At age 21 she developed
purpura and ecchymosis. The platelet count was 0/microL. Bone marrow biopsy
(BM) showed a normal erytropoiesis and myelopoiesis and a large number of
megakaryocytes. Autoantibodies were negative. A concomitant diagnosis of
immune thrombocytopenia was achieved. 1 mg/Kg/die Prednisone and
immunoglobulin were given without any response on platelet counts. Splenec-
tomy was not considered due to known bone complication risk in splenec-
tomised GD patients. The patient developed also a severe anemia due to metr-
orrhagia. Rituximab was given without any results on platelet count. Eltrom-
bopag (dose 50 mg) was initiated raising platelet count from 3,000/µL to
25,000/µL. The dose was increased to 75 mg raising patelet count of 60,000/µL
after 5 we3eks. Same dose Romiplostim is maintained for the last 6 months
with platelet counts between 40,000 and 80,000/µL without any bleeding
events. Repeated BMB showed slight increase of fibrosis and marked hyper-
plasia of atypical megakaryocytes.
Results: Thrombocytopenia is often present in GD and may be severe in
approximately 15% of the patients. Persistent cytopenias may be caused by
other underlying pathologies such as autoimmune disorders and it’s important
to recognize other causes. Before ERT era GD patients with hypersplenism
and severe cytopenia were splenectomised. Risks of splenectomy include seri-
ous bacterial infection and vascular complications limiting its use in chronic
refractory ITP. Splenectomy is avoided in Gaucher patients, because of risk of
increasing of skeletal complications (bone infarcts, avascular necrosis). Stable
bone marrow results regarding fibrosis in our patients are consistent with data
from a recent 2-year follow-up of 100 ITP patients receiving Romiplostim treat-
ment with no evidence of BM fibrosis.
Summary/Conclusions: For patients with type I Gaucher disease and con-
comitant ITP, adjunctive treatment with Eltrombopag was successful in main-
taining haemostatic platelet counts without adverse effects. Traditional treatment
based on corticosteroids and splenectomy should be used with caution or avoid-
ed in GD patients due to possible risk of Gaucher skeletal disease, osteopenia
and avascular necrosis, usually determining increased morbidity in this cohort
of patients. Use of TPO-RA should be considered in GD patients with ITP.
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IDIOPATHIC THROMBOCYTOPENIC PURPURA: DESCRIPTIVE AND
RETROSPECTIVE STUDY OF 151 PATIENTS
R haifa*, A Bechir, B emna, BS nesrine, BY yosra, K abdrrahim
Hematology, Farhat Hached Hospital, Sousse, Tunisia
Background: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune dis-
ease characterized by a variable intensity of thrombocytopenia related to the
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presence of anti-platelet antibody originally of a destruction of platelets by the
spleen macrophages associated with production Medullar quantitatively or qual-
itativement inadequate. The ITP treatment todate remains poorly standardized.
Aims: We report the results of a clinical study, biology and therapeutic study
realized from 151 patients.
Methods: This is a retrospective and monocentric study of 151 patients with
ITP (a platelet count <100 10 3/mm 3) collected in the department of hematology
hospital Farhat Hached Sousse over a period of 10 years (2004-2014).
Results: The data of 151 patients were included in our study. The average age
was 40 years (15-85 years). The sex ratio was to 0.42 (m/f). The average rate
of platelets at diagnosis was 20 000 G/L (0-50000). Thrombocytopenia was
discovered incidentally in blood cell in 21.2% of cases. In addition 78.8% of
patients experienced a hemorrhagic syndrome of varying intensity but not bind-
ing prognosis in any case. Eight percent of these patients received platelet
concentrate transfusions because of active bleeding. A functional anemic syn-
drome was present in 17.8% of patients. Regarding treatment, corticosteroid
was prescribed first line in 92.1% of cases and only 7.9% of patients received
immunoglobulin. The response rate was 83.4% with an complete responce
estimated at 62.9%. A relapse occurred in 29.8% of patients and ITP evolves
to chronicity in 47% of cases. Only 3 patients (2%) were splenectomized with
a normalization of the number of platelets in a patient. 23 patients (15.2%)
received treatment with rituximab, the response rate was 39%. After a mean
follow-up 38 months, only one death was occurred and it wasn’t related to PTI.
Summary/Conclusions: ITP is a rare disease that affects a middle aged pop-
ulation. It evaluate to a chronic mode, the prognosis is good and only a minority
patient progresses to a severe form of the disease. Indeed, the rate of relapse
or non-response is important and imposed using several therapeutic lines.
Place of new treatments receptor agonists such as thrombopoietin (TPO) or
new anti lymphocyte B therapies remain to be defined.
PB2085
SUSTAINED RESPONSES FOLLOWING STOPPED TREATMENT WITH
ROMIPLOSTIM IN IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTRE
EXPERIENCE
L Torres Miñana*, MDM Perera Alvarez, M Torres Ochando, H Luzardo,
T Molero Labarta
Hematology, H. Dr Negrin GC, Las Palmas de GC, Spain
Background: Thrombopoietin-receptor agonists (Tpo-RAs) are highly effective
in immune thrombocytopenia (ITP). In the last years, cases of durable remission
after Tpo-RA discontinuation in adults’ ITP have been reported. This observation
raises the possibility that these agents may restore immune tolerance to Tpo-
RAs in some patients and supports the practice of down titrating the dose. In
this moment, there are no studies that show association with the remission and
the variables studied.
Aims: Our objective is to remark the results about the remission and the dis-
continuation to thrombopoietin-receptor agonists in our population.
Methods: We analyzed 28 patients in treatment with romiplostin from Dr. Negrin
Hospital from 2009 to nowadays. Five of them were Primary ITP and 3 had a
Secondary ITP (SLE, Crohn’s Disease, and hypothyroidism). The average of
previously received treatments before the use of romiplostin was either 1 or 2.
8 out of 28 patients, maintained the platelet response in spite of having discon-
tinued therapy with Romiplostim. The discontinued therapy was performed in
different ways: 1 patient’s drug was decreased weekly to 1 µg/kg and then
stopped. In another patient we maintained the dose but increased the interval
between treatments to every 3 weeks until off treatment, and as to the remaining
6 patients, the minimal dose was performed every 2-3 weeks until suspension.
All of them have maintained the platelet count without therapy.
Results: The median dose of romiplostim was 2 µg/kg weekly (range 1–10
µg/kg). The median duration of romiplostim treatment was 21 months (range
8-46 months). 8 patients (28%) responded (platelet count >100x109 /L without
concomitant ITP therapy). In seven patients (26.3%) remission was sustained
for longer than 6 months after discontinuing romiplostim therapy. Characteristics
of these patients are outlined in Table 2.
Table 1.
Summary/Conclusions: There is more than one possible mechanism which
might explain the lasting responses seen in our patients. For example, natural
remission or a change in immune regulation through an impact on T regulatory
cells with restoration of immune tolerance. In our retrospective study, and in
the other reported studies, we found no relationship between the different vari-
ables (age and number of previous lines) or the response pattern (early or late)
and the possibility of discontinuance. In addition, we observed that the use of
demand doses does not predict the loss of long-term response. The throm-
bopoietin receptor agonists could be used for short term treatment to cover
invasive procedures and to treat patients who are at risk of bleeding and are
refractory to other therapies but prospective studies should be set up to confirm
the observation of sustained response off therapy and to identify potential pre-
dictive factors of response.
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NEONATAL OUTCOMES OF PREGNANCY WITH IDIOPATHIC
THROMBOCYTOPENIC PURPURA
A Bay1,*, A Melekoglu1, E Aktekin1, M Yılmaz2, E Sivasli1
1Pediatric Hematology, 2Internal medicine, Gaziantep University, Gaziantep,
Turkey
Background: Neonates born to mothers with idiopathic thrombocytopenic pur-
pura (ITP) have an increased risk for neonatal thrombocytopenia and hemor-
rhagic complications.
Aims: The aim of this study was to determine the maternal and neonatal out-
comes of pregnancies with ITP and also to identify risk factors that predicts
neonatal thrombocytopenia
Methods: We performed a retrospective analysis of 40 pregnancies with ITP
and their 40 neonates. 
Results: Among the 40 neonates, thrombocytopenia (platelet count of less
than 150×109/L) was detected in 15 neonates (37,5%) whom 8 of them had
severe thrombocytopenia (platelet count of less than 50×109/L). Ten of the 15
neonates with thrombocytopenia required treatment to increase the platelet
counts. There was statistically significant association between neonatal throm-
bocytopenia and maternal splenectomy history and maternal duration of throm-
bocytopenia. There was no statistically significant correlation between maternal
platelet count and neonatal platelet count. 
Summary/Conclusions: Clinicians should pay special attention in these
neonates because of risk for development of neonatal thrombocytopenia.
Maternal and neonatal outcomes in patients with idiopathic thrombocytopenic
purpura is generally good.
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SAFETY AND EFFICACY OF RITUXIMAB IN ADULT IMMUNE
THROMBOCYTOPENIA
C Biagiotti*, V Carrai, F Bacchiarri, M Di Gioia, G Raugei, A Bosi
Hematology, Careggi Hospital, Florence, Italy
Background: Immune thrombocytopenia is characterized by immune-mediated
destruction and suboptimum production of platelets. Despite the absence of
supporting evidence, the anti-CD20 chimeric monoclonal antibody rituximab
has been effectively used off-label in the treatment of patients with primary
immune thrombocytopenia (pITP). 
Aims: The aim of this analysis is to describe our experience with Rituximab in
patients affected by chronic ITP.
Methods: In this monocentric analysis we retrospectively evaluated 43 adult
patients affected by chronic ITP resistant to 2 or more lines of therapy that were
treated with four weekly infusions of 375 mg/mq rituximab to asses safety and
efficacy.
Results: Of 43 patients treated with Rituximab, 39 were retrospectively evalu-
ated. 20 F, 19 M. Median age was 60 years (range 29-91 years) and median
platelets value at start treatment was 16.000/μl (range 5.000-40.000). 24/39
(62%) showed an initial response, 17/39 (44%) patients obtained complete
response (CR) and 7/39 (18%) showed partial response (R). Of those achieving
an overall response 4 (17%) patients relapsed, median time to relapse was 30
months (range 8-45). Of these 4 patients relapsed, 3 received re-treatment
with four weekly infusions of 375 mg/mq rituximab and 2 patients achieved a
complete response, one was no-responder. With a median follow-up of 22
months (range 2-95 months), 17/24 patients (71%) showed a lasting response
out of treatment, of these 15 patients maintained a complete response with a
median platelets count of 156.000/μl (100.000-362.000/μl) and 2 patients was
in partial response. 7 patients underwent further line of therapy (6 treated with
TPO-mimetics and 1 with splenectomy) During the follow-up, no opportunistic
or severe infectious complications were observed. 
Summary/Conclusions: In our limited experience these data confirm, over a
long period of observation, the efficacy and safety of Rituximab treatment in
the management of patients with resistant ITP and Rituximab used off-label
may remain a valid option for treating persistent or chronic ITP in adults. Further
investigations and specific clinical trials are warrented.
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EFFICACY OF TPO-MIMETICS IN PATIENTS WITH CHRONIC IMMUNE
THROMBOCYTOPENIA
F Bacchiarri*, V Carrai, C Biagiotti, G Raugei, M Di Gioia, A Bosi
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Copenhagen, Denmark, June 9 – 12, 2016
Hematology, AOU Careggi, Firenze, Italy
Background: Immune thrombocytopenic purpura (ITP) is an autoimmune dis-
order in which antibodies are produced to circulating platelets. The isolation of
TPO and better understanding of its role in thrombopoiesis has led to the devel-
opment of new highly effective tTPO analogs had some successes in treating
highly refractory ITP patients but were taken out of development due to TPO-
antibody induction.
Aims: The aim of this study is to describe our experience with thrombopoietin
receptor agonists (TPO-RA).
Methods: From November 2008 and April 2015 54 patients (29 M; 25 F) were
treated with TPO-mimetics: 38 underwent therapy with Romiplostim and 16 to
Eltrombopag. Median age was 71 years (range 39-94 years). 8/54 (14%)
patients received both of therapies: 5 (4 F; 1 M) switched from Romiplostim to
Eltrombopag and 3 (3 M) switched from Eltrombopag to Romiplostim.
Results: In the group of patients treated with Romiplostim, 16/38 had already
received more than 4 lines of therapy, while 10 were at the 3rd line of therapy,
and 5 were at 2nd line. Only 2/16 patients who received Eltrombopag were at
the 2nd line of therapy, and the others were at least at the 3rd line. The median
platelet count was 17.000/µl at the start of Romiplostim and 10.000/µl in
patients treated with Eltrombopag. With median follow-up of 36 months (4-74),
we observed 33 responses (86%) with Romiplostim (19 complete response,
14 partial response) and 5 no responders; we had also 3 loss of response. In
our study 18 (33%) patients stopped Romiplostim after a median time of 23
months (1-56): 6 for stable response; 2 for adverse events; 3 for loss of
response; 2 underwent splenectomy; 5 for no response. The median platelet
count at suspension of Romiplostim was 94.000/µl (2.000-739.000); the
patients discontinued Romiplostim after a median time of 26,6 months. Now 7
patients are out of treatment with a stable platelet count (median time after
discontinuation: 25 months). In patients treated with Eltrombopag 13 (81%)
achieved a response (9 complete response, 4 partial response), 3 were no
responders. 11 (69%) patients stopped Eltrombopag after a median time of 10
months (1-16): 5 for adverse events; 3 for no response; 2 for stable response;
1 for splenectomy. The median platelet count at suspension was 74.000/µl
(2.000-739.000); the patients discontinued Eltrombopag after a median time
of 11,1 months and now are out of treatment from 3 months.
Summary/Conclusions: Several studies reported Romiplostim and Eltrom-
bopag to be highly effective against chronic ITP, with average immediate
responses exceeding 80% in our study. TPO-mimetics have proved efficacy in
patients with ITP and their use can be applied in several conditions: bridge to
splenectomy, sustained response, switch and discontinuation.
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NOVEL PERSPECTIVES IN PATIENTS WITH REFRACTORY CHRONIC
IMMUNE THROMBOCYTOPENIA FOLLOWING ELTROMBOPAG TREATMENT
M Kaliou*, E Gavriilaki, Z Bousiou, S Papadimitriou, G Papaioanou, K Tsirou,
A Syrigou, M Iskas, A Anagnostopoulos
Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki,
Greece
Background: Primary immune thrombocytopenia (ITP) is characterized by an
antibody-mediated accelerated destruction and inadequate production of
platelets. Therapeutic strategies in ITP aim not only to increase and maintain
platelet counts in safe levels without bleeding episodes but also to improve
quality of life in this chronically ill patient population. Eltrombopag is the first
oral thrombopoietin agonist approved for patients with ITP refractory to at least
one line of treatment.
Aims: The present study aims to evaluate the safety and efficacy of etrom-
bopag in clinical practice.
Methods: Eltrombopag was administered in 13 patients, 5 male: 8 female with
a median age of 46 years (range 19-48) for a median 6.4 months (0.5-32.4).
Patients had received 1 to 7 lines of treatment (median=1), including corticos-
teroids (13 patients), immunoglobulins (4 patients), rituximab (1 patient), vin-
cristine (1 patient), cyclosporine (1 patient), romiplostim (1 patient), danazol (1
patient) and splenectomy (1 patient). In accordance with previous clinical trials,
complete response to treatment was defined as a platelet count of ≥100x109/L.
Results: At initiation of eltrombopag treatment, the majority of patients (7/13)
showed thrombocytopenia (WHO grade 4, <25x109/L). Initial dose was 50 mg,
increased to 75 mg daily in 3 patients for optimal treatment. In 10/13 patients
eltrombopag was administered in combination with corticosteroids that were
gradually tapered by the fifth week of eltrombopag administration. Median
platelet value by the second week of administration was 125x109/L (5-
450x109/L); whereas, by the fourth week platelets increased to 185x109/L (16-
500x109/L). At the end of follow-up, median platelet count was 132x109/L (60-
400x109/L). All patients achieved complete response to treatment (platelet
count≥100x109/L), except for one patient with a platelet count of 60x109/L at
the end of follow-up. Regarding adverse events, one patient developed grade
2 hepatobiliary abnormalities and one patient grade 1 hemolytic anemia. Both
adverse events resolved when the drug was temporarily discontinued. Only
one patient switched to another treatment due to pulmonary embolism during
the first month of treatment.
Summary/Conclusions: In the daily clinical practice eltrombopag is safe, well
tolerated and highly effective in maintaining a safe platelet count when admin-
istered in ITP patients refractory to at least one line of treatment. Eltrombopag
role in other subgroups of ITP patients remains to be investigated. In addition,
larger studies with longer follow-up are needed to determine the incidence,
predisposing factors and prophylactic measures to prevent severe adverse
events.
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HIGH-DOSE DEXAMETHASONE AND ELTROMBOPAG IN CHRONIC
IMMUNE THROMBOCYTOPENIA: A SINGLE INSTITUTION EXPERIENCE
D Magro1, L Levato1, E Piro1, MG Kropp1, S Molica2,*
1Hematology and Oncology Az. Osp. Pugliese Ciaccio Catanzaro, SOC Hema-
tology, 2Hematology and Oncology Az. Osp. Pugliese Ciaccio Catanzaro, SOC
Hematology and Oncology, Catanzaro, Italy
Background: Eltrombopag is a thrombopoietin (TPO) nonpeptide mimetic that
has been shown to raise the platelet count in both continued long-term admin-
istration and in a repeated short-term administration in chronic immune throm-
bocytopenia (ITP). However, information dealing with the concomitant use of
eltrombopag and dexamethasone in patients with chronic ITP are lacking.
Aims: The purpose of this study was to assess the efficacy of eltrombopag in
combination with dexamethasone in a consecutive, unselected series of
patients with chronic ITP followed up in a single institution in the period May
2014- December 2015.
Methods: Eleven patients (6 F/ 5 M) with median age 53 years (range, 29-70)
who had at least a 6-month history of ITP (median 26 months; range 6-220
months) were considered eligible for the present analysis. All patients had a
platelet count lower than 30x109/Land bleeding manifestations were present in
7 out of 11. No patient had an active infection, drug-associated thrombocytopenia,
positive serology for HIV, hepatitis B or hepatitis C, malignant diseases or was
pregnant. After initiating eltrombopag (50 mg once a day)doses were adjusted
to achieve and maintain a platelet count ≥50,000/μl as necessary to reduce the
risk for bleeding. Eltrombopag dose did not exceed 75 mg/day. Dexamethasone
40 mg/day was given for 4 days every 28 days. Patients with glucose intolerance
or diabetes needing therapy received an mitigated dose of dexamethasone (20
mg/day). Response and complete response (CR) were defined as an increase
in platelets ≥30 <100x109/L and ≥100x109/L, respectively.
Results: All patients achieved a responseduring the treatment while a CR was
obtained in 10 of 11 patients. Maximum response was reached after a median
time of 12 weeks (range, 3-39). After a median follow-up time of 29 weeks
(range, 8-89) response was still maintained in all patients while 5 patients lost
CR. Four patients who lost CR were receiving maintainence therapy with
eltrombopag (25 mg/day from a period ranging between 2 and 14 weeks). In
the fifth patient CR was lost 7 weeks after treatment was interrupted because
of pregnancy. Finally, the median probability of maintaining CR-free survival
was 42 weeks.
Summary/Conclusions: Results of this study although limited by the small
sample sizeand the lack of a comparative randomized design suggest that
dexamethasone in combination with a thrombopoiesis stimulating agent led to
a long-lasting remission of ITP. High-dose dexamethasone may modify the
immunological milieu, resulting in an enhanced response to the thrombopoietin
receptor agonist.
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THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF
PRIMARY ITP: EXPERIENCE OF APPLICATION IN CLINICAL PRACTICE
ONE MEDICAL CENTER
I Zotova*, S Gritsaev, E Shilova, K Abdulkadyrov, A Chechetkin
Hematology, Russian Research Institute of Hematology, Saint-Petersburg,
Russian Federation
Background: Therapy of thrombopoietin receptor agonists(aTPO-r) is a new
approach to the treatment of patients with resistant primary ITP.Data on the
effectiveness and safety of aTPO-r outside of controlled clinical trials is limited.
Aims: To study the efficacy and safety of prolonged use of aTPO-r in routine
clinical practice in patients with chronic ITP in case of loss or inadequate
response to at least one line of therapy. To evaluate the possibility of achieving
a sustained response after the cessation of the aTPO-r therapy.
Methods: A retrospective analysis of aTPO-r threatment results in chronic ITP
patients in the outpatient department in the period from 2010 to 2015.Romi-
plostim therapy received 45 patients(group 1) and eltrombopag therapy-15
patients(group 2).Efficacy was evaluated by levels of platelet response and
the percentage of patients who managed to cancel or reduce the dose of drugs
for concomitant ITP therapy.The main indicators of safety were incidence of
adverse events,including thrombotic complications,bleeding and abnormalities
in laboratory parameters.
Results: Twenty-one patients (47%) from 1 group and four (28%) from group
2 received two or more lines ITP therapy, nine of them underwent splenectomy.
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Platelet response was achieved in 88% patients treated with romiplostim and
in 93% eltrombopag. During aTPO-r therapy the majority of patients (92% from
group 1 and 100% group 2) were able to completely cancel the previous long-
term steroid therapy. Resistant to aTPO-r therapy were 8 patients-5(11%) from
romiplostim group and 1(7%) eltrombopag group),three of them were splenec-
tomised in future. The most frequent adverse events in romiplostim group were
headache,arthralgia and dermatitis. This events were minimal and not require
change in therapy.In eltrombopag group noted shot-term hepatotoxicity with
the need for correction or therapy(dose reduction or treatment interruption)with-
out additional hepatotropic therapy. Cancel aTpo-r therapy was required in con-
nection with the development of thrombotic complications: 4% patients romi-
plostim group and 6% eltrombopag. Five patients (4 from the romiplostim group
and 1 from eltrombopag) maintained a stable remission after discontinuation
of aTPO-r therapy without any treatment.
Summary/Conclusions: Presented results confirm high efficiency,favorable
safety profile aTPO-r,importance of this drugs in the modern ITP therapy algo-
rithms,which was reflected in the inclusion of aTPO-r in national treatment stan-
darts of ITP therapy.
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ELTROMBOPAG FOR CHRONIC IMMUNE THROMBOCYTOPENIA: A
SINGLE CENTER EXPERIENCE
E Arshanskaya1,2, S Semochkin3,*, V Ivanova1, V Ptushkin1,2,3
1Hematology, City Clinical Hospital n.a. S.P. Botkin, 2Adolescent and Young
Hematology, Federal Research Clinical Center for Pediatric n.a. D.Rogachev,
3Oncology, Hematology and Radiotherapy, Pirogov Russian National Research
Medical University, Moscow, Russian Federation
Background: Immune thrombocytopenia (ITP) is an autoimmune disorder that
leads to peripheral destruction, as well as a decreased production of platelets.
The incidence of ITP in adults is around 3-4 per 100000 people per year. The
probability of spontaneous remission in adults is low. Up to 90% of cases
become chronic, and 10% do not respond to standard therapy. Eltrombopag is
a non-peptide thrombopoietin receptor agonist that has been approved for sec-
ond-line treatment of ITP.
Aims: The primary aims of the study were to determine the efficacy and safety
of long-term eltrombopag treatment in their own clinical practice.
Methods: Fifty adult chronic ITP patients who were refractory to previous ITP
treatments (platelet count <30,000 cells/µL) were enrolled in the study in the
period from October 2012 to December 2015. Treatment was started in all
patients with 50 mg/d oral eltrombopag. Response was assessed at 1, 2, 3
and 12 months. The target platelet response was defined as an increase in the
platelet count ≥50,000 cells/µL. The analysis is performed at the time of Feb-
ruare 2016.
Results: The median age was 57.4 years (range, 18.2-87.1 years), and 35
patients were women. The median number of prior ITP treatments was 2 (range,
0-4), including 9 (18%) patients who had undergone a splenectomy and 14
(28%) - rituximab. The median ITP duration before eltrombopag treatment was
3.1 (range, 0.6-37.9) years. The median platelet count at baseline was 12,000
(range, 1,000-27,000) cells/µL. After 1 month 25 (50%) achieved the target
platelet count (>50,000 cells/µL). The median platelet count reached 50,000
(range, 9,000-334,000) cells/µL. After 3 month 35 (70%) achieved the target
platelet count with median platelet count is 84,000 (range, 9,000-334,000)
cells/µL. After 12 month 37 (74%) achieved the target platelet count with median
platelet count is 107,000 (range, 22,000-330,000) cells/µL. The current median
duration of eltrombopag treatment was 14.8 (range, 1.1-40.3) months. 43 (86%)
patients continued therapy, and 7 (14%) patients who have not achieved a
response were excluded from the study for 2-3 months. On the likelihood of
achieving a platelet response at 3 months do not affect gender, age, previous
therapy (rituximab, splenectomy) and an initial platelet counts of less than or
more 15,000 cells/µL (p>0.05). Twelve patients had bleeding episodes of mild
to moderate severity. Thromboembolic events were not reported. Eltrombopag
is a well-tolerated treatment. Most reported adverse effects have been mild-
moderate and have not led to cessation of treatment.
Summary/Conclusions: Eltrombopag is well tolerated and effectively achieves
target platelet counts in refractory adult chronic ITP patients.
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MANAGEMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA, SINGLE
CENTRE EXPERIENCE
C Ionita1, I Ionita2, L Cheveresan2, D Calamar2, M Ionita3, D Oros2, H Ionita2,*
1Surgery, 2Hematology, 3Internal Medicine, University of Medicine and Farmacy
Victor Babes Timisoara, Timisoara, Romania
Background: The investigation and management of patients with Chronic
immune thrombocytopenic purpura (ITP) varies widely.
Aims: To evaluate the treatment of ITP patients in Departament of Hematology,
County Hospital, Timisoara during 10 years (I.2000-XII.2014).
Methods: A retrospective study for 325 ITP patients was performed. Patients
demographics, medical history, current treatments and side effects, were
abstracted from the patient’s medical charts for the 12 months prior to their
most recent visit.
Results: The average age was 43.2 years, with 57% women and 43% men.
Median time from the diagnosis of ITP to the start of the observational period
was 20 months. Prior to the observational period, 34% of patients have been
splenectomized and the most used treatment was corticosteroids. During the
observational period, 76% of the patients were treated. The most frequent rea-
sons given for treatment was low platelet count (67%), followed by bleeding
symptoms (53%). Corticosteroids represented 64% of treatments, followed by
IVIg (20%), azathioprine (8%), rituximab (8%). Only a few patients (six) were
treated with Nplate (Romiplostim). Splenectomies (15% of patients) and platelet
transfusions (32% of patients) were performed during the observational period.
For monitoring the platelet levels, 78% of patients visited their hematologist 1
to 10 times during the observation. Main reasons for a visit were low platelet
count (46% of visits) and bleeding (37% of visits). Overall, 39% of patients
required hospitalization. Mean duration of hospitalization was10,5 days.
Summary/Conclusions: The retrospective study of 325 patients provides ther-
apeutic outcomes resulting from treatment methods from our department. It
showed that bleeding symptoms remained quite frequent among patients with
chronic ITP, but lifethreatening bleeding rarely occur. Corticosteroids and
splenectomy represent the most used treatments from our department.
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PREGNANCY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA:
OUTCOMES DEPENDING ON THE THERAPEUTIC APPROACH
M Vinogradova1,*, E Mykhailova2, T Kirsanova1, Z Fidarova2, R Shmakov3
1Hematology, Federal Scientific Center for Obstetrics, Gynecology and Peri-
natology, 2Hematology, Federal Scientific Center for Hematology, 3Obstetrics,
Federal Scientific Center for Obstetrics, Gynecology and Perinatology, Moscow,
Russian Federation
Background: The management of paroxysmal nocturnal hemoglobinuria
(PNH) during pregnancy recently has been challenging because of a high risk
of severe maternal and fetal complications. Now pregnancy planning and
eculizumab treatment changed the prognosis and made it possible to minimize
complications associated with pregnancy in PNH.
Aims: To analyze the pregnancy outcomes in PNH depending on the thera-
peutic approach- using eculizumab or symptomatic treatment only. Establish-
ment of effective and safe algorithms for the management of pregnancy, deliv-
ery and postpartum period in PNH patients is crucial to their quality of life.
Methods: From 1999 to 2015, we have analyzed 17 pregnancies in eight
women with PNH, treated in our centers. Only three patients had planned the
pregnancy, most of cases- 14 (82,4%) were unplanned. The median age at
the start of pregnancy - 25 years (21-34). All of them were diagnosed with PNH
following treatment for aplastic anemia (AA) with antithymocyte globulin,
cyclosporine A and splenectomy in two cases before pregnancy. Most patients
were in partial remission of AA at the time of pregnancy- 8 (47,1%), complete
remission was achieved in 6 (35,3%). Three patients (17,6%) from 2013
exposed to eculizumab: two- started the treatment before conceiving, one-
received eculizumab from third trimester. Other women received only sympto-
matic therapy (82,3%), such as anticoagulation with low molecular weight
heparin in 29,4%, erythrocytes or platelets transfusion -35,3%, immunosupres-
sive therapy -17,6%. 
Results: The median of PNH granulocyte clone at the start of pregnancy was
74,7% (17,8-94,1). Progression of aplasia observed during 23,5% pregnancies,
but it was not severe and special treatment delayed until the completion of preg-
nancy. No thrombotic events during pregnancy and postpartum have been
observed. There were pregnancy complications: abortion threat 76,5%, fetal
growth retardation syndrome 3/9, preeclampsia 2/9. Pregnancies resulted in
the birth of healthy infants in 9 (52,9%) cases - three girls and six boys. There
were no adverse effects in the newborns from PNH patients both on eculizumab
and without it. Newborn health status differed from the norm only in the group
of patients without the targeted therapy due to the presence of complications,
mainly related to prematurity. Successful outcomes were in 3/3 pregnancies on
eculizumab treatment and in 6 (42,9%) cases without the drug. Caesarean sec-
tions were performed in all of births, early surgical delivery (30-34 weeks)- in
4/9 cases (preeclampsia-2, placenta previa- 1, breakthrough hemolysis-1).
Adverse pregnancy outcomes occurred only in patients not receiving eculizumab
and amounted to 8/14 (57,1%). 28,6% cases of pregnancy in the midst of illness
required the abortion for medical reasons. Spontaneous miscarriage was reg-
istered in 3 (21,4%) patients, fetal death on 27th gestation week- in one case
(7,1%). Transfusion requirements increased in two pregnancies (14,3%) with
symptomatic therapy, but did not increase on eculizumab. PNH granulocyte
clone size decreased in 2/3 cases of eculizumab treatment during pregnancy.
Summary/Conclusions: Pregnancy in PNH with symptomatic treatment with
a high probability ends adversely. The risk of complications during pregnancy
and postpartum in PNH may be minimized by pregnancy planning and applying
the management algorithm with eculizumab treatment. Despite the small num-
ber of observations, we can conclude that pregnancy outcomes in PNH patients
with eculizumab are better than with symptomatic therapy. Our experience con-
firms that eculizumab can be safely used in PNH during pregnancy. This ther-
apeutic approach may result in improved quality of life in PNH.
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EVALUATION OF THE IMPLEMENTATION OF A NURSE CASE-MANAGER
FOR THE DIAGNOSIS AND FOLLOW UP OF PATIENTS WITH SYMPTOMATIC
MULTIPLE MYELOMA
E Abella1,*, R Ben Azaiz Ben Lashen2, F García-Pallarols1, E Gimeno1, C Besses1
1Servei d’Hematologia, 2Case-manager, Servei d’Hematologia, Hospital del
Mar. IMIM, Barcelona, Spain
Background: An early diagnosis and prompt treatment of patients with symp-
tomatic multiple myeloma (SMM) is essential. Hence, the reduction in the timing
of diagnostic tests is a key element that allows to initiate early treatment and
to avoid secondary complications. The nurse case-manager (NCM) has a cru-
cial role reducing the time needed for the completion of tests and results as
well as in the optimization of visits in order to start therapy as soon as possible.
In addition, the NCM may improve the follow-up of patients by reducing admis-
sions and random visits, thus potentially decreasing costs.
Aims: To assess the intervention of the NCM in relation to: 1) the time needed
to establish the diagnosis and start treatment and 2) the follow-up process.
Methods: From September 2014 to January 2016 a prospective, single center
study in patients with suspected SMM (interventional group; IG) was started.
Results were compared to a control group (CG) of patients diagnosed of SMM
in the two years previous to the study. Primary end-points were: 1. Time from
referral to first visit in the Hematology Dept., 2. Time from referral to completion
of diagnostic tests, and 3. Time from referral to initiation of treatment. Secondary
objective was to assess hospital admission incidence during the first year of
follow-up in both groups. The effect of the NCM in time to event variables was
investigated using a multiple linear regression (MLR), using the corresponding
time variable as the dependent variable (Log10 transformed due to left skewed
distributions) and admission at diagnostic period as a confounder. Fisher exact
test was used for assessing incidence ratios. In IG, a 11-item patient satisfaction
questionnaire (PSQ) was obtained and a log of phone calls (PC) was recorded.
This log collects all contacts to the NCM made by IG patients. Bilateral p value
of 0.05 was considered statistically significant.
Results: During this period, 22 patients were studied in the IG and compared
to a CG of 37 patients. Table 1 shows the results of the effect of the NCM in
the three main end-points.The median value of PSQ was of 8,5/10, highlighting
a significant patient satisfaction. A reduction in the incidence of admissions
was observed (odds ratio: 1.20 p<0.05). During the study, 262 PC were col-
lected and divided according to the discussed topic. 48.2% of PC were due to
symptoms control: 85,7% were resolved by NCM or Physician and 14,3% were
attended at the hospital. 26.7% of PC were related to treatment information:
86,6% were resolved by NCM or Physician and only 13.3% needed to attend
the site. Finally, 25.1% of PC were related to schedule information and, of note,
98.4% were resolved during the call.
Table 1.
*5% trimmed mean;
cp value of CM effect in MLR.
Summary/Conclusions: The incorporation of a NCM for the diagnostic and
follow up of patients with SMM has allowed to reduce time from referral to visit,
completion of tests and initiation therapy in the IG when compared with CG.
Data collected during follow-up suggests that NCM involvement may lead to a
decrease in hospital costs, with a significant patient perceived satisfaction.
Further observation is warranted to confirm our preliminary findings.
PB2096
RELATIONS BETWEEN FAMILY FUNCTIONING AND HEALTH STATE OF
PATIENTS WITH CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
Y Lu*,xZhang, J Zhang, Y Zou,xQin
The third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Background: Chronic graft-versus-host disease(cGVHD) is a common com-
plication after allogeneic hematopoietic stem cell transplantation(allo-HSCT).
Patients with cutaneous cGVHD always changed much in appearance and
many of them were in the bad health of psychology.
Aims: The aim of this study was to explore the relations between family func-
tioning and health state of patients with cutaneous cGVHD.
Methods: A questionnaire survey was undertaken among patients with cuta-
neous cGVHD by the way of Family APGAR and COOP/WONGA. According
to the scores gained from family APGAR index questionnaire, the patients were
divided into two groups: family dysfunction group with scores between 0 and
6 and better family function group with scores between 7 and 10. The scores
of each item gained from COOP/WONGA were further compared between the
two groups and the correlations of the results were analyzed.
Results: 38.7 percent of the patients had good functioning families and 61.3
percent of them had defective functioning families.The differences between the
two type families in the total healthy state, emotion, social communication, daily
activity and pain had statistical significance (P<0.05). The family functioning
had positive relation with the health state in patients with cutaneous
cGVHD(r=0.901, P<0.01).The adaptability, cooperation, growth, emotion and
intimation in Family APGAR questionnaire survey and ten items in COOP/WON-
GA had positive relations (r=0.711 ~ 0.925, P<0.05, P<0.01).
Summary/Conclusions: The relation between the family functioning and the
health state of patients with cutaneous cGVHD is close. Medical workers should
pay attention to the desirable effects of the good family functioning on these
patients.
834 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
PB2097
REAL-WORLD CHARACTERISTICS, TREATMENT PATHWAYS AND
HEALTHCARE RESOURCE USE IN PATIENTS TREATED FOR RELAPSED
REFRACTORY MULTIPLE MYELOMA IN SPAIN: PRELIMINARY RESULTS
FROM THE PREMIERE STUDY
J Martinez-Lopez1, P Martín-Regueira2, A Zagorska2,*, C Lefevre2, C Roldán Acevedo2,
N Qizilbash3, B San José3, I Méndez3, LF Casado Montero4
1Hospital 12 de Octubre, Madrid, Spain, 2BMS, Princeton, United States, 3Oxon
Epidemiology Limited, Madrid, 4Hospital Virgen de la Salud, Toledo, Spain
Background: The management of patients (pts) with multiple myeloma (MM)
has changed considerably in recent years. Pts’ life expectancy has significantly
increased, and in some cases MM is now considered a chronic disease, with
pts receiving multiple lines of therapies. Real-world data on health and resource-
related outcomes of different treatment patterns may help promote more effi-
cient resource allocation within the National Health System.
Aims: To describe baseline characteristics, treatment patterns and healthcare
resource utilization (HCRU) in a cohort of pts treated for relapsed refractory
(RR) MM in Spain. 
Methods: The PREMIERE study is a retrospective chart review study conduct-
ed in a representative cohort of pts with RRMM in Spain. Enrolled pts were
aged ≥18 years, had ≥1 prior treatment for MM, and began a new line of therapy
(index therapy) during the recruitment period of 1st July 2010–30th June 2012
due to relapsing or refractory disease. Pts were followed from initiation of index
therapy (index date) for 3 years, or until death, loss to follow-up, or enrollment
into a clinical trial for MM. Using an interim data extraction from November 30th
2015, descriptive statistics of pt characteristics at initiation of index therapy
were calculated, and treatment patterns and HCRU in pts with complete data
at the end of the 3-year follow-up estimated. 
Results: Overall, 100 pts were included in this interim analysis; 91.0% had
received only 1 prior treatment for MM. 61.0% were male, 69.0% were aged
≥65 years; median weight was 70 kg (Q1–Q3: 62–80 kg). Median time from
MM diagnosis to enrollment was 2.2 years (range: 0.1–15.5 years). Most pts
had relapsed (74.0%) or refractory (13.0%) MM. The majority of pts were in
MM ISS stage II (31.3%) or III (29.3%). Most common previous therapies were
bortezomib (74.0%) and melphalan (68.0%). 28.0% of pts had received a stem
cell transplant (all autologous), 96.4% (27 pts) were single transplantations,
2.6% (1 pt) was a double transplant. 56 pts completed the 3-year follow-up
period. During the follow-up period, 50.0% (28 pts) initiated a subsequent 2nd
line of therapy after index therapy, 23.2% (13 pts) initiated a 3rd RR line, and
7.1% (4 pts) initiated a 4th. In 2nd, 3rd, and 4th lines, the most commonly pre-
scribed treatments were RevDex or bortezomib-based combination therapies.
The most commonly prescribed classes of medications for index therapy were
immunomodulators (24 pts, 42.9%; of whom 18 pts received RevDex), and
proteasome inhibitors (17 pts, 30.4%; of whom 13 pts received VelDex). 11 pts
(19.6%) received chemotherapeutic agents. Time from the start of index therapy
to the next line differed between RevDex and VelDex, with longer treatment
durations on RevDex (16.2 months) compared to VelDex (12.5 months; Table).
However, duration of subsequent lines (after progression on index therapy)
was longer for pts treated with VelDex as the 1st RR line (RevDex: 9.3 months;
VelDex: 15.1 months; Table). HCRU during the time spent on-therapy with the
index therapy during the 3-year follow up period showed overall higher resource
use for VelDex treated pts, especially for hospital consultations (Table).
Table 1.
Summary/Conclusions: These are the first data published describing treat-
ment patterns and HCRU in Spanish clinical practice. The most common pat-
terns for relapsed/refractory pts are bortezomib and lenalidomide-based
schemes. Data should be interpreted with caution given the small sample size;
final analyses of this study with the complete sample population will be pre-
sented at EHA.
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PHARMACOECONOMIC MODELLING OF TARGET THERAPY CHRONIC
MYELOGENOUS LEUKEMIA: EARLY AND LATE SWITCHING
V Shuvaev1,*, O Shukhov2, M Fominykh1, E Chelysheva2, I Martynkevich1,
A Turkina2, K Abdulkadyrov1
1Russian Research Institute of Hematology and Transfusiology, Saint-Peters-
burg, 2Hematology Research Center, Moscow, Russian Federation
Background: Early molecular response (EMR) achievement (BCR-ABL≤10%
by IS) at 3 months of tyrosine kinase inhibitors (TKI) treatment of chronic myel-
ogenous leukemia (CML) is recognized as an important prognostic marker of
subsequent therapy efficiency and survival. The time point of TKI switch from
first to second generations is one of the main differences between different
CML treatment guidelines. The attractive perspective of further improvement
in CML management is treatment free remission phase (TFR),-stop the TKI
therapy in patients with deep sustained molecular response under thorough
molecular monitoring.
Aims: The pharmacoeconomic modelling of comparison between early (3
moths) and late (6 months) switching from Imatinib to second generation TKI
(TKI2) depending on EMR achievement (BCR-ABL≤10% at 3 months of treat-
ment) with subsequent TKI therapy cessation in patients with stable long-lasting
(2 years) deep molecular response (MR4.0=BCR-ABL≤0,01% by IS).
Methods: We have used previously described Markov chain model for CML
management1. We constructed two model variances for early (3 months) and
late (6 months) time points of switches from Imatinib to TKI2 depending on
EMR achievement with subsequent TFR phase for patients with MR4.0 2-years
duration. The model size was 700 newly diagnosed CML patients yearly and
time horizon was 5 years. The transition rates (TKI response rates, MR4.0
rates, successful TFR rates) have been chosen from clinical trials (ENESTnd,
TIDEL-II, STIM, FILMC, DADI and own data). We have recalculated the total
costs from Russian roubles to Euros for clearly representation (February 2016).
Results: Early versus late switching lead to more frequent successful transition
to TFR (13,59% for early switch and 10,46% for late switch). The early switching
takes 8.54% more expenses (figure 1), but provided 6099 additional quality-
adjusted life years (QALY). Incremental cost-effectiveness ratio for early com-
pared to late switching is 543.2€ per 1 additional QALY, that is reasonable to
economically based implementation. Sensitivity analysis shows that in case of
TKI second generic substitution the costs for early and late switching should
be equal. It can yield extra cost-free efficiency.
Figure 1.
Summary/Conclusions: The pharmacoeconomic modelling can simulate
budget burden for various modifications of diagnostic and therapeutic tech-
niques in CML management with evaluation of its economical and clinical worth.
References
1. V.A.Shuvaev, A.S.Abdulkadyrova, I.S.Martynkevich, V.Y.Udaleva, M.S.Fominykh,
    I.I.Zotova, R.A.Golovchenko, A.A.Zhernyakova, L.S.Martynenko, E.V.Petrova, 
    M.A.Kozlovskaya, M.P.Ivanova, N.Y.Cybakova, A.V.Schmidt, K.M.Abdulkadyrov.
    Bonus free life’s in CML-pharmacoeconomic modeling first and second
    generation TKIs in first-line CML treatment with therapy cessation ELN




THE APPLICATION OF GENOMIC MEDICINE IN HAEMATOLOGY: THE
CHALLENGES AND ETHICAL IMPLICATIONS
J Rubasingham*
Department of Medicine, Wexham Park Hospital, Slough, United Kingdom
haematologica | 2016; 101(s1) | 835
Copenhagen, Denmark, June 9 – 12, 2016
Background: Two scientists walked into a Cambridgeshire pub in 1953 and
announced that they had discovered ‘the secret of life’. Since the discovery of
DNA by Watson and Crick, the field of human molecular biology and genetics
has grown in leaps and bounds over the last few decades. Although it took
almost ten years for the first ever human genome to be sequenced, today, with
technology referred to as the ‘next generation sequencing’, millions of frag-
ments of DNA from a sample are analysed on parallel sequencing platforms,
facilitating high-throughput sequencing and allowing the entire genome to be
sequenced in less than a day, at a considerably less cost. The effects of these
advancements have been felt in clinical haematology, arguably more so than
in the other specialties, given the application of cancer genomics in haematol-
ogy. ‘Targeted therapy’ and ‘personalised medicine’ have become the buzz
words in any specialty dealing with cancer. Are these new developments the
pinnacle of modern medicine as we are often led to believe?
Aims: Although there is an abundance of studies on the scientific aspects of
genomic medicine, there is surprisingly sparse amount of literature exploring
the ethical implications and challenges of genomic medicine, even more so as
it applies to haematology. This study aims to evaluate the place of genomic
medicine in clinical haematology and provide a critical appraisal, focussing on
the challenges it poses and ethical implications that arise from it. 
Methods: MEDLINE database was searched using the keywords ‘genomic’,
‘haematology’ and ‘ethics’ to identify the relevant literature. The governing prin-
ciples of modern medical ethics were applied to the topic in question. 
Results: Several issues were identified from studies looking at ethical issues
arising from genomic medicine. A common theme was responsibility placed on
researchers to disclose potentially beneficial genetic information to the partic-
ipants or patients. This is further complicated when the patient has made an
advance decision explicitly expressing that s/he would not want to be contacted
should further information become available. Although most would respect the
patient’s autonomy in this context, some might argue (controversially) that
depending on the gravity of information being withheld, a paternalistic approach
would be warranted. A similar conundrum may also arise when a clinician may
be aware of genetic information of potential benefit to a patient which they may
have acquired from the patient’s relative. Although next generation sequencing
has made genomic medicine much cheaper, it still remains a commodity which
is not commonly used in everyday clinical practice. There is inter-regional and
intraregional variation in the availability of this specialist service, raising the
ethical issues of resource allocation, justice and equity. Of recent times, there
have been many large population based genomic studies such as the 1000
genomes project and the recently launched 100 000 genomes project in the
UK. Although some of these projects obtain genomic data from patient popu-
lations who donate their genetic material with altruistic motives, it can open up
opportunities for pharmaceutical companies to benefit financially from these
studies, creating a very grey area in modern ethics.
Summary/Conclusions: Although there has been tremendous benefits to
patients from the advances in genomic medicine, particularly as it applies to
cancer genomics and targeted therapy in haematology, it is not without chal-
lenges. Several ethically ambiguous issues arise, particularly in the conduct of
research in this rapidly advancing field.
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PROSPECTIVE MULTICENTER PROGRAM OF REMOTE CONTROL IN 
ANTIVITAMIN K ANTICOAGULANTS
M Gómez Crespo1,*, A Pascual Martinez2, C Teran Benzaquen3, R Vidal Laso3,
P Llamas Sillero3
1Hematology, Fundación Jimenez Díaz, 2Hospital Infanta Elena, 3Hematology,
MADRID, Spain
Background: The use of oral anticoagulant therapy with VKA (OAT) has pro-
gressively increased in the cardiovascular diseases, such as atrial fibrillation,
valvular diseases,and venous thromboembolic disorders. The OAT is currently
used in 1.7-2% of the population. The grade of anticoagulation control is a vital
aspect in the quality of clinical care of these patients. The fact that they remain
above or below the optimal range exposes the patients to an increased risk of
bleeding or stroke. The new technologies of information and communication
allow us to optimize the control of these treatments significantly improving their
quality of life and safety 
Aims: 1. To evaluate the efficacy and safety of remote control (RC) of OAT in
a group of 100 patients. 2. To analyze the degree of satisfaction and quality of
life of patients included in the program.
Methods: Prospective multicenter study of the first 100 patients included in
our program. The study has been carried out from June 2015 to nowadays.
The institutional review board waived informed consent for this health care
program that was compliant with the Spanish law in force. The participating
centers are: Hospital Universitario Fundación Jiménez Díaz, Hospital Univer-
sitario Infanta Elena, Hospital Universitario Rey Juan Carlos and Hospital Gen-
eral de Villalba. Patients were included if meeting the following inclusion criteria:
a history of use of OAT for at least three months, a valid chronic indication for
the treatment and patients that were capable of handling computerized devices.
The exclusion criteria were: patients under age of 16 years, patients with severe
diseases or with less than 3 month of treatment with OAT and those who
expressed their desire not to participate in the study. We created a reference
unit of OAT composed of doctors and specialized nurses: the doctors made
the prescription and gave the specific instructions to the nurses. Once they
were taught, they are in charge of the active education of patients.
Results: In the first 100 patients included, there there isn’t any complication
with the treatment and the preliminar results of the quality life surveys are very
good. The patients were evaluated in the OAT clinics, and were included when
meeting the above mentioned inclusion criteria. Once they had signed the
informed consent. After work, in a remote service,we generated a note that
was accesible online to the patients in the web Patient Folder. The medical
note consists of the prescription. When the control was needed, patient can
introduce the result of the digital INR in the same Patient Portal. This web inter-
action prevents unnecessary movements of the patients and/or family mem-
bers. There is no separation from the center. 
Summary/Conclusions: Our RC program is a new technological system that
assists patients in the control of OAT from their home.The program consists in
adapting new technologies to the healthcare system to gain in quality of life,
with fewer complications, greater safety and comfort for patients and reducing
travelling to the hospital and costs. With this program the patients are an actives
subjects in the management of their disease.
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A NEW MODEL OF ORAL HYGIEN FOR REDUCTION AND PREVENTION
OF MUCOSITIS IN PATIENTS UNDERGOING MYELOABLATIVE STEM
CELL TRANSPLANTATION
V Stacchini1,*, M Miceli1, E Orciuolo2, F Papineschi2, L Iovino2, M Gabriele1,
MR Giuca1, E Benedetti2, M Petrini2
1UO Odontostomatologia e Chirurgia del cavo orale, 2UO Ematologia, Univer-
sity Of Pisa, Pisa, Italy
Background: Mucositis is a very common complication of allogeneic stem cell
transplantation (allo-SCT). The damage due to radio-chemotherapy is com-
bined with the risk of superinfection. Protocols of oral hygiene play an important
role to prevent the onset of oral infections and may improve disconfort due to
mucositis. 
Aims: We are we presenting data on mucositis prevention using professional
oral hygiene and specific dental aids.
Methods: We prospectively enrolled patients who underwent allo-SCT for
haematological malignancies. We joined to standard procedures (toothbrush,
clorexidine mouthwashes) a set of specific tools, with a daily schedule of appli-
cation. An oral hygiene session was performed in all patients before the date
of recovery. The protocol provide, from the first day of hospitalization, the use
of: manual toothbrush with bristles of 0,12 mm of diameter, super-soft; anti-
bacterial toothpaste containing colostrum and antimicrobial enzymes; antibac-
terial mouthwash containing lisozyme, lactoferrin, lactoperoxidase and extract-
ed colostrum, fluorine, xilitole and aloe vera. From the day 1 after stem cell
infusion: manual toothbrush with bristles of 0,10 mm of diameter, ultra-soft;
mouthwash containing maltodextrin, propylene glycol, hydroxyethylcellulose,
sodium hyaluronate, sodium saccarhin and citric acid. Patients were clinically
supervised every day, until engraftment or resolution of mouth lesions, through
clinical examination, WHO grading of mucositis, VAS scale for the pain.
Results: We prospectively enrolled 8 patients that underwent to myeloablative
conditioning regiment with TBF for haematological malignancies, comparing
results with an historical cohort. Results are expressed in figure.
Figure 1.
Summary/Conclusions: Patients who followed a regular schedule of oral
hygiene, before and after the transplant, had a lower pain reported in VAS
scale, a significant lower level of mucosyte, and a later onset of mouth lesions,
in comparison of patients who did not follow the procedure and in comparison
of a control group, extracted by the clinical records of allo-SCTs of the previous
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year. It has implication for the administration of analgesic drugs (opioids),
notably lower in patients treated with protocol. This finding demonstrate the
importance of oral hygiene in allo-SCT setting in preventing high-grade
mucosytis, suggesting the institution of specific profession of dental hygienist
for haematological patients.
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EVALUATION OF PRE-ANALYTIC AND POST-ANALYTIC PHASES OF THE
COAGULATION LABORATORY IN HACETTEPE UNIVERSITY HOSPITALS
ZG Dikmen, F Akbiyik*
Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: The pre-analytical and post-analytical phase in a test cycle con-
tributes up to 93% of total laboratory errors. Our coagulation laboratory provides
routine and stat tests for inpatients and outpatients in Hacettepe University
Hospitals, including 1000 beds. Joint Commission International guidelines is
followed in our laboratory; we document the unsuitable samples rejected by
laboratory and we record critical value notifications, including the person who
received the notification (physician, nurse or medical staff), the time and the
date of communication. Hence, rejection of unsuitable samples and critical
value notification are the quality indicators of our laboratory.
Aims: In this study, we aimed to evaluate the pre-analytical problems and crit-
ical values recorded on coagulation and hemostasis tests over one year period
in 2015.
Methods: Venous blood samples for routine coagulation testing were consid-
ered unsuitable for analysis according to the following specimen rejection cri-
teria of our laboratory; inappropriate clinical orders, inappropriate volume (inad-
equate blood to anticoagulant ratio), incorrect tube, clotting, delayed transport
and visible hemolysis or fibrin following centrifugation. During day time and
night shift, authorized laboratory secretary was responsible for reporting of crit-
ical values by telephone communication and reverse reading. The critical values
in our laboratory were as follows; prothrombin time/international normalized
ratio (PT/INR)>5, activated partial thromboplastin time (aPTT)>100 seconds,
fibrinogen<100 mg/dL, factor levels<5% and anti-thrombin III<50%.
Results: Total coagulation test request was 155.945 in one year and 5.090
tubes were rejected according to the rejection criteria of our laboratory. On over-
all, the more frequent pre-analytical problems could be referred as clotting
(38.4%), following inappropriate volume (33.2%), inappropriate clinical orders
(7.3%), misidentification (6.5%), hemolysis (6%), incorrect tube (3.8%), fibrin
(3.3%) and delayed transport (1.5%), respectively. Among 155.945 tests per-
formed in 2015, we reported 475 critical values, the ratio was 0.3% in total. The
critical value notification ratio was 56% for INR, 23% for factor levels, 12.2% for
fibrinogen, 5.5% for antithrombin III and 3% for aPTT. The critical value reporting
rate was 97-99%, dropped call ratio was approximately 1-3% of all.
Summary/Conclusions: We detected an overall specimen rejection rate of
3.2% in coagulation laboratory. By documentation of rejected samples and peri-
odic training of healthcare personnel, we expect to decrease sample rejection
ratios below 1% and to improve total quality management of the laboratory.
Our critical value reporting rate was 97-99%, and clinicians were notified of
patients’ life-threatening results within 15 minutes. We believe that rapid noti-
fication of abnormal test results has an impact on patient outcomes. This is the
first report on the pre-analytical and post-analytical phases of coagulation lab-
oratory in Turkey. To improve patient outcome, each laboratory has to establish
its own specimen rejection criterias and reporting policy for critical values.
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DEVELOPMENT OF PATIENT-REPORTED OUTCOMES SYMPTOM MEASURE
FOR PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA
(NTDT-PRO)
A Taher1,*, A Saliba1, A Kattamis2, R Ward3, G Harding4,xHu5, D Mahmoud5
1American University Beirut, Beirut, Lebanon, 2Aghia Sophia Children’s Hos-
pital, Athens, Greece, 3University Health Network, Toronto, Canada, 4Evidera,
Bethesda, 5Celgene Corp., Summit, United States
Background: Currently, there is no disease-specific Patient-Reported Out-
comes (PRO) measure available to assess key symptoms experienced by
patients with non-transfusion-dependent thalassemia (NTDT).
Aims: To develop a symptom outcomes measure for patients with NTDT for
use in clinical trials.
Methods: A qualitative study was conducted to develop the NTDT-PRO symp-
tom measure consistent with regulatory requirements. The instrument was
developed based on concept elicitation interviews, input from clinical experts,
and refined through a process of cognitive interviews. Concept elicitation inter-
views were conducted among a total of 25 NTDT patients recruited from three
countries (Lebanon, Greece, and Canada). Findings from these interviews were
used to generate an item pool, inform response options, and determine appro-
priate recall period. Cognitive interviews were subsequently conducted among
subjects in Greece and Lebanon (N=21) to further support saturation and exam-
ine the relevance, clarity and understanding of the items among the target pop-
ulation. All interviews were conducted in person in the local language with writ-
ten informed consent obtained, audio-recorded, transcribed and translated back
into English for evaluation.
Results: Based on findings from concept elicitation interviews, saturation of
important underlying concepts was obtained and a total of nine symptoms were
included in the NTDT-PRO Version 1. Instructions and item stems were derived
from patient language elicited during the interviews. An 11-point numeric rating
scale (0-10) was used for the response options, anchored on either end by the
absence of the symptom and extreme symptom. A daily recall period (“during the
past 24 hours”) was selected based on the day-to-day variability in the symptom
experience. Findings from the cognitive interviews indicate that subjects under-
stood the instructions and that the daily recall period was appropriate. Subjects
understood the items as intended, with a few minor exceptions. Four items were
deleted as they were not considered core symptoms, and one item was added
to address the symptom both with and without physical activity. The NTDT-PRO
Version 2 includes six items that address three key symptoms of tiredness, weak-
ness, and shortness of breath both during physical activity and at rest.
Summary/Conclusions: The NTDT-PRO Version 2 consists of six items to
assess the key symptoms of NTDT, including tiredness, weakness, and short-
ness of breath using a 24-hour recall period, with plans to further evaluate the
measures in an ongoing observational study and for eventual inclusion into a
randomized phase 3 study.
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IMPACT OF ECONOMIC CRISIS ON THE MANAGEMENT OF HEMOPHILIA
PATIENTS IN GREECE
A Teli1, V Gourtsa1, G Lakaki1, I Christou2, M Economou1,*
11st Pediatric Department, Aristotle University of Thessaloniki, 2Pharmacy, Hip-
pokration General Hospital of Thessaloniki, Thessaloniki, Greece
Background: Economic crisis has had a major impact on public health in
Greece during the last years, negatively affecting both ability for health insur-
ance coverage and availability of medical services. As all patients suffering
from chronic illnesses, hemophilia patients have had to face difficulties resulting
from the austerity measures. 
Aims: Purpose of the present retrospective study was to evaluate the impact
of economic crisis on management of hemophilia patients for the 6 year crisis
period (January 2010 - December 2015) in a single pediatric institution. 
Methods: The study included hemophilia A patients followed at the Pediatric
Center for Bleeding Disorders of Aristotle University of Thessaloniki, one of the
two pediatric hemophilia centers in Greece. Data were recorded 23 for patients
with severe hemophilia (FVIII <1%) or moderate hemophilia (FVIII 1-5%) pre-
senting with a severe bleeding phenotype. Patients with inhibitor presence were
excluded from the study. A subgroup consisting of 12 patients on regular pro-
phylaxis throughout the studied years was separately evaluated. Data assessed
included annual factor consumption (IU/kg) and annual cost for the years stud-
ied. The prices for factor concentrates were obtained from the Greek National
Organization for Medicines. Changes in patients’ family working status and
subsequent insurance coverage were also recorded.
Results: Mean age of patients was 11.3 year (range 2-19 years). The mean
annual factor consumption did not significantly differ between the onset of crisis
and the following years in both groups studied (i.e. total and regular prophylaxis
patients). Similarly, the average annual cost per patient did not significantly
change during the crisis years for either group. In specific, mean factor con-
sumption for the whole group at starting and closing years was
334.167±227.536 U/KG and 318.235±105.92 U/KG, respectively, with respec-
tive mean annual costs 114,864±82,097 and 108,989±62,862 euros. For the
regular prophylaxis group mean factor consumption for starting and closing
years was 350.16± 268482 U/KG and 318.235±105.92 U/KG, respectively, with
mean annual costs 114,187±97,772 and 134,61±54,159 euros. With regards
to employment and insurance ability, one patient lost coverage due to parents’
unemployment. However, Social Security provided cost-free factor administra-
tion, enabling patient to continue his treatment. The only change recorded
between crisis onset and following years was a significant increase in number
of hospital visits required in order to have access to factor administration, as a
result of limited amount of factor administered by the hospital at each visit for
home treatment.
Summary/Conclusions: Although Greece has seriously suffered during the
last years because of the economic crisis, provision for health has managed to
survive - at least for hemophilia patients. Albeit, without some cost on the
patients’ part.
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TO PROMOTE THE MEDICAL QUALITY OF HEMATOPOIETIC MALIGNANCIES
BY INTERGRATION OF QUALITY CONTROL CIRCLE AND PHS WIN-WIN
CONCEPT
QL Jiang1,*, QF Liu1, WY Li1, HS Wu1, PL Hu1, J Sun1, CJ Zhao2, H Huang1,
QS Mai2
1Nanfang Hospital, 2Southern Medical University, Guangzhou, China
Background: Infection and bleeding contribute to about 2/3 and 1/3 of mortality
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associated with hematopoietic malignancies in Nanfang Hospital, China.
Patients, hospital staff, medical students and social groups were involved in
this QCC.
Aims: To promote the medical quality, two rounds of Quality Control Circle (QCC)
were carried out, with the aim to solve the above mentioned complications.
Methods: 1 The perianal infection is the most common infection for hematopoi-
etic malignancies (up to 60%—100%, Ann Hematol. 2003; 82:S167). With
severe immunodeficiency, the perianal infection rate was 17.2% in the bone
marrow transplantation center (2013Apr.-Sep.). Then QCC1 was carried out
following the 10 steps of Plan-Do-Check-Action. Bacterial colony culture exper-
iments from perianal skin before and after sanitization were performed. Since
warm aqueous solution of potassium permanganate are recommended for san-
itization, such bacterial colony culture is also used to find a proper drug concen-
tration, water temperature and soaking time etc. Eventually a tool kit was devel-
oped (CN patent No.201520820954.7) to ensure the standardization of proce-
dures. 2 With the team of QCC1, we started QCC2 for decreasing mortality due
to bleeding, the shortfall being the insufficient supply of platelets. Tackling of
this condition is more complicated and demanding, which also exists in many
developing countries. We integrated the functioning of PHS, which stands for
patients (P); hospital staff (H); students and social workers (S); in accordance
with the complementary advantages (Table 1) for co-operation. Four strategies
were incorporated as: Establishing a professional team, systematic education,
setting up a platelet donor bank and a new platelet harvest station.
Results: 1 The perianal infection rate gradually decreased from 17.2% to
5.25% and subsequently declined in the following year. Apparently each case
of perianal infection could detrimentally prolong hospitalization by ≥2w and
approximately 28,000 Yuan of expenditure for treatment, as well as witnessing
>4,000/year such hospitalized cases in Nanfang Hospital and from amongst
40,000 new findings of leukemia in China, this QCC1 was awarded the first
Prize of Chinese QCC in 2014. 2 Comparing 9 months(m) before QCC2
(2014Feb.-Oct.) and 9 m later (2014Nov.-2015July), we found that the number
of platelet transfusions in the department of Hematology increased from 2815U
to 3674U (130.5%) and the success rate of applications increased from 58.67%
to 75.77%. Within 9 m, QCC2 helped to establish a professional team named
as Blood and Bone marrow China (BBCn) which have conducted 19 public
lectures, a proficient platelet donors Bank with 448 volunteers and donated
135U of platelet directly. Interestingly, a new platelet harvest station is under
construction in Nanfang Hospital, which will harvest thousands of new blood
platelets each year. Mortality due to bleeding will significantly decrease there-
after. Table 1. Analysis of patient, hospital stuff, student and society (PHS)
Table 1.
Figure 1.
Summary/Conclusions: QCC and PHS win-win concept could promote the
medical quality of hematopoietic malignancies. Most beneficially, they will also
alleviate the social conflicts between doctors and patients tremendously in China.
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PREGNANCY-ASSOCIATED ATYPICAL HEMOLYTIC UREMIC SYNDROME
T Kirsanova, M Vinogradova*
Hematology, Federal Scientific Center for Obstetrics, Gynecology and Perina-
tology, Moscow, Russian Federation
Background: Pregnancy-associated atypical hemolytic uremic syndrome (P-
aHUS) is a rare catastrophic disorder defined by the occurrence of fibrin and/or
platelet thrombi in the microvasculature, resulting in microangiopathic hemolytic
anemia (MAHA) and thrombocytopenia without Shiga toxin and ADAMTS13
deficiency. An estimated incidence of P-aHUS is approximately 1 in 25,000
pregnancies during antepartum and puerperium. It is associated with a signif-
icant perinatal or maternal morbidity and mortality. 
Aims: The evaluation of outcomes in P-aHUS. The establishment of adequate
strategies for the timely diagnosis and treatment is very important to improve
patient survival and pregnancy outcomes.
Methods: This is a retrospective analysis of aHUS during pregnancy treated
in our center and other clinics via telemedicine between November 2010 and
February 2016. Nine women mean age 30,4 years (range: 21-36) were diag-
nosed with aHUS. Most of them (8/9) presented postpartum, 1/9 developed
aHUS in II trimester. All had MAHA, thrombocytopenia and severe organ dys-
function. 7/9 had at least one pregnancy before the onset of P-aHUS. 
Results: Mean nadir hemoglobin was 60,3 g/L (range 46-69); mean nadir platelet
count- 53,000/mm3 (range 16,000-100,000); mean peak serum creatinine- 454
mkmol/l (range 67-998), mean peak LDH- 2,953 IU/L (range 996–11,360). 6/9
required hemodialysis and mechanical ventilation. All underwent plasmaex-
change or plasma infusion and all of them was appointed unfractionated or low
molecular weight heparins. Signs of mild preeclampsia were observed in 8/9
patients with an average of 7 days (3-14) to debut P-aHUS, 4 of them were diag-
nosed with fetal death on 27-34 gestation weeks. Live births resulted in 5/9 of
pregnancies on 28-38 weeks (median 32). Since the onset of the disease state
of the patient rapidly deteriorated: acute renal failure was detected in 8/9 patients
(6 cases performed hemodialysis), adult respiratory distress syndrome, requiring
mechanical ventilation, was diagnosed in 6/9, 6/9 have pankreatit, neurological
symptoms were accompanied by observations of 5/9, 2/9 observed in dilated
cardiomyopathy and ischemic colitis in one case. The most common organ dys-
function was kidney failure (8/9). 8/9 patients received therapy with fresh frozen
plasma. Treatment with eculizumab was started on 4 patients on 5-17 days from
the time of P-aHUS debut (median, 7), but the full course was not held anyone:
performed from 1 to 3 injections of 900 mg (median 1). All patients received pro-
phylactic anticoagulation. Outcomes as a whole are extremely unfavorable: 5 of
9 patients died (3/5 causes of death-septic complications, thrombosis- 1, hem-
orrhage- 1), 2/9 - reached end-stage renal failure by 1 month, 2/9 gained the
renal function impairment (CKD3-4) by last follow-up.
Summary/Conclusions: P-aHUS is a severe life-threatening disorder asso-
ciated with a significant perinatal and maternal morbidity and mortality. We
evaluated the outcomes of P-aHUS. Currently, they are extremely pessimistic
now. Diagnostic and therapeutic approaches for this disease requires further
study in order to optimize results. Clinical suspicion, early identification and
effective approaches including target therapy can improve the pregnancy out-
comes and prognosis in general.
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LAMIVUDINE FOR PREVENTION OF REACTIVATION IN OCCULT HEPATITIS
B IN PATIENTS WITH NON-HODGKIN LYMPHOMA CD20+ UNDERGOING
CHEMOTHERAPY: A COST-EFFECTIVE ANALYSIS
C Cerchione1,*, A De Renzo2, M Masarone3, C Cimmino4, M Di Perna4,
G Signoriello5, M Persico3, F Pane1
1Hematology, Università Federico II, 2Ematologia e trapianto/au federico ii,
Napoli, 3Hepatology, Ospedale di Salerno, Salerno, 4Hematology, Ematologia
e trapianto/au federico ii, 5Statistica, Università Federico II, Napoli, Italy
Background: Occult HBV infections (OBI) are defined by the persistence of
HBV in the liver without serum HBsAg and HBV-DNA. They can represent a life
threatening event during immunosuppressive CHT. OBI occur in approximately
18% of HBcAb+ patients. Guidelines suggest surveillance for HBV markers in
immunosuppressed patients, in particular in treatment with monoclonal antibod-
ies. In our study, the prevalence of OBI reactivation in NHL, in 498 patients of
our centre, was 10.42% in HBcAb+ HBsAb- patients. In this work, a cost-effec-
tiveness analysis regarding the use of Lamivudine for the prevention of reacti-
vation in OBI in patients with NHL undergoing chemotherapy with or without
Rituximab was performed. In fact, considering guidelines and literature, universal
prophylaxis should have been applied to all HBcAb + HBsAg - patients. A cost-
benefit issue arises: is it more cost-effective to treat all the HBcAb + HBsAg -
patietns with Lamivudine to prevent the OBI reactivation occurence in a small
quote of them, or may it be more effective a “wait and see” protocol?
Aims: Our idea was to perform a cost-effectiveness analysis, comparing the
costs of prophylaxis of an eventual HBV reactivation and the “monitoring”
approach that was used in our patients based on international guidelines.
Methods: The cost of Lamivudine prophylaxis was calculated in a time interval
of 12 months, which encompasses the time of a standard Rituximab-containing
regimen and a minimum time of follow-up. It has been noticed that, very often,
NHL patients need more than one treatment to obtain remission, and, some-
times, if they do not obtain a CR, undergo to long-term “maintenance” with Rit-
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uximab. These patients (HBcAb +) are at high risk of HBV reactivations, due to
long periods of immunosuppression.
Results: Nevertheless, even if our calculations underestimated the costs of
prophylaxis, the “monitoring approach” resulted cost-effective. Moreover, even
though in our series no serious events in terms of morbidity and/or mortality
occurred, in other papers a monitoring approach did not guarantee patients
survival. These detrimental results could be ascribed to the delayed start of
lamivudine treatment if the monitoring is not adequately strict. Also, it has been
reported that performing only the transaminase monitoring should not be
acceptable to prevent severe reactivations.
Table 1.
Summary/Conclusions: Our monitoring approach resulted efficacious prob-
ably because of the monthly ALT assay was strictly observed.
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AN HPLC AND 1H NMR STUDY OF THE CYTARABINE DEGRADATION IN
CLINICAL CONDITIONS TO AVOID DRUG WASTE, DECREASE THERAPY
COSTS AND IMPROVE PATIENT COMPLIANCE
M De Nisco1, C Cerchione2,*, V Martinelli2, N Pugliese2, S Pedatella1, L Catalano2,
M Manfra3, N Marra4, VD Iula5, F Pagano6, M Picardi2, F Pane2
1Dipartimento di Scienze Chimiche, Università di Napoli Federico II, 2Hematol-
ogy, Ematologia e trapianto/au federico ii, Napoli, 3Dipartimento di Scienze,
Università della Basilicata, Potenza, 4Oncoematologia, A.O.R.N. Santobono-
Pausilipon Hospital, 5Microbiologia Clinica, Dipartimento di Medicina Moleco-
lare e Biotecnologie Mediche, Napoli, 6Dipartimento di Farmacia, Università di
Salerno, Fisciano (SA), Italy
Background: Cytarabine, the 4-Amino-1-(β-D-arabinofuranosyl)-2(1H)-pyrim-
idinone, (ARA-C), is an antimetabolite cytidine analogue used worldwide as
key drug in the management of leukaemia. As specified in the manufacturers’
instructions, once the components-sterile water and ARA-C powder-are unpack-
aged and mixed, the solution begins to degrade after 6 hours at room temper-
ature and 12 hours at 4°C.
Aims: To evaluate how to avoid wasting the drug in short-term low dose treat-
ment regimens, the reconstituted samples, stored in the dark at 25° and 4° C,
were analyzed every day of the test week by reversed phase high-performance
liquid chromatography (RP-UHPLC) and high-field nuclear magnetic resonance
spectroscopy (1H NMR).
Methods: All the samples remained unchanged for the entire week, which cor-
responds to the time required to administer the entire commercial drug package
during low-dose therapeutic regimens. The drug solution was stored in a glass
container at 4 °C in an ordinary freezer and drawn with sterile plastic syringes;
during this period, no bacterial or fungal contamination was observed. After
one month, the samples presented evidence of a degradation product (0.8%
of starting material), identified as 1-(β-D-arabinofuranosyl)-pyrimidine-2,4-
(1H,3H)-dione (ARA-U). 
Results: Our findings provide evidence of an optimal physico-chemical stability
and microbiological sterility of ARA-C solution stored for one week in the dark,
at 4°C. This encourages the use of the reconstituted drug for the time required
for short-term multi-dose treatments, avoiding drug waste, patient stress and
hospital crowding. Moreover, it seems possible to leave in the same container
surplus of different ARA-C packages, improving the cost-effectiveness of the
treatment without affecting its efficacy and safety. An additional advantage is
the fact that patients are able to have the treatment administered at home.
Summary/Conclusions: Our results show that a solution of reconstituted ARA-
C could be employed for a longer period that what suggested by the manufac-
turers. In fact, patients could receive a safe aliquot to be used at home for
short-term treatments, thus optimizing the use of aliquot residues and avoiding
vial manipulation and the production of special waste material.
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COST ANALYSIS OF THE END OF LIFE CARE IN HEMATOLOGICAL
MALIGNANCY PATIENTS
M Chiba1,*, M Kurita1, S Osawa1, S Suzuki2, E Sasai1, K Sugai2, S Hagiwara3
1Department of Nursing, 2Hospital Information Management Office, 3Division
of Hematology, Internal Medicine, National Center for Global Health and Med-
icine, Shinjuku, Japan
Background: Most hematological malignancies remain chemo-sensitiveness
even in the end stage, unlike solid tumors. Sometimes it is difficult to determine
the timing to switch to palliative care. Therefore, aggressive treatments often
apply to patients in the end of life (EOL). On the other hand, aggressive EOL
care causes deterioration of patients’ quality of life, depression among family
members, and increase of medical expenses.
Aims: We analyzed the contents of medical treatment and the costs to clarify
the issues of aggressive EOL care for patients with hematological malignancies.
Methods: Hematological malignancy patients who died in the hemato-oncology
unit of a general acute hospital from September 2010 to August 2015, and as
the control group, all patients who discharged alive in the same period were
studied. The duration of hospital stay, medical cost, contents of treatment, treat-
ment policy, intervention by palliative care team, disease, and disease status
were analyzed. T-test and univariate analysis of variance were used to test the
factors associated with the cost using SPSS version 23.
Results: We analyzed 2984 patients who were discharged alive and 164
patients who died in our hospital. In patients who died, the mean age was 65.3
years old, 116 (70.7%) were men. Diseases were 54 (32.9%) with multiple
myeloma, 38 with (56.1%) malignant lymphoma, 27 (16.5%) with leukemia, 41
(25.0%) with myelodysplastic syndrome. Twelve (7.3%) were in complete
response, 6 (3.7%) in partial response, 19 (11.6%) in stable disease, 105
(60.4%) in progression of disease, and 22 (13.4%) were with newly diagnosed
disease. Treatment policies were 95 (57.9%) in aggressive anti-tumor and/or
support therapy, 69 (42.1%) in palliative care. In patients who died in the hos-
pital, mean medical cost of last hospitalization was 60,200 euro, and the dura-
tion of stay was 63.4 days. Those were significantly higher than the mean cost
(14,550 euro, p<0.001) and the duration of hospital stay (23.3 days, p<0.001)
of patients who were discharged alive. Though the number of patients who
died was only 5% of total number of inpatients, the medical expense accounted
for 18.5% of total medical cost in the hematology department. Although, the
treatment policy was shifted from aggressive therapy to palliative care in most
patients (68% in the last 2 weeks, and 71% in the last week), the medical cost
per week increased (p=0.020). The half of the cost in the last 2 weeks was the
fee for blood transfusion and antibiotics. In the last 2 weeks, 11 days of blood
sugar monitoring, 9 times of blood examination, and 5 times of roentgenological
examination was performed per patient. In the last week, intravenous hyperal-
imentation was given in 50.6% of patients, vasopressors was used in 31.7%,
hemodialysis was performed in 8.5%, and 6.9% was admitted to ICU. Analysis
using univariate analysis of variance revealed that the significant factors which
contributed to saving medical cost were palliative care policy on admission
(p=0.020), older age (p<0.001), and patients who have care giver(s) (p=0.048).
The intervention by palliative care team did not affect the cost.
Summary/Conclusions: In this study, we clarified that aggressive EOL care
was given in the most hematological malignancy patients. Blood transfusion
and antibiotics were continued until death. Furthermore, prospective study on
the aggressiveness of EOL care and quality of life is needed.
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AMBULATORY MANAGEMENT OF ANEMIA: A RETROSPECTIVE VIEW
FROM AN ITALIAN MULTIDISCIPLINARY TEAM
L Del Corso1, A bellodi1, R Ghio1, N Bardi1, E Molinari1, F Puppo1, P Mangini2,
P Strada3, S Beltramini4, MT Van Lint5, E Arboscello1,*
1Internal Medicine, Departement of hemato-oncology, irccs-auo san martino-
ist, 213th Health District ASL3, Genova, 3Immuno-Hematology and Transfu-
sional Centre, 4Pharmacy, 5Hematology and Bone Marrow Transplantation,
irccs-auo san martino-ist, Genova, Italy
Background: Anemia is one of the most prevalent clinic condition leading to a
specialist medical consult. In 2014 our Internal Medicine unit started a Multidis-
ciplinary Anemia Ambulatory (Internist, Immune-Hematologist, Hematologist)
with the purpose to rapidly manage, diagnosis and treatment of anemic pts, giv-
ing a direct connection between general practitioners and hospital services.
Aims: Evaluate if Multidisciplinary Anemia Ambulatory and its diagnostic-ther-
apeutic path, with the involvement of different Specialists, resulte in an improve-
ment of the coordination and continuity of care, reducing sanitary cost in terms
of hospitalization, drugs rationalization and quality of life for patients.
Methods: Retrospective analysis of 212 patients came to our attention for
internist consult due to anemia from January 1st 2014 to January 2015.
Results: A total of 212 patients came to our attention for internist consult due
to anemia: 165 female and 47 male, medium age 63,23 years (range 19-100).
A precise classification of anemia was determined for 187 pts: 130 had iron defi-
ciency anemia (IDA, 61,32%), 17 multifactorial anemia (inflammatory disorders,
chronic kidney disease and combined deficiency, 8,02%), 16 combined defi-
ciency anemia (iron and vitamins, 7,55%), 9 chronic kidney disease related ane-
mia (4,25%), 7 anemia secondary to inflammatory chronic disorder (3,30%), 5
B12 deficiency (2,36%), 2 both folate and B12 deficiency (0,94%), 1 folate defi-
ciency (0,47%). Twenty-five pts were not classified due to lack of data. Severity
of anemia was defined according to WHO criteria: 53 pts (25%) presented mild
anemia, 123 (58%) moderate anemia, 33 (15,6%) severe anemia.We considered
comorbidities of internistic relevance, which could be worsened by anemia: car-
diovascular (coronary heart disease, arrhythmias, heart failure), 30 pts; neuro-
logic (ischemic and degenerative diseases), 19 pts; respiratory disease (COPD
and asthma), 11 pts.Pts were treated according to clinical practice in relation to
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type, severity and clinical manifestation of anemia.130 pts needed more than
one access to ambulatory to correct anemia; data from the second access were:
pt responders (normalization of Hb levels or improvement of at least 20 g/L): 78
pts; partial responders (improvement of Hb levels from 5 to 20 g/L): 34 pts; non
responders: 18 pts. Fourteen pts needed at least 1 blood red cells transfusion,
12 with severe anemia and 2 with moderate anemia. A total of 93 pts needed
deep diagnostic insight through specialist pathways, such as hematologic (4
pts), gastroenterologic (39 pts), gynecologic (37 pts), both gastroenterologic
and gynecologic (13 pts). All pts were managed as outpatients, except for 8 pts
which required hospitalization due to severity of clinical findings: 4 pts were
hospitalized.Among IDA pts, 92 were treated with intravenous iron supplement:
32 with sodium ferric gluconate (SFG) (medium 16,68 vials, range 8-43) and 50
with ferric carboxymaltose (FC) (medium 1,04 vials).FC patients fully responded
in 76% and 22% were partial responders.
Summary/Conclusions: These preliminary data shows that Multidisciplinary
Anemia Ambulatory and its diagnostic-therapeutic path, with the involvement
of different Specialists and Operative Unit, resulted in an improvement of the
coordination and continuity of care, reducing sanitary cost in terms of hospital-
ization, drugs rationalization and quality of life for patients. More data will derive
from the newborn Anemia Regional Register, which will lead to a better com-
prehension of the real size of anemia in our local epidemiology.
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DYNAMICS OF QUALITY OF LIFE IN ANEMIC PATIENTS WITH LYMPHO
PROLIFERATIVE DISORDERS TREATED WITH RED BLOOD CELL
TRANSFUSIONS AND ERYTHROPOIESIS-STIMULATING AGENTS
N Romanenko1,*, N Potikhonova1, S Tiranova1, A Romanenko2, M Zenina1,
S Bessmeltsev1
1Clinical Hematology, Russian Research Institute of Hematology and Transfu-
siology, 2Clinikal Neurology, Children Hospital of St. Olga, Saint-Petersburg,
SANKT-PETERBURG, Russian Federation
Background: Anemia is a frequent complication of lymphoproliferative disor-
ders (LPD) and antitumor therapy decreasing overall survival rate and Quality
of Life (QoL). Anemia’s pathogenesis is based on suppression by proinflam-
matory cytokines, decreasing erythroid precursor’s sensitivity to serum ery-
thropoietin and the myelosuppressive effects of chemotherapy. The main meth-
ods of anemia’s correction are red blood cells transfusions (RBCsT) and using
of erythropoiesis-stimulating agents (ESA). Both of them increase hemoglobin
concentration and improve QoL. However RBCsT are used in patients with
severe anemia and ESA are used to treat mild or middle anemia therefore
alteration of QoL after correction may differ.
Aims: The aim of the work was to compare dynamics of QoL in LPD patients
during anemia’s correction using RBCsT and applying of ESA. 
Methods: In this study anemic patients with lymphoproliferative disorders were
included. The efficacy of anemia’s correction by means RBCsT and applying
of ESA was assessed in the base of clinical, laboratory methods and Quality
of Life by using the questionnaire FACT-An.
Results: In the first group patients (n=54) with severe or middle anemia with
initial Hb concentration of 70.0±1.6 g/l were included. To correct anemia they
were prescribed RBCsT. After transfusions (Me=3 Units) the Hb level was
increased up to 93.1±1.2 g/l. In the second group patients (n=77) with mild or
middle anemia with initial Hb concentration of 88.4±1.4 g/l were included. All
these patients were treated with erythropoiesis-stimulating agents. After ESA-
therapy a positive response as increase of Hb concentration ≥20 g/l was in 52
(67.5%) out of 77 patients. Herewith the Hb concentration of patients with pos-
itive response increased up to 123.1±2.4 g/l. Analysis of dynamics of QoL
patients after RBSsT revealed the significant alteration in “Physical well-being”,
“Emotional,well-being”, “Functional well-being” and “Anemia” scales. After EPO-
therapy significant alteration were revealed in “Physical well-being” and “Ane-
mia” scales. However in comparative analysis of QoL in both groups of patients
the maximal improvement was revealed in the scale of “Physical well-being”
(in the first group after RBCsT it was from 12.9±0.7 to 11.0±08 points; p<0.001,
in the second one after ESA-therapy-from 11.6±0.7 to 9.6±0.7 points; p<0.02)
and scale of “Anemia”: after RBCsT it was from 41.1±2.0 to 34.2±2.1 points
(p<0.001), after ESA-therapy-from 34.5±1.7 to 30.1±1.6 points (p<0.001).
Summary/Conclusions: RBCsT and ESA-therapy may significantly increase
the Hb concentration and improve Quality of Life. However QoL of patients
after ESA-therapy was better than after RBCsT because Hb concentration was
achieved to normal level after applying erythropoiesis-stimulating agents. Nev-
ertheless both methods for anemia correction are effective and ESA-therapy
may be prescribed to prolong treatment of anemia after RBCsT.
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THE TREATMENT- ASSOCIATED SIDE EFFECTS IN PATIENTS WITH
IDIOPATHIC THROMBOCYTOPENIC PURPURA
AM Gaman1,2,*, MA Gaman3
1Pathophysiology, University of Medicine and Pharmacy of Craiova, 2Hema-
tology, Filantropia City Hospital, Craiova, 3”Carol Davila” University of Medicine
and Pharmacy, Bucharest, Bucharest, Romania
Background: Idiopathic thrombocytopenic purpura (ITP) is a disease charac-
terized by the presence of antiplatelet antibodies which accelerate platelet
destruction and prevent the release of platelets from megakaryocytes, resulting
in various types of bleeding. The primary objective of treatment is to prevent
bleeding by increasing the platelet count by reducing destruction of antibody-
coated platelets (e.g. corticosteroids, immunoglobulins, splenectomy) or by
stimulating platelet production (thrombopoietin receptor agonists, TPO-RAs)
with the fewest possible side effects associated with treatment.
Aims: To evaluate the side effects associated with treatment and the quality of
life in patients with ITP treated with corticosteroids versus TPO-RAs.
Methods: We studied 34 patients with ITP hospitalized in the Clinic of Hema-
tology of Craiova (informed consent obtained) in between 2013 and 2015.
Twenty-five patients received corticosteroids (prednisone or high dose dexam-
ethasone) as first line therapy and nine patients with refractory or relapsed ITP
were treated with eltrombopag (50 mg once daily as initial dose, followed by
25 mg once daily after platelet count ≥150.000/μL). We evaluated the side
effects associated with treatment in both groups. We mention that patients
treated with eltrombopag did have not hepatitis B/C or HIV infection, severe
cardiovascular diseases or risk factors for thrombosis.
Results: Nineteen patients (76%) treated with corticosteroids presented one or
more complications: infections (fungal, bacterial, viral) - 10 cases, arterial hyper-
tension - 4 cases, duodenal ulcer hemorrhage - 1 case, dyspepsia - 2 cases,
decompensation of diabetes mellitus - 2 cases, hyperglycemia - 3 cases, cataract
- 1 case, insomnia - 2 cases, anxiety - 1 case, peripheral edema - 4 cases. Five
patients (55%) treated with eltrombopag presented: headache - 1 case, transient
increase of alanin aminotransferase - 3 cases, indirect hyperbilirubinemia - 1 case.
Summary/Conclusions: The treatment with eltrombopag was responsible for
less side effects (and also less severe) in comparison with the treatment with
corticosteroids, and contributed to the improvement of the quality of life in
patients with ITP.
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MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS
STIMULATING AGENTS (ESAS): A REAL-LIFE EXPERIENCE
C Cerchione1,*, O Vitagliano1, AE Pareto1, M Di Perna1, G Cerciello1, I Sori-
ente2, F Alfinito1, F Pane1
1Hematology, Ematologia e trapianto/au federico ii, Napoli, 2Hematology,
Ospedale Umberto I, Nocera Inferiore (SA), Italy
Background: ESAs are the frontline treatment in low-risk anemic MDS patients
and an employment of this therapy in the earlier stage of the disease can delay
the need for RBC transfusion, hypothetically by slowing the disease course.
It’s matter of debate whether the clinical response is a result of proliferation
and maturation of the dysplastic clone or stimulation of residual normal ery-
thropoiesis by ESAs. 
Aims: Macrocytosis is one of the cytological hallmarks of dyserithropoiesis in
MDS: an analysis of the erythropoietic response to ESAs therapy in a cohort
of anemic non trasfusion-dependent MDS patients, enrolled in a retrospective
register, RECAMDS, subgroup of Italian register, was performed.
Methods: 159 patients, treated with standard-dose ESAs, have been retrospec-
tively analyzed (Table 1). Data analysis was performed, according to IWG 2006
criteria, at the baseline, after 3 and 6 months of continuous treatment, with a
subanalysis of the patients according to WHO and R-IPSS risk stratification.
ESAs were started at mean Hb concentration of 9.43 g/dl, mean serum EPO
concentration: 42 mU/L, after a mean time from diagnosis of 6 months (r.1-118).
Results: Overall response rate (ORR) was 83.6% (133/159), no difference
among WHO and IPSS subgroups was found :75.6% achieved response after
3 months of treatment, while other 8% after 6 months. 2 patients with SD (non
responders IWG), in which treatment was continued, achieved response after
9 months. In the macrocytic-responders group 85.5% exhibits again macrocy-
tosis after 3 months, while 13% become normocytic. In the normocytic-respon-
ders group 91.7% exhibits again normocytosis, while 4/52 (8%) become macro-
cytic: in these 4 patients after 3 months there was a contemporary worsening
in neutropenia and thrombocytopenia, with transfusion-dependence, regarded
as first signs of progression of disease. Non responders were 27/159 (16.9%):
in the macrocytic-non responders group 89% exhibit again macrocytosis after
3 months, while 11% become normocytic; in the normocytic group 80% exhibits
again macrocytosis, while 20% become normocytic (r.1-23). 
Summary/Conclusions: These preliminary data can suggest that, in the
majority of MDS patients responsive to ESAs, the increase of Hb concentration
occurs mainly stimulating erythroid production in MDS clones; in the minority
of patients probably it happens recruiting residual polyclonal erythropoiesis. It
is interesting to note that stimulating effects of ESAs last even when the expres-
sion of dysplasia progresses.
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SPLENOMEGALY IN NEOPLASTIC HEMATOLOGICAL DISORDERS
L Diaz1,*, E Gonzalez1, A Seguro2, I Villanego1, V Diaz1, A Ureña3, L Gutierrez1,
C Salas1, J Jaen1
840 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
1Radiation Oncology, H.U. Puerta del Mar, Cádiz, 2Radiophysics, H.U Rey
Juan Carlos, Móstoles, 3Radiophysics, H.U. Puerta del Mar, Cádiz, Spain
Background: Splenic irradiation has been used as first treatment for several
hematological neoplasms, including chronic leukemia or myeloid malignancies,
but with the availability of new drugs its application was restricted. 
Aims: In selected cases, not only with palliative intentions, irradiation can be
useful treatment modality
Methods: Our study included 13 patients: 5 with chronic lymphocytic leukemia,
6 with high-grade B-cell lymphoma and 2 with diagnose of polycythaemia Vera.
In 5 patients the treatment was with radical intention (all of them with high grade
lymphoma) and the rest were palliatives as treatment of pain or normalization
of red blood cell that allows more time between transfusions. The doses were
generally low with range between 5 and 10 Gy in 0.5Gy daily fractions because
doses higher than 10Gy did not provide benefits according to literature. 
Results: We got 5 complete responses confirmed by PET but after 2 years 2
of them relapsed and were treated with radiotherapy again with the same
scheme and obtain the same response to the present day. In terms of palliative
intention, splenic irradiation provided a relief of pail from 6 to 12 months, and
in 4 patients the disease progressed without new splenic symptoms. One
patient received 3 courses of radiotherapy for painful splenomegaly with a gap
of 12, 9 and 6 months without acute toxicity and died due to non-splenic
leukemia progression. 
Summary/Conclusions: In selected patients who are not responsive, not suit-
able for systemic treatment or palliative, splenic irradiation can be an efficient
therapy with little toxicity and sustained response over time. f of pail from 6 to
12 months, and in 4 patients the disease progressed without new splenic symp-
toms. One patient received 3 courses of radiotherapy for painful splenomegaly
with a gap of 12, 9 and 6 months without acute toxicity and died due to non-
splenic leukemia progression.
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MOLECULAR DIAGNOSIS OF RBC ENZYMOPATHY BY MULTI-GENE
TARGET SEQUENCING IN KOREA
DS Lee1,*, Q Choi1, SN Park2, JA Kim1, KO Im2
1Dept of Laboratory Medicine, Seoul National University College of Medicine,
2Department of cancer molecular biology, Cancer Research Institute, Seoul,
Korea, Republic Of
Background: RBC enzymopathy occurs due to the intrinsic deficiency or a
defect in red blood cell (RBC) enzyme and defective function of RBC enzyme
causes hemolysis. Practically, functional analysis of enzymes related to RBC
enzymopathy are not available easily. Furthermore, differential diagnosis form
paroxysmal nocturnal hemoglobinuria, hemoglobinopathy and congental
dyseryhtropoiesis is required.
Aims: We aimed to investigate the frequnecy and patterns of gene mutation
relevant to RBC enzyme in Korea.
Methods: We performed targeted sequencing in 15 patients suspected for
RBC enzymopathy in whom RBC membranopathy was excluded after labora-
tory workup. Forty two genes were targeted including 20 genes relevant with
enzymopathy and 17 genes relevant with RBC memebranopathy. For the dif-
ferential diagnosis, Phosphatidylinositol Glycan Anchor Biosynthesis Class A
(PIGA gene), 3 thalassemia genes (hemoglobin alpha1, hemoglobin alpha2,
hemoglobin beta, and hemoglobin beta), and congenital dyserythropoietic ane-
mia II gene (Sec23 homolog B) were included in target sequencing, additionally.
Targeted sequencing of 42 selected genes was performed using IlluminaHiSeq
2500. Putative mutations were analyzed in comparison to normal reference
control population. 
Results: The mean sequencing depth for the 60 samples was 984X (range
534–1171X). PKLR mutation in 10 patients, ALDOB mutation in 1 patient and
G6PD mutation in 1 patients. Of note, gene mutation related to PNH and tha-
lassemia were detected in 2 patients; PIGA mutation in 1 patient and tha-
lassemia alpha point mutation in 1 patient. Among 15 patients, no mutation
was detected in 1 patient. Collectively, target sequencing revealed gene muta-
tions related to RBC enzymopathy in 80% and gene mutations other than enzy-
mopathy in 13.3% among 15 patients suspected for enzymopathy in Korea.
Figure 1.
Summary/Conclusions: Distribution of RBC enzymopathy mutations was sim-
ilar between USA and Korea. Considering that 13.3% of patients showed gene
mutaions unrelevant to RBC enzymopathy, molecular analysis of RBC enzy-
mopathy is necessary for clinical diagnosis.
PB2117
A NOVEL IN-VITRO REVERSAL OF SICKLED ERYTHROCYTES BY COCOS
NUCIFERA WATER AND HIGH K+ -ISOTONIC SOLUTIONS
O Ajayi1,*, D Agbaminoja2
1Physiology, University of Benin, Benin City, 2Medical Laboratory Science,
Achievers University, Owo, Nigeria
Background: Red cell sickling and adhesion are favoured by cellular dehy-
dration, which increases the rate of hemoglobin polymerization and cell sickling.
Potassium chloride co-transport and calcium-activated potassium channel (Gar-
dos channel) mediate erythrocyte dehydration in sickle cell disease and β-tha-
lassemia, but their role in vaso-modulation is less defined. Blocking the pota-
sium leakage has been suggested as a means of inhibiting dehydration and
enhancing normal shape of the sickle cells. We investigated the in-vitro effect
of various concentration of K+ ion in physiological solutions (PSS) as well as in
cocos nucifera water which is a natural drink known for its natural high potas-
sium content and health benefits.
Aims: This study has therefore been designed to highlight the possibility of
reversing the Na+/K+,membrane counter-movement in the extra cellular medium
and observe the impact on sickled erythrocyte especially in the dehydrated
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state using a natural medium with very high potassium but isotonic solution -
Cocos nucifera water
Methods: Twenty blood samples from sickle cell anaemia subjects were col-
lected and studied with different high potassium isotonic media. Firstly with
Cocos nucifera water (with K+ of 240mM); erythrocytes sickling test was done,
then repeated after incubation with the fluid for 30 mins. Another part was treat-
ed with Sodium Metabisulphite (Na2S5O7) solution to induce maximum sickling
as controls, then later incubated with the fluid. Subsequently, we subjected the
samples to different high concentrations of K+ in Physiological Salt Solution
(PSS) (40mM, 80mM, respectively) and their percentage sickling activities were
enumerated using a thin blood smear stained with Leishman dye before and
after the treatment. Later experiments to study the effects of the Cocos nucifera
water on Osmotic fragility of red cells from different haemoglobin protein elec-
trophoresis before and after incubation with coconut water. 
Results: The result showwed statistically significant counts of discoid shaped
cells in the blood samples incubated with 80mM and Cocos nucifera water
(P<0.05, respectively) over the native and the sickled- induced samples while
the 40mM PSS did not show significant discoid cells over the sickled cells
(P>0.05). In 80mM K+PSS, values of (18% against 78%; before and after treat-
ment); Cocos nucifera (22% against 85%; before and after treatment) were
obtained. In addition, all the samples treated with cocos nucifera water have
significantly reduced osmotic fragilities (P<0.05, respectively) irrespective of
their haemoglobin protein status.
Summary/Conclusions: High extracellular potassium in an isotonic medium
could reverse the membrane permeability to K+ exflux from the sickled ery-
throcyte by possibly overwhelming the Na+/K+ counter movement across the
membrane thereby promoting rehydration through K-Cl cotransporter and ulti-
mately reverses the sickling. The inhibition of Gardos channel is suggested as
a possible mechanism in the interim, also cocos nucifera water has shown in
this study, the tendency to reduce osmotic pressure lysis of sickle cells and
possibly prolong its life span.
PB2118
ERYTHROBLASTS IN PERIPHERAL BLOOD AS AN OCCASIONAL FINDING
IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB
M Piris-Villaespesa1,*, D Velasco-Rodriguez1, J Marquet1, S Lopez-Gonzalez1,
G Pinto-Solano1, L Costa-Frossard2, S Sainz de la Maza2, E Monreal2,
JC Alvarez-Cermeño2, J Villarrubia1
1Hematology and Hemotherapy, 2Neurology, Hospital Universitario Ramón y
Cajal, Madrid, Spain
Background: Natalizumab (NTZ) is a recombinant humanized IgG4 mono-
clonal antibody directed against the α4 subunit of the α4 β1 (VLA-4) integrin of
the lymphocytes. VLA-4 plays a critical role in erythropoiesis and is involved in
mobilization of hematopoietic progenitors to peripheral blood. NTZ is used in
autoimmune diseases such as multiple sclerosis and Crohn disease, and has
been reported to induce CD34+ hematopoietic progenitor cells mobilization
and erythroblasthaemia in multiple sclerosis patients.
Aims: To identify and report the presence of erythroblasts in peripheral blood
in our cohort of NTZ-treated patients.
Methods: Peripheral blood smears (PBS) of patients treated with NTZ from
September 2014 to February 2016 were retrospectively reviewed. PBS were
prepared and dyed with May-Grünwald-Giemsa stain and examined by light
microscopy by an experienced hematologist. The cohort included 53 patients
treated on a monthly basis at different time points. 
Results: A total of 82 PBS were reviewed in 53 patients. Fifteen of them
(28.3%) showed 1 or more erythroblasts in peripheral blood. Mean time on
treatment when PBS was reviewed was 20.5 months (1-74). Mean time on
treatment when erythroblastaemia was documented was 14 months (1-71).
Once erythroblastemia was described, mean follow up was 10.67 months. No
hematologic malignancy was reported in these patients. 
Summary/Conclusions: The pressence of erythroblasts in peripheral blood
is usually a sign of alarm requiring further investigation since it is generally
associated with severe underlying disorders. As previously data support, NTZ
is a cause of erythroblastemia and should be taken in consideration in differ-
ential diagnosis in cases with erythroblasts in peripheral blood, at any time
while on therapy. Knowledge of this frequent side effect is crucial for the correct
interpretation of PBS in NTZ-treated patients and to avoid unnecessary diag-
nostic procedures. Investigation of the mechanisms underlying this effect is
needed in order to estimate its repercussion and potential benefits.
PB2119
ROLE OF GENETIC DIAGNOSIS FOR PATIENTS WITH SUSPICION OF
THALASSEMIA INTERMEDIATE/MINOR
D Babikyan1,2,*, A Zakharyan3
1Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi,
2Center of Medical Genetics and Primary Health Care, 3Hematology, Yerevan
State Medical University after Mkhitar Heratsi, Yerevan, Armenia
Background: Armenia is situated in the link of Mediterranean and Indo-
Mediterranean belts of thalassemia. However, due to the scarcity of information
restricted only for very rare reported cases it was traditionally underestimated
the need of provision of genetic analysis for thalassemia associated with vari-
able degree of anemia and hematological findings. Our previous results from
population screening study suggested rather low carrier frequency however
with a higher rate for alpha than for beta thalassemia.
Aims: To provide sound data about the mutation spectrum of alpha and beta
globin genes in Armenia and to assess the role of genetic testing for patients
with ssuspected clinical phenotype, we carried out the first genetic analysis in
a cohort of Armenian patients.
Methods: All 48 sporadic and 11 familial cases of Armenian ethnicity with sus-
picion of mainly thalassemia intermedia or thalassemia minor had genetic testing
for alpha and beta thalassemia genes who have been defined by specific hema-
tological features, mainly by hypochromia, microcytosis, and marked variations
in size and shape of the red blood cells and/or suffering from minimal anemia.
Screening of 22 beta globin gene and 21 alpha globin gene mutations common
for the Mediterranean and Indo-Mediterranean regions was performed using
multiplex PCRs of DNA purified from blood samples of affected cases and family
members. Further biotinylated amplification products were reverse-hybridized
to allele-specific oligonucleotides immobilized on membrane teststrips.
Results: 30 patients were diagnosed as simple heterozygotes for one of the
following b0 or b+ globin gene mutations (-30 [T>A], cd8 [-AA], cd15
[TGG>TGA], cd44 [-C], IVS2.1 [G>A]) responsible for thalassemia minor or
intermedia with specific hematological features. In 2 cases 3.7 alpha single
gene and 20.5 alpha double gene deletion were detected, while a compound
heterozygous genotype of alpha genes consisting of 20.5 alpha double gene
deletion and a1 cd59 [GGC>GAC] (Hb Adana) mutation was detected in one
patient. More interestingly, two patients were detected with simple heterozygous
beta globin gene mutations (cd8 [-AA] or IVS1.110 [G>A]) with the co-inherited
triplicated alpha globin gene rearrangement which indeed developed a clinical
phenotype of intermediate beta-thalassemia. All 5 families were detected with
alpha or beta globin gene mutations. Particularly, sibs in four families were
detected with single b0,mutations or 20.5 alpha double gene deletion. A proband
of another family had compound heterozygous genotype for beta globin muta-
tions (cd8 [-AA]/IVS2.848 [C>A]) and parents were carriers of the beta globin
mutations along with anti-3.7 alpha globin gene triplication. 13 patients had no
alpha globin neither beta globin gene mutations detected.
Summary/Conclusions: This is the first report of genetic screening of sus-
pected thalassemia cases in Armenia. Despite of former pessimistic view on
thalassemia in the country compared to the neighboring countries, 80% detec-
tion rate of mutations among symptomatic cases emphasizes the importance
of development of genetic screening among patients with suspected phenotype
with minor or intermediate thalassemia. Meanwhile, the genetic diagnosis has
become possible only after having more differentiated clinical and hematolog-
ical analysis. Furthermore, the screening data does not reject possibility of
detection of other mutations, particularly in patients with no mutation through
sequencing analysis which raises the importance of genetic testing. In contrast
to the population screening data, beta thalassemia was found more frequent
than alpha thalassemia. Further larger screening study is required to better
understand and assess the role of mutations identified in heterozygous beta-
thalassemia cases and the clinical-molecular relationships, as well as mecha-
nisms leading to clinical and hematological severity in simple heterozygotes.
PB2120
IDENTIFICATION OF CARRIERS OF GENETIC ALTERATIONS IN THE HBB
GLOBIN CLUSTER: HEMATIMETRIC AND BIOCHEMICAL DATA IN 462
HETEROZYGOTE INDIVIDUALS
J M Nieto*, M Guijorro, F De La Fuente-Gonzalo, FA Gonzalez, A Villegas,
P Ropero, R Martinez
Hematology, Hospital Clinico San Carlos, Madrid, Spain
Background: The β globin cluster (HBB cluster) contains several genes dif-
ferentially expressed over development. Most common alterations in this cluster
are point mutations in the β globin gene (βº, β+ or β++,mutations depending on
the severity) that produce β thalassemia. Additionally, large deletions of one or
more genes can occur in the HBB cluster, leading to β like thalassemias (εγδβ,
δβ or β thalassemia) or Hereditary Persistence of Fetal Hemoglobin (HPFH).
Homozygotes or compound heterozygotes for HBB cluster alterations present
variable transfusional requirements, depending on the combination of inherited
alterations. In many centers, identification of carriers of these alterations is
commonly done at hematimetric and biochemical level. Thus, effective identi-
fication of carriers and discrimination between different types of HBB alterations
at this level is necessary for an appropriate genetic counseling.
Aims: To describe the hematimetric and biochemical profile of individuals bear-
ing heterozygous alterations in the HBB cluster in order to facilitate their iden-
tification.
Methods: Large deletions and β gene point mutations were identified by Mul-
tiplex Ligation dependent Probe Amplification (MLPA) and sequencing, respec-
tively. Most common alterations in the HBA globin cluster were assessed with
the Alpha-Globin StripAssay. Hematimetric data were obtained with a Coulter
LH 750 analyzer. HbF and HbA2 levels were obtained by ion exchange HPLC.
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In line with literature, individuals were categorized according to the type of dele-
tion (εγδβº, δβº, HPFH or βº) or point mutation (βº, β+ or β++) in the HBB cluster.
Coinheritance of alterations in the HBA globin cluster was a reason for exclusion.
462 carriers of alterations in the HBB cluster were finally included in the study.
Results: Means and standard deviations for hematimetric data variables, HbF
and HbA2 levels for different HBB alterations are summarized in Table 1.
Table 1.
Summary/Conclusions: Within deletions, only βº deletions have elevated
HbA2 levels (≥3,5%). The main differences between δβ thalassemia and HPFH
were HbF levels, MCV and RDW. εγδβ thalassemia cases had variable features
in relation to age; severe microcytic anemia was observed in neonates (4 out
of 5 required transfusions) and marked microcytosis with mild anemia in adults.
Many εγδβ thalassemias are caused by de novo deletions, so this condition
should be suspected when severe microcytic anemia occurs in neonates, even
if there is no history of familiar microcytosis. Roughly, 10% of δβ thalassemias
have normal HbF (≤2%) and mimic an α thalassemia phenotype (microcytic
and hypocromic red cells, normal HbA2 and HbF levels). When an alpha tha-
lassemia trait is present, elevated RDW (≥16) makes us to suspect that the
patient is actually a carrier of a δβº deletion. When a point mutation is present,
phenotype aggravates accordingly to β globin production impairment. Generally,
these individuals can be easily identified because of elevated HBA2 levels. In
conclusion, phenotypes associated with alterations in the HBB cluster are fre-
quently distinctive, although phenotypic overlap can be seen in a subset of
cases and molecular analysis may be required.
PB2121
ERYTHROCYTES OF INDIVIDUALS WITH HEMOGLOBIN C TRAIT ARE
DENSER AND SMALLER THAN ERYTHROCYTES OF OF INDIVIDUALS
WITH HEMOGLOBIN S TRAIT
D Velasco-Rodríguez1,*, JM Alonso-Domínguez2, FA González-Fernández3,
J Villarrubia1, M Tenorio1, M Sopeña4, L Abalo4, P Ropero-Gradilla3, J Martínez-Nieto3,
F de la Fuente-Gonzalo3, G Moreno1, A Jiménez-Martín1, FJ López-Jiménez1,
F Cava4
1Hematology, Hospital Ramón y Cajal, 2Hematology, Fundación Jiménez Díaz,
3Hematology, Hospital Clínico San Carlos, 4Hematology, Laboratorio Central
de la Comunidad de Madrid BR Salud, Madrid, Spain
Background: Since HbS and HbC are by far the two most prevalent structural
hemoglobinopathies in our geographical area, it seems reasonable to develop
efficient and rapid tools to discriminate between them in daily practice. Carriers
are asymptomatic, and clinicians need to accurately identify them and provide
adequate genetic counselling to them in order to prevent the occurrence of
homozygous or compound heterozygous offspring.
Aims: The aim of our study was to identify red blood cell (RBC) laboratory
parameters of the complete blood count (CBC) that discriminate between HbAS
and HbAC individuals.
Methods: The CBC of 355 HbAS and 104 HbAC subjects were run on an Advia
2120 analyser (Siemens Medical Solutions Diagnostics, Tarrytown, New York,
USA). All of these Hb variants were detected by HPLC in the HA-8160 analyzer
(Menarini Diagnostics, Florence, Italy) and further characterised according to
their alkaline and acid electrophoretic pattern using cellulose acetate elec-
trophoresis. Classic hematological parameters and RBC populations of the
complete blood count (CBC) were assessed in all subjects. Independent sample
t-test was used to compare laboratory parameters between HbAS and HbAC,
and receiver operating characteristic (ROC) curves were plotted.
Results: The following parameters were significantly higher in HbAC than in
HbAS: RBCs (5.09x1012/L vs 4.91x1012/L, p=0.004), Hb (13.97 g/dL vs 13.47
g/dL, p=0.017), MCHC (35.35 g/dL vs 33.29 g/dL, p<0.001), RDW (15.16% vs
14.51%, p=0.002), HDW (2.68% vs 2.48%, p=0.001),%MICRO (7.35% vs
4.58%, p=0.006),%HYPER (3.04% vs 0.82%, p<0.001) and M/H (22.37 vs
4.59, p<0.001). The following parameters were significantly higher in HbAS
than in HbAC: MCV (82.92 fL vs 79.15 fL, p<0.001),%MACRO (0.45% vs
0.27%, p=0.033) and%HYPO (4.51% vs 1.27%, p<0.001). When only HbAS
and HbAC without iron deficiency and α-TT were evaluated, differences
remained significant only in MCV, MCHC,%MICRO,%HYPER and M/H (Table
1).%HYPER (AUC=0.842), M/H (AUC=0.839) and MCHC (AUC=0.833) were
the most efficient parameters to discriminate between HbAS and HbAC. A cut-
off point of 1.15% for%HYPER provided a sensitivity of 79.9% and a specificity
of 74.4%. A cut-off point of 34.55 g/dL for MCHC provided a sensitivity of 80.6%
and a specificity of 72.1%. A cut-off point of 7.3 for M/H provided a sensitivity
of 81.6% and a specificity of 76.7%.
Summary/Conclusions: RBCs of HbAC subjects are denser than HbAS ery-
throcytes, possibly because the K+:Cl− cotransporter may be more active in
HbAC subjects, since lysine (HbC) is more positively charged than valine (HbS),
and thus its binding to band 3 may be even further increased. If a patient with
a variant Hb not yet identified shows hyperchromia (% HYPER >1.15% and/or
MCHC >34.55 g/dL and/or M/H >7.3), the diagnosis is more likely to be HbAC.
PB2122
MUTATIONS FOUND, IN THE PROMOTER REGION OF THE Β-GLOBIN
GENE, IN ONLY ONE HOSPITAL IN MADRID
P Ropero*, FA González, JM Nieto, F de la Fuente-Gonzalo, A Villegas,
R Martínez
Hematology, Hospital Clínico San Carlos, Madrid, Spain
Background: The β+-thalassemia is characterized by reduced production of
beta chains, which can be produced by mutations in the promoter area (either
the CACCC or TATA box). Depending on the extent of reduction of beta globin
chain, the β+-thalassemia mutations may be classified into mild and silent.
Silent β-thalassemia is characterized in the heterozygous state by normal MCV
and MCH, normal or more frequently borderline HbA2, and normal HbF. Globin
chain synthesis ratio is only slightly imbalanced, and sometimes even normal.
This phenotype may escape detection by the usual methods, so DNA study
being necessary for proper identification. Compound heterozygosity of these
mutations with a severe mutation always produces very mild thalassemia inter-
media. Frequently the diagnosis is made in adulthood or even in the elderly.
Mild β-thalassemia mutations are characterized by a residual high β-chain pro-
duction, show moderate thalassemia-like hematological features and imbalance
chain synthesis. This group of molecular defects includes transcriptional
mutants in the proximal CACCC box and in the TATA box. Homozygotes or
compound hetrozygotes for these mild mutations usually have thalassemia
intermedia. So far a total of 37 alterations have been described in the promoter
region, some of which are ethnic specific, -87 C>T are common in Mediter-
ranean areas, while -29 A>G and -88 C>T are frequently found in blacks.
Aims: In this report we present a compilation of the mutations found, in the
promoter region of the β-globin gene, in only one Hospital in Madrid.
Methods: The hematological parameters were determined with Coulter LH750
Analyzer. HbA2 and HbF levels, as well as the different hemoglobins, were
measured and analyzed by ion-exchange HPLC (VARIANTTM II). Hemoglobins
were studied by capillary zone electrophoresis (CE) (Sebia). Genetic analysis
of the β and Gγ globin genes was carried out by automatic sequencing and, in
the case of α genes, by multiplex PCR. 
Results:
Table 1.
Summary/Conclusions: All these mutations show the importance of the pro-
moter region in the β globin genes. Except for the mutation located at the distal
CACCC (-101 C>T) that presents a β-thalassemia silent, the rest behaves as
a β-thalassemia mild, generally high levels of HbA2 HbF and being the cause
most likely the partial removal of competitiveness to limit transcription factors,
facilitating their access to the promoters of both genes as the δ γ genes. Thus,
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as seen, any alteration in the CACCC proximal box and the TATA box, cause
a moderate decline in the synthesis of the β globin chain, which has been
tested both cases of thalassemia intermedia that they made their debut in the
second decade of life with a moderate clinical as when associated with a HbS
where the disease is mild sickle cell anemia as there is a residual activity of
20% HbA. The identification of such mutations is important for a good genetic
counseling that will provide information to individuals and couples at risk (both
carriers) in relation to the mode of inheritance, the genetic risk of having affected
children and history nature of the disease, including treatment and thus make
an informed decision about their reproductive options.
PB2123
PERFORMANCE EVALUATION OF RETICULOCYTE COUNT ADOPTING
NEW CALIBRATOR XN CAL ON THE SYSMEX XN SERIES
HR Kim*, YK Lim
Chung-Ang University College of Medicine, Seoul, Korea, Republic Of
Background: Reticulocyte counts have been known as an accurate index of
erythropoietic activity. Currently, automated hematology analyzer could meas-
ure the reticulocyte count with increased precision and accuracy. The newly
introduced Sysmex XN (Sysmex Corporation, Kobe, Japan) has been intro-
duced calibration of reticulocyte count that was not applied by the previous
hematology analyzer XE series.
Aims: to clarify the effect of calibration, we evaluated the performance of retic-
ulocyte counting with the Sysmex XN and XE series.
Methods: The XN-9000 was calibrated with new calibrator XN CAL and total
40 blood samples were analyzed to evaluate accuracy of reticulocyte count.
The results from the XN-9000 and previous hematology analyzer (XE-2100)
were compared with those obtained by manual reticulocyte count as reference
method. The precision profiles of the XN-9000 were also evaluated with quality
control materials according to Clinical & Laboratory Standards Institute (CLSI)
document EP05-A3.
Results: There were perfectly matched results between the XN-9000 and ref-
erence method, however the XE-2100 consistently gave significantly lower val-
ues compared with reference method. In precision evaluation, the XN-9000
showed impressively improved precision profiles than those of the XE-2100.
Summary/Conclusions: Our study has shown that correlation between the
two instruments are good, but the bias of reticulocyte count significantly exists
in the XE-2100, thus the effort of calibrating reticulocyte is critical to minimize
instrument-to-instrument difference. By calibrating reticulocyte count, the XN
series could provide more accurate results of reticulocyte count, as well as
improved precision. 
Red blood cells and iron - Clinical
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EVALUATION OF A MORE EFFECTIVE TREATMENT REGIMEN AND DOSE
OF RECOMBINANT HUMAN ERYTHROPOIETIN FOR MEDICATION OF
ANEMIA IN PREGNANCY
V Demikhov1,*, M Ayari1, E Klimovskaya2, E Zinovieva3, I Mirov2, E Demikhova1
1Research Clinical Center for Hematology, Oncology and Immunology,
2Ryazan State Medical University named after I.P.Pavlov, 3Ryazan Maternity
Hospital №1, Ryazan, Russian Federation
Background: There is evidence that pathogenesis of anemia in pregnancy
(AP) is multifactorial. It has not relation to ineffective erythropoiesis, caused by
iron or folate deficiency only. Blunted erythropoiesis is one of main AP causes.
According to our own data inadequately low production of erythropoietin (EPO)
for the degree of the anemia found at more 50% of anemic pregnants. That is
why recombinant human erythropoietin (rHuEPO) combined with iron is effec-
tive method in the therapy of anemic pregnant women, who had been ineffec-
tively treated with iron alone. Because EPO does not cross the placenta, this
protects the fetus from its use during pregnancy. Most recent studies show
overall the effect of rHuEpo is of clinical benefit in treating of anemia in preg-
nancy. But there is no standard dose for this medication during pregnancy.
Aims: To carry out the comparative study to identify more effective treatment
regimen and dose of rHuEPO for medication of AP. 
Methods: Three groups of anemic pregnant women were enrolled. All groups
were stratified according to age, gestational aged and initial mean Hb levels at
anemic pregnant women. All of them met the following criteria for inclusion in
the study: gestational age above 20 weeks, Hb concentration <9.5 g/dl, ineffi-
ciency of iron therapy alone for at least 4 weeks, and absence of pregnancy
complications, or severe systemic diseases. The treatment protocol comprised
a combined therapy with rHu-EPO (epoetin-α) subcutaneously and 200 mg
iron sulphate orally daily. We used next regimens of rHuEPO dosing: Group 1
(n=18)-75 IU/kg three times per week (225 IU/kg per week); Group 2 (n=21)-
100 IU/kg three times per week (300 IU/kg per week) and Group 3 (n=16)-120
IU/kg two times per week (240 IU/kg per week). We evaluated Hb levels weekly
beginning before start of rHuEPO therapy during three weeks at all groups of
anemic pregnants. The advance of target Hb level (10.5 g/dl for I trimester and
11.0 g/dl for II trimester) in 2 week of rHuEPO therapy we considered as com-
plete response to the medication. Informed consent was obtained from all
patients for being included in the study.
Results: Response to the rHuEPO therapy depended on the regimen of dosing
(Table 1). The mean Hb levels, before and in 3 weeks after medication, in group
1 were 8.45±0.28 g/dl and 9.87±0.21 g/dl, in group 2-8.17±0.53 g/dl and
10.52±0.28 g/dl, in group 3-8.16±0.46 g/dl and 9.87±0.28 g/dl respectively
(Fig.). We did not observe any serious adverse effects during the therapy with
rHu-EPO.
Table 1.
Figure 1. Comparison of hemoglobin trends in groups of anemic pregnant
women who treated with different doses of rHuEPO.
Summary/Conclusions: Effectiveness of rHuEPO therapy is dose-dependent.
The use of rHu-EPO at dose 100 IU/kg subcutaneously three times per week
is more effective treatment regimen for medication of AP.
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ADENOTONSILLECTOMY IN SICKLE CELL DISEASE: IS TRANSFUSION
NEEDED?
M Elshinawy1,*, N Al Marhoobi2, Y Wali3
1Pediatric Hematology, SQUH and Faculty of Medicine, University of Alexandria,
Muscat & Alexandria, 2ENT, Oman Medical Specialty Board, 3Pediatric Hema-
tology, College of Medicine and Health Sciences, Muscat, Oman
Background: Adenotonsillar hypertrophy in patients with sickle cell disease
(SCD) can predispose to several complications including obstructive sleep
apnea, vasocclusive crisis (VOC), pulmonary hypertension, and acute chest
syndrome. Traditionally, all children with sickle cell disease (SCD) indicated for
adenoidectomy and/or tonsillectomy have been exposed to exchange transfu-
sion preoperatively aiming at reduction of both surgical and SCD-related com-
plications.
Aims: To address the need for transfusion in patients with SCD undergoing
adenotonsillectomy and to report its risks and benefits.
Methods: All patients with SCD admitted in SQUH for adenotonsillectomy from
July 2006 till January 2015 were included in the study. Between 2006 and 2012,
patients’ files were reviewed for retrospective data recording. After 2012, the
study has been prospective.
Results: The current cohort included 70 patients with SCD. They were cate-
gorized into three groups. (No transfusion, simple transfusion and exchange
transfusion group). Almost 33% of patients with SCD didn’t need any preoper-
ative transfusion before surgery (23 out of 70 patients). There was no statisti-
cally significant difference between the 3 studied groups as regards the devel-
opment of surgical or SCD related complication. Development of postoperative
vaso-occlusive crisis and acute chest syndrome was comparable in the three
groups. As an advantage, there was a markedly significant less blood used in
patients given simple top-up transfusion as compared to exchange transfusion
group. All results are shown in table 1.
Table 1.
Summary/Conclusions: We conclude that it is safe to do adenotonsillectomy
in patients with SCD with hemoglobin above 8 g/dl without any transfusion.
Exchange transfusion before surgery is not indicated and it does not improve
surgical or SCD-related outcome.
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CARDIAC AND HEPATIC IRON ASSESSMENT BY MR IMAGING IN
PATIENTS WITH BETA THALASSEMIA: SINGLE CENTER EXPERIENCE
Z Karakas1,*, Y Yilmaz2, S Aydogdu1, S Karaman1, M Dursun3
1Department of Pediatric Hematology and Oncology, 2Department of Pediatrics,
3Department of Radiology, Istanbul Medical School, Istanbul, Turkey
Background: Cardiac and hepatic magnetic resonance imaging for iron load
becomes more of an issue in patients with thalassemia. The planning of chela-
tion therapy needs more guidance in terms of signs or markers. 
Aims: The aim of the study is to assess the relationship between cardiac and
hepatic magnetic resonance imaging (MRI) values with serum ferritin level,
splenectomy status, and chelation therapy in patients with thalassemia major
and intermedia.
Methods: A total of 117 patients (58 male, 59 female) with thalassemia major
(n=90) and thalassemia intermedia (n=24) who were followed up in Istanbul
Medical Faculty Thalassemia Center were enrolled in the study. Their cardiac
and hepatic magnetic resonance imaging was evaluated by specialist radiolo-
gist and T2* with R2* values were calculated. The chelation therapy status and
splenectomy status of patients was recorded. Patients were divided into three
groups according to Cardiac T2* findings: high risk group (T2* MRI <10 ms),
medium risk group (T2* MRI 10–20 ms) and low-risk group (T2* MRI >20 ms).
The statistical analysis between MRI findings and chelation therapy was per-
formed by SPSS 21 version.
Results: The mean age was 24,77±9,87 years. The mean length of disease
was 21,36±10,11 years. Splenectomy was performed in 40 patients. Fifty-four
patients used DFX (deferasirox), 13 patients used DFP (deferiprone), 6 patients
received DFO (deferoxamine), 2 patients received DFO plus DFX, and one
patient was administered DFX plus DFP. The mean level of ferritin was 2093
±1,97 ng/ml (median 1252 ng/ml). The correlations of ferritin with MR parame-
ters were executed and results were found as following: a weak negative cor-
relation with Cardiac T2* values (p=0,00, r=-0,35), a strong positive correlation
with Hepatic R2* and liver iron concentration (p=0,00, r=0,61; p=0,00, r=0,77
respectively). There was also weak positive correlation between ferritin and
ALT and AST (p=0,00, r=0,39; p=0,00, r=0,36 respectively). The gender effect
on findings was found Hepatic R2* (296,7 vs 495,8 Hz) and liver iron concen-
tration (9,6 vs 15,8 mg/g) were significantly lower in females (p=0,00). When
analyzed according to chelation therapy, there was no significant relationship
apart from Hepatic T2* values which were significantly higher in patients receiv-
ing DFX (6,7 vs 3,9 ms; p=0,04). The ferritin (2291 vs 1262 ng/ml) and liver
iron concentration (13,8 vs 8,7 mg/g) were significantly increased in patients
with thalassemia major compared to intermedia group. The ferritin level was
significantly decreased from medium risk group to low-risk group (4038 vs 1758
ng/ml; p=0,00). The liver iron concentration was significantly decreased from
high risk group to low-risk group (21 vs 19 and 11 mg/g; p=0,03 and p=0,02
respectively).
Summary/Conclusions: Cardiac T2* and Hepatic R2* were better correlated
with ferritin. When combined with negative correlation of ferritin with Cardiac
T2* values, it may be supposed that the choice of chelation therapy may be
done according to Cardiac T2* and Hepatic R2* results. 
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A INSIDIOUS LINE BETWEEN THALASSEMIA INTERMEDIA AND LEFT
VENTRICULAR NON-COMPACTION DISEASE: THE ROLE OF CARDIAC
MAGNETIC RESONANCE
A Meloni1,*, F Macaione2, A Barison1, V Positano1, P Cavalli3, C Gerardi4,
A Scaccetti5, C Cosmi6, MC Resta7, S Novo2, P Assennato2, A Pepe1
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Univer-
sità degli Studi di Palermo, Policlinico “Paolo Giaccone”, Palermo, 3Day Hospital
di Talassemia, Ospedale “V. Fazzi”, Lecce, 4Presidio Ospedaliero “Giovanni
Paolo II” - Distretto AG2 di Sciacca, Sciacca (AG), 5Servizio Immunematologia
e Trasfusionale, Azienda Ospedaliera “S. Maria”, Terni, 6Clinica Pediatrica,
Azienda Ospedaliero-Universitaria di Sassari, Sassari, 7Struttura Complessa
di Radiologia, Ospedale “SS. Annunziata” ASL Taranto, Taranto, Italy
Background: Differentiation of left ventricle non-compaction (LVNC) from hyper-
trabeculated LV due to a negative heart remodeling in thalassemia intermedia
(TI) can depend on the selected cardiac magnetic resonance (CMR) criterion.
Aims: We verified whether the diastolic non-compacted to compacted
myocardium (NC/C) ratio criterion could actually discriminate the abnormal tra-
beculations observed in β-TI from LVNC patients and we compared this diag-
nostic approach with the CMR criterion suggested by Grotoff M et al. (Eur Rad
2012), which has been reported to be highly sensitive and specific for the LVNC
diagnosis.
Table 1.
Methods: CMR images were analyzed in 180 patients with β-TI consecutively
enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) Network and
20 patients with proved diagnosis LVNC studied at FTGM MRI Lab in Pisa from
2002 to 2014. The CMR diagnostic criteria applied in β-TI patients were: a
modified CMR Petersen’s criterion proposed by Piga et al (Am J Haem 2012)
based on a more restrictive ratio of diastolic NC/C >2.5 at a segmental level
and the Grothoff’s criteria (percentage of trabeculated left ventricular myocardial
mass (LV-MM) ≥25% of global LV mass and a total LV-MMI NC ≥15 g/m2). In
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the 20 patients with LVNC the final diagnosis was performed based on Grotoff’s
criteria and on the clinical/functional criteria for LVNC to further increase the
pre-test probability of the disease.
Results: In β-TI patients at least 1 positive NC/C segment was found in 18
patients (10%). Compared with LVNC patients, in 18 β-TI patients the non-
compaction areas were less frequent (3.70±2.22 vs 1.62±1.16; P=0.007). The
LV-MM NC percentage and LV-MMI NC g/m2 were significantly higher in LVNC
than in β-TI patients 27.21±2.45% vs 10.88±3.96%, P<0.001; 20.35±5.60%
vs.7.30±4.77%, P<0.001). None of the β-TI patients fulfilled the Grothoff’s cri-
teria. The table shows the comparison of CMR parameters. LVNC patients had
significant lower LV stroke volume index and LV ejection fraction and they had
an higher frequency of myocardial fibrosis detected by the LGE technique,
although the statistical significance was not reached.
Summary/Conclusions: Differentiation of LVNC from hypertrabeculated LV
in β-TI patients due to a negative heart remodeling depends on the selected
CMR criterion. Based on our data in all β-TI patients with a NC/C ratio >2.5 we
suggest to use Grothoff’s criteria to improve the specificity of the diagnosis of
LVNC.
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GENOTYPE/PHENOTYPE PATTERN IN EGYPTIAN PATIENTS WITH SICKLE
CELL DISEASE
AA Tantawy1,*, NH Elsherif1, TM Kamal2, CA Kirolos1
1Pediatric Hematology & Oncology, 2Molecular Genetcs, Ain Shams University,
Cairo, Egypt
Background: Sickle cell disease (SCD) refers to all different genotypes that
cause this clinical syndrome, yet secondary effectors genes are likely to mod-
ulate its phenotype.
Aims: This study aimed to evaluate genotype variation and allele segregation
among SCD patients and its relation to the different clinical presentations.
Methods: This cross-sectional study included 38 SCD patients. Genotyping
for beta thalassemia gene(BT) mutations was performed using polymerase
chain reaction (PCR) and reverse hybridization. Assessment of genotype rela-
tion to phenotype was based on: Onset of the disease, transfusion history,
baseline MCV, HbF%, frequency of pain episodes, and hospitalization, per-
centage of patients who suffered from acute chest syndrome, stroke and avas-
cular necrosis, sickling score, echocardiographic, carotid doppler findings.
Results: The most common BT gene mutation among SCD patients was
Codon 6[A>T] HbS/β̊ IVS1-1[G>A] (18%), then Codon 6[A>T] HbS/β+ IVS1-
110[G>A] (8%). 55% of the patients were diagnosed by baseline Hb elec-
trophoresis as Sβ+. Only 52% of sickle cell disease patients by genotype had
MVC normal and 72% had HbA2 <3.6%. Eighty eight% of Sβ,0patients by
genotype had low MCV, while half of Sβ +patients had HbA2 >5%. Although,
we found a higher baseline Hb S% and a lower Hb F% among homozygous
sickle cell patients compared with the 2 other groups, yet the results did not
reach statistical significance Homozygous SCD patients had a significantly
earlier age of onset, a higher baseline MCV and a lower HbF% compared with
Sβ0 and Sβ+ patients, but a comparable baseline markers of hemolysis. Eighty
percent of our studied Sickle cell patients had acute painful episodes, 18%
suffered from at least one attack of acute chest syndrome, 5.3% had avascular
necrosis of femur 15.8% had single episode of stroke while 6% had cardiac
morbidity, 13% had impaired left ventricular contractility, (8%) had cardiomy-
opathy, none had pulmonary hypertension, and all had normal transcranial
Doppler. We did not find significant difference between all 3 groups as regard
the frequency of painful Crises, the need for hospitalization, the percentage of
patients with avascular necrosis, cerebral stroke, acute Chest Syndrome and
the sickling score. Causes for transfusion varied among different groups, the
most common cause in homozygous sickle cell disease and sickle β0 patients
was painful crises and stroke (36%&20%), while in sickle β+ thalassemia
patients, the only cause was anemia(100%).This variation was not statistically
significant, and all 3 groups had comparable mean pretransfusion Hb level,
number of transfusion, transfusion requirement. Moreover, we did not find sig-
nificant difference between the three groups as regard number of patients on
Hydroxyurea treatment (76% among homozygous sickle cell patients, 67%
among Sβ0 and 75% among Sβ,+patients.
Summary/Conclusions: the presence and the nature of associated β-thalas-
saemia mutations influences the clinical presentation of sickle cell disease.
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DETECTING THE PREVALENCE AND AWARENESS OF CARRIER RATE
OF THALASSEMIA IN A COHORT OF UNIVERSITY STUDENT POPULATION
IN SRI LANKA
D Gunawardena1,*, N Wasana2, P Hearth3
1Haematology, 2Allied Health Sciences, University of Sri Jayawardenapura,
3Haematology, Medical Research Institute, Colombo, Sri Lanka
Background: The thalassemias are a group of autosomal recessive disorders
caused by a reduction or absent production of one or more of the globin chains
that make up the haemoglobin tetramers. Two main types, α and β tha-
lassemias are seen according to the type of globin chain involved, and there
are other types although not common such as δβ γδβ thalassemias which are
identified. Thalassemias pose an increasing health problem for the Indian sub-
continent and many Asian countries. Worldwide 56,000 conceptions have a
thalassemia major of which approximately 30,000 are affected by β-thalassemia
major and 3500 succumb to hydrops fetalis syndrome. Most of these patients
are born in developing and low income countries where they create an enor-
mous health burden. There is a significant increment of thalassemia carrier
rate in Sri Lanka, probably an unestimated increment in alpha thalassemia.
The increment of the number of patients with thalassemia form 2,094 in the
year 2005 to 4,924 by the year 2010 in Sri Lanka is a major concern where fur-
ther attention is necessary in investigating in to the failure of the general under-
standing and counselling the of thalassemia carriers. An analytical cross sec-
tional study was done on 384 undergraduates in University of Sri Jayewar-
denepura, Sri Lanka during year 2015. Objective of this study was to determine
the prevalence and awareness of thalassemia trait among the students of Uni-
versity of Sri Jayewardenepura. 
Aims: Aim is to screen the university student population who are the next gen-
eration to be married and a potential group of the population where effective
screening and genetic counseling for thalassemia can be done. This university
represents students from all parts of the country and hence a cross section of
the country is represented.
Methods: Venous blood was obtained from the students from the four faculties
and pre tested self-administered questionnaire was used to gather information
regarding awareness about thalassemia trait among the participants. Samples
were analyzed by the fully automated hematology analyzer Sysmex SX 500i.
The initial diagnosis of thalassemia carrier was done by using red cell indices
of the analyzer report combined with the blood picture reported by the consult-
ant haematologist. Final confirmation was done by quantifying the HbA2 levels
by HPLC. (High Performance Liquid Chromatography)
Results: Of the 384 blood samples tested, 53 (13.8%) had hypochromic micro-
cytic red cell indices (MCV <80 fL, MCH <27 pg) with normal iron studies. Fifteen
students (3.9%) were possible alpha thalassemia carriers where they showed
thalassemia indices with normal iron profile and HPLC (A2 levels <3.5%) with
the blood picture showing typical changes of thalassemia carrier. Eleven stu-
dents (2.9%) were carriers of beta thalassemia. Out of 384, twenty seven stu-
dents (7%) showed a haemoglobin level between 7-11.5g/dl with no obvious
thalassemia indices or blood pictures finding of thalassemia and they had low
serum ferritin levels. Out of 384 questionnaires, only two hundred and twenty
two (77.6%) were aware of thalassemia major and out of them, only hundred
and sixty five (88.7%) knew that pre- marital screening could prevent tha-
lassemia. This knowledge was mainly obtained by news items and television.
Summary/Conclusions: The awareness of thalassemia in the cohort of stu-
dents tested was not satisfactory and it highlights the importance of introducing
methods to improve their basic knowledge of the disease. This also detected
the Beta thalassemia carrier rate to be 2.9% which are compatible with the
results of the studies done previously on thalassemia in Sri Lanka, however
there seems to be a trend in higher levels of suspected alpha thalassemia rate
which was found to be 3.9% which needs attention. These need to be confirmed
by genetic studies which are financially difficult in the current set up. An incidental
finding of anaemia of 27 students was important in a young university student
population who are the future workforce of the country. This study highlights the
importance of continuing the screening campaigns specially the student screen-
ing programmes, pre-marital counseling and new born screening service that
are of paramount importance in reducing the births of thalassemia major.
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REFRACTORY AUTOIMMUNE HAEMOLYTIC ANEMIA IN ELDERLY
EFFECTIVELY TREATED WITH MYCOPHENOLATE MOFETIL
G Karras1, M Alexandrakis2, E Georgiadi1, C Doxani1, E Rouka1,*, D Kyriakou1
1Laboratory of Hematology and Transfusion Medicine, University Hospital of
Larisa, Larisa, 2Hematology Department, University Hospital of Heraklion, Her-
aklion, Greece
Background: Autoimmune haemolytic anemia (AIH) is a rare disorder that
sometimes may be lifethreatening. The treatment is not evidence based and
corticosteroids, azathioprine, cyclophosphamide, rituximab, and mycopheno-
late mofetil have been used effectively although there is not enough evidence
for the effectiveness and safety of the later one.
Aims: We present here 7 patients with AIH that were treated effectively with
mycophenolate mofetil.
Methods: Seven patients, 6 males and 1 female aged 75-82 years were refered
to our department diagnosed with autoimmune haemolytic anaemia 12 to 60
months ago. Three patients had received corticosteroids, azathioprine
cyclophosphamide and rituximab without gaining a PR or better and without
obtaining stable condition maintaining Hb levels about 9g/dl. Two patients
obtained PR with costicosteroids and rituximab but relapsed within 6 months
and could not get rid of the drugs for more than 4 months. The remaining 2
were on contineous corticosteroid treatment and occasionally rituximab for
more than 4 years maintaining hemoglobin levels between 8 and 10 g/dl. All
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the patients started mycophenolate mofetin for 3 months and corticosteroid
tapering thereafter. 
Results: Within 6 months 6 patients reached normal levels of haemoglobin
and reduced DAT titer to equal or less than half. They continued the drug for
26-36 months when DAT was negative and remained in remmision for 15-22
months without any drug. The 7th patient continues taking mycophenolate for
5 years with haematological remission (Hb=14g/dl) but DAT (+). All the patients
tolerated the drug very well without major adverse events. Lymphocytopenia
grade 2 and hypoglobulinaemia grade was a common condition in all patients
without infections. The 7th patient was prophylactically indroduced to antiviral
therapy as well as to cotrimoxazol/azathioprine.
Summary/Conclusions: Mycophenolate mofetil is an effective and well-toler-
ated drug in elderly patients with haemolytic anemia refractory to conventional
therapies.
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DIFFERENTIAL IRON STATUS AND TRAFFICKING IN BLOOD AND PLACENTA
OF ANEMIC AND NON-ANEMIC PRIMIGRAVIDA SUPPLEMENTED WITH
DAILY AND WEEKLY IRON FOLIC ACID TABLETS
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Background: Iron deficiency (ID) globally impact billions of people; mostly preg-
nant women. Anemia during pregnancy is mainly associated with ID; and pro-
phylaxis includes daily supplementation of iron folic acid (IFA) tablets. During
pregnancy, increased foetal iron demand leads to fluctuations in body iron
reserves; thus supplemental iron is recommended to meet the iron demand.
The effectiveness of weekly IFA supplementation in comparison to daily IFA
intake during pregnancy is still shadowy, as the available data from well-defined
clinical trials is inconsistent. The amount of quantifiable iron circulating in blood
and stored in placenta, in both the supplementation schemes and their correla-
tion with pregnancy outcomes is pre-requisite to reach any firm conclusion.
Owing to this, the present study was conducted to providing better understanding
of hemodynamics and molecular mechanism in human placental iron transfer.
Aims: To investigate the iron dynamics in anemic and healthy pregnant women
supplemented with daily and weekly IFA supplementation and its relation with
clinical outcome.
Methods: The subjects include non-anemic primigravida (NAP) (Hemoglobin
(Hb) >11 g/ dl, N= 60) and anemic primigravida (AP) (8.0 <Hb <11 g/ dl, N=60)
were followed across pregnancy at three time-points i.e. baseline (13-16 weeks
of gestation), after three months (25-28 weeks) and 6 weeks postpartum. The
subjects (NAP and AP) were randomly allocated to daily dose comprised 100
mg iron and 500 μg folic acid tablets and weekly dose contained two IFA tablets/
week till six weeks postpartum. Corresponding changes in hematological mark-
ers, iron status indicators viz. ferritin, iron and soluble transferrin receptor (sTfR)
in blood and placental ferritin expression was studied. Birth outcome, gesta-
tional length, infant weight and placental weight were recorded. The statistical
significance level (p <0.05) between the groups were assessed by applying
unpaired t-test using SPSS (version 20.0).
Results: Weekly IFA supplementation for three months has significantly altered
the Hb, hematocrit and red blood cell (RBC) count (p<0.05) and increased the
level of serum sTfR (p<0.002) at postpartum in AP. After three months of sup-
plementation, serum iron and sTfR were significantly different (p<0.01) between
the two supplemental groups in NAP; whereas, serum ferritin (p<0.001) was
significantly high at postpartum in daily IFA group of NAP. Placental ferritin
expression was increased in NAP supplemented with daily IFA in comparison
to weekly IFA. The placentas obtained from AP supplemented with weekly IFA
showed significantly low ferritin (p<0.05) expression when compared with daily
IFA supplementation. However, birth outcome, infant weight, gestational length
and placental weight were comparable in both the supplementation groups. 
Summary/Conclusions: The placental ferritin expression and its serum level
showed similar trend among anemic and non-anemic primigravidas supple-
mented with daily and weekly IFA tablets. Although, significantly lower placental
ferritin was observed in AP supplemented with weekly IFA tablets; but there
was not any difference in birth outcome, infant weight or gestational length
between two supplementation groups. The modulation in iron transporter
expression may be involved in anemic placentas to flux iron for developing
fetus, thereby maintaining the healthy pregnancy. The results of this study
revealed that blood iron status/ hematological markers may be helpful to assess
the optimum amount of supplemental iron required during pregnancy.
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THE USE OF NEW ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS
C VIRUS (HCV) INFECTION IN PATIENTS WITH THALASSAEMIA:
PRELIMINARY DATA ON SAFETY AND EFFICACY
P Ricchi1,*, A Spasiano2, S Costantini2, P Cinque2, B Ziello2, M Caputo3,
E Assentato3, A Lanza4, A Filosa2
1AORN Cardarelli, Naples, Italy, 2Oncoematologia, 3Biologia Molecolare di
Virologia Immunodiagnostica dei Trapianti, 4Gastroenterologia, AORN Car-
darelli, Naples, Italy
Background: Several adult patients with thalassaemia major (TM) and talas-
saemia intermedia (TI) following the failure of combination therapy with pegylated
interferon (PEG-IFN) and ribavirin are still affected by Hepatitis C virus (HCV)
infection and need to be treated with new antiviral drug. To date, no data are
available on interaction between chelation treatment and new antiviral drugs.
Aims: Here we report our preliminary data on their efficacy and safety during
different chelation treatments on the first four weeks of antiviral therapy.
Methods: Since December 2015, 17 patients with TM, 2 with TI, 2 with sickle
cell/thalassaemia were considered for treatment. Twelve received Ledipasvir-
Sofosbuvir, 7 Ledipasvir-Sofosbuvir-ribavirin, 1 sofosbuvir-ribavirin, one
daclatasvir-sofosbuvir. All patients but three, were and continued to be under
chelation treatment: five were under deferasirox (DFX), 3 under deferiprone
(DFP), 2 under desferioxamine (DFO), 6 under alternate DFO/DFP, 1 under
DFO and DFX combined treatment. During the first four weeks of therapy all
patients had weekly monitoring of serum ferritin, liver enzymes, creatinin level,
complete blood count and biweekly monitoring HCV RNA copies. 
Results: All treatments were very well tolerated; patients receiving ribavirin
still not presented significant increase in blood transfusion requirements. Fol-
lowing one week of treatment liver enzyme decreased significantly from base-
line: mean±SD alanine transaminase (ALT) and aspartate transaminase (AST)
decreased from 103±127 to 35±U/L (p=0.03) and from 83±85 to 33±27 (p=0.02)
U/L, respectively; mean±SD ferritin level and HCV RNA copies decreased from
1556±1436 to 1334±1355 ng/ml (p=0.68) and from 1,650000±1472378 to 0
copies/ml (p=0.000014). A further decline was observed at fourth weeks in
mean (± SD) ALT, AST and ferritin level which dropped to 28±29 U/L (p=0.02),
30±20 U/L(p=0.01) and 1058±1011 ng/ml (p=0.26), respectively. No increase
in glomerural filtration rate (GFR) and impairment in urinary albumin/creatinine
ratio were observed among patients treated with DFX with respect to basal lev-
el. No event of neutropenia and agranulocytosis neither reduction in neutrophil
count with respect to basal level occurred among patients treated with DFP
Summary/Conclusions: All treatments were effective in promptly drop viral
copying. The observed reduction in ferritin level is likely linked to reduced hepat-
ic lysis and shouldn’t be used to modify chelation therapy. Our opening data
show that chelation treatment is feasible and safe. The termination of treatments
and further studies on larger population are needed to confirm these preliminary
observations.
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CMR FOR MYOCARDIAL IRON OVERLOAD ASSESSMENT: CALIBRATION
CURVE FROM THE MIOT PROJECT
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tologia, Policlinico Umberto 1, Roma, 5Centro Microcitemie, Azienda
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Background: The measurement of myocardial iron by T2* cardiovascular mag-
netic resonance (CMR) has been established as fundamental to the best prac-
tice management of thalassemia. However, iron calibration data in humans is
limited and CMR calibration varies according to instrumentation and technique.
Aims: The aim of this study was to calibrate the T2*-CMR technique for non-
invasive cardiac iron assessment, by considering a segmental approach.
Figure 1.
Methods: Four human hearts were studied from transfusion-dependent
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patients after their death within the MIOT network (Myocardial Iron Overload
in Thalassemia). A multislice multiecho T2* approach was adopted. After CMR,
used as guidance, the heart was cut in three short-axis slice and each slice
was cut into different equiangular segments, the same ones in which the T2*
was assessed. Tissue iron concentration in the segments was measured with
inductively coupled plasma atomic emission spectroscopy.
Results: T2* and iron concentration were overall assessed in 36 myocardial
segments: 6 in the first heart (year 2004), 6 in the second one (year 2004), 8 in
the third one (year 2005), and 16 in the fourth one (year 2010), Figure 1A shows
the segmental iron concentration (in milligrams per gram dry weight) plotted
versus the correspondent segmental T2* value (in milliseconds). As expected,
the relationship was not linear. In Figure 1B the R2* values (R2*=1000/T2*, in
s-1) were considered. Regression analysis yielded a linear calibration of the fol-
lowing form: [Fe]R2*=0.0079xR2*-0.1262 (R-square=0.999).
Summary/Conclusions: As in the only previously proposed calibration curve
by Carpenter et al (Circulation 2011), we did not collected hearts with an inter-
mediate iron burden. We found an excellent linear agreement between R2*
and cardiac iron with a model similar to the calibration curve in the gerbil
showed by Wood J et al (Circulation 2005). The results further validate the cur-
rent clinical practice of monitoring cardiac iron in vivo by CMR.
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REDUCED INSULIN NEED IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
(T2DM)WITH IRON DEFICIENCY ANEMIA THREATED WITH SUCROSOMIAL
IRON VS INTRAVENOUS SODIUM FERRIGLUCONATE. MULTICENTRIC
PROSPECTIVE STUDY
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Background: About one out of four diabetic patient shows iron deficiency ane-
mia. I.v. sodium ferrigluconate is frequently used as iron deficiency anemia
therapy. The sucrosomial iron is a new compound used in the therapy, made
of sucrose ester containing liposomal iron. Sodium ferrigluconate increases
the amount of free radicals. The increase of free radicals increases inflamma-
tion. Inflammation reduces insulin sensitivity in diabetic patients.
Aims: To assess whether the use of sucrosomial iron involves less use of
insulin in patients with T2DM with iron deficiency anemia
Methods: This study is a multicentric randomized study. We considered 40
T2DM patients with iron deficiency anemia, with TIBC saturation <10% and hemo-
globin <10 g/dl, without documented infections, tumors or autoimmune diseases.
All patients received diabetic diet. They received lispro insulin TID + glargine
insulin once daily. In group A 20 patients, M: F=12/8, median age 75 years (R65-
82), median blood glucose 230 mg/dl (R170-350), median CRP at onset 10
mm/Ih (R2-22), were treated with sodium ferrigluconate 62.5 mg in 250 cc NS ic
iv in 4 hours/day for 12 days. In group A, 10 patients had anemia by gastroin-
testinal hemorrhage, 5 by atrophic gastritis, 5 by insufficient intake. In group B,
20 patients, M: F=11/9, median age 78 years (R67-83), median blood glucose
220 mg/dl (R180-380), median CRP at onset 12 mm/Ih (R2-20), were treated
with sucrosomial iron 1CP 30 mg orallyx2/day for 30 days. In group B, 12 patients
had anemia by gastrointestinal hemorrhage, 4 by atrophic gastritis, 4 by insuffi-
cient intake. Differences between the two groups were not statistically significant.
Statistical analysis was done with Fisher exact test and with Chi Square test.
Results: In group A at day 6 of iron support the median values of CRP were
38 mm/Ih (R4-127), with 5-documented infections (urinary 3, lung 1, skin 1);
only 8 patients achieved blood glucose values <or=140 mg/dl with a median
total lispro insulin dose of 42 U(R25-60) and glargine insulin dose of 22U (R10-
28). In group B at day 6 of iron support the median values of CRP were 12
mm/Ih (R2-12), with 2-documented infections (urinary 2); 15 patients achieved
blood glucose values <or=140 mg/dl with a median total lispro insulin dose of
20 U(R12-23) and glargine insulin dose of 20U (R10-22).
Summary/Conclusions: In diabetic patients with iron deficiency anemia sup-
ported with sucrosomial iron the median lispro insulin need appears to be lower
than that of the patients supported with i.v. sodium ferrigluconate. This study
needs confirmation on a larger cohort of patients.
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HYPERFERRITINEMIA: CLINICAL COURSE AND THERAPEUTIC STRATEGY
V Papadopoulos1,*, S Effraimidou1, E Sevdali2, E Papadakis1, M Topalidou1,
K Kokoviadou1, A Banti1, M Speletas2, A Kioumi1
1Hematology Department, Papageorgiou General Hospital, Thessaloniki,
2Department of Immunology & Histocompatibility, School of Health Sciences,
Faculty of Medicine, University Hospital of Larissa, University of Thessaly,
Larissa, Greece
Background: Hyperferritinemia is a common laboratory finding, which requires
assessment of iron status and investigation for underlying disorders, such as
hereditary hemochromatosis, inflammatory and malignant conditions. True iron
overload is found in approximately 10% of patients presenting with hyperfer-
ritinemia (Adams & Barton. Journal of Hepatology 2011;453-8). Although
research of the last decades has given insight into new molecules and muta-
tions and their role in iron homeostasis, the clinical consequences of all these
mutations are not straighforward, and there are still cases of hyperferritinemia
with no underlying cause identified.
Aims: Objective of the study is to assess the clinical course of patients with
hyperferritinemia and the therapeutic manoeuvres performed.
Methods: Data was collected retrospectively for 17 patients with hyperferritine-
mia, followed up for a mean of 5.75 years. They were negative for classic HFE
mutations (C282Y homozygosity, C282Y/H63D compound heterozygosity) and
had no underlying malignancy, inflammation or alcohol abuse. Hepatic iron
was assessed with MRI T2* or liver biopsy. The decision to propose therapeutic
phlebotomy was based on presence of iron overload, eligibility for blood dona-
tion and patient preferences.
Results: Seven patients were heterozygous for ferroportin (FPN) R178Q muta-
tion. At diagnosis their mean serum ferritin level (SF) was 2,017ng/ml (range
800-5077) and trasferrin saturation (TS) was normal. Three patients with mod-
erate iron overload were offered regular phlebotomies once per month; iron
overload was diminished, while SF did not change significantly. In the main-
tainance phase, phlebotomies were performed once in 3 months, and inter-
rupted during pregnancy and puerperium. Patients without iron overload were
encouraged to become blood donors. Seven patients, albeit negative for tested
HFE and ferroportin mutations, had mild to moderate hepatic iron accumulation,
with mean SF at 880ng/ml (range 435-1351); three of them had elevated TS,
that is over 45%, and two had fatty liver on imaging studies. Venesections were
performed to all of them, once in 1-2months initially and then every 3-6 months.
Iron accumulation and SF were reduced even down to normal ranges; vene-
sections were well tolerated at the aforementioned frequency. A patient
homozygous for HFE-H63D mutation, with high SF and high TS, had no iron
overload; SF was reduced without any intervention during the follow-up. A
teenage girl with ferroportin polymorphism had isolated hyperferritinemia with-
out iron overload nor high TS, which remained so after 8 years. A patient with
hyperferritinemia, high TS and catarract, was tested positive for the light ferritin
5’-UTR iron response element (L-FT IRE) mutation, which has been identified
in the so-called ‘hereditary hyperferritinemia-catarract syndrome’. No iron over-
load was detected at diagnosis and after 5 years of follow-up. These changes
of SF and TS from baseline values are depicted in the figure (blue lines: FPN
heterozygotes, orange lines[wt]:no mutation identified).
Figure 1.
Summary/Conclusions: In all of the described cases, a benign course of the
patients with hyperferritinemia is evident. Even in the cases with moderate
hepatic iron overload, a less stringent phlebotomies program (once per 1-2
months, compared to higher frequency of weekly venesections, recommended
for classic and juvenile hereditary hemochromatosis types by European Asso-
ciation for the Study of the Liver, Journal of Hepatology 2010;53:3–22) seems
to provide satisfactory response, removing excess iron from tissues and being
very well tolerated. This proposal could be incorporated into prospective trials,
in order for clear evidence-based guidelines to be developed in the future.
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EFFECT OF L-TYPE CALCIUM CHANNEL BLOCKER (AMLODIPINE) ON
MYOCARDIAL IRON DEPOSITION IN PATIENTS WITH THALASSEMIA
MAJOR: A RANDOMIZED CONTROL TRIAL
N Alvi1,*, F Tipoo1, A Rizvi1, Z Fadoo1, A Imran1, A Sadaf1, A Shakoor1,
F Quadri1, Z Sajjad1, M Khurshid1, U Fatima1, S Ashiqali1, S Colan2, B Hasan1
1Aga Khan University, Karachi, Pakistan, 2Boston Children’s, Boston, United
States
Background: Sideroblastic cardiomyopathy is a feared complication in Tha-
lassemia Major (TM). Recent evidence suggests a role for L-type-Ca2+-chan-
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nels (LTCC), in addition to standard chelation therapy, in mediating myocardial
iron-uptake.
Aims: Our primary objective was to determine the efficacy of Amlodipine in
reducing myocardial iron-load when compared to controls. Changes in echocar-
diographic derived LV function, liver T2* and iron-content were also sought.
Methods: Participants managed for over a year with a transfusion need of
≥180 ml/kg/year, having received ≥10 blood transfusions in life-time and with
serum ferritin ≥1000 ng/dL were invited. All patients with known hypersensitivity
to amlodipine, history of developing tetany with calcium channel blockers or
systolic blood pressures ≤ 2 SD for age at baseline and pre-existing cardiac
conditions were excluded. Twenty patients in a 1:1 allocation ratio were ran-
domized into the intervention and control arms. Conventional echocardiographic
measures, global longitudinal strain (GLS), T2* CMR and liver T2* were
obtained at baseline, 6 and 12 months. Continuous and categorical variables
were reported as mean (SD and CI)/median (IQR) and frequency/percent
respectively. Mann-Whitney U test and Fisher exact test were used. Change in
outcomes with respect to time and treatment were tested using repeated meas-
ure ANOVA. P-value of <0.05 was considered significant.
Results: 10 participants in intervention arm (median age 18 IQR 15.8-19.3
years) and 9 controls (median age 16 IQR 13-18 years) were analyzed. The
two groups were statistically similar at baseline. Adjusting for age, years on
transfusion and chelation compliance, a statistically non-significant trend of
improved cardiac T2* was seen from baseline (15.8ms, CI 6.9-24.6) to 6 months
(T2*= 17.3ms, CI 8.8-25.9) in the intervention arm (p=0.77) when compared
with controls. This change was sustained at 12 months (figure 1). MIC, con-
ventional echocardiographic parameters and GLS, liver T2* and LIC did not
change significantly throughout the study between the two arms.
Figure 1.
Summary/Conclusions: Calcium channel blockers such as amlodipine show
promise but larger clinical trials are needed to establish their role.
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IRON STATUS IN BETA THALASSAEMIA TRAIT
Y Yousafzai1,*, S Khan2, T Jalil3, A Mir4, K Ayaz1, F Raziq4
1Institute of Basic Medical Sciences, Khyber Medical University, 2Department
of Haematology, Rehman Medical Institute, 3Department of Pathology, Khyber
Girls Medical College, 4Department of Pathology, Rehman Medical Institute,
Peshawar, Pakistan
Background: Iron overload remains the cause of morbidity and mortality in
patients with beta thalassaemia major. Repeated transfusions and ineffective
erythropoiesis lead to excessive iron stores in the body. However, not much is
known about the status of iron in carriers of beta thalassaemia mutation. In
Pakistan nearly 1/3rd population has iron deficiency and the policymakers have
suggested global flour fortification with iron. This may have implications for the
nearly 7% BTT population. Without knowing whether the BTT individuals are
prone to develop iron overload or deficiency, this may be potentially harmful to
such individuals.
Aims: The aim of this study was to determine whether carriers of beta thalas-
saemia trait could develop iron deficiency or iron overload. 
Methods: Beta thalassaemia trait was diagnosed with HPLC (HbA2>3%) and
serum Ferritin levels were measured using sandwitch ELISA method. A total of
101 individuals (50 males and 51 females) with BTT were assessed for serum
ferritin levels. None of these subjects were on oral or injectable iron therapy or
has any recent inflammatory event. 
Results: Overall, 93% carriers of beta thalassaemia trait were anaemic where-
as 7% had Hb within the normal range. Serum ferritin levels of 18.8% were low
(mean serum ferritin while 8.3±4.25 ng/ml) while 75.2% individuals were iron
replete. Interestingly, 6% individuals had serum ferritin levels higher (mean
911±788 ng/ml) than the reference range. This iron overload was more common
in adults (4%) and males (4%). The results imply that iron deficiency a common
occuring in beta thalassaemia trait individuals in Pakistan. However, a smaller
proportion of carriers may also develop iron overload.
Summary/Conclusions: This pilot study was carried out to determine the sta-
tus of iron balance in beta thalassaemia trait individuals. Both iron deficiency
and overload were observed. These findings are significant and provide a ration-
ale for more robust epidemiological studies.
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ACQUIRED IRON-REFRACTORY IRON DEFICIENCY ANEMIA (ACQUIRED
IRIDA): A TUMOR RELATED DISORDER
R Angel F.1,*, R Joan1, C Vanesa1, SG Jana1, PC Anna1, S Marta1, T Josep2,
F Júlia2
1Hematology, 2Biochemistry, Hospital de Sant Pau, Barcelona, Spain
Background: Mutations in the TMPRSS6 (matriptase-2) gene are associated with
severe iron-refractory iron deficiency anemia (IRIDA) resulting from an overexpres-
sion of hepcidin. Microcytic anemia is the hallmark of this disorder. A similar form
of acquired microcytic anemia has been observed in several situations, including
benign tumors (1) or malignant tumors (1), treatment with m-TOR inhibitors (3).
Aims: To evaluate the prevalence of this acquired form of microcytic anemia.
Methods: From the group of patients with anemia studied in our red cell pathol-
ogy unit for a year those with microcytic anemia and biochemical data similar
to IRIDA were clinically evaluated. 
Results: A total of 3911 anemia patients were studied for a year, including 882
(22.5%) with microcytic anemia. Nine of these 882 patients (1% of microcytic
anemia, and 0.2% of total) showed a pattern similar to IRIDA. Main analytical
data of these 9 patients are included the table below. 
The microcytic anemia showed mixed inflammatory (increased SR and SF)
and iron deficiency (low SI and high sTfR) signs. In all cases the diagnosis of
the microcytic anemia was at the onset of the disease, and in 8 out of the 9
was related to neoplasia, including: renal carcinoma (2 cases), carcinomatosis
peritoneal due to bladder neoplasia, disseminated mesotelioma, bladder car-
cinoma and lung carcinoma, renal lymphoma, disseminated neoplasia of prob-
able bladder origin, rectal adenocarcinoma with a perirenal mass. Six of them
died. The remaining case was an HIV patient with pneumocystis jirovecii pneu-
monia, after pneumonia treatment anemia disappeared.
Table 1.
Summary/Conclusions: This microcytic anemia was rare, but it was related
with malignant tumor with very poor prognosis, mainly involving kidney. Despite
its rarity, this diagnosis should be considered owing to the poor prognosis. The
term acquired IRIDA is proposed for this type of acquired microcytic anemia. 
References
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GENOTYPE IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE:
RELATION TO VASCULAR COMPLICATIONS AND SUBCLINICAL
ATHEROSCLEROSIS
A Tantawy1,*, A adly1, E ismail2, Y Elhenawy1
1Pediatrics, 2Clinical Pathology, Ain Shams University, Cairo, Egypt
Background: Sickle cell disease (SCD) has a wide spectrum of complications.
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Many factors contribute to the variability in SCD including genetic determinants.
Aims: To assess the relation between different genotypes among 38 children
and adolescents with SCD and vascular markers, iron overload as well as vas-
cular complications and subclinical atherosclerosis.
Methods: SCD patients (21 males and 17 females), in steady state were stud-
ied. All patients were subjected to full history and thorough clinical examination
with special emphasis on history of sickling crisis, cardiopulmonary disease,
acute chest syndrome, stroke, bone manifestations, nephropathy, spleen sta-
tus, transfusion history and hydroxyurea/chelation therapy. Laboratory inves-
tigations included hematological profile, liver and kidney functions, markers of
hemolysis (lactate dehydrogenase [LDH] and indirect bilirubin) and serum fer-
ritin. Soluble CD163 (sCD163) was measured by enzyme linked immunosor-
bent assay while analysis of platelet microparticles (PMPs) was done by flow
cytometry. Pediatric SCD severity index was assessed based on both clinical
and laboratory variables. DNA genotyping was identified using on polymerase
chain reaction and reverse hybridization. Echocardiography and assessment
of carotid intima media thickness were performed. 
Results: Based upon DNA genotyping, patients were categorized as either
homozygous sickle cell disease (HbSS) or heterozygous sickle cell disease
(Hb S/β); 24 (63.2%) patients had sickle cell anemia (SCA), 10 (26.3%) patients
had sickle βº thalassemia and 4 (10.5%) patients had sickle β+ thalassemia.
Comparison between patients with SCA (n=24) and those with sickle β-tha-
lassemia (n=14) revealed no significant difference as regards age, sex, anthro-
pometric measures, Tanner stage, family history or residency (p>0.05). A trend
towards higher incidence of consanguineous marriage among families of
patients with sickle β-thalassemia was found (p=0.082). Patients with SCA had
significantly higher incidence of pulmonary hypertension, acute chest syn-
drome, frequent sickling crisis, avascular bone necrosis and nehropathy while
those with sickle β-thalassemia had higher incidence of splenectomy, viral
hepatitits and heart disease (p<0.05). The degree of hemolysis and iron over-
load was increased in sickle β-thalassemia patients compared with SCA group
as shown by elevated transfusion index, LDH and serum ferritin (p<0.05).
Patients with SCA displayed an evident state of inflammation, vascular injury
and subclinical atherosclerosis reflected by high white blood cells (p=0.018),
monocyte count (p=0.017), HbS, sCD163 levels (p<0.001), PMPs (p<0.001)
and CIMT (p=0.029). Upon comparing genotypes among patients with
mild/moderate versus severe disease, SCA genotype represented the higher
incidence in severity (80.8%) followed by sickle βº thalassemia (19.2%) while
all patients with sickle β+ thalassemia (n=4) were in the mild/moderate group.
Genotype, in addition to HbS and parameters of vascular dysfunction (sCD163,
PMPs and CIMT) were independently related to disease severity in logistic
regression analysis. The cutoff values the studied vascular markers in relation
to disease severity were determined.
Summary/Conclusions: Our findings could be of pathophysiological impor-
tance, because they provide evidence that genotyping may not only have a
role in predicting disease severity in young SCD patients but it is potentially
involved in determining the type of vasculopathy developed in those patients,
allowing better individualized treatment.
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MARKED HYPERFERRITINEMIA (SERUM FERRITIN>10000ΜG/L). A POOR
PROGNOSIS FACTOR
R Angel F.1,*, R Joan1, C Vanesa1, SG Jana1, PC Anna1, S Marta1, T Josep2,
F Júlia2
1Hematology, 2Biochemistry, Hospital de Sant Pau, Barcelona, Spain
Background: Iron overload is a poor prognosis factor in patients with myelodys-
plasic syndromes or patients undergoing hematopoietic stem cell transplantation
(HSCT) when considering a serum ferritin (Ft) of 1000 µg/l as a threshold.
Marked hyperferritinemia (MHFT) is a hallmark of hemophagocytic syndromes
and is a diagnostic criterion of the hemophagocytic lymphohistiocytosis.
Aims: The characteristics of patients with MHFT (Ft>10000µg/l) were studied.
Methods: Cases with hyperferritinemia (>1000 µg/l) and the characteristics of
the patients with MHFT (Ft>10000 µg/l) were studied for a year. Serum Ft was
evaluated using an Architect c.i. 16200 (Abbott Diagnostics).
Results: A total of 1056 samples presented Ft ≥1000 µg/l, 40 of which showed
a MHFT(3.8%) in 25 patients. Of these, 12 died (48%) between 2 and 67 days
after the determination, including: 4 non hematological neoplasias with metas-
tasis; 3 with infection after HSCT; 2 with hemophagocytic syndrome associated
with chronic myelomonocytic leukemia and diffuse large B-cell lymphoma (DLB-
CL); 1 respiratory infection during T-cell lymphoma treatment; 1 acute myeloid
leukemia in pancytopenia postchemotherapy and 1 chronic lymphatic leukemia
that evolved into a Hodgkin’s lymphoma. Of the 13 who survived, 7 presented
infection while undergoing HSCT (viral infection caused by CMV in three cases,
type A influenza virus in 2 and 1 viral encephalitis; 1 fungal infection (aspergillus)
and 2 bacterial sepsis (pseudomonas). The six remaining cases showed 2
hepatopathy (1 hepatic cirrhosis with MRSA sepsis and 1 on the onset of
autoimmune hepatitis); 2 presented MHFT during chemotherapy (1 acute
myeloid leukemia and 1 for DLBCL plus aspergillus infection); 1 was a
myelodysplastic undergoing HSCT with severe previous transfusional hemo-
siderosis; and, finally, 1 with pancytopenia in a kidney transplanted patient.
Summary/Conclusions: MHFT is a poor prognosis factor and half of the
patients died after a few days. In those who survived, MHFT appeared during
infection, especially viral infections, in patients undergoing HSCT or receiving
chemotherapy. In this regard, MHFT is a useful sign of viral infection. Further
studies are warranted to confirm the clinical value of MHFT.
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LIPOSOMIAL IRON IS SAFE AND COST-EFFECTIVE IN HCV PATIENTS
WITH TYPE II DIABETES AND ANEMIA DUE TO ESOPHAGEAL OR
GASTRIC BLEEDING
G Giordano1,*, A Parente2, R Gigli3, M Magri1, G Berardi4, B Carabellese5,
F D’Amico2, L Luciano2, R Fratangelo2, G Niro3, A Licianci6, L Di Marzio6, M Gasperi7
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7endocrinology, molise university, Campobasso, Italy
Background: HCV patients frequently show anemia due to esophageal or
gastric bleeding and type 2 diabetes. Iron support reduces degree of anemia.
Iron support might cause hepatic function worsening or hepatocellular cancer
onset. Non transferrin bound iron may sustain inflammation and increase insulin
resistance.
Aims: Aim of this study is to verify if sucrosomial oral iron support vs ferric glu-
conate iv iron support vs transfusional support is safe and effective in patients
with HCV treatment with iron deficiency anemia.
Methods: 35 patients with HCV related anemia for esophageal varices and
gastric bleeding with a median Hb level of 8 g/dl (R8-9.5 g/dl), were treated 15
with sucrosomial oral iron 30 mg 1 tablets t.i.d for 3 months (group A), 10 with
i.v. ferric gluconate 62.5 mg/day for 15 days (group B) and 10 with 1 blood
transfusion/day (group C) until Hb increase level of 1 g/dl was reached. Median
Hb and glucose level in group A were 8 g/dl and 140 mg/dl respectively, in
group B 9.5 g/dl and 130 mg/dl, in group C were 7 g/dl and 160 mg/dl. All
patients received an abdomen echography to detect hepatocellular carcinoma
(HCC) at 1, 3, 6 months.
Results: Patients in group A gained 1 g/dl Hb after 1 month (R 3-6 weeks),
with a median blood glucose level of 130 mg/dl (R120-230) and a median cost
of 30€/month (R 20-80), patients in group B gained 1 g/dl in 7 days (R 6-13
days), with a median blood glucose level of 310 mg/dl (R190-430) and a median
cost of 1240€/month (R 830-2800), patients in group C gained 1 g/dl in 1 day
(R 2-4 days), with a median blood glucose level of 210 mg/dl (R160-330) and
a median cost of 400€/month (R 350-950). Only 1 patient in group B and 1
patient in group C developed HCC at 6 months. Worsening of liver function
blood test was observed only in group C.
Summary/Conclusions: Liposomial iron is safe and cost-effective in HCV
patients with type II diabetes and anemia due to esophageal or gastric bleeding.
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THROMBOCYTOPENIA AFTER IRON INFUSION: A CASE SERIES OF
FOUR PATIENTS AND REVIEW OF LITERATURE
B Lioger1,2,*, P Beurier1, J Biogeau1, AP Jonville-Bera3, S Ollier4, N Ferreira-Maldent1,
F Maillot1,2
1Service de Médecine Interne, University Hospital of Tours, 2Université François
Rabelais, 3Pharmacologie clinique, centre régional de pharmacovigilance, Uni-
versity Hospital of Tours, Tours, 4Médecine interne et immunopathologie clinique,
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
Background: Among all the etiologies of anemia worldwide, iron deficiency
remains the leading cause and might be present in 1 to 2% of adults. A throm-
bocytosis between 500 to 700x109/L or more rarely a thrombocytopenia under
100x109/L have also been described. The management of iron deficiency
involves the research and treatment of a bleeding; an iron uptake quantification
with a dietary survey followed by an oral or intravenous iron supplementation.
However, published cases of secondary thrombocytopenia after an iron injec-
tion remain troublesome and underline our partial understanding of its mech-
anism of action.
Aims: The objective of our study was to describe the clinical and biological
characteristics of thrombocytopenia occurring after iron infusion in patients.
Methods: Two strategies have been applied to collect cases. On one side, we
have searched through the French Pharmacovigilance Database (FPVD); and
on the other side, we have performed a systematic review. We used “thrombo-
cytopenia” as high level term (MedDRA 11.0) and drug exposition was defined
by the presence in the report of intravenous iron coded “suspect” according to
the WHO criteria, whatever the level of causality assessment.
Results: This study found 9 patients (1M, 8F) having thrombocytopenia after
intravenous iron products, four from the FPVD and five from the literature. The
median age at diagnosis was 37 years old (range 16-90). The spectrum of iron
supplementation included bleeding (n=6), malabsorption (n=1), a peritoneal
dialysis (n=1), and an inflammatory anemia (n=1). The hemoglobin level was
5.7±2.3 g/L (range 3.1-9.6) with a median MCV 63 fL and a median platelet
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counts of 172±133x109/L (range 102-434). Two patients had thrombocytosis
before admission. Before intravenous iron products, four patients have received
oral iron drugs and units of packed red blood cells for two patients. Treatment
of intravenous iron consisted of iron sucrose (n=8) and ferric carboxymaltose
(n=1). One patient was treated with intramuscular injection of iron sucrose. The
median time to the onset of the thrombocytopenia was 3±2.4 days (range 2-8).
The average decrease in platelets count compared to the baseline was 85%.
The available bone marrow aspirations showed a megakaryocytic hypoplasia
(n=4) or no abnormality of the megakaryocytes (n=2). Two patients have expe-
rienced hemorrhagic events. One has epistaxis and the other one purpuric
ecchymosis. Only one patient received packed of platelets. We aimed to identify
some subsets of patients according to their baseline characteristics. However,
there was no difference between patients with early (<3 days) or late (>3 days)
thrombocytopenia.
Summary/Conclusions: As we reported only nine cases in this study, we
hypothesize that thrombocytopenia secondary to an iron infusion remains an
uncommon adverse drug reaction. Our statement is also supported by the
absence of similar data from the European Medicines Agency and the Food
and Drug Administration. The appearance of thrombocytopenia does not seem
specific of the intravenous form because some cases of thrombocytopenia
have been reported with oral iron products. Withdraw of IV iron remained the
first option of treatment and platelet transfusions was added if necessary. The
main entity in the differential diagnosis of iron-induced thrombocytopenia is
thrombocytopenia associated with IDA. In conclusion, clinicians should be
aware of this possibility, as in one hand iron is the treatment of thrombocytope-
nia and on the other hand, iron might be the trigger of the thrombocytopenia.
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AUTOIMMUNE HEMOLYTIC ANEMIA IN CHILDHOOD. LONG TERM
EXPERIENCE FROM A SINGLE CENTER
M Economou1,*, A Teli1, D Adamidou2, P Panagopoulou3, E Farmaki1, A Kattamis4
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al and Kapodistrian University of Athens, Athens, Greece
Background: Autoimmune hemolytic anemia (AIHA) is an immune mediated
cytopenia rarely encountered in the first years of life. Childhood AIHA is char-
acterized by diagnostic complexity in many cases and prognostic uncertainty
in most, while therapeutic approach remains not well determined. 
Aims: Aim of study was to report on the clinical presentation, management
and long term outcome of cases with AIHA followed at a single pediatric hema-
tology department during a 12year period.
Methods: The study was retrospective, covering the period between January
2004 and December 2015. Hospital files were used to record data including
age at diagnosis, personal and family medical history, laboratory investigation,
treatment, time of follow up, complications and relapses.
Results: During the given time period, 16 patients were diagnosed with AIHA.
Mean age at diagnosis was 7.8 years (4 months-13 years) and mean time of
follow up 5.08±4.18 years (4 months-12 years). A family history of autoimmune
disorder was reported in 2/16 patients (12.5%). A known history of congenital
hemolytic anemia was reported in 3/16 patients (18.7%) and of autoimmune
thyroiditis in 1/16 patients (6.25%, while a history of recent infection was record-
ed in 11/16 patients (68.7%). In 12/16 cases (75%) AIHA was considered pri-
mary and in 4/16 (25%) found to be secondary to other conditions - EBV infec-
tion in 2 cases, systemic lupus erythematosus in one case and autoimmune
lymphoproliferative syndrome in one case. Mean Hb at diagnosis was 6.29
±2.22 gr/dl and median reticulocyte count 11.2% (0.8-32%) - 2 patients initially
presenting with reticulocytopenia. In all but 2 cases (93.7%) direct Coombs
test was IgG-IgG/C3d positive, in one case IgA positive and in one case initially
negative. As to immunology studies, 8 patients presented with transient ANA,
1 patient with findings consistent with SEL (presence of ANA with low C3 and
C4) and 2 patients with positive ATA (one already diagnosed with autoimmune
thyroiditis). As to management, in 7/16 cases (43.75%) at least one urgent
transfusion was required, while in 5/16 cases (31.26%) more than two. All
patients received IVIG 1-6g/kg and solu-medrol pulse therapy at least once
depending on clinical course, while 4/16 patients (25%) were put on monthly
administration for 12 months. Oral prednisolone was administered in 11/16
patients (68.5%) for 3 to 118 months and cyclosporine in 7/16 patients (43.75%)
for 3 to 24 months. In total, 6/16 patients (37.5%) required multiple pharma-
ceutical agents, i.e. IVIG, corticosteroids, cyclosporine and rituximab. As to
complications, 4 patients presented with gall bladder lithiasis and 1 with growth
retardation and adrenal insufficiency due to chronic corticosteroid use. With
regards to clinical course, 3/16 patients (18.7%) presented with an acute course
lasting for less than 3 months and 13/16 patients (81.3%) presented with a
chronic course. Of these 13 patients, 8 presented with 1 or more (up to 6)
relapses during follow-up. 
Summary/Conclusions: AIHA in children may present with chronic course
and unsatisfactory control of hemolysis, requiring prolonged immunosuppres-





SHOULD WE ALWAYS USE THE MCV TO DEFINE ANAEMIA?
W Thomas1,*, A Whiteley2, A Cowley1
1Haematology, Plymouth Hospitals NHS Trust, Plymouth, 2Lexacom, Banbury,
United Kingdom
Background: How reliable is it to base testing serum ferritin on the presence
of a microcytic anaemia? Traditional use of the term ‘hypochromic microcytic
anaemia’ has fallen from favour. Most publications now concentrate on the
‘microcytic anaemias’.
Aims: The aim of this study was to ascertain in a large regional teaching Hos-
pital whether MCH or MCV is better at predicting for a low serum ferritin (SF)
indicative of iron deficiency.
Methods: This study was based upon data extracted from our Hospital’s lab-
oratory information and results management system. Our large combined lab-
oratory uses Sysmex XE2100 analysers. The majority of UK haematology labs
use Sysmex analysers. We collected a year’s worth of full blood count (FBC)
data and paired the results with serum ferritin values that were just below the
lower limit of normal range. The request for SF had to be made within 4 weeks
of the FBC.
Results: Of the 501 patient samples that could be paired, a greater proportion of
serum ferritin levels between 10 and 12 mcg/l inclusive, showed hypochromia in
comparison to microcytosis (72% vs 31% respectively). The median results were:
Haemoglobin 117g/l, MCV 83.6fl, MCH 26.6pg (men and women combined). Over
a four day period by analysis of 100 consecutive samples microcytosis was
observed to be the greater trigger for a serum ferritin request compared to
hypochromia (39% vs 28% respectively). Over the same 4 day period, of approx-
imately 7000 samples, hypochromia was seen in 6% and microcytosis in 3%.
Summary/Conclusions: In conclusion, although in the literature and in practice
microcytosis is the predominant trigger for serum ferritin testing, it is hypochro-
mia that has the better predictive capacity in our laboratory for the presence of
iron deficiency. Clinicians need to look at the MCH and consider iron deficiency
when the value is low, even in the presence of a normal MCV.
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MRI PROSPECTIVE SURVEY ON CARDIAC IRON AND FUNCTION AND
ON HEPATIC IRON IN NON TRANSFUSION-DEPENDENT THALASSEMIA
INTERMEDIA PATIENTS TREATED WITH DESFERRIOXAMINE OR NON
CHELATED
A Meloni1,*, P Ricchi2, D Maddaloni3, R Rosso4, M Benni5, C Salvatori6,
G Restaino7, A Vallone8, V Positano1, A Pepe1
1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, 2Unità
Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda
Ospedaliera di Rilievo Nazionale “A. Cardarelli, Napoli, 3Unità Operativa Com-
plessa di Pediatria, Ospedale “Engles Profili”, Fabriano, 4Unità Operativa
Talassemie ed Emoglobinopatie, Ospedale “Ferrarotto”, Catania, 5Servizio di
Immunoematologia e Medicina Trasfusionale Area Metropolitana di Bologna,
Policlinico S. Orsola “L. e A. Seragnoli”, Bologna, 6UO Sistemi Informatici, Fon-
dazione G. Monasterio CNR-Regione Toscana, Pisa, 7Dipartimento di Immag-
ini, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, 8Reparto
di Radiologia, Azienda Ospedaliera “Garibaldi” Presidio Ospedaliero Nesima,
Catania, Italy
Background: Few studies have evaluated the efficacy of iron chelation therapy
in thalassemia intermedia (TI) patients.
Aims: Our study aimed to prospectively assess by quantitative Magnetic Res-
onance imaging (MRI) the efficacy of Desferrioxamine (DFO) and its advan-
tages with respect to the absence of chelation therapy in non transfusion-depen-
dent (NTD) TI patients.
Methods: Among the 185 TI patients enrolled in the MIOT (Myocardial Iron
Overload in Thalassemia) network and with a MRI follow-up (FU) study at 18±3
months, we selected 65 NTD patients. Cardiac iron overload was assessed by
the multislice multiecho T2* technique. LV function parameters were quantified
by cine SSFP sequences. Liver T2* values were converted into liver iron con-
centration (LIC) values.
Results: We considered 18 patients who have not received any chelation ther-
apy (50% males; mean age: 37.83±14.29 years) and 33 patients who had
received DFO alone between the two MRI scans (51.5% males; mean age:
38.85±7.83 years). The two groups were comparable for age, sex and baseline
MRI data. No patient treated with DFO had cardiac iron. At baseline only one
non-chelated patient showed a pathological global heart T2* value (<20 ms)
and he recovered at the FU. The percentage of patients who maintained a nor-
mal global heart T2* value was 100% in both groups. A significant increase in
the right ventricular ejection fraction was detected in DFO patients (-3.48±7.22%;
P=0.024). The changes in cardiac T2* values and in the global systolic biven-
tricular function were not significantly different between the two groups (Table
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1). In patients with hepatic iron at baseline (MRI LIC ≥3 mg/g/dw), the reduction
in the MRI LIC values was significant only in the DFO group (-2.20±4.84
mg/g/dw; P=0.050). The decrease in MRI LIC values was comparable between
the groups (P=0.155).
Table 1.
Summary/Conclusions: In this small population of sporadically or non trans-
fused TI patients, DFO therapy showed no advantage in terms of cardiac iron
but its administration allowed and improvement in right ventricular function and
hepatic iron overload.
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CHELATION THERAPY IN NON-TRANSFUSION-DEPENDENT IRON LOADING
ANEMIA. EXPERIENCE IN A TERTIARY HOSPITAL
R Del Orbe Barreto1,*, B Arrizabalaga2, X Martin Martitegui2, S Erquiaga2,
JC García-Ruiz2
1Hematology, BioCruces Health Research Institute, 2Hematology, Cruces Uni-
versity Hospital, Barakaldo, Spain
Background: Iron loading anemia (ILA) encompasses a group of inherited
and acquired anemias characterized by ineffective erythropoiesis, low hepcidin
levels, excessive intestinal iron absorption and secondary iron overload. This
iron accumulation occurs more slowly compared to transfusion-dependent
patients, and complications do not arise until later in life. It remains crucial
monitoring and appropriately treat their iron burden, for this reason it is essential
to manage it appropriately with iron chelation therapy, especially since phle-
botomy is not an option in these patients.
Aims: To describe the clinical management of chelation therapy in patients
with non-transfusion-dependent iron loading anemia.
Methods: This retrospective study was conducted at Cruces University Hos-
pital in Barakaldo-Spain, from February 2009 to February 2016. Clinical data
and results of Hemoglobin, serum ferritin and transferrin saturation, Liver Iron
Concentration (LIC) and Cardiac T2* measured by MRI was obtained from
patient’s medical records. All patients were treated with Deferasirox 500 mg/day
as compassionate use since none was transfused. Safety profile was studied
in terms of gastrointestinal side effects, rash and change in serum creatinine
and AST-ALT values.
Results: Seven patients were included (5 male, 2 female). Medium age was
57 years (min 26, max 74). 1 patient was diagnosed with non-severe Aplastic
anemia/Paroxysmal nocturnal hemoglobinuria (AA/PNH), 3 with Glucose-6-
phosphate dehydrogenase (G6PD) deficiency, 2 Congenital Dyseritropoietic
Anemia (CDA) and 1 Refractory anemia with ring sideroblasts (RARS). None
was splenectomized. Medium serum ferritin before treatment was 1109,5 ng/mL
(min 644, max 1561) and after at least 12 months post-treatment was 538
ng/mL (min 86, max 969). In 5 patients LIC was evaluated after treatment, in
4 of them a reduction was observed. At baseline 4 patients were evaluated
with T2* and anyone showed cardiac iron overload. No adverse events were
observed in any patient.
Table 1.
Summary/Conclusions: There are currently no standard clinical practice
guidelines for the treatment of iron overload in Iron Loading Anemia. In our
experience, using Deferasirox in this kind of patients is a useful and safely
strategy to manage Iron overload. Prospective studies are needed to evaluate
efficacy and safety of chelation therapy in this setting.
PB2148
EFFECT OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT ON
PARAMETERS OF BONE METABOLISM
B Andemariam1,*, S Jones1, L Xiao2, W Zempsky3, D Adams4, M Hurley2, P Taxel2
1Hematology/Oncology, 2Endocrinology, University of Connecticut, Farmington,
3Pediatrics, Connecticut Childrens Medical Center, Hartford, 4Orthopedic Sur-
gery, University of Connecticut, Farmington, United States
Background: Sickle cell disease (SCD) has sequelae for bone health including
infarcts, low BMD and osteomyelitis. Sickle cell trait (SCT) is clinically silent
but common in individuals of African descent (AD), many of whom are unaware
of their status. Although SCD poses increased risk for low BMD and vitamin D,
there are no data on the relationship between SCT status and BMD, vitamin D
level, and serum markers of bone metabolism. We hypothesized that pre-
menopausal AD women with SCT have a significantly lower BMD and higher
serum bone turnover markers than race- and age-matched control AD women
and are intermediate between healthy controls and subjects with SCD.
Aims: To compare BMD, vitamin D level, and serum bone turnover markers in
pre-menopausal AD women with and without SCT and SCD.
Methods: To assess the effect of sickle cell disorders on bone homeostasis in
pre-menopausal AD women, we recruited AD subjects with SCT and SCD fol-
lowing informed consent and compared serum and radiographic bone param-
eters to control ADs. We compared vitamin D level, hemoglobin (g/dL), body
mass index (BMI), daily calcium intake, BMD of lumbar spine (L-spine), femoral
neck (FN) and total hip (TH), as well as serum bone turnover biomarkers
between control, SCT and SCD premenopausal AD women. Serum bone
turnover markers included CTX, P1NP, osteocalcin, sclersostin, vitamin D bind-
ing protein, IGF-1 and iPTH. Subjects were 35-45 years old with regular men-
strual periods, not taking oral contraceptives or medications that influence bone
metabolism, and without known metabolic bone disorders. Statistical analysis
included a one-way ANOVA test and two-group t-tests for comparing group
means using SPSS statistical software.
Results: A preliminary data analysis was performed on 21 subjects including
9 controls, 5 with SCT, and 7 with SCD. The mean age of the cohort was
40.8±4.8 years, and mean BMI was 29.8±7.6 kg/m2.,BMI was lower in the SCD
group compared with SCT (24.5 vs 34.1 kg/m2, p=0.01). Mean hemoglobin
levels were lower in SCD (8.7±2.8 g/dL) versus control (12.7±0.9 g/dL) and
SCT (12.3±2.8 g/dL) subjects (p=0.001). Daily calcium intake did not differ
between groups. Mean vitamin D level for the entire cohort was 21±6 ng/dl
and there was no difference between groups. BMD T-scores were normal for
all groups at all anatomic sites; however, compared to controls, mean L-spine
and FN BMD was significantly lower in the SCD group (1.4±0.2 g/cm2,vs.
1.1±0.2 g/cm2, p=0.04; 1.1±0.2 g/cm2 vs 0.9±0.1 g/cm2, p= 0.03, respectively).
FN BMD in the SCD group was lower than SCT (p= 0.046). Overall, BMI cor-
related with mean TH BMD (r=0.666, p=0.001); and serum IGF-1 correlated
with mean FN (r= 0.633, p=0.003) and mean TH BMD (r= 0.513, p=0.021).
Mean serum sclerostin levels were significantly decreased in both SCT and
SCD subjects (Control 2975±786, SCT 2141±402, SCD 1613±598, p=0.002).
The groups did not demonstrate a difference in serum CTX, P1NP, osteocalcin,
vitamin D binding protein or iPTH.
Summary/Conclusions: In this preliminary analysis we assessed parameters
of bone metabolism in SCT and SCD compared with controls. In the overall
cohort, IGF-1, a reflection of bone formation, positively correlated with FN and
TH BMD. Sclerostin, an inhibitor of Wnt-signaling and bone formation, was
decreased among SCT and SCD subjects, although the explanation is unclear.
Further study in an expanded population is needed to verify and further eluci-
date the pathophysiologic basis of these findings.
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Β-THALASSEMIA INTERMEDIA IN CHILDREN AND ADOLESCENTS: Β
CHAIN GENOTYPE IN RELATION TO DISEASE PHENOTYPE AND
PULMONARY HYPERTENSION
I Ragab1,*, A Hamed1, S Abdel-Ghany1, W El-Guindy2, T Kamal3, G El-Sayed1,
H Abdel-Naby1
1Pediatrics, 2Pediatric Cardiology, 3Genetics, Ain Shams University, Cairo,
Egypt
Background: Prediction of β-thalassemia intermedia (BTI) phenotype from
the genotype remains problematic.
Aims: Our aim is to study the different β-chain mutations in a group of Egyptian
patients with BTI, its impact on clinical presentation, laboratory parameters
and complications laying stress on pulmonary hypertension.
Methods: A cross-sectional study including 37 patients with BTI was performed
in Pediatric Hematology Clinic, Children’s Hospital, Ain Shams University. Revi-
sion of hospital records for age of diagnosis, blood transfusion, frequency,
transfusion index over the last year and recording of complications as pubertal
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delay, gall stones, leg ulcers together with splenectomy status and hydroxyurea
treatment was performed. Physical examination for weight and height standard
deviation scores, liver and spleen size then calculation of clinical score. Labo-
ratory investigations included complete blood picture, initial hemoglobin elec-
trophoresis, total, direct bilirubin, LDH, s.ferritin and β-Chain mutation analysis.
35 patients underwent echocardiography with recording of tricuspid regurgitant
jet velocity and estimation of right ventricular systolic pressure.
Results: The studied patients had mean age of 10.3±4.55 years (range 4-18),
female/male 20 /1.7, mean age at diagnosis 4.14±1.77 years (range 2-8), 10
(27.0%) had been diagnosed less than the age of 3 years, 19 (51.4%) between
3-6 years, 8 (21.6%) from 6-8 years, with a mean hemoglobin 6.38±1.26 gm/dl
(4-10). Positive consanguinity was detected in 14 (37.8%) patients and positive
family history in 20 (54.1%). 18 (48.6%) became transfusion dependent (TD),
9 (22.5%) patients had never been transfused, 8 (20.0%) receive one or two
yearly transfusion, 23 (57.5%) receive more than two transfusions per year.
Transfusion index ranged from 38-186 cc/kg/year in the TD group. Their mean
height SDS -0.81±1.17; 75.7% of them had no obvious thalassemic facies,
and5.4% had definite facies. Mild Pubertal delay was present in 16.22% and
advanced delay in 5.41%. Splenectomy was performed in 5 (13.5%) patients;
64.86% were on hydroxyurea therapy. As regards β-chain genotype results, 14
(37.84%) have compound heterozygous with IVS1.6/codon6 and IVS1.6/
IVS1.1and IVS1.1/codon2.7 most frequent genotypes, 10(27.03%) had het-
erozygous with IVS1.1 mutation most common, and 13 (35.14%) have homozy-
gous mutations with IVS1.6 the commonest mutation with no significant differ-
ence between the three groups as regards age at diagnosis, hemoglobin at
diagnosis. Mean pretransfusion hemoglobin was higher in heterozygous 8.90
±1.29 gm/dl compared to compound heterozygous 7.29±0.61 gm/dl and
homozygous 7.92±0.49 gm/dl. As Regards pulmonary hypertension (PHTN),
Patients with PHTN had higher total serum bilirubin 2.15±0.71mg/dl, higher
LDH 515.21±190.86IU/L, serum ferritin 1757.00 ng/ml (1082-2239), reticulocyte
count 3.13±1.05% compared to those with normal pulmonary pressure
1.55±0.56 mg/ml, P=.009, 333.55±96.00 IU/L, P=0.001, 576.00 (296-1716)
ng/ml, P=0.042; 2.45±0.55%, P=0.019 respectively; while they had lower initial
hemoglobin level 6.41±1.43 gm/dl P=0.008. Compound heterozygotes formed
57.1%, heterozygotes 14.3% and homozygote mutations 28.6% of patients
with PHTN compared to 30%, 30% and 40% in patients without PHTN,
P=0.267.
Summary/Conclusions: Conclusion: Compound heterozygous are the most
frequent β-chain genotype in patients with β-TI and it presents with more severe
hemolysis and more frequent pulmonary hypertension.
Stem cell transplantation - Clinical
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OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA
T Xu*, J Chen, Z Jin, M Miao, C Fu, H Qiu,xTang, Y Han, A Sun, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Patients with non-Hodgkin lymphoma (NHL) who have relapsed
or refractory disease, may not achieve long-term disease-free (DFS) even after
autologous hematopoietic stem cell transplantation (auto-HSCT). The long-
term survival or curability is still challenging. Given this situation, allogeneic
(allo)-HSCT for the treatment of aggressive-relapsed or refractory NHL is
appealing for the prospect of providing both a tumour-free graft and the graft-
versus-lymphoma (GVL) effect. However, there have been only limited matched
sibling dornor for allo-HSCT. For those patients who do not have suitable
dornors, the related partially HLA-matched dornors may be a good choice.
Related haploidentical (haplo)-HSCT may offer the opportunity to achieve long-
term survival and cure for those select patients.
Aims: To explore the efficacy and safety of haploidentical hematopoietic stem
cell transplantation(HSCT) for refractory-relapsed or highly aggressive non-
hodgkin lymphoma(NHL) patients.
Methods: 26 refractory-relapsed or highly aggressive NHL patients who
received haploidentical HSCT from Jan 2004 to Mar 2015 were analyzed ret-
rospectively. 17 patients were treated with the conditioning regimen consisting
of modified busulfan/cyclophosphamide(Bu/Cy) plus anti-human thymocyte
globulin(ATG). 9 patients were given the regimen comprised of total body irra-
diation(TBI)/Cy plus ATG. All patients were pretreated with cyclosporin A(CsA),
methotrexate(MTX), mycophenolate mofetil(MMF) and ATG to prevent graft-
versus-host disease(GVHD).
Results: The patients included 4 cases of diffuse large B-cell lymphoma, 1
case of follicular lymphoma, 5 cases of B-lymphoblastic lymphoma/leukemia,
9 cases of T- lymphoblastic lymphoma/leukemia, 1 case of anaplastic large cell
lymphoma(ALK-), 5 cases of peripheral T-cell lymphoma(NOS), and 1 case of
NK/T-cell lymphoma. 19 patients were refractory or relapsed. All patients
achieved full donor chimerism. With a median follow-up of 13.5(4-136) months,
20 cases(76.92%) survived, 15(57.69%) survived without lymphoma, and
7(26.92%) relapsed. 6 patients died, 4 because of recurrence/progress, 2
because of the complication of HSCT. 8 patients developed acute GVHD grades
II-IV, which risk at 100 days was 30.80%. The risk of chronic GVHD at 2 years
was 25.10%. The estimated 2-year recurrence rate was 42.20%. The estimated
1-year overall survival(OS) and disease-free survival(DFS) rate was 84.60%
and 61.10%, respectively. The 2-year OS and DFS rate was 71.60% and
48.90%, respectively. Univariate analysis showed that disease status (complete
remission/ not complete remission) before haploidentical HSCT may be a factor
affecting OS and DFS. 
Summary/Conclusions: Haploidentical HSCT is effective for relapsed-refrac-
tory or highly aggressive NHL. It may prolong DFS in part of those patients and
even cure them.
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HIGH-SENSITIVE MONITORING OF CHIMERISM IN BLOOD AFTER
HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDHOOD
LEUKAEMIA
AK Haugaard1,*, HO Madsen2, HV Marquart2, S Rosthøj3, TN Masmas1,
K Müller1, CJ Heilmann1, M Ifversen1
1Department for Children and Adolescents, 2Department of Clinical Immunology
section 7631, Rigshospitalet, University Hospital of Copenhagen, 3Section of
Biostatistics, Department of Public Health, University of Copenhagen, Copen-
hagen, Denmark, Copenhagen, Denmark
Background: We hereby report from a study aiming to evaluate the ability of
microchimerism to predict relapse in a retrospective Danish cohort. Final results
are pending. Relapse is the primary treatment failure after haematopoietic stem
cell transplantation (HCT) for acute leukaemia in childhood, with a cumulative
risk of 20-35%. Early detection of increasing minimal residual disease (MRD)
or recipient chimerism is increasingly important to monitor imminent post HCT
relapse. Chimerism analysis by polymerase chain reaction (PCR) of short tan-
dem repeats is the gold standard and has a sensitivity of 1-5%. However,
chimerism analysis based on real time, quantitative PCR (RQ-PCR) analysis
(microchimerism) is more sensitive, with a reported detection level of 0.1-0.01%.
We aimed to evaluate the ability of microchimerism to predict relapse in a ret-
rospective Danish paediatric cohort.
Aims: It is the purpose of this study to evaluate the ability of microchimerism
to predict early relapse following allogeneic SCT in children with leukaemia,
with clinical and molecular relapse as primary outcome parameters.
Microchimerism will be compared to results from detection of MRD in bone
marrow and to standard STR-PCR based chimerism analysis.
Methods: Children transplanted for acute lymphoid (ALL) or acute myeloid
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leukaemia (AML), between 2008 and 2014 at the Department for Children and
Adolescents, University Hospital of Copenhagen, were included.
Microchimerism was analysed on peripheral blood DNA using a commercially
available kit (GenDx), based on allele-specific RQ- PCR of insertions/deletion
polymorphisms. Results were compared with bone marrow MRD analysis and
with standard, peripheral blood (PB) chimerism in DNA from unseparated whole
blood, and PB cells positive for CD66b, CD4 and CD8. Transplant related data
was collected from the European society for Blood and Marrow Transplantation
(EBMT) database. We defined complete chimerism (CC) as no detectable recip-
ient-cell chimerism at any time point, stable mixed chimerism (SMC) as a single
increase below upper sensitivity limit, and increasing mixed chimerism (IMC)
as two or more increases or a single increase above upper sensitivity limit.
Results: We included 59 children (ALL n=34, AML n=25), seven of these were
re-transplanted due to relapse or rejection. Two transplants were excluded
from further analysis due to lack of available DNA. Median age at HCT was 9
(1-8) years, and median follow up time was 23 (1-72) months. In total, 686
samples of frozen DNA were available for analysis, with a median (range) of
11 (2-22) samples per transplant. HCT was performed in 1st complete remission
(CR) in 30 (47%), 2nd CR in 23 (36%), 3rd CR in 6 (%) and five (8%) performed
without remission. Transplant characteristics and outcome data are displayed
in Table 1. Seven children (21%) with ALL and 9 (36%) with AML relapsed, a
median of 7 (1-52) months from HCT. One child re-transplanted in second
remission subsequently relapsed again. In total, seventeen (29%) children died
a median of 266 (60-1391) days from latest HCT, 10 (59%) of relapsed disease
and 7 (41%) from transplant-related causes. For standard chimerism, 12/16
with IMC relapsed, versus 2/16 and 3/25 with SMC and CC, respectively.
Cumulative incidence between the groups SMC, CC and IMC was statistically
different for relapse (P<0.0001), and remained so after grouping CC and SMC.
Table 1.
Summary/Conclusions: Final results of microchimerism analysis are currently
pending and will be presented at the EHA conference.
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MULTIPLEX REAL TIME PCR SYSTEM FOR CHIMERISM MONITORING
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION
I Fevraleva1,*, N Risinskaya1, E Parovichnikova2, A Sudarikov1
1Department of Molecular Hematology, 2Department of Hematological Oncol-
ogy and BMT, National Hematology Research Center, Moscow, Russian Fed-
eration
Background: Modern chimerism techniques require high sensitivity and capac-
ity to predict relapse after allogeneic hematopoietic stem cells transplantation
(allo-HSCT) several months prior its clinical presentation. These techniques
have to be simple in use, time saving and inexpensive permitting repetitive
measure in the course of treatment. Here we propose multiplex real time poly-
merase chain reaction technique targeted to unique polymorphic sites in recip-
ient/donor alleles conforming these requirements.
Aims: To develop high sensitive and versatile test-system based on multiplex
real time PCR technique for donor/recipient chimerism analysis after allo-HSCT.
Methods: We have used the panel of primers and molecular probes, proposed
by M. Alizadeh et al., targeted to biallelic polymorphisms sites (insertions/dele-
tions) in the human genome. All probes were modified by one of four fluorescent
dyes: FAM, R&G, ROX and Cy5, and appropriate quenchers: BQH1 or BQH2.
Genomic DNAs of donors and patients were isolated from the bone marrow or
peripheral blood. Informative markers for each donor/recipient pair were select-
ed by initial screening. For special cases (sibling transplantation) with no inform-
ative markers found among Alizadeh set we extend analyzed panel with addi-
tional primers and Taqman probes for other genome SNPs (for example
rs1801131, rs1801133, rs587776796). Chimerism was detected also with STR-
PCR using COrDIS Plus multiplex kit for amplification of 19 polymorphic STR-
markers and amelogenin loci (“GORDIZ”Ltd., Moscow, Russia).
Results: We have combined twenty pairs of primers and twelve Taqman fluo-
rescent probes into seven parallel real time PCR multiplex reactions. Each of
seven simultaneous PCR was analyzed by four channel, detecting FAM, R&G,
ROX and Cy5 fluorescence. Alleles present only in donor or recipient DNA
were considered informative and used for chimerism monitoring. Sensitivity of
the method was estimated in control experiments with serial donor/recipient
DNA sample dilutions. The same sample dilutions were analyzed with classic
method, based on PCR of short tandem repeats (STR-PCR) followed by frag-
ment analysis of the PCR-products. Multiplex method proposed detects as low
as 0.03% recipient DNA admixture to donor DNA, while the standard STR-
PCR method accuracy is limited to 1%.
Summary/Conclusions: We have developed fast multiplex Taqman real time
PCR technique for evaluating polymorphic alleles informative for donor/recipient
chimerism analysis after allo-HSCT. Method is convenient, simple, time saving,
more sensitive and could replace classic STR-PCR approach.
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TREOSULFAN-BASED CONDITIONING AND UNMANIPULATED PERIPHERAL
BLOOD HAPLOIDENTICAL TRANSPLANTATION (HAPLOSCT) FOR
PRIMARY REFRACTORY AND RELAPSED AML: RESULTS IN 63
PATIENTS
F Lorentino1,*, M Bernardi1, M Carrabba1, C Messina1, A Forcina1, E Sala1,
F Pavesi1, L Vago1, B Gentner1, R Milani2, F Giglio1, M Morelli1, R Greco1,
C Corti1, J Peccatori1, F Ciceri1
1Hematology and Bone Marroww Transplantation Unit, 2Laboratory Medicine-
Cytomorphology, San Raffaele Scientific Institute, Milano, Italy
Background: Allogeneic stem cell transplantation is the only potentially cura-
tive therapy for primary refractory (PR-AML) and relapsed acute myeloid
leukemia (R-AML) patients (pts). HaploSCT could be an option for eligible pts
whose clinical status warrants expedient treatment and who could benefit from
a more potent alloreactivity.
Aims: Retrospective analysis of 63 consecutive pts with PR-AML and R-AML
who received a first unmanipulated haploSCT at our center
Methods: We retrospectively analyzed 63 pts undergoing a first unmanipulated
haploSCT from January 2006 to December 2015. PR-AML was defined as the
failure to achieve hematological remission following induction treatment.
Results: Median age was 56 years (y) (20-77); 40% of pts were classified as
PR-AML after a median of 2 induction courses (1-5), while 60% of pts had R-
AML (51% 1st and 9% 2nd relapses). Median blast cell count in bone marrow
was 33% (55-93%); median HCT-comorbidity index by Sorror et al. (HCT-CI)
was 2 (0-8). Overall, 51% of pts received a reduced intensity conditioning (RIC)
regimen based on Treosulfan (14 g/m2/d from -6 to -4), Fludarabine (30 mg/m2/d
from -6 to -2) and anti-thymocyte globulin (ATG); 49% underwent a myeloablative
conditioning (MAC) based on the same Treosulfan-Fludarabine schedule with
the addiction of TBI 4Gy and ATG (23%) or Melphalan 70 mg/m2/d from -2 to -1
(26%). Source of stem cells were T-cell repleted G-CSF-mobilized peripheral
blood stem cells from haploidentical familiar donors. All pts received post-grafting
immunosuppression with mycophenolate mofetil and sirolimus; moreover, pts
undergoing the Treo-Flu-Mel conditioning received post transplant Cyclophos-
phamide (PTCy) as backbone for GvHD prophylaxis. The complete remission
(CR) rate was 78% after a median of 30 days (d) (21-41). Neutrophil engraftment
occurred in 92% of pts with a median of 16 d (9-51). The 100-d cumulative inci-
dence (CI) of grade ≥2 acute GvHD (aGvHD) was 30±10% and of grade≥3
aGvHD 19±8%; the 2y CI of chronic GvHD was 14±8%. With a median follow-
up for survivors of 24 months (4-95), the 2y probabilities of leukemia-free survival
(LFS) and overall survival (OS) were 13±7% and 14±7%, respectively. For pts
who achieved CR, the 2-y LFS and OS were 17±8% and 18±8%, respectively;
CI of relapse at 1y and 2 y were 45±13% and 53±14%, respectively, with a
median time to relapse of 160 d (47-727); CI of non-relapse mortality (NRM) at
1y and 2 y was 30±12%, with a median time of 63 d (42-375). In univariate analy-
sis, the only factors influencing 2y-LFS were the intensity of conditioning regimen
(29±14% for MAC and 5±4% for RIC recipients, p 0.05) and HCT-CI (35±13% if
≤2 and 4±3% if >2, p 0.01). In a Cox-multivariate model including pts age, blasts
percentage, cytogenetic risk, HCT-CI, intensity of conditioning regimen, GvHD
prophylaxis backbone (ATG vs PTCy), disease status (PR- vs R-AML) and inter-
val from diagnosis to haploSCT, the only predictive factor for better LFS was an
HCT-CI ≤2 with an hazard ratio of 0.46 (95% confidence interval: 0.2-0.8, p 0.01).
Summary/Conclusions: A consistent proportion of PR-AML and R-AML pts
can achieve CR after an unmanipulated haploSCT. Median time to relapse of
160 days opens the window to early post transplant treatment aimed at a remis-
sion prolongation and enhancement of immune control. 
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BIOSIMILARS OF FILGRASTIM HAVE AN EQUIVALENT EFFICACY WHEN
USED AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
C Nicol1, C Henry1, P Delepine2, C Tripogney2, C Buors3, G Guillerm1,
MA Coutourier1, C Berthou1, A Tempescul1,*, JC Ianotto1
1Clinical Hematology, Teaching Hospital Brest, 2EFS Brest, EFS Bretagne,
3Laboratory Of Hematology, Teaching Hospital Brest, Brest, France
Background: The biosimilars of G-CSF are sometimes the object of discus-
sions about their efficiency and their harmlessness compared to historical prod-
ucts. Their use and efficiency for mobilization of the peripheral stem cells
(PBSCH) or the regeneration post-reinjection of these CSP were little studied.
Aims: We wished to compare the efficacy of two products, biosimilars of fil-
grastim, Ratiograstim® and Zarzio®, compared to the original products in post-
autograft stimulation.
Methods: Between February, 2008 and November, 2014, we identified all the
patients who underwent autologous stem cell transplantation (ABSCT), in our
Sector of Intensive Care, for of a lymphoma or of a multiple myeloma. The
patients with lymphoma had a conditioning regimen by standard BEAM
chemotherapy meanwhile the patients with myeloma had a high dose Melpha-
lan (HDM) conditioning regimen. The reinjection of the PBSC was made 24
hours after the end of conditioning chemotherapy. All of the patients were stim-
ulated by daily injection of G-SCF from J5 post-transplant until reach 1 giga/L
of PNN. We collected the information concerning the times of hospitalization,
the results of blood counts, transfusion needs, clinical data and infectious com-
plications. The results) are expressed in median.
Results: We supported 187 patients (114 men and 73 women) for autologous
stem cell transplantation (lymphoma/myeloma=99/88). We treated 51 consec-
utive patients Neupogen®-Amgen Inc (26 lymphoma and 25 myeloma, respec-
tively), 74 patients Ratiograstim®-Ratiopharm AG (44 lymphoma and 30 myelo-
ma) and 62 patients Zarzio® Sandoz AG (29 lymphoma and 33 myeloma).
Within the patients with lymphoma, length of hospital stay was 22 days (16-64
days). The median use of filgrastim was for a period of 7.5 days (4-13 days).
Cytopenias were deep in CSP post-reinjection with at least 10 days to less
than 1 giga/L leukocytes and 13 days to less than 50 giga/L of plates. There
was no difference for the results ragardinf the different types of filgrastim. The
percent of patients transfused in red cells was 85%, and platelets 99%, without
differences between the products. Three patients had bone pain (all under
Ratiograstim®). Ten patients transferred into intensive care unit (ICU) because
of infectious complications (5 under Zarzio® and 4 under Ratiograstim®). Four
patients died within 100 days, two of them were under Neupogen®. Within the
patients with myeloma, length of hospital stay was 16 days (13-42 days) and
the administration of filgrastim was for period of 7.5 days (1-16 days). Cytope-
nias lasts for 6 days, under 1 giga/L leukocytes (the minimum of 6 days under
Zarzio®, p=0.03), 0 days under 9 g/dL of hemoglobin (non-significant) and 6
days under 50 giga/L platelets s (more than 7 days within Neupogen®, p=0.04).
The percent of patients transfused in red cells was 26% and in platelet 91%,
without differences between the products. Eighteen patients had bone pain (9
under Ratiograstim® and 6 under Neupogen®). Four patients transferred into
ICU (2 in Neupogen®). No patients died within 100 days post-autograft.
Summary/Conclusions: We compared the efficacy and safety in post-autolo-
gous of three G-CSF products, two biosimilars and one originator product. This
retrospective analysis shows that for most of the parameters studied, the tree
products have similar efficacy and side effects. By analyzing these results we
concluded that biosimilars as well as princeps products may be use for stimu-
lation after peripheral blood stem cell transplantation.
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DIAGNOSTIC VALUE OF SERUM STREM-1, PROCALCITONIN AND CRP
IN PATIENTS WITH FEBRILE NEUTROPENIA
C Michel*, D Teschner, P Stein, M Theobald, E Wagner, M Radsak
Third Department of Medicine (Hematology, Oncology, and Pneumology), Uni-
versity Medical Center of the Johannes Gutenberg University, Mainz, Germany
Background: The triggering receptor expressed on myeloid cells (TREM)-1 is
a transmembrane glycoprotein predominantly expressed on neutrophils and
monocytes/macrophages and an important regulator of inflammatory respons-
es. Under inflammatory conditions, TREM-1 is released in a soluble form
(sTREM-1) which is of diagnostic value in patients with pneumonia or sepsis in
the absence of neutropenia. Severe sepsis in patients with autologous stem
cell transplantation is the most abundant cause of death in the first 30 days
after transplantation. Early diagnosis of sepsis and adjustment of medical treat-
ment might improve outcome of these patients. Up to date, the potential and
diagnostic value of sTREM-1 to predict sepsis and outcome in neutropenic
patients undergoing stem cell transplantation has not been explored.
Aims: The aim of our work is to elucidate the diagnostic value of soluble TREM-
1 and the correlation with procalcitonin and CRP in patients with febrile neu-
tropenia.
Methods: Blood serum was obtained from 12 male and 5 female inpatients
(n=17; median age 62 -IQR 58 to 63y) with a hematological malignancy (8 mul-
tiple myeloma, 9 lymphoma) undergoing high dose chemotherapy, followed by
autologous stem cell transplantation and presenting for the first time with fever
(axillary temp. >38.3°) and neutropenia (PMN <500/μl). sTREM-1 was meas-
ured with our self made sTREM-1 ELISA. Procalcitonin and CRP were meas-
ured by immunoassays under routine laboratory conditions.All human studies
were performed in accordance with the declaration of Helsinki and were
approved by the Landesaerztekammer Rhineland-Palatine Ethics Committee
according to the institutional guidelines.
Results: At the first episode of febrile neutropenia, the patients had increased
levels of CRP of 91 (IQR 42.5 to 161.5) mg/l and PCT of 0.29 (IQR 0.16 to 1.5)
ng/ml. Despite severe neutropenia (leukocyte count median 30 (IQR 20 to 60)
/nl, median sTREM-1 levels were increased with 33.7 (IQR 14.7 to 98.5) pg/ml.
In 12 of 17 patients a bacterial blood infection was documented by positive
blood cultures. Patients undergoing a bacterial sepsis showed significantly
upregulated levels of sTREM-1 in serum (p=0.001). Additionally elevated
sTREM-1 levels significantly correlated with elevated PCT level (r²=0.30;
P=0.02). No significant correlation was found between sTREM-1 and CRP
(r²=0.04; p= 0.42) or CRP and PCT (r²=0.18; p=0.08).The response to initial
empiric antibiotic treatment as well as the subsequent development of serious
complications were independent of sTREM-1 levels during first episode of fever.
All patients survived 30 days after autologous stem cell transplantation.
Summary/Conclusions: We detect elevated levels of sTREM-1 in patients
with febrile neutropenia after high dose chemotherapy and autologous stem
cell transplantation in the absence of measurable amount of neutrophils and
monocytes. Increased level of sTREM-1 significantly correlates with PCT and
sepsis. Our results suggest that sTREM-1 might be a useful marker for the
early detection of sepsis also in neutropenic patients. However, it is currently
unclear whether the malignant hematological disease itself, chemotherapy or
autologous stem cell transplantation have an influence on the serum level of
sTREM-1. Therefore further prospective studies are on the way to evaluate of
sTREM-1 as a clinically relevant or alternative sepsis disease marker in neu-
tropenic patients compared to other well-known markers like PCT or IL-6.
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OUTCOMES OF HIGH GRADE GASTROINTESTINAL GVHD POST-HSCT
IN CHILDREN
V Uygun1, H Daloğlu1, S Öztürkmen1, G Karasu2, V Hazar3, A Yeşilipek1,*
1MedicalPark Antalya Hospital Pediatric BMT Unit, Bahcesehir University
School of Medicine, Antalya, 2MedicalPark Göztepe Hospital Pediatric BMT
Unit, Bahcesehir University School of Medicine, 3Pediatric Hematology Oncol-
ogy Unit, Medipol University School of Medicine, İstanbul, Turkey
Background: The high grade acute graft versus host disease (aGVHD) of typ-
ically involved organs (skin, gastrointestinal system (GIS) and liver) have spe-
cific features of therapeutic challenges, among which high grade GIS aGVHD
has a distinctive and remarkable place in this context. 
Aims: Our study intend to bring out the risk factors and clinical course of high
grade gastrointestinal system (GIS) GVHD in children.
Methods: This is a retrospective analysis of 28 pediatric patients presented
with a clinical diagnosis of stage 3 and 4 acute GVHD of the GIS who were
selected from allogeneic hematopoetic stem cell transplantation (HSCT) per-
formed. The demographics, the regimen used for conditioning and GVHD pro-
phylaxis, clinical characteristics of GVHD including follow-up, laboratory param-
eters during GVHD, treatment modalities used for GVHD, response assessment
in every week, complications of GVHD, and survival data were recorded.
Results: Patient and transplant characteristics were summarized in Table 1.
Table 1.
Summary/Conclusions: Overall survival at 3 months after the onset of stage
3 or 4 gut GVHD was 54%. Better outcome than the adult data might be related
with more usage of bone marrow as a stem cell source or different character-
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istics of pediatric gastrointestinal system. In general, GVHD started 14 days
post-HSCT, extended to GIS GVHD in a week and progressed to high grade
GIS GVHD in 10 days. The initial day of GVHD, days to extending to GIS
GVHD and progressing to high grade did not influence the mortality. Melphalan
and ATG usage in conditioning regimen and the drugs used in GVHD prophy-
laxis were not associated with survival. Low albumin level at any time of the
severe GIS GVHD was associated with high mortality possibly due to more
inflammatory GIS state of lost patients. Because ATG usage in the treatment
of GIS GVHD significantly increased the mortality in our study, it should not be
used in a routine manner. Better but not significant outcome with non-immuno-
suppressants seems a better treatment approach. Today best approach to GIS
GVHD is to prevent and recognize it early. Treatment without immunosuppres-
sive therapy like Photopheresis and mesenchymal stem cells seems a better
approach which deserves further research with more patients.
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EFFECTIVENESS AND TOXICITY OF SECOND AUTOLOGOUS STEM
CELL TRANSPLANTATION AS SALVAGE THERAPY FOR RELAPSED OR
PROGRESSIVE MULTIPLE MYELOMA
R El Fatmi*, M Bahri, D Balloumi, N Ben Abdeljelil, L Torjemane, A Lakhal,
S Ladeb, T Ben Othman
1Centre National de Greffe de Moelle Osseuse de Tunis (CNGMO). Faculté
de médecine de Tunis. Université Tunis El Manar, Tunis, Tunisia
Background: Multiple myeloma (MM) is still an incurable disease despite the
introduction of novel therapy. Relapse or progression (R/P) following autologous
stem cell transplantation is common. Therapeutic options may include novel
agents often followed by second ASCT.
Aims: We aimed to evaluate the effectiveness and toxicity of salvage ASCT in
R/P multiple myeloma.
Methods: We retrospectively analyzed the outcome of patients who underwent
second autologous stem cell transplantation as salvage therapy for R/P MM,
between February 2007 and February 2014. 
Results: Thirty four patients underwent salvage ASCT. Conditioning regimen
was melphalan 200 mg/m2(n=32) or 140mg/m2 (n=2). The median age was 54
years (36- 60 years) at first ASCT and 57 years (37- 63 years) at second ASCT.
Twenty patients (59%) were men. Median duration of response after first ASCT
was 28 months (4-61 months), 6 patients (17%) relapsed within the first year
of ASCT. Twenty nine (85%) patients received a salvage therapy: Thalidomide-
Dexamethasone (n=17), Bortezomib based (n=10), Lenalidomide-Dexametha-
sone (n=1) and Melphalan-Prednisone (n=1). Median interval between first
and salvage ASCT was 37.6 months (9-72 months). Twenty one patients (72%)
were at least in partial response before second ASCT. Non relapse mortality
(NRM) was 9%. Response was assessable at 3 months post-ASCT in 30
patients: 25 patients (83%) achieved at least partial response, 4 had progressed
disease and 1 stable disease. After salvage ASCT, 9 patients received thalido-
mide maintenance therapy. The median progression-free survival (PFS) after
second ASCT was 12 months (0.7-35 months) and median overall survival
(OS) was 21 months (0.7-65.4 months).
Summary/Conclusions: Salvage ASCT is an effective therapeutic option for
relapsed or progressive multiple myeloma although associated with a high NRM.
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THE EFFECT OF THE DHAP REGIMEN ON STEM CELL MOBILIZATION
AND TRANSPLANT OUTCOMES OF PATIENTS WITH NON-HODGKIN
LYMPHOMA WHO ARE CANDIDATES FOR UP-FRONT AUTOLOGOUS
STEM CELL TRANSPLANTATION
JY Kwak1,*, HY Yhim1, SY Jeon1, JA Kim2, DH Yang3, HS Kim4
1Internal Medicine, Chonbuk National University Hostpital, Jeonju, 2Internal
Medicine, Catholic University of Korea College of Medicine, Seoul, 3Internal
Medicine, Chonnam National University Hwasun Hospital, Jeollanam-do,
4Department of Nursing, Chonbuk National University, Jeonju, Korea, Republic Of
Background: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as
a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for
up-front autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma
(NHL) are limited. 
Aims: The aims of this study were to compare the efficacy of peripheral blood
stem cell (PBSC) mobilization of DHAP regimen with HDC in combination with
G-CSF in patients with aggressive NHL who were candidates for up-front ASCT,
and to investigate the effect of DHAP mobilization on overall survival (OS).
Methods: We conducted a multicenter, retrospective cohort study on patients
who were diagnosed with aggressive NHL and treated with CHOP or ritux-
imab-CHOP and subsequent PBSC mobilization using HDC (4.0g/m2) or DHAP
(cisplatin 100mg/m2 D1, cytarabine 4.0g/m2 D2, dexamethasone 40mg D1-4)
plus G-CSF regimens for up-front ASCT in 3 Korean institutions between 2004
and 2014. Successful mobilization was defined as collected CD34+ cell count
≥5.0x106/kg, but mobilization failure was defined as collected CD34+ cells
<2.0x106/kg.
Results: Ninety-six patients (57 male, 39 female) with a median age of 48
years (range, 18-66) were included. Thirty-one patients (32.3%) received DHAP
regimen and 65 (67.7%) received HDC. Diffuse large B-cell lymphoma (DLBCL,
54.2%) was the most common histologic type, and remaining included periph-
eral T-cell lymphoma (PTCL), not otherwise specified (28.1%), anaplastic lym-
phoma kinase-negative anaplastic large cell lymphoma (12.5%) and angioim-
munoblastic T-cell lymphoma (5.2%). The number of total CD34+ cells collected
per patient was significantly higher in the DHAP group than the HDC group
(median, 16.1 vs. 6.1 × 106/kg, P=0.001). More patients in the DHAP group
achieved successful mobilization compared to the HDC group (87.1% vs.
61.5%; P=0.011), whereas the rate of mobilization failure was higher in the
HDC group (33.8% vs. 3.2%; P=0.032). In multivariate analysis, no bone mar-
row involvement (odds ratio [OR], 4.60 [95% CI, 1.20-17.61]), no prior radio-
therapy (OR, 11.78 [1.68-82.39]), WBC counts at first apheresis day >1,785/uL
(OR, 9.25 [2.89-29.58]), and the DHAP regimen (OR, 4.12 [95% CI, 1.12-
15.17]) were independent predictors for successful mobilization. Febrile neu-
tropenia developed 3 patients (9.7%) in DHAP group, which was less frequent
than HDC group (N=21 [32.3%], P=0.043). Of the 96 patients, 2 patients did
not proceed to up-front ASCT (1 failed mobilization, 1 patient’s refusal). Fol-
lowing the reinfusion of PBSC, median time to neutrophil/platelet engrafts did
not significantly different according to mobilization regimen. With a median fol-
low-up of 57.4 months (range, 9.1-143.4), the 5-year OS rates were not signif-
icantly different between the DHAP and the HDC groups (74.0% vs. 72.2%;
P=0.936). Because of the heterogeneous histologic types in the study, addi-
tional subgroup analyses were performed separately based on the histologic
types, but the OS in patients with either DLBCL or PTCL was not different
according to the mobilizing regimens (P>0.05). 
Summary/Conclusions: Our study showed that the DHAP regimen was asso-
ciated with higher efficacy for PBSC mobilization and less frequent episodes
of febrile neutropenia compared to the HDC regimen. Although there was no
clinically meaningful OS improvement in the DHAP group, the DHAP regimen
reduced significant rates of mobilization failure. Therefore, DHAP plus G-CSF
can be effective in patients with NHL undergoing up-front ASCT.
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IMPACT OF THE METHYLENETETRAHYDROFOLATE REDUCTASE (MTH-
FR) C677T GENE POLYMORPHISM ON CLINICAL OUTCOMES OF HLA-
MATCHED SIBLING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
MF Mohammed Saleh1,*, AM Kamel2, EA El Beih1, OM Herdan3, GT Ebid2,
R Abdel Fattah4
1Clinical Hematology Unit, Internal Medicine Department, Assiut University
Hospital, Assiut, 2Clinical Pathology Department, National Cancer Institute,
Cairo University, Cairo, 3Internal Medicine Department, Assiut University Hos-
pital, Assiut, 4Medical Oncology Department, National Cancer Institute, Cairo
University, Cairo, Egypt
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is
widely used to treat various hematological malignant and bengin diseases. The
occurrence of complications following HSCT-as graft versus host disease
(GVHD), hepatic veno-occlusive disease (VOD), oral mucositis (OM), drug
induced hepatic and renal adverse events- is highly variable and dependent on
a multitude of host, donor, and treatment factors. Identifying important genetic
variables will allow for better prediction of HSCT-related outcomes, that could
help to develop targeted interventions. A common genetic polymorphism, C677T,
has been described for Methylenetetrahydrofolate reductase (MTHFR);results
in amino acid changes, at codons 222. The homozygous 677TT genotype has
been shown to have 30% of the MTHFR wild-type enzyme activity in vitro, and
the heterozygous (CT) genotype has approximately 60% of wild-type enzyme
activity (Liew and Gupta, 2015 Eur J Med Genet, 58, 1-10).
Aims: To evaluate impact of the C677T polymorphism of 5,10-methylenete-
trahydrofolate reductase (MTHFR) on the clinical outcomes of patients treated
using human leukocyte antigen-matched sibling stem cell transplantation as
acute GVHD,VOD,severe oral mucositis (SOM), drug induced hepatic and
renal toxicity, transplant related mortality(TRM) and overall survival(OS).
Methods: The study subjects were 46 patients receiving allogeneic HSCT at
a bone marrow transplantation unit in Nasser institute for research and treat-
ment from 2010 to 2014,with complete clinical records ; and DNA available for
genotyping. MTHFR genotyping was performed by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP).Acute GVHD was
assessed using conventional criteria (Jacobsohn and Vogelsang, 2007
Orphanet J Rare Dis, 2, 35), necessity of parenteral nutrition used to identify
SOM, and VOD of the liver was defined according to McDonald et al.(1993
Ann Intern Med, 118, 255-67).We evaluated renal and hepatic toxicity based
on peak serum creatinine and peak total bilirubin, AST, and ALT levels during
the first 30 days after allogeneic HSCT.TRM was defined as death by any
cause during the course of treatment, other than the relapse of underlying dis-
ease.
Results: Median age at the time of HSCT was 22 years (range 3-42 years);
32 patients (69.6%) above ≥18 years, and the median follow-up period of sur-
vivors was 21 months. Acute myeloid leukemia (AML) was the most common
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underlying diagnosis 23 patients (50%) of them 12 (26%) are in complete remis-
sion 1 (CR1).The most commonly used conditioning regimen consisted of
Busulfan (BU), and Cyclophosphamide (CY) (n=26, 56.5%). All received periph-
eral blood stem as a stem cell source with mean CD34+ stem cell dose
(6.6+2.3) 106/kg. Twenty-seven patients (58.7%) were males. Methotrexate
(MTX) in addition to Cyclosporine (CsA) was used as GVHD prophylaxis in 40
patients (87%).The frequencies of the MTHFR C677T genotypes in patients
were 43.5% (20 patients) for 677CC, 50% (23 patients) for 677CT, and 6.5%
(3 patients) for 677TT ;the allelic frequency of the 677T was 31.5%. Recipient
MTHFR677 in CT or TT showed higher incidence of acute GVHD (7/26) 26.9%
versus (2/20) 10% in CC, but not statistically significant; p=0.26. MTHFR C677T
in CT or TT showed higher incidence of hepatic toxicity (11/26) 42.3% versus
(5/20) 25% in CC; also higher transplant related mortality (5/26) 19.2% versus
(2/20) 10% in CC, but not statistically significant; p=0.22 & 0.45 respectively.In
log rank survival analysis,recipients with variant allele MTHFR 677T were asso-
ciated with lower non statistically significant overall survival; p=0.15.VOD was
diagnosed in 1 patient (2.2%) and had heterogeneous status of the polymor-
phism, MTHFR 677 CT genotype.
Figure 1.
Summary/Conclusions: Genotyping for MTHFR C677T before HSCT could
have clinical significance, not statistically proven in our study, in prediction
patients at high risk of developing poor outcomes. Large multicentric, highly
standardized prospective studies are needed to identify such potential phar-
macogenetic markers with sufficiently strong evidence to be used in clinical
practice.
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TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IS
STRONGLY ASSOCIATED WITH SEVERE GRAFT VS HOST DISEASE
POST UNRELATED ALLOGENEIC TRANSPLANT FOR HEMATOLOGIC
DISEASES
I Sakellari1,*, I Batsis1, Z Bousiou1, D Mallouri1, V Constantinou1, M Iskas1,
A Vardi1, S Papadimitriou1, AK Panteliadou1, C Smias1, E Yannaki1,
A Fylaktou2, A Tsombanakou1, C Vadikoliou1, P Kaloyannidis1, T Natse3,
G Bamihas3, E Gavriilaki1, A Anagnostopoulos1
1Haematology department - BMT unit, George Papanicolaou Hospital,
2Immunology Department, Hippokration Hospital, 3Nephrology Department,
George Papanicolaou Hospital, Thessaloniki, Greece
Background: Allogeneic hematopoietic cell transplantation (HCT) is a curative
treatment in hematologic disorders, but morbidity and mortality remain high.
Transplant-associated thrombotic microangiopathy (taTMA) is a multifactorial
and often fatal syndrome.
Aims: In a retrospective single-centre study we aimed to investigate the inci-
dence of taTMA in patients (pts) undergone HCT from unrelated donors (URD)
and identify prognostic factors and treatment outcome.
Methods: We enrolled consecutive pts who underwent URD HCT from 2003 to
2015. TaTMA diagnosis was based on EBMT criteria: increased (>4%) schisto-
cytes in peripheral blood, thrombocytopenia, increased lactate dehydrogenase
and decrease in Hb concentration. Anti-thymocyte globulin (ATG, rabbit) was
used as standardised part of the conditioning in almost all pts (total dose of 5-
7.5mg/kg). Anti-GVHD prophylaxis consisted of cyclosporine or tacrolimus plus
methotrexate in myeloablative and mycophenolate mofetil plus cyclosporine in
reduced intensity and toxicity conditioning transplants. Upon identification of
taTMA, all possible causative factors were fully investigated. The mainstay of
treatment strategy was withdrawal of calcineurin inhibitors, plasma infusion and
plasma exchange combined with corticosteroid administration and in refractory
cases, humanized anti-CD20 monoclonal antibody (Rituximab).
Results: We studied 179 pts (74 male, 105 female), aged 37±14 years, who
underwent HCT from matched HLA A/B/C/DRB1 (8/8, n=88) and allele or anti-
gen mismatched (n=91) URD. Grafts derived from peripheral blood (157), bone
marrow (18) and umbilical stem cells (4). Conditioning regimens were mye-
loablative (139), reduced intensity (28) and toxicity (12). Median follow-up was
11.5 (0.1–147.4) months.TaTMA was diagnosed in 29 (16.2%) pts (12 male,
17 female), aged 34±12 years, 78 (9–721) days post-HCT for acute leukemia
(21), Hodgkin (3) and non-Hodgkin (1) lymphoma, MDS (2), MPD (1) and aplas-
tic anemia (1). Conditioning regimens were myeloablative in 24 (12 TBI-based)
and reduced intensity in 5 pts. Among pts with taTMA, 10 (34%) presented
severe (grade III-IV) acute GVHD, 15 (52%) extensive chronic GVHD, 12 (41%)
bacterial, 2 (7%) fungal and 21 (71%) viral infectious episodes. In univariate
analysis age, gender, diagnosis, disease phase, previous lines of treatment,
conditioning (intensity and TBI-based), ABO and HLA incompatibility, infections,
acute and chronic GVHD were studied. The presence of taTMA was associated
with severe acute and extensive chronic GVHD (p=0.001 and p=0.035 respec-
tively) and TBI-based conditioning (p=0.043). In multivariate analysis, severe
acute GVHD was the only independent factor associated with taTMA (β=3.4,
p=0.038). Regarding treatment-outcome, 8 pts responded to cyclosporine ces-
sation and plasma infusions. The rest (21) underwent plasma-exchange ses-
sions; in 14 the syndrome resolved, 1 responded to additional Rituximab treat-
ment, while 6/21 pts were refractory and eventually succumbed. Treatment-
related mortality was 33.3% (9/29) in taTMA pts and was directly associated
with refractory microangiopathic syndrome in 6/29 (20.6%).
Summary/Conclusions: Despite the progress achieved concerning classic
thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in
terms of diagnosis and novel therapies, taTMA seems to be a far more complex
syndrome. Since the pathogenetic factors leading to taTMA are not fully eluci-
dated, treatment of this syndrome often fails. According to our findings, GVHD
was the most predisposing factor for the development of taTMA, possibly relat-
ed to associated endothelial damage.
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THE BENEFITS AND PITFALLS OF PERIPHERAL BLOOD STEM CELLS
MOBILIZED BY ETOPOSIDE: THE EFFECT OF CUMULATIVE DOSAGES
OF ETOPOSIDE
D Kim1,*, KW Kang1, SR Lee1, HJ Sung1, SJ Kim2, CW Choi1, BS Kim1, Y Park1
1Hematology & Oncology, Korea University School of Medicine, 2Hematology
& oncology, Sungkyunkwan University School of Medicine, Seoul, Korea,
Republic Of
Background: Successful collection of adequate hematopoietic stem cells is
necessary for autologous stem cell transplantation (AutoSCT). However, the
optimal mobilization strategy for transplantation has still not been established.
High dose cyclophosphamide with granulocyte-colony stimulating factor (G-
CSF) is one of the most widely used mobilization strategies; however, in a pro-
portion of patients, it fails to secure the collection of sufficient cells. Therefore,
effective and safe alternative mobilization strategies are required.
Aims: We conducted a retrospective study to determine the impact of etoposide
mobilization strategy for AutoSCT in patients with lymphoid malignacies.
Methods: We compared the effectiveness and safety profiles of chemomobi-
lization using three regimens: intermediate-dose etoposide (750 mg/m2) fol-
lowed by the late addition of G-CSF, high dose cyclophosphamide and G-CSF,
and G-CSF alone. A total of 116 patients (60 multiple myeloma, 56 lymphoma)
who underwent autologous stem cell transplantation (autoSCT) were included
in this study.
Table 1.
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Results: Median CD34+ cell yield was significantly higher in the etoposide
group (12.3x106,cells/kg) compared to the cyclophosphamide group (4.99x106,
cells/kg) and the G-CSF group (3.8x106,cells/kg) (p<.001). The rate of successful
mobilization (≥5x106,cells/kg) was also significantly higher in the etoposide group
(86.1%) compared to the cyclophosphamide (49.1%) and the G-CSF group
(22.2%) (p <.001). There were no significant differences in neutrophil and platelet
counts at the nadir between the etoposide and the cyclophosphamide group.
Severe febrile neutropenia and mobilization-related mortality were not observed
in any group. However, platelet engraftment was slower in the etoposide group
compared to the other groups (p=0.029). Furthermore, the proportion of delayed
platelet engraftment (≥30 days) was also greater in the etoposide group than in
the cyclophosphamide and the G-CSF group (20.6% vs 6.7% vs 3.8%, p=0.032).
In multivariate analysis, the etoposide mobilization strategy (p=0.025) and the
high cumulative etoposide dose (≥2500 mg, p=0.003) were significantly asso-
ciated with delayed platelet recovery.
Summary/Conclusions: Intermediate dose etoposide with the late addition
of G-CSF may be an effective mobilization strategy. However, high cumulative
doses of etoposide, including systemic chemotherapy, mobilization, and con-
ditioning of autoSCT may delay platelet engraftment.
PB2162
SUCCESSFUL PERIPHERAL BLOOD STEM CELL MOBILIZATION WITH
A COST-EFFICIENT FIXED SINGLE-DOSE PLERIXAFOR SCHEDULE IN
POOR MOBILIZERS
C Greil*, C Kiote-Schmidt, G Fink, S Hildenbeutel, R Bosse, J Duyster, M Engelhardt,
R Wäsch
University hospital Freiburg, Freiburg, Germany
Background: Collection of hematopoietic stem cells (HSC) from the peripheral
blood (PB) is routinely conducted prior to high-dose chemotherapy and autolo-
gous transplantation. Despite safety and efficiency of current apheresis proce-
dures including mobilizing chemotherapy and granulocyte colony-stimulating fac-
tor (G-CSF), there is still a significant rate of mobilization failures due to different
patient-dependent factors necessitating additional agents like plerixafor. A stan-
dardized strategy for its application in poor stem cell mobilizers is still lacking.
Aims: To evaluate the efficacy of a cost-efficient fixed single-dose of plerixafor
in poor mobilizers on successful HSC mobilization.
Methods: We analyzed 46 patients who underwent autologous HSC trans-
plantation at our academic center between 2011 and 2015 and received pler-
ixafor because they were expected to be poor mobilizers due to low counts of
CD34+ cells in PB samples prior to apheresis or after a first apheresis day with
insufficient yield or as a rescue strategy after insufficient harvest with previous
mobilizing chemotherapy. We examined CD34+ cell counts in PB and in
apheresis products to identify those patients who were able to collect a sufficient
CD34+ cell count for transplantation after a single application of plerixafor.
Results: Plerixafor could be safely administered, leading in 83% and 48% to
apheresis yields of >2 and >4x106 CD34+ cells/kg body weight (bw) and cor-
relating with median CD34+ PB cell counts of 8.0 and 17.8/µl, respectively. Of
note, 35/46 (76%) patients showed a substantial benefit of plerixafor vs G-CSF
alone, with increased PB CD34+ cells (13.3 vs 4.7/µl, p=0.0001) prior to
apheresis and 4-fold higher CD34+ cell numbers per single apheresis (1.2 vs
0.3x106 CD34+/kg bw, respectively, p=0.00005). A patient subset of 24% had
<5/µl PB CD34+ cells before plerixafor application and profited less from addi-
tional plerixafor administration.
Summary/Conclusions: As the number of patients with extensive pretreat-
ment, including new immunomodulatory drugs and with long disease courses
will even increase in the future, it is highly important to develop selection criteria
for patients with expected benefit of additional plerixafor application, also with
regard to cost efficiency. Our data suggest that most patients in preemptive
and rescue settings with <5/µl CD34+ cells detectable in PB may fail to sub-
stantially benefit and should therefore be carefully selected, whereas those
with >5/µl PB CD34+ cells can greatly benefit of a single application with medi-
an CD34+ apheresis yield increases of 2.9 and median total apheresis collec-
tions of 4.6x106/kg bw. 
PB2163
AVASCULAR NECROSIS OF BONE IN ADULT PATIENTS SURVIVING
MORE THAN 2 YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
IN YEARS 2001-2012 - EXPERIENCE OF SLOVAK TRANSPLANTATION
CENTRE
M Martišová1,*, E Bojtárová1, L Roziaková1, M Mistrík1
1Clinic of Hematology and Transfusiology of Medical Faculty of Comenius Uni-
versity, University Hospital Bratislava, Bratislava, Slovakia
Background: Avascular necrosis (AVN) of bone is the most debilitating late
skeletal complication of stem cell transplantation (SCT) that often remains
underestimated.
Aims: To evaluate potential risk factors of AVN, its clinical manifestation and
treatment in patients after SCT.
Methods: One hundred thirty-five patients surviving more than 24 months after
allogeneic SCT in years 2001-2012 in Slovak Transplantation Centre were
evaluated retrospectively for AVN. All patients were disease-free after SCT for
malignant and non-malignant hematological diseases. AVN was confirmed by
magnetic resonance imaging or scintigraphy. We investigated correlations
between AVN and primary diagnosis (malignant/non-malignant), conditioning
regimens, donor and patient gender, type of donor (related/unrelated), HLA
match, AB0 compatibility, source of stem cells (peripheral/bone marrow),
immunosuppressive therapy, GvHD (acute/chronic), exposure time and cumu-
lative dose of corticosteroids. We analysed time to first symptoms, time to diag-
nosis of AVN, number of joints, most affected sites, correlation between joint
pain and imaging exams, types of treatment and their results.
Results: Seven patients surviving 30-169 months (median, 69 months) after
SCT developed AVN (5.2%). We experienced more AVN in male patients (83%),
but found no correlation with other factors. Cumulative dose of corticosteroids
was 0-5264mg (median, 3960mg) and exposure time was 0-327 days (median,
53days). Patients developed arthralgias 9-56 months (median, 28 months)
after SCT. AVN was confirmed 1-17 months (median, 6 months) after onset of
the symptoms and 14-62 months (median, 36 months) after SCT. We confirmed
AVN of 19 joints (2.71 joints per patient)-hip (12), shoulder (5) and sacroiliacal
joints (2). We recognized higher incidence of AVN in patients who suffered
from AVN of at least one joint, although the other affected joints weren’t always
marked as painful (hip: 8 painful joints in correlation with 12 joints with proved
AVN in 6 patients; shoulder: 4 painful joints in correlation with 5 joints with
proved AVN in 3 patients). We confirmed bilateral occurrence of AVN of hip
joints regardless of the number of painful hip joints. Because of lack of MRI of
painful knees we weren’t able to evaluate the rate of AVN although knees were
the second most painful joints. AVN of sacroiliacal joints was asymptomatic.
Conservative treatment was performed in shoulder joints, surgical treatment
was performed just in hip joints - 4 of 6 patients underwent total hip replacement
(THR) of 6 joints. Age median of patients undergoing THR was 26 years. One
patient in an early stage of AVN underwent forrage and 1 patient was on con-
servative treatment while waiting for THR. Out of 6 THRs we experienced no
septic or aseptic loosening in an early post-operative period. We followed the
patients after THR for 11-143 months (median, 30 months). Out of 6 replaced
hip joints we experienced deliberation of acetabular and distal femoral compo-
nent in 1 patient, 8 years after implantation. Reimplantation was performed
without any complications.
Summary/Conclusions: Avascular necrosis occurred more in male patients
in our study. We didn’t define any other risk factor for AVN. We observed the
highest incidence of AVN of hip joints with 100% bilateral occurrence, where
imaging exams were more sensitive than corresponding clinical symtomatology.
Surgical methods of AVN treatment remain to be gold standard for higher stages
of AVN of hip joints with favorable benefit-risk ratio.
PB2164
HIGH FERRITIN LEVELS IN FEVER OF UNKNOWN ORIGIN: POSSIBLE
FIRST SIGN OF HEMOPHAGOCYTOSIS IN BMT PATIENTS?
Y Yaman1,*, V Hazar1, E Sarıbeyoğlu1, K Ozdilli2, S Anak1
1Pediatric hematology, 2Medipol Mega University Hospital, istanbul, Turkey
Background: Fever of unknown origin is a major problem in transplant patients.
The management of prolonged fever without any signs and symptoms of a specific
microorganism such as bacteria, virus or molds is controversial and debateful.
Aims: While checking other biological parameters of FUO, we also included
ferritin to rule out hemophagocytosis. 
Methods: Between January 2015-February 2016 out of 37 allogeneic trans-
plantations (21 MFD, 3 haploidentical, 12 MUD, 1 cord blood), 6 patients (4
girls/2 boys, 3 MFD/ 3 MUD, 2 malignant diseases/ 4 nonmalignant disease)
developed high fever with hepatosplenomegaly at median day 28 (14-45 days).
They were treated with broad spectrum antibiotics, they were all receiving pro-
phylactic viral treatment with acyclovir and prophylactic flucanozol. No micro-
biological agent causing the fever could be detected. In patients with fever
more than 5 days, CT scan of the chest, abdominal ultrasonography were per-
formed, without any diagnostic findings. At the onset of fever none of the
patients had GvHD.
Results: The ferritin levels of these patients were found to be very high (median
93.486 ng/ml, 3587-381.300 ng/ml) Other major parameters of hemophagocy-
tosis such as hypertriglyceridemia, pancytopenia etc were not detected. The
patients were treated with steroids and fever resolved in all patients within 48
hours. One patient died of graft rejection, one patient received steroid and
plasma exchange due to severe multiorgan dysfunction. They received steroids
for a median of 29,5 days (24-34 days).
Summary/Conclusions: In transplant patients fever can be sometimes very
hard to manage. If a microbiological cause of fever could not be detected we
think that checking the ferritin level is very important, even if some of the diag-
nostic parameters for hemophagocytosis are missing. High ferritin levels could
be the first sign of hemophagocytosis in these patients and it can be treated
with steroids excluding etoposide to secure the graft.
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CLINICAL ASSESSMENT OF PATHOGENETIC VIRUSES IN HEMORRHAGIC
CYSTITIS AFTER ALLOGENEIC CELL TRANPLANTATION: HOW HIGH IS
HIGH FOR URINE BK POLYOMA VIRAL LOAD
A Papalexandri*, D Mallouri, V Konstantinou, P Zerva, E Koravou, M Kalliou,
I Batsis, E Yannaki, T Touloumenidou, C Smias, A Anagnostopoulos, I Sakellari
Hematology Department and HCT Unit, G.Papanikolaou Hospital, Thessaloniki,
Greece
Background: Hemorrhagic cystitis (HC) after allogeneic hematopoetic cell
transplantation (allo-HCT) has been recognized to be a relatively common
severe complication with increased morbidity requiring hospitalization. Apart
from conditioning toxicity, the most common pathogens implicated are
cytomegalovirus (CMV) and BK-polyoma virus (BKPV). Data concerning the
clinical relevance of molecular monitoring of these viruses in urine are scarce. 
Aims: We conducted a retrospective study enrolling patients who developed
cystitis after allo-HCT to evaluate the urine viral load of both CMV and BKV
that is potentially associated with HC. 
Methods: CMV and BKPV viral load in urine and CMV in plasma were meas-
ured with RQ-PCR in symptomatic patients with cystitis. Macroscopic hematuria
(+/-clots) led to the diagnosis of hemorrhagic cystitis. 
Results: Twenty-nine patients (female=14, male=15), aged 16-61 years (medi-
an 35) who developed cystitis after allo-HCT and for who viral load data were
available for both pathogens were included in the study. Patients suffered from
hematological malignancies and underwent allo-HCT following myeloablative
(21) or reduced intensity conditioning regimen (8). The majority of patients
(17/29) received graft from a matched volunteer, 8/29 from siblings and 4 from
a haplo-identical relative donor. Median time for the onset of cystitis was 48
days (7-677). Fourteen out of 29 (48%) patients experienced HC requiring hos-
pitalization. CMV viral load in urine was positive in 7/29 samples (median: 1270
copies/ml, range: 180-1490000). Concordant CMV viremia was documented
in 15 patients (median: 2570 copies/ml, range: 26-81000). BKPV viral load in
urine was positive in 23/29 patients (median 2,5x107 copies/ml, range:
1,18x102-3,2x1010). Bacterial infection by klebsiella pneumonia was document-
ed in one patient. Hemorrhagic cystitis was significantly associated with BKPV
viral load: 2,5x107 in HC patients vs 1,9x104 in non-HC, p=0.018. A cut- off of
5,1x104 copies/ml could strongly predict the development of hematuria in ROC
analysis. CMV viral load in urine and plasma tended to be higher in HC patients
without a significant difference: (i) in urine: 106575 vs 523 copies/ml and (ii) in
plasma: 9004 vs 2584 copies/ml for HC vs non-HC patients respectively, p=ns.
No other clinical or biological factors could predict the development of HC.
Cytology was available in 9 patients with HC but only two were found positive
(BKPV load >1x108 copies/ml in both patients). Patients were treated with
antiviral agents, mostly val/gancyclovir and foscarnet and cidofovir was added
in persisting cases. In 12 patients with HC, >2 consecutive samples were avail-
able after the first documentation of BK (median 5, 3-7). In these patients a
slow reduction of BK load was observed (median reduction: 0.9 log in 30 days)
and all the patients maintained a high BKPV load (>1x105in 9/12) regardless
of the resolution of cystitis.
Summary/Conclusions: In our study BKPV was related with the development
of hemorrhagic cystitis after allo-HCT, with viral loads higher than 5,1x104
copies/ml strongly predicting hematuria. Despite the fact that CMV was also
detected, CMV viruria or viremia were not found to be significant co-factors.
Prospective studies are warranted to answer the benefit of viral molecular mon-
itoring in urine among transplanted patients.
PB2166
THE ANALYSIS OF PATIENTS WITH POOR MOBILIZATION AND
MOBILIZATION FAILURE: CAN RDW BE A PREDICTIVE FACTOR?
N Buyukkurt, P Aytan*, I Kozanoglu, E Maytalman, M Yeral, C Gereklioglu,
S Solmaz, A Korur, H Ozdogu, C Boga
Hematology, Baskent University Adana Medical and Research Hospital Bone
Marrow and Transplantation Centre, ADANA, Turkey
Background: Autologous hematopoetic stem cell transplantation (AHSCT) has
been routinely used in the treatment of hematologic malignancies. Stem cell
collection procedure from the patients has been accomplished with apheresis
equipments. G-CSF is usually used alone or with chemotherapy for the purpose
of the mobilization.
Aims: The aim of the present study is to assess retrospectively the patients
who had been mobilized with different chemotherapy protocols between 2012
and 2016 and to analyze the patients with poor mobilization or mobilization fail-
ure and to determine the possible causes. 
Methods: This study has been planned as a cross sectional study in a center
that has been a member of EBMT and had been accreditated by JACIE between
the years 2012 and 2016. All the data were obtained from the hospital data
bases. Spectra Optia (Terumo BCT, Denver, USA) which utilizes continous flow
centrifuge technique was used for the collection of stem cells. Peripheral and
product CD 34 counts were done with FACS Canto II (BD Bioscience, USA)
device and ISAGE method. Mobilization techniques used in the patients had
been planned in accordance to the standart application (SOP number; KIT-
KU009) methods. The patients with CD34 counts less than 20 cells/uL had been
defined as “poor mobilization” whereas patients with stem cell counts less than
2x106/kg in product had been accepted as “mobilization failure”. In the day of
stem cell collection peripheral blood count (Sysmex, XN 1000, Tokyo, Japon)
had been performed and RDW, hemoglobin and platelet counts were noted.
Results: In our center there has been a total of 27 poor mobilization cases
(8.82%;23 patients) between 2012 and 2016. A total of 279 stem cell apheresis
procedures had been performed during the same period and in 35 cases
(12.54%) mobilization failure was observed. 5 of the patients in the poor mobi-
lization group had 3 consequtive chemotherapy protocols (1 patient radiother-
apy), 12 of them received 2 consequtive and 6 of them received 1 chemother-
apy protocolIn this group mobilization was tried to be accomplished with G-
CSF alone in 6 patients, with G-CSF and plerixefor in 2 patients and with
chemotherapy and G-CSF in 15 patients. For the comparison of RDW, Hb and
platelet numbers among the mobilization groups, first day laboratory results of
the patients had been used. There were no statistically significant difference
with respect to platelet and Hb levels among the groups; however, the RDW
was found to be significantly lower in the patients with successfull mobilization
when compared with the patients in the poor mobilization and mobilisation fail-
ure groups (median [minimum-maximum] values were 15.4(12.08-25.20),16.4
(13.3-21.6) and 16.3(13.5-24.9) in successfully mobilized, poorly mobilized and
mobilization failed groups (p=0.029). Mobilization failure was observed during
stem cell collection in 6 of the 60 patients in 2012, 5 of 63 patients in 2013, 4
of 44 patients in 2014 and 7 in 49 patients in 2015. The median number of
chemotherapy before mobilization procedure was 2 (1-3), and the median
platelet levels during peripheral CD34 count was 95500/µL (10000-384000/µL).
The median CD34 cell count from the peripheral blood was 9 cell/µL(0-17) and
the median percentage of CD34 was 0,03(0,00-0,11).
Summary/Conclusions: Our results support the hypothesis that multiple
chemotherapy independent from age results in poor mobilization and mobiliza-
tion failure. RDW was shown to be lower in patients with successfull mobilization
compared with poor mobilization or mobilization failure patients. The role of
RDW in prediction of mobilization success has to be clarified in further studies.
PB2167
SUCCESSFUL REDUCE OF 60 PATIENTS FOR REFRACTORY/RECURRENT
LEUKEMIA BY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
AND PROPHYLACTIC IMMUNOTHERAPY
W Jingbo*, F Xinhong, C Haoyu, Y Yuming, Z Weijie, X Song, H Junbo, Y Fan,
G Jiangying, L Qian, Z Shuqin, L Mengqi
Hematology Department, Aerospace Center Hospital Of Peking University, Bei-
jing, China
Background: Refractory /Recurrent leukemia always has a poor prognosis.
Aims: To retrospectively evaluate the results of allogeneic hematopoietic stem
cell transplantation and Prophylactic Immunotherapy for Refractory/Recurrent
leukemia.
Methods: From June 2012 to January 2015, 60 patients with high-risk leukemia
were enrolled, including 18 cases of ALL, 37cases of AML and 5 case of CML-
BP. The average leukemia burden was 53(20-95)% in bone marrow. All patients
received HLA haplo-identical stem cells transplantation from parent or sibling
donors. Myeloablative conditioning regimens consist of 7cases of BuCy, 26 cases
of TBI/FLAG, 15 cases of TBI/Cy, and 12 cases of FLAG that followed by reduced-
intensified BUCY. All patients received cyclosporine A, MMF and methotrexate
for GVHD prophylaxis. All patients received DLI,DC-CIK and NK according to dif-
ferent status after allogeneic HSCT .Analyzed outcomes were hematological
engraftment, incidence of acute and chronic GVHD, incidence of relapse, and
nonrelapse mortality (NRM), Overall survival and Disease-free survival.
Results: The MNC and CD34+ for transfusion were 9.08(7.02-24.4)*108/Kg
and 3.42(0.8-12.1)*106/Kg. All 60patients achieved stable engraftment. The
median time of ANC≥0.5*109/L was 16 (8-23) days. And for platelet ≥20*109/L,
the median was 22 (8-150) days.38 patients developed acute GVHD, the accu-
mulative incidence of aGVHD was 66.4%, the accumulative incidence of II-IV
grade aGVHD was 35%, and the accumulative incidence of III-IV grade aGVHD
was 15%. 26 patients developed cGVHD (12 patients extensive, 14 patients
limited), the accumulative incidence of cGVHD was 88.2% and for extensive
type, the accumulative incidence was 67.4%. The accumulative incidence of
CMV infection was 54.1%, and the accumulative incidence of EBV infection
was 16.3%. 10 patients developed virus cystitis. The number of Bacterial and
fungal infected patients were51 and 27, respectively. The median follow-up
time post transplantation was 11(1-36) months, 14 patients relapsed and the
accumulative incidence of relapse was 27%. For AML, ALL and CML-BP
patients, the accumulative incidence of relapse were26.6%, 34.8and 0 ,
respectively.The median follow-up time post transplantation was 11months, 21
patients died and the main causeswere relapse (11 cases), infection (5 cases),
cGVHD(2 cases) and diffuse alveolar hemorrhagediffuse alveolar hemor-
rhage(3 cases). Among 60 patients, 39 patients survived. The one-year and
two-year accumulative incidences of OS were61.8% and 49.5%, respectively.
The one-year and two-year accumulative incidences of DFS were 53.8% and
47.8%, respectively.For AML, ALL and CML-BP patients, the two-year accu-
mulative incidence were 52.6%, 34.4% and66.7%, respectively. The non-
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relapse mortality was 10. The one-year and two-year accumulative incidences
of NRM were 19.4% and 28.4%, respectively.
Summary/Conclusions: Our clinical results have shown that the salvaged HSCT
is a promising modality for treatment of high-risk AL with high leukemia burden.
PB2168
STEM CELL MOBILIZATION WITH HIGH DOSE ETOPOSIDE PREDICT AND
IMPROVE THE OUTCOME OF AUTOLOGOUS PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION IN PATIENTS WITH REFRACTORY OR
RELAPSED LYMPHOMA
Y Cai1,*, L Wan2, C Wang1
1Hematology, Shanghai general Hospital, 2Hematology, Shanghai general Hos-
pital, Shanghai, China
Background: Autologous hematopoietic stem cell transplantation is an effec-
tive treatment for refractory and relapsed lymphoma patients.Most studies
show that chemotherapy sensitivity is an important prognostic factor for these
patients.A significant proportion of patients with relapsed and refractory lym-
phomas fail to respond to conventional salvage therapy and never proceed to
transplantation, most often due to chemotherapy-resistant disease.Etoposide
is an epipodophyllotoxin that has a topoisomeraseII-inhibiting function and
causes DNA-strand breaks. Several groups have described the effectiveness
of etoposide alone or in combination regimens to mobilize PBSCs.
Aims: We report a respective study in treating 88 patients with relapsed or
refractory lymphomas who received high-dose etoposide (VP16) in mobilization
plus autologous peripheral blood stem cell transplantation as rescue therapy.To
investigate the efficacy of stem cell mobilization with high-dose etoposide and
granulocyte colony stimulating factor followed by autologous peripheral blood
stem cell transplantation in patients with relapsed or refractory lymphoma as
salvage therapy. We hypothesized that the response to high-dose etoposide
may predict the outcome of ASCT.
Methods: From November 2005to December 2014, 88 patients with refractory
or relapsed non-Hodgkin’s lymphoma (NHL, n=61) or Hodgkin lymphoma (HD,
n=27) received high-dose etoposide (VP16 20~25mg/kg/d ×2) and G-CSF for
stem cell mobilization. The median age of 59 male and 29 female patients was
33 years (range 16–60)Patients’ remission status prior to mobilization were
partial remission (PR) (n=39) and progressive disease (PD) (n=49). All patients
underwent autologous peripheral blood stem cell transplantation (auto-PBSCT).
Conditioning regimen was BEAM (n=30) or CBV (n=58).
Results: Among 88 patients, 65 (73.9%) patients had response. 36 of 39
(92.3%) PR patients had response, 30 of 49 (61.2%) PD patients had response.
Median follow-up was 21.5 (1~85) months after stem cell transplantation. 58
(65.9%) patients achieved CR, 18 (20.45%) patients attained PR, 10 (11.36%)
patients suffered disease progression, 1 (1.1%) patients relapsed, and 1 (1.1%)
patient died of bone marrow failure. Among PR group, the estimated 2-year
DFS for patients who had response and no response to etoposide were 83.6%
and 33.0% respectively. In PD group, the estimated 2-year DFS for patients
who had response and no response to etoposide were 69.4% and 26.7%,
respectively. P <0.01. The estimated 2-year OS for responders and non-respon-
ders were 72.0% and 25.9%, respectively. P <0.01 .
Summary/Conclusions: Stem cell mobilization with high dose etoposide and
G-CSF followed by auto-PBSCT was beneficial in the treatment of refractory
lymphoma. Disease-free survival over 2 years can be achieved in some
patients. Patients’ response to high dose etoposide was correlated to 2-year
DFS and OS, which could also predict the outcome of auto-PBSCT for those
patients. Utilizing high dose etoposide, we can select some chemotherapy-
sensitive patients from refractory lymphoma. The outcome of autologous trans-
plantation is correlated to the response of high dose etoposide.
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EFFECT OF TRANSFUSION OF THE THIRD PARTY UMBILICAL CORD BLOOD
ON HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
W Jingbo*, F Xinhong, C Haoyu, Y Yuming, Z Weijie, X Song, H Junbo, Y Fan,
G Jiangying, L Qian, Z Shuqin, L Mengqi
Hematology Department, Aerospace Center Hospital Of Peking University, Bei-
jing, China
Background: Cord blood stem cells have multiple functions in haploidentical
stem cell transplantation
Aims: To retrospectively evaluate the effect of the third party umbilical cord
blood on haplo-identical hematopoietic stem cell transplantation.
Methods: From June 2012 to May 2015, 125 leukemia patients were enrolled,
including 41 cases of ALL, 62cases of AML, 12 cases of MDS, 7 cases of CML-
BP, 2 cases of acute mixed leukemia and 1 case of Blastcell dendritic cell
tumor. Inclusion criteria: 1) AL patients; 2) halpo-identical HSCT; 3) 3/6 matched
cord blood was available. Patients were divided into two groups, ie. groupA
(HSCT, n=65) and groupB (HSCT plusumbilical cord blood transfusion group,
n=60). Myeloablative conditioning regimens consisted of BuCy, TBI/FLAG,
TBI/Cy, and FLAG that followed by reduced-intensified BUCY. The median
dose of mononuclear cells in groupA and B were 8.58x108/kg and 9.01x108/kg,
respectively. The median dose of CD34+ cells fortransfusion in each group
were 3.67x106/kg and 2.94x106/kg, respectively. The dose of grafted UCB
MNCsand CD34+ cells for groupB were 3.5x107/kg and 2x105/kg, respectively.
All patients received cyclosporineA,MMF and methotrexate for GVHD prophy-
laxis. The endpoints of this study were hematological engraftment,incidence
of acute and chronic GVHD, incidence of relapse, transplant-related
mortality(TRM), non-relapsemortality(NRM), Overall survival(OS) and Disease-
free survival(DFS) in each group.
Results: The median follow-up time was 17(3-29) months in groupA and 18(3-
35) months in groupB.Patients in groupA reached a sustained ANC of more
than 0.5*109/L at a median of 11 days, whereas 14 daysin groupB. Platelet
more than 20*109/L occurred at a median of 19 days in groupA, whereas 17
days in groupB (P= .4). The rate of aGVHD was not significantly different in the
two groups, 56.9% in groupA and 48.3% in groupB (P= .21). The accumulative
incidence of II-IV grade aGVHD was 35.4% in groupA and 30% in groupB (P=
.42). The incidence of chronic GVHD was 79.2% in groupA and 71% in groupB
(P= .47). The incidence of extensive type was lower in groupB, 69.2% vs 35%,
P=0.09. The incidence of CMV was lower in groupB, 80% vs 60% (P= .01).
The accumulative incidence of EBV was lower in groupB, 35.4% vs 3.3%
(P<0.01). At two years, the accumulative incidence of relapse was 24.4% in
groupA and 17.2% in groupB, P=0.13. The two-year accumulative incidence
of OS was 72.9% in groupA and 84.8% in groupB, P=0.07. The one-year accu-
mulative incidence of DFS in each group were 65.7% and 79.4%, respectively,
P=0.03.
Summary/Conclusions: Our clinical results have shown that HSCT with trans-
fusion of the third party umbilical cord bloodis a promising modality for induction
of immunity reconstitution. Better survival results may benefit from lower inci-
dence of GVHD and virus infection. x108/kg and 9.01x108/kg, respectively. The
median dose of CD34+ cells fortransfusion in each group were 3.67x106/kg
and 2.94x106/kg, respectively. The dose of grafted UCB MNCs and CD34+
cells for groupB were 3.5x107/kg and 2x105/kg, respectively. All patients
received cyclosporineA,MMF and methotrexate for GVHD prophylaxis. The
endpoints of this study were hematological engraftment,incidence of acute and
chronic GVHD, incidence of relapse, transplant-related mortality(TRM), non-
relapsemortality(NRM), Overall survival(OS) and Disease-free survival(DFS)
in each group.
PB2170
ENGRAFTMENT POST AUTOLOGOUS STEM CELL TRANSPLANT FOR
MULTIPLE MYELOMA IS UNAFFECTED BY LENGTH OF STEM-CELL
STORAGE- EXPERIENCES FROM THE ROYAL MARSDEN HOSPITAL, UK
S Chavda*, R Mellor, C Pawlyn, A Smith, M Ethell, M Potter, C Anthias, C Dear-
den, M Kaiser
Haemato-oncology, Royal Marsden Hospital NHS Foundation Trusts/ Institute
of Cancer Research, London, United Kingdom
Background: Multiple myeloma(MM) is the is the second most common bone
marrow cancer with almost 5000 patients diagnosed in the UK each year,
accounting for 10% of all haematological malignancies. Triplet chemotherapy
followed by autologous stem cell transplantation (ASCT) is the gold standard
induction treatment in younger fit patients and has significantly improved overall
survival rates. A second ASCT at relapse can also improve subsequent remis-
sion duration. Peripheral blood stem cell (PBSC) harvest and storage is, there-
fore, routinely performed by transplant centres with the aim to collect enough
cells to enable patients to undergo two ASCTs over the course of their treat-
ment. As survival of patients with MM has dramatically improved in the era of
novel agents, duration of storage and associated costs incurred have
increased. It is therefore important to examine the feasibility and clinical utility
of long term cell storage. There is conflicting data on viability of stored stem
cells, with some studies reporting reduced CD34+ count and cell viability over
time, and others reporting successful transplantation outcomes with stem cells
stored for up to 11 years.
Aims: We analysed the effects of stem cell storage duration on time to engraft-
ment in patients undergoing ASCTs for MM in our centre.
Methods: We undertook a retrospective analysis of all patients undergoing
ASCT for MM between 2008 and 2015. Patients undergoing tandem ASCTs
were excluded. Days to engraftment was defined as number of days from stem
cell infusion to neutrophil count >0.5 X109/L.
Results: 406 patients underwent ASCT between 2008 and 2015, with a median
patient age of 65 years (range 25-78 years). 80.3% of patients (n=326) under-
went one ASCT and 19.7% (n=80) underwent two. Of those patients receiving
a second stem cell transplant, 81.2% percent had stem cells stored for between
0-60 months at the time of second transplant, and 18.8% for between 61-170
months. 80% of patients required only one therapy regimen prior to ASCT and
79% of patients were in a complete remission or very good partial response
pre-transplant. Novel agents (bortezomib, lenalidomide and thalidomide) were
used in 95% of cases as front-line therapy. PBSCs were stored on average for
32 months before being used. Melphalan 200mg/m2 was used as conditioning
chemotherapy pre-transplant (140mg/m2 in renal impairment or medical comor-
bidities) with stem-cell return on Day 0. All patients successfully engrafted.
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There was no significant difference in time to engraftment in all patients with
PBSCs stored between 0-60 months (11.3 days+/-2.3 days) and 60-170 months
(11.0 days+/-2.6 days), p=0.42 (Student’s unpaired t test). The longest period
of time PBSCs were stored was 165 months with successful engraftment at 12
days. 19.7% of patients had stem cells stored between 60-120 months (n=80)
and of these 22.5% of patients went on to have second autograft using stored
PBSCs. All patients with PBSCs stored for more than 120 months went on to
have a second successful ASCT (n=3). These patients were all treated with
novel agents prior to ASCT.
Summary/Conclusions: Our results show that prolonged periods of PBSC
storage does not affect stem cell engraftment in MM patients undergoing ASCT.
These results support the rationale of ongoing long-term PBSC storage in the
era of novel agents as salvage ASCT remains an important treatment option
for relapsed or progressive MM.
PB2171
REVIEW OF THE EFFECTIVENESS OF PALONOSETRON IN PREVENTION
OF NAUSEAS AND VOMITS INDUCED FOR MELPHALNAN IN AUTOLOGUS
TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS
C Saenz Fernandez*, M Pereiro Sanchez, A Rodriguez Vazquez, N Martinez
Torrens, A Gomez Marquez, JL Sastre
Hematology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
Background: Prevention of nauseas and vomits induced for melphalan in auto-
logus transplant of hematopoietic progenitor cells is an important issue. There
is not an standar of care until now. In our work we review the effectiveness of
Palonosetron for these patients.
Aims: Assess the effectiveness and security of Palonosetron in the prevention
of nauseas and vomits induced for melphalan at high dose (200mg/m2) in auto-
logus transplant of hematopoietic progenitor cells
Methods: Observational study, descriptive and retrospective in which have
been included patients older than 18 year old diagnosed of multiple myeloma
and with autologus transplant of hematopoietic progenitor cells during the period
March 2009-February 2014 which received Melphalan 200mg/m2 in day -4.
For prevention of nauseas and vomits a dose of Palonosetron 250mcg was
administer intravenous half an hour before the infusion of Mephalan was start-
ed. The identification of the subjects was done through the computer program
of prescription, validation and preparation of cytostatic mixtures Oncofarm®.
To assess the effectiveness a survey was used where patients had reflected
nauseas and vomits during the four days after the administration of Mephalan
and the notes of nursing and medical staff on the medical records. The variables
used were, age, sex, toxic habits (tobacco, alcohol), scale of basal activity
ECOG, digestive disease, regular medication, previous chemotherapy and
anticipatory nauseas and vomits
Results: 31 patients were included, 20 women (64.5%) and 11 men, mean age
59.4 years old. The 77.4% were not smokers and the 80.6% declared drink less
than 30 grams of alcohol per week. At the moment of the transplant one patient
had ECOG 1, and all the other patients ECOG 0. Nine patients (29%) were suf-
fering some sort of digestive disease (Dyspepsia, peptic ulcer, hiatus hernia,
gastroesophageal reflux disease or obstruction). The 71% (n=22) was been
treated with opioids, antacids and/or benzodiazepines. The schemes of
chemotherapy previous given were Bortezomid + Dexamethasone (n=24), Borte-
zomid +Thalidomide + Dexamethasone (n=5), Bortezomid + Dexamethasone +
Cyclophosphamide (n=2), lenalidomide (n=3) and Vincristine + Doxorubicin +
Dexamethasone (n=1). The 12.9% of the patients had nauseas or vomits in the
last cycles. At the moment of the admission for the transplant only two patients
had anticipatory nauseas. In the first 24 hours after mephalnan infusion and
palonosetron administration 54.8% (n=17) suffered an episode of nauseas (eight
patients grade 1, eight grade 2, and one grade 3), and only nine had vomits
(seven grade 1, one grade 2 and one grade 3). Between the next 24-96 hours
19 patients (61.3%) had nauseas (14 grade 1, two grade 2 and three grade 3),
and 12 patients (38.7%) vomits (nine grade! and three grade 2). As rescue med-
ication levomepromazine was used in the 35.5%. all the others were treated
with metoclopramide, dexamethasone, domperidone and/or benzodiazepines.
The only adverse effect documented after Palonosetron administration was con-
stipation (n=2, 6.4%).
Summary/Conclusions: We can confirm the effectiveness and security of
palonosetron in the prevention of nauseas and vomits induced for high dose of
Mephalan. The results are similar to those reported in the available bibliography.
PB2172
STENOTROPHOMONAS MALTOPHILIA BLOODSTREAM INFECTION IN
CHILDREN WITH HEMATOLOGIC DISEASES
C Albayrak*, D Albayrak
Pediatric Hematology Department, Ondokuz Mayıs University Medical Faculty,
Samsun, Turkey
Background: Stenotrophomonas maltophilia (S. maltophilia) causes serious
infections in immunocompromised hosts which early use of susceptible anti-
bacterial may be lifesaving. 
Aims: We investigated the clinical characteristics of S. maltophilia bloodstream
infection (BSI) in children with hematologic diseases.
Methods: We retrospectively reviewed the medical and microbiological records
of all consecutive episodes of S. maltophilia BSIs in children with hematologic
diseases and hematopoietic Stem Cell Transplantation (HCT) recipients at the
University Hospital (Samsun, Turkey) between January 2006 and January 2016.
Results: Among 762 patients identified as S. maltophilia BSIs during 10-year
period, 26 children were identified as hematologic diseases; 7 ALL, 3 AML, 2
Fanconi anemia, 5 aquired aplastic anemia, 2 Diamonnd Blackfan anemia, 1
Griscelli syndrome, 1 Diskerotozis Congenita, 1 Ataksia telengiektasia, 1 JMML,
1 MPS type I, 1 Hereditery spherocytosis and splenectomy, 1 JRA and
macrophage activation syndrome. Fifteen of them were HCT recipients. Other
eleven of them have been treated with immunesupresive drugs. Fifteen (58%)
patients were female. The median patient age was 8.6 years (range: 0.6–18
years). Five patient have cutaneous infection (ecthyma gangrenosum). in vitro
susceptibilities to trimethoprim-sulfamethoxazole (TMP-SXT) were 100%.
Summary/Conclusions: S. maltophilia BSIs may cause to sepsis, especially
in patient with severe neutropenia, shock, and pneumonia. It should be in mind
when fever, sepsis and ecthyma gangrenosum finding continued although the
use of standard antibiotics of febril neutropenia. TMZ-SXT should be first treat-
ment choice for S. maltophilia BSIs in hematologic patients based upon drug
susceptibility testing.
PB2173
FEASIBILITY AND SAFETY OF BENDAMUSTINE, ETOPOSIDE, CYTARABINE,
MELPHALAN (BEEAM) CONDITIONING REGIMEN BEFORE AUTOLOGOUS
STEM CELL TRANSPLANTATION (ASCT) IN 33 PATIENTS WITH MALIGNANT
LYMPHOMA
M Bedoui1,*, P Brault1, S Glaisner2, R Elias Shamieh2, F Kuhnowski1
1Hematology, Institut Curie, PARIS, 2Hematology, Institut Curie, Saint Cloud,
France
Background: High-Dose Chemotherapy supported by Autologous Stem Cell
Transplantation (HDC/ASCT) is considered the treatment of choice for
relapsed/refractory or high risk malignant lymphoma. However, several questions
on efficacy and feasibility of HDC/ASCT remain, such as the best candidates
for this strategy, the optimal conditioning regimen, and acute and late effects. To
date, few comparative randomized trials have been performed, and no regimen
has demonstrated superiority to another. The commonly used conditioning reg-
imens is BEAM (BICNU...). To overcome the sourcing out of Carmustine in
France we have decided to replace this product with Bendamustine, demon-
strated significantly superior efficacy compared with standard therapy in B cell
lymphoma, and this based on the work published by Visani and al in 2011.
Aims: We report our experience in a retrospective study concerning 33 patients
treated with this conditioning regimen
Methods: From July 2012 to February 2016, 33 patients with median age 56
(28 -70) years, 8 had more than 65 years, Sex ratio (M/F) 22/11, underwent
this procedure. This regimen BeEAM combined Bendamustine 100 mg/m² d-7
to d-6; Etoposide 200 mg/m² d-5 to d-2; Cytarabine 200 mg/m² twice daily d-5
to d-3; Melphalan 140 mg/m² d-1 and the reinjection of hematopoietic stem cell
was done at d0. We did a reduction of 30% of Cytarabine and Etoposide doses
because of age (6 patients). The diagnosis was NHL in 30 cases, composite
hemopathy in 2 cases, and HD in 1 case. 30 patients had advanced stage dis-
ease (III-IV) of Ann Arbor classification, and a Bulky disease in 4 cases. For 10
patients with DLBCL in first line treatment, the IPIaa was ≥2 in all cases. 15
patients received intensification followed by ASCT in first line treatment, 12 in
relapse disease and 6 were primary refractory. The median number of previous
line therapy was 2 (1-4). The status at the time of ASCT was evaluated by
PET/CT in 29 cases. 23 were in complete remission (CR) and 6 in partial remis-
sion (PR). 4 patients was evaluated only by CT-scan (3 PR, 1 CR).
Results: Among the 33 patients treated, the number of autologous CD34+
cells infused was systematically >to 2x10^6 CD34+/kg, and we observed that
the median time to myeloid engraftment (ANC>0.5x10^9/l) was 8 days (4-16),
and the median time to platelet engraftment (≥20x10^9/l) was 15 days (6-39).
The digestive toxicity was important with 16 patients who present a diarrhea
grade III-IV, and 23 oral mucositis grade III-IV. One patient presented a veno
occlusive disease (VOD) treated with Defibrotide®. We observed 3 cases of
cardiac toxicity (3 heart failure grade III partially reversible with medical treat-
ment), 5 renal failure grade I-II. One patient died due to a septic choc with mul-
tidrug resistant bacteria before hematological recovery after transplant, pro-
ducing an overall transplant related mortality (TRM) of 0.03%. 2 patients died
at distance of intensification by other causes (one patient with multiple infections
caused by opportunistic agents, and the other one with secondary myeloid
hemopathy) and the others 30 patients still alive, 29 in continuous CR.
Summary/Conclusions: The new effective regimen BeEAM is not safe in this
population of patients with High Risk malignant non Hodgkin and Hodgkin lym-
phoma. The switch of Carmustine to Bendamustine in the intensive conditioning
regimen, required a randomized trial to compare BeEAM and BEAM in new con-
ditioning strategies, and advances in the supportive care will probably reduce
transplantation related mortality (TRM). Limited data are available to optimize
elderly patients selection for transplantation while minimizing the risk of TRM.
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ACQUIRED HYPER-IGM SYNDROME FOLLOWING CD20 MAB THERAPY
FOR EPSTEIN-BARR VIRUS (EBV) REACTIVATION POST-ALLOGENEIC
STEM CELL TRANSPLANT (ALLO-SCT)
FP Tambaro1,*, S Luponio2, MR D’Amico1, WG Wierda3, G De Simone1,
L Del Vecchio4, C Pignata5, V Poggi6, M Ripaldi1
1Bone Marrow Transplantation, Ospedale Pausilipon, 2Hematology, Università
Federico II, Napoli, Italy, 3Leukemia, MD Anderson Cancer Center, Houston,
United States, 4Biotecnologie Avanzate, 5Pediatria, Università Federico II,
6Ematologia, Ospedale Pausilipon, Napoli, Italy
Background: EBV reactivation can be a complication of allogeneic stem cell
transplant (allo-SCT) that may lead to EBV-related B Cell Post Transplant Lym-
phoproliferative Disorder (PTLD).Preemptive treatment with the CD20 mAb rit-
uximab eliminates CD20+ lymphocytes, thereby blocking virus replication, is
indicated for rising EBV viral load.
Aims: Here we report 2 cases of acquired hyper-IgM syndrome as a late com-
plication in kids who underwent allo-SCT and received rituximab for treatment
of EBV reactivation.
Methods: An 11 yo boy and 8 yo girl underwent allo-SCT in 10/2008 and 8/2010
for ALL and Hemophagocytic Lymphohistiocytosis (HLH), respectively. Patient
(pt) and allo-SCT characteristics are shown (Table).
Results: EBV reactivation occurred on day +59 and +33 with 34860 and 40325
EBV DNA copies in the pt with ALL and HLH, respectively. Pts received ritux-
imab (Table) with complete elimination of viremia. Both pts developed
hypogammaglobulinemia (IgM, IgG and IgA) post-transplant and received IVIG
(0.5 g/kg) monthly for the first 3 months after transplant, then every 3 months,
thereafter. The pts developed recurrent sino-pulmonary and enteric infections
treated with antibiotics beginning 30 and 18 months post-all-SCT for the ALL
and HLH pts, respectively (Figure). In the setting of these recurrent infections,
and supportive IVIG, both pts developed progressive increase in IgM level.
The ALL pt began to lose full donor chimerism, with no evidence of ALL relapse.
He also had recurrent autoimmune thrombocytopenia, which responded to
IVIG.Neither pt nor respective donor had mutation in CD154. Flow cytometry
for the ALL pt showed decreased mature lymphocytes (CD19+ IgG+), memory
lymphocytes (CD19+CD27+IgM+), switched memory (CD19+CD27+IgM-), and
transitional lymphocytes (CD 19+CD27+IgM+), and no plasma cells in blood.
Flow cytometry studies are ongoing for the HLH pt.
Table 1.
Figure 1.
Summary/Conclusions: We hypothesize that both EBV and rituximab played
roles in development of these cases. EBV is responsible of B cell proliferation,
maturation arrest, defective DNA repair, leading to hematological neoplasms.
EBV infection and reactivation are also associated with autoimmune disorders,
transiently elevated IgM during viremia, and monoclonal gammopathy after
allo-SCT. Preemptive treatment with rituximab eliminates CD20+ cells where
the virus replicates, thereby blocking EBV proliferation, but reduces lymphocyte
counts for more than 6 months post BMT, which can alter immunological sur-
veillance. These cases demonstrate development of acquired hyper-IgM syn-
drome as a late complication of EBV reactivation treated with rituximab post-
allo-SCT, which is not previously described. We recommend diligent prolonged
monitoring of IgM level post-allo-SCT, particularly in patients who develop
autoimmune cytopenia or recurrent infections.
PB2175
BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN
BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
DM Dunia1,*, M Dolores2, S Dolores1, G Nuria2, D Miguel2, A Jaime2, G Helga2,
V Alejandro2, H Sonia2, P Blanca2
1Hematologia, 2Hospital universitario de Guadalajara, Guadalajara, Spain
Background: The combination of bortezomib and high-dose melphalan (HDM)
is an attractive approach to improve the efficacy of the conditioning regimen.
Furthermore, this association was expected to be safe because bortezomib and
melphalan do not share common toxicities (mainly neurologic toxicity for borte-
zomib and hematologic toxicity for HDM). We followed a phase 2 study of the
Intergroupe Francophone du Myélome (IFM) (Blood 7 Jan 2010, 115 (1); 32-36).
Aims: 1) to evaluate response rates after intensive therapy; 2) to assess the
toxicity of this new conditioning regimen. 
Methods: We reported 29 Multiple Myeloma (MM) diagnosed patients [18
Males/11 Females, median age 59 years (34-73)]. Patients were treated
between February 2010 and December 2015 to receive Bortezomib and mel-
phalan as conditioning regimen (Bor-HDM). Bortezomib was administered sub-
cutaneous at 1 mg/m2 on days -6, -3, 1, and 4. Melphalan was administered
intravenously at 200 mg/m2 on day -2. All patients received induction treatment
with VCD (Bortezomib 1,3 mg/m2 S.C. D1, D4, D8, D11; Cyclophosphamide
600mg/m2 D1, D8; Dexamethasone 40 mg D1, D4, D8, D11) 6-8 cycles/21
days. Overall, 80% of patients achieved PR, including 8%VGPR and 12%
patients with CR before ASCT. Peripheral blood stem cells [median 2.83x106
CD34+ cells/kg (1.97-4.39)] were infused on day 0.
Results: There was no engraftment failure. Neutrophils (ANC ≥0.5x109/L) and
platelets (≥20x109/L without transfusion) recovered in median times of 11 days
(range, 11-13 days) and 13 days (range, 11-18 days), respectively. Patients
were discharged from the transplantation unit in median times of 27.5 days
(range, 21-25 days). There were two treatment-related deaths, at +11 day of
candidiasis (C. glabrata) and +15 day caused by Enterobacter sepsis. Some
serious adverse events were reported: 1) Infections (51% patients): bacteremia
was documented: 4 Staphylococcus epidermidis, 1 Enterococcus faecalis, 1
Pseudomonas aeruginosa. 1 Salmonella diarrhea and 1 pneumonia; 2) Mucosi-
tis: grade 4 non-hematologic toxicities were mucositis of upper and lower diges-
tive tract sites (10%); the most frequently reported grade 1 or 2 adverse events
were digestive (diarrhea, mucositis 55%). It should be noted that peripheral
neuropathy (PN) was present at the time of ASCT in one patient and did not
get worse after Bor-HDM treatment. At time of reporting, median follow-up time
from induction therapy was 30 months (range, 3-72 months). Overall survival
was 75%. 2 patients relapsed at 3 and 9 months after ASCT, and they died of
progressive disease. Evaluation of response rate at 100 days after ASCT
upgraded in 35% patients (reached CR/sCR).
Summary/Conclusions: Our experience shows that Bortezomib can safely be
combined with HDM as a preparative regimen followed by ASCT. This regimen
was well tolerated with no increased toxicity. Engraftment was not affected by
the addition of Bortezomib. PN did not worse after this conditioning regimen.
PB2176
MONITORING MINIMAL RESIDUAL DISEASE IN AUTOLOGOUS CELLU-
LAR THERAPY PRODUCTS COLLECTED BY APHERESIS-EXPERIENCE
OF A THERAPY CELLULAR CENTER
S Ferreira*, F Amado, S Lopes, F Bordalo, C Pinho, S Roncon
Cellular Therapy, IPO PORTO, Porto, Portugal
Background: The autologous transplant of peripheral blood stem cells (PBSC),
harvested by apheresis on oncologic patients after high-dose chemotherapy
and/or radiotherapy, is a therapeutic strategy used in hematologic diseases
and solid tumors. Some studies suggest that incomplete disease eradication
before collection could lead to the reinfusion of tumor cells and be associated
with patient relapse and a lower survival. The search for minimal residual dis-
ease (MRD) has been performed in some centers through highly sensitive
genetic techniques, contributing to improve the clinical decision and the patient
outcome.
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Aims: This study aims to evaluate the percentage of MRD-contaminated grafts
in patients proposed to hematopoietic transplant with initial genetic alterations
in our hospital. 
Methods: A retrospective study was performed from May 2006 to February
2016. The inclusion criteria was patients with genetic alterations at diagnosis
or relapse. The research was performed using fluorescent in situ hybridization
(FISH) or/and real time polymerase chain reaction (RT-PCR) techniques. The
data was analysed using an excel program.
Results: MRD was researched in samples of PBSC collected from 39 male
and 28 female patients (n=67), with a median age of 51 years old (7 months-
70 years). Their diagnosis were: non Hodgkin’s lymphoma (NHL) n=24, multiple
myeloma (MM) n=16, neuroblastoma n=17, acute myeloid leukemia (AML) n=5,
acute lymphoblastic leukemia (ALL) n=2, Hodgkin’s disease (HD) n=2 and
Ewing’s sarcoma (Ewing S.) n=1. Only 6 grafts were MRD positive, but with a
very low tumour cell contamination (1-2%): 1 AML with PML-RARA fusion RNA;
1 ALL with BCR-ABL mRNA; 2 MM with deletion of 13q14; 1 Ewing S. with
translocation of 22q12; 1 neuroblastoma with deletion of 11q23. Three con-
taminated grafts were eliminated: 2 patients (1 AML and 1 neuroblastoma) were
proposed to different chemotherapy lines, undergone new mobilization and col-
lection program and received a negative cellular therapy product; the ALL
patient died before the second mobilization. Two MM patients were infused
with the autologous grafts. In the remaining patient (Ewing S.), we performed
a positive selection of CD34+ cells after thawing and before graft infusion. At
present, 2 patients are alive and in complete remission, 9 and 10 years after
treatment (Ewing S. and AML); 3 patients deceased 1, 7 and 4 years after
transplant (2 MM and 1 neuroblastoma, respectively).
Summary/Conclusions: As it was a very small and heterogeneous sample,
conclusive remarks of the role of MRD significance in stem cells grafts are not
possible. In the same way, we only performed one ex vivo tumoral purging with
identical results to those found on literature. Future prospective trials should
address physicians to choose which is the best option to eradicate tumor cells
(chemotherapy pretransplantation or immunotherapy postransplantation).
PB2177
VERY LOW INCIDENCE OF NEUROTOXICITY WITHOUT ANTICONVULSANT
PROPHYLAXIS DURING THE CONDITIONING REGIMEN WITH BUSULFAN
IN PATIENTS UNDERGOING STEM CELL TRANSPLANTATION
MM Rivera Franco*, E Leon Rodriguez, C Balderas Delgado
Hematology-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Sal-
vador Zubiran, Mexico City, Mexico
Background: Since neurotoxicities, including seizures, have been reported
with the use of busulfan (BU), it is a trend to administer anticonvulsant prophy-
laxis during a conditioning regimen with this alkylating agent in patients under-
going hematopoietic stem cell transplantation (HSCT). On the other hand, anti-
convulsant medications interact with busulfan metabolism, affecting its serum
concentration and therapeutic activities, and have their own side effects on the
patient which can alter the outcome of the transplant.
Aims: To analyze the frequency of neurotoxicity in patients who underwent
stem cell transplantation with conditioning regimen including high doses of
busulfan, without anticonvulsant prophylaxis, at INCMNSZ, from November
1998 to January 2016.
Methods: A retrospective analysis was performed in 97 patients receiving high-
dose BU as part of their HSCT preparative regimen, at INCMNSZ, determining
the frequency of seizures and other neurotoxicities.
Results: Ninety seven patients undergoing stem cell transplantation with con-
ditioning regimen including busulfan, from November 1998 to January 2016,
were included. Patients (male, 59%) had a median age of 33 years (range 15-
61). The patients had a following range of underlying diseases: myelodysplastic
syndrome (n=17, 17.5%), chronic myeloid leukemia (CML, n=13, 13.4%), acute
lymphoblastic leukemia (LLA, n=19, 19.6%), acute myeloid leukemia (AML,
n=31, 32%), or others (n=17, 17.5%). Patients who underwent an autologous
transplant received high doses of busulfan, 16 mg/kg (n=24, 25%), and doses
of 12mg/kg (n=73, 75%) were given for allogeneic transplant patients. None of
the patients received anticonvulsant prophylaxis. Only one patient (1%), trans-
planted in 2011, presented seizures after the administration of BU, and was
treated with phenytoin and benzodiazepines without further crisis.
Summary/Conclusions: From the beginning of our transplant program no
anticonvulsant prophylaxis was given to patients receiving BU-based condi-
tioning regimen for HSCT. Since neurotoxicities were not reported, we continued
deferring the anticonvulsant prophylaxis. According to this data, we emphasize
that in our experience, seizures are not frequent side effect of conditioning reg-
imens including high dose busulfan, and therefore, anticonvulsant prophylactic
regimens are not always necessary.
PB2178
SUCCESFUL STEM CELL COLLECTION IN NEWLY DIAGNOSED MULTIPLE
MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD
V Martinez-Robles, N De Las Heras, B Ballina, Ja Rodriguez-Garcia, F Escalante*
Hematología, Complejo Asistencial Universitario de León, LEON, Spain
Background: High-dose therapy plus autologous stem cell transplantation
(ASCT) is considered the standard of care for front-line treatment of younger
patients with newly diagnosed multiple myeloma (NDMM). Eligibility for this
procedure are based in almost all health institutions on chronological age more
than on biological or functional age.
Aims: Retrospective analysis of characteristics of the mobilisation and collec-
tion procedures of NDMM ASCT-candidates patients from 2009 to 2014 com-
paring 2 groups of age: under vs over 65 years old.
Methods: 54 mobilization and apheresis procedures were analysed. 36 patients
were under-65y (median 57y, range 48-65y) and 18 in over-65y (median 68y,
range 66-71y). Induction Regimen were Bortezomib-based schemes in 50 of
54 patients and 4 received chemotherapy-based scheme before collecting
Peripheral Blood Stem Cell (PBSC). PBSC collection was programmed after -
at least- 3rd induction cycle. The virtual absence of failures of collection with
Bor-Based schemes have permitted us to program mobilisation at any time of
induction phase, even after the last cycle, without any complications or failures
on the collection. Almost all patients were mobilized with granulocyte colony
stimulating factors (G-CSF) alone. Only 1 patient was mobilized with cyclophos-
phamide and GCSF. Plerixafor was added in predifined by CD34 account poor
mobilizers.
Results: G-CSF doses administered was different between the 2 groups of
age: group under-65y received a median dose of 10 mcg/Kg/24 hours and the
over-65y group a median dose of 10 mcg/Kg/12 hours. Median days of GCSF
administration was similar: 5 days. There were no differences on mobilisation
failure and/or on the indication of plerixafor administration (7/36 vs 2/18, p=ns)
The number of aphaeresis needed to reach the CD34 target was similar: medi-
an= 1 (range: 1-3). The amount of CD34 cells collected was similar, with no
statistical difference: median of 6.35 (2.5-17.67) vs 5.8 (2.6-11.6)x10E6
CD34/kg cells between groups. There were no differences in complications
after the procedure (bleeding, readmissions ...) between groups. There were
no differences in terms of safety and engraftment of ASCT between groups.
Summary/Conclusions: Mobilisation and collection of PBSC in NDMM over-
65y patients with current induction schemes is feasible and without differences
in terms of efficacy and safety (number apheresis, number of harvested cells,
need of plerixafor ...) compared with under-65y group. New induction Bor-Based
schemes have a good profile in terms of mobilisation and collection of PBSC,
independently of the age Age “per se” is not a restriction to collect stem cells
to support an ASCT.
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DIFFERENCES IN ATTITUDE TOWARDS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) BETWEEN PHYSICIANS AND NURSES
O Pasvolsky*, U Rozovski, M Navon, A Pek, J Dreyer, T Klebovsky, I Vaxman,
A Shacham, L Shargian, P Raanani, M Yeshurun
Instiute of Hematology, Beilinson Hospital, Petach Tikva, Israel
Background: Hematopoietic stem cell transplantation (HSCT) is a highly inten-
sive medical procedure and the medical staff at a transplant unit experiences
high levels of psychological distress. Since doctors and nurses differ in their
clinical training, the level of professional indoctrination and in the duration and
nature of exposure to the patients, we hypothesized that they hold different
perspective towards the procedure.
Aims: To study how doctors and nurses perceive HCST and whether profes-
sional perspectives affect the attitude of physicians and nurses towards the
procedure.
Methods: This is a single center study. All the nurses and physicians at our
transplant unit were asked to fill out an electronic questionnaire that included
24 items. Five of the items were scenarios, each describing a clinical situation
in which transplant is one of the therapeutic options. In order to ensure that the
answers do not reflect differences in medical knowledge, there were only min-
imal or no medical clues to guide participants in these scenarios. Following
each scenario, participants had to rank on a 1 to 5 Likert Scale whether they
would undergo transplant or recommend it to their close relatives or friends
under these circumstances, if this were their doctors’ advice. Participants were
also asked to rank their level of confidence in the transplant procedure. In addi-
tion, we included a work satisfaction questionnaire and basic demographic
details were also documented.
Results: We delivered the questionnaire to 51 members of the medical staff,
23 doctors and 28 nurses, who work at our department. The median age was
40 (range: 24 to 78) years and 32 (63%) were females. Nurses were younger,
more of them were unmarried and they had less professional experience. Nurs-
es and doctors had similar distributions of male to female ratios, country of
origin and both groups expressed similar levels of professional and religious
beliefs. When asked directly, physicians and nurses expressed similar level of
confidence in the process of HSCT. Intriguingly, only 21 (42%) of responders
expressed a high degree of confidence in allogeneic transplantation, while 31
(62%) expressed a high degree of confidence in autologous transplantation.
However, almost all doctors (20/21, 96%) but only 50% of nurses (14/28)
expressed high levels of confidence in reduced intensity conditioning HSCT
(P=.002). When asked if they would undergo transplant or recommend it to
their close relatives, in 3 of 5 scenarios presented to responders significantly
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more nurses were reluctant to undergo transplant despite their doctors’ rec-
ommendation.
Summary/Conclusions: At our transplant unit, the attitude of physicians and
nurses towards HCST differs significantly. Physicians perceive the procedure
in a more positive way and tend to consider undergoing HSCT themselves or
recommend it to their relatives if indicated. Nurses more often tend to consider
palliative care and express more critical attitude towards the procedure. This
study exposes fundamental differences in the professional point-of view and
we call for open discussions around these issues in which the various per-
spectives are expressed and acknowledged. We believe that this approach
will ultimately improve the communication and prevent unnecessary confronta-
tions among medical staff.
PB2180
ARTERIAL HYPERTENSION IN LONG-TERM SURVIVORS AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
C Arranto1,*, T Burkard2, O Pfister2, J Halter1
1Hematology, 2Cardiology, University Hospital Basel, Basel, Switzerland
Background: Improvement of transplantation techniques and supportive care
lead to an increasing number of long-term survivors after allogeneic hematopoi-
etic stem cell transplantation (HSCT). Recipients of allogeneic HSCT have a
higher prevalence of cardiovascular risk factors. 
Aims: To determine the prevalence of ambulatory hypertension in patients
after HSCT.
Methods: Patients ≥1 year after allogeneic HSCT were included during their
annual hematological check at University Hospital Basel, Switzerland. Blood
pressure (BP) was measured on both arms in the office after 5 minutes rest.
Arterial hypertension (HT) was defined as BP ≥140/90 mmHg. 24h ambulatory
BP measurement (ABPM) was performed with a device for noninvasive con-
tinuous BP monitoring on the same day. 24h-, day- and nighttime HT was
defined as ≥130/80, ≥135/85 and ≥120/70mmHg, respectively. Non-dipping
was defined as a nocturnal BP decrease of <10%.
Results: 66 patients were enrolled between April 2015 and December 2015.
Median age at study entry was 56 (range 22-73) with median 9 (range 1-29)
years after transplantation. 47% of the patients were female. Nine (14%)
patients had a BMI ≥30kg/m2, 19 (29%) patients had a sedentary lifestyle and
12 (18%) patients were current smokers. Fifteen (23%) patients had treatment
with calcineurin inhibitors and 4 (6%) patients had cortison. Thirty patients
(45%) had office HT: Isolated systolic, isolated diastolic and combined HT was
documented in 17, 2, and 11 patients, respectively. Systolic BP difference
between arms of ≥20mmHg was measured in 3 patients. 24h- HT was docu-
mented in 41 patients (62%) with 6 systolic, 8 diastolic and 27 systolic and
diastolic HT patterns. 32 (48%) patients had day-time HT and 54 (82%) patients
had nighttime HT. 48 (73%) patients were non-dippers. White-coat HT and
masked HT was diagnosed in 2 (3%) and 12 patients (18%), respectively. 32
(48%) had treatment with antihypertensive drugs. However, 23 patients were
still hypertensive, 17 patients detected with office BP and further 6 patients
were hypertensive on ABPM. 
Summary/Conclusions: Arterial hypertension is common in patients after allo-
geneic HSCT and is often missed by office BP measurements only. ABPM





THE TROUBLE THAT HEMATOLOGISTS DEALING WITH: VARICELLA-ZOSTER
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
M Comert Ozkan*, I Nizam Özen, I Dolaşık, E Kaya, MA Erkurt, I Kuku
Adult Hematology, Inonu University, School of Medicine, Malatya, Turkey
Background: Reactivation of varicella zoster virus (VZV) is a common event in
patients undergoing allogeneic and autologous bone marrow transplantation (BMT).
Aims: The morbidity associated with VZV reactivation and post-herpetic neu-
ralgia results in an impairment of the quality of life, which may also lead to an
increase in transplantation related costs and hospitalization. Determining the
risk factors for VZV reactivation was aimed. 
Methods: We retrospectively analyzed the incidence, clinical outcome, and
risk factors for VZV infections in 237 adult patients undergoing BMT between
Jan 2011 and Feb 2016 in Inonu University Bone Marrow Transplantation Unit.
All of the patients were treated with acyclovir prophylaxis for 3 months after
the allogeneic BMT and 30 days for autologous BMT.
Results: Fourteen (5.9%) of the patients developed VZV reactivation. Five
(35.7%) of them were autologous BMT and 9 (64.3%) were allogeneic BMT
patients. All of the patients were presented with pain and dermatomal zoster.
A median day of VZV was 413 days (range 63-820) after transplantation for
autologous BMT and 302 days (range 61-1140) for allogeneic BMT. Twenty-
one percent (n=3) of VZV reactivation occurred in the first 100 days and 14%
(n=2) after the first 24 months. Six (66.6%) of allogeneic BMT patients were
under immunsupressive treatment (cyclosporine±mikofenolat mofetil) and 1
(11.1%) had lymphocytopenia when VZV was clinically detected. Sixty-six per-
cent (n=6) of patients with VZV who were treated with allogeneic BMT were
acute myeloid leukemia patients. Sixty-four percent (n=9) of the cases was
presented in January-march peirod. The most frequent complication was post-
herpetic neuralgia. There was no statistically significant difference between
the type of hematologic diseases, type of transplantation and lymphocyte count
through VZV reactivation. But season of the year (winter) revealed statistically
significant difference in VZV reactivation. (p<0.05)
Summary/Conclusions: VZV reactivation rates of our BMT unit is significantly
lower than the literature especially in autologous BMT. But winter season was
defined as an risk factor for VZV reactivation. Longer acyclovir phrophylaxis
after autologous BMT and additional phrophylaxis programme for winter months
for 2 years after the BMT can be an effective strategy for VZV prevention.
Another important key point can be the CD4/CD8 evaluation. Acyclovir phro-
phylaxis can be maneaged with CD4/CD8 numbers. Phrophylaxis can be con-
tinued until the normal CD4/CD8 values.
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PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE IN PATIENTS WITH
APLASTIC ANEMIA AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
WITH BONE MARROW DONOR DERIVED MULTIPOTENT MESENCHYMAL
STROMAL CELLS
O Koroleva1,*, L Kuzmina1, E Mikhaylova2, E Parovichnikova1, Z Fidarova2,
V Vasilyeva1, M Drokov1, I Shipunova3, N Petinati3, N Drize3, I Galtseva1,
V Savchenko1
1BMT, 2Hematology department, 3Physiology of hematopoiesis laboratory,
National Research Center for Hematology, Moscow, Russian Federation
Background: Aplastic anemia (AA) is a rare disease characterized by bone
marrow failure and pancytopenia. Allogeneic bone marrow transplantation (allo-
BMT) is a standard treatment for young patients with a HLA-identical sibling
donor. Incidence of acute and chronic graft versus host disease (GVHD) is
13% and 14%, respectively. If paroxysmal nocturnal hemoglobinuria clone
(PNH) is detected in AA patients the incidence of acute and chronic GVHD
increases up to 47% and 70%, respectively. It is known that multipotent mes-
enchymal stromal cells (MMSC) injection for GVHD prophylaxis after HLA-
identical sibling donor transplants significantly decreases incidence of GVHD
(ClinicalTrials.gov ID-NCT 01941394).
Aims: Estimate the effectiveness of MMSC injection for GVHD prophylaxis in
patients with AA after allo-BMT.
Methods: Nine patients (6 males and 3 females) with AA received allo-BMT
from HLA-identical sibling donor in our center between December 2011 and
December 2015. Median patients age at the time of transplantation was 24 years
(range 17-33). PNH clone was detected in 8 patients (the median granulocytes
PNH clone size was 2,5% /range 0,19-97,1%/). PHN clone with intravascular
hemolysis (LDH more then 1,5 ULN) was revealed in 2 patients. There were no
thrombotic events in all patients. Eight patients received allo-BMT as first line
therapy, for one patient allo-BMT was performed for relapse after immunosup-
pression therapy. The non-myeloablative conditioning regimen was used (ATG
(100mg/kg) for 4 days, ﬂudarabine (100mg/m2) for 4 days, and cyclophos-
phamide (100mg/kg) for 4 days). For graft versus host disease (GVHD) prophy-
laxis cyclosporine and methotrexate were used. MMSC were infused intravenous-
ly at the moment of WBC count recovery to 1*109/l. On average, 1.09 (1.0-
1.2)x106 MMSC per kilogram of the patient’s body weight were injected.
Results: One patient had graft failure at day + 30 after allo-BMT. Other patients
had stable engraftment. Leucocytes recovery occurred at median 21 days
(range 17-25). Patients had no complications after MMSC injection. Only in 1
out of 8 patients (12,5%) acute GVHD was diagnosed, despite the presence
of PNH clone in 7 out of 8 patients. Acute GVHD with liver involvement (grade
III) was developed at 27 days in the patient with chronic hepatitis B virus infec-
tion. PNH clone elimination in 6 patients occurred during 1-18 mounts after
allo-BMT. All 8 patients had undulating mixed donor chimerism (85-100%) at
different time after allo-BMT. One patient with mixed donor chimerism has graft
rejection at day + 286. No chronic GVHD in any patients developed. All patients
are alive with a median follow-up 16 months (range 1-49).
Summary/Conclusions: We can suggest that in patients with AA bone marrow
donor MMSC administration at the moment of leukocytes count recovery after
allo-BMT is an effective method for acute GVHD prevention.
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BK VIRUS INFECTIONS IN PATIENTS WITH UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
B Antmen*, I Sasmaz, B Karagun, M Serbest
Pediatric Bone Marrow Transplantation Unit, Adana Acibadem Hospital, Adana,
Turkey
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Background: Hemorrhagic cystitis (HC) is a well-known complication following
allogeneic hematopoietic stem cell transplantation (allo-HSCT) that can be cat-
egorized as early-onset or late-onset. Early-onset HC is usually caused by ade-
novirus or cytomegalovirus whereas late-onset HC mainly by polyomavirus BK.
BU-containing myeloablative conditioning, unrelated donors and GVHD has
been reported as risk factors increasing the chance of infection in bone mar-
row-transplant patients. Furthermore reactivation of human polyomavirus BK
(BKV) may cause polyomavirusassociated nephropathy or polyoma virus-asso-
ciated hemorrhagic cystitis.
Aims: We aimed to present 17 patients with BK polyoma virus (BKV) ascociated
hemorrhagic cystitis and 2 patients with BK polyoma virus associated hemor-
rhagic cystitis and nephritis.
Methods: Between 2013 and 2015, 90 patients received an allogeneic BMT at
Acibadem Adana Hospital Pediatric Bone Marrow Transplantation Unit. 17
patients experienced BKV associated hemorrhagic cystitis and nephritis. BKV
was detected in the urine analysis and blood by PCR (polymerase chain reac-
tion) in all patients.
Results: We presented 17 patients with BKV infection, age ranging from 3 to
20 with an average of 11.7 years. They underwent allo-HSCT due to thalassemia
major (9 patients), aplastic anemia (3 patients) and leukemia (5 patients). The
patients were treated with hydration, continuous bladder irrigation, ciprofloxacin,
cidofovir and weekly intravesical hyaluronic acid instillation for four weeks. Ten
patients showed complete resolution of hematuria. Three patients with refractory
following therapy also received hyperbaric oxygen. Hemodialysis was performed
in two patients who developed renal failure due to nephritis.
Summary/Conclusions: Past exposures with the BK virus is widespread but
significant consequences of infection are uncommon in the immunocompetent
population. Reactivation of infection occurs under conditions of immunosup-
pression such as during GVHD treatment with patients who underwent HSCT.
Early detection and treatment is crucial for successful management of BKV
cystitis and nephritis. Neverthless even when treated with all the modalities, in
some patients treatment faillure can be observed.
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IMPACT OF DISEASE STATUS ON OUTCOMES OF ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT
OF REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
J Cao, X Tang*, X Zhu, A Sun, H Qiu, Z Jin, M Miao, F Chen, X Ma, S Xue,
X Wu, D Wu
The First Affiliated Hospital of Soochow University,Jiangsu Institute of Hema-
tology, Suzhou, China
Background: Treatment of refractory and relapsed acute lymphoblastic
leukemia (ALL) remains challenging. Allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is the only potential curative approach for these patients.
However, whether patients will benefit by achieving remission before transplant
remains controversial.
Aims: To evaluate the impact of disease status on the outcomes of allo-HSCT
in the treatment of patients with refractory and relapsed ALL.
Methods: We retrospectively analyzed the outcome of 52 patients with refrac-
tory and relapsed ALL, including 19 cases in advanced stage, such as: nonre-
mission (NR) and 33 cases in more than second complete remission (≥CR2),
who underwent allo-HSCT after myeloablative conditioning regimen in our
department. 
Results: 51 patients engrafted successfully, the transplantation-related mor-
tality (TRM) rate of NR and ≥CR2 was 10.5% vs 12.1% (P=0.815). The inci-
dence of acute GVHD(aGVHD) was 52.6% vs 57.6% (P=0.730), including
42.1% vs 33.3% (P=0.527) with mild (grade I-II) aGVHD and 10.5% vs 24.3%
(P=0.399) with severe (grade III-IV) aGVHD, and chronic GVHD(cGVHD) was
41.6% vs 57.9% (P=0.660). With a median follow-up of 12(1.8-44.5) months,
the cumulative relapse rate was 47% vs 34.3%, P=0.425) of NR and ≥CR2.
The estimated 2 year overall survival (OS) and 2 year leukemia-free survival
(LFS) rate were 42.6% vs 45.7% (P=0.487) and 46.3% vs 46.2% (P=0.571)
respectively. Multi-parameter analysis results showed that, OS and LFS was
significantly better in patients with the appearance of cGVHDFor relapsed
patients, OS was significantly better with first CR duration>6 month and time
to transplant ≤2 months.
Summary/Conclusions: In this retrospective single center study, we can dis-
tinctly note that the survival of patients in NR and ≥CR2 before transplant is
similar. Thus, it is suggested that allo-HSCT is an effective salvage therapy for
patients with refractory and relapsed ALL and transplantation can be conducted
directly for those who could not tolerate salvage chemotherapy. However, given
the limited number of patients and observation time, an expanded sample size
and prospective cohort study is needed to confirm the results.
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IMPACT OF THE IL28B RS12979860 CT POLYMORPHISM ON THE
CYTOMEGALOVIRUS REACTIVATION IN AUTOLOGOUS STEM CELL
TRANSPLANT PATIENTS
O Annibali1,*, E Riva2, L Piccioni2, V Tomarchio1, E Circhetta3, C Sarlo1,
L Franceschini4, M Rizzo4, G Ciangola4, P Berti3, T Petitti5, M Cantonetti4,
MC Tirindelli3, W Arcese4, G Avvisati1
1Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cel-
lular Therapy, Department of Medicine, Università Campus Bio-Medico for the
Rome transplant Network, 2UOS of Virology, 3Unit of Hematology, Stem Cell
Transplantation, Transfusion Medicine and Cellular Therapy, Department of
Medicine, Università Campus Bio-Medico Roma, 4Hematology and Stem Cell
Transplant Unit, University Tor Vergata for The Rome Transplant Network, 5Unit
of Hygiene Public Health and Statistics, Università Campus Bio-Medico Roma,
Roma, Italy
Background: CMV infection represents one of the main cause of morbility and
mortality after stem cell transplantation (SCT). Type III interferons (IFNs), includ-
ing IFNl1 (IL29), IFNl2 (IL28A) and IFNll3 (IL28B), are thought to display potent
antiviral and immunomodulatory properties in vivo, which may partially overlap
with those exerted by type I IFNs. Type I and Type III IFNsl both generate an
antiviral state by triggering the JAK-STAT pathway, ultimately upregulating the
expression of interferon-stimulated genes. Rs12979860 single nucleotide poly-
morphism (SNP) in IL28B gene region is well known to influence the sponta-
neous and treatment-induced clearance in HCV infection. Although the rele-
vance of such a SNP in other vir. CMV infection represents one of the main
cause of morbility and mortality after stem cell transplantation (SCT). Type III
interferons (IFNs), including IFNl1 (IL29), IFNl2 (IL28A) and IFNll3 (IL28B), are
thought to display potent antiviral and immunomodulatory properties in vivo,
which may partially overlap with those exerted by type I IFNs. Type I and Type
III IFNsl both generate an antiviral state by triggering the JAK-STAT pathway,
ultimately upregulating the expression of interferon-stimulated genes.
Rs12979860 single nucleotide polymorphism (SNP) in IL28B gene region is
well known to influence the spontaneous and treatment-induced clearance in
HCV infection. Although the relevance of such a SNP in other viral infections is
still debated, Bravo et al. recently documented a protective effect of the T allele
against CMV infection in the Allogeneic SCT (Journal of Medical Virology
2014,86:838). Al infections is still debated, Bravo et al. recently documented a
protective effect of the T allele against CMV infection in the Allogeneic SCT
(Journal of Medical Virology 2014,86:838).
Aims: the current study was aimed at investigating whether the IL28B poly-
morphism Rs12979860 may affect the CMV reactivaction in the setting of Autol-
ogous SCT (Auto-SCT).
Methods: From October 2014, 67 patients undergoing an Auto-SCT for hema-
tological malignancies were included in the study. The patients, with a median
age of 56 years (range, 16-66 yrs), were distributed according to the underlying
disease as follows: 75% had Multiple Myeloma, 16% non Hodgkin Lymphoma,
6% Hodgkin Lymphoma and 3% Acute Myeloid Leukemia. The Rs12979860
IL28B SNP (C/T) genotype was determined by Melthing analysis on DNA
derived from peripheral blood samples. CMV DNAemia was determined by
quantitative Real-Time PCR with a limit detection of 50 copies/mL (Artus, Qia-
gen). Patients were monitored for CMV DNAemia weekly for three months after
transplantation.
Results: According to the lowest frequency of TT genotype harboring in general
population, the detected genotypes were CC in 31 patients (46%) CT in 27
(40%) and TT in only 9 (14%). Although not statistically significant, a CMV reac-
tivation (symptomatic and asymptomatic) was higher in patients carrying TT
genotype (n=7 ;77.7%) with respect to patients carrying CC (n21.;67.7%) and
CT genotype (n=12; 44.4%). According to the logistic regression analysis, the
incidence of CMV reactivation was significantly lower in patients carrying IL-28B
CT compared to the cumulative group of patients with CC and TT genotype
(44.4% versus 70% ; p=0.039, CI 95%, OR 2.91) (codominat genetic model).
Summary/Conclusions: Our data suggest that in the Auto-SCT setting the
carriage of IL-28B CT genotype might express a protective effect against CMV
infection
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MAJOR QUALITY PARAMETERS OF LONG-TERM CRYOPRESERVED
CORD BLOOD UNITS - A SINGLE CENTER EXPERIENCE
F Bordalo*, F Amado, S Ferreira, C Pinho, S Lopes, S Roncon
Cellular Therapy, IPO PORTO, Porto, Portugal
Background: Cord Blood (CB) is a well-recognized source of stem cells for
hematopoietic transplant. Its main advantage is to be stored for long-term with
a ready availability for the intended recipient and no risk for the donor.
Aims: The aim of this study was to evaluate the quality of 15 cord blood units
cryopreserved in our direct donation bank. for the intended recipient and no
risk for the donor.
Methods: All these units were processed without red cells reduction, in a 24
hours period after collection, then were cryopreserved with a controlled-rate
freezer and transferred to a liquid nitrogen container. We used cryogenic bags
(Kapton/Teflon), highly resistant to very low temperatures. However, due to
missing data we do not considered these CB units suitable for transplant. In
this study, the CB were thawed and washed based on the New York Blood
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Center method in our ISO 7 cleanroom, inside of an air flow cabinet. We per-
formed cellular counts, viability assays (by flow cytometry using 7-aminoactin-
omycin), sterility testing (bacterial and fungal cultures) and clonogenicity
(colony-forming units-granulocyte/macrophage - CFU-GM - growth). The cor-
relation between CD34+ cell and CFU-GM counts was evaluated by linear
regression analysis.
Results: The CB units were stored during 11-20 years (mean 16±3). We ana-
lyzed 12 CB because 3 bags were broken during storage (20%); this percent-
age is much higher than that found in our daily practice (4%), which may be
caused by the long cryopreservation period. Visual examination of the product
showed evidence of hemolysis in 10 CB and fibrin clots in 1. The recovery of
total nucleated cells (TNC) was 73±14%; CD34+ cells enumeration
48.3±29.3x105 and CFU-GM quantification 28.5±19.3x104. The TNC and
CD34+ cells viability was 70±8% and 91±5%, respectively. We obtained a
strong positive relationship between CD34+ cell and CFU-GM (R2=0.758). We
found 4 contaminated CB, one of them was already positive after processing
(Enterococcus faecalis, Escherichia coli and Streptococcus mitis). We hypoth-
esize that the pre-freezing hemocultures were not representative of the product;
however, we cannot exclude a cross-contamination during the storage.
Summary/Conclusions: Despite our small serie, the results of cellular viability,
purity and potency indicate that long-term cryopreservation does not negatively
affect the quality of CB units for further use, even in the presence of contami-
nation, hemolysis signs and aggregates. We think that every cord blood bank
should have an expert to help transplant physicians select the best cord blood
for his patient based on the control quality results performed before final
release.
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PERIPHERAL BLOOD HEMATOPOETIC STEM CELLS (PBSC) MOBILIZATION
WITH GENERIC VERSION OF PLERIXAFOR: AN EXPERIENCE AT A
NORTH INDIAN TERTIARY CARE REFERRAL INSTITUTE
K Sahu1,*, A Khadwal1, U Yanamandra1, T Sehgal1, N Jain1, A Jain1, M Sachdeva1,
G Prakash2, P Malhotra2, S Varma2
1PGIMER, Chandigarh, India, 2Internal Medicine, PGIMER, Chandigarh, India
Background: Plerixafor is used to mobilize hematopoietic stem cells in cancer
patients into the bloodstream. Developed by AnorMED, plerixafor was approved
by the U.S. Food and Drug Administration (FDA) on 15 December 2008. Hence-
forth, Genzyme (USA based company) took a step forward and launched pler-
ixafor from benchside to bedside. Brilliant success story of this new molecule
was hindered by the expensive cost thereby debarring large population of world
from the benefit of this drug. Many Indian companies (eg. Hetero and panacea
pharmaceutical companies) took the challenge to curb down the cost price and
have come up recently with generic version of plerixafor. For a successful out-
come of Hematopoetic Stem cell transplant a minimum dose of 2x106/Kg
CD34+ cells are required. Standard mobilisation procedure involves use of G-
CSF or GM-CSF alone in combination with chemotherapy. Those with certain
risk factors like old age, previous multiple chemotherapy regimens, radiother-
apy, bone marrow involvement with disease and exposure to agents like
lenalidomide etc. may not mobilise adequately. We share our experience with
generic plerixafor which is approximately 4-4.5 times cheaper than the original
molecule and yet efficacious.
Aims: To study the efficacy of generic plerixafor which is approximately 4-4.5
times cheaper than the original molecule.
Methods: Study was conducted from December 2013 to February 2016 (26
months). In total, 66 transplants were carried out (autologous= 35 and allo-
geneic= 31) in our institute. Generic plerixafor was used along with G-CSF for
in autologous PBSCs mobilisation in 20 out of 36 instances (Multiple myeloma
=7, Hodgkins lymphoma=6, Nonhodgkin’s lymphoma=6, APML= 1).
Results: Mean age of the patients was 39.5 years (range 17-63 years) with 13
males and 7 females. Average interval from disease diagnosis to transplant
interval was 18.4 months (range 6- 96 months). Number of prior chemotherapy
regimens used ranged from 2-4 and 6 patients also got radiotherapy in addition.
Conditioning regimens used were-(1) Inj. melphalan=7, (2) BEAM regimen=10,
(3) LACE regimen =2, (4) CY-TBI=1. Inj. Plerixafor was given in dose of 24
microgram/kg on day 4 and/or day 5 of G-CSF (10 microgram/kg/day) mobili-
sation depending on peripheral blood CD34+ cells (when available) and the
yield of first harvest. Most of the patients (14 out of 20) required a single dose,
while the remaining six needed an additional dose. Majority of patients (17 out
of 20) underwent two apheresis session while two required single session.
One had initial mobilisation failure with GCSF and 2 doses of plerixafor. But he
subsequently mobilised successfully after 14 days with repeat GCSF and single
plerixafor dose. Mean CD34+ cells obtained was 5.44x106,/kg (range 2.7-
13.13x106/kg). Neutrophilic and platelet engraftment occurred on day+13
(range 10 -20 days) and day +16 (range 10-36) respectively. Median units of
PRBC and Platelet (SDAP) transfused were 3 (range 0-13) and 7 (2-15) respec-
tively. There was only one death on day +7 due to acute cardiomyopathy. 
Summary/Conclusions: Generic version of plerixafor with GCSF is an effec-
tive and safe strategy to mobilise stem cells.
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PREDICTIVE FACTORS FOR RELAPSE IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA SUBMITTED TO ALLOGENEIC STEM CELL
TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
D Pastore*, M Delia, P Carluccio, A Ricco, A Russo Rossi, C Germano,
C Pasciolla, P Pinto, P Casieri, F Albano, G Specchia
Hematology with Transplantation,University of Bari, Policlinico, Bari, Italy
Background: Adults with high risk acute myeloid leukemia features at diagnosis,
primary induction failure (PIF) or with recurrent disease have a poor outcome after
chemotherapy and are candidates for allogeneic stem cell transplantation (allo
SCT). However, the relapse rate in these patients remains a matter of concern.
Aims: Aim of the study is to identify the main factors influencing acute myeloid
leukemia (AML) relapse after allo SCT in a single center.
Methods: 118 adult AML patients (median age 42 y [range 16-68], 50 M/ 68 F)
received an alloSCT at our Institution from 2000 to 2015. Donors for HCT were
HLA-matched related donors in 68/118 (57%) and “alternative donors”
(matched unrelated or haploidentical donors) in 50/118 (43%) transplantations.
The source of hematopoietic stem cells was peripheral blood in 110/118 (93%)
and bone marrow in 8/118(7%) patients; 90% patients underwent a myeloab-
lative conditioning regimen and 10% a reduced intensity regimen. Disease sta-
tus (1st CR versus not[2nd/3nd CR and “active disease”]), molecular-cytogenetic
risk(intermediate versus poor-risk), response to first chemotherapy(responders
versus primary induction failure/PIF), time from diagnosis to transplantation
(more or less than 6 months), stem cell source (bone marrow or peripheral
blood), donor type (matched related or alternative), severe acute GvHD (grade
IIII-IV), chronic GvHD, serological risk CMV status were analyzed as predis-
posing factors for relapse. Multivariate analysis was performed with the vari-
ables identified as relevant at univariate analysis. 
Results: Transplantation for AML was done in 1st CR in 53/118 (44%) patients
and not in 1st CR in 65/118 (56%) patients. Thirty-nine patients (33%) were
PIF and 83/118 (70%) transplants were done within 6 months from diagnosis;
28/118(23%)patients were classified as poor molecular-cytogenetic risk. Twen-
ty-six (18%) suffered GvHD grade III-IV and 32%, 15% and 8% of evaluable
patients developed limited, moderate and severe cGvHD. The 2-year relapse
incidence was 55%: 36% for patients in CR1 and 75% for patients not in
CR1(p=0.001). At multivariate analysis the disease status (1st CR)(p=0.02 HR
0.73, 95%CI 1.0-2.8) and cGvHD(p=0.001 HR 0.2, 95%CI 0.1-0.4) were the
factors associated with a lower relapse incidence. Donor type, molecular-cyto-
genetic risk, response to first chemotherapy, stem cell source, acute GvHD did
not seem to significantly influence relapse.
Summary/Conclusions: In our experience allogeneic transplants performed
in 1stCR and cGvHD were the main factors influencing the risk of relapse in
adult patients with AML. Transplanted patients not in 1st CR and without cGvHD
may be a “high relapse risk group” that could benefit from pre-emptive therapy
post transplantation also with new drugs.
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COMPARABLE OUTCOME OF ALLOGENEIC VERSUS AUTOLOGOUS
HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTION
IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE AND
FLT3-ITD NEGATIVE
H K Mahmoud1,*, A ElHaddad1, O Fahmy2, M Samra1, R AbdelFattah1,
Y ElNahass1, G Fathy3, H ElAshtoukhy4, F ElRefaey1
1National Cancer Institute, 2Cairo University, 3Nasser Institute, Cairo, 4faculty
of medicine, Banha, Egypt
Background: Optimal post-remission treatment for acute myeloid leukemia
with normal karyotype (AML-NK) in first complete remission (CR1) is still not
well-defined. 
Aims: To compare the outcome of allogeneic versus autologous peripheral
blood stem cell transplantation (PBSCT) in adult AML patients regarding toxi-
cities of transplant procedure, transplant-related mortality (TRM), disease free
survival (DFS) and overall survival (OS).
Methods: 43 patients were included; 34 patients (with a median age 28 years)
received myeloablative allogeneic PBSCT from a matched sibling donor while
9 patients (with a median age 36 years) received PBSC autograft. All patients
had a normal karyotype, FLT3 ITD negative and were in CR1.
Results: After a median follow up of 21.5 months (0.3– 46.5), the cumulative
2-year OS and DFS in the allogeneic group were 73.5% and 70.6% respectively
compared to 74.1% and 64.8%, respectively in the autologous group (p=0.690
and 0.768). Increasing number of consolidation cycles (>3) and lower CD34
+ve stem cell dose were associated with lower relapse rates and higher DFS
in the autologous group.
Summary/Conclusions: Preliminary data show comparable outcome of autol-
ogous compared to allogeneic PBSCT in patients with AML-NK and FLT3 ITD
negative in CR1. In absence of matched sibling donor, autologous PBSCT may
provide acceptable post-remission therapy for patients with low risk molecular
profile.
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CAN RED CELL DISTRIBUTION WIDTH BE A NEW PARAMETER FOR
PREDICTING HIGHER CD34+ CELL COUNT IN THE HARVEST?
E Gunduz1,*, H Uskudar Teke1, N Andic1, A Musmul2
1Hematology, 2Biostatistics, Eskisehir Osmangazi University, Eskisehir, Turkey
Background: The red cell distribution width (RDW) is a simple and unexpen-
sive parameter and is traditionally used for differential diagnosis of anemias.
However, the number of articles mentioning about the relationship between
RDW and human disorders has increased over the past decades. In tranplan-
tation practice, the peripheral blood is the most common source of hematopoi-
etic stem cells. There are many factors affecting the success of stem cell mobi-
lization. 
Aims: In this study, we tried to find a relationship between increased RDW and
CD34+ cell count in the harvest. 
Methods: Fifty patients who underwent stem cell mobilization between March
2014 and October 2015 are included in the study. Mean age was 56.82± 10
years, 28 (%56) patients were male and 22 (%44) patients were female. Diag-
nosis were multiple myeloma (n=32), non Hodgkin lymphoma (n=9), Hodgkin
lymphoma (n=6), primary amyloidosis (n=1), Waldenstrom’s macroglobulinemia
(n=1) and testicular carcinoma (n=1). Mobilization regimens were cyclophos-
phamide plus G-CSF in 35 (%70) patients, G-CSF alone in 2 (%4) patients,
etoposide plus G-CSF in 2 (%4) patients and salvage chemotherapy plus G-
CSF in 11 (%22) patients. Five (%10) patients had a history of radiotherapy.
Bone marrow infiltration for patients except myeloma was found in 6 (%35)
patients. Patients received mean 1.61± 0.6 lines and 4.94±2.6 courses of
chemotherapy. 
Results: RDW was not correlated with peripheral blood CD34+ cell count
(r=0.064, p=0.75, n=28) and CD34+ cell count in the harvest (r=-0.14, p=0.34,
n=50). Other parameters previously reported to affect stem cell mobilization
(age, weight, number of chemotherapy courses before mobilization, hemoglo-
bin, white blood cell count, absolute neutrophil count, absolute lymphocyte
count, platelet count, albumin, LDH) were also evaluated. Peripheral blood
CD34+ cell count (r=0.694, p=0.001, n=50) and the number of chemotherapy
courses before mobilization (r=-0.451, p=0.008, n=28) were found as the only
parameters that affect CD34+ cell count in the harvest. In order to assess the
effect of increased RDW on the CD34+ cell count in the harvest; above 16 was
set as a cut-off for increased RDW and patients were divided into 2 groups.
Sex, primary diagnosis, stage, bone marrow infiltration, mobilization regimen,
chemotherapy courses, radiotherapy, comorbidities, number of leukapheresis
days were not different between two groups. LDH was the only parameter dif-
ferent between 2 groups. It was found higher in the increased RDW group
(p=0.005). Although peripheral blood CD34+ cell count and CD34+ cell count
in the harvest were not different statistically between 2 groups, the numbers
were lower in the increased RDW group (10.48±5.94 vs 8.07±5.01).RDW was
not correlated with peripheral blood CD34+ cell count and CD34+ cell count in
the harvest in both groups. 
Summary/Conclusions: To our knowledge, this is the first study evaluating
the relationship between RDW and stem cell mobilization in cancer patients.
Although it has not been definitely established, it seems reasonable to suggest
using RDW far beyond the differential diagnosis of anemias. Stem cell mobi-
lization can be a potential candidate in this era.
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THE INFLUENCE OF HAPLOTYPE HLA-C(C1/X,C2/X) IN EVOLUTION
AFTER HSCT
D Bratu1,*, I Constantinescu2, A Moise2
1Haematology, 2Immunogenetics, Clinical Institute Fundeni, Bucharest, Romania
Background: Haplotypes of patients with acute leukemia like ligands or not
for inhibitories and activatories donors KIR allele in HSCT are subjects of stud-
ies in a few specialised clinics; it is an evidence that haplotypes can be protec-
tive or not against postHSCT complication, easier to try to demonstrate at
patients with genoidentical donors.
Aims: Haplotype HLA-C(C1/X,C2/X), homozygot and heterozygot variants
(HLA-C1/C1,HLA-C1/C2,HLA-C2/C2) seems to have influence at patients with
acute leukemia after HSCT.
Methods: Eighteen pairs patients-donors are evaluated: patients with acute
leukemia, lymphoblastic and non-lymphoblastic and their genoidentics donors.
One patient have HLA-C1/C1 haplotype, seven HLA-C1/C2, ten HLA-C2/C2.
Following the impact of inhibitory KIR2DL1, like ligand for C2,KIR2DL2,
KIR2DL3 for C1, activatory KIR2DS1 for C2,KIR2DS4 for C1, on survival and
complication development, we proved the protective effect of presence of HLA-
C2/X haplotype, HLA-C1/X, respectively. The source of HSCT was PBSC. The
method used was PCR-SSP (Innotrain DIAGNOSTIK GMBH, Dynal BIOTECH
PEL-FREEZE). The complications like graft versus host disease acute and
chronic, relapse, TMA and the recovery with leucocytes and thrombocytes are
followed.
Results: Presence of HLA-C1 haplotype is protective in presence of KIR2DS4
(activatory allele) with statistical significance for thrombocyte recovery but no
influence against aGVHD and relapse; in presence of KIR2DL2, KIR2DL3
(inhibitory allele) against relapse, TMA, a/cGVHD, leucocytes and thrombocytes
recovery, without statistical significance. HLA-C2, in presence of KIR2DS1, and
also in presence of KIR2DL1 protective against TMA and relapse, cGVHD, also
leucocyte and thrombocytes recovery, without statistical significance, except
aGVHD (no influence) and observation for absence HLA-C2 with protective
effect against relapse (...missing ligand”).
Summary/Conclusions: Presence of HLA-C1/X,HLA-C2/X4 improve survival
and offer minor protection against most complication at patients with acute
leukemia and related donors with 100% allele match, in presence of both types
of KIR alleles.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC
PATIENTS WITH MIXED PHENOTYPE ACUTE LEUKEMIA
JA Park1,*, H Chueh2, JY Lim3, YT Lim4
1Pediatrics, Inje University Haeundae-Paik Hospital/ Inje University College of
Medicine, 2Pediatrics, Dong-A university hospital, Busan, 3Pediatrics,
Gyeongsang National University Hospital, JInju, 4Pediatrics, Busan National
University Hospital, Busan, Korea, Republic Of
Background: Mixed phenotype acute leukemia (MPAL) is a rare disease
accounting for about 2-5% of all acute leukemia, and patients with MPAL have
poor prognoses, particularly in patients with T/myeloid immunophenotype. How-
ever, there is no standardized treatment for MAPL and no consensus about
the incorporation of hematopoietic stem cell transplantation (HCT) as an integral
part of therapy. Due to its rarity, outcomes of HCT for pediatric MPAL have not
been fully determined.
Aims: We investigated outcomes of HCT for pediatric patients with MPAL with
multicenter study.
Methods: We retrospectively analyzed transplant outcomes for 12 pediatric
patients with primary MPAL, undergoing HCT between 2001 and 2014 in 10
institutes in Youngnam province, Korea. By WHO 2008 classification, 1 (8%)
had MPAL with t(v;11q23); MLL rearranged, 9 (75%) had MPAL, T/myeloid,
NOS, and the remaining 2 (17%) had MPAL, B/myeloid, NOS. Before HCT, 10
patients were in first complete remission (CR), 1 patient in second CR, and
one patient relapsed and had persistent disease. Donor was matched-related
in 6, matched-unrelated in 2, umbilical cord blood (UCB) in 2, and autologous
in 2, respectively. Conditioning regimen was busulfan, cyclophosphamide
and/or melphalan based myeloablative (MA) in 10 patients and busulfan and
fludarabine based nonmyeloablative (NMA) in 1 patients. One case of autolo-
gous transplant used cyclophosphamide, etoposide, cytarabine and BCNU as
a conditioning regimen. For prophylaxis of GVHD following allogeneic HCT,
cyclosporine and short-term methotrexate were used.
Results: Median age at the time of HCT was 9.0 years (range, 1.3-13.3 years),
and median interval between diagnosis and transplantation was 6.1 months
(range, 2.8-14.2 months). Cumulative incidences of neutrophil and platelet
engraftment by day 28 were 100%. After median follow-up of 6.2 years (range,
0.8-17.4), 9 of 12 patients survived. Cumulative incidence of treatment-related
mortality (TRM) and relapse were 9% and 35.8%. Event-free survival (EFS)
and overall survival (OS) after HCT were 64.2% (50%>78%, 95% CI) and 72.7%
(59%>86% 95% CI), respectively. WHO classification did not significantly affect-
ed EFS after HCT for pediatric MPAL patients (p=0.371).
Summary/Conclusions: Many studies have reported that patients with MPAL
had poor prognosis, and patients with T/myeloid phenotype had a worse out-
come than patients with B/myeloid phenotype. We found that WHO classifica-
tion 2008 for MPAL was not significantly associated with patients’ outcome after
HCT and that patients with MPAL, T/myeloid, NOS had more favorable outcome
compared to historical data. Our data suggested that HCT may improve the
outcome of pediatric patients with MPAL, particularly T/myeloid phenotype. This
study needs to be confirmed in larger, prospective studies including more pedi-
atric MPAL patients.
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THE ROLE OF LYMPHOCYTE RECOVERY AFTER HIGH DOSE THERAPY
AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH
RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND MULTIPLE
MYELOMA
M Todorovic Balint1,*, J Jelicic1, J Bila1, B Balint2, B Andjelic1, D Antic1, A Sretenovic1,
D Vujic3, N Kraguljac Kurtovic1, D Sefer1, D Sefer1, V Djurasinovic1, M Smiljanic1,
V Vukovic1, B Mihaljevic1
1Clinical Center of Serbia, University of Belgrade, Clinic of Hematology, 2Insti-
tute for transfusiology and hemobiology, Military Medical Academy, 3Institute
for mother and child health care “ Dr Vukan Cupic”, Medical faculty University
of Belgrade, Belgrade, Serbia
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Background: In Non Hodgkin lymphoma as well as in Hodgkin lymphoma
(HL) and multiple myeloma (MM), lymphocyte recovery after autologous stem
cell transplantation (ASCT) has been reported to have association with clinical
outcome, but also with contradictory data.
Aims: The aim of study was to evaluate the role of parameters that may be
associated with outcome after ASCT.
Methods: The study included 61 patients with relapsed/refractory HL (34
males/ 37 females) aged 30 years (range 18-46) and 85 MM patients (42 males/
43 females) aged 54 years (range 36-65) who were treated with high dose
chemotherapy followed with ASCT. Advanced stage of HL disease (Ann Arbor
III-IV) had 41.0% patients. Majority of patients had constitutional B symptoms
(88.5%) and bulky disease (54.1%). Low IPS had 15 patients (22.6%). All
patients received ABVD therapy and in the course of relapse or refractory dis-
ease, DHAP as first salvage therapy, and BEAM (54 patients, 88.5%) or CBV
(7 patients, 11.5%) as conditioning regimen due to ASCT. The average value
of collected CD34+cells was 11.3x106/kg (range 2-24x106/kg) in the volume of
250 ml (range 100-900ml). The mean aplasia duration was 11 days (range 6-
28 days). After ASCT 29 patients achieved CR (47.5%), 21 patients PR (34.3%),
3 had SD (4.9%) and 8 patients (13.1%) had PD. Median time to recovery of
absolute lymphocyte count on 500x106/l (ALC500) was 15 days (range 9-32).
Regarding MM population, majority of patients had IgG (59, 69.4%) and IgA
(12 pts, 14.1%) type of MM. According to the clinical stage (CS) 6 pts (7.1%)
had I, 16 (18.8%) II, and 63 (74.5%) III CS. Renal impairment was present in
15pts (17.6%). MM patients were initially treated with protocol VAD (29 pts,
34.1%) or CTD (56 pts, 65.9%) and high dose Melphalan (200mg/m2) was
conditioning regimen prior to ASCT in the first treatment line. The average
value of collected CD34+cells was 6.5x106/kg (range 2-96x106/kg) in the vol-
ume of 300 ml (range 100-660ml). The mean aplasia duration was 8 days
(range 4-26 days). After ASCT only 1 patient (1.2%) had PD, while 22 (25.9%)
had PR and the rest achieved at least VGPR (52, 73.0%). Median time to
ALC500 recovery was 15 days (range 9-23days).
Results: In HL patients survival after ASCT was 39 (2-100) months, and OS
was 70 (16-192) months. Patients with low IPS (0-2 ) had better survival com-
pared to those with high IPS score (≥3) (Log Rank=3.68, p=0.05). Survival
after ASCT was markedly influenced by prolonged recovery duration of
ALC500≥18 days (Log Rank=4.54, p=0.03). However, the duration of ALC500
recovery was not in correlation with treatment response (p>0.05). Furthermore,
survival was significantly inferior in patients with PD or SD after ASCT (Log
Rank=6.07, p=0.014). As expected, treatment response after ASCT significantly
influenced OS (Log Rank=11.27, p=0.004). Multivariate Cox regression among
independent prognostic factors in univariate analysis (IPS, therapeutic outcome
and ALC500 recovery) pointed out therapeutic outcome at D+100 and delayed
ALC500 recovery as the most important parameters that influenced both OS
and EFS (p<0.05). In MM patients survival after ASCT was 29 (2-115) months,
and OS was 48 (16- 127) months. However, delayed recovery of ALC500 after
18th. day from ASCT did not influence neither OS nor survival after ASCT.
Summary/Conclusions: According to results of Cox regression analysis in
HL, no responders at D+100, and delayed recovery of ALC500 are parameters
of inferior prognosis and shorter survival. However, similar cut off values of
ALC500 are not predictable in MM patients.
Stem cell transplantation - Experimental
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COMPARISON BETWEEN SERUM AND FECAL CALPROTECTIN AS
MARKER OF GRAFT-VERSUS-HOST DISEASE
E Metafuni*, S Giammarco, D De Ritis, M Rossi, A Bacigalupo, S Sica, P Chiusolo
Hematology Department, Fondazione Policlinico Universitario Agostino Gemel-
li, Rome, Italy
Background: Graft-versus-host disease (GvHD) is one of the complication
occurring after hematopoietic stem cell transplantation (SCT) responsible for
high morbility and mortality. The main strategy to reduce GvHD-related mortality
is the correct diagnosis and prompt steroid administration. In the last few years,
different proteins have been evaluated as reliable biomarker of GvHD. In our
experience, fecal calprotectin (FC), a heterodimer of two S100 family proteins
S100A8/S100A9 secreted by activated macrophages, appeared useful to dif-
ferentiate gut GvHD from liver/skin GvHD, and to distinguish between gut GvHD
and enteritis due to other causes.
Aims: The aim of our study was to compare fecal (FC) and serum (SC) levels
of calprotectin in a cohort of patients (pts) submitted to SCT, in order to define
if a correspondence there was between the two determinations in the same
patient (pt).
Methods: We enrolled 21 pts submitted to SCT in our department since
December 2009 al July 2012, 9 females and 12 males, with a median age of
55 years (range 35-63), affected by acute lymphoblastic leukemia in 2 cases,
acute myeloid leukemia in 14 cases, non-Hodgkin lymphoma in 1 case, myelo-
proliferative disease in 1 case and myelodisplastic syndrome in 3 cases. Con-
ditioning regimes was MAC in 2 pts and RIC in 19 pts. GvHD prophylaxis was
performed with short course methotrexate plus CSA in 15 cases and with
CSA+MMF in 6 pts. Donor was related in 14 cases and unrelated in 7 pts.
Serum and stools samples were provided for each pt at the time of GvHD onset
and, for pts who did not developed GvHD samples were collected around day
+30. Calprotectin detection was made using commercial ELISA kit for Calpro-
tectin assay on stools and serum samples. 
Results: Fourteen pts (66,7%) developed acute GvHD after a median time of
25,5 days (range 6-80): grade I in 3 pts (21,4%), grade II in 3 pts (21,4%),
grade III in 7 pts (50%) and grade IV in 1 pt (7,2%). Organ involvement was:
isolated skin in three pts, skin and liver in one pt, isolated liver in 2 pts, isolated
gut in 2 pts, gut and skin in 5 pts, skin and gut and liver in one pt. FC median
level was 198,9 mg/Kg (range 58.4-500) in pts with aGvHD and 32.2 mg/Kg
(range 15.6-89) in the others (Mann Whitney, p=0.0005, Fig 1A), while SC
median level was 2756.5 ng/ml (range 173.3-10690) in pts with aGvHD and
1328 ng/ml (range 410.9-4241) in the others (Mann Whitney, p=0.22, Fig 1B).
Among pts with aGvHD, FC median levels was 134.9 mg/Kg (range 58.4-292.3)
in pts with grade I-II aGvHD and 396.6 mg/Kg (range 95.2-500) in grade III-IV
(Mann Whitney, p=0.029), while SC median level was 231.2 ng/ml (range
173.3-5575) in pts with grade I-II aGvHD and 3601 ng/ml (range 868.5-10390)
in grade III-IV (Mann Whitney, p=0.4). Finally, FC median level was 396.6
mg/Kg (range 142.1-500) in pts with gut aGvHD and 115.2 mg/Kg (range 58.4-
292.3) for non-gut aGvHD (Mann Whitney, p=0.02, Fig 1C), while SC median
level was 3232.25 ng/ml (range 868.5-10390) in pts with gut aGvHD and 2312
ng/ml (range 173.3-5575) in non-gut aGvHD (Mann Whitney, p=0.57, Fig 1D).
Figure 1: A) median FC level in pts with (yes) or without (no) aGvHD; B) median
SC level in pts with (yes) or without (no) aGvHD; C) median level of FC in pts
with gut or liver/skin GvHD; D) median level of SC in pts with gut or liver/skin
GvHD.
Figure 1.
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Summary/Conclusions: There was no correspondence between serum and
fecal camprotectin. Our studies suggest that fecal but not serum calprotectin
levels may be considered a marker of gut GvHD after SCT.
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ANALYSIS OF CHIMERISM AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN THE STUDY OF GENETIC POLYMORPHISMS
ASSOCIATED WITH THROMBOPHILIA
E Butina*, N Minaeva, G Zaitseva, A Kiseleva
Immunogematology, Federal State Institute of Science “Kirov research Institute
of Hematology and Blood Transfusion of the Federal Medical and Biological
Agency of Russia”, Kirov, Russian Federation
Background: Currently, much attention is paid to the development of simple
and relatively inexpensive methods of diagnosing hematopoietic chimerism.
Aims: To study the possibility of using gene allelic variants of thrombophilia as
markers chimerism after allogeneic hematopoietic stem cell transplantation
(allo-HSCT). 
Methods: The results of examination of 10 patients, which in 2015 was per-
formed allogeneic HSCT. Donors of hematopoietic stem cells for 8 patients were
siblings, donors for 2 patients were selected from the Bone Marrow Transplant
Registry. In all cases the donors and recipients were HLA-identical class I and
II. Allo-HSCT utilizing a myeloablative regimen was performed in 7 patients.
HSCT in the mode of increased intensity was used in 3 patients. The gene poly-
morphisms were analyzed by polymerase chain reaction in real time. In order to
identify information markers analyzed gene polymorphism F2, F5, F7, F13, FGB,
ITGA2, ITGB3, PAI-1, MTHFR: 665, MTHFR: 1286, MTR, MTRR. Chimerism
was investigated at 28, 42, 56, 70, 100, 120 days after HSCT.
Results: Genetic differences were detected in 9 of the 10 donor-recipient pairs
(from 1 to 7, median -5). The greatest number of distinctions obtained in the
study of allelic variants of the gene FGB (7 out of 10 couples). In the analysis
of gene MTHFR: 1286 differences were detected in 6 pairs; ITGA2, ITGB3,
PAI-1- in 4 pairs, F13, MTHFR: 665, MTRR - in 3 pairs. For each pair were
chosen polymorphisms that act as molecular markers allow to differentiate
donor and recipient cells after HSCT. In three cases, the donors and recipients
were homozygous for different alleles of one gene. In other cases, an identifi-
cation mark considered polymorphism, in which one allele was common to both
donor and recipient, the second - only for specific recipient. Complete donor
chimerism was established in 7 patients on day 28 after HSCT.
Summary/Conclusions: Genetic polymorphisms associated with thrombophil-
ia meet the basic requirements of the markers hematopoietic chimerism: analy-
sis is based on the identification of regions of the genome that differ one
nucleotide sequence; investigated two allelic variants of the gene; frequency
of occurrence in the population of homo- and heterozygous for this is sufficient
for the detection of genetic differences at 90% of donor-recipient pairs.
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IMMUNE RECONSTITUTION AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: THE EFFECT OF
CLINICAL FETAURES
G Rossi1,*, AM Carella1, R Angarano1, MM Greco1, M Merla1, C De Waure2,
GS Leuconoe2, MM Minervini1, N Cascavilla1
1Hematology and Stem Cell Transplantation Unit, IRCCS “Casa Sollievo della
Sofferenza”, San Giovanni Rotondo, 2Department of Hygiene, Catholic Uni-
versity of Sacred Heart, Rome, Italy
Background: The reconstitution of different immune cell subsets after allo-
geneic stem cell transplantation (allo-SCT) occurs at different timelines. Anyway,
majority of studies following allo-SCT focused on levels of the single cell line
while recovery of the entire immune system was generally reviewed. Similarly,
few reports addressed on the effect of clinical factors on the restoration of
immunity and studies on bone marrow (BM) samples are lacking
Aims: Thus, we prospectively investigated changes in lymphocyte and dendritic
subsets after allo-SCT in BM samples with respect to minimal residual disease
(MRD), GvHD, infections and HSCT type.
Methods: BM samples from patients (n=25) with acute myeloid leukemia(AML)
who underwent to allo-SCT were collected from january 2012 and december
2014 at specific time-points: +1, +3 and +6 months after transplant. Lymphocyte
subpopulations (B cells, hematogones,T cells, helper/inducer T cells,
cytotoxic/suppressor T cells, regulatory T cells (TREGs), natural killer (NK)
cells) and dendritic cells (plasmocytoid and myeloid) were investigated using
6-color flow-cytometry. In order to assess differences in cell subsets between
cases and BM healthy controls the Mann-Whitney test was applied. A p-value
≤ 0.05 was considered significant.Variation of cell subsets at + 1,+3, +6 months
after transplant was evaluated using the Friedman test.Post-hoc pairwise com-
parisons with Bonferroni correction for multiple comparison were carried out.
Results:. Significant differences between patients and controls were found
with respect to TREGs, T cells, helper/inducer T cells and NK cells. In particular,
patients showed a significantly higher level of TREGs and NK and a significantly
lower count of T- and helper/inducer T cells at +1 and +3 months from trans-
plant. B cells and hematogones was significantly increased at six months from
transplant while no differences between TREGs were found at this time point.
Significant effect of timelines from transplant was found for B cells, regulatory
T cells, T cells, helper/inducer T cells and cytotoxic/suppressor T cells. A sta-
tistically significant raise was found from +1 to +6 months for T cells and cyto-
toxic/suppressor T cells and from +1 to +3 months for helper/inducer T cells
and cytotoxic/suppressor T cells. On the contrary, a statistically significance
decrease was observed at any time for TREGs count. Univariate analysis
showed a statistically significant association between cytotoxic/suppressor T
cell count and the presence of infection (p=0,027) with patients having viral or
bacterial infection showing higher counts. No differences were found for any
other association.
Summary/Conclusions: In conclusion, immune reconstitution following allo-SCT
on BM samples was similar to data reported from peripheral blood.Viral and bacterial
infectionsplay an important role in increasing cytotoxic/suppressor T cells.
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A SINGLE CENTRE EXPERIENCE MEASURING RIVAROXABAN LEVELS
WITH A SPECIFIC ANTI XA ASSAY AND THE EFFECT ON THE STANDARD
COAGULATION SCREEN
A Niblock*, P Murray, AM Kearney, G Benson
Haematology, Belfast City Hospital, Belfast, United Kingdom
Background: Direct oral anticoagulants drugs are now commonly used in clin-
ical practice. Rivaroxaban inhibits free factor Xa and hence prothrombinase
activity as well as clot bound Xa, thus effectively blocking thrombin generation.
One main advantage over vitamin K antagonists is that blood coagulation mon-
itoring is not necessary. However introducing a static change into a dynamic
cascade always raises concern. The concentration may potentially need to be
measured in certain clinical situations. These may include urgent surgery, peri-
operative management, thromboembolic events, bleeding events and suspect-
ed overdose. All routine coagulation screens performed in Northern Ireland are
undertaken on a Sysmex Coagulaometer using the Innovin reagent. The
Regional Specialty Coagulation Laboratory uses a Stago analyser with the
STA Neoplastine CI+ reagent. The effect on the coagulation screen by rivarox-
aban is known to vary between analysers making interpretation difficult.
Aims: To assess the effect of rivaroxaban on the current coagulation screen
to help aid clinicians in making urgent decisions. To assess the variation of
rivaroxaban concentrations between patients invivo rather than a controlled
dilutional experiment.
Methods: Recording the dose and time from last drug ingestion we were able
to measure the effect on the standard coagulation screen with both analysers.
On the same samples the rivaroxaban concentration was measured with the
specific anti-Xa rivaroxaban assay. Each recruited patient had their age, renal
function and other co prescribed medications recorded to assess variation with-
in these parameters. As a control, healthy volunteers on no anticoagulation
had their rivaroxaban levels measured. The volunteers’ rivaroxaban levels
ranged from 15-21ug/l and therefore we assume no drug is present when levels
fall into, and below, this range.
Results: The effect on the PT and APTT was variable between analysers. The
PT, in line with previous publications, was more sensitive than the APTT at
smaller drug concentrations. The Neoplastine CI plus reagent on the Stago
analyser was more sensitive than the Innovin reagent to rivaroxaban concen-
trations. The Neoplastine CI PT was prolonged in all samples taken within 17
hours of rivaroxaban ingestion. Our results compare with University Hospital
Hotel Dieu (Paris) which found peak concentrations up to 400ug/l and trough
concentrations up to160ug/l. However our results demontrated more variation
with some patients have a higher rivaroxaban level than expected 600ug/l.
These patients were also taking verapamil. We noted the SPC advises rivarox-
aban not to be used in patients who are receiving concomitant combined P-gp
and moderate CYP3A4 inhibitors unless the potential benefit justifies the poten-
tial risk 2. There is a positive correlation between rivaroxaban concentration
and Neoplastine CI PT reagent with prolongation up to a certain concentration
and beyond this the effect on Neoplastine CI PT appears to plateau. The
patients with a rivaroxaban concentration in excess of 600ug/l had a similar
PT than those with a rivaroxaban concentration of 450ug/l.
Figure 1.
Summary/Conclusions: The PT, provided it is sensitive to rivaroxaban, is a
quick test and may be useful to ascertain rivaroxaban presence or not but
given the plateau effect, not necessarily reassurance that rivaroxaban levels
are excessive. Although smaller amounts of rivaroxaban (<100ug/l) may still
be present when the PT is normal its clinical significance and its anticoagulant
needs to be judged on a case by case basis. Rivaroxaban anti Xa assay will
quantify the drug concentration however turnaround time is slower. There is
significant variation in rivaroxaban when co prescribed with other medications
utilising CYP3A4. Although the results demonstrated when used with an
inhibitor the elevated rivaroxaban concentration may not necessary have addi-
tion anticoagulant effect this raises the concern when the opposite siituation
arises. If a patient is found to have a clot while on rivaroxaban it may be appro-
priate to check the rivaroxaban specific anti Xa to ensure its therapeutic espe-
cially when patients have co prescribed CYP3A4 inducers.
PB2200
FREQUENCY AND MANAGEMENT OF VENOUS THROMBOSIS IN ADULT
ACUTE LEUKEMIA PATIENTS AT A TERTIARY CARE HOSPITAL OF PAK-
ISTAN
S Sarwar1,*, U shaikh2
1Oncology, 2Oncology/Hematology, Aga Khan University Hospital Karachi Pak-
istan, Karachi, Pakistan
Background: Solid tumors are well associated with thromboembolic compli-
cations, but the incidence of thrombosis is not widely studied in patients with
acute leukemia and their management which is a great challenge. However
this may be obscured by the significant morbidity and mortality due to other
complications such as bleeding and infections.No established guidelines are
present to treat these difficult patients. Case-controlled studies of patients with
cancer revealed a fourfold increase in thromboembolic occurrence in acute
leukemia, with about the same rate in acute myelogenous leukemia (AML) and
in acute lymphocytic leukemia (ALL). Among patients with acute leukemia,
thrombosis has the highest incidence in acute promyelocytic leukemia (APL)
.Of interest, increased thromboembolic events take place even prior to the
diagnosis of acute leukemia, similar to the situation seen in solid tumors, indi-
cating that a prothrombotic state is present even at the earliest phase of
leukemia. The use of central venous catheter and chemotherapeutic agents
such as L-asparaginase and other medicine used in the treatment of hemato-
logical malignancies particularly steroids may play an important thrombogenic
role. 
Aims: To determine the frequency of venous thrombosis and treatment strategy
in patients with acute leukemia at a tertiary care Hospital of Pakistan.
Methods: Retrospective, observational study of case charts of hospitalized
patients with diagnosed case of acute leukemia at department of oncology Aga
Khan University Hospital Karachi during the 18 months period (January 2014
to June 2015). Data was retrieved by using ICD 9 coding for acute leukemia
patients. Investigations were obtained from electronic medical record system.
Finally data was analyzed for frequencies and percentages by using SPSS
version 19.
Results: Total of 107 patients presented during the study period. Among them
76 were males and 31 were females with median age ranges from 18 to 60
years. These patients were stratified into 2 major groups according to type of
leukemia.63.5% patients were with Acute myeloid leukemia in which 4.7%
patient developed venous thrombosis among them highest in APML 22.2%
while 36.4% patients were with acute lymphocytic leukemia(ALL) in which 2.5%
of patients developed venous thrombosis. Three patients were treated suc-
cessfully with LMWH during their consolidation phase of chemotherapy.
Summary/Conclusions: Venous thrombosis in acute leukemia is not uncom-
mon which can lead to fatal results if left untreated. Anticoagulation with inter-
mittent use of LMWH for 3-6 months with close monitoring of platelet counts
would be the appropriate option for treatment.
PB2201
CYTOMETRY OF HBA1C
F Malergue1,*, A Van Agthoven1, C Godefroy2, EM Rabellino2
1Beckman Coulter Immunotech, Marseille, France, 2Beckman Coulter Inc, Mia-
mi, United States
Background: In the field of routine diabetes testing, flow cytometry does not
play an important role.
Aims: In an innovative effort we try to show that the application of flow cytom-
etry of a widely accepted parameter as HbA1c can improve the understanding
of the course of the disease and can be applied to other diseases as well.
Methods: In a new experimental assay, blood was diluted in an environment
that removed the red cell membrane and precipitated hemoglobin. The particles
of precipitated and condensate hemoglobin look similar to normal red cells in
flow cytometry. The precipitation is irreversible and the particles in physiological
conditions can be stained with a fluorescent conjugated monoclonal antibody
against HbA1c. In an inhibition assay with hemoglobin in solution it was shown
that the accessibility of the HbA1c antigen did not differ between soluble and
condensate hemoglobin. Another property of the condensate particle in flow
cytometry is that the side scatter of the particles reflects the hemoglobin content
of the original red cell. The cellular hemoglobin content of samples that were
analyzed on a Sysmex hematologic analyzer and the mean values of the side
scatter of the same samples that were treated as above for flow cytometry
showed good correlation.
Results: A good correlation was also found with conventional HbA1c meas-
urements. From 120 diabetic patients, the HbA1c percentage values were
obtained by taking the mean of three different methods as measured by a ref-
870 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
erence laboratory. The blood samples of these patients were also analyzed by
cytometry and the quotients of the side scatter and the HbA1c staining reflecting
the HbA1c percentage were compared with the HbA1c reference values.
Frozen hemoglobin particles with a known HbA1c percentage were used as a
reference. The novelty of this assay is that using flow cytometry, the HbA1c
percentage can be measured cell by cell. This permits to see beyond the mean
value of HbA1c percentage of a sample. Presenting a lower deformability, cells
with the highest HbA1C concentration may play a crucial role toward microvas-
culature obstruction. To further assess the validity of the approach of red cell
age measurement, we collected from 26 diabetic patients the booklets in which
they had administrated several glucose values every day over a time-span of
several months. At the moment of collection of the booklets, blood samples
were taken and cytometry of HbA1c was performed. The glucose values of the
booklets, showed considerable varieties during a day. Therefore a mean daily
glucose was used. The comparison of the two sets of data showed a striking
correlation.
Summary/Conclusions: Showing proof of principle of HbA1c cytometry and
the possibility to read the memory of the blood, other parameters can be read.
Within the assay cellular hemoglobin content can be read against time. Also
the representation of cells of a certain age can be established. Both these
parameters could be of interest for diseases like anemia.
PB2202
INHERITED AND AQUIRED THROMBOPHILLIAS IN WOMEN WITH RECCURENT
PREGNANCY LOSS- 5 YEAR EXPERIENCE
E Miljkovic*, D Markovic, M Vucic
Hematology, Clinical Center Nis, Nis, Serbia
Background: Inherited thrombophilias are the leading cause of maternal throm-
boembolism and are associated with an increased risk of certain adversy preg-
nancy outcomes including second and third trimester fetall loss, abruptions,
severe intrauterine growth restriction and early onset severe preeclampsia.
The antiphospholipid antibody syndrome (APS) is an acquired autoimmune
thrombophyllia in which vascular thrombosis and/or reccurent pregnancy losses
occur in patients having laboratory evidence for antibodies againts phospho-
lipids or phospholipid-binding protein cofactors in their blood. Pregnant women
with these highly thrombogenic conditions are at very high risk for both throm-
boembolism and adverse pregnancy outcomes.
Aims: Aim was to determine the presense of inherited or acquired throm-
bophillias in women with reccurent pregnancy losses (RPL).
Methods: Women with RPL were tested for heterozygosity for the factor V Lei-
den and prothrombin G 20210A mutations, homo and heterozygosity in the
type 1 plasminogen activator inhibitor gene (PAI-1) and the thermolabile variant
of the methylentetrahydrofolate reductase gene (MTHFR). They were also test-
ed for deficiencies of protein C, protein S and antithrombin, as well as for
antiphospholipid antibodies-anti beta 2 glycoprotein I antibodies, anticardiolipin
antibodies and lupus anticoagulant assays.
Results: From January 2011 till January 2016, 445 women were tested for the
presense of inherited or acquired thrombophillias because of reccurent preg-
nancy loss or treatment of infertility. Median age of patients was 33.2 (19-46).
18 women (4%) was negative for both inherited or APS and others 427 (96%)
were positive. Criteria for APS fullfilled 68 patinets (15.2%), 10 patients (2.2%)
had only APS and 58 patients (13%) had APS with some of inherited throm-
bophillias. 246 patients (94.6%) were positive for one or more inherited throm-
bophillias. The most common inherited thrombophillia was PAI1 mutation, found
in 313 women (70%).then MTHFR mutation found in 303 women (68%).Het-
erozygous mutation for Factor V Leiden was found in 45 women (10%) and
heterozygous mutation for protrombin G 201210A in 16 women (3.6%). 173
women were positive for 1 inherited thrombophillia (38.9%), 222 for 2 (49.9%)
and 21 women (4.7%) for 3 inherited thrombophillias. 105 patients (40.3%) with
low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone had suc-
cessfully pregnancy outcome-live birth.
Summary/Conclusions: Some form of thrombophillia-inherited or acquired
was found in most of tested women with reccurent pregnancy loss (96%) and
273 patients (61.3%) had more then one thrombophillia. With adequate antico-
agulant therapy patients with these conditions had chance for successfully
pregnancy outcome.
PB2203
THROMBOLYTIC THERAPY USING UROKINASE FOR MANAGEMENT OF
CVC IN HEMODIALYSIS: OUR EXPERIENCE
A Bruzzese1,*, A Bruzzese2, G Battista3, C Larosa3, M Alviano3, P Orlando3,
V Bruzzese3
1Dipartimento di Biotecnologie ed Ematologia, Università “La Sapienza”, Roma,
2UOC Nefrologia e Dialisi, Policlinico Universitario, Messina, 3UO Emodialisi,
ASP 5 RC, Taurianova, Italy
Background: The need to use the CVC (central venous catheter) for hemodial-
ysis is an occurrence in growth, related to the aging of the population on dialysis
and the high prevalence of the disease and thrombotic angiosclerotica-uremic
coaugulativa of the subject. The CVC is almost always a second best solution
precisely in those subjects with situations of vascular compromise and/or coag-
ulation disorder that does not allow the creation of the FAV (arteriovenous fis-
tula). For this reason, the CVC meets very often malfunction situations for intra-
luminal thrombotic events. The malfunction of the CVC is directly related to the
duration of use, for a higher probability of thrombotic affixing on the inner wall
with the passage of time. However, some patients show that they are prepared
to meet very early in the CVC occlusive events, probably due to altered
Hemorheological situations, not always clearly defined. In the case of thrombotic
occlusion of the CVC is sweeping the use of thrombolytic agents to try to ricanal-
izzarli. Among the various substances being used for the urokinase thrombolytic
there is, even if the bleeding risk potentially related to its use has hampered
the use on a large scale.
Aims: We conducted a retrospective case series of patients on hemodialysis
with CVCs pertaining to a single dialysis center over the past 15 years, from
2001 to 2016, analyzing the effectiveness of the use of urokinase for “declotting”
of CVC for hemodialysis and the manner of its use, in the search for better
therapeutic efficacy with the lowest risk of adverse events.
Methods: We have analyzed 48 cases of patients with CVC, inserted in 35
patients, for whom it was deemed appropriate to proceed with declotting uroki-
nase due to malfunction for thrombotic occlusion. Even in our series, despite
the routine filling of the lumen of the catheter with heparin sodium or sodium
citrate between a dialysis and the next, the thrombotic complication of the CVC
was very common, affecting in time 27% of the CVC. Our usual therapeutic
protocol for the declotting of the CVC with urokinase included the following
steps 1) slow-fill with positive pressure of each lumen of the CVC with a solution
of 25,000 IU/ml of urokinase, by reason of the priming volume indicated by the
manufacturer of the CVC and reported in writing on the same; 2) wait/bus
station 30 minutes, carefully avoiding the marketing of the drug circle; 3) the
total intake of the luminal contents and a few ounces of blood; 4) at a high
pressure irrigation with saline solution.
Results: In our experience, 75% (36/48) of cases of CVC occluded by throm-
bosis were already passed on successfully with urokinase. We detected in
some cases the need for repeated short-term treatment of thrombolytic therapy
with urokinase, in subjects in which the position of the tip and or the side holes
of the catheter had assumed a decubitus position on the vessel wall in which
the CVC was allocated. In these people, the success rate of the individual
thrombolytic treatment resulted however very high.
Summary/Conclusions: In our series, the unblocking of the CVC for hemodial-
ysis with thrombolytic therapy using urokinase has proved very effective, without
being burdened by any adverse reactions and/or side effects related to treatment.
PB2204
THROMBOTIC COMPLICATIONS IN HEMATOLOGIC MALIGNANCIES
M Popescu1,*, D Georgescu1, M Balea1, M Tevet1, O Patrinoiu1, M Murat1,
F Mihai1, C Dragan1, V Popov1, AN Ciuhu2
1Hematology, Colentina Clinical Hospital, 2Oncology and Palliative Care, St
Luke Hospital, Bucharest, Romania
Background: In patients with cancer there is an increased risk of thromboem-
bolism, especially in certain types of solid tumors and hematologic malignan-
cies. Occurrence of venous thromboembolism in patients with cancer is linked
to a hypercoagulable state due to synthesis of pro-coagulants factors or local
hypoxia. The risk of thrombotic complications increases during chemotherapy,
hospitalization or surgery. Thrombosis is a frequent complication in acute
leukemia as well, but its pathogenesis is not entirely known, being probably
determined by a combination of factors related to the patient, disease and treat-
ment regimens used.
Aims: To analyze the causes of thrombotic complications in patients with hema-
tologic malignancies, excluding those with myeloproliferative neoplasms, mul-
tiple myeloma treated with immunomodulatory agents and acute promyelocytic
leukemia, known to be associated with increased risk of thrombosis. Also, we
excluded cases of catheter-related thrombosis.
Methods: We analyzed data of 41 patients with hematologic malignancies
admitted in our institution during a period of 9 years which presented with at
least one episode of thrombosis.
Results: There were 23 females and 18 males. The diagnosis distribution was:
4 cases of acute myeloid leukemia, 1 case of hairy cell leukemia, 1 case of
acute lymphoblastic leukemia, 1 case of myelodysplastic syndrome, 2 cases
of Hodgkin Lymphoma, 27 cases of Non-Hodgkin Lymphoma, 5 cases of mul-
tiple myeloma. The median age was 65 years (ranges from 37-81 years). After
location of thrombosis, there were 37 cases of venous thrombosis, 4 cases of
arterial thrombosis, 2 cases of DIC. Additional risk factors besides cancer were
identified in 8 cases, including recent history of splenectomy, secondary throm-
bocytosis, phospholipidic syndrome, presence of clone of paroxysmal nocturnal
hemoglobinuria, status post-autologous stem cell transplantation and chronic
venous insufficiency. No additional risk factors were identified in the other
patients. Inherited thrombophilia was not tested, but personal and family history
was not suggestive for thrombophilia in the reported cases.
Summary/Conclusions: Thrombosis is the second cause of death and a major
cause of morbidity in cancer patients, and improving antithrombotic prophylaxis
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and treatment in this subset of patients may have important prognostic impli-
cations. An important issue is to identify patients at risk in order to establish
proper prophylaxis. Score models were elaborated based on site of cancer,
hemoglobin value, platelet and leukocyte count, and body mass index. How-
ever, in a subset of patients additional risk factors besides cancer could not be
identified. Furthermore, in some patients thrombosis occur in the setting of
severe thrombocytopenia. In this context, it could be important to identify some
biological markers for thrombosis, such as the well known and used D-Dimer,
and other studied markers, but not yet in clinical use, such as tissue factor, P-
selectin or VEGF. We present an important lot of patients with hematologic
malignancies and thrombosis, of note that most of these patients had no iden-
tifiable risk factors of thrombosis. Moreover some of these patients developed
thrombosis in the setting of severe thrombocytopenia in the absence of DIC.
We find important to identify biological markers useful in patients with cancer
to predict thrombosis. We intend to screen patients with hematologic malig-
nancies and thrombosis for D-Dimer, tissue factor and VEGF.
PB2205
TREATMENT AND OUTCOME OF PEDIATRIC CEREBRAL SINOVENOUS
THROMBOSIS: A SINGLE CENTER EXPERIENCE
S Aytac*, I Altan, B Kuskonmaz, I Yaman Bajin, S Unal, B Tavil, M Cetin, M
Tuncer, F Gumruk
Pediatric Hematology, Hacettepe University, Ankara, Turkey
Background: Pediatric cerebral sinevenous thrombosis(CVST) is a rare but
potentially life threatining condition with a 3-12% reported mortality rate. Clinical
findings mostly depend on the initial age at presentation, anatomic localization
and extent of thrombosis, presence of infarct and /or symptomps of increased
intracranial pressure, intracranial hemorrhage. Moreover, it was reported that
most of those children with CVST have diffuse neurologic findings on admission.
Aims: We aim to analyse treatment and prognosis of childhood CVST.
Methods: In this study we retrospectively evaluate clinical presentation, under-
lying disorders, risk factors (genetic and acquired), anticoagulant treatments
and prognosis of our 34 patients with CVST diagnosed between January 2009
to June 2015 at Hacettepe University Faculty of Medicine, Ihsan Doğramacı
Children’s Hospital.
Results: In this study we retrospectively evaluate clinical presentation, under-
lying disorders, risk factors (genetic and acquired), anticoagulant treatments
and prognosis of our 34 patients with CVST diagnosed between January 2009
to June 2015 at Hacettepe University Faculty of Medicine, Ihsan Doğramacı
Children’s Hospital. There were 14 female and 20 male children with a median
age of 7.3 years(1 month to 17,5 years). When we grouped initial ages 9 (26%)
patients were under one year of age and 14(41%) patients were older than 10
years of age on admission. Initial complaints include headage(n=15;44%),
seizures(n=5;15%), loss of consciousness (n=4;12%), focal neurological impair-
ment (n=6;%17), diffuse neurological impairment (n=1; 3%) and pseudotumor
cerebri (n=3; 9%). Risk factors included underlying disorders (Nephrotic syn-
drome, Acute leukemia, homocysteinemia, Behçet disorders, etc.) were found
to be positive in 59% of the children and 15(44%) of them had hereditary pro-
thrombotic risk factors (Heterozygous Factor V G1691A mutation (n=4),
Homozygous Factor V G1691A mutation(n= 2), Heterozygous Prothrombin
G20210A mutation(n=2), homozygous MTHFR C 677T mutation (n=4), PAI
4G/5G mutation(n=2)). Nearly all patients were given anticoagulant treatment
and initial treatment were mostly included LMWH(73%) with an median 6 months
(1 month to 9 months)of treatment period and 66% of them obtained partial or
complete resolution of thrombosis with treatment. Mortality rate was 6%.
Summary/Conclusions: This study shows that CVST was more common
under 10 years of age (60%)in our group however there was no increased rate
of CVST for the neonatal period which was found to be 11% inconsistently
lower than the reported rate(57%). Neonatal CVST occured more than half of
the patient without a known prothrombotic or underlying risk factors.
PB2206
MANAGEMENT OF PEDIATRIC THROMBOSIS IN A SINGLE TERTIARY
CARE MEDICAL CENTER
F Yus Cebrian1,*, C Coello de Portugal1, N Fernandez-Mosteirin1, R Rupay
Rojas1, M Andrade Campos2, P Delgado Beltran1, JM Calvo Villas1
1Haematology, 2Hospital Miguel Servet, Zaragoza, Spain
Background: Venous and arterial thrombosis is increasingly encountered in
the pediatric population. 
Aims: The aim of this retrospective study was to summarize our experience
regarding clinical characteristics, diagnosis and management of pediatric
thrombosis in a single tertiary care medical center.
Methods: We reviewed clinical files of patients (pts) under 18 years old diag-
nosed of arterial thrombosis (AT) and/or venous thromboembolic (VTE) events
in our institution between March 2006 and June 2015. Clinical data, thrombotic
risk factors (TRF), thrombophilia test results, thrombosis location and therapy
were analized.
Results: 49 AT and/or VTE events were diagnosed in 48 pts, median age at
diagnosis was 1 year (0-17); 24 pts were infants (25% neonates) and 24 (50%)
>1year; out of 48 pts, 29 were ♂ and 19 ♀. Clinical presentation: arterial isquemic
stroke 19 (38.7%), lower extremities deep venous thrombosis (DVT) 13 (26.6%),
cerebral venous sinus thrombosis 8 (16.3%), portal and inferior vena cava throm-
bosis 4 (8.2%), lower extremity arterial ischemia 2 (4.08%), purpura fulminans
1 (2.04%), subclavian vein thrombosis 1 (2.04%) and suprahepatic vein throm-
bosis 1 (2.04%). Age classification of pts was: 18 (37.5%) newborns: <1 month;
6 (12.5%) infants: <1 year, 12 (25%) children: 1-13 years and 12 (25%) adoles-
cents: 14-17 years. According to the age classification the most common clinical
presentations were arterial isquemic stroke in newborns 12 (66.6%); DVT 2
(33%) and portal/ inferior vena cava thrombosis 2 (33%) in infants; cerebral
sinus thrombosis 4 (30%) in children and DVT 6 (50%) in adolescents. Adquired
risk factors included systemic sepsis and oncologic diseases in 15 and 6 pts, 4
central venous catheter carriers, 3 congenital heart disease (CHD), 2 systemic
sepsis + CHD, 4 artery malformations, 1 immobilization after ankle injury, 1 hor-
monal contraceptives therapy + sepsis, and 1 perinatal hypoxic-ischemic
encephalopathy. The most important risk factor for thrombosis was systemic
sepsis. In 12 cases no risk factors for thrombosis were found. Thrombophilia
testing was performed in 36 cases (73.4%). Thrombophilic risk factors were
found in 9 pts 25%: 2 prothrombin G20210A mutation, 1 prothrombin G20210A
+ MTHFR mutations, 1 R506Q mutation, 1 Protein S decreased, 1 lupus anti-
coagulant, 1 Protein S decreased + lupus anticoagulant and 1 antiphospho-
lipid-like syndrome. Anticoagulation therapy was initiated in 3 pts with unfrac-
tioned heparin to achieve therapeutic aPTT and 30 pts received enoxaparin at
a mean dose of 1 mg/kg/12 h to achieve anti-Xa therapeutic level. Median dura-
tion of anticoagulation was 3 months. Median number of anti-Xa level was 6.96
(1-22), and range controls 4.61 (0-19). Intraarterial fibrinolytic therapy followed
by enoxaparin was administered in 1 pt with stroke, 4 pts with stroke were anti-
aggregated with AAS. No anticoagulation/ antiaggregation was given to 15 pts.
Overall recurrence rate of thrombosis was 6.2% (3/48); mortality rate 4.1%
(2/48). Mortality was related to underlying diseases: 1 pt perinatal hypoxic
encephalopathy and 1 pt tumor progression. Gastrointestinal bleeding linked to
anticoagulation was observed in 1 pt.
Summary/Conclusions: The distribution of thrombosis was similar to already
published. Acquired thrombotic risk factors were associated with both AT and
VTE. We must be cautious about interpretation of thrombophilia test because the
haemostatic system is still developing. Adjustment in enoxaparin dosage to target
anti-Xa level is a valuable tool for anticoagulant therapy in pediatric thrombosis.
PB2207
CEREBRAL STROKE IN A CHILD WITH CONGENITAL DYSERYTHROPOIETIC
ANEMIA TYPE II
A Ozcan1, T Patiroglu1, H Acer2, H Gumus2, S Senol3, M Karakukcu1, MA Ozdemir1,
E Unal1,*
1Department of Pediatrics, Division of Pediatric Hematology Oncology, 2Depart-
ment of Pediatrics, Division of Pediatric Neurology, 3Department of Radiology,
Divison of Interventional Radiology, Erciyes University, Faculty of Medicine,
Kayseri, Turkey
Background: Congenital Dyserythropoietic Anemia type II (CDA II) belongs to
a subtype of bone marrow failure syndromes characterized by monolineage
involvement and typical morphological abnormalities in erythroid precursor
cells resulting with different degree of hyporegenerative anemia. Moreover
reticulocytosis, which is not corresponding to the degree of anemia (ineffective
erythropoiesis) with jaundice and splenomegaly are major diagnostic criteria.
Causative gene is located at SEC23B. Although stroke among children is rare,
it can cause significant morbidity and mortality.
Aims: Herein we present three years old boy who had diagnosed with CDA II
and eventually experienced stoke.
Methods: A newborn male baby referred to us with complaints of icterus and
anemia. From his medical history it was learned that his parents were consan-
guineous. Initial physical examination showed pallor, icterus,
hepatosplenomegaly and cryptorchidism. Laboratory finding showed anemia,
reticulocytosis, hyperbilurinemia. Bone marrow aspiration showed morpholog-
ical abnormalities of the erythroblasts. The genetic studies showed double het-
erozygous mutations in SEC23B.Regular transfusions were started. At age of
four he admitted to emergency department with complaints of aphasia and
physical examination showed facial paralysis. The MRI revealed acute infarcts
at left frontal lobe and digital subtraction angiograph showed occlusion of left
internal carotid artery suggestive of fibromusculer dysplasia. Enoxiparine was
started. And he is under outpatient control without any neurological sequel.
Results: Pediatric stroke is an important cause of long-term disability, In our
recent manuscript we observed seizures in 53%, long-term significant neuro-
logical deficits in 67%, and death in 14%. Risk factors for stroke in childhood
are different from those traditionally observed in adults. Over 100 risk factors
for stroke in children have been reported, but in up to one third of patients, no
cause is identified, and these cases are classified as idiopathic. In literature
search we did not encounter any individual with CDA II who had stroke.
Summary/Conclusions: To best of our knowledge this case presentation
reports an interesting combination of CDA and stroke. This combination can
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be coincidental but clinicians who manage patients with CDA must be vigilant
about the neurological complications including stroke.
PB2208
CROATIAN EXPERIENCE OF THROMBOPHILIA TESTING-A HUGE VARIETY
OF REFERRING PRIMARY PHYSICIANS, DIFFERENT INDICATIONS, AND
PATIENTS’ CHARACTERISTICS
D Pulanic1,*, M Vodanovic2, M Kos3, A Kustura3, A Boban4, J Belev2, S Zupancic Salek1,
D Nemet1
1Department of Internal Medicine, Division of Hematology, University Hospital
Center Zagreb, Medical School University of Zagreb, Faculty of Medicine J.J.
Strossmayer University of Osijek, 2Department of Internal Medicine, Division of
Hematology, University Hospital Center Zagreb, 3Medical School University of
Zagreb, 4Department of Internal Medicine, Division of Hematology, University
Hospital Center Zagreb, Medical School University of Zagreb, Zagreb, Croatia
Background: Thrombophilia is a predisposition to thrombosis and is not dis-
ease per se, but exposes carriers to increased risks for thrombosis compared
with non-carriers. Some earlier studies showed also association between throm-
bophilia and adverse pregnancy outcomes. However, it is still a matter of intense
debate who should undergo comprehensive and expensive laboratory testing
for thrombophilia and its usefulness in clinical practice.
Aims: The aim of this work was to analyze indications, patients’ characteristics
and specializations of referring primary physicians who requested thrombophilia
testing with hematology consultation.
Methods: We analyzed patients referred for thrombophilia testing with hema-
tology consultation to the Coagulation Outpatient Unit of the Division of Hema-
tology, Department of Internal Medicine, University Hospital Center Zagreb,
Zagreb, Croatia, from 2013-2014. Study was approved by the Medical ethic
committee.
Results: There were 351 new patients sent from different specialists for throm-
bophilia work-up, median age 38 years (range 18-82 years), and among them
majority were female patients (68.1%). The most frequent specialists who
requested testing of the patients were gynecologists (30.2%), followed by inter-
nal medicine specialists with different subspecialisations (20.5%), cardiologists
(11.96%), hematologists from other institutions (9.4%), family physicians (9.1%),
neurologists (7.7%), vascular surgeons (5.1%), ophthalmologists (1.7%), and
others. The most common indication for thrombophilia testing was personal
history of venous thromboembolism (VTE) (deep vein thrombosis, pulmonary
embolism or both) in 50.9% of analyzed patients. Among patients who had
VTE, 64.4% had idiopathic VTE and 18.9% had recurrent VTE. The most com-
mon causes of secondary VTE were trauma, surgery and immobilization (34.3%
of secondary VTE). The second most common indication for thrombophilia test-
ing were gynecology/obstetric reasons (recurrent or even the first time miscar-
riages, pregnancy complications (intrauterine fetal growth restriction,
preeclampsia, abruption placentae), and sterility) among 28.5% of all patients
(41.8% of female patients). Other indications for request for thrombophilia test-
ing with hematology consultation were stroke (5.7%), varicose veins (5.4%),
recurrent thrombophlebitis (5.1%), myocardial infarction (1.9%), retinal vein
thrombosis (1.7%), and other. More than 1 reason for testing had 14.5% of
patients, and 25.15% of patients had positive family history for VTE. In addition
to request for laboratory hypercoagulable work-up, 27.9% of the patients con-
firmed that were active smokers.
Summary/Conclusions: Although in general majority of patients sent for
thrombophilia testing with hematology consultation were younger people with
previously unprovoked VTE, there was huge variety of indications and different
kind of specializations of primary physicians who requested testing. Gynecol-
ogists as referring physicians and gynecology/obstetric reasons were especially
frequent, what might change in the following years with new data about clinical
indications and usefulness of thrombophilia testing.
PB2209
ANTIPHOSPHOLIPID ANTIBODIES, PREGNANCY AND SPONTANEOUS
MISCARRIAGES. EXPERIENCE FROM A RECENTLY OPENED CENTER
C Muñoz Novas1,*, C Heras Benito1, I González Gascon y Marín1, MS Infante1,
Y Mena2, M Zafra2, MA Foncillas1, K Marín1, JA Hernández Rivas1
1Hematology, 2Ginecologia y Obstetricia, Hospital Infanta Leonor, Madrid, Spain
Background: Antiphospholipid syndrome (APS) is an autoimmune disorder
characterized by the appearance of arterial or venous thrombotic events and/or
obstetric complications in the presence of antiphospholipid antibodies (aPL).
These include: lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and
anti-beta2 glycoprotein I antibodies (aβ2GPI). APLs are found in up to 40% of
women who suffer recurrent miscarriages and/or fetal deaths. LA has been
associated with preeclampsia, intrauterine growth retardation (IUGR) and fetal
loss. ACA are linked to preeclampsia and late fetal loss. The aβ2GPI to
preeclampsia, IUGR and late fetal loss. The presence of any of them in preg-
nancy is a predictor of adverse outcome and should be considered a high risk
factor for venous thromboembolism (VTE). The management of these patients
could be controversial, especially in cases with moderate-high titles of LA and/or
aCL with neither thrombotic nor obstetric signs, although this approach has not
been tested in prospective clinical trials. The combined therapy of acetylsalicylic
acid (ASA) and low molecular weight heparin (LMWH) has shown efficacy and
birth rates close to 80%, with less toxicity than other schemes including corti-
costeroids and/or immunoglobulins
Aims: determine the prevalence and clinical significance of the aPL in women
with recurrent miscarriages and obstetric complications
Methods: Retrospective analysis of patients with a previous history of recurrent
miscarriages or fetal deaths, between 2009 and 2015, referred to the hematol-
ogy consultation in which the presence of aPL was confirmed in two separate
determinations at least 12 weeks apart
Results: The presence of aPL was confirmed in 20 patients and 13 were diag-
nosed according to the Sydney classification criteria for APS. The accompany-
ing clinical manifestations in those patients with positive aPL were: recurrent
miscarriages in 18/20 (90%), median of 3 abortions <12 weeks; VTE disease
2/20 (10%); 1 patient with a history of fetal loss at 24 weeks; 1case of eclampsia
in previous pregnancy and 1 case of IUGR (See table). The antibody most fre-
quently involved was aCL, present in 13/20 (65%). The LA was observed in
9/20 (45%), including this group, the only 2 cases with VTE in the series and
the only case with IUGR. 25% (5/20) of the patients had more than one positive
aPL, one of these patients had having a previous history of pulmonary embolism
(PE) before the diagnosis of APS. After the diagnosis of APS 18/20 cases (90%)
had new pregnancies including 15 full-term newborns and 3 ongoing pregnan-
cies. All these patients were treated with ASA and LMWH at prophylactic doses,
with monitoring levels of anti-Xa. Once treatment was established the only com-
plication was one pregnancy loss at weeks eight of gestation in an obese patient
who did not reach levels of anti-Xa at prophylactic range, but later had a suc-
cessful pregnancy by increasing the dose of LMWH. There were no fetal deaths
or new cases of VTE or hemorrhagic complications.
Table 1.
Summary/Conclusions: Combination therapy with ASA and LMWH is safe
and effective in the secondary prevention of obstetric complications in patients
with APS. As in other series, our study confirms that more than one positive aPL
determination and LA positivity are associated with an increase of the number
and severity of complications in patients with APS. Further studies to improve
the current evidence for the management of these patients are needed.
PB2210
INFLUENCE ADRENOCORTICOTROPIC HORMONE ANALOG SEMAX ON
FUNCTIONAL ACTIVITY OF BLOOD CELLS DURING IMMOBILIZATION
STRESS
M Golubeva*
Biology Faculty, Moscow State University, Moscow, Russian Federation
Background: Bokgraund It is known that many disease states are associated
with impaired red blood cell membrane. It is the activity of these blood cells
associated normal microcirculation. At present, special attention is given to
researchers semax neuropeptide derived from pituitary adrenocorticotropic hor-
mone. The peptide penetrates the blood-brain barrier and has an impact on a
number of functions of the central nervous system. Experiments have shown
that peptide can affect blood cells, particularly red blood cells. The red blood
cells increase the biochemical reactivity and functional only activated platelets.
Change erythrocytes platelet biochemistry is very important for understanding
the interaction of blood cells in hemostasis. It was found that the immobilization
of the animal’s body are also changes of erythrocyte membrane.
Aims: The aim of this work was to determine the effect of Semax on the func-
tional activity of red blood cells and their interaction with platelets and the influ-
ence of these processes immobilization stress.
Methods: To reproduce the experimental stress reaction used immobilization
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stress by fixing the rats on their backs for 60 minutes. In in vitro experiments
semax in the concentration range 10-1 - 10-10 M is added to a pool of platelet-
rich plasma (PRP), or PPP and the mixture washed erythrocytes (e) and
change in aggregation was determined by the action of ADP. In experiments in
vivo semaks administered intravenously prior to or after the immobilization was
determined and osmotic fragility of erythrocytes and the platelet aggregation
in normal and by animals immobilized.
Results: in vitro experiments have shown that, when added to semax pool PRP
concentration of 10-10M only caused a significant enhancement of platelet
aggregation. Adding PRP mixture of washed red blood cells significantly
increased platelet aggregation. When added to the mixture PRP + erythrocyte
as a peptide, and directivity of physiological saline retained reactions. in vivo
experiments demonstrated that intravenous administration of semax at a dose
of 1 mg/ml in a physiological standard had no significant effect on platelet aggre-
gation. In the study of changes in the wholesale electricity market it has shown
that semaks increases resistance of the membrane of red blood cells, reducing
the percentage of haemolysed cells. The prophylactic administration of semax
as well as the administration of the peptide on the background of immobilization
stress significantly increased the resistance of erythrocytes to hemolysis.
Summary/Conclusions:. Our studies have shown that neuropeptide semaks,
on the one hand, no significant effect on hemostasis in a physiological condition,
and with another - increased stability of the erythrocyte membrane to the stres-
sor exposure.
PB2211
A CASE REPORT OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCY-
TOSIS WITH CNS DEMYELINATION COMPLICATED WITH THROMBOSIS
S Ciraci1, A Ozcan2, Mm Ozdemir2, Scc Chiang3, B Tesi4, Ma Ozdemir2,
M Karakukcu2, T Patiroglu2, S Doganay1, H Gumus5, Yt Brysecon3, E Unal2,*
1Department of Radiology, Division of Pediatric Radiology, 2Department of
Pediatrics, Division of Pediatric Hematology Oncology, Erciyes University, Fac-
ulty of Medicine, Kayseri, Turkey, 3Centre for Infectious Medicine, Department
of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockolm,
Sweden, 4Centre for Infectious Medicine, Department of Medicine, Karolinska
Institutet, Karolinska University Hospital, Stockolm, 5Department of Pediatrics,
Division of Pediatric Neurology, Erciyes University, Faculty of Medicine, Kayseri,
Turkey
Background: Hemophagocytic lymphohistiocytosis (HLH) is a fatal disease
affecting infants and very young children, including high fever,
hepatosplenomegaly and pancytopenia. Hemophagocytic syndrome may be
spontaneous or secondary to infection, malignancy or autoimmune disease,
and mechanisms involved are poorly understood. The main histopathologic
feature is increased proliferation and activation of macrophages with hemo-
phagocytic lymphohistiocytosis throughout the reticuloendothelial system.
Aims: We present a case with cranial involvement of HLH showing diffuse
infiltration of white matter complicated with intracranial thrombosis.
Methods: A 5 year-old girl with fever, and pancytopenia was referred to our
hematology unit. Also she had a history of recurrent infections. Her parents
were consanguine. Lymphadenopathy, and hepatosplenomegaly were detected
in physical examination. Ultrasound examination displayed hepatosplenomegaly
and intraabdominal free fluid. Hemophagocytic lymphohistiocytosis was
revealed on bone marrow aspiration biopsy. Anomaly in NK and T lymphocyte
cytotoxicity and degranulation tests was determined. İn genetic analysis, syn-
taxin gene mutation was depicted. Immunosuppressive therapy was performed
to the patient, diagnosed with familial HLH. Brain MR imaging was performed
because of the suspicion of cranial involvement. On MRI diffuse hyperintense
signal changes of cerebral white matter on T2-W and T2 FLAIR images, show-
ing demiyelination were detected. There wasn’t any mass effect, contrast
enhancement and restricted diffusion on MRI. A repeated brain MR performed
a month after the first cranial imaging, showed an acute infarct involving left
temporooccipital region. Follow up images showed that the infarct was disap-
peared but white matter lesions was stable on the brain MR imagines. The
cerebral white matter lesions were stable but hyperintense signal changes
were appeared in cerebellar white matter, accepted as progression. She was
died in despite of immunosuppressive therapy.
Results: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of patho-
logic immune activation, in association with a variety of triggers and is promi-
nently associated with cytopenias and combination of clinical signs and symp-
toms of extreme inflammation. The histopathologic findings of HLH in pediatric
patients with cranial involvement is various. The common CNS involvement of
HLH is leptomeningeal infiltration of lymphocytes and histiocytes/macrophages
with a sterile CSF lymphocytosis. If parenchymal involvement occurs perivas-
cular infiltrations are seen. In more severe cases, demiyelination and tissue
necrosis of the cerebral white matter may be seen. The previously reported
MR findings of HLH with cranial involvement, include diffuse leptomeningeal
and perivascular enhancement showing infiltrations of histiocytes and lympho-
cytes, T2W hyperintense white matter lesions on cerebrum, cerebellum and
spine, parenchymal necrotic lesions with ring enhancement and diffuse atrophy
of the cerebrum and cerebellum. In our patient we displayed diffuse white mat-
ter lesions in cerebrum and cerebellum showing demiyelination on T2W MR
sequences. There wasn’t any contrast enhancement or restricted diffusion.
The spine was normal. 
Summary/Conclusions: The HLH treatment is an induction therapy including
steroid amd chemotheuropetics. Without therapy, survival of patients with HLH
is very short, especially in familial form and cranial involvement. CNS involve-
ment may occur at the beginning or during the treatment. Patients with CNS
involvement should be treated with intrathecal agents. Depiction of the cranial
involvement, is important for patient’s survival and treatment. All patients with
HLH should had brain MRI, even if asymptomatic.
PB2212
VENOUS THROMBOEMBOLISM IN WOMEN USING HORMONAL
CONTRACEPTION. FINDINGS FROM A SINGLE CENTER
AS Vilches*, A Latorre, J Cachá
Hematología y Hemoterapia, Hospital Universitario de Móstoles, Móstoles,
Spain
Background: Venous thrombosis including deep-vein thrombosis (DVT) and
pulmonary embolism (PE) is considered a multifactorial disease associated
with genetic and acquired risk factors. In women of reproductive age, the main
cause of venous thromboembolic disease (VTD) is the hormonal contraception.
However, other risk factors interact to produce VTD. 
Aims: Identifying the risk factors for DVT and PE, may intervene in risk situa-
tions and limit the occurrence of VTD with its potential morbidity and mortality.
Methods: We reviewed the characteristics of our series of 103 women with
objectively confirmed VTD associated with hormonal contraception. We ana-
lyzed its clinical data and thrombophilia studies which were performed in more
than 80% of them and included anticoagulant proteins, genetic tests, antiphos-
pholipid antibodies and factor VIII level. Statistical analysis was performed with
SPSS 18.0 software. bidi-font-size:12.0pt;font-family:Calibri;mso-ansi-lan-
guage:EN’>.
Results: The mean age of our patients was 29±7.4 years old. A high percent
of them (46%) had a body mass index >25 Kg/ m². The most important clinical
risk factors for venous thromboembolism were inmmobility (31%), family history
(27%) and polycystic syndrome (9.8%). The combined oral contraceptive
including antiandrogen and third generation progestogen were the most fre-
cuently used for our patients. Thromobophilia test revealed factor V Leiden in
13%, prothrombin mutation in 20%, antiphospholipid syndrome in 3%, protein
C deficiency in 0%, protein S deficiency in 2.4%, antithrombin deficiency in 0%
and increased factor VIII (>195%) in 18.7%.
Table 1.
Summary/Conclusions: Contraceptive use remains the most important risk
factor for VTD in women of reproductive age. We observe additional risk factors
such as obesity, immobilization, polycystic ovary syndrome or family history of
VTD and certain thrombophilic defects. G20210A prothrombin and G1691A
factor V Leiden mutations as well as elevated factor VIII (which has been asso-
ciated to blood group non O) are frequent in women at a fertile age and should
be part of thrombophilia study. Defining high risk patients may improve inter-
ventions in risk situations (e.g. administering antithrombotic prophylaxis or dis-
continuing contraceptive use after lower limb trauma) in order to prevent VTD.
Finally, the increased thrombotic risk of antiandrogen and third generation con-
traceptives should be also taken into account.
PB2213
THE RICK OF THROMBOEMBOLISM IN SURGICAL AND ONCOLOGICAL
PATIENTS WITH ANTITHROMBIN III, PROTEIN S AND PROTEIN C
DEFICIENCY
I Fotopoulou*, E Kokkalis, P Masoura, S Kotsali, H Vorilla, A Nikolopoulou
Laboratory of Hematology, General Hospital of Patras ‘St. Andrew’, Patras,
Greece
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Background: Thrombophilia is a condition where the blood has an increased
tendency to form clots. Blood clots can cause problems such as deep vein
thrombosis (DVT) or pulmonary embolism. Natural coagulation inhibitors in
hemostasis are Antithrombin III (ATIII), Protein S (PS) and Protein C (PC). Con-
genital AT III deficiency is an autosomal dominant disorder in which an individual
inherits one copy which encodes AT III. This condition leads to increased risk
of venous and arterial thrombosis. This form is most commonly diagnosed dur-
ing childhood after a child has had a thrombotic event. Severe congenital AT III
deficiency, in which the individual inherits 2 defective genes, is a rare autosomal
recessive condition associated with increased thrombogenesis, typically noted
in the neonatal period or early infancy. This condition is rarely compatible with
life. Acquired AT III deficiency is a deficiency of antithrombin primarily due to
consumption, such as disseminated intravascular coagulation (DIC). Protein S
deficiency may be hereditary or acquired; the latter is usually due to hepatic
diseases or a vitamin K deficiency. Protein S deficiency usually manifests clin-
ically as venous thromboembolism (VTE). Protein C deficiency is a congenital
or acquired condition that leads to increased risk for thrombosis. Congenital
PC deficiency is one of several inherited thrombophilias, which are a hetero-
geneous group of genetic disorders associated with an elevated risk of venous
thromboembolism.
Aims: The aim of this study is to measure AT III, P S and P C in patients from
oncology department, urology department and the department of obstetrics
and gynecology.
Methods: The study took place of observation at the general hospital of Patras
(Greece) and included a total of 280 patients (male and female). The blood of
patients was examined and the ATIII, P S and P C values were recorded. AT III
measurement is a chromogenic determination based on an amydolitic method.
Moreover the control of P C include the study of the functionality and antigenicity
with chromogenic method. Also, the control of P S is based on the study of the
functionality and the antigenicity of free P S (batch method).
Results: We studied 280 patients. From these patients, 200 were surgery
patients from gynecological and urological department and 80 were patients
from oncology department (table 1). Results for surgical patients were: AT III
deficiency 4 patients (2%), P C deficiency 2 patients (1%) and P S deficiency
1 patient (0,5%). Furthermore, results for oncological patients were: AT III defi-
ciency 3 patients (3.75%), P C deficiency 2 patients (2,5%) and P S deficiency
1 patient (1,25%).
Table 1.
Summary/Conclusions: It is a fact that, either oncological or surgical patients
are associated with a number of complications, mainly thrombosis. In addition
deficiency in a classic coagulation factor is a high rick of venous thrombosis.
The obvious conclusion to be drawn is that, measurement of AT III, P S and P
C should be performed. Thus we should evaluate the impact of VTD or pul-
monary embolism on the survival of these patients.
PB2214
ANTICOAGULANT TREATMENT WITH APIXABAN IN INHERITED
ANTITHROMBIN DEFICIENCY
N Bermejo*, R Sigüenza, I Casas, FDA Pérez-Leal, MH Bañas, F Ibáñez,
S Cáceres, JM Bergua
Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain
Background: Apixaban, a direct inhibitor of activated factor X, has at least the
same efficacy and safety as vitamin K antagonists (VKA) for secundary pre-
vention of recurrent venous thrombosis in adults, but no data in patients with
inherited Antithrombin Deficiency are available.
Aims: Evaluate apixaban as a valid anticoagulation alternative in adults patients
with inherited Antithrombin Deficiency and difficulty for treatment with VKA.
Methods: We report a case of a 49-year-old man with Crohn disease, on long-
term anticoagulation with low molecular weight heparin (LMWH) by recurrent
episodes of venous thrombosis due to inherited Antithrombin Deficiency. Due
with the difficulty for treatment with VKA because his severe Crohn disease, it
was decided to maintain anticoagulation with intermedie doses of LMWH (ther-
apeutic doses were associated with rectal bleeding). To obviate LMWH-asso-
ciated osteoporosis, the use of calcium and vitamin D supplementation, and
weight-bearing exercise were recommended. Proximal femur bone and lumbar
spine density measurements were taken at baseline and each 6 months. Two
years later, significant osteopenia was observed at the proximal femur bone,
so heparin was replaced by 2.5mg/12h apixaban. Nine months later, he has
not suffered thrombotic recurrence neither bleeding complications, but there
were not any changes in bone densitometry.
Results: This is the first description of the use of apixaban in secundary pre-
vention of recurrent venous thrombosis induced by Inherited Antithrombin Defi-
ciency. Our patient on long-term anticoagulation with apixaban has not experi-
enced bleeding or thrombotic complications months after transitioning to apix-
aban, but osteopenia has stayed without changes.
Summary/Conclusions: We believe that apixaban may be considered as a
valid anticoagulant alternative in adults with inherited Antithrombin Deficiency
and difficulty for treatment with VKA, although until results of prospective ran-
domised trials are available, we recommend caution in using apixaban in
patients with inherited thrombophilia. However, LMWH-associated osteopenia
does not seem to improve after transitioning to apixaban.
PB2215
RELATIONSHIP BETWEEN TYPE AND INTENSITY OF ANTICOAGULANT
THERAPY AND RECURRENCE OF ARTERIAL THROMBOSIS ON
ANTIPOSPHOLIPID SYNDROME
R Siguenza*, N Bermejo, I Casas, FDA Perez, H Fernandez, F Ibañez,
S Cáceres, JM Bergua
Hematology, Hospital San Pedro de Alcantara, Cáceres, Spain
Background: The optimal type and intensity of anticoagulant therapy for the
treatment of Antipospholipid Syndrome (APS) remain controversial issues, par-
ticularly for arterial thrombosis.
Aims: We investigated if there are difference between the development of recur-
rence of arterial thrombosis on APS taking anticoagulant therapy with vitamin K
antagonist (VKA), antiplatelet therapy with ASA, or both VKA and ASA.
Methods: Retrospective we investigated the development of recurrence arterial
thrombosis in 23 patients consecutive diagnosed in our hospital of APS with
previous arterial thrombosis, from 1 February 2000 to 31 December of 2015.
The patients ages were between 25 to 88, gender 39.1% male and 60.9%.
Patients were treated well with ASA 100 or 300 mg either VKA for objective 2.5
INR, adding or ASA 100 mg depending on the thrombotic risk (depending on
the location of thrombosis and the presence of thrombophilia and established
cardiovascular risk factors). 10 patients present Stroke, including Cryptogenic
Ischemic Stroke, 6 present Transient Ischemic Attack, 4 Myocardial Infarction,
and 3 other periferical arterial thrombosis (ocular, laberintical and popliteal). Of
this 23 patients, suffered recurrence arterial thrombosis 4 of 12 were taking
AAS, 4 of 8 patients taking VKA, and 1 of 3 taking VKA and ASA. The statistical
analysis was performed with Pearson test realized by JMP 9.
Results: We not found statistically significant difference between the APS
patients taking VKA, ASA or VKA and AAS and the development of recurrence
arterial thrombosis (OR 0.12, IC 95% -0.21 -0.46, p=0.73).
Summary/Conclusions: Although we found more patients with APS develop-
ment recurrence arterial thrombosis taking AAS than VKA, we cannot establish
an association between recurrence of arterial thrombosis and treatment without
VKA. The location of thrombosis and the presence of classical cardiovascular
risk factors do not seem to be good predictors of thrombotic recurrence. Future
studies that delineate thrombotic risk in APS and evaluate current and novel
anticoagulants as well as non anticoagulant therapies are required.
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HOME BLOOD TRANSFUSION, A SAFETY OPTION IN SPAIN
C De La Mata Espinosa*, P Caballero, N Madrid
Hematología, Hospital Universitario San Rafael, Granada, Spain
Background: The terms “Home medical care” generically designate a wide
range of support services for palliative patients and people with disabilities.
The designation includes everything, to improve quality of life for both the
patient and the family. Quite often chronic and terminally ill patients who are
being treated with Domiciliary Hospitalization usually require a blood transfu-
sion. Commonly the form of action is to transfer the patient to the hospital. In
many cases, this transfer can be uncomfortable and painful for the patient and
implies costs of medical transport or transfer costs assumed by the patient.
Aims: San Rafael Hospital in Granada, Spain provides a Home medical service
for chronic patients and palliative patients. A recent initiative of the Haematology
Department of the Hospital is to offer home transfusions which aims to reduce the
demand for emergency services and the need for hospital admission. To carry out
this activity we must emphasize that all blood transfusion must ensure the patient
safety, always carried out by qualified personnel of Home Hospitalization units
(HHU).
Methods: San Rafael Hospital has a written a standard operating procedure,
reviewed by the hematologist and the personal of the Medical Blood Bank.
Before performing the blood transfusion, the patient (or the person authorized
to sign Relation to Patient) has signed Informed Consent Form.
Results:, 100% of home transfusions in our Center have signed informed con-
sent. A copy is recorded in the patient’s history. Before the blood transfusion,
the patient is visited by the HHU which is composed by a Physician and a qual-
ified nurse, which has verified that the place where it is going to be performed
the activity, has the minimum requirements. Patients who have requested this
service had oncological diseases and are palliative patients. 88% transfusions
of the total had been red blood cells and 11% platelet units. No reaction has
been registered. After transfusion, the doctor UHD had visit the patient to
assess the improvement and to make the following diagnostic tests.
Summary/Conclusions: The Home blood transfusion is an accessible and
safety alternative for chronic patients and palliative patients in Granada Spain
that decrease associated costs, reduce the hospital admissions and demand
on acute services.
PB2217
EVALUATING THE EVALUATORS. EXPERIENCE OF A CENTER AND
STATE OF ACCREDITATION IN TRANSFUSION MEDICINE IN ANDALUSIA
JR Garcia Fernandez*, F Lopez Berenguel, JJ Perez Guerrero
Hematologia, Hospital de Baza. Servicio Andaluz de Salud, BAZA, Spain
Background: In transfusion medicine implementing a quality management
system certified by an external entity,allows the development of a safe and
efficient activity, while contributing to the involvement of all staff to improving a
continuous quality system. In Spain there are two entities accredited byENAC
for certification in transfusion: Transfusion Accreditation Committee (CAT) and
the Agency for Health Quality of Andalusia (ACSA), although the latter with a
specific program limited to transfusion centers
Aims: To describe the situation related to quality management system in trans-
fusion medicine in Andalusia, a region in the south of Spain.
Methods: On the basis of data published by the CAT and ACSA we exposed the
number of certified centers in Andalusia compared to national data. The experi-
ence of the local hospital was also evaluated Baza as externally certified center.
Results: 1. Although only half transfusion centers are certified by CAT, 100%
of them are validated by the ACSA specific program. 2. 34% of centers accred-
ited in Spain are accredited in Andalusia. 3. The relationship with the referral
hospital and transfusion center seems to be the most important predisposing
factor for a certification program. With respect to the certification program in
the form of management is notfully adapted to “little” hospital, because if it’s
true that there is a hospital responsible for haemovigilance, hemotherapy isn’t
an exclusive dedication for him. In the aspect of non-conformities, the effort in
a program of continuous improvement quality is very significant. Comparing
our data center initial certification (2010) in which the 3rd edition of the stan-
dards was used, with reaccreditation (2014) which use the 4th. Table 2 shows
comparative nonconformity according to the specific field deviations observed:
it is noteworthy that the percentage remains the same, the most frequent on
the requirements of quality control system.
Summary/Conclusions: 1. The implementation of a management system cer-
tified qualityby an external entity is a clear need in all transfusional centers
involved, although the percentage of certified centers in Andalusia is less than
50%, representing a 34% of the certified centers nationwide. 2. Certification of
CAT hospital is the only feasible option, but its adaptation to community hospitals
is so complicated which is evident in the low number of certified centers. 3.
Continuous quality improvement represents an additional workload sometimes
unacceptable, it would be required a limited version adapted to district centers.
Table 1. Transfusion centers and hospital of public national health service
in Andalusia, classified in provinces. Between parentheses certified cen-
ters.
Table 2. Evaluation of non-compliance related to, in two consecutives
external audits.
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ERYTHROCYTE’S GENOMIC IN RUSSIAN MULTITRANSFUSED HEMATOLOGICAL
PATIENTS
L L Golovkina1,*, A Stremoukhova1, M Vasiljeva1, R Kalandarov1, T Pushkina1,
G Atroshchenko1, B Khasigova1, E Parovichnikova2
1Immunohematology, 2Bone Marrow Transplantation, National Research Cen-
tre for Hematology of Ministry of Healthcare Service Russian Federation,
Moscow, Russian Federation
Background: The patients suffering with ineffective hematopoiesis and periph-
eral cytopenias need frequent RBC transfusions. There are minimum two pop-
ulations of red blood cells (RBC) in transfused within the four previous month
patients-own and donor’s. This situation is called posttransfusion chimerism
and serological blood typing becomes unreliable. It’s known about the immuno-
genicity of such blood group antigens as A, B, D, c, C, E. e in antigen-negative
patients. DNA analysis is available for clinical use in various situations, especially
in identification of blood group antigens in multitransfused hematological
patients.
Aims: true blood group identification in multitransfused hematological patients
Methods: The blood samples drawn into citrate, EDTA anticoagulant were
serotyped for RhD, Rh C/c and RhE/e antigens by anti-D, anti-C, anti-Cw, anti-
c, anti-E and anti-e monoclonal antibodies (Moabs) (Hematolog, Russia). Hemag-
glutination typing in gel columns ID-Cards “DiaClon ABO/D+Reverse Grouping”
and “DiaClon Rh-subgroups+K” (Bio-Rad, Switzerland) were used for confirma-
tion of mixed chimerism in transfused patients: agglutinated cells forming a red
line on the surface of the gel and no agglutinated cells formed compact button
on the bottom of the microtube. DNA extraction was followed by commercial
PCR-SSP kits with primers for typing ABO, RHD, and RHCE (BAG, Germany).
Results: We serotyped blood samples from 2055 Russians hematological
patients (HP) in 2015. The problems in blood group (BG) identification for ABO
system were caused by posttransfused chimerism (PTCh) in 32 primary
patients (1,6%) and for Rhesus system-in 64 primary patients (3,1%). 24
patients provided informed consent for genotyping. All patients suffered with
idiopathic or symptomatic cytopenia or separate anemia (aplastic anemia -5,
different forms of acute leukemia -3, myelodisplastic syndrome -4, multiple
myeloma-2, β-thalassemia -1, PNH-1, unidentified anemia-6, partial red cell
aplasia-1, with renal transplant -1) and were transfused before hospitalization
to National Research Centre for Hematology. Two patients had a problem with
identification in ABO BG: 50% chimerism was detected with anti-A and anti-B
Moabs in one and 50% no agglutinated RBC with anti-A-in another one. Geno-
typing revealed B1B1 and A1B1 BG in these patients. We couldn’t identified
Rhesus phenotype in 23 HP: RhC-in 17 (percent of agglutinated RBC ranged
from 40 to 90), Rhc-in 13 (agglutinated RBC 50%>90%), RhD-in 4 (agglutinated
RBC 20%>90%), RhE-in 18 (agglutinated RBC 30%>90%), Rhe-in 7 (aggluti-
nated RBC 50%>95%), RhCw-in 3 (agglutinated RBC 5%>50%). So PTCh for
1 Rh antigen was detected in 5 HP, for 2 Rh antigens-in 7, for 3-in 6, for 4-in 5
and for 5 Rh antigens-in one. The presence of RhCw was confirmed in two HP
with 50% RhCw chimerism by genotyping. Molecular method predicted the
presence of RhC in 5 HP with chimerism from 20% to 95%, Rhc-in 9 HP
(chimerism ranged from 40% to 90%), RhD-in 3 (chimerism ranged from 20%
to 90%), RhE-in 9 (chimerism ranged from 30% to 90%) and Rhe-in 3 HP with
chimerism 95%. Monitorig of BG in all HP after four month.
Summary/Conclusions: The determination of ABO and Rhesus phenotypes
is very important for previously transfused patients and for patients with known
irregular antibodies. The erythrocyte’s genomics has enabled the application
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of molecular methods to transfusion medicine and allows preventing the alloim-
munization to the most clinically significant blood group antigens.
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RHD VARIANTS INCLUDING REGULATORY TYPE RHNULL IN RUSSIANS
L L Golovkina1,*, A Stremoukhova1, R Kalandarov1, T Pushkina1, M Vasiljeva1,
G Atroshchenko1, V Surin2, A Doescher3, T Schaffert4, S Penickova5,
E Parovichnikova6, V Savchenko7
1Immunohematology, 2Gene ingeneering, National Research Centre for Hema-
tology of Ministry of Healthcare Service Russian Federation, Moscow, Russian
Federation, 3For research and development, Red Cross Blood Transfusion
service, Oldenburg, 4Molecular genetic, BAG Health Care GmbH, Lich, Ger-
many, 5Marketing, BAG Health Care GmbH, Prague, Czech Republic, 6Bone
marrow transplantation, 7General director, National Research Centre for Hema-
tology of Ministry of Healthcare Service Russian Federation, Moscow, Russian
Federation
Background: In clinical transfusions the D antigen of the Rhesus blood group
system (BGS) is the third most relevant behind the A and B antigens of the
ABO BGS Approximately 1%>2% of Caucasians show weak expression of D
antigen on the RBC surface, which is caused by various types of mutations in
the RHD gene. There are three D antigen variants in RH system: weak D,
partial D and Del. It’s essential to know D variant distribution in each population
in order to define whether a patient has a high or low probability to produce
anti-D alloimmune antibodies during erythrocyte’s transfusion therapy.
Aims: to determine the distribution of D antigen variants in Russians.
Methods: Blood samples from 5100 Russians. 65 people have been investi-
gated in our lab due to diminished D expression, discordant results with different
anti-D reagents, or D negative samples with atypical Rh phenotype. D antigen
was typed with 5 serological methods saline and indirect antiglobulin tests. The
blood samples were serotyped for Rh C/c and Rh E/e antigens by correspon-
ding Moabs. DNA extraction was followed by commercial SSP-PCR kits with
primers for typing RHD, RHCE, 11 weak D types, partial D (BAG, Germany).
Mutations in RHD (for confirmations of weak D type 3 - two cases and weak D
type 15 - one case) and RHAG genes was detected by direct Taq cycle-
sequencing, computer based sequence analysis and comparison with reference
sequences from GenbankTM.
Results: In 2014-2015 years we revealed low expression of RhD antigen in
109 (2%) persons by screening. Genotyping 65 of them revealed six weak D
types in 62 persons: weak D type 3 (47,7%; n=31; phenotypes-C+c+E-e+ in 28
cases, C+c-E-e+ in two and atypical one C-c+E-e+) and weak D type 1 (27,7%;
n=18; phenotypes-C+c+E-e+) were the most frequent. Weak D type 2 was
detected in 12,3% (n=8; phenotypes-C-c+E+e+), weak D type 15-in 4,6% (n=3;
phenotypes-C+c-E-e+, C+c+E-e+ and atypical one C-c+E+e+), weak D types
4.2 (DAR; phenotype C-c+E-e+) and weak D type 6 (phenotype C+c+E-e+)-
each in one person (1,5% accordingly). All except 2 weak D types were iden-
tified by serological methods, and the most sensitive method was antiglobulin
test in gel columns. Two cases with RhCe and RhcE phenotype were D-nega-
tive in all serological methods, and only molecular method allowed identifying
weak D type 15. More one sample with diminished D expression was partial D
variant DNB with phenotype C+c-E-e+. Two erythrocyte’s samples had true D-
negative phenotype: one - RHDΨ with phenotype C-c+E-e+, and first in Russia
(since 1926) we found regulatory type Rhnull with predicted phenotype
D+C+c+E-e+ in woman with meningioma. RHAG sequencing shows polymor-
phism in exon 4 of the RHAG gene at position 571 (C >T) which leads to an
earlier Stop-codon (amino acid position 191 [R191]) and the additional mutation
at position 724 of exon 5 (G >A).
Summary/Conclusions: The distribution of D variants in Russians was identi-
fied. These data may help to improve the transfusion strategy of the D variant.
PB2220
EVALUATION OF PROTEINURIA IN Β-THALASSEMIA MAJOR PATIENTS
WITH AND WITHOUT DIABETES MELLITUS TAKING DEFERASIROX
M Karimi1,*, A Avazpour2, S Haghpanah1, F Toosi2, A Badie3
1Hematology Research Center, Shiraz University Of Medical Sciences, Shiraz,
Iran, 2Pediatrics, Hematology Research Center, Shiraz University Of Medical Sci-
ences, 3Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
Background: Beta-Thalassemia is the most common heredity disease in Iran.
Regular blood transfusion is critical to sustain life and normal growth. Deferasirox
is an oral chelator. One of the side effects of the Deferasirox is proteinuria.
Aims: This study aimed to investigate the safety of deferasirox on kidney func-
tion in diabetic and non-diabetic Beta-Thalassemia Major patients.
Methods: In this cross-sectional study, 70 patients who take deferasirox
(Exjade-Novartis) 20-40mg/kg/day were studied. Exclusion criteria included
patient with renal failure, proteinuria, hepatitis B, hepatitis C and the patients
who refused to continue the study to the end. Subjects were divided into dia-
betics and non-diabetics groups. Spot urine protein/creatinine ratio, Urinary
analysis, Alanine transaminase, Aspartate Transaminase, Creatinine, Fasting
Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked every 3
months. Patients were followed for a period of one year.
Results: In the 9th month after therapy there was a significant relationship in
mean change of Spot urine protein/creatinine ratio between diabetic and non-
diabetic (p=0.011). Spot urine protein/creatinine ratio in diabetic and non-dia-
betic group was 0.19±0.18 and 0.1±0.05, respectively which showed no signif-
icant relationship between the two groups at the end of study (P=0.162). E,
Fasting Blood Sugar, Blood Urea Nitrogen and serum ferritin were checked
every 3 months. Patients were followed for a period of one year.
Summary/Conclusions: The results of our study showed that consumption of
deferasirox is safe since there was no significant relationship between Spot
urine protein/creatinine ratio in diabetic and non-diabetic group. Deferasirox
consumption is not associated with increased proteinuria in diabetic patients
compared to non-diabetic group having only a transient proteinuria.
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COMPARISON AMONG PERIODS FOR HEMOGLOBIN EQUILIBRATION
AFTER BLOOD TRANSFUSION
A Tantiworawit1,*, K Karndumri1, C Chai-Adisaksopha1, A Limsukon2, D Pruksakorn3,
S Karndumri3, T Rattanathammethee1, S Hantrakool1, E Rattarittamrong1,
L Norasetthada1
1Internal medicine, Division of Hematology, 2Intermal Medicine, 3Orthopedic,
Chiang Mai University, Maung Chiang Mai, Thailand
Background: Target hemoglobin (Hb) varies among different clinical situations
but mainly at 7 g/dL. Many institutes include ours follow Hb and hematocrit
(Hct) after transfusion at 4 hours for achieving target level. But previous study
showed that equilibration after red cell transfusion was at 24 hours. We sought
to find out the appropriate time point after red cell transfusion. The result may
help physicians to provide earlier and proper treatment.
Aims: This research was aimed to determine the equilibration time point of Hb
and Hct after red cell transfusion.
Methods: This is a prospective randomized trial conducted from December
2014 to August 2015 at Chiang Mai University Hospital. Inclusion criteria was
adult patient who received 1 unit of red cell without active bleeding and hemol-
ysis. Number of patient was calculated by match pair method from previous
study. Hb and Hct were measured at baseline before transfusion. Patients were
randomized into 3 groups according to baseline characteristics to follow Hb
and Hct at 1, 4 or 24 hours after transfusion. Mean difference of Hb and Hct
were compared between each group.
Results: Sixty patients were eligible in this study. Median age was 51 years
old. There was male predominance (83.33%). Most common indication for
transfusion was post-operative anemia (88.33%). There were 20 patients per
each group. All baseline characteristics were not significantly different in each
group which included age, sex, body weight, body surface area, transfusion
indication, creatinine clearance, transfusion volume, congestive heart failure
history, diuretics use, fever, intravenous fluid, blood group, baseline Hb and
Hct. The median volume of red cell transfusion was 260.00, 262.50 and 257.50
ml for each group (P=0.638), Baseline median Hb before transfusion was 8.60,
8.50 and 8.60 g/dL for each group (P=0.553). Baseline median Hct before trans-
fusion was 26.65, 26.30 and 27.05% for each group (P=0.570). Mean difference
of Hb level among different time point at 1, 4 and 24 hours was 1.21, 1.19 and
0.95 g/dL for each group (P=0.109), Mean difference of Hct level among differ-
ent time point at 1, 4 and 24 hours was 3.62, 3.63 and 3.09% for each group
(P=0.398). The equilibration of Hb and Hct after red cell transfusion was not
statistically different between these three groups.
Summary/Conclusions: The equilibration of Hb and Hct after transfusion was
not different at 1, 4 and 24 hours. Target Hb and Hct can be determined at 1
hour after transfusion which can provide early further treatment.
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WHY ARE WE LOSING OUR PRECIOUS BLOOD DONORS?. A SYSTEMATIC
REVIEW FROM PAKISTAN
A Memon*, B Moiz
Department of Pathology & Laboratory Medicine, Aga Khan University Hospital,
karachi, Pakistan
Background: Worldwide, a great majority of blood donors are deferred and
many of these deferrals are for temporary reasons. This may cause loss of
precious blood donors. This is also a common practice in Pakistan. Given the
limited number of blood donors in our setting it is undesirable to defer a signif-
icant number of blood donors. This systematic review was conducted to docu-
ment the various reasons for temporary deferral in Pakistan. 
Aims: To carry out a systematic review of the surveys addressing the reasons
of temporary blood donor deferral in Pakistan.
Methods: PAKMEDINET, GOOGLE SCHOLAR, PUBMED, CINAHIL and
EMBASE search engines were used for literature search by using following
terms ‘’ pre donation deferrals Pakistan’’, ‘’temporary reasons for blood donation
deferrals’’, ‘’questionnaire related deferrals in Pakistan’’ and’’ temporary blood
donor deferrals Pakistan’’ from January 2010 to December 2015. Studies which
addressed transfusion transmitted infections and permanent causes of donor
deferrals were excluded. Case reports were also excluded. Finally 4 relevant
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studies were selected and reviewed and results were analyzed by using SPSS
version 21. Forest plot was made to analyze these studies and p value <0.05
was taken significance.
Results: The search generated 8459 records for the year 2010 to 2015. 4 rele-
vant studies were selected and reviewed. These studies were carried out in var-
ious blood banks located in different provinces of Pakistan. Based on the collec-
tive findings of these studies; anemia 31%, low blood pressure 21%, medications
8%, donation in last 3 months 8% and low weight for age 5% were identified to
be the commonly observed factors for temporary blood donor deferral.
Summary/Conclusions: Anemia was found to be the most frequent cause of
temporary blood donation deferral in our population. It is important to provide
donors with a clear message regarding their deferral status. They should be
encouraged to come again after their deferral period. Public awareness and
education regarding blood donation may decrease deferral rates and can pre-
vent an unfavorable impact on the donor as well as on blood donations.
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RESULTS OF AN ANEMIA PREOPERATIVE’S CIRCUIT CORRECTION AS
TECHNIQUE TO SAVE BLOOD IN MAJOR GYNECOLOGICAL SURGERY
SINCE 2010 TO 2015 IN A THIRD NEVEL HOSPITAL
MA García Ruiz1,*, AB Ortega López2, P Romero García1, E Morente Constan-
tin1, A Martínez Tellerias2, M Jurado Chacón1
1Servicio de Hematología y Hemoterapia, 2Servicio de Anestesia y Reani-
mación, Complejo Hospitalario Universitario de Granada, Granada, Spain
Background: Anemia is not only the biggest risk factor for transfusion, but
also an independent predictor of perioperative mortality and morbidity, including
more infectious complications and increased hospital stay. Its prevalence in
surgical patients varies in the range from 10 to 70%, depending on their defi-
nition and the type of intervention. Iron-deficiency anemia is the most common
cause in the patient’s proposal for mayor gynecological surgery (MGS).
Aims: This surgery presents a transfusion rate of 14% and secondary to peri-
operative anemia without bleeding complications of 13%. Since late 2010, with
the creation of a multidisciplinary group of saving blood (PAS). We implemented
a circuit for the correction of preoperative anemia in patients scheduled for this
surgery with the aim to reduce the rate transfusional. We propose a retrospec-
tive study to analyze the effectiveness of this strategy saving blood.
Methods: The proposed patients for MGS with Hb<12 g/dl, we programed, in
susceptible cases, the administration of iv iron (sucrose and carboxymaltose)
for 2-4 weeks before surgery. The day before the intervention, we monitored a
preoperative blood count to assess treatment response and we measured the
proportion of transfused patients. 103 patients were included in PAS until Feb-
ruary 2015 (Figure 1). 5 patients were transfused: 2 due to hemorrhagic post-
operative complications and 3 due to preoperative anemia.
Figures.
Results: Hemoglobin of the patients, which were included in our protocol, an
average of 2.46 g/dl and 5.42% hematocrit increased, being the response to
treatment statistically significant. We study the evolution of the number of red
blood cells concentrates transfused in the gynecology before and after the
implementation of our strategy. We observed a decrease of 34.8% in 2010,
22.6% in 2011, 38.4% in 2012, 23.6% in 2013 and 18% in 2014 compared to
2009. (Figure 2). Regarding the incidence of perioperative transfusion, the per-
centage of patients transfused included in the PAS is 4.9%, while in the histor-
ical cohort is 26.5% and this difference being also statistically significant (p
<0.001). We compare our patients with a historical cohort obtained from the
database at our center, selecting all patients undergoing major surgery gyne-
cological (MSG) available from 2008 to the implementation circuit that meet
the same criteria for our group. Preoperative hemoglobin (Hbpre) before
(HbprePAS) was analyzed and after our intervention (HbpostPAS), postoper-
ative hemoglobin (HbpostIQ) and the incidence of perioperative transfusion in
both groups. Hb levels were compared with a general linear model and the
percentage of transfusion with the chi-square test. P value <0.05 was consid-
ered significant. The historical cohort was constituted with 223 patients. Before
treatment with iv iron patients exhibit inferior circuit Hbpre the cohort historical
statistically significant (p <0.001). After PAS, the change in Hb is statistically
significant (p <0.001), so that the Hbpre of treated patients is 12.7 g/dl versus
11.14 g/dl group untreated. The average value of the HbpostQ is also superior
in our group significantly (p <0.001). Figure 3.
Summary/Conclusions: This circuit is effective to correct the preoperative
anemia of the patients proposed for MSG. This protocol has improved Hb levels
and preoperative hematocrit of these patients. The results were statistically
significant. Treatment with intravenous iron for the correction of preoperative
anemia in GMS as blood conservation strategy is effective to increase Hbpre
statistically significant. Patients included in the circuit have a lower incidence
of transfusion and have greater HbpostQI that patients not treated with iv iron.
This protocol has improved Hb levels and preoperative hematocrit of these
patients. The results were statistically significant. This measure seems effective
in reducing the transfusion risk.
PB2224
EFFECT OF THIOCYANATE ON THE ACTIVITY OF BLOOD CLOТTING
FACTOR VIII
N Shurko1,*, D Taras1, D Olha2
1Laboratory biochemistry of blood, 2Hematology, State Institution «Institute of
Blood Pathology and Transfusion Medicine NAMS of Ukraine», Lviv, Ukraine
Background: The transmissions of viral agents have been associated with
blood transfusion, particularly with the factor coagulation concentrates (for
example, factor VIII, vWF, factor IX and prothrombin complex). The blood clot-
ting concentrates should have not only a high specific activity, but to be viral
safety. The safety of the ﬁnal plasma protein сoncentrates has a paramount
importance. The specific steps for the inactivation of the virus have been includ-
ed in each process to enhance the safety of the products by reducing the virus
load during manufacturing. Currently, there are several technologies to help
ensure the safety of plasma products: solvent-detergent method, heat treat-
ment, sodium caprylate and low pH, chromatography, nanoﬁltration and chem-
ical reagents (for example, sodium hydroxide, guanidine chloride, sodium or
ammonium thiocyanate) for purification of proteins and sanitizing chromatog-
raphy systems.
Aims: studies of the effect of ammonium thiocyanate (NH4SCN) on the activity
of blood clotting factor VIII (FVIII).
Methods: The commercial concentrate of FVIII («Immunate») was initial raw
material for the work (working activity 1.6 IU/ml). Determination of activity of
FVIII conducted the one-stage clotting method which is based upon the acti-
vated partial thromboplastin time (APTT) and using of congenital severe hemo-
philia A plasma or artificially prepared of FVIII deficiency plasma as a substrate.
To investigate the effect of NH4SCN on the activity of FVIII, to enzyme working
solution were added a buffered solutions of different concentrations of reagent.
Removing of NH4SCN was performed in stages by ultrafiltration (used the
filters Amicon Ultra-0.5 10k; Centrifuge Eppendorf 5702-R).
Results: Virus inactivation by NH4SCN is shown earlier in studies of various
scientists. NH4SCN was used as an antiviral agent in the manufacture of factors
coagulation from plasma of blood. We conducted the study of this effect on the
activity of clotting FVIII, to determine the possibility of its use in the manufacture
of investigational factor. Experimental studies were performed in stages: in the
reaction mixture was added buffered solutions of various concentrations of
NH4SCN and was measured activity of FVIII. As a result of the research we
showed that thiocyanate reversibly inhibits the activity of the investigated FVIII
(Table.1). When it had removed from the reaction mixture, factor activity recov-
ered.
Table 1. Comparative characteristics of FVIII activity depending on the
concentration of thiocyanate.
Summary/Conclusions: Thiocyanate may be used for antiviral treatment and
as the eluting agent of coagulation FVIII in chromatographic process purifica-
tion.
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TRANSFUSION PROTOCOLS OF BLOOD CENTRE OF ASL CASERTA
(MANAGEMENT AND MONITORING)
MR Dell’aversana*, E Munno, G De Caprio, A Orefice, G Salerno, G Donciglio,
S Misso
Servizio Trasfusionale, ASL Caserta, Aversa, Italy
Background: The red blood cell is an immunologically competent cell for the
presence of various exposed antigens, inherited genetically. Transfusion is a
medical procedure extremely important, and certainly not without risks. Our
Trasfusion Centre implemented transfusion protocols to ensure that all patients
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have best treatment possible; these protocols provide for the identification of
two groups of patients:chronic and acute. The first transfusing compatibility
with the Rh, kell Duffy, Kidd, MNS systems with apheresis or filtered red blood
cell, the seconds one with Rh and Kell systems compatibility, by decomposition
of red blood cells. This is possible thanks to the availability of blood guaranteed
by the excellent cooperation with voluntary associations, particularly for the
production of red blood cells by apheresis.
Aims: The aim of our study was to evaluate the effectiveness of our transfusion
protocols and their impact on health patients (immunological complications)
Methods: A retrospective study was done on all patients transfused in 2015
year, the patients were divided in chronic and acute and we studied the per-
centage of immunization and the most frequent antibody (computer system
Eliot Enginnering Health)
Results: In the year 2015 were carried out 14,277 transfusions to 7000 patients
(2500 chronic and 4500 acute). There were no immunizations in chronic
patients while in the acute patient the percentage was 0.6%. The identified
antibodies were: anti-D: 36.4%, anti-K: 27%, anti-E: 15%, anti-C: 1%, anti-c
:6%, anti-e: 3%, anti FyA :2%, anti-Fyb: 1%, anti M: 3.4%, anti LeA :2.2%.
Summary/Conclusions: The results show that the cases of immunizations
are all at the expense of acute patients, this confirming as the transfusion pro-
tocols guarantee the best possible therapy trying to preserve all chronic patients
from ineffective transfusions. The frequencies of the detected antibodies reflect
the immunogenicity scale. The choice to transfuse the chronich patients
respecting such scale have preserved to immunizations. These protocols may
seem expensive for the company budget assigned to the blood transfusion
service, the savings are long-term evident in reality as it reduces the number
of immunized patients and then the cost of their management.
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INDICATIONS FOR TRANSFUSING NAT UNTESTED BLOOD PRODUCTS
ARE THESE RATIONAL?
S A Ali*, F Karim
Pathology and laboratory Medicine, Aga Khan University Hospital, Karachi,
Pakistan
Background: Blood transfusion is a life-saving therapeutic option in many con-
ditions. However, blood transfusion is never safe and is associated with risks
of transfusion transmitted infections (TTI). To minimize the risk of TTI, all blood
donations are screened for infectious diseases as per W.H.O standard. In emer-
gency situation where blood products are required urgently and screened prod-
ucts are unavailable, it may be necessary to transfuse unscreened or partially
screened blood products. Some of the indications where use of such products
can be justified include: Critical Laboratory Results (defined as Hb <7gm/dl
and platelets <20x109/L), active bleeding, emergency surgical/ radiological
intervention and sepsis. Irrational transfusion of unscreened blood puts a patient
at risk of acquiring an infectious disease which can cause severe long term
complications. So it is very important they must only be transfused in dire need
when screened products are not available and transfusion is the only life-saving
option. In our hospital all products are serologically tested and then all sero-
negative samples undergo molecular testing known as Nucleic acid testing
(NAT). The rate and indications of dispensing NAT untested blood products in
our hospital is unknown
Aims: The aim of this study is to recognize the indications for transfusing NAT
untested blood products and assess whether these are rational or not.
Methods: This was a clinical audit conducted by Blood Bank, Section of
Haematology, Department of Pathology and Laboratory Medicine, The Aga
Khan University Hospital. The Study duration was from May-July 2015. All the
request forms received to Blood bank requesting release of NAT untested blood
products were reviewed. Additional information regarding the need and indica-
tion was extracted from the online integrated laboratory data and medical record
chart of patients. Data was recorded on a predesigned proforma. Statistical
package for social sciences version 19 was used for data analysis.
Results: During the study period, 254 requisition slips were received to blood
bank for 234 patients. Six hundred and seventy two NAT untested blood prod-
ucts were released during study period. The products released included: 154
packed red cell, 493 random donor platelets and 25 whole blood units. Most of
the cases where blood bank was not able to provide screened blood were from
Section of Clinical Haematology (n=61, 24%) followed by General Surgery
(n=46, 18%) and Internal Medicine (n=40, 16%). The location of patients was
Emergency room (n=58, 23%), Operating room (n=46, 18%), Wards (n=45,
18%) and special care units (n=28, 11%). In 224 out of 254 (88.2%) requests,
the indications for transfusion were rational. The most common indication for
the release of NAT untested products was Critical Laboratory results (n=106,
42%) followed by Surgical/Radiological Intervention (n=65, 26%) active bleed-
ing (n=53, 21%) and sepsis (n=12, 5%). Seven percent (18/254) of the requests
were not fulfilling any of the indication and transfusion in these cases was not
justified. Majority of these requests (n=14, 77.8%) were from oncology day care
transfusion area.
Summary/Conclusions: Majority of the indications for transfusion of NAT
untested products were rational (93%). Few cases of irrational transfusion of
NAT untested products were identified. The audit identified the areas in the
hospital which need re-inforcement on the rational use of NAT untested blood
products.
PB2227
A NEW PROTOCOL FOR OBTAINING PLATELET RICH IN GROWTH FACTORS
(PRP). A DESCRIPTIVE STUDY IN 15 PATIENTS AND COMPARISON WITH
RESULTS PUBLISHED IN LITERATURE
J Alcaraz Rubio*, JM Sánchez López
Ciencias de La Salud-Grado en Medicina-Facultad de Ciencias de la Salud,
Ucam Universidad San Antonio de Murcia, Cobatillas-Murcia, Spain
Background: The diversity of procedures for obtaining platelet and plasmatic
growth factors, the absence of control in most of them and the growing field of
clinical application, makes them necessary methods adequately structured,
documented, controlled and tested, playable by any author. The present series
of clinical cases aims to introduce and test a specific technique for obtaining
PRP, with precise characteristics both production and final composition of com-
pound got, in 15 hematological healthy patients, comparing our results with
those obtained by other procedures scientifically tested.
Aims: introduce and test a specific technique for obtaining PRP, with precise
characteristics both production and final composition of compound got, in 15
hematological healthy patients, comparing our results with those obtained by
other procedures scientifically tested.
Methods: 15 caucasian patients were selected, 8 male and 7 female with age
range between 35 and 65, healthy haematologically. The procedure for obtain-
ing the PRP, consisted of a single centrifugation of the blood sample for 30
minutes at 3500 rpm in a angular shaft of 16 tubes centrifuge serie (CEMCON
2) and micropipetting the protein fraction rich in platelet and plasmatic growth
factors and cell through open technique under aseptic conditions in horizontal
laminar flow hood Grade A at a temperature of 22 ° C, with the use of leuco-
platelet or Buffy-coat layer (PRP rich in leukocytes).
Results: No correlation between the amount of concentrated platelets and the
amount of growth factors finally obtained was observed. The protocol set forth
concentrated levels of platelets and leukocytes approximately 3 to 5 times high-
er than baseline levels with a predominance of mononuclear. Levels of growth
factors from 7-10 times greater than the patient’s baseline levels, with little vari-
ation in them. The growth factor levels were stable in the blood of each patient
within 24 h of treatment between 7 and 9 times higher compared to the previous
baseline. Compared with other procedures discussed in the literature; This
method achieves concentration between 1.5 and 3 times more platelets in the
final product, with a purification of growth factors overall type VEGF and TGF-
B clearly superior.
Summary/Conclusions: the technique disclosed is more effective since con-
centrate achieves greater amount of platelets and growth factors and efficient
since it maintains a serum protein in these stable sera of patients after 24 hours
of administration thereof.
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PEDIATRIC PATIENT WITH BOTH LEUKOCYTE ADHESION DEFICIENCY
II AND BOMBAY BLOOD GROUP
Y Yaman1,*, S Aydın2, C Acıpayam3, E Sarıbeyoglu1, F Genel4
1Pediatric hematology, Medipol Mega University Hospital, istanbul, 2Pediatric
hematology, İzmir Behçet Uz Childrens Hospital, İzmir, 3Pediatric hematology,
Kahramanmaraş Medical Faculty, Kahramanmaraş, 4Pediatric Immunology,
İzmir Behçet Uz Childrens Hospital, İzmir, Turkey
Background: Leukocyte adhesion deficiency type II (LAD II) is a rare autosomal
recessive inherited immunodeficiency disease that induces frequent, recurrent
infections, persistent leukocytosis, severe mental and growth retardation and
impaired wound healing. Therewithal, Bombay blood group is rare phenotype
that is characterized by deficiency of H, A and B antigens on red cell surface.
Aims: LAD II and Bombay blood group have rarely been present together
because both of them associated with a global defect in common pathway of
fucose metabolism.
Methods: 11-year-old boy was evaluated due to diarrhea. He was born to
healthy first degree consanguineous parents at term with a birth weight of 1.250
gr (<3th). He had a history of hospitalization for intrauterine growth retardation
during first three weeks of life. As an infant, he suffered from delayed separation
of the umbilical cord. He developed multiple recurrence infections such as
pneumonia, diarrhea, fever and recurence skin abscess. On the examination,
his height and weight were both below the third percentile for age. He had 2
cm of hepatomegaly and 4 cm of splenomegaly. Physical examination revealed
the dysmorphic features such as coarse facial appearance, flattened nose,
long prominent philtrum. He had numerous scars of abscess in the bilateral
inguinale region. On neurological examination, he had severe growth and psy-
chomotor retardation (Figure 1). İnitial laboratory evaluation revealed elevated
white blood cell count (72.1x103/µL) with neutrophilia (80% neutrophils, 20%
lymphocytes). His hemoglobin level was 11.6 g/dL and his platelet was
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456,000/mm3. The other blood parameters of the patient were normale. His
disease was identified Leukocyte Adhesion Deficiency (LAD) which was char-
acterized by recurrent infections, persistent leukocytosis, delayed separation
of the umbilical cord and severe mental and growth retardation. 
Results: The presence of Lea, Leb, and H antigens on the erythrocytes of
patient was investigated by hemagglutination tests performed with commercial
monoclonal antiserums (ALBAclone, Alba Bioscience, United Kingdom) derived
from mouse. At same hospital, his blood grouping was again interpreted as O
Rh D positive by the ABO and Rh typing on gel card. Forward reverse grouping
on tube showed the blood group to be O Rh D positive. Indirect Coomb’s Test
and antibody screening was 4+ reactivity, direct Coomb’s Test (DCT) of patient
was negative. It was found to be incompatible with strength of 4+ agglutination
in all cross match by reverse analysis conducted with erythrocytes of A1, A2,
B and O blood group. Reaction with anti H lectin was negative. The blood
group was finally interpreted as Bombay blood group with naturally occuring
anti-H antibodies in plasma. The moleculer basis of LAD II was demonstrated
according flow cytometric results; the deficient expression of the CD15 adhe-
sion molecules on the surface of leukocytes while expression LFA-1
(CD11a/CD18), Mac-1 (CD11b/CD18), p150/95 (CD11c/CD18) are normal.
Summary/Conclusions: When a patient with Bombay Phenomenon is detect-
ed, the investigation for leukocyte adhesion deficiency type 2 must been done. 
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TRANSFUSION IN THE PRESENCE OF MULTIPLE ALLOANTIBODIES
PLUS COLD-REACTIVE AGGLUTININS/DAT+
JR Garcia Fernandez*, F Lopez Berenguel, S López Hinojosa
Hematologia, Hospital de Baza. Servicio Andaluz de Salud, BAZA, Spain
Background: Transfusion in the presence of allloantibodies is a common pro-
cedure in blood-banks. The challenge appears when alloantibodies are multiple
and associated with “benign” antibodies or another inespecific laboratory finding
that cover up the clinically significant antibodies. The grade of difficulty grow
up if the presentation of alloantibodies is detected at the same time rather than
in succession.
Aims: We exposed two cases of multiple clinically significant alloantibodies,
classified as group I (antibodies that react at 37ºC and that cause a significant
majority of transfusion reactions, related to systems: AB0, Rh, Kell, Duffy, Kidd
and Ss).
Methods: We describe the last two complex positive inmunohematological
studies perfomed in our community hospital 
Results: Case1: Pluripathological woman 86 years old, without pregnancies
and without previous studies in our hospital. She has received just one trans-
fusion of 2 red cells concentrates, two years before in another hospital. IAT
Positive in emergency room with subsequent study in table 1. Probability to
find compatible 0 positive blood: 2%. Case 2: Man 68 years old with sever
hepatic disease, multiple blood transfusion in the past 7 years due to gastroin-
testinal bleeding. He needs urgent transfusion for the same reason. Previously
he has developed several alloantibodies successively as reported in table 1.
Probability to find compatible 0 positive blood: 6%. The challenge of transfusion
in these cases are associated with four facts: 1. Number and specificity of
alloantibodies; 2. Timing of apparition of alloantibodies; 3. Absolute necessity
of blood transfusion in life-threatening situations; 4. Presence of others events
that difficult the identification of alloantibodies: cold-reactive antibodies, positive
direct antiglobulin test.
Table 1. Antibodies detected in blood transfusion recipients.
Summary/Conclusions: The presentation of multiple anti-erythrocytes alloan-
tibodies associated with non-specific/bening serological findings in life-threat-
ening situations required and appropriated and immediate evaluation of the
patient to decide if transfusion can be delayed or not, simultaneously efforts
can be made in order to identify the facts clinically significatives to avoid sero-
logical related conditions that mask the real problem focussed in antibodies
group I related. We think that transfusion of incompatible blood, in a hemody-
namic unstable patient due to others diseases, should be avoided. If anaemia
is the exclusively cause of instability we should consider the risk of transfusing
incompatible blood.
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ANALYSIS OF PLATELETPHERESIS DONOR DEFERRAL RATE,
CHARACTERISTICS AND ITS PREVENTABILITY
MH Dogu1,*, I Sarı2, S Hacıoglu2, A Keskin2
1Hematology, Istanbul Training and Research Hospital, Istanbul, 2Hematology,
Pamukkale University Faculty of Medicine, Denizli, Turkey
Background: Plateletpheresis is a procedure included in donor apheresis in
which the donor blood is passed through an extraction machine, the platelets
are extracted, and the remainder is returned into the circulation. Donor selection
is important because donors are the only source for meeting blood product needs.
Aims: In our study we aimed to evaluate deferral reasons in applications for
plateletpheresis donation and reveal determine the preventable ones among them.
Methods: The persons who were admitted to our Blood Center to be platelet-
pheresis donors during the period between August 2013-February 2014, after
a demand/request for platelet suspension was issued by the clinics. Their eli-
gibility for being plateletapeheresis donors was decided 
Results: A total of 1098 persons have applied to be plateletpheresis donors;
1045 were male and 53 female. A total of 787 persons were found to be eligible
for being plateletpheresis donors; 772 were male and 15 female. 891 units of
apheresis platelets were obtained from apheresis donors, including double
units collected from 104 of them. Applications of 311 persons were deferred
due to various reasons. The most common reason for donor deferral was inap-
propriate vascular access in 80 persons (25.7%, 69 males, 11 females). This
is followed by abnormal laboratory values in 57 persons (18.3%) and drug use
(most commonly analgesics) in 46 persons (14.7%).
Summary/Conclusions: During the assessment of blood product donors,
proper selection of the candidates should be considered very carefully in order
to not to harm the donor but to supply the demand of the recipient properly.
When the deferral reasons were evaluated, improvement of in-hospital techni-
cal reasons and education sessions for people in order to increase the social
awareness may substantially decrease the deferral rates.
PB2231
RED CELL PHENOTYPING AMONG MULTITRANSFUSED EGYPTIAN
THALASSEMIC PATIENTS
M Sarhan1,*, M Fouda2, D Ghannam2, S Abdelaziz2, A Elemery2
1Pediatrics, 2Clinical Pathology, Faculty of Medicine - Mansoura University,
Mansoura, Egypt
Background: Thalassemia is an inherited hemolytic disorder caused by partial
or complete deficiency of α or β-globin chain synthesis. Regular transfusions
are essential for patients with thalassemia to maintain growth and development
during childhood and to sustain good quality of life during adulthood. The devel-
opment of hemolytic alloantibodies and red blood cell (RBC) autoantibodies
complicates transfusion therapy in patients with thalassemia.
Aims: of this research is to determine the prevalence of red blood cells antigens
among multitransfused thalassemic patients attending Mansoura University
Children Hospital, Mansoura, Egypt and a sample of blood donors, as an
approach for prevention of alloimmunization.
Methods: The present study comprised 70 mulitransfused thalassemic
patients. They were 38 males and 32 females and in addition 65 adult male
donors. All were subjected to Laboratory tests for blood group antigens (ABO),
and (Rh system, Kell system), using ID-cards, Also a CBC was done.
Results: 1) Blood group O is the most prevalent blood group in our patients but
B group is the most prevalent in our donors. 2) Kell negative group is prevalent
in the patients compared to the donors. 3) There is significant difference between
the patients and the donors in Rosenfield: (1,2,3,4,5) and (1-2-3,4,5), More
prevalent in the donors, But Rh (1,2-3-4,5) is prevalent in the patients versus
the donors. 4) There is significant increase in (c), (E) and marginal increase of
(k) antigens in donors versus the patients. 5) Patients below five years old
showed significant increase of negative kell group and Rosenfield Rh (1,2-3-
4,5). 6) No relation between sex and blood group phenotypes of the patients.
7) Significant increase of kell negative group and Rosenfield Rh (1, 2-3-4,5) in
patients who were younger in age of first transfusion and who received frequent
transfusions. 8) High incidence of pallor in patients with blood group O. Also
patients with Rosenfield Rh (1,2-3-4,5). 9) Splenectomizd patients had signifi-
cantly higher incidence of negative kell group and Rosenfield Rh (1,2-3-4,5).
Summary/Conclusions: From the present study, in order to minimize the haz-
ards of blood transfusion, especially the immunological reactions the following
could be done: 1) Pre transfusion matching of blood for ABO and Rh D antigens
is important as a routine work, which helps in determining the true blood groups
and it assists in the identification of suspected alloantibodies and selection of
antigen-negative RBCs for transfusion. 2) Extended phenotype matching of
blood for Rh (other than D) and Kell have been proposed as effective method
which could reduce morbidity in thalassemic patients.
PB2232
SHOULD BLOOD DONORS WITH HARRIS PLATELET SYNDROME BE
EXCLUDED FROM PLATELET DONATION?
A Das1,*, HK Elias2, S Harris3, HV Naina4
1Cardiology, Beth Israel Deaconess Medical Center, Boston, 2Internal Medicine,
Icahn School of Medicine at Mount Sinai St Luke’s- Roosevelt Hospital,
880 | haematologica | 2016; 101(s1)
21st Congress of the European Hematology Association
NewYork, 3Division of Gastroenterology, UT southwestern, 4Department of
Internal Medicine, Plaza Medical center, Dallas, United States
Background: Harris platelet syndrome (HPS) is an autosomal dominant
macrothrombocytopenia with mild to moderately severe thrombocytopenia and
normal platelet function. HPS has been reported from Indian subcontinent blood
donors, especially from the northeastern part of India. Approximately a third of
blood donors from state of West Bengal have been found to have HPS.The
Indian NACO 2007 guideline recommends one bag of PRC from 350 ml of
whole blood should have a platelet count above 3.5 X10 9/l.
Aims: We designed a study to assess whether PRC (platelet rich concentrate)
obtained from those with HPS contained adequate platelets as recommended
by the Indian guidelines. 
Methods: HPS is defined as healthy blood donors having a mean platelet vol-
ume (MPV) greater than 12 fL (normal <10 fL) with or without concomitant
thrombocytopenia in the absence of any significant past history of bleeding dis-
order in either themselves or their first degree relatives. In our study, we col-
lected 350 ml of blood from each donor and via Platelet Rich Plasma Separation
Method (PRPSM) we separated out PRC and PRBC in separate bags.A CBC
was performed at the time of donation and from PRC bag blood collected in
EDTA tubes, and analyzed using SYSMEX XP-100.
Results: A total of 28 donors were included. The median age of the donors
was 33 years(21-62) and 21 (75%) were male.Pre donation CBC showed a
median platelet count of 1.93±0.54 X109/ L (0.99-2.98 X109) and platelet count
from PRC showed a median platelet count 1.16±1.77x109/ L(0.03-8.25X109)
which is much below the national guidelines. It is possible that platelet yield is
lower in these donors as during separation, the platelet concentration gradient
was influenced by the larger platelet size [1].
Table 1.
Summary/Conclusions: This study shows that PRC from HPS donors are not
able to keep the international standard and should not be used in the future.
Our study is the first one to date to assess the candidacy of those with inherited
giant platelet disorders being blood donors.
Reference
1. Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich 
    Plasma: A Review and Author’s Perspective. J Cutan Aesthetic Surg. 
    2014;7(4):189–97.
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* Iclusig is a tyrosine kinase inhibitor (TKI) indicated in adult patients with1
• chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) 
 - who are resistant to dasatinib or nilotinib;
 -  who are intolerant to dasatinib or nilotinib and for whom subsequent treatment  
with imatinib is not clinically appropriate;
 - or who have the T315I mutation
References: 1. Iclusig (ponatinib). Latest Summary of Product Characteristics (March 2016). 2. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive 
leukemias. N Engl J Med2013;369:1783-96.
Unlock efficacy for resistant or intolerant CML and Ph+ ALL patients:
Iclusig® ▼ opens up new perspectives for your CML patients. 
Fast response
 Median time to MCyR in CP-CML responders: 2.8 months1,2 
Median time to MMR in CP-CML responder: 5.5 months1,2
Deep response
38 % of CP-CML patients reached MMR or even better1
Durable response
87 % of CP-CML responders maintained MCyR at 28 months1
- Once daily




PRESCRIBING INFORMATION – Iclusig® ▼ (ponatinib) ▼ This medicinal product is subject to additional monitoring. Antineoplastic agent, protein kinase inhibitor, ATC code: L01XE24.
Presentation: Film-coated tablets containing 15 mg or 45 mg of ponatinib (as hydrochloride). Indications: Iclusig is indicated in adult patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukaemia 
(CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, and in adult patients with Philadelphia 
chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. 
Dosage and administration: Therapy should be initiated by a physician experienced in the diagnosis and treatment of patients with leukaemia. Haematologic support such as platelet transfusion and haematopoietic growth factors can be 
used during treatment if clinically indicated. Before starting treatment with ponatinib, the cardiovascular status of the patient should be assessed, including history and physical examination and cardiovascular risk factors should be actively 
managed. Cardiovascular status should continue to be monitored and medical and supportive therapy for risk factors optimised during treatment with ponatinib. The recommended starting dose is 45 mg once daily. Response should be 
monitored according to standard clinical guidelines and treatment discontinuation considered if a complete haematological response has not occurred by 3 months. It should also be discontinued when there is evidence of disease progression 
or severe adverse reactions. Tablets should be swallowed whole and not crushed or dissolved, and may be taken with or without food. Dose adjustments – The risk of vascular occlusive events is likely to be dose related. In a patient suspected 
of developing an arterial or venous occlusive event, Iclusig should be immediately interrupted. After the event is resolved, the decision to re-start treatment should be directed by a benefit-risk assessment. Dose modifications, or interruptions, 
should be considered for haematological and non-haematological toxicities. Treatment should be withheld in the case of severe adverse reactions. Dose modifications are recommended for neutropenia or thrombocytopenia unrelated to 
leukaemia, pancreatitis and elevation of lipase/amylase and prescribers should consult the SmPC for full details. When adverse reactions have resolved, or become less severe, dose escalation back to the prior daily dose may be considered, 
if clinically appropriate. Dose reductions may be considered for patients who have achieved a Major Cytogenetic Response and the SmPC should be consulted for risk-benefit and monitoring details. Contraindications: Hypersensitivity 
to ponatinib or to any of the excipients. Warnings and precautions: Myelosuppression – Iclusig is associated with severe thrombocytopenia, neutropenia, and anaemia. The frequency of these events is greater in patients with AP-CML or 
BP-CML/Ph+ ALL than in CP-CML. A complete blood count should be performed every 2 weeks for the first 3 months and then monthly or as clinically indicated. Vascular occlusion – Arterial and venous thrombosis and occlusions, including 
fatal myocardial infarction (MI), stroke, retinal vascular occlusions associated in some cases with permanent visual impairment or vision loss, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, kidney artery 
stenosis, the need for urgent revascularization procedures have occurred with Iclusig; these events were more frequent with increasing age, or in patients with prior history of ischaemia, hypertension, diabetes, or hyperlipidaemia. Iclusig 
should not be used in patients who have suffered an MI, prior revascularisation or stroke, unless there is a positive benefit-risk assessment; other treatment options should also be considered. Monitoring for thromboembolism and vascular 
occlusion should occur throughout treatment with Iclusig, which should be stopped immediately if an event occurs. If decreased vision or blurred vision occurs, an ophthalmic examination (including fundoscopy) should be performed. 
Hypertension (including hypertensive-crisis) has occurred with Iclusig and can contribute to the risk of arterial thrombotic events, so blood pressure should be monitored at each visit and any associated symptoms treated urgently. Iclusig 
should be interrupted in the event of uncontrolled or treatment resistant hypertension. Congestive heart failure – Fatal and serious events have occurred with Iclusig including events associated with prior vascular occlusion. Patients should 
be monitored and treated as clinically indicated, including interruption of Iclusig. If serious heart failure develops, Iclusig should be discontinued. Pancreatitis and serum lipase – Iclusig is associated with pancreatitis. The frequency of 
pancreatitis is greater in the first 2 months of use. Check serum lipase every 2 weeks for the first 2 months and then periodically thereafter. Dose interruption or reduction may be required. If lipase elevations are accompanied by abdominal 
symptoms, Iclusig should be withheld and patients evaluated for evidence of pancreatitis. Caution is recommended in patients with a history of pancreatitis or alcohol abuse. Patients with severe or very severe hypertriglyceridaemia should 
be appropriately managed to reduce the risk of pancreatitis. Lactose – Iclusig contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 
should not take this medicinal product. Effects on ability to drive and use machines – Adverse reactions such as lethargy, dizziness and vision blurred have been associated with Iclusig. Therefore, caution should be recommended when driving 
or operating machines. QT prolongation – a thorough QT study has not been performed; therefore a clinically significant effect on QT cannot be excluded. Hepatotoxicity – Iclusig may result in elevation in ALT, AST, bilirubin, and alkaline 
phosphatase. Hepatic failure (including fatal outcome) has been observed. Liver function tests should be performed prior to treatment and periodically, as clinically indicated. Haemorrhage – Serious and fatal haemorrhagic events have 
occurred with Iclusig, most commonly cerebral and gastric bleeding. Most events were associated with grade 3 & 4 thrombocytopaenia. Iclusig should be interrupted for serious and severe events. Hepatic impairment – Caution is 
recommended when administering Iclusig to patients with severe hepatic impairment. Renal impairment – Caution is recommended when administering Iclusig to patients with estimated creatinine clearance of <50 mL/min or end-stage renal 
disease. Elderly patients – Are more likely to experience adverse reactions. Paediatric population – The safety and efficacy of Iclusig in patients less than 18 years of age have not been established. Interactions: Co-administration of Iclusig 
with strong CYP3A4 inducers should be avoided; caution should be exercised with concurrent use of Iclusig and strong CYP3A inhibitors and a starting dose of 30 mg considered; caution should also be exercised with concurrent 
administration of substrates of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP). Caution should be taken with concomitant use of anti-clotting agents in patients who may be at risk of bleeding. Pregnancy and breastfeeding: 
Women of childbearing age should be advised not to become pregnant, and men should be advised not to father a child during treatment. An effective method of contraception should be used during treatment - it is unknown if Iclusig affects 
systemic hormonal contraceptives so an alternative or additional method should be used. There are no adequate data from the use of Iclusig in pregnant women. Studies in animals have shown reproductive toxicity. If Iclusig is used during 
pregnancy, the patient must be informed of the potential risk to the foetus. Breastfeeding should be stopped during treatment. Undesirable effects: Very common ADRs (≥1/10) – Upper respiratory tract infection, insomnia, anaemia, decreased 
platelet count, decreased neutrophil count, decreased appetite, headache, dizziness, hypertension, dyspnoea, cough, abdominal pain, diarrhoea, vomiting, constipation, nausea, increased lipase, increased alanine aminotransferase, 
increased aspartate aminotransferase, rash, dry skin, bone pain, arthralgia, myalgia, pain in extremity, back pain, muscle spasms, fatigue, asthenia, peripheral oedema, pyrexia, pain. Common ADRs (≥1/100 to <1/10) – Pneumonia, sepsis, 
folliculitis, pancytopenia, febrile neutropenia, decreased white blood cell count, hypothyroidism, dehydration, fluid retention, hypocalcaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypertriglyceridaemia, hypokalaemia, 
decreased weight, cerebrovascular accident, cerebral infarction, peripheral neuropathy, lethargy, migraine, hyperaesthesia, hypoaesthesia, paraesthesia, transient ischaemic attack, blurred vision, dry eye, periorbital oedema, eyelid oedema, 
cardiac failure, myocardial infarction, congestive cardiac failure, coronary artery disease, angina pectoris, pericardial effusion, atrial fibrillation, decreased ejection fraction, peripheral arterial occlusive disease, peripheral ischaemia, peripheral 
artery stenosis, intermittent claudication, deep vein thrombosis, hot flush, flushing, pulmonary embolism, pleural effusion, epistaxis, dysphonia, pulmonary hypertension, pancreatitis, increased blood amylase, gastrooesophageal reflux 
disease, stomatitis, dyspepsia, abdominal distension, abdominal discomfort, dry mouth, increased blood bilirubin, increased blood alkaline phosphatase, increased gamma-glutamyltransferase, pruritic rash, exfoliative rash, erythema, 
alopecia, pruritis, skin exfoliation, night sweats, hyperhidrosis, petechia, ecchymosis, skin pain, exfoliative dermatitis, musculoskeletal pain, neck pain, musculoskeletal chest pain, erectile dysfunction, chills, influenza-like illness, non-cardiac 
chest pain, mass, face oedema. Uncommon ADRs (≥1/1000 to <1/100) – Tumour lysis syndrome, cerebral artery stenosis, retinal vein thrombosis, retinal vein occlusion, retinal artery occlusion, visual impairment, myocardial ischaemia, acute 
coronary syndrome, cardiac discomfort, ischemic cardiomyopathy, arteriospasm coronary, left ventricular dysfunction, atrial flutter, poor peripheral circulation, splenic infarction, venous embolism, venous thrombosis, hypertensive crisis, 
kidney artery stenosis, gastric haemorrhage, hepatotoxicity, hepatic failure, jaundice. Denmark packages & prices: 15 mg: 60 tabl. 45 mg: 30 tabl. See prices at www.medicinpriser.dk Danish prescription group: BEGR, hospitals only. 
Marketing Authorisation Holder: ARIAD Pharma Ltd., Riverbridge House, Guildford Road, Leatherhead, KT22 9AD, United Kingdom. This text has been rewritten and/or abbreviated compared to the authorised summary of product 
characteristics (2016-03-22). The summary of product characteristics can be ordered free of charge from ARIAD. Product information may differ internationally. Date of preparation: April 2016; UK/ICLG/15/0060.
Copyright © 2016 ARIAD Pharmaceuticals, Inc. All rights reserved. Date of preparation: April 2016; EU/ICLG/16/0028
• Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)
 - who are resistant to dasatinib;
 -  who are intolerant to dasatinib and for whom subsequent treatment 
with imatinib is not clinically appropriate;
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